t participants can consume.
215110326|NCT02716623|BEHAVIORAL|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
215110327|NCT04191317|OTHER|Pain Neuroscience Education and gradual exposure|Education covering the pathophysiology of apin and exercises based on the gradual exposure principle
215110328|NCT04191317|OTHER|Pilates and postural education|Postural education and pilates exercises
215110329|NCT01067144|DRUG|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
215110330|NCT01067144|DRUG|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
215110331|NCT01067144|DRUG|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
215110332|NCT02813161|BIOLOGICAL|cellular and tissue based therapy|
215110333|NCT02813161|DEVICE|negative pressure wound therapy|
215110334|NCT02813161|PROCEDURE|debridement|
215110335|NCT02813161|PROCEDURE|advanced wound therapy|
215110336|NCT02813161|DIETARY_SUPPLEMENT|Nutritional screening|
215110337|NCT02813161|DEVICE|off-loading|
215110338|NCT02813161|DEVICE|Hyperbaric oxygen Therapy|
215110339|NCT01821859|DRUG|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
215110340|NCT01821859|DRUG|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
215110341|NCT05971537|DRUG|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
215110342|NCT05971537|DRUG|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
215110343|NCT06160934|BEHAVIORAL|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, \& Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
215110344|NCT05383456|DIAGNOSTIC_TEST|Diagnostic Test|Standard diagnostic tests.
215110345|NCT05383456|DRUG|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
215110346|NCT02978196|PROCEDURE|Injection of 99mTc-NM-01|Patient is injected with micro-dose of 99mTc-NM-01
215110347|NCT02978196|PROCEDURE|Injection of 68Ga-NM-01|Patient is injected with micro-dose of 68Ga-NM-01
215110348|NCT00203424|DRUG|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
215110349|NCT04182243|OTHER|Evaluation of job satisfaction in emergency health care providers by questionnaire|
215110350|NCT04215900|BEHAVIORAL|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
215110351|NCT04741919|PROCEDURE|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
215110352|NCT00010283|DRUG|beclomethasone dipropionate|
214424815|NCT05520086|DRUG|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
215110353|NCT05844267|BEHAVIORAL|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
215110354|NCT05844267|BEHAVIORAL|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
215110355|NCT05796895|BEHAVIORAL|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
215110356|NCT05796895|BEHAVIORAL|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
214424816|NCT05375188|DRUG|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
214424817|NCT05375188|DRUG|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
214424818|NCT05733936|OTHER|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
214424819|NCT05116839|DEVICE|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
214424820|NCT05116839|DEVICE|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
214424821|NCT05116839|DEVICE|i gel air way|supraglottic air way device
214510005|NCT00682318|DIETARY_SUPPLEMENT|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
215110357|NCT00555672|DRUG|5-fluorouracil|5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
215110358|NCT00555672|DRUG|cisplatin|Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
215110359|NCT00555672|DRUG|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
215110360|NCT01053988|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
215110361|NCT01053988|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
215110362|NCT01053988|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
215110363|NCT01053988|DRUG|Placebo|Placebo
215110364|NCT03079089|DRUG|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
215110365|NCT03079089|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at DO
215110366|NCT03079089|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
215110367|NCT03079089|DRUG|Care supports|According to the protocols of each center
215110368|NCT03079089|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II."
215110369|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
215110370|NCT04759157|BEHAVIORAL|Couples-based treatment|Couples will attend 3, video based sessions for couples-based treatment
215110371|NCT04759157|OTHER|Standardized education|Patients will receive standardized educational materials
215110372|NCT06528431|DRUG|Clinical tapering strategy|Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
215110373|NCT06528431|DRUG|Step Wedge trial|Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
215110374|NCT00921791|DEVICE|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
215110375|NCT00921791|DEVICE|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
215110376|NCT00921791|BEHAVIORAL|Pharmaceutical care|consultations with the pharmacists
215110377|NCT00921791|OTHER|Usual care|Consultation with the physician.
215110378|NCT04385459|OTHER|Coronary artery disease|Exposure
215110379|NCT04814147|PROCEDURE|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
215110380|NCT00013741|BEHAVIORAL|Tailored Education Messages|
215110381|NCT01824355|DEVICE|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
215110382|NCT01635881|DEVICE|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
215110383|NCT01860313|BEHAVIORAL|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
215110384|NCT01860313|BEHAVIORAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
215110385|NCT06268938|PROCEDURE|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
215110386|NCT00943332|PROCEDURE|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
215110387|NCT06852859|PROCEDURE|Transurethral resection of the prostate|Thermocoagulation is used in contrast to the other methods
215110388|NCT06852859|PROCEDURE|Transurethral vaporization of the prostate|Heat is used to vaporize prostate
215110389|NCT06852859|PROCEDURE|GreenLight laser enucleation of the prostate|laser is used in contrast to the other methods
215110390|NCT06968676|OTHER|Conventional Upper Limb Treatment|Control group (CG) will receive two 60-minute sessions per week for a period of ten weeks (a total of 20 sessions per group). The CG will receive a specific conventional physiotherapy intervention by a physiotherapist with expertise in the care of people with MS. This intervention will be based on conventional physiotherapy exercises \[23\], including shoulder, elbow, wrist and finger joint mobilization, forearm and hand muscle strengthening exercises, gross and fine motor work and functional task practice with the aim of mimicking the movements included in the settings specifically designed for the experimental intervention.
215110391|NCT06968676|OTHER|Experimental intervention with mixed reality|Experimental group will receive the same conventional physiotherapy treatment (40 minutes) in addition to a mixed reality protocol, using Meta Quest 3.0. glasses (20 minutes), by retraining on tasks specifically designed for this project and linked to the specific locations (kitchen, bathroom, living room, bedroom and garden-terrace. The intervention will be carried out by a physiotherapist skilled in the use of the technology. The patient's initial position will be seated facing a table at mid-trunk height, with the elbow at 90° of flexion and the forearm in neutral pronation-supination. The therapist will provide manual assistance as needed, moving to upright-high seated or standing positions as the protocol progresses and as tasks require, and work will be done bilaterally.
215110392|NCT04427072|DRUG|Capmatinib|400 mg, capmatinib tablets, administered orally twice daily
215110393|NCT04427072|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 by intravenous infusion every 21 days
215110394|NCT06976671|DRUG|Bevacizumab|intra-articular bevacizumab
215110395|NCT06975215|DEVICE|Concomitant embolization|This will include EVAR, following the standard pathway of care, associated with embolization. The decision to perform side-branch embolization or aneurysm sac embolization will be left to each participating centre/physician.
215110396|NCT06975215|PROCEDURE|EVAR|Endovascular aortic aneurysm repair
215110397|NCT06976385|DIETARY_SUPPLEMENT|White tea|White tea mouth rinse applied topically twice daily.
215110398|NCT06976385|DIETARY_SUPPLEMENT|Wheat grass solution|wheat grass solution mouth rinse applied topically twice daily.
215110399|NCT06976866|PROCEDURE|implant surgery|surgery
215110400|NCT06974890|OTHER|Shuttle Balance Training|Shuttle balance training is a form of dynamic balance exercise that uses a shuttle system-often a platform or track with resistance bands or gliders-to help improve stability, coordination, and strength. In children, this type of training plays a significant role in enhancing gait, balance, and posture by engaging core and lower limb muscles in controlled, functional movements. It encourages proprioceptive development, helping children become more aware of their body's position in space, which is crucial for maintaining upright posture and walking efficiently. Through repetitive and playful activities, shuttle balance training can aid in correcting abnormal gait patterns, improving postural alignment, and boosting confidence in physical activities.
215110401|NCT06974890|OTHER|Baseline Treatment|"Baseline treatment sets a foundation for managing the patient's condition effectively. It ensures that the patient receives appropriate care based on current medical knowledge and guidelines, with the goal of improving health outcomes and quality of life. Duration of session will be 45 min and 3 sessions per week.~Control Group Considerations: Clarifying how participants assigned to the control group will receive standard care or placebo intervention to maintain ethical standards and enable comparison with the intervention group."
215110402|NCT06975332|RADIATION|Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)|Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.
215110403|NCT06976931|DRUG|YY2201|This is a multicenter, open-label, dose-escalation phase I study. participants will receive one single target dose of YY2201 on Cycle 0 Day 1 (C0D1) to observe safety and collect PK blood samples up to 48 h post-dose. On the third day after the first dose (Cycle 1 Day 1, C1D1), subjects will start to receive multiple doses of YY2201 orally twice daily (approximately 12 h interval) for 3 days followed by 4 days off in a 21-days treatment cycle.
215110404|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
215110405|NCT06078059|OTHER|Knee aspiration|Knee aspiration
214424822|NCT01501188|OTHER|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
214424823|NCT01501188|OTHER|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
214424824|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
214424825|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
214424826|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
214424827|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
214424828|NCT04957225|BEHAVIORAL|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
214424829|NCT01331863|PROCEDURE|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
214424830|NCT00346684|DRUG|Rituximab|
214424831|NCT01688089|DRUG|ODM103|
214424832|NCT01688089|DRUG|Placebo|
214424833|NCT01688089|DRUG|Entacapone|
214424834|NCT01688089|DRUG|Levodopa/carbidopa|
214424835|NCT03630939|DRUG|ESR-114|ESR-114 Topical Gel
214424836|NCT03630939|OTHER|Placebo|Placebo Topical Gel
214424837|NCT05132348|DIAGNOSTIC_TEST|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
214424838|NCT01599897|BIOLOGICAL|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
214424839|NCT01599897|BIOLOGICAL|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
214424840|NCT02878772|DRUG|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
214424841|NCT02878772|DRUG|Aspirin|100mg, once daily, oral medication
214424842|NCT00506298|DRUG|bezafibrate + diflunisal|bezafibrate + diflunisal
214424843|NCT00506298|DRUG|bezafibrate + placebo|bezafibrate + placebo
214424844|NCT00977223|DRUG|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
215110406|NCT03375489|OTHER|Telehealth Palliative Care|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
215110407|NCT03375489|OTHER|In-person Palliative Care|"In-person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
215110408|NCT06855355|DIETARY_SUPPLEMENT|Clostridium butyricum MIYAIRI 588|A butyrate-producing probiotic, has demonstrated potential anti-inflammatory and anti-tumorigenic effects.
215110409|NCT06548373|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Point-of-Care Echocardiography|"A wireless, AI-guided handheld ultrasound probe will be used on adult male patients who present with a clinical indication for peri-anesthesia point-of-care echocardiography examination.~Residents will document personal interpretation of the completed point-of-care ultrasound (POCUS) examination, important clinical findings, and assessment of whether obtaining a formal echocardiogram is warranted on an exam assessment form. The residents will complete 11 examinations with 10 specific scans each. The first 10 examinations will be AI-guided, and the final 11th examination will be done via a standard (non-AI guided) ultrasound system to gauge the resident's growth in point-of-care echocardiography skill."
215110410|NCT05854368|PROCEDURE|Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine care.|Collection of an additional blood volume (9 mL) as part of a blood sampling performed during routine care or specific for the research if not part of routine care.
215110411|NCT05854368|PROCEDURE|Blood collection|Blood sample collection (10 mL)
215110412|NCT06706219|DRUG|Sacituzumab tirumotecan plus pembrolizumab|"Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients."
215110413|NCT01350245|RADIATION|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
215110414|NCT01350245|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
215110415|NCT01350245|DRUG|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
215110416|NCT01350245|DRUG|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
215110417|NCT01350245|DRUG|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
215110418|NCT01350245|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
215110419|NCT04351724|DRUG|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
215110420|NCT04351724|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
215110421|NCT04351724|OTHER|Best standard of care|best standard of care
215110422|NCT04351724|DRUG|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
215110423|NCT04351724|DRUG|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
215110424|NCT04351724|DRUG|Candesartan|starting dose 4mg once daily, titrated to normotension
215110425|NCT04351724|DRUG|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
215110426|NCT04351724|DRUG|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
215110427|NCT04351724|DRUG|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
215110428|NCT04351724|DRUG|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
215110429|NCT04351724|DRUG|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
214424845|NCT00463788|DRUG|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
215110430|NCT04351724|DRUG|Pentaglobin|7ml/kg/day for 12h for 5 days
215110431|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
215110432|NCT06842901|DEVICE|Portable Rehabilitation (PoRi) device|Once the calibration is complete, the device moves the fingers to close and open the hand for a total of 20 minutes.
215110433|NCT02104947|DRUG|idarucizumab|idarucizumab
215110434|NCT01707082|DRUG|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
215110435|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
215110436|NCT01707082|DRUG|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
215110437|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
215110438|NCT01707082|DRUG|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
215110439|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
215110440|NCT01707082|DRUG|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
215110441|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
215110442|NCT01707082|DRUG|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
215110443|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
215110444|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
215110445|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
215110446|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
215110447|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
215110448|NCT04212689|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
215110449|NCT04212689|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
215110450|NCT01520025|RADIATION|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
215110451|NCT02973308|OTHER|Observer|Observer A and observer B
215110452|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
215110453|NCT02732431|OTHER|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
215110454|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
215110455|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
215110456|NCT03393949|DRUG|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
215110457|NCT03393949|DRUG|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
215110458|NCT03114384|OTHER|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
215110459|NCT06155539|OTHER|No intervention|No intervention
215110460|NCT03777319|DRUG|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
215110461|NCT03777319|DRUG|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
215110462|NCT04672122|DEVICE|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
215110463|NCT00328861|DRUG|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
215110464|NCT00328861|BIOLOGICAL|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
215110465|NCT00328861|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
215110466|NCT00328861|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
215110467|NCT05107622|OTHER|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
215110468|NCT05107622|OTHER|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
215110469|NCT05998577|DEVICE|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
215110470|NCT03406117|DRUG|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
214510006|NCT00682318|DIETARY_SUPPLEMENT|Ethanol|"Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
215110471|NCT03406117|OTHER|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
215110472|NCT00883441|OTHER|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
215110473|NCT02610452|OTHER|Clown therapy|"The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
215110474|NCT04698993|DIAGNOSTIC_TEST|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
215110475|NCT00145574|DRUG|colesevelam HCl|Tablets
215110476|NCT00145574|DRUG|placebo|Matching Tablets
215110477|NCT04846465|OTHER|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
215110478|NCT04487925|DRUG|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
215110479|NCT04487925|DRUG|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
215110480|NCT00527904|DRUG|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
215110481|NCT00527904|DRUG|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
215110482|NCT03998969|DRUG|Pantoprazole|Pantoprazole 40mg tablet
215110483|NCT03998969|DRUG|DA-5204|DA-5204 tablet
215110484|NCT03998969|DRUG|Placebo|Film-coated tablet manufactured to mimic DA-5204
215110485|NCT00514371|DRUG|tanespimycin|High dose
215110486|NCT00514371|DRUG|Bortezomib|Mid dose, and low dose
215110487|NCT02021955|BEHAVIORAL|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
215110488|NCT01122615|DRUG|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
215110489|NCT01122615|DRUG|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
215110490|NCT03728179|COMBINATION_PRODUCT|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
215110491|NCT00001317|DRUG|interferon-gamma|
215110492|NCT03727906|OTHER|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
215110493|NCT03727906|OTHER|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
215110494|NCT03727906|OTHER|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
215110495|NCT04582955|DRUG|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
215110496|NCT02012660|OTHER|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
215110497|NCT03002714|OTHER|Exercise|
215110498|NCT01366885|DRUG|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
214424846|NCT00463788|DRUG|cisplatin|"Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
215110499|NCT03546114|OTHER|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
215110500|NCT03062111|PROCEDURE|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
215110501|NCT03062111|PROCEDURE|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
215110502|NCT05386693|PROCEDURE|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
215110503|NCT02356289|DRUG|Placebo|
215110504|NCT02356289|DRUG|MYK-461|
215110505|NCT01320202|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
215110506|NCT01320202|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
215110507|NCT00635882|DRUG|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
215110508|NCT00635882|DRUG|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
215110509|NCT00635882|DRUG|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
215110510|NCT00635882|DRUG|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
215110511|NCT00635882|DRUG|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
215110512|NCT00635882|DRUG|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
215110513|NCT00858637|DRUG|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
215110514|NCT00858637|DRUG|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
215110515|NCT00858637|DRUG|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
215110516|NCT00858637|DRUG|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
215110517|NCT00289081|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
215110518|NCT00289081|DEVICE|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
215110519|NCT05813002|OTHER|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
214424847|NCT01257932|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
215110520|NCT05813002|OTHER|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
215110521|NCT05813002|OTHER|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
215110522|NCT02371603|DRUG|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
215110523|NCT02371603|DRUG|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
215110524|NCT02371603|DRUG|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
215110525|NCT02371603|DRUG|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
214424848|NCT00957411|BIOLOGICAL|cetuximab|Given IV
214424849|NCT00957411|DRUG|cisplatin|Given IV
214424850|NCT00360698|DRUG|Insulin Glargine|One daily injection at bedtime
214424851|NCT00360698|DRUG|Glimepiride|At same dosage as during the run-in period
214424852|NCT00360698|DRUG|Insulin Glulisine|One bolus given before the main meal
215110526|NCT05910008|PROCEDURE|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
215110527|NCT05910008|PROCEDURE|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
215110528|NCT02642380|DRUG|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
215110529|NCT02642380|DRUG|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
215110530|NCT02305238|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
215110531|NCT05836467|PROCEDURE|Valvular interventions|Any kind of intervention on heart valves
215110532|NCT03263338|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
215110533|NCT03191045|DIAGNOSTIC_TEST|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
215110534|NCT05439538|DIAGNOSTIC_TEST|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
215110535|NCT04941846|DRUG|nimodipine and euvolemia|administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration
215110536|NCT02513472|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
215110537|NCT02513472|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
215110538|NCT02748928|DEVICE|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
215110539|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
215110540|NCT03153995|PROCEDURE|soft tissue expansion|"Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months"
215110541|NCT04367090|DRUG|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
215110542|NCT04367090|DRUG|Pyrotinib|Pyrotinib 400/320 mg orally daily
215110543|NCT04083157|BIOLOGICAL|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
215110544|NCT04083157|BIOLOGICAL|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
215110545|NCT04683445|DRUG|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
215110546|NCT04683445|DRUG|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
215110547|NCT04683445|DRUG|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
214510007|NCT00682318|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
214510008|NCT00682318|DIETARY_SUPPLEMENT|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)"
214510009|NCT05561244|DEVICE|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
215110548|NCT04683445|DRUG|Pyrotinib|Pyrotinib，400mg，oral，every day
215110549|NCT04683445|DRUG|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
215110550|NCT04683445|DRUG|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
215110551|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
215110552|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
214424853|NCT00360698|DRUG|Metformin|At same dosage as during the run-in period
214424854|NCT05943171|DEVICE|Cognitive Behavioral Therapy|All participants will receive Cognitive Behavioral Therapy. They will be randomized to either Digital RITch®CBT or Standard CBT
215110553|NCT05547308|DEVICE|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
214424855|NCT03178292|DRUG|Levofloxacin|Levofloxacin 500Mg daily for 5 days
214424856|NCT03178292|DRUG|Placebo|Placebo Oral Tablet daily for 5 days
214424857|NCT00281008|DRUG|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
215110554|NCT00888342|DRUG|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
214424858|NCT00281008|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
214424859|NCT00281008|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
215110555|NCT00888342|DRUG|zopiclone|5 mg sedative given approximately 1 hour before sleep
215110556|NCT00888342|OTHER|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
215110557|NCT05351866|DEVICE|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
215110558|NCT05351866|DEVICE|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
215110559|NCT04560075|BEHAVIORAL|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
215110560|NCT04560075|BEHAVIORAL|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
215110561|NCT05311787|PROCEDURE|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
215110562|NCT02088021|DEVICE|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
215110563|NCT00325390|DRUG|clopidogrel (SR25990C)|
214424860|NCT00281008|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
215110564|NCT05504993|OTHER|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
215110565|NCT03447847|OTHER|Water|1 liter of water in meals; 1 liter out of meals
215110566|NCT02964442|OTHER|Capsinoids|12 mg of Gel capsules
215110567|NCT02964442|OTHER|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
215110568|NCT01100775|DRUG|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
214424861|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
214424862|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
214424863|NCT04425408|DEVICE|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
215028405|NCT05559047|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
214510010|NCT02553616|BEHAVIORAL|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
214510011|NCT03425461|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
214510012|NCT03425461|BIOLOGICAL|Ipilimumab|Given IV
214510013|NCT03425461|OTHER|Laboratory Biomarker Analysis|Correlative studies
214510014|NCT03425461|BIOLOGICAL|Nivolumab|Given IV
214510015|NCT03425461|OTHER|Pharmacological Study|Correlative studies
214510016|NCT04596358|OTHER|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
214510017|NCT03559452|PROCEDURE|Eccentric exercise|300 eccentric contractions of the knee extensors
215028406|NCT01334567|DRUG|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
215028407|NCT00747201|BEHAVIORAL|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
215028408|NCT00747201|BEHAVIORAL|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
215028409|NCT00945880|DRUG|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
215028410|NCT00779610|PROCEDURE|Vibration with flexion|Vibration with forearm flexion (active contraction)
215028411|NCT00779610|PROCEDURE|Vibration without flexion|Vibration without forearm flexion (passive)
215028412|NCT03914833|OTHER|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
215028413|NCT03914833|OTHER|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
215028414|NCT05985174|DIAGNOSTIC_TEST|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
215028415|NCT03163329|PROCEDURE|TAVR|Transcatheter Aortic Valve Replacement
215028416|NCT03163329|PROCEDURE|SAVR|Surgical Aortic Valve Replacement
215028417|NCT02416479|BEHAVIORAL|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
215028418|NCT02416479|BEHAVIORAL|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
215028419|NCT06569862|PROCEDURE|Postoperative day 1 dressing|The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
215028420|NCT06569862|PROCEDURE|Postoperative day 6+/-1 dressing|The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
215028421|NCT06572020|OTHER|education|simulation-based training on blood pressure and ECG measurement
215028422|NCT03827317|RADIATION|[18F]GE-226|\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
215028423|NCT06122597|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
215110569|NCT01100775|DRUG|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
215110570|NCT03803384|OTHER|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
215110571|NCT05118399|DRUG|Bupivacaine Injection [Marcaine]|Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
215110572|NCT05118399|DRUG|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
214692210|NCT05872971|DEVICE|Dry Needling|Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.
214692211|NCT05872971|DEVICE|Lasertherapy|Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
214692212|NCT02437097|OTHER|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
214692213|NCT02437097|OTHER|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
215110573|NCT04924998|DRUG|current treatment of AL-CM|current treatment of AL-CM
215110574|NCT04720742|DRUG|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
215110575|NCT03910114|DRUG|Magnevist|GBCA enhancement
215110576|NCT03910114|DRUG|Dotarem|GBCA enhancement
215110577|NCT03910114|DRUG|Gadovist|GBCA enhancement
215110578|NCT05266677|OTHER|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
215110579|NCT05266677|OTHER|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
215110580|NCT03554447|DRUG|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
215110581|NCT03554447|DRUG|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
215110582|NCT01481077|DRUG|Latanoprost-PPDS|Sustained release for 12 weeks
215110583|NCT01162915|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
215110584|NCT04623814|OTHER|Food|HEC113995 20mg will be taken orally fasted or with food
215110585|NCT04623814|DRUG|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
215110586|NCT04623814|DRUG|placebo|The placebo will be administered fasted or with food for 10 days.
215110587|NCT03227666|BEHAVIORAL|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
215110588|NCT01196832|PROCEDURE|blood sample|blood sample for fibrocytes analysis
215110589|NCT01196832|PROCEDURE|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
215110590|NCT04565951|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
215110591|NCT04565951|BEHAVIORAL|Sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
215110592|NCT03076294|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
215110593|NCT03076294|OTHER|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
215110594|NCT04165499|COMBINATION_PRODUCT|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
215110595|NCT04165499|COMBINATION_PRODUCT|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
215110596|NCT04682535|OTHER|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
215110597|NCT04677504|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
215110598|NCT04677504|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
215110599|NCT04677504|OTHER|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
215110600|NCT04677504|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
215110601|NCT04677504|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
215110602|NCT00082914|BIOLOGICAL|denileukin diftitox|
215110603|NCT01061502|DEVICE|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
215110604|NCT01061502|DEVICE|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
215110605|NCT04067414|BIOLOGICAL|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells."
215110606|NCT06447402|DRUG|Normal saline|5 mL of normal saline will be nebulised in the control arm
215110607|NCT06447402|DRUG|Amphotericin B deoxycholate|2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
215110608|NCT05018078|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
215110609|NCT03301298|DRUG|SXC-2023|Oral capsule
215110610|NCT03301298|DRUG|Placebo oral capsule|Placebo given as oral capsule.
215110611|NCT02513576|OTHER|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
215110612|NCT02186145|DRUG|Association of metronidazole; nystatin and dexamethasone|
215110613|NCT02186145|DRUG|Flagyl|Vaginal cream of metronidazole and nystatin
215110614|NCT04044742|DRUG|Resiniferatoxin|Receiving Resiniferatoxin injection
215110615|NCT04044742|DRUG|Placebo|Receiving Placebo injection
215110616|NCT03897855|OTHER|Post Traumatic Stress Disorder|"The test Think / No-Think"
215110617|NCT00066027|DRUG|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
215110618|NCT00066027|DRUG|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
215110619|NCT05914207|BEHAVIORAL|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
215110620|NCT05914207|OTHER|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
215110621|NCT04238507|DEVICE|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
215110622|NCT04238507|DEVICE|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
215110623|NCT05091125|DIAGNOSTIC_TEST|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
215110624|NCT04887987|OTHER|Pilates training + active PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
215110625|NCT04887987|OTHER|Pilates training + sham PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
215110626|NCT04887987|OTHER|Multicomponent training + active PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
215110627|NCT04887987|OTHER|Multicomponent training + sham PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
215110628|NCT05320003|DIAGNOSTIC_TEST|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
215110629|NCT05320003|DIAGNOSTIC_TEST|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
215110630|NCT05320003|DIAGNOSTIC_TEST|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
215110631|NCT03460912|DEVICE|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
215110632|NCT02978950|OTHER|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
215110633|NCT02978950|OTHER|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
215110634|NCT03771274|DEVICE|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
215110635|NCT00112125|DEVICE|OPTIMIZER System|
215110636|NCT02917395|DEVICE|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
215110637|NCT01710631|DRUG|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
215110638|NCT01710631|DRUG|placebo|placebo
215110639|NCT00778908|RADIATION|Late-course accelerated hyperfractionated IMRT|"1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
215110640|NCT00778908|DRUG|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
215110641|NCT00778908|RADIATION|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
215110642|NCT05818267|DRUG|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
215110643|NCT03668093|OTHER|ICCM|comprehensive system for caries management
215110644|NCT03668093|OTHER|CAMBRA|Caries risk assessment model
215110645|NCT04292613|OTHER|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
215110646|NCT03600532|BEHAVIORAL|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
215110647|NCT00128115|DRUG|MK0677|
215110648|NCT02133092|OTHER|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
215110649|NCT03676140|DRUG|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
215110650|NCT03676140|DRUG|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
215110651|NCT03676140|DRUG|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
215110652|NCT03676140|DRUG|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
215110653|NCT03676140|DRUG|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
215110654|NCT00167310|DRUG|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
214510018|NCT04276740|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~* MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~* MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~* MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~* MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~* Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
214510019|NCT04276740|OTHER|Placebo|Placebo
215110655|NCT00167310|DRUG|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
215110656|NCT05504005|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
215110657|NCT05684029|DEVICE|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
215110658|NCT05684029|DIAGNOSTIC_TEST|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
215110659|NCT00761722|DRUG|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
214510020|NCT00000111|PROCEDURE|Oral mucosal graft|
214510021|NCT03596697|DRUG|CRV431|Single or multiple dose(s) of CRV431
214510022|NCT03596697|DRUG|Placebo|Single Placebo dose
214510023|NCT03596697|DRUG|TDF|Single or multiple dose(s) of TDF
214510024|NCT01064778|OTHER|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
215110660|NCT04448769|BIOLOGICAL|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
215110661|NCT01178203|DRUG|Placebo|Placebo
215110662|NCT01178203|DRUG|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
215110663|NCT01178203|DRUG|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
215110664|NCT01178203|DRUG|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
215110665|NCT03543137|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
215110666|NCT03543137|DRUG|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
215110667|NCT04247295|DEVICE|Traditional Cast|Application of a traditional cast
215110668|NCT04247295|DEVICE|Woodcast|Application of a woodcast
215110669|NCT03154437|BIOLOGICAL|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
215110670|NCT00002847|BIOLOGICAL|aldesleukin|
215110671|NCT00002847|BIOLOGICAL|recombinant interferon alfa|
215110672|NCT00002847|PROCEDURE|conventional surgery|
215110673|NCT03779087|DRUG|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
215110674|NCT03779087|DRUG|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
215110675|NCT03939936|OTHER|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
215110676|NCT03939936|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
215110677|NCT03939936|OTHER|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
214510025|NCT01064778|OTHER|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
214510026|NCT03477266|DRUG|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
214692214|NCT02437097|OTHER|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
215110678|NCT00053872|DRUG|cisplatin|
214510027|NCT03477266|DRUG|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
215110679|NCT00053872|DRUG|lomustine|
215110680|NCT00053872|DRUG|vincristine sulfate|
215110681|NCT00053872|PROCEDURE|adjuvant therapy|
215110682|NCT00053872|RADIATION|radiation therapy|
215110683|NCT04481360|DEVICE|CT of the chest|Degree of affection on the lung infected by COVID19
215110684|NCT00411814|DRUG|GSK679586|Active Drug
215110685|NCT00411814|DRUG|Placebo|Saline
215110686|NCT03252002|DRUG|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
215110687|NCT03252002|DRUG|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
215110688|NCT06444802|DRUG|Linezolid|Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
215110689|NCT03876899|DIETARY_SUPPLEMENT|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
215110690|NCT03876899|DIETARY_SUPPLEMENT|Placebo|Pill
215110691|NCT04236739|DRUG|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
215110692|NCT05814952|GENETIC|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
215110693|NCT03473899|DEVICE|rESWT|"rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
215110694|NCT03473899|DEVICE|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
215110695|NCT02037906|RADIATION|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
215110696|NCT02037906|RADIATION|Constant Energy SWL|Constant dose at 20 kv
215110697|NCT02037906|RADIATION|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
215110698|NCT06070909|DEVICE|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
215110699|NCT02848391|OTHER|Environmental|hypobaric flight simulation
215110700|NCT04480632|BIOLOGICAL|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
215110701|NCT01781559|DIETARY_SUPPLEMENT|phenolic acid|phenolic acid
215110702|NCT05665907|OTHER|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
215110703|NCT01835730|DRUG|PE0139 Injection|
215110704|NCT01835730|DRUG|Placebo|
215110705|NCT05271448|OTHER|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
215110706|NCT05271448|OTHER|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
215110707|NCT01462396|DEVICE|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
214692215|NCT02437097|OTHER|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
215110708|NCT05826847|PROCEDURE|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
215110709|NCT05826847|PROCEDURE|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
215110710|NCT05826847|PROCEDURE|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
214424864|NCT05319288|DEVICE|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
215028424|NCT05552365|BEHAVIORAL|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
215028425|NCT05552365|OTHER|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
215110711|NCT05024708|OTHER|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
215110712|NCT02157077|DRUG|Aflibercept|Intravitreal Injection
215110713|NCT00571805|DRUG|varencline|2.0 mg/day varencline (1.0 mg BID)
215110714|NCT00571805|DRUG|placebo|matching placebo
214424865|NCT05709431|OTHER|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
215028426|NCT05067985|PROCEDURE|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
215028427|NCT02862262|DEVICE|ARIES Bordetella Assay|
215028428|NCT03463681|DRUG|Cabometyx|cabozantinib 60 mg orally once daily
215110715|NCT06077942|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
215110716|NCT05686564|DRUG|ALXN1840|bis-choline tetrathiomolybdate
215110717|NCT04198077|DRUG|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
215110718|NCT01799824|BIOLOGICAL|ANT-1403|
215110719|NCT01799824|BIOLOGICAL|placebo|
215110720|NCT05367843|DRUG|PRIME-2-CoV_Beta|Intramuscular (IM) injection
215110721|NCT04787354|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
215110722|NCT04787354|DRUG|Capecitabine|Capecitabine: 2,000 mg/m2/day
215110723|NCT05095350|BIOLOGICAL|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
215110724|NCT05095350|BIOLOGICAL|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
215110725|NCT03666221|DRUG|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
215110726|NCT03275038|BEHAVIORAL|Tai-Chi exercise|Behavioral: Tai-Chi exercise
215110727|NCT03275038|BEHAVIORAL|Aerobic exercise|Behavioral: Aerobic exercise
215110728|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
215110729|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
215110730|NCT01398748|DRUG|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
215110731|NCT00445770|DRUG|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
215110732|NCT00445770|DRUG|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
215110733|NCT00445770|DRUG|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
215110734|NCT03857542|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
215110735|NCT03857542|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
215110736|NCT01548196|PROCEDURE|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
215110737|NCT01301170|PROCEDURE|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
215110738|NCT03002883|BEHAVIORAL|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
215110739|NCT03002883|BEHAVIORAL|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
215028429|NCT05704088|DRUG|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
215028430|NCT05704088|DRUG|placebo|randomized control trial, control group will receive placebo tablets
215028431|NCT00027599|BIOLOGICAL|bevacizumab|
215028432|NCT00027599|BIOLOGICAL|prostatic acid phosphatase-sargramostim fusion protein|
215028433|NCT00027599|BIOLOGICAL|sipuleucel-T|
215028434|NCT00027599|BIOLOGICAL|therapeutic autologous dendritic cells|
215028435|NCT00027599|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
215028436|NCT05908760|DEVICE|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
215028437|NCT01161966|DRUG|Zonisamide|Zonisamide capsules 100 mg
215028438|NCT01161966|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
215028439|NCT00833703|DRUG|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
215028440|NCT00833703|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
215028441|NCT06363708|DRUG|Tislelizumab|Tislelizumab 200mg D1 ,Q3W
215028442|NCT06363708|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 ) D1,Q3W
215028443|NCT06363708|DRUG|Carboplatin|Carboplatin(AUC=5) D1,Q3W
215028444|NCT03960346|PROCEDURE|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
215028445|NCT00122473|DRUG|Imatinib (Glivec)|
215028446|NCT03368144|DEVICE|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
215028447|NCT01993550|BEHAVIORAL|Telephone counseling|
215028448|NCT01993550|BEHAVIORAL|Education|
215028449|NCT01784484|OTHER|No intervention|
215028450|NCT06327425|DEVICE|Magnetocardiography|Magnetocardiography
215028451|NCT06142305|PROCEDURE|DDH surgery and casting|DDH surgery and casting
215028452|NCT01904279|DRUG|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
215028453|NCT05276856|DRUG|Levothyroxine|"Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
215028454|NCT03056469|OTHER|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
215028455|NCT03583294|OTHER|MRI pelvic|Pelvic MRI
215028456|NCT03599076|OTHER|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
215110740|NCT03002883|BEHAVIORAL|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
215110741|NCT06186986|DRUG|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
215110742|NCT05820984|OTHER|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
215110743|NCT05820984|OTHER|Usual practice|Peer review as it is usual practice at the journal
215110744|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 60 degrees.
215110745|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
215110746|NCT00934128|DEVICE|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
215110747|NCT00934128|DEVICE|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
215110748|NCT05781464|PROCEDURE|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
215110749|NCT05781464|PROCEDURE|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
215110750|NCT03203434|DIAGNOSTIC_TEST|Urinary volatile organic compound analysis|
215110751|NCT01001793|DEVICE|Levacor Ventricular Assist Device|Surgical procedure
215110752|NCT02340910|PROCEDURE|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
214510028|NCT03054766|PROCEDURE|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
215110753|NCT02340910|PROCEDURE|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
215110754|NCT01985425|DRUG|Colchicine 0.6 mg|
215110755|NCT01985425|DRUG|Placebo Colchicine|
215110756|NCT02797782|OTHER|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
215110757|NCT00312026|DRUG|efalizumab|
215110758|NCT01946152|DRUG|Dexamethasone|Given PO
215110759|NCT01946152|BIOLOGICAL|Filgrastim-sndz|Given SC
215110760|NCT01946152|OTHER|Laboratory Biomarker Analysis|Correlative studies
215110761|NCT01946152|DRUG|Pomalidomide|Given PO
215110762|NCT03742583|OTHER|Square Knot|Standard square knot
215110763|NCT03742583|OTHER|RHAP Knot|Reversing half-hitch alternating post knot
215110764|NCT01867502|DRUG|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
215110765|NCT01867502|DRUG|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
215110766|NCT01698814|DRUG|AL-4943A Ophthalmic Solution|
215110767|NCT01698814|DRUG|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
215110768|NCT05168033|OTHER|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
215110769|NCT05168033|OTHER|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
215110770|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
215110771|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
215110772|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
215110773|NCT05902988|DRUG|VLS-1488|VLS-1488 tablets will be given orally.
214510029|NCT03054766|DRUG|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
214510030|NCT05636306|DRUG|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
214510031|NCT05636306|DRUG|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
215110775|NCT06278766|DRUG|ABBV-552|Oral Solution
214510032|NCT05057819|DRUG|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
215110776|NCT01186991|DRUG|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
215110777|NCT01186991|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
215110778|NCT01186991|DRUG|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
215110779|NCT01186991|DRUG|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
215110780|NCT01186991|DRUG|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
215110781|NCT02227004|DIAGNOSTIC_TEST|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
214510033|NCT05057819|DRUG|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
215110782|NCT01061359|DRUG|Epirubicin: Observational Study|Observational: Chemotherapy
215110783|NCT01182155|PROCEDURE|Exhaled Breath Sampling|Standard of care
215110784|NCT04230915|OTHER|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
215110785|NCT01975363|DIETARY_SUPPLEMENT|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
215110786|NCT01975363|OTHER|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
215110787|NCT01975363|OTHER|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
215110788|NCT01975363|OTHER|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
215110789|NCT01776034|BEHAVIORAL|SystemCHANGE Group Lifestyle counseling|
215110790|NCT01776034|BEHAVIORAL|Phone Lifestyle Counseling|
215110791|NCT02505659|BEHAVIORAL|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
215110792|NCT04014062|COMBINATION_PRODUCT|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
215110793|NCT04014062|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
215110794|NCT02737579|PROCEDURE|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
215110795|NCT02930902|DRUG|Gemcitabine Hydrochloride|Given IV
215110796|NCT02930902|OTHER|Laboratory Biomarker Analysis|Correlative studies
215110797|NCT02930902|DRUG|Nab-paclitaxel|Given IV
214510034|NCT00003599|DIETARY_SUPPLEMENT|Vitamin E (AT)|Orally daily
214510035|NCT00003599|DRUG|Isotretinoin|Orally daily
214510036|NCT00539604|PROCEDURE|MDCT and Coronary Angiography|
214510037|NCT00535626|DEVICE|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
215110798|NCT02930902|DRUG|Paricalcitol|Given IV
215110799|NCT02930902|BIOLOGICAL|Pembrolizumab|Given IV
215110800|NCT02930902|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
215110801|NCT03488966|BEHAVIORAL|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
215110802|NCT05425329|DIETARY_SUPPLEMENT|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
215110803|NCT05425329|DIETARY_SUPPLEMENT|Placebo treatment|Capsule containing maltodextrin.
215110804|NCT02637583|DRUG|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
214510038|NCT01838707|DRUG|0.125% Bupivacaine HCL @ 4-5 ml/h|
214510039|NCT01838707|DRUG|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
214510040|NCT01838707|DRUG|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
215110805|NCT02637583|DRUG|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
215110806|NCT03571126|DRUG|Olanzapine|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
215110807|NCT03571126|DRUG|Placebos|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
215110808|NCT03038126|OTHER|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
215110809|NCT03038126|OTHER|Usual care|Standard clinical care
215110810|NCT03847935|PROCEDURE|surgery|A1 pulley release of finger
215110811|NCT03847935|PROCEDURE|corticosteroid injections|corticosteroid injection to A1 pulley
215110812|NCT03847935|OTHER|Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
215110813|NCT03847935|OTHER|Modality Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
215110814|NCT01635595|PROCEDURE|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
215110815|NCT01635595|PROCEDURE|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
215110816|NCT04011657|OTHER|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
215110817|NCT03854838|DRUG|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
215110818|NCT03854838|RADIATION|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
215110819|NCT02610777|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
215110820|NCT02610777|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
215110821|NCT01724866|DRUG|SPI-2012|SPI-2012 SC injection.
215110822|NCT01724866|DRUG|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
215110823|NCT01724866|DRUG|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
215110824|NCT01724866|DRUG|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
215110825|NCT04094974|DEVICE|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
215110826|NCT02038335|DRUG|DMPA|Depot medroxyprogesterone acetate
215110827|NCT02038335|DRUG|NET-EN|Norethisterone enantate
215110828|NCT02038335|DRUG|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
215110829|NCT02038335|DEVICE|LNG-I|Levonorgestrel subdermal implant
215110830|NCT02038335|DEVICE|ENG-I|Etonogestrel subdermal implant
215110831|NCT02038335|DEVICE|Cu-IUD|Copper IUD
215110832|NCT03666871|BIOLOGICAL|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
215110833|NCT03666871|BIOLOGICAL|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
215110834|NCT05694455|DIAGNOSTIC_TEST|Starling Stroke Volume (Starling SV)- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an Starling SV device to look at Stroke Volume change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
215110835|NCT05694455|DIAGNOSTIC_TEST|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging performed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
215110836|NCT05694455|DIAGNOSTIC_TEST|Venous Excess Ultrasound Scoring (VExUS)|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the Inferior Vena Cava diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
215110837|NCT05694455|OTHER|Urine Collection|The urine assay is collected passively from the patient will be ran through a Dimethylmethylene blue (DMMB assay)- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
215110838|NCT06288048|PROCEDURE|Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|"Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization"
215110839|NCT06288048|PROCEDURE|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
215110840|NCT03032263|DEVICE|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
215110841|NCT03032263|DEVICE|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
215110842|NCT03385148|DRUG|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
215110843|NCT04724863|PROCEDURE|Angioscan|"The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination."
215110844|NCT01424501|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
215110845|NCT01424501|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
215110846|NCT01980095|DRUG|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
215110847|NCT01980095|DRUG|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
215110848|NCT06390683|OTHER|Rewilding|Yards of the assisted living centers will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
215110849|NCT02772744|DRUG|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
215110850|NCT02772744|DRUG|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
215110851|NCT02772744|DRUG|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
215110852|NCT03148041|OTHER|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2\. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
215110853|NCT03079063|BIOLOGICAL|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
215110854|NCT03079063|BIOLOGICAL|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
215110855|NCT04046146|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
215110856|NCT04046146|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
215110857|NCT00531869|BEHAVIORAL|biases towards products|
215110858|NCT01382238|DRUG|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
215110859|NCT01382238|DRUG|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
215110860|NCT00491933|PROCEDURE|Quantiferon-TB Gold assay|
215110861|NCT00491933|PROCEDURE|Tuberculin skin test|
215110862|NCT05334628|PROCEDURE|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
215110863|NCT05334628|PROCEDURE|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
215110864|NCT05873998|DIAGNOSTIC_TEST|Slow pressure-volume curve|Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
215110865|NCT04502966|BIOLOGICAL|Dupixent®|An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.
215110866|NCT04502966|BIOLOGICAL|Grazax®|"One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA."
215110867|NCT04502966|DRUG|Dupixent® Placebo|"Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient."
215110868|NCT04502966|DRUG|Grazax® Placebo|"One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units."
214510041|NCT04845542|BEHAVIORAL|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
215110869|NCT05195541|DRUG|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
215110870|NCT03974945|DEVICE|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
214510042|NCT03814226|OTHER|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
214510043|NCT05201625|DIAGNOSTIC_TEST|real time PCR|real time PCR
214510044|NCT06306937|DIAGNOSTIC_TEST|Evalution of serum levels of vitamin D and IL8|"Group 1 (Periodontitis Group): The intervention involves observing and analyzing individuals diagnosed with periodontitis based on established clinical criteria. The focus is on assessing vitamin D and IL8 levels in the serum and correlating these levels with the severity of periodontitis, determined by clinical indices such as probing depth, clinical attachment loss, and bleeding on probing.~Group 2 (Control Group): The intervention involves observing and analyzing individuals without any signs or history of periodontal disease. The focus is on assessing vitamin D and IL8 levels in the serum for comparison with the periodontitis group. This group serves as the healthy control for the study."
214510045|NCT02710669|DRUG|(R)-propafenone|
214510046|NCT02710669|DRUG|(S)-Propafenone|
214510047|NCT02710669|DRUG|Placebo|
214510048|NCT01386632|DRUG|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
214424866|NCT04088032|DRUG|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
214424867|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
214424868|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
214424869|NCT05789771|DRUG|Abemaciclib|Abemaciclib 200 mg orally every 12 hours
214424870|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status"
214424871|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
214424872|NCT01042639|BEHAVIORAL|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
214424873|NCT04414098|DRUG|INC424 / Ruxolitinib|"1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
214424874|NCT02277288|OTHER|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
214424875|NCT05816486|DIAGNOSTIC_TEST|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
214424876|NCT04062760|DRUG|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
214424877|NCT04062760|DRUG|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
214424878|NCT05142202|RADIATION|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
214424879|NCT05165082|DRUG|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
214424880|NCT05165082|PROCEDURE|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
215110871|NCT03974945|DEVICE|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
215110872|NCT06794619|DIETARY_SUPPLEMENT|Placebo|Placebo
215110873|NCT06794619|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing probiotic and prebiotic ingredients
215110874|NCT06796452|OTHER|Ribs Mobilization|Three sets of 6-8 repetitions in each session and conventional(Baseline) Physical therapy Treatment.
215110875|NCT06796452|OTHER|Conventional treatment|"* Hot pack for 8 min~* Maitland Generalized Cervical Mobilizations (6-8 REPS,3 sets)~* Isometric Strengthening Exercise"
215110876|NCT05576818|DRUG|Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers|Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
214510049|NCT01386632|DRUG|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
214510050|NCT04738370|OTHER|Sample collection|Bloods +/- urine +/- vaginal swabs taken
214510051|NCT03062488|DRUG|IV acetaminophen|multi-modal analgesia with IV acetaminophen
214510052|NCT03062488|DRUG|Fentanyl|single modal analgesia
215110877|NCT02983461|DRUG|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
215110878|NCT02983461|DRUG|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
215110879|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
215110880|NCT06476548|DEVICE|EMI|Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
215110881|NCT06184503|DRUG|Velmanase Alfa|Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
215110882|NCT05384015|DRUG|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
215110883|NCT05384015|DRUG|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
215110884|NCT05384015|DRUG|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
215110885|NCT05384015|DRUG|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
215110886|NCT05878054|OTHER|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
215110887|NCT03274414|DRUG|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
215110888|NCT03274414|RADIATION|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
215110889|NCT03274414|PROCEDURE|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
215110890|NCT03274414|DRUG|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
215110891|NCT03262168|OTHER|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
215110892|NCT02092792|DRUG|DLYE5953A|Escalating doses of DLYE5953A
215110893|NCT02092792|DRUG|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
215110894|NCT00398567|DRUG|HKI-272|HKI-272 by mouth
214424881|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
214424882|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
215110895|NCT00398567|DRUG|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
215110896|NCT02837029|OTHER|Laboratory Biomarker Analysis|Correlative studies
215110897|NCT02837029|BIOLOGICAL|Nivolumab|Given IV
215110898|NCT02837029|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
215110899|NCT02397538|DRUG|Fimasartan|
215110900|NCT02397538|DRUG|Amlodipine|
215110901|NCT02397538|DRUG|Rosuvastatin|
215110902|NCT06304623|BIOLOGICAL|Autologous adipose-derived SVF IV administration|Subjects received an intravenous injection of autologous adipose-derived SVF.
215110903|NCT01969695|DRUG|ABT-199|ABT-199 continuous once daily dosing
215110904|NCT04108611|PROCEDURE|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
215110905|NCT02034877|BIOLOGICAL|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
215110906|NCT02034877|PROCEDURE|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
215110907|NCT05408715|OTHER|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
214424883|NCT01059877|DEVICE|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
215110908|NCT00526591|DRUG|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
215110909|NCT00526591|PROCEDURE|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
215110910|NCT04426318|BEHAVIORAL|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
214424884|NCT01059877|DEVICE|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
214510053|NCT03062488|DRUG|PO acetaminophen|multi-modal analgesia with PO acetaminophen
214510054|NCT02014402|BIOLOGICAL|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
214510055|NCT02014402|BIOLOGICAL|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
214510056|NCT03463291|DEVICE|MRI|"* T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
214510057|NCT02297464|OTHER|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
214510058|NCT02297464|OTHER|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
214510059|NCT03105024|OTHER|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
215110911|NCT04395079|BIOLOGICAL|Durvalumab|Given IV
215110912|NCT04395079|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
215110913|NCT04395079|BIOLOGICAL|Tremelimumab|Given IV
215110914|NCT05205291|DRUG|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
215110915|NCT05205291|RADIATION|PET/MR with [11C]PBR28|A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
215110916|NCT03750227|PROCEDURE|Conventional Surgery|Undergo surgery
215110917|NCT03750227|OTHER|Questionnaire Administration|Ancillary studies
215110918|NCT03750227|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
215110919|NCT03750227|PROCEDURE|Computed Tomography|Undergo CT
215110920|NCT03750227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215110921|NCT03750227|PROCEDURE|Biospecimen Collection|Undergo blood sample, tissue and CSF sample collection
215110922|NCT04075981|DRUG|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
215110923|NCT04075981|OTHER|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
214510060|NCT03105024|OTHER|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
214510061|NCT01985945|OTHER|Yoga|
214510062|NCT03650972|OTHER|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
214510063|NCT03684772|DRUG|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
214510064|NCT03684772|DRUG|Furosemide Topical Gel|Furosemide (0.125%)
214692216|NCT06065527|BEHAVIORAL|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
215110924|NCT04168372|OTHER|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
215110925|NCT04168372|OTHER|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
215110926|NCT04168372|OTHER|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
215110927|NCT04168372|OTHER|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
215110928|NCT06448026|DRUG|Cemiplimab|Given by IV
215110929|NCT06448026|DRUG|Cetuximab|Given by IV
215110930|NCT05949957|BEHAVIORAL|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
215110931|NCT05949957|BEHAVIORAL|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
215110932|NCT05949957|BEHAVIORAL|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
214510065|NCT03684772|DRUG|Digoxin Topical Gel|Digoxin (0.125%)
214510066|NCT03684772|DRUG|Vehicle Topical Gel|Vehicle Gel
214510067|NCT05228964|DEVICE|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
214510068|NCT04823078|OTHER|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
214510069|NCT04823078|OTHER|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
214510070|NCT04156256|BIOLOGICAL|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
214510071|NCT02542202|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
214510072|NCT04785261|DRUG|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
214510073|NCT04785261|DRUG|Carbomer|1 drip each time, at bedtime, for 12 weeks.
214510074|NCT04785261|DRUG|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
214510075|NCT05313477|DRUG|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
214510076|NCT05313477|DRUG|Calcium carbonate|1000mg of Calcium carbonate daily
214510077|NCT04768556|OTHER|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
214510078|NCT04768556|OTHER|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
214510079|NCT02312544|DRUG|OTX-TP|OTX-TP and placebo drops
214510080|NCT02312544|DRUG|Timolol|Timolol drops and placebo punctum plug
214510081|NCT06152497|DRUG|Placebo|Oral placebo
214510082|NCT06152497|DRUG|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
214510083|NCT06152497|BEHAVIORAL|Resistance training|Resistance training: lower body exercise
214510084|NCT06113393|PROCEDURE|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
215110933|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
215110934|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
215110935|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
214510085|NCT06093451|DRUG|Dexmedetomidine|Moderate agitation: 120 mcg Severe agitation: 180 mcg
214510086|NCT06093451|DRUG|Lorazepam 2 MG/ML|2 mg
214510087|NCT04674605|DEVICE|biomarkers|biomarkers
214510088|NCT02642640|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
214692217|NCT06065527|BEHAVIORAL|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
214692218|NCT01125176|DRUG|thalidomide|50 mg oral dosing every other day
215110936|NCT06378957|DRUG|D-Limonene|Oral Limonene administered via capsule
215110937|NCT06378957|DRUG|Delta-9-THC|Oral delta-9-THC in ethanol vehicle administered via capsule
215110938|NCT06378957|DRUG|Placebo|Placebo (cellulose) administered via capsule
215110939|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
215110940|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
215110941|NCT05613257|DEVICE|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
215110942|NCT05613257|PROCEDURE|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
215110943|NCT05380505|BEHAVIORAL|Racially Congruent Ads|Facebook food ads that are racially congruent.
215110944|NCT05380505|BEHAVIORAL|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
215110945|NCT00390039|DRUG|Intranasal Morphine|MNS075 7.5mg q1h PRN
215110946|NCT00390039|DRUG|Placebo|IN Placebo q1h PRN
215110947|NCT00390039|DRUG|IV morphine|IV morphine 7.5mg q3h PRN
215110948|NCT00390039|DRUG|Placebo|IV Placebo q3h PRN
215110949|NCT00390039|DRUG|Intranasal morphine|MNS075 15mg q3h PRN
214692219|NCT01125176|DRUG|lenalidomide|varying oral doses every other day (max 25 mg/day)
215110950|NCT00390039|DRUG|Placebo|IN Placebo q3h PRN
215110951|NCT04054141|DEVICE|Mag Stim|rTMS
215110952|NCT00192816|BEHAVIORAL|reaction to pain|
214510089|NCT02642640|DRUG|placebo|
214510090|NCT03493282|DRUG|Active Treatment- CT1812 100 mg|CT1812
214510091|NCT03493282|DRUG|Active Treatment- CT1812 300 mg|CT1812
214510092|NCT03493282|DRUG|Placebo|Matching Placebo
214510093|NCT04580732|DEVICE|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
214692220|NCT01125176|BIOLOGICAL|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
214510094|NCT02333747|DEVICE|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
214510095|NCT00070707|DRUG|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
214510096|NCT00070707|DRUG|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
214692221|NCT01373567|DRUG|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
214692222|NCT01096082|DRUG|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
214692223|NCT01096082|DRUG|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
215110953|NCT01647893|DRUG|CTB-001|IV bolus or IV infusion
215110954|NCT03653143|BEHAVIORAL|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
215110955|NCT00783614|DRUG|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
215110956|NCT00783614|DRUG|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
215110957|NCT00694018|OTHER|Education and standard care|Educational program for individuals with chronic back pain.
215110958|NCT00694018|BEHAVIORAL|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
215110959|NCT01331980|DEVICE|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
215110960|NCT01331980|DEVICE|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
215110961|NCT01564732|DEVICE|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
215110962|NCT01564732|DEVICE|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
215110963|NCT01159015|DRUG|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
215110964|NCT01159015|DRUG|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
215110965|NCT03139123|OTHER|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
215110966|NCT01036321|DRUG|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
214510097|NCT00070707|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
214510098|NCT04859465|DRUG|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
214510099|NCT04475874|OTHER|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
215110967|NCT01036321|DRUG|Methyl cellulose blend|Placebo - Take 2 capsules daily
215110968|NCT01351116|RADIATION|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
215110969|NCT01351116|RADIATION|EBR|EBR of 20 Gy in 5 daily fractions over one week
215110970|NCT01425125|DRUG|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
215110971|NCT01957202|DRUG|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
215110972|NCT01957202|DRUG|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
215110973|NCT01957202|DRUG|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
215110974|NCT01957202|DRUG|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
215110975|NCT00838240|DRUG|clofarabine|Given IV
215110976|NCT00838240|DRUG|cytarabine|Given IV
215110977|NCT00838240|DRUG|idarubicin|Given IV
215110978|NCT01942174|BIOLOGICAL|Prevenar 13|Vaccination at the beginning of the study (day 0)
215110979|NCT01942174|BIOLOGICAL|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
215110980|NCT01942174|DRUG|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
215110981|NCT01942174|DRUG|Methotrexate - Delay|"For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13"
215110982|NCT05550935|DEVICE|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
215110983|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
215110984|NCT04808141|OTHER|Conventional physical therapy|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled physical therapy sessions.
215110985|NCT00381693|DRUG|azacitidine|
215110986|NCT01671033|BEHAVIORAL|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
215110987|NCT01671033|BEHAVIORAL|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
215110988|NCT03120130|BIOLOGICAL|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
215110989|NCT06237400|DRUG|ZG19018|ZG19018 Given by PO (mouth)
215110990|NCT02766712|PROCEDURE|Pace During 1st Half of Lesion|
215110991|NCT02766712|PROCEDURE|Pace During 2nd Half of Lesion|
215110992|NCT04677010|OTHER|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
215110993|NCT05761990|OTHER|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
215110994|NCT05761990|OTHER|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
215110995|NCT05596604|OTHER|survey- no intervention|survey- no intervention
215110996|NCT04054076|DEVICE|Prefabricated insoles|The participants received prefabricated insoles
215110997|NCT04054076|DEVICE|Soft custom-made insoles|The participants received soft custom-made insoles
215110998|NCT04054076|DEVICE|Hard custom-made insoles|The participants received hard custom-made insoles
215110999|NCT00345865|DRUG|carmustine|Day -6, 300 mg/m\^2 over 2 hour
215111000|NCT00345865|DRUG|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
215111001|NCT00345865|DRUG|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
215111002|NCT00345865|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
214510100|NCT04475874|OTHER|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
214510101|NCT06584955|OTHER|Weighted Blanket|Participants will be given a weighted blanket
214510102|NCT01523392|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
215111003|NCT00345865|RADIATION|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."
215111004|NCT00345865|BIOLOGICAL|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."
215111005|NCT00345865|DRUG|Cytarabine|100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
215111006|NCT06135935|OTHER|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
215111007|NCT06135935|OTHER|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
215111008|NCT00005024|DRUG|carboplatin|
215111009|NCT00005024|DRUG|cyclophosphamide|
215111010|NCT00005024|DRUG|doxorubicin hydrochloride|
215111011|NCT00005024|DRUG|granisetron hydrochloride|
215111012|NCT05771740|DEVICE|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
215111013|NCT02553395|DEVICE|Phenacite (Test) contact lens|
215111014|NCT02553395|DEVICE|comfilcon A contact lens|
215111015|NCT02159976|DRUG|Pantoprazole|Pantoprazole 40mg bid
215111016|NCT02159976|DRUG|Amoxicillin|Amoxicillin 1000mg bid
215111017|NCT02159976|DRUG|Clarithromycin|Clarithromycin 500mg bid
214510103|NCT01523392|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
215111018|NCT02159976|DRUG|Metronidazole|Metronidazole 500mg tid
215111019|NCT02159976|DRUG|Tetracycline|Tetracycline 1000mg bid
215111020|NCT02159976|DRUG|Bismuth|Bismuth 600mg bid
215111021|NCT04517565|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
214510104|NCT00893100|DRUG|Diltiazem|2%,3 times daily
215111022|NCT04517565|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
215111023|NCT04576026|BEHAVIORAL|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
215111024|NCT04576026|BEHAVIORAL|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
215111025|NCT04576026|BEHAVIORAL|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
215111026|NCT05044858|PROCEDURE|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
215111027|NCT05044858|PROCEDURE|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
215111028|NCT03045523|DRUG|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
215111029|NCT03045523|DRUG|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
215111030|NCT03045523|DRUG|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
215111031|NCT00972725|BIOLOGICAL|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
214510105|NCT03462966|DRUG|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
214510106|NCT02239991|PROCEDURE|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
214510107|NCT02301507|BEHAVIORAL|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
214692224|NCT05155696|DIETARY_SUPPLEMENT|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
215111032|NCT00972725|DRUG|Chloroquine|One dose of 300 mg
215111033|NCT05876468|DEVICE|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~* First CACC : the applied pressure is equal to the one observed in the prone position~* Second CACC : The applied pressure is set at 60 - 80 cmH20"
215111034|NCT00248586|BEHAVIORAL|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
215111035|NCT00248586|BEHAVIORAL|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
215111036|NCT05900232|DIAGNOSTIC_TEST|Anti _KU antibodies|aim of the work is to determine the relationship between Anti\_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
215111037|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
215111038|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
215111039|NCT03549377|BEHAVIORAL|Deception|Participants will be deceived during delayed gratification task.
215111040|NCT00694668|BEHAVIORAL|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
215111041|NCT00694668|BEHAVIORAL|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
215111042|NCT02548338|PROCEDURE|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
215111043|NCT04853719|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
215111044|NCT03936257|OTHER|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
215111045|NCT03936257|OTHER|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
215111046|NCT03936257|OTHER|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
215111047|NCT04459871|BIOLOGICAL|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
215111048|NCT04459871|BIOLOGICAL|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
215111049|NCT03202719|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
215111050|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
215111051|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
215111052|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
215111053|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
215111054|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
215111055|NCT01330329|BEHAVIORAL|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
215111056|NCT01330329|BEHAVIORAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
215111057|NCT04703764|DRUG|HSG4112|Once-daily, 14-day multiple oral administration
215111058|NCT04703764|DRUG|Placebo|Once-daily, 14-day multiple oral administration
215111059|NCT00529425|DRUG|Ropivacaine|
215111060|NCT03523767|BIOLOGICAL|S.typhi Injection|0.5 ml of S.typhi injection
215111061|NCT03523767|BIOLOGICAL|Normal Saline Injection|0.5 ml of normal saline injection
215111062|NCT02144857|DRUG|etanercept|50 mg
215111063|NCT02144857|DRUG|ustekinumab|45 mg
215111064|NCT02144857|DRUG|cyclosporine|Cyclosporine 2.5-3 mg/kgr
215111065|NCT02144857|DRUG|Secukinumab|300 mg
215111066|NCT02144857|DRUG|Apremilast|30mg
215111067|NCT01004289|PROCEDURE|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
215111068|NCT01004289|PROCEDURE|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
215111069|NCT00351910|DRUG|Quetiapine|
215111070|NCT00351910|DRUG|Amitriptyline|
215111071|NCT00351910|DRUG|Bupropion|
215111072|NCT00351910|DRUG|Citalopram|
215111073|NCT00351910|DRUG|Duloxetine|
215111074|NCT00351910|DRUG|Escitalopram|
215111075|NCT00351910|DRUG|Fluoxetine|
215111076|NCT00351910|DRUG|Paroxetine|
215111077|NCT00351910|DRUG|Sertraline|
215111078|NCT00351910|DRUG|Venlafaxine|
215111079|NCT01854034|DRUG|AUY922|AUY922 administered intravenously once a week at 70mg/m2
215111080|NCT02036125|DEVICE|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
215111081|NCT02036125|DRUG|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
215111082|NCT06029049|DRUG|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
215111083|NCT06029049|DRUG|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
215111084|NCT04590573|BEHAVIORAL|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
215111085|NCT05431504|DRUG|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
215111086|NCT00973687|DRUG|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
215111087|NCT00973687|DRUG|Dexamethasone|
215111088|NCT01922271|DRUG|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
215111089|NCT01922271|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
215111090|NCT01922271|DRUG|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
215111091|NCT01922271|DRUG|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
215111092|NCT01922271|DRUG|Salbutamol|Used as resuce medication
215111093|NCT05933668|BIOLOGICAL|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
215111094|NCT01103570|PROCEDURE|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
215111095|NCT01103570|PROCEDURE|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
215111096|NCT00260624|DRUG|Escitalopram (Lexapro)|
215111097|NCT04471506|OTHER|interval training|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
215111098|NCT04471506|OTHER|diet recommendations|the control group will follow diet recommendations for 12 weeks
215111099|NCT04471506|OTHER|mindfulness breathing|Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
215111100|NCT06412783|DIAGNOSTIC_TEST|blood test|performing blood tests on the participants for specific markers.
215111101|NCT03276897|OTHER|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
215111102|NCT00632619|BEHAVIORAL|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
215111103|NCT00632619|DRUG|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
215111104|NCT00632619|BEHAVIORAL|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
214692225|NCT05155696|DIETARY_SUPPLEMENT|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
214692226|NCT01131221|OTHER|laboratory biomarker analysis|
214692227|NCT04058054|DEVICE|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
215111105|NCT05541575|OTHER|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
215111106|NCT06206915|DRUG|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
215111107|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
215111108|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
215111109|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
215111110|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
215111111|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
215111112|NCT05703581|PROCEDURE|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
215111113|NCT06557239|DRUG|Lysergic Acid Diethylamide (LSD)|one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
215111114|NCT05490030|DRUG|TNO155|Single oral dose of TNO155 on Day 1
215111115|NCT00836186|RADIATION|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
215111116|NCT06419504|OTHER|SAP block group|US-guided SAP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
215111117|NCT06419504|OTHER|PECS II block group|US-guided PECS II block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
215111118|NCT06419504|OTHER|ESP block group|US-guided ESP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
215111119|NCT06419504|OTHER|Control group|No intervention
215111120|NCT00147121|DRUG|Rituximab + Standard CHOP|Rituximab + Standard CHOP
215111121|NCT00147121|DRUG|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
215111122|NCT02203994|DEVICE|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
215111123|NCT02954614|BEHAVIORAL|Active play in after school programs (ASP)|"* A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
215111124|NCT03864302|BEHAVIORAL|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
215111125|NCT02923856|DEVICE|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
215111126|NCT02923856|DEVICE|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
215111127|NCT02923856|DEVICE|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
215111128|NCT01865643|DEVICE|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
215111129|NCT03475589|DRUG|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
215111130|NCT03854513|DEVICE|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
215111131|NCT04406649|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
215111132|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
215111133|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
215111134|NCT04806737|DRUG|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
215111135|NCT02576795|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
215111136|NCT04742361|DRUG|[18F]PSMA-1007|diagnostic radiopharmaceutical for PET scan
215111137|NCT06540794|OTHER|PEEP TITRATION|Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
215111138|NCT05650905|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
215111139|NCT05650905|DEVICE|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
215111140|NCT05650905|DEVICE|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
215111141|NCT05650905|DEVICE|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
215111142|NCT05650905|DIAGNOSTIC_TEST|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
215111143|NCT02032225|OTHER|Skin biopsy|
215111144|NCT06967792|DEVICE|Terahertz (THz) scanning using THz Imaging system.|The Terahertz (THz) scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
215111145|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
215111146|NCT05759858|OTHER|None of intervention|None of the interventions was applied.
215111147|NCT03301610|OTHER|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
215111148|NCT03301610|OTHER|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
215111149|NCT05799066|DIAGNOSTIC_TEST|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
215111150|NCT05799066|DIAGNOSTIC_TEST|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
215111151|NCT04210622|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
215111152|NCT02284087|DEVICE|PAS|
215111153|NCT05232864|DRUG|Secukinumab|300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
215111154|NCT06976372|DRUG|AMG 133|AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.
214692228|NCT04058054|DEVICE|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
215111155|NCT06975241|DIETARY_SUPPLEMENT|EPA 2.4g/day|EPA from fish oil will be supplemented to an equal number of males and females for 12 weeks.
215111156|NCT06974708|OTHER|Home Healthcare Virtual Simulation Training System|Interactive Virtual Occupational Safety Training Software Program for Home Healthcare Workers and Agencies
215111157|NCT06974812|DRUG|IBI3014|12 mg/kg D1 IV Q3W
215111158|NCT06974812|DRUG|IBI3014|6 mg/kg D1 IV Q3W
215111159|NCT06974812|DRUG|IBI3014|1 mg/kg D1 IV Q3W
215111160|NCT06974812|DRUG|IBI3014|15 mg/kg D1 IV Q3W
215111161|NCT06974812|DRUG|IBI3014|9 mg/kg D1 IV Q3W
215111162|NCT06974812|DRUG|IBI3014|3 mg/kg D1 IV Q3W
214692229|NCT04058054|DEVICE|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
215111164|NCT06974578|PROCEDURE|phacoemulsification|cataract extracton with phacoemulsification
215111165|NCT06974578|DEVICE|CTR|insertion of capsualr tension ring
215111166|NCT06974578|DEVICE|hydrophilic IOL|implantation of hydrophilic IOL
215111167|NCT06974578|DEVICE|Hydrophobic IOL|insertion of hydrophobic IOL
215111168|NCT06976333|DIAGNOSTIC_TEST|Tumor-infliltrating lymphocyte (TIL) percentage|TIL percentage was calculated as the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]
215111169|NCT06976333|DIAGNOSTIC_TEST|Grey level co-occurrence matrix (GLCM)|The GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterized more structured images with distinct TIL patterns.
215111170|NCT06976333|DIAGNOSTIC_TEST|Fractal dimension (FD)|Quantification of the complexity of TIL
215111171|NCT05723263|BEHAVIORAL|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
215111172|NCT05723263|BEHAVIORAL|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
215111173|NCT05723263|OTHER|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 U.S. Dollars (USD) per test) and no community engagement component
215111174|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
215111175|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
215111176|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
215111177|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
215111178|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
215111179|NCT01870505|DRUG|BYL719|
215111180|NCT01870505|DRUG|Letrozole|
215111181|NCT01870505|DRUG|Exemestane|
215111182|NCT06975787|DRUG|Vonsetamig|Administered as per the protocol
215111183|NCT06974669|DRUG|oral steroid-dexamethasone|this study is the first according to the best of our knowledge assessing the value of adding mini oral pulse steroid therapy to non cultured epidermal suspension in treatment of stable acral and difficult to treat vitiligo
215111184|NCT06974669|PROCEDURE|non cultured epidermal suspension|this is the best surgical technique for surgical treatment of vitiligo that would be done for both arms
215111185|NCT06975111|DRUG|Metformin|Metformin will be given to participants who have a elevated HbA1c and also for weightloss.
215111186|NCT06975111|DRUG|semaglutide|Overweight women and women with obesity will take Semaglutide for weight-loss
215111187|NCT06975111|DRUG|Anti-hypertensives|a. Antihypertensives, with the goal of maintaining blood pressure at 130/80 or lower per ACC guidelines19. Per current clinical guidelines and standard of care, hypertension will be treated first with monotherapy using either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium channel blocker, or a thiazide diuretic provided that are no contraindications.
215111188|NCT06975111|DRUG|Lipid Lowering Medication|. First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.
215111189|NCT06975111|BEHAVIORAL|Life style intervention|will simply be followed and given preventive advice (maintenance of a normal BMI and physical activity, moderation in salt intake, and no more than 1 alcoholic drink per day). They will be provided with a wearable activity monitor. This advice will be based on guidelines by the American Heart Association and the Menopause Society.
215111190|NCT06975111|DRUG|Fezolinetant|Women with menopausal symptoms will be treated with hormone therapy (estrogen and progesterone) if appropriate, or with a neurokinin receptor antagonist (Fezolinetant). This can be treatment for women in any arm of the study as well as an arm by its self.
215111191|NCT06975111|DRUG|Hormonal therapy|Participants will be treated with estrogen and/or progesterone for treatment of hot flashes in women during the study.
215111192|NCT00870987|BIOLOGICAL|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
215111193|NCT00870987|BIOLOGICAL|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
215111194|NCT03812315|COMBINATION_PRODUCT|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
215111195|NCT03812315|COMBINATION_PRODUCT|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
215111196|NCT06009835|OTHER|Recommended treatment plan|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
215111197|NCT03427723|DEVICE|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
215111198|NCT03427723|OTHER|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
215111199|NCT03667469|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
215111200|NCT03667469|DIETARY_SUPPLEMENT|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
215111201|NCT04067609|DRUG|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
215111202|NCT04067609|OTHER|placebo|100mL of normal saline (placebo)
215111203|NCT04765202|PROCEDURE|AG Tx|Control treatment that is meshed autograft alone applied to a burn area.
215111204|NCT04765202|BIOLOGICAL|SOMA Tx|Meshed autograft applied to the burn area and covered with StrataGraft.
215111205|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
215111206|NCT06356922|DRUG|Experimental drug [177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
215111207|NCT06975995|DIETARY_SUPPLEMENT|Yi'en Yuan Honey Fermented Drink|The oral postbiotics product used in the trial is called Yi'en Yuan Honey Fermented Drink. The product is made from water, edible brown sugar, and honey as raw materials. It is fermented by a mixture of plant lactic acid bacteria and coagulating Bacillus, and then inactivated at high temperature. The product meets the food and beverage standard. Participants will receive the product for 150ml per day.
215111208|NCT06975124|DEVICE|transcutaneous auricular vagus nerve stimulation|Ear clip electrodes attached to the left cymba conchae to target vagus nerve branches.
215111209|NCT06975124|DEVICE|Sham condition|Electrode placement attached on the left earlobe.
215111210|NCT06976996|DRUG|normal saline|normal saline (0.15 ml/kg)
215111211|NCT06976996|DRUG|esketamine|esketamine (0.15 mg/kg)
215111212|NCT06976996|DRUG|propofol|propofol (2 mg/kg)
215111213|NCT06976996|DRUG|etomidate-ciprofol (EC) mixture|etomidate-ciprofol (EC) mixture (0.2 ml/kg)
214510108|NCT02169609|DRUG|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
214510109|NCT02002689|DRUG|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
215111214|NCT06976996|DRUG|ciprofol|ciprofol (0.5 mg/kg)
215111215|NCT06976996|DRUG|etomidate-propofol (EP) mixture|etomidate-propofol (EP) mixture (0.2 ml/kg)
215111216|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
215111217|NCT06975202|OTHER|No intervention|No intervention
215111218|NCT06975709|OTHER|Questionnaire and Physical Exam|"The diagnostic questionnaires will be administered and the participants' responses will subsequently be analyzed, evaluating the presence of temporomandibular disorders (DTMs) in patients with sleep disorders.~The questionnaires will be administered to patients with a previous diagnosis of sleep disorder carried out at a specialist centre, consecutively belonging to the outpatient clinics of both centers U.O of Neurology-Sleep Disorders Center and U.O of Dentistry."
215111219|NCT06976489|DRUG|PA-111|PA-111 1Tab., Per Oral
215111220|NCT04459468|DRUG|Lipiodol|Lipiodol TACE procedure
215111221|NCT06594198|DEVICE|Cerebral monitor|The study procedure consists of monitoring the values of 3 cerebral parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor. These 3 parameters will be recorded and compared after the intervention with 3 parameters considered as standard: SctO2 measured by the INVOS 7100 cerebral oximeter, the bispectral index (BIS) measured by the BIS monitor and the ANI measured by the MDoloris monitor. These 3 reference parameters are once again usually monitored and recommended for all cardiac surgery.
215111222|NCT04283097|DRUG|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
215111223|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
215111224|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
215111225|NCT04140045|OTHER|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
215111226|NCT01224366|DRUG|Vildagliptin|
215111227|NCT01224366|DRUG|Placebo|
215111228|NCT05370443|BEHAVIORAL|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
215111229|NCT02687139|DRUG|18F-DCFPyL|
214510110|NCT04330612|OTHER|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
214510111|NCT04524676|PROCEDURE|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
215111230|NCT02687139|PROCEDURE|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
215111231|NCT05010603|GENETIC|Blood Draw|Collection of blood samples for genetic testing
215111232|NCT05010603|OTHER|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
215111233|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
214510112|NCT01377844|DRUG|EGT0001442|
214510113|NCT01377844|DRUG|Placebo|
214510114|NCT00009763|BIOLOGICAL|filgrastim|
215111234|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
215111235|NCT06658132|DRUG|0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.|Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
214510115|NCT00009763|BIOLOGICAL|monoclonal antibody m170|
214510116|NCT00009763|DRUG|cyclosporine|
214510117|NCT00009763|DRUG|paclitaxel|
215111236|NCT03591315|DIAGNOSTIC_TEST|resting state fMRI|Define the visual resting state network.
215111237|NCT03591315|DIAGNOSTIC_TEST|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
215111238|NCT03591315|DIAGNOSTIC_TEST|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
215111239|NCT03591315|DIAGNOSTIC_TEST|automated visual field|Identify the existence and type of visual field defect.
215111240|NCT03591315|DIAGNOSTIC_TEST|visual acuity|Assess the visual acuity by using ETDRS scales.
215111241|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
215111242|NCT06350123|DRUG|Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
215111243|NCT06350123|DRUG|Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
215111244|NCT06350123|DRUG|Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
215111245|NCT01635855|DEVICE|Belotero®|Hyaluronic acid dermal filler
215111246|NCT06340672|OTHER|Augmented Reality Enhanced Preoperative Counseling|For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.
215111247|NCT06340672|OTHER|Standard preoperative counseling|Control patients will undergo standard preoperative counseling.
215111248|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
215111249|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
215111250|NCT04203004|PROCEDURE|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
215111251|NCT04174196|DRUG|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
215111252|NCT04174196|DRUG|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
215111253|NCT04174196|RADIATION|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
214510118|NCT00009763|PROCEDURE|peripheral blood stem cell transplantation|
214510119|NCT00009763|RADIATION|yttrium Y 90 monoclonal antibody m170|
214510120|NCT00612521|DRUG|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
214510121|NCT00972036|DEVICE|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
215111254|NCT06600581|BIOLOGICAL|IMM01-STEM|IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
215111255|NCT06600581|OTHER|Placebo|Saline. This intervention is given 2mL twice a week.
215111256|NCT06600581|BIOLOGICAL|IMM01-STEM alternating with placebo (saline)|This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
215111257|NCT05803720|BEHAVIORAL|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
215111258|NCT06170372|DRUG|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
215111259|NCT06170372|DRUG|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
215111260|NCT06129903|OTHER|referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.|The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
215111261|NCT06921993|DIAGNOSTIC_TEST|LUNG ULTRASOUND|"All subjects randomly assigned to the investigational arm will undergo lung ultrasound (LUS) .~Ultrasound still images and ultrasound clips will be acquired according to the study protocol. Detailed methodology of the ultrasound examination and parameters is provided as appendix to the study protocol"
215111262|NCT03922893|OTHER|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
215111263|NCT03922893|GENETIC|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
215111264|NCT03922893|GENETIC|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
215111265|NCT03922893|OTHER|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
215111266|NCT03711760|BEHAVIORAL|telepsychology|CBT delivered by telepsychology
215111267|NCT05399212|DRUG|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
215111268|NCT06863194|DRUG|Probiotic Supplementation (Lactobacillus plantarum)|"Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. The dose is one tablet daily for 6 months.~This probiotic is intended to modulate gut microbiota, reduce systemic inflammation, and decrease uremic toxins (indoxyl sulfate) in CKD patients. The intervention will be compared to a placebo to evaluate its effectiveness in slowing CKD progression and improving metabolic and inflammatory markers."
215111269|NCT06863194|DRUG|Placebo Tablets|"Participants in this group will receive an inert placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. The dose is one tablet daily for 6 months.~The placebo serves as a control to compare the effects of the probiotic intervention. Both groups will undergo identical monitoring and follow-up assessments to determine whether the probiotic has a significant effect on kidney function, inflammation, and gut microbiota composition."
215111270|NCT00998088|OTHER|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
215111271|NCT00998088|DRUG|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
215111272|NCT00998088|DEVICE|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
215111273|NCT00998088|DEVICE|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
215111274|NCT00998088|OTHER|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
215111275|NCT00998088|OTHER|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
215111276|NCT00998088|DEVICE|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
214510122|NCT01331278|PROCEDURE|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
215111277|NCT06977022|DEVICE|Chest wall reconstruction|Extended resection of chest wall tumors with subsequent biodegradable polycaprolactone (PCL) 3D-printed rib prosthetic reconstruction
215111278|NCT06725238|OTHER|Acute-to-chronic glycemic ratio|This ratio could be related to diabetic foot ulcer
215111279|NCT06725589|OTHER|metabolic disease|metabolic disease
215111280|NCT06727292|DIETARY_SUPPLEMENT|Food supplement|Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).
215111281|NCT06727292|DIETARY_SUPPLEMENT|Placebo|Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
215111282|NCT06726213|OTHER|Walk and talk|An hour long walk at a slow pace lead by a trained walking leader.
214510123|NCT01331278|PROCEDURE|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
215111283|NCT06725134|BEHAVIORAL|Therapy dog presence|A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
215111284|NCT06725134|BEHAVIORAL|Standard-of-care basic behavior guidance|Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
215111285|NCT07048132|DIAGNOSTIC_TEST|Headache Screening Questionare|"The Headache Screening Questionnaire (HSQ) is a 10-item tool developed to screen for migraine and tension-type headache (TTH), based on the ICHD-3 beta criteria.~Each item reflects a diagnostic criterion for migraine or TTH. Participants complete the HSQ and are also evaluated by a neurologist for diagnosis.~A score of 6 or higher suggests probable migraine or probable TTH."
215111286|NCT07046702|DIAGNOSTIC_TEST|68Ga-MY6349|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
214510124|NCT05190224|OTHER|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
214510125|NCT02638558|OTHER|written + oral explanation|
215111287|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
215111288|NCT06893068|DEVICE|AI-based clinical intelligent management system|The clinical intelligent management system, integrated with AR glasses and powered by a multimodal foundational model, is designed to improve the quality of outpatient care at community health service centers.
215111289|NCT06526819|DRUG|SMP3124LP|Liposomal encapsulation formulation of SMP-3124
215111290|NCT06714851|DIETARY_SUPPLEMENT|Chondractiv Move|The dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day.
215111291|NCT06714851|OTHER|Placebo|Placebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day.
215111292|NCT06897241|OTHER|Resistant starch|Participants will consume 80 grams of carbohydrates from resistant starch during the meal challenges and two times daily during the 14-day intervention period
215111293|NCT06897241|OTHER|Slow digestible starch|Participants will consume 80 grams of carbohydrates from slow digestible starch during the meal challenges and two times daily during the 14-day intervention period
215111294|NCT06897241|OTHER|Rapid digestible starch|Participants will consume 80 grams of carbohydrates from rapid digestible starch during the meal challenges and two times daily during the 14-day intervention period
215111295|NCT03828019|BIOLOGICAL|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
215111296|NCT03828019|DRUG|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
215111297|NCT07066280|DRUG|Skin Repairing Cream|Skin Repairing Cream containing natural weak-acid
215111298|NCT07066280|OTHER|Cetaphil® Moisturizing Cream as Inactive Control|Cetaphil® Moisturizing Cream
215111299|NCT07065565|PROCEDURE|non-intubated tracheal and carinal reconstruction|non-intubated tracheal and carinal reconstruction
215111300|NCT07065565|PROCEDURE|intubated tracheal and carinal reconstruction|intubated tracheal and carinal reconstruction
215111301|NCT07065474|OTHER|education material|For students in Grades 6 to 7, the intervention comprises a coloring book that integrates storytelling and coloring assignments designed to explain key concepts related to ARF and RHD. In addition, students in these grades will watch video sessions that cover the symptoms, causes, prevention, and treatment of ARF and RHD. These videos serve to visualize the information introduced in the books. Complementing these materials, the intervention includes interactive classroom sessions facilitated by the trained field team, during which students will participate in guided discussions and activities to enhance their understanding and retention of health messages. For students in Grades 8 to 9, the intervention uses a more advanced format tailored to older adolescents. These students will receive an activity book that includes heart anatomy coloring assignments and games such as puzzles, scrambled words, and maze runs that incorporate facts and concepts about RHD.
215111302|NCT07065396|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
215111303|NCT07065396|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
215111304|NCT07065396|PROCEDURE|Placebo CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
215111305|NCT07065318|BEHAVIORAL|LV-HIIT (Low-Volume High-Intensity Interval Training)|30-sec intervals at 85-100% peak workload, 30-sec rest at 40%, total 20-30 min.
214692230|NCT04058054|DRUG|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
214692231|NCT04058054|DRUG|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
214692232|NCT04360187|DRUG|Crisaborole Ointment|Crisaborole ointment 2%
214692233|NCT04360187|DRUG|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
215111306|NCT07065318|BEHAVIORAL|MICT (Moderate-Intensity Continuous Training)|Continuous cycling at 60-80% peak workload for 20-30 min.
215111307|NCT07065318|DEVICE|Ergometer cycle|Electronically Ergometer cycle custo ec5000, CustoMed used for all exercise sessions. Calibrated before each trial.
215111308|NCT07065994|DEVICE|Virtual Reality Glasses Application|The day before the surgery, you will be shown a video of nature images with relaxing music for 10-15 minutes using virtual reality glasses.
215111309|NCT07066462|OTHER|Fatigue Exercise Protocol with Biosignal Monitoring|Participants will complete two fatiguing exercises, including static bicycling and dumbbell squats. During each exercise, surface electromyography (sEMG), electroencephalography (EEG), and heart rate (HR) will be recorded to analyze fatigue levels.
215111310|NCT07065825|PROCEDURE|robot-assisted partial nephrectomy|Robotic-Assisted Partial Nephrectomy (RAPN) is a minimally invasive surgical procedure performed with the help of a robotic system to remove a kidney tumor while preserving as much healthy kidney tissue as possible. It is commonly used to treat small to medium-sized kidney tumors. Thanks to the precision of robotic technology, RAPN offers faster recovery, less postoperative pain, and fewer complications compared to traditional open surgery.
215111311|NCT07066787|BEHAVIORAL|psychological group|fill the psychological section
215111312|NCT07066787|DIAGNOSTIC_TEST|somatic|fill the somatic section
215111313|NCT07066059|DRUG|Shouhui Tongbian Capsules|2 pills twice daily from admission to the night before surgery, then resuming after bowel sound recovery and oral intake postoperatively, with a 3-day post-discharge regimen
215111314|NCT07065097|OTHER|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.
215111315|NCT07065383|DRUG|Semaglutide administration plus dietary counselling and physical activity encouragement|Semaglutide administration plus dietary counselling and physical activity encouragement
215111316|NCT07065383|DRUG|Semaglutide plus a personalised and supervised program of resistance and endurance training|Semaglutide administration plus a personalised and supervised program of resistance and endurance training.
215111317|NCT07064798|DEVICE|Paxman Limb Cryocompression System|An investigational device designed to provide controlled cooling and compression to participant limbs during chemotherapy administration. The device is comprised of a control unit, connecting hose, and two limb wraps. The customizable limb wraps delivers continuous-flow cooling-and-compression to participant extremities
215111318|NCT07066072|DEVICE|Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer).|the Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer) will be assigned to TECAR group
215111319|NCT07066072|OTHER|standard pharmacological therapy in sickle cell disease like hydroxyurea,paracetamol,ibubrofen and blood transfusion if needed|this is the standard medical care assigned to control group
215111320|NCT07066423|OTHER|Ai prediction photo of the patients|Ai prediction photo generated by specially designed ai model to help patients see how they will look after orthodontic extraction and retraction
215111321|NCT07066423|PROCEDURE|Fixed orthodontic brackets with premolars extraction|Subjects will undergo orthodontic fixed brackets treatment, four premolar extractions from the mandibular and maxillary arches, followed by anterior segment retraction. This treatment will achieve dental alignment, profile, and facial enhancement.
215111322|NCT07066800|BEHAVIORAL|Mindfulness-Based Online Training Program|"A 4-week web-based mindfulness program developed by the research team, designed to improve attention, emotional regulation, and mental health in adults with a history of maltreatment.~* The intervention includes:~  * Weekly educational videos (5-10 minutes each)~ * Weekly mindfulness practice videos (5-10 minutes each)~ * Assigned home practices each week~ * Optional support via KakaoTalk channel for Q\&A and participant engagement~* Weekly themes include:~  * Breathing and muscle relaxation~ * Mindfulness breathing meditation~ * Body scan meditation~ * Mindful walking"
215111323|NCT07066137|DEVICE|CAREN|"The interventions include proprioceptive stimuli combined with specific rehabilitation protocols, such as Tabata training, plyometric training, and visual-cognitive-motor enhancement with the S.V.T.A. method.~Healthy subjects and athletes (about 50) will participate in intensive aerobic and anaerobic training, including sensory-motor-cognitive training and exercises on the CAREN platform. Another 25 participants will have TMS/tDCS and music therapy added to their regimen.~Regarding neurological patients, 50 participants will undergo posture and gait rehabilitation using the CAREN platform, while 25 will receive non-invasive neuromodulation to enhance their rehabilitation outcomes. This arm of the study focuses on the recovery of motor and cognitive functions.~This study uses the CAREN system as a tool for physical rehabilitation in neurological and healthy participants. The device is not being investigated for new indications and the study is conducted entirely in Italy."
215111324|NCT07066137|OTHER|Control group|"the control group is typically the group that does not receive the experimental treatment or intervention, serving as a baseline to compare the effects of the intervention. However, in the context you're describing with healthy subjects and athletes, here's how it's structured:~Healthy subjects and athletes (around 50 participants) will undergo:~Intensive aerobic and anaerobic training Sensory-motor-cognitive training~Additionally, 25 of these participants will receive:~Transcranial Magnetic Stimulation (TMS) Transcranial Direct Current Stimulation (tDCS) Music therapy This approach allows for a comparison between the effects of the physical and cognitive training alone versus the enhanced effects when combined with neuromodulation (TMS, tDCS) and music therapy. This design will help in assessing the added value of these interventions on performance"
215111325|NCT06660173|DRUG|Maridebart Cafraglutide|Solution for subcutaneous injection.
215111326|NCT06660173|DRUG|Placebo|Solution for subcutaneous injection.
214424885|NCT05858073|OTHER|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
214510126|NCT02638558|OTHER|written explanation|
214510127|NCT01212822|BIOLOGICAL|bevacizumab|Given IV
215111327|NCT05996185|DRUG|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
215111328|NCT05996185|DRUG|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
215111329|NCT07066527|COMBINATION_PRODUCT|The addition of sodium hyaluronate to poly (cinnamyl alcohol-RRB- produces a more stable foam|According to the study, the half-life of 1% poly (cinnamyl alcohol-RPol(POL) foam with a liquid-to-gas ratio of 1:4 was 142.8(64.32) seconds, in this study, the half-life of the foam made from 1% POL containing 0.05% hyaluronic acid (HA) was 390.4(613.06) seconds, human blood contains a certain amount of HA, according to the literature reported that 0.05% concentration of HA injected into human blood is safe, so this more stable foam preparation method was patented, and published in international journals.
215111330|NCT07065526|BEHAVIORAL|Emodin|Following the pre-test in the first encounter, the participants were administered the first EFT lasting 30-40 minutes by the first author, who is a certified EFT facilitator, followed by the CPS. Afterwards, a total of 4 sessions of EFT were administered at 1-week intervals. The CPS was applied before and after each EFT. After the last EFT session, SUE, PSQI and MENQOL post-tests were administered.
215111331|NCT07065630|DRUG|Volrustomig|500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.
215111332|NCT07065630|DRUG|Carboplatin|100mg/m2 IV day 1 and day 8.
215111333|NCT07065630|DRUG|Paclitaxel|AUC 5 IV day 1
215111334|NCT06756230|OTHER|Pulmonary Rehabilitation|"8 weeks, 2 sessions per week,~Aerobic training will be provided as treadmill walking. It will be performed either downhill or on a flat treadmill, depending on the group.~Warm-up and stretching exercises~Resistance exercises will be performed with a load equivalent to 50% of 1 maximum repetition. 10 repetitions will be performed in sets, one set in each session. Based on the differences in the general condition of the patients, different workloads and modifications will be used when creating an exercise program for each patient. Resistance exercises will focus on both upper and lower extremity muscles."
215111335|NCT06756230|OTHER|Downhill Walking|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Downhill walking training will continue with a constant -10% incline.
215111336|NCT06756230|OTHER|Treadmill Walking without incline|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Traditional walking training will initially involve walking with a neutral incline.
215111337|NCT03400176|DRUG|VAY736|Experimental
215111338|NCT03400176|DRUG|ibrutinib|Approved medication
215111339|NCT05719675|BEHAVIORAL|Intervention|"The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
215111340|NCT06920641|OTHER|Tagatose|"Sachet containing 10g tagatose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
215111341|NCT06920641|OTHER|Placebo|"Sachet containing 10g sucrose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
215111342|NCT06913387|COMBINATION_PRODUCT|Lipid Based Artificial Tears|30 participants received lipid-based artificial tears (Recuro) in this study arm. The intervention involved the administration of RECURO EYE DROPS, which contain Sodium carboxymethylcellulose 0.5%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
215111343|NCT06913387|COMBINATION_PRODUCT|Aqueous Based Artificial Tears|30 participants received aqueous-based artificial tears (Softeal) in this study arm. The intervention involved the administration of SOFTEAL EYE DROPS, which contain Hydroxypropylmethyl Cellulose 0.3%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
215111344|NCT03399474|DRUG|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
215111345|NCT03399474|DRUG|Dexmedetomidine 0.5 ug/kg|pecedex
215111346|NCT03399474|DRUG|Dexmedetomidine Injection 0.25 ug/kg|pecedex
215111347|NCT00119821|BEHAVIORAL|Weight Reducing Diet|Behavioral intervention
215111348|NCT00119821|BEHAVIORAL|Exercise|Moderate exercise implemented plus behavioral intervention.
215111349|NCT00119821|BEHAVIORAL|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
214424886|NCT05858073|OTHER|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
214692234|NCT00548080|DRUG|MK0991, caspofungin acetate / Duration of Treatment:|
214692235|NCT02290054|PROCEDURE|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
214692236|NCT02290054|PROCEDURE|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
215111350|NCT03180970|DRUG|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
215111351|NCT03180970|DRUG|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
215111352|NCT03180970|DRUG|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
215111353|NCT03180970|DRUG|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
215111354|NCT03180970|DRUG|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
215111355|NCT01262534|OTHER|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
215111356|NCT01262534|OTHER|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
215111357|NCT01262534|OTHER|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
215111358|NCT03107494|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
215111359|NCT06351059|DIAGNOSTIC_TEST|InModi acoustic emission analysis|All diagnosis tests
215111360|NCT03430232|DRUG|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
215111361|NCT03430232|DRUG|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
215111362|NCT03430232|DRUG|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
215111363|NCT03430232|DRUG|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
215111364|NCT03430232|DRUG|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
215111365|NCT03430232|DRUG|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
215111366|NCT03430232|DRUG|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
215111367|NCT03430232|DRUG|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
215111368|NCT03430232|DRUG|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
215111369|NCT03430232|DRUG|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
215111370|NCT03430232|DRUG|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
215111371|NCT03430232|DRUG|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
215111372|NCT03430232|DRUG|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
215111373|NCT05998174|OTHER|Faecal Microbiota Transplantation|treatment with capsules
215111374|NCT00206440|DRUG|esomeprazole|nexium
215111375|NCT00206440|OTHER|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
215111376|NCT03815565|PROCEDURE|continuous femoral block|infusion of anesthetic by PCA pump
215111377|NCT03870412|DRUG|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
215111378|NCT01298765|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
215111379|NCT04152798|PROCEDURE|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
215111380|NCT04152798|PROCEDURE|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
215111381|NCT06354478|DRUG|Dexmedetomidine Hydrochloride 0.5 MG/ML|Will be used either alone or in combination of gabapentin
215111382|NCT06354478|DRUG|Gabapentin|Will be used either alone or in combination of Dexmedetomidine
215111383|NCT03723109|PROCEDURE|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
215111384|NCT03401671|DRUG|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
215111385|NCT03259061|DEVICE|Flexible fiberoptic nasopharyngoscopy|"1. Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~2. Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
215111386|NCT00959738|PROCEDURE|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
215111387|NCT00959738|PROCEDURE|diverting loop ileostomy without rod|diverting loop ileostomy without rod
215111388|NCT03302247|BIOLOGICAL|Nivolumab|Monoclonal antibody against non small cell lung cancer
215111389|NCT03302247|DRUG|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
215111390|NCT02681289|OTHER|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
215111391|NCT04090242|DEVICE|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
215111392|NCT03931694|DEVICE|e-DOL|e-health program (smartphone and web platform)
215111393|NCT02487004|DEVICE|hemodialysis|
215111394|NCT03214406|DRUG|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
215111395|NCT03214406|DRUG|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
215111396|NCT04030793|DEVICE|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
215111397|NCT04030793|DEVICE|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
215111398|NCT01898013|DRUG|Pregnenolone|
215111399|NCT01898013|DRUG|Placebo|
215111400|NCT01957410|DRUG|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
215111401|NCT01957410|DRUG|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
215111402|NCT01098305|DRUG|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
215111403|NCT01098305|BEHAVIORAL|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
215111404|NCT03761342|BEHAVIORAL|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
215111405|NCT03761342|BEHAVIORAL|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
215111406|NCT02536924|BEHAVIORAL|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
215111407|NCT02536924|BEHAVIORAL|Treatment as usual.|The patient will receive treatment as usual.
215111408|NCT02322970|DEVICE|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
214510128|NCT01212822|DRUG|oxaliplatin|Given IV
215111409|NCT01716780|OTHER|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
215111410|NCT05466357|PROCEDURE|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
215111411|NCT03182907|BIOLOGICAL|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
215111412|NCT03182907|DRUG|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
215111413|NCT03182907|DRUG|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
215111414|NCT04161261|PROCEDURE|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
215111415|NCT00429169|DRUG|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
215111416|NCT00429169|DRUG|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
215111417|NCT02183233|DRUG|Eschscholtzia Californica|
215111418|NCT02183233|DRUG|Eschscholtzia Californica Placebo|
215111419|NCT03634254|OTHER|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
215111420|NCT06279507|DRUG|Sodium Hyaluronate|Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
215111421|NCT06279507|DRUG|Normal Saline|0.9% sodium chloride 2 mL prepared in plastic syringe
215111422|NCT06279507|DRUG|Triamcinolone Acetonide 10mg/mL|10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
215111423|NCT01652131|OTHER|Tetrastarch (130/0.4)|
215111424|NCT02296255|BIOLOGICAL|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
215111425|NCT03747640|DEVICE|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
215028457|NCT05095285|OTHER|Swaddling|"* Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
215028458|NCT05095285|OTHER|Oropharyngeal colostrum|"* Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
215028459|NCT03562156|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
214692237|NCT02290054|PROCEDURE|Intra-venous anesthesia|
214692238|NCT03220048|DRUG|PrEP-001|
214692239|NCT03220048|OTHER|Placebo Comparator|
214692240|NCT03577093|OTHER|There is no intervention at all.|There is no intervention at all.
214692241|NCT02593747|DRUG|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
214692242|NCT02593747|DRUG|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
215028460|NCT03562156|DRUG|Placebo|matching placebo capsule
215028461|NCT03575598|DRUG|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
215028462|NCT03575598|BIOLOGICAL|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
215028463|NCT03926013|DRUG|JNJ-63898081|JNJ-63898081 will be administered.
215028464|NCT02400684|BIOLOGICAL|blood samples|Evolution of AMH before and after deep endometriosis surgery
215028465|NCT02772692|BEHAVIORAL|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
215111426|NCT03747640|BEHAVIORAL|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
215111427|NCT03747640|DEVICE|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
214510129|NCT01212822|DRUG|leucovorin calcium|Given IV
214510130|NCT01212822|DRUG|fluorouracil|Given IV
214510131|NCT01212822|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214510132|NCT01212822|OTHER|laboratory biomarker analysis|Correlative studies
214510133|NCT04195789|OTHER|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
214510134|NCT01959776|PROCEDURE|Vitrectomy|
214510135|NCT03811665|PROCEDURE|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
214510136|NCT03811665|RADIATION|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
214510137|NCT01493882|DRUG|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
214510138|NCT01493882|DRUG|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
215111428|NCT03747640|BEHAVIORAL|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
215028466|NCT01078532|OTHER|SMART PHR|Patient receives an active PHR
215028467|NCT01078532|OTHER|usual care|Usual passive PHR
215028468|NCT00829465|DRUG|Licartin|Licartin
215028469|NCT00829465|PROCEDURE|Transcatheter arterial chemoembolization|TACE
215028470|NCT01752179|PROCEDURE|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
215028471|NCT03512730|DEVICE|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
215028472|NCT03512730|OTHER|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
215028473|NCT05952310|OTHER|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
215028474|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
215028475|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
215028476|NCT06336564|OTHER|Pelvic floor muscle training|"Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days."
215028477|NCT06336564|DEVICE|Microablative Radiofrequency|Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
215028478|NCT02552264|BEHAVIORAL|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
214424887|NCT02975310|PROCEDURE|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
214424888|NCT02975310|PROCEDURE|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
214424889|NCT02975310|OTHER|General Anesthesia|ESS will be performed under general anesthesia in the operating room
215111429|NCT04984577|DRUG|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
215111430|NCT04984577|DRUG|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
214424890|NCT02975310|OTHER|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
214424891|NCT02903615|OTHER|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
214424892|NCT02903615|OTHER|Standard diet|Standard diabetes diet recommendations
214424893|NCT03024606|BEHAVIORAL|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
214424894|NCT02838342|DRUG|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
214424895|NCT02838342|DRUG|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
214424896|NCT06103630|OTHER|Oropharyngeal Exercises|Oropharyngeal Exercises
214424897|NCT06103630|OTHER|Mandibular advancement device|Mandibular advancement device
214424898|NCT04598321|DRUG|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
214424899|NCT00502424|DEVICE|Splint|
214424900|NCT06478680|BEHAVIORAL|Exoskeleton mediated gait training|"1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training"
215111431|NCT04984577|DRUG|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
215111432|NCT04984577|DRUG|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
215111433|NCT03964324|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
215111434|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
215111435|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
215111436|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
215111437|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
215111438|NCT03416452|DEVICE|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
215111439|NCT03416452|DEVICE|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
215111440|NCT03401268|DRUG|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
215111441|NCT02721095|OTHER|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
215111442|NCT02721095|OTHER|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
215111443|NCT00442221|DRUG|Sumatriptan and Naproxen sodium|
215111444|NCT00759421|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
215111445|NCT00759421|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
215111446|NCT00296920|DEVICE|Deep Brain Stimulation|
215111447|NCT02815644|DRUG|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
215111448|NCT03663335|BIOLOGICAL|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
215111449|NCT03663335|DRUG|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
215111450|NCT05015270|DIAGNOSTIC_TEST|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
215111451|NCT02777489|DRUG|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
215111452|NCT01180296|DRUG|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
215111453|NCT01180296|DRUG|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
215111454|NCT00169208|DRUG|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
215111455|NCT00169208|DRUG|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
215111456|NCT00169208|DRUG|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
215111457|NCT02396355|DEVICE|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
214424901|NCT06478680|BEHAVIORAL|High intensity gait training|"2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement"
214424902|NCT04068207|DRUG|Minocycline|Tab. Minocycline 100mg po per day for 12 months
214424903|NCT04949035|DIAGNOSTIC_TEST|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
214510139|NCT01493882|DRUG|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
215111458|NCT02396355|DEVICE|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
215111459|NCT02396355|DEVICE|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
215111460|NCT01921764|BEHAVIORAL|Workplace physical exercise|
215111461|NCT01921764|BEHAVIORAL|Home physical exercise|
215111462|NCT01718444|DRUG|Progestin|
215111463|NCT01718444|DRUG|Clomiphene Citrate|
215111464|NCT00038558|DRUG|Filgrastim SD/01|
215111465|NCT00038558|DRUG|Adriamycin|
215111466|NCT00038558|DRUG|Bleomycin|
215111467|NCT00038558|DRUG|Vinblastine|
215111468|NCT00038558|DRUG|DTIC|
215111469|NCT00379067|DRUG|Tamsulosin OCAS|Adrenoceptor antagonist
215111470|NCT00379067|DRUG|Placebo|placebo
215111471|NCT01511081|RADIATION|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
215111472|NCT01511081|RADIATION|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
215111473|NCT05009290|DRUG|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
215111474|NCT05009290|DRUG|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
215111475|NCT04138290|DEVICE|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
215111476|NCT05226299|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
215111477|NCT05226299|BIOLOGICAL|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
215111478|NCT04326049|DEVICE|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
215111479|NCT04326049|DEVICE|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
215111480|NCT01371552|DEVICE|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
215111481|NCT01371552|DEVICE|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
215111482|NCT01371552|DEVICE|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
215111483|NCT03364309|DRUG|Ixekizumab|Administered SC
215111484|NCT03364309|DRUG|Placebo|Administered SC
215111485|NCT06523244|PROCEDURE|PHOTODYNAMIC THERAPY|Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
215111486|NCT04747587|OTHER|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
215028479|NCT05888064|DIAGNOSTIC_TEST|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
215111487|NCT01850407|BEHAVIORAL|Education Counseling|
214424904|NCT00656721|DEVICE|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
214424905|NCT00448721|DRUG|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
214424906|NCT00695071|DRUG|Itraconazole|Oral
214424907|NCT04559659|OTHER|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
214424908|NCT04195516|OTHER|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
214424909|NCT04444258|OTHER|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
214424910|NCT04444258|OTHER|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
214424911|NCT01407393|DEVICE|Glucosanol|2 tablets 3x daily for 12 weeks
214424912|NCT01407393|DEVICE|Placebo|2 tablets 3x daily for 12 weeks
214424913|NCT05992298|OTHER|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
214424914|NCT02249988|DRUG|ABX203 therapeutic Hepatitis B vaccine treatment arm|
214424915|NCT03601910|DRUG|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
215028480|NCT00078260|DRUG|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
215028481|NCT05167708|PROCEDURE|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
215028482|NCT06112015|OTHER|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
215028483|NCT06149169|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor(CAR) T Cells|Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
215111488|NCT03413709|OTHER|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
215111489|NCT02430883|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
215111490|NCT01750723|DRUG|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
215111491|NCT01882504|DRUG|gevokizumab|
215111492|NCT03145948|DRUG|ABBV-553|It is administered orally.
215111493|NCT03145948|DRUG|Placebo|It is administered orally.
215111494|NCT04014569|DEVICE|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
215111495|NCT05268952|OTHER|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
215111496|NCT05268952|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
215111497|NCT04078581|OTHER|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
215111498|NCT05995236|DRUG|PSMA radionuclide therapy|Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
215111499|NCT03482492|DRUG|Tramadol|Tramadol iv
215111500|NCT03482492|DRUG|Paracetamol|Paracetamol iv
215111501|NCT00810992|BEHAVIORAL|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
215111502|NCT00810992|BEHAVIORAL|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
215111503|NCT02720406|DRUG|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
215111504|NCT02720406|DRUG|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
215111505|NCT02720406|DRUG|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
215111506|NCT02720406|DRUG|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
215111507|NCT00365040|PROCEDURE|Prk with mitomycin vs Lasik|
215111508|NCT02718092|DEVICE|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
215111509|NCT02718092|DEVICE|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
215111510|NCT06197620|OTHER|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
215111511|NCT01325805|BEHAVIORAL|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
214424916|NCT03601910|DRUG|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
214424917|NCT01667796|DIETARY_SUPPLEMENT|Vitamin D3|
214424918|NCT00880477|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
214424919|NCT00880477|BIOLOGICAL|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
214424920|NCT00880477|BIOLOGICAL|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
214424921|NCT02364349|DRUG|Bee Venom (BV)|Raw Bee Venom
214424922|NCT02364349|DRUG|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
214424923|NCT00761436|BIOLOGICAL|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
214424924|NCT02547922|BIOLOGICAL|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
214424925|NCT02547922|DRUG|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
214424926|NCT04836806|DRUG|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
214424927|NCT04836806|DRUG|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
214424928|NCT02167906|OTHER|arterial stiffness measurement|
214424929|NCT00710515|DRUG|AZD6244|75mg
215111512|NCT01325805|BEHAVIORAL|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
215111513|NCT04954157|DIAGNOSTIC_TEST|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
215111514|NCT04954157|DIAGNOSTIC_TEST|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
215111515|NCT05921799|PROCEDURE|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
215111516|NCT03540199|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
215111517|NCT03540199|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
215111518|NCT04921904|DRUG|Abemaciclib|150mg dose administered orally twice daily every day
215111519|NCT04921904|DRUG|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
215111520|NCT04320901|DEVICE|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
215111521|NCT04320901|DEVICE|Harmonic|Harmonic ACE 7+
215111522|NCT00795301|DRUG|Capecitabine, Cetuximab, Oxaliplatin|
215111523|NCT03304873|DRUG|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
215111524|NCT03304873|DRUG|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
215111525|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with tumor lysate|
215111526|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with MUC-1/WT-1 peptides|
215111527|NCT05037617|DRUG|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
215111528|NCT01294969|DRUG|AL-4943A|Once daily topical ocular allergy medication used for 7 days
215111529|NCT02267161|OTHER|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
215111530|NCT06203769|DRUG|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
215111531|NCT06203769|DRUG|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
215111532|NCT01546688|DRUG|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
215111533|NCT01546688|DRUG|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
215111534|NCT00648700|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
215111535|NCT00648700|DRUG|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
215111536|NCT00667849|DEVICE|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
215111537|NCT00667849|DEVICE|Sham|sham device identical to active device with the exception of administration of ultrasound
215111538|NCT01895959|DRUG|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
215111539|NCT01895959|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
215111540|NCT06040853|DRUG|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
215111541|NCT06040853|DRUG|Saline|Participant was given intravenous 100 ml saline
215111542|NCT03116256|DIETARY_SUPPLEMENT|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
215111543|NCT03116256|OTHER|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
214424930|NCT04614675|PROCEDURE|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
214424931|NCT04614675|PROCEDURE|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
214424932|NCT00432718|PROCEDURE|Saline Instillation before Tracheal Suctioning|
214424933|NCT04843306|BEHAVIORAL|Biofeedback|Relaxation coaching will be used in this study.
215111544|NCT03116256|OTHER|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
214424934|NCT04843306|BEHAVIORAL|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
214424935|NCT05429034|BEHAVIORAL|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
214424936|NCT05429034|BEHAVIORAL|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
214510140|NCT01493882|DRUG|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
214510141|NCT02236611|DRUG|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
214510142|NCT02236611|DRUG|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
214510143|NCT01229904|BEHAVIORAL|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
214510144|NCT04131257|BEHAVIORAL|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
214510145|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
215111545|NCT00465023|PROCEDURE|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
215111546|NCT00995423|DEVICE|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
215111547|NCT00995423|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent
215111548|NCT02366156|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
215111549|NCT02366156|DIETARY_SUPPLEMENT|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
215111550|NCT02366156|DIETARY_SUPPLEMENT|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
215111551|NCT00118950|DRUG|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
215111552|NCT00118950|DRUG|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
215111553|NCT00118950|DRUG|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
215111554|NCT00118950|DRUG|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
215111555|NCT00118950|OTHER|Diet-only.|Diet-only treatment. Duration: One month.
215111556|NCT01760343|BIOLOGICAL|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
215111557|NCT01760343|BIOLOGICAL|CSL830|CSL830 is a formulation of Berinert.
215111558|NCT01052077|DRUG|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
215111559|NCT01052077|DRUG|Placebo|Placebo
215111560|NCT01052077|DRUG|ADT|
215111561|NCT04534322|DRUG|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
215111562|NCT04534322|DRUG|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
215111563|NCT00520156|DEVICE|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
215111564|NCT00202956|DRUG|Bugusan|
215111565|NCT03512379|DEVICE|TIANJI Robot|A robotic system for spinal surgery
215111566|NCT03512379|DEVICE|Fluoroscopy|For fluoroscopy-based free hand surgery
215111567|NCT03512379|DEVICE|Navigation|For navigation-assisted spinal surgery
215111568|NCT05155774|DEVICE|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
215111569|NCT06025409|DRUG|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
215111570|NCT03288922|PROCEDURE|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
214510146|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
214510147|NCT01049516|BEHAVIORAL|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
214510148|NCT01049516|BEHAVIORAL|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
215111571|NCT03288922|PROCEDURE|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
215111572|NCT01775605|DRUG|Synera|Synera Pain Patch
215111573|NCT03172572|PROCEDURE|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
215111574|NCT03172572|PROCEDURE|Open pancreatoduodenectomy|Open resection
215028484|NCT01137084|DRUG|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
215028485|NCT01137084|DRUG|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
215028486|NCT00712283|DRUG|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
215028487|NCT05903079|DEVICE|s-Tdcs|Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
215028488|NCT05308810|PROCEDURE|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
215028489|NCT03709017|DRUG|Ponatinib|Iclusig 45mg, 15mg
215028490|NCT02373657|BEHAVIORAL|instruction in soap-making and hygiene education|
215028491|NCT03514576|DRUG|Pasireotide 0.3 MG/ML|See arm description
215028492|NCT03514576|DIAGNOSTIC_TEST|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
215028493|NCT05558579|OTHER|No sling use|Patients will not use standard of care sling
215111575|NCT02465203|DRUG|Previous treatment in DEB025 study|Follow-up after DEB025 active study
215111576|NCT00042991|DRUG|gefitinib|Given orally
215111577|NCT00042991|RADIATION|radiation therapy|Undergo standard brain irradiation
215111578|NCT00042991|OTHER|pharmacological study|Correlative studies
215111579|NCT00042991|OTHER|laboratory biomarker analysis|Correlative studies
215111580|NCT03689816|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
215111581|NCT03689816|PROCEDURE|gastric bypass|gastric bypass
215111582|NCT06394245|OTHER|Progressive muscle exercises|The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
214424937|NCT04970979|OTHER|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
214424938|NCT03107767|PROCEDURE|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
214424939|NCT01528306|BIOLOGICAL|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
215028494|NCT02489279|BEHAVIORAL|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
215028495|NCT02489279|BEHAVIORAL|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
215028496|NCT01055951|DEVICE|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
215028497|NCT05613127|BIOLOGICAL|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
214424940|NCT01528306|OTHER|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
214424941|NCT03221777|DIAGNOSTIC_TEST|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
214424942|NCT02282085|DRUG|Aripiprazole Once-Monthly|
214424943|NCT02282085|DRUG|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
214424944|NCT01867632|DEVICE|Acellular Dermal Matrix|
214424945|NCT06307223|DRUG|30% supramolecular salicylic acid|The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
214424946|NCT06307223|DRUG|supramolecular active zinc|The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
214424947|NCT00739141|DRUG|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
214424948|NCT02336438|DIETARY_SUPPLEMENT|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
214424949|NCT02607670|DRUG|TAT4 Gel|
214424950|NCT02607670|DRUG|Matching placebo|
215111583|NCT05819320|OTHER|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
215111584|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
214510149|NCT01056159|DRUG|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
214510150|NCT01056159|DRUG|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
214510151|NCT04870775|BEHAVIORAL|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
214510152|NCT02399605|OTHER|Stimulation|Subcutaneous abdominal electrical stimulation
214510153|NCT00004474|DRUG|Anti-thymocyte globulin|Given via IV over 4 hours
214510154|NCT00004474|DRUG|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
215111585|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
215111586|NCT03770117|PROCEDURE|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
215111587|NCT03770117|PROCEDURE|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
215111588|NCT04188145|DRUG|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
215111589|NCT04188145|DRUG|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
215111590|NCT02223806|BEHAVIORAL|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
215111591|NCT02223806|BEHAVIORAL|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
215111592|NCT05506527|OTHER|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~\- Children of the study group B will receive sensorimotor program alone."
215111593|NCT04072887|DRUG|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
215111594|NCT04072887|DRUG|Placebo|Placebo oral capsules administered twice a day for 24 weeks
215111595|NCT04072887|DRUG|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
215111596|NCT00988572|OTHER|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
214424951|NCT06484504|DIETARY_SUPPLEMENT|Kombucha beverage|After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
214424952|NCT01317420|DRUG|BI 836845|Intravenous infusion
214424953|NCT02993588|DRUG|Melatonin|Melatonin 6 mg tablet once daily
214510155|NCT00004474|PROCEDURE|Bone marrow transplantation|Given on Day 0
214510156|NCT02311062|OTHER|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
214510157|NCT02311062|OTHER|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
214510158|NCT02311062|OTHER|Control|Only soccer training
214510159|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
215111597|NCT03193736|DEVICE|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
215111598|NCT02487862|BEHAVIORAL|Stress Reduction Protocol|Stress Reduction Protocol
215111599|NCT05825391|DRUG|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
215111600|NCT03268291|OTHER|Standard outpatient observation|Outpatient management according to Ministry of health standards
214424954|NCT02993588|OTHER|Placebo|one tablet once daily
214424955|NCT04210505|DRUG|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
215111601|NCT03268291|BEHAVIORAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
215111602|NCT00423449|DRUG|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
215111603|NCT00423449|DRUG|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
215111604|NCT00423449|DRUG|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
215111605|NCT00267852|OTHER|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
215111606|NCT06195410|OTHER|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
215111607|NCT02697435|OTHER|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
215111608|NCT02697435|OTHER|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
215111609|NCT01670435|DRUG|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
215111610|NCT03433352|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
215111611|NCT03433352|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
215111612|NCT00429533|DRUG|Dapsone|
215111613|NCT02505113|DRUG|Montelukast|Montelukast (10mg, q.d., p.o.)
215111614|NCT00006208|DRUG|Efavirenz|
215111615|NCT00006208|DRUG|Emtricitabine|
215111616|NCT00006208|DRUG|Stavudine|
215111617|NCT00006208|DRUG|Didanosine|
215111618|NCT04371666|DRUG|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
215111619|NCT04371666|DRUG|Placebo|Matching placebo per schedule specified in the arm description
215111620|NCT04371666|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
215111621|NCT00240500|BIOLOGICAL|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
215111622|NCT00214058|DRUG|Carboplatin|
215111623|NCT00214058|DRUG|Docetaxel|
215111624|NCT04043078|OTHER|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
215111625|NCT01445080|OTHER|Laboratory Biomarker Analysis|Correlative studies
215111626|NCT01445080|OTHER|Pharmacological Study|Correlative studies
215111627|NCT01445080|DRUG|Sorafenib Tosylate|Given orally
215111628|NCT02757118|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
214424956|NCT04210505|OTHER|Standard Care|Control group will receive standard care as provided by the dialysis center
214424957|NCT03194958|BEHAVIORAL|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
214424958|NCT03194958|BEHAVIORAL|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
214424959|NCT04003805|DRUG|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
214424960|NCT04003805|DRUG|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
215111629|NCT02757118|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
215111630|NCT06223126|OTHER|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
215111631|NCT06223126|OTHER|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
215111632|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
215111633|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
215111634|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
215111635|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
215111636|NCT02358226|BEHAVIORAL|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
215111637|NCT02358226|BEHAVIORAL|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
215111638|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
215111639|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
215111640|NCT04859374|BEHAVIORAL|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
215111641|NCT04859374|DRUG|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
215111642|NCT02123576|DRUG|Pentoxyfylline|
215111643|NCT02123576|DRUG|Placebo|
215111644|NCT02123576|DRUG|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
215111645|NCT02477189|PROCEDURE|Silicone Block|
215111646|NCT03811301|DEVICE|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
215111647|NCT02199561|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
215111648|NCT05137769|BEHAVIORAL|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
215111649|NCT05840536|DRUG|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
214424961|NCT04828148|BEHAVIORAL|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
214424962|NCT00317226|DRUG|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
215111650|NCT05840536|DRUG|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
214424963|NCT04206215|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
214424964|NCT04206215|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
214424965|NCT02511613|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
214424966|NCT02511613|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
214424967|NCT02511613|DRUG|ranibizumab|ranibizumab intravitreal injection
215111651|NCT04649177|DEVICE|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
215111652|NCT00241592|DRUG|Cannabis|
215111653|NCT01428531|DRUG|Fondaparinux Sodium|
215111654|NCT01735266|OTHER|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
215111655|NCT01735266|OTHER|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
215111656|NCT01966822|DRUG|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
215111657|NCT01966822|DRUG|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
215111658|NCT03824002|DRUG|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
215111659|NCT03824002|DRUG|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
215111660|NCT03824002|DRUG|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
215111661|NCT03824002|DRUG|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
215111662|NCT03824002|DRUG|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
215111663|NCT00640848|DRUG|almorexant|1 dose of 400 mg in two treatment sequences
215111664|NCT00640848|DRUG|almorexant|1 dose of 200 mg in two treatment sequences
215111665|NCT00640848|DRUG|almorexant|1 dose of 100 mg in two treatment sequences
215111666|NCT00640848|DRUG|almorexant|1 dose of 50 mg mg in two treatment sequences
215111667|NCT00640848|DRUG|almorexant|1 dose of 1000 mg in two treatment sequences
215111668|NCT00002399|DRUG|Posaconazole|
215111669|NCT00002399|DRUG|Fluconazole|
215111670|NCT04364295|DEVICE|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
215111671|NCT05015569|DEVICE|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
215111672|NCT05015569|OTHER|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
215111673|NCT01669772|DRUG|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
215111674|NCT01669772|DRUG|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
215111675|NCT01361100|DEVICE|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
215111676|NCT02363621|DRUG|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
215111677|NCT02363621|DRUG|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
215111678|NCT00003727|BIOLOGICAL|filgrastim|
215111679|NCT00003727|BIOLOGICAL|recombinant interferon alfa|
215111680|NCT00003727|BIOLOGICAL|sargramostim|
215111681|NCT00003727|BIOLOGICAL|therapeutic autologous lymphocytes|
215111682|NCT00003727|DRUG|carmustine|
215111683|NCT00003727|DRUG|cyclophosphamide|
215111684|NCT00003727|DRUG|etoposide|
215111685|NCT00003727|DRUG|gemcitabine hydrochloride|
215111686|NCT00003727|DRUG|melphalan|
215111687|NCT00003727|PROCEDURE|bone marrow ablation with stem cell support|
215111688|NCT00003727|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
215111689|NCT02697318|DRUG|Timolol maleate 0.5% ophthalmic solution|
215111690|NCT02638649|PROCEDURE|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
215111691|NCT02638649|DEVICE|ultrasound|
215111692|NCT03676244|DEVICE|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
215111693|NCT03226834|DEVICE|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
215111694|NCT03226834|OTHER|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
215111695|NCT00193817|PROCEDURE|Two field vs Three field lymphadenectomy|
215111696|NCT04279535|DRUG|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
215111697|NCT04564157|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
215111698|NCT04564157|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
214510160|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
215028498|NCT05613127|BIOLOGICAL|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
214510161|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
214510162|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
214510163|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
215028499|NCT02892279|OTHER|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
215028500|NCT02263547|DRUG|teriflunomide|
215028501|NCT02263547|DRUG|Colestipol|
215028502|NCT00038935|DRUG|ReFacto AF|
215028503|NCT00245479|DRUG|Primary nocturnal enuresis|Desmopressin
215028504|NCT04720807|DRUG|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
215028505|NCT05751109|PROCEDURE|ipack+adduktor kanal|nerve block
215028506|NCT04519333|PROCEDURE|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
215028507|NCT04448379|DRUG|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
215028508|NCT00095576|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016."
215028509|NCT00095576|DRUG|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
215028510|NCT03287986|OTHER|MRI|Structural and functional sequences
215028511|NCT04120987|DRUG|Lifitegrast 5% Ophthalmic Solution|BID OU
215028512|NCT04862494|OTHER|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
215028513|NCT04862494|PROCEDURE|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
215028514|NCT01344356|RADIATION|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
215028515|NCT01344356|RADIATION|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
215028516|NCT04078867|PROCEDURE|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
215028517|NCT02911727|PROCEDURE|Fast-track discharge|As described above
215028518|NCT01138722|RADIATION|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
215111699|NCT04564157|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
215111700|NCT06164665|DRUG|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
215111701|NCT06164665|OTHER|Placebo|100% microcrystalline cellulos
215111702|NCT02155777|DRUG|OrthoNovum 1/35|
215111703|NCT03499184|DIETARY_SUPPLEMENT|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
215111704|NCT03499184|DIETARY_SUPPLEMENT|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
215111705|NCT03499184|DRUG|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
214424968|NCT01968226|DRUG|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
214424969|NCT00886145|DEVICE|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
214424970|NCT06331611|DEVICE|TOF monitoring|Reversal with Sugammadex will be based on TOF monitoring
214424971|NCT00903227|DRUG|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
214424972|NCT00903227|DRUG|Placebo|1 puff of inhaled Placebo twice a day
214424973|NCT00903227|DRUG|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
214424974|NCT00903227|DRUG|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
215111706|NCT03499184|DRUG|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
215111707|NCT00601497|DEVICE|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
215111708|NCT00354393|DRUG|Cisplatin|
215111709|NCT00354393|DRUG|Methotrexate|
215111710|NCT00354393|DRUG|Vinorelbine ditartrate|
215111711|NCT00354393|PROCEDURE|Adjuvant therapy|
215111712|NCT00354393|PROCEDURE|Conventional surgery|
215111713|NCT00354393|PROCEDURE|Neoadjuvant Therapy|
215111714|NCT00354393|RADIATION|3-dimensional conformal radiation therapy|
215111715|NCT00354393|RADIATION|Intensity-modulated radiation therapy|
215111716|NCT03012048|DEVICE|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
215111717|NCT03012048|DEVICE|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
214424975|NCT00903227|DRUG|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
214510164|NCT00156845|PROCEDURE|AI-700 contrast-enhanced echocardiography|
214510165|NCT02132520|DEVICE|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
215111718|NCT03012048|DEVICE|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
215111719|NCT05855369|DEVICE|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
215111720|NCT05855369|OTHER|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
215111721|NCT05855369|OTHER|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
214424976|NCT02971488|OTHER|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
215111722|NCT05690555|OTHER|Preoperative and Postoperative Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
215111723|NCT05690555|OTHER|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
215111724|NCT05690555|OTHER|Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
215111725|NCT06114888|DIAGNOSTIC_TEST|MeMed BV + Usual Care|We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
215111726|NCT06114888|OTHER|Usual Care Alone|Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
215111727|NCT06532279|OTHER|Best Practice|Receive usual symptom management
215111728|NCT06532279|PROCEDURE|Biospecimen Collection|Undergo collection of blood, serum, and/or plasma samples
215111729|NCT06532279|DRUG|Cisplatin|Given cisplatin
215111730|NCT06532279|PROCEDURE|Computed Tomography|Undergo CT
215111731|NCT06532279|RADIATION|Image Guided Radiation Therapy|Undergo image-guided radiation therapy
215111732|NCT06532279|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
215111733|NCT06532279|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215111734|NCT06532279|DRUG|MnSOD Mimetic BMX-001|Given SC
215111735|NCT06532279|DRUG|Placebo Administration|Given SC
215111736|NCT06532279|OTHER|Questionnaire Administration|Ancillary studies
215111737|NCT06367699|BEHAVIORAL|Usual Care|Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
215111738|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
214424977|NCT02010138|PROCEDURE|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
214424978|NCT02010138|PROCEDURE|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
214424979|NCT02456506|RADIATION|Hyperfractionated IMRT|
214424980|NCT02456506|RADIATION|Conventional Fraction IMRT|
214424981|NCT01368198|OTHER|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
214424982|NCT01368198|OTHER|OPTIVE™|One instillation of the eye drop in each eye
214424983|NCT02202824|OTHER|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
214424984|NCT00237770|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
215111739|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
215111740|NCT06367699|BEHAVIORAL|ECA-HPV App with Adolescent Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
215111741|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
215111742|NCT05327686|BIOLOGICAL|Avelumab|Given IV
215111743|NCT05327686|DRUG|Axitinib|Given PO
215111744|NCT05327686|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215111745|NCT05327686|PROCEDURE|Bone Scan|Undergo bone scan
215111746|NCT05327686|DRUG|Cabozantinib|Given PO
215111747|NCT05327686|PROCEDURE|Computed Tomography|Undergo CT
215111748|NCT05327686|BIOLOGICAL|Ipilimumab|Given IV
215111749|NCT05327686|DRUG|Lenvatinib|Given PO
215111750|NCT05327686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215111751|NCT05327686|BIOLOGICAL|Nivolumab|Given IV
215111752|NCT05327686|BIOLOGICAL|Pembrolizumab|Given IV
215111753|NCT05327686|RADIATION|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
215111754|NCT03827057|BEHAVIORAL|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
215111755|NCT03827057|BEHAVIORAL|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
215111756|NCT05437562|PROCEDURE|Ewing Below Knee Amputation|Ewing Below Knee Amputation
215111757|NCT05437562|PROCEDURE|Standard Below Knee Amputation|Standard Below Knee Amputation
215111758|NCT04784143|DRUG|Midomafetamine|120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
215111759|NCT04784143|BEHAVIORAL|Psychotherapy|Manualized psychotherapy performed by therapist team
215111760|NCT05484739|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
214424985|NCT00237770|PROCEDURE|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
214424986|NCT01827345|DIETARY_SUPPLEMENT|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
215111761|NCT05484739|OTHER|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
215111762|NCT05484739|OTHER|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
215111763|NCT05484739|OTHER|Control|Participants will NOT receive either water spray or a fan exposure.
215111764|NCT06455852|BIOLOGICAL|oral cholera vaccine or typhoid conjugate vaccine|One group of participants will receive a 2 dose oral cholera vaccine, the other set will receive a typhoid conjugate vaccine
215111765|NCT05757557|DRUG|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
215111766|NCT05757557|DRUG|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
215111767|NCT06507943|BEHAVIORAL|Promotora Home Visit|For each participating family, Promotora home visits will be scheduled 6-8 weeks apart, with in-person or virtual visits conducted per the family's preference. The visits will begin with a survey which will evaluate concerns related to asthma for the child and the family, including their asthma control (via the ACT), their home environment (via screening for environmental exposures), and quality of life for the child. These surveys will be available in both online or physical forms for potential connectivity concerns, and Promotoras will have IPads for the online forms. The Promotoras, who have received specialized asthma training, will then address concerns raised by families, using the Clinical Pathway which will have resources for asthma-related concerns that are raised.
215111768|NCT04040088|PROCEDURE|Computed Tomography|Undergo PET/CT
215111769|NCT04040088|DRUG|Gallium Ga 68-DOTATATE|Given IV
215111770|NCT04040088|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215111771|NCT02974257|DRUG|Thiamine|Thiamine 500mg IV twice daily for 2 days
215111772|NCT02974257|OTHER|placebo|100mL normal saline IV every 12 hours for 2 days
215111773|NCT05130151|BEHAVIORAL|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
215111774|NCT05140460|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
215111775|NCT05140460|BEHAVIORAL|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
215111776|NCT01744548|BEHAVIORAL|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
215111777|NCT00657163|DRUG|fluoxetine|fluoxetine per os 20 mg daily
215111778|NCT00657163|DRUG|placebo|placebo per os daily
214424987|NCT01845259|DRUG|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
214424988|NCT01845259|DRUG|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
214424989|NCT05704751|DEVICE|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
214424990|NCT04333355|BIOLOGICAL|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
214424991|NCT04975308|DRUG|Imlunestrant|Administered orally.
214424992|NCT04975308|DRUG|Exemestane|Administered orally.
214424993|NCT04975308|DRUG|Fulvestrant|Administered IM.
214424994|NCT04975308|DRUG|Abemaciclib|Administered orally.
214424995|NCT02709655|DRUG|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
214424996|NCT02709655|DRUG|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
214424997|NCT02709655|DRUG|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
214424998|NCT02709655|OTHER|Placebo|Encapsulated tablet, orally
215111779|NCT03921931|OTHER|White light stimulation|Stimulation of the retina with white light
215111780|NCT06845527|OTHER|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
215111781|NCT05415007|BEHAVIORAL|GOLD Program|Participant will receive a 2-hour interventional session
215111782|NCT05415007|BEHAVIORAL|Treatment as usual (TAU)|Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
215111783|NCT02586870|DEVICE|Intravascular Ultrasound|
215111784|NCT01866358|PROCEDURE|Intraosseous infusion|Using intraosseous infusion for resustation in this group
215111785|NCT01866358|PROCEDURE|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
215111786|NCT05610527|OTHER|Proposed study design and randomization scenarios|Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
215111787|NCT05610527|OTHER|Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments|We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
214424999|NCT03461575|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
215028519|NCT04277247|DRUG|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
214425000|NCT03461575|DRUG|Restasis|cyclosporine 0.05%
214425001|NCT03461575|DRUG|Moisview|trehalose 3%
215028520|NCT04277247|DRUG|Placebo|0.9% saline placebo injection
215028521|NCT04927702|DEVICE|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
215028522|NCT04927702|DEVICE|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
215028523|NCT04927702|DEVICE|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
215028524|NCT03088683|DEVICE|Nathanson Retractor|Liver will be retracted with Nathanson retractor
215028525|NCT03088683|DEVICE|Reveel Retractor|Liver will be retracted with Reveel retractor
215028526|NCT00121979|DRUG|Racivir, a non-nucleoside reverse transcriptase inhibitor|
215028527|NCT04967456|DIAGNOSTIC_TEST|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
215028528|NCT05876520|PROCEDURE|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
215028529|NCT05797623|DRUG|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
215028530|NCT05797623|DRUG|Placebo ; ciclosporin|Placebo combined with ciclosporin
215028531|NCT02568319|DRUG|LIPO-202|
215028532|NCT02568319|DRUG|Placebo|
215028533|NCT02156947|PROCEDURE|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
215028534|NCT00924092|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces Cerevisia|
215028535|NCT00924092|DRUG|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
215028536|NCT00421564|DRUG|DBT-Danggui Buxue Tang|
215028537|NCT01490021|PROCEDURE|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
215028538|NCT01490021|PROCEDURE|rTMS/Placebo TBS|rTMS/Placebo TBS
215028539|NCT01910155|DRUG|Ciprofloxacin/Dexamethasone|
215028540|NCT01910155|DRUG|Ciprodex (R)|
215028541|NCT01910155|DRUG|Placebo|
215028542|NCT00006427|DRUG|Amitriptyline|
215028543|NCT00586157|DRUG|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
215028544|NCT00586157|DRUG|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
215028545|NCT01537328|OTHER|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
215028546|NCT04618094|OTHER|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
215028547|NCT00145730|DRUG|Ibuprofen|
215028548|NCT04556006|OTHER|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
215028549|NCT02014467|DRUG|Denosumab|Injection
215028550|NCT02014467|DRUG|Placebo|Injection
215028551|NCT02014467|DIETARY_SUPPLEMENT|Elemental Calcium|Oral, at least 600 mg
215028552|NCT02014467|DIETARY_SUPPLEMENT|Vitamin D|Oral, at least 400 IU
215028553|NCT00213525|OTHER|Questionnary for environmental factors research|Questionnary for environmental factors research
215111788|NCT05610527|OTHER|Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing|In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
215111789|NCT03053570|DEVICE|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
215111790|NCT03053570|DEVICE|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
215111791|NCT00237497|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
215111792|NCT00237497|DRUG|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
215111793|NCT00237497|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
215111794|NCT05138029|DRUG|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
215111795|NCT05138029|PROCEDURE|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
215111796|NCT05138029|DRUG|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
215111797|NCT02124213|DRUG|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
215111798|NCT02124213|DRUG|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
215111799|NCT02124213|DRUG|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
215111800|NCT05355662|OTHER|Age|The study was retrospective and did not involve the application of interventions.
215111801|NCT03336294|RADIATION|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
215111802|NCT03571555|BEHAVIORAL|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
215111803|NCT03835299|BEHAVIORAL|Fear Intervention|Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
215111804|NCT06841328|PROCEDURE|Stem cells|The administration of stem cell or stem cell-derived exosome therapy as a regenerative treatment for gonadal failure in both men and women. The intervention involves a single intra-gonadal injection (testicular or ovarian) of adipose-derived stem cells (ADSCs) or exosomes.
215111805|NCT04386941|PROCEDURE|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
215111806|NCT04386941|PROCEDURE|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
215111807|NCT05213702|DEVICE|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
215111808|NCT00139048|BEHAVIORAL|Decision Aid|
215111809|NCT06114199|BEHAVIORAL|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
215111810|NCT06114199|BEHAVIORAL|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
215111811|NCT01191177|DRUG|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
215111812|NCT01191177|DIETARY_SUPPLEMENT|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
214425002|NCT00102063|DRUG|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
214425003|NCT00102063|DRUG|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
215111813|NCT05509426|BEHAVIORAL|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
215111814|NCT04984486|DEVICE|dental implant|"The procedure used to accomplish its intended use is as follows :~* The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~* After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
215111815|NCT00001212|DRUG|prednisone|
215111816|NCT00001212|DRUG|cyclophosphamide|
215111817|NCT00001212|DRUG|cyclosporin A|
215111818|NCT03401255|OTHER|Partosure test|To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal swab provided in the PAMG-1 Detection Test Kit.After removing the swab from its packaging, hold the swab in the middle of the stem and carefully insert the end of the swab into the vagina over a length of 5-7cm (using a speculum). Is not necessary for sampling), when the patient is lying down.Remove the swab from the vagina after 30 seconds. Once the swab has been removed, immediately place the end in the solvent vial provided for this purpose, then rinse the swab by repeating several rotations for 30 seconds. The strip is removed as soon as two bands are clearly visible in the test area, or after 5 minutes.Two bands in the test area indicate a positive result, while a line in the test area indicates a negative result. It is not recommended to read or interpret results beyond 10 minutes of immersion.
215111819|NCT05230472|DRUG|Simvastatin|simvastatin 60 mg tab
215111820|NCT00318799|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
215111821|NCT00318799|DRUG|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
215111822|NCT05681065|DEVICE|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
215111823|NCT03376737|DRUG|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
215111824|NCT02828436|DEVICE|Precision Spectra System|Spinal Cord Stimulation
215111825|NCT02828436|BEHAVIORAL|Exercise Intervention|Standard Exercise
215111826|NCT01090193|PROCEDURE|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
215111827|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
215111828|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
215111829|NCT01136408|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
215111830|NCT00270062|DRUG|epoetin alfa|
215111831|NCT03867357|DRUG|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
215111832|NCT03461640|OTHER|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
215111833|NCT03461640|BEHAVIORAL|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
215111834|NCT05490576|RADIATION|[18F] PI-2620 Tau Ligand|Tau binding ligand
215111835|NCT03310814|OTHER|Personalized nutrition|Receives individualized nutrition information
215111836|NCT02502942|BEHAVIORAL|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
214425004|NCT00102063|DRUG|Placebo tablet|Placebo tablet po qd x 42 days
214425005|NCT03957213|DEVICE|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
214425006|NCT03957213|BEHAVIORAL|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
214425007|NCT00224601|PROCEDURE|Colonoscopy with chromoscopy|
214425008|NCT03695536|BEHAVIORAL|ultrasound use during resuscitation|ultrasound use during resuscitation
214510166|NCT02132520|BEHAVIORAL|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
215111837|NCT02502942|BEHAVIORAL|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
215111838|NCT01485328|DRUG|AMARGOL®|per oral solution, 40 mL single dose
215111839|NCT01299181|DRUG|Atorvastatin|80mg once daily orally
215111840|NCT04220554|OTHER|Improved support by health-care professionals|Improved support to patients prescribed topical antipsoriatic drugs
214510167|NCT00113308|DRUG|GW406381|
214510168|NCT03403036|DRUG|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
214510169|NCT01411657|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
214692243|NCT06856005|OTHER|Music intervention|"to evaluate the effectiveness of personalized music playlists in reducing procedural anxiety among young dentists performing crown preparations for porcelain-fused-to-metal (PFM) crowns and to compare the crown preparation performance of students who listened to music with those who did not.~• Experimental Group:~o Participants in the experimental group were asked to use personalized music playlists during the procedure. These playlists were already available on their personal devices (e.g., smartphones) and reflected their individual music preferences. Participants selected music they found relaxing or enjoyable, ensuring the intervention was tailored to their unique tastes."
214692244|NCT04051021|BEHAVIORAL|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
214692245|NCT04051021|OTHER|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
214692246|NCT00450203|BIOLOGICAL|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
215111841|NCT00002984|DRUG|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
215111842|NCT00002984|DRUG|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
215111843|NCT00002984|DRUG|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
215111844|NCT00002984|PROCEDURE|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
215111845|NCT00002984|RADIATION|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
214510170|NCT03175406|DIAGNOSTIC_TEST|Manipal cervical scoring system|
214510171|NCT03862898|OTHER|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
214510172|NCT01630304|BEHAVIORAL|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
214510173|NCT04349319|DEVICE|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
214510174|NCT00568087|DRUG|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
214510175|NCT00568087|DRUG|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
214510176|NCT00815100|DRUG|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
214692247|NCT00450203|DRUG|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
215111846|NCT04615039|DEVICE|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
215111847|NCT05440422|DRUG|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
215111848|NCT05440422|OTHER|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
215111849|NCT05615740|DIAGNOSTIC_TEST|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
215111850|NCT00655616|DRUG|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
215111851|NCT00655616|DRUG|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
215111852|NCT03782701|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
215111853|NCT03782701|OTHER|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
215111854|NCT04421482|OTHER|Standard room temperature (RTS) feeding of milk/formula|Standard room temperature (RTS) milk/formula will be given for an entire feeding (15-20 minutes).
215111855|NCT04421482|OTHER|Cold temperature (CS, at 4-9°C) of milk/formula|If the infant shows signs of dysphagia cold temperature (CS, at 4-9°C) milk/formula will be given for an entire feeding (15-20 minutes).
215111856|NCT01013194|OTHER|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2."
215111857|NCT03502473|DEVICE|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer"
215111858|NCT05604027|DIAGNOSTIC_TEST|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
215111859|NCT00087334|DRUG|capecitabine|
215111860|NCT00087334|DRUG|gefitinib|
215111861|NCT00087334|DRUG|oxaliplatin|
215111862|NCT02682732|PROCEDURE|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
215111863|NCT03736941|OTHER|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
215111864|NCT04770038|BEHAVIORAL|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
215111865|NCT02085694|DRUG|Lactobacillus brevis CD2|
215111866|NCT02128724|DRUG|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
215111867|NCT01347242|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
215111868|NCT02780492|OTHER|Set of assessment tools|
215111869|NCT02644317|DEVICE|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
215111870|NCT05624580|DRUG|NNC0582-0001|Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.
214692248|NCT00450203|DRUG|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
215111871|NCT05624580|DRUG|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
215111872|NCT01057186|DIETARY_SUPPLEMENT|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
215111873|NCT01057186|DRUG|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
215111874|NCT03524014|OTHER|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
215111875|NCT03550274|DEVICE|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
214692249|NCT00450203|DRUG|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
214692250|NCT00450203|PROCEDURE|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
214510177|NCT00815100|DRUG|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
214510178|NCT02701296|DRUG|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
214510179|NCT02701296|DRUG|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
215111876|NCT01731366|OTHER|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
215111877|NCT01731366|OTHER|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
215111878|NCT03368586|DEVICE|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (\<4.0 mmol/L) or high (\>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
214510180|NCT05483166|BEHAVIORAL|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~1. Becoming aware of the child's core strengths and difficulties~2. Helping the child to be optimally responsive to the guidance of the parent(s), and~3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
214510181|NCT02751710|OTHER|Whole-body FDG PET-CT alone|FDG PET-CT imaging
214510182|NCT01844401|DRUG|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
214510183|NCT01844401|DRUG|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
214510184|NCT05019859|BEHAVIORAL|low carb diet|low carb diet
214692251|NCT00450203|PROCEDURE|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
215111879|NCT06403267|DRUG|NoNO-42|a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
215111880|NCT06457425|DRUG|Flonoltinib 50mg|Flonoltinib 50mg, QD
215111881|NCT06457425|DRUG|Flonoltinib 100mg|Flonoltinib 100mg, QD
214510185|NCT06509321|PROCEDURE|subinguinal loupe-assisted varicocelectomy (LV)|to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
214692252|NCT00450203|PROCEDURE|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
214692253|NCT00450203|DRUG|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
214692254|NCT02075762|PROCEDURE|Transbronchial biopsy|
214692255|NCT02075762|PROCEDURE|Cryoprobe biopsy|
214692256|NCT02075762|PROCEDURE|VATS biopsy|
214692257|NCT00635947|OTHER|isotonic solution|1.5 L- during 2-4hours
215111882|NCT06457425|DRUG|Ruxolitinib|For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
215111883|NCT05287425|DRUG|Gentamicin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
215111884|NCT05287425|DRUG|Ciprofloxacin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
215111885|NCT05287425|DRUG|Povidone Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
215111886|NCT05287425|DRUG|Povidone and Benzalkonium Chloride Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
215111887|NCT06334718|BEHAVIORAL|Interviews and simulation|Work package 1: interview study Work package 2: simulated cardiac arrest study with AED delivered by drone following a simulated emergency (999) call.
215111888|NCT05055843|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D MRI
215111889|NCT04961112|DEVICE|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
215111890|NCT04961112|DEVICE|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
215111891|NCT06500715|DEVICE|Acupuncture|Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
215111892|NCT02761122|PROCEDURE|Human biological samples|"* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
215111893|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection low dose administered by subcutaneous injection
214510186|NCT06509321|PROCEDURE|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
215111894|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection medium dose administered by subcutaneous injection
215111895|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection high dose administered by subcutaneous injection
215111896|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection lowest dose administered by subcutaneous injection
215111897|NCT06425341|DRUG|HRS-5635 Injection (low dose) and Peg-IFN-α|HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection
215111898|NCT06425341|DRUG|HRS-5635 Injection (high dose) and Peg-IFN-α|HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection
215111899|NCT06425341|DRUG|Peg-IFN-α|Peg-IFN-α, administered by subcutaneous injection
215111900|NCT05945524|OTHER|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
215111901|NCT05989230|BEHAVIORAL|Emotional Awareness and Expression Therapy|The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
215111902|NCT03329092|DRUG|ATM-AVI|"(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
215111903|NCT03329092|DRUG|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
215111904|NCT03329092|DRUG|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
215111905|NCT03329092|DRUG|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
215111906|NCT05786508|OTHER|Partners4Pain program|"Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
215111907|NCT05786508|OTHER|Key to Wellbeing program|"Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
215111908|NCT05969067|PROCEDURE|Tunneling Technique during RA SCP|As described in the intervention arm above
215111909|NCT05969067|PROCEDURE|Dissection Technique during RA SCP|As described in the intervention arm above
215111910|NCT04770116|DEVICE|Auditory Stimulation|The device records biosignals and precisely plays tones to enhance sleep slow waves.
215111911|NCT05396248|BEHAVIORAL|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
215111912|NCT05396248|BEHAVIORAL|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
215111913|NCT02312817|OTHER|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
215111914|NCT02312817|OTHER|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
215111915|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
215111916|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
215111917|NCT06359210|BEHAVIORAL|Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
214692258|NCT00635947|OTHER|water|1.5 L- during 2-4hours
214510187|NCT02082990|BEHAVIORAL|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
214510188|NCT02082990|BEHAVIORAL|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
215111918|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
215111919|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
215111920|NCT04662554|DEVICE|1-mm Resolution Clinical PET camera|1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
215111921|NCT05547048|BEHAVIORAL|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
215111922|NCT05547048|COMBINATION_PRODUCT|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
215111923|NCT05833438|DRUG|VEN+AZA-5|Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
215111924|NCT05350644|OTHER|Primary exposure variable|"1. Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~2. Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
215111925|NCT05350644|OTHER|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
215111926|NCT04239235|BEHAVIORAL|CRAFT|CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
215111927|NCT04273893|RADIATION|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
215111928|NCT04273893|RADIATION|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
215111929|NCT04273893|DIAGNOSTIC_TEST|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
215111930|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
215111931|NCT02081313|OTHER|Biopsy|
215111932|NCT02081313|OTHER|Blood sample|
215111933|NCT03906071|BIOLOGICAL|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
215111934|NCT03906071|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
215111935|NCT03906071|DRUG|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
215111936|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
215111937|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
215111938|NCT04299282|DEVICE|CanGaroo|CIED ECM envelope
215111939|NCT02700386|COMBINATION_PRODUCT|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
215111940|NCT05328596|BEHAVIORAL|CBT-treatment|Cognitive Behavioral Treatment for Gaming Disorder.
215111941|NCT05328596|BEHAVIORAL|Wait list control|No intervention
215111942|NCT06005844|DIAGNOSTIC_TEST|Cerebellar Cognitive-Affective Syndrome Scale|The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
215111943|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
215111944|NCT03657290|DRUG|vadadustat|Vadadustat Tablets
215111945|NCT06071650|BEHAVIORAL|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
215111946|NCT01295957|BEHAVIORAL|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
215111947|NCT01295957|BEHAVIORAL|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
215111948|NCT01295957|OTHER|control|advise and informal counseling
215111949|NCT02353715|DRUG|Enzalutamide|
215111950|NCT02353715|DRUG|Abiraterone acetate|
214510189|NCT05103891|DRUG|Binimetinib Oral Tablet|two-period, crossover study
214510190|NCT00714207|BEHAVIORAL|NOT program|Students in this arm of the study received the reformatted NOT intervention
214510191|NCT00714207|BEHAVIORAL|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
214510192|NCT00714207|BEHAVIORAL|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
214510193|NCT00714207|BEHAVIORAL|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
214510194|NCT01869465|OTHER|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
214510195|NCT01869465|BEHAVIORAL|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
215111951|NCT02353715|DRUG|Sipuleucel-T|
214510196|NCT02832128|DRUG|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
215111952|NCT01761019|DRUG|Taclonex Topical Suspension|topical medication for psoriasis
215111953|NCT05426070|BEHAVIORAL|Strength training-based exercise|Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
215111954|NCT04618289|DIETARY_SUPPLEMENT|Vitamin D3-fortified fruit juice supplement|Vitamin D3-fortified fruit juice supplement
215111955|NCT02497729|PROCEDURE|Written Checklist|Use of a written checklist pre and peri-intubation
215111956|NCT02497729|PROCEDURE|Head of Bed Up|Raising the patient's head of bed to 25 degrees
215111957|NCT00225498|DRUG|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
214510197|NCT02832128|DRUG|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
215111958|NCT04775641|OTHER|questionnaire|questionnaire
214510198|NCT02074228|DRUG|Methylphenidate (Concerta)|
214692259|NCT00635947|OTHER|water|200mL- during 2-4hours
215111959|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
215111960|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
215111961|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
215111962|NCT04577430|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
215111963|NCT03956966|DRUG|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
215111964|NCT03956966|DRUG|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
215111965|NCT03956966|DRUG|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
215111966|NCT03919474|DIAGNOSTIC_TEST|microvascular markers|follow up of microvascular biomarkers during patient follow up
215111967|NCT01517555|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
215111968|NCT01517555|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
215111969|NCT01517555|DRUG|paracetamol|One single dose of 1 g. Tablet
215111970|NCT03456232|OTHER|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
215111971|NCT03456232|OTHER|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
215111972|NCT05639296|OTHER|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
215111973|NCT01456169|DRUG|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
215111974|NCT01456169|DRUG|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
215111975|NCT02598297|DRUG|Ruxolitinib|5 mg tablet for oral use
215111976|NCT02598297|DRUG|Ruxolitinib Placebo|5 mg placebo tablet for oral use
215111977|NCT01888224|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
215111978|NCT01222780|DRUG|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
215111979|NCT05547126|DEVICE|Transcranial direct current stimulation|"It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy."
215111980|NCT05651867|DEVICE|EPIONE device|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
215111981|NCT02984917|PROCEDURE|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
215111982|NCT02984917|PROCEDURE|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
215111983|NCT02398604|DRUG|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
215111984|NCT02398604|DRUG|Placebo|Placebo
215111985|NCT03114332|PROCEDURE|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
215111986|NCT04355403|DEVICE|Hyalo Gyn gel in prefilled applicators|One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
214510199|NCT01020266|PROCEDURE|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
215111987|NCT02859103|DRUG|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
215111988|NCT05021146|OTHER|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
214510200|NCT01020266|PROCEDURE|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
214692260|NCT03951961|DRUG|Midostaurin|50mg Midostaurin bid for 12 months
214692261|NCT06142747|DIAGNOSTIC_TEST|Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)|Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
215111989|NCT05021146|OTHER|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
215111990|NCT05021146|OTHER|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
215111991|NCT00412243|DRUG|Clofarabine|40 mg/m\^2 Daily for 3 Days
215111992|NCT00412243|DRUG|Cyclophosphamide|Beginning dose 200 mg/m\^2 every 12 hours for 3 days
215111993|NCT03060278|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials.
215111994|NCT03060278|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
215111995|NCT03060278|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
215111996|NCT03060278|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
215111997|NCT00933868|DRUG|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
215111998|NCT00933868|DRUG|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
215111999|NCT00935311|DRUG|ABT-712 Extended-release|ABT-712 extended-release tablet
215112000|NCT00935311|DRUG|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
215112001|NCT00935311|DRUG|Placebo|Placebo tablet
215112002|NCT03223116|PROCEDURE|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
215112003|NCT04336072|BEHAVIORAL|RFPP|
215112004|NCT04336072|BEHAVIORAL|TFCBT|
215112005|NCT00729625|DEVICE|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
215112006|NCT00870012|DRUG|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
215112007|NCT00870012|OTHER|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
215112008|NCT02914574|OTHER|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
215112009|NCT00394706|DEVICE|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
215112010|NCT00394706|DEVICE|Sham ITD|Sham ITD
214692262|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.
215112011|NCT00394706|OTHER|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
215112012|NCT00394706|OTHER|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
215112013|NCT04270799|DIAGNOSTIC_TEST|Machine Learning Classification|Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
215112014|NCT01593124|DRUG|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
215112015|NCT01593124|OTHER|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
215112016|NCT01593124|DRUG|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
215112017|NCT04498442|BEHAVIORAL|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
215112018|NCT04498442|BEHAVIORAL|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
215112019|NCT04846322|DIAGNOSTIC_TEST|PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)|"1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan."
215112020|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
215112021|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
215112022|NCT01561521|DRUG|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
215112023|NCT04861935|DEVICE|ultrasound evaluation|ultrasound evaluation of normal patients and patients who have a sacral dimple
214425009|NCT06335654|DIAGNOSTIC_TEST|artificial intelligence system|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
214510201|NCT05137366|DIAGNOSTIC_TEST|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~1. Suprasternal window~2. Parasternal long axis window~3. Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
214510202|NCT00240994|DRUG|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
215112024|NCT02466282|DEVICE|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
215112025|NCT02466282|DEVICE|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
215112026|NCT05878847|DIETARY_SUPPLEMENT|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
215112027|NCT05878847|DIETARY_SUPPLEMENT|Placebo|Placebo
215112028|NCT01649934|BEHAVIORAL|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
215112029|NCT01649934|BEHAVIORAL|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
215112030|NCT05478083|DRUG|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
215112031|NCT03737539|DIAGNOSTIC_TEST|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
215112032|NCT00960492|DRUG|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
215112033|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
215112034|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
215112035|NCT00960492|RADIATION|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
215112036|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
214510203|NCT00240994|DRUG|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
214510204|NCT00240994|DRUG|Mycophenolate mofetil|Per recommendation
215112037|NCT04270968|DEVICE|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
215112038|NCT04270968|DRUG|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
214692263|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
214692264|NCT02426242|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
215112039|NCT01469273|DRUG|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
215112040|NCT05185999|DRUG|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
215112041|NCT06113055|DRUG|L-serine|Active comparator
215112042|NCT06113055|DRUG|Placebo|Placebo comparator
215112043|NCT04684069|DEVICE|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
215112044|NCT04684069|DEVICE|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
215112045|NCT06165328|DIAGNOSTIC_TEST|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
215112046|NCT03369249|BEHAVIORAL|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
215112047|NCT03316638|DRUG|W0101 - Cohort A1|Administered once every 2 weeks
215112048|NCT03316638|DRUG|W0101 - Cohort A2|Administered every 3 weeks
215112049|NCT03316638|DRUG|W0101 - Expansion Phase|Administered according to the recommended dose for expansion
215112050|NCT02770924|DEVICE|AT LISA TRI TORIC|phacoemulsification with IOL implantation
215112051|NCT02770924|DEVICE|AT LISA TRI|phacoemulsification with IOL implantation
215112052|NCT02003534|DRUG|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
215112053|NCT01247961|DRUG|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
215112054|NCT01247961|OTHER|Placebo|Normal saline
215112055|NCT00640497|BIOLOGICAL|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
215112056|NCT02133885|DRUG|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
215112057|NCT02133885|OTHER|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
215112058|NCT05330832|DIAGNOSTIC_TEST|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
215112059|NCT04473027|DIAGNOSTIC_TEST|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
215112060|NCT00321451|BEHAVIORAL|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
215112061|NCT00321451|BEHAVIORAL|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
215112062|NCT00321451|OTHER|Usual care|3 outpatient visits with study physician
215112063|NCT03441386|BEHAVIORAL|Physical Exercise Session|
214425010|NCT05150054|DEVICE|CardioFlux|Not an intervention
214425011|NCT05082025|DRUG|Copanlisib|Given by IV
214425012|NCT05082025|DRUG|fulvestrant|Given by IM
214425013|NCT04210180|DRUG|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
215112064|NCT00445185|BIOLOGICAL|Henogen HB vaccine|Month 12, 24 and 36
215112065|NCT00445185|BIOLOGICAL|Fendrix vaccine|Month 12, 24 and 36
215112066|NCT04287387|DRUG|Glucophage 500Mg Tablet|0.5g three times daily
215112067|NCT04287387|DRUG|Acarbose Tablets|50mg three times daily
215112068|NCT04287387|DRUG|Sitagliptin tablet|100mg once daily
215112069|NCT04287387|DRUG|Dapagliflozin Tablet|10mg once daily
215112070|NCT04287387|DRUG|Pioglitazone Tablets|30mg once daily
215112071|NCT04287387|DRUG|Glimepiride Tablets|2mg once daily
215112072|NCT02652156|DRUG|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
214510205|NCT00240994|DRUG|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
214510206|NCT05484336|OTHER|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214510207|NCT05484336|OTHER|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214510208|NCT05484336|OTHER|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214510209|NCT05484336|OTHER|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214510210|NCT01437540|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
214510211|NCT01437540|DRUG|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
214510212|NCT04083209|BEHAVIORAL|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
214510213|NCT00130091|DRUG|clonidine|2 mcg clonidine added to local anesthetic
215112073|NCT02652156|DRUG|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
215112074|NCT02652156|DRUG|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
215112075|NCT00342849|DRUG|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
215112076|NCT00342849|DRUG|Placebo|
215112077|NCT02178761|DEVICE|drug-eluting balloon|angioplasty completed with drug-eluting balloons
215112078|NCT02178761|DEVICE|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
215112079|NCT02178761|DEVICE|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
215112080|NCT02178761|DEVICE|Stent System|stenting with either bare-metal stents or drug-eluting stents
215112081|NCT04031859|DRUG|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
215112082|NCT05564455|OTHER|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
215112083|NCT05564455|OTHER|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
215112084|NCT04405973|DEVICE|vv-ECMO|vv-ECMO required in severe COVID-19 ARDS
215112085|NCT00002695|GENETIC|DNA stability analysis|
215112086|NCT00002695|GENETIC|microsatellite instability analysis|
215112087|NCT00002695|GENETIC|mutation analysis|
215112088|NCT00002695|OTHER|laboratory biomarker analysis|
215112089|NCT03709004|OTHER|Pacifier|Pacifier given to mom.
215112090|NCT05697562|PROCEDURE|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
215112091|NCT05697562|PROCEDURE|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
214692265|NCT00118170|DRUG|sorafenib tosylate|Given orally
214692266|NCT00118170|OTHER|pharmacological study|Correlative studies
214692267|NCT00222729|DRUG|Pemetrexed|500 mg/m2 day 1 q 21 days
214692268|NCT00222729|DRUG|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
214692269|NCT03777956|DRUG|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
214425014|NCT04210180|OTHER|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
214692270|NCT03777956|DRUG|Placebo|Identical placebo are given as capsules and taken orally twice a day.
214692271|NCT01729364|DRUG|crystalloid|
214425015|NCT02220816|BEHAVIORAL|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
214425016|NCT02220816|BEHAVIORAL|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
214425017|NCT01179334|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
214425018|NCT01179334|DRUG|Placebo|Placebo for 12 weeks
214425019|NCT01179334|DRUG|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
214425020|NCT01325558|BIOLOGICAL|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
214425021|NCT01912131|BEHAVIORAL|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
214425022|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
214425023|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
214425024|NCT01912131|BEHAVIORAL|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
214425025|NCT01912131|BEHAVIORAL|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
214425026|NCT00092898|DRUG|MK0653, ezetimibe|
214425027|NCT00092898|DRUG|Comparator: placebo|
214425028|NCT04329793|DEVICE|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
214425029|NCT04329793|OTHER|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
214425030|NCT00043654|DRUG|Mifepristone|
214425031|NCT05893459|BEHAVIORAL|Debrief|Post-Stressor Discussion with a Friend
214425032|NCT05357365|OTHER|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
214692272|NCT01729364|DRUG|colloid|
214692273|NCT05212194|OTHER|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
214425033|NCT00316953|DRUG|dasatinib|Given orally
214425034|NCT00316953|OTHER|pharmacological study|Correlative studies
214425035|NCT00316953|OTHER|laboratory biomarker analysis|Correlative studies
214692274|NCT02124187|DEVICE|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
214692275|NCT02124187|DEVICE|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
214692276|NCT02124187|DEVICE|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
214692277|NCT04592276|DIETARY_SUPPLEMENT|PS128|Participants took two capsules with PS128 after dinner for 30 days.
214692278|NCT04592276|DIETARY_SUPPLEMENT|placebo|Participants took two capsules without PS128 after dinner for 30 days.
215112092|NCT05697562|PROCEDURE|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
214425036|NCT06289348|BEHAVIORAL|socio-psychological questionnaire|ton collecte socio-demographic variable
215112093|NCT04513548|DRUG|Ligelizumab|One injection every four weeks
215112094|NCT04513548|DRUG|Placebo|One injection every four weeks
215112095|NCT01073449|PROCEDURE|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
215112096|NCT06209827|BEHAVIORAL|Intervention for reducing benzodiazepines long-term use.|"Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor."
215112097|NCT00195286|DRUG|piperacillin/tazobactam|
215112098|NCT00936000|DIETARY_SUPPLEMENT|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
215112099|NCT02593942|DRUG|Remifentanil|0.1-0.5 mcg/kg/min infusion
215112100|NCT02593942|DRUG|Propofol|75-200 mcg/kg/min infusion
215112101|NCT04107532|OTHER|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
215112102|NCT01071421|DEVICE|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
215112103|NCT03932695|DIETARY_SUPPLEMENT|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
215112104|NCT03932695|DIETARY_SUPPLEMENT|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
215112105|NCT03932695|DIETARY_SUPPLEMENT|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
215112106|NCT05781074|DRUG|Sintilimab|a PD-1 immune checkpoint inhibitor
215112107|NCT05781074|DRUG|Lenvatinib|Lenvatinib capsules
215112108|NCT05781074|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
215112109|NCT02342223|DEVICE|Voluma|
215112110|NCT02223338|DRUG|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
215112111|NCT02223338|DRUG|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
215112112|NCT00496080|DEVICE|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
215112113|NCT03349125|BEHAVIORAL|Collar On|
215112114|NCT03349125|BEHAVIORAL|Collar Off|
215112115|NCT06004986|DRUG|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
215112116|NCT03636789|OTHER|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
215112117|NCT05725980|DIAGNOSTIC_TEST|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
215112118|NCT03101254|DRUG|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
215112119|NCT03101254|DRUG|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
215112120|NCT03101254|DRUG|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
215112121|NCT01200368|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
215112122|NCT01200368|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
215112123|NCT01200368|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
215112124|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
215112125|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
215112126|NCT01675518|DRUG|ASP7991|oral
215112127|NCT01675518|DRUG|Placebo|oral
215112128|NCT04429191|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
215112129|NCT00570310|DRUG|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
215112130|NCT00570310|DRUG|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
215112131|NCT00856063|DRUG|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
215112132|NCT00108862|OTHER|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
214510214|NCT04417309|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
214510215|NCT04417309|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
214510216|NCT04986371|DRUG|Niraparib|Usage following drug insert is recommended
214510217|NCT01375790|DEVICE|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
214510218|NCT01375790|OTHER|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
214510219|NCT03142932|DEVICE|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
214510220|NCT03142932|OTHER|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
214510221|NCT03142932|BEHAVIORAL|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
214510222|NCT01934322|OTHER|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
215112133|NCT00108862|OTHER|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
215112134|NCT01817023|RADIATION|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
215112135|NCT01817023|DRUG|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
215112136|NCT03094741|OTHER|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
215112137|NCT05878535|DRUG|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
215112138|NCT05878535|DRUG|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
215112139|NCT05139784|OTHER|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
215112140|NCT06144554|DEVICE|Omnipod 5|"The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs.~Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment."
215112141|NCT04054986|DIAGNOSTIC_TEST|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
215112142|NCT04054986|OTHER|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
215112143|NCT01497301|BEHAVIORAL|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
215112144|NCT00117260|DRUG|Seasonale (levonorgestrel and ethinyl estradiol)|
214692279|NCT05547373|BEHAVIORAL|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
214692280|NCT03342612|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|
214425037|NCT06289348|BEHAVIORAL|revised event impact scale (IER-S)|22 items assessed on a scale of frequency from 0 (not at all) to 4 (extremely)
214425038|NCT06289348|OTHER|Non directive interview|composed of a very broad opening sentence to encourage the parents' discourse
214425039|NCT06289348|OTHER|Stern interview|54 questions to investigate the impact of the announcement and the parenthood construction
214510223|NCT05448222|DIAGNOSTIC_TEST|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
214510224|NCT03688087|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
214510225|NCT03688087|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
214510226|NCT02414594|DRUG|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
214510227|NCT02414594|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214510228|NCT04188457|OTHER|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
214510229|NCT04188457|OTHER|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
214425040|NCT06289348|OTHER|semi-directive interview|to propose ideas for improving and harmonizing practices
214425041|NCT05787964|PROCEDURE|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
214425042|NCT05190419|DRUG|Orismilast modified release tablets|Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
214510230|NCT01942525|OTHER|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
214510231|NCT04131036|OTHER|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
214510232|NCT05164926|OTHER|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
214510233|NCT05858359|BEHAVIORAL|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
214510234|NCT00259363|DRUG|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
214510235|NCT00973414|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
215112145|NCT05232331|DIETARY_SUPPLEMENT|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming \~ 350 mg of nitrate daily from vegetables
214425043|NCT05190419|DRUG|Placebo|Matching placebo tablets
215112146|NCT06535620|OTHER|red wine with alcohol|200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
215112147|NCT06535620|OTHER|red wine without alcohol|200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
215112148|NCT03056742|BIOLOGICAL|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
214425044|NCT04537065|OTHER|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
214510236|NCT00973414|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
214510237|NCT03665714|OTHER|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
214510238|NCT03665714|OTHER|Enteral Nutrition Emulsion(TPF-T)|TPF-T
214510239|NCT03237026|OTHER|No intervention required|No intervention required
214510240|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
214510241|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
214510242|NCT05964309|OTHER|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
214510243|NCT05964309|OTHER|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
214510244|NCT00244452|DRUG|Cetrorelix|
214510245|NCT02395692|OTHER|Treatment|Correlative studies
214510246|NCT02395692|DRUG|Methoxyamine|Given PO
214510247|NCT02395692|DRUG|Temozolomide|Given PO
214510248|NCT04221165|DRUG|Opioids|Opioids will be prescribed as per institutional standards.
214510249|NCT04221165|DRUG|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
214425045|NCT04643340|OTHER|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
214425046|NCT03426072|OTHER|modified IHI breakthrough series|"There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5\. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
214425047|NCT00114699|DRUG|CCR5mAb004|
214425048|NCT00919763|DRUG|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
214425049|NCT00919763|DRUG|Vehicle Ointment, twice daily|Topical Ointment
214425050|NCT01094405|BIOLOGICAL|Recombinant Epstein-Barr Virus (EBV) Vaccine|
214692281|NCT02937103|BIOLOGICAL|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214425051|NCT04705922|DRUG|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
214425052|NCT04705922|DRUG|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
214510250|NCT05576779|OTHER|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
214510251|NCT01039909|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
214510252|NCT01039909|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
214510253|NCT01941576|DRUG|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
214510254|NCT01941576|DRUG|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
214510255|NCT00854594|BEHAVIORAL|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
214510256|NCT05308888|DIAGNOSTIC_TEST|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG (\[18F\]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
214510257|NCT00534677|DRUG|Terlipressin|2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
214425053|NCT00036036|DRUG|CP-461|
214425054|NCT03516435|DEVICE|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
214425055|NCT03516435|DEVICE|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
214692282|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
215112149|NCT01862523|BIOLOGICAL|Capsaicin|Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
215112150|NCT01862523|BIOLOGICAL|diluent|diluent
214425056|NCT04036630|DEVICE|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
214510258|NCT00534677|DRUG|Octreotide|Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
214510259|NCT06021002|DRUG|R848|Nasal R848 administration
214510260|NCT06021002|DRUG|Saline|Nasal saline administration
214510261|NCT01753440|PROCEDURE|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
214510262|NCT06038747|OTHER|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
214510263|NCT06038747|OTHER|Individual Psychotherapy|Individual psychotherapy sessions
214510264|NCT05918549|DEVICE|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
214425057|NCT04036630|DEVICE|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
214425058|NCT00624026|DRUG|Memantine-HCl|20 mg per day (once daily)
214425059|NCT03133117|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
214425060|NCT01336283|OTHER|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
214425061|NCT01336283|OTHER|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
214425062|NCT01336283|OTHER|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
214425063|NCT03697538|PROCEDURE|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
214425064|NCT03992417|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214425065|NCT00710892|BIOLOGICAL|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
214425066|NCT05389644|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
214425067|NCT05931887|DEVICE|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|A foley catheter is assigned and used according to regular standard of care
214510265|NCT03162835|OTHER|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
214692283|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
214692284|NCT01318083|DRUG|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
214692285|NCT05990660|DEVICE|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
214692286|NCT01741194|DRUG|AC-1204|AC-1204 taken once daily, by mouth
214425068|NCT02024542|OTHER|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
214425069|NCT05754814|OTHER|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
214425070|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
214425071|NCT04580901|BEHAVIORAL|Group Interpersonal Psychotherapy|Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
214425072|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
214425073|NCT05968573|OTHER|Video Format with Captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
214510266|NCT03471442|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
214510267|NCT03471442|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
214510268|NCT03471442|DRUG|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
214692287|NCT01741194|DRUG|Placebo|Placebo taken once daily, by mouth
214692288|NCT03702205|DIETARY_SUPPLEMENT|Betaine supplementation|Group taking oral betaine supplementation
214692289|NCT03702205|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
214510269|NCT03471442|DRUG|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
214425074|NCT05968573|OTHER|Video Format without Captions|A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
214425075|NCT05968573|OTHER|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
214425076|NCT05854017|DIETARY_SUPPLEMENT|Theanine for stress relief formulation|Theanine for stress relief formulation tablet
214425077|NCT05854017|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
214425078|NCT06425042|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program
214425079|NCT06425042|DIETARY_SUPPLEMENT|Placebo|Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
214425080|NCT04602598|DRUG|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
214425081|NCT05677633|DRUG|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
214425082|NCT03418961|DRUG|Carvedilol|Given PO
214425083|NCT03418961|OTHER|Laboratory Biomarker Analysis|Correlative studies
214510270|NCT03471442|DRUG|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
214510271|NCT00749944|DRUG|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
214510272|NCT00749944|DRUG|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
214510273|NCT01382706|DRUG|docetaxel|Given IV
214692290|NCT03380117|BEHAVIORAL|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
214692291|NCT03408496|OTHER|Myofascial release|Manual therapy
214692292|NCT03408496|OTHER|Muscle stretching|Muscle stretching
214692293|NCT03408496|OTHER|Control|Medical appointment
214425084|NCT03418961|OTHER|Patient Observation|Undergo observation
214425085|NCT06288932|DRUG|Mycophenolate Mofetil (MMF) Treatment|The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
214425086|NCT03729453|DEVICE|SpyGlass|Visualization of main pancreatic duct with SpyGlass catheter.
214425087|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
214425088|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
214425089|NCT06581939|PROCEDURE|Rehabilitation group|In the rehabilitation group, patients will follow an individualized rehabilitation program started early in the ICU and continued in the post-ICU ward then at home for 12 weeks, combining goal-directed nutrition and physical activity, tailored to gains made over time by each patient, with the involvement of dieticians, physiotherapists, and adapted-physical-activity instructors.
214425090|NCT06581939|PROCEDURE|Control group|In the control group, patients will receive usual care from day-0 to day-180.
214425091|NCT04482400|BEHAVIORAL|NEAT!2|8 week sedentary reduction program
214425092|NCT04482400|BEHAVIORAL|MyKneeGuide|8 week surgery recovery education program
214425093|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter
214425094|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
214510274|NCT01382706|DRUG|lapatinib ditosylate|Given PO
214510275|NCT01382706|OTHER|immunohistochemistry staining method|Correlative studies
214510276|NCT01382706|GENETIC|fluorescence in situ hybridization|Correlative studies
214510277|NCT01382706|OTHER|laboratory biomarker analysis|Correlative studies
214510278|NCT00913445|PROCEDURE|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
214510279|NCT00201656|PROCEDURE|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
214510280|NCT00201656|PROCEDURE|Removal of Cerclage|Immediate removal of Cerclage following randomization
214510281|NCT00201656|PROCEDURE|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
214510282|NCT00006214|DRUG|flutamide|
214510283|NCT00006214|OTHER|placebo|
214425095|NCT05216510|BIOLOGICAL|TNX-2110|TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
214425096|NCT05216510|BIOLOGICAL|TNX-2120|TNX-2120 represents the spike protein and is administered intradermally.
214425097|NCT05216510|BIOLOGICAL|TNX-2130|TNX-2130 represents non-spike proteins and is administered intradermally.
214425098|NCT05216510|BIOLOGICAL|CANDIN|Candida albicans antigens to be administered intradermally as a positive control.
214425099|NCT05216510|BIOLOGICAL|Diluent|Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
214425100|NCT05574192|BEHAVIORAL|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~1. arts-based activities.~2. physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
214425101|NCT06649097|DEVICE|IRRAflow® CNS (Active Fluid Exchange) System|The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
214425102|NCT05452720|DEVICE|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
214425103|NCT04408898|GENETIC|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
214425104|NCT06097000|DEVICE|powered exoskeletons|Whether to use powered exoskeletons for exercise rehabilitation
214425105|NCT06369623|OTHER|Monetary Incentive Delay Task|The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
214425106|NCT05959356|DRUG|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
214425107|NCT05959356|DRUG|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
214425108|NCT06849401|BIOLOGICAL|VGO-Cs01p|Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)
214425109|NCT05746247|BEHAVIORAL|Testing centralized referral mechanism for PCPs|"For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed."
214510284|NCT01995734|DRUG|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
214510285|NCT02629575|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
214510286|NCT03556267|DEVICE|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
214692294|NCT02461485|OTHER|Fermented milk product containing Probiotics|2 pots/day during 28 days
214425110|NCT05746247|BEHAVIORAL|Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation|All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
214510287|NCT04577391|OTHER|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
214692295|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
214692296|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
214692297|NCT02461485|OTHER|Non fermented Milk Product|2 pots/day during 28 days
214692298|NCT00256867|DRUG|GSK523338|
214692299|NCT06316258|BEHAVIORAL|Compassion focused therapy group|6 session compassion focused therapy group for adults with ABI
214425111|NCT01047735|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
214425112|NCT01047735|PROCEDURE|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
214425113|NCT01047735|BEHAVIORAL|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
214425114|NCT04143646|BEHAVIORAL|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
214425115|NCT05748067|PROCEDURE|SDF|Silver diamine fluoride
214425116|NCT05748067|PROCEDURE|HVGIC restoration|High viscosity glass ionomer restoration
214510288|NCT04577391|OTHER|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
214425117|NCT05748067|PROCEDURE|SSC|Stainless steel crown
214510289|NCT02547974|BIOLOGICAL|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214510290|NCT02547974|BIOLOGICAL|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214510291|NCT02547974|BIOLOGICAL|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214510292|NCT02547974|DRUG|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214510293|NCT02290353|DEVICE|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
214510294|NCT01721694|DRUG|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
214510295|NCT01721694|DRUG|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
215028554|NCT03197519|BEHAVIORAL|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
214425118|NCT03858205|OTHER|Quality-of-Life Assessment|Ancillary studies
214425119|NCT03858205|OTHER|Questionnaire Administration|Ancillary studies
214425120|NCT03858205|RADIATION|Radiation Therapy|Receive low-dose radiation therapy
214425121|NCT05514717|DRUG|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
214510296|NCT04271865|OTHER|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
214425122|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
214425123|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
214425124|NCT05133362|DEVICE|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
214425125|NCT05133362|PROCEDURE|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
214425126|NCT03752840|OTHER|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
214510297|NCT04271865|OTHER|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
214510298|NCT04271865|OTHER|recipe book|3\) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
214425127|NCT03752840|OTHER|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
214425128|NCT03752840|OTHER|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
214510299|NCT04271865|OTHER|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
214425129|NCT03752840|OTHER|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
214510300|NCT01648114|OTHER|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
214510301|NCT05730192|DEVICE|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
214510302|NCT03264222|OTHER|Security screening procedure|Screening procedure with security device (model QPS 100)
214510303|NCT00211042|OTHER|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
214510304|NCT04181385|DRUG|Olanzapine 10 milligram|Oral olanzapine capsule
214510305|NCT04181385|DRUG|Bromocriptine 5 milligram|Oral bromocriptine capsule
214510306|NCT04181385|DRUG|Placebo oral tablet|oral placebo capsules
214510307|NCT02212626|DEVICE|Rotarex S|
214510308|NCT06340984|DRUG|Montelukast 10 Mg Oral Tablet|group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
214510309|NCT03308500|BEHAVIORAL|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
214510310|NCT03308500|BEHAVIORAL|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
215028555|NCT03197519|BEHAVIORAL|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
215028556|NCT04642976|DEVICE|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
214425130|NCT03752840|OTHER|Fundus Photography|Fundus cameras will be used to image the macula and optic nerve. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
214510311|NCT00579839|PROCEDURE|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
214510312|NCT00579839|PROCEDURE|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
214425131|NCT02819336|DEVICE|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
214425132|NCT02819336|DEVICE|Sham electroacupuncture|"1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
214425133|NCT04414683|PROCEDURE|staging surgery|laparoscopic or laparotomic staging surgery
214425134|NCT04510454|DIAGNOSTIC_TEST|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
214425135|NCT05997836|OTHER|Implementation Facilitation|Implementation Facilitation involves and External Facilitator (from outside of the participating medical center) and an Internal Facilitator (from inside the participating medical center) working together to help BHIP teams within the site adopt care practices that are more consistent with the CCM
214425136|NCT05997836|OTHER|Centralized Technical Assistance|Centralized Technical Assistance involves having external experts available for ad hoc consultation related to collaborative BHIP care practices.
214425137|NCT05800977|BIOLOGICAL|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
214425138|NCT00256243|DRUG|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
214425139|NCT00256243|DRUG|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
214425140|NCT00256243|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
214425141|NCT00256243|DRUG|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
214425142|NCT00256243|DRUG|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
214425143|NCT00256243|DRUG|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
214425144|NCT03969823|DRUG|Tagrisso|Osimertinib 80mg once daily until disease progression
214425145|NCT02490982|DRUG|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
214425146|NCT03207854|PROCEDURE|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
214425147|NCT03207854|OTHER|Laboratory Biomarker Analysis|Correlative studies
214425148|NCT03207854|OTHER|Questionnaire Administration|Ancillary studies
214510313|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
214510314|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
214425149|NCT03310996|OTHER|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
214425150|NCT01267838|PROCEDURE|PCI|PCI of bifurcation lesions with double stenting
214425151|NCT05061693|DRUG|INCB054707|Oral; Tablet
214425152|NCT05061693|DRUG|Placebo|Oral; Tablet
214425153|NCT05707052|OTHER|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
214425154|NCT05707052|OTHER|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
214425155|NCT06153641|OTHER|N/A-Observational Study|N/A-Observational Study
214425156|NCT06129370|DEVICE|Standard practice|Lexicomp and manual calculator
214425157|NCT06129370|DEVICE|Medication dosing software|Medication dosing software
214425158|NCT05561803|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.
214510315|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
214510316|NCT00251147|PROCEDURE|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
214692300|NCT05344079|DEVICE|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
215028557|NCT04053504|BEHAVIORAL|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
214425159|NCT01152190|DRUG|Tadalafil|Administered orally, once daily for 8 weeks
214425160|NCT01152190|DRUG|Placebo|Administered orally, once daily for 8 weeks
214425161|NCT03823911|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
214425162|NCT03823911|PROCEDURE|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
214425163|NCT01469949|OTHER|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
214425164|NCT04539951|DRUG|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
214425165|NCT04539951|DRUG|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
214425166|NCT04539951|DRUG|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
214425167|NCT04539951|DRUG|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
214425168|NCT04539951|DRUG|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
214425169|NCT04539951|DRUG|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
214425170|NCT03261596|DRUG|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
214425171|NCT02266641|BEHAVIORAL|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
214510317|NCT00251147|PROCEDURE|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
214510318|NCT01924117|OTHER|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
214425172|NCT02266641|DIETARY_SUPPLEMENT|multivitamin supplement|
214425173|NCT03439904|OTHER|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
214425174|NCT01677104|DRUG|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
214425175|NCT01677104|DRUG|Placebo|
214425176|NCT03709693|DEVICE|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
214510319|NCT01393600|DRUG|NBI-98854|12.5 mg powder in bottle once daily for 14 days
214510320|NCT01393600|DRUG|NBI-98854|50 mg powder in bottle once daily for 14 days
214510321|NCT01393600|DRUG|Placebo|Solution containing no active substance
214510322|NCT04996186|OTHER|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
214510323|NCT02687841|DRUG|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
214510324|NCT02687841|DRUG|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
214510325|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
214425177|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
214425178|NCT02318771|RADIATION|Radiation Therapy (RT)|Undergo RT
214425179|NCT02318771|DRUG|MK-3475|Given IV
214425180|NCT00547118|DRUG|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
214425181|NCT00547118|DRUG|Placebo|One placebo tablet given 1 time per day for 112 days.
214425182|NCT05101148|DRUG|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
214425183|NCT01335542|PROCEDURE|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
214425184|NCT01335542|PROCEDURE|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
214425185|NCT02404233|DRUG|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
214510326|NCT00603798|DRUG|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
214510327|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
214510328|NCT03677271|BEHAVIORAL|Physical Activity|
214510329|NCT03555656|BEHAVIORAL|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
214510330|NCT03555656|BEHAVIORAL|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
214510331|NCT01623609|DRUG|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
214510332|NCT01623609|DRUG|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
214510333|NCT01765023|DRUG|Period I : atorvastatin, Period II : atorvastatin and metformin|
214510334|NCT01765023|DRUG|Period I : metformin, Period II : atorvastatin and metformin|
214425186|NCT02404233|DRUG|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
214510335|NCT00312949|BEHAVIORAL|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
214510336|NCT00312949|BEHAVIORAL|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
214425187|NCT00920881|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
214425188|NCT04789798|DEVICE|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
214425189|NCT04789798|OTHER|Usual care|Usual diabetes care, as provided by primary care providers
214425190|NCT01233713|PROCEDURE|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
214425191|NCT01233713|PROCEDURE|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
214425192|NCT00567515|DEVICE|AtriCure LAA Exclusion System|Placement of clip of LAA.
214425193|NCT03083119|DRUG|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
214425194|NCT03083119|DRUG|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
214425195|NCT00982618|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
214425196|NCT00982618|PROCEDURE|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
214425197|NCT00982618|DRUG|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
214510337|NCT04766996|BEHAVIORAL|Guided mindfulness exercises|Guided Meditation twice daily
214510338|NCT04766996|OTHER|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
214510339|NCT04766996|DRUG|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
215112151|NCT05020080|OTHER|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
215112152|NCT01947751|PROCEDURE|CVC exchange|CVC exchange when related infection is suspected
214510340|NCT04766996|DRUG|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
215112153|NCT01947751|DRUG|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
215112154|NCT03534141|DEVICE|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
215112155|NCT03534141|OTHER|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
215112156|NCT03534141|OTHER|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
215112157|NCT05154318|PROCEDURE|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
215112158|NCT05154318|PROCEDURE|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
215112159|NCT00411372|DRUG|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
214510341|NCT04766996|DRUG|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
214510342|NCT04766996|DRUG|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
214510343|NCT04766996|DRUG|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
214510344|NCT04766996|DRUG|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
214510345|NCT04766996|DRUG|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
214510346|NCT04766996|DRUG|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
214425198|NCT02927132|BEHAVIORAL|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
214425199|NCT02927132|BEHAVIORAL|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
214425200|NCT03750942|DEVICE|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
214425201|NCT05510544|DRUG|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
214425202|NCT01918163|DIETARY_SUPPLEMENT|Pomegranate pills|
214425203|NCT00947986|OTHER|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
214425204|NCT05672797|OTHER|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
214425205|NCT05672797|BEHAVIORAL|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
214425206|NCT03034681|OTHER|Physiotherapy technique: TENS|
214425207|NCT03034681|OTHER|Physiotherapy technique: Vojta Therapy|
214425208|NCT00442117|DRUG|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
214425209|NCT00442117|DRUG|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
214510347|NCT04766996|DRUG|Zofran|Zofran 4 mg pre-operative
214510348|NCT04766996|DRUG|Pepcid|Pepcid 20 mg pre-operative
214510349|NCT04766996|DRUG|Reglan|Reglan 10 mg pre-operative
214510350|NCT04766996|DRUG|Versed|Versed 2 mg pre-operative
214510351|NCT04766996|DRUG|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
214510352|NCT04766996|DRUG|Propofol|Propofol 10-125 mcg/kg/min intraoperative
214510353|NCT04766996|DRUG|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
214510354|NCT04766996|DRUG|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
214510355|NCT04766996|DRUG|Decadron|Decadron 10 mg intraoperative
214510356|NCT04766996|DRUG|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
214510357|NCT04766996|DRUG|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
214510358|NCT05624814|DEVICE|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
214510359|NCT05624814|OTHER|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
214510360|NCT00508183|PROCEDURE|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
215028558|NCT00839501|DIETARY_SUPPLEMENT|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
215028559|NCT00839501|DRUG|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
215028560|NCT00900614|DRUG|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
215028561|NCT04409444|DIAGNOSTIC_TEST|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
215028562|NCT04409444|DIAGNOSTIC_TEST|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
215028563|NCT00088946|DIETARY_SUPPLEMENT|Polyphenon E|4-200mg capsules PO daily for 12 months
215028564|NCT00088946|DRUG|erlotinib hydrochloride|100 mg PO daily for 12 months
215028565|NCT00088946|OTHER|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
215028566|NCT00088946|OTHER|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
214510361|NCT00508183|PROCEDURE|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
215112160|NCT04253002|BEHAVIORAL|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
215112161|NCT04253002|BEHAVIORAL|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
215112162|NCT05267119|PROCEDURE|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
215112163|NCT03271502|PROCEDURE|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
215112164|NCT03271502|PROCEDURE|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
214425210|NCT06355388|DEVICE|Active tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
215112165|NCT05981482|DIAGNOSTIC_TEST|OxVPS|Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
215112166|NCT05642520|PROCEDURE|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
215112167|NCT05642520|PROCEDURE|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
214510362|NCT01613456|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
214510363|NCT01613456|DIETARY_SUPPLEMENT|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
214510364|NCT01554332|DEVICE|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
214510365|NCT06122818|OTHER|Immobile patients receiving home health care|Demographic characteristics, duration of immobility, sarcopenia presence, thigh circumference , Hand grip strength , bioelectrical impedance analysis
214510366|NCT01113736|BIOLOGICAL|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
214510367|NCT05454059|PROCEDURE|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
214425211|NCT06355388|DEVICE|Sham tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
214510368|NCT05454059|DIAGNOSTIC_TEST|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
214425212|NCT04796337|BIOLOGICAL|Sotatercept|Sotatercept SC injection at a dose of 0.3 to 0.7 mg/kg.
214425213|NCT01568073|DRUG|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
214425214|NCT01568073|DRUG|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
214425215|NCT01568073|DRUG|Placebo|200 mg
214425216|NCT01568073|DRUG|Levodopa|
214425217|NCT01568073|DRUG|Carbidopa|DOPA decarboxylase inhibitor
214425218|NCT01568073|DRUG|Benserazide|DOPA decarboxylase inhibitor
214425219|NCT04151407|DRUG|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
214425220|NCT00305591|DRUG|l-ornithine l-aspartate|
214425221|NCT02801071|DRUG|15g L-citrulline daily p.o.|
214425222|NCT02801071|DRUG|Placebo|
214425223|NCT04009577|DRUG|LEM 5 mg|LEM tablet.
214510369|NCT05454059|OTHER|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
214510370|NCT05454059|OTHER|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
215028567|NCT05326295|DIAGNOSTIC_TEST|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
215028568|NCT03638375|DRUG|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
215112168|NCT03077230|BEHAVIORAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
214425224|NCT04009577|DRUG|LEM 10 mg|LEM tablet.
214425225|NCT02613806|DRUG|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
214425226|NCT02613806|DRUG|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
214425227|NCT03690596|OTHER|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
214425228|NCT03690596|OTHER|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
214425229|NCT03690596|OTHER|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
214425230|NCT02165761|DEVICE|GORE® Hybrid Vascular Graft|
214425231|NCT02165761|DEVICE|Non-heparin bonded synthetic graft|
214425232|NCT00176839|PROCEDURE|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
214425233|NCT00176839|DRUG|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
214510371|NCT05454059|DIAGNOSTIC_TEST|HbA1c Level|Measurement of HbA1c levels from blood tests
214425234|NCT00176839|DRUG|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
214425235|NCT00176839|DRUG|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
214425236|NCT00176839|DRUG|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
214425237|NCT00176839|DRUG|ATG|ATG will be administered to umbilical cord blood recipients.
214425238|NCT00788853|OTHER|No treatment given|No treatment is given
214425239|NCT00202865|BIOLOGICAL|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
214425240|NCT00202865|BIOLOGICAL|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
215112169|NCT02849119|PROCEDURE|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
215112170|NCT03162822|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
214425243|NCT00786942|PROCEDURE|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
214425244|NCT00786942|PROCEDURE|higi tibial osteotomy|the gap of the tibia is unfilled
214510372|NCT02988713|DEVICE|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
214510373|NCT04852471|BEHAVIORAL|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
214510374|NCT04852471|BEHAVIORAL|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
214510375|NCT06172036|DRUG|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
214510376|NCT06172036|DRUG|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
214510377|NCT03138005|OTHER|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
214510378|NCT03138005|OTHER|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
214510379|NCT02424968|BIOLOGICAL|Anti-Thymocyte Globulin|Given per standard institutional practice
214510380|NCT02424968|DRUG|Cyclosporine|Given PO
214510381|NCT02424968|DRUG|Mycophenolate Mofetil|Given PO
214510382|NCT02424968|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
214510383|NCT02424968|BIOLOGICAL|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
214510384|NCT02424968|RADIATION|Total Nodal Irradiation|Undergo TLI
214510385|NCT06144437|DIAGNOSTIC_TEST|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
214510386|NCT03610620|PROCEDURE|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
214510387|NCT02065609|DRUG|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
214510388|NCT02065609|DRUG|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
215112171|NCT03162822|OTHER|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
215112172|NCT03162822|OTHER|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
215112173|NCT03162822|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
215112174|NCT03238690|DEVICE|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
215112175|NCT04475120|DRUG|liposomal lactoferrin|oral and intra-nasal formulation
215112176|NCT04475120|DRUG|SOC therapy|oral administration
215112177|NCT01664182|BIOLOGICAL|Bevacizumab|Given IV
215112178|NCT01664182|DRUG|Pazopanib Hydrochloride|Given PO
215112179|NCT01664182|DRUG|Sorafenib Tosylate|Given PO
215112180|NCT01664182|DRUG|Sunitinib Malate|Given PO
215112181|NCT01664182|BIOLOGICAL|Trebananib|Given IV
214425245|NCT01595906|PROCEDURE|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
215112182|NCT00437814|DRUG|Ketamine, effect on intracranial pressure|
215112183|NCT05170763|DRUG|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
214425246|NCT04905225|PROCEDURE|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
214425247|NCT05127499|OTHER|progressive relaxation exercises|progressive relaxation exercises will do
214425248|NCT04157530|DEVICE|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
214425249|NCT04157530|DEVICE|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
214425250|NCT04157530|DEVICE|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
214425251|NCT02538263|DEVICE|Volume-targeted noninvasive ventilation|
214425252|NCT00868569|PROCEDURE|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
214425253|NCT00868569|PROCEDURE|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
214425254|NCT01987154|OTHER|Marketed cow milk-based premature infant formula|
214425255|NCT01987154|OTHER|Marketed extensively hydrolyzed casein infant formula|
214425256|NCT03795558|DRUG|Etelcalcetide|Up-Titration
214425257|NCT04704778|COMBINATION_PRODUCT|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
214425258|NCT04704778|COMBINATION_PRODUCT|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
214425259|NCT04704778|DIAGNOSTIC_TEST|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
214425260|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Sport|Vitamin -supplemented chewing gum
214425261|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Immunity|Vitamin -supplemented chewing gum
214425262|NCT03230396|DIETARY_SUPPLEMENT|Placebo|Control chewing gum. No vitamin content.
214425263|NCT02891525|DIETARY_SUPPLEMENT|50g glucose|
214510389|NCT04947709|BEHAVIORAL|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
214510390|NCT05958966|OTHER|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
214510391|NCT01861015|DRUG|Epinephrine|
214510392|NCT01861015|DRUG|Vasopressin|
215112184|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
215112185|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
214425264|NCT02891525|DIETARY_SUPPLEMENT|25g fructose|
214425265|NCT02891525|DIETARY_SUPPLEMENT|220mg acesulfame-K|
214425266|NCT02891525|DIETARY_SUPPLEMENT|250mL tap water|
214425267|NCT05857969|DEVICE|Functional Precision Medicine|Ex Vivo Drug Sensitivity Testing + Genomic Tumor Profiling
214425268|NCT02425917|DEVICE|geko|neuromuscular electrostimulator
214425269|NCT02425917|DEVICE|IPC-Calf|IPC used on calf with or without geko
214425270|NCT04279548|DEVICE|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
214425271|NCT05619861|BIOLOGICAL|CAR-T|Patients will receive CAR-T treatment
214425272|NCT01980641|BEHAVIORAL|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
214425273|NCT01980641|DEVICE|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
214510393|NCT04347941|PROCEDURE|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
214510394|NCT04347941|PROCEDURE|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
214425274|NCT03122574|OTHER|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
214510395|NCT04248868|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
214510396|NCT04248868|DRUG|r-tPA|Pulse spray and infusion
214510397|NCT02418689|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
214510398|NCT03131713|DRUG|Acetaminophen|Acetaminophen 1000mg
214510399|NCT01504984|DRUG|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
214692301|NCT05344079|DEVICE|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
214692302|NCT01913210|DIETARY_SUPPLEMENT|Ginseng|
214692303|NCT03742336|DRUG|PF-04965842|Single oral 200 mg dose of PF-04965842
214692304|NCT03742336|DRUG|Dabigatran|Single 75 mg dose of dabigatran
214692305|NCT03223220|DRUG|Ketamine|IV infusion
214692306|NCT03223220|OTHER|Normal Saline|IV infusion
214692307|NCT03223220|DRUG|Midazolam injection|Injection
214692308|NCT05818293|DEVICE|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
214425275|NCT03122574|OTHER|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
214425276|NCT04074577|DIAGNOSTIC_TEST|Standard technique First|colonoscopy without automated polyp detection software
214425277|NCT04074577|DIAGNOSTIC_TEST|combination technique First|automated polyp detection software
214425278|NCT00005772|DEVICE|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
214425279|NCT00005772|DEVICE|Control|Control group: standard care
214425280|NCT00092885|DRUG|MK0476, montelukast sodium|
214425281|NCT00092885|DRUG|Comparator: placebo|
214425282|NCT00841035|DRUG|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
214425283|NCT02705937|OTHER|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
214425284|NCT02705937|DEVICE|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
214425285|NCT04364594|DIAGNOSTIC_TEST|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
214425286|NCT06261996|DRUG|Fospropofol|Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
214425287|NCT03072953|DRUG|APD334|APD334 active treatment
214425288|NCT03932981|DRUG|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
214425289|NCT02994654|DEVICE|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
214425290|NCT02207075|DRUG|[C11]PK-1195 PET scan|PET scan with tracer \[C11\]PK-1195
214425291|NCT05917249|DEVICE|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
214425292|NCT03367494|DIAGNOSTIC_TEST|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
214425293|NCT03276039|DIAGNOSTIC_TEST|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
214425294|NCT04346888|DRUG|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
214510400|NCT01504984|DRUG|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
214425295|NCT04346888|DRUG|Placebos|Placebo, HBM9161 Injection (340mg)
214510401|NCT02208843|DRUG|Afatinib|Afatinib tablet once daily until progression
214510402|NCT00916409|DEVICE|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
214510403|NCT00916409|DRUG|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
214510404|NCT01976507|DRUG|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
214425296|NCT04346888|DRUG|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
214425297|NCT01611376|DEVICE|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
214425298|NCT03414710|BEHAVIORAL|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
214692309|NCT02851680|BIOLOGICAL|blood samples|
214510405|NCT01676298|DEVICE|Spartan FRX CYP2C19 Test System|
214692310|NCT05029596|DRUG|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
215112186|NCT05170763|DRUG|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
214425299|NCT03414710|BEHAVIORAL|Health education booklet only|Participants in the intervention group will only receive a health education booklet
214425300|NCT00385801|DRUG|Risperidone|
214425301|NCT00385801|DRUG|Placebo|
214510406|NCT04996654|BEHAVIORAL|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
214692311|NCT05029596|DRUG|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
214692312|NCT06181396|DRUG|Oxytocin|Native oxytocin analog
214692313|NCT00364546|DRUG|CG 5503;tapentadol|
215112187|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
214425302|NCT05161507|PROCEDURE|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
214425303|NCT05161507|PROCEDURE|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
214510407|NCT04996654|BEHAVIORAL|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
214510408|NCT01762982|DRUG|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
214510409|NCT01762982|DRUG|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
215112188|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
215112189|NCT05170763|DRUG|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
214425304|NCT05161507|PROCEDURE|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
214425305|NCT05535530|DEVICE|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
214425306|NCT04747457|DEVICE|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
214425307|NCT00003604|BIOLOGICAL|aldesleukin|
214425308|NCT03324152|OTHER|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
214425309|NCT03324152|OTHER|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
214425310|NCT03324152|OTHER|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
214425311|NCT06116058|OTHER|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
214425312|NCT06116058|OTHER|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
214510410|NCT01762982|DRUG|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
214510411|NCT01762982|OTHER|Empty Finn Chamber|Empty Finn Chamber
214510412|NCT03003104|DRUG|DMT210 Topical Gel 5%|
214510413|NCT03003104|OTHER|Vehicle Control|
215112190|NCT00004030|DRUG|VX-853|
215112191|NCT00004030|DRUG|pegylated liposomal doxorubicin hydrochloride|
214425313|NCT06116058|OTHER|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
214425314|NCT03854006|PROCEDURE|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
214425315|NCT04297982|OTHER|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
214425316|NCT04297982|OTHER|Routine nursing care|Interventions routinely implemented by nurses in the clinic
214425317|NCT04073914|BEHAVIORAL|Type 1 Teamwork Program|Psychoeducational web program
214425318|NCT01138215|BIOLOGICAL|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
214425319|NCT02614118|DRUG|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
215112192|NCT02919046|BIOLOGICAL|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
215112193|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
215112194|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
215112195|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
215112196|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
215112197|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
214510414|NCT02912247|DRUG|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
214510415|NCT02912247|DRUG|adalimumab|adalimumab, 40mg,subcutaneous injection,once
214510416|NCT02799849|OTHER|Sleep and metabolism assessment|
214510417|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
214510418|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
215112198|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
214425320|NCT02614118|DRUG|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
214425321|NCT02614118|DRUG|Placebo|placebo 45 minutes before root canal treatment
214425322|NCT02204618|DEVICE|cochlear implantation|
214425323|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
215112199|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
215112200|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
214425324|NCT02707913|DRUG|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
214425325|NCT02707913|DRUG|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
214425326|NCT03398811|DRUG|Depot medroxy-progesterone acetate|Injection every 3 months
214425327|NCT03398811|DRUG|Etonogestrel|68 mg implant
214425328|NCT03398811|DRUG|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
214425329|NCT00402155|BEHAVIORAL|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
214425330|NCT04225780|DRUG|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
214425331|NCT05541458|OTHER|Food as medicine|"* Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~* Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~* Increase nutrition literacy.~* Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
214425332|NCT06666608|DEVICE|Bone Stimulator|Subjects will be asked to wear their device (if applicable) for a minimum of 30 minutes a day for 12 weeks with no maximum usage time. The device will track compliance. Bone stimulator should be worn at rest.
214425333|NCT06666608|OTHER|Standard of Care Spondylolysis Treatment|Participants will follow the standard of care regimen for spondylolysis treatment at Houston Methodist which will involve physical therapy and wearing a back brace.
214425334|NCT04925674|DRUG|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
214425335|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
214425336|NCT06473506|DIAGNOSTIC_TEST|Saliva collection|Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
214425337|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
214425338|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
214425339|NCT06295614|DEVICE|ARC-IM System implantation|Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
214425340|NCT03290937|BIOLOGICAL|Cetuximab|Given IV
214425341|NCT03290937|DRUG|Irinotecan Hydrochloride|Given IV
214425342|NCT03290937|OTHER|Pharmacodynamic Study|Correlative studies
214425343|NCT03290937|BIOLOGICAL|Utomilumab|Given IV
214425344|NCT06834633|OTHER|Standard-of-care|Management according to current ICU practices
214425345|NCT06834633|OTHER|Systematic nephroprotection bundle-of-care|"The nephroprotection bundle-of-care includes 5 components:~1. Prevention of drugs' nephrotoxicity~2. Hemodynamic optimization, for 24h~3. Blood glucose control and avoidance of hyperglycemia~4. Early detection of rhabdomyolysis~5. Monitoring of renal function"
214510419|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
215112201|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
214425346|NCT04632901|DIAGNOSTIC_TEST|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
214425347|NCT04632901|DIAGNOSTIC_TEST|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
214510420|NCT04514081|DRUG|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
214510421|NCT04514081|DRUG|Decitabine+Camrelizumab|Decitabine+Camrelizumab
214510422|NCT02684032|DRUG|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
214510423|NCT02684032|DRUG|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
214510424|NCT02684032|DRUG|Letrozole|Letrozole at 2.5 mg daily
214510425|NCT02684032|DRUG|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
214510426|NCT02160301|DRUG|Gabapentin|PO
214510427|NCT02160301|DRUG|Acetaminophen|PO
214510428|NCT02160301|DRUG|Acetaminophen|IV
214510429|NCT02160301|DRUG|Celecoxib|PO
214510430|NCT02160301|DRUG|Dexamethasone|IV
214510431|NCT02160301|DRUG|Oxycodone|PO
214510432|NCT00569439|DRUG|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
215112202|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
215112203|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
215112204|NCT04228367|DEVICE|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
215112205|NCT03785405|DRUG|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
214510433|NCT00569439|DRUG|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
214510434|NCT00569439|DRUG|NS|Normal Saline solution at 125 cc/hr
214510435|NCT01794299|BIOLOGICAL|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
214510436|NCT03630549|OTHER|Standard of Care|Clinic-based HIV care
214510437|NCT03630549|OTHER|Village-based ART refill|Option to get ART refill and care by the village health worker
214510438|NCT03575507|DEVICE|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
215112206|NCT06635980|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
215112207|NCT06635980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215112208|NCT06635980|PROCEDURE|Breast Surgery|Undergo breast surgery
215112209|NCT06635980|DRUG|Chemotherapy|Receive SOC chemotherapy
215112210|NCT06635980|PROCEDURE|Computed Tomography|Undergo CT
215112211|NCT06635980|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEDM
215112212|NCT06635980|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiotherapy
215112213|NCT06635980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215112214|NCT06635980|PROCEDURE|Positron Emission Tomography|Undergo PET
215112215|NCT06635980|OTHER|Survey Administration|Ancillary studies
215112216|NCT06635980|PROCEDURE|Tissue Collection|Undergo tissue collection
215112217|NCT06635980|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
215112218|NCT02584270|DEVICE|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and articulation therapy are necessary for this therapy to be effective.
215112219|NCT02584270|OTHER|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy in either arm.
215112220|NCT04923568|DEVICE|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
215112221|NCT00133601|BEHAVIORAL|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
215112222|NCT05373264|DRUG|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
215112223|NCT05373264|DRUG|Placebo|A matching oral capsule containing placebo
214510439|NCT05474326|DEVICE|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
215112224|NCT05094648|OTHER|high flow nasal therapy|effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
215112225|NCT02195375|DRUG|Flutiform 500/20 µg BID|
214425348|NCT05328297|DRUG|JNJ-55308942|JNJ-55308942 capsules will be administered orally.
214425349|NCT05328297|DRUG|Placebo|Matching placebo capsules will be administered orally.
214425350|NCT06104514|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214425351|NCT04019327|DRUG|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
214425352|NCT04019327|DRUG|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8"
214510440|NCT04453488|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
214510441|NCT04453488|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
215112226|NCT02195375|DRUG|Flutiform 250/10 µg BID|
215112227|NCT02195375|DRUG|Seretide Accuhaler 50/500 µg BID|
215112228|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
214425353|NCT03063944|DRUG|STAT Inhibitor OPB-111077|Given PO
214425354|NCT03063944|DRUG|Decitabine|Given IV
214425355|NCT03063944|DRUG|Venetoclax|Given PO
214425356|NCT03063944|OTHER|Laboratory Biomarker Analysis|Correlative studies
214425357|NCT06381570|DRUG|Tovorafenib|"Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)"
214510442|NCT01029704|DRUG|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
214510443|NCT01029704|DRUG|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
214510444|NCT00383383|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
214510445|NCT00383383|BIOLOGICAL|Engerix-B|
214510446|NCT02105571|BEHAVIORAL|Intervention|
215112229|NCT05081232|DEVICE|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
215112230|NCT05109624|PROCEDURE|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
215112231|NCT03825302|DIAGNOSTIC_TEST|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
215112232|NCT03825302|DIAGNOSTIC_TEST|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
215112233|NCT05605912|OTHER|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
215112234|NCT05605912|DEVICE|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
215112235|NCT06248333|DEVICE|STN-DBS ON|Stimulation ON
215112236|NCT06248333|DEVICE|STN-DBS OFF|Stimulation OFF
215112237|NCT05394831|DRUG|JIN-A02|PO, QD
215112238|NCT06433479|DRUG|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
215112239|NCT02881762|DRUG|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
215112240|NCT00795236|DRUG|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
214425358|NCT06381570|DRUG|Vinblastine|vinblastine in combination with tovorafenib
214425359|NCT06792188|DEVICE|Galaxy Watch 4, Samsung Electronics Co., Ltd., South Korea|Use of the Galaxy Watch 4 during sleep for approximately two weeks prior to the polysomnography test, including the night of the test.
214510447|NCT02144597|DIETARY_SUPPLEMENT|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
214510448|NCT02144597|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
214510449|NCT02144597|OTHER|Control diet|
215112241|NCT02856204|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood
215112242|NCT02856204|OTHER|Laboratory Biomarker Analysis|Correlative studies
215112243|NCT03269058|DRUG|Dapagliflozin|Dapagliflozin 10 mg daily per os
215112244|NCT03269058|DRUG|Placebos|Placebo of Dapagliflozin per day per os
215112245|NCT05017467|DRUG|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
215112246|NCT04137731|DEVICE|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
215112247|NCT05822180|DRUG|NANOS1 , argent colloïdal ,|orally, during 5 day
215112248|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
215112249|NCT04763941|DIAGNOSTIC_TEST|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
215112250|NCT01151371|DEVICE|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
215112251|NCT01151371|DEVICE|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
215112252|NCT01151371|DEVICE|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
215112253|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
215112254|NCT02877303|DRUG|Cyclophosphamide|Given IV
215112255|NCT02877303|DRUG|Cytarabine|Given IT and IV
214510450|NCT02364856|DEVICE|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
215112256|NCT02877303|DRUG|Dexamethasone|Given PO
215112257|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
215112258|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
215112259|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
215112260|NCT02877303|DRUG|Mercaptopurine|Given PO
215112261|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
215112262|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
215112263|NCT02877303|DRUG|Prednisone|Given PO
215112264|NCT02877303|BIOLOGICAL|Rituximab|Given IV
215112265|NCT02877303|DRUG|Vincristine Sulfate|Given IV
215112266|NCT03983304|DEVICE|The ZELTIQ EMS System|The Zeltiq EMS device will be used to perform treatments for abdominal and gluteal toning.
215112267|NCT02712528|DRUG|remifentanil-based|
215112268|NCT02712528|DRUG|sevoflurane-sufentanil balanced|
215112269|NCT01897948|OTHER|Milk-based beverage without DHA|
215112270|NCT01897948|OTHER|Milk-based beverage with DHA at mid level|
215112271|NCT01897948|OTHER|Milk-based beverage with DHA at high level|
215112272|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
215112273|NCT00310817|BIOLOGICAL|MenACWY polysaccharide vaccine|
215112274|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
215112275|NCT03830346|OTHER|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
215112276|NCT01702246|DRUG|Simvastatin|40 mg, orally, once daily for 3 months
215112277|NCT03225378|OTHER|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
215112278|NCT03225378|OTHER|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
214425360|NCT06791525|DRUG|Tirbanibulin ointment 1%|Topical application
214425361|NCT05798117|DRUG|YTB323|Single infusion of YTB323
214425362|NCT04029194|BEHAVIORAL|Assistance with old age pension application|The intervention will offer elderly assistance in applying for the old age pension.
214425363|NCT05952934|BIOLOGICAL|0.5 mL Candin®/injection|Candin or placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
214425364|NCT05952934|OTHER|Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)|Placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
214425365|NCT06453798|OTHER|cervical spine exercises|Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.
215112279|NCT02290977|RADIATION|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
215112280|NCT02523378|BEHAVIORAL|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
215112281|NCT02523378|BEHAVIORAL|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
215112282|NCT01587040|DRUG|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
215112283|NCT01587040|DRUG|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
215112284|NCT04667741|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
215112285|NCT00432341|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
215112286|NCT00432341|BIOLOGICAL|botulinum toxin type A|500 Units at Visit 1 (Day 1)
215112287|NCT04886778|DIETARY_SUPPLEMENT|Low-carbohydrate diet|Participants will be instructed to maintain a daily dietary energy intake of less than 1600 kcal.Based on the low-carbohydrate diet model, the proportion of daily intake of carbohydrate was about 30%, and this ratio was up to 30%, 40% of protein and fat respectively.Participants should choose unprocessed whole grains, potatoes, vegetables, meat, fish, eggs, soy products, sugar-free dairy products, designated varieties of low-GI fruits and nuts, etc. as breakfast, and avoid processed meats and high-fat red meat and poultry skins. Standard nutritious meal instead of daily lunch and dinner meals, that is to say, participants should take one nutritional bar for lunch and dinner (310 kcal totally, provided by Guangzhou Nanda Fett Nutrition and Health Consulting Co., Ltd.), and avoid starchy foods. Other food varieties are required to be the same as breakfast. Plant oil is the main cooking oil, and participants will be instructed to drink 2L water every day.
215112288|NCT04886778|DIETARY_SUPPLEMENT|Probiotic compound preparations|The probiotic compound preparation，named Junyi Yili® Probiotics，is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus and Bifidobacterium lactis, and resistant dextrin contained water-soluble dietary fiber. The subjects will take this probiotic compound preparations with purified water after three meals every day, 1 sachet each time.
214425366|NCT06453798|OTHER|Neuromobilization|Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
214425367|NCT05317390|DIAGNOSTIC_TEST|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
215112289|NCT04886778|DIETARY_SUPPLEMENT|Placebo|Placebo is made of resistant dextrin which contained water-soluble dietary fiber. The subjects were taken this placebo with purified water after three meals every day, 1 sachet each time.
215112290|NCT00933998|OTHER|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
215112291|NCT05039944|DRUG|SI-B001|In Arm\_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort\_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
215112292|NCT05039944|DRUG|Irinotecan|Administration by intravenous infusion, 180 mg/m2 Q2W.
215112293|NCT05039944|DRUG|FOLFIRI Protocol|FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
214425368|NCT01494103|BIOLOGICAL|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
214425369|NCT01494103|DRUG|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
214510451|NCT05640505|BEHAVIORAL|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
214510452|NCT01246804|DRUG|raltegravir single dose|single dose 400mg raltegravir
214510453|NCT01246804|DRUG|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
214510454|NCT04166084|OTHER|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
215112294|NCT05039944|DRUG|FOLFOX Protocol|FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
215112295|NCT05385003|DIETARY_SUPPLEMENT|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
215112296|NCT05385003|DIETARY_SUPPLEMENT|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
215112297|NCT05385003|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
215112298|NCT00970437|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
215112299|NCT00970437|BEHAVIORAL|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
215112300|NCT03081650|DEVICE|Airvo Humidifier|
215112301|NCT01518374|DRUG|Florbetapir F 18|370 MBq (10 mCi)
215112302|NCT03485235|PROCEDURE|D&C|Dilatation and curettage
215112303|NCT03485235|PROCEDURE|ICSI|Intra Cytoplasmic Sperm Injection
214425370|NCT06019299|BEHAVIORAL|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
214425371|NCT03967704|PROCEDURE|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
214510455|NCT04166084|OTHER|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
215028569|NCT02069847|DRUG|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
215112304|NCT01737125|RADIATION|Magnetic Resonance Imaging (MRI)|"* spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~* MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
215112305|NCT06577792|PROCEDURE|Lobectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.
215112306|NCT06577792|PROCEDURE|Lymphadenectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
214425372|NCT03882554|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
214425373|NCT02139696|RADIATION|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
214425374|NCT06795152|OTHER|No intervention|Observational. Natural history study.
214425375|NCT06545604|OTHER|Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation|Two visits per week with a yoga therapist while receiving neoadjuvant chemotherapy to cover dietary counseling, yoga-based movement practices, breathwork practices, mind practices, and behavioral support for the purpose of preparing patients' mind and body for a planned surgery.
214425376|NCT06545604|OTHER|Usual care supportive services including nutrition counseling per usual care|Usual care supportive services while receiving neoadjuvant chemotherapy.
214425377|NCT02496377|DRUG|ferrous glycine sulfate Tardyferon|
214425378|NCT02496377|DRUG|Epoetin Alfa|
214510456|NCT00765544|DEVICE|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
214510457|NCT00765544|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
214510458|NCT03587415|DIAGNOSTIC_TEST|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
214510459|NCT00077558|DRUG|fludarabine phosphate|
214510460|NCT00077558|DRUG|triapine|
214510461|NCT02163148|BEHAVIORAL|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
214510462|NCT00831948|GENETIC|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
214510463|NCT01968824|PROCEDURE|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
214510464|NCT04999072|PROCEDURE|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
215112307|NCT04300309|DRUG|artemether:lumefantrine (2.5 mg:30 mg)|Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.
214510465|NCT04226456|DRUG|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
214510466|NCT02280759|DRUG|Gelatin Tannate|
214510467|NCT02280759|DRUG|Placebo|Placebo consists of an identical formulation, except active substance
214510468|NCT00089791|DRUG|placebo|Placebo administered by subcutaneous injection
214425379|NCT02496377|DRUG|ferric carboxymaltose Ferinject|
214425380|NCT02755181|BEHAVIORAL|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
214425381|NCT06837142|DRUG|Triazolam and TS-172|Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
214425382|NCT06837142|DRUG|TS-172 and itraconazole|Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase
214425383|NCT05437094|DRUG|CRD-740|CRD-740
214425384|NCT05437094|DRUG|Itraconazole|Itraconazole
214425385|NCT01613118|DRUG|RE-021 (Sparsentan)|Oral, once-daily
214425386|NCT01613118|DRUG|Irbesartan|Oral, once-daily
214425387|NCT00038506|DRUG|abacavir/lamivudine/zidovudine|
214425388|NCT00038506|DRUG|tenofovir|
214425389|NCT03332758|PROCEDURE|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
214510469|NCT00089791|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection
214510470|NCT06080087|BEHAVIORAL|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
214510471|NCT04885673|DEVICE|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
214510472|NCT04885673|DEVICE|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
214510473|NCT04176952|DRUG|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
214510474|NCT04176952|DRUG|AG|"* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
215112308|NCT06970158|OTHER|AI-Designed Passive Plate Therapy|A removable passive orthopedic plate designed using an AI-assisted digital workflow based on intraoral scan data. The design process is automated via a Blender-based software plugin that identifies anatomical landmarks and generates a custom-fit plate. The plate is 3D printed using biocompatible material and fitted shortly after birth. It is worn continuously until primary surgical repair, typically around 4 months of age. The intervention aims to reduce cleft width prior to surgery without requiring traditional impressions or extensive manual design effort.
214425390|NCT03332758|PROCEDURE|External drainage|Standard of care treatment for retinal detachment.
214425391|NCT06630884|BIOLOGICAL|Typhoid VI Polysaccharide Vaccine Injectable Solution|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
214425392|NCT06630884|OTHER|Saline Placebo (0.5mL injection)|The placebo injection will consist of 0.5mL of saline.
214425393|NCT03656406|BEHAVIORAL|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
214425394|NCT03656406|DEVICE|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
214425395|NCT02968225|BEHAVIORAL|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
214425396|NCT00443001|DEVICE|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
214425397|NCT00117130|DRUG|Aranesp®|
214425398|NCT02861846|BIOLOGICAL|profile of CSF biomarkers of AD|dosage of biomarker of AD
214510475|NCT00148122|DRUG|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
214510476|NCT00148122|DRUG|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
214510477|NCT04179565|BEHAVIORAL|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
214510478|NCT04738149|DRUG|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
214510479|NCT04738149|DEVICE|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
214510480|NCT04738149|DEVICE|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
214510481|NCT00904085|DRUG|Oxymorphone IR|5 mg
214510482|NCT00017355|BIOLOGICAL|filgrastim|
214510483|NCT00017355|BIOLOGICAL|therapeutic autologous dendritic cells|
214510484|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 supplement|
215112309|NCT05209438|DEVICE|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
215112310|NCT06967662|PROCEDURE|Selective plasma adsorption of extracellular DNA|Selective plasma adsorption of extracellular DNA using NucleoCor® sorption columns (Pocard Ltd., Russia) on the Spectra Optia™ Apheresis System (Terumo Blood and Cell Technologies, USA). NucleoCor® is a sorption column for plasma adsorption containing porous spherical agarose beads with a ligand that selectively binds extracellular DNA. This medical device has a Registration Certificate No. РЗН 2022/18982 in Russian Federation. Participants will receive selective plasma adsorption of extracellular DNA twice: once during the tumor removal surgery (the procedure will be initiated at the time of pancreatic tumor mobilization and will be stopped an hour after removal of the organ complex) and once on the day after the surgery.
214510485|NCT01662193|DIETARY_SUPPLEMENT|calcium supplement|
214510486|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 and calcium supplement|
214510487|NCT01662193|DIETARY_SUPPLEMENT|placebo|
214510488|NCT00276679|DRUG|temozolomide|
214510489|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
214510490|NCT02334605|DEVICE|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
214510491|NCT02334605|DEVICE|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
215112311|NCT06968312|OTHER|Cognitive Processing Therapy + Hexadecanal|Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.
215112312|NCT06968312|OTHER|Hexadecanal - Molecule Distribution in the Therapy room|Distribution of a naturally secreted molecule from body odor (Hexadecanal).
214425399|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
214425400|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
214425401|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
215112313|NCT05059535|DRUG|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
215112314|NCT06080061|RADIATION|Hypofractionated accelerated radiation therapy|Hypofractionated accelerated radiation therapy
214425402|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
214425403|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
214425404|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
214425405|NCT02297061|BIOLOGICAL|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
214425406|NCT05208372|DIAGNOSTIC_TEST|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
214425407|NCT05208372|DIAGNOSTIC_TEST|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
214425408|NCT04921293|BEHAVIORAL|Ketogenic diet|A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
214425409|NCT04921293|DIETARY_SUPPLEMENT|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
214425410|NCT04921293|BEHAVIORAL|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
214425411|NCT01450228|DRUG|KI1001|Prolonged release melatonin 2mg
214425412|NCT01450228|DRUG|Placebo KI1001|Placebo KI1001 tablets
214425413|NCT05583253|PROCEDURE|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
214425414|NCT02788604|OTHER|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
214425415|NCT02788604|OTHER|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
214425416|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
214425417|NCT06667557|DEVICE|Superpulse Thulium Fiber Laser (sTFL) Treatment|The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
214425418|NCT06667557|DEVICE|Holmium:YAG Laser (Ho:YAG) Treatment|The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
214425419|NCT05425199|OTHER|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
214425420|NCT05425199|OTHER|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
214425421|NCT05425199|OTHER|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
214425422|NCT05961462|BEHAVIORAL|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
214425423|NCT03584152|DRUG|Norco 5Mg-325Mg Tablet|Opioid Analgesics
214425424|NCT03584152|DRUG|Tylenol 325Mg Caplet|Non opioid analgesics
214425425|NCT03584152|DRUG|Ibuprofen 200 mg|Non opioid analgesics
214510492|NCT01827748|DEVICE|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
214510493|NCT01827748|DEVICE|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
215112315|NCT04390399|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
215112316|NCT04390399|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
214425426|NCT00457275|DRUG|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
214425427|NCT03544515|DEVICE|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
214425428|NCT03544515|PROCEDURE|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
214425429|NCT03544515|DEVICE|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
214425430|NCT03175172|BIOLOGICAL|CRS-207|Administered by IV infusion over approximately 1 hour.
214425431|NCT03175172|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
214510494|NCT03608111|OTHER|single task balance training|single task balance training
214510495|NCT03608111|OTHER|dual task balance training|dual task balance training
214510496|NCT01738997|DEVICE|Dilation 10 sec|
214510497|NCT01738997|DEVICE|Dilation 2 min|
214425432|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
214425433|NCT03169244|DRUG|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
214425434|NCT03169244|DRUG|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
214425435|NCT05561881|OTHER|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
214425436|NCT05561881|OTHER|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
214425437|NCT05887063|OTHER|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
214425438|NCT05929105|PROCEDURE|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
214510498|NCT05247307|BIOLOGICAL|convalescent plasma infusion covid 19|"Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts."
214510499|NCT02689011|PROCEDURE|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
214510500|NCT02689011|PROCEDURE|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
214510501|NCT02377544|DIETARY_SUPPLEMENT|Probiotic|
214510502|NCT02377544|OTHER|Placebo|
214510503|NCT02936544|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
214510504|NCT05508477|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
214510505|NCT05508477|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
214510506|NCT03661398|DEVICE|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
214510507|NCT06395207|BEHAVIORAL|Proactive community case management|Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
215112317|NCT04390399|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
215112318|NCT04390399|DRUG|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
215112319|NCT04390399|DRUG|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
215112320|NCT04390399|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
215112321|NCT04390399|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
215112322|NCT04390399|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214510508|NCT06395207|BEHAVIORAL|Strengthened SBCC and stock out mitigation|Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
214510509|NCT00920985|DRUG|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
214510510|NCT00920985|DRUG|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
214510511|NCT00161122|BIOLOGICAL|trivalent inactivated influenza vaccine|
214510512|NCT00161122|BIOLOGICAL|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
215112323|NCT04390399|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214425439|NCT05929105|OTHER|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
214425440|NCT02889718|DEVICE|CONCERT-CL® station|"During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare"
214425441|NCT02889718|OTHER|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
214425442|NCT02810184|RADIATION|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
214425443|NCT01662336|DRUG|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
214425444|NCT01662336|BEHAVIORAL|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
214425445|NCT06248229|DRUG|Dyanavel XR|"Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
214510513|NCT00519207|DRUG|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
214510514|NCT00519207|DRUG|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
214510515|NCT01785056|BIOLOGICAL|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
214510516|NCT04514978|PROCEDURE|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
214510517|NCT01989845|DRUG|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
214510518|NCT00439686|DRUG|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
214510519|NCT02016365|DRUG|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
214510520|NCT02016365|DRUG|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
214510521|NCT03698383|DRUG|Trastuzumab biosimilars(Herzuma), Gedatolisib|"* Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
214510522|NCT03730038|DRUG|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
214510523|NCT03730038|BEHAVIORAL|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
214510524|NCT01319058|PROCEDURE|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
214510525|NCT04827849|OTHER|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
214510526|NCT01672242|DEVICE|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
214510527|NCT01672242|DEVICE|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
214510528|NCT02613767|OTHER|Protein meal|Ingestion of protein
214510529|NCT02613767|OTHER|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
214510530|NCT06092736|DRUG|Compound Danshen Dropping Pills|Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
214510531|NCT06092736|DRUG|Placebo|placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
214510532|NCT04697615|DEVICE|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
214425446|NCT06248229|DRUG|Placebo|"Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
214425447|NCT00962234|OTHER|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
214425448|NCT00962234|BIOLOGICAL|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
214425449|NCT00962234|PROCEDURE|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
214425450|NCT06258668|DRUG|Deucravacitinib|As per product label
214425451|NCT05133154|BIOLOGICAL|Blood samples|In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
214425452|NCT05714332|OTHER|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
214510533|NCT04709185|DRUG|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
214510534|NCT04709185|DRUG|Placebo|oral placebo at 23:00-24:00 the night before AVS
214510535|NCT04834830|DIAGNOSTIC_TEST|Pleural effusion will be examined for various cytokines and PD1-lymphocytes.|Examination of pleural effusion
214510536|NCT02079259|PROCEDURE|Ultrafiltration|
214510537|NCT05376397|BEHAVIORAL|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
214510538|NCT06505096|PROCEDURE|cataract surgery|Phaco+IOL implention
214510539|NCT02817360|DRUG|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
214510540|NCT02817360|OTHER|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
214510541|NCT05575349|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
214510542|NCT00237705|DRUG|metoclopramide|
214425453|NCT05714332|OTHER|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
214425454|NCT06005051|OTHER|Dietary intervention|Using different combination of foods to see if the glucose response to a load of carbohydrates can be mitigated.
214425455|NCT04532658|BEHAVIORAL|Coaching program|"* Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement"
214425456|NCT06345027|BIOLOGICAL|Treatment Arm A|"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."
214425457|NCT06123195|OTHER|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
214425458|NCT02840149|DRUG|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
214510543|NCT01137682|DRUG|Pasireotide|"* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
214510544|NCT01137682|DRUG|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
214510545|NCT01137682|DRUG|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
214510546|NCT02970578|PROCEDURE|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
214510547|NCT00038597|DRUG|SCH66336|
214510548|NCT01365546|BIOLOGICAL|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
214425459|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214425460|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
214425461|NCT04425733|DRUG|Frespaciguat|Frespaciguat administered at a dose of 180 µg or ≤360 µg QD via inhalation
214425462|NCT04425733|DRUG|Placebo|Frespaciguat-matching placebo administered QD via inhalation
214425463|NCT04872478|DRUG|MRX-2843|MRX-2843 capsules
214425464|NCT03472573|DRUG|Palbociclib|Given PO
214510549|NCT00861315|DRUG|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
214510550|NCT00861315|DRUG|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
214510551|NCT00861315|DRUG|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
214425465|NCT03472573|DRUG|Dexamethasone|Given PO
214510552|NCT00861315|DRUG|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
214510553|NCT04217798|DRUG|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
214510554|NCT00721734|DRUG|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
214510555|NCT00472082|DRUG|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
214510556|NCT04037592|DEVICE|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
214510557|NCT04037592|DEVICE|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
214510558|NCT04037592|DEVICE|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
214510559|NCT04617847|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
214510560|NCT04252794|PROCEDURE|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
214510561|NCT04252794|OTHER|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
214510562|NCT00296686|DRUG|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
214510563|NCT00296686|DRUG|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
214425466|NCT01627093|OTHER|Medical Chart Review|Review of medical records
214425467|NCT01627093|OTHER|Questionnaire Administration|Complete questionnaires
214425468|NCT02986178|BIOLOGICAL|lerapolturev|A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant
214425469|NCT02986178|DRUG|Lomustine|one cycle of oral lomustine
214510564|NCT00296686|DRUG|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
214510565|NCT06301867|DIAGNOSTIC_TEST|Plateau Pressure|Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
214510566|NCT06052943|BEHAVIORAL|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
214425470|NCT06419231|DIETARY_SUPPLEMENT|Butyrate Formulation|Butyrate Formulation capsule: Take daily
214425471|NCT06419231|DIETARY_SUPPLEMENT|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation capsule: Take daily
214425472|NCT06419231|DIETARY_SUPPLEMENT|Placebo|Placebo: Take daily
214510567|NCT06052943|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
214510568|NCT06052943|BEHAVIORAL|Physical Activity|Combines aerobic and resistance training though game play.
214510569|NCT06052943|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
214425473|NCT05318105|DEVICE|Aquadex Smartflow® System|ultrafiltration
214425474|NCT05318105|DRUG|IV Loop Diuretics|diuretics
214425475|NCT06104397|OTHER|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
214425476|NCT06104397|OTHER|Physical therapy|A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
214510570|NCT06052943|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
214510571|NCT06052943|BEHAVIORAL|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
214510572|NCT05129722|DRUG|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
215112324|NCT04390399|DRUG|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
215112325|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
215112326|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
214425477|NCT04947189|DRUG|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
214425478|NCT04947189|DRUG|Docetaxel|Use of docetaxel chemotherapy for solid tumours
214425479|NCT05537038|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
214425480|NCT05537038|BIOLOGICAL|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
214425481|NCT05537038|OTHER|Placebo|Placebo
214425482|NCT02206841|PROCEDURE|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
214425483|NCT02206841|DEVICE|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
214425484|NCT02206841|DEVICE|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
214425485|NCT02206841|DEVICE|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
214425486|NCT03023631|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214425487|NCT05575024|DEVICE|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
214425488|NCT05575024|DEVICE|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
214425489|NCT03622593|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
214425490|NCT03622593|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
214425491|NCT03622593|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
214510573|NCT05129722|DRUG|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
214510574|NCT02189434|OTHER|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
214510575|NCT03620474|DRUG|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
214510576|NCT05782894|DRUG|Remimazolam besylate|0\~2.0mg/kg/h
215112327|NCT06058013|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
215112328|NCT06058013|DRUG|Placebo|Placebo will be administered orally
215112329|NCT04275973|DEVICE|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
214425492|NCT06325111|OTHER|Determinants of T1D glycaemic control|DNA genotyping, microbiome, DNA methylation and microRNAs analysis
214425493|NCT02016352|BIOLOGICAL|patient CSF extraction with hydrocephalus|CSF extraction
214425494|NCT02016352|BIOLOGICAL|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
214425495|NCT05685030|DIETARY_SUPPLEMENT|Placebo|product vehicle (sunflower oil)
214425496|NCT05685030|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
214425497|NCT05685030|DIETARY_SUPPLEMENT|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
214425498|NCT02957812|DEVICE|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
214425499|NCT04219930|DIAGNOSTIC_TEST|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
214425500|NCT03432403|DEVICE|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
214425501|NCT03432403|DEVICE|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
214510577|NCT05782894|DRUG|Propofol|0.3\~4.0mg/kg/h
215112330|NCT04275973|DEVICE|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
215112331|NCT04275973|DEVICE|Footwear|Different footwear will be used.
215112332|NCT05499533|PROCEDURE|implant site preparation|a hole were created in the edentulous ridge area before implant placement
215112333|NCT06352645|DEVICE|Bixdo Ultra Compact Water Flosser|Use of water flosser, in addition to standard tooth brushing, twice a day for 8 weeks.
215112334|NCT06352645|DEVICE|Manual toothbrush|For those in the control group, they will be asked to use only the study-provided manual toothbrush, twice a day for 8 weeks.
214425502|NCT03762668|DEVICE|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
214425503|NCT03762668|DEVICE|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
214425504|NCT02206763|DRUG|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
214425505|NCT02206763|DRUG|Erlotinib|Tablet(s) administered orally once daily.
214425506|NCT05936333|PROCEDURE|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
215028570|NCT05126420|PROCEDURE|biopsy|biopsy to identify the lesion in the oral mucosa
214425508|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
214425509|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
214425510|NCT03886116|OTHER|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
214425511|NCT03061552|DIAGNOSTIC_TEST|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
214425512|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
214425513|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
214425514|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
214425515|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
214425516|NCT04658030|DEVICE|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
214425517|NCT04658030|OTHER|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
214425518|NCT00178399|PROCEDURE|Stereotactic Body Radiation Therapy|
214425519|NCT00470899|PROCEDURE|drainage of placenta of fetal blood|
214425520|NCT01750463|OTHER|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
214425521|NCT01750463|OTHER|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
214425522|NCT03118804|DIAGNOSTIC_TEST|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
214425523|NCT01393119|DRUG|GTx-758|3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
214425524|NCT04992156|DRUG|Palbociclib|Palbociclib 125mg/d
214425525|NCT02894242|DEVICE|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
214425526|NCT06475508|BIOLOGICAL|Complarate®|The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
214425527|NCT06475508|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
214425528|NCT05543837|DRUG|Capsaicin|Patients will receive a fixed dose of capsaicin
214425529|NCT06246435|OTHER|moderate aerobic exercise|
214425530|NCT00842049|DEVICE|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
214425531|NCT00842049|OTHER|No lumbar drain|No lumbar drain
214425532|NCT00001730|DRUG|Thyrogen|
214425533|NCT00238212|DRUG|sorafenib tosylate|Given orally
214425534|NCT00238212|OTHER|laboratory biomarker analysis|Correlative studies
214425535|NCT02544152|DRUG|Lubiprostone|8 mcg administered orally twice daily (BID)
214425536|NCT02544152|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
214425537|NCT06638112|PROCEDURE|Brachial Plexus Block|Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam or propofol.
214425538|NCT06638112|PROCEDURE|General Anesthesia (control group)|General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
214425539|NCT01723410|BEHAVIORAL|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
214425540|NCT01723410|OTHER|Writing about places, objects|
214425541|NCT02338245|DRUG|ASLAN001|ASLAN001 400mg BID
214425542|NCT02338245|DRUG|Lapatinib|Lapatinib 1250mg QD
214425543|NCT02338245|DRUG|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
214425544|NCT03571191|DRUG|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
215028571|NCT03797937|OTHER|Magnetic resonance imaging (MRI)|MRI scanner
215028572|NCT00831389|DEVICE|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
215028573|NCT06465238|DRUG|SHR-A2009|Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
215028574|NCT06465238|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
215028575|NCT05348941|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
215028576|NCT03350945|PROCEDURE|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
214510578|NCT05782894|DRUG|Remifentanil|1.5\~12μg/kg/h
214510579|NCT04813224|BEHAVIORAL|TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT|Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
214510580|NCT02730624|DRUG|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
214425545|NCT00415272|BEHAVIORAL|Pulmonary Rehabilitation|
214425546|NCT06565208|DRUG|SAT-3247|SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
214425547|NCT06565208|DRUG|matched placebo|matched placebo
214510581|NCT01989689|DRUG|Etanercept|Etanercept 50mg twice weekly
214510582|NCT01989689|DRUG|Placebo|
214425548|NCT00506727|DRUG|Mixed amphetamine salts (ADDERALL XR)|
214425549|NCT00506727|DRUG|Atomoxetine hydrochloride|
214425550|NCT04157426|OTHER|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
214425551|NCT04157426|OTHER|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
214425552|NCT00646035|DRUG|paricalcitol capsules|baseline iPTH/60
214425553|NCT06480552|DRUG|TEV-56278|Administered intravenously
214425554|NCT06480552|DRUG|Pembrolizumab|Administered intravenously
214510583|NCT00426205|BIOLOGICAL|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
214510584|NCT00761267|DRUG|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
214510585|NCT00761267|DRUG|Fluconazole|Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
214510586|NCT04492475|DRUG|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
214510587|NCT04492475|OTHER|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
214425555|NCT06266780|BEHAVIORAL|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
214425556|NCT06123871|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
214510588|NCT04492475|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
214510589|NCT03795532|PROCEDURE|SWL|Shock wave lithotripsy
214425557|NCT06412341|BEHAVIORAL|Accepting your Body after Cancer|See 'Arm Description'
214425558|NCT06412341|BEHAVIORAL|Macmillan body image booklet|See 'Arm Description'
214510590|NCT03451695|DRUG|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
214425559|NCT04409912|DEVICE|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
214425560|NCT04409912|DEVICE|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
214510591|NCT03451695|DRUG|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
214510592|NCT00491101|OTHER|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
214510593|NCT00491101|OTHER|spirometry|spirometry
214425561|NCT00534937|PROCEDURE|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
214510594|NCT03154775|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
214510595|NCT02160600|OTHER|Standard multiphase CT|
214510596|NCT02160600|OTHER|split bolus Dual energy CT|
214510597|NCT01758068|PROCEDURE|Coconut Oil Application|Coconut oil - 4 ml
214510598|NCT04698694|DEVICE|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
214510599|NCT04698694|DEVICE|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
214510600|NCT04602949|DIAGNOSTIC_TEST|Breath Biopsy Analysis|Analysis of a single breath Biopsy
214510601|NCT00972920|PROCEDURE|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
214510602|NCT01034488|BIOLOGICAL|Suine|5000UI /mL
214510603|NCT01034488|BIOLOGICAL|Suine|5000UI/mL
214510604|NCT03251456|OTHER|Tertiary care|"1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
214692314|NCT02993224|DRUG|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
215112335|NCT06468618|BEHAVIORAL|DREAMS Program Video and Care Kit|A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
215112336|NCT06665347|OTHER|Progressive muscle relaxation|The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.
215112337|NCT06665347|OTHER|Yoga|The participants will receive yoga for 30 minutes/session, 3 sessions/week for 8 weeks. The session will begin with 5 minutes for warming up. Twenty minutes of wind relieving position (pavanmuktasana), corpse position (savasana), standing side stretch position, seated forward bend (paschimothanasana), cobra position (bhujangasana), and chair position (utkatasana). Five minutes of cooling down.
214510605|NCT03251456|OTHER|Usual Care|"1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
214510606|NCT04396210|OTHER|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
214510607|NCT05983861|DIAGNOSTIC_TEST|Identification o Multi Drug Resistant Bacteria|Identification o Multi Drug Resistant Bacteria
214510608|NCT00524069|BIOLOGICAL|bevacizumab|
214510609|NCT00524069|DRUG|capecitabine|
214510610|NCT00524069|DRUG|gemcitabine hydrochloride|
214510611|NCT00524069|OTHER|flow cytometry|
214510612|NCT00524069|OTHER|laboratory biomarker analysis|
214510613|NCT00524069|PROCEDURE|adjuvant therapy|
214510614|NCT00524069|PROCEDURE|computed tomography|
214510615|NCT00524069|PROCEDURE|neoadjuvant therapy|
214510616|NCT05749237|OTHER|respiratory exercises|respiratory exercises
214510617|NCT05749237|OTHER|relaxation exercises|relaxation exercises
214425562|NCT00534937|PROCEDURE|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
214425563|NCT06490159|DRUG|Paclitaxel|Gastric cancer second-line chemotherapy
214425564|NCT00844636|DEVICE|Sharp needle|
214425565|NCT00844636|DEVICE|Blunt needles|
214425566|NCT04432688|DRUG|Lurasidone HCl|This is a non-interventional, observational study
214425567|NCT03601780|DRUG|local wound infiltration plus usual care|local wound infiltration plus usual care
214510618|NCT00661206|DRUG|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
214425568|NCT03601780|DRUG|usual care only|usual care only
214510619|NCT00661206|DRUG|Placebo|Patients randomized in this group will receive placebo for 6 months.
214510620|NCT00164996|PROCEDURE|Local pharyngeal anaesthesia|
215112338|NCT05092009|OTHER|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
214510621|NCT00164996|DEVICE|Ultrathin endoscope|
214510622|NCT05918107|DRUG|PM8002|IV infusion
214510623|NCT05918107|DRUG|Pemetrexed|IV infusion
214510624|NCT05918107|DRUG|Cisplatin|IV infusion
214510625|NCT05918107|DRUG|Carboplatin|IV infusion
214510626|NCT04417075|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
214510627|NCT04417075|BEHAVIORAL|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
214510628|NCT00515242|BEHAVIORAL|massage|therapeutic massage
214510629|NCT00515242|BEHAVIORAL|thermotherapy|heat therapy
214510630|NCT00515242|BEHAVIORAL|relaxing environment|time in a relaxing environment
214510631|NCT03989232|DRUG|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
214510632|NCT03989232|DRUG|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
214510633|NCT01872104|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
214510634|NCT04546555|DEVICE|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
214510635|NCT04546555|OTHER|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
214510636|NCT04546555|OTHER|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
215112339|NCT06974006|OTHER|Devices: Kardia Mobile 6L; Omron M7 BP ; Beurer PO30; Datospir Peak-10; NUTRILAB BIA 101 BIVA® PRO; JAMAR® Smart.|Use of the Kardia Mobile 6L portable device to assess electrocardiogram; Omron M7 BP for blood pressure; Beurer PO30 for oxygen saturation; Datospir Peak-10 for peak flow; NUTRILAB BIA 101 BIVA® PRO for body composition; questionnaires for the nutritional status (Mini-Nutritional Assessment, Malnutrition Universal Screening Tool), JAMAR® Smart for handgrip strength; The Short Physical Performance Battery for frailty status and fall risk; the Geriatric Depression Scale to evaluate depression status; the Fried's frailty phenotype to assess the frailty status; the International Physical Activity Questionnaire for the physical activity levels; SARC-F to identify older adults at risk of sarcopenia; and the Timed-Up and Go for mobility, walking ability and fall risk.
214510637|NCT02718885|DIETARY_SUPPLEMENT|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
214510638|NCT02718885|DIETARY_SUPPLEMENT|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
214510639|NCT03192189|OTHER|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
214510640|NCT03868878|OTHER|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
214510641|NCT04976946|OTHER|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
214425569|NCT03784768|OTHER|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
214510642|NCT00869609|BEHAVIORAL|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
215112340|NCT06968442|PROCEDURE|Venipuncture|Simple blood collection
214425570|NCT03784768|OTHER|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
214510643|NCT00869609|BEHAVIORAL|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
214510644|NCT04411771|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
214510645|NCT04411771|BEHAVIORAL|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
214510646|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
214510647|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
214692315|NCT02993224|DRUG|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
214425571|NCT04114149|DEVICE|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
214425572|NCT04114149|DRUG|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
214692316|NCT01834924|OTHER|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
214692317|NCT06463769|BEHAVIORAL|8 week predominantly plant-based New Nordic LPF-diet program|An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.
214692318|NCT06463769|BEHAVIORAL|maintenance of the predominantly plant-based New Nordic LPF-diet|Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
214692319|NCT04286412|BIOLOGICAL|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
214692320|NCT01032512|DIETARY_SUPPLEMENT|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
214425573|NCT05185830|OTHER|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
214692321|NCT01032512|DIETARY_SUPPLEMENT|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
214692322|NCT05331612|BEHAVIORAL|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
214425574|NCT01681381|DEVICE|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
214425575|NCT01681381|DEVICE|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
214425576|NCT01287286|DIETARY_SUPPLEMENT|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
214425577|NCT01287286|DIETARY_SUPPLEMENT|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
214425578|NCT02488200|OTHER|No intervention|No intervention
214425579|NCT03700853|DIAGNOSTIC_TEST|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
214425580|NCT01474707|BEHAVIORAL|Group one|Group 1 will view the knowledge-based video only
214425581|NCT01474707|BEHAVIORAL|Group two|Group two will view the motivational video only
214425582|NCT01474707|BEHAVIORAL|Group three|Group three will view both knowledge-based and motivational videos
214425583|NCT01474707|BEHAVIORAL|Group four|Group four will view the printed educational pamphlet and will not view either video
214425584|NCT06515951|DIAGNOSTIC_TEST|STANDING algorithm|The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
214425585|NCT05965388|DRUG|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
214425586|NCT06255795|DRUG|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
214425587|NCT06255795|DRUG|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
214425588|NCT01959126|BEHAVIORAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
214425589|NCT00516321|DRUG|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
214510648|NCT00299507|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
214510649|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
214510650|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
214510651|NCT01861041|DRUG|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
214510652|NCT01861041|DRUG|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
214510653|NCT03528304|BEHAVIORAL|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
214425590|NCT00516321|DRUG|placebo|matched placebo taken once daily orally
214425591|NCT05674136|DEVICE|INVSENSOR00061|Noninvasive pulse oximeter sensor
214425592|NCT04738058|DRUG|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
214425593|NCT04738058|DRUG|placebo|placebo
214425594|NCT00583817|DEVICE|Endovascular stent-graft implantation|Endovascular repair of aorta
214425595|NCT04906369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214425596|NCT04306354|DRUG|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
214425597|NCT04306354|DRUG|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
214425598|NCT02329457|BIOLOGICAL|Zostavax|varicella zoster vaccine
214425599|NCT02329457|BIOLOGICAL|Normal Saline|normal saline placebo vaccine
214425600|NCT04783454|OTHER|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
214510654|NCT01554267|DEVICE|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
214510655|NCT05081726|DIAGNOSTIC_TEST|Functional MRI|Series of MRI scans of the brain
214510656|NCT00004085|BIOLOGICAL|filgrastim|as prescribed by physician
214425601|NCT02027558|BEHAVIORAL|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
214510657|NCT00004085|PROCEDURE|autologous bone marrow transplantation|1-2 weeks prior to treatment
214510658|NCT00004085|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
214510659|NCT00004085|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
214510660|NCT02354144|OTHER|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
214510661|NCT02354144|OTHER|Control gel|A gel not containing carrageenan
214510662|NCT03212638|DRUG|Baricitinib suspension|Administered orally
214510663|NCT03212638|DRUG|Baricitinib tablet|Administered orally
214510664|NCT01827761|BEHAVIORAL|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
214510665|NCT04923022|OTHER|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
214510666|NCT04923022|OTHER|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
214510667|NCT00748891|DRUG|Recentin (Cediranib)|30mg once daily, oral dose
214510668|NCT01960972|OTHER|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
214510669|NCT03069209|BIOLOGICAL|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
214510670|NCT04014452|PROCEDURE|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
214510671|NCT04014452|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
214510672|NCT04910711|DRUG|Dolutegravir|Dolutegravir-based antiretroviral therapy
214510673|NCT04910711|DRUG|Levonorgestrel implant|Women initiating the levonorgestrel implant
214510674|NCT04910711|DRUG|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
214510675|NCT00125905|BEHAVIORAL|Advice|
214425602|NCT02027558|BEHAVIORAL|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
214692323|NCT05025072|DRUG|Hydroxycarbamide dispersible tablets|Hydroxycarbamide dispersible tablets (20 x 50 mg)
214425603|NCT02139046|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
214425604|NCT02139046|DRUG|Febuxostat XR|Febuxostat XR over-encapsulated capsules
214425605|NCT02139046|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
214425606|NCT02139046|DRUG|Colchicine|Colchicine tablets
214425607|NCT02139046|DRUG|Naproxen|Naproxen tablets
214425608|NCT02139046|DRUG|Lansoprazole|Lansoprazole capsules
214425609|NCT01574859|OTHER|levothyroxine|titration of T4 according to biochemical values
214510676|NCT00125905|BEHAVIORAL|Motivational Interviewing|
214510677|NCT00125905|DRUG|Nicotine Gum and Patch|
214510678|NCT00125905|DRUG|Bupropion|
214510679|NCT04365205|PROCEDURE|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
214510680|NCT01948024|DRUG|SAPHRIS|10 mg BID sublingual tablet
214510681|NCT01948024|DRUG|Asenapine|10 mg BID sublingual tablet
214692324|NCT05025072|DRUG|Hydroxycarbamide film-coated tablet|Hydroxycarbamide film-coated tablet (1000 mg)
214692325|NCT02998437|DRUG|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
214692326|NCT02998437|DRUG|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
214692327|NCT02998437|DRUG|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
214425610|NCT02383472|DEVICE|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
214425611|NCT02383472|DEVICE|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
214425612|NCT01111526|DRUG|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
214425613|NCT02013830|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
214425614|NCT02013830|DRUG|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
214425615|NCT06426823|OTHER|Saline / placebo|NaCl (9 mg/ml)
214425616|NCT06426823|OTHER|GIPR antagonist / study tool|GIP(3-30)NH2
214425617|NCT02015546|DRUG|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
214425618|NCT00136058|PROCEDURE|bone densitometry (DEXA)|
214510682|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
214510683|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
215112341|NCT06668454|PROCEDURE|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
215112342|NCT03035331|PROCEDURE|Cryosurgery|Undergo cryosurgery
214425619|NCT00136058|DRUG|alendronate or risedronate|
214425620|NCT01438086|DRUG|mecasermin|Intracoronary bolus
214425621|NCT01438086|DRUG|mecasermin|Intracoronary bolus
214425622|NCT01438086|DRUG|0.9% sodium chloride injection|Intracoronary bolus
214425623|NCT04436393|DIAGNOSTIC_TEST|Guardant360 test|tumor cfDNA testing
214425624|NCT04424641|BIOLOGICAL|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
214425625|NCT00597038|DRUG|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."
214425626|NCT01087255|DEVICE|Electronic Pillbox Monitoring System|Daily exposure for six months
214425627|NCT04094532|DRUG|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
214425628|NCT04094532|DRUG|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
214425629|NCT04238429|DRUG|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
214425630|NCT04238429|DRUG|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
214510684|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
214510685|NCT01206972|DRUG|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
214510686|NCT02954289|BEHAVIORAL|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
214510687|NCT00514306|DRUG|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
214510688|NCT01323790|DRUG|NKTR-118|12.5 mg oral tablet once daily
214510689|NCT01323790|DRUG|NKTR-118|25 mg oral tablet once daily
214510690|NCT01323790|DRUG|Placebo|Placebo to NKTR-118
214510691|NCT01351259|DEVICE|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
214510692|NCT03352726|DRUG|DBV712 IHRP|DBV712 Solution for Skin Prick Test
214692328|NCT01930799|BEHAVIORAL|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
215112343|NCT03035331|BIOLOGICAL|Dendritic Cell Therapy|Given IT
215112344|NCT03035331|OTHER|Laboratory Biomarker Analysis|Correlative studies
215112345|NCT03035331|BIOLOGICAL|Pembrolizumab|Given IV
215112346|NCT03035331|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
215112347|NCT03035331|OTHER|Quality-of-Life Assessment|Ancillary studies
215112348|NCT06974188|OTHER|AI-risk Stratification|With the results being disclosed as 'high-risk' or 'low-risk' in the experimental arm, clinicians have to adhere to a specific 'high-risk' and 'low-risk' management protocol for participants.
214425631|NCT03446859|OTHER|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
214425632|NCT06480942|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
214425633|NCT06313125|OTHER|3-dimensional foot-ankle extension exercises|In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
214425634|NCT06313125|OTHER|Clam exercise|In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
214425635|NCT06313125|OTHER|Short-foot exercise|In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
214425636|NCT03245580|DIAGNOSTIC_TEST|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
214425637|NCT00304135|DRUG|cisplatin|
214425638|NCT00304135|DRUG|gemcitabine hydrochloride|
214425639|NCT00304135|DRUG|oxaliplatin|
214425640|NCT02769468|OTHER|The Back|
214510693|NCT06359548|PROCEDURE|Peeled ILM Reposition|"The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required."
214510694|NCT06359548|PROCEDURE|ILM Peeling|The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
214510695|NCT02676011|DRUG|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
214510696|NCT02676011|DRUG|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
214510697|NCT02676011|DRUG|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
214510698|NCT02676011|DRUG|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
214510699|NCT02676011|DRUG|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
214692329|NCT02915367|BEHAVIORAL|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
214510700|NCT02676011|DRUG|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
214692330|NCT00972400|GENETIC|protein analysis|
214692331|NCT00972400|OTHER|laboratory biomarker analysis|
214510701|NCT01263496|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
214692332|NCT00972400|OTHER|mass spectrometry|
214692333|NCT00972400|OTHER|questionnaire administration|
214692334|NCT00972400|PROCEDURE|assessment of therapy complications|
214692335|NCT00972400|PROCEDURE|cognitive assessment|
214692336|NCT00972400|PROCEDURE|quality-of-life assessment|
214425641|NCT02769468|OTHER|Chest|
214425642|NCT02769468|OTHER|Left Axilla|
214425643|NCT01876602|BEHAVIORAL|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
214425644|NCT05672888|DRUG|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
214425645|NCT05672888|DRUG|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
214425646|NCT05701397|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
214425647|NCT03431922|DEVICE|endovascular denervation|multi-electrode catheter-based endovascular denervation
214425648|NCT02207972|DEVICE|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
214425649|NCT02207972|PROCEDURE|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
214425650|NCT05554185|DIETARY_SUPPLEMENT|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
214425651|NCT04988568|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
214510702|NCT01263496|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
214510703|NCT01263496|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
214510704|NCT01263496|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
214510705|NCT01263496|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
214510706|NCT02842957|BEHAVIORAL|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
214510707|NCT00198185|PROCEDURE|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
214510708|NCT01668394|BEHAVIORAL|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
214510709|NCT01668394|OTHER|Control arm|Usual care. Teaching style: deductive.
214510710|NCT06413888|PROCEDURE|pancreaticoduodenectomy|Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
214510711|NCT00006045|BIOLOGICAL|lintuzumab|
214510712|NCT00006045|DRUG|cytarabine|
214510713|NCT00006045|DRUG|etoposide|
214692337|NCT00722553|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
214425652|NCT01426269|DRUG|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
214510714|NCT00006045|DRUG|mitoxantrone hydrochloride|
214510715|NCT01720706|DEVICE|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
214510716|NCT01990625|DEVICE|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
214510717|NCT00018512|PROCEDURE|Implant-supported denture|
214425653|NCT01426269|DRUG|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
214425654|NCT01426269|DRUG|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
214510718|NCT01404338|DRUG|Halobetasol 0.05% ointment|
214510719|NCT01404338|DRUG|Placebo Ointment|
214510720|NCT05664776|DEVICE|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
214510721|NCT02432274|DRUG|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
214510722|NCT02432274|DRUG|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
214510723|NCT02432274|DRUG|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
214510724|NCT02432274|DRUG|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
214510725|NCT02432274|DRUG|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
214510726|NCT02432274|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
214510727|NCT02432274|DRUG|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
214425655|NCT05857371|PROCEDURE|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
214425656|NCT05857371|PROCEDURE|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
214425657|NCT05857371|DRUG|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
214425658|NCT04739280|DEVICE|CardioFlux Magnetocardiography|Magnetocardiography
214510728|NCT02432274|DRUG|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
214510729|NCT02432274|DRUG|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
214510730|NCT06238934|BIOLOGICAL|Bone marrow aspirate matrix|Bone marrow aspirate \* Hyaluronic acid
214510731|NCT06238934|BIOLOGICAL|Bone marrow aspirate|Bone marrow aspirate
214510732|NCT06238934|DEVICE|Hyaluronic acid|Hyaluronic acid
214510733|NCT05758584|OTHER|Intervention|Vibrating tourniquet
214510734|NCT05758584|OTHER|Distraction card|Distraction card
214510735|NCT04696900|PROCEDURE|Exercise training|exercise training in an approved rehabilitation program
214510736|NCT02176577|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
214425659|NCT01909258|OTHER|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
214425660|NCT01909258|OTHER|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
214692338|NCT00722553|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
214425661|NCT01909258|OTHER|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
214425662|NCT04580160|DEVICE|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
214425663|NCT06322797|DEVICE|rTMS|"Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min."
214692339|NCT00722553|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
214692340|NCT04357353|BIOLOGICAL|Platelet rich plasma|PRP will be used in the experimental arm.
214425664|NCT06322797|DEVICE|rTMS|Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
214425665|NCT06322797|DEVICE|Sham|In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
214510737|NCT04057261|DRUG|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
214510738|NCT04057261|DRUG|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
214510739|NCT05305508|DRUG|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
214510740|NCT05305508|DRUG|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
214510741|NCT06140550|DEVICE|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
214510742|NCT06140550|DEVICE|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
214510743|NCT03428438|OTHER|Rehabilitation at home via SMS|Cardiac rehabilitation
214510744|NCT05794659|BIOLOGICAL|AST-201|i.d. (3-week interval, 3 cycles in total)
214510745|NCT05794659|DRUG|Paclitaxel|3-week interval, 6 cycles in total
214510746|NCT05794659|DRUG|Carboplatin|3-week interval, 6 cycles in total
214510747|NCT05794659|DRUG|Placebo|i.d. (3-week interval, 3 cycles in total)
214510748|NCT05794659|DRUG|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
214510749|NCT00781118|DEVICE|Guardian System|There is no intervention in this study. The device is a diagnostic only.
214510750|NCT01728298|BIOLOGICAL|SLITone ULTRA HDM immunotherapy|
214510751|NCT05086874|OTHER|butylphthalide|Observational only and no predesigned interventions in this study
214425666|NCT05906875|OTHER|Lateral Stepping Exercise 1|1\. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
214425667|NCT05906875|OTHER|Active Control Group Exercise 1|1\. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
214510752|NCT01486459|DRUG|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
214425668|NCT05906875|OTHER|Active Control Group Exercise 2|2\. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
214425669|NCT05906875|OTHER|Active Control Group Exercise 3|3\. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
214510753|NCT00005943|BIOLOGICAL|aldesleukin|
214425670|NCT05906875|OTHER|Active Control Group Exercise 4|4\. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
214425671|NCT05906875|OTHER|Lateral Stepping Exercise 2|2\. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
214510754|NCT00005943|BIOLOGICAL|staphylococcal enterotoxin B|
214510755|NCT00779194|DRUG|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
214510756|NCT03526406|DIETARY_SUPPLEMENT|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
214510757|NCT03526406|DIETARY_SUPPLEMENT|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
214425672|NCT05906875|OTHER|Lateral Stepping Exercise 3|3\. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
214425673|NCT05906875|OTHER|Lateral Stepping Exercise 4|4\. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
214510758|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
214510759|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
214510760|NCT00354237|OTHER|Conventional antidiabetic treatment|No intensive treatment
214510761|NCT00354237|OTHER|Intensive insulin treatment|Intensive insulin treatment
214510762|NCT00513071|DRUG|saracatinib|Given orally
214510763|NCT00513071|OTHER|laboratory biomarker analysis|Correlative studies
214510764|NCT05842382|DRUG|Active Ingredient|IV Vitamin C (12g/day)
214510765|NCT05842382|DRUG|Placebo|IV dextrose 5%
214510766|NCT02089529|DRUG|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
214692341|NCT04357353|OTHER|Placebo Sham Injection|sham injection
214510767|NCT02089529|DRUG|Placebo|Placebo with no information, positive information and neutral information
214510768|NCT05679479|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
214510769|NCT05679479|OTHER|Normal saline|0.9% normal saline
214510770|NCT03977805|DRUG|Hetrombopag Olamine|a single oral taking
214510771|NCT02368652|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
214510772|NCT02368652|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
214510773|NCT01479010|DRUG|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
214510774|NCT01660659|DEVICE|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
214510775|NCT02481804|OTHER|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
214510776|NCT02481804|OTHER|Standard treatment|Standard treatment will be continued
214425674|NCT05906875|OTHER|Lateral Stepping Exercise 5|5\. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
214425675|NCT00155415|BEHAVIORAL|Different timing of taking polyethylene glycol(PEG)|
214425676|NCT00051272|DRUG|Extended-release Bupropion Hydrochloride|
214425677|NCT02764944|PROCEDURE|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
214425678|NCT02722070|DEVICE|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
214425679|NCT00959582|PROCEDURE|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
214425680|NCT00186186|DRUG|Depakote ER|Depakote ER
214425681|NCT02327611|DRUG|Custodiol|
214425682|NCT02327611|DRUG|Enriched Ringer's lactate solution|
214425683|NCT02301442|BEHAVIORAL|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
214425684|NCT02301442|BEHAVIORAL|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
214425685|NCT00427323|PROCEDURE|light exposure|
214425686|NCT05377567|BEHAVIORAL|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
214425687|NCT05377567|BEHAVIORAL|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
214425688|NCT05377567|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
214425689|NCT00003540|DRUG|gemcitabine hydrochloride|
214425690|NCT01337635|DRUG|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
214425691|NCT03176654|PROCEDURE|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
214510777|NCT01573338|DRUG|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
214510778|NCT01573338|DRUG|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
214510779|NCT01573338|DRUG|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
214425692|NCT03176654|PROCEDURE|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
214425693|NCT02086097|DRUG|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
214425694|NCT02086097|DRUG|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
214425695|NCT02086097|DRUG|PLACEBO|INACTIVE SUGAR PILLS
214425696|NCT06347172|BEHAVIORAL|Nudge Intervention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
214425697|NCT05898191|OTHER|vaginal laser treatment|non-ablative vaginal laser application
214425698|NCT01402531|DRUG|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
214425699|NCT00289835|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
214510780|NCT01573338|DRUG|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
214510781|NCT05348603|OTHER|Traditional Letter|Patients receive a traditional letter.
214510782|NCT05348603|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
214510783|NCT05348603|OTHER|Chatbot|Patients are contacted by a chatbot via the portal.
214510784|NCT05348603|OTHER|Banner|Patients are exposed to a banner ad via the portal.
214510785|NCT03056066|DEVICE|Plethysmograph|A full Body Plethysmography examination
214510786|NCT00002294|DRUG|Fluconazole|
214510787|NCT00286325|DRUG|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
214425700|NCT05932615|DEVICE|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
214425701|NCT05932615|DEVICE|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
214425702|NCT00839371|DRUG|Propofol|i.v. propofol titration until adequate depth of sedation
214425703|NCT00839371|DRUG|Midazolam|i.v. midazolam titration until adequate depth of sedation
214510788|NCT04568213|DRUG|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
214510789|NCT04565652|DEVICE|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
214510790|NCT06143124|DRUG|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
214425704|NCT03990272|DRUG|AIT drops|once a day
214425705|NCT03990272|DRUG|placebo drops|once a day
214510791|NCT05443698|DEVICE|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
214692342|NCT05609747|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
214692343|NCT01706445|OTHER|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
214692344|NCT00952289|DRUG|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
214692345|NCT00952289|DRUG|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
215112349|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
215112350|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
214425706|NCT00161733|DRUG|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
214425707|NCT00161733|DRUG|TISSEEL VH fibrin sealant|
214425708|NCT04608955|DRUG|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
214425709|NCT04608955|DRUG|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
214425710|NCT04608955|DRUG|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
214425711|NCT04608955|DRUG|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
214425712|NCT04561219|DRUG|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
215112351|NCT00764062|DRUG|Amoxicillin|Amoxicillin :drug
215112352|NCT04683653|RADIATION|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
215112353|NCT04683653|OTHER|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
215112354|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
215112355|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
215112356|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
214425713|NCT04561219|DRUG|Placebo|Placebo three times a day for 5 days
214425714|NCT05300061|BEHAVIORAL|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
214425715|NCT05300061|BEHAVIORAL|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
214425716|NCT00437346|PROCEDURE|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
214425717|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
214425718|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
214425719|NCT04873336|DEVICE|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
215112357|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
215112358|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
215112359|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
215112360|NCT03724890|DRUG|M3814|Participants received M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
215112361|NCT03724890|DRUG|M3814|Participants received M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
215112362|NCT03724890|DRUG|Avelumab|Participants received avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
215112363|NCT03724890|RADIATION|Radiotherapy|Participants received radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
215112364|NCT06043063|PROCEDURE|Topical lidocaine|Topical anesthetic
215112365|NCT06043063|PROCEDURE|EMLA cream|Topical anesthetic
215112366|NCT06043063|PROCEDURE|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
214425720|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
214425721|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
214425722|NCT03959241|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
214425723|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
214425724|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
214425725|NCT03959241|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
214425726|NCT03959241|DRUG|Cyclophosphamide|Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
214425727|NCT02919176|DRUG|Mirabegron|Mirabegron 50 mg/day
214425728|NCT02919176|DRUG|Pioglitazone|Pioglitazone 30 mg/day
214425729|NCT02919176|DRUG|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
214425730|NCT00877422|DIETARY_SUPPLEMENT|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
214425731|NCT01145885|DRUG|BI 6727|PLK-1 inhibitor
214425732|NCT01023490|DRUG|Vitamin D|34,5000 IU vitamin D per week
214425733|NCT01023490|DRUG|Placebo|Placebo
214425734|NCT02673788|OTHER|observation without intervention in this follow up study|observation without intervention in this follow up study
214425735|NCT04243304|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
214510792|NCT03146026|BEHAVIORAL|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
214510793|NCT00667732|DRUG|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
215112367|NCT02314221|DEVICE|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
215112368|NCT06483854|DIAGNOSTIC_TEST|HIV counseling and testing from a traditional health practitioner|Healer provided HIV counseling and testing services offered to clients
215112369|NCT06209736|DRUG|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
215112370|NCT04607837|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
214425736|NCT04243304|OTHER|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
214510794|NCT00667732|DRUG|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
214425737|NCT03547479|BEHAVIORAL|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
214425738|NCT03547479|BEHAVIORAL|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
214425739|NCT02100371|DRUG|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
214425740|NCT03691428|BEHAVIORAL|Wish Outcome Obstacle Plan|"1\. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan."
214425741|NCT03329391|BEHAVIORAL|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
214425742|NCT02527148|DEVICE|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
214510795|NCT01240590|DRUG|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
214510796|NCT01240590|DRUG|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
214510797|NCT03890484|BEHAVIORAL|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
215112371|NCT04607837|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
215112372|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
215112373|NCT06260943|BEHAVIORAL|Target Navigation Pilot Program|Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.
215112374|NCT06184438|DRUG|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
215112375|NCT06184438|DRUG|Placebo|Received placebo after surgery.
215112376|NCT06976957|DEVICE|MyPlan / Movisalud App|Those patients in experimental arm will be followed through a mobile app that offers different functionalities designed to improve clinical-patient communication, empower the patient in the management of his disease and treatment, detect symptoms early and individualize the interventions of professionals thanks to the patient records on the platform
215112377|NCT06976125|DEVICE|Decision Aid-prediction model|"ER physician will input the necessary de-identified data into the decision aid application.~The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics.~Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture.~The culture call-back team, consisting of clinical pharmacists, will be notified."
214510798|NCT03890484|BEHAVIORAL|Peer Type - Close Friends|Participants drink with 2 close friends
214510799|NCT02123940|DEVICE|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
214510800|NCT02106325|DRUG|Ketamine|IV of Ketamine (.25mg/kg)
214510801|NCT02106325|DRUG|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
214510802|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
214692346|NCT03091062|DEVICE|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
214692347|NCT03091062|DEVICE|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
215112378|NCT06974825|DRUG|BGM0504 Administered SC|5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
215112379|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
215112380|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
215112381|NCT06974825|DRUG|Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
215112382|NCT06974825|DRUG|Placebo Administered SC|Placebo Comparator: Placebo Placebo administered SC once a week.
214425743|NCT02527148|DEVICE|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
214425744|NCT02527148|PROCEDURE|Total Knee Replacement|
214425745|NCT02527148|DEVICE|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
214425746|NCT06554860|OTHER|scapular Blackburn stabilization plus exercise|scapular Blackburn stabilization
214425747|NCT06554860|OTHER|PNF plus Exercise|PNF plus Exercise
214425748|NCT06554860|OTHER|exercise only|Exercise only
214425749|NCT02144584|DRUG|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
214425750|NCT02144584|DRUG|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
214425751|NCT06405555|DRUG|Midodrine Oral Tablet|Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
214425752|NCT02667808|OTHER|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
214425753|NCT02667808|OTHER|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
214425754|NCT03091010|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
214425755|NCT03091010|DRUG|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
214425756|NCT04973735|DRUG|LY-CovMab|single IV infusion
214510803|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
214692348|NCT04356144|DIAGNOSTIC_TEST|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
215112383|NCT06975462|COMBINATION_PRODUCT|SHR-A1811 and radiotherapy|SHR-A1811:4.8mg/kg radiotherapy: 800cGY\*5
215112384|NCT06976593|DIAGNOSTIC_TEST|Functional Exercise Testing and Muscle Oxygen Saturation Measurement|Participants will complete three physical performance tests: (1) the 6-Minute Walk Test (6MWT), (2) the 30-Second Sit-to-Stand Test, and (3) a submaximal treadmill test. Muscle oxygen saturation (SmO2) will be continuously monitored during the tests using near-infrared spectroscopy (NIRS) devices placed on the intercostal, quadriceps, and triceps surae muscles. Additional variables such as heart rate, perceived exertion, respiratory pressures, pulmonary function, and fatigue will be assessed during or after the tests.
214425757|NCT04097418|BEHAVIORAL|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
214425758|NCT05489406|DRUG|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
214425759|NCT05489406|DRUG|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
214425760|NCT05888584|OTHER|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
214425761|NCT00488410|DEVICE|Doppler echocardiography|
214425762|NCT04908371|PROCEDURE|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
214510804|NCT02284607|DRUG|Placebo|Matching placebo to MHAA4549A administration
214510805|NCT00420368|DIETARY_SUPPLEMENT|No food supplement|
214510806|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: fortified spread|
214510807|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|
214510808|NCT03167008|DIAGNOSTIC_TEST|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
214510809|NCT03167008|DIAGNOSTIC_TEST|blood sample|blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
214510810|NCT04707599|OTHER|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
214510811|NCT00738959|DRUG|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
214510812|NCT02120807|DRUG|Certolizumab|
214510813|NCT02120807|DRUG|cisplatin|
214510814|NCT02120807|DRUG|pemetrexed|
214425763|NCT04908371|PROCEDURE|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
214510815|NCT00470483|DRUG|Placebo treatment during 8 weeks|comparator
214510816|NCT00470483|DRUG|Paroxetine treatment during 8 weeks|treatment drug
214425764|NCT03702673|DRUG|K-877 CR Tablet A|K-877 Controlled Release Tablet A
214510817|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
215112385|NCT06975488|PROCEDURE|LASER Lithotripsy ( Fragmentation modality)|Group-A patients will be treated with fragmentation modality utilizing Holmium YAG laser.
215112386|NCT06975488|PROCEDURE|LASER lithotripsy (Dusting Modality)|Group-B patients will be treated with dusting modality utilizing Holmium YAG laser.
214425765|NCT03702673|DRUG|K-877 CR Tablet B|K-877 Controlled Release Tablet B
214425766|NCT03702673|DRUG|K-877 CR Tablet E|K-877 Controlled Release Tablet E
214425767|NCT03702673|DRUG|K-877 IR Tablet|K-877 Immediate Release Tablet
214425768|NCT05800405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214425769|NCT05800405|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
214510818|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
214510819|NCT03824340|DRUG|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
214510820|NCT00364455|DRUG|Epoetin alfa|
215112387|NCT06253923|DRUG|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
215112388|NCT06253923|DRUG|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
215112389|NCT04346654|DRUG|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
214425770|NCT05800405|PROCEDURE|Computed Tomography|Undergo PET/CT
214425771|NCT05800405|RADIATION|External Beam Radiation Therapy|Undergo radiation therapy
214425772|NCT05800405|PROCEDURE|Leukapheresis|Receive leukapheresis
214510821|NCT03864159|OTHER|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
214510822|NCT03864159|OTHER|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
215112390|NCT04346654|DRUG|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
215112391|NCT05470374|PROCEDURE|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
215112392|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
215112393|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
215112394|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
215112395|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
215112396|NCT06976164|PROCEDURE|The standard antenatal care.|Antenatal Protocol.
215112397|NCT06976164|PROCEDURE|Foot reflexology.|A manual therapy technique.
215112398|NCT00219505|PROCEDURE|acupuncture|
214425773|NCT05800405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214425774|NCT05800405|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214425775|NCT04864925|DRUG|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
214425776|NCT04864925|DRUG|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
214425777|NCT06176716|DRUG|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
214510823|NCT02282215|BIOLOGICAL|CLT-008|Single intravenous infusion
214425778|NCT02871999|DEVICE|Acupuncture therapy|
214425779|NCT02871999|PROCEDURE|Laparoscopic Surgery|
214425780|NCT06961630|DRUG|Rivaroxaban|Rivaroxaban 2.5mg will be orally administered twice daily for 6 months.
214425781|NCT06961630|DRUG|Atorvastatin|Atorvastatin 80mg will be orally administered daily for 6 months.
214510824|NCT02282215|BIOLOGICAL|G-CSF|Daily subcutaneous injections
214510825|NCT04987801|OTHER|Drug Toxicity|Patients who took over dose of Drugs
214425782|NCT01581736|DRUG|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
214425783|NCT01581736|OTHER|Exercise|Single episode of exercise riding a stationary bike.
214510826|NCT03695757|BIOLOGICAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
214510827|NCT03695757|BIOLOGICAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
215112399|NCT06393647|OTHER|Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
215112400|NCT05484219|DEVICE|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
215112401|NCT01480310|DRUG|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
215112402|NCT01480310|DRUG|Placebo|may receive up to 3 subcutaneous doses of placebo
215112403|NCT06672003|DIAGNOSTIC_TEST|4 meter walking speed and hand grip strength|4 meter walking seconds are noteed for each of participants
215112404|NCT06671821|DRUG|HRS-7535|HRS-7535
215112405|NCT06705257|DIAGNOSTIC_TEST|Studying the effects of varying levels of PEEP using Electrical impedance tomography|Feasibility of using EIT, to study the effect of varying levels of PEEP/Continous distending pressure on lung recruitment as measured by changes in functional lung scores and silent spaces in preterm infants (\<32 weeks) who are on mechanical ventilation or receiving primary or post extubation CPAP support.
215112406|NCT01073202|DRUG|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
215112407|NCT01073202|DRUG|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
215112408|NCT06784375|BEHAVIORAL|Unblinded CGM/Nutrition Therapy|Personalized nutrition counseling based on CGM data
214425784|NCT03802266|DEVICE|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
214425785|NCT03802266|DEVICE|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
215112409|NCT06784375|BEHAVIORAL|Blinded CGM/Nutrition Therapy|Standard nutrition education which does not incorporate CGM data
215112410|NCT06784375|BEHAVIORAL|Unblinded CGM/No Nutrition Therapy|CGM and general diabetes education (no nutrition education)
215112411|NCT06784375|BEHAVIORAL|Blinded CGM/No Nutrition Therapy|General diabetes education (no nutrition education)
215112412|NCT06748950|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks
215112413|NCT06748950|OTHER|Diet-as-Usual (DAU)|Participant's usual diet
215112414|NCT07065786|OTHER|Generative model|Prospectively enroll pretreatment imaging data from patients with unresectable hepatocellular carcinoma undergoing TACE in combination with immunotherapy plus targeted therapy. Utilize a generative model to create virtual images that represent optimal treatment responses, and compare these virtual images with actual treatment response images collected during follow-up to evaluate the reliability of the generative model.
215112415|NCT07065201|DEVICE|Mobile application for preoperative patient guidance|The mobile application provides patients with tailored information during the preoperative period until seven days after surgery. 1) Before the preoperative outpatient clinic visits, patient will receive information regarding the preoperative screening process and an overview of available anesthesia techniques through videos embedded in the app. 2) After approval for surgery and during the period leading up to the day of surgery, they will receive instructions concerning medication adjustment, lifestyle modifications, fasting rules, and hygiene measures.
215112416|NCT07065201|DEVICE|Mobile application and standard care|Patients in the control group will be asked to download the same mobile app but they will not receive the same tailored information as those in the intervention group. Instead, they will be provided with standard preoperative information and instructions. In addition, they will be asked to fill out the same questionnaire as the intervention group.
214425786|NCT04116515|BEHAVIORAL|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
214510828|NCT00105963|BEHAVIORAL|Education about infant crying|
214510829|NCT05997563|DRUG|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
214510830|NCT00366470|DRUG|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
214510831|NCT00366470|OTHER|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
214692349|NCT04356144|DIAGNOSTIC_TEST|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
214692350|NCT00469196|PROCEDURE|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
214692351|NCT02767141|BEHAVIORAL|Coping Strategies|Coping strategies for households in the US with food insecurity
214425787|NCT04116515|BEHAVIORAL|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
214425788|NCT04116515|BEHAVIORAL|Standard clinical care|Each clinic will provide standard clinical care to the participants.
214425789|NCT03160781|BIOLOGICAL|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
214692352|NCT00377624|DRUG|sodium hyaluronate|
214425790|NCT00810680|DRUG|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
214425791|NCT01282346|DEVICE|SOLX Gold Shunt|Single use implant
214425792|NCT00206024|DRUG|Esomeprazole magnesium (Nexium)|
214425793|NCT01831791|DRUG|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
214425794|NCT03587168|OTHER|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
214510832|NCT05356676|OTHER|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
214510833|NCT05356676|OTHER|Combination Therapy|"1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
214510834|NCT00563134|DRUG|GR270774|
214510835|NCT04919395|DEVICE|Clip device for Nexplanon Removal|The clip device will be used to assist in the removal procedure to remove the Nexplanon implant from the subject.
214510836|NCT04919395|PROCEDURE|Standard of Care procedure|The participants Nexplanon will be removed per standard of care.
214425795|NCT03587168|OTHER|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
214425796|NCT03587168|OTHER|Four Square Step Test|The Four Square Step Test measures dynamic balance.
214425797|NCT03587168|OTHER|Functional Reach Test|The Functional Reach Test assesses limits of stability.
214425798|NCT03587168|OTHER|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
214425799|NCT03587168|OTHER|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
214425800|NCT03587168|OTHER|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
214425801|NCT03587168|OTHER|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
214425802|NCT04932707|OTHER|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
214510837|NCT06597591|DEVICE|VR headset|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
215028577|NCT05655767|OTHER|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
215028578|NCT05107076|DIAGNOSTIC_TEST|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"* Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
214425803|NCT04932707|OTHER|Neurodynamic mobilization|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
214425804|NCT04932707|OTHER|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
214425805|NCT00494780|DRUG|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
214425806|NCT00494780|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
214425807|NCT00494780|DRUG|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
214425808|NCT00494780|DRUG|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
214425809|NCT00494780|DRUG|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
214425810|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
214425811|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
214425812|NCT04045106|OTHER|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
214425813|NCT06640387|DIAGNOSTIC_TEST|Daily Influenza, RSV or SARS-CoV-2 PCR testing for 10 days|Each participant will undergo daily PCR testing for Influenza, RSV or SARS-CoV-2 to assess viral dynamics
214425814|NCT02600052|OTHER|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
214425815|NCT02600052|DEVICE|treadmill|AEROBIC TRAINING
214425816|NCT01385891|DRUG|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
214425817|NCT00625937|DRUG|cisplatin|
214425818|NCT00625937|DRUG|docetaxel|
214425819|NCT00625937|DRUG|tegafur-gimeracil-oteracil potassium|
214510838|NCT06597591|DEVICE|Tablet|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
214510839|NCT06951997|DRUG|QL1706|5mg/kg, q3w
214425820|NCT00625937|RADIATION|radiation therapy|
214425821|NCT04735341|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
214510840|NCT06951997|DRUG|Chidamide|20mg, biw, q3w
214510841|NCT06951997|DRUG|Gemcitabine|1000mg/m2 Q3W
214510842|NCT06951997|DRUG|Nab-paclitaxel|125mg/m2 Q3W
214425822|NCT05214287|DRUG|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
214510843|NCT02709265|DRUG|amikacin/fosfomycin|single aerosolized dose
214425823|NCT06233591|DRUG|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
214425824|NCT00867191|DRUG|Placebo|Placebo, 1 tablet daily, per os., 15 days
214425825|NCT00867191|DRUG|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
214425826|NCT06089694|DEVICE|Enabling Sensor Research Holter Mode feature|The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
214425827|NCT02120911|DRUG|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
214425828|NCT02846480|OTHER|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
214425829|NCT02846480|OTHER|surgical treatment|Surgical correction of POP.
214510844|NCT04565873|DIAGNOSTIC_TEST|TSH|retrospective TSH level
214510845|NCT02860702|OTHER|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
214510846|NCT02860702|OTHER|Human/Bovine Milk|Bovine milk derived fortification
214510847|NCT05095077|DRUG|Tadalafil 40 MG|Single dose on study day 1/2
214510848|NCT05095077|DRUG|Placebo|Identical to active IMP
214510849|NCT01184027|BEHAVIORAL|nutrition /swallowing counseling|general nutrition and swalling information
214510850|NCT01184027|BEHAVIORAL|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
214510851|NCT01184027|BEHAVIORAL|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
214510852|NCT06060847|PROCEDURE|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
214510853|NCT06060847|PROCEDURE|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
215028579|NCT00470522|DRUG|Methotrexate and folic acid|
215028580|NCT02191163|DRUG|Antistax®|
215028581|NCT02191163|DRUG|Placebo|
215028582|NCT04389060|DIETARY_SUPPLEMENT|Grape seed extract|Two capsule grape seed extract (total 600 mg)
215028583|NCT00784017|DRUG|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
215028584|NCT00784017|DRUG|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
215028585|NCT04626934|OTHER|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
215028586|NCT04626934|OTHER|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
214425830|NCT02846480|OTHER|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
214510854|NCT06585579|DEVICE|Mucogyne Ovule|In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)
214425831|NCT00777244|DRUG|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
214425832|NCT06639282|DRUG|Siponimod|Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
214425833|NCT06639282|DRUG|Placebo|A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
214510855|NCT04669366|DRUG|sunitinib|As provided in real world
214510856|NCT04669366|DRUG|axitinib|As provided in real world
214510857|NCT02474004|PROCEDURE|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
214510858|NCT00680134|DRUG|AN2690|AN2690 1% Solution, once daily for 180 days
214510859|NCT00680134|DRUG|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
214692353|NCT02672319|PROCEDURE|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
214692354|NCT01528800|DRUG|Vitamin K1|10mg orally three times a week for 12 months
214692355|NCT01528800|DRUG|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
214425834|NCT05289349|DRUG|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
214425835|NCT05289349|DRUG|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
214425836|NCT03616639|DRUG|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
214425837|NCT03616639|DRUG|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
214425838|NCT03590080|DRUG|Methylprednisolone|
214425839|NCT04051255|DRUG|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
214425840|NCT02462551|DEVICE|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
214425841|NCT03686891|OTHER|Skin prick tests with four native legumes|Skin prick tests with four native legumes
214425842|NCT02203630|DRUG|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
214510860|NCT00488605|DRUG|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
214692356|NCT04032496|BEHAVIORAL|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
214692357|NCT04032496|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
215112417|NCT06900205|DRUG|Esketamine|loading dose:intravenous infusion of 0.25mg/kg esketamine after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail+1mg/kg esketamine diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
215112418|NCT06900205|DRUG|0.9 % saline|loading dose:intravenous infusion the same volume of 0.9% saline as the other group after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
215112419|NCT07065162|OTHER|Subtle Touch Technique|3 cycles of ACBT along with subtle touch technique for 15 minutes 3 times daily for 8 weeks, in addition to the standard COPD care and medication.
214692358|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 1|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
214692359|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 2|Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
215112420|NCT07065162|OTHER|Active Cycle of Breathing Technique|3 cycles of ACBTs technique for 15 minutes 3 times daily for 8 weeks, along with standard COPD care and medication.
215112421|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
214692360|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 3|Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
214692361|NCT05336526|DEVICE|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
215112422|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
215112423|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
215112424|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
215112425|NCT06772064|DRUG|Rifaximin (drug)|Rifaximin 0.4g bid for 2 weeks
215112426|NCT05715242|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
215112427|NCT05715242|BEHAVIORAL|Easier Step Goal|Participants will receive an easier daily step goal.
215112428|NCT05715242|BEHAVIORAL|Harder Step Goal|Participants will receive a more challenging daily step goal.
215112429|NCT05715242|BEHAVIORAL|Easier Calorie Goal|Participants will receive an easier daily calorie goal.
215112430|NCT05715242|BEHAVIORAL|Harder Calorie Goal|Participants will receive a more challenging daily calorie goal.
215112431|NCT05715242|BEHAVIORAL|Easier Eating Window Goal|Participants will receive an easier daily eating window goal.
215112432|NCT05715242|BEHAVIORAL|Harder Eating Window Goal|Participants will receive a more challenging daily eating window goal, akin to time-restricted eating.
215112433|NCT05715242|BEHAVIORAL|Easier Red Zone Food Goal|Participants will receive an easier daily Red Zone Food goal.
215112434|NCT05715242|BEHAVIORAL|Harder Red Zone Food Goal|Participants will receive a more challenging daily Red Zone Food goal.
215112435|NCT06661798|PROCEDURE|orthognathic surgery|Mandibular setback, Maxillary advancement, Bilateral sagital split osteotomy
215112436|NCT06661798|PROCEDURE|USG examination|Comparison of blood flow in the mental foramen before and 1week, 1 month and 3 month after orthognathic surgery using ultrasound examination
215112437|NCT06661798|PROCEDURE|Subjective evaluation - Neuro-sensitivity tests|Direction determination, two-point separation, pinprick, and brush tests, along with neurosensitivity VAS and pressure VAS, were applied to the patients. These tests were performed before surgery (T0), seven days after surgery (T1), one month after surgery (T2), and three months after surgery (T3).
214425843|NCT02203630|DRUG|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
214425844|NCT01422616|DRUG|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
214425845|NCT01422616|DRUG|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
214425846|NCT01422616|OTHER|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
214425847|NCT01422616|OTHER|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
214425848|NCT00281489|DEVICE|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
214425849|NCT00281489|BEHAVIORAL|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
214510861|NCT00488605|DRUG|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
214510862|NCT01169402|DRUG|Fluconazole|25mg/kg intravenously once weekly while on ECMO
215112438|NCT07066085|DEVICE|Serial Blood Count Study|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
215112439|NCT07066085|DEVICE|Athelas Home device|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
215112440|NCT06906185|BEHAVIORAL|Calm Moms-V|Calm Moms-V is the trauma-informed treatment developed and refined by the PI and being tested in the current study. Calm Moms-V is an online treatment program for trauma-exposed pregnant Veterans designed to target anxiety, stress, low mood, and trauma-related symptoms using empirically supported CBT techniques. Calm Moms-V includes four sessions and a booster session closer to delivery/postpartum. Sessions 1-4 are designed to be completed across four weeks (one session delivered each week). Each session is self-paced and designed to take approximately 45 minutes to complete.
214425850|NCT01471392|DEVICE|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
214425851|NCT03897413|DRUG|S-888711|Administered orally as three 0.25 mg tablets
214425852|NCT03897413|DIETARY_SUPPLEMENT|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
214510863|NCT01626833|DRUG|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
214510864|NCT01626833|BIOLOGICAL|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
214510865|NCT02499991|BEHAVIORAL|memory|keep track of social events in diary for memory recall. Used by treatment group
214692362|NCT02714673|DRUG|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
214692363|NCT00791713|DRUG|Paliperidone ER|
214692364|NCT02932475|DRUG|Metformin|1000 mg twice a day
214692365|NCT02932475|DRUG|Placebo|Delivered to match active drug
214692366|NCT02003651|DIETARY_SUPPLEMENT|Quick Defense|Echinacea product from Gaia Herbs.
214692367|NCT02003651|DIETARY_SUPPLEMENT|Placebo|Placebo
214425853|NCT02651233|OTHER|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
214425854|NCT01948648|DRUG|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
214425855|NCT01948648|DIETARY_SUPPLEMENT|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
214425856|NCT01948648|DRUG|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
214692368|NCT00367497|DRUG|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
214510866|NCT01928732|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
214425857|NCT03883529|OTHER|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
214425858|NCT00929617|BEHAVIORAL|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
214425859|NCT00929617|OTHER|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
214425860|NCT04911439|OTHER|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
214425861|NCT04911439|OTHER|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
214425862|NCT04911439|OTHER|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
214425863|NCT02219178|DRUG|lenalidomide|25mg days 1 - 14 of 21 day schedule
214425864|NCT02219178|DRUG|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
214425865|NCT02219178|DRUG|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
214510867|NCT01928732|BEHAVIORAL|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
214425866|NCT05881577|OTHER|Observational|Impact of AR on educational outcomes
214425867|NCT02744521|OTHER|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
214510868|NCT01185340|DRUG|LY2216684|
214510869|NCT01185340|DRUG|Placebo|
214510870|NCT01185340|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
214510871|NCT02639234|BIOLOGICAL|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
214425868|NCT05700513|COMBINATION_PRODUCT|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
214425869|NCT05700513|DRUG|Placebo capsules|Placebo capsules containing maltodextrin
214425870|NCT00145743|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
214425871|NCT03897348|DRUG|Placebo|Oral medication
214425872|NCT03897348|DRUG|Lacosamide 100 mg|Oral medication
214425873|NCT03897348|DRUG|Lacosamide 200 mg|Oral medication
214425874|NCT01990924|RADIATION|15 FPS|X-ray pictures
214510872|NCT02639234|DRUG|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
214510873|NCT00087516|DRUG|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
214510874|NCT00087516|DRUG|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
214510875|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
214692369|NCT04353960|DIAGNOSTIC_TEST|electrocardiograph|electrocardiograph monitor during strabismus surgery
214692370|NCT02686697|DRUG|L-Carnosine|
214692371|NCT02686697|DRUG|Placebo|
214692372|NCT02686697|BEHAVIORAL|Cognitive Training|Cognitive Training for 2 weeks
214425875|NCT01990924|RADIATION|7.5 FPS|X-ray pictures
214425876|NCT01340079|BEHAVIORAL|virtual world|health education using virtual world Second Life
214425877|NCT01340079|BEHAVIORAL|face to face|health education delivered in face to face groups
215028587|NCT01001689|BEHAVIORAL|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
215028588|NCT04669795|DRUG|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
215112441|NCT06906185|BEHAVIORAL|Care As Usual|"The control condition will be Care As Usual (CAU). CAU at SLVHCS involves participation in available services chosen by the patient with input from their providers. Further, for all pregnant Veterans that use VHA maternity benefits, CAU includes routine phone calls (throughout pregnancy and up to one-year postpartum) conducted by the site MCC to coordinate maternity benefits, facilitate additional services, and arrange for specific supplies (e.g., breast pump). Further, the SLVHCS MCC mails each pregnant Veteran enrolled in VHA a welcome packet that includes national, local, and VHA MH and physical health resources that may be useful to them during the perinatal period. Veterans in the CAU condition will be assessed at the same intervals as those in the active condition."
215112442|NCT06903936|OTHER|Group 1: GNB (GENICULAR NERVOUS NERVOUS BLOCK) group:|6 ml of solution consisting of 5 ml 2% lidocaine hydrochloride and 1 ml 40 mg triamcinolone acetonide will be injected equally into the superomedial, inferomedial and superolateral genicular nerve branches using a 23G (0.6\*60mm) needle under ultrasound guidance.
215112443|NCT06903936|OTHER|Group 2: PT (PHYSICAL THERAPY) group|Group 2: PT (PHYSICAL THERAPY) group: In the PT group, all interventions will be performed with the patient supine and knees in extension. First, superficial heating will be applied using a hotpack for 20 minutes, followed by therapeutic ultrasound in continuous mode at a frequency of 1 MHz and 1.5 Watt/cm2 for 5 minutes to achieve deep thermal effects. Then traditional transcutaneous electrical nerve stimulation (TENS) will be applied for 15 minutes for a total of 15 sessions.
214425878|NCT00084903|PROCEDURE|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
214425879|NCT00084903|PROCEDURE|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
214425880|NCT01901510|DRUG|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
214425881|NCT01901510|OTHER|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
214425882|NCT04054635|DEVICE|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
214425883|NCT02457117|RADIATION|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
214425884|NCT05491031|OTHER|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
214425885|NCT03768869|DRUG|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
214425886|NCT03768869|DRUG|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
214425887|NCT03768869|DRUG|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
214425888|NCT06281808|DEVICE|Photon Counting Detector CT|Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
214425889|NCT05296811|PROCEDURE|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
214510876|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
214510877|NCT00087516|DRUG|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
215112444|NCT06903936|OTHER|Group 3: Exercise group|Group 3: Control group: For 3 weeks, exercise therapy will be applied by the patient. Knee range of motion exercises, quadriceps strengthening exercises, hamstring stretching exercises will be taught to the patients by the doctor and they will be asked to do them every day, 2 times a day, 10 repetitions for a total of 3 weeks. The use of NSAIDs will be restricted during the treatment period.
215112445|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
215112446|NCT06913075|DRUG|GnRH agonist downregulation|Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval
214425890|NCT05204615|OTHER|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
214510878|NCT02020200|DRUG|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.
214510879|NCT02020200|DRUG|Placebo|
214510880|NCT05304221|OTHER|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
214510881|NCT02001649|GENETIC|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
214425891|NCT02576613|OTHER|MPP-S|\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
214425892|NCT02576613|OTHER|TAU|standard medical treatment without structured psychotherapeutic intervention
214425893|NCT00148369|DRUG|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
214425894|NCT02700191|DEVICE|uCor|
214425895|NCT01013246|OTHER|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
214510882|NCT02001649|GENETIC|SNP genotyping|
214510883|NCT02065895|DEVICE|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
214510884|NCT02065895|DEVICE|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
214510885|NCT02065895|DEVICE|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
214510886|NCT01093690|DRUG|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
214510887|NCT01093690|DRUG|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
214510888|NCT01682928|DRUG|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
214425896|NCT04109534|DIAGNOSTIC_TEST|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
214425897|NCT04109534|DIAGNOSTIC_TEST|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
214425898|NCT04109534|DIAGNOSTIC_TEST|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
214425899|NCT04109534|DIAGNOSTIC_TEST|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
214425900|NCT00891930|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
214425901|NCT00891930|BIOLOGICAL|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
214425902|NCT00891930|DRUG|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
214425903|NCT05398965|DRUG|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
214425904|NCT05398965|DRUG|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
214425905|NCT04688268|DRUG|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
214425906|NCT02038868|DRUG|ASP4901|oral
214425907|NCT02038868|DRUG|Tamsulosin|oral
214425908|NCT02038868|DRUG|Placebo|oral
214425909|NCT02403596|DRUG|Exacyl®|
214425910|NCT02403596|OTHER|Placebo of Exacyl®|
214425911|NCT03040661|PROCEDURE|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
214425912|NCT00889499|DRUG|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
214425913|NCT00889499|DRUG|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
214425914|NCT00889499|DRUG|Placebo|NHCL 0,9%
214425915|NCT03999866|DEVICE|airtraq|airtraq videolaryngoscope
214425916|NCT03999866|DEVICE|mcgrath mac x-blade|mcgarth mac videolaryngoscope
214425917|NCT03999866|DEVICE|storz c-mac|storz c-mac videolaryngoscope
214425918|NCT03999866|DEVICE|storz d-blade|storz d-blade video laryngoscope
214425919|NCT00004266|DRUG|Lisinopril|
214425920|NCT00004266|DRUG|Nifedipine|
214425921|NCT00004266|DRUG|Simvastatin|
214425922|NCT03234088|BEHAVIORAL|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
214425923|NCT01556971|DRUG|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
214425924|NCT01556971|DRUG|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
214425925|NCT05262478|DEVICE|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
214425926|NCT01926678|OTHER|Swedish massage therapy|
214425927|NCT01926678|OTHER|Light touch therapy|
214425928|NCT04679571|BIOLOGICAL|Albumin|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
214425929|NCT04679571|DRUG|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
214425930|NCT06363357|DEVICE|Shoulder orthosis|muscle-mimicking, fabric-type shoulder orthosis
214425931|NCT04191265|DIAGNOSTIC_TEST|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
214425932|NCT05007665|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
214425933|NCT00846066|OTHER|Hands on training|Hands on training by a pediatric dentist on preventive oral health
214425934|NCT00846066|OTHER|Web based training|Web based training alone
214425935|NCT01574807|DRUG|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
214425936|NCT01574807|DRUG|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
214425937|NCT02537522|DEVICE|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
214425938|NCT02537522|DEVICE|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
214425939|NCT03151590|BEHAVIORAL|exercise training|
214425940|NCT01379014|BEHAVIORAL|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
214425941|NCT01379014|OTHER|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
214510889|NCT01682928|OTHER|Hydrotherapy|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
214510890|NCT01008917|DRUG|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
214510891|NCT03605420|OTHER|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
214510892|NCT05498051|PROCEDURE|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
214510893|NCT04224597|DIAGNOSTIC_TEST|ultrasonography|all participants will be determined by ultrasonography.
214510894|NCT05519306|BEHAVIORAL|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
214510895|NCT03682003|DIAGNOSTIC_TEST|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
214510896|NCT03656198|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
214425942|NCT06170593|DRUG|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
214425943|NCT06300489|DRUG|irinotecan liposomes+capecitabine|"Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD)."
214425944|NCT00239083|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214425945|NCT04906278|DEVICE|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
214425946|NCT04906278|PROCEDURE|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
214425947|NCT04906278|DRUG|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
214510897|NCT03656198|DRUG|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
214510898|NCT02597699|DRUG|Remifentanil + Lidocaïne|
214510899|NCT02597699|DRUG|Sufentanil + Lidocaïne|
214510900|NCT00569166|BEHAVIORAL|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
215112447|NCT06913075|DRUG|GnRH agonist and Letrozole|Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts
215112448|NCT06917014|PROCEDURE|360°|reset the proximal and distal part of the niche, widely 360° coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
215112449|NCT06917014|PROCEDURE|traditional|reset the proximal part of the niche, and coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
214425948|NCT02147535|DRUG|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
214425949|NCT03339024|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
214510901|NCT00569166|BEHAVIORAL|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
215112450|NCT03265457|OTHER|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
215112451|NCT06917989|OTHER|Relaxation Exercise|Jacobson muscle relaxation technique
215112452|NCT06917989|OTHER|Virtual Reality Application|Virtual Reality Application will be done using virtual reality glasses
215112453|NCT06917989|OTHER|Patient Education|Participants will be informed about oral care, food consumption, nutrition and sleeping position.
215112454|NCT06919380|DRUG|MSC-exos Nebulization Therapy|"The intervention in this study, Nebulized MSC-exos for Anti-MDA5+ RP-ILD Treatment, is distinguished by its use of mesenchymal stem cell-derived exosomes (MSC-exos) for direct pulmonary delivery via nebulization. This targeted approach aims to modulate immune responses and reduce inflammation specific to lung diseases, offering a novel therapeutic strategy. This method stands out for its potential to provide a safer and more effective treatment for RP-ILD compared to traditional therapies."
215112455|NCT06922344|DRUG|Fluconazole|Oral fluconazole prescribed to group A
215112456|NCT06922344|DRUG|Itraconazole|Oral itraconazole prescribed to Group B
215112457|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
215112458|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
215112459|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
215112460|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
215112461|NCT02915978|DRUG|Fentanyl|Fentanyl delivered via sublingual spray
215112462|NCT02915978|DRUG|Placebo|Matching placebo delivered via sublingual spray
215112463|NCT03262636|DRUG|Indocyanine Green|Indocyanine Green
215112464|NCT03605914|DRUG|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
215112465|NCT03605914|DRUG|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
215112466|NCT04811482|BEHAVIORAL|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
215112467|NCT02275156|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
215112468|NCT03257683|DRUG|Ranolazine|Study group will receive additional therapeutic dosing of drug.
215112469|NCT03779815|DRUG|[18F]Florbetaben|"* Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously"
215112470|NCT00902707|DRUG|Mucinex 1200mg|Compared to Placebo
215112471|NCT00902707|DRUG|Placebo|Compare to active Mucinex
214425950|NCT03339024|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
214425951|NCT02244060|OTHER|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
214425952|NCT01211093|PROCEDURE|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
214425953|NCT01211093|PROCEDURE|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
214425954|NCT01211093|PROCEDURE|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
214425955|NCT03626558|OTHER|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
214510902|NCT00569166|BEHAVIORAL|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
214510903|NCT04276506|OTHER|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
214510904|NCT04276506|OTHER|information group|A visual information booklet which is prepared by the researchers will be used
214510905|NCT03940339|OTHER|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
214510906|NCT03940339|OTHER|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
214510907|NCT06027970|DRUG|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
215112472|NCT02343406|DRUG|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
215112473|NCT02343406|DRUG|Temozolomide|Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
215112474|NCT02343406|DRUG|Lomustine|Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
215112475|NCT02816528|BEHAVIORAL|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
214692373|NCT02322320|DRUG|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
215112476|NCT02451124|DEVICE|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
215112477|NCT02451124|OTHER|Questionnaire Administration|Ancillary studies
215112478|NCT02451124|OTHER|Laboratory Biomarker Analysis|Correlative studies
215112479|NCT02451124|PROCEDURE|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
215112480|NCT01324362|DRUG|Placebo|Twice daily dosing
215112481|NCT01324362|DRUG|Placebo|Twice daily dosing
215112482|NCT01324362|DRUG|FP 100mcg|Twice daily dosing
215112483|NCT01324362|DRUG|FP 250mcg|Twice daily dosing
214510908|NCT06027970|OTHER|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
214510909|NCT00653185|DRUG|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
214510910|NCT00653185|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
215112484|NCT01324362|DRUG|FP 500mcg|Twice daily dosing
215112485|NCT01324362|DRUG|FSC 100/50mcg|Twice daily dosing
214510911|NCT00653185|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
214510912|NCT00653185|DRUG|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
214510913|NCT00653185|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
214510914|NCT03840096|DEVICE|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
215112486|NCT01324362|DRUG|FSC 250/50mcg|Twice daily dosing
215112487|NCT01324362|DRUG|FSC500/50mcg|Twice daily dosing
215112488|NCT04585841|DRUG|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
214510915|NCT06509685|OTHER|Ladder Training|9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).
214692374|NCT04836143|DRUG|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
215112489|NCT00196456|PROCEDURE|photosensitisation|
215112490|NCT00004050|BIOLOGICAL|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
215112491|NCT01189981|BEHAVIORAL|Lifestyle counseling|One health conversation at baseline
215112492|NCT01189981|BEHAVIORAL|eHealth intervention|SMS based encouragements to intensive exercise
214425956|NCT03996863|DEVICE|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
214425957|NCT03996863|DEVICE|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
214425958|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
214425959|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
214510916|NCT06509685|OTHER|balance training|9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
214510917|NCT01582321|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
214510918|NCT01582321|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
214692375|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
214692376|NCT01323257|DRUG|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
214510919|NCT03950206|OTHER|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
214510920|NCT03555812|OTHER|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
214510921|NCT04546451|BEHAVIORAL|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
214510922|NCT04546451|BEHAVIORAL|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
214425960|NCT02747381|DIETARY_SUPPLEMENT|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
214510923|NCT00000872|DRUG|Abacavir sulfate|
214510924|NCT00000872|DRUG|Nelfinavir mesylate|
214510925|NCT00000872|DRUG|Nevirapine|
214692377|NCT01323257|DRUG|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
214692378|NCT01323257|DRUG|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
214692379|NCT01323257|DRUG|TMC435|50 mg capsule once daily for 7 days (Trt F)
214692380|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
215112493|NCT02799498|DEVICE|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
215112494|NCT02799498|OTHER|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
215112495|NCT02799498|DRUG|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
215112496|NCT02017925|BEHAVIORAL|exercise intervention|Undergo pulmonary rehabilitation
215112497|NCT02017925|PROCEDURE|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
215112498|NCT02017925|PROCEDURE|quality-of-life assessment|Ancillary studies
215112499|NCT02017925|OTHER|questionnaire administration|Ancillary studies
215112500|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
214425961|NCT05727241|DIAGNOSTIC_TEST|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
214425962|NCT03772457|DRUG|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
214425963|NCT05757388|DRUG|Parecoxib + paracetamol|Administers after induction of anesthesia.
214425964|NCT05757388|DRUG|Normal saline|Administers after induction of anesthesia.
214425965|NCT00259961|PROCEDURE|open fundoplication|
214425966|NCT00259961|PROCEDURE|laparoscopic fundopliaction|
214425967|NCT04431388|DEVICE|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
214425968|NCT04431388|DRUG|Levobupivacaine|using the same AL
214425969|NCT05932082|PROCEDURE|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
214425970|NCT05786898|OTHER|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
214510926|NCT00000872|DRUG|Lamivudine|
214510927|NCT00000872|DRUG|Stavudine|
214510928|NCT00000872|DRUG|Zidovudine|
214510929|NCT03803150|PROCEDURE|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
214692381|NCT04575857|DRUG|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
214692382|NCT04575857|DRUG|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
214692383|NCT01766830|DEVICE|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
214510930|NCT03803150|PROCEDURE|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
214425971|NCT01323777|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214425972|NCT00392054|PROCEDURE|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
214510931|NCT05005247|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
214510932|NCT02994498|DRUG|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
214510933|NCT00484198|DRUG|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
214510934|NCT00484198|DRUG|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
215112501|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
214510935|NCT00484198|DRUG|Rivoglitazone|1.0 mg tablet administered orally, once daily
214510936|NCT00484198|DRUG|Rivoglitazone|1.5 mg tablet administered orally, once daily
214510937|NCT04213768|PROCEDURE|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
214510938|NCT04213768|PROCEDURE|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
214510939|NCT00407498|DRUG|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
215112502|NCT02085304|PROCEDURE|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
215112503|NCT02085304|RADIATION|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
215112504|NCT02085304|RADIATION|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
215112505|NCT02085304|DRUG|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
214510940|NCT01116609|DRUG|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
214510941|NCT03077256|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
214510942|NCT06470152|PROCEDURE|Correction strategy in reference to our PI-dependent clustering of sagittal alignment|For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
214692384|NCT01766830|DEVICE|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
214692385|NCT01766830|DEVICE|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
215112506|NCT02302391|OTHER|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
215112507|NCT04673578|DRUG|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
215112508|NCT04673578|OTHER|Placebo|Microcrystalline cellulose
215112509|NCT06388798|OTHER|Education|Psychoeducational training
215112510|NCT02249039|DRUG|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
215112511|NCT06301932|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
215112512|NCT05182268|PROCEDURE|endoscopic ear surgery|a ear surgery via endoscopic
215112513|NCT05182268|PROCEDURE|microscopic ear surgery|a ear surgery via microscopic
215112514|NCT00274677|DRUG|Placebo|Experimental treatment arm
215112515|NCT00274677|DRUG|lamotrigine|Experimental treatment
214425973|NCT00392054|DRUG|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
214425974|NCT02176772|OTHER|Stable iron isotopes, non-drug intervention|
214425975|NCT02771171|RADIATION|CT Scan|CT imaging
214425976|NCT01493778|DRUG|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
214510943|NCT06470152|PROCEDURE|Correction strategy in reference to the SAAS score|"This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1."
214510944|NCT05765526|DEVICE|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
214510945|NCT01299285|DRUG|LY3009104|Administered orally
215112516|NCT00766051|OTHER|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
214425977|NCT05082077|DEVICE|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
214425978|NCT00857649|DRUG|Memantine|20 mg Oral Tablets Once Daily
214425979|NCT00857649|DRUG|Placebo|Oral Tablets Once Daily
214425980|NCT00833365|DRUG|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
214425981|NCT00833365|DRUG|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
214425982|NCT00147485|DRUG|AG-024322|
214425983|NCT03681652|DRUG|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
214510946|NCT03709225|BEHAVIORAL|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
214510947|NCT00197444|DRUG|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
214510948|NCT00197444|RADIATION|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
214510949|NCT04059575|OTHER|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
214692386|NCT01766830|DEVICE|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
215112517|NCT05165758|OTHER|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
214425984|NCT03681652|DRUG|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
214425985|NCT05722535|BEHAVIORAL|Family Media Check-In (FMC)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
214425986|NCT05286632|DEVICE|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
214425987|NCT04137536|DRUG|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~\- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
214425988|NCT06132854|OTHER|VR|The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.
214425989|NCT06132854|OTHER|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
214425990|NCT04785989|OTHER|[U-13C]glucose|\[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
214510950|NCT04059575|OTHER|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
214692387|NCT01766830|DEVICE|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
215112518|NCT04374006|DRUG|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
215112519|NCT04374006|DRUG|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
215112520|NCT04374006|OTHER|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
215112521|NCT00305149|PROCEDURE|interim therapy scintigraphy study gallium scan or PET/CT|
215112522|NCT00305149|PROCEDURE|"interim gallium or PET/CT"|
215112523|NCT03296943|COMBINATION_PRODUCT|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
215112524|NCT03296943|COMBINATION_PRODUCT|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
215112525|NCT03296943|BEHAVIORAL|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
215112526|NCT01459744|BEHAVIORAL|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
215112527|NCT01459744|OTHER|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
215112528|NCT03345537|OTHER|Non interventional study|Non interventional study - only data collected and one blood sample additional
215112529|NCT03325036|DIAGNOSTIC_TEST|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
215112530|NCT04008251|GENETIC|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
215112531|NCT04227132|DEVICE|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
214510951|NCT03728452|PROCEDURE|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
214510952|NCT05691400|DRUG|Palbociclib 125Mg Tab|125 mg single dose
214510953|NCT05691400|DRUG|Ribociclib 200Mg Oral Tablet|200 mg single dose
215112532|NCT04227132|DEVICE|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
214425991|NCT04785989|OTHER|[13C5]glutamine|6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
214425992|NCT05732207|PROCEDURE|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
214510954|NCT05691400|DRUG|Abemaciclib 150 MG Oral Tablet|150 mg single dose
214510955|NCT00486954|DRUG|Lapatinib|6 pills at 250 mg each once daily
214510956|NCT00486954|DRUG|Paclitaxel|Infusion at 80 mg/m2 weekly
214510957|NCT03230448|OTHER|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
215112533|NCT03865641|DEVICE|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
215112534|NCT03514875|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
215112535|NCT03514875|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
215112536|NCT01497249|DIETARY_SUPPLEMENT|A dietary fiber (FCHO)|15 g twice per day in beverage
215112537|NCT01497249|DIETARY_SUPPLEMENT|Placebo|Placebo drink
215112538|NCT00912457|DRUG|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
215112539|NCT00912457|DRUG|placebo|placebo 1 p/day for 28 days
215112540|NCT03256318|OTHER|No intervention|No intervention; surveys/questionnaires only
214510958|NCT01617811|PROCEDURE|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
214692388|NCT01766830|DEVICE|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
214692389|NCT01766830|DEVICE|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
215112541|NCT05352425|DEVICE|MobiusHD|The MobiusHD® device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
215112542|NCT05370833|DEVICE|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
215112543|NCT01273324|DEVICE|ADM Cup|ADM Cup
215112544|NCT02818049|PROCEDURE|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
214425993|NCT06223152|OTHER|parental support|parental support
214425994|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
215112545|NCT06137599|OTHER|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
215112546|NCT05485285|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
215112547|NCT03483545|COMBINATION_PRODUCT|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
215112548|NCT06077032|DRUG|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
214510959|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
214425995|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
214425996|NCT04704830|BIOLOGICAL|R21/Matrix-M|Adjuvanted malaria vaccine
214425997|NCT04704830|BIOLOGICAL|Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine|Placebo Comparator
214510960|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
214510961|NCT05727111|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
214510962|NCT05727111|BEHAVIORAL|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
214510963|NCT06169345|OTHER|Echocardiographic evaluation|Echocardiographic follow-up
214510964|NCT02445404|DRUG|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
214510965|NCT02445404|DRUG|fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
214692390|NCT01766830|DEVICE|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
214692391|NCT01766830|DEVICE|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
215112549|NCT06077032|DRUG|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
215112550|NCT06077032|DRUG|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
215112551|NCT00028327|DRUG|Lamivudine/Zidovudine|
215112552|NCT00028327|DRUG|Nelfinavir mesylate|
215112553|NCT00028327|DRUG|Efavirenz|
215112554|NCT00028327|DRUG|Lamivudine|
215112555|NCT00028327|DRUG|Zidovudine|
215112556|NCT01022099|PROCEDURE|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
215112557|NCT04009395|OTHER|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
215112558|NCT04009395|OTHER|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
214425998|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
215112559|NCT05407155|COMBINATION_PRODUCT|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
215112560|NCT00979771|DRUG|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
215112561|NCT00979771|DRUG|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
214425999|NCT04187131|BEHAVIORAL|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
214426000|NCT04860336|OTHER|Observational|Observational
214426001|NCT06476067|PROCEDURE|Surgery|Esophagectomy
214426002|NCT06500377|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
214426003|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing only meditation
214426004|NCT06500377|PROCEDURE|Meditation Therapy|Learn focused attention only meditation
215112562|NCT02161055|DRUG|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
215112563|NCT03274856|DRUG|GLWL-01|Oral administration of 3 capsules, twice a day
215112564|NCT03274856|DRUG|Placebo|Oral administration of 3 capsules, twice a day
215112565|NCT03121703|OTHER|lumbar stabilization exercise|lumbar stabilization exercise
215112566|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
215112567|NCT01714401|DRUG|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
215112568|NCT01714401|DRUG|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
215112569|NCT00030862|DRUG|cisplatin|
215112570|NCT00030862|DRUG|irinotecan hydrochloride|
215112571|NCT06300073|DEVICE|Experimental: U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
215112572|NCT06300073|DEVICE|Placebo Comparator: Soft Manual Toothbrush|Twice daily brushing for 2 minutes with fluoride toothpaste
215112573|NCT00451256|DRUG|AVI-5126|
215112574|NCT03969095|BEHAVIORAL|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
215112575|NCT03058692|BIOLOGICAL|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
215112576|NCT03058692|OTHER|Placebo|Placebo is saline injection
215112577|NCT03058692|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
215112578|NCT01392547|DRUG|vatreptacog alfa (activated)|1-3 doses per bleeding episode
215112579|NCT01392547|DRUG|eptacog alfa (activated)|1-3 doses per bleeding episode
215112580|NCT02736201|DEVICE|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
214426005|NCT06500377|PROCEDURE|Meditation Therapy|Learn mindfulness only meditation
214426006|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing, focused attention, and mindfulness combined meditation
214426007|NCT06500377|OTHER|Questionnaire Administration|Ancillary studies
215112581|NCT02736201|OTHER|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
215112582|NCT01042925|DRUG|XL147 (SAR245408)|administered orally once daily as tablet(s)
215112583|NCT01042925|BIOLOGICAL|trastuzumab|administered by IV once every 3 weeks
215112584|NCT01042925|DRUG|paclitaxel|administered by IV once every week
215112585|NCT00841334|BEHAVIORAL|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
215112586|NCT00841334|BEHAVIORAL|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
215112587|NCT02754921|PROCEDURE|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
214426008|NCT04652076|DRUG|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
214426009|NCT04652076|DRUG|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
214426010|NCT04652076|DRUG|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
214426011|NCT04652076|DRUG|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
214426012|NCT04811053|DRUG|HR021618|Treatment group A: HR021618 injection
214426013|NCT04811053|DRUG|Placebo|Treatment group B: Saline injection
215112588|NCT02754921|PROCEDURE|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
215112589|NCT01718457|DEVICE|Endobarrier|
215112590|NCT01759797|BIOLOGICAL|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
215112591|NCT04012541|PROCEDURE|active dental procedure|scaling and root planing
215112592|NCT04012541|DRUG|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
215112593|NCT04012541|RADIATION|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
215112594|NCT05852067|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
215112595|NCT05852067|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
215112596|NCT03476148|DEVICE|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
215112597|NCT03476148|OTHER|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
215112598|NCT04130321|DIETARY_SUPPLEMENT|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
214426014|NCT05065736|DRUG|18F-Clofarabine|The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
214426015|NCT05489211|DRUG|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
214426016|NCT05489211|DRUG|Capecitabine|Administered orally
214426017|NCT05489211|DRUG|5-Fluorouracil|Administered as an IV
214510966|NCT01967394|OTHER|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
214510967|NCT01967394|OTHER|No use of social media|No social media ads will be available in these counties.
214510968|NCT01765855|DRUG|Betrixaban single oral dose|
214510969|NCT04130282|BIOLOGICAL|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
214692392|NCT01766830|DEVICE|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
214692393|NCT01452126|DRUG|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
215112599|NCT04130321|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo daily during 12 weeks
215112600|NCT00571974|DEVICE|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
215112601|NCT00571974|DRUG|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
215112602|NCT00571974|PROCEDURE|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
215112603|NCT01390896|DRUG|Fondaparinux Sodium|
215112604|NCT01105208|DRUG|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
214426018|NCT05489211|DRUG|Volrustomig|Administered as an IV
214426019|NCT05489211|DRUG|Carboplatin|Administered as an IV
215112605|NCT01105208|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
215112606|NCT04791436|DIAGNOSTIC_TEST|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
215112607|NCT04791436|DIAGNOSTIC_TEST|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
214426020|NCT05489211|DRUG|Leucovorin LV|Administered as an IV
214426021|NCT05489211|DRUG|Bevacizumab|Administered as an IV
214426022|NCT05489211|DRUG|Rilvegostomig|Administered as an IV
214426023|NCT05489211|DRUG|Prednisone/ prednisolone|Administered orally
214426024|NCT05489211|DRUG|Cisplatin|Administered as an IV
214426025|NCT06488625|DRUG|Low-Dose CICR-NAM|2 g/d CICR-NAM (blinded)
214426026|NCT06488625|DRUG|High-Dose CICR-NAM|3 g/d CICR-NAM (blinded)
214426027|NCT06488625|DRUG|0 g/d CICR-NAM (blinded)|Placebo (blinded)
214426028|NCT06488625|DRUG|Open-Label|3 g/d CICR-NAM (open label)
214426029|NCT05437588|GENETIC|Genetic testing|Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
214510970|NCT04257500|DRUG|Etonogestrel/ethinyl estradiol vaginal ring|16 weeks of continuous use of contraceptive vaginal ring
214510971|NCT06430606|PROCEDURE|Tint Time|Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
214510972|NCT06430606|PROCEDURE|T0 Time|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
215112608|NCT00851617|DEVICE|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
215112609|NCT04632771|OTHER|N/A (observational study)|N/A (observational study)
214426030|NCT06511791|DRUG|FE 999302|Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
214426031|NCT06511791|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
214426032|NCT06511791|DRUG|Placebo FE 999302|No active ingredient, subcutaneous injection.
214510973|NCT06430606|PROCEDURE|T1|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
214692394|NCT03762122|DRUG|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
214692395|NCT02385825|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
215112610|NCT01281540|DRUG|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
214426033|NCT06448364|BIOLOGICAL|PF-07329640|an anti-lymphotoxin beta receptor agonist
214426034|NCT06448364|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
214510974|NCT02359071|OTHER|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
215112611|NCT01281540|DRUG|Placebo|one placebo tablet 4 times a day for 8 weeks
214426035|NCT06448364|BIOLOGICAL|bevacizumab|a monoclonal antibody that blocks VEGF
215112612|NCT06362018|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
214426036|NCT03845114|OTHER|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
214426037|NCT03845114|OTHER|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
214426038|NCT03845114|OTHER|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
214426039|NCT03845114|OTHER|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
214426040|NCT05674825|DRUG|Targeted agent|"The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment."
214426041|NCT05674825|DRUG|Standard of care agent|Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
214426042|NCT03096262|DEVICE|Citizen Science intervention using kinect|Users are asked to tag objects on a screen
214426043|NCT04177394|DEVICE|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
214426044|NCT01491698|PROCEDURE|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
215112613|NCT06217094|DRUG|NP-101 (3 g)|Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
215112614|NCT06217094|DRUG|NP-101 (4.8 g)|Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
215112615|NCT06217094|DRUG|NP-101 (6 g)|Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
214426045|NCT01491698|PROCEDURE|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
214426046|NCT02343211|DRUG|Immunoglobulin|
215112616|NCT03392246|DRUG|Osimertinib|"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
215112617|NCT03392246|DRUG|Selumetinib|"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
215112618|NCT05241093|DRUG|HYML-122; cytarabine|HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
214426047|NCT05947045|OTHER|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
214426048|NCT05947045|OTHER|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
214426049|NCT06368089|OTHER|Inspiratory muscle training (IMT) group|The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
214426050|NCT06368089|OTHER|Early mobilization (EM) group|The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
214426051|NCT01603810|OTHER|OCT|Optical coherence tomography of periocular basal cell carcinoma
214426052|NCT02813486|BIOLOGICAL|Biological: GC3111 vaccine|0.5mL, Intramuscular
214426053|NCT02813486|BIOLOGICAL|Biological: Boostrix® vaccine|0.5mL, Intramuscular
214426054|NCT04894318|BEHAVIORAL|Low-fat and low-cholesterol diet|Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
214510975|NCT00419172|DRUG|Deferasirox|
214510976|NCT00419172|DRUG|Rifampicin|
214692396|NCT01967667|DIETARY_SUPPLEMENT|Liposomal glutathione|Escalating dose steps
214426055|NCT04472806|DRUG|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
214426056|NCT04472806|DRUG|chemotherapy in combination with Endostar|chemotherapy+ Endostar
214426057|NCT01219218|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
214426058|NCT06966297|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography|Measurement of calf muscle Perfusion via Multispectral optoacoustic Tomography
214426059|NCT06966076|PROCEDURE|calisthenic training|"COMMAND AND TARGET MUSCLE GROUP~1. LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND IN FRONT. LOWER THEM BACK DOWN WITHOUT TOUCHING THE FLOOR.~   TARGETS HIP FLEXOR~2. SIDE LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND AND TAKE IT TO SIDE MAXIMALL WITHOUT TOUCHING THE FLOOR.~   TARGETS LOWER ABS AND HIP ABDUCTORS~3. GLUTE BRIDGES ( BACK STRENGTH) LIE ON YOUR BACK WITH YOUR KNEES BENT. LIFT YOUR HIPS OFF THE GROUND, SQUEEZING YOUR GLUTES. LOWER AND REPEAT. TARGETS GLUTES AND HAMSTRINGS.~4. QUADRUPTED POSITION:~   ASK THE PATIENT TO RIDE YOUR KNEES PLAY 'HORSY' AND SLOWLY MOVE YOUR KNEES TO AND FRO AND SIDEWAYS SO THAT TO SHIFT WEIGHT FROM SIDE TO SIDE.~5. WALL LEG LIFTS IN STANDING STAND WITH YOUR SIDE FACING A WALL. LIFT YOUR LEG OUT TO THE SIDE AS HIGH AS POSSIBLE.~   LOWER AND REPEAT WITH THE OTHER LEG. TARGETS HIP ABDUCTERS~6. KNEELING~7. VERTICLE LIFT~8. Squats"
214426060|NCT06966076|PROCEDURE|Conventional physical therapy group|CONVENTIONAL PHYSICAL THERAPY CONVENTIONAL PHYSICAL THERAPY Week 1 Orientation of exercises Week 2-3 UPPER LIMB (20 MINS) Lifting a glass of water with elbow extended Moving objects from the table to a box Combing Hairs LOWER LIMB (20 MINS) Lifting the lower extremity and lowering in o nto a footstool sit to stand Standing up with loaded trey in hand corner hamstring stretch butterfly stretch Week 4-5 UPPER LIMB (20 MINS) Grasping and releasing objects lifting a glass of water to a level of 90° shoul der flexion with an extended elbow Moving objects from the table to a box LOWER LIMB (20 MINS) Reciprocal leg flexion and extension single leg stance Kicking a ball Week 5-8 UPPER LIMB (20 MINS) Opening Jars Throwing Balls Same As previous weeks LOWER LIMB (20 MINS) Squatting
214426061|NCT03052361|DRUG|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
214426062|NCT03052361|DRUG|Placebos|similar looking and tasting liquid placebo
214426063|NCT06423742|DEVICE|Transcranial direct current stimulation|The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
214426064|NCT01789489|DEVICE|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
214426065|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
214426066|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
214510977|NCT03559777|OTHER|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
214510978|NCT03559777|OTHER|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
214510979|NCT03564184|BEHAVIORAL|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
214692397|NCT01967667|DIETARY_SUPPLEMENT|Placebo|escalating dose steps
215112619|NCT02574273|BEHAVIORAL|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
215112620|NCT02574273|OTHER|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
215112621|NCT00961363|DRUG|Sitagliptin|sitagliptin 100 mg per day
214426067|NCT03080038|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
214426068|NCT04267250|DRUG|PF-06700841|60 mg by mouth (PO) once daily (QD).
214426069|NCT04267250|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
214426070|NCT02331004|OTHER|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
214426071|NCT02331004|OTHER|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
214426072|NCT03561610|DIETARY_SUPPLEMENT|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
214426073|NCT03561610|DIETARY_SUPPLEMENT|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
214426074|NCT00234091|DRUG|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
214426075|NCT00234091|DRUG|Efavirenz|200 to 600 mg taken orally once daily
214426076|NCT00234091|DRUG|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
214426077|NCT00234091|DRUG|Lopinavir/Ritonavir|230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
214426078|NCT00234091|DRUG|Nelfinavir|45-55 mg/kg taken orally twice daily with food
214426079|NCT00234091|DRUG|Nevirapine|120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
214426080|NCT00234091|DRUG|Zidovudine|180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
214426081|NCT02430740|DRUG|recFSH|
215112622|NCT00961363|DRUG|Placebo|Placebo
214426082|NCT01477879|OTHER|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
214426083|NCT01477879|OTHER|placebo (versabase gel only)|versabase gel only
214426084|NCT02140138|BIOLOGICAL|CV9104|
214426085|NCT02140138|DEVICE|needle free injection device (Tropis®)|
214426086|NCT05088629|DIAGNOSTIC_TEST|Clinical Tests|Clinical Tests
214426087|NCT04042129|OTHER|gynecologic operations with urological complications|
214426088|NCT00707135|DRUG|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
214426089|NCT00486005|DRUG|Olanzapine Hydrochloride|
214426090|NCT00486005|DRUG|Nizatidine|
214426091|NCT00486005|DRUG|Placebo|
214426092|NCT00630786|DRUG|Panitumumab|Administered by intravenous infusion
214426093|NCT00630786|DRUG|Conatumumab|Administered by intravenous infusion
214426094|NCT02412774|BEHAVIORAL|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
214426095|NCT02412774|BEHAVIORAL|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
214426096|NCT03393078|DEVICE|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
214426097|NCT03393078|DEVICE|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
214426098|NCT00238836|BEHAVIORAL|Self-management of chronic illness|
214426099|NCT06522295|DEVICE|ultrasonography|Ultrasonographic Measurement of Optic Nerve Sheath Diameter
214426100|NCT05004935|DIETARY_SUPPLEMENT|beetroot juice|single intake of beetroot juice containing 800mg nitrates
214426101|NCT05004935|OTHER|nitrate|single intake of 800mg nitrates
214692398|NCT01290081|OTHER|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
215112623|NCT00252070|BEHAVIORAL|Functional Exercise for People with Arthritis (FEPA)|
215112624|NCT06362317|DRUG|Toripalimab|Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.
215112625|NCT06362317|DRUG|Lenvatinib|When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
215112626|NCT06362317|DRUG|Gemox Chemotherapy（Gemox or GC）|"Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1."
215112627|NCT04734717|DIAGNOSTIC_TEST|Neurology test|movement examination of patients with covid19 disease
215112628|NCT05083429|DRUG|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
215112629|NCT05083429|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference
215112630|NCT02346461|DRUG|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
215112631|NCT02346461|DRUG|ManNAc|At doses of 6 g twice daily (12 g per day).
215112632|NCT04803266|RADIATION|Internal mammary node irradiation|Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
215112633|NCT04803266|RADIATION|No internal mammary node irradiation|Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
214426102|NCT02881944|BEHAVIORAL|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
214426103|NCT02881944|BEHAVIORAL|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
214426104|NCT03199235|DEVICE|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
214426105|NCT03199235|OTHER|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
214426106|NCT02523651|GENETIC|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
214426107|NCT02523651|OTHER|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
214426108|NCT00412321|DRUG|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
214692399|NCT03342391|OTHER|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
214692400|NCT01506778|DEVICE|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
214692401|NCT05307822|OTHER|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
214692402|NCT05307822|OTHER|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
214692403|NCT05307822|OTHER|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
214692404|NCT05307822|OTHER|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
215112634|NCT00799266|DRUG|Zoledronic acid|intravenous infusion
215112635|NCT00799266|DRUG|Placebo|intravenous infusion
215112636|NCT02669342|DEVICE|Radiance™ Clear Sharklet® Silicone Foley Catheter|
215112637|NCT02669342|DEVICE|Silicone Foley Catheter|
215112638|NCT02883374|DRUG|Chidamide|
215112639|NCT02535325|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
215112640|NCT02535325|DRUG|Cisplatin|Given IV
215112641|NCT02535325|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215112642|NCT02535325|DRUG|Methoxyamine|Given PO
215112643|NCT02535325|DRUG|Methoxyamine Hydrochloride|Given PO
215112644|NCT02535325|DRUG|Pemetrexed|Given IV
214426109|NCT03978468|OTHER|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
214426110|NCT03978468|OTHER|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
214426111|NCT02496806|DIETARY_SUPPLEMENT|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
214426112|NCT03092713|BEHAVIORAL|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
214426113|NCT03092713|BEHAVIORAL|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
214426114|NCT01649180|DRUG|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
214426115|NCT00233519|DRUG|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
214426116|NCT03289611|BIOLOGICAL|sFlt-1 / PlGF ratio|"* Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued"
214426117|NCT01235884|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
214426118|NCT01235884|DIETARY_SUPPLEMENT|Placebo|5 drops daily for 28 days
214426119|NCT00000760|DRUG|Ro 24-7429|
214426120|NCT00000760|DRUG|Zidovudine|
214426121|NCT00000760|DRUG|Didanosine|
214426122|NCT03659201|DRUG|Neosil complete|Oral, during 24 weeks.
214426123|NCT03659201|DRUG|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
214426124|NCT03659201|DRUG|Neosil|Oral, during only 12 weeks.
214426125|NCT03870191|OTHER|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
214426126|NCT04552886|BIOLOGICAL|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
214426127|NCT03603717|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
214426128|NCT03603717|BEHAVIORAL|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
214426129|NCT04280913|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
214426130|NCT02026219|DRUG|Clopidogrel|Clopidogrel 600mg loading
214426131|NCT02026219|DRUG|Ticagrelor|Ticagrelor 180mg loading
215112645|NCT02535325|DRUG|Pemetrexed Disodium|Given IV
214426132|NCT04727424|DIETARY_SUPPLEMENT|Spirulin Platensis|Two tablets every 12 hours since randomization through day 09 following randomization
214426133|NCT04727424|DRUG|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
215112646|NCT01779232|DRUG|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
215112647|NCT01779232|DRUG|placebo|administered daily like the active comparator
214426134|NCT04727424|DRUG|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
214426135|NCT04727424|DRUG|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
214426136|NCT00939991|DRUG|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
214426137|NCT06656689|PROCEDURE|Rezum (water vapor thermal therapy)|Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
215112648|NCT00954993|DRUG|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
214426138|NCT02355158|DRUG|clonidine hydrochloride topical gel, 0.1%|
214426139|NCT00003516|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
214426140|NCT04390529|OTHER|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
214426141|NCT06023329|DRUG|ropivacaine|will receive SCPB with ropivacaine via regional anesthesia team
214426142|NCT06023329|DRUG|Saline|will receive SCPB with saline via regional anesthesia team
214510980|NCT03564184|BEHAVIORAL|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
214510981|NCT03564184|OTHER|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
214426143|NCT05217628|DRUG|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
214426144|NCT05217628|OTHER|Placebo|Participant randomized to receive matching placebo once daily.
214426145|NCT01947088|BEHAVIORAL|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
214510982|NCT04989023|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
214510983|NCT00585793|DRUG|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
214510984|NCT02917148|OTHER|Peripheral Venipuncture or Blood draw from Central Line|
214510985|NCT01229332|DRUG|Saline|Continuous 24 h administration
214510986|NCT01229332|DRUG|Carbidopa|Continuous 24 h administration
214510987|NCT06305910|DRUG|Treatment with CD200AR-L|Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
214510988|NCT04776122|DEVICE|Therapy|Device-assisted breathing for relaxation
214510989|NCT04776122|OTHER|No device|Breathing platform without device
214426146|NCT01725464|DEVICE|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
214426147|NCT06846684|DRUG|SB17170|PO, QD
214426148|NCT06846684|DRUG|SB_MDZ|IV
214510990|NCT01061307|DIETARY_SUPPLEMENT|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
214510991|NCT02751294|DRUG|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
214426149|NCT06162897|BEHAVIORAL|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
214510992|NCT02751294|DRUG|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
214510993|NCT02751294|DRUG|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
214510994|NCT00929526|PROCEDURE|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
214510995|NCT00929526|PROCEDURE|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
214510996|NCT00519844|DRUG|somatropin|
214510997|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
214510998|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
214510999|NCT01583855|PROCEDURE|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
214511000|NCT01583855|DEVICE|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
214426150|NCT04373590|BEHAVIORAL|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
214426151|NCT02343029|OTHER|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
214426152|NCT02343029|OTHER|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
214426153|NCT04663698|OTHER|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
214426154|NCT04663698|OTHER|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
214426155|NCT04663698|OTHER|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
214426156|NCT04663698|OTHER|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
214426157|NCT04663698|OTHER|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
214426158|NCT05398861|DRUG|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
214426159|NCT04229368|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
214426160|NCT03808558|DRUG|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
214511001|NCT02723799|BEHAVIORAL|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
214426163|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
214511002|NCT02723799|OTHER|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
214511003|NCT02807285|DRUG|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
214692405|NCT03568149|PROCEDURE|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
215112649|NCT03112265|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
214426164|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
214426165|NCT05856084|BIOLOGICAL|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
214511004|NCT00753155|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
214511005|NCT00264888|DRUG|PTC124|
214511006|NCT06121765|OTHER|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
214426166|NCT05856084|BIOLOGICAL|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
214511007|NCT01428609|PROCEDURE|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
214511008|NCT04062383|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
215112650|NCT03112265|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
215112651|NCT03112265|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
215112652|NCT04548466|DEVICE|PEP bottle|
215112653|NCT05482828|DRUG|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
215112654|NCT05482828|DRUG|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
214426167|NCT05856084|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
214426168|NCT05856084|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
214426169|NCT04668339|BIOLOGICAL|ARCT-021 single dose priming|ARCT-021 higher dose (one dose) + placebo (one dose)
214426170|NCT04668339|BIOLOGICAL|ARCT-021 two lower dose priming|ARCT-021 lower dose (two doses, Day 0 and Day 28)
214426171|NCT04668339|BIOLOGICAL|ARCT-021 two higher dose priming|ARCT-021 higher dose (two doses, Day 0 and Day 28)
214426172|NCT04668339|BIOLOGICAL|Placebo (two doses), priming|Placebo (two doses, Day 0 and Day 28)
214426173|NCT04668339|BIOLOGICAL|Randomized booster|ARCT-021 (single dose) OR placebo, booster
214426174|NCT04668339|BIOLOGICAL|Placebo booster|Placebo (single dose)
214426175|NCT03830658|BEHAVIORAL|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
214426176|NCT05390749|DRUG|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
214426177|NCT05390749|DRUG|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
214426178|NCT05390749|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
214426179|NCT05390749|DRUG|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
214426180|NCT02823106|DRUG|Verapamil and Citicoline|Single dosing strategy will be used.
215112655|NCT00062179|DRUG|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
215112656|NCT00062179|DRUG|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
215112657|NCT00062179|DRUG|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
215112658|NCT00062179|OTHER|Placebo|placebo 3-7 days before first dose of chemotherapy
214426181|NCT02823106|OTHER|Placebo|Single matching dosing strategy will be used.
214426182|NCT05607186|RADIATION|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
214426183|NCT00964730|DRUG|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
214426184|NCT00964730|DRUG|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
214426185|NCT00964730|DRUG|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
214426186|NCT05551065|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
214511009|NCT01984216|PROCEDURE|Roux-en-Y for the gastrojejunostomy reconstruction|
214511010|NCT01984216|PROCEDURE|Billroth II for the gastrojejunostomy reconstruction|
215112659|NCT02826343|DRUG|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
215112660|NCT02826343|DRUG|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
215112661|NCT02826343|DRUG|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
215112662|NCT03353844|BEHAVIORAL|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
215112663|NCT02477124|DEVICE|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
215112664|NCT02477124|OTHER|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
215112665|NCT00629863|DRUG|cisplatin|
215112666|NCT00629863|DRUG|fluorouracil|
214426187|NCT03265886|DRUG|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
214426188|NCT03265886|DRUG|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
214426189|NCT05011734|OTHER|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
214426190|NCT01180192|DRUG|oxygen|either 8 L/minute O2 via face mask for 2 hours
214426191|NCT04934904|DRUG|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
214426192|NCT01731041|DRUG|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
214426193|NCT01731041|DRUG|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
214426194|NCT00003868|DRUG|cyclophosphamide|
214426195|NCT00003868|DRUG|methotrexate|
214426196|NCT00003868|PROCEDURE|allogeneic bone marrow transplantation|
214426197|NCT00003868|PROCEDURE|peripheral blood stem cell transplantation|
214426198|NCT00003868|RADIATION|iodine I 131 monoclonal antibody BC8|
214426199|NCT00003868|RADIATION|radiation therapy|
214426200|NCT01890811|DIETARY_SUPPLEMENT|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
214426201|NCT00166283|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
214426202|NCT00166283|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
214426203|NCT06335576|OTHER|This study is a single-arm and observational study with no intervention.|This study is a single-arm and observational study with no intervention.
214426204|NCT05103423|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
214426205|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
214426206|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
214426207|NCT02986412|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
214426208|NCT01904071|PROCEDURE|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
214426209|NCT01904071|PROCEDURE|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
214426210|NCT01904071|DRUG|IVMS (IV Morphine)|Intravenous Morphine
214511011|NCT01282645|DEVICE|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
215112667|NCT00629863|OTHER|questionnaire administration|
215112668|NCT00629863|PROCEDURE|diagnostic endoscopic procedure|
214426211|NCT06355492|DEVICE|Virtual reality goggles (VR )|Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
214426212|NCT06355492|DEVICE|regular screen|Patients will take buccal infiltration anaethesia using (regular screen ).
214426213|NCT02819414|DRUG|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
214426214|NCT02819414|OTHER|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
214426215|NCT05834842|BEHAVIORAL|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
214426216|NCT03230786|DRUG|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
214426217|NCT02329132|DRUG|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
215112669|NCT00629863|PROCEDURE|neoadjuvant therapy|
215112670|NCT00629863|PROCEDURE|quality-of-life assessment|
215112671|NCT00629863|PROCEDURE|therapeutic conventional surgery|
215112672|NCT00629863|PROCEDURE|therapeutic endoscopic surgery|
215112673|NCT00629863|PROCEDURE|ultrasound imaging|
215112674|NCT00629863|RADIATION|radiation therapy|
215112675|NCT00629863|RADIATION|radioisotope therapy|
215112676|NCT03469648|PROCEDURE|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
215112677|NCT04450940|BEHAVIORAL|PACV survey|
215112678|NCT04450940|BEHAVIORAL|Placebo survey|
215112679|NCT01831167|OTHER|dynamic light|
214426218|NCT02860286|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
214426219|NCT00598377|DRUG|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
214426220|NCT00164333|BEHAVIORAL|TAP: Treatment Advocacy Program|
214426221|NCT04625257|OTHER|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
214426222|NCT04625257|OTHER|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
214426223|NCT04625257|OTHER|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
214426224|NCT04625257|OTHER|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
214426225|NCT05816902|OTHER|The location of the patient's treatment|The location of the patient's treatment
214426226|NCT04529382|DIAGNOSTIC_TEST|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
214426227|NCT01354769|DEVICE|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
214426228|NCT00002842|DRUG|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
214426229|NCT00002842|DRUG|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
214426230|NCT00002842|DRUG|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
214426231|NCT00002842|PROCEDURE|adjuvant therapy|Chemotherapy given after hepatic resection
214426232|NCT00002842|PROCEDURE|conventional surgery|Hepatic resection
214426233|NCT04133298|PROCEDURE|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
214426234|NCT04133298|PROCEDURE|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
214426235|NCT00540748|DRUG|oxytocin|5 U i.v. during surgical abortion
214426236|NCT04978051|DRUG|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
214426237|NCT04978051|OTHER|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
214426238|NCT03801967|DRUG|AZD9977|Randomized participants will receive oral dose of AZD9977.
214426239|NCT03801967|DRUG|Placebo|Randomized participants will receive oral dose of matching placebo.
214426240|NCT03939195|OTHER|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
214426241|NCT03381820|OTHER|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
214426242|NCT05260086|DEVICE|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
214426243|NCT03675581|DRUG|Microgynon|fixed sequence trial
214426244|NCT03675581|DRUG|Nintedanib|fixed sequence trial
214426245|NCT03557008|BIOLOGICAL|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
214511012|NCT01729767|DRUG|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
214426246|NCT03557008|DRUG|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
214511013|NCT01729767|DRUG|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
214511014|NCT05513729|DRUG|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
214511015|NCT05513729|DRUG|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
214511016|NCT01271894|DRUG|Efavirenz|600 mg once daily; given as 3 x 200 mg once
214511017|NCT01271894|DRUG|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
214511018|NCT01049698|BEHAVIORAL|Resistance Training|3 d/wk resistance training
214511019|NCT01049698|BEHAVIORAL|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
214511020|NCT02064686|OTHER|Exhaled breath temperature|
214511021|NCT03332316|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone injection
214511022|NCT03332316|DRUG|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
214511023|NCT03332316|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
214511024|NCT04728035|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection
214511025|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214692406|NCT03568149|PROCEDURE|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
215112680|NCT00808119|DRUG|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
215112681|NCT01980329|DRUG|Maraviroc|
214426247|NCT03557008|DRUG|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
214426248|NCT03557008|DRUG|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
214426249|NCT00523146|DRUG|Kanion Capsule|
214426250|NCT00701896|DRUG|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
214426251|NCT00701896|DRUG|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
214511026|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214511027|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214511028|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214511029|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214511030|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
214511031|NCT03914586|DEVICE|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
214511032|NCT05832970|OTHER|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
214511033|NCT01236898|DRUG|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
214511034|NCT04169802|DIAGNOSTIC_TEST|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
214511035|NCT04169802|DIAGNOSTIC_TEST|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
214511036|NCT00321971|BEHAVIORAL|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
214426252|NCT00701896|OTHER|Biological Control|No treatment intervention only information and procedures.
214511037|NCT00321971|BEHAVIORAL|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
214426253|NCT00701896|BEHAVIORAL|Motivational Interview|60 minute one-on-one Interview
214426254|NCT00853918|OTHER|$20 cash|$20 cash incentive mailed with survey
214511038|NCT05640245|DRUG|Sonelokimab|randomized treatment; parallel group
214692407|NCT01081223|BIOLOGICAL|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
214426255|NCT00853918|OTHER|$50 cash|$50 cash incentive mailed with survey
214426256|NCT00853918|OTHER|$50 check|$50 check incentive mailed with survey
214426257|NCT00853918|OTHER|$100 check|$100 check incentive mailed with survey
214426258|NCT03335748|OTHER|Cognitive training Cogmed program|Cognitive training Cogmed program
214426259|NCT00300131|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
214426260|NCT06224946|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
214692408|NCT02391506|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
214692409|NCT01727635|OTHER|body-mind-spirit group therapy|8-session therapy
215112682|NCT05076201|BEHAVIORAL|Patients with completed rehab|The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
215112683|NCT06835647|DEVICE|Investigational Fetal Monitor|Investigational Fetal Monitoring Device Device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
214426261|NCT01098344|DRUG|Notch signaling pathway inhibitor MK0752|
214426262|NCT01098344|DRUG|gemcitabine hydrochloride|
214426263|NCT01098344|OTHER|imaging biomarker analysis|
214426264|NCT01098344|OTHER|laboratory biomarker analysis|
214426265|NCT01098344|OTHER|pharmacological study|
214426266|NCT05918614|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
214511039|NCT05640245|DRUG|Placebo|randomized treatment; parallel-group
214511040|NCT05640245|DRUG|Adalimumab|randomized treatment; parallel-group
214511041|NCT05309057|DIETARY_SUPPLEMENT|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
214511042|NCT00831194|BEHAVIORAL|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
214426267|NCT05918614|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
214426268|NCT02355197|DRUG|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
214426269|NCT04149548|DIAGNOSTIC_TEST|ultrasound|Obstetric ultrasound to pregnant women
214426270|NCT00003005|DRUG|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
214426271|NCT00003005|DRUG|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
214426272|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 3)|
214426273|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5)|
214426274|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5D)|
214426275|NCT00006327|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
214426276|NCT03473522|DEVICE|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
214426277|NCT03473522|BEHAVIORAL|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
214511043|NCT03064256|BEHAVIORAL|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
215028589|NCT04946214|BEHAVIORAL|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
215028590|NCT03527667|BEHAVIORAL|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
214426278|NCT01426295|DEVICE|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0."
214426279|NCT01426295|DRUG|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
214426280|NCT05157022|DEVICE|ESWT|Extracorporeal Shock-wave Therapy
214426281|NCT00141349|DRUG|UK-369,003|
214426282|NCT04670159|BEHAVIORAL|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
214426283|NCT04670159|BEHAVIORAL|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
214511044|NCT03064256|BEHAVIORAL|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
214511045|NCT00299676|DRUG|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
214511046|NCT00520663|DRUG|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
214511047|NCT02464072|PROCEDURE|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
214511048|NCT02464072|PROCEDURE|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
215112684|NCT06835647|DEVICE|Ultrasound Imaging Device|The Ultrasound imaging device is a general-purpose diagnostic ultrasound system for use in measurement, display and analysis of the human body and fluid.
215112685|NCT00776854|DEVICE|Noveon laser|870 and 930nm wavelengths
215112686|NCT03058926|OTHER|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
215112687|NCT03833726|PROCEDURE|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
215112688|NCT03833726|PROCEDURE|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
215112689|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
215112690|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
215112691|NCT06237959|DIETARY_SUPPLEMENT|Keranat™|300 mg/capsule(proso millet and wheat extract 600 mg/day)
215112692|NCT06237959|DIETARY_SUPPLEMENT|placebo|300 mg/capsule(600 mg/day as placebo)
215112693|NCT01186185|DRUG|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
214511049|NCT02464072|PROCEDURE|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
214511050|NCT04454112|DEVICE|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
215112694|NCT00031473|DRUG|Virazole (Ribavirin) Inhalation Solution|
215112695|NCT01186302|OTHER|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
215112696|NCT05921435|DRUG|CKD-341, D958|A single dose of 1tablet under fasting condition
215112697|NCT01793623|OTHER|atrial tissue|retrieval of discarded atrial tissue
215112698|NCT05531981|OTHER|detect HPV E7 ctDNA|Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR
215112699|NCT03671213|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
215112700|NCT02804126|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
215112701|NCT02804126|PROCEDURE|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
214426284|NCT04830501|DRUG|TT-00434|Once daily \[QD\], 28 days/cycle.
214426285|NCT06176482|DEVICE|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
214426286|NCT03203538|DEVICE|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
215112702|NCT02804126|DRUG|Bupivacaine|In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
214426287|NCT03203538|DEVICE|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
214426288|NCT03203538|DEVICE|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
214426289|NCT03203538|DEVICE|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
214426290|NCT03203538|DEVICE|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
214426291|NCT03203538|DEVICE|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
214426292|NCT01673516|PROCEDURE|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
214426293|NCT01673516|DEVICE|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
214426294|NCT02522468|PROCEDURE|Radioactive Seed Localization|
214426295|NCT02522468|PROCEDURE|Wire Localization|
214426296|NCT00142558|DRUG|MK0663; etoricoxib / Duration of Treatment: 5 Days|
214426297|NCT00142558|DRUG|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
214426298|NCT02405559|DRUG|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
214426299|NCT04413838|DRUG|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
214426300|NCT04413838|OTHER|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
214426301|NCT01742169|BEHAVIORAL|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
214426302|NCT06336473|PROCEDURE|skin biopsy|Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
214426303|NCT05492409|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection.
214426304|NCT01113931|DRUG|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
214426305|NCT01113931|DRUG|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
214426306|NCT02250118|DRUG|Bevacizumab|Intrapleural Bevacizumab
214426307|NCT02567656|DRUG|RP6530|Tablet starting at 200 mg
214426308|NCT00134069|DRUG|sorafenib tosylate|Given orally
215112703|NCT02804126|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
215112704|NCT02804126|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
215112705|NCT02804126|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
215112706|NCT02804126|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
215112707|NCT02804126|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
215112708|NCT00681889|DRUG|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
215112709|NCT03223337|DRUG|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
215112710|NCT01362608|DRUG|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
215112711|NCT01362608|DRUG|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
215112712|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
215112713|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
215112714|NCT03275324|DEVICE|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
214426309|NCT00134069|DRUG|cetuximab|Given IV
215112715|NCT03403439|DRUG|BI 1015550|Reference and Test Treatment
215112716|NCT03403439|DRUG|itraconazole|Test treatment
214426310|NCT00134069|DRUG|irinotecan hydrochloride|Given IV
214511051|NCT05928494|OTHER|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
214426311|NCT03454646|DRUG|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
214426312|NCT00034528|DRUG|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
214511052|NCT00988130|OTHER|laboratory biomarker analysis|
214511053|NCT00988130|OTHER|questionnaire administration|
214511054|NCT00988130|PROCEDURE|assessment of therapy complications|
214511055|NCT00988130|PROCEDURE|high-intensity focused ultrasound ablation|
214511056|NCT00988130|PROCEDURE|quality-of-life assessment|
214511057|NCT04470089|DRUG|Myramistin|Oromucosal application
214511058|NCT05758532|BIOLOGICAL|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
214511059|NCT06080945|OTHER|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
214511060|NCT01333709|DRUG|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
215112717|NCT01679132|DEVICE|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
215112718|NCT00877240|BEHAVIORAL|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
215112719|NCT06351449|OTHER|The patch under study is photographed using the SkinCam®|Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.
215112720|NCT04257526|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
214511061|NCT01333709|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
214511062|NCT01333709|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
215112721|NCT05547568|PROCEDURE|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
215112722|NCT00863005|DRUG|K201|Cream
215112723|NCT00863005|DRUG|K201|
215112724|NCT01336140|DRUG|Aminophylline|75 mg of intravenous aminophylline
215112725|NCT01336140|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
215112726|NCT05726006|OTHER|No Intervention in This study|No Intervention in This study
215112727|NCT01978041|OTHER|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
215112728|NCT01978041|OTHER|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
215112729|NCT01978041|OTHER|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
215112730|NCT01978041|OTHER|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
214426313|NCT00034528|DRUG|Fludarabine|30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
214426314|NCT00034528|DRUG|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
214426315|NCT00034528|DRUG|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
214426316|NCT00525486|DRUG|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
214426317|NCT00354653|DRUG|LAMIVUDINE|
214426318|NCT05622123|DRUG|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
214426319|NCT01424397|DRUG|SB-705498|12mg intranasal
214426320|NCT01424397|DRUG|FP|200ug intranasal
214426321|NCT01424397|DRUG|placebo|placebo intranasal
214426322|NCT06116708|DEVICE|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
214426323|NCT06116708|DEVICE|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
214426324|NCT01340859|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
214426325|NCT01718041|DRUG|Experimental: VRS-317|Active treatment arm
214426326|NCT04134793|PROCEDURE|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
214426327|NCT00002893|DRUG|fluorouracil|
214511063|NCT01333709|RADIATION|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
214511064|NCT01333709|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
214511065|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
215112731|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
215112732|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
215112733|NCT05115032|DEVICE|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
215112734|NCT05115032|BEHAVIORAL|At-home rehabilitation exercises|6 weeks of daily rehabilitation exercises involving nodding and shaking of the head
215112735|NCT00971139|BEHAVIORAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
214426328|NCT00002893|DRUG|leucovorin calcium|
214426329|NCT00002893|DRUG|raltitrexed|
214426330|NCT04559126|DRUG|EDP-297|EDP-297 Oral solution
214426331|NCT04559126|DRUG|Placebo|placebo to match EDP-297
214426332|NCT02459782|PROCEDURE|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
214426333|NCT04735315|OTHER|Preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
214511066|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
215112736|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
215112737|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
215112738|NCT04506502|DEVICE|The ZELTIQ System|The MMS device will be used to perform the treatments.
215112739|NCT06797128|PROCEDURE|One Anchor|Participant will receive one standard anchor
215112740|NCT06797128|PROCEDURE|Two Mini Anchors|Participant will receive two mini anchors
215112741|NCT05475522|DEVICE|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
214426334|NCT06096142|DEVICE|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
214426335|NCT06096142|DEVICE|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
214426336|NCT00111722|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
214426337|NCT00111722|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
214426338|NCT01241435|DRUG|LY2216684|Administered orally
214426339|NCT03444649|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
214426340|NCT03444649|DRUG|Idarubicin|Standard chemotherapy d1-d3 cycle 1
214426341|NCT03444649|DRUG|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
214426342|NCT03444649|DRUG|Daunorubicin|Standard chemotherapy d1-3 cycle 2
214426343|NCT02418013|OTHER|Fresh cord blood(experimental group A)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
214426344|NCT02418013|OTHER|Frozen cord blood(experimental group B)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
214511067|NCT00813709|DRUG|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
214426345|NCT02418013|OTHER|Frozen plasma(experimental group C)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
214426346|NCT02418013|OTHER|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
214426347|NCT06537167|DEVICE|Transcutaneous electrical acupoint stimulation|Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
214511068|NCT00813709|DRUG|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
214511069|NCT00708799|OTHER|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
214511070|NCT02753075|DEVICE|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
214511071|NCT02753075|DEVICE|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
214511072|NCT02753075|OTHER|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
214511073|NCT02753075|DRUG|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
214511074|NCT05529485|PROCEDURE|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
214511075|NCT01780272|OTHER|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
214511076|NCT02010866|BEHAVIORAL|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
214511077|NCT04151147|PROCEDURE|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
214511078|NCT04151147|PROCEDURE|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
214511079|NCT04867772|OTHER|Home based rehabilitation|
214511080|NCT00942500|PROCEDURE|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
214511081|NCT00392652|DRUG|oral microencapsulated diindolylmethane|Given PO
214511082|NCT00789971|DRUG|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
214511083|NCT00789971|DRUG|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
214511084|NCT01662232|DIETARY_SUPPLEMENT|Green tea beverage|
214426348|NCT06537167|DEVICE|Sham stimulation|Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
214426349|NCT01057758|DRUG|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
214511085|NCT01662232|DIETARY_SUPPLEMENT|Green tea extract|
214511086|NCT01662232|DIETARY_SUPPLEMENT|EGCG|
214511087|NCT01662232|OTHER|Placebo|
214511088|NCT04323514|DIETARY_SUPPLEMENT|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
214511089|NCT04570488|OTHER|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
215028591|NCT04936555|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
215028592|NCT02228928|DRUG|CAPNP, 50 ug/cm2 capsaicin patch|
215028593|NCT02228928|DRUG|CAPNP, 100 ug/cm2 capsaicin patch|
215028594|NCT02228928|DRUG|0.075% capsaicin cream|
215028595|NCT02228928|OTHER|Placebo patch|
215028596|NCT00694863|DRUG|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
214426350|NCT01057758|DRUG|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
214426351|NCT05230680|DRUG|ACHOP|"1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
214426352|NCT06357819|DEVICE|INSTI HCV Self Test|Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
214426353|NCT01948999|PROCEDURE|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
214426354|NCT01948999|PROCEDURE|SHAM ECT|Anesthesia and concomitant muscular paralysis
214426355|NCT01948999|DRUG|Anesthesia|Temporary induced state of analgesia
214426356|NCT03156712|DIETARY_SUPPLEMENT|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
214426357|NCT00980330|DRUG|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
214426358|NCT00980330|DRUG|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
214426359|NCT00980330|DRUG|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
214426360|NCT00980330|DRUG|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
214426361|NCT05117372|OTHER|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
214426362|NCT05117372|OTHER|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
214426363|NCT03860532|DRUG|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
214426364|NCT03860532|DRUG|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
214426365|NCT03103295|BIOLOGICAL|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
214426366|NCT01630564|BIOLOGICAL|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
214426367|NCT01630564|PROCEDURE|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
214426368|NCT01630564|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
214426369|NCT00666276|DRUG|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
214426370|NCT04749017|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
215112742|NCT05475522|DEVICE|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
215112743|NCT05411120|OTHER|Western Diet|Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.
215112744|NCT05411120|OTHER|CLEAN-MED|Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
214426371|NCT04749017|OTHER|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
214426372|NCT04617652|DRUG|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
214426373|NCT04617652|DRUG|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
214426374|NCT00389246|BEHAVIORAL|Consultation without genetic information|
214426375|NCT00389246|BEHAVIORAL|Consultation with genetic information|
214426376|NCT02778958|DRUG|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
214426377|NCT02778958|DRUG|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
214426378|NCT01065220|DRUG|Testolactone undecanoate|4ml i.m.
214426379|NCT01065220|DRUG|Lynestrenol|2/day
214426380|NCT01065220|DRUG|Cyproterone Acetate|50mg per day
214426381|NCT01065220|DRUG|Estradiol|100 microgram TTS twice a week
214426382|NCT01065220|DRUG|5-alpha reductase inhibitor|1mg daily
214426383|NCT05824442|BIOLOGICAL|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
214426384|NCT02582437|OTHER|History for opioid use|
214511090|NCT02254902|BEHAVIORAL|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
214511091|NCT00783185|BEHAVIORAL|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
214511092|NCT00783185|BEHAVIORAL|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
214511093|NCT02374372|DEVICE|conventional hemodialysis|
214511094|NCT02374372|DEVICE|hemodiafiltration On-line|
214426385|NCT04091152|OTHER|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
214426386|NCT00915330|PROCEDURE|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
214426387|NCT00915330|PROCEDURE|TBNA|transbronchial needle aspiration
214426388|NCT00194623|DRUG|Botulinum Toxin A (Botox)|
214426389|NCT03299816|BEHAVIORAL|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
214426390|NCT03299816|BEHAVIORAL|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
214511095|NCT03848741|BEHAVIORAL|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
214511096|NCT03848741|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
215112745|NCT06796491|OTHER|Post Isometric relaxation|Group A will receive Post Isometric Relaxation (PIR) Patient applied the sub-maximal contraction almost 20%. Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained.4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week for 4 weeks conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
214511097|NCT03848741|DIETARY_SUPPLEMENT|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
214511098|NCT03848741|DIETARY_SUPPLEMENT|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
214511099|NCT04195919|DRUG|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
214511100|NCT04195919|DRUG|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
214511101|NCT04326894|DRUG|25 mg/week oral methotrexate tablets|
214426391|NCT03520413|OTHER|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
214511102|NCT04326894|DRUG|25mg/week oral placebo tablets|
214511103|NCT05116306|DRUG|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
214511104|NCT05116306|DRUG|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
214426392|NCT03520413|OTHER|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
214426393|NCT02311907|DRUG|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
214426394|NCT02311907|DRUG|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
214426395|NCT02311907|OTHER|Laboratory Biomarker Analysis|Correlative studies
214426396|NCT02311907|DRUG|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
214426397|NCT02311907|OTHER|Placebo|Given IV
214426398|NCT02311907|OTHER|Quality-of-Life Assessment|Ancillary studies
214426399|NCT00482378|DRUG|Pamidronate|90 mg by IV monthly.
214426400|NCT00482378|DRUG|Zoledronic acid|4 mg by IV monthly.
215028597|NCT00338611|BEHAVIORAL|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
215028598|NCT00338611|BEHAVIORAL|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
215028599|NCT00338611|BEHAVIORAL|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
215028600|NCT00338611|BEHAVIORAL|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
215028601|NCT05684302|OTHER|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
215028602|NCT01716637|BIOLOGICAL|Etanercept|
215112746|NCT06796491|OTHER|Post Facilitation stretch|Group B will receive Post Facilitation Stretch (PFS) Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained. 4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week 4 weeks. for hamstring flexibility conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
215112747|NCT05446220|BEHAVIORAL|Lifestyle intervention|Dietary advise and/or advise on physical activity monitored by pedometer
215112748|NCT04073420|DEVICE|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
215112749|NCT04073420|DEVICE|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
215112750|NCT02275741|BIOLOGICAL|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
215112751|NCT01378767|DIETARY_SUPPLEMENT|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
215112752|NCT03769558|OTHER|Non-Interventional|Non-Interventional
215112753|NCT00971074|DRUG|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
215112754|NCT00971074|OTHER|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
215112755|NCT05556668|DEVICE|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
214511105|NCT05746468|BEHAVIORAL|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
215112756|NCT05947617|DRUG|VIX001|"This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes."
215112757|NCT02030522|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
215112758|NCT01569620|BEHAVIORAL|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
214511106|NCT05746468|BEHAVIORAL|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
214511107|NCT01613703|DRUG|ONO-2952|1 mg to 200 mg QD at a single descending dose
214511108|NCT04006015|OTHER|No intervention being delivered.|No interventions are being delivered.
215112759|NCT01569620|BEHAVIORAL|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
215112760|NCT01569620|BEHAVIORAL|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
215028603|NCT01716637|DIETARY_SUPPLEMENT|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
215028604|NCT05593939|BEHAVIORAL|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
215028605|NCT05593939|BEHAVIORAL|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
215028606|NCT05593939|DIETARY_SUPPLEMENT|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
215028607|NCT02321475|DRUG|EGb761®|
215112761|NCT05078372|DRUG|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
215112762|NCT05078372|DRUG|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
215112763|NCT01870115|DIETARY_SUPPLEMENT|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
215112764|NCT01870115|DIETARY_SUPPLEMENT|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
215112765|NCT00941317|DEVICE|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
215112766|NCT02083536|RADIATION|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
214426401|NCT00482378|RADIATION|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
214426402|NCT01043263|DRUG|EN3324 (axomadol)|twice daily dosing
214426403|NCT01043263|DRUG|Placebo|twice daily dosing
214426404|NCT04825366|DEVICE|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
215112767|NCT02083536|DRUG|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
215112768|NCT00699608|DRUG|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
215112769|NCT06023706|DRUG|Capsaicin 179 Mg Cutaneous Patch|1 patch applied once for 1 hour
215112770|NCT06023706|DRUG|Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)|1 patch applied once for 1 hour
215112771|NCT01426672|OTHER|Monovision Correction (with the help of glasses or contact lenses)|
215112772|NCT00566462|DRUG|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
215112773|NCT00566462|DRUG|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
215112774|NCT02245945|DRUG|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
215112775|NCT02245945|DRUG|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
215112776|NCT00449124|DRUG|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
215112777|NCT00449124|BIOLOGICAL|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
214426405|NCT04825366|OTHER|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
214426406|NCT04825366|OTHER|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
214426407|NCT04825366|OTHER|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
214426408|NCT04825366|OTHER|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
214426409|NCT04825366|OTHER|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
214426410|NCT04825366|OTHER|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
214426411|NCT04825366|OTHER|Well-being|The WHO-5 well-being index will be used to assess well-being.
214426412|NCT04825366|OTHER|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
214426413|NCT04825366|OTHER|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
214426414|NCT04825366|DEVICE|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
214426415|NCT04825366|DEVICE|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
214426416|NCT04825366|OTHER|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
214426417|NCT04584099|DEVICE|Radiofrequency device treatment|TempSure firm
214426418|NCT03567369|DRUG|Dexamethasone|Dexamethasone 4,0 mg/mL
214426419|NCT03567369|DRUG|Traumeel S|Traummel S 2,2 mg/mL
214426420|NCT04660214|DEVICE|septotomy|endoscopic diverticulotomy
214426421|NCT05126004|DRUG|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
214426422|NCT05126004|DRUG|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
214426423|NCT05500664|DRUG|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
214426424|NCT06319586|PROCEDURE|Radial Forearm Flap|"* Elevate the flap from ulnar to radial side toward the FCR~* Elevate flap from radial to ulnar side to the brachioradialis tendon. Ligate and divide the radial artery and venae comitantes distally.~* incise the skin over the cephalic vein proximally to the cubital fossa. Identify the venous branching pattern and perforating vein.~* Elevate the skin and subcutaneous paddles proximally off of the FCR and brachioradialis.~* Define the venous anatomy at the cubital fossa. In most cases, the median basilic vein and continuation of the median vein contribution to the cephalic vein can be harvested proximal to the perforating vein. This anatomy allows two large veins to be harvested that drain both the deep and superficial systems. Occasionally, one large vein will be identified.~* Closure is performed by harvesting a 0.018-inch skin graft to cover the donor defect. The radial skin edge should be advanced to cover the exposed radial nerve."
214511109|NCT05371002|BEHAVIORAL|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
214511110|NCT05371002|OTHER|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
214511111|NCT03153566|BIOLOGICAL|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
214511112|NCT03153566|DEVICE|cryotherapy|10 sec 1 cycle into all genital warts
214426425|NCT04154241|DIAGNOSTIC_TEST|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
214511113|NCT04372732|DIAGNOSTIC_TEST|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
214511114|NCT02245620|DRUG|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
214511115|NCT02245620|DRUG|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
215112778|NCT06123000|PROCEDURE|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
214426426|NCT03133039|PROCEDURE|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
214511116|NCT04528602|PROCEDURE|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
214511117|NCT04528602|PROCEDURE|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
214511118|NCT04366895|OTHER|conventional single implant overdenture|conventional manufactured implant overdenture
214426427|NCT00860717|PROCEDURE|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
214426428|NCT00860717|RADIATION|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
214426429|NCT02245581|PROCEDURE|SVV-guided fluid management|
214426430|NCT02245581|PROCEDURE|CVP-guided fluid management|
214426431|NCT04303156|DRUG|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
214426432|NCT03393377|DRUG|fluvastatin 10 mg and valsartan 20 mg|
214426433|NCT03393377|DRUG|placebo|
214426434|NCT02014766|PROCEDURE|Interscalene block|Ultrasound-guided interscalene block is performed.
214426435|NCT02014766|PROCEDURE|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
214426436|NCT05233007|PROCEDURE|Minor endoscopic biopsy|As per standard of care
214426437|NCT06491888|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|Photoelectric detection was carried out on the subjects of the experimental group.
214426438|NCT00362869|DRUG|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
214426439|NCT00362869|DRUG|Placebo|Sodium bicarbonate solution
214426440|NCT00362869|BIOLOGICAL|Enteroaggregative E. coli (EAEC)|Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
214426441|NCT05072171|PROCEDURE|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
214426442|NCT06092697|OTHER|3D printed PEEK restorations|Indirect dental restoration
214426443|NCT05001945|DRUG|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
214426444|NCT05001945|OTHER|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
214426445|NCT05001945|OTHER|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
214426446|NCT05001945|DRUG|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
214426447|NCT06108271|DEVICE|Triglotix®|The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
215112779|NCT06123000|PROCEDURE|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
215112780|NCT03010319|DEVICE|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
214426448|NCT06108271|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube that is currently used worldwide
214426449|NCT01833364|PROCEDURE|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
214426450|NCT02448446|DRUG|ranibizumab 0.3mg|intravitreally administered
214426451|NCT02201173|BEHAVIORAL|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
214426452|NCT02055794|PROCEDURE|Suturing of the perineal skin|
214426453|NCT02055794|PROCEDURE|Closing perineal skin with surgical glue|
214426454|NCT02055794|PROCEDURE|No suturing of the perineal skin|
214426455|NCT00661648|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
214426456|NCT05746273|DRUG|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
214426457|NCT05746273|DRUG|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
214426458|NCT00365157|DRUG|Eribulin Mesylate|Given IV
214511119|NCT04366895|OTHER|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
215112781|NCT03010319|DEVICE|Secondary Dressings|Dressings to ensure moist wound environment
215112782|NCT03010319|DEVICE|Offloading device|Offloading device to decrease pressure to wound area
214511120|NCT05982756|DRUG|DAG pre-excitation regimen with Bortezomib|Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
214426459|NCT00365157|OTHER|Laboratory Biomarker Analysis|Correlative studies
214426460|NCT00365157|OTHER|Pharmacological Study|Correlative studies
214426461|NCT04367415|DIAGNOSTIC_TEST|Darwish test for a free endometrial cavity|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
214426462|NCT04367415|DIAGNOSTIC_TEST|Darwish test for an endometrial cavity with endometrial polyps|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
214426463|NCT01801410|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
214426464|NCT01801410|DRUG|Misoprostol|25mcg every 2 hours for maximum of 12 doses
214426465|NCT02425111|DRUG|Vedolizumab|Vedolizumab intravenous injection
214426466|NCT01663519|OTHER|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
214426467|NCT01663519|OTHER|Prefabricated insoles|Prefabricated insoles
214511121|NCT02745509|OTHER|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
214511122|NCT01285167|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
214511123|NCT03039322|DIAGNOSTIC_TEST|Serum Golgi Protein 73|Serum test
214511124|NCT02327806|DEVICE|pulsed electromagnetic field therapy|
214511125|NCT03596775|DRUG|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
215112783|NCT04121702|PROCEDURE|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
215112784|NCT01908478|DRUG|Veliparib|
215112785|NCT01908478|DRUG|Gemcitabine|
215112786|NCT01908478|RADIATION|Intensity modulated radiation therapy|
215112787|NCT01817426|DRUG|Infliximab|
215112788|NCT01817426|OTHER|Placebo|
215112789|NCT03371693|DEVICE|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
215112790|NCT03371693|DEVICE|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
214511126|NCT03596775|DRUG|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
214511127|NCT00896740|GENETIC|microarray analysis|
214511128|NCT00896740|PROCEDURE|biopsy|
215112791|NCT03371693|DEVICE|IVCT|platinum-based intravenous chemotherapy
215112792|NCT03897556|DIETARY_SUPPLEMENT|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
215112793|NCT03897556|OTHER|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
215112794|NCT02057172|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
215112795|NCT02057172|DRUG|liraglutide|Liraglutide is a GLP-1 agonist.
214426468|NCT01663519|OTHER|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
214426469|NCT04332666|DRUG|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
214426470|NCT04332666|DRUG|Placebos|infusion of NaCl 0.9% without diluted peptide in it
214426471|NCT00162292|DRUG|BMS-582949 and Methotrexate|
214426472|NCT04385355|DEVICE|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
214426473|NCT04385355|DEVICE|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
214511129|NCT00035256|DRUG|teriparatide|
214511130|NCT00035256|DRUG|raloxifene HCl|
214511131|NCT00035256|DRUG|placebo|
214511132|NCT02264847|DRUG|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
214511133|NCT02264847|DRUG|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
214511134|NCT05180175|DRUG|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
214511135|NCT05534776|OTHER|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
215112796|NCT02057172|DRUG|Placebo|Placebo
215112797|NCT06492590|BEHAVIORAL|Multicomponent intervention|Multicomponent intervention based on psycho-education and physical rehabilitation.
215112798|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
215112799|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
215112800|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
214511136|NCT00889473|DRUG|Larazotide acetate|gelatin capsule
214426474|NCT06178978|DEVICE|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
214426475|NCT00411138|RADIATION|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
214426476|NCT00411138|DRUG|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
214426477|NCT00411138|DRUG|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
214426478|NCT00411138|DRUG|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
214426479|NCT04593914|DEVICE|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
214426480|NCT06142851|OTHER|Data collection|data collection
214426481|NCT03598478|BEHAVIORAL|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
214426482|NCT03598478|BEHAVIORAL|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
214426483|NCT03598478|BEHAVIORAL|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
214426484|NCT03127995|RADIATION|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
214426485|NCT03127995|RADIATION|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
214426486|NCT03009305|OTHER|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
214426487|NCT03009305|DEVICE|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
214426488|NCT03009305|DEVICE|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
214426489|NCT04283552|DEVICE|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
214426490|NCT02033148|DRUG|icotinib hydrochloride|Given PO
214426491|NCT02033148|OTHER|laboratory biomarker analysis|Correlative studies
214426492|NCT02033148|OTHER|pharmacological study|Correlative studies
214426493|NCT06386237|OTHER|Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
214426494|NCT03379935|PROCEDURE|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
214426495|NCT02756377|DRUG|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
214426496|NCT02756377|DRUG|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
214426497|NCT00545077|DRUG|Letrozole|
214426498|NCT00545077|DRUG|Bevacizumab|
214426499|NCT00545077|DRUG|Fulvestrant|
214426500|NCT04201041|PROCEDURE|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
214426501|NCT04136470|BIOLOGICAL|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
214426502|NCT02202499|DRUG|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
214511137|NCT00889473|DRUG|Placebo|gelatin capsule
214511138|NCT00889473|DIETARY_SUPPLEMENT|Gluten 900 mg|gelatin capsule
214511139|NCT00623649|DRUG|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
214511140|NCT00623649|DRUG|Placebo|Dose escalation study with a full review of all safety data following each cohort.
215112801|NCT05817305|OTHER|Medical history and functional evaluation|During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
214426503|NCT02202499|OTHER|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
214426504|NCT02202499|OTHER|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
214426505|NCT06306313|DEVICE|ReoGo|ReoGo is a fixed arm rehabilitation exoskeleton that comes on a small and compact wheeled platform. The end-effector extension is capable of producing a wide range or repeatable movements in 3D space. ReoGo can be used by both adults and children. It is an arm rehabilitation exoskeleton with a fixed base. Its design allows limited controlled movements of the shoulder as well as the elbow and wrist.
214426506|NCT06306313|OTHER|Conventional Physiotherapy|Physiotherapy protocols will be created with traditional physiotherapy practices such as neurodevelopmental techniques based on muscle strengthening and task-oriented exercises. Protocols in general terms; It will include passive and active joint range of motion exercises, stretching exercises, stimulation and facilitation techniques, strengthening exercises, fine motor skills and functional task training for daily living activities. Protocols will be tailored to each patient's level of motor impairment and functional needs.
214426507|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
214426508|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
214426509|NCT03123198|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
214426510|NCT01288326|DRUG|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
214426511|NCT04956679|DIAGNOSTIC_TEST|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
214426512|NCT02976116|DRUG|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
214426513|NCT02976116|DRUG|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
214426514|NCT04358939|OTHER|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
214426515|NCT01219205|PROCEDURE|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
214426516|NCT02092519|DEVICE|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
214426517|NCT02092519|DEVICE|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
214426518|NCT00535145|DRUG|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
214426519|NCT01043458|DRUG|ABT-126|ABT-126 Low Dose \& ABT-126 High Dose
214426520|NCT01043458|DRUG|Placebo for ABT-126|Matching Placebo for Arms 1 \& 2
214426521|NCT02622672|DIETARY_SUPPLEMENT|water-soluble ubiquinol|100 mg/d
214426522|NCT02622672|DIETARY_SUPPLEMENT|Placebo|glycerin.soy-lecithin, and water
214426523|NCT04461197|DEVICE|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
214426524|NCT04461197|DEVICE|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
214426525|NCT03127280|OTHER|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
214426526|NCT02872753|BIOLOGICAL|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
214426527|NCT02872753|OTHER|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
214426528|NCT02929485|DRUG|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
215112802|NCT05817305|OTHER|Health education|Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
215112803|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
214426529|NCT02929485|DRUG|Placebo|Placebo (200mg) administered at study visit
214426530|NCT02929485|DRUG|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
214426531|NCT03161990|PROCEDURE|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
215112804|NCT04587050|DIAGNOSTIC_TEST|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
215112805|NCT04587050|DIAGNOSTIC_TEST|Cervical cytology|Cervical cytology
215112806|NCT04587050|DIAGNOSTIC_TEST|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
214426532|NCT03161990|PROCEDURE|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
214426533|NCT00548574|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
214426534|NCT00548574|DRUG|Mesalazine|
214426535|NCT03189329|DRUG|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
214426536|NCT03189329|DRUG|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
214426537|NCT04957069|PROCEDURE|fixation|double row fixation with 3-4 wire anchors
214511141|NCT04389086|DRUG|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
214511142|NCT04389086|RADIATION|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
214511143|NCT04389086|PROCEDURE|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
214511144|NCT04418609|OTHER|further processing of health data|further processing of biological materials and health related personal data for research
214511145|NCT05310292|BIOLOGICAL|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
214511146|NCT05310292|BIOLOGICAL|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
214511147|NCT05656456|OTHER|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
215112807|NCT02588261|DRUG|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
215112808|NCT02588261|DRUG|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
214426538|NCT04957069|PROCEDURE|primary repair|end-to-end repair
214426539|NCT00176371|BEHAVIORAL|physical exercise|
214426540|NCT06554041|DEVICE|Dental Crown with Titanium-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
214426541|NCT06554041|DEVICE|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
214426542|NCT06554041|DEVICE|Dental Crown with Zirconia-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
214511148|NCT03368274|DRUG|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
214511149|NCT00811239|DRUG|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
214511150|NCT00811239|OTHER|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
214511151|NCT00005635|BIOLOGICAL|trastuzumab|
214511152|NCT00005635|DRUG|paclitaxel|
214511153|NCT06121778|OTHER|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
215112809|NCT02588261|DRUG|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
215112810|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
215112811|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
215112812|NCT00004052|BIOLOGICAL|QS21|
215112813|NCT00004052|BIOLOGICAL|bcr-abl peptide vaccine|
215112814|NCT05716932|PROCEDURE|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
215112815|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
214511154|NCT03633318|DEVICE|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
214511155|NCT04891497|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
215112816|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
215112817|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
215112818|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
214426543|NCT06554041|DEVICE|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
214426544|NCT00478738|DRUG|GSK961081|
214426545|NCT04206098|OTHER|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
214426546|NCT00002380|DRUG|Nelfinavir mesylate|
214511156|NCT04891497|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
214511157|NCT01102426|DRUG|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
214511158|NCT01102426|DRUG|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
214511159|NCT02899533|DRUG|[18F] FES|\[18F\] FES PET/CT scan, imaging tracer
214511160|NCT03358485|DRUG|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
214511161|NCT03358485|OTHER|Placebo|Placebo
214511162|NCT00002977|BIOLOGICAL|filgrastim|
214511163|NCT00002977|DRUG|melphalan|
214511164|NCT00002977|DRUG|thiotepa|
214511165|NCT00002977|PROCEDURE|peripheral blood stem cell transplantation|
215112819|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
215112820|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
215112821|NCT06104111|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
215112822|NCT03213288|DIETARY_SUPPLEMENT|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
215112823|NCT03213288|DIETARY_SUPPLEMENT|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
215112824|NCT03213288|DIETARY_SUPPLEMENT|Placebo|No anthocyanins
215112825|NCT01101789|PROCEDURE|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
215112826|NCT01101789|PROCEDURE|regular sutures for surgical wound closure|
215112827|NCT04359160|DEVICE|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
215112828|NCT04359160|OTHER|Questionnaire|Paper questionnaire follow-up, with questions and score
215112829|NCT05082246|OTHER|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
215112830|NCT05082246|OTHER|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
214426547|NCT00002380|DRUG|Saquinavir|
214426548|NCT05167877|OTHER|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
214426549|NCT01686906|PROCEDURE|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
214426550|NCT04906161|DIAGNOSTIC_TEST|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
214426551|NCT02200770|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
214426552|NCT02200770|OTHER|Placebo|Participants will receive IV placebo matched to inebilizumab.
214426553|NCT00362778|DRUG|Insulin|intravenous continuous insulin infusion for 48 hours
214426554|NCT01647438|BEHAVIORAL|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
214426555|NCT01647438|OTHER|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
214511166|NCT02407288|DEVICE|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
214511167|NCT02407288|DEVICE|Sham tDCS|
214511168|NCT02491645|OTHER|Sensory interventions|"1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done."
214511169|NCT06315465|DIETARY_SUPPLEMENT|Modified Atkin's Diet with standard of care|children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
214511170|NCT06315465|OTHER|Standard of Care|Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
214511171|NCT02084576|DRUG|Nepafenac|One drop in the study eye 3 times daily for 30 days
214511172|NCT02084576|DRUG|Ketorolac|One drop in the study eye 4 times daily for 30 days
214511173|NCT00889863|DRUG|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
214511174|NCT00889863|DRUG|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
214426556|NCT01531075|BIOLOGICAL|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
214426557|NCT01531075|BIOLOGICAL|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
214426558|NCT03697655|DRUG|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
214426559|NCT01068756|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
214426560|NCT01068756|DRUG|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
214511175|NCT04211194|PROCEDURE|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
214511176|NCT03800771|DEVICE|Cycléo BRAU|Practice dual-task tests.
214511177|NCT03800771|DEVICE|GAITRITE®|Routine practice dual-task tests.
214511178|NCT00475969|DRUG|duloxetine|
214511179|NCT00475969|DRUG|placebo|
214511180|NCT03656822|DIAGNOSTIC_TEST|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
214511181|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
214511182|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
215112831|NCT05082246|OTHER|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
214426561|NCT00592813|BEHAVIORAL|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
214426562|NCT00592813|BEHAVIORAL|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
214426563|NCT05654467|BIOLOGICAL|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
214511183|NCT03656822|DIAGNOSTIC_TEST|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
214426564|NCT05654467|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
214426565|NCT01587053|OTHER|therapeutic education program|
214426566|NCT05579106|DEVICE|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
214426567|NCT05579106|DEVICE|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
214426568|NCT05579106|OTHER|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
214426569|NCT03875963|OTHER|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
214426570|NCT01224015|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
214511184|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
214511185|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
214511186|NCT00213317|PROCEDURE|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
214511187|NCT01532609|BEHAVIORAL|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
215112832|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
214426571|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
214426572|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
214426573|NCT04877067|BIOLOGICAL|Wharton jelly derived mesenchymal stem cell|WJ-MSC
214511188|NCT01118156|OTHER|Education|75-minute training teaching utilization of new standardized suicide nomenclature
214511189|NCT05645445|DEVICE|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
214511190|NCT02607176|DRUG|Heweizhixie capsule|3 #, Tid, Oral for 3 days
214426574|NCT04877067|DEVICE|Repetitive electromagnetic stimulation|rEMS
214426575|NCT05920642|DRUG|Intrathecal morphine administration|Administration of morphine into the spinal canal.
215112833|NCT05600244|PROCEDURE|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
215112834|NCT05600244|PROCEDURE|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
215112835|NCT05600244|PROCEDURE|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
215112836|NCT01035619|DRUG|moxidectin|Single Dose Moxidectin 4 mg
215112837|NCT03781778|OTHER|Dietary Intervention (resistant starch)|Eat foods with resistant starch
215112838|NCT03781778|OTHER|Dietary Intervention (regular starch)|Eat foods with regular corn starch
215112839|NCT03781778|OTHER|Questionnaire Administration|Ancillary studies
215112840|NCT00255788|DRUG|everolimus|
214426576|NCT05920642|DRUG|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
215112841|NCT02287467|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
215112842|NCT02287467|BIOLOGICAL|Placebo for IVIG|Administered IV as 500 mL of normal saline
214426577|NCT02646358|DRUG|Vepoloxamer|
214426578|NCT03436277|DRUG|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
214426579|NCT03436277|DIETARY_SUPPLEMENT|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
214426580|NCT03423277|DEVICE|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
214426581|NCT04410510|DRUG|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
214426582|NCT04410510|OTHER|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
214426583|NCT00712335|DRUG|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
214426584|NCT00712335|DRUG|Montelukast|PO 10 mg QHS for 3 weeks
214426585|NCT00712335|DRUG|Salmeterol|DPI 50mg BID for 3 weeks
214426586|NCT03738111|DRUG|TG02 Citrate|TG02 citrate capsules
214426587|NCT01996917|DEVICE|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
214511191|NCT05843526|DEVICE|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
215112843|NCT00909506|DRUG|Placebo|"Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day)."
214426588|NCT03401112|DRUG|IMR-687|Oral administration of IMR-687 once daily with or without HU.
214426589|NCT03401112|DRUG|Placebo|Oral administration of placebo once daily with or without HU.
214426590|NCT05777317|DEVICE|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
214426591|NCT05777317|OTHER|CMM alone|Conventional medical management alone
214426592|NCT04676321|OTHER|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
214426593|NCT02648503|DRUG|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
214426594|NCT02648503|DRUG|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
214426595|NCT04692909|DEVICE|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
214426596|NCT03475316|BEHAVIORAL|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
214426597|NCT03475316|BEHAVIORAL|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
214426598|NCT03131037|BIOLOGICAL|CAN-2409 + valacyclovir|CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
214426599|NCT03352024|OTHER|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
214426600|NCT03352024|OTHER|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
214426601|NCT00424645|DRUG|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
214426602|NCT00424645|DRUG|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
214426603|NCT01622413|PROCEDURE|joimax TESSYS|Transforaminal Endoscopic Surgery System
214511192|NCT01245998|DRUG|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
214511193|NCT01245998|DRUG|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
214511194|NCT03618888|OTHER|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
215112844|NCT00909506|DRUG|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks."
215112845|NCT00909506|DRUG|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day)."
215112846|NCT05189119|DIAGNOSTIC_TEST|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
214426604|NCT01622413|PROCEDURE|Microdiscectomy|Standard procedure for disc surgery
214426605|NCT00142285|DRUG|Zinc sulphate (20 mg)|
214426606|NCT05235698|PROCEDURE|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
214426607|NCT05235698|PROCEDURE|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
214426608|NCT03946046|PROCEDURE|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
214426609|NCT03946046|PROCEDURE|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
214426610|NCT05142878|DEVICE|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
214426611|NCT05298020|DRUG|Envafolimab|400mg,sc,d1,Q4W
214426612|NCT05298020|DRUG|Endostar|210mg，CIV72h，d1-3，Q4W
214426613|NCT05298020|DRUG|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
214426614|NCT05298020|DRUG|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
214426615|NCT05035303|PROCEDURE|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
214426616|NCT02799134|DRUG|Dexamethasone|
214426617|NCT02799134|DRUG|Vitamin C|
214426618|NCT03675256|BIOLOGICAL|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
214511195|NCT03618888|OTHER|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
215112847|NCT03647826|BEHAVIORAL|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
215112848|NCT05435664|BEHAVIORAL|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
215112849|NCT00988988|DRUG|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
214426619|NCT03675256|BIOLOGICAL|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
214426620|NCT03675256|BIOLOGICAL|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
215112850|NCT00988988|DRUG|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
215112851|NCT00988988|DRUG|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
215112852|NCT05715164|DEVICE|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
215112853|NCT05715164|DRUG|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
215112854|NCT05715164|OTHER|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
215112855|NCT00756249|DRUG|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
215112856|NCT00756249|DRUG|Placebo|Vials with solution for IV infusion
215112857|NCT06206525|OTHER|Initial insulin dosing using the calculator|Participants will receive initial insulin doses by the calculator on hospital admission.
215112858|NCT00024180|DRUG|romidepsin|
214426621|NCT02555215|DRUG|dimethyl fumarate|administered orally
214426622|NCT03148600|BEHAVIORAL|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
214426623|NCT03148600|OTHER|Standard arm|Standard medical and nursing care
214426624|NCT05407571|BEHAVIORAL|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
214426625|NCT00529789|DRUG|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
214426626|NCT03806348|PROCEDURE|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
214511196|NCT02405000|OTHER|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
214511197|NCT03161665|OTHER|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
214511198|NCT04180072|DRUG|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
214511199|NCT04180072|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
215112859|NCT00900666|DRUG|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
214511200|NCT05917756|OTHER|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
214511201|NCT05917756|OTHER|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
214511202|NCT05121376|GENETIC|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
214426627|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
214426628|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
214426629|NCT00368186|BIOLOGICAL|Pneumo 23|
214426630|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
214426631|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
214426632|NCT05221736|PROCEDURE|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
214426633|NCT04476810|DEVICE|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
214426634|NCT03212079|BEHAVIORAL|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
214426635|NCT03212079|BEHAVIORAL|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
214426636|NCT00401206|DRUG|dexmedetomidine|
214426637|NCT04236973|DEVICE|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
215112860|NCT00900666|DRUG|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
215112861|NCT02807207|DRUG|A: pacritinib|Treatment A
215112862|NCT02807207|OTHER|B: Placebo|Treatment B
215112863|NCT02807207|DRUG|C: moxifloxacin|Treatment C
215112864|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.
214426638|NCT04236973|OTHER|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
214426639|NCT02697201|DRUG|Intralipid|0.55 ml/kg/h
214426640|NCT02697201|DRUG|Saline|0.55 ml/kg/h for
214511203|NCT05121376|GENETIC|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
214511204|NCT05121376|GENETIC|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
214511205|NCT05121376|GENETIC|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
214511206|NCT05121376|GENETIC|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
214511207|NCT05121376|GENETIC|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
214511208|NCT05121376|GENETIC|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
214511209|NCT01070199|BEHAVIORAL|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
215112865|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in controls|Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.
214426641|NCT02025257|OTHER|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
215112866|NCT05421208|DIAGNOSTIC_TEST|Effect on inflammation after chronic PNS stimulation|Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
215112867|NCT03472950|DRUG|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
215112868|NCT03472950|DRUG|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
215112869|NCT05829109|DRUG|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~* Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~* Step 2: Bowel preparation with 10 ounces of magnesium citrate.~* Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
214426642|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
214426643|NCT04470258|DEVICE|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
214426644|NCT03389191|DRUG|Acyclovir|
214426645|NCT03411291|DEVICE|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
214426646|NCT02896699|BEHAVIORAL|PrEP Intervention Group|
214426647|NCT02896699|OTHER|Control Group|
214426648|NCT01820182|DEVICE|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
214426649|NCT06175572|DEVICE|coronary physiological indices|coronary physiological indices
214426650|NCT00959946|DRUG|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
214426651|NCT00959946|DRUG|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
214426652|NCT02866435|DRUG|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
214426653|NCT02866435|DRUG|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
214426654|NCT02866435|DRUG|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
214426655|NCT02154217|DRUG|Bimatoprost|
214426656|NCT02154217|DRUG|Latanoprost/Timolol|
214511210|NCT01070199|BEHAVIORAL|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
215112870|NCT02608463|BEHAVIORAL|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
215112871|NCT02608463|BEHAVIORAL|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
215112872|NCT02608463|BEHAVIORAL|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
214426657|NCT06199323|BEHAVIORAL|Routine rehabilitation training|"1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
214426658|NCT06199323|BEHAVIORAL|Swallowing rehabilitation training|"1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week."
214426659|NCT06199323|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
214426660|NCT05288868|OTHER|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
214426661|NCT02348658|DRUG|TAK-536TCH|TAK-536TCH tablets
214426662|NCT04777968|DRUG|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
214426663|NCT01202955|DRUG|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
214426664|NCT01202955|DRUG|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
214426665|NCT04324333|BEHAVIORAL|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
214426666|NCT00223535|BEHAVIORAL|Cognitive Remediation|
214426667|NCT00223535|BEHAVIORAL|Social Skills Training|
214426668|NCT04782635|DEVICE|mobile based application|Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
214426669|NCT04782635|BEHAVIORAL|Pamphlet|A pamphlet which will be provide knowledge to the patients
214426670|NCT04592393|DIAGNOSTIC_TEST|Abbreviated PB MRI|Annual non-contrast PB MRI.
214426671|NCT04592393|GENETIC|Gene mutation test|K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
214426672|NCT04592393|DIAGNOSTIC_TEST|Conventional follow-up|Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
214426673|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
214511211|NCT01070199|BEHAVIORAL|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
214426674|NCT05675150|BEHAVIORAL|Expressive Arts-Based Intervention|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflection and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in intervention may seek meaning, clarity, insight and healing.
214426675|NCT00988975|PROCEDURE|Insertion of pelvicol graft|Pelvicol graft
214426676|NCT00813059|DRUG|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
214426677|NCT01860820|DEVICE|Geko device|
214426678|NCT06405880|OTHER|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
214426679|NCT01993160|DRUG|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
214426680|NCT01993160|RADIATION|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
214426681|NCT01993160|RADIATION|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
214426682|NCT05028673|DRUG|Lu AG06466 Capsule|Hard capsule
214426683|NCT05028673|DRUG|Lu AG06466 Tablet|Film-coated tablet
214426684|NCT05028673|DRUG|Antacid|Oral suspension
214426685|NCT02115139|DRUG|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
214426686|NCT03982303|DRUG|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
214426687|NCT04783168|OTHER|Best Practice|Receive usual care
214426688|NCT04783168|OTHER|Health Promotion and Education|Install and use Fitbit app
214426689|NCT04783168|OTHER|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
214426690|NCT04783168|OTHER|Quality-of-Life Assessment|Ancillary studies
214426691|NCT04783168|OTHER|Questionnaire Administration|Ancillary studies
214426692|NCT01736891|DRUG|Rasagiline|Tablets, qd
214426693|NCT01736891|DRUG|Placebo|Tablets, qd
214426694|NCT00841633|DRUG|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
214426695|NCT01909778|DRUG|BI 201335|single oral doses
214426696|NCT06513455|DRUG|Irinotecan liposome（40mg/m2）|irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
214426697|NCT06513455|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
214426698|NCT06513455|DRUG|Gemcitabine|gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
214426699|NCT06513455|DRUG|Irinotecan Liposome（60mg/m2）|irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
214426700|NCT05261815|OTHER|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
214426701|NCT05261815|OTHER|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
214426702|NCT04088123|DRUG|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
214426703|NCT06456255|DRUG|Sensorcaine with Epinephrine|The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.
214426704|NCT06456255|OTHER|Sham injection|Punctures without any medication injected onto the septum
214426705|NCT06480812|DIETARY_SUPPLEMENT|Synbiotic|"The proposed protocol will provide a simple but robust intervention study using a synbiotic (pre and probiotic combination) in order to improve our understanding of the mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.~This pilot study will comprise a controlled randomised intervention in which participants will be grouped into the active synbiotic arm or the control arm. The ratios will be 10g of the prebiotic supplement and 170ml of kefir. Randomisation will control for equal distribution of age and biological sex; characteristics that may confound between group comparisons and will be assessed by analysis of baseline data."
214426706|NCT04231721|DEVICE|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
214426707|NCT05750823|DRUG|Ruxolitinib Cream|Ruxolitinib cream will be applied twice daily for upto 48 weeks
215112873|NCT02608463|BEHAVIORAL|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
215112874|NCT02608463|BEHAVIORAL|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
214511212|NCT01070199|BEHAVIORAL|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
214511213|NCT05187520|DEVICE|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
214511214|NCT05187520|DRUG|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
214426708|NCT06357143|OTHER|REMOVE|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
214426709|NCT06357143|OTHER|CONTROL|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
214426710|NCT03687892|DEVICE|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
214426711|NCT03687892|DEVICE|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
214426712|NCT04783610|OTHER|Ethanol|Ethanol will be administered via oral route.
214511215|NCT04361617|BEHAVIORAL|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
214511216|NCT00930644|DRUG|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
214511217|NCT04300764|BEHAVIORAL|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
214511218|NCT02416349|OTHER|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
214511219|NCT02416349|OTHER|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
214511220|NCT03260270|DIAGNOSTIC_TEST|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
214511221|NCT04214808|DRUG|AD-208|Dutasteride 0.2mg
214511222|NCT04214808|DRUG|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
214511223|NCT03199495|OTHER|electroacupuncture|acupuncture needle with TENS device
214511224|NCT05798065|PROCEDURE|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
214511225|NCT01974258|DRUG|Cobimetinib|Escalating dose
214511226|NCT01974258|DRUG|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
214511227|NCT01974258|DRUG|Onartuzumab|Administered by IV infusion every 2 weeks
214511228|NCT01974258|DRUG|Vemurafenib|Orally administered twice daily
214511229|NCT01193205|BEHAVIORAL|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
214511230|NCT03082313|BEHAVIORAL|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
215112875|NCT02608463|BEHAVIORAL|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
214511231|NCT05996315|OTHER|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
214511232|NCT05996315|OTHER|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
214426713|NCT02471755|DEVICE|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
214426714|NCT02471755|DEVICE|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
214426715|NCT01591733|DRUG|FOLFIRINOX|Up to Eight-14 day cycles
214426716|NCT01591733|DRUG|Capecitabine|Orally, for 10 days
214511233|NCT05765331|DEVICE|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
214426717|NCT01591733|RADIATION|Short Course Radiation|Five or ten days
214426718|NCT01591733|PROCEDURE|Surgery|1-4 weeks after completion of capecitabine therapy
214426719|NCT05682183|BEHAVIORAL|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
214426720|NCT05682183|OTHER|Treatment as usual|Care management from assigned care manager
214426721|NCT03666403|PROCEDURE|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
214426722|NCT03666403|PROCEDURE|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
214511234|NCT02116075|PROCEDURE|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
214511235|NCT02116075|PROCEDURE|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
214511236|NCT01752959|DRUG|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
214511237|NCT01752959|DRUG|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
214511238|NCT01918033|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
214511239|NCT01918033|DRUG|Placebo|Matching placebo to desloratadine 5 mg tablets
214511240|NCT02311413|DRUG|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
214511241|NCT02311413|DRUG|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
214511242|NCT05279066|DEVICE|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
215112876|NCT02608463|DEVICE|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
214426723|NCT03666403|PROCEDURE|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
214426724|NCT04520490|BEHAVIORAL|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
214426725|NCT04520490|DRUG|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
214426726|NCT04520490|DRUG|Placebo|Weekly placebo injections
214426727|NCT06221046|DRUG|Control (Standard treatment)|Patients in the control arm will be treated with a standard zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
214426728|NCT06221046|OTHER|Novel Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
215112877|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 16mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
215112878|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 8mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
215112879|NCT06519604|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU
215112880|NCT03071822|DRUG|cisplatin|PIGLETs
215112881|NCT03071822|DRUG|ifosfamide|PIGLETs
215112882|NCT03071822|DRUG|gemcitabine|PIGLETs
214426729|NCT05927935|OTHER|Supervised strength exercise intervention|A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.
214426730|NCT05927935|OTHER|Minimal educational intervention (usual care)|Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, patients will receive a referral for physiotherapy and supplementary a minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like.
214426731|NCT06086925|DRUG|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
214426732|NCT05019144|PROCEDURE|Face-to-face burn care|If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.
214426733|NCT05019144|PROCEDURE|Telemedicine enhanced burn care|Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
214426734|NCT05868122|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
214426735|NCT05868122|DRUG|Placebo|Placebo will be administered orally.
214426736|NCT03618654|DRUG|Metformin|Given PO
214426737|NCT03618654|BIOLOGICAL|Durvalumab|Given IV
214426738|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
214426739|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
214426740|NCT05839873|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
214426741|NCT05245786|BIOLOGICAL|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
214426742|NCT05245786|PROCEDURE|Imaging Technique|Undergo imaging
214426743|NCT06261398|BEHAVIORAL|BETTER: motivational interviewing and text messaging|Motivational interviewing to encourage individuals to address their social needs and engage with text messages that allow individuals to connect to their care team, a local organization that can help them address their social needs, and/or a resource that enables them to find help to address their needs based on their zip code.
214426744|NCT06261398|BEHAVIORAL|Standard of care|No motivational interviewing or text messages will be provided.
214426745|NCT04834414|BIOLOGICAL|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
214426746|NCT04834414|BIOLOGICAL|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
214426747|NCT03893487|DRUG|Fimepinostat|Fimepinostat capsules
214426748|NCT03893487|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214426749|NCT06229392|BIOLOGICAL|Fluzone Quadrivalent|Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu
214426750|NCT06342778|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study under fed conditions
214426751|NCT06342778|DRUG|Diclectin|A single dose of R or T drug in each of 2 periods of the study under fed conditions
214426752|NCT05323734|DRUG|Ganaxolone|GNX will be administered
214426753|NCT05323734|DRUG|Placebo|Placebo will be administered
214426754|NCT02281838|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
214426755|NCT04975048|DIETARY_SUPPLEMENT|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
214426756|NCT04975048|DIETARY_SUPPLEMENT|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
214426757|NCT04541914|DIAGNOSTIC_TEST|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
214426758|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
214426759|NCT05930041|PROCEDURE|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
214426760|NCT05930041|PROCEDURE|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
214511243|NCT06269731|BEHAVIORAL|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
214511244|NCT01338506|BEHAVIORAL|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
214511245|NCT00529204|DRUG|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
215112883|NCT03071822|DRUG|L-asparaginase|PIGLETs
215112884|NCT03071822|DRUG|etoposide|PIGLETs
214511246|NCT03810170|BEHAVIORAL|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
215112885|NCT03071822|DRUG|dexamethasone|PIGLETs
215112886|NCT05187039|OTHER|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
215112887|NCT00517361|DRUG|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
215112888|NCT00517361|DRUG|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
215112889|NCT00894868|DRUG|vildagliptin|
215112890|NCT00894868|DRUG|placebo of vildagliptin|
215112891|NCT01156103|BEHAVIORAL|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
214511247|NCT03810170|OTHER|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
214426761|NCT05431192|BEHAVIORAL|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
214426762|NCT05431192|OTHER|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
214426763|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
214426764|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
215112892|NCT00669708|DEVICE|cooling compound (ph5 Eucerin)|application twice daily to the skin
214426765|NCT05548621|OTHER|Decision aid|Online interactive decision aid for RCC
214426766|NCT05562271|RADIATION|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
214426767|NCT05562271|RADIATION|sham radiation therapy|sham radiation therapy to involved knee joint
214426768|NCT06312618|DRUG|Propofol|"After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) ."
214426769|NCT06312618|DRUG|Dexmedetomidine|After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
214426770|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by local anesthesia during treatments|Patients were divided according to the randomization procedure. infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
214511248|NCT00427440|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
214511249|NCT00427440|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
215112893|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
215112894|NCT02898896|BIOLOGICAL|blood test|Additional 21 ml of blood will be collected
215112895|NCT04364360|DIETARY_SUPPLEMENT|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
215112896|NCT04064060|DRUG|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
215112897|NCT00195091|DRUG|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
215112898|NCT02466763|PROCEDURE|Cochlear implant surgery|Surgical placement of a cochlear implant device.
215112899|NCT00856765|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
215112900|NCT00856765|DEVICE|Bare metal stent|Bare metal stent
215112901|NCT00856765|DEVICE|Drug eluting stent|Paclitaxel eluting stent
215112902|NCT00945256|OTHER|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
215112903|NCT00945256|DRUG|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
215112904|NCT00945256|DIETARY_SUPPLEMENT|Amino Acid Drink|7.5 gram Amino Acid drink
215112905|NCT05413161|BIOLOGICAL|ADL-018|150 mg/mL, Solution for injection in PFS
215112906|NCT05413161|BIOLOGICAL|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
215112907|NCT05413161|BIOLOGICAL|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
215112908|NCT01814475|DRUG|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
215112909|NCT01814475|DRUG|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
215112910|NCT06330168|DRUG|bupivacaine-calcitonin-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml).
215112911|NCT06330168|DRUG|Bupivacaine-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
214426771|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by topical anesthesia during treatments|Patients were divided i according to the randomization procedure. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
214426772|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by the application of rubber dam during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
214511250|NCT03072303|OTHER|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
214511251|NCT02695199|PROCEDURE|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
215112912|NCT05468437|BEHAVIORAL|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
214511252|NCT02695199|PROCEDURE|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
214511253|NCT03878966|DEVICE|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
214511254|NCT01857999|DRUG|Losartan|
214511255|NCT01857999|DRUG|Placebo|
214511256|NCT02246699|DEVICE|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
214511257|NCT02246699|OTHER|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
214511258|NCT01402518|PROCEDURE|Per-oral enodscopic myotomy|
214511259|NCT01702259|DEVICE|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
214511260|NCT01702259|DEVICE|Placebo device|Inactive Erchonia GLS.
215112913|NCT05788094|DRUG|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
215112914|NCT05788094|DRUG|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
215112915|NCT05788094|DRUG|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
214511261|NCT05012462|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value.
214511262|NCT05012462|DEVICE|CM-1600|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors Bioelectrical Impedance, Photoplethysmography (PPG) Amplitude, ECG Amplitude and Skin Temperature. A combination of these parameters is represented by a single number known as the Relative Index value.
214426773|NCT06779448|OTHER|Evaluation of the objective and subjective stress parameters caused by the application of cotton rolls during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
214426774|NCT04426786|OTHER|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
214426775|NCT04426786|OTHER|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
214426776|NCT06779188|DEVICE|Transcranial Magnetic Stimulation|TMS (in the form of theta burst stimulations) will be delivered over Supplementary Motor Area while the subject is seated in the Treatment group. TMS is capable to induce neuroplastic facilitatory changes in the brain that last beyond the duration of stimulation. TMS will be delivered once daily, 5 days per week, for 4 weeks.
214426777|NCT06779188|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS will be delivered in the sham group using a sham coil once daily, 5 days per week, for 4 weeks.
214426778|NCT05697497|BEHAVIORAL|Daily exercise intervention|Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
214426779|NCT02486718|DRUG|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
215112916|NCT05370014|BEHAVIORAL|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
214511263|NCT04666181|BEHAVIORAL|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
214511264|NCT06510244|DEVICE|EEG EMOTIV|The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
215112917|NCT03667092|BIOLOGICAL|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
214426780|NCT02486718|DRUG|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
214426781|NCT02486718|DRUG|Vinorelbine|Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
214426782|NCT02486718|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
214426783|NCT02486718|DRUG|Gemcitabine|Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
214426784|NCT02486718|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
214426785|NCT04795128|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
214426786|NCT05848583|OTHER|Compleat 1.5|EN Formula
214426787|NCT05924412|DRUG|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
214511265|NCT01669356|OTHER|Parenteral supplement with enteral nutrition for patients after esophagectomy|
215112918|NCT02627989|DRUG|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
214426788|NCT05924412|OTHER|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
214426789|NCT00518726|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
215112919|NCT02627989|DRUG|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
214426790|NCT04288219|DEVICE|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
214511266|NCT01669356|OTHER|Enteral Nutrition alone for patients after esophagectomy|
214511267|NCT06499142|DEVICE|Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.|"The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line."
215112920|NCT00245037|BIOLOGICAL|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
215112921|NCT00245037|DRUG|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
215112922|NCT00245037|DRUG|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~\- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
215112923|NCT00245037|DRUG|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments."
215112924|NCT00245037|DRUG|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
214426791|NCT04288219|DRUG|Nifedipine|Nifedipine 30mg, Pharmacotherapy
214426792|NCT04288219|OTHER|supplemental oxygen|supplemental oxygen
214426793|NCT02608528|RADIATION|[18F]fluoroglucose(FDG)|
214511268|NCT00644566|OTHER|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
214511269|NCT06088576|OTHER|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
214511270|NCT01846715|BIOLOGICAL|Implantation of SRC|
214511271|NCT01540591|DRUG|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
214426794|NCT03806751|DRUG|[O-15]Water|All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
214426795|NCT03806751|DRUG|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
214426796|NCT02248480|DRUG|Duloxetine|Administered orally
214426797|NCT02248480|DRUG|Placebo|Administered orally
214426798|NCT01595321|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
214511272|NCT01540591|DRUG|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
214426799|NCT01595321|BIOLOGICAL|GVAX Pancreas Vaccine|GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
214426800|NCT01595321|RADIATION|Stereotactic Body Radiation|"Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX."
214511273|NCT05870085|BEHAVIORAL|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
214511274|NCT05760950|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
214511275|NCT03195803|BEHAVIORAL|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
214511276|NCT02417285|DRUG|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
214511277|NCT02417285|DRUG|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
214511278|NCT05224232|DEVICE|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
214511279|NCT05224232|DEVICE|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
214511280|NCT05323032|DEVICE|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
214511281|NCT04775537|DEVICE|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
214511282|NCT03259568|DEVICE|Repetitive TMS|1-10 Hertz rTMS will be administered
214511283|NCT00234000|DRUG|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
214511284|NCT00234000|DRUG|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
214511285|NCT03136861|BIOLOGICAL|AIN457|anti IL-17a monoclonal antibody
214511286|NCT03136861|DRUG|AIN457 Placebo|Placebo matching AIN457
214511287|NCT03855384|DRUG|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
214511288|NCT03855384|DRUG|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
214511289|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
214511290|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
214511291|NCT00982527|DRUG|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
214511292|NCT00982527|DRUG|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
214511293|NCT02346357|PROCEDURE|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
215112925|NCT00245037|PROCEDURE|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
215112926|NCT00245037|RADIATION|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
214511294|NCT02346357|DRUG|Ropivacaine|
214511295|NCT02346357|DRUG|Placebo Saline|
214511296|NCT06142799|PROCEDURE|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
214511297|NCT06091709|OTHER|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
214511298|NCT06091709|OTHER|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
214511299|NCT04136990|PROCEDURE|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
214511300|NCT04136990|PROCEDURE|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
214511301|NCT02417350|OTHER|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
214511302|NCT02417350|OTHER|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
214511303|NCT03150758|DEVICE|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
214511304|NCT03150758|DEVICE|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
214511305|NCT03150758|DEVICE|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
214511306|NCT03150758|DEVICE|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
214511307|NCT02696200|DEVICE|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
214511308|NCT05729386|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
215112927|NCT00245037|DRUG|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
215112928|NCT00245037|DRUG|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
215112929|NCT00245037|DRUG|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
214426801|NCT01595321|DRUG|FOLFIRINOX|"FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus."
214426802|NCT03213249|OTHER|Normal saline|Intraoperative pocket irrigation with normal saline
214426803|NCT03213249|DRUG|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
214426804|NCT03213249|PROCEDURE|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
214426805|NCT03213249|PROCEDURE|Bilateral skin- or nipple-sparing mastectomies|Standard of care
214511309|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
214511310|NCT05729386|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
214511311|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
214511312|NCT05277285|DRUG|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
214511313|NCT05205213|OTHER|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
214511314|NCT05394636|OTHER|None, pure observational study|None, pure observational study
214511315|NCT01235936|DRUG|AKB-6548|Different dose levels
214511316|NCT02359916|OTHER|Time delays on delivery of less healthy snacks|
214511317|NCT02359916|OTHER|25%/$0.25 discount on healthy snacks|
214511318|NCT02359916|OTHER|25%/$0.25 tax on less healthy snacks|
214426806|NCT03213249|DEVICE|Tissue expander|Standard of care
214426807|NCT03213249|DEVICE|Breast implant|"* Standard of care~* Either breast implant or autologous flap"
214426808|NCT03213249|PROCEDURE|Autologous flap|"* Standard of care~* Either breast implant or autologous flap"
214426809|NCT03213249|OTHER|Acellular dermal matrix sling|Standard of care
214426810|NCT03213249|DRUG|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
214511319|NCT04454476|DRUG|Trametinib treatment|1 mg taken by mouth once a day for 14 days
215112930|NCT04658043|OTHER|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
214426811|NCT03213249|DRUG|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
214426812|NCT01638611|DRUG|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
214426813|NCT01638611|DRUG|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
214511320|NCT04454476|PROCEDURE|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
214511321|NCT03398798|DEVICE|".014"|".014 CuNiTi orthodontic arch wire"
214511322|NCT03398798|DEVICE|".016"|".016 CuNiTi orthodontic arch wire"
214511323|NCT03398798|DEVICE|Twin brackets|Ormco Insignia Metal Twin brackets
214511324|NCT03398798|DEVICE|Self-ligating brackets|Ormco Insignia SL brackets
214511325|NCT01847859|PROCEDURE|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
214511326|NCT03200574|DIAGNOSTIC_TEST|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
214511327|NCT03200574|DEVICE|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
214511328|NCT04508777|BEHAVIORAL|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
214511329|NCT04266496|OTHER|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
214511330|NCT04266496|DIAGNOSTIC_TEST|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
214511331|NCT04266496|DIAGNOSTIC_TEST|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
214511332|NCT04266496|DIAGNOSTIC_TEST|Blood sample|Blood collection to measure plasma sodium and osmolality.
214511333|NCT04266496|DIAGNOSTIC_TEST|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
214426814|NCT04978935|OTHER|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
214426815|NCT01641913|OTHER|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
214426816|NCT02602106|BEHAVIORAL|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
214426817|NCT01533519|DRUG|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
214426818|NCT04504916|DRUG|Zilovertamab vedotin|Intravenous infusion
214426819|NCT02950896|OTHER|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
214426820|NCT00687388|DRUG|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
214426821|NCT00687388|DRUG|celecoxib|200mg daily for 8 weeks
214426822|NCT00687388|DRUG|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
214426823|NCT03371966|DIETARY_SUPPLEMENT|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
214426824|NCT03371966|DIETARY_SUPPLEMENT|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
214426825|NCT03726268|DRUG|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
214426826|NCT03726268|DRUG|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
214426827|NCT03726268|DRUG|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
214426828|NCT03726268|DRUG|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
214426829|NCT03726268|DRUG|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
214426830|NCT01334320|PROCEDURE|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
214426831|NCT05026086|OTHER|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
214426832|NCT05026086|OTHER|isometric exercises|10 patients will be treated with isometric exercises
214426833|NCT02238210|DRUG|Atrovent®|
214426834|NCT02884544|DRUG|HLD100|Treatment
214426835|NCT01714882|BEHAVIORAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
214426836|NCT01714882|BEHAVIORAL|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
214426837|NCT00373529|DRUG|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
214426838|NCT00381173|DRUG|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
214426839|NCT02951013|OTHER|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
214426840|NCT02951013|OTHER|liberal transfusion|
214426841|NCT01600729|DRUG|No Intervention|No intervention.
214426842|NCT01227876|DRUG|Ster|prednisolone 1% ophthalmic suspension
214426843|NCT01227876|DRUG|Pred Fort|prednisolone 1% ophthalmic suspension
214426844|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
214426845|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
214426846|NCT04605016|DEVICE|Hydrophilic surface implants|A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
214426847|NCT04605016|DEVICE|Hydrophobic surface implants|A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
214426848|NCT04826575|OTHER|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
214426849|NCT06334549|DRUG|Ephedrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
214426850|NCT06334549|DRUG|Phenylephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
215112931|NCT00003512|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215112932|NCT04786795|DRUG|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
215112933|NCT04786795|DRUG|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
215112934|NCT04438317|PROCEDURE|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
215112935|NCT04438317|PROCEDURE|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
214511334|NCT00838994|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
214511335|NCT06405906|OTHER|Fat-free diet|The low-fat diet will consist of instructions to avoid fatty foods.
215112936|NCT04734067|OTHER|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
215112937|NCT03031366|OTHER|3d roadmap guidance|TIPS was established using 3d roadmap
215112938|NCT03031366|OTHER|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
215112939|NCT02246426|OTHER|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
215112940|NCT02246426|OTHER|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
214426851|NCT06334549|DRUG|Norepinephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
214426852|NCT06334549|DRUG|Ephedrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
214511336|NCT06405906|OTHER|Balanced WHO diet|The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
214511337|NCT00364988|DRUG|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
214511338|NCT00364988|DRUG|losartan|losartan (100 mg daily)
214511339|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
214511340|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
215112941|NCT03604796|DRUG|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
214511341|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
214511342|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
215112942|NCT03604796|DRUG|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
215112943|NCT00032981|BEHAVIORAL|Behavior Therapy|
215112944|NCT00684775|COMBINATION_PRODUCT|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
214511343|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
214511344|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
214511345|NCT04183491|BIOLOGICAL|Placebo|Placebo (administered either IM or SC)
214511346|NCT04296734|BEHAVIORAL|Mothers and Babies|Mothers \& Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers \& Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
215112945|NCT01124279|DRUG|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
215112946|NCT05906433|DRUG|Kenalog with bupivacaine Injection|Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
215112947|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
215112948|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
215112949|NCT05376176|DRUG|Placebo (Vehicle) BID|Placebo (vehicle) BID
215112950|NCT02845323|DRUG|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
214426853|NCT06334549|DRUG|Phenylephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
214426854|NCT06334549|DRUG|Norepinephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
214426855|NCT02771938|OTHER|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
214426856|NCT04576858|DIAGNOSTIC_TEST|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
214426857|NCT00327665|BIOLOGICAL|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
215028608|NCT02398019|DEVICE|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
214426858|NCT00327665|BIOLOGICAL|Pneumo 23™|Single-dose intramuscular injection.
214426859|NCT00327665|BIOLOGICAL|Placebo|1 intramuscular injection.
214426860|NCT00327665|BIOLOGICAL|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
214426861|NCT06974292|DRUG|[14C]VC005|Take a suspension of 50 mg VC005 ,containing about 120 μCi \[14C\]VC005, in fasting within 5 minutes
214426863|NCT06266455|DIETARY_SUPPLEMENT|Standardized Fortification|Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
214426864|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
214426865|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
214426866|NCT04382963|OTHER|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
214511347|NCT02221778|RADIATION|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
214511348|NCT04003792|DRUG|oxaliplatin|intra-arterial oxaliplatin administration
214511349|NCT04003792|DRUG|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
214426867|NCT04382963|OTHER|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
214426868|NCT04382963|OTHER|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
214426869|NCT06174636|PROCEDURE|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
214426870|NCT03956004|OTHER|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
214426871|NCT03956004|OTHER|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
214426872|NCT06575413|OTHER|Direct Electrical Stimulation|The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.
214426873|NCT01579916|BIOLOGICAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
214426874|NCT01579916|OTHER|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
214426875|NCT03950609|DRUG|Everolimus|Given PO
214426876|NCT03950609|DRUG|Lenvatinib|Given PO
214426877|NCT06974305|RADIATION|FDG-PET/fMRI/EEG imaging|Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
214511350|NCT04003792|DRUG|Bevacizumab|systemic bevacuzimab therapy
214511351|NCT01122134|DRUG|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
214511352|NCT01262456|DRUG|Desmopressin|
214511353|NCT01262456|DRUG|Placebo|
214511354|NCT03407976|DRUG|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
214511355|NCT03407976|DRUG|Pembrolizumab|200 mg Q3 weeks IV
214511356|NCT01727193|DRUG|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
214511357|NCT01727193|DRUG|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
214426878|NCT04658771|DEVICE|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
214426879|NCT06778642|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Posterior Superior Intercostal Plane Block (SPSIPB) with bupivacaine after induction and before the surgical procedure begins.
214426880|NCT06778642|PROCEDURE|Serratus Anterior Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Anterior Plane Block (SAPB) with bupivacaine after induction and before the surgical procedure begins.
214426881|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
214426882|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a.|3 months of treatment
214426883|NCT02570542|PROCEDURE|leukapheresis|
214426884|NCT02570542|DRUG|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
214426885|NCT02570542|DRUG|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
214426886|NCT02570542|PROCEDURE|Autologous Stem Cell Transplantation|
214426887|NCT06369350|DRUG|Vitamin B6 25 MG|Vitamin B6 25 mg/day will be given for up to 31 days.
214426888|NCT06369350|DRUG|Vitamin B6 50 MG|Vitamin B6 50 mg/day will be given for up to 31 days.
214426889|NCT06369350|DRUG|Vitamin B6 100 MG|Vitamin B6 100 mg/day will be given for up to 31 days.
214426890|NCT06369350|DRUG|Placebo|Placebo capsule will be given for up to 31 days.
214426891|NCT06459817|DEVICE|BB-02 therapy|Biophysical stimulation with magnetic fields
214426892|NCT05076656|DIETARY_SUPPLEMENT|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
214426893|NCT05076656|BIOLOGICAL|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
214426894|NCT05076656|DRUG|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
214426895|NCT02763124|PROCEDURE|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
214426896|NCT01981330|BIOLOGICAL|aMSC|aMSC injected into the vocal fold of the patient
214426897|NCT01981330|BIOLOGICAL|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
214426898|NCT02050724|DRUG|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
214426899|NCT02050724|DEVICE|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
214426900|NCT02050724|DEVICE|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
214426901|NCT02247063|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
214426902|NCT01123928|BEHAVIORAL|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
214426903|NCT02619266|OTHER|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
214426904|NCT02619266|OTHER|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
214426905|NCT02619266|DRUG|Megestrol Acetate|Megestrol Acetate 160mg tablet
214426906|NCT02619266|DRUG|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
214426907|NCT00290849|DRUG|Bivalirudin|
214426908|NCT00732381|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
214426909|NCT00732381|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
214426910|NCT00755118|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214426911|NCT00755118|DRUG|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214426912|NCT00755118|DRUG|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214426913|NCT00755118|DRUG|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214426914|NCT00755118|DRUG|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214426915|NCT00755118|DRUG|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
214511358|NCT02538094|DEVICE|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
214511359|NCT02538094|DEVICE|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
214511360|NCT01264874|DRUG|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
214426916|NCT00956982|DRUG|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing \< 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
215112951|NCT02845323|DRUG|Nivolumab monotherapy|Two cycles of Nivolumab alone
215112952|NCT05844475|PROCEDURE|Conventional Free Gingival Graft Approach (FGG)|Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting
214426917|NCT04090190|DRUG|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
214511361|NCT01264874|OTHER|placebo|For 3 years IU every 50 days
214511362|NCT04027452|BEHAVIORAL|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
215112953|NCT05844475|PROCEDURE|Buccal Strip Graft with a collagen matrix (bSG + CM)|A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
215112954|NCT05723471|OTHER|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
215112955|NCT05463406|OTHER|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
215112956|NCT05463406|OTHER|Usual care|Management as usual
215112957|NCT06341556|DRUG|Zanubrutinib|Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
215112958|NCT05982496|DRUG|FES|16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
215112959|NCT05982496|PROCEDURE|PET/MRI A|An additional FES PET/MRI will be performed before surgery.
214426918|NCT00390728|DRUG|Insulin Glargine|
214426919|NCT04391283|DRUG|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
215112960|NCT05982496|PROCEDURE|PET/MRI B|Two additional PET/MRI will be performed before and after induction ET.
215112961|NCT05982496|PROCEDURE|PET/MRI C|Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
215112962|NCT05982496|PROCEDURE|PET/MRI D|Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
214426920|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
214426921|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
214426922|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
215112963|NCT05982496|GENETIC|Translational analysis|Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
215112964|NCT01991236|BEHAVIORAL|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
215112965|NCT01991236|BEHAVIORAL|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
215112966|NCT00666406|DRUG|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
215112967|NCT00666406|DRUG|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
215112968|NCT02542826|OTHER|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
215112969|NCT02037334|DEVICE|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
215112970|NCT06577506|BEHAVIORAL|Deaf Diabetes Can Together|10-week diabetes self-management telehealth intervention for deaf adults with diabetes.
215112971|NCT06268964|DRUG|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
214426923|NCT00457691|DRUG|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
214426924|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
214426925|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
214426926|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
214426927|NCT00457691|DRUG|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
214426928|NCT02644239|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet with high fat (90%)
214426929|NCT02168335|OTHER|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
214426930|NCT02168335|OTHER|Sea salt|Unmedicated sea salt
214426931|NCT01252316|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
214426932|NCT01252316|OTHER|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
214426933|NCT05344300|OTHER|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
214426934|NCT00042224|PROCEDURE|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
214426935|NCT00042224|DRUG|Clozapine|Patients with psychotic symptoms will receive clozapine
214426936|NCT04316234|OTHER|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
214426937|NCT00028093|DRUG|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
214511363|NCT04027452|BEHAVIORAL|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
215028609|NCT04118426|RADIATION|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
215112972|NCT06268964|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
215112973|NCT06268964|OTHER|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
214426938|NCT00028093|DRUG|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
214426939|NCT04670419|OTHER|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
214426940|NCT05907551|OTHER|Questionnaires|25-items questionnaire
214426941|NCT05429424|OTHER|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
214426942|NCT05429424|OTHER|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
214426943|NCT05429424|OTHER|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
214426944|NCT05744206|OTHER|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
214511364|NCT00120107|DRUG|Black Tea|
215028610|NCT02346669|PROCEDURE|gastroscopy|as detailed in arm description
215112974|NCT06821620|DIETARY_SUPPLEMENT|Breakfast|Breakfast in one condition will be high carbohydrate and in the other protein enriched
214426945|NCT04628650|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
214426946|NCT03915613|DRUG|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
214426947|NCT03915613|DRUG|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
214426948|NCT01656096|DEVICE|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
215028611|NCT02346669|DRUG|Fecal Microbiota Transplantation|as detailed in arm description
215028612|NCT02346669|OTHER|high fat low fiber diet|as detailed in arm description
215028613|NCT02346669|OTHER|sham diet|as detailed in arm description
214426949|NCT01656096|OTHER|Sham procedure|
214426950|NCT05944822|OTHER|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
214426951|NCT01180153|DRUG|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
214426952|NCT04114968|OTHER|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
214426953|NCT03772379|DEVICE|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
214426954|NCT03772379|PROCEDURE|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
214426955|NCT01121549|DRUG|Aromasin|25 mg daily continuously
214426956|NCT02754999|DRUG|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
214426957|NCT03967717|OTHER|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
214426958|NCT06199648|OTHER|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
214426959|NCT01018212|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
214426960|NCT01278888|PROCEDURE|Anterolateral thoracotomy|Standard anterolateral thoracotomy
214426961|NCT01278888|PROCEDURE|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
214426962|NCT01278888|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
214426963|NCT01278888|PROCEDURE|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
214426964|NCT03210129|BEHAVIORAL|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
214426965|NCT03547804|DRUG|Apatinib|500 mg qd/250mg
214426966|NCT03547804|DRUG|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
214426967|NCT01470040|DRUG|discontinuation of aspirin therapy|discontinuation of aspirin therapy
214426968|NCT01470040|DRUG|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
214426969|NCT00012740|BEHAVIORAL|Casefinding and Referral System|
214426970|NCT03861949|OTHER|5 cmH2O CPAP|
214426971|NCT03861949|OTHER|head-up position|
214426972|NCT02403219|DRUG|Botulinum toxin type A injection|Injection of botulinum toxin type A
214426973|NCT02403219|OTHER|Saline solution injection|Injection of saline solution
215028614|NCT02346669|OTHER|low fat high fiber diet|as detailed in arm description
215028615|NCT04427345|OTHER|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
215028616|NCT00451737|DEVICE|Isokinetic test|
215028617|NCT01378195|BEHAVIORAL|CBT-based program for dementia caregivers|Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
215028618|NCT01378195|BEHAVIORAL|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
215028619|NCT00406926|DRUG|Somatropin|
214426974|NCT03055416|OTHER|Mobile Men App Prototype|Testing of app functionality
214426975|NCT02791750|OTHER|questionnary of quality of life|
214426976|NCT06401174|BEHAVIORAL|Delivery of patient navigation|Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
214426977|NCT02021760|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
214426978|NCT04414904|OTHER|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
214426979|NCT01694823|DRUG|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
214426980|NCT02315157|DRUG|Bendamustine|Given IV
214511365|NCT05785650|DIAGNOSTIC_TEST|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
214511366|NCT00053118|BIOLOGICAL|filgrastim|IV
214511367|NCT00053118|DRUG|carboplatin|IV
214511368|NCT00053118|DRUG|etoposide|IV
214511369|NCT00053118|PROCEDURE|bone marrow ablation with stem cell support|IV
214511370|NCT00053118|PROCEDURE|peripheral blood stem cell transplantation|IV
214511371|NCT03553225|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
214511372|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
214511373|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
214511374|NCT03877783|DIETARY_SUPPLEMENT|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
214511375|NCT03877783|BEHAVIORAL|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
214511376|NCT03877783|OTHER|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg."
214511377|NCT02602691|OTHER|AlloMap®|
214511378|NCT02602691|PROCEDURE|Endomyocardial biopsies|
214426981|NCT06001320|DRUG|Letermovir 480 mg once daily|We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
214426982|NCT06001320|OTHER|Historical/Control|The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
214426983|NCT05972720|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
214426984|NCT05972720|DRUG|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
214426985|NCT05972720|DRUG|firi-cel (Experimental drug)|Investigational agent
214426986|NCT03882671|DEVICE|EpiTel Epilog|EEG recording device
214426987|NCT03882671|DEVICE|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
214426988|NCT03882671|DEVICE|GENEActiv|Temperature, light level and accelerometry recording device
214426989|NCT04848909|RADIATION|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
214426990|NCT01284920|DRUG|MDV3100|oral
214426991|NCT02594813|PROCEDURE|Biopsy, cold or hot snare polypectomy, or EMR|
214426992|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
214426993|NCT06634030|DRUG|Saline|Normal saline
214426994|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
215112975|NCT02843672|PROCEDURE|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
215112976|NCT02843672|PROCEDURE|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
215112977|NCT06964165|DRUG|Niraparib|Niraparib will be administered
215112978|NCT06964165|DRUG|Carboplatin|Carboplatin will be administered
214426995|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
215112979|NCT06964165|DRUG|Paclitaxel|Paclitaxel will be administered
215112980|NCT01407757|GENETIC|DNA analysis|
215112981|NCT01407757|GENETIC|gene expression analysis|
215112982|NCT01407757|OTHER|laboratory biomarker analysis|
215112983|NCT01407757|OTHER|pharmacogenomic studies|
215112984|NCT03758534|OTHER|No intervention|This is a retrospective chart review study.
215112985|NCT03700567|OTHER|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
214426996|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
214426997|NCT04925661|DRUG|HEC53856|Either dose of HEC53856 will be administered after fasting .
214426998|NCT04925661|DRUG|Roxadustat|Roxadustat will be administered after fasting .
214426999|NCT04925661|DRUG|Placebo|Either dose of placebo will be administered after fasting .
214427000|NCT01420250|DRUG|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
214427001|NCT01420250|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
214427002|NCT01420250|DRUG|Anti-Androgen Therapy: Bicalutamide|"* Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT"
214427003|NCT01420250|GENETIC|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"* First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form"
214427004|NCT06513572|DEVICE|FlowSense|This study collects data using non-invasive devices for assessing CSF shunt flow using thermal anisotropy measurements in a prospective study setting. The study will collect data to compare measurements from flowing shunts, non-flowing shunts, and off-shunt locations.
214427005|NCT05073159|BIOLOGICAL|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
214427006|NCT04995627|DIETARY_SUPPLEMENT|Salt (NaCl)|12 grams of salt (NaCl) per day
214427007|NCT04995627|OTHER|Placebo|Placebo
214427008|NCT04816799|BEHAVIORAL|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
214427009|NCT04257409|OTHER|Physical intervention by exercise|12 week lasting exercise intervention
214427010|NCT06105333|PROCEDURE|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
214427011|NCT01366677|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
214427012|NCT01522898|PROCEDURE|AV nodal ablation|Percutaneous catheter ablation of the AV node.
214427013|NCT01522898|DRUG|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
214427014|NCT03344588|PROCEDURE|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
214427015|NCT03344588|PROCEDURE|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
214427016|NCT04993898|OTHER|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
214427017|NCT04993898|OTHER|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
214427018|NCT04143204|OTHER|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
214427019|NCT00493649|DRUG|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
214427020|NCT00493649|DRUG|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
214427021|NCT00493649|DRUG|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
214427022|NCT05053321|DRUG|Valbenazine|All participants will be treated with Valbenazine for 6 weeks.
214427023|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
214427024|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
214427025|NCT06081049|DRUG|Colchicine|0.5 mg once daily
214427026|NCT06081049|DRUG|Placebo|Once daily
214427027|NCT03086369|DRUG|Olaratumab|Administered IV
214427028|NCT03086369|DRUG|Nab-paclitaxel|Administered IV
214427029|NCT03086369|DRUG|Gemcitabine|Administered IV
214427030|NCT03086369|DRUG|Placebo|Administered IV
214427031|NCT02639286|DRUG|ISIS 304801|300 mg of ISIS 304801 administered as SC
214427032|NCT02639286|DRUG|Placebo|Placebo administered via SC
214427033|NCT05341869|PROCEDURE|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
214427034|NCT00105313|DRUG|MEDI-507|
214427035|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
215112986|NCT05730413|DRUG|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
215112987|NCT05730413|DRUG|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
214427036|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
214427037|NCT04779333|BEHAVIORAL|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
214427038|NCT04779333|BEHAVIORAL|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
214427039|NCT03594500|OTHER|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
214427040|NCT03594500|OTHER|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
214427041|NCT04297371|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
214427042|NCT02833506|OTHER|Laboratory Biomarker Analysis|Correlative studies
214427043|NCT02833506|BIOLOGICAL|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
214427044|NCT02833506|DRUG|Sirolimus|Given PO
214427045|NCT03402633|OTHER|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
214427046|NCT00767754|DRUG|Paxil CR|12 week treatment of Paxil(20-40mg)
214427047|NCT01123408|DRUG|Clozapine|500 mg/day
214427048|NCT01123408|DRUG|Olanzapine|20 mg/day
214427049|NCT01123408|DRUG|Haloperidol|20 mg/day
214427050|NCT05452759|DEVICE|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
214511379|NCT03189303|DEVICE|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
214511380|NCT05198219|DEVICE|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
215112988|NCT05905367|DRUG|Fentanyl|Symptom-inhibited IV fentanyl induction
215112989|NCT05905367|DRUG|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
214427051|NCT05452759|DEVICE|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
214427052|NCT04898140|DIAGNOSTIC_TEST|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
214427053|NCT04898140|DIAGNOSTIC_TEST|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
214427054|NCT04898140|DIAGNOSTIC_TEST|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
214511381|NCT05198219|DEVICE|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
214427055|NCT04064866|DEVICE|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
214427056|NCT04064866|OTHER|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
214427057|NCT04064866|DEVICE|ProPlaz PPC|Trademarked name of an FDA-cleared product
214427058|NCT00004423|DRUG|-aminosalicylic acid|
214427059|NCT00048217|DRUG|T-1249|
214427060|NCT00002964|DRUG|porfimer sodium|
214427061|NCT00002964|OTHER|fluorophotometry|
214427062|NCT00232349|DRUG|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
214427063|NCT04413812|BEHAVIORAL|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
214427064|NCT00069901|DRUG|CT-2103 (poly(L)glutamate-paclitaxel)|
214427065|NCT00069901|DRUG|carboplatin|
214427066|NCT04866238|DEVICE|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
214427067|NCT04866238|DEVICE|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
214427068|NCT00921154|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
214427069|NCT04630600|OTHER|No intervention|Normal waiting room without an aquarium
214427070|NCT04630600|OTHER|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
214511382|NCT02676726|PROCEDURE|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
215112990|NCT05905367|DRUG|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
215112991|NCT01546662|DIETARY_SUPPLEMENT|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
214427071|NCT04630600|OTHER|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
214427072|NCT01765543|DRUG|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
214427073|NCT01765543|DRUG|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
214511383|NCT02676726|PROCEDURE|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
215112992|NCT01546662|DIETARY_SUPPLEMENT|Placebo|1/ 2 capsules, twice daily for 12 weeks
215112993|NCT00907504|DRUG|CP-751,871|CP-751,871 20mg/kg every 3 weeks
215112994|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
215112995|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
215112996|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
215112997|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
214427074|NCT03658460|OTHER|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
214427075|NCT06041373|DEVICE|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
214427076|NCT06041373|DEVICE|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
214427077|NCT06041373|DEVICE|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
214427078|NCT03632811|OTHER|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
214427079|NCT03097679|DEVICE|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
214427080|NCT03097679|DEVICE|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
215112998|NCT04298957|PROCEDURE|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
214427081|NCT02263573|OTHER|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
214427082|NCT02263573|OTHER|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
214427083|NCT04572945|DIAGNOSTIC_TEST|kidney function test|laboratory and imaging
214427084|NCT03753308|BIOLOGICAL|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
214427085|NCT03753308|BIOLOGICAL|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
214427086|NCT05661994|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
214427087|NCT05279157|PROCEDURE|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
214427088|NCT05279157|PROCEDURE|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
214427089|NCT01074788|BEHAVIORAL|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
214427090|NCT05082636|OTHER|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
214427091|NCT02437006|OTHER|exercise|cycle ergometry
214427092|NCT04833179|BIOLOGICAL|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
214427093|NCT04833179|OTHER|placebo|placebo
214427094|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
215112999|NCT05505006|DRUG|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
214427095|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
215113000|NCT05505006|DRUG|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
214427096|NCT00746655|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
214427097|NCT00746655|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
214427098|NCT03644849|DEVICE|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
214427099|NCT03644849|OTHER|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
214427100|NCT01346254|DRUG|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
214427101|NCT01346254|DRUG|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
214427102|NCT01346254|BEHAVIORAL|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
215113001|NCT05505006|DRUG|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
214427103|NCT03305536|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
214427104|NCT04048668|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
214427105|NCT01988649|DRUG|Intranasal Oxytocin|Administration of intranasal Oxytocin
214427106|NCT01988649|DRUG|Placebo (saline)|Administration of normal saline intranasally.
214427107|NCT00989469|DRUG|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
214427108|NCT00071799|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
214427109|NCT00071799|OTHER|Physician Choice|"Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
215113002|NCT05035732|RADIATION|18F-fluciclovine|IV
214427110|NCT04072328|DRUG|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
214427111|NCT04072328|DRUG|Midazolam|midazolam with propofol
214427112|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
214427113|NCT02393001|OTHER|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
214427114|NCT02393001|OTHER|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
215113003|NCT03977103|BIOLOGICAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
215113004|NCT02732782|OTHER|Isometric exercise|
215113005|NCT02732782|OTHER|Eccentric exercise|
215113006|NCT03084003|DIETARY_SUPPLEMENT|Almonds|
215113007|NCT03084003|DIETARY_SUPPLEMENT|Graham crackers|
215113008|NCT04983355|DIETARY_SUPPLEMENT|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
215113009|NCT04983355|DIETARY_SUPPLEMENT|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
215113010|NCT05715216|DRUG|Nivolumab|Given by IV (vein)
215113011|NCT05715216|DRUG|Etigilimab|Given by IV (vein)
214427115|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
214427116|NCT00979992|OTHER|Laboratory Biomarker Analysis|Correlative studies
214427117|NCT00979992|DRUG|Sunitinib Malate|Given PO
214427118|NCT05919368|DIETARY_SUPPLEMENT|Yam pill|It consists of sweet potato, white art and ginseng
214427119|NCT05094050|DRUG|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
215113012|NCT00420069|DEVICE|MRTX device|device for ventilation
215113013|NCT02440685|DRUG|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
215113014|NCT02440685|DRUG|ASN002 RD|Recommended dose of ASN002 from Part A
214427120|NCT02623868|DRUG|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
214427121|NCT02623868|DRUG|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
214427122|NCT02623868|DRUG|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
214427123|NCT00002919|BIOLOGICAL|filgrastim|
214427124|NCT00002919|DRUG|cisplatin|
214427125|NCT00002919|DRUG|doxorubicin hydrochloride|
214427126|NCT00002919|DRUG|methotrexate|
214427127|NCT00002919|DRUG|vinblastine sulfate|
214427128|NCT00002919|PROCEDURE|conventional surgery|
214427129|NCT03913715|OTHER|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
214427130|NCT06107959|OTHER|Pre-surgical nutrition, hydration, RMR, and body composition assessments|Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.
214427131|NCT06107959|OTHER|Post-surgical nutrition, hydration, RMR and body composition assessments|Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.
214427132|NCT02350842|DEVICE|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
214427133|NCT02350842|DEVICE|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
214427134|NCT05048251|DEVICE|cTBS|continuous theta burst stimulation
214427135|NCT05048251|DEVICE|iTBS|intermittent theta burst stimulation
214427136|NCT05048251|DEVICE|sham|sham stimulation
214427137|NCT00769353|BEHAVIORAL|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
214427138|NCT00769353|BEHAVIORAL|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
214427139|NCT04032353|OTHER|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
214511384|NCT03788226|DRUG|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
215028620|NCT01355666|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
214427140|NCT05089097|OTHER|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
214427141|NCT03593213|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
214427142|NCT03593213|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
214427143|NCT01269749|RADIATION|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
214427144|NCT01269749|DRUG|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
214427145|NCT03703518|OTHER|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
214427146|NCT03703518|OTHER|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
214427147|NCT01292681|OTHER|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
214427148|NCT03238326|DRUG|Brexpiprazole|Once daily, oral tablets
214427149|NCT05076435|DRUG|Isotonic crystalloids|"Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
215028621|NCT03781063|DRUG|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
215028622|NCT03781063|DRUG|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
215028623|NCT00967252|DRUG|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
215028624|NCT00967252|DRUG|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
215028625|NCT00967252|DRUG|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
215028626|NCT00967252|DRUG|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
215028627|NCT00967252|OTHER|Control|No statin being taken
215028628|NCT03712761|DIETARY_SUPPLEMENT|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
215028629|NCT02248233|DRUG|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
215028630|NCT02248233|DRUG|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
215113015|NCT06127589|BEHAVIORAL|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
215113016|NCT06127589|DRUG|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
214427150|NCT03078634|OTHER|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
214427151|NCT03078634|OTHER|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
214427152|NCT01254019|DRUG|GSK2402968 6mg/kg/week|subcutaneous
214427153|NCT05462561|OTHER|Quality-of-Life Assessment|Ancillary studies
214427154|NCT05462561|PROCEDURE|Robotic Vascularized Composite Bladder Allograft Transplantation|Undergo robotic VCBA transplantation.
214427155|NCT04867291|DIETARY_SUPPLEMENT|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
214427156|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Sheets|Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
214427157|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
214427158|NCT04867291|DIETARY_SUPPLEMENT|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
215113017|NCT06127589|BEHAVIORAL|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
215113018|NCT06127589|BEHAVIORAL|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for \>2 times) at 3-month follow-up.
214427159|NCT02599818|BEHAVIORAL|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
214427160|NCT05625282|PROCEDURE|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
214427161|NCT05625282|PROCEDURE|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
214427162|NCT01145170|RADIATION|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
215113019|NCT06127589|BEHAVIORAL|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
215113020|NCT06127589|BEHAVIORAL|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
214427163|NCT01145170|BIOLOGICAL|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
214427164|NCT05093218|DIETARY_SUPPLEMENT|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
214427165|NCT05093218|OTHER|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
214427166|NCT05211544|OTHER|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
214427167|NCT05211544|OTHER|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
214427168|NCT05211544|OTHER|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
214427169|NCT01291615|DRUG|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
214427170|NCT01291615|DRUG|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
214427171|NCT04337307|BIOLOGICAL|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
215113021|NCT04887519|OTHER|No Intervention|This is a non-interventional study.
215113022|NCT05293184|OTHER|Observational study only|
214427172|NCT02700958|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
215113023|NCT04289311|BEHAVIORAL|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
215113024|NCT02434562|OTHER|Serum (with or without urine) samples|
215113025|NCT02624453|DRUG|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
215113026|NCT02624453|DRUG|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
215113027|NCT03321422|OTHER|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
215113028|NCT01514201|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214427173|NCT02700958|PROCEDURE|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
214427174|NCT00568854|BIOLOGICAL|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
214427175|NCT02129582|RADIATION|total marrow irradiation|Undergo TMI
214427176|NCT02129582|DRUG|fludarabine phosphate|Given IV
214427177|NCT02129582|DRUG|busulfan|Given IV or PO
214427178|NCT02129582|PROCEDURE|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
214427179|NCT02129582|BIOLOGICAL|anti-thymocyte globulin|Given IV
214427180|NCT02129582|DRUG|tacrolimus|Given IV or PO
214427181|NCT02129582|DRUG|methotrexate|Given IV
215113029|NCT01514201|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214427182|NCT02129582|OTHER|laboratory biomarker analysis|Correlative studies
214427183|NCT05360043|DEVICE|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
214427184|NCT00103025|DRUG|Sodium Nitrite|
214427185|NCT00103025|DRUG|Sodium Nitrite Injection|
214427186|NCT03697616|DEVICE|Ridge augmentation with sticky bone and GBR|"* Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
214427187|NCT00190931|DRUG|Atomoxetine Hydrochloride|
214427188|NCT00190931|DRUG|placebo|
214427189|NCT03853655|RADIATION|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
214427190|NCT05400707|DIAGNOSTIC_TEST|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
214427191|NCT05400707|DIAGNOSTIC_TEST|Assessment of patient mobility at presentation|Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
215113030|NCT01514201|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215113031|NCT01514201|OTHER|Pharmacological Study|Correlative studies
215113032|NCT01514201|DRUG|Temozolomide|Given PO
215113033|NCT01514201|DRUG|Veliparib|Given PO
215113034|NCT05888181|OTHER|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
215113035|NCT03491111|OTHER|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
215113036|NCT03491111|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
214427192|NCT05400707|DIAGNOSTIC_TEST|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
214427193|NCT05400707|DIAGNOSTIC_TEST|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
214427194|NCT05400707|DIAGNOSTIC_TEST|Assessment of what matters most in patients of 65 years and older|"Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?."
214427195|NCT05400707|DIAGNOSTIC_TEST|Assessment of Decision-making in senior physicians|Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
214427196|NCT05400707|DIAGNOSTIC_TEST|Pain Numeric Rating Scale (NRS)|"The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))"
214427197|NCT05400707|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
214427198|NCT00007956|BIOLOGICAL|monoclonal antibody mono-dgA-RFB4|
214427199|NCT00576134|DEVICE|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
214427200|NCT02765438|DEVICE|BOBO|"Each subject will play four games with the BOBO system."
214427201|NCT05480358|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
214427202|NCT04959136|DEVICE|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
214427203|NCT01283750|BEHAVIORAL|care coordination|dementia-related care coordination
214427204|NCT04153435|DRUG|Calcium Chloride|Calcium chloride 5 mmol
214427205|NCT04153435|DRUG|Sodium chloride 0.9%|Placebo
214427206|NCT06436144|DRUG|Osimertinib|Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
214427207|NCT01511172|DRUG|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
214427208|NCT01511172|DRUG|metformin|1000 mg daily, administered orally
214427209|NCT01511172|DRUG|placebo|Metformin placebo administered orally. 1000 mg daily
214511385|NCT03788226|DRUG|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
214511386|NCT04389788|DEVICE|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
214511387|NCT04389788|DEVICE|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
214427210|NCT01511172|DRUG|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
215113037|NCT03491111|OTHER|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
214427211|NCT01511172|DRUG|glimepiride|Individually adjusted dose, administered orally
215113038|NCT00398099|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
214427212|NCT04102462|DRUG|BI 764198|Capsules
214427213|NCT04102462|DRUG|Matching placebo|Capsules
214427214|NCT01317719|PROCEDURE|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
214427215|NCT03264755|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
215113039|NCT00305487|DRUG|Ciclesonide nasal spray|
215113040|NCT04647968|PROCEDURE|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
215113041|NCT04647968|PROCEDURE|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
215113042|NCT02421718|RADIATION|Radiotherapy|
215113043|NCT03688516|BEHAVIORAL|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
215113044|NCT03688516|BEHAVIORAL|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
215113045|NCT03688516|BEHAVIORAL|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
214427216|NCT05238194|OTHER|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
214427217|NCT06490991|DRUG|HRS-5965 tablets；HRS-5965 capsules|Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
214427218|NCT00665444|DRUG|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
214427219|NCT00092105|DRUG|MK0476, montelukast sodium|
214427220|NCT00092105|DRUG|Comparator: placebo|
214427221|NCT06326632|OTHER|Constant-load Aerobic Exercise|The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
214427222|NCT06326632|OTHER|Graded Aerobic exercise|The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.
214427223|NCT06326632|OTHER|Respiratory Re-training|The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
214427224|NCT00338299|DRUG|Epoetin alfa|
214427225|NCT06174662|DEVICE|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
214427226|NCT01637662|DRUG|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
214427227|NCT05022251|PROCEDURE|Lumbar discectomy|surgically removing a hernia
214427228|NCT03089840|DEVICE|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
215113046|NCT03124836|DEVICE|Pulse Oximeter Sensor|
215113047|NCT04890288|PROCEDURE|Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.|Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 \> 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).
215113048|NCT00646425|DRUG|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
215113049|NCT00646425|DRUG|Placebo|Placebo to match basiliximab
215113050|NCT03827525|BEHAVIORAL|Cognitive and Behavioral Therapy|9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
215113051|NCT03054649|DEVICE|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
215113052|NCT03054649|PROCEDURE|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
215113053|NCT02735343|DRUG|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
215113054|NCT02735343|DRUG|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
215113055|NCT00637416|DRUG|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
214427229|NCT05677438|DRUG|CKD-498 dose#1|oral, once daily, 24 weeks
214427230|NCT05677438|DRUG|CKD-498 dose#2|oral, once daily, 24 weeks
214427231|NCT05677438|DRUG|CKD-498 dose#3|oral, once daily, 24 weeks
214427232|NCT05677438|DRUG|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
214427233|NCT05677438|DRUG|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
215113056|NCT00637416|OTHER|Placebo|placebo taken by mouth daily for 3 months
215113057|NCT03852667|BEHAVIORAL|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
215113058|NCT03852667|OTHER|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
215113059|NCT00311883|DRUG|hydroxychloroquine|
215113060|NCT00756990|DRUG|Depot Naltrexone|228mg of injectable naltrexone
215113061|NCT02563236|OTHER|Parabolic flight|
215113062|NCT02595619|DEVICE|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
214427234|NCT05677438|DRUG|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
214511388|NCT05914532|OTHER|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
214427235|NCT03842488|DRUG|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
214427236|NCT03842488|DRUG|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
214427237|NCT05284812|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
214427238|NCT05284812|BIOLOGICAL|High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
214427239|NCT05284812|BIOLOGICAL|High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
214427240|NCT05284812|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
214427241|NCT00717626|DRUG|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
214427242|NCT04688801|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
215113063|NCT02534909|BIOLOGICAL|LFG316|"LFG316 20 mg/kg was administered to all patients enrolled in the study:~* Treatment Periods 1 to 3: LFG316 20 mg/kg as i.v. infusion every 2 weeks~* Treatment Period 4: LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions)."
215113064|NCT02534909|DRUG|LNP023|Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.
214511389|NCT03885544|OTHER|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
214511390|NCT03885544|OTHER|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
215113065|NCT01389869|BIOLOGICAL|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
214427243|NCT04688801|DRUG|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
214427244|NCT03783754|DRUG|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
214427245|NCT03783754|DRUG|Placebo oral capsule|matched placebo
214427246|NCT04562259|RADIATION|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
214427247|NCT05084612|DEVICE|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
215113066|NCT01389869|BIOLOGICAL|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
214427248|NCT05084612|DEVICE|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
214427249|NCT05249036|PROCEDURE|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
214427250|NCT05249036|PROCEDURE|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
214427251|NCT05919017|DRUG|Naltrexone implant|Naltrexone implant
214427252|NCT05919017|DRUG|Placebo|Placebo
214427253|NCT04450199|DRUG|Vitamin D2|Vitamin D tablets
214427254|NCT04450199|OTHER|Placebo|Over encapsulated sugar pills
214427255|NCT00638963|DRUG|temozolomide|Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
214427256|NCT01778283|BIOLOGICAL|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
214427257|NCT00187941|DRUG|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
214427258|NCT00761709|DRUG|AL-39256 Ophthalmic Suspension, 1%|
215113067|NCT01389869|BIOLOGICAL|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
215113068|NCT01389869|BIOLOGICAL|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
214427259|NCT00761709|DRUG|Latanoprost Ophthalmic Solution, 0.005%|
214427260|NCT00761709|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
214427261|NCT00210509|DRUG|almotriptan malate|
214511391|NCT03885544|OTHER|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
214511392|NCT03845881|DRUG|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
214511393|NCT03845881|DRUG|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
214511394|NCT01542983|BEHAVIORAL|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
215113069|NCT01804881|BEHAVIORAL|Lifestyle counseling|Six week program to address problematic eating
214427262|NCT00004004|DRUG|procarbazine hydrochloride|
214427263|NCT02399865|OTHER|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
214427264|NCT01499771|DRUG|Atorvastatin|80 Mg tablets
214427265|NCT06333717|DIETARY_SUPPLEMENT|Whole grain bread|Consumption of high-fibre bread as a dietary supplementation
214427266|NCT06333717|DIETARY_SUPPLEMENT|Control bread|Consumption of control bread as a dietary supplementation
214427267|NCT03443453|DRUG|MIV-711|MIV-711 administered as tablets and capsules at four occasions
214427268|NCT00823225|PROCEDURE|standard therapy|wound debridement, moist wound dressing
214427269|NCT00823225|DRUG|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU"
214427270|NCT02070666|BEHAVIORAL|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O"
214511395|NCT01542983|BEHAVIORAL|treatment as usual|Standard treatment for fatigue and insomnia
214511396|NCT02662816|DEVICE|Proton magnetic resonance spectroscopy (1H MRS)|
214511397|NCT02662816|OTHER|a protein rich breakfast at home|
214511398|NCT02662816|OTHER|a protein rich lunch at the Clinical Investigation Center|
214511399|NCT00734682|DRUG|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
214511400|NCT02486107|PROCEDURE|surgical procedure|
214511401|NCT00898313|GENETIC|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
215113070|NCT01625000|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
215113071|NCT01625000|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
215113072|NCT01625000|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
215113073|NCT01625000|DRUG|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
215113074|NCT01625000|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
215113075|NCT00566852|DRUG|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
215113076|NCT00566852|OTHER|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
215113077|NCT00566852|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
215113078|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
215113079|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
215113080|NCT00904904|DRUG|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
215113081|NCT00904904|DRUG|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
215113082|NCT05681806|DIETARY_SUPPLEMENT|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
215113083|NCT05681806|DIETARY_SUPPLEMENT|Creatine Monohydrate|5g creatine monohydrate
215113084|NCT03165916|DEVICE|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
215113085|NCT00577824|DRUG|exenatide|subcutaneous injection, 5mcg, twice a day
214427271|NCT02070666|BEHAVIORAL|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O."
214427272|NCT02070666|OTHER|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
214427273|NCT00477035|DRUG|CIK cells|2x10e8 cells/kg
214427274|NCT00477035|DRUG|etoposide|60 mg/kg
214427275|NCT00477035|DRUG|bcnu|15 mg/kg
214427276|NCT00477035|DRUG|cyclophosphamide|100 mg/kg
214427277|NCT00477035|DRUG|gemcitabine|1250 mg/m2
214427278|NCT00477035|DRUG|vinorelbine|30 mg/m2
214427279|NCT00477035|DRUG|melphalan|200 mg/m2
214427280|NCT04554082|PROCEDURE|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
214511402|NCT00898313|GENETIC|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
215113086|NCT00577824|DRUG|exenatide|subcutaneous injection, 10mcg, twice a day
214511403|NCT00898313|GENETIC|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
215113087|NCT00577824|DRUG|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
215113088|NCT01378442|OTHER|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
214427281|NCT01465516|DRUG|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
214427282|NCT06196177|DRUG|Levosimontane injection|Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
214427283|NCT01240330|DEVICE|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
214427284|NCT01812148|PROCEDURE|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
214427285|NCT00177086|OTHER|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
214427286|NCT03267966|DIAGNOSTIC_TEST|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
214427287|NCT00478478|PROCEDURE|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
214427288|NCT03260140|BEHAVIORAL|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
214427289|NCT02304952|PROCEDURE|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
214427290|NCT02304952|OTHER|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
214427291|NCT02304952|DEVICE|Arthrocare Topaz MicroDebrider|
214427292|NCT03961906|BEHAVIORAL|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
214427293|NCT02773303|DEVICE|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
214427294|NCT02773303|DEVICE|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
214427295|NCT04129619|DRUG|ORP-101|Oral tablet
214427296|NCT04129619|DRUG|Placebo|Oral tablet
214427297|NCT02455752|PROCEDURE|LE-TME|Retroperitoneal approach for total mesorectal excision
214427298|NCT03434652|DEVICE|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
214427299|NCT00436072|DRUG|ZD6474|Orally on a daily basis
214511404|NCT00898313|OTHER|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
215113089|NCT04079816|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
214427300|NCT00436072|DRUG|Cetuximab|Infusion once weekly
214427301|NCT00436072|DRUG|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
214427302|NCT01372761|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
214427303|NCT01372761|DRUG|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
214427304|NCT00126646|DRUG|BL22 immunotoxin|
214427305|NCT00126646|PROCEDURE|antibody-drug conjugate therapy|
214427306|NCT00126646|PROCEDURE|immunotoxin therapy|
214427307|NCT05420090|BEHAVIORAL|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
214427308|NCT05420090|BEHAVIORAL|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
214427309|NCT05420090|BEHAVIORAL|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
214427310|NCT01708798|DRUG|Eplerenone|
214427311|NCT01708798|DRUG|Placebo|
214511405|NCT00898313|PROCEDURE|nasal brushing|Using a brush, superficial cells are removed from the nose.
214511406|NCT00898313|PROCEDURE|Blood draw|Venous blood will be collected
214511407|NCT00898313|PROCEDURE|Urine collection|Subjects will be asked to provide a urine specimen.
214511408|NCT00898313|PROCEDURE|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
214511409|NCT00898313|PROCEDURE|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
215113090|NCT00785473|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
215113091|NCT00785473|DIETARY_SUPPLEMENT|calcium carbonate|calcium carbonate 500 mg daily for 2 years
215113092|NCT01434849|DRUG|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
215113093|NCT01434849|DRUG|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
214511410|NCT00898313|PROCEDURE|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
214427312|NCT05133375|PROCEDURE|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
214511411|NCT00898313|PROCEDURE|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
214511412|NCT03654482|DEVICE|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
214427313|NCT06552624|DRUG|Magaldrate|A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
214427314|NCT06552624|DRUG|Magaldrate|A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
214427315|NCT04949581|OTHER|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
214427316|NCT04949581|OTHER|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
214511413|NCT06003244|OTHER|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
214511414|NCT06003244|OTHER|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
214692410|NCT02007785|BEHAVIORAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
214692411|NCT04212338|OTHER|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
214511415|NCT02661958|DRUG|S6G5T-3|once a day topical cream
215113094|NCT00638495|DRUG|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
215113095|NCT00638495|DRUG|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
215113096|NCT06069414|OTHER|Type of anesthesia induction|Patients will receive inhalatory or intravenous anesthesia at their choice; both groups will be evaluated with lung ultrasound after induction to detect ultrasonografic signs of atelectasis
214511416|NCT02661958|DRUG|S6G5T-1|once a day topical cream
215113097|NCT04057430|DEVICE|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
215113098|NCT04057430|DEVICE|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
215113099|NCT01435486|DRUG|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
214511417|NCT02661958|DRUG|S6G5T-5|once a day topical cream
214511418|NCT02661958|DRUG|S6G5T-6|once a day topical cream
214511419|NCT02661958|DRUG|S6G5T-7|once a day topical cream
214692412|NCT04212338|OTHER|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
215113100|NCT01435486|DRUG|Normal saline|Placebo with an equivalent volume of normal saline.
214427317|NCT05689125|DEVICE|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
214427318|NCT05689125|DEVICE|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
214511420|NCT02661958|DRUG|S6G5T-8|once a day topical cream
214511421|NCT01187888|DRUG|Rasagiline|tablet once daily 1 mg 1 year
214511422|NCT01187888|DRUG|Sugar pill|tablet once daily one year
214511423|NCT05662930|BEHAVIORAL|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
214692413|NCT03136185|DRUG|Bomedemstat|Oral (capsule) administration according to dose allocation.
214427319|NCT05689125|DEVICE|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
214427320|NCT06552819|OTHER|No intervention|No intervention
214427321|NCT00107796|DRUG|Modafinil|
214427322|NCT00678912|DEVICE|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
214427323|NCT00405535|DRUG|glycine|
214427324|NCT00405535|OTHER|placebo|
214427325|NCT00002072|DRUG|Epoetin alfa|
214427326|NCT01444417|DRUG|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
214427327|NCT01444417|DRUG|Placebo|Matching placebo administered by subcutaneous injection
214427328|NCT03370796|OTHER|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
214427329|NCT00322920|DRUG|Topotecan|
214427330|NCT00322920|DRUG|Cisplatin|
214427331|NCT02423291|DRUG|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
214427332|NCT04018924|DEVICE|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
214427333|NCT03957798|BEHAVIORAL|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
214427334|NCT00291824|BEHAVIORAL|Cardiovascular risk factors and willingness to change|
214427335|NCT05086159|BEHAVIORAL|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
214427336|NCT05086159|BEHAVIORAL|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
214427337|NCT05086159|BEHAVIORAL|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
214427338|NCT01653834|PROCEDURE|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
214511424|NCT05662930|BEHAVIORAL|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
215113101|NCT00192413|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
214511425|NCT05662930|BEHAVIORAL|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
214511426|NCT05662930|BEHAVIORAL|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
215113102|NCT00192413|BIOLOGICAL|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
215113103|NCT02457468|DEVICE|coflex|
214427339|NCT02367924|DRUG|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
214427340|NCT02436213|OTHER|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
214427341|NCT02436213|PROCEDURE|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
214427342|NCT01760564|DRUG|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
214427343|NCT01832467|DRUG|cetuximab-containing chemotherapy|
214427344|NCT03963336|DRUG|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
214427345|NCT03963336|DRUG|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
214427346|NCT04925765|OTHER|Virtual Reality Biofeedback Session|"The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression."
214427347|NCT04297306|BEHAVIORAL|Exercise Prescription|Standardised Exercise Prescription.
214427348|NCT04297306|DEVICE|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
214427349|NCT06161844|DRUG|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
214427350|NCT06161844|DRUG|Ozempic®|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
214427351|NCT04246307|DIAGNOSTIC_TEST|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~* before the surgery (S1)~* during the hepatectomy, 10 minutes before the anhepatic phase (S2)~* in the anhepatic phase, before starting portal vein anastomosis: (S3)~* in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~* in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~* haemodynamic measurements by PiCCO~* arterial blood gas analysis from radial artery catheter~* central venous blood gas analysis from subclavian vein catheter~* blood temperature measurement in the femoral artery by PiCCO catheter~* hourly urinary output"
214427352|NCT01683149|DRUG|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
214427353|NCT01683149|DRUG|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
214427354|NCT06449170|OTHER|Mango Ataulfo|In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
214427355|NCT06449170|OTHER|Avocado Hass|In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
214427356|NCT06449170|OTHER|Nopal|In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
214427357|NCT06449170|OTHER|3 corn tortilla|In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
214427358|NCT06449170|OTHER|Guava|In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
214427359|NCT06449170|OTHER|Amaranth|In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
214427360|NCT06449170|DIETARY_SUPPLEMENT|Control Beverage (Supportan Drink ® Capuccino)|In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
214511427|NCT05662930|BEHAVIORAL|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
214511428|NCT05662930|BEHAVIORAL|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
214511429|NCT00209885|DRUG|Gabapentin|
214511430|NCT00209885|DRUG|S-ketamine|
214511431|NCT00209885|DRUG|Lidocaine|
214511432|NCT00209885|DRUG|Droperidol|
214427361|NCT01214824|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
214427362|NCT03094182|DRUG|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
214427363|NCT03094182|DRUG|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
214427364|NCT01680250|DRUG|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
214427365|NCT05339893|DEVICE|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
214427366|NCT03899324|DRUG|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
215113104|NCT02750488|DRUG|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
215113105|NCT02750488|OTHER|Untreated skin|One site is patched without treatment as control
215113106|NCT02535143|OTHER|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
215113107|NCT02535143|DRUG|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
215113108|NCT02535143|OTHER|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
214427367|NCT03899324|DRUG|Placebo white, oblong, scored tablet|placebo intake identically to group 1
214427368|NCT02287441|OTHER|Tomato|Tomato Products (tomato)
214427369|NCT02287441|OTHER|Raw|Vegetables Prepared Raw (raw).
214427370|NCT05283395|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
214427371|NCT04212195|GENETIC|Next generation sequencing|Saliva samples
214427372|NCT04212195|DIAGNOSTIC_TEST|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
214427373|NCT01854229|DEVICE|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
214427374|NCT03433690|BEHAVIORAL|HIIT|High Intensity Interval Training for twelve weeks
214427375|NCT03433690|BEHAVIORAL|Moderate training|Moderate training for twelve weeks
214427376|NCT04452539|PROCEDURE|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
214427377|NCT03702647|DRUG|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
214427378|NCT03702647|DRUG|Normal saline|30mL of normal saline placed in the POEM tunnel
214427379|NCT04892290|OTHER|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
214427380|NCT05865145|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
214427381|NCT06121349|DRUG|ocrelizumab|infusion therapy administered every six months
214427382|NCT06121349|DRUG|ofatumumab|self-injectable every month
214427383|NCT05979870|PROCEDURE|Valvuloplasty,|Choice of type of intervention decided on a multidisciplinary conference
214427384|NCT03302741|DRUG|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
214427385|NCT03302741|OTHER|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
214511433|NCT02053714|BEHAVIORAL|Diabetes self-management and education|
214511434|NCT00070421|PROCEDURE|complementary or alternative medicine procedure|
214511435|NCT00070421|PROCEDURE|management of therapy complications|
214511436|NCT00070421|PROCEDURE|psychosocial assessment and care|
214511437|NCT05851014|DRUG|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
215113109|NCT02535143|DIETARY_SUPPLEMENT|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
215113110|NCT05100914|OTHER|Couple-based family nursing|Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
215113111|NCT00362648|BIOLOGICAL|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
214427386|NCT03302741|DEVICE|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
215113112|NCT00362648|BIOLOGICAL|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
215113113|NCT04746820|OTHER|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
214427387|NCT03302741|DEVICE|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
214427388|NCT04287478|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
214427389|NCT06164756|OTHER|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
214427390|NCT06164756|OTHER|Treatment As Usual (TAU)|Participants will receive standard of care treatment
214427391|NCT05390567|BEHAVIORAL|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
214427392|NCT05390567|BEHAVIORAL|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
214427393|NCT05390567|BEHAVIORAL|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
214427394|NCT06603090|BEHAVIORAL|Text message influenza vaccine reminders|Text message influenza vaccine reminders
214427395|NCT06603090|BEHAVIORAL|Text message COVID-19 vaccine reminders|Text message COVID-19 vaccine reminders
214427396|NCT06603090|BEHAVIORAL|Text message influenza and COVID-19 vaccine reminders|Text message influenza and COVID-19 vaccine reminders
214427397|NCT06532435|DIETARY_SUPPLEMENT|DHA & ARA Candy|Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
214427398|NCT05764187|OTHER|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
214427399|NCT06972524|DIETARY_SUPPLEMENT|a special probiotics from Mengniu Group, supplemented with milk powder|Sorbitol 、Xylitol 、Paracaseobacterium LC19 、Bifidobacterium lactis subsp. animalis MN-Gup 、Mulberry Leaf Extract 、Bitter Melon Powder 、Resistant Dextrin 、White Kidney Bean Extract 、Stachyose 、Galactooligosaccharides 、Food Flavoring、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide
214511438|NCT05851014|DRUG|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
214511439|NCT00297297|OTHER|No intervention. Applying gene profiling on needle aspirates|
214511440|NCT03778788|OTHER|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
214511441|NCT03778788|OTHER|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
214692414|NCT03972592|DRUG|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
214427400|NCT06972524|DIETARY_SUPPLEMENT|regular milk powder does not contain any additional supplementation, and the color, flavor, shape, taste, and weight are same with the probiotic milk powder|Sorbitol、Xylitol 、Food Flavoring 、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide、Maltodextrin
214427401|NCT06974136|DEVICE|transcranial electrical stimulation|Transcranial electrical stimulation (tES) is a non-invasive neuromodulation technique that applies low-intensity electrical currents to the scalp to modulate brain activity. It targets specific brain regions to influence neuronal excitability, connectivity, and plasticity, offering potential therapeutic benefits for neurological and psychiatric conditions. tES is portable, cost-effective, and generally well-tolerated, with minimal side effects such as mild tingling or itching at the stimulation site.
214427402|NCT06973200|COMBINATION_PRODUCT|Dihydroartemisin-piperaquine|All children with S. mansoni and/or S. haematobium infections at enrolment will then be treated with dihydroartemisinin-piperaquine (DP) and followed up on days 1, 2, 3, 4, 28, and 42 to assess the efficacy and safety of DP.
215113114|NCT06965361|DRUG|carboplatin|carboplatin use due to its effectiveness in increasing pathological complete remission (pCR) rates and improving survival outcomes
214427403|NCT05990894|DRUG|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
214427404|NCT05103527|DEVICE|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
214427405|NCT03144674|DRUG|Parsaclisib|Parsaclisib at the protocol-defined dose.
214427406|NCT04100109|DIETARY_SUPPLEMENT|Polylactose|Polylactose 15 g/day
215113115|NCT06965361|DEVICE|carboplatin|used in the treatment of triple-negative breast cancer (TNBC) due to its effectiveness in achieving pathological complete response (pCR) and breast-conserving surgery (BCS) rates.
215113116|NCT05956652|DEVICE|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
215113117|NCT06967701|BEHAVIORAL|Exercise program|Participants will receive a free Garmin smartwatch and a free program membership providing exercise coaching + personalized feedback about the relationship among their insulin, carbohydrates, exercise, sleep, and blood sugar.
215113118|NCT06967701|BEHAVIORAL|Self-monitoring|Wear a fitness watch and keep daily health diary
215113119|NCT06969469|DIETARY_SUPPLEMENT|Give the Placebo and test article|"Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.~Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days."
214427407|NCT04100109|OTHER|Placebo|Cellulose 15 g/day
215113120|NCT05737654|OTHER|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
214427408|NCT03008018|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
214427409|NCT03614611|DEVICE|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
214427410|NCT04169399|DRUG|Toripalimab|240mg intravenously every 3 weeks
214427411|NCT04169399|RADIATION|Stereotactic body radiotherapy|Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
214427412|NCT05788146|OTHER|Cognitive Behavioural Therapy|A psychological intervention used to target depression
215113121|NCT06370819|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
215113122|NCT06575660|BEHAVIORAL|Mental health support session|a single AI-VR mental health support session using the XAIA application
214427413|NCT05968833|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
214427414|NCT05232630|DRUG|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
214427415|NCT06969495|OTHER|xLr oral gel|25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative.
214427416|NCT06969495|OTHER|Placebo|oral gel base formulation without the Lignosus rhinocerus extract
214427417|NCT06969495|DRUG|Kanolone|Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%)
214427418|NCT06973447|PROCEDURE|Anterior suprascapular nerve block (ASSNB)|10 mL of 0.25% bupivacaine
214427419|NCT06973447|PROCEDURE|Infraclavicular Brachial Plexus Block (ICBPB)|15 mL of 0.25% bupivacaine
214427420|NCT06973447|PROCEDURE|Costoclavicular brachial plexus block (CCBPB)|15 mL of 0.25% bupivacaine
214427421|NCT05482399|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
215113123|NCT06975930|PROCEDURE|Percutaneous Coronary Intervention (PCI)|"Patients with Aortoostial coronary lesion undergoing PCI will be blindly randomized into 2 groups Conventional group: patients who will undergo 2D convnetional angiography Aorto-ostial coronary stenting.~Floating Wire group: Patients who will undergo Aorto-ostial coronary stenting with Floating wire technique."
215113124|NCT06976749|DEVICE|myobrace appliance|functional appliance
215113125|NCT06976749|DEVICE|Twin block|functional appliance
214427422|NCT00922649|DEVICE|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
214511442|NCT03778788|OTHER|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
214511443|NCT00916656|BIOLOGICAL|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
215113126|NCT06975228|BEHAVIORAL|TRUST|Six-session psychological intervention focussing on values and imagery Session 1: Assessment, formulation and psychoeducation Session 2: Values and values-based goals Session 3-5: Harnessing imagery to pursue values and imagery focussed strategies to change negative beliefs about self and others Session 6: Review
214427423|NCT05576181|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
214427424|NCT05576181|DRUG|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
214427425|NCT05576181|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214427426|NCT05576181|DRUG|VP-16|VP-16 is used for lymphodepletion.
214427427|NCT05576181|PROCEDURE|HSCT|Hematological stem cell transplantation
214427428|NCT06225388|OTHER|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
214427429|NCT06225388|OTHER|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
214511444|NCT00916656|BIOLOGICAL|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
214511445|NCT05253092|OTHER|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
214511446|NCT01552083|OTHER|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
214511447|NCT02383797|BIOLOGICAL|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
214511448|NCT02074384|DEVICE|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
214511449|NCT02074384|DEVICE|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
214511450|NCT02074384|OTHER|Clinician|Survey of clinicians after study visits
214511451|NCT05926557|PROCEDURE|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
214511452|NCT05926557|PROCEDURE|NSMD|Only mechanical debridement with curettes and scaler peek tips
214511453|NCT04121234|OTHER|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
215113127|NCT06976983|DEVICE|Portable ergonomic helmet for real tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
214427430|NCT03611205|PROCEDURE|Computed Tomography|Undergo dPET/CT
214427431|NCT03611205|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
214427432|NCT03209037|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
214427433|NCT05592925|DIAGNOSTIC_TEST|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
214427434|NCT06491212|DIAGNOSTIC_TEST|Determination of Foot Deformity Level|One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.
214427435|NCT06491212|DIAGNOSTIC_TEST|Foot Function Index|Evaluation of Foot Function
214427436|NCT06491212|DIAGNOSTIC_TEST|UFAA-International Physical Activity Questionnaire|To determination of physical activity level.
214427437|NCT06491212|DIAGNOSTIC_TEST|Diaphragm ultrasound measurements|Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.
214427438|NCT06491212|DIAGNOSTIC_TEST|NeuruCom Balance Master Balnce and Performans Test|Balance master will be used for postural stability, static and dynamic balance measurements.
214427439|NCT06491212|DIAGNOSTIC_TEST|Plantar Pressure Assessment|When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
214427440|NCT04488783|DIETARY_SUPPLEMENT|zinc and ascorbate|oral zinc and ascorbate
215113128|NCT06976983|DEVICE|portable ergonomic helmet for placebo tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
215113129|NCT04857502|DRUG|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
214427441|NCT00223587|OTHER|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
214427442|NCT00206375|DRUG|Growth hormone|Growth hormone + Synthroid + Lupron
214427443|NCT00206375|DRUG|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
214427444|NCT04145492|DRUG|Vitamin K2|Patients will take 90 ug of vitamin K2
214427445|NCT04145492|DRUG|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
214427446|NCT04145492|DRUG|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
214427447|NCT06328985|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
214427448|NCT06328985|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
214427449|NCT06328985|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
214427450|NCT06465979|BEHAVIORAL|Speech Manipulation|"The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition."
214427451|NCT04988451|BEHAVIORAL|ASL Services|ASL specialist meets with participants and provides ASL instruction
214427452|NCT05503251|OTHER|Best Practice|Receive usual care
214427453|NCT05503251|BEHAVIORAL|Neuropsychological Assessment|Undergo neuropsychological evaluation
214427454|NCT05503251|OTHER|Quality-of-Life Assessment|Ancillary studies
214511454|NCT00223769|DRUG|Oxandrolone|
214511455|NCT06160453|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
214692415|NCT03972592|DRUG|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
214692416|NCT01920620|BEHAVIORAL|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
215113130|NCT04857502|PROCEDURE|Computed Tomography|Undergo SPECT/CT
214692417|NCT01920620|BEHAVIORAL|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
214692418|NCT00833235|OTHER|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
215113131|NCT04857502|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215113132|NCT06975306|PROCEDURE|autologous bone grafts|group will be treated with autologous bone graft for BTB ACLR
215113133|NCT06975306|OTHER|Demineralized bone matrix (DBM)|Demineralized bone matrix (DBM) is a biologic allograft product derived from bone tissue that has undergone a process of demineralization to remove inorganic mineral components while retaining the organic matrix, including proteins and growth factors.
215113134|NCT06976021|DIAGNOSTIC_TEST|Baseline 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
214427455|NCT05503251|OTHER|Questionnaire Administration|Ancillary studies
214427456|NCT06238063|BEHAVIORAL|Nurse-led Advance Care Planning (ACP) Intervention|An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
214427457|NCT03368664|DRUG|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
214427458|NCT03368664|DRUG|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
214427459|NCT03368664|DRUG|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
214427460|NCT03368664|DRUG|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
215113135|NCT06976021|DIAGNOSTIC_TEST|Proteomic assay|Assessment of the proteomic profile before and periodically after treatment
215113136|NCT06976021|DIAGNOSTIC_TEST|Follow-up 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy
214427461|NCT03368664|DRUG|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
214427462|NCT03368664|DRUG|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
214427463|NCT03368664|DRUG|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
214427464|NCT03368664|DRUG|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
214427465|NCT03368664|DRUG|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
214511456|NCT06160453|DEVICE|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
214511457|NCT01297088|DRUG|BAY86-9596|One single dose administration of a diagnostic agent
214511458|NCT01278914|BIOLOGICAL|Dendritic Cells (DC) prostate|
214427466|NCT03368664|DRUG|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
214511459|NCT02461979|OTHER|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
214692419|NCT03055104|OTHER|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
214427467|NCT03368664|DRUG|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
214427468|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
214427469|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
214511460|NCT06466759|DEVICE|Mc Grath Videolaryngoscope|Use of Videolaryngoscope with Mc Grath versus direct laryngoscopy
214511461|NCT03096132|BEHAVIORAL|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
214511462|NCT03096132|BEHAVIORAL|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
214692420|NCT04148924|OTHER|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
215113137|NCT06976788|OTHER|Tomography exam|Brain imaging examination
214511463|NCT02950883|DRUG|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
214511464|NCT02950883|DRUG|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
214511465|NCT02186106|DRUG|Cholecalciferol|
214511466|NCT04431128|BEHAVIORAL|infant feeding position|correlation with allergy, GER or feeding position
214511467|NCT06237621|DEVICE|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
215113138|NCT06974851|DRUG|HRS9531|HRS9531
214427470|NCT01547741|DRUG|Doxorubicin|
214427471|NCT01547741|DRUG|Cyclophosphamide|
214427472|NCT01547741|DRUG|Docetaxel|
214427473|NCT01547741|DRUG|Paclitaxel|
214427474|NCT00466076|DRUG|Copaxone (Glatiramer acetate)|
214427475|NCT00837616|DRUG|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
214511468|NCT02773732|DRUG|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
214511469|NCT02773732|DRUG|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
214511470|NCT02773732|DRUG|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
215113139|NCT06974851|DRUG|HRS9531placebo|HRS9531placebo
215113140|NCT06976151|DRUG|Non-steroidal anti-inflammatory drugs (NSAID)|The participants will receive non-steroidal anti- inflammatory drugs (NSAID), Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.
215113141|NCT06976151|OTHER|Transcutaneous Electrical Acupoint Stimulation (TEAS)|"The participants will receive transcutaneous electrical acupoint Stimulation (TEAS). These acupoints will include large intestine 14 (LI4) , gall bladder 34 (GB34), large intestine 11 (LI11), Gall bladder 39 (GB39) and stomach 36 (ST 36). The session will be applied for 30 minutes / 3 days/ week, in addition to Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.~."
214511471|NCT02773732|DRUG|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
214511472|NCT06041438|DRUG|BI 1584862|BI 1584862
214511473|NCT06041438|DRUG|itraconazole|itraconazole
214427476|NCT00837616|DRUG|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
214427477|NCT00605904|DRUG|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
214427478|NCT00605904|DRUG|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
214427479|NCT00605904|DRUG|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
214427480|NCT00605904|DRUG|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
214427481|NCT03505099|BIOLOGICAL|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
214427482|NCT04178941|BEHAVIORAL|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
214427483|NCT04178941|BEHAVIORAL|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
214427484|NCT01979913|DRUG|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
214427485|NCT03161392|DIAGNOSTIC_TEST|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
214427486|NCT03161392|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
214427487|NCT01810263|DIETARY_SUPPLEMENT|high protein supplement|Dietary Supplement: high protein supplement
214427488|NCT04910932|OTHER|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
214427489|NCT04910932|OTHER|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
214511474|NCT01074528|BEHAVIORAL|mindfulness based stress reduction program|8-week mindfulness training program
214511475|NCT03652610|BIOLOGICAL|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
214427490|NCT00562679|OTHER|There is no intervention|
214427491|NCT04448418|OTHER|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
214511476|NCT03652610|BIOLOGICAL|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
214511477|NCT06459128|DEVICE|Limbic Care|"Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener."
214511478|NCT06459128|DEVICE|Digital Workbook|The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
214511479|NCT06148636|DRUG|[212Pb] VMT-α-NET|Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
214511480|NCT06148636|DIAGNOSTIC_TEST|[203Pb] VMT-α-NET SPECT/CT|The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.
214511481|NCT00003259|DRUG|vinorelbine tartrate|
214511482|NCT05596006|DRUG|ASIMOMMY®|ASIMOMMY 500 mg
214511483|NCT05596006|DRUG|Domperidon|Domperidone capsule 10 mg
214511484|NCT05596006|DRUG|Placebo|Capsules of placebo 500mg.
214427492|NCT00696618|DRUG|Fleet Enema|hyper-osmolar preparation
214427493|NCT00696618|DRUG|tap water enema|hypo-osmolar preparation
214427494|NCT00696618|DRUG|Normosol-R enema|iso-osmolar preparation
214427495|NCT05593146|BEHAVIORAL|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
214427496|NCT05593146|BEHAVIORAL|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
214427497|NCT03400969|DEVICE|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
214427498|NCT03400969|DEVICE|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
214427499|NCT03400969|DEVICE|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
214427500|NCT00295074|PROCEDURE|neuropsychologic testing|
214427501|NCT02214693|DRUG|DA-1229|
214427502|NCT02095899|DRUG|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
214427503|NCT02163954|DRUG|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
214427504|NCT02163954|DRUG|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
214427505|NCT00688519|DRUG|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
214427506|NCT00688519|DRUG|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
214427507|NCT01818401|DEVICE|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
214427508|NCT01818401|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
214427509|NCT01156935|OTHER|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
214427510|NCT04998903|PROCEDURE|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
214427511|NCT05664100|DRUG|FX-345|Single intratympanic injection of FX-345
214427512|NCT05664100|DRUG|Placebo|Single intratympanic injection of placebo
214427513|NCT01685606|BIOLOGICAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
214427514|NCT01838824|BEHAVIORAL|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
214427515|NCT01803516|BEHAVIORAL|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
214427516|NCT00009646|DRUG|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
214427517|NCT00009646|DRUG|Indomethacin|0.1 mg per kilogram of body weight
214427518|NCT00009646|DRUG|Placebo|0.1 mg per kilogram of body weight
214427519|NCT04407780|OTHER|No interventions are planned|Non applicable
214427520|NCT01456078|DRUG|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
214427521|NCT01348880|DRUG|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
214427522|NCT01348880|DRUG|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
214427523|NCT01526642|DEVICE|Non Invasive Ventilation|NIV during night
214427524|NCT03546634|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
214427525|NCT01559519|DRUG|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
214427526|NCT01165658|RADIATION|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
214427527|NCT00138138|DRUG|Ritalin|
214427528|NCT01353963|DRUG|desvenlafaxine succinate|50 mg tablet once daily
214427529|NCT00001063|DRUG|Stavudine|
214427530|NCT00001063|DRUG|Zidovudine|
214427531|NCT00001063|DRUG|Didanosine|
214427532|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
214427533|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
214427534|NCT04789408|DRUG|Cyclophosphamide|Administered intravenously
214427535|NCT04789408|DRUG|Fludarabine|Administered intravenously
214427536|NCT04789408|BIOLOGICAL|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
214427537|NCT04021667|OTHER|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
214427538|NCT06028984|DEVICE|Intervention app|An app-based intervention for depression
214511485|NCT01579071|PROCEDURE|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
214511486|NCT04828109|DEVICE|Virtual Reality|Use of any virtual reality experiences available
214511487|NCT04828109|DEVICE|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
214427539|NCT06028984|OTHER|Control app|An app with non-therapeutic content
214511488|NCT04498780|DRUG|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
214511489|NCT00785499|BEHAVIORAL|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
214427540|NCT03654235|OTHER|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
214427541|NCT03654235|OTHER|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
214427542|NCT03654235|OTHER|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
214427543|NCT02808039|OTHER|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
214427544|NCT00687011|DRUG|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
214427545|NCT00211731|BEHAVIORAL|Chronic Disease Self Management Course|
214427546|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)"
214427547|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
214427548|NCT06011525|OTHER|standard cold cap|"Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device."
214427549|NCT06011525|OTHER|scalp-cooling technique|Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
214427550|NCT06184451|OTHER|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
214427551|NCT06184451|DEVICE|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
214427552|NCT06184451|DEVICE|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
214427553|NCT01403168|OTHER|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
214427554|NCT01403168|OTHER|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
214511490|NCT03116191|DRUG|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
214511491|NCT03116191|DRUG|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
214511492|NCT00326183|BIOLOGICAL|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
215113142|NCT06975553|DEVICE|endotracheal intubation-type end-tidal carbon dioxide sampling tube|In addition to routine monitoring (ECG, NIBP, and SpO2), an endotracheal intubation-type end-tidal carbon dioxide sampling tube is used for end-tidal carbon dioxide IPI monitoring.
214427555|NCT06974318|OTHER|ABCDEF Bundle to Prevent Delirium|The ABCDEF Care Bundle-comprising components focused on pain management (A), spontaneous awakening and breathing trials (B), choice of sedation and analgesia (C), delirium assessment and management (D), early mobility (E), and family engagement (F)-was developed to promote patient-centered care in the ICU and improve clinical outcomes. Nurses play a central role in the effective implementation of this bundle, given their continuous patient interaction and responsibility for early detection and response to delirium symptoms.
214427556|NCT06974318|OTHER|Standard Care to Prevent Delirium|Standard care inclued pain management, Glasgow Coma Scale evaluation, Richmond Agitation-Sedation Scale evaluation and control of the stimulations.
214427557|NCT06972992|DRUG|ASC47 +Semaglutide|ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
214427558|NCT06972992|DRUG|Placebo+Semaglutide|Placebo single subcutaneous injection + Semaglutide QW for 4 weeks
214427559|NCT06429852|BEHAVIORAL|The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program|The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
214511493|NCT00326183|BIOLOGICAL|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
214511494|NCT03791190|OTHER|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
214427560|NCT05857813|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
214511495|NCT03791190|OTHER|No-anticoagulation|Patients accepted CRRT without anticoagulant.
215113143|NCT04493203|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
214511496|NCT04017299|OTHER|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
215113144|NCT04493203|DRUG|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
215113145|NCT01407198|DRUG|Nilotinib|Orally, daily 200 - 400 mg BID
215113146|NCT01407198|RADIATION|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
215113147|NCT06783413|BEHAVIORAL|Intervention group (Laughter Yoga)|Laughter yoga is a practice that includes physical laughing exercises and breathing techniques. Sessions will be conducted as group therapy with a trained guide. The intervention will be applied to evaluate changes in participants' fatigue, sleep quality and psychological well-being.
215113148|NCT06783413|OTHER|Control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
215113149|NCT06575647|DRUG|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
215113150|NCT02123823|DRUG|Everolimus|10mg dose
214427561|NCT06813976|DRUG|mFOLFORINOX|"mFOLFIRINOX every 2 weeks during 12 cycles (24 weeks):~* Oxaliplatin 85 mg/m²~* Irinotecan 150 mg/m²~* Leucovorin 400 mg/m²~* Fluorouracil 2400 mg/m² during 46 hours"
214427562|NCT06813976|DRUG|Capecitabine or gemcitabine|"investigator's choice:~* Capecitabine 1250 mg/m² BID, 2 weeks on, 1 week off during 8 cycles (24 weeks) OR~* Gemcitabine 1000 mg/m² in 30 min; 3 weeks on, 1 week of, during 6 cycles ((24 weeks)"
214427563|NCT06813976|OTHER|Quality of life questionnaires: QLQ-C30 and PAN26|Before treatment, during treatment (every 12 weeks in any treatment arm Until disease progression or end of follow-up) and after treatment discontinuation (30 days after the end of treatment)
214511497|NCT05174026|OTHER|Fludeoxyglucose F-18|Given IV
215113151|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
215113152|NCT02123823|DRUG|BI 836845|1000 mg, recommended dose per Phase Ib part. Human monoclonal antibody. Dose escalation in Phase Ib. 2 dose levels (high or low) depending on the dose cohort explored
215113153|NCT05650879|DRUG|ELVN-002|capsule
215113154|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
215113155|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
215113156|NCT06169982|DRUG|LY3209590|Administered SC
215113157|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)
215113158|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).
215113159|NCT05176808|BEHAVIORAL|Early Achievements- Parent Coaching Intervention|Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
215113160|NCT05154773|BEHAVIORAL|Kidney donation and transplant information made easy|Same as arm description
214427564|NCT06813976|BIOLOGICAL|Biological assessment|Before each course of treatment and between courses of treatment if necessary
214427565|NCT06813976|DIAGNOSTIC_TEST|Paraclinical examinations|Every 3 months
214427566|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
214427567|NCT06615869|DRUG|Molnupiravir|Oral Administration.
214427568|NCT03957681|DRUG|KHK4827|210 mg Q2W, SC
214427569|NCT03957681|DRUG|Placebo|Q2W, SC
214427570|NCT04861532|DIAGNOSTIC_TEST|Imaging|MRI scanning using new protocols
214427571|NCT02578589|PROCEDURE|Plica resection vs conservative treatment|Plica resection vs conservative treatment
214511498|NCT05174026|PROCEDURE|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
215113161|NCT06503653|DIAGNOSTIC_TEST|syncope channel|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation."
214511499|NCT05174026|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
214511500|NCT01341769|OTHER|Dietary Intervention|
214511501|NCT01341769|OTHER|Dietary Intervention|
214511502|NCT01341769|OTHER|Dietary Intervention|
215113162|NCT06503653|DIAGNOSTIC_TEST|routine care|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals"
215113163|NCT06975280|BEHAVIORAL|Trauma - Focused Cognitive Behavioral Therapy|TF-CBT is a comprehensive, evidence-based, short-term therapeutic protocol aimed at reducing trauma-related symptoms in children and adolescents aged 3-18. The protocol consists of 12 double sessions conducted with both the child and their caregiver. Developed for children who have experienced sexual abuse and multiple traumas, TF-CBT has since been successfully applied to a variety of traumatic experiences. Core components of the protocol include psychoeducation, relaxation techniques, emotional regulation, cognitive processing, trauma narrative, in vivo exposure, conjoint child/caregiver sessions, and safety planning. The intervention is culturally informed and flexible to meet individual needs. Adjustments have been made in the context of unaccompanied minors (UAMs), where caregiver involvement is not feasible, due to specific circumstances in accommodation centers and Supportin Greece.
215113164|NCT06975280|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual (TAU) approach involves routine clinical management and psychological support, without the use of a structured therapeutic framework. This intervention consists of general, non-specific support provided by clinical staff, including informal counseling and monitoring of the child's psychological well-being. Unlike more structured therapeutic protocols, TAU does not follow a predefined set of interventions or techniques, allowing for a flexible and individualized approach, though lacking the formal therapeutic focus of interventions like TF-CBT.
215113165|NCT06974799|DIAGNOSTIC_TEST|Fatty acids measurement|Serum analysis for metabolomic biomarker identification
215113166|NCT06976034|DEVICE|Optical Transmission Tomography (OTT)|Multiple imaging sessions added by research using the systems described (OTT) will be carried out by two different operators at different positions during these sessions.
215113167|NCT06976034|DEVICE|Optical Coherence Tomography (OCT)|Multiple imaging sessions (OCT) already used in standard of care will be performed by two different operators at different positions during these sessions.
214511503|NCT01341769|OTHER|Dietary Intervention|
214511504|NCT00006079|DRUG|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
214511505|NCT00006079|OTHER|Placebo|Patients receive oral placebo daily for 28 days.
214511506|NCT05603949|DEVICE|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
214511507|NCT04214457|PROCEDURE|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
214511508|NCT05254067|DEVICE|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
214511509|NCT02971215|DEVICE|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~\+ Physical Therapy protocol."
214511510|NCT02971215|DEVICE|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
214427572|NCT04954196|DRUG|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
215113168|NCT06976034|DEVICE|Specular Microscopy (SM)|Multiple imaging sessions (SM) already used in standard of care will be performed by two different operators at different positions during these sessions.
215113169|NCT06976047|BEHAVIORAL|Tell-Show-Do|"The inferior alveolar nerve block will be administered utilizing a combination of the Tell-Show-Do technique and verbal distraction. Initially, the procedure will be explained to the child in simple, age-appropriate language to reduce fear and foster understanding (Tell). This will be followed by a demonstration of the materials and sensations involved, using models or non-threatening demonstrations on the child's hand (Show). Once the child appears comfortable, the actual administration of the nerve block (Do) will proceed exactly as explained, maintaining consistency between the explanation and the action. Throughout the process, verbal distraction will be continuously employed, engaging the child in non-procedural conversation, offering positive reinforcement, and using calming, encouraging language."
214511511|NCT03241810|DRUG|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
214511512|NCT03241810|DRUG|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
214511513|NCT03241810|DRUG|Placebo|Placebo
214511514|NCT04566263|DEVICE|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
214511515|NCT04255251|DRUG|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
214511516|NCT04255251|DRUG|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
214511517|NCT01773746|OTHER|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
214511518|NCT04140643|DEVICE|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
214511519|NCT04140643|BEHAVIORAL|Oral hygiene instructions|Oral Hygiene instructions
214511520|NCT04290533|DEVICE|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
214511521|NCT04290533|DEVICE|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
214511522|NCT06454929|PROCEDURE|operative|open reduction : fixation by k-wires or screws
214511523|NCT06454929|PROCEDURE|non-operative|close reduction : by cast Immobilization
214511524|NCT03445364|OTHER|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
214511525|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
214692421|NCT04148924|OTHER|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
214427573|NCT04954196|DRUG|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
214427574|NCT06820879|DEVICE|Viscoelastic Tests (ROTEM)|Viscoelastic Tests (2-6 tests for the study over the first 24 hours)
214427575|NCT06657976|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
214427576|NCT06657976|BEHAVIORAL|Attention Control|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
214427577|NCT06657976|COMBINATION_PRODUCT|Nitrate-Rich Beetroot Juice + supervised exercise therapy|Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
214427578|NCT06657976|COMBINATION_PRODUCT|Placebo + supervised exercise therapy|Participants randomized to this group will drink placebo while engaged in supervised exercise.
215113170|NCT06976047|BEHAVIORAL|Visual distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The light in the thumb sleeve is controlled by pressing a battery that turns the light on and off. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. Once the child appears comfortable, the actual administration of the nerve block will proceed."
214511526|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
214511527|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
214511528|NCT02252822|BEHAVIORAL|Overcoming Bulimia Online Programme|
215113171|NCT06976047|BEHAVIORAL|Sensory distraction|During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure.
215113172|NCT06976047|BEHAVIORAL|Visual and sensory distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure."
215113173|NCT06975345|OTHER|Multicomponent intervention. Hip flexors stretching, Strengthening exercises and education and medical treatment (Medication and medical counselling)|"Hip flexors stretching (Adaptation from Evjenth and Hamberg)~Strengthening Exercise~* Deep squats~* Flexo-extension of the ankle on a step over the head of metatarsal bones~* Plank~* Strengthening knee flexors and hip extensors~* Lunges with a stick behind the patient back~Education Pain relieving positions identified will be taught to the patient to use when they feel their pain.~Identifying and learning to avoid pain positions or activities that increase pain.~When the pain occur self stretching of hip flexors on the couch or the chair must be done"
215113174|NCT06975345|DRUG|Medical treatment.|A medical doctor will prescribe the treatment following the standard of care in Polish public health services. Treatment will consist of medication and counseling.
215113175|NCT06081920|BIOLOGICAL|IBI363|IBI363 monotherapy
215113176|NCT03453489|OTHER|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
215113177|NCT03453489|OTHER|Laboratory Biomarker Analysis|Correlative studies
214427579|NCT06463470|BEHAVIORAL|Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
214427580|NCT00541333|DRUG|Copaxone Injection|
214427581|NCT06613204|BEHAVIORAL|STELLA-FTD Control|Participants receive information about FTD and support via weekly group video-conference-based meetings.
214427582|NCT06613204|BEHAVIORAL|STELLA-FTD Test|The test group receives a information and support, but with a focus that is different from the Control Group
214511529|NCT04434651|PROCEDURE|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
214511530|NCT03592524|BEHAVIORAL|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
214511531|NCT06047535|DRUG|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
214692422|NCT04242017|DRUG|Triptoreline|Comparison of the duration of ADT (Triptoreline)
214692423|NCT02876055|DRUG|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
215113178|NCT03453489|PROCEDURE|Positron Emission Tomography|Undergo AMT-PET
214511532|NCT04295382|DEVICE|Software Application|A software application targeting suicidal ideation via interactive exercises.
214511533|NCT03529994|OTHER|Enrollment|All infants enrolled will have work of breathing assessed.
214511534|NCT03602950|BIOLOGICAL|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
214427583|NCT04036058|OTHER|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
214427584|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
214427585|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
214511535|NCT03524131|OTHER|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
214511536|NCT03524131|OTHER|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
214511537|NCT03524131|OTHER|current national leaflet|4-sided leaflet
214511538|NCT01706666|DRUG|bortezomib|Given SC
214511539|NCT01706666|DRUG|cyclophosphamide|Given PO
214511540|NCT01706666|DRUG|lenalidomide|Given PO
215113179|NCT03453489|DRUG|Telotristat Etiprate|Given PO
215113180|NCT04668872|RADIATION|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
215113181|NCT04668872|DIAGNOSTIC_TEST|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
214427586|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
214427587|NCT06668467|BEHAVIORAL|Mindfulness-based Stress Reduction|An 4-week Mindfulness-based stress reduction training programme
214511541|NCT01706666|OTHER|laboratory biomarker analysis|Correlative studies
214511542|NCT01706666|DRUG|dexamethasone|Given PO
214511543|NCT01706666|PROCEDURE|quality-of-life assessment|Ancillary studies
214511544|NCT01249209|DEVICE|lifestyle advice|
214511545|NCT05011292|BEHAVIORAL|Educational Video about SCB|3-4 minutes video about SCB.
214511546|NCT05011292|BEHAVIORAL|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
215113182|NCT04668872|DIAGNOSTIC_TEST|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
215113183|NCT05216263|DRUG|Atogepant|Oral Tablet
215113184|NCT06363240|DEVICE|Broadband Light|Broadband Light treatment
215113185|NCT05499871|BEHAVIORAL|Gait retraining intervention|Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.
214427588|NCT05485129|DEVICE|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
214427589|NCT06994806|DRUG|KQB168|Oral KQB168
214427590|NCT06994806|DRUG|Pembrolizumab|Intravenous pembrolizumab
214427591|NCT06673316|OTHER|Design thinking workshop|The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice.
214511547|NCT05011292|BEHAVIORAL|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
214511548|NCT03908164|BIOLOGICAL|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
214511549|NCT03375424|BIOLOGICAL|vedolizumab|duration of disease and kind of therapy
214511550|NCT02732132|DRUG|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
214511551|NCT02732132|DRUG|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
214511552|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
214511553|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
214511554|NCT04728282|PROCEDURE|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
214511555|NCT04728282|PROCEDURE|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
214511556|NCT01528605|DIETARY_SUPPLEMENT|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
214511557|NCT01528605|DIETARY_SUPPLEMENT|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
214511558|NCT01528605|DIETARY_SUPPLEMENT|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
214511559|NCT01528605|DIETARY_SUPPLEMENT|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
214511560|NCT01528605|DIETARY_SUPPLEMENT|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
214511561|NCT01528605|DIETARY_SUPPLEMENT|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
215113186|NCT05499871|DEVICE|Transition to minimalist footwear.|Participants will receive a running minimalist footwear.
215113187|NCT02989584|DRUG|Atezolizumab|
215113188|NCT02989584|DRUG|Gemcitabine|
215113189|NCT02989584|DRUG|Cisplatin|
214427592|NCT06671717|OTHER|Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation|"Drug: Pralatrexate, Chidamide~1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)~2. After the 6-week therapy, the patients should receive PET/CT evaluation.~3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.~4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies."
214427593|NCT06993870|DRUG|HBT-708|bispecific antibody
214427594|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 800 IU/day|Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
214511562|NCT01156675|DEVICE|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
214511563|NCT01156675|DEVICE|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
214427595|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 400 IU/day|Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
214427596|NCT05909566|OTHER|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
214427597|NCT05909566|DEVICE|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
214427598|NCT02487316|DRUG|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
214427599|NCT04848090|DIAGNOSTIC_TEST|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
214427600|NCT06677411|OTHER|Observention of vitamin D|It is an observational study
214427601|NCT07002073|DRUG|ketamine-dexmedetomidine admixture induction of Anesthesia|To compare incidence of hypotension following ketodex versus ketofol during induction of general anesthesia in elderly patients
214511564|NCT00390845|DRUG|SB681323|15 milligrams (mg)/day
214511565|NCT00390845|DRUG|Placebo|
215113190|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
214427602|NCT06871774|DEVICE|Single Perclose Pro vascular closure device|Use of a single Perclose device for pre-closure of vascular access site after removal of TAVR sheath.
214427603|NCT06871774|DEVICE|Dual Perclose vascular closure device|Use of two Perclose devices for pre-closure of vascular access site after removal of TAVR sheath.
214427604|NCT06862908|OTHER|placebo|placebo administered subcutaneously(SC), once a week
215113191|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
215113192|NCT06074159|BEHAVIORAL|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
214427605|NCT06862908|DRUG|IBI362|IBI362 administered subcutaneously(SC), once a week
214427606|NCT06677528|OTHER|Questionnaire|Questionnaire on Aortic Valve Disease, HADS-D, SCL-27, MLHFQ
214427607|NCT02999477|DRUG|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
214427608|NCT02999477|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
214511566|NCT04733417|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
214511567|NCT04733417|DRUG|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
214511568|NCT01463475|PROCEDURE|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
214511569|NCT04074252|DEVICE|Lofstrand Crutches|Device: Set of Lofstrand Crutches
214511570|NCT04074252|DEVICE|Axillary Crutches|Device: Set of Axillary Crutches
214511571|NCT03473041|PROCEDURE|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
214511572|NCT03473041|PROCEDURE|TVT-O|midurethral transobturator vaginal tape
214511573|NCT02326220|DRUG|Placebo|
214511574|NCT02326220|DRUG|Alirocumab|
214511575|NCT02699099|DIETARY_SUPPLEMENT|Vitamin A|Oral administration of Vitamin A (1 dose)
214511576|NCT02699099|BIOLOGICAL|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
214511577|NCT02699099|BIOLOGICAL|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
215113193|NCT04827992|DRUG|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
215113194|NCT04827992|BEHAVIORAL|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
215113195|NCT05286346|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
215113196|NCT05286346|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
215113197|NCT02093962|DRUG|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
215113198|NCT02093962|DRUG|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
214427609|NCT02999477|PROCEDURE|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
214427610|NCT06611982|OTHER|Unconditional cash transfer|$1000/month for 12 months
214427611|NCT06611982|OTHER|Contact information for social worker and financial counselor|Information on financial toxicity and contact information for social worker and financial counselor
214427612|NCT07019506|OTHER|Cardiac rehabilitation|Sessions are conducted individually in accordance with cardiac rehabilitation guidelines, with a frequency of 2-3 times per week, each lasting 1 hour. Intensity is progressively increased on a weekly basis, with adaptations made according to each patient's specific needs. A total of 20 sessions are delivered, focused on improving the patient's cardiovascular capacity
214427613|NCT06631976|DRUG|1ml of Depo-Medrol® injection|1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
214427614|NCT06631976|OTHER|Rehabilitation|Rehabilitation
214427615|NCT06631976|DRUG|Nerve block with 4ml of 2% lidocaine|Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
214427616|NCT06631976|DRUG|Tropocells® PRP injection|Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
214427617|NCT07023965|DRUG|NL003|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
214427618|NCT07023965|DRUG|Placebo|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
214427619|NCT07023094|DRUG|Ropivacaine 0.2% for PENG Block|U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
214427620|NCT07023094|DRUG|Ropivacaine 0.2% for LFCB|LFCB (0.1 mL/kg) with 0.2% ropivacaine
214427621|NCT07023094|DRUG|Ropivacaine 0.2% for L-ESPB|Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
214427622|NCT07023094|DRUG|Ropivacaine 0.2% for S-ESPB|Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
214427623|NCT07025304|DEVICE|REFLEX ULTRA 45|One time use for surgery
214427624|NCT06240715|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
214427625|NCT06701201|DRUG|SynKIR-110|Autologous T cells Transduced with Mesothelin KIR-CAR
214427626|NCT06701201|DRUG|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
214427627|NCT06423781|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
214427628|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
214427629|NCT03719092|OTHER|Best Practice|Receive usual care
214427630|NCT07033585|DRUG|Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
214427631|NCT07033585|DRUG|China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
214427632|NCT06711315|BEHAVIORAL|Oral Mucosit Care Protocol|"The children in the intervention group were subjected to a four-stage intervention carried out by the nurse researcher. The practices in each stage were as follows.~Stage 1: Oral care protocol training to prevent oral mucositis Stage 2: Introduction and application of training material (brochure) Stage 3: Introduction and implementation of oral care calendar Stage 4: Implementation of oral care protocol"
214427633|NCT06712615|BIOLOGICAL|PG-102|"* Participants will receive PG-102 by subcutaneous (SC) injection.~* Other Names: MG12"
214427634|NCT06712615|OTHER|Placebo|Participants will receive placebo by SC injection
214427635|NCT05669014|DRUG|Daxdilimab|Participants will be administered daxdilimab by subcutaneous (SC) injection.
214427636|NCT05669014|DRUG|Placebo|Participants will be administered identically matching placebo by SC injection.
214427637|NCT00573833|OTHER|questionnaire administration|
214427638|NCT00573833|PROCEDURE|quality-of-life assessment|
214427639|NCT00573833|RADIATION|brachytherapy|
214427640|NCT06720987|DRUG|KQB365|Intravenous KQB365
214427641|NCT06720987|DRUG|Cetuximab|Intravenous cetuximab
214427642|NCT07041099|DRUG|CLN-978|Specified dose on specified days
214427643|NCT07039539|BEHAVIORAL|Harm Reduction intervention|Care intervention guided by the harm reduction paradigm. Based on the acceptance of participants' needs as a starting point for constructing care responses. Guidance will be provided in collective meetings with information based on reliable scientific evidence and will support the construction of new knowledge and practices of mutual support.
214427644|NCT01128790|OTHER|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
214427645|NCT01128790|OTHER|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
214511578|NCT02699099|BIOLOGICAL|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
214511579|NCT01472159|BEHAVIORAL|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
214692424|NCT02876055|DRUG|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
215113199|NCT03930121|OTHER|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
214427646|NCT07047274|BEHAVIORAL|Education group (DBM/BMP)|A structured web-based training program, consisting of ten one-hour sessions, was delivered to students in the intervention group. To foster active engagement and reinforce learning outcomes, each session incorporated interactive, game-based activities through the Kahoot platform. The content of the training was developed in collaboration with a panel of 12 subject-matter experts, including specialists in emergency care, public health, internal medicine, surgery, and education. Additionally, the structure and thematic scope of the program were aligned with the emergency action guidelines of AFAD, Türkiye's official disaster management authority. The curriculum encompassed a comprehensive range of topics, including the classification of disasters, disaster awareness, risk assessment, use of personal protective equipment, triage procedures, post-disaster management, basic first aid practices, and the psychosocial dimensions of disaster response.
214427647|NCT07046351|BEHAVIORAL|weSIPsmarter|weSIPsmarter is grounded by the Theory of Planned Behavior as well as Satter's Feeding Dynamic Model. weSIPsmarter will also integrate relevant behavior change techniques and target concepts from health literacy, health numerary, media literacy, and eHealth literacy.
214427648|NCT07046351|BEHAVIORAL|weLearn2Read|weLearn2Read participants will have access to a website with resources to improve reading readiness, including 6 structured parent lessons, setting reading goals, and 6 children's books (one mailed home each week), and options to receive weekly reminders (e.g., email or text) to encourage reading readiness.
214427649|NCT07041684|DIETARY_SUPPLEMENT|Very Low Energy Ketogenic Therapy with vegan meal replacements|Metagenomics analysis of gut microbiota at baseline and after 45 days
214427650|NCT02186197|OTHER|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
215113200|NCT05814328|OTHER|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
214511580|NCT03572894|DEVICE|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~* T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~* T1 : Vt 8 mL/Kg of PBW during 5 minutes~* T2 : Vt 10 mL/kg of PBW during 5 minutes~* T3 : Vt 6 mL/kg of PBW during 5 minutes~* T4 : A single recruitment maneuver~Data will be recorded at each step."
214511581|NCT00241826|PROCEDURE|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
214511582|NCT00241826|PROCEDURE|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
215113201|NCT03201861|DRUG|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
214511583|NCT04012905|DRUG|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
214511584|NCT02656199|PROCEDURE|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
215113202|NCT03201861|DRUG|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
215113203|NCT06975774|DRUG|Purified Protein Derivative of BCG（BCG-PPD）|Thirty subjects were randomized, double-blinded to perform a homogeneous double-arm BCG-PPD skin test.
215113204|NCT06482112|DRUG|Efinopegdutide|SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
215113205|NCT06975839|DRUG|Metformin|local application of metformin gel after surgical removal of lower third molar tooth
215113206|NCT06975839|DRUG|non metformin gel|local application of placebo gel after surgical removal of lower third molar tooth
215113207|NCT06976905|PROCEDURE|Total laparoscopic hysterectomy|Hysterectomy by laparoscope using uterine manipulator or myoma screw as a manipulator of large uterus
215113208|NCT06974539|DIAGNOSTIC_TEST|Multiparametric ultrasound with contrast (Sonovue and Optison)|Participants will receive 3D mpUS using both Sonovue and Optison contrast agents during a single transrectal imaging session.
214511585|NCT00016107|DRUG|estramustine phosphate sodium|Given orally
214511586|NCT00016107|DRUG|docetaxel|Given IV
214511587|NCT00016107|BIOLOGICAL|bevacizumab|Given IV
214511588|NCT00016107|OTHER|laboratory biomarker analysis|Correlative studies
215113209|NCT06974513|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the auditory localization performance in patients with a first episode of psychosis. Results of this Arm 1 will be compared to those of Arm 2.
215113210|NCT05858892|OTHER|usual care|usual care(rehabilitation program)
215113211|NCT00585520|DRUG|Progesterone|200mg BID for 5 days
215113212|NCT00585520|DRUG|Placebo|Placebo
215113213|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
214511589|NCT00036140|DRUG|Investigational drug|
214511590|NCT04396938|DRUG|Lamotrigine|Active Drug Capsule
214511591|NCT04396938|DRUG|Placebos|Placebo Capsule
214511592|NCT01319344|DRUG|Eplerenone|25 mg o.d. per os
214511593|NCT00774605|DRUG|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
214511594|NCT00774605|DRUG|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
214511595|NCT04084262|DEVICE|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
215113214|NCT05941741|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.
215113215|NCT05941741|DRUG|Chemotherapy|Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles
215113216|NCT05941741|BIOLOGICAL|Immune checkpoint inhibitor|Cadonilimab: 10mg/kg, Q3W, 3 cycles
214427651|NCT07049861|OTHER|Comprehensive Multidisciplinary Obesity Care|CMOC is an innovative approach to obesity care delivery that leverages policy, clinical and community linkages, and digital technology for scalability. CMOC involves training providers (medical providers, registered dietitians, and behavioral health providers) to deliver guideline-based obesity care for youth and adults with obesity who receive Medicaid. Guidelines-based care involves screening, identification, weight counseling, and referral to intensive behavioral treatment by medical providers, and delivery of multicomponent intensive behavioral treatment by behavioral health providers and registered dietitians.
214427652|NCT07049861|OTHER|Implementation as Usual Control|The standard of care implemented in FQHCs in the absence of CMOC training.
214427653|NCT07053410|DEVICE|Direct 3D-Printed Retainer|Orthodontic retainers fabricated using direct 3D printing technology from digital STL models. The retainers are printed with biocompatible clear resin using an additive manufacturing process.
215113217|NCT05941741|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy will be performed to study group, with the use of IMRT.
215113218|NCT03953300|BIOLOGICAL|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
215113219|NCT03953300|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
215113220|NCT06974838|DEVICE|intermittent theta burst stimulation|stimulatory protocol
215113221|NCT06974643|OTHER|Thoracic epidural block|Patients will preoperatively receive an awake thoracic epidural block.
215113222|NCT06974643|OTHER|Paravertebral block|Patients will preoperatively receive a paravertebral block.
215113223|NCT06337032|DRUG|F/TAF (High Dose Tablet)|200/25 mg fixed-dose combination (FDC) tablet administered orally
215113224|NCT06337032|DRUG|F/TAF (Low Dose Tablet)|200/10 mg FDC tablet administered orally
215113225|NCT06337032|DRUG|F/TAF (Lowest Dose Tablet)|120/15 mg FDC tablet administered orally
214427654|NCT07053410|DEVICE|Single-Layer Thermoformed Retainer|Clear orthodontic retainers fabricated by thermoforming a single-layer thermoplastic sheet over a 3D printed dental model using a vacuum forming machine.
214427655|NCT07053410|DEVICE|Multi-Layer Thermoformed Retainer|Orthodontic retainers fabricated using a multi-layer thermoforming technique combining different thermoplastic materials to enhance durability and fit accuracy.
214427656|NCT07052916|OTHER|Music Therapy/MT|Therapeutic music lessons are the core component of the Music Therapy/MT intervention. Other components include guided music listening to help participants use music as a tool for regulating mood, energy, and attention, as well as music-centered discussions to help participants discover songs with personal meaning that they will enjoy learning to play.
214511596|NCT06402292|PROCEDURE|OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL|25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
214511597|NCT05528692|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
214511598|NCT01130870|DEVICE|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
215113226|NCT06337032|DRUG|F/TAF (High Dose TOS)|60/7.5 mg tablet for oral suspension (TOS) administered orally
215113227|NCT06337032|DRUG|F/TAF (Low Dose TOS)|30/3.75 mg TOS administered orally
215113228|NCT06337032|DRUG|F/TAF (Lowest Dose TOS)|15/1.88 mg TOS administered orally
215113229|NCT06337032|DRUG|E/C/F/TAF|150/150/200/10 mg tablet administered orally
215113230|NCT06337032|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg tablet administered orally
215113231|NCT06337032|DRUG|Cobicistat (High Dose)|150 mg tablet administered orally
215113232|NCT06337032|DRUG|Cobicistat (Low Dose)|90 mg tablet administered orally
215113233|NCT06337032|DRUG|Cobicistat (TOS)|30 mg TOS administered orally
215113234|NCT06337032|DRUG|B/F/TAF (High Dose)|50/200/25 mg FDC tablet administered orally
215113235|NCT06337032|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablet administered orally
215113236|NCT06337032|DRUG|B/F/TAF (High Dose TOS)|15/60/7.52 mg TOS administered orally
215113237|NCT06337032|DRUG|B/F/TAF (Low Dose TOS)|7.5/30/3.76 mg TOS administered orally
215113238|NCT06337032|DRUG|B/F/TAF (Lowest Dose TOS)|3.76/15/1.88 mg TOS administered orally
215113239|NCT06337032|DRUG|3rd ARV Agent|A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
215113240|NCT06337032|DRUG|Nucleos(t)ide reverse transcriptase inhibitors (NRTI)|NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
215113241|NCT06337032|DRUG|ATV|Administered according to the prescribing information
215113242|NCT06337032|DRUG|DRV|Administered according to the prescribing information
214427657|NCT07052916|OTHER|Therapist-Attention Music Education/TAME Control|Participants will receive 12, weekly 60-minute TAME sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts and serve as transitions to subsequent sessions. The TAME control group will involve board-certified music therapists guiding participants through music listening exercises.
214427658|NCT06896162|OTHER|Expert Review|Expert reflexive review of next-generation sequencing (NGS) results will be visible in electronic health records (EPIC) for provider review at the University of North Carolina Health System. Expert review will include recommendations for Genome-informed therapy (GIT), identification of available clinical trials, recommendations for additional testing, and/or referrals for genetic counseling.
214511599|NCT01130870|DEVICE|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
214511600|NCT01130870|DEVICE|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
214511601|NCT04718285|DRUG|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
214511602|NCT04718285|DRUG|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
215113243|NCT06337032|DRUG|Lopinavir Boosted with ritonavir (LPV/r)|Administered according to the prescribing information
214427659|NCT06896162|OTHER|Blood or tissue samples collection.|Blood or tissue samples will be collected for next-generation sequencing (NGS) per standard of care.
214427660|NCT06896162|OTHER|The Precision Oncology Navigation|The precision oncology navigator will coordinate the collection of blood and /or tissue for next-generation sequencing (NGS), as well as order the NGS if not already ordered. Precision oncology navigator will also assist in NGS financial aid applications, if applicable.
214427661|NCT02216500|DIETARY_SUPPLEMENT|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
214427662|NCT05844826|DEVICE|SIMBA Capsule|Participants will swallow capsule
214427663|NCT07054138|DRUG|Dexmedetomidine|Patients will be nebulized with dexmedetomidine 1 mcg/kg in 3 ml of 0.9 % saline 15 minutes before shifting the patients to the operating room with a face mask 6 L/min in a sitting position.
214427664|NCT07054138|DRUG|Normal Saline|Patients will be nebulized with 3 ml of 0.9% normal saline 15 minutes before shifting the patients to the operating room with a face mask, 6 L/min in a sitting position.
214427665|NCT07055529|DRUG|Group A recieving PUVA therapy|This group A will recieve PUVA therapy twice weekly for 6 months
214427666|NCT07055529|DRUG|Group B receiving Tablet Tofacitinib|This group will be given tablet Tofacitinib 5mg twice daily for 6 months
214427667|NCT07056179|BEHAVIORAL|Brief behavioural intervention|Participants will receive a brief behavioural intervention comprising a regularity-focused sleep diary, 10 tips for maintaining sleep regularity, and a sleep education information sheet. The regularity-focused sleep diary is designed to emphasize in-bed and out-of-bed times, drawing participants' attention to their sleep regularity. Participants will be provided with a yellow marker to highlight their sleep periods. The 10 tips for maintaining sleep regularity include establishing a consistent out-of-bed time, using natural light to regulate the circadian clock, adjusting mealtimes, etc. The sleep education sheet contains information on reducing caffeine intake in the afternoon, limiting screen time before bed, etc.
214427668|NCT07056179|BEHAVIORAL|Health education|Participants will receive general health information without specific emphasis on sleep, such as weight control, smoking cessation, etc.
214511603|NCT04718285|DRUG|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
214511604|NCT03507998|DRUG|CGX1321|CGX1321 capsules for oral administration
214511605|NCT01182532|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
214511606|NCT01182532|DRUG|TCM Syndrome Differentiation and Treatment|"1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
215113244|NCT04200417|PROCEDURE|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
215113245|NCT04200417|DRUG|Mitomycin C|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
215113246|NCT04200417|DRUG|Lipiodol|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
215113247|NCT04200417|DRUG|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
214427669|NCT03995069|BEHAVIORAL|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
214427670|NCT03995069|BEHAVIORAL|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
214427671|NCT07060625|BEHAVIORAL|Semi-reclining position|During anesthesia recovery, the patient's position should be in a semi-recumbent position
214427672|NCT07060430|PROCEDURE|Kaltenborn Mobilization|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Kaltenborn mobilizations with each mobilization technique performed for 10 repetitions, and each repetition maintained for 2 to 3 seconds. Mobilizations included palmar (volar) glide, dorsal glide, radial glide, and ulnar glide. In addition to wrist mobilizations, anterior and posterior glides were applied to the distal radioulnar joint.
214427673|NCT07060430|PROCEDURE|Mulligan Mobilization with Movement|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Mulligan's Mobilization with Movement (MWM) technique, which involved 10 repetitions of each mobilization, with each repetition held for 2 to 3 seconds. First, a lateral glide or rotational movement of the carpal bones on the radius was applied, accompanied by the patient actively performing the intended wrist movement, such as flexion, extension, or deviation. Second, an ulnar-directed mobilization of the radius was provided simultaneously with active patient movement.
214427674|NCT07061639|DRUG|QLS5133|antibody drug conjugate (ADC)
214427675|NCT07061886|DRUG|LSD|The serotonin 2A receptor agonist LSD
214427676|NCT07061886|DRUG|Placebo|Distilled water (0.26 mL)
214427677|NCT07059676|DRUG|Zejula (Niraparib)|PARPi inhibitors have been incorporated into managing first-line advanced ovarian cancer with different approvals depending on homologous recombination (HR) status. Niraparib has received approval independent from HR status. Although the benefit is more remarkable in HR-deficient patients, there is no biomarker to predict sustained response to niraparib at the start of treatment helping the clinician to make decisions among the different treatment options.
214511607|NCT01182532|OTHER|Western therapy plus TCM treatment|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
214427678|NCT07061665|BEHAVIORAL|Multi-level, Multi-component Intervention Package|The CBH COPI intervention applies multi-level strategies to improve children's environments and foster healthy behaviors. In schools, activities include schoolyard enhancements (e.g., hopscotch), inter-school sports events, nutrition lectures, healthy snacks, and educational materials linking health and academics. In parks and roads, improvements include cycling/walking promotions, signage, healthier vending machines, and community events. Supermarkets support healthy choices through menu information, loyalty incentives, cooking classes, product placement, and healthy food sales. At home and in communities, the Min-Challe app supports habit formation, with athletes, mascots, and ambassadors promoting healthy living. The coordinated program aims to naturally promote healthy eating, physical activity, and sustained lifestyle change among children aged 6-12 in Chiba City.
215113248|NCT05380349|DRUG|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
214427679|NCT07059780|DEVICE|Virtual Reality Glasses|Participants in the intervention group wore virtual reality (VR) glasses during the gynecological examination. The VR content included immersive nature-themed scenes accompanied by calming background music. The intervention aimed to provide a multisensory distraction to reduce perceived anxiety and pain levels during the procedure.
214511608|NCT00509756|DRUG|FXR-450|capsule, single oral doses from 10 mg to 450 mg
214511609|NCT00509756|DRUG|Placebo|capsule similar to active drug
214511610|NCT05308589|DEVICE|CPPF|Continuous Postoperative Pericardial Flush
214511611|NCT06452212|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
214511612|NCT04885166|OTHER|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
214511613|NCT04885166|BEHAVIORAL|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
214511614|NCT06989359|DRUG|ADX-038|siRNA duplex oligonucleotide
214511615|NCT05184062|DRUG|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
214511616|NCT05184062|DRUG|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
214511617|NCT01558544|PROCEDURE|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
214511618|NCT04084522|DIETARY_SUPPLEMENT|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
214511619|NCT04084522|DIETARY_SUPPLEMENT|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
214692425|NCT02876055|DRUG|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
215113249|NCT03106324|DRUG|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
215113250|NCT01985919|OTHER|Obtaining human tissue for basic research or biospecimen bank|
215113251|NCT05408091|DRUG|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
215113252|NCT03190460|OTHER|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
215113253|NCT03190460|OTHER|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
215113254|NCT05870865|DRUG|ASN008|ASN008 topical gel applied twice daily.
214427680|NCT07060040|DIETARY_SUPPLEMENT|BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g|Oral nutritional supplementation: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g
214427681|NCT07060040|DIETARY_SUPPLEMENT|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g
214427682|NCT07061444|OTHER|Inspiratory Muscle Training|Inspiratory muscle training will be performed at 40% of MIP workload, 1 set of 8-10 diaphragmatic respirations for 15 minutes, with 5-10 seconds rest intervals between sets. 5 days a week, 2 sessions per day.
214427683|NCT07061444|OTHER|Functional Inspiratory Muscle Training|This study investigates the integration of functional inspiratory muscle training (IMT) with conventional physiotherapy. Patients will perform inspiratory muscle training using the threshold loading technique with the POWERbreathe IMT device, combined with functional exercises. The functional IMT protocol will be administered face-to-face, 3 days a week, for 30 minutes per session over a 6-week period. Resistance on the IMT device will be set to 40% of the patient's maximal inspiratory pressure (MIP) and adjusted weekly based on measured MIP values. Exercises will be categorized into three progressive difficulty levels (easy, medium, and hard), with each stage lasting 2 weeks. Patients will inhale through the POWERbreathe IMT device during exercise movements and exhale during the return phase, ensuring simultaneous respiratory muscle activation and functional training.
214427684|NCT07061444|OTHER|Sham Inspiratory Muscle Training|Control group will be performed at 10% of the MIP workload, 1 set of 8-10 diaphragmatic breaths for 15 minutes, with 5-10 seconds rest intervals between sets. 2 sessions per day, 5 days a week.
214427685|NCT07060066|DEVICE|Active rTMS stimulation|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
214427686|NCT07060066|DEVICE|Sham rTMS stimulation|Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
214511620|NCT04851197|OTHER|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
214511621|NCT04865172|OTHER|Remote collection of passive and active data for 28 consecutive days|Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
214511622|NCT03263572|BIOLOGICAL|Blinatumomab|Given IV
214511623|NCT03263572|DRUG|Cytarabine|Given intrathecally via spinal tap
214511624|NCT03263572|DRUG|Methotrexate|Given intrathecally via spinal tap
214511625|NCT03263572|DRUG|Ponatinib|Given PO
214511626|NCT06362291|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
215113255|NCT05870865|OTHER|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
215113256|NCT06990698|DRUG|FP008 for injection|FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.
215113257|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
215113258|NCT06251115|DRUG|QY-1-T|QY-1-T is a TCR-T drug targeting HBV-related HCC
215113259|NCT04551807|PROCEDURE|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
215113260|NCT04551807|PROCEDURE|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
215113261|NCT06128369|DRUG|Dexamethasone Ophthalmic Suspension|Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
215113262|NCT06128369|OTHER|Vehicle of OCS-01|inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
215113263|NCT06674525|DRUG|626|Single subcutaneous injection
215113264|NCT06674525|DRUG|Placebo|Single subcutaneous injection
214511627|NCT06362291|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
214511628|NCT02321137|PROCEDURE|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
214511629|NCT02321137|PROCEDURE|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
214427687|NCT07060872|DIETARY_SUPPLEMENT|Spirulina Syrup|A natural dietary supplement derived from Spirulina algae, administered orally as a syrup formulation. Used as an adjunct therapy to assess its potential effect on reducing anxiety symptoms in children with non-idiopathic autism. Dosage and duration are standardized according to study protocol.
214427688|NCT07060872|DIETARY_SUPPLEMENT|Placebo Syrup|Placebo Syrup
214427689|NCT07060872|DRUG|Risperidone|Risperidone
214427690|NCT07060313|PROCEDURE|Ganglion Impar Block|The ganglion impar was accessed with a Quincke spinal needle, transsacrococcygeally (from between the first and second coccygeal vertebrae if sacrococcygeal access could not be achieved). Then, 1 mL of non-ionic contrast medium was administered, and fluoroscopic anterior-posterior and lateral imaging was performed to confirm the appropriate spread of contrast (Figure 1). After this confirmation, 2 mL of 0.5% bupivacaine, 2 mL of saline, and 40 mg of methylprednisolone acetate were injected.
214511630|NCT06621771|OTHER|Music intervention|Participants will engage in a step-by-step piano training consisting in playing piano pieces designed to involve all 5 digits of the paretic hand and increasing in complexity. They will be using a Musical Instrument Digital Interface (MIDI) piano program called Synthesia to display musical pieces on a computer screen that is adapted for people with no music reading abilities and will be playing on a touch sensitive piano keyboard. The supervised session will also be complemented with a unsupervised home program consisting of piano sequence exercises comprising short excerpts of the same musical pieces practiced during the supervised sessions and they will receive a roll-up flexible piano
214511631|NCT06621771|OTHER|Occupational Therapy|Participants will receive conventional occupational therapy treatment (e.g., mobility, ADL, IALD, information session), excluding treatments focusing specifically on arm and hand motor recovery.The supervised session will also be complemented with an unsupervised home program consisting of assignments related to occupational therapy exercises and/or IALD/ADLs.
214511632|NCT07013591|DRUG|MIB-626|An orally-administered stable crystalline tablet formulation of NMN
214511633|NCT07013591|OTHER|Placebo|matching placebo tablets
214511634|NCT07013240|DRUG|Botulinum toxin injection|"Intervention will be made immediately after surgery, still under general anesthesia, by the cardiac surgeon, after suture.~Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®, Allergan aesthetics) diluted in 1 mL of saline to enable injection of 5 IU at each point, every centimeter, at 1 cm of each scar side.~An equivalent volume of saline will be injected under the same modalities in the other part of the scar."
214511635|NCT07012889|DRUG|lidocaine infusion|The lidocaine group will receive initial intravenous bolus dose of 1.5mg/kg lidocaine over 10 min, followed by a continuous infusion of 1.5 mg/kg/h lidocaine until the end of surgery. The dose of lidocaine will be calculated according to ideal body weight. The placebo group will be administered normal saline at the same volume, infusion rate and timing.
214511636|NCT07012889|OTHER|Placebo|The placebo group will be administered normal saline 0.9% at the same volume, infusion rate and timing as lidocaine in the lidocaine group
214427691|NCT07060313|PROCEDURE|Ganglion Impar Block and Pericoccygeal Injection|In the combination therapy group who underwent pericoccygeal injection in addition to impar block, following the same procedure, 5 mL of 0.25% bupivacaine and 20 mg of methylprednisolone were injected into the posterior pericoccygeal region while the needle was withdrawn, thus also targeting blockade of the anococcygeal nerve.
214427692|NCT07060196|DIAGNOSTIC_TEST|Distant Visual Acuity|Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.
214427693|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical Coherence Tomography of the macula will be performed to all patients.
214427694|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography of the macula will be performed to all patients.
214427695|NCT07060196|DIAGNOSTIC_TEST|Autofluorescence imaging|Autofluorescence imaging using fundus camera for AMD staging.
214511637|NCT07013292|DRUG|SKYCLARYS (omaveloxolone)|"Skyclarys is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 and over. Opaque capsule with RTA 408 printed in white ink on the light green body and 50 printed in white ink on the blue cap. Capsules (size 0) measure 21.7 ± 0.3 mm in length and the outer diameter of the cap is 7.64 ± 0.06 mm. Omaveloxolone should be initiated and monitored by physicians experienced in treating patients with patients with Friedreich's ataxia. The recommended dose is 150 mg omaveloxolone (3 x 50 mg capsules) once daily."
215113265|NCT01768195|DRUG|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
215113266|NCT06921538|DEVICE|AscenZ-IV neuromodulation device|AscenZ-IV neuromodulation device is a novel treatment modality that utilizes 2 non-invasive neuromodulation technologies - tPCS and TENS - concurrently within a device. The home-based, non-invasive AscenZ-IV Stimulator therapy has been shown to improve spasticity and motor function
214427696|NCT07061743|BEHAVIORAL|activity management training|In activity management training, first week awareness training, second week ergonomics training, third week activity stepping training, fourth week joint-energy conservation training, and fifth week relaxation training will be given.
214511638|NCT07013188|OTHER|Neuromuscular function|Assessing their neuromuscular abilities using some functional and electromyography assessments
214511639|NCT05628363|DEVICE|Ethos Varian treatment system|Device that will be used to administer radiotherapy
214511640|NCT05628363|RADIATION|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
214511641|NCT05628363|DRUG|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
215113267|NCT06684587|BEHAVIORAL|Exercise Program|In this 10-week intervention, participants will be given strengthening exercises and neuromuscular re-education exercises.
215113268|NCT06684587|BEHAVIORAL|Mindful Exercise|In this 10-week intervention, mindfulness meditation will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis.
215113269|NCT06627205|BEHAVIORAL|Sleep Restriction Therapy|Therapist led sleep restriction therapy sessions.
215113270|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
215113271|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
215113272|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
215113273|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
215113274|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
215113275|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
215113276|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
215113277|NCT04838236|OTHER|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
215113278|NCT04838236|OTHER|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
215113279|NCT06727357|DRUG|Chemotherapy|in according to institutional guidelines
214427697|NCT07060443|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Indocyanine Green (ICG) is used to guide the extent of D3 lymph node dissection during right hemicolectomy. After informed consent, participants randomized to the experimental group undergo bowel preparation and receive an endoscopic submucosal injection of ICG (0.25 mg/ml in saline) at two sites adjacent to the tumor one day prior to surgery. During surgery, near-infrared laparoscopic or robotic imaging systems detect the fluorescence emitted by ICG, guiding targeted D3 lymph node dissection at the origins of the ileocolic artery (ICA) and middle colic artery (MCA).
214427698|NCT07060443|OTHER|Standard Right Hemicolectomy (Non-ICG)|Participants in the control group undergo standard right hemicolectomy with D3 lymph node dissection without the use of Indocyanine Green (ICG) or fluorescence imaging. The extent of dissection is determined by conventional anatomical landmarks and the surgeon's clinical judgment.
214427699|NCT07060599|OTHER|INvasion Screening with Intelligent Guidance for Histopathology Triage (INSIGHT) Workflow|An AI-generated segmentation model are refined through a post-processing pipeline: retaining only invasive carcinoma (IC) regions, filtering detections \<500 µm², grouping adjacent IC areas, and generating per-cluster bounding boxes (red boxes). This converted raw segmentations into clinically actionable ROI proposals, balancing sensitivity and specificity for pathologist review in external testing and clinical validation. The INSIGHT workflow addresses key diagnostic challenges in EIC cases by pre-screening whole-slide images (WSIs) and intelligently marking potential IC regions. This guides pathologists to prioritize diagnostically critical areas across multiple slides or within extensive DCIS - a task particularly valuable when IC is multifocal or presents as subtle micro-invasive foci easily overlooked during routine manual examination.
214427700|NCT07060144|BEHAVIORAL|Regular CPT|Standard-model Cognitive Processing Therapy (CPT) - one 60-min session per week for 12 weeks total
214427701|NCT07060144|BEHAVIORAL|Massed CPT|Massed CPT - two 60-min sessions each day for 5 consecutive days (10 sessions total)
214427702|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Cetuximab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
215113280|NCT06727123|OTHER|motivational interviewing|Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
215113281|NCT06727123|OTHER|Control|No application will be made. Routine follow-ups will be made.
215113282|NCT06726304|BEHAVIORAL|Baby Carrier Intervention|Mothers in the intervention group will have the opportunity to choose between two different soft ergonomic baby carriers and will receive instructions on how to use the carrier of their choice. Infants will be placed chest-to-chest in the carrier, supported by the mother's upper torso for a prescribed amount of time during the period of six weeks.
214427703|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Bevacizumab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
214427704|NCT07059689|DEVICE|High Flow Nasal Cannula (HFNC)|Participants in this arm will receive High Flow Nasal Cannula therapy using the Airvo™3 Nasal High Flow System immediately after planned extubation following cardiac surgery
214692426|NCT01239186|OTHER|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
214692427|NCT04065477|BEHAVIORAL|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
214427705|NCT07059689|DEVICE|Non-Invasive Ventilation (NIV)|Participants in this arm will receive Non-Invasive Ventilation (NIV) immediately after planned extubation following cardiac surgery. NIV will be delivered using standard ICU ventilator settings, with parameters tailored to each patient's clinical condition
215113283|NCT06390007|DEVICE|Sham press needle|The plester used is a round plaster that resembles the shape of an acupuncture press needle.
214511642|NCT06698380|OTHER|Conventional Physical Therapy|The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
214511643|NCT06698380|OTHER|Mirror Therapy|A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
214511644|NCT06699511|BEHAVIORAL|Exercise|Exercise
214511645|NCT06699576|DRUG|HS-20093|HS-20093: administered as an IV infusion
214511646|NCT06699576|DRUG|Anlotinib|Anlotinib: 12mg once daily (QD) orally
214511647|NCT06699576|DRUG|Epirubicin|Epirubicin: administered as an IV infusion
214511648|NCT06699576|DRUG|Adebrelimab|Adebrelimab: administered as an IV infusion
215113284|NCT06390007|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
215113285|NCT06726499|DEVICE|Spherical CRT|Contact lens for myopia progression
215113286|NCT06726499|DEVICE|Toric CRT|Contact lens for myopia progression
215113287|NCT05379673|OTHER|Oxygen Gas for Inhalation|Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
215113288|NCT06722014|BEHAVIORAL|STAMP + CBT|A mobile health, smartphone application that provides tailored multi-media, cancer pain psycho-education and pain management coping skills using algorithm-based technology to provide in the moment symptom monitoring and feedback.
214427706|NCT07061795|BEHAVIORAL|healthy living behaviors|Effect of prenatal care with home visits on healthy lifestyle behaviors during pregnancy
214427707|NCT07061223|PROCEDURE|SFIB|The block technique is based on administration of a local anesthetic under the iliac fascia to block the femoral, lateral femoral cutaneous, and obturator nerves. It is assumed that further leakage of local anesthetic through the interfascial space leads to blocking of the branches of the lumbar plexus in the small pelvis.
214427708|NCT07061223|PROCEDURE|PENG block|The hip capsule is the main source of pain because the innervation of the joint capsule is a developed network of articular branches of the femoral, sciatic and obturator nerves. The main idea of this technique is to block these branches at the point of common passage between the tendon of the lumbar muscle and the crest of the pubic bone. The block technique is based on administration of a local anesthetic under the ileo-lumbar tendon. Anesthetic spreads through the hip joint capsule and blocks small sensitive branches of the femoral and obturator nerves.
214427709|NCT07061223|PROCEDURE|Patient control analgesia|In the postoperative period, if pain occurs, the patient will be offered the opportunity to use 20 ug Fentanyl solution bolus according to the patient control analgesia (PCA) without a basic infusion.
214427710|NCT07061223|PROCEDURE|General inhalation anaesthesia|General inhalation anesthesia will be performed in all groups, Desflurane with a minimal alveolar concentration (MAC) of 0.6-0.8 will be used for maintenance
214511649|NCT06698484|DRUG|CAR-T cells|2×10\^6 CAR T cells/kg
214511650|NCT06881966|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Patients in the intervention group will consume 2 omega-3 capsules (Omevie) daily, which contain 36% and 24% of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, during a period of 3 months.
214511651|NCT06881966|OTHER|Placebo|The control group who will receive placebo supplementation, over a period of 3 months.The placebo capsules will be olive oil-based and will have the same visual as the omega-3 capsules. They will be developed by Vital Company.
215113289|NCT06722014|BEHAVIORAL|Digital Cancer Pain Education Packet|Packet including Articles from the Association for Clinical Oncology and the National Cancer Institute and the pain and medication monitoring form.
215113290|NCT05604989|DRUG|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
215113291|NCT05604989|DRUG|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
215113292|NCT06742281|BIOLOGICAL|CVXGA (CVXGA50)|CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
215113293|NCT06742281|BIOLOGICAL|COMIRNATY®|COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
215113294|NCT06893666|OTHER|Play based therapy|Experimental group was given pay based therapy. Total of 4 sessions were given each session of 40min.
215113295|NCT06893666|OTHER|Child centered play therapy|Control group was given child centered play therapy. Total of 4 sessions were given each session of 40min.
215113296|NCT06067269|DRUG|Apalutamide|Given PO
214511652|NCT06724419|BEHAVIORAL|Nutrition education-based intervention|The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 60-120 minutes.The aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational interventions, and each participant will be provided with the PMS management booklet.
214511653|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
214511654|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
214427711|NCT07060404|DRUG|Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water|Women will receive daily doses of PQ (0.5 mg/kg per day) for 14 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
214427712|NCT07060404|DRUG|Daily primaquine 1 mg/kg per day for 7 days given with food and water|Women will receive daily doses of PQ (1 mg/kg per day) for 7 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
214427713|NCT07060404|DRUG|Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort|Women will receive a single dose of 300mg tafenoquine. Treatment will be given with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
214427714|NCT07060703|DIAGNOSTIC_TEST|Osteodensitometry|"exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology.~comparison of ultrasound parameters (cortical thickness and porosity, among others) with BMD values (spine, right and left femoral necks) obtained by DXA.~\[Time Frame: 20 MIN\]"
214427715|NCT07061314|DEVICE|Elastic Barbell|A flexible plastic barbell that creates top-down perturbations during movement. Participants perform single-leg deadlifts using this elastic bar at three different speeds: normal (2 sec), fast (1 sec), and power (as fast as possible). The bar is loaded to 30% of the participant's estimated 1RM.
214427716|NCT07061314|DEVICE|Inelastic Barbell|A standard rigid steel barbell with no elasticity. Participants perform single-leg deadlifts using this barbell under the same speed conditions and loading parameters as the elastic barbell.
214427717|NCT07061652|BEHAVIORAL|Survey|Participants will receive up to eight coaching sessions with a caregiver coach and resource materials and access to an online tool designed to help caregivers find resources.
214511655|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
214511656|NCT07052825|PROCEDURE|CTR implantation|Phaco+IOL with CTR implantation
214511657|NCT06442748|DRUG|Levetiracetam|Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
214511658|NCT07099157|DRUG|Brivudine|brivudine 125 mg per dose, once daily, 7 days
215113297|NCT06067269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214427718|NCT07061652|OTHER|the resource booklet from the American Cancer Society|The caregiver will receive the resource booklet from the American Cancer Society.
214427719|NCT07061600|BEHAVIORAL|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in youth as well as its Social Media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e. short videos with overlays of text and music). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
214427720|NCT07061600|BEHAVIORAL|Instagram profile that provides educational content|The participants of the control group asked to follow an Instagram profile that provides educational content produced by a public broadcaster (https://www.instagram.com/terrax/) and is not dedicated to the topic of mental health. This channel also posts several times a week and provides educational or informational content.
214427721|NCT07061210|DRUG|HRS-2189|HRS-2189
214427722|NCT07061210|DRUG|Adebrelimab|Adebrelimab
214427723|NCT07061210|DRUG|BP102|BP102
215113298|NCT06067269|PROCEDURE|Computed Tomography|Undergo PSMA-PET/CT
215113299|NCT06067269|OTHER|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
215113300|NCT06067269|RADIATION|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
215113301|NCT06067269|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
215113302|NCT06067269|PROCEDURE|Positron Emission Tomography|Undergo PSMA-PET/CT
214511659|NCT07099157|DRUG|Famciclovir|orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
214511660|NCT07099989|DRUG|Zelquistinel 3 mg|Subjects will receive Zelquistinel 3 mg in fed and fasted state (high fat meal).
214511661|NCT07099989|DRUG|Zelquistinel 10 mg|Subjects will receive Zelquistinel 10 mg in fed and fasted state (high fat meal).
214511662|NCT01553214|DRUG|Filgrastim|Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.
214511663|NCT01553214|DRUG|Dexamethasone|Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
214511664|NCT06919718|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|2,000 IU Vitamin D
214511665|NCT06919718|OTHER|Placebo|Placebo
214511666|NCT06945549|DIAGNOSTIC_TEST|18F-FAPI PET Imaging|The ROI of the target lesions was delineated based on 18F-FAPI PET Imaging, and the lesions were divided on the cross section to obtain the lesions SUVmax, SUVmean, SUVpeak, FAPI metabolic volume (FAV), MTV, TBR, and TLG.
215113303|NCT06067269|OTHER|Questionnaire Administration|Ancillary studies
215113304|NCT03491787|DEVICE|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
215113305|NCT04748289|DEVICE|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~1. ICU Cockpit COVID-19 for remote monitoring of isolated patients,~2. ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~3. ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
214427724|NCT07059559|OTHER|Rhythmic walking|Patients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group.
215113306|NCT07061392|OTHER|standardized-patient simulation|"Intervention Arm (Group M) Participants randomized to Group M (n = 45 enrolled; 43 analyzed) first completed baseline assessments of meaningful learning self-awareness , perceived learning, and stoma-care skill , as well as a 10-item demographic survey. They then attended a two-hour didactic session-covering stoma indications, types, perioperative care, evidence-based practices, complications, and the stoma-care nurse's role-delivered by a certified stoma-care nurse in small groups.~Immediately following the lecture, each nurse participated in a two-hour hands-on simulation with a trained standardized patient. The standardized patient had been prepared with a realistic stoma moulage (transparent drape and egg-biscuit mixture) and received two hours of role-training. Simulation sessions adhered to INACSL Standards (pre-briefing, in-scenario, observation, and debrief"
214427725|NCT07060352|DIAGNOSTIC_TEST|Ankle Dorsiflexion Index (ADI) measurement|Ankle Dorsiflexion Index (ADI) measurement at D0 and W8
214427726|NCT07060170|DEVICE|Augmented Reality Glasses|The child will wear the augmented reality glass, and a cartoon movie will be displayed during the injection of local anesthesia
214427727|NCT07060170|DEVICE|Virtual Reality Glasses|The child will wear the glass, and a cartoon movie will be displayed during the injection of local anesthesia.
214427728|NCT07061587|BEHAVIORAL|Gout action plan|Gout action plan (that we aim to develop and refine during the study based on traffic light color system which will be categorized into zone system- green zone (well controlled), yellow zone (mild symptoms), red zone (severe symptoms). It will outline how to manage gout, identifying triggers, recognizing symptoms, appropriate medication usage, and when to seek medical attention)
214427729|NCT07061093|DRUG|Ethynyl estradiol and Drospirenone|Oral ethynyl estradiol (20 mcg) and 3 mg drospirenone for 24 days and 4 days free of hormones
214427730|NCT07061093|DRUG|Drospirenone|A drospirenone (4mg) only pill
214427731|NCT07061093|DRUG|Estetrol and Drospirenone|Oral estetrol (15 mg) and drospirenone (3 mg) for 24 days and 4 days of interval free of hormone
214427732|NCT07059871|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
214427733|NCT07059871|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
214427734|NCT07061171|DEVICE|Continuous Positive Airway Pressure|Using a ResMed S9 AutoSet-S device with a pressure range of 4-20 cmH2O. Used for 5-7 hours per night, at least 5 nights per week, for 3 months.
214427735|NCT07061171|DRUG|Herbal Decoction|A daily dose of a decoction containing Ban Xia, Ju Hong, Shi Chang Pu, Yu Jin, Lai Fu Zi, Fu Ling, Bai Zhi, Cang Er Zi, and Gan Cao, administered orally in two divided doses.
214427736|NCT07061171|PROCEDURE|Acupuncture|Daily sessions with needle retention for 30 minutes, 5 times per week. Acupoints included Anmian (EX-HN22), Lianquan (CV23), Shanzhong (CV17), Zhongwan (CV12), Kongzui (LU6), Pishu (BL20), Fenglong (ST40), Zusanli (ST36), Yinlingquan (SP9), and Zhaohai (KI6).
214427737|NCT07061171|PROCEDURE|Tuina Massage|Includes massage techniques applied to the head and occipital region to relax muscles and improve local circulation.
214427738|NCT07060885|BIOLOGICAL|HDM SLIT-tablet (12 SQ-HDM)|"For daily administration (1 tablet per day)~Other Names: Acarizax, Odactra"
214427739|NCT07060885|OTHER|Placebo|For daily administration (1 tablet per day)
214427740|NCT07061015|PROCEDURE|osseodenification with osseodensifying burs|different osseodensification techniques to be studied
214427741|NCT07061015|PROCEDURE|reverse drilling|using the conventional drills in reverse mode
214427742|NCT07061015|PROCEDURE|rotary expanders|expanders in clockwise direction
214511667|NCT05640895|PROCEDURE|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
214511668|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
214427745|NCT07059832|DRUG|68Ga-NODAGA-SNA006|68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
214427746|NCT07061574|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
214511669|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
214427747|NCT07061574|DRUG|verapamil extended-release capsule|Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
214427748|NCT07061574|DRUG|Adalimumab|40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.
214427749|NCT07060534|BEHAVIORAL|Building Healthy Eating and Self-Esteem Together for University Students|Building Healthy Eating and Self-Esteem Together for University Students (BEST-U) is an mHealth program that includes modules based on second- and third-wave behavior therapy deployed through a smart phone app paired with 20-30-minute coaching sessions. BEST-U incorporates a range of evidence-based skills, and the electronic format allows coaches immediate and easy access to participant reports. BEST-U provides a comprehensive all-in-one assessment and intervention package, is easy-to-implement, brief, and has been tested across genders and in diverse ages and ethnic groups. BEST-U, therefore, has the potential to deliver effective, time-limited, interventions applicable to all university students in routine student healthcare settings.
214427750|NCT07060534|BEHAVIORAL|Present-Centered Therapy|"Present-Centered Therapy (PCT) is a brief intervention that focuses on building adaptive responses to current life stressors that are directly or indirectly related to psychopathology. PCT focuses on resolving interpersonal disconnection through the development of a positive therapeutic relationship, encouraging connection with others, and addressing interpersonal concerns. PCT was originally developed as a placebo intervention for post-traumatic stress disorder but is significantly more efficacious than wait-list in reducing psychiatric symptoms."
214427751|NCT07060274|PROCEDURE|Doppler Ultrasound|Doppler ultrasound of temporal arteries at D0, D3 and D7 (+ D15 if halo detected at D7) after initiation of corticosteroid therapy.
214427752|NCT07059611|BIOLOGICAL|RP2|Upper endoscopy with RP2 intra-tumoral injection of 1 x 10(6) plaque forming units (PFU)/mL for first intra-tumoral injection, up to 10mL of 1x107 PFU/mL of RP2 for subsequent intra-tumoral injections. Injection will occur within 4 days prior of each cycle FLOT.
214427753|NCT07059611|COMBINATION_PRODUCT|5-Fluorouracil|5-Fluorouracil as part of the FLOT regimen 2,600mg/m2 intravenous infusion over 24 hours on day 1 of each 14-day cycle for 4 cycles.
214427754|NCT07059611|COMBINATION_PRODUCT|Leucovorin|Leucovorin as part of the FLOT regimen 200mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
214427755|NCT07059611|COMBINATION_PRODUCT|Oxaliplatin|Oxaliplatin as part of the FLOT regimen 85mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
214511670|NCT06415227|DRUG|Vericiguat|The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
214511671|NCT04445337|DRUG|Stellate Ganglion Block|"An injection of local anesthetic into the front of the neck. SGB involves placing a small tube into the front of your neck, toward nerves at the back of your neck. This is done with the help of an x-ray machine or ultrasound device. The tube is left in place so you can get medication thru it for five days. Then the tube is taken out.~The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block. These medications are approved by the Food and Drug Administration (FDA)."
214511672|NCT03659136|DRUG|Xentuzumab|Intravenous infusion
214511673|NCT03659136|DRUG|Placebo|Intravenous infusion
214511674|NCT03659136|DRUG|Everolimus|Tablet
214427756|NCT07059611|COMBINATION_PRODUCT|Docetaxel|Docetaxel as part of the FLOT regimen 50mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
214427757|NCT07059611|DRUG|Pegfilgrastim|Pegfilgrastim or Filgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
214511675|NCT03659136|DRUG|Exemestane|Tablet
215113307|NCT07061392|OTHER|a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model|"Control Arm (Group K) Participants randomized to Group K (n = 45 enrolled; 44 analyzed) underwent the identical sequence of baseline assessments and the same two-hour didactic session as Group M. For the practical component, they performed stoma-care simulation on a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model.~Hands-on practice was structured in small groups over two hours and included:~Pre-briefing: Overview of objectives and materials.~In-scenario: Individual stoma-care performance on the mannequin, guided by the certified stoma-care nurse with cueing as needed.~Observation: Peers observed from a separate area with scenario summaries.~Debriefing: Reflection and feedback using the PEARLS framework to consolidate learning and discuss transfer to clinical practice.~Immediate post-training assessments using the same three scales captured outcomes in meaningful learning self-awareness, perceived learning, and stoma-care skill level."
214427758|NCT07059611|DRUG|Filgrastim|Filgrastim or Pegfilgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
214511676|NCT04832724|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
214511677|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
214511678|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
214511679|NCT03644082|BEHAVIORAL|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
214511680|NCT03644082|BEHAVIORAL|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
214511681|NCT03644082|BEHAVIORAL|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
214511682|NCT03644082|BEHAVIORAL|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
214511683|NCT03644082|BEHAVIORAL|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
214511684|NCT03644082|BEHAVIORAL|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
215113308|NCT06757764|DRUG|Aspirin|"Aspirin 100mg qd (21days)~* In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
215113309|NCT06757764|DRUG|Clopidogrel|"Clopidogrel 75mg qd (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
215113310|NCT06757764|DRUG|Cilostazol|"Cilostazol SR 100mg x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
215113311|NCT06757764|DRUG|Placebo|"Placebo x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
215113312|NCT07061483|BEHAVIORAL|Experimental (Gratitude Journaling)|60-Day Gratitude Journaling With Guided Prompts
215113313|NCT07061483|BEHAVIORAL|Control (journaling without gratitude)|60-Day Journaling Without a Gratitude Focus
215113314|NCT07056751|DEVICE|Air negative ion intervention study|The observation group received air negative ion intervention every night for one week before entering the plateau (from 22:00 to 06:00). Before entering the plateau, they were in Putian City, China, where the temperature was about 28°C, humidity was about 68%, and the concentration of negative ions was approximately 800/cm³. The air negative ion converter used was the Mi Energy ET-21 model from RELTEC Medical Devices Corporation. Air negative and positive ion concentrations were measured using an ion detector (NKMH-103, HOKUTO, Japan) to ensure that each participant's room had a negative ion concentration of around 100,000/cm³.
215113315|NCT07056751|DEVICE|No air negative ion intervention|No air negative ion intervention
215113316|NCT05376267|DEVICE|Therapeutic Hypothermia|"Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours."
214427759|NCT07059611|PROCEDURE|Surgical Resection of Primary Tumor|Following 4 cycles of preoperative FLOT with RP2 injections, surgical resection of esophageal, GEJ, or gastric primary tumor per standard of care practice.
214427760|NCT07061002|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. In this group, just before extubation, the patients in this group will be given 6 breaths with a tidal volume of 2 times the vital capacity, an inspiratory/expiratory ratio of 1/1 and a lung plateau pressure of \< 35 cmH2O, and a recruitment maneuver will be performed at the end of the surgery.
214427761|NCT07061002|OTHER|Positional Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens the length of hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. Patients in this group will be placed in the right and then left lateral decubitus position before extubation at the end of surgery and a recruitment maneuver will be performed by giving 6 breaths in each position, with a tidal volume twice the vital capacity, a 1/1 inspiratory/expiratory ratio, and a lung plateau pressure \< 35 cmH2O.
214427762|NCT07060651|OTHER|Present odors to participants while recording and stimulating brain activity|Present odors to participants while recording brain activity
214427763|NCT07061249|BEHAVIORAL|Waltz Dance|Participants in this arm will receive a structured Waltz dance intervention as moderate-intensity aerobic exercise. The program consists of 3 supervised sessions per week for 12 weeks, each lasting 105 minutes. Each session includes a 5-minute warm-up, 50 minutes of solo and partner Waltz practice, a 5-minute rest, 40 minutes of choreographed combinations, and a 5-minute cool-down. The dance routines are progressive and designed to improve cardiovascular fitness, coordination, and balance. Exercise intensity is maintained at 50-70% of estimated maximum heart rate, with music tempo and movement complexity adjusted as needed. Physical activity is monitored using accelerometers to ensure target intensity is achieved.
214427764|NCT07060183|PROCEDURE|Ross procedure|aortic valve replacement
214427765|NCT07061418|OTHER|Dental Implant|Dental implants were placed to volunteers in need of implantation in mandible, maxilla or both
214427766|NCT05242744|DRUG|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
214427767|NCT04580485|DRUG|INCB106385|INCB106385 will be administered orally QD
214427768|NCT04580485|DRUG|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
214427769|NCT06835400|DRUG|Paclitaxel Capsule|Paclitaxel Capsule
214427770|NCT06835400|DRUG|IV Paclitaxel|IV Paclitaxel
214427771|NCT06835400|DRUG|Encequidar tablet|Encequidar tablet
214427772|NCT07061730|BEHAVIORAL|Traditional Therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP.
214427773|NCT07061730|BEHAVIORAL|Hybrid therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP. In addition to these weekly sessions, the child will practice using the AI-based speech therapy tool, Jessica, at home between sessions for 60 minutes per week. The tool will provide real-time feedback on the child's articulation and track their progress. The child will be asked to practice specific speech exercises, such as producing target sounds (e.g., /r/, /s/) in words, phrases, or sentences.
214427774|NCT07061873|PROCEDURE|Aerobic excersise|20 aerobic exercise sessions, with a duration of 45 to 60 minutes, for 10 weeks.
214427775|NCT07061873|PROCEDURE|Muscle strength limbs, inspiratory muscle strength|20 sessions of exercise Muscle strength limbs, inspiratory muscle strength, with a duration of 60 minutes, for 10 weeks
214427776|NCT06655675|DEVICE|Ultrasound|Ultrasound scan of the umbilical artery
214427777|NCT06835569|DRUG|ALTA3263|Oral ALTA3263 tablets will be administered at a protocol-defined dose
214511685|NCT03644082|BEHAVIORAL|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
214511686|NCT03644082|BEHAVIORAL|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
214511687|NCT03644082|BEHAVIORAL|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
214511688|NCT03909074|BIOLOGICAL|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
214511689|NCT03909074|BIOLOGICAL|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
214511690|NCT03909074|BIOLOGICAL|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
214511691|NCT04173000|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
214511692|NCT04173000|OTHER|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
215113317|NCT06895629|BEHAVIORAL|PRO-MAMAS (Promoting participation, health and wellbeing through meaningful maternal-role activities after stroke)|PRO-MAMAS - a novel occupational therapy intervention program to promote participation, health and wellbeing of older mothers with chronic stroke.
214511693|NCT01578304|DRUG|Imidafenacin|Tablet, 12 weeks twice daily
215113318|NCT06771921|DRUG|GEN1078|Specified dose on specified days.
214511694|NCT01578304|DRUG|Fesoterodine|Tablet, 12 weeks once daily
214427778|NCT05508737|DRUG|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
214427779|NCT02290834|OTHER|Cognitive, functional and subjective assessments|Cognitive and functional assessments
214511695|NCT06012799|DIAGNOSTIC_TEST|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
214511696|NCT01190488|BEHAVIORAL|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
214511697|NCT01190488|BEHAVIORAL|Active Comparator|TAU
214427780|NCT02290834|DEVICE|MRI|Magnetic Resonance Imaging (MRI) Scan
214511698|NCT06049199|OTHER|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
215113319|NCT07064772|OTHER|First Rib Mobilization|Participants in the mobilization group will receive either a seated or supine three stage progressive muscle energy technique (MET) plus a singular high-velocity, low-amplitude thrust (HVLAT) mobilization technique directed to their first rib on their symptomatic side based on the discretion of the treating physical therapist.
214427781|NCT02290834|RADIATION|PET Scan|Positron Emission Tomography (PET) Scan
214427782|NCT02677974|DEVICE|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
214427783|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
214427784|NCT05399329|DRUG|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
215113320|NCT07064772|OTHER|Sham Comparator|Participants in the sham mobilization (control) group will be placed in a supine, hook-lying position identical to the mobilization group; however, they will be instructed to inhale and exhale 3 times using diaphragmatic breathing (avoiding upper chest recruitment) as the physical therapist gently rests his or her hand over the area of the upper trapezius muscle just proximal to the first rib to simulate a sham mobilization hand placement. Therefore, physical therapists will not use any significant compressive force to the musculature, perform any tactile cueing for upper chest breathing, perform any mobilizations, nor perform any HVLAT techniques to participants in the sham mobilization group.
214511699|NCT02830893|DEVICE|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
214511700|NCT02830893|BEHAVIORAL|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
214511701|NCT01277302|DRUG|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
214511702|NCT06470347|DRUG|A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy|During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
214511703|NCT05185674|OTHER|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
214511704|NCT00731692|DRUG|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
214511705|NCT00731692|DRUG|Placebo|Matching placebo capsules were administered orally once daily
214511706|NCT01404702|DRUG|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
214511707|NCT01404702|BIOLOGICAL|Aldesleukin|"Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
214511708|NCT00972686|DRUG|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
214511709|NCT05646602|DRUG|Collagenase Clostridium Histolyticum|Intralesional injection
214511710|NCT05646602|DEVICE|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
214511711|NCT05293691|BEHAVIORAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
214511712|NCT05293691|BEHAVIORAL|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
214511713|NCT03627572|OTHER|No intervention|Not applicable (no intervention)
214511714|NCT04443556|DRUG|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
214511715|NCT04443556|OTHER|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
215113321|NCT07066982|BIOLOGICAL|CD146/HER2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/HER2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD146/HER-2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/HER-2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
214511716|NCT01666171|DRUG|metformin hydrochloride|
214511717|NCT01666171|OTHER|clinical observation|
214511718|NCT01666171|OTHER|diagnostic laboratory biomarker analysis|
214511719|NCT01666171|OTHER|imaging biomarker analysis|
215113322|NCT07065682|DRUG|Aloevera + dutasteride|Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day
214511720|NCT01666171|OTHER|medical chart review|
214511721|NCT01666171|PROCEDURE|digital mammography|
214511722|NCT05652452|OTHER|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
214511723|NCT05652452|OTHER|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
214511724|NCT01394406|DRUG|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
214511725|NCT01394406|DRUG|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
214511726|NCT01581333|DRUG|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
214511727|NCT01581333|DRUG|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
214511728|NCT05935072|BEHAVIORAL|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON\_Calibré: control condition with a calibrated test meal; CON\_AdLib: control condition with an ad libium test meal; EX\_Calibré: exercise condition with a calibrated test meal; EX\_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
214511729|NCT02596178|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
214511730|NCT03332589|DRUG|E6201|E6201 formulated in cyclodextrin for IV administration.
214511731|NCT03332589|DRUG|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
214511732|NCT01275872|OTHER|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
214511733|NCT05283200|BEHAVIORAL|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
214511734|NCT05283200|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
214511735|NCT05283200|BEHAVIORAL|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
214511736|NCT03990376|OTHER|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
214511737|NCT00279409|DRUG|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
214511738|NCT00279409|DRUG|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
214511739|NCT05653609|DEVICE|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
214511740|NCT03957759|DIAGNOSTIC_TEST|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
215113323|NCT07065682|DRUG|Dutasteride (0.5mg)|Control
215113324|NCT07065006|DIAGNOSTIC_TEST|Qor-40 test (The recovery quality test)|Scale of postoperative recovery quality at first 24th hour. Minimum score is 40=bad ,maximum score is 200=good
215113325|NCT07065006|OTHER|Calculation of postoperative opioid consumption|Postoperative opioid consumptions on the pca (patient controlled analgesia) device of the patients will be recorded in Postoperative 30.min,1.,6.,12.,24. Opioid consumptions on the pca device of the patients will be recorded in 30.min,1.,6.,12.,24. hours.
214511741|NCT03161509|DRUG|Paracetamol|single dose of 1 gr paracetamol
214511742|NCT03161509|DRUG|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
214511743|NCT04745455|OTHER|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
215113326|NCT07066241|DEVICE|Virtual Reality Glasses|The Effect of Virtual Reality on Stress, Pain Levels and Vital Signs in Patients with Hyperthyroidism Undergoing Fine Needle Biopsy
214511744|NCT03627299|DRUG|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
214427785|NCT05399329|DRUG|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
214427786|NCT06909838|DEVICE|radial Extracorporeal shockwave therapy (rESWT)|4 rESWT interventions, with a one week interval, are added to the conventional treatment plan
214427787|NCT06909838|OTHER|Conventional treatment|Usual conventional therapy, including physiotherapy, ergotherapy, hippotherapy,..
214427788|NCT06325696|DRUG|hymecromone|400 mg
214427789|NCT06905626|DRUG|Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule|Qsymia
214427790|NCT06905626|DRUG|Placebo|Placebo
214427791|NCT03996083|OTHER|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
214427792|NCT03996083|OTHER|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
214427793|NCT03815396|DRUG|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
214427794|NCT06937879|OTHER|Hand Grip Strength|The grip strength of the participants will be performed with a hydraulic hand dynamometer on a chair with back and arm support. The participant will be asked to squeeze the dynamometer with maximum force. The measurement will be performed 3 times and the average value will be recorded.
214427795|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
214427796|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
214427797|NCT06943599|OTHER|Text Message Reminder|Participants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit.
214427798|NCT06943599|OTHER|Health Worker Visit|Participants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit.
214427799|NCT06940414|OTHER|No Intervention|This is an observational study with no interventions. POCT devices, provided by Eaglenos Sciences, Inc., are used to measure blood glucose, creatinine, uric acid, hemoglobin, and potassium levels in non-dialysis CKD patients for data collection purposes only.
214427800|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
214427801|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
214427802|NCT07060989|DRUG|NTS071|Oral administration
214511745|NCT00108355|DRUG|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
214511746|NCT00108355|DRUG|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
214511747|NCT00108355|DRUG|Midodrine|Midodrine oral tablet at 10 mg three times a day.
214511748|NCT00108355|DRUG|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
214511749|NCT00108355|DRUG|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
214511750|NCT00108355|DRUG|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
214511751|NCT00108355|PROCEDURE|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
214511752|NCT06580990|PROCEDURE|specific neck exercises with the Spinetrack|This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack
214511753|NCT06580990|PROCEDURE|specific neck exercises|This group will receive a telerehabilitation programme with exercise for the deep neck musculature
214511754|NCT00961597|PROCEDURE|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
214511755|NCT00961597|PROCEDURE|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
214511756|NCT04172688|DIETARY_SUPPLEMENT|Prebiotic oligofructose-enriched inulin|Synergy1
214511757|NCT04172688|DIETARY_SUPPLEMENT|Placebo maltodextrin|Equicaloric dose of maltodextrin
214511758|NCT00386399|DRUG|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
214511759|NCT06046807|OTHER|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
214511760|NCT01523184|DRUG|Placebo Capsule|This is the placebo capsule
214427803|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (2X)|The (1) control group (2X) will receive an exercise screening checklist and 24 group training sessions, 2 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults.
214427804|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (3X)|The (3) experimental group (3X) will receive an exercise screening checklist and 36 group training sessions, 3 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults. This additional session will increase weekly exercise volume compared to the control group, also being closer to complying to the WHO International Guidelines of weekly physical activity (Bull et al., 2020)
214427805|NCT03047239|DEVICE|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
214511761|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
214511762|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
214427806|NCT06205303|OTHER|Patient Decision Aid (Video)|Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
214427807|NCT05334004|DRUG|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
214427808|NCT04854863|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
214427809|NCT03204565|PROCEDURE|coronally advanced flap|coronally advanced flap alone (CAF- control)
214427810|NCT03204565|DEVICE|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
214427811|NCT03351075|OTHER|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
215113327|NCT07065071|OTHER|Mentalization-Based Therapy|Group MBT that takes place as part of treatment as usual within Derbyshire Healthcare NHS Foundation Trust's Older Adult Community Mental Health Team's service.
214427812|NCT03351075|OTHER|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
214427813|NCT03351075|OTHER|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
214427814|NCT05664204|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
214427815|NCT06394284|DRUG|MDMA-AT|As described above in arm description
214427816|NCT06394284|BEHAVIORAL|SEA-IT|As described in arm description
214427817|NCT06459063|DRUG|Allocetra - Safety run-in phase|Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
214427818|NCT06459063|OTHER|Placebo|Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
214427819|NCT06459063|DRUG|Allocetra - Randomization phase|Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
214511763|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
214511764|NCT00674037|OTHER|monetary incentive|75 euros for each patient included
214511765|NCT04529824|DEVICE|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
214511766|NCT01043614|BEHAVIORAL|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
214511767|NCT02283086|BEHAVIORAL|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
214511768|NCT03776604|DRUG|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
215113328|NCT07064733|OTHER|Music Therapy|"The music therapy intervention consists of listening sessions using specially recorded handpan music, designed to promote relaxation and reduce anxiety in pregnant women. The handpan is a melodic percussion instrument known for its soothing and harmonic sound qualities.~Participants will listen to a 30-minute handpan music recording at home, in a quiet and dimly lit room, while resting in a semi-fowler or left lateral position. The sound volume will be kept below 60 decibels to ensure comfort and prevent overstimulation. Sessions will be scheduled three times per week, in the morning and evening, over a two-week period.~Before each session, participants will be reminded by phone and instructed to measure their blood pressure immediately prior to and at 0, 30, and 60 minutes after the music listening. The therapy aims to create a calming environment that encourages positive thoughts and bonding with the fetus."
214427820|NCT00925899|DRUG|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
214427821|NCT00925899|DRUG|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
214427822|NCT05049434|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
214427823|NCT05049434|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
214427824|NCT02396316|DRUG|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
214511769|NCT04128956|DRUG|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
214511770|NCT01128673|DEVICE|mRI|
214511771|NCT02915003|BEHAVIORAL|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
214511772|NCT06102278|OTHER|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
214511773|NCT03833765|PROCEDURE|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
214511774|NCT03833765|PROCEDURE|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
214511775|NCT01718223|DRUG|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
215113329|NCT07064733|OTHER|warm water foot bath therapy|"The warm water foot bath therapy involves soaking the participant's feet in water heated to 37-40°C for 10-15 minutes per session. This therapy is designed to promote relaxation, improve peripheral circulation, and reduce anxiety symptoms.~Participants will perform the foot bath in a safe and comfortable setting, ensuring water temperature is monitored with a thermometer before each session. After soaking, feet should be thoroughly dried to prevent slipping, and participants are advised to have a companion nearby when standing up to avoid falls.~The intervention will be applied three times weekly, in the morning and evening, over a two-week period. Blood pressure measurements will be taken immediately before and at 0, 30, and 60 minutes after each session."
214427825|NCT02396316|DRUG|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
214427826|NCT00425152|DRUG|fluorouracil|
214427827|NCT00425152|DRUG|leucovorin calcium|
214511776|NCT01718223|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214511777|NCT01718223|OTHER|laboratory biomarker analysis|Correlative studies
214511778|NCT01718223|DRUG|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
215113330|NCT07066904|DIAGNOSTIC_TEST|Standard echocardiography|Routine ultrasound examination with standardized recordings for the study, incorporating volumetric assessment techniques
215113331|NCT07066904|DIAGNOSTIC_TEST|2D phase-contrast magnetic resonance imaging|A cardiac MRI will be performed on a 1.5 Tesla system, including a biventricular function study with a series of short-axis slices, three long-axis slices, a 2D phase-contrast acquisition orthogonal to the aortic root. Additionally, standard T1 mapping sequences will be acquired on three short-axis slices, 15 minutes after the injection of 0.2 mmol/kg of body weight of gadolinium, for myocardial and blood T1 measurements.
215113332|NCT07066904|DIAGNOSTIC_TEST|4D flow magnetic resonance imaging|A sagittal 4D flow acquisition lasting between 6 and 10 minutes of free breathing to cover all four cardiac chambers is added to the 2D acquisition.
215113333|NCT07066904|DIAGNOSTIC_TEST|Cardiac ultrafast ultrasound imaging|Ultrafast sequences are added to the standard echocardiography acquisition.
215113334|NCT07065539|DRUG|GnRH-a-1M|Pre-treatment with one dose GnRH agonist before endometrial preparation.
215113335|NCT07065539|DRUG|GnRH-a-2M|Pre-treatment with two doses GnRH agonist before endometrial preparation.
215113336|NCT07065539|DRUG|GnRH-a+LE-1M|Pre-treatment with one dose GnRH agonist, along with daily 2.5 mg letrozole for 28 days before endometrial preparation.
215113337|NCT07065539|DRUG|GnRH-a+LE-2M|Pre-treatment with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation.
214427828|NCT00425152|DRUG|levamisole hydrochloride|
214427829|NCT03160599|OTHER|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
214427830|NCT03475524|DRUG|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
214427831|NCT03475524|DRUG|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
214427832|NCT03475524|DRUG|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
214427833|NCT03475524|DRUG|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
214427834|NCT04185571|DEVICE|PEPA|
214427835|NCT00566735|DRUG|Razadyne|The starting dose of study medication is 4 mg twice a day
214427836|NCT00566735|DRUG|Placebo|4 mg, 2 times a day
214427837|NCT01946854|BEHAVIORAL|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
214427838|NCT05049382|PROCEDURE|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
214427839|NCT05986734|DRUG|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
214427840|NCT04679662|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
214427841|NCT00402896|DRUG|ZD6474|300 mg/day orally for 10 weeks.
214427842|NCT06522724|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.
214427843|NCT06522724|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
214427844|NCT05212675|OTHER|Short daily dialysis|7 days 2hours dialysis
214427845|NCT00654589|DRUG|Deferasirox|
214427846|NCT00925587|DRUG|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
214427847|NCT00274417|DRUG|dutasteride|
214427848|NCT05132816|DIAGNOSTIC_TEST|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
214511779|NCT02757456|BEHAVIORAL|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
214427849|NCT00490802|DRUG|Oxytocin|Intranasal Oxytocin
214511780|NCT02757456|OTHER|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
214511781|NCT00005867|BIOLOGICAL|bleomycin sulfate|
214511782|NCT00005867|DRUG|CHOP regimen|
214511783|NCT00005867|DRUG|cyclophosphamide|
214511784|NCT00005867|DRUG|doxorubicin hydrochloride|
214511785|NCT00005867|DRUG|etoposide|
214511786|NCT00005867|DRUG|mitoxantrone hydrochloride|
214427850|NCT00490802|DRUG|Placebo|Placebo Comparator
214427851|NCT04996680|DEVICE|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
214427852|NCT04996680|OTHER|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
214427853|NCT04996680|DEVICE|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
214427854|NCT05511766|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
214427855|NCT05511766|DRUG|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
214511787|NCT00005867|DRUG|prednisolone|
214511788|NCT00005867|DRUG|vincristine sulfate|
214511789|NCT00993434|BEHAVIORAL|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
214427856|NCT05511766|DRUG|Placebo|not containing drugs
214427857|NCT05658406|DRUG|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
214427858|NCT05658406|DRUG|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
214427859|NCT05658406|DRUG|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
214427860|NCT05658406|DRUG|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
214427861|NCT03780686|DRUG|Norepinephrine, dopamine|drugs to decrease bleeding
214427862|NCT04135040|DIETARY_SUPPLEMENT|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
214427863|NCT00977158|PROCEDURE|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
214427864|NCT00929760|BEHAVIORAL|specialised renal care|"* Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
214511790|NCT00993434|BEHAVIORAL|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
214511791|NCT02462447|DRUG|11C-sarcosine|Radiotracer injection for PET/CT scan
214511792|NCT02462447|DRUG|11C-choline|Radiotracer injection for PET/CT scan
214511793|NCT06309641|DIAGNOSTIC_TEST|Blood sample after treatment|Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.
214511794|NCT06309641|OTHER|Case reports|Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
214427865|NCT05956613|PROCEDURE|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
214427866|NCT03197090|DEVICE|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
214511795|NCT04662320|DEVICE|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
214511796|NCT00647699|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
214511797|NCT00647699|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
214511798|NCT06160375|DIAGNOSTIC_TEST|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
214511799|NCT03696563|DEVICE|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
214511800|NCT03696563|OTHER|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
214511801|NCT05483478|COMBINATION_PRODUCT|mobile health combined Multi-course Program|mobile health combined Multi-course Program
214511802|NCT04113226|DRUG|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
215113338|NCT07066839|DIETARY_SUPPLEMENT|LipoMicel Chrysin|A maximum single oral dose of 1000 mg chrysin
214427867|NCT03462823|DEVICE|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
214427868|NCT03462823|DEVICE|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
214427869|NCT06518876|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
214427870|NCT02213744|DRUG|MM-302|
214427871|NCT02213744|DRUG|Gemcitabine|
214427872|NCT02213744|DRUG|Capecitabine|
214427873|NCT02213744|DRUG|Vinorelbine|
214427874|NCT02213744|DRUG|Trastuzumab|
214427875|NCT03454529|OTHER|Laboratory Biomarker Analysis|Correlative studies
214511803|NCT04113226|DRUG|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
214511804|NCT04113226|OTHER|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,…) on which treatment may impact.
214511805|NCT04113226|OTHER|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
214511806|NCT04532333|DRUG|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
214511807|NCT04532333|DRUG|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
214511808|NCT03902327|DIETARY_SUPPLEMENT|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
214511809|NCT03902327|DIETARY_SUPPLEMENT|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
214511810|NCT02430259|DRUG|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
214511811|NCT00413283|BIOLOGICAL|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
214511812|NCT00413283|DRUG|Placebo|Placebo subcutaneous injection.
214511813|NCT00413283|DRUG|Gemcitabine|Intravenous infusion
214511814|NCT00413283|DRUG|Carboplatin|Intravenous infusion
215113339|NCT07066839|DIETARY_SUPPLEMENT|Non-Micellar Chrysin|A maximum single oral dose of 1000 mg chrysin
215113340|NCT07066839|DIETARY_SUPPLEMENT|Standard/Unformulated Chrysin|A maximum single oral dose of 1000 mg chrysin
215113341|NCT07064759|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
215113342|NCT07064759|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
215113343|NCT07064967|DIAGNOSTIC_TEST|Magnetoencephalography|Participants will undergo magnetoencephalography scan in both resting and tasking state.
214427876|NCT03454529|DRUG|Simvastatin|Given PO
214427877|NCT02768545|DRUG|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
214427878|NCT00421070|PROCEDURE|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
214427879|NCT01582100|DEVICE|Reletex|Neuromodulation device worn on the wrist
214427880|NCT04447482|DEVICE|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
214427881|NCT04447482|PROCEDURE|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
214427882|NCT00105807|BEHAVIORAL|participation in low intensity exercise|
214427883|NCT00105807|BEHAVIORAL|participation in art and music activities|
214511815|NCT00413283|DRUG|Cisplatin|Intravenous infusion
214511816|NCT01117402|RADIATION|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
214511817|NCT04627168|DEVICE|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
214511818|NCT02354417|BIOLOGICAL|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
214511819|NCT04150016|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
214511820|NCT03680768|OTHER|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
214511821|NCT03100851|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
215113344|NCT07066930|PROCEDURE|Magneto-Dynamic Ridge Expansion|A ridge expansion technique using the Magnetic Mallet device. Controlled magneto-dynamic impulses are applied to split the alveolar ridge and compact bone prior to immediate implant placement.
215113345|NCT07066930|PROCEDURE|Osseodensification with Versah Drills|"A ridge expansion method using Versah drills (Densah burs) in osseodensification mode. The drills densify bone without removing it, enhancing bone density and implant stability.~Arm Assignment: Versah Osseodensification (Active Comparator arm)"
214427884|NCT00813657|BEHAVIORAL|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
214427885|NCT01332045|PROCEDURE|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
214427886|NCT01332045|PROCEDURE|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
214427887|NCT02930954|DRUG|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
214427888|NCT02930954|DRUG|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
214427889|NCT02930954|DRUG|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
214427890|NCT03466931|OTHER|Milk|Meals containing Milk and Milk
214427891|NCT00039000|DRUG|HSPPC-96 or Oncophage|
214427892|NCT02334436|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
214427893|NCT02334436|OTHER|0.9% sterile, unpreserved saline|Placebo Comparator Arm
214427894|NCT00756405|BEHAVIORAL|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
214427895|NCT00756405|DIETARY_SUPPLEMENT|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
214427896|NCT00756405|DIETARY_SUPPLEMENT|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
214427897|NCT00483093|DRUG|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
214427898|NCT00483093|DRUG|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
214427899|NCT02345174|DRUG|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
214427900|NCT02345174|DRUG|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
214427901|NCT02474238|DEVICE|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
214427902|NCT02474238|DEVICE|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
214427903|NCT05728684|BIOLOGICAL|CM310|CM310 Injection
214427904|NCT04468698|OTHER|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
214427905|NCT00947453|DRUG|montelukast|montelukast 10 mg once daily for 8 weeks
214427906|NCT02663297|DRUG|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"
214511822|NCT01326624|DEVICE|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
215113346|NCT05178303|DRUG|SB-1121(1)|The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
215113347|NCT05178303|DRUG|SB-1121(2)|The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
215113348|NCT06904963|DEVICE|Motivation for oral hygiene through oral scanner|The oral scanner is used to create a digital model of the patient's mouth with which the operator will provide personalized oral hygiene instructions.
215113349|NCT07065370|DEVICE|Group I ( volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.|Volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.
215113350|NCT07065370|DEVICE|Group II: (volume-controlled ventilation with tidal volume 6-8ml/kg )|group received volume-controlled ventilation with tidal volume 6-8ml/kg predicted body weight with respiratory rate 18-20 cycle/minute
215113351|NCT06902636|BEHAVIORAL|Geriatric trauma care program|The experiment group will implement the Geriatric trauma care program (GTCP) and routine care. The GTCP will be implemented by a nurse practitioner and equipped with digitalized educational material, including six units of intervention for older adults with traumatic injuries who live alone.
215113352|NCT06158815|OTHER|proprioceptive neuromuscular facilitation exercise|The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
215113353|NCT02741765|BEHAVIORAL|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
215113354|NCT02741765|OTHER|Real rTMS|Subjects will participate in a combination of rTMS
215113355|NCT02741765|BEHAVIORAL|Supervised aerobic exercise|
215113356|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
215113357|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
215113358|NCT04752332|DRUG|Abemaciclib|Administered orally.
215113359|NCT04752332|DRUG|Standard Adjuvant ET|Administered according to label instructions.
215113360|NCT04752332|DRUG|Placebo|Administered orally.
215113361|NCT06914778|OTHER|Blood draw for the laboratory assessment|Blood plasma collection for for lipidomic and metabolomic analysis
215113362|NCT06914778|OTHER|Urine sample|Urine sampling for aqueous metabolomics
215113363|NCT06920576|DRUG|Esketamine|Intravenous esketamine 0.25 mg/kg was administered 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
215113364|NCT06920576|DRUG|Magnesium sulfate|Intravenous magnesium sulphate 30 mg/kg was administered within 10 min before induction of anaesthesia, followed by continuous pumping at 30 mg/(kg-h) until the end of the operation
215113365|NCT06920576|DRUG|Saline|Pumping equal volumes of saline over the same time period
214427907|NCT04532528|DRUG|Dabigatran|Dabigatran
214511823|NCT04554199|DEVICE|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
214427908|NCT06065332|OTHER|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
214427909|NCT00648349|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
214427910|NCT00648349|DRUG|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
214511824|NCT01547689|BIOLOGICAL|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
214511825|NCT01435499|BIOLOGICAL|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
214511826|NCT01435499|DRUG|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
214511827|NCT05411471|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
214511828|NCT00246129|DRUG|Campath|Monoclonal antibody induction therapy
214511829|NCT00246129|DRUG|Daclizumab|Monoclonal antibody induction therapy
214427911|NCT06181916|BEHAVIORAL|Amp|Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
214427912|NCT01824056|DRUG|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
214427913|NCT04425551|PROCEDURE|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
214427914|NCT02255877|DEVICE|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
214427915|NCT02255877|DEVICE|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
214427916|NCT03001362|RADIATION|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
214427917|NCT01203306|DRUG|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
214427918|NCT00829348|OTHER|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
214427919|NCT00829348|BEHAVIORAL|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
214427920|NCT04302805|DRUG|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
214427921|NCT04302805|DRUG|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
214511830|NCT02704026|OTHER|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
215113366|NCT03465995|DEVICE|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
215113367|NCT03392818|OTHER|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
215113368|NCT03392818|OTHER|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
215113369|NCT03392818|DEVICE|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
215113370|NCT00200668|DRUG|FDG = fluorodeoxyglucose|
215113371|NCT06284733|DEVICE|Whole-body vibration plus conservative care|Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.
215113372|NCT06284733|OTHER|conservative care|"1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care."
215113373|NCT00053144|DRUG|cytarabine|
215113374|NCT00053144|DRUG|irinotecan hydrochloride|
215113375|NCT00952393|DRUG|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
214427922|NCT04302805|OTHER|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
214511831|NCT03469258|DRUG|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
215113376|NCT03908814|DRUG|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
214427923|NCT05342818|DRUG|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
214427924|NCT05342818|DRUG|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
214427925|NCT05342818|DRUG|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
214427926|NCT05342818|OTHER|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
214427927|NCT05342818|OTHER|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
214427928|NCT04706078|DIAGNOSTIC_TEST|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
214427929|NCT01231568|DRUG|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
214427930|NCT01231568|DRUG|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
214427931|NCT01231568|DRUG|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
214427932|NCT01231568|DRUG|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
214427933|NCT06450730|BEHAVIORAL|Cognitive-Behavioral Therapy: face-to-face + app|"This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos)."
214427934|NCT03663842|OTHER|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
214427935|NCT02561949|BEHAVIORAL|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
214427936|NCT02561949|OTHER|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
214427937|NCT03166449|DIETARY_SUPPLEMENT|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
214427938|NCT03166449|DIETARY_SUPPLEMENT|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
215113377|NCT05630677|DRUG|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
214427939|NCT01071408|OTHER|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
214427940|NCT01442935|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
214427941|NCT01442935|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
214427942|NCT01442935|DRUG|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
214427943|NCT01442935|DRUG|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
214427944|NCT01442935|DRUG|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
214427945|NCT01442935|DRUG|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
214427946|NCT01442935|DRUG|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
214427947|NCT05033301|DEVICE|Nurse Ned Clinic|Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
214427948|NCT05752006|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
214427949|NCT00495417|BIOLOGICAL|AFFITOPE AD01|s.c. injection
214427950|NCT00495417|BIOLOGICAL|AFFITOPE AD01 adjuvanted|s.c. injection
214427951|NCT02455141|DRUG|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
214427952|NCT02455141|DRUG|Taxanes|Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
214427953|NCT02455141|DRUG|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
214511832|NCT06328725|DRUG|EN001|"Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals."
214427954|NCT03204396|DRUG|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
214427955|NCT03204396|DRUG|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
214511833|NCT04205669|DRUG|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
214427956|NCT05756010|DEVICE|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
214511834|NCT03590496|DIETARY_SUPPLEMENT|Calcium-Propionate 500mg|Calcium-Propionate capsules
214427957|NCT00631579|DRUG|Rasburicase (SR29142)|
215113378|NCT05630677|DRUG|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
214427958|NCT02118077|BIOLOGICAL|G17DT|
214427959|NCT06311799|BEHAVIORAL|WIC Referral|Clinical team will refer study participants to WIC
214427960|NCT06311799|BEHAVIORAL|RDN Referral|Clinical team will refer study participants to a RDN
214427961|NCT03280017|DRUG|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
214427962|NCT03280017|DRUG|Normal saline|normal saline infusion
214427963|NCT05317910|OTHER|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
214427964|NCT02874430|DRUG|Metformin Hydrochloride|Given orally
214427965|NCT02874430|DRUG|Doxycycline|Given orally
215113379|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
214427966|NCT04589689|BEHAVIORAL|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
214427967|NCT03637231|DIAGNOSTIC_TEST|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
214427968|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 6-min per time, with focus, until the completion of the study.
214427969|NCT05315180|DRUG|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
214511835|NCT03590496|OTHER|Placebo|Placebo capsules without any active ingredient
214511836|NCT02005172|DEVICE|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
214692428|NCT06553274|PROCEDURE|Individualized nutrition intervention|"After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists."
214427970|NCT03061474|DRUG|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
214427971|NCT03061474|DRUG|Placebo Comparator|Oral Tablet
214427972|NCT01587755|OTHER|TTOP|Patient is taken care of in an intensified, optimised manner
214427973|NCT01587755|OTHER|non-TTOP|Standard medical care
214427974|NCT00001354|DRUG|Interleukin-2/Zidovudine (AZT)|
214427975|NCT02888080|DRUG|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
214427976|NCT02888080|DRUG|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
214427977|NCT05201976|OTHER|Virtually administered Cardiac Rehab program|Virtual cardiac rehab program delivered through the CardaHealth platform.
214427978|NCT05201976|OTHER|Standard of Care in person Cardiac Rehab Program|Clinically ordered standard of care cardiac rehab program (in-person).
214427979|NCT00845832|DRUG|Placebo|iv on days 1 and 15 (Parts 1 and 2)
214427980|NCT00845832|DRUG|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
214427981|NCT00845832|DRUG|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
214427982|NCT00190619|DRUG|Duloxetine|
214427983|NCT00190619|DRUG|Placebo|
214427984|NCT01665092|DRUG|Levo-Carnitine|
214427985|NCT01665092|DRUG|placebo|
214427986|NCT00189202|DRUG|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
214427987|NCT03417492|DRUG|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
214427988|NCT03147391|DEVICE|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
214427989|NCT05657730|DIETARY_SUPPLEMENT|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
215113380|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
215113381|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
215113382|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
214427990|NCT06204055|OTHER|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
214427991|NCT02910388|DEVICE|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
214427992|NCT02910388|OTHER|LLETZ without colposcopy|Loop procedure without using a colposcope
214427993|NCT06466902|OTHER|Quality assessment of D2 lymphadenectomy using the PhotoNode Score|"During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers."
214427994|NCT00317902|DRUG|Epoetin alfa|
214427995|NCT03050788|DEVICE|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
214427996|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
214427997|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
214427998|NCT01039688|DRUG|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
214427999|NCT05861063|DEVICE|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
214428000|NCT05861063|DRUG|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
214428001|NCT02466672|OTHER|none - observational only|
214428002|NCT04201249|DRUG|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
214428003|NCT04201249|DEVICE|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
214428004|NCT00668863|DRUG|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214428005|NCT00668863|DRUG|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
214428006|NCT02995655|DRUG|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
214428007|NCT02995655|DRUG|Azacitidine|Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
214428008|NCT02995655|PROCEDURE|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
214428009|NCT02995655|PROCEDURE|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
214428010|NCT02768571|DRUG|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
214428011|NCT02768571|DRUG|Placebo|Placebo- saline 100 ml/day \* 21 days with rehabilitation
214428012|NCT01883908|DEVICE|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
214428013|NCT01883908|OTHER|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
214428014|NCT01296191|DRUG|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
214428015|NCT01296191|DRUG|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
214428016|NCT03844269|DEVICE|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
214428017|NCT05652933|DIAGNOSTIC_TEST|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
214428018|NCT01932450|PROCEDURE|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
214428019|NCT01932450|DRUG|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
214428020|NCT02540746|BEHAVIORAL|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
214428021|NCT02540746|BEHAVIORAL|Motivational Enhancement|Three week Motivational Enhancement group
214428022|NCT02540746|BEHAVIORAL|Family Skills Training|12-week group-based family skills training using Family Connections model
214428023|NCT00864786|DRUG|PF03635659|Inhaled doses of 200 mcgQD
214428024|NCT00864786|DRUG|PF03635659|Inhaled doses of 600 mcg QD
214428025|NCT00864786|DRUG|PF03635659|Inhaled doses of 1000 mcg QD
215113383|NCT03501940|PROCEDURE|Computed Tomography|Undergo 18F-DCFPyL PET/CT
215113384|NCT03501940|RADIATION|Fluorine F 18 DCFPyL|Given IV
214428026|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
214511837|NCT06121739|BEHAVIORAL|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
214511838|NCT05413200|DRUG|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
214511839|NCT02402270|DRUG|NuLYTELY® (PEG 3350)|
215113385|NCT03501940|OTHER|Laboratory Biomarker Analysis|Correlative studies
214511840|NCT02402270|DRUG|ECP-019|
214511841|NCT02402270|DRUG|MoviPrep® (PEG 3350)|
214511842|NCT00009191|DRUG|Sertraline [Zoloft]|
214511843|NCT00327730|DRUG|Eperisone|
214511844|NCT03950661|OTHER|Walking|
214511845|NCT04111159|DRUG|HSK3486|Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
214511846|NCT04111159|DRUG|Propofol|Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
214428027|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
214511847|NCT00236470|DRUG|risperidone|
214511848|NCT00087256|DRUG|Celecoxib|
214511849|NCT00087256|OTHER|placebo|
214511850|NCT00003754|DRUG|cyclophosphamide|
214511851|NCT00003754|DRUG|thalidomide|
214511852|NCT03340259|PROCEDURE|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
214511853|NCT02670408|PROCEDURE|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
214511854|NCT01197924|OTHER|IRMf Bold|IRMf BOLD of the working memory
214511855|NCT04403178|DIAGNOSTIC_TEST|Radiographic examination with a Migration of > 40 %|Radiographic examination
214511856|NCT05710614|DIETARY_SUPPLEMENT|Animal protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.
215113386|NCT03501940|PROCEDURE|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
215113387|NCT03167021|OTHER|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
215113388|NCT00407303|DRUG|Obatoclax mesylate|30 mg, 45 mg
215113389|NCT00407303|DRUG|Bortezomib|1.0mg/m2, 1.3 mg/m2
215113390|NCT03579810|OTHER|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
214428028|NCT01733238|DRUG|PNT2258|
214428029|NCT00101010|BIOLOGICAL|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
214428030|NCT00101010|BIOLOGICAL|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
214428031|NCT00101010|BIOLOGICAL|Rituximab|375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
214511857|NCT05710614|DIETARY_SUPPLEMENT|Plant Protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
214692429|NCT02715960|DRUG|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
214692430|NCT05437224|DRUG|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
214692431|NCT02241746|OTHER|no intervention|
215113391|NCT03579810|OTHER|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
215113392|NCT02277912|DEVICE|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
215113393|NCT02277912|DEVICE|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
215113394|NCT02277912|DEVICE|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
215113395|NCT01354119|PROCEDURE|Aortic stent-graft|Early intervention with aortic stent-graft
215113396|NCT03818451|DIETARY_SUPPLEMENT|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
214428032|NCT00101010|DRUG|Cyclophosphamide|750 mg/m\^2 IVPB on day 1
214428033|NCT00101010|DRUG|Pegylated liposomal doxorubicin hydrochloride|40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
214428034|NCT00101010|DRUG|Prednisone|40 mg/m\^2 oral days 1 - 5.
214428035|NCT00101010|DRUG|Vincristine Sulfate|2 mg IV, day 1
214428036|NCT03855891|DIAGNOSTIC_TEST|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
214428037|NCT01271452|BIOLOGICAL|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
214428038|NCT01271452|BIOLOGICAL|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
214428039|NCT00910767|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
214428040|NCT00910767|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
214428041|NCT04433429|DIETARY_SUPPLEMENT|Liposcudil Plus|
214428042|NCT00246714|DRUG|repeated injections of endotoxin during 5 days|
214428043|NCT00230399|DRUG|Celecoxib|
214428044|NCT00230399|DRUG|Capecitabine|
214428045|NCT00230399|DRUG|Irinotecan|
214428046|NCT00814047|DRUG|Yohimbine hydrochloride|
214428047|NCT01809392|DRUG|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
214428048|NCT00869323|BIOLOGICAL|rituximab|375 mg/m\^2 intravenously on Days 1,8, 15 and 22
214428049|NCT00869323|DRUG|bortezomib|1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
214428050|NCT00992173|DRUG|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
214428051|NCT01740310|BEHAVIORAL|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
214428052|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
214428053|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
214428054|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
214428055|NCT01135511|DRUG|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
214428056|NCT01135511|DRUG|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
214428057|NCT03312309|PROCEDURE|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
214428058|NCT05971680|DRUG|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
214428059|NCT05971680|DEVICE|intra-uterine contraceptive device|intra-uterine contraceptive device
214428060|NCT04705376|DEVICE|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
214428061|NCT04705376|DEVICE|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
214428062|NCT01573130|BEHAVIORAL|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
214428063|NCT03098810|DRUG|Zinc sulphate|Oral syrup zinc sulphate
214428064|NCT03098810|OTHER|Placebo|Oral syrup placebo
214428065|NCT05486364|DIAGNOSTIC_TEST|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
214428066|NCT05486364|DIAGNOSTIC_TEST|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
214428067|NCT05473260|OTHER|Control|In-patient care.
214428068|NCT05473260|OTHER|Experimental|Early discharge and outpatient follow-up.
215113397|NCT02240602|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
215113398|NCT02240602|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
214511858|NCT01965990|OTHER|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
214511859|NCT04371406|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
214511860|NCT04371406|DIETARY_SUPPLEMENT|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
214511861|NCT00001615|DRUG|Corticosteroid|
215113399|NCT02240602|DRUG|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
214428069|NCT04813419|DEVICE|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
214428070|NCT04813419|DEVICE|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
214428071|NCT04181463|DRUG|Isopropyl Alcohol|Given via nasal inhalation
214428072|NCT04181463|OTHER|Placebo|Given via nasal inhalation
214428073|NCT04181463|OTHER|Questionnaire Administration|Ancillary studies
214428074|NCT05176964|RADIATION|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
214428075|NCT05176964|DRUG|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
214511862|NCT00750477|DIETARY_SUPPLEMENT|NEM|see Treatment Arms
214511863|NCT00750477|DIETARY_SUPPLEMENT|Placebo|Placebo comparator containing inactives
214511864|NCT05122026|DRUG|Rifapentine|As included in arm/group description
214511865|NCT05122026|DRUG|Isoniazid|As included in arm/group description
214511866|NCT03340961|DRUG|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
214511867|NCT03340961|DRUG|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
214511868|NCT03340961|DRUG|Oraycea® (doxycycline) Capsules|Oral Treatment
215113400|NCT03702036|DRUG|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
215113401|NCT00976833|OTHER|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
215113402|NCT00976833|OTHER|Usual Care|Usual Physical Therapy care
214511869|NCT03340961|DRUG|Placebo Capsules|Oral Treatment
214511870|NCT05300594|DIETARY_SUPPLEMENT|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
214511871|NCT05300594|DIETARY_SUPPLEMENT|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
214428076|NCT05176964|DRUG|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
214428077|NCT01814033|OTHER|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
214428078|NCT01814033|OTHER|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
214428079|NCT06167525|DEVICE|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
214428080|NCT00971789|RADIATION|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
214511872|NCT04929509|OTHER|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
214428081|NCT00971789|DRUG|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
214511873|NCT04929509|OTHER|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
214511874|NCT04929509|OTHER|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
215113403|NCT03863808|BEHAVIORAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
215113404|NCT03863808|OTHER|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
214428082|NCT00971789|OTHER|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
214428083|NCT00471627|PROCEDURE|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
214428084|NCT04802369|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
214428085|NCT06073860|DRUG|Luspatercept|According to the approved label
214511875|NCT00248898|PROCEDURE|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
214511876|NCT01853384|BIOLOGICAL|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
214511877|NCT01853384|OTHER|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
215113405|NCT02741427|OTHER|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
215113406|NCT02741427|OTHER|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
215113407|NCT02741427|OTHER|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
215113408|NCT00397436|PROCEDURE|UV Irradiation|UV irradiation
215113409|NCT05056506|PROCEDURE|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
215113410|NCT05056506|PROCEDURE|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
215113411|NCT01868477|DRUG|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
215113412|NCT01868477|DRUG|Erythropoietin alpha|
215113413|NCT01868477|DRUG|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
215113414|NCT01618006|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
215113415|NCT01618006|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
215113416|NCT01618006|DRUG|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
215113417|NCT05510674|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
215113418|NCT01802125|OTHER|laboratory biomarker analysis|Correlative studies
215113419|NCT04685525|BEHAVIORAL|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
215113420|NCT02819791|OTHER|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
215113421|NCT02819791|BEHAVIORAL|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
215113422|NCT04387578|DEVICE|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
215113423|NCT05260762|DIETARY_SUPPLEMENT|Arabinoxylan|Dietary fiber product
214511878|NCT00001628|DRUG|Angiotensin II type 1 receptor antagonists|
214428086|NCT04395235|OTHER|Survey|A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
214428087|NCT04010006|PROCEDURE|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
214428088|NCT04010006|PROCEDURE|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
214428089|NCT03989986|BEHAVIORAL|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
214428090|NCT01257555|DEVICE|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
214428091|NCT04674371|OTHER|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
214428092|NCT02384070|PROCEDURE|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
214428093|NCT02384070|DRUG|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
214428094|NCT02384070|DRUG|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
214428095|NCT02384070|DRUG|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
214428096|NCT06038916|DRUG|STSA-1002 Injection Placebo|Intravenous infusion
214511879|NCT04022707|OTHER|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
214428097|NCT06038916|DRUG|STSA-1002 Injection|Intravenous infusion
215113424|NCT05260762|DIETARY_SUPPLEMENT|Control|Potato starch
214428098|NCT05706168|DEVICE|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
214428099|NCT05706168|DEVICE|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
215113425|NCT04059120|OTHER|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
215113426|NCT04059120|OTHER|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
214511880|NCT04022707|OTHER|Educational control|Lectures on health and fitness
214511881|NCT00000284|DRUG|Cotinine fumarate|
214511882|NCT00525616|DRUG|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
214511883|NCT01221402|DRUG|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
214511884|NCT04311983|BEHAVIORAL|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
214511885|NCT04311983|BEHAVIORAL|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
214511886|NCT00024245|DRUG|pralatrexate|
214511887|NCT00024245|DRUG|probenecid|
214511888|NCT01039506|DRUG|CPT-11 based regimens|
214511889|NCT01759459|DRUG|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
215113427|NCT02219074|DEVICE|Sebacia microparticle and laser treatment|
215113428|NCT02219074|DEVICE|Vehicle and laser treatment|
215113429|NCT06284512|DIAGNOSTIC_TEST|Sonography, color fundus photography|Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
215113430|NCT02528786|OTHER|No Intervention|No study drug will be administered in this study.
214428100|NCT06187246|BEHAVIORAL|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
214428101|NCT06187246|OTHER|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
214511890|NCT01759459|DRUG|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
214511891|NCT01759459|DRUG|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
214511892|NCT05147207|PROCEDURE|Superpath Approach|This is a minimally invasive surgical approach for THA.
214511893|NCT04794244|BEHAVIORAL|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
214511894|NCT01205126|DRUG|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
214511895|NCT01205126|DRUG|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
214511896|NCT01205126|DRUG|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
214511897|NCT00311545|BIOLOGICAL|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
214511898|NCT03340662|DRUG|CC-122|CC-122
214511899|NCT03340662|DRUG|Itraconazole|CYP3A Inhibitor
214511900|NCT03340662|DRUG|Fluvoxamine|CYP1A2 Inhibitor
214511901|NCT03340662|DRUG|Rifampin|CYP3A Inducer
214511902|NCT00903214|DRUG|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
214511903|NCT00903214|GENETIC|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
214511904|NCT00903214|PROCEDURE|axillary lymph node biopsy|
214511905|NCT00903214|PROCEDURE|digital image analysis|
214511906|NCT00903214|PROCEDURE|needle biopsy|
214511907|NCT00903214|PROCEDURE|sentinel lymph node biopsy|
214511908|NCT00903214|PROCEDURE|therapeutic conventional surgery|
214511909|NCT01751295|DRUG|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
214511910|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
214511911|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
214511912|NCT05889832|DIAGNOSTIC_TEST|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
214511913|NCT01711788|PROCEDURE|Intrabone infusion of umbilical cord blood stem cells|
214511914|NCT04702594|BEHAVIORAL|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
214511915|NCT02050815|DRUG|MEK162|
214511916|NCT06144723|DRUG|HS-20105|Administered intravenously every 21 days.
214511917|NCT03331978|BEHAVIORAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
214511918|NCT03706872|OTHER|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
214511919|NCT05581394|DEVICE|BabySat V3|Evaluation of Accuracy of BabySat V3
214511920|NCT05670561|DRUG|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
214511921|NCT05670561|DRUG|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
214511922|NCT00638456|DRUG|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
214428102|NCT04260906|DEVICE|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
214428103|NCT04260906|OTHER|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
214511923|NCT00638456|DRUG|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
214511924|NCT02204202|DRUG|[18F]FDG|10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
214511925|NCT02204202|DRUG|[18F]ISO-1|8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
214511926|NCT00903981|DRUG|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
214511927|NCT00903981|DRUG|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
214511928|NCT00903981|DRUG|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
214511929|NCT03236779|OTHER|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
214511930|NCT03108430|OTHER|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
214511931|NCT00552461|DRUG|rituximab|IV, 1000 mg, two weeks, 2 times
214511932|NCT04562883|OTHER|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
214511933|NCT02499809|OTHER|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
214511934|NCT00673088|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
214511935|NCT00514670|OTHER|Alcohol-based hand sanitizer & quaternary ammonium wipes|
214511936|NCT03060785|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|
214511937|NCT00667953|DRUG|Gleevec|Gleevec (600 mg) daily.
214511938|NCT00667953|DRUG|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
214511939|NCT05179772|DRUG|Olanzapine|Olanzapine (2.5 mg to 20 mg)
214511940|NCT06220578|DEVICE|Oculus pentacam HR|Examination of corneal parameters by pentacam
214511941|NCT05817292|DIETARY_SUPPLEMENT|Probiotics|Assumption of commercial probiotics
214511942|NCT05817292|OTHER|No intervention|No assumption of probiotics
214511943|NCT03204175|OTHER|FIT Plus|"* Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste"
214511944|NCT03204175|OTHER|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
215113431|NCT02462018|DEVICE|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
214428104|NCT02806557|DEVICE|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
214428105|NCT01981837|DRUG|ALN-TTRSC (revusiran) for subcutaneous administration|
214428106|NCT02861066|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
214428107|NCT03410446|DRUG|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
214428108|NCT03264443|BEHAVIORAL|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
214511945|NCT01784107|DRUG|Belotecan and Ifosfamide|
214511946|NCT00053300|DRUG|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
214511947|NCT00053300|PROCEDURE|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
215113432|NCT03311789|DRUG|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
214428109|NCT03264443|BEHAVIORAL|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
214428110|NCT01839981|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214428111|NCT04275245|DRUG|Meplazumab for Injection|humanized MAb against CD147
214428112|NCT01373697|DRUG|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
214428113|NCT01373697|DRUG|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
214428114|NCT00930098|DRUG|clofarabine|
214428115|NCT01493310|DRUG|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
214511948|NCT00687297|DRUG|vandetanib induction|100 mg daily by mouth
214511949|NCT00687297|DRUG|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
214511950|NCT00687297|DRUG|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
214511951|NCT00687297|DRUG|Placebo|
214511952|NCT00687297|DRUG|Vandetanib maintenance|300 mg daily by mouth
214428116|NCT01493310|DRUG|placebo|Given orally
214428117|NCT01493310|DRUG|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
214428118|NCT02561039|DRUG|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
214428119|NCT04691635|OTHER|evaluation of movements with sensors|evaluation of movements with sensors
214511953|NCT05404997|DEVICE|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
214511954|NCT05404997|OTHER|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
214511955|NCT06177821|DEVICE|Rezum®|Rezum® Water vaporization device
214511956|NCT01230970|DRUG|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
214511957|NCT03949257|DEVICE|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
214511958|NCT02481856|DRUG|SQ tree SLIT-tablet|
214511959|NCT02481856|DRUG|Placebo|
214428120|NCT04896034|DEVICE|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
214428121|NCT04896034|DEVICE|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
214428122|NCT05985512|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
214511960|NCT04927468|PROCEDURE|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
214511961|NCT04927468|PROCEDURE|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
214511962|NCT04370561|PROCEDURE|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
214511963|NCT04370561|PROCEDURE|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
214511964|NCT03006393|DRUG|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
214511965|NCT03006393|OTHER|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
214511966|NCT03498365|BEHAVIORAL|MCDA|Experimental decision support
214511967|NCT03498365|BEHAVIORAL|Delphi|Standard support
214428123|NCT04457752|BIOLOGICAL|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
214428124|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
214428125|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
214428126|NCT03009864|DRUG|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
214428127|NCT03009864|DRUG|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
214428128|NCT00376363|DEVICE|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
214428129|NCT00376363|DEVICE|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
214511968|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
215113433|NCT04289792|DRUG|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
215113434|NCT04289792|RADIATION|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
215113435|NCT01076387|PROCEDURE|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
214511969|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
214511970|NCT03331536|PROCEDURE|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
214511971|NCT03331536|PROCEDURE|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
214428130|NCT04377698|BIOLOGICAL|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
214511972|NCT03954860|OTHER|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
214511973|NCT03954860|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
214511974|NCT03954860|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
214692432|NCT01443455|BEHAVIORAL|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
214692433|NCT01443455|BEHAVIORAL|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
215113436|NCT01076387|PROCEDURE|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
215113437|NCT03862235|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
214428131|NCT04377698|BIOLOGICAL|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
214428132|NCT05997966|OTHER|Progresive Resistance Exercises|At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).
214428133|NCT05997966|OTHER|No intervation|After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
214428134|NCT05025995|BEHAVIORAL|Serious health game|Serious health game
214428135|NCT05815797|DRUG|SDD formula|SDD formula consists of 23 herbal medicines
214428136|NCT05815797|DRUG|Placebo|Placebo
214428137|NCT05372588|DRUG|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
215113438|NCT03862235|DIAGNOSTIC_TEST|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
215113439|NCT01821703|DRUG|LY3045697|Administered as oral solution
215113440|NCT01821703|DRUG|Placebo|Administered as oral solution
215113441|NCT01821703|DRUG|Spironolactone|Administered as capsule
214428138|NCT05372588|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
214428139|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
214428140|NCT05372588|DRUG|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
214428141|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
214428142|NCT04456751|OTHER|Redo op|Patients with a redo operation
214428143|NCT00547469|DRUG|DDP733|
214428144|NCT01084031|DRUG|propofol|intravenous propofol with sevoflurane inhalation induction
214428145|NCT01906788|DRUG|Artemether Lumefantrine|
214428146|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
214428147|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
214428148|NCT00906529|DRUG|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
214428149|NCT01691690|DRUG|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
214428150|NCT01691690|DRUG|Normal Saline Flush|Saline placebo will be infused intraoperatively.
214428151|NCT01691690|DRUG|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
214428152|NCT01691690|DRUG|Sevoflurane|Sevoflurane for anesthesia induction.
214428153|NCT01691690|DRUG|Nitrous Oxide/Oxygen|Combination of NO2 \& O2 for anesthesia induction.
214428154|NCT01691690|DRUG|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
214428155|NCT01691690|DRUG|Morphine|Morphine 0.1 mg/kg given prior to intubation.
214428156|NCT01691690|DRUG|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
214428157|NCT01691690|DRUG|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
214428158|NCT01869946|DRUG|Ropivacaine|
214428159|NCT04958343|PROCEDURE|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
214428160|NCT01755949|DRUG|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
214428161|NCT01755949|DRUG|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
214428162|NCT01449422|DEVICE|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
214428163|NCT01449422|DEVICE|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
214428164|NCT00024141|DRUG|fluorouracil|
214428165|NCT00024141|DRUG|irinotecan hydrochloride|
214428166|NCT00648726|DRUG|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
214428167|NCT00648726|DRUG|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
214428168|NCT00648726|DRUG|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
214428169|NCT06215053|OTHER|erector spine plane block|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
214428170|NCT04454151|DRUG|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
214428171|NCT05164094|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
214428172|NCT05164094|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214511975|NCT01485809|DRUG|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
214511976|NCT00291941|BIOLOGICAL|Henogen HBV vaccine|20µg, Month 0, 2 and 6
214511977|NCT00291941|BIOLOGICAL|FENDRIX|20 µg,Months 0, 1, 2 and 6
214511978|NCT00605137|DRUG|insulin detemir|
214511979|NCT00605137|DRUG|insulin NPH|
214511980|NCT01474382|DRUG|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
215113442|NCT01821703|DRUG|Placebo|Administered as capsule
215113443|NCT01453608|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
215113444|NCT01453608|DRUG|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
215113445|NCT05417087|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
215113446|NCT05417087|DRUG|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
215113447|NCT06009328|OTHER|fundamental movement skills|measured by test of gross motor development
215113448|NCT00903305|OTHER|medical chart review|
215113449|NCT00903305|OTHER|questionnaire administration|
215113450|NCT00903305|PROCEDURE|fatigue assessment and management|
215113451|NCT00903305|PROCEDURE|psychosocial assessment and care|
215113452|NCT00903305|PROCEDURE|quality-of-life assessment|
215113453|NCT02387554|DRUG|HGP0904|
215113454|NCT02387554|DRUG|HGP0608|
215113455|NCT02387554|DRUG|HGP1405|
214428173|NCT06075069|DEVICE|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
214428174|NCT02060669|DRUG|Xeloda|Xeloda
214428175|NCT00824135|DRUG|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
214428176|NCT00824135|PROCEDURE|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
214428177|NCT00824135|OTHER|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
214428178|NCT00824135|DRUG|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
214428179|NCT00824135|DRUG|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
214428180|NCT00824135|DRUG|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
214428181|NCT00824135|DRUG|Rituximab|375 mg/m2 intravenous for 1 dose total
214428182|NCT00824135|OTHER|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
214428183|NCT03967626|DEVICE|external cooling with the xxxxx device|external cooling with the xxxxx device
214428184|NCT05468411|OTHER|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
214428185|NCT05468411|OTHER|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
214428186|NCT00640250|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
215113456|NCT05526898|DEVICE|SyntrFuge System|Microsized Adipose Tissue
215113457|NCT05526898|DRUG|Triamcinolone Injection|Corticosteroid
215113458|NCT00856297|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
215113459|NCT00856297|BIOLOGICAL|Licensed comparator|
215113460|NCT05797636|DEVICE|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
215113461|NCT02659436|OTHER|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
215113462|NCT02659436|OTHER|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
215113463|NCT04701736|DEVICE|Picture Medication Calendar|
215113464|NCT04499989|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
215113465|NCT04499989|DRUG|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
214428187|NCT05082935|BEHAVIORAL|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
214428188|NCT05082935|BEHAVIORAL|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
214428189|NCT02589340|DRUG|Buspirone|
214428190|NCT02589340|DRUG|Placebo|Sugar Pill
214428191|NCT02122445|DEVICE|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
214428192|NCT05692778|OTHER|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
214428193|NCT05692778|OTHER|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
214511981|NCT01474382|OTHER|Sham injection|No drug administered, simulation of injection used in same manner as drug
214511982|NCT01596465|OTHER|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
214511983|NCT01596465|OTHER|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
215113466|NCT00801398|DRUG|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
215113467|NCT01885624|BIOLOGICAL|TAB08|monoclonal antibody
215113468|NCT01179152|DRUG|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
215113469|NCT00138775|DRUG|D-serine|
214511984|NCT05392972|BEHAVIORAL|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
215113470|NCT00370565|DRUG|Inhaled Human Insulin|
214511985|NCT01864980|PROCEDURE|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
214511986|NCT01864980|PROCEDURE|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
214511987|NCT03191448|PROCEDURE|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
214511988|NCT03191448|DEVICE|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
215113471|NCT05515835|DEVICE|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
215113472|NCT04081922|PROCEDURE|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
215113473|NCT00918099|PROCEDURE|Avaulta mesh|Insertion of a mesh vs conventional repair
215113474|NCT00918099|PROCEDURE|Anterior repair|Conventional repair
214428194|NCT03132922|GENETIC|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
214428195|NCT03132922|RADIATION|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
214428196|NCT02957136|DEVICE|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
214428197|NCT02045459|BEHAVIORAL|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
214511989|NCT03191448|DEVICE|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
214511990|NCT02715388|DEVICE|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
214511991|NCT05185973|DIETARY_SUPPLEMENT|"For Baby supplements provided as powder"|One sachet daily
214511992|NCT05185973|DIETARY_SUPPLEMENT|Micronutrient powder provided as powder|One sachet daily
214428198|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
214511993|NCT00926107|DRUG|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
214511994|NCT04024709|PROCEDURE|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
214511995|NCT04723979|DRUG|Eptacog alfa|Recombinant coagulation factor VII activated
214511996|NCT04723979|OTHER|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
214428199|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
214511997|NCT04803045|OTHER|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
214511998|NCT04970602|DRUG|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
214511999|NCT05320133|DRUG|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
214512000|NCT05320133|DRUG|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
214512001|NCT01584648|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily
214512002|NCT01584648|DRUG|Trametinib|Trametinib 2 mg once daily
214512003|NCT01584648|DRUG|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
214512004|NCT06462378|RADIATION|Proton therapy|External beam proton therapy combined with standard cisplatin and brachytherapy
214512005|NCT05684809|OTHER|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
214512006|NCT05684809|OTHER|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
214512007|NCT05684809|OTHER|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
214512008|NCT05671549|PROCEDURE|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
214512009|NCT01435720|BIOLOGICAL|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
214512010|NCT01435720|BIOLOGICAL|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
214512011|NCT01435720|BIOLOGICAL|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
214512012|NCT01435720|BIOLOGICAL|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
214512013|NCT02757378|PROCEDURE|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
214512014|NCT02757378|PROCEDURE|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
214512015|NCT01328756|DRUG|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
214512016|NCT00652600|DRUG|Propranolol|ER Capsules, 160 mg, single-dose
214512017|NCT00652600|DRUG|Inderal-LA|ER Capsules, 160 mg, single-dose
214512018|NCT04031794|DEVICE|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
214512019|NCT00325845|PROCEDURE|Synvisc viscosupplementation|
214512020|NCT03975361|OTHER|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
214512021|NCT01266837|DRUG|Everolimus|10 mg p.o once daily
215113475|NCT06063694|DEVICE|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
214512022|NCT03999294|OTHER|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
214512023|NCT00838045|DEVICE|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
214512024|NCT02070276|PROCEDURE|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
215113476|NCT00406601|DRUG|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
215113477|NCT02750852|PROCEDURE|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
214512025|NCT02070276|PROCEDURE|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
214512026|NCT06284356|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
215113478|NCT03933813|OTHER|Iron Sucrose|Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
215113479|NCT02621307|DIETARY_SUPPLEMENT|Salba|
215113480|NCT02621307|DIETARY_SUPPLEMENT|Flax|
215113481|NCT02621307|DIETARY_SUPPLEMENT|Control|
215113482|NCT00389844|BEHAVIORAL|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
214512027|NCT00722865|DRUG|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
214512028|NCT00323778|DRUG|Hyalgan|
214512029|NCT03044756|DRUG|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
214512030|NCT05770206|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
214512031|NCT05770206|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
214512032|NCT06186063|OTHER|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
214512033|NCT06186063|OTHER|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
214512034|NCT01002586|OTHER|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
214512035|NCT01002586|OTHER|Walking exercise program|walking exercise program
214512036|NCT01543945|DRUG|Dexamethasone|4 mg iv before induction for high and extremely high risk
214512037|NCT01543945|DRUG|Ondansetron|4 mg iv before ended surgery 30 min
214512038|NCT01543945|DRUG|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
214512039|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
215113483|NCT00389844|BEHAVIORAL|Plus component (motivation) of the Exercise Plus Program|Motivation only
215113484|NCT00389844|BEHAVIORAL|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
215113485|NCT05508022|BEHAVIORAL|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
215113486|NCT03501732|BEHAVIORAL|Values Affirmation|Experimental Group selects two values and describes why they are important
214428200|NCT00591708|DIETARY_SUPPLEMENT|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
214428201|NCT00591708|DIETARY_SUPPLEMENT|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
214428202|NCT01480505|PROCEDURE|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
214428203|NCT02710708|DRUG|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
214428204|NCT02324010|DRUG|Sitagliptin|100mg mane for 2 days
214512040|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
214512041|NCT03624114|PROCEDURE|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
214512042|NCT05323643|DEVICE|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
214512043|NCT00244751|DRUG|GI262570 0.5 mg|GI262570 0.5 mg
214512044|NCT00244751|DRUG|GI262570 1.0 mg|GI262570 1.0 mg
214512045|NCT00244751|DRUG|Placebo|Placebo
214512046|NCT04213235|BEHAVIORAL|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
214512047|NCT05450159|BEHAVIORAL|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
214512048|NCT05450159|BEHAVIORAL|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
214512049|NCT02368288|DRUG|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
214512050|NCT04120623|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
214512051|NCT04120623|DRUG|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
214512052|NCT05634161|OTHER|Cognitive improvement software|Cognitive improvement software
214512053|NCT02714244|OTHER|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
214512054|NCT00729261|PROCEDURE|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
214512055|NCT00729261|PROCEDURE|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
214428205|NCT02324010|DRUG|Placebo|Inactive drug (Placebo)
214428206|NCT00119951|BEHAVIORAL|Participation on the ACOR Listserv|
214428207|NCT04630535|PROCEDURE|aorto-bifemoral bypass surgery|aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
214428208|NCT00345007|PROCEDURE|Scleral buckling|
214512056|NCT00741923|OTHER|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
214512057|NCT03722732|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
214428209|NCT00742300|PROCEDURE|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
214428210|NCT02359188|DEVICE|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
214428211|NCT06328023|OTHER|SCOAT 6 to find association|we will use SCOAT 6 to find the association between concussion , sleep and physical performance
214428212|NCT05458817|OTHER|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
214512058|NCT02222649|DIETARY_SUPPLEMENT|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
214512059|NCT02222649|DIETARY_SUPPLEMENT|Placebo|Capsules of starch, no therapeutic action
214512060|NCT05094947|PROCEDURE|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
214512061|NCT05094947|PROCEDURE|trial without catheter|catheter Foley
214512062|NCT05094947|DRUG|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
214428213|NCT01595802|DEVICE|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
214512063|NCT06248021|BEHAVIORAL|Ecological Footprint Awareness Program|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
214512064|NCT02206607|DRUG|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
214512065|NCT02206607|DRUG|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
214512066|NCT02206607|DRUG|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
214512067|NCT02206607|DRUG|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
214512068|NCT00879710|DRUG|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
214512069|NCT03417479|OTHER|Gabapentin|
214512070|NCT00548444|BIOLOGICAL|MVA85A|Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
214512071|NCT00548444|OTHER|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
214512072|NCT06081608|DIAGNOSTIC_TEST|kidney function test|blood sample for kidney function test
214512073|NCT04671875|DRUG|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
214512074|NCT03072706|DEVICE|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
214512075|NCT03072706|OTHER|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
214512076|NCT03860129|DRUG|Isoflurane|Group A: Isoflurane (0.5 MAC)
214512077|NCT03860129|DRUG|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
214512078|NCT03860129|DRUG|Desflurane|Group C: Desflurane (0.5 MAC)
215113487|NCT03501732|BEHAVIORAL|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
215113488|NCT01285934|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
215113489|NCT01285934|DRUG|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
215113490|NCT03814408|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
214428214|NCT01595802|DEVICE|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
214428215|NCT00010738|PROCEDURE|Meditation|
214428216|NCT01909167|BEHAVIORAL|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
214428217|NCT01909167|OTHER|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
215113491|NCT06794021|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for seven days
215113492|NCT06794021|OTHER|Placebo|Eligible subjects will receive Placebo to take daily for seven days
215113493|NCT03526146|BEHAVIORAL|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
214512079|NCT02140879|DIETARY_SUPPLEMENT|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
215113494|NCT01717872|DEVICE|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
215113495|NCT03564652|DIETARY_SUPPLEMENT|Balanced energy-protein (BEP)|Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
214428218|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
214428219|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
214428220|NCT01595061|DRUG|Cisplatin|Given IV
214428221|NCT01595061|DRUG|Gemcitabine Hydrochloride|Given IV
214428222|NCT01595061|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214428223|NCT01595061|PROCEDURE|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
214428224|NCT06190522|DIAGNOSTIC_TEST|Emergency physician clinical ultrasound|Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
214428225|NCT05459259|OTHER|Interviews and Delphi Survey|no intervention delivered
214428226|NCT03164408|PROCEDURE|Orthopaedic Implant Removal|
214428227|NCT00960141|DRUG|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
214428228|NCT00960141|DRUG|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
214428229|NCT00960141|DRUG|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
214428230|NCT01204359|RADIATION|Iodine 131|iodine 131，185、370、555mBq，6 months
214428231|NCT01323166|PROCEDURE|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
214428232|NCT05806476|DIETARY_SUPPLEMENT|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
214428233|NCT05806476|DIETARY_SUPPLEMENT|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
214428234|NCT05605535|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
214428235|NCT05605535|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
214428236|NCT05605535|DRUG|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
214428237|NCT05605535|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
214428238|NCT02444598|DEVICE|Vaccum Assisted Closure device|Negative-pressure wound therapy
214428239|NCT02444598|PROCEDURE|Conventional wound dressings|Conventional wound dressings
214428240|NCT02492048|DEVICE|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
214428241|NCT02492048|PROCEDURE|Split Thickness Skin Graft|Split Thickness Skin Graft
214428242|NCT02577198|OTHER|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
214428243|NCT04082611|BEHAVIORAL|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
214428244|NCT04082611|BEHAVIORAL|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
214428245|NCT00857545|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428246|NCT00857545|BIOLOGICAL|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
214428247|NCT00857545|BIOLOGICAL|Saponin-based Immunoadjuvant OBI-821|Given SC
214428248|NCT05395546|OTHER|dCBT-I|"1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
214428249|NCT00566527|BIOLOGICAL|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
214428250|NCT00457743|DRUG|Sunitinib malate (SU011248)|SU011248
214428251|NCT05290168|DIAGNOSTIC_TEST|abdominal Doppler|"1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler"
214428252|NCT00356265|DRUG|Procedure: Regional phenylephrine arterial infusion|
214428253|NCT06114615|DEVICE|LiveCare|Patient use LiveCare device to monitor their blood pressure and data is transmitted to dashboard.
214428254|NCT06114615|BEHAVIORAL|Text Messages|Patients also receive text messages after their PCI procedure for follow up appointment reminders, enrollment in cardiac rehab, and diet and exercise counseling.
214428255|NCT06114615|OTHER|Conventional Care|No digital monitoring with LiveCare device and no text messages.
214428256|NCT01784653|BEHAVIORAL|iMET|Self-completed, computerized motivational enhancement therapy
214428257|NCT01784653|BEHAVIORAL|MET|Clinician-delivered Motivational Enhancement Therapy
214512080|NCT02140879|DIETARY_SUPPLEMENT|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
215113496|NCT03564652|DRUG|Azithromycin|A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
214428258|NCT00739739|DRUG|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
214512081|NCT01368484|DIETARY_SUPPLEMENT|Sunflower oil|1500 mg sunflower/day for 10 weeks
214428259|NCT00739739|DRUG|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
214428260|NCT00739739|DRUG|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
214428261|NCT03929770|PROCEDURE|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
214428262|NCT03929770|PROCEDURE|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
214428263|NCT05874830|OTHER|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
214428264|NCT00851708|DRUG|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
214428265|NCT06327386|DIAGNOSTIC_TEST|18F-FAPI#18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
214428266|NCT05364632|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
214428267|NCT05364632|OTHER|Aerobic Training|The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
214512082|NCT01368484|DIETARY_SUPPLEMENT|Docosahexanoic acid|1500mg/day for 10 weeks
214512083|NCT03770897|PROCEDURE|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
214428268|NCT01837966|OTHER|Lavender oil|2 drops for aromatherapy
214428269|NCT01837966|OTHER|Placebo|2 drops unscented mineral oil for aromatherapy
214428270|NCT02074488|OTHER|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
214428271|NCT02074488|OTHER|Informational Brochure|Informational Brochure on falls prevention
214428272|NCT06168149|DIAGNOSTIC_TEST|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
214512084|NCT03770897|PROCEDURE|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
214512085|NCT03137849|OTHER|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
214512086|NCT03137849|OTHER|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
214512087|NCT03137849|OTHER|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
214512088|NCT05298540|BEHAVIORAL|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
214428273|NCT03910491|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
214428274|NCT03293498|BIOLOGICAL|NanoFlu|Vaccine
214428275|NCT03293498|BIOLOGICAL|Fluzone HD - Day 0|Vaccine
214428276|NCT03293498|BIOLOGICAL|Fluzone HD - Day 21|Vaccine
214428277|NCT03293498|OTHER|Saline - Day 21|Placebo
214428278|NCT01917097|DRUG|Dexmedetomidine|
214512089|NCT05260944|DEVICE|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
214512090|NCT05260944|DEVICE|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
214512091|NCT05260944|OTHER|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
214512092|NCT00986505|DRUG|Lidocaine|Intravenous lidocaine once a week
214512093|NCT02500433|OTHER|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
214512094|NCT02500433|OTHER|Conventional therapy|
214512095|NCT03392844|OTHER|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
214512096|NCT04506047|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
214512097|NCT05033756|DRUG|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
214512098|NCT05033756|DRUG|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
214512099|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
214512100|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
215113497|NCT05096065|DRUG|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
214428279|NCT05536037|DRUG|Metformin|Given PO
214428280|NCT05536037|PROCEDURE|Biopsy|Undergo biopsy
214428281|NCT04046575|RADIATION|Intensity Modulated Radiation Therapy|-15 fractions of treatment
214428282|NCT04046575|DRUG|Carboplatin|Begins on day 1 of radiotherapy
214428283|NCT04046575|OTHER|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
214428284|NCT04046575|OTHER|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
214428285|NCT04046575|OTHER|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
214512101|NCT00277277|BEHAVIORAL|Healthium|
214512102|NCT02399449|DRUG|Brand sodium ferric gluconate|brand product
214512103|NCT02399449|DRUG|Generic sodium ferric gluconate|generic product
214512104|NCT02993094|DRUG|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
214512105|NCT02993094|DRUG|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
214512106|NCT05711433|PROCEDURE|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
214512107|NCT02516202|DRUG|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
214512108|NCT02516202|DEVICE|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
214512109|NCT02516202|OTHER|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
214512110|NCT02516202|OTHER|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
214512111|NCT03595670|OTHER|standardized questionnaires|standardized questionnaires concerning the perception
215113498|NCT05096065|DRUG|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
215113499|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
214428286|NCT04046575|OTHER|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
214428287|NCT04046575|OTHER|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
214428288|NCT04046575|PROCEDURE|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
214428289|NCT04046575|PROCEDURE|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
214428290|NCT04046575|DRUG|Paclitaxel|Begins on day 1 of radiotherapy
214428291|NCT03995082|OTHER|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
214428292|NCT01006824|OTHER|Capsule endoscopy|Capsule endoscopy
214428293|NCT01006824|OTHER|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
214428294|NCT04993807|OTHER|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
214428295|NCT02308618|OTHER|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
214428296|NCT02308618|OTHER|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
214512112|NCT03595670|OTHER|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
214512113|NCT01531413|OTHER|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
214428297|NCT01278394|DRUG|AN2690 Solution, 5.0%|Once daily application for 360 days
214428298|NCT00818805|DRUG|Olopatadine 0.1%|one drop in one eye
214512114|NCT03597152|DIETARY_SUPPLEMENT|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
214512115|NCT03597152|DIETARY_SUPPLEMENT|Placebo|Inert placebo custom manufactured for the sponsor
214512116|NCT05430555|BIOLOGICAL|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
214512117|NCT05659836|DEVICE|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
214428299|NCT00818805|DRUG|Tranilast 0.5%|one drop in one eye
214428300|NCT00818805|DRUG|Placebo (Olopatadine)|one drop in contralateral eye
214428301|NCT00818805|DRUG|Placebo (Tranilast)|one drop in contralateral eye
214512118|NCT02365402|DRUG|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
214512119|NCT00839085|DRUG|GSE|grape seed extract (100 mg/6h), PO
214512120|NCT00839085|DRUG|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
214512121|NCT00337610|DRUG|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
214512122|NCT00337610|DRUG|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
214512123|NCT02451072|DRUG|Placebo|Capsules containing mannitol looking identical to LSD per os
214512124|NCT02451072|DRUG|LSD|100µg per os, single dose
215113500|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
215113501|NCT05096065|DRUG|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
215113502|NCT02305771|DEVICE|Electroencephalography|
214512125|NCT02451072|DRUG|Ketanserin|40mg per os, single dose looking identical to LSD per os
214512126|NCT00952640|DIETARY_SUPPLEMENT|vitamin A|high dose vitamin A, 200.000 IU
214512127|NCT04943640|OTHER|kinesio taping|Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
214512128|NCT04943640|OTHER|rigid taping|The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
214692434|NCT01443455|BEHAVIORAL|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~\--------------------------------------------------------------------------------"
215113503|NCT02305771|DEVICE|MRI|
215113504|NCT04627155|DRUG|LY03003|Rotigotine,extended-release microspheres
215113505|NCT02214290|DRUG|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
214428302|NCT02961010|BEHAVIORAL|Keeping Safe|A whole school Preventative Education programme
214428303|NCT02232295|DEVICE|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
214428304|NCT02232295|DEVICE|Mirror Box|A resource used for many pain and disability states of the hands and feet.
214692435|NCT02231255|DRUG|Sifrol®|
214692436|NCT05320770|PROCEDURE|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
215113506|NCT02214290|DRUG|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
215113507|NCT02214290|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
215113508|NCT03158324|DRUG|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
214428305|NCT04565418|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
214428306|NCT01236560|BIOLOGICAL|Bevacizumab|Given IV
214428307|NCT01236560|DRUG|Temozolomide|Given PO
214428308|NCT01236560|DRUG|Vorinostat|Given PO
214428309|NCT01320215|PROCEDURE|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
214428310|NCT01320215|PROCEDURE|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
214428311|NCT02472275|DRUG|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
214428312|NCT02472275|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428313|NCT02472275|DRUG|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
214428314|NCT02472275|RADIATION|Radiation Therapy|Undergo radiation therapy
214428315|NCT02197975|DRUG|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
214428316|NCT02197975|DRUG|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
214428317|NCT02197975|DRUG|Placebo MDI|Placebo MDI. Administered as 2 inhalations
214428318|NCT06028503|BEHAVIORAL|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
215113509|NCT05159518|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion
215113510|NCT02517541|DEVICE|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
215113511|NCT01615016|OTHER|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
215113512|NCT01510158|DRUG|Lesinurad|Tablets, 200 mg once daily (qd)
215113513|NCT01510158|DRUG|Lesinurad|Tablets, 400 mg qd
215113514|NCT01510158|DRUG|Placebo|Tablets, Placebo qd
215113515|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
214428319|NCT06028503|DEVICE|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
215113516|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
214428320|NCT06028503|OTHER|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
214428321|NCT04327167|BEHAVIORAL|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
214512129|NCT04943640|OTHER|placebo taping|Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
214512130|NCT01277679|PROCEDURE|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
214428322|NCT00125645|DRUG|Irbesartan Oral Tablet|
214428323|NCT01079065|DRUG|Famotidine|Tablets
214428324|NCT01813773|DRUG|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
214428325|NCT03688360|BEHAVIORAL|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
214512131|NCT04898582|OTHER|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
214512132|NCT05576233|PROCEDURE|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
215113517|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
215113518|NCT01929382|DRUG|interferon gamma 1b|Standard therapy vs dose titration
215113519|NCT03827603|DRUG|Ibrutinib|Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
215113520|NCT05303818|DRUG|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
215113521|NCT01067274|DRUG|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
215113522|NCT01067274|DRUG|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
215113523|NCT01067274|DRUG|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
215113524|NCT06514001|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
214428326|NCT03516240|OTHER|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
215113525|NCT03078556|DRUG|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
215113526|NCT03078556|DRUG|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
215113527|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
215113528|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
215113529|NCT00068614|BIOLOGICAL|HER-2/neu peptide vaccine|
215113530|NCT04555564|PROCEDURE|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
214428327|NCT03516240|OTHER|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
215113531|NCT05549830|OTHER|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
215113532|NCT04593758|DRUG|CPI-613 + Hydroxychloroquine|"dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg"
215113533|NCT04542954|OTHER|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
215113534|NCT05718856|DRUG|TPO-RAs|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.
215113535|NCT05718856|DRUG|TPO-RAs combining anti-CD 20 monoclonal antibody|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater."
215113536|NCT03741972|DRUG|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
215113537|NCT01278992|DIETARY_SUPPLEMENT|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
214428328|NCT03114410|BEHAVIORAL|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
214428329|NCT06630442|OTHER|Educational Intervention|Attend a food safety educational training program
214428330|NCT06630442|OTHER|Questionnaire Administration|Ancillary studies
214428331|NCT06554353|DEVICE|Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
214428332|NCT04356820|OTHER|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
214428333|NCT06178588|PROCEDURE|Biopsy|Undergo tumor biopsy
214428334|NCT06178588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214428335|NCT06178588|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214428336|NCT06178588|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214428337|NCT06178588|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214428338|NCT06178588|BIOLOGICAL|Sacituzumab Govitecan|Given IV
214428339|NCT00963625|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
214428340|NCT00963625|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
214692437|NCT01685632|PROCEDURE|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
214692438|NCT01685632|PROCEDURE|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
215113538|NCT04633382|COMBINATION_PRODUCT|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
215113539|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
215113540|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
215113541|NCT03314987|DIETARY_SUPPLEMENT|L-carnosine|a naturally occurring di-peptide
215113542|NCT03314987|OTHER|placebo|an identically appearing supplement
215113543|NCT03769259|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|Participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
215113544|NCT03769259|BEHAVIORAL|Present-Centered Therapy (PCT)|Participants in PCT will receive will include 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. PCT consists of (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors among military personnel; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions.
215113545|NCT03769259|BEHAVIORAL|Treatment as Usual (TAU)|"All participants will receive the following interventions or procedures, regardless of treatment assignment:~* Suicide risk assessment using the Columbia Suicide Severity Rating Scale~* VA's safety planning intervention, which include Military Crisis Line contact information and lethal means access reduction~* Caring contacts and outreach~* Psychotropic medication, group therapy, substance abuse counseling, and other mental health interventions provided routinely as a part of treatment as usual"
215113546|NCT05462860|OTHER|Suprathel®|Application of standard of care dressing.®
215113547|NCT03574779|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
215113548|NCT03574779|BIOLOGICAL|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
214428341|NCT05028959|OTHER|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
214428342|NCT05066958|BIOLOGICAL|boost anti-viral immunity after T-cell depleted HSCT|"* Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening"
214428343|NCT02284412|DRUG|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
214428344|NCT02284412|DRUG|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
214692439|NCT06520176|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
214428345|NCT02284412|DRUG|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
214428346|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
214428347|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
214428348|NCT05158387|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
214428349|NCT05855291|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
215113549|NCT03574779|BIOLOGICAL|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
215113550|NCT03574779|DRUG|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
214428350|NCT03123809|DEVICE|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
214428351|NCT02044523|DEVICE|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
214428352|NCT02530073|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
214428353|NCT00521833|PROCEDURE|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
214428354|NCT02748590|DEVICE|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
214428355|NCT03538912|OTHER|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
214428356|NCT03538912|OTHER|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
214428357|NCT00664430|DRUG|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
214428358|NCT00664430|DRUG|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
214428359|NCT03404583|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
214428360|NCT02035969|BEHAVIORAL|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
214428361|NCT06088225|DEVICE|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
214428362|NCT00018785|PROCEDURE|donor bone marrow infusion|
214428363|NCT03340714|DEVICE|Monitoring Device|Wear ADAMM
214428364|NCT05096663|DIETARY_SUPPLEMENT|Cobalamin|Given intramuscularly
214428365|NCT05096663|DRUG|Dexamethasone|Given orally (PO)
214428366|NCT05096663|DRUG|Docetaxel|Given IV
214428367|NCT05096663|DIETARY_SUPPLEMENT|Folic Acid|Given PO
215113551|NCT03574779|DRUG|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
215113552|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
215113553|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
215113554|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
215113555|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
215113556|NCT02751580|OTHER|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
214428368|NCT05096663|DRUG|Gemcitabine|Given IV
214428369|NCT05096663|DRUG|Nogapendekin Alfa|Given SC
214428370|NCT05096663|BIOLOGICAL|Pembrolizumab|Given IV
214428371|NCT05096663|DRUG|Pemetrexed|Given IV
214428372|NCT05096663|BIOLOGICAL|Ramucirumab|Given IV
214692440|NCT06520176|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
215113557|NCT02751580|OTHER|Questionnaire Administration|Ancillary studies
215113558|NCT06535958|BEHAVIORAL|OHI|All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
215113559|NCT06535958|PROCEDURE|OHI+PMPR|Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
215113560|NCT04778826|PROCEDURE|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
214512133|NCT01123174|BEHAVIORAL|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
214428373|NCT04589208|DRUG|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
214428374|NCT03184038|PROCEDURE|Cognitive Assessment|Undergo assessment of neurocognitive function
214428375|NCT03184038|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214512134|NCT00000170|DRUG|Atropine|Atropine
214512135|NCT00000170|DEVICE|Eye Patch|Patching
214512136|NCT02615132|BEHAVIORAL|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
214512137|NCT05953909|DRUG|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
214512138|NCT05953909|DRUG|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
214512139|NCT05953909|DRUG|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
214512140|NCT02387385|DEVICE|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
214512141|NCT04090502|OTHER|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
214512142|NCT04090502|OTHER|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
214512143|NCT00002232|BIOLOGICAL|APL 400-003|
214512144|NCT00869856|DRUG|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
214512145|NCT01275859|DRUG|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
214512146|NCT05702190|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
214512147|NCT05702190|DRUG|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
214512148|NCT00084825|DRUG|Docetaxel|30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
215113561|NCT03020706|DRUG|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
215113562|NCT04233541|DIAGNOSTIC_TEST|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
214428376|NCT03184038|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214428377|NCT03184038|OTHER|Quality-of-Life Assessment|Ancillary studies
214428378|NCT03180502|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214428379|NCT03180502|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214428380|NCT03180502|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428381|NCT03180502|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214428382|NCT03180502|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214512149|NCT00084825|DRUG|Imatinib mesylate|600 mg orally daily
214512150|NCT03107156|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
214512151|NCT01543789|PROCEDURE|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
214512152|NCT01543789|PROCEDURE|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
214512153|NCT05847114|OTHER|Stres ball|Stress ball compression for 15 minutes during surgery
214512154|NCT03541369|DRUG|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
214512155|NCT02262988|PROCEDURE|Total knee replacement|Total knee replacement (TKA)
214512156|NCT02583113|DEVICE|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
215113563|NCT03106636|BEHAVIORAL|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
214512157|NCT04012970|OTHER|Manual spinal mobilisations|
214512158|NCT00005820|DRUG|nitrocamptothecin|
214512159|NCT01981746|PROCEDURE|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
214512160|NCT05302882|BEHAVIORAL|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
214512161|NCT05302882|BEHAVIORAL|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
214428383|NCT03180502|OTHER|Quality-of-Life Assessment|Ancillary studies
214512162|NCT03205488|DRUG|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
214512163|NCT03205488|DRUG|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
214512164|NCT03205488|DRUG|Placebo|2 capsules taken once daily
214512165|NCT04886674|DIETARY_SUPPLEMENT|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
214512166|NCT02181179|BEHAVIORAL|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
214512167|NCT06475248|OTHER|Placebo Technique|For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).
214512168|NCT06475248|OTHER|Stretching technique|"Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally."
214428384|NCT03180502|OTHER|Questionnaire Administration|Ancillary studies
214428385|NCT03180502|DRUG|Temozolomide|Drug
214512169|NCT06475248|OTHER|Inhibition of the suboccipital|"Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions."
214512170|NCT01987518|OTHER|Procedure surgery behavioral and genetic diagnosis|Observational Study
214512171|NCT01987518|PROCEDURE|quality of life after different type of surgery|
214692441|NCT06520176|DRUG|Pegfilgrastim|Day 6: 6mg
214692442|NCT06520176|DRUG|Cyclophosphamide|Day 1\~Day 2: 1～2g/m\^2
214692443|NCT06520176|DRUG|G-CSF|Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
215113564|NCT03106636|BEHAVIORAL|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
214428386|NCT06804096|DRUG|Faropenem|Tab. Faropenem 200mg three times daily
214428387|NCT06804096|DRUG|Co-amoxiclav|Tab. Co-Amoxiclav 625mg three times daily
214428388|NCT06804096|DRUG|Clarithromycin 500 mg|Tab. Clarithromycin 500mg two times daily
214428389|NCT05444244|OTHER|Relational Research Recruitment and Engagement Intervention|"* Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)"
214428390|NCT05001477|DEVICE|TULSA Procedure|Transurethral ultrasound ablation procedure
214428391|NCT00296751|PROCEDURE|ECG recording|
214428392|NCT00296751|PROCEDURE|Epidural catheter insertion|
214428393|NCT00296751|DRUG|Intravenous meperidine injection|
214428394|NCT00296751|DRUG|Epidural Bupivacaine and fentanyl injection|
214428395|NCT06534554|BEHAVIORAL|Patient Navigation|A lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
214512172|NCT03631966|DRUG|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
214512173|NCT04890899|PROCEDURE|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
214512174|NCT04867382|BEHAVIORAL|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
214512175|NCT01888484|BIOLOGICAL|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
215113565|NCT02630303|DEVICE|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
214428396|NCT06510348|DIETARY_SUPPLEMENT|Supplemental Parenteral Nutrition (SPN)|Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
214428397|NCT01792830|DRUG|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
214428398|NCT01792830|DRUG|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c \> 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
214428399|NCT01792830|DRUG|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
214428400|NCT04220827|DRUG|Paclitaxel|Given IP
214428401|NCT03568292|OTHER|Best Practice|Receive standard of care
214428402|NCT03568292|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428403|NCT03568292|DEVICE|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
214428404|NCT03568292|OTHER|Questionnaire Administration|Ancillary studies
214428405|NCT04826445|OTHER|Data collection|Imaging collection
214428406|NCT01824485|DRUG|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
214428407|NCT01824485|DRUG|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
214428408|NCT03230942|OTHER|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
214428409|NCT03230942|OTHER|Pos-operative rehabilitation|Physical therapy treatment
214428410|NCT05766189|BEHAVIORAL|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
214428411|NCT06453317|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
214428412|NCT06453317|BIOLOGICAL|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
214512176|NCT02548299|OTHER|Nutrition Education|Nutrition classes will be led by a registered dietician.
214512177|NCT02548299|OTHER|Cooking Lecture|
214512178|NCT02548299|OTHER|Cooking Demo|
215113566|NCT02630303|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
215113567|NCT04890470|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
214512179|NCT02548299|OTHER|Hands-on Cooking|
214512180|NCT02548299|OTHER|e-Coaching|
215113568|NCT04890470|DRUG|Vasopressin|intranasal administration of vasopressin (20 IU)
215113569|NCT04890470|DRUG|Placebo|intranasal administration of placebo
214512181|NCT00989118|PROCEDURE|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
214428413|NCT06633614|DEVICE|Supervised prehabilitation programme|Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
214512182|NCT03681132|OTHER|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
214512183|NCT03731767|PROCEDURE|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
214512184|NCT01124942|DEVICE|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
215113570|NCT00974623|DEVICE|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
214512185|NCT01124942|DEVICE|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
214512186|NCT04103099|DIETARY_SUPPLEMENT|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
214512187|NCT03887611|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
214512188|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation."
214512189|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation."
214512190|NCT01326455|DEVICE|Clo-Sur-P.A.D.|"A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1."
214512191|NCT05445557|DRUG|RZL-012|small synthetic molecule for submental fat reduction
214512192|NCT05445557|DRUG|Placebo|Placebo
214512193|NCT01448109|DRUG|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
214512194|NCT01448109|DRUG|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
214512195|NCT02482324|DRUG|ALZT-OP1a|Mast cell stabilizer
214512196|NCT02482324|DRUG|ALZT-OP1b|anti-inflammatory
214512197|NCT02482324|DEVICE|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
214512198|NCT05778253|DIAGNOSTIC_TEST|WES and ctDNA detection|WES and ctDNA detection
214512199|NCT02834559|DRUG|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
214512200|NCT02834559|DRUG|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
214512201|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised CARE program
214512202|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised TARE program
214512203|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo home-based stretching program
214512204|NCT03091842|OTHER|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
214512205|NCT03091842|OTHER|Laboratory Biomarker Analysis|Correlative studies
214512206|NCT03091842|OTHER|Quality-of-Life Assessment|Ancillary studies
215113571|NCT01915173|DRUG|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
215113572|NCT01915173|DRUG|Placebo|Lactose tablets
215113573|NCT01915173|BEHAVIORAL|Expanded Interview|
215113574|NCT01915173|BEHAVIORAL|Standard Interview|
214428414|NCT05894005|OTHER|Immersive Virtual Reality (IVR)|Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route.
214428415|NCT05894005|OTHER|Traditional 2-D Video|Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.
214428416|NCT06971848|OTHER|Drug skin tests (investigating hypersensitivity to a biotherapy)|allergologic skin tests (prick tests and intradermal tests)
214428417|NCT06173765|OTHER|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
214512207|NCT03091842|OTHER|Questionnaire Administration|Ancillary studies
214512208|NCT00167999|DRUG|piperacillin-tazobactam|
214512209|NCT01515501|PROCEDURE|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
214512210|NCT02008916|DRUG|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
214512211|NCT02008916|DRUG|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
214512212|NCT06648785|DRUG|oxaliplatin|85 mg/m2 oxaliplatin
214512213|NCT06648785|DRUG|Fluoropyrimidine|oral fluoropyrimidine 1000mg/m2
214512214|NCT03803475|DRUG|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
214512215|NCT03803475|DEVICE|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
214512216|NCT03803475|DEVICE|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
215113575|NCT00830466|DRUG|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
215113576|NCT03421912|OTHER|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
215113577|NCT03421912|OTHER|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
214692444|NCT06520176|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
215113578|NCT05599971|DRUG|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
215113579|NCT05599971|DRUG|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
215113580|NCT05599971|OTHER|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
215113581|NCT02272712|BEHAVIORAL|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
215113582|NCT05668598|DIAGNOSTIC_TEST|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
215113583|NCT02152761|DRUG|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
215113584|NCT02152761|OTHER|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
215113585|NCT00609570|DIETARY_SUPPLEMENT|NanoGreens|fruits and vegetables
215113586|NCT00609570|DIETARY_SUPPLEMENT|Whey protein|Whey
215113587|NCT00609570|DIETARY_SUPPLEMENT|Calcium pills|CA
215113588|NCT03079895|BEHAVIORAL|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
215113589|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue
214428418|NCT06173765|OTHER|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
214428419|NCT06173765|OTHER|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
214428420|NCT04930159|BEHAVIORAL|Facilitated group support|Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.
214428421|NCT04930159|BEHAVIORAL|1:1 Peer Support|1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.
214428422|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 20-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
214428423|NCT06016478|DIETARY_SUPPLEMENT|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214428424|NCT06016478|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214512217|NCT04672967|DIAGNOSTIC_TEST|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
214512218|NCT03279406|DEVICE|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
215113590|NCT01255618|DEVICE|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
214512219|NCT03481751|DIAGNOSTIC_TEST|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
214512220|NCT03927651|DRUG|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
214512221|NCT04255498|DRUG|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
214512222|NCT04255498|DRUG|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
214512223|NCT01971255|BIOLOGICAL|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
214428425|NCT02265276|DRUG|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
214512224|NCT05364385|DRUG|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
214512225|NCT05364385|DRUG|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
214512226|NCT06459544|DIAGNOSTIC_TEST|Bobath Technique with core stability|exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.
214428426|NCT02265276|DRUG|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
214428427|NCT01954407|BEHAVIORAL|Smoking-Related Messages|
214512227|NCT06459544|OTHER|Conventional treatment for balance|like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
214512228|NCT00392197|DRUG|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
214512229|NCT01802619|OTHER|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
214512230|NCT01802619|OTHER|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
214512231|NCT00059384|BEHAVIORAL|Concentration-controlled therapy|
214512232|NCT00145145|BIOLOGICAL|MAGE-3.A1 peptide and CpG 7909|
214512233|NCT05514184|DIETARY_SUPPLEMENT|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
214428428|NCT05913869|BEHAVIORAL|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
214428429|NCT06973941|OTHER|Virtual reality relaxation|"10-minute VR relaxation application, part of the app Nature Treks VR by Greenergames (released on May 21, 2019), used with a Metaquest head-mounted display"
214428430|NCT06973941|OTHER|Guided imagery relaxation|10-minute guided imagery relaxation where an investigator reads a dream journey
214428431|NCT06973954|OTHER|Text Message Intervention|This intervention was prepared by the researcher with the support of artificial intelligence to increase the activation of diabetic individuals in the experimental group. It consists of short messages with the themes of gain, loss and motivation related to diabetes and self-management.
214428432|NCT06973733|BEHAVIORAL|Clinical data and biospecimen collection|"Clinical Data Collection: Case report forms were utilized to systematically capture multimodal clinical data, including: demographic characteristics, clinical symptoms and physical signs, laboratory test results, chest imaging data, organ support parameters, pharmacological interventions , complications and clinical outcomes.~Biospecimen Collection: ARDS patients underwent biospecimen collection at days 1, 4, and 7 post-diagnosis. High-risk ARDS cohorts provided specimens within 24 hours of ICU admission. Specimens included: peripheral blood, Sputum/BALF, stool and urine."
214428433|NCT06973889|BIOLOGICAL|Helicobacter pylori eradication therapy|12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day).
214428434|NCT06974227|DEVICE|Assistive Pulse Data Collection (APDC) Device|An Assistive Pulse Data Collection Device prototype has been designed and manufactured by the Logistics and Supply Chain MultiTech R\&D Centre, Hong Kong. The device comprises a pulse sensor to record the patient's pulse and digitalize the pulse feature into waveform data. The digitalized waveform data is then converted the electronic signal into mechanical vibration that responds to the patient's pulse.
214428435|NCT06972329|OTHER|Cerebral Near infrared spectroscopy (NIRSc).|Continuous cerebral near-infrared spectroscopy (NIRSc) during resuscitation in a patient treated for out-of-hospital cardiac arrest (OHCA).
214428436|NCT06972589|DEVICE|Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
214428437|NCT06972589|DEVICE|Conventional mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
214428438|NCT06973980|OTHER|Exercise|The exercises will be applied only to the intervention group for 12 weeks and will be progressively intensified every 4 weeks.
214428439|NCT06972862|OTHER|Osteogenic Index Optimized Exercise Training Program|The OI- Optimized Training is 6 months of planned, non-linear periodized training on a leg press machine called the PPM (Athletic Republic, Salt Lake City, UT) with a maintenance program during the semester breaks, as necessary.
214428440|NCT06974266|DIETARY_SUPPLEMENT|Probiotic|Subjects receive AKM Lab-01 Enteric-coated once daily by oral, 34B TFU/day , within half an hour after breakfast for 3 months.
214428441|NCT06974266|DIETARY_SUPPLEMENT|Placebo|Subjects receive placebo once daily by oral, one capsule/day, within half an hour after breakfast for 3 months.
214428442|NCT06973343|DRUG|Group A|Sintilimab 200mg Bevacizumab 7.5mg/kg Oxaliplatin 130mg/m2 Capecitabine 1250mg/m2
214428443|NCT06973343|DRUG|Group B|Sintilimab 200mg Bevacizumab 7.5mg/kg Irinotecan 150mg/m2 Capecitabine 1250mg/m2
214428444|NCT06972836|PROCEDURE|modified pericardial window|(H) shaped lines done by diathemy hoke above phrenic nerve then the upper and lower pericardial flabs reflelected outward in upper and lower directions respectively then 3 large clips applied on each angle of the reflected pericardial anlgles then heavy non absorbable suture is taken from the centre of the free reflected edge to adjacent upper and lower pericardium
214428445|NCT06972836|PROCEDURE|traditional pericardial window|A portion of pericardium (2 cm diameter) was resected anterior to the phrenic nerve by diathermy hook
214428446|NCT06973759|DEVICE|Bright light therapy|Exposure to blue-enriched white light for 15-30 minutes a day for 8 weeks
214428447|NCT06973759|DEVICE|Dim red light|Exposure to dim red light for 15-30 minutes a day for 8 weeks.
214428448|NCT04290117|BEHAVIORAL|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
214428449|NCT04290117|BEHAVIORAL|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
214428450|NCT00971022|BEHAVIORAL|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
214428451|NCT00971022|BEHAVIORAL|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
214428452|NCT00441636|DEVICE|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
214428453|NCT00310154|DRUG|docetaxel|
214428454|NCT00310154|DRUG|gefitinib|
214428455|NCT00310154|OTHER|laboratory biomarker analysis|
214428456|NCT00310154|RADIATION|radiation therapy|
214428457|NCT05068362|DEVICE|Auricular reconstruction|Medpor implant for treatment of microtia
214428458|NCT01198028|DRUG|Erlotinib|Given PO
214428459|NCT01576952|DRUG|ISV-303|Bromfenac in DuraSite
214428460|NCT01576952|OTHER|DuraSite Vehicle|DuraSite Vehicle
214428461|NCT06362278|OTHER|multi-omics studies|15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
214428462|NCT00658996|DEVICE|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
215113591|NCT01494077|OTHER|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
215113592|NCT03755882|DEVICE|ACUVUE® DEFINE™ Vivid Style|TEST Lens
214512234|NCT05330000|DRUG|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
214428463|NCT00658996|DEVICE|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
214428464|NCT04470401|DRUG|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
214428465|NCT04470401|DRUG|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
214428466|NCT06020651|DIAGNOSTIC_TEST|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
214428467|NCT02079844|DRUG|Roflumilast|Roflumilast tablets
214428468|NCT02079844|DRUG|Placebo|Roflumilast placebo-matching tablets
214428469|NCT02079844|DRUG|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
214428470|NCT04771351|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
214428471|NCT04771351|DRUG|Placebo|Diluent solution
214428472|NCT01420549|DRUG|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
214512235|NCT05330000|DRUG|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
214512236|NCT02481011|DRUG|antithrombotic drugs|
214512237|NCT03406390|PROCEDURE|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
214512238|NCT00428714|DRUG|enzastaurin|Administered orally
214512239|NCT03489356|BEHAVIORAL|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
214428473|NCT01420549|DRUG|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
215113593|NCT03755882|DEVICE|LACELLE™ Sparkling Brown|CONTROL Lens
214428474|NCT06546605|DEVICE|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training is a novel training modality that involves the simultaneous electrical stimulation of multiple muscle groups while performing dynamic exercises. Participants in the WB-EMS Training Group will use the miha bodytec device (Augsburg, Germany), which consists of a special suit with integrated electrodes covering major muscle groups. The device generates electrical impulses (85 Hz, 350 μs) that cause involuntary muscle contractions during exercises like squats, lunges, and trunk rotations.Each 20-25-minute WB-EMS session will be conducted twice a week during the two 8-week intervention periods. Sessions will include a warm-up followed by 4-6 WB-EMS exercises performed for 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the stimulation and exercises will be progressively increased based on individual adaptation and tolerance, with the stimulation intensity set at 70-85% of the maximal tolerable level.
214428475|NCT06546605|BEHAVIORAL|Plyometric Training|"Plyometric Training is a high-intensity, explosive strength training modality that involves quick, powerful movements designed to increase muscle power, speed, and agility. Participants in the Plyometric Training Group will engage in a progressive plyometric training program that emphasizes eccentric muscle loading followed by rapid concentric contractions.~The plyometric exercises will include various types of jumps, hops, and bounds, such as box jumps, depth jumps, split squat jumps, and single-leg hops. Each training session will begin with a dynamic warm-up, followed by 4-6 plyometric drills performed for 3-5 sets of 8-12 repetitions, with 60-90 seconds of rest between sets. The intensity and volume of the exercises will be gradually increased over the two 8-week intervention periods."
214512240|NCT04535440|OTHER|No intervention|No intervention
215113594|NCT02639442|DEVICE|ClearRing™|
214512241|NCT01681511|DEVICE|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
215113595|NCT05639140|OTHER|Data collection|Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
215113596|NCT04679194|BIOLOGICAL|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
215113597|NCT01011140|BEHAVIORAL|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
215113598|NCT05184634|OTHER|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
215113599|NCT05184634|OTHER|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
215113600|NCT05184634|OTHER|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
214428476|NCT06546605|BEHAVIORAL|Functional Training|"Functional Training is a training approach that focuses on exercises that simulate the demands of specific sports or daily activities, targeting multiple muscle groups and movement patterns simultaneously. Participants in the Functional Training Group will engage in a tailored functional training program designed to enhance their performance in basketball or volleyball.~The functional training exercises will incorporate multi-joint, multi-planar movements that mimic game-specific actions, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills. Each session will start with a dynamic warm-up, followed by 6-8 functional exercises performed for 3-4 sets of 8-12 repetitions, with 60 seconds of rest between sets. The program will also include core stability and injury prevention exercises."
214512242|NCT01681511|DEVICE|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
214512243|NCT04725032|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
214512244|NCT04725032|DRUG|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
214428477|NCT04592211|DRUG|olaparib+pembrolizumab+paclitaxel|olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly
214428478|NCT01228916|BEHAVIORAL|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
214512245|NCT04813133|OTHER|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
214512246|NCT04813133|OTHER|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
214512247|NCT04813133|OTHER|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
214512248|NCT02151994|DRUG|BIA 5-1058|oral administration
214512249|NCT02151994|DRUG|Placebo|oral administration
214512250|NCT04875767|DEVICE|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
215113601|NCT05184634|OTHER|QUALITY OF LIFE|To determine the quality of life of MetS individuals
215113602|NCT02292446|DRUG|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
215113603|NCT00224588|DRUG|Ketamine (or placebo : isotonic saline solution)|
215113604|NCT01311609|OTHER|Systane|Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
215113605|NCT04524234|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of cardiac function
215113606|NCT02124681|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
214512251|NCT06356532|BEHAVIORAL|intensive care unit diary|The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
214512252|NCT01932632|OTHER|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
214512253|NCT04405310|BIOLOGICAL|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
214512254|NCT04405310|OTHER|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
214512255|NCT02738307|OTHER|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
214512256|NCT00090519|DRUG|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
215113607|NCT02124681|OTHER|Placebo|Placebo PO for 13±1 weeks
214512257|NCT00090519|DRUG|placebo|QD oral for up to 36 months
214512258|NCT01013584|DIETARY_SUPPLEMENT|cholecalciferol|daily dose
214512259|NCT05298813|BIOLOGICAL|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
214512260|NCT05298813|OTHER|Placebo|Matching Placebo
214512261|NCT03908775|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
214512262|NCT03908775|DEVICE|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
215113608|NCT02538601|BEHAVIORAL|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
214428479|NCT06044545|DIAGNOSTIC_TEST|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
214428480|NCT03062137|DIAGNOSTIC_TEST|blood gas sampling|
214512263|NCT06251336|OTHER|UroialTM Plus|Nutraceutical
214512264|NCT06251336|OTHER|Placebo|Placebo sachet
214512265|NCT03510052|BEHAVIORAL|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
214512266|NCT05474313|BEHAVIORAL|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
214512267|NCT05474313|BEHAVIORAL|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
214512268|NCT02295189|DRUG|Ketorolac Tromethamine|anti-inflammatory injection
214512269|NCT02295189|DRUG|Triamcinolone Acetonide|corticosteroid injection
214512270|NCT00054938|DRUG|pravastatin|
214512271|NCT00054938|DRUG|aspirin|
214512272|NCT00054938|DRUG|ramipril|
214692445|NCT03894527|BEHAVIORAL|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
215113609|NCT02538601|BEHAVIORAL|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
215113610|NCT02735148|OTHER|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~1. Body Weight Supported Treadmill Training,~2. Conventional Training and~3. Combined Training."
214428481|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
214428482|NCT05719077|BEHAVIORAL|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
214428483|NCT06034665|OTHER|Exercise|All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
214512273|NCT00054938|DRUG|Vitamins: B6, B12, and folate|
214512274|NCT00054938|BEHAVIORAL|heart health educational program|
214512275|NCT00840775|DEVICE|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
214512276|NCT01971112|DIETARY_SUPPLEMENT|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
214512277|NCT02349516|DRUG|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
214512278|NCT02161146|DRUG|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
214512279|NCT02161146|DRUG|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
214512280|NCT02161146|DRUG|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
214512281|NCT02871661|DRUG|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
214512282|NCT02871661|OTHER|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
214512283|NCT02871661|DEVICE|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
214692446|NCT03894527|BEHAVIORAL|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
214428484|NCT05977634|BEHAVIORAL|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
214428485|NCT05977634|DEVICE|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
214428486|NCT06034678|BEHAVIORAL|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
214428487|NCT00928213|DRUG|Progesterone|40 units daily admission
214428488|NCT00928213|DRUG|Low molecular weight Heparin|40-80 mg/day
214428489|NCT00928213|DRUG|No Drug|no treatment
214428490|NCT06490003|DRUG|Fluoro Uracil|Esophageal cancer chemotherapy（First line treatment)
214428491|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
214428492|NCT00039455|BIOLOGICAL|trastuzumab|Given IV
214428493|NCT00039455|DRUG|alvocidib|Given IV
214428494|NCT00039455|OTHER|laboratory biomarker analysis|Correlative studies
214428495|NCT00039455|OTHER|pharmacological study|Correlative studies
214428496|NCT06615375|BIOLOGICAL|Shigella4V2|Shigella4V2 is a tetravalent bioconjugate vaccine
214428497|NCT06615375|BIOLOGICAL|Placebo|Phosphate-buffered saline
214428498|NCT06383442|OTHER|L-HIIT|the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
214512284|NCT03709849|DRUG|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
214512285|NCT03709849|DRUG|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
214512286|NCT05811273|OTHER|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
214512287|NCT05811273|OTHER|Control group|general exercises
214428499|NCT06383442|OTHER|M-HIIT|the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
214428500|NCT01048931|PROCEDURE|single-port LAVH|single-port LAVH
214512288|NCT05590559|DRUG|Morphine|Opiates
214428501|NCT05604937|OTHER|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
214428502|NCT05604937|DRUG|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
214428503|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
214428504|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
214428505|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
214428506|NCT00981630|BIOLOGICAL|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
214428507|NCT06677281|OTHER|Systematic Review of COVID-19's Impact on Pregnancy Outcomes|This study is a systematic review of existing literature that examines the effects of COVID-19 on pregnancy outcomes, including maternal health, neonatal health, and obstetric complications. It synthesizes data from various studies to provide an overview of the potential risks associated with COVID-19 infection during pregnancy. This intervention does not involve any new clinical trials or direct patient interaction.
214428508|NCT06677515|OTHER|VR training|The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
214428509|NCT06677099|PROCEDURE|chest physiotherapy|Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique , positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
214512289|NCT05590559|OTHER|Ultrasound-guided erector spinae plane block|PVB
214512290|NCT01072838|RADIATION|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
214512291|NCT01072838|DEVICE|Contura MLB Breast Brachytherapy Catheter|
214512292|NCT00003087|DRUG|cisplatin|
214512293|NCT00003087|DRUG|paclitaxel|
214512294|NCT00003087|PROCEDURE|surgical procedure|
214512295|NCT00003087|RADIATION|radiation therapy|
214428510|NCT06677099|PROCEDURE|EIT-guided chest physiotherapy|EIT-guided modified postural drainage combined with vibrations and chest percussion: tidal variation images in EIT reveals heterogeneously ventilated regions. Physiotherapist identified such regions at the bedside and instructed the patient to take the appropriate drainage position, so that the poorly ventilated regions became gravity non-dependent regions. Subsequently, the physiotherapist put her hands on the poorly ventilated area with a vibratory force. A compressive pressure was produced by the therapist's arms.
214428511|NCT06676124|DIETARY_SUPPLEMENT|Piper crocatum Extract Cookie|Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction
214428512|NCT06676124|DIETARY_SUPPLEMENT|Placebo Comparator|Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
214428513|NCT05836285|OTHER|ARRC|Eligible for ARRC and managed in ARRC unit
214428514|NCT05836285|OTHER|Usual Care|Eligible for ARRC but managed elsewhere as no ARRC bed available
214428515|NCT06092138|DEVICE|Wearable Device|Whether to use wearable devices.
214428516|NCT06864299|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
214428517|NCT06861894|DRUG|Adebrelimab and nab-paclitaxel and carboplatin|Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy
214428518|NCT06861894|RADIATION|Radiation|concurrent chemoradiotherapy
214428519|NCT06861894|PROCEDURE|standard oesophagectomy|standard oesophagectomy
214512296|NCT03628313|OTHER|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
214512297|NCT00309751|DRUG|Pitavastatin|Pitavastatin 4 mg QD
214512298|NCT00309751|DRUG|Atorvastatin|Atorvastatin 20 mg
214512299|NCT05162339|OTHER|No intervention was made|No intervention was made
214512300|NCT02613403|DRUG|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
214428520|NCT06861894|OTHER|active surveillance|active surveillance
214428521|NCT07008898|PROCEDURE|Midurethral sling placed before robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
214428522|NCT07008898|PROCEDURE|Midurethral sling placed after robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
215113611|NCT02735668|OTHER|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands)."
215113612|NCT02735668|OTHER|Multimodal Physiotherapy|"The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
215113613|NCT02735668|OTHER|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
215113614|NCT02735668|BEHAVIORAL|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
215113615|NCT04407988|DRUG|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
215113616|NCT04803851|DRUG|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
215113617|NCT01810003|DIETARY_SUPPLEMENT|High DHA|10 week supplementation period
215113618|NCT01810003|DIETARY_SUPPLEMENT|High EPA|10 week supplementation period
214428523|NCT06377345|DEVICE|AeviceMD device|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
214512301|NCT02613403|DRUG|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
214512302|NCT03512782|OTHER|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
214512303|NCT05532072|DRUG|Rapamycin|Rapamycin plus Methylprednisolone
214512304|NCT05532072|DRUG|Methylprednisolone|Methylprednisolone Alone
214428524|NCT06377345|BEHAVIORAL|Standard care|All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
214428525|NCT05799963|DEVICE|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
214428526|NCT06676605|DIETARY_SUPPLEMENT|Withania somnifera|The experimental supplement administered to patients in this study was Withania somnifera, commonly known as ashwagandha. It is classified as a dietary supplement and is regulated similarly to pharmaceutical medications. The supplement has been authorized for commercialization and use by the Food and Drug Administration (FDA). Participants received the supplement in the form of 500 mg capsules, taken daily over a 40-day period, following the manufacturer's instructions. The range of the recommended daily dose is between 240 and 600 mg. The purpose of administering this supplement was to evaluate its impact on various health parameters, including serum lipid concentrations and body composition, in the study's participants.
214428527|NCT06676605|OTHER|Placebo Intervention|The product administered to the placebo group was designed to simulate the appearance and administration of the experimental supplement but without containing any active ingredients. Participants in the placebo group received capsules/tablets filled with starch rice. These capsules were taken daily over the same 40-day period as the experimental group, ensuring that the placebo group followed identical administration and monitoring procedures. The use of starch rice capsules aimed to serve as a neutral control, allowing for a comparison between the effects of the actual Withania somnifera supplement and the placebo.
214428528|NCT06676397|PROCEDURE|Blood Punction|venous blood sampling
214428529|NCT06676696|DRUG|Continue low dose calcineurin inhibitor (CNI)|CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study
214512305|NCT03388736|BEHAVIORAL|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
214512306|NCT05389618|OTHER|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
214512307|NCT02189759|OTHER|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
214512308|NCT02189759|OTHER|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
214512309|NCT02189759|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
214512310|NCT02189759|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
214512311|NCT03153176|BEHAVIORAL|Training|Training program 30 hours accumulated before, during and after intervention
214512312|NCT03153176|BEHAVIORAL|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
214512313|NCT03153176|BEHAVIORAL|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
214692447|NCT04997889|COMBINATION_PRODUCT|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
214428530|NCT06676696|DRUG|Calcineurin inhibitor withdrawal at 6 months|CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
215113619|NCT01810003|DIETARY_SUPPLEMENT|Placebo|10 week supplementation period
215113620|NCT01403155|BIOLOGICAL|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
215113621|NCT04359199|RADIATION|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
214428531|NCT06677216|PROCEDURE|Botulinum Toxin, Type A|All participants will receive a solution of BTX-A (Xeomin, Merz Pharma GmbH, Frankfurt am Main, Germany) in the masseter and temporalis muscles (total of 100 units reconstituted with 4cc unpreserved 0.9% sodium chloride). The injection will be provided by the same maxillofacial surgeon. The participants are asked to clench their teeth to determine the site of the most intense muscle activity in the masseter and temporal muscles with palpation. Intramuscular BTX-A injections are administered on both sides at the location of the most intense muscle activity of the masseter (80 units) and temporalis (20 units).
214428532|NCT06676930|DEVICE|Colonoscopy With Computer-Aided Detection|Use of Computer-Aided Detection During Colonoscopy
214428533|NCT06676930|PROCEDURE|Colonoscopy without Computer-Aided Detection|Colonoscopy without Computer-Aided Detection (AI)
214428534|NCT05251493|DRUG|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
214428535|NCT05251493|DRUG|Iron sucrose|iron sucrose 100 mg/mL
214428536|NCT06676826|DEVICE|Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)|Infrabony defects will be filled with a volume-stable collagen matrix
214428537|NCT06676826|DEVICE|Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen|Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
214428538|NCT06676202|BEHAVIORAL|Progressive Relaxation Exercises|It combines the contraction and relaxation of large muscle groups such as the face, arms, legs, neck and back with deep breathing exercises. Before applying progressive relaxation exercises, the environment should be quiet, dimly lit, a comfortable chair or armchair should be sat or lying down, and clothing should be loose and comfortable, and it is recommended to apply it one hour after eating. In the application of progressive relaxation exercises, it is first asked to breathe regularly. After our breathing rhythm is regulated, the hands, arm muscles, shoulder and neck muscles, chest, abdominal and hip muscles, legs, feet and facial muscles are contracted with a 5-7 second breathing exercise and relaxed during exhalation. This is repeated with 4-5 breathing exercises for each muscle and the exercise is ended when the eyelids are opened.
214428539|NCT02163876|DRUG|HuCNS-SC cells|surgery arm
214428540|NCT04313868|DRUG|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
214428541|NCT06109129|DEVICE|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
214428542|NCT06328127|BEHAVIORAL|PATH|PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
214428543|NCT07022340|BEHAVIORAL|Resistance Training Intervention|Participants will complete a brief aerobic warm-up and dynamic stretching prior to each strength training session. Participants will complete 9 exercises for all major muscle groups. Strength testing at the baseline study visit will be used to determine initial load. Participants will complete 1 set of moderate-intensity loads (\~50% maximum and \~12 repetitions) in week 1, 2 sets in week 2, and 3 sets in week 3. By week 4, participants will be completing 3 sets at 60% of maximum. Weight loads will be progressively increased so volitional fatigue is reached by 8-12 repetitions/set.
214428544|NCT06631222|BEHAVIORAL|cognitive behavioral therapy|The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.
214428545|NCT06631222|OTHER|sub-occipital inhibitory pressure|The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.
214512314|NCT04809376|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
214512315|NCT04809376|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
214512316|NCT04809376|DRUG|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
214512317|NCT04809376|DRUG|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
215113622|NCT04359199|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
215113623|NCT04359199|DRUG|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
215113624|NCT04359199|DRUG|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
215113625|NCT00554450|DRUG|Dapagliflozin|Tablets, Oral, once daily
215113626|NCT02340065|PROCEDURE|standard colonoscopy|examination of the colon with a conventional colonoscope
215113627|NCT02340065|PROCEDURE|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
214428546|NCT06631222|OTHER|deep friction massage|Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
214428547|NCT06631222|OTHER|Spinal manipulation|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateral flexion will be used. Application will be bilateral. First, cephalic decompression will be performed lightly, followed by small circumductions. Selective tension will be applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique will be applied with the aim of increasing occiput, atlas, and axis joint mobility.
214512318|NCT04798534|BEHAVIORAL|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
214512319|NCT00042926|OTHER|immunohistochemistry staining method|
214512320|NCT00042926|PROCEDURE|conventional surgery|
214512321|NCT00042926|PROCEDURE|lymphangiography|
214512322|NCT00042926|PROCEDURE|radionuclide imaging|
214512323|NCT00042926|PROCEDURE|sentinel lymph node biopsy|
214512324|NCT00042926|RADIATION|technetium Tc 99m sulfur colloid|
214512325|NCT06163300|DIAGNOSTIC_TEST|MRI advanced techniques|Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
214512326|NCT02198300|PROCEDURE|Coronary angioplasty with stent implantation|
214512327|NCT02198300|DRUG|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
214512328|NCT00278499|BEHAVIORAL|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
215113628|NCT01822457|DEVICE|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
215113629|NCT00091234|DRUG|gemtuzumab ozogamicin|
215113630|NCT03691597|DIAGNOSTIC_TEST|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G"
215113631|NCT00472901|DRUG|Afamelanotide (CUV1647)|16mg implant
215113632|NCT06147141|BEHAVIORAL|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
214512329|NCT00278499|BEHAVIORAL|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
214512330|NCT02440438|BIOLOGICAL|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
214512331|NCT05473117|DIAGNOSTIC_TEST|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
215113633|NCT06147141|BEHAVIORAL|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
215113634|NCT00004893|BIOLOGICAL|recombinant interleukin-12|
214512332|NCT02667366|BEHAVIORAL|Tel-PT|
214512333|NCT02667366|BEHAVIORAL|TAU and text messages|
214512334|NCT02717819|DIETARY_SUPPLEMENT|Protein|Daily intake of supplement
214512335|NCT02717819|DIETARY_SUPPLEMENT|Placebo|Daily intake of supplement
214512336|NCT02717819|OTHER|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
214512337|NCT02717819|DIETARY_SUPPLEMENT|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
214428548|NCT06631222|OTHER|Exercises for forward head posture|"Scapular stabilization exercises:~1. In quadruped position, the patient lift¬ up his arms alternatively with shoulder abduction and 120 ° flexion.~2. In sitting position, with 90° knee flexion on a stool or bed without backrest, patient hold a pair of dumb¬bells (2 kg) in each hand and lift them up laterally while maintaining scapulae's height below 80°. The patient was instructed to hold each stage for 10 seconds and then re-turn to the starting position and three sets of 10 repetitions with 30-second pause in between were completed.~3. As for the progression of scapular stability exercise, T to Y the patient was instructed to lie in prone lying position on Swiss ball with arms abducted to 90° (the letter T); then she asked to flex elbows to 90°, retract scapulae and externally ro¬tate arms while keeping arm in 90° abductions. While maintaining the retraction of scapula, the patient is asked to raise his arms above head and extend the elbow while his arm flexed and abducted to 120°"
214428549|NCT06630299|DRUG|ISL/LEN|Tablet administered orally
214428550|NCT06630299|DRUG|Antiretroviral Combinations|2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
214428551|NCT06630390|DRUG|Daridorexant 50 mg|Administered consistent with labeling from the US Food and Drug Administration.
214428552|NCT06630390|OTHER|Placebo|Identical appearing to daridorexant
214428553|NCT06630546|DEVICE|first generation iStent (Glaukos, San Clemente, CA, USA) insertion|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
214428554|NCT06630546|DEVICE|phacoemulsification|A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
214428555|NCT07023107|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride
214428556|NCT07023107|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine
214428557|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine
214428558|NCT07023120|DRUG|Dexamethasone 4mg|perineural 4mg Dexamethasone
214428559|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|10ml 0.2% Ropivacaine
214428560|NCT06873763|DRUG|Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab|Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.
214428561|NCT06689501|COMBINATION_PRODUCT|SPICE BLEND CAPSULE|The study product is a powder mix of L-carnitine tartrate yeast protein hydrolysate and dihydrocapsiate.in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
214428562|NCT06689501|OTHER|Placebo|The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
214428563|NCT06705517|BEHAVIORAL|Mediterranean Diet|The MD emphasizes a plant-based approach, with a high consumption of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate amounts of fish, seafood, and dairy, while limiting meat, particularly red and processed varieties. Olive oil serves as the main fat source in the diet. In the case of this study participants will also be instructed to limit dairy intake, that although traditionally part of the MD, might exacerbate disease symptomatology in PD patients, likely due to the urate lowering effect of dairy.
214428564|NCT06728644|DRUG|L-arginine intervention|L-arginine intervention for 3 months, 3 g per day.
214428565|NCT07052188|PROCEDURE|without any preoperative stenting|Patients will have RIRS without any preoperative stenting.
214428566|NCT07052188|PROCEDURE|(DJ) stent placed with sedation and undergo RIRS within 2-4 weeks|Patients will have a double-J (DJ) stent placed with sedation and undergo RIRS within 2-4 weeks.
214428567|NCT07052188|PROCEDURE|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks.|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks
214428568|NCT07053163|DRUG|Crystalloid and blood as resuscitation|Patients receive crystalloid and blood as resuscitation
214428569|NCT07053163|DRUG|crystalloid, blood and low dose of norepinephrine|Group 2: receive crystalloid, blood and low dose of norepinephrine
214428570|NCT07052877|DIAGNOSTIC_TEST|PSMA PET/CT scan|PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
214512338|NCT02067819|DEVICE|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
215113635|NCT00352001|DRUG|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
215113636|NCT00352001|DRUG|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
215113637|NCT01372566|DEVICE|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
214428571|NCT06299657|BEHAVIORAL|IMPROVE|"IMPROVE is an individual manualized intervention.~Session1 includes:~* psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations~* guided discussion of maladaptive thoughts about bodily sensations related to anxiety~* how to challenge bodily sensations cognitively~* generating three takeaways about the benign nature of anxiety~Session 2 includes:~* review of homework~* psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty.~* when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty.~Session 3 includes:~* review interoceptive exposure (IE) and behavioral exercises (BE) for progress~* revisit beliefs related to cognitive biases~* discuss areas where skills can be used moving forward"
214428572|NCT06299657|BEHAVIORAL|PHET|"Clinicians will administer PHET using a Powerpoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. PHET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
214428573|NCT07060157|DRUG|resveratrol 1 % gel|left side of face the patient will be given resveratrol 1 % gel once daily at night (Home use ).
214428574|NCT07060157|DRUG|TCA20%|left side of face the patient will be given resveratrol 1 % gel once daily at night (homThee use ).
214428575|NCT07061106|OTHER|Otago exercise program|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group A received Otago Exercise Program and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). The Otago Exercise Program is a fall prevention well designed program for older adults. It includes 17 strength and balance exercises and a walking program, which are typically performed three times a week and helps to prevent falls in older adults by strengthening muscles and improving balance. In this study, modified form of Otago would be used that focuses on balance and strengthening exercises.
214428576|NCT07061106|OTHER|Kitchen Sink Balance Exercises|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group B received Kitchen Sink Balance Exercises and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). Kitchen sink balance exercises are beneficial for improving overall Individual's stability, strength, and coordination. These exercises can be easily integrated into daily routine and it also providing a practical way to enhance balance and overall fitness.
214428577|NCT07061236|OTHER|Elastomeric Pump Education|This intervention involves a 15-20 minute face-to-face training session about the use of the elastomeric pump with 5-FU, supported by visual materials and an educational booklet developed by the researchers based on current literature and expert opinion
214428578|NCT07061808|DIAGNOSTIC_TEST|Lipedema Screening Questionnaire|The Lipoedema screening questionnaire (LSQ) is a practical tool that can be applied quickly and easily and is used to identify patients with lipoedema during history taking and physical examination.
214428579|NCT07061756|PROCEDURE|SRP|Full-mouth scaling and root planing (SRP) was performed using an ultrasonic scaler (EMS AIR-FLOW MASTER PIEZON®) supplemented by Gracey curettes for subgingival instrumentation. All procedures were conducted under local anesthesia by a calibrated periodontist, with each quadrant treated for a minimum of 30 minutes. Patients received standardized oral hygiene instructions and were scheduled for a 3-month postoperative follow-up.
214428580|NCT07061756|PROCEDURE|ND|"In addition to the identical SRP protocol described above, adjunctive Nd:YAG laser therapy (Wiser Waterlase MD, Vista Dental) was applied immediately post-SRP. Laser parameters were set at 150 mJ/pulse, 20 Hz frequency with water (level 1) and air (level 3) coolant. The fiber optic tip (300 μm diameter) was moved in a continuous Zig-zag pattern along the root surface and pocket epithelium, maintaining 2-second irradiation per site at a 30° angle to the tooth axis. Standardized oral hygiene instructions and 3-month follow-up were similarly provided."
214428581|NCT07060794|DRUG|Tafenoquine|Tafenoquine in combination with DHA-piperaquine
214512339|NCT02067819|DEVICE|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
214512340|NCT03582566|BEHAVIORAL|Phonological Awareness|Earobics training
214512341|NCT03582566|BEHAVIORAL|Working Memory|Cogmed training
214512342|NCT03582566|BEHAVIORAL|Phonological Awareness + Working Memory|Earobics + Cogmed training
214512343|NCT03582566|BEHAVIORAL|Active Control|Spashmath
215113638|NCT01372566|OTHER|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
214512344|NCT00800176|DRUG|Placebo|po daily for 12 weeks
214512345|NCT00800176|DRUG|RO4998452|2.5mg po daily for 12 weeks
214512346|NCT00800176|DRUG|RO4998452|5mg po daily for 12 weeks
214512347|NCT00800176|DRUG|RO4998452|10mg po daily for 12 weeks
214512348|NCT00800176|DRUG|RO4998452|20mg po daily for 12 weeks
214512349|NCT00800176|DRUG|RO4998452|40mg po daily for 12 weeks
214512350|NCT04755972|OTHER|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
214512351|NCT04755972|OTHER|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
214512352|NCT04755972|OTHER|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
214512353|NCT04000399|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
214512354|NCT04614805|BEHAVIORAL|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
214512355|NCT00003041|DRUG|pyrazoloacridine|
215113639|NCT03329846|DRUG|BMS-986205|specified dose on specified day
214428582|NCT07060027|PROCEDURE|horizontal bone augmentation using single tenting screw|Patients in this group will undergo guided bone regeneration (GBR) using a single titanium bone screw placed in the crestal position to stabilize the graft material. The surgical procedure includes sulcular and vertical releasing incisions, elevation of full-thickness buccal and palatal/lingual flaps, and multiple cortical perforations to enhance angiogenesis. The defect will be filled with particulate allograft extended 10-12 mm apicocoronally and covered with a bovine pericardium membrane. A tension-free primary closure will be achieved using 5-0 polypropylene sutures. Bone screw removal and implant placement will occur 6 months postoperatively. This group is distinguished by the use of a single crestal screw for graft stabilization compared to dual-screw fixation in the control group.
214428583|NCT07060027|PROCEDURE|horizontal bone augmentation using Double tenting screw|Participants in this group will receive guided bone regeneration (GBR) with two titanium bone screws for enhanced graft stabilization. One screw will be placed at the crestal level, while a second screw will be inserted 5 mm apical to the first, providing vertical stabilization of the graft material. The procedure involves sulcular and vertical releasing incisions, full-thickness flap elevation on both buccal and palatal/lingual aspects, and multiple cortical perforations to stimulate vascularization. The defect will be filled with particulate allograft extending 10-12 mm apicocoronally and covered with a bovine pericardium membrane. Tension-free primary closure will be performed using 5-0 polypropylene sutures. At 6 months, screws will be removed and dental implants placed. This intervention is distinguished by the dual-screw fixation technique, designed to provide greater mechanical stability compared to the single-screw approach used in the comparator group.
214428584|NCT07060391|PROCEDURE|Deep cervical lymphatic-venous anastomosis|Lymph node reconstruction was carried out using microsurgical techniques,improve cerebral lymphatic circulation and return, accelerate the excretion of pathological proteins, the metabolic products of the brain, from the brain. This is to delay the degenerative changes of the brain and the progression of Alzheimer's disease.
214428585|NCT07060391|DRUG|Donepezil drug treatment|All patients stopped taking cognitive-enhancing drugs after enrollment, and marketed therapeutic drugs include ginkgo biloba, high-dose vitamin E, lecithin, estrogen, non-steroidal anti-inflammatory drugs, memegan, etc.
214428586|NCT07061561|DEVICE|Peak Expiratory Flow Measurement Using Peak Flow Meter and Lorio Device|This intervention involves the use of two respiratory measurement devices to assess cough strength in tracheotomized patients: the traditional Peak Flow meter, which measures peak expiratory flow (PEF), and the Lorio device, a novel tool designed for respiratory rehabilitation with customizable training exercises. Measurements are taken at multiple time points before and after decannulation to compare accuracy, reproducibility, and patient usability.
214428587|NCT07061028|BEHAVIORAL|Progressive Muscle Relaxation|This intervention involves five weekly 30-minute sessions of Progressive Muscle Relaxation (PMR) based on the ABC relaxation theory. The PMR protocol developed by Smith (2005) involve tense-and-release exercises for 11 different muscle groups, including hands, arms, sides, back, shoulders, face, neck, stomach, chest, legs, and feet. For five to ten seconds, each muscle group is contracted, and for twenty to thirty seconds, it is relaxed. The sensations of stress and relaxation were the participants' main concern. To release any residual tension, they looked at each muscle group after the workout. With the exception of the time needed for measurements and instructions, the entire operation took roughly thirty minutes.
214428588|NCT07061028|OTHER|Control Group|The control group received no intervention from the researcher during the study. However, following the intervention, the control group participants were given the audio recordings of the intervention protocol along with an explanation of them.
214428589|NCT07061353|BEHAVIORAL|Therapeutic touch|Therapeutic touch will be performed
214428590|NCT07060664|PROCEDURE|open reduction internal fixation|treatment with open reduction and plates/screws
214428591|NCT07060664|PROCEDURE|intramedullary nail|open reduction and intramedullary nail
214428592|NCT07060664|PROCEDURE|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
214428593|NCT07061184|DRUG|FLCWK|FLCWK and matching placebo to be taken in a randomised order for 9 months
214428594|NCT07061184|DRUG|Placebo|FLCWK and matching placebo to be taken in a randomised order for 9 months
214512356|NCT03836651|OTHER|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
215113640|NCT03329846|BIOLOGICAL|Nivolumab|Specified dose on specified day
215113641|NCT03329846|DRUG|Placebo|Specified dose on specified day
215113642|NCT03066193|DRUG|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
215113643|NCT05523336|OTHER|observation|observation and prospective data collection
215113644|NCT01946217|OTHER|questionnaire administration|Ancillary studies
215113645|NCT00043511|BIOLOGICAL|pGA2/JS2 Plasmid DNA Vaccine|
215113646|NCT00697931|BIOLOGICAL|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
215113647|NCT00697931|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
215113648|NCT02631551|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
215113649|NCT02631551|DRUG|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
215113650|NCT02631551|DRUG|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
215113651|NCT02631551|DRUG|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
214428595|NCT07060833|DEVICE|External pressure transducer|The delivered CPAP pressure will be measured using an ultra-thin, multi-use catheter pressure transducer inserted into a port in the expiratory limb of the bubble CPAP circuit.
214428596|NCT07060833|DEVICE|Standard microphone|The bubble sound of the water tank will be collected with a standard condenser microphone directly affixed to the pole holding the water tank, with a secure clip.
214428597|NCT07060833|DEVICE|Wireless acoustic sensor|The wireless acoustic sensor contains a dual microphone capable of capturing target sounds as well as ambient noise. The frequencies associated with ambient noise will be subtracted to maximize the signal-to-noise ratio of the bubble sound waveform. The wireless sensor will be placed on the suprasternal notch of the infant for monitoring the bubble sounds transmitted to the lungs and secured using a silicone-based tape approved for use in neonates. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller and stored for future analysis.
214428598|NCT07060833|DEVICE|Internal pressure transducer|The transmitted CPAP pressure will be measured using an ultra-thin, single-use catheter pressure transducer inserted through the mouth to the level of the infant's nasopharynx. The data will be acquired with a sampling rate of 10kHz and stored for later analysis.
214428599|NCT07061158|BEHAVIORAL|Structured Yoga Course Intervention|Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, body balance training, and coordination of breath with movement), and meditation and relaxation (e.g., supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
214428600|NCT04080427|DRUG|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
214428601|NCT04080427|DRUG|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
214428602|NCT07060937|OTHER|Physiotherapy Protocol|Each participant consenting to the study will be given a physiotherapy session on post-op day 1 and day 2 by a physiotherapist. The session will include bed mobility exercises including active ROM exercises of all extremities, breathing exercises, nebulization and chest physical therapy, incentive spirometer. Progressing to supported sitting at the edge of bed, sitting on a chair under supervision, supported walk inside the room , sitting independently in chair and lastly before discharge climbing 2 flights of stair.
214428603|NCT07061626|DRUG|Rhenium-186 Nanoliposome|Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL), BMEDA-chelated-186rhenium encapsulated within liposomes, allows the 186Re to be directly delivered to the site of the tumor through CED and maintain localization at the site of infusion.
214428604|NCT07059741|OTHER|integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized low dose RT: 1-1.5Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
214512357|NCT03836651|OTHER|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
214512358|NCT02548585|DRUG|MEDI0382|MEDI0382 administered subcutaneously.
215113652|NCT02949726|DRUG|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
215113653|NCT02949726|DEVICE|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
215113654|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
215113655|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
215113656|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
215113657|NCT01935635|BIOLOGICAL|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
215113658|NCT05170451|DRUG|CBD|Topical CBD 50 mg/ml applied in 1mL amounts twice daily
215113659|NCT05170451|OTHER|Control|Topical shea butter applied in 1mL amounts twice daily
215113660|NCT06122623|OTHER|Health Education|As previously mentioned, the intervention for this study will be a gaming education program that will be conducted once with each participant. Implementation of the program will occur at different times. Each performance will include a maximum of 60 participants who will be divided into small groups within the same room. Seven to 10 participants will comprise a small group, and each group will have one facilitator. The facilitator will be either a member of the research team or a Health lecturer who will be recruited and trained by the Japanese and Indonesian research teams.
215113661|NCT01405300|DIETARY_SUPPLEMENT|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.
215113662|NCT01405300|DIETARY_SUPPLEMENT|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
215113663|NCT01022658|DRUG|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
215113664|NCT03355846|DRUG|Centella|after meals twice a day for 15 days
215113665|NCT03355846|DRUG|Proctocella|after hygiene treatment for 4 weeks;
215113666|NCT03355846|DRUG|Flavonil® cps|after meals twice a day for 15 days
215113667|NCT03355846|DRUG|Flavonil® Cream|"treatment for 4 weeks;~."
215113668|NCT03355846|DRUG|Rectalgan Mousse|for 4 weeks
215113669|NCT01137032|DRUG|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
214428605|NCT07059741|OTHER|integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized high dose RT: 3-6Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
215113670|NCT04218409|DRUG|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
215113671|NCT04218409|DRUG|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
214428606|NCT07061535|DRUG|Tafolecimab|Patients will receive Tafolecimab 300 mg every 3 weeks.
214428607|NCT07061535|DRUG|Sintilimab (approved)|Patients will receive Sintilimab 200 mg every 3 weeks.
214428608|NCT07061535|DRUG|Etoposide|Patients will recieve Etoposide (100 mg/m2) intravenously on days 1, 2, and 3 of each 3-week cycle.
214428609|NCT07061535|DRUG|Carboplatin / Cisplatin|Patients will receive carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2) intravenously on day 1 of each 3-week cycle for up to 4 to 6 cycles.
214428610|NCT07056335|BEHAVIORAL|Self-monitoring|Self-monitoring as a behavior change technique to support pain self-care behaviors
214428611|NCT07056335|BEHAVIORAL|Physical activity and percussive massage therapy education|Participants will receive education on why physical activity and massage are important for pain self-care. They will also receive daily physical activity and massage goals.
214428612|NCT07056335|DEVICE|Percussive massage therapy|Participants will receive a massage gun to support daily pain self-care.
214428613|NCT07061782|PROCEDURE|Group A|"Treatment protocol given to the both groups will be carried out for 7 sessions for 2 weeks on alternative days.~It will consist of a 10 minute hot pack.~Neuromuscular reeducation for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors Neuromuscular reeducation It will break adhesion result in loosen the scar tissue will increase the temperature and cause in increase of blood flow . Muscles contract when myosin pulls actin filaments together using energy from ATP shortening the muscle fiber and causing contraction. They relax when calcium is removed, allowing the filaments to slide apart muscle will return to its resting state. The continuously muscle contraction and relaxation help to loosen up and become more flexible .~Strengthening exercises"
214428614|NCT07061782|PROCEDURE|Group B|"Treatment protocol was given to both groups for 7 session sessions for 2 weeks on alternative days.~It was comprises of HOT PACK for 10 minutes . Post facilitation stretch for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors~Post facilitation stretch :~Post Facilitation Stretch is an isometric Contraction in which he participants were instructed to contract the muscles to the maximum voluntary capacity that involves first putting the target muscle through a high-intensity isometric contraction (roughly 75-100% of maximal effort) for 5-10 seconds, and then quickly and continuously passively stretching the same muscle for at least 10 seconds.~Strengthening exercises"
214428615|NCT07060482|DIAGNOSTIC_TEST|Panel of biomarkers including Gastrin 17, pepsinogen 1 and 2, and anti-helicobacter pylori antibodies.|This study will be assessing the diagnostic accuracy of this panel of biomarkers for diagnosing gastric atrophy in the Irish population for the first time. This reflects the assessment of these biomarkers in diagnosing gastric atrophy in a low-risk Western population.
214428616|NCT07059806|BEHAVIORAL|T1CARE|The intervention includes navigation by a Community Health Navigator (CHN), who will assess and help address patients' SDOH-related needs, coordinate care, and provide social support.
214428617|NCT06816979|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214428618|NCT06816979|PROCEDURE|Lumbar Puncture|Undergo LP
214428619|NCT06816979|DEVICE|Magnetic Resonance Imaging|Undergo MRI
214428620|NCT02479698|BIOLOGICAL|Allogeneic BK-specific Cytotoxic T-lymphocytes|Given IV
214428621|NCT02479698|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428622|NCT06773026|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
214428623|NCT03971253|DRUG|Peficitinib|Oral
214428624|NCT06906029|DRUG|Catheter Sclerotherapy|Place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.
214428625|NCT04120454|BIOLOGICAL|Pembrolizumab|Given IV
214428626|NCT04120454|BIOLOGICAL|Ramucirumab|Given IV
215113672|NCT04218409|OTHER|Placebo Oxycodone|Oxycodone 0 mg orally
215113673|NCT04218409|OTHER|Placebo oxytocin|Intranasal placebo administration
215113674|NCT04218409|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
215113675|NCT05419232|OTHER|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
215113676|NCT05419232|OTHER|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
214512359|NCT02548585|DRUG|Placebo|Placebo administered subcutaneously.
214428627|NCT05114980|PROCEDURE|Parathyroid Allotransplant|Patients that meet inclusion criteria and are enrolled in the trial will undergo parathyroid allotransplantation
214428628|NCT06923670|DIAGNOSTIC_TEST|NGS testing|The investigators will test in NGS the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
214428629|NCT06923670|DIAGNOSTIC_TEST|NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies|The investigators will evaluate the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
214428630|NCT06945458|DRUG|KT-621|Oral drug
214428631|NCT07060547|DEVICE|HepQuant DuO Test|HepQuant DuO is commercially available in the U.S. as a Laboratory Developed Test (LDT), but it will be used in this study as a nonsignificant risk investigational device to measure change in liver function over time.
214428632|NCT04926181|DRUG|Apalutamide|240 mg once daily, for a 28 day cycle
214428633|NCT04926181|BIOLOGICAL|Cetrelimab|480 mg given through intravenous infusion (IV) on day 1 of every 28-day treatment cycle and administered over a 60-minute infusion
214428634|NCT03694691|DIAGNOSTIC_TEST|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
214428635|NCT06409299|DRUG|Azithromycin 40 MG/ML|Maintenance Antibiotic treatment
214428636|NCT06409299|OTHER|Placebo|Placebo
214428637|NCT00683696|DEVICE|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
214428638|NCT05636332|DIAGNOSTIC_TEST|12 lead Electrocardiogram|12 lead Electrocardiogram
214428639|NCT03648762|BEHAVIORAL|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
214428640|NCT03648762|BEHAVIORAL|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
214428641|NCT03648762|BEHAVIORAL|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
214428642|NCT00326144|DRUG|Quetiapine fumarate|
214428643|NCT00835952|DRUG|ATX-101|ATX-101 single doses
214428644|NCT05627336|DIAGNOSTIC_TEST|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
214428645|NCT01234363|DEVICE|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
214428646|NCT03724578|DRUG|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
214428647|NCT03724578|DRUG|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
214428648|NCT03724578|DRUG|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
214428649|NCT00030238|DRUG|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
214428650|NCT00030238|DRUG|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
214428651|NCT04581733|DRUG|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
214428652|NCT05099549|DRUG|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
214428653|NCT05099549|BIOLOGICAL|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
214428654|NCT05100589|DIETARY_SUPPLEMENT|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
214428655|NCT05100589|DIETARY_SUPPLEMENT|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
214428656|NCT06278870|DRUG|disitamab vedotin|disitamab vedotin 2mg/kg iv q2w
214428657|NCT06278870|DRUG|Pyrotinib|pyrotinib 400mg po q28d
214428658|NCT06278870|DRUG|trastuzumab|trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
214428659|NCT06278870|DRUG|Pertuzumab|pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
214428660|NCT06278870|DRUG|taxane drug|Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
214428661|NCT04117789|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
214428662|NCT04117789|BEHAVIORAL|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
214512360|NCT01666821|OTHER|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
214512361|NCT02757911|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
214512362|NCT00629564|DRUG|Esomeprazole|20mg oral
214512363|NCT00629564|DRUG|Esomeprazole|15 minute intravenous infusion
214512364|NCT02429973|DRUG|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
214512365|NCT02875730|PROCEDURE|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
214512366|NCT02875730|PROCEDURE|CMRI|Cardiac Magnetic Resonance Imaging
214512367|NCT01355692|DEVICE|Nd: YLF laser treatment|grid selective retinal treatment
214512368|NCT01691677|DRUG|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
214512369|NCT01691677|DRUG|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
214512370|NCT04218877|OTHER||There will be no intervention, only observation
214512371|NCT02033174|OTHER|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
214512372|NCT02033174|OTHER|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
214512373|NCT01696500|DRUG|Intravenous immunoglobulin|
214512374|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
214512375|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
215113677|NCT06212024|BEHAVIORAL|Mentalization Based Treatment-early|MBT-early is an early intervention program for young people at risk for developing BPD that has been developed as an adaptation of MBT, an empirically supported treatment for BPD. MBT-early is a time-limited intervention that has been designed for early-stage BPD and focuses on improving personality functioning. MBT-early is a two-phase treatment that integrates interventions at the individual, family, and context level. MBT-early provides a combination of treatment modalities, including individual and family sessions, case management, and treatment reviews. Interventions are tailored to the specific needs of the young person and his/her family. The treatment consists of 16 weekly individual sessions, 3 family sessions, and case management. The initial treatment phase (16 weeks) is followed by a booster period (6 months) with 4 booster sessions. Since MBT-early involves a flexible approach, this standard package may be downscaled in cases of rapid improvement, or upscaled when needed.
215113678|NCT02595255|OTHER|No intervention|No intervention
214428663|NCT04117789|OTHER|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
214428664|NCT04295915|DEVICE|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
214428665|NCT03825978|BEHAVIORAL|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
214512376|NCT03242863|OTHER|Food proportionality|Proportions of high and low energy dense foods manipulated
214512377|NCT00895076|DRUG|dexamethasone|iontophoretic patch and injection
214512378|NCT02998658|DEVICE|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
214512379|NCT02998658|DEVICE|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
214512380|NCT03570970|DRUG|Banapenem|Banapenem to be used anti-infection
214512381|NCT02424201|DRUG|Misoprostol|experimental
214512382|NCT02424201|DRUG|vitamin c|control
214512383|NCT02739100|DRUG|Triferic|
214512384|NCT01202513|DRUG|Bimatoprost 0.03% topical ophthalmic solution|
214512385|NCT00687869|BEHAVIORAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
214512386|NCT00687869|BEHAVIORAL|Case management|Usual stroke aftercare plus patient-information-notes
214512387|NCT05473806|DRUG|Pioglitazone 15 Mg Oral Tablet|24weeks dose
214512388|NCT05473806|DRUG|Evogliptin 5mg|24weeks dose
214512389|NCT01489774|DRUG|Placebo|single and multiple dose
214512390|NCT01489774|DRUG|CJ-12406|single and multiple dose
214512391|NCT04486820|OTHER|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
214512392|NCT05561491|BIOLOGICAL|ONCOS-102|Oncolytic virus
214512393|NCT05561491|BIOLOGICAL|Balstilimab|Anti PD-1
214512394|NCT03528603|OTHER|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
214512395|NCT03528603|OTHER|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
214512396|NCT00336791|DRUG|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle."
215113679|NCT01318408|DRUG|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
215113680|NCT05636852|DRUG|Altropane (123I) Injection|Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.
215113681|NCT00377858|DRUG|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
215113682|NCT00377858|DRUG|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
215113683|NCT05225857|DRUG|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
215113684|NCT05225857|DRUG|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
214428666|NCT01485653|DRUG|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
214428667|NCT01175317|PROCEDURE|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
214428668|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
214428669|NCT01507038|DRUG|YH14617|1mg once weekly
214428670|NCT01507038|DRUG|YH14617|1.6mg once weekly
214428671|NCT01507038|DRUG|YH14617|2mg once biweekly
214428672|NCT01507038|DRUG|Placebo|Once weekly
214428673|NCT01549756|BEHAVIORAL|bulletin board and teleophone depth interview|qualitative based research
214428674|NCT02120430|OTHER|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
214428675|NCT02825368|BIOLOGICAL|MMR|0.5 mL, subcutaneous
214428676|NCT02825368|BIOLOGICAL|Tdap|0.5 mL, intramuscular
214428677|NCT02825368|OTHER|Diphtherinum®|
214428678|NCT02825368|OTHER|Pertussinum®|
214428679|NCT02825368|OTHER|Tetanotxicum®|
214428680|NCT02825368|OTHER|Morbilinum®|
214428681|NCT02825368|OTHER|Ourlianum®|
214428682|NCT02825368|OTHER|Sterile saline|0.5 mL, intramuscular
214428683|NCT02825368|OTHER|Sugar pellets|
214428684|NCT04134611|DEVICE|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
214512397|NCT00336791|DRUG|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle."
214512398|NCT00336791|DRUG|Doxorubicin|FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
214428685|NCT04134611|DEVICE|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
214428686|NCT04734132|DIETARY_SUPPLEMENT|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
214428687|NCT04734132|DIETARY_SUPPLEMENT|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
214428688|NCT02003469|DEVICE|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
214428689|NCT03510676|DEVICE|NiTiDES|
214428690|NCT01405807|DRUG|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
214428691|NCT03465527|DRUG|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
214428692|NCT04592575|OTHER|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
214428693|NCT00654316|BIOLOGICAL|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
214428694|NCT02652091|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
214428695|NCT02652091|DEVICE|BETACONNECT device|Used to apply Betaseron.
214428696|NCT04700189|DEVICE|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
214512399|NCT00336791|DRUG|Paclitaxel|80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
214512400|NCT00336791|DRUG|Epirubicin|FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
214512401|NCT01840722|OTHER|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
214512402|NCT05985200|DRUG|BI 3032950|BI 3032950
214512403|NCT05985200|DRUG|Placebo matching BI 3032950|Placebo matching BI 3032950
214512404|NCT03547206|DRUG|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
214512405|NCT03547206|OTHER|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
214512406|NCT03547206|DRUG|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
214512407|NCT03547206|OTHER|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
214512408|NCT01079949|DRUG|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
215113685|NCT06064695|DEVICE|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
215113686|NCT02630914|DEVICE|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
214428697|NCT01294215|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
214428698|NCT01733095|DRUG|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
214428699|NCT00083902|DRUG|Thalidomide|
214428700|NCT00083902|DRUG|Dexamethasone|
214428701|NCT05531708|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
214428702|NCT05531708|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
214428703|NCT05531708|DRUG|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
214428704|NCT01178034|GENETIC|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
214428705|NCT04676334|DRUG|Rucaparib|Rucaparib will be administered daily.
214428706|NCT02259543|OTHER|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
214512409|NCT01079949|DRUG|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
214512410|NCT01079949|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
214512411|NCT01079949|DRUG|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
214512412|NCT02060084|DRUG|a control group|the same dose of luke warm water
214512413|NCT02060084|DRUG|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
214512414|NCT04108104|DRUG|Cyproheptadine|3-month treatment
214512415|NCT04108104|DRUG|Alpress LP|3-month treatment
215113687|NCT04521244|OTHER|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
214512416|NCT02144285|DRUG|LY3113593|Administered IV
214512417|NCT02144285|DRUG|LY3113593|Administered SC
215113688|NCT04521244|OTHER|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
215113689|NCT06127719|OTHER|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
215113690|NCT05959460|OTHER|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
215113691|NCT02564185|OTHER|Usual practice|
215113692|NCT02564185|OTHER|Education program|
215113693|NCT04146662|DIAGNOSTIC_TEST|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
214428707|NCT00448734|DRUG|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
214428708|NCT00448734|DRUG|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
214428709|NCT02106182|DRUG|Silodosin|
214428710|NCT02106182|OTHER|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
214428711|NCT02106182|OTHER|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
214428712|NCT02106182|OTHER|12 weeks|
214428713|NCT00404573|DRUG|RGH-188|
214428714|NCT02624258|BIOLOGICAL|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
214428715|NCT03795194|DRUG|ampicillin/clavulanate|FDA-approved antibiotic
214512418|NCT02144285|DRUG|Placebo|Administered IV
214512419|NCT02144285|DRUG|Placebo|Administered SC
214512420|NCT01529632|DRUG|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
215113694|NCT05503342|OTHER|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
215113695|NCT05503342|OTHER|Asthma control assessment|Asthma control assessment questionnaire application in paper format
215113696|NCT03631758|OTHER|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
214428716|NCT01426698|PROCEDURE|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
214512421|NCT01529632|DRUG|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
214512422|NCT01529632|DRUG|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
214512423|NCT01529632|DRUG|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
214512424|NCT01267552|PROCEDURE|Non drains will be placed during operation|Non drains will be placed during operation
214512425|NCT01267552|PROCEDURE|Closed suction drainage|Closed suction drainage will be placed during operation
214512426|NCT01600196|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
214512427|NCT04998552|RADIATION|Cyberknife|5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
214512428|NCT03040856|DIETARY_SUPPLEMENT|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
214512429|NCT03040856|DIETARY_SUPPLEMENT|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
215113697|NCT03631758|BEHAVIORAL|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
215113698|NCT03631758|OTHER|Sham information|Educational information not specific to mammography or cancer screening
215113699|NCT05370053|DIAGNOSTIC_TEST|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
215113700|NCT01685697|PROCEDURE|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
215113701|NCT01685697|PROCEDURE|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
214428717|NCT03567252|BEHAVIORAL|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
214428718|NCT01040689|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
214512430|NCT03040856|OTHER|Placebo|Placebo capsules containing olive oil
214512431|NCT02759575|DRUG|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
214512432|NCT02759575|RADIATION|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
214512433|NCT02759575|DRUG|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
214512434|NCT02410109|BEHAVIORAL|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
214512435|NCT01051271|DRUG|midazolam|midazolam 1.5 mg
214512436|NCT04318834|OTHER|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
214512437|NCT00937183|BIOLOGICAL|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
214428719|NCT01040689|DRUG|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
214428720|NCT01040689|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
214428721|NCT01040689|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
214428722|NCT01040689|DRUG|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
214428723|NCT01429805|DEVICE|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
214428724|NCT01812096|OTHER|Subcutaneous bortezomib|
214428725|NCT01812096|OTHER|Intravenous bortezomib|
214428726|NCT04174768|PROCEDURE|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
214512438|NCT00937183|BIOLOGICAL|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
214512439|NCT00937183|BIOLOGICAL|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
214428727|NCT06214442|OTHER|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
214428728|NCT04837976|OTHER|Semi-structured interviews and a consensus workshops using nominal group techniques.|Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
214428729|NCT00158782|DRUG|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
214428730|NCT00158782|DRUG|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
214428731|NCT03570437|DRUG|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
214428732|NCT03570437|DRUG|Cediranib|20 mg per day
214428733|NCT03570437|DRUG|Olaparib|Olaparib tablets, 300 mg twice-daily
214428734|NCT01185561|BEHAVIORAL|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
214428735|NCT01058785|BIOLOGICAL|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
214428736|NCT01824420|DRUG|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
214428737|NCT01824420|DRUG|Detrusitol 4mg QD|Control group
214428738|NCT03032913|PROCEDURE|Blood samples|Blood samples for both group
214428739|NCT03032913|PROCEDURE|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
214428740|NCT02432950|DIETARY_SUPPLEMENT|Dietary Intervention|Participate in the PNP
214428741|NCT02432950|OTHER|Educational Intervention|Participate in the PNP
214428742|NCT02432950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214428743|NCT02432950|OTHER|Quality-of-Life Assessment|Ancillary studies
214428744|NCT02616900|DEVICE|eSight Eyewear|primary intervention
214428745|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
214428746|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
214428747|NCT01488734|DIETARY_SUPPLEMENT|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
214428748|NCT01488734|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
215113702|NCT04321434|OTHER|Hyperoxia|
214428749|NCT01488734|DRUG|Placebo|Placebo for the fortified mushroom arms
214512440|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
214512441|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
214512442|NCT03898505|OTHER|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
214512443|NCT03674515|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
214512444|NCT03674515|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
214512445|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
214512446|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
214428750|NCT00338650|DRUG|adalimumab|
214428751|NCT02075736|PROCEDURE|KTP laser|
214428752|NCT02075736|PROCEDURE|TUR-P|device
214428753|NCT02403297|DEVICE|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
214512447|NCT00974805|DRUG|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
214512448|NCT03680287|DRUG|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
214512449|NCT05552924|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
214512450|NCT06100159|DEVICE|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
214428754|NCT02813369|DRUG|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
214428755|NCT02813369|DRUG|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
214428756|NCT04085874|BEHAVIORAL|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
214428757|NCT04085874|BEHAVIORAL|Nutrition counseling from standard health services care|once nutrition counselling from health services
214428758|NCT02499159|DRUG|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
214428759|NCT02499159|DRUG|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
214428760|NCT00002287|DRUG|Zidovudine|
214428761|NCT00036244|DRUG|RG1068 (Synthetic Human Secretin)|
214428762|NCT00002036|DRUG|Anti-HIV Immune Serum Globulin (Human)|
214428763|NCT05384366|DRUG|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
214428764|NCT01477255|BEHAVIORAL|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
214428765|NCT00710775|PROCEDURE|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
214428766|NCT04373434|BEHAVIORAL|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
214512451|NCT00278304|RADIATION|brachytherapy|
214512452|NCT00278304|RADIATION|radiation therapy|
214512453|NCT04615416|BEHAVIORAL|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
214512454|NCT03383848|DEVICE|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
214512455|NCT07013227|OTHER|experimental group|Labor pain and comfort level will be measured by applying virtual reality glasses to the control group.
214428767|NCT04373434|BEHAVIORAL|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
214428768|NCT03592602|PROCEDURE|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
214428769|NCT04079244|BEHAVIORAL|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
214428770|NCT04079244|BEHAVIORAL|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
214428771|NCT03903614|BEHAVIORAL|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
214428772|NCT03903614|BEHAVIORAL|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
214428773|NCT00752713|PROCEDURE|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
215113703|NCT04321434|OTHER|Normoxia|
215113704|NCT04321434|DEVICE|laser Doppler|laser Doppler
215113705|NCT00117039|DRUG|Aranesp®|
215113706|NCT01103583|DRUG|Hydroxyurea|500 mg/die per os for two years
215113707|NCT01103583|OTHER|placebo|500 mg/die per os for two years
215113708|NCT01646281|DRUG|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
215113709|NCT01646281|DRUG|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
214428774|NCT02242487|DRUG|CVT-301|
214428775|NCT00629096|PROCEDURE|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
214428776|NCT00133458|DRUG|Albendazole|
214428777|NCT03216213|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
214428778|NCT03216213|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
214428779|NCT06025318|DRUG|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
214428780|NCT05150912|OTHER|Manual therapy|strching neck
214428781|NCT01599793|DRUG|cabozantinib|Given PO
214428782|NCT01599793|OTHER|laboratory biomarker analysis|Correlative studies
214428783|NCT01599793|PROCEDURE|magnetic resonance imaging|Undergo MRI
214428784|NCT03112135|DRUG|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
214428785|NCT03112135|DRUG|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
214428786|NCT03112135|DRUG|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
214428787|NCT04370314|OTHER|Dental prosthetics|Implant-supported crowns
214428788|NCT04400136|DRUG|Lansoprazole oral tablets 30 mg|Post operative prescription
214428789|NCT04522466|DRUG|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
214512456|NCT03247595|DIETARY_SUPPLEMENT|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
214512457|NCT03247595|OTHER|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
214512458|NCT03247595|OTHER|Dulcolax Tablets|4 Dulcolox Tablets
215113710|NCT02460809|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
215113711|NCT02795585|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
215113712|NCT00398697|DRUG|Perifosine|
215113713|NCT00398697|DRUG|Gemcitabine|
215113714|NCT04381169|DRUG|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
215113715|NCT05974930|DEVICE|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
215113716|NCT01076036|DEVICE|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
215113717|NCT01076036|DEVICE|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
215113718|NCT03698227|DRUG|Olaratumab|iv infusion
215113719|NCT03698227|DRUG|Dexrazoxane|iv infusion
215113720|NCT03698227|DRUG|Doxorubicin|iv infusion
215113721|NCT05341115|DRUG|Leuprorelin Acetate Depot 3M|Leuprorelin Acetate Depot 3M SC injections.
215113722|NCT05501704|DRUG|Tamoxifen|Taken orally
215113723|NCT05501704|DRUG|Anastrozole|Taken orally
215113724|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
215113725|NCT05501704|DRUG|Abemaciclib|Taken orally
214512459|NCT05906966|OTHER|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
214512460|NCT06696508|PROCEDURE|Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty|"After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered"
214428790|NCT04235738|OTHER|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
214428791|NCT05369936|OTHER|Aromatherapy|Lavender will be inhaled through three phases
214428792|NCT05369936|OTHER|Placebo|Vapors of the distal water will be inhaled through three phases
214428793|NCT01794858|OTHER|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
214512461|NCT06696508|PROCEDURE|Classic Laparoscopic Dismembered Pyeloplasty|the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
215113726|NCT05637593|BEHAVIORAL|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
214428794|NCT01296815|DRUG|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
214428795|NCT03976557|DEVICE|BIP CVC|Central venous access with noble metal coated CVC
214428796|NCT03976557|DEVICE|Standard CVC|Central venous access with standard uncoated CVC
214428797|NCT02115828|DRUG|Vismodegib|
214428798|NCT05294393|DRUG|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
214428799|NCT05294393|DRUG|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
214428800|NCT05294393|DRUG|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
214428801|NCT04294862|DRUG|TNP-2092|TNP-2092 for injection 100mg/vial
214428802|NCT00204672|DRUG|Achipex|
214428803|NCT02129595|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
214428804|NCT02129595|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
214428805|NCT03434496|DEVICE|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
214428806|NCT03769870|DRUG|Teneligliptin 20mg/day|cross-over
214428807|NCT03769870|DRUG|Atorvastatin 40mg/Day|cross-over
214428808|NCT03769870|DRUG|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
214428809|NCT04436900|PROCEDURE|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
214428810|NCT00995696|BEHAVIORAL|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
214428811|NCT04761016|OTHER|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
214428812|NCT04761016|OTHER|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
214428813|NCT06232889|DIAGNOSTIC_TEST|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
214428814|NCT02564744|DRUG|Debio 1562|Administered as IV Infusion.
214428815|NCT02564744|DRUG|Rituximab|Administered as IV Infusion.
214428816|NCT01245400|DEVICE|Z-Lig|ACL replacement
214428817|NCT01245400|DEVICE|allograft|ACL replacement
214428818|NCT03810859|BIOLOGICAL|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
214428819|NCT02799875|OTHER|Higher permissive hypercapnia|"* pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;"
214428820|NCT02799875|OTHER|Lower Permissive Hypercapnia|"* pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;"
214428821|NCT03122236|BEHAVIORAL|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
214428822|NCT03122236|BEHAVIORAL|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
214512462|NCT06699862|BEHAVIORAL|High Intensity Interval Training|Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature
214512463|NCT06699862|BEHAVIORAL|High Intensity Interval Training with Competition|Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
214512464|NCT06699186|OTHER|Sleep|A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.
214428823|NCT03122236|DEVICE|Sham Transcranial Direct Current Stimulation (Sham tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
214428824|NCT03122236|DEVICE|Active Transcranial Direct Current Stimulation (Active tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
214428825|NCT00012805|PROCEDURE|Telephone Monitoring|
214428826|NCT03447236|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
214428827|NCT01715636|DRUG|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
214428828|NCT03572257|DRUG|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
214428829|NCT03572257|OTHER|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
214428830|NCT00002900|PROCEDURE|management of therapy complications|
214428831|NCT04781790|OTHER|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
214428832|NCT00491959|PROCEDURE|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
214428833|NCT00508924|DRUG|Argatroban|
214428834|NCT00508924|DRUG|Argatroban|
214428835|NCT00508924|DRUG|Argatroban|
214428836|NCT00508924|DRUG|Heparin|
214428837|NCT04695483|DRUG|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
214428838|NCT04695483|DRUG|Follitropin Beta|Daily controlled ovarian stimulation protocol
214428839|NCT02460549|BEHAVIORAL|therapeutic education program|
214428840|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
214428841|NCT01109498|DRUG|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
214428842|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
214428843|NCT01109498|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
214428844|NCT02755805|BEHAVIORAL|CO-OP|
214428845|NCT02755805|BEHAVIORAL|Attention Control|
214428846|NCT01355549|BIOLOGICAL|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
214428847|NCT02369484|DRUG|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
214428848|NCT04067219|PROCEDURE|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
214428849|NCT02178241|DRUG|Eribulin Mesylate|Given IV
214428850|NCT02178241|DRUG|Gemcitabine Hydrochloride|Given IV
214428851|NCT05641506|DRUG|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
214428852|NCT05641506|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
214428853|NCT06160518|BEHAVIORAL|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
214428854|NCT00329264|DRUG|Quetiapine fumarate|
214428855|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
214428856|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
214428857|NCT02520349|DEVICE|MarkTen and e-Go e-cigarettes|
214428858|NCT01125254|DRUG|Amlodipine|5mg po for 12 months
214428859|NCT03590275|DRUG|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
214512465|NCT06699186|OTHER|Non-sleep|A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
214512466|NCT03377023|DRUG|Nivolumab|Intravenous nivolumab every 2 weeks.
214512467|NCT03377023|DRUG|Ipilimumab|Intravenous ipilimumab every 6 weeks.
214512468|NCT03377023|DRUG|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
214428860|NCT03754036|BEHAVIORAL|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
214428861|NCT01091649|DRUG|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
214428862|NCT01091649|DRUG|ritonavir|ritonavir see Arm Description for more information
214428863|NCT01091649|DRUG|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
214428864|NCT03819166|DEVICE|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
214428865|NCT03819166|DEVICE|without deep touch pressure application|The deep touch pressure will not be applied.
214428866|NCT03149302|OTHER|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
214428867|NCT03149302|OTHER|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
214428868|NCT03149302|OTHER|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
214428869|NCT03149302|OTHER|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
214428870|NCT06145932|DEVICE|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
214428871|NCT06145932|DEVICE|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
214512469|NCT04174378|DRUG|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
214512470|NCT04953793|BEHAVIORAL|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
214512471|NCT04953793|OTHER|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
214428872|NCT01238874|DEVICE|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
214428873|NCT03045354|OTHER|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
214428874|NCT03045354|OTHER|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
214428875|NCT03045354|OTHER|Breakfast skipping|No breakfast
214428876|NCT03045354|OTHER|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
214428877|NCT03045354|OTHER|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
214428878|NCT02021006|DRUG|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
214428879|NCT02021006|OTHER|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
214428880|NCT02021006|DRUG|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
214512472|NCT04436484|DIAGNOSTIC_TEST|Peripheral blood sampling|Non-interventional study
214512473|NCT05361083|DRUG|F18CETO|Injection of F18CETO or O15water followed by PET/CT
214512474|NCT06170983|DRUG|Azithromycin|500 mg once daily for 3 days
214512475|NCT06170983|DIAGNOSTIC_TEST|Biopsy|Skin punch biopsy
214512476|NCT06170983|OTHER|Skin inflammation model|LPS- or imiquimod induced skin inflammation
214512477|NCT06402916|DIETARY_SUPPLEMENT|Blueberry drink|Blueberry drink equivalent to 240g fresh blueberries.
214512478|NCT06402916|DIETARY_SUPPLEMENT|Placebo drink|Drink containing no active ingredient.
214512479|NCT04117477|DRUG|Xylitol|Xylitol dental wipes
214512480|NCT04117477|OTHER|Placebo|Placebo dental wipes
214428881|NCT02021006|DRUG|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
214428882|NCT02021006|DRUG|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
214428883|NCT04669028|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
214428884|NCT04669028|DRUG|Placebo|capsules that do not contain NE3107
214428885|NCT04380155|OTHER|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
214512481|NCT01513447|DRUG|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
214512482|NCT02316821|DRUG|RTA 402|
214512483|NCT02316821|DRUG|Placebo|
214512484|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
214512485|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
214512486|NCT01346826|DRUG|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
214512487|NCT01346826|DRUG|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
214512488|NCT01346826|DRUG|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
215113727|NCT05637593|BEHAVIORAL|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
215113728|NCT05396911|BEHAVIORAL|UP2UTobacco|The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. UP2UTobacco targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
215113729|NCT04713163|DRUG|covid19 vaccine|Vaccine
215113730|NCT01543074|DIETARY_SUPPLEMENT|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
214428886|NCT02291094|DRUG|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
214428887|NCT02291094|DRUG|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
214428888|NCT03050957|DIETARY_SUPPLEMENT|menthol|Alimentary bolus supplemented with menthol
214428889|NCT05254912|DRUG|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
214428890|NCT05254912|DRUG|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
214428891|NCT05254912|OTHER|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
214428892|NCT02252042|BIOLOGICAL|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
214428893|NCT02252042|DRUG|Methotrexate|40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
214428894|NCT02252042|DRUG|Docetaxel|75 mg/m\^2 IV on Day 1 of each 3- week cycle
214428895|NCT02252042|BIOLOGICAL|Cetuximab|400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
214428896|NCT05456334|DEVICE|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
214428897|NCT05456334|DEVICE|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
214428898|NCT05456334|DRUG|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
214428899|NCT04820049|DRUG|F573|F573 for injection
214428900|NCT04820049|OTHER|Placebo|Water for injection
214512489|NCT01276509|DRUG|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
214512490|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
214428901|NCT00604955|DRUG|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
214428902|NCT02273999|DEVICE|RecoveryRx™|Appliance of the device after surgery
214428903|NCT04124185|DIAGNOSTIC_TEST|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
214428904|NCT05122468|PROCEDURE|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
214428905|NCT05122468|PROCEDURE|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
214428906|NCT06267131|DEVICE|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
215113731|NCT01543074|DIETARY_SUPPLEMENT|Garlic oil|1 pill = 30 mg garlic oil/day
214428907|NCT06227637|OTHER|Local Muscle Vibration compared to Muscle energy technique in SIJD|Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
214428908|NCT02949206|DRUG|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
214428909|NCT02949206|DRUG|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
214512491|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
214512492|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
214512493|NCT05560061|OTHER|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
215113732|NCT01543074|DRUG|BSE|2 pills = 200 micromoles of Sulforaphane/day
215113733|NCT01543074|DIETARY_SUPPLEMENT|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
214428910|NCT02949206|DRUG|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
214428911|NCT00994097|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
215113734|NCT01069965|DRUG|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
215113735|NCT01069965|DRUG|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
214512494|NCT05560061|OTHER|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
214512495|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
214512496|NCT04995601|DEVICE|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
214512497|NCT03161652|DRUG|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
214512498|NCT03161652|DRUG|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
214512499|NCT03161652|DRUG|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
215113736|NCT01069965|DRUG|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
215113737|NCT01069965|DRUG|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
215113738|NCT01069965|DRUG|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
214428912|NCT00994097|DRUG|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
214428913|NCT00994097|DRUG|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
214428914|NCT00994097|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
214428915|NCT01189513|DRUG|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
214428916|NCT02229019|BEHAVIORAL|Volunteer mealtime assistance|
214428917|NCT01865253|DEVICE|Renal Denervation|Renal Denervation
214512500|NCT03161652|DRUG|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
214512501|NCT03161652|DRUG|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
214512502|NCT03161652|DRUG|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
214512503|NCT03161652|DRUG|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
214512504|NCT03161652|DRUG|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
214512505|NCT05667012|OTHER|Educational videos|There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
215113739|NCT01069965|DRUG|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
215113740|NCT06122974|DEVICE|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
215113741|NCT06122974|DEVICE|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
215113742|NCT04034004|BEHAVIORAL|Mindfulness|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
214428918|NCT03784378|DRUG|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
215113743|NCT04034004|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
215113744|NCT04034004|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
214428919|NCT02671344|OTHER|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
214428920|NCT00944372|DRUG|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
214428921|NCT04889131|BEHAVIORAL|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
214428922|NCT04889131|BEHAVIORAL|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
214428923|NCT04889131|OTHER|Activity Monitor|Garmin VivoSmart activity monitor throughout study
214428924|NCT02658240|DRUG|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
214428925|NCT02658240|DRUG|Epinephrine|0.5 mg epinephrine
214428926|NCT01460290|DRUG|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
214428927|NCT01881386|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
214512506|NCT05755178|BEHAVIORAL|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
214512507|NCT01534052|DRUG|Enzalutamide|Oral
214692448|NCT04997889|OTHER|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
215113745|NCT04034004|BEHAVIORAL|Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
215113746|NCT02726412|PROCEDURE|Acute vs elective|non-intverention study
214428928|NCT03553212|RADIATION|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
214428929|NCT06386627|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
214428930|NCT06386627|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation to assess the integrity of corticospinal connections
214428931|NCT05717751|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
214428932|NCT06371196|DRUG|Babaodan Capsule|Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
214428933|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
214428934|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
214428935|NCT06241235|DRUG|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
214428936|NCT06241235|DRUG|Paclitaxel|IV infusion
214512508|NCT04906759|BEHAVIORAL|Meals plus exercise|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
214512509|NCT04906759|BEHAVIORAL|Meals only|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
214428937|NCT06241235|BIOLOGICAL|Bevacizumab|IV infusion
215113747|NCT04723017|OTHER|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
214428938|NCT06241235|DRUG|Cisplatin|IV infusion
214428939|NCT06241235|DRUG|Carboplatin|IV infusion
214428940|NCT01035658|DRUG|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
214512510|NCT06067958|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
215113748|NCT04723017|OTHER|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
214428941|NCT01035658|DRUG|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
214428942|NCT00987961|BEHAVIORAL|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
214428943|NCT04466904|DRUG|IBI362|Administrated by subcutaneous injection
214428944|NCT04466904|DRUG|Placebo|Administrated by subcutaneous injection
214428945|NCT04466904|DRUG|Dulaglutide|Administrated by subcutaneous injection
214428946|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
214428947|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
214428948|NCT05064930|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
214428949|NCT00817830|DRUG|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
214512511|NCT06067958|DRUG|Saline|Intranasal administration of saline 0.9% will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
214428950|NCT02397317|RADIATION|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
215113749|NCT02212041|OTHER|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
215113750|NCT02931552|BEHAVIORAL|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
215113751|NCT00183105|BEHAVIORAL|Brief Intervention (adaptation of motivational interviewing)|
214428951|NCT03908671|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
214428952|NCT01190007|DRUG|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
214428953|NCT04129658|BEHAVIORAL|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
214428954|NCT02962791|PROCEDURE|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
214428955|NCT02962791|DEVICE|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
214428956|NCT02962791|DEVICE|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
214428957|NCT02962791|DEVICE|Echocardiography|Standard Echocardiography will de bone for patient
214428958|NCT00475319|DRUG|placebo|comparison of different dosages of drug
214428959|NCT00475319|DRUG|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
214428960|NCT00475319|DRUG|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
214428961|NCT06441539|DEVICE|Bingo® Paclitaxel coated balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
214428962|NCT06441539|DEVICE|Xience® Alpine Everolimus Eluting Coronary Stent System|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
214428963|NCT04339855|OTHER|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
214428964|NCT01394510|DRUG|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
214428965|NCT01613274|OTHER|gum chewing|gum chewing three times a day for up to 20 minutes
214428966|NCT01613274|OTHER|no gum chewing|no gum chewing
214428967|NCT05179486|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, and blood
214428968|NCT05179486|OTHER|Questionnaire Administration|Complete questionnaire
214512512|NCT06720181|DIAGNOSTIC_TEST|MRI|Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain
214512513|NCT05179109|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
215113752|NCT03084692|BEHAVIORAL|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
215113753|NCT00005857|BIOLOGICAL|trastuzumab|
215113754|NCT00005857|DRUG|docetaxel|
214428969|NCT00439569|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
214428970|NCT02755116|DRUG|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
214428971|NCT02755116|DRUG|Placebo|placebo by mouth prior to anesthetic induction
214428972|NCT04239586|DRUG|Sulfonylurea|Starting treatment with sulfonylurea class of drug
214428973|NCT00120367|DRUG|Enfuvirtide|
214428974|NCT00120367|DRUG|Tenofovir-Emtricitabine|
214428975|NCT05007678|DRUG|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
214428976|NCT02990546|DRUG|midodrine|Midodrine will be given to treatment arm as enteral medication
214428977|NCT02990546|OTHER|Standard of Care|Patients in the control arm will receive standard of care for septic shock
214428978|NCT04665440|OTHER|Voice alone|mother's voice without tactile stimuli
214428979|NCT04665440|OTHER|Voice + tactile stimuli|mother's voice with tactile stimuli
214428980|NCT04363996|OTHER|New Bioactive Restorative Material|Filling material
214428981|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
214512514|NCT04564898|DRUG|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
214512515|NCT04564898|DRUG|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
214512516|NCT04564898|DRUG|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
215113755|NCT05007756|RADIATION|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
215113756|NCT05985486|BEHAVIORAL|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
215113757|NCT05985486|BEHAVIORAL|Health Education|Monthly health education sessions delivered remotely.
215113758|NCT02346175|DRUG|SHR3824|
215113759|NCT02346175|DRUG|Placebo|
215113760|NCT01561235|OTHER|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
215113761|NCT00726635|BEHAVIORAL|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
215113762|NCT00726635|OTHER|Control group|A one hour conversation with a nurse
215113763|NCT00726635|OTHER|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
215113764|NCT02304523|DRUG|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
215113765|NCT02304523|DRUG|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
215113766|NCT02304523|DRUG|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
215113767|NCT02168907|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214428982|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
214428983|NCT02710851|BIOLOGICAL|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
214428984|NCT02710851|BIOLOGICAL|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
214428985|NCT01973816|DRUG|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
214428986|NCT01973816|PROCEDURE|rectal shaving; rectal disc excision; colorectal resection|
214428987|NCT01973816|DRUG|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
214428988|NCT01973816|DRUG|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
214428989|NCT00911521|DRUG|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
214428990|NCT06519253|OTHER|Virtual reality (VR) music intervention|The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
214428991|NCT06519253|OTHER|Music only control|The control group consists of the same musical performances, with the audio only
215113768|NCT02168907|DRUG|bendamustine hydrochloride|Given IV
215113769|NCT02168907|BIOLOGICAL|rituximab|Given IV
214428992|NCT03948997|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
214428993|NCT01124734|DRUG|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
214428994|NCT01124734|DRUG|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
215113770|NCT02168907|OTHER|laboratory biomarker analysis|Correlative studies
215113771|NCT01787630|DEVICE|Hyaluronic acid|Injection in connection with ultrasound
215113772|NCT02539901|BEHAVIORAL|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
214428995|NCT03924882|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214428996|NCT04277221|BIOLOGICAL|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
214428997|NCT02779062|OTHER|Interview|Interview
214428998|NCT04614636|DRUG|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
214512517|NCT05159076|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|"The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time."
214512518|NCT03854734|BEHAVIORAL|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
215113773|NCT02539901|BEHAVIORAL|Free hearing test categorization|Free hearing test categorization evaluation
215113774|NCT02539901|BEHAVIORAL|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
215113775|NCT02539901|BEHAVIORAL|psychomotor infancy development scale|
215113776|NCT02539901|BEHAVIORAL|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
215113777|NCT06171685|DRUG|Teclistamab Monotherapy|standard of care
215113778|NCT06171685|DRUG|Teclistamab|investigational doses compared to SOC
215113779|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
215113780|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
215113781|NCT05651932|DRUG|Cohort A1 & A2: KTX-1001|KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
215113782|NCT05651932|DRUG|Cohort B1 & B2: KTX-1001+Mezigdomide|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly
215113783|NCT05651932|DRUG|Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle
215113784|NCT05651932|DRUG|Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle
215113785|NCT01966289|DRUG|CY|CY is administered intravenously at 200 mg/m2
215113786|NCT01966289|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
215113787|NCT01966289|DRUG|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
215113788|NCT00793507|OTHER|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
215113789|NCT04117529|OTHER|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
215113790|NCT00506688|DRUG|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
215113791|NCT00506688|DRUG|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
215113792|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
215113793|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
215113794|NCT01397461|DRUG|ozenoxacin placebo|cream
215113795|NCT01397461|DRUG|retapamulin 1% ointment|ointment
215113796|NCT01397461|DRUG|ozenoxacin 1% cream|1% cream
215113797|NCT03604029|DEVICE|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
215113798|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
214428999|NCT04614636|DRUG|Cyclophosphamide|Lympho-conditioning Agent
214429000|NCT04614636|DRUG|Fludarabine|Lympho-conditioning Agent
214512519|NCT03854734|BEHAVIORAL|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
214429001|NCT04614636|DRUG|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
214429002|NCT04614636|DRUG|Elotuzumab|Monoclonal Antibody
214429003|NCT00435578|DRUG|Glufosfamide|
214429004|NCT01711905|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
214429005|NCT02034903|OTHER|Feedings warmed with commercial warmer|
214429006|NCT01860612|DEVICE|Artificial Iris (CustomFlex)|
214429007|NCT00946582|BEHAVIORAL|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
214512520|NCT05693272|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
214512521|NCT05693272|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
214512522|NCT06415357|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.
214512523|NCT06415357|BEHAVIORAL|Motivational Text Messaging (MTM)|Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.
214692449|NCT01227538|OTHER|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
215113799|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
214429008|NCT00667056|DRUG|tacrolimus ointment|topical
214429009|NCT00667056|DRUG|placebo ointment|topical
214429010|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
214429011|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
214429012|NCT01353001|BEHAVIORAL|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
214512524|NCT06415357|BEHAVIORAL|Standard ART Counseling|All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
214512525|NCT02196259|DRUG|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
214512526|NCT05700279|PROCEDURE|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
214512527|NCT05700279|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
214692450|NCT00122005|BIOLOGICAL|GM-CSF gene transduced allogeneic vaccine GVAX|
214692451|NCT00488033|PROCEDURE|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
214429013|NCT01353001|BEHAVIORAL|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
214512528|NCT00353106|BEHAVIORAL|Interview|30-minute interviews of participating patients and their caregiver(s).
214512529|NCT00353106|BEHAVIORAL|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
214512530|NCT01668355|OTHER|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
214512531|NCT00162006|DRUG|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
214512532|NCT04889326|OTHER|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
214512533|NCT03734432|DEVICE|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
214512534|NCT06193915|DEVICE|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
214512535|NCT06193915|PROCEDURE|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
214512536|NCT01439399|DRUG|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
214512537|NCT01439399|DRUG|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
214512538|NCT01439399|DRUG|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
214512539|NCT01439399|DRUG|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
214512540|NCT05839743|OTHER|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
214512541|NCT05839743|OTHER|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
214512542|NCT05839743|OTHER|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
214512543|NCT00286832|PROCEDURE|PET scan|One extra PET scan after 1 cycle of treatment.
214512544|NCT04894136|PROCEDURE|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
214512545|NCT03514667|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
214512546|NCT03514667|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
214692452|NCT00965705|BEHAVIORAL|Therapy|Individual Therapy and Group Therapy
214692453|NCT01926054|DRUG|Acthar gel|
214692454|NCT01769079|DRUG|Nitrate|Two arms: placebo and nitrate
214692455|NCT01769079|DRUG|Placebo|
215113800|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
214429014|NCT01353001|BEHAVIORAL|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
214512547|NCT03243838|DRUG|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
214429015|NCT05976295|DRUG|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
214429016|NCT05976295|DRUG|Placebo|The control group will receive a placebo treatment.
214429017|NCT00917202|DRUG|Methylenblue|
214512548|NCT06213363|DRUG|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
214512549|NCT00215943|DRUG|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
214512550|NCT00215943|DRUG|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
214512551|NCT00215943|DRUG|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
214512552|NCT00215943|DRUG|vincristine|As outlined in VAD Treatment Arm
214512553|NCT00215943|DRUG|adriamycin|As outlined in VAD Treatment arm
214512554|NCT03530735|OTHER|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day."
214512555|NCT04690309|DRUG|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
214512556|NCT04887857|DRUG|CC-486|Specified dose on specified days
214512557|NCT04887857|DRUG|Venetoclax|Specified dose on specified days
214512558|NCT04401943|OTHER|online fatigue intervention|on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
214512559|NCT02565225|BEHAVIORAL|RheumaLive App use|
214429018|NCT02214160|DRUG|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
214429019|NCT03380611|DIETARY_SUPPLEMENT|Wakame|Consumption of 4.8 grams wakame per day for 17 days
214429020|NCT03380611|DIETARY_SUPPLEMENT|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
214429021|NCT03380611|DIETARY_SUPPLEMENT|Control|Consumption of microcrystalline cellulose for 17 days
214429022|NCT00181753|DRUG|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.
214512560|NCT02820909|PROCEDURE|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
214512561|NCT02820909|PROCEDURE|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
214512562|NCT00002409|DRUG|Lamivudine/Zidovudine|
214512563|NCT00002409|DRUG|Abacavir sulfate|
214512564|NCT04221321|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg
214512565|NCT04221321|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
214512566|NCT04221321|DRUG|RAPA114|RAPA114 tablet
214512567|NCT02765984|DEVICE|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
214512568|NCT00996164|DRUG|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
214512569|NCT00996164|DRUG|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
214512570|NCT05213585|DRUG|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
214512571|NCT06231667|OTHER|Education|four training sessions were applied to the intervention group
214512572|NCT01228565|OTHER|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
214429023|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant infusion
214512573|NCT01228565|OTHER|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
214512574|NCT06139835|BIOLOGICAL|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
214512575|NCT01962402|DRUG|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
214429024|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
214429025|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
214429026|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
214429027|NCT02423798|DEVICE|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
214429028|NCT04882553|PROCEDURE|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
214429029|NCT04882553|PROCEDURE|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
214429030|NCT04882553|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
214512576|NCT01962402|BEHAVIORAL|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
214512577|NCT00994708|DRUG|esomeprazole|
214429031|NCT03596853|OTHER|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
214429032|NCT03596853|OTHER|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
214429033|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
214429034|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
214429035|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
214429036|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
214429037|NCT04113096|DRUG|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
214429038|NCT04113096|DRUG|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
214429039|NCT04113096|DRUG|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
214429040|NCT04113096|DRUG|Cancer of the Prostate Placebo|20 mg once daily for 6 months
214429041|NCT04191486|DRUG|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
214429042|NCT04191486|DRUG|Placebo|Placebo once daily
214429043|NCT02962817|OTHER|Educational intervention|
214429044|NCT02962817|OTHER|Video explaining the clinical practice guidelines on low back pain|
214429045|NCT01063972|BEHAVIORAL|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
214429046|NCT01063972|BEHAVIORAL|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
214429047|NCT04134273|DRUG|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
214512578|NCT00827294|BEHAVIORAL|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
214429048|NCT04134273|DRUG|Clindamycin|Clindamycin Phosphate topical gel 1%
214429049|NCT04134273|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
214512579|NCT04594876|OTHER|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
214429050|NCT00634621|DRUG|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
214429051|NCT04114786|DEVICE|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
214429052|NCT04114786|DEVICE|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
214429053|NCT04719858|BEHAVIORAL|#LIFEGOALS|"Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention."
214429054|NCT02579031|DEVICE|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
214429055|NCT02579031|DEVICE|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
214429056|NCT02742571|OTHER|non applicable|
214429057|NCT04224792|OTHER|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
214429058|NCT04224792|OTHER|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
214429059|NCT03427216|DRUG|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
214429060|NCT03427216|DRUG|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
214512580|NCT02504762|PROCEDURE|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
214512581|NCT02504762|PROCEDURE|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
214512582|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
214512583|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
214429061|NCT03284567|BEHAVIORAL|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors"
214429062|NCT06445699|OTHER|Photodynamic therapy|A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
214429063|NCT06445699|OTHER|Hydrogel dressing|Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
214429064|NCT05877352|RADIATION|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
214429065|NCT05877352|PROCEDURE|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
214512584|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
214512585|NCT02556606|DRUG|Midazolam|single 40 min infusion of MID 0.03mg/Kg
214429066|NCT02191319|DRUG|Viramune®|
214429067|NCT04933890|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
214429068|NCT00521131|DRUG|Levocetirizine dihydrochloride|
214429069|NCT03668197|BIOLOGICAL|microbiological analysis|microbiological analysis of the peritoneal fluid
214429070|NCT01635712|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
214429071|NCT02063425|DRUG|Fluoxetine|1 pill of 20mg / day, during 3 months
214512586|NCT00403845|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214512587|NCT00403845|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214512588|NCT00403845|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214512589|NCT03147586|DRUG|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
214512590|NCT03147586|DRUG|placebo|placebo
214512591|NCT02383693|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
214512592|NCT02183402|DRUG|Digoxin|
214512593|NCT02183402|DRUG|BI 1356|
214512594|NCT03206398|DEVICE|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
214429072|NCT02063425|DRUG|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
214512595|NCT01271361|PROCEDURE|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
214512596|NCT01271361|PROCEDURE|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
214429073|NCT00855686|DRUG|Memantine|20mg once daily oral dose
214512597|NCT05130099|OTHER|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
214512598|NCT00805792|DRUG|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
214429074|NCT00855686|DRUG|Placebo|Daily oral dose
214512599|NCT05044286|OTHER|no intervention|no intervention
214512600|NCT03015688|RADIATION|x-ray images|
214512601|NCT02049684|PROCEDURE|Patch|
214429075|NCT05973578|RADIATION|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
214429076|NCT01510717|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
214512602|NCT00567606|OTHER|Strength/Weight Training & Drug/Supplement|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
214512603|NCT00567606|COMBINATION_PRODUCT|Drug/Supplement only|G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
214429077|NCT01510717|DEVICE|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
214429078|NCT03873896|DIAGNOSTIC_TEST|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
214429079|NCT03873896|PROCEDURE|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
214429080|NCT00042848|DRUG|modafinil|
214429081|NCT01264679|DRUG|Ferumoxytol|IV Ferumoxytol
214512604|NCT03674788|DEVICE|Transcatheter valve intervention|
214512605|NCT00635635|BEHAVIORAL|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
214512606|NCT00635635|BEHAVIORAL|Music Audio|Music only audio to be listened to 5x per week
214512607|NCT02462278|DEVICE|TempuRing|
214512608|NCT04349709|BEHAVIORAL|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
214512609|NCT00304642|DRUG|dapivirine (TMC120) vaginal gel|
214512610|NCT04257916|OTHER|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
214512611|NCT04257916|OTHER|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
214512612|NCT04159545|OTHER|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
214429082|NCT01747070|OTHER|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
214429083|NCT01747070|OTHER|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
214429084|NCT01747070|OTHER|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
214512613|NCT01596985|PROCEDURE|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
214429085|NCT01747070|OTHER|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
214429086|NCT04153747|OTHER|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
214429087|NCT04153747|OTHER|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
214429088|NCT04153747|OTHER|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
214429089|NCT04153747|DIAGNOSTIC_TEST|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
214429090|NCT02981888|RADIATION|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
214512614|NCT01596985|PROCEDURE|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
214512615|NCT02684656|PROCEDURE|Hemodialysis|Hemodialysis \>/=4h
214512616|NCT02684656|PROCEDURE|Hemodiafiltration|Hemodiafiltration \>/=4h, \> 20l convection
214512617|NCT02948309|DRUG|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
214512618|NCT02948309|DRUG|Placebo|1ml subcutaneous injection 3 times/week
214512619|NCT00689637|DRUG|AZD3480|AZD3480 capsules qd, 12 days
214512620|NCT00689637|DRUG|Placebo|Placebo capsules qd, 12 days
214512621|NCT00689637|DRUG|Warfarin|Warfarin: single dose on day 6
214512622|NCT02903602|BEHAVIORAL|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
214512623|NCT02903602|BEHAVIORAL|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
214512624|NCT01117285|OTHER|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
214692456|NCT06291103|DRUG|Conversion to Belatacep|CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
214692457|NCT06291103|DRUG|Standard of care treatment (SOC regimen) with Tacrolimus|Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
214429091|NCT05146271|PROCEDURE|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
214429092|NCT02455297|DRUG|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
214429093|NCT05878470|BEHAVIORAL|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
214429094|NCT00000223|DRUG|Buprenorphine|
214429095|NCT02476409|DRUG|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
214429096|NCT02476409|OTHER|Placebo|Placebo for tolvaptan
214429097|NCT04608305|BIOLOGICAL|IIBR-100, low dose (prime)|Single administration of IIBR-100 1\*10E5 pfu/ml
214429098|NCT04608305|BIOLOGICAL|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1\*10E6 pfu/ml
214429099|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1\*10E7 pfu/ml
214429100|NCT04608305|BIOLOGICAL|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
214429101|NCT04608305|OTHER|Saline Placebo (single)|Single administration of saline placebo
214429102|NCT04608305|OTHER|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
214429103|NCT04608305|BIOLOGICAL|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
214429104|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
214429105|NCT04608305|BIOLOGICAL|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
214429106|NCT00275392|BEHAVIORAL|Vestibular rehabilitation|vestibular adaptation and substitution exercises
214429107|NCT00275392|BEHAVIORAL|Placebo|placebo vestibular exercises
214429108|NCT01830738|PROCEDURE|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
214429109|NCT01830738|PROCEDURE|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
214429110|NCT04498663|BEHAVIORAL|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
214429111|NCT03848572|DIAGNOSTIC_TEST|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
214429112|NCT02779634|DRUG|ubiquinol|Ubiquinol three times daily
214429113|NCT02779634|DRUG|Placebo|Sugar pill three times daily
214512625|NCT01117285|OTHER|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders."
214429114|NCT04532450|DEVICE|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
214429115|NCT01983371|DRUG|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
214429116|NCT01983371|OTHER|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
214429117|NCT00468052|DRUG|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
214429118|NCT00468052|DRUG|fentanyl|1 microgram/kilogram as a bolus
214429119|NCT03189589|DRUG|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
214429120|NCT03189589|DRUG|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
214692458|NCT02800564|BEHAVIORAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
214429121|NCT02204982|DRUG|Duvelisib|PI3K Inhibitor
214429122|NCT02204982|DRUG|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
214429123|NCT02204982|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
214429124|NCT01884441|DRUG|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
214429125|NCT01884441|DRUG|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
214429126|NCT01884441|DRUG|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
214429127|NCT00709423|DRUG|Moxaverine|
214429128|NCT00709423|DRUG|Moxaverin 150mg|intravenous administration
214429129|NCT00709423|DRUG|NaCl|intravenous administration
214429130|NCT06034886|DRUG|Troriluzole|BHV-4157 140mg, 200mg or 280mg once daily by mouth.
214429131|NCT00092274|DRUG|HuMax-CD20|
214429132|NCT01247831|PROCEDURE|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
214429133|NCT00003432|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
214429134|NCT05794568|DEVICE|OITcontrol app monitoring|App to monitor OIT patients
214429135|NCT03576833|DEVICE|Elipse Balloon system|intragastic balloon
214429136|NCT00185549|BEHAVIORAL|CF. DOC|
214429137|NCT00718939|DEVICE|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
214429138|NCT05992701|DEVICE|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
214429139|NCT03071653|PROCEDURE|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
214429140|NCT03071653|OTHER|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
214429141|NCT04479969|BEHAVIORAL|Video Chat|Video chat with health coach using a computer tablet.
214429142|NCT01512810|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
214429143|NCT00981643|BEHAVIORAL|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
214429144|NCT03216538|DRUG|AS101 1% oral solution|0.4 ml daily p.o.
214512626|NCT03925909|DIETARY_SUPPLEMENT|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
215113801|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
214429145|NCT03216538|DRUG|Placebo|0.4 ml daily p.o.
214429146|NCT02779998|OTHER|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
214429147|NCT02779998|OTHER|Standard oxygen therapy with facial mask|
214429148|NCT04421261|DEVICE|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
214429149|NCT04421261|DEVICE|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
214429150|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
214429151|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
214429152|NCT02178423|PROCEDURE|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
214429153|NCT01885793|DEVICE|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
214429154|NCT02983669|DIETARY_SUPPLEMENT|Thyme|Thyme capsule 350 mg twice daily
214429155|NCT02983669|OTHER|Placebo|Placebo capsule 350 mg twice daily
214429156|NCT00159783|DRUG|asenapine|Asenapine, 40 weeks
214429157|NCT00159783|DRUG|Olanzapine|Olanzapine, 40 weeks
214429158|NCT00592410|DRUG|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
214429159|NCT03104387|OTHER|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
214429160|NCT03104387|OTHER|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
214429161|NCT02928224|DRUG|Encorafenib|Orally, once daily.
214429162|NCT02928224|DRUG|Binimetinib|Orally, twice daily.
214429163|NCT02928224|DRUG|Cetuximab|Standard of care.
214429164|NCT02928224|DRUG|Irinotecan|Standard of care.
214429165|NCT02928224|DRUG|Folinic Acid|Standard of care.
215113802|NCT01997424|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
215113803|NCT01997424|DEVICE|FibroScan, Echosens, Paris, France|
215113804|NCT04430569|DRUG|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
215113805|NCT04430569|DRUG|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
215113806|NCT05729568|DRUG|Teropavimab|Administered intravenously
215113807|NCT05729568|DRUG|Zinlirvimab|Administered intravenously
215113808|NCT05729568|DRUG|Lenacapavir Tablet|Administered orally
215113809|NCT05729568|DRUG|Lenacapavir Injection|Administered subcutaneously
215113810|NCT05729568|DRUG|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
215113811|NCT04181762|DRUG|secukinumab|STUDY DRUG
215113812|NCT04181762|DRUG|Placebo|Placebo
214429166|NCT02928224|DRUG|5-Fluorouracil|Standard of care.
214429167|NCT06034028|DEVICE|J-Valve TF System|The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
214429168|NCT04525651|DEVICE|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
214429169|NCT04525651|OTHER|Manual Acupuncture|Manual acupuncture to acheive de qi.
214429170|NCT04525651|OTHER|Sham Acupuncture|Sham acupuncture to avoid de qi.
214429171|NCT00378222|PROCEDURE|Autologous Stem Cell Transplantation|
214429172|NCT05467319|DRUG|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
214429173|NCT05467319|DRUG|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
214429174|NCT01337622|PROCEDURE|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
214429175|NCT01337622|PROCEDURE|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
214429176|NCT03107806|DEVICE|OptiScanner®|"1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®"
214429177|NCT05981157|DRUG|Anrotinib plus Tirelizumab|Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
214429178|NCT03281382|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
214429179|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 14 days
214512627|NCT03284840|DIAGNOSTIC_TEST|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
214512628|NCT03284840|DIAGNOSTIC_TEST|Thyroid size|Thyroid size by ultrasound.
214512629|NCT02035852|OTHER|MRI|3T MRI vs. 7T MRI
214512630|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols and fish oil|4 weeks intervention, 3 times daily
214512631|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols|4 weeks intervention, 3 times daily
214512632|NCT01313988|DIETARY_SUPPLEMENT|Placebo|4 weeks, 3 times daily
215113813|NCT05720390|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
214429180|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
214429181|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 28 days
214429182|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
214429183|NCT02034773|DRUG|Placebo|Placebo will be administered once daily for up to 28 days
214429184|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
214429185|NCT02034773|DRUG|CC-220|CC-220 1mg (once every 7 days for 28 days)
214429186|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
214429187|NCT04415528|OTHER|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
214512633|NCT00483457|DRUG|enzyme inhibitor therapy|enzyme inhibitor therapy
214512634|NCT00483457|GENETIC|protein expression analysis|protein expression analysis
214512635|NCT00483457|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
214512636|NCT00483457|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214512637|NCT00483457|PROCEDURE|biopsy|biopsy
214512638|NCT02167191|BEHAVIORAL|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
214512639|NCT00587756|PROCEDURE|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
214512640|NCT00755794|DRUG|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
214512641|NCT04078217|DEVICE|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
214512642|NCT04078217|OTHER|Booklet|Home-based exercise program using a paper booklet (not the technology).
214692459|NCT02800564|BEHAVIORAL|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
214692460|NCT01218412|BEHAVIORAL|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
214692461|NCT01613014|DRUG|ABT-436|Target dose - 400mg BID
214692462|NCT01613014|DRUG|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
214692463|NCT00406952|PROCEDURE|electronic diary|
214692464|NCT00406952|DRUG|Sertraline|
214692465|NCT00406952|DRUG|Placebo|
214692466|NCT00406952|PROCEDURE|voice acoustics|
214512643|NCT06510946|BEHAVIORAL|(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease|"The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet."
215113814|NCT05720390|OTHER|L-leucine|L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
215113815|NCT05720390|OTHER|Combination of quinine and L-leucine|In this condition, both quinine and L-leucine will be administered as 'active'.
214429188|NCT05600335|PROCEDURE|ERAS protocol|Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
214429189|NCT02855034|OTHER|Blood samples|Blood samples for dosage: copeptin and protein S100B
214429190|NCT05915533|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
214429191|NCT04593251|BIOLOGICAL|CALY-002|1-hour intravenous infusion
214429192|NCT04593251|BIOLOGICAL|Placebo|1-hour intravenous infusion
214429193|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
214429194|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
214429195|NCT05166889|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
214429196|NCT06063733|OTHER|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
214429197|NCT01618643|PROCEDURE|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
214429198|NCT01497704|DRUG|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
214429199|NCT03665779|DRUG|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
215113816|NCT05720390|OTHER|Control|In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
215113817|NCT03750266|OTHER|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
215113818|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
215113819|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
215113820|NCT03965143|DEVICE|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
214429200|NCT03665779|DRUG|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
214429201|NCT00882934|OTHER|Induction to efficient treatment|Informative letters.
214429202|NCT00882934|OTHER|Doubt to the efficacy of treatment|Informative letters.
214429203|NCT00882934|OTHER|Induction to ineffective treatment|Informative letters
214429204|NCT01837940|DIETARY_SUPPLEMENT|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
214429205|NCT01837940|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
214429206|NCT00468910|DRUG|acetylsalicylic acid|Given orally
214429207|NCT00468910|DRUG|placebo|Given orally
214429208|NCT00468910|OTHER|laboratory biomarker analysis|Correlative study
214429209|NCT04531592|DRUG|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
214429210|NCT04531592|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
214429211|NCT04367272|PROCEDURE|First Arthroplasty|First Knee
214512644|NCT03627156|BEHAVIORAL|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
214512645|NCT06200909|OTHER|Mindfulness Meditation|8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.
214512646|NCT06200909|OTHER|Psychoeducation|"A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content."
214512647|NCT06200909|OTHER|Wait list control|Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
214512648|NCT04255823|OTHER|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
214512649|NCT04255823|OTHER|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
214512650|NCT06257563|OTHER|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
214512651|NCT05585398|DRUG|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
214512652|NCT05822791|DIAGNOSTIC_TEST|Prolonged cardiac monitoring|Prolonged cardiac monitoring
214512653|NCT05822791|DIAGNOSTIC_TEST|ECG|Electrocardiogram
214512654|NCT01237977|DRUG|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
214512655|NCT01237977|DRUG|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
214512656|NCT05803122|OTHER|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
214512657|NCT05658809|PROCEDURE|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
214512658|NCT01728090|OTHER|hand sanitizer|alcohol-based, hydroalcoholic gel
214692467|NCT01117688|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
214512659|NCT00286013|DRUG|Association of gemcitabine, oxaliplatin and radiotherapy|
214512660|NCT02152384|DRUG|Insulin Peglispro|Administered SC
214512661|NCT02152384|DRUG|Insulin Lispro|Administered SC
215113821|NCT02197663|PROCEDURE|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
215113822|NCT02503228|PROCEDURE|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
214512662|NCT02152384|DRUG|Insulin Glargine|Administered SC
214512663|NCT00823966|DRUG|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
214512664|NCT00941447|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
214512665|NCT00941447|BEHAVIORAL|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
214512666|NCT00941447|BEHAVIORAL|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
214512667|NCT03483714|PROCEDURE|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
214512668|NCT04471805|DEVICE|Sham transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
214512669|NCT04471805|DEVICE|Transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214512670|NCT00037934|DEVICE|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
214512671|NCT00037934|OTHER|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
214512672|NCT02142218|DRUG|Nivolumab|
214512673|NCT06240806|OTHER|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
214512674|NCT06240806|OTHER|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
214512675|NCT05063175|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
214692468|NCT01187108|DRUG|N-acetylcysteine|NAC 600 mg oral once daily
214692469|NCT01187108|DRUG|Acetazolamide|Acetazolamide 250 mg oral once daily
214692470|NCT01187108|DRUG|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
215113823|NCT00653588|DRUG|Rosuvastatin|40mg
215113824|NCT00653588|DRUG|Atorvastatin|80mg
215113825|NCT02526004|DRUG|Ceftazidime|
214429212|NCT04367272|PROCEDURE|Second Arthroplasty|Second Knee
214429213|NCT04672018|OTHER|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
214429214|NCT04672018|DRUG|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
214429215|NCT06198114|OTHER|Multi Sensory Therapy|This group will be treated with activity based training by place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box. 5 days in a week
214512676|NCT05063175|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
214429216|NCT06198114|OTHER|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).5 days a week for an hour/daily.
214429217|NCT05676450|DIAGNOSTIC_TEST|cell-free DNA|Given by IV (vein)
214429218|NCT03663036|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
214429219|NCT01290185|DEVICE|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
214429220|NCT06113146|OTHER|ultra-processed slow eating rate diet|Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
214429221|NCT06113146|OTHER|Ultra-processed fast eating rate diet|Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
214429222|NCT02191098|DRUG|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
214429223|NCT05320796|DIAGNOSTIC_TEST|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
214429224|NCT06240351|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a Janus kinase (JAK) inhibitor
214429225|NCT06114745|DRUG|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
214429226|NCT06114745|DRUG|Placebo|Placebo will be administered through IV infusion
214429227|NCT05631938|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
214429228|NCT06029023|COMBINATION_PRODUCT|MTA Cement, propolis nano particle, curcumin nanoparticles|MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.
214429229|NCT06406816|COMBINATION_PRODUCT|Neoantigen Vaccine plus Capecitabine|"1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination."
214512677|NCT00101387|OTHER|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
214512678|NCT00101387|OTHER|Lumbar PENS|As above
214512679|NCT00101387|OTHER|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
214512680|NCT00101387|OTHER|Control PENS + exercise|as above
214512681|NCT00915629|DIETARY_SUPPLEMENT|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
215113826|NCT02526004|DRUG|Tobramycin|
215113827|NCT06457841|BEHAVIORAL|Direct Interpersonal Exchange|Simulated a negative personally relevant interpersonal experience that is received directly from a perpetrator, commonly experienced in everyday lives
215113828|NCT06457841|BEHAVIORAL|Vicarious Interpersonal Exchange|Hearing or observing a negative personally relevant interpersonal experience that is reported by another person of the same background
215113829|NCT06457841|BEHAVIORAL|Daily Hassles|Day-to-day stressors associated with school, work, finances
215113830|NCT05706220|DIAGNOSTIC_TEST|Eye tracking|Eye tracker will be used to evaluate eye movements
215113831|NCT05706220|DIAGNOSTIC_TEST|Microperimetry|Perimetric examination with Expert Exam strategy Microperimetry be used for fixation test
215113832|NCT05706220|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Macular Cube 512x128 or 200x200 scan. OCT will be used to analysis of retinal nerve fiber layer, ganglion cell complex and ganglion-cell/inner plexiform layer
214429230|NCT01168154|DIETARY_SUPPLEMENT|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
214429231|NCT01168154|DIETARY_SUPPLEMENT|placebo|placebo
214429232|NCT06201819|DRUG|Liraglutide injection|Liraglutide (GLP-1 analog) injection during 3 months
214429233|NCT04396730|DRUG|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
214429234|NCT04396730|DRUG|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
214429235|NCT04396730|DRUG|Combined oral contraceptive pill|All participants will receive oral contraceptives
214429236|NCT00149864|DRUG|Mycophenolate sodium (enteric coated)|
214429237|NCT01576484|DRUG|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
214429238|NCT01576484|DRUG|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
214429239|NCT06145568|OTHER|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
214429240|NCT00581854|DRUG|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
214512682|NCT01558765|OTHER|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
214512683|NCT01099878|DEVICE|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
214512684|NCT01099878|DEVICE|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
214512685|NCT01040299|DEVICE|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
214512686|NCT01040299|DEVICE|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
214512687|NCT01040299|OTHER|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
214512688|NCT02166723|DEVICE|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
214692471|NCT04715230|BIOLOGICAL|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
214429241|NCT05286710|DEVICE|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was \>50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was \>50% after PTA treatment.
214429242|NCT01217905|DRUG|AZD7687|Oral suspension
214429243|NCT05254535|OTHER|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
214429244|NCT06571747|BEHAVIORAL|Cardiovascular-Focused Nudge Communication|Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.
214429245|NCT03217305|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
214429246|NCT04565925|DRUG|Sildenafil Citrate|Sildenafil 20mg TID for 4 weeks
214429247|NCT04565925|DRUG|Placebo|Placebo (Lactose) TID for 4 weeks
214429248|NCT05393726|PROCEDURE|Ultrasound-Guided Suprainguinal Fascia Iliaca Block Versus Lumbar Erector Spinae Plane Block|"Suprainguinal Fascia Iliaca Block group will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~Lumbar Erector Spinae Plane Block group will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40 ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~control group will underwent surgery under general anesthesia and receive the perioperative routine protocol of analgesia"
214429249|NCT06523374|PROCEDURE|Endoscopic brush cytology|A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.
214429250|NCT06073769|DRUG|Oral azacitidine|Maintenance therapy according to the approved label
214512689|NCT02166723|DEVICE|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
214512690|NCT04706442|OTHER|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
214429251|NCT05689307|DEVICE|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
214429252|NCT04474301|OTHER|Survey Administration|Complete survey
214429253|NCT06777498|OTHER|Whole Grain Intervention then fruits and vegetables|"TREATMENT 1: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
214429254|NCT06777498|OTHER|Fruit and Vegetable Intervention and then whole grains|"TREATMENT 1: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
214429255|NCT06326320|PROCEDURE|Combined SAPB|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the supine position. 40 ml of 0.25% bupivacaine will be used in applications.
214429256|NCT04275102|OTHER|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
214429257|NCT05388110|BEHAVIORAL|SKY Breath Intervention|Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
214429258|NCT00793754|DRUG|Aspirin|100 mg / day for 8 weeks
214429259|NCT00793754|DRUG|Atorvastatin|40 mg / day for 8 weeks
214429260|NCT00793754|DRUG|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
214429261|NCT02245100|OTHER|Cytology specimen|Correlative studies
214429262|NCT02245100|OTHER|Laboratory biomarker analysis|Correlative studies
214512691|NCT05615506|PROCEDURE|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
214512692|NCT04931498|OTHER|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
214429263|NCT06410885|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
214429264|NCT02995252|OTHER|Blood draws|
215113833|NCT05706220|DIAGNOSTIC_TEST|Visual processing speed test|"Visual processing speed test will be used for assessing subject visual stimulus search and reach times.~Thirty-two different everyday visual stimuli divided in four complexity groups that were presented along 8 radial visual field positions at three different eccentricities."
214429265|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
214512693|NCT04931498|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
214429266|NCT02995252|OTHER|Knowledge Index Questionnaire|
214429267|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
214429268|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
214429269|NCT06025357|DIETARY_SUPPLEMENT|L-Citrulline supplementation|4 weeks of L-Citrulline supplementation (10 grams/day).
214429270|NCT06025357|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline Cellulose supplementation.
214429271|NCT01630772|OTHER|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
214429272|NCT01630772|OTHER|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
214429273|NCT04585074|PROCEDURE|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
214429274|NCT04585074|PROCEDURE|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
214429275|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
214429276|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
214429277|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
214429278|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
214429279|NCT03381053|DRUG|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
214429280|NCT01943799|BIOLOGICAL|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
214429281|NCT01943799|DRUG|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
214429282|NCT01865149|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
214429283|NCT04594759|DRUG|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
214429284|NCT02887625|DRUG|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
214512694|NCT04931498|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
214512695|NCT04931498|PROCEDURE|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry"
214692472|NCT04715230|DRUG|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
214429285|NCT02887625|DRUG|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c \<7.0%
214429286|NCT00771446|BIOLOGICAL|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
214429287|NCT00771446|OTHER|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
214429288|NCT05678972|OTHER|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
214429289|NCT03532711|DRUG|fluorouracil|chemotherapy treated patients
214429290|NCT03559348|DRUG|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
214429291|NCT05072743|DEVICE|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
214512696|NCT04931498|PROCEDURE|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays"
214512697|NCT05581108|DIETARY_SUPPLEMENT|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
214512698|NCT05581108|DIETARY_SUPPLEMENT|Placebo|matched placebo (2 capsules)
214429292|NCT03811574|DRUG|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
214429293|NCT03811574|DRUG|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
214429294|NCT01583712|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
214429295|NCT01583712|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
214429296|NCT01832480|DRUG|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
214429297|NCT01832480|DRUG|MTZ 2 g|MTZ 2 g
214429298|NCT03087578|OTHER|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
214512699|NCT04543188|DRUG|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
214512700|NCT04543188|DRUG|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
214512701|NCT04543188|DRUG|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
214429299|NCT03087578|DRUG|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
214512702|NCT03761199|OTHER|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
214512703|NCT04823156|DIETARY_SUPPLEMENT|Calcium|Daily calcium food supplement.
214512704|NCT01163214|DRUG|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
214429300|NCT00870207|BEHAVIORAL|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
214429301|NCT03114267|OTHER|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
214512705|NCT01163214|DRUG|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
214512706|NCT06399939|BEHAVIORAL|Nap|Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
214512707|NCT06399939|BEHAVIORAL|Wake|Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
214429302|NCT01806116|DRUG|decitabine|
214512708|NCT03248076|DRUG|Fentanyl Citrate|1γ/Kg fentanyl
214512709|NCT00847977|DRUG|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
215113834|NCT06617936|DRUG|neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)
214429303|NCT05763524|PROCEDURE|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
214429304|NCT02620813|DRUG|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
214429305|NCT02620813|DRUG|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
214429306|NCT00158769|DRUG|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
214429307|NCT06969404|BIOLOGICAL|capillary blood sampling|capillary blood sampling during the hospital transfert
214429308|NCT01652417|DRUG|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
214429309|NCT06968221|DEVICE|Bioabsorbable Staple Line Reinforcemen|cingular Bioabsorbable Staple Line Reinforcement
214429310|NCT00390273|DRUG|Metformin|
214429311|NCT04578392|PROCEDURE|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
214429312|NCT04578392|PROCEDURE|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
214512710|NCT00847977|DRUG|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
214512711|NCT03427645|BEHAVIORAL|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
214512712|NCT01779492|DRUG|GL2907|once a day
214512713|NCT01779492|DRUG|Oxycontine CR 10mg|twice a day
214512714|NCT02197494|DRUG|Valsartan|320mg tablets
214512715|NCT03883178|PROCEDURE|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
214512716|NCT03578744|PROCEDURE|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
214512717|NCT04103333|PROCEDURE|Lumbar Puncture|Administered as specified in the treatment arm.
215113835|NCT06617936|PROCEDURE|surgery|Patients who are discussed by the MDT panel to evaluate surgical resection will undergo surgery.Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
214429313|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
214429314|NCT02672722|DRUG|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
214429315|NCT02672722|OTHER|Exercise|
214429316|NCT02672722|OTHER|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
214429317|NCT02997280|DRUG|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
214429318|NCT02825485|PROCEDURE|Voiding cystourethrogram|
214429319|NCT03316521|DRUG|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
214429320|NCT06014424|DRUG|CBD|Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
214512718|NCT04103333|PROCEDURE|Blood Collection|Administered as specified in the treatment arm.
214512719|NCT00880724|DEVICE|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
214512720|NCT00375323|DRUG|NovoSeven|
214692473|NCT04715230|DRUG|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
215113836|NCT06617936|DRUG|Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.
215113837|NCT06617936|OTHER|Standard Treatment|Patients assessed by the MDT panel as inoperable for surgical treatment will be selected by the investigator for a standard treatment protocol determined by the MDT discussion
214429321|NCT06014424|OTHER|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
214429322|NCT04489823|DEVICE|AVP III|Transcatheter closure of a paravalvular leak using AVP III
214429323|NCT05473364|DRUG|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
214429324|NCT05545111|DRUG|NBI-1117568|Active treatment with orally administered NBI-1117568
214429325|NCT05545111|DRUG|Placebo|Placebo matching NBI-1117568
214429326|NCT06028074|DRUG|GIM122|GIM-122 administered IV once every 3 weeks or every 2 weeks
214429327|NCT04956757|OTHER|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
214429328|NCT06140953|DRUG|Trimetazidine|trimetazidine at dose 20 mg three times daily to be taken by intervention group
214429329|NCT06140953|DRUG|Conventional therapy|conventional therapy
214429330|NCT06140953|DRUG|Placebo|placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only
214429331|NCT06647017|DEVICE|Volta tAN System|Transcutaneous auricular neurostimulation (tAN)
214429332|NCT06647017|DEVICE|SHAM Volta tAN System|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
214429333|NCT06821399|DIAGNOSTIC_TEST|Fundus Examination|Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
214429334|NCT06821399|DIAGNOSTIC_TEST|Metabolomics analysis|Conduct metabolomics testing at enrollment.
214429335|NCT04168541|OTHER|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
215113838|NCT04043039|PROCEDURE|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
215113839|NCT04043039|PROCEDURE|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
215113840|NCT05383716|DRUG|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
214429336|NCT05530109|OTHER|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
214429337|NCT04923724|DEVICE|tourniquet|tourniquet is a device used during total knee surgery.
214429338|NCT04923724|DEVICE|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
214429339|NCT05790837|BEHAVIORAL|"Computer prompt Stand up for your Health®"|"The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions."
215113841|NCT03221244|DEVICE|VR Treatment|Distractors
215113842|NCT03221244|DEVICE|VR Active Control|No distractors
215113843|NCT04211441|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
215113844|NCT02000297|PROCEDURE|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
215113845|NCT02000297|PROCEDURE|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
214429340|NCT05378815|PROCEDURE|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
214429341|NCT05378815|PROCEDURE|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
214429342|NCT00958633|DRUG|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group:~* escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
214512721|NCT00785031|OTHER|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
215113846|NCT03643627|DRUG|SYNT001|single IV infusion
215113847|NCT03643627|DRUG|Placebo|single IV infusion
214429343|NCT00958633|DRUG|Bupropion XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group:~* bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
214429344|NCT03104439|DRUG|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
214429345|NCT03104439|DRUG|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
214429346|NCT03104439|RADIATION|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
214429347|NCT03819816|OTHER|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
214429348|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
214429349|NCT00126997|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
214512722|NCT05711589|PROCEDURE|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
214512723|NCT05711589|PROCEDURE|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
214512724|NCT02714998|DRUG|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
214512725|NCT02714998|PROCEDURE|salpingectomy|Laparoscopic unilateral salpingectomy
214512726|NCT06288750|DEVICE|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
214512727|NCT06288750|DEVICE|No indocyanine green|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
214512728|NCT05639166|BIOLOGICAL|IBIO123|IBIO123 10 mg
214512729|NCT05639166|OTHER|Placebo|Matching Placebo
214512730|NCT05062226|DIETARY_SUPPLEMENT|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
214512731|NCT01393964|DRUG|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
214512732|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
214512733|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
215113848|NCT03939975|DRUG|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
214429350|NCT02728349|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
214429351|NCT03994705|BIOLOGICAL|Descartes-11|CAR T-Cells
214429352|NCT03994705|DRUG|Fludarabine|Pre-conditioning chemotherapy
214512734|NCT01393964|DRUG|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
214512735|NCT01393964|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214512736|NCT03240471|PROCEDURE|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
214512737|NCT03240471|PROCEDURE|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
214512738|NCT02125799|DEVICE|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
214512739|NCT04405180|DRUG|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
214512740|NCT04405180|DRUG|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
214512741|NCT05923606|DEVICE|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
214512742|NCT05923606|DEVICE|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
215113849|NCT00303225|DRUG|Vaccine: SIGA-246|
215113850|NCT05799768|BEHAVIORAL|Ketogenic diet|Ketogenic diet counseling
215113851|NCT03890744|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
214429353|NCT03994705|DRUG|Cyclophosphamide|Pre-conditioning therapy
214429354|NCT06974240|OTHER|Experimental Group|The training sessions were carried out following a strict order. The first phase was dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, videos were shown and participants answered targeted questions asked by the Nao Robot to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, which re-enacted the situations seen in the videos, involving all the members of the group in turn. During the last phase, participants were asked to share experiences in their lives in which they had used or could have used the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
214512743|NCT05585827|BEHAVIORAL|Online cognitive behavioral therapy|"The e-CBT treatment manual is an adjusted version of a previously published treatment manuals for neuropsychiatric symptoms in PD, which is tailored to the preferences and needs for each participant. This manual encompass both modules from manuals for depression in PD and anxiety in PD. Individualization is ensures by including several interventions modules in the manual, wherein 5 sessions are considered core modules, and four modules that can be offered depending on the patients individual needs. The participant may include partners or caregivers. The treatment is schedules to be completed within 13 weeks, with maximum ten sessions during this period. Following each e-CBT session, the participant will be asked to complete a short survey evaluating the acceptability and relevance of the session, and evaluate the therapeutic alliance."
214512744|NCT05955885|DRUG|Flurbiprofen Oral Lozenge|This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
214512745|NCT05955885|DRUG|Difflam|This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
214512746|NCT05955885|DRUG|Flurbiprofen 8.75 MG|This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
214512747|NCT06030739|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
214512748|NCT03879538|DRUG|Nitrous Oxide|A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
214512749|NCT03879538|DRUG|Oxygen|A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
214512750|NCT00241618|DRUG|Pegylated interferon alpha 2|
214512751|NCT00241618|DRUG|Ribavirin|
214512752|NCT04756271|BIOLOGICAL|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
214512753|NCT02173288|DRUG|Standard medical therapy|
214512754|NCT02173288|DRUG|Tolvaptan|
214512755|NCT02173288|DRUG|Midodrine|
214512756|NCT01072045|DRUG|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
214512757|NCT01072045|DRUG|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
214512758|NCT05281081|DRUG|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
214512759|NCT02680262|BEHAVIORAL|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
214512760|NCT02680262|BEHAVIORAL|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
214512761|NCT02680262|BEHAVIORAL|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
214512762|NCT01159236|DRUG|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
214512763|NCT01159236|DRUG|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
214512764|NCT01159236|DRUG|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
214512765|NCT01159236|DRUG|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
214512766|NCT01159236|DRUG|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
214512767|NCT01159236|DRUG|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
214512768|NCT06041165|DRUG|JS401|Single dose of JS401 by subcutaneous (sc) injections
214512769|NCT06041165|DRUG|Placebo|Calculated volume to match active treatment
214512770|NCT01466569|DRUG|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
214512771|NCT01466569|DRUG|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
214512772|NCT02142725|DRUG|LT-02|four times per day
214512773|NCT02142725|DRUG|LT-02|two times per day
214429355|NCT06974240|OTHER|control group|The entire intervention was carried out in a group entirely mediated by an operator without the use of a social robot. The first phase is dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, stories were read and participants answered target questions to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, in which all members of the group participated in turn, recalling the situations seen in the videos. During the last phase, participants were asked to share experiences from their lives in which they used or could use the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
214512774|NCT02142725|DRUG|Placebo|four times per day
214512775|NCT04207372|DIETARY_SUPPLEMENT|whey protein isolate|whey protein isolate
214512776|NCT04207372|DIETARY_SUPPLEMENT|Zein|zein protein
214429356|NCT06973681|DRUG|BGM0504|Administered SC
214429357|NCT06973681|DRUG|BGM0504|Administered SC
214429358|NCT06973681|DRUG|BGM0504|Administered SC
214429359|NCT06973681|DRUG|Placebo|Administered SC
214429360|NCT06972940|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
214429361|NCT06974123|DRUG|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis|"Patients clinically diagnosed with radiation proctitis of CTCAE grade I-II will receive oral administration. Three dose groups of Teslanbai bacteria are tentatively planned, formulated as capsules with viable bacterial counts per capsule of ≥1107 CFU, 1108 CFU, and 1\*109 CFU, respectively. A 3+3 dose-escalation design will be adopted. Each dose group will enroll 3 subjects. If 1 subject experiences a grade ≥3 adverse reaction, 3 additional patients will be added. If 2 subjects exhibit adverse reactions, enrollment into higher dose groups will be discontinued. The final dosage for subsequent use of Teslanbai bacteria will be determined based on efficacy and safety data.~Approximately 9 subjects are planned for enrollment. After determining the optimal dosage, investigators and sponsors will decide whether to proceed to Phase II based on the study results and external data."
214429362|NCT06974123|DRUG|Teslanbai oral therapy|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis
214429363|NCT06972706|DIETARY_SUPPLEMENT|Shatavari|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
214429364|NCT06972706|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
214429365|NCT06972706|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
214429366|NCT06973421|DRUG|Utidelone Capsules|60 mg/m2 orally, days 1 to 5, per cycle
214429367|NCT06973421|DRUG|Fruquintinib Capsules|5 mg orally, days 1 to 14, per cycle
214429368|NCT06974084|DRUG|Maraviroc (MVC)|Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet
214429369|NCT06974084|DRUG|Atorvastatin, 10mg, 20mg, 40mg|Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg
214429370|NCT06974084|DRUG|Placebo, Maraviroc|Placebo of Maraviroc, 300mg
214429371|NCT06974084|DRUG|Placebo, Atorvastatin|Placebo of Atorvastin, 10mg
214429372|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
214429373|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
214512777|NCT04207372|OTHER|protein-free|protein free
214512778|NCT03847545|DRUG|Fampridine|sustained-release tablet 10 mg morning and evening.
214512779|NCT03265132|BIOLOGICAL|anakinra|sub cutaneous injection
214692474|NCT05630404|DRUG|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
214429375|NCT06973850|BEHAVIORAL|The Self-Efficacy Building Nursing Program|"Intervention Description~The Self-Efficacy Building Nursing Program is a structured, theory-based educational intervention grounded in Bandura's Self-Efficacy Theory. It aims to enhance participants' confidence in their ability to perform daily foot self-care behaviors and perceive their risk of complications accurately. The content includes:~Educational modules on diabetes and foot health.~Training on daily foot inspection, hygiene, nail and skin care, and appropriate footwear.~Motivational strategies, goal setting, and problem-solving skills.~Video demonstrations, live discussions, and Q\&A sessions with a diabetes nurse educator.~The program will be delivered over four weekly virtual sessions, each lasting approximately 45-60 minutes, via a user-friendly telehealth platform (e.g., Zoom or WhatsApp Video). Follow-up support and reminders will be provided through weekly text messages and phone check-ins."
214429376|NCT00786006|DRUG|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
214429377|NCT00786006|DRUG|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
214512780|NCT03265132|DRUG|Placebo|sub cutaneous injection
214512781|NCT04723615|OTHER|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
214512782|NCT04723615|OTHER|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
214512783|NCT04723615|OTHER|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
214429378|NCT05582694|BIOLOGICAL|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
214429379|NCT04655131|DIETARY_SUPPLEMENT|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
214429380|NCT04148040|PROCEDURE|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
214429381|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
214429382|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
214429383|NCT03470662|OTHER|Care bundle|Care bundle
214429384|NCT03624166|DRUG|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
214429385|NCT03624166|DRUG|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
214429386|NCT06839144|DRUG|Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)|"\- Intervention Arm: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor). Name: Propranolol (slow-Release) and Etodolac.~Propranolol Dosage Schedule:~5 days pre-surgery: 20mg twice daily (BID), Day of surgery: 80mg BID,~1-week Post-surgery: 40mg BID, week 2-11 post-surgery: 20mg BID.~Etodolac Dosage Schedule:~5 days pre-surgery until 3 weeks post-surgery: 400mg BID.~Administration Route: Oral."
214429387|NCT06839144|DRUG|Placebo (Matching for Propranolol & Etodolac)|\- Placebo Arm: Placebo (Matching for Propranolol \& Etodolac). Inert placebo tablets matching propranolol and etodolac in appearance and dosing schedule. Administration Route: Oral.
214429388|NCT05454228|BEHAVIORAL|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
214429389|NCT02601170|BIOLOGICAL|Platelet-Rich Plasma Intra-Articular Injection|
214429390|NCT02601170|DRUG|Hyaluronic Acid Viscosupplementation|
214429391|NCT05484297|BEHAVIORAL|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
214429392|NCT05484297|BEHAVIORAL|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
214429393|NCT06974032|DRUG|Xylocaine jelly 2%|To determine if a 6cc of 2% lidocaine jelly decreases pain of paracervical block injection before IUD placement in nulliparous women
214429394|NCT06974032|DRUG|Surgilube|To determine if the placebo gel increases pain of paracervical block injection before IUD placement in nulliparous women
214429395|NCT06150079|PROCEDURE|Pes-Guided PEEP titration|Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (PL = PEEP - Pes). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
214429396|NCT04845685|DEVICE|Continuous Glucose Monitor (CGM)|A device that measures blood sugar levels every 1-5 minutes
214429397|NCT06306768|DEVICE|Activity Monitoring|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
214429398|NCT05132842|OTHER|Survey Administration|Complete a Survey
214512784|NCT04723615|OTHER|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
215113852|NCT05971069|PROCEDURE|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
214429399|NCT01145248|DEVICE|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
214429400|NCT01145248|DEVICE|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
214429401|NCT02674750|DRUG|CUDC-907|
214429402|NCT01010919|DIETARY_SUPPLEMENT|Chicory root extract|
214512785|NCT01407874|DRUG|Placebo|Oral dose administered daily for 84 days.
214512786|NCT01407874|DRUG|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
214512787|NCT01407874|DRUG|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
214512788|NCT01344980|PROCEDURE|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
214512789|NCT01344980|PROCEDURE|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
215113853|NCT05971069|PROCEDURE|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
215113854|NCT05971069|PROCEDURE|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
214512790|NCT01344980|BEHAVIORAL|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
214512791|NCT01344980|BEHAVIORAL|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
214512792|NCT00088166|DRUG|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
214512793|NCT00088166|DRUG|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
214512794|NCT02671266|DRUG|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
214512795|NCT02671266|DRUG|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
214512796|NCT00666705|DRUG|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
214512797|NCT00666705|DRUG|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
214512798|NCT00666705|DRUG|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
214512799|NCT00666705|DRUG|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
214512800|NCT01812330|DRUG|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
214429403|NCT00777816|DRUG|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
214512801|NCT01812330|DRUG|Ticagrelor|90mg Bid
214512802|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
214512803|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
214512804|NCT00688415|DRUG|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
214512805|NCT01109979|DRUG|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
214512806|NCT01109979|DRUG|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
214512807|NCT01228734|DRUG|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
214512808|NCT01228734|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
214512809|NCT01228734|DRUG|Folinic Acid|FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
214512810|NCT01228734|DRUG|5Fluorouracil|5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
214512811|NCT03500406|DEVICE|RestoreX|Penile traction therapy in the straight position
214512812|NCT03500406|OTHER|Control|No treatment
214512813|NCT03678792|DRUG|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
214512814|NCT03678792|DRUG|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
214512815|NCT03678792|DRUG|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
214429404|NCT00777816|DRUG|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
214429405|NCT04645394|DIETARY_SUPPLEMENT|Aronia melanocarpa|Administered once (acute study)
214429406|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
214429407|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
214429408|NCT04645394|DIETARY_SUPPLEMENT|Placebo|Administered once (acute study)
214429409|NCT04689425|DRUG|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
214429410|NCT04689425|DRUG|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
214512816|NCT01997866|OTHER|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
214512817|NCT01997866|OTHER|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
214512818|NCT06470633|DRUG|Adebrelimab|Adebrelimab 1200mg iv q3w
214512819|NCT06470633|PROCEDURE|High Intensity Focused Ultrasoun（HIFU）|HIFU treatment at lesion site
214512820|NCT06470633|DRUG|Cyclophosphamide|600mg/m2 iv q3w
214512821|NCT06470633|DRUG|Epirubicin|90mg/m2 iv q3w
214429411|NCT00582478|BEHAVIORAL|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
214429412|NCT03413748|PROCEDURE|Elective Cesarean Section|lower segment cesarean section
214429413|NCT03413748|OTHER|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
214429414|NCT03477149|DEVICE|Easyx|Embolization will be done with Easyx liquid agent.
214429415|NCT01815450|DRUG|BLI1100|BLI1100 topical cream
214429416|NCT01815450|DRUG|BLI1100 - modified formulation|BLI1100 topical cream
214429417|NCT01815450|DRUG|Placebo|Placebo topical cream
214429418|NCT03566186|OTHER|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
214429419|NCT03566186|OTHER|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
214429420|NCT03566186|OTHER|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
214429421|NCT04210765|DRUG|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
214512822|NCT06470633|DRUG|Docetaxel|75mg/m2 iv q3w
214429422|NCT01597258|DRUG|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
214429423|NCT01415349|DRUG|SSP-002358|1 mg, oral, once
214429424|NCT01415349|DRUG|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
214512823|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
214512824|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-2|Taking 7 capsules a day for six months
214512825|NCT04301752|DIAGNOSTIC_TEST|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
214512826|NCT03128099|BEHAVIORAL|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
214512827|NCT04018300|DIETARY_SUPPLEMENT|Ferrous sulfate|65 mg Fe as ferrous sulfate
215113855|NCT01922908|BIOLOGICAL|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
214429425|NCT02697877|DRUG|Regadenoson|
214429426|NCT01105169|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
214429427|NCT01105169|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
214429428|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
214429429|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
214429430|NCT01616459|BIOLOGICAL|Synflorix™|Intramuscular injection
214429431|NCT01616459|BIOLOGICAL|Prevnar 13™|Intramuscular injection
214429432|NCT01616459|BIOLOGICAL|Infanrix hexa™|Intramuscular injection
214429433|NCT04425616|OTHER|Exercise|"At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
214512828|NCT04018300|DIETARY_SUPPLEMENT|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
214512829|NCT04018300|OTHER|Placebo|Contains maltodextrin.
214512830|NCT01005030|OTHER|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
214512831|NCT00005654|DRUG|clomiphene citrate|
214512832|NCT00005654|DRUG|metformin|
214512833|NCT01102699|DRUG|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
214512834|NCT06322368|OTHER|Myofunctional and respiratory training program|The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
214512835|NCT06322368|OTHER|Range of motion and thermal and mechanical stimulation exercising|The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
214512836|NCT01474356|OTHER|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
214512837|NCT05334433|PROCEDURE|Local anesthesia injection|Local anesthesia administration
214512838|NCT01841385|OTHER|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
214512839|NCT03345706|PROCEDURE|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
214512840|NCT03345706|PROCEDURE|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
215113856|NCT01922908|BIOLOGICAL|Placebo Comparator|Normal saline
215113857|NCT02524002|DIETARY_SUPPLEMENT|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
215113858|NCT02524002|DIETARY_SUPPLEMENT|Usual clear diet|Usual clear liquids
215113859|NCT04906304|DRUG|Everolimus Pill|standard dose versus low dose Sandimun
215113860|NCT04906304|DRUG|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
214429434|NCT04425616|BEHAVIORAL|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
214512841|NCT01680432|DIETARY_SUPPLEMENT|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
214512842|NCT01680432|DIETARY_SUPPLEMENT|Regular Cheese|
214512843|NCT00952003|DRUG|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
214429435|NCT04425616|OTHER|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
214429436|NCT03089866|DRUG|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
214429437|NCT04980755|OTHER|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
214429438|NCT06375668|DIETARY_SUPPLEMENT|Probiotic|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
214429439|NCT06375668|OTHER|Placebo|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
214429440|NCT05375344|BEHAVIORAL|Exercise Group|Home-based exercise group intervention
214429441|NCT07060053|OTHER|sesame oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
214429442|NCT07060053|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
214429443|NCT04163614|OTHER|IBPS-Guided Ultrafiltration|Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
214429444|NCT05363137|OTHER|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
214429445|NCT05363137|OTHER|Standard care|The physiotherpy treatment will be standard care
214429446|NCT05051436|DRUG|Mirabegron 50 MG|Mirabegron 50 mg/day will be administered for 14 weeks.
214429447|NCT05051436|DRUG|Tadalafil 10 MG|Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
214429448|NCT05051436|DRUG|Placebo|Placebo will be administered for 14 weeks after baseline procedures.
214429449|NCT06833411|DRUG|Prednisone|Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
214429450|NCT06833411|DRUG|Prednisone|Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
214429451|NCT06829797|DRUG|Neoadjuvant Therapy(QL1706+SOX Chemotherapy)|Preoperative QL1706 combined with SOX regimen (4 cycles) → Radical surgery (D2) → Postoperative QL1706 combined with SOX regimen (4 cycles). QL1706 (50mg/2mL) , at a dose of 5mg/kg, the desired volume of drug is withdrawn and slowly infused into an IV bag of 0.9% NaCl, prepared as a diluent with a final concentration of 1-10mg/mL, mixed, and infused intravenously, Q3W, administered on the first day of each cycle.
214429452|NCT06829797|DRUG|Neoadjuvant Therapy(SOX Chemotherapy)|Preoperative SOX regimen (4 cycles) → radical surgery (D2) → postoperative SOX regimen (4 cycles).
214429453|NCT06829797|PROCEDURE|Radical surgery (D2)|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
214429454|NCT06829797|DRUG|Drug: Adjuvant therapy(QL1706+SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of QL1706+SOX chemotherapy.
214429455|NCT06829797|DRUG|Drug: Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
214429456|NCT06499324|DRUG|BTA group|It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
214429457|NCT06499324|DRUG|Placebo group|It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
214512844|NCT06254976|BEHAVIORAL|exercise|2 weeks of home exercise
214512845|NCT06254976|BIOLOGICAL|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
215113861|NCT02352844|DRUG|Everolimus|
214429458|NCT06832761|BEHAVIORAL|Personalized lifestyle intervention|The lifestyle intervention in Group A comprises three parts (1) three individual consultations with a trained lifestyle coach, (2) a voucher program to encourage brain healthy activities, and (3) access to an online self-management tool for dementia risk reduction (www.breinzorg.nl).
214429459|NCT06831253|OTHER|injections of Platelet-Rich Plasma in lacrimal gland|injections of Platelet-Rich Plasma in lacrimal gland
214512846|NCT05445050|DIAGNOSTIC_TEST|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
214512847|NCT00774592|BEHAVIORAL|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
214512848|NCT00774592|BEHAVIORAL|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
214512849|NCT00774592|BEHAVIORAL|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
214512850|NCT00774592|BEHAVIORAL|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
214512851|NCT00774592|BEHAVIORAL|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
214512852|NCT00774592|BEHAVIORAL|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
214512853|NCT04894942|OTHER|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
214512854|NCT00001004|DRUG|Tumor Necrosis Factor|
214512855|NCT00001004|DRUG|Interferon gamma-1b|
214512856|NCT03286907|BEHAVIORAL|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
214512857|NCT03286907|BEHAVIORAL|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
215113862|NCT00590863|DRUG|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
215113863|NCT00590863|DRUG|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
215113864|NCT00590863|DRUG|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
215113865|NCT05194800|OTHER|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
215113866|NCT06383416|OTHER|Neck pain by VAS|chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index.
215113867|NCT06976619|DRUG|Liraglutide Pen Injector|Liraglutide 0.6mg
215113868|NCT06976619|OTHER|Saline Injections|Saline in syringes to serve as placebo for single blind study
215113869|NCT06975150|DRUG|HK-660S 100mg|Administered orally
215113870|NCT06975150|DRUG|HK-660S 200mg|Administered orally
215113871|NCT06975150|DRUG|Placebo|Administered orally
215113872|NCT04964947|DRUG|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
215113873|NCT06974747|DIETARY_SUPPLEMENT|Imunoglukan P4H® chewable tablets|IMG® 50 mg + Zinc 5 mg + Vitamin D 10 μg in 1 tablet
215113874|NCT06974747|DIETARY_SUPPLEMENT|Placebo chewable tablets|Zinc 5 mg + Vitamin D 10 μg in 1 tablet
214429460|NCT05143632|DEVICE|ClearSight|The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
214429461|NCT04765111|DRUG|Acalabrutinib|Given PO
214429462|NCT04765111|BIOLOGICAL|Rituximab|Given IV
214512858|NCT03286907|BEHAVIORAL|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
214512859|NCT03293043|DEVICE|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
214512860|NCT03456856|DRUG|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
214429463|NCT05261633|DEVICE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
214512861|NCT00774878|DRUG|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
214512862|NCT00774878|DRUG|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
214512863|NCT03711279|DRUG|SHR-1210 plus Apatinib|SHR-1210 200 mg q3w+ Apatinib 500 mg qd
214512864|NCT03711279|DRUG|ADM plus IFO or IFO alone|ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
214512865|NCT03608436|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
214512866|NCT03608436|DRUG|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
214429464|NCT04094038|DRUG|Olimel N12|A mixture of glucose, lipids, amino acids.
214512867|NCT03806205|OTHER|regular follow-up|we give a regular follow-up and supervision on the study group
214512868|NCT04534738|BEHAVIORAL|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
214512869|NCT06248255|OTHER|Pads|Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
214512870|NCT03481985|OTHER|Fenestration status|The exposure variable will be status of the Fontan fenestration
214512871|NCT01606098|PROCEDURE|Surgery of the primary tumour|Surgical resection of the colon tumour
214512872|NCT01606098|DRUG|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
214512873|NCT00907959|DRUG|BZL101|Oral BZL101 20 grams/day (10 grams BID).
214512874|NCT01655082|DRUG|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
214512875|NCT01655082|DRUG|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
214512876|NCT05015699|DEVICE|HT Supreme|HT Supreme ( R\&D by Sinomed, Tianjin, China)
214512877|NCT06129981|BEHAVIORAL|Imaginary exposure therapy augmented by vocal feedback|"The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site."
214512878|NCT00476294|OTHER|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
214512879|NCT02624830|DRUG|Sulfonylurea|See Arm description.
214429465|NCT04094038|DRUG|Glucose IV|Glucose 5%
214512880|NCT06477549|DRUG|Bendamustine Hydrochloride|Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
214512881|NCT06477549|DRUG|Ruxolitinib|Days -7 through -2: ruxolitinib 5 mg tid per os
214512882|NCT04635657|OTHER|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
214512883|NCT02542696|DRUG|APL-130277|"Used to treat up to 5 OFF episodes per day"
214512884|NCT00078832|DRUG|anastrozole|aromatase inhibitor
214512885|NCT00078832|DRUG|placebo|Arimidex placebo
214429466|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
214429467|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
214429468|NCT04709601|DRUG|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
214429469|NCT05021328|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
214429470|NCT05021328|DRUG|Anlotinib|Anlotinib 12 mg/d, d1-14, q3w.
214429471|NCT05021328|DRUG|SBRT 7Gy✖️5 QD|SBRT 7Gy✖️5 QD
214429472|NCT06434402|BEHAVIORAL|Behavioral Intervention|Write about cancer experiences
214429473|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
214429474|NCT03215095|DRUG|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
214429475|NCT03215095|RADIATION|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
214429476|NCT05869890|DEVICE|MOSES laser system|A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
214429477|NCT04617314|DRUG|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
214429478|NCT04548024|DEVICE|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
214429479|NCT00304031|DRUG|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
214429480|NCT00304031|RADIATION|Concurrent radiation therapy|60 Gy in 2 Gy fractions
214429481|NCT00304031|DRUG|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
214429482|NCT00304031|DRUG|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
214429483|NCT06530758|OTHER|Altered ASRS format, without shading and with grouping|Participants will be asked to complete the ASRS form without shading and with grouping.
214429484|NCT06530758|OTHER|Altered ASRS format, with shading and without grouping|Participants will be asked to complete the ASRS form with shading and without grouping.
214429485|NCT06530758|OTHER|Altered ASRS format, without shading and without grouping|Participants will be asked to complete the ASRS form without shading and without grouping.
214429486|NCT06548607|DRUG|RD06-04 or RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
214429487|NCT06222567|DEVICE|15 minutes pumping with INITIATE program|15 minutes pumping with INITIATE program
214512886|NCT01379885|BEHAVIORAL|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
214512887|NCT01379885|BEHAVIORAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
214512888|NCT01097811|DRUG|Erythromycin|250 mg orally q.i.d.
214512889|NCT01097811|DRUG|Neomycin|1 g orally q.i.d.
214512890|NCT00505427|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|
214512891|NCT03924362|PROCEDURE|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
215113875|NCT06876233|BEHAVIORAL|Wellth App|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
215113876|NCT06876233|BEHAVIORAL|Action Planning|"Participants will learn about habits and the importance of contextual cues for triggering their AH pill taking, and be asked to complete an electronic worksheet with a detailed description of their personalized contextual cue in terms of its: 1) location (e.g., where in the participant's house or office does this cue occur); 2) time of day; 3) preceding action (e.g., I usually go to the bathroom before making coffee); and 4) a visual cue (e.g., my coffee cup will trigger pill taking)."
214429488|NCT06222567|DEVICE|5 minutes extra pumping with MAINTAIN program|Additional 5 minutes extra pumping with MAINTAIN program
214429489|NCT06439017|OTHER|Questionaire|The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
214512892|NCT04927507|BEHAVIORAL|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
214512893|NCT01662388|DEVICE|Separation ring|Separation ring placed along with automatrix band
214512894|NCT01662388|DEVICE|automatrix band|band placed with a tightening device
214512895|NCT01736488|DRUG|Fimasartan|Fimasartan 60mg
214512896|NCT01736488|DRUG|Atenolol|Atenolol 50mg
214512897|NCT02855762|OTHER|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
214512898|NCT02469025|OTHER|Manual caudal traction mobilization in resting position|
214512899|NCT02469025|OTHER|Manual caudal traction mobilization in end range position|
214429490|NCT06455826|DRUG|VP-001|A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
214429491|NCT04701307|BIOLOGICAL|Dostarlimab|Given IV
214429492|NCT04701307|DRUG|Niraparib|Given PO
214429493|NCT03048279|BEHAVIORAL|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
214512900|NCT02469025|OTHER|Selftreatment|Each subject is advice to do some exercises at home
214512901|NCT03076853|OTHER|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
214512902|NCT03691441|PROCEDURE|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
214512903|NCT03691441|RADIATION|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
214512904|NCT03691441|DRUG|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
214512905|NCT03691441|PROCEDURE|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
214512906|NCT01856062|DRUG|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
214512907|NCT01856062|DRUG|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
214512908|NCT02410278|DRUG|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
214512909|NCT02410278|DRUG|montelukast|As described in the treatment arm
214512910|NCT02410278|DRUG|Placebo|Matched placebo
214429494|NCT06506045|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of known non-functional and functional implanted shunts will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
215113877|NCT06876233|BEHAVIORAL|Wellth + Cue|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in (plus evidence of their contextual cue) within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
215113878|NCT06725979|DEVICE|maxillary expansion using hyrax expander|The rapid expansion of the upper jaw will be performed using palatal expander with hyrax screw, which will be activated 2x a day, until the needed width is reached (according to the cast analysis).
215113879|NCT06726746|DEVICE|Fractional CO2 laser|". Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic."
215113880|NCT06720090|BEHAVIORAL|Light therapy|5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
215113881|NCT05747027|PROCEDURE|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
214429495|NCT04527822|OTHER|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
214429496|NCT02803801|BEHAVIORAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
214429497|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
214429498|NCT04391101|DRUG|Convalescent plasma|400-500ml convalescent plasma
214429499|NCT01188655|DRUG|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
214429500|NCT01555099|DRUG|AZD5423|oral inhaled
214429501|NCT01555099|DRUG|Budesonide|oral inhaled
214429502|NCT01555099|DRUG|Placebo|oral inhaled
214429503|NCT04241354|BIOLOGICAL|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
215113882|NCT05747027|PROCEDURE|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
214429504|NCT04425668|BEHAVIORAL|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
214429505|NCT04425668|OTHER|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
214429506|NCT05721105|OTHER|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
214429507|NCT02326987|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
214429508|NCT02326987|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
214429509|NCT01277250|BEHAVIORAL|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
214512911|NCT02499094|OTHER|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
214429510|NCT00897169|OTHER|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
214429511|NCT00897169|OTHER|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
214429512|NCT01402479|DRUG|Ramipril|ramipril 2.5mg twice a day
214429513|NCT02703246|PROCEDURE|abdominal morcellation|patients will be randomized to receive abdominal morcellation
214429514|NCT02703246|PROCEDURE|vaginal morcellation|patients will be randomized to receive vaginal morcellation
214429515|NCT03059394|DEVICE|Non intervention study|Test - Retest of measurements
214429516|NCT00027729|BIOLOGICAL|etaracizumab|
214429517|NCT03022994|OTHER|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
214429518|NCT03368768|OTHER|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
214429519|NCT04565028|BEHAVIORAL|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
214429520|NCT05869123|RADIATION|Online adaptive radiotherapy|PTV with 5 margins covers CTV
214429521|NCT05915546|DRUG|Emraclidine|Tablets
214429522|NCT05012241|DIAGNOSTIC_TEST|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
214429523|NCT00798642|BEHAVIORAL|Hypnotherapy|8 weeks of gut-directed hypnotherapy
214429524|NCT00798642|BEHAVIORAL|Standard care|8 weeks of standard of care
214429525|NCT00798642|BEHAVIORAL|Mind Body Therapy|8 weeks of mind-body therapy
214429526|NCT05083728|DIAGNOSTIC_TEST|CT|Clinicians are free to choose the adult subjects in whom a non-contrast calibrated CT-scan will be performed as a part of routine clinical care. The decision to order a noncontrast CT-scan of the shoulder must be made prior to, and independently from, the decision to enroll the patient.
214429527|NCT04780035|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
214512912|NCT05548049|DEVICE|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
215113883|NCT07051850|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
215113884|NCT07051850|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
215113885|NCT07051850|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
215113886|NCT07051850|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
214429528|NCT04780035|OTHER|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
214429529|NCT02198469|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
214429530|NCT02198469|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
214429531|NCT00412308|PROCEDURE|Tidal volume used in mechanical ventilation|
214429532|NCT00000994|DRUG|Zidovudine|
214429533|NCT04044807|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
214429534|NCT03791892|OTHER|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
214429535|NCT03791892|OTHER|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
214429536|NCT02135679|RADIATION|Radiotherapy|
214429537|NCT04112069|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
214429538|NCT04112069|OTHER|Usual Care|Usual care
214429539|NCT00306397|DRUG|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
215113887|NCT07051850|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
215113888|NCT07051850|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
214429540|NCT01875848|DRUG|buprenorphine/naloxone|partial opioid agonist
215113889|NCT06456580|BIOLOGICAL|Telitacicept|Subcutaneous injection
214429541|NCT01875848|DRUG|opioid dose escalation|up to 25% increase in patient's current opioid dose
214429542|NCT01782170|DRUG|Iocide Oral Rinse|
214429543|NCT01782170|DRUG|Placebo|
214429544|NCT00006368|RADIATION|yttrium Y 90-edotreotide|
214429545|NCT06285149|DRUG|Icaritin|This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
214429546|NCT01186159|DRUG|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
214429547|NCT02189252|DRUG|Epanova|
214429548|NCT02189252|DRUG|Lovaza|
214429549|NCT00973115|DRUG|Simvastatin CR|
214429550|NCT00864552|DRUG|Kogenate (BAY14-2222)|Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
214429551|NCT02872480|OTHER|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
214429552|NCT03941119|OTHER|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
214429553|NCT00526006|DRUG|esomeprazole|40 mg od for 8 wks
214429554|NCT00840177|DRUG|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
214429555|NCT00840177|DRUG|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
214429556|NCT00840177|DRUG|pravastatin sodium|1,280 mg/day given orally on days 1-8
214429557|NCT01391832|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
214429558|NCT01391832|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
214512913|NCT05548049|DEVICE|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
214512914|NCT01144533|PROCEDURE|isotonic saline injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
215113890|NCT06456580|DRUG|Placebo|Subcutaneous injection
215113891|NCT07059663|OTHER|Schroth Method with Core Stabilization Exercises|The Schroth method will focus on postural correction techniques aimed at improving spinal alignment, reducing the curvature of the spine, and enhancing trunk control. Key exercises will include spinal elongation, de-rotation, and specific breathing techniques to help reduce the scoliotic curve. Core stabilization exercises will target the deep trunk muscles, such as the transversus abdominis and multifidus, to improve spinal stability. These exercises will involve bodyweight exercises, resistance bands, and stability balls, aimed at increasing muscle endurance and promoting better posture. The interventions will be performed three times a week for 10 weeks, with each session lasting 60 minutes
214429559|NCT01391832|DEVICE|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
214429560|NCT03618524|OTHER|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
214429561|NCT04787653|DEVICE|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
214429562|NCT04787653|DEVICE|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
214429563|NCT05052450|OTHER|Observational|Patients data were collected throughout the following time
214512915|NCT01144533|PROCEDURE|steroid injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
214512916|NCT01144533|PROCEDURE|sodium hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
214512917|NCT01144533|PROCEDURE|steroid and hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
214512918|NCT00201825|DRUG|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
214512919|NCT00201825|DRUG|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
214512920|NCT03695185|DRUG|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
214429564|NCT01154985|DRUG|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
214429565|NCT01154985|DRUG|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
214512921|NCT03695185|DRUG|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
214512922|NCT00738348|DRUG|sivelstat|sivelstat sodiumhydrate
214512923|NCT00738348|DRUG|glucose|glucose
214512924|NCT01106885|BEHAVIORAL|Medication Care Management (MCM)|"* Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
214512925|NCT01106885|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"* Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each"
214512926|NCT05962099|BEHAVIORAL|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
214512927|NCT05919732|DRUG|Bupivacaine, Dexmedetomidine, Caffeine, Tylenol|bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
214512928|NCT05919732|DRUG|Propofol, rocuronium, caffeine, Tylenol, bupivacaine|"propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)"
214512929|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
215113892|NCT07059663|OTHER|Schroth Method|The control group will receive the Schroth method alone, focusing solely on postural correction exercises. These exercises will aim to improve spinal alignment, reduce curvature, and enhance postural control through spinal elongation, de-rotation, and specific breathing techniques designed to address the scoliosis. The control group will not receive any core stabilization exercises in addition to the Schroth method. This intervention will also be performed three times a week for 10 weeks, with each session lasting 60 minutes
215113893|NCT06811922|BEHAVIORAL|GBE (Ghya Bharaari Ekatra) intervention|"Ghya Bharaari Ekatra (Marathi for Take a flight together) intervention~The intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of sessions are 2 hours.~GBE will be delivered to a total of 500 dyads."
214512930|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214512931|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214429566|NCT01154985|DRUG|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
214512932|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214512933|NCT06275841|DRUG|vepdegestrant|experimental
214512934|NCT06275841|DRUG|esomeprazole|Experimental treatment to assess an endpoint
215113894|NCT06811922|BEHAVIORAL|Ethical standard of care|Ethical standard of care includes information on IPV and mental and reproductive/sexual health resources) to prevent IPV experience. This intervention will be delivered to a total of 350 dyads.
215113895|NCT07066592|BEHAVIORAL|Prehabilitation education provided via mobile compatible website|The prehabilitation education delivered through a mobile-compatible website was developed specifically for patients who are candidates for stem cell transplantation. Through this platform, patients can easily and quickly access accurate information on managing potential symptoms during the transplant process, as well as guidance on nutrition and exercise aimed at improving their quality of life.
214429567|NCT04803409|DEVICE|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
214429568|NCT04949503|DRUG|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
214429569|NCT03815136|OTHER|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
214429570|NCT03815136|OTHER|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
214429571|NCT02711436|DEVICE|Computed Tomography Scan|
214429572|NCT02711436|DEVICE|Fast Magnetic Resonance Imaging|
214429573|NCT03345901|DRUG|Pemafibrate|0.2 mg orally BID - twice daily
214429574|NCT03345901|DRUG|Placebo|orally BID - twice daily
214429575|NCT01696916|PROCEDURE|6-minute walking test|submaximum exercise test
214429576|NCT00722046|BIOLOGICAL|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
214512935|NCT01884207|OTHER|MRI|
214512936|NCT06432023|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diagnostic and research scanning using magnetic resonance imaging.
214512937|NCT03823690|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
214512938|NCT03823690|DEVICE|The pyloro-duodenal stent|As listed in the arms description
214512939|NCT02066155|BEHAVIORAL|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
214512940|NCT02066155|BEHAVIORAL|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
214512941|NCT02137785|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
214512942|NCT02137785|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
214512943|NCT02137785|DEVICE|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
214512944|NCT02584257|OTHER|methacholine chloride|
214512945|NCT02584257|DRUG|placebo ProAir HFA|
214512946|NCT02584257|DRUG|ProAir HFA|
215113896|NCT07064720|DRUG|Dexmedetomidine with Mannitol|receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
214512947|NCT02584257|DRUG|Lupin albuterol HFA MDI|
214512948|NCT02584257|DRUG|placebo Lupin albuterol HFA MDI|
214512949|NCT03477799|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
215113897|NCT07064720|DRUG|Mannitol (20%)|receive 0.5 g/kg of mannitol
215113898|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 14 G Needle|Each participant underwent Percutaneous Tru-cut Biopsy with 14G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
214429577|NCT00722046|BIOLOGICAL|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
214429578|NCT00722046|BIOLOGICAL|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
214429579|NCT00722046|DRUG|Placebo|Placebo every 60 days (10 doses total)
214429580|NCT00722046|BIOLOGICAL|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
214429581|NCT00722046|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
214429582|NCT05514275|DRUG|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
214429583|NCT05107024|DEVICE|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
214429584|NCT05107024|DEVICE|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
214429585|NCT03822520|DRUG|Celecoxib|Celecoxib 400mg capsule
214429586|NCT03822520|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet
214429587|NCT03822520|OTHER|Water|Pure water 150ml
214429588|NCT05602285|DEVICE|Dislodgement device|Breakaway device that prevents IV dislodgement
214429589|NCT06524973|OTHER|Telemedicine|Attend telehealth self-management coaching sessions
214429590|NCT06524973|OTHER|Counseling|Attend telehealth self-management coaching sessions
214429591|NCT06524973|OTHER|Best Practice|Receive standard of care
214429592|NCT06524973|OTHER|Questionnaire Administration|Ancillary studies
214429593|NCT06524973|OTHER|Inrweview|Ancillary studies
214429594|NCT04897945|BEHAVIORAL|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
214429595|NCT00445952|OTHER|clinical observation|
214429596|NCT00445952|PROCEDURE|management of therapy complications|
214429597|NCT06553053|OTHER|"Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
214429598|NCT06553053|OTHER|"Nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
214512950|NCT05293093|OTHER|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
214512951|NCT01670877|DRUG|Neratinib|
214512952|NCT01670877|DRUG|Fulvestrant|
214512953|NCT01670877|DRUG|Trastuzumab|
214512954|NCT01670877|PROCEDURE|Tumor biopsy|-Optional at baseline and disease progression
214512955|NCT01670877|PROCEDURE|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
214512956|NCT06354725|OTHER|Plyometric|Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
214512957|NCT05658900|OTHER|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
214512958|NCT05658900|OTHER|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
214512959|NCT02464215|PROCEDURE|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
215113899|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 16G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 16 tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
215113900|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 18G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 18G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
215113901|NCT07066618|BEHAVIORAL|Breakfast-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 50% of daily energy intake was provided at breakfast, 35% at lunch, and 15% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
214429599|NCT02368626|DEVICE|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
214429600|NCT02089763|BIOLOGICAL|pegylated recombinant human arginase|
214429601|NCT02164240|DRUG|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
214429602|NCT02164240|DRUG|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
214429603|NCT04938752|DRUG|DA-2811|single dose administration (one tablet once a day)
214429604|NCT04938752|DRUG|DA-2811-R|single dose administration (one tablet once a day)
214429605|NCT03348722|OTHER|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
214429606|NCT03348722|PROCEDURE|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
214429607|NCT03348722|RADIATION|Radiotherapy|External radical radiotherapy or brachitherapy
214429608|NCT03348722|PROCEDURE|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
214429609|NCT05959590|DRUG|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
214429610|NCT04296019|DRUG|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
214429611|NCT05455424|DRUG|Niraparib Oral Product|Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
214429612|NCT05455424|OTHER|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
214429613|NCT06338241|COMBINATION_PRODUCT|Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin|The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.
214429614|NCT06338241|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
214429615|NCT04979299|OTHER|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
214512960|NCT02464215|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
214512961|NCT01420198|BEHAVIORAL|Lifestyle intervention|Increased physical activity and improved food habits
214429616|NCT02843217|BEHAVIORAL|Lifestyle, screening|
214429617|NCT05519813|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
214429618|NCT05519813|DRUG|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
214429619|NCT00200213|BEHAVIORAL|portion or unportioned food|
214429620|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
214429621|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
214429622|NCT01519752|DRUG|Placebo|Placebo applied to affected area once a day for 28 days
214429623|NCT03737591|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
214429624|NCT00686855|DRUG|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
214429625|NCT00686855|DRUG|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
214429626|NCT02961569|PROCEDURE|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
214512962|NCT05509881|DEVICE|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
214512963|NCT05509881|DEVICE|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
215113902|NCT07066618|BEHAVIORAL|Dinner-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 15% of daily energy intake was provided at breakfast, 35% at lunch, and 50% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
215113903|NCT07065916|BEHAVIORAL|Modified Constraint Induced Movement Therapy|Constraint Induced Movement Therapy and Bimanual Therapy
214429627|NCT00085436|BIOLOGICAL|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
214429628|NCT00085436|BIOLOGICAL|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
214429629|NCT00085436|BIOLOGICAL|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
214429630|NCT04773327|OTHER|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
214429631|NCT05340114|DEVICE|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
214429632|NCT06124066|DRUG|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
214429633|NCT04038814|PROCEDURE|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
214429634|NCT04038814|PROCEDURE|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage"
214429635|NCT01668940|OTHER|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
214429636|NCT01668940|OTHER|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
214512964|NCT03659942|OTHER|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
214512965|NCT03132909|OTHER|Feelings Determination|Determine the feelings of doctors caring for their colleagues
214512966|NCT01223014|DRUG|AZD2423|AZD2423
214512967|NCT05104684|OTHER|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
214512968|NCT05104684|OTHER|routine medical treatment|medical treatment
214512969|NCT01308879|BEHAVIORAL|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
214512970|NCT00558441|DEVICE|IVMRI|Intra Vascular Magnetic Resonance Imaging
214512971|NCT04432155|DRUG|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
214512972|NCT04432155|DRUG|Placebo|30% oxygen, and 70% nitrogen
214512973|NCT01064609|PROCEDURE|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
214512974|NCT01064609|PROCEDURE|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
214512975|NCT03390166|BIOLOGICAL|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
214512976|NCT03390166|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
214512977|NCT00268697|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
214429637|NCT01668940|OTHER|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
214429638|NCT03555214|OTHER|Manual Therapy based on soft tissues|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique."
214512978|NCT00268697|DRUG|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
214512979|NCT00268697|DRUG|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
214512980|NCT03125148|DEVICE|Enteral stenting|Enteral stent for malignant duodenal obstruction
214512981|NCT06404736|DRUG|Bispecific antibody (bsAb) targeting PD-1 and CLTA-4|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
214429639|NCT03555214|OTHER|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
214429640|NCT03555214|OTHER|Manual Therapy based on structural techniques|"Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique."
214429641|NCT03555214|OTHER|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique."
214429642|NCT02731755|OTHER|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
214429643|NCT02731755|OTHER|Control|60g cream of rice
214429644|NCT04423146|OTHER|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
214512982|NCT06404736|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
214429645|NCT01951508|DRUG|Methylphenidate|60mg per os, single dose
214512983|NCT06404736|DRUG|Carboplatin|Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
214512984|NCT01500070|DEVICE|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
214512985|NCT00689416|DRUG|rosuvastatin|40 mg, tablet, once daily for 3 months.
215113904|NCT07065435|DRUG|Disitamab Vedotin (RC48)|A HER2-targeted antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via a cathepsin-cleavable MC-VC-PAB linker to the microtubule inhibitor MMAE (drug-to-antibody ratio ≈4). Administered intravenously at 2.0 mg/kg every 2 weeks.
214429646|NCT01951508|DRUG|Modafinil|600mg per os, single dose
214429647|NCT01951508|DRUG|MDMA|125mg per os, single dose
214512986|NCT00689416|DRUG|placebo|40 mg, tablet, once daily for 3 months
214512987|NCT01684540|OTHER|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
214429648|NCT01951508|DRUG|Placebo|per os
214512988|NCT01684540|DRUG|Sinupret forte|
214512989|NCT00457834|DEVICE|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
214512990|NCT01577875|DEVICE|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
214512991|NCT04251325|OTHER|Basic Life Support Courses|4 hours basic life support courses for laypersons
214512992|NCT00576550|DRUG|Urea|Urea cream applied twice daily up to six months
214512993|NCT00576550|DRUG|betamethasone valerate|Application once daily for two weeks
214512994|NCT00576550|DRUG|betamethasone valerate|Application twice daily for two weeks
214512995|NCT06498323|DRUG|tenecteplase|Intravenous thrombolytic agents administration
214429649|NCT02250235|OTHER|Health risk information|
214429650|NCT06320912|DEVICE|The intraparenchymal portal vein covered stent|The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
214429651|NCT06320912|DEVICE|TIPS Covered Stent System GORE|The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
214512996|NCT00950456|BIOLOGICAL|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
214512997|NCT02602548|OTHER|Culture|Specimens will be obtained and sent to the lab for cultures.
214512998|NCT04760028|PROCEDURE|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
214512999|NCT01762839|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
214513000|NCT01762839|DRUG|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
214513001|NCT01762839|DRUG|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
214513002|NCT02763657|OTHER|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
214513003|NCT00500604|DRUG|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
214513004|NCT00500604|DRUG|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
214513005|NCT00500604|DRUG|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
214513006|NCT00547326|PROCEDURE|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
214513007|NCT00547326|PROCEDURE|Treatment with placebo|Treatment with placebo
214513008|NCT00648466|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
214513009|NCT00648466|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fasting
214513010|NCT03921775|DRUG|Remimazolam Tosilate|For induction and maintenance of general anesthesia
214513011|NCT03921775|DRUG|Propofol|For induction and maintenance of general anesthesia
214513012|NCT00020527|DRUG|caspofungin acetate|
214513013|NCT01933945|PROCEDURE|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
214429652|NCT03508518|OTHER|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
214513014|NCT01933945|DRUG|Sorafenib (Nexavar, BAY43-9006)|
214513015|NCT03693989|DRUG|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
214513016|NCT03693989|DRUG|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~\- Route of administration: topical ophthalmic"
214513017|NCT03956927|OTHER|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
214513018|NCT03956927|OTHER|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
214513019|NCT02418065|OTHER|training on ergonomic bicycle|
214513020|NCT02418065|DRUG|Testosterone|
214513021|NCT02418065|DRUG|Oral nutritional supplementation|
215113905|NCT07065435|DRUG|Bevacizumab|A recombinant humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. Administered intravenously at 7.5 mg/kg every 2 weeks in combination with RC48.
214513022|NCT02418065|DRUG|n3 polyunsaturated fatty acid|
214513023|NCT00457314|BEHAVIORAL|Exercise|Regular exercise training
214513024|NCT03575494|OTHER|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
214513025|NCT01073722|DEVICE|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
214513026|NCT01073722|DEVICE|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
214513027|NCT05649891|OTHER|Emergency Manual|Collection of crisis checklists and fact sheets
214513028|NCT01381445|DRUG|GW870086 0.2%|White to slightly coloured opaque cream
214513029|NCT01381445|DRUG|GW870086 2%|White to slightly coloured opaque cream
214513030|NCT01381445|DRUG|Clobetasol Propionate|White cream
214513031|NCT01381445|DRUG|Placebo|White to slightly coloured opaque cream
214513032|NCT01017159|DRUG|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
214513033|NCT05100511|DEVICE|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
214429653|NCT03508518|OTHER|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
214429654|NCT03019614|DRUG|Hydrocortisone|Generic hydrocortisone
214513034|NCT05100511|DEVICE|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
214513035|NCT02939742|DRUG|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
215113906|NCT07065435|DRUG|Pyrotinib|An irreversible pan-HER tyrosine kinase inhibitor targeting HER1, HER2, and HER4, inhibiting downstream PI3K/Akt and MAPK signaling. Administered orally at 320 mg once daily (post-meal) in combination with RC48.
214429655|NCT03019614|DRUG|Chronocort|Modified formulation of hydrocortisone
214513036|NCT02939742|DRUG|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
214513037|NCT04489914|DEVICE|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
214513038|NCT00187356|PROCEDURE|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
214513039|NCT00113529|DRUG|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
214513040|NCT02304445|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
214513041|NCT02304445|RADIATION|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
214513042|NCT00309673|DRUG|lidocaine / Prilocaine|
214513043|NCT01553617|DRUG|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
214513044|NCT01553617|DRUG|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
214513045|NCT00787475|OTHER|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
215113907|NCT07065578|OTHER|STAR condition 1|"* Basic module: HF information and doing symptom awareness exercises.~* Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse~* Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse~* Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse"
214513046|NCT04478552|PROCEDURE|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
214513047|NCT04478552|PROCEDURE|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
214513048|NCT03001635|DRUG|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
214513049|NCT03001635|DRUG|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
214513050|NCT01411605|BEHAVIORAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
214513051|NCT04184271|DRUG|38% silver diamine fluoride|Topical application of SDF to teeth
214429656|NCT04616963|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
214513052|NCT03315195|DIETARY_SUPPLEMENT|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
214513053|NCT06100354|OTHER|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
214513054|NCT04505215|OTHER|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
214513055|NCT04505215|OTHER|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
214429657|NCT04616963|DRUG|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
214429658|NCT05849311|DRUG|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
214429659|NCT05849311|DRUG|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
214429660|NCT02655588|BEHAVIORAL|Interactive Media-Based Problems Solving Treatment|
214429661|NCT02726828|DRUG|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
214429662|NCT02726828|DRUG|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
214429663|NCT02726828|DRUG|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
214429664|NCT03157401|DRUG|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
214429665|NCT03157401|DRUG|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
214429666|NCT03157401|DRUG|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
214429667|NCT03356223|DRUG|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
214429668|NCT05573334|DEVICE|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
214429669|NCT03209778|OTHER|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
214429670|NCT04730362|DEVICE|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
214429671|NCT04730362|DEVICE|supraglottic airway|supraglottic airway
214429672|NCT04730362|DRUG|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
214513056|NCT04505215|OTHER|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
214692475|NCT05630404|DRUG|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
214692476|NCT05261672|DRUG|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
214692477|NCT05261672|DRUG|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
214692478|NCT05199350|OTHER|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
214429673|NCT02925351|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214429674|NCT02925351|RADIATION|Fluorine F 18 Clofarabine|Given IV
214429675|NCT02925351|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214429676|NCT05355623|PROCEDURE|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
214429677|NCT02205853|OTHER|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
214429678|NCT02205853|OTHER|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
214429679|NCT04586309|BEHAVIORAL|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~1. Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~2. Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~3. First Day of Verification of Correct Practice and Further Instruction.~4. Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~5. Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
214429680|NCT03388281|OTHER|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
214429681|NCT03999671|OTHER|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
214429682|NCT03999671|OTHER|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
214429683|NCT02628171|OTHER|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
214429684|NCT02628171|OTHER|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
214429685|NCT03524534|OTHER|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
214513057|NCT03605147|DIETARY_SUPPLEMENT|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
214513058|NCT03605147|DIETARY_SUPPLEMENT|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
214513059|NCT04371029|OTHER|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
214513060|NCT00004400|DRUG|testosterone|
214513061|NCT05739409|BIOLOGICAL|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
214513062|NCT05258929|OTHER|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
214429686|NCT03524534|OTHER|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
214513063|NCT02825550|DEVICE|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
214513064|NCT03989609|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
214513065|NCT03989609|DRUG|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
214513066|NCT03425500|PROCEDURE|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
215113908|NCT07065578|OTHER|STAR condition 2|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
214513067|NCT03425500|PROCEDURE|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
214513068|NCT03425500|DEVICE|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
214513069|NCT01505309|DEVICE|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
214429687|NCT04125433|BEHAVIORAL|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
214429688|NCT04574349|PROCEDURE|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
214429689|NCT01292252|BIOLOGICAL|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
214429690|NCT01292252|BIOLOGICAL|Placebo|Saline solution
214429691|NCT05517616|DRUG|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
214429692|NCT04178239|DIAGNOSTIC_TEST|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
214513070|NCT02082639|BIOLOGICAL|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
214429693|NCT02071836|BEHAVIORAL|Right Turns web application|
214429694|NCT02071836|BEHAVIORAL|Treatment as usual|
214429695|NCT05762159|OTHER|data collected|"data collected:~* Morphological data of the patients~* Data of the erector block realization~* Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
214429696|NCT04521530|OTHER|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
214429697|NCT04521530|OTHER|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
214429698|NCT00414544|DEVICE|CosmetaLife|Dermal filler
214429699|NCT00414544|DEVICE|Restylane|Dermal filler
214429700|NCT01267383|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
215113909|NCT07065578|OTHER|STAR condition 3|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
214429701|NCT01888848|DIETARY_SUPPLEMENT|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
214513071|NCT02082639|BIOLOGICAL|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
214513072|NCT00042939|BIOLOGICAL|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
214513073|NCT00042939|DRUG|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
214513074|NCT00042939|DRUG|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
214429702|NCT01888848|DIETARY_SUPPLEMENT|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
214513075|NCT01308099|DEVICE|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
214513076|NCT03518450|PROCEDURE|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
214513077|NCT03518450|PROCEDURE|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
214513078|NCT03518450|PROCEDURE|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
214513079|NCT00795639|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
214513080|NCT00795639|DRUG|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
214513081|NCT01159314|PROCEDURE|Baerveldt Device surgical Procedure|Implant surgery
214513082|NCT03122444|DRUG|Imipramine|Imipramine will be given daily for 21-30 days.
214513083|NCT01074996|DRUG|S-1|40-60mg bid , days 1-14, every 3 weeks
214429703|NCT06006949|DRUG|Roxadustat|Roxadustat (150 mgqod)
214429704|NCT06006949|DRUG|Luspatercept|Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg)
214429705|NCT03960606|COMBINATION_PRODUCT|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
214429706|NCT03960606|COMBINATION_PRODUCT|Placebo|PUR1900 placebo
214429707|NCT00373386|DRUG|growth hormone|Growth Hormone treatment
214429708|NCT03875040|BEHAVIORAL|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
214429709|NCT04414995|DRUG|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
214429710|NCT04414995|DRUG|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
214429711|NCT04414995|DRUG|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
214429712|NCT00799396|DRUG|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
214429713|NCT00799396|DRUG|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
214429714|NCT01556724|DRUG|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
214429715|NCT02190097|OTHER|Paleolithic diet|see procedures section for more details
214429716|NCT02190097|OTHER|American Diabetes Association diet|see procedures section
214429717|NCT01318382|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
214429718|NCT01867216|DRUG|Placebo|Administered orally as capsules
214429719|NCT01867216|DRUG|LY2922470|Administered orally as capsules
214513084|NCT01074996|DRUG|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
214513085|NCT03846817|OTHER|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
215113910|NCT07065578|OTHER|STAR condition 4|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
215113911|NCT07065578|OTHER|STAR condition 5|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; written feedback HF nurse
214429720|NCT05512182|DRUG|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
214429721|NCT02772263|OTHER|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
214429722|NCT01599104|DRUG|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
214429723|NCT01599104|DRUG|Olmesartan|Olmesartan 20 mg capsule one daily
214429724|NCT01599104|DRUG|Placebo|Placebo to LCZ696 or Olmesartan
214429725|NCT03396146|OTHER|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
214429726|NCT03396146|OTHER|Fecal sample|Fecal sample at inclusion
214513086|NCT00798837|RADIATION|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
214513087|NCT02525744|DRUG|LY900014|Administered SC
214513088|NCT02525744|DRUG|Insulin Lispro (Humalog)|Administered SC
214513089|NCT04631874|DRUG|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
214513090|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
214513091|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
214429727|NCT02639091|DRUG|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
214429728|NCT02639091|DRUG|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
214429729|NCT02639091|DRUG|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
214429730|NCT01317446|DRUG|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
214429731|NCT00019747|DRUG|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
214429732|NCT00019747|PROCEDURE|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
214429733|NCT00019747|OTHER|Placebo|oral placebo once daily
214429734|NCT02461264|DRUG|Single red blood packed cells Transfusion|
214429735|NCT02461264|DRUG|Two packed red blood cells Transfusion|
214429736|NCT04479865|DRUG|Aricept 5mg Tablet|1 tablet once daily
214429737|NCT04479865|DRUG|Aricept 10mg Tablet|1 tablet once daily
214429738|NCT04479865|DRUG|DA-5207 150mg|1 patch once weekly
214429739|NCT04479865|DRUG|DA-5207 170mg|1 patch once weekly
214429740|NCT00073684|BEHAVIORAL|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
214429741|NCT00073684|BEHAVIORAL|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
214429742|NCT00073684|BEHAVIORAL|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
214429743|NCT00073684|BEHAVIORAL|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
214429744|NCT00073684|BEHAVIORAL|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
215113912|NCT07065578|OTHER|STAR condition 6|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
214429745|NCT00714714|DRUG|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
214429746|NCT00714714|DRUG|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
214429747|NCT04701879|OTHER|Spine decompression with core stability exercises|"* 50 minutes per session~* Decompression with core stability on alternate days for 8 visits."
215113913|NCT07065578|OTHER|STAR condition 7|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
214429748|NCT04701879|OTHER|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
214429749|NCT01925469|DRUG|Benzocaine|
214429750|NCT01925469|DRUG|Saline spray|A saline spray will be used in the placebo group
214429751|NCT00091650|DRUG|Olanzapine|
214429752|NCT00091650|DRUG|placebo|
214429753|NCT02313363|DEVICE|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
214429754|NCT06435637|DIETARY_SUPPLEMENT|Collagen protein|Ingestion of 40, 20, 20 and 20 gram of collagen protein right after and every 2 hours after a bout of exercise
214429755|NCT06435637|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
214429756|NCT01853410|DEVICE|gekoTM|
214429757|NCT02467946|DRUG|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
214429758|NCT02377726|BEHAVIORAL|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
214429759|NCT02377726|BEHAVIORAL|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
214429760|NCT02377726|BEHAVIORAL|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
214429761|NCT00269789|DRUG|Ritalin|
214429762|NCT00269789|DRUG|OROS Methylphenidate HCl|
214429763|NCT00269789|DRUG|Placebo|
214429764|NCT02780440|BEHAVIORAL|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
214429765|NCT02780440|BEHAVIORAL|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
214429766|NCT02780440|BEHAVIORAL|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
214429767|NCT05662449|DEVICE|Syndesmosis fixation using Activascrew|as described prior
214429768|NCT04933526|DRUG|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
214429769|NCT04933526|DRUG|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
214429770|NCT02382328|DRUG|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
214429771|NCT02382328|DRUG|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
214429772|NCT00773370|BEHAVIORAL|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
214429773|NCT00773370|BEHAVIORAL|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
214429774|NCT03797924|DRUG|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
214429775|NCT03797924|BEHAVIORAL|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
214429776|NCT01801514|DEVICE|Computed Tomography scan|Routine Computed Tomography scan
214429777|NCT06155877|BEHAVIORAL|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
214429778|NCT06155877|BEHAVIORAL|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
214429779|NCT00693121|DRUG|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
214429780|NCT00693121|DRUG|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
214429781|NCT00226772|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
214429782|NCT00226772|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
214429783|NCT05284565|DEVICE|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
214429784|NCT00947635|DIETARY_SUPPLEMENT|Dietary intervention - supplements|Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
214429785|NCT01914913|BIOLOGICAL|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
214429786|NCT04544904|DEVICE|PAARx|Prescription Physical Activity Programming Application
214429787|NCT04544904|DEVICE|JM|Joint Management (JM) web-based joint management resource.
214429788|NCT06408493|BEHAVIORAL|MYCardio-PEER|MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
214513092|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
214513093|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
214513094|NCT02938286|DEVICE|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
214513095|NCT02938286|DRUG|AHES|Topical application at test region I-IV under occlusion for 15 minutes
214513096|NCT00346359|BIOLOGICAL|anti-thymocyte globulin|
214513097|NCT00346359|DRUG|busulfan|
214513098|NCT00346359|DRUG|fludarabine phosphate|
214513099|NCT00346359|DRUG|methotrexate|
214513100|NCT00346359|DRUG|tacrolimus|
214513101|NCT00346359|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214429789|NCT03677349|PROCEDURE|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
214513102|NCT00346359|PROCEDURE|peripheral blood stem cell transplantation|
215113914|NCT07065578|OTHER|STAR condition 8|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
215113915|NCT07066007|BEHAVIORAL|First Aid Education Programme|A six-module behavioral education program for parents, designed to improve first aid knowledge, application skills, and self-efficacy. Delivered face-to-face in three 120-minute sessions using theoretical lectures, demonstrations, and case-based simulations.
214429790|NCT06361953|DEVICE|EEG Neurofeedback|neurofeedback training over five weeks, comprising 15 sessions. Each neurofeedback training session lasted 30 minutes.
214429791|NCT03573518|DRUG|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
214429792|NCT03573518|DRUG|Vehicle|Placebo
214429793|NCT06100458|OTHER|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
214429794|NCT03200626|PROCEDURE|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
214429795|NCT06103149|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
214429796|NCT02823938|OTHER|existing database on data collection.|This is an observational study on an existing database.
214429797|NCT01308567|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
214429798|NCT01308567|DRUG|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
214429799|NCT01308567|DRUG|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
214429800|NCT00493350|PROCEDURE|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
214429801|NCT03595852|DRUG|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
214429802|NCT03595852|DRUG|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
214429803|NCT06349655|DRUG|Azvudine|Antiviral drug
214429804|NCT06349655|DRUG|Paxlovid|Antiviral drug
214429805|NCT00382681|DEVICE|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
214429806|NCT00382681|DEVICE|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
214429807|NCT01714492|DEVICE|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
214429808|NCT05391464|PROCEDURE|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
214429809|NCT01153880|DRUG|Retapamulin|Prescription sales claim of retapamulin
214429810|NCT01153880|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
214429811|NCT05481242|OTHER|retrospective observational study|retrospective observational study
214429812|NCT05863481|PROCEDURE|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
214429813|NCT04108923|DEVICE|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
214429814|NCT04108923|PROCEDURE|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
214429815|NCT01437605|DRUG|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
214429816|NCT01437605|DRUG|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
214429817|NCT01112670|DRUG|Sitagliptin|sitagliptin 100 mg x 1 dose
214429818|NCT01112670|DRUG|atorvastatin|atorvastatin 40 mg x 5 doses
214429819|NCT03973892|DIAGNOSTIC_TEST|Cere|Magnetic Rseonance imaging for brain tumour follow-up
214429820|NCT00557024|PROCEDURE|RFA|radiofrequency ablation
214429821|NCT00557024|PROCEDURE|radiotherapy after RFA|radiotherapy after RFA
214429822|NCT03895346|BEHAVIORAL|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
214429823|NCT03895346|BEHAVIORAL|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
214429824|NCT02909413|DRUG|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
214429825|NCT02909413|DRUG|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
215113916|NCT07067073|OTHER|Anti-Dynamic Line Cream|Topical cream (Formula# 899675 44A) applied to the full face and neck twice daily for 8 weeks. Participants apply 1 g each time in the morning and evening after cleansing, with massage on wrinkle-prone areas. Used after a 2-week wash-out period with standard skincare.
214429826|NCT03828240|OTHER|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
214429827|NCT02282267|DRUG|Gefitinib|Iressa 250mg oral daily
214429828|NCT05016830|DEVICE|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
214429829|NCT02931214|DRUG|GMI-1359|
214429830|NCT02931214|DRUG|Placebo|
214429831|NCT05677061|DEVICE|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
214429832|NCT05677061|DEVICE|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
214429833|NCT03606915|BEHAVIORAL|pain evaluation|collect CSF during spinal anesthesia
214429834|NCT01820780|OTHER|Natriuretic peptides levels to J7 and J14|
214429835|NCT01820780|OTHER|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
214429836|NCT01820780|OTHER|Phone calls in 6 months and 12 months|
214429837|NCT01820780|OTHER|Natriuretic peptides levels at 6 months|
214429838|NCT01820780|OTHER|Consultation with the general doctor or the cardiologist to J30 with blood results|
214429839|NCT03813433|OTHER|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
214429840|NCT01593319|DRUG|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
214513103|NCT00202228|DRUG|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
214513104|NCT02370953|DEVICE|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
215113917|NCT07065942|DRUG|Lactulose oral solution|Oral, 30 mL once daily administered during breakfast.
215113918|NCT07065942|DRUG|Live Combined B. Subtilis and E. Faecium Enteric-coated Capsules|Oral, 2 tablets (500 mg per tablet) three times daily (TID).
214429841|NCT01593319|DRUG|Natrium chloride|Placebo injection of Natrium chloride solution
214429842|NCT00320762|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
214429843|NCT04033107|DRUG|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
214429844|NCT04033107|DRUG|Metformin|Participants will orally take metformin 4g daily.
214429845|NCT00450359|PROCEDURE|breast imaging study|
214429846|NCT00450359|PROCEDURE|comparison of screening methods|
214429847|NCT00450359|PROCEDURE|radiomammography|
214429848|NCT00223067|DRUG|TAIZ|
214429849|NCT06419569|OTHER|high power laser|Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
214429850|NCT06419569|OTHER|low level laser|patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
214429851|NCT06419569|OTHER|conventional physical therapy|the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
214429852|NCT01557855|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
214429853|NCT04504786|OTHER|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
214429854|NCT04504786|OTHER|Control|Participants maintained their daily activities.
214429855|NCT04290572|DRUG|Isotretinoin capsules|Jelly capsules of isotretinoin
214429856|NCT00779870|OTHER|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
214429857|NCT02206750|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214429858|NCT02206750|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214429859|NCT00130156|DRUG|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
214429860|NCT00130156|DRUG|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
214429861|NCT00130156|DRUG|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
214429862|NCT01149369|DRUG|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
214429863|NCT01149369|DRUG|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
214429864|NCT01218698|DRUG|Losartan Potassium Tablets|
214429865|NCT04511767|OTHER|Do not take any interventions|Do not take any interventions
214429866|NCT03415360|PROCEDURE|cryoablation|cryoablation of nerve responsible for phantom limb pain
214429867|NCT04816175|BEHAVIORAL|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
214429868|NCT04043169|DIAGNOSTIC_TEST|Clearblue pregnancy test|Urine pregnancy test
214429869|NCT06510881|PROCEDURE|Rhinoplasty with or without cleft alveolus repair|"* Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years ."
214429870|NCT02426996|PROCEDURE|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
214429871|NCT02189772|DRUG|Metadoxine extended release|MG01CI
214429872|NCT02189772|DRUG|Placebo|Inactive drug
214429873|NCT04942184|BEHAVIORAL|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
214429874|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
214429875|NCT04942184|OTHER|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
214429876|NCT04942184|BEHAVIORAL|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
214429877|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
214429878|NCT04942184|OTHER|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
214429879|NCT02593149|DEVICE|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
214429880|NCT05247437|BEHAVIORAL|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
214429881|NCT05247437|BEHAVIORAL|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
214429882|NCT04620421|OTHER|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
214429883|NCT00043966|DRUG|Lopinavir/ritonavir|
214513105|NCT02370953|PROCEDURE|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
214513106|NCT05756101|DEVICE|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
214513107|NCT06180109|DRUG|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
214513108|NCT06180109|DRUG|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
214513109|NCT04117659|OTHER|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
214513110|NCT01278511|OTHER|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
214513111|NCT04722471|DRUG|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
214429884|NCT00043966|DRUG|Tenofovir DF|
214429885|NCT00043966|DRUG|Emtricitabine|
214429886|NCT01571557|DRUG|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
215113919|NCT07066436|DRUG|MRI contrast-enhancing agents|"1. Ferumoxytol will be injected as an off-label MRI contrast agent at a dose of 4 mg/kg body mass. For safety (in accordance with prior research), ferumoxytol will be diluted 1:4 in saline, and administered slowly over at least 15 minutes, with patient monitoring during and post injection.~2. ImmunoMRI will be performed using an iron sensitive fat-suppressed, fast spoiled gradient echo T2\* mapping sequence. At each time point (i.e. pre-treatment and post-treatment), T2\* mapping will be performed before and \~24h after ferumoxytol injection."
215113920|NCT07065175|DRUG|Kangfupen (liquid dressing) retention enema administration|"Dosage: 50 mL per administration, once daily Duration: 3-6 months of continuous therapy~Procedure:~Enema depth determined by colonoscopy-identified lesion location Administered as retention enema (minimum 30-minute retention time)"
215113921|NCT07065656|DEVICE|Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH)|Oxygen therapy will be given via the Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH) using a small-bore cannula, with a flow rate of up to 45 L/min, starting temperature of 37oC and FiO2 of up to 1.0.
215113922|NCT07065656|DEVICE|Respironics Vision V60|Ventilation will be performed with the Respironics Vision V60 (Philips Healthcare, Murrysville, PA) using an oronasal mask of appropriate size, with FiO2 (up to 1.0), inspiratory (IPAP 12 to 20 cmH2O) and expiratory (EPAP 5 to 10 cm H2O) pressures titrated to alleviate patient's respiratory distress.
215113923|NCT07065604|PROCEDURE|Non-intubated VATS for mediastinal neoplasm|Non-intubated VATS for mediastinal neoplasm
215113924|NCT07065604|PROCEDURE|Intubated VATS for mediastinal neoplasm|Intubated VATS for mediastinal neoplasm
214429887|NCT02379715|DRUG|Remifentanil|
214429888|NCT02379715|DRUG|Desflurane|
214429889|NCT04807556|OTHER|Alusti Test|Physical and psychological functional conditions are key factors in the elderly population
214429890|NCT02740595|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
214429891|NCT02740595|OTHER|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
214429892|NCT02740595|OTHER|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
214429893|NCT04722237|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
214429894|NCT01636687|DRUG|Placebo|2 injections of placebo to secukinumab 150mg per dose
214429895|NCT01636687|DRUG|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
214429896|NCT01636687|DRUG|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
214429897|NCT03924037|BEHAVIORAL|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
214429898|NCT03924037|BEHAVIORAL|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
214429899|NCT03809936|DEVICE|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
214429900|NCT03809936|DEVICE|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
214429901|NCT00567333|OTHER|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
214429902|NCT00567333|OTHER|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
214429903|NCT03522454|DIETARY_SUPPLEMENT|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
214429904|NCT03522454|BEHAVIORAL|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
214513112|NCT02586961|DRUG|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
214513113|NCT02586961|DRUG|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
214513114|NCT02586961|DRUG|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
214513115|NCT02586961|DRUG|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
214513116|NCT02241642|DEVICE|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
214513117|NCT04810104|DRUG|AZD0328|Active study drug
214513118|NCT04810104|DRUG|Placebo|Non-active study drug
215113925|NCT06915571|OTHER|Plantar Fascia Stretching.|It consists of participants who will undergo plantar fascia stretching.
215113926|NCT06915571|OTHER|Graston Technique|It consists of participants who will underwent graston technique application.
214429905|NCT02771899|DEVICE|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
214429906|NCT02771899|DEVICE|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
214429907|NCT03835819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
214429908|NCT03835819|DRUG|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
214429909|NCT00681525|DRUG|ABT-335|One ABT-335 135 mg capsule QD for 10 days
214429910|NCT00681525|DRUG|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
214429911|NCT00681525|DRUG|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
214429912|NCT03318484|DRUG|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
214429913|NCT03318484|COMBINATION_PRODUCT|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
214429914|NCT04333589|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
214513119|NCT00220649|DRUG|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
214513120|NCT04165018|PROCEDURE|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
214513121|NCT01604122|OTHER|No drug|No drug.
214513122|NCT01604122|OTHER|No drug|No drug.
214513123|NCT05702788|DRUG|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
214513124|NCT05702788|DRUG|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
214513125|NCT05702788|OTHER|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
214513126|NCT02173457|DRUG|Chiglitazar|Take orally
214513127|NCT02173457|DRUG|Sitagliptin|Take orally
214429915|NCT00470938|DEVICE|SpineForce Reactive Neuromuscular Trainer|
214513128|NCT01138657|BIOLOGICAL|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
215113927|NCT07065266|OTHER|Binary pain questionnaire|Post-operative questionnaire that asks if pain is 'tolerable' or 'intolerable'
215113928|NCT07065266|OTHER|Numerical Pain Rating Scale (NPRS)|Standard 10-point pain scale used post-operatively to assess pain
215113929|NCT07066111|DRUG|Tramadol|The control group routinely injected tramadol 100mg(Tramal) intramuscularly
214429916|NCT01321411|OTHER|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
214513129|NCT01138657|DRUG|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
214513130|NCT01138657|DRUG|Placebo|Administered by subcutaneous injection
214513131|NCT02675322|DRUG|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
214513132|NCT02675322|OTHER|Placebo|Placebo with no chemical effects.
214513133|NCT01396629|PROCEDURE|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
214513134|NCT04131855|OTHER|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
214513135|NCT04131855|OTHER|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
214513136|NCT01564472|OTHER|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
214513137|NCT04955054|DIAGNOSTIC_TEST|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
214513138|NCT05376839|DRUG|Cedirogant|Capsule, Oral
214513139|NCT03150589|DRUG|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
214513140|NCT03150589|DRUG|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
214513141|NCT03937752|OTHER|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
214513142|NCT02841449|BEHAVIORAL|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
214513143|NCT02841449|BEHAVIORAL|Rehydrated|Participants rehydrate after the heat tent procedure
214429917|NCT01321411|OTHER|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
214429918|NCT00115713|BEHAVIORAL|Aerobic Exercise Training|
214429919|NCT00115713|BEHAVIORAL|Resistance Exercise Training|
214429920|NCT02462369|DRUG|Saxagliptin|
214429921|NCT02462369|DRUG|glimepiride|
214429922|NCT02353988|DRUG|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
214429923|NCT02353988|OTHER|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
214429924|NCT04805996|BEHAVIORAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
214429925|NCT00771160|DRUG|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
214429926|NCT04520880|DIAGNOSTIC_TEST|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
214513144|NCT04976829|DEVICE|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
214513145|NCT01000649|DRUG|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
214513146|NCT01000649|DRUG|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
214513147|NCT01000649|DRUG|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
214513148|NCT01000649|OTHER|Placebo|Isotonic saline infused.
214513149|NCT05748184|DEVICE|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
214513150|NCT05748184|DEVICE|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
214513151|NCT05748184|DEVICE|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
214513152|NCT03015428|OTHER|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
214513153|NCT00346398|BIOLOGICAL|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
215113930|NCT07066111|DRUG|bupivacaine liposome (ultrasound-guided high iliofascial space block)|the experimental group was given ultrasound-guided high iliofascial space block: High-frequency linear probe (5-13 MHZ, Sonosite, USA) was used to identify the iliac bone, iliac muscle and deep circumiliac artery. Then a short oblique puncture needle was used, with the intraplanar technique, and the needle was inserted from the outside. When the needle tip reached the surface of the iliac muscle (iliac fascia space), 20ml of bupivacaine liposome was injected. After the operation, electrocardiogram monitoring(Mindray) was performed for 1 hour to observe adverse reactions.
215113931|NCT07064993|OTHER|Observation|Routine monitoring and observation
215113932|NCT07064993|PROCEDURE|Experimental|Administration of tramadol and dexmethasone to arthroscopy solution
214429927|NCT04520880|DIAGNOSTIC_TEST|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
214429928|NCT02847702|DRUG|VM902A 200-mg Capsules|Taken orally with food twice daily
214429929|NCT02847702|DRUG|VM902A 400-mg Capsules|Taken orally with food twice daily
214429930|NCT02847702|DRUG|Naproxen 500-mg Capsules|Taken orally with food twice daily
214429931|NCT02847702|DRUG|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
214429932|NCT02472782|DRUG|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
214429933|NCT00886951|DRUG|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
214429934|NCT02599935|DIETARY_SUPPLEMENT|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
214429935|NCT02599935|OTHER|standard treatment|No other than standard treatment
214429936|NCT02599935|OTHER|educational structured counseling|Nutritional counseling leaded to patient and caregivers
214429937|NCT01222910|DRUG|Valacyclovir hydrochloride|
214429938|NCT03174171|DRUG|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
214429939|NCT02434107|PROCEDURE|Completion Lymphadenectomy|
214429940|NCT02434107|PROCEDURE|Clinical Monitoring (Palpation and node ultrasound)|
214429941|NCT04291729|DRUG|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
214429942|NCT02242695|DRUG|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
214429943|NCT02242695|DRUG|Canesten vaginal tablets|one vaginal tablet for 7 days
214429944|NCT03802318|DRUG|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
214429945|NCT03561064|BEHAVIORAL|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
214429946|NCT03583125|DRUG|EOC317|tablet(s) PO
214429947|NCT02368171|OTHER|measure exhaled carbon monoxide and nitric oxide|
214429948|NCT01254188|DRUG|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
214429949|NCT01428297|DRUG|BPR277 ointment (controlled application)|
214429950|NCT01428297|DRUG|Placebo (Vehicle)|
214429951|NCT01428297|DRUG|BPR277 ointment|
214429952|NCT01428297|DRUG|Placebo (Vehicle)|
214429953|NCT01428297|DRUG|BPR277|
214429954|NCT01428297|DRUG|Placebo (Vehicle)|
214429955|NCT03631953|DRUG|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
214429956|NCT03631953|DRUG|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
214429957|NCT03631953|BIOLOGICAL|Blood sample|Therapeutic biomarkers
214429958|NCT03631953|DEVICE|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
214429959|NCT01338675|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
214429960|NCT04328155|PROCEDURE|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
214429961|NCT04328155|PROCEDURE|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
214429962|NCT04328155|PROCEDURE|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
214429963|NCT04328155|PROCEDURE|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
214429964|NCT00065832|BEHAVIORAL|Reading Instruction|
214429965|NCT00107159|BIOLOGICAL|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
214429966|NCT01579370|OTHER|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
214429967|NCT01579370|OTHER|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
214513154|NCT00346398|BIOLOGICAL|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
214429968|NCT01579370|OTHER|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
214429969|NCT01579370|OTHER|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
214429970|NCT00826475|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
214429971|NCT00826475|BEHAVIORAL|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
215113933|NCT07064681|PROCEDURE|Surgery with and without the aid of Indocyanine Green (ICG)|Enrolled patients will receive surgery and be follow up for 2 years
214429972|NCT04149808|DEVICE|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
214429973|NCT04149808|DEVICE|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
214429974|NCT03482011|DRUG|Mirikizumab|Administered SC
214429975|NCT03482011|DRUG|Placebo|Administered SC
214429976|NCT03017625|OTHER|Blood is drawn|Blood analyses
214429977|NCT05425862|DRUG|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
214429978|NCT05425862|DRUG|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
214513155|NCT05032651|DEVICE|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
214513156|NCT00668226|DRUG|Lactic acid (Dermacid)|
214513157|NCT03979040|BEHAVIORAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
214513158|NCT03979040|BEHAVIORAL|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Depression (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
214513159|NCT00969007|BEHAVIORAL|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
215113934|NCT04988880|OTHER|Multiple Sclerosis Expert Patient Program of Catalonia|It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
215113935|NCT06927583|OTHER|sensory integration therapy|sensory integration therapy include 2 categories that comprised of 9 strategies.
215113936|NCT06927583|OTHER|Traditional Speech therapy|Control group was given traditional speech therapy .total number of 5 sessions give t o each participant that comprised of 30 minutes.
215113937|NCT06923410|DEVICE|AI model|The clinical intelligent AI system is equipped with an AI agent doctor, enabling patients to conduct self-consultations and receive care anytime and anywhere without the need for a real doctor.
214429979|NCT05865938|DEVICE|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
214429980|NCT04221828|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
214429981|NCT03877198|DEVICE|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
214429982|NCT03877198|DEVICE|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
214429983|NCT01598870|OTHER|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
214429984|NCT00003834|DRUG|fluorouracil|
214429985|NCT00003834|DRUG|leucovorin calcium|
214429986|NCT00003834|DRUG|oxaliplatin|
214429987|NCT01226849|DRUG|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
214429988|NCT02928354|DRUG|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
214429989|NCT02928354|DRUG|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
214429990|NCT02928354|DRUG|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
214429991|NCT05297175|DEVICE|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
214429992|NCT03272087|DEVICE|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
214429993|NCT03272087|DEVICE|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
214429994|NCT03741049|DEVICE|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
214429995|NCT03741049|DEVICE|Seldinger technique (plastic laryngeal model)|Melker Set
214429996|NCT03741049|DEVICE|Surgical technique (plastic laryngeal model)|Scalpel and speculum
214429997|NCT03741049|DEVICE|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
214429998|NCT03741049|DEVICE|Surgical technique (porcine laryngeal model)|Scalpel and speculum
214429999|NCT06413095|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214430000|NCT06413095|COMBINATION_PRODUCT|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214430001|NCT06413095|COMBINATION_PRODUCT|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214430002|NCT05089526|DRUG|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
214430003|NCT05089526|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
214430004|NCT04202393|BEHAVIORAL|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
214430005|NCT04202393|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
214430006|NCT04431375|BIOLOGICAL|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
214430007|NCT04431375|DRUG|Tenofovir|Tenofovir \[antiviral\] 300mg PO once a day .
215113938|NCT07066670|BEHAVIORAL|Strain Counterstrain with Routine Physical Therapy|This intervention involves applying the Strain Counterstrain (SCS) technique in combination with standard physical therapy. SCS targets tender points through passive positioning to reduce muscle tension and pain. The patient is positioned in a position of comfort for 90 seconds while monitoring the tender point. This is followed by gradual return to neutral. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), strengthening (short arc quads, terminal knee extension), and stretching exercises. The therapy is administered 5 days per week over 8 weeks.
214430008|NCT04431375|OTHER|Fecal Mircobiota Transplantation|FMT for 7 days
214430009|NCT03794635|BEHAVIORAL|Weekly 45 minute Sessions|"The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention."
214430010|NCT00210691|DRUG|Risperidone|
214430011|NCT04216394|PROCEDURE|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
214430012|NCT03419013|OTHER|New adhesive strip|This strip is made of a newly developed adhesive
214430013|NCT02083692|DRUG|Metformin|
214430014|NCT02721901|BEHAVIORAL|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
214513160|NCT05790759|OTHER|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
214513161|NCT02607956|DRUG|DTG|50 mg tablets administered orally, once daily
214513162|NCT02607956|DRUG|F/TAF|200/25 mg tablets administered orally, once daily
214513163|NCT02607956|DRUG|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
214513164|NCT02607956|DRUG|DTG Placebo|Tablets administered orally, once daily
214513165|NCT02607956|DRUG|F/TAF Placebo|Tablets administered orally, once daily
214513166|NCT02607956|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
214513167|NCT01662713|DEVICE|OFDI|Imaging of skin
214513168|NCT03204357|OTHER|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
214513169|NCT03204357|OTHER|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
214513170|NCT06377137|BEHAVIORAL|Small-sided soccer games groups (SSSG)|Physical exercise intervention
214513171|NCT06377137|BEHAVIORAL|Traditional soccer training groups (TSG)|Physical exercise intervention
214513172|NCT04724265|BIOLOGICAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
214513173|NCT04789174|DRUG|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
214513174|NCT04789174|DRUG|Placebo|Placebo
214513175|NCT06147466|DEVICE|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
214513176|NCT00602732|BEHAVIORAL|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
214513177|NCT00602732|BEHAVIORAL|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
214513178|NCT04154085|OTHER|Psychotherapy|Group psychotherapy
214513179|NCT01005914|DRUG|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
214513180|NCT01005914|DRUG|cytarabine|Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
214513181|NCT01005914|DRUG|dexamethasone|Day 1-4; 11-14: 40 mg daily
214513182|NCT01005914|DRUG|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
214513183|NCT01005914|DRUG|imatinib mesylate|600 mg/day
214513184|NCT01005914|DRUG|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
214513185|NCT01005914|DRUG|methylprednisolone|Day 1-3: 50mg IV BID
214513186|NCT01005914|DRUG|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
214513187|NCT01005914|DRUG|vincristine sulfate|Day 4 \& 11: 2 mg IV
214513191|NCT01141075|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
214513192|NCT01240785|DRUG|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
214513193|NCT01240785|DRUG|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
214513194|NCT02815345|DEVICE|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
214513195|NCT03985397|OTHER|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
214513196|NCT04788407|DRUG|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
214513197|NCT04788407|DRUG|Placebo|Subjects will receive placebo TID for 7 days
214513198|NCT02173990|DRUG|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
214430015|NCT02721901|BEHAVIORAL|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
214430016|NCT03113266|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
214430017|NCT03700294|DRUG|ADCT-601|Intravenous (IV)
215113939|NCT07066670|BEHAVIORAL|Muscle Energy Technique with Routine Physical Therapy|This intervention combines Muscle Energy Technique (MET) with routine physical therapy. MET involves voluntary muscle contractions against resistance, followed by stretching to restore range of motion and relieve pain. Techniques include post-isometric relaxation and slow eccentric isotonic stretching, particularly targeting hamstring and quadriceps tightness. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), as well as structured strengthening and stretching exercises. The intervention was delivered 5 days a week for 8 weeks.
214430018|NCT06353165|DRUG|Stannous fluoride toothpaste|product containing 0.45% stannous fluoride
214430019|NCT06353165|DRUG|Colgate Dental Cream|product containing 0.76% sodium monofluorophosphate
214430020|NCT01510977|DRUG|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
215113940|NCT06907147|DEVICE|Multi-Organ Denervation Gemini System|After angiography according to standard procedures, subjects are treated with renal denervation followed by hepatic denervation.
215113941|NCT06474845|DEVICE|T-Control® catheter|Patients will be catheterized with T-Control® for 4 weeks
215113942|NCT06474845|DEVICE|Foley-type catheter|Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
214430021|NCT01510977|DRUG|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
214430022|NCT02012569|DRUG|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
215113943|NCT07066319|BEHAVIORAL|Gait Training with Proprioceptive Neuromuscular Facilitation (PNF)|A physiotherapeutic intervention combining structured gait training with Proprioceptive Neuromuscular Facilitation (PNF) techniques. Sessions include rhythmic initiation, diagonal movement patterns, and resistance-based facilitation to enhance lower limb motor control and balance in stroke survivors. Delivered 3 times/week for 12 weeks, 45 minutes per session.
214430023|NCT02012569|DRUG|Placebo|
214430024|NCT04193969|DIAGNOSTIC_TEST|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
214430025|NCT04193969|DIAGNOSTIC_TEST|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
214430026|NCT04193969|DIAGNOSTIC_TEST|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
214430027|NCT04193969|DIAGNOSTIC_TEST|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
214430028|NCT04193969|DIAGNOSTIC_TEST|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
214430029|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
214513199|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
214513200|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
214513201|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
214513202|NCT00696241|DRUG|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
215113944|NCT07066319|BEHAVIORAL|Gait Training with Conventional Physiotherapy|A rehabilitation protocol integrating traditional gait training (step drills, overground walking) with conventional physiotherapy exercises focused on lower limb strength, range of motion, and postural balance. Conducted over 12 weeks, 3 sessions per week, 45 minutes each.
215113945|NCT07066319|BEHAVIORAL|Combined PNF and Conventional Physiotherapy (without direct gait training)|This intervention blends Proprioceptive Neuromuscular Facilitation (PNF) with conventional physiotherapy, excluding dedicated gait tasks. It includes rhythmic stabilization, functional mobility drills, and resistance-based exercises aimed at improving neuromuscular re-education, balance, and independence. Delivered 3 times/week for 12 weeks, 45 minutes per session.
215113946|NCT04843904|DRUG|Venetoclax|Tablet, taken by mouth
214430030|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
214513203|NCT00696241|DRUG|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
215113947|NCT04843904|DRUG|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
214430031|NCT02720965|OTHER|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
214430032|NCT05083702|PROCEDURE|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
214430033|NCT05083702|PROCEDURE|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
214430034|NCT00995904|DRUG|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
214430035|NCT00995904|DRUG|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
214430036|NCT00995904|DRUG|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
214430037|NCT02490254|OTHER|Surveillance card|
214430038|NCT03009136|DRUG|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
214430039|NCT03009136|DRUG|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
214430040|NCT02730923|DRUG|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
214430041|NCT02730923|DRUG|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
214430042|NCT01691326|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
214430043|NCT01691326|BIOLOGICAL|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
214430044|NCT03557411|DRUG|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
214430045|NCT03220425|DRUG|Insulin detemir|
214430046|NCT03220425|DRUG|NPH insulin|
214430047|NCT03378141|BEHAVIORAL|Maternal Nutrition Behavior change|Counseling and community mobilization
214430048|NCT05609032|BEHAVIORAL|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
214430049|NCT04224142|DIETARY_SUPPLEMENT|PKU sphere|"PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU).~It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA.~It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe."
214430050|NCT04696575|BIOLOGICAL|Atezolizumab|Given IV
214430051|NCT04696575|DRUG|Carboplatin|Given IV
214430052|NCT04696575|DRUG|Etoposide|Given IV
214430053|NCT04696575|DRUG|Lamivudine|Given PO
214430054|NCT06086561|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
215113948|NCT04843904|DRUG|Rituximab|Given as an infusion into the vein (intravenous, IV).
215113949|NCT06768515|OTHER|No interventtion|to enhance the understanding of the factors associated with the number of organs retrieved from patients admitted to the ICU for organ donation
215113950|NCT06937164|BEHAVIORAL|Isometric Exercise Training (IET)|Participants perform four repetitions of 90 degree bilateral isometric leg extensions on a dynamometer at 30% of their maximum voluntary contraction (MVC). Each contraction is held for 2 minutes, with 2-minute rest intervals between bouts. Sessions are performed three times per week for four weeks. This behavioral intervention is designed to investigate the acute and chronic effects of isometric exercise on blood pressure, heart rate variability, and muscle fatigue.
214430055|NCT04176380|BIOLOGICAL|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
214430056|NCT04343885|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
214430057|NCT04343885|DRUG|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
214430058|NCT06496230|BEHAVIORAL|Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder|Two-pronged intervention model: 1) behavioral intervention utilizing interoceptive exposures and cognitive behavioral therapy for insomnia and, 2) mobile application that facilitates medication adherence.
214430059|NCT02261467|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
214430060|NCT02261467|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
214430061|NCT01243619|DRUG|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
214430062|NCT00389012|PROCEDURE|exercise therapy|
214430063|NCT00389012|PROCEDURE|walking rehabilitation|
214430064|NCT06131268|DRUG|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
214430065|NCT05993351|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
214430066|NCT05993351|DIAGNOSTIC_TEST|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
214430067|NCT05993351|BEHAVIORAL|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
214430068|NCT01919645|OTHER|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
214430069|NCT05156892|DRUG|SUBA-itraconazole|150 mg BD
214430070|NCT05156892|DRUG|Tamoxifen|"Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study"
214430071|NCT03213327|DEVICE|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
214430072|NCT04287894|DRUG|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
214430073|NCT04287894|DRUG|Tremelimumab|Per day 75mg
214430074|NCT04287894|DRUG|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
214430075|NCT04287894|DRUG|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
214430076|NCT04287894|RADIATION|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
214430077|NCT04287894|PROCEDURE|Resection|After CIT-CRT
215113951|NCT06937164|BEHAVIORAL|Expectation-Enhancing Informational Framing|Participants receive a brief standardized presentation highlighting isometric exercise as an evidence-based intervention for lowering blood pressure. The presentation includes statements designed to enhance outcome expectations based on prior literature and expert framing.
215113952|NCT06945263|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath blocks using an in-plane ultrasound-guided technique with 0.25% bupivacaine with epinephrine 1:200 000 at 0.8 mL/kg (half of total volume per side) up to a maximum of 20 mL prior to the incision.
214430078|NCT06041516|DRUG|ADCT-701|ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
214430079|NCT06973369|OTHER|LEININGER THEORY BASED CREATIVE DRAMA EDUCATION METHOD|The effects of Leininger theory-based creative drama training given to nursing students for five weeks on the students' cultural sensitivity and effectiveness levels will be determined.
214430080|NCT06973369|OTHER|TRADITIONAL EDUCATION METHOD|Leininger theory training will be given to nursing students for five weeks and its effects on the students' cultural sensitivity and effectiveness levels will be determined.
214430081|NCT06972368|DEVICE|tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of home-based transcranial Direct Current Stimulation (tDCS), administered twice daily for 30 minutes over 7 consecutive days. Each session will use a 2mA current with a SNAPstrap™ montage targeting the left dorsolateral prefrontal cortex (F3) with the anode and the right DLPFC (F4) with the cathode. Sessions include a 30-second ramp-up and ramp-down. The total delivered charge will be 48 coulombs.~Enhancement component:~Each session will be paired with cognitive and emotional enhancement strategies:~Emotion regulation script (DBT-inspired, personalized and pre-written based on a moderately dysregulated situation).~Cognitive training via Lumosity, targeting executive functions and memory."
214430082|NCT06972368|PROCEDURE|Treatment as Usual (TAU)|"Description:~Throughout the study, participants are required to maintain stable pharmacological and psychotherapeutic regimens, defined as:~No changes in medications or therapy for at least 6 weeks after tDCS initiation.~TAU is provided by participants' regular treating physician or mental health professional, independent of the study team.~TAU includes psychotropic medication, psychotherapy, and case management, as clinically indicated."
214430083|NCT06972368|PROCEDURE|Psychoeducation|"All participants receive access to a structured online psychoeducation program before randomization.~This includes:~* Short videos (8-14 minutes each) covering BPD, depression, neuromodulation, therapeutic success factors, and tDCS.~* Multiple-choice quizzes (MCQs) to ensure comprehension.~* Delivered in French with English subtitles. Designed to improve understanding of BPD and associated treatments, including the rationale for tDCS."
214430084|NCT06972368|DEVICE|Sham-tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of sham tDCS, with identical scheduling and device setup as the active condition. The session mimics real tDCS (same SNAPstrap montage, ramp-up and ramp-down of 30 seconds), but no current is delivered after the initial 30 seconds.~Enhancement component:~Participants follow the same emotional regulation script and Lumosity cognitive training during"
215113953|NCT06945263|DRUG|Local Anesthetic at the Umbilical Port Site|0.25% bupivacaine with epinephrine 1:200 000. Total dose of 0.8 mL/kg (maximum 20 mL) at the umbilical port site.
215113954|NCT06945263|DRUG|Intravenous Dexamethasone|Intravenous Dexamethasone delivered concurrent to the RSB. Total dose of 150 mcg/kg up to a maximum of 8 mg.
215113955|NCT06945263|DRUG|Local Anesthetic at the Incision Site|The remaining volume of local anesthetic (0.2 mL/kg) can be infiltrated at each of the incision sites at the discretion of the surgeon up to a maximum of 10 mL.
215113956|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
215113957|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
215113958|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
215113959|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
215113960|NCT00048347|DRUG|AVONEX|30µg IM every week for 12 weeks
215113961|NCT04216576|OTHER|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
214430085|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
214430086|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous
214430087|NCT06973772|BIOLOGICAL|Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
214692479|NCT05540470|DRUG|PART|"Chloroquine (150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~1. Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A.~   Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~2. OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria."
214692480|NCT05540470|DRUG|Malakit|"delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~* 1 laminated sheet with illustrated instruction~* 1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~  * A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~ * Two 15 mg tablets of primaquine, to be given as a single dose (145)~* 1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~* 3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies."
214513204|NCT03927118|PROCEDURE|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
214513205|NCT04607356|DEVICE|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
214513206|NCT04607356|OTHER|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
214513207|NCT01742832|DRUG|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
214513208|NCT01742832|DRUG|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
215113962|NCT04216576|OTHER|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
215113963|NCT05510336|PROCEDURE|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
215113964|NCT00262899|BEHAVIORAL|counseling intervention|
215113965|NCT00262899|OTHER|educational intervention|
215113966|NCT00262899|PROCEDURE|psychosocial assessment and care|
215113967|NCT00273429|DRUG|timolol maleate 0.5%|
215113968|NCT00273429|DRUG|dorzolamide/timolol maleate fixed combination|
215113969|NCT00273429|DRUG|latanoprost 0.005%|
215113970|NCT00273429|DRUG|placebo|
215113971|NCT00268541|BEHAVIORAL|Physical activity|
215113972|NCT05463250|DEVICE|Smartwatch|Wearing a smartwatch and having access to its data
215113973|NCT02450513|DRUG|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
215113974|NCT00958165|DEVICE|CardioFocus EAS-AC|PVI for PAF
215113975|NCT00484978|PROCEDURE|Stereotactic Radiosurgery|
215113976|NCT01279603|DRUG|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
214430090|NCT06973044|DEVICE|Checkpoint Cardio wireless continuous monitoring device|Continuous monitoring of respiratory rate and heart rate
214430091|NCT06974344|DRUG|Octreotide (drug)|Continuous intravenous octreotide acetate infusion initiated at hepatic reperfusion during living donor liver transplantation (LDLT). The initial dose is 1 mcg/kg/hr, titrated intraoperatively based on portal venous flow (PVF) and hepatic artery flow / resistive index (RI) measurements. The infusion continues postoperatively in the ICU until stable graft hemodynamics are achieved (target PVF \<5 mL/min/g and presence of diastolic hepatic arterial flow). Dose adjustments are permitted for efficacy or safety concerns, with all modifications documented. The intervention is administered via central venous access using standard infusion protocols
214430092|NCT06974344|PROCEDURE|Splenic Artery Ligation (SAL)|Intraoperative ligation of the splenic artery performed during living donor liver transplantation (LDLT) using non-absorbable suture material (e.g., polypropylene). The ligation is typically placed near the splenic artery origin for maximal portal flow modulation, with exact positioning determined by surgeon assessment of vascular anatomy and intraoperative hemodynamics (targeting portal venous flow \<5 mL/min/g). The procedure is performed under direct visualization during the transplant operation, with post-ligation Doppler ultrasound confirmation of hemodynamic response within 60 minutes of biliary anastomosis.
214430093|NCT06974214|OTHER|FAM-ICU|This multi-component intervention comprises several concrete and manageable components and operationalizing patient- and family-centered care principles in clinical practice.
214430094|NCT06973213|OTHER|core exercises|the intervention group underwent approximately 45 minutes of core stabilization exercises daily.
214430095|NCT06973122|PROCEDURE|combined paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block|paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block
214430096|NCT06973122|PROCEDURE|laparoscopic assisted transversus abdominis plane block|laparoscopic assisted transversus abdominis plane block
214430097|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
214430098|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 20 minutes at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11)
214430099|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
214430100|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 30 seconds at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11). However the electrodes will be kept for 20 minutes to mask the stimulation
214430101|NCT06973824|OTHER|Frequency of disease recurrence|To collect data of pituitary disease recurrence
214430102|NCT06972602|DRUG|Topotecan|Intravitreal injection of topotecan at a dosage of 100μg was performed at week 1.Then based on the tumor response and vitreous seeding, it will be decided whether to continue the injection by ophthalmologists.
214430103|NCT06972602|OTHER|Collection of aqueous humor|Patients' aqueous humor samples will be collected for Inflammatory factor testing and IOP control every 4 weeks.
214430104|NCT06972602|OTHER|Electroretinogram|Electroretinogram was performed every 4 weeks.
214430105|NCT06973590|DEVICE|Blood flow restriction (BFR)|BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). The pressure system remains inflated throughout active training phases and is systematically deflated during inter-exercise intervals.
214430106|NCT06973590|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
214430107|NCT06973590|DEVICE|Sham blood flow restriction (Sham-BFR)|Sham BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). But the pressure system remains deflated throughout active training and resting phases.
214430108|NCT06973590|DEVICE|Sham transcutaneous electrical nerve stimulation (Sham-TENS)|Sham TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching. But the stimulator will only be applied for the first and last 30 seconds.
214430109|NCT06973590|BEHAVIORAL|Low-intensity resistance training (LIRT)|The LIRT protocol utilizes 20% of one-repetition maximum (1-RM) as the standardized training load. LIRT including leg extensions, leg presses, and load-bearing squats focused on the affected limb. Each resistance exercise consists of 3 sets of 20 repetitions with rest intervals.
214430110|NCT06973499|DIAGNOSTIC_TEST|Microbiome Profiling and Symptom Assessment|"GERD symptom assessment: Standardized GERD-Q questionnaire to evaluate reflux symptoms (heartburn, acid regurgitation) and high-risk behaviors.~Microbiome analysis: 16S rDNA sequencing of upper gastrointestinal and intratumoral microbiota."
214430111|NCT06974370|RADIATION|Active Surveillance|Following systemic therapy, participants will undergo active surveillance with brain MRI every 3 months. Radiation therapy will only be initiated if disease progression is observed on imaging, at the discretion of the treating physician.
215113977|NCT01523509|DEVICE|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
215113978|NCT05636761|DIAGNOSTIC_TEST|Heart rate variability|Collection and Analysis of Heart Rate Variability
215113979|NCT06479941|OTHER|antibiotic treatment|AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
214430112|NCT06973187|DRUG|BGB-16673|BGB-16673 will be administered orally
214430113|NCT06973187|DRUG|Pirtobrutinib|Pirtobrutinib will be administered orally
214513209|NCT02518399|OTHER|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
214513210|NCT02518399|OTHER|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
214513211|NCT01778803|DRUG|defactinib|
214513212|NCT01778803|DRUG|Paclitaxel|
214513213|NCT04271813|DRUG|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
214513214|NCT05329142|DIAGNOSTIC_TEST|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
214513215|NCT01589341|OTHER|laboratory biomarker analysis|Correlative studies
214513216|NCT04913532|RADIATION|Hypofractionation with simultaneous integrated boost|Hypofractionation with simultaneous integrated boost
214513217|NCT01683188|DRUG|vemurafenib + HD IL-2|
214513218|NCT06575725|BIOLOGICAL|Balstilimab|Given IV
214513219|NCT06575725|PROCEDURE|Biopsy|Undergo biopsy
214513220|NCT06575725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214513221|NCT06575725|BIOLOGICAL|Botensilimab|Given IV
214513222|NCT06575725|PROCEDURE|Computed Tomography|Undergo CT
214513223|NCT06575725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214513224|NCT06575725|DRUG|Regorafenib|Given PO
214430114|NCT06972511|COMBINATION_PRODUCT|neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases|neoadjuvant apadamide plus ADT: apadamide 240 mg qd po + leuproprolirelin 3.75mg subcutaneous injection once every month. After 4 months of neoadjuvant therapy, radical prostate cancer + extended lymph node dissection, lymph node dissection to the level of bilateral common iliac arteries, and radiotherapy for metastases was completed within 3 months after surgery.Postoperative adjuvant ADT therapy, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
214513225|NCT02757469|DRUG|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
214513226|NCT04198441|DEVICE|Wound dressing|Clean wound, fill wound, dress wound
214513227|NCT03347396|DRUG|BIVV009|Sutimlimab was administered as intravenous (IV) infusion.
214513228|NCT06509308|OTHER|Psychological Questionnaires|Patients will be asked to complete a series of questionnaires regarding disease expectations, cognitions, and representations of their health status. Additionally, sociodemographic data and clinical variables will be collected from medical records.
214513229|NCT00010868|DRUG|Omega-3 Fatty Acids|
214513230|NCT02399202|DRUG|osilodrostat|
214513231|NCT00221988|DRUG|Levetiracetam (Keppra)|
214513232|NCT04347148|PROCEDURE|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
214513233|NCT04347148|PROCEDURE|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
214513234|NCT04780607|DEVICE|mitral valve repair|different repair techniques to construct rheumatic mitral valve lesion
214513235|NCT02962024|DRUG|Morphine Sulfate|
214513236|NCT02962024|DRUG|Bupivacaine Hydrochloride|
214513237|NCT06352307|OTHER|Diagnosis of ACM|Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
214513238|NCT01780428|DRUG|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
214513239|NCT01780428|DRUG|Placebo|
214513240|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
214513241|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
214513242|NCT05547724|OTHER|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
214513243|NCT02399072|OTHER|No intervention|No intervention administered in this study
214513244|NCT06100406|OTHER|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
214513245|NCT02947880|DRUG|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
214513246|NCT02947880|DRUG|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
214692481|NCT05540470|OTHER|CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS|Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample
214692482|NCT05540470|OTHER|QUALITATIVE STUDY|Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
214430115|NCT06972511|DRUG|Standard ADT treatment|leuproprolirelin 3.75mg subcutaneous injection once every month, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
214513247|NCT03060525|BEHAVIORAL|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
214430116|NCT06973707|BEHAVIORAL|Passive Digital Tools|Dynamic organizational chart of care team members Guide to general medicine service Plan for the day
214430117|NCT06973707|BEHAVIORAL|Active Digital Tools|Guide: why patient engagement is important Sample questions with answers Ability to create, organize, and store questions to ask the medical team; reminder to ask them during rounds Electronic journal function with categories: symptoms, emotions, function, what I learned; reminder to share with medical team during rounds
214513248|NCT02724501|BEHAVIORAL|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
214513249|NCT02724501|PROCEDURE|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
214513250|NCT05461053|DRUG|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
214513251|NCT01932203|DRUG|aspirin|100mg once a day
214513252|NCT01932203|DRUG|cilostazol|200mg once a day
214513253|NCT05225753|DIAGNOSTIC_TEST|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
214513254|NCT00476385|DRUG|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
214513255|NCT04783025|BEHAVIORAL|Blended Gaming COVID-19 Training System (BGCTS)|"BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training."
214513256|NCT04783025|BEHAVIORAL|Usual care, infection control briefing|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
214513257|NCT01974102|BEHAVIORAL|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
214513258|NCT01974102|BEHAVIORAL|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
214513259|NCT00333372|DRUG|Z-338|
214513260|NCT02966249|DRUG|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
214513261|NCT02966249|DRUG|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
214513262|NCT02966249|DRUG|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
214692483|NCT00277316|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
215113980|NCT04440657|BEHAVIORAL|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
214513263|NCT02966249|DRUG|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
214513264|NCT02966249|DRUG|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
214513265|NCT02966249|DRUG|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
214692484|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
214692485|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
214692486|NCT02204241|DRUG|Carfilzomib|
214692487|NCT02204241|DRUG|Cyclophosphamide|
214692488|NCT02204241|DRUG|Dexamethasone|
214692489|NCT04913714|BEHAVIORAL|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
214430118|NCT06972628|DRUG|Administering Lutetium-177-PSMA-617 (PLUVICTO)|The study begins with a first cohort of three participants, each receiving a dose of 100 millicuries (mCi). After administration, participants are monitored for any dose-limiting toxicities (DLTs) during a predefined observation window. If fewer than two participants experience a DLT in a given cohort, the dose will be escalated for the next group. The dose escalation schedule is structured as follows: the second cohort receives 130 mCi (a 30% increase), the third cohort receives 162.5 mCi (a 25% increase), and the fourth cohort receives 200 mCi, a dose that is already FDA-approved and clinically accepted for mCRPC. This stepwise escalation continues until the 200 mCi dose is reached, or until two or more DLTs are observed in any cohort. If that occurs, escalation stops immediately, and the maximum tolerated dose is considered to be the previous lower dose. This becomes the optimal tolerated dose (OTD). After identifying the OTD, additional participants will be enrolled for treatment.
214430119|NCT06972693|GENETIC|BRCA testing|BRCA 1 and 2 testing
214430120|NCT06973109|DRUG|Romosozumab|Monthly subcutaneous injection (210 mg total dose) administered as two separate 105 mg injections, one per arm. Administered for 12 months to female patients ≥65 years undergoing spine surgery.
214430121|NCT06973109|DRUG|Alendronate (Fosamax)|Weekly oral dose (70 mg) administered for 12 months. Used as active comparator in control arm of study.
214430122|NCT06973109|DRUG|Placebo Romosozumab|Monthly subcutaneous injections mimicking romosozumab in appearance and administration schedule. Administered to control group.
214430123|NCT06973109|DRUG|Placebo Alendronate|Weekly oral placebo pill mimicking alendronate. Administered to treatment group.
214430124|NCT06974071|OTHER|Local cold therapy.|It will be applied by means of a refrigerated unit based on gel pack, these units will be stored in the refrigerator of the Unit, which is kept between 2 - 6 degrees, the application protocol is described in Annex B, this was reviewed in conjunction with quality nurses of the Cardiovascular Unit, to avoid biases.
214430125|NCT06974071|OTHER|Lavender oil.|"Lavender essential oil will be used by applying 5 drops in a sterile dressing 15x15 which will be placed on the side of the patient's bedside at 10 cm from the patient.~To maintain the safety of the patients and ensure the quality of the products, two essential oils will be chosen, certified by the Institute of Public Health (ISP), the first one Lavender essential oil, body and aromatherapy use of the Weleda brand, with sanitary authorization N° 154C-15 and the essential oil Doterra, sanitary authorization N° 2832C-6/21, with authorization by the Food and Drugs Administration (FDA), in charge of ensuring the quality of substances that are marketed from the United States to the rest of the world.~These oils will be subjected to a characterization process, choosing the one with the highest quality and purity, through the protocol sent by the Scientific and Technological Nucleus in Bioresources (BioRen), which are specified in section 5.10."
214430126|NCT06974045|OTHER|Single-stage LC + LCBDE|Choledochotomy and transductal common bile duct exploration or transcystic choledochoscopy and common bile duct exploration
214430127|NCT06972433|PROCEDURE|single visit root canal treatment|Root canal procedure performed in a single visit using ProTaper file system, sodium hypochlorite irrigation, and lateral compaction with gutta-percha and sealer. Final restoration with GIC.
214430128|NCT06972433|PROCEDURE|Multiple visit root canal treatment|Root canal procedure performed over two or more visits using the same instrumentation and irrigation protocol. Canals are medicated between appointments before obturation and restoration.
214430129|NCT06967220|OTHER|Single leg training|All subjects will train one leg twice daily.
214430130|NCT06973694|DEVICE|Bulbicam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~26 grids glaucoma screening perimetry 64 grids full perimetry (NeuroField64) Pupil and Relative Afferent Pupil Defect (RAPD) assessment Semi-automatic ptosis (droopy eyelid) grading Video-based nystagmus test Dynamic acuity and contrast sensitivity test Dark adaptation test Smooth pursuit eye movements Saccade movements Eye fixation stability BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
214513266|NCT04870398|PROCEDURE|Vital Pulp therapy-Partial pulpotomy|Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
214513267|NCT05537012|DIAGNOSTIC_TEST|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
214513268|NCT02280031|DRUG|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
214513269|NCT02280031|DRUG|Placebo|Capsule containing placebo pill with lactose
214513270|NCT03609099|DRUG|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
214513271|NCT03609099|DRUG|Placebo|once a day oral treatment during 3 days.
214513272|NCT03650465|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
214513273|NCT05295706|BEHAVIORAL|Counterfactual Intervention|"The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate."
214513274|NCT01510314|BIOLOGICAL|C-reactive protein and procalcitonin dosages|
214513275|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
214513276|NCT05996458|OTHER|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
214513277|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
214430131|NCT06973382|BEHAVIORAL|Comprehensive Pulmonary Rehabilitation Program|"Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Continuous or interval training (15-30 minutes)~* 5-minute cool-downesistance Exercise Component~Mode: Dumbbell exercises + cycle ergometry~Frequency: 3 sessions per week~Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Training session (10-20 minutes)~* 5-minute cool-down"
214430132|NCT06973382|BEHAVIORAL|Standard Pulmonary Rehabilitation|"xercise Components:~Aerobic Exercise~Mode: Walking or jogging~Resistance Exercise~Mode: Elastic bands or dumbbells~Training Parameters:~Session Duration: ≥35 minutes (combined aerobic + resistance)~Frequency: 3-5 sessions per week~Program Duration: 12 weeks"
214513278|NCT00747149|DRUG|Rosuvastatin|Oral
214513279|NCT03322579|DEVICE|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
214513280|NCT06103721|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
214513281|NCT06103721|DRUG|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
214513282|NCT03412045|DEVICE|hyperbaric oxygen therapy|Participants in vaso-occlusive crisis from sickle cell anemia will receive 1-3 hyperbaric oxygen (HBO) sessions depending on response to the therapy. Each session will be approximately 2 hours in length at 2.5 ATM. Minimum time between HBO sessions of 4 hours.
214513283|NCT05132088|DRUG|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
214513284|NCT05132088|DRUG|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
214513285|NCT00212290|DRUG|pioglitazone|
214513286|NCT00212290|DRUG|nateglinide|
214513287|NCT00212290|DRUG|placebo|
214513288|NCT03265847|BEHAVIORAL|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
214513289|NCT00212862|OTHER|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
214513290|NCT06415552|BEHAVIORAL|Mindfulness-Based Stress Reduction|Eight iterations of the MBSR course will be delivered, over a total period of 24 months. Each iteration will take place over 8 weeks. Courses would consist of 8 weekly sessions, led by certified mindfulness instructors. Sessions will include core meditation practices, psychoeducation, and home practices.
214513291|NCT05620654|DRUG|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
214430133|NCT06973174|BIOLOGICAL|Premature neonates with invasive infection caused by Bacillus cereus|The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.
214513292|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section.
214513293|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
214513294|NCT00762554|DRUG|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
214513295|NCT05001815|DEVICE|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
214513296|NCT05001815|DEVICE|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
214513297|NCT05522777|OTHER|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
214513298|NCT04620122|OTHER|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
214513299|NCT02248753|DRUG|Pharmacological cardioversion - Flecainide|
214513300|NCT02248753|PROCEDURE|Electrical cardioversion|
214513301|NCT02248753|DRUG|Metoprolol|
214513302|NCT02248753|DRUG|Verapamil|
214513303|NCT02248753|DRUG|Digoxin|
214513304|NCT02248753|DRUG|Pharmacological cardioversion - Amiodarone|
214430134|NCT06972966|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
214430135|NCT06972966|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
214692490|NCT01152164|BEHAVIORAL|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
214692491|NCT02704221|BEHAVIORAL|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
214430136|NCT06972680|DRUG|Bupivacaine Liposomes(BL)|Prior to surgery, an interscalene brachial plexus block was performed, injecting the preset volume of 0.5% bupivacaine liposomes according to the Bayesian optimal interval method.
214430137|NCT06974422|BEHAVIORAL|Partial weight bearing during aerobic exercise training|Partial weight bearing (25% weight support) during the moderate intensity aerobic exercise training on the antigravity treadmill
214430138|NCT06974422|BEHAVIORAL|Full weight bearing during aerobic exercise training|Full weight bearing (100% weight loading, 0% weight support) during moderate intensity aerobic exercise training on the antigravity treadmill.
214430139|NCT06974422|DRUG|Regular oral anti-diabetic medications.|Participants in the control group (group C) received regular oral anti-diabetic medications.
214430140|NCT06965634|DEVICE|Lung ultrasound|Lung ultrasonography ; lung ultrasonography will be applied in 4 quadrants according to the LUS protocol and LUS score will be created.
214513307|NCT04985266|DRUG|Palbociclib 125Mg Tab|Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
214513308|NCT04985266|DRUG|Fulvestrant injection|Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
214513309|NCT04985266|DRUG|Tamoxifen|As per clinical guidelines
214513310|NCT04985266|DRUG|Letrozole|As per clinical guidelines
214513311|NCT04985266|DRUG|Exemestane|As per clinical guidelines
214513312|NCT04985266|DRUG|Anastrozole|As per clinical guidelines
214513313|NCT06406049|OTHER|Control group|Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.
214513314|NCT06406049|BEHAVIORAL|Social network intervention|Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.
214513315|NCT04276259|DRUG|Buprenorphine|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~6 hours) and an oral placebo tablet.
214692492|NCT02704221|BEHAVIORAL|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
214692493|NCT02704221|BEHAVIORAL|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
214692494|NCT03453151|DRUG|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
214692495|NCT06998147|OTHER|correlation and regression analyses|to evaluate the association interplay among balance, functional mobility, cognitive function, psychological well-being, and community participation in addition to identify the anticipated contributing factors that function as predictors of MS features.
214692496|NCT00385567|DRUG|PEHRG214|
214692497|NCT04935060|BEHAVIORAL|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
214692498|NCT04935060|BEHAVIORAL|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
215113981|NCT06480318|DEVICE|TENS|The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
215113982|NCT03193710|DRUG|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
215113983|NCT03193710|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
215113984|NCT03193710|DRUG|Remifentanil|Remifentanil will be used for analgesia in both groups.
214430141|NCT06973018|BEHAVIORAL|eRehabCog|eRehabCog is a manualised internet delivered compensatory cognitive rehabilitation program (10 weeks, 1 hour per week, 10 hours in total). It is designed to improve patient self efficacy and participation in everyday life activities through compensatory strategy learning
214430142|NCT06973018|BEHAVIORAL|CogMed QM|CogMed QM is an internet delivered training program (5 weeks, 2 hours per week, 10 hours in total) designed to improve patients working memory
214430143|NCT06973564|DRUG|JAB-23E73|Oral administration
214430144|NCT06973564|DRUG|JAB-23E73|Oral administration
214430145|NCT06973564|DRUG|JAB-23E73|Oral administration
214430146|NCT06972537|DRUG|Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g administered four times a day (QID), with each infusion lasting for 4 hours.
214430147|NCT06972537|DRUG|Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g administered three times a day (TID), with each infusion lasting for 3 hours.
214430148|NCT06973915|OTHER|AI model for movement and pain assessment in low back pain|This intervention involves developing an artificial intelligence (AI) model to objectively assess four physical parameters relevant to low back pain (LBP): 1) sit-to-stand performance, 2) trunk range of motion, 3) gait pattern, and 4) facial expression-based pain levels during movement. The AI model processes video recordings of participants performing these tasks to extract movement and facial data, providing standardized measurements. The tool is designed to assist physiotherapists in clinical decision-making by offering consistent and accurate assessments compared to traditional observational methods.
214430149|NCT06973278|PROCEDURE|SMILE|Small Incision Lenticule Extraction
214430150|NCT06973278|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
214430151|NCT06243796|PROCEDURE|Flap fixation technique|After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
214430152|NCT03739372|OTHER|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
214430153|NCT05026476|DIETARY_SUPPLEMENT|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
214430154|NCT06692283|DRUG|denifanstat|Tablet
214430155|NCT06692283|DRUG|Placebo|Matching tablet
214430156|NCT06073093|DRUG|SAR441566|Tablet
214430157|NCT06073093|DRUG|Placebo|Tablet
214430158|NCT06042166|BEHAVIORAL|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
214430159|NCT06368453|DEVICE|INSTI® HIV Self-Test|"Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing."
214430160|NCT05831007|GENETIC|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
214430161|NCT02177318|DRUG|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
214430162|NCT01192633|DRUG|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
214430163|NCT00148434|BEHAVIORAL|Patient-held guideline for hypertension|
214430164|NCT05076058|DIETARY_SUPPLEMENT|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
214430165|NCT05076058|OTHER|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
214430166|NCT03934658|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
214430167|NCT03934658|DEVICE|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
214430168|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
214430169|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
214430170|NCT03639350|BEHAVIORAL|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
214430171|NCT03639350|BEHAVIORAL|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
214430172|NCT02705183|RADIATION|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
214430173|NCT02906735|PROCEDURE|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
214430174|NCT00893425|DRUG|ramipril|
214430175|NCT00433199|DRUG|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
214430176|NCT00433199|DRUG|Placebo|Placebo Control
214430177|NCT01166152|BEHAVIORAL|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
214430178|NCT04141865|DEVICE|Xen|Xen microstent implantation
214430179|NCT04141865|DEVICE|Aqueous shunt|Aqueous shunt implantation
214430180|NCT01460563|DRUG|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
214430181|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
214430182|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
214430183|NCT04728724|DRUG|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
214430184|NCT04728724|DRUG|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
214430185|NCT04512651|OTHER|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
214430186|NCT04512651|OTHER|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
214430187|NCT00064012|DRUG|bortezomib|
214430188|NCT00064012|DRUG|docetaxel|
214692499|NCT04543474|OTHER|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
214513316|NCT04276259|DRUG|Naltrexone|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours) and a saline IM injection.
214513317|NCT04276259|DRUG|Oral Placebo|Oral placebo: to match the oral naltrexone.
214513318|NCT04276259|DRUG|IM Placebo|IM saline placebo: to match the i.v. buprenorphine.
214430192|NCT00262730|DRUG|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
214430193|NCT00262730|DRUG|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
214430194|NCT00262730|RADIATION|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
214430195|NCT01170962|DRUG|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
214430196|NCT01170962|DRUG|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
214430197|NCT01170962|DRUG|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
214430198|NCT01170962|DRUG|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
214430199|NCT01170962|DRUG|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
214430200|NCT02781766|OTHER|Thrombin generation measurement.|
214430201|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
214430202|NCT02998450|DRUG|IMR-687|1 of 6 possible single doses administered orally following overnight fast
214513319|NCT04276259|DEVICE|Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.|Participants will receive two blocks of each TBS form. During the first block, stimulation intensity will be gradually escalated in 5% increments (from 80% to 110% rMT) in order to enhance tolerability. In all conditions, the investigators will apply 600 pulses of theta burst at 110% RMT. Each block of iTBS will consist of 20 trains, each lasting 2s with intertrain intervals of 8s, for a total of 192s. Each block of cTBS will consist of one continuous train of 40s. The sTBS will make use of two surface electrodes placed on the scalp.
214513320|NCT03440177|DRUG|Ramipril|Patients are tested for their normal prescription ramipril medication
214513321|NCT06562972|OTHER|Occlusal equilibration of complete denture using articulating paper|Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.
214430203|NCT02998450|DRUG|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
214430204|NCT06974331|BEHAVIORAL|Multimedia Protocol about Asthma Control|Addressing this multifaceted problem is essential for the well-being of individuals and communities worldwide. Therefore, this study aims to evaluate the effect of multimedia protocol about asthma control on asthmatic children's adaptation in the era of climate.
215113985|NCT05758428|DRUG|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
214430205|NCT05102656|OTHER|Best Practice|Physician conversations occur in-person
214430206|NCT05102656|PROCEDURE|Discussion|Physician conversations occur via video call
214430207|NCT05102656|OTHER|Questionnaire Administration|Ancillary studies
214430208|NCT05253118|DRUG|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
214430209|NCT05253118|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
214430210|NCT06195475|OTHER|high vs low tidal volume|The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.
214430211|NCT05714696|BEHAVIORAL|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
214430212|NCT05714696|BEHAVIORAL|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
214430213|NCT01872026|DRUG|ASP7991|oral
214430214|NCT00704626|OTHER|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
214430215|NCT00704626|OTHER|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
214430216|NCT00118066|DIETARY_SUPPLEMENT|calcitriol|Given orally
214430217|NCT00118066|PROCEDURE|observation|No initial intervention
214430218|NCT04926571|DRUG|Dexamethasone Oral|New users of Dexamethasone
214430219|NCT06552533|OTHER|Resistance Exercises with Plyometric exercises|"We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.~Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane).After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises,Plyometric Ankle Jumps Ankle Circles"
214430220|NCT06552533|OTHER|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will be maintained, the therapist will assure that the targeted musculature will being maximally loaded
214430221|NCT05594576|PROCEDURE|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
214430222|NCT05594576|PROCEDURE|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
215113986|NCT05758428|DRUG|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
215113987|NCT06120439|COMBINATION_PRODUCT|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
215113988|NCT06120439|COMBINATION_PRODUCT|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
214430223|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
214430224|NCT02422095|PROCEDURE|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
214430225|NCT02422095|PROCEDURE|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
214430226|NCT04257435|BEHAVIORAL|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
214430227|NCT04257435|BEHAVIORAL|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
214430228|NCT03542630|DIAGNOSTIC_TEST|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
214430229|NCT03542630|OTHER|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
214430230|NCT03542630|OTHER|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
214430231|NCT05319522|BEHAVIORAL|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
214430232|NCT06680752|BIOLOGICAL|ARD103|ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
214430233|NCT06680752|DRUG|Cyclophosphamide|iv administration for lymphodepletion
214430234|NCT06680752|DRUG|Fludarabine|iv administration for lymphodepletion
214430235|NCT07060378|DEVICE|Contrast-enhanced endobronchial ultrasound|Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.
214430236|NCT07060417|DRUG|Empagliflozin|Empagliflozin 10 mg, encapsulated to match the placebo, will be used.
214430237|NCT07060417|DRUG|Placebo|Matching placebo will be used.
214430238|NCT07061431|DIETARY_SUPPLEMENT|High Dose of Vitamin C with ir without 50 mg of flavonoids|The anti-inflammatory and anti-platelet efficacy and synergy of a supplement containing high dose (1 g) of vitamin C and a low dose (50 mg) citrus and rose bioflavonoids (VCF), was assessed in platelets of blood samples collected from healthy subjects, prior the oral administration (t=0 days) and just after this administration for 1 month (VCF Group), VERSUS the findings from the same procedure contacted for a supplement containing only high dose (1 g) of vitamin C (VC Group)
214430239|NCT07060014|DRUG|Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months|The study drugs will be administered per the regimen defined in the NAPOLI-3 clinical trial. Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months.
214430240|NCT06898346|BEHAVIORAL|Nutrition Education|The treatment group will receive nutrition education (NE) and counseling 6 times. The 1st and 6th counselling sessions will be administered by a Registerd Dietitan in a health facility (weeks 21-22 and weeks 31-32). Four (4) bi-weekly follow-ups between these 2 sessions will be administered by Field Assistants (weeks 23, 25, 27 and 29) at the participant's home. NE will focus on dietary diversity and minimum meal frequency (Daniel et al, 2016; Gyimah et al., 2021), protein and energy intakes (Ota et al, 2015), intake of iron-rich foods (Otoo and Adam, 2016), guidelines for pregnancy with an emphasis on appropriate weight gain (Abubakar et al, 2016), and appropriate ingredients and food preparation methods required to optimize nutrition.
214513322|NCT06562972|OTHER|Occlusal equilibration of complete denture using occulosense|Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
214513323|NCT04556227|BEHAVIORAL|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
214430241|NCT06842966|DRUG|4-MUST|128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.
214430242|NCT06842966|DRUG|Placebo|Placebo tablet.
214430243|NCT06498518|DRUG|IMM-101, Pembrolizumab, Gemcitabine|Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle
214430244|NCT07060105|OTHER|Hypertonic Saline ( 3% Sodium Chloride Saline)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
214430245|NCT07060105|OTHER|Normal Saline (0.9% NaCl)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
214430246|NCT07061119|OTHER|Conventional treatment|"Trampolinejumping:5times. Gym ball exercise:5reps'Sensory diet:- Joint compressions: 1 set x 10reps on limbs, neck, and head region.~Deeppressure:1 setx10reps. Balance board exercises."
214430247|NCT07061119|OTHER|cawthorne cooksey exercises|"Cawthorne Cooksey exercises~* Start with low to moderate intensity.~* Gradually increase range, speed, and Complexity over time~* Trampoline jumping- Gym ball exercise- Sensory diet~* Cawthorne Cooksey exer cise Training~Phase1-In bed exerercises:- Eye movements:~1)Up and down 2)Side to side 3)Moving finger away from face~* Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed~* bending forward and backward~* turning from side to side.~  --Shoulder shrugging and circling~* Bending forward and picking up objects from the ground~* Phase 3 - Standing:~* Eye, Head, Shoulder movements~* Throwing ball from hand to hand, hand under knee~* Switch to sitting to standing and turning around in between.~* Phase 4 - Walk: with eyes closed and open:~* Across room~* Slope and Stairs"
214430248|NCT06756477|BEHAVIORAL|mindfulness group|Online training will be implemented 2 times a week for 8 sessions. A 30-45 minute reminder training will be given 1 month after the training. Mindfulness-Based Healthy Living Behaviors Education (MTSYDE) booklet will be sent online to guide students' home practices. Taking into account the possibility of forgetting and demotivation in students, audio recordings will be used, reminder messages will be sent and counseling will be given regarding the program. A post-test will be administered 1 month after the reminder training.
214430249|NCT06756477|OTHER|control group|Menstruation-specific Healthy Living Behaviors training of 30-45 minutes in 8 sessions 2 times a week will be provided online. A standard training booklet will be sent 1 month after the training as a reminder. Standard reminder messages will be sent considering the possibility of forgetting and demotivation in students. A post-test will be administered 1 month after the reminder training.
214430250|NCT07061132|OTHER|AI-Based Interview Simulation|The intervention group participated in a structured, text-based job interview simulation supported by ChatGPT-4o, using nine standardized prompts based on ICN (2008) and ICM (2024) core competencies. Developed by experts in simulation and nursing education, the intervention aimed to enhance self-efficacy and reduce interview-related anxiety. Each session lasted 15-20 minutes and concluded with structured feedback provided by ChatGPT. Participants were also offered an optional preparation guide with 40 reflective questions across themes such as communication, anxiety, and self-awareness. This preparation was not mandatory and not included in the simulation time.
214513324|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
215113989|NCT03007602|OTHER|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
215113990|NCT02233023|DRUG|Pramipexole|
215113991|NCT02233023|DRUG|Bromocriptine and other dopamine agonists|
215113992|NCT06272123|OTHER|no intervention|no intervention
215113993|NCT05712954|OTHER|music group|music
215113994|NCT05712954|OTHER|video group|video
215113995|NCT05651672|DRUG|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
214430251|NCT03005678|DRUG|Denosumab|active treatment group
214430252|NCT03005678|DRUG|Alendronate|comparator
214430253|NCT06908226|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
214430254|NCT06941155|BEHAVIORAL|Gamified-Combined Cognitive Bias Modification|A gamified version of the combined cognitive bias modification (CBM-C) intervention, which includes both attention and interpretation bias modification tasks. The attention component is a modified dot-probe task, and the interpretation component consists of OCD-related scenarios with word-completion exercises. Gamification elements such as feedback and visual rewards are embedded to enhance motivation and engagement. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
214692500|NCT04543474|OTHER|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
215113996|NCT03240770|DEVICE|VPro5 device|Use of the VPro5 device for 5 minutes a day
215113997|NCT03240770|OTHER|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
215113998|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
215113999|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
215114000|NCT06525584|OTHER|Control|Without ketamine
214430255|NCT06941155|BEHAVIORAL|Standard Combined Cognitive Bias Modification|A standard version of the combined cognitive bias modification (CBM-C) intervention, consisting of attention and interpretation bias tasks without gamification features. The attention task is a modified dot-probe paradigm, and the interpretation task involves OCD-related scenarios followed by word-completion exercises. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
214430256|NCT06941155|BEHAVIORAL|Placebo|A placebo version of the standard CBM-C intervention that retains the same structure and timing but omits all active bias modification elements. The attention task (modified dot-probe) presents probes equally behind threat and neutral stimuli, and the interpretation task includes OCD-related scenarios with word-completion items that lead to neutral outcomes. No manipulations are applied to shift cognitive bias. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
214430257|NCT04268550|DRUG|Selpercatinib|Given PO
214430258|NCT06951815|DEVICE|Hearing aids programmed to each participant's hearing loss.|This study is not investigating the efficacy of hearing aids, rather it is investigating the effect of adjusting hearing on cognitive resources, listening effort, and fatigue.
214430259|NCT01109745|OTHER|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
214430260|NCT01109745|OTHER|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
214430261|NCT06233565|DRUG|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
214430262|NCT06233565|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
214430263|NCT06233565|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
214430264|NCT06126510|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
214430265|NCT05700006|DRUG|Aromatase inhibitor|Standard of care anastrozole, exemestane, or letrozole
214430266|NCT05436561|DRUG|MBF-RIC|Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
214430267|NCT04469699|DRUG|Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
214430268|NCT04469699|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
214430269|NCT04897880|DRUG|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
214430270|NCT04453020|DEVICE|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
214430271|NCT03101917|DEVICE|The Microtable® Stereotactic System|x
214430272|NCT06276465|DRUG|Darolutamide 300 mg|2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
214430273|NCT06276465|RADIATION|Stereotactic body radiation therapy|Over one week,30 Gy in 3 fractions of 10 Gy
214430274|NCT06276465|DRUG|Androgen deprivation therapy|Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
214430275|NCT06522061|DEVICE|Stream™ Platform|Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
214430276|NCT03400085|OTHER|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
214430277|NCT05240586|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
214513325|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
214430278|NCT05240586|PROCEDURE|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
214513326|NCT06107335|DRUG|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
214430279|NCT05240586|PROCEDURE|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
214430280|NCT06232304|BEHAVIORAL|TEACH|TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
214430281|NCT06814288|DRUG|Botulinum toxin A|Twenty keloid patients will be injected botulinum toxin A intralesional every 4 weeks.
214430282|NCT06814288|DRUG|Triamcinolone Acetonide|Twenty keloid patients will be injected triamcinolone acetonide intralesional every 4 weeks.
214430283|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
214430284|NCT01758328|DRUG|busulfan|
214430285|NCT01758328|DRUG|melphalan|
214430286|NCT01758328|DRUG|fludarabine|
214430287|NCT01758328|BIOLOGICAL|anti-thymocyte globulin (ATG)|
214513327|NCT06107335|DRUG|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
214513328|NCT06107335|DEVICE|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
214513329|NCT03803423|OTHER|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
214513330|NCT06005441|DRUG|CBL-514 injection|Provided as a ready for use injectable CBL-514 solution
214513331|NCT06005441|DRUG|CBL-A1 Injection|Provided as a ready for use injectable CBL-A1 solution
214430288|NCT01758328|PROCEDURE|a T cell depleted stem cell transplant|
214430289|NCT05733442|OTHER|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
214430290|NCT05733442|OTHER|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
214513332|NCT06005441|DRUG|CBL-A2 Injection|Provided as a ready for use injectable CBL-A2 solution
214513333|NCT06005441|DRUG|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
214513334|NCT06235567|DRUG|Dextenza 0.4Mg Ophthalmic Insert|This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
214430291|NCT03624712|DIAGNOSTIC_TEST|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
214430292|NCT04505371|BEHAVIORAL|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
214430293|NCT03927027|DRUG|Isosulfan Blue|Given SC
214430294|NCT03927027|PROCEDURE|Axillary Lymph Node Dissection|Undergo ALND
214430295|NCT03927027|PROCEDURE|Mapping|Undergo ARM
214430296|NCT03927027|OTHER|Quality-of-Life Assessment|Ancillary studies
214430297|NCT03927027|OTHER|Questionnaire Administration|Ancillary studies
214513335|NCT06235567|DRUG|topical prednisolone acetate 1% (PredForte) eye drops|The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
214430298|NCT05726604|OTHER|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
214430299|NCT02582736|DRUG|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
214430300|NCT02582736|DRUG|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
214513336|NCT06373731|DRUG|Elamipretide|Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks
214513337|NCT06373731|DRUG|Placebo|Subjects will receive once daily SC doses of Placebo 96 weeks
214513338|NCT06790095|DRUG|Cyclosporine (CsA)|Intravenous (IV) injection, loading dose of 2.5 mg/kg (diluted in 0.9% NaCl to a final volume of 50 ml) given over 2 hours, immediately followed by a continuous IV infusion of of 5 mg/kg/day (diluted in 0.9% NaCl to a final volume of 250 ml) for 3 days (72-hour).
214513339|NCT06790095|DRUG|Placebo|"Intravenous (IV) injection of 0.9% NaCl with the same dosing strategy as CsA: loading dose given over 2 hours, immediately followed by a continuous IV infusion for 3 days (72-hour)."
214513340|NCT06791551|DEVICE|active RIPC and tDCS|Preoperative use of a therapeutic device with sleeves fixed on the upper side of both arms, compressing the bilateral brachial arteries to 200mmHg for 5 minutes, resting for 5 minutes, repeating 5 times, recorded as 1 time, training once in the morning and afternoon each day, and continuing treatment for at least 3 days; Administer transcranial electrical stimulation, 2mA, 30min, for 3 days;
214430301|NCT02582736|DRUG|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
214430302|NCT02582736|DRUG|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
214430303|NCT05670834|GENETIC|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
214430304|NCT05670834|DIAGNOSTIC_TEST|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
214430305|NCT06357559|DEVICE|OCTA|Optical Coherence Tomography Angiography
214430306|NCT04861233|OTHER|No Intervention|This is a non-interventional study.
214430307|NCT00338442|DRUG|VariZIG™|Biological / Vaccine
214430308|NCT05886218|DEVICE|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
214430309|NCT05324878|OTHER|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
214513341|NCT06791551|DEVICE|Sham (No Treatment)|received sham treatment with the same appearance instrument;
214513342|NCT06069544|BIOLOGICAL|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
214513343|NCT06069544|OTHER|Placebo|Isotonic NaCl solution (0.9%)
214513344|NCT04831398|DIETARY_SUPPLEMENT|melatonin|A 5mg dose of melatonin spay will be delivered sublingually.
214430310|NCT01510236|BEHAVIORAL|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
214513345|NCT04831398|OTHER|Placebo|10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
214513346|NCT05006703|BEHAVIORAL|Breathe for Teens (Breathe4T)|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
214430311|NCT03612375|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214430312|NCT03612375|OTHER|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214513347|NCT00334438|BIOLOGICAL|rituximab|250mg/m2, IV, Days 1 and 8
214513348|NCT00334438|DRUG|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
214513349|NCT00334438|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
214513350|NCT00334438|RADIATION|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
214513351|NCT06633133|PROCEDURE|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
214513352|NCT05121012|OTHER|Study procedures|"All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up."
214513353|NCT06519955|COMBINATION_PRODUCT|Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)|"Weight 50-74.9 kg:~* ropivacaine 100mg/epinephrine 50 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 75-99.9 kg:~* Ropivacaine 150mg/epinephrine 100 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 100+ kg:~* Ropivacaine 200mg/epinephrine 150 mcg/ketorolac 15 mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total"
214513354|NCT00576485|PROCEDURE|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
214513355|NCT02992496|DRUG|Ketamine|1mg/kg, 6 applications over 2 weeks
214513356|NCT02992496|DRUG|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
214513357|NCT02827851|PROCEDURE|Liposuction|
214513358|NCT02827851|OTHER|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
214513359|NCT02827851|OTHER|Intraarticular administration of autologous SVF|
214513360|NCT05261100|OTHER|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
214513361|NCT05261100|OTHER|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
215114001|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
215114002|NCT01969630|DEVICE|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
214513362|NCT00211276|DRUG|ONTAK (denileukin diftitox)|
215114003|NCT01969630|DEVICE|PES|Systematic Paclitaxel eluting stent angioplasty
215114004|NCT00002138|DRUG|Tecogalan sodium|
215114005|NCT05050864|PROCEDURE|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
214430313|NCT04925336|OTHER|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
214430314|NCT00484055|DRUG|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
214430315|NCT00484055|PROCEDURE|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
214430316|NCT00589277|BEHAVIORAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
214430317|NCT00589277|BEHAVIORAL|Standard care counseling + standard materials|Standard messages for quitting smoking
214430318|NCT03762434|OTHER|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
214513363|NCT03527329|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
214513364|NCT01655199|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
214513365|NCT04683900|OTHER|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
214513366|NCT04683900|OTHER|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
214513367|NCT00360035|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
214513368|NCT06571292|DEVICE|Intensive training with robotic exoskeleton for upper limbs|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
214513369|NCT06571292|DEVICE|Task specific training|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
214513370|NCT06570993|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
214513371|NCT00372099|DRUG|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
214430319|NCT06147167|DEVICE|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
214430320|NCT06147167|DEVICE|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
214430321|NCT06147167|DEVICE|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
214430322|NCT03400254|DRUG|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
214430323|NCT03400254|DRUG|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped."
214430324|NCT03698396|BIOLOGICAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
214430325|NCT01039948|BIOLOGICAL|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
214430326|NCT01039948|DRUG|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
214430327|NCT00908505|PROCEDURE|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
214430328|NCT01460446|DEVICE|Aviva Expert blood glucose meter|
214430329|NCT01460446|DEVICE|Aviva Nano blood glucose meter|
214430330|NCT02231983|GENETIC|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
214430331|NCT04645147|BIOLOGICAL|EBV gp350-Ferritin Vaccine|A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.
214513372|NCT04250181|OTHER|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
214513373|NCT04636099|DEVICE|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
214513374|NCT04287361|OTHER|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
214513375|NCT05491837|OTHER|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
214513376|NCT05491837|OTHER|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
215114006|NCT05050864|PROCEDURE|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
214430332|NCT04645147|OTHER|Matrix-M1|Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
214430333|NCT06445257|DRUG|zanubrutinib 160 mg BID orally|The ZRMT induction and maintenance regimen
214430334|NCT01449123|DRUG|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
214430335|NCT05346978|DIETARY_SUPPLEMENT|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
214430336|NCT05346978|DIETARY_SUPPLEMENT|Placebo|collagen colored with green pigment used in the food industry
214430337|NCT00580112|DRUG|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
215114007|NCT00001094|DRUG|Lamivudine/Zidovudine|
215114008|NCT00001094|DRUG|Nelfinavir mesylate|
215114009|NCT00001094|DRUG|Saquinavir|
215114010|NCT00001094|DRUG|Delavirdine mesylate|
215114011|NCT00550693|DEVICE|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
214430338|NCT00580112|DRUG|Trabectedin|Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
214513377|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
214513378|NCT03430609|DIAGNOSTIC_TEST|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
214513379|NCT03430609|DIAGNOSTIC_TEST|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
214513380|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
214513381|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
214513382|NCT01381549|DRUG|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
214430339|NCT02520908|PROCEDURE|HSCT|Hematopoietic stem cell transplantation
214430340|NCT02520908|OTHER|Standard Care|
214430341|NCT01263613|PROCEDURE|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
214430342|NCT00542789|DRUG|Esomeprazole|20mg once daily oral
214430343|NCT00542789|DRUG|Placebo|once daily oral
214513383|NCT01381549|DRUG|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
214513384|NCT01381549|OTHER|Placebo|saline placebo
215114012|NCT02930915|DEVICE|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
215114013|NCT02481245|DRUG|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
215114014|NCT00195663|BIOLOGICAL|Adalimumab|
215114015|NCT00195663|DRUG|Methotrexate|
215114016|NCT00195663|BIOLOGICAL|Adalimumab placebo|
215114017|NCT00195663|DRUG|Methotrexate placebo|
214430344|NCT00681213|DRUG|Tacrolimus/Sirolimus|
214430345|NCT00681213|DRUG|Tacrolimus/MMF|
214430346|NCT00681213|DRUG|Neoral/Sirolimus|
214430347|NCT00808405|DRUG|acyclovir|400mg taken orally three times daily for 5 days
214430348|NCT00808405|DRUG|matching placebo|matching placebo taken orally three times daily for 5 days.
214430349|NCT04040413|PROCEDURE|bariatric surgery|All bariatric procedures
214430350|NCT00636207|DRUG|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
214430351|NCT00636207|DRUG|Placebo|Placebo dry powder inhaler
214430352|NCT03109795|DRUG|Clonidine Pill|sympathetic nerve activity blockade
214430353|NCT03109795|DRUG|Hydrochlorothiazide|Blood pressure-lowering control condition
214430354|NCT02838199|DEVICE|SAPIEN 3|
214430355|NCT02838199|PROCEDURE|SAVR|
214430356|NCT02050763|BEHAVIORAL|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
215114018|NCT00604695|DRUG|Tenecteplase|Intracoronary injection of IV tenecteplase.
215114019|NCT00604695|DRUG|Sterile Saline|Intracoronary injection of IV sterile saline
215114020|NCT04659525|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
214430357|NCT04277715|BEHAVIORAL|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
214430358|NCT03753841|OTHER|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
214430359|NCT02076451|DRUG|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
214430360|NCT01641198|DEVICE|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
214513385|NCT06123936|OTHER|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
214513386|NCT00824057|DRUG|AZD6280|oral
214430361|NCT01641198|DEVICE|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
214430362|NCT01641198|DEVICE|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
214430363|NCT04193410|BEHAVIORAL|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
214430364|NCT02390544|DRUG|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
214430365|NCT01396837|DEVICE|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
214513387|NCT00824057|DRUG|Midazolam|oral
214513388|NCT00824057|DRUG|Caffeine|oral
214513389|NCT02198105|DEVICE|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length."
214513390|NCT05779696|OTHER|No-intervention|This is a non-intervention study.
214513391|NCT01821599|OTHER|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
214513392|NCT01821599|OTHER|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
214513393|NCT04338568|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
214430366|NCT01694446|OTHER|Intraduodenal glucose or fructose|
214430367|NCT02954016|DEVICE|ePass|Subject is implanted with the device for up to 3 years.
214430368|NCT02378337|OTHER|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
214430369|NCT00643929|DRUG|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
214430370|NCT02641990|DRUG|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
214430371|NCT02641990|DRUG|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
214513394|NCT04874142|DRUG|YYC506-T|single administration
214430372|NCT00316836|PROCEDURE|mammography|
214430373|NCT02473419|DRUG|Vayarin|
214513395|NCT04874142|DRUG|YYC506-A|single administration
214513396|NCT04874142|DRUG|YYC506-T + YYC506-A|concomotant administration
215114021|NCT04659525|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
214513397|NCT04874142|DRUG|YYC506-A + YYC506-T|concomotant administration
214430374|NCT02473419|DRUG|Placebo|
214513398|NCT05238337|DRUG|[14C]-PBI-200|\[14C\]-radio-labeled-PBI-200
214513399|NCT00169923|DRUG|rosiglitazone|
214513400|NCT00578344|DRUG|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
214513401|NCT00578344|BIOLOGICAL|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
214513402|NCT00578344|DRUG|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
214513403|NCT03422705|DEVICE|Optimised programming|Optimised programming to avoid RV pacing when possible.
214513404|NCT03422705|DRUG|Lisinopril|Uptitration of lisinopril
214430375|NCT02594735|DRUG|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
214430376|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
214430377|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
214513405|NCT03422705|OTHER|Standard care|No pacemaker adjustment or medical therapy
214513406|NCT06322589|DIETARY_SUPPLEMENT|SOD like Super Drink|consume 1 bottle per day
214513407|NCT06322589|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
214513408|NCT04836871|COMBINATION_PRODUCT|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
214430378|NCT05898152|OTHER|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
214430379|NCT02529995|DRUG|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
214430380|NCT02529995|DRUG|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
214430381|NCT02621632|DEVICE|(Socknleg)To done of a novel compression system|To done a novel compression system.
214513409|NCT00690313|DRUG|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
214513410|NCT02935673|DRUG|lumicitabine|Oral administration of lumicitabine as tablet.
214513411|NCT02935673|DRUG|Placebo|Oral administration of matching placebo.
214513412|NCT03898999|OTHER|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
215114022|NCT04659525|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
215114023|NCT04551950|DRUG|M7824|Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
214513413|NCT01077440|GENETIC|DNA analysis|DNA analysis will be performed on samples collected.
214513414|NCT01077440|GENETIC|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
214513415|NCT01077440|OTHER|flow cytometry|Flow cytometry will be done on the samples collected.
214513416|NCT01077440|OTHER|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
214513417|NCT02772510|DEVICE|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
214513418|NCT02772510|DEVICE|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
214513419|NCT02635698|OTHER|Optifast|medically-supervised weight management program
214513420|NCT02635698|OTHER|Food-Based|low-energy, low-fat diet
214513421|NCT01303471|DRUG|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
214513422|NCT02894086|OTHER|database.|database
214513423|NCT01444404|DRUG|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
214513424|NCT04328467|DRUG|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
214513425|NCT04328467|OTHER|Placebo|Placebo; tablet; oral
215114024|NCT04551950|DRUG|Carboplatin|Carboplatin was administered intravenously as per standard of care.
214430382|NCT04567407|DRUG|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
214430383|NCT03301025|DRUG|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
214430384|NCT03301025|DRUG|placebo|given a placebo identical capsule once one hour before anesthesia
214430385|NCT01316263|BIOLOGICAL|Olaratumab|Administered IV
214430386|NCT01318655|DRUG|NKTR-118|Tablet, Oral, Once daily
214430387|NCT01318655|DRUG|Placebo|Tablet, Oral, Once daily
214513426|NCT03093532|OTHER|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1\) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
214513427|NCT03093532|OTHER|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
214513428|NCT02017509|PROCEDURE|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
215114025|NCT04551950|DRUG|Paclitaxel|Paclitaxel was administered intravenously as per standard of care.
215114026|NCT04551950|DRUG|Bevacizumab|Bevacizumab was administrated as indicated for standard of care.
215114027|NCT04551950|DRUG|Cisplatin|Cisplatin was administered intravenously as per standard of care.
215114028|NCT04551950|RADIATION|Radiotherapy|Participants received radiotherapy as per standard of care.
215114029|NCT04070612|OTHER|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
214430388|NCT05957900|BEHAVIORAL|Multisensory stimulation module|"* Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~* Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~* Vestibular Stimulation; neonates placed in a hammock for 3 min.~* Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~* Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~* Olfactory Stimulation for 3 min. using mother's milk.~* Auditory Stimulation listening to mother's heart beats for 3 min."
214430389|NCT01885806|DEVICE|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
214430390|NCT01885806|DEVICE|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
214430391|NCT02928874|BEHAVIORAL|% COMPX (low ED vs. high ED preload)|
214430392|NCT02928874|BEHAVIORAL|EAH (low ED vs. high ED snacks)|
214430393|NCT04969172|DRUG|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
214430394|NCT03823196|DIETARY_SUPPLEMENT|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
214513429|NCT02017509|PROCEDURE|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
214513430|NCT02017509|PROCEDURE|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
214513431|NCT02017509|GENETIC|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
214513432|NCT02952170|OTHER|MRI|MRI to assess hepatic steatosis
214513433|NCT00990184|DRUG|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
214513434|NCT00990184|OTHER|placebo|tablet (s) orally given with evening meal
214513435|NCT01558999|DRUG|High concentration SI-614|1 drop in each eye 4 times a day
214513436|NCT01558999|DRUG|Low concentration SI-614|1 drop in each eye 4 times a day
214513437|NCT01558999|DRUG|Vehicle|1 drop in each eye 4 times a day
214513438|NCT02769130|DRUG|Losartan|Losartan is given for 12 months
214513439|NCT01521702|DRUG|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
214513440|NCT01521702|PROCEDURE|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
215114030|NCT00014833|OTHER|No intervention|No intervention
214513441|NCT02705885|DIETARY_SUPPLEMENT|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
214513442|NCT02705885|DIETARY_SUPPLEMENT|Placebo IgY|Placebo IgY
214513443|NCT04897347|DEVICE|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
214513444|NCT04897347|DEVICE|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
214513445|NCT03835416|DIETARY_SUPPLEMENT|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
214513446|NCT05830032|DIETARY_SUPPLEMENT|Soluble corn fibre|As a powdered beverage
214430395|NCT03823196|DIETARY_SUPPLEMENT|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
214430396|NCT02080650|DEVICE|Mesenchymal-marker based ferrofluid (c-MET)|
214430397|NCT02080650|DEVICE|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
214430398|NCT00413257|DRUG|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
214430399|NCT00413257|DRUG|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
214430400|NCT00413257|DRUG|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
214430401|NCT03470142|PROCEDURE|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
214430402|NCT03470142|PROCEDURE|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
214430403|NCT06250413|OTHER|FMT|Capsulated oral auto fecal microbiota transplant
214430404|NCT06250413|OTHER|Placebo|Capsulated hot chocolate powder
214430405|NCT06250413|DRUG|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
214430406|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
214430407|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
214430408|NCT03511651|PROCEDURE|PEEP|Two PEEP levels will be used during mechanical ventilation.
214430409|NCT05311137|PROCEDURE|Radiofrequency ablation|Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
214430410|NCT02957006|DEVICE|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
214430411|NCT04370418|DRUG|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
214430412|NCT01075217|DRUG|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
214513447|NCT05830032|DIETARY_SUPPLEMENT|Inulin|As a powdered beverage
214513448|NCT05830032|DIETARY_SUPPLEMENT|soluble corn fibre and inulin|As a powdered beverage
214513449|NCT05830032|DIETARY_SUPPLEMENT|Maltodextrin|As a powdered beverage
214513450|NCT03697018|OTHER|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
214513451|NCT01792505|BIOLOGICAL|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
214513452|NCT03200509|OTHER|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
214513453|NCT03200509|OTHER|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
214430413|NCT01075217|DRUG|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
214430414|NCT01032798|DRUG|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
214430415|NCT05702658|BEHAVIORAL|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
214430416|NCT00214591|DRUG|GALIDA|
214430417|NCT02969863|DEVICE|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
214430418|NCT02969863|DEVICE|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
214430419|NCT02969863|OTHER|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
214430420|NCT02969863|OTHER|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
214430421|NCT04072653|PROCEDURE|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
214430422|NCT06518538|DRUG|CPI-613, modified Folfirinox|"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"
214430423|NCT03737240|DRUG|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
214430424|NCT03737240|DRUG|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
214430425|NCT03737240|DRUG|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
214430426|NCT03420209|BEHAVIORAL|Group applying PNF technique|
214513454|NCT01079117|DRUG|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
214513455|NCT01079117|DRUG|Slow release oral morphine|
214513456|NCT01079117|DRUG|Methadone|
214513457|NCT03301597|BIOLOGICAL|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
214513458|NCT03301597|DRUG|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
214430427|NCT04164056|DEVICE|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
214430428|NCT04722588|OTHER|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
214430429|NCT02600520|DRUG|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
214430430|NCT02600520|DRUG|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
214430431|NCT02600520|DRUG|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
214430432|NCT01431586|DRUG|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
214430433|NCT04075942|PROCEDURE|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
214430434|NCT01068743|DRUG|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
214430435|NCT01068743|DRUG|metformin|Tablets, Oral, 850 mg, once daily, single dose
214430436|NCT01068743|DRUG|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
214430437|NCT04155177|PROCEDURE|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
214513459|NCT00126620|DRUG|erlotinib hydrochloride|
214513460|NCT00126620|DRUG|sorafenib tosylate|
214513461|NCT05326685|OTHER|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
214513462|NCT01506700|DEVICE|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
214513463|NCT01442207|PROCEDURE|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
214513464|NCT01442207|PROCEDURE|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
214430438|NCT00080639|OTHER|physiologic testing|
214430439|NCT00080639|PROCEDURE|study of high risk factors|
214430440|NCT00364013|DRUG|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
214430441|NCT00364013|DRUG|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
214430442|NCT05744193|OTHER|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
214430443|NCT01434862|DRUG|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
214430444|NCT01434862|DEVICE|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
214430445|NCT01434862|DRUG|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
214430446|NCT06259474|COMBINATION_PRODUCT|Hypopressive Exercises and (heat therapy, medication, and progressive strength training)|20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
214430447|NCT00006224|DRUG|gemcitabine hydrochloride|
214430448|NCT05090930|DEVICE|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
214430449|NCT05090930|DEVICE|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
214430450|NCT03586817|DRUG|Palonosetron|75 mcg during the anesthesia
214430451|NCT03586817|DRUG|Fosaprepitant|150 mg during the anesthesia
214430452|NCT01591239|BEHAVIORAL|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
214430453|NCT01591239|BEHAVIORAL|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
214430454|NCT00011531|PROCEDURE|Prevention of Pressure Ulcers|
214430455|NCT01599117|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
214430456|NCT01599117|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
214430457|NCT05172388|OTHER|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
214430458|NCT03068078|DIETARY_SUPPLEMENT|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
214430459|NCT01591304|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
214430460|NCT01962844|DIETARY_SUPPLEMENT|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
214430461|NCT01962844|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months
214430462|NCT06277401|OTHER|Neuromuscular training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
214430463|NCT06277401|OTHER|High-load strength training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
214430464|NCT06488079|OTHER|Summary Label|The Nutri-Score Front-of-Pack nutritional label
214430465|NCT06488079|OTHER|Nutrient-specific label|The NutrInform Battery Front-of-Pack nutritional label
214430466|NCT06488079|OTHER|No label|Conventional food educational flyer
214430467|NCT05124847|BEHAVIORAL|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
214430468|NCT05124847|BEHAVIORAL|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
214513465|NCT05959902|OTHER|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
214513466|NCT05959902|OTHER|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
214513467|NCT02409888|BEHAVIORAL|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
214513468|NCT02409888|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
214513469|NCT02409888|OTHER|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
214430469|NCT01430858|DEVICE|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
215114031|NCT06015087|OTHER|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
215114032|NCT04443309|DRUG|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
215114033|NCT04443309|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
215114034|NCT03460561|PROCEDURE|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
215114035|NCT03460561|PROCEDURE|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
215114036|NCT05848427|OTHER|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
215114037|NCT04180332|DIAGNOSTIC_TEST|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
214430470|NCT01430858|OTHER|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured."
214430471|NCT05544643|DEVICE|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
215114038|NCT04967027|DEVICE|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
214430472|NCT00396513|DRUG|Simvastatin|
214430473|NCT00396513|DRUG|Simvastatin and Metformin|
214430474|NCT00396513|DRUG|Metformin|
214430475|NCT00199966|DRUG|Divalproex sodium extended release|
214430476|NCT02831712|DIETARY_SUPPLEMENT|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
214430477|NCT04356430|DRUG|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
214430478|NCT04356430|DRUG|Prednisone|5 mg oral low dose prednisone, once daily
215114039|NCT03360474|BEHAVIORAL|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
215114040|NCT05695274|BEHAVIORAL|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
215114041|NCT05789563|OTHER|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
215114042|NCT02058563|BIOLOGICAL|Priorix®|1 dose administered as a subcutaneous (SC) injection.
215114043|NCT02058563|BIOLOGICAL|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
215114044|NCT00166439|DRUG|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
215114045|NCT05942599|BIOLOGICAL|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
215114046|NCT04326582|OTHER|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
215114047|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
215114048|NCT06329206|DRUG|GH2616 Tablets|GH2616 tablets will be given orally
214430479|NCT04356430|DRUG|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
214430480|NCT04575740|DEVICE|PAP|Positive airway pressure to treat sleep apnea
214430481|NCT02658370|DEVICE|animated home-based exercises (Wii-fit)|
214513470|NCT02409888|OTHER|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
214513471|NCT00047684|BEHAVIORAL|Brief Integrative Therapy|
214513472|NCT05941156|BIOLOGICAL|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
214692501|NCT04319562|PROCEDURE|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
214692502|NCT04319562|DEVICE|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
214692503|NCT01251172|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
215114049|NCT01999725|DRUG|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
215114050|NCT01999725|DRUG|Placebo|Matching placebo capsules or matching suspension
215114051|NCT02481817|PROCEDURE|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
215114052|NCT02481817|PROCEDURE|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
215114053|NCT02481817|PROCEDURE|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
214430482|NCT02658370|PROCEDURE|conventional home-based exercise program|
214430483|NCT02272452|DEVICE|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
214430484|NCT05878158|DRUG|Simvastatin|pulpotomy of immature permanent teeth
214430485|NCT04655859|DIAGNOSTIC_TEST|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
214430486|NCT02947958|OTHER|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
214430487|NCT02947958|OTHER|Hospital (control)|The patient will keep his usual care at the tertiary care.
214430488|NCT01742481|BEHAVIORAL|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
214430489|NCT04469855|DRUG|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
214513473|NCT02835209|OTHER|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
214513474|NCT01692652|DRUG|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
214513475|NCT01692652|OTHER|warm compress only group|
214692504|NCT01251172|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
214692505|NCT01251172|PROCEDURE|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
214692506|NCT01251172|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
214692507|NCT01251172|OTHER|Laboratory Biomarker Analysis|Correlative studies
214692508|NCT01251172|DRUG|Melphalan|Given IV
214692509|NCT04284982|BEHAVIORAL|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
214692510|NCT02539082|DEVICE|Regenseal|Regenseal, collagen, injection in the defect area
214692511|NCT02539082|DRUG|normal saline|placebo, normal saline, injection in the defect area
214692512|NCT03445858|DRUG|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
215114054|NCT05463016|DEVICE|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
215114055|NCT05463016|DEVICE|Placebo Group 1: Placebo Lenses|Placebo Lenses
215114056|NCT05463016|DEVICE|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
215114057|NCT05463016|DEVICE|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
215114058|NCT05463016|DEVICE|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
214513476|NCT04255004|DEVICE|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
214513477|NCT01602900|DRUG|GSK356278|Investigational Medicinal Product
214513478|NCT01602900|DRUG|Rolipram|Challenge Agent
214513479|NCT04824456|PROCEDURE|bilateral sagittal split osteotomy using separators.|The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.
214513480|NCT02568202|OTHER|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
214430490|NCT03996278|OTHER|Grafalon|None interventional study but there are two groups
214430491|NCT01032486|DRUG|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
214430492|NCT03696966|DIETARY_SUPPLEMENT|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
214430493|NCT03696966|BEHAVIORAL|Low-Calorie Diet|Restrict calorie intake daily
214430494|NCT03696966|BEHAVIORAL|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
214430495|NCT06108778|DEVICE|MRI|Investigations as CT,MRI.serum ammonia and lactate
214430496|NCT00137371|DRUG|PVC (daily for 21 days, 7 days off)|
214430497|NCT00137371|DRUG|PVC (twice weekly)|
214430498|NCT05323266|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
214430499|NCT05323266|DEVICE|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
214430500|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
214430501|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
214430502|NCT03410966|PROCEDURE|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
214430503|NCT05688644|DEVICE|InterStim II|Sacral neuromodulation
214430504|NCT03003845|OTHER|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
214430505|NCT03003845|OTHER|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
214430506|NCT04496050|DRUG|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
214430507|NCT00585533|DRUG|Erlotinib (Tarceva)|Erlotinib
214513481|NCT01090739|DEVICE|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
214513482|NCT00441168|DRUG|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
214513483|NCT00441168|DRUG|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
214513484|NCT00441168|DRUG|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
214692513|NCT03445858|DRUG|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
214430508|NCT00643071|DRUG|Tacrolimus|Oral
214430509|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
214513485|NCT00441168|DRUG|vincristine|vincristine: 0.4mg IV push on days 1 to 4
214513486|NCT03868774|PROCEDURE|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
214513487|NCT00459849|PROCEDURE|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
214513488|NCT04078373|BEHAVIORAL|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
214513489|NCT04078373|BEHAVIORAL|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
214513490|NCT00924755|DEVICE|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
214430510|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
214430511|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
214430512|NCT01238744|DIETARY_SUPPLEMENT|Control drink|Control drink
214513491|NCT05396755|PROCEDURE|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
214513492|NCT03741634|OTHER|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
214430513|NCT01368016|DRUG|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
214430514|NCT01368016|DRUG|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
214430515|NCT00523237|DRUG|Raltegravir|400 mg Twice daily for 24 weeks
214430516|NCT01090544|DEVICE|Nasal Insufflation|Breathing therapy
214430517|NCT04929587|OTHER|This is a observational research, there is no intervention|This is a observational research, there is no intervention
214430518|NCT05454163|OTHER|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
214430519|NCT05081570|DEVICE|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
214430520|NCT01369498|DRUG|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
214430521|NCT01369498|DRUG|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
214430522|NCT04352283|DEVICE|Preprocedural ultrasound exam of lumbar spine|Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
214430523|NCT00620997|DRUG|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
214430524|NCT00620997|DRUG|saline drops|saline drops continuously PRN for up to 7 days
214430525|NCT00534300|DRUG|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
214430526|NCT00534300|DRUG|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
214430527|NCT01698125|PROCEDURE|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
214513493|NCT04610125|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
214513494|NCT04610125|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
214513495|NCT04610125|PROCEDURE|Leukapheresis|Leukapheresis
214513496|NCT04745338|DEVICE|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
214513497|NCT04745338|DIETARY_SUPPLEMENT|low calolric diet|low caloric diet (1200cal/day)
214513498|NCT03909100|DEVICE|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
214692514|NCT03445858|RADIATION|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
214430528|NCT04395378|DEVICE|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
214430529|NCT00622219|OTHER|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
214430530|NCT00171184|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
214430531|NCT00171184|DRUG|Placebo|Placebo tablet once daily with sham titration
214430532|NCT01472146|DRUG|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
214430533|NCT00819325|DRUG|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
214430534|NCT00819325|DRUG|oral hypoglycemic agents|sulfonylurea or metformin
214430535|NCT06549582|OTHER|Taohong Tongluo Xiaoban Prescription|"Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose"
214430536|NCT06549582|OTHER|Fundamental medical treatment|The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
214430537|NCT02627183|PROCEDURE|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
214430538|NCT02627183|BEHAVIORAL|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
214430539|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
214430540|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
214430541|NCT01845532|DRUG|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)
214430542|NCT01845532|DRUG|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
214430543|NCT03474822|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
214430544|NCT00233337|DRUG|Co-artemether|
214430545|NCT00623792|BEHAVIORAL|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
214430546|NCT04326192|DEVICE|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
214430547|NCT01120418|DRUG|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
214430548|NCT04034771|DRUG|Melatonin 10 MG Oral Tablet|Melatonin tablets
214430549|NCT04034771|DRUG|Propofol|propofol amp
214430550|NCT04034771|DRUG|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
214430551|NCT05035966|OTHER|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
214513499|NCT04252157|OTHER|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
214513500|NCT04252157|OTHER|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
214513501|NCT04252157|OTHER|Control|no kinesio or tape will be applied
214513502|NCT01166191|RADIATION|Radiotherapy|Radiotherapy
214430552|NCT04910555|OTHER|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
214430553|NCT03933605|DRUG|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
214430554|NCT03933605|DRUG|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
214513503|NCT00893009|DRUG|Theophylline|100 mg twice a day
214513504|NCT00893009|DRUG|Placebo|Placebo
214513505|NCT00807599|PROCEDURE|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
214513506|NCT00807599|DRUG|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
214430555|NCT02882035|OTHER|OFA|
214430556|NCT01236001|DRUG|Lacosamide|
214430557|NCT00214266|DRUG|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
214430558|NCT05944003|PROCEDURE|Resuscitative thoracotomies|Resuscitative thoracotomies is an effective life saving measure in appropriate populations \[1-8\]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% \[1-8\]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT \[1-
214430559|NCT02840422|DEVICE|ARTHRUM H 2%|ARTHRUM H 2%
214513507|NCT01062438|GENETIC|DNA analysis|
215114059|NCT04039217|DRUG|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
214430560|NCT03691922|PROCEDURE|Erector Spinae Plane (ESP) Block|"1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
214513508|NCT01062438|GENETIC|RNA analysis|
214513509|NCT01062438|GENETIC|gene expression analysis|
214513510|NCT01062438|GENETIC|gene rearrangement analysis|
214513511|NCT01062438|GENETIC|mutation analysis|
214513512|NCT01062438|OTHER|laboratory biomarker analysis|
214513513|NCT02802332|BEHAVIORAL|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
214513514|NCT05145348|BIOLOGICAL|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
214513515|NCT03713476|OTHER|Motor task training|motor task specific training
214513516|NCT05868356|DRUG|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
214513517|NCT05868356|DRUG|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
214513518|NCT00591136|DRUG|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
214513519|NCT03392805|BEHAVIORAL|physical activity|beginning of regular physical activity under the supervision of a coach
214513520|NCT00529529|DRUG|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
214513521|NCT00529529|DRUG|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
214430561|NCT03691922|PROCEDURE|Periarticular Infiltration (PAI)|"1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
214430562|NCT00253110|DRUG|risperidone|
214513522|NCT00529529|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
214513523|NCT00529529|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
214513524|NCT03500809|PROCEDURE|Aqueous release of the wound|"1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
214513525|NCT00914056|DRUG|lactulose|withdrawal of lactulose
214513526|NCT01020435|OTHER|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
214513527|NCT01020435|OTHER|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
214692515|NCT01214746|DRUG|Placebo|1 tablet Unikalk 1 time pr day for 5 days
214692516|NCT01214746|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
214692517|NCT00958308|OTHER|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
214692518|NCT00958308|OTHER|Placebo|Placebo is devoid of microorganisms.
214430563|NCT00253110|DRUG|haloperidol|
214513528|NCT00160758|PROCEDURE|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
214513529|NCT03576378|DRUG|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
214692519|NCT01554540|DRUG|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
214513530|NCT03858556|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214513531|NCT03858556|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
214430564|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
214430565|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
214430566|NCT00117936|COMBINATION_PRODUCT|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
214430567|NCT02867670|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
214513532|NCT03858556|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214513533|NCT03858556|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214513534|NCT03858556|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214513535|NCT03858556|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214513536|NCT03858556|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214513537|NCT03858556|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
215114060|NCT00406536|DIETARY_SUPPLEMENT|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
215114061|NCT00406536|DIETARY_SUPPLEMENT|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
215114062|NCT04575207|DIAGNOSTIC_TEST|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
215114063|NCT04575207|DIAGNOSTIC_TEST|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
215114064|NCT00496288|RADIATION|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
215114065|NCT05613023|RADIATION|SBRT|Stereotactic Body Radiotherapy
215114066|NCT01833572|DRUG|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
214430568|NCT01371968|DRUG|alfentanil|Alfentanil is administered intravenously at the end of surgery.
214513538|NCT03851809|DRUG|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
214513539|NCT01394835|DRUG|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
214513540|NCT01394835|DRUG|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
214513541|NCT01394835|DRUG|AAT|Inhalation twice daily' 160mg
214513542|NCT00007306|DRUG|Parathyroid hormone ointment|
214513543|NCT03397147|BEHAVIORAL|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
214513544|NCT04817345|DRUG|Plerixafor|Subcutaneous
214513545|NCT00425971|DRUG|BMEC-1217B|
214430569|NCT01891084|DRUG|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
214430570|NCT01891084|DRUG|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
214430571|NCT01891084|DRUG|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
214430572|NCT00879749|BIOLOGICAL|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
214430573|NCT00879749|BIOLOGICAL|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
214430574|NCT00879749|BIOLOGICAL|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
214430575|NCT00879749|BIOLOGICAL|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
214430576|NCT00879749|BIOLOGICAL|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
214430577|NCT00879749|OTHER|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
214430578|NCT05845528|DEVICE|s-tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
214430579|NCT05845528|DEVICE|a- tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
214430580|NCT03546998|DIAGNOSTIC_TEST|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
214430581|NCT02933944|BIOLOGICAL|TG02-treatment|
214430582|NCT02933944|DRUG|Pembrolizumab|
214430583|NCT02881203|DEVICE|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
214430584|NCT02881203|DEVICE|RPM|Varian Real-time Position Management (RPM) system
214430585|NCT04002622|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214430586|NCT06176391|DEVICE|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
214430587|NCT05496842|BEHAVIORAL|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
214430588|NCT01302236|DRUG|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
214430589|NCT01336543|DRUG|Chemotherapy following concurrent Chemoradiotherapy|"1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
214430590|NCT04008550|PROCEDURE|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
214430591|NCT00382850|PROCEDURE|Nissen fundoplication|
214430592|NCT01736514|DRUG|febuxostat|oral
214430593|NCT01736514|DRUG|Allopurinol|oral
214430594|NCT04291092|DRUG|Immunotherapy|Immunotherapy for brain metastasis
214430595|NCT04291092|RADIATION|WBRT|local therapy for brain metastasis
214430596|NCT04291092|DRUG|Chemotherapy|Chemotherapy for brain metastasis
214513546|NCT00458094|BEHAVIORAL|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
214513547|NCT00458094|BEHAVIORAL|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
214513548|NCT01450774|DRUG|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
214513549|NCT01450774|DRUG|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
214513550|NCT03121417|BIOLOGICAL|Nivolumab|240 mg given IV
214513551|NCT02837419|BEHAVIORAL|Health related Quality of life EQ-5D|Quality of Care
214430597|NCT00026234|DRUG|floxuridine|Given intra-arterially
214430598|NCT00026234|DRUG|dexamethasone|Given intra-arterially
214430599|NCT00026234|DRUG|oxaliplatin|Given IV
214430600|NCT00026234|DRUG|capecitabine|Given orally
214430601|NCT03941067|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
214430602|NCT02538107|DRUG|Methoxy-polyethyleneglycol epoetin beta|
214430603|NCT04160429|PROCEDURE|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
214430604|NCT04160429|OTHER|Medical Chart Review|Review of medical chart
214430605|NCT04160429|OTHER|Questionnaire Administration|Complete questionnaire
215114067|NCT04864951|DIAGNOSTIC_TEST|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
215114068|NCT04864951|OTHER|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
215114069|NCT00615992|DRUG|Tiotropium|
214430606|NCT04126707|DRUG|[14C] HQP1351|Orally, single dose of 30mg
214430607|NCT01130194|OTHER|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
214430608|NCT01997944|BIOLOGICAL|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
214692520|NCT01984034|BEHAVIORAL|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
214692521|NCT01984034|OTHER|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
214430609|NCT01997944|BIOLOGICAL|Pegasys|180 mcg dosing every week
214430610|NCT01943916|DEVICE|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
214430611|NCT01943916|DEVICE|Imagio gray scale ultrasound|gray scale ultrasound alone
214430612|NCT05782231|BEHAVIORAL|GetActive+|10-week group mind body program focused on improving self-report, performance-based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota-based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
214430613|NCT03646279|DEVICE|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
214430614|NCT04871750|DIETARY_SUPPLEMENT|Soy protein|Daily consumption for 24 weeks
214430615|NCT04871750|DIETARY_SUPPLEMENT|Casein protein|Daily consumption for 24 weeks
214430616|NCT00372450|PROCEDURE|management of therapy complications|
214430617|NCT00372450|PROCEDURE|quality-of-life assessment|
214430618|NCT01366664|DRUG|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
214430619|NCT01366664|DRUG|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
214430620|NCT05274217|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
214430621|NCT03802149|DRUG|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
214430622|NCT03615495|DEVICE|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
214430623|NCT06497894|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.
214430624|NCT06497894|DRUG|Hormone Replacement Therapy (HRT)|Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.
214430625|NCT06497894|BEHAVIORAL|Sleep Hygiene|Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
214430626|NCT03085498|OTHER|No intervention|no intervention
214430627|NCT06973967|BEHAVIORAL|delirium|Postoperatively, patients were monitored for delirium for seven days.
214430628|NCT06974162|DIAGNOSTIC_TEST|Metagenomic sequencing of aqueous humor|Metagenomic Sequencing on aqueous humor surplus to diagnostic requirements
214430629|NCT06974162|DIAGNOSTIC_TEST|Ocular Imaging|Ocular imaging with anterior segment OCT, laser flare photometry, confocal microscopy and colour fundus photography.
214430631|NCT01834703|PROCEDURE|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
214430632|NCT01834703|PROCEDURE|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
214430633|NCT00597103|OTHER|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
214430634|NCT00597103|OTHER|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
214430635|NCT00597103|OTHER|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
214430636|NCT05475106|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
214430637|NCT00995150|DRUG|LNG20|levonorgestrel-releasing intrauterine system for contraception
214430638|NCT00995150|DRUG|Mirena|Mirena intrauterine system
214430639|NCT00303836|DRUG|cyclophosphamide|Given IV
214430640|NCT00303836|DRUG|fludarabine phosphate|Given IV
214430641|NCT00303836|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214430642|NCT00303836|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
214430643|NCT00303836|BIOLOGICAL|gp100 antigen|Given SC
214430644|NCT00303836|BIOLOGICAL|MART-1 antigen|Given SC
214430645|NCT00303836|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
214430646|NCT00303836|BIOLOGICAL|filgrastim|Given SC
214430647|NCT00303836|BIOLOGICAL|aldesleukin|Given IV
214430648|NCT00158028|DRUG|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
214430649|NCT00158028|DRUG|Placebo|placebo match in identical tablets
214430650|NCT02833272|BEHAVIORAL|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
214430651|NCT01463046|DRUG|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
214430652|NCT01463046|DRUG|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
214430653|NCT01463046|DRUG|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
214430654|NCT01499654|DRUG|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
214430655|NCT01373346|PROCEDURE|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
214430656|NCT02964195|DRUG|Rifaximin|ALFA WASSERMANN S.p.A.
214430657|NCT03534869|PROCEDURE|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
214430658|NCT03534869|DRUG|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
214430659|NCT04168801|DIETARY_SUPPLEMENT|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
214430660|NCT01141010|OTHER|Language|Plain language without psychological intervention
214430661|NCT01141010|OTHER|Language|Psychological linguistic intervention will be given
214430662|NCT00005027|DRUG|becatecarin|
214430663|NCT00590551|OTHER|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
214430664|NCT00551980|BEHAVIORAL|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
214430665|NCT00465192|DRUG|estradiol, 10 mcg|
215114070|NCT02518373|BIOLOGICAL|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
215114071|NCT02518373|DRUG|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
214430666|NCT00465192|DRUG|estradiol, 25 mcg|
214430667|NCT00465192|DRUG|placebo|
214430668|NCT04540822|OTHER|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
214430669|NCT04540822|OTHER|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
214430670|NCT01395758|DRUG|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
214430671|NCT01395758|DRUG|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
214430672|NCT00705328|BEHAVIORAL|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
214430673|NCT00705328|BEHAVIORAL|Recreation Coordination Model (REC)|Recreation coordination service delivery
214430674|NCT00705328|BEHAVIORAL|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
214430675|NCT00357097|DRUG|Ropinirole|
214430676|NCT03238391|PROCEDURE|Ischemic preconditioning|It is mentioned before in arm/group descriptions
214430677|NCT03366701|OTHER|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
214430678|NCT06300424|DRUG|almonertinib|110mg qd
214430679|NCT06300424|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
214430680|NCT06300424|DRUG|Nab paclitaxel|135 mg/m2, d1,d8 every 3 weeks
214430681|NCT00794118|OTHER|As per clinical practice|As per clinical practice
214430682|NCT02717117|OTHER|Soup meal|Soup meal as above
214430683|NCT06840574|DIETARY_SUPPLEMENT|Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid|27 mg vitamin C, organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, and calcium stearate
214430684|NCT06840574|DIETARY_SUPPLEMENT|Low Dose Vitamin C|27 mg ascorbic acid
214430685|NCT06840574|DIETARY_SUPPLEMENT|High Dose Vitamin C|500 mg ascorbic acid
214513552|NCT00103857|DRUG|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
214692522|NCT05369117|BEHAVIORAL|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
215114072|NCT03802591|DRUG|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
214513553|NCT00103857|DRUG|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
214513554|NCT00103857|DRUG|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
214513555|NCT00103857|DRUG|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
214513556|NCT00103857|DRUG|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
214513557|NCT00103857|DRUG|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
214430686|NCT00838253|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
214430687|NCT00838253|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
214430688|NCT00838253|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
214513558|NCT05125549|DRUG|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
214513559|NCT05125549|DRUG|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
214513560|NCT04618211|DRUG|Deucrictibant|deucrictibant soft capsules for oral use
214430689|NCT00838253|DRUG|Placebo|Placebo continuous i.v. infusion for 24 hours
214513561|NCT04618211|DRUG|Placebo|Matching placebo capsules for oral use
214513562|NCT05307653|PROCEDURE|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
214513563|NCT05307653|PROCEDURE|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
214513564|NCT05307653|PROCEDURE|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
214513565|NCT00000497|BEHAVIORAL|diet, sodium-restricted|
214513566|NCT00000497|BEHAVIORAL|diet, reducing|
214513567|NCT05764395|DRUG|Rigosertib|Given by mouth
215114073|NCT03802591|DRUG|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
215114074|NCT03802591|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
215114075|NCT03802591|DRUG|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
215114076|NCT04386694|DEVICE|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
214430690|NCT06499246|PROCEDURE|Donor Parathyroid|Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
214430691|NCT04305405|DRUG|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
214430692|NCT02528188|DRUG|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
214430693|NCT02528188|BIOLOGICAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
214430694|NCT02528188|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
214430695|NCT03968354|BIOLOGICAL|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"* Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
214513568|NCT05764395|BIOLOGICAL|Pembrolizumab|Given by IV
214513569|NCT05764395|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214513570|NCT05764395|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214513571|NCT05764395|PROCEDURE|Biopsy|Undergo tissue biopsy
214513572|NCT03093064|DRUG|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
214513573|NCT03093064|OTHER|Placebo: normal saline|Normal saline, intravenous infusion
215114077|NCT04386694|DEVICE|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
215114078|NCT02597387|DRUG|Mitoxantrone HCL Liposome Injection|
214430696|NCT00371085|BEHAVIORAL|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
214430697|NCT02647268|DRUG|Oxytocin|Oxytocin, 10-5M solution
214430698|NCT02647268|DRUG|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
214430699|NCT06409286|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow
214430700|NCT02083575|DRUG|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
214430701|NCT02083575|DRUG|deferiprone , deferesarox|iron chelator
214430702|NCT03914859|BIOLOGICAL|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
214430703|NCT06235424|DRUG|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
214513574|NCT00004939|DRUG|,4-diaminopyridine|
214513575|NCT02978183|BIOLOGICAL|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
214430704|NCT06235424|DRUG|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
214513576|NCT02978183|DRUG|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
214513577|NCT03560154|OTHER|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
214513578|NCT02132195|DRUG|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
214513579|NCT03343041|DIETARY_SUPPLEMENT|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
214513580|NCT03343041|DIETARY_SUPPLEMENT|Standard enteral nutrition|standard enteral nutrition
214513581|NCT02805075|OTHER|Fructooligosaccharide|Given PO
214513582|NCT02805075|OTHER|Laboratory Biomarker Analysis|Correlative studies
214513583|NCT00376324|DRUG|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
214513584|NCT01317914|OTHER|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
214692523|NCT00300300|PROCEDURE|Computer-assisted surgery|no description
214692524|NCT02730507|DEVICE|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
214513585|NCT05352555|DEVICE|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
214513586|NCT05352555|OTHER|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
214430705|NCT05560659|DRUG|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
214430706|NCT00529659|DRUG|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
214430707|NCT00529659|DRUG|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
214430708|NCT06647628|DRUG|MK-1708|MK-1708 oral suspension
214430709|NCT06647628|DRUG|Placebo|Placebo oral suspension
214513587|NCT05223309|OTHER|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
215114079|NCT04522141|BEHAVIORAL|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
215114080|NCT04522141|BEHAVIORAL|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
215114081|NCT01397942|OTHER|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
215114082|NCT02048085|DRUG|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
214430710|NCT00095667|DRUG|lapatinib ditosylate|Given orally
214430711|NCT00095667|OTHER|laboratory biomarker analysis|Correlative studies
214430712|NCT03887650|DRUG|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
214430713|NCT03887650|DRUG|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
214430714|NCT01503749|DRUG|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
214430715|NCT01503749|OTHER|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
214430716|NCT06972745|PROCEDURE|Ultrabrief pulse electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the right hemisphere, using ultrabrief pulses (≤0.3 ms).
214430717|NCT06972745|PROCEDURE|Brief pulse Electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the temporal hemisferes, using brief pulses (≥0.5 ms).
214430718|NCT06972316|OTHER|The Global postural reeducation|The Global postural reeducation (GPR) is a series of postures and gentle active movements are performed aimed at stretching shortened muscles, decompressing and aligning joints, with breath¬ing contro
214430719|NCT06972316|OTHER|Traditional treatments|Thermotherapy (hot packs) , Dynamic neck exercises, stretching exercise and posture advice
214430720|NCT06972758|DRUG|Certirobell®|Patients enrolled in the study will initiate oral administration of Certirobell® between 4 to 6 weeks after hepatic resection. The medication will be taken for a duration of 92 weeks, twice daily at approximately 12-hour intervals. The initial dosage is 1.0 mg per dose (twice daily). For patients with a Child-Pugh score of 6, the starting dose will be reduced to 0.75 mg per dose (twice daily). At each visit, the blood concentration of Certirovel will be measured, and the investigator will adjust the dosage as needed to maintain levels within the target range of 3-8 ng/mL. If HCC recurrence is confirmed during treatment, the administration of the drug will be discontinued.
214430721|NCT03343197|DRUG|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
214513588|NCT05990556|PROCEDURE|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
214513589|NCT03853941|BEHAVIORAL|Intervention|Theory-based communication training programme delivered to healthcare professionals
214513590|NCT05601167|DRUG|nirmatrelvir/ritonavir|Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
214513591|NCT05601167|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
214430722|NCT03343197|DRUG|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
214430723|NCT05854433|OTHER|Non-interventional study|No intervention will be administered as part of this study.
214430724|NCT03445598|BEHAVIORAL|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
214430725|NCT03445598|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
214430726|NCT03445598|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
214430727|NCT00074633|BEHAVIORAL|Health at Every Size (HAES)|
214430728|NCT00074633|BEHAVIORAL|Diet (Traditional, moderate energy restriction)|
214430729|NCT02592954|DRUG|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
214430730|NCT02592954|DRUG|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
214430731|NCT04890821|DEVICE|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
214430732|NCT02824159|OTHER|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
214430733|NCT02824159|OTHER|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
214513592|NCT05796271|DRUG|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
214513593|NCT01790659|DRUG|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
214513594|NCT01790659|DRUG|Paromomycin|Paromomycin alone
214513595|NCT01772212|DRUG|Terbinafine 250 mg|Test product
214513596|NCT01772212|DRUG|Terbinafine 250 mg|Reference product
214513597|NCT05371821|DEVICE|Echocardiography|Echocardiographic parameters in obese and overweight
214513598|NCT03394105|DRUG|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
214513599|NCT01709006|RADIATION|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
214513600|NCT05794074|DIETARY_SUPPLEMENT|luteine and zeaxanthine|luteine and zeaxanthine
214513601|NCT05794074|DIETARY_SUPPLEMENT|luteine|luteine
214513602|NCT05794074|DIETARY_SUPPLEMENT|zeaxanthine|zeaxanthine
214513603|NCT05794074|DIETARY_SUPPLEMENT|Placebo|Placebo
214513604|NCT03065400|DRUG|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
214430734|NCT02824159|OTHER|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
214430735|NCT02824159|OTHER|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
214430736|NCT02824159|GENETIC|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
214430737|NCT02824159|GENETIC|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
214430738|NCT02824159|OTHER|Biological statement|"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
214430739|NCT02824159|OTHER|Clinical examination|"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
214430740|NCT03589651|DRUG|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
214430741|NCT03589651|DRUG|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
214430742|NCT03589651|DRUG|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
214430743|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
214430744|NCT05566587|OTHER|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
214430745|NCT02576340|DRUG|otilonium bromide|otilonium bromide was administered before the procedure
214430746|NCT00553189|DRUG|ABT-888|
214430747|NCT00553189|DRUG|Topotecan|
214430748|NCT04139538|PROCEDURE|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
214513605|NCT03773497|OTHER|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
214513606|NCT03773497|OTHER|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
214430749|NCT01406028|BEHAVIORAL|Phone calls|Phone calls to offer emotional support
214513607|NCT03773497|OTHER|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
214513608|NCT03773497|OTHER|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
214430750|NCT00301990|BIOLOGICAL|aldesleukin|
214430751|NCT00301990|BIOLOGICAL|bevacizumab|
214430752|NCT00603356|DRUG|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
214513609|NCT02102724|DIETARY_SUPPLEMENT|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
214513610|NCT02102724|DIETARY_SUPPLEMENT|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
214513611|NCT05485493|BEHAVIORAL|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
214513612|NCT05485493|OTHER|healthy nutrition education|60-minute single session healthy eating training
214513613|NCT06034977|DRUG|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
214513614|NCT03072862|DEVICE|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
214513615|NCT01790100|DRUG|VX-135|12 weeks of VX-135
214513616|NCT01790100|DRUG|Ribavirin|12 weeks of ribavirin
214513617|NCT02203513|DRUG|LY2606368|105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
214513618|NCT01196364|OTHER|Dietary Supplement: water with noncalorie sweetener|
214430753|NCT00415389|BEHAVIORAL|interactive educational program|2-session interactive stroke educational program
214430754|NCT00415389|BEHAVIORAL|usual medical care|standard educational materials and usual care
214430755|NCT03140735|OTHER|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
214430756|NCT03140735|OTHER|Control group without heart disease|Control group without heart disease
214430757|NCT04333329|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
214430758|NCT02961179|BEHAVIORAL|Increased dairy product|
214430759|NCT02961179|BEHAVIORAL|Dietary counselling|
214513619|NCT01196364|OTHER|Activity: With noncalorie sweetener or glucose|
214513620|NCT05431322|DRUG|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
214513621|NCT05114811|PROCEDURE|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
214513622|NCT05114811|PROCEDURE|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
214513623|NCT03183856|DEVICE|Morning walk|a end-effector typed gait robot with a saddle
214430760|NCT00059241|BEHAVIORAL|Parent-child communication education|
214430761|NCT00059241|BEHAVIORAL|Service learning|
214430762|NCT00059241|BEHAVIORAL|Classroom health curriculum|
214430763|NCT04021381|DIETARY_SUPPLEMENT|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
214430764|NCT04021381|DIETARY_SUPPLEMENT|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
214430765|NCT05663918|BEHAVIORAL|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
214430766|NCT04441593|BEHAVIORAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
214430767|NCT04441593|BEHAVIORAL|Treatment as Usual|Psychoeducation and Information about Treatment Resources
214430768|NCT01830946|OTHER|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
214430769|NCT01830946|OTHER|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
214430770|NCT01830946|OTHER|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
214430771|NCT00829751|DEVICE|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
214430772|NCT00829751|DEVICE|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
214513624|NCT03183856|OTHER|no Morning walk|ambulation voluntary or with a help of walker
214513625|NCT02751125|DRUG|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
215114083|NCT02048085|DRUG|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
215114084|NCT03508609|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34 cells
215114085|NCT04563962|BEHAVIORAL|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
215114086|NCT04563962|BEHAVIORAL|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
215114087|NCT05633173|PROCEDURE|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
214430773|NCT03393117|DRUG|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
214430774|NCT03393117|DRUG|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
214430775|NCT03393117|DRUG|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
214430776|NCT03393117|DRUG|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
214430777|NCT01850017|DRUG|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
214513626|NCT05390710|COMBINATION_PRODUCT|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
214513627|NCT00976651|DRUG|human menopausal gonadotropin|200 IU per day in the late follicular phase
214513628|NCT02513667|DRUG|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
214513629|NCT02513667|RADIATION|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
214513630|NCT04717570|DEVICE|Foldax TRIA Mitral Valve|Mitral Valve Replacement
214430778|NCT01514734|DRUG|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
214430779|NCT04861012|DEVICE|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
214430780|NCT00815750|OTHER|Information Gathering|An information gathering phase leading to development of a new decision aid.
214430781|NCT00815750|OTHER|Decision Aid|To test the newly developed decision aid.
214430782|NCT02747602|DRUG|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
214430783|NCT02747602|DRUG|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
214430784|NCT02747602|DRUG|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
214430785|NCT02852681|DRUG|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
214430786|NCT03512756|DRUG|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
214430787|NCT03512756|DRUG|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
214430788|NCT05803850|DRUG|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
214430789|NCT01029717|DEVICE|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
214430790|NCT01029717|DEVICE|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
214430791|NCT01029717|DEVICE|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
214430792|NCT04291586|OTHER|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
214430793|NCT04291586|OTHER|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
214430794|NCT00060099|BIOLOGICAL|HspE7|
214430795|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
214430796|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
214430797|NCT00736853|DRUG|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
214513631|NCT03745170|DRUG|Sintilimab|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
214513632|NCT03745170|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
215114088|NCT05633173|PROCEDURE|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
215114089|NCT00555217|DRUG|losartan|50 or 100mg/day
215114090|NCT00555217|DRUG|lisinopril|10, 20 or 40 mg/day
215114091|NCT00718705|DRUG|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
215114092|NCT00718705|DRUG|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
215114093|NCT05860153|DRUG|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
214430798|NCT03419325|GENETIC|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
214430799|NCT03419325|DIAGNOSTIC_TEST|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
214430800|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
214430801|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
214430802|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
214430803|NCT00092937|DRUG|Busulfan|
214430804|NCT00917241|DRUG|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
214430805|NCT00917241|DRUG|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
214430806|NCT00138619|DRUG|vildagliptin|
214513633|NCT03745170|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
215114094|NCT05860153|DRUG|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
214430807|NCT02590952|DRUG|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
214430808|NCT03319706|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
214430809|NCT03319706|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
214430810|NCT01039142|DRUG|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
214430811|NCT01607372|DRUG|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
214430812|NCT01607372|DEVICE|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
214430813|NCT01607372|OTHER|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
214430814|NCT00551876|DRUG|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
214430815|NCT00551876|DRUG|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
214430816|NCT03150238|OTHER|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
214430817|NCT03942835|OTHER|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
214430818|NCT03942835|OTHER|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
214430819|NCT03942835|OTHER|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
214430820|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
214430821|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
214430822|NCT00758433|DRUG|Placebo patch|Placebo patch q.d. 24 hours for 7 days
214430823|NCT02336776|OTHER|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
214430824|NCT01199705|BIOLOGICAL|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
214430825|NCT00461747|DRUG|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
214513634|NCT03745170|DRUG|placebo|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
215114095|NCT01653990|DRUG|moxifloxacin|oral dose of 400mg moxifloxacin
215114096|NCT01653990|DRUG|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
215114097|NCT04659473|OTHER|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
215114098|NCT03680183|DRUG|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
214430826|NCT00461747|DRUG|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
214430827|NCT00461747|DRUG|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
214430828|NCT05082714|DRUG|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
214430829|NCT05082714|DRUG|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
214430830|NCT02113072|DRUG|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
214430831|NCT02113072|DRUG|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
214430832|NCT02113072|DRUG|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
214430833|NCT03226899|DRUG|Lesinurad|200 mg oral tablet
215114099|NCT04771702|DEVICE|Edmon|Exhaled air will be analyzed for propofol
214513635|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
214513636|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
214513637|NCT04345068|BEHAVIORAL|Calm Meditation Mobile App|The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
214430834|NCT03226899|DRUG|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
214430835|NCT03226899|DRUG|Placebo|matching placebo oral tablet
214430836|NCT03226899|DRUG|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
214430837|NCT03226899|DRUG|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
214430838|NCT02032069|OTHER|no intervention|
214430839|NCT02047981|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
214430840|NCT02047981|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
214430841|NCT02108236|DEVICE|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
214430842|NCT03618134|BIOLOGICAL|Durvalumab|Given IV
214513638|NCT04345068|BEHAVIORAL|Health Education Podcast Mobile App|The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
214513639|NCT06445244|DIETARY_SUPPLEMENT|Alpha-ketoglutarate supplied as 1000mg capsule|AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
214430843|NCT03618134|PROCEDURE|Modified Radical Neck Dissection|Undergo modified radical neck dissection
214430844|NCT03618134|OTHER|Quality-of-Life Assessment|Ancillary studies
214430845|NCT03618134|OTHER|Questionnaire Administration|Ancillary studies
214430846|NCT03618134|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214430847|NCT03618134|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
214430848|NCT03618134|BIOLOGICAL|Tremelimumab|Given IV
214430849|NCT00739518|PROCEDURE|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
214430850|NCT06193005|OTHER|no intervention|no intervention
214430851|NCT02840006|PROCEDURE|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
214430852|NCT02840006|PROCEDURE|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
214430853|NCT04257136|DRUG|VBI-S|VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
214430854|NCT04781439|PROCEDURE|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
214430855|NCT04658914|BIOLOGICAL|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
214430856|NCT04658914|BIOLOGICAL|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
214430857|NCT01764464|DRUG|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
214430858|NCT01764464|DRUG|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
214430859|NCT03039361|BEHAVIORAL|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
214430860|NCT00253734|BIOLOGICAL|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
214513640|NCT06445244|BEHAVIORAL|Behavioral: Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
214430861|NCT00253734|BIOLOGICAL|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
214430862|NCT04706052|OTHER|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
214430863|NCT04855903|DEVICE|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
214430864|NCT05362110|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
214430865|NCT05362110|DRUG|RLD2002|Take it once daily for 8 weeks orally.
214430866|NCT05362110|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
214430867|NCT05362110|DRUG|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
214430868|NCT06299228|OTHER|Experimental Group|Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening
214430869|NCT06299228|OTHER|Control Group|Active range of motion, active assisted range of motion and strengthening
214430870|NCT02163252|BEHAVIORAL|Standard|
214430871|NCT02163252|BEHAVIORAL|Early Intervention|
214430872|NCT03322124|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
214513641|NCT03738384|DEVICE|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
214513642|NCT05746234|BEHAVIORAL|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
215114100|NCT01963156|BEHAVIORAL|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
214513643|NCT02429115|OTHER|Mentoring|Six months of peer-mentoring.
214513644|NCT03158415|BEHAVIORAL|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
214513645|NCT02762201|PROCEDURE|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
214513646|NCT02762201|PROCEDURE|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
214513647|NCT00240175|OTHER|No Intervention|No Intervention
214430873|NCT03322124|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
214430874|NCT00096915|DRUG|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
214513648|NCT01503970|DEVICE|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
214430875|NCT02299752|PROCEDURE|single-gloving system|single-gloving system was used during Catheterization
214430876|NCT02299752|PROCEDURE|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
214430877|NCT05308056|DEVICE|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
214430878|NCT01495624|OTHER|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
214430879|NCT01495624|OTHER|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
214430880|NCT06331494|DRUG|Butylphthalide|Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
214430881|NCT06331494|DRUG|Placebo|Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
214430882|NCT06521541|BEHAVIORAL|Multimodal prehabilitation program|Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
214513649|NCT00726505|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
214513650|NCT04243941|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
214513651|NCT04452383|DRUG|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
214513652|NCT04452383|DRUG|propofol|effect of IV propofol alone for patients undergoing DISE surgery
214513653|NCT02417376|DEVICE|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
214513654|NCT02417376|DEVICE|Gracey curettes|set of 7 instruments number #1-14
214513655|NCT02508441|DRUG|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
214513656|NCT02372318|DRUG|Nalmefene|18mg of Nalmefen will be administered orally
214513657|NCT02372318|DRUG|Placebo|Placebo tablet
214513658|NCT05193526|OTHER|No intervention|No intervention
214513659|NCT01590134|DIETARY_SUPPLEMENT|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
214513660|NCT01590134|DRUG|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
214513661|NCT02669576|BEHAVIORAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
214513662|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
214513663|NCT02745756|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
214513664|NCT02745756|BIOLOGICAL|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
214513665|NCT05371899|DRUG|Chiauranib|Take Chiauranib 50mg orally once daily
214513666|NCT01331408|DEVICE|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
214513667|NCT01650051|DRUG|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
214513668|NCT01650051|DRUG|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
214513669|NCT01450397|BIOLOGICAL|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
214513670|NCT04806906|DRUG|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
214513671|NCT01966679|DRUG|AZD7325|
214513672|NCT01966679|DRUG|Placebo|
214513673|NCT04549688|PROCEDURE|high-intensity focused ultrasound, HIFU|see above
214513674|NCT04106739|DEVICE|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
214513675|NCT02717208|BIOLOGICAL|HL036|
214513676|NCT02717208|BIOLOGICAL|Vehicle|
214513677|NCT02398955|DEVICE|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
214513678|NCT01964547|DRUG|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
214513679|NCT01964547|DRUG|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
215114101|NCT04036929|DRUG|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
215114102|NCT04036929|DRUG|Placebo oral tablet|Placebo oral tablet
215114103|NCT01239823|OTHER|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
215114104|NCT01239823|OTHER|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
215114105|NCT05505864|BEHAVIORAL|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
215114106|NCT01135095|RADIATION|low-dose imaging|"The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
214430883|NCT06521541|BEHAVIORAL|ERAS program|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
214513680|NCT04364399|BIOLOGICAL|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
214513681|NCT04364399|BIOLOGICAL|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
214430884|NCT05239650|DRUG|HLX07|1000mg
214430885|NCT05239650|DRUG|HLX10|200mg
214430886|NCT05239650|DRUG|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
214430887|NCT00040313|DRUG|pegaptanib sodium (Macugen)|
214430888|NCT03953859|GENETIC|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
214430889|NCT02245555|DRUG|Tamsulosin|
214430890|NCT01608347|DRUG|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
214430891|NCT01608347|DRUG|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
214430892|NCT01401023|DRUG|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
214430893|NCT05493449|COMBINATION_PRODUCT|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
214430894|NCT05493449|COMBINATION_PRODUCT|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
214430895|NCT06192043|BEHAVIORAL|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
214430896|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (combination)|
214430897|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
214430898|NCT02515305|DRUG|Placebo gel (combination)|
214430899|NCT04580420|DRUG|DCR-PHXC|Monthly dosing throughout study period
214430900|NCT04654598|OTHER|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
214430901|NCT06972953|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
214430902|NCT06972953|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
214430903|NCT00376519|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
214430904|NCT00376519|DRUG|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
214430905|NCT00376519|DRUG|fludarabine phosphate|Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
214430906|NCT00376519|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
214430907|NCT00376519|PROCEDURE|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
214430908|NCT00376519|PROCEDURE|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
214430909|NCT00376519|RADIATION|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
214430910|NCT05849233|OTHER|no intervention|no intervention
214430911|NCT04744402|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
214513682|NCT00912964|DRUG|Mirabegron|Mirabegron tablets
214513683|NCT00912964|DRUG|Placebo|Matching mirabegron placebo tablets.
214513684|NCT06239532|DRUG|HAIC+TAE|Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
214513685|NCT06239532|DRUG|Tislelizumab|Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
214513686|NCT06239532|DRUG|Surufatinib|Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
214513687|NCT05398289|DRUG|4-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
214430912|NCT01897272|BEHAVIORAL|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
214430913|NCT06051175|OTHER|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
214430914|NCT06051175|OTHER|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
214430915|NCT06051175|OTHER|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
214513688|NCT05398289|DRUG|6-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
214513689|NCT04197622|DRUG|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
214513690|NCT06455683|PROCEDURE|Glaucoma Surgery|"One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment"
214513691|NCT02978716|DRUG|Trilaciclib|G1T28
214513692|NCT02978716|DRUG|Gemcitabine|Gemcitabine
214513693|NCT02978716|DRUG|Carboplatin|Carboplatin
214513694|NCT00960206|DEVICE|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
215114107|NCT03920943|OTHER|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
215114108|NCT03057860|OTHER|No study intervention|
215114109|NCT03524638|OTHER|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
214513695|NCT00960206|DEVICE|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
214513696|NCT00960206|DEVICE|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
214513697|NCT05134103|BEHAVIORAL|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
214513698|NCT05134103|OTHER|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
215114110|NCT03524638|PROCEDURE|Colorectal Surgery|Colorectal surgery alone
215114111|NCT03483415|DRUG|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
215114112|NCT03483415|DRUG|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
215114113|NCT00367835|DRUG|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
215114114|NCT00367835|DRUG|Placebo|Placebo
214513699|NCT02470806|DEVICE|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
214430916|NCT06051175|OTHER|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
214430917|NCT06051175|OTHER|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
214430918|NCT02043054|DRUG|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
214430919|NCT02043054|DRUG|Sitagliptin|Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
214430920|NCT00492271|DRUG|Friulimicin B|Intravenous, once daily, single dose
214430921|NCT03032224|PROCEDURE|Resection of the esophagus and the gastroesophageal junction|
214430922|NCT00086775|BIOLOGICAL|alemtuzumab|
214430923|NCT00086775|BIOLOGICAL|rituximab|
214430924|NCT00086775|DRUG|fludarabine phosphate|
214430926|NCT04134078|DRUG|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
214430927|NCT00087880|DRUG|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
214430928|NCT04942249|OTHER|No intervention|No intervention
214513700|NCT02470806|DEVICE|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
215114115|NCT03320135|PROCEDURE|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
215114116|NCT03320135|PROCEDURE|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
215114117|NCT04119193|DEVICE|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
214430929|NCT03163212|DIETARY_SUPPLEMENT|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
214430930|NCT05633628|BEHAVIORAL|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
215114118|NCT02091843|PROCEDURE|DBS of the Basolateral Nucleus of the Amygdala|
215114119|NCT02091843|DEVICE|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
215114120|NCT04338971|DEVICE|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
215114121|NCT04379401|DEVICE|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
215114122|NCT04478604|OTHER|applied forms to pregnant women|
215114123|NCT05458804|DEVICE|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
215114124|NCT02397044|PROCEDURE|Implant surgery|Compare surgical protocols
214513701|NCT00038038|DRUG|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
214513702|NCT00038038|PROCEDURE|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
214513703|NCT02018549|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
214513704|NCT01147471|DEVICE|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
214513705|NCT01147471|PROCEDURE|operative rib fixation surgery|
214513706|NCT05120336|DEVICE|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
214513707|NCT05120336|DEVICE|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
215114125|NCT01900743|DRUG|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
214513708|NCT04950920|DRUG|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
214513709|NCT04950920|DRUG|d-borneol|60 μg d-borneol OR， Bid
214513710|NCT04221711|DEVICE|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
214513711|NCT04221711|PROCEDURE|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
215114126|NCT01900743|DRUG|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
215114127|NCT03920930|PROCEDURE|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
215114128|NCT03920930|PROCEDURE|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
215114129|NCT01025830|DRUG|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
215114130|NCT01025830|DRUG|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
215114131|NCT03642730|DEVICE|TransThoracic Echocardiography imaging|ultrasound scanning
215114132|NCT01229306|PROCEDURE|Ablation|Ablation of atrial fibrillation
215114133|NCT00601549|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery
215114134|NCT00601549|PROCEDURE|Traditional open surgery|Open surgery
215114135|NCT05843929|DIAGNOSTIC_TEST|LSCI|"1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
215114136|NCT03866564|DIAGNOSTIC_TEST|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
215114137|NCT03866564|DIAGNOSTIC_TEST|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
215114138|NCT03866564|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
215114139|NCT03866564|DIAGNOSTIC_TEST|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
215114140|NCT06229327|BEHAVIORAL|THERAPEUTICGAMES|THERAPEUTICGAMES
215114141|NCT03761810|DRUG|S6G5T-3|Once a day topical cream
215114142|NCT03761810|DRUG|S6G5T-8|Once a day topical cream
215114143|NCT04792411|BEHAVIORAL|Prehabilitation|Multimodal, tailored prehabilitation programme
215114144|NCT06273397|DRUG|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
214430931|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
214430932|NCT04375813|DRUG|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
214430933|NCT04375813|DRUG|Placebos|placebo capsules visually identical to eRapa oral capsules
214430934|NCT01037634|DRUG|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
214430935|NCT03817060|PROCEDURE|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
214430936|NCT03817060|PROCEDURE|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
214513712|NCT04645849|BIOLOGICAL|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
214513713|NCT02888821|BEHAVIORAL|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
214513714|NCT00880074|DRUG|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
214513715|NCT00880074|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214513716|NCT00880074|PROCEDURE|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
214513717|NCT03494413|DIAGNOSTIC_TEST|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
214513718|NCT03494413|DIAGNOSTIC_TEST|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
214513719|NCT02579915|BEHAVIORAL|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
214513720|NCT02579915|BEHAVIORAL|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
214513721|NCT02046304|DRUG|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
214430937|NCT04190316|OTHER|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
214430938|NCT05053113|DEVICE|Activity Monitor|Monitor physical activity with FitBit
214513722|NCT02046304|RADIATION|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
214513723|NCT00157105|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
214513724|NCT03715985|DRUG|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
214513725|NCT00222898|PROCEDURE|DNA analysis of pancreatic cyst fluid / buccal swab|
214513726|NCT04090632|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
214513727|NCT03094546|DIETARY_SUPPLEMENT|Polyamine|12 months of polyamine supplementation (6 capsules/day)
214513728|NCT03094546|DIETARY_SUPPLEMENT|Placebo|12 months of placebo intake (6 capsules/day)
214430939|NCT05053113|DEVICE|Activity Monitor|Wear accelerometer
214430940|NCT05053113|OTHER|Educational Intervention|Receive educational newsletter
214430941|NCT05053113|OTHER|Survey Administration|Ancillary studies
214430942|NCT05053113|BEHAVIORAL|Telephone-Based Intervention|Receive phone call from health coach
214430943|NCT06677268|PROCEDURE|rehabilitation|Patients will undergo a respiratory rehabilitation program (24 exercise sessions of 90 minutes each, three times a week for 8 weeks and up to 9 therapeutic education workshops of 1 hour of the patient\&#39;s choice)
214430944|NCT06706752|DIETARY_SUPPLEMENT|Shengbai Oral Formula|Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.
214513729|NCT04663256|OTHER|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
214513730|NCT04561089|DIAGNOSTIC_TEST|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
214513731|NCT01217099|DRUG|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
214430945|NCT06706752|OTHER|Inactive Placebo|Inactive placebo will be taken by mouth three times per day for 14 days.
214430946|NCT00050375|DRUG|oregovomab|
214430947|NCT07037771|DRUG|zodasiran Injection|ARO-ANG3 Injection
214430948|NCT07037771|DRUG|Placebo|sterile normal saline (0.9% NaCl)
214430949|NCT06722716|OTHER|Swab collection|Nasopharyngeal swab
214430950|NCT07044102|OTHER|Patients Undergoing Low Tidal Volume Ventilation During CABG|Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass
214430951|NCT07044102|OTHER|Patients Undergoing Apneic Ventilation During CABG|"Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass"
214430952|NCT07048743|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
214430953|NCT06721962|BIOLOGICAL|TRX103|TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.
215114145|NCT06273397|DRUG|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
214513732|NCT01217099|DRUG|azithromycin|control patients were iv azithromycin for 5 days.
214513733|NCT02339259|OTHER|Observation|
214513734|NCT01584674|DEVICE|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
214513735|NCT00384514|DEVICE|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
214513736|NCT01320800|BEHAVIORAL|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
214430954|NCT06721962|DRUG|Cyclophosphamide|Low dose cyclophosphamide conditioning.
214430955|NCT06888115|DRUG|CS0159|Single oral dose of CS0159 4mg
214430956|NCT06886451|OTHER|ML-based intervention|For each patient, a ML model will predict the risk of vomiting within the next 96 hours. Patients will then receive care pathway-consistent interventions based on the ML model predictions.
214430957|NCT06526299|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214430958|NCT06526299|PROCEDURE|Bone Scan|Undergo bone scan
214430959|NCT06526299|PROCEDURE|Computed Tomography|Undergo SPECT/CT and CT
214430960|NCT06526299|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214430961|NCT06526299|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214430962|NCT06526299|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT
214430963|NCT06526299|OTHER|Questionnaire Administration|Ancillary studies
214430964|NCT06526299|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214430965|NCT05741827|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention focusing on diet and physical activity
214430966|NCT03129555|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214430967|NCT03129555|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214430968|NCT03129555|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214513737|NCT01320800|BEHAVIORAL|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
214513738|NCT02594709|RADIATION|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
214513739|NCT04253951|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
214513740|NCT04892251|COMBINATION_PRODUCT|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
214513741|NCT04892251|BEHAVIORAL|MORE|Mindfulness-Oriented Recovery Enhancement
214513742|NCT06510673|DRUG|Platelet rich plasma|Platelet-rich plasma for the heel
214513743|NCT06510673|OTHER|High power LASER|High power LASER sessions for the heel
214430969|NCT03129555|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214430970|NCT07054892|BEHAVIORAL|FAAM - Activities of Daily Living (ADL) Subscale|The FAAM score is scientifically validated and allows for the assessment of foot and ankle functional ability
214430971|NCT07053358|GENETIC|LX111 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.
214430972|NCT07053293|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
214513744|NCT06510673|OTHER|Shockwave therapy|Shockwave therapy sessions for the heel
214430973|NCT07056192|OTHER|Structured education group|Structured education group
214430974|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd|Standard-Dose Palbociclib + Endocrine therapy
214430975|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|Standard-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
214430976|NCT07061717|DRUG|Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|High-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
214430977|NCT07055464|PROCEDURE|eTEP-RS Hernia Repair|Laparoscopic retromuscular mesh repair using the enhanced view totally extraperitoneal (eTEP-RS) technique for ventral or incisional hernia.
214430978|NCT07055464|PROCEDURE|IPOM Plus Hernia Repair|Intraperitoneal onlay mesh (IPOM Plus) repair involving laparoscopic fascial defect closure and mesh placement for abdominal wall hernias.
214430979|NCT07060586|PROCEDURE|Sphenopalatine Ganglion Block|A bilateral transnasal sphenopalatine ganglion block with cotton tips soaked in a mixture of 0.5 mL lidocaine 4% and 0.5 mL ropivacaine 0.5% plus injection through the cotton tips of an additional 1 mL of the mixture. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
214430980|NCT07060586|PROCEDURE|Sham Block|A sham block with two bilaterally inserted cotton tips not reaching the posterior part of the nasopharyngeal making not contact with the ganglion. Cotton tips are soaked in 1 mL placebo (saline) and have a total of 1 mL saline injected through the cotton tips. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
214430981|NCT07061704|BIOLOGICAL|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses.|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first. Chemotherapy + Immune Checkpoint Inhibitor (ICI): Administered via intravenous infusion once every 3 weeks.
214513745|NCT06510673|OTHER|Ice application|Ice application for the heel
214513746|NCT06510673|OTHER|Sham LASER|Sham LASER for the heel
214513747|NCT03234959|DEVICE|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
214513748|NCT03234959|OTHER|Infant Massage|Infants will received IM by their parents
214513749|NCT03153306|DRUG|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
214513750|NCT04787198|DRUG|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
214513751|NCT04787198|DRUG|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
214513752|NCT01564498|OTHER|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
214513753|NCT02544191|DRUG|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
214513754|NCT02813174|BEHAVIORAL|Compassionate Mind Training from Compassion-Focused Therapy|
214513755|NCT02553148|OTHER|Need for children's palliative care|Need for children's palliative care
214513756|NCT05866354|DRUG|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
215114146|NCT06273397|DRUG|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
215114147|NCT05749328|DIETARY_SUPPLEMENT|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
215114148|NCT01574651|DRUG|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
215114149|NCT01574651|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
214513757|NCT03479892|DRUG|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
214430982|NCT07061262|PROCEDURE|External Oblique Intercostal Plane Block|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, an external oblique plane block will be performed by the same anesthesiologist under ultrasound guidance, using an external oblique muscle approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the external oblique space.
214430983|NCT07061262|PROCEDURE|Subcostal TAP block and spinal anesthesia group (STAP)|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, a subcostal block will be performed by the same anaesthesiologist under ultrasound guidance with a subcostal approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the subcostal space.
214430984|NCT07060911|DEVICE|Lung monitoring with the Neola device|Lung monitoring with the Neola device
214430985|NCT07059988|OTHER|Stable isotope tracers|Deuterium-labelled non-radioactive stable isotopes of glucose, phenylalanine and glycerol.
214430986|NCT07059988|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition infused a rate corresponding to 100% of measured energy expenditure, started after blood sampling during a baseline fasting period.
214430987|NCT04873102|DRUG|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
214513758|NCT03479892|DRUG|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
214513759|NCT03136822|OTHER|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
214513760|NCT03136822|DEVICE|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
214513761|NCT04859062|DRUG|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
214513762|NCT04859062|OTHER|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
214513763|NCT00502294|DRUG|Visilizumab (HuM291; Nuvion®)|
214513764|NCT02314975|DEVICE|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
214513765|NCT02314975|DEVICE|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
214430988|NCT07059884|OTHER|Exercise intervention|Complete supervised TH progressive resistance exercise sessions
214430989|NCT07059884|OTHER|Telemedicine|Complete supervised TH progressive resistance exercise sessions
214513766|NCT02314975|OTHER|Fixed appliance only|Fixed appliance treatment only
214513767|NCT01562184|DEVICE|Sham tDCS device|Sham tDCS
214513768|NCT01562184|DEVICE|Soterix tDCS device|Active tDCS
214513769|NCT06360978|DRUG|Docetaxel|Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
214430990|NCT07059884|OTHER|Aerobic Exercise Intervention|Complete unsupervised aerobic exercise sessions
214513770|NCT00003984|BIOLOGICAL|lintuzumab|
214513771|NCT02779426|BEHAVIORAL|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
214513772|NCT04665583|OTHER|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
214513773|NCT00814749|PROCEDURE|midureteral sling|midureteral sling
214513774|NCT00814749|OTHER|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
214513775|NCT00610337|DRUG|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
214513776|NCT00610337|PROCEDURE|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
214513777|NCT00268333|DRUG|fluorouracil|
214513778|NCT00268333|DRUG|leucovorin calcium|
214513779|NCT00268333|DRUG|oxaliplatin|
214513780|NCT00268333|PROCEDURE|neoadjuvant therapy|
215114150|NCT01574651|DRUG|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
215114151|NCT01574651|DRUG|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
215114152|NCT01574651|DRUG|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
214513781|NCT01873898|DEVICE|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
215114153|NCT01574651|DRUG|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
214430991|NCT07059884|OTHER|Dumbbell Exercise Intervention|Receive adjustable-weight dumbbells
214430992|NCT07059884|PROCEDURE|Accelerometry|Wear accelerometer
214430993|NCT07059884|OTHER|Questionnaire Administration|Ancillary studies
214430994|NCT07059884|OTHER|Interview|Ancillary studies
214430995|NCT07059884|OTHER|Electronic Health Record Review|Ancillary studies
214430996|NCT07060521|OTHER|soft tissue mobilization|massage
214430997|NCT07060521|OTHER|Self Stretching|self stretching
214430998|NCT07060261|PROCEDURE|Transoral robotic surgery+MRI|During the standard of care MRI, there will be an added T2 and T2 SPACE sequences. These sequences are estimated to take an additional 6 minutes, with no added risk to the patient.
214430999|NCT07059754|DEVICE|Topical Ophthalmic Cooling|Targeted topical ophthalmic cooling treatment using the ETX-4143 cooling device
214431000|NCT06843330|DEVICE|blood glucose meter; blood lactate meter|Blood lactate level measured by finger-stick with over the counter meter. Blood glucose level measured by finger-stick.
214513782|NCT03376763|DRUG|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
215114154|NCT03229733|DEVICE|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
215114155|NCT03229733|BEHAVIORAL|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
215114156|NCT03887221|DRUG|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
215114157|NCT03887221|DRUG|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
214431001|NCT07059897|BEHAVIORAL|Animation video and mobile phone application|"An animation video scenario and MEKTUP mobile phone application were prepared by the researchers in light of the literature, in line with the National Breast Cancer Screening Program and by taking expert opinions."
214431002|NCT07060131|DEVICE|Far Infrared Eye Masks|Using far-infrared eye masks on the acupoints around the eyes, including Jingming, Taiyang, Sibai, Tongziliao, and Si Zhu Kong to assess whether there is an improvement in the symptomatic indicators of dry eye disease.
214431003|NCT07061041|OTHER|Strength training|"The group will perform one workout per week consisting of 3 series of the Romanian deadlift exercise of 10 repetitions. Each repetition will be performed at a specific pace - 3s in eccentric contraction and 1s in concentric contraction. The aforementioned exercise, the Romanian deadlift, will be performed by the subjects on a platform (elevation) in order to achieve maximum range of motion."
214431004|NCT07061041|OTHER|Streching group|The group performed one training session per week consisting of 2 sets of 60 seconds of static stretching
214431005|NCT07061197|OTHER|Patient leaflet with the EMA's proposed key information section including qualitative statements.|The standard patient leaflet supplemented with a key information section. This section included qualitative descriptions of the goal of treatment, the main benefits, contraindications, and the most serious side effects. The content was designed to reflect the EMA's proposed format for improving the patient information leaflet.
215114158|NCT04926246|DRUG|R1: Reference Product X|under fasted conditions
215114159|NCT04926246|DRUG|T1: Test Product M|under fasted conditions
215114160|NCT04926246|DRUG|T2: Test Product N|under fasted conditions
214431006|NCT07061197|OTHER|Control (standard patient leaflet)|The standard patient information leaflet for a recently approved cancer drug, tivozanib (Fotivda), obtained electronically from the EMA website. The standard patient information does not contain structured benefit information.
214513783|NCT03607591|OTHER|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
214513784|NCT03187704|OTHER|HEPA air filtration|Air filters were placed in participant homes
215114161|NCT04926246|DRUG|T3: Test Product O|under fasted conditions
215114162|NCT04926246|DRUG|T4: Test Product O|under fed conditions
215114163|NCT04926246|DRUG|R2: Reference Product Y|under fasted conditions
215114164|NCT04926246|DRUG|T5: Test Product P|under fasted conditions
215114165|NCT04926246|DRUG|T6: Test Product P|under fed conditions
215114166|NCT04926246|DRUG|T7: Test Product Q|under fasted conditions
215114167|NCT04926246|DRUG|R3: Reference Product Z|under fasted conditions
215114168|NCT04926246|DRUG|T8: Test Product S|under fasted conditions
215114169|NCT04926246|DRUG|T9: Test Product S|under fed conditions
215114170|NCT04926246|DRUG|T10: Test Product U|under fasted conditions
214431007|NCT07061197|OTHER|Patient leaflet with a key information section providing both qualitative and quantitative information on drug benefits and harms.|The standard patient leaflet, supplemented with a key information section including quantitative data on the drug's main benefits and side effects, presented in a summary table format. This section provided structured information about the indication and goal of treatment, how the drug was studied (the comparator treatment and number of patients enrolled in the clinical trial that supported the drug's approval), and data on the drug's benefits and side effects.
214431008|NCT06892379|DRUG|HS-20110 (Phase Ia：Dose escalation )|HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles
214431009|NCT06892379|DRUG|HS-20110 (Phase Ib:Dose expansion )|The recommended dose from the dose-escalation stage and other potential doses will be further explored
214431010|NCT07059845|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
214431011|NCT07059845|DRUG|Bevacizumab|IV Infusion
214431012|NCT07059845|DRUG|Carboplatin|IV Infusion
214431013|NCT06770998|DEVICE|EEG-neurofeedback training|15 training sessions (twice/week) plus two booster training sessions added to treatment as usual.
214431014|NCT06770998|DEVICE|Sham training|15 sham sessions (twice/week) plus two sham booster sessions added to treatment as usual.
214431015|NCT07061405|OTHER|Multidisciplinary management associated with mobile application Doado|multidisciplinary program including physiotherapists, rheumatologists, physical medicine and rehabilitation specialists, occupational physicians, psychologists, etc., associated with Doado mobile application
214431016|NCT07061405|OTHER|Physiotherapy management alone associated with mobile application Doado|monodisciplinary physiotherapy rehabilitation program consisting of active treatment with a physiotherapist associated with Doado mobile application
214431017|NCT07059702|OTHER|There will be no intervention.|There will be no intervention. This is an observational study that uses EEG and FDG-PET results as parameters. These investigations will b e performed on a clinical basis.
214431018|NCT07060326|OTHER|Survey using a questionnaire.|REDCap Survey
214431019|NCT05710172|DEVICE|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
215114171|NCT02134470|DRUG|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
215114172|NCT04454242|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
215114173|NCT02487030|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
215114174|NCT02487030|DRUG|RBV|Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215114175|NCT00586885|DRUG|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
215114176|NCT02092025|DRUG|Azilsartan|Azilsartan tablets
215114177|NCT06260553|DRUG|tislelizumab and metronomic oral vinorelbine|tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
215114178|NCT03308253|DEVICE|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
215114179|NCT03308253|DRUG|Vancomycin|0.5 g Vancomycin per patient
215114180|NCT03308253|DRUG|Tobramycin|120 mg tobramycin per patient
215114181|NCT03308253|OTHER|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
214431020|NCT04930289|DEVICE|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
214431021|NCT04930289|DEVICE|BAROGuard|"The BAROguard (the System) is ultraportable hypothermic preservation and transport system intended for use with donor lungs. BAROguard is a legally marketed, FDA cleared medical device in the United States. The intended organ storage time for BAROguard™ is up to 8 hours."
214431022|NCT06838806|DIAGNOSTIC_TEST|blood draw|Plasma samples will be collected in NTU Hospital or NTUCC. ChLIA kits and all other reagents will be provided by Volition. ChLIA analysis of samples will be performed by a Volition designated laboratory in Taiwan( NTU Centres of Genomic and Precision Medicine).
214431023|NCT07061834|DEVICE|Biofeedback training|The intervention consists of biofeedback training using the Nexus 10 device, which provides real-time feedback on physiological signals including galvanic skin response and peripheral temperature. Participants undergo sessions where they learn to consciously regulate their autonomic nervous system activity by observing and modifying these signals. This training aims to improve stress regulation and enhance physiological self-control. Unlike other biofeedback interventions, this protocol focuses on combined skin conductance and temperature measures delivered through the Nexus 10 system over multiple sessions.
214431024|NCT07061834|OTHER|control group|The control group received no intervention.
214431025|NCT05051657|DIETARY_SUPPLEMENT|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
214431026|NCT06648031|DRUG|Arm 1 - DehydraTECH-CBD alone|Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule
214431027|NCT06648031|DRUG|Arm 2 - DehydraTECH-semaglutide alone|Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
214431028|NCT06648031|DRUG|Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide|"DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks.~\- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule"
214431029|NCT06648031|DRUG|Arm 4 - Rybelsus medication (semaglutide) alone|Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
214431030|NCT06648031|DRUG|Arm 5- Tirzepatide|Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks
214513785|NCT03121885|BEHAVIORAL|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
214513786|NCT03121885|OTHER|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
214513787|NCT06363604|PROCEDURE|VOMEI + PVI + linear ablation of mitral isthmus|The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
214513788|NCT06363604|PROCEDURE|Posterior wall isolation|PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
214431031|NCT06813430|DEVICE|Non-contact Low Frequency Ultrasound|NCLF-US therapy involves delivering low-frequency (40 kHz), low-intensity (0.1-0.8 W/cm2) ultrasound energy via sterile water mist.
214513789|NCT01094106|DRUG|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
214513790|NCT01094106|DRUG|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
214513791|NCT03020498|BIOLOGICAL|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
214513792|NCT03020498|BIOLOGICAL|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
214431032|NCT06813430|OTHER|Lalonde Protocol (standard of care)|Standard of care local wound therapy using the Lalonde protocol - rinsing the site with clean water, applying a grease layer, wrapping with a one-inch gauze wrap, and securing with Coban tape.
214513793|NCT03725020|OTHER|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
214513794|NCT00637663|DRUG|Entecavir|entecavir 0.5 mg QD
214513795|NCT00637663|DRUG|Lamivudine|lamivudine 100 mg QD
214513796|NCT02558205|RADIATION|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
214513797|NCT02558205|RADIATION|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
214692525|NCT02730507|DEVICE|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
214513798|NCT02467985|PROCEDURE|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
214513799|NCT00004496|DRUG|alpha-melanocyte stimulating hormone|
214513800|NCT04743388|BIOLOGICAL|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
214513801|NCT04743388|BIOLOGICAL|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
214513802|NCT05862402|DRUG|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
214513803|NCT05110794|DRUG|LY3502970|Administered Orally.
214513804|NCT01403285|DRUG|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
214513805|NCT01403285|BIOLOGICAL|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
214513806|NCT01403285|BIOLOGICAL|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
214513807|NCT01403285|DRUG|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
214513808|NCT04921540|PROCEDURE|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
214513809|NCT04921540|PROCEDURE|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
214513810|NCT01294644|DRUG|Deoxycholic acid injection|
214513811|NCT01294644|DRUG|Placebo|Phosphate buffered saline placebo for injection
214513812|NCT00078156|BEHAVIORAL|Behavior Therapy|
214513813|NCT03075878|DRUG|ALXN1830|Administered via IV infusion.
214431035|NCT06085755|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
214431036|NCT06085755|DRUG|Afatinib|Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
214431037|NCT06385340|OTHER|Lipikar Baume AP+M|• Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
214431038|NCT04415879|OTHER|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
214431039|NCT04415879|OTHER|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
214431040|NCT06913010|OTHER|No interventions.|This is an observational study with no interventions.
214431041|NCT02021799|DIETARY_SUPPLEMENT|Moringa and Lactobacillus rhamnosus GR-1|
214431042|NCT03801499|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214431043|NCT06890728|BEHAVIORAL|Culinary focused nutrition education|Culinary focused nutrition education based on MyPlate with an emphasis on taste and enjoyment of healthy foods.
214431044|NCT06890728|BEHAVIORAL|Standard low intensity nutrition education|Provided by a written MyPlate resource
214431045|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
214431046|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
214431047|NCT06937073|BEHAVIORAL|dietary intake guidance and exercise guidance|"In the Fugu Medical WeChat mini program, the intervention plan for the intervention group included: (1) dietary intake guidance and (2) exercise guidance.~1. Dietary intake guidance: The dietary guidance was mainly based on the general dietary guidelines for the elderly issued by the Chinese Nutrition Society.~2. Exercise guidance Exercise guidance included resistance training and balance training."
214431048|NCT06937073|BEHAVIORAL|Control|Participants in the control group only received rehabilitation program articles in the form of images and text through the mobile application. These materials also included dietary intake guidance and exercise instructions. The frequency and intensity of the exercise instructions were sent to the patients at the same time. However, their daily adherence, including whether the training was completed or whether the dietary intake was appropriate, was not checked, verified, or followed up.
214513814|NCT03822806|OTHER|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
214431049|NCT06935253|OTHER|Large Language Model|The intervention is a Large Language Model.
214431050|NCT06949566|OTHER|100 Hz Local Vibration|Participants in this group will receive 100 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
214431051|NCT06949566|OTHER|50 Hz Local Vibration|Participants in this group will receive 50 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
214431052|NCT06949566|OTHER|Sham Local Vibration|Participants in this group will receive sham vibration following the muscle fatigue protocol. The vibration device will be turned on but held near the muscle without making contact for 10 minutes. Participants will be informed that they are being treated with an electromagnetic vibration device.
214431053|NCT01523158|BIOLOGICAL|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
214431054|NCT06337227|DIAGNOSTIC_TEST|lncRNA signature analyses|Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
214431055|NCT05299762|DEVICE|INFUSE™ Bone Graft|Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
214431056|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
214431057|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
214431058|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
214431059|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
214431060|NCT04725890|DEVICE|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
214431061|NCT04356976|DEVICE|Ventralex|Repair of hernia using Ventralex patch in sublay position
214431062|NCT04356976|OTHER|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
214431063|NCT04246372|DRUG|Tofacitinib|Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome
214431064|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
214513815|NCT01106807|DRUG|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
214431065|NCT03554382|OTHER|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
214431066|NCT02936388|PROCEDURE|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
214431067|NCT02936388|PROCEDURE|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
214431068|NCT06302101|BEHAVIORAL|chair-based exercises|"Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises."
214431069|NCT06302101|BEHAVIORAL|cognitive exercises|Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
214431070|NCT05199571|BIOLOGICAL|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
214431071|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
214431072|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
214431073|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
214431074|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
214431075|NCT06245954|OTHER|simulated training|Simulation training of bronchoscopists by means of simulators and extracorporeal lungs
214431076|NCT06245954|OTHER|traditional bedside teaching|TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
214513816|NCT01106807|DRUG|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
214513817|NCT01106807|DRUG|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
214513818|NCT01106807|DRUG|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
214513819|NCT01492127|BIOLOGICAL|Blood test|Blood test
214513820|NCT00234676|DRUG|Premarin ®|Premarin ® 0.625 mg per day orally
214513821|NCT01811615|OTHER|alcohol-free experimental mouth rinse|
214513822|NCT01811615|OTHER|alcohol-containing mouth rinsing|
214513823|NCT01705756|DRUG|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
214513824|NCT03750682|OTHER|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
214513825|NCT03750682|OTHER|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
214513826|NCT02188459|DRUG|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
214431077|NCT02964611|BEHAVIORAL|Observational Study|This is an observational study.
214431078|NCT05054309|DIETARY_SUPPLEMENT|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
214513827|NCT02992652|DRUG|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
214513828|NCT00184444|BEHAVIORAL|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
214513829|NCT00184444|BEHAVIORAL|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
214431079|NCT04095221|DRUG|Prexasertib|"DOSE LEVELS FOR PATIENTS \> 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
214513830|NCT04317937|OTHER|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
214431080|NCT04095221|DRUG|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
214431081|NCT03215927|DRUG|Abatacept|Abatacept 125mg subcutaneous weekly
214431082|NCT03215927|OTHER|Placebo|Placebo
214431083|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
214431084|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
214431085|NCT05344599|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.
214431086|NCT05344599|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit
214431087|NCT05344599|DIAGNOSTIC_TEST|Urine Testing|Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine
214431088|NCT05344599|DIAGNOSTIC_TEST|Blood laboratory Testing|"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"
214431089|NCT04263792|DRUG|[18F]fluoropropyl-trimethoprim|\[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
214431090|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
214431091|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
214431092|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
214513831|NCT04317937|OTHER|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
214431093|NCT03889925|DRUG|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
214431094|NCT03889925|BIOLOGICAL|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
214431095|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Exposed to Passive Smoking|This study is designed to evaluate the relationship between passive smoking and the vital parameters of children undergoing deep sedation. Additionally, the study aims to comprehensively assess and document the entire treatment process from start to finish by using the RASS, MASS, and PAED scales for postoperative evaluation.
214431096|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Not Exposed to Passive Smoking|This study is designed to measure the differences in vital parameters of children undergoing deep sedation who are not exposed to passive cigarette smoke at home. Furthermore, the study aims to comprehensively evaluate and document the entire treatment process from start to finish using the RASS, MASS, and PAED scales for postoperative assessment.
215114182|NCT01478308|DRUG|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
215114183|NCT01478308|DRUG|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
215114184|NCT01478308|DRUG|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
214431097|NCT06833203|DRUG|Amantadine+ Pregabalin|Two hours preoperative, patient will receive two capsules, one of them is Amantadine (Amantadine Hydrochloride) 100 mg and the other is Pregabalin (Lyrica) 75 mg and continued on both of them twice daily for 5 days postoperative.
214431098|NCT06833203|DRUG|Pregabalin|Two hours preoperative, the patient will receive two capsules, one of them is pregabalin 75 mg, and the other is a placebo capsule similar to the amantadine capsule and continued on both of them twice daily for 5 days postoperative.
215114185|NCT02145065|DRUG|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
214431099|NCT05116085|DRUG|Tislelizumab|Administered intravenously
214431100|NCT06732778|OTHER|Pain Neuroscience Education (PNE)|"PNE was planned online for clients 1 week before menstruation in the form of speaking sessions in a presentation format. The training will be conveyed in relation to pain during menstruation. Visual aids, examples and metaphors will be used to improve patient understanding in the training. Ankle sprain picture, speeding bus picture, action potential picture, picture showing membrane resting potential, rusty nail picture, whole body nervous system picture, neuromatrix picture, lion and lion cub picture that helps explain stress responses, curious neighbors picture etc. will be used. The training session is planned to last between 2 and 4 hours.~The distribution of pain neuroscience training topics will be implemented in the order given below, with 10 main headings.~* Pain and the Biopsychosocial Model~* Injury and pain are not equivalent, pain is a brain output rather than an input~* Action potential, normal electrical activity of nerves and conduction~* Biological process of ion chann"
214431101|NCT06732778|OTHER|Control Group (CG)|The control group will not receive any training or practice.
214431102|NCT05376878|OTHER|Copper Cu 64-DOTA-Trastuzumab|Given IV
214431103|NCT05376878|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214431104|NCT05376878|DEVICE|Positron Emission Tomography|Undergo PET/MRI
214431105|NCT05376878|BIOLOGICAL|Trastuzumab|Given IV
214431106|NCT05376878|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214431107|NCT04522271|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
214431108|NCT04522271|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
214431109|NCT06834516|DEVICE|ClearSight baby cuff|Noninvasive device for continuous blood pressure monitoring
214431110|NCT03382145|OTHER|No intervention|No intervention
214431111|NCT05937750|DRUG|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
214431112|NCT05937750|OTHER|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study|Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
214431113|NCT05457972|DRUG|Estradiol|Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
214431114|NCT05457972|DEVICE|Vaginal Moisturizer|Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
214431115|NCT01000623|DRUG|venlafaxine|Given orally
214431116|NCT01000623|DRUG|placebo|Given orally
214431117|NCT01000623|PROCEDURE|hypnotherapy|Practice hypnosis
214431118|NCT01000623|PROCEDURE|mind-body intervention procedure|Practice focused attention
214513832|NCT04317937|OTHER|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
215114186|NCT02145065|DEVICE|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
215114187|NCT02562859|DRUG|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
215114188|NCT02562859|DRUG|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
215114189|NCT04673539|DIAGNOSTIC_TEST|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
214431119|NCT04084223|OTHER|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
214431120|NCT05430997|DEVICE|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
214431121|NCT05430997|DEVICE|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
214431122|NCT03073941|DEVICE|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
214513833|NCT04317937|OTHER|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
214431123|NCT03073941|DEVICE|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
214431124|NCT05250310|BEHAVIORAL|Chair Yoga|Yoga poses performed in a chair
214431125|NCT04586270|DRUG|TAS0612|oral tablets
214431126|NCT05988749|OTHER|Biofourmis Digital Platform|The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
214431127|NCT06302660|DIAGNOSTIC_TEST|Breath test|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath.
214431128|NCT06302660|DIAGNOSTIC_TEST|Saliva sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of saliva.
214431129|NCT06302660|DIAGNOSTIC_TEST|Blood sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of blood.
214513834|NCT03357237|OTHER|medical device|"patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo"
214513835|NCT01868061|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
214513836|NCT01868061|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
214692526|NCT06409078|DEVICE|repeated transcranial magnetic stimulation treatment group|Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.
214513838|NCT06196294|BIOLOGICAL|Cell therapy for solid tumors|Transfer γδT cells into patients for anti-ancer therapy.
214431130|NCT06302660|DIAGNOSTIC_TEST|Urine sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of urine.
214431131|NCT06302660|DIAGNOSTIC_TEST|Stool sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of stool.
214431132|NCT06302660|DIAGNOSTIC_TEST|Health-related Quality of life questionnaires|Participants will attend an outpatient clinic and complete validated healthy-related quality-of-life questionnaires.
214431133|NCT05252884|DIAGNOSTIC_TEST|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
214431134|NCT05252884|DRUG|routine postoperative calcium and calcitriol|The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
214513839|NCT01986348|DRUG|Selinexor|One cycle is 28 days (4 weeks).
214513840|NCT03511495|DIAGNOSTIC_TEST|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
214513841|NCT00841711|BEHAVIORAL|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
214513842|NCT01947114|DRUG|Propofol|
214513843|NCT01947114|DRUG|Ketamine|
214513844|NCT01947114|DRUG|Remifentanil|
215114190|NCT02164266|DRUG|Placebo|Matching placebo daily oral administration
215114191|NCT02164266|DRUG|RO6799477|Daily oral administration of RO6799477
215114192|NCT02399657|DRUG|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
214431135|NCT03712813|DEVICE|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
214431136|NCT05465187|OTHER|Non applicable|Non applicable
214431137|NCT05649930|OTHER|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
214431138|NCT05361369|DRUG|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
214431139|NCT05684432|OTHER|No intervention|No intervention
215114193|NCT05805891|DRUG|bortezomib|bortezomib 2mg/week subcutaneous injection
215114194|NCT00264537|DRUG|Placebo injections|SC injections
215114195|NCT00264537|DRUG|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
215114196|NCT00264537|DRUG|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
215114197|NCT00264537|BIOLOGICAL|Golimumab 50 mg injections|SC injections
214431140|NCT03755102|DRUG|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
214431141|NCT03755102|DRUG|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
215114198|NCT00264537|BIOLOGICAL|Golimumab 100 mg injections|SC injections
214431142|NCT06374836|DRUG|Phenylephrine|"At the OR, the patient will be sedated and have a transoesophageal echo (TEE) catether inserted, which is part of standard clinical care. When a patient becomes hypotensive and the attending anesthesiologist decides to infuse any of the following drugs (phenylephrine, ephedrine, norepinephrine, nitroprusside, or nicardipine), before infusion, the anesthesiolgist will acquire with TEE 10 beats of the thoracic ascending and descending aorta respectively. This is defined as one measurement. Five minutes after infusion the same measurement is repeated. A maximum of 10 measurements (5 before and 5 after infusion of a drug) per patient will be performed.~We want to explicitly mention that for study purposes the surgery or anesthesia will never be prolonged or modified, nor will any drugs be give for study purposes."
214431144|NCT04250883|OTHER|Low intra-abdominal pressure|8 mmHg
214431145|NCT04250883|OTHER|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
214431146|NCT04250883|OTHER|Standard intra-abdominal pressure|14 mmHg
214431147|NCT04250883|OTHER|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
214431148|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
214431149|NCT06104332|DEVICE|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
214431150|NCT06104332|DEVICE|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
214431151|NCT06104332|DEVICE|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
214513845|NCT00011102|BEHAVIORAL|Weight Gain Prevention for Women Project|
214431152|NCT06104332|DEVICE|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
214513846|NCT01739972|DRUG|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
215114199|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
215114200|NCT05695144|DEVICE|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
214431153|NCT06104332|DEVICE|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
214431154|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
214431155|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
214431156|NCT05969574|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
214431157|NCT05969574|DIAGNOSTIC_TEST|Blood test AMH|Measurement of AMH performed on the day of first consultation
214431158|NCT06450301|PROCEDURE|Endometrial Biopsy|"An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and~generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example)."
214431159|NCT01643499|DRUG|oxaliplatin|Given IV
214431160|NCT01643499|DRUG|irinotecan hydrochloride|Given IV
214431161|NCT01643499|DRUG|leucovorin calcium|Given IV
214431162|NCT01643499|DRUG|fluorouracil|Given IV
214513847|NCT01739972|DRUG|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
214513848|NCT03876886|DRUG|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
214431163|NCT01643499|OTHER|laboratory biomarker analysis|Correlative studies
214431164|NCT02871206|BIOLOGICAL|Fluad|
214431165|NCT02871206|BIOLOGICAL|Fluzone|
214431166|NCT05563740|OTHER|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
214431167|NCT03643939|DEVICE|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
214431168|NCT03643939|DEVICE|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
214431169|NCT00227994|DRUG|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
214431170|NCT00227994|DRUG|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
214431171|NCT03803605|BIOLOGICAL|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
214431172|NCT03803605|DRUG|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
214431173|NCT05680389|DRUG|Minocycline|100 mg twice daily for 3 months
214431174|NCT05680389|DRUG|Placebo|twice daily for 3 months
214431175|NCT01823536|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
214431176|NCT00945607|OTHER|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
214431177|NCT01186549|DRUG|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
214431178|NCT01186549|DRUG|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
214431179|NCT01186549|DRUG|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
214431180|NCT01186549|DRUG|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
214431181|NCT01186549|DRUG|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
214431182|NCT04073199|PROCEDURE|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
214513849|NCT03876886|DRUG|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
214513850|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*4cycles
214513851|NCT03876886|DRUG|Carboplatin|carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
214513852|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*8cycles
214513853|NCT03942107|PROCEDURE|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
214513854|NCT03942107|PROCEDURE|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
214513855|NCT01211509|DRUG|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
214513856|NCT04520321|DRUG|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
214513857|NCT04520321|OTHER|Vehicle (placebo)|Placebo
214513858|NCT02913300|DRUG|Lignocaine 1% concentration solution|
214513859|NCT02913300|DRUG|Lignocaine 2% concentration solution|
215114201|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
214431183|NCT04073199|PROCEDURE|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
214431184|NCT00737035|BEHAVIORAL|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
214431185|NCT00737035|BEHAVIORAL|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
214431186|NCT01892683|DRUG|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
214431187|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
214431188|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
214431189|NCT02250937|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
214431190|NCT02250937|DRUG|Busulfan|Given IV
214431191|NCT02250937|DRUG|Cladribine|Given IV
214431192|NCT02250937|DRUG|Fludarabine Phosphate|Given IV
214513860|NCT00316797|DRUG|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
214513861|NCT02698956|DEVICE|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
214431193|NCT02250937|OTHER|Laboratory Biomarker Analysis|Correlative studies
214431194|NCT02250937|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214431195|NCT02250937|OTHER|Pharmacological Study|Correlative studies
214513862|NCT01201837|DRUG|Placebo|Weekly injection
214513863|NCT01201837|DRUG|CER-001|Weekly injection
214513864|NCT03734978|DIAGNOSTIC_TEST|Diagnosis|biochemistry
214513865|NCT02935894|DRUG|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
214431196|NCT02250937|DRUG|Venetoclax|Given PO
214431197|NCT01285986|PROCEDURE|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
214513866|NCT02935894|OTHER|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
214513867|NCT02935894|DRUG|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
214513868|NCT02050555|DIETARY_SUPPLEMENT|Placebo|
214513869|NCT02050555|DIETARY_SUPPLEMENT|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
214513870|NCT05954247|DRUG|DWJ1543|DWJ1543
214513871|NCT05954247|DRUG|DWC202216|DWC202216
214513872|NCT03230084|DEVICE|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
214431198|NCT03891927|DIETARY_SUPPLEMENT|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
214431199|NCT04151082|DRUG|Methylprednisolone|Given IV
214431200|NCT04151082|DRUG|Prednisone|Given PO
214431201|NCT04151082|OTHER|Quality-of-Life Assessment|Ancillary studies
214431202|NCT04151082|OTHER|Questionnaire Administration|Ancillary studies
214431203|NCT03364595|PROCEDURE|plate fixation|ORIF of the radial head fracture
214513873|NCT03224988|DEVICE|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
214513874|NCT01602302|DRUG|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
214513875|NCT01499251|DRUG|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
214513876|NCT01499251|DRUG|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
214513877|NCT01499251|DRUG|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
214513878|NCT00853957|DRUG|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
214513879|NCT00853957|DRUG|Amlodipine|Amlodipine 5 mg titrated to 10mg
214513880|NCT06417372|DIAGNOSTIC_TEST|intraoperative fluorescent staining combined with microscopy|Through the modified formulation of sodium fluorescein and methylene blue, the surface of the suspected cut edge of the patient's glioma was stained intraoperatively, and the surgical microscope image acquisition and processing system was used to determine whether the cut edge of the surgically resected tissue was positive or not.
215114202|NCT05695144|DEVICE|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
214513881|NCT05188378|BIOLOGICAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
214513882|NCT05188378|BIOLOGICAL|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
214513883|NCT04267952|BEHAVIORAL|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
214513884|NCT04267952|BEHAVIORAL|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
214431204|NCT03364595|PROCEDURE|replacement|replacement of the radial head fracture
214431205|NCT02672930|DEVICE|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
214431206|NCT05639777|DRUG|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
214431207|NCT05639777|OTHER|control group|That will receive the same volume of 2 ml of intranasal normal saline
214513885|NCT05448794|OTHER|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
215114203|NCT03451123|DRUG|FET PET/MRI|FET PET/MRI scan before and after surgery
215114204|NCT06141876|DRUG|APEX-002-A02|Active
215114205|NCT06141876|OTHER|Placebo|placebo
215114206|NCT00932867|DRUG|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
215114207|NCT05495165|OTHER|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
214431208|NCT03017183|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
214431209|NCT03017183|PROCEDURE|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
214431210|NCT02424318|DRUG|Topiramate|topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
214431211|NCT04425629|DRUG|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
214431212|NCT03262623|OTHER|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
214431213|NCT03262623|OTHER|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
214431214|NCT01958866|DRUG|Tinospora Crispa-extract Product|
214431215|NCT01958866|DRUG|Acetaminophen|
214431216|NCT01958866|OTHER|Placebo|
214513886|NCT01519557|DRUG|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
214513887|NCT01519557|DRUG|Placebo|Placebo
214513888|NCT02158806|DRUG|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
214513889|NCT02158806|DRUG|Placebo|Matching placebo capsule containing inert bulking agent
214431217|NCT01323686|OTHER|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
214431218|NCT01016522|DIETARY_SUPPLEMENT|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
214431219|NCT02290470|DRUG|Olanzapine|"* Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
214431220|NCT02290470|DRUG|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
214431221|NCT05001529|BIOLOGICAL|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
214431222|NCT04085094|DIETARY_SUPPLEMENT|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
214431223|NCT04085094|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
214431224|NCT04085094|DIAGNOSTIC_TEST|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
214513890|NCT05320874|BIOLOGICAL|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
214513891|NCT02383043|DRUG|Cocaine|
215114208|NCT04136730|BEHAVIORAL|Home-based|Resistance exercise carried out unsupervised at home
214431225|NCT04085094|OTHER|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
214431226|NCT03658408|DRUG|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
214431227|NCT03658408|DRUG|placebo|2.5 mg sugar pill given orally 4 times a day
214431228|NCT04801563|OTHER|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
214431229|NCT03221023|DRUG|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
214431230|NCT03221023|DRUG|Saline Solution|Individuals in the control arm will receive intrawound saline solution
214513892|NCT02383043|DRUG|Sustained Release d-Amphetamine|
214513893|NCT01898299|DEVICE|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
214513894|NCT01898299|DEVICE|Sham tDCS|Sham (inactive) tDCS treatment
214513895|NCT00348361|DRUG|Fluticasone Propionate|
214513896|NCT03417700|DIETARY_SUPPLEMENT|NW training|NW training
214513897|NCT03417700|DIETARY_SUPPLEMENT|Placebo|training with placebo
214513898|NCT03417700|DIETARY_SUPPLEMENT|HICT|Training and vitamin D
214513899|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
215114209|NCT02908750|DRUG|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
215114210|NCT02908750|DRUG|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
215114211|NCT00391950|DRUG|Zoledronic acid|
215114212|NCT00627341|BEHAVIORAL|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
215114213|NCT00627341|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
215114214|NCT05419544|BEHAVIORAL|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
215114215|NCT02395614|DRUG|Chlorhexidine irrigation|\- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
214431231|NCT05346523|DEVICE|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
214431232|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
214431233|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
214431234|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
214431235|NCT04218110|DRUG|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
214431236|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
214431237|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
214513900|NCT01219127|OTHER|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
214513901|NCT04337593|DRUG|Basiliximab|20mg d1,8, repeated every 3 weeks
214431238|NCT06044467|DRUG|Placebo - Study Part One|Placebo Comparator
215114216|NCT02395614|DRUG|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
215114217|NCT03228212|DEVICE|CONTROL|ACUVUE OASYS
215114218|NCT03228212|DEVICE|TEST|senofilcon A with new UV blocker
214431239|NCT06044467|DRUG|Placebo - Study Part Two|Placebo Comparator
214431240|NCT02713906|DEVICE|X-Ray Knee Guide group|
214431241|NCT02271854|DRUG|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
214431242|NCT02271854|DRUG|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
214431243|NCT03884296|BIOLOGICAL|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
214431244|NCT02450344|BEHAVIORAL|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
214431245|NCT02450344|BEHAVIORAL|Passive health promotion|An electronic package of information related to alcohol
214431246|NCT04760938|BEHAVIORAL|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
214431247|NCT04760938|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
214513902|NCT04337593|DRUG|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
214513903|NCT02551705|OTHER|functional Imaging|Brain responses associated with emotional memory will be investigated
214513904|NCT05469516|DEVICE|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~\- Non-invasive treatment of Axillary Hyperhidrosis"
214513905|NCT05469516|DEVICE|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
214513906|NCT02709044|DRUG|Ringer lactate|
214513907|NCT02054351|DRUG|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
215114219|NCT00851929|DRUG|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
215114220|NCT05297513|DRUG|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
214431248|NCT06414850|BEHAVIORAL|Animal Assisted Therapy (AAT)|A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
214431249|NCT01101594|DRUG|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
214431250|NCT02285413|BIOLOGICAL|DC vaccination|DC vaccination without cisplatinum
214431251|NCT02285413|BIOLOGICAL|DC vaccination with cisplatinum|DC vaccination with cisplatinum
214431252|NCT00240149|DRUG|Regular Insulin via Insulin-Glucose Algorithm|
214431253|NCT06324903|OTHER|echocardiography and percutaneous cardiac catheterization|pre- cardiac catheterization, intraprocedural and post-catheterization echocardiography.
214513908|NCT02056379|DRUG|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
214513909|NCT02056379|DRUG|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
214513910|NCT03409159|DEVICE|LAAC|Left atrial appendage closure
214513911|NCT06387550|PROCEDURE|Eccentric Training|Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
214513912|NCT01653392|BIOLOGICAL|Observational Intervention|This is an observational study, therefore no interventions are specified.
214513913|NCT03535636|OTHER|Polysomnography|Sleep architecture will be assessed by polysomnography
214513914|NCT03758248|GENETIC|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.
214513915|NCT01942915|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
214513916|NCT00848952|OTHER|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
214513917|NCT03731741|DRUG|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
214513918|NCT05437653|OTHER|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
214513919|NCT05437653|OTHER|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
214513920|NCT04598139|OTHER|Study group|The study group uses a web-based medication error notification system
214513921|NCT04895085|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
214513922|NCT03112005|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
214513923|NCT03112005|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
214513924|NCT00128765|BEHAVIORAL|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
214513925|NCT00128765|BEHAVIORAL|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
214431254|NCT04981158|PROCEDURE|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
214431255|NCT04981158|PROCEDURE|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
214513926|NCT00128765|BEHAVIORAL|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
214513927|NCT03941977|DEVICE|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
214513928|NCT03941977|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
214513929|NCT03941977|BIOLOGICAL|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
214513930|NCT06662630|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
214513931|NCT06203873|DEVICE|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
214431256|NCT01933802|BIOLOGICAL|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
214431257|NCT05752175|DRUG|WPV01|WPV01 tablets
214431258|NCT05752175|DRUG|Placebo|Placebo tablets
214431259|NCT06092255|RADIATION|Postoperative radiotherapy for SVZ|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
214431260|NCT06266936|OTHER|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
214431261|NCT02330458|PROCEDURE|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall \>3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
214431262|NCT00446459|DRUG|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
214431263|NCT04999917|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
214431264|NCT05779215|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
214431265|NCT03917303|DRUG|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
214513932|NCT06203873|DEVICE|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
214513933|NCT00004080|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
214513934|NCT00004080|PROCEDURE|conventional surgery|
214513935|NCT04399772|BEHAVIORAL|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
214513936|NCT04399772|BEHAVIORAL|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
214513937|NCT03477214|DIAGNOSTIC_TEST|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
214513938|NCT00598390|DRUG|[11C]MePPEP|
214513939|NCT06681350|DEVICE|Ocular surface imaging|Telemedical examination of high-resolution, all-in-focus images of the cornea, sclera, conjunctiva, and lid margins for montioring of postoperative complications
214513940|NCT07013162|PROCEDURE|High power diode laser + SRT|2W laser will be applied to periodontal pockets
214513941|NCT07013162|PROCEDURE|Low diode diode laser + SRT|A 0.5W low laser is applicated to periodontal pockets after mechanical debridement
214513942|NCT07013162|PROCEDURE|Curettage (SRT) only|Mechanical debridement for pocket
214431266|NCT03917303|DRUG|standard step-up care|conventional step-up care starting with corticosteroids
214692527|NCT06409078|DRUG|Western medicine group|Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
214692528|NCT00347854|OTHER|Systane Free lubricant eye drops|
214692529|NCT00347854|OTHER|Visine Tears Lubricant Eye Drops|
214692530|NCT00347854|OTHER|Refresh Liquigel Lubricant Eye Drops|
215114221|NCT04205617|OTHER|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
215114222|NCT02468349|OTHER|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
214513943|NCT06683157|DIAGNOSTIC_TEST|not drug|"Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on."
214431267|NCT01631851|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
214431268|NCT03791593|DRUG|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
214431269|NCT03003624|DEVICE|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
214431270|NCT03003624|DEVICE|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
214431271|NCT03003624|DEVICE|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
214513944|NCT03650166|OTHER|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
214513945|NCT03650166|OTHER|Personal BP monitor|Battery-powered BP monitor for personal use
214513946|NCT07013851|DRUG|Dostarlimab|"Patients will be treated in the neoadjuvant setting with dostarlima 500 mg (30') every 3 weeks for 4 cycles.All participants will undergo surgery within 6 weeks following the final dose of neoadjuvant dostarlimab. After surgery, adjuvant chemotherapy, including dostarlimab, will be administered as follows:~Stage II EC:~VBT/EBRT (completed within \>14 weeks after surgery) + Adjuvant dostarlimab 1000 mg Q6W x 9 cycles (54 weeks total).~Stage III EC:~1. Concurrent EBRT+cisplatin followed by carboplatin + paclitaxel OR~2. Sequential: EBRT followed by carboplatin + paclitaxel OR~3. Chemotherapy alone: carboplatin + paclitaxel~   * Adjuvant dostarlimab 500 mg Q3W x 4-6 cycles (in combination with chemotherapy) plus 1000 mg Q6W x 6-7 cycles (54 weeks total)."
214513947|NCT05331872|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
214513948|NCT05931406|BEHAVIORAL|Control|A normal working day from of 12h
214513949|NCT05931406|BEHAVIORAL|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
214513950|NCT05931406|BEHAVIORAL|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
214431272|NCT03610594|OTHER|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
214513951|NCT04919499|DRUG|BI 765128|BI 765128
214513952|NCT04919499|OTHER|Sham comparator|Sham comparator
214513953|NCT07026071|OTHER|Positional Release Technique|Positional Release Technique will be repeated 3 times in each session for each muscle with an aim to produce a decrease in perceived pain and an increase in pressure tolerance Iliopsoas Quadratus Lumborum Hamstrings
214513954|NCT07026071|OTHER|Stretching Exercises|These exercises will be performed with three repetitions per set, three sets per visit and with 30 seconds hold and 30 seconds rest Iliopsoas Quadratus Lumborum Hamstrings
214513955|NCT06699693|PROCEDURE|ultrasonography-guided PENG block|This study aimed to evaluate the effect of ultrasonography-guided PENG block prior to joint mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment, in comparison with a control group
214692531|NCT00347854|OTHER|Refresh Plus Lubricant Eye Drops|
214692532|NCT02994069|DRUG|Cisplatin|Cisplatin
214692533|NCT02994069|RADIATION|XRT|Radiation Therapy
214692534|NCT02065622|DRUG|Adalimumab|
214692535|NCT02065622|OTHER|Placebo|
214431273|NCT00000493|DRUG|propranolol|
214431274|NCT00000493|DRUG|hyaluronidase|
214431275|NCT03229044|GENETIC|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
214431276|NCT01178632|DRUG|Passiflora|01 tablet Passiflora p.o., b.i.d.
214692536|NCT02117167|DRUG|AZD2014|Target: m-TOR
214431277|NCT01178632|DRUG|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
214431278|NCT02918279|DRUG|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
214431279|NCT02918279|DRUG|Placebo|Administered once daily subcutaneously (s.c., under the skin)
214513956|NCT06699693|OTHER|Mobilization|The mobilization methods encompassed the scapula and clavicular joints, in addition to the glenohumeral (GH) joint, taking into consideration their biomechanical interactions. These exercises were supervised and administered by the physiotherapist during each session. Additionally, the patients were provided with a home exercise program that included exercises for posture, thera band, and finger ladder, with instructions to perform 10-15 repetitions twice a day independently \[
214513957|NCT06699745|BEHAVIORAL|Music intervention|In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.
214513958|NCT06699745|BEHAVIORAL|white noise intervention|White noise will be played at a decibel level appropriate for the children in the group.
214513959|NCT06699147|DEVICE|Hyaluronic Acid (HA)|6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis
214513960|NCT06699667|DIAGNOSTIC_TEST|Computed tomography|
214513961|NCT06699316|OTHER|Individualized prognostic counselling|Individualized prognostic counselling on life expectancy using the prognostic model 'OncologIQ Palliative'
214513962|NCT06699329|DRUG|Enlicitide Decanoate|multiple doses, oral tablet
214513963|NCT06699329|DRUG|Semaglutide|multiple doses, oral tablet
214513964|NCT06699537|DIETARY_SUPPLEMENT|probiotic product|During the study, subjects take one sachet of Lactobacillus rhamnosus LRa05 daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the intervention.
214513965|NCT06699537|DIETARY_SUPPLEMENT|Maltodextrin|During the study, subjects in the control group take one sachet of maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the 8-week trial.
214513966|NCT06700200|DEVICE|taVNS|transauricular vagus nerve stimulation
214431280|NCT04378361|DEVICE|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
214431281|NCT00309907|BIOLOGICAL|etanercept|Given IV and subcutaneously
214431282|NCT00309907|DRUG|methylprednisolone|Given IV and orally
214431283|NCT00244855|OTHER|pharmacological study|Correlative studies
214431284|NCT00244855|BIOLOGICAL|rituximab|Given IV
214431285|NCT00244855|DRUG|dexamethasone|Given IV
214431286|NCT00244855|OTHER|laboratory biomarker analysis|Correlative studies
214431287|NCT04816487|DRUG|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
214431288|NCT05608343|DRUG|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
214431289|NCT05608343|DRUG|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
214431290|NCT00599716|DRUG|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
214431291|NCT00599716|DRUG|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
214431292|NCT02957981|BEHAVIORAL|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
214431293|NCT02957981|BEHAVIORAL|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
214431294|NCT00660439|BEHAVIORAL|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
214431295|NCT06110416|OTHER|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
214431296|NCT00117702|DRUG|Tacrolimus|day 0-100, then taper
214431297|NCT00117702|DRUG|Everolimus|day 0-56
214431298|NCT03966508|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
214431299|NCT01895023|DRUG|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
214513967|NCT06699121|DRUG|LB-P8 low-dose|One capsule QD (1×10\^10 CFU/day) oral administration
214513968|NCT06699121|DRUG|LB-P8 high-dose|One capsule QD (1×10\^11 CFU/day) oral administration
214513969|NCT06699121|DRUG|Placebo|One capsule QD oral administration
214513970|NCT06699043|PROCEDURE|nanocrystalline hydroxyapatite in putty form|"decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty)."
214431300|NCT01895023|DRUG|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
214513971|NCT06699043|PROCEDURE|Demineralized Bone Matrix allograft putty|decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
214431301|NCT01895023|DRUG|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
214513972|NCT06698679|OTHER|No intervention|There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
214513973|NCT06698627|DEVICE|Daily Disposable Continence Device|The Poise® Impressa® is an over-the-counter intravaginal device for women over the age of 21 years with SUI. It is a disposable, one-time use tampon-like device that comprises a core, cover, and applicator. The device is inserted and removed like a vaginal tampon and comes in three sizes.
214513974|NCT06698627|DEVICE|Monthly Disposable Continence Device|The Revive® is another over the counter vaginal insert for the treatment of SUI. This is a self-deployable, double-loop pessary device.
215114223|NCT04861376|DRUG|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
214431302|NCT01093430|PROCEDURE|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
214431303|NCT01093430|PROCEDURE|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
214513975|NCT06699095|DEVICE|Telerehabilitation|Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
214513976|NCT06698965|DRUG|Chemotherapy （Etoposide and Carboplatin）|"Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle."
214513977|NCT06698965|DRUG|Immunotherapy （Envafolimab）|Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
214513978|NCT06698965|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
214513979|NCT06700031|DEVICE|Inertial measurement unit|A sensor, an inertial measurement unit (IMU), will be attached to the thigh when the individual is on the postoperative ward and will be worn throughout the hospital stay. The IMU measures 7.9 x 3.2 x 0.8 cm and records body positions, movements, and gait parameters.
214513980|NCT06699420|DRUG|Qishenyiqi dripping pills 1 bag, three times a day|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
214692537|NCT02117167|DRUG|AZD4547|Target: FGFR
215114224|NCT04861376|DRUG|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
215114225|NCT04861376|OTHER|Placebo|The placebo group will take the same dose as the other two groups.
215114226|NCT01674777|DRUG|ASP1941|oral
214431304|NCT06214117|DRUG|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
214431305|NCT06214117|DRUG|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
214431306|NCT03101410|BEHAVIORAL|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
214431307|NCT03101410|BEHAVIORAL|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
214431308|NCT00727922|DRUG|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
214431309|NCT00428519|DRUG|Placebo|Placebo for 14 days
214431310|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
214431311|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
214513981|NCT06699420|DRUG|Placebo 1 bag, three times a day|Placebo, 1 bag once, three times a day, 12 months
214431312|NCT01760109|DRUG|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
214431313|NCT04853602|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
214431314|NCT01061203|DRUG|Grazax|Treatment with 75.000 SQ-T once daily
214431315|NCT01061203|DRUG|Placebo|Tablet with no active grass component.
214431316|NCT06131892|OTHER|Defibrillation|Defibrillation
214431317|NCT03653169|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site. In this study, individuals will receive 10 treatments with intermittent theta burst stimulation (twice daily for 5 days).
214431318|NCT00869258|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
214431319|NCT00869258|RADIATION|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
214431320|NCT05622396|PROCEDURE|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
214431321|NCT04306718|PROCEDURE|membrane peeling|ERM and ILM are peeled routinely during surgery
214431322|NCT01336439|DRUG|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
214431323|NCT05996588|DRUG|Propofol 1 % Injectable Suspension|Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
214431324|NCT05996588|DRUG|Sevoflurane|Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
214431325|NCT02928757|OTHER|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
214431326|NCT00767013|OTHER|DSCT, TTE|One assessment each
214431327|NCT06148727|DEVICE|Dental implant placement|Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed
214431328|NCT06148727|DEVICE|Bar attachment|Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
214431329|NCT06555718|BEHAVIORAL|The Peer Support Program|Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.
214431330|NCT06555718|BEHAVIORAL|Standart care|The standard care provided by the institution will continue.
214513982|NCT06698913|PROCEDURE|Rotational Therapy|Sample1- Ventilator settings where adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment for both sides. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O. Sample2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT.
214513983|NCT06699407|DRUG|Qishenyiqi dripping pills|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
215114227|NCT04678947|BEHAVIORAL|Baxter Retching Faces (BARF) scale|"* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
215114228|NCT06043973|DRUG|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
214513984|NCT06699407|DRUG|Placebo|Placebo, 1 bag once, three times a day, 12 months
215114229|NCT05247281|DIAGNOSTIC_TEST|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
215114230|NCT05247281|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
215114231|NCT02260947|DRUG|PF-06273340|PF-06273340 50 mg
215114232|NCT02260947|DRUG|PF-06273340|PF-06273340 400 mg
214431331|NCT04861324|BEHAVIORAL|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
214431332|NCT03615417|DEVICE|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
214431333|NCT03615417|DEVICE|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
214431334|NCT00875160|DRUG|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
214431335|NCT02706717|DRUG|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
214431336|NCT02706717|DRUG|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
214513985|NCT06699355|DRUG|Enlicitide Decanoate|Oral administration
214431337|NCT01977638|DRUG|CXD101|Capsules, administered orally
214431338|NCT01911169|DRUG|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
214431339|NCT04122937|PROCEDURE|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
214431340|NCT03634280|OTHER|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
214431341|NCT04446078|DEVICE|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
214431342|NCT00464399|DRUG|everolimus|
214431343|NCT02512965|RADIATION|20 Gy in 5 fractions|
214431344|NCT02512965|RADIATION|Conventional SBRT: 24 Gy in 2 fractions|
215114233|NCT02260947|DRUG|Pregabalin|Pregabalin 300 mg
215114234|NCT02260947|DRUG|Ibuprofen|Ibuprofen 600 mg
215114235|NCT02260947|DRUG|Placebo|Matching Placebo
215114236|NCT03222401|DRUG|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
215114237|NCT03222401|DRUG|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
215114238|NCT03222401|DRUG|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
215114239|NCT00741442|DRUG|RDEA806|Uricosuric agent for the treatment of gout
214513986|NCT06699355|DRUG|Atorvastatin|Oral administration
215114240|NCT00741442|DRUG|Placebo|Matching Placebo.
215114241|NCT04519281|DRUG|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
215114242|NCT05711472|OTHER|birth ball exercise|birth ball exercise used in childbirth
214431345|NCT02328768|DRUG|Omegaven|
214513987|NCT06700317|DEVICE|HSS1|Surgery performed using HSS1
214513988|NCT06699719|BEHAVIORAL|Expressive writing|"Participants are asked to complete four 20-minute sessions of a writing task on consecutive days, which is sent to their email address via an online link. Participants are instructed for the next 20 minutes to please use the provided box to write their very deepest thoughts and feelings about a negative issue or personal problem that they are currently being affected by. In their writing, they are encouraged to let go and explore their emotions and thoughts regarding this issue or problem, and to not worry about spelling or grammar. They are asked to consider setting a timer or have a clock handy to make sure they write for 20 minutes. Instructions are accompanied by a text box, which allows participants to write freely for the allotted time."
214692538|NCT02117167|DRUG|AZD5363|Target: AKT
214692539|NCT02117167|DRUG|AZD8931|Target: HER2, EGFR
214431346|NCT05549869|DIAGNOSTIC_TEST|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
214431347|NCT05628493|BEHAVIORAL|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
214431348|NCT03401190|DRUG|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
214431349|NCT03401190|DRUG|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
214431350|NCT00835770|DRUG|dimethyl fumarate|BG00012 capsules
214431351|NCT00835770|DRUG|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
214431352|NCT02888808|OTHER|Gastroscopy|Upper gastrointestinal endoscopy procedure
214431353|NCT00226538|DRUG|Phenytoin|
214431354|NCT00226538|DRUG|Rifampicin|
214431355|NCT00226538|DRUG|Diclophenac|
214431356|NCT00226538|DRUG|Fluconazole|
214431357|NCT01185782|DRUG|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
214431358|NCT01185782|DRUG|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
214431359|NCT03222323|DRUG|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
214431360|NCT03222323|DRUG|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
214431361|NCT03222323|DRUG|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
214431362|NCT03222323|DRUG|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
214431363|NCT03222323|DRUG|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
214431364|NCT05076799|DRUG|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
214431365|NCT05076799|DRUG|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
214431366|NCT05076799|DRUG|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
214431367|NCT05076799|DRUG|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
214431368|NCT01998711|BEHAVIORAL|Memory group|Five 1-1.5 hour weekly session of memory training
214431369|NCT05700630|BIOLOGICAL|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
214431370|NCT05700630|DRUG|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
214431371|NCT00705588|DRUG|Tadalafil|Orally, titrated to maximum 20mg od
214431372|NCT00705588|DRUG|Vardenafil|Orally, titrated to 10 mg bid
214431373|NCT03202199|DEVICE|PET/MRI|2 PET/MRI examinations
214431374|NCT05278871|DEVICE|Constructive Shearwave Interference (CSI)|handheld ultrasound
214431375|NCT03480854|OTHER|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
214431376|NCT02006940|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
214431377|NCT02570568|DEVICE|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
214431378|NCT02570568|DEVICE|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
214431379|NCT02570568|PROCEDURE|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
214431380|NCT02943629|DEVICE|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
214431381|NCT02943629|DEVICE|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
214692540|NCT02117167|DRUG|Selumetinib|Target: MEK
214692541|NCT02117167|DRUG|Vandetanib|Target : VEGF, EGFR
214692542|NCT02117167|DRUG|Standard maintenance for squamous NSCLC|
214692543|NCT02117167|DRUG|Pemetrexed|Standard maintenance for non squamous NSCLC
214431382|NCT02943629|DEVICE|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
214431383|NCT02500264|DEVICE|TENS|
214431384|NCT01126918|BEHAVIORAL|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
214431385|NCT02916758|OTHER|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
214431386|NCT01077934|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
214513989|NCT06698393|PROCEDURE|Suture 3.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 3.0 Diameter.
214513990|NCT06698393|PROCEDURE|Suture 6.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 6.0 Diameter.
214513991|NCT05082948|OTHER|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
214513992|NCT05082948|OTHER|Non suture|Standard placement of stent without suture fixation
214513993|NCT06699069|OTHER|Control or Euthyroid group|Fed on normal standard diet
214513994|NCT06699069|OTHER|Hypothyroid group|Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
214513995|NCT06699069|OTHER|Hypothyroid group received exercise|Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
214513996|NCT05934175|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
214513997|NCT05934175|BEHAVIORAL|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
214513998|NCT00463944|BEHAVIORAL|Effect of an electronic voting system|
214513999|NCT03582085|BIOLOGICAL|Bacillus Calmette Guerin Vaccine|Experimental
214514000|NCT03582085|BIOLOGICAL|Saline Injection|Placebo
214514001|NCT06857279|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214514002|NCT06857279|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214431387|NCT03352778|RADIATION|IMRT|66Gy by intensity-modulated radiotherapy
214431388|NCT03352778|RADIATION|2DRT|66Gy by 2-dimensional radiotherapy
214431389|NCT03022812|OTHER|Neck-specific exercise|Neck-specific exercise
214431390|NCT04928248|OTHER|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
214431391|NCT04232371|PROCEDURE|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
214431392|NCT04232371|PROCEDURE|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
214431393|NCT04141150|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
214514003|NCT06857279|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214514004|NCT05406713|DRUG|Pembrolizumab|400 mg intravenously
214514005|NCT06903455|OTHER|Fit-folk cardio dance|"Fitfolk is a new cardiovascular dance discipline that combines fitness exercises with music and dance from Chilean and Latin American folklore. This discipline promotes physical and emotional well-being and celebrates national folklore."
214692544|NCT02117167|DRUG|Durvalumab|Target: PD-L1
214514006|NCT06903455|OTHER|Conventional physical exercise|conventional physical exercise program that uses resistance exercise and cardiorespiratory training
214431394|NCT05579054|DIAGNOSTIC_TEST|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
214431395|NCT00861029|DRUG|Pazopanib|Subjects treated with pazopanib
214431396|NCT00861029|OTHER|Placebo for pazopanib|Control for comparison with pazopanib
214431397|NCT00861029|DRUG|Moxifloxacin|Comparator for pazopanib
214431398|NCT00861029|OTHER|Placebo for moxifloxacin|Placebo for moxifloxacin
214431399|NCT02347436|PROCEDURE|24-hr ambulatory blood pressure measurement|
214431400|NCT00149838|PROCEDURE|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
214431401|NCT00149838|DRUG|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
214431402|NCT00149838|PROCEDURE|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
214431403|NCT01061151|DRUG|Zidovudine (ZDV)|300 mg twice daily
214431404|NCT01061151|DRUG|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
214431405|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
214431406|NCT01061151|DRUG|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
214431407|NCT01061151|DRUG|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
214431408|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
214514007|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
214514008|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
214514009|NCT05620979|BEHAVIORAL|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
214514010|NCT06911788|DRUG|Vepdegestrant (Reference)|Participants will receive a single intravenous (IV) dose of Vepdegestrant on Period 1 Day 1
214431409|NCT01061151|DRUG|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
214431410|NCT01061151|DRUG|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
214431411|NCT01061151|OTHER|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail."
214431412|NCT01061151|OTHER|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
214431413|NCT01061151|OTHER|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
214431414|NCT03740009|DRUG|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
214431415|NCT01684150|DRUG|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
214431416|NCT00139672|DRUG|PD-217,014|
214431417|NCT05032794|OTHER|Unrestricted diet before colonoscopy|Free diet, without restrictions
214431418|NCT05032794|OTHER|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
214431419|NCT05032794|DRUG|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
214514011|NCT06911788|DRUG|Vepdegestrant (Test)|Participants will receive a 200 mg single oral dose of Vepdegestrant tablet formulation on Period 2 Day 1
214514012|NCT06910293|DIAGNOSTIC_TEST|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.
214431420|NCT02944188|PROCEDURE|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
214431421|NCT02944188|PROCEDURE|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
214514013|NCT06924398|DRUG|Postoperative EGFR-TKI Therapy|"A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.~Before formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.~If the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment."
214514014|NCT06936696|BEHAVIORAL|Broad Target Speech Recast|"Broad Target Speech Recasts (BTSR) is a speech intervention technique in which an adult immediately recasts a child's incorrect articulation by providing a corrected version of the word in a naturalistic, meaningful context. Unlike traditional articulation therapy, which focuses on isolated sound drills, BTSR integrates correction seamlessly into conversation without requiring the child to repeat or imitate the model.~This approach is rooted in principles of implicit learning, where repeated exposure to accurate speech models facilitates phonological development over time. BTSR differs from traditional minimal pair or phonetic placement techniques in that it does not involve explicit instruction or direct prompts for self-correction. Instead, it provides high-frequency, naturalistic exposure to correct phoneme production within functional language use."
214514015|NCT06936696|BEHAVIORAL|Traditional Speech Therapy|"Traditional Speech Therapy is clinician-led and includes structured, drill-based approaches. Techniques such as placement cues, direct feedback, and reinforcement are used to help children achieve correct articulation. The structured nature of this approach is often more effective in remediating persistent speech errors than parent-implemented strategies alone.~This study examines whether the combination of parent-implemented BTSR and clinician-led traditional articulation therapy leads to improved speech sound production and long-term maintenance of correct articulation in elementary-aged DHH children."
214514016|NCT03127605|DRUG|Inotuzumab Ozogamicin|
214514017|NCT06276660|OTHER|BCTT|"Participants will complete the Buffalo Concussion Treadmill Test, which involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
214514018|NCT06276660|OTHER|Dynamic ExIT|The modified EXiT test will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
214514019|NCT06952270|OTHER|plyometric exercise|Upper limb plyometric exercise (proprioceptive neuromuscular facilitation of extensor and flexor pattern, external rotation exercise at 90º-90º, chest throw, external rotation and overhead and wall flexion).
214514020|NCT06952270|OTHER|Strength training exercise|Strength training exercises (Squats, Stair climbing and jumps, Bench Press, Push-ups, Core Exercises (Plank, Bridge)).
214514021|NCT06951412|OTHER|Foot Reflexology Massage|Reflexology Massage
214514022|NCT01003743|DEVICE|endolumenal tissue approximation|
214514023|NCT05722912|DRUG|Ruxolitinib|Ruxolitinib Cream
214514024|NCT06542289|DEVICE|BlinkER device.|Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
214514025|NCT04858295|DEVICE|Texting|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
214514026|NCT04858295|DEVICE|mHealth app|Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
214514027|NCT05222906|DRUG|Venglustat|tablet; oral
214514028|NCT05222906|DRUG|imiglucerase|sterile lyophilized product; intravenous
214692545|NCT02117167|DRUG|savolitinib|target : MET
214692546|NCT02117167|DRUG|Olaparib|target : PARP
215114243|NCT01807299|DIETARY_SUPPLEMENT|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
215114244|NCT01807299|OTHER|Physical Training|
215114245|NCT05186506|DRUG|Ensatinib|225 mg administered once daily orally for two years.
214431422|NCT04811950|DEVICE|Emerald|Complete blood countdevice
214431423|NCT02999022|DRUG|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
214431424|NCT02999022|DRUG|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
214431425|NCT04217512|DRUG|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
214431426|NCT04217512|DRUG|Pantoprazole high dose|Pantoprazole 1.6 mg\\kg
214431427|NCT04217512|OTHER|Standard hydration|Standard hydration alone
214431428|NCT04217512|DRUG|Cisplatin|Cisplatin
214431429|NCT01117519|DRUG|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
214514029|NCT05522569|DRUG|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
214514030|NCT03016091|DRUG|Pembrolizumab|anti PD-L1
214431430|NCT03264846|DIAGNOSTIC_TEST|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
214514031|NCT05597618|OTHER|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~1. Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~2. Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
214514032|NCT04843371|DIAGNOSTIC_TEST|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
214514033|NCT06317168|DIAGNOSTIC_TEST|Mean awake ambulatory BP measurements|Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
214514034|NCT06023615|OTHER|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
214431431|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
214431432|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
214431433|NCT04135989|DRUG|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
214431434|NCT04135989|DRUG|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
214431435|NCT04114422|OTHER|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
214431436|NCT04434586|DEVICE|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
214431437|NCT03484065|OTHER|Questionnaire quality of life|
214514035|NCT04129450|OTHER|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
214514036|NCT04129450|OTHER|Usual PCP care|Usual one on one PCP care for chronic lower back pain
214514037|NCT04520256|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
214514038|NCT04520256|BEHAVIORAL|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
214514039|NCT04520256|BEHAVIORAL|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
214514040|NCT04520256|BEHAVIORAL|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
214514041|NCT04520256|BEHAVIORAL|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
214514042|NCT04520256|BEHAVIORAL|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
214514043|NCT03083678|DRUG|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
214514044|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
214431438|NCT02082548|OTHER|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
214431439|NCT01432613|PROCEDURE|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
214431440|NCT03950778|DRUG|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
214431441|NCT05660993|DRUG|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
214514045|NCT05241873|DRUG|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
214514046|NCT05241873|DRUG|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
214514047|NCT05241873|DRUG|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
214514048|NCT02609789|DRUG|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
214431442|NCT02147678|DRUG|Etomidate|
214431443|NCT02147678|DRUG|Propofol|
214431444|NCT02147678|DRUG|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
214431445|NCT02147678|DRUG|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
214431446|NCT03324945|BEHAVIORAL|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
214431447|NCT00144144|DRUG|Angiotensin II receptor antagonists, Calcium channel blocker|
214431448|NCT00338624|DRUG|oxybutynin chloride extended release|
214431449|NCT04577612|DRUG|CHI-554|hemp-derived CBD in MCT oil
214431450|NCT00459745|DRUG|Pravafen|
214431451|NCT00459745|DRUG|Pravastatin|
214431452|NCT00459745|DRUG|Fenofibrate|
214431453|NCT02906891|DEVICE|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
214431454|NCT03926039|BEHAVIORAL|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
214431455|NCT01406223|DRUG|Varenicline|
214431456|NCT01406223|DRUG|Bupropion|
214431457|NCT01406223|DRUG|Nicotine patches|
214431458|NCT01406223|OTHER|Placebo varenicline|
214431459|NCT01406223|OTHER|Placebo bupropion|
214431460|NCT01406223|OTHER|Placebo patch|
214431461|NCT05512858|BEHAVIORAL|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
214431462|NCT00873405|PROCEDURE|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
214431463|NCT00873405|PROCEDURE|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
214514049|NCT02609789|DRUG|Placebo|0.9 percent (%) normal saline.
214692547|NCT05866471|DRUG|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
214692548|NCT05866471|DEVICE|Transcutaneous auricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
214692549|NCT05866471|BEHAVIORAL|Psychosocial Support Alone|Participants assigned to Psychosocial Support Alone will not receive taVNS following psilocybin dosing.
214431464|NCT03551535|BEHAVIORAL|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
214431465|NCT01667302|DRUG|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
214431466|NCT02722473|BIOLOGICAL|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
214431467|NCT02722473|BIOLOGICAL|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
214431468|NCT06196788|DRUG|Gemcitabine|1000 mg per square meter
214431469|NCT06196788|DRUG|Nab paclitaxel|120 mg per square meter of body-surface area
214431470|NCT02559362|BEHAVIORAL|Survey|
214431471|NCT04725305|DEVICE|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
214431472|NCT04725305|PROCEDURE|Standard of care|This method would involve removal of tonsils using electrocautery technique
214431473|NCT00479635|DRUG|TPI 287|160 mg/m2 every three weeks for six cycles
214431474|NCT00479635|DRUG|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
214431475|NCT00067353|DRUG|Fluoride varnish|
214431476|NCT03833661|DRUG|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
214514050|NCT05054751|DRUG|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
214514051|NCT05054751|DRUG|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
214431477|NCT02514278|DRUG|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2"
214431478|NCT02514278|RADIATION|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
214431479|NCT02514278|PROCEDURE|Local excision in good responders|"If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
214514052|NCT05267951|DEVICE|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
214431480|NCT02514278|PROCEDURE|Rectal excision in bad responders|
214431481|NCT02514278|DRUG|Capecitabine|1600 mg/m2 daily 5 days/7
214431482|NCT05765019|OTHER|Spinal mobilization|Spinal mobilization and core stabilization exercise
214514053|NCT05267951|DEVICE|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
214514054|NCT05267951|OTHER|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
214514055|NCT02705196|GENETIC|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
214514056|NCT02705196|DRUG|gemcitabine|chemotherapy
214514057|NCT02705196|DRUG|nab-paclitaxel|chemotherapy
214514058|NCT02705196|BIOLOGICAL|atezolizumab|anti-PD-L1 antibody
214514059|NCT03786471|OTHER|Health System-based Dementia Care|Active comparator
214431483|NCT05765019|OTHER|Core stabilization exercise|Stabilization exercises for the spine
214431484|NCT06109220|BEHAVIORAL|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
214431485|NCT02869334|DEVICE|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
214431486|NCT02869334|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
214431487|NCT02869334|BEHAVIORAL|Auditory Remediation|Computer program designed to improve discrimination between sounds
214431488|NCT02869334|BEHAVIORAL|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
214431489|NCT04875624|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
214431490|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
214431491|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
214431492|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
214431493|NCT02986269|PROCEDURE|general anesthesia across LMA|general anesthesia across LMA
214431494|NCT02986269|PROCEDURE|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
214431495|NCT02986269|PROCEDURE|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
214431496|NCT04272645|DRUG|Abemaciclib 200 MG|200 MG orally BID Days 1-21
214431497|NCT04272645|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
214431498|NCT04272645|DRUG|Abemaciclib 150 MG|150 MG orally BID Days 1-21
214431499|NCT01836133|DRUG|Erlotinib 150 mg|
214514060|NCT03786471|OTHER|Community-based Dementia Care|Active comparator
214431500|NCT05652244|DEVICE|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
214431501|NCT05652244|DEVICE|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
214431502|NCT01674699|DEVICE|EXCOR Pediatric|Ventricular Assist Device
214431503|NCT04348617|OTHER|Moderate exercise|50 minutes of moderate exercise on treadmill
214431504|NCT04348617|OTHER|Rest|50 minutes of rest or sedentary activity
214431505|NCT00024063|DRUG|orantinib|
214431506|NCT04377815|OTHER|General Public cohort|No intervention is being tested
214431507|NCT02883660|GENETIC|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
214431508|NCT01003405|DRUG|KUC-7483|
214431509|NCT05877469|OTHER|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
214431510|NCT05877469|OTHER|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
214514061|NCT03786471|OTHER|Usual Care|Control
214514062|NCT05492786|BEHAVIORAL|Alert|Non-interruptive best practice alert in the electronic health record
214514063|NCT05492786|BEHAVIORAL|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
214514064|NCT05492786|BEHAVIORAL|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
214514065|NCT05492786|BEHAVIORAL|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
214431511|NCT05376436|DIAGNOSTIC_TEST|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
214431512|NCT04303325|DRUG|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
214431513|NCT04303325|DRUG|Saline Solution|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
214431514|NCT02108210|DRUG|Anakinra|
214431515|NCT02108210|DRUG|Placebo|
214431516|NCT01964937|BIOLOGICAL|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
214431517|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
214431518|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
214431519|NCT01964937|BIOLOGICAL|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
214431520|NCT01964937|BIOLOGICAL|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
214431521|NCT06392633|PROCEDURE|spastic hand sugery|Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
214514066|NCT03346200|DRUG|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
214514067|NCT03346200|DRUG|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
214514068|NCT00132925|DRUG|Triamcinolone|
214692550|NCT05866471|OTHER|Sham taVNS|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
214514069|NCT04757961|BEHAVIORAL|LifeStories|The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
214514070|NCT01282983|DIETARY_SUPPLEMENT|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
214514071|NCT01282983|DIETARY_SUPPLEMENT|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
214514072|NCT04120064|DRUG|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
214431522|NCT06392633|DRUG|Botulinum Toxin A|Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
214431523|NCT04666857|OTHER|early motor intervention|infants with CHD after open heart surgery will receive early intervention
214431524|NCT01779999|OTHER|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
214431525|NCT02779517|OTHER|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
214431526|NCT02779517|OTHER|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
214431527|NCT00035841|DRUG|TLK286|
215114246|NCT05186506|DRUG|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
215114247|NCT00543335|DRUG|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
215114248|NCT00543335|PROCEDURE|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
214431528|NCT02202395|DRUG|LTS 0.25mg|use LTS 0.25mg/d
214431529|NCT02202395|DRUG|LTS 0.5mg|use LTS 0.5mg/d
214431530|NCT02202395|DRUG|LTS 1.0mg|use LTS 1.0mg/d
214431531|NCT02202395|DRUG|Placebo|use placebo once daily
214431532|NCT05135013|DRUG|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration"
214431533|NCT00297674|DRUG|Intravenous Clarithromycin|
214431534|NCT06248788|DEVICE|PoC Device|PoC Device for Testing Salivary IgA
215114249|NCT04859816|OTHER|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
214431535|NCT02808585|DRUG|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
214431536|NCT02808585|DRUG|Placebo Injection|Four weekly subcutaneous injections of placebo.
214431537|NCT00993369|OTHER|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
214431538|NCT03998280|DEVICE|Assessment|Neck proprioception and postural stability
214514073|NCT04765540|BEHAVIORAL|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station"
214514074|NCT04765540|BEHAVIORAL|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement"
214514075|NCT04765540|BEHAVIORAL|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
214514076|NCT02534129|DRUG|Difinsa53|Difinsa53 cream is applied to one half of radiation field
214514077|NCT02534129|DRUG|Aquaphor|Aquaphor is applied to one half of radiation field
214514078|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
214514079|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
214514080|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
215114250|NCT04859816|OTHER|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
214431539|NCT04586686|PROCEDURE|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
214431540|NCT04586686|PROCEDURE|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
214431541|NCT06051786|DRUG|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
214431542|NCT06051786|DRUG|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
214431543|NCT06238869|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.
214431544|NCT06238869|BEHAVIORAL|Music Therapy|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
214431545|NCT06238869|BEHAVIORAL|Health education|Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.
214431546|NCT02298751|BEHAVIORAL|Cue Exposure Treatment|
214431547|NCT05567822|DRUG|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
214514081|NCT04369664|DRUG|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
214514082|NCT04369664|DRUG|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
214514083|NCT04369664|DRUG|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
214514084|NCT03840200|DRUG|Ipatasertib|Ipatasertib will be administered orally.
214514085|NCT03840200|DRUG|Rucaparib|Rucaparib will be administered orally.
214514086|NCT01298219|DRUG|Lubiprostone|24 mcg administered orally twice daily (BID)
214431548|NCT05567822|DRUG|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
214431549|NCT01692730|BEHAVIORAL|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
214514087|NCT01298219|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
214514088|NCT04105764|DRUG|Rocuronium|DEEP block to PTC 1-3
214514089|NCT04105764|DRUG|Rocuronium bromide|MODERATE block to TOF1-2
214514090|NCT05230823|BEHAVIORAL|CR with added BWLT|12 week outpatient cardiac rehab (CR) program consisting of twice-weekly supervised exercise and risk factor modification (e.g. smoking cessation, support with medication). Concurrently, the patients will attend a weekly behavioural weight loss treatment (BWLT). Weekly goal-setting facilitated by the interventionist will focus on behavioural changes in nutrition and moderate calorie reduction while also emphasizing physical activity consistent with an individualized CR exercise prescription. Patients will track caloric intake, weekly exercise, weekly weight, and success/challenges with other health goals (e.g., challenging negative thoughts, body image, mindful eating, etc.) using a daily health diary. ASPIRE-AF will be delivered virtually to small groups (8-12 patients) by senior PhD students with advanced training in cognitive-behavioural therapy and motivational communication principles.
214514091|NCT06791018|OTHER|Exercise|Participants will be asked to use a cancer-specific exercise mobile app for 12 weeks. The program is designed to achieve the goal of exercising for at least 90 minutes per week, including aerobic exercise three times a week and resistance training twice a week. While exercise equipment is not required, the app supports the optional use of an elastic resistance band or a pair of dumbbells. The app comes with various features to support the exercise journey. Participants will be able to track their progress through periodic testing, access a library of resources that includes information on exercise, and log any additional workouts they perform outside the app. The exercise prescription will be tailored to daily fatigue levels that will be rated before each workout. This ensures that the program is customized to meet individual needs and abilities.
214514092|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
214514093|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
214431550|NCT01692730|BEHAVIORAL|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
214514094|NCT06187350|DEVICE|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score \> 7 will be double-reviewed as normal.
214514095|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with low protein content|Young-child formula with low protein content
214514096|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
214514097|NCT04142398|OTHER|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
214514098|NCT04142398|PROCEDURE|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
214514099|NCT04142398|OTHER|Laboratory Biomarker Analysis|Correlative studies
214514100|NCT04142398|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
214514101|NCT04142398|PROCEDURE|Physical Examination|Undergo targeted physical exam
214514102|NCT04142398|OTHER|Questionnaire Administration|Ancillary studies
214514103|NCT02372734|OTHER|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
215114251|NCT04859816|OTHER|MRS|Magnetic resonance spectroscopy of liver fat content
215114252|NCT04859816|OTHER|Feces collection|4-day feces collection
215114253|NCT03759691|BEHAVIORAL|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
214431551|NCT03599453|PROCEDURE|Biopsy|Undergo Biopsy
214431552|NCT03599453|PROCEDURE|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
214431553|NCT03599453|DRUG|Celecoxib|Given by mouth
214431554|NCT03599453|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given intravenously
214431555|NCT03599453|DRUG|Rintatolimod|Given intravenously
214431556|NCT03599453|BIOLOGICAL|Pembrolizumab|Given intravenously
214431557|NCT04759066|DEVICE|HEALiX|HEALiX is a non-restraint patient safety device
214431558|NCT00222326|BEHAVIORAL|Pelvic floor muscle training and lifestyle modification|
214514104|NCT05755698|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
214514105|NCT03380143|BEHAVIORAL|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
214514106|NCT03380143|BEHAVIORAL|Standard Practice|Community development intervention
214514107|NCT05513417|DEVICE|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
214514108|NCT05504720|DRUG|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
214514109|NCT05504720|DRUG|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
214514110|NCT05504720|DRUG|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
214514111|NCT03497156|DRUG|Lercanidipine|Patients are tested for their normal prescription lercanidipine medication
214514112|NCT05489770|DIETARY_SUPPLEMENT|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid has been used as a supplement since 1991 with no reports of adverse effects received by the Manufacturer.
214514113|NCT05489770|DIETARY_SUPPLEMENT|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom
214514114|NCT05487300|DRUG|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
214514115|NCT03736265|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
214692551|NCT04349306|DRUG|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
215114254|NCT00630435|DRUG|Premarin®/MPA formulation A|
215114255|NCT00630435|DRUG|Premarin®/MPA formulation B|
215114256|NCT00630435|DRUG|Premarin®/MPA formulation C|
215114257|NCT00630435|DRUG|Premarin®/MPA currently marketed product|
214431559|NCT00933400|DIAGNOSTIC_TEST|CT Coronary Angiography (CTCA)|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
214431560|NCT00933400|PROCEDURE|Traditional Strategy|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
214431561|NCT04618614|DEVICE|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
214431562|NCT04618614|DEVICE|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
214431563|NCT04618614|DEVICE|Sham control|Sham stimulation of the right primary somatosensory cortex
214431564|NCT00570219|DRUG|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
214431565|NCT00010309|BIOLOGICAL|MART-1 antigen|
214431566|NCT00010309|BIOLOGICAL|gp100 antigen|
214431567|NCT00030888|DRUG|7-hydroxystaurosporine|
214431568|NCT04301635|PROCEDURE|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
214431569|NCT05729672|BEHAVIORAL|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
214431570|NCT04653935|BEHAVIORAL|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
214431571|NCT04653935|BEHAVIORAL|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
214431572|NCT00976625|PROCEDURE|Aortic Valve Replacement|Surgical valve replacement of the aorta
214431573|NCT01041417|DRUG|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
214431574|NCT01041417|DRUG|Placebo|Saline injection
214431575|NCT02299375|DRUG|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
214431576|NCT02299375|DRUG|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
214431577|NCT02299375|DRUG|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
214431578|NCT03760627|BEHAVIORAL|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
214431579|NCT03760627|BEHAVIORAL|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
214431580|NCT05184946|DRUG|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
214431581|NCT02457845|BIOLOGICAL|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
214431582|NCT03093298|OTHER|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
214431583|NCT00704184|DRUG|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
214431584|NCT00704184|DRUG|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
214431585|NCT00704184|DRUG|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
214431586|NCT00704184|DRUG|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
214431587|NCT00666068|OTHER|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
214431588|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
214431589|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
214431590|NCT00866203|DRUG|HDS vs ProMECE/CytaBOM|
214431591|NCT00592241|DEVICE|"Adi Insulin Pump Usability"|no intervention
214431592|NCT00328835|PROCEDURE|Brief Elevation of IOP|
214431593|NCT02378155|DEVICE|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
214692552|NCT02307721|DRUG|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
214431594|NCT06212141|DEVICE|VisCalor Bulk,VOCO,Germany|"It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec."
214431595|NCT06212141|DEVICE|Admira Fusion x-tra,VOCO,Germany|"Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds."
214431596|NCT06212141|DEVICE|Filtek One Bulk,3M,Germany|"Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations."
214431597|NCT03995498|OTHER|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
214431598|NCT03995498|OTHER|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
214431599|NCT03995498|OTHER|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
214514116|NCT05606809|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
214514117|NCT00060268|DRUG|HPPH|iv
214514118|NCT05384522|OTHER|blood samples collection|Blood samples will be drawn at baseline and at 6 and 12 months from baseline
214514119|NCT04746690|OTHER|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
214514120|NCT04282018|DRUG|BGB-10188|Administered as specified in the treatment arm
214514121|NCT04282018|DRUG|Zanubrutinib|Administered as specified in the treatment arm
214514122|NCT04282018|DRUG|Tislelizumab|Administered as specified in the treatment arm
214514123|NCT05499507|BEHAVIORAL|COH|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
214514124|NCT05499507|BEHAVIORAL|COH+|Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
214514125|NCT05987956|DRUG|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
214514126|NCT05987956|DRUG|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
214514127|NCT05898789|BEHAVIORAL|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
214514128|NCT06155487|DRUG|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
214514129|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 100 mg
214514130|NCT06155487|DRUG|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
214514131|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 200 mg
214514132|NCT06155487|DRUG|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
214514133|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 300 mg
214514134|NCT06155487|DRUG|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
214514135|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 400 mg
214514136|NCT06155487|DRUG|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
214514137|NCT06155487|DRUG|Placebo|Oral Tablet,Single dose of Placebo 600 mg
214514138|NCT06155487|DRUG|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
214514139|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 800 mg
214514140|NCT06155487|DRUG|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
214514141|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
214431600|NCT01388881|OTHER|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
214431601|NCT02400099|DIETARY_SUPPLEMENT|High-protein low calorie diet|
214431602|NCT02400099|DIETARY_SUPPLEMENT|Control low calorie diet|
214431603|NCT02400099|OTHER|Anthropometrical measurements|
214431604|NCT02400099|OTHER|Body composition|
214431605|NCT02400099|OTHER|8-h metabolic profile|
214514142|NCT06155487|DRUG|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
214431606|NCT02400099|OTHER|Liver biopsy|
214431607|NCT01347125|DEVICE|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
214431608|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
214431609|NCT00700336|DRUG|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
214431610|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
214431611|NCT02701257|DEVICE|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
214431612|NCT02701257|DEVICE|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
214431613|NCT02701257|DRUG|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
214431614|NCT02701257|DRUG|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
214431615|NCT02701257|DEVICE|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
214431616|NCT02701257|DEVICE|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
214431617|NCT03366636|BEHAVIORAL|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1\. Thinking about the future~* 2\. Present actions to achieve future success~* 3\. Safeguarding one's future~* 4\. Creating a Healthy Life Plan~* 5\. Navigating service systems"
214431618|NCT05515900|DIETARY_SUPPLEMENT|Sodium|Daily sodium supplementation of 2000 mg.
214514143|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
214514144|NCT06155487|DRUG|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
214514145|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
214514146|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat positive control|Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
214514147|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat negative control|Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
214692553|NCT02307721|DRUG|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
214514148|NCT06314425|PROCEDURE|Immediate dental implants placements on fresh sockets after tooth extraction|Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to be placed within the fresh extraction sockets. The immediate implants are placed using a minimally invasive technique without vertical releasing incisions. Implant placements are performed following the SDS osteotomy protocol after sulcus marginal and crestal incision or flapless surgery. The same surgeon places implants for all patients. Infected sites are debrided using piezo surgery touch.
214431619|NCT05515900|DIETARY_SUPPLEMENT|HMB|Daily HMB supplementation of 3 g.
214431620|NCT05515900|OTHER|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
214431621|NCT03336515|DEVICE|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
214431622|NCT03336515|DEVICE|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
214431623|NCT03336515|BEHAVIORAL|Group A-General Recommendation|General recommendation not sleeping in supine position
214431624|NCT02118675|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
214431625|NCT02118675|OTHER|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
214431626|NCT02118675|OTHER|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
215114258|NCT01808235|BEHAVIORAL|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
215114259|NCT01984918|OTHER|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
214431627|NCT02118675|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
214431628|NCT02118675|OTHER|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
214431629|NCT02118675|OTHER|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
214514149|NCT03011801|BEHAVIORAL|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
214514150|NCT03011801|BEHAVIORAL|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
214514151|NCT00265252|DRUG|Alendronate|
214514152|NCT03095261|BEHAVIORAL|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
214514153|NCT03095261|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
214514154|NCT03095261|BEHAVIORAL|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
214514155|NCT03095261|BEHAVIORAL|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
214431630|NCT02118675|OTHER|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
215114260|NCT01984918|OTHER|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
214431631|NCT02487927|BEHAVIORAL|weaning|T piece
214431632|NCT02147054|DRUG|Rocuronium|
214431633|NCT02147054|DRUG|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
214431634|NCT00765271|DRUG|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
214431635|NCT00765271|DRUG|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
214431636|NCT00765271|DRUG|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
214431637|NCT01735019|DRUG|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
214431638|NCT01047852|PROCEDURE|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
214431639|NCT02708927|OTHER|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
214431640|NCT02708927|OTHER|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
214431641|NCT03187860|PROCEDURE|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
214431642|NCT03187860|OTHER|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
214431643|NCT01524952|DEVICE|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
214431644|NCT02828943|BEHAVIORAL|IMT with High Resistance EMT|
214431645|NCT02828943|BEHAVIORAL|IMT with Low Resistance EMT|
214431646|NCT02738320|OTHER|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
214431647|NCT01291381|DRUG|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
214431648|NCT01291381|DRUG|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
214431649|NCT04600440|BIOLOGICAL|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
214431650|NCT04578496|DRUG|Afamelanotide|
214431651|NCT04044651|DRUG|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
214431652|NCT04044651|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
214431653|NCT06113770|OTHER|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
214431654|NCT06113770|OTHER|preparation of the tooth to receive CAD CAM PMMA custom made crown|"* Open the interproximal contacts .~* The tooth should be reduced circumferentially by approximately 0.5-1mm .~* The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~* Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~* The final crown will be cemented using glass ionomer cement ."
214514156|NCT01362309|DRUG|d-cycloserine.|50 mg administered on two occasions.
214514157|NCT05541185|BIOLOGICAL|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
214514158|NCT05541185|BIOLOGICAL|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
214514159|NCT05541185|BIOLOGICAL|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
214514160|NCT06721663|OTHER|Multisensory environment stimulation therapy|A Multi Sensory Environment is a dedicated space or room where sensory stimulation can be controlled (intensified or reduced), presented in isolation or combination, packaged for active or passive interaction
215114261|NCT04503720|DEVICE|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
214431655|NCT03244046|BEHAVIORAL|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
214431656|NCT03244046|BEHAVIORAL|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
214431657|NCT05357469|DEVICE|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
214514161|NCT06721663|OTHER|selected physical therapy intervention|therapeutic balance training and functional therapeutic exercises
214514162|NCT06721728|BEHAVIORAL|Oral health educational program|Flyer distributed on the children with data about oral hygiene measures as well as diet advice related to their condition, in addition to modeling the correct tooth brushing habits using a cast and tooth brush.
214514163|NCT03553056|OTHER|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
214514164|NCT03553056|OTHER|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
214514165|NCT05759143|BEHAVIORAL|Nest Platform|Patient- and clinician-facing portal via secure link
214514166|NCT06721390|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 12 weeks.
214514167|NCT06721390|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 12 weeks.
214514168|NCT05054517|DIETARY_SUPPLEMENT|Glutamine|Oral Supplement
214514169|NCT05400525|DIETARY_SUPPLEMENT|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
214514170|NCT05400525|OTHER|Placebo control|3g Maltodextrin (i.e. DE 10) daily
214514171|NCT05458271|DEVICE|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
214514172|NCT05458271|PROCEDURE|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
214514173|NCT05181839|DRUG|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
214514174|NCT02713217|OTHER|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
214514175|NCT02713217|OTHER|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
214514176|NCT03457168|PROCEDURE|Treatment of elevated asleep SBP mean|To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
214431658|NCT05357469|DEVICE|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
214431659|NCT06005857|OTHER|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
214431660|NCT06005857|OTHER|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
214431661|NCT01282840|DRUG|Tolterodine SR|Tolterodine SR 4 mg qd
214514177|NCT02880293|DRUG|melphalan|melphalan (140 mg/m2 IV on day -7)
214514178|NCT02880293|DRUG|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
214514179|NCT02880293|DRUG|thiotepa|thiotepa (5 mg/kg IV on day -67)
214514180|NCT02880293|DRUG|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
214514181|NCT02880293|DRUG|Mesna|
214514182|NCT02880293|DRUG|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
214514183|NCT02880293|DRUG|Filgrastim|
214514184|NCT02880293|DRUG|Tacrolimus|
214514185|NCT06395987|PROCEDURE|Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.|Use Of Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.
214514186|NCT05109065|DIAGNOSTIC_TEST|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
215114262|NCT04503720|DEVICE|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
215114263|NCT00675220|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215114264|NCT00338923|DRUG|HO/03/03|
215114265|NCT05413720|OTHER|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
215114266|NCT04688255|BEHAVIORAL|MSTEP|Aerobic exercise that is advanced weekly
215114267|NCT04688255|BEHAVIORAL|Stretching|Stretching exercises that are advanced weekly
215114268|NCT00811174|DRUG|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
215114269|NCT04730531|PROCEDURE|Local infiltration with 0.25% bupivacaine and epinephrine|The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
214431662|NCT02721134|OTHER|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
214431663|NCT02834598|DEVICE|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
214431664|NCT06075212|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
214431665|NCT02694666|OTHER|Controlled whole-body vibration training|The intervention is an 8-week program
214431666|NCT00511160|PROCEDURE|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
214431667|NCT00511160|PROCEDURE|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
214431668|NCT00174434|DRUG|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
214431669|NCT00174434|DRUG|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
214431670|NCT00150241|DRUG|CP-526,555 (varenicline)|
214431671|NCT04916145|DEVICE|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
214431672|NCT00237991|BIOLOGICAL|Hepatitis A|
214431673|NCT03473340|DRUG|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
214431674|NCT03473340|DRUG|Placebo Capsule|"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
214431675|NCT03394885|DRUG|Atezolizumab|1200mg IV q3weeks
214431676|NCT03394885|DRUG|Carboplatin|5-6mg/ML IV q3 weeks
214431677|NCT03394885|DRUG|Paclitaxel|70-80 mg/m2 IV q1 week
214431678|NCT03394885|DRUG|Bevacizumab|15 mg/kg IV q3 weeks
214431679|NCT05100784|BIOLOGICAL|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
214431680|NCT05674149|DEVICE|camera|photographs using multi-spectral camera
214431681|NCT01925365|DIETARY_SUPPLEMENT|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
214431682|NCT01925365|DIETARY_SUPPLEMENT|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
214431683|NCT05688592|PROCEDURE|PET-CT|"This is a before-and-after study (not a clinical trial)~* in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~* in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
214431684|NCT01212991|DRUG|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
214431685|NCT01212991|DRUG|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
214431686|NCT03813706|PROCEDURE|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
214431687|NCT00414999|DRUG|TG100801|
214431688|NCT03949335|DEVICE|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
214431689|NCT03949335|DEVICE|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
214431690|NCT01351272|DRUG|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
214431691|NCT01351272|DRUG|Placebo|
214431692|NCT05498363|BIOLOGICAL|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
214431693|NCT04616911|PROCEDURE|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
214431694|NCT04616911|PROCEDURE|LIFT|Ligation of the intersphincteric fistula tract
214431695|NCT05727397|DRUG|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
214431696|NCT05727397|DRUG|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
214431697|NCT05006092|DEVICE|ENDOMIND|CADe system for Polyp detection
214514187|NCT05109065|DIAGNOSTIC_TEST|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
214514188|NCT05109065|DIAGNOSTIC_TEST|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
214514189|NCT05109065|DIAGNOSTIC_TEST|Vitals|Height and weight will be measured in order to calculate BMI.
214514190|NCT05109065|DIAGNOSTIC_TEST|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
214514191|NCT05109065|DIAGNOSTIC_TEST|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
214514192|NCT05109065|DIAGNOSTIC_TEST|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
214514193|NCT05109065|DIAGNOSTIC_TEST|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
214514194|NCT04440579|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
214514195|NCT04440579|PROCEDURE|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
214514196|NCT04440579|PROCEDURE|Standard Cystoscopy|Patient will undergo standard cystoscopy
214514197|NCT02004834|DRUG|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
214514198|NCT04944836|DRUG|Clomiphene Citrate|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
214514199|NCT04944836|PROCEDURE|Rotator Cuff Repair|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
214514200|NCT05953415|DEVICE|active iTBS|Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
214514201|NCT05953415|DEVICE|sham iTBS|Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
214514202|NCT01811459|DRUG|Quetiapine|PO
214514203|NCT01811459|DRUG|Haloperidol|IV
214514204|NCT01811459|DRUG|Placebo|PO or IV
214514205|NCT06288685|PROCEDURE|percutaneous A1 pulley release|Treatment trigger finger by release A1 pulley by percutaneous procedure
214514206|NCT06288685|DRUG|Triamcinolone|Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
214431698|NCT01926977|DRUG|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
214431699|NCT01926977|DRUG|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
214431700|NCT03484611|DRUG|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
214431701|NCT03484611|DRUG|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
214431702|NCT03484611|DRUG|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
214514207|NCT00264576|BIOLOGICAL|Influenza Virus Vaccine|
214514208|NCT01921166|DRUG|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
214514209|NCT01921166|DRUG|Leuprolide flare|Leuprolide flare ovulation induction
214514210|NCT00990132|DEVICE|Home mechanical ventilation|Nocturnal non-invasive ventilation
214514211|NCT00990132|DEVICE|Long term oxygen therapy|LTOT established as per national guidelines
214514212|NCT02470312|PROCEDURE|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
214514213|NCT02470312|DEVICE|MediGuide|
214514214|NCT02470312|PROCEDURE|EP|
214514215|NCT03471637|OTHER|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
214431703|NCT03484611|PROCEDURE|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
214431704|NCT03484611|DRUG|Progesterone|vaginal prontogest 400 mg twice daily
214431705|NCT03843021|OTHER|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
214431706|NCT02531152|DRUG|Latanoprost|
214431707|NCT02531152|DRUG|SAR366234|
214431708|NCT06087133|BEHAVIORAL|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
214431709|NCT06087133|OTHER|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
214431710|NCT06049732|DEVICE|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
214431711|NCT00801983|DEVICE|Alternative Keyboard|Subjects use either a typical or alternative keyboard
214431712|NCT05148897|OTHER|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
214431713|NCT02447874|DRUG|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours"
214431714|NCT02447874|DRUG|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
214431715|NCT02447874|DRUG|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
214431716|NCT04287114|BEHAVIORAL|Acute exercise|Acute exercise with different exercise intensities
214431717|NCT05924958|DRUG|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
214431718|NCT06280105|DRUG|Cadonilimab+regorafenib|cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first
214431719|NCT05210257|OTHER|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
214431720|NCT05210257|OTHER|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
214431721|NCT01251354|DRUG|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
214431722|NCT02711293|OTHER|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
214431723|NCT02711293|OTHER|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
214431724|NCT03680703|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
214431725|NCT02270645|DEVICE|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
214431726|NCT02449070|DRUG|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
214431727|NCT03149991|DRUG|Brexpiprazole|Administration of up to 3mg brexpiprazole
214431728|NCT03149991|DRUG|Ketamine|administration 6 times over two weeks of inhaled ketamine
214431729|NCT03149991|DRUG|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
214431730|NCT06602973|BEHAVIORAL|Rest|Participants will eat breakfast but abstain from exercise
214431731|NCT06602973|BEHAVIORAL|Fed Exercise|Participants will eat breakfast and engage in 30 minutes of physical activity at 75% of their personal V02max.
214431732|NCT06602973|BEHAVIORAL|Fasted Exercise|Participants will engage in 30 minutes of physical activity at their personal 75% V02max after abstaining from breakfast.
214431733|NCT06501612|OTHER|Continuous Glucose Monitor and Undermyfork App|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
214431734|NCT06501612|OTHER|Continuous Glucose Monitor|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
214431735|NCT05724472|DRUG|rVSV∆G-SEBOV-GP Vaccine or Placebo|rVSV∆G-SEBOV-GP Vaccine or Placebo
214431736|NCT05332054|BIOLOGICAL|Caribou-sponsored investigational therapy|N/A this is an observational study
214431737|NCT02744859|OTHER|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
214431738|NCT02427633|OTHER|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
214431739|NCT02427633|OTHER|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
214431740|NCT03731377|DRUG|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
214431741|NCT06312683|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
214431742|NCT05850026|PROCEDURE|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
214431743|NCT01856335|OTHER|Patient Education|
214431744|NCT01856335|OTHER|exercise: increase physical activity/goal setting|
214431745|NCT06162858|OTHER|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
214431746|NCT01786525|BEHAVIORAL|House Calls|60-minute home based educational intervention which will be administered by a health educator
214431747|NCT01786525|BEHAVIORAL|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
214431748|NCT05264844|OTHER|Masking tape|IV catheters will be fixed with masking tape
214431749|NCT06661590|OTHER|Nutritional Messaging|Dieticians will evaluate nutritional messages created by LLM and Human Experts.
214431750|NCT01278433|BIOLOGICAL|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
214431751|NCT03546608|DRUG|Tepotinib|Participants received a single oral dose of tepotinib in Part 1.
214431752|NCT06594523|DRUG|Denifanstat|Tablet
214431753|NCT06594523|DRUG|Placebo|Matching Tablet
214431754|NCT06589830|DRUG|TL938 Capsules|Oral administration
214431755|NCT06589830|DRUG|Trastuzumab|Intravenous (IV) infusion
214431756|NCT06024291|OTHER|8-week HIIT programme|See arm description
214431757|NCT06024291|OTHER|Physical activity recommendation|See arm description
214431758|NCT04543201|BEHAVIORAL|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
214431759|NCT01939171|DRUG|Thymoglobulin|
214431760|NCT06555159|BEHAVIORAL|Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)|Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
214431761|NCT06555159|BEHAVIORAL|Control group: Continuous aerobic physical exercise|Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
214431762|NCT03856099|DRUG|TTAC-0001|"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"
214431763|NCT06671561|DEVICE|Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)|Observational data collection
214431764|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
214431765|NCT04022239|DRUG|Bendamustine|Given IV
214431766|NCT04022239|DRUG|Cyclophosphamide|Given IV
214431767|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
214431768|NCT04022239|DRUG|Fludarabine|Given IV
214431769|NCT04022239|DRUG|Melphalan|Given IV
214431770|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
214431771|NCT04022239|BIOLOGICAL|Rituximab|Given IV
214431772|NCT04022239|DRUG|Tacrolimus|Given IV and PO
214431773|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
214431774|NCT06859164|PROCEDURE|Genicular Artery Embolization|Embolization of genicular arteries that demonstrate neoangiogenesis or blush on angiogram.
214431775|NCT06859164|DEVICE|Lipiodol|3:1 emulsion of Lipiodol to Optiray
214431776|NCT06859164|PROCEDURE|Simple angiogram|Simple angiogram of the genicular arteries
214431777|NCT06860633|DRUG|Efgartigimod|Dose of 10 mg/kg for IV infusion on days 1, 4, 11 and 18
214431778|NCT02971943|PROCEDURE|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
214431779|NCT06677437|OTHER|This is an observational and retrospective study|"It concerns all patients with chronic renal failure awaiting a kidney transplant, and presenting a contraindication to the transplant due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses. They can only receive the kidney transplant after arterial preparation. These patients will be included and will benefit from endovascular preparation for the kidney transplant using a tailor-made arterial stent.~Imaging examinations and follow-up clinical data will be analyzed. Reinterventions and causes of death will be analyzed.~An information sheet will be given to patients; if the patient refuses the use of their data, it will not be collected.~Data collection will be carried out by ARCs or PIs of the centers from medical records. The data will be pseudo-anonymized, entered into a REDCAP database shared between each center."
214431780|NCT03807778|DRUG|Mobocertinib|Mobocertinib capsule.
214431781|NCT06677125|PROCEDURE|Electrical Mallet|The osteotome will be directly attached and pushed by magnetic mallet and a shock wave will be pushed on their tip. The electrical mallet will be imparted to osteotomes a longitudinal movement along a central axis moving up and down toward pilot bone hole providing a driving mechanism of longitudinal movements. Then the sinus lift instruments (Sweden and Martina) will be used to slowly lift the sinus. After that implant will be placed with the help of implant drilling device.
214431782|NCT06677125|PROCEDURE|Densah bur|The implant motor will be adjusted on reverse-densifying mode with 800 to 1200 rpm. According to the desired implant dimension, it will be started with the smallest densah bur. The first densah bur will advanced in densifying mode with bouncing motion in and out movement with copious irrigation until.
214514216|NCT01633359|DRUG|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
215114270|NCT04730531|PROCEDURE|Placebo of equal volume injectable saline|An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
215114271|NCT04578067|BEHAVIORAL|Lifestyle intervention|on physical activity and healthier eating
215114272|NCT01938040|DRUG|ibuprofen|single preoperative dose prior to surgery
215114273|NCT01938040|OTHER|sugar water/placebo|single preoperative dose prior to surgery
215114274|NCT06230939|OTHER|Examination|"Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method."
215114275|NCT03217994|DRUG|gel HP|gel of hygrogen peroxide for teeth bleaching
215114276|NCT05128201|RADIATION|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
215114277|NCT03621657|DRUG|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
215114278|NCT03621657|DRUG|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
215114279|NCT03621657|DRUG|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
215114280|NCT00999544|DRUG|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
214514217|NCT01633359|DRUG|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
214514218|NCT04693013|DEVICE|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
214514219|NCT00700557|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
214514220|NCT00700557|DIETARY_SUPPLEMENT|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
214514221|NCT03976102|BIOLOGICAL|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
214514222|NCT03976102|OTHER|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
215114281|NCT00999544|DRUG|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
215114282|NCT00999544|DRUG|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
215114283|NCT00999544|DRUG|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
215114284|NCT00999544|DRUG|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
215114285|NCT00999544|DRUG|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
215114286|NCT00999544|DRUG|Oxycodone 0mg, IN|Oxycodone 0mg, IN
215114287|NCT00999544|DRUG|Oxycodone 15mg, IN|Oxycodone 15mg, IN
215114288|NCT00999544|DRUG|Oxycodone 30mg, IN|Oxycodone 30mg, IN
215114289|NCT02601404|DEVICE|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
215114290|NCT00112632|DRUG|imatinib mesylate|
214431783|NCT06496958|DEVICE|CO2 insufflation with an abdominal compression device|For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.
214431784|NCT06496958|DEVICE|CO2 insufflation with a sham abdominal compression device|The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.
214431785|NCT06496958|DEVICE|Water exchange colonoscopy|In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
215114291|NCT00112632|PROCEDURE|conventional surgery|
215114292|NCT00112632|PROCEDURE|neoadjuvant therapy|
214431786|NCT06625346|DRUG|Fixed-Dose Combination of Amlodipine/Valsartan|Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
214431787|NCT05685316|DEVICE|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
214431788|NCT06874192|DRUG|Low-dose colchicine at 0.5mg daily|LODOCO is low-dose colchicine at 0.5mg daily, ii is an FDA approved anti-inflammatory drug, to prevent cardiovascular events in patients with coronary artery disease. LODOCO works by inhibiting microtubule formation and reducing the activity of neutrophils, which play a key role in inflammation.
214431789|NCT06874192|OTHER|Placebo|Matching placebo
214431790|NCT06691919|DEVICE|Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement|Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.
214431791|NCT06691919|PROCEDURE|Transgastric Surgical Necrosectomy|Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
214431792|NCT06702059|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Subjects will undergo pre-operative cardiopulmonary exercise testing.
214431793|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214431794|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
214431795|NCT05600556|OTHER|Best Practice|Review imaging on standard computer screen
214431796|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
214431797|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214514223|NCT03527888|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214514224|NCT02233075|DRUG|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
214514225|NCT00965471|DRUG|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
214514226|NCT00965471|DRUG|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
215114293|NCT03196804|DRUG|LC28-0126|LC28-0126
215114294|NCT03196804|DRUG|Placebo|Placebo
215114295|NCT00574717|PROCEDURE|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
215114296|NCT01827150|DRUG|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
215114297|NCT04958369|DEVICE|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
215114298|NCT04958369|DEVICE|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
215114299|NCT06302582|BIOLOGICAL|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm
215114300|NCT06302582|OTHER|Control group|Standard therapy for patients with stage 3 and 4 stress injury
214431798|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
214431799|NCT05600556|OTHER|Virtual Technology Intervention|Review virtual reality images
214431800|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
214431801|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
214431802|NCT04024293|DEVICE|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
214431803|NCT06703944|OTHER|risk model in diagnosis and prognosis|"In this study, we construct and evaluate the bone marrow cytology-based AI model for detection and prognosis of NB.~1. For the diagnostic model, we use AUC metrics to evaluate the model in terms of sensitivity, specificity, accuracy, positive predictive value and negative predictive value at different classification thresholds.~2. For the prognostic model, we use AUC as the performance metric and calculating sensitivity and specificity. Survival curves were constructed according to the Kaplan-Meier method."
214431804|NCT06708169|BEHAVIORAL|preemptive education provided by anesthesiologists|A preemptive education about 4 stages (prepare, anethesia, surgery, and recovery) by anesthesiologists within 15 minute.
214431805|NCT06882005|BEHAVIORAL|Rested & Ready to Learn|The intervention targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
214431806|NCT06725823|PROCEDURE|suprascapular nerve block group|A volume of (10 ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) will be injected to both groups.
214431807|NCT06725823|PROCEDURE|shoulder anterior capsular block group|A volume of (10ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40mg) will be injected to both groups.
214431808|NCT06890065|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
214431809|NCT06925217|DEVICE|CamAPS HX|The CamAPS HX fully closed-loop system consists of an insulin pump, a continuous glucose monitoring (CGM) sensor, as well as the CamAPS HX app, which resides on a smartphone and communicates wirelessly with the insulin pump.
214431810|NCT06925217|DEVICE|Standard insulin therapy with CGM|Participants will continue their standard insulin therapy with a Freestyle Libre 3 CGM
214431811|NCT06728059|DEVICE|Automated Insulin Delivery Adaptive NETwork (AIDANET)|Group A participants will use the AIDANET system at home for 7 days/6 nights. They will continue use of AIDANET system for 18 hours during the hotel session and then use AIDANET+BPS\_RL for 18 hours during the hotel session.
214431812|NCT06728059|DEVICE|AIDANET+ BPS_RL→AIDANET|Group B participant will use the AIDANET+BPS\_RL system for 18 hours during the hotel session and will then use AIDANET system for 18 hours during the hotel session. They will continue to use AIDANET+BPS\_RL system at home for 7 days/6 night and then use the AIDANET system at home for 7 days/6 nights.
214431813|NCT06883123|DRUG|Simbrinza 0.2%-1% Ophthalmic Suspension|brinzolamide and brimonidine tartrate
214431814|NCT06883123|DRUG|Rocklatan 0.02%-0.005% Ophthalmic Solution|netarsudil and latanoprost
214431815|NCT06883123|DRUG|Cosopt PF 2%-0.5% Ophthalmic Solution|dorzolamide hydrochloride and timolol maleate
214431816|NCT06883123|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost
214431817|NCT06740890|DRUG|Olanzapine-samidorphan + exercise|8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise
214431818|NCT05135000|DRUG|LTP001|LTP001, 6 mg, was administered orally once daily in the morning
214431819|NCT05135000|DRUG|Placebo|Placebo to LTP001 was administered once daily in the morning
214431820|NCT06893211|DRUG|Tirzepatide|Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It will be administered via subcutaneous injection once weekly in a dose-titration scheme: starting at 2.5 mg, and increased every 4 weeks by 2.5 mg up to a maximum of 15 mg, based on tolerability. The medication will be supplied in prefilled pens identical in appearance to placebo pens.
214431821|NCT06893211|DRUG|Placebo|Placebo will be administered via subcutaneous injection once weekly using pens that are visually indistinguishable from those used for tirzepatide. Dose escalation will follow the same schedule (2.5 mg-equivalent increments every 4 weeks) to preserve blinding integrity.
215114301|NCT05733858|DEVICE|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
214431822|NCT07053657|DRUG|Dietary Supplement: Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
214431823|NCT07053657|DRUG|Dietary Supplement: Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
214431824|NCT07054099|BIOLOGICAL|MG1111 (Barycela inj.)|MG1111 (Barycela inj.)
214431825|NCT07054099|BIOLOGICAL|VARIVAX™|Varivax™
214431826|NCT07053306|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
214431827|NCT07054840|BEHAVIORAL|Capsaicin 0.1% cream combined with a heat pack and applied to the lower leg|Capsaicin is applied to the skin of one of the lower legs, then covered with a heat pack that is secured to the leg with self-adhesive wrap.
214431828|NCT06750302|DRUG|Methoxyflurane - Penthrox|3ml
214431829|NCT06750302|OTHER|Placebo|saline + one drop of methoxyflurane
214431830|NCT06083181|DEVICE|Perf-Fix Otologic Gel Patch|Gel patch application
214431831|NCT06887660|OTHER|Orthodontic diagnosis|"Initial Assessment Orthodontic residents assessed each patient based on their existing knowledge of speech therapy. They rated the necessity for a speech therapy consultation on a scale from 1 to 10, with 1 indicating not necessary and 10 indicating absolutely necessary.~Protocol-Guided Assessment The same residents then reassessed the same patients using the Interdisciplinary Orofacial Evaluation Protocol. After this evaluation, they again rated the necessity for a speech therapy consultation using the same 1 to 10 scale.~Speech-therapist Evaluation Subsequently, a speech therapy specialist independently evaluated each patient using the same protocol and provided their rating for the necessity of a speech therapy consultation on the same scale."
214431832|NCT06741085|DRUG|osimertinib|oral EGFR-TKI
214431833|NCT06741085|RADIATION|stereotactic radiosurgery (SRS)|"0-20mm-18Gy x 1, 21Gy x 1 ,9Gy x 3~20mm or larger- 9Gy x 3, 6Gy x 5, 5Gy x 5"
214431834|NCT06724640|DRUG|VH4011499 Injection|VH4011499 Injection will be administered either subcutaneously or intramuscularly.
214431835|NCT06724640|DRUG|Placebo for VH4011499 Injection|Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
214431836|NCT07060001|DIAGNOSTIC_TEST|5hmC Biomarker|The 5hmC marker will be used to determine treatment modality post-induction therapy. After Week 4 of standard-of-care therapy (either HMA-based treatment or intensive induction chemotherapy), 5hmC biomarker testing will be performed. If MRD is positive, patients will continue the same standard-of-care treatment or crossover to the other arm of the study. If MRD is negative, patients will proceed with consolidation (either HSCT or continue on same treatment). For patients receiving HMA-based treatment, blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy. For patients receiving intensive chemotherapy blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy.
214431837|NCT07060001|DRUG|Venetoclax|Venetoclax is a BCL-2 inhibitor FDA Approved for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine.
214431838|NCT07060001|DRUG|Decitabine 20 mg/m²/day for 5 days|Decitabine is a nucleoside metabolic inhibitor that is administered as an intravenous infusion over a 1-3 hours.
214431839|NCT07060001|DRUG|Azacitidine (AZA)|Azacitidine can be given as a sub-cutaneous injection or intravenously.
214431840|NCT07060001|DRUG|Cytarabine (Ara-C)|Cytarabine is FDA approved chemotherapy (pyrimidine analog) infusion that is frequently used with other drug such as anthracycline to treat acute myeloid leukemia, acute lymphoblastic leukemia. Common side effects include low counts, immune suppression, nausea, neutropenic fever.
214431841|NCT07060001|DRUG|Anthracycline|Anthracyclines are chemotherapy infusions which topoisomerase II inhibition. Other than having side effects similar to cytarabine, it may cause weakening of heart pumping function few years later. Both of these medications may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.
214431842|NCT07060287|PROCEDURE|Clock-Guided Minimally Invasive Surgery|All participants underwent video-assisted thoracoscopic surgery (VATS) for pulmonary nodule resection. Nodule localization was performed using a clock-guided anatomical positioning technique with a 3D reconstruction system. The surgical procedure included wedge resection, segmentectomy, or lobectomy based on clinical judgment.
214431843|NCT07061769|DEVICE|SHIFT|SHIFT is a low intensity PEMF cranial device. It has been designated as a Non-Significant Risk device by the FDA.
214431844|NCT07060092|BEHAVIORAL|Trail Making Task|Participants will perform a modified, life-size version of the Trail Making Test (TMT) while standing upright, either on a stable (force plates) or unstable (balance board) surface. The task involves visually searching for and tracing a sequential path through spatially randomized numerical targets projected onto a large screen using a laser pointer. This dual-task condition simultaneously engages cognitive, visual, and motor planning systems while requiring continuous postural control. The task is designed to elicit suprapostural coordination, capturing the dynamic interplay between postural stability and goal-directed behavior.
214431845|NCT07060092|BEHAVIORAL|Balance board|Participants will maintain an upright stance on a commercially available balance board positioned atop dual force plates. The unstable surface introduces controlled postural instability, requiring continuous sensorimotor adaptation to preserve balance without external support. This condition is administered alone and in combination with the Trail Making Task to simulate dual-task challenges that more closely resemble real-world balance demands.
214431846|NCT05091970|PROCEDURE|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)|Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.
214431847|NCT02788773|DRUG|Durvalumab|
214431848|NCT02788773|DRUG|Tremelimumab|
214431849|NCT00130117|DRUG|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
214431850|NCT00130117|DRUG|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
214431851|NCT00130117|OTHER|Placebo|placebo (no active medication)
214431852|NCT05788536|GENETIC|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~* LD Cohort (lower dose)~* HD Cohort (high dose) - not implemented"
214431853|NCT05788536|GENETIC|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
214431854|NCT06253663|DRUG|KTE-X19|A single infusion of chimeric antigen receptor (CAR) T cells
214431855|NCT06253663|DRUG|Cyclophosphamide|Administered intravenously
214431856|NCT06253663|DRUG|Fludarabine|Administered intravenously
215114302|NCT05733858|DEVICE|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
214431857|NCT06924450|DEVICE|1.2 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.2 cm monofilament polypropylene mesh. The modified mesh width is being evaluated for its effect on surgical success, symptom improvement, and postoperative complications.
214431858|NCT06924450|DEVICE|1.0 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.0 cm monofilament polypropylene mesh, which is the standard procedure. This group serves as a comparator to assess the impact of the modified mesh width.
214431859|NCT02678572|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
214431860|NCT06925724|DRUG|Ivonescimab|Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)
214431861|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
214431862|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
214431863|NCT06935019|GENETIC|Genome sequencing pre-geneticist evaluation|The intervention is receiving immediate clinical routine GS, prior to evaluation by a medical geneticist. Pre-test counselling will be done by a research genetic counsellor. Results of GS will be returned during the participant's first visit to Genetics Clinic by their clinical team. Subsequent clinical care (including any other clinically indicated genetic testing or workup) will be arranged by the medical geneticist in clinic.
214431864|NCT06937853|DRUG|Ibuprofen 600 mg|A single oral dose of 600 mg ibuprofen will be administered prior to the endodontic procedure to evaluate its preemptive analgesic effect on postoperative dental pain.
214431865|NCT06937853|DRUG|diclofenac sodium|A single oral dose of 100 mg diclofenac sodium will be administered to participants in the Diclofenac Sodium Group prior to the endodontic procedure. This intervention is designed to assess the preemptive analgesic efficacy of diclofenac sodium in the control of postoperative dental pain.
215114303|NCT05733858|DEVICE|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
214431866|NCT06937853|DRUG|Placebo|A single oral dose of a placebo tablet, identical in appearance to the active drugs, will be administered to participants in the Placebo Group prior to the endodontic procedure. This group serves as the control to evaluate the true analgesic efficacy of the active interventions.
214431867|NCT04756323|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
214431868|NCT04756323|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
214431869|NCT04756323|BIOLOGICAL|Placebo|placebo
214431870|NCT05094141|OTHER|Virtual reality|Virtual reality game played during port needle access.
214431871|NCT05640154|BEHAVIORAL|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
214431872|NCT05682924|DIAGNOSTIC_TEST|taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry|In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
214431873|NCT01170026|BEHAVIORAL|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion \& Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
214431874|NCT01170026|BEHAVIORAL|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
214514227|NCT03662737|DIAGNOSTIC_TEST|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
214514228|NCT01491100|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
214514229|NCT02894216|PROCEDURE|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
214514230|NCT04555694|DRUG|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
214514231|NCT04555694|DRUG|Loteprednol Etabonate|Used to treat inflammation of the eye
214514232|NCT04555694|DRUG|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
214514233|NCT02834624|DRUG|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
214514234|NCT02834624|DRUG|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
214514235|NCT00092456|BIOLOGICAL|rotavirus vaccine, live, oral, pentavalent|Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
214514236|NCT00092456|BIOLOGICAL|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
214514237|NCT00456235|DRUG|Mycophénolate Mofétil|
214514238|NCT00456235|DRUG|Ciclosporine A|
214431875|NCT04411056|OTHER|Barrier box|Placement of barrier box ( a plastic box for shielding)
214431876|NCT06162013|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 3000mg/day
214431877|NCT06162013|OTHER|Placebo|Placebo. Identical in taste and appearance as the intervention.
214431878|NCT04239040|PROCEDURE|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
214514239|NCT00456235|DRUG|Tacrolimus|
214514240|NCT01368549|OTHER|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
214514241|NCT06202547|BIOLOGICAL|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
214514242|NCT02952235|OTHER|SPF50+|Sun protection
214514243|NCT02952235|OTHER|SPF100+|Sun protection
214514244|NCT03522909|OTHER|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   \- Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate"
214431879|NCT04239040|BIOLOGICAL|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
214431880|NCT04239040|DRUG|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
214431881|NCT04239040|DRUG|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
214431882|NCT05415800|BEHAVIORAL|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
214431883|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
214514245|NCT04783389|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
214514246|NCT04783389|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214514247|NCT04843956|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided biopsy|"Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)"
214514248|NCT00804765|OTHER|Therapeutic education|Intensive training individual and collective teaching
214514249|NCT00804765|OTHER|Follow-up|classical follow-up with two individual consultations
214514250|NCT00451906|DRUG|Platinum-based chemotherapy|As prescribed
214431884|NCT06352775|DIETARY_SUPPLEMENT|Calcium Carbonate|We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
214431885|NCT04781335|DRUG|Dexycu|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
215114304|NCT05733858|BEHAVIORAL|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
214431886|NCT04781335|DRUG|Standard of Care post operative eye drops (steroid, antibiotic, NSAID)|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
214431887|NCT02098343|DRUG|APR-246|Intravenous infusion.
214431888|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
214514251|NCT00451906|DRUG|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
214514252|NCT03918187|DRUG|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
214514253|NCT03918187|DRUG|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
214514254|NCT03918187|DRUG|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
215114305|NCT03415204|OTHER|acupuncture|acupuncture for post operative pain
215114306|NCT05456737|OTHER|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
215114307|NCT00199121|DRUG|Zidovudine (drug)|
215114308|NCT02688244|PROCEDURE|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
215114309|NCT02688244|PROCEDURE|No irrigation|Suction only, using suction device
215114310|NCT01387126|DIETARY_SUPPLEMENT|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
215114311|NCT05889715|OTHER|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
215114312|NCT00013520|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
215114313|NCT00013520|DRUG|Atazanavir|
215114314|NCT00013520|DRUG|Lamivudine/Zidovudine|
215114315|NCT00013520|DRUG|Abacavir sulfate|
215114316|NCT00013520|DRUG|Efavirenz|
215114317|NCT00013520|DRUG|Nevirapine|
215114318|NCT00013520|DRUG|Lamivudine|
215114319|NCT00013520|DRUG|Stavudine|
215114320|NCT00013520|DRUG|Zidovudine|
215114321|NCT00013520|DRUG|Didanosine|
214431889|NCT05515562|DRUG|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
214514255|NCT01250717|DRUG|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
214514256|NCT01250717|DRUG|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
214514257|NCT01250717|DRUG|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
214514258|NCT01250717|DRUG|Zoladex|Given subcutaneously for 4 doses every three months
214514259|NCT01250717|DRUG|Casodex|Taken orally once a day for 6 months
214514260|NCT01250717|PROCEDURE|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
214514261|NCT04004923|PROCEDURE|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
214514262|NCT04004923|PROCEDURE|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
214514263|NCT06234449|PROCEDURE|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
214514264|NCT04388748|BEHAVIORAL|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
214431890|NCT06423677|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
214431891|NCT06423677|DEVICE|patient controlled analgesia|intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
214431892|NCT06777108|DIETARY_SUPPLEMENT|Inorganic Nitrate|The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.
214431893|NCT05459142|DRUG|Medical Abortion|Medical Abortion
214431894|NCT05491616|DRUG|Nivolumab|In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
214431895|NCT06334575|DRUG|Budesonide|receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
214431896|NCT06474169|OTHER|1 blood sample for each participant|"Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)"
214431897|NCT05314634|BEHAVIORAL|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
214431898|NCT05314634|BEHAVIORAL|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
214431899|NCT06021314|OTHER|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
214431900|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
214431901|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
214431902|NCT06069115|RADIATION|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
214431903|NCT06069115|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
214431904|NCT06069115|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
214431905|NCT06069115|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
214431906|NCT06069115|DIAGNOSTIC_TEST|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
214431907|NCT06069115|DIAGNOSTIC_TEST|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
214431908|NCT06069115|OTHER|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
214431909|NCT06025942|BEHAVIORAL|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
214431910|NCT05996497|BEHAVIORAL|behavioral measures|behavioral measures
214431911|NCT05996497|OTHER|Electrophysiological measures|Electrophysiological measures
214431912|NCT05996497|OTHER|Training 1|Training 1
214431913|NCT05996497|OTHER|Training 2|Training 2
214431914|NCT05132205|PROCEDURE|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
214431915|NCT06551987|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
214431916|NCT06551987|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
214431917|NCT05679271|DEVICE|Venous stenting|venous stenting associated to antiaggregation protocol
214431918|NCT05679271|OTHER|Standard of care|observation: no treatment
214431919|NCT04987476|BIOLOGICAL|analyzes in singles cells|genome expression analyzes in single cells
214431920|NCT04729816|OTHER|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
214692554|NCT02307721|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
215114322|NCT04683835|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
214431921|NCT04973566|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
214431922|NCT04973566|DRUG|Etanercept|Etanercept will be administered subcutaneously.
214431923|NCT04973566|DRUG|Hydroxychloroquine|HCQ will be administered orally.
214431924|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
214431925|NCT05219058|PROCEDURE|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
214431926|NCT05219058|PROCEDURE|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
214431927|NCT05219058|PROCEDURE|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
215114323|NCT06062979|DRUG|rilpivirine/cabotegravir|WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
215114324|NCT02697266|OTHER|No intervention|This is an observational study.
215114325|NCT04950361|OTHER|talocalcaneal coalition|patients with talocalcaneal coalition
215114326|NCT02407223|DRUG|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
214431928|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
214431929|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
214431930|NCT06189131|DEVICE|Ventriject|Ventriject is a non-exercise method for estimating V02Max
214431931|NCT05758246|DRUG|Fisetin-dose 1|20mg/kg once a day for one day.
214431932|NCT05758246|DRUG|Fisetin-dose 2|20mg/kg once a day for two days
214431933|NCT05758246|DRUG|Placebo|Placebo treatment
214431934|NCT06245525|OTHER|This is not an interventional study|This is not an interventional study
214431935|NCT05588479|DIETARY_SUPPLEMENT|Pomegranate extract|Two capsules of pomegranate extract (740 mg) will be taken daily at any time of the day for a period of 12 weeks.
214692555|NCT02307721|DEVICE|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
214431936|NCT05588479|DIETARY_SUPPLEMENT|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
214431937|NCT05164536|DRUG|Amyvid|All participants will undergo a single β-amyloid PET scan with Amyvid.
214431938|NCT03224949|OTHER|Blood draw|Patients will have a one time blood draw
214431939|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
214692556|NCT01787643|OTHER|Height-Adjustable Desk Intallation in Office|
214431940|NCT03952507|DRUG|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
214514265|NCT05591378|OTHER|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
214514266|NCT05591378|OTHER|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
214431941|NCT03952507|DRUG|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
214431942|NCT06164613|DRUG|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
214431943|NCT06164613|DRUG|Placebo|400 mg PO Canola oil soft gel capsule
214431944|NCT05632913|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
214431945|NCT05470868|DRUG|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
214431946|NCT06134089|BEHAVIORAL|Perceived Effectiveness Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
214431947|NCT06134089|BEHAVIORAL|Perceived Shareability Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
214431948|NCT04948866|BEHAVIORAL|ADRD-PC Program|Included in arm/group descriptions
214431949|NCT05341739|OTHER|Pre-operative Stereotactic Radiosurgery|Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
214514267|NCT06569589|DIAGNOSTIC_TEST|23NaMRI Scan|23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
214514268|NCT06569589|DIETARY_SUPPLEMENT|Potassium Chloride (KCl)|K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level
214514269|NCT02014298|RADIATION|non-ablative fractional laser|3 treatments with 4-6 weeks interval
214514270|NCT02014298|OTHER|control|observation, comparison to laser-treated area
214514271|NCT02127645|PROCEDURE|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
214514272|NCT02127645|PROCEDURE|LRT-TEM|TEM following 46 Gy RT
214514273|NCT02127645|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
214514274|NCT02127645|PROCEDURE|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
214514275|NCT03538834|DIETARY_SUPPLEMENT|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
215114327|NCT02407223|DRUG|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
215114328|NCT02407223|DRUG|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
215114329|NCT01845935|DEVICE|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
214431950|NCT05894798|OTHER|Acupuncture|Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
214431951|NCT05419076|RADIATION|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
214514276|NCT03538834|DIETARY_SUPPLEMENT|Control|Placebo
214514277|NCT00588042|DEVICE|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
215114330|NCT04130607|OTHER|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
215114331|NCT01056939|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
215114332|NCT01056939|DEVICE|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
215114333|NCT05628142|RADIATION|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
215114334|NCT05011812|DRUG|PBI-0451 Dose 1|Dose level 1 of PBI-0451
215114335|NCT05011812|DRUG|PBI-0451 Dose 2|Dose level 2 of PBI-0451
215114336|NCT05011812|DRUG|PBI-0451 Dose 3|Dose level 3 of PBI-0451
215114337|NCT05011812|DRUG|PBI-0451 Dose 4|Dose level 4 of PBI-0451
215114338|NCT05011812|DRUG|Ritonavir|Ritonavir will be co-administered with the study drug in Treatments J and K
215114339|NCT05011812|DRUG|Midazolam|Midazolam will be co-administered with the study drug in Treatment L
215114340|NCT05011812|DRUG|Placebo|Placebo to match
215114341|NCT05011812|DRUG|PBI-0451|Dose level of PBI-0451 with a projected exposure
215114342|NCT05011812|DRUG|PBI-0451 Dose 5|Dose level 5 of PBI-0451
215114343|NCT03552666|DIETARY_SUPPLEMENT|vitamin D3|
215114344|NCT02582645|PROCEDURE|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
215114345|NCT02582645|PROCEDURE|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
215114346|NCT02507323|DRUG|ticagrelor|A platelet aggregation inhibitor
214431952|NCT05419076|PROCEDURE|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
214514278|NCT00588042|DEVICE|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
215114347|NCT02507323|DRUG|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
215114348|NCT02507323|DRUG|Placebo|placebo
215114349|NCT00074334|BIOLOGICAL|TGFa-PE38 immunotoxin|
215114350|NCT00074334|PROCEDURE|conventional surgery|
214514279|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
214514280|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
215114351|NCT02611726|OTHER|Acupuncture|Acupuncture
215114352|NCT03481335|OTHER|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
215114353|NCT04864639|OTHER|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
215114354|NCT00004561|BEHAVIORAL|exercise|
215114355|NCT06492434|BEHAVIORAL|Peer decision coaching|Peer Decision Coaching is a brief, personalized intervention grounded in evidence-based decision- and peer support principles. During the intervention, a trained peer specialist supports the young person in identifying a decision related to community participation that they need to make, such as whether to work or go to school, helping them address decision-making needs, and assisting them with developing and implementing a decision-making plan. Ultimately, the intervention aims to support young people in pursuing their community participation interests and goals.
215114356|NCT00267215|DRUG|Lumiracoxib|
215114357|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
215114358|NCT03771651|DRUG|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
215114359|NCT00615017|DRUG|AZD9773 (CytoFab)|intravenous infusions
215114360|NCT00615017|OTHER|Placebo|Placebo
215114361|NCT00806988|PROCEDURE|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~1. All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~2. The heart will be arrested with cardioplegia.~3. A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
215114362|NCT00806988|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
214431953|NCT02398825|DRUG|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
214431954|NCT06738251|DRUG|SHR-A2102 for Injection|SHR-A2102 for Injection.
214431955|NCT06738251|DRUG|Docetaxel Injection|Docetaxel Injection.
214431956|NCT06738251|DRUG|Paclitaxel Injection|Paclitaxel Injection.
214431957|NCT06738251|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
214431958|NCT06738251|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection.
214431959|NCT02763319|DRUG|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
214431960|NCT02763319|DRUG|Tafasitamab|Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
214431961|NCT02763319|DRUG|Bendamustine (BEN)|
214431962|NCT03710798|DIETARY_SUPPLEMENT|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
214431963|NCT02682485|DRUG|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
214431964|NCT02682485|PROCEDURE|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
214431965|NCT02682485|DRUG|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
214431966|NCT04894565|PROCEDURE|rehabilitation|physical therapy 24 hrs after surgery
214431967|NCT00089544|DRUG|Dacarbazine|Given IV
214431968|NCT00089544|DRUG|Doxorubicin Hydrochloride|Given IV
214431969|NCT00089544|BIOLOGICAL|Filgrastim|Given subcutaneously
214431970|NCT00089544|DRUG|Ifosfamide|Given IV
214431971|NCT00089544|OTHER|Laboratory Biomarker Analysis|Correlative studies
214514281|NCT06026826|DEVICE|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
214514282|NCT06026826|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
215114363|NCT01550536|BEHAVIORAL|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
215114364|NCT04658329|DRUG|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
215114365|NCT06060795|DIAGNOSTIC_TEST|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
214431972|NCT00089544|RADIATION|Radiation Therapy|Undergo radiotherapy
214431973|NCT00089544|DRUG|Thalidomide|Given orally
214431974|NCT00089544|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214431975|NCT03807908|OTHER|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
214431976|NCT03807908|OTHER|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
214431977|NCT00014040|DRUG|Nitric Oxide and INOpulse Delivery System|
214431978|NCT01331044|DIETARY_SUPPLEMENT|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
214431979|NCT01331044|DIETARY_SUPPLEMENT|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
214431980|NCT01150383|OTHER|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
214514283|NCT03872661|DRUG|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
214514284|NCT03872661|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
214514285|NCT03872661|DRUG|Pemetrexed|Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
214514286|NCT03872661|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
214514287|NCT03872661|PROCEDURE|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
214514288|NCT05472194|BEHAVIORAL|InSchool Training Program|The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.
214514289|NCT05472194|BEHAVIORAL|Regular school activities|Children in the control group will be playing with the regular school activities.
214514290|NCT03471390|OTHER|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
214514291|NCT03267069|OTHER|survey|surveys will be administered at inclusion and follow-ups
214514292|NCT02121808|PROCEDURE|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
214514293|NCT02121808|PROCEDURE|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
214514294|NCT01578278|DRUG|Bepotastine besilate formulation|Nasal Spray
214514295|NCT01578278|DRUG|Fluticasone propionate|Nasal Spray
214514296|NCT01578278|DRUG|Bepotastine besilate-fluticasone propionate|Nasal Spray
214514297|NCT01578278|DRUG|Placebo Comparator|Nasal Spray
214514298|NCT04512560|BEHAVIORAL|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
214514299|NCT04512560|BEHAVIORAL|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
214514300|NCT03126266|RADIATION|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
215114366|NCT02310412|BIOLOGICAL|INTERCEPT treated platelets|
215114367|NCT02534545|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
215114368|NCT02534545|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
215114369|NCT01429493|RADIATION|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
215114370|NCT01429493|RADIATION|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
215114371|NCT01429493|RADIATION|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
214514301|NCT04593004|DEVICE|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
214514302|NCT04593004|OTHER|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
214514303|NCT03670771|DIAGNOSTIC_TEST|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
214514304|NCT04521647|DRUG|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
214514305|NCT04820023|DRUG|BBT-176, QD|BBT-176 given orally alone, QD
214514306|NCT04820023|DRUG|BBT-176, BID|BBT-176 given orally alone, BID
214514307|NCT06579287|DRUG|SHJ002|Topical ophthalmic
214514308|NCT06579287|DRUG|Atropine|Topical ophthalmic
214514309|NCT06348394|OTHER|Intracardiac Echocardiography|Transesophageal echocardiography will be performed under general anesthesia.
214514310|NCT05066230|DRUG|KSI-301|Intravitreal injection
214514311|NCT05066230|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
214514312|NCT05872958|DRUG|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
214514313|NCT05872958|OTHER|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
214514314|NCT06512116|DRUG|SIBP-A17|"Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design."
214431981|NCT01150383|OTHER|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
214431982|NCT03821246|DRUG|Atezolizumab|Given IV
214431983|NCT03821246|DRUG|Tocilizumab|Given IV
214431984|NCT03821246|DRUG|Etrumadenant|Given Orally
214431985|NCT03500393|BEHAVIORAL|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
214431986|NCT03500393|BEHAVIORAL|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
214431987|NCT03046810|DEVICE|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
214431988|NCT05150106|OTHER|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
214431989|NCT00477308|PROCEDURE|salvage therapy|
214431990|NCT03097770|BIOLOGICAL|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
214431991|NCT00233090|DRUG|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
214431992|NCT00233090|DRUG|Placebo|daily dose of placebo for four weeks.
215114372|NCT03947177|BEHAVIORAL|GMIT|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
215114373|NCT03947177|BEHAVIORAL|GMIT+|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
215114374|NCT06525779|DEVICE|Use of macintosh laryngoscope|The requirement of external laryngeal manipulation recorded in use of macintosh vs mcGrath laryngoscope in double lumen tube insertion
215114375|NCT06525779|DEVICE|Use of mcGarth laryngoscope|Use of mcGarth laryngoscope
215114376|NCT02908126|DRUG|Oxytocin|Oxytocin drug
215114377|NCT00938678|DRUG|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
214431993|NCT06444958|DIAGNOSTIC_TEST|observational study without any intervention component.|"extracting and analyzing the following data:~Outpatient department records: Diagnoses, treatments, patient demographics Inpatient admission records: Admission diagnoses, treatments, patient outcomes (discharged, transferred, died) Mortality records: Causes of death for pediatric patients"
214431994|NCT01745016|DIETARY_SUPPLEMENT|Placebo|
214431995|NCT01745016|DIETARY_SUPPLEMENT|Beta-alanine|
214431996|NCT00063713|DRUG|VELCADE TM (bortezomib) for Injection|
214431997|NCT03049319|DEVICE|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
214431998|NCT03049319|DEVICE|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
214431999|NCT03049319|DEVICE|Psoriashield|The psoriashield will be applied to patient's back.
214432000|NCT03049319|DEVICE|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
214432001|NCT03049319|DEVICE|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
214432002|NCT03049319|DEVICE|Xtrac laser|The Xtrac laser will be applied to patient's back.
214432003|NCT05886634|DRUG|Etrumadenant|Will be administered PO daily for 24 weeks
214514315|NCT05847634|DEVICE|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
214514316|NCT02164578|DRUG|Rivaroxaban|
214514317|NCT02164578|DRUG|Aspirin|
214514318|NCT05690477|PROCEDURE|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
214432004|NCT05886634|DRUG|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
214432005|NCT00507338|PROCEDURE|PCI|early PCI for NSTEMI; primary PCI for STEMI
214432006|NCT04351386|DEVICE|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
214432007|NCT01622868|OTHER|Laboratory Biomarker Analysis|Correlative studies
214432008|NCT01622868|DRUG|Lapatinib Ditosylate|Given PO
214432009|NCT01622868|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214432010|NCT01622868|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214432011|NCT01010685|PROCEDURE|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
214432012|NCT03359317|BEHAVIORAL|jogging|Jogging as instructed for 1 year
214514319|NCT05426434|DRUG|Dihydroartemisinin-Piperaquine (DP)|DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
214432013|NCT03039244|OTHER|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
214432014|NCT03039244|OTHER|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
214432015|NCT03039244|DEVICE|Diode Laser|
214432016|NCT03990285|DRUG|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
214432017|NCT05806060|DRUG|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
214432018|NCT05806060|DRUG|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
214432019|NCT05806060|DRUG|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
214432020|NCT05806060|DRUG|VEGFR and TPC|VEGFR bevacizumab and TPC
214432021|NCT06009120|OTHER|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
214432022|NCT04339348|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
214432023|NCT04339348|DRUG|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
214432024|NCT04339348|DRUG|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
214432025|NCT03117023|DRUG|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
214432026|NCT04261465|DRUG|Olaparib|PARP INHIBITOR
214432027|NCT04261465|DRUG|Paclitaxel|Chemotherapy
214432028|NCT04261465|DRUG|Carboplatin|Chemotherapy
215114378|NCT00938678|DRUG|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
215114379|NCT05804669|DRUG|atumelnant|Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
214432029|NCT02761239|DEVICE|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
214432030|NCT03260010|DRUG|Fosfomycin|Infectofos 5 g
214432031|NCT03113617|PROCEDURE|Computed Tomography|Undergo PET/CT
214432032|NCT03113617|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
214432033|NCT03113617|OTHER|Laboratory Biomarker Analysis|Correlative studies
214432034|NCT03113617|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214432035|NCT05806255|DEVICE|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
214514320|NCT05426434|DRUG|Sulfadoxine pyrimethamine (SP)|SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
214514321|NCT02507297|DEVICE|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
215114380|NCT02685306|BIOLOGICAL|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
215114381|NCT02685306|DRUG|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
215114382|NCT00257699|DRUG|Metronidazole placebo|
215114383|NCT00257699|DRUG|ciprofloxacin placebo|
215114384|NCT00257699|DRUG|ciprofloxacin|500 mg bid po
215114385|NCT00257699|DRUG|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
215114386|NCT05597774|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
215114387|NCT05597774|OTHER|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
214514322|NCT06306222|DEVICE|Laser lithotripsy|Ureteroscopic laser lithotripsy
214514323|NCT02929758|BEHAVIORAL|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
215114388|NCT05597774|OTHER|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
214432036|NCT05810194|DEVICE|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
214432037|NCT05810194|DRUG|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
214514324|NCT05589129|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
214514325|NCT05589129|DIETARY_SUPPLEMENT|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
214514326|NCT04750902|DRUG|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
214514327|NCT04750902|DRUG|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
214514328|NCT04750902|DRUG|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
215114389|NCT00842556|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
214514329|NCT04750902|DRUG|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
214514330|NCT05266209|OTHER|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
214514331|NCT01018992|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
214514332|NCT01018992|DRUG|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
214514333|NCT00819078|DRUG|Bupropion|300 mg/d
214514334|NCT00819078|DRUG|Placebo|no dosage
214514335|NCT00215709|DRUG|docetaxel|
215114390|NCT00842556|DRUG|Glimepiride|Tablets, Oral, 4 mg, Single Dose
214514336|NCT01525459|PROCEDURE|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
214514337|NCT01525459|OTHER|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
214514338|NCT05886465|DRUG|Atezolizumab|1200 mg, iv.drip, Q3W
215114391|NCT00842556|DRUG|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
215114392|NCT01181466|DEVICE|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
215114393|NCT04930523|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
214432038|NCT05810194|DRUG|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
214432039|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
214432040|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
214432041|NCT02474394|DEVICE|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
214432042|NCT02474394|DEVICE|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
214432043|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
214432044|NCT05263336|DRUG|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
214432045|NCT01279798|BIOLOGICAL|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
214432046|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
214432047|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
214432048|NCT02653508|BEHAVIORAL|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
214432049|NCT02653508|BEHAVIORAL|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
214432050|NCT06290882|PROCEDURE|Robotic Heller Myotomy|Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.
214432051|NCT06290882|PROCEDURE|Peroral Endoscopic Myotomy|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
214432052|NCT02489695|DRUG|Axitinib|axitinib 10mg twice a day
214514339|NCT05886465|DRUG|Bevacizumab|15mg/kg, iv.drip, Q3W
214514340|NCT05886465|PROCEDURE|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
214514341|NCT03029585|DRUG|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
214432053|NCT04257071|BEHAVIORAL|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
215114394|NCT04930523|OTHER|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
215114395|NCT03853135|DIAGNOSTIC_TEST|measurement of serum endocan|measurement of serum levels of endocan
214432054|NCT04257071|BEHAVIORAL|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
214432055|NCT05831969|DRUG|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
214432056|NCT00973986|DRUG|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
214432057|NCT01808768|DRUG|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
214432058|NCT05447975|OTHER|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
214432059|NCT01149707|DRUG|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
214432060|NCT01149707|DRUG|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
214432061|NCT01149707|DRUG|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
214432062|NCT01149707|DRUG|Placebo Enema|Placebo Enema, once-daily, intrarectally
214432063|NCT00610649|DRUG|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
214514342|NCT03029585|DRUG|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
215114396|NCT04001413|DRUG|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
215114397|NCT04001413|DRUG|Durvalumab|Durvalumab is an investigational drug in this study.
215114398|NCT06157866|OTHER|Electroacupuncture|During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. A low-amplitude, sub-sensory electrical current will be activated by the acupuncturist.
215114399|NCT06157866|BEHAVIORAL|Cognitive Training|Cognitive training with a pain specialist.
215114400|NCT06157866|BEHAVIORAL|Education Training|Education training with a pain specialist.
215114401|NCT02610686|DRUG|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
215114402|NCT03461107|OTHER|No intervention|
214432064|NCT00610649|DRUG|Placebo|Orally administered matching placebo capsules.
214432065|NCT02250430|DRUG|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
214432066|NCT02236793|DRUG|BioChaperone PDGF-BB|
214432067|NCT02236793|OTHER|Standard of Care|
214432068|NCT02582086|OTHER|BOR15001L7|Active cream with 5% 15019L0
214432069|NCT02582086|OTHER|Placebo|Placebo Cream with 0% 15019L0
214432070|NCT04252586|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
214514343|NCT03029585|DRUG|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
214432071|NCT00232180|DRUG|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
214432072|NCT01295697|DRUG|EZN-2208|Experimental
214432073|NCT04517136|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
214432074|NCT04517136|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
214432075|NCT04517136|DEVICE|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
214432076|NCT04517136|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
214432077|NCT02486835|DEVICE|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
214432078|NCT02486835|DEVICE|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
214514344|NCT03029585|DRUG|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
215114403|NCT06202495|DEVICE|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
214432079|NCT03346616|OTHER|Texting Group|See above in arm/group description
214432080|NCT03346616|OTHER|Non Texting Group|See above in arm/group description
214432081|NCT06199973|DRUG|SHR-A1811|SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
214432082|NCT06199973|DRUG|TAS-102, Regorafenib , Fruquintinib|physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
214432083|NCT04728906|DEVICE|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
214432084|NCT00731497|DEVICE|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
214432085|NCT02271789|OTHER|problematic tooth|problematic tooth
214432086|NCT00310726|OTHER|abrupt weaning at 4 months|abrupt weaning at 4 months
214432087|NCT00310726|OTHER|Continued exclusive breastfeeding|Continued exclusive breastfeeding
214432088|NCT03273777|PROCEDURE|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
214432089|NCT00386958|DRUG|Povidone-Iodine|
214432090|NCT00296361|DRUG|Tacrolimus|immunosuppression
214432091|NCT00768235|OTHER|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
214432092|NCT00194974|DRUG|methyldopa|
214432093|NCT00194974|DRUG|labetalol|
214432094|NCT00194974|DRUG|nifedipine|
214432095|NCT00194974|DRUG|clonidine|
215114404|NCT06202495|OTHER|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
215114405|NCT04973072|BEHAVIORAL|One large reward treatment|Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
215114406|NCT04973072|BEHAVIORAL|Small wins treatment|The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
215114407|NCT04945759|DEVICE|Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon|Evaluation and treatment will be done with the Cybex humac device.
215114408|NCT01478971|DRUG|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
215114409|NCT01478971|DRUG|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
215114410|NCT05940116|DRUG|HS-20117|"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"
215114411|NCT03094117|OTHER|News items with spin|Interpretation of news items with spin
215114412|NCT03094117|OTHER|News items without spin|Interpretation of news items without spin
215114413|NCT04399395|DRUG|Naltrexone/bupropion|Approved drug for obesity treatment
215114414|NCT04399395|OTHER|Lifestyle|Lifestyle
215114415|NCT05307354|OTHER|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
214432096|NCT03452189|DRUG|Vancomycin|Oral vancomycin 250mg capsules
214432097|NCT03452189|OTHER|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
214432098|NCT03390296|BIOLOGICAL|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
214432099|NCT03390296|DRUG|Avelumab|Given IV
214432100|NCT03390296|DRUG|Azacitidine|Given IV or SC
214432101|NCT03390296|DRUG|Gemtuzumab Ozogamicin|Given IV
214432102|NCT03390296|DRUG|Glasdegib|Given PO
214432103|NCT03390296|DRUG|Glasdegib Maleate|Given PO
214432104|NCT03390296|DRUG|Venetoclax|Given PO
214432105|NCT03390296|DRUG|Azacitidine|Given IV or SC
214432106|NCT06326931|DEVICE|thermal pulsation|Single, in-office bilateral treatment with Systane iLux thermal pulsation
214432107|NCT06326931|OTHER|warm compress|Twice daily, 10-minute at-home treatment with Bruder warm compress mask for 8 weeks
214432108|NCT00991497|DEVICE|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
214432109|NCT03344536|DRUG|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
214432110|NCT03344536|DRUG|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
214432111|NCT01571596|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
214432112|NCT04192305|PROCEDURE|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
214432113|NCT04192305|PROCEDURE|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
214432114|NCT00891332|DRUG|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
214432115|NCT03577223|OTHER|Whole Eggs|3 whole eggs per day for 4 weeks
214432116|NCT03577223|OTHER|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
214432117|NCT03419299|OTHER|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
214432118|NCT06009536|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
214432119|NCT01950780|DRUG|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
214432120|NCT02548806|DRUG|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
214432121|NCT02548806|DRUG|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
214432122|NCT02548806|DRUG|Catapres 100μg|Catapres tablet 100μg, single dose
214432123|NCT00257998|PROCEDURE|Mobilization|manualtherapy techniques
214432124|NCT05119764|PROCEDURE|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
214432125|NCT04010435|DEVICE|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
214432126|NCT04010435|DEVICE|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
214432127|NCT00281554|DRUG|RSD1235|IV
214432128|NCT04929067|DRUG|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
214432129|NCT03259516|DRUG|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
214432130|NCT03259516|DRUG|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
214432131|NCT03259516|DRUG|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
214432132|NCT03259516|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
214432133|NCT03259516|DRUG|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
214432134|NCT03259516|DRUG|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
214432135|NCT03259516|DRUG|Sildenafil|20 mg per os three times a day during the whole course of treatment
214432136|NCT03259516|DRUG|Melphalan|2 mg per os daily during the whole course of treatment
215114416|NCT05307354|OTHER|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
215114417|NCT04327791|DRUG|Baloxavir|administered PO once
214432137|NCT00687713|DRUG|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
214432138|NCT00687713|OTHER|Placebo|Placebo
214432139|NCT01557335|DRUG|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
214432140|NCT01557335|DRUG|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
214432141|NCT03561519|OTHER|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
214514345|NCT03029585|DRUG|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
214514346|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
214514347|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
214514348|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
215114418|NCT04327791|DRUG|Placebos|administered PO once
214432142|NCT03561519|OTHER|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
214432143|NCT04954638|OTHER|endodontic desinfection|"* outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation"
214432144|NCT03976570|BEHAVIORAL|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
214432145|NCT01873313|DRUG|Ropivacaine|
214432146|NCT03926936|DRUG|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
214432147|NCT06545565|DRUG|sodium acetate group will receive sodium acetate in the neonatal PN.|This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
214432148|NCT06545565|DRUG|sodium chloride group will receive sodium chloride in the neonatal PN.|This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
214432149|NCT06282822|OTHER|Transthoracic echocardiography|All enrolled patients underwent noninvasive transthoracic echocardiography.
214432150|NCT02767765|DRUG|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
214432151|NCT01951170|DRUG|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
214432152|NCT01318967|DRUG|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
214432153|NCT01318967|OTHER|Placebo|
214432154|NCT05594511|PROCEDURE|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
214432155|NCT05594511|PROCEDURE|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
214432156|NCT01305252|DRUG|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
214432157|NCT01305252|DRUG|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
214432158|NCT03015311|DRUG|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
214432159|NCT03015311|DRUG|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
214432160|NCT04980274|OTHER|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
214432161|NCT00700986|DRUG|AZD9056|Oral tablet, 800mg, one single administration
215114419|NCT03072264|BEHAVIORAL|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
215114420|NCT03072264|DRUG|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
215114421|NCT03072264|BEHAVIORAL|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
215114422|NCT01493401|PROCEDURE|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
215114423|NCT00584012|DRUG|Lovastatin|Given PO
214432162|NCT00700986|DRUG|Placebo|Single dose
214432163|NCT02275377|OTHER|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
214432164|NCT02275377|OTHER|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
214432165|NCT03020979|DRUG|Apatinib|Patients will take 500mg apatinib daily orally.
214432166|NCT00774904|DRUG|Losartan|Angiotensin II Type 1 Receptor Blockers
214432167|NCT03266081|DRUG|0.75% bupivacaine|topical anesthetic
214432168|NCT03450200|OTHER|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
214432169|NCT03450200|OTHER|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
214514349|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
214514350|NCT01092325|DRUG|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
215114424|NCT00584012|DRUG|Docetaxel|Given IV
215114425|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
214514351|NCT01092325|DRUG|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
215114426|NCT01525615|DRUG|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
214432170|NCT04743440|DEVICE|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
214432171|NCT05146375|BIOLOGICAL|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
214432172|NCT06033118|DRUG|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
214432173|NCT05445440|DRUG|Methotrexate|Specified dose on specified days
214514352|NCT00430586|DRUG|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
214514353|NCT00430586|DRUG|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
214514354|NCT06165497|BEHAVIORAL|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
214514355|NCT06165497|OTHER|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
214514356|NCT00430911|DRUG|Radiotherapy|
214514357|NCT02092285|DRUG|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
214514358|NCT01825785|DRUG|Romosozumab|Administered by subcutaneous injection
214514359|NCT01825785|DRUG|Placebo|Administered by subcutaneous injection
214514360|NCT04721600|DEVICE|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
214514361|NCT04759378|DIAGNOSTIC_TEST|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
214432174|NCT05445440|DRUG|Leucovorin|Specified dose on specified days
214514362|NCT04998825|DIETARY_SUPPLEMENT|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
214514363|NCT04998825|OTHER|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
214514364|NCT03733756|PROCEDURE|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
214514365|NCT03733756|PROCEDURE|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
214514366|NCT05077046|OTHER|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
214514367|NCT02006914|DIETARY_SUPPLEMENT|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
214514368|NCT01219751|DRUG|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
214514369|NCT02917434|DIETARY_SUPPLEMENT|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
215114427|NCT01525615|DRUG|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
215114428|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
215114429|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
215114430|NCT01525615|DRUG|placebo to tiotropium+olodaterol|comparator
215114431|NCT06362096|DRUG|Trastuzumab+pyrotinib+taxene|Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes
215114432|NCT04658004|DRUG|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
215114433|NCT04050618|DEVICE|fanfilcon A test lens|Silicone hydrogel contact lens
215114434|NCT04050618|DEVICE|ocufilcon D control lens|hydrogel contact lens
215114435|NCT04050618|DEVICE|etafilcon A control lens|hydrogel contact lens
215114436|NCT02722200|DRUG|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
215114437|NCT02722200|OTHER|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
214432175|NCT05445440|DRUG|BMS-986371|Specified dose on specified days
214432176|NCT05445440|DRUG|Sulfasalazine|Specified dose on specified days
214432177|NCT03298724|BEHAVIORAL|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
214432178|NCT06371170|DRUG|Rivaroxaban|Oral anticoagulation
214432179|NCT03068624|BIOLOGICAL|Aldesleukin|Given SC
214432180|NCT03068624|BIOLOGICAL|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
214432181|NCT03068624|DRUG|Cyclophosphamide|Given IV
214432182|NCT03068624|BIOLOGICAL|Ipilimumab|Given IV
214432183|NCT01647581|DEVICE|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
214432184|NCT01647581|DEVICE|NO hemoclip placement|No hemoclip placement (placebo / sham)
214432185|NCT01807481|DRUG|Mircera|Once Monthly Mircera
214432186|NCT04512482|DRUG|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
214432187|NCT04512482|OTHER|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
214432188|NCT02395744|OTHER|Paclitaxel administration using the OPC|
214432189|NCT00181311|PROCEDURE|hysterectomy|
214432190|NCT01105117|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
214432191|NCT01105117|DRUG|Flolan®|per Prescribing Information
214432192|NCT06340100|OTHER|find association between vestibular impairment , cognitive fiunction with concussin|SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
214432193|NCT02955407|OTHER|no intervention|observational case-control study
214432194|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
214432195|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
214432196|NCT00123903|DRUG|metoprolol xl|
214432197|NCT00123903|DRUG|carvedilol MR|
214432198|NCT00123903|DRUG|lisinopril|
214432199|NCT05326971|PROCEDURE|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
214432200|NCT03999034|DIAGNOSTIC_TEST|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
214432201|NCT00006017|DRUG|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
214432202|NCT00044863|BIOLOGICAL|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
214432203|NCT00797017|DRUG|fentanyl|Infection, starting with 12mcg/h (flexible dose)
214432204|NCT00797017|DRUG|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
214514370|NCT01371227|DRUG|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
214432205|NCT00797017|DRUG|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
214432206|NCT00797017|DRUG|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
214432207|NCT00797017|DRUG|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
214432208|NCT00797017|DRUG|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
215114438|NCT04404556|BEHAVIORAL|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
214432209|NCT00797017|DRUG|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
214432210|NCT03290859|PROCEDURE|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
214432211|NCT03041584|PROCEDURE|Guided placement|implant placement with use of guide
214432212|NCT03041584|PROCEDURE|Non-guided placement|conventional implant placement
214432213|NCT03041584|DEVICE|Astra Tech TX implant|
214432214|NCT02492516|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
214432215|NCT04682418|DEVICE|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
214432216|NCT00007163|DRUG|J695|
214432217|NCT03002428|DRUG|Teriparatide (PF708)|Subcutaneous injection
214432218|NCT03002428|DRUG|Teriparatide (Forteo)|Subcutaneous injection
214432219|NCT00774397|DRUG|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
214432220|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
214432221|NCT00774397|DRUG|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
214514371|NCT02382185|OTHER|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
214514372|NCT02382185|DRUG|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
214514373|NCT02382185|DEVICE|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
214432222|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
214432223|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
214432224|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
214432225|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
214432226|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
214432227|NCT00774397|DRUG|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
214432228|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
214432229|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
214432230|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
214432231|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
214432232|NCT00774397|DRUG|Placebo|Placebo
214432233|NCT04884295|DRUG|XVR011|Single dose of XVR011 via intravenous (IV) infusion
214432234|NCT05277441|DIAGNOSTIC_TEST|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
214432235|NCT02675829|DRUG|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
214432236|NCT02944760|OTHER|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
214432237|NCT02186743|OTHER|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
214432238|NCT04971070|OTHER|Observation and follow-up|Observation and follow-up study
214432239|NCT02010944|DRUG|solifenacin succinate|oral
214432240|NCT02010944|DRUG|mirabegron|oral
214432241|NCT02010944|DRUG|mirabegron/solifenacin succinate|oral
214432242|NCT02538458|DRUG|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
214432243|NCT02538458|DRUG|3 % hypertonic saline up to 24H|"* Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
214432244|NCT00225797|DRUG|Oxymorphone Extended Release|
214432245|NCT02355236|DRUG|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
214432246|NCT02355236|DRUG|Celecoxib 200mg|Capsule, o.d.
214432247|NCT02355236|DRUG|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
214432248|NCT02355236|DRUG|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
214432249|NCT02810236|PROCEDURE|Ultrasound|Ultrasound will be performed.
214432250|NCT02810236|BEHAVIORAL|Discussion|Radiologist will discuss with the patient the findings on mammogram.
214432251|NCT02259049|DIETARY_SUPPLEMENT|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
214432252|NCT02259049|DIETARY_SUPPLEMENT|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
214432253|NCT00077675|DRUG|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
214432254|NCT00077675|DRUG|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
214432255|NCT01863485|DRUG|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
215114439|NCT04404556|BEHAVIORAL|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
214432256|NCT03787966|OTHER|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
214432257|NCT03787966|OTHER|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
214432258|NCT05965141|DRUG|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
214432259|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
214432260|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
214432261|NCT03296540|DRUG|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
214432262|NCT03296540|DRUG|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
214432263|NCT00137722|BEHAVIORAL|Education of providers and their staff|
214432264|NCT00137722|BEHAVIORAL|Case management|
214432265|NCT00137722|BEHAVIORAL|Payment for desired behaviors|
215114440|NCT06555952|DIETARY_SUPPLEMENT|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
215114441|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
215114442|NCT00006116|DRUG|cisplatin|
215114443|NCT00006116|DRUG|gemcitabine hydrochloride|
215114444|NCT02334293|DRUG|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
215114445|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
215114446|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
214432266|NCT03311893|PROCEDURE|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
214432267|NCT00079846|DRUG|Implitapide|
214432268|NCT04788212|BEHAVIORAL|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
214432269|NCT03556449|DIAGNOSTIC_TEST|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
214432270|NCT05591872|DRUG|LD+I+TRB|Same as in the arm description
214432271|NCT03036176|BEHAVIORAL|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
214514374|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
214432272|NCT03036176|OTHER|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
214432273|NCT00634075|DRUG|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
214432274|NCT00634075|DRUG|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
214432275|NCT00809068|DRUG|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
215114447|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
214432276|NCT00809068|DRUG|tibolone|tibolone 2.5 mg daily 23 weeks
215114448|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
214432277|NCT00397475|DRUG|Colecalciferol|
214432278|NCT02040831|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
215114449|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
215114450|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
214432279|NCT02040831|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
214432280|NCT00687856|PROCEDURE|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
214432281|NCT00004149|DRUG|arsenic trioxide|
214432282|NCT05546710|DEVICE|miraDry treatment|The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
214432283|NCT01311622|DRUG|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
214432284|NCT01311622|DRUG|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
214432285|NCT01644032|OTHER|Teleconsultation|Teleconsultation between paramedics and an EMS physician
214432286|NCT05985590|DRUG|BMS-986278|Specified dose on specified days
214432287|NCT05985590|DRUG|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
214432288|NCT04530149|DRUG|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
214432289|NCT04530149|DRUG|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
214514375|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
215114451|NCT04184830|DEVICE|non-invasive brain stimulation|
215114452|NCT05031793|OTHER|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
215114453|NCT05031793|OTHER|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
215114454|NCT02219854|PROCEDURE|Laparoscopic gastrectomy|
215114455|NCT02219854|PROCEDURE|Open gastrectomy|
215114456|NCT06834971|DRUG|Colistimethate sodium (CMS)|CMS (colistimethate sodium, 75mg, solubilized in 4 mL 0.9% saline), twice daily. Nebulization will be performed using a vibrating mesh nebulizer (Aeroneb solo, Aerogen, Galway, Ireland) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry for three consecutive days of mechanical ventilation. To ensure the experiment is conducted under blind conditions, the Nebulizer will be covered by stickers. A filter will be placed on the expiratory limb to protect the ventilator.
214514376|NCT04999800|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
215114457|NCT00855959|DRUG|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
214514377|NCT04999800|DRUG|Anlotinib|Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
214432290|NCT04530149|DRUG|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
214514378|NCT04254965|OTHER|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
214514379|NCT04254965|DEVICE|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
214514380|NCT04526171|BEHAVIORAL|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
214514381|NCT04972318|PROCEDURE|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
214514382|NCT04972318|PROCEDURE|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
214514383|NCT03476954|OTHER|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
214514384|NCT01094600|DRUG|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
214514385|NCT02440919|OTHER|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
214514386|NCT02440919|OTHER|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
214514387|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
214514388|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
214514389|NCT03145142|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
215114458|NCT00855959|DRUG|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
215114459|NCT03685227|OTHER|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
215114460|NCT03214575|DEVICE|Conventional method|
215114461|NCT03214575|PROCEDURE|GPS Method|
215114462|NCT02917785|DEVICE|Karman curettage|
215114463|NCT03168828|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
215114464|NCT02451943|DRUG|Olaratumab|Administered IV
215114465|NCT02451943|DRUG|Doxorubicin|Administered IV
214432291|NCT00829036|DEVICE|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
214432292|NCT02381470|DRUG|Faropenem|Faropenem 600mg
214432293|NCT02381470|DRUG|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
214432294|NCT02381470|DRUG|Cefadroxil|Cefadroxil 1g
214432295|NCT02381470|DRUG|Rifampicin|Rifampicin 10mg/kg
214432296|NCT00244673|BIOLOGICAL|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
214432297|NCT05900505|OTHER|Social Navigator|The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
214432298|NCT02809794|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
214432299|NCT01514149|DRUG|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
214432300|NCT01514149|DRUG|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
214432301|NCT04653506|DRUG|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
214432302|NCT04653506|DRUG|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
214432303|NCT04977700|BEHAVIORAL|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
214432304|NCT04962750|DEVICE|Low level laser therapy|Low level laser therapy from suitable machine
214432305|NCT04962750|OTHER|Sham device|The device wasn't working
215114466|NCT02451943|DRUG|Placebo|Administered IV
215114467|NCT03845127|DEVICE|Revivent TC Ventricular Enhancement System|Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
215114468|NCT03845127|DRUG|GDMT|Guideline Directed Medical Therapy
215114469|NCT00368641|DRUG|Extraneal|Periotneal Dialysis
214432306|NCT01057459|OTHER|laboratory biomarker analysis|Correlative studies
214432307|NCT00391898|DRUG|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
214432308|NCT00391898|DRUG|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
214432309|NCT05561452|OTHER|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
214432310|NCT05561452|OTHER|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
214432311|NCT05561452|OTHER|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
214432312|NCT00143234|DRUG|Amlodipine/atorvastatin single pill|
214432313|NCT00749749|DRUG|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
214432314|NCT00749749|DRUG|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
214432315|NCT04834219|PROCEDURE|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
214432316|NCT04834219|PROCEDURE|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
214432317|NCT01962090|OTHER|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
214432318|NCT01962090|OTHER|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
214432319|NCT04045886|BEHAVIORAL|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
214432320|NCT04194749|OTHER|Digital Media Based Physical Therapy|This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
214432321|NCT04194749|OTHER|Traditional Physical Therapy|This intervention is a 12 week therapist supervised clinic-based therapy protocol.
214432322|NCT00329251|BIOLOGICAL|Hepatitis A|
214432323|NCT00329251|BIOLOGICAL|Hepatitis B|
214432324|NCT00329251|BIOLOGICAL|Influenza|
214432325|NCT00329251|BIOLOGICAL|Pneumococcal|
214432326|NCT00329251|BIOLOGICAL|Tetanus-diphteria|
214432327|NCT00329251|BIOLOGICAL|Varicella|
214432328|NCT00329251|BIOLOGICAL|Measles-Mumps-Rubella|
214432329|NCT02949583|DRUG|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
214432330|NCT02949583|DRUG|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
214432331|NCT03931265|DIAGNOSTIC_TEST|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
214432332|NCT03953222|DEVICE|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
214432333|NCT05173324|BIOLOGICAL|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
214514390|NCT03145142|PROCEDURE|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
214432334|NCT05173324|DIAGNOSTIC_TEST|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
214432335|NCT05173324|BIOLOGICAL|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
214432336|NCT00293293|OTHER|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
214514391|NCT02857686|PROCEDURE|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
214514392|NCT02857686|PROCEDURE|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
214514393|NCT00278395|DRUG|Vorinostat|Given orally
214514394|NCT03518047|DRUG|risankizumab|rizankizumab subcutaneous (SC) infusion
214514395|NCT03518047|DRUG|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
214514396|NCT02494076|DRUG|EzPAP|
214514397|NCT02494076|OTHER|Standard Care|
214514398|NCT01961934|DRUG|Sodium Acetate C11 PET/CT Imaging|
215114470|NCT06322199|BEHAVIORAL|ASSIP (Attempted Suicide Short Intervention Program) flex|"ASSIP is a specific therapy for patients after a suicide attempt. The brief therapy ASSIP consists of 3-4 sessions of approximately 50 min. each. ASSIP flex delivers ASSIP in the patient's personal environment as an outreach home treatment. The structure of the ASSIP is the same as in the regular ASSIP, but the program is delivered in the patient's environment.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her personal story, which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
215114471|NCT03148327|DRUG|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
215114472|NCT03148327|RADIATION|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
215114473|NCT05294913|BEHAVIORAL|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
215114474|NCT05294913|BEHAVIORAL|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
214432337|NCT00293293|OTHER|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
214432338|NCT00293293|OTHER|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
214432339|NCT00293293|DRUG|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
214432340|NCT03221478|OTHER|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
214432341|NCT03221478|OTHER|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
214432342|NCT03221478|OTHER|Kinesio Taping with tension|Kinesio Taping with tension
214432343|NCT03873337|BEHAVIORAL|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
214432344|NCT03873337|DRUG|Nicotine patch|All participants will receive 10 weeks of nicotine patch
214514399|NCT04135183|PROCEDURE|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
214514400|NCT06390176|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG powder|Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
214514401|NCT06390176|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
214514402|NCT06390176|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
214514403|NCT03096496|OTHER|QoL questionnaires|Quality of life questionnaires
214432345|NCT05384210|DRUG|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
214432346|NCT05384210|DRUG|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
214432347|NCT05384210|DRUG|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
214514404|NCT04389684|OTHER|Psycho-Social Questionnaire|Patients, after enrollmenet in the study, receive a paper questionnaire during the month following COVID19 related confinement and all the material to send it back to the institution. They receive the same questionnaire 3 months later with all the material to send it back to the institution. The intervention is the same for all patients wether their treatment was modified or not.
214514405|NCT05530083|BEHAVIORAL|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
214514406|NCT05530083|BEHAVIORAL|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
215114475|NCT04668885|DRUG|CPX-351|"Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
215114476|NCT00000424|PROCEDURE|Tidal lavage vs. sham lavage of the knee|
215114477|NCT06244667|PROCEDURE|facet median block with prilocain|facet median block with prilocain
215114478|NCT06244667|PROCEDURE|facet median block with lidocaine|facet median block with lidocaine
214432348|NCT05434624|DRUG|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
214432349|NCT05434624|DRUG|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
214432350|NCT06383117|DIETARY_SUPPLEMENT|Calcium carbonate|2 capsules containing 600 mg of calcium carbonate each
214432351|NCT06383117|DIETARY_SUPPLEMENT|Placebo Control|2 capsules containing methylcellulose
214432352|NCT03705442|DIETARY_SUPPLEMENT|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
214432353|NCT03705442|DRUG|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
214432354|NCT03419442|DRUG|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
214432355|NCT03419442|DRUG|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
214432356|NCT03419442|DRUG|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
214432357|NCT03813498|BEHAVIORAL|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
214432358|NCT03813498|BEHAVIORAL|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
214432359|NCT00851669|BEHAVIORAL|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
214432360|NCT00851669|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
214432361|NCT01232712|BIOLOGICAL|ImMucin, hGM-CSF|"* Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
214514407|NCT00551187|BIOLOGICAL|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
214514408|NCT00551187|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
214514409|NCT00551187|BIOLOGICAL|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
214514410|NCT01588847|PROCEDURE|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
214514411|NCT01588847|PROCEDURE|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
214514412|NCT03740737|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
215114479|NCT02420704|PROCEDURE|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
215114480|NCT01793766|DEVICE|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
215114481|NCT01793766|DEVICE|Sham modulation|
215114482|NCT05813457|OTHER|PRESTO Early Identification Program|"The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
215114483|NCT03633110|BIOLOGICAL|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
215114484|NCT03633110|DRUG|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
214514413|NCT03740737|OTHER|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
214514414|NCT02375243|DRUG|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
214514415|NCT05671211|OTHER|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
214514416|NCT05671211|OTHER|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
214514417|NCT04929600|DRUG|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
214514418|NCT04929600|DRUG|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
214514419|NCT05217758|DRUG|Mifepristone|1200 mg/day, once daily, 7 days
215114485|NCT03633110|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
214514420|NCT05217758|DRUG|Placebo|Placebo, once daily, 7 days
214514421|NCT06526442|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.
214514422|NCT00947895|DRUG|Methylprednisolone|IV 1000 mg daily for 3 days
215114486|NCT02029911|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
215114487|NCT02857608|DRUG|Lymphoseek|
214514423|NCT00947895|DRUG|ACTH|IM ACTH 80 mg/day for 5 days.
214514424|NCT00947895|OTHER|IV placebo|IV placebo (saline) daily for 3 days.
214514425|NCT00947895|OTHER|IM placebo|IM placebo (saline) daily for 5 days.
214514426|NCT02243449|PROCEDURE|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
215114488|NCT03785704|DRUG|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
215114489|NCT00483470|BIOLOGICAL|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
215114490|NCT00483470|BIOLOGICAL|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
215114491|NCT03373149|DRUG|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
214432362|NCT02988817|BIOLOGICAL|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
214432363|NCT04597658|BEHAVIORAL|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
214432364|NCT04597658|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
214432365|NCT05369169|BEHAVIORAL|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
214432366|NCT05369169|BEHAVIORAL|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
214432367|NCT05187975|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
214432368|NCT02634970|DRUG|Ranibizumab|0.5 mg, intravitreal injection
214432369|NCT05881317|DEVICE|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
214432370|NCT01206504|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
214432371|NCT00869011|OTHER|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
214432372|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis|Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
214432373|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis and acute kidney injury|Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
214514427|NCT02243449|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
214514428|NCT00759798|DRUG|Fludarabine|25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
214514429|NCT00759798|DRUG|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
214514430|NCT00759798|DRUG|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
214514431|NCT04223323|DIETARY_SUPPLEMENT|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
214514432|NCT04223323|DIETARY_SUPPLEMENT|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
214514433|NCT06268782|BEHAVIORAL|Rehabilitate your core|The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
214514434|NCT02932280|DRUG|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
214514435|NCT00849446|DEVICE|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
214514436|NCT02148120|DRUG|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
214514437|NCT02148120|DRUG|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
214514438|NCT02148120|DRUG|Placebo|
215114492|NCT03373149|DRUG|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
215114493|NCT00825188|DRUG|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
215114494|NCT00825188|DRUG|eplerenone|Eplerenone 25-50mg daily x 8 weeks
215114495|NCT00825188|DRUG|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
215114496|NCT00825188|DRUG|amlodipine|amlodipine 5-10mg daily for 8 weeks
215114497|NCT05065359|DRUG|Rodatristat Ethyl 300 mg BID|Tablets, oral, 300 mg, BID 14 days
215114498|NCT05065359|DRUG|Rodatristat Ethyl 600 mg BID|Tablets, oral, 600 mg, BID 14 days
214432374|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine miRNA and biochemical parameters|Laboratory examination will be performed to determine miRNA and biochemical parameters.
214432375|NCT01336946|BEHAVIORAL|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
214432376|NCT01336946|BEHAVIORAL|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
214514439|NCT01307306|DRUG|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
214514440|NCT01307306|DRUG|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
214514441|NCT06001515|DEVICE|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
214514442|NCT06001515|DEVICE|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
214514443|NCT05601362|DEVICE|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
214514444|NCT05601362|DEVICE|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
215114499|NCT05065359|DRUG|Placebo|Tablets, oral, 0 mg, BID for 14 days
215114500|NCT05155813|DEVICE|WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.
214514445|NCT04475406|OTHER|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
215114501|NCT02379169|DIETARY_SUPPLEMENT|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
214432377|NCT04967742|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
214432378|NCT06383793|PROCEDURE|overlap|Π
214432379|NCT01248260|DIETARY_SUPPLEMENT|Folic Acid|4mg of higher strength folic acid once a day until delivery
214432380|NCT01937507|DRUG|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
214432381|NCT05282472|DIAGNOSTIC_TEST|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
214432382|NCT05282472|DIAGNOSTIC_TEST|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
214432383|NCT05193695|OTHER|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
215114502|NCT02379169|DIETARY_SUPPLEMENT|Placebo|Triglycerides of medium chain fatty acids
214432384|NCT00721565|BEHAVIORAL|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
214432385|NCT04238793|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
214432386|NCT04238793|OTHER|Placebo|Normal Saline (0.9%) administered by transforaminal epidural injection
214432387|NCT04478851|BEHAVIORAL|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
214432388|NCT03430258|DEVICE|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
214432389|NCT03430258|DEVICE|Conventional oxygen therapy|Conventional oxygen therapy
215114503|NCT00040170|BIOLOGICAL|MVA-MUC1-IL2|
214432390|NCT05199142|DRUG|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
214514446|NCT04475406|OTHER|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
214692557|NCT06519552|GENETIC|JWK008 Single intravenous infusion administration|"Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant."
214692558|NCT00267332|DRUG|Modafinil|
214692559|NCT03265509|DIETARY_SUPPLEMENT|glutamine supplementation|30 g/day glutamine supplementation for three months
215114504|NCT00381758|DRUG|Methylphenidate Extended Release Capsules|
215114505|NCT06499493|OTHER|Myofascial induction in gastrocnemius muscle|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
215114506|NCT03113994|DRUG|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
215114507|NCT03113994|DRUG|Placebo Oral Tablet|Placebo, daily for 12 months
215114508|NCT03113994|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg CoQ10, daily for 12 months
215114509|NCT03113994|DIETARY_SUPPLEMENT|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
215114510|NCT03113994|DIETARY_SUPPLEMENT|Vitamin D|2000IU Vitamin D, daily for 12 months
215114511|NCT03594682|OTHER|Intervention/treatment|"experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd"
215114512|NCT03787121|PROCEDURE|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
215114513|NCT05930652|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
215114514|NCT02802839|DEVICE|Virtual Reality|
215114515|NCT06337695|BIOLOGICAL|Vedolizumab|300 mg IV at weeks 0, 3, 6, 14, and 22
214432391|NCT05199142|DRUG|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
214432392|NCT02344641|DRUG|Exenatide|
214514447|NCT04475406|OTHER|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
214692560|NCT03265509|DIETARY_SUPPLEMENT|fantomalt supplementation|30 g/day fantomalt supplementation for three months
214432393|NCT00757133|PROCEDURE|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
214432394|NCT00757133|PROCEDURE|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
214432395|NCT00946842|DRUG|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
214432396|NCT00946842|DRUG|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
214432397|NCT00946842|DRUG|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
214432398|NCT00946842|DRUG|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
214432399|NCT00946842|DRUG|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
214432400|NCT00946842|DRUG|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
214432401|NCT04530747|DRUG|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
214514448|NCT00433706|PROCEDURE|Control position by 3DOBI before the fraction|
214514449|NCT00433706|PROCEDURE|Standard imaging|
214514450|NCT00082667|DRUG|gefitinib|
214514451|NCT00082667|PROCEDURE|Surgery|
214514452|NCT00409903|DRUG|Eprosartan|
214514453|NCT01286311|BEHAVIORAL|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
214514454|NCT00265902|PROCEDURE|diagnostic imaging|
214514455|NCT05397509|OTHER|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
214514456|NCT05397509|OTHER|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
214514457|NCT03034863|BEHAVIORAL|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
214692561|NCT00129805|DRUG|MCI-9042|
215114516|NCT06337695|BIOLOGICAL|Placebo|300 mg IV at weeks 0, 3, 6, 14, and 22
215114517|NCT00226057|DRUG|Raptiva|Open Label
215114518|NCT00763386|DEVICE|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
215114519|NCT00763386|DEVICE|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
214692562|NCT00129805|DRUG|Aspirin|
214692563|NCT01947244|BEHAVIORAL|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
214692564|NCT01947244|BEHAVIORAL|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
214692565|NCT03496363|DIAGNOSTIC_TEST|TSH , T4|Thyroid stimulating hormone
214692566|NCT04408859|DRUG|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
214692567|NCT00066625|DRUG|oxaliplatin|Given IV
214692568|NCT00066625|DRUG|bortezomib|Given IV
214692569|NCT00066625|OTHER|laboratory biomarker analysis|Correlative studies
215114520|NCT00555880|DRUG|Midodrine hydrochloride|one dose, 10-30mg, given orally
215114521|NCT00555880|DRUG|Placebo|Placebo
214432402|NCT04530747|DRUG|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
215114522|NCT00890747|DRUG|sunitinib malate|Given PO
214432403|NCT04792905|DEVICE|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
214432404|NCT00940524|DRUG|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
214432405|NCT00078624|OTHER|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
214432406|NCT00078624|OTHER|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
214432407|NCT03292913|BEHAVIORAL|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
214432408|NCT03292913|BEHAVIORAL|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
214432409|NCT04460313|OTHER|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
214432410|NCT04460313|OTHER|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
214432411|NCT02219724|DRUG|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
214432412|NCT00181740|DRUG|atomoxetine (Strattera)|
214432413|NCT01831700|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
214432414|NCT01831700|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
214432415|NCT06051955|OTHER|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
214432416|NCT01902784|BEHAVIORAL|Storytelling Interview|
215114523|NCT00890747|OTHER|pharmacological study|Correlative studies
215114524|NCT00890747|OTHER|laboratory biomarker analysis|Correlative studies
215114525|NCT03623763|DIAGNOSTIC_TEST|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
214432417|NCT06148831|DEVICE|Infant Carrier|"The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat)."
214432418|NCT03950622|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
214432419|NCT03950622|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
214432420|NCT02772471|DEVICE|HS-1000|
214432421|NCT00110864|DRUG|PN2034|
214432422|NCT00110864|DRUG|Insulin|
214432423|NCT02200094|DRUG|Low dose of Telmisartan, once daily|
214432424|NCT02200094|DRUG|High dose of Telmisartan, once daily|
214432425|NCT01001936|DRUG|SKI-606|
214432426|NCT03817476|DRUG|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
214432427|NCT03817476|DRUG|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
214432428|NCT03817476|DRUG|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
215114526|NCT04258826|DRUG|LY3154207|LY3154207 administered orally.
214432429|NCT02479217|DRUG|Docetaxel|
214432430|NCT02479217|DRUG|Xeloda|
214432431|NCT04169698|DRUG|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
214432432|NCT04169698|DRUG|Alendronate 70Mg Tab|Bisphosphonates
214432433|NCT03752151|DEVICE|MARVEL 2 Algorithm Monitor Mode then Adaptive Mode|Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
214432434|NCT00529516|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
214432435|NCT00529516|BIOLOGICAL|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
215114527|NCT04258826|DRUG|Placebo|Placebo administered orally.
215114528|NCT04870502|DRUG|Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG|In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
215114529|NCT01290757|DRUG|Dabigatran etexilate|150 mg Capsugel (T)
215114530|NCT01290757|DRUG|Dabigatran etexilate|150 mg Qualicaps (R)
215114531|NCT02931032|PROCEDURE|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
214432436|NCT02850744|DRUG|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
214432437|NCT02304055|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
214432438|NCT02304055|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
214432439|NCT01869543|OTHER|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
214432440|NCT01869543|OTHER|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
214432441|NCT00548418|DRUG|Topotecan|
214432442|NCT00548418|DRUG|Cisplatin|
214432443|NCT00548418|DRUG|Bevacizumab|
214432444|NCT03195608|DEVICE|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
214432445|NCT03195608|BEHAVIORAL|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
214432446|NCT04968756|DEVICE|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
214432447|NCT01935544|DEVICE|Botulinum toxin injection|
214432448|NCT02639910|BIOLOGICAL|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
214432449|NCT02639910|DRUG|Idelalisib|idelalisib dose: 150 mg twice daily orally
214432450|NCT02639910|DRUG|Venetoclax|venetoclax dose: 400 mg once daily orally
214514458|NCT03034863|BEHAVIORAL|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
214514459|NCT05676372|PROCEDURE|CRC+HIPEC|Sample prelevation of cytoreductive surgery
214514460|NCT01472796|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
214514461|NCT01472796|DRUG|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
214514462|NCT01819857|DRUG|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
214514463|NCT01819857|DRUG|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
215114532|NCT01751009|DIETARY_SUPPLEMENT|Vitamin A supplements|Sprinkles with Vitamin A
214432451|NCT04805216|PROCEDURE|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible."
214432452|NCT00664690|DRUG|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
214432453|NCT00664690|DRUG|placebo|placebo given preop and BID postop
214432454|NCT00788034|DRUG|Lu AA21004|5 or 10 mg/day
214432455|NCT00788034|DRUG|Placebo|Once daily
214432456|NCT00843687|DRUG|Risperidone long-acting injectable|
214432457|NCT03469596|DIAGNOSTIC_TEST|MRI sequence|several MRI sequence before and after contrast product injection.
214432458|NCT05519670|DRUG|Niraparib Oral Product|Niraparib + capecitabine treatment
214432459|NCT00296868|DRUG|ascorbic acid (vitamin C) versus placebo|
214432460|NCT00077493|DRUG|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
214432461|NCT00077493|PROCEDURE|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
214432462|NCT00077493|PROCEDURE|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
214432463|NCT00077493|PROCEDURE|monoclonal antibody therapy|administered intravenously over 30 minutes.
214432464|NCT01319617|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
214514464|NCT01819857|DRUG|Zofran 8 mg|intravenous administration of 8 mg ondansetron
214692570|NCT00066625|OTHER|pharmacological study|Correlative studies
214432465|NCT05877807|DRUG|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
214432466|NCT05877807|OTHER|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
214432467|NCT05101954|PROCEDURE|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
214432468|NCT05101954|PROCEDURE|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
214432469|NCT03697707|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
214432470|NCT01592448|BEHAVIORAL|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
214432471|NCT05955989|OTHER|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
214432472|NCT02337036|OTHER|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
214432473|NCT02337036|OTHER|Pharmacogenetic|Pharmacogenetic study
214432474|NCT02337036|DRUG|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
214432475|NCT03991754|PROCEDURE|transcatheter aortic valve implantation|transcatheter aortic valve implantation
214432476|NCT03918967|DRUG|CT-G11|oral tablet of CT-G11 Experimental Drug
214432477|NCT03918967|DRUG|CT-G20|oral tablet of CT-G20 Experimental Drug
214432478|NCT03918967|DRUG|CT-G11 Placebo|oral tablet of Placebo
214432479|NCT03918967|DRUG|CT-G20 Placebo|oral tablet of Placebo
214432480|NCT04768712|BEHAVIORAL|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
214432481|NCT01717820|DIETARY_SUPPLEMENT|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
214432482|NCT06451016|DIETARY_SUPPLEMENT|Vitamin D supplements|70 mcg/day (equal to 2800 IU) of cholecalciferol
214432483|NCT06451016|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
214432484|NCT00137995|DRUG|Rituximab|375 mg/m² D-2/D1
214432485|NCT00137995|DRUG|Etoposide|100 mg/m² D1-D2-D3
214432486|NCT00137995|DRUG|Carboplatine|max 800mg D2
214432487|NCT00137995|DRUG|Ifosfamide + Mesna|5 g/m² from D2 to D13
214432488|NCT00137995|DRUG|Cisplatine|100 mg/m² from D1 to D13
214432489|NCT00137995|DRUG|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
214432490|NCT00137995|DRUG|Dexamethasone|40 mg From D1 to D4
214432491|NCT00137995|PROCEDURE|Autologous Stem Cell Transplantation|
214432492|NCT00137995|DRUG|BCNU|300mg/m² on D-6
214432493|NCT00137995|DRUG|Etoposide|200 mg/m² from D-6 to D-3
214432494|NCT00137995|DRUG|Cytarabine|100 mg/m² from D-6 to D-3
214432495|NCT00137995|DRUG|Melphalan|140 mg/m² on D-2
214432496|NCT03437369|DRUG|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
214432497|NCT03437369|OTHER|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
214432498|NCT05412199|DEVICE|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
214432499|NCT05412199|DEVICE|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
214432500|NCT05412199|OTHER|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
214432501|NCT02413866|BEHAVIORAL|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
214432502|NCT02413866|BEHAVIORAL|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
214432503|NCT00939510|BIOLOGICAL|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
214432504|NCT00939510|DRUG|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
214432505|NCT00939510|OTHER|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
214432506|NCT05834270|DRUG|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
214432507|NCT05834270|DRUG|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
215114533|NCT01751009|DIETARY_SUPPLEMENT|Sprinkles without Vitamin A|Active comparator
214432508|NCT04217850|OTHER|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
214432509|NCT04217850|OTHER|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
214432510|NCT04133337|DRUG|Apatinib|Apatinib Mesylate Tablets
214432511|NCT04133337|DRUG|SHR-1210|Camrelizumab for Injection
214432512|NCT01402830|OTHER|Visual analogue scales (EVAs)|This scale measures the pain intensity.
214432513|NCT04086966|DRUG|[68Ga]PSMA-PET/MRI or PET/CT|\[68Ga\]PSMA-PET/MRI or PET/CT
214432514|NCT03110965|BEHAVIORAL|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
214432515|NCT01612169|BEHAVIORAL|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
214432516|NCT01612169|BEHAVIORAL|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
214432517|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
214432518|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
214432519|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
214432520|NCT03925558|DIETARY_SUPPLEMENT|Probiotics|
214432521|NCT03925558|DIETARY_SUPPLEMENT|Placebo|
214432522|NCT03487172|DEVICE|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
214432523|NCT03487172|DEVICE|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
214432524|NCT03278587|OTHER|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
214432525|NCT03278587|OTHER|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
214432526|NCT03278587|OTHER|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
214432527|NCT05475041|PROCEDURE|Major liver resection|Major liver resection (3 or more contiguous segments)
214432528|NCT05475041|PROCEDURE|Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
214432529|NCT01558986|PROCEDURE|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
214514465|NCT01324648|BEHAVIORAL|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
214514466|NCT01324648|BEHAVIORAL|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
214514467|NCT01324648|OTHER|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
214432530|NCT01558986|PROCEDURE|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
214432531|NCT04731948|DIETARY_SUPPLEMENT|Folic Acid|400µg Folic Acid per day for 16 weeks
214432532|NCT04731948|DIETARY_SUPPLEMENT|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
214432533|NCT04731948|DIETARY_SUPPLEMENT|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
214432534|NCT04731948|DIETARY_SUPPLEMENT|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
214432535|NCT04431297|OTHER|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
215114534|NCT05318703|BEHAVIORAL|tai ji quan|cognitively enhanced tai ji quan exercise
215114535|NCT05318703|BEHAVIORAL|Stretching|Stretching exercise
214432536|NCT04589520|BEHAVIORAL|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
214432537|NCT04410458|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
215114536|NCT00887549|DRUG|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
215114537|NCT00887549|DRUG|cisplatin|Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
214432538|NCT06258824|DIAGNOSTIC_TEST|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
214432539|NCT00263952|BIOLOGICAL|bee venom|
214432540|NCT03300492|OTHER|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."
214432541|NCT00000834|DRUG|Lamivudine|
214432542|NCT00000834|DRUG|Methotrexate|
214432543|NCT00000834|DRUG|Zidovudine|
214432544|NCT00799552|DRUG|RX-10045|RX-10045 eye drop
214432545|NCT00799552|DRUG|Placebo|Placebo eye drop
214432546|NCT04247074|BIOLOGICAL|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
214432547|NCT04247074|BIOLOGICAL|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
214432548|NCT03855397|OTHER|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
214432549|NCT03855397|OTHER|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
214432550|NCT03855397|OTHER|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
214432551|NCT06070337|DEVICE|H-Guard|A novel Haemodialyser primer used for one treatment only
214432552|NCT04459897|OTHER|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
214432553|NCT00621569|BEHAVIORAL|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
214432554|NCT00621569|BEHAVIORAL|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
214432555|NCT02059382|BEHAVIORAL|ChiRunning training|
214432556|NCT02059382|BEHAVIORAL|unblinded accelerometer|
214432557|NCT02059382|BEHAVIORAL|participation in online social network|
214432558|NCT02059382|BEHAVIORAL|participation in study website|
214432559|NCT02059382|BEHAVIORAL|Technology support for behavior change|
215114538|NCT03348280|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
214432560|NCT01895699|OTHER|Contrast agent|
214432561|NCT00006517|DEVICE|bright light box|10,000 lux bright light therapy
214432562|NCT00006517|DEVICE|dawn simulator|gradual rise in bedroom illumination prior to wake-up
214432563|NCT00006517|DEVICE|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
214432564|NCT00006517|DEVICE|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
214432565|NCT00006517|DEVICE|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
214432566|NCT01855334|DRUG|Spironolactone|
214432567|NCT01855334|DIETARY_SUPPLEMENT|L-arginine|
214432568|NCT01855334|DRUG|Placebo|
214432569|NCT05157724|PROCEDURE|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
214432570|NCT02725294|OTHER|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
214432571|NCT02829931|RADIATION|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
214432572|NCT02829931|DRUG|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
214432573|NCT02829931|DRUG|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
214432574|NCT02829931|DRUG|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
214432575|NCT02444416|PROCEDURE|blood sample|
214432576|NCT03569982|OTHER|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
214514468|NCT00000532|BEHAVIORAL|diet, fat-restricted|
215114539|NCT00622375|DRUG|mesalamine|encapsulated mesalamine granules
215114540|NCT05599737|RADIATION|Integrated boost|Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
214432577|NCT06243744|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
214514469|NCT00446576|DRUG|Epoetin Alfa|
214514470|NCT02226237|PROCEDURE|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
214514471|NCT02226237|PROCEDURE|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
214514472|NCT05214521|DEVICE|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
214432578|NCT04592250|OTHER|Survey Administration|Complete survey
214432579|NCT06647784|OTHER|pulmonary aeration in supine and ventral decubitus|The addition of repeated periods of 30 minutes of lateralization of 30° amplitude in dorsal decubitus and in ventral decubitus in patients with moderate to severe ARDS. Included patients will benefit from sessions of lateral decubitus for 30 minutes on each side (with an inclination of 30°) with alternation right/left (total one hour). During this period, the upper part of the bed will be inclined by 30°. Patients will then be positioned in strict prone position for a period of 6 hours after which, the same pattern of alternating lateral decubitus will be applied for 12 hours while the patient is still in the prone position. After reversal in supine position, an observation period of 1 hour will be respected before carrying out the last measurements. The total duration of the intervention will be 20 hours.
214432580|NCT02943590|DRUG|Placebo|A pill taken once a day
214432581|NCT02943590|DRUG|Atorvastatin|A pill taken once a day
214432582|NCT05733364|DIETARY_SUPPLEMENT|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
214432583|NCT05733364|OTHER|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
214432584|NCT03316482|DRUG|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
214432585|NCT02034968|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
214432586|NCT02685189|OTHER|Previous exposure to stannsoporfin|No intervention in this protocol
214432587|NCT04213053|PROCEDURE|strabismus surgery|Lees screen before and after concomitant strabismus surgery
214432588|NCT05316246|DRUG|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
214514473|NCT06401590|DIAGNOSTIC_TEST|FROZEN SENTINEL LYMPH NODE BIOPSY|FROZEN SENTINEL LYMPH NODE BIOPSY
214514474|NCT00838448|BEHAVIORAL|Exercise|Exercise performed on a treadmill for 20-30 minutes
214432589|NCT00156741|DEVICE|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
214432590|NCT00156741|PROCEDURE|Required pacemaker setting|
214432591|NCT03049969|DEVICE|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
214432592|NCT04567043|BEHAVIORAL|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
214432593|NCT04567043|BEHAVIORAL|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
214514475|NCT01632085|DEVICE|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
214514476|NCT06378281|OTHER|Modified teach-to-goal informed consent|Enhanced procedure to improve informed consent in vulnerable populations.
214514477|NCT04818476|PROCEDURE|diagnostic endoscopic resection|diagnostic endoscopic resection
214514478|NCT01572896|BEHAVIORAL|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
214514479|NCT01572896|BEHAVIORAL|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
214514480|NCT01581320|DRUG|Test group|Once a month, administration of DP-R206 \& placebo for 16 weeks
214514481|NCT01581320|DRUG|Reference group|Once a month, administration of Bonviva \& placebo for 16 weeks
214514482|NCT06037577|DRUG|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
214514483|NCT06037577|DRUG|Placebo|Placebo Comparator
214514484|NCT00027209|DRUG|prempro|
214432594|NCT03071081|DRUG|TOP1288|Oral TOP1288
214432595|NCT03071081|DRUG|Placebo to TOP1288|Oral placebo to TOP1288
214432596|NCT04794959|DIAGNOSTIC_TEST|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
214432597|NCT02904759|DRUG|Desmopressin|
214432598|NCT02904759|DRUG|Placebo|
214514485|NCT03368105|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
215114541|NCT06527781|DRUG|PD5K3|Six dose levels will be evaluated. intravenous injection
214432599|NCT04111328|DRUG|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
214432600|NCT04111328|DRUG|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
214432601|NCT04111328|DRUG|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
214432602|NCT04111328|DRUG|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
214514486|NCT05333835|DRUG|HR17031 injection|HR17031 injection
214514487|NCT05333835|DRUG|INS068 injection|INS068 injection
214514488|NCT05333835|DRUG|SHR20004 injection|SHR20004 injection
214514489|NCT06298747|OTHER|Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
214514490|NCT00506025|DIETARY_SUPPLEMENT|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
215114542|NCT06527781|DRUG|Placebo|intravenous injection
215114543|NCT06527781|DRUG|Pegaspargase|Six dose levels will be evaluated. intramuscular injection
215114544|NCT02637765|BEHAVIORAL|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
215114545|NCT00759161|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
215114546|NCT00759161|DRUG|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
215114547|NCT00479336|DRUG|OPC-41061 7.5mg|7.5mg, 1 tablet a day
215114548|NCT00479336|DRUG|OPC-41061 placebo|placebo, 1 tablet a day
214432603|NCT04111328|DRUG|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
214432604|NCT04111328|DRUG|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
214432605|NCT04111328|DRUG|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
214432606|NCT04111328|DRUG|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
214432607|NCT02240446|DEVICE|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
214514491|NCT00506025|DIETARY_SUPPLEMENT|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
214692571|NCT02317406|DRUG|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
215114549|NCT00479336|DRUG|OPC-41061 15mg|15mg, 1 tablet a day
215114550|NCT00479336|DRUG|OPC-41601 30mg|30mg, 1 tablet a day
215114551|NCT02158871|BEHAVIORAL|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
215114552|NCT02158871|BEHAVIORAL|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
214432608|NCT02240446|DEVICE|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
214432609|NCT03639558|DRUG|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
214432610|NCT03639558|DRUG|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
214432611|NCT02990949|OTHER|Timing of trigger|
214432612|NCT00943358|BIOLOGICAL|MF59 H1N1 vaccine|3.75-7.5ug dose
214432613|NCT00943358|BIOLOGICAL|Plain H1N1 vaccine|7.5-15ug
214432614|NCT01897155|OTHER|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
214432615|NCT01897155|OTHER|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
214432616|NCT03532906|DRUG|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
214432617|NCT03532906|DRUG|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
214432618|NCT03416712|OTHER|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
214432619|NCT04974450|DIETARY_SUPPLEMENT|Trigona honey|composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
214514492|NCT06035627|OTHER|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
214432620|NCT04974450|DIETARY_SUPPLEMENT|control|Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
214432621|NCT00925210|PROCEDURE|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
214432622|NCT03380234|OTHER|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
214432623|NCT03380234|OTHER|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.
214432624|NCT03380234|OTHER|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
214432625|NCT03380234|OTHER|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
214432626|NCT06972849|DRUG|Caffeine citrate|Clinically indicated for apnea of prematurity.
214432627|NCT05180591|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
214432628|NCT05180591|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
214432629|NCT02414204|DRUG|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
214432630|NCT02414204|OTHER|Placebo|Placebo will be over encapsulated to identical to drug comparison
214432631|NCT00586586|BEHAVIORAL|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
214432632|NCT03995992|BEHAVIORAL|sport|10 days of sport (diving or multisport), once training per day
214432633|NCT03560934|DRUG|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
214432634|NCT06553911|OTHER|Artificial Intelligence-based medical imaging interpretation|In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
214432635|NCT04294173|BEHAVIORAL|video education|tracheostomy care will be given to student nurses with video training
214514493|NCT06201949|OTHER|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
214432636|NCT04843475|DIAGNOSTIC_TEST|Echocardiography|Trans-thoracic Echocardiography
214514494|NCT06201949|OTHER|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
214514495|NCT03303547|DIAGNOSTIC_TEST|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
214514496|NCT04499898|DRUG|Carvedilol|Carvedilol
214514497|NCT04499898|PROCEDURE|Endoscopic band ligation|Endoscopic band ligation
214432637|NCT01726842|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
214432638|NCT04092231|BEHAVIORAL|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
214514498|NCT02386085|PROCEDURE|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
214514499|NCT02430909|BIOLOGICAL|Bimekizumab|"* Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion"
214514500|NCT02430909|BIOLOGICAL|Certolizumab Pegol|"* Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
214432639|NCT01844492|BEHAVIORAL|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
214432640|NCT01844492|OTHER|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
214432641|NCT03272399|OTHER|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
214514501|NCT02430909|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion"
214514502|NCT02441829|DRUG|Eleclazine|Eleclazine tablets administered orally in morning with food
214514503|NCT04651426|DEVICE|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
214514504|NCT03262714|OTHER|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
214514505|NCT03262714|OTHER|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
214514506|NCT03262714|OTHER|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
214514507|NCT04510493|DRUG|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
214514508|NCT04510493|DRUG|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
214514509|NCT02981953|DEVICE|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
214514510|NCT04604717|OTHER|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
214514511|NCT05651802|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
214514512|NCT05651802|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
214514513|NCT05651802|DRUG|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
214432642|NCT04992364|OTHER|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
214514514|NCT01900015|DRUG|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
214514515|NCT01900015|DRUG|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
214432643|NCT06389266|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of rTMS with functional magnetic resonance imaging allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.
214432644|NCT05720078|RADIATION|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
214432645|NCT06972654|PROCEDURE|Group Nalupnine|Patients will receive a unilateral ultrasound-guided pericapsular nerve group (PENG) block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml nalbuphine (20 mg), with total volume 22ml.
214432646|NCT06972654|PROCEDURE|Group Dexamethasone|Patients will receive a unilateral ultrasound-guided PENG block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml dexamethasone (8 mg), with total volume 22ml.
214432647|NCT03942042|DRUG|Ixekizumab|Administered SC
214432648|NCT01535833|PROCEDURE|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
214432649|NCT01834248|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
214432650|NCT01834248|DRUG|Decitabine|Given IV
214432651|NCT01834248|OTHER|Laboratory Biomarker Analysis|Correlative studies
214432652|NCT01834248|DRUG|Poly ICLC|Given SC
214432653|NCT01787760|DEVICE|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
214432654|NCT01787760|DEVICE|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
214432655|NCT01787760|DEVICE|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
214432656|NCT03963128|DIETARY_SUPPLEMENT|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
214432657|NCT03963128|DIETARY_SUPPLEMENT|Placebo|Placebo administred every two months
214432658|NCT05640791|DRUG|Cisplatin|25mg/m2；d1, 8, 21 d cycle
214514516|NCT03660527|OTHER|Not refered|No intervention was refered.
214514517|NCT00383812|DRUG|Intravitreal Bevacizumab|
214432659|NCT05640791|DRUG|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
214514518|NCT00774826|DRUG|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
214514519|NCT00774826|DRUG|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
214514520|NCT00774826|DRUG|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
214514521|NCT06523686|PROCEDURE|Guided bone regeneration|Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
214432660|NCT05640791|DRUG|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
214432661|NCT05640791|DRUG|Durvalumab|1000mg；d1, 21 d cycle
214432662|NCT04720014|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
214432663|NCT02726490|DRUG|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
214432664|NCT02726490|DRUG|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
214432665|NCT02994173|DRUG|Oxycodone|Current clinical practice, used as a control in this study
214432666|NCT02994173|DRUG|S-Ketamine 0.25|dosage
214432667|NCT02994173|DRUG|S-Ketamine 0.5|dosage
214432668|NCT02994173|DRUG|S-Ketamine 0.75|dosage
214514522|NCT02889900|DRUG|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
214514523|NCT02769754|DEVICE|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
214432669|NCT00092664|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
214432670|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
214432671|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
214432672|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
214432673|NCT01353170|OTHER|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
214432674|NCT00395603|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
214432675|NCT00395603|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
214514524|NCT02769754|OTHER|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
214514525|NCT06226623|DIETARY_SUPPLEMENT|Coconut|Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
214514526|NCT03607851|DRUG|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
214514527|NCT03607851|DRUG|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
214692572|NCT02317406|DRUG|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
214514528|NCT03607851|DRUG|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
214514529|NCT02453269|BEHAVIORAL|Transdisciplinary program|
214514530|NCT00595725|OTHER|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
214432676|NCT01441934|DRUG|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
214432677|NCT01441934|DRUG|Sugar pills|placebo t.i.d.
214514531|NCT06255132|DEVICE|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
214514532|NCT02090478|OTHER|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
214514533|NCT02090478|OTHER|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
214514534|NCT01735214|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
214514535|NCT02591082|DEVICE|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
214514536|NCT01079104|DEVICE|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
214514537|NCT01079104|PROCEDURE|Standard Medical Therapy|Standard of care treatment
214514538|NCT05243602|DRUG|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
214514539|NCT05243602|DRUG|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
214514540|NCT03146845|DEVICE|ALLEVYN Life Non-Bordered|Foam Dressing
214514541|NCT03146845|DEVICE|Standard Care|Foam Dressing
214514542|NCT04527965|OTHER|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
214514543|NCT04527965|OTHER|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
214514544|NCT04527965|OTHER|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
214432678|NCT02081274|PROCEDURE|Surgery for congenital heart disease|
214514545|NCT01942772|DEVICE|Ankle-Foot Orthosis|
214514546|NCT03403153|BEHAVIORAL|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
214514547|NCT03946631|DIAGNOSTIC_TEST|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
214692573|NCT03047993|DRUG|Azacitidine|Given IV or SC
214692574|NCT03047993|DRUG|Glutaminase Inhibitor CB-839|Given PO
215114553|NCT03718026|OTHER|The timed 360° turn test|"* The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
215114554|NCT02118974|PROCEDURE|Hysterectomy|Hysterectomy
215114555|NCT02021643|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214692575|NCT07029399|DRUG|NKT5097 CDK2/CDK4 dual degrader|NKT5097 will be distributed in tablet form and dosed daily or twice a day
214432679|NCT03143348|PROCEDURE|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
214432680|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 6 peri-operative time points.
214432681|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 7 peri-operative time points
214432682|NCT02439827|BEHAVIORAL|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
214432683|NCT03621917|DEVICE|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
214432684|NCT01849055|DRUG|Placebo|Administered orally
214432685|NCT01849055|DRUG|LY3023703|Administered orally
214432686|NCT01849055|DRUG|Celecoxib|Administered orally
214432687|NCT01892553|DEVICE|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
214432688|NCT01970891|DEVICE|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
214432689|NCT00901069|DRUG|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
214514548|NCT00185692|PROCEDURE|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
214432690|NCT01100125|DRUG|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
214432691|NCT01100125|DRUG|insulin dose increase|insulin dose increase
214432692|NCT01239316|OTHER|Laboratory Biomarker Analysis|Correlative studies
214432693|NCT01239316|OTHER|Pharmacological Study|Correlative studies
214432694|NCT01239316|DRUG|Vismodegib|Given PO
214432695|NCT05273242|DRUG|Artesunate Injection|"* Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
214432696|NCT06238752|DRUG|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
214432697|NCT05463003|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
214432698|NCT03716557|DEVICE|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
214432699|NCT03716557|DEVICE|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
214432700|NCT03716557|DEVICE|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
214432701|NCT06756646|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise intervention will utilize an ergometer. The program will be conducted 2-3 times per week over a 3-month period.
214432702|NCT06756646|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about COPD self-care and home-based exercise approach.
214432703|NCT06756646|BEHAVIORAL|Blood flow restriction (BFR) intervention|Blood flow restriction (BFR) intervention will combine aerobic exercise on the ergometer with BFR training. The program will be conducted 2-3 times per week over a 3-month period.
214514549|NCT00185692|DRUG|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
214514550|NCT00185692|DRUG|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
214514551|NCT00185692|DRUG|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
214432704|NCT03838926|DRUG|Trichostatin A|Intravenous Infusion
214432705|NCT05601505|OTHER|circulating tumor DNA|This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
214432706|NCT04786457|BIOLOGICAL|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
214432707|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
214514552|NCT00185692|DRUG|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
215114556|NCT02021643|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
215114557|NCT02021643|DRUG|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
215114558|NCT04995536|BIOLOGICAL|CpG-STAT3 siRNA CAS3/SS3|Given intratumorally
214432708|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
214514553|NCT00185692|DRUG|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
214514554|NCT00185692|DRUG|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
214514555|NCT00185692|DRUG|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
214432709|NCT04514107|OTHER|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
214432710|NCT04514107|OTHER|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
214432711|NCT03414775|OTHER|Nourish|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
214432712|NCT03414775|OTHER|Pediasure|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
214432713|NCT06758440|DRUG|chitosan|Evaluate Effectiveness of hydroxyapatite reinforced chitosan hydrogel in modulation of osseintegration round immediate dental implant in a Randomized single blind control study
214514556|NCT00185692|DRUG|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
214514557|NCT02206906|BEHAVIORAL|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
214514558|NCT03996577|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
214514559|NCT03996577|DRUG|placebo|the control group will be given the same volume of saline.
214514560|NCT04127747|DRUG|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
214514561|NCT04127747|DRUG|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
214692576|NCT07029334|OTHER|Social Prescribing|"The SP intervention consists of a series of intervention components delivered across the SP pathways:~Intervention components~GP:~1. Social prescribing from physician to patient~   Link Worker:~2. Initial phone contact~3. Clarification and follow-up consultations~4. Personalized matching with local services and activities~5. Care coordination~6. Introductory visits to local services and activities~7. Accompanied (if needed)~8. Follow-up conversations~9. Concluding conversations~10. Group-based courses~    GP / Link Worker:~11. Re-prescribing (where appropriate)~Each intervention component is described in detail in the TIDieR checklist"
215114559|NCT04995536|RADIATION|Radiation Therapy|Undergo radiation therapy
214514564|NCT04657718|DEVICE|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
214514565|NCT03214614|DRUG|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
214514566|NCT03214614|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
215114560|NCT03331900|DRUG|COR388|Administered as oral capsule
215114561|NCT03331900|DRUG|Placebo|Administered as oral capsule
215114562|NCT05154110|OTHER|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
214432714|NCT04623008|BEHAVIORAL|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
214432715|NCT06757959|COMBINATION_PRODUCT|Wet Needling|This involve the use of needles to inject a local anesthetics into trigger points or areas of muscle tightness around the knee particularly in the quadriceps surrounding soft tissue implicated in patellofemoral pain syndrome .To reduce localized pain, release muscle tension and improve tissue function.
214432716|NCT06757959|DIAGNOSTIC_TEST|Kinesiotaping|Application of kinesiotape around knee joint or quadricep following a specific technique aimed at reducing pain and improving joint stability . The tape is typically applied to encourge proper movement patterns , reducing swelling and provide sensory feedback to brain. Strengthening exercises : To strenghthen the quadriceps , gluteal muscles and other key stabilizing muscles of lower limbs. This is aimed at reducing the mechanical stress on the joint and improve overall function.
214432717|NCT05970991|BEHAVIORAL|Brief Online Training (BOLT) for measurement-based care (MBC)|Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.
214514567|NCT03214614|DRUG|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
214514568|NCT03214614|DRUG|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
214514569|NCT04017598|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
214514570|NCT04017598|DIETARY_SUPPLEMENT|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
214514571|NCT04017598|DIETARY_SUPPLEMENT|Placebo of microcrystalline cellulose|placebo
214514572|NCT00405834|DEVICE|Envision® Patient Support System|
214514573|NCT06275256|PROCEDURE|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
214432718|NCT05970991|BEHAVIORAL|Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)|The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.
214514574|NCT06275256|DEVICE|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
214432719|NCT05970991|BEHAVIORAL|Live Post-Training Consultation|Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.
214432720|NCT05970991|BEHAVIORAL|Asynchronous Discussion Board|An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
214432721|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
214432722|NCT05328375|BEHAVIORAL|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
214432723|NCT05328375|BEHAVIORAL|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
214432724|NCT04219826|DRUG|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
214432725|NCT04219826|DRUG|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
214514575|NCT03571906|BEHAVIORAL|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
214514576|NCT04448613|OTHER|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
214514577|NCT03442998|OTHER|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
214514578|NCT03442998|OTHER|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
214514579|NCT02597166|DRUG|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
214514580|NCT00184743|DRUG|somatropin|
214432726|NCT04219826|DRUG|Placebo for CK-3773274|Placebo administered orally
214432727|NCT06346834|BIOLOGICAL|sIPV|One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
214514581|NCT00761332|DRUG|teriparatide|treatment will be prescribed according to usual standard of care
214514582|NCT00761332|DRUG|antiresorptives|treatment will be prescribed according to usual standard of care
214432728|NCT03122886|DIETARY_SUPPLEMENT|Fat Emulsion|Given IV
214432729|NCT03122886|OTHER|Placebo|Given IV
214514583|NCT01020578|OTHER|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
214514584|NCT00651599|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
214514585|NCT00651599|DRUG|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
214514586|NCT03544047|DRUG|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
214514587|NCT01740284|DRUG|Grazax + Aerius|
214514588|NCT01740284|DRUG|Grazax + placebo|
214432730|NCT05356234|BEHAVIORAL|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
214432731|NCT03779048|BEHAVIORAL|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
214432732|NCT03779048|DRUG|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
214432733|NCT03779048|DRUG|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
214432734|NCT04169763|DRUG|Cisplatin|Given IV
214432735|NCT04169763|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214432736|NCT04169763|DRUG|Nelfinavir|Given PO
214432737|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
214432738|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
214432739|NCT05302817|COMBINATION_PRODUCT|Hyperpolarized xenon MRI|Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.
214432740|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
214514589|NCT03029156|DEVICE|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
214514590|NCT03029156|DEVICE|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
214514591|NCT03384342|DEVICE|Narrow-band UV-B therapy|"* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
214514592|NCT06222437|DRUG|Semaglutide|effectiveness of semaglutide in PCOS
214514593|NCT04004754|DRUG|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
214514594|NCT00711022|DEVICE|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
214514595|NCT03861884|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
214514596|NCT04446949|OTHER|Register follow-up|Number of adverse pregnancy outcomes
214514597|NCT01535261|DRUG|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
214514598|NCT02404298|DRUG|IVIg|
214514599|NCT04812977|DRUG|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
214514600|NCT05881213|DRUG|CKD-378 (low-dose)|Quaque day (QD), PO
214514601|NCT02040038|BEHAVIORAL|LIVE|3-D Virtual Environment for DSMT/S
214514602|NCT02040038|BEHAVIORAL|Website|2-D Website participation for DSMT/S
214514603|NCT05798598|OTHER|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
214514604|NCT05991518|COMBINATION_PRODUCT|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
214432741|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
214432742|NCT05985044|OTHER|Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention|The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
214432743|NCT06343636|DRUG|VG-3927|Dose Escalation
214432744|NCT06343636|DRUG|Placebo|Dose Escalation
214432745|NCT06343636|DRUG|VG-3927|One Dose Level
214432746|NCT03974854|DRUG|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
214432747|NCT03974854|DRUG|Gemcitabine|chemotherapy with Gemcitabine regimen
214432748|NCT06789835|DEVICE|Fluorescence imaging of disclosed and undisclosed plaque|Teeth are imaged using a fluorescence camera/an intraoral scanner before and after plaque disclosure.
214432749|NCT05613673|OTHER|No intervention - observational study only|No intervention - observational study only
214514605|NCT05991518|COMBINATION_PRODUCT|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
214514606|NCT04917601|BEHAVIORAL|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
214514607|NCT04917601|BEHAVIORAL|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
214514608|NCT01075854|DRUG|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
214514609|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
214432750|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
214432751|NCT06788743|DRUG|TIVA ( anesthesia with propofol and remifentanil)|Participants assigned to the TIVA group will receive propofol combined with remifentanil for anesthesia maintenance during the surgery
214432752|NCT06788743|DRUG|VA（anesthesia with sevoflurane and remifentanil）|Participants assigned to the VA group will receive sevoflurane combined with remifentanil for anesthesia maintenance during the surgery.
214432753|NCT05830058|PROCEDURE|Biospecimen Collection|Undergo blood collection
214514610|NCT01757288|DRUG|PACLITAXEL|
214514611|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
214514612|NCT02081976|BEHAVIORAL|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
214432754|NCT05830058|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214432755|NCT05830058|PROCEDURE|Positron Emission Tomography|Undergo PET
214432756|NCT05830058|OTHER|Questionnaire Administration|Ancillary studies
214432757|NCT05830058|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214432758|NCT00682032|DIETARY_SUPPLEMENT|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
214432759|NCT06772753|DRUG|Placebo|inactive substance
214432760|NCT06772753|DRUG|Psilocybin|active comparator for psychedelic effects
214432761|NCT06772753|DRUG|Ketamine|psychoactive substance
214432762|NCT06772753|DRUG|Dextromethorphan (DXM)|psychoactive substance
214432763|NCT06772753|DRUG|Dimethyltryptamine (DMT)|psychoactive substance
214432764|NCT06772753|DRUG|Methylenedioxymethamphetamine (MDMA)|psychoactive substance
214432765|NCT06772753|DRUG|Tetrahydrocannabinol (THC)|psychoactive substance
214432766|NCT04588259|DRUG|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
214432767|NCT04588259|DRUG|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
214432768|NCT04588259|DRUG|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
214432769|NCT06961929|OTHER|Control Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will not be given an experimental cooling modality.
214432770|NCT06961929|OTHER|Cool water limb immersion|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also immerse their hands and forearms in cool water.
214432771|NCT06961929|OTHER|Skin-Wetting Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also be sprayed with water periodically.
214432772|NCT06963814|DRUG|HC006|Specified dose on specified days
214432773|NCT06963814|DRUG|KEYTRUDA ®( Pembrolizumab)|Specified dose on specified days
214432774|NCT02846506|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
214432775|NCT02846506|DRUG|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214514613|NCT02081976|OTHER|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
214514614|NCT03883984|DRUG|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
214514615|NCT03883984|DRUG|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
214514616|NCT04202263|DRUG|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
214514617|NCT04202263|DRUG|Placebos|Placement of minocycline cream 0%
214514618|NCT01029639|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
214514619|NCT01516710|PROCEDURE|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
214514620|NCT01516710|PROCEDURE|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
214514621|NCT00195988|DRUG|tacrolimus, steroids, mycophenolate mofetil|
214514622|NCT02791308|DRUG|Pimecrolimus Cream 1% (Valeant)|
214514623|NCT02791308|DRUG|Vehicle cream|
214514624|NCT02791308|DRUG|Pimecrolimus Cream, 1%|
214514625|NCT02212275|DRUG|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
214514626|NCT00111865|BEHAVIORAL|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
214514627|NCT02493556|DEVICE|LLLT before muscle damage|
214514628|NCT02493556|DEVICE|Placebo LLLT before muscle damage|
214514629|NCT02493556|DEVICE|LLLT after muscle damage|
214514630|NCT02493556|DEVICE|Placebo LLLT after muscle damage|
214514631|NCT02669056|OTHER|5-HT measurement|
214514632|NCT02669056|OTHER|cerebral MRI|
214514633|NCT02669056|OTHER|Video recording|
214514634|NCT02669056|OTHER|EEG|
214514635|NCT02669056|OTHER|growth curves|
214514636|NCT02669056|OTHER|ASQ questionnaire|
214514637|NCT01962376|DRUG|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
214514638|NCT01962376|DRUG|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
214514639|NCT03349476|DEVICE|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
214514640|NCT05481008|DEVICE|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
214514641|NCT03607578|BEHAVIORAL|Other: Control Group - Minimal Intervention|Basic Campaign Folder
214432776|NCT02846506|DRUG|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214432777|NCT02846506|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214514642|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
214514643|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
214432778|NCT05381987|DEVICE|Radial shockwave therapy|Shockwave Storz Medical device, Doulith SD1, Tower (BT)
214514644|NCT02297854|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
214514645|NCT02634528|DRUG|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
214514646|NCT02634528|DRUG|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
214514647|NCT04584736|DRUG|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
214514648|NCT02301078|PROCEDURE|Percutaneous Needle Aponeurotomy|single procedure (day 0)
214432779|NCT04761939|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0"
214432780|NCT05056493|OTHER|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
214432781|NCT05222139|BIOLOGICAL|COVID-19 vaccination|Monitoring COVID-19 vaccination
214432782|NCT05878288|DRUG|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
214432783|NCT02740283|BEHAVIORAL|glycemic monitoring|
214432784|NCT02740283|DIETARY_SUPPLEMENT|dietary guide|
214432785|NCT06795386|PROCEDURE|Bariatric Surgery|Participants will include people with chronic widespread pain who will undergo bariatric surgery. All participants will receive this intervention and will not be randomized to this or other interventions.
214432786|NCT05912738|OTHER|Interventional therapy|Interventional therapy for postherpetic neuralgia includes nerve blocks, pulsed radiofrequency therapy, etc
214432787|NCT06215547|DEVICE|Enterra HDE|"Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit"
214432788|NCT01837238|DIETARY_SUPPLEMENT|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
214432789|NCT01837238|DIETARY_SUPPLEMENT|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
214432790|NCT01168544|DIETARY_SUPPLEMENT|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
214432791|NCT01168544|DIETARY_SUPPLEMENT|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
214432792|NCT01168544|DIETARY_SUPPLEMENT|Vitamin D 800 IU /day|800 IU vit D3/day
214432793|NCT01969981|PROCEDURE|PICC placement with Sherlock 3CG|
214432794|NCT01164098|DRUG|Rituximab|Induction therapy
214432795|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
214432796|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
214432797|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
214432798|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
214432799|NCT03664401|DEVICE|Kerecis Oral™|
214432800|NCT03664401|OTHER|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
214432801|NCT04030624|DEVICE|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
214432802|NCT01941758|BIOLOGICAL|trivalent influenza vaccine|
214432803|NCT01941758|OTHER|laboratory biomarker analysis|Correlative studies
214432804|NCT00175292|DRUG|Probiotic - VSL#3|
214432805|NCT00262782|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
214432806|NCT00872872|DRUG|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
214432807|NCT05792293|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
214432808|NCT05792293|OTHER|Placebo|Placebo
214432809|NCT01043601|DRUG|Inhaled PT005|inhaled, twice daily for 1 week duration
214432810|NCT01043601|DRUG|Inhaled Placebo|inhaled, twice daily for 1 week duration
214432811|NCT01043601|DRUG|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
214432812|NCT04704258|PROCEDURE|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
214432813|NCT04704258|DEVICE|FLOWer Embolic Protection System|FLOWer Embolic Protection System
214432814|NCT02545920|OTHER|no intervention|observational study
214432815|NCT03631433|DRUG|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
214432816|NCT03631433|DRUG|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
214514649|NCT02301078|DRUG|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
214514650|NCT04188353|DEVICE|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
214514651|NCT04188353|DRUG|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
214514652|NCT01709045|OTHER|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
214432817|NCT01970813|DEVICE|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
214432818|NCT01970813|DEVICE|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
214432819|NCT00006349|DIETARY_SUPPLEMENT|vitamin E|
214432820|NCT00006349|DRUG|donepezil hydrochloride|
214432821|NCT00006349|OTHER|placebo|
214432822|NCT05343715|BIOLOGICAL|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
214432823|NCT05343715|BIOLOGICAL|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
214432824|NCT01404598|DRUG|naproxcinod 750 bid|naproxcinod 750 bid
214432825|NCT01404598|DRUG|naproxcinod 3000 mg od|naproxcinod 3000 mg od
214432826|NCT01404598|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
214432827|NCT00175864|DRUG|Seletracetam (ucb 44212)|
214432828|NCT02416115|DRUG|Ramosetron|Ramosetron was given iv.
214432829|NCT02416115|DRUG|Naloxone|Naloxone added to PCA was given iv.
214432830|NCT02416115|DRUG|saline|Saline was given iv.
214432831|NCT02416115|DRUG|Morphine|Morphine in the PCA was given iv.
214432832|NCT03639896|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
214432833|NCT03639896|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
214432834|NCT06037993|DIETARY_SUPPLEMENT|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
214432835|NCT03107117|BEHAVIORAL|Computer Counseling|two computer counseling online programs for a teen and a parent
214432836|NCT03107117|BEHAVIORAL|Standard Care|A referral for substance use counseling
214432837|NCT04759482|DIAGNOSTIC_TEST|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
214432838|NCT03029598|DRUG|Carboplatin|Given IV
214432839|NCT03029598|OTHER|Laboratory Biomarker Analysis|Correlative studies
214432840|NCT03029598|BIOLOGICAL|Pembrolizumab|Given IV
214432841|NCT00151567|DRUG|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
214432842|NCT00151567|DRUG|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
214432843|NCT03051165|DEVICE|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
214432844|NCT00052364|DRUG|oxaliplatin|Given IV
214432845|NCT00052364|OTHER|laboratory biomarker analysis|Correlative studies
214432846|NCT03681522|PROCEDURE|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
214432847|NCT03681522|PROCEDURE|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
214432848|NCT03554460|DEVICE|dual-limb NIV|dual-limb NIV was served with servo i ventilator
214432849|NCT03922061|BIOLOGICAL|dmLT|double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
214432850|NCT03922061|BIOLOGICAL|fIPV|fractional-dose inactived polio vaccine
214432851|NCT02092116|DRUG|Romidepsin|Latency reversing agent
214432852|NCT02092116|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
214432853|NCT02092116|BIOLOGICAL|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
214432854|NCT04137497|DIAGNOSTIC_TEST|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
214432855|NCT01471756|PROCEDURE|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
214432856|NCT00105092|DRUG|Enzastaurin HCL|
214432857|NCT03427632|DRUG|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
214432858|NCT04593056|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
214514653|NCT01709045|RADIATION|Dual-Energy Computed Tomography (DECT)|
214514654|NCT01709045|OTHER|Ultrasound|
214514655|NCT01709045|OTHER|Transcranial doppler|
214514656|NCT02536534|OTHER|Correlation assessment|
214514657|NCT04417907|DRUG|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
214432859|NCT04593056|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
214432860|NCT02361918|PROCEDURE|Colon surgery|
214514658|NCT04417907|DRUG|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
214514659|NCT04417907|DRUG|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
214514660|NCT04417907|DRUG|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
214514661|NCT06327997|BIOLOGICAL|Fast CAR T cells|This study designed three dose groups, each with a dosage of 5.0 × 10\^5/kg、1.0×10\^6/kg、5.0×10\^6/kg
214514662|NCT00674765|DRUG|Seroquel|400 mg/day
214514663|NCT00674765|DRUG|Placebo|400 mg/day
214514664|NCT02875444|OTHER|Angio-CT|
214514665|NCT00795392|OTHER|ASA scale|ASA scale evaluation before operation
214514666|NCT00795392|OTHER|Full-scale psychological assessment|Full-scale psychological evaluation before operation
214514667|NCT00604396|DRUG|insulin detemir|
214514668|NCT00604396|DRUG|insulin NPH|
214432861|NCT04065958|BEHAVIORAL|Yoga-mindfulness|Body-mind therapy
214514669|NCT04421456|DRUG|GWP42003-P|oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
214432862|NCT04065958|BEHAVIORAL|Patient education and physiotherapy|Lectures and physiotherapy
214432863|NCT03206684|DRUG|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
214514670|NCT04421456|DRUG|Placebo|oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
214514671|NCT00623844|BEHAVIORAL|physical activity|activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
214514672|NCT00274287|DRUG|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
214514673|NCT06285058|DIAGNOSTIC_TEST|No interventions|The high-throughput extraction of large amounts of quantitative image features from medical images
214514674|NCT02054442|DRUG|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
214514675|NCT02054442|DRUG|Methotrexate|
214514676|NCT05151016|DRUG|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
214514677|NCT05151016|DRUG|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
214514678|NCT03118609|OTHER|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
214514679|NCT05500261|DRUG|Dexmedetomidine|intranasal administration of dexmedetomidine
214514680|NCT04955886|DRUG|Surufatinib(HMPL-012)|Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
214432864|NCT03206684|DRUG|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
214432865|NCT00915239|DRUG|Pantoprazole|40 mg pantoprazole once daily for 28 days
214432866|NCT00915239|DRUG|Placebo|identical placebo once daily for 28 days
214432867|NCT03074331|DRUG|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
214432868|NCT03257644|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
214514681|NCT03522688|DRUG|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
214514682|NCT03522688|DRUG|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
214514683|NCT03114592|OTHER|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
214514684|NCT00330135|DRUG|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
214514685|NCT00330135|DRUG|placebo injection|placebo injection - 1 injection
214514686|NCT02596542|OTHER|Water immersion|Different temperatures of cold water immersion will be assessed
214514687|NCT03683212|PROCEDURE|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
214514688|NCT01161706|OTHER|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
214514689|NCT00054730|DRUG|CX516 (Ampalex®)|
214514690|NCT00925327|OTHER|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
214514691|NCT01694199|DEVICE|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
214514692|NCT01694199|DEVICE|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
214514693|NCT02785822|DRUG|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
214514694|NCT02785822|DRUG|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
214514695|NCT02270606|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214514696|NCT02270606|DRUG|fluorouracil|Given IV
214514697|NCT02270606|DRUG|oxaliplatin|Given IV
214514698|NCT02270606|DRUG|leucovorin calcium|Given IV
214514699|NCT02270606|PROCEDURE|therapeutic conventional surgery|Undergo total mesorectal excision
214432869|NCT05494294|PROCEDURE|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
214514700|NCT00972114|PROCEDURE|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
214514701|NCT00972114|PROCEDURE|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
214514702|NCT00972114|PROCEDURE|CABG alone|Coronary artery bypass graft surgery alone
214514703|NCT01449760|OTHER|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
214514704|NCT01449760|OTHER|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
214514705|NCT04721483|PROCEDURE|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
214514706|NCT04266821|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
214514707|NCT03051074|BEHAVIORAL|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
214514708|NCT03051074|BEHAVIORAL|Comparison|Watching a relaxing film for up to 90 minutes
214514709|NCT00399828|DEVICE|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
214514710|NCT04459572|DIAGNOSTIC_TEST|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
214514711|NCT04552015|DIAGNOSTIC_TEST|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
214514712|NCT00110032|DRUG|EF5|Given IV
214514713|NCT00110032|PROCEDURE|conventional surgery|Undergo surgery
214514714|NCT00110032|PROCEDURE|positron emission tomography|Undergo PET
214514715|NCT00110032|RADIATION|fluorine F 18 EF5|Given IV
214514716|NCT00110032|OTHER|pharmacological study|Correlative studies
214514717|NCT06427239|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
214514718|NCT06427239|DRUG|Adebrelimab|Adebrelimab will be administrated per dose level in which the patients are assigned
214514719|NCT02466958|DRUG|levomilnacipran|antidepressant
214514720|NCT02466958|DRUG|Placebo|an inactive drug
214514721|NCT04895774|OTHER|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
214514722|NCT04895774|OTHER|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
214514723|NCT04895774|OTHER|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
214514724|NCT02362386|DEVICE|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
214514725|NCT03938207|DIAGNOSTIC_TEST|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
214514726|NCT03938207|DIAGNOSTIC_TEST|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214514727|NCT03938207|DIAGNOSTIC_TEST|TCM pattern|We want to use TCM pattern to investigate the difference among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
214514728|NCT03938207|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease will take to do the DNA Exome sequencing.
214514729|NCT03938207|DIAGNOSTIC_TEST|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
214514730|NCT03938207|DIAGNOSTIC_TEST|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
214514731|NCT03938207|DIAGNOSTIC_TEST|HLA typing|Using HLA typing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214514732|NCT03938207|DIAGNOSTIC_TEST|Full-length 16S Amplicon Sequencing|Using Full-length 16S Amplicon Sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214514733|NCT03938207|DIAGNOSTIC_TEST|Epigenomic|Using Epigenomic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214432870|NCT05494294|PROCEDURE|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
214514734|NCT03938207|DIAGNOSTIC_TEST|Metabolomics|Using Metabolomics from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214432871|NCT06282107|PROCEDURE|BiSAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
214432872|NCT06282107|PROCEDURE|traditional triple antihypertensive treatment|traditional triple antihypertensive treatment
214432873|NCT05176054|OTHER|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
214432874|NCT03753984|OTHER|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
214432875|NCT05700487|OTHER|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
214432876|NCT05705856|DRUG|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
214514735|NCT03938207|DIAGNOSTIC_TEST|Environmental Toxic|Using Environmental Toxic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214514736|NCT03938207|DIAGNOSTIC_TEST|Medical Image|Using Medical Image from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
214514737|NCT04620642|BIOLOGICAL|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
214514738|NCT03400748|DEVICE|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
214514739|NCT00836537|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
214514740|NCT00836537|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
214514741|NCT01883609|BIOLOGICAL|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
214514742|NCT01883609|BIOLOGICAL|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
214514743|NCT01883609|BIOLOGICAL|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
214432877|NCT01546753|DRUG|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
214432878|NCT01546753|DRUG|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
214514744|NCT06037044|OTHER|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
214514745|NCT06037044|OTHER|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
214514746|NCT02054208|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
214514747|NCT02054208|OTHER|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
214514748|NCT04464499|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
214514749|NCT02770274|DRUG|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
214514750|NCT02770274|DRUG|Aspirin|Monotherapy with aspirin 100 mg once daily
214514751|NCT02379975|PROCEDURE|Non-surgical Periodontal Therapy|
214514752|NCT03031782|DRUG|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
214514753|NCT03031782|OTHER|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
214514754|NCT06031506|DEVICE|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
214514755|NCT03388957|DRUG|Propranolol|This drug will be given before the extraction procedure
214514756|NCT03388957|DRUG|Midazolam|This drug will be given before the extraction procedure
214514757|NCT00361088|DRUG|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
214514758|NCT00361088|DRUG|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
214432879|NCT01546753|DRUG|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
214432880|NCT03125863|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
214432881|NCT02652806|DRUG|FG-4592|
214432882|NCT02652806|DRUG|Epoetin Alfa|
214432883|NCT04350541|OTHER|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
214432884|NCT04350541|OTHER|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
214432885|NCT05451095|DRUG|BI 474121|BI 474121
214432886|NCT05451095|DRUG|Placebo|Placebo
214432887|NCT05451095|DRUG|Ketamine hydrochloride|Ketamine hydrochloride
215114563|NCT05154110|OTHER|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
214432888|NCT06136351|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
214432889|NCT06136351|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
214432890|NCT06136351|DRUG|Bendamustin|90mg/m\^2 ivgtt, D0 of each 28-day cycle
214432891|NCT01483066|DEVICE|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
214432892|NCT02853565|DRUG|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
214432893|NCT01790672|DIETARY_SUPPLEMENT|Ethanol|Vodka Absolut
214432894|NCT01790672|OTHER|Water|Lemon-flavored water
214432895|NCT01790672|DIETARY_SUPPLEMENT|Alcoholized wine|Wine 13º or wine 8º
214432896|NCT01790672|DIETARY_SUPPLEMENT|De-alcoholized wine|Wine 0º
214432897|NCT00000338|DRUG|Lisuride|
214432898|NCT01706354|PROCEDURE|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
214432899|NCT01706354|PROCEDURE|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
214432900|NCT05705505|DRUG|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
214432901|NCT05705505|DRUG|Letrozole 2.5mg|Tablet
214432902|NCT01796236|DEVICE|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
214432903|NCT01796236|DEVICE|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
214432904|NCT05801198|DIETARY_SUPPLEMENT|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
214432905|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
214432906|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
214432907|NCT00145314|DRUG|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
214514759|NCT02109913|DRUG|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
214514760|NCT01930188|DRUG|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
214432908|NCT00546754|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
214432909|NCT00546754|DRUG|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
214432910|NCT06079931|DRUG|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
214432911|NCT03375151|DEVICE|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
214432912|NCT03375151|BEHAVIORAL|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
214432913|NCT03375151|BEHAVIORAL|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
214432914|NCT04877496|DRUG|History of exposure to anti-CD20 treatment since 01/01/2010|Intravenous treatment history of anti-CD20 treatment since 01/01/2010
214514761|NCT01930188|DRUG|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
214514762|NCT01930188|DRUG|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
214514763|NCT01930188|DRUG|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
214514764|NCT02514824|DRUG|MLN0128|Investigational mTOR kinase inhibitor
214514765|NCT00620139|BIOLOGICAL|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
214514766|NCT03576118|DRUG|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
214514767|NCT03576118|DRUG|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
214514768|NCT03855514|OTHER|NuShield|NuShield® is a dehydrated placental allograft.
214514769|NCT02170207|DRUG|Lansoprazole|Lansoprazole 30 mg injection
214514770|NCT02341222|DEVICE|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
214514771|NCT02341222|DEVICE|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
214514772|NCT04619108|BIOLOGICAL|Thrombosomes®|
214514773|NCT04263688|OTHER|Non-Intervention|Non-Intervention
214514774|NCT00362284|BEHAVIORAL|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
214514775|NCT00886834|DRUG|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
214514776|NCT00886834|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
214514777|NCT05647538|PROCEDURE|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
214514778|NCT02099409|DEVICE|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
214432915|NCT04877496|BIOLOGICAL|Completion of COVID19 vaccine at least 4 weeks ago|Completion of COVID19 vaccination course at least 4 weeks ago.
214432916|NCT06169501|BEHAVIORAL|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
214432917|NCT01622400|OTHER|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
214432918|NCT04762875|BIOLOGICAL|MGTA-145|MGTA-145 will be be administered as an IV infusion
214432919|NCT04762875|BIOLOGICAL|Plerixafor|240 µg/kg subcutaneously
214432920|NCT05857267|DRUG|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
214432921|NCT05857267|DRUG|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
214432922|NCT05444517|PROCEDURE|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
214432923|NCT05444517|PROCEDURE|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
214432924|NCT04535882|DIAGNOSTIC_TEST|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
214432925|NCT05105646|PROCEDURE|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
214432926|NCT04831190|BEHAVIORAL|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
214432927|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
214432928|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
214432929|NCT00311363|DRUG|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
214514779|NCT00900302|GENETIC|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
214692577|NCT06692829|PROCEDURE|robotic rehabilitation|In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
214692578|NCT06692829|PROCEDURE|conventional rehabilitation|It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
214432930|NCT03830866|BIOLOGICAL|Durvalumab|IV infusion every 4 weeks
214432931|NCT03830866|DRUG|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
214432932|NCT03830866|DRUG|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
214692579|NCT06693713|OTHER|Mental Health Youth Series|The Mental Health Youth Series is an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics. The intervention package includes a facilitation guide and a guide for parents and caregivers. The program is intended to be conducted by an experienced facilitator, although there is no specific training provided for facilitators outside of the facilitation guide.
214692580|NCT06693778|OTHER|electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI|eCDS tool for risk stratification of pediatric mTBI patients
214692581|NCT06692634|OTHER|mechanical ventilation setting|VT reduction, EIP setting, RR reduction, and a new EIP programing.
214692582|NCT06692751|BIOLOGICAL|Blood sampling|2 tubes of 5 mL
214432933|NCT03830866|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
214432934|NCT03751943|DEVICE|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
214432935|NCT00430872|BEHAVIORAL|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
214432936|NCT01359436|DEVICE|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
214432937|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
214432938|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
214432939|NCT02725762|DEVICE|LT-300 Active (PBM)|
214432940|NCT02725762|DEVICE|LT-300 Inactive (Sham)|
214432941|NCT06397144|DRUG|Paxlovid|Reference 1
214432942|NCT06397144|DRUG|Paxlovid|Reference 2
214432943|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 1
214432944|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 2
214514780|NCT00900302|OTHER|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
214514781|NCT00900302|OTHER|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
214514782|NCT00900302|PROCEDURE|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
214514783|NCT05687825|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
214514784|NCT02535585|DEVICE|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
214514785|NCT02535585|DEVICE|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
214514786|NCT02434991|DEVICE|Barostat|"* During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment."
214432945|NCT01759771|DRUG|Vitamin D3|4,000 IU of VD3 for at least one year
214514787|NCT03122860|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
214514788|NCT03122860|OTHER|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
214514789|NCT03122860|OTHER|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
214514790|NCT01406041|BIOLOGICAL|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
214514791|NCT03679299|OTHER|Observational - No intervention|See outcomes
214692583|NCT06692751|PROCEDURE|Ophthalmological examination|"angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A."
214692584|NCT06692751|OTHER|angina severity questionnaire|at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
214692585|NCT03492463|DRUG|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
214432946|NCT01759771|DRUG|Placebo|Placebo for at least one year
214432947|NCT02541188|GENETIC|Genetic analysis|
214432948|NCT06553261|PROCEDURE|suturing of leak, lavage, drainage|Operative suturing of the leak, lavage, drainage within a revision surgery.
214432949|NCT06553261|PROCEDURE|Formation of a new anasthomosis|Operative resection of the old leaking anastomosis and formation of a new one.
214514792|NCT05990868|DRUG|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
214514793|NCT01357902|DRUG|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
214514794|NCT03511781|RADIATION|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
214432950|NCT06553261|PROCEDURE|Fecal diversion|Formation of a deviating stoma.
214514795|NCT00882323|DRUG|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
214432951|NCT05861193|PROCEDURE|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
214432952|NCT00204646|DRUG|Adriamycin|
214432953|NCT00204646|DRUG|Ifosfamide|
214432954|NCT00204646|DRUG|Etoposide|
214432955|NCT00204646|DRUG|Carboplatin|
214514796|NCT04480957|BIOLOGICAL|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
214514797|NCT04480957|BIOLOGICAL|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
214514798|NCT04480957|BIOLOGICAL|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
214514799|NCT04480957|BIOLOGICAL|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
214514800|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
214514801|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
214514802|NCT04480957|OTHER|Placebo|Sterile 0.9% saline
214514803|NCT02055079|DRUG|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
214514804|NCT02055079|DRUG|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
214514805|NCT02578004|OTHER|biochemical and molecular analysis|
214514806|NCT06153784|DRUG|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
214514807|NCT04901585|PROCEDURE|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
214514808|NCT02166684|DEVICE|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
214514809|NCT00001255|DRUG|ADA PBSC|
214514810|NCT00001255|DRUG|ADA Umbilical Cord Blood Cells|
214514811|NCT00001255|DRUG|Transduced Lymphocytes|
214514812|NCT00074425|DRUG|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
214514813|NCT00074425|DRUG|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
214514814|NCT00074425|DRUG|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
214514815|NCT03610685|DRUG|Prednisolone|Given daily for 2 weeks
214432956|NCT00505791|DRUG|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure \> 100 mmHg.
214432957|NCT00060684|DRUG|Pixantrone (BBR 2778)|
214514816|NCT03610685|DRUG|Placebo oral capsule|Given daily for 2 weeks
214514817|NCT06465537|GENETIC|BD113vVLP|CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
214514818|NCT03662841|PROCEDURE|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
214514819|NCT03067337|DEVICE|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
214514820|NCT03067337|DEVICE|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
214432958|NCT00060684|DRUG|fludarabine|
214514821|NCT03875729|BIOLOGICAL|teplizumab|Treatment
214514822|NCT03875729|BIOLOGICAL|Placebo|Control
214432959|NCT00060684|DRUG|dexamethasone|
214432960|NCT00060684|DRUG|rituximab|
214432961|NCT02616068|DRUG|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
214432962|NCT02616068|DRUG|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
214432963|NCT02616068|DRUG|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
214432964|NCT02616068|DRUG|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
214432965|NCT03480451|OTHER|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
214432966|NCT03104036|OTHER|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
214432967|NCT03104036|DRUG|Mesalazine 4G Enema|Standard mesalazine enema
214432968|NCT04581850|BEHAVIORAL|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
214432969|NCT04581850|BEHAVIORAL|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
214432970|NCT04581850|OTHER|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences"
214692586|NCT03492463|OTHER|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
214432971|NCT03035994|OTHER|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
214692587|NCT03492463|OTHER|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
215114564|NCT06162780|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.
215114565|NCT06162780|PROCEDURE|TEER|Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.
215114566|NCT02947646|DEVICE|BabyGentleStick™ ON|experimental intervention
214432972|NCT06647641|OTHER|Whole genome sequencing will be performed at the NIH|All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
215114567|NCT02947646|DEVICE|BabyGentleStick™ OFF|active comparator
215114568|NCT03122210|DEVICE|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
214432973|NCT03108703|RADIATION|SBRT|35-40 Gy delivered in 5 fractions
214432974|NCT02575560|OTHER|history data|history data of PFS after 1st line or second line theray
214432975|NCT03098368|DRUG|Rotigotine|
214432976|NCT03098368|DRUG|Placebo|Placebo of rotigotine patch
214692588|NCT03492463|OTHER|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
214432977|NCT01316731|OTHER|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
214432978|NCT05403567|OTHER|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
214432979|NCT01605773|DRUG|repaglinide|Dose individually adjusted and conducted according to labeling
214432980|NCT01605773|DRUG|glyburide|Dose individually adjusted and conducted according to labeling
214432981|NCT04775992|OTHER|gabapentoids|Preemptive analgesia
214432982|NCT00581035|BIOLOGICAL|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
214432983|NCT00581035|BIOLOGICAL|Prevenar|1 dose at 2,3.5,6 and 12 months
214432984|NCT00581035|BIOLOGICAL|Meningitec|1 dose at 2,6 and 12 months
214692589|NCT06691906|DRUG|Enlicitide decanoate|Oral tablet
214692590|NCT04867655|OTHER|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
214692591|NCT04867655|OTHER|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
214692592|NCT06880939|DIETARY_SUPPLEMENT|Krill Oil Functional Food|Take 2g of krill oil orally daily, with each krill oil capsule containing 1g, by consuming one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The supplementation period begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
214432985|NCT03872635|OTHER|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
214432986|NCT02007044|DRUG|Ibrutinib|Given PO
214432987|NCT02007044|OTHER|Quality-of-Life Assessment|Ancillary studies
214432988|NCT02007044|OTHER|Questionnaire Administration|Ancillary studies
214432989|NCT02007044|BIOLOGICAL|Rituximab|Given IV
214432990|NCT02918591|DRUG|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
214432991|NCT06973616|PROCEDURE|Zirconia crown|A zirconia esthetic crown will be randomly placed on one side of the jaw
214432992|NCT06973616|PROCEDURE|Bioflx crown|A Bioflx esthetic crown will be randomly placed on one side of the jaw
214432993|NCT06321458|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
214432994|NCT06321458|BEHAVIORAL|Usual care|Usual care
214432995|NCT05576844|BEHAVIORAL|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
214432996|NCT05576844|OTHER|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
214432997|NCT00092027|DRUG|MK0217, alendronate sodium/Duration of Treatment: 6 months|
214692593|NCT06880939|DIETARY_SUPPLEMENT|Olive Oil|Instead of taking krill oil orally, use placebo capsules that are visually similar, with the contents being olive oil, each capsule containing 1g. Take one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The duration of intake begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
214432998|NCT00092027|DRUG|Comparator: placebo / Duration of Treatment: 6 months|
214432999|NCT04821336|OTHER|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
214692594|NCT07031089|OTHER|Non-interventional study (RIPH category 3)|The study aims to describe and evaluate an existing care pathway, implemented within the framework of current clinical practice, without modifying the modalities of care or adding specific interventions. No additional procedures are imposed on participants, apart from data collection for evaluation purposes and telephone interviews.
215114569|NCT02768779|OTHER|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
214692595|NCT06704178|DIETARY_SUPPLEMENT|NuBest Tall Growth Protein Powder|NuBest Tall Growth Protein Powder includes a proprietary blend of vitamins, minerals, and probiotics designed to enhance children's health outcomes.
214692596|NCT06704178|DIETARY_SUPPLEMENT|Placebo Powder|The placebo powder is designed to mimic the appearance and taste of the NuBest Tall Growth Protein Powder but does not contain the active ingredients.
214692597|NCT07032727|DRUG|Olutasidenib|Given by po
214692598|NCT07032727|DRUG|Cladribine (CLAD)|Given by IV
214692599|NCT07032727|DRUG|Venetoclax|Given by po
214692600|NCT07032727|DRUG|Gilteritinib|Given by po
215114570|NCT05659823|DRUG|Bupivacaine-fentanyl-morphine elective group|Guideline recommended analgesia in elective caesarian section.
215114571|NCT05659823|DRUG|Bupivacaine-fentanyl elective group|Current analgesia in elective caesarian section.
215114572|NCT05659823|DRUG|Bupivacaine-fentanyl emergency group|Current analgesia in emergency caesarian section.
215114573|NCT00988078|DRUG|Placebo|Capsule (without biologic action) administered three times a day for six months
215114574|NCT00988078|DRUG|Metformin|Metformin 500mg three times a day for six months
215114575|NCT04854551|DRUG|Naltrexone|Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
215114576|NCT04854551|OTHER|Placebo|Placebo will be used to control for expectancy effects
214433000|NCT00563537|RADIATION|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
214433001|NCT02101190|DRUG|BIA 9-1067|Opicapone, OPC
214433002|NCT04141943|OTHER|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
214433003|NCT02240550|DEVICE|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
214433004|NCT02240550|DEVICE|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
214433005|NCT02399943|DRUG|Trametinib|
214433006|NCT02399943|DRUG|Panitumumab|
214433007|NCT03848234|DRUG|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
214433008|NCT03848234|DEVICE|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
214433009|NCT00923871|PROCEDURE|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
214433010|NCT03668288|OTHER|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
214433011|NCT03014973|BIOLOGICAL|intra-prostatic concentration of sexual steroids|
214433012|NCT03014973|PROCEDURE|Trans-rectal biopsy|
214692601|NCT07032727|DRUG|Ruxolitinib|Given by po
214692602|NCT07032727|DRUG|Cytarabine|Given SQ
214692603|NCT00229372|BEHAVIORAL|Prolonged Exposure (PE) therapy|
214692604|NCT00187707|DRUG|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
214692605|NCT04166045|DEVICE|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
214692606|NCT04166045|DEVICE|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
214433013|NCT02910635|DRUG|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
214433014|NCT02910635|DRUG|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
214433015|NCT02910635|DRUG|Placebo|
214433016|NCT06058104|DEVICE|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
214433017|NCT04237155|OTHER|Questionnaire|Subjects will complete a verbal material scoring questionnaire
214433018|NCT04237155|OTHER|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
214433019|NCT01638039|OTHER|Laboratory Tests|Stool, blood, urine and saliva samples
214433020|NCT02139943|DRUG|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
214433021|NCT02139943|DRUG|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
214433022|NCT02139943|DRUG|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
214433023|NCT00179335|PROCEDURE|Blood drawing to determine drug levels|
214514823|NCT01474759|BEHAVIORAL|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
214514824|NCT01474759|BEHAVIORAL|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
214514825|NCT01474759|OTHER|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
214514826|NCT01474759|BEHAVIORAL|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
215114577|NCT05821244|BEHAVIORAL|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
215114578|NCT04341714|OTHER|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
215114579|NCT02444949|DRUG|endostar|
215114580|NCT02444949|RADIATION|intensity modulated radiation|
215114581|NCT02444949|DRUG|cisplatin|
214433024|NCT04120597|DRUG|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
214433025|NCT04120597|DRUG|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
214433026|NCT03009994|PROCEDURE|Repair of uterine incision|
214433027|NCT03009994|PROCEDURE|Exteriorization of the uterus|
214433028|NCT03009994|PROCEDURE|Non exteriorization of the uterus|
214433029|NCT06193850|OTHER|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
214433030|NCT03798080|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214433031|NCT03798080|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214433032|NCT03798080|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214433033|NCT02569866|DRUG|Cephalexin|Capsules containing cephalexin/500mg
214433034|NCT02569866|DRUG|Placebo|Capsules containing placebo/500mg
214514827|NCT02579109|OTHER|memory test|
214514828|NCT01473459|PROCEDURE|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
214514829|NCT01473459|PROCEDURE|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
214514830|NCT03340922|DEVICE|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
214514831|NCT03340922|DEVICE|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
214514832|NCT03037827|PROCEDURE|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
215114582|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
214433035|NCT03339258|DRUG|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
214433036|NCT03339258|DRUG|Placebo|Placebo, or inactive pill.
214433037|NCT04631003|DIAGNOSTIC_TEST|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
214433038|NCT03995446|DEVICE|low-level laser|low level laser emission on specific acupuncture points
214514833|NCT03037827|DEVICE|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
214514834|NCT06413459|OTHER|Luminex; scRNAsec|Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
214514835|NCT02764320|OTHER|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
214514836|NCT02764320|OTHER|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
214514837|NCT05297097|DIETARY_SUPPLEMENT|Trulacta breastmilk supplement|one supplement daily
214514838|NCT00799331|DRUG|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
214514839|NCT00799331|DRUG|placebo|Oral suspension.
214514840|NCT04155814|DRUG|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
214514841|NCT04155814|DRUG|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
214514842|NCT01742585|DRUG|ASP1585|oral
214514843|NCT01742585|DRUG|placebo|oral
214514844|NCT05008003|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
215114583|NCT00349817|BEHAVIORAL|web-based learning, didactic lecture and role-play|
215114584|NCT03596203|DEVICE|TransCutaneous Magnetic Stimulator (TCMS)|TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
214433039|NCT03995446|DEVICE|Sham laser|Sham laser
214433040|NCT01294033|OTHER|Fractional inspired oxygen (FiO2) 0.21|
214433041|NCT01294033|OTHER|Fractional inspired oxygen 0.28|Supplemental oxygen
214514845|NCT05008003|DIETARY_SUPPLEMENT|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
214514846|NCT05303324|DRUG|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
214514847|NCT02684994|BEHAVIORAL|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
214514848|NCT03853889|PROCEDURE|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
214514849|NCT03780634|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
214514850|NCT03780634|DRUG|PD-1 antibody|200mg intravenously every 3 weeks
214514851|NCT03780634|DRUG|Sorafenib|400 mg Bid Po
214514852|NCT06063915|DEVICE|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
214514853|NCT06063915|OTHER|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
214514854|NCT03220815|PROCEDURE|Drilling at low speed|
214514855|NCT03220815|PROCEDURE|Conventional drilling at high speed|
214514856|NCT02045914|OTHER|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
214514857|NCT05328817|DRUG|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
214514858|NCT00866541|DEVICE|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
214514859|NCT01405508|DRUG|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
214514860|NCT01405508|DRUG|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
214514861|NCT01405508|DRUG|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
214514862|NCT01405508|OTHER|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
214514863|NCT02398539|DRUG|Silver Nitrate|Silver Nitrate Sticks
214514864|NCT02398539|DRUG|Triamcinolone|0.5% cream
214433042|NCT05167656|OTHER|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
214433043|NCT05167656|OTHER|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
214433044|NCT05167656|OTHER|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
214433045|NCT05684094|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
214433046|NCT05684094|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
214433047|NCT03268577|OTHER|Internet-Based Intervention|Complete ASA24
214433048|NCT03268577|OTHER|Internet-Based Intervention|Complete ACT24 reporting
214433049|NCT03268577|DEVICE|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
214433050|NCT03268577|OTHER|Questionnaire Administration|Ancillary studies
214433051|NCT05498818|DIETARY_SUPPLEMENT|Synaquell|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
214433052|NCT05498818|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
214433053|NCT01429350|DRUG|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
214433054|NCT01429350|DEVICE|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
214433055|NCT05202912|DRUG|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
214433056|NCT05202912|DRUG|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
214433057|NCT01843101|DEVICE|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
214433058|NCT00288392|DRUG|Soluble beta-1,3/1,6-glucan|
214433059|NCT04526834|DRUG|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
214433060|NCT03661957|PROCEDURE|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
214433061|NCT03661957|PROCEDURE|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
214433062|NCT00716859|DRUG|Timolol|Timolol 0.5% dosed twice-daily
214433063|NCT00716859|DRUG|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
214433064|NCT02088424|OTHER|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
214433065|NCT02990117|OTHER|No Intervention|No Intervention
214433066|NCT03161327|DEVICE|ABI using QuantaFlo™|"Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
214433067|NCT05817097|DRUG|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
215114585|NCT04112303|DRUG|SOF/VEL|Tablets administered orally once daily
214433068|NCT03750968|DRUG|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
214433069|NCT03750968|DIETARY_SUPPLEMENT|Control Group|Placebo ingredients: Safflower oil
214433070|NCT05862610|DRUG|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
214433071|NCT05862610|DRUG|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
214433072|NCT03394976|DIAGNOSTIC_TEST|No intervention|No intervention
214514865|NCT05904210|DRUG|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
215114586|NCT02285335|DIETARY_SUPPLEMENT|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
214433073|NCT06323902|PROCEDURE|Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation|In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
214433074|NCT04125810|BIOLOGICAL|Probiotic|Probiotic
214433075|NCT04125810|OTHER|Placebo|Placebo
214433076|NCT03294499|OTHER|Questionnaire|Patients will be asked to complete one off questionnaire.
214433077|NCT04093908|OTHER|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
214433078|NCT02699385|OTHER|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
214433079|NCT02699385|DRUG|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
214433080|NCT02699385|DRUG|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
214433081|NCT00970658|DRUG|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
214433082|NCT00970658|DRUG|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
214433083|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
214433084|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
214433085|NCT00088413|BIOLOGICAL|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
214433086|NCT00088413|BIOLOGICAL|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
215114587|NCT01373658|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
215114588|NCT03106064|BEHAVIORAL|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
215114589|NCT03106064|OTHER|Usual Care|Usual hospital care
215114590|NCT01855737|DRUG|Warfarin|Prescribe warfarin to the patients who are needed.
215114591|NCT01449435|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
215114592|NCT05703321|BEHAVIORAL|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
215114593|NCT04569292|OTHER|No intervention on patients|No intervention on patients
215114594|NCT02879825|DEVICE|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
214433087|NCT00088413|DRUG|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
214433088|NCT04747743|OTHER|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
214433089|NCT06369701|DEVICE|Compressive tissue floss band|Compressive tissue flossing (CTF) is a compressive technique that uses a latex elastic band to compress the tissues and restrict the circulation of fluids in the targeted area for a short time. CTF acts on the mechanoreceptors in the underlying fascial layers, causing blood reperfusion of the compressed tissue, and/or causing fascial shearing and the sliding potential of the fascia to be restored (Starrett \& Cordoza, 2015). Proposed benefits from references include improving joint mobility in the joints of the limbs (Starrett \& Cordoza, 2015), improving muscular power, and decreasing pain with motion (Angelopoulos et al., 2021) (Cage et al., 2022) (Jianhong et al., 2021).
214433090|NCT04294329|PROCEDURE|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
214433091|NCT04294329|DRUG|Bupivacaine|Bupivacaine
214514866|NCT06244563|DEVICE|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
215114595|NCT03881111|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
215114596|NCT03881111|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
214433092|NCT04294329|DRUG|Saline|normal saline
214433093|NCT00922220|OTHER|stationary bike|Participants rode a stationary bike for five minutes
214433094|NCT00922220|OTHER|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
214433095|NCT00922220|OTHER|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
214433096|NCT05833906|DRUG|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
214433097|NCT05833906|DRUG|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
214433098|NCT05833906|DRUG|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
214433099|NCT05833906|DRUG|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
214433100|NCT05833906|DRUG|Placebo|Placebo comparator.
214433101|NCT04701866|OTHER|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
214433102|NCT03762213|DEVICE|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
214433103|NCT03762213|DEVICE|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
214433104|NCT01094613|DRUG|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
214433105|NCT01094613|DRUG|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
214433106|NCT01663584|PROCEDURE|Blood draw|
214433107|NCT02190578|DEVICE|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
214433108|NCT06112977|PROCEDURE|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
214433109|NCT03131869|OTHER|Thickened Beverages Nectar|Thickened beverages in nectar consistency
214433110|NCT03131869|OTHER|Thickened Beverage Honey|Thickened beverages in honey consistency
214433111|NCT01115959|DRUG|valproic acid|treatment of 1 month dosage of 400 mg BID
215114597|NCT03881111|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
215114598|NCT03881111|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
215114599|NCT04200690|OTHER|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
215114600|NCT04200690|OTHER|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
215114601|NCT00193921|DRUG|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
215114602|NCT00193921|RADIATION|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
215114603|NCT00193921|DRUG|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
215114604|NCT00193921|DRUG|Cisplatin|20mg/m2, IV, weekly
215114605|NCT00193921|RADIATION|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
214433112|NCT01115959|DRUG|placebo bid|
214433113|NCT05401474|DEVICE|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
214433114|NCT05401474|DEVICE|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
214433115|NCT05401474|DEVICE|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
214433116|NCT00716924|DRUG|Clopidogrel|300 mg
214433117|NCT00716924|DRUG|Clopidogrel|600 mg
214433118|NCT02024685|BEHAVIORAL|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
215114606|NCT01435213|DRUG|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
215114607|NCT01435213|DRUG|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
215114608|NCT01435213|DRUG|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
215114609|NCT01435213|OTHER|Cold pressor test|30-45 min cold pressor test of the foot
215114610|NCT01435213|DRUG|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
215114611|NCT01435213|DRUG|Placebo|A single dose of placebo (capsules) administered orally
214433119|NCT02024685|BEHAVIORAL|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
214433120|NCT01551355|BEHAVIORAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
214433121|NCT02309034|BEHAVIORAL|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
214433122|NCT02309034|BEHAVIORAL|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
214433123|NCT02309034|OTHER|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
214514867|NCT06244563|DEVICE|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
214514868|NCT06244563|PROCEDURE|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
214514869|NCT06244563|PROCEDURE|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
214514870|NCT02767037|DEVICE|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
215114612|NCT05276258|DEVICE|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
215114613|NCT05276258|DRUG|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
215114614|NCT02848534|BIOLOGICAL|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
215114615|NCT04208555|DRUG|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
215114616|NCT04208555|DRUG|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
215114617|NCT06530199|PROCEDURE|Enamel matrix derivative|connective tissue graft and Enamel matrix derivative in the defect area
215114618|NCT00089037|DRUG|methotrexate|
215114619|NCT00089037|DRUG|sirolimus|
215114620|NCT00089037|DRUG|tacrolimus|
215114621|NCT00640965|DRUG|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
215114622|NCT00640965|DRUG|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
215114623|NCT00726232|DRUG|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
215114624|NCT05337800|BEHAVIORAL|stress managment program|A four-session stress management program will be applied to the experimental group students.
215114625|NCT03654937|BIOLOGICAL|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB."
215114626|NCT01201720|PROCEDURE|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
215114627|NCT03083301|OTHER|Medical Files data extraction|Medical Files data extraction
215114628|NCT06090565|DRUG|Cefixime|Two 400 mg tablets will be administered orally to equal a 800 mg dose.
215114629|NCT06090565|DRUG|Doxycyclin|One 100 mg tablet will be administered orally twice a day for 7 days
215114630|NCT06090565|DRUG|Ceftriaxon|Dose of 1 g intramuscular one time
215114631|NCT06090565|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 g dose.
215114632|NCT06466460|OTHER|Motion based - Virtual cycling|To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment. (Intervention study)
215114633|NCT01688375|DRUG|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
215114634|NCT03667157|DRUG|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
214433124|NCT02509637|DEVICE|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
215114635|NCT03667157|DRUG|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
214433125|NCT02509637|OTHER|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
214433126|NCT02509637|OTHER|Control|
214433127|NCT02509637|OTHER|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
214433128|NCT02509637|OTHER|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
214433129|NCT02509637|OTHER|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
214433130|NCT02509637|DEVICE|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
214433131|NCT02509637|OTHER|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
214433132|NCT00915564|DRUG|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
214433133|NCT00915564|OTHER|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
214433134|NCT01901081|DEVICE|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
214433135|NCT03876210|COMBINATION_PRODUCT|PK101|PK101-001 + PK101-002 (combination)
214433136|NCT03876210|DRUG|PK101-001, PK101-002|coadministration
214433137|NCT04177459|BEHAVIORAL|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
214433138|NCT04177459|OTHER|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
214433139|NCT00411216|OTHER|Control exercises|saccadic eye movements against a plain background; no head movements
214433140|NCT00411216|OTHER|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
214433141|NCT00417950|DRUG|Acarbose|
214433142|NCT01692483|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
214433143|NCT01692483|DRUG|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
214433144|NCT02376842|BEHAVIORAL|Severe sepsis early warning best practice alert|
214433145|NCT02376842|BEHAVIORAL|Standard care|
214433146|NCT00418613|DRUG|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
214433147|NCT00418613|DRUG|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
214433148|NCT01850511|PROCEDURE|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
214433149|NCT01850511|DRUG|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
214433150|NCT00217841|DRUG|Aurograb|
214433151|NCT06150508|BEHAVIORAL|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
214514871|NCT02767037|GENETIC|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
214514872|NCT00999336|DRUG|Betrixaban|80 mg betrixaban qd for 8 days
214514873|NCT00476957|DEVICE|Stent|Stent implantation
214514874|NCT00476957|DEVICE|Stent|Stent implantation
215114636|NCT05900544|OTHER|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
215114637|NCT02233634|DRUG|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
215114638|NCT02233634|OTHER|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
214433152|NCT06027489|BEHAVIORAL|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
214433153|NCT06027489|BEHAVIORAL|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
214433154|NCT05003778|OTHER|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
214433155|NCT05003778|OTHER|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
214514875|NCT05951335|OTHER|m-Health Transition Care Program|The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
214514876|NCT01424345|DRUG|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
214514877|NCT01424345|DRUG|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
214514878|NCT06341946|DEVICE|Endoscopic third ventriculostomy|role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
214514879|NCT02159352|DRUG|Daclatasvir|
214514880|NCT02159352|DRUG|Darunavir|
214514881|NCT02159352|DRUG|Ritonavir|
214514882|NCT02159352|DRUG|Lopinavir/Ritonavir|
214514883|NCT02788994|DEVICE|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
214514884|NCT02788994|DEVICE|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
214514885|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
214514886|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
214514887|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
214514888|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
214514889|NCT03046888|PROCEDURE|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
214514890|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
214514891|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
214514892|NCT05066022|BIOLOGICAL|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
214514893|NCT06083051|DEVICE|6Fr Percuflex ureteral stents|The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
214514894|NCT06083051|DEVICE|6Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
214514895|NCT06083051|DEVICE|4.8Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
214514896|NCT06083051|DEVICE|4.8Fr Percuflex ureteral stents|The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
214433156|NCT05003778|OTHER|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
214433157|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
214433158|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
214433159|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
214433160|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
214433161|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
214433162|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
214433163|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
214433164|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
214514897|NCT04228068|OTHER|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
215114639|NCT02233634|OTHER|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
215114640|NCT06161129|DEVICE|Lenses|The filter lenses will be worn by participants for one month all day.
215114641|NCT03391934|DRUG|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
215114642|NCT01167374|RADIATION|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
215114643|NCT03936153|DRUG|abexinostat|abexinostat tablet
215114644|NCT00695526|DIETARY_SUPPLEMENT|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
215114645|NCT04034784|DEVICE|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
215114646|NCT04034784|OTHER|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
215114647|NCT00985868|DRUG|multikinase inhibitor AT9283|
215114648|NCT00985868|OTHER|enzyme-linked immunosorbent assay|
215114649|NCT00985868|OTHER|immunohistochemistry staining method|
215114650|NCT00985868|OTHER|laboratory biomarker analysis|
215114651|NCT00985868|OTHER|pharmacological study|
215114652|NCT02445872|DRUG|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
215114653|NCT02445872|DRUG|Palonosetron|
215114654|NCT02445872|DRUG|Dexamethasone|
215114655|NCT03547310|BEHAVIORAL|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
215114656|NCT03766659|DIAGNOSTIC_TEST|MOSE|EUS-FNB with MOSE
215114657|NCT03766659|DIAGNOSTIC_TEST|ROSE|EUS-FNA with ROSE
215114658|NCT02896283|RADIATION|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
215114659|NCT02896283|RADIATION|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
215114660|NCT06022796|OTHER|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
215114661|NCT06022796|OTHER|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
215114662|NCT02182934|DRUG|Ginsana|
215114663|NCT02182934|DRUG|Placebo|
215114664|NCT01957371|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
215114665|NCT02549001|DRUG|P-3058 10%|
214433165|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
214433166|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours|Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
215114666|NCT02549001|DRUG|vehicle of P-3058 10%|
215114667|NCT02549001|DRUG|amorolfine 5%|
214433167|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours|Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
214433168|NCT03809312|DRUG|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
214433169|NCT03809312|DRUG|Placebos|Placebos BID x 10 days
214433170|NCT00044057|DRUG|YM872 (zonampanel), t-PA (alteplase)|
214433171|NCT01348217|RADIATION|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
214433172|NCT01348217|RADIATION|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
214433173|NCT01348217|RADIATION|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
214433174|NCT01348217|DRUG|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
214433175|NCT06465446|BIOLOGICAL|Tislelizumab|IV infusion
214433176|NCT06465446|BIOLOGICAL|IMM01|2.0mg/kg, IV infusion
214433177|NCT06465446|DRUG|Bendamustine|IV infusion
214433178|NCT06465446|DRUG|Gemcitabine|IV infusion
214433179|NCT02918071|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
214433180|NCT02052219|DRUG|Blisibimod|Blisibimod administered subcutaneously
214433181|NCT02052219|DRUG|Placebo|Placebo administered subcutaneously
214433182|NCT02912208|DRUG|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
214433183|NCT02912208|OTHER|Placebo|The administration is the same of eltrombopag
214433184|NCT04423016|DEVICE|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
214433185|NCT04423016|DEVICE|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
214433186|NCT02094807|DRUG|NSAID|Will be used if other drugs are not tolerated.
214433187|NCT02094807|PROCEDURE|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
214433188|NCT02094807|DRUG|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
214433189|NCT02094807|DRUG|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
214433190|NCT02094807|PROCEDURE|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
215114668|NCT01022138|BIOLOGICAL|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
214433191|NCT03185650|DEVICE|tPAD Device|A novel, transnasal aerosol generator
214433192|NCT03185650|DEVICE|PARI LC Star Nebulizer|Standard oral nebulizer
214433193|NCT03250052|DRUG|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
214514898|NCT04228068|OTHER|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
214514899|NCT04228068|OTHER|Conventional care|The control group will receive the usual care provided by the healthcare system.
214514900|NCT05562492|DEVICE|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
215114669|NCT01022138|DRUG|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
215114670|NCT01022138|OTHER|Laboratory biomarker analysis|The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
215114671|NCT05447663|DRUG|Siremadlin|Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
214433194|NCT03250052|DRUG|(fimasartan and linagliptin) x 7days|Part A \& Part B: Co-administration of fimasartan and linagliptin
214433195|NCT01550549|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
214433196|NCT05106270|DIAGNOSTIC_TEST|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
214433197|NCT02332512|DRUG|Apatinib|
214433198|NCT02332512|DRUG|Placebo|
214433199|NCT04255290|OTHER|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
214433200|NCT04255290|OTHER|Control group|The subjects included in the control group will perform an eccentric work protocol
214433201|NCT06366984|OTHER|plastibell|plastibell used for circumcision
214433202|NCT06366984|OTHER|open method|open method used for circumcision
214433203|NCT06223048|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
214433204|NCT04135885|DRUG|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
214433205|NCT04135885|DRUG|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
214433206|NCT05519202|DRUG|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
214514901|NCT05562492|OTHER|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
214514902|NCT05473130|DEVICE|Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System
214514903|NCT05967156|DRUG|Empagliflozin10Mg Tab|10 mg daily
214433207|NCT02740400|PROCEDURE|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
214433208|NCT02740400|PROCEDURE|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
214433209|NCT00124878|PROCEDURE|Male circumcision|Sleeve circumcision
214433210|NCT03074617|OTHER|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
214433211|NCT03074617|OTHER|sham field|no electromagnetic field
214514904|NCT04765020|BEHAVIORAL|Experimental: moderate to high-intensity exercise|"Four parts:~1. Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~2. Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~3. Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~4. Activity trackers with individual movement goals that will be adjusted every two weeks"
214514905|NCT05625438|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
214514906|NCT06492226|DRUG|NKF-INS(A)|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
214514907|NCT06492226|DRUG|EU-NovoRapid®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
214514908|NCT06492226|DRUG|US-NovoLog®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
214514909|NCT01538056|DEVICE|Fenestrated Endovascular Graft or Company Manufactured Terumo Aortic Fenestrated TREO Endovascular Graft|PMEG endovascular graft with fenestrations or the Company Manufactured Terumo Aortic Fenestrated TREO Abdominal Stent Graft System to allow for blood flow to vital visceral vessels such as the renal arteries, celiac, and SMA (Superior Mesenteric Artery).
214514910|NCT03458494|OTHER|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
214514911|NCT03458494|OTHER|Low-fat diet|Participants will receive meals with a low content of total fat.
214514912|NCT06794723|DIETARY_SUPPLEMENT|5-strain probiotic plus prebiotic natural health product|"The investigational product is a 5-strain probiotic plus prebiotic natural health product for patients with Type 2 diabetes. Other ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening. There is ≥ 2 billion AFU per dose in total."
214514913|NCT06794723|OTHER|Placebo|"Ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening."
214514914|NCT01672255|DRUG|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
214514915|NCT01672255|DRUG|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
214514916|NCT06802328|DRUG|Foralumab TZLS-401 50 µg|"Foralumab 50 µg/dosing day for patients who have failed current therapies. Patients will be dosed in 3-week cycles, with foralumab dosing on Days 1, 3 and 5 of the first and second weeks, followed by a rest week. Patients will receive Day 1 doses of nasal foralumab under supervision at the Center for Clinical Investigation at BWH."
214514917|NCT04526587|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
214514918|NCT04526587|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214514919|NCT04526587|OTHER|Medical Chart Review|Patient's electronic health records are reviewed
214514920|NCT04810351|OTHER|observational study|There is no intervention. It is an observational study
214514921|NCT03682289|DRUG|Ceralasertib|Given orally
214514922|NCT03682289|DRUG|Olaparib|Given orally
214433212|NCT03855007|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214433213|NCT03855007|DRUG|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
214433214|NCT03855007|DRUG|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
214433215|NCT03855007|DRUG|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
214514923|NCT03682289|DRUG|Durvalumab|Given intravenously (IV)
214514924|NCT04764695|DIAGNOSTIC_TEST|D2O dilution technique|Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
214514925|NCT02301117|DRUG|TAS-102|
214433216|NCT04877652|OTHER|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
214433217|NCT01003834|BEHAVIORAL|Computerized brief intervention|Intervention based on Motivational Interviewing technique
214433218|NCT01003834|BEHAVIORAL|Computerized health screening|Behavioral intervention
214433219|NCT01003834|BEHAVIORAL|Computerized assessment|Behavioral intervention
214433220|NCT01003834|BEHAVIORAL|Therapist-delivered motivational intervention|Behavioral intervention
214433221|NCT01957124|PROCEDURE|PRF (Platelet-Rich Fibrin)|
214433222|NCT04250935|DIAGNOSTIC_TEST|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
214433223|NCT03116620|OTHER|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
214433224|NCT02901197|BEHAVIORAL|Education and Reminder Posters|See arm description
214433225|NCT02901197|OTHER|Policy Change|See arm description
214433226|NCT01646749|DIETARY_SUPPLEMENT|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
214433227|NCT01029587|DRUG|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
214433228|NCT00225004|PROCEDURE|DEXA scan|orto
214433229|NCT03133234|DRUG|osimertinib|Oral dose of 80mg once daily
214433230|NCT05900921|DRUG|Trilaciclib|IV infusion, d1
214433231|NCT05900921|DRUG|Carboplatin|IV infusion, d1
214433232|NCT05900921|DRUG|Paclitaxel|IV infusion, d1
214514926|NCT06296277|OTHER|Intraoperative mechanical ventilation for surgery|Any IMV during general anesthesia for surgery
214514927|NCT02805023|BIOLOGICAL|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
214514928|NCT02805023|BIOLOGICAL|Control medium|Intramuscular injections - single treatment session
214514929|NCT04396717|BIOLOGICAL|Pritumumab|Pritumumab IgG1 human monoclonal antibody
214433233|NCT05900921|DRUG|Tislelizumab|IV infusion, d1
214433234|NCT04644341|COMBINATION_PRODUCT|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
214433235|NCT03969524|DEVICE|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
214433236|NCT04773678|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
214433237|NCT04773678|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214433238|NCT03649113|PROCEDURE|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
214433239|NCT05707624|OTHER|video education|In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
214433240|NCT05707624|OTHER|the routine procedure|the routine procedure
214692607|NCT06925672|OTHER|Questionnaire|"This is an anonymous questionnaire; based upon previous similar studies.~The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:~A. Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.~B. Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.~C. Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.~This questionnaire will be presented in its Arabic version."
214514931|NCT04620733|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
214514932|NCT04620733|DRUG|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
214514933|NCT04620733|DRUG|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
214514934|NCT02221934|DEVICE|Altius|Electrical signal
214514935|NCT05290155|DRUG|anti-CD7 CAR-T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
214692608|NCT06736431|BEHAVIORAL|Text-based resource referral platform with diabetes educational materials|Text-based resource referral platform with diabetes educational materials
214433241|NCT00391196|DRUG|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
214433242|NCT00391196|DRUG|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
214433243|NCT00391196|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
214433244|NCT01761487|DEVICE|Gentamicin and polymyxin E|
214433245|NCT03608995|DIAGNOSTIC_TEST|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
214514936|NCT04410003|BIOLOGICAL|Fecal microbial transplant|Fecal microbial transplant
214514937|NCT05715957|OTHER|No intervention|No intervention
214514938|NCT06847997|OTHER|Addition of telemedicine to standard medical dispatching process (Experimental Group)|In the experimental group, the same approach is used, with the addition of telemedicine using video calls. Callers are invited to use their smartphone camera to enable real-time video assessment. The medical dispatcher sends a secure link (via a platform provided by Enovacom, Nomadeec, Bordeaux, France) to the caller's smartphone, allowing video streaming through a secure internet connection. Once the link is validated by the caller, the live video feed from the smartphone camera is transmitted directly to the dispatcher's computer screen, providing a visual evaluation to support clinical decision-making.
214514939|NCT03809169|PROCEDURE|Rapid on-site evaluation (ROSE)|Pathologist on site for direct evaluation of specimen adequacy
214514940|NCT03809169|PROCEDURE|Slim bronchoscope without a guide sheath|peripheral endobronchial ultrasound performed with a slim bronchoscope (3.0 mm outer diameter with a 1.7mm channel) combined with a radial ultrasound probe but without the use of a guide sheath.
214514941|NCT03809169|PROCEDURE|Standard pEBUS with guide sheath|Using a flexible bronchoscope with minimal outer diameter of 4.2mm.
214514942|NCT03121261|DRUG|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
214514943|NCT03121261|DRUG|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
214514944|NCT05045664|RADIATION|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
214514945|NCT05045664|RADIATION|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
214514946|NCT05045664|DRUG|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
214514947|NCT05045664|DRUG|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
214514948|NCT02795052|PROCEDURE|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
214433246|NCT03608995|DIAGNOSTIC_TEST|Quikcheck fFN ™|\- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
214433247|NCT04080141|DIAGNOSTIC_TEST|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
214433248|NCT04080141|PROCEDURE|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
214433249|NCT05736094|DEVICE|SURF|Dual-frequency ultrasound
214433250|NCT03310866|DEVICE|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
214433251|NCT03310866|DEVICE|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
214514949|NCT05928689|DRUG|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
214514950|NCT05928689|BEHAVIORAL|Reminder|Reactivation of misophonia trigger memory
214514951|NCT05928689|BEHAVIORAL|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
214514952|NCT05928689|DRUG|Placebo|Matching placebo tablet
214514953|NCT03565640|DEVICE|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
214514954|NCT03565640|DEVICE|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
214514955|NCT05941715|DRUG|Aflibercept 40 MG/ML|treat-and-extend
214514956|NCT05941715|DRUG|Faricimab 120 MG/ML|treat-and-extend
214514957|NCT05169580|DRUG|Pociredir oral capsule(s)|Participants will receive Pociredir
214692609|NCT01327040|OTHER|light exposure|12-hour light exposure of approximately 200 lux
214692610|NCT06759194|PROCEDURE|Holmium Laser Enucleation of the Prostate|Enucleation of the prostate gland using holmium laser energy
215114672|NCT05662956|DRUG|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
215114673|NCT03501225|PROCEDURE|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
215114674|NCT03501225|PROCEDURE|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
215114675|NCT00226382|DRUG|Pegylated Interferon-alfa-2a|Pegasys once weekly
215114676|NCT00391144|PROCEDURE|intravitreal triamcinolone injection of avastin (1.25 mg)|
215114677|NCT05287646|DEVICE|Suction Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
215114678|NCT05287646|DEVICE|Elevated Vacuum Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
214433252|NCT01086982|DRUG|Octreotide acetate LAR|30 mg, single dose
214433253|NCT01086982|DRUG|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
214433254|NCT06972303|BEHAVIORAL|Instructed bedtime app-guided mindfulness meditation|All participants will access the a smartphone app, and the mindfulness meditation practice may involve techniques such as breathing exercise, imagery, body scan, and relaxation. The investigators will provide instructions for participants who are assigned to practice at bedtime.
214433255|NCT06972303|BEHAVIORAL|Uninstructed app-guided mindfulness meditation|The guided mindfulness meditation practice will also be based on the same app. The investigators will not provide instructions for participants, and they have complete freedom to use the app as real-world users.
214433256|NCT06972303|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education will be based on recognized, general, non-personalized sleep hygiene advice, for example, recommendations about bedtime routines and use of alcohol and caffeine, tips on creating a sleep-conducive bedroom environment.
214433257|NCT06972342|BEHAVIORAL|education|Participants will be intervened after the baseline measurements, including two training classes.
214433258|NCT00203411|DRUG|Capecitabine (Xeloda)|1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
214433259|NCT00203411|DRUG|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
214433260|NCT06973408|BEHAVIORAL|Behavioral Treatment|Behavioral support is designed to help participants adhere to the dietary recommendations through personalized coaching and motivational strategies. Participants engage in weekly or bi-weekly coaching sessions, either online or in person, where they receive guidance on overcoming challenges and maintaining dietary changes. The coaching incorporates evidence-based behavior change techniques, such as goal setting, self-monitoring, feedback on performance, problem-solving, and stimulus control. To further support behavior change, participants receive practical tools, including visual aids, educational videos, and structured meal planning resources. The overall goal of behavioral support is to encourage sustainable dietary habits by providing continuous encouragement and individualized strategies.
214433261|NCT06973408|BEHAVIORAL|Food support|Food support, which is provided exclusively to participants in the Optimized Lifestyle Intervention Group, ensures that they have access to key foods required to meet dietary targets. These foods include whole grains such as whole grain bread, oats, and pasta; vegetables in both fresh and frozen forms; fruits and berries, including apples, pears, and frozen berries; legumes such as lentils, beans, and chickpeas; and seafood, including fatty fish, lean fish, and mussels. To facilitate adherence, participants also receive recipes and meal plans that incorporate these foods. Some fresh food items are made available at supermarkets near participants' residences to improve accessibility and convenience. Food support aims to reduce barriers to dietary change by ensuring that participants have the necessary ingredients to follow the SWITCH diet effectively.
214433262|NCT06973408|BEHAVIORAL|Dietary Advice|Dietary advice consists of a simple document outlining the SWITCH diet, which is based on European and Nordic dietary guidelines. Participants receive this information in written form without any additional guidance, counseling, or support. The SWITCH diet emphasizes increased consumption of whole grains, vegetables, fruits, legumes, and seafood while limiting processed foods, added sugars, and excessive salt.
214433263|NCT06446076|BEHAVIORAL|Gamification (Gain/Loss framing)|"Participants will take part in a 6-week game-based program designed to help them reach their daily step goals. They are encouraged to maintain their daily step counts to achieve their daily step target over the 6-week intervention period. The gamification design incorporates two theoretically effective behavioral economics principles, Fresh Start and Loss Aversion. All participants start from the Silver rank (middle rank), and their rank changes based on each final point of the week. The ranks are set from top to bottom as Platinum, Gold, Silver, Bronze, and Blue. In loss framing, if the daily step target is 6000 steps, maintaining 70 points for achieving 6000 steps on day 1, and a deduction of 10 points for not achieving it. In gain framing, achieving 6000 steps on day 1 results in an addition of 10 points, with no increase for not achieving it. After one week, ranks increase if the points at midnight on Sunday are 40 or above, and decrease if below this threshold."
214433264|NCT06446076|BEHAVIORAL|Social support|Participants in this group are asked to designate a family member or friend to provide social support. This supporter is encouraged to check the participant's progress and provide support during the interventional period. The supporter will also receive weekly emails throughout the period, informing them about the participant's daily step counts, achievement status, points, levels, and other relevant information.
214692611|NCT06759194|PROCEDURE|Bipolar Enucleation of the Prostate|Enucleation of the prostate gland using bipolar energy
214692612|NCT07082556|OTHER|US-guided PNM|Stimulation will be applied for 15 minutes at 4 Hz, using a 250 ms pulse duration.
215114679|NCT06041919|DRUG|RESP301|Nitric Oxide agent
215114680|NCT06041919|DRUG|HRZE|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
215114681|NCT05948631|BEHAVIORAL|MISC intervention|MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
215114682|NCT05948631|BEHAVIORAL|Treatment as Usual (TAU)|TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
215114683|NCT05996328|OTHER|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
215114684|NCT05996328|OTHER|Study -defined standard of care|study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
215114685|NCT03519633|DRUG|Sugammadex|Reversal of deep NMB
215114686|NCT03519633|DRUG|Neostigmine|Reversal of moderate NMB
215114687|NCT06050135|OTHER|Roadmap to Parenthood|web-based decision support
215114688|NCT06050135|OTHER|Informational Booklet|web-based informational booklet about young adult cancer survivorship
215114689|NCT06042920|DRUG|Deucravacitinib|Specified dose on specified days
215114690|NCT06042920|DRUG|Placebo|Specified dose on specified days
214433265|NCT05755100|BEHAVIORAL|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
214433266|NCT04773639|BEHAVIORAL|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
214433267|NCT04773639|BEHAVIORAL|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
214433268|NCT06570213|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line, gold-standard psychotherapy intervention for the treatment of PTSD.
214433269|NCT06570213|DRUG|Stellate Ganglion Block|Stellate Ganglion Blocks are an injection of local anesthetic into the stellate ganglion, a collection of nerves in the side of the neck.
214433270|NCT04325048|DEVICE|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
214433271|NCT03182010|DEVICE|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
214433272|NCT03182010|DEVICE|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
214433273|NCT04410055|BEHAVIORAL|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
214433274|NCT04410055|BEHAVIORAL|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
214514958|NCT05324605|PROCEDURE|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
214433275|NCT04410055|BEHAVIORAL|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
214514959|NCT06149416|DEVICE|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
214514960|NCT06039566|DRUG|IV N-acetylcysteine|N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
214514961|NCT06039566|DRUG|IV Placebo|Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
214514962|NCT06363487|DRUG|Semaglutide, 0.5 mg/mL|Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
214433276|NCT00590369|DEVICE|KCI -VAC|Negative pressure wound therapy device
214514963|NCT06363487|OTHER|Placebo, 0.9% NaCl 1.5mL|Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
215114691|NCT06516159|DIAGNOSTIC_TEST|MBI-C Scale in French|"The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes."
215114692|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
214433277|NCT00590369|DEVICE|Versatile One (EZCare)|Negative pressure wound therapy device
214433278|NCT01923012|DRUG|Vitamin K2 (Menaquinone)|
214433279|NCT02634541|DRUG|Adalimumab|Biologic drug
214433280|NCT02634541|OTHER|PET/CT imaging|PET/CT imaging
214433281|NCT00002632|DRUG|paclitaxel|
214433282|NCT00939978|DRUG|rhEPO|recombinant human erythropoietin(rhEPO)
214433283|NCT00295724|DRUG|Bicifadine|
214433284|NCT04928703|DRUG|Ketamine|Ketamine IV administration
214433285|NCT01177696|BEHAVIORAL|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
214433286|NCT03421678|DIAGNOSTIC_TEST|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
214433287|NCT00632424|DRUG|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
214433288|NCT02531113|DRUG|RPC1063|
214433289|NCT00002049|DRUG|Thymopentin|
214433290|NCT03680417|BIOLOGICAL|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
214433291|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
214433292|NCT06972823|DEVICE|3D printed custom-made mouthguards|Participants in the first group will receive 3D printed custom-made mouthguards
214433293|NCT06972823|DEVICE|Traditional custom-made mouthguards|Participants in the active comparator arm will receive traditional custom-made mouthguards as an intervention
214433294|NCT06974019|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement in nulliparous women
214433295|NCT06974019|DRUG|Lidocaine 1% Injectable Solution|To determine if the unbuffered 1% lidocaine paracervical block offers any less pain control with IUD placement for nulliparous women
214433296|NCT06972615|DRUG|intravesical Chemotherapy docetaxel/gemcitabine|intravesical quimiotherapy plus intravenous immunotherapy
214433297|NCT06974253|PROCEDURE|Nasopalatine Implants, Trans-Sinus Implants, and Trans-Nasal Implants for Full-Arch Rehabilitation|"Pre-surgery (Implant Placement):~Clinical examination, panoramic radiography, film guide creation, and CBCT imaging will be performed. Based on CBCT data and the film guide, bone measurements will be taken, and a treatment plan with virtual implants will be developed. 4-6 pilot holes will be made, adjusting for critical structures like the maxillary sinus, inferior alveolar nerve, and planned implant sites. Full blood count and coagulation tests will be done.~During Surgery:~Implant surgery will be performed under local anesthesia/sedation. Incision and mucosal flap reflection will expose the implant site. A clip will be fixed to the anterior maxilla with screws, connected to the monitoring device. The dynamic navigation system will guide the placement of nasopalatine, trans-sinus, and trans-nasal implants, ensuring optimal placement.~Post-surgery:~Post-operative CBCT will be performed to check the implant positions, confirming the accuracy of the implant placement."
214433298|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery
214433299|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods: [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.|GFR will be measured using three methods: \[68Ga\]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.
215114693|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
214433300|NCT06972550|PROCEDURE|pronator quadratus sparing|the pronator quadratus was spared when doing orif and the plare was slided beneath it
214433301|NCT03031561|DEVICE|Ultrasound|Undergo standard ultrasound
214433302|NCT03031561|DEVICE|MicoPure ultrasound|Undergo MicoPure ultrasound
214433303|NCT03031561|PROCEDURE|Biopsy of Breast|Undergo breast biopsy or surgical resection
214433304|NCT06119048|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
214433305|NCT03013504|DRUG|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
214433306|NCT03013504|DRUG|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
214433307|NCT03013504|DRUG|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
214433308|NCT03013504|DRUG|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
214433309|NCT03013504|DRUG|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
215114694|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
215114695|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
215114696|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
214433310|NCT06828159|DIETARY_SUPPLEMENT|Wild blueberry|Freeze-dried wild blueberry powder 25g/day
214433311|NCT06828159|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for calories and no polyphenols
214433312|NCT06643507|OTHER|Connective tissue graft|regenerative properties
215114697|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
214433313|NCT06643507|BIOLOGICAL|ALB-PRF|regenerative properties
214433314|NCT03350542|DEVICE|SYNERGY 48 mm|A drug eluting coronary stent system
214433315|NCT04873245|BEHAVIORAL|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
214433316|NCT04873245|DRUG|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
214433317|NCT00774852|DRUG|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
214433318|NCT00774852|DRUG|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
214514964|NCT05683821|BEHAVIORAL|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~* SmokefreeTXT (if ready to set a quit date in the next 14 days)~* Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~* Daily Challenges (if not ready to quit, but willing to make some changes)"
214514965|NCT05683821|DRUG|Nicotine replacement therapy sampling|"Participants may request:~* Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~* Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
214514966|NCT05683821|COMBINATION_PRODUCT|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
214514967|NCT05683821|COMBINATION_PRODUCT|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
214514968|NCT05683821|COMBINATION_PRODUCT|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
214514969|NCT05683821|BEHAVIORAL|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
215114698|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
214433319|NCT00774852|DRUG|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
214433320|NCT00774852|DRUG|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
214433321|NCT00774852|DRUG|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
214514970|NCT02659059|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
215114699|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
215114700|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
215114701|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
215114702|NCT05802862|DRUG|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
215114703|NCT00983320|DRUG|quetiapine|flexible dosage (50 to 300 mg)
215114704|NCT00983320|DRUG|placebo|placebo
215114705|NCT04981652|DIETARY_SUPPLEMENT|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
214433322|NCT00774852|DRUG|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
214433323|NCT04026594|OTHER|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
214433324|NCT04026594|OTHER|Relaxation group|control group
214433325|NCT06986161|OTHER|Mango|Mango beverage
214433326|NCT06986161|OTHER|Control Beverage|Italian Ice beverage
214433327|NCT00899899|GENETIC|microarray analysis|
214433328|NCT00899899|GENETIC|reverse transcriptase-polymerase chain reaction|
214433329|NCT00899899|OTHER|laboratory biomarker analysis|
214433330|NCT03206554|DRUG|Ropivacaine|Large volume local anaesthetic intraarticularly
214433331|NCT03206554|OTHER|Saline|sham injection
214433332|NCT03997916|DEVICE|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
214514971|NCT02659059|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
214514972|NCT02659059|DRUG|Platinum Doublet Chemotherapy|
214514973|NCT01970072|DRUG|Remimazolam Tosylate|
214514974|NCT01970072|DRUG|Midazolam|
215114706|NCT04981652|DIETARY_SUPPLEMENT|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
215114707|NCT04981652|DIETARY_SUPPLEMENT|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
215114708|NCT02500953|DRUG|ASP3325|
215114709|NCT02500953|DRUG|Placebo|
215114710|NCT00314964|DRUG|PD-0299685|
215114711|NCT01502228|DRUG|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
215114712|NCT01502228|DRUG|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
215114713|NCT01502228|PROCEDURE|Positron Emission Tomography|PET Scan
215114714|NCT01502228|DRUG|Sunitinib|
214433333|NCT03997916|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
214433334|NCT05936411|DEVICE|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
214433335|NCT05936411|DEVICE|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
214433336|NCT04310358|OTHER|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
214433337|NCT04310358|OTHER|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
214433338|NCT01761552|DRUG|Sugammadex Reversal|
214433339|NCT01761552|DRUG|Atropine/Neostigmine|
214433340|NCT06216860|BEHAVIORAL|Laughter Yoga|In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
214433341|NCT04193579|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
214514975|NCT04057300|DRUG|Ticagrelor 90mg|Ticagrelor tablet
214514976|NCT04057300|DRUG|Clopidogrel 75mg|Clopidogrel tablet
215114715|NCT04175028|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
215114716|NCT00584519|OTHER|non-interventional|non-interventional
215114717|NCT06648772|DRUG|Roflumilast Cream 0.3%|Roflumilast Cream 0.3%
215114718|NCT06648772|DRUG|Vehicle cream|Vehicle cream
215114719|NCT02655549|BIOLOGICAL|Px563L, RPA563, or placebo|Two intramuscular injections
214433342|NCT04193579|BEHAVIORAL|Control Treatment|Standard of Care
214433343|NCT04754425|PROCEDURE|Biopsy|Undergo biopsy
214433344|NCT04754425|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow
214433345|NCT04754425|DRUG|Erdafitinib|Given PO
214433346|NCT06168474|OTHER|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
214433347|NCT06168474|OTHER|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
214433348|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
214433349|NCT00000919|DRUG|Indinavir sulfate|
214433350|NCT00000919|DRUG|Lamivudine/Zidovudine|
214433351|NCT00000919|DRUG|Ritonavir|
214433352|NCT00000919|DRUG|Hydroxyurea|
214433353|NCT00000919|DRUG|Abacavir sulfate|
214433354|NCT00000919|DRUG|Amprenavir|
214514977|NCT04057300|DRUG|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
214514978|NCT04110392|DIETARY_SUPPLEMENT|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
214514979|NCT05449756|OTHER|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
214692613|NCT07082309|DIETARY_SUPPLEMENT|Ketone Monoester (KE) and whey protein beverage|Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)
214433355|NCT00000919|DRUG|Nelfinavir mesylate|
214433356|NCT00000919|DRUG|Efavirenz|
214433357|NCT00000919|DRUG|Lamivudine|
214514980|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
214514981|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
214433358|NCT00000919|DRUG|Stavudine|
214433359|NCT00000919|DRUG|Zidovudine|
214433360|NCT00000919|DRUG|Didanosine|
214433361|NCT04562844|OTHER|sociale cognition|several social cognition test
214433362|NCT02858882|OTHER|Screening|Screening of elite swimmers
214433363|NCT05919446|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
214433364|NCT05919446|BEHAVIORAL|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
214433365|NCT01275105|DRUG|Vehicle|one drop in each eye at designated visits
214433366|NCT01275105|DRUG|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
215114720|NCT03954080|DEVICE|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
215114721|NCT04488926|DIETARY_SUPPLEMENT|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
215114722|NCT04488926|OTHER|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
215114723|NCT04488926|DRUG|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
215114724|NCT04488926|DRUG|Rescue Drug|Use as needed allowed
215114725|NCT04007263|DRUG|Placebo|Placebo via 30 minute infusion once daily for 5 days
215114726|NCT04007263|DRUG|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
215114727|NCT00291603|DEVICE|FX-class of dialyser|
215114728|NCT05765123|DIAGNOSTIC_TEST|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
215114729|NCT06020781|DRUG|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
215114730|NCT06020781|DRUG|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
215114731|NCT06020781|DRUG|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
215114732|NCT01588444|DEVICE|cortical FDBA|cortical mineralized freeze-dried bone allograft
214433367|NCT01275105|DRUG|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
215114733|NCT01588444|DEVICE|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
214433368|NCT01275105|DRUG|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
214433369|NCT01339234|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
214433370|NCT06859788|DRUG|Ebselen|Glutathione peroxidase mimetic
214433371|NCT05256290|DRUG|silevertinib (BDTX-1535) monotherapy|Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
214433372|NCT03796884|DRUG|Linaclotide|Given PO
214433373|NCT03796884|OTHER|Placebo|Given PO
214433374|NCT06540898|BEHAVIORAL|Mindfulness-Based Eating and Movement Program|"This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states."
214514982|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
215114734|NCT04999436|BEHAVIORAL|APOL1 Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
215114735|NCT05621551|DRUG|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
215114736|NCT04477759|RADIATION|50 Gy Radiation Therapy|Ionizing radiation
215114737|NCT04477759|RADIATION|55 Gy Radiation Therapy|Ionizing radiation
215114738|NCT04477759|RADIATION|60 Gy Radiation Therapy|Ionizing radiation
215114739|NCT04477759|DRUG|Concurrent Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
215114740|NCT04477759|DRUG|Adjuvant Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year.
215114741|NCT06494358|OTHER|liquid biopsies and surgery specimen analysis|liquid biopsies and surgery specimen analysis
215114742|NCT06049303|OTHER|Paraffin wax bath therapy and Maitland joint mobilization techniques|"In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)"
215114743|NCT06049303|OTHER|Maitland knee joint mobilization|"Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above"
215114744|NCT00335296|DEVICE|PFx catheter|
215114745|NCT00779493|DIETARY_SUPPLEMENT|curcumin|curcumin 900mg twice daily by mouth
215114746|NCT00779493|DIETARY_SUPPLEMENT|placebo|placebo capsule to simulate 900mg curcumin capsule
215114747|NCT04563195|DRUG|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
215114748|NCT05822622|OTHER|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
215114749|NCT02661243|DEVICE|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
215114750|NCT01712802|OTHER|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
215114751|NCT01712802|OTHER|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
215114752|NCT01712802|OTHER|Saline|work as control for Denture Adhesives: Cream and Powder
215114753|NCT01221350|DIETARY_SUPPLEMENT|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
215114754|NCT01221350|DIETARY_SUPPLEMENT|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
214433375|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
214514983|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
214433376|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
214433377|NCT06363253|OTHER|No specific intervention|"Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well."
214433378|NCT03151655|BEHAVIORAL|MATTeRS Video|Narrative-based video intervention and accompanying workbook
214433379|NCT03151655|BEHAVIORAL|Didactic Video|Education only video
214433380|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
214433381|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
214433382|NCT06666972|DIAGNOSTIC_TEST|PCR MTB/NTM|• The Polymerase chain reaction (PCR) MTB/NTM MDR-TB test is an innovative technology that offers a cutting-edge approach to the precise diagnosis of tuberculosis and nontuberculous mycobacterial infections (NTM).
214433383|NCT05158153|OTHER|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
214433384|NCT05158153|DRUG|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
214433385|NCT03833648|OTHER|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
214433386|NCT00648011|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
214433387|NCT00648011|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
214433388|NCT00481182|DRUG|fosamprenavir + ritonavir + methadone|
214433389|NCT05763277|DIAGNOSTIC_TEST|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
214433390|NCT06290609|DEVICE|Vibrotactile Coordinated Reset|The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
214433391|NCT03840668|DEVICE|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
214433392|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
214433393|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
214692614|NCT07082309|DIETARY_SUPPLEMENT|Control|Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
215114755|NCT01444846|DRUG|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
215114756|NCT01444846|DRUG|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
215114757|NCT01444846|DRUG|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
215114758|NCT01444846|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
215114759|NCT00369213|DEVICE|Additional spermicidal lubricant to condoms|
214692615|NCT07067801|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|Study of the Standard of care versus Placebo
215114760|NCT03838081|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
215114761|NCT03838081|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
215114762|NCT03838081|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
214433394|NCT05527717|PROCEDURE|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
214433395|NCT05527717|PROCEDURE|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
214433396|NCT06140615|DEVICE|Ultrasound|Ultrasound of lungs
214433397|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
214433398|NCT05983575|DEVICE|Placebo|Placebo
214433399|NCT06336031|OTHER|blood-injection-injury (BII) phobia stimuli|498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
214433400|NCT06336031|OTHER|neutral stimuli|498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
214433401|NCT06280157|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
214433402|NCT06376383|PROCEDURE|Tonsillectomy|Standard tonsillectomy
214433403|NCT06376383|PROCEDURE|Tonsillotomy|Tonsillotomy
214514984|NCT03467594|BEHAVIORAL|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
214514985|NCT05203003|OTHER|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
214433404|NCT05518396|DIAGNOSTIC_TEST|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
214433405|NCT05015010|DRUG|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
214433406|NCT06677372|DIAGNOSTIC_TEST|Body temperature measurement|Comparative analysis of temperature between esophageal temperature and skin temperature
214433407|NCT06676644|DRUG|adjuvanted|adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
214433408|NCT06676644|DRUG|non-adjuvanted|non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
214433409|NCT06676007|OTHER|Gd-IgA1 test|collect and test Gd-IgA1 test in enrolled subjects
214433410|NCT06677294|PROCEDURE|Placenta remove|This is an observational study. No intervention was performed
214514986|NCT01163929|DRUG|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
214514987|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
214692616|NCT07067801|DRUG|Placebo|Control
215114763|NCT03838081|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
215114764|NCT00003154|DRUG|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
215114765|NCT05377619|DRUG|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
214433411|NCT06676761|PROCEDURE|nipple sparing mastectomy without reconstruction|nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
214433412|NCT06677008|DEVICE|Disposable endoscopic linear cutter stapler|Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
214433413|NCT06677034|OTHER|Exercise|Mobile Game-Based Exercise Training
214433414|NCT06676553|DEVICE|Radiofrequency ablation alone, re-denervation to main and/or branch renal artery|Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
214433415|NCT06676553|PROCEDURE|Radiofrequency ablation alone, no further renal denervation|No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
214433416|NCT06677463|DEVICE|Virtual Reality|Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process
214433417|NCT06677476|OTHER|mobile application training|Researchers compiled literature information and used their expertise to create mobile application content. This content will be downloaded to mobile phones via mobile application software and participants will be trained.
214433418|NCT06676527|OTHER|Follow-up study of the treated cohort|For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
215114766|NCT05377619|DRUG|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
214433419|NCT06676865|DIAGNOSTIC_TEST|the palm print test|"The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation."
214433420|NCT06677073|BEHAVIORAL|High-intensity interval training|High-intensity interval training
214433421|NCT06677073|BEHAVIORAL|Maximal fat oxidation exercise|Maximal fat oxidation exercise
214433422|NCT06676410|OTHER|ICF|Application of Informed Consent Form.
214433423|NCT06676410|BEHAVIORAL|Eligibility Assessment|Assessment of inclusion, exclusion and discontinuation criteria.
214433424|NCT06676410|OTHER|Demographic data|Collection of demographic data.
214433425|NCT06676410|DIAGNOSTIC_TEST|Weight, height and BMI|Weight and height measurement and body mass index calculation.
214433426|NCT06676410|OTHER|Vital Signs|HR, BP and FR and T°, in addition to oximetry.
214433427|NCT06676410|DIAGNOSTIC_TEST|Medical evaluation|Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
214514988|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
214514989|NCT00230009|BEHAVIORAL|Brief motivational intervention|
214514990|NCT04641156|OTHER|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
214514991|NCT02227888|DRUG|N91115|S nitrosoglutathione reductase inhibitor
214514992|NCT05299099|DRUG|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
214514993|NCT05299099|DRUG|RCN301|RCN301 will be injected continuously for 3 days.
214514994|NCT06678048|DRUG|Arsenous Acid plus Chemotherapy|Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
215114767|NCT05377619|DRUG|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
215114768|NCT01902329|DRUG|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
215114769|NCT01902329|DRUG|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
215114770|NCT03715244|PROCEDURE|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery \< 90 minutes
214514995|NCT04827602|OTHER|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
214514996|NCT01976156|DIETARY_SUPPLEMENT|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
215114771|NCT03715244|PROCEDURE|General anesthesia (current standard)|General anesthesia in patients with duration of surgery \< 90 minutes
215114772|NCT04975776|BEHAVIORAL|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
215114773|NCT04975776|BEHAVIORAL|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
215114774|NCT06236386|OTHER|VR Experience|VR headset and video experience.
215114775|NCT04635917|OTHER|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
215114776|NCT04635917|OTHER|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
215114777|NCT06149078|DIAGNOSTIC_TEST|serum uric acid|to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
214433428|NCT06676410|DIAGNOSTIC_TEST|Safety exam|Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
214433429|NCT06676410|DIAGNOSTIC_TEST|Pregnancy test|β-HCG in urine in non-sterile women
214433430|NCT06676410|DIAGNOSTIC_TEST|Serology|HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
214514997|NCT01976156|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
214433431|NCT06676410|OTHER|Randomization|Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
214433432|NCT06676410|DIAGNOSTIC_TEST|Apoptosis markers|Caspases and Annexin V.
215114778|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
215114779|NCT04449510|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
214433433|NCT06676410|DIAGNOSTIC_TEST|Cell activation markers|PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
214433434|NCT06676410|DIAGNOSTIC_TEST|Inflammation markers|ultrasensitive CRP, D-dimer.
214433435|NCT06676410|DIAGNOSTIC_TEST|Proviral DNA:|Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
214433436|NCT06676410|DIAGNOSTIC_TEST|HIV-specific antibodies|Anti-HIV-1 specific antibody titers in plasma.
214433437|NCT06676410|DIAGNOSTIC_TEST|HIV viral load (RNA)|Performed on plasma.
214433438|NCT06676410|BEHAVIORAL|Codivir® Training|The participant is trained to self-inject Codivir®
214433439|NCT06676410|DRUG|Dispensing Codivir®|the participant receives Codivir®
214433440|NCT06676410|OTHER|Codivir® Accounting|The Codivir® used since the last visit is accounted for
214433441|NCT06676410|OTHER|Concomitant medication|Record of concomitant medications used.
214514998|NCT02173561|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
214514999|NCT02173561|BEHAVIORAL|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
214692617|NCT07084714|BEHAVIORAL|Moderate Aerobic Exercise|"Participants will complete moderate intensity aerobic exercise for 30 minutes per session, progressing from three to five days per week to meet the minimum recommended aerobic physical activity guideline of 150 minutes per week set by the American College of Sports Medicine (ACSM) over two menstrual cycles. Moderate intensity is defined as maintaining a heart rate within 40-59% heart rate reserve and a rate of perceived exertion of 11-14 light to somewhat hard on the Borg 6-20 scale."
214433442|NCT06676410|OTHER|Adverse events|Collection and recording of adverse events.
214433443|NCT06676410|DRUG|Antiretrovirals|"Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day"
214433444|NCT06676800|DRUG|Yiqi Gubiao pill|Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
214433445|NCT06676800|DRUG|Yiqi Gubiao Pill placebo|The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
214433446|NCT05756699|DIAGNOSTIC_TEST|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
214433448|NCT06679530|OTHER|Mindful Music Listening (MML)|Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
215114780|NCT06559826|DRUG|Ketamine|Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
215114781|NCT06559826|BEHAVIORAL|Psychotherapy|Each week following KAP, there will be a separate 60-minute integration session 1-6 days afterwards. Integration sessions will focus on processing experiences and material that emerged in KAP sessions (such as assimilating challenging experiences, making meaning of experiences and imagery, working through memories and emotions, and exploring emerging relational patterns) as well as strengthening insights. Within one week of the completion of all KAP sessions, there will be one additional integration session focused on consolidating the insights and improvements gained from KAP treatment.
215114782|NCT06174129|OTHER|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
215114783|NCT04444466|DRUG|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
215114784|NCT04444466|OTHER|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
214515000|NCT04970966|DEVICE|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
214515001|NCT04970966|DEVICE|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
214515002|NCT00002761|BIOLOGICAL|filgrastim|
214515003|NCT00002761|BIOLOGICAL|recombinant interferon gamma|
214515004|NCT00002761|DRUG|busulfan|
214515005|NCT00002761|DRUG|cyclophosphamide|
214515006|NCT00002761|DRUG|cyclosporine|
214515007|NCT00002761|DRUG|cytarabine|
214515008|NCT00002761|DRUG|idarubicin|
214433449|NCT04924218|PROCEDURE|endoscopic surgical intervention|The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
214433450|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
214433451|NCT05396794|BEHAVIORAL|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
215114785|NCT01493973|DRUG|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
215114786|NCT01493973|DRUG|Placebo|Placebo
214433452|NCT05396794|BEHAVIORAL|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
214433453|NCT06870682|BEHAVIORAL|ROBUST|During a 4-week intervention, participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. This intervention can be distinguished from others since it integrates both motor and sensory function, with focus on sensory processing. It combines robot-based therapy, a transfer package to daily activities, and a home program.
214433454|NCT06676228|BEHAVIORAL|Fear of cancer recurrence therapy (FORT)|"FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content"
214433455|NCT06676228|BEHAVIORAL|cognitive-behavioural therapy (CBT) group|"The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise"
214433456|NCT06676787|OTHER|Transportation Voucher, Comunity engagement and microplannnig support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. This is in addition to support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
214433457|NCT06676787|OTHER|Direct Facility Funding, Community Engagement, and Microplaning Support|Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly performance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
214433458|NCT06676787|OTHER|Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly oerformance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
214433459|NCT02474147|OTHER|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
214433460|NCT02474147|OTHER|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
215114787|NCT04339673|PROCEDURE|masseteric nerve block|regional bloc of masseter
215114788|NCT04339673|PROCEDURE|trigger point injection|trigger point injection with local anesthetic
215114789|NCT04339673|PROCEDURE|dry needling|needling with acupuncture needles of trigger points in masseter
215114790|NCT03243357|PROCEDURE|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
215114791|NCT03243357|PROCEDURE|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
214515009|NCT00002761|PROCEDURE|peripheral blood stem cell transplantation|
214515010|NCT02800135|DRUG|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
214515011|NCT03072238|DRUG|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
214515012|NCT03072238|DRUG|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
214515013|NCT03072238|DRUG|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
214515014|NCT03072238|DRUG|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
214515015|NCT00112827|RADIATION|total marrow irradiation|Undergo irradiation
214515016|NCT00112827|DRUG|melphalan|Given IV
214515017|NCT00112827|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
214515018|NCT00112827|BIOLOGICAL|filgrastim|Given IV
214433461|NCT06057480|DEVICE|APM|Investigational programming software module, the Assisted Programming Module (APM)
214433462|NCT01827787|DRUG|Eribulin|
214433463|NCT06607588|OTHER|Not applicable- observational study|Not applicable- observational study
214433464|NCT06618664|DRUG|SHR-8068|SHR-8068: injection, 50 mg/10 mL, intravenous infusion
214433465|NCT06618664|DRUG|Adebrelimab|Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
214515019|NCT00112827|GENETIC|fluorescence in situ hybridization|Correlative studies
214515020|NCT00112827|GENETIC|cytogenetic analysis|Correlative studies
214515021|NCT00112827|DRUG|cyclophosphamide|Given IV
214433466|NCT06618664|DRUG|Bevacizumab|Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
214433467|NCT06618664|DRUG|Sintilimab|Sintilimab: injection, 100 mg/10 mL, intravenous infusion
214433468|NCT03482635|DRUG|Spesolimab|Solution for infusion
214433469|NCT03482635|DRUG|Placebo|Solution for infusion
214433470|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
214433471|NCT03472755|OTHER|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
214433472|NCT06625931|DRUG|NTCB01-1|3 Days infusion
214433473|NCT06625931|DRUG|NTCB-P|3 Days infusion
214433474|NCT06629155|DIAGNOSTIC_TEST|Infrared oculography|Eye movements will be captured through infrared oculography and processed via in-house algorithms.
214433475|NCT01116180|DRUG|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
214515022|NCT00112827|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
214515023|NCT00112827|DRUG|lenalidomide|Given orally
214515024|NCT03924193|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
214515025|NCT03924193|BEHAVIORAL|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
214515026|NCT03924193|OTHER|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
214515027|NCT05856955|BEHAVIORAL|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
214515028|NCT05856955|BEHAVIORAL|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
214515029|NCT02446860|DRUG|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
214515030|NCT05655260|OTHER|Comparison of chemotherapy vs. chemoradiotherapy|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
214515031|NCT05655260|OTHER|Comparison of VBT vs. WPRT|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
214515032|NCT05684120|BEHAVIORAL|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
214515033|NCT04789018|OTHER|Educational Intervention|Attend virtual genetics board
214433476|NCT01116180|DRUG|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
214433477|NCT06699953|OTHER|Observational study in patients receiving fentanyl for surgery|"This observational study enrolls patients receiving fentanyl, a drug routinely administered during surgery under general anesthesia. The primary difference in the investigators' research protocol is the inclusion of a 5-minute interval between fentanyl administration and the induction of general anesthesia. Fentanyl will be given in two boluses of 2 mcg/kg (ideal body weight), spaced 2 minutes apart, totaling 4 mcg/kg. If the participant remains conscious, an additional 2 mcg/kg bolus will be administered after 2 minutes. Additionally, participants will complete a drug-liking questionnaire before the first bolus and every 30 seconds until anesthesia induction, rating how much they liked the drug on a 0-100 scale."
214433478|NCT06708754|DEVICE|Photobiomodulation (PBM) Therapy|"PBM is a low-intensity form of light therapy and employs visible or near-infrared (NIR) light generated from a laser or Light Emitting Diode (LED).~In this study, PBM will be delivered using an LED device emitting 660 and 850nm with the purpose of research. The output power typically ranges from 5 to 200 mW with wavelengths ranging 600-1,000nm."
214433479|NCT06708754|DEVICE|Sham PBM|Sham PBM will be delivered using a matching shame device that emits no output power.
214433480|NCT06728579|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|eight weekly two-hour MORE sessions
214433481|NCT06728579|OTHER|Questionnaires|filled out up to 24 weeks
214515034|NCT04789018|OTHER|Survey Administration|Complete survey
214515035|NCT04789018|OTHER|Interview|Complete interview
215114792|NCT05178602|BEHAVIORAL|Tai Chi Intervention Group|Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
215114793|NCT05622565|DIAGNOSTIC_TEST|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
215114794|NCT00234923|DRUG|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
215114795|NCT00234923|DRUG|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
215114796|NCT05349357|OTHER|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
215114797|NCT05349357|OTHER|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
215114798|NCT05349357|OTHER|Stretching exercises|Stretching exercises
214433482|NCT06728579|BEHAVIORAL|Supportive Psychotherapy (SG)|eight weekly two-hour SG sessions
214433483|NCT06889688|DRUG|Camrelizumab+Apatinib+Eribulin|Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
215114799|NCT05349357|DEVICE|TENS|TENS
215114800|NCT06537726|DIAGNOSTIC_TEST|Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)|Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
214433484|NCT06889688|DRUG|Physician's choice chemotherapy|Physician's Choice Chemotherapy
214433485|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by bone tumor resection
214515036|NCT02032134|BIOLOGICAL|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
214515037|NCT02489799|BEHAVIORAL|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
215114801|NCT05074940|DRUG|Amivantamab|Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
215114802|NCT03319134|DEVICE|active anodal HD-tDCS|1\) active anodal HD-tDCS with memory task
215114803|NCT03319134|DEVICE|sham HD-tDCS|2\) sham HD-tDCS with memory task
215114804|NCT03319134|DEVICE|active cathodal HD-tDCS|3\) active cathodal HD-tDCS with memory task
215114805|NCT00799435|DRUG|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
215114806|NCT05888987|BIOLOGICAL|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
215114807|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
215114808|NCT06799390|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
215114809|NCT06799390|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
215114810|NCT06975514|DRUG|YZJ-1139|YZJ-1139 20mg tablets, once daily in the evening
215114811|NCT06975514|DRUG|Zolpidem|Zolpidem 10mg tablets, once daily in the evening
215114812|NCT06976814|OTHER|Neuro muscular electrical stimulation|electrical stimulation to facial nerve to improve facial palsy
215114813|NCT06976814|OTHER|Beckmann's oral motor exercises|Oral motor exercises to improve facial palsy.
214433486|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by aseptic loosening of orthopaedic hardware
214433487|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by trauma-related conditions
214433488|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
214515038|NCT02489799|BEHAVIORAL|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
214515039|NCT02195219|PROCEDURE|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
214433489|NCT06754137|DIAGNOSTIC_TEST|AI-Assisted Fracture Detection System|The intervention involves the use of an AI-assisted fracture detection system (Aidoc or Gleamer BoneView), which is integrated into the hospital's Picture Archiving and Communication System (PACS). These AI tools analyze X-ray images in real time, highlighting potential fracture sites for physician review. The AI output serves as an additional aid, while the final diagnosis remains the responsibility of the physician.
214433490|NCT06754137|DIAGNOSTIC_TEST|Standard Physician-Interpreted Fracture Detection|Physicians interpret X-ray images using their standard diagnostic practices without any assistance from AI. This represents the traditional approach to diagnosing fractures.
215114814|NCT06975540|OTHER|Multidomain physical exercise|The intervention includes a daily intake of two 200-mL of Meritene nutritional supplements (199 Kcal, 16g of protein, 25g of carbs, 3.6g of fats, and enriched with vitamins and minerals/bottle) plus a supervised and personalized multicomponent exercise program. Multicomponent exercise program (MEP) includes endurance, strength, coordination, balance, and flexibility exercises. The sessions last 65 min a day, 3 days/week for 24 weeks. All the sessions are supervised and delivered in groups by sports scientists.
214515040|NCT02195219|OTHER|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
214515041|NCT06585059|DRUG|TQB2928 injection + Almonertinib Mesilate Tablets|"TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug."
214515042|NCT04909593|DEVICE|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
214515043|NCT02415335|DRUG|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
214515044|NCT02415335|DRUG|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
214515045|NCT01993342|OTHER|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
214515046|NCT01993342|OTHER|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
214515047|NCT02625168|DRUG|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
214515048|NCT02625168|DRUG|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
214515049|NCT01771081|DRUG|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
214515050|NCT06343662|BEHAVIORAL|MERAKI_ABI|"The music therapy session will focus on the themes of reidentification and involvement. The aim is to accompany the patient during the illness process, allowing them to express their emotional state, relate to music, promote listening and communication between family members, help and value preserved abilities, and promote personal involvement in the rehabilitation process.~The session will work with songs, taking into account musical preferences."
215114815|NCT06974552|PROCEDURE|microbead-filled support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using microbead-filled support surfaces. This support surface will remain in place throughout the duration of the surgery.
214515051|NCT01241448|DRUG|LY2409021|Administered Orally
214433491|NCT06761534|OTHER|Screening of comprehensive geriatic assessment.|The participants are screened before anti-tumor therapy with a comprehensive assessment screening tool developed for elderly cancer patients, which is more suitable for individualized decision-making in anti-tumor treatment.
214433492|NCT06761534|OTHER|the G8 assessment|The G8 is a rapid geriatric screening test that takes only a few minutes to complete. It is used as a calibration standard to validate the novel screening tool in this study.
214433493|NCT06761534|OTHER|Comprehensive Geriatric Assessment (CGA)|The participants screened as a high frailty risk will undergo CGA to determine the most appropriate treatment plan.
214515052|NCT01241448|DRUG|Placebo|Administered Orally
214515053|NCT00300339|DRUG|SL650472, Clopidogrel|
214515054|NCT02540915|OTHER|Standard of Care - Registry|Standard of Care - Registry
214515055|NCT03622372|PROCEDURE|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
215114816|NCT06974552|PROCEDURE|Jel support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using jel support surfaces. This support surface will remain in place throughout the duration of the surgery.
215114817|NCT06976177|DRUG|MT1013|MT1013 is a novel calcimimetic agent
215114818|NCT06977035|DEVICE|Nerve Conduction Study|Sensory and Motor Nerve Conduction study on upper and lower limbs.
215114819|NCT06976840|DEVICE|Intermittent theta burst stimulation|Aimed at potentiating the stimulation target.
215114820|NCT06976840|DEVICE|Sham theta burst stimulation|No effect is expected on stimulation target
215114821|NCT06976840|DEVICE|Continuous theta burst stimulation|Aimed at depotentiating the stimulation target
214433494|NCT04242940|DEVICE|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
214433495|NCT04777851|DRUG|Regorafenib in combination with pembrolizumab|Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
214433496|NCT04777851|PROCEDURE|Loco-regional therapy|"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
214433497|NCT04240808|BIOLOGICAL|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)
214433498|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
214515056|NCT03622372|DEVICE|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
214515057|NCT03622372|DEVICE|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
214515058|NCT00630409|DRUG|Gemcitabine|800 mg IV day 1 and 8
215114822|NCT05061862|DEVICE|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure and/or non-invasive diagnostic collection at follow-up visits, as applicable.
215114823|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
215114824|NCT06554743|BEHAVIORAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
215114825|NCT06554743|BEHAVIORAL|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
215114826|NCT06665035|BIOLOGICAL|TDV|TDV SC injection.
214515059|NCT00630409|DRUG|Doxil|24 mg/m2 every 21 days IV
215114827|NCT06665035|OTHER|Placebo|Placebo SC injection.
215114828|NCT03960177|DRUG|Glucarpidase|Given IV
215114829|NCT03960177|OTHER|Quality-of-Life Assessment|Ancillary studies
215114830|NCT05836259|GENETIC|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
215114831|NCT06285396|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature.
215114832|NCT06285396|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature.
215114833|NCT06285396|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature.
214433499|NCT06735950|BEHAVIORAL|Volunteering in Place Program|Implementation of the VIP Program consists of 4 steps guided by the Social Ecological Model (SEM) with Interpersonal interventions guided by Social Cognitive Theory (SCT), and will be implemented over a 6-month period by research supported Volunteer Coordinators. The four steps of the VIP Program are: Step 1: Stakeholder Team, Staff and Family Education; Step 2: Assessment of AL Environment and Residents Abilities and Interests; Step 3: Ongoing Implementation of the Volunteer Plan; and Step 4: Reassessment of the Volunteer Activity. Participants will volunteer three time per week for approximately 30 minutes.
214433500|NCT06735950|BEHAVIORAL|Recreational activity|The Recreational Activities group intervention will consist of similar staff education regarding the benefits of engaging residents in meaningful activities as described in Step 1 above, without other steps associated with the VIP Program. The Recreational Activities group will be exposed to a research team RA coordinator who will provide a current events activity (reviewing the daily newspaper) for the participants in the RA group three times per week for approximately 30 minutes as an attention control.
214433501|NCT05579392|DEVICE|Bright Light Therapy|Device: Bright Light Therapy Retimer
214433502|NCT05579392|DEVICE|Placebo Retimer Device|Device: Placebo Retimer Device with no bright light therapy
214433503|NCT06897514|DIAGNOSTIC_TEST|Prediction algorithm for intraoperative hypotension|All participants will receive five non-invasive monitoring during their surgery. Data from these monitoring device will be put into the prediction algorithm.
214433504|NCT06555757|OTHER|Height, weight, and BMI|Height, weight measurement and BMI calculation
214433505|NCT06555757|OTHER|Medical history|Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
214433506|NCT06555757|OTHER|Physical examination|Brief physical examination
214433507|NCT06555757|DIAGNOSTIC_TEST|Venous blood samples|Venous blood samples, to include WCC, HB, CRP and NTproBNP
214433508|NCT06555757|OTHER|Resting vital signs|HR, BP, RR, oxygen saturations on air)
214433509|NCT06555757|DIAGNOSTIC_TEST|Transthoracic echocardiogram|LVEF, IVC collapsibility, LV filling pressure, PA pressure
214433510|NCT06555757|OTHER|Sound recordings|Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
214433511|NCT06555757|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound
214433512|NCT06555757|OTHER|KCCQ questionnaire|Kansas City Cardiomyopathy Questionnaire
214433513|NCT06555757|OTHER|ASCEND-HF score|An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
214433514|NCT06555757|OTHER|Composite Everest congestion score|A shortened version of the original 18-point score from the EVEREST trial
214433515|NCT06555757|DIAGNOSTIC_TEST|Bio impedance and total body water measurement|Bio impedance and total body water measurement using TANITA device
214433516|NCT06215183|OTHER|Music therapy|Women applying for IUD application will receive music therapy for 5 minutes before the procedure, during the IUD application, and for 5 minutes after the procedure.
214433517|NCT06754163|DRUG|Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)|"Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet."
214433518|NCT06903234|DRUG|Iptacopan|Adult patients with PNH treated with iptacopan
214433519|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
214433520|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
214433521|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
215114834|NCT06285396|DRUG|Oxytocin|Oxytocin, at applicable concentrations based on literature.
214433522|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
214433523|NCT03918694|DIETARY_SUPPLEMENT|Vitamin C|Daily use of Vit C tablets
214433524|NCT03918694|DIETARY_SUPPLEMENT|Placebo|Daily use of placebo tablets
214433525|NCT04898829|DIETARY_SUPPLEMENT|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~\- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~\- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
214433526|NCT04449679|OTHER|Patient Monitoring System|Receive RT-CAMSS
214433527|NCT04449679|OTHER|Questionnaire Administration|Complete questionnaires
214433528|NCT04449679|OTHER|Consultation|Receive tailored feedback, including consultation with nurse
214433529|NCT06914648|PROCEDURE|Portal Vein Embolization|Description: Portal Vein embolization with Glue by a transhepatic approach
214433530|NCT06914648|PROCEDURE|Hepatic Vein Embolization|Hepatic Vein Embolization with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
214433531|NCT05062317|DRUG|Leucovorin|Given by PO
214433532|NCT05062317|DRUG|5-FLUOROURACIL|Given by IV
214433533|NCT05062317|DRUG|Oxaliplatin|Given by PO
214433534|NCT05062317|DRUG|Irinotecan|Given by IV
214433535|NCT05062317|DRUG|Capecitabine|Given by IV
214515060|NCT03425175|OTHER|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
214515061|NCT02346786|DIETARY_SUPPLEMENT|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
215114835|NCT06603012|BEHAVIORAL|GET Up PD|"* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-3 sets, 8-12 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GET Up PD program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
215114836|NCT06603012|BEHAVIORAL|Stretching and Flexibility|"* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GET Up PD program, and account for activity, social-contact, and attention.~* Other components of the Stretching and Flexibility program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GET Up PD program."
215114837|NCT06584357|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
215114838|NCT06584357|RADIATION|MK6240|Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
214515062|NCT02346786|DIETARY_SUPPLEMENT|tap water|
214515063|NCT01690000|DRUG|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
214515064|NCT02065297|OTHER|1 blood sample|
214515065|NCT02065297|OTHER|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
214515066|NCT01714908|OTHER|Erlotinib w Concurrent Radiotherapy|
214515067|NCT01714908|OTHER|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
214515068|NCT02165202|DRUG|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
215114839|NCT06807580|DRUG|Placebo|The placebo will be nearly identical in size, color, and shape to micronized progesterone
215114840|NCT06807580|DRUG|Progesterone|Oral micronized progesterone 200 mg
215114841|NCT06391489|BEHAVIORAL|HOBSCOTCH-PACS|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
214433536|NCT05062317|DRUG|Bevacizumab|Given by IV
214515069|NCT02165202|DRUG|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
214433537|NCT00025324|BIOLOGICAL|filgrastim|
214433538|NCT00025324|DRUG|carboplatin|
214433539|NCT00025324|DRUG|cyclophosphamide|
214433540|NCT00025324|DRUG|etoposide|
214433541|NCT00025324|DRUG|thiotepa|
214433542|NCT00025324|PROCEDURE|autologous bone marrow transplantation|
214433543|NCT00025324|PROCEDURE|bone marrow ablation with stem cell support|
214433544|NCT00025324|PROCEDURE|conventional surgery|
214433545|NCT00025324|PROCEDURE|peripheral blood stem cell transplantation|
214433546|NCT00025324|RADIATION|radiation therapy|
214515070|NCT04785794|BIOLOGICAL|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
214515071|NCT04785794|OTHER|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
214515072|NCT01557439|DRUG|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
214433547|NCT06922786|DEVICE|Hemadsorption filter|"Plasma titers neurodepressing drug:~* At admission to the hospital (standard of care)~* 2 hours after admission (+/- 15 minutes)~* 4 hours after admission (+/- 15 minutes)~* 6 hours after admission (+/- 15 minutes)~* 8 hours after admission (+/- 15 minutes)~* Just before start hemadsorption~Hemadsorption via dialysis catheter in patients still fulfilling inclusion criteria 8 hours after admission.~Subsequent plasma titers pre- and post-hemadosorption filter:~* 15 minutes after start of hemadsorption (+ 15 minutes)~* 4 hours after start of hemadsorption (+/- 15 minutes)~* 8 hours after start of hemadsorption (+/- 15 minutes)~* 12 hours after start of hemadsorption (+/- 15 minutes)~* 16 hours after start of hemadsorption (+/- 15 minutes)~* 20 hours after start of hemadsorption (+/- 15 minutes)~* 24 hours after start of hemadsorption (+/- 15 minutes)~* Every other 24 hours until cessation of hemadsorption or normalization of the plasma titer (+/- 15 minutes)"
214433548|NCT00431704|DRUG|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
214433549|NCT00431704|DRUG|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
214433550|NCT00431704|DRUG|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
214433551|NCT06107894|BIOLOGICAL|Tumor-infiltrating lymphocytes|After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
214433552|NCT06107894|DRUG|IL-2|IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
214515073|NCT03441256|DEVICE|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
214515074|NCT03441256|DEVICE|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
214515075|NCT04876430|DRUG|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
214515076|NCT03681067|DRUG|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
214515077|NCT03681067|DRUG|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
214515078|NCT01689740|DRUG|Active Placebo Dose MDMA-assisted therapy (25 mg)|Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.
214433553|NCT05335798|DEVICE|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
214433554|NCT05335798|DEVICE|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
214433555|NCT01304277|BIOLOGICAL|agalsidase alfa|
214445437|NCT04764500|OTHER|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
214445438|NCT04764500|OTHER|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
214515079|NCT01689740|DRUG|Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
214515080|NCT01689740|DRUG|Open-Label Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
214515081|NCT01689740|BEHAVIORAL|Psychotherapy|Non-directive psychotherapy will be conducted throughout the study.
215114842|NCT00581906|RADIATION|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
215114843|NCT04923126|DRUG|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
215114844|NCT06580561|BEHAVIORAL|Personalized exercise coaching|"This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions)."
215114845|NCT06580561|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|"This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises."
215114846|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
215114847|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
215114848|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
215114849|NCT04954859|DRUG|Bepirovirsen|No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
215114850|NCT04954859|DRUG|Placebo|No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
215114851|NCT06982183|DRUG|Propranolol|An administration of a 40-mg propranolol capsule immediately after tarantula exposure
215114852|NCT06982183|DRUG|Hydrocortisone|An intramuscular administration of 62.5 mg/1 ml of hydrocortisone immediately after tarantula exposure
215114853|NCT06982183|DRUG|Morphine|An intramuscular administration of 5 mg/1 ml of morphine immediately after tarantula exposure
215114854|NCT06982183|DRUG|Placebo (oral)|An administration of a placebo capsule after tarantula exposure
215114855|NCT06982183|DRUG|Placebo (IM)|An intramuscular administration of 1 ml of saline immediately after tarantula exposure
215114856|NCT04209205|DRUG|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
215114857|NCT04209205|DRUG|Placebo|Matching placebo to AIN457 i.v. infusion
215114858|NCT04209205|DRUG|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
215114859|NCT05244564|OTHER|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)|"Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy."
214433556|NCT05808608|DRUG|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
214433557|NCT05808608|DRUG|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
214433558|NCT06548282|OTHER|Acceptance and commitment therapy|"Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude."
214433559|NCT06326645|DRUG|Crofelemer Oral Product|Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
215114860|NCT06593496|BEHAVIORAL|Text Message Reminder|Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.
214433560|NCT05578898|BEHAVIORAL|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
214433561|NCT05331521|DRUG|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
214433562|NCT05331521|DRUG|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
214433563|NCT05331521|RADIATION|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
214515082|NCT04714359|DRUG|Midomafetamine HCl|Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.
215114861|NCT06595914|OTHER|Clinical implementation strategies|Clinical implementation strategies, selected based on ED clinician survey/interview findings from Aim 1 using the Implementing Promoting Action on Research Implementation in Health Services (i-PARIHS) implementation science framework
215114862|NCT03254940|BEHAVIORAL|Charge|Text messaging-based study to determine effect of different components on weight loss.
215114863|NCT03966872|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
215114864|NCT03966872|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
215114865|NCT02784847|DRUG|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
215114866|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
215114867|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
215114868|NCT06990737|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Participants will have SLNs excised from the affected area(s) per standard of care
215114869|NCT06990737|PROCEDURE|Lymphadenectomy|Surgeon preference will dictate the order of the surgery for resecting the primary tumor. Elective neck dissection (END) will include nodal basins based on the primary site of disease, at-risk nodal basins, and any additional dissection per the surgeon's discretion. In the event of a positive SLN, the completion neck dissection (CND) should be completed.
215114870|NCT06990737|DRUG|Adjuvant Definitive Therapy|Use of chemotherapy will depend on the specific phase of treatment and high-risk features as per standard of care and NCCN Head and Neck Cancer-Clinical Practice Guidelines in Oncology
215114871|NCT06996665|OTHER|High-flow device flow rate setting|To evaluate the feasibility of diaphragmatic speckle tracking, images acquired under three different high-flow settings (low, medium, and high) will be compared with those obtained under the clinically applied flow rate previously used for each patient.
214433564|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
214433565|NCT02279095|DRUG|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
214433566|NCT02279095|DRUG|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
214433567|NCT02279095|DRUG|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
214433568|NCT02279095|DRUG|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
214433569|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
214433570|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
214433571|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
214433572|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
214433573|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
214433574|NCT02918331|DRUG|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
214433575|NCT02918331|DRUG|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
214515083|NCT01773707|DRUG|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
214515084|NCT01773707|DRUG|Placebo|Saline given as 30 minute IV infusion
215114872|NCT06996665|OTHER|PEEP titration through different approaches|To investigate the clinical value of diaphragmatic speckle tracking, this study compares PEEP titrated by ultrasound-based assessment with PEEP determined by conventional P/F ratio tables, and analyzes differences in clinical outcomes between the two groups.
215114873|NCT06996210|DEVICE|Acupuncture|The needles will be inserted to 12.5-30 mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
215114874|NCT06996210|DEVICE|sham acupuncture|The needle will be inserted to 2-3mm in sham Baihui acupoint. For the remaining sham acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
215114875|NCT04742920|DEVICE|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
215114876|NCT04742920|PROCEDURE|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
214433576|NCT02918331|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
214433577|NCT05971303|OTHER|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
214433578|NCT02397083|DRUG|Everolimus|Given PO
214515085|NCT03272815|DEVICE|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
214433579|NCT02397083|OTHER|Laboratory Biomarker Analysis|Correlative studies
214515086|NCT03272815|DEVICE|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
214515087|NCT01255709|DRUG|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
214515088|NCT01255709|DRUG|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
214515089|NCT01255709|DRUG|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
214515090|NCT00629993|BEHAVIORAL|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
214433580|NCT02397083|DEVICE|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
214515091|NCT00249366|DRUG|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
214515092|NCT00249366|DRUG|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
214515093|NCT02814409|DRUG|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
214433581|NCT03646045|OTHER|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
214433582|NCT06834919|OTHER|Observational|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
214515094|NCT02814409|DRUG|Intravenous Tenecteplase|IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
214515095|NCT01477866|DIETARY_SUPPLEMENT|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
214433583|NCT06780163|DRUG|17β-estradiol 10 mcg|17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
214515096|NCT01477866|OTHER|conventional therapy|conventional therapy for colon-rectal cancer
214515097|NCT01420328|DRUG|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
214515098|NCT01420328|DRUG|Placebo|Placebo treatment for 6 weeks
214515099|NCT02749253|OTHER|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
214515100|NCT05553730|BEHAVIORAL|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
214433584|NCT06780358|DEVICE|AI supported detection of bladder cancer|AI-model-supported detection of bladder cancer during white light cystoscopy
214515101|NCT01859689|RADIATION|brachytherapy|Undergo image-guided HDR brachytherapy
214515102|NCT01859689|RADIATION|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
214515103|NCT01859689|OTHER|laboratory biomarker analysis|Correlative studies
214515104|NCT05636345|OTHER|pain science education|A full day of pain science education
214515105|NCT04148794|BEHAVIORAL|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
214515106|NCT01527643|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
214433585|NCT06780865|DRUG|Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine|Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
214433586|NCT06780865|DRUG|Placebo-controlled group|Participants are treated with corresponding placebo
214515107|NCT02287948|DEVICE|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1\) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
214433587|NCT05644444|DEVICE|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
215114877|NCT06999304|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Intermittent theta burst - Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Continuous theta burst - Number of pulses per session: 1800 pulses; Pulse frequency in burst: 50 Hertz
215114878|NCT06999928|BEHAVIORAL|Enhanced Mentor Mother Strategy|The enhanced Mentor Mother strategy introduces a structured approach to differentiated PMTCT support, led by trained peer counselors/Mentor Mothers (MM). Mentor Mothers will be trained on how to perform risk stratification, and they will use a standardized form to identify and document psychosocial and clinical risk factors. Based on these, MMs then deliver tailored interventions, including additional counseling, community outreach, and referrals. Fidelity assessments and a process of audit and feedback will be used to further refine the strategy, which builds on national differentiated service delivery guidelines and integrates into routine care without requiring added clinic staff.
215114879|NCT07001449|BEHAVIORAL|Pain Neuroscience Education with Communication Training|"This intervention includes individualized physiotherapy based on a Pain Neuroscience Education (PNE) framework delivered by physiotherapists who completed the full Algo(S)Therapy training program. The training includes education in the neurophysiology of pain, clinical reasoning for chronic musculoskeletal pain management, and structured communication skills development (e.g., motivational interviewing, empathy, active listening). The intervention is delivered twice per week over 5 weeks (10 sessions total)."
215114880|NCT07001449|BEHAVIORAL|Pain Neuroscience Education without Communication Training|"A structured PNE program focusing on the neurophysiology and clinical management of chronic musculoskeletal pain. Delivered by physiotherapists trained only in the scientific modules of the Algo(S)Therapy program. Does not include communication skills training. Includes 10 sessions (2/week for 5 weeks), alongside standard physiotherapy care."
215114881|NCT07001449|BEHAVIORAL|Usual Physiotherapy Treatment|"Usual care based on medical referral and physiotherapy assessment. Delivered by physiotherapists who have not received training in Pain Neuroscience Education or communication techniques. No components of the Algo(S)Therapy program are included."
215114882|NCT03427749|DIAGNOSTIC_TEST|SPECT Imaging with 99mTc-Tetrofosmin Research Imaging|This is an observational study; patients will be managed according to the standard clinical care of the local site. Study end will be defined as completion of all SPECT imaging at rest and stress. Studies will be acquired at 6 initial sites with mixed prior experience at MBF imaging, to demonstrate feasibility of use in a clinical setting.
215114883|NCT06867991|DRUG|Ofatumumab combined with daratumumab|All participants will begin acute first-line therapy prior to randomization, and participants who were receiving oral or intravenous corticosteroids at baseline will need to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Patients will be randomly assigned to receive ofatumumab followed by daratumumab or ofatumumab followed by repeated intravenous globulin. The ofatumumab group will receive subcutaneous ofatumumab at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24, while the ofatumumab-daratumumab group will receive daratumumab intravenously (on the second day of ofatumumab) in addition to ofatumumab, with a dose of 8 mg/kg at weeks 0, 1, 2, and 4, and a dose of 4 mg/kg at weeks 8, 12, 16, 20, and 24. The study will investigate the effects of up to 24 cycles of daratumumab.
215114884|NCT06867991|DRUG|Ofatumumab|All participants were started on acute first-line therapy before randomization, and participants who were receiving oral or intravenous glucocorticoids at baseline were required to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Ofatumumab was administered subcutaneously at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24 in the ofatumumab group.
215114885|NCT06867991|DRUG|Repeated intravenous immunoglobulin/plasma exchange therapy|Repeated intravenous immunoglobulin/plasma exchange therapy
215114886|NCT07009626|OTHER|Computer-based high-validity birth simulator|Computer-based high-validity birth simulator: All students in the intervention group underwent the same scenario of birth. Initially, the aim was to diagnose shoulder dystocia by ensuring that the shoulders were not delivered after the fetal head was delivered.
215114887|NCT07008105|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain through reframing thoughts and encouraging behavioral change.
215114888|NCT07008105|BEHAVIORAL|Pain Reprocessing Therapy|PRT advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and bodily injury and providing education on the neuroscience of pain.
215114889|NCT07008105|BEHAVIORAL|Emotion Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
215114890|NCT06867497|DRUG|BR2021|intravenous administration for 30 minutes
215114891|NCT06867497|DRUG|BR2021-1|intravenous administration for 30 minutes
215114892|NCT07010341|DIAGNOSTIC_TEST|ntra-operative Indocyanine Green (ICG) Fluorescence Quantification|After a single intravenous bolus of indocyanine green (25 µg/kg), a near-infrared sensor records raw fluorescence intensity from the superior parathyroid gland and the ipsilateral common carotid artery at 60-120 seconds. No images are stored; only peak intensity values are logged to calculate the perfusion ratio R = PTG / CCA. The measurement is observational, adds ≤2 minutes to operative time, and involves no therapeutic intent.
215114893|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
215114894|NCT06491238|BEHAVIORAL|Light Intensity Exercise|12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
214515108|NCT00239642|DRUG|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
214515109|NCT00239642|DRUG|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
214515110|NCT00239642|DRUG|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
214433588|NCT05644444|DEVICE|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
214515111|NCT00911716|BIOLOGICAL|bevacizumab|
214515112|NCT00911716|DRUG|cyclophosphamide|
214515113|NCT00911716|DRUG|docetaxel|
214515114|NCT00911716|PROCEDURE|adjuvant therapy|
214515115|NCT04151888|DEVICE|Foley catheter|Thin sterile tube will be inserted in choana
215114895|NCT06491238|BEHAVIORAL|Moderate Intensity Exercise|12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
215114896|NCT04205838|BIOLOGICAL|Anakinra|Given SC
215114897|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
215114898|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
215114899|NCT04205838|DRUG|Fludarabine|Given via infusion
215114900|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
215114901|NCT07022119|DRUG|VX-407|Suspension for oral administration.
215114902|NCT07022119|DRUG|Placebo|Suspension for oral administration.
214515116|NCT00842959|DEVICE|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
214515117|NCT00842959|DEVICE|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
214515118|NCT03402399|OTHER|Molecular analysis|Blood test
215114903|NCT06697899|DRUG|TGRX-678|All participants are given TGRX-678 orally at 240 mg
214515119|NCT02837705|OTHER|blood draw|
215114904|NCT07029776|DRUG|teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance|teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
215114905|NCT07029776|PROCEDURE|melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy|Subjects who are MRD-positive (a threshold of 10\^5) will receive a single melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by a 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
215114906|NCT04770701|DRUG|Ahah Drug|"\- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
215114907|NCT04770701|DEVICE|Ahah Placebo|"\- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
215114908|NCT06883630|DRUG|RC148 plus Carboplatin and Paclitaxel/pemetrexed|RC148; Carboplatin; Paclitaxel; pemetrexed
215114909|NCT06883630|DRUG|RC148|RC148 Monotherapy
215114910|NCT06877897|DIAGNOSTIC_TEST|Submental ultrasound criteria|According to the submental ultrasound criteria, a maximum hyoid bone displacement of ≥1.38 cm is required in the swallowing function assessment to qualify for the oral feeding diet and tube removal training protocol.
214515120|NCT05771285|OTHER|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
214515121|NCT02575014|DRUG|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
214515122|NCT01141985|DEVICE|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
214515123|NCT03927963|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
214515124|NCT03927963|DRUG|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
214515125|NCT05728372|DRUG|Copper Cu 64-DOTA-pembrolizumab|Given IV
214515126|NCT05728372|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214515127|NCT05728372|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214515128|NCT04249700|DEVICE|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
214515129|NCT03788278|DEVICE|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
214515130|NCT01655498|DEVICE|vaginal bowel control system (LivSure)|
214515131|NCT06416605|PROCEDURE|Maxillary Alveolar Ridge Augmentation|using tooth graft or bone graft to increase alveolar ridge width to be able to insert dental implant
214515132|NCT00892970|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
214515133|NCT00892970|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
214433589|NCT06830278|BEHAVIORAL|The SUN Program|"The SUN Program is a manualized bystander program for high-school adolescents. The program includes ten 50-to-60 minute weekly sessions. The central contents of the program include sexual and reproductive rights, sexual violence throughout the lifespan in different contexts, bystander attitudes and behaviors, and empathy. Every session includes psychoeducation components as well as skills-training moments. The sessions must be delivered by two psychologists with supervision.~Session contents are divided as following:~Session 1: Introduction to sexual violence and sexual rights; Session 2: Sexual violence: behaviors and contexts, Session 3: Sexual consent; Session 4: Sexual violence myths; Session 5: Sexual violence in intimate relationships; Session 6: The role of the bystanders; Session 7: The bystander effect; Session 8: Bystander intervention; Session 9: Empathy; Session 10: Summary"
214433590|NCT06821893|DEVICE|Vibrational stimulation|"The auricular stimulation device produces continuous vibrational stimulation directly to the conchae of the auricle. It is designed to stimulate the vagus nerve for neuromodulation to treat a variety of clinical indications. The system includes a pulse generator and an ear electrode device. Participants will use a vibration motor in a custom-created soft plastic clip for the left ear.~Each participant will receive their own device by mail, which they will wear during the the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
214433591|NCT06821893|DEVICE|Sham|"The sham device looks and is used identically to the auricular stimulation device, but does not produce vibrational stimulation. There will be no difference in the usage directions of the sham device compared to the stimulation device.~Each participant will receive their own device by mail, which they will wear during the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
214433592|NCT05307328|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
214433593|NCT05307328|DRUG|Placebo|Inactive tablets identical to SPI-62 tablets
214433594|NCT03851445|DRUG|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
214433595|NCT05702060|PROCEDURE|Radial Artery Puncture Method for Coronary Angiography and Intervention|Radial Artery Puncture Method for Coronary Angiography and Intervention
214433596|NCT06296147|OTHER|Virtual Reality Headset|The interventions are for supportive care ONLY.
214433597|NCT06296147|OTHER|Aromatherapy Patch|The interventions are for supportive care ONLY.
214433598|NCT06296147|OTHER|Standard of Care|Participant will undergo a transperineal prostate biopsy.
214433599|NCT05907980|DRUG|ROSE12|ROSE12 as a IV infusion
214433600|NCT05907980|DRUG|Atezolizumab|Atezolizumab as a IV infusion
214515134|NCT01668498|DRUG|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
214515135|NCT01668498|DRUG|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
214515136|NCT05278117|PROCEDURE|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
214515137|NCT05894551|OTHER|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
215114911|NCT06877897|DIAGNOSTIC_TEST|Routine swallowing function assessment of speech-language pathologist|The speech-language pathologist (SLP) assessment includes the evaluation of sensory and motor functions of the oral and facial muscles, phonation, swallowing motion, and other relevant factors.
215114912|NCT06886412|BEHAVIORAL|Maternal Holding Intervention Group|The infant is required to be held in the mother's arms before, during, and after the procedure. The maternal holding method will be shown or explained to the mother by the researchers.
215114913|NCT06886412|BEHAVIORAL|Breast Feeding Intervention Group|The infant's mother is instructed to begin breastfeeding 2 minutes before the procedure, continuing during and after the procedure. The breastfeeding position for the infant will be shown or explained to the mother by the researchers.
215114914|NCT06725316|BEHAVIORAL|4-7-8 breathing exercises|Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
215114915|NCT06725394|OTHER|Filling out the survey|Data were collected using an information form, the Smartphone Addiction Scale-Short Version (SAS-SV), the Perceived Stress Scale (PSS-10), and the Neck Disability Index (NDI).
215114916|NCT06725966|PROCEDURE|Conventional Epley maneuver|Epley maneuver using a mechanized chair
215114917|NCT06725966|PROCEDURE|Personalized Epley maneuver|Personalized Epley maneuver, using a mechanized chair
215114918|NCT06726512|DEVICE|XEOS AURA 10|Surgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
214433601|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
214433602|NCT04661982|OTHER|Long-term Follow-up|Undergo long term follow-up
214433603|NCT04661982|OTHER|Questionnaire Administration|Ancillary studies
214433604|NCT04661982|OTHER|Quality-of-Life Assessment|Ancillary studies
214433605|NCT06785623|DIETARY_SUPPLEMENT|Gastrodia elata Blume water extract|Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
214433606|NCT06114602|BEHAVIORAL|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
214433607|NCT02529839|PROCEDURE|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
214433608|NCT02529839|DRUG|Fludarabine|30mg/m2 on days -6 through -3
214433609|NCT02529839|DRUG|Cyclophosphamide|50mg/kg on days -5 through -4
214515138|NCT05894551|OTHER|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
214515139|NCT05894551|OTHER|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
214433610|NCT02529839|DRUG|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
214433611|NCT04922268|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
214433612|NCT04922268|OTHER|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
214433613|NCT05727657|DRUG|Satralizumab|120mg subcutaneous Day 0 and Day 14
214433614|NCT05436834|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214433615|NCT05436834|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
214433616|NCT05271435|DEVICE|PAMSys Activity Monitoring System|This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
214433617|NCT05271435|BEHAVIORAL|Motor, Speech, and Handwriting Assessment|"These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).~* 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.~* Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.~* Handwriting Assessment Battery (HAB) (15 minutes) \[Faddy2008\] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.~* Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room."
214433618|NCT05284240|DEVICE|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
214433619|NCT05980052|BEHAVIORAL|Physical Activity|Theory-driven behavioral physical activity promotion intervention.
214433620|NCT06781957|DRUG|Gonadotropins Subcutaneos|Gonadotropins s.c. single dose
214433621|NCT06782074|OTHER|emotional and neuropsychological assessment|The tests for evaluating emotional-behavioral functioning and quality of life will be self-administered by the patient/caregiver during regular follow-up visits. The cognitive assessment will be conducted by the clinician using standardized tests.
214433622|NCT06782048|DRUG|Placebo|Participants will receive placebo by mouth once each day for a total of 14 days.
214433623|NCT06782048|DRUG|Pyrvinium|Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
214515140|NCT00997152|DRUG|JTT-654|Tablets
214433624|NCT06782048|PROCEDURE|Blood biomarkers analyses|Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.
214515141|NCT00997152|DRUG|JTT-654 Placebo|Tablets
214515142|NCT02958826|OTHER|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
214515143|NCT04497818|OTHER|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
215114919|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by packs|GROUP A: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by packs on non woven gauzes entirely covering the area. Eventually, if dried, gauzes are externally watered with additional sulphurous thermal water during the 20 minutes. After water application the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
214433625|NCT06782048|PROCEDURE|Oesophagogastroduodenoscopy (OGD) and biopsy|Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
214433626|NCT06782048|OTHER|Gastric juice, saliva and stool collection and analyses|Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
214433627|NCT05254678|BEHAVIORAL|general exercise|A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
214433628|NCT05688436|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
214433629|NCT05688436|BIOLOGICAL|Alemtuzumab|Administered as specified in the treatment arm.
214433630|NCT05688436|DRUG|Fingolimod|Administered as specified in the treatment arm.
214433631|NCT05688436|DRUG|Glatiramer acetate|Administered as specified in the treatment arm.
214433632|NCT05688436|BIOLOGICAL|Interferon beta|Administered as specified in the treatment arm.
214433633|NCT05688436|BIOLOGICAL|Natalizumab|Administered as specified in the treatment arm.
214433634|NCT05688436|BIOLOGICAL|Ocrelizumab|Administered as specified in the treatment arm.
214433635|NCT05688436|BIOLOGICAL|Ofatumumab|Administered as specified in the treatment arm.
214433636|NCT05688436|DRUG|Ozanimod|Administered as specified in the treatment arm.
214433637|NCT05688436|BIOLOGICAL|Peginterferon beta-1a|Administered as specified in the treatment arm.
214433638|NCT05688436|DRUG|Ponesimod|Administered as specified in the treatment arm.
214433639|NCT05688436|DRUG|Siponimod|Administered as specified in the treatment arm.
214433640|NCT04869020|DEVICE|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
214433641|NCT04869020|DEVICE|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
214433642|NCT04869020|DEVICE|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
214433643|NCT02987192|DEVICE|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
214433644|NCT02987192|DEVICE|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
214433645|NCT03936660|OTHER|Intense Education Intervention|Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
214433646|NCT06119711|OTHER|No intervention|No intervention
214433647|NCT00214240|DRUG|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
214433648|NCT00761553|OTHER|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
214433649|NCT00761553|DIETARY_SUPPLEMENT|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
214433650|NCT04757155|BEHAVIORAL|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
214433651|NCT03788590|DEVICE|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
214433652|NCT02541565|DRUG|Cyclophosphamide|Given IV
214433653|NCT02541565|DRUG|Doxorubicin Hydrochloride|Given IV
214433654|NCT02541565|OTHER|Laboratory Biomarker Analysis|Correlative studies
214433655|NCT02541565|BIOLOGICAL|Pembrolizumab|Given IV
214433656|NCT02541565|DRUG|Prednisone|Given PO
214433657|NCT02541565|BIOLOGICAL|Rituximab|Given IV
214433658|NCT02541565|DRUG|Vincristine Sulfate|Given IV
214433659|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).
214433660|NCT01819571|DRUG|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
214433661|NCT05242562|DRUG|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
214515144|NCT02269072|DRUG|Testosterone|Testosterone cream applied daily for two weeks
214515145|NCT02269072|DRUG|Nesiritide|Administered IV once during the study
214515146|NCT02269072|DRUG|Leuprolide|Administered twice during the study by injection
214515147|NCT02269072|DRUG|Anastrozole|Daily pill for 8 weeks
214515148|NCT02269072|DRUG|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
214433662|NCT05242562|DRUG|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
214433663|NCT01526954|DEVICE|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
214433664|NCT06134882|BEHAVIORAL|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
214433665|NCT06134882|BEHAVIORAL|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
214433666|NCT06134882|BEHAVIORAL|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
214515149|NCT04540952|DEVICE|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
214515150|NCT04540952|DEVICE|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
214515151|NCT05467267|PROCEDURE|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
214515152|NCT02602002|DRUG|Remifentanil|IV
214515153|NCT02602002|DRUG|Placebo|Placebo
214515154|NCT00401050|PROCEDURE|chiropractic manipulative therapy|
214515155|NCT00401050|PROCEDURE|knee exercises|
214515156|NCT00401050|PROCEDURE|Graston Instrument Soft Tissue Mobilization (GISTM)|
214515157|NCT02720705|DRUG|Dexmedetomidine|oral dexmedetomidine
214515158|NCT02720705|DRUG|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
214515159|NCT00074932|BIOLOGICAL|Myozyme|20 mg/kg
215114920|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by limb full immersion|GROUP B: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by limb full immersion in a limb tub. After the immersion, the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
215114921|NCT06725992|DRUG|IY-NS250|Ilaprazole 20mg + Sodium bicarbonate 500mg
215114922|NCT06725992|DRUG|IY-NT-SR|Ilaprazole 10mg
215114923|NCT06726278|DRUG|Misoprostol 400mcg Tab|Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
215114924|NCT06726278|DRUG|Placebo|participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
215114925|NCT06885424|OTHER|No additional intervention administered in this long term follow-up study|Safety follow-up for A2 Bio GT products administered in a previous interventional study
214433667|NCT06134882|BEHAVIORAL|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
214433668|NCT06134882|BEHAVIORAL|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
214433669|NCT06134882|BEHAVIORAL|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
214433670|NCT06441136|OTHER|PhoRTE Program|Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.
214433671|NCT06441136|OTHER|University of California Los Angeles (UCLA) Loneliness Scale|A questionnaire measuring levels of loneliness.
214433672|NCT06441136|OTHER|Social Disconnectedness Scale|A questionnaire that asks about social network size and the frequency of social activities attended.
214433673|NCT06441136|OTHER|Patient Health Questionnaire 9|A questionnaire measuring levels of depression.
214515160|NCT05341713|BIOLOGICAL|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
214515161|NCT00950235|BEHAVIORAL|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
214515162|NCT00950235|OTHER|Usual Care|Standard nutrition counseling from Health Plan
214515163|NCT02558907|OTHER|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
214515164|NCT00362258|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
214515165|NCT05890781|PROCEDURE|Skin biopsy|Skin biopsy
214515166|NCT05890781|PROCEDURE|Fresh tumor sample|Fresh tumor sample
214515167|NCT05890781|BIOLOGICAL|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
214515168|NCT05890781|PROCEDURE|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
214515169|NCT05890781|PROCEDURE|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
214515170|NCT02291861|DRUG|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
214515171|NCT02291861|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
214433674|NCT06441136|OTHER|Aging Voice Index|A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.
214433675|NCT06441136|OTHER|The Edmonton Frail Scale|A questionnaire that measures frailty levels.
214433676|NCT06441136|OTHER|Vocal Effort Scale|A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.
214433677|NCT06441136|OTHER|Montreal Cognitive Assessment|A screening tool used to test for cognitive impairment.
214433678|NCT06441136|OTHER|Voice Handicap Index-10|A questionnaire used to measure quality of life impact of dysphonia.
214433679|NCT06441136|OTHER|Voice Problem Impact Scales|A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.
214433680|NCT06441136|OTHER|Cough Severity Index|A 10 question survey asking to rate severity of cough.
214433681|NCT06441136|PROCEDURE|Laryngoscopy|Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.
214433682|NCT06441136|OTHER|Acoustic, perceptual, and aerodynamic assessments|Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
214433683|NCT04987021|DEVICE|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
214433684|NCT02594631|PROCEDURE|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
214433685|NCT02594631|PROCEDURE|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
214433686|NCT02186769|DRUG|Risperdal® Consta®|
214433687|NCT02186769|DRUG|LY03004|
214433688|NCT00010777|PROCEDURE|Multiple Component Mind/Body therapy|
214433689|NCT02724592|DEVICE|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
214433690|NCT02724592|DEVICE|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
214433691|NCT00140790|DRUG|valsartan|valsartan 40 or 160 (80) mg per day
214433692|NCT04336059|PROCEDURE|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
214433693|NCT02584829|DRUG|Avelumab|Given IV
214433694|NCT02584829|OTHER|Laboratory Biomarker Analysis|Correlative studies
214433695|NCT02584829|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
214515172|NCT02690792|OTHER|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
214515173|NCT02690792|DIETARY_SUPPLEMENT|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
214433696|NCT02584829|RADIATION|Radiation Therapy|Undergo radiation therapy
214433697|NCT02584829|BIOLOGICAL|Recombinant Interferon Beta|Given via intra-tumor injection
214433698|NCT05984212|DRUG|Ultrasound guided rectus sheath block with dexmedetomidine|Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)
214433699|NCT05984212|DRUG|Ultrasound guided rectus sheath block with normal saline|Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)
214433700|NCT05365191|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
214433701|NCT00920738|OTHER|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
214433702|NCT00920738|OTHER|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
214433703|NCT01586936|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
214433704|NCT01091740|DEVICE|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
214433705|NCT01091740|DEVICE|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
214445439|NCT04764500|OTHER|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
214445440|NCT03052608|DRUG|Lorlatinib|ALK-positive NSCL treatment
214515174|NCT04590625|DRUG|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
214515175|NCT04590625|DRUG|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
214433706|NCT05223517|DEVICE|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
214433707|NCT05223517|DEVICE|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
214433708|NCT03210896|DIETARY_SUPPLEMENT|Orange juice|Sub group I will drink Orange juice and have repeat measures.
214433709|NCT02390570|OTHER|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
214433710|NCT01761201|DRUG|Levofloxacin|Levofloxacin
214433711|NCT01761201|DRUG|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
214433712|NCT04458454|DIAGNOSTIC_TEST|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
215114926|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
215114927|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
215114928|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
215114929|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
215114930|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
214433713|NCT00238797|DRUG|Gefitinib|
214433714|NCT03772015|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
214433715|NCT02088372|DEVICE|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
214433716|NCT03470376|DIETARY_SUPPLEMENT|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
214433717|NCT03470376|BEHAVIORAL|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
214433718|NCT00067496|DRUG|Modafinil|
214445441|NCT03052608|DRUG|Crizotinib|ALK-positive NSCL treatment
214433719|NCT05766540|DRUG|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
214433720|NCT02111889|OTHER|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
214433721|NCT05772923|RADIATION|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
214433722|NCT05772923|PROCEDURE|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
214433723|NCT04910698|DRUG|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
214433724|NCT06516328|OTHER|Observational|GCF and saliva samples obtained.
214433725|NCT04723394|DRUG|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
214433726|NCT04723394|DRUG|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
214433727|NCT03513367|OTHER|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
214433728|NCT03513367|OTHER|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
214433729|NCT01006434|OTHER|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
214433730|NCT00374192|DRUG|Eszopiclone|3 mg per day
214433731|NCT00374192|DRUG|Placebo|Placebo
214433732|NCT00861770|OTHER|Ultrafiltration|Ultrafiltration based on standard of care.
214433733|NCT00861770|OTHER|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
214433734|NCT06514417|OTHER|US-guided external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner."
214433735|NCT04894851|BEHAVIORAL|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
214433736|NCT01727375|OTHER|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
214433737|NCT00810849|DRUG|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
215114931|NCT04712097|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
215114932|NCT04712097|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
215114933|NCT04712097|DRUG|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
214445442|NCT03113500|DRUG|Brentuximab Vedotin|Given IV
214445443|NCT03113500|DRUG|Cyclophosphamide|Given IV
214445444|NCT03113500|DRUG|Doxorubicin|Given IV
214445445|NCT03113500|DRUG|Doxorubicin Hydrochloride|Given IV
214445446|NCT03113500|DRUG|Etoposide|Given IV
214445447|NCT03113500|DRUG|Etoposide Phosphate|Given IV
215114934|NCT04712097|DRUG|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
215114935|NCT07052305|DRUG|NT-I7|Provided by NeoImmune Tech
215114936|NCT07052305|BIOLOGICAL|CAR T-cell therapy|Will be given on day 0
215114937|NCT07066696|BEHAVIORAL|Mindfulness and Compassion Program|"The CUIDA2 program is an adaptation of the manual The practice of compassion. Kindness with others and with oneself (2019) by Dr. Javier García Campayo. It comprises a total of 9 sessions of approximately 50 minutes (one class).~This program is structured in 3 modules: Module I mindfulness, module II compassion and module III convergence of the previous elements. Each module includes group dynamics, short meditation practices adapted to the trainees and the explanation of the main theoretical contents through exercises and stories."
214433738|NCT00810849|BIOLOGICAL|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
214433739|NCT01965665|DEVICE|MediHoney HCS dressing|
214433740|NCT00253890|DRUG|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
214433741|NCT00253890|DRUG|Placebo|1-3 at bedtime
214433742|NCT05397262|OTHER|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
214433743|NCT05397262|RADIATION|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
214433744|NCT05397262|DRUG|Chemotherapy 5-Fluorouracil|600 mg/m\^2 civ 120h; d 1-5, 29-33
214433745|NCT05397262|DRUG|Chemotherapy Cisplatin|20 mg/m\^2; d1-5, 29-33
214433746|NCT03466242|DRUG|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
214433747|NCT03466242|DRUG|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
214433748|NCT03584659|DEVICE|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
214433749|NCT04718909|DRUG|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
214433750|NCT04718909|DRUG|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
214433751|NCT03002675|DRUG|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
214433752|NCT03955575|DRUG|Liraglutide 6 MG/ML|Liraglutide as injections.
214433753|NCT03955575|DRUG|Colesevelam|3 x 625 miligram 2 times a day.
214433754|NCT01462149|DRUG|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
214433755|NCT01462149|DRUG|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
214433756|NCT01816672|DEVICE|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
214433757|NCT01816672|OTHER|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
214433758|NCT01797354|BEHAVIORAL|Cognitive-behavioral therapy and hypnosis group|
214433759|NCT01797354|BEHAVIORAL|Support group|
214433760|NCT00083551|DRUG|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
214433761|NCT00083551|DRUG|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
214433762|NCT00083551|DRUG|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
214433763|NCT00083551|DRUG|Cisplatin|"Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) \> 3.0 mg/dl"
214433764|NCT00083551|DRUG|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
214433765|NCT00083551|DRUG|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
214433766|NCT00083551|DRUG|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
214433767|NCT00083551|DRUG|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
214433768|NCT00083551|DRUG|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
214433769|NCT00083551|DRUG|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
214433770|NCT00083551|DRUG|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
214433771|NCT00083551|DRUG|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
214433772|NCT00083551|DRUG|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
214433773|NCT05379075|OTHER|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
214515176|NCT04590625|DRUG|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
214433774|NCT05379075|OTHER|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
214433775|NCT02765100|DRUG|Minocycline|Minocycline 100 mg twice a day
214433776|NCT00961831|DRUG|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
214433777|NCT00961831|DRUG|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
214433778|NCT02675244|PROCEDURE|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
214433779|NCT02675244|PROCEDURE|MVS|MVS will be performed using standard surgical techniques
214433780|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
214433781|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
214433782|NCT01900249|DRUG|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
214433783|NCT00081601|DRUG|CEP-701|
214515177|NCT04590625|DRUG|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
215114938|NCT07066696|BEHAVIORAL|Relaxation|The active control group is composed of a relaxation program consisting of 9 sessions. The sessions will be given weekly (once a week) and have an estimated duration of 50 minutes. Different breathing practices and exercises and relaxation techniques such as visualization, Jacobson's progressive relaxation and Schultz's autogenic relaxation will be used.
215114939|NCT07066878|PROCEDURE|treatment received in the group of patients suffering from malignant lesions of the head and neck.|This protocol focuses on a retrospective, single-center analysis, analyzing the factors that influence survival as the main objective, and secondarily the development of complications and the quality of life based on the treatment received in the group of patients suffering from malignant lesions of the head and neck.
215114940|NCT07065877|DRUG|vit D mixed with xenograft|Topical application of vitamin D solution mixed with xenograft in the jumping gap around immediate implant
215114941|NCT07065877|DRUG|only xenograft without vit D|grafting the jumping gap with xenograft only around immediate implant
215114942|NCT07065760|DEVICE|Endovascular Aneurysm Repair with Physician Modified Endograft|The surgeon will make an incision to access the femoral artery and insert a thin wire to guide the catheter to the juxtarenal aortic aneurysm. The main graft will be modified by hand to match the participant's anatomy, then reloaded and guided through the artery to the aorta. Once in place, the graft will be deployed, and additional stents will be inserted into vital arteries that supply the kidneys and bowels. Two smaller grafts will be placed into the iliac arteries.This allows blood to flow to the target organs and legs, protecting the aneurysm from rupture. All catheters will then be removed, leaving the graft in place, and the incisions will be closed.
215114943|NCT07066748|PROCEDURE|group P:pressure support ventilation mode|Group P: Weaning trial will be done for patients using PSV 8 cmH2O without ATC
215114944|NCT07066748|PROCEDURE|group A:automatic tube compensation (ATC).|Group A: Weaning trial will be done for patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).
215114945|NCT07065461|OTHER|200 g serving of white chocolate-based confection product|200 g serving of white chocolate-based confection product
215114946|NCT07066488|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
215114947|NCT07066943|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
215114948|NCT07064889|DRUG|Dexamethasone|Dexamethasone, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
215114949|NCT07064889|DRUG|Upadacitinib|Upadacitinib 15mg qd for 12 weeks
214433784|NCT00162422|DRUG|albuterol|
214433785|NCT02652442|BEHAVIORAL|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
214433786|NCT02652442|BEHAVIORAL|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
214433787|NCT02652442|BEHAVIORAL|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
214445448|NCT03113500|OTHER|Laboratory Biomarker Analysis|Correlative studies
214445449|NCT03113500|DRUG|Prednisone|Given PO
214445450|NCT05535257|DEVICE|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
214445451|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain Russian BCG-I|"* Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
214433788|NCT04003259|BEHAVIORAL|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
214433789|NCT01065506|BEHAVIORAL|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
214433790|NCT01065506|DRUG|Nicotine Patch|Nicotine Patch
214433791|NCT01065506|BEHAVIORAL|Wellness Program|Wellness Program
214433792|NCT01065506|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise
214433793|NCT00098553|DRUG|everolimus|
214433794|NCT00534183|DRUG|Olanzapine|Olanzapine in dose range of 10-20mg
214433795|NCT00534183|DRUG|Risperidone|Risperidone 1-6mg
214433796|NCT00534183|DRUG|Haloperidol|Haloperidol 10-20mg
214433797|NCT05945017|DIETARY_SUPPLEMENT|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
214433798|NCT03544736|DRUG|Nivolumab|Experimental: Nivolumab
214433799|NCT03544736|RADIATION|Radiotherapy|Radiotherapy
214433800|NCT03544736|DRUG|Chemotherapy|Chemotherapy
214433801|NCT03544736|PROCEDURE|Surgery|Surgery
214433802|NCT05951140|OTHER|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
214433803|NCT03565055|BEHAVIORAL|IPCST|"Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care"
214433804|NCT03565055|BEHAVIORAL|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services"
214433805|NCT05384691|DRUG|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
214433806|NCT03241017|DRUG|Durvalumab|Immunotherapy with Durvalumab after ASCT
214433807|NCT03062332|GENETIC|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
214433808|NCT05419570|OTHER|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
214433809|NCT05103358|DRUG|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
214515178|NCT01598389|OTHER|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
214515179|NCT02032004|BIOLOGICAL|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
214433810|NCT02866968|PROCEDURE|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
214433811|NCT03947346|OTHER|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
214433812|NCT06427863|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
214433813|NCT06427863|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
214515180|NCT02032004|OTHER|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
214515181|NCT02601859|DRUG|Lithium Carbonate|
214515182|NCT03560804|DRUG|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
214515183|NCT03560804|DRUG|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
214433814|NCT04698655|OTHER|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
214433815|NCT04698655|OTHER|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
214433816|NCT04698655|OTHER|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
214433817|NCT00108823|DRUG|Roflumilast|
214433818|NCT01047241|DRUG|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
214433819|NCT06154876|DEVICE|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
214433820|NCT01477268|DRUG|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
214433821|NCT05235906|DRUG|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
214433822|NCT00681603|DRUG|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
214433823|NCT01845844|DRUG|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
214515184|NCT02183272|DRUG|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
214433824|NCT01796067|BEHAVIORAL|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
214433825|NCT01796067|BEHAVIORAL|Basic Health Education|This group will receive the comprehensive basic health education intervention.
214433826|NCT01796067|BEHAVIORAL|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
214433827|NCT01796067|BEHAVIORAL|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
214433828|NCT00744913|DRUG|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
214433829|NCT00744913|OTHER|Counselling|Women in this arm of the study will receive standard counseling only.
214433830|NCT00319293|DRUG|Metformin|
214433831|NCT06145867|OTHER|Photobiomodulation therapy|deep red light therapy (670nm)
214515185|NCT02183272|DRUG|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
214515186|NCT06508762|DRUG|VX-993|Tablet and Suspension for Oral Administration.
214515187|NCT06509555|OTHER|non-intervention|non-intervention
214433832|NCT06159569|DEVICE|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
214433833|NCT00025610|DRUG|carboplatin|
214433834|NCT00025610|DRUG|cyclophosphamide|
214433835|NCT00025610|DRUG|doxorubicin hydrochloride|
214433836|NCT00025610|DRUG|etoposide|
214433837|NCT00025610|DRUG|vincristine sulfate|
214433838|NCT04887675|DIAGNOSTIC_TEST|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
214433839|NCT00273624|DRUG|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
214433840|NCT00273624|DRUG|Placebo|placebo
214433841|NCT00016341|BIOLOGICAL|filgrastim|
214433842|NCT00016341|DRUG|cisplatin|
214433843|NCT00016341|DRUG|doxorubicin hydrochloride|
214433844|NCT00016341|DRUG|megestrol acetate|
214433845|NCT00016341|DRUG|paclitaxel|
214433846|NCT00016341|DRUG|tamoxifen citrate|
214433847|NCT06499558|OTHER|Classical Training|Students in the education group will practice family planning education skills in the professional skills laboratory.
214433848|NCT06499558|OTHER|Standard Patient Interviews|Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
214433849|NCT00035828|DRUG|ABX-IL8|
214433850|NCT05228054|PROCEDURE|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
214515188|NCT00391066|DRUG|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
214515189|NCT00391066|DRUG|FCR|Dose, schedule, and duration specified in protocol
214515190|NCT01331174|DEVICE|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
214515191|NCT00963924|DRUG|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
214515192|NCT00963924|DRUG|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
214515193|NCT00963924|BEHAVIORAL|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
214515194|NCT04101045|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
214515195|NCT04309578|DRUG|Trastuzumab, Capecitabine and Cisplatin|"* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
214433851|NCT05228054|PROCEDURE|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
214515196|NCT03259126|DEVICE|SCUT|Two different home made curtains were attached to the angiographic table
215114950|NCT07065812|OTHER|Surgical team familiarity|Surgical team familiarity: the degree of collaboration within the surgical team is statistically described based on data regarding team personnel and composition, which is used to calculate the Intraoperative Familiarity Score (IFS)-the core component of this study. The specific methodology includes IFS=（X1+X2+X3+X4+X5+X6…）/ N N=nCr=n!/r!(n-r)! Here, X represents the number of times a pair of team members has worked together over a specified period (this process is repeated for all possible pairings in the team), and N is the total number of possible pairwise combinations in the team.
214433852|NCT00741455|PROCEDURE|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
214433853|NCT00741455|DRUG|G-CSF|10 mcg/kg/day on days 5, 6, and 7
214433854|NCT00741455|DRUG|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
214433855|NCT00741455|DRUG|cyclophosphamide|1 g/m2/d IV on days -3 and -2
214433856|NCT00741455|DRUG|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
214433857|NCT00741455|DRUG|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
214433858|NCT03014375|DRUG|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
214433859|NCT04549831|GENETIC|Massive parallel sequencing of host genome|Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
214433860|NCT05733507|PROCEDURE|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
214515197|NCT05597215|RADIATION|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
214515198|NCT00237809|DRUG|D-serine|D-serine (30 mg/kg)
214515199|NCT00237809|BEHAVIORAL|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
214515200|NCT00237809|DRUG|Placebo|Placebo D-serine Drug
214515201|NCT00237809|BEHAVIORAL|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
214515202|NCT04250623|OTHER|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
214515203|NCT00764582|DRUG|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
214515204|NCT00764582|DRUG|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
214515205|NCT05832593|OTHER|Immunohistochemistry|Immunohistochemical expression of ERCC1
214433861|NCT05733507|PROCEDURE|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
214433862|NCT03689920|DEVICE|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
214433863|NCT03980496|DRUG|Omeprazole|
214433864|NCT01284075|BEHAVIORAL|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
214433865|NCT01284075|BEHAVIORAL|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
214433866|NCT01284075|OTHER|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
214433867|NCT02459015|DEVICE|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
214433868|NCT01995903|DIAGNOSTIC_TEST|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
214433869|NCT02419703|DEVICE|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
214433870|NCT03262831|OTHER|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
214433871|NCT03262831|PROCEDURE|Blood draw|"* Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
214433872|NCT03262831|BEHAVIORAL|FACT-G questionnaire|"* 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much"
214433873|NCT03262831|PROCEDURE|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
214433874|NCT03262831|BEHAVIORAL|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
214433875|NCT03262831|BEHAVIORAL|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
214433876|NCT04657887|BIOLOGICAL|Voncento®|Solution for injection
215114951|NCT07065812|OTHER|Composition and Dynamics of the Surgical Team|"Basic indicators reflecting surgical team personnel and composition:~1. Number of surgical, anesthesia, and nursing team members participating in procedures: are obtainable via the Anesthesia Information Management System (AIMS).~2. Shift changes among surgical, anesthesia, and nursing teams during individual procedures: can be tracked through the AIMS.~3. Gender ratio within surgical, anesthesia, and nursing teams: will be derived from the Hospital Information System (HIS)."
214433877|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
214433878|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
214433879|NCT00914589|DRUG|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
214433880|NCT01747707|DRUG|Docetaxel|
214433881|NCT01747707|DRUG|Cisplatin|
214433882|NCT01747707|DRUG|S-1|
214433883|NCT00257049|DRUG|levofloxacin|
214445452|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain TICE|"* Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
214445453|NCT05152732|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
214445454|NCT04204278|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
214445455|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
214445456|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
214445457|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
214445458|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
214445459|NCT05653856|DRUG|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
214445460|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
214445461|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
214445462|NCT06492694|DIETARY_SUPPLEMENT|Fish oil + wild orange essential oil supplement|This supplement contains fish oil and wild orange essential oil as its active ingredients.
214445463|NCT06492694|DIETARY_SUPPLEMENT|Fish oil supplement|This supplement contains fish oil as its active ingredient.
214515206|NCT01253798|OTHER|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
214433884|NCT05328271|DIETARY_SUPPLEMENT|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
214433885|NCT01831284|PROCEDURE|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
214433886|NCT05048680|PROCEDURE|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
214515207|NCT02434705|OTHER|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
214515208|NCT01297595|DRUG|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
214515209|NCT06510855|DEVICE|DurAVR™ THV System|DurAVR™ THV System - Transcatheter Aortic Valve Implantation (TAVI) Procedure
214515210|NCT03637075|OTHER|intranasal insulin|intranasal administration of insulin (160 IU)
214515211|NCT03637075|OTHER|Placebo|placebo intranasal administration
214515212|NCT04919668|BEHAVIORAL|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
214515213|NCT01047709|DEVICE|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
214433887|NCT00055705|BIOLOGICAL|PV701|
214433888|NCT04146519|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
214515214|NCT00871715|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
214515215|NCT00871715|BEHAVIORAL|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
214515216|NCT00871715|BEHAVIORAL|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
214515217|NCT02237937|DRUG|Paroxetine|
214515218|NCT02237937|DRUG|Sertraline|
214515219|NCT02237937|DRUG|Citalopram|
214515220|NCT02237937|DRUG|Venlafaxine|
214515221|NCT02237937|DRUG|Amitriptyline|
214515222|NCT02237937|DRUG|Escitalopram|
214515223|NCT02237937|DRUG|Amitriptylinoxide|
214515224|NCT02237937|DRUG|Nortriptyline|
214433889|NCT04146519|OTHER|Placebo|Saline solution
214433890|NCT04153058|PROCEDURE|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
214433891|NCT04153058|PROCEDURE|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
214433892|NCT05125874|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214433893|NCT03820050|DEVICE|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
214433894|NCT02007590|DEVICE|Aerosure 25 Hz|Active Aerosure device
214433895|NCT02007590|DEVICE|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
214515225|NCT02237937|DRUG|Trimipramine|
214515226|NCT04637100|OTHER|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
214692618|NCT07084727|OTHER|Arterial stiffness|"Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another.~Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates."
214433896|NCT01290341|DRUG|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
214433897|NCT01290341|DRUG|Placebo|Topical; applied once daily for two weeks.
214433898|NCT02059538|OTHER|Adipose tissue biopsies (omental and subcutaneous) liver|
214515227|NCT04637100|OTHER|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
214515228|NCT00071500|DEVICE|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
214515229|NCT05827185|BIOLOGICAL|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
214515230|NCT05827185|BIOLOGICAL|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
214515231|NCT05827185|BIOLOGICAL|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
214515232|NCT05827185|BIOLOGICAL|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
214515233|NCT03221881|DRUG|Pegylated Liposomal Doxorubicin and docetaxel|
214515234|NCT01366456|DEVICE|Moxibustion|Comparison of different kinds of moxibustion
214515235|NCT01656512|DRUG|zolendronic acid|"patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg."
214515236|NCT01656512|DRUG|calcium & vitamin D|patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
214515237|NCT03566901|DEVICE|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
214515238|NCT03566901|OTHER|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
214433899|NCT02059538|RADIATION|CT-scan|
214433900|NCT02059538|OTHER|Stools sampling|
214433901|NCT02059538|OTHER|DNA sampling|
214433902|NCT02059538|OTHER|Blood sampling|
214433903|NCT02059538|OTHER|Urine sampling|
214433904|NCT02059538|RADIATION|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
214433905|NCT01450163|DRUG|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
214433906|NCT01450163|DRUG|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
214433907|NCT04691024|OTHER|Exercise|Spinal stabilization exercises
214433908|NCT01755936|OTHER|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
215114952|NCT07065864|DIETARY_SUPPLEMENT|Ketone ester|Standardized light meal, questionnaires, blood measurements (finger stick), resting physiology and steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo (in randomized order).
215114953|NCT07065864|OTHER|Placebo|steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo
215114954|NCT07065279|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.
215114955|NCT07067047|BEHAVIORAL|Nursing Decision Support System|A behavioral intervention involving a nurse-led decision support system designed to manage fluid volume overload in heart failure patients. The intervention guided nursing care planning, monitoring, and evaluation during hospitalization and through home follow-up visits.
215114956|NCT07064837|OTHER|Conecta Familia|The Conecta intervention is a Spanish language contraceptive need screening and referral process that includes a screener and referral to social needs navigation bundled with developmental screener in 0-12 month old pediatric well visit for written completion by the mother of the patient
214433909|NCT01755936|OTHER|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
214433910|NCT01755936|OTHER|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
214433911|NCT00139984|DEVICE|24 hour blood pressure measurement|
214433912|NCT05820594|BIOLOGICAL|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
214433913|NCT05397275|OTHER|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
214433914|NCT05397275|OTHER|breathe exercises|breathe exercises
214433915|NCT01919450|DRUG|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
214433916|NCT01919450|RADIATION|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
214433917|NCT02352909|OTHER|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
214433918|NCT02352909|OTHER|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
214433919|NCT02352909|OTHER|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
214433920|NCT04324099|OTHER|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
214433921|NCT04324099|OTHER|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
214433922|NCT04324099|OTHER|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
214433923|NCT04324099|OTHER|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
214433924|NCT04324099|OTHER|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
214433925|NCT04324099|OTHER|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
214515239|NCT02072330|DRUG|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
215114957|NCT07064837|OTHER|Contraceptive need survey|brief survey describing demographic information and contraceptive need, use, and experience
215114958|NCT07066865|DEVICE|omniLenz|sutureless dehydrated amniotic membrane (omnigen) mounted on contact lens (omnilenz)
215114959|NCT07065695|PROCEDURE|transposition surgery|Reconstructs spermatic vein drainage via end to side/end to end anastomosis with vessels (e.g., inferior epigastric vein) under 8-15× magnification, preserving testicular arteries/lymphatics.
215114960|NCT07065695|PROCEDURE|microscopic simple ligation|Blocks venous reflux via double ligation and division of spermatic veins under microscopy, with identical surgical exposure and vascular protection.
214515240|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
214433926|NCT04324099|OTHER|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
214433927|NCT04324099|OTHER|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
214515241|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
214515242|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
214515243|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
214515244|NCT00923169|DRUG|Anti-Transforming Growth Factor-beta (GC 1008)|
214515245|NCT03015220|DRUG|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
214515246|NCT03015220|DRUG|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
214433928|NCT04324099|OTHER|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
214433929|NCT04324099|OTHER|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
214433930|NCT04324099|OTHER|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
214433931|NCT04324099|OTHER|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
214433932|NCT04324099|OTHER|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems."
214433933|NCT04324099|OTHER|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
214433934|NCT04324099|OTHER|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
214515247|NCT01673256|DEVICE|SJM Confirm ICM|
214515248|NCT01670526|DRUG|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
214515249|NCT05667311|DEVICE|ECG|Finapres electrocardiography machine
214515250|NCT04880837|OTHER|Educational Intervention|Attend educational session
214515251|NCT04880837|OTHER|Informational Intervention|Receive handouts
214515252|NCT04880837|OTHER|Survey Administration|Complete surveys
214515253|NCT02358304|DRUG|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
214515254|NCT02358304|DRUG|Placebo|
214515255|NCT04256148|BIOLOGICAL|ALXN1830|Administered via intravenous (IV) infusion
214515256|NCT04256148|OTHER|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
214515257|NCT00911404|BEHAVIORAL|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
214515258|NCT00911404|DIETARY_SUPPLEMENT|High CHO diet|Diet with 55% total calories from carbohydrates.
214515259|NCT05615285|OTHER|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
214515260|NCT04816305|DEVICE|rTMSc|In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.
214515261|NCT04816305|BEHAVIORAL|Neurofunctional physiotherapy|All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
214515262|NCT04816305|DEVICE|rTMS sham|During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
215114961|NCT07063290|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
215114962|NCT07066826|DRUG|Huperzine A Controlled-Release Tablets|During the trial, the patients should take huperzine A controlled-release tablets in the morning
215114963|NCT07066826|DRUG|Donepezil hydrochloride tablets|During the trial, the patients should take donepezil hydrochloride tablets before going to bed in the evening
214433935|NCT03230903|OTHER|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
214433936|NCT03230903|OTHER|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
214433937|NCT03377205|DEVICE|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
214433938|NCT03377205|DEVICE|Acumed Fibular Rod System|intramedullary nailing of fibula
214433939|NCT03777696|DRUG|Misoprostol|400 μg of buccal misoprostol
214433940|NCT03777696|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
214433941|NCT03777696|DRUG|placebo to misoprostol|placebo tablets to misoprostol buccal
214433942|NCT03777696|DRUG|placebo to TA|110 ml saline iv
214433943|NCT04055246|DIETARY_SUPPLEMENT|Inulin|9 grams of food grade inulin added to custom made fiber bars.
214433944|NCT04055246|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
214433945|NCT00373373|DRUG|Sorafenib|2 x 400 mg/d
214433946|NCT00373373|DRUG|Placebo|Chemotherapy + Placebo
214433947|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
214433948|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
214433949|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
214433950|NCT06478238|DRUG|calcium folinate|Intravenous infusion and/or oral therapy
214433951|NCT03830086|DRUG|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
214433952|NCT03830086|DRUG|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
214433953|NCT03830086|DRUG|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
214433954|NCT03830086|DRUG|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
214433955|NCT03830086|DRUG|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
214433956|NCT03830086|DRUG|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
214433957|NCT04688866|OTHER|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
214433958|NCT02931175|DRUG|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
215114964|NCT07066826|DRUG|Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo|During the trial, the patients should take huperzine A controlled-release tablets placebo in the morning and donepezil hydrochloride tablets placebo before going to bed in the evening
214433959|NCT02125695|PROCEDURE|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
214433960|NCT02125695|PROCEDURE|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
214433961|NCT02125695|PROCEDURE|Skin Biopsy|As described in the treatment arm
214433962|NCT01620034|RADIATION|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
214433963|NCT03036813|DRUG|voxelotor|
214433964|NCT03036813|OTHER|Placebo|
214433965|NCT00544752|OTHER|16|indoor temperature of 16 degrees celcius
214433966|NCT00544752|OTHER|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
214433967|NCT00544752|OTHER|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
214433968|NCT00094016|DRUG|beclomethasone dipropionate|
214433969|NCT02698228|DRUG|Bupivacaine (femoral nerve block)|0.5% bupivacaine
214433970|NCT02698228|DRUG|Morphine|Intravenous injection of 0.1mg/kg of morphine
214433971|NCT02698228|DEVICE|Ultrasound|
214433972|NCT06251570|OTHER|Evaluation of Dual Task Performance|"The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill."
214433973|NCT03993704|DRUG|LHF-535|Oral suspension administered once daily for 14 days
214433974|NCT05045534|DRUG|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
214433975|NCT01102231|DRUG|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
214433976|NCT01102231|DRUG|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
214433977|NCT01102231|RADIATION|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
214433978|NCT03674034|OTHER|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
214433979|NCT03903822|DRUG|PF-06700841|PF-06700841 topical cream
214433980|NCT03903822|DRUG|Vehicle (Placebo)|Vehicle topical cream
214433981|NCT04319432|BEHAVIORAL|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
214433982|NCT01370343|DRUG|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
214433983|NCT01370343|DRUG|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
214433984|NCT03339115|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
214433985|NCT04261231|PROCEDURE|Surgery and anesthesia|Elective surgery in adults
214433986|NCT02752230|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
214433987|NCT02752230|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
214433988|NCT00233038|PROCEDURE|Ethanol injection into a cyst|
214433989|NCT02462616|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
214433990|NCT02546999|DRUG|botox|The agent will be given only once at point zero in the time scheme for the project.
214433991|NCT02546999|DRUG|placebo|The agent will be given only once at point zero in the time scheme for the project.
214515263|NCT01257724|OTHER|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
214433992|NCT01251224|OTHER|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
214433993|NCT01251224|OTHER|Education|This group will receive education about mouse IPM.
214433994|NCT00785512|DRUG|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
214433995|NCT00785512|DRUG|Placebo|Matching placebo tablets, oral administration
214433996|NCT00194714|BIOLOGICAL|HER-2/neu Peptide Vaccine|Given ID
214433997|NCT00194714|OTHER|Laboratory Biomarker Analysis|Correlative studies
214433998|NCT00899015|OTHER|pharmacological study|
214515264|NCT03294187|DEVICE|Wrist-worn wearables|See arm/group description.
214515265|NCT06296784|OTHER|e-health psychoeducation|e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
214515266|NCT01995214|DRUG|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
214433999|NCT05848531|DRUG|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
214434000|NCT05820269|BEHAVIORAL|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
214434001|NCT05760235|PROCEDURE|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
214434002|NCT02677129|OTHER|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
214434003|NCT03167736|OTHER|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
214434004|NCT03167736|OTHER|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
214515267|NCT01995214|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
214434005|NCT03113630|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
214434006|NCT03113630|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
214434007|NCT03113630|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
214434008|NCT03113630|DEVICE|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
214434009|NCT03113630|DEVICE|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
214434010|NCT03113630|DEVICE|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
214434011|NCT00047931|DRUG|VRC-HIVDNA009-00-VP|
214434012|NCT03013452|DEVICE|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
214515268|NCT03400007|DEVICE|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
214434013|NCT03013452|BEHAVIORAL|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
214434014|NCT02502344|BEHAVIORAL|healthy lifestyle|food control and intensive exercise to lose weight
214434015|NCT02502344|DRUG|Metformin|use metformin to reduce insulin resistance
214434016|NCT00895531|DRUG|Depodur|7.5 mg Depodur via the epidural catheter
214434017|NCT00895531|PROCEDURE|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
214434018|NCT03819829|OTHER|Blood sample|Blood sample
214434019|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
214434020|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
214434021|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
214434022|NCT01070940|DRUG|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
214434023|NCT02059616|DRUG|Amlodipine 5mg|Daily oral administration for 8 weeks
214434024|NCT02059616|DRUG|Amlodipine 10mg|Daily oral administration for 8 weeks
214434025|NCT02059616|DRUG|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
214434026|NCT02059616|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
214434027|NCT05463549|OTHER|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
214434028|NCT03119558|DRUG|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
214434029|NCT00529100|DRUG|Pemetrexed Phase 1|300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
214434030|NCT00529100|DRUG|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles."
214434031|NCT00529100|PROCEDURE|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
214434032|NCT00529100|DRUG|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
214434033|NCT00529100|DRUG|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
214434034|NCT01818713|DRUG|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
214434035|NCT03238313|BEHAVIORAL|Plan A|
214434036|NCT03238313|BEHAVIORAL|Toxic Life Cycle of a Cigarette|Video
214515269|NCT03400007|DEVICE|Colpocystodefecography|Colpocystodefecography (CCD)
214434037|NCT01471145|DRUG|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
214434038|NCT00003017|BIOLOGICAL|recombinant interleukin-12|
214434039|NCT00295464|DRUG|Betamethasone sodium phos (drug)|
214434040|NCT01407458|OTHER|Upper Limb Exercises|Upper limb exercises
214434041|NCT01407458|OTHER|Normal physical exercises|Exercises usually done by children in physical education classes
214434042|NCT03733119|DRUG|Akt/ERK Inhibitor ONC201|Given PO
214434043|NCT03733119|DIETARY_SUPPLEMENT|Methionine-Restricted Diet|Given PO
214434044|NCT01781585|PROCEDURE|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
214515270|NCT04592926|DEVICE|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
214434045|NCT02253537|DEVICE|CST001|
214434046|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
214515271|NCT04592926|OTHER|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
214515272|NCT02214095|DRUG|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
214434047|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
214434048|NCT02545036|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
214434049|NCT00192946|PROCEDURE|Temporary cardiac resynchronization therapy|
214434050|NCT04702256|DRUG|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
214434051|NCT04702256|DRUG|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
214434052|NCT04702256|DRUG|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
214434053|NCT05957016|PROCEDURE|CIETAI-R|"1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w"
214434054|NCT02678936|BIOLOGICAL|PRP|Application of platelet-rich plasma during surgery
214434055|NCT02618486|PROCEDURE|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
214434056|NCT04750044|OTHER|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
214434057|NCT04750044|OTHER|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
214434058|NCT02387242|DRUG|Rifampicin|Single oral dose of rifampicin
214434059|NCT00661869|OTHER|Wellness Program|36 weeks of educational and supportive interventions
214434060|NCT01839526|DRUG|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
214434061|NCT04445870|OTHER|data record|Data record on registers without medical files
214434062|NCT04629625|BIOLOGICAL|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
214434063|NCT04629625|BIOLOGICAL|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
214434064|NCT04629625|BIOLOGICAL|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
214434065|NCT00244959|DRUG|anastrozole|1 mg orally daily for 12 months
214434066|NCT00244959|PROCEDURE|adjuvant therapy|treatment received after breast cancer surgery
214434067|NCT00903851|DRUG|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
214434068|NCT02148185|DRUG|MT-1303|
214434069|NCT03631238|DIAGNOSTIC_TEST|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
214434070|NCT02773524|DRUG|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
214434071|NCT02773524|OTHER|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
214434072|NCT02828618|PROCEDURE|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
214434073|NCT02828618|PROCEDURE|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
214434074|NCT02828618|PROCEDURE|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
214434075|NCT02828618|PROCEDURE|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
214434076|NCT02828618|DRUG|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
214434077|NCT03580135|DRUG|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
214434078|NCT03580135|DRUG|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
214434079|NCT05096559|DEVICE|Microcirculation cytocam|Visualization of tongue microcirculation
214434080|NCT04577924|OTHER|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
214434081|NCT00665340|DRUG|Placebo|Matching placebo
214434082|NCT00665340|DRUG|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
214434083|NCT00004440|DRUG|ibuprofen|
214434084|NCT00530569|PROCEDURE|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
214434085|NCT04907513|OTHER|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
214434086|NCT02009228|PROCEDURE|Ovarian cystectomy|
214434087|NCT02318407|DRUG|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
214434088|NCT02318407|DRUG|Placebo|contains no active drug
214434089|NCT05457049|DIAGNOSTIC_TEST|Molecular residual disease test|OncoMRD Lung
214434090|NCT01634516|BEHAVIORAL|Dietary support|Face to face intervention plus subsequent telephone support
214434091|NCT01634516|BEHAVIORAL|No dietary support|No face to face intervention or subsequent telephone support
214434092|NCT02894658|DEVICE|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
214434093|NCT02894658|PROCEDURE|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
214434094|NCT03231358|BEHAVIORAL|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. Participants receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
214434095|NCT02804425|OTHER|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
214434096|NCT06028282|RADIATION|SPECT|SPECT of thyroid traced with I-131
214434097|NCT06143371|BIOLOGICAL|CAN10|Single dose intravenous or Multiple doses subcutaneously
214515273|NCT02214095|DRUG|lactose capsules|
214515274|NCT03572907|OTHER|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
214515275|NCT01745666|OTHER|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
214515276|NCT01745666|OTHER|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
214515277|NCT00919815|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
214515278|NCT00919815|DRUG|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
214515279|NCT02291549|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
214515280|NCT02291549|DRUG|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
214515281|NCT02291549|PROCEDURE|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
214515282|NCT01000467|DRUG|probucol|group 3: 250 mg 1 tablet in the morning and evening
214434098|NCT06143371|BIOLOGICAL|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
214434099|NCT02972944|PROCEDURE|Laparoscopic cholecystectomy|
214434100|NCT02972944|PROCEDURE|Non-operative treatment|
214434101|NCT05702775|PROCEDURE|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
214434102|NCT05209581|DIAGNOSTIC_TEST|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
214434103|NCT04470375|BEHAVIORAL|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
214434104|NCT06154746|DIAGNOSTIC_TEST|slit lamb & OCT|"1. The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~2. OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
214434105|NCT02239913|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
214434106|NCT02239913|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
214434107|NCT02239913|DRUG|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
214434108|NCT02239913|DRUG|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
214515283|NCT01000467|DRUG|probucol|group 1: 250 mg
214515284|NCT01000467|DRUG|probucol|group 2: 250 mg 2 tablets at once in the morning
214515285|NCT01489683|DRUG|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
214515286|NCT01489683|DRUG|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
214515287|NCT05244954|DRUG|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
214515288|NCT05244954|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
214515289|NCT03980236|DEVICE|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
214515290|NCT05123755|DRUG|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
214515291|NCT05123755|DRUG|AV-001 Placebo Injection|D-PBS
214515292|NCT00147615|DRUG|Eplerenone|
214515293|NCT05652114|BEHAVIORAL|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
214515294|NCT01763307|DRUG|RECONVAL CREAM|
214515295|NCT01763307|DRUG|PLACEBO|
214515296|NCT03210298|COMBINATION_PRODUCT|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
214434109|NCT03888768|DRUG|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
214434110|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
214434111|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
214434112|NCT00807937|DRUG|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
214434113|NCT00807937|DRUG|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
214434114|NCT03611972|DIETARY_SUPPLEMENT|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
214434115|NCT00255359|DRUG|XTL-2125|
214434116|NCT04625231|BEHAVIORAL|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
214434117|NCT05712993|PROCEDURE|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
214434118|NCT04139434|DRUG|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
214434119|NCT04139434|DRUG|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
214434120|NCT00575614|DRUG|prucalopride|1 mg o.d.
214434121|NCT00575614|DRUG|placebo|o.d.
214434122|NCT03877250|DIAGNOSTIC_TEST|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
214434123|NCT03877250|DIAGNOSTIC_TEST|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
214434124|NCT03877250|DIAGNOSTIC_TEST|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
214434125|NCT03877250|DIAGNOSTIC_TEST|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
214434126|NCT06408662|OTHER|mindfulness-based intervention for tics (MBIT)|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practice
214434127|NCT06408662|OTHER|psychoeducation with relaxation and supportive therapy (PRST)|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
214434128|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
214434129|NCT03630055|DRUG|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
214515297|NCT02626494|DRUG|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
214515298|NCT02626494|DRUG|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
214515299|NCT06275802|BEHAVIORAL|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
214434130|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
214434131|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
214434132|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
214434133|NCT04104776|DRUG|Tulmimetostat|Tulmimetostat dosed once per day orally in 28 day cycles
214434134|NCT04104776|DRUG|Enzalutamide|Enzalutamide dosed once per day orally in 28 day cycles
214434135|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
214515300|NCT06275802|BEHAVIORAL|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
214515301|NCT06084988|BIOLOGICAL|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
214515302|NCT01795989|DEVICE|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
214434136|NCT03337399|OTHER|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
214434137|NCT03337399|OTHER|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
214434138|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
214434139|NCT06127147|DEVICE|IMT|The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
214434140|NCT06127147|DEVICE|Sham-IMT|The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
214434141|NCT01721343|BEHAVIORAL|telephone-based intervention|Undergo telephonic monitoring
214434142|NCT01721343|OTHER|case management|Participate in an individualized conditioning program with an RCM
214434143|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
214434144|NCT01721343|PROCEDURE|physical therapy|Participate in an individualized conditioning program with an RCM
214434145|NCT01721343|OTHER|questionnaire administration|Ancillary studies
214434146|NCT01721343|PROCEDURE|quality-of-life assessment|Ancillary studies
214434147|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care
214434148|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care
214434149|NCT01721343|OTHER|educational intervention|Participate in an individualized conditioning program with an RCM
214434150|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM
214434151|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM
214434152|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
214434153|NCT06964035|PROCEDURE|Aortic valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~8 Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
214434154|NCT03324035|DRUG|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
214515303|NCT03149484|DEVICE|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
214515304|NCT03149484|OTHER|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
214515305|NCT03335059|COMBINATION_PRODUCT|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
214515306|NCT00025376|DRUG|PS-341|
214515307|NCT00025376|PROCEDURE|Tumor Biopsy|
214515308|NCT04850092|OTHER|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
214515309|NCT04206618|DRUG|Teriparatide|1 subcutaneous injection daily for 12 months
214515310|NCT04206618|DRUG|Denosumab|1 subcutaneous injection every 6 months for 12 months
215114965|NCT07066163|DEVICE|Kinesia U|KinesiaU is a commercially available wearable technology, which includes a smart watch and a mobile application which can continuously monitor and quantify motor symptoms such as tremor, bradykinesia, dyskinesia, gait parameters throughout the day. The technology has been validated for motor symptoms and has high agreement with clinician ratings of motor severity. The motion sensor records data using KinesiaU smart watch and is then transmitted to a secure cloud database, where specialized algorithms analyze the information to detect motor symptoms and compute severity scores every 2 minutes. The results are then not only available to clinicians in the form of detailed reports for review but also for PwP in easily understandable format on the phone application . The validity of this device has been studied to assess tremor, bradykinesia and dyskinesia.
215114966|NCT07066163|OTHER|Standard of care treatment|Participants in the control group will receive standard of care, consisting of regular management of their motor symptoms and monitoring using motor dairy, interview by their neurologist, family physician, and other healthcare providers.
215114967|NCT07066605|DRUG|Group A (Dexmedetomidine Group)|patients will receive dexmedetomidine infusion starting at 0.2 mcg/kg/hr.
215114968|NCT07066605|DRUG|Group B (Control Group)|patients will receive standard ICU sedation protocol without dexmedetomidine (e.g., fentanyl)
215114969|NCT06810778|DRUG|Duvelisib|15 and 25 mg BID
215114970|NCT06810778|DRUG|Venetoclax|200, 400, and 800 mg QD
215114971|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
215114972|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
215114973|NCT07065032|DRUG|ZT002 Placebo|Participants will receive the same volume as the study drug in each cohort.
215114974|NCT07065734|DEVICE|NWPT group|Patients submitted to negative pressure wound therapy
215114975|NCT06771544|DRUG|Pembrolizumab|Given IV
215114976|NCT06771544|DRUG|Cyclophosphamide|Given PO
215114977|NCT07065591|DRUG|Metformin|The intervention group will receive metformin (max: 500mgx4=2000mg daily). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
215114978|NCT07065591|OTHER|Placebo|The placebo group will receive placebo. The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
215114979|NCT06907693|DIAGNOSTIC_TEST|CT Pulmonary Angiography Scan|Computed tomography (CT) pulmonary angiography scan of the chest with IV contrast
215114980|NCT03071393|DEVICE|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
215114981|NCT03071393|DEVICE|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
215114982|NCT05253443|BEHAVIORAL|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
215114983|NCT05253443|BEHAVIORAL|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
215114984|NCT07064668|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|TUDCA administered orally according to protocol-defined dosage.
215114985|NCT07064668|DRUG|Immune checkpoint inhibitor (ICI)|Administered intravenously according to standard practice or protocol.
215114986|NCT07065669|DEVICE|Dorsal medial Prefrontal Cortex intermittent theta burst stimulation|iTBS stimulation of the dmPFC is a FDA-approved treatment for adults with OCD
215114987|NCT07065669|DEVICE|cTBS to ROFC|continuous theta burst stimulation (cTBS) 1,800 pulses per session
214434155|NCT03324035|DRUG|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
214434156|NCT03324035|DRUG|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
214434157|NCT03477695|DEVICE|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
214434158|NCT06006052|COMBINATION_PRODUCT|regeneration technique|clinical procedure of regenerative endodontic as AAE mentioned using different material in each group
214434159|NCT02708108|BEHAVIORAL|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
214434160|NCT02708108|BEHAVIORAL|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
214434161|NCT03185338|BEHAVIORAL|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
214434162|NCT03185338|BEHAVIORAL|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
214434163|NCT03185338|BEHAVIORAL|Active school recess|Teachers will design games and activities and will encourage children for being active
214434164|NCT03185338|BEHAVIORAL|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
214434165|NCT03185338|BEHAVIORAL|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
214434166|NCT00035971|DRUG|raloxifene HCI and alendronate Na|
214515311|NCT04182217|OTHER|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
214515312|NCT03432871|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
214515313|NCT01970527|BIOLOGICAL|Ipilimumab|Given IV
214515314|NCT01970527|OTHER|Laboratory Biomarker Analysis|Correlative studies
214515315|NCT01970527|OTHER|Pharmacological Study|Correlative studies
214515316|NCT01970527|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214434167|NCT03588715|DRUG|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
214515317|NCT02090205|PROCEDURE|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
214515318|NCT02090205|PROCEDURE|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
214515319|NCT02090205|PROCEDURE|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
214515320|NCT02090205|DEVICE|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
214515321|NCT02090205|DEVICE|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
214515322|NCT05333757|OTHER|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
214434168|NCT03588715|DRUG|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
214434169|NCT04802148|PROCEDURE|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
214434170|NCT04802148|PROCEDURE|collagen plug|after tooth extraction, the socket was filled with collagen plug
214434171|NCT01703897|DEVICE|Manometry and Impedance analysis|
214434172|NCT03540381|OTHER|neoatherosclerosis|
214434173|NCT03083197|DRUG|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
214434174|NCT03083197|DRUG|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
214434175|NCT03083197|DRUG|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
214434176|NCT00510887|DRUG|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
214434177|NCT00510887|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
214434178|NCT00510887|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
214434179|NCT00510887|DRUG|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
214434180|NCT00510887|DRUG|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
214434181|NCT01828775|OTHER|palliative care|Receive early PCI
214434182|NCT01828775|OTHER|palliative care|Receive delayed PCI
214434183|NCT01828775|PROCEDURE|quality-of-life assessment|Ancillary studies
214434184|NCT01828775|OTHER|survey administration|Ancillary studies
214515323|NCT01846078|DEVICE|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
214515324|NCT05690178|OTHER|Deep Tissue Massage|The Deep Tissue Massage lasted 45 minutes. The entire therapy included 4 treatments over a period of 2 weeks. The interval between treatments was 3 days. The conducted therapy included techniques for: quadratus lumborum muscle, erector spinae muscle, thoracolumbar fascia, iliopsoas muscle. All techniques were performed on both sides of the patient's body.
214515325|NCT02707302|DEVICE|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
214515326|NCT02707302|PROCEDURE|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
214515327|NCT01115309|DEVICE|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
214434185|NCT04783012|PROCEDURE|Catheter removal|Catheter management strategy after surgery
214434186|NCT02882698|BEHAVIORAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
214434187|NCT02882698|BEHAVIORAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
214434188|NCT02882698|BEHAVIORAL|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
214434189|NCT02882698|BEHAVIORAL|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
214434190|NCT01542229|BEHAVIORAL|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
214434191|NCT01542229|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
214434192|NCT03038217|DRUG|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
214434193|NCT03038217|PROCEDURE|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
214434194|NCT03038217|PROCEDURE|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
214515328|NCT03643445|BEHAVIORAL|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
215114988|NCT04866680|PROCEDURE|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
215114989|NCT07065799|DEVICE|Group 1: NHF/LTOT|Patients assigned to this group will start NHF (Nasal High Flow) + oxygen therapy at home and undergo a preliminary trial with NHF to set the optimal flow using the MyAIRVO 3 (Fisher \& Paykel Healthcare, Auckland, New Zealand) with Optiflow+Duet interface. Patients assigned to this group will be required to use NHF for a minimum of 6 hours per night during sleep, while no restrictions will be set on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the control respiratory strategy (HMV+LTOT) will begin.
215114990|NCT07065799|DEVICE|Group 2: HMV/LTOT|Patients assigned to this group will start home treatment with HMV (Home Mechanical Ventilation) + oxygen therapy and will be treated with HMV using a pressure support (PS) ventilator. HMV will be administered via nasal mask or full face mask according to patients' preference. Patients assigned to this group will be required to use HMV for a minimum of 6 hours per night in addition to daily home oxygen therapy for at least 15 hours. Moreover, no restrictions will be imposed on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the studied respiratory strategy (NHF+LTOT) will begin.
215114991|NCT06915831|DEVICE|Continuous positive airway pressure (CPAP)|All-night CPAP will be applied with bedtimes 23:00h to 7:00h.
215114992|NCT02599779|DRUG|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
215114993|NCT02599779|RADIATION|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
214434195|NCT03038217|OTHER|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
215114994|NCT06914440|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The prescribed dose of radiation is 24 Gy delivered in 3 fractions (8 Gy/fraction) using SBRT technique. Subjects received SBRT for the primary breast cancer lesion at 8Gy/Fraction each time for 3 consecutive days, 1 week before the start of systemic therapy. The first day of radiation is C1D1.
215114995|NCT06914440|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion every 3 weeks (q3w). The first dose is given on Cycle 2 Day 1 (C2D1), followed by dosing on the first day of each subsequent cycle for a total of 4 cycles. (Toripalimab×4 240mg D1 q3w)
215114996|NCT06914440|DRUG|Neoadjuvant Chemotherapy|Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day cycle) for 4 cycles.(T×4, Nab-Paclitaxel 125mg/m2，D1、D8、D15 q3w).
215114997|NCT06914440|PROCEDURE|Surgery|Surgery will be performed 2-6 weeks after completion of neoadjuvant therapy. The surgical approach will be determined by the investigator based on disease status and patient preference.
215114998|NCT06914440|DRUG|Adjuvant Chemotherapy|The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide (body surface area-adjusted 600 mg/m²). Both drugs were administered intravenously every 3 weeks, and then the first day of each course was administered for 4 cycles. (EC×4, Epirubicin 50 mg/m² or Liposomal Doxorubicin 30 mg/m², comined with Cyclophosphamide 600 mg/m², D1, q3w)
215114999|NCT06914440|RADIATION|Adjuvant Radiotherapy|Conventional radiotherapy will be delivered to the breast/chest wall and regional lymph nodes (investigator-selected technique), with explicit prohibition of tumor bed boost irradiation.
215115000|NCT06914440|DRUG|Endocrine therapy|Investigator-selected adjuvant endocrine therapy will be deterimend according to applicable guidelines, considering menopausal status, recurrence risk, treatment history, comorbidities as well as patient preference.
215115001|NCT03162471|DIAGNOSTIC_TEST|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
215115002|NCT06921057|OTHER|exergame|playing exergames
214515329|NCT03643445|BEHAVIORAL|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
214515330|NCT03715634|DRUG|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
214515331|NCT03715634|DRUG|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
214515332|NCT03715634|DRUG|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
214515333|NCT03715634|DRUG|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
214515334|NCT04447287|DRUG|ASP8062|Oral
214515335|NCT04447287|DRUG|Placebo ASP8062|Oral
214434196|NCT00971906|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
214434197|NCT00254657|DRUG|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
214434198|NCT00254657|DRUG|Placebo|
214434199|NCT04711213|DRUG|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
214434200|NCT04711213|DRUG|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
214434201|NCT04711213|DRUG|Placebo Dose 1|Placebo suspension dose 1
214434202|NCT04711213|DRUG|Placebo Dose 2|Placebo suspension dose 2
214434203|NCT02214550|DRUG|cyclic microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
214434204|NCT02214550|DRUG|continuous microgestin 1/20|Continuous OC use - Pills containing hormones will be taken every day for 1 year
214434205|NCT04304924|OTHER|The personalized telephone based intervention|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
214434206|NCT03876249|OTHER|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
214515336|NCT04447287|DRUG|buprenorphine/naloxone|Sublingual
214515337|NCT05700851|DIETARY_SUPPLEMENT|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
214515338|NCT03648749|BEHAVIORAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
214515339|NCT04772963|GENETIC|blood sample|During the arteriography a peripheral venous sampling
214434207|NCT00370019|DRUG|Estradiol/Medroxyprogesterone acetate|
214434208|NCT05238480|DEVICE|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
214434209|NCT05238480|DEVICE|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
214434210|NCT02615769|BEHAVIORAL|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
214434211|NCT02615769|BEHAVIORAL|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
214434212|NCT01981174|PROCEDURE|30-gauge needle|
214434213|NCT01981174|PROCEDURE|32-gauge needle|
214434214|NCT01130246|DRUG|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
214434215|NCT01130246|DRUG|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
214515340|NCT04406701|OTHER|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
214515341|NCT00613405|OTHER|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
214434216|NCT00367159|PROCEDURE|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
214434217|NCT01897870|BEHAVIORAL|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
214434218|NCT01369004|BEHAVIORAL|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
214434219|NCT05950542|DRUG|Baricitinib|JAK inhibit0rs
214434220|NCT00094822|OTHER|PI Discretion|PI Discretion
214434221|NCT03485950|DRUG|Cefepime|Given IV
214434222|NCT03485950|DRUG|Ceftolozane|Given IV
214434223|NCT03485950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214434224|NCT03485950|DRUG|Meropenem|Given IV
214434225|NCT03485950|DRUG|Piperacillin-Tazobactam|Given IV
214434226|NCT03485950|DRUG|Tazobactam|Given IV
214434227|NCT05208125|BIOLOGICAL|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
214434228|NCT05208125|OTHER|Normal saline solution|Intramuscular administration of normal saline solution
214434229|NCT03011489|DEVICE|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
214434230|NCT00103324|DRUG|lapatinib ditosylate|Given orally
214434231|NCT00103324|OTHER|laboratory biomarker analysis|Correlative studies
214434232|NCT03433586|DRUG|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
214434233|NCT03433586|DRUG|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
214434234|NCT02929147|DRUG|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
214434235|NCT02929147|DRUG|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
214434236|NCT02929147|DRUG|Placebo|In the Group 3 the PCA will contain placebo.
214434237|NCT03532243|PROCEDURE|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
214434238|NCT05360901|BEHAVIORAL|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
214434239|NCT06004505|OTHER|Vestibular Rehabilitation|The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
214434240|NCT00988858|DRUG|LY2603618|150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
214434241|NCT00988858|DRUG|Pemetrexed|500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
214434242|NCT04619290|DRUG|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
214515342|NCT00613405|OTHER|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
214515343|NCT02147093|DEVICE|Test (multi-focal)|contact lens was to be worn a daily wear.
214515344|NCT02147093|DEVICE|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
214515345|NCT01302158|DRUG|ASP1941|oral
214515346|NCT01302158|DRUG|Glimepiride|oral
214515347|NCT03246724|DRUG|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
214515348|NCT03246724|DRUG|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
214515349|NCT03246724|DRUG|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
214515350|NCT03246724|DRUG|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
214515351|NCT03961841|RADIATION|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
214515352|NCT03961841|DRUG|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
214515353|NCT03961841|DRUG|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
214434243|NCT04619290|OTHER|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
214434244|NCT04286113|BEHAVIORAL|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
214434245|NCT04286113|BEHAVIORAL|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
214434246|NCT04432389|BIOLOGICAL|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
214434247|NCT04432389|OTHER|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
214434248|NCT03562884|DRUG|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
214515354|NCT03782870|DIAGNOSTIC_TEST|echocardiography, lab tests|
214515355|NCT00276601|DRUG|arsenic trioxide|
214515356|NCT00276601|DRUG|cytarabine|
214515357|NCT00276601|DRUG|daunorubicin hydrochloride|
214515358|NCT00276601|DRUG|mercaptopurine|
214515359|NCT00276601|DRUG|methotrexate|
214515360|NCT00276601|DRUG|tretinoin|
214515361|NCT00001958|DRUG|Hydroxyurea|
214515362|NCT00655824|DRUG|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
214434249|NCT03562884|DRUG|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
214434250|NCT04368663|DRUG|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
214434251|NCT02182336|DRUG|BI 201335 NA|"1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23"
214434252|NCT02182336|DRUG|Caffeine|days 1, 10 and 19
214434253|NCT02182336|DRUG|Warfarin sodium|days 1, 10 and 19
214434254|NCT02182336|DRUG|Vitamin K|days 1, 10 and 19
214434255|NCT02182336|DRUG|Omeprazole|days 1, 10 and 19
214434256|NCT02182336|DRUG|Dextromethorphan hydrobromide|days 1, 10 and 19
214434257|NCT02182336|DRUG|Midazolam HCl solution|Days 3 and 21
214434258|NCT02182336|DRUG|Midazolam HCl oral syrup|days 1, 10 and 19
214434259|NCT02182336|DRUG|Digoxin|Days 2 and 20
214434260|NCT03764475|DRUG|Roflumilast|Roflumilast cream 0.3% for topical application
214434261|NCT00936507|OTHER|Energy Density/Portion Size|
214515363|NCT04611334|BEHAVIORAL|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
214515364|NCT05121259|OTHER|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
214434262|NCT05629793|OTHER|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
214434263|NCT00744224|DRUG|Placebo|Single dose of placebo with saline infusion
214434264|NCT00744224|DRUG|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
214434265|NCT00744224|DRUG|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
214434266|NCT05113771|DRUG|Liafensine|Liafensine
214434267|NCT05113771|DRUG|Placebo|Placebo
214434268|NCT04191434|DRUG|Flamboyant 125/12|Flamboyant 125/12 capsule
214434269|NCT04191434|DRUG|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
214434270|NCT04191434|OTHER|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
214434271|NCT04191434|OTHER|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
214434272|NCT01063140|BIOLOGICAL|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
214434273|NCT01063140|BIOLOGICAL|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
214434274|NCT04357951|DRUG|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
214434275|NCT04357951|DRUG|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
214434276|NCT04357951|BEHAVIORAL|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
214434277|NCT02827474|OTHER|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
214434278|NCT02827474|OTHER|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
214434279|NCT05912088|BEHAVIORAL|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
214434280|NCT05912088|BEHAVIORAL|Control Group|Subjects will receive the usual care advice
214434281|NCT06091865|DRUG|Odronextamab|Odronextamab will be administered by intravenous (IV) infusion
214434282|NCT06091865|DRUG|Rituximab|Rituximab will be administered IV, or subcutaneously (SC)
214434283|NCT06091865|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV as part of chemotherapy
214434284|NCT06091865|DRUG|Doxorubicin|Doxorubicin will be administered IV as part of chemotherapy
214434285|NCT06091865|DRUG|Vincristine|Vincristine will be administered IV as part of chemotherapy
214434286|NCT06091865|DRUG|Prednisone/Prednisolone|Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
214434287|NCT06972667|OTHER|Video to promote colonoscopy|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to have a colonoscopy. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
214434288|NCT06972667|OTHER|Video to promote screening for colorectal cancer with home tests|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to screen for colorectal cancer with a home test. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
214434289|NCT06973538|OTHER|Music-based Calisthenic Exercise|Participants in this group will perform 8 weeks of calisthenic exercises with background music. Each session includes a 10-minute warm-up, 30 minutes of music-based exercises (e.g., seated leg lifts, chair squats, arm curls), and a 10-minute cool-down. Elastic resistance bands will be introduced from week 5 to increase intensity. Music tracks are selected to enhance motivation and engagement.
214434290|NCT06972498|DRUG|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
214434291|NCT06973135|PROCEDURE|Bioceramic sealer root canal obturation|Mandibular molars root canal obturation with bioceramic sealer after non surgical endodontic retreatment and then immediate periapical radiograph will be done to record PAI
214434292|NCT06973135|PROCEDURE|resin sealer root canal obturation|non surgical root canal retreatment of mandibular molar teeth will be done using resin based sealer in obturation and periapical radiograph will be taken immediately to record PAI
214434293|NCT06973057|PROCEDURE|Pulpotomy|The entire coronal pulp will be amputated to the level of canal orifices, after hemostasis, NeoMTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
214434294|NCT06973057|PROCEDURE|Direct pulp capping (DPC)|At the exposure site hemostasis will be achieved, neo MTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
214434295|NCT05510245|DRUG|PF-07081532|One PF-07081532 20 mg tablet, administered orally
214434296|NCT05851391|DRUG|Burst Suppression EEG Target Intravenous Anesthesia|The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
214434297|NCT05851391|DRUG|Seizure Suppression EEG Target Intravenous Anesthesia|is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
215115003|NCT06921681|DEVICE|Cryobiopsy of lymph nodes group 6 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
215115004|NCT06921681|DEVICE|Cryobiopsy lymphnode group 3 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
215115005|NCT06920836|DRUG|QR052107B 100 mg|QR052107B 100 mg QD
214434298|NCT02133404|DRUG|ASP7991|oral
214434299|NCT02133404|DRUG|Cinacalcet|oral
214434300|NCT02133404|DRUG|Placebo|oral
214434301|NCT01788930|DEVICE|CPAP|
214434302|NCT00979537|DRUG|Nisoldipine Extended-release Tablets, 40 mg|
214434303|NCT00979537|DRUG|Sular Tablets, 40 mg|
214434304|NCT03302819|DIAGNOSTIC_TEST|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
214434305|NCT06972407|BIOLOGICAL|Exendin 9-39|A competitive antagonist of the GLP-1 receptor
214434306|NCT06972407|OTHER|Saline|Saline infusion will serve as an inactive comparator
214434307|NCT05908942|DEVICE|Nerve ablation|radiofrequency and phenol ablation of the genicular nerves will be performed
214434308|NCT00390299|BIOLOGICAL|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
214434309|NCT00390299|OTHER|Laboratory Biomarker Analysis|Correlative studies
214434310|NCT00390299|PROCEDURE|Therapeutic Conventional Surgery|Undergo en bloc resection
214434311|NCT00134446|DEVICE|transcranial magnetic stimulation|
214515365|NCT00104949|BIOLOGICAL|trastuzumab|
214515366|NCT00589628|DRUG|infliximab|5mg/kg/dose IV at 4 week intervals
214515367|NCT00589628|DRUG|infliximab|10mg/kg/dose IV at 4 week intervals
214515368|NCT01862159|PROCEDURE|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
214434312|NCT04661410|BEHAVIORAL|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
214434313|NCT04661410|BEHAVIORAL|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
214434314|NCT00235508|DRUG|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
214434315|NCT02751138|PROCEDURE|Surgery|Tumor resection
214434316|NCT01898741|RADIATION|24 Gy in 3 fractions|
214434317|NCT05887180|OTHER|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
214434318|NCT02689180|DRUG|Placebo|Replacement of furosemide by placebo
214515369|NCT04078607|BEHAVIORAL|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
214515370|NCT04078607|BEHAVIORAL|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
214515371|NCT04988542|DIETARY_SUPPLEMENT|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
214515372|NCT03353636|DIETARY_SUPPLEMENT|Magnesium|150mg elemental magnesium
214515373|NCT03353636|DIETARY_SUPPLEMENT|Placebo|Rice flour
214515374|NCT00507767|DRUG|dasatinib|Given PO or via PEG tube
214515375|NCT00507767|PROCEDURE|pharmacological study|Correlative studies
215115006|NCT06920836|DRUG|QR052107B 400 mg|QR052107B 400 mg QD
214434319|NCT02689180|DRUG|Furosemide|Maintenance of furosemide on usual doses
214434320|NCT00731185|DRUG|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
214434321|NCT00731185|DRUG|Placebo|
214434322|NCT03592069|DRUG|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
215115007|NCT06920836|DRUG|Placebo|placebo QD
215115008|NCT06919315|BEHAVIORAL|CO-OP intervention|CO-OP intervention: Initial phase: Goalsetting is mandatory and based on the participant's prioritized ADL performance issues identified in their baseline COPM. Education phase: Individual education in the metacognitive Goal-Plan-Do-Check strategy. Training phase: CO-OP training that involves repetitive use of the Goal-Plan-Do-Check for problem solving and skill acquisition. The therapist employs dynamic performance analysis and guided discovery to help participants understand performance issues and formulate plans for achieving their goals. Participants then execute and evaluate these plans, with a focus on developing domain-specific cognitive strategies. The therapist actively encourages generalization and transfer of skills. Homework is mandatory.
214434323|NCT03592069|DRUG|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
214434324|NCT05075941|OTHER|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
214434325|NCT04481672|DRUG|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
214434326|NCT01186198|DEVICE|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
214515376|NCT00507767|PROCEDURE|laboratory biomarker analysis|Correlative studies
214515377|NCT04784390|DEVICE|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
214515378|NCT04784390|DEVICE|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
214515379|NCT01427400|DRUG|Botulinum Toxin-A|100 Units diluted in 25cc saline
214515380|NCT01427400|DRUG|Saline|Dispensed in a 25cc syringe
214515381|NCT00877305|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
214515382|NCT00877305|OTHER|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
214515383|NCT00663819|DEVICE|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
214515384|NCT00663819|PROCEDURE|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
214434327|NCT00970359|BIOLOGICAL|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
214434328|NCT03861364|DRUG|Propofol|2,4 mg/kg
214434329|NCT03861364|DRUG|Propofol|1,4 mg/kg
214434330|NCT04572191|DIAGNOSTIC_TEST|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
214434331|NCT02095184|DRUG|Anastrozole|1 mg daily
214434332|NCT02095184|DRUG|Letrozole|2.5 mg daily
214434333|NCT01803139|DEVICE|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
214434334|NCT04835181|BEHAVIORAL|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
214434335|NCT04835181|BEHAVIORAL|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
214434336|NCT04329364|COMBINATION_PRODUCT|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
214434337|NCT04329364|PROCEDURE|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
214434338|NCT00068601|DRUG|cyclophosphamide|Part of planned chemotherapy regimen
214434339|NCT00068601|DRUG|goserelin acetate|Given subcutaneously
214515385|NCT04871555|OTHER|MRI|structural imaging
214515386|NCT02334917|PROCEDURE|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
214515387|NCT06081738|DRUG|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
214515388|NCT06081738|DRUG|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
214434340|NCT01061671|DRUG|simvastatin|40 mgms of simvastatin daily
214434341|NCT01061671|DRUG|Placebo|Matched placebo pill daily
214434342|NCT02359370|DRUG|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
214434343|NCT02359370|DRUG|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
214515389|NCT02313350|DEVICE|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
214515390|NCT02313350|PROCEDURE|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
214515391|NCT02428556|OTHER|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
214515392|NCT02428556|OTHER|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
214515393|NCT02428556|OTHER|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
215115009|NCT06919315|BEHAVIORAL|Usual practice|Usual practice: Initial phase: Goalsetting is optional and may be based on previous assessment or on a conversation with the participant. Training phase: Different approaches may be taken such as observation and practice of activities or consultation about performance issues and how participants may deal with them. The therapist may guide the participant's performance verbally, physically or trough picture materials. Homework may be included.
214515394|NCT02428556|OTHER|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
214515395|NCT02428556|OTHER|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
215115010|NCT06921824|OTHER|Glucagon|A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)
214515396|NCT01502813|DRUG|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
214434344|NCT06403956|OTHER|Training with video|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
214434345|NCT06403956|OTHER|Training with paint|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
214434346|NCT05368831|DRUG|NST-1024|Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
214515397|NCT00725959|BEHAVIORAL|Online social networking HIV prevention|messages about HIV posted in online social networking sites
214434347|NCT05110534|BEHAVIORAL|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
214434348|NCT05326607|DEVICE|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
214434349|NCT05326607|DEVICE|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
214434350|NCT00519389|BIOLOGICAL|H5N1 VLP Vaccine|Two doses - Day 0 \& Day 28
214515398|NCT01397006|DRUG|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
214515399|NCT03488043|PROCEDURE|Needle lung biopsy|Needle lung biopsy
214515400|NCT04603300|DRUG|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
214515401|NCT04603300|DRUG|Placebo|Fully functional toothpaste containing no immunotherapy agents
214692619|NCT07084727|OTHER|Flow-meditad dilatation|"This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes.~When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques."
214434351|NCT00519389|BIOLOGICAL|Placebo|Two doses - Day 0 \& Day 28
214434352|NCT06301204|DRUG|Tranexamic acid injection|tranexamic acid administration 250mg or 500 mg
214434353|NCT06301204|DRUG|Saline|onyl ıv saline (NaCl 0.09%)
214434354|NCT06079515|PROCEDURE|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
214434355|NCT06079515|PROCEDURE|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
214434356|NCT01306786|DRUG|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
214515402|NCT00476463|DRUG|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
214515403|NCT03102632|OTHER|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
214515404|NCT05120674|BEHAVIORAL|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
214515405|NCT05120674|BEHAVIORAL|CPT|Cognitive Therapy for PTSD
214515406|NCT05120674|BEHAVIORAL|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
214515407|NCT05120674|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
214515408|NCT03004625|DRUG|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
214692620|NCT07084727|OTHER|Dynamic retinal vessel analyzer|Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.
214434357|NCT01306786|DRUG|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
214434358|NCT05592028|DEVICE|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
214434359|NCT02820116|DRUG|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
214434360|NCT05207241|OTHER|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
214434361|NCT05431114|DIAGNOSTIC_TEST|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
214434362|NCT02837497|OTHER|ICU-RESUS CPR Improvement Bundle|"1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings"
214434363|NCT02072213|DRUG|GL2702 GLARS-NF1|0.4mg once a day
214434364|NCT02072213|DRUG|Omix Ocas|0.4mg once a day
214434365|NCT05272046|PROCEDURE|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
214434366|NCT05272046|DEVICE|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
214434367|NCT04507945|DRUG|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
214515409|NCT03004625|DRUG|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
214515410|NCT03004625|DRUG|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
214515411|NCT04639999|OTHER|Echocardiography|LV vortex flow in Echocardiography
214515412|NCT03032198|DEVICE|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
214692621|NCT07082829|DRUG|ORX142 Tablets|ORX142 Tablets
215115011|NCT06927115|OTHER|Maitland Mobilization|Provide maitland mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
215115012|NCT06927115|OTHER|Mulligan Mobilization|Provide mulligan mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
215115013|NCT06936176|DEVICE|Neurovascular Intravascular Shockwave Catheter|"Device:~Neurovascular Intravascular Shockwave Catheter (single-use, rapid-exchange balloon catheter with integrated shockwave emitters).~Intravascular Shockwave Therapy Device (IVL-HVG-N01, generates localized shockwaves to fracture calcifications).~Procedure:~Patients undergo standard CAS preparation with guidewire placement and cerebral protection.~If conventional balloon angioplasty fails (residual stenosis \>70%), the IVL catheter is advanced to the target lesion.~Shockwave therapy is applied at 6 atm, followed by low-pressure balloon dilation (8 atm) if needed.~Subsequent stent deployment is performed per standard practice."
215115014|NCT00924443|DRUG|clofarabine|
215115015|NCT06947824|BEHAVIORAL|Fasted Morning Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after a 12h overnight fast. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
215115016|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (6h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 6h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
215115017|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 12h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
215115018|NCT06947824|BEHAVIORAL|Fed Morning Exercise (12h AMEx-Fed)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after consuming a small pre-exercise snack (30 min before exercise). The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
214434368|NCT02845050|DRUG|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
214515413|NCT05266300|GENETIC|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"
214692622|NCT07082829|OTHER|Placebo Tablets|Placebo Tablets
214692623|NCT07082712|OTHER|Thyroid profile|Thyroid profile in patients with acute coronary syndrome within 24 hour from admission
214434369|NCT02845050|DRUG|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
214434370|NCT02845050|PROCEDURE|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
214434371|NCT00687622|DRUG|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
214434372|NCT04835870|DRUG|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
214434373|NCT04835870|DRUG|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
214434374|NCT04835870|DRUG|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
214434375|NCT04835870|DRUG|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
214434376|NCT04835870|DRUG|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
214434377|NCT04835870|DRUG|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
214434378|NCT04234776|DRUG|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
214434379|NCT04234776|DIAGNOSTIC_TEST|Cognition|Composite tools
214515414|NCT01860300|DRUG|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
214515415|NCT01860300|DRUG|placebo|
214434380|NCT04234776|OTHER|Suicide risk|MADRS (10) and HAM-D (3)
214434381|NCT04234776|OTHER|Depression thoughts|EPD
214515416|NCT00679406|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
214515417|NCT02934932|DRUG|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
214515418|NCT03536845|DRUG|Vitamin D 3|oral drops
214515419|NCT06318559|PROCEDURE|3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy|"The operation is performed using the Da Vinci HD robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted.~Then a radical prostatectomy is performed."
214692624|NCT07082621|DRUG|N-acetylcysteine (NAC) spray|N-acetylcysteine (NAC) mucoadhesive nanoparticles in the form of spray 3 times daily for 6 weeks
214434382|NCT04234776|OTHER|Quality of life and disability|Quality of life and disability
214434383|NCT04234776|OTHER|Clinical and epidemiological factors|Variables and categories
214434384|NCT04234776|DEVICE|Safety of ketamine IM|Vital signs
214434385|NCT04234776|OTHER|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
214434386|NCT05904925|OTHER|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
214434387|NCT03426839|DIAGNOSTIC_TEST|Coagulation tests|
214434388|NCT00223795|DEVICE|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
214434389|NCT00513526|BIOLOGICAL|Gardasil|week 0, 8, 24, 128
214434390|NCT00475501|DRUG|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
214434391|NCT00475501|DRUG|Finasteride|5 mg, oral, once/day, for 52 weeks
214434392|NCT00475501|OTHER|Placebo|Placebo
214434393|NCT00969137|DRUG|saline|intravenous saline
214434394|NCT00969137|DRUG|Nicotine|Intravenous nicotine
214434395|NCT02738372|OTHER|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
214434396|NCT04585412|DRUG|Palonosetron|Pharmacokinetic study under fasting conditions
214434397|NCT04732338|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
214434398|NCT04820361|DRUG|Cannabis sativa L., folium cum flore|Muscle Relaxation
214434399|NCT04820361|DRUG|Placebo|Muscle Relaxation
214434400|NCT04426500|DRUG|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
214434401|NCT04426500|DRUG|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
214434402|NCT04426500|DRUG|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
214434403|NCT00160914|BEHAVIORAL|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
214434404|NCT01803555|DRUG|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
214434405|NCT01803555|DRUG|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
215115019|NCT06951685|DEVICE|Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit|The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 33cm length and 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The XPAD conduit is in a straight configuration and may be implanted above the knee for elective femoral popliteal bypass surgery.
214434406|NCT01803555|DRUG|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
214434407|NCT01803555|DRUG|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
214434408|NCT05344924|DRUG|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
214434409|NCT02617069|BIOLOGICAL|botulinum toxin injection|
214434410|NCT02617069|BIOLOGICAL|0.9% normal saline injection|
214434411|NCT02617069|DEVICE|Implantable loop recorder|
214434412|NCT04764994|DEVICE|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
214434413|NCT04764994|OTHER|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
214434414|NCT03348917|DRUG|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
214434415|NCT03348917|DRUG|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
215115020|NCT06949644|COMBINATION_PRODUCT|Light and Citalopram|Participants will receive placebo or citalopram, followed by bright light exposure
214434416|NCT03348917|DRUG|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
214434417|NCT03427346|PROCEDURE|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
214434418|NCT03427346|PROCEDURE|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
214434419|NCT04083664|DIAGNOSTIC_TEST|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
214434420|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental|Combination of pre-probiotic
214434421|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Inert compound
214434422|NCT03697876|DRUG|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
214434423|NCT03697876|DRUG|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
214434424|NCT04223297|PROCEDURE|lung ultrasound|"The lung ultrasound will be performed by following the  Blue protocol "
214434425|NCT03554876|DEVICE|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
214434426|NCT03554876|DEVICE|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
214434427|NCT03554876|DEVICE|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
214434428|NCT05775055|OTHER|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
214515420|NCT01450657|DIETARY_SUPPLEMENT|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
214515421|NCT03705663|BEHAVIORAL|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
214515422|NCT02318810|DRUG|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
215115021|NCT06537674|DRUG|Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection|Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
215115022|NCT02822261|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66\_R84-088)
215115023|NCT04676035|DRUG|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
215115024|NCT01678612|OTHER|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
215115025|NCT00364091|DRUG|R89674 0.025% ophthalmic solution|
215115026|NCT03944291|PROCEDURE|Pudendal Nerve Block|Pudendal Nerve Block
214515423|NCT02318810|DRUG|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
214515424|NCT02318810|DRUG|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
214515425|NCT02318810|DRUG|Placebo|Patients receive saline
214515426|NCT04348669|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
215115027|NCT02711007|DRUG|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
215115028|NCT01210586|BEHAVIORAL|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
214434429|NCT05436639|DRUG|SPI-62 dose|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
214434430|NCT04086771|BEHAVIORAL|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
214434431|NCT04086771|OTHER|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
214434432|NCT04079348|DEVICE|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
214434433|NCT04079348|OTHER|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
214434434|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
214515427|NCT03434600|OTHER|Oxford UKA vs Sigma UKA|
214515428|NCT01536964|DRUG|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
214515429|NCT01536964|DRUG|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
214515430|NCT01307800|DRUG|LY2140023|Administered orally
214515431|NCT01307800|DRUG|Placebo|Administered orally
214515432|NCT05655000|PROCEDURE|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
214515433|NCT01667198|PROCEDURE|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
214515434|NCT01667198|BEHAVIORAL|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
214515435|NCT03365232|DEVICE|non custom base attachment|non custom base attachment
214515436|NCT03365232|DEVICE|custom base attachment|custom base attachment
214515437|NCT02892019|DRUG|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
214515438|NCT02892019|DRUG|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
214515439|NCT06455306|PROCEDURE|Air-polishing with erythritol at different time points|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months
214515440|NCT06455306|PROCEDURE|Single Air-polishing with erythritol|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
214434435|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
214434436|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
214434437|NCT04086017|OTHER|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
214434438|NCT06260878|OTHER|Intravenous Ringer's lactate|Intravenous Ringer's lactate
214434439|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
214434440|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
214434441|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
214515441|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
214515442|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
214515443|NCT06509646|OTHER|Tia Chi Exercise|"• Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
215115029|NCT01622387|PROCEDURE|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
214692625|NCT07082621|DRUG|Conventional treatment|"topical anesthetics agents (BBC \[Benzocaine, Benzydamine, and Cetalkonium chloride\] oral spray - oracure gel), topical antifungal agents (Miconaz oral gel)\*, sodium bicarbonate mouth wash (Alkamsir sachets), ice chip,s and anti-inflammatory mouth wash.~(Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology \[MASCC/ISSO\] guidelines) 3 times daily for 6 weeks."
214692626|NCT07083375|DRUG|QL1706 , bevacizumab, etoposide , cisplatin or carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1), bevacizumab (7.5 mg/kg, IV, day 1), etoposide (100 mg/m², IV, days 1-3), plus either cisplatin (75 mg/m² split over days 1-2, IV) or carboplatin (AUC=5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) and bevacizumab (7.5 mg/kg, IV, day 1) every 21 days, continued until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or other protocol-defined criteria. All participants will receive dual-agent maintenance therapy.
214692627|NCT06930222|DIAGNOSTIC_TEST|blood sampling|blood samples obtained for 3 different days, limited to 5cc
214692628|NCT03042013|DRUG|ASP8273|Oral
214692629|NCT06916754|BEHAVIORAL|Combined Behavioral Intervention|The intervention includes 12 weekly sessions integrating Motivational Interviewing, Cognitive Behavioral Therapy, and relapse prevention strategies. Techniques include enhancing motivation to change, identifying cognitive distortions, managing high-risk situations, and developing alternative coping strategies.
215115030|NCT01622387|PROCEDURE|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
215115031|NCT01907763|DRUG|SOTB07 200mg|
215115032|NCT01907763|DRUG|SOTB07 400mg|
215115033|NCT01907763|DRUG|SOTB 200mg placebo|Placebo of SOTB07 200mg
215115034|NCT01907763|DRUG|SOTB 400mg placebo|Placebo of SOTB07 400mg
215115035|NCT03559933|DEVICE|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
215115036|NCT01581060|DRUG|WX-554|Capsules of WX-554
215115037|NCT00716846|DRUG|simvastatin|10mg, 2 weeks
215115038|NCT00716846|DRUG|atorvastatin|10mg
215115039|NCT00716846|DRUG|pitavastatin|2mg
214434442|NCT02160756|DRUG|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
214434443|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
214434444|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
214434445|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
214434446|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
214434447|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
214434448|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
214434449|NCT04339140|DRUG|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
214434450|NCT06775912|DRUG|RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
214434451|NCT06777069|PROCEDURE|Leucocyte and platelet rich fibrin membrane application|Leukocyte and platelet rich membrane, obtained by centrifuging 10 ml of venous blood collected from the patient's antecubital vein, was sutured to the donor sites.
214434452|NCT05590923|DRUG|OLA group: Olanzapine|"OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)."
214434453|NCT05590923|DRUG|DEX group: Dexamethasone|"DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC)."
214434454|NCT06209047|DRUG|Local instillation of gentamicin and Budesonide|Bronchoscopic local instillation of gentamicin and Budesonide
214434455|NCT06209047|DRUG|Local instillation of Levofloxacin and Budesonide|Bronchoscopic local instillation of Levofloxacin and Budesonide
214434456|NCT06209047|PROCEDURE|Bronchoscopic mechanical secretion suction and lavage|Bronchoscopic mechanical secretion suction and lavage
214434457|NCT06209047|PROCEDURE|Sham Bronchoscopy|Bronchoscopy for airway visualization only, no lavage or drug instillation (sham procedure).
214434458|NCT03867747|RADIATION|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
214434459|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
214434460|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
214434461|NCT02460900|DRUG|Varenicline|
214434462|NCT02460900|BEHAVIORAL|Positively Smoke Free|
214434463|NCT02460900|DRUG|Placebo|
214434464|NCT02460900|BEHAVIORAL|Standard of Care|
214434465|NCT00248456|DRUG|Calcipotriol plus betamethasone dipropionate ointment|
214434466|NCT04527887|DRUG|Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
214434467|NCT04527887|OTHER|ProLong™ collagen plugs|The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
214434468|NCT05165485|DRUG|Revefenacin|Revefenacin 175 mcg administered once daily for 84 days via nebulization
214434469|NCT05165485|DRUG|Tiotropium|Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
214434470|NCT05165485|DRUG|Revefenacin Placebo|Placebo for Revefenacin administered once daily for 84 days via nebulization
214434471|NCT05165485|DRUG|Tiotropium Placebo|Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
214434472|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
214434473|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
214434474|NCT04888637|DIAGNOSTIC_TEST|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
214434475|NCT04888637|BEHAVIORAL|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
214434476|NCT04888637|BEHAVIORAL|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
214434477|NCT00987025|BEHAVIORAL|Telehealth|Use of telehealth blood pressure station every week
214434478|NCT00987025|BEHAVIORAL|Educational materials|Control
214434479|NCT05537207|DEVICE|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
214692630|NCT06916754|BEHAVIORAL|Ericksonian Hypnotherapy|This therapy includes 12 weekly sessions involving individualized trance induction, indirect suggestion, therapeutic metaphor, and ego-strengthening techniques. The sessions follow Ericksonian principles and are delivered by certified hypnotherapists.
214692631|NCT05380388|BIOLOGICAL|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
214692632|NCT05380388|BIOLOGICAL|HBV vaccine|HBV Vaccine
214692633|NCT05383235|OTHER|ROUTINE CARE|1\. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
215115040|NCT05297188|DEVICE|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
215115041|NCT00130611|OTHER|BNP measurement|
215115042|NCT00130611|OTHER|Clinical examination|
215115043|NCT01252030|DEVICE|physical activity monitors|physical activity monitors
215115044|NCT01252030|OTHER|No physical activity monitors|No physical activity monitors
215115045|NCT01447186|BEHAVIORAL|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
215115046|NCT01447186|BEHAVIORAL|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
215115047|NCT01447186|BEHAVIORAL|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
215115048|NCT03478735|PROCEDURE|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
215115049|NCT03478735|PROCEDURE|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
214434480|NCT05537207|OTHER|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
214515444|NCT06509646|OTHER|Frenkel's Exercise|"Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
214515445|NCT03985566|DIETARY_SUPPLEMENT|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
214515446|NCT03985566|DIETARY_SUPPLEMENT|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
214515447|NCT00689351|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
214515448|NCT00689351|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
214515449|NCT03111706|PROCEDURE|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
214515450|NCT00392899|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
214515451|NCT06510972|PROCEDURE|Strategy for continuing oral intake|Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
214515452|NCT06510972|PROCEDURE|Fasting strategy|The patient will not be able to ingest liquids or solid food.
214515453|NCT01766206|BIOLOGICAL|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
214515454|NCT01670799|DRUG|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
214515455|NCT01662505|DRUG|Volasertib|Patient to receive volasertib
214515456|NCT02633085|DEVICE|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
215115050|NCT03469713|DRUG|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
214434481|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
214434482|NCT04955210|OTHER|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
214434483|NCT06307964|PROCEDURE|Biological sampling|"* A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible"
214434484|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
214515457|NCT04813666|DIAGNOSTIC_TEST|Urinary LAM ELISA:|
214434485|NCT06415591|DEVICE|Percutaneous electrical nerve field stimulation|FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
214515458|NCT01313663|DRUG|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
214515459|NCT01313663|DRUG|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
214515460|NCT02790632|DRUG|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
214515461|NCT02790632|DRUG|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
214515462|NCT02191540|DRUG|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
214515463|NCT04251988|DEVICE|Oculus Go VR|virtual reality headset
214515464|NCT02586272|DEVICE|Daifert|
214515465|NCT02586272|PROCEDURE|Control Group|
214515466|NCT03486509|DRUG|Afatinib|afatinb 40mg po bid
214515467|NCT02255474|DEVICE|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
214515468|NCT02255474|DEVICE|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
214515469|NCT02255474|DEVICE|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
214515470|NCT02725697|OTHER|TCM treatment|
214692634|NCT05383235|DEVICE|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2\. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing."
215115051|NCT00502008|DRUG|Coccinia Cordifolia (herbal extract)|
214434486|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
214434487|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
214434488|NCT04225598|DRUG|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
214434489|NCT04225598|DRUG|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
214434490|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
214434491|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
214434492|NCT05577624|DRUG|AMG 510|Oral tablet
214434493|NCT05577624|DRUG|Rifampin|Oral capsule
214434494|NCT04805437|DEVICE|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
214434495|NCT04805437|DEVICE|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
214515471|NCT03967015|OTHER|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
214515472|NCT04494399|DRUG|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
214515473|NCT04494399|DRUG|Ribavirin|5-day course of oral ribavirin 400mg twice daily
214515474|NCT02394912|DEVICE|vena cava filter implantation (LUMIFI with Crux VCF System)|
214515475|NCT04863339|DRUG|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
214515476|NCT04863339|DRUG|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
215115052|NCT02057159|BIOLOGICAL|NeuroVax|TCR peptides in IFA
215115053|NCT02057159|BIOLOGICAL|IFA Placebo|IFA Placebo
215115054|NCT02956317|DRUG|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
215115055|NCT02956317|DRUG|Placebo|Normal Saline
215115056|NCT01746225|DRUG|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
215115057|NCT00573014|OTHER|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
215115058|NCT02800083|DRUG|Pitolisant (BF2.649)|
215115059|NCT02800083|DRUG|Placebo|
215115060|NCT03580226|OTHER|No intervention|No intervention
215115061|NCT03405818|DRUG|Tavaborole 5% Topical Solution|topical solution for application to toenails
215115062|NCT01834352|DRUG|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
215115063|NCT01834352|DRUG|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
215115064|NCT02237755|DRUG|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
214434496|NCT05681702|DRUG|aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
214692635|NCT06077292|BEHAVIORAL|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
215115065|NCT02237755|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
215115066|NCT02913950|OTHER|validation of pediatric stool scale|validation of pediatric stool scale
215115067|NCT02451514|BIOLOGICAL|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
215115068|NCT03197376|BIOLOGICAL|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
215115069|NCT03197376|BIOLOGICAL|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
214434497|NCT05681702|DRUG|prasugrel or ticagrelor|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
214515477|NCT00162318|DRUG|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
214434498|NCT04043442|DEVICE|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
214515478|NCT03479918|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
214434499|NCT05550129|DRUG|AMG 510|Oral tablet
214434500|NCT05550129|DRUG|Metformin|Oral tablet
214515479|NCT03479918|DRUG|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
214515480|NCT03479918|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
214515481|NCT03479918|DRUG|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
214515482|NCT06270862|BEHAVIORAL|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
214515483|NCT06270862|BEHAVIORAL|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
214515484|NCT06270862|BEHAVIORAL|physical exercise|Engage in age-appropriate physical exercises.
214515485|NCT06270862|BEHAVIORAL|social interaction|Engage in social discussion with peers in the group.
214515486|NCT06270862|BEHAVIORAL|workshop series|Watch a series of workshops targeting the older adult population.
215115070|NCT02864160|BEHAVIORAL|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
214434501|NCT05969704|PROCEDURE|MRI fusion targeted prostatic biopsy|combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
214434502|NCT05969704|PROCEDURE|MRI cognitive targeted prostatic biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
214434503|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
214515487|NCT06211595|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
214515488|NCT02629666|BEHAVIORAL|ERS and/or Self-management Strategies|
214515489|NCT01535352|BEHAVIORAL|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
214515490|NCT01535352|BEHAVIORAL|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
214692636|NCT06077292|BEHAVIORAL|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
215115071|NCT02864160|BEHAVIORAL|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
215115072|NCT02303028|DRUG|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
215115073|NCT04836845|DEVICE|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
215115074|NCT04836845|DEVICE|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
214434504|NCT05460377|BIOLOGICAL|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
214434505|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
214434506|NCT05460377|BIOLOGICAL|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
214434507|NCT04099290|OTHER|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
214434508|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
214434509|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
214515491|NCT06509282|BEHAVIORAL|Concurrent training|"Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual."
214515492|NCT03430518|DRUG|Durvalumab|1.12g given IV on day 1 every 21 day cycle
214515493|NCT03430518|DRUG|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
214515494|NCT03098199|DRUG|300IU Gonal-F|\<1.5 AMH group
214692637|NCT01667068|OTHER|Comprehensive non invasive cardiovascular examination|"* Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
215115075|NCT04836845|DEVICE|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
215115076|NCT02606799|DEVICE|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
215115077|NCT02676934|DEVICE|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
215115078|NCT05305963|RADIATION|Mammogram|mammogram
214434510|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
214434511|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
214434512|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
214434513|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
214434514|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
214434515|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
215115079|NCT00373178|DRUG|rosiglitazone|
215115080|NCT00373178|DRUG|metformin|
215115081|NCT00373178|DRUG|Anti-diabetic medications|
214434516|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
214434517|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
215115082|NCT03218176|DEVICE|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115083|NCT03218176|DEVICE|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115084|NCT03218176|DEVICE|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
214434518|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
214434519|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
214434520|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
214434521|NCT05263284|DRUG|8-Chloroadenosine|Given IV
214434522|NCT05263284|DRUG|Venetoclax|Given PO
214434523|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
214434524|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
214434525|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
214434526|NCT05333445|OTHER|usual care|standard care
214434527|NCT05274048|DRUG|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
214434528|NCT05274048|DRUG|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
214515495|NCT03098199|DRUG|150IU Menopur|\<1.5 AMH group
214515496|NCT03098199|DRUG|225IU Gonal-F|1.6-2.5 AMH group
214515497|NCT03098199|DRUG|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
214515498|NCT03098199|DRUG|150IU Gonal-F|2.6-6.9 AMH group
214515499|NCT03098199|DRUG|75IU Gonal-F|\>7.0 AMH group
214515500|NCT03142490|OTHER|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
214515501|NCT03142490|OTHER|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
214515502|NCT05539118|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
214515503|NCT05539118|DRUG|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
214692638|NCT06283784|OTHER|Yovis Capsules|Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
214692639|NCT06283784|OTHER|Placebo|Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
214692640|NCT03754933|BIOLOGICAL|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
214692641|NCT03754933|DRUG|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia.
214692642|NCT00244894|PROCEDURE|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
215115085|NCT03218176|DEVICE|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115086|NCT03218176|DEVICE|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
214434529|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
214434530|NCT06781840|BEHAVIORAL|Playing Playfully to Overcome Adversity|The intervention will consist of two parts: (a) five 45-minute-long parent group online sessions; and (b) one 30-minute long online guided play session with OTS/OT.The training will consist of asynchronous module and PowerPoint presentations followed by role play and discussions.
214434531|NCT06834399|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 is administered every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, study end, or other discontinuation criteria are met.
214434532|NCT06834399|PROCEDURE|TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization|TATE treatment is given every 21 days. Patients receive two initial cycles. Whether to continue TATE treatment from the third cycle onward is decided by the investigator based on tumor necrosis. If a patient experiences intrahepatic tumor progression (recurrence or new tumors) during follow-up after the third cycle and still meets the treatment criteria, additional TATE treatment may be given.
214434533|NCT06434506|OTHER|no intervention|No intervention
214515504|NCT05539118|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
214515505|NCT02444962|DEVICE|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
214515506|NCT01217736|DRUG|aliskiren|single dose, tablet
214515507|NCT01217736|DRUG|placebo|single dose, tablet
214515508|NCT01217736|DRUG|VTP-27999|single dose, tablet
215115087|NCT03218176|DEVICE|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115088|NCT03218176|DEVICE|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115089|NCT03218176|DEVICE|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
215115090|NCT00003199|DRUG|tamoxifen citrate|Given orally
215115091|NCT00003199|DRUG|busulfan|Given orally
215115092|NCT00003199|DRUG|thiotepa|Given IV
215115093|NCT00003199|DRUG|melphalan|Given IV
214434534|NCT06782425|DRUG|XKDCT225|Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
214434535|NCT04183426|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
214434536|NCT04183426|DIAGNOSTIC_TEST|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
214515509|NCT05208294|DRUG|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
214515510|NCT05208294|DRUG|Placebo|Participants receive an inactive placebo capsule.
214515511|NCT05208294|BEHAVIORAL|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
214515512|NCT05208294|BEHAVIORAL|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
214515513|NCT01903109|DRUG|Cevimeline|
214434537|NCT06781736|BEHAVIORAL|Talking Circle intervention|Talking Circle intervention
214515514|NCT04588207|DRUG|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
214515515|NCT06432257|DEVICE|head mounted magnifying glass assistance|When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
214515516|NCT02729246|PROCEDURE|Laparoscopic Gastric Bypass|
214515517|NCT01894737|OTHER|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
214515518|NCT01894737|OTHER|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
214515519|NCT06041932|DRUG|Carvedilol|Carvedilol
214692643|NCT00244894|PROCEDURE|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
214692644|NCT00244894|PROCEDURE|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
215115094|NCT00003199|BIOLOGICAL|aldesleukin|Given SC
214692645|NCT00244894|PROCEDURE|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
214692646|NCT00244894|PROCEDURE|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
215115095|NCT00003199|BIOLOGICAL|sargramostim|Given SC
215115096|NCT00003199|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
215115097|NCT00003199|RADIATION|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
215115098|NCT04305847|OTHER|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
215115099|NCT01890564|OTHER|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
215115100|NCT01890564|OTHER|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
215115101|NCT01890564|OTHER|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
215115102|NCT03888729|DRUG|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
215115103|NCT03888729|DRUG|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
215115104|NCT04600583|DEVICE|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
215115105|NCT03742453|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
214434538|NCT06422702|OTHER|Psychosomatic Symptoms Intervention|Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.
214434539|NCT06422702|OTHER|Extended supportive care|The control group implemented continuity of supportive care based on primary care
214434540|NCT06780904|PROCEDURE|Dry Needling|"Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times."
215115106|NCT03742453|DIAGNOSTIC_TEST|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
215115107|NCT00089466|DRUG|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
215115108|NCT02229409|BEHAVIORAL|Walkadoo|Walkadoo is a MeYou Health, LLC product.
215115109|NCT02137096|DRUG|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
214434541|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms)"|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
214434542|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms)"|Transcranial Magnetic Stimulation 5ms
214434543|NCT02188420|DEVICE|"ranscranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms)"|Transcranial Magnetic Stimulation 7ms
214434544|NCT02188420|DEVICE|Transcranial Magnetic Stimulation Time 100ms|Active Compator
214434545|NCT06781996|OTHER|multimodal Resilience© digital companion|"Resilience© is a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app.~Intervention duration : 3 weeks"
214434546|NCT06781996|OTHER|Standard supportive care|standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
214515520|NCT06041932|DRUG|Pentoxifylline|Pentoxiphylline
214692647|NCT04046406|DEVICE|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
215115110|NCT02137096|DRUG|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
215115111|NCT02137096|DRUG|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
215115112|NCT02137096|PROCEDURE|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
215115113|NCT01223183|DRUG|hypertonic saline (7%)|single treatment by inhalation
215115114|NCT01223183|DRUG|isotonic saline|single treatment by inhalation
214515521|NCT01229176|BIOLOGICAL|Vi-CRM197 vaccine|
214515522|NCT01229176|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
214515523|NCT01229176|BIOLOGICAL|Pneumococcal conjugate vaccine|
214515524|NCT01528683|RADIATION|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
214515525|NCT01127737|BEHAVIORAL|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
214515526|NCT01127737|BEHAVIORAL|Placebo|Completed surveys
214515527|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|"* Day 0: presentation of the study~* During pregnancy between Day 0 and 36-38SA: inclusion~* During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~* Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~* In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~* In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~* In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
214515528|NCT03130946|DEVICE|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
214515529|NCT03130946|DEVICE|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
214515530|NCT01082159|PROCEDURE|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
214515531|NCT00788606|DRUG|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
214515532|NCT00444054|BEHAVIORAL|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
214515533|NCT04348357|OTHER|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
214515534|NCT04348357|OTHER|Office visit|Patient comes to the office to receive routine postoperative care
214515535|NCT05514678|BEHAVIORAL|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
214515536|NCT02736175|DRUG|Dexamethasone|
214515537|NCT02736175|OTHER|Placebo Vehicle|
214515538|NCT06245902|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
214515539|NCT06245902|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
214515540|NCT06245902|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
214515541|NCT06245902|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
215115115|NCT06069635|OTHER|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
215115116|NCT06069635|OTHER|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
215115117|NCT00924339|DIETARY_SUPPLEMENT|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
214515542|NCT06245902|DRUG|Matching Placebo|Two Placebo capsules
214515543|NCT01295099|DRUG|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
214515544|NCT01295099|RADIATION|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
214515545|NCT01295099|DRUG|Triamcinolone|TAC 10mg in 1ml injected intralesional
214515546|NCT01446640|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
214515547|NCT03453645|PROCEDURE|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
214515548|NCT02367794|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
214515549|NCT02367794|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
214515550|NCT02367794|DRUG|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
214515551|NCT02367794|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
214515552|NCT00834379|DRUG|pravastatin sodium|40 mg Tablet
214515553|NCT00834379|DRUG|Pravachol®|40 mg tablet
214515554|NCT05643222|DEVICE|red tint contact lenses|to compare the performance of these lenses.
214434549|NCT04817670|DRUG|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
214434550|NCT04817670|DRUG|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
214434551|NCT04817670|DRUG|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
214515555|NCT00882050|DRUG|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
214515556|NCT00882050|DRUG|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
214515557|NCT00882050|DRUG|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
214515558|NCT03803657|DEVICE|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
214515559|NCT00115167|DRUG|Placebo|Q4W
214515560|NCT00115167|DRUG|Darbepoetin alfa|Q4W
214515561|NCT02442557|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injection
214515562|NCT02442557|OTHER|placebo comparator|intravenous injection
214515563|NCT00681226|DRUG|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
214515564|NCT02010684|BEHAVIORAL|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
214434552|NCT04817670|DRUG|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
214692648|NCT00213928|DRUG|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
215115118|NCT00924339|DIETARY_SUPPLEMENT|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
215115119|NCT01459445|DRUG|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
215115120|NCT05342558|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcgs|Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
215115121|NCT05342558|DRUG|Umeclidinium/Vilanterol 62.5/25 mcgs|Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
215115122|NCT00858026|OTHER|Breastmilk|Exclusively breastfed babies
214434553|NCT04817670|DRUG|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
214434554|NCT03312907|DRUG|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
214434555|NCT03312907|DRUG|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
214434556|NCT03312907|DRUG|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
214434557|NCT03312907|DRUG|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
214434558|NCT03312907|DRUG|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
214434559|NCT03312907|DRUG|Steroid Taper|Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
214434560|NCT05434156|DRUG|ELE-101|ELE-101 solution for intravenous infusion
214515565|NCT05661240|DEVICE|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
214515566|NCT05661240|DRUG|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
214515567|NCT02612285|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
214515568|NCT00805441|DRUG|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
214515569|NCT00805441|DRUG|Placebo|Daily by oral route for 12 weeks
214515570|NCT02214914|DRUG|BI 11634 drinking solution|
214515571|NCT02214914|DRUG|BI 11634 tablet|
214515572|NCT02214914|DRUG|Placebo|
214515573|NCT04249115|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
214515574|NCT05062070|DRUG|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
214515575|NCT05062070|DRUG|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
214515576|NCT02364648|DIETARY_SUPPLEMENT|MitoQ|Mitochondria targeted antioxidant
214515577|NCT02364648|DIETARY_SUPPLEMENT|Placebo|Placebo
214515578|NCT02399111|DEVICE|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
214515579|NCT01285882|OTHER|Representations|"1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
214515580|NCT00135278|PROCEDURE|CSF Drainage|See Detailed Description
214515581|NCT00135278|PROCEDURE|No CSF Drainage|See Detailed Description
214515582|NCT05920538|DRUG|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
214515583|NCT05920538|OTHER|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
214515584|NCT03717233|DEVICE|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
214515585|NCT06501027|BEHAVIORAL|Mindfulness Based Self Compassion|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
214515586|NCT06318572|BEHAVIORAL|Psychological intervention|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
214515587|NCT06318572|BEHAVIORAL|Placebo|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
214515588|NCT01884571|DRUG|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
214515589|NCT01884571|DRUG|Methylprednisolone|125 mg, IV (in the vein) on day 1.
214515590|NCT01884571|DRUG|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
214515591|NCT01884571|DRUG|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
214515592|NCT01884571|DRUG|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
215115123|NCT00858026|OTHER|Standard milk|Weaning babies fed with the standard formula
214434561|NCT05434156|DRUG|ELE-101 Placebo|ELE-101 placebo matching solution for intravenous infusion
214434562|NCT06270615|OTHER|Ambispective validation of machine learning-based predictive model|Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
214515593|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
214434563|NCT06192693|DRUG|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
214434564|NCT06192693|DRUG|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
214434565|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
214515594|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
214515595|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
214515596|NCT01569399|OTHER|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
214515597|NCT04258891|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
214515598|NCT00882375|DRUG|Nicotine|Nicotine administered using novel NRT user instructions
214515599|NCT00882375|DRUG|Placebo|Placebo administered using novel NRT user instructions
214515600|NCT03103945|DEVICE|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
214515601|NCT00091572|DRUG|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
215115124|NCT00858026|OTHER|Fermented milk|Weaning babies fed with the fermented formula
215115125|NCT00905463|PROCEDURE|Lung transplantation|Lung transplantation
215115126|NCT06054100|DRUG|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
215115127|NCT02309944|PROCEDURE|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.
215115128|NCT02309944|DEVICE|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
215115129|NCT03049917|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
215115130|NCT01480622|DRUG|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
215115131|NCT03742765|BEHAVIORAL|Incentivizing planning|Participants receive bonus incentives for planning their workouts
215115132|NCT03742765|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
215115133|NCT00771199|DRUG|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
215115134|NCT04614727|COMBINATION_PRODUCT|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
215115135|NCT03332381|BEHAVIORAL|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
215115136|NCT03332381|BEHAVIORAL|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
215115137|NCT02232022|DEVICE|Reveal LINQ Insertable Cardiac Monitor|
215115138|NCT00478842|DEVICE|Deep brain stimulation|Deep brain stimulation
215115139|NCT06429150|BIOLOGICAL|CAR-T cells|Infusion of multi-CAR-T cells
215115140|NCT02947386|OTHER|Laboratory Biomarker Analysis|Correlative studies
215115141|NCT02947386|BIOLOGICAL|Nimotuzumab|Given IV
215115142|NCT02947386|BIOLOGICAL|Nivolumab|Given IV
215115143|NCT01922713|OTHER|white maize and a corn oil capsule|\~ 0 ug RAE/d
215115144|NCT01922713|OTHER|orange maize and a corn oil capsule|\~600 ug RAE/d
214434566|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
214515602|NCT00091572|DRUG|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
214515603|NCT05458544|DRUG|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
214515604|NCT01695044|DRUG|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
214515605|NCT05885516|PROCEDURE|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
214515606|NCT02942771|DRUG|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
214515607|NCT02942771|DRUG|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
214515608|NCT02942771|DRUG|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
214515609|NCT02942771|DRUG|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
214515610|NCT02942771|DRUG|Placebo|0.9% sodium chloride
214515611|NCT04899557|PROCEDURE|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
215115145|NCT01922713|OTHER|white maize and a vitamin A capsule|600 ug RAE/d
214515612|NCT00798863|PROCEDURE|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
214515613|NCT00126958|PROCEDURE|urinary analysis|
214515614|NCT01453764|PROCEDURE|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
214515615|NCT00803985|PROCEDURE|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
215115146|NCT01218581|DRUG|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
215115147|NCT05229185|DEVICE|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
215115148|NCT01217762|DEVICE|IRay|Low voltage stereotactic radiotherapy system
215115149|NCT04403412|PROCEDURE|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
215115150|NCT04403412|PROCEDURE|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
215115151|NCT04403412|PROCEDURE|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
215115152|NCT00649506|DRUG|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
215115153|NCT00649506|DRUG|Macrodantin® 100 mg Capsules|100mg, single dose fed
214515616|NCT00803985|PROCEDURE|Lichtenstein|Operation for primary inguinal hernias i men
214515617|NCT03506802|RADIATION|18F-FHBG|Given IV
214515618|NCT03506802|BIOLOGICAL|Aldesleukin|Given SC
214515619|NCT03506802|BIOLOGICAL|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
214515620|NCT03506802|PROCEDURE|Computed Tomography|Undergo PET/CT
215115154|NCT03777059|DRUG|Atogepant|Atogepant tablet
215115155|NCT03777059|DRUG|Placebo|Placebo-matching atogepant tablets
215115156|NCT02322437|OTHER|Home treatment|Patients are treated at home whenever possible and appropriate
215115157|NCT02322437|OTHER|Treatment As Usual|Patients are treated at a mental hospital
214515621|NCT03506802|BIOLOGICAL|Filgrastim|Given SC
214515622|NCT03506802|OTHER|Laboratory Biomarker Analysis|Correlative studies
214515623|NCT03506802|DRUG|Lenalidomide|Given PO
214515624|NCT03506802|PROCEDURE|Leukapheresis|Undergo leukapheresis
214515625|NCT03506802|DRUG|Melphalan|Given IV
215115158|NCT05541146|COMBINATION_PRODUCT|Intraperitoneal chemotherapy|Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
214434567|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
214434568|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
214434569|NCT05948709|OTHER|Incentives for Physical Activity|Participants earn a meal donation and monetary incentives for each day that they reach 7,500 steps. Meals are donated by the investigators on behalf of participants.
214515626|NCT03506802|DRUG|Plerixafor|Given SC
214434570|NCT01868490|DRUG|cytokine induced killer cells|at least 10\*9 CIK cells, IV on day 0, 14, 28
214434571|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
215115159|NCT02813889|DEVICE|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
215115160|NCT01026012|DRUG|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
215115161|NCT05589610|DRUG|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
215115162|NCT05927844|DRUG|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
215115163|NCT05927844|DRUG|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
215115164|NCT02607618|DRUG|Iclaprim|Experimental treatment
214434572|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
214434573|NCT04614311|DRUG|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
214434574|NCT06832345|OTHER|Experimental group|Web-based training will be shared with patient relatives before the patient is discharged. A home visit will be made 2-3 days after the patient is discharged. Data collection forms will be collected by the researcher at each home visit. A total of four home visits and eight telephone follow-ups will be made within two months.
214434575|NCT06786117|OTHER|SLP swallowing exercises|Clinical speech language pathologists will provide standard exercises based on the abnormalities seen on the modified barium swallow. Exercises are expected to include the effortful swallow, the Mendelsohn maneuver, expiratory muscle strength training with the EMST-150, supraglottic swallow, super supraglottic swallow, chin tuck against resistance isokinetic exercise, chin tuck against resistance isometric exercise, Masako maneuver, Shaker isometric head lift exercise, Shaker isokinetic head lift exercise, Falsetto high pitch glide exercise, tongue press exercise
215115165|NCT02607618|DRUG|Vancomycin|Active comparator
215115166|NCT02720341|DEVICE|ARMin|single sessions of about one hour each
215115167|NCT03730532|OTHER|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
214434576|NCT06786117|OTHER|myofunctional exercises|Participants will get a variety of exercises aimed at improving bolus formation, strengthening the seal of the soft palate with the tongue, and habituating nasal breathing. There will also be exercises aimed at stabilizing the epiglottis and strengthening the muscles supporting the lateral pharyngeal walls. Expiratory muscle strength training with the EMST-150 will also be done.
214434577|NCT06785311|BEHAVIORAL|Native Spirit After-School Program|Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
214434578|NCT06453057|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
214434579|NCT06534125|PROCEDURE|Acupressure Therapy|Undergo self-administered acupressure therapy to planned pressure points
214515627|NCT03506802|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215115168|NCT03730532|OTHER|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
215115169|NCT00655538|DRUG|Placebo|po daily for 36 weeks
215115170|NCT00655538|DRUG|dalcetrapib|600mg po daily for 36 weeks
215115171|NCT04452630|OTHER|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
215115172|NCT00211016|DRUG|doripenem|
215115173|NCT01494792|DEVICE|In Vitro Diagnositc aid for diagnosis|
215115174|NCT01003847|DRUG|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
215115175|NCT03351647|BIOLOGICAL|Evaluation of biological predictive factors of clinical response to ustekinumab|The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
215115176|NCT01002651|DIETARY_SUPPLEMENT|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
215115177|NCT01002651|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
215115178|NCT05402670|OTHER||
215115179|NCT03202342|OTHER|Water|Water, 300 ml, at room temperature
214434580|NCT06534125|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy with acupuncture needles applied to planned pressure points
214434581|NCT06534125|DRUG|Aromatase Inhibition Therapy|Receive SOC AI therapy
214515628|NCT00884676|DRUG|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."
214515629|NCT00884676|DRUG|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
214515630|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head \& neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
214515631|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
214434582|NCT06534125|OTHER|Discussion|Ancillary studies
214434583|NCT06534125|OTHER|Survey Administration|Ancillary studies
214434584|NCT03568994|DRUG|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
214434585|NCT03568994|DRUG|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
214434586|NCT03568994|DRUG|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
214434587|NCT03568994|DRUG|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
215115180|NCT03202342|OTHER|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
215115181|NCT03202342|OTHER|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
215115182|NCT03202342|OTHER|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
215115183|NCT03202342|OTHER|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
215115184|NCT06504810|OTHER|light|light level
215115185|NCT01101035|DRUG|Febuxostat|Febuxostat tablets
215115186|NCT01101035|DRUG|Allopurinol|Allopurinol tablets
215115187|NCT00210782|DRUG|topiramate, phenytoin|
215115188|NCT00915863|PROCEDURE|Billroth-II-type reconstruction|surgical procedure
215115189|NCT00915863|PROCEDURE|Isolated Roux-en-Y type reconstruction|surgical procedure
215115190|NCT01694381|DRUG|M5|single point mutant of serine protease prourokinase
215115191|NCT01694381|DRUG|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
215115192|NCT03558919|DRUG|Mirabegron 25mg|
215115193|NCT03558919|DRUG|Solifenacin Succinate 5 MG|
215115194|NCT03157375|DEVICE|Intraocular Lens Implantation|
215115195|NCT02385747|PROCEDURE|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
215115196|NCT01172626|DRUG|valproate sodium|oral administration,15-30mg/kg,daily
215115197|NCT01172626|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
215115198|NCT01172626|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
215115199|NCT00277771|BEHAVIORAL|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
215115200|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
215115201|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
215115202|NCT01681160|OTHER|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
215115203|NCT01681160|OTHER|conventional therapy|patients receive ordinary treatment for diabetic foot
215115204|NCT02859259|DRUG|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
214434588|NCT03568994|DRUG|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
214434589|NCT02576574|DRUG|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
214434590|NCT02576574|DRUG|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
214434591|NCT02576574|DRUG|Paclitaxel|Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
214434592|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
214434593|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
214434594|NCT02576574|DRUG|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
214434595|NCT02576574|DRUG|Cisplatin|Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
214434596|NCT02576574|DRUG|Carboplatin|Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
214434597|NCT02576574|DRUG|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
214434598|NCT06469749|BEHAVIORAL|Theory-based and peer-led intervention on Instagram|"A pilot randomized controlled trial of the 12-weeks social media intervention for non-medical use of prescription opioids (NMUPO) among young adults will be developed upon the formative research (Aim 1) grounded in the information-motivation-behavioral-skills (IMB) model. Intervention will be delivered by peer leaders, who are well-trained recovery coaches, via private groups on Instagram. Intervention contents will be tailored to psychosocial factors contributing to NMUPO.~Intervention components. Incorporating Instagram functions, the intervention is planned to include four intervention modules: (1) NMUPO knowledge module, (2) self-care module, (3) virtual goal setting/monitoring module, (4) peer support module. Intervention will be delivered by peer leaders (assisted by clinical psychology trainees a) via private groups operated by their Instagram accounts. The process will be overseen by certificated experts in clinical psychology and addiction treatment."
214434599|NCT06083298|PROCEDURE|control group|patients will be operated under general anesthesia
214434600|NCT06083298|PROCEDURE|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
214434601|NCT06083298|PROCEDURE|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
215115205|NCT02859259|DRUG|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
215115206|NCT04058041|PROCEDURE|Neural Mobilization|neural exercise Will be performed in the patients
214434604|NCT05716477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214434605|NCT05716477|OTHER|Survey Administration|Complete survey
214515632|NCT00598234|DRUG|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
214515633|NCT05041894|OTHER|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
214515634|NCT05107453|DRUG|Levobupivacaine|"The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
215115207|NCT04058041|PROCEDURE|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
215115208|NCT04058041|PROCEDURE|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
215115209|NCT05374239|OTHER|Multi-component implementation intervention|The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
215115210|NCT00681629|DRUG|Quetiapine XR|400-800 mg, oral, bid
215115211|NCT00681629|OTHER|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
215115212|NCT04427865|DRUG|prophylactic lactoferrin daily|200 mg oral lactoferrin daily
214434606|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
214434607|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
214434608|NCT05044637|DRUG|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
214515635|NCT04990037|DRUG|CAN04|Administered intravenously
214515636|NCT04990037|DRUG|FOLFIRINOX|Administered intravenously
214515637|NCT01090258|DEVICE|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
214515638|NCT01090258|OTHER|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
214515639|NCT01049490|BIOLOGICAL|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
214515640|NCT04780685|BIOLOGICAL|hMSC|IV administration
215115213|NCT03160339|BIOLOGICAL|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
214434609|NCT05501756|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
214434610|NCT00274105|DRUG|telmisartan|
214434611|NCT00274105|DRUG|Placebo|
214434612|NCT04969471|DEVICE|enVast stent|In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
214434613|NCT04969471|PROCEDURE|conventional treatment|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
214434614|NCT02980276|DRUG|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
214515641|NCT02315209|DEVICE|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
214434615|NCT02980276|OTHER|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
214434616|NCT04955821|DIAGNOSTIC_TEST|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
214515642|NCT00044759|DRUG|Piperacillin/Tazobactam (Tazocin)|
214515643|NCT06360367|BEHAVIORAL|HI-FLY Curriculum|Participants receive the standard HI-FLY Curriculum over 6 weeks.
214434617|NCT06749977|DRUG|Remineralization with SAP11-4|The WSL were treated with SAP11-4 according to the manufacturer's instruction
214434618|NCT06749977|DRUG|Remineralization with sodium fluoride varnish|The WSL were treated with sodium fluoride varnish according to the manufacturer's instruction
214434619|NCT05786248|OTHER|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
214434620|NCT06273605|OTHER|Egg Ladder|12 month protocol of graded and gradual egg introduction
214515644|NCT06360367|BEHAVIORAL|HI-FLY Curriculum + PortionSize Ed app|Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
214515645|NCT06470945|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
214515646|NCT06470945|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
214515647|NCT04932083|DRUG|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
214515648|NCT04932083|DRUG|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
214515649|NCT04932083|DRUG|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
214692649|NCT02964286|DEVICE|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
214692650|NCT02522832|OTHER|Titre 1|Virus infection
214692651|NCT02522832|OTHER|Titre 2|Virus infection
214692652|NCT02522832|OTHER|Titre 3|Virus infection
214434621|NCT04950868|DRUG|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
214434622|NCT04879524|PROCEDURE|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
214434623|NCT05178745|DRUG|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
214434624|NCT05178745|DRUG|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
214434625|NCT05178745|DRUG|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
214434626|NCT01067287|DRUG|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
214434627|NCT01067287|BIOLOGICAL|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
214434628|NCT06493032|DEVICE|Gastric Alimetry System|medical device that uses a large sheet of electrodes to assess gastric motility
214434629|NCT05646563|DRUG|NM8074|NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
214434630|NCT05646563|DRUG|Soliris|Complement C5 blocker administered intravenously
214692653|NCT06234618|OTHER|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
215115214|NCT03160339|BIOLOGICAL|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
215115215|NCT02588235|DRUG|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
215115216|NCT02588235|DRUG|Atorvastatin|atorvastatin (20 mg/day）
215115217|NCT01398007|PROCEDURE|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
215115218|NCT00411671|DRUG|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
215115219|NCT00002092|DRUG|Cimetidine|
215115220|NCT01764711|DRUG|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
215115221|NCT00883961|OTHER|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
214434631|NCT04068844|BEHAVIORAL|Exercise training|Exercise training, either whole body or isolated single leg
214434632|NCT05941637|DRUG|Axitinib 5 MG|Patients will receive Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit - 5mg daily
214434633|NCT06260865|DEVICE|MORA Cure|MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
214434634|NCT06260865|OTHER|Treatment as Usual|In the control group, education is delivered and self-exercise is recommended.
214434635|NCT05894967|BEHAVIORAL|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately \~80% contrast threshold) across all training sessions.
214692654|NCT03522350|DEVICE|EmbryoScope|Standard of care arm
214692655|NCT03522350|DEVICE|EmbryoScope+|Experimental arm
215115222|NCT03556163|PROCEDURE|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
215115223|NCT03556163|PROCEDURE|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
215115224|NCT03796637|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
215115225|NCT05931926|DEVICE|Fluispotter®|The Fluispotter® has been developed for automated extraction, collection and storage of up to 20 dried venous dried blood spot samples of 3-10 μl over the course of up to 20 hours. The system is attached to the patient through a multilumen microcatheter inserted into a peripheral vein in the arm. The Fluispotter will be inserted in both healthy subjects and patients with adrenal insufficiency.
214434636|NCT05894967|BEHAVIORAL|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
214434637|NCT05894967|BEHAVIORAL|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
214434638|NCT05894967|BEHAVIORAL|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
215115226|NCT02898363|OTHER|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
215115227|NCT05089643|DRUG|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
214434639|NCT05894967|BEHAVIORAL|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
214434640|NCT05894967|BEHAVIORAL|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
214434641|NCT05894967|BEHAVIORAL|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
214434642|NCT05894967|BEHAVIORAL|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
214434643|NCT05894967|BEHAVIORAL|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
214434644|NCT05894967|BEHAVIORAL|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
214434645|NCT05894967|BEHAVIORAL|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
214434646|NCT05894967|BEHAVIORAL|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
214434647|NCT05894967|BEHAVIORAL|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
214434648|NCT02993315|BIOLOGICAL|nDC vaccination|
214434649|NCT02993315|BIOLOGICAL|placebo injection|
214434650|NCT04483089|DEVICE|Transcatheter heart valve procedure|Transcatheter treatment of TR with Abbott TriClip™.
214515650|NCT04932083|DRUG|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
214434651|NCT06219187|OTHER|Questionnaire completion|"To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data"
214434652|NCT02437123|BEHAVIORAL|The Cedar Project mHealth intervention|
214434653|NCT04302259|DEVICE|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
214434654|NCT04139668|DRUG|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
214434655|NCT04139668|BEHAVIORAL|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
214434656|NCT03718065|DRUG|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
214434657|NCT03718065|DRUG|Placebo|Placebo comparator.
215115228|NCT05089643|DRUG|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
215115229|NCT01173601|DRUG|LY2216684|
215115230|NCT01173601|DRUG|Placebo|
215115231|NCT01173601|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
215115232|NCT04403451|BEHAVIORAL|True North|Love Notes, Financial Stability, Jobs
215115233|NCT02042521|DRUG|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
215115234|NCT02042521|DRUG|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
215115235|NCT03089021|OTHER|mulligan mobilization|mobilization with movement for spinous process or facet joint.
215115236|NCT03089021|OTHER|maitland mobilization|posterioanterior of spinous process or facet joint.
215115237|NCT03951077|DRUG|Elagolix|Capsule administered orally
215115238|NCT03951077|DRUG|Placebo|Capsule administered orally
215115239|NCT00748670|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
215115240|NCT00889512|DRUG|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
215115241|NCT00889512|DRUG|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
215115242|NCT03147352|DEVICE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
215115243|NCT02297386|DRUG|[18F] DIHYDRO-TESTOSTERONE|
215115244|NCT02297386|DEVICE|PET scan|
215115245|NCT02297386|DEVICE|MRI|
215115246|NCT02297386|OTHER|Blood draw|
215115247|NCT02399709|DRUG|simvastatin|
215115248|NCT02399709|DRUG|Placebo|
215115249|NCT02009488|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
215115250|NCT02009488|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
215115251|NCT02009488|DRUG|Placebo|One placebo capsule (inactive medication) once daily.
215115252|NCT00488540|DRUG|Paracetamol|Suppository
215115253|NCT00488540|DRUG|Placebos|Suppository
215115254|NCT01001117|DEVICE|LensAR laser surgery|Use of laser for cataract surgery
215115255|NCT01001117|DEVICE|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
214434658|NCT06190392|OTHER|MODS Modified simplified diagnostic strategy|"The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied."
214434659|NCT06640972|DRUG|RDX-002|Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
214434660|NCT06640972|DRUG|Placebo|Matching placebo
214434661|NCT05396872|OTHER|Participant Surveys|Online surveys administered post appointment
214515651|NCT02340806|DEVICE|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
214515652|NCT04419571|PROCEDURE|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
215115256|NCT02922335|BEHAVIORAL|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
215115257|NCT02922335|BEHAVIORAL|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
215115258|NCT01395901|DRUG|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
215115259|NCT01395901|DRUG|Ondansetron|"Single dose Ondansetron IV:~* 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg;~* 13 years to less than 17 years dose: 4 mg"
215115260|NCT01395901|DRUG|Placebo to Ondansetron|
215115261|NCT01395901|DRUG|Placebo to Palonosetron|
215115262|NCT03923790|BEHAVIORAL|Educational Packet|The patient will receive an educational packet.
215115263|NCT03923790|BEHAVIORAL|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
215115264|NCT03923790|BEHAVIORAL|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
214434662|NCT05396872|OTHER|Mobile app|Mobile application installed on mobile device
215115265|NCT03923790|BEHAVIORAL|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
215115266|NCT03923790|DIAGNOSTIC_TEST|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
215115267|NCT05759494|DIAGNOSTIC_TEST|rapid diagnostic test (multiplex PCR filmArray)|"novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis."
215115268|NCT04775485|DRUG|Tovorafenib|Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.
214434663|NCT02665195|OTHER|saliva specimen|
214434664|NCT02665195|BEHAVIORAL|questionnaire|
214434665|NCT03256240|OTHER|side-to-side functional end anastomosis|type of anastomosis
214434666|NCT03256240|OTHER|Kono-S analstomosis|antimesenteric anastomosis
214434667|NCT06071858|BEHAVIORAL|Care Coordination|"* The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed.~* The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care.~* The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization."
214515653|NCT02819609|PROCEDURE|myomectomy|Myomectomy as part of routine clinical care
214515654|NCT02819609|PROCEDURE|endometrial ablation|Endometrial ablation as part of routine clinical care
214515655|NCT02819609|PROCEDURE|uterine artery embolization|Uterine artery embolization as part of routine clinical care
214515656|NCT02819609|PROCEDURE|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
214515657|NCT01186809|BIOLOGICAL|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
214434668|NCT06071858|BEHAVIORAL|Individual Peer Support|• Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.
214434669|NCT06071858|BEHAVIORAL|Digital Outreach|• mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.
214434670|NCT06071858|BEHAVIORAL|Cognitive Remediation|"* For participants identified as needing and/or wanting support around cognition.~* The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities."
214434671|NCT06071858|BEHAVIORAL|Multi-Family Group Therapy|"* Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician.~* Each group may include 5-8 families and include a mixture of in-person and virtual formats.~* These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics."
214434672|NCT06558006|DRUG|Predimenol tablet|2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).
214434673|NCT06558006|DRUG|Predimenol tablet + Placebo tablet of Predimenol|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).
214515658|NCT03305185|COMBINATION_PRODUCT|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
214515659|NCT03305185|DEVICE|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
214434674|NCT06558006|DRUG|Placebo tablet of Predimenol|2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
214515660|NCT00452452|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
214515661|NCT02751957|BEHAVIORAL|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
214515662|NCT04878679|OTHER|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
214515663|NCT04878679|OTHER|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
214515664|NCT04878679|OTHER|Control group|No physical activity
214515665|NCT04851782|DEVICE|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
214434675|NCT03309748|PROCEDURE|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
214434676|NCT03309748|DEVICE|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
214434677|NCT06235242|BIOLOGICAL|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
214434678|NCT06307782|DIETARY_SUPPLEMENT|whey protein intake before surgery|Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
214434679|NCT06307782|DIETARY_SUPPLEMENT|Water before surgery|Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
214434680|NCT04732117|DRUG|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
214515666|NCT04069455|OTHER|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
214515667|NCT03014037|PROCEDURE|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
214515668|NCT03014037|PROCEDURE|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
215115269|NCT00873600|DRUG|chemotherapy|
214434681|NCT04732117|DRUG|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
214515669|NCT02761356|OTHER|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
214515670|NCT00213759|DRUG|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
214515671|NCT00213759|DRUG|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
214515672|NCT01303744|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
214515673|NCT01303744|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
214515674|NCT01303744|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
215115270|NCT00873600|OTHER|medical chart review|
215115271|NCT00873600|OTHER|questionnaire administration|
215115272|NCT00873600|PROCEDURE|adjuvant therapy|
215115273|NCT00873600|PROCEDURE|assessment of therapy complications|
214434682|NCT04562688|OTHER|CICADAS only|Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. The NB-TCT exercises are adaptive with the task difficulty adjusting on a trial-to-trial and session-by-session basis to the abilities of each individual. A second set of computerized assessments was administered following the intervention period. Participants had to log in to access these assessments and exercises using a study provided username that contained no personally identifiable information.
214515675|NCT01303744|DRUG|Placebo|oral tablet, once a day in the morning for 12 weeks
214515676|NCT00230906|PROCEDURE|Haemodialysis with either low or high flux membranes|
214515677|NCT05232357|DRUG|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
214515678|NCT02591056|DEVICE|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
214515679|NCT02591056|DEVICE|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
214515680|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
214515681|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
214515682|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose open label
214515683|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose
214515684|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
214515685|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily low dose
214515686|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
214515687|NCT05894291|OTHER|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
214515688|NCT05894291|OTHER|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
215115274|NCT00873600|PROCEDURE|cognitive assessment|
214515689|NCT04015050|OTHER|milk based infant formula|Cows milk ased infant formula
214515690|NCT06671353|BEHAVIORAL|video decision aid|video decision aid for advance care planning
215115275|NCT00873600|PROCEDURE|psychosocial assessment and care|
215115276|NCT00873600|PROCEDURE|quality-of-life assessment|
215115277|NCT02279667|DRUG|BIA 2-093|oral suspension 50 mg/mL
215115278|NCT02279667|DRUG|BIA 2-093|200 mg tablet
215115279|NCT02279667|DRUG|BIA 2-093|800 mg tablet
214515691|NCT02426931|DEVICE|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
214515692|NCT02426931|DEVICE|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
214515693|NCT03029299|DEVICE|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
214515694|NCT05144659|PROCEDURE|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
214515695|NCT05144659|PROCEDURE|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
215115280|NCT03686293|OTHER|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
215115281|NCT01267305|DRUG|Fondaparinux|2.5mg IH qd(8AM) after operation
215115282|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
215115283|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
215115284|NCT00713544|DRUG|AZD5672|20 mg oral, once daily
215115285|NCT00713544|DRUG|Etanercept|50 mg, subcutaneous injection, weekly
215115286|NCT00713544|DRUG|Placebo|placebo, oral, once daily
215115287|NCT00713544|DRUG|AZD5672|50 mg oral, once daily
215115288|NCT00713544|DRUG|AZD5672|100 mg oral, once daily
215115289|NCT00713544|DRUG|AZD5672|150 mg oral, once daily
215115290|NCT04799249|DRUG|Trilaciclib|Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
214515696|NCT04433091|DRUG|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
214515697|NCT04433091|OTHER|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
214434683|NCT04562688|OTHER|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
214434684|NCT04562688|OTHER|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
214434685|NCT03025789|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
214515698|NCT07009600|DRUG|immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)|
214515699|NCT03229291|DRUG|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
214515700|NCT03229291|DRUG|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
214515701|NCT07009197|OTHER|Instrument Assisted Soft Tissue Mobilization|the treatment will start by disinfect the instrument between patients to avoid transfer of infections. It is recommended to disinfect the instrument with intermediate-level disinfectants (e.g. isopropyl alcohol), then wash it with soap and water to remove any residuals of the chemical disinfectant off the instrument. If the tools contacts blood, bodily fluids, mucous membranes, or non-intact skin then disinfecting it with high-level disinfectant should be done .IASTM will be done at 30-60 degrees angle for 40-120 seconds+ radiational therapy
214434686|NCT05286385|DEVICE|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
214434687|NCT05286385|DEVICE|CP1150 NF|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
214434688|NCT05286385|DEVICE|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
214434689|NCT05286385|DEVICE|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
214434690|NCT04733040|DRUG|MOR202|MOR202 will be administered as an intravenous infusion
214434691|NCT00658827|OTHER|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
214434692|NCT06589466|OTHER|Surgery|this study in observational study, no intervention.
214434693|NCT06471257|COMBINATION_PRODUCT|Budesonide/Albuterol metered dose inhaler, MDI|Combination Product (Drug + Device)
214434694|NCT06471257|COMBINATION_PRODUCT|Albuterol sulfate metered dose inhaler, MDI|Combination Product (Drug + Device)
214515702|NCT07009197|OTHER|traditional therapy|the patients will receive traditional therapy in the form of ultrasound, scar massage, and stretching exercises.
215115291|NCT04799249|DRUG|Placebo|Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
215115292|NCT04799249|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
215115293|NCT04799249|DRUG|Carboplatin|Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
215115294|NCT06303102|OTHER|Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.
215115295|NCT06303102|OTHER|Manual PT/Conventional PT Treatment|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
215115296|NCT02380287|DRUG|humanized monoclonal antibody against human IL-17|
215115297|NCT05767840|OTHER|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
214434695|NCT04981730|BEHAVIORAL|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
214434696|NCT05384249|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214434697|NCT05384249|DRUG|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214434698|NCT02789228|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
214434699|NCT06084455|OTHER|Aerobic exercise|30 minutes of aerobic exercise on a stationary bike
214434700|NCT06049589|DIETARY_SUPPLEMENT|Coconut Oil|Coconut oil rinsing
214515703|NCT05586165|BEHAVIORAL|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
214515704|NCT05586165|BEHAVIORAL|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
214515705|NCT05586165|BEHAVIORAL|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
214515706|NCT04097535|OTHER|PET/MRI|Imaging scan
214515707|NCT02265354|BEHAVIORAL|Collective-Intelligence computer tailored health communication|
214515708|NCT02265354|BEHAVIORAL|Rule-based computer tailored health communication|
214515709|NCT06692998|OTHER|Rehabilitation|Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
214515710|NCT06694441|OTHER|Light Exposure|The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
214515711|NCT06694441|OTHER|Placebo|Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
214515712|NCT06696105|DRUG|Resin infiltration|"Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization."
214515713|NCT06696105|DRUG|Vanish XT varnish (resin modified glass ionomer restoration)|Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
214515714|NCT06698562|OTHER|Distraction with Virtual reality glassess|the injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. The patient and the physician wore protective goggles during the whole procedure to prevent possi
215115298|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
214434701|NCT06049589|DRUG|Chlorhexidine mouthwash|Chlorhexidine rinsing
214434702|NCT06049589|OTHER|Water mouthwash|Control with water rinsing
214434703|NCT06681090|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
214434704|NCT06681090|DEVICE|980 nm diode laser|First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
215115299|NCT04293341|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
215115300|NCT04293341|BEHAVIORAL|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
214515715|NCT06698562|OTHER|Distraction with Virtual reality glassess + LLLT|The injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
214515716|NCT06698562|OTHER|Tell Show Do Group + LLLT|The injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. During the whole procedure, the patient wore virtual glasses and the physician wore protective go
215115301|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
215115302|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
215115303|NCT03384368|DEVICE|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
215115304|NCT01641601|DEVICE|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
215115305|NCT04768621|OTHER|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
215115306|NCT05897034|DRUG|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
214434705|NCT06360432|BEHAVIORAL|Dietary modification program|Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.
214434706|NCT06360432|BEHAVIORAL|Exercise training|Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.
214515717|NCT06698562|OTHER|Tell Show Do Group|In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
214515718|NCT06698783|DIETARY_SUPPLEMENT|Fortimel|In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
214515719|NCT06699017|OTHER|Continuous anterior chest compression|CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
215115307|NCT05897034|DRUG|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
215115308|NCT05897034|DRUG|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
215115309|NCT04577469|DRUG|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
215115310|NCT04577469|DRUG|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
214515720|NCT06700252|OTHER|Vestibular Rehabilitation|This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.
215115311|NCT04977713|OTHER|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
215115312|NCT04977713|OTHER|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
214434707|NCT06360432|BEHAVIORAL|The EatWellLog App|Only participants in the M-health group will be instructed to use the EatWellLog app for daily diet self-management. This App supports participants with SO by providing a structured approach to managing a diet that encourages steady weight loss while maintaining muscle mass, in line with current nutritional recommendations for this demographic. The EatWellLog App has the following features: i) tracking participants' dietary habits by logging meals and snacks from a food list, ii) personalized online coaching and reminders by a multidisciplinary healthcare team, iii) participation of family caregivers through an interactive messaging function, iv) accessing health information via multiple channels, including animations, an at-a-glance display, and a reminder, and v) utilization of game elements, such as educational animations and video games to disseminate health and nutritional information related to SO.
214434708|NCT06421051|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
214434709|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
214434710|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
214434711|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
214434712|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
214434713|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
214692656|NCT03431324|BEHAVIORAL|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
215115313|NCT01591941|OTHER|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
215115314|NCT02423655|OTHER|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
214434714|NCT04907474|DRUG|tropicamide-phenylephrine fixed combination ophthalmic solution|Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
215115315|NCT02423655|OTHER|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
214515721|NCT06700252|OTHER|Traditional Protocol|This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
214434715|NCT06084221|BEHAVIORAL|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
214434716|NCT06084221|BEHAVIORAL|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
214434717|NCT04009967|DRUG|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
214434718|NCT06099249|DEVICE|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
214434719|NCT03827304|DEVICE|Virtual Reality Distraction for Burns patients|Patients wore a VR headset while undergoing a burns dressing change
214434720|NCT04649021|BIOLOGICAL|BNT162b2|Intramuscular injection
214434721|NCT04649021|OTHER|Placebo|Intramuscular injection
214434722|NCT05488080|BEHAVIORAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
214434723|NCT02411084|BIOLOGICAL|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
214515722|NCT06698718|PROCEDURE|Periodontal basic treatment|Accept periodontal basic treatment
214515723|NCT00264654|DRUG|BRL29060A|
214515724|NCT00264654|DRUG|paroxetine hydrochloride hydrate|
214515725|NCT06699485|DIETARY_SUPPLEMENT|Low carb diet|Low-carbohydrate diet contains (\<26% carbohydrates) or less than 130 g/d
214515726|NCT06698432|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
214515727|NCT05219708|DIETARY_SUPPLEMENT|Calorie protein supplement|Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure
214515728|NCT05219708|OTHER|Control|Standard of care for heart failure
215115316|NCT01908530|DEVICE|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
214434724|NCT02411084|BIOLOGICAL|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
214515729|NCT03070301|DRUG|LEE011|LEE011 200 mg daily
214515730|NCT03070301|DRUG|everolimus|everolimus 5 mg daily or 2.5mg daily
214515731|NCT06200792|DEVICE|eSense device|eSense device for monitoring electrodermal activity. Visual analogic scale (VAS) for pain and discomfort; TOL-R tests for investigating working performances.
214515732|NCT06051864|DEVICE|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
214515733|NCT06051864|DEVICE|Sham Device|Placebo comparator sham device (no active stimulation)
214515734|NCT06168045|DIAGNOSTIC_TEST|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
214515735|NCT03242239|BIOLOGICAL|ALT02|
214515736|NCT03242239|BIOLOGICAL|EU-licensed Herceptin|
214515737|NCT03242239|BIOLOGICAL|US-licensed Herceptin|
214515738|NCT01697605|DRUG|BGJ398|
214515739|NCT04416100|DIAGNOSTIC_TEST|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
214515740|NCT04416100|DIAGNOSTIC_TEST|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
214515741|NCT04416100|BIOLOGICAL|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
214515742|NCT03277456|BIOLOGICAL|MVA-NP+M1|Intramuscular injection of novel vaccine
214515743|NCT02529605|DIETARY_SUPPLEMENT|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
214434725|NCT02663778|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
214434726|NCT02663778|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
214434727|NCT02663778|BEHAVIORAL|Flexibility training|stretches to improve flexibility
214434728|NCT02663778|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
214434729|NCT02663778|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
214434730|NCT04879368|DRUG|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
214434731|NCT04879368|BIOLOGICAL|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
214434732|NCT04879368|DRUG|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
214434733|NCT04879368|DRUG|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
214434734|NCT04879368|DRUG|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
214434735|NCT04879368|DRUG|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
215115317|NCT02228317|DEVICE|Telemedicine consultation|Telemedicine consultation done by telephone or video
214434736|NCT04291638|BEHAVIORAL|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
214434737|NCT04291638|BEHAVIORAL|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
214434738|NCT03000595|DRUG|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
214434739|NCT03000595|DRUG|Placebo|The vehicle cream
214434740|NCT05239156|DEVICE|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
214692657|NCT03431324|BEHAVIORAL|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
214692658|NCT01044381|DRUG|Luliconazole Solution, 10%|28 days of daily application
214692659|NCT05909605|DEVICE|sphygmomanometer|Comparison to the ultrasound sensor
215115318|NCT04585204|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test
214434745|NCT03303651|PROCEDURE|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
214515744|NCT02529605|DIETARY_SUPPLEMENT|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
215115319|NCT00950846|DRUG|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
215115320|NCT00950846|DRUG|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
215115321|NCT00950846|DRUG|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
215115322|NCT00950846|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
214434746|NCT03303651|PROCEDURE|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
214434747|NCT00713063|BEHAVIORAL|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
214434748|NCT00713063|BEHAVIORAL|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
214434749|NCT04259450|DRUG|14 mg AFM24|14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434750|NCT04259450|DRUG|40 mg AFM24|40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434751|NCT04259450|DRUG|80 mg AFM24|80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434752|NCT04259450|DRUG|160 mg AFM24|160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434753|NCT04259450|DRUG|320 mg AFM24|320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434754|NCT04259450|DRUG|480 mg AFM24|480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434755|NCT04259450|DRUG|720 mg AFM24|720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
214434756|NCT00711581|DEVICE|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
214434757|NCT03319680|OTHER|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
214434758|NCT04667780|DRUG|Colchicine|Colchicine tablet 0.5 mg
214434759|NCT04667780|DRUG|Standard COVID-19 care|As per the hospital guidelines
214434760|NCT01534494|DRUG|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
214434761|NCT00075933|DRUG|ARQ 501|
214434762|NCT03984357|DRUG|PD-1 blocking antibody|"1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
214434763|NCT03984357|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
214434764|NCT03984357|DRUG|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
214434765|NCT03984357|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
214434766|NCT03872310|DEVICE|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
214434767|NCT00131638|DRUG|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
214434768|NCT00131638|DRUG|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
214434769|NCT04997616|DIETARY_SUPPLEMENT|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
214434770|NCT01871324|BEHAVIORAL|Lifestyle counseling|group therapy
214434771|NCT02797444|OTHER|semi-structured interviews|
214434772|NCT01991301|DRUG|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
214434773|NCT02553161|DRUG|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
214434774|NCT02553161|BEHAVIORAL|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
214434775|NCT03118323|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
214434776|NCT02880137|DRUG|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
214434777|NCT02880137|PROCEDURE|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
214434778|NCT02617771|DRUG|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
214515745|NCT04998266|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
214515746|NCT04998266|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
214515747|NCT00801528|DRUG|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
214515748|NCT02797899|DEVICE|Platelet Rich Fibrin|Native growth factors
214515749|NCT01975701|DRUG|BGJ398|Capsule for oral use.
214692660|NCT05909605|DEVICE|Arterial Line|Comparison to the ultrasound sensor
214434779|NCT00434304|DRUG|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
214434780|NCT04418973|OTHER|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
214515750|NCT04492085|OTHER|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
214515751|NCT02717780|DRUG|Fentanyl and sevoflurane|
214515752|NCT02717780|DRUG|Remifentanil and desflurane|
215115323|NCT04829149|OTHER|Observational|Statin therapy group and Rosuzet tablet group
215115324|NCT00242541|DRUG|Octreotide acetate|
215115325|NCT01278563|BEHAVIORAL|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
215115326|NCT01115868|DRUG|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
215115327|NCT01115868|DRUG|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
214434781|NCT02356341|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
214434782|NCT06516315|PROCEDURE|Preoperative ultrasound examination.|Preoperative ultrasound examination performed the day before or the day of surgery.
214434783|NCT06516315|PROCEDURE|Peroperatoire angiography procedure and QFR analysis|Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
214434784|NCT02894879|DEVICE|BreatheMAX®|"Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
214434785|NCT02894879|OTHER|Routine treatment|"Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
214434786|NCT04045782|DRUG|single arm|switch from originator (Humira) to biosimilar (Imraldi)
214434787|NCT00348322|DRUG|Systane Free Lubricant Eye Drops|
214434788|NCT00804648|DRUG|Timolol Maleate in Sorbate|0.5%
215115328|NCT01115868|DRUG|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
215115329|NCT01115868|DRUG|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
215115330|NCT02178995|DRUG|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
214434789|NCT00804648|DRUG|Timolol hemihydrate|0.5%
214434790|NCT00804648|DRUG|Timolol maleate gel forming solution|0.5%
214434791|NCT00485459|DRUG|Atomoxetine Hydrochloride|
214434792|NCT00485459|DRUG|Placebo|
214515753|NCT00242086|PROCEDURE|CT, PET and MRI|
214515754|NCT02270502|DEVICE|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
214515755|NCT02270502|OTHER|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
214515756|NCT02270502|OTHER|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
214515757|NCT05804552|DEVICE|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
215115331|NCT00587158|DRUG|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
214434793|NCT01643616|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
214434794|NCT01643616|DRUG|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
215115332|NCT00587158|OTHER|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
215115333|NCT01637155|DRUG|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
214434795|NCT01643616|DRUG|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
214434796|NCT01643616|DRUG|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
214434797|NCT01643616|DEVICE|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
214434798|NCT01643616|DEVICE|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
214434799|NCT05191810|BEHAVIORAL|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
214434800|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
214434801|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
214434802|NCT05255835|DEVICE|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
214434803|NCT05255835|DEVICE|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
214434804|NCT01939899|DRUG|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
214434805|NCT05958836|DEVICE|pacemaker|Micra TPS or traditional PM group
214434806|NCT00710567|DEVICE|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
214434807|NCT04644679|DIAGNOSTIC_TEST|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
214434808|NCT04644679|DIAGNOSTIC_TEST|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
214434809|NCT05576857|OTHER|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
214434810|NCT02061501|OTHER|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
214434811|NCT02061501|OTHER|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
214434812|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg|
214434813|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 75µg|
214434814|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 100µg|
214434815|NCT05674669|DRUG|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
214434816|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
214434817|NCT00162344|DRUG|Technetium Tc99m Sestamibi|
214434818|NCT00585052|DRUG|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
214434819|NCT00585052|DRUG|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
214434820|NCT02551536|DRUG|Montelukast|
214434821|NCT02551536|DRUG|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
214515758|NCT01379677|DRUG|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
214515759|NCT01379677|DRUG|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
214434822|NCT02551536|DRUG|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
214434823|NCT03847259|DIAGNOSTIC_TEST|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
214434824|NCT00031785|DRUG|megestrol acetate|
214434825|NCT00031785|RADIATION|radiation therapy|
214434826|NCT04613700|DRUG|Secretin|Native hormone
214434827|NCT04613700|OTHER|Placebo|Saline
214434828|NCT05000424|OTHER|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
214434829|NCT05000424|OTHER|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
214434830|NCT00532142|DRUG|Intravitreal Triamcinolone|
214434831|NCT00532142|PROCEDURE|Radial Optic Neurotomy|
214434832|NCT00532142|OTHER|Placebo - Sham Intravitreal Injection|
214434833|NCT01913691|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
214434834|NCT05286489|COMBINATION_PRODUCT|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
214434835|NCT05436119|DIETARY_SUPPLEMENT|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
214434836|NCT04038736|DEVICE|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
214434837|NCT05121467|OTHER|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
214434838|NCT05121467|OTHER|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
214434839|NCT05121467|OTHER|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
214515760|NCT05185102|OTHER|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
214515761|NCT05045456|DEVICE|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
214692661|NCT00683475|BIOLOGICAL|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
214434840|NCT05121467|OTHER|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
214434841|NCT00858117|BIOLOGICAL|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
214434842|NCT00858117|BIOLOGICAL|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
214434843|NCT04741113|OTHER|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
214434844|NCT05296213|DRUG|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
214434845|NCT05296213|DRUG|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
214434846|NCT05296213|DRUG|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
214434847|NCT01714960|DRUG|MRZ-99030 eye drops 5mg/mL|
214434848|NCT01714960|DRUG|MRZ-99030 eye drops 20mg/mL|
214434849|NCT01714960|DRUG|Placebo to MRZ-99030 eye drops|
214434850|NCT05043272|BIOLOGICAL|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
214434851|NCT00371787|DEVICE|Soft contact lens|Soft contact lens
214434852|NCT03308292|OTHER|Exercise|Aerobic exercise program
214434853|NCT01240434|PROCEDURE|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
214434854|NCT02798367|BEHAVIORAL|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
214434855|NCT02798367|DRUG|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
214434856|NCT02798367|DRUG|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
214434857|NCT05178459|DIAGNOSTIC_TEST|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
214434858|NCT02415088|PROCEDURE|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
214434859|NCT02415088|PROCEDURE|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
214434860|NCT03277534|OTHER|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
214515762|NCT03108222|OTHER|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
214515763|NCT01301183|DRUG|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
215115334|NCT02402582|OTHER|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
214434861|NCT03277534|OTHER|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
214434862|NCT04425863|DRUG|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
214515764|NCT01301183|DRUG|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
214515765|NCT04514094|DRUG|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
214515766|NCT04514094|PROCEDURE|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
214515767|NCT05177029|DRUG|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
214434863|NCT04425863|OTHER|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
214515768|NCT05177029|DRUG|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
214515769|NCT01330745|OTHER|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
214515770|NCT03799757|DRUG|40ml of 0.25% bupivacaine|
215115335|NCT02402582|OTHER|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
215115336|NCT05635513|DEVICE|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
215115337|NCT04080102|OTHER|High Intensity Interval Training|Exercise
215115338|NCT04080102|DIETARY_SUPPLEMENT|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
215115339|NCT04080102|OTHER|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
215115340|NCT04479332|PROCEDURE|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
215115341|NCT02104466|PROCEDURE|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
215115342|NCT05258149|DEVICE|JJVC Investigational Multifocal Contact Lenses|TEST
215115343|NCT05258149|DEVICE|Dailies Total 1® Multifocal Contact Lenses|CONTROL
214434864|NCT04425863|OTHER|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
214434865|NCT04460807|DRUG|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
214434866|NCT04460807|OTHER|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
214434867|NCT02355275|PROCEDURE|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
214434868|NCT06358534|BEHAVIORAL|psychoeducation based on acceptance and commitment therapy|psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
214434869|NCT03323775|DIAGNOSTIC_TEST|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
214434870|NCT04860401|DEVICE|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
214434871|NCT05801367|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
214434872|NCT05801367|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
214434873|NCT04677192|COMBINATION_PRODUCT|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
214434874|NCT06450496|BEHAVIORAL|Positive parenting on-line program|Positive parenting on-line program focused on parenting and personal competences relevant for parents with adolescents exhibiting mental health problems
214434875|NCT02233595|RADIATION|Chemoradiation|
214434876|NCT04218890|DIAGNOSTIC_TEST|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
214434877|NCT03285542|DEVICE|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
214434878|NCT03285542|DEVICE|Staples|staples for skin closure
214434879|NCT01902147|OTHER|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
215115344|NCT00832416|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
214434880|NCT05398224|DRUG|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
214434881|NCT04961021|PROCEDURE|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
214515771|NCT03799757|DRUG|40ml of 0.9% normal saline|
214434882|NCT01854385|DRUG|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
214434883|NCT00329862|PROCEDURE|Laparoscopic Truncal Vagotomy|
214434884|NCT05469841|OTHER|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
214515772|NCT06453759|PROCEDURE|Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei|"The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts."
214515773|NCT02896673|PROCEDURE|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
214515774|NCT00473031|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
214515775|NCT00473031|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
214515776|NCT00473031|BEHAVIORAL|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
214515777|NCT01072149|DRUG|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
214515778|NCT01072149|DEVICE|placebo|placebo
214515779|NCT00091520|DRUG|Nesiritide|
214515780|NCT05779254|DRUG|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
214692662|NCT00683475|DRUG|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
214515781|NCT04977089|DIAGNOSTIC_TEST|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
214515782|NCT01781923|BEHAVIORAL|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
214515783|NCT01781923|BEHAVIORAL|Small group social skills training|Meet once per week for duration of 40 weeks.
214515784|NCT01566552|DRUG|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
214692663|NCT00683475|DRUG|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
214434885|NCT01472900|DEVICE|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
214434886|NCT01472900|DRUG|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
214515785|NCT02391259|DRUG|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
214515786|NCT02391259|DRUG|Placebo|contains no active drug
214515787|NCT03763409|DRUG|Losartan Potassium|active drug
214515788|NCT03763409|OTHER|placebo|placebo
214692664|NCT00683475|BIOLOGICAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
214692665|NCT04783532|BEHAVIORAL|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
215115345|NCT00832416|DRUG|Placebo|One Placebo tablet daily.
214434887|NCT02966275|DEVICE|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
214434888|NCT02966275|DEVICE|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
214434889|NCT05079126|DRUG|Trans Sodium Crocetinate|Single IV Bolus
214434890|NCT05079126|DRUG|Placebo|Single IV Bolus
214434891|NCT02080754|OTHER|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
214434892|NCT02080754|OTHER|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
214434893|NCT03392038|PROCEDURE|Thin ADM|Use of soft tissue allograft for root coverage
214434894|NCT03392038|PROCEDURE|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
214434895|NCT03072316|OTHER|3D surface imaging|3D photography
214434896|NCT03072316|OTHER|semi-structured interview|qualitative analysis using semi structured interview
214434897|NCT03072316|OTHER|applanation tonometry|measurement of breast compressibility
214434898|NCT04014179|DIAGNOSTIC_TEST|Xpert HCV Viral Load Fingerstick|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.
214515789|NCT06207383|DEVICE|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
214515790|NCT06207383|PROCEDURE|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
214515791|NCT06207383|PROCEDURE|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
215115346|NCT02114606|DEVICE|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
215115347|NCT03570814|DRUG|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
215115348|NCT03570814|DRUG|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
214434899|NCT04014179|DIAGNOSTIC_TEST|Aptima HCV Quant DX Assay|"The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.~The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment."
214434900|NCT02808351|DRUG|Berberine|
214434901|NCT00277355|DRUG|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
214434902|NCT00277355|DRUG|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
214434903|NCT00538759|DEVICE|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
214434904|NCT00538759|OTHER|Sham Control|
214434905|NCT05680649|OTHER|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
214434906|NCT00735852|DRUG|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
214434907|NCT03096236|DEVICE|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
214434908|NCT05953675|DRUG|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
214434909|NCT05953675|DRUG|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
214434910|NCT05530161|OTHER|hypocalcemia|hypocalcemia or normocalcemia
214515792|NCT05387629|BEHAVIORAL|Education|Nursing students will be trained through social media.
214515793|NCT02784834|DRUG|dimethyl fumarate|
214515794|NCT04392856|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
215115349|NCT03570814|DRUG|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
215115350|NCT03570814|DRUG|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
215115351|NCT02275663|DRUG|Azacytidine|
215115352|NCT02275663|DRUG|Fludarabine|
215115353|NCT02275663|DRUG|Cytarabine|
214434911|NCT05447936|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
214434912|NCT05073224|DIAGNOSTIC_TEST|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
214434913|NCT05073224|OTHER|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
214434914|NCT05073224|OTHER|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
214434915|NCT05073224|DIAGNOSTIC_TEST|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
214434916|NCT04733833|DRUG|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
214434917|NCT04733833|DRUG|Standard of care|Standard of care
214434918|NCT05656664|DIETARY_SUPPLEMENT|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
214434919|NCT05656664|OTHER|Placebo|Placebo group to assess arsenic metabolite excretion
214434920|NCT00642850|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
214515795|NCT04392856|BEHAVIORAL|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
214515796|NCT00635752|OTHER|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
214515797|NCT00635752|OTHER|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
214515798|NCT00048477|DRUG|L-NMMA and Sodium Nitrite|
214515799|NCT03563170|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214515800|NCT03563170|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
214515801|NCT03563170|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
215115354|NCT02275663|DRUG|Filgrastim|G-CSF
214515802|NCT03563170|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
214515803|NCT03563170|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214515804|NCT03563170|DRUG|Cyclophosphamide|anhydrous
214515805|NCT03563170|DRUG|5-Fluorouracil|5-FU; Fluorouracil
214515806|NCT03563170|DRUG|Leucovorin|Leucovorin calcium salt
214515807|NCT03563170|DRUG|nab-Paclitaxel|ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
214515808|NCT03563170|DRUG|Sorafenib|NEXAVAR® tablets, for oral use
214515809|NCT03563170|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214515810|NCT03563170|BIOLOGICAL|Aldoxorubicin hydrochloride|HCl
215115355|NCT06334848|PROCEDURE|transobturator tape|Women with stress urinary incontinence are treated by transobturator tape versus mini sling
214515811|NCT03563170|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214515812|NCT03563170|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
214515813|NCT03563170|BIOLOGICAL|GI-6207|CEA yeast vaccine
215115356|NCT04355208|OTHER|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
215115357|NCT02382445|DEVICE|Anesthesia depth monitor|
215115358|NCT02382445|DEVICE|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
215115359|NCT02382445|DRUG|propofol and sevoflurane|
215115360|NCT02822898|DRUG|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
214434921|NCT06509243|BIOLOGICAL|tablets Acarizax|sublingual immunotherapy to house dust mites
214434922|NCT06509243|BIOLOGICAL|dupilumab|dupilumab - biologic therapy for atopic dermatitis
214434923|NCT06509243|DRUG|cyclosporine|cyclosporine used in atopic dermatitis
214434924|NCT04040296|OTHER|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 2 hours of AKI detection. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
214434925|NCT02387645|PROCEDURE|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
214434926|NCT01690572|DEVICE|Paclitaxel coated balloon catheter|Dilatation of the target lesion
214434927|NCT01690572|DEVICE|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
214434928|NCT05298397|OTHER|EAT-PTSD adapted for youth for anxiety|"This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion."
214434929|NCT00219791|DRUG|glucarpidase (50 Units/kg)|
214434930|NCT02984332|OTHER|Lower limb immobilisation (leg brace)|
214434931|NCT03978728|DEVICE|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
214434932|NCT00223600|BEHAVIORAL|Nutritional and life style counseling|
214434933|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
214434934|NCT02837796|PROCEDURE|transobturator tape|
214434935|NCT04807790|OTHER|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
214434936|NCT03929432|DEVICE|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
214434937|NCT03929432|DEVICE|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
214434938|NCT02926794|BEHAVIORAL|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
214515814|NCT03563170|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214515815|NCT03563170|DRUG|Cetuximab|ERBITUX® injection, for IV infusion)
214515816|NCT03563170|BIOLOGICAL|N-803|Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
214515817|NCT00976053|PROCEDURE|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
214515818|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
215115361|NCT02822898|DRUG|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
215115362|NCT02109991|DEVICE|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
215115363|NCT04280055|DRUG|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
214515819|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
215115364|NCT00981461|DEVICE|HairMax LaserComb|Device application 3 times week, for 26 weeks
215115365|NCT00981461|DEVICE|Control Device|Device application 3 times week, for 26 weeks
215115366|NCT03187119|BEHAVIORAL|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
214434939|NCT02926794|BEHAVIORAL|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
214434940|NCT02926794|BEHAVIORAL|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
214434941|NCT02926794|BEHAVIORAL|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
214434942|NCT06831474|DRUG|Rivaroxaban 10 MG Oral Tablet|10mg rivaroxaban daily
214434943|NCT06831474|DRUG|Rivaroxaban 20 MG Oral Tablet|20mg rivaroxaban daily
214434944|NCT05038618|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
214515820|NCT02143713|DRUG|Elagolix|Elagolix tablets administered orally
214515821|NCT02167230|PROCEDURE|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
214515822|NCT02167230|PROCEDURE|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
214515823|NCT05487937|OTHER|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
214515824|NCT00021333|BIOLOGICAL|filgrastim|
214515825|NCT00021333|DRUG|cisplatin|
214515826|NCT00021333|DRUG|paclitaxel|
214515827|NCT00021333|RADIATION|radiation therapy|
215115367|NCT03187119|BEHAVIORAL|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
215115368|NCT03306992|BEHAVIORAL|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
215115369|NCT05432752|DEVICE|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
215115370|NCT01999400|DRUG|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
215115371|NCT01999400|DRUG|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
214515828|NCT03411408|DEVICE|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
214515829|NCT03411408|RADIATION|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
214515830|NCT03918733|PROCEDURE|surgical treatment|surgical treatment will be done of failed root canal treated teeth
214515831|NCT03918733|PROCEDURE|Non surgical retreatment|Non surgical retreatment will be done.
214515832|NCT01241032|DRUG|Udenafil|200mg Single Oral Dose of
214515833|NCT01241032|DIETARY_SUPPLEMENT|Alcohol|Alcohol 39g / 240ml
214515834|NCT04264156|COMBINATION_PRODUCT|Lucinactant for Inhalation|A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
214515835|NCT04264156|OTHER|nCPAP Only|Nasal continuous positive airway pressure (nCPAP) alone
214515836|NCT01768572|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
214515837|NCT01768572|DRUG|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
214515838|NCT01768572|DRUG|hydroxychloroquine|Dispensed according to local practice.
215115372|NCT01999400|DRUG|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
215115373|NCT01999400|DRUG|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
215115374|NCT01994616|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
215115375|NCT01466127|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
214515839|NCT01768572|DRUG|methotrexate|Dispensed according to local practice.
214515840|NCT01768572|DRUG|sulfasalazine|Dispensed according to local practice.
214515841|NCT01768572|DRUG|leflunomide|Dispensed according to local practice.
215115376|NCT01466127|DRUG|Placebo|Matched nasal spray placebo
214515842|NCT01768572|DRUG|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
214515843|NCT01768572|DRUG|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
214515844|NCT02771561|PROCEDURE|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
214434945|NCT05500326|DRUG|Ivermectin Tablets|"ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
214515845|NCT02255006|DEVICE|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
215115377|NCT01657175|OTHER|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
215115378|NCT01910402|DRUG|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
215115379|NCT01910402|DRUG|Atazanavir|Atazanavir capsule 300 mg
214434946|NCT06097390|DRUG|Semaglutide|Oral administration
214434947|NCT05012072|BEHAVIORAL|The Mastery Lifestyle Intervention|Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
214434948|NCT05662917|BEHAVIORAL|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
214434949|NCT02748954|BEHAVIORAL|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
214434950|NCT02748954|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
214434951|NCT02748954|BEHAVIORAL|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
214434952|NCT02748954|BEHAVIORAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
214434953|NCT02748954|BEHAVIORAL|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
214434954|NCT05188781|DRUG|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
214434955|NCT00609310|DIETARY_SUPPLEMENT|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
214434956|NCT05489484|DEVICE|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
214434957|NCT05650567|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
214434958|NCT05650567|DRUG|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
214434959|NCT02156050|DEVICE|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
214434960|NCT03429998|DRUG|evolocumab|evolocumab 140 mg/biweekly
214434961|NCT03429998|DRUG|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
214434962|NCT03429998|PROCEDURE|LDL apheresis|LDL apheresis biweekly
214434963|NCT01537419|BEHAVIORAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
214434964|NCT01537419|BEHAVIORAL|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
214434965|NCT04496362|DRUG|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
214434966|NCT00420901|DRUG|sildenafil|
214434967|NCT03152344|PROCEDURE|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
214434968|NCT05741996|BEHAVIORAL|Taping|Taping types and brace acute effects for knee osteoartritis
214434969|NCT02860910|BEHAVIORAL|Cognitive Behavioral Group Therapy|
214434970|NCT05822063|DRUG|Lidocaine topical|lidocaine spray
214434971|NCT05822063|OTHER|cold packs|ice packs
214434972|NCT05822063|DEVICE|flash lights|flash lights by camera
214434973|NCT02519517|PROCEDURE|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
214434974|NCT06223113|DEVICE|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
214434975|NCT01351493|DRUG|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
214434976|NCT01351493|DRUG|placebo|placebo Gel, once or twice per day, 12weeks
214434977|NCT02620410|DEVICE|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
214434978|NCT03678558|OTHER|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
214434979|NCT05993507|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
214692666|NCT01524172|BEHAVIORAL|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
214434980|NCT00444600|DRUG|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
214434981|NCT00444600|DRUG|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
214692667|NCT01524172|BEHAVIORAL|Standard Mental Health Treatment|Trauma and evidence informed therapy
214434982|NCT00444600|DRUG|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
214692668|NCT02922634|OTHER|Mini Cog|short cognitive screen, short Frailty screen
215115380|NCT01910402|DRUG|Ritonavir|Ritonavir tablet 100 mg
215115381|NCT01910402|DRUG|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
215115382|NCT03610841|DIAGNOSTIC_TEST|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
214434983|NCT00444600|DRUG|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
214515846|NCT02255006|DEVICE|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
214434984|NCT00481390|PROCEDURE|Cheek cells sample|Cheek cells sample
214434985|NCT00481390|PROCEDURE|Blood sample|Blood sample
214434986|NCT05132478|OTHER|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
214434987|NCT05132478|OTHER|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
214434988|NCT05386498|PROCEDURE|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
214434989|NCT05386498|PROCEDURE|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
214434990|NCT05386498|PROCEDURE|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
214434991|NCT00865436|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
214434992|NCT00865436|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
214434993|NCT05032638|BEHAVIORAL|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
214434994|NCT05032638|BEHAVIORAL|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
214434995|NCT01852071|GENETIC|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
214434996|NCT01852071|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
214515847|NCT02255006|DRUG|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
214515848|NCT02255006|DRUG|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
214434997|NCT01852071|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
214434998|NCT02235272|DRUG|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
214434999|NCT02235272|DRUG|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
214435000|NCT00827346|DRUG|Clopidogrel|600 mg now
214435001|NCT00827346|DRUG|Clopidogrel|600 mg now and 600 mg in 3 hours
214435002|NCT00827346|DRUG|Clopidogrel|900 mg now
214435003|NCT00827346|DRUG|Clopidogrel|600 mg now and 300 mg in 3 hours
214435004|NCT06152939|OTHER|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
214435005|NCT02396602|BEHAVIORAL|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
215115383|NCT03610841|DIAGNOSTIC_TEST|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
215115384|NCT05527444|DRUG|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
215115385|NCT05527444|DRUG|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
215115386|NCT05527444|DRUG|NSAID|stable dose
215115387|NCT05527444|DRUG|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
215115388|NCT00483405|BIOLOGICAL|cetuximab|250 mg/m2, intravenously, once per week
214435006|NCT01843569|BIOLOGICAL|In Vitro maturation|
214435007|NCT04065802|RADIATION|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
214435008|NCT06220097|DRUG|Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells|Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
214435009|NCT05973812|DIETARY_SUPPLEMENT|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
214435010|NCT05973812|DIETARY_SUPPLEMENT|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
214435011|NCT03701386|PROCEDURE|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
214435012|NCT03701386|PROCEDURE|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
214435013|NCT01414738|RADIATION|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
214435014|NCT01116596|DRUG|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
214435015|NCT01075113|DRUG|sorafenib tosylate|Given orally
214515849|NCT02332525|DEVICE|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
214435016|NCT01075113|DRUG|vorinostat|Given orally
214435017|NCT01839331|BIOLOGICAL|4 mL injection of Ampion|4 mL Injection of Ampion
214435018|NCT01839331|BIOLOGICAL|10 mL Injection of Ampion|10 mL Injection of Ampion
214435019|NCT01839331|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
214435020|NCT01839331|DRUG|10 mL Injection of Placebo|10 mL Injection of Placebo
214435021|NCT04056624|DIETARY_SUPPLEMENT|High carotenoid juice|Juice with high carotenoids
214435022|NCT04056624|DIETARY_SUPPLEMENT|Placebo control - Apple juice|Juice with negligible carotenoids
214435023|NCT04215172|DRUG|Macrolides|administration of azithromycin three times weekly for six months
214435024|NCT03449173|DRUG|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
214435025|NCT03224390|OTHER|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
214435026|NCT00243529|BIOLOGICAL|autologous dendritic cell vaccine|
214435027|NCT00703820|DRUG|Cytarabine|See Detailed Description
214435028|NCT00703820|DRUG|Daunorubicin|See Detailed Description
214435029|NCT00703820|DRUG|Etoposide|See Detailed Description
214435030|NCT00703820|DRUG|Clofarabine|See Detailed Description
214515850|NCT00391651|DRUG|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
214515851|NCT00391651|DRUG|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
214515852|NCT00080119|DRUG|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
214515853|NCT00080119|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
214515854|NCT00080119|DRUG|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
214515855|NCT03733860|PROCEDURE|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
214435031|NCT00703820|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214435032|NCT06015399|PROCEDURE|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
214435033|NCT06015399|PROCEDURE|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
214435034|NCT03977935|DEVICE|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
214435035|NCT03440034|DRUG|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
214435036|NCT05951309|DRUG|inofolic combi|The patients in this group were given inofolic combi once a day for 12-16 weeks
214435037|NCT05951309|DRUG|Glucophage 500Mg Tablet|The patients in this group were given glucophage three times a day for 12-16 weeks
214435038|NCT00586222|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
214435039|NCT00586222|OTHER|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
214435040|NCT03289468|DIAGNOSTIC_TEST|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
214435041|NCT02586597|DEVICE|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
214435042|NCT04978233|OTHER|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
214435043|NCT03531840|DRUG|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
214435044|NCT03531840|DEVICE|ClinOmics|Non-significant risk (NSR) device
214435045|NCT00377182|DRUG|Copegus|1000/1200mg po daily for 4 weeks
214435046|NCT00377182|DRUG|PEGASYS|180 micrograms sc weekly for 4 weeks
214435047|NCT00377182|DRUG|RO5024048 1500mg|1500mg po bid for 4 weeks
214435048|NCT00377182|DRUG|RO5024048 3000mg|3000mg po bid for 4 weeks
214435049|NCT00770757|DRUG|CC-4047|
214435050|NCT04834648|BEHAVIORAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
214435051|NCT01152398|BIOLOGICAL|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
214435052|NCT06433102|OTHER|Visual perceptual training based on the lateral masking paradigm|Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
214435053|NCT05110105|BEHAVIORAL|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
214435054|NCT05110105|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
214435055|NCT00761605|DRUG|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
215115389|NCT00483405|DRUG|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
214692669|NCT03611517|BEHAVIORAL|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
214692670|NCT04637945|DIETARY_SUPPLEMENT|ACRB|Product will be consumed once daily, preferably with breakfast.
215115390|NCT00483405|DRUG|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
215115391|NCT06198387|RADIATION|hormone and RT|The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).
214435056|NCT00452270|DRUG|Xylometazoline|
214515856|NCT03733860|PROCEDURE|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
214515857|NCT03733860|PROCEDURE|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
214515858|NCT01062165|DRUG|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
214515859|NCT01919489|DRUG|Liraglutide + OADs|Liraglutide subcutaneously daily
214515860|NCT01919489|DRUG|Glargine + OADs|Glargine once daily subcutaneously
214692671|NCT04637945|OTHER|Placebo|Product will be consumed once daily, preferably with breakfast.
214692672|NCT04485091|COMBINATION_PRODUCT|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
214692673|NCT04485091|OTHER|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
215115392|NCT06198387|DRUG|ADT combined with abiraterone|The patients will receive a two-year course of ADT combined with abiraterone.
214435057|NCT01504659|DRUG|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
214515861|NCT04187456|DRUG|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
215115393|NCT03261388|BEHAVIORAL|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
215115394|NCT00571038|BEHAVIORAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
214435058|NCT01504659|DRUG|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
214435059|NCT02267824|DEVICE|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
214435060|NCT02267824|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
214435061|NCT00867256|DEVICE|Large Diameter Metal on Metal|
214435062|NCT06294275|BIOLOGICAL|LP-001 Dose 1 (Single)|A single dose of LP-001 (Dose 1) was administered subcutaneously.
214435063|NCT06294275|BIOLOGICAL|LP-001 Dose 2 (Single)|A single dose of LP-001 (Dose 2) was administered subcutaneously.
214435064|NCT06294275|BIOLOGICAL|LP-001 Dose 3 (Single)|A single dose of LP-001 (Dose 3) was administered subcutaneously.
214435065|NCT06294275|BIOLOGICAL|LP-001 Dose 4 (Single)|A single dose of LP-001 (Dose 4) was administered subcutaneously.
214435066|NCT06294275|BIOLOGICAL|LP-001 Dose 5 (Single)|A single dose of LP-001 (Dose 5) was administered subcutaneously.
214435067|NCT06294275|BIOLOGICAL|LP-001 Dose 6 (Single)|A single dose of LP-001 (Dose 6) was administered subcutaneously.
214435068|NCT06294275|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered subcutaneously.
214435069|NCT06294275|BIOLOGICAL|LP-001 Dose 7 (Multiple)|LP-001 (Dose 7) was administered multiple times subcutaneously.
215115395|NCT00571038|BEHAVIORAL|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
215115396|NCT00261027|DRUG|Exemestane|
215115397|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
215115398|NCT03545438|BIOLOGICAL|LIB003|LIB003 or placebo
214435070|NCT06294275|BIOLOGICAL|LP-001 Dose 8 (Multiple)|LP-001 (Dose 8) was administered multiple times subcutaneously.
214435071|NCT06294275|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
214435072|NCT01088659|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
214435073|NCT01088659|DRUG|placebo|orally daily, 96 weeks
214435074|NCT01088659|DRUG|tenofovir|245mg po daily, 96 weeks
214435075|NCT06059560|DIETARY_SUPPLEMENT|Nutritional therapy|Intensive nutritional therapy based on real world therapy
214435076|NCT02578836|PROCEDURE|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
214435077|NCT00978172|DRUG|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
214515862|NCT04187456|DRUG|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
214515863|NCT05908136|OTHER|restorative materials|two types of composite with strip crown in primary molars
214515864|NCT05749315|OTHER|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
215115399|NCT01062152|DRUG|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
215115400|NCT01062152|DRUG|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
214435078|NCT03792620|COMBINATION_PRODUCT|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
214435079|NCT03085394|DRUG|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
214435080|NCT03085394|DRUG|Placebo|Preoperative intravenous administration of 10 ml saline
214435081|NCT02904642|BEHAVIORAL|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
214435082|NCT02904642|BEHAVIORAL|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
214435083|NCT02153541|DRUG|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
214435084|NCT02153541|OTHER|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
214435085|NCT01604161|DRUG|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
214435086|NCT02073578|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
214435087|NCT00098319|DRUG|Folic acid (0.4mg vs. 4.0mg)|
214435088|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
214435089|NCT03451721|DEVICE|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
214435090|NCT00350792|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
214435091|NCT00350792|DRUG|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
214435092|NCT00775294|DRUG|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
214435093|NCT03054415|PROCEDURE|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
214435094|NCT06001190|DIETARY_SUPPLEMENT|probiotic:Lactobacillus crispatus|We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
214435095|NCT03750214|DEVICE|Biop Colposcopy System|"The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis"
214435096|NCT04011813|OTHER|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
214435097|NCT03488745|BEHAVIORAL|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
214435098|NCT00623987|DRUG|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
214435099|NCT01985334|DRUG|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
214515865|NCT05749315|OTHER|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
214515866|NCT00670852|PROCEDURE|X-rays and CT scan|CT Scan x-rays
214435100|NCT01985334|DRUG|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
214515867|NCT01322386|DRUG|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
214515868|NCT00507845|DRUG|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
214515869|NCT03800563|DEVICE|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
214515870|NCT04161976|DRUG|LY900027|LY900027 administered to participants with T1DM using CSII.
214515871|NCT04161976|DRUG|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
214515872|NCT04119700|PROCEDURE|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
214515873|NCT04119700|PROCEDURE|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
214515874|NCT06299345|OTHER|Motor imagery training|MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
215115401|NCT05887050|DIETARY_SUPPLEMENT|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
215115402|NCT05887050|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
215115403|NCT05504044|OTHER|Glucose control|50 g glucose dissolved in 250 mL water
214515875|NCT06299345|OTHER|NO motor imagery training|The participants performed the physical task only. It is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
215115404|NCT05504044|OTHER|Bread control|91.4 g white bread
214435101|NCT01985334|DRUG|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
215115405|NCT05504044|OTHER|Almond paste|88.7 g white bread and 15 g almond paste
215115406|NCT05504044|OTHER|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
215115407|NCT05504044|OTHER|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
215115408|NCT01442714|DRUG|Azacitidine|Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
215115409|NCT01442714|DRUG|Lenalidomide|Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
214435102|NCT01985334|DRUG|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
215115410|NCT05392309|OTHER|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
214515876|NCT03448302|RADIATION|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
214435103|NCT01985334|DRUG|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
214435104|NCT01985334|DRUG|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
214435105|NCT01985334|DRUG|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
214435106|NCT02315456|PROCEDURE|capsulorhexis|
214515877|NCT00949234|DRUG|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
214515878|NCT06463509|OTHER|Establishment of an in-deepth tumor profiling platform|In-depth tumor profiling beyond genomics
214515879|NCT04794465|DIAGNOSTIC_TEST|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
214515880|NCT00883272|DIETARY_SUPPLEMENT|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
214515881|NCT05804734|DRUG|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
215115411|NCT05392309|OTHER|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
215115412|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
215115413|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
215115414|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
215115415|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
215115416|NCT00116220|DRUG|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
215115417|NCT00116220|RADIATION|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
215115418|NCT03641170|BEHAVIORAL|Physical activity|Interval walking performed after each main meal.
215115419|NCT03641170|BEHAVIORAL|Inactivity|Inactivity after each main meal.
215115420|NCT03641170|OTHER|Fixed diet.|Participants will receive a fixed diet through out the intervention period and control period.
215115421|NCT02889211|BEHAVIORAL|Gambling Task|
215115422|NCT03173404|PROCEDURE|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
215115423|NCT04306510|DRUG|TEGSEDI|SC injection.
215115424|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
215115425|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
214435107|NCT00245791|DRUG|Levofloxacin|
214435108|NCT05528549|OTHER|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
214435109|NCT04329130|DRUG|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
214435110|NCT05619952|DIETARY_SUPPLEMENT|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
214435111|NCT01195883|DRUG|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
215115426|NCT05395741|DRUG|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
215115427|NCT01409447|DEVICE|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
215115428|NCT06068426|DIAGNOSTIC_TEST|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
214435112|NCT01195883|DRUG|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
214435113|NCT05738707|BIOLOGICAL|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
214435114|NCT04245644|BEHAVIORAL|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
215115429|NCT03765541|DRUG|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\])."
215115430|NCT03765541|DRUG|Amsacrine|"* Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])"
215115431|NCT03765541|DRUG|Cytarabine|"Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
215115432|NCT03765541|DRUG|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
214435115|NCT04960098|PROCEDURE|arthroplasty|patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
214435116|NCT00127049|DRUG|gemcitabine, ifosfamide, cisplatin, G-CSF|
214435117|NCT02639975|DRUG|PBF-677|once daily oral administration
214435118|NCT02639975|DRUG|Placebo|once daily oral administration
214435119|NCT00126308|DEVICE|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
214435120|NCT00126308|DEVICE|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
214435121|NCT00396084|DRUG|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
214435122|NCT00396084|DRUG|Isoniazid|Isoniazid 300 mg/day x 7 days.
214435123|NCT00396084|DRUG|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
214435124|NCT00396084|DRUG|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
214435125|NCT00396084|DRUG|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
214435126|NCT01502969|BIOLOGICAL|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
214435127|NCT01502969|BIOLOGICAL|cell culture medium in absence of virus|Placebo
214435128|NCT02502708|DRUG|Indoximod|Indoximod will be administered orally twice daily.
214435129|NCT02502708|DRUG|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
214435130|NCT02502708|RADIATION|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
214435131|NCT02502708|DRUG|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
214435132|NCT02502708|DRUG|Etoposide|Etoposide will be administered orally daily.
214435133|NCT03522337|OTHER|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
214435134|NCT03522337|OTHER|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
214435135|NCT05188430|DEVICE|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
214435136|NCT05188430|OTHER|Placebo|Oral administration: 3 tablets twice a day before the main meals
214435137|NCT02537483|DRUG|IDP-120 Gel|Investigational Product: IDP-120 Gel
214435138|NCT02537483|DRUG|IDP-120 Component A|Comparator Product: IDP-120 Component A
214435139|NCT02537483|DRUG|IDP-120 Component B|Comparator Product: IDP-120 Component B
214435140|NCT02537483|DRUG|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
214435141|NCT00879463|PROCEDURE|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
214435142|NCT00879463|PROCEDURE|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
214435143|NCT05155917|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
215115433|NCT04489810|DIETARY_SUPPLEMENT|Placebo|Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules
215115434|NCT04489810|DIETARY_SUPPLEMENT|Elevase®|1 capsule containing 350 mg of Elevase®
214435144|NCT06473090|OTHER|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
214435145|NCT06473090|OTHER|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
214435146|NCT05010655|DEVICE|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
214435147|NCT01628419|BEHAVIORAL|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
215115435|NCT04489810|DIETARY_SUPPLEMENT|DE111®|1 capsule containing Bacillus subtilis DE111
214435148|NCT03100513|DRUG|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
214435149|NCT03100513|DRUG|Polyethylene Glycol|PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
214435150|NCT00220272|DRUG|SR57667B|
214435151|NCT06514937|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
214435152|NCT02142751|DRUG|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
215115436|NCT04489810|OTHER|Meal A|Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
214435153|NCT02142751|DRUG|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
214435154|NCT02142751|DRUG|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
214435155|NCT04350567|OTHER|Sleep Deprivation|On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
214435156|NCT05528380|BEHAVIORAL|LPA + Fitbit Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
214435157|NCT05528380|BEHAVIORAL|Fitbit Only|Participants will receive a Fitbit to track activity levels and participate in 6 brief check-ins to assess any issues with the Fitbit device or app.
214435158|NCT06970847|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA
214435159|NCT05304377|DRUG|ELVN-001|orally once or twice daily
214435160|NCT06130020|BEHAVIORAL|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
215115437|NCT04489810|OTHER|Meal B|Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
215115438|NCT05230524|DEVICE|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
215115439|NCT04914533|DEVICE|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
215115440|NCT01898429|DEVICE|SCC DBS|Deep Brain Stimulator
215115441|NCT05705427|DRUG|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
214435161|NCT06130020|BEHAVIORAL|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
214435162|NCT06130020|BEHAVIORAL|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
214435163|NCT06645665|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
214435164|NCT06645665|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214435165|NCT04110743|DEVICE|EXPLORER PET/CT|Intervention: PET/CT using different protocols
215115442|NCT05705427|BIOLOGICAL|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
215115443|NCT05705427|DRUG|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
215115444|NCT04829916|DRUG|RMC-035|Multiple dosing during 48 hours following cardiac surgery
215115445|NCT04829916|DRUG|Placebo|Multiple dosing during 48 hours following cardiac surgery
215115446|NCT04343755|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
215115447|NCT05900908|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
215115448|NCT05900908|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
214435166|NCT04764006|DRUG|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
214435167|NCT04474379|BEHAVIORAL|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
214435168|NCT04821219|OTHER|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
214435169|NCT04718688|OTHER|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
214435170|NCT02517450|BEHAVIORAL|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
214435171|NCT02517450|OTHER|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
214435172|NCT02512341|DEVICE|Computer Aided Auscultation (CAA)|
214435173|NCT02665988|DEVICE|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
214435174|NCT02665988|DEVICE|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
214435175|NCT01750866|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
214435176|NCT01750866|DRUG|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
214435177|NCT01750866|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
214435178|NCT05517564|DRUG|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
214515882|NCT04873986|DIAGNOSTIC_TEST|Scoliosis Tele-Screening Test|Scoliosis Tele-Screening test will be applied to children by parents at home. Participants with moderate and high risks will be invited to the physical examination to the centers or virtual assessment via e-mail. The researchers will be evaluated the TRACE and Adams' test from the photo and sent their opinions to the parents via e-mail.
214515883|NCT00068809|PROCEDURE|Short Cycle Antiretroviral Therapy|
214515884|NCT03441464|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
214515885|NCT01928888|DRUG|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
214515886|NCT01928888|DRUG|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
214515887|NCT01928888|DRUG|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
214515888|NCT05230056|BEHAVIORAL|PG|Shoulder Digital therapy
214515889|NCT05230056|BEHAVIORAL|CTRL|Shoulder non-digital therapy
214515890|NCT04464148|DRUG|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
214515891|NCT04464148|DRUG|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
214515892|NCT04830345|BIOLOGICAL|ATGC-100 100U|Clostridium botulinum toxin type A
214515893|NCT04830345|BIOLOGICAL|Botox 100U|Clostridium botulinum toxin type A
215115449|NCT04848272|DRUG|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
214515894|NCT01539902|BIOLOGICAL|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
215115450|NCT04848272|OTHER|Saline control|Saline control
215115451|NCT03506997|DRUG|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
215115452|NCT05722548|DRUG|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
214515895|NCT01539902|DRUG|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
214515896|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
214515897|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
215115453|NCT05722548|OTHER|Standard Medical Treatment|Standard Medical Treatment
215115454|NCT03372967|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
215115455|NCT03372967|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
215115456|NCT03372967|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
214435179|NCT05517564|OTHER|Placebo|Placebo-to-match GM-60106 capsules
214435180|NCT01565148|DRUG|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
214435181|NCT01565148|DRUG|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
214435182|NCT01565148|DRUG|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
214435183|NCT01565148|DRUG|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
214435184|NCT02414412|DIETARY_SUPPLEMENT|Ulmus macrocarpa water extract|
214435185|NCT00422006|PROCEDURE|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
214435186|NCT00422006|PROCEDURE|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
214435187|NCT00422006|BEHAVIORAL|diet|diet
214435188|NCT00422006|OTHER|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
214435189|NCT00180258|DEVICE|Cardiac Resynchronization Therapy with & without defibrillator|
214435190|NCT03832894|DRUG|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
214435191|NCT02748486|BEHAVIORAL|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
214435192|NCT02748486|BEHAVIORAL|Group discussion|Group discussion of current events
214435193|NCT02748486|BEHAVIORAL|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
214435194|NCT03571711|DRUG|Meropenem Injection|Meropenem is administered as prescribed by treating physician
214435195|NCT01763970|RADIATION|SBRT|
215115457|NCT00106327|BEHAVIORAL|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
215115458|NCT00106327|BEHAVIORAL|Diet|11 nutrition education sessions
215115459|NCT01366599|DRUG|HEC or MEC|Any HEC or MEC, including aprepitant
215115460|NCT04267835|PROCEDURE|MIDCAB|Surgery: MIDCAB
215115461|NCT04267835|PROCEDURE|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
215115462|NCT02968342|DEVICE|Vaginal progesterone 8%|vaginal self application
214435196|NCT03920566|OTHER|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
214435197|NCT05464316|DEVICE|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
214435198|NCT05464316|DEVICE|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
214435199|NCT05487118|DEVICE|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
214435200|NCT05487118|DEVICE|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
214435201|NCT03609008|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
214435202|NCT03609008|DRUG|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
214515898|NCT00871494|DRUG|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
214515899|NCT02755909|BEHAVIORAL|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
214515900|NCT02933645|DRUG|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
214515901|NCT02933645|DRUG|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
214515902|NCT02933645|RADIATION|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
214515903|NCT02933645|DRUG|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
214435203|NCT03741517|RADIATION|18F-FDG-PET|Fludeoxyglucose F18
214435204|NCT03741517|RADIATION|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
214435205|NCT03741517|RADIATION|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
214515904|NCT01863082|OTHER|exercise|practice of physical exercise
214515905|NCT03630432|BEHAVIORAL|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
214515906|NCT03630432|OTHER|Usual Care|Usual Care
214515907|NCT02079402|DRUG|Isotonic crystalloids|
214515908|NCT03761849|DRUG|RO7234292|Intrathecal injection
215115463|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
215115464|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
215115465|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
215115466|NCT06323109|DEVICE|MRI-UDS; US-UDS; MCUD|Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
215115467|NCT05484011|BIOLOGICAL|odetiglucan|Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
215115468|NCT05484011|BIOLOGICAL|CDX-1140|A fully human agonist anti-CD40 monoclonal antibody
214515909|NCT03761849|DRUG|Placebo|Intrathecal injection
214515910|NCT01913444|DRUG|Recombinant Antithrombin|
214515911|NCT05466760|RADIATION|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
214515912|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy|
214515913|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
214515914|NCT02412345|OTHER|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
214515915|NCT05322447|DRUG|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
214515916|NCT05322447|DRUG|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
214435206|NCT03741517|OTHER|Core needle biopsy|Core needle biopsy of metastatic lesions
214435207|NCT03741517|OTHER|Phlebotomy|Phlebotomy from peripheral vein
214435208|NCT01506934|DRUG|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
214435209|NCT03217669|DRUG|Epacadostat|Epacadostat tablet: 100mg or 300mg
214435210|NCT03217669|DRUG|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
214515917|NCT02637999|DRUG|PEG IFN alfa-2a|
214515918|NCT02637999|DRUG|Myrcludex B|
214515919|NCT05722756|OTHER|craniosacral therapy|subtle form of applied touch, type of osteopathy
214515920|NCT01430416|DRUG|AEB071|
214515921|NCT03001141|OTHER|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
214515922|NCT02271841|DEVICE|PVI|Pleth Variability Index
214515923|NCT03727334|BEHAVIORAL|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
214515924|NCT06008665|OTHER|Action Observation Therapy and Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
214515925|NCT06008665|OTHER|Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs."
214515926|NCT04645303|DRUG|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
214435211|NCT04095715|OTHER|Haemostasis consultation|Haemostasis consultation
214515927|NCT04645303|DRUG|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
214515928|NCT03933098|BIOLOGICAL|Test Vaccine Vi-DT Typhoid conjugate|"* Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
214515929|NCT03933098|BIOLOGICAL|Control Vaccine Typbar TCV®|"* Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml"
214515930|NCT03344458|DRUG|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
214515931|NCT04585048|BEHAVIORAL|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
215115469|NCT04484870|DRUG|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
214435212|NCT04095715|BIOLOGICAL|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
215115470|NCT03449069|DRUG|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
215115471|NCT02665182|BEHAVIORAL|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
215115472|NCT05532358|DRUG|anle138b (TEV-56286)|Anle138b (TEV-56286) as perpetrator
214435213|NCT01193894|OTHER|Profermin|Medical Food (food for special medical purposes)
214435214|NCT01193894|OTHER|Fresubin|Medical food (food for special medical purposes)
214435215|NCT03373708|DRUG|Epirubicin|100mg/m2
214435216|NCT03373708|DRUG|Cyclophosphamide|600mg/m2
214435217|NCT03373708|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
214435218|NCT03373708|DRUG|Goserelin acetate|3.6mg every month
214435219|NCT03373708|DRUG|Tamoxifen|10mg twice daily oral
214435220|NCT03373708|DRUG|Letrozole|2.5mg every daily oral
214435221|NCT04465734|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
214435222|NCT04465734|DRUG|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
214435223|NCT04465734|DRUG|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
215115473|NCT05532358|DRUG|Fluvoxamine 100 mg QD for 5 days|Anle138b (TEV-56286) as victim
215115474|NCT01504022|OTHER|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
215115475|NCT05072938|DRUG|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
215115476|NCT05072938|DRUG|Axid Capsule 150mg|Nizatidine Monotherapy
215115477|NCT03418636|BEHAVIORAL|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
214435224|NCT02615210|DEVICE|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
214435225|NCT01673555|DRUG|GSK1278863|GSK1278863
214435226|NCT01673555|DRUG|Placebo|Placebo
214435227|NCT05921708|OTHER|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
214435228|NCT05921708|OTHER|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
214435229|NCT05921708|OTHER|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
214435230|NCT05921708|OTHER|Assessment4|Body-Cathexis Scale (BCS)
214435231|NCT05921708|OTHER|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
214435232|NCT00955695|DRUG|erlotinib hydrochloride|
214435233|NCT00955695|DRUG|gefitinib|
214435234|NCT00955695|OTHER|questionnaire administration|
214435235|NCT00955695|PROCEDURE|quality-of-life assessment|
214435236|NCT00955695|RADIATION|whole-brain radiation therapy|
214515932|NCT03840993|DRUG|MT-2990|over 16 weeks
214515933|NCT03840993|DRUG|Placebo|over 16 weeks
214515934|NCT00543049|DRUG|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
214435237|NCT03359889|DRUG|PraxbindTM|Drug
214435238|NCT05593159|OTHER|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
214435239|NCT05593159|OTHER|RM-GIC|RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
214435240|NCT05593159|OTHER|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
214435241|NCT05593159|OTHER|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
214435242|NCT05593159|OTHER|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
214435243|NCT05593159|OTHER|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
214435244|NCT01199575|DRUG|Revlimid|
214435245|NCT01199575|DRUG|Rituximab|
214435246|NCT05345951|BEHAVIORAL|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
214435247|NCT05345951|BEHAVIORAL|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
214515935|NCT00543049|DRUG|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
214515936|NCT02975609|RADIATION|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
214515937|NCT02975609|RADIATION|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
214515938|NCT03799965|OTHER|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
214515939|NCT03799965|OTHER|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
214515940|NCT00002723|DRUG|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
214515941|NCT00002723|DRUG|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
214435248|NCT03435770|DEVICE|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
214435249|NCT05176106|BEHAVIORAL|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
214435250|NCT04985136|DRUG|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
214435251|NCT04985136|DRUG|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
214435252|NCT04985136|DRUG|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
214435253|NCT04985136|DRUG|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
214435254|NCT01361945|DRUG|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
214435255|NCT04380467|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
214435256|NCT03014947|DRUG|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
214435257|NCT03014947|DRUG|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
214435258|NCT03014947|DRUG|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
214435259|NCT06335446|OTHER|Novel mapping algorithm|Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
214435260|NCT01457612|DIETARY_SUPPLEMENT|Strawberry|20g twice per day (BID) in beverage
214435261|NCT01457612|DIETARY_SUPPLEMENT|Placebo1|Placebo Beverage 1 without fiber
214515942|NCT00002723|DRUG|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
214515943|NCT00728325|BEHAVIORAL|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
214515944|NCT00728325|BEHAVIORAL|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
214515945|NCT00489697|DEVICE|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
214515946|NCT00004250|BIOLOGICAL|dactinomycin|
214515947|NCT00004250|DRUG|isolated limb perfusion|
214515948|NCT00004250|DRUG|melphalan|
214515949|NCT00988429|DRUG|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
214515950|NCT00988429|DRUG|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
214515951|NCT00988429|DRUG|Placebo|Placebo tablet given QD
214515952|NCT01074229|DRUG|Placebo|placebo injection
214515953|NCT01074229|DRUG|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
214435262|NCT01457612|DIETARY_SUPPLEMENT|Placebo2|Placebo Beverage 2 with Fiber
214515954|NCT01074229|DRUG|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
214515955|NCT02463292|OTHER|no intervention|no intervention
214435263|NCT00212134|DEVICE|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
214435264|NCT00212134|DEVICE|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
214435265|NCT04951362|DRUG|intranasal spray ivermectin|intranasal spray of saline
214435266|NCT04912791|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
214435267|NCT05684354|OTHER|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
214435268|NCT02409667|BIOLOGICAL|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
214435269|NCT01925339|DEVICE|Test (immediate restoration)|Test (immediate restoration)
214435270|NCT01925339|DEVICE|Control: delayed restoration|Control: delayed restoration
214435271|NCT03399669|DRUG|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
214515956|NCT04909099|OTHER|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
214515957|NCT01502241|DRUG|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
214515958|NCT01502241|RADIATION|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
214515959|NCT02994329|DEVICE|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
214515960|NCT03335722|BEHAVIORAL|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
214515961|NCT03335722|DEVICE|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
215115478|NCT03418636|BEHAVIORAL|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
215115479|NCT04707495|DEVICE|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
215115480|NCT04707495|DEVICE|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
215115481|NCT00016679|DRUG|1-Octanol|
215115482|NCT04859426|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
215115483|NCT00203164|DRUG|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
215115484|NCT00193206|DRUG|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
214435272|NCT00967434|DRUG|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
214435273|NCT00967434|DRUG|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
214435274|NCT00967434|DRUG|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
214435275|NCT02280148|PROCEDURE|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
214435276|NCT02280148|DEVICE|Driving Simulator|
214435277|NCT02280148|DRUG|Propofol|2mg / kg
214435278|NCT02378896|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
214515962|NCT03335722|DEVICE|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
214515963|NCT03009123|OTHER|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
214515964|NCT04392648|DRUG|TAK-573|TAK-573 intravenous infusion.
214515965|NCT04392648|DRUG|Pomalidomide|Pomalidomide capsules orally.
215115485|NCT00193206|DRUG|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
214435279|NCT02378896|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
214435280|NCT04545918|DEVICE|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
215115486|NCT00193206|DRUG|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
215115487|NCT03981679|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
215115488|NCT05143034|DIETARY_SUPPLEMENT|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
214435281|NCT04045938|OTHER|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
214435282|NCT06103916|OTHER|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
214435283|NCT01896349|OTHER|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
214435284|NCT01896349|DRUG|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
214435285|NCT01896349|DRUG|sertraline|
215115489|NCT05143034|DIETARY_SUPPLEMENT|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
215115490|NCT02766868|DRUG|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
215115491|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
215115492|NCT05877144|OTHER|Medical Device Usage and Evaluation|Receive LiSWT
215115493|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
215115494|NCT05877144|OTHER|Survey Administration|Ancillary studies
215115495|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
215115496|NCT05877144|PROCEDURE|Sham Intervention|Receive sham LiSWT
215115497|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
215115498|NCT05877144|OTHER|Survey Administration|Ancillary studies
214435286|NCT01896349|DRUG|paroxetine|
214435287|NCT01896349|DRUG|Citalopram|
214435288|NCT01896349|DRUG|escitalopram|
214435289|NCT01896349|DRUG|fluvoxamine|
214435290|NCT01896349|DRUG|Venlafaxine|
214435291|NCT01896349|DRUG|Duloxetine|
214435292|NCT01896349|DRUG|Bupropion|
214435293|NCT01896349|DRUG|Lithium|
214435294|NCT01896349|DRUG|Risperidone|
214435295|NCT01896349|DRUG|tranylcypromine|
214435296|NCT01896349|DRUG|Imipramine|
214435297|NCT01896349|DRUG|amitriptyline|
214435298|NCT01896349|DRUG|Clomipramine|
214435299|NCT01896349|DRUG|nortriptyline|
214435300|NCT01896349|DRUG|trazodone|
214435301|NCT01896349|DRUG|Mirtazapine|
214435302|NCT01896349|DRUG|sulpiride|
214435303|NCT04580316|BEHAVIORAL|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
214435304|NCT04580316|BEHAVIORAL|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
214435305|NCT03960463|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
214435306|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
214435307|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
214435308|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
214435309|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
214435310|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
214435311|NCT04577911|OTHER|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
214435312|NCT06557161|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214435313|NCT06557161|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214435314|NCT06557161|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
214435315|NCT06833905|BEHAVIORAL|Virtual reality: Beach|Session 1 or 2 (counterbalanced): Exposure to a beach landscape
214435316|NCT06833905|BEHAVIORAL|Virtual Reality: Forest|Session 1 or 2 (counterbalanced): Exposure to a forest landscape
214435317|NCT06833905|BEHAVIORAL|Hypnosis: Magic Hand|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: the magic hand
214435318|NCT06833905|BEHAVIORAL|Hypnosis: Pain Manipulation|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: manipulating the pain
214435319|NCT06833905|BEHAVIORAL|Session 1bis - 1 week|Repetition of the Session 1 one week after Session 4
214435320|NCT06833905|BEHAVIORAL|Follow-up|Repetition of the Session 1 three weeks after Session 4
214435321|NCT03133182|DRUG|Polypharmacy|Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery
214435322|NCT04703686|DRUG|Obinutuzumab|1000mg - prephase - one infusion at D-3
214515966|NCT04392648|DRUG|Bortezomib|Bortezomib injection subcutaneously.
215115499|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
215115500|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
215115501|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
215115502|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
215115503|NCT02876107|DRUG|Carboplatin|Given IV
214435323|NCT04703686|DRUG|RO7082859|2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
214435324|NCT06829433|OTHER|No intervention|Observational cross-sectional study
214435325|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
214435326|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test (without giving result)|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
214435327|NCT05972473|DRUG|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
214435328|NCT05972473|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
214435329|NCT05782972|DRUG|dapagliflozin (Forxiga)|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
214435330|NCT05532241|DEVICE|fixed metal orthodontic appliance|fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))
214435331|NCT05532241|DEVICE|fixed non-metal orthodontic appliance|fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))
214435332|NCT05532241|PROCEDURE|oral hygiene|conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)
214435333|NCT05532241|DRUG|Chlorhexidine mouthwash|conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
214435334|NCT03742245|DRUG|Olaparib|PARP inhibitor
214435335|NCT03742245|DRUG|Vorinostat|HDAC inhibitor
214435336|NCT06700590|BEHAVIORAL|Intensive Treatment|"Participants engage in two preparatory sessions once weekly, lasting 50 minutes each, which focus on psychoeducation and case conceptualization. The core treatment consists of five days of twice-daily sessions delivered over one or two weeks. The first session of the day consists of prolonged exposure (PE). The second session consists of eye movement desensitization and reprocessing (EMDR). Both treatments are performed in strict adherence to their respective manualized protocol. Two closing sessions focus on lessons learned, integration and a prevention plan. The treatment in total lasts 6 weeks and contains 800 minutes of treatment.~To enhance practicality, treatment rotation is allowed and encouraged. Rigorous checks on treatment adhenrence will be implemented."
214515967|NCT04392648|DRUG|Cyclophosphamide|Cyclophosphamide tablets orally.
214515968|NCT04392648|DRUG|Dexamethasone|Dexamethasone tablets orally.
214515969|NCT01107509|DRUG|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
215115504|NCT02876107|OTHER|Laboratory Biomarker Analysis|Correlative studies
215115505|NCT02876107|DRUG|Paclitaxel|Given IV
214515970|NCT01448993|DRUG|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
214515971|NCT01448993|DRUG|Placebo|
215115506|NCT02876107|BIOLOGICAL|Panitumumab|Given IV
215115507|NCT06415344|DRUG|GTX-102|Antisense Oligonucleotide
215115508|NCT02940496|DRUG|Elbasvir/Grazoprevir|Given PO
215115509|NCT02940496|OTHER|Laboratory Biomarker Analysis|Correlative studies
215115510|NCT02940496|BIOLOGICAL|Pembrolizumab|Given IV
215115511|NCT02940496|DRUG|Ribavirin|Given PO
214435337|NCT06700590|BEHAVIORAL|Treatment as usual|Spaced/weekly treatment consists of a treatment-as-usual condition, increasing the representativeness of the control condition. Treatment duration is 800 minutes, either 13 weeks of 60 minutes (with the last sessions being 80 minutes), or 16 weeks of 50 minutes. All evidence-based treatment modalities of the Dutch guidelines are allowed: PE, EMDR, brief eclectic psychotherapy for PTSD (BEPP), narrative exposure therapy (NET), and imaginary rescripting (ImRs). All have common elements of psychoeducation, imaginal exposure, emotional processing, cognitive restructuring and/or meaning making. Treatment adherence will be monitored throughout the intervention. Therapist rotation is not performed
214435338|NCT04266041|DIAGNOSTIC_TEST|High-density electroencephalogram (HD-EEG)|This study will focus on obtaining a special type of high-density scalp electroencephalography (HD-EEG) recordings in patients with neurological disorders (i.e., epilepsy, brain tumor, stroke, etc.) and appropriately matched controls. HD-EEG is a scalp EEG which uses up to 256 channels compared to the standard 21 channels used for routine clinical applications. The reason for using more channels to record is for more precise localization of epileptogenic foci and/or more precise mapping of brain functions. This type of EEG requires the use of patient's own MRI scan to precisely localize activity. Therefore, all patients and controls getting an HD-EEG will require a structural MRI scan.
214435339|NCT06549946|BIOLOGICAL|Ixovex-1|Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
214435340|NCT06549946|BIOLOGICAL|Pembrolizumab|Humanised antibody
214435341|NCT06265961|OTHER|Education|"In line with the Papadopoulos Tilki Taylor cultural competence development model used in the research, a training presentation titled overview and basic concepts of intercultural nursing will be held at the beginning of the intervention in order to increase the cultural knowledge levels of nurses. In order to test the effectiveness of the bibliotherapy method, training will be given online via Google Meet to both groups (both study and control) at the beginning of the research."
214435342|NCT06265961|OTHER|Bibliotherapy|"The intervention consists of 1 online intercultural nursing training, 2 book and 2 short story reading activities and 1 film evaluation to be carried out over a 3-month period.~After the training, the nurses in the study group will be asked to read the introductions of the books on the reading list and choose 2 books that they feel close to and that they have not read before. Participants will complete readings and assignments (evaluation form, reflective thought essay) asynchronously in time periods convenient to them.~In addition to books, a supporting film will be used to raise awareness. At the end of the movie, they will be asked to write on their notes how they can relate to intercultural nursing, how they can behave when faced with similar situations, and what differences there are between their ideas about intercultural nursing before and after the movie."
214435343|NCT04498052|OTHER|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~In period 1:~* An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~* Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~In period 2:~\- Same as period 1 + simple patient reminders in the patient portal.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
214435344|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
214515972|NCT00591084|DRUG|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
214515973|NCT00591084|DRUG|placebo|infusion placebo (group B)once a day and continued for 14 days
214515974|NCT00591084|DRUG|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
215115512|NCT05132218|DRUG|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
215115513|NCT04477577|BEHAVIORAL|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
215115514|NCT04477577|BEHAVIORAL|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
215115515|NCT00820469|DRUG|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
215115516|NCT00820469|DRUG|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
215115517|NCT02489292|BIOLOGICAL|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
215115518|NCT03318016|DRUG|Cyclophosphamide 500 MG|ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
215115519|NCT03318016|DRUG|Cyclophosphamide 1000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
215115520|NCT03318016|DRUG|Cyclophosphamide 2000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
215115521|NCT03318016|DRUG|Cyclophosphamide 3000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
215115522|NCT03318016|DRUG|Cyclophosphamide 4000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
215115523|NCT04355546|OTHER|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
215115524|NCT05842148|OTHER|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
215115525|NCT05842148|OTHER|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
214435345|NCT05488496|BEHAVIORAL|Nature-based social intervention (NBSI), referred as Friends in Nature (FiN)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
214435346|NCT05488496|BEHAVIORAL|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
214435347|NCT06262529|OTHER|Cerebral MRI|Cerebral MRI at 72h / 3 months / 12 months
214435348|NCT06389474|BIOLOGICAL|INM004|Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
214435349|NCT06389474|OTHER|Placebo|Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
214435350|NCT02567201|OTHER|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
214435351|NCT02567201|OTHER|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
214435352|NCT04306380|OTHER|no intervention, database study|data collection from EMR for database
214435353|NCT06345976|OTHER|questionnaire|On-line self-questionnaire, in the form of an 18-question form, the link to which is sent by e-mail to patients with albinism who have agreed to take part in the study.
214435354|NCT04497168|DRUG|Citalopram 20mg|20mg daily
214435355|NCT04497168|DRUG|Placebo|matching placebo pills
214435356|NCT04933903|DRUG|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
214435357|NCT04933903|DRUG|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
214435358|NCT04933903|RADIATION|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
214435359|NCT03970057|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
214435360|NCT03970057|OTHER|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
214435361|NCT04543773|DEVICE|rTMS|rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
214435362|NCT05430373|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
214435363|NCT04499690|BEHAVIORAL|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
214435364|NCT02124668|DRUG|Enzalutamide|oral
215115526|NCT05842148|OTHER|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
214435365|NCT04999085|OTHER|Supportive care interventions|Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
214435366|NCT06142890|OTHER|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
214435367|NCT06142890|OTHER|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
214435368|NCT03535922|OTHER|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
214435369|NCT06761638|COMBINATION_PRODUCT|Rhythmic Auditory Stimulation Therapy|Rhythmic auditory stimulation (RAS) is a therapeutic technique that uses rhythmic auditory cues, like a metronome or music, to improve motor control and coordination. It is often used in rehabilitation for conditions such as stroke, Parkinson's disease, and other movement disorders to enhance gait and other motor functions through the synchronization of movements to auditory rhythms.
214435370|NCT06761638|COMBINATION_PRODUCT|Task-Specific Training|Task-specific training is a rehabilitation approach that involves practicing specific tasks or activities to improve the performance of those tasks. It is based on the principle that repetitive practice of functional tasks enhances neuroplasticity, leading to better motor skills and functional recovery, especially in stroke and neurological rehabilitation.
214435371|NCT05896683|DRUG|Lazertinib|Lazertinib will be administered orally.
214435372|NCT06815250|BEHAVIORAL|Influenza and Tdap Vaccination Educational and Learning Module|Influenza and Tdap learning and educational module delivered via website. The module will cover importance of vaccination for both pregnant women and infant, safety and efficacy of the influenza and TdaP vaccines, timing of vaccination, and addressing common concerns and misconceptions.
214435373|NCT02746081|DRUG|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
214435374|NCT06835491|DRUG|Amiodarone|Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.
214435375|NCT04077073|DEVICE|ReIn-Hand|ReIn-Hand assists the hand opening
214435376|NCT04077073|DEVICE|Robot|Robot supports the shoulder load
214515975|NCT06328296|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214435377|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
214435378|NCT06784323|BEHAVIORAL|Catered diet|For a period of 8 weeks the participant will receive catered food, the study team will provide the participants breakfast, lunch and dinner. Participants will receive catered food for 3 daily meals, and record daily food intake. Catered diet will be sent to participants' homes on a weekly basis. The diet will consist of primarily whole foods with few additives, with a focus on Hispanic cultural foods.
214435379|NCT06784323|BEHAVIORAL|Diet guidance sessions|Participants will receive virtual weekly diet guidance with a dietitian regarding food safety preparation methods and cooking practices. Patients will receive weekly gift cards for grocery stipend. On average, initial counseling session with dietitian will last 30 minutes, and 7 follow-up sessions will last 20 minutes.
214435380|NCT06784323|BEHAVIORAL|Dietary counseling|Participants will receive dietary counseling weekly on Zoom for up to 30 minutes. Dietitian will meet with participants to explain benefits of adhering to diet therapy.
214435381|NCT06784323|BEHAVIORAL|Feedback sessions|Participants will be involved in one-time 50-minute feedback session over Zoom with dietitian and principal investigator. During the session, participants will discuss preferred foods/recipes during active disease, likeability of recipes, ease of recipe preparation, dietary adherence, and healthy food affordability.
215115527|NCT05175586|DIAGNOSTIC_TEST|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
215115528|NCT05175586|PROCEDURE|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
214435382|NCT06549634|DRUG|Daratumumab|Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration
214435383|NCT02581215|DRUG|mFOLFIRINOX|"mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
214435384|NCT02581215|DRUG|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
214435385|NCT02581215|OTHER|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
214435386|NCT03860272|DRUG|Botensilimab|An Fc-engineered anti-CTLA-4 monoclonal antibody
214435387|NCT03860272|DRUG|Balstilimab|A fully human monoclonal anti-PD-1 antibody
214435388|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
214435389|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
214435390|NCT03613740|DRUG|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
214435391|NCT03613740|DRUG|Placebo|Intervention will be administered 30 minutes before breakfast.
214435392|NCT04188379|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
214435393|NCT04188379|OTHER|Placebo|Intravenous infusion of placebo
214435394|NCT06780735|PROCEDURE|The margin-positive rate using the localization technique|Localization of breast cancer using indocyanine green fluorescence (ICG-F)
214435395|NCT06234943|OTHER|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
214435396|NCT06789614|DRUG|intravenous CYCLIZINE ,Metaclopromide|US giuded measure of GRV in bariatrics surgery upon recieving drugs of study
214435397|NCT05704283|DEVICE|Ultrasound Imaging|Undergo 3D-US
214435398|NCT05836116|OTHER|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
214435399|NCT05793593|OTHER|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
214435400|NCT05793593|OTHER|Colorectal Cancer (CRC) education alone|CRC education alone.
214435401|NCT05780528|OTHER|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
214435402|NCT05780528|OTHER|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
214435403|NCT05780528|OTHER|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
215115529|NCT05175586|OTHER|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
215115530|NCT01499966|PROCEDURE|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
215115531|NCT06427473|BEHAVIORAL|Dietary program|Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.
214435404|NCT06958159|PROCEDURE|Endoscopic Stricturotomy|"Endoscopic stricturotomy is performed using either a needle knife or an insulated-tip (IT) knife (Olympus, Tokyo, Japan), selected based on the location and morphology of the stricture. Electrosurgical cutting is delivered using the Endo Cut I mode on an ERBE VIO 300D or VIO 3 electrosurgical unit (Erbe Elektromedizin, Germany), with standardized settings: Effect 3, Cut Duration 1, Cut Interval 3.~Radial incisions are initially made across the stricture, followed by circumferential cutting in non-ulcerated areas to relieve luminal narrowing. The goal is to achieve adequate stricture opening while minimizing the risk of perforation."
214435405|NCT06958159|PROCEDURE|Endoscopic Balloon Dilation|"Endoscopic balloon dilation is performed using a Controlled Radial Expansion (CRE) balloon (Boston Scientific, USA). The size of the balloon is selected based on the estimated diameter of the stricture, presence or absence of ulceration, and the anatomical location.~The balloon is gradually inflated under endoscopic visualization to a maximum diameter of 12-20 mm, tailored to the baseline luminal narrowing. The balloon is maintained at full inflation for 60 seconds to achieve controlled and uniform dilation of the stricture."
214435406|NCT03295747|DRUG|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
214435407|NCT06958198|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
214435408|NCT06958198|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
214435409|NCT06958198|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
214435410|NCT06958198|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
214515976|NCT06328296|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
214515977|NCT02862288|DEVICE|Microwave ablation with Acculis Accu2i pMTA Applicator|
214515978|NCT04984980|DRUG|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
214515979|NCT02662023|DRUG|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
214515980|NCT02662023|DRUG|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
215115532|NCT06427473|BEHAVIORAL|Exercise program|Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.
215115533|NCT06427473|BEHAVIORAL|Mindfulness program|Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
214435411|NCT05406258|DEVICE|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
214435412|NCT05406258|DEVICE|Standard Self-Catheterization Mirror|Following training, participants will have a standard, hospital-provided mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
214435413|NCT02229812|DRUG|alteplase|
214435414|NCT02566902|DEVICE|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
214435415|NCT02566902|DEVICE|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
214435416|NCT02566902|DRUG|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
214435417|NCT02566902|PROCEDURE|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
214435418|NCT02566902|PROCEDURE|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
214515981|NCT05444777|DRUG|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
214515982|NCT01678755|DRUG|ABT-126|ABT-126 Low Dose
214515983|NCT01678755|DRUG|ABT-126|ABT-126 High Dose
214515984|NCT01678755|DRUG|Placebo|Placebo
215115534|NCT01147055|DRUG|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
215115535|NCT01147055|DRUG|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
214435419|NCT04138316|DRUG|Candesartan|Treatment with Candesartan
214435420|NCT00321867|PROCEDURE|Graft augmented posterior repair|Posterior repair with graft
214435421|NCT00321867|PROCEDURE|Control|Native tissue repair
214435422|NCT06360458|DRUG|Methylprednisolone sodium succinate|Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
215115536|NCT01147055|DRUG|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
215115537|NCT01443702|DRUG|Lapis Judaicus|2 g capsule per day.
215115538|NCT01443702|DRUG|Placebo|2 g capsule per day.
215115539|NCT02672462|DEVICE|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
215115540|NCT00132808|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous
215115541|NCT00132808|DRUG|Placebo|Physiologic 0.9% normal saline
215115542|NCT02848807|DIETARY_SUPPLEMENT|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
214435423|NCT06360458|DRUG|Placebo (normal saline)|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
214435424|NCT06122298|OTHER|fMRI|A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.
214435425|NCT06122298|OTHER|Ecological Momentary Assessment|studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour
214435426|NCT03825575|DEVICE|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
214435427|NCT01238042|DRUG|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
214435428|NCT00199407|DRUG|Istradefylline (KW-6002)|
214435429|NCT05990452|DRUG|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
214435430|NCT00459212|DRUG|GTI-2040|Given IV
214435431|NCT00459212|PROCEDURE|pharmacological study|Correlative study
214435432|NCT00459212|PROCEDURE|laboratory biomarker analysis|Correlative study
214515985|NCT02435498|OTHER|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
214515986|NCT02435498|OTHER|Video|The online video will contain the same information within the website.
214515987|NCT02435498|OTHER|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
214515988|NCT01567176|BIOLOGICAL|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
215115543|NCT02411019|BIOLOGICAL|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
215115544|NCT05237323|DRUG|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
215115545|NCT05237323|DRUG|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
215115546|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
215115547|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
214435433|NCT01108003|DRUG|broccoli sprout extract|Given orally
214435434|NCT01108003|OTHER|laboratory biomarker analysis|Correlative studies
214435435|NCT01108003|OTHER|Mango Juice|given orally
214435436|NCT02652585|DRUG|Naltrexone|
214435437|NCT02652585|DRUG|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
214435438|NCT04209712|BIOLOGICAL|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
214435439|NCT00803387|DRUG|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
214435440|NCT03941665|DEVICE|Gelronate|Gel for topical use
214435441|NCT03941665|OTHER|Aloevera|Gel for topical use
214435442|NCT05412017|DIAGNOSTIC_TEST|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
214435443|NCT03676413|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
214435444|NCT03676413|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
214435445|NCT03676413|DRUG|Placebo|twice daily inhalation throughout the study
214435446|NCT05688423|BEHAVIORAL|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
214515989|NCT03336749|BEHAVIORAL|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
214515990|NCT03336749|OTHER|Control group|Traditional task-specific training
214515991|NCT06480396|DIAGNOSTIC_TEST|High-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
215115548|NCT05929287|PROCEDURE|Tablet-based CT|This group will perform digital CT tasks.
214515992|NCT06480396|DIAGNOSTIC_TEST|Lower-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
214515993|NCT06365177|OTHER|Physical consultation|"The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation."
214515994|NCT06365177|OTHER|Teleconsultation|"Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it."
214515995|NCT01162564|DEVICE|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
214515996|NCT02444884|DRUG|MLN8237|
214515997|NCT06644391|DIAGNOSTIC_TEST|Carebot AI Bones|The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
215115549|NCT05929287|PROCEDURE|Paper-and-pencil CT group|This group will perform paper-and-pencil CT tasks.
215115550|NCT04891133|DRUG|Baricitinib|4 mg baricitinib (2 tablets of 2 mg) once daily
215115551|NCT04891133|DRUG|Placebo|4 mg placebo (2 tablets of 2 mg) once daily
214435447|NCT05688423|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
214435448|NCT03951142|DRUG|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
214435449|NCT01778907|OTHER|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
214435450|NCT05185245|PROCEDURE|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
214515998|NCT04036773|DIETARY_SUPPLEMENT|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
214515999|NCT02105727|BEHAVIORAL|Community-based salt reduction|
215115552|NCT03785379|BEHAVIORAL|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
214435451|NCT03435367|DEVICE|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
214435452|NCT03435367|DEVICE|iPad Tablet|iPad with headphones
214435453|NCT04846959|DRUG|Risankizumab|Subcutaneous Injection
214435454|NCT04846959|DRUG|Comparator|Subcutaneous or Intravenous Injection
214435455|NCT03112174|DRUG|Ibrutinib|Administered orally once daily
214435456|NCT03112174|DRUG|Venetoclax|Administered orally once daily
215115553|NCT03785379|BEHAVIORAL|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
215115554|NCT06108128|OTHER|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
215115555|NCT05710042|DEVICE|Revivent TC System|The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.
215115556|NCT00604630|DRUG|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
215115557|NCT00604630|DRUG|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
214516000|NCT00825734|DRUG|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
214516001|NCT00825734|DRUG|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
214516002|NCT01731444|DRUG|Phenylephrine|
214516003|NCT00003412|BIOLOGICAL|recombinant interleukin-12|
214516004|NCT01829646|OTHER|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
214516005|NCT01829646|OTHER|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
214435457|NCT03112174|DRUG|Placebo Oral tablet to match Venetoclax|Administered orally once daily
214435458|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
214435459|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
214435460|NCT04501744|DRUG|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
214435461|NCT04501744|DRUG|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
214435462|NCT04501744|DRUG|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
214435463|NCT04501744|DRUG|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
214435464|NCT04501744|DRUG|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
214435465|NCT04501744|DRUG|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
214435466|NCT04501744|DRUG|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
214435467|NCT03340857|OTHER|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
214435468|NCT00476346|DIETARY_SUPPLEMENT|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
214435469|NCT02036424|DRUG|Ozurdex|intravitreal steroid
214435470|NCT02036424|DRUG|Bevacizumab|antiVEGF
214435471|NCT01905462|OTHER|Data Collection|Analyses of data collected within the CPRD GOLD database.
214435472|NCT01905462|BIOLOGICAL|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
214435473|NCT02748317|DRUG|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
214435474|NCT01131780|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
214435475|NCT00687167|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
214435476|NCT00687167|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
214435477|NCT05381233|OTHER|Gross motor function classification System (GMFCS)|assessment
214516006|NCT01829646|OTHER|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
214435478|NCT05381233|OTHER|Arabic Version of Zarit burden Inventory measure|assessment
214435479|NCT05381233|OTHER|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
214435480|NCT02343913|DEVICE|PAC checklist|
214435481|NCT04847414|DIAGNOSTIC_TEST|HbA1C, other investigations|we will do some necessary investigations for prospective group
214516007|NCT02823574|BIOLOGICAL|Nivolumab|
214516008|NCT02823574|BIOLOGICAL|Ipilimumab|
214516009|NCT02823574|OTHER|Placebo|
214516010|NCT06275594|DRUG|Byfavo|For induction and maintenance of sedation
214516011|NCT06275594|DRUG|Midazolam|For induction and maintenance of sedation
214516012|NCT00590759|DEVICE|GORE TAG® Thoracic Endoprosthesis|implant
214516013|NCT02802111|DRUG|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
214516014|NCT02802111|DRUG|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
214516015|NCT03516071|DRUG|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
214435482|NCT04421924|PROCEDURE|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
214435483|NCT04421924|PROCEDURE|standard of care|2\) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
214435484|NCT04050644|DRUG|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
214435485|NCT04050644|DRUG|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
214435486|NCT01634893|DRUG|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
214435487|NCT06267690|PROCEDURE|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
214435488|NCT00989183|OTHER|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
214435489|NCT01335828|DEVICE|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
214435490|NCT00332241|DRUG|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
214435491|NCT00332241|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
214435492|NCT05356689|OTHER|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
214435493|NCT00924807|DRUG|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
214435494|NCT03647969|DRUG|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
214435495|NCT03647969|DRUG|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
214435496|NCT03647969|DRUG|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
214435497|NCT03647969|DRUG|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
214516016|NCT03516071|DRUG|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
214516017|NCT03233542|BEHAVIORAL|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
214435498|NCT04601974|GENETIC|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
214516018|NCT04422405|PROCEDURE|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
214516019|NCT04884191|DRUG|Pacritinib|Pacritinib
214516020|NCT05670457|DRUG|Diosmin|diosmin 500 mg twice daily
214435499|NCT02378597|BEHAVIORAL|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
214435500|NCT00802464|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
214435501|NCT00802464|BIOLOGICAL|Placebo|2 vaccinations at Months 0 and 2 with placebo
214435502|NCT00468806|DRUG|GSK598809, using [11C]-(+)-PHNO|
214435503|NCT03669913|OTHER|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
214435504|NCT00002270|DRUG|Interferon alfa-2b|
214435505|NCT00002270|DRUG|Zidovudine|
214516021|NCT00003152|BIOLOGICAL|filgrastim|
214516022|NCT00003152|BIOLOGICAL|recombinant interferon alfa|
214516023|NCT00003152|DRUG|cyclophosphamide|
214516024|NCT00003152|DRUG|prednisone|
214516025|NCT00003152|DRUG|vincristine sulfate|
215115558|NCT00135889|DRUG|Femoral perineural infusion|
214516026|NCT00003152|PROCEDURE|autologous bone marrow transplantation|
214516027|NCT00003152|PROCEDURE|bone marrow ablation with stem cell support|
214516028|NCT00003152|PROCEDURE|peripheral blood stem cell transplantation|
214516029|NCT00003152|RADIATION|radiation therapy|
214516030|NCT04834804|OTHER|Physical activity|12 weeks of exercise training
214516031|NCT00022490|DRUG|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
214516032|NCT00022490|DRUG|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
214516033|NCT04252638|BEHAVIORAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
214435506|NCT00402246|OTHER|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
214435507|NCT00402246|OTHER|In-Office Care|Routine in-office care
214435508|NCT05669170|BEHAVIORAL|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
214435509|NCT05669170|DRUG|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
214435510|NCT00825630|DRUG|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
214435511|NCT00825630|DRUG|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
214435512|NCT00825630|DRUG|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
214435513|NCT00825630|DRUG|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
214435514|NCT00739531|DEVICE|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
214516034|NCT04252638|BEHAVIORAL|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
214516035|NCT06332118|OTHER|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
214516036|NCT06231680|DRUG|Camrelizumab|Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
214516037|NCT06231680|DRUG|Thalidomide 50mg|Thalidomide 50mg，po qd；
214516038|NCT06231680|DRUG|Thalidomide 100mg|Thalidomide 100mg，po qd；
214516039|NCT06231680|DRUG|Thalidomide 200mg|Thalidomide 200mg，po qd；
214516040|NCT06231680|DRUG|Chemotherapy|"Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles."
214435515|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fasted|
214435516|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fed|
214435517|NCT02133820|DRUG|12 hourly capsule strong painkiller with antagonist fasted)|
214435518|NCT02133820|DRUG|4 mg 12 hourly capsule strong painkiller with antagonist fed|
214435519|NCT04140331|DEVICE|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
214516041|NCT03645161|DIAGNOSTIC_TEST|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
214435520|NCT05872724|DRUG|Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|"* Radiation therapy:~  1\. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy."
214435521|NCT05872724|DRUG|Chemoradiotherapy (small pelvic) + Zimberelimab|"Radiation therapy:~1\. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy."
214516042|NCT03845517|DRUG|Placebo|Placebo
214516043|NCT03845517|DRUG|PF-06700841 15 mg|PF-06700841 15 mg
214516044|NCT03845517|DRUG|PF-06700841 30 mg|PF-06700841 30 mg
214516045|NCT03845517|DRUG|PF-06700841 45 mg|PF-06700841 45 mg
214516046|NCT01494467|DRUG|CD5024|CD5024 1% Cream, once daily
214516047|NCT01494467|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
214516048|NCT04957277|OTHER|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
214516049|NCT00872859|PROCEDURE|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
214516050|NCT00033241|DRUG|erlotinib hydrochloride|
214516051|NCT00033241|DRUG|gemcitabine hydrochloride|
214516052|NCT01906905|DEVICE|Transcranial Magnetic Stimulation|
214516053|NCT06022198|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar Lavage
214516054|NCT03006718|OTHER|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
214516055|NCT03271359|BEHAVIORAL|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
214516056|NCT03271359|BEHAVIORAL|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
214516057|NCT05192902|DEVICE|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
214516058|NCT05192902|DEVICE|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
214516059|NCT03391700|DRUG|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
214516060|NCT03391700|DRUG|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
214516061|NCT00015132|DRUG|Sertraline|
214516062|NCT02841020|PROCEDURE|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
214516063|NCT00417885|DRUG|exemestane|25 mg, oral, daily dosing
214516064|NCT00417885|DRUG|sunitinib malate|37.5 mg, oral, continuous dosing, daily
214516065|NCT05873296|BEHAVIORAL|Health Education|The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
214516066|NCT06356142|DEVICE|Palmar Cooling|Palmar cooling device will be utilized for 2 minutes during rest breaks.
214516067|NCT06356142|DEVICE|Placebo Palmar Cooling|Placebo Palmar cooling device will be utilized for 2 minutes during rest breaks
214516068|NCT03169855|DIAGNOSTIC_TEST|Slit lamp (LOCS III Score)|Diagnostic procedure only
214516069|NCT04699578|DIAGNOSTIC_TEST|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
214516070|NCT06505785|OTHER|The creative drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
214516071|NCT02349815|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
214516072|NCT06387940|OTHER|nEB Diet, followed for 36 hours|nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
214435522|NCT02851667|BEHAVIORAL|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
214516073|NCT06387940|OTHER|LC25 Diet, followed for 36 hours|LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet
214435523|NCT05114967|OTHER|mPAS questionnaire|The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
214435524|NCT05262738|DRUG|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
214435525|NCT05262738|DRUG|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
214435526|NCT01804387|DRUG|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
214435527|NCT01804387|DRUG|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
214516074|NCT06387940|OTHER|LCEB Diet, followed for 36 hours|LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
214516075|NCT02861716|DRUG|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
214516076|NCT02861716|DRUG|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
215115559|NCT02954393|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
215115560|NCT02954393|DRUG|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
215115561|NCT02954393|DRUG|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
214435528|NCT04372316|DRUG|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
214435529|NCT03504423|DRUG|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
214435530|NCT03504423|DRUG|Folfirinox|Folfirinox
214435531|NCT02538653|OTHER|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
214435532|NCT02538653|OTHER|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
215115562|NCT02954393|DRUG|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
215115563|NCT02954393|DRUG|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
215115564|NCT02954393|DRUG|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
215115565|NCT02954393|DRUG|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
215115566|NCT04806074|BEHAVIORAL|Experimental Group|Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
215115567|NCT04806074|BEHAVIORAL|Comparison Group|Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
215115568|NCT05276817|DEVICE|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
214435533|NCT02837211|BEHAVIORAL|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
214435534|NCT02837211|BEHAVIORAL|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
214435535|NCT03122158|DRUG|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
214435536|NCT03177044|BEHAVIORAL|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
214435537|NCT04334746|OTHER|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
214435538|NCT03079700|BIOLOGICAL|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
214435539|NCT01183936|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
214435540|NCT01183936|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
214516077|NCT02861716|DRUG|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
214692674|NCT02723604|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
214435541|NCT01471691|DRUG|ranibizumab 0.5mg|Standard dose
214435542|NCT01471691|DRUG|ranibizumab 1.0mg|High dose
214435543|NCT00637585|DRUG|Fexofenadine|
214435544|NCT01808339|DRUG|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
214435545|NCT01808339|DRUG|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
214516078|NCT01595425|DRUG|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
214516079|NCT01595425|DRUG|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
214516080|NCT03804866|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
214692675|NCT00696462|DEVICE|forced-air warming|forced-air warming device
214692676|NCT03191669|OTHER|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
214692677|NCT05386654|DEVICE|imPulse™ Tor System|Self-directed blood pressure data capture
214692678|NCT03830814|PROCEDURE|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
215115569|NCT05276817|DRUG|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
215115570|NCT05276817|DEVICE|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
215115571|NCT05711121|PROCEDURE|Transforaminal epidural steroid injection|Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
215115572|NCT05711121|PROCEDURE|Caudal epidural steroid injection|Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
215115573|NCT05154526|OTHER|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
215115574|NCT05154526|OTHER|Exercise Program|Exercise program
215115575|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
215115576|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
215115577|NCT04320784|OTHER|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
215115578|NCT04320784|OTHER|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
215115579|NCT02276703|DEVICE|Skin Conductance Monitor|monitors skin conductance values
214435546|NCT05212181|DEVICE|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
214435547|NCT03586258|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
215115580|NCT06352749|BEHAVIORAL|Advice to increase physical activity and reduce sedentary behavior|After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations will be transmitted verbally and through written material.
215115581|NCT06352749|BEHAVIORAL|Online Physical Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised online by trained physiotherapists or sports physiologists."
214435548|NCT03586258|OTHER|Brain Imaging|Anatomical, diffusion, and/or functional MRI
214435549|NCT03586258|OTHER|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
214435550|NCT02298452|DEVICE|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
214435551|NCT03311737|COMBINATION_PRODUCT|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
214435552|NCT03311737|COMBINATION_PRODUCT|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
214435553|NCT02622568|DRUG|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
214435554|NCT02622568|PROCEDURE|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
214435555|NCT01116635|DRUG|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
214435556|NCT05076942|RADIATION|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
214435557|NCT05076942|DRUG|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
214435558|NCT06322446|OTHER|Exercise|16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
214435559|NCT02262767|DRUG|PF-06649751|Experimental Pfizer compound.
214435560|NCT02262767|DRUG|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
214516081|NCT03804866|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
214516082|NCT03804866|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
214435561|NCT06298305|DEVICE|Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software|Quantib Prostate is an AI-driven solution that provides an intuitive workflow for assessment of prostate MRI. The product integrates essential prostate MRI reading features into one workflow making it easy for the user to read, assess and report each patient case from within the same software interface. With automatic forwarding in place, the software preprocesses the MRI right after scanning. This allows the user to access calculations and analysis immediately when they open the software interface. Thanks to these features, the professional may experience an accelerated workflow, making it easier to manage their heavier workload.
214435562|NCT05018013|DRUG|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
214435563|NCT05018013|DRUG|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
214435564|NCT05018013|DRUG|Placebo to Ammoxetine|Placebo to Ammoxetine
214435565|NCT05018013|DRUG|Placebo to Duloxetine|Placebo to Duloxetine
214435566|NCT06523205|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples."
214435567|NCT05443542|DEVICE|Virtual Reality|Game to be played is a commercially available VR game
214435568|NCT05443542|OTHER|Control intervention|Sodoku, crossword puzzles
214435569|NCT04623567|DRUG|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
214435570|NCT04623567|DRUG|Metformin|The metformin tablets (500mg) will be administrated.
214516083|NCT02469324|BEHAVIORAL|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
215115582|NCT06352749|BEHAVIORAL|Face-to-Face Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists."
214435571|NCT05848817|DEVICE|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
214435572|NCT02097394|DRUG|Combizym|Combizym( 1 tablet, po, tid)
215115583|NCT02728453|DRUG|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
215115584|NCT02728453|DRUG|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
215115585|NCT02898402|PROCEDURE|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
215115586|NCT03015324|DRUG|Hydroxychloroquine|Hydroxychloroquine
215115587|NCT05028452|OTHER|Internet based support|Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.
214435573|NCT02097394|DRUG|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
214435574|NCT02097394|DRUG|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
214435575|NCT00006241|BIOLOGICAL|filgrastim|
214435576|NCT00006241|DRUG|chemotherapy|
214435577|NCT00006241|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214435578|NCT00006241|PROCEDURE|peripheral blood stem cell transplantation|
214435579|NCT00006241|RADIATION|radiation therapy|
214435580|NCT03960398|DRUG|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
214435581|NCT04152421|OTHER|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
214435582|NCT04004819|DRUG|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
214435583|NCT05126121|DRUG|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
214516084|NCT02469324|BEHAVIORAL|Compassionate Mind Training|see above
214516085|NCT00801606|DRUG|Zinc|Zinc 20 mg/day
214435584|NCT06149819|OTHER|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
214435585|NCT00106080|BEHAVIORAL|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
214516086|NCT00801606|DRUG|Micronutrient without zinc|Multimineral 2 RDA
214516087|NCT00801606|DRUG|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
214435586|NCT03535558|DRUG|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
214435587|NCT03535558|DRUG|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
214516088|NCT00801606|DRUG|Placebo|Placebo
215115588|NCT02403999|OTHER|Test shampoo|Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
215115589|NCT02403999|OTHER|Test bath foam|Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
215115590|NCT02403999|OTHER|Test head to toe wash|Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
215115591|NCT04828278|DIETARY_SUPPLEMENT|Arginine|Bonded Arginine Silicate
215115592|NCT04828278|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215115593|NCT06965725|DEVICE|Annuloplasy ring sizing device|A single time use of a novel sizing tool for mitral valve repair surgery (used ONLY in an observational capacity - this device does NOT influence decision-making during the conduct of the operation in any way).
215115594|NCT02204072|DRUG|BI 836845|
215115595|NCT02204072|DRUG|Enzalutamide|
215115596|NCT02204072|DRUG|Enzalutamide|
215115597|NCT05943015|PROCEDURE|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
215115598|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
215115599|NCT05943015|PROCEDURE|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
215115600|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
214435588|NCT03535558|DRUG|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
214435589|NCT06335472|PROCEDURE|3 nerves pulsed radiofrequency with hydrodissection|"Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt"
214516089|NCT01190436|DRUG|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
214516090|NCT01431157|PROCEDURE|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
214516091|NCT01431157|OTHER|No nasal oxygen|Patients will have no intervention for sleep apnea
214516092|NCT02378584|OTHER|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
214516093|NCT03955406|PROCEDURE|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
214516094|NCT03955406|PROCEDURE|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
214516095|NCT01995565|OTHER|PLR|
214516096|NCT02721147|BEHAVIORAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
214692679|NCT04573127|OTHER|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
214692680|NCT05160558|DRUG|BIIB132|Administered as specified in the treatment arm
214692681|NCT05160558|DRUG|BIIB132-Matching Placebo|Administered as specified in the treatment arm
214435590|NCT06335472|PROCEDURE|suprascapular nerve pulsed radiofrequency with hydrodissection|"The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt."
214516097|NCT02721147|BEHAVIORAL|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
214516098|NCT02721147|BEHAVIORAL|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
214516099|NCT02721147|BEHAVIORAL|Behavioral, Psychological or Informational Intervention|Receive educational information and support
214516100|NCT05931224|DRUG|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
214516101|NCT05931224|DRUG|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
214516102|NCT01722097|DRUG|Rocuronium|
214516103|NCT01722097|DRUG|placebo|
214516104|NCT02209376|BIOLOGICAL|CART-EGFRvIII T cells|
214516105|NCT03619044|OTHER|2 FES-PET Imaging will be performed:|"* before treatment initiation~* before treatment cycle 3 initiation"
214516106|NCT00328120|DRUG|Fulvestrant|500 mg intramuscular injection
214516107|NCT05647941|DIAGNOSTIC_TEST|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
214516108|NCT04471415|DRUG|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
214516109|NCT04471415|BIOLOGICAL|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
214516110|NCT01714479|OTHER|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
214516111|NCT01714479|OTHER|Placebo|
215115601|NCT05943015|PROCEDURE|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
215115602|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
215115603|NCT04137458|BIOLOGICAL|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
215115604|NCT02428569|BEHAVIORAL|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
215115605|NCT03885024|OTHER|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
215115606|NCT01930942|RADIATION|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
215115607|NCT00128310|DRUG|Vinorelbine|
215115608|NCT00128310|DRUG|Gemcitabine|
214516112|NCT00408109|DRUG|VRC-AVIDNA036-00-VP|
214516113|NCT02765204|DRUG|Dapagliflozin|
214516114|NCT02765204|DRUG|Saxagliptin|
214516115|NCT02765204|DRUG|Glucose|
214516116|NCT00005713|BEHAVIORAL|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
214516117|NCT03529435|BEHAVIORAL|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
214692682|NCT00724724|DRUG|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
214692683|NCT00724724|DRUG|Aspirin|Aspirin 100mg Qd for 1 year
215115609|NCT05332847|DEVICE|POC-US|Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
215115610|NCT05710549|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
214435591|NCT03418805|DRUG|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
214435592|NCT03418805|DRUG|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
214435593|NCT03418805|DRUG|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
214435594|NCT02549170|BIOLOGICAL|HYQVIA|Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
214516118|NCT03529435|BEHAVIORAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
214516119|NCT00257309|DRUG|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
214516120|NCT00257309|PROCEDURE|Primary angioplasty|
215115611|NCT05710549|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
215115612|NCT05725746|DIAGNOSTIC_TEST|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
215115613|NCT06975761|DRUG|Resin Based sealer|Post-operative pain after Root Canal Therapy by using resin based sealer
215115614|NCT06975761|DRUG|ZnO eugenol based sealers|Post-operative pain after Root Canal Therapy by using ZnO eugenol based sealer
215115615|NCT06578663|OTHER|conventional physical therapy|including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)
215115616|NCT06578663|OTHER|Electrical Dry Needling|In electrical dry needling, needle electrodes are used to deliver an electric current to the taut muscle band or the pain-generating trigger point. Low-frequency currents are thought to improve the physiological effects of the therapy by using electrical stimulation to enhance certain physiological reactions and achieve a speedier analgesic and anesthetic effect than that obtained with standard dry needling.
214435595|NCT02549170|BIOLOGICAL|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
214435596|NCT02549170|BIOLOGICAL|IGIV GAMMAGARD LIQUID/KIOVIG|Participants will receive GAMMAGARD LIQUID/KIOVIG
214435597|NCT02549170|BIOLOGICAL|IGIV GAMUNEX®-C|Participants will receive GAMUNEX®-C
214435598|NCT00898846|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
214435599|NCT05106946|BIOLOGICAL|ThisCART22 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
214435600|NCT03319797|DRUG|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
214435601|NCT02722551|DEVICE|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
214435602|NCT02379819|DEVICE|Nucleus Hybrid L24 Implant|
214435603|NCT02118064|BIOLOGICAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
214435604|NCT05204394|DRUG|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
214516121|NCT02107235|DRUG|oral rigosertib|
215115617|NCT06578663|OTHER|Glucosamine sulfate iontophoresis|Galvanic current mode will be used to deliver the cream through the skin. One gram of GS will be placed on positive electrode (being positively charged using Trans-arthral electrode placement technique) for administration of Iontophoresis \[40mA-min (2mA x 20minutes)\].
215115618|NCT04596826|DRUG|Dronabinol 5 MG|oral administration
215115619|NCT04596826|DRUG|Dronabinol 10 MG|oral administration
214435605|NCT05204394|OTHER|Standard of Care|Any oral 1st line approved HIV treatment regimen
214435606|NCT04728568|DRUG|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
214435607|NCT03172234|OTHER|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
214435608|NCT03172234|DRUG|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
214435609|NCT03172234|DRUG|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
214435610|NCT03803748|DEVICE|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
214516122|NCT02107235|DRUG|cisplatin|
214516123|NCT02107235|RADIATION|Radiotherapy|
214435611|NCT01522573|PROCEDURE|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
214435612|NCT04771780|DRUG|KHK7791|oral administration
214516124|NCT02344706|DEVICE|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
215115620|NCT04596826|DRUG|Placebo|oral administration
214435613|NCT00855400|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
214435614|NCT00855400|PROCEDURE|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
214435615|NCT01730352|DRUG|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
214435616|NCT02796586|OTHER|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
214435617|NCT04727840|DRUG|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
214435618|NCT04597684|PROCEDURE|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
214435619|NCT04597684|PROCEDURE|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
214435620|NCT01625104|OTHER|Non Intervention|Business as usual
214435621|NCT01625104|OTHER|Agressive Intervention Process Improvement Strategies|
214435622|NCT01574794|OTHER|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
214435623|NCT01574794|OTHER|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
214435624|NCT03065569|DRUG|Bupivacaine|16 mL of 0.125% bupivacaine
214435625|NCT02310113|OTHER|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
214435626|NCT05264168|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
214435627|NCT05264168|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
214435628|NCT00541268|DEVICE|ICD|Intracardioverter defibrillators from 2 different manufacturers
214435629|NCT00541268|OTHER|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
214435630|NCT01671449|DRUG|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
214435631|NCT01671449|DRUG|Cisplatin|60 mg/m2/day Day 1
214516125|NCT05792683|DEVICE|lumbar drain|"Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day."
214516126|NCT01843049|RADIATION|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
215115621|NCT05773222|DRUG|Apixaban|Single Group Assignment
214435632|NCT01671449|DRUG|Oxaliplatin|130 mg/m2/day Day 1
214435633|NCT02545634|DIETARY_SUPPLEMENT|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
214435634|NCT02545634|OTHER|Placebo|
214435635|NCT04966416|DIETARY_SUPPLEMENT|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
214435636|NCT04966416|DIETARY_SUPPLEMENT|Placebo|Glucose in gelatine capsules.
214435637|NCT03632616|OTHER|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, 6 and 12 months post-intervention.
215115622|NCT01890837|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
215115623|NCT01890837|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
215115624|NCT04030520|BEHAVIORAL|POPPi|behavioral intervention with offer of HIV self test
215115625|NCT04030520|BEHAVIORAL|Comparison|standard of care
214435638|NCT06516861|DRUG|Magnesium Sulfate 20 MG/ML|Administered intravenously with a dose of 30 mg/kg
214435639|NCT06516861|DRUG|Lidocaine IV|Administered intravenously with a dose of 1.5mg/Kg
214435640|NCT06516861|DRUG|saline solution|Administered intravenously with 20 ml
214435641|NCT01947634|OTHER|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
214435642|NCT00204113|DEVICE|Multi-purpose rehabilitation frame|
214435643|NCT00204113|DEVICE|Surface Functional Electrical Stimulation|
214435644|NCT03021369|DEVICE|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
214435645|NCT01074567|DRUG|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
214435646|NCT05915715|OTHER|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
214435647|NCT05915715|OTHER|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
214435648|NCT01277614|BEHAVIORAL|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
214435649|NCT04930718|OTHER|Thumb active Exercises|Active específico exercises; Reeducation program
214435650|NCT03386539|DRUG|Everolimus|Everolimus tablet
214435651|NCT03386539|DRUG|Tacrolimus|Tacrolimus capsule or liquid suspension
214516127|NCT01843049|DRUG|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
214516128|NCT01236144|DRUG|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
214516129|NCT01236144|DRUG|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
214516130|NCT01236144|DRUG|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
214516131|NCT01128439|OTHER|No intervention|No intervention
214516132|NCT04454723|PROCEDURE|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
214516133|NCT04454723|PROCEDURE|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
214516134|NCT02009332|DRUG|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
214516135|NCT02009332|DRUG|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
214435652|NCT03386539|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
214435653|NCT02613546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
214435654|NCT02613546|BEHAVIORAL|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
214435655|NCT04167020|DEVICE|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
214435656|NCT03279861|DRUG|Entresto|First line therapy in Entresto arm
214435657|NCT03279861|DRUG|Valsartan|"First line therapy in usual meds arm"
214435658|NCT03921580|OTHER|Control Canned Tuna|210 g/day
214435659|NCT03921580|OTHER|Enriched Canned Tuna Variety 1|210 g/day
214435660|NCT03921580|OTHER|Enriched Canned Tuna Variety 2|210 g/day
214435661|NCT03769571|BEHAVIORAL|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
214435662|NCT01675258|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
214435663|NCT03145155|BEHAVIORAL|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
214435664|NCT03145155|BEHAVIORAL|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
214435665|NCT00595790|BIOLOGICAL|IC51|
214435666|NCT03080324|DRUG|Fentanyl sublingual|Fentanyl sublingual
214435667|NCT03080324|DRUG|Fentanyl ev|Fentanyl ev
214435668|NCT03080324|DRUG|Placebo sublingual|Placebo sublingual
214435669|NCT03080324|DRUG|Placebo ev|Saline
214435670|NCT03988023|BIOLOGICAL|Ampion|4 mL injection of Ampion
214435671|NCT03988023|DRUG|Saline|Saline solution, 4 mL, single intra-articular injection
214435672|NCT02424071|DRUG|Melatonin|
214435673|NCT02424071|DRUG|placebo|
214435674|NCT01969461|BEHAVIORAL|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
214435675|NCT00182975|DRUG|DHEA replacement|
214435676|NCT04223388|DIETARY_SUPPLEMENT|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
214435677|NCT04223388|OTHER|Placebo|Placebo product, serving size = 1 capsule/day
214435678|NCT01611246|DEVICE|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
214435679|NCT01957969|DEVICE|Sacral Nerve Stimulation|
214435680|NCT01255501|DRUG|NI-0701|
214516136|NCT04004832|DIAGNOSTIC_TEST|there is not any intervention procedure|there is not any intervention procedure
214516137|NCT04276649|DRUG|Caltrate|Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
214516138|NCT01912599|DEVICE|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
214516139|NCT01912599|DEVICE|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
214516140|NCT03807934|OTHER|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
214516141|NCT04660110|DRUG|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
214435681|NCT01255501|DRUG|Placebo|
214435682|NCT02716246|BIOLOGICAL|UX111|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
214435683|NCT02716246|DRUG|Prophylactic Immunomodulatory (IM) Therapy|
214516142|NCT03503500|OTHER|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
214435684|NCT02716246|DRUG|Optimized Prophylactic IM Therapy|
214435685|NCT02716246|DRUG|Adjuvant IM Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
214435686|NCT03067116|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
214435687|NCT03067116|DIAGNOSTIC_TEST|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
214435688|NCT03067116|DIAGNOSTIC_TEST|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
214435689|NCT03067116|OTHER|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
214435690|NCT04857294|PROCEDURE|TMJ unilateral discectomy|All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
214435691|NCT01244672|PROCEDURE|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
214435692|NCT01244672|PROCEDURE|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
214435693|NCT03315481|PROCEDURE|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
214435694|NCT03315481|PROCEDURE|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
214435695|NCT01723631|DEVICE|Trap Myelin Test|
214435696|NCT05246124|OTHER|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
214516143|NCT03503500|OTHER|Standard care|"2\. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
214516144|NCT04739306|BIOLOGICAL|CT-P42|2mg/0.05 mL by Intravitreal injection
214516145|NCT04739306|BIOLOGICAL|Eylea|2mg/0.05 mL by Intravitreal injection
214516146|NCT05059145|DRUG|Chlorhexidine Gluconate|Vaginal cream 1%
214516147|NCT05059145|DRUG|Fluconazole|150 mg oral capsule
214516148|NCT01390753|DIETARY_SUPPLEMENT|Human donor milk|
214516149|NCT03699761|PROCEDURE|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
214516150|NCT03699761|PROCEDURE|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
214516151|NCT00993278|DIETARY_SUPPLEMENT|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
214516152|NCT00993278|DIETARY_SUPPLEMENT|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
214516153|NCT02912338|BEHAVIORAL|Resistant Training|
214516154|NCT02912338|OTHER|Control Group|
214516155|NCT02077114|BIOLOGICAL|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
215115626|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
215115627|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
215115628|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
215115629|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
214516156|NCT05114499|DRUG|Donepezil|Donepezil 5mg qd
214516157|NCT05114499|DRUG|GV-971|GV-971 450mg bid
214516158|NCT04501588|BEHAVIORAL|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
214516159|NCT04501588|BEHAVIORAL|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
214435697|NCT01858831|DRUG|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
214516160|NCT02374294|DEVICE|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
214516161|NCT00087724|DRUG|FK962|
214516162|NCT02611193|PROCEDURE|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
214435698|NCT01858831|DRUG|Atovaquone|Atovaquone
214435699|NCT01014273|PROCEDURE|Percutaneous Coronary Intervention|
214435700|NCT01000831|BIOLOGICAL|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
214435701|NCT02650544|DRUG|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
214435702|NCT02650544|DRUG|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
214435703|NCT01777750|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
214516163|NCT02611193|PROCEDURE|Simulated manipulative treatment|Simulated Manipulative Treatment
214435704|NCT03017469|OTHER|ARISE|"1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)"
214435705|NCT00682708|DIETARY_SUPPLEMENT|PlumpyNut|
214516164|NCT04748705|DRUG|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
214516165|NCT04748705|DRUG|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
214516166|NCT05656651|BEHAVIORAL|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
214516167|NCT02283632|PROCEDURE|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
214516168|NCT03258983|OTHER|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
215115630|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
215115631|NCT06986642|OTHER|core stability exercises|"core stability exercises General Exercises~1. Brisk walking (30 minutes)~2. Squats (3 sets, 10-15 repetitions)~3. Lunges (3 sets, 10-15 repetitions per leg)~4. Push-ups (3 sets, 10-15 repetitions)~5. Seated row (3 sets, 10-15 repetitions)~1\. Brisk walking (30 minutes) 2. Squats (3 sets, 10-15 repetitions) 3. Lunges (3 sets, 10-15 repetitions per leg) 4. Push-ups (3 sets, 10-15 repetitions) 5. Seated row (3 sets, 10-15 repetitions)"
214516169|NCT03386344|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
214516170|NCT03386344|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
214516171|NCT02416947|DIETARY_SUPPLEMENT|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
214516172|NCT02416947|DIETARY_SUPPLEMENT|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
214516173|NCT02416947|DIETARY_SUPPLEMENT|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
214516174|NCT02443532|BEHAVIORAL|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
215115632|NCT06986642|OTHER|Genreal Exercises|Genreal Exercises
215115633|NCT03310528|BEHAVIORAL|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
215115634|NCT03310528|PROCEDURE|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
215115635|NCT03886168|OTHER|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
215115636|NCT03069131|DRUG|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
215115637|NCT03069131|OTHER|Placebo|twice daily administration of 1 rifaximin placebo tablet
215115638|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
215115639|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT)|This application includes rehabilitation methods frequently used in pediatric rehabilitation.
214435706|NCT00682708|DIETARY_SUPPLEMENT|PlumpyDoz|
214435707|NCT01501604|DRUG|BKM120|100 MG PO QD in cycles of 28 days
214435708|NCT00780949|OTHER|intestinal biopsies|intestinal biopsies during routine endoscopy
214435709|NCT00925977|DRUG|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
214435710|NCT00925977|DRUG|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
214435711|NCT05075083|BIOLOGICAL|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
215115640|NCT06720155|BEHAVIORAL|Sleeper stretch|Participants will complete their regularly scheduled workout activities over 8 weeks, with the addition of the sleeper stretch into the dynamic warm-up. Participants will be instructed to lie side-lying with the dominant arm downward, the trunk rotated posteriorly 20 to 30°, the shoulder raised to 90°, the elbow flexed to 90°, and both knees semi-flexed to ensure stability. Participants will then be asked to use the opposite hand to grasp the dominant hand below the wrist and gradually internally rotate the forearm towards the floor; (i.e., the participant will perform passive internal rotation with the opposite arm). This stretch position will be completed on both sides. Participants will be instructed to complete 2 sets of 10 repetitions for each arm and hold the position for \~2 seconds.
214435712|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
214435713|NCT03572075|PROCEDURE|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
215115641|NCT06720155|BEHAVIORAL|Standard workout|Participants will complete their regularly programmed dynamic warm-ups before scheduled workout for 8 weeks.
214516175|NCT02443532|BEHAVIORAL|Individual education|Usual care (individual consultations as routinely performed)
214516176|NCT06359977|OTHER|Quantitative EEG monitoring and beside ultrasound evaluation|After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
214516177|NCT05444374|DRUG|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
214516178|NCT05444374|DRUG|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
214516179|NCT06181513|DRUG|Probiotic Blend Capsule|20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)
214516180|NCT04182542|DEVICE|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
214516181|NCT03481725|DEVICE|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
214516182|NCT03481725|DEVICE|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
214516183|NCT01016730|DRUG|Bortezomib|Given IV
214516184|NCT01016730|OTHER|Laboratory Biomarker Analysis|Correlative studies
214516185|NCT01016730|OTHER|Questionnaire Administration|Ancillary studies
214516186|NCT04026022|DRUG|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
214516187|NCT04026022|DRUG|Placebo|Placebo plaster in the ER or PACU
214516188|NCT01874717|OTHER|Conscious sedation for dental care|
215115642|NCT07046689|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two cycles of Trop2-ADC therapy.
215115643|NCT06726538|BIOLOGICAL|Intravenous administration of Autologous, adipose-derived mesenchymal stem cells|"Patients in group A will receive two infusions of autologous, adipose-derived mesenchymal stem cells at day 0 and day 90 ± 14 at a dose of 10\^6 cells/kg.~Autologous, adipose-derived mesenchymal stem cells used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5%. For clinical use, cells at passage 3 will be harvested in 100 mL Ringer's lactate. Therapeutic ASC products must pass the following releasing criteria: (1) negative for bacteria, fungi and mycoplasma; (2) more than 90% viability; (3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and (4) endotoxin \<5 EU/kg. The patient will be infused with 1x106 cells/kg body weight within 60 minutes via the intravenous route."
215115644|NCT06725940|DEVICE|68Ga-GZMB PET/CT|68Ga-GZMB PET/CT
215115645|NCT07066579|BEHAVIORAL|Valsalva Maneuver|Patients are instructed to perform the Valsalva maneuver by blowing into a 10-cc syringe to generate approximately 20 mmHg pressure for 15-20 seconds before arteriovenous fistula cannulation during each dialysis session.
215115646|NCT07065136|BIOLOGICAL|627|subcutaneous injection
215115647|NCT07065136|OTHER|Placebo|Single subcutaneous injection
214435714|NCT03572075|PROCEDURE|standard care protocol|the treatment is the same as usual in our center
214516189|NCT01874717|DRUG|midazolam|
214516190|NCT00237718|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
215115648|NCT07064811|PROCEDURE|Exercise Intervention Protocol|Subjects participated in the supervised exercise program twice weekly (with a 48-72-hour interval between sessions) for 24 weeks, totaling 48 supervised sessions. The progressive resistance training program used velocity-based training principles \[24-26\], a novel approach in exercise oncology that allows for precise load management and indi-vidualization based on daily performance capacity
214435715|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
214435716|NCT00780351|DEVICE|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
214435717|NCT03822234|PROCEDURE|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
214435718|NCT01393067|DEVICE|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
214435719|NCT01393067|DEVICE|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
214435720|NCT05621499|DRUG|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
214435721|NCT05621499|DRUG|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
214435722|NCT05621499|DRUG|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
214435723|NCT05758012|DRUG|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
214435724|NCT05758012|DRUG|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
214435725|NCT03632759|DRUG|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
214435726|NCT03632759|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
214435727|NCT00585624|DIETARY_SUPPLEMENT|Impact Advanced Recovery|Nutritional supplement
214435728|NCT00585624|DIETARY_SUPPLEMENT|No supplement|No supplement
214435729|NCT01651767|DRUG|Placebo|Form=suspension, route=oral.
214435730|NCT01651767|DRUG|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
214435731|NCT06449859|DRUG|TQC2938 Injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
214435732|NCT06449859|DRUG|TQC2938 Placebo|TQC2938 Placebo is a placebo comparator
214435733|NCT04646031|DRUG|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
214435734|NCT05618132|DIAGNOSTIC_TEST|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
214435735|NCT03210454|OTHER|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
214516191|NCT00237718|DRUG|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
214516192|NCT00237718|DRUG|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
214516193|NCT00237718|DRUG|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
214516194|NCT01733199|OTHER|questionnaires|Summons of patients and filling questionnaire.
214516195|NCT05264311|OTHER|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
214516196|NCT01100372|DRUG|gemcitabine hydrochloride|
214516197|NCT01100372|DRUG|liposome-encapsulated doxorubicin citrate|
214516198|NCT01100372|PROCEDURE|quality-of-life assessment|
214516199|NCT01623180|DEVICE|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
214516200|NCT01623180|DEVICE|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
214435736|NCT03210454|OTHER|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
214435737|NCT05866978|BEHAVIORAL|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
215115649|NCT07064811|PROCEDURE|SPoRT-Control Intervention|structured written instructions for a personalized home-based resistance training program. The protocol was designed to prioritize safety, progressive adaptation, and individualization based on each participant's functional capacity and available resources at home. The program was intended to be performed two to three times per week on non-consecutive days, focusing exclusively on lower-body training through a single primary movement. Each session consisted of three effective sets of 12 repetitions, which served as the standard training volume for the main exercise.
215115650|NCT04960709|DRUG|Durvalumab|Anti- PD-L1 Antibody
215115651|NCT04960709|DRUG|Tremelimumab|Human IgG2 mAb
215115652|NCT04960709|DRUG|Enfortumab Vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate
214435738|NCT00527540|DRUG|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
215115653|NCT04960709|PROCEDURE|Radical Cystectomy|For cisplatin-ineligible or cisplatin-refusal patients
215115654|NCT06241170|PROCEDURE|mesentery-guided resection margin|Mesentery-guided resection margin where the mesentery adjacent to the intestine completely transitions from abnormal to normal upon palpation and transillumination, compared to the proximal normal mesentery. Open, laparoscopic, hand-assisted, or robotic mobilization are all acceptable, but extracorporeal resection and anastomosis are required. After intestinal mobilization , the diseased intestinal segment is exteriorized from the abdominal cavity.
215115655|NCT06241170|PROCEDURE|traditional resection margin|"2 cm proximal to the site where gross lesions disappear. After transecting the bowel, re-examine the mucosal condition; if mucosal ulcers or obvious scars are present, extend the incision until reaching the site with normal mucosa. Definition of gross lesions: Evaluation from the outer intestinal wall: The site where the tough texture, thickening, or contracture at the mesenteric edge of the intestinal wall disappears; evaluation from the intestinal lumen: The site where mucosal ulcers, fissures, or obvious scars disappear. Mucosa appearing seemingly abnormal is considered normal."
215115656|NCT07065019|OTHER|The Internalized Stigma Scale in Mental Illness (ISS)|The ISS consists of 29 items and is a self-report scale assessing internalized stigma. ISS includes 5 subscales: 1. Alienation (6 items), 2. Confirmation of Stereotypes (7 items), 3. Perceived Discrimination (5 items), 4. Social Withdrawal (6 items), 5. Resistance to Stigmatization (5 items). ISS is a Likert-type scale calculated as 'strongly disagree' (1 point), 'disagree' (2 points), 'agree' (3 points), 'strongly agree' (4 points). The items of the 'Resistance to stigmatization' subscale are reverse scored. High scores on this scale indicate how aggressive the person's internalized stigma is negatively. ISS has been adapted for many diseases other than mental illnesses in our country and its validity and reliability have been demonstrated.
215115657|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 18.5-24.99
215115658|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 25-39.99
215115659|NCT06916494|DRUG|Rutin|Rutin 40 mg tid. Treatment will be given for 2 cycles (21 days per cycle)
215115660|NCT06916494|DRUG|Gemcitabine, Cisplatin|Cisplatin 100 mg/m² D2 q3w, and Gemcitabine 1000 mg/m² D1, D8 q3w. Treatment will be given for 2 cycles (21 days per cycle)
215115661|NCT06916494|DRUG|Tislelizumab|Tislelizumab 200 mg D1 q3w Treatment will be given for 2 cycles (21 days per cycle)
215115662|NCT06921018|BEHAVIORAL|change in diet|the participants will either be assigned consumption of a vegan diet or their habitual average danish diet with a high intake of meat for the intervention period which is 4 weeks.
215115663|NCT06920706|DEVICE|RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (200 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
215115664|NCT06920706|DEVICE|Sham-RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (60 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
215115665|NCT04148430|DRUG|Anakinra|100mg subcutaneous
215115666|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
215115667|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
215115668|NCT06921174|DEVICE|"Use of the Crescendo 2 Intravaginal Device"|"Self-administered perineal massage at home with Crescendo device.~Three times per week, 10 minutes each session, over a 12-week period."
215115669|NCT06921174|PROCEDURE|Classical Perineal Massage Therapy|"Performed manually by a pelvic floor physiotherapist.~One 30-minute session per week for 12 weeks."
214435739|NCT04487431|DRUG|BAY1817080|Oral single dose
214435740|NCT04487431|DRUG|[14C]BAY1817080|Oral single dose
214435741|NCT00241241|DRUG|pegylated interferon-alfa 2a|
215115670|NCT06919133|DEVICE|The MENTINA app|A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.
215115671|NCT06919133|OTHER|Control|The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.
215115672|NCT02583555|BEHAVIORAL|Interview followed by frequent telephone support|Interview followed by telephone support
214435742|NCT04226664|PROCEDURE|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
214435743|NCT00411034|DRUG|OROS Hydromorphone HCI|
214516201|NCT05067816|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
214516202|NCT05852496|DRUG|Vitamin D|vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
214516203|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
214516204|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
214516205|NCT04243954|DRUG|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
214516206|NCT05567029|DRUG|Risankizumab Dose A|Prefilled Syringe
214516207|NCT05567029|DRUG|Risankizumab Dose B|Prefilled Syringe
214516208|NCT06210178|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI scans including abdominal 4D Flow MRI.
214516209|NCT02545426|OTHER|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
214516210|NCT01795183|DRUG|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
214516211|NCT06266676|OTHER|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
215115673|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
215115674|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
215115675|NCT02640495|DRUG|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
215115676|NCT06750497|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
215115677|NCT03657849|DEVICE|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
214516212|NCT06266676|OTHER|slide presentation|Provide online presentations.
214516213|NCT05748808|BEHAVIORAL|Use of biofeedback and virtual reality in the treatment of aggressive outbursts|Participants are trained to identify their physiological response when they are relaxed and when an outburst is coming. They are treated with cognitive, behavioral and emotional self-regulation therapies for managing anger and learning positive coping skills. Biofeedback toghether with virtual reality help them to improve their recognition and control of emotions.
214435744|NCT03703336|BIOLOGICAL|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
214435745|NCT03703336|BIOLOGICAL|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
214435746|NCT01064336|DRUG|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
214435747|NCT00533910|DRUG|Rifaximin|550mg BID rifaximin for 8 weeks
215115678|NCT02621294|OTHER|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
214435748|NCT00533910|DRUG|placebo|same as the experimental arm
214516214|NCT01643538|BEHAVIORAL|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
214516215|NCT01643538|BEHAVIORAL|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
215115679|NCT05879497|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
215115680|NCT04208438|DIAGNOSTIC_TEST|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
215115681|NCT04208438|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
215115682|NCT01521663|DRUG|IPX159|
215115683|NCT01521663|DRUG|Placebo|
215115684|NCT00874848|BIOLOGICAL|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
215115685|NCT00874848|BIOLOGICAL|Cetuximab|initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
215115686|NCT00874848|DRUG|Paclitaxel|200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
215115687|NCT00874848|DRUG|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
215115688|NCT01037738|PROCEDURE|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
215115689|NCT01558050|DIETARY_SUPPLEMENT|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
215115690|NCT02033746|DEVICE|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
215115691|NCT03325595|DRUG|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
215115692|NCT03325595|DRUG|Placebo|Matching capsule placebo
215115693|NCT05345301|DIAGNOSTIC_TEST|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
215115694|NCT03625336|DIAGNOSTIC_TEST|MRI|An MRI will be obtained utilizing 3 different MRI sequences
215115695|NCT02034838|DRUG|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
215115696|NCT03089541|BEHAVIORAL|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
215115697|NCT01053039|DRUG|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
215115698|NCT01053039|DRUG|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
215115699|NCT02324816|DEVICE|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
215115700|NCT01088620|DRUG|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
215115701|NCT01088620|DRUG|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
215115702|NCT01088620|DRUG|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
215115703|NCT05169424|DEVICE|Trelegy Ellipta|Trelegy Ellipta
215115704|NCT05169424|DEVICE|Stiolto Respimat|Stiolto Respimat
214435749|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd), then high carbohydrate diet|Sixty % of the energy content is based on fat, then sixty % of the energy content is based on carbohydrates
214435750|NCT02088853|DIETARY_SUPPLEMENT|high carbohydrate diet, then high fat diet|Sixty % of the energy content is based on carbohydrates, then sixty % of the energy content is based on fat
215115705|NCT05169424|DRUG|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
215115706|NCT05169424|DRUG|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
215115707|NCT05613829|OTHER|Burn surgery|Patients underwent burn surgery
215115708|NCT04022655|OTHER|ICU Care|No intervention
215115709|NCT02037217|DEVICE|ExAblate Transcranial MRgFUS System|
214516216|NCT01643538|BEHAVIORAL|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
214516217|NCT01643538|BEHAVIORAL|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
214435751|NCT05189223|BEHAVIORAL|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
214516218|NCT05441410|DRUG|Pyronaridine Tetraphosphate, Artesunate Drug Combination|Combination drug for treatment of uncomplicated malaria
215115710|NCT01227863|DRUG|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
215115711|NCT01227863|DRUG|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
215115712|NCT00916019|OTHER|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
215115713|NCT00005818|DRUG|irinotecan hydrochloride|Given IV
215115714|NCT00005818|DRUG|semaxanib|Given IV
215115715|NCT00005818|OTHER|laboratory biomarker analysis|Correlative studies
215115716|NCT03748719|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
215115717|NCT05854979|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
215115718|NCT03570359|DRUG|Interferon Beta-1A|Interferon Beta-1A via inhalation
215115719|NCT03570359|OTHER|Placebo|Placebo via inhalation
215115720|NCT01836926|PROCEDURE|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
215115721|NCT01836926|DEVICE|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
215115722|NCT01870726|DRUG|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
215115723|NCT01870726|DRUG|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
215115724|NCT01292096|OTHER|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
215115725|NCT02402140|OTHER|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
215115726|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
215115727|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
215115728|NCT00286429|DRUG|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
214435752|NCT05189223|BEHAVIORAL|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine, methadone, or naltrexone prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
215115729|NCT00942825|DRUG|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
214435753|NCT05917509|DRUG|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
214435754|NCT05917509|DRUG|Cabotegravir (CAB) LA|CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
214435755|NCT05917509|DRUG|Rilpivirine (RPV) LA|RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
215115730|NCT00942825|DRUG|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
215115731|NCT06058325|OTHER|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
215115732|NCT03941626|BIOLOGICAL|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
215115733|NCT03933761|DRUG|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
215115734|NCT01516463|DRUG|Collagenase Santyl|Applied topically (2 mm thickness once daily)
215115735|NCT01516463|BIOLOGICAL|Bacitracin|Applied topically (2 mm thickness) once daily
215115736|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
215115737|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
215115738|NCT00249678|BEHAVIORAL|Behavior Therapy|
215115739|NCT03704909|DRUG|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
215115740|NCT03704909|DRUG|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
215115741|NCT02168218|OTHER|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
215115742|NCT03162419|DRUG|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
214435756|NCT05896774|DRUG|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
214435757|NCT06536530|BEHAVIORAL|Exergame-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
214435758|NCT06536530|BEHAVIORAL|Cognitive-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
214435759|NCT06536530|BEHAVIORAL|Wait-List|Participants will not train with any program and they will not assist to any specific session or intervention
214435760|NCT06013423|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214435761|NCT06013423|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
214435762|NCT06013423|DRUG|Cyclophosphamide|Receive IV
214435763|NCT06013423|DRUG|Cyclosporine|Receive IV or PO
214435764|NCT06013423|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
214435765|NCT06013423|PROCEDURE|Echocardiography|Undergo ECHO
214435766|NCT06013423|DRUG|Fludarabine Phosphate|Receive IV
214435767|NCT06013423|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214516219|NCT05441410|BIOLOGICAL|PfSPZ Challenge (NF54)|cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation
214516220|NCT05441410|BIOLOGICAL|MVA ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
215115743|NCT03162419|BIOLOGICAL|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
214435768|NCT06013423|DRUG|Mycophenolate Mofetil|Receive IV
214435769|NCT06013423|OTHER|Survey Administration|Ancillary studies
214435770|NCT06013423|DRUG|Thiotepa|Receive IV
214435771|NCT06013423|RADIATION|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
215115744|NCT03162419|BIOLOGICAL|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
215115745|NCT06508671|DRUG|DL-3-n-butylphthalide|Take butylphthalide soft capsules orally
215115746|NCT06508671|DRUG|Empty Medication Capsules|Take empty medication capsules orally
215115747|NCT01238302|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
215115748|NCT01238302|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
215115749|NCT02240355|DRUG|RO6885247|oral solution
214516221|NCT05441410|BIOLOGICAL|ChAd63 ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)
214516222|NCT05441410|BIOLOGICAL|Sodium chloride (NaCl) 0.9%|0.9% NaCl solution for injection
214435772|NCT06013423|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
214516223|NCT00614354|DRUG|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
214516224|NCT00074607|DRUG|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
214516225|NCT05185167|DRUG|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
214516226|NCT05185167|DRUG|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
214516227|NCT02991118|DRUG|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
214516228|NCT02991118|DRUG|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
214516229|NCT00595959|DEVICE|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
215115750|NCT02240355|DRUG|placebo|oral solution
214516230|NCT03488550|BIOLOGICAL|ANX007|Single ascending dose
214516231|NCT06251791|OTHER|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
214516232|NCT06251791|OTHER|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
215115751|NCT05487911|DEVICE|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
215115752|NCT04720677|OTHER|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
215115753|NCT04601805|DEVICE|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
215115754|NCT01092910|DEVICE|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
215115755|NCT02106520|DRUG|Bevacizumab|
215115756|NCT02106520|DRUG|placebo|
215115757|NCT00908804|PROCEDURE|open appendectomy|
215115758|NCT00908804|PROCEDURE|laparoscopic appendectomy|
215115759|NCT00258934|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
215115760|NCT00258934|BIOLOGICAL|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
215115761|NCT06383260|BEHAVIORAL|Behavioral diagnostic|Diagnosing the behavioral pattern
214516233|NCT06117215|OTHER|Data collection|data collection
215115762|NCT01622465|BEHAVIORAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
215115763|NCT01622465|BEHAVIORAL|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
215115764|NCT03481699|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
214435773|NCT01306864|DEVICE|Hemospray Kit|Hemostasis of Arterial GI Bleeding
214435774|NCT03443661|DRUG|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
214435775|NCT01274299|PROCEDURE|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
214435776|NCT03767907|BEHAVIORAL|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
214435777|NCT03767907|BEHAVIORAL|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
214435778|NCT03882502|OTHER|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
214516234|NCT03676504|BIOLOGICAL|CD19.CAR T Cells|Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
214516235|NCT03676504|DRUG|Fludarabine|3 days of fludarabine 30 mg/m\^2/day
214516236|NCT03676504|DRUG|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m\^2/day
214516237|NCT06061900|OTHER|Group exercise program|Group fitness program
214516238|NCT04373967|DRUG|Victoza®.|Patients will receive Victoza®. Both products will be provided as pen-injector.
214516239|NCT04373967|DRUG|Metformin Hydrochloride|Patients who were receiving metformin prior to study will continue to receive it during the study.
214516240|NCT04373967|DRUG|TQZ2451|Patients will receive TQZ2451.Both products will be provided as pen-injector.
214516241|NCT00254124|DEVICE|The Diet Plate (R) TM portion control plate and bowl|
215115765|NCT03481699|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
215115766|NCT04357483|DRUG|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
215115767|NCT04357483|DRUG|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
215115768|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
215115769|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
215115770|NCT00032734|DRUG|satavaptan (SR121463B)|
214435779|NCT04528472|OTHER|Acupuncture Treatment|stimulate acupoints to accelerate recovery
214435780|NCT04528472|OTHER|Regular Treatment|Oral Medicine and Rehabilitation Treatment
214435781|NCT02568683|DRUG|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
214435782|NCT02568683|DRUG|Vincristine|VCR administered intravenously
214435783|NCT04434677|RADIATION|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
214435784|NCT04434677|RADIATION|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
214516242|NCT03190148|OTHER|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
214516243|NCT03190148|OTHER|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
214516244|NCT03190148|OTHER|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
214516245|NCT05017454|DRUG|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
214516246|NCT05017454|DRUG|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
214516247|NCT04144088|DRUG|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
214516248|NCT04144088|DRUG|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
214516249|NCT04144088|DRUG|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
214516250|NCT00829400|BEHAVIORAL|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
214516251|NCT00829400|BEHAVIORAL|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
214516252|NCT01049152|DEVICE|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
214516253|NCT00263900|DEVICE|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
214516254|NCT06464666|PROCEDURE|Renal interlobar artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
214516255|NCT06464666|PROCEDURE|Renal inter-lobular artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
214516256|NCT06253962|OTHER|coronary agiongraphy|severity of coronary atherosclerosis
214516257|NCT02077374|DRUG|IDN-6556|25 mg BID for 28 days
214516258|NCT02077374|OTHER|Placebo|Placebo BID for 28 Days
215115771|NCT01680744|OTHER|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
215115772|NCT01288001|DRUG|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
215115773|NCT02059603|PROCEDURE|Electroacupuncture|
215115774|NCT02059603|PROCEDURE|Fast-track program|
215115775|NCT04325620|DRUG|HIP1601|HIP1601
215115776|NCT04325620|DRUG|HGP1805|Placebo of HIP1601
215115777|NCT01518842|BIOLOGICAL|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
215115778|NCT00603122|BEHAVIORAL|ascent protocol|ascent protocol for the two groups has different acclimatization time
215115779|NCT05917054|OTHER|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
215115780|NCT02384512|DRUG|Azilect®|AZILECT® 1mg Tablets
215115781|NCT01998308|DRUG|Crespine gel|50 Knees will have single injection of Crespine gel
215115782|NCT01998308|DRUG|Intragel|50 Knees will have single injection of 2 ampules of Intragel
215115783|NCT01998308|DRUG|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
215115784|NCT01998308|DRUG|Monovisc|50 Knees will have single injection of Monovisc
215115785|NCT05310331|COMBINATION_PRODUCT|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
215115786|NCT03691571|DEVICE|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
215115787|NCT03691571|DEVICE|Control|Standard of care involves standard temperature probe monitoring.
215115788|NCT03945149|DIETARY_SUPPLEMENT|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
215115789|NCT03945149|DIETARY_SUPPLEMENT|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
215115790|NCT02221388|DRUG|BI 671800 HEA, 200 mg tablets|
215115791|NCT02221388|DRUG|BI 671800 HEA EC, 200 mg tablets|
215115792|NCT02221388|DRUG|BI 671800 HEA, 50 mg tablets|
215115793|NCT02221388|DRUG|BI 671800 ED, 100 mg capsules|
215115794|NCT02221388|OTHER|Standard meal|
215115795|NCT03135938|PROCEDURE|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
215115796|NCT03135938|PROCEDURE|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
215115797|NCT02415270|OTHER|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
215115798|NCT02415270|OTHER|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
215115799|NCT02415270|OTHER|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
215115800|NCT02909374|OTHER|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
215115801|NCT02321345|OTHER|Palliative Care Support|Palliative care meetings Quality of Life Assessments
215115802|NCT03240094|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
215115803|NCT00825903|BEHAVIORAL|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
214435785|NCT00386516|DRUG|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
214435786|NCT00386516|DRUG|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
214435787|NCT03381781|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
214435788|NCT03381781|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
214435789|NCT03381781|DRUG|Cytarabine|15mg/m\^2,hypodermic injection,q12h,d1-7
214435790|NCT02190643|BEHAVIORAL|Cessation counseling with adherence focus|
214435791|NCT02190643|BEHAVIORAL|Cessation counseling without adherence focus|
214435792|NCT01548170|DRUG|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
214435793|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
214435794|NCT01548170|DRUG|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
214435795|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
214435796|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
214435797|NCT04564196|PROCEDURE|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
214435798|NCT01736215|DRUG|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
214435799|NCT01024881|PROCEDURE|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
214435800|NCT01024881|PROCEDURE|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
214435801|NCT02241538|DEVICE|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
214435802|NCT02241538|DEVICE|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
214435803|NCT02241538|DEVICE|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
214435804|NCT02241538|DEVICE|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
214435805|NCT05291104|DIETARY_SUPPLEMENT|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
214435806|NCT02778828|DRUG|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
214435807|NCT01598259|DRUG|Melatonin|po 1 hour before bedtime
214435808|NCT01598259|OTHER|placebo|po, 1 hour before bed
214435809|NCT01581372|OTHER|Pharmacist care|Pharmacist prescribing, education, drug management
214435810|NCT02346526|PROCEDURE|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
214435811|NCT02346526|PROCEDURE|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
214435812|NCT02346526|PROCEDURE|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
214435813|NCT02346526|DRUG|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
214435814|NCT02346526|PROCEDURE|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
214435815|NCT04340479|DIAGNOSTIC_TEST|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
214435816|NCT01840826|OTHER|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
214435817|NCT06020313|DIETARY_SUPPLEMENT|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
214435818|NCT05221281|BEHAVIORAL|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
214435819|NCT05221281|BEHAVIORAL|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
214435820|NCT02652689|RADIATION|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
214435821|NCT02209415|BEHAVIORAL|standard follow-up|Outpatient clinic visits
214435822|NCT02209415|PROCEDURE|PET/CT and EUS|PET/CT and EUS
214435823|NCT00194896|DRUG|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
214435824|NCT00194896|DRUG|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
214435825|NCT00677469|DRUG|Cholestyramine|2 grams BID
214435826|NCT00677469|DRUG|Cholestyramine|1 gram BID
214435827|NCT00677469|DRUG|Placebo powder|1 gram BID
214435828|NCT02818335|DRUG|LY3023414 Reference Fasted|Administered Orally
214435829|NCT02818335|DRUG|LY3023414 Test Fasted|Administered Orally
214435830|NCT02818335|DRUG|LY3023414 Test Fed|Administered Orally
215115804|NCT01996085|DRUG|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"
215115805|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
215115806|NCT01996085|DRUG|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"
215115807|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
215115808|NCT01996085|DRUG|Amlodipine|1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
215115809|NCT01996085|DRUG|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
215115810|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
214435831|NCT05424796|COMBINATION_PRODUCT|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
214435832|NCT05424796|COMBINATION_PRODUCT|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
214435833|NCT05424796|DEVICE|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
214435834|NCT00663624|DRUG|aspart insulin|subcutaneous aspart insulin every 2 hours
215115811|NCT01996085|DRUG|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
215115812|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
215115813|NCT01996085|DRUG|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
214435835|NCT00663624|DRUG|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
214435836|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
214435837|NCT02405013|DRUG|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
214435838|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
215115814|NCT02197091|OTHER|questionnaire administration|Ancillary studies
214435839|NCT02405013|DRUG|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
214516259|NCT01338532|OTHER|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
214516260|NCT01338532|OTHER|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
215115815|NCT02197091|OTHER|medical chart review|Ancillary studies
215115816|NCT00186901|DRUG|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
214516261|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
214516262|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
215115817|NCT00186901|OTHER|Placebo|Placebo
215115818|NCT04079075|OTHER|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
215115819|NCT04079075|BEHAVIORAL|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
214516263|NCT02742805|DRUG|Omalizumab|Standard of care dose.
215115820|NCT04079075|BEHAVIORAL|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
215115821|NCT04079075|BEHAVIORAL|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
215115822|NCT04079075|DIAGNOSTIC_TEST|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
215115823|NCT03848936|OTHER|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
214516264|NCT06301620|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
215115824|NCT02955537|OTHER|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
215115825|NCT00525005|DRUG|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
214435840|NCT05293431|OTHER|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
214435841|NCT05293431|OTHER|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
214516265|NCT06301620|BEHAVIORAL|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
214516266|NCT00251199|DRUG|VX-950|
214516267|NCT00251199|DRUG|peginterferon|
214516268|NCT01018550|DRUG|AMG 853|AMG 853 5 mg (BID)
215115826|NCT05130749|OTHER|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
215115827|NCT02921490|DEVICE|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
215115828|NCT05138627|OTHER|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
215115829|NCT05179525|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
215115830|NCT05179525|DRUG|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
215115831|NCT02682992|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
215115832|NCT03618862|BIOLOGICAL|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
215115833|NCT03274063|OTHER|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
215115834|NCT03274063|OTHER|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
214435842|NCT01006577|PROCEDURE|side-to-end anastomosis|Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
214435843|NCT01006577|PROCEDURE|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
214435844|NCT01248936|DRUG|RO5185426|
214435845|NCT01086826|DRUG|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
214435846|NCT01086826|DRUG|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
214435847|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
214435848|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
214435849|NCT06967051|DRUG|Tetrahydrocannabinol (10 mg)|10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule
214435850|NCT06967051|DRUG|Tetrahydrocannabinol (25 mg)|25 mg of THC provided as a softgel capsule.
214435851|NCT06967051|DIAGNOSTIC_TEST|Pupillary Light Reflex (PLR) Test|SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)
214435852|NCT06967051|DIAGNOSTIC_TEST|Pupillometer|NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.
214435853|NCT06243094|DRUG|Antibiotic|All antibiotic therapy characteristics are monitored.
214435854|NCT05933213|DRUG|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
214435855|NCT05933213|DRUG|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
214435856|NCT05933213|DRUG|Glucocorticoids|glucocorticoids
214435857|NCT00258297|DRUG|gefitinib|
214435858|NCT00258297|PROCEDURE|conventional surgery|
214435859|NCT00258297|PROCEDURE|enzyme inhibitor therapy|
214435860|NCT00258297|PROCEDURE|neoadjuvant therapy|
214435861|NCT00258297|PROCEDURE|protein tyrosine kinase inhibitor therapy|
214435862|NCT00258297|PROCEDURE|surgery|
214516269|NCT01018550|DRUG|AMG 853|AMG 853 200 mg (QD)
214516270|NCT01018550|DRUG|AMG 853|AMG 853 25 mg (BID)
214516271|NCT01018550|DRUG|AMG 853|AMG 853 100 mg (BID)
215115835|NCT00881816|DRUG|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
214516272|NCT01018550|DRUG|Placebo|Placebo
214516273|NCT04849091|DEVICE|iReadMore|Digital Alexia Therapy
214516274|NCT03434106|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
214516275|NCT03434106|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
214516276|NCT05922774|DEVICE|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
214516277|NCT04727099|DEVICE|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
215115836|NCT03156283|BEHAVIORAL|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
215115837|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
214435863|NCT03930420|BEHAVIORAL|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
214435864|NCT04854772|BEHAVIORAL|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
214435865|NCT04556981|BIOLOGICAL|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
214435866|NCT04556981|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
214435867|NCT00144066|DRUG|platinum-based chemotherapy alone (up to six cycles)|
214435868|NCT00144066|DRUG|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
214516278|NCT01992497|DIETARY_SUPPLEMENT|Probiotic|
214516279|NCT00446095|DRUG|fostamatinib|200 mg PO BID
214516280|NCT05434507|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
214516281|NCT03155399|OTHER|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
214516282|NCT03155399|OTHER|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
214435869|NCT06518070|DIAGNOSTIC_TEST|Cerviray AI|Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.
214516283|NCT05128799|OTHER|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
214435870|NCT05770427|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
214435871|NCT06565065|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant
214435872|NCT06565065|OTHER|Sham Light Touch|A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.
214435873|NCT06565065|OTHER|Exercise Protocol|A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.
214435874|NCT03079817|OTHER|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
214435875|NCT03079817|OTHER|Proprioceptive Drills|Active balance and proprioception drills
214435876|NCT04595305|DEVICE|Cardiac resynchronization therapy by CRT-P or CRT-D implantation|Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
214435877|NCT05188118|DRUG|Cabozantinib|60mg oral once daily for 12 weeks
214435878|NCT05188118|DRUG|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
214435879|NCT05188118|DRUG|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
214435880|NCT05188118|DRUG|Lenvatinib|18mg oral once daily for 12 weeks
214435881|NCT05188118|DRUG|Everolimus|5mg oral once daily for 12 weeks
214435882|NCT04163042|BEHAVIORAL|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
214516284|NCT02595788|OTHER|Change from supine to prone position|Change from supine to prone position
215115838|NCT05141461|PROCEDURE|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
214435883|NCT00609336|DRUG|gemcitabine hydrochloride|Given IV
214435884|NCT00609336|DRUG|docetaxel|Given IV
214435885|NCT00609336|DRUG|capecitabine|Given PO
214435886|NCT00609336|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214435887|NCT00609336|DRUG|oxaliplatin|Given IV
214435888|NCT00609336|PROCEDURE|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
214435889|NCT00609336|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
214435890|NCT00609336|OTHER|laboratory biomarker analysis|Correlative studies
214435891|NCT05712694|DRUG|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
214435892|NCT05712694|OTHER|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
214435893|NCT05742815|OTHER|No intervention|This is an observational collection of data from purchased donor milk samples
214435894|NCT02238483|DRUG|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
214435895|NCT02238483|DRUG|Placebo|Inhaled placebo solution
214435896|NCT01322477|OTHER|F18-FDG PET/CT|
214435897|NCT05305846|DEVICE|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
215115839|NCT05141461|PROCEDURE|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
215115840|NCT01628055|BIOLOGICAL|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
214435898|NCT01388361|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
214435899|NCT01388361|DRUG|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
214435900|NCT01388361|DRUG|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
214435901|NCT05320666|BEHAVIORAL|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
214435902|NCT01595334|DRUG|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm
214435903|NCT01595334|DRUG|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
214435904|NCT06057116|OTHER|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
214435905|NCT03481608|OTHER|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
214435906|NCT03481608|OTHER|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
214435907|NCT01297101|DRUG|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
214435908|NCT00539734|DRUG|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
214435909|NCT01945125|OTHER|rhTSH Group|Patients receiving rhTSH for RIT stimulation
214435910|NCT00355095|DRUG|Erythropoietin|intravenous daily 3.3 \*10\^4 Units, duration 3 days
214435911|NCT01061034|DRUG|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
214435912|NCT06261606|OTHER|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131"
214435913|NCT00004104|BIOLOGICAL|liposomal interleukin-2|
214435914|NCT00004104|BIOLOGICAL|polyvalent melanoma vaccine|
214435915|NCT00004104|BIOLOGICAL|recombinant interferon alfa|
214435916|NCT03991286|DIETARY_SUPPLEMENT|Astaxanthin 8 mg|experimental
214435917|NCT03991286|OTHER|placebo|Matching placebo pill
214435918|NCT01691846|DRUG|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
214435919|NCT01691846|DRUG|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
214435920|NCT02000349|OTHER|PGD|PGD using Next generation sequencing
214435921|NCT05079646|OTHER|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
214516285|NCT06500403|DIAGNOSTIC_TEST|liver and stiffness measurement|liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
214516286|NCT03713229|DIAGNOSTIC_TEST|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
214435922|NCT03320746|DEVICE|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
214435923|NCT01514344|DRUG|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
214435924|NCT01514344|BIOLOGICAL|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
214516287|NCT02393456|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
214435925|NCT02093312|DIETARY_SUPPLEMENT|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
214435926|NCT03175861|OTHER|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
214435927|NCT05033938|PROCEDURE|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
214435928|NCT05033938|PROCEDURE|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
214435929|NCT00049790|DRUG|recombinant human Angiostatin protein|
214435930|NCT00049790|DRUG|paclitaxel|
214435931|NCT00049790|DRUG|carboplatin|
214435932|NCT04643899|DEVICE|Muscle Electrostimulation|"* Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
214435933|NCT01070069|DEVICE|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
214435934|NCT01070069|DEVICE|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
214435935|NCT01070069|DEVICE|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
214435936|NCT05876143|DEVICE|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
214435937|NCT02668250|PROCEDURE|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
214435938|NCT02668250|PROCEDURE|Usual Care|Patients receive the usual care.
214516288|NCT02393456|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
214516289|NCT04413175|OTHER|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
214516290|NCT01589211|BEHAVIORAL|Brief advice|Brief advice of about 10 min accompanied by self-help material
215115841|NCT01628055|OTHER|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
214516291|NCT01589211|BEHAVIORAL|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
214516292|NCT01589211|BEHAVIORAL|Standard cessation course|Cessation course over 6 dates. Group setting.
214516293|NCT04014686|OTHER|No exercise intervention group|no exercise intervention
215115842|NCT04918511|DRUG|OPD5|OPD5 solution for i.v. infusion
215115843|NCT04992845|DEVICE|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
214435939|NCT00002542|DRUG|CMF regimen|
214435940|NCT00002542|DRUG|cyclophosphamide|
215115844|NCT02656953|OTHER|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
215115845|NCT02656953|OTHER|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
215115846|NCT02121249|DEVICE|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
215115847|NCT02121249|PROCEDURE|free hand technique|"No specific device is necessary in the free hand technique"
214435941|NCT00002542|DRUG|doxorubicin hydrochloride|
214435942|NCT00002542|DRUG|epirubicin hydrochloride|
214435943|NCT00002542|DRUG|fluorouracil|
214435944|NCT00002542|DRUG|methotrexate|
214435945|NCT00002542|DRUG|tamoxifen citrate|
214435946|NCT00002542|RADIATION|radiation therapy|
214435947|NCT05386953|DRUG|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
214435948|NCT05386953|DRUG|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
214435949|NCT06150287|OTHER|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
214435950|NCT03742050|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
214435951|NCT02434744|DRUG|KD026|Dosed in combination
214435952|NCT02434744|DRUG|Placebo|Dosed in combination
214435953|NCT02434744|DRUG|Metformin|Drug prescribed by each subject's prescribing physician
214435954|NCT05521061|DIETARY_SUPPLEMENT|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
214435955|NCT04948801|DRUG|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
214435956|NCT04290013|DRUG|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
214435957|NCT04290013|DRUG|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
214435958|NCT00971724|DRUG|Placebo|Oral administration, once daily, for 15 days
214435959|NCT00971724|DRUG|Prednisolone|Oral administration
214435960|NCT00991107|DRUG|HE3286|HE3286 20 mg (10 mg BID) for 28 days
214516294|NCT04014686|BEHAVIORAL|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
214435961|NCT03635151|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
214435962|NCT03635151|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
215115848|NCT02709603|DRUG|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
215115849|NCT02709603|DRUG|placebo|oral placebo; 2 tablets 30 minutes before the procedure
214435963|NCT06322316|PROCEDURE|The Ultrasound-guided Retrolaminar Block Group|"The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture."
214435964|NCT06322316|PROCEDURE|The Ultrasound-guided Erector Spinae Plane Block Group|"The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected."
214435965|NCT03631550|DEVICE|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
214435966|NCT03631550|DEVICE|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
214435967|NCT01823133|DRUG|gemigliptin only|gemigliptin 50mg qd on day 1\~7
214435968|NCT01823133|DRUG|rosuvastatin only|rosuvastatin 20mg qd on day 1\~7
214435969|NCT01823133|DRUG|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
214435970|NCT05330234|DEVICE|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
214435971|NCT05848609|DIAGNOSTIC_TEST|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
214435972|NCT03314675|DEVICE|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
214435973|NCT00566072|BEHAVIORAL|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
214435974|NCT02541461|PROCEDURE|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
214435975|NCT03429972|DEVICE|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
214435976|NCT03429972|DRUG|Paclitaxel|80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
214435977|NCT01877343|DEVICE|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
214435978|NCT01137708|DRUG|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
214435979|NCT01137708|DRUG|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
214435980|NCT05265481|DEVICE|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
214435981|NCT05265481|DEVICE|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
214435982|NCT05265481|DEVICE|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
214435983|NCT01566968|OTHER|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
214435984|NCT01566968|OTHER|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
214435985|NCT01566968|OTHER|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
214435986|NCT00440011|DRUG|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
214435987|NCT00440011|DRUG|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
214435988|NCT01837472|DRUG|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
214435989|NCT01837472|DRUG|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
214435990|NCT00822367|DIETARY_SUPPLEMENT|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
214435991|NCT02035670|OTHER|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
214435992|NCT03208491|OTHER|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
214435993|NCT03208491|OTHER|usual care|usual care of patient
214435994|NCT03760354|DRUG|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
214435995|NCT03760354|OTHER|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
214435996|NCT00419341|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration|
214435997|NCT06003517|PROCEDURE|Screening with PSI check list|Screening PSI with institutional check list
214435998|NCT00004387|PROCEDURE|fetal nigral transplantation|
214435999|NCT04141514|OTHER|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
214436000|NCT00168753|DRUG|Alefacept|IM
214436001|NCT06971432|PROCEDURE|Group SAPB|Using ultrasound guidance, the needle is advanced in-plane at approximately 45° toward the fifth rib. For the superficial SAPB, the local anesthetic is injected anteriorly to the serratus anterior in the plane created with the latissimus dorsi muscle. The thoracodorsal artery runs in this plane, and while care should be taken not to puncture this vessel, the spread of the injectate around the vessel confirms the appropriate injection plane. For the deep SAPB, the local anesthetic is injected anteriorly to the rib and deep to the serratus anterior. Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment. All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered.
214436002|NCT06971432|PROCEDURE|Group SAPB + LIA|"SAPB is applied similarly to the other group.Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment.At the end of the surgical procedure, while the incision line is still open, a catheter will be placed in the subcutaneous tissue, at the most lateral part of the incision. A 0.20% bupivacaine solution will be prepared and at the end of the operation, a 10 ml bolus will be administered, followed by a 2 ml/hour infusion for 48 hours.~All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered."
214436003|NCT06342999|PROCEDURE|Fetal Aortic Valvuloplasty Procedure|Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.
214436004|NCT06342999|DEVICE|Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter|Balloon Catheter
214436005|NCT06342999|DEVICE|Trek RX and Mini Trek RX Coronary Dilatation Catheter|Coronary Dilation Catheter
214436006|NCT04200365|DRUG|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
214436007|NCT02792374|OTHER|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
214436008|NCT00014599|DRUG|paclitaxel|
214436009|NCT06012331|PROCEDURE|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
214436010|NCT06012331|PROCEDURE|Blood Clot (BC)|"1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
214436011|NCT03617978|PROCEDURE|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
214436012|NCT01281163|DRUG|Akt Inhibitor MK2206|Given PO
214436013|NCT01281163|OTHER|Laboratory Biomarker Analysis|Correlative studies
214436014|NCT01281163|DRUG|Lapatinib Ditosylate|Given PO
214436015|NCT01281163|OTHER|Pharmacogenomic Study|Correlative studies
214436016|NCT01281163|OTHER|Pharmacological Study|Correlative studies
214436017|NCT00000699|DRUG|Inosine pranobex|
214436018|NCT00000699|DRUG|Ribavirin|
214436019|NCT01717677|PROCEDURE|radical prostatectomy|
214436020|NCT01717677|RADIATION|percutaneous radiation therapy|
214436021|NCT01717677|RADIATION|permanent seed implantation|
214436022|NCT01717677|PROCEDURE|Active Surveillance|
214436023|NCT04152694|OTHER|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
214436024|NCT05075213|BEHAVIORAL|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
214436025|NCT05075213|BEHAVIORAL|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
214436026|NCT05075213|BEHAVIORAL|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
214436027|NCT03837431|DIAGNOSTIC_TEST|Skin slit|Skin slit microscopy, RDT and PCR
214436028|NCT03837431|DIAGNOSTIC_TEST|Dental broach|Dental broach RDT and PCR
214436029|NCT03837431|DIAGNOSTIC_TEST|Tape disc|Tape disc PCR
214436030|NCT01268813|OTHER|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
214436031|NCT00711217|OTHER|Medical Food|twice daily
214436032|NCT00711217|OTHER|Drink mix calorically similar to experimental product|twice daily
214436033|NCT05486897|OTHER|None, pure observational study|None, pure observational study
214436034|NCT02336386|DRUG|CDD|Chemotherapy
214436035|NCT02336386|DRUG|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
214436036|NCT03799783|DRUG|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
214436037|NCT04152317|DRUG|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
214436038|NCT04152317|DRUG|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
214436039|NCT00995306|DRUG|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
214436040|NCT02711059|PROCEDURE|parathyroidectomy|surgical treatment of hyperparathyroidism
214436041|NCT02020252|BEHAVIORAL|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
214436042|NCT02793154|DRUG|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
214436043|NCT02793154|DRUG|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
214436044|NCT01323231|BEHAVIORAL|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
214436045|NCT03641703|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
214436046|NCT04292132|PROCEDURE|Implant placement|interforaminal placement of 2 implants
214516295|NCT06197035|PROCEDURE|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
214516296|NCT06197035|PROCEDURE|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
214516297|NCT03717558|DRUG|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
214516298|NCT03717558|DRUG|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
214516299|NCT03717558|DRUG|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
214516300|NCT00409747|DRUG|Minocycline|
215115850|NCT05906459|DIAGNOSTIC_TEST|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
214516301|NCT00817739|DRUG|Leuprorelin|Leuprorelin injection
214516302|NCT00817739|DRUG|Flutamide|Flutamide tablets
214516303|NCT00098735|DRUG|FTY720|
214436047|NCT04292132|PROCEDURE|immediate loading|immediate loading with a locator retained mandibular overdenture
214436048|NCT04292132|PROCEDURE|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
214436049|NCT00616668|DEVICE|Air- Limb|
214436050|NCT01000597|DRUG|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
214516304|NCT03132571|DRUG|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
214516305|NCT03132571|DRUG|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
214516306|NCT03132571|OTHER|Placebo|Oral placebo taken once daily for the course of the study (16 week)
215115851|NCT02331667|OTHER|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
215115852|NCT02331667|OTHER|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
215115853|NCT00020124|DRUG|doxorubicin hydrochloride|
214436051|NCT04783246|BEHAVIORAL|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
214436052|NCT04783246|OTHER|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
214436053|NCT06215092|OTHER|Psychological assessment|Psychological assessment of cognitive and social-emotional functioning.
214436054|NCT06233500|PROCEDURE|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used"
214436055|NCT02283242|DRUG|Galantamine|Oral use for 12 weeks
214516307|NCT05688891|OTHER|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
214516308|NCT05688891|OTHER|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
214516309|NCT01741207|DRUG|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
214516310|NCT00165035|DEVICE|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
214516311|NCT00165035|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
214516312|NCT05567848|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
214516313|NCT01790542|OTHER|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
214516314|NCT01790542|OTHER|Iron fortified cereal with fruit|
214516315|NCT01790542|OTHER|Meat|
215115854|NCT02363959|DRUG|Hyperbaric Oxygen Therapy|2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
214516316|NCT01916109|DRUG|Gemcitabine|
214516317|NCT01916109|DRUG|Carboplatin|
214516318|NCT01916109|DRUG|Panitumumab|
214516319|NCT01916109|PROCEDURE|radical cystectomy|
215115855|NCT02363959|PROCEDURE|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
215115856|NCT04168099|DRUG|Cefotaxime|Cefotaxime IV
215115857|NCT04168099|DRUG|Gemifloxacin|Gemifloxacin oral
214436056|NCT02283242|DRUG|Placebo (for galantamine)|Oral use for 12 weeks
214436057|NCT02703701|BEHAVIORAL|Physician at triage|A physician embedded at triage
214436058|NCT02703701|OTHER|Usual Care|No physician at triage
214436059|NCT00694447|PROCEDURE|Acupuncture|
214436060|NCT03399916|BEHAVIORAL|Prompt sent|
214436061|NCT00886756|DRUG|AZD8529|Oral
214436062|NCT00886756|DRUG|Placebo|Oral
214436063|NCT04113798|OTHER|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
214436064|NCT04113798|OTHER|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
214436065|NCT04113798|OTHER|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
215115858|NCT04422704|BEHAVIORAL|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
214436066|NCT04113798|BEHAVIORAL|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
214436067|NCT04113798|BEHAVIORAL|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
214436068|NCT04113798|OTHER|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
214516320|NCT00001806|OTHER|Genetic Education and Counseling|Group Education and Counseling
214516321|NCT00001806|OTHER|Genetic Education and Counseling|Individual Education and Counlseing
214516322|NCT03987815|DRUG|Nivolumab|Nivolumab
214516323|NCT05924373|DRUG|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
214516324|NCT00490906|DRUG|Copaxone|20 mg, subcutaneous injections, taken daily
214516325|NCT00490906|DRUG|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
214516326|NCT00490906|DRUG|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
214516327|NCT01036932|DRUG|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
214436069|NCT04597203|DEVICE|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
214436070|NCT04597203|DRUG|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
214436071|NCT02728765|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
214436072|NCT05485389|OTHER|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
214436073|NCT04638322|OTHER|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
214436074|NCT01538719|DRUG|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
214436075|NCT01538719|OTHER|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
214436076|NCT02971085|PROCEDURE|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
214436077|NCT05623553|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
214436078|NCT00018603|DRUG|guanfacine|
214436079|NCT06014216|OTHER|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
214436080|NCT06014216|OTHER|Water|Water from tap, one cup given by recovery nurses.
214436081|NCT03657030|DRUG|CVN424|SAD / MAD
214516328|NCT01036932|DRUG|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
214436082|NCT03657030|DRUG|Placebo|Placebo
214436083|NCT05239013|DRUG|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
214436084|NCT04877340|DEVICE|needle punction|EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
214436085|NCT06093204|OTHER|Dietary evaluation|Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
214436086|NCT02703558|DRUG|Phenazopyridine|
214436087|NCT02703558|DRUG|Fluorescein|
214436088|NCT00645034|DRUG|placebo|placebo by mouth as a single dose
214516329|NCT03032965|DRUG|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
214436089|NCT00645034|DRUG|sildenafil|sildenafil 100 mg by mouth as a single dose
214436090|NCT01030107|BEHAVIORAL|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
214436091|NCT01030107|BEHAVIORAL|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
214436092|NCT03664960|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
214436093|NCT06394375|DRUG|Dexmedetomidine|OFA
214436094|NCT06394375|DRUG|Fentanyl|Given as analgesia in opioid balanced anesthesia (control) group
214436095|NCT04761536|OTHER|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
214436096|NCT05729997|OTHER|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
214436097|NCT06294834|OTHER|Part 1 of intervention A - Wheelchair skills training modules|"Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair"
214436098|NCT06294834|OTHER|Part 2 of intervention A - Asynchronous feedback from a remote trainer|Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
214436099|NCT06294834|OTHER|Intervention B: Education on wheelchair provision|Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
214436100|NCT03401138|OTHER|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
214436101|NCT01616888|DEVICE|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
214436102|NCT05054920|OTHER|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
214436103|NCT05054920|OTHER|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
214436104|NCT05054920|OTHER|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
214436105|NCT01616472|DRUG|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
214436106|NCT01893970|BEHAVIORAL|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
214436107|NCT01893970|BEHAVIORAL|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
214436108|NCT05301543|BEHAVIORAL|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
214436109|NCT05301543|BEHAVIORAL|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
214436110|NCT05005728|COMBINATION_PRODUCT|vudalimab + carboplatin + cabazitaxel|Vudalimab IV, carboplatin IV, cabazitaxel IV
214436111|NCT05005728|COMBINATION_PRODUCT|vudalimab + olaparib|Vudalimab IV, olaparib oral
214436112|NCT05005728|BIOLOGICAL|vudalimab monotherapy|Vudalimab IV
214436113|NCT05005728|COMBINATION_PRODUCT|vudalimab + docetaxel|Vudalimab IV, docetaxel IV
214436114|NCT05005728|COMBINATION_PRODUCT|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
214436115|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
214436116|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
214436117|NCT04999826|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
214436118|NCT04999826|OTHER|Quality-of-Life Assessment|Ancillary studies
214436119|NCT04999826|OTHER|Questionnaire Administration|Complete questionnaires
215115859|NCT01511016|DRUG|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
214516330|NCT03032965|DRUG|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
214436120|NCT06981702|OTHER|Exercise|. In our study, demographic information (age, gender, height, weight, education, marital status, occupation, where and with whom they live), additional diseases, medications used, whether they live in a rural or urban area, whether they have had any sleep problems before, and whether they have had any psychiatric diagnoses before will be recorded for all subjects. Before the exercise, students will fill out the Pittsburgh Sleep Quality Index to determine their sleep quality, the Morningness-Eveningness Scale to assess their chronotype, and the Beck Depression Inventory to measure their depressive symptom levels, and the results will be recorded. Students taking the body mechanics course will be asked to do aerobic exercises they learned in class, three days a week, including warm-up and cool-down, for a total of 60 minutes of exercise. The exercises will be performed on the same days and times each week. All exercises performed by the students for 8 weeks will be monitored by the resea
214436121|NCT06675968|PROCEDURE|Direct Suture|A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
214436122|NCT06675968|PROCEDURE|Transosseus Suture|A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
214436123|NCT06214897|DIETARY_SUPPLEMENT|C-RUSF (Ready-to-use Supplemental Food with added Choline)|Ready-to-use Supplemental Food with added Choline
214436124|NCT06214897|DIETARY_SUPPLEMENT|S-RUSF (Ready-to-use Supplemental Food without added Choline)|Standard Ready-to-use Supplemental Food
214436125|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
214436126|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
214436127|NCT06936449|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells
214436128|NCT06936449|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
214436129|NCT06932926|DRUG|Egg shell hydrogel|"I. Nano-eggshell powder preparation: After cleaning, A small crack will be made in each eggshell to split it into two halves to evacuate the content. The eggshells will be disinfected in a hot water at 100°C for 10 minutes to facilitate the detachment of the inner membrane. They will be exposed to steam sterilization. Then they will be crushed using a sterile mortar and pestle. The crushed particles will be milled using a zirconia ball-milling machine at 200 rpm . This will result in a nano-sized eggshell powder to incorporate them into a gel form.~II. Preparation of eggshell hydrogel formulations: through dispersing a suitable concentration of egg shell powder in distilled water, followed by dissolving the gelling agent; sodium carboxymethyl cellulose at a concentration of 5-10% under continuous stirring. The formed hydrogel will be kept at 8°C for a period of 24 hours before further use. This will produce a paste of consistency that is appropriate for handling and application."
214436130|NCT06932926|DRUG|Fluoride varnish|five percent sodium fluoride varnish (Charm varnish -Dentkist- Korea).
214516331|NCT00165048|DRUG|Vioxx (Rofecoxib)|
214516332|NCT01821040|DRUG|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
214516333|NCT01821040|DRUG|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
214516334|NCT00636168|DRUG|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
214516335|NCT00636168|DRUG|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
214436131|NCT06940492|OTHER|Dry needling|Dry needling is a force-based manipulation technique used by health care providers. Force-based manipulation describes when forces external to the body are passively applied to tissue with a therapeutic intent. During dry needling, a filiform needle (i.e., one without medication) is inserted into a muscle to target a trigger point, often times with the intent of eliciting a localized twitch response
214436132|NCT05678088|BEHAVIORAL|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
214436133|NCT05678088|BEHAVIORAL|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
214516336|NCT02033915|OTHER|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
214516337|NCT01634295|DRUG|CKD-828 2.5/40mg|"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
214516338|NCT01634295|DRUG|CKD-828 5/40mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
214516339|NCT01634295|DRUG|CKD-828 5/80mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."
214516340|NCT01634295|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."
214516341|NCT01634295|DRUG|S-amlodipine 5mg|"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."
214516342|NCT02951702|DRUG|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
214516343|NCT01870895|DRUG|YM060|oral
214516344|NCT01870895|DRUG|Placebo|oral
214436134|NCT03971448|DEVICE|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
214436135|NCT03971448|DEVICE|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
214436136|NCT04708509|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
214436137|NCT04870645|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
214436138|NCT04870645|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
214436139|NCT04870645|DRUG|Gadolinium-Chelate|Contrast agent
214436140|NCT04870645|DRUG|Iopamidol|Contrast agent
214436141|NCT04888169|DEVICE|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
214436142|NCT04888169|DEVICE|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
214436143|NCT04888169|DEVICE|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
214436144|NCT04888169|DEVICE|SMART Mobile App - Control|Participants will only answer questions.
214436145|NCT04046224|BIOLOGICAL|ST-920|Single dose of investigational product ST-920
214436146|NCT04650386|BEHAVIORAL|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
214436147|NCT05720884|DEVICE|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
214436148|NCT05720884|DEVICE|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
214436149|NCT05002257|OTHER|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
214436150|NCT05002257|OTHER|No music therapy|Usual care
214436151|NCT05026749|DRUG|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
214436152|NCT05026749|OTHER|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
215115860|NCT01511016|DRUG|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
215115861|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
215115862|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
215115863|NCT00950248|DRUG|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
215115864|NCT00950248|OTHER|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
215115865|NCT01303198|DEVICE|APAP - Therapy|automatic positive pressure therapy
215115866|NCT02240511|DIETARY_SUPPLEMENT|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
215115867|NCT02240511|OTHER|Resistance Exercise|
215115868|NCT05397249|BEHAVIORAL|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
214436153|NCT05941234|OTHER|Biological biomarker analysis|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
214436154|NCT03783026|DRUG|Apremilast|Tablets for oral administration
214436155|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
215115869|NCT06026878|DRUG|gemcitabine,nimotuzumab, toripalimab|same as before
214436156|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
214436157|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
214436158|NCT05255146|DEVICE|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
214436159|NCT03239626|RADIATION|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
214436160|NCT06075446|BEHAVIORAL|ACT Raising Safe Kids|American Psychological Association ACT Raising Safe Kids
214436161|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
214436162|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
214436163|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
214436164|NCT01143298|DRUG|LEO 27847 oral solution|
214436165|NCT04156581|DRUG|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
214436166|NCT04156581|DRUG|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
214436167|NCT04156581|OTHER|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
215115870|NCT06026878|DRUG|gemcitabine, cisplatin|same as before
215115871|NCT02578199|BEHAVIORAL|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
215115872|NCT06038422|DRUG|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
215115873|NCT00535119|DRUG|Carboplatin|Given IV
215115874|NCT00535119|OTHER|Laboratory Biomarker Analysis|Correlative studies
215115875|NCT00535119|DRUG|Paclitaxel|Given IV
215115876|NCT00535119|OTHER|Pharmacological Study|Correlative studies
215115877|NCT00535119|DRUG|Veliparib|Given PO
214436168|NCT03602612|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
214436169|NCT03602612|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
214436170|NCT03602612|BIOLOGICAL|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
214436171|NCT05568615|DRUG|MT-1186|Suspension
214436172|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
214436173|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
214436174|NCT03947827|DRUG|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
214436175|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
214436176|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
214436177|NCT05722522|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
214436178|NCT05722522|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
214436179|NCT06780059|RADIATION|Adjuvant Radiotherapy|Postoperative Radiotherapy with 3D-CRT and IMRT Techniques Following R0 Resection in BoPT and MPT Patients
214436180|NCT06780059|PROCEDURE|R0 resection|Patients who received R0 resection (complete resection without tumor margin)
214436181|NCT06780397|DIAGNOSTIC_TEST|Joint ultrasonography|"Patients will undergo rheumatologic visits at baseline and scheduled follow-ups.~Rheumatologic visit procedures:~* collection of patients' anamnesis of rheumatologic diaseases.~* identification of painful and/or swollen joints and enthesis.~* evaluation of joint and enthesis pain.~* joint ultrasonography and assessment of joint structures and enthesis."
214516345|NCT01622023|PROCEDURE|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
215115878|NCT00230542|DRUG|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
215115879|NCT00230542|DRUG|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
215115880|NCT02329899|OTHER|Second step of investigations|"Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia."
215115881|NCT04667546|OTHER|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
215115882|NCT05400772|OTHER|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
215115883|NCT03151187|OTHER|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
215115884|NCT00148876|DRUG|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
215115885|NCT00148876|DRUG|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
215115886|NCT04791631|PROCEDURE|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
214436182|NCT06780397|OTHER|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0|"Patients will undergo dermatologic visits at baseline and scheduled follow-ups.~Dermatologic visit procedures:~* collection of patients' oncologic anamnesis and general personal and lifestyle information.~* administration of the quality of life questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0) to assess the impact of rheumatologic adverse events on patients' quality of life."
214436183|NCT06835790|DIAGNOSTIC_TEST|Ph-measurement|Ph measurement before and after the surgery
214436184|NCT06835790|OTHER|Questionnaires|GERD-HRQL Reflux symptom index scale before and after surgery
214436185|NCT06835790|DIAGNOSTIC_TEST|gastroduodenal transit|Imaging test that uses the properties of X-rays - after the administration of a radiopaque contrast agent (usually barium) - to visualize the upper digestive tract: the esophagus, stomach, and duodenum (the upper segment of the small intestine).
214436186|NCT06834802|PROCEDURE|PRF|PRF membrane will be used for soft tissue grafting around implant
214436187|NCT06834802|PROCEDURE|Human amniotic membrane|Human amniotic membrane will be used for soft tissue grafting around implan
214516346|NCT06473571|OTHER|Intervention Protocol (The 3GT)|"Participants will be asked to identify three things that went well that day and their role for this occurring \[What went well today, and what was your role in making it happen? as adapted from (Sexton \& Adair, 2019)\]. They will be asked to engage in this exercise for 15 days during the evening."
214516347|NCT06473571|OTHER|Control Group|Participants will be asked to reflect on early memories of their life, with no specific prompts provided, for 15 days during the evening. This activity is consistent with prior efficacy studies of 3GT (Seligman et al., 2005).
215115887|NCT05175742|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
215115888|NCT05175742|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
215115889|NCT05175742|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
215115890|NCT04629690|OTHER|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
215115891|NCT04109326|OTHER|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
214436188|NCT06834802|PROCEDURE|No grafting|No soft tissue grafting around implant
214436189|NCT06782438|OTHER|artificial intelligence algorithm|to apply an artificial intelligence algorithm to treat the imaging
214436190|NCT06790901|PROCEDURE|LUNG ULTRASOUND|Determination of atelectsis By Lung Ultrasound Score
215115892|NCT04209933|DRUG|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
215115893|NCT04209933|DRUG|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
215115894|NCT04209933|DRUG|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
215115895|NCT04209933|DRUG|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
215115896|NCT02267538|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
215115897|NCT02267538|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery."
214516348|NCT04109651|OTHER|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
215115898|NCT00576225|DRUG|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
215115899|NCT00576225|DRUG|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
215115900|NCT00869518|DRUG|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
215115901|NCT00869518|DRUG|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
214436191|NCT06792162|DRUG|Carilizumab and Apatinib|After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
214516349|NCT06202898|OTHER|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
214436192|NCT06783894|BEHAVIORAL|exercise (elliptical training)|twenty irritable bowel syndrome men with sexual dysfunction ( weak erection of penis or erectile dysfunction) will perform ellpitical physical activity (40 minutes on elliptical trainer three times weekly. the duration of physical activity will be 12 weeks.
214436193|NCT06788860|PROCEDURE|Tri-directional Ultrasound-guided Needle Knife Release|"This procedure involves ultrasound-guided tri-directional needle knife release for the treatment of trigger finger. Local anesthesia using 3-5 ml of 1% lidocaine and 0.25% bupivacaine will be administered for patient comfort. It aims to ensure precise tissue dissection while minimizing risks and improving outcomes.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
214436194|NCT06783231|BEHAVIORAL|Identifying with the aggressor|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the aggressor' group will be asked to try to identify, understand and adopt the point of view of Lori (the perpetrator)
214516350|NCT06202898|OTHER|ENTRUST|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
215115902|NCT03413306|DRUG|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
214516351|NCT06202898|OTHER|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
214516352|NCT01960738|OTHER|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
215115903|NCT03413306|DRUG|IST (ATG + CsA)|
215115904|NCT01629277|DEVICE|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
215115905|NCT01629277|DEVICE|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
215115906|NCT03892239|BEHAVIORAL|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
215115907|NCT03892239|BEHAVIORAL|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
215115908|NCT01364025|PROCEDURE|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
215115909|NCT06399250|OTHER|meal service|We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
215115910|NCT04556019|PROCEDURE|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
215115911|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
215115912|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
215115913|NCT00947115|PROCEDURE|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
215115914|NCT00947115|PROCEDURE|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
215115915|NCT01587430|DRUG|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
215115916|NCT01587430|DRUG|standard dose ARA-C|
215115917|NCT01169935|DRUG|Administration of intra-dermal Endorem|single dose, intradermal
215115918|NCT01169935|BIOLOGICAL|Mantoux test|single dose, intradermal
214436195|NCT06783231|BEHAVIORAL|Identifying with the victim|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the victim' group will be asked to try to identify, understand and adopt the point of view of Sophia (the victim)
214436196|NCT06783231|BEHAVIORAL|Neutral|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The control group will be asked to pay attention to the story's details and to try and remember as much details as they can.
214436197|NCT06788665|DEVICE|Medical Device Dermalyser|Dermalyser is an Artificial Intelligence (AI) application (app) that allows medical professionals to take pictures of cutaneous lesions with the help of a smartphone camera. A dermatoscope is connected to the smartphone camera and is used to take the digital image of cutaneous lesions with suspicion of melanoma. Based on image processing algorithms, the app does a detailed analysis of the captured cutaneous lesion. In this clinical investigation, the objective is to test the device performance in a prospective setting in patients with a suspicion of primary cutaneous melanoma, to validate the added AI component. The intended purpose of the device is not to replace the physician's assessment, but rather to assist physicians in their assessment. Consequently, the final device should be regarded as a second opinion to augment clinical decision-making. The ultimate aim is to develop a tool that may augment clinical decision-making.
214436198|NCT06833684|DEVICE|ICE Treatment|Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
214436199|NCT06833684|PROCEDURE|TAI Standard-of-Care Treatment|Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
214436200|NCT06832943|PROCEDURE|Unicorn system|Patients with airway stenosis undergo stent placement with the help of RBS.
214436201|NCT06814184|BEHAVIORAL|app-based nurse-led virtual diabetes care|A nurse-led, app-based behavioral intervention consisting of (1) education via MyChart messaging, (2) problem solving with an action plan via phone, and (3) remote patient monitoring via mySugr app to identify the need to adjust treatment
214436202|NCT04906343|PROCEDURE|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
214436203|NCT05676203|DRUG|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
214436204|NCT05676203|DRUG|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
214436205|NCT05676203|DRUG|Docetaxel|Docetaxel
214436206|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
214436207|NCT03035500|OTHER|Educational Intervention|Receive health education
214436208|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
214436209|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
214436210|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
214436211|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
214436212|NCT06834256|BEHAVIORAL|intermittent fasting|Group A participants followed the IF diet for 6 weeks . intermittent fasting , specifically time-restricted feeding (TRF), involves consuming all of one's energy requirements inside an 8-h.The fasting interval was designated as 16 h, and the other 8-h was the eating period . During the 8-h eating window, the patient consumes a well-balanced meal consisting of 55%-65% carbs, 7%-20% protein, and 15%-30% fat .
214436213|NCT06834256|BEHAVIORAL|low volume high intensity interval training|. Group B engaged in low-volume HIIT exercise (aerobic activity) three times weekly for six weeks. The exercise routine consisted of a 5-min warm-up phase at 70% of MHR, followed by four intervals of 2-min maximum effort cycling sessions (4 × 2 HIIT) compared to a sub-maximal workload at 85%-90% of MHR. The participants engaged in four work bouts, with each bout lasting around 4 min and followed by a 4-min rest period. During the workouts, the participants maintained an HR of 60%-70% of their MHR. This resulted in 8 min of intense physical activity during each training session. Additionally, there was a 5-min cooling down phase at 70% of the MHR. The treatment's intensity was adapted based on the modified Bruce protocol.
214436214|NCT06831656|OTHER|Placebo-Pre|No dietary supplementation prior to undergoing the placebo supplement
214436215|NCT06831656|DIETARY_SUPPLEMENT|Placebo-Post|14 days of supplementation with 25 mg/day hemicellulose crystalline
214436216|NCT06831656|OTHER|Tetraselmis chuii-Pre|No dietary supplementation prior to undergoing the tetraselmis chuii supplement
214436217|NCT06831656|DIETARY_SUPPLEMENT|Tetraselmis chuii-Post|14 days of supplementation with 25 mg/day tetraselmis chuii
214436218|NCT03066843|DRUG|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
215115919|NCT01169935|BIOLOGICAL|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
215115920|NCT01169935|DRUG|Administration of Endorem|single dose, intravenous
215115921|NCT01709656|BIOLOGICAL|MSC|"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
214436219|NCT03066843|DEVICE|Blue light therapy|Subjects will be exposed to blue light
214436220|NCT05741879|BEHAVIORAL|Gamified exercise training|"Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s)."
214436221|NCT05741879|BEHAVIORAL|Standard Care|This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
214436222|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
214436223|NCT03237481|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
214436224|NCT03237481|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
214516353|NCT05068050|PROCEDURE|Horse-assisted therapy|"12 horse-assisted therapy sessions (45 mins each) for 6 weeks.~Each session will comprise the next stages:~Groundwork, Approachment and preparation of the horse, Warm up exercises~Development of the main part (riding):~Introduction - beginning: Breathing control and body awareness, maintain sitting (riding position) while walking on the horse, perceiving the movement Exercises for the postural and balance control: Variations in the walking of the horse, realize different figures in the arena (circles, serpentines, change direction…), Stopping and Walking, Arms situation combined with the movement of the horse All exercises are determined in the track design protocol Exercises for the acquisition of motion skills: Finished the riding with relaxation activities. Final part: Dismount the horse, Unsaddled and unbridle, feedback and goodbye procedure."
214516354|NCT05068050|PROCEDURE|Physical exercise|"12 physical exercise sessions (45 mins each) for 6 weeks. Each session Each session Lessons will be held by physical activity professionals. The proposed exercises are focussed on improving the articular movements, aerobic resistance and the proprioception, always on the premises of No Pain.~Lessons will be divided in three parts :~1\. Warmup - 2. Main part - 3. Return to calm~Lessons will be hold online"
215115922|NCT01709656|DRUG|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
214516355|NCT02296593|DEVICE|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
214516356|NCT03705572|DIETARY_SUPPLEMENT|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
214516357|NCT03705572|OTHER|Placebo|Placebo milk drink.
215115923|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
215115924|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
215115925|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
215115926|NCT01481454|BIOLOGICAL|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
215115927|NCT03058900|DRUG|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
215115928|NCT03058900|OTHER|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
214436225|NCT03237481|DRUG|Saline placebo|Saline placebo by instillation
215115929|NCT03058900|DRUG|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
215115930|NCT04483609|OTHER|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
215115931|NCT04483609|OTHER|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
215115932|NCT05977062|OTHER|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
215115933|NCT05977062|OTHER|Phone call|Phone call at the beginning of the program and at the middle and at the end.
215115934|NCT05977062|OTHER|Online questionnaires|To be completed at week 1, 6, 12 and 24.
215115935|NCT03063905|DRUG|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
215115936|NCT02087969|PROCEDURE|Dry Needling|
215115937|NCT02087969|PROCEDURE|Stretching|
214436226|NCT03237481|DEVICE|Luer-lock applicator|Applicator for instillation
214436227|NCT03237481|DEVICE|Vial access device|Device for withdrawal of drug product
214436228|NCT00788684|DRUG|rituximab|IV infusion once weekly for four doses
215115938|NCT03893500|DEVICE|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
215115939|NCT01228526|DEVICE|PriMatrix|
214436229|NCT00788684|DRUG|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
214436230|NCT03501719|DRUG|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
214436231|NCT03439891|BIOLOGICAL|Nivolumab|Given IV
214436232|NCT03439891|DRUG|Sorafenib|Given PO
215115940|NCT03133351|DEVICE|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
214436233|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
214436234|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
214436235|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
214436236|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
214436237|NCT05661942|DRUG|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
214436238|NCT05661942|OTHER|Placebo|Placebo/ no calcium pre-treatment.
214436239|NCT04511455|DRUG|Cabozantinib|Cabozantinib 60 mg/day peroral
214436240|NCT04780568|DRUG|Osimertinib|Given PO
214436241|NCT04780568|DRUG|Tegavivint|Given IV
214436242|NCT03915418|PROCEDURE|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
214436243|NCT03731455|DEVICE|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
214436244|NCT06365385|OTHER|Carbohydrate-last meal pattern|Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
214436245|NCT06365385|OTHER|Carbohydrate-first meal pattern|White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
215115941|NCT01659684|BIOLOGICAL|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
214436246|NCT05132114|DIAGNOSTIC_TEST|Lugol's iodine test|Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)
214436247|NCT06008912|OTHER|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
214436248|NCT06008912|OTHER|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
214436249|NCT06371833|DEVICE|Shoulder Arthroplasy with PRIMA humeral stem|Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
214436250|NCT06527066|COMBINATION_PRODUCT|Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
214436251|NCT06527066|OTHER|Gel Sérum Biocompatível All.me Beauty®|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
214436252|NCT02476695|DEVICE|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
214436253|NCT02476695|DEVICE|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
214436254|NCT02476695|DEVICE|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
214436255|NCT04301089|DEVICE|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
214436256|NCT06830148|OTHER|Post-frenotomy manual manipulation|Parents assigned to the treatment group will be instructed to perform post-frenotomy stretches and exercises four times daily, after every other feed, until the time of their postoperative visit 2-3 weeks later.
214436257|NCT05925881|PROCEDURE|Surgical Repair of Large to Massive Rotator Cuff Tears|Surgical procedure to reconstruct the rotator cuff
214436258|NCT06523088|DRUG|PN20|Six dose levels of PN20 will be evaluated
214436259|NCT06523088|DRUG|Placebo|Placebo of PN20
214436260|NCT05281510|DRUG|Vesatolimod|Administered orally
214436261|NCT05281510|BIOLOGICAL|VRC07523LS|Administered intravenously
214436262|NCT05281510|BIOLOGICAL|CAP256V2LS|Administered intravenously
214436263|NCT05423379|DEVICE|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
214436264|NCT06366672|BIOLOGICAL|JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection|live, nonreplicating vaccine delivered according to the FDA approved package insert
215115942|NCT03469687|DEVICE|Symax uncemented hip stem|
215115943|NCT00662545|DRUG|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
215115944|NCT00662545|DRUG|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
215115945|NCT00653380|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
215115946|NCT00653380|DRUG|Monodox|Capsules, 100 mg, single-dose
215115947|NCT02941224|DEVICE|SELUTION DCB (sirolimus coated balloon)|
215115948|NCT00050947|DRUG|oxcarbazepine|
215115949|NCT02177682|DRUG|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
214436265|NCT06366672|PROCEDURE|Phlebotomy|Research blood draw
214436266|NCT06366672|PROCEDURE|Research bronchoscopy|Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.
214436267|NCT06366672|PROCEDURE|Skin punch biopsy|Skin punch biopsy performed with topical anesthesia.
214436268|NCT06366672|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration performed with local anesthesia.
214516358|NCT06403410|OTHER|Delirium Prevention Guideline|Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
214516359|NCT02707952|DRUG|ABT-493/ABT-530|Co-formulated tablet
214516360|NCT02707952|DRUG|OBV/PTV/r|Co-formulated tablet
214516361|NCT01555307|OTHER|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
214516362|NCT01555307|OTHER|Typical group|Seven typical exercises, 10 times each, 3 times a day
214516363|NCT02648841|RADIATION|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
215115950|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
215115951|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
215115952|NCT02587819|DRUG|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
215115953|NCT01487850|BIOLOGICAL|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
215115954|NCT06423131|PROCEDURE|TCRαβ Depleted haploidentical HCT|Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
215115955|NCT03772665|DRUG|Emixustat|Once daily oral tablet taken for 24 months
215115956|NCT03772665|DRUG|Placebo|Once daily oral tablet taken for 24 months
215115957|NCT00187473|PROCEDURE|liver biopsy|Liver biopsy every 5 years
215115958|NCT04395807|DEVICE|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
215115959|NCT04395807|DEVICE|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
215115960|NCT02986711|BEHAVIORAL|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
215115961|NCT02986711|BEHAVIORAL|Control|Only survey questions about smoking status
215115962|NCT03059316|COMBINATION_PRODUCT|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
215115963|NCT03059316|DRUG|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
215115964|NCT03059316|DRUG|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
215115965|NCT02921672|OTHER|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
214436269|NCT03873779|DEVICE|The ZELTIQ System|Participants received cryolipolysis treatment in submental and submandibular areas using the CoolSculpting System and CoolMini applicator for fat layer reduction on Day 0, which was followed with a radiofrequency treatment performed 12 weeks after CoolSculpting.
214436270|NCT00766584|OTHER|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
214436271|NCT05144321|OTHER|Impact of environment upon obstetrical|Impact of environment upon obstetrical
214436272|NCT05144321|OTHER|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
214436273|NCT04270526|DRUG|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
214436274|NCT04270526|DRUG|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
214436275|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
214516364|NCT02648841|DRUG|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
214516365|NCT02648841|DRUG|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
214516366|NCT05660811|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
214516367|NCT05660811|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
214436276|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
214436277|NCT03043599|RADIATION|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
214436278|NCT03043599|DRUG|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
214436279|NCT03043599|DRUG|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
214436280|NCT05428033|DRUG|centanafadine capsule|capsule
214436281|NCT05428033|OTHER|placebo capsule|capsule
214436282|NCT06004167|RADIATION|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
214436283|NCT02740491|OTHER|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
214436284|NCT05693129|DRUG|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
214516368|NCT05660811|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
214516369|NCT05660811|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
214516370|NCT03217123|DEVICE|Deep Brain stimulation|Electrical stimulation at subcortical level
214436285|NCT00290069|DRUG|Tacrolimus|
214436286|NCT00290069|DRUG|Rapamycin|
214436287|NCT02002845|DEVICE|robotic surgery using the da Vinci Surgical System|
214436288|NCT05938426|DEVICE|ET-101|Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
214436289|NCT05938426|DEVICE|Sham Device|Sham device has only cognitive function test excluding training programs.
214436290|NCT05883696|OTHER|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~1. Assessments of palliative care needs~2. Initiating palliative care 2D. End of life care.~3. After death. In this study only the first part of the S-PCG will be used."
214436291|NCT04880876|DRUG|25mg Eluxadoline|Oral Tablets
214436292|NCT04880876|DRUG|100mg Eluxadoline|Oral Tablets
214436293|NCT02657733|DEVICE|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
214436294|NCT02657733|DEVICE|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
214436295|NCT02657733|DEVICE|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
214436296|NCT01365598|DRUG|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
214436297|NCT05773313|BEHAVIORAL|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
214436298|NCT03966846|DIETARY_SUPPLEMENT|Kefir|
214436299|NCT03966846|DIETARY_SUPPLEMENT|Milk|
214436300|NCT04965415|BEHAVIORAL|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
214436301|NCT04965415|BEHAVIORAL|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
214436302|NCT01111513|DRUG|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
214436303|NCT01111513|DRUG|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
214516371|NCT00799838|DRUG|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
214436304|NCT01111513|DRUG|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
214436305|NCT02125110|DEVICE|MRI|
214436306|NCT02125110|OTHER|neuropsychological assessment|
214436307|NCT06229301|PROCEDURE|AI-predicted Nomogram|
214436308|NCT00639860|DEVICE|OSSIX-Plus|resorbable collagen membrane
214436309|NCT02374463|BEHAVIORAL|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
214516372|NCT00799838|DRUG|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
214516373|NCT00799838|DRUG|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
214436310|NCT02374463|BEHAVIORAL|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
214436311|NCT01814839|DRUG|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
214436312|NCT01814839|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214436313|NCT04576975|DRUG|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
214436314|NCT04576975|DRUG|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
214436315|NCT04576975|DRUG|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
214436316|NCT02987816|DEVICE|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
214516374|NCT03996798|OTHER|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
215115966|NCT04891016|DRUG|FLOT combined with toripalimab|Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
214436317|NCT02987816|DEVICE|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
214516375|NCT00027014|DRUG|St. John's Wort|
214516376|NCT00027014|DRUG|oxycodone|
214516377|NCT00027014|DRUG|fentanyl|
214516378|NCT00909909|RADIATION|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
214516379|NCT00909909|RADIATION|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
215115967|NCT05042700|DRUG|Melatonin|Enema with 25 mg melatonin
215115968|NCT05042700|DRUG|Placebo|Enema without melatonin
215115969|NCT02536027|PROCEDURE|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
215115970|NCT04050059|DRUG|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
215115971|NCT04050059|DRUG|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
214436318|NCT01534741|OTHER|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
214436319|NCT01534741|DEVICE|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
214436320|NCT06090786|DIAGNOSTIC_TEST|MRD assessment|Bone marrow withdrawal for MRD quantification
214436321|NCT00004243|DRUG|docetaxel|
214436322|NCT00004243|DRUG|oxaliplatin|
214436323|NCT01538914|PROCEDURE|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
214436324|NCT01538914|PROCEDURE|PCA|Postoperative pain is controlled with intravenous PCA.
214436325|NCT02979808|DEVICE|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
214436326|NCT01448317|DRUG|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214436327|NCT01448317|DRUG|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
214436328|NCT01448317|DRUG|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214436329|NCT01448317|DRUG|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
214436330|NCT03107546|DEVICE|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
214436331|NCT03107546|OTHER|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
214436332|NCT04804046|DIETARY_SUPPLEMENT|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
214436333|NCT04804046|OTHER|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
214436334|NCT00960024|BEHAVIORAL|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
214436335|NCT00960024|BEHAVIORAL|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
214436336|NCT04204993|DEVICE|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
214436337|NCT05150067|OTHER|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
214436338|NCT05150067|OTHER|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
214436339|NCT03200808|DRUG|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
214436340|NCT01062087|DRUG|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
214436341|NCT01266122|BEHAVIORAL|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
214436342|NCT00421889|DRUG|belinostat|
214436343|NCT00421889|DRUG|Paclitaxel|
214436344|NCT00421889|DRUG|Carboplatin|
214436345|NCT03756571|OTHER|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
214436346|NCT03756571|OTHER|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
214436347|NCT05435313|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
214436348|NCT05435313|DRUG|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
214436349|NCT05435313|DRUG|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
214436350|NCT05435313|DRUG|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
214436351|NCT05435313|DRUG|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
214436352|NCT05435313|DRUG|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
214436353|NCT00978042|DEVICE|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
214436354|NCT04244500|PROCEDURE|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
214436355|NCT02065024|DIETARY_SUPPLEMENT|b-cryptoxanthin plus phytosterols|
214436356|NCT03062813|DRUG|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
214436357|NCT03062813|DRUG|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
214436358|NCT04263519|DRUG|Tacrolimus|Oral Immunosuppressant
214436359|NCT00520546|OTHER|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
214436360|NCT00520546|OTHER|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
214436361|NCT03401372|DRUG|Doxycycline|Oral doxycycline 100mg twice daily
214436362|NCT03401372|DRUG|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
215115972|NCT05413408|OTHER|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
215115973|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
215115974|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|
215115975|NCT00004652|DRUG|pimozide|
215115976|NCT01916382|DRUG|Nitisinone|drug
215115977|NCT06172686|DRUG|Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).|The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
215115978|NCT06172686|DRUG|Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
215115979|NCT04977401|PROCEDURE|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
215115980|NCT04977401|DEVICE|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
215115981|NCT04977401|DEVICE|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
215115982|NCT02734745|DEVICE|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
215115983|NCT03308006|BIOLOGICAL|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
215115984|NCT03211494|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
215115985|NCT03211494|OTHER|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
214436363|NCT03401372|DRUG|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
215115986|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
215115987|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine|standart support
215115988|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
215115989|NCT02277600|DRUG|BMS-663068|BMS-663068
215115990|NCT02277600|DRUG|Darunavir|Darunavir
215115991|NCT02277600|DRUG|Cobicistat|Cobicistat
215115992|NCT01553903|DRUG|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
215115993|NCT01553903|DRUG|Exemestane|Exemestane 25mg/day during 5 years
214436364|NCT03401372|DRUG|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
215115994|NCT01553903|DRUG|Anastrozole|Anastrozole 1 mg/day during 5 years,
215115995|NCT01553903|DRUG|Letrozole|Letrozole 2.5 mg/day during 5 years,
215115996|NCT06422195|OTHER|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
215115997|NCT06422195|OTHER|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
215115998|NCT02999906|DRUG|Oral Treprostinil|Sustained release oral tablets for three times daily administration
214436365|NCT00708188|DEVICE|Multidetector raw CT|Multidetector raw CT
214436366|NCT02101281|DRUG|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
214436367|NCT02101281|DRUG|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
214436368|NCT04626011|PROCEDURE|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
214436369|NCT00180505|DEVICE|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
214436370|NCT04050969|PROCEDURE|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
214436371|NCT04050969|PROCEDURE|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
214436372|NCT00002755|BIOLOGICAL|filgrastim|
214436373|NCT00002755|DRUG|CMF regimen|
214436374|NCT00002755|DRUG|cyclophosphamide|
214436375|NCT00002755|DRUG|doxorubicin hydrochloride|
214436376|NCT00002755|DRUG|fluorouracil|
214436377|NCT00002755|DRUG|methotrexate|
214436378|NCT00002755|DRUG|tamoxifen citrate|
214436379|NCT00002755|DRUG|thiotepa|
214436380|NCT00002755|PROCEDURE|autologous bone marrow transplantation|
214436381|NCT00002755|PROCEDURE|peripheral blood stem cell transplantation|
214436382|NCT00002755|RADIATION|low-LET cobalt-60 gamma ray therapy|
214436383|NCT00002755|RADIATION|low-LET electron therapy|
214436384|NCT00002755|RADIATION|low-LET photon therapy|
214436385|NCT05724420|BEHAVIORAL|STRIVE course delivery|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
214436386|NCT04641741|DRUG|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
214436387|NCT01019213|OTHER|Septal pacing|Septal lead activated
214436388|NCT01019213|OTHER|His lead activated|His lead will be activated 80 ms before septal lead
214436389|NCT04456725|BEHAVIORAL|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
214436390|NCT04456725|BEHAVIORAL|Control|Usual care
214436391|NCT06093243|OTHER|data collection|data collection
215115999|NCT02999906|DRUG|Placebo|Placebo (sugar pill) for three times daily oral administration
215116000|NCT06340945|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
214436392|NCT04452318|DRUG|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
214436393|NCT04452318|DRUG|Placebo|SC or IM injections
214436394|NCT04320771|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
215116001|NCT06035705|OTHER|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
214436395|NCT04666493|OTHER|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
214436396|NCT01828554|DRUG|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
214436397|NCT02172872|DRUG|standard combination chemotherapy|"1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days"
214436398|NCT02172872|DRUG|decitabine|"1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
214436399|NCT02831361|DRUG|Gemigliptin|
214436400|NCT02831361|DRUG|Gemigliptin placebo|
214436401|NCT02831361|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
214436402|NCT02831361|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
214436403|NCT00543816|DRUG|MK0767|
214516380|NCT04659382|DRUG|Atezolizumab|Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
215116002|NCT03264365|BEHAVIORAL|Intervention|"Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed"
215116003|NCT00330603|PROCEDURE|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
215116004|NCT00996463|PROCEDURE|Electro-thermo-coagulation|Electro-thermo-coagulation
215116005|NCT00996463|DRUG|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
215116006|NCT00996463|DRUG|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
215116007|NCT00988013|RADIATION|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
215116008|NCT00988013|RADIATION|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
215116009|NCT00988013|RADIATION|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
215116010|NCT00988013|RADIATION|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
215116011|NCT01599663|OTHER|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
215116012|NCT05047861|PROCEDURE|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
214516381|NCT04659382|DEVICE|Therasphere|Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.
214516382|NCT04659382|DRUG|XELOX|standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
214436404|NCT06135246|DEVICE|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
214436405|NCT06135246|OTHER|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
214436406|NCT03428698|DEVICE|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
214436407|NCT06384820|DRUG|cemiplimab|Administered Intravenous (IV) infusion every three weeks (Q3W)
214436408|NCT06384820|DRUG|fianlimab|IV infusion Q3W
214436409|NCT05338307|DIETARY_SUPPLEMENT|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
214436410|NCT03951805|DRUG|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
214436411|NCT03951805|DRUG|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
214436412|NCT01154387|DRUG|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
214436413|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
214436414|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
214436415|NCT01154387|DRUG|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
214436416|NCT01154387|DRUG|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
214436417|NCT01154387|DRUG|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
214436418|NCT01765231|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
214436419|NCT01765231|DRUG|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
214436420|NCT03638674|OTHER|DXA + CT|Two dual-energy X-ray scans + CT scan
214436421|NCT03196882|DRUG|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
214436422|NCT03196882|DRUG|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
214436423|NCT03196882|DRUG|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
214436424|NCT03840122|OTHER|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
214436425|NCT03840122|OTHER|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
214516383|NCT04659382|DRUG|Bevacizumab|standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
214516384|NCT00039884|DRUG|NESP - Novel Erythropoiesis Stimulating Protein|
214516385|NCT03437655|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
214516386|NCT03437655|PROCEDURE|Relative isolation|Relative isolation with cotton and gauze.
214516387|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
214516388|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
214516389|NCT03437655|PROCEDURE|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
214516390|NCT03437655|PROCEDURE|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
214516391|NCT02613052|DRUG|normal saline|10 mL of normal saline agitated prior to IV administration
214516392|NCT02613052|DRUG|human albumin|10 mL of 5% albumin agitated prior to IV administration
214516393|NCT02613052|DRUG|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
214516394|NCT02006641|DRUG|Placebo|Once daily, matching placebo capsules, orally
214516395|NCT02006641|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
215116013|NCT05047861|PROCEDURE|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
215116014|NCT03217955|BEHAVIORAL|CBT-SA|Info has been included in arm description
214516396|NCT03165825|DRUG|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
214516397|NCT03165825|DRUG|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
214516398|NCT03776565|OTHER|Ultrasound|Ultrasound of antrum of stomach
214516399|NCT03611985|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
215116015|NCT03217955|BEHAVIORAL|Standard Treatment|Info has been included in arm description
215116016|NCT03348839|DEVICE|NeLLY service|Telesurveillance and therapeutic support
215116017|NCT00028847|DRUG|cytarabine|
215116018|NCT00028847|DRUG|imatinib mesylate|
215116019|NCT00020917|BIOLOGICAL|cetuximab|
215116020|NCT00020917|DRUG|fluorouracil|
215116021|NCT00020917|DRUG|irinotecan hydrochloride|
215116022|NCT00020917|DRUG|leucovorin calcium|
215116023|NCT05851833|BEHAVIORAL|Early Mobilization|The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
215116024|NCT04593108|DEVICE|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
215116025|NCT04593108|DRUG|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
215116026|NCT06408571|OTHER|etiology|As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
215116027|NCT04410718|OTHER|Glycaemic levels|Glycaemic levels during admission for COVID-19
215116028|NCT05189912|DEVICE|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
215116029|NCT05189912|BEHAVIORAL|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
215116030|NCT02328248|PROCEDURE|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
215116031|NCT02618265|PROCEDURE|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
215116032|NCT02618265|PROCEDURE|traditional management|aspirin or clopidogrel monotherapy or double treatment for
215116033|NCT02618265|PROCEDURE|website platform management|second prevention based on website platform management
215116034|NCT05927766|DEVICE|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
215116035|NCT06184607|OTHER|Distance from contact point to attachment level|A periodontal probe will be used to measure distance between contact point to attachment level in maxillary central incisors
215116036|NCT02300363|DRUG|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
215116037|NCT02300363|DRUG|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
215116038|NCT02300363|DRUG|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
214516400|NCT03611985|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
214516401|NCT06462248|DRUG|CUCART19|anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
215116039|NCT06185582|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
215116040|NCT01209351|DRUG|Placebo|placebo
215116041|NCT01209351|DRUG|teduglutide|teduglutide 4 mg
215116042|NCT05519514|DRUG|Cortiment|Budesonide 9 mg prolonged release tablets
215116043|NCT05519514|DRUG|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
215116044|NCT04502641|DRUG|Docetaxel|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
215116045|NCT04502641|DRUG|5-fluorouracil|600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.
214436426|NCT06342154|BEHAVIORAL|Endorphin Massage|The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
215116046|NCT04502641|DRUG|Cisplatin|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
214436427|NCT00405054|DRUG|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
214436428|NCT04132141|OTHER|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
214436429|NCT01695954|DRUG|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
214436430|NCT01695954|DRUG|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
214436431|NCT01695954|DRUG|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
214436432|NCT01695954|DRUG|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
214436433|NCT06407882|BEHAVIORAL|Conductive Exercises|Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
214436434|NCT06407882|BEHAVIORAL|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
214436435|NCT03921866|DRUG|Palbociclib|Palbociclib
214436436|NCT02782507|BEHAVIORAL|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon \& Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
214436437|NCT04328727|DRUG|eltrombopag|Tablet 25mg and 12.5mg
214436438|NCT04328727|DRUG|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
214436439|NCT04328727|DRUG|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
214436440|NCT03888105|DRUG|Odronextamab|Administered by intravenous (IV) infusion
214436441|NCT06329973|DRUG|Fruquintinib in combination with Sintilimab and CAPEOX|Different doses of fruquintinib combined with sintilimab and CAPEOX
214436442|NCT00522782|DRUG|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
214436443|NCT00522782|DEVICE|Nitric Oxide Analyzer|Niox NO analyzer
214436444|NCT03581357|BEHAVIORAL|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
214436445|NCT03581357|BEHAVIORAL|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
214436446|NCT03684044|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
214436447|NCT03684044|OTHER|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
214436448|NCT06045845|DIETARY_SUPPLEMENT|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
214436449|NCT06045845|DIETARY_SUPPLEMENT|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
214436450|NCT00418496|DRUG|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
214436451|NCT00418496|DRUG|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
214436452|NCT00595413|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
214436453|NCT00595413|DRUG|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
214436454|NCT00595413|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
214436455|NCT00595413|BIOLOGICAL|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
214436456|NCT02376244|OTHER|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
214436457|NCT02376244|OTHER|Standard care|Standard care cardiac rehabilitation according to current guidelines
214436458|NCT04149002|BEHAVIORAL|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
214436459|NCT04149002|OTHER|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
214436460|NCT05537935|DRUG|Low Dose Naltrexone|Participants will start with 3mg LDN orally administered daily for one week, with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided with a 4-week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which are seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
214436461|NCT03908060|DRUG|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
214516402|NCT03930173|DRUG|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
214516403|NCT03930173|DEVICE|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
214516404|NCT01287832|DRUG|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
214516405|NCT01287832|DRUG|Daptomycin|
214516406|NCT00780078|PROCEDURE|extubation|extubation failure in patients intubated orotracheally
214436462|NCT03908060|DRUG|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
214516407|NCT03062124|PROCEDURE|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
214516408|NCT00447109|DEVICE|Closed system suction|
214516409|NCT00582920|RADIATION|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
214516410|NCT01894503|DRUG|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
214436463|NCT03498768|OTHER|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
214436464|NCT05322252|DRUG|Mifepristone|200mg orally
214516411|NCT04749797|DRUG|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
214516412|NCT04749797|DRUG|Bupivacaine Injection|Used as cranial block for craniotomy surgery
214516413|NCT04749797|DRUG|Saline|Used as cranial block for craniotomy surgery
214516414|NCT00632736|DRUG|Ropinirole XL (formerly CR)|
214436465|NCT05322252|DRUG|Misoprostol|Per clinician
214436466|NCT06288334|OTHER|1-3 Cetirizine Pharmacokinetic samples|Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
214516415|NCT01985256|BIOLOGICAL|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
214516416|NCT01985256|DRUG|Toca FC|
214516417|NCT02919059|DRUG|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
214516418|NCT02919059|DRUG|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
214516419|NCT05401188|OTHER|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
214516420|NCT05401188|OTHER|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
214516421|NCT01441596|DRUG|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
214516422|NCT01441596|DRUG|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
214436467|NCT03440346|OTHER|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
214436468|NCT03427021|DRUG|Oxaliplatin|Infusion
214516423|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
214516424|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
214516425|NCT06165133|OTHER|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
214516426|NCT06165133|OTHER|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
214516427|NCT03024021|DEVICE|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia \[36.5 C\]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
214516428|NCT06455488|PROCEDURE|Ventricular Tachycardia Ablation|This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
214516429|NCT06455488|DEVICE|ICD Implant|A pacemaker or defibrillator implant to prevent SCD
214516430|NCT06455488|DRUG|Antiarrhythmic drug|Drug therapies
214516431|NCT06455488|DIAGNOSTIC_TEST|EKG|Monitoring EKG testing done on registry patients
214516432|NCT06455488|DIAGNOSTIC_TEST|Cardioversion|Monitoring cardioversions on registry patients
214516433|NCT06455488|DIAGNOSTIC_TEST|Echocardiogram|Monitoring echocardiogram testing done on patients
214516434|NCT05177432|DEVICE|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
214516435|NCT01329107|BEHAVIORAL|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
214516436|NCT01529866|DEVICE|New Abutment Connection implant|New abutment connection implant
214516437|NCT01529866|DEVICE|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
214516438|NCT03854565|DIAGNOSTIC_TEST|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
214516439|NCT02221011|DEVICE|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
214436469|NCT01327664|BIOLOGICAL|AIN457|
214516440|NCT00445757|PROCEDURE|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
215116047|NCT04502641|RADIATION|Intensity Modulated Radiation Therapy|The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.
214436470|NCT05363436|DRUG|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
214436471|NCT01119313|DRUG|LAS 41002|LAS 41002, once daily
214436472|NCT01119313|DRUG|Active|Active, once daily
214436473|NCT05891366|DRUG|WAL0921|Investigational product WAL0921
214436474|NCT05891366|DRUG|Placebo|Placebo product
214436475|NCT04629950|DRUG|Rimegepant|Active Agent
214436476|NCT04629950|DRUG|Placebo|Placebo Comparator
214516441|NCT00445757|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
215116048|NCT04502641|DRUG|Platinum|100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
215116049|NCT00228358|DRUG|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
215116050|NCT00228358|DRUG|cyclophosphamide|Given IV
215116051|NCT00228358|BIOLOGICAL|denileukin diftitox|Given IV
215116052|NCT00228358|OTHER|flow cytometry|Intracellular cytokine staining (correlative study)
215116053|NCT00228358|OTHER|immunoenzyme technique|ELIspot assay (correlative study)
215116054|NCT02871635|DRUG|BI 695501|
215116055|NCT02871635|DRUG|HUMIRA|
215116056|NCT03530826|OTHER|No intervention|No Intervention
214436477|NCT05634499|DRUG|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
214436478|NCT05587491|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
214436479|NCT04111471|DIETARY_SUPPLEMENT|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
214436480|NCT04111471|DIETARY_SUPPLEMENT|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
214436481|NCT03233633|DRUG|Medical Marijuana|oral capsule, high ratio CBD:THC
214436482|NCT02508038|PROCEDURE|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
214436483|NCT02508038|DRUG|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
214436484|NCT05315258|DRUG|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
214436485|NCT05768802|DEVICE|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
214516442|NCT02626117|DEVICE|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
214516443|NCT02626117|DEVICE|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
214516444|NCT01794689|DRUG|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
214516445|NCT01794689|DRUG|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
214516446|NCT01794689|BEHAVIORAL|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
214516447|NCT01794689|BEHAVIORAL|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
214516448|NCT04838509|OTHER|no intervention|retrospective descriptive without intervention
214516449|NCT01697956|DRUG|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
214516450|NCT01697956|DRUG|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
214516451|NCT00663429|DRUG|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
214516452|NCT00130026|DRUG|Caffeine|500 mg IV
214516453|NCT00149409|DIETARY_SUPPLEMENT|Omacor|
214516454|NCT03385447|BEHAVIORAL|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
214516455|NCT00003996|DRUG|carmustine|
214436486|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
214516456|NCT00003996|DRUG|chemotherapy|
214516457|NCT00003996|DRUG|cisplatin|
214516458|NCT00003996|DRUG|etoposide|
214516459|NCT00003996|RADIATION|radiation therapy|
214516460|NCT00349661|DRUG|impact on VASP test|
214436487|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
214436488|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
214516461|NCT05475717|DRUG|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
214516462|NCT06126887|DEVICE|Incrediwear Daytime Back Brace|Incrediwear Daytime Back Brace
214516463|NCT06126887|DEVICE|Incrediwear Sham Daytime Back Brace|Incrediwear Sham Daytime Back Brace
214516464|NCT06126887|DEVICE|Control Daytime Back Brace|Control Daytime Back Brace
214516465|NCT06126887|DEVICE|Incrediwear 24 Hour Back Brace|Incrediwear 24 Hour Back Brace
214516466|NCT00062907|BIOLOGICAL|Recombinant DNA- pVAX/L523S|
214516467|NCT00062907|BIOLOGICAL|Recombinant adenovirus- Ad/L523S|
214436489|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
214436490|NCT05949190|DRUG|Azithromycin|1g dose
214516468|NCT02907905|BIOLOGICAL|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
214516469|NCT04423796|DEVICE|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
214516470|NCT04423796|OTHER|Early mobilization|Early mobilization by health care professionals without robotic assistance.
214516471|NCT03428633|DRUG|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
214516472|NCT03428633|DRUG|Morphine|Morphine intraoperatively and postoperatively
214516473|NCT05577936|DEVICE|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
214516474|NCT05577936|OTHER|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
214516475|NCT03852069|DIETARY_SUPPLEMENT|Inulin|Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
214516476|NCT03852069|DIETARY_SUPPLEMENT|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
214436491|NCT05949190|DRUG|Albendazole|400mg dose
214436492|NCT05949190|DRUG|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
214436493|NCT05949190|BEHAVIORAL|Cognitive behavioral therapy|Novel program developed for illiterate end-users
214436494|NCT05949190|OTHER|Insecticide-treated mosquito net|Bed net to prevent malaria
214436495|NCT02131597|DRUG|Guadecitabine|Given SC
214436496|NCT04818138|DEVICE|Narrowband UVB phototherapy|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
214436497|NCT04818138|DEVICE|Broadband UVB phototherapy|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
214436498|NCT05635123|OTHER|No intervention|This is a prospective observational study with no intervention.
214436499|NCT01198145|DRUG|sulfasalazine|Given orally
214436500|NCT01198145|OTHER|placebo|Given orally
214436501|NCT05474105|DIETARY_SUPPLEMENT|Oral nutritional supplement|Daily drink 125 ml together with meal
214436502|NCT02449863|OTHER|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
214436503|NCT05086354|BEHAVIORAL|JUMP|Warm-up, stretching, jumping rope, cool-down
214516477|NCT05213312|DRUG|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
214516478|NCT05213312|DRUG|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
214516479|NCT05213312|DRUG|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
214436504|NCT03757572|OTHER|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
214436505|NCT03757572|OTHER|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
214436506|NCT00891436|DRUG|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
214436507|NCT00891436|DRUG|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
214436508|NCT01697969|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
214436509|NCT02768467|PROCEDURE|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
214436510|NCT02768467|PROCEDURE|No Stitches|Subject will not receive stitches post buccal mucosa removal.
214436511|NCT00081250|DIETARY_SUPPLEMENT|creatine monohydrate|Given orally
214516480|NCT05213312|DRUG|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
214516481|NCT05213312|PROCEDURE|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
214516482|NCT05299034|DIAGNOSTIC_TEST|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
214516483|NCT05299034|DIAGNOSTIC_TEST|Non contrast CT+CT angiography|NCCT+CTA
214436512|NCT00081250|OTHER|placebo|Given orally
214516484|NCT04108403|OTHER|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
214516485|NCT04108403|OTHER|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
214436513|NCT02655458|DRUG|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
214436514|NCT02655458|DRUG|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
214436515|NCT02655458|OTHER|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
214436516|NCT02655458|OTHER|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
214436517|NCT00314860|DRUG|ropinirole Extended Release (XR)|
214436518|NCT00484913|PROCEDURE|abdominal hot compress|
214436519|NCT01561989|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
214436520|NCT01561989|OTHER|questionnaire administration|Ancillary studies
214436521|NCT01561989|BIOLOGICAL|trivalent influenza vaccine|Given IM
214436522|NCT03135184|DEVICE|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
214436523|NCT00737542|DRUG|lidocaine|
214436524|NCT00737542|DRUG|NACL 0.9%|
214436525|NCT03425734|DRUG|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
214516486|NCT04108403|OTHER|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
214516487|NCT04108403|OTHER|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
214516488|NCT04838860|DRUG|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
214516489|NCT01291472|DRUG|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
214516490|NCT05892445|BEHAVIORAL|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
214516491|NCT03293238|PROCEDURE|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
214516492|NCT03293238|PROCEDURE|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
214516493|NCT03293238|PROCEDURE|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
214436526|NCT06497374|DRUG|Efgartigimod Alfa Injection|Efgartigimod+IVMP; IVMP; Efgartigimod
214436527|NCT06497374|DRUG|High-dose intravenous methylprednisolone|Efgartigimod+IVMP; IVMP; Efgartigimod
214436528|NCT05284136|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
214436529|NCT05284136|DRUG|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
214436530|NCT03000049|OTHER|bedside blood culture|
214436531|NCT00006330|DRUG|Digoxin|
214436532|NCT00006330|DRUG|Hawthorn|
214436533|NCT04366908|DRUG|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
214436534|NCT04366908|DRUG|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
214436535|NCT03792204|DIAGNOSTIC_TEST|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
214436536|NCT03010813|PROCEDURE|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
214436537|NCT05952895|PROCEDURE|Conventional quadrant-wise scaling and root planing (SRP)|SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
214516494|NCT03293238|PROCEDURE|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
214516495|NCT02647333|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
214516496|NCT02647333|DIETARY_SUPPLEMENT|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
214516497|NCT04161716|DEVICE|NIRS recording|Patient has a NIRS module during their urodynamic exam.
214516498|NCT00233610|DRUG|Bicalutamide|
214516499|NCT00233610|DRUG|Tamoxifen|
214516500|NCT04586348|COMBINATION_PRODUCT|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
214516501|NCT04586348|COMBINATION_PRODUCT|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
214516502|NCT02300467|DRUG|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
214516503|NCT02302157|BIOLOGICAL|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
214516504|NCT03064594|PROCEDURE|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
214516505|NCT01282957|BEHAVIORAL|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
214516506|NCT01282957|BEHAVIORAL|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
214516507|NCT02115659|DRUG|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
214516508|NCT02115659|DRUG|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
214516509|NCT00778856|PROCEDURE|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
214516510|NCT06509581|DIETARY_SUPPLEMENT|vitamin E|Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
214516511|NCT06509581|OTHER|PLACEBO|placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
214516512|NCT05095974|DEVICE|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
214516513|NCT05095974|DEVICE|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
214516514|NCT05095974|DEVICE|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
214516515|NCT00866619|BIOLOGICAL|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
214516516|NCT00866619|BIOLOGICAL|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
214516517|NCT00866619|BIOLOGICAL|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
214516518|NCT00866619|BIOLOGICAL|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
214436538|NCT00392249|BEHAVIORAL|Supervised Treatment of Schizophrenia by a family member|
214436539|NCT00697489|PROCEDURE|correction of POP plus preventive continence procedure|
214436540|NCT00697489|PROCEDURE|POP surgery followed by eventual incontinence procedure|
214436541|NCT05660941|DRUG|Lispro|Ultra rapid Lispro
214436542|NCT05660941|DRUG|Lispro|Conventional Lispro
214436543|NCT02195297|OTHER|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
214436544|NCT00971269|DEVICE|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
214436545|NCT04364451|OTHER|Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase|Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).
214436546|NCT05575622|DEVICE|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
214436547|NCT01381406|DRUG|TIO|Patients receiving tiotropium bromide at index within the study period.
214436548|NCT01381406|DRUG|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
214436549|NCT05859152|OTHER|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
214436550|NCT05859152|OTHER|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
214436551|NCT02628678|DIETARY_SUPPLEMENT|FOS|
214516519|NCT00866619|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
214516520|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
214516521|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
214516522|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
214516523|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
214516524|NCT03413826|BEHAVIORAL|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
214516525|NCT05710757|OTHER|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
214516526|NCT05710757|DEVICE|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
214516527|NCT05710757|OTHER|myofascial release|Sham MFR.
214516528|NCT03987074|DRUG|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
214436552|NCT05143996|DRUG|CLN-049|\[FLT3\] x \[CD3\] bispecific T cell engager
214436553|NCT01066026|PROCEDURE|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
214436554|NCT01066026|DRUG|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
214436555|NCT05426317|OTHER|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
214436556|NCT06966960|BEHAVIORAL|Online RPG adventure games and e-book learning.|Learning obstetric fetal heart rate monitoring technology through online RPG adventure games and e-book learning.
214436557|NCT06966960|BEHAVIORAL|E-book|E-book learning mode for obstetric fetal heart rate monitoring technology.
214436558|NCT03447249|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
214436559|NCT03447249|DRUG|IVA|Participants received IVA orally once daily in the evening.
214436560|NCT03447249|DRUG|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
214436561|NCT00885924|DRUG|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
214516529|NCT03987074|DRUG|Firsocostat|Tablets administered orally once daily
214436562|NCT00885924|DRUG|Placebo|NaCl 0.9%
214436563|NCT04760834|OTHER|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
214436564|NCT04164940|OTHER|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
214436565|NCT00890305|DRUG|CT-011|
214436566|NCT00890305|DRUG|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
214436567|NCT03206515|DEVICE|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
214436568|NCT03206515|DEVICE|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
214516530|NCT03987074|DRUG|Cilofexor|Tablets administered orally once daily
214516531|NCT03152435|BIOLOGICAL|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
214516532|NCT02281266|PROCEDURE|curative resection|
215116057|NCT00613496|DRUG|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
215116058|NCT00613496|DRUG|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
215116059|NCT01771978|DRUG|Placebo|Received 250 ml of a 5% dextrose solution as placebo
215116060|NCT01771978|DRUG|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
215116061|NCT01771978|DRUG|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
215116062|NCT01771978|DRUG|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~* bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~* 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
214516533|NCT02281266|DRUG|thymalfasin|1.6mg twice a week, 12 months
214516534|NCT02281266|DRUG|nucleoside analog (suggest to use entecavir)|
214516535|NCT03100370|DEVICE|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
215116063|NCT02420379|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
215116064|NCT06106048|OTHER|Closed kinetic chain exercises|"Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
215116065|NCT06106048|OTHER|Abdominal contraction exercises|"Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
215116066|NCT00502671|DRUG|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
215116067|NCT01768507|DIETARY_SUPPLEMENT|Resveratrol|5 g (10 capsules) as single oral dose on day 1
214516536|NCT03100370|DEVICE|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
215116068|NCT06271044|OTHER|With radioiodine treatment|Postoperative radioiodine not given
215116069|NCT06271044|PROCEDURE|With postoperative radioiodine treatment|Postoperative radioiodine given
214436569|NCT05580380|OTHER|Limited Relationship|In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
214436570|NCT05580380|OTHER|Enhanced Relationship|A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
214436571|NCT04014634|DRUG|Methylprednisolone|Single GON injection with methylprednisolone
214436572|NCT04014634|OTHER|Placebo|Single GON-injection with NaCl
214436573|NCT00006446|PROCEDURE|Training in parenting skills and communication|
214436574|NCT02215707|BIOLOGICAL|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
214436575|NCT03476811|DRUG|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
214436576|NCT03476811|DEVICE|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
214436577|NCT06177444|DRUG|Antibiotic|Postoperative antibiotic treatment
214436578|NCT02189915|DRUG|Creatine monohydrate|
214436579|NCT02574455|DRUG|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
214436580|NCT02574455|DRUG|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
214436581|NCT02574455|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
214436582|NCT02574455|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
214436583|NCT02574455|DRUG|Vinorelbine|25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
214436584|NCT03914664|DIAGNOSTIC_TEST|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
214436585|NCT03914664|DIAGNOSTIC_TEST|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
214436586|NCT01571466|DRUG|Vaccination|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
214436587|NCT01571466|DRUG|Placebo|3 immunisations at week 0, 4 and 16
214436588|NCT02387866|DRUG|AG-221|
214436589|NCT04804241|DRUG|Senicapoc|10 mg oral tablet
214436590|NCT04804241|OTHER|Placebo Tablet|Placebo Oral Tablet
214436591|NCT02677896|DRUG|Enzalutamide|Oral
214436592|NCT02677896|DRUG|Placebo|Oral
214436593|NCT06089057|BEHAVIORAL|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
215116070|NCT03633344|DRUG|Carbowhite|
214436594|NCT06089057|BEHAVIORAL|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
214436595|NCT06490770|DIAGNOSTIC_TEST|Gait analysis, Magnetic Resonance Imaging|Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
214436596|NCT06212271|DRUG|Colchicine|See arm description.
214436597|NCT06212271|DRUG|Placebo|See arm description.
214436598|NCT04557228|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplements
214436599|NCT04557228|DIETARY_SUPPLEMENT|Phosphatidylserine|4 weeks of phosphatidylserine supplements
214436600|NCT03148496|DEVICE|Biologic Mesh|Biologic mesh placed during surgery
214436601|NCT03148496|PROCEDURE|Small Bites|0.5 cm x 0.5 cm sutures used
214436602|NCT03148496|PROCEDURE|Large Bites|1.0 x 1.0 sutures used
214436603|NCT02390986|DRUG|LON002|Extension study to provide continuing access to LON002 medication.
214436604|NCT00593866|RADIATION|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
214436605|NCT00593866|DRUG|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
214436606|NCT05447871|PROCEDURE|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
214436607|NCT05447871|PROCEDURE|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
214436608|NCT05447871|DRUG|Bupivacaine 0.25%|bupivacaine 0.25%
215116071|NCT03633344|DRUG|Carbowhite placebo|
215116072|NCT00235586|PROCEDURE|10 vit. D deficient subjects take vit. D for 3 months.|
215116073|NCT05191693|PROCEDURE|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
215116074|NCT03795116|DEVICE|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
215116075|NCT03795116|DEVICE|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
215116076|NCT02620592|DRUG|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
215116077|NCT02620592|DRUG|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
215116078|NCT01204177|DRUG|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
214436609|NCT01741441|PROCEDURE|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
214436610|NCT02395913|DRUG|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
215116079|NCT01051687|DRUG|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
215116080|NCT03540108|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
215116081|NCT03540108|DIETARY_SUPPLEMENT|Placebo Comparator: Maltodextrin|Please see intervention description above.
215116082|NCT00412893|DRUG|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
215116083|NCT00412893|DRUG|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
215116084|NCT04344223|DEVICE|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
215116085|NCT04344223|DEVICE|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
215116086|NCT05503849|BEHAVIORAL|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
215116087|NCT01301313|DRUG|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
215116088|NCT01301313|DRUG|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
215116089|NCT01776606|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
215116090|NCT01776606|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
215116091|NCT01199419|PROCEDURE|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
215116092|NCT00853151|DRUG|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
215116093|NCT00853151|DRUG|TT223|subcutaneous injection once a day for 4 weeks
215116094|NCT00853151|DRUG|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
215116095|NCT00853151|DRUG|Placebo for TT223|subcutaneous injection once a day for 4 weeks
215116096|NCT01311336|DRUG|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
215116097|NCT01311336|DRUG|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
215116098|NCT02376868|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
215116099|NCT02376868|DEVICE|iVue|OCT machines used for diagnostic purposes
214436611|NCT02395913|DRUG|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
215116100|NCT01304602|DRUG|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
215116101|NCT01304602|DRUG|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
215116102|NCT00475566|DEVICE|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
214436612|NCT02395913|DRUG|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
214436613|NCT02395913|DRUG|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
214516537|NCT03100370|DEVICE|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
214436614|NCT02704507|DRUG|Triamcinolone|topical application nightly to half the face for 4 weeks
214516538|NCT03100370|DEVICE|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
214436615|NCT02704507|DRUG|Tretinoin|topical application nightly for 8 weeks
214436616|NCT02704507|DRUG|Emollient|topical application nightly to half the face for 4 weeks
214436617|NCT03565315|BIOLOGICAL|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
214436618|NCT03565315|BIOLOGICAL|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
214436619|NCT00496743|DEVICE|Low-dose total skin electron beam therapy (4 Gy)|
214436620|NCT01576107|OTHER|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
214436621|NCT01576107|OTHER|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
214436622|NCT00345150|DRUG|Ng-monomethyl-L-arginine (drug)|
214436623|NCT05769764|OTHER|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
214436624|NCT05946421|DEVICE|exhaled breath analysis|non invasive technology to measure components of exhaled breath
214436625|NCT05798273|PROCEDURE|intra-arterial injection|"All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
214436626|NCT05798273|DEVICE|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
214436627|NCT05798273|OTHER|Radiopharmacon Contrast agent|Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
214436628|NCT02729506|PROCEDURE|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
214436629|NCT02729506|PROCEDURE|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
214436630|NCT03372473|DRUG|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
214436631|NCT03372473|DRUG|Montelukast|Montelukast 5mg
214436632|NCT00051571|DRUG|SGN-15|
214516539|NCT04862598|DEVICE|Oculus Virtual Reality|The patient will receive standard care, augmented with virtual reality. Their post-operative satisfaction score will be recorded.
214516540|NCT05715632|DRUG|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
214516541|NCT03683615|PROCEDURE|repair of orbital floor fractures using resorbable plates|
214436633|NCT00051571|DRUG|Docetaxel|
214436634|NCT02570191|DRUG|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
214436635|NCT01544270|DIETARY_SUPPLEMENT|Yogurt-like snacks|twice a day 120 g for four weeks
214436636|NCT01499199|DRUG|Dolutegravir|50mg Once Daily
214436637|NCT02692417|DEVICE|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
214436638|NCT00282971|DRUG|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
214436639|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
214436640|NCT06354140|DRUG|Tegafur|Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
214436641|NCT00536341|DRUG|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
214436642|NCT00536341|DRUG|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
214436643|NCT00536341|DRUG|Fludarabine|25 mg/m2 on Days 1, 2, and 3
214436644|NCT05369507|BEHAVIORAL|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
214436645|NCT02725086|DRUG|Leucostim®|
214436646|NCT02725086|DRUG|Neupogen®|
214436647|NCT00344994|DRUG|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
214516542|NCT03477032|BIOLOGICAL|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
214516543|NCT02740426|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
214516544|NCT00779805|DRUG|Pseudoephedrine hydrochloride 120 mg ER tablets|
214436648|NCT04115683|OTHER|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
214436649|NCT04115683|OTHER|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
214436650|NCT06188377|DEVICE|measured by a impedance analyzer|the healthy chinese neonates will be measured by a impedance analyzer, and will be compared with that of other ethnicity whose data have been reported by literatures.
214436651|NCT03628235|BEHAVIORAL|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
214436652|NCT00533546|DRUG|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
214436653|NCT03365895|PROCEDURE|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
214436654|NCT03365895|OTHER|Laboratory Biomarker Analysis|Correlative studies
214436655|NCT03365895|PROCEDURE|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
214436656|NCT03365895|OTHER|Questionnaire Administration|Ancillary studies
214516545|NCT03143036|DRUG|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
214516546|NCT00977678|OTHER|open access gastroscopy|access to gastroscopy without preceding appointment
214516547|NCT00977678|OTHER|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
215116103|NCT00475566|DEVICE|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
215116104|NCT04830579|DRUG|Etoricoxib film-coated tablet 120 mg|Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
215116105|NCT04830579|DRUG|Arcoxia® film-coated tablet 120 mg|Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
215116106|NCT04053166|DEVICE|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
215116107|NCT04053166|OTHER|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
215116108|NCT04053166|BIOLOGICAL|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
215116109|NCT04053166|OTHER|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
215116110|NCT04053166|OTHER|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
215116111|NCT00269919|DRUG|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
215116112|NCT00200603|DEVICE|calcium phosphate macroporous bioceramics|
215116113|NCT03235947|DRUG|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
215116114|NCT03235947|DRUG|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
215116115|NCT03235947|DRUG|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
215116116|NCT04132310|OTHER|N/A This is an observational study.|This is an observational study.
214436657|NCT02945098|OTHER|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
214436658|NCT02945098|OTHER|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
214436659|NCT03435666|DRUG|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
214436660|NCT03435666|DRUG|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
214436661|NCT01637246|DRUG|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
214516548|NCT03234478|OTHER|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
214516549|NCT03531892|DRUG|AJM300|AJM300 film-coated tablets.
215116117|NCT05743088|BEHAVIORAL|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
215116118|NCT05295875|DRUG|ALT-801|Injected subcutaneously (SC)
215116119|NCT05295875|OTHER|Placebo|Injected subcutaneously (SC)
215116120|NCT00659113|DRUG|cisplatin|
215116121|NCT00659113|DRUG|tegafur-gimeracil-oteracil potassium|
215116122|NCT00659113|OTHER|cytology specimen collection procedure|
215116123|NCT00659113|PROCEDURE|endoscopic biopsy|
215116124|NCT00997919|DRUG|MABT5102A|single SC dose
215116125|NCT00997919|DRUG|MABT5102A|single IV dose
214436662|NCT02550691|PROCEDURE|blood sampling|A blood sample will be taken on subject carrying specific genotype
214436663|NCT00779636|DRUG|Desloratadine|Desloratadine 10 mg daily x 28 days
214436664|NCT00779636|DRUG|Placebo|Placebo daily x 28 days
214436665|NCT04713735|DIETARY_SUPPLEMENT|Control: Placebo|Placebo
214516550|NCT03531892|DRUG|Placebo|Placebo matched to AJM300 tablets.
214516551|NCT03720028|BEHAVIORAL|Observation|Describe communication and sensory profile using standardized tests and observations.
214516552|NCT03720028|BEHAVIORAL|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
214516553|NCT03949959|OTHER|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
214516554|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
215116126|NCT02967653|DRUG|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
215116127|NCT01689142|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
215116128|NCT01689142|DRUG|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
215116129|NCT06507306|DRUG|KQB198|Oral KQB198
215116130|NCT06507306|DRUG|osimertinib|Oral osimertinib
215116131|NCT04473963|DEVICE|Electrographic Flow™ guided ablation|"In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
215116132|NCT04869839|OTHER|oral examination|examination done by dentist
215116133|NCT03984214|DRUG|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
215116134|NCT03984214|DRUG|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
215116135|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
215116136|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
215116137|NCT00410878|DRUG|OROS Hydromorphone HCI (slow release)|
215116138|NCT01613677|DRUG|BKM120|
215116139|NCT01404780|DEVICE|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
215116140|NCT01404780|DEVICE|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
215116141|NCT00037492|PROCEDURE|home-based sessions/family meetings with trained clinician|
215116142|NCT05185726|BEHAVIORAL|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
214436666|NCT04713735|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|600 mg
214436667|NCT00644475|DRUG|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
214436668|NCT00644475|DRUG|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
214436669|NCT04652583|DEVICE|Earstim - Active Stimulation|Intramuscular stimulation
214436670|NCT04652583|DEVICE|Earstim - Sham Stimulation|Sham stimulation
214436671|NCT01215552|DRUG|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
214436672|NCT04695197|DRUG|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
214436673|NCT04695197|DRUG|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
214436674|NCT04404686|DRUG|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
214436675|NCT04404686|DRUG|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
214436676|NCT03276871|PROCEDURE|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
214436677|NCT03276871|DEVICE|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
214436678|NCT04987294|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
214516555|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
214516556|NCT01063465|DEVICE|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
214516557|NCT06146088|BIOLOGICAL|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
214516558|NCT03115879|OTHER|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
215116143|NCT05185726|BEHAVIORAL|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
215116144|NCT05185726|BEHAVIORAL|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
215116145|NCT05158517|DRUG|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
215116146|NCT03701672|OTHER|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
214436679|NCT04987294|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
214436680|NCT04077164|OTHER|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
214436681|NCT06048172|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
214436682|NCT02372253|DRUG|Verapamil|
214436683|NCT02372253|DRUG|Placebo|
214436684|NCT04372004|DIAGNOSTIC_TEST|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
214436685|NCT00629850|DEVICE|Powerlung Performer|Inspiratory/Expiratory muscle trainer
214436686|NCT04127669|DRUG|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
214436687|NCT04127669|DRUG|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
214516559|NCT03115879|OTHER|Hip manipulation simulation|Hip manipulation simulation
214436688|NCT00925886|PROCEDURE|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
214516560|NCT04457583|DEVICE|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
215116147|NCT04935073|DRUG|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
215116148|NCT04935073|DRUG|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
214436689|NCT05143658|PROCEDURE|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
214436690|NCT00393484|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
214436691|NCT00393484|DRUG|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
214436692|NCT00393484|DRUG|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
214436693|NCT00393484|DRUG|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
214436694|NCT05073562|DIETARY_SUPPLEMENT|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
214436695|NCT05073562|BEHAVIORAL|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
214436696|NCT05073562|DRUG|Mebendazole Pill|One-time deworming treatment with mebendazole.
214436697|NCT05073562|OTHER|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
214436698|NCT01846936|PROCEDURE|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
214436699|NCT01846936|PROCEDURE|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
215116149|NCT04168229|DEVICE|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
215116150|NCT04168229|DEVICE|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
215116151|NCT06375174|PROCEDURE|Thrombectomy|All procedures correspond to standard care and clinical routine
215116152|NCT02123849|DRUG|Aspirin|Given PO
215116153|NCT02123849|OTHER|Laboratory Biomarker Analysis|Correlative studies
215116154|NCT02123849|OTHER|Placebo|Given PO
215116155|NCT04451941|DEVICE|Experimental: RecoveriX with individual EEG calibration|RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
215116156|NCT04451941|DEVICE|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
215116157|NCT03469466|DIAGNOSTIC_TEST|bedside ultrasound|bedside ultrasound imaging of the lungs
215116158|NCT01941329|PROCEDURE|Panretinal Photocoagulation (PRP)|
215116159|NCT01941329|DRUG|Intravitreous injection of ranibizumab|
214436700|NCT01846936|PROCEDURE|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
214436701|NCT00247208|DEVICE|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
214436702|NCT00247208|DEVICE|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
214436703|NCT05300542|OTHER|Topical Placebo Cream|Application of test products before and after irradiation
214436704|NCT05300542|OTHER|Topical Cream with 0.5% Active|Application of test products before and after irradiation
214436705|NCT05300542|OTHER|Topical Cream with 1% Active|Application of test products before and after irradiation
214436706|NCT03201562|DRUG|Aceclidine+tropicamide combination|Ophthalmic Solution
214436707|NCT03201562|DRUG|Aceclidine|Ophthalmic Solution
214436708|NCT03201562|DRUG|Vehicle|Ophthalmic Solution
214436709|NCT05198531|DRUG|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
215116160|NCT04914065|OTHER|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~1. Inspiratory muscles: diaphragm~2. Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~1. Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~2. Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
215116161|NCT01582620|PROCEDURE|Telestroke|remote videoconference consultations
215116162|NCT04486651|DRUG|Irinotecan Hydrochloride Injection|160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
215116163|NCT04486651|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
215116164|NCT04486651|DRUG|Placebo|Administered as IV infusion on Day 1 of each 21-day cycle.
214516561|NCT05973669|DEVICE|MED-EL Remote Care|Remote cochlear implant support
215116165|NCT05809843|DEVICE|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
214436710|NCT05198531|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214436711|NCT05198531|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
214436712|NCT05198531|DRUG|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
214436713|NCT00001277|DRUG|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
214436714|NCT00001277|DRUG|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
214436715|NCT03912961|OTHER|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
214436716|NCT01069471|BIOLOGICAL|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
214436717|NCT01811407|BEHAVIORAL|Precommitment announcement|
214436718|NCT01811407|BEHAVIORAL|Results announcement|
214436719|NCT01811407|BEHAVIORAL|Walking program|
214436720|NCT00242359|DRUG|omalizumab|
214436721|NCT02441881|DEVICE|Venefit|Endovenous radiofrequency device
214436722|NCT02441881|DEVICE|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
214436723|NCT02441881|DEVICE|Endovenous Radiofrequency|Endovenous radiofrequency device
214436724|NCT02897882|OTHER|Lung transplant|Pain evaluation
214436725|NCT00879060|DRUG|Spironolactone|spironolactone 50mg daily
214436726|NCT00879060|DRUG|Placebo|inactive placebo pill daily
214436727|NCT04767698|DRUG|Belimumab|200 mg SC weekly for 36 months
214436728|NCT04767698|DRUG|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
214436729|NCT04767698|DRUG|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
214436730|NCT02879760|BIOLOGICAL|Ad-MAGEA3|Intramuscular injection
214436731|NCT02879760|BIOLOGICAL|MG1-MAGEA3|Intravenous infusion
214436732|NCT02879760|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214436733|NCT04962477|OTHER|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
214436734|NCT03569072|RADIATION|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
214436735|NCT00485329|OTHER|Papain|15,000 USP U/ml
214436736|NCT00485329|OTHER|Papain|30,000 USP U/ml
214436737|NCT00485329|OTHER|Papain|60,000 USP U/ml
215116166|NCT05041283|OTHER|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
215116167|NCT05041283|OTHER|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
215116168|NCT05408390|OTHER|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
214436738|NCT00715494|BEHAVIORAL|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
214436739|NCT01381471|DRUG|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
214436740|NCT01563380|BIOLOGICAL|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
214436741|NCT05936177|OTHER|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
214436742|NCT04746131|DRUG|IMM0306|IMM0306 is an bi-specific antibody
214516562|NCT06114641|DRUG|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
214436743|NCT04730713|DEVICE|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
214516563|NCT06487871|DIETARY_SUPPLEMENT|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
214516564|NCT06487871|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
214516565|NCT01562275|DRUG|Ipatasertib|multiple doses
214516566|NCT01562275|DRUG|Cobimetinib|multiple doses
214516567|NCT01682447|OTHER|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
214436744|NCT05796323|OTHER|No intervention.|The subjects will complete a survey related to workplace violance.
214436745|NCT00957242|DRUG|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
214436746|NCT00957242|DRUG|placebo|Oral placebo (1mg or 2.5mg)
214436747|NCT03307278|BIOLOGICAL|House dust mite|As a stimulant to induce inflammasome activation
214436748|NCT02539225|DRUG|Ramucirumab|Administered IV
214436749|NCT02539225|DRUG|Placebo|Administered IV
214436750|NCT02539225|DRUG|S-1|Administered PO
214516568|NCT01863368|OTHER|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
214516569|NCT01863368|OTHER|Systane® ULTRA lubricant eyedrops|
214516570|NCT01863368|OTHER|OPTIVE® lubricating eyedrops|
214516571|NCT06124118|RADIATION|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
214516572|NCT06124118|DEVICE|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
214516573|NCT06124118|DRUG|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
215116169|NCT05408390|OTHER|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
215116170|NCT05408390|OTHER|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
215116171|NCT05408390|OTHER|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
214436751|NCT02539225|DRUG|Oxaliplatin|Administered IV
214436752|NCT02539225|DRUG|Paclitaxel|Administered IV
214436753|NCT00974831|OTHER|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
214516574|NCT06029920|OTHER|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
214516575|NCT03528161|OTHER|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
214516576|NCT05118009|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
215116172|NCT00165178|DRUG|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
215116173|NCT00165178|DRUG|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
215116174|NCT00165178|DRUG|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
214436754|NCT00974831|OTHER|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
214436755|NCT04865146|DEVICE|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
214516577|NCT02988232|DRUG|Sogyeonghwalhyeol-tang|herbal extract
214436756|NCT00111085|DRUG|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
214436757|NCT00111085|DRUG|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
214436758|NCT00111085|DRUG|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
214436759|NCT00111085|DRUG|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
214516578|NCT02988232|DRUG|Placebo|extract powder with same appearance, odor and color as SGHH
214516579|NCT02450786|DRUG|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
214516580|NCT05672862|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
214516581|NCT04371471|DIAGNOSTIC_TEST|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
214516582|NCT00755248|PROCEDURE|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
214516583|NCT05538156|PROCEDURE|Control group|Vitrectomy and gas tamponade without internal limiting membrane peeling
214516584|NCT05538156|PROCEDURE|Intervention group|Vitrectomy, internal limiting membrane peeling and gas tamponade
214516585|NCT05152992|BEHAVIORAL|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
215116175|NCT00165178|DRUG|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
214516586|NCT06174779|DRUG|HM11260C|Test drug
214516587|NCT06174779|DRUG|Placebo|Placebo drug
214516588|NCT05582447|OTHER|ektacytometry of red blood cells|Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
214516589|NCT05360199|BEHAVIORAL|PROMs|evaluate the impact of recall bias on post proms scores
214516590|NCT00778141|DRUG|metformin HC1 750 mg extended-release tablets|
214516591|NCT00214318|DRUG|Terbutaline plus Metoprolol or carvedilol|
214516592|NCT02832219|DIETARY_SUPPLEMENT|Molecular hydrogen|
215116176|NCT00165178|DRUG|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
215116177|NCT00165178|DRUG|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
215116178|NCT00165178|DRUG|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
215116179|NCT00165178|DRUG|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
215116180|NCT00165178|DRUG|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
215116181|NCT00165178|DRUG|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
215116182|NCT01799226|OTHER|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
215116183|NCT01799226|OTHER|Triclosan|this intervention will use Colgate Total which contains triclosan
214436760|NCT00847834|DRUG|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
214436761|NCT00847834|DRUG|Irbesartan 150mg|Once a day
214436762|NCT04385680|DRUG|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
214436763|NCT03101371|DRUG|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
214436764|NCT03101371|PROCEDURE|Standard of care catheter insertion|Catheter inserted right out of package.
214436765|NCT05911581|OTHER|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
214436766|NCT05911581|OTHER|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
214436767|NCT04854395|DRUG|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
214436768|NCT02743195|DIETARY_SUPPLEMENT|Polyphenol/prebiotic blend|
214516593|NCT02832219|DIETARY_SUPPLEMENT|Placebo|
214516594|NCT01020487|DRUG|Paricalcitol|Paricalcitol capsules taken with water.
214516595|NCT01020487|DRUG|Placebo|Placebo capsules taken with water
214516596|NCT05424952|OTHER|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
214516597|NCT04049578|DRUG|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
214516598|NCT04618575|DRUG|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
214516599|NCT04618575|DRUG|Ursodeoxycholic acid only|Ursodeoxycholic acid only
214436769|NCT02318134|PROCEDURE|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
214436770|NCT02318134|DRUG|normal saline|Normal saline via a nasoduodenal tube.
214436771|NCT04307511|DRUG|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
214436772|NCT04307511|DRUG|Aspirin|Aspirin
214436773|NCT04784026|OTHER|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
214436774|NCT04784026|OTHER|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
214436775|NCT04784026|OTHER|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
214436776|NCT03240978|BEHAVIORAL|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
214436777|NCT05957653|DRUG|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
214436778|NCT05957653|DRUG|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
214436779|NCT04804930|PROCEDURE|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
214436780|NCT04766034|BEHAVIORAL|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
214436781|NCT04838496|DRUG|FOLFOXIRI Protocol|"FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age."
214436782|NCT04900766|DRUG|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
214436783|NCT01339130|BEHAVIORAL|Computerized tests and Electrophysiological measurements|"* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
214436784|NCT03638440|DRUG|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
214436785|NCT01976312|OTHER|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
214436786|NCT01976312|DRUG|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
214436787|NCT03778242|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
214436788|NCT03778242|DRUG|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
214436789|NCT00293358|DRUG|carboplatin|
214436790|NCT00293358|DRUG|cisplatin|
214436791|NCT00293358|DRUG|etoposide phosphate|
214436792|NCT00293358|DRUG|ifosfamide|
214436793|NCT00293358|PROCEDURE|adjuvant therapy|
214436794|NCT00293358|PROCEDURE|conventional surgery|
214436795|NCT00293358|PROCEDURE|neoadjuvant therapy|
214436796|NCT00293358|RADIATION|radiation therapy|
214436797|NCT03010631|DRUG|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
215116184|NCT02137824|PROCEDURE|sinus floor elevation|
214436798|NCT03010631|DRUG|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
214436799|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
214436800|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
214436801|NCT04680520|OTHER|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
214436802|NCT04680520|OTHER|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
214436803|NCT02497716|DRUG|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
214436804|NCT04834141|OTHER|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
214436805|NCT00746343|BEHAVIORAL|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
214436806|NCT00746343|BEHAVIORAL|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
214436807|NCT05799742|PROCEDURE|Bilateral hernioplasty|
214436808|NCT00006431|BIOLOGICAL|DC RCC-RNA|
214436809|NCT03945123|DIETARY_SUPPLEMENT|Red ginseng|Red ginseng tablet 120g
214436810|NCT04513314|DRUG|Valproate|Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
214436811|NCT04513314|DRUG|Quetiapine|Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
214436812|NCT04513314|OTHER|Standard of Care|Standard of Care is a combination of IV dexmedetomidine (D), midazolam (M), ketamine (K) and propofol (P), at the discretion of treating physician.
214436813|NCT03359967|DRUG|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
214436814|NCT02076659|DRUG|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
214436815|NCT02076659|DRUG|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
214436816|NCT01286714|DEVICE|CLIP OST|
214436817|NCT04131153|PROCEDURE|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
214436818|NCT04131153|PROCEDURE|radiofrequency ablation|Conventional radiofrequency ablation
214436819|NCT02009215|DRUG|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
214436820|NCT03159273|DIETARY_SUPPLEMENT|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
214436821|NCT04048382|BEHAVIORAL|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
214436822|NCT04048382|OTHER|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
214436823|NCT02556138|DEVICE|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
214436824|NCT00698919|OTHER|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
214436825|NCT00490100|DRUG|Increlex|
214436826|NCT03671252|DRUG|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
214436827|NCT03671252|DRUG|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
214436828|NCT03671252|OTHER|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
214436829|NCT03671252|PROCEDURE|TME operation|TME operation
214436830|NCT03671252|PROCEDURE|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
214436831|NCT04827524|OTHER|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
214436832|NCT04426916|OTHER|Spondylolisthesis|Spondylolisthesis at a single level
214436833|NCT02545738|DRUG|Liraglutide|active treatment
214436834|NCT02545738|DRUG|placebo|placebo
214436835|NCT05208242|DRUG|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
214436836|NCT05208242|DRUG|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
214436837|NCT01657604|DRUG|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
214436838|NCT01657604|DRUG|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
214436839|NCT00212693|DRUG|ONO-2506PO|
214516600|NCT04748497|OTHER|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
214516601|NCT06582277|BIOLOGICAL|OVX836 shot|One single administration intramuscularly at Day 1.
214516602|NCT06789159|DRUG|VK-2019|VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.
214516603|NCT04479020|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy requiring the use an APERIO® or APERIO® Hybrid(17) Thrombectomy device due to an thrombotic occlusion in a distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA)
214516604|NCT01366976|DRUG|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
214516605|NCT04358588|DRUG|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
214516606|NCT06056726|PROCEDURE|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
214692684|NCT05747131|BEHAVIORAL|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
215116185|NCT02987751|DRUG|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
215116186|NCT02987751|DRUG|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
215116187|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
215116188|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
215116189|NCT06436118|BEHAVIORAL|RELAX® glasses|Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use.
215116190|NCT03714724|DIAGNOSTIC_TEST|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
215116191|NCT05699824|DRUG|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
215116192|NCT05699824|OTHER|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
215116193|NCT05699824|DRUG|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
215116194|NCT02139072|DEVICE|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
215116195|NCT02139072|PROCEDURE|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
215116196|NCT05961657|DIAGNOSTIC_TEST|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
214436840|NCT01139944|GENETIC|DNA methylation analysis|
214436841|NCT01139944|GENETIC|polymerase chain reaction|
214436842|NCT01139944|OTHER|laboratory biomarker analysis|
214436843|NCT03807752|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
214436844|NCT03807752|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
214436845|NCT04005287|DRUG|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
214436846|NCT04005287|DRUG|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
214436847|NCT04005287|DRUG|Placebo Low Dose|Topical Solution
214436848|NCT04005287|DRUG|Placebo High Dose|Topical Solution
214436849|NCT01985542|DRUG|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
214436850|NCT03498196|DRUG|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
214436851|NCT01205048|DEVICE|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
214436852|NCT01205048|DEVICE|Juvederm® Ultra|24mg/mL
214436853|NCT02752503|DRUG|Nalmefene|
215116197|NCT02274792|DRUG|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
215116198|NCT04120415|BIOLOGICAL|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
215116199|NCT04120415|BIOLOGICAL|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
215116200|NCT04120415|BIOLOGICAL|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
215116201|NCT05809193|BEHAVIORAL|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
215116202|NCT00022802|DEVICE|Image-guided surgical system|
215116203|NCT03189160|BIOLOGICAL|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
215116204|NCT03189160|BIOLOGICAL|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
214436854|NCT04187599|DEVICE|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
214436855|NCT03964870|DIAGNOSTIC_TEST|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
214436856|NCT01255670|DRUG|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
214436857|NCT02269475|DRUG|MEDI3250|MEDI3250
214436858|NCT02269475|DRUG|Placebo|Placebo
214436859|NCT01037985|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
214436860|NCT01037985|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
214436861|NCT05949359|OTHER|Nintendo RingFit-augmented exercise program|"Participants in the NRE group received an 8-week exercise training program using the Nintendo RingFit (60 minutes for each session, two sessions a week). In each session, the participants first performed 5 minutes of walk-up exercises (i.e., simple jogging), followed by 50 minutes of Nintendo RingFit exercises and 5 minutes of cool down exercises.~The exercise intensity, in terms of repetitions, holding time of the exercise and advancement to difficult tasks, progressed gradually in 8 weeks."
214436862|NCT03063866|DRUG|Propofol|Propofol 1 mg/kg i.v
214436863|NCT03063866|DRUG|Midazolam|Midazolam 3 mg i.v
214436864|NCT03063866|DRUG|Fentanyl|fentanyl 0.5 ug/kg
214436865|NCT02730871|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
214436866|NCT02730871|DRUG|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
214436867|NCT02730871|DRUG|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
214436868|NCT02247817|DEVICE|Hybrid CRT-D/P implantation|
214436869|NCT03489187|DEVICE|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
214436870|NCT01298934|DRUG|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
214436871|NCT00823472|DRUG|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
214436872|NCT00996749|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
214436873|NCT00996749|OTHER|bone scan|Correlative studies
214436874|NCT00996749|OTHER|dual x-ray absorptometry|Correlative studies
214436875|NCT00996749|OTHER|laboratory biomarker analysis|Correlative studies
214436876|NCT00996749|PROCEDURE|biopsy|Correlative studies
214436877|NCT06137105|DRUG|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
214436878|NCT04649996|PROCEDURE|Appendectomy|comparison between operative and conservative treatment
214436879|NCT01754636|OTHER|No intervention|
214516607|NCT05386537|COMBINATION_PRODUCT|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
214516608|NCT05386537|DEVICE|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
214516609|NCT05386537|OTHER|Games only|Using VR-video games only
214516610|NCT05386537|OTHER|Control|conventional UE therapy at a rehabilitation facility
214516611|NCT04003558|OTHER|No interventions|As this is a patient registry, there are no interventions.
214516612|NCT01239641|PROCEDURE|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
214516613|NCT04176549|OTHER|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
214516614|NCT04176549|OTHER|Management of termination of pregnancy|Surgical termination of pregnancy
214516615|NCT04176549|OTHER|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
214516616|NCT04543669|BIOLOGICAL|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
214516617|NCT02400749|DRUG|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
214516618|NCT02400749|DRUG|Placebo|Placebo tablets will be provided to sites in blister cards.
214516619|NCT05776329|BEHAVIORAL|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
214516620|NCT05776329|BEHAVIORAL|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
214516621|NCT06005116|RADIATION|[68Ga]-NOTA-SGC8|Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate cleanly before irrigation, and then irrigated \[68Ga\]-NOTA-SGC8 into the bladder via catheter for 30 minutes to make full contact between the injection and tumor. After 30 minutes, the injection will be withdrawn and 300ml normal saline will be injected into the bladder to maintain the shape of the bladder.
214516622|NCT02240810|DEVICE|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
214516623|NCT03647800|BIOLOGICAL|APVO436|APVO436
214516624|NCT04620265|OTHER|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
214692685|NCT05747131|BEHAVIORAL|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
214692686|NCT03397927|DEVICE|orthosis|
214692687|NCT02307669|BEHAVIORAL|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
214516625|NCT04620265|OTHER|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
214516626|NCT04620265|OTHER|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
214516627|NCT04620265|OTHER|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
214516628|NCT04620265|OTHER|The conventional exercise program|This group received the conventional exercise program only.
214516629|NCT04425252|DRUG|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
214516630|NCT04425252|OTHER|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
215116205|NCT03189160|OTHER|Non-treatment control group|
215116206|NCT03010033|OTHER|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
214436880|NCT04019444|BIOLOGICAL|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
214436881|NCT04019444|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
214436882|NCT04019444|BIOLOGICAL|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
214436883|NCT05908669|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
214436884|NCT01609218|DRUG|LY2140023|
215116207|NCT00476827|DRUG|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
214436885|NCT01609218|DRUG|Aqueous activated charcoal|
214436886|NCT00199082|DRUG|Adriamycin|
214436887|NCT00199082|DRUG|Cyclophosphamide|
214436888|NCT00199082|DRUG|Cytarabine|
214436889|NCT00199082|DRUG|Dexamethasone/Prednisolone|
214436890|NCT00199082|DRUG|VP16|
214436891|NCT00199082|DRUG|Ifosfamide|
214436892|NCT00199082|DRUG|Methotrexate|
214436893|NCT00199082|DRUG|G-CSF|
214436894|NCT00199082|DRUG|Rituximab|
214436895|NCT00199082|DRUG|Vincristine/Vindesine|
214436896|NCT00199082|PROCEDURE|Irradiation (in specific conditions)|
214436897|NCT03035396|DEVICE|Diassess Influenza A and B Test|
214436898|NCT06854471|OTHER|Placebo beverage, kiwi-strawberry flavor|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose
214436899|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436900|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436901|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436902|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436903|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 2|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436904|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436905|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436906|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214436907|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214516631|NCT00307489|DRUG|tenofovir DF|300 mg tablet, once daily (QD)
214516632|NCT00307489|DRUG|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
215116208|NCT00476827|DRUG|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
215116209|NCT00476827|DRUG|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
214436908|NCT01996605|DRUG|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
214436909|NCT01996605|DRUG|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
214436910|NCT01996605|DRUG|Placebo|placebo will be administered spinally
214436911|NCT01472003|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
214436912|NCT01472003|DRUG|ABT-806i|ABT-806i will be administered by intravenous infusion.
214436913|NCT06019923|OTHER|No intervention|No intervention
214436914|NCT06684782|OTHER|Screening for symptoms of restless leg syndrome|The patients will be screened for restless leg syndrome by clinical questioning.
214436915|NCT04317794|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
214436916|NCT06859723|DRUG|Placebo Comparator: Placebo|Placebo
214436917|NCT06859723|DRUG|Low dose THC|Smoked low dose THC
214436918|NCT06859723|DRUG|High dose THC|Smoked high dose THC
214436919|NCT06859684|DRUG|Durvalumab|Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined by the investigator); during maintenance therapy: 1500 mg Q4W
214436920|NCT06859684|DRUG|hepatic arterial infusion chemotherapy (HAIC)|hepatic arterial infusion chemotherapy (HAIC) : GemCis regimen was adopted, with the specific regimen as follows: cisplatin 60 mg/m2 on the first day, arterial infusion for half an hour, gemcitabine 1000 mg/m2 on the first day, arterial infusion for half an hour, repeated once every 3 weeks, and 4-6 cycles of treatment (the specific number of cycles was determined by the investigator according to the patient's condition).
214516633|NCT05363839|DRUG|ACH-000029|ACH-000029 will be administered orally via a capsule.
214516634|NCT05363839|DRUG|Placebo|Placebo will be administered orally via a capsule.
214436921|NCT06859684|DRUG|Lenvatinib|Lenvatinib 8mg (weight \<60 kg) or 12mg (weight ≥60 kg) oral QD, during combination therapy, starting on day 3 of each 3-week cycle (determined by the investigator)
214436922|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
215116210|NCT00476827|DRUG|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
215116211|NCT00476827|DRUG|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
215116212|NCT00476827|DRUG|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
215116213|NCT03370042|PROCEDURE|semilunar coronally positioned flap with free gingival graft|
215116214|NCT03370042|PROCEDURE|semilunar coronally positioned flap alone|
215116215|NCT03590314|DEVICE|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
215116216|NCT03590314|OTHER|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
215116217|NCT00227812|DRUG|Bupropion|
215116218|NCT01912196|DRUG|MSI-195|
215116219|NCT01912196|DRUG|Placebo|
215116220|NCT03708718|DRUG|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
214436923|NCT04220229|DRUG|Cabozantinib S-malate|Given PO
214436924|NCT04220229|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214436925|NCT02286154|DRUG|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
214436926|NCT04428112|BEHAVIORAL|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
214436927|NCT04428112|BEHAVIORAL|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
214436928|NCT06859372|BEHAVIORAL|Nurturing Care Family Navigator|The Nurturing Care Family Navigator (NCFN) is a comprehensive barrier-focused and long-term family-centered intervention that will offer screenings for food insecurity, referrals to community resources, and follow-up with families experiencing very low or low food security in the past 12 months. The goal of the NCFN is to increase knowledge (cognitive factors) and self-efficacy (behavioral factors) to navigate barriers across the four pillars of food insecurity by securing enrollment and sustaining engagement with a set of community nurturing care services (environmental factors) to improve levels of food security, and ultimately maternal-child health and nutrition outcomes of low-income families during the postpartum phase.
214436929|NCT05349331|PROCEDURE|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
214436930|NCT05925140|DRUG|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
214436931|NCT05925140|DRUG|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
214516635|NCT03473665|DRUG|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
214516636|NCT03473665|DRUG|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
214516637|NCT03473665|DRUG|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
214516638|NCT03473665|DRUG|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
215116221|NCT03708718|DRUG|Placebo oral capsule; From August 2020 'no additional treatment'|Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
215116222|NCT03361293|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
215116223|NCT03361293|BEHAVIORAL|Cognitive training|BrainHQ Computerized cognitive training
215116224|NCT03361293|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
214436932|NCT05925140|DRUG|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
214436933|NCT05925140|OTHER|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if \>80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
214436934|NCT07007260|DIETARY_SUPPLEMENT|niacinamide supplementation|Patients will take niacinamide supplementation (500mg) every day for 1 year
214436935|NCT06315179|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy (EGD) with biopsy|Esophagogastroduodenoscopy (EGD) is a test procedure to examine the lining of the esophagus, stomach, and first part of the small intestine.
214516639|NCT03361202|OTHER|blood sampling|"* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge."
214516640|NCT01592422|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
214516641|NCT01592422|OTHER|Best Supportive Care|Best Supportive Care in the absence of disease progression
214516642|NCT05235815|PROCEDURE|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
214516643|NCT01621321|DRUG|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
214516644|NCT01621321|DRUG|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
214516645|NCT05351788|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
214516646|NCT05351788|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
214516647|NCT05351788|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
215116225|NCT01761448|DEVICE|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
215116226|NCT01761448|DEVICE|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
215116227|NCT01761448|DEVICE|Control group training without Guided Exercise system at home|
215116228|NCT02229188|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
215116229|NCT02229188|BEHAVIORAL|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
215116230|NCT02229188|BEHAVIORAL|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
215116231|NCT05726487|BEHAVIORAL|ACTION Intervention|Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
215116232|NCT05726487|OTHER|Education Control|Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
215116233|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
214436936|NCT06315179|DIAGNOSTIC_TEST|Colonoscopy w/ biopsy|Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
214436937|NCT02792114|DRUG|Cyclophosphamide|
214436938|NCT02792114|BIOLOGICAL|Mesothelin-targeted T cells|
214436939|NCT02792114|DRUG|AP1903|
214436940|NCT01207492|DRUG|nilotinib|Taken orally twice daily
214436941|NCT02769858|DEVICE|Light therapy|Light therapy glasses
214436942|NCT02807779|DRUG|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
214436943|NCT02807779|DEVICE|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
214516648|NCT05351788|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
214516649|NCT02889172|BEHAVIORAL|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
214516650|NCT01612897|OTHER|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
214516651|NCT01544894|DRUG|Raloxifene|60 mg/d for one year
214516652|NCT01544894|DRUG|Strontium ranelate|2 g/d, for one year
214692688|NCT02307669|BEHAVIORAL|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
214516653|NCT01441336|PROCEDURE|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
214516654|NCT01717625|DRUG|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
214692689|NCT01865435|GENETIC|cord blood sample|
215116234|NCT06173154|OTHER|Routine care|standard care without any specific system in place
215116235|NCT06440629|DRUG|Therapeutic drug monitoring (TDM) of adalimumab|"In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range:~* Serum drug level within therapeutic range : keep dose~* Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week~* Low drug levels, ADAb high levels : Switch to another therapy~* High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks"
214436944|NCT02807779|DEVICE|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
214436945|NCT06693804|OTHER|Digital Otoscope and Ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination and magnification during physical examinations.
214436946|NCT06693804|OTHER|Conventional otoscope and ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination during physical examinations.
214436947|NCT07071103|RADIATION|Low-dose radiotherapy to the intestine (ILDR)|A single total dose of 1 Gy irradiation targeting the jejunum and ileum. Primary tumor or metastatic lesions that are within the irradiation field are irradiated concurrently.
214436948|NCT07071103|DRUG|PD-1/PD-L1 monoclonal antibodies|Pre-progression immunotherapy regimen continues or switches to an alternative PD-1/PD-L1 monoclonal antibody according to clinical guidelines.PD-1/PD-L1 monoclonal antibody will be given 1 day after ILDR at a 3-week interval.
214436949|NCT07070414|BEHAVIORAL|Brief Negotiation Interview intervention (BNI) (adapted)|A brief motivational interview designed to increase motivation to reduce alcohol and/or cannabis use and engagement in treatment referral.
214436950|NCT03897127|DRUG|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
214436951|NCT03897127|DRUG|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
214436952|NCT03897127|DRUG|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3"
214692690|NCT03978182|DEVICE|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
214692691|NCT02130479|BEHAVIORAL|Contingency Management-Family Engagement|
214692692|NCT02130479|BEHAVIORAL|Treatment as Usual|
214692693|NCT00310570|DEVICE|Circumferential thermoplastic thimble splint|
214692694|NCT00310570|DEVICE|"dorsal aluminium foam Mexican Hat splint"|
214692695|NCT00310570|DEVICE|stack splint (control)|
214692696|NCT01258530|DRUG|over-encapsulated oseltamivir|75 mg once
214692697|NCT01258530|DRUG|oseltamivir|75 mg once
214692698|NCT00304265|BIOLOGICAL|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
214692699|NCT00352755|PROCEDURE|Surgical debulking with peritonectomy|
214436953|NCT05020756|DIETARY_SUPPLEMENT|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
214436954|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
214436955|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
214436956|NCT06923267|DIAGNOSTIC_TEST|No Pressure Support No Positive End Expiratory Pressure Spontaneous Breathing Trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing both the positive end-expiratory pressure (PEEP) and the pressure support to 0 cmH2O, for 15 minutes.
214436957|NCT06923267|DIAGNOSTIC_TEST|Pressure Support Spontaneous Breathing trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing the positive end-expiratory pressure (PEEP) to 0 cmH2O and the pressure support to 7 cmH2O, for 15 minutes. A 10-minute washout period is left before the start of the next SBT modality.
214436958|NCT06923267|DIAGNOSTIC_TEST|Humidified High Flow Spontaneous Breathing Trial|The spontaneous breathing trial is carried out with humidified high flow ventilator mode set at 50 liters per minute for 15 minutes. The patient will be connected to the ventilator via a specific connector enabling the administration of humidified high flow. A 10-minute washout period is left before the start of the next SBT modality.
215116236|NCT02461927|DRUG|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
215116237|NCT02461927|DRUG|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
215116238|NCT02461927|DRUG|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
215116239|NCT05092945|OTHER|Cold exposure|The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
215116240|NCT05092945|DRUG|Oral Nicotinic acid|A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
215116241|NCT05460988|PROCEDURE|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
215116242|NCT05460988|PROCEDURE|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
215116243|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
215116244|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
215116245|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
215116246|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
215116247|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
215116248|NCT06319703|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) Videos|Text message-delivered video-based DSMES intervention.
215116249|NCT06319703|BEHAVIORAL|Community Health Worker Support (CHW)|Assess participants' SDOH barriers to Type 2 diabetes care and link them to available resources in the community.
214436959|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
214436960|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) combined with face-to-face videoconferencing sessions with a therapist in BF-GROw group|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022)combined with face-to-face videoconferencing sessions with a therapist (blended) . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. BF-GROw group will receive a treatment module every 10-12 days. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
214692700|NCT00352755|DRUG|Intraperitoneal 5FU|
214692701|NCT00352755|DRUG|FOLFOX|
214692702|NCT05293652|OTHER|Iontophoresis|Hydrocortisone iontophoresis
214692703|NCT05293652|OTHER|Phonophoresis|Hydrocortisone Phonophoresis
215116250|NCT06139601|BEHAVIORAL|Virtual single session intervention|A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
215116251|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
214436961|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) supported by the App developed which contains the EMA and EMI tools in iGROw group.|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022) supported by the App developed which contains the Ecological Momentary Assessment (EMA) and Ecological Momentary Intervention (EMI) tools . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
214516655|NCT05145634|OTHER|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
214436962|NCT01871675|DRUG|IPI-145|
214436963|NCT01871675|DRUG|Rituximab|
214436964|NCT01871675|DRUG|Bendamustine|
214436965|NCT03638427|DIAGNOSTIC_TEST|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
214516656|NCT01123005|PROCEDURE|PET Scan|radiation calculated per patient
214516657|NCT01123005|DRUG|EF5|10 mCi, IV
214516658|NCT01123005|DRUG|Carbogen|Calculated per patient
214516659|NCT01123005|DRUG|Dichloroacetate|
214516660|NCT02446015|DRUG|SYSTANE® ULTRA Lubricant Eye Drops|
214516661|NCT01233245|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
214516662|NCT00553813|DRUG|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
214516663|NCT04694053|PROCEDURE|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
214516664|NCT05350709|OTHER|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
214436966|NCT02181660|DRUG|Gilteritinib|oral
214436967|NCT00675246|DRUG|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
214516665|NCT03438968|BEHAVIORAL|Exercise training|Cardiac Rehabilitation exercise training
214516666|NCT00275314|DRUG|Valganciclovir|
214516667|NCT01705444|DEVICE|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
214516668|NCT04179799|DEVICE|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
214516669|NCT05483556|DEVICE|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
214516670|NCT05483556|DEVICE|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
214516671|NCT04816539|DEVICE|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
214516672|NCT01411683|DEVICE|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
214516673|NCT05340283|PROCEDURE|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
214516674|NCT02964234|BEHAVIORAL|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
214516675|NCT02964234|BEHAVIORAL|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
214516676|NCT02165696|OTHER|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
214516677|NCT02165696|OTHER|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
214692704|NCT05293652|OTHER|traditional PT program|Ultrasound and deep friction massage
214692705|NCT04104906|OTHER|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
215116252|NCT02468726|DEVICE|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
214436968|NCT06953284|OTHER|KINESOTAPING|Kinesio Taping (KT) is commonly used in sport injuries, in neurology and oncology patients following the surgical protocols, and for paediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception.7-9 Although its mechanism of action has not been fully understood, it is believed that activation of the cutaneous receptors could influence neuromuscular functions.10 The cutaneous sensory system provides preliminary information about limb positions and muscle forces to the central nervous system for monitoring and controlling limb movements, planning actions, and providing fluent movement.11 Common causes of unilateral spastic CP are middle cerebral artery infarct, hemi-brain atrophy, periventricular lesions, and brain malformations that disturb the integrity of the motor areas. Middle cerebral artery infarctions can particularly impair the somatosensory sy
214436969|NCT06953284|OTHER|Functional Electrical Stimulation|This systematic review is the first to examine the effect of FES on activity in children with CP using only randomized trials.However, evidence was limited with only 5 trials being included. This limited evidence suggests that FES is effective, that is, it is better than no FES intervention, but that it is no more effective than activity training, that is, practicing the activity without FES will be just as effective. Furthermore, no evidence was found on whether any benefits are maintained beyond the intervention period because even though a follow-up measurement was reported for 2 studies, the authors failed to provide data. Even though the review was restricted to the highest standard of evidence, randomized trials, firm conclusions cannot be made. This is primarily because of the absence of group data (means and SD) in the papers, preventing a meta-analysis. This poor reporting is disappointing given that 3 of the 5 trials were published within the last 5 years. Therefore, we may b
214436970|NCT02089698|DEVICE|Mini-flared|Mini-flared Kelman tip
214436971|NCT02089698|DEVICE|Reversed tip|Reversed Kelman tip
214436972|NCT06334666|OTHER|Encourage using pedometer|MASLD patient used pedometer recording actively with encourage by care provider or investigator
214436973|NCT03795220|DRUG|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
214436974|NCT03795220|DRUG|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
215116253|NCT02468726|DRUG|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
214436975|NCT03795220|DRUG|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
214436976|NCT03795220|DRUG|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
214436977|NCT06335628|DEVICE|Geistlich Fibro-Gide®|Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.
214436978|NCT03757949|OTHER|Laboratory Biomarker Analysis|Correlative studies
214436979|NCT03757949|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive SIM PO
214692706|NCT04104906|OTHER|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
215116254|NCT00149903|DRUG|Mycophenolate sodium (enteric coated)|
215116255|NCT04575571|OTHER|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
215116256|NCT03325842|DIAGNOSTIC_TEST|ASKp|30 items questionnaire
215116257|NCT05663463|DRUG|Fluzone High-Dose - 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
215116258|NCT05663463|DRUG|Fluzone High-Dose - 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
215116259|NCT02362750|OTHER|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
214436980|NCT03757949|OTHER|Placebo Administration|Given PO
214436981|NCT03757949|OTHER|Quality-of-Life Assessment|Ancillary studies
214436982|NCT03757949|OTHER|Questionnaire Administration|Ancillary studies
214436983|NCT06298786|DIAGNOSTIC_TEST|Functional 6-minute mastication test|All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
214436984|NCT05884775|OTHER|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
214436985|NCT05290597|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
214436986|NCT06155708|DIETARY_SUPPLEMENT|Ketone|\- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
214436987|NCT06155708|DIETARY_SUPPLEMENT|Water|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
214436988|NCT05655819|DRUG|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
214436989|NCT05655819|DRUG|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
214436990|NCT03647423|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
214436991|NCT03647423|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214436992|NCT03647423|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214436993|NCT03647423|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
214436994|NCT03647423|BIOLOGICAL|GI-6301|Brachyury yeast
214436995|NCT03647423|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
214436996|NCT03647423|DRUG|Avelumab|injection
214436997|NCT03647423|DRUG|Cetuximab|Injection
214436998|NCT03647423|DRUG|Cyclophosphamide|Capsules
214436999|NCT03647423|RADIATION|SBRT|Stereotactic body radiation therapy
214437000|NCT04170062|DEVICE|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
214437001|NCT04170062|DEVICE|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
214437002|NCT05786482|BEHAVIORAL|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
214437003|NCT05786482|BEHAVIORAL|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
215116260|NCT02362750|OTHER|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
214437004|NCT06472492|BEHAVIORAL|Adjuvant yoga intervention|The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
214437005|NCT06530212|PROCEDURE|SGJIB|sleeve gastrectomy with jejunoileal bypass with anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction.
214437006|NCT06530212|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.
214437007|NCT05146427|DEVICE|Slow-wave enhancement|A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.
214437008|NCT05146427|DEVICE|Sham device|A headband that measures slow-wave activity during sleep but has no auditory stimulation.
214692707|NCT04597281|OTHER|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
214437009|NCT05736159|DIAGNOSTIC_TEST|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
214437010|NCT05736159|DIAGNOSTIC_TEST|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
214437011|NCT06290427|DEVICE|DaVinci RAPN|Robot-assisted Partial Nephrectomy with DaVinci® Surgical System
214437012|NCT06290427|DEVICE|Hugo RAS RAPN|Robot-assisted Partial Nephrectomy with Hugo™ RAS System
214437013|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their primary care physician (PCP). This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
214437014|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
214437015|NCT04961164|DIETARY_SUPPLEMENT|Resistant Potato Starch, Corn Starch|Consume resistant potato starch at study period 1, then consume corn starch at study period 2.
214437016|NCT04961164|DIETARY_SUPPLEMENT|Corn Starch, Resistant Potato Starch|Consume corn starch at study period 1, then consume resistant starch at study period 2.
214437017|NCT06756282|PROCEDURE|Pacemaker and defibrillator|only patients with pacemaker implantation will be evaluated in the study
215116261|NCT02362750|OTHER|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
215116262|NCT02362750|OTHER|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
214437018|NCT05657119|BEHAVIORAL|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
214437019|NCT05657119|BEHAVIORAL|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
214437020|NCT05657119|BEHAVIORAL|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement"
214437021|NCT05657119|BEHAVIORAL|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
214437022|NCT01701986|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
214437023|NCT01701986|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic BMT or PBSCT
214437024|NCT01701986|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214437025|NCT01701986|DRUG|Busulfan|Given IV
214437026|NCT01701986|DRUG|Clofarabine|Given IV
214437027|NCT01701986|DRUG|Gemcitabine Hydrochloride|Given IV
214437028|NCT01701986|DRUG|Mycophenolate Mofetil|Given IV then PO
214437029|NCT01701986|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214437030|NCT01701986|OTHER|Pharmacological Study|Correlative studies
214437031|NCT01701986|BIOLOGICAL|Rituximab|Given IV
214437032|NCT01701986|DRUG|Tacrolimus|Given IV then PO
214437033|NCT00777582|DRUG|AZD2281|Oral single dose formulation
214437034|NCT06247371|BEHAVIORAL|Decision aid|The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
214437035|NCT04295317|DRUG|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
214437036|NCT04295317|DRUG|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
214437037|NCT03702842|DEVICE|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
214437038|NCT03702842|OTHER|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
214437039|NCT04814186|DRUG|Tafamidis|61 mg, once daily, oral administration, for 12 months.
214437040|NCT06062069|DRUG|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
214437041|NCT06062069|DEVICE|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
214437042|NCT06062069|DRUG|CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
214437043|NCT06757231|BEHAVIORAL|Nurse Counseling Based on the Chronic Care Model (CCM)|"This intervention involves personalized nurse counseling for patients diagnosed with Inflammatory Bowel Disease (IBD) based on the Chronic Care Model. The intervention includes:~Biweekly phone consultations and weekly informational messages to provide education and support for symptom management, stress reduction, and quality-of-life improvement.~An educational booklet to aid self-management. Follow-ups to assess progress, address concerns, and provide guidance on IBD management strategies."
215116263|NCT02362750|OTHER|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
215116264|NCT02362750|OTHER|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
215116265|NCT02362750|OTHER|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
215116266|NCT03599791|DRUG|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
215116267|NCT03599791|DRUG|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
214437044|NCT04404569|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
214437045|NCT01703078|DRUG|Ingenol once daily for two consecutive days|
214437046|NCT06694025|BIOLOGICAL|Efluelda Tetra Pre-filled syringe|Suspension for injection in a pre-filled syringe
214437047|NCT05391750|BIOLOGICAL|Tocilizumab|Given IV
214437048|NCT05391750|DRUG|Venetoclax|Given PO
214437049|NCT06429605|DRUG|duloxetine|In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
214437050|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
214516678|NCT02327975|OTHER|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
214516679|NCT02327975|OTHER|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
214516680|NCT02327975|OTHER|Control group|No received intervention.
214516681|NCT01727076|OTHER|Laboratory Biomarker Analysis|Correlative studies
214516682|NCT01727076|OTHER|Pharmacological Study|Correlative studies
214516683|NCT01727076|BIOLOGICAL|Recombinant Human Interleukin-15|Given SC
214516684|NCT03669419|DIAGNOSTIC_TEST|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
214516685|NCT02363153|OTHER|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
214516686|NCT02163499|DRUG|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
214516687|NCT00091676|BIOLOGICAL|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
214516688|NCT00091676|BIOLOGICAL|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
214516689|NCT01412398|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
214437051|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
214437052|NCT06040190|DRUG|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
214437053|NCT06040190|DRUG|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
214437054|NCT06040190|DIETARY_SUPPLEMENT|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
214437055|NCT06040190|OTHER|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
214516690|NCT02646878|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
214516691|NCT00816816|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
214516692|NCT01118429|DRUG|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
215116268|NCT03599791|DRUG|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
215116269|NCT02960607|DRUG|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
215116270|NCT00214513|BEHAVIORAL|Home-based exercise training|
214437056|NCT06040190|RADIATION|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
214437057|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
214437058|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
214516693|NCT01118429|DRUG|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
215116271|NCT01952236|BEHAVIORAL|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
215116272|NCT01952236|BEHAVIORAL|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
215116273|NCT00200720|BEHAVIORAL|Atkins diet (low carbohydrate diet)|
215116274|NCT00200720|BEHAVIORAL|DASH diet (high carbohydrate diet)|
215116275|NCT06172647|DIAGNOSTIC_TEST|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
215116276|NCT03516422|PROCEDURE|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
215116277|NCT03516422|OTHER|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
215116278|NCT03636126|DEVICE|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
215116279|NCT02473900|DRUG|HIP1403|Oseltamivir 75mg
215116280|NCT02473900|DRUG|HGP0919|Oseltamivir phosphate 75mg
215116281|NCT02814942|DEVICE|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
215116282|NCT03255317|BEHAVIORAL|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
215116283|NCT03255317|BEHAVIORAL|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
214437059|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
214437060|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
214437061|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
214437062|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
214437063|NCT04919590|BEHAVIORAL|This is Quitting|Text message-based intervention for quit vaping support.
214516694|NCT01219400|DRUG|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
215116284|NCT06345625|DIAGNOSTIC_TEST|Cognition|"1. The CatchU® app quantitatively and objectively measures the ability to integrate visual-somatosensory information using reaction time test data.~2. Digit Symbol Substitution test assesses processing speed and attention by requiring individuals to match symbols with corresponding numbers within a specified time frame.~3. Trail Making Test part 1 and 2: assesses cognitive flexibility, visual attention, and task-switching by having individuals connect numbered circles in sequence (part 1) and then alternate between numbers and letters (Part 2).~4. Go/No Go test measures an individual's ability to inhibit a prepotent response (No-Go) and execute a response when required (Go). This test provides insights into executive functioning, particularly inhibitory control."
214437064|NCT04919590|OTHER|Assessment only control|Assessment only
214437065|NCT04919590|OTHER|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
214437066|NCT06060158|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 sessions
214437067|NCT05443594|DEVICE|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
214437068|NCT05443594|DEVICE|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
214516695|NCT01701089|DRUG|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
214437069|NCT06417229|DRUG|BMS-986365|Specified dose on specified days
214437070|NCT06417229|DRUG|Rabeprazole|Specified dose on specified days
214437071|NCT06464458|OTHER|management on hydroxyurea by therapeutic pharmacological monitoring|"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."
214437072|NCT06423183|BEHAVIORAL|A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)|Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
214437073|NCT06526741|OTHER|Longitudinal data collection|This is an observational ambispective non-interventional registry collecting longitudinal real-world data only. There is no intervention.
214437074|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
214437075|NCT01853748|DRUG|Trastuzumab|
214437076|NCT01853748|DRUG|Paclitaxel|
214437077|NCT01853748|DRUG|Trastuzumab emtansine|
214437078|NCT02631603|DRUG|Placebo|Administer Placebo as anti-inflammatory
214437079|NCT02631603|DRUG|Prednisolone|Administer Prednisolone as anti-inflammatory
214516696|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for 14 days
214516697|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for up to 17 days
214516698|NCT03117218|DIAGNOSTIC_TEST|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
214516699|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
214516700|NCT00857311|BIOLOGICAL|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
214516701|NCT00857311|BIOLOGICAL|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
214516702|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
214516703|NCT02261922|DRUG|ticagrelor|
214437080|NCT05115968|PROCEDURE|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
214437081|NCT03575013|DRUG|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
214437082|NCT03575013|DRUG|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
214437083|NCT06088888|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
214437084|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
214437085|NCT03632941|BIOLOGICAL|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
214516704|NCT02261922|DRUG|prasugrel|
214516705|NCT01189045|BEHAVIORAL|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
214437086|NCT03632941|BIOLOGICAL|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
214437087|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
214437088|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
214437089|NCT05736432|DIETARY_SUPPLEMENT|Blueberries|Experimental condition
214516706|NCT01189045|BEHAVIORAL|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
214516707|NCT02965352|DEVICE|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
214437090|NCT05736432|DIETARY_SUPPLEMENT|Placebo|Placebo condition
214437091|NCT03342027|DRUG|Bupropion|medication for smoking cessation
214437092|NCT03342027|BEHAVIORAL|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
214437093|NCT03342027|OTHER|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
214437094|NCT05958719|DRUG|Chidamide|chidamide 30mg biw, p.o, 21 days for a cycle.
214437095|NCT05958719|DRUG|Azacitidine|75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.
214437096|NCT05958719|DRUG|liposomal mitoxantrone|12mg/m2， d1,21 days for a cycle.
214437097|NCT05958719|DRUG|prednisone|60mg/m2，d1-5,21 days for a cycle.
214437098|NCT06083649|BEHAVIORAL|The AI-assisted tool used in this study was called Dental Monitoring (DM).|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
214437099|NCT02376049|DRUG|Pimecrolimus cream|
214437100|NCT02376049|DRUG|Betamethasone dipropionate cream|
214437101|NCT02376049|DRUG|Clobetasol propionate cream|
214437102|NCT02376049|DRUG|Glaxal Base cream vehicle|
214437103|NCT03566043|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
214437104|NCT05583136|DEVICE|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
214437105|NCT05583136|DEVICE|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
214437106|NCT05583136|DEVICE|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
214516708|NCT02965352|DEVICE|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
214516709|NCT02965352|DEVICE|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
214437107|NCT06462118|DRUG|Astegolimab|Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
214437108|NCT03863288|PROCEDURE|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
214437109|NCT03863288|DRUG|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
214437110|NCT03863288|DRUG|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
214437111|NCT03863288|DRUG|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
214516710|NCT03512041|BEHAVIORAL|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
214516711|NCT03512041|BEHAVIORAL|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
214437112|NCT03863288|DRUG|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
214437113|NCT03863288|DRUG|Placebo|Placebo intranasal spray liquid administration
214437114|NCT02237417|DRUG|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
214437115|NCT02237417|DRUG|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
214437116|NCT02237417|OTHER|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
214437117|NCT06775938|OTHER|resident exam|Resident exam in May 2024.
214437118|NCT05413759|OTHER|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
214437119|NCT05374395|BEHAVIORAL|Peer Recovery Support-Delivered Dropout Prevention enhancement|Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
214437120|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
214437121|NCT05794581|DRUG|CT-868|CT-868
214437122|NCT05794581|DRUG|Placebo|Placebo as SC Injection
214437123|NCT05794581|DRUG|Victoza|Victoza as active comparator as SC Injection
214437124|NCT04043455|DRUG|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
214437125|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
214437126|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
214437127|NCT04043455|DRUG|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
214437128|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
214437129|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
214437130|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
214437131|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
214437132|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
214437133|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
214437134|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
214437135|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
214437136|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
214437137|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
215116285|NCT06345625|DIAGNOSTIC_TEST|Sensory function|"1. Cervical Sensorimotor control will be measured through a wireless wearable sensor 3D-cervical trainer by Sensamove on the placed on the head of the participant. The 3DCT registers cervical position sense by the Head Repositioning Accuracy test where the subject must relocate the head to the previously memorized (neutral) head position with the eyes closed and the joint position error degrees are registered. Cervical movement sense is examined using 'The Fly'-test where the subject ought to follow a movement pattern displayed on the screen in front of them. The movement of the neck-head unit is there upon tracked by the 3DCT and projected on the screen.~2. Vestibular function will be assessed through 3D-video Head Impulse Testing (vHIT), examining the state of the three semicircular canals by delivering the vestibulo-ocular reflex (vor) gain and vor gain asymmetry.~3. For the assessment of static and dynamic visual acuity, functional Head Impulse Testing (fHIT) will be used."
214437138|NCT04147585|OTHER|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
214437139|NCT05137587|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
214437140|NCT05137587|DRUG|propofol|propofol
214437141|NCT05137587|DRUG|ketamine|ketamine
214437142|NCT05370105|OTHER|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
214437143|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310
214516712|NCT03512041|BEHAVIORAL|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
214516713|NCT03512041|BEHAVIORAL|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
214516714|NCT03512041|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
214516715|NCT03512041|BEHAVIORAL|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
214516716|NCT03512041|BEHAVIORAL|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
214516717|NCT06506630|DIETARY_SUPPLEMENT|coenzyme Q10|300 mg capsule twice a day
214516718|NCT06506630|DIETARY_SUPPLEMENT|placebo|300 mg capsule twice a day
214516719|NCT03961178|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
214516720|NCT03961178|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
214516721|NCT04088305|DRUG|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
214516722|NCT05449145|DIETARY_SUPPLEMENT|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
214516723|NCT05449145|DIETARY_SUPPLEMENT|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
214516724|NCT05959226|BEHAVIORAL|Exercise Intervention|"1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
214516725|NCT05959226|DIETARY_SUPPLEMENT|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
214516726|NCT06068803|DIETARY_SUPPLEMENT|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
214516727|NCT06068803|DIETARY_SUPPLEMENT|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
214516728|NCT03498456|DRUG|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
214516729|NCT03498456|DRUG|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
214516730|NCT01697982|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
214437144|NCT03447379|DRUG|P2Y12 antagonist monotherapy|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
214437145|NCT03447379|DRUG|Aspirin plus P2Y12 antagonist|DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
214437146|NCT05194917|OTHER|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
214437147|NCT05194917|OTHER|Control Motivational Message|"One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code."
214516731|NCT01697982|BEHAVIORAL|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
214516732|NCT05971615|OTHER|peripheral venous blood gases|peripheral venous blood gases
214516733|NCT04893824|DEVICE|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
214516734|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 20mg
214516735|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 40mg
214516736|NCT04503629|DRUG|Rabeprazole sodium|Rabeprazole sodium 10mg
214516737|NCT01956396|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
215116286|NCT06345625|DIAGNOSTIC_TEST|Frailty|Frailty will be assessed using the Fried criteria, comprising 5 categories (each accounting for 1 point if scored positive): Unintentional weight loss (interview), weakness (grip strength with hand-held dynamometer), poor endurance and energy (two statements of the CES-D Depression Scale), slowness (walking speed over 15ft through gait analysis) and low physical activity level (Minnesota Leisure Time Activity questionnaire)(Fried et al., 2001).
215116287|NCT06345625|OTHER|Biomechanical movement analysis|Markers will be placed on the predefined anatomical locations and surface electrodes for electromyography will be applied at the predefined muscle locations following the SENIAM-guidelines. The Microsoft HoloLens 2 is fixated on the participant's head which will, on one hand, provide the cue to the participant for the head movement and on the other hand track eye and head movements. A safety harness is attached to the body and the ceiling of the lab. At the start of the trial, the subject will see a projection by the HoloLens 2 on the real environment moving to the left; right; upward; downward (cue in randomized order) which the participant is ought to follow with eyes and head. First while standing still and second while walking the 10-meter overground walkway at a self-preferred walking speed.
215116288|NCT06345625|OTHER|Screening|"The researcher will visit the possible participants (at their home, community centre, etc.) and after written consent on screening procedure is provided, the tests for eligibility will be performed.~1. Interview: asking about age (years), gender (male/female), medical history and the number of falls in the last 12 months .~2. Timed Up-and-Go (TUG) to check walking ability. TUG is a sensitive and specific measure for identifying risk for falls (Shumway-Cook et al., 2000)."
215116289|NCT06345625|OTHER|Follow up|Participants are followed up for 12 months. They fill in a fall diary and telephone reminders will be performed monthly to encourage participants to complete and return their diaries.
215116290|NCT06097026|PROCEDURE|Alveolar recruitment maneuver|Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.
215116291|NCT06097026|DRUG|Nitric Oxide|Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
215116292|NCT01550757|BEHAVIORAL|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
214437148|NCT05844566|DEVICE|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
214516738|NCT05683639|OTHER|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
214516739|NCT03539497|DIAGNOSTIC_TEST|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
214516740|NCT03101098|PROCEDURE|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
214516741|NCT03101098|PROCEDURE|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
214516742|NCT00828139|BIOLOGICAL|ziv-aflibercept|Given IV
214516743|NCT00828139|DRUG|topotecan hydrochloride|Given IV
214516744|NCT03110783|BIOLOGICAL|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
214516745|NCT06031493|COMBINATION_PRODUCT|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
214516746|NCT01714947|DRUG|[^14C]-alisertib|\[\^14C\]-alisertib oral solution
214516747|NCT01714947|DRUG|alisertib|Alisertib enteric coated tablets
214437149|NCT06364059|PROCEDURE|Decompressive craniectomy with evacuation of subdural hematoma|Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
214437150|NCT06130163|PROCEDURE|endoscopic retrograde cholangiopancreatography|endoscopical clearance of the common bile duct
214437151|NCT06296173|OTHER|"Protective open-lung extubation"|Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
214437152|NCT06296173|OTHER|Conventional extubation|Emergence using 100% FiO2, dorsal decubitus position with assistance or manual bag ventilation without PEEP
214437153|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
214437154|NCT05386134|DEVICE|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
214437155|NCT06254040|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
214437156|NCT06254040|DIETARY_SUPPLEMENT|mixture of extracts and DHA|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
214437157|NCT04520061|BEHAVIORAL|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
214437158|NCT06513338|DRUG|Eculizumab|eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
214437159|NCT04610853|DIAGNOSTIC_TEST|rotational thromboelastometry|ROTEM will be conducted and DIC score calculated within 24 hours after the diagnosis of Sepsis as well as on day 3 and 5 of ICU stay
214437160|NCT05000021|BEHAVIORAL|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
214437161|NCT05000021|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
214437162|NCT04385940|DIETARY_SUPPLEMENT|Ddrops® products, 50,000 IU, Oral|Vitamin D3
214437163|NCT04385940|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 1000IU
214437164|NCT05588414|PROCEDURE|Standardization of the sentinel node detection procedure|All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
214516748|NCT03737188|DEVICE|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
214516749|NCT01922102|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
214516750|NCT01922102|DRUG|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
214437165|NCT06282770|DEVICE|Laser Diode Brace|The device is a brace with laser diodes. The braces light up and the red light has therapeutic abilities.
214437166|NCT06282770|DEVICE|Sham Laser Diode Brace|The Sham brace has no therapeutic ability and will act as a placebo.
214437167|NCT03207594|OTHER|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
214437168|NCT03207594|OTHER|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
214437169|NCT03207594|OTHER|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
214516751|NCT01922102|DRUG|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
214516752|NCT00677742|OTHER|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
214516753|NCT00677742|OTHER|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
214516754|NCT04462159|BEHAVIORAL|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
214692708|NCT04836819|DRUG|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
214516755|NCT04034732|BEHAVIORAL|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
214437170|NCT05436106|BEHAVIORAL|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app."
214437171|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
214437172|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
214437173|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
214437174|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
214437175|NCT05124249|DIAGNOSTIC_TEST|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
214516756|NCT04034732|BEHAVIORAL|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
214516757|NCT00554905|PROCEDURE|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
214516758|NCT00554905|PROCEDURE|TACE|TACE first, then RFA within 2 weeks
214516759|NCT02920645|OTHER|AVM-related ICH|
214516760|NCT00463957|DRUG|sildenafil|
214516761|NCT00463957|DRUG|tadalafil|
215116293|NCT02134717|DRUG|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
215116294|NCT02134717|PROCEDURE|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
215116295|NCT02134717|PROCEDURE|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
215116296|NCT02134717|PROCEDURE|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
215116297|NCT04182841|DEVICE|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
215116298|NCT00051493|DRUG|ALIMTA|
215116299|NCT00051493|DRUG|Carboplatin|
215116300|NCT03335735|BEHAVIORAL|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
214437176|NCT05124249|PROCEDURE|PCI|Patients who undergoing PCI
214437177|NCT06207396|DIAGNOSTIC_TEST|serum and urine analysis|Spiking will be analyzed by immunoassay testing and high-resolution screening
214437178|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
214437179|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
214437180|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
214437181|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
214437182|NCT02992015|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
214516762|NCT00463957|DRUG|placebo|
214437183|NCT04246203|OTHER|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
214437184|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
214437185|NCT00724334|DRUG|SAR302503 (TG101348)|orally administered, once a day
214437186|NCT05570006|DRUG|ABBV-668|Oral Capsule
214437187|NCT04922021|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
214437188|NCT04922021|DRUG|LEO 138559 placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
214437190|NCT06826742|DRUG|Intravenous line (IV) Methadone|"Subjects will receive standardized spinal anesthesia without intrathecal morphine (intrathecal 1.6-2 mL 0.75% bupivacaine + dextrose, 15 mcg fentanyl) and intravenous methadone (0.2mg/kg total body weight up to max dose of 20 mg, with saline added to make total volume 2 mL)~The Intravenous line (IV) methadone will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
214437191|NCT06826742|DRUG|Intrathecal Morphine|"Subjects will receive standardized spinal anesthesia with intrathecal morphine 150 micrograms and no methadone (2cc dose of IV normal saline)~The Intravenous line (IV) saline will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
214437192|NCT06835517|BEHAVIORAL|Theory of Dissonance|The design of this intervention will consist of presenting information that generates dissonance with the subjects' attitudes and beliefs about clinical errors. Dissonance will be intensified by experiential experiences through simulations that provide compelling information that supports the idea of accepting honest errors as learning opportunities within the framework of a Just Culture.
214437193|NCT06835517|BEHAVIORAL|Theory of Reasoned Action|"The intervention will consist of the presentation, to the different groups, of testimonies, narratives, statements and analysis of everyday clinical practice situations that promote a change in the so-called subjective norms (a person's beliefs about whether significant people in his or her life approve or disapprove of a specific behavior) in relation to the acceptance of honest mistakes (including learning and improving health care from error)."
214437194|NCT06781528|OTHER|Ultrasound evaluation|All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
214516763|NCT00370747|DRUG|Ecabet|ophthalmic solution 2.83%
214516764|NCT00370747|DRUG|Ecabet|ophthalmic solution 3.70%
214516765|NCT00370747|DRUG|Placebo|
214516766|NCT00518596|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
214516767|NCT00878904|DRUG|epirubicin hydrochloride|
214516768|NCT00878904|DRUG|panobinostat|
214516769|NCT00878904|GENETIC|gene expression analysis|
214516770|NCT00878904|GENETIC|protein expression analysis|
214516771|NCT00878904|GENETIC|western blotting|
214516772|NCT00878904|OTHER|immunologic technique|
214516773|NCT00878904|OTHER|laboratory biomarker analysis|
214516774|NCT00878904|OTHER|pharmacological study|
214516775|NCT04523909|DIAGNOSTIC_TEST|Trajectory of neuroinflammatory proteins in CSF and blood|Kinetics of neuroinflammatory markers in CSF and blood
214516776|NCT01289899|DRUG|BR-A-657|120, 360mg or placebo 7days
214516777|NCT03420729|PROCEDURE|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
214516778|NCT03420729|DEVICE|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
214516779|NCT01094665|PROCEDURE|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
214516780|NCT00850954|OTHER|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
214516781|NCT00850954|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
214516782|NCT00850954|OTHER|Survey Administration|Ancillary studies
214516783|NCT00101296|DRUG|tipifarnib|Given orally
214516784|NCT00101296|OTHER|pharmacological study|Correlative studies
214516785|NCT00101296|OTHER|laboratory biomarker analysis|Correlative studies
214516786|NCT05486988|DRUG|Immunotherapy|PD-1/PD-L1 inhibitors
214516787|NCT05486988|DRUG|Chemotherapeutic Agent|2 cycles
214437195|NCT06715306|OTHER|Oral treatment|Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).
214437196|NCT06780202|DRUG|medrol dosepak|"Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg)."
214437197|NCT06780202|DRUG|HYDROcodone Oral Tablet|This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
214437198|NCT06145802|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
214437199|NCT06779929|DRUG|Tirzepatide|Tirzepatide
214437200|NCT06779929|DRUG|Dulaglutide|Dulaglutide
214516788|NCT05486988|DRUG|Chemotherapy|4\~6 cycles
214437201|NCT06834464|DRUG|Nanohydroxyapatite paste|nanohydroxyapatite paste will be applied with a brush on the surface of the teeth
214437202|NCT06834464|DRUG|HCl liquid|HCl liquid will be applied for 60 seconds prior to application of nanohydroxyapatite paste in certain groups
214437203|NCT06834464|DRUG|microabrasion|the material will be applied on the surface of teeth then microabrasion will be done with a rubber cup for 60 seconds
214437204|NCT06780813|BEHAVIORAL|Supplemental oxygen therapy|In this grou participants will receive supplemental oxygen in the form of a Venturi mask upon low oxygen saturation in oximetry (SaO2\<95%) and a nasal oxygen mask in all other cases during the first 2 postoperative days
214437205|NCT05741034|DEVICE|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
214437206|NCT05741034|OTHER|Control|No-treatment control
214692709|NCT04836819|DRUG|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
214437209|NCT06786104|OTHER|VIDEO-PEDS|Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.
214516789|NCT01330875|OTHER|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
214516790|NCT03274934|BEHAVIORAL|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
214516791|NCT03274934|BEHAVIORAL|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
214516792|NCT03274934|BEHAVIORAL|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
214516793|NCT03948958|OTHER|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
214516794|NCT03948958|OTHER|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
214516795|NCT03948958|OTHER|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
214516796|NCT03948958|OTHER|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
214437210|NCT06786104|OTHER|VIDEO-PEDS pilot|This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.
214437211|NCT06786104|OTHER|Focus Group|Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
214437212|NCT06785844|DRUG|Botulinum Toxin A (Botox )|Botulinum Toxin injection
214437213|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
214437214|NCT06783127|DRUG|Olaparib|Olaparib given according the clinical practice to BRCA positive mCRPC patients
214516797|NCT03948958|OTHER|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
214437215|NCT05786391|OTHER|Flat position|Flat patient position during the cystoscopy
214437216|NCT05786391|OTHER|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
214437217|NCT05786391|DEVICE|Insufflation|Insufflation to 15 mm Hg
214437218|NCT06788574|DEVICE|TECAR device: MCRR. The sign producer is an INDIBA® 448 kHz RF device that has a vaginal/ or rectum electrode (made in Barcelona, Spain)|TECAR (Transfer Electrical, Capacitive, and Resistive) is originally used in Italy. TECAR therapy is a radiofrequency (RF) therapy, which produces high-frequency waves. RF can be capacitive or resistive The capacitive mode (CET) generates energy in electrolyte-rich soft tissues such as muscles and vascular or lymphatic tissues . The resistive mode (RET) directs energy to deeper tissues that contain more fat and fibers (such as bones, ligaments, and tendons;
214437219|NCT06788574|PROCEDURE|pelvic floor exercises|pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each
214437220|NCT06788574|DEVICE|Sham device|sham treatment by Tecar device for 15 min without producing any waves.
214437221|NCT05086406|OTHER|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
214437222|NCT06834490|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
214437223|NCT06834490|DRUG|Placebo|Placebo IV solution, Placebo tablets
214437224|NCT04968990|DEVICE|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
214437225|NCT04968990|DRUG|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
214437226|NCT04968990|PROCEDURE|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
214437227|NCT04968990|PROCEDURE|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
214437228|NCT04968990|PROCEDURE|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
214437229|NCT05327543|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
214437230|NCT05327543|BEHAVIORAL|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
214437231|NCT06783166|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
214437232|NCT06783166|DRUG|Acetazolamide 500mg|Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
214437233|NCT06792357|OTHER|Vagal Active Tone Application Procedure|"First section; A video will be created that includes pictures and visuals describing the vagus nerve, explaining its benefits, and providing information about its effects and usage during the birth process.~Second section; Deep breathing and focus exercises;~Feather Breath:~Candle Breath: The pregnant woman inhaled and exhaled as if she was trying to blow out a candle.~Relaxation Breath: Deep breath Third section; Body relaxation exercises; Fourth section; Facial muscle relaxation exercises; Fifth section; Neck and larynx muscle relaxation exercises;"
214437234|NCT06701903|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
214437235|NCT06701903|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
214437236|NCT06701903|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
214437237|NCT06783530|BEHAVIORAL|Splint Therapy with Enhanced Doctor-Patient Communication|A structured communication protocol aimed at improving doctor-patient interaction and treatment adherence.
214437238|NCT06783530|DEVICE|Splint Therapy|A custom-fitted occlusal splint designed to alleviate symptoms of temporomandibular disorders (TMD).
214437239|NCT06294912|OTHER|Plasmodium falciparum|Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
214437240|NCT06294912|DRUG|MK-7602|Capsules to be administered orally.
214437241|NCT06294912|DRUG|Artemether/lumefantrine|Tablets to be administered orally as definitive antimalarial treatment.
214437242|NCT06294912|DRUG|Primaquine|Tablets to be administered orally as definitive antimalarial treatment.
214437243|NCT06294912|DRUG|Artesunate|Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
214437244|NCT06294912|DRUG|Atovaquone/proguanil|Tablets to be administered orally as definitive antimalarial treatment.
214437245|NCT06784622|DRUG|Treatment as usual|Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
214437246|NCT06835179|RADIATION|SBRT|SBRT short course radiotherapy (total dose 30-60 Gy, completed in 3-5 sessions)
214437247|NCT06835179|DRUG|PD-1 Inhibitors|Tislelizumab (200mg on day 1)
214692710|NCT04836819|DRUG|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
214692711|NCT01278017|DRUG|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
214437248|NCT06835179|DRUG|CapeOX + bevacizumab|intravenous administration of bevacizumab (7.5mg/kg on day 1), oxaliplatin (135mg/m² on day 1), as well as oral capecitabine (1g/m² twice daily from day 1 to day 14)
214437249|NCT03817684|DRUG|BPN14770|Drug BPN14770
214437250|NCT03817684|DRUG|Placebo|Placebo
214437251|NCT04105335|DRUG|MTL-CEBPA|Intravenous administration
214437252|NCT04105335|DRUG|Pembrolizumab|Intravenous administration
214437253|NCT04626479|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
214437254|NCT04626479|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
214437255|NCT04626479|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
214437256|NCT04626479|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
214437257|NCT04626479|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
214437258|NCT04626479|DRUG|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
214437259|NCT03108443|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
214437260|NCT06831279|OTHER|EXERCISE|Conventional Physiotherapy + Dual-Task Approach During Walking and Balance Exercises:
214437261|NCT00411905|DRUG|Bortezomib|
214437262|NCT04620187|DRUG|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
214437263|NCT04620187|RADIATION|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
214437264|NCT04620187|DRUG|Standard of Care Chemotherapy|Intravenous injection
214437265|NCT05588700|BEHAVIORAL|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
214437266|NCT05588700|BEHAVIORAL|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
214437267|NCT05588700|BEHAVIORAL|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
214437268|NCT06832800|COMBINATION_PRODUCT|MDT|"（actually not combination product, but have to select that option in order to delete warning in study desine）MDT method for sNH with the description as follow： 1. diagnosis of neonatal hemolysis：~The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they met one criterion from Category A or two criteria from Category B:~Category A:~1. Positive DAT~2. Significantly elevated ETCOc;~3. Significant morphological abnormalities~Category B:~1. Positive release test;~2. Elevated ETCOc;~3. COHb \> 1.2%;~4. Hb \< 140 g/L or Hct) \< 40%;~5. Ret \> 6%. 2.Exchange transfusion (ET) therapy for sNH： any of the following criteria are met:~(1) TSB ≥ the current ET threshold; (2) TSB \> (ET - 2) mg/dL or the increase of TSB \> 0.5 mg/dL/h, accompanied by abnormal aEEG findings; (3) TSB \> (ET - 2) mg/dL or \> 0.5 mg/dL/h, accompanied by a BIND score of 4-6; (4) Presence of clinical manifestations of acute ABE; (5) BIND score of 7-9."
214437269|NCT06832800|OTHER|control (current management)|"Control (current) method for sNH (severe neonatal hemolysis) with the description as follow：~1. Diagnosis of neonatal hemolysis： The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they have positive Direct Antiglobulin Test (DAT) or positive release test result.~2. Exchange transfusion (ET) therapy for sNH： The neonatal subjects with symptom of hyperbilirubinemia are treated with ET therapy if their Total serum bilirubin (TSB) reaches or exceeds the current exchange transfusion threshold;"
214437270|NCT06535542|GENETIC|Whole Genome Sequencing|Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
214437271|NCT06679556|DRUG|Strength A Sublingual Minoxidil|One single dose of Strength A sublingual minoxidil
214437272|NCT06679556|DRUG|Strength B Sublingual Minoxidil|One single dose of Strength B sublingual minoxidil
214437273|NCT05029258|PROCEDURE|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
214437274|NCT05029258|DIAGNOSTIC_TEST|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
214692712|NCT00478725|DRUG|GW786034, oral|oral, 800 mg
214692713|NCT00478725|DRUG|GW786034, IV|IV, 5 mg
214692714|NCT00478725|DRUG|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
214692715|NCT04486963|DRUG|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
214692716|NCT04486963|DRUG|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
214437275|NCT06830356|RADIATION|Dose escalation of radiation therapy, based on somatostatin receptor PET imaging|Radiation treatment with higher doses than the standard and defined using PET imaging
214437276|NCT06090266|DRUG|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
214437277|NCT06090266|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
214437278|NCT06835361|DRUG|Clotrimazole+Lactulose.|Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)
214437279|NCT06835361|DRUG|Canesten (Clotrimazole)|Vaginal tablets containing clotrimazole (100 mg)
214437280|NCT06835361|DRUG|Lactulose|Vaginal suppositories containing lactulose (300 mg)
214437281|NCT03314753|OTHER|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
214437282|NCT03713528|DRUG|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
215116301|NCT03335735|BEHAVIORAL|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
214437283|NCT01285999|DEVICE|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
214437284|NCT01285999|DEVICE|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
214437285|NCT05861076|OTHER|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
214437286|NCT05861076|OTHER|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
214437287|NCT05861076|OTHER|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
214437288|NCT05470595|DRUG|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
214437289|NCT06829407|OTHER|injection time|give an injection
214437290|NCT06829407|OTHER|palm stimulator|give an injection
214437291|NCT06829407|OTHER|injection time and palm stimulator|give an injection
214437292|NCT06832488|BEHAVIORAL|Diet|To compare the total food and energy intake of the diet with textures that require reduced oral processing versus the diet with textures that require increased oral processing by measuring weight before and after consumption of each meal and snack
214437293|NCT06832228|DRUG|Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）|"All patients will receive the PPR regimen (a total of 4-6 cycles, 28 days for each cycle):~* pomalidomide: 4 mg, orally, once daily from Day 1 to Day 21.~* Rituximab: 375 mg/m², administered on Day 1.~* PD-1: 200 mg, administered on Days 1."
214437294|NCT06559345|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214437295|NCT06559345|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214437296|NCT06559345|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
214437297|NCT06284408|OTHER|Centralized Screening Unit Implementation|The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
214692717|NCT01760993|DRUG|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
214437298|NCT06834061|PROCEDURE|Ultrasound|All patients underwent high-resolution real-time sonography of the carpal tunnel (both hands) using an Ultrasound (US) machine and a 12 MHz linear array transducer. US examination will be performed before and 3 months after surgery.
214437299|NCT06832605|BEHAVIORAL|MBCT group|"MBCT is a systematic training in mindfulness meditation techniques to teach participants skills to prevent relapse/recurrence of depression. Treatment includes weekly 2-hour classes over an 8-week period with home exercises, a full day of practice (6 hours long, adapted for online delivery), and 4 booster sessions offered every 3 months from the start of the programme.~Standard pharmacological treatment usually provided to patients suffering depression."
214437300|NCT06832605|BEHAVIORAL|MBCT self-help|"The 'MBCT self-help' is based on the book 'The Mindfulness Way: An 8-week plan to free yourself from depression and emotional stress'. The book presents the 8-week MBCT course as a self-help booklet. Participants are asked to guide themselves using the self-help book. The book provides elaborate and practical mindfulness guidelines that can be exercised each week, as well as questions to help with reflection, ways to check progress and valuable feedback from others who have undertaken this MBCT programme.~Standard pharmacological treatment usually provided to patients suffering depression."
214437301|NCT06832605|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering depression.
214437302|NCT06449053|PROCEDURE|ORGANIZATIONAL|A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
214692718|NCT03363334|DRUG|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
215116302|NCT02995317|OTHER|Number of falls based on an one year follow-up|
215116303|NCT04840082|DIAGNOSTIC_TEST|Nasopharyngeal swab for COVID-19 testing|A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
214437303|NCT06832553|OTHER|surgical incision drep|To compare the efficacy of surgical incision with silk plaster in ETT fixation.
214692719|NCT03363334|DRUG|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
214437304|NCT05777954|OTHER|Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage|"Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques"
214437305|NCT05777954|OTHER|Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines|Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
214437306|NCT03726554|DEVICE|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
214437307|NCT03726554|DEVICE|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
214437308|NCT05593341|OTHER|Opioid education in person|"The presentation and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
214437309|NCT05593341|OTHER|Opioid education via video|"The video and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
214437310|NCT06782685|DRUG|Irinotecan liposoma|Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1
214437311|NCT06782685|DRUG|oxaliplatin|Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1
214437312|NCT06782685|DRUG|bevacizumab|5mg/kg，i.v.，d1
214437313|NCT06782685|DRUG|5-FU|2400mg/m\^2, i.v.，46h
214437314|NCT06782685|DRUG|LV|400mg/m\^2, i.v.，d1
214437315|NCT06782685|DRUG|Irinotecan Liposomal|70mg/m\^2, i.v.，d1
214437316|NCT06782685|DRUG|Irinotecan Liposomal|Phase II recommended dose
214437317|NCT06782685|DRUG|Oxaliplatin|Phase II recommended dose
214437318|NCT06785909|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. fear of movement, pain catastrophizing, sense of coherence, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress) and inflammatory mediators.
214437319|NCT06784271|DIETARY_SUPPLEMENT|Phenylcapsaicin|2.5mg of Phenylcapsaicin
214437320|NCT06784271|DIETARY_SUPPLEMENT|Placebo|Placebo
214437321|NCT06788977|DEVICE|external Trigeminal Nerve Stimulation|"External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.~The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes."
214437322|NCT04578808|OTHER|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
214437323|NCT06778174|OTHER|observational study|"The interventions are not determined by the study, which is purely observational on real world data."
214437324|NCT06778499|OTHER|Plyometric training for experimental group|The experimental groups will undergo 3 interventions a week, with one session lasting 90 minutes. The experimental group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of plyometric training, and 15 minutes of relaxation stretching.
214437325|NCT06778499|OTHER|Traditional training for control group|The control group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of general training, and 15 minutes of relaxation stretching.
214692720|NCT04366752|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
214692721|NCT04366752|OTHER|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
214692722|NCT01928121|OTHER|Care provided by AF expert program|
215116304|NCT04098809|DEVICE|16 French urinary catheter|16 French urinary catheter
214437326|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
214516798|NCT04054856|DEVICE|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
214516799|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
214516800|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
214516801|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
214516802|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
214516803|NCT05736237|GENETIC|Whole exome sequencing|With Next Generation Sequenzing
214516804|NCT00992849|DRUG|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
214516805|NCT04343989|DRUG|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
214516806|NCT04343989|DRUG|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
214516807|NCT04343989|OTHER|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
214516808|NCT00814359|DRUG|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
214516809|NCT00814359|DRUG|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
214516810|NCT01176747|DRUG|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
214516811|NCT02539602|BEHAVIORAL|The Need to Know students received the N2K curriculum as described previously|
214516812|NCT02161588|DRUG|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
214692723|NCT03021434|OTHER|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
214692724|NCT03021434|OTHER|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
214692725|NCT03021434|OTHER|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
214692726|NCT03632252|DEVICE|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
214437327|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
214437328|NCT04843332|BEHAVIORAL|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
214516813|NCT02161588|DRUG|placebo|Once-daily oral administration as tablets.
214437329|NCT02544074|BEHAVIORAL|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
214437330|NCT02544074|BEHAVIORAL|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
214437331|NCT03137095|OTHER|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.
214437332|NCT03137095|OTHER|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
214437333|NCT03646604|DRUG|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
214437334|NCT03121469|DEVICE|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
214437335|NCT05526963|OTHER|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
214437336|NCT05526963|BEHAVIORAL|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
214437337|NCT06497439|DRUG|Silfamin|2 tablets of Silfamin 150 mg twice daily
214437338|NCT06497439|DRUG|Placebo tablet of Silfamin|2 tablets of Silfamin Placebo twice daily
214516814|NCT05534854|GENETIC|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
214516815|NCT04944589|PROCEDURE|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
214437339|NCT05396443|BEHAVIORAL|Black Girls for Wellness Telehealth|Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
214516816|NCT02454647|DRUG|Induction chemotherapy|
214437342|NCT05630053|DEVICE|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
214437343|NCT05630053|DEVICE|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
214437344|NCT06117020|DRUG|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
214437345|NCT06389539|OTHER|SBD111 medical food|SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
214437346|NCT06389539|OTHER|Placebo|Placebo
214437347|NCT05469815|BEHAVIORAL|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
214437348|NCT05558527|BEHAVIORAL|social support|social support is provided in the form of social touch (hand holding)
214437349|NCT04354636|DRUG|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
214437350|NCT04354636|OTHER|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
214437351|NCT05320614|OTHER|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
214437352|NCT05320614|OTHER|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
214437353|NCT06360705|DEVICE|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
214516817|NCT02454647|RADIATION|Radiotherapy with concurrent chemotherapy|
214516818|NCT02454647|PROCEDURE|Salvage surgery|
214516819|NCT00004662|DRUG|dehydroepiandrosterone|
214516820|NCT03946345|DRUG|Iohexol Inj 300 MG/ML|"* Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
214516821|NCT04502745|DEVICE|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
214516822|NCT01628263|OTHER|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
214516823|NCT02119572|BEHAVIORAL|peer support|
214516824|NCT02119572|OTHER|usual education lectures|
214516825|NCT02159456|OTHER|Continuous enteral feeding via infusion pump|
214516826|NCT02159456|OTHER|Intermittent enteral feeding via gravity-based infusion|
214437354|NCT03189524|DRUG|Zanubrutinib|Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
214437355|NCT05800574|RADIATION|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
214437356|NCT05800574|RADIATION|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
214437357|NCT05800574|DRUG|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
214437358|NCT05607719|DRUG|Bevespi|Two puffs twice a day
214437359|NCT05607719|DRUG|Bretzri|Two puffs twice a day
214516827|NCT01835847|DRUG|Tipepidine Hibenzate|
215116305|NCT04098809|DEVICE|20 French urinary catheter|20 French urinary catheter
214437360|NCT06720298|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
214437361|NCT06433297|PROCEDURE|INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS|"After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique."
214437362|NCT04357288|OTHER|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
214437363|NCT04357288|OTHER|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
214437364|NCT03746327|DRUG|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
214437365|NCT05154448|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
214437366|NCT05154448|OTHER|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
214437367|NCT05291286|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
214516828|NCT00582855|DRUG|AQW051|
214516829|NCT00582855|DRUG|Placebo|
214516830|NCT01123356|DRUG|Ofatumumab|"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"
215116306|NCT05336578|OTHER|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
215116307|NCT04560933|PROCEDURE|Blood sample collection|Blood sample collection
215116308|NCT03009474|DRUG|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
215116309|NCT03009474|DRUG|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
214437368|NCT05291286|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
214437369|NCT04384250|DIAGNOSTIC_TEST|Whole Exome Sequencing|Genetic study of patients
214516831|NCT01123356|DRUG|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
214437370|NCT04090528|BIOLOGICAL|pTVG-HP|pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
214437371|NCT04090528|BIOLOGICAL|pTVG-AR|pTVG-AR is a plasmid DNA
214516832|NCT01531699|DRUG|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
214516833|NCT01531699|OTHER|saline control|single application for up to 6 hours
214516834|NCT01531699|DRUG|Betadine ophthalmic prep solution|single application for up to 6 hours
214516835|NCT06474234|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
214516836|NCT06474234|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
214516837|NCT06502678|BIOLOGICAL|Fcr blocker of autoantibodies|in vitro assays, combined with multi-omics approach and in vitro experimental models, will gain insights into the pathogenesis of Systemic Sclerosis (SSc)dissecting the consequences of treatment with Fcblocker on functional and phenotypic cell behavior. Healthy microvascular endothelial cells, fibroblasts and monocytes will be challenged with serum and autoantibodies prior to or upon treatment with Efgartigimod in order to assess both the prevention and the recovery capacity of the FcR blocker. The putative modulatory effect of Efgartigimod on vascular remodeling, endothelial-to-mesenchymal transition, fibroblast-to-myofibroblasts transition and monocyte behavior will be evaluated in in-vitro consolidated assays. Integrated Omics analyses will support and complement the in vitro findings by unveiling potential prognostic signatures and by identifying specific treatment-related profiles that might guide the modulation of the drug usage in order to maximize its beneficial effect
214516838|NCT00110422|DRUG|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
214516839|NCT00110422|DRUG|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
214516840|NCT00110279|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
214516841|NCT03991325|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
214516842|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
214516843|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
214516844|NCT04201847|DIAGNOSTIC_TEST|Serum test|Serum Fetuin A and fetuin B
214516845|NCT05480280|DRUG|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
214516846|NCT05480280|DRUG|Oxaliplatin injection|85mg/m², ivdrip, D1
214516847|NCT05480280|DRUG|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
214516848|NCT05480280|DRUG|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
214437372|NCT04090528|DRUG|Pembrolizumab|Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
214437373|NCT02307812|DRUG|Ramucirumab|Administered intravenously (IV)
214437374|NCT02307812|DRUG|Paclitaxel|Administered IV
214437375|NCT06814678|BEHAVIORAL|Interactive Exergaming with Otago Exercise Program|Participants will receive a 12-week structured program combining interactive exergaming and Otago Exercise Program. Sessions include balance training, strength exercises, and functional mobility activities delivered through interactive gaming platforms, supervised by trained instructors.
214437376|NCT06814678|OTHER|Control Group with Usual Care|Participants will maintain their regular activities at community centers or facilities, including cognitive therapy, oral exercises, and upper limb training programs, during the 12-week study period
214437377|NCT02723955|DRUG|feladilimab (GSK3359609)|
214437378|NCT02723955|DRUG|GSK3174998|
214437379|NCT02723955|DRUG|Pembrolizumab|
214437380|NCT02723955|DRUG|Docetaxel|
214437381|NCT02723955|DRUG|Pemetrexed|
214437382|NCT02723955|DRUG|Paclitaxel plus Carboplatin|
214437383|NCT02723955|DRUG|Gemcitabine plus Carboplatin|
214437384|NCT02723955|DRUG|Fluorouracil (5-FU) plus carboplatin or cisplatin|
214437385|NCT02723955|DRUG|Dostarlimab|
214437386|NCT02723955|DRUG|Cobolimab|
214437387|NCT02723955|DRUG|Bintrafusp alfa|
214437388|NCT06750263|OTHER|Balance exercise with clamshell|balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
214516849|NCT05719155|DRUG|CKD-379|1 tablet administration under fed condition
214516850|NCT05719155|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
214516851|NCT04394078|OTHER|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
214516852|NCT02674867|OTHER|Blood draw|
214516853|NCT00000499|DRUG|chlorthalidone|
214516854|NCT00000499|DRUG|reserpine|
214516855|NCT00000499|DRUG|hydralazine|
214516856|NCT00000499|DRUG|metoprolol|
214692727|NCT04092244|DIAGNOSTIC_TEST|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
214437389|NCT06750263|OTHER|Balance exercise|Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
214437390|NCT06757283|BIOLOGICAL|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
214437391|NCT06502145|DRUG|Azacitidine Level -1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
214437392|NCT06502145|DRUG|Azacitidine Level 0|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
214437393|NCT06502145|DRUG|Azacitidine Level 1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
214437394|NCT06502145|DRUG|Iadademstat Level -1|75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
214516857|NCT03889327|BEHAVIORAL|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
214437395|NCT06502145|DRUG|Iadademstat Level 0|75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
214437396|NCT06502145|DRUG|Iadademstat Level 1|100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
214437397|NCT04300647|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214437398|NCT04300647|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214437399|NCT06815224|DEVICE|Sonar|Abdominal sonar
214437400|NCT03657212|DRUG|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
214437401|NCT03408613|PROCEDURE|Positive Airway Pressure|See arm/group description
214437402|NCT03408613|PROCEDURE|Supplemental Oxygen|See arm/group description
214437403|NCT03408613|PROCEDURE|Sham|See arm/group description
214437404|NCT06784479|DRUG|Remimazolam and Propofol|Application of Remimazolam and Propofol to induce sleep
214437405|NCT06784479|DRUG|Propofol|Application of Propofol to induce sleep
214437406|NCT06784479|DRUG|Midazolam and propofol|Application of Midazolam and Propofol to induce sleep
214437407|NCT05423483|BEHAVIORAL|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
214437408|NCT06786806|OTHER|Gamified Infection Control Education Program|A four-week educational program integrating gamification techniques such as physical games, case studies, and escape rooms to teach infection control practices.Designed to enhance engagement, learning motivation, and cognitive achievement among nursing students.
214437409|NCT06786806|OTHER|Traditional Lecture-Based Instruction|Standard didactic teaching method focusing on infection control principles without incorporating gamification. Served as the comparator to evaluate the effectiveness of the gamified program.
214437410|NCT05402280|BEHAVIORAL|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
214437411|NCT04050176|BEHAVIORAL|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
214692728|NCT06163443|DIETARY_SUPPLEMENT|Vitamin B|MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription
214437412|NCT04050176|BEHAVIORAL|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
214437413|NCT06790628|PROCEDURE|Fibula free flap|"surgical technique used in reconstructive surgery where a segment of the fibula bone, along with its blood vessels, is taken from the lower leg and transplanted to reconstruct defects in the mandible due to its length, strength, and ability to support dental implants.~The blood vessels are connected to nearby vessels at the reconstruction site to ensure the bone's survival and integration.~The procedure is highly versatile and often referred to as the gold standard for mandibular reconstruction."
214437414|NCT06790212|DRUG|Ivonescimab|20mg/kg Q3W，D1
214437415|NCT06790212|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2，D1，Q3W；
214437416|NCT06790212|DRUG|Capecitabine|Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
214437417|NCT06285682|DIETARY_SUPPLEMENT|OliPhenolia®)|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
214437418|NCT02824029|DRUG|Ibrutinib|Given PO
214437419|NCT02824029|OTHER|Laboratory Biomarker Analysis|Correlative studies
214437420|NCT02824029|OTHER|Pharmacological Study|Correlative studies
214437421|NCT03845829|PROCEDURE|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
214437422|NCT03806465|OTHER|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
215116310|NCT04260789|DEVICE|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
215116311|NCT02741596|DRUG|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
214437423|NCT03806465|OTHER|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
214516858|NCT03889327|BEHAVIORAL|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
214516859|NCT03012321|DRUG|Olaparib|
214516860|NCT03012321|DRUG|Abiraterone Acetate|
215116312|NCT02741596|DRUG|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
215116313|NCT01426958|DRUG|afatinib|standard therapeutic dose
215116314|NCT01426958|DRUG|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
215116315|NCT01426958|DRUG|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
215116316|NCT02195570|OTHER|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
215116317|NCT02195570|BEHAVIORAL|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
215116318|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
215116319|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
215116320|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
215116321|NCT02236468|BEHAVIORAL|WASH/malaria behavior change|WASH/malaria behavior change communication
215116322|NCT02236468|DIETARY_SUPPLEMENT|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
215116323|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
215116324|NCT03958058|DRUG|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
214437424|NCT03806465|OTHER|Community mortality surveillance|A verbal autopsy will be performed
214437425|NCT06790355|DEVICE|multi-cancer early detection|Blood collection for multi-cancer early detection（MCED）, followed by clinical diagnosis based on the results of MCED and standard-of-care screening
214516861|NCT03012321|DRUG|Prednisone|
214692729|NCT06163443|DIETARY_SUPPLEMENT|Placebo|MTHFR, MTR, and MTRR polymorphysm based placebo prescription
214692730|NCT01797510|BEHAVIORAL|Web Based Health Coaching|
214692731|NCT01694420|DRUG|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
214692732|NCT03808038|OTHER|None- Observational Study|None- Observational Study
215116325|NCT03958058|OTHER|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
214437426|NCT06786481|BEHAVIORAL|Educational with milnacipran|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
214516862|NCT05256836|OTHER|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
214516863|NCT01074099|BIOLOGICAL|BMAC|Injection of BMAC into ischemic myocardium during CABG
214516864|NCT01074099|PROCEDURE|CABG only|Control subjects will undergo CABG surgery without BMAC injection
214516865|NCT02325752|OTHER|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
214516866|NCT04272099|OTHER|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
214516867|NCT04272099|DEVICE|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
214516868|NCT04272099|OTHER|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
214516869|NCT00913055|DRUG|octreotide acetate|subcutaneous implant
215116326|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
214516870|NCT01461967|DRUG|Placebo|Single ascending doses
214516871|NCT01461967|DRUG|RO5508887|Single ascending doses
214516872|NCT01461967|DRUG|RO5508887|Single doses
214516873|NCT06252454|DRUG|Furosemide 40 mg|Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
214516874|NCT06252454|DRUG|Levodropropizine|Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
214516875|NCT06252454|OTHER|Placebo - saline|Placebo will be used as a comparator
214516876|NCT03847727|DRUG|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
214516877|NCT03262389|DRUG|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
215116327|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
215116328|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
214516878|NCT03262389|DRUG|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
214516879|NCT03262389|DRUG|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
214516880|NCT03262389|DRUG|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
214516881|NCT00607607|DRUG|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
214516882|NCT00899795|GENETIC|cytogenetic analysis|
214516883|NCT00899795|GENETIC|fluorescence in situ hybridization|
214516884|NCT00899795|OTHER|flow cytometry|
215116329|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
215116330|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
215116331|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
215116332|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
215116333|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
215116334|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
215116335|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
215116336|NCT00109824|DRUG|decitabine|Given IV
215116337|NCT00109824|DRUG|valproic acid|Given PO
215116338|NCT00109824|OTHER|pharmacological study|Correlative studies
215116339|NCT00109824|OTHER|laboratory biomarker analysis|Correlative studies
214437427|NCT06786481|BEHAVIORAL|Locally Directed Therapy|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
214437428|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophil creatinine index will be calculated
215116340|NCT02832934|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
214516885|NCT00899795|PROCEDURE|biopsy|
214516886|NCT00119782|BEHAVIORAL|Diet|A dietary intervention that will promote lower calorie intake
214516887|NCT00119782|BEHAVIORAL|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
214516888|NCT00119782|BEHAVIORAL|Environment|Increase worksite access to both healthy foods and physical activity
214516889|NCT00274196|PROCEDURE|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
214437429|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophi creatinine index will be calculated in all patients
214516890|NCT00274196|PROCEDURE|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
214516891|NCT03740386|DRUG|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
214516892|NCT01465399|BIOLOGICAL|Plasma Rich in Growth Factors PRGF-Endoret|
214516893|NCT01465399|PROCEDURE|Conventional closure of the lesion|
214516894|NCT01052272|DRUG|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
215116341|NCT02832934|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
215116342|NCT00021749|DRUG|Oblimerson sodium, G3139|
215116343|NCT04301466|DRUG|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
215116344|NCT04301466|DRUG|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
215116345|NCT06518044|DRUG|N Acetyl L Cysteine|For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
215116346|NCT06151444|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
215116347|NCT06151444|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
214437430|NCT06791590|PROCEDURE|intermittent oro-esophageal|A disposable gastric tube was used to perform enteral nutrition support therapy, and contraindications were evaluated again. Inform the patient and family members of the precautions for intermittent feeding through oral tube, and play the video of the operation process to make them actively cooperate with the operation.
215116348|NCT04348266|DEVICE|Radiofrequency ablation (RFA)|Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
215116349|NCT05177497|DRUG|SHR-1701|SHR-1701 administered by iv
214437431|NCT06791590|PROCEDURE|Naso-intestinal tube nutrition support|For patients at risk of repeated aspiration and regurgitation, and for patients with gastric nutritional intolerance that cannot be improved by gastrointestinal motivity drugs, indwelling intestinal tube and retropyloric feeding are given.
214437432|NCT06575296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214437433|NCT06575296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214516895|NCT01052272|DRUG|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
214516896|NCT01052272|DRUG|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
214437434|NCT06575296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214437435|NCT06575296|PROCEDURE|Echocardiography|Undergo ECHO
214437436|NCT06575296|OTHER|Electronic Health Record Review|Ancillary studies
214437437|NCT06575296|OTHER|Quality-of-Life Assessment|Ancillary studies
214437438|NCT06575296|OTHER|Questionnaire Administration|Ancillary studies
214437439|NCT06575296|DRUG|Revumenib|Given PO
214437440|NCT06833814|DRUG|Prednisone|Either 150 mg over 3 days or 250 mg over 7 days or 350 mg over 10 days
214437441|NCT04655235|GENETIC|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
214437442|NCT04751526|DEVICE|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
214437443|NCT04751526|DEVICE|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
214437444|NCT05766657|DIETARY_SUPPLEMENT|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
214437445|NCT05766657|DIETARY_SUPPLEMENT|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
214437446|NCT06547905|DEVICE|Ostomy Leakage Detection System|A system that is used to detect ostomy leaks
214437447|NCT04689607|OTHER|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
214437448|NCT04689607|OTHER|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
214437449|NCT04605458|COMBINATION_PRODUCT|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
214437450|NCT04605458|COMBINATION_PRODUCT|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
214437451|NCT06075771|DRUG|Carbidopa Levodopa|Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
214437452|NCT06075771|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
214437453|NCT06764758|PROCEDURE|Endodontic treatment|Root-canal therapy applied in asymptomatic teeth with deep carious lesion required endodontic treatment.
214437454|NCT06764758|PROCEDURE|Restorative treatment|Composite resin restoration applied in teeth previously applied endodontic treatment.
214437455|NCT04928001|OTHER|internet based iCBT program, Youth Thrive|iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
214437456|NCT01722695|OTHER|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
214437457|NCT01693120|DEVICE|Medtronic Phased RF Ablation System|Phased RF ablation
214437458|NCT05863598|BEHAVIORAL|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
214437459|NCT05863598|BEHAVIORAL|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
214437460|NCT06436833|DRUG|2-Liter polyethylene glycol plus elobixibat|Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
214437461|NCT06436833|DRUG|4-Liter polyethylene glycol|Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
214437462|NCT04097743|BEHAVIORAL|Coping Statement|Daily practice of coping statement
214437463|NCT06803940|PROCEDURE|clear aligner|closing of spacing in anterior teeth with clear aligner therapy
214437464|NCT06803940|PROCEDURE|orthodontic treatment|conventional fixed orthodontic appliance
214516897|NCT02439892|BEHAVIORAL|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
214516898|NCT02439892|BEHAVIORAL|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
214516899|NCT06176118|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
214437465|NCT04654585|OTHER|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
214437466|NCT04654585|OTHER|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
214516900|NCT04362618|OTHER|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
214516901|NCT04362618|BEHAVIORAL|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
214516902|NCT06506552|PROCEDURE|IMA preserving|Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
214516903|NCT06506552|PROCEDURE|IMA sectioning|Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
214516904|NCT02936258|PROCEDURE|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
214516905|NCT02936258|PROCEDURE|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
214516906|NCT02936258|PROCEDURE|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
215116350|NCT03378817|PROCEDURE|HOPE|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
215116351|NCT03378817|OTHER|Conventional cold storage|No intervention
215116352|NCT04713280|PROCEDURE|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
215116353|NCT05855772|DEVICE|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
215116354|NCT05855772|BEHAVIORAL|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
215116355|NCT04550637|DRUG|Oral apixaban|apixaban (5 mg bid) is given until 12 weeks after surgery
215116356|NCT05583123|DEVICE|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
215116357|NCT05583123|DEVICE|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
215116358|NCT05258604|PROCEDURE|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
214437467|NCT06798740|DEVICE|Sugita Titanium Aneurysm Clip II|Aneurysm clipping is a surgical procedure used to treat brain aneurysms.
214516907|NCT06225323|DRUG|Lidocaine|"Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
214516908|NCT06225323|OTHER|Saline|"Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
215116359|NCT05258604|PROCEDURE|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
215116360|NCT05617781|BEHAVIORAL|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
215116361|NCT06119113|OTHER|Evaluation of the wound infection at the 10th day post-op check-up among all groups|Discharge, redness, increased temperature, and dehiscence were accepted as wound infection.
214437468|NCT04153565|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
214516909|NCT03941366|PROCEDURE|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
214516910|NCT04063449|DRUG|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
214516911|NCT04063449|DRUG|endostar|Antiangiogenic therapy plus chemotherapy
214516912|NCT03066986|DRUG|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
214516913|NCT03066986|BIOLOGICAL|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined."
214516914|NCT06501508|DEVICE|Stratafix Symmetric|Use of Stratafix Symmetric for primary fascial closure
214516915|NCT00452894|DRUG|varenicline tartrate|
214516916|NCT02060175|DEVICE|Cilotax drug-eluting stents implantation|
214516917|NCT02060175|DEVICE|DESyne drug-eluting stents implantation|
214516918|NCT04292795|DEVICE|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
214516919|NCT04292795|DEVICE|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
215116362|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 2nd month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
215116363|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 6th month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
215116364|NCT02968368|DRUG|Ferric maltol|
215116365|NCT02968368|OTHER|Placebo|
214437469|NCT04153565|DRUG|Pemetrexed|Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
214437470|NCT04153565|DRUG|Cisplatin|Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
214516920|NCT01366352|DRUG|MNTX tablet (Formulation 1)|
214516921|NCT01366352|DRUG|MNTX tablet (Formulation 2)|
214516922|NCT02450747|DEVICE|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
214516923|NCT03071523|PROCEDURE|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
214516924|NCT03071523|PROCEDURE|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
214516925|NCT05792475|DIAGNOSTIC_TEST|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
215116366|NCT01966523|BEHAVIORAL|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
214437471|NCT05236296|BEHAVIORAL|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
215116367|NCT01966523|OTHER|Control|
214437472|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
214437473|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
214437474|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
214437475|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
214437476|NCT01741363|OTHER|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
214437477|NCT01741363|OTHER|FIT only|HPSA+FIT compared with FIT alone.
214437478|NCT06255262|DRUG|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
214437479|NCT06255262|DRUG|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
215116368|NCT00469703|DRUG|Thalidomide|
215116369|NCT01802008|PROCEDURE|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
215116370|NCT01802008|PROCEDURE|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
215116371|NCT04838535|DIAGNOSTIC_TEST|Raman spectrum|The wavelength of the follicular fluids were scaned by Raman spectrum
215116372|NCT00940940|BIOLOGICAL|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
215116373|NCT00940940|BIOLOGICAL|Placebo vaccine|0.65 mL subcutaneous
215116374|NCT04164134|OTHER|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
215116375|NCT04585425|BEHAVIORAL|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
215116376|NCT04585425|BEHAVIORAL|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
215116377|NCT02859246|DRUG|Mucinex®|Mucinex®
215116378|NCT01811888|BEHAVIORAL|Quantitative sensory testing (QST)|
215116379|NCT05406336|OTHER|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
215116380|NCT02218684|DRUG|Telmisartan|
214437480|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
214437481|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
214437482|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
214437483|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
214437484|NCT01479647|DRUG|PH-797804|Tablet, 24 mg, single dose
214516926|NCT04430400|DIAGNOSTIC_TEST|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level \<500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
215116381|NCT02218684|DRUG|Lacidipine|
215116382|NCT02218684|DRUG|Placebo|
215116383|NCT00100789|DRUG|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
215116384|NCT00100789|DRUG|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
215116385|NCT04212598|DRUG|Sintilimab|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
214437485|NCT06191939|BEHAVIORAL|Mindful Self-Compassion for Lung Cancer (MSC-LC)|"The overall goal of this 10-week, group-based, virtually-delivered, psychosocial intervention is to enhance recognition and responsiveness to difficult thoughts and emotions and to build self-compassion skills that facilitate patients' ability to turn inward to those thoughts and feelings with mindfulness, connectedness, and self-kindness. Each weekly session is designed to be 90 minutes and follows an agenda with highly structured scripts covering self-compassion topics (e.g., pain of disconnection, listening with compassion), which are carefully organized to build upon one another. In each session, didactic topics (e.g., What is self-compassion?) taught by trained interventionists lead into guided experiential learning practices (e.g., guided meditation), which are then followed by inquiry into the participants' direct experiences of the practices. The treatment manual is adapted based on the Mindful Self-Compassion Teacher Guide (from the Center for Mindful Self-Compassion)."
214437486|NCT06191939|OTHER|Enhanced standard of care with waitlist|Participants in the enhanced standard of care control condition will be provided with an information sheet from the NCI about how to find helpful organizations and resources in their community. Self-report will be used to describe any supportive care services pursued by the participant. Additionally, control participants will be added to a waiting list for receiving the MSC-LC intervention program. After completing all questionnaire assessments (16 weeks following study entry), the study team will offer the MSC-LC intervention program to participants on the waiting list.
214437487|NCT02479906|DEVICE|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
214437488|NCT02479906|DEVICE|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
214437489|NCT06791135|OTHER|Health and Life in Balance|"Health and Life in Balance is an intervention for patients 65 years and older, with 2 or more chronic diseases, and an increased care need. It involved for the patient to meet with a district nurse during 1-2 meetings to set up a care plan and then have scheduled follow-ups during 6 months. During the 1-2 meetings they went through ICAN discussion aid to discuss aspects of capacity and workload in the patient's life and healthcare. The district nurse and the patient's GP had improved communication during the intervention period.~No use of drugs or devices was part of the intervention."
214437490|NCT06791135|OTHER|Care as usual|Care as usual
215116386|NCT01701206|BEHAVIORAL|HIV knowledge Intervention|
215116387|NCT05361824|DRUG|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
215116388|NCT05361824|DRUG|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
215116389|NCT05005481|OTHER|NIL intervention|NIL intervention will be performed on patients.
215116390|NCT01746368|OTHER|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
215116391|NCT01746368|OTHER|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
215116392|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
214437491|NCT05701709|DRUG|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
214437492|NCT06471322|DEVICE|Continuous Glucose Monitoring (CGM)|Patients will wear a continuous glucose monitor upon discharge from the hospital for six months
214437493|NCT06471322|OTHER|Standard of Care|Standard of Care - retrospective review
214437494|NCT05234853|DRUG|PUR001|Monoclonal antibody
214437495|NCT02262468|RADIATION|x ray|
214437496|NCT05056402|BIOLOGICAL|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
214437497|NCT05056402|BIOLOGICAL|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
214437498|NCT02632071|DRUG|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
214437499|NCT02632071|DRUG|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
214437500|NCT00280228|BEHAVIORAL|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
214437501|NCT00280228|BEHAVIORAL|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
214437502|NCT05209477|OTHER|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application"
214437503|NCT06521411|BEHAVIORAL|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
214437504|NCT00790894|DRUG|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
214437505|NCT00790894|DRUG|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
214437506|NCT00361205|DEVICE|Electronic Monitoring cap|
214437507|NCT06146374|OTHER|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
214437508|NCT06146374|DRUG|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
214437509|NCT03593642|DRUG|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
214437510|NCT03593642|DRUG|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
214437511|NCT04407975|OTHER|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
214516927|NCT05671055|OTHER|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
214516928|NCT04878809|OTHER|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
214516929|NCT04878809|OTHER|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
214516930|NCT01077284|DRUG|Febuxostat|Febuxostat capsules
214516931|NCT01077284|DRUG|Allopurinol|Allopurinol capsules
214516932|NCT01077284|DRUG|Placebo|Placebo-matching capsules
214516933|NCT05992584|DRUG|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
214516934|NCT02199444|DRUG|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
214516935|NCT02199444|DRUG|Placebo|
214437512|NCT04407975|OTHER|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
214516936|NCT03468348|DRUG|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
214516937|NCT02326194|BIOLOGICAL|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
214437513|NCT04148170|PROCEDURE|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
214516938|NCT02326194|BIOLOGICAL|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
214516939|NCT02326194|BIOLOGICAL|placebo (one dose)|placebo, one doses
214516940|NCT02326194|BIOLOGICAL|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
214516941|NCT02104375|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
215116393|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
214516942|NCT03612102|BEHAVIORAL|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
214516943|NCT05863585|DRUG|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
214516944|NCT01280721|DRUG|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
214516945|NCT01180400|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
214516946|NCT01180400|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
214516947|NCT00966745|DRUG|milrinone|
215116394|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
215116395|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
214516948|NCT00966745|DRUG|placebo|
214516949|NCT01293201|DRUG|STAHIST|STAHIST dosed one tablet, BID
214516950|NCT01293201|DRUG|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
214516951|NCT05188248|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
214516952|NCT05793580|DEVICE|Vibrant Soundbridge active middle ear implant|active middle ear implant
215116396|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
215116397|NCT05280717|BIOLOGICAL|sotrovimab|via IV injection
215116398|NCT05280717|BIOLOGICAL|sotrovimab|via IV infusion
215116399|NCT04234867|DRUG|Dapagliflozin|once daily for 5 days
215116400|NCT04234867|DRUG|Placebo oral tablet|once daily for 5 days
215116401|NCT04234867|OTHER|Stress|single dose after last administration of experimental drug
215116402|NCT04234867|OTHER|Placebo Stress|single dose after last administration of experimental drug
215116403|NCT04917484|DRUG|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
215116404|NCT06246110|DRUG|EIK1001|EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
214437514|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
214437515|NCT05438160|DEVICE|Clinical Learning Study smartphone app (i.e., the study app)|The study app is designed to provide 7-weeks of the medication tracking and educational components in a clinical learning study version of CT-155. This design allows inferences to be made about the usability and acceptability of these components of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
215116405|NCT06246110|DRUG|Pembrolizumab|PD-1 inhibitor
215116406|NCT06246110|DRUG|Paclitaxel|Chemotherapy
214516953|NCT05387785|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
214437516|NCT06250283|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol (500 mg)
214437517|NCT06250283|DIETARY_SUPPLEMENT|Placebo|Placebo (500 mg)
214437518|NCT05506085|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
214437519|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (5-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
214437520|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) CAPS-A hypernasality rating of 1 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
214437521|NCT03230747|DEVICE|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
214437522|NCT05717127|BEHAVIORAL|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
214437523|NCT05717127|BEHAVIORAL|Standard lifestyle|Standard lifestyle recommendations
214437524|NCT06476197|DEVICE|SAT-003|Device: SAT-003(Software) Using SAT-003 for 12 weeks
214516954|NCT05387785|DRUG|Placebo|Orally administered placebo capsule
214516955|NCT05605158|DRUG|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
214516956|NCT05605158|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
214516957|NCT05293379|OTHER|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
215116407|NCT06246110|DRUG|Pemetrexed|Chemotherapy
215116408|NCT06246110|DRUG|Carboplatin|Chemotherapy
215116409|NCT05733156|RADIATION|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
215116410|NCT06433323|OTHER|Anti-aging cosmetic care product|"This is an intra-individual comparison study.~* frequency of application: Once a day (in the evening)~* modalities of application: Apply the cream on the tested area determined by the randomization~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)"
215116411|NCT01302028|DRUG|ASP1941|Oral
215116412|NCT00080301|DRUG|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
215116413|NCT00080301|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
215116414|NCT03934567|DRUG|Abexinostat|Abexinostat tablets
214437525|NCT04754022|OTHER|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
214437526|NCT04754022|OTHER|Liberal transfusion strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
214437527|NCT05350592|DRUG|Tocilizumab|Single bolus
214437528|NCT05350592|DRUG|Dobutamine|Continous weight-adjusted infusion
214437529|NCT05350592|DRUG|NaCl 0.9%|Placebo comparator and diluent
214437530|NCT03948867|DRUG|Hydroxyurea|Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
214437531|NCT03948867|DIAGNOSTIC_TEST|Elevated Arm TCD Examination|"TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months."
214516958|NCT00096278|BIOLOGICAL|Bevacizumab|Given IV
214516959|NCT00096278|DRUG|Fluorouracil|Given IV
214516960|NCT00096278|DRUG|Leucovorin Calcium|Given IV
214516961|NCT00096278|DRUG|Oxaliplatin|Given IV
214516962|NCT00041639|DRUG|hMN14 (labetuzumab)|
214516963|NCT00754533|OTHER|Continuous versus interval training|Influence of different exercise training programs
214516964|NCT04642495|DIAGNOSTIC_TEST|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
214516965|NCT00158847|DRUG|fluticasone 500 mcg|
214516966|NCT00158847|DRUG|fluticasone 500 mcg + salmeterol 50 mcg|
214516967|NCT01529372|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
214437532|NCT03948867|DIAGNOSTIC_TEST|Normal Arm TCD Examination|TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
214437533|NCT05339113|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
214437534|NCT06326125|BEHAVIORAL|TICK-B|TICK-B as art-based distraction
214437535|NCT06326125|DRUG|TKTX-Cream|TKTX-Cream as local anesthesia cream
214437536|NCT06326125|OTHER|TICK-B and TKTX-C|TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
214437537|NCT05660603|OTHER|control|patients will receive standard general anesthesia
214437538|NCT05660603|PROCEDURE|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
214437539|NCT05660603|PROCEDURE|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
214437540|NCT05660603|DEVICE|Ultrasound|ultrasound
214437541|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
214437542|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
214437543|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
214437544|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
215116415|NCT04602117|DRUG|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
214437545|NCT05623163|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
214437546|NCT02802995|DRUG|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
214437547|NCT01285635|DRUG|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
214437548|NCT01285635|DRUG|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
214437549|NCT03990649|DRUG|Soticlestat|Soticlestat tablets
214437550|NCT03990649|DRUG|Placebo|Soticlestat matching placebo tablets
214437551|NCT05447507|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
214437552|NCT05447507|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
214437553|NCT04689685|OTHER|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
214437554|NCT00505934|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
214437555|NCT01296646|DRUG|Naltrexone|50 mg oral naltrexone once/day
214437556|NCT01296646|BEHAVIORAL|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
214437557|NCT01296646|DRUG|Placebo|An inactive pill to control for non-pharmacological responses.
214437558|NCT04196504|DEVICE|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
214437559|NCT04080336|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
214437560|NCT04080336|DRUG|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
214437561|NCT04080336|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
214437562|NCT05032534|DEVICE|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
214437563|NCT05032534|DEVICE|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
214437564|NCT04853706|DIAGNOSTIC_TEST|3d cam|The 3D-CAM is a short interview that uses verbal responses and allows completion of the Confusion Assessment Method (CAM) diagnostic algorithm
214437565|NCT04853706|DIAGNOSTIC_TEST|DSM 5|The DSM-5 is the gold standard for diagnosing delirium. But proper use requires professional psychiatric background and training.
214437566|NCT03496103|BIOLOGICAL|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
214437567|NCT03305146|GENETIC|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR\_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."
214437568|NCT03565523|OTHER|Beetroot|Containing 385 mg nitrate
214437569|NCT03565523|OTHER|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
214437570|NCT00209742|DRUG|UFT|P.O. everyday
214516968|NCT05362279|OTHER|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
214516969|NCT03704363|DRUG|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
214516970|NCT03704363|OTHER|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
214516971|NCT01249794|PROCEDURE|non invasive ventilation|continuous positive airways pressure
214516972|NCT00248794|BEHAVIORAL|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
214516973|NCT00248794|BEHAVIORAL|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
215116416|NCT06960187|BEHAVIORAL|Weyera Intervention|"Weyera intervention is an eight-week program featuring weekly, two-hour facilitated group sessions with 6-10 participants in each group, led by trained lay facilitators. Each session will address the weekly topic and introduce an evidence-based coping strategy (e.g., mindfulness, positive refocusing) that participants can practice over the following week. Within this outline, we will create intervention activities based on theory-based change methods and practical applications matched to objectives and determinants in the Logic Model of Change.~Outline of major modules for the eight weeks:~1. Introduction to mental health~2. Stress and family pressure~3. Self-exploration and critical reflection~4. Intersectional Identities~5. Family Relationships~6. Discussing mental health in the Ethiopian and Eritrean communities~7. Trauma and Abuse~8. Navigating mental health services"
214437571|NCT00209742|DRUG|USEL/Leucovorin|P.O. everyday
214437572|NCT00209742|DRUG|Krestin|P.O. everyday
214437573|NCT03050814|DRUG|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
214437574|NCT03050814|BIOLOGICAL|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
214437575|NCT03050814|DRUG|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
214437576|NCT03050814|DRUG|5-Fluorouracil (FU)|400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
214437577|NCT03050814|DRUG|Leucovorin|400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
214437578|NCT03050814|DRUG|Oxaliplatin|85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
214516974|NCT00248794|BEHAVIORAL|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
214516975|NCT03366571|DRUG|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
214516976|NCT03213379|DEVICE|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
214516977|NCT04062279|DIAGNOSTIC_TEST|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
214516978|NCT05107232|OTHER|MRI|MRI
214437579|NCT03050814|DRUG|Capecitabine|625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
214516979|NCT03449979|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
214516980|NCT03449979|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
214516981|NCT02632747|DRUG|Empagliflozin|Empagliflozin will be taken once daily
214516982|NCT02632747|DRUG|Placebo (matching empagliflozin)|Placebo will be taken once daily
214437580|NCT03050814|DRUG|5-Fluorouracil (FU)|2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
214437581|NCT05075694|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
214437582|NCT05075694|OTHER|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
214437583|NCT02692469|PROCEDURE|Duodenal Switch|Bariatric procedure
214437584|NCT02692469|PROCEDURE|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
214437585|NCT05304546|DRUG|Pembrolizumab|Solution for IV
214437586|NCT05304546|DRUG|Encorafenib|Oral QD
214437587|NCT05304546|DRUG|Binimetinib|Oral BID
214437588|NCT02333513|DRUG|Lomustine/Vincristine/Procarbazine|
214516983|NCT02632747|DRUG|ramipril|Ramipril will be taken once or twice daily
214516984|NCT04362059|DEVICE|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
214437589|NCT01443845|DRUG|Roflumilast|Roflumilast 500 µg, oral administration, once per day
214516985|NCT04362059|OTHER|Standard of Care|Standard of care treatment for respiratory illness
214516986|NCT02326493|DEVICE|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
214516987|NCT02069379|DRUG|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
214516988|NCT02069379|DRUG|Placebo|Placebo capsules prepared identically to Metformin capsules
214516989|NCT03095378|PROCEDURE|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
214516990|NCT03095378|PROCEDURE|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
214437590|NCT01443845|DRUG|Placebo|Dose-matched placebo, oral administration, once per day.
214437591|NCT02014129|DRUG|LY2835219|Administered orally
214437592|NCT00164216|DRUG|mefloquine plus artesunate|
214516991|NCT03095378|PROCEDURE|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
214516992|NCT00420498|DRUG|Atomoxetine (Strattera™)|
214516993|NCT02732470|OTHER|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
215116417|NCT06960187|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (pre-intervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
215116418|NCT00651716|OTHER|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
215116419|NCT00651716|OTHER|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
215116420|NCT00651716|OTHER|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
215116421|NCT00697372|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
215116422|NCT00697372|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
215116423|NCT02234804|DEVICE|Xience Prime Stent|
215116424|NCT02234804|DEVICE|Medtronic Resolute Integrity stent|
215116425|NCT02234804|PROCEDURE|Angiography|
215116426|NCT02234804|PROCEDURE|OCT|
215116427|NCT05465343|DRUG|Furmonertinib|Furmonertinib 160mg orally QD
215116428|NCT04270708|DRUG|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
215116429|NCT04270708|DRUG|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
215116430|NCT00366691|DRUG|Acular LS|
215116431|NCT00366691|DRUG|Lotemax|
215116432|NCT01103427|DEVICE|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
214437593|NCT03849352|BEHAVIORAL|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
214437594|NCT03465813|BEHAVIORAL|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
214437595|NCT04454879|DRUG|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
214437596|NCT05137236|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
214437597|NCT05137236|BIOLOGICAL|mRNA-1283.211|Sterile liquid for injection
214437598|NCT05137236|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214437599|NCT05137236|BIOLOGICAL|mRNA-1283.529|Sterile liquid for injection
214516994|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
215116433|NCT01103427|DEVICE|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
215116434|NCT01103427|DEVICE|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
214437600|NCT02627469|BEHAVIORAL|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
214437601|NCT02627469|DEVICE|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
214437602|NCT02627469|DEVICE|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
214437603|NCT00538122|DEVICE|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
214516995|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
214516996|NCT01201278|DRUG|Insulin LISPRO|Subcutaneous insulin lispro 8 U
215116435|NCT01103427|DEVICE|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
215116436|NCT04851054|PROCEDURE|Surgery for colon cancer with intention to cure|Surgery by open or laparoscopic approach
215116437|NCT00740584|DRUG|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
215116438|NCT03187444|PROCEDURE|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
215116439|NCT02754531|DEVICE|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
215116440|NCT02754531|OTHER|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
215116441|NCT04397744|BEHAVIORAL|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
215116442|NCT05434390|BEHAVIORAL|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
215116443|NCT05434390|BEHAVIORAL|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
215116444|NCT06324292|PROCEDURE|complete denture, CG|fabrication of conventional complete denture followed by a digital denture
215116445|NCT06324292|PROCEDURE|complete denture, DG|fabrication of digital complete denture followed by a conventional one
215116446|NCT00950313|OTHER|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
215116447|NCT00950313|OTHER|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
214437604|NCT01612312|PROCEDURE|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
214437605|NCT01612312|PROCEDURE|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
214437606|NCT02317874|DRUG|Carboplatin|Given IV
214437607|NCT02317874|DRUG|Paclitaxel|Given IV
214437608|NCT02317874|DRUG|Talazoparib|Given PO
214437609|NCT02487069|PROCEDURE|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
214437610|NCT02487069|PROCEDURE|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
214437611|NCT02487069|PROCEDURE|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
214437612|NCT02487069|DRUG|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
214437613|NCT02487069|DRUG|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
214437614|NCT02487069|DRUG|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
214437615|NCT02487069|DRUG|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
214437616|NCT00580593|DEVICE|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
214437617|NCT00580593|OTHER|sham-NIPPV|a sham-device
214437618|NCT05101941|PROCEDURE|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
214437619|NCT05558423|BEHAVIORAL|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
214437620|NCT05589441|DRUG|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
214437621|NCT05589441|DRUG|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
214437622|NCT02724956|DEVICE|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
214437623|NCT02724956|DEVICE|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
214437624|NCT02724956|DEVICE|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
214437625|NCT05928637|DRUG|D745, D759, D150|QD, PO for 5 days
214437626|NCT02134951|DRUG|Ketamine|intravenous infusion of saline solution with ketamine
214437627|NCT02134951|DRUG|Normal saline|Normal saline will be used for placebo in this group
214437628|NCT03807661|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
214437629|NCT03807661|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
214437630|NCT05927896|DIAGNOSTIC_TEST|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
214437631|NCT04015349|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
214437632|NCT02555475|OTHER|community based hepatitis C care and treatment|
214437633|NCT03039803|PROCEDURE|uterine closure during cesarean section|
214437634|NCT02005406|DEVICE|Experimental group and control groupl|JET
214437635|NCT01463176|BEHAVIORAL|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
214437636|NCT00431834|DEVICE|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214437637|NCT00431834|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214437638|NCT03312322|OTHER|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
215116448|NCT03000855|PROCEDURE|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
215116449|NCT03000855|PROCEDURE|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
215116450|NCT03786536|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
215116451|NCT04249817|OTHER|Video Conferencing with Exteneded Role Practitioner (VC-ERP)|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
215116452|NCT05674019|OTHER|MRI exam|Brain MRI Morphometric exam
214437639|NCT03312322|OTHER|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
214437640|NCT03312322|OTHER|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
214437641|NCT04071756|DRUG|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
214437642|NCT04071756|OTHER|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
214437643|NCT03628885|BEHAVIORAL|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
214437644|NCT03628885|BEHAVIORAL|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
214437645|NCT05055752|DRUG|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
214437646|NCT05715398|DRUG|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
214437647|NCT06222983|PROCEDURE|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
214437648|NCT01066767|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
214437649|NCT05310916|DRUG|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
214437650|NCT05310916|DRUG|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
214437651|NCT06302920|DEVICE|Kinesiotape|Lymphatic correction technique
214437652|NCT02461628|BEHAVIORAL|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
214437653|NCT06107101|DRUG|Mepolizumab|100mg of mepolizumab every 4 weeks subcutaneously for 6 months
214437654|NCT01955226|OTHER|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
214437655|NCT01955226|OTHER|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
214437656|NCT02941484|PROCEDURE|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
214437657|NCT02941484|PROCEDURE|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
214437658|NCT00000777|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214437659|NCT04106869|OTHER|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
214437660|NCT04106869|OTHER|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
214437661|NCT02167958|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care."
214437662|NCT02167958|DRUG|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
214437663|NCT02167958|DRUG|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
214437664|NCT02167958|RADIATION|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
214437665|NCT02167958|OTHER|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
214437666|NCT02167958|DRUG|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
214437667|NCT02167958|DRUG|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
214437668|NCT02167958|DRUG|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is \> 1,000/mm3 for three consecutive days.
214437669|NCT01522794|DRUG|NOX-H94|single i.v. infusion
214437670|NCT01522794|DRUG|Placebo solution|single i.v. infusion
214437671|NCT02515071|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
214516997|NCT03195127|OTHER|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
215116453|NCT04402879|PROCEDURE|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements."
215116454|NCT00123123|DRUG|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
215116455|NCT00123123|DRUG|placebo|
215116456|NCT02794766|DRUG|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
215116457|NCT02794766|DRUG|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
215116458|NCT02794766|DRUG|Placebo|Placebo 1 gum each 12 hours for 10 days
214437672|NCT02515071|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
214437673|NCT06464224|BEHAVIORAL|low respiratory effort|patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)
214437674|NCT06464224|BEHAVIORAL|high respiratory effort|patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
215116459|NCT03038295|DRUG|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
214437675|NCT02634892|DEVICE|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
214437676|NCT06451770|DRUG|VERVE-201|Intravenous (IV) infusion
214437677|NCT04238858|BIOLOGICAL|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
214437678|NCT04282824|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
214437679|NCT04282824|PROCEDURE|Computed Tomography|Undergo PET/CT
214437680|NCT04282824|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214437681|NCT04282824|DIETARY_SUPPLEMENT|Monosodium Glutamate|Given PO
214437682|NCT04282824|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214437683|NCT04014439|DIAGNOSTIC_TEST|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
214437684|NCT04014439|DIAGNOSTIC_TEST|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
214516998|NCT02276937|DRUG|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
214516999|NCT04195334|DEVICE|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
214437685|NCT05835934|DRUG|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
214437686|NCT04667858|DEVICE|Home Ovulation Test|Visual read home ovulation test
214437687|NCT03304041|DIETARY_SUPPLEMENT|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
214437688|NCT03304041|DIETARY_SUPPLEMENT|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
214437689|NCT00324350|DRUG|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
214437690|NCT03331575|RADIATION|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
214437691|NCT02930200|BEHAVIORAL|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
214437692|NCT02930200|BEHAVIORAL|QuitGuide|NCI QuitGuide Treatment App
214437693|NCT02930200|BEHAVIORAL|Smart-T|Smart-Treatment App
214517000|NCT03059147|DRUG|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
214517001|NCT03059147|DRUG|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
214517002|NCT03964272|DEVICE|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
214517003|NCT03059056|DRUG|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
214517004|NCT00014508|BIOLOGICAL|sargramostim|
214517005|NCT00014508|DRUG|cyclophosphamide|
214437694|NCT01310348|DEVICE|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
214437695|NCT01310348|DEVICE|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
214437696|NCT04255706|DEVICE|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
214437697|NCT04255706|DEVICE|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
214437698|NCT04255706|DEVICE|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
214437699|NCT00334776|BIOLOGICAL|MART-1 antigen|
215116460|NCT03038295|DRUG|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
215116461|NCT03071887|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
215116462|NCT02073682|DRUG|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
215116463|NCT02073682|DRUG|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
214437700|NCT00334776|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
214437701|NCT00334776|BIOLOGICAL|therapeutic autologous dendritic cells|
214437702|NCT00334776|BIOLOGICAL|tyrosinase peptide|
214437703|NCT02647905|DEVICE|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
214437704|NCT00133250|DRUG|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
214437705|NCT00133250|OTHER|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
214437706|NCT01762475|DRUG|Sildenafil|
214437707|NCT02015520|DRUG|Clazakizumab|
214437708|NCT02015520|DRUG|Placebo (Matching with Clazakizumab)|
214437709|NCT00415402|DRUG|Vitamin D3|
214437710|NCT02531737|DRUG|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
214437711|NCT02531737|DRUG|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
214437712|NCT00972075|DRUG|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
214437713|NCT00972075|DRUG|placebo|one tablet per day 2 hours before going to bed
214437714|NCT01294956|OTHER|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
214437715|NCT01294956|OTHER|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
214437716|NCT02065193|BEHAVIORAL|ADOS/ADI-R/Clinical assessment|
214437717|NCT01746641|DRUG|Remifentanil|
214437718|NCT01746641|DRUG|Propofol|
214437719|NCT05119855|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
214437720|NCT05119855|BIOLOGICAL|mRNA-1273 Vaccine|mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
214437721|NCT02932579|OTHER|Pharmacogenomic Testing|Saliva collection (5mL)
214437722|NCT02932579|DRUG|Ibuprofen|400 mg
214437723|NCT02932579|DRUG|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
214437724|NCT02932579|DRUG|acetominophen|650 mg
214437725|NCT02932579|DRUG|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
214437726|NCT00414024|DRUG|Tegaserod|
214437727|NCT01972724|DRUG|Pioglitazone|Pioglitazone tablets
214437728|NCT01972724|DRUG|Metformin|Metformin as prescribed in clinical practice
214437729|NCT01972724|DRUG|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
214437730|NCT03791008|OTHER|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
214437731|NCT04542005|BEHAVIORAL|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
214437732|NCT06191016|DEVICE|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
214437733|NCT06191016|DEVICE|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
214437734|NCT02846909|DRUG|Progesterone|400mg progesterone pessaries
214517006|NCT00014508|DRUG|cyclosporine|
214517007|NCT00014508|DRUG|fludarabine phosphate|
214517008|NCT00014508|DRUG|melphalan|
214517009|NCT00014508|PROCEDURE|peripheral blood stem cell transplantation|
214437735|NCT06392412|BEHAVIORAL|fi-VR Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
214437736|NCT06392412|BEHAVIORAL|Traditional Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
214437737|NCT00944593|DIETARY_SUPPLEMENT|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
214437738|NCT00944593|DIETARY_SUPPLEMENT|Normal Saline|200ml Normal Saline 0.9%
214437739|NCT06211972|BEHAVIORAL|OpiVenture|"OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up."
214437740|NCT02168400|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
214517010|NCT03258099|GENETIC|detection of genotype|detection of genotype by next generation sequencing
214437741|NCT06958666|DEVICE|Digital Inhaled Therapy Management|"The subjects will be trained on their inhalation techniques with the Digital Medication Administration Device consists of an inhalation device with a display and inhalation technique assessment module. The device will show a standardized video demonstration and will evaluate the subjects' inhalation technique. A printed report will be available afterwards.~A home-based inhalation management service package will be provided to the subjects including a digital sensor that records the time, frequency, and key inhalation technique parameters for each use of metered-dose inhalers or dry powder inhalers, and automatically synchronizes the data to the cloud. The data is then analyzed for adherence and technique performance. Based on the data, subjects will receive medication reminders and voice alerts for any technique errors on the app provided with the package. Visual charts of medication adherence and inhalation technique will be available to reinforce self-management."
214437742|NCT06958666|DEVICE|Inspiratory Muscle Training|The subjects will receive standardized verbal training and demonstration of inhalation techniques and any questions will be answered Inspiratory muscle training equipment, ancillary software, inspiratory muscle training plan, and equipment user guide will be sent home with the patient.
214437743|NCT06160791|DRUG|Ruxolitinib|Administered Orally (PO)
214437744|NCT06160791|DRUG|Etoposide|Administered IV
214437745|NCT06160791|DRUG|Dexamethasone|Administered PO or IV
214437746|NCT06160791|PROCEDURE|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
214517011|NCT02721849|BEHAVIORAL|Yoga for adolescents|12 week hatha yoga course for adolescents
214517012|NCT02721849|BEHAVIORAL|Yoga for parents|12 week hatha yoga course
214517013|NCT02282137|DRUG|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
214437747|NCT06160791|PROCEDURE|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
214437748|NCT06160791|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214437749|NCT06347640|BIOLOGICAL|induced bleeding|revascularization of tooth is achieved by induced bleeding
214437750|NCT06347640|BIOLOGICAL|plasma rich fibrin|revascularization of tooth is achieved by plasma rich fibrin
214437751|NCT06299098|DRUG|Trevogrumab-Part A|Administered IV or SC in Part A
214437752|NCT06299098|DRUG|Trevogrumab-Part B and Part C|Administered SC in Part B, Part C
214437753|NCT06299098|DRUG|Garetosmab|Administered IV in Part B
214437754|NCT06299098|DRUG|Semaglutide|Administered SC in Part B and Part C
214437755|NCT06299098|DRUG|Matching Placebo-Part A|Administered IV or SC in Part A
214437756|NCT06299098|DRUG|Matching Placebo-Trevogrumab|Administered SC in Part B and Part C
214437757|NCT06299098|DRUG|Matching Placebo-Garetosmab|Administered IV in Part B
214437758|NCT04239092|DRUG|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
214437759|NCT04239092|DRUG|Irinotecan|Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.
214437760|NCT04239092|DRUG|Temozolomide|Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.
214517014|NCT01789593|OTHER|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
215116464|NCT02073682|DRUG|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
215116465|NCT03461146|DRUG|MT-6548|Oral tablet
215116466|NCT04841616|PROCEDURE|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
214437761|NCT04239092|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
214437762|NCT04239092|DRUG|Topotecan|Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
214437763|NCT04086745|DRUG|Baricitinib|Administered orally.
214437764|NCT04086745|DRUG|TNF Inhibitor|Administered SC
214437765|NCT04174742|DRUG|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
215116467|NCT04841616|PROCEDURE|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
215116468|NCT04392843|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
214437766|NCT02942355|DRUG|anastrozole|Anastrozole by mouth daily
214437767|NCT02942355|DRUG|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
214437768|NCT04207294|OTHER|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
214437769|NCT04207294|OTHER|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
215116469|NCT04392843|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
215116470|NCT00181766|DRUG|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
215116471|NCT01086774|OTHER|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
215116472|NCT00270309|BEHAVIORAL|Self-management|
215116473|NCT05336747|BEHAVIORAL|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
215116474|NCT03353480|DRUG|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
214437770|NCT05608564|PROCEDURE|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
214437771|NCT05608564|PROCEDURE|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
214437772|NCT03593733|OTHER|Photobiomodulation Therapy|Photobiomodulation Therapy
214437773|NCT03593733|OTHER|Cold Water Immersion|Cold Water Immersion
214437774|NCT05920746|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
214437775|NCT02825641|DRUG|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
214437776|NCT02825641|DRUG|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
214437777|NCT01739907|OTHER|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
214437778|NCT01676558|DRUG|131I-rituximab|
214437779|NCT03898024|DRUG|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
214437780|NCT03898024|DRUG|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
214437781|NCT01515436|OTHER|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
214437782|NCT01515436|OTHER|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
214437783|NCT05901896|OTHER|there are no intervention|no intervention
214437784|NCT02917343|BEHAVIORAL|mirror therapy and repetitive task training|
215116475|NCT03353480|DRUG|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
215116476|NCT00987311|DIETARY_SUPPLEMENT|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
215116477|NCT00987311|DIETARY_SUPPLEMENT|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
215116478|NCT00987311|DIETARY_SUPPLEMENT|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
214437785|NCT00945789|DRUG|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
214437786|NCT00945789|PROCEDURE|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
214437787|NCT00945789|BIOLOGICAL|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
214437788|NCT05177939|DRUG|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
214437789|NCT05177939|DRUG|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
214437790|NCT00111813|DRUG|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
214437791|NCT00111813|DRUG|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
214437792|NCT03649243|DRUG|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
214517015|NCT05569018|BEHAVIORAL|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
214437793|NCT02060955|BIOLOGICAL|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
214437794|NCT02060955|DRUG|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
214517016|NCT05569018|BEHAVIORAL|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
214437795|NCT02292329|DIETARY_SUPPLEMENT|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
214437796|NCT02292329|DIETARY_SUPPLEMENT|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
214437797|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
214437798|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
214437799|NCT01228669|DRUG|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
214437800|NCT03926442|OTHER|Italian Herb meal|Italian Herb in active breakfast meal
214437801|NCT03926442|OTHER|Cinnamon Meal|Cinnamon in active breakfast meal
214437802|NCT03926442|OTHER|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
214437803|NCT03926442|OTHER|Placebo meal|Placebo in breakfast meal
214517017|NCT00992030|DRUG|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
214517018|NCT00992030|RADIATION|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
214517019|NCT04432909|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
214517020|NCT01064180|DRUG|Carvedilol|Carvedilol Tablets 25 mg
214437804|NCT03084549|DRUG|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
214437805|NCT03084549|DRUG|Administration of placebo|Administration of placebo in the margins of the episiotomy
214517021|NCT01862224|DRUG|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
214517022|NCT01862224|DRUG|Placebo|Matching placebo once daily (Week 0 to Week 12).
214517023|NCT01862224|DRUG|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
214517024|NCT00700999|DRUG|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
214517025|NCT04056598|DIAGNOSTIC_TEST|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
214517026|NCT02618109|BIOLOGICAL|Collection of blood samples|Collection of blood samples
214437806|NCT01499992|PROCEDURE|Standard physical therapy program PLUS aquatic physical therapy|2\. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
214437807|NCT01499992|OTHER|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
214437808|NCT01020643|DRUG|controlled administration of propofol|comparison of propofol sedation
214437809|NCT01753986|BEHAVIORAL|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
214517027|NCT02919865|DEVICE|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
214517028|NCT05088122|OTHER|no intervention|no intervention, not applicable
214437810|NCT01753986|BEHAVIORAL|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
214437811|NCT02660970|OTHER|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
214517029|NCT05789407|DIAGNOSTIC_TEST|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
214517030|NCT05813249|DRUG|Rybelsus Oral Product|Oral Semaglutide
214517031|NCT05813249|DRUG|Ozempic Injectable Product|Subcutaneous Semaglutide
214517032|NCT05813249|DRUG|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
214517033|NCT05863871|DRUG|Linperlisib|80 mg, qd
214517034|NCT05250362|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
214517035|NCT02327702|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
214517036|NCT04552184|OTHER|GPOEM|gastric per oral endoscopic pyloromyotomy
214517037|NCT04552184|OTHER|SHAM Procedure|intrapyloric injection of saline solution
214517038|NCT06361576|DRUG|Nivolumab|As per product label
214692733|NCT05996172|BEHAVIORAL|CAMS Single Session Consultation|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation. CAMS is based around a model of STB which states that youth become suicidal in response to overwhelming pain, and treatment identifies and targets the drivers of suicide as the primary focus of assessment and intervention.
215116479|NCT05586984|PROCEDURE|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
215116480|NCT05586984|PROCEDURE|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
215116481|NCT00402870|DEVICE|ProSeal LMA|ProSeal LMA vs Tracheal Tube
215116482|NCT00402870|DEVICE|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
215116483|NCT01968330|BEHAVIORAL|Go!®to sleep|
215116484|NCT02742220|OTHER|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
215116485|NCT02742220|OTHER|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
214517039|NCT03651271|BIOLOGICAL|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
214517040|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
214437812|NCT02660970|OTHER|Placebo-band|Children will have to wear a 'placebo-wristband'
214437813|NCT02660970|DRUG|Iberogast|Children will have to take Iberogast drops
214437814|NCT02660970|OTHER|Placebo-drops|Children will have to take placebo-drops
214437815|NCT01929759|DRUG|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
214437816|NCT02847689|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
214437817|NCT02847689|BEHAVIORAL|Control Treatment|Standard of Care
214437818|NCT01661569|OTHER|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
214437819|NCT03372070|DEVICE|cNEP|soft silicon collar applied to anterior neck with negative pressure
214692734|NCT05996172|BEHAVIORAL|Driver Focused Skills Training|The CAMS approach focuses on therapeutic assessment, collaborative identification and treatment of the patient-defined STB drivers (i.e., the problems that make suicide compelling to the patient) and utilizes problem-focused treatment sessions to address the drivers in order to reduce the wish to die. In the SOARS brief intervention model, specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality.
215116486|NCT05498168|GENETIC|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
215116487|NCT00855816|BEHAVIORAL|Breathing training|relaxation training
215116488|NCT04496856|DIETARY_SUPPLEMENT|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
215116489|NCT03393494|DRUG|Adapalene and Benzoyl Peroxide Topical Gel|Test product
215116490|NCT03393494|DRUG|Epiduo Topical Product|RLD product
215116491|NCT03393494|DRUG|Placebo|Placebo gel
215116492|NCT00536237|DRUG|Comparator: niacin / Duration of Treatment: 17 Weeks|
215116493|NCT00536237|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
215116494|NCT00536237|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
215116495|NCT03530943|BEHAVIORAL|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
215116496|NCT03530943|BEHAVIORAL|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
214437824|NCT06181695|DRUG|Sufentanil|Administration of intranasal sufentanil
214437825|NCT00038454|DRUG|Hemolink (hemoglobin raffimer IV solution)|
214437826|NCT00335049|DEVICE|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
214437827|NCT00335049|DEVICE|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
214437828|NCT00171431|DRUG|Tegaserod|
214437829|NCT03048994|DIETARY_SUPPLEMENT|Glutamine|"* Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
214437830|NCT03048994|DIETARY_SUPPLEMENT|Placebo|"* Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
214437831|NCT05998330|BEHAVIORAL|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
214437832|NCT05307536|COMBINATION_PRODUCT|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
214437833|NCT05307536|COMBINATION_PRODUCT|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
214437834|NCT03693937|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
214437835|NCT01000480|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
214437836|NCT01000480|DRUG|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
214437837|NCT01000480|RADIATION|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
214437838|NCT00570700|DRUG|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
214437839|NCT06284642|DRUG|Urokinase|On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
214437840|NCT06284642|DRUG|Placebo|On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
214437841|NCT06438094|PROCEDURE|Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
214437842|NCT06438094|PROCEDURE|Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
215116497|NCT03222687|DRUG|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
215116498|NCT03222687|DRUG|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
214437843|NCT05027607|PROCEDURE|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
214517041|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
215116499|NCT00002404|DRUG|Valacyclovir hydrochloride|
215116500|NCT02096016|PROCEDURE|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
215116501|NCT03337334|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
215116502|NCT00378781|DRUG|Heparin|Heparin flush solution into CVC once daily.
215116503|NCT00378781|DRUG|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
214437844|NCT04446598|DEVICE|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
214437845|NCT04446598|DRUG|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
215116504|NCT01965704|DRUG|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
215116505|NCT01965704|DRUG|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
215116506|NCT01526213|DRUG|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
215116507|NCT00061893|DRUG|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
215116508|NCT00061893|DRUG|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
215116509|NCT00061893|DRUG|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
214437846|NCT01346982|DRUG|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
214437847|NCT04992585|DEVICE|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
214437848|NCT04374916|DEVICE|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
215116510|NCT00061893|DRUG|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
215116511|NCT00061893|DRUG|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
215116512|NCT00061893|DRUG|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. \[Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.\]
215116513|NCT00061893|DRUG|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
214437849|NCT04374916|DEVICE|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
214437850|NCT05372146|PROCEDURE|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
214437851|NCT01671267|BEHAVIORAL|Strength training|
214437852|NCT01671267|BEHAVIORAL|Ergonomic|
214437853|NCT06350812|DRUG|PB-119|Administered subcutaneously once a week
214437854|NCT06350812|DRUG|Placebo|Administered subcutaneously once a week
214517042|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
214517043|NCT02362100|OTHER|Non operative|non operative treatment
215116514|NCT00061893|PROCEDURE|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
215116515|NCT00061893|RADIATION|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
215116516|NCT00061893|DRUG|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
214437855|NCT01699152|DRUG|TG02 citrate|TG02 citrate capsules
214437856|NCT00174382|DRUG|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
214437857|NCT04153110|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214437858|NCT04153110|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214437859|NCT04175899|OTHER|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
214437860|NCT06477848|OTHER|Integrated Behavioral Health System with SUD Resources|This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
214437861|NCT04403789|OTHER|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
214517044|NCT02362100|PROCEDURE|locking plate surgical fixation|
214517045|NCT04398355|COMBINATION_PRODUCT|acupuncture|acupuncture
214517046|NCT04398355|COMBINATION_PRODUCT|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
214517047|NCT01870687|DRUG|20mg VAC BNO 1095 FCT|
214517048|NCT01870687|DRUG|Placebo|
214517049|NCT01736722|DEVICE|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
214437862|NCT04403789|BEHAVIORAL|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
214437863|NCT05537675|OTHER|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
214437864|NCT06375603|OTHER|Ultrasound scans|Clinical experts will conduct non-invasive ultrasound scans from the specified nerve or plane block views and record the acquired data.
214437865|NCT02102841|PROCEDURE|Skin biopsy|
214437866|NCT02102841|PROCEDURE|Skin suction blister|
214437867|NCT02102841|BIOLOGICAL|Mantoux test|
214437868|NCT03949101|DRUG|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
214437869|NCT03949101|DRUG|atropine 0.01% eye drop|use one drop into subconjunctiva
214437870|NCT00296036|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Given orally
214437871|NCT00296036|DRUG|urea/lactic acid-based topical cream|Applied topically
214437872|NCT00296036|OTHER|placebo|Given orally or applied topically
215116517|NCT00061893|DRUG|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
215116518|NCT04526912|DRUG|VIB7734|Single subcutaneous dose
215116519|NCT04526912|DRUG|Placebo|Intravenous single dose matched to VIB7734.
215116520|NCT00687804|DRUG|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
214437873|NCT03428620|OTHER|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
214437874|NCT03428620|OTHER|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
214437875|NCT01482975|OTHER|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
214437876|NCT01482975|OTHER|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
214437877|NCT02650791|DRUG|Tranexamic Acid|
214437878|NCT01154439|DRUG|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
214437879|NCT01154439|DRUG|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
214437880|NCT01154439|DRUG|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
215116521|NCT00687804|PROCEDURE|Laser|Laser photocoagulation treatment
215116522|NCT00687804|PROCEDURE|Sham laser|Sham to laser procedure.
214437881|NCT01154439|DRUG|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
214437882|NCT01154439|DRUG|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
214437883|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
214437884|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
214437885|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
214437886|NCT06489262|BEHAVIORAL|"Healthy Together (Juntos)"|"Parent-adolescent dyads will log in to a secured website for six months. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in approximately weekly (during the first 3 months), and monthly (during the following 3 months) 20-30-minute sessions regarding the family's progress throughout the intervention period."
214437887|NCT06026319|DRUG|CD79b-19 CAR T cells|Intravenous infusion
214437888|NCT06026319|DRUG|Cyclophosphamide|Intravenous infusion
214437889|NCT06026319|DRUG|Fludarabine|Intravenous infusion
214437890|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
214437891|NCT05348889|DRUG|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
214437892|NCT06782529|DRUG|Triamcinolone Acetonide Low Dose|"Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)"
214437893|NCT06782529|DRUG|Triamcinolone Acetonide Standard Dose|"Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)"
214437894|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 tablet orally once daily for 6 weeks.
214437895|NCT05686408|DRUG|Placebo|Patients will take 1 tablet orally once daily for 6 weeks.
214437896|NCT06832670|OTHER|intervention|Participants in the intervention group will receive vaccine education, video animation and game practice.
214437897|NCT06832670|OTHER|active comparator|There will be no intervention in this group. It will continue its active education.
214437898|NCT05810259|DEVICE|Caravan Wellness app|Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
214517050|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
214517051|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly placebo plus 800 calcium alone
214517052|NCT02625636|DRUG|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214517053|NCT02625636|DRUG|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214517054|NCT02625636|DRUG|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214517055|NCT01615523|OTHER|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
214517056|NCT03444155|DIETARY_SUPPLEMENT|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
214517057|NCT03444155|DIETARY_SUPPLEMENT|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
214517058|NCT00821093|DRUG|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214517059|NCT00821093|DRUG|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
214517060|NCT00821093|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214517061|NCT00821093|DRUG|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
214517062|NCT00761241|DRUG|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
215116523|NCT00687804|DRUG|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
215116524|NCT02870153|DRUG|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
215116525|NCT02870153|DRUG|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
215116526|NCT04992663|DEVICE|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~* Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~* Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~* Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~* Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~* Counseling video (cesarean section, epidural anesthesia)"
215116527|NCT02837458|DEVICE|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
215116528|NCT02837458|DEVICE|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
215116529|NCT02686918|OTHER|Advanced Practice Nurse consultation|
214517063|NCT00761241|BIOLOGICAL|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
214517064|NCT00761241|RADIATION|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
214517065|NCT00761241|PROCEDURE|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
214517066|NCT06050837|OTHER|No intervention|No intervention
214517067|NCT00109161|DRUG|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
215116530|NCT00006343|BIOLOGICAL|recombinant interferon alfa|
214517068|NCT01484015|DRUG|cefepime hydrochloride|Given IV
214437899|NCT02576509|DRUG|Nivolumab|Specified Dose on Specified Days
214437900|NCT02576509|DRUG|Sorafenib|Specified Dose on Specified Days
214437901|NCT03271762|DEVICE|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
214437902|NCT03271762|PROCEDURE|cardiac surgery|mitral valve repair or mitral valve remplacement
214437903|NCT04688450|DEVICE|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
214437904|NCT05367245|DRUG|Cal-Mag Butyrate|Supplements
214517069|NCT02368977|DEVICE|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
214517070|NCT05028283|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
214517071|NCT05664009|DIETARY_SUPPLEMENT|Redsenol-1 Plus|Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
214517072|NCT05664009|OTHER|Placebo|Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
214517073|NCT02535598|BEHAVIORAL|Normal presentation|All the material will be presented as plain text.
215116531|NCT00006343|DRUG|cytarabine|
214437905|NCT05367245|DRUG|Placebo|Only Cal-Mag but no Butyric acid
214437906|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
214437907|NCT06830083|RADIATION|Hypofractionated Radiation Therapy|Hypofractionation regimen: Total dose to the chest wall and the regional lymph nodes is 4050 cGy, and each fraction consists of 270 cGy per day(daily, Monday through Friday )
214437908|NCT06830083|RADIATION|Conventional fraction radiotherapy|Total dose of plan tumor volume is 5000 cGy，and each fraction will consist of 200 cGy per day. 25 fractions(daily, Monday through Friday) to the chest wall and to the supraclavicular (with or without axillary) lymph nodes.
214437909|NCT06301477|OTHER|Resistant Starch|7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption
214437910|NCT06301477|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
214437911|NCT03746054|COMBINATION_PRODUCT|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
214437912|NCT03746054|COMBINATION_PRODUCT|usual clinical practice|usual clinical practice in each center
214437913|NCT06786416|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
214437914|NCT03599843|BEHAVIORAL|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
214517074|NCT02535598|BEHAVIORAL|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
214517075|NCT02535598|BEHAVIORAL|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
214517076|NCT02535598|BEHAVIORAL|Enhanced support|Participants are offered daily support through the internet from trained therapists.
214517077|NCT01706393|DIETARY_SUPPLEMENT|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
214517078|NCT01706393|DIETARY_SUPPLEMENT|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
214517079|NCT03003923|BEHAVIORAL|Taste exposure|Exposure to the same vegetable
214517080|NCT03003923|BEHAVIORAL|Nutritional education|Eat Well and Strive for Five nutritional education
214437915|NCT06347393|DIAGNOSTIC_TEST|Mammography and Breast Ultrasound|Patients will be scanned using mammography and Breast Ultrasound for Breast Cancer Screening
214437916|NCT06788145|BEHAVIORAL|Social Support Single-Session Intervention|Single-session intervention to increase self-efficacy, social support, help-seeking, and recovery-oriented behaviors to address disordered eating.
214437917|NCT06686602|OTHER|No drug|This is a non-interventional study and no study drug will be administered.
214437918|NCT00263718|DRUG|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
214437919|NCT05676645|DRUG|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
214437920|NCT03089125|BEHAVIORAL|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness"
214437921|NCT03089125|OTHER|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
214437922|NCT06472609|BEHAVIORAL|enhanced interactive education|The present study is a prospective randomized open-label study. Patients with diabetes mellitus who have HbA1c% more than 9% during the recent 1 year are enrolled. The intervention group receives, besides routine medical control of diabetes,enhanced interactive education program through weekly phone call for 12 weeks.
214437923|NCT05351281|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
214437924|NCT02574728|DRUG|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
214437925|NCT02574728|DRUG|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
214437926|NCT02574728|DRUG|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
214437927|NCT02574728|DRUG|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
214437928|NCT06434701|DIAGNOSTIC_TEST|Nasopharyngeal swab sampling for COVID-19|The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
214437929|NCT06785922|PROCEDURE|Stomach biopsy for gastric microbiota|Stomach biopsy for gastric microbiota testing (16S RNA sequencing)
214437930|NCT05327829|COMBINATION_PRODUCT|External non-invasive stimulation|The participants are randomized into the block design of sham or tACS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.
214517081|NCT03225092|BIOLOGICAL|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
214517082|NCT03296488|DRUG|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
214517083|NCT03296488|DRUG|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
215116532|NCT00006343|DRUG|imatinib mesylate|
215116533|NCT04390243|DRUG|Binimetinib|Given PO
214517084|NCT02877680|BEHAVIORAL|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
215116534|NCT04390243|DRUG|Encorafenib|Given PO
214437931|NCT05327829|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
214437932|NCT06395051|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone monoester supplement (395 mg/kg body mass)
214437933|NCT06395051|DIETARY_SUPPLEMENT|Placebo|The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
215116535|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
215116536|NCT04142801|DEVICE|MeMo web application|The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
214437934|NCT06525532|OTHER|follow up|performing a 3 Tesla MRI of the operated foot
214437935|NCT06785545|DIAGNOSTIC_TEST|CA19-9|All patients Ca19-9 levels calculated from their urinary samples
214437936|NCT06262477|DRUG|BIIB800|Administered as specified in the treatment arm.
214437937|NCT06262477|DRUG|Actemra|Administered as specified in the treatment arm.
214437938|NCT06046443|DRUG|LB54640|Oral daily administration
214437939|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
214437940|NCT01353313|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
214437941|NCT01353313|DRUG|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
214437942|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
214437943|NCT06356662|DRUG|Tenofovir Disoproxil Fumarate|take tenofovir disoproxil fumarate 300mg/d
214437944|NCT05371327|BEHAVIORAL|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
214517085|NCT01264484|DEVICE|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
214517086|NCT00003611|DRUG|acitretin|
214517087|NCT00003611|OTHER|placebo|
214517088|NCT01133678|DRUG|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
215116537|NCT04142801|OTHER|Control group|the patient have the classical follow up at the memory center (consultation)
215116538|NCT04851912|OTHER|Winterlight Apps|Longitudinal speech recordings
215116539|NCT05682339|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
215116540|NCT05682339|OTHER|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
214437945|NCT02879162|DRUG|Durvalumab|
214437946|NCT02879162|DRUG|Tremelimumab|
214437947|NCT05997602|DRUG|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
214437948|NCT06234033|BEHAVIORAL|Discrimination Acuity test|Estimating the just-noticeable difference of auditory loudness and vibrotactile displacement to fit a psychometric function for each modality with parameters: threshold, slope, sensitivity, and response criterion.
214437949|NCT06234033|DIAGNOSTIC_TEST|Transiently Evoked Otoacoustic Emission|Examination of integrity of outer hair cells in the inner ear; with and without contralateral suppression.
214437950|NCT06234033|OTHER|Questionnaires|Caregiver questionnaires send to parents online to acquire demographic information Autism Quotient (AQ), Child Behavior Checklist (CBCL6-16), Sensory Profile 2 (SP-2).
214437951|NCT06234033|BEHAVIORAL|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|Estimates intelligence quotient
215116541|NCT05682339|OTHER|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
215116542|NCT05682339|OTHER|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
215116543|NCT04104607|DRUG|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
215116544|NCT04800250|PROCEDURE|Treatment of gingival recessions|Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
215116545|NCT04572763|DRUG|Copanlisib|Intravenous infusion
214517089|NCT01133678|DRUG|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
214437952|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ASD|Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2)
214437953|NCT06234033|OTHER|Electroencephalography (EEG) with auditory or vibrotactile stimuli|Two paradigms will be used: an auditory frequency tagging paradigm with interspersed pitch oddballs and a classical sensory gating paradigm with either vibrotactile stimuli or auditory clicks.
214437954|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ADHD|ADHD-Rating Scale (ADHD-RS)
214437955|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
214437956|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
214437957|NCT06783023|OTHER|validity and reliability study|In the study, which will include at least 24 individuals with CIED determined by power analysis, unassisted arm exercise capacity and arm function/endurance, maximum arm exercise capacity, double product, heart recovery, comorbidity level, hand grip strength, fear of movement, activities of daily living and quality of life will be evaluated.
214437958|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
214437959|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
214437960|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
214437961|NCT06502262|DRUG|Bupivacaine Hydrochloride|patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.
214437962|NCT06502262|DRUG|Fentanyl|patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally
214517090|NCT03022734|DRUG|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
214517091|NCT03022734|RADIATION|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
215116546|NCT04572763|DRUG|Venetoclax|Tablet taken orally
215116547|NCT06091735|DRUG|OSS|experimental
215116548|NCT06091735|DRUG|OSS+Linzess|experimental
214437963|NCT06502262|DRUG|Dexmedetomidine|patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally
214437964|NCT05149157|OTHER|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
214437965|NCT04452955|BIOLOGICAL|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
214437966|NCT05659030|OTHER|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
214437967|NCT06831539|DRUG|PEGLyte bowel preparation|"Volunteers will be administered 4L of PEG bowel preparation. The following instructions will be provided with the prescription:~1. Fill the supplied container containing the bowel cleanse powder with lukewarm water (to facilitate dissolution) to the 4-liter fill line. The solution is clear and colourless when reconstituted to a final volume of 4 liters.~2. After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. The solution is more palatable if chilled prior to drinking. When reconstituted use within 48 hours.~3. Attempt to drink a maximum of 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters has been consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously.~4. The first bowel movements should occur approximately one hour after the start of bowel cleanse administration. Continue drinking until the watery stool is clear and free of solid matter."
214437968|NCT06475352|DRUG|FOLFOX regimen|Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
214437969|NCT06475352|DRUG|CAPOX regimen|Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
214437970|NCT06689839|DEVICE|F2 Filter and Delivery System|Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
214437971|NCT06689839|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
214437972|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
214437973|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
214517092|NCT05096741|DEVICE|OCS Liver|Transplanted with a OCS preserved liver
214517093|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
215116549|NCT06091735|DRUG|PEG-Interferon Alfa|Placebo Comparator
215116550|NCT03826069|OTHER|Augmented reality-based curriculum|Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
215116551|NCT03826069|OTHER|Conventional Simulation Curriculum|Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
215116552|NCT03754517|DIAGNOSTIC_TEST|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
214437974|NCT06828926|BEHAVIORAL|Tai Chi|The Tai Chi program content is based on the Harvard Medical School (HMS) Guide to Tai Chi, developed by clinical scientist Dr. Peter M. Wayne. Each participant will receive a workbook that describes the philosophy, evidence, and practice of Tai Chi, along with a video series for home practice that features the exercises from the HMS Guide to Tai Chi program. The in-person classes will be led by the PI and delivered weekly over 8 weeks, with 75-minute sessions. The in-person and video series will include an introduction to the principles of practice and tips on establishing and maintaining a practice, followed by a series of warm-up exercises, Tai Chi movements, and cool-down exercises. The Tin-person (and offer virtual live sessions for those who cannot attend in-person) over 8 weeks, accompanied by a workbook and video-recorded practices to promote self-management.
214437975|NCT06791031|DRUG|inclisiran|"Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group."
214437976|NCT06507579|DEVICE|Hydra transcatheter aortic valve (THV) series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
214437977|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB).
214437978|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)
214437979|NCT06784557|DRUG|Atorvastatin 40mg|High intensity HMG-CoA reductase inhibitor
214437980|NCT06784557|DRUG|Atorvastatin 20mg+Ezetimibe 10mg|Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
214437981|NCT06830668|DRUG|Regimen：BIC+FTC+TAF|"Same-day restart of BIC+FTC+TAF among HIV patients who experienced discontinuation from previous NNRTI-based regimens"
214437982|NCT03272438|DEVICE|Accelerometer|Participants use an accelerometer to monitor their steps activity
214437983|NCT03272438|BEHAVIORAL|Step goal|Participants are given a daily step goal to aim for
214437984|NCT03272438|BEHAVIORAL|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
214437985|NCT03272438|BEHAVIORAL|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
214437986|NCT06784856|OTHER|PICC AR APP|"This study utilized Vuforia software and Unity 2022 LTS as the primary development platforms to create an AR-Enhanced and Game-Assisted Teaching curriculum. The designed PICC AR Exploration APP was developed for both iOS and Android platforms. The PICC-related content was based on the 8th Edition of the Infusion Therapy Standards of Practice published by the Infusion Nurses Society (INS) in 2021 and the 2022 Clinical Guidelines for Vascular Access Devices.~The required items for PICC care procedures were photographed and used to create 3D object elements and animations for developing AR scenarios and interactive gaming elements. The design and content of the PICC AR Exploration APP are described as follows:~Game Design Concept:~The PICC AR Exploration APP includes a learning unit system and a quiz unit system:~Learning Unit System Content:~Topic 1: Updates to guidelines and an introduction to clinical applications. Topic 2: PICC catheter care, dressing change steps, and techni"
214437987|NCT06784856|OTHER|Classroom Teaching and Case Sharing|"Introduction to Updated CVAD-PICC Guidelines and Clinical Applications~PICC Catheter Care Management of Common PICC-Related Complications Case Sharing on PICC Complication Management: Researchers"
214437988|NCT06586216|DRUG|PF-07817883|Experimental
214437989|NCT06833216|OTHER|Genetic variation|To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.
214517094|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
215116553|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010; placebo|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
214517095|NCT00323895|DEVICE|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
214517096|NCT04659083|DEVICE|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
215116554|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
215116555|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
215116556|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
215116557|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
215116558|NCT04200092|OTHER|Placebo|Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.
215116559|NCT06463262|DIAGNOSTIC_TEST|ctDNA|the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA
215116560|NCT05986214|OTHER|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
214437990|NCT06786143|BEHAVIORAL|Esmadem Education Model|"Application Application of the Research The implementation of the research was done in 3 steps.~Step 1: In the first stage of the research, after the risky pregnant women who come to the polyclinic are informed about the study, the participants who agree to participate and meet the criteria for inclusion in the research will be determined by randomization. After the pregnant women assigned to the training or control group sign the voluntary consent form and their consent is obtained, Personal InformationForm, Mishel Uncertainty in Illness Scale Depression-Anxiety-Stress Scale Depression-Anxiety-Stress Scale (DASÖ-21) scales will be applied. After the first interviews, the study group will be informed about the sessions and the training will start via zoom.~In educational sciences, since the number of groups is between 2-20 people in the acquisition of target behaviors at the conceptual level, two training groups will be created and 15 pregnant women will be in the first group, 15 preg"
214437991|NCT06835296|DRUG|YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.|Dose: Ascending doses (SAD stage: 200, 800, 1600, or 3200 mg; MAD stage: two dosages will be determined based on the results from the SAD stage) Mode of administration: Oral, once daily.
214437992|NCT06835855|OTHER|Passive Viewing Task|Infants will complete a computer-based task in which they view facial displays of emotion (angry, happy, sad, neutral) while an eye tracker records their gaze.
214517097|NCT05759000|DRUG|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
214517098|NCT06405516|DEVICE|Autologous blood cell salvage with in-house device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
214517099|NCT06405516|DEVICE|Autologous cell salvage with i-Sep SAME device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
214517100|NCT03424187|DIETARY_SUPPLEMENT|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
215116561|NCT06848699|DRUG|HLX43 dose 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214517101|NCT05830305|OTHER|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
214517102|NCT05609721|OTHER|no intervention, only observational study|no intervention, only observational study
214517103|NCT04581356|DRUG|Voxelotor|daily voxelotor 1500mg oral medication
215116562|NCT06848699|DRUG|HLX43 dose 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215116563|NCT06848699|DRUG|HLX43 dose 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215116564|NCT06848699|DRUG|HLX43 dose 4|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215116565|NCT06848699|DRUG|HLX43 dose 5|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215116566|NCT06848699|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
215116567|NCT00196664|DRUG|Paroxetine|
215116568|NCT06845488|BEHAVIORAL|CBT|"Participants will receive will receive 12 weeks of weekly CBT for Social Anxiety, including an intervention to improve conversational skills. The CBT for Social Anxiety will include imaginal exposure, which is a way of using the imagination to work with situations that produce anxiety. Participants will also receive a mindfulness intervention."
215116569|NCT06845488|DEVICE|VR|The VR software, the Virtual Communicator (VC) consists of a highly realistic avatar that interacts with the client in one of several situations. The therapist controls its gestures, facial expressions, body movements, and speech and builds and saves modular combinations of gestures and facial expressions that can be assembled in any order to create a conversational interaction. The software has two adult avatars of ambiguous race/ethnicity, male and female. The VC is delivered without a headset interactively over the internet, on a secure, password-protected connection that increase access by not requiring headsets and not requiring the client to come to the office. The VC can be done in English, or in Spanish where appropriate. Treatment will be done for 12 sessions. The VR software is used to provide CBT exposures to reduce anxiety and also to practice social interactions.
215116570|NCT06256445|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
215116571|NCT06256445|DRUG|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
215116572|NCT06419036|DEVICE|Pneumowave DC|Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
214517104|NCT05749939|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
214517105|NCT04491370|DRUG|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
215116573|NCT05671380|BEHAVIORAL|Longitudinal Proactive Outreach (LPO).|All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.
214437993|NCT06835855|OTHER|Interaction Task|Mother and infants will also complete a standardized interaction task during which we assess infant gaze and psychophysiology. The task consists of three stages, each of which lasts three minutes. For the first stage (Free Play 1), infants sit in a highchair and mothers are asked to play with their baby as they normally would, without any toys or other objects. In the second stage (Sad), mothers are asked to think about times when they are sad or depressed and do not feel able to effectively play with their child. They are instructed to look at their child but speak in a monotone and minimize body movement or any physical contact with the infant. In the third stage (Free Play 2), mothers again interact with their infants normally for three minutes.
214437994|NCT06014775|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
214437995|NCT04663399|OTHER|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
214437996|NCT02217904|DRUG|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
214437997|NCT02217904|DRUG|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
214437998|NCT02217904|DRUG|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
214437999|NCT02217904|DRUG|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
214438000|NCT02217904|DRUG|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
214438001|NCT02217904|DRUG|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
214438002|NCT05949801|DRUG|Neucardin|10 days IV infusion of 0.6 ug/kg/day
214438003|NCT05949801|DRUG|Placebo|10 days IV infusion of 0 ug/kg/day
214438004|NCT05338970|DRUG|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
214438005|NCT05338970|DRUG|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W
214438006|NCT04200729|DRUG|Irrigation with PVI|The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
214517106|NCT05104242|OTHER|Diet low in Advanced Glycation End-Products (AGE)|The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
214517107|NCT05986279|OTHER|Rehab|6 weeks of vestibular rehabilitation guided by the MINDGAPS decision support system
214517108|NCT04080778|DEVICE|magnetic seizure therapy (MST)|MST will be performed with the MagPro XP (120 V) device under anesthesia 2-3 times a week up to 15 sessions.Treatment is performed by magnetic stimulation of both hemispheres inducing a focal stimulation above vertex, using a serial of pulse trains with a frequency of at least 25 Hz but up to 100 Hz for 4-6 s (up to 10 s), which is sufficient to induce a tonic clonic seizure.
214438007|NCT04200729|PROCEDURE|Usual care|The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (\> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
214438008|NCT01218490|PROCEDURE|ovarian cancer surgery|
214438009|NCT03734393|OTHER|HIVD+/R+|Liver from an HIV-infected deceased donor
214438010|NCT05114720|DRUG|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
214438011|NCT05114720|DRUG|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
214438012|NCT06840951|DEVICE|rTMS|rTMS is a non-invasive procedure that uses electromagnetic field pulses to stimulate regions of the brain. rTMS can induce excitatory and inhibitory neural activity in the neural circuits of the motor cortex.
214438013|NCT06840951|BEHAVIORAL|CBT|CBT for OCD is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaviour. CBT will be conducted in a group setting according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions with step-by-step strategies.
214438014|NCT00670046|DRUG|valproic acid|given orally
214438015|NCT00670046|OTHER|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
214438016|NCT06051032|DEVICE|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
214438017|NCT06051032|DEVICE|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
214438018|NCT04194710|BIOLOGICAL|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
214438019|NCT04194710|PROCEDURE|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
214517109|NCT04080778|DEVICE|electroconvulsive therapy (ECT)|ECT will be performed with MECTA 5000Q, 4th generation ECT devices provided by MECTA Corporation under anesthesia 2-3 times a week up to 15 sessions. For initial procedure Seizure Threshold (ST) will be estimated by empiric titration in the first session of each participant. ST will be then determined as by the manufacturer of ECT Device by the titration schedule for the initial titration session. The subsequent treatment sessions were dosed at 6 times the charge of the seizure threshold.
214517110|NCT01864200|BIOLOGICAL|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
214517111|NCT01864200|BIOLOGICAL|Placebo|Saline placebo
214517112|NCT01892176|DIETARY_SUPPLEMENT|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
214517113|NCT03979352|DRUG|empagliflozin|Treatment with empagliflozin 25mg orally once a day
215116574|NCT05671380|BEHAVIORAL|Ask-Advice-Connect (AAC)|Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
215116575|NCT04945642|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR-BT
215116576|NCT04945642|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214438020|NCT06409897|OTHER|Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation|Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
214438021|NCT03961451|DEVICE|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
214438022|NCT00335036|DEVICE|ICD lead implant|Randomization of ICD lead type at implant
214438023|NCT00335036|DEVICE|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
214438024|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
214438025|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
214438026|NCT05300022|OTHER|TeKnO T1D: Parents|app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
214438027|NCT04995718|OTHER|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
214438028|NCT02146716|OTHER|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
214438029|NCT01254006|DRUG|forskolin, rutin and vitamins B1 and B2|
214438030|NCT02872675|DIETARY_SUPPLEMENT|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
214438031|NCT02872675|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator: Maltodextrin.
215116577|NCT05262270|DRUG|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
215116578|NCT05262270|DRUG|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
214438032|NCT03775785|DIETARY_SUPPLEMENT|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
214438033|NCT02308319|DRUG|Tenofovir disoproxil fumarate|300mg q.d. per oral
214438034|NCT03698084|PROCEDURE|venepuncture|sample collection for analysis
214438035|NCT03698084|PROCEDURE|nasopharyngeal swab|sample collection for analysis
214438036|NCT01095822|DRUG|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
214438037|NCT05412316|OTHER|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
214438038|NCT04502901|DRUG|KX0826|investigational AR antagonist
214438039|NCT04502901|OTHER|Placebo|Placebo of KX-826
214438040|NCT02121002|DRUG|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
214438041|NCT02121002|DRUG|Voltaren Topical Gel, 1%|Opaque, white gel
214438042|NCT02121002|DRUG|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
215116579|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-NTX|3 doses of intramuscular injections (Week 0, 3, 6)
214438043|NCT03647241|DEVICE|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
215116580|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-BUP|2 doses of subcutaneous injections (Week 0, 4)
215116581|NCT06122584|DRUG|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
214438044|NCT03647241|DEVICE|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
214438045|NCT03647241|PROCEDURE|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
214438046|NCT03818893|DRUG|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
214438047|NCT06803407|OTHER|Home exercise|The study group will be given exercises that include temporomandibular joint and neck as a home exercise program.
214438048|NCT06803407|OTHER|Patient education|Information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to avoid, posture training
214438049|NCT01596933|DIETARY_SUPPLEMENT|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
214438050|NCT01596933|DIETARY_SUPPLEMENT|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
214438051|NCT03403413|DEVICE|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
214438052|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).
214438053|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive and behavioral influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
214438054|NCT03655262|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
214438055|NCT02309996|BEHAVIORAL|Supervisor Training Program|
214438056|NCT03201822|OTHER|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
214438057|NCT03201822|OTHER|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
214438058|NCT03201822|OTHER|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
214438059|NCT03201822|OTHER|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
214438060|NCT00996229|BEHAVIORAL|Caloric restriction|20-30% CR for 6 months
214438061|NCT00996229|DIETARY_SUPPLEMENT|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
214438062|NCT00996229|DIETARY_SUPPLEMENT|Placebo|Daily corn oil capsules for 6 months
214438063|NCT00996229|DIETARY_SUPPLEMENT|Resveratrol|daily resveratrol for 6 months
214438064|NCT04081779|OTHER|Survivorship Care Plan|Receive patient-generated SCP
214438065|NCT04081779|OTHER|Educational Intervention|Receive telephone-based educational counseling session
214438066|NCT04081779|OTHER|Questionnaire Administration|Ancillary studies
214438067|NCT04081779|OTHER|Supportive Care|Receive generic information on survivorship care
214438068|NCT03966898|DRUG|SHR6390 Tablets|SHR6390 Tablets
214438069|NCT03966898|DRUG|Placebo Tablets|Placebo Tablets
214438070|NCT03966898|DRUG|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
214438071|NCT03501264|BEHAVIORAL|Online Game|LGBTQ Bullying game
214438072|NCT03501264|BEHAVIORAL|LGBTQ Resources|This group receives LGBTQ Resources
214438073|NCT02505321|OTHER|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
214438074|NCT02505321|PROCEDURE|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
214438075|NCT05555719|DEVICE|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
214438076|NCT05555719|DEVICE|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
214438077|NCT01579968|DRUG|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
214438078|NCT02076568|BEHAVIORAL|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
214438079|NCT04748939|BIOLOGICAL|recombinant subunit herpes zoster vaccine|vaccine administration
214438080|NCT03292120|OTHER|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
214438081|NCT01833923|DRUG|anlotinib|oral medicine.
214438082|NCT00903539|DEVICE|SecurAcath Securement System|Subcutaneous catheter securement system
214438083|NCT00830934|PROCEDURE|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
214517114|NCT03979352|DEVICE|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
214517115|NCT00927966|DRUG|RAD001|Taken orally once a day.
214438084|NCT00830934|PROCEDURE|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
214438085|NCT05953870|OTHER|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
214438086|NCT04047719|DIAGNOSTIC_TEST|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
214438087|NCT01672060|BEHAVIORAL|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
215116582|NCT03869008|DEVICE|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
215116583|NCT03869008|DEVICE|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
214438088|NCT01672060|BEHAVIORAL|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
214438089|NCT02974465|PROCEDURE|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
214438090|NCT02974465|PROCEDURE|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
214438091|NCT02974465|PROCEDURE|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
214438092|NCT06520332|PROCEDURE|Dental Implant Surgery - short implant group (less than or equal to 6mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
214438093|NCT06520332|PROCEDURE|Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
214438094|NCT04705675|BEHAVIORAL|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
214438095|NCT02158819|DEVICE|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
214438096|NCT04965272|DRUG|Cariprazine 0.75 mg/day|Oral Capsule
214438097|NCT04965272|DRUG|Cariprazine 1.5 mg/day|Oral Capsule
215116584|NCT05630001|DRUG|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
214438098|NCT04965272|DRUG|Cariprazine 3.0 mg/day|Oral Capsule
214438099|NCT04965272|OTHER|Placebo|Oral Capsule
214438100|NCT05434273|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
215116585|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
215116586|NCT05564754|DEVICE|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
215116587|NCT05564754|OTHER|High MAP|A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.
215116588|NCT05564754|OTHER|Deep sedation|Deep sedation for at least 36h
215116589|NCT05564754|OTHER|Fever control without a device|Management of fever in the ICU without a device
214517116|NCT00927966|DRUG|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
214517117|NCT05034588|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameter
214517118|NCT04325737|DRUG|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
215116590|NCT05564754|OTHER|Low MAP|A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.
214517119|NCT04325737|DRUG|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
214517120|NCT04558021|DRUG|Niclosamide suspension|200mg/10ml
214517121|NCT04558021|OTHER|Placebo|10ml placebo(absent of niclosamide)
214517122|NCT00681135|DEVICE|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
215116591|NCT05564754|OTHER|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
214517123|NCT00681135|DEVICE|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
214438101|NCT05434273|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
214438102|NCT00002697|BIOLOGICAL|filgrastim|
214438103|NCT00002697|BIOLOGICAL|sargramostim|
214438104|NCT00002697|DRUG|carboplatin|
214438105|NCT00002697|DRUG|etoposide|
214438106|NCT00002697|DRUG|ifosfamide|
214517124|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
214517125|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
214517126|NCT03726502|PROCEDURE|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
214517127|NCT03726502|PROCEDURE|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
214517128|NCT03726502|PROCEDURE|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
214517129|NCT03726502|PROCEDURE|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
214517130|NCT05325983|OTHER|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
215116592|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
215116593|NCT04559893|BEHAVIORAL|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
215116594|NCT04700098|BEHAVIORAL|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
215116595|NCT04700098|BEHAVIORAL|Online insomnia patient education|Online insomnia patient education
215116596|NCT05774717|DRUG|Tranexamic acid|1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
215116597|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
215116598|NCT05297786|DRUG|Placebo|Placebo injection
215116599|NCT06434012|OTHER|registry|This is registry for Infective Endocarditis
214438107|NCT00002697|PROCEDURE|autologous bone marrow transplantation|
214438108|NCT00002697|PROCEDURE|bone marrow ablation with stem cell support|
214438109|NCT00002697|PROCEDURE|peripheral blood stem cell transplantation|
214438110|NCT00002697|RADIATION|radiation therapy|
214438111|NCT03434587|PROCEDURE|Syndactyly|Syndactyly
214438112|NCT03434587|PROCEDURE|Reduction and inmobilization|Closed reduction and inmobilization with splint
214438113|NCT00774124|OTHER|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
214438114|NCT00774124|OTHER|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
214438115|NCT04797923|DRUG|1. Treatment: IP chemotherapy + Systemic chemotherapy|1\. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
214438116|NCT04797923|PROCEDURE|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2\. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles."
215116600|NCT06275412|BEHAVIORAL|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
214438117|NCT02753738|DRUG|Escitalopram|Tablet 10mg, 21 days
214438118|NCT02753738|DRUG|Placebo|Tablet, 21 days
215116601|NCT06275412|BEHAVIORAL|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
214438119|NCT02753738|OTHER|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
214438120|NCT02753738|BEHAVIORAL|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
214438121|NCT02753738|BEHAVIORAL|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
214438122|NCT05899270|OTHER|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
214438123|NCT05899270|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
214438124|NCT02877797|DEVICE|Cap|cap assisted esophagogastroduodenoscopy
215116602|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
215116603|NCT05314998|DRUG|Oxaliplatin|85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
215116604|NCT05314998|DRUG|Irinotecan|150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
215116605|NCT05314998|DRUG|Folinic acid|400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
214438125|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
214438126|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
214438127|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
214438128|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
214438129|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
214438130|NCT05598554|OTHER|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
214438131|NCT05598554|OTHER|information|A one-session training was provided on the effects of exercise on quality of life.
214438132|NCT03221959|DEVICE|Medical Device Vittamed 205|Intracranial pressure measurement
214438133|NCT03214185|PROCEDURE|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
214438134|NCT03214185|GENETIC|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
214438135|NCT03214185|OTHER|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
214438136|NCT05444075|OTHER|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
214438137|NCT04611932|DRUG|CKD-330 Tab. and D090 Tab.|1T
214438138|NCT04611932|DRUG|CKD-333 Tab.|1T
214438139|NCT05065203|PROCEDURE|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
214438140|NCT01343459|RADIATION|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy"
214438141|NCT05216770|OTHER|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
214438142|NCT05216770|DRUG|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
214517131|NCT05325983|OTHER|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
215116606|NCT05314998|DRUG|5-fluorouracil|2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
215116607|NCT05314998|DRUG|Gemcitabine|1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
215116608|NCT05314998|DRUG|Capecitabine|1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
215116609|NCT06800274|DRUG|NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL|80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
215116610|NCT06800274|DRUG|azelastine hydrochloride 0.05%|54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
215116611|NCT06113211|DRUG|Narcotic pain medication|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
215116612|NCT06113211|DRUG|Nonnarcotic pain medications|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
215116613|NCT05528341|BIOLOGICAL|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
215116614|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
214517132|NCT03647449|DIETARY_SUPPLEMENT|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
214438143|NCT05104294|DIAGNOSTIC_TEST|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
214438144|NCT05104294|DIAGNOSTIC_TEST|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
214438145|NCT00215397|DRUG|Formoterol Fumarate|
214438146|NCT06171412|BEHAVIORAL|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
214438147|NCT06647082|DEVICE|Pediatric Knee Exoskeleton|The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
214517133|NCT03647449|BEHAVIORAL|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
215116615|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
215116616|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
214438148|NCT04206813|DRUG|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
214438149|NCT04206813|DRUG|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
214438150|NCT04206813|DRUG|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
214438151|NCT05976581|BEHAVIORAL|Electronic alert|An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
214517134|NCT03647449|DIETARY_SUPPLEMENT|Plant-based meal|Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
214517135|NCT01739738|DEVICE|Ureteral Stent|patients who need to receive stent as per standard of care
214517136|NCT04449822|PROCEDURE|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
214517137|NCT04449822|PROCEDURE|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
215116617|NCT05939999|OTHER|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
215116618|NCT05939999|OTHER|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
215116619|NCT00206336|DRUG|Topiramate (drug)|Topiramate 25 mg to 200 mg
215116620|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
215116621|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
214438152|NCT05976581|BEHAVIORAL|Structured communication of test results|A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
215116622|NCT04639024|DRUG|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
215116623|NCT01196026|BIOLOGICAL|Fluarix™|One or two intramuscular injections
215116624|NCT01196026|BIOLOGICAL|Havrix™ Junior|Two intramuscular injections
215116625|NCT01687296|DRUG|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
215116626|NCT01687296|DRUG|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
215116627|NCT01687296|DRUG|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
215116628|NCT01687296|DRUG|placebo tablet|placebo soluble tablet, oral ,once daily
215116629|NCT01687296|DRUG|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
215116630|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
215116631|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
215116632|NCT01471834|DEVICE|BAROSTIM NEO System|
215116633|NCT01471834|DRUG|Medical Management|
215116634|NCT05152108|DEVICE|BCI feasibility test|Testing the feasibility of BCI device by determining the accuracy of BCI control
215116635|NCT05326633|COMBINATION_PRODUCT|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
215116636|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.5 mg/kg
215116637|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.25 mg/kg
215116638|NCT04912583|DEVICE|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
215116639|NCT04912583|DEVICE|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
215116640|NCT04300101|OTHER|Prospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
215116641|NCT04300101|OTHER|Retrospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
215116642|NCT06551168|OTHER|Heat exposure|Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.
215116643|NCT06551168|OTHER|Control group|Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
215116644|NCT00752479|BIOLOGICAL|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
214438153|NCT01294020|DRUG|Tacrolimus|Oral capsule
214438154|NCT01294020|DRUG|Tacrolimus prolonged release|Oral capsule
214438155|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
214438156|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
214438157|NCT01352429|RADIATION|Proton Therapy|
214438158|NCT01352429|RADIATION|IMRT|
214438159|NCT03568188|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
214438160|NCT03568188|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
214438161|NCT03568188|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
214438162|NCT03568188|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
214438163|NCT03568188|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
215116645|NCT00752479|DRUG|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
215116646|NCT00213265|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
215116647|NCT00213265|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
215116648|NCT02072265|DEVICE|Infrared thermal images|
215116649|NCT04979650|DRUG|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
215116650|NCT04979650|DRUG|Normal saline|500 g of normal saline without methylprednisolone succinate
215116651|NCT04131946|OTHER|Community-Based (Intervention Arm)|Community dispensed FIT
215116652|NCT05088057|DRUG|Camrelizumab|200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
215116653|NCT05088057|DRUG|Doxorubicin|60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
215116654|NCT05088057|DRUG|Cyclophosphamide|600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
215116655|NCT05088057|DRUG|Docetaxel|75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
215116656|NCT02378324|OTHER|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
215116657|NCT01463241|BEHAVIORAL|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
215116658|NCT02486016|DRUG|Duragesic reference fentanyl TDS|25 µg/hour
215116659|NCT02486016|DRUG|Apotex generic fentanyl TDS|25 µg/hour
215116660|NCT02486016|DRUG|Mylan generic fentanyl TDS|25 µg/hour
215116661|NCT00056979|DRUG|CAMPATH-1H|
215116662|NCT00056979|DRUG|Anti-CD45|
215116663|NCT00056979|DRUG|FK506|
215116664|NCT00056979|DRUG|Fludarabine|
215116665|NCT05747183|PROCEDURE|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
215116666|NCT05747183|PROCEDURE|ProTaper Gold|Root canal preparation using ProTaper Gold files.
215116667|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
215116668|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
215116669|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
215116670|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
215116671|NCT01552863|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
215116672|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
215116673|NCT05865522|OTHER|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
215116674|NCT05865522|OTHER|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
215116675|NCT03672292|DRUG|SCY-078|Oral tablets of SCY-078
214438164|NCT03568188|BIOLOGICAL|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
214438165|NCT03568188|BIOLOGICAL|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
215116676|NCT03672292|DRUG|Voriconazole|Voriconazole IV vials or oral tablets
215116677|NCT03672292|OTHER|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
214438166|NCT04902391|OTHER|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
214438167|NCT05902312|DEVICE|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
214438168|NCT05522868|DRUG|SB17170|SB17170 capsules, Oral administration 21days/cycle
214438169|NCT04448366|BEHAVIORAL|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
214438170|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a physiotherapist|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Initially guided and supervised every 3 months by a physiotherapist.
214438171|NCT05682872|BEHAVIORAL|Adequacy of the environment|A home study and the environment will be made to diagnose fall risks. Guided and supervised by a occupational therapist during a home visit.
214438172|NCT05682872|BEHAVIORAL|Polypharmacy review|Assessment of the medication that patients receives related to fall risks proposing its adjustment. Revised by a primary care doctor different from care routine.
214438173|NCT05682872|BEHAVIORAL|Health education related to falls prevention (4 sessions)|"SESSION 1: Fall Risk factors. Pharmacology. Nutrition and falls (Primary Care Doctor and Primary Care Nurse)~SESSION 2: Accident prevention through environmental modification (Occupational Therapist)~SESSION 3: Importance of physical exercise to prevent falls (Physiotherapist)~SESSION 4: Footwear and foot care. How to react to a fall?: what to do and how to get up? (Primary Care Nurse)"
214438174|NCT05682872|BEHAVIORAL|General Assement|General assessment (feet, footwear, nutrition, cognitive/psychological, social of risk factors) carried out by Primary Care Doctor and Primary Care Nurse
214517138|NCT02428595|DEVICE|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
214517139|NCT01818999|DRUG|IXABEPILONE|injection
214517140|NCT01818999|RADIATION|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
214517141|NCT02588521|DRUG|AL-794|
215116678|NCT05730309|BEHAVIORAL|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
215116679|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
215116680|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
215116681|NCT01035671|DRUG|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
215116682|NCT00799903|DRUG|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
215116683|NCT00799903|DRUG|Placebo|Placebo administered in addition to standard therapy
214517142|NCT02588521|OTHER|Placebo/Vehicle|Suspension vehicle without active drug
214517143|NCT03374722|DRUG|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
214517144|NCT00424476|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
214517145|NCT00424476|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
214517146|NCT00424476|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
214517147|NCT05073393|BEHAVIORAL|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
214517148|NCT01653106|PROCEDURE|cryotherapy|Receive shaved ice
214438175|NCT05682872|BEHAVIORAL|Evaluation of patients by an expert group|Evaluation of the patient by an expert group (Primary care doctor, primary care nurse, polypharmacy review doctor, occupational therapist, frailty group) and decision-making for correction of fall risk factors.
214438176|NCT05682872|BEHAVIORAL|Information brochures on the importance of physical exercise|Integrated Assistance Process for prevention falls in elderly. Benefits of physical exercise and fall prevention at home. Prepared by the Junta de Comunidades de Castilla-La Mancha and Servicio de Salud de Castilla-La Mancha.
214517149|NCT01653106|OTHER|questionnaire administration|Participate in PROMS
214517150|NCT01653106|OTHER|pharmacological study|Correlative studies
214517151|NCT05504447|OTHER|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
214517152|NCT05504447|OTHER|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
214517153|NCT05526937|OTHER|Bread|Bread portions of 50 gram available carbohydrates.
214438177|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a primary care doctor or primary care nurse|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Supervised by primary care doctor o primary care nurse according to passport recommendations.
214517154|NCT03014349|OTHER|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
215116684|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
214517155|NCT01327014|DRUG|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
214517156|NCT01327014|DRUG|Placebo|4 capsules twice a day for 12 weeks.
215116685|NCT01216813|OTHER|informational intervention|
214438178|NCT05682872|BEHAVIORAL|Regular assessment and follow-up by primary care doctor and primary care nurse|General assessment related to falls with the established protocols at primary care routine.
215116686|NCT01216813|PROCEDURE|assessment of therapy complications|
215116687|NCT01216813|PROCEDURE|psychosocial assessment and care|
215116688|NCT02518971|DRUG|Tamsulosin|0.4 mg daily
215116689|NCT02518971|DRUG|Placebo|one capsule daily
215116690|NCT06130241|PROCEDURE|sentinle lymphnode biopsy|intraoperative sentinle lymphnode biopsy
214438179|NCT05682872|BEHAVIORAL|Health education related to falls prevention (1 session)|There will be a single session. The session will cover the following topics: Fall Risk factors. Pharmacology. Nutrition and falls. Accident prevention through environmental modification. Importance of physical exercise to prevent falls. Footwear and foot care. How to react to a fall?: what to do and how to get up?
214517157|NCT00004731|DRUG|Coenzyme Q10|
215116691|NCT06534008|BEHAVIORAL|12-week home-based exercise intervention|All participants will be given the same 12-week distance-based exercise intervention.
215116692|NCT02011100|DIETARY_SUPPLEMENT|Carnosine|
215116693|NCT02336230|DRUG|remestemcel-L|Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
215116694|NCT02524171|BEHAVIORAL|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
215116695|NCT06316349|OTHER|Isolated Resistance Training Program|The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.
215116696|NCT06316349|OTHER|Neuromuscular electrical stimulation|For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
215116697|NCT00704886|OTHER|video|video of dementia
215116698|NCT02781675|OTHER|Dietary Intervention|3 wk dietary intervention with prescribed menus and \~50% foods provided.
215116699|NCT02463279|DEVICE|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
215116700|NCT01314131|BEHAVIORAL|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
215116701|NCT02316080|OTHER|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
214438180|NCT04531475|DRUG|X842|X842 capsules
214438181|NCT04531475|DRUG|X842 Placebo|X842 placebo-matching capsules
214438182|NCT04531475|DRUG|Lansoprazole|Lansoprazole capsules
214438183|NCT04531475|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214438184|NCT06070428|OTHER|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
215116702|NCT02316080|OTHER|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
215116703|NCT00940901|DRUG|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
215116704|NCT00940901|OTHER|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
215116705|NCT00757237|DRUG|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
215116706|NCT00757237|DRUG|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
214438185|NCT06070428|OTHER|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
214438186|NCT05593666|DRUG|LXE408|Film-coated tablets
214438187|NCT05593666|OTHER|Placebo|Placebo film-coated tablets
214438188|NCT05593666|DRUG|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
214438189|NCT04583423|DRUG|MK-3655|MK-3655 50, 100 or 300 dose for injection
214438190|NCT04583423|DRUG|Placebo|Matching placebo to MK-3655
214438191|NCT02462460|DEVICE|MRI|
214438192|NCT02462460|BEHAVIORAL|Optional Screening Questionnaire|
214438193|NCT05509855|GENETIC|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
214438194|NCT04472793|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
214438195|NCT05797545|DIAGNOSTIC_TEST|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
214438196|NCT03351699|DRUG|MK-4250|MK-4250 tablets for oral administration
214438197|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
214438198|NCT02616562|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
214517158|NCT03845088|PROCEDURE|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
214517159|NCT01995981|DRUG|Pazopanib|
215116707|NCT02718729|PROCEDURE|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
215116708|NCT04995575|PROCEDURE|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
215116709|NCT06175481|OTHER|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
215116710|NCT04579640|DIETARY_SUPPLEMENT|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
214438199|NCT02616562|DRUG|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
214438200|NCT02616562|DRUG|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once-weekly.
214438201|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
215116711|NCT06383806|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
215116712|NCT05150990|BEHAVIORAL|Virtual Reality|Older adults (residents of senior living communities) engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children participate remotely from their own homes.
214438202|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
214438203|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
214438204|NCT05094609|BIOLOGICAL|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
214438205|NCT05094609|BIOLOGICAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
214438206|NCT05172596|BIOLOGICAL|PHE885|Intravenous (IV) infusion
214438207|NCT04704284|DIAGNOSTIC_TEST|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
214438208|NCT05644730|DEVICE|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
214517160|NCT02574286|DRUG|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
214517161|NCT02574286|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
214517162|NCT03137446|OTHER|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
214517163|NCT03530644|DEVICE|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
214517164|NCT03530644|DEVICE|P0.1|The investigational medical device will collect spectral Raman data from tissue.
214438209|NCT01051635|DRUG|LMP400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
214438210|NCT01051635|DRUG|LMP776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
214438211|NCT06406348|DRUG|ALIA-1758|Intravenous or subcutaneous doses
214438212|NCT06406348|OTHER|Placebo|Intravenous or subcutaneous doses
214438213|NCT06117306|DRUG|3,4 Methylenedioxymethamphetamine|1 MDMA session
214438214|NCT06117306|BEHAVIORAL|Prolonged Exposure|12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
214438215|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
214438216|NCT05224765|OTHER|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
214438217|NCT06549192|OTHER|20 meter shuttle run test|20 Meter Shuttle Run Test: Subjects run distance of 20 meters round trip. Running speed is monitored at certain intervals with help of a tape recorder that gives a signal. Subjects start running when they hear first beep and must reach other line(one foot must cross the line) by second beep. When they hear second signal, they return to starting line. The speed, which is slow at beginning, gradually increases every 10 seconds. The subject adjusts his/her pace so that he/she is on the other line at the second signal. If subject misses one signal and catches second signal, test continues. If subject misses two signals in row and doesn't reach line at other signal, test is terminated. At end of test, aerobic power values are calculated from VO2max estimation table in ml/kg/min according to number of sit-ups run. At end of test, marks obtained by athlete are calculated and VO2max value of subject is calculated in ml/kg/min from evaluation table.
214438218|NCT05430334|COMBINATION_PRODUCT|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
214438219|NCT05430334|COMBINATION_PRODUCT|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
214438220|NCT05430334|COMBINATION_PRODUCT|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
214438221|NCT05430334|COMBINATION_PRODUCT|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
214438222|NCT05430334|COMBINATION_PRODUCT|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
214438223|NCT05430334|COMBINATION_PRODUCT|e-liquid 6|30/70 PG/VG ratio with nicotine concentration 0mg/ml
214438224|NCT05430334|COMBINATION_PRODUCT|e-liquid 7 and e-liquid 8|e-liquid 7: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 8: 30/70 PG/VG ratio with nicotine concentration 8mg/ml protonated
214438225|NCT05430334|COMBINATION_PRODUCT|e-liquid 9 and e-liquid 10|e-liquid 9: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 10: 70/30 PG/VG ratio with nicotine concentration 4mg/ml protonated
214438226|NCT05946551|DRUG|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
214438227|NCT05946551|DRUG|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
214438228|NCT05946551|DRUG|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
214438229|NCT05946551|DRUG|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
214438230|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
214438231|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
214438232|NCT06239701|BEHAVIORAL|LPA+Fitbit Intervention|"1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
214438233|NCT06239701|BEHAVIORAL|Fitbit Only|"1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
214438234|NCT06499051|OTHER|cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanisms|self-administered questionnaires
214438235|NCT05460793|DEVICE|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
215116713|NCT05150990|BEHAVIORAL|Video Chat|Older adults (residents of senior living communities) engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children participate remotely from their own homes.
215116714|NCT00466921|DRUG|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
215116715|NCT04007016|PROCEDURE|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
215116716|NCT06562127|BEHAVIORAL|TRAIN-Vets|The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in personalized risk factor reduction sessions based at SFVAHCS focused on other risk factors and symptoms.
215116717|NCT06562127|BEHAVIORAL|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and dementia risk factor reduction over 8 months, as well as regular contact with study staff.
215116718|NCT03534193|OTHER|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
215116719|NCT03534193|OTHER|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
214438236|NCT05624554|DRUG|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
214438237|NCT05624554|DRUG|Fludarabine|25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
215116720|NCT04002947|DRUG|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
214438238|NCT05624554|DRUG|Cyclophosphamide|250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
214517165|NCT02619825|DEVICE|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
214517166|NCT02619825|DEVICE|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
214517167|NCT00863902|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
214517168|NCT00863902|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
214517169|NCT04245722|DRUG|FT596|Experimental Interventional Therapy
214517170|NCT04245722|DRUG|Cyclophosphamide|Lympho-conditioning agent
215116721|NCT04002947|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
215116722|NCT04002947|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
215116723|NCT04002947|DRUG|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
214438239|NCT05624554|DRUG|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
214517171|NCT04245722|DRUG|Fludarabine|Lympho-conditioning agent
214517172|NCT04245722|DRUG|Rituximab|Monoclonal Antibody
214517173|NCT04245722|DRUG|Obinutuzumab|Monoclonal Antibody
214517174|NCT04245722|DRUG|Bendamustine|Conditioning agent
214517175|NCT05726994|BIOLOGICAL|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
214438240|NCT05624554|BIOLOGICAL|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
214438241|NCT05624554|BIOLOGICAL|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
214438242|NCT05624554|BIOLOGICAL|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
214438243|NCT05624554|BIOLOGICAL|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
214438244|NCT03348150|PROCEDURE|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
214438245|NCT03348150|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
214438246|NCT04895748|DRUG|DFF332|Hif2alpha inhibitor
214517176|NCT05726994|OTHER|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
214517177|NCT01280656|DRUG|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
214517178|NCT01280656|DRUG|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
214438247|NCT04895748|DRUG|RAD001|mTOR inhibitor
214438248|NCT04895748|DRUG|PDR001|anti-PD-1
214438249|NCT04895748|DRUG|NIR178|Adenosine A2A antagonist receptor
214438250|NCT01837875|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
214438251|NCT01837875|BEHAVIORAL|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
214438252|NCT01837875|BEHAVIORAL|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
214438253|NCT01837875|BEHAVIORAL|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
214438254|NCT00603954|DRUG|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
214438255|NCT00603954|DRUG|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
214438256|NCT01626612|PROCEDURE|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
214517179|NCT01280656|DRUG|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
214517180|NCT01280656|DRUG|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
214517181|NCT00039052|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
214517182|NCT04842006|DRUG|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
214517183|NCT04842006|DIAGNOSTIC_TEST|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
214517184|NCT04842006|RADIATION|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
215116724|NCT06493734|RADIATION|Stereotactic body radiation therapy|SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
215116725|NCT05708001|DEVICE|transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
214438257|NCT01626612|PROCEDURE|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
214438258|NCT01542593|DEVICE|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
214438259|NCT03366870|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
214438260|NCT03366870|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
214517185|NCT00572494|DEVICE|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
214517186|NCT00572494|DEVICE|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
214517187|NCT04330573|OTHER|No intervention. Observational study|Observational study
214517188|NCT05435105|BEHAVIORAL|Virtual reality|Distraction method
214517189|NCT05435105|BEHAVIORAL|Local cold-vibration|Distraction method
214438261|NCT06530056|OTHER|Costovertebral Mobilization+Conventional Therapy|"Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks"
214438262|NCT06530056|OTHER|Conventional Therapy|"Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session"
214438263|NCT05758597|DRUG|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
214438264|NCT05758597|DRUG|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
214438265|NCT01922830|DIETARY_SUPPLEMENT|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
214438266|NCT01922830|DIETARY_SUPPLEMENT|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
214438267|NCT02962141|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
214438268|NCT02962141|DEVICE|Balloon Dilatation Catheter|Control group
214438269|NCT00151424|DRUG|asenapine|Asenapine 5-10mgBID
214438270|NCT00151424|DRUG|Placebo|Matched against asenapine and olanzapine
214438271|NCT00151424|DRUG|Olanzapine|10-20 mg QD
214438272|NCT02633267|BEHAVIORAL|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
214438273|NCT02633267|BEHAVIORAL|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
214438274|NCT06966648|OTHER|Core stabilization on stable surfaces|Participants will perform a structured core stabilization training program on stable surfaces, such as the floor and rigid foam blocks. The program includes functional exercises targeting trunk control, postural alignment, and balance, delivered three times per week over a 7-week period.
214517190|NCT01858324|OTHER|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
214517191|NCT02138838|DRUG|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
214517192|NCT02138838|DIETARY_SUPPLEMENT|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
214517193|NCT05235685|OTHER|Medical air|Exercise under medical air, both arms exposed.
214517194|NCT05235685|OTHER|Hyperoxia|Exercise under hyperoxia, only experimental arm exposed.
214517195|NCT06372600|DEVICE|Extracorporeal shock wave therapy device|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
215116726|NCT05708001|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
214517196|NCT06372600|BIOLOGICAL|Platelet-rich plasma|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
214438275|NCT06966648|OTHER|Core stabilization on unstable surfaces|Participants will perform the same structured core stabilization training program as the stable surface group, but on unstable surfaces such as BOSU balls and wobble boards. The intervention is designed to challenge balance, proprioception, and core muscle activation. Sessions are conducted three times per week over a 7-week period.
214438276|NCT00224510|DRUG|lamotrigine|
214438277|NCT04042207|DEVICE|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
214438278|NCT04042207|DEVICE|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
214438279|NCT00103363|OTHER|cytology specimen collection procedure|
214438280|NCT00103363|OTHER|physiologic testing|
214438281|NCT00103363|PROCEDURE|annual screening|
214438282|NCT00103363|PROCEDURE|study of high risk factors|
214438283|NCT00479700|DRUG|SAM-531|
214438284|NCT00946413|BEHAVIORAL|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
215116727|NCT05708001|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
215116728|NCT01884896|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
215116729|NCT01884896|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
214438285|NCT00946413|BEHAVIORAL|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
214438286|NCT00547352|DRUG|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
214438287|NCT00547352|DRUG|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
214438288|NCT00310635|BIOLOGICAL|Meningococcal C conjugate vaccine|
214438289|NCT03727958|DIAGNOSTIC_TEST|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
214438290|NCT03727958|DIAGNOSTIC_TEST|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
214438291|NCT02641938|DRUG|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
214438292|NCT02641938|DRUG|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
214438293|NCT05984589|BEHAVIORAL|RISE Personalized Self-Management Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
214517197|NCT02106078|BEHAVIORAL|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
214517198|NCT02106078|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies"
214517199|NCT02106078|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
214517200|NCT04853654|OTHER|exercise|exercise training for 8 weeks
215116730|NCT05395325|OTHER|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
215116731|NCT05395325|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
215116732|NCT05395325|OTHER|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
215116733|NCT02864901|DRUG|KSL-W|Antimicrobial KSL-W Plaque reducing chewing gum
214517201|NCT04994093|OTHER|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
215116734|NCT04905745|PROCEDURE|Korean integrative medicine|"Any kind of Korean integrative medicine will be applicable and the treatment will be entirely determined by experienced clinicians. On the premise of the above, the following examples are the treatments applicable to the subject of this observational study.~* Chuna: Chuna therapy is performed on the face and cervical spine to induce decompression of the captured facial nerve. In addition, SJS Non-Resistance Technique-Facial palsy (SJS NRT-F), a technique of Chuna, can be performed to stimulate the intrinsic receptive sensation of the facial muscles to promote the neuromuscular response.~* Acupuncture: acupuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Pharmacopuncture: pharmacopuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Herbal medicine: It is prescribed according to clinical judgment according to the patient's symptoms and disease status."
215116735|NCT04777331|DRUG|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
215116736|NCT04777331|DRUG|Placebo|Prasinezumab placebo will be administered to participants.
215116737|NCT01219985|OTHER|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
215116738|NCT06314607|GENETIC|Prospective Biological Collection|"All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)"
215116739|NCT06314607|GENETIC|Retrospective Biological Collection|Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
214438294|NCT05984589|BEHAVIORAL|Standardized Self-Management Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the occupational therapy (OT) interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
214438295|NCT05814146|DRUG|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions"
214438296|NCT05814146|DEVICE|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
214438297|NCT02480205|DEVICE|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes"
214438298|NCT00760136|PROCEDURE|Computed Tomography|CT imaging of bilateral knee
214517202|NCT00780741|PROCEDURE|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
214517203|NCT00780741|PROCEDURE|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
214517204|NCT01653925|OTHER|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
215116740|NCT00812773|DRUG|GSK2190915|Investigational Product
215116741|NCT04770220|DRUG|Experimental: ALZ-801|ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
215116742|NCT04770220|DRUG|Placebo Comparator: Placebo|Placebo tablet BID
215116743|NCT04797780|DRUG|Tamibarotene|Administered as specified in the treatment arm
215116744|NCT04797780|DRUG|Placebo|Administered as specified in the treatment arm
215116745|NCT04797780|DRUG|Azacitidine|Administered as specified in the treatment arm
214517205|NCT01653925|DRUG|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
214517206|NCT00237224|DRUG|Letrozole|
214517207|NCT03332875|BEHAVIORAL|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
214517208|NCT01274507|OTHER|Medical tests|All participants will undergo medical tests and will be observed.
214517209|NCT01120457|DRUG|BMS-936564 (Anti-CXCR4)|
214517210|NCT01314066|DRUG|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
214517211|NCT01314066|DRUG|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
214517212|NCT02993926|DRUG|Enantone|Enantone suspension for injection
214517213|NCT02993926|DRUG|GnRH agonist|A non-Enantone GnRH agonist
214517214|NCT06194695|PROCEDURE|drug eluting beads-transcatheter arterial chemoembolization|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
214517215|NCT06194695|DRUG|envatinib plus anti-PD(L)1|oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.
214517216|NCT00540566|DEVICE|Optical Biopsy imaging|Optical Biopsy imaging
214517217|NCT02412904|DRUG|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
214517218|NCT02412904|DRUG|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
214517219|NCT05813990|OTHER|recostructive ear surgery|recostructive ear surgery in pediatric population
214517220|NCT05333276|DRUG|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
214517221|NCT00860457|DRUG|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
214517222|NCT00860457|DRUG|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
214517223|NCT00860457|DRUG|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
214517224|NCT01084772|OTHER|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
214517225|NCT01084772|OTHER|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
214517226|NCT02442037|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
214517227|NCT02442037|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
215116746|NCT04669301|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
215116747|NCT04669301|BEHAVIORAL|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
215116748|NCT04305171|PROCEDURE|non-surgical periodontal treatment|scaling and root planing, home care instruction
215116749|NCT06369389|OTHER|Patients eligible for CAR-T treatment|Patients eligible for CAR-T treatment for their hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
215116750|NCT02225093|DRUG|Caffeine|Oral
214517228|NCT03782285|PROCEDURE|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
214517229|NCT05982366|OTHER|distal radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
214517230|NCT05982366|OTHER|conventional radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
214517231|NCT01867307|DRUG|Empagliflozin|
214517232|NCT01867307|DRUG|BI 10773|open label
214517233|NCT02298998|OTHER|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
214517234|NCT02298998|OTHER|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
215116751|NCT02225093|DRUG|Dextromethorphan|Oral /.L
215116752|NCT02225093|DRUG|Enzalutamide|Oral
214438299|NCT04105712|BEHAVIORAL|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
215116753|NCT02225093|DRUG|Enzalutamide Placebo to Match (PTM)|Oral
215116754|NCT04903535|DEVICE|Alonefire SV003 10W 365nm UV Flashlight|Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
214438300|NCT01838343|OTHER|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
214438301|NCT03408041|OTHER|Medical file data extraction|Medical file data extraction
214438302|NCT00580866|DEVICE|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
214438303|NCT03018561|OTHER|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
214438304|NCT02477605|DEVICE|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
214438305|NCT02477605|DEVICE|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
214438306|NCT02477605|PROCEDURE|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
214438307|NCT00198315|COMBINATION_PRODUCT|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
214438308|NCT00198315|PROCEDURE|Tumor surgical excision|Patients have their tumor surgically removed.
214438309|NCT05261139|DRUG|nirmatrelvir|PF-07321332
214438310|NCT05261139|DRUG|ritonavir|ritonavir
214438311|NCT06973655|OTHER|Social Work support|Participants enrolled during the treatment phase at their clinic will receive social work support for 6 months from the time of enrollment. They will have an intake appointment with the social worker before or during their initial fracture clinic visit to assess their needs, identify goals that they can address with the support of the social worker, and collaboratively formulate a personalized care plan tailored to their specific circumstances. The social worker will then implement the plan, which may involve educating participants and their support network, coordinating delivery of care and benefits, making referrals to community services, advocating for the participant, and providing emotional support and brief counselling. The social worker will be accessible to participants for 6 months post-enrollment, following up via telephone, telemedicine or in-person to evaluate the effectiveness of the care plan and offer sustained ongoing support.
214438312|NCT05467904|OTHER|Xltranplus, Xltran|Xltranplus and Xltran are full hemp flower formulations
214438313|NCT00567489|DRUG|Physioneal|Physioneal 40 or Physioneal 35
214438314|NCT00567489|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
214438315|NCT00567489|DRUG|Extraneal|7.5% Icodextrin
214438316|NCT00567489|DRUG|Nutrineal|Amino Acids 1.1%
214438317|NCT03429582|DEVICE|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
214438318|NCT03429582|DEVICE|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
214438319|NCT03429582|DEVICE|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
214438320|NCT04724421|DRUG|Voxelotor|tablet or powder for oral suspension
214438321|NCT05003843|DEVICE|Indigo Aspiration System|Indigo Aspiration System
214438322|NCT06560125|OTHER|Standard care|Treatment appropriate for wound condition
214438323|NCT04455841|DRUG|INCB000928|INCB000928 will be administered at protocol defined dose.
214438324|NCT04455841|DRUG|ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
214438325|NCT05967065|DIAGNOSTIC_TEST|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
214438326|NCT01813812|DRUG|DA-6034|
214438327|NCT01813812|DRUG|Rebamipide 300mg|
214438328|NCT05647070|PROCEDURE|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
214438329|NCT01655888|DRUG|Tremelimumab|Tremelimumab is administered as endovenous infusion
214438330|NCT03086161|BEHAVIORAL|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
214438331|NCT03086161|BEHAVIORAL|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
214438332|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
214438333|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
214438334|NCT01666704|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
214438335|NCT00726544|DRUG|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
214438336|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
214438337|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
214438338|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
214438339|NCT00979563|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
214438340|NCT02597751|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
214438341|NCT05718089|OTHER|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
214438342|NCT05718089|OTHER|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
214438343|NCT05718089|OTHER|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
214438344|NCT02206269|DEVICE|Alair System|The Alair system is used for doing bronchial thermoplasty.
214438345|NCT06307301|DRUG|Abatacept Injection [Orencia] and Proleukin (aldesleukin)|Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
214438346|NCT02764242|OTHER|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
214438347|NCT02764242|OTHER|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
214517235|NCT01049854|DRUG|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
214438348|NCT04982536|DEVICE|VMCore Biopsy System|Prostate Examine
214438349|NCT04982536|DEVICE|Standard of Care Biopsy Needle|Prostate Examine
214438350|NCT03837886|DIETARY_SUPPLEMENT|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
214438351|NCT03837886|DIETARY_SUPPLEMENT|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
214517236|NCT01049854|DRUG|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
214517237|NCT01049854|DRUG|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
214438352|NCT06411743|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
215116755|NCT04118387|DRUG|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
214438353|NCT06411743|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
214438354|NCT02120222|DRUG|selinexor|Given PO
214517238|NCT01049854|DRUG|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
214517239|NCT04705389|OTHER|Samples|blood samples
214517240|NCT04327089|DRUG|Setanaxib|Nox 1/4 inhibitor
214517241|NCT00000269|DRUG|Pergolide|
214517242|NCT00518206|BIOLOGICAL|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
214517243|NCT00518206|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
215116756|NCT04118387|DRUG|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
215116757|NCT04118387|DRUG|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
215116758|NCT06538922|BEHAVIORAL|Single Session Family Intervention|A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
214438355|NCT02120222|OTHER|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
214438356|NCT04346732|OTHER|Vapocoolant spray|Vapocoolant spray
215116759|NCT06553495|OTHER|Nerve block|Analgesic effect of different nerve blocks
215116760|NCT04383782|BEHAVIORAL|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
214438357|NCT02570022|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
215116761|NCT04383782|BEHAVIORAL|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
215116762|NCT04383782|BEHAVIORAL|Control|Neutral reading condition (see description in study arms).
215116763|NCT03553524|OTHER|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
215116764|NCT03553524|OTHER|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
214438358|NCT02570022|PROCEDURE|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
214438359|NCT02570022|DRUG|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
214438360|NCT01350024|PROCEDURE|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
214438361|NCT01350024|PROCEDURE|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
214438362|NCT06133049|DRUG|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
214438363|NCT06133049|DRUG|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
214438364|NCT06133049|DRUG|No DMTs|Women with MS not exposed to any DMTs during pregnancy
214438365|NCT01620203|OTHER|No intervention/treatment is given|
214438366|NCT04110223|GENETIC|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
214438367|NCT01952769|BIOLOGICAL|MDV9300|"The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
214438368|NCT00332813|BEHAVIORAL|HIV Risk Behavior Intervention|
214438369|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
214438370|NCT00041938|DRUG|aspirin|325 mg per day
214438371|NCT00041938|DRUG|Warfarin|INR 2.5-3.0; target INR 2.75
214438372|NCT03877016|PROCEDURE|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
214438373|NCT02942862|DRUG|Orcein staining|Prognostic value of venous emboli detected by orcein staining
214438374|NCT05378828|DEVICE|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
214438375|NCT05378828|OTHER|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
214438376|NCT01464034|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
214438377|NCT01464034|DRUG|Pomalidomide|PO daily on Days 1-21, every 28 Days
214517244|NCT01111006|DEVICE|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
214438378|NCT01464034|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
214438379|NCT02058875|DRUG|Myfortic®|
214438380|NCT02058875|DRUG|Neoral®|
214438381|NCT02058875|DRUG|Cellcept®|
214517245|NCT02894099|OTHER|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
215116765|NCT03728010|DIAGNOSTIC_TEST|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
215116766|NCT06184594|OTHER|eNav|The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).
215116767|NCT06184594|OTHER|Standard of Care|Standard of care procedures for selecting their CRC screening test.
215116768|NCT06383598|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
214438382|NCT02058875|DRUG|Prednisone|
214438383|NCT03101930|DRUG|Liraglutide|subcutaneous liraglutide daily
214438384|NCT03101930|DRUG|Sitagliptin|oral sitagliptin daily
214438385|NCT03101930|OTHER|hypocaloric diet|Reduced calorie intake to achieve weight loss.
214438386|NCT03101930|DRUG|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
214438387|NCT03101930|DRUG|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
214438388|NCT01367405|PROCEDURE|Surgical decompression|Surgical decompression within 24 hour postinjury
214438389|NCT01367405|PROCEDURE|Conservative treatment|Usual conservative treatment without surgery
214438390|NCT01340716|OTHER|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
214438391|NCT01340716|OTHER|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
214438392|NCT04775654|DIETARY_SUPPLEMENT|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
214438393|NCT04775654|OTHER|Placebo|Two capsules containing an inert material.
214438394|NCT02806934|PROCEDURE|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
214438395|NCT04739527|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
214438396|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
214438397|NCT06648226|BEHAVIORAL|Climate swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more climate-friendly products (e.g., with a A or B climate label)."
214438398|NCT06648226|BEHAVIORAL|Combined health and climate swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or climate-friendliness) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
214438399|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
214438400|NCT04385056|BIOLOGICAL|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
214438401|NCT00462358|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
214517246|NCT02894099|OTHER|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
214517247|NCT02894099|OTHER|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
215116769|NCT07021274|BEHAVIORAL|DBT skills training adjusted to autistic needs|Adjustments to fit the specific learning style of people with autism. Simplified skills - fewer words, ,more pictures, autism relevant examples. Hands- on training using props and role play. adjustments so sensory sensitivities.
215116770|NCT06696027|DIAGNOSTIC_TEST|Single nucleotide polymorphisms (SNP)|Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
215116771|NCT06696027|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
215116772|NCT06696027|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array|Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
215116773|NCT06696027|DIAGNOSTIC_TEST|Flow Cytometry|Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
215116774|NCT06696027|DIAGNOSTIC_TEST|Laboratory assessment|Serum Chemistry
215116775|NCT06696027|DIAGNOSTIC_TEST|Assessment of Pulmonary Involvement|Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
214438402|NCT00462358|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
214438403|NCT04381975|BEHAVIORAL|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
214438404|NCT04381975|BEHAVIORAL|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
214438405|NCT04162444|DIAGNOSTIC_TEST|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
214438406|NCT04162444|DIAGNOSTIC_TEST|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
214438407|NCT04162444|DIAGNOSTIC_TEST|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
214517248|NCT02894099|OTHER|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
214438408|NCT04162444|OTHER|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors"
214438409|NCT04162444|DIAGNOSTIC_TEST|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve"
214438410|NCT04162444|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
214438411|NCT04162444|DIAGNOSTIC_TEST|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads"
214438412|NCT01625234|DRUG|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
214517249|NCT05576701|BEHAVIORAL|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
214517250|NCT05576701|OTHER|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
214517251|NCT04070937|DIAGNOSTIC_TEST|vestibular test 1|videonystagmography
215116776|NCT07036120|DEVICE|orthosis|(1) one pair of two orthoses, regardless of the right and left sides; (2) loosen the two Velcro straps, put the large Velcro strap into the arch of the foot, and put the small Velcro strap on the thumb; (3) place the rigid plastic fixation plate along the medial edge of the foot and align the axis of rotation with the 1st metatarsalphalangeal joint; (4) tighten the Velcro straps as much as possible to prevent dislocation of the orthoses, without interfering with sleep; (5) tighten the Velcro straps to prevent dislocation of the orthoses, and to prevent the orthoses from moving out of position. Tighten the Velcro straps as much as possible without disturbing sleep to prevent the orthosis from shifting and to position the phalanx correctly in the outer table. Contact the laboratory staff for a new pair of orthotics if the adhesive tape is not sufficiently sticky to maintain positional fixation during sleep.
215116777|NCT07036120|BEHAVIORAL|foot exercises|"1. Warm-up: 30 seconds per movement~   1. Joint loosening~  2. Plantar relaxation~2. Toe spreading: 10 reps/set, 3 sets/day~3. Toe grasping towel: 10 times/set, 3 sets/day~4. Standing Heel Raise: 10 times/group, 3 groups/day~5. Short Foot Exercise: 10 times/sets, 3 sets/day~6. Relax the soles of the feet again at the end of all exercises."
215116778|NCT06725056|OTHER|DS-MCE and EGD examinations|sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
214438413|NCT01625234|DRUG|Phase II: X-396 (ensartinib)|Expanded Cohort
214438414|NCT03761472|BIOLOGICAL|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
214438415|NCT03761472|BIOLOGICAL|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
214517252|NCT04070937|DIAGNOSTIC_TEST|vestibular test 2|video head impulse test
214517253|NCT04070937|DIAGNOSTIC_TEST|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
214517254|NCT04070937|DIAGNOSTIC_TEST|audiometry|tonal liminar audiometric thresholds
214517255|NCT04070937|DIAGNOSTIC_TEST|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
214517256|NCT04070937|GENETIC|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
214517257|NCT03326037|GENETIC|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
215116779|NCT06919562|PROCEDURE|Percutaneous coronary intervention with protocolized implantation of a second generation thin-strut bioresorbable scaffold guided by intracoronary imaging|Percutaneous coronary intervention (PCI) with implantation of the MeRes100 thin-strut BRS with protocolized PSP (predilatation, sizing, postdilatation) method and intracoronary imaging guidance.
214438416|NCT05572060|DRUG|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
214438417|NCT05572060|OTHER|standardized protocol|standardized protocol
214438418|NCT00871130|PROCEDURE|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
214438419|NCT05043805|DRUG|Dextromethorphan|add on therapy
214438420|NCT05043805|OTHER|placebo|add on therapy
214438421|NCT00364702|DRUG|methylphenidate|
214438422|NCT04353531|DEVICE|High-flow nasal cannula|High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.
214438423|NCT04353531|DEVICE|Surgical mask|A procedure mask will be used to cover patient's face after HFNC is initiated.
214438424|NCT04353531|PROCEDURE|bronchoscopy examination|is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube
214438425|NCT04353531|PROCEDURE|intubation|Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.
214438426|NCT04353531|PROCEDURE|tracheostomy|A tracheostomy is a medical procedure - either temporary or permanent - that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.
214438427|NCT04353531|DEVICE|nebulization|A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs
214438428|NCT04353531|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange.
214438429|NCT05229835|OTHER|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
215116780|NCT06744621|OTHER|Fingerstick|fingersticks during their labor process
215116781|NCT06680427|DEVICE|Siegel Transcatheter Aortic Valve (TAVR)|Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.
214438430|NCT05180851|DRUG|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
214438431|NCT01083316|DRUG|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
214438432|NCT01083316|DRUG|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
214438433|NCT01083316|DRUG|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
214438434|NCT00000587|PROCEDURE|erythropoietin, recombinant|
214438435|NCT00331136|DRUG|Pyronaridine-Artesunate|Once a day for 3 days
214438436|NCT00000936|DRUG|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
214438437|NCT00000936|DRUG|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
214438438|NCT00000936|DRUG|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
215116782|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
215116783|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
214438439|NCT05280275|DRUG|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
214438440|NCT05280275|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
214438441|NCT05280275|DRUG|Lenalidomide|Lenalidomide will be administered per os.
214438442|NCT05280275|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
214438443|NCT00074919|BIOLOGICAL|alglucosidase alfa|20 mg/kg qow
214517258|NCT02741557|DRUG|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
214438444|NCT02860741|BEHAVIORAL|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
214438445|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
214517259|NCT02741557|DRUG|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
214438446|NCT02681900|BEHAVIORAL|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
214438447|NCT02681900|BEHAVIORAL|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
214438448|NCT04515641|DRUG|Islatravir|Two ISL 30 mg capsules taken by mouth.
214438449|NCT04553770|DRUG|Anastrozole|Given PO
214438450|NCT04553770|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214438451|NCT04553770|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214438452|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
214517260|NCT02741557|DRUG|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
214517261|NCT00651326|DRUG|bicalutamide|
214517262|NCT00651326|DRUG|buserelin|
214517263|NCT00651326|DRUG|flutamide|
214517264|NCT00651326|DRUG|goserelin|
214517265|NCT00651326|DRUG|leuprolide acetate|
214517266|NCT00651326|PROCEDURE|neoadjuvant therapy|
214517267|NCT00651326|PROCEDURE|quality-of-life assessment|
215116784|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
214438453|NCT00542035|DRUG|Placebo; oral|dose 1, dose 2
214438454|NCT00542035|DRUG|Placebo; oral|dose 1
214438455|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
214517268|NCT00651326|RADIATION|radiation therapy|"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"
214517269|NCT00651326|DRUG|Docetaxel|
214517270|NCT02573129|OTHER|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
214517271|NCT02573129|OTHER|Red Meat Rich|Mediterranean diet rich in red meat
214517272|NCT04439825|DRUG|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
214517273|NCT04439825|DRUG|Placebo|Saline solution (preservative free)
214517274|NCT00623714|DRUG|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
214517275|NCT00623714|DRUG|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
214517276|NCT01354080|OTHER|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
214438456|NCT04448158|DIAGNOSTIC_TEST|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
214438457|NCT04222686|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
214438458|NCT04222686|DRUG|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
214438459|NCT02988037|BEHAVIORAL|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
214438460|NCT01215344|DRUG|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
214438461|NCT01215344|DRUG|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
214438462|NCT01215344|DRUG|Dexamethasone|20 mg the day before and the day after receiving VELCADE
214517277|NCT01354080|OTHER|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
214517278|NCT05352854|DRUG|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
214517279|NCT01314482|DRUG|Minocycline|200mg bd for 3 days before surgery
214438463|NCT01215344|DRUG|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
214438464|NCT01215344|DRUG|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
214438465|NCT01215344|DRUG|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
214438466|NCT01215344|DRUG|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
214438467|NCT00065260|DRUG|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
214438468|NCT00065260|DRUG|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
214438469|NCT00065260|DRUG|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
214438470|NCT03576742|DIAGNOSTIC_TEST|potential biomarkers|facs analysis, microbiome analysis
214438471|NCT06011109|DRUG|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
214438472|NCT03608475|OTHER|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
214517280|NCT00772902|DRUG|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
214517281|NCT00772902|DRUG|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
214517282|NCT04704557|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
214438473|NCT03608475|OTHER|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
214517283|NCT01128322|DRUG|S-Amlodipine, Telmisartan|
214517284|NCT01128322|DRUG|S-Amlodipine|
214438474|NCT05725135|DRUG|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
214517285|NCT01128322|DRUG|Telmisartan|
214517286|NCT01128322|DRUG|Placebo|
214517287|NCT05596916|OTHER|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
214517288|NCT05596916|OTHER|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
214438475|NCT05446363|DEVICE|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
214517289|NCT03824743|DRUG|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
214517290|NCT03824743|DRUG|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
214438476|NCT03718598|BEHAVIORAL|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
214438477|NCT03567798|DIETARY_SUPPLEMENT|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
214438478|NCT03567798|OTHER|Placebo|Placebo
214438479|NCT03437850|OTHER|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
214517291|NCT04265235|OTHER|Home-based exercise program|see 'arm' section
214517292|NCT01848132|DRUG|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
214517293|NCT01848132|DRUG|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
214517294|NCT01848132|DRUG|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
214517295|NCT01848132|DRUG|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
214517296|NCT01848132|DRUG|Prednisone|Prednisone: oral, 100 mg, days 1-5
214517297|NCT01848132|DRUG|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
214517298|NCT04086342|DRUG|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
214517299|NCT04086342|DRUG|Placebo|Placebo is a vehicle oil that will match CHI-902.
214517300|NCT05304676|OTHER|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
214517301|NCT05304676|OTHER|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
214517302|NCT05230394|DIAGNOSTIC_TEST|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
214517303|NCT05230394|DIAGNOSTIC_TEST|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
214517304|NCT02256826|DRUG|BILR 355 BS|
214438480|NCT06407258|BEHAVIORAL|SLEEPAC|"6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs."
214438481|NCT00780234|PROCEDURE|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
214438482|NCT00780234|PROCEDURE|quantitative high resolution CT scan|High resolution CT scan of the chest
214438483|NCT00780234|DRUG|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
214438484|NCT01387906|DRUG|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
214438485|NCT02178098|DRUG|ETC-1002|ETC-1002 capsules taken once daily
214438486|NCT02178098|DRUG|Placebo|Placebo capsules taken once daily
214438487|NCT00826852|DRUG|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
214438488|NCT05161429|DRUG|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
214438489|NCT05161429|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
214438490|NCT05161429|DRUG|Basal Insulin|degludec, detemir, glargine and NPH
214438491|NCT05161429|DRUG|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
214438492|NCT05161429|DRUG|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
214694180|NCT04158908|BEHAVIORAL|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
214517305|NCT02256826|DRUG|Ritonavir (RTV)|NORVIR®
214517306|NCT02256826|DRUG|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
214517307|NCT02267109|BIOLOGICAL|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
214517308|NCT02267109|BIOLOGICAL|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
214517309|NCT03602807|DEVICE|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
214517310|NCT06192459|DEVICE|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
214517311|NCT06192459|OTHER|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
214517312|NCT02759406|DEVICE|coronary stent|
214517313|NCT02289885|DEVICE|SonoScape|Ultrasonography device
214517314|NCT01237600|PROCEDURE|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
214517315|NCT02865109|DRUG|Nusinersen|Administered by intrathecal injection
214517316|NCT04034966|DEVICE|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
214517317|NCT05893615|BEHAVIORAL|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
214517318|NCT02616926|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
214517319|NCT02616926|PROCEDURE|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
214517320|NCT02616926|PROCEDURE|RFA|RFA will be performed 1 week after TACE.
214438493|NCT04997213|OTHER|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
214438494|NCT04997213|OTHER|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
214438495|NCT04011631|PROCEDURE|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
214438496|NCT03432858|DRUG|Vancomycin|Vancomycin - 1-gram dosing
214438497|NCT03432858|DRUG|Cefazolin|2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
214438498|NCT03432858|DRUG|Saline Solution|Placebo
214438499|NCT02382744|DEVICE|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
214438500|NCT02382744|DEVICE|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
214517321|NCT01054118|DRUG|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
214438501|NCT05231317|OTHER|Plant-based diet|16 days with all foods provided
214517322|NCT01054118|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
214517323|NCT01054118|DRUG|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
214517324|NCT01054118|DRUG|Placebo|Placebo suspension and placebo capsule administered as single doses
214517325|NCT05950607|BEHAVIORAL|TRAIN AD 2.0|"The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. ."
214517326|NCT04335474|PROCEDURE|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
214438502|NCT05231317|OTHER|Western diet|16 days with all foods provided
214438503|NCT03743506|DIAGNOSTIC_TEST|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
214438504|NCT03743506|DIAGNOSTIC_TEST|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
214438505|NCT03208881|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
214438506|NCT02265432|BEHAVIORAL|General physical activity educational materials|
214438507|NCT02265432|DEVICE|Wearable activity tracking devices (fitbit)|
214438508|NCT02265432|OTHER|online map|
214438509|NCT02265432|OTHER|Personalized text messages|
214438510|NCT05264012|PROCEDURE|Neurosurgery|Neurosurgery
214438511|NCT05074069|PROCEDURE|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
214438512|NCT02940951|OTHER|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
214438513|NCT02940951|OTHER|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
214438514|NCT00000924|DRUG|Ritonavir|
214438515|NCT00000924|DRUG|Nelfinavir mesylate|
214438516|NCT00000924|DRUG|Nevirapine|
214438517|NCT00000924|DRUG|Stavudine|
214438518|NCT00000924|DRUG|Didanosine|
214438519|NCT01411592|OTHER|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
214438520|NCT01411592|OTHER|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
214438521|NCT01044303|DRUG|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
214438522|NCT03059212|DEVICE|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
214438523|NCT03059212|BEHAVIORAL|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
214438524|NCT00301652|DRUG|mycophenolate mofetil|MMF,1.0g/d
214438525|NCT01603758|DRUG|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
214438526|NCT05563168|DRUG|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
214438527|NCT03858413|DIAGNOSTIC_TEST|No intervention|No intervention
214438528|NCT01058499|BEHAVIORAL|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
214438529|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
214438530|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
214438531|NCT00211419|DRUG|Anecortave Acetate 15 mg|
214438532|NCT00211419|DRUG|Triamcinolone Acetate 4 mg|
214438533|NCT00211419|PROCEDURE|Photodynamic Therapy with Verteporfin|
214438534|NCT00211419|PROCEDURE|Thermal Laser|
214438535|NCT01849978|BEHAVIORAL|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
214438536|NCT01849978|BEHAVIORAL|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
214438537|NCT01849978|BEHAVIORAL|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
214438538|NCT01849978|BEHAVIORAL|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
214438539|NCT00003612|BIOLOGICAL|trastuzumab|
214438540|NCT00003612|DRUG|carboplatin|
214438541|NCT00003612|DRUG|paclitaxel|
214517327|NCT04335474|PROCEDURE|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
214438542|NCT05900765|DRUG|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
214438543|NCT06516250|OTHER|Virtual serious game GEMAS|Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
214438544|NCT01109524|DRUG|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
214438545|NCT01109524|DRUG|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
214438546|NCT01109524|DRUG|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
214438547|NCT02407834|OTHER|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
214438548|NCT02407834|OTHER|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
214438549|NCT02407834|OTHER|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
214438550|NCT02407834|OTHER|S4|Immersion in Saline solution for 20 minutes, during 7 days.
214517328|NCT00173706|DRUG|L-Carnitine Injection|
214438551|NCT01519037|DRUG|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
214438552|NCT01519037|DRUG|Placebo oral tablet|one tablet of placebo
214438553|NCT06412770|BEHAVIORAL|Tai chi|Participants will be asked to do Tai Chi for 30 minutes three times a week
214438554|NCT06412770|BEHAVIORAL|Tai Chi imagery|Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
214438555|NCT06412770|OTHER|no-intervention|The comparison group will be given usual care
214438556|NCT01553058|DRUG|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
214438557|NCT01553058|DRUG|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
214438558|NCT01553058|OTHER|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
214438559|NCT00110929|DRUG|AMG 073|
214438560|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
214438561|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
214438562|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
214438563|NCT02903199|DIETARY_SUPPLEMENT|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
214438564|NCT02903199|DIETARY_SUPPLEMENT|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
214438565|NCT02903199|DIETARY_SUPPLEMENT|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
214438566|NCT06514027|DRUG|BEBT-109 Capsules|BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
215116785|NCT06710860|BEHAVIORAL|The intelligent voice-interactive tailored communication system-based intervention|Participants in intervention group will receive the ScreenTalk intervention consisting of 3 modules:(1) a measurement module, (2) an algorithmic tailoring module, and (3) an open di-alogue module. All participants will be required to complete 3 modules within 1 month. If the intervention group does not undergo CRC screening at the follow-up time point, the system will repeatedly provide tailored communication intervention to further enhance the CRC risk perception of FDRs based on the current evaluation results. The primary outcome (uptake of CRC screening) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), 9 months post-intervention (T3) and 12 months post-intervention (T4).
215116786|NCT06911840|OTHER|No Intervention: Observational Cohort|No intervention
215116787|NCT06763991|PROCEDURE|Two-stage connection|Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.
215116788|NCT06763991|PROCEDURE|One-stage connection|One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.
215116789|NCT06927167|OTHER|Chin Tuck Exercise|Chin Tuck Exercises and Cervical Extension Exercises on Forward Head Posture
215116790|NCT06927167|OTHER|Seated cervical extension exercises|Perform seated cervical extension exercises focusing on activating posterior neck muscles
215116791|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
215116792|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
214438567|NCT06514027|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
214438568|NCT06514027|DRUG|Carboplatin Injection|Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
214438569|NCT06514027|DRUG|Cisplatin Injection|Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
214438570|NCT03493724|OTHER|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
214438571|NCT00002383|DRUG|Saquinavir|
214438572|NCT04900636|DEVICE|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
214438573|NCT00975039|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
214438574|NCT00194610|DRUG|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
214438575|NCT00194610|OTHER|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
214517329|NCT03397459|DIAGNOSTIC_TEST|Spine teleradiography EOS|
214438576|NCT03237416|DRUG|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
214438577|NCT03237416|DRUG|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
214438578|NCT03237416|DRUG|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
214438579|NCT03019913|OTHER|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
214438580|NCT02745340|OTHER|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
214438581|NCT00338572|BEHAVIORAL|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
214438582|NCT00338572|BEHAVIORAL|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
214438583|NCT00031694|DRUG|paclitaxel|Given IV
214517330|NCT04828915|OTHER|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
214517331|NCT04828915|OTHER|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
214517332|NCT06226116|PROCEDURE|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
214517333|NCT06226116|PROCEDURE|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
214517334|NCT06226116|PROCEDURE|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
215116793|NCT06939790|BEHAVIORAL|Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I)|The digital CBT-I (dCBT-I) is a self-guided online program replicating the structure and content of standard face-to-face CBT-I, aiming to offer a more accessible treatment for chronic insomnia. It includes video lessons, interactive exercises, and relaxation techniques, with core components such as sleep education, sleep restriction, stimulus control and cognitive restructuring. Supervision is provided through periodic check-ins.
215116794|NCT06939790|BEHAVIORAL|standard face-to-face group-based Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The control group will receive standard face-to-face group-based CBT-I, the current gold-standard treatment for chronic insomnia. Delivered by trained professionals, the intervention includes seven structured sessions covering core components such as sleep education, sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. Sessions last about 90 minutes and aim to improve sleep quality through evidence-based strategies.
215116795|NCT03223376|COMBINATION_PRODUCT|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
214438584|NCT00031694|DRUG|bryostatin 1|Given IV
214438585|NCT05123742|DIAGNOSTIC_TEST|COVID-19 Testing|Testing for the SARS-CoV-2 virus
214438586|NCT05239182|DRUG|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
214517335|NCT02610322|BEHAVIORAL|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
214517336|NCT02610322|BEHAVIORAL|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
214438587|NCT05239182|DRUG|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
214438588|NCT05239182|DRUG|Gemcitabine|cytotoxic chemotherapy agent
214438589|NCT05239182|DRUG|Abraxane|cytotoxic chemotherapy agent
214438590|NCT00903162|DRUG|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
214438591|NCT00903162|DRUG|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
214438592|NCT00903162|DRUG|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
214438593|NCT00047528|DRUG|Alcon Investigational Agent|
214517337|NCT04321109|OTHER|Allograft|Corticocancellous mineralized allograft
214517338|NCT04321109|OTHER|Collagen cone|Collagen matrix
214517339|NCT02496559|PROCEDURE|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
214438594|NCT03467529|OTHER|Non interventional study|Non interventional study
214438595|NCT00997490|DRUG|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
214438596|NCT00997490|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
214517340|NCT06238310|DIAGNOSTIC_TEST|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
214517341|NCT01801202|DEVICE|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
214517342|NCT01223053|DRUG|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
214517343|NCT01223053|DRUG|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
214517344|NCT05051709|PROCEDURE|Corrective osteotomy|First metatarsal distal corrective osteotomy
214517345|NCT05051709|PROCEDURE|Fusion of First ray|Fusion of first ray with soft tissue procedure
214517346|NCT02926313|OTHER|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
214517347|NCT04412174|BIOLOGICAL|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
214517348|NCT01199302|BIOLOGICAL|Brodalumab|Administered intravenously once every 4 weeks
214517349|NCT00506896|DRUG|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
214517350|NCT00002090|DRUG|Azithromycin|
214517351|NCT01892007|BEHAVIORAL|Cogmed RM - Online adaptive working memory training|
214517352|NCT01892007|BEHAVIORAL|Cogmed RM - Online non-adaptive (placebo) working memory training|
214517353|NCT04240197|DEVICE|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
214517354|NCT03820024|BEHAVIORAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
214517355|NCT06157294|PROCEDURE|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
215028631|NCT04605250|OTHER|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
214438597|NCT03333018|DRUG|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
214438598|NCT03333018|DRUG|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
214438599|NCT03333018|DRUG|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
214438600|NCT03776500|DRUG|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
214438601|NCT03776500|DRUG|Placebo|matching placebo supplied as powder for oral solution
214438602|NCT01865474|DRUG|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
214438603|NCT01865474|DRUG|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
214438604|NCT05161585|DIAGNOSTIC_TEST|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
214517356|NCT06157294|PROCEDURE|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
214517357|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
214517358|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
214517359|NCT01027247|DEVICE|Ologen TM|
214517360|NCT03583944|DRUG|Eribulin Mesylate|Eribulin mesylate IV infusion.
214517361|NCT04800263|DRUG|SHR-1905|SHR-1905 will be injected subcutaneously
214517362|NCT04800263|DRUG|Placebo|Placebo will be injected subcutaneously
214517363|NCT02741921|DEVICE|VivaSight DL|intubation using VivaSight DL tube
214517364|NCT02741921|DEVICE|conventional double-lumen tube|intubation using conventional double-lumen tube
214517365|NCT03054194|DRUG|E2730|capsules
214517366|NCT03054194|DRUG|Placebo|capsules
214517367|NCT01092689|DRUG|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
214438605|NCT05477316|RADIATION|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
214438606|NCT02960204|DRUG|Emricasan|
214438607|NCT02960204|DRUG|Placebo|
214438608|NCT02134106|DRUG|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
214438609|NCT02134106|DRUG|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
214438610|NCT00475241|BEHAVIORAL|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
214438611|NCT00475241|BEHAVIORAL|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
214517368|NCT01156922|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
214517369|NCT00183222|DRUG|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
214517370|NCT01448447|DEVICE|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
214438612|NCT02044809|DRUG|Cannabidiol|
214438613|NCT02044809|DRUG|Placebo|
214438614|NCT03933800|DEVICE|High flow nasal cannula|High flow nasal cannula therapy
214438615|NCT03933800|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure therapy
214517371|NCT01448447|DEVICE|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
214517372|NCT01945593|BIOLOGICAL|BAX855|Antihemophilic Factor (Recombinant), PEGylated
214517373|NCT04792541|OTHER|HY containing gel; GUM® Afta Clear Gel, Sunstar|
214517374|NCT04792541|OTHER|saline solution|
214517375|NCT04466917|DRUG|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
214517376|NCT04466917|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
214517377|NCT04466917|DRUG|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
215028632|NCT03017001|DIETARY_SUPPLEMENT|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
214438616|NCT06374004|OTHER|Exercise Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes.
214438617|NCT06374004|OTHER|Thoracic Mobilization Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes. Thoracic mobilization will be applied to segments where passive accessory movement is insufficient or painful. 30 repetitions/4 sets will be applied to each determined segment. Thoracic mobilization will be performed with the patient lying prone position.
214438618|NCT05663502|PROCEDURE|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
214438619|NCT06488781|DRUG|Azithromycin|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
214438620|NCT06488781|DRUG|Placebo|Placebo given in place of other two active drugs
214438621|NCT00173524|BEHAVIORAL|PharmacoEconomic Assessment|Collecting PE data.
214438622|NCT05115058|OTHER|relex Smile module|
214438623|NCT03087708|DRUG|Naloxegol|Given PO
214438624|NCT03087708|OTHER|Placebo|Given PO
214438625|NCT03087708|OTHER|Laboratory Biomarker Analysis|Correlative studies
214438626|NCT03087708|OTHER|Quality-of-Life Assessment|Ancillary studies
214438627|NCT06978166|OTHER|Just-In-Time Adaptive Interventions (JITAIs)|JITAIs are digital interventions that aim to deliver support to a user when the person is most in need and receptive to the intervention. In this study, multiple JITAIs will be tested and refined through completion of an iterative series of randomized trials that are interspersed with qualitative participant interviews. The purpose of each JITAI under investigation is to improve engagement with the Wysa for Chronic Pain app.
214517378|NCT04466917|DRUG|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
214517379|NCT04024436|DRUG|Futibatinib|Futibatinib 20mg once daily on a 28 day cycle
214517380|NCT04024436|DRUG|Futibatinib plus Fulvestrant|Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
214517381|NCT02793557|DRUG|FOL-005|Intradermal injection of 50 μl solution
214517382|NCT02793557|OTHER|Placebo|
214517383|NCT05441176|OTHER|Questionnaires|Scoring of the DASH is performed according to references.
214517384|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
214517385|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
215028633|NCT03017001|DRUG|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
214438628|NCT06978166|BEHAVIORAL|Wysa for Chronic Pain|Wysa for Chronic Pain is an app-based digital mental health intervention that uses a behavioral activation framework and encourages users to work toward pain acceptance. The intervention also includes cognitive behavioral therapy, mindfulness, and sleep tools.
214438629|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
214438630|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
214438631|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
214438632|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
214438633|NCT05180344|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
214438634|NCT06025383|DIETARY_SUPPLEMENT|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
214438635|NCT06025383|DIETARY_SUPPLEMENT|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
214438636|NCT06187298|DIETARY_SUPPLEMENT|A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care|(Enterophytol® PLUS) alongside standard of care
214438637|NCT06815653|DRUG|Psilocybin 25mg|Psilocybin PEX010 is an investigational drug provided in capsule form, containing a 25 mg dose of synthetic psilocybin. The product is manufactured under Good Manufacturing Practice (GMP) standards to ensure purity, potency, and consistency. Each participant will receive a single oral dose of 25 mg psilocybin in a hydroxypropyl methylcellulose (HPMC) capsule. The intervention is administered once during the study session, with the effects expected to last approximately 4 to 6 hours.
214438638|NCT06860113|PROCEDURE|T-tilting of the patient during surgery|Patients will be placed at the T-Tilt position (15 degrees Trendelenburg and 15 degrees away from the surgical side kidney) during surgery.
214438639|NCT06860113|PROCEDURE|standard lithotomy position|Patients will be placed in regular lithotomy position with operating table at 0 degrees of tilting.
214438640|NCT03281694|DRUG|Placebo|placebo skin patch and placebo oral solution
215116796|NCT03223376|COMBINATION_PRODUCT|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
214438641|NCT03281694|DRUG|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
214438642|NCT03281694|DRUG|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
214438643|NCT03281694|DRUG|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
214438644|NCT06864988|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
214438645|NCT06864988|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
214438646|NCT04674293|DRUG|Revelisa|Thrombolytic therapy for patients with ischemic stroke
214438647|NCT07004374|DEVICE|a percussion massage gun|Participants receive percussion massage therapy (33 Hz) applied to the quadriceps and gastrocnemius muscles using a handheld massage device for 5 minutes per muscle group.
214438648|NCT07004374|DEVICE|specially designed stainless-steel instruments|Participants receive instrument-assisted soft tissue mobilization (IASTM, Graston technique) applied to the quadriceps and gastrocnemius muscles using stainless steel tools with standardized techniques (Sweep, Fan, Brush) for 6 minutes.
215116797|NCT02377648|DEVICE|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
214438649|NCT07034092|DEVICE|ePATH System will be used to create an endoAVF|An endoAVF will be created in subjects that need fistulas for hemodialysis
214438650|NCT06717152|DRUG|SJP-0132|Aqueous eye drop, one drop each time and four times each day, 8 weeks in treatment period in SJP-0132 group.
214438651|NCT06717152|DRUG|Placebo|Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.
214438652|NCT07036198|BEHAVIORAL|Customizable personalized normative feedback (CPNF)|The CPNF intervention allows individuals to explore normative feedback for a wider variety of referent groups so that PNF is a truly personalized and engaging experience.
214438653|NCT07036198|BEHAVIORAL|Personalized normative feedback (PNF)|Correcting misperceptions about peers' alcohol use behaviors and contrasting one's own use to the actual norms of their peers.
214694181|NCT02244723|OTHER|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
214694182|NCT00303108|DRUG|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
214694183|NCT00303108|DRUG|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
215116798|NCT04093440|OTHER|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
215116799|NCT02863328|DRUG|semaglutide|Oral administration once-daily.
214517386|NCT03374423|PROCEDURE|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
214438654|NCT07036198|BEHAVIORAL|Attention-Matched Control (AMC)|Participants in the AMC condition will complete all measures at the same time as participants in the CPNF condition but will not receive any information on drinking norms. Instead, participants in the AMC will receive normative feedback on sleep health, video game use, and gambling behaviors, and will similarly be able to choose the normative referent groups they wish to view feedback on for these behaviors. The AMC will thus serve as a non-treatment comparison that controls for assessment reactivity and effects of history and maturation.
214438655|NCT07041242|PROCEDURE|"ligament reconstruction using the single-bundle over-the-top technique"|"Patients who have undergone anterior cruciate ligament reconstruction using the single-bundle over-the-top technique with gracilis and semitendinosus tendons, combined with a lateral extra-articular tenodesis, will be enrolled"
214438656|NCT07043751|DRUG|TQB6411 injection|TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.
214438657|NCT06724809|DRUG|eculizumab|Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.
214438658|NCT01740531|BIOLOGICAL|S-303 Treated Red Blood Cells (RBCs)|
214517387|NCT03374423|PROCEDURE|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
214517388|NCT02162927|DIETARY_SUPPLEMENT|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
214517389|NCT02162927|DIETARY_SUPPLEMENT|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
214517390|NCT01024023|DEVICE|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
214517391|NCT01195402|PROCEDURE|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
214517392|NCT06129656|OTHER|Routine diagnostics|Data collection of routine diagnostics
214517393|NCT06129656|OTHER|Routine treatment|Data collection of routine treatment
214517394|NCT02020902|OTHER|Cetrizine hydrochloride|As provided on the patient information leaflet
214517395|NCT01846156|DRUG|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
214517396|NCT02990845|DRUG|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
215116800|NCT02863328|DRUG|empagliflozin|Oral administration once-daily.
215116801|NCT00398320|DRUG|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
215116802|NCT00398320|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
215116803|NCT00398320|DRUG|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
215116804|NCT02682082|PROCEDURE|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
215116805|NCT02682082|DRUG|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
215116806|NCT00685113|DRUG|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
215116807|NCT00685113|DRUG|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
215116808|NCT00685113|DRUG|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
215116809|NCT05538143|OTHER|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
215116810|NCT03219346|OTHER|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
214438659|NCT01740531|BIOLOGICAL|Conventional, untreated Red Blood Cells|
214438660|NCT06738056|DEVICE|Nerivio|Remote electrical neuromodulation (REN) wearable device for the treatment of migraine. The device delivers electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214438661|NCT06891235|OTHER|Biologic testing for THC|Participants will be asked to complete at-home urine test(s) and a series of oral fluid tests.
214438662|NCT01303445|DRUG|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
214438663|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
214438664|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
214438665|NCT01303445|DRUG|Omeprazole alone|omeprazole 80 once daily for 7 days
214438666|NCT06893146|BEHAVIORAL|Reduction of Sedentary Behavior|The intervention group will receive an intervention that will include two group sessions, bimonthly phone calls and a face-to-face visit with the study nurse. Phone calls will be made every two months using motivational interviewing techniques with the aim of educating on habits and behaviors that reduce sedentary lifestyles, addressing needs and concerns on an individual basis, and enhancing patients motivation, well-being and quality of life. The same purpose is served by the face-to-face visit that will be conducted in the third month of the study. The study's interventions have a personalized approach, which considers individual preferences and needs to consolidate the new habits acquired in the long term. The active intervention has a duration of 6 months and will be carried out by nursing professionals.
214438667|NCT06893146|BEHAVIORAL|Educational support|Every two months, this group will receive detailed written information about healthy lifestyle habits via email, emphasizing the importance of maintaining an active lifestyle. Additionally, they will be provided with standard educational material on the management of type 2 diabetes.
214438668|NCT07051980|DEVICE|Supraglottic Oxygen Delivery via an Endotracheal Tube|patients use the Supraglottic Oxygen Delivery via an Endotracheal Tube
214438669|NCT06846138|DIETARY_SUPPLEMENT|Polyherbal Formulation (PHF)|"Description: A polyherbal formulation with known beneficial effects on gut microbiota and metabolic regulation. The formulation contains selected plant extracts studied for their hypoglycemic, antioxidant, and gut microbiota-modulating properties.~Administration: Oral, daily dosage as per study protocol. Supplier: Arya Vaidya Pharmacy (AVP), Coimbatore, India (GMP-certified)."
214438670|NCT06846138|OTHER|Placebo|"Type: Placebo Comparator Description: A placebo formulation that matches PHF in appearance, texture, and administration schedule.~Administration: Oral, daily dosage as per study protocol."
214438671|NCT06846138|DRUG|Metformin (Standard Treatment for Type 2 Diabetes)|"Description: Metformin is an FDA and EMA-approved antihyperglycemic medication that improves glycemic control by reducing hepatic glucose production and enhancing insulin sensitivity.~Administration: Oral, per standard dosing guidelines. Availability: Provided to all participants per the national reimbursement scheme for T2D patients in Latvia."
214438672|NCT07070271|OTHER|Respiratory neurophysiological facilitation techniques|The respiratory neurophysiological facilitation techniques in form of (anterior basal lift, intercostal stretch, abdominal co-contraction) once a day for 5 days.
214438673|NCT07070271|OTHER|conventional chest physical therapy|conventional chest physical therapy program in form of (postural drainage, chest percussion, vibration and suction if needed) once a day for 5 days.
214438674|NCT06749028|DIETARY_SUPPLEMENT|Intervention Arm: Omega-3 + Phospholipids.|Intervention Arm: Omega-3 + Phospholipids.
214438675|NCT06749028|DIETARY_SUPPLEMENT|Comparator Arm: Omega-3 alone.|Comparator Arm: Omega-3 alone.
214438676|NCT07061067|PROCEDURE|Lumbar Spine Surgery|Patients undergoing lumbar spine surgery Presenting symptoms include lumbar back pain, lumbar radiculopathy, neurogenic claudication, lower-extremity weakness, bowel or bladder symptoms, and duration of symptoms.
214438677|NCT07057648|DEVICE|Shape-sensing Robotic-assisted Bronchoscopy (ssRAB)|"Diagnostic procedure using the ION endoluminal system (Intuitive Surgical, Sunnyvale, CA) for navigation and tissue sampling of peripheral pulmonary nodules. The procedure involves:~1. Pre-procedure 3D navigation planning using thin-section chest CT~2. Shape-sensing catheter navigation to target nodules~3. Real-time position monitoring with fiber optic sensors~4. Tissue sampling using various tools (biopsy needles, forceps, brush, or cryobiopsy)~5. Optional radial endobronchial ultrasound (rEBUS) confirmation~6. Fluoroscopic guidance when needed~The procedure is performed under deep sedation or general anesthesia through an endotracheal tube."
214438678|NCT07058948|RADIATION|lattice radiation therapy|"Eligible patients will receive treatment using a medical linear accelerator. Within the largest tumor's gross tumor volume (GTV), spheres (0.5 - 3 cm in diameter) will be created as high - dose targets (LRT targets), spaced 2.0 - 5.0 cm apart. The LRT targets must be drawn within the GTV, avoiding blood vessels, with a margin of at least 1 cm from the GTV edge and a volume ratio of 1% - 10% of the GTV.~For a single lesion, the D95 of the GTV will be ≥1 Gy per fraction, and the D95 of the LRT target will be 8 - 12 Gy per fraction, while keeping the single - fraction dose to organs at risk as low as possible. All other irradiated metastases will receive low - dose radiotherapy at 100 - 300 cGy × 5 fractions. Brain and bone metastases will be treated with palliative radiotherapy as per clinical routine and are not included in the low - dose radiotherapy. Immunotherapy will be administered during or within one week after radiotherapy."
214517397|NCT01512355|DRUG|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
214517398|NCT01512355|DRUG|placebo group|normal saline\_02mcg/kg/hr
214517399|NCT00062478|DRUG|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
214517400|NCT02246556|DEVICE|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
214517401|NCT02246556|OTHER|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
214517402|NCT02246556|DEVICE|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
214517403|NCT05107921|DRUG|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
214517404|NCT00551954|DRUG|acarbose|100 mg (tablets) t.i.d.
214517405|NCT00551954|DRUG|placebo|one tablet t.i.d.
214517406|NCT05670600|OTHER|foot and ankle exercise|"Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
214517407|NCT03348800|PROCEDURE|Dental anesthesia|A tooth extraction will be performed
214694184|NCT00303108|DRUG|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
214694185|NCT01150955|DIETARY_SUPPLEMENT|Resveratrol|500 mg three times a day for five weeks.
215116811|NCT02831517|DRUG|BIIB074|Administered as specified in the treatment arm
214438679|NCT06455215|BEHAVIORAL|Community garden activities|The gardens in the intervention group will receive an 8-week intervention that includes 1) educational materials, 2) healthy cooking demonstrations, food and transportation support and 3) garden social activities. The control group will be asked to abstain from intervention activities. The control group will receive the delayed 8-week intervention one month after the intervention group.
214438680|NCT07062393|BEHAVIORAL|Traditional Counseling → MAR Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
214438681|NCT07062393|BEHAVIORAL|MAR Counseling → Traditional Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
214438682|NCT07064512|OTHER|Endogenous heating|Exercise was used as the endogenous heating modality, the participant cycled at 60% of his VO2max until rectal temperature reached 39°C
214438683|NCT07064512|OTHER|Exogenous heating|Hot-water immersion was used as the exogenous heating modality, where the participants sat immersed in a water bath at 43.5 ± 0.5°C and remained submerged until rectal temperature reached 39°C.
214438684|NCT07064694|PROCEDURE|Hybrid Parastomal Endoscopic Repair (HyPER)|Combined laparoscopic and open surgical approach involving adhesiolysis, hernia sac excision, intraperitoneal mesh fixation, and stoma revision or relocation as indicated. Standard mesh used was DynaMesh-IPST®; in selected cases, a cost-effective modification with macroporous polypropylene mesh and omental interposition was applied.
214438685|NCT06769997|DEVICE|Optilume® BPH Catheter System|The technology is based on a device/drug combination consisting of two catheters: the Optilume BPH Prostatic Pre-dilation Catheter which is a non-drug coated catheter used to start commissurotomy between the lateral lobes of the prostate and the Optilume BPH Prostatic Dilatation DCB Catheter which is a drug coated catheter used to complete the commissurotomy and transfers drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Hence, the device applies a mechanical dilatation to open prostatic urethral lumen to increase urine flow, followed by the transfer of paclitaxel drug to inhibit cell proliferation and maintain this dilatation.
214438686|NCT06769997|DEVICE|Rezum Water Vapor Therapy|The Rezum system is minimally invasive therapy for LUTS secondary to BPH. The system injects water vapor at 103°C generated by radiofrequency to create thermal energy via a transurethral approach. The vapor disperses through the tissue interstices within the treatment zone (transition zone). The injection of vapor last for approximatively 9 seconds and the number of injections depends on the prostate volume and length of the prostatic urethra.
214438687|NCT07064551|BEHAVIORAL|Cognitive behavioural therapy-based stepped-care intervention|After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]). Mild symptoms (PHQ-9=5-9): 6 weekly low intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderate symptoms (PHQ-9=10-14): 6 weekly high intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderately severe symptoms (PHQ-9≥15): high intensity individual or group CBT-based intervention. Trained peer supporters will be matched to participants to walk them through the process with regular follow-up.
214438688|NCT07064551|OTHER|Self-management booklet|The booklet incorporates components of behavioural activation, which encourages participants to engage in meaningful activities in daily life to change their mood. Trained research assistants will regularly check in with the participants to monitor their depressive symptoms.
214438689|NCT07065084|PROCEDURE|Virtual Reality glasses|"In the study, the patients in the intervention group were fitted with VR goggles by the researcher immediately after the spinal anesthesia was administered by the researcher during the operation in hernia patients who received spinal anesthesia for the study, when the patient was placed on the operating table and given the operating position, just before the surgical incision started. The procedures were performed without interfering with anesthesia and general operating room functioning. When the surgical incision was to be made, videos were started to be watched from the VR glasses simultaneously. During the 20 minute procedure, the licensed product Relax with Nature with music background with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel screen resolution display unit, China) was watched with virtual reality application. Patients were shown videos of lakes, forests, waterfalls, rivers and beaches. In the studies, it was stated that these videos"
214438690|NCT07071181|DIETARY_SUPPLEMENT|Original flavour kefir|"Participants will consume 250ml of original flavour kefir daily for 4 weeks. According to the manufacturer, packed with billions of live cultures to support Gut health."
214438691|NCT07071181|OTHER|Milk|Participants will consume 250 ml milk daily for 4 weeks. This milk will not contain any live cultures.
214438692|NCT07071662|OTHER|delivery mode|To observe the different modes of delivery and evaluate the characteristics of the patients as well as maternal and fetal well being in the post partum period.
214438693|NCT07071857|DIAGNOSTIC_TEST|ECG CT angiography|Preoperative: electrocardiography-gated computed tomographic angiography.
214438694|NCT07071857|DIAGNOSTIC_TEST|TTFM|Intraoperative: TTFM after weaning from cardiopulmonary bypass and just before sternal closure.
214438695|NCT07071857|DIAGNOSTIC_TEST|computed tomography of the aorta and/or grafts|computed tomography of the aorta and/or grafts within 2 weeks after surgery.
214438696|NCT07070882|DRUG|Methylprednisolone|Patients will receive a tapered dose of methylprednisolone with the standard of care pain management
214438697|NCT07069920|DEVICE|BRDE33-100|BRDE33-100 will be injected once at Visit 2 (Baseline).
214438698|NCT07069920|DEVICE|Soonsoofill|Soonsoofill will be injected once at Visit 2 (Baseline).
214694186|NCT01150955|OTHER|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
215116812|NCT02831517|DRUG|Placebo|Matched Placebo
215116813|NCT00003968|DRUG|bryostatin 1|
215116814|NCT04611828|DEVICE|Philips SmartSleep|closed-loop auditory stimulation
214438699|NCT07070934|BIOLOGICAL|CAR-T|The T cells are genetically modified to expressa chimeric antigen receptor targeting BCMA andare infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
214438700|NCT07070934|BIOLOGICAL|ASCT|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT).
214438701|NCT07069686|PROCEDURE|Ultrasound guided airway nerve block for Endotracheal intubation|Glossopharyngeal nerve block: 1.5 mL 2% lidocaine, ultrasound probe on lateral neck below mandible, landmark = hyoid bone, tilt cephalad to target pharyngeal wall near tonsil; right side needle inserted out-of-plane from superior probe edge to avoid artery. Bilateral superior laryngeal nerve blocks: out-of-plane at lateral thyroid cartilage, orient probe medially, inject 1 mL 2% lidocaine into thyrohyoid membrane between hyoid and thyroid cartilage using 25-G 25 mm needle. Bilateral recurrent laryngeal nerve blocks: translaryngeal out-of-plane, locate cricothyroid membrane below thyroid cartilage, insert 25-G 25 mm needle 1.5 cm, confirm air backflow, inject 2 mL 2% lidocaine.
214438702|NCT07069686|PROCEDURE|lidocaine topical anesthesia for Endotracheal intubation|will receive topical lidocaine 10% spray directly on the tongue and oropharynx without exceeding toxic doses.
214438703|NCT07070102|OTHER|blood samples|2 blood samples of 1 mL
214438704|NCT07070908|DEVICE|Antrum calibration|For antral calibration, a 50 cc balloon catheter was used to guide the staple line.
214438705|NCT07070908|PROCEDURE|Fudus calibration|"Fundus transection was performed 1 cm from the fat pad in calibrated cases (an anatomically constant area near the short gastric vessels that contains minimal fat and facilitates dissection toward the diaphragmatic crus)."
214438706|NCT07070908|PROCEDURE|No antrum calibration|In patients without antrum calibration, gastric transection was performed 5 cm from the pylorus.
214438707|NCT07070908|PROCEDURE|No fundus calibration|"Fundus transection was performed adjacent to the fat pad in no calibrated cases."
214438708|NCT07070843|OTHER|Control Group: Standard Eye Care Group|There is no established protocol or guideline for eye care in the intensive care unit where the study will be conducted. Routine eye care involves the use of sterile gauze and sterile saline. During routine suctioning procedures, patients' eyes are not closed. If a patient is unable to achieve full eyelid closure, their eyes are covered with an eye patch or sterile gauze. The Schirmer test will be administered to both eyes on the first day (prior to the first eye care intervention), as well as on the fifth, seventh, and tenth days after eye care is performed. Signs and symptoms of eye infection and chemosis will be evaluated daily after the second eye care procedure. Data for this group will be collected, and the administration and documentation of eye care will be monitored.
214438709|NCT07070843|OTHER|Intervention Group 1: Eye Care Using an Eye Care Kit|Eye care will be performed using an eye care kit. All nursing staff in the intensive care unit will receive training regarding the contents and usage of the kit. Patients in this group will receive eye care solely using the kit, following a 4-times-daily care protocol. For patients with lagophthalmos, eyes will be covered using the eye closure pad provided in the kit. The Schirmer test will be performed on both eyes on the first day prior to the initial eye care intervention, and on the fifth, seventh, and tenth days following eye care, with results recorded. Signs of infection and chemosis will be assessed daily after the second eye care session. Data collection will be done using , and eye care administration will be tracked.
214438710|NCT07070843|OTHER|Intervention Group 2: Eye Care According to an Eye Care Protocol|"* All ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving care under the protocol.~* Patients' ocular risk factors will be assessed daily, followed by eye care based on the protocol.~* Changes in ocular condition will be assessed and documented, and ICU physicians will be informed as necessary.~* In cases of incomplete eyelid closure, eyes will be covered upon physician notification.~* Patients will be assessed daily for signs of eye infection and conjunctival edema in accordance with the protocol. If signs of infection or complications occur during the day, they will be marked with a (+) symbol on the form.~* The Schirmer test will be applied on the first day (prior to the initial eye care session) and after eye care on days 5, 7, and 10, with results documented."
214438711|NCT07070843|OTHER|Intervention Group 3: Eye Care Using Both the Eye Care Protocol and the Eye Care Kit|"* ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving this combined care.~* Eye care will be performed using the Eye Care Kit developed by the researchers in accordance with the protocol.~* Patients will be assessed for ocular risk factors daily, and eye care will be provided according to the management guidelines of the protocol.~* In cases of incomplete eyelid closure, the eyes will be covered with physician knowledge.~* Patients will be assessed daily for signs of infection and conjunctival edema as per the protocol. Any signs of infection or complications will be marked with a (+) on the form.~* The Schirmer test will be performed on both eyes before the first eye care session on day 1, and following eye care on days 5, 7, and 10, with results recorded."
214438712|NCT07071584|DEVICE|Cutaneous Prosthesis Control System|Prosthesis control system using a multi-electrode cutaneous sensor array
214517408|NCT04160871|BEHAVIORAL|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
214517409|NCT04160871|BEHAVIORAL|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
214517410|NCT00019344|DRUG|alvocidib|
214694187|NCT02844023|BEHAVIORAL|Clinical evaluation|With questionnaire.
214438713|NCT07069764|DEVICE|Doctor smile 635nm For Arm 1|Participants will receive low-level laser therapy using a diode laser with a wavelength of 635 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
214438714|NCT07069764|DEVICE|Doctor smile 980 nm For Arm2|Participants will receive low-level laser therapy using a diode laser with a wavelength of 980 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
214438715|NCT07066735|DEVICE|ESWT|Transperineal Shockwaves that are applied once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)
214438716|NCT07066735|DRUG|Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin|1capsule tob be taken twice daily for one month.
214438717|NCT07070531|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a transdiagnostic, emotion-focused cognitive-behavioral treatment designed to address a range of emotional disorders, including anxiety, depression, and related conditions. It targets core mechanisms such as emotional avoidance, cognitive rigidity, and maladaptive emotion regulation strategies. The UP consists of structured modules focused on increasing emotional awareness, cognitive flexibility, and exposure to emotionally evocative situations. By addressing common underlying processes across disorders, the UP enhances treatment efficiency and applicability in both individual and group formats. Its flexibility makes it suitable for diverse populations and settings, including community and clinical contexts.
214438718|NCT07071064|BEHAVIORAL|Food Box + Nutrition Classes|The Nutrition Security Intervention is a 12-month project enrolling 400 adults across four sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. Individuals receiving this intervention will receive bi-weekly food boxes, containing 15-20 pounds of fresh produce, grains, and legumes. They will also participate in a bi-weekly nutrition class, led by a Registered Dietician.
214438719|NCT07071064|BEHAVIORAL|Food Box Only|The intervention is a 12-month project enrolling 400 adults across four partner sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. In this intervention, participants will receive a bi-weekly food box only (no nutrition education) during the intervention period. They will have the opportunity to participate in the educational component after the completion of the intervention period.
214517411|NCT06416345|DEVICE|Cue2Walk|24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
214517412|NCT06416345|OTHER|Usual Care|24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
214438720|NCT07070622|DRUG|patients were assigned to receive TNT or iTNT management|TNT or iTNT
214438721|NCT07070778|OTHER|Upper Extremity Aerobic Exercise Training Program|12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.
214438722|NCT07070648|DRUG|POLA-R-CHP|Pola-R-CHP treatment for 6 cycles (IPI score 2-5)
214438723|NCT07070557|OTHER|neutrophil lymphocyte ratio and platelet lymphocyte ratio|explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients
214438724|NCT07071285|BEHAVIORAL|E-Book|Breastfeeding eBook learning mode.
214438725|NCT07071285|BEHAVIORAL|face-to-face teaching|face-to-face teaching of breastfeeding
214438726|NCT07071571|DEVICE|neuromonitoring|new neuromonitorin device will use
214438727|NCT07070739|DRUG|HSK44459 tablets|Orally, twice a day
214438728|NCT07070635|OTHER|Nutritional intervention with Fermented Seaweed Enriched English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea + 1 g fermented seaweed) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
214517413|NCT00004045|DRUG|exatecan mesylate|
214517414|NCT04315428|BEHAVIORAL|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
214438729|NCT07070635|OTHER|Nutritional intervention with Control English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
214438730|NCT07069634|OTHER|Individual training using the Teach Back Method|"Day 1 (Monday): Patients are introduced to the study; consent forms are signed, and initial forms are completed. An educational booklet is provided and explained. General information about hemodialysis and treatment is delivered using the Teach-Back Method.~Day 2 (Wednesday): Patients recall previous session topics; unclear points are clarified. Education focuses on fluid and dietary restrictions and the importance of adherence, using the Teach-Back Method.~Day 3 (Friday): Patients summarize previous content; the researcher reinforces unclear areas. Education covers medication adherence and lifestyle habits, again using the Teach-Back Method."
214517415|NCT04315428|BEHAVIORAL|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
214517416|NCT03555617|DRUG|TD-1473|oral capsule/tablet, QD
214517417|NCT03555617|DRUG|Itraconazole|oral solution, QD
214517418|NCT00022399|DRUG|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
214517419|NCT00022399|DRUG|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
214517420|NCT04515745|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
214517421|NCT04515745|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
214517422|NCT00234832|DRUG|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
214694188|NCT02844023|OTHER|Paraclinical evaluation|Symptom inflammatory, biomarkers.
215116815|NCT03565614|BEHAVIORAL|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
214438731|NCT07070583|PROCEDURE|Stent placement|Patients with an aorto-iliac occlusion will receive a stent, according to standard care
214517423|NCT00234832|DRUG|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
214517424|NCT00234832|DRUG|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
214517425|NCT06187155|OTHER|INR self-management|will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
215116816|NCT03565614|BEHAVIORAL|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
215116817|NCT00121186|DRUG|fludarabine phosphate|30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).
215116818|NCT00121186|DRUG|melphalan|70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).
215116819|NCT00121186|DRUG|methotrexate|5 mg/m\^2 on days 1, 3, and 7 post-transplant.
215116820|NCT00121186|DRUG|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
215116821|NCT00121186|PROCEDURE|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
215116822|NCT00121186|PROCEDURE|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
215116823|NCT01002183|DRUG|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
215116824|NCT02085109|DIETARY_SUPPLEMENT|Fat milkshake|
215116825|NCT02085109|DIETARY_SUPPLEMENT|Theobromine|
215116826|NCT03767751|BIOLOGICAL|Dual Specificity CD38 and bcma CAR-T Cells|1\) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
214438732|NCT07070505|OTHER|Experimental|"* Before applying hand massage, the individual/patient's hand or arm will be evaluated for thrombus, phlebitis, ecchymosis, hematoma, deterioration in skin integrity and change in skin color in order to determine whether there is a risk.~* Hand massage application is a massage performed with western technique that includes five basic classical massage manipulations including efflorescence, petrissage, friction, tapotment and vibration.~* Massage should be performed in a way that creates light pressure on the individual, then the applied pressure should be gradually increased."
214517426|NCT03189550|PROCEDURE|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
214517427|NCT03189550|PROCEDURE|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
214517428|NCT03189550|PROCEDURE|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
215116827|NCT00863291|DRUG|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
215116828|NCT00863291|DRUG|placebo|Placebo in a manner similar to the active comparator
215116829|NCT02151890|BIOLOGICAL|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
215116830|NCT05768035|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
215116831|NCT01707901|DRUG|ONO-8539|Treatment
215116832|NCT01707901|OTHER|Placebo|Placebo
215116833|NCT01112878|DRUG|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
215116834|NCT01112878|DRUG|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
215116835|NCT01112878|DRUG|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
214438733|NCT07070453|PROCEDURE|Non-surgical periodontal treatment|Removal of deposits above and below the gum line using hand or ultrasonic tools and thorough smoothing of root surfaces to discourage re-accumulation of bacteria.
214438734|NCT07070453|PROCEDURE|Scaling and root planing + aPDT|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light, and oxygen to generate reactive oxygen species (ROS) that kill bacteria.
214694189|NCT02844023|DEVICE|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
214694190|NCT02844023|OTHER|Ophthalmologic examination|
214694191|NCT02844023|BIOLOGICAL|Dosage of biomarkers|Control patients.
215116836|NCT04933487|DEVICE|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
214438735|NCT07070011|COMBINATION_PRODUCT|EC/EP + ICIs|Collect blood samples from patients with small cell lung cancer before receiving immunotherapy combined with chemotherapy.
214438736|NCT07071493|DEVICE|tPBM Group, taVNS Group, Combined Treatment Group: Stimulation Program (5 Weeks)|"Stimulation Program (5 Weeks) Each participant will follow one of the following programs, assigned randomly, five days a week for a total duration of five weeks.~tPBM Group: Participants will receive transcranial photobiomodulation (tPBM) for 15 minutes per day.~taVNS Group: Participants will receive transcutaneous auricular vagus nerve stimulation (taVNS) for 15 minutes per day.~Combined Treatment Group: Participants will simultaneously receive both tPBM and taVNS for 15 minutes per day."
214438737|NCT07069933|DRUG|Standard care +itraconazole 200mg|Is an antifungal used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals.
214438738|NCT07069933|DRUG|Chemotherapy|Standard Care (in control arm)
214438739|NCT07069998|OTHER|virtual assistant|Programming codes that interpret atrial fibrillation symptoms and design management plans based on algorithms that reflect the European Society of Cardiology (ESC) 2024 guidelines and the expertise of consultant cardiologists, finally checked and approved by a cardiologist.
214438740|NCT07069998|OTHER|Standard AF care|AF care provided via the National Health System (NHS) standard AF care system
214438741|NCT07069842|DIAGNOSTIC_TEST|Multiplex Immunofluorescence Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment.Meanwhile, detect the expression of cytokines, NLR, PLR, SII, and tumor markers in peripheral blood.Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.In situ hybridization with chromogenic detection was performed to assess the EBER status.
214438742|NCT07069842|DIAGNOSTIC_TEST|Co-Immunoprecipitation (Co-IP) Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment
214438743|NCT07069842|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.
214438744|NCT07069842|DIAGNOSTIC_TEST|In situ hybridization with chromogenic detection|In situ hybridization with chromogenic detection was performed to assess the EBER status.
214438745|NCT07070466|DRUG|Ivonescimab|Humanized immunoglobulin G1 monoclonal antibody
214438746|NCT07070466|DRUG|5-Fluorouracil|Nucleoside metabolic inhibitor
214438747|NCT07070466|DRUG|Oxaliplatin|Platinum-based drug and organoplatinum complex
214438748|NCT07070466|DRUG|Leucovorin|5-formyl derivative of tetrahydrofolic acid
214438749|NCT07070245|PROCEDURE|Instrument assisted soft tissue mobilization|The treatment protocol will be two sessions. given per week for 4 weeks.
214438750|NCT07070245|PROCEDURE|Positional release|The treatment protocol will be two sessions. given per week for 4 weeks.
214438751|NCT07070245|PROCEDURE|Exercises|The treatment protocol will be two sessions. given per week for 4 weeks.
214438752|NCT07071038|DRUG|Switch|Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively. The choice of AI in the first line setting will be at the discretion of the treating oncologist. If side effects persist after the 1st line switch, the participant will have the option to switch to another AI not yet tried, or to tamoxifen at 20mg daily
214438753|NCT07071038|OTHER|Guideline Directed Intervention (GDI)|"Subjects in this group will receive a guideline-directed intervention GDI using medication and/or non-medication treatment options according to the National Comprehensive Cancer Network (NCCN) supportive care guidelines. A GDI Book was created for this trial that lists treatment options and resources for each of the common side effects of hormonal therapy and is available for providers and staff to help select treatment options. For less common side effects with limited evidence-based options, treatment will be determined in collaboration with the treating provider and PI, using best available evidence."
214438754|NCT04939246|RADIATION|Stereotactic ablative body radiation therapy|Single-fraction of stereotactic ablative body radiation (SABR) therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian Linac). The prescription dose is dependent on the anatomic location of the lesion and based on previously published safety data.
214438755|NCT04994509|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
214438756|NCT04994509|DRUG|Subcutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
214438757|NCT04994509|DRUG|F/TAF|Tablets administered orally
214438758|NCT04994509|DRUG|F/TDF|Tablets administered orally
214438759|NCT04994509|DRUG|Placebo SC LEN|Administered via SC injections
214438760|NCT04994509|DRUG|PTM Oral LEN|Tablets administered orally
214438761|NCT04994509|DRUG|PTM F/TAF|Tablets administered orally
214438762|NCT04994509|DRUG|PTM F/TDF|Tablets administered orally
214438763|NCT03411369|DIETARY_SUPPLEMENT|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
214438764|NCT03411369|OTHER|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
215116837|NCT04375345|DEVICE|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
215116838|NCT03152591|DRUG|LIK066|LIK066 tablets for oral administration
215116839|NCT03152591|DRUG|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
215116840|NCT00163020|DRUG|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
215116841|NCT00163020|DRUG|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
215116842|NCT04649814|OTHER|Questionnaire|Questionnaire for all, interview for part of the respondents.
214438765|NCT03764787|COMBINATION_PRODUCT|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
214438766|NCT02051491|DEVICE|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
214438767|NCT02051491|DEVICE|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
214438768|NCT01700296|BEHAVIORAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
214438769|NCT05289310|OTHER|Normobaric hypoxia (NH)|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
214438770|NCT05289310|OTHER|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
214438771|NCT05642598|BEHAVIORAL|Pivot for Vape|"Pivot for Vape vaping cessation smartphone app and program"
214438772|NCT06312904|PROCEDURE|paravertebral block|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.
214438773|NCT06312904|PROCEDURE|Local infiltration anesthesia|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.
214438774|NCT06779851|DRUG|BPT567|Immunocytokine infusion
215028634|NCT03017001|OTHER|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
215028635|NCT04656912|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
215028636|NCT03574363|DRUG|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
215028637|NCT03574363|DRUG|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
215028638|NCT00003451|BIOLOGICAL|recombinant interferon alfa|
215028639|NCT00003451|BIOLOGICAL|recombinant interleukin-12|
215028640|NCT02998866|PROCEDURE|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
215028641|NCT04023045|DEVICE|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
215028642|NCT04023045|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
215028643|NCT01968278|OTHER|Baked milk|
215028644|NCT02624856|DRUG|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
215028645|NCT02624856|DRUG|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
215028646|NCT02132260|DRUG|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
215028647|NCT02132260|DRUG|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
215028648|NCT02132260|DRUG|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
215028649|NCT03277599|DRUG|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
215028650|NCT03277599|DRUG|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
215028651|NCT03277599|DRUG|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
215028652|NCT04467255|OTHER|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
215028653|NCT01232140|OTHER|CRP-guided antibiotic treatment|If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
215028654|NCT06642701|DEVICE|Electrical Impedance Tomography|According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy
214438775|NCT06247332|OTHER|Review of available clinical data sources related to use cases|There will be a review of available clinical data sources related to use cases. In addition, this information will be complemented by a cohort of anonymized retrospective data of 100 cases obtained from the clinical information resulting from the assistance to COVID-19 patients managed by the Primary Care Health District of Sevilla Norte and the Infectious Diseases Department of the Virgen Macarena University Hospital
214438776|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block|For the block, the ultrasound (USG)probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site. After the block site is confirmed, 30 ml of 0.25% bupivacaine (Marcain 0.5%® AstraZeneca, England) will be administered. The block catheter (Perifix® Braun, Germany) will then be inserted to block area
214517429|NCT05635994|DIAGNOSTIC_TEST|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
214517430|NCT03369119|DRUG|Montelukast 4 Mg Oral Granule|
214517431|NCT03369119|DRUG|Placebos|
214517432|NCT00559871|DRUG|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
215116843|NCT02820675|OTHER|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
214517433|NCT01540474|BIOLOGICAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
214517434|NCT01540474|BIOLOGICAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
214517435|NCT01540474|BIOLOGICAL|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
214517436|NCT01540474|OTHER|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
214517437|NCT04454125|BEHAVIORAL|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
214517438|NCT04454125|OTHER|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
214692735|NCT05996172|BEHAVIORAL|Caregiver Skills Training|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills adapted from evidence-based treatments for youth suicidality including DBT and CBT.48,49 Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
215116844|NCT02820675|OTHER|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
215116845|NCT01311882|DRUG|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
214517439|NCT04280978|DIAGNOSTIC_TEST|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
215116846|NCT01311882|DRUG|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
215116847|NCT01311882|DRUG|Zopiclone|1 x 7.5 mg Zopiclone tablet
214517440|NCT01125345|PROCEDURE|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
214517441|NCT03470701|OTHER|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
214517442|NCT05981586|OTHER|Plyometric strengthening exercises|Comparative effects 1
215116848|NCT01311882|DRUG|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
214517443|NCT05981586|OTHER|Isotonic strengthening exercises|Comparative effects 2
214517444|NCT00004806|GENETIC|Cystic fibrosis transmembrane conductance regulator|
214517445|NCT05090904|DRUG|Brensocatib|Oral tablet
214517446|NCT05090904|DRUG|Placebo|Oral tablet
214438777|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block + Serratus Anterior Plane Block|For ESPB, USG probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site and 30 ml of 0.25% bupivacaine (Marcain®) will be administered. The block catheter (Perifix®) will be inserted. For SAPB, the USG probe will be placed parasagittal to the mid-axillary line at the 5th-6th rib level and the anechoic shadow of the costa together with the latissumus dorsi and serratus anterior muscles will be visualized. Then using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the serratus anterior muscle and the block site will be confirmed and 30 ml of 0.25% bupivacaine will be administered.
214438778|NCT06265597|OTHER|Healthy Nutrition and Yoga Program|"* Healthy Nutrition Program~  * At the beginning of the Healthy Nutrition and Yoga Program by the researcher give education to families and children in 3 sessions (Importance of Nutrition in School Age, Obesity in School Age, Nutrition Recommendations for Obese Children).~ * Providing individual counseling to children every 2 weeks from the start of the Healthy Nutrition Program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~ * After the 2nd session of the healthy nutrition education and from the beginning of the Yoga Program, in the 2nd, 4th, 6th, 8th and 10th weeks, children are asked to keep a food diary for 2 weekdays and 1 weekend (Thursday-Friday-Saturday) and planning is made according to reaching basic healthy nutrition behavior goals.~* Yoga Program \*Children's yoga is applied to each group twice a week for 12 weeks."
214438779|NCT06834087|PROCEDURE|Laser-Assisted Gingival Depigmentation|This intervention involves the use of a diode laser (970 nm wavelength, 2.0 W power, continuous mode) with a 200 µm fiber tip. The laser is applied in a sweeping motion over the pigmented gingiva in contact mode for 30 seconds per site to achieve depigmentation.
214517447|NCT01587703|DRUG|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
214517448|NCT03532568|OTHER|skin biopsy|4mm punch skin biopsy
214517449|NCT03532568|RADIATION|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
214517450|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
214517451|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
214517452|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
214517453|NCT01878955|GENETIC|AMH level difference between patient with PCOS and multicystic ovaries.|
214517454|NCT01817088|PROCEDURE|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
214517455|NCT01817088|PROCEDURE|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
214517456|NCT03060356|BIOLOGICAL|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
215116849|NCT01311882|DRUG|Matching Placebo for MK-4305|Matching Placebo for MK-4305
215116850|NCT01522326|DRUG|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
215116851|NCT01522326|DRUG|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
215116852|NCT03947710|OTHER|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
215116853|NCT03947710|OTHER|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
215116854|NCT03947710|OTHER|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
215116855|NCT05904561|RADIATION|low level laser therapy|"comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest"
215116856|NCT03553758|DRUG|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
215116857|NCT00487357|BEHAVIORAL|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
215116858|NCT02205671|BEHAVIORAL|Building Better Caregivers Small-group Workshop|
215116859|NCT04388761|DRUG|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
215116860|NCT00670904|OTHER|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
214517457|NCT00452322|DRUG|Testosterone Substitution by Testosterone Undecanoate i.m.|
214517458|NCT05849220|DRUG|Dapagliflozin|Dapagliflozin
214438780|NCT06834087|DRUG|Photodynamic Therapy with Conventional Methylene Blue|This intervention consists of applying a 0.1% methylene blue solution to the pigmented gingiva for 2 minutes before activation with a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site. This is followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
214438781|NCT06834087|DRUG|Photodynamic Therapy with Methylene Blue Nanoparticles|This intervention involves the application of 0.1% methylene blue nanoparticles to the pigmented gingiva for 2 minutes to allow deeper tissue penetration. It is then activated using a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site, followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
214438782|NCT06785116|DRUG|Placebo|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
214438783|NCT06785116|DRUG|Dapagliflozin 10mg Tab|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
214438784|NCT06792617|OTHER|Mobility (Central or Femoral Cannulation)|"Functional Mobility \& ADL's~1. Assisted sitting with progression to unassisted; ADL's~2. Assisted standing with progression to unassisted; ADL's~   1. VitalGo bed will be used if unsafe/unable to perform assisted standing.~  2. Leg press (VitalGo bed)~3. Ambulation; ADL's"
214438785|NCT06792617|OTHER|Resistance Training|Repetitions will be counted and documented per session per structured exercise.
214517459|NCT05849220|OTHER|Standard of Care|Standard of Care
214517460|NCT06106776|DRUG|Chimeric Antigen Receptor|This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).
214517461|NCT05256355|OTHER|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
214517462|NCT01799993|DRUG|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
215116861|NCT00670904|OTHER|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
215116862|NCT02892526|OTHER|Abdominoplasty with exeresis of cutaneous tissue|
215116863|NCT02892526|OTHER|Collection of cutaneous tissue|
215116864|NCT05577338|BEHAVIORAL|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
215116865|NCT05577338|BEHAVIORAL|health education|disease-related health knowledge
215116866|NCT03210207|PROCEDURE|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
215116867|NCT06106126|DRUG|GST-HG171 Tablets|150mg GST-HG171 100mg Tablets and ritonavir
215116868|NCT00497445|PROCEDURE|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
215116869|NCT00497445|PROCEDURE|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
215116870|NCT00597402|DRUG|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
215116871|NCT00597402|DRUG|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
214517463|NCT01799993|DRUG|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
214517464|NCT01181193|OTHER|Surgery|Craniotomy with total or partial removal of the brain tumor
214517465|NCT01181193|RADIATION|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
214517466|NCT01181193|DRUG|Temozolomide|"1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
214517467|NCT01181193|DRUG|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
215116872|NCT00597402|RADIATION|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
215116873|NCT00597402|DRUG|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
214438786|NCT06830304|BEHAVIORAL|Multi-level Education and Navigation Program for Gastrointestinal Cancer Screening|"This multi-level intervention consists of two major components implemented at community, healthcare provider, and individual levels:~Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills~3. Individual level: Tailored educational materials and one-on-one counseling~Navigation Component:~1. Patient needs assessment and barrier identification~2. Personalized navigation services including:~Appointment scheduling assistance Transportation coordination Insurance/financial counseling Reminder calls/messages Social/psychological support"
214438787|NCT06830304|BEHAVIORAL|Health education|"Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills"
214438788|NCT06787313|OTHER|precision palliative care|Participants receive precision palliative care based on scale screening result.
214438789|NCT06791213|OTHER|Digital Multimedia Health Education|"This study aims to investigate the effectiveness of digital multimedia in reducing pain, enhancing medication adherence, and improving pain control satisfaction among patients. The goal is to overcome the limitations of busy healthcare providers, allowing patients to learn independently, understand pain and analgesic use, dispel myths about pain medications, and enhance pain control, ultimately improving self-care capabilities, pain control satisfaction, and quality of life."
214438790|NCT06790875|DEVICE|Airway Pressure Release Ventilation (APRV)|In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.
214438791|NCT06790537|DRUG|Pregabalin 75 mg|75 mg of pregabalin will be given at night for the intervention group along with emollient local application
214438792|NCT06790537|OTHER|Placebo Oral Capsule|placebo capsule will be identical in appearance to the pregabalin capsule. it will be given at the same time of the day like pregabalin. same Emollient which is used in the Intervention arm will be applied locally on the areas of itching, morning after bathing .
214438793|NCT06787833|OTHER|Questionnaire|to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3).The same questionnaire was refilled at the end of the week in which music was played (T4).
214438794|NCT06787833|OTHER|listening to music|Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes)23,55, Mozart's Serenata Notturna KV239 (12.50 minutes)18,19, and Pachelbel's Canon in D major (6.16 minutes)24,25 were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period.
214438795|NCT06772415|DRUG|GenSci122 tablet 50mg|Orally Once Daily
214438796|NCT06772415|DRUG|GenSci122 tablet 250mg|Orally Once Daily
214438797|NCT05198583|OTHER|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
214438798|NCT05782010|DEVICE|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
214438799|NCT05522231|DRUG|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
214438800|NCT05522231|DRUG|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
214438801|NCT05522231|DRUG|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
214438802|NCT06546657|OTHER|Breakfast|Breakfast meal
214438803|NCT02514525|DEVICE|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
214438804|NCT03442244|DRUG|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
214438805|NCT03442244|DRUG|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
214438806|NCT03254589|DRUG|Methotrexate|See arm descriptions
214438807|NCT03254589|DRUG|Sulfasalazine|See arm description
214438808|NCT03254589|DRUG|Other DMARDs|See arm
214438809|NCT04529707|BEHAVIORAL|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
214438810|NCT01999062|OTHER|IMRT + CT + MR scan|
214438811|NCT05039177|DRUG|ERAS-007|Administered orally
214438812|NCT05039177|DRUG|Encorafenib|Administered orally
214438813|NCT05039177|DRUG|Cetuximab|Administered via intravenous infusion
214517468|NCT02648737|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).
214517469|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
214438814|NCT05039177|DRUG|Palbociclib|Administered orally
214517470|NCT00160329|DRUG|Atazanavir|300 mg with ritonavir boosting or 400 mg without
214517471|NCT02068079|DRUG|Vemurafenib and Trientine|
214517472|NCT02122354|BEHAVIORAL|"Hide and Seek videogame"|
215116874|NCT04657471|OTHER|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score \<2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
215116875|NCT06125366|DRUG|BAY1747846|Single dose; IV injection.
215116876|NCT06125366|DRUG|Matching placebo|Single dose; IV injection.
215116877|NCT05754853|DRUG|MRG002|Administrated intravenously
215116878|NCT05754853|DRUG|Docetaxel Injection|Administrated intravenously
214517473|NCT04348799|OTHER|BPD|It is a observation research.we didn't intervene anything.
215116879|NCT05754853|DRUG|Paclitaxel Injection|Administrated intravenously
215116880|NCT05754853|DRUG|Gemcitabine Hydrochloride for Injection|Administrated intravenously
215116881|NCT05754853|DRUG|Pemetrexed Disodium Injection|Administrated intravenously
214438815|NCT05589220|OTHER|Music Intervention|Music therapy carried out with MUSIC CARE©
214438816|NCT05589220|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
214438817|NCT03595059|DRUG|ABBV-155|Intravenous (IV) Infusion
214517474|NCT04105699|DEVICE|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
214517475|NCT04271254|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
214517476|NCT04756986|DRUG|malic acid|1% malic acid spray
214517477|NCT02272608|OTHER|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
214438818|NCT03595059|DRUG|Paclitaxel|Intravenous (IV) Infusion
214438819|NCT03595059|DRUG|Docetaxel|Intravenous (IV) Infusion
214438820|NCT06694857|DRUG|HA filler|patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. Patients are limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
214517478|NCT03534778|DIAGNOSTIC_TEST|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
214517479|NCT00965393|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
214692736|NCT05996172|BEHAVIORAL|Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means safety over two, 30-minute modules delivered across 2 sessions.
215116882|NCT05113511|DRUG|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
215116883|NCT05113511|DRUG|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
215116884|NCT00447226|DRUG|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
214438821|NCT04007744|BIOLOGICAL|Pembrolizumab|Given IV
214438822|NCT04007744|DRUG|Sonidegib|Given PO
214438823|NCT06651255|PROCEDURE|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
214438824|NCT06651255|PROCEDURE|Standard of care management|Standard of care management
214438825|NCT03231878|DRUG|MIN-102|MIN-102 treatment
214438826|NCT03231878|DRUG|Placebos|Placebo
215116885|NCT03969914|PROCEDURE|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
215116886|NCT03868254|DEVICE|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
215116887|NCT03868254|PROCEDURE|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
215116888|NCT04145882|PROCEDURE|additional osteotomies|varisation osteotomy, supination osteotomy or both
215116889|NCT02433886|PROCEDURE|Gamma Ventral Capsulotomy|
214438827|NCT04418271|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
214438828|NCT05078528|DEVICE|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
214438829|NCT03410875|DRUG|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
214438830|NCT03410875|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
214438831|NCT06703177|DRUG|SHR-1826|SHR-1826
214438832|NCT06703177|DRUG|SHR-4642|SHR-4642
215116890|NCT02620969|OTHER|Blood and dialysate sampling|Blood and dialysate sampling
214438833|NCT06703177|DRUG|SHR-9839|SHR-9839
214438834|NCT06703177|DRUG|SHR-8068|SHR-8068
214438835|NCT06703177|DRUG|Bevacizumab Injection|Bevacizumab Injection
214438836|NCT06703177|DRUG|Fluorouracil Injection|Fluorouracil Injection
214438837|NCT06703177|DRUG|Calcium Folinate Injection|Calcium Folinate Injection
215116891|NCT06040411|OTHER|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
215116892|NCT02585362|BEHAVIORAL|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
214438838|NCT06703177|DRUG|Adebrelimab Injection|Adebrelimab Injection
214438839|NCT06204432|DRUG|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
214438840|NCT06204432|DRUG|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
214438841|NCT06204432|OTHER|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
214438842|NCT05663034|BEHAVIORAL|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
214438843|NCT05663034|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
214438844|NCT01495806|DRUG|Glucomannan|2 x 5g
214438845|NCT01495806|DRUG|placebo|glucose 5 g
214438846|NCT06062017|DIETARY_SUPPLEMENT|Water and Potassium supplementation|All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium chloride powder.
214438847|NCT05573048|DEVICE|Trans-Perineal Grid|A small square piece of plastic with many holes in it placed between the legs to help guide the path of the interventional instruments and to facilitate the prostate intervention. The guide grid will help with needle placement using the grid technology.
214438848|NCT05833360|DEVICE|Exai oncRNA blood test|A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
214438849|NCT06094426|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
214517480|NCT00965393|DRUG|Placebo|Systemic infusion of placebo (saline)
214517481|NCT00965393|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
214517482|NCT06335667|DIAGNOSTIC_TEST|mpMRI + Diagnostic TURBT|mpMRI in addition to the TURBT surgical procedure
214517483|NCT02781233|OTHER|Progressive resistance training|Progressive resistance training program
214517484|NCT02781233|OTHER|Normal daily activities|Usual daily activities
214517485|NCT04945044|DEVICE|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
215116893|NCT02585362|BEHAVIORAL|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
215116894|NCT02585362|DIETARY_SUPPLEMENT|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
215116895|NCT06435377|PROCEDURE|Procedure: Cold EMR + APC|"* Initial submucosal injection of saline solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare~* Biopsy of the resection bed~* Ablation of the defect using argon plasma coagulation (APC)."
215116896|NCT00258492|BEHAVIORAL|Aerobic exercise|
214438850|NCT06113666|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
214438851|NCT06113666|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
214438852|NCT04804358|BEHAVIORAL|Exposition Test|"During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system."
214438853|NCT03738553|DEVICE|MRI|Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI
214438854|NCT03738553|DRUG|Trastuzumab|Single dose of Trastuzumab prior to surgery
214438855|NCT04510064|DRUG|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
214438856|NCT04510064|PROCEDURE|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
214438857|NCT06780254|DRUG|MH-001|capsules
214438858|NCT06780254|DRUG|Placebo|capsules
214438859|NCT02702869|PROCEDURE|cleft lip repair|
214438860|NCT02702869|PROCEDURE|cleft palate repair|
214438861|NCT02702869|PROCEDURE|oronasal fistula repair|
214438862|NCT02702869|PROCEDURE|pharyngoplasty|
214438863|NCT02702869|PROCEDURE|gingivoperiosteoplasty|
214438864|NCT02702869|PROCEDURE|LeFort-1 maxillary repositioning|
214438865|NCT02702869|PROCEDURE|rhinoplasty|
214438866|NCT02702869|PROCEDURE|myringotomy and tympanostomy tube placement|
214438867|NCT02702869|OTHER|speech therapy|
214438868|NCT02702869|PROCEDURE|orthodontia|
214438869|NCT02702869|PROCEDURE|presurgical orthopedics|
214438870|NCT02702869|DEVICE|sound amplification for hearing|
214438871|NCT05985902|OTHER|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
215116897|NCT02320006|OTHER|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
215116898|NCT03086096|DEVICE|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
214438872|NCT05985902|OTHER|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
214438873|NCT06536192|OTHER|Model group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam."
214438874|NCT04278586|BEHAVIORAL|Live-Online M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
214517486|NCT04945044|BEHAVIORAL|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
215116899|NCT01860287|DRUG|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
215116900|NCT01860287|DRUG|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
214438875|NCT04278586|BEHAVIORAL|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
215116901|NCT01860287|DRUG|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
215116902|NCT02848222|DEVICE|Bruder Moist Heat Compress|
214438876|NCT05231655|DIAGNOSTIC_TEST|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
214438877|NCT05403723|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
214438878|NCT05403723|DRUG|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
214438879|NCT05403723|DRUG|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
214438880|NCT05403723|DRUG|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
214438881|NCT05403723|DEVICE|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
214438882|NCT06397547|OTHER|Flipped Learning|Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
214517487|NCT03701022|DRUG|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
215116903|NCT02848222|OTHER|Washcloth|
215116904|NCT06096649|OTHER|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Instructions: Apply to the entire face twice daily - morning and evening
215116905|NCT06096649|OTHER|Topical Vehicle|Instructions: Apply to the entire face twice daily - morning and evening
214517488|NCT01082354|DRUG|recombinant somatropin|as per standard practice
214517489|NCT02147652|OTHER|Personalized music|
214517490|NCT01396122|PROCEDURE|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
214517491|NCT02259959|DRUG|Single rising doses of BI 1744 CL, solution for oral inhalation|
214517492|NCT02259959|DRUG|Tiotropium, fixed dose, solution for oral inhalation|
214517493|NCT02259959|DRUG|Placebo|
214517494|NCT04410445|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
214517495|NCT04410445|BIOLOGICAL|Nivolumab|Specified dose on specified days
214438883|NCT05540535|OTHER|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
215116906|NCT05653414|OTHER|short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife|4 consultations with a psychologist over 2 months maximum
214438884|NCT05540535|OTHER|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
214438885|NCT04301726|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
215116907|NCT05653414|OTHER|encouragement of early support consultation with generalist practitioner or midwife|encouragement of early support consultation with generalist practitioner or midwife
215116908|NCT02219646|DRUG|Vardenafil|Vardenafil 10 mg twice daily for six months
214438886|NCT04301726|DRUG|Placebo oral tablet|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
214438887|NCT05994209|DEVICE|quitSTART Mobile Application|Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
214438888|NCT05994209|BEHAVIORAL|Chatbot Feature in quitSTART Mobile Application|In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
214438889|NCT05306080|DRUG|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
214438890|NCT06226220|PROCEDURE|Sacral neuromodulation|Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
214438891|NCT06402942|OTHER|Gamified occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
214517496|NCT01072058|DRUG|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
214517497|NCT03401411|BEHAVIORAL|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
214692737|NCT05784337|DEVICE|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
215116909|NCT02219646|DRUG|Placebo|Placebo two tablets daily for 6 months
215116910|NCT04537975|DEVICE|C2Rx|Hemofiltration
215116911|NCT04537975|OTHER|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
215116912|NCT03814707|DRUG|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
215116913|NCT03814707|BIOLOGICAL|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
215116914|NCT01145534|DRUG|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
215116915|NCT01145534|OTHER|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
215116916|NCT02372526|OTHER|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
215116917|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
215116918|NCT02372526|OTHER|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
214438892|NCT06402942|OTHER|Classic occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
214438893|NCT06389188|PROCEDURE|RHB Group|The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
214517498|NCT03401411|BEHAVIORAL|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
214692738|NCT05053997|BEHAVIORAL|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
214692739|NCT03121833|DRUG|Endostar|Recombinant Human Endostatin Injection
214692740|NCT03121833|DRUG|Placebo|500ml 0.9% sodium chloride
214692741|NCT03121833|DRUG|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
214517499|NCT01320683|DRUG|oxaliplatin|Given IV
214517500|NCT01320683|DRUG|leucovorin calcium|Given IV
214517501|NCT01320683|DRUG|fluorouracil|Given IV
214517502|NCT01320683|BIOLOGICAL|bevacizumab|Given IV
214517503|NCT01320683|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
214517504|NCT01320683|OTHER|laboratory biomarker analysis|Correlative studies
214517505|NCT01320683|OTHER|pharmacological study|Correlative studies
214692742|NCT06194175|PROCEDURE|Bariatric surgery|"Participants whose application for bariatric surgery was accepted, regardless of the type of surgical intervention (e.g., sleeve gastrectomy, Roux-en-Y Gastric Bypass).~This longitudinal study includes five measurement times: before surgery and then, 6 months, one year, one and a half years and two years after surgery. At each measurement time, participants are asked to respond to a set of online questionnaires. Responses are anonymous."
214517506|NCT01320683|DRUG|irinotecan hydrochloride|Given IV
214692743|NCT05611099|DEVICE|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
214692744|NCT05611099|OTHER|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
214692745|NCT04815551|DRUG|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
214692746|NCT04815551|DRUG|Placebo|Placebo is sterile liquid for IV infusion.
215116919|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
214438894|NCT06239155|DRUG|AST-3424|liquid formulation for Intravenous infusion
214438895|NCT04997096|OTHER|Exercise|16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
214438896|NCT04997096|OTHER|Attention Control|Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
214438897|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
214438898|NCT04713618|OTHER|Survey|Complete surveys
214438899|NCT05386238|BEHAVIORAL|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
214438900|NCT05386238|BEHAVIORAL|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
214517507|NCT00307671|DRUG|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
214517508|NCT00307671|DRUG|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
214517509|NCT00307671|DRUG|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
214517510|NCT05248269|PROCEDURE|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
214517511|NCT02211599|OTHER|15% protein|Meal to provide 15%en from protein.
214517512|NCT02211599|OTHER|30% protein|Meal to provide 30%en from protein.
214517513|NCT02211599|OTHER|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
214517514|NCT00759681|DEVICE|ArterX Surgical Sealant|Apply at the suture site.
214517515|NCT00759681|DEVICE|Gelfoam and Thrombin|Apply at the suture site.
214517516|NCT04779047|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
214517517|NCT04779047|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
214517518|NCT04779047|DRUG|Tocilizumab|Tocilizumab 800 mg once.
214517519|NCT04779047|DRUG|Lopinavir/ Ritonavir|Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
214517520|NCT04779047|DRUG|Ivermectin|Ivermectin 36 mg at day 1,3 and 6.
214692747|NCT03987919|DRUG|Tirzepatide|Administered SC
214692748|NCT03987919|DRUG|Semaglutide|Administered SC
214692749|NCT02222389|BEHAVIORAL|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
214692750|NCT02222389|BEHAVIORAL|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
214692751|NCT02222389|BEHAVIORAL|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
214517521|NCT02426424|DEVICE|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
214517522|NCT02426424|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
214692752|NCT02222389|BEHAVIORAL|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
214438901|NCT06109038|OTHER|Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions)."
214438902|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).
214517523|NCT02321371|DRUG|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
214517524|NCT02321371|DRUG|Lactulose|Continuation of Lactulose therapy for further 48 hours.
214517525|NCT01693393|DRUG|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
214517526|NCT03966599|DIAGNOSTIC_TEST|Pain|Patient's pain in order to VAS
214517527|NCT03966599|DIAGNOSTIC_TEST|Hemodynamic changes|changes in hemodynamic states
214517528|NCT01608919|OTHER|blood tests|thromboelastogram platelet mapping
214517529|NCT04304898|OTHER|Home spirometry|"* Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
214517530|NCT03663049|DRUG|discontinue statin|Discontinue statin as prescribed for 12 weeks
214517531|NCT01295619|DEVICE|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
214517532|NCT02275806|DRUG|Irinotecan|
214438903|NCT05989347|DRUG|Dapagliflozin 10mg|10 mg tablets for oral administration daily throughout chemotherapy treatment
214517533|NCT02275806|DRUG|Cisplatin|
214692753|NCT03726619|BEHAVIORAL|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
214692754|NCT03726619|BEHAVIORAL|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
214692755|NCT01194804|DRUG|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
214692756|NCT02883777|BEHAVIORAL|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
214692757|NCT02883777|BEHAVIORAL|Conventional Diet|Conventional diet over 1 year after transplantation.
214692758|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
214692759|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
214692760|NCT05057546|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
214692761|NCT05304910|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
215116920|NCT05229393|OTHER|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
214438904|NCT04659408|DIETARY_SUPPLEMENT|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
215116921|NCT05229393|OTHER|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
215116922|NCT05229393|OTHER|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
215116923|NCT01803425|OTHER|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
215116924|NCT05941416|DIAGNOSTIC_TEST|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
215116925|NCT01436578|DRUG|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
215116926|NCT01606709|DRUG|GnRH agonist|GnRH agonist 1mg one dose
215116927|NCT01606709|DRUG|hCG|5,000 IU one dose
215116928|NCT02857673|BEHAVIORAL|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
215116929|NCT02857673|BEHAVIORAL|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
214438905|NCT04659408|DIETARY_SUPPLEMENT|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
214438906|NCT06819280|BIOLOGICAL|GT307 injection|GT307 injection to treat Advanced Colorectal Cancer
214438907|NCT04714320|DRUG|Placebo|ISIS 757456 matching placebo administered by SC injection.
214438908|NCT04714320|DRUG|IONIS-AGT-LRx|IONIS-AGT-LRx administered by SC injection.
214438909|NCT05057897|BIOLOGICAL|AZD1222|10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
214438910|NCT06197165|OTHER|Targeted Shiatsu|"demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu"
214438911|NCT04120766|DRUG|Nicorandil|20 mg po qd
214438912|NCT04120766|DRUG|Placebo|Matching tablet
214438913|NCT06791343|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.
214438914|NCT06484478|OTHER|Wearable technology monitoring|Observational study (no intervention delivered)
214438915|NCT06464172|OTHER|Acute Oral gamma-aminobutyric acid (Natural Health Product in Canada)|1800 mg (3 capsules of 600mg) of GABA taken at the research center under the supervision of the research team.
214438916|NCT06464172|OTHER|Acute Placebo|A capsule filled with powdered sugar taken under the supervision of the research team.
214438917|NCT06785220|OTHER|ORAL FACIAL FACILITATION|"A group will receive oral facial facilitation which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)"
214438918|NCT06785220|OTHER|ORAL MOTOR THERAPY|"B group will receive oral motor therapy which included exercise for given,~1. A volcano bubbles~2. Party blower target~3. Bubble blowing~4. Curly straws"
214438919|NCT06785220|OTHER|ORAL FACIAL FACILITATION WITH ORAL MOROR THERAY|"C group will receive oral facial facilitation and oral motor therapy which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)~5. A volcano bubbles~6. Party blower target~7. Bubble blowing~8. Curly straws"
214438920|NCT03346538|DRUG|Continuous infusion high-dose MCI-186|intravenous injection
215116930|NCT00397384|DRUG|cetuximab|Given IV
214692762|NCT05304910|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
215116931|NCT00397384|DRUG|erlotinib hydrochloride|Given PO
215116932|NCT00397384|OTHER|laboratory biomarker analysis|Correlative studies
215116933|NCT01708512|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
215116934|NCT04360746|OTHER|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
215116935|NCT04360746|OTHER|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
215116936|NCT04515212|OTHER|Optic Nerve Ultrasounds|Patients will have up to four ultrasounds of the optic nerve.
215116937|NCT04295525|DIETARY_SUPPLEMENT|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
215116938|NCT04295525|DIETARY_SUPPLEMENT|placebo mucoadhesive oral tablet|placebo
215116939|NCT02722954|DRUG|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
215116940|NCT02722954|DRUG|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
214438921|NCT03346538|DRUG|Continuous infusion low-dose MCI-186|intravenous injection
214438922|NCT03346538|DRUG|Continuous infusion placebo|intravenous injection
214438923|NCT03346538|DRUG|Approved dosing regimen MCI-186|intravenous injection
214438924|NCT03346538|DRUG|Approved dosing regimen placebo|intravenous injection
214438925|NCT04930432|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
214438926|NCT06783608|BEHAVIORAL|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). Patients were asked to measure and record their blood glucose value before breakfast. The yoga session was started 30 minutes after breakfast, and after the session was completed, they were asked to measure and record their blood glucose value again at 120 minutes after breakfast.
215116941|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
215116942|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
215116943|NCT04915443|DEVICE|Periotome|"Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth."
214438927|NCT04533503|DEVICE|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
214438928|NCT06398340|OTHER|High Calorie Meal Intervention|Subjects will receive a unhealthy meal high in calorie, sugar and fat
214438929|NCT06398340|OTHER|Low Calorie Meal Intervention|Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre
214438930|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438931|NCT05062889|DRUG|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438932|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438933|NCT05062889|DRUG|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438934|NCT05062889|DRUG|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
214438935|NCT05062889|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438936|NCT05062889|DRUG|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
214692763|NCT00262418|DRUG|Administration of ivermectin or permethrin|
214438937|NCT05062889|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
214438938|NCT05062889|DRUG|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
214438939|NCT05062889|DRUG|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
214517534|NCT04362722|DRUG|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
214517535|NCT03185858|BEHAVIORAL|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
214517536|NCT03117842|OTHER|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
214517537|NCT05843149|BEHAVIORAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
214517538|NCT05843149|BEHAVIORAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
214517539|NCT02920216|DRUG|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
214517540|NCT03439800|OTHER|Mental and Physical Practice|"1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait."
214517541|NCT03439800|OTHER|Physical Practice|"1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
214438940|NCT05062889|DRUG|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
214438941|NCT04358276|OTHER|Computer-Assisted Intervention|Complete online course
214438942|NCT04358276|DEVICE|Dermatoscope|Receive dermatoscope
214438943|NCT04358276|OTHER|Educational Intervention|Receive study packet
214438944|NCT04358276|OTHER|Educational Intervention (Physician)|Receive physician directed letter and educational package
214438945|NCT04358276|OTHER|Questionnaire Administration|Ancillary studies
214438946|NCT04358276|OTHER|Text Message|Receive text messages
214438947|NCT06789289|DRUG|TQC2938 injection|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
214438948|NCT06789289|DRUG|TQC2938 injection Placebo|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
214438949|NCT06782880|PROCEDURE|Fecal microbiota transplantation (FMT)|To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
214438950|NCT02865226|OTHER|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
214438951|NCT02865226|OTHER|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
214438952|NCT05986526|PROCEDURE|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
214438953|NCT05986526|PROCEDURE|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
214438954|NCT06828757|DRUG|nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy|Oral suspension of nanocrystalline megestrol is taken orally once a day until disease progression or 12 weeks (maximum duration of 12 weeks) PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
214438955|NCT06828757|DRUG|PD-1/L1 inhibitor combined with chemotherapy|PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
214438956|NCT05672667|DRUG|intravenous oxytocin|Oxytocin given by intravenous route
214438957|NCT05672667|DRUG|intranasal oxytocin|Oxytocin given by intranasal administration
214438958|NCT06816069|DEVICE|VOLNEWMER|Monopolar radiofrequency device
214438959|NCT03286868|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
214438960|NCT03286868|DEVICE|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
214438961|NCT05377840|BEHAVIORAL|Psychologist-administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For psychologist-administered CBT: Participants will have individual weekly sessions (virtually) lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
214438962|NCT05377840|BEHAVIORAL|Self-Administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For self-administered CBT: Participants will be given a book written for patients on CBT for IBD with instructions on how to self-administer CBT.
214438963|NCT06788522|DRUG|Suvorexant|Suvorexant pills (10-20 mg)
214438964|NCT06788522|DRUG|Placebo|Matching placebo pills
214438965|NCT04157322|DIAGNOSTIC_TEST|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
215116944|NCT04915443|DEVICE|Piezotome|"Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL."
215116945|NCT04052308|BEHAVIORAL|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
215116946|NCT04052308|BEHAVIORAL|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
214438966|NCT06828744|OTHER|Exercise|Participants in this group will follow an exercise and stretching program for five weeks, performed three times per week.
214438967|NCT06828744|OTHER|Exercise plus Joint Mobilization|Participants in this group will follow a five-week exercise and stretching program, performed three times per week, in combination with an ankle joint mobilization program.
215116947|NCT04052308|BEHAVIORAL|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
215116948|NCT04052308|BEHAVIORAL|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
215116949|NCT04052308|BEHAVIORAL|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
215116950|NCT04052308|BEHAVIORAL|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
215116951|NCT02348125|DRUG|Mitochondrial Cocktail|
215116952|NCT04811066|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period."
215116953|NCT00977171|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
215116954|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
215116955|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
215116956|NCT04766463|DRUG|Placebo|Saline Solution
215116957|NCT04766463|DRUG|Morphine|Morphine
214438968|NCT03789747|OTHER|As a observational study, there is no intervention.|As a observational study, there is no intervention.
214438969|NCT06726772|BEHAVIORAL|Group Psychotherapy|Group psychotherapy based on Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) elements
214438970|NCT06784635|BEHAVIORAL|In person|Participant dyads will meet in person for a mock clinical interview, seated at a desk opposite their counterpart. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
214438971|NCT06784635|BEHAVIORAL|Online interaction|Participant dyads will meet online in a mock clinical interview, via an encrypted video call, seated at a desk. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
214438972|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
214438973|NCT06788041|OTHER|Hamman experience|There will be a circuit in the Hammam Al Andalus baths with baths in all pools (warm, hot or cold water) and sauna for 30 minutes. The time in each pool will be determined by the sensation and tolerance of each participant. In addition, participants will receive foam with aromatic oils on the participant's body (arms, trunk and legs). This foam will be left for about 10 minutes on the participant's body, while a manual body therapy is performed. The force to be applied will be very weak, a superficial rubbing will be performed to prepare the tissue, followed by a maintained pressure and then sliding pressures are performed. The application time should not exceed 15 minutes.
214438974|NCT06788041|OTHER|Massage|Duration of 45 minutes. A complete dorsal and ventral body massage will be performed, with superficial maneuvers at a slow pace of traditional massage.
214438975|NCT06788041|OTHER|Placebo Comparator|The person will be instructed to stay for 45 minutes during which he/she will receive different electrotherapy techniques with the devices disconnected, a mobile device that simulates a beep will be placed so that the patient believes that the device is connected.
214438976|NCT06792318|DIAGNOSTIC_TEST|FAPI PET-CT|"FAPI PET-CT imaging protocol:~Single dose 68Ga/18F-FAPI (2 MBq/kg)~Two imaging sessions:~First: 10 and 30 minutes post-injection Second: 60 and 80 minutes post-injection Ultra-low dose CT for attenuation correction and anatomical localization"
214517542|NCT05745259|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
214517543|NCT05745259|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
215116958|NCT00797277|DRUG|IM olanzapine|10mg olanzapine IM
215116959|NCT00797277|DRUG|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
215116960|NCT02911870|DRUG|SNAC|Oral administration
215116961|NCT02911870|DRUG|Placebo|Oral administration
215116962|NCT02911870|DRUG|Moxifloxacin|Oral administration
215116963|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (10 mg QD) for 17 weeks
215116964|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg QD\] + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (30 mg QD) for 17 weeks
215116965|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
215116966|NCT05221502|DRUG|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
215116967|NCT01157247|PROCEDURE|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
215116968|NCT03697642|PROCEDURE|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
215116969|NCT03697642|PROCEDURE|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
215116970|NCT04494906|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
215116971|NCT04494906|OTHER|Square stepping exercise|Square stepping exercise
215116972|NCT04110782|OTHER|Radium223|55 kBq/ Kg
215116973|NCT01388907|OTHER|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
215116974|NCT01388907|DEVICE|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
215116975|NCT05650021|DEVICE|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
215116976|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
215116977|NCT05904795|OTHER|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
215116978|NCT05904795|OTHER|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
215116979|NCT02502045|DEVICE|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
215116980|NCT02502045|DEVICE|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
215116981|NCT03263624|DEVICE|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
215116982|NCT03263624|DRUG|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
215116983|NCT03187132|DEVICE|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
215116984|NCT03187132|DEVICE|Active Control|An active control TENS unit used to reduce acute localized pain.
215116985|NCT03594773|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
215116986|NCT03594773|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
215116987|NCT00918177|DRUG|AP09004|
215116988|NCT00918177|DRUG|Carbidopa/Levodopa, immediate release|
215116989|NCT03618420|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
215116990|NCT03618420|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
215116991|NCT01243723|DRUG|Eductyl suppository|One suppository every morning during 21 days
215116992|NCT01243723|DRUG|Placebo suppository|One suppository every morning during 21 days
215116993|NCT04640649|OTHER|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
215116994|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
215116995|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
215116996|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
214438977|NCT06785649|OTHER|Lavender herbal tea|The participant will be allocated 14 pieces of lavender tea bags consisting of 2 grams and originating from Turkey. During 14 days, the participant will be advised to use 2 g of lavender herb brewed in 300 mL hot water for 10-15 minutes in the morning and evening. Participants will be able to use 1 lavender tea bag twice a day.
214517544|NCT00003376|DRUG|carboplatin|
214517545|NCT00003376|DRUG|cisplatin|
214517546|NCT00003376|DRUG|doxorubicin hydrochloride|
214517547|NCT00003376|DRUG|methotrexate|
214438978|NCT06784206|DRUG|Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy|"Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death"
214438979|NCT06785142|DIETARY_SUPPLEMENT|Functional Shot|60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins
214438980|NCT06785142|DIETARY_SUPPLEMENT|Placebo Shot|Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients
214438981|NCT06792370|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (for children with MAM)|Each child with MAM will be supplemented with RUTF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks.
214438982|NCT06792370|DIETARY_SUPPLEMENT|Ready-to-use supplementary food|Each child with MAM will be supplemented with RUSF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery
214438983|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 1|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
214438984|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Standard dose|Each child with SAM will be treated with a standard dose (according to the national protocol for the integrated management of acute malnutrition in Burkina Faso) for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery.
214438985|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 2|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until the child is no longer severely malnourished and does not have nutritional oedema then 100-130 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
214438986|NCT06397963|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
214438987|NCT06833658|OTHER|Experimental: Aromatherapy with essential oil intervention|Aromatherapy, customized to meet the psychological needs of pancreatic cancer patients, was employed as part of the intervention. A senior aromatherapist developed the protocol, selecting pleasant essential oils diluted at a ratio of 1-2 drops in 70ml of water. The aromatherapy was administered twice daily for one hour each session using an aromatherapy diffuser.During aromatherapy, nurses should inspect patients every 30 minutes to ensure comfort, and take immediate action if discomfort is reported.
214438988|NCT06833658|OTHER|Control Group 0.9% Isotonic Saline|1\. Pre - operation: Present pancreatic cancer knowledge, such as causes, common symptoms, treatment methods, and the need for surgery. Answer patients' queries promptly to reduce their fear of the disease and surgery. 2. Post - operation: Report the surgical outcome, explain common post - op complications and solutions to relieve negative emotions. 3. Post - operation: Intensify post - op education on drainage tube care, activity guidelines, disease knowledge, and diet advice. Strengthen mental health education, encourage family members to show more concern for patients, and enhance family support. 4. Pre - discharge: Provide discharge instructions to patients and their families. Guide patients who need tube removal and suture removal after discharge to make online appointments for outpatient follow - up.
214438989|NCT05804708|DRUG|GH001|GH001 is administered via inhalation
214517548|NCT00003376|DRUG|paclitaxel|
214517549|NCT00003376|DRUG|vinblastine|
215116997|NCT03315572|OTHER|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
215116998|NCT03315572|OTHER|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
215116999|NCT03315572|OTHER|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
215117000|NCT05195658|DEVICE|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
214517550|NCT00476151|DRUG|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
214517551|NCT00476151|DRUG|placebo cream|inactive placebo cream applied two times daily
214517552|NCT05028322|DRUG|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
214517553|NCT05028322|BIOLOGICAL|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
214692764|NCT00355212|PROCEDURE|percutaneous ablation of hepatocellular carcinoma|
214692765|NCT01919918|DRUG|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
214517554|NCT02962609|OTHER|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
214517555|NCT02962609|OTHER|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
214438990|NCT06829355|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Thymalfasin: 4.8 mg, administered subcutaneously twice weekly.
214438991|NCT06829355|DRUG|Regorafenib (BAY 73-4506)|Regorafenib: Start at 80 mg once daily, orally, taken at a fixed time for 2 consecutive weeks and then stopped for 1 week. If the patient tolerates it well, increase to 120 mg/d in Cycle 2.
214438992|NCT06829355|DRUG|Tislelizumab (BGB-A317)|Tislelizumab: 200 mg, iv.gtt, single infusion, 21 days as a cycle, Day 1.
214438993|NCT06788678|BEHAVIORAL|MOVED|MOVED includes 8 self-guided, web-based sessions administered over 4 weeks. Web-based sessions include 3 core components: (1) elicit moral elevation, (2) engage in reflection about moral elevation response, and (3) set a behavioral goal that is inspired by the moral elevation exercise.
214438994|NCT06788678|OTHER|Supportive Care Control|A present-centered, nondirective intervention that aims to control for the nonspecific therapeutic effects of supportive care. In this case, the effects of engaging in regular web-based sessions that convey information about PTSD symptoms. Sessions will include psychoeducation materials about PTSD symptoms, functioning, and resources for dealing with related stressors. Key components of MOVED will be strictly excluded.
214517556|NCT02792296|OTHER|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
214517557|NCT00893477|BIOLOGICAL|rituximab|
214517558|NCT00893477|BIOLOGICAL|sargramostim|
214517559|NCT00893477|GENETIC|gene expression analysis|
214517560|NCT00893477|GENETIC|gene rearrangement analysis|
214517561|NCT00893477|GENETIC|polymerase chain reaction|
214517562|NCT00893477|GENETIC|polymorphism analysis|
215117001|NCT03423316|BEHAVIORAL|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
214517563|NCT00893477|OTHER|laboratory biomarker analysis|
215117002|NCT03349788|PROCEDURE|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
215117003|NCT03349788|PROCEDURE|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
215117004|NCT02167516|DRUG|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
215117005|NCT02167516|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
215117006|NCT04585282|BEHAVIORAL|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
215117007|NCT04585282|BEHAVIORAL|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
215117008|NCT04389723|DIETARY_SUPPLEMENT|Qualia Mind|Multi-ingredient Dietary supplement
215117009|NCT04389723|DIETARY_SUPPLEMENT|Placebo|Multi-ingredient Placebo
214438995|NCT06788171|RADIATION|Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy|PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.
214438996|NCT06788171|DRUG|Bevacizumab|Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.
215117010|NCT01574235|BIOLOGICAL|Nivestim®|
215117011|NCT01598467|PROCEDURE|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
214438997|NCT06788171|DRUG|Capecitabine|Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
214438998|NCT06788171|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
214438999|NCT06788171|DRUG|Sintilimab|Sintilimab: 200mg, d1, q3w, 6 cycles.
214517564|NCT04650919|PROCEDURE|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
214439000|NCT06834412|DIAGNOSTIC_TEST|68Ga-Pentixafor and 18F-FDG PET/CT Scan|The imaging agent 68Ga-Pentixafor and 18F-FDG used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is about 4; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
215117012|NCT02481739|OTHER|retrospective study|
215117013|NCT00991939|DRUG|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
215117014|NCT00991939|DRUG|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
215117015|NCT01699165|DEVICE|Nasal filter|Active nasal filter
215117016|NCT01699165|DEVICE|Placebo nasal filter|Placebo nasal filter
215117017|NCT01631994|DRUG|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
215117018|NCT03211975|OTHER|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
215117019|NCT04666896|OTHER|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
215117020|NCT04666896|OTHER|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
215117021|NCT04185675|DEVICE|The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.|All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
215117022|NCT00714415|DRUG|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
215117023|NCT02278861|DRUG|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
215117024|NCT02278861|DRUG|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
215117025|NCT02278861|DRUG|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
215117026|NCT06153368|DRUG|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
214439001|NCT06834048|OTHER|observation alone|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
214439002|NCT06791928|BEHAVIORAL|Peer distribution of self testking kits|Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
214439003|NCT05306041|DRUG|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
214439004|NCT05306041|DRUG|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
214439005|NCT05306041|DRUG|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
214439006|NCT06831617|OTHER|AI-based low dose CBCT reconstructed images system|Participants in the experimental group undergo AI-based low dose (radiation dose is 1/6th of the dose used in the clinic) CBCT reconstructed images guided lung puncture procedures.
214439007|NCT06831617|OTHER|Conventional CBCT images system|Participants in the experimental group undergo conventional CBCT images guided lung puncture procedures.
214439008|NCT06791005|DRUG|Preoperative Injection of Carbon Nanoparticles|1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
214439009|NCT06791005|DRUG|Intraoperative Injection of Carbon Nanoparticles|Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
214439010|NCT06790277|DEVICE|Mepilex Border Sacrum dressings|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
214439011|NCT06790277|DEVICE|Polyurethane foams (Pink Pad)|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
214439012|NCT02984124|BEHAVIORAL|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
214439013|NCT02984124|BEHAVIORAL|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
214439014|NCT06783803|DIAGNOSTIC_TEST|Linkage Analysis|WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies
214439015|NCT04524390|DRUG|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
214439016|NCT04524390|OTHER|Placebo|Identical to maralixibat except for the active drug substance
215117027|NCT00307905|DRUG|Traumeel S|homeopathic remedy
215117028|NCT00307905|DRUG|Placebo remedy|identical size, shape and taste of treatment medication
215117029|NCT00123318|DRUG|epirubicin|50mg/m2 IV day 1
215117030|NCT00123318|DRUG|cisplatin|60mg/m2 IV day 1
215117031|NCT00123318|DRUG|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
214439017|NCT05666362|DRUG|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
214439018|NCT05666362|DRUG|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
214439019|NCT05840003|RADIATION|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
214439020|NCT05412615|PROCEDURE|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
214439021|NCT05412615|PROCEDURE|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
214439022|NCT06360640|DRUG|APC148 and Placebo|IV infusion
214439023|NCT05820789|OTHER|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
214439024|NCT05921032|OTHER|Exercise intervention|8 weeks of exercise with two session in a week
214439025|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
214439026|NCT06085274|PROCEDURE|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
214439027|NCT02949284|DRUG|Abiraterone Acetate|Given PO
214439028|NCT02949284|DRUG|Androgen Receptor Antagonist ARN-509|Given PO
214439029|NCT02949284|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC
214439030|NCT02949284|DRUG|Prednisone|Given PO
214439031|NCT02949284|OTHER|Quality-of-Life Assessment|Ancillary studies
214439032|NCT02949284|OTHER|Questionnaire Administration|Ancillary studies
214439033|NCT02949284|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
215117032|NCT00123318|RADIATION|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
215117033|NCT00724672|DRUG|etanercept|etanercept 50 mg subcutaneously once weekly
215117034|NCT00724672|DRUG|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
215117035|NCT00724672|DRUG|adalimumab|adalimumab 40 mg subcutaneously biweekly
214439034|NCT05587361|DRUG|Propranolol|Propranolol Capsule; 40 mg IR
214439035|NCT05587361|DRUG|Nicotine Patch|Nicotine Patch; 14 mg
214439036|NCT05587361|DRUG|Placebo Propranolol|Placebo Capsule, no active ingredients
214517565|NCT04205045|DIAGNOSTIC_TEST|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
214439037|NCT05587361|DRUG|Placebo Patch|Placebo Patch, no active ingredients
214439038|NCT05928169|DRUG|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
214439039|NCT02839070|OTHER|Sleep/Wake Schedule|Timing of sleep and wake
214439040|NCT05398250|BEHAVIORAL|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
214439041|NCT05398250|BEHAVIORAL|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation"
214439042|NCT02274805|PROCEDURE|Adults presenting for surgery in the neck area|
214439043|NCT01630850|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
214517566|NCT04205045|OTHER|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
214517567|NCT04205045|OTHER|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
214517568|NCT01025921|DRUG|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
214517569|NCT01025921|OTHER|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
214439044|NCT01630850|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
214439045|NCT01582893|DEVICE|HCO1100|Dialysis
214439046|NCT01582893|DEVICE|P210H|Dialysis
214439047|NCT03004664|BEHAVIORAL|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
214439048|NCT03004664|BEHAVIORAL|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
214517570|NCT01498354|PROCEDURE|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
214517571|NCT01498354|PROCEDURE|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
214517572|NCT03258905|BEHAVIORAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
214517573|NCT03258905|BEHAVIORAL|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
214517574|NCT01476137|DRUG|GSK1120212|MEK inhibitor
214517575|NCT01476137|DRUG|GSK2110183|AKT inhibitor
215117036|NCT03769038|DEVICE|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
214439049|NCT04328038|OTHER|Survey|Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
214439050|NCT06306755|PROCEDURE|Risk Assessment and Individualized Surveillance|"1. An epidemiological questionnaire-based risk assessment for UGIC conducted prior to the endoscopic examination;~2. Individuals identified as high-risk receive the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Individualized reexamination and surveillance strategy will be given to participants diagnosed with premalignant lesions, based on evaluation of risk progression using endoscopic characteristics, pathological diagnosis, and biomarkers."
214439051|NCT06306755|PROCEDURE|Universal screening|"1. A questionnaire investigation;~2. All participants undergo the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment."
214439052|NCT05568082|DRUG|AMG 510|Oral tablet
214439053|NCT05568082|DRUG|Itraconazole|Oral capsule
214439054|NCT05930782|DRUG|Piperaquine Tetraphosphate uncoated tablets|Piperaquine tetraphosphate hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
214439055|NCT05930782|DRUG|Piperaquine Tetraphosphate dispersible granules|Piperaquine tetraphosphate dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
214439056|NCT06170307|OTHER|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
214439057|NCT05534165|DRUG|Tecovirimat|600 mg po BID
214439058|NCT05534165|DRUG|Placebo|identical placebo 600 mg po BID
214439059|NCT03791112|DRUG|BPI-16350|BPI-16350 capsules administered orally
214439060|NCT03344276|DIAGNOSTIC_TEST|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
214439061|NCT03344276|DIAGNOSTIC_TEST|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
214439062|NCT03344276|PROCEDURE|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
214439063|NCT05600088|DEVICE|CryoTherapy System (CTS)|local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
214439064|NCT06267768|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
214439065|NCT06216509|DEVICE|Endoscopic ultrasound pressure measurement|all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
214439066|NCT06803966|OTHER|Post Operative Analgesia|"Group A will receive local wound infiltration at port sites with inj bupivacaine (bupivacaine Hydrochloride) 0.5 %~Group B will receive Transversus Abdominal Plane Block on both sides by inj bupivacaine (bupivacaine Hydrochloride) 0.25%"
214439067|NCT06802666|RADIATION|short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with AK112 regimen for 6 cycles.
214439068|NCT06802666|DRUG|Ivonescimab|AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W)
214439069|NCT06802666|DRUG|capecitabine|1000mg/m2, bid, po, d1-14,q3w
214439070|NCT06802666|DRUG|oxaliplatin|130mg/m2, ivgtt, d1,q3w
214439071|NCT06802666|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
214439072|NCT06750341|DRUG|QLC7401|QLC7401 combined with lipid-lowering agents
214439073|NCT06750341|DRUG|Placebo|Placebo combined with lipid-lowering agents
214439074|NCT06788548|PROCEDURE|combined endoscopic-laparoscopic sentinel lymph node navigation surgery|"1. Determination of tumor location and sentinel lymph node: endoscopic staining (2mg indocyanine green, four-quadrant submucosal injection) was used to determine the location of the lesion during laparoscopic surgery combined with endoscopic localization to ensure effective and safe resection margins. The staining technique was used to identify the sentinel lymph nodes basin, and en bloc resection of the lymph node basin biopsy was performed.~2. Standard of lymph node basin dissection: All sentinel nodes are located within the lymphatic basin, which is considered the primary lymphatic drainage area for each patient. Follow the SENORITA trail criteria\[9\], lymphatic basin is delineated by the distribution of dye within the lymphatic channels, as seen in dye mapping. The proximal extent of the lymphatic basin is demarcated by the fatty tissue adjacent to the stomach wall, while the distal boundary is marked by the most distant stained node from the stomach."
214439075|NCT06788548|PROCEDURE|Laparoscopic D2 radical gastrectomy|Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
214439076|NCT06477042|OTHER|Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score|Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
214439077|NCT05871892|DIAGNOSTIC_TEST|18F-FDGal PET/CT or PET/MRI|All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
214439078|NCT04540913|DEVICE|RHA 3|Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.
214439079|NCT04540913|DEVICE|Restylane-L|Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
214517576|NCT04544514|DIAGNOSTIC_TEST|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
214517577|NCT03980171|DRUG|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
214517578|NCT03980171|DRUG|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
215117037|NCT06236685|DEVICE|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
215117038|NCT02766634|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
214439080|NCT05809271|DRUG|MDMA 120 mg + MDMA 60 mg|An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
214439081|NCT05809271|DRUG|MDMA 120 mg + placebo|An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.
214517579|NCT03980171|DRUG|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
214517580|NCT01157442|BEHAVIORAL|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
214517581|NCT00739388|DRUG|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
214692766|NCT00948818|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
214692767|NCT00948818|DRUG|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
214694192|NCT02253706|DEVICE|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
215117039|NCT02766634|BIOLOGICAL|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
215117040|NCT03165422|OTHER|Non-Interventional|Non-Interventional
215117041|NCT02694302|DEVICE|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
215117042|NCT02694302|DEVICE|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
215117043|NCT03315039|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
215117044|NCT01460758|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
215117045|NCT01460758|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
215117046|NCT01460758|DEVICE|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
215117047|NCT00612755|DRUG|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
215117048|NCT03029910|OTHER|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
214439082|NCT05809271|DRUG|Placebo|An oral placebo will be administered followed by a placebo two hours later.
214439083|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
214439084|NCT06478121|OTHER|Data and Blood collection|Data and Blood collection
214439085|NCT06478121|OTHER|MRI|MRI (optional)
214439086|NCT06699901|OTHER|Massive Transfusion Group|This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
214439087|NCT06699901|OTHER|Control Group|This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
214439088|NCT06821230|BEHAVIORAL|Dyadic mindfulness|The dyadic mindfulness intervention group will receive 8 weekly 90-min sessions, with a total of 12 contact hours. The intervention will be delivered in a small group format with 6-8 dyads each and led by a certified yoga instructor with mindfulness qualifications. The program content mindfulness meditation, mindful breathing, and yoga sequences with warm-up and cool-down and each component is modified to pair-based practices.
214439089|NCT06820944|OTHER|dark chocolate|Consumption of 100 g/day of 72% dark chocolate bar for 14 days consecutively
214439090|NCT06820944|OTHER|white chocolate|Consumption of 80 g/day of white chocolate bar for 14 days consecutively
214439091|NCT05607030|COMBINATION_PRODUCT|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.
214439092|NCT05607030|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
214439093|NCT05607030|DRUG|SOC Antibiotics|Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
214439094|NCT05607030|DRUG|Experimental Antibiotics|After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
214439095|NCT06755099|DRUG|Botox|"The patient will be placed in gynecological position. Subsequently, the patient will be anesthetized with propofol bolus, a total of 270 mg IV sterilization of valval area with antiseptic solution then digital examination to assess the spasm of intriotus and vaginal walls under lowest possible doses then increasing the doses to allow for intra vaginal injection of Botox under full sedation. Pacik technique will be adopted for Botox Injection in the vagina .~. One vial of frozen Botox 100 U will be diluted with 2 mL saline, without foaming or shaking the vial, giving a concentration of 2.5 U/0.05 mL . Using a small sized speculum and after bending the needle to 30° to facilitate injection into sub mucosal area,1 mL (50 U) of Botox will be injected into the right bulbocavernosus then into the left side ."
214439096|NCT06755099|DEVICE|Radiofrequency|"Patients will be placed in prone position. After proper disinfection, the ischial spine (IS) and insertion point of the sacrospinous ligament will be identified using fluoroscopy medial to IS. 5 ml Lidocaine 2 % will be used to apply local anesthesia to the skin at the expected entry point for the radiofrequency cannula. Then a 20 G, 10 cm long and 1 cm active tip radiofrequency cannula will be introduced gradually utilizing 2 Hz motor stimulation until pudendal nerve is identified visually by the occurrence of contraction of the external anal sphincter muscle.~Subsequently, pulsed radiofrequency lesioning at temperature limit of 42 C will be applied bilaterally to the pudendal nerves for 240 s (2 cycles of 120 s) after applying local anesthesia using 2 cm 2% lidocaine in its vicinity."
214439097|NCT06364358|BEHAVIORAL|Computerized CKD Education|The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.
214439098|NCT06364358|BEHAVIORAL|Usual Hospital Care|Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
214439099|NCT02204085|DRUG|GO-203-2c|
214439100|NCT02204085|DRUG|GO-203-2c + Decitabine|
214439101|NCT06040892|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
214517582|NCT03896971|DRUG|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
214517583|NCT04549948|PROCEDURE|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
214517584|NCT04549948|PROCEDURE|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
214517585|NCT04549948|PROCEDURE|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
215117049|NCT03029910|OTHER|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
215117050|NCT02258646|BEHAVIORAL|Exercise training at home|
214517586|NCT02558322|OTHER|Primary medical care|All study participants receive primary care as usual in the respective region
214517587|NCT06023771|PROCEDURE|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
214517588|NCT04282200|DRUG|Ketorolac|intravenous ketorolac 30 mg every 6 hours
214517589|NCT02497547|DRUG|Oxytocin|
215117051|NCT02258646|BEHAVIORAL|Telemonitoring and education/self-management|
214517590|NCT02497547|DRUG|Placebo|
214517591|NCT01828476|DRUG|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
214517592|NCT01828476|DRUG|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
214517593|NCT01828476|DRUG|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
214694193|NCT02253706|DEVICE|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
214694194|NCT02915406|DEVICE|CliniMACs|
214439102|NCT06040892|DIAGNOSTIC_TEST|FRASIMAT Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
214439103|NCT06040892|DIAGNOSTIC_TEST|Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
214439104|NCT06040892|OTHER|spatial hearing rehabilitation program|The tool makes it possible to propose rehabilitation programs adapted to the performance and expectations of each child. This program will manipulate both the ambient sound with varying background noise to simulate daily life environments (i.e. making auditory detection more or less complex), and also manipulate virtual immersive environment (i.e. giving more or less relevant visual cues related to real sound location).
214439105|NCT05444335|DEVICE|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
214439106|NCT04794608|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
214439107|NCT03438188|OTHER|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
214439108|NCT02476864|DRUG|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
214439109|NCT02476864|DRUG|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
214439110|NCT02705287|OTHER|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
214439111|NCT02705287|OTHER|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
214439112|NCT06241703|PROCEDURE|ICCAUT|For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
214439113|NCT06241703|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
214439114|NCT06391931|DRUG|Cipepofol|0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
214517594|NCT04332991|DRUG|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
215117052|NCT05766176|DIAGNOSTIC_TEST|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
214517595|NCT04332991|DRUG|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
215117053|NCT03236077|BEHAVIORAL|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
215117054|NCT05467384|DRUG|Amlodipine|5mg/day in two divided doses
215117055|NCT04233203|DRUG|Insulin Faster Aspart|Currently receiving Faster Aspart during 3 or more months.
215117056|NCT04233203|DEVICE|Insulin pump|Currently receiving CSII therapy during 6 or more months.
214439115|NCT06391931|DRUG|Propofol|3.0 mg/kg induce + 5.0 mg/kg/h maintain
214439116|NCT01141309|DRUG|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
214439117|NCT03578198|DRUG|Rituximab + MG4101|"1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)"
214439118|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
214439119|NCT06798961|PROCEDURE|Ablation|Patient treated with an ablation to eliminate the accessory conduction pathway in the heart.
214439120|NCT06798961|PROCEDURE|Standard of care without ablation|Patient diagnosed with accessory pathway but elected against cardiac ablation as a treatment option at the time of diagnosis.
214517596|NCT01684345|DRUG|Placebo|Solution for subcutaneous injection
214439121|NCT06295289|DEVICE|Hybrid Closed-loop Insulin Delivery System|The Hybrid Closed-loop Insulin Delivery System system consisted of a Medtronic pump, a continuous glucose monitoring system（SIBIONICS®）and an open-source algorithm integrated into the phone. Insulin pump therapy group consisted of a Medtronic pump, and a continuous glucose monitoring system（SIBIONICS®). The difference between the two groups is that the artificial pancreas system automatically regulates the basal rate to maintain blood glucose in a target range.
214439122|NCT06295289|DEVICE|Insulin pump|Participants used conventional insulin pumps to control blood glucose, At the same time, a continuous glucose monitoring system was used to monitor glucose changes. Health care providers adjust the insulin dose of patients according to their blood glucose level.
214517597|NCT01684345|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
214517598|NCT01684345|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
214517599|NCT04043663|DEVICE|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
214517600|NCT04043663|PROCEDURE|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
214517601|NCT02067000|BEHAVIORAL|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
214517602|NCT03382535|BEHAVIORAL|Voice therapy|Voice therapy with direct and indirect therapy elements.
214517603|NCT03382535|BEHAVIORAL|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
214517604|NCT03382535|OTHER|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
214517605|NCT02005484|DRUG|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
214517606|NCT01129011|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
214517607|NCT01129011|DRUG|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
214517608|NCT02416973|DEVICE|Provant|
214517609|NCT01767376|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
214517610|NCT01767376|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
214517611|NCT05990088|DEVICE|Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept|The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate
214517612|NCT05990088|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
215117057|NCT04789876|OTHER|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
215117058|NCT04789876|BEHAVIORAL|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
215117059|NCT01594229|DRUG|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
215117060|NCT01594229|DRUG|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
214439123|NCT04053842|DIAGNOSTIC_TEST|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.
214517613|NCT03600506|DRUG|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
214517614|NCT03600506|DRUG|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
214517615|NCT03214055|DRUG|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
214517616|NCT01545271|DRUG|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
214517617|NCT01545271|DEVICE|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
214517618|NCT04673305|OTHER|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
214517619|NCT00358722|DRUG|Fermagate|Film coated tablet 500mg
214517620|NCT02395588|OTHER|Guideline based care|Patient education using guideline based teaching guides
214517621|NCT01113541|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
214517622|NCT03745651|DRUG|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
214517623|NCT03745651|DRUG|Vehicle cream|Ruxolitinib matching vehicle cream.
214694195|NCT02954003|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
215117061|NCT01594229|DRUG|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
215117062|NCT05060770|GENETIC|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
214439124|NCT04053842|DRUG|[18F]PSMA-1007 Injection|\[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
214439125|NCT04053842|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
214439126|NCT04053842|DIAGNOSTIC_TEST|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
215117063|NCT03093337|OTHER|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
214439127|NCT06796374|DIETARY_SUPPLEMENT|Fisetin|"A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
215117064|NCT02068625|DRUG|Rasagiline|Rasagiline 1mg daily orally for 7 days
214439128|NCT06796374|DIETARY_SUPPLEMENT|Fisetin + Quercetin|"A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
215117065|NCT02068625|DRUG|Placebo|Oral treatment with placebo for 7 days
215117066|NCT04472234|OTHER|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
215117067|NCT01461707|BEHAVIORAL|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
215117068|NCT01461707|BEHAVIORAL|Activity monitor|Participants will receive an activity monitor
215117069|NCT00075621|DRUG|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
215117070|NCT00075621|DRUG|melphalan|200 mg/kg over 2 days
215117071|NCT00075621|PROCEDURE|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
215117072|NCT00672919|DRUG|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
215117073|NCT00535002|DRUG|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
215117074|NCT00535002|DRUG|Placebo|
215117075|NCT04668768|DRUG|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
214439129|NCT05993416|DRUG|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (\>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing \< 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
214439130|NCT06841016|OTHER|Virtual Nephrologist|Quality improvement (QI) pilot of an interactive, conversational virtual healthcare agent to educate and engage patients with advanced CKD about transplantation
214439131|NCT03215069|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
214439132|NCT03215069|DRUG|Placebo oral capsule|Placebo PO daily
214439133|NCT06793553|DRUG|Induction therapy|2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
214439134|NCT06791980|OTHER|CM-TCM|To assess the long-term effects of integrated case management model involving traditional Chinese medicine (CM-TCM) model. The persons participating will be invited to enroll in this stage, and they will be assigned to receive either the usual care or a usual care plus integrated 3-month CM-TCM
214439135|NCT05882253|OTHER|Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)|An advanced imaging software that supports improved prostate cancer detection and diagnosis
215117076|NCT01327677|DRUG|Fentanyl|25-50 mcg every 20 minutes
215117077|NCT01327677|DRUG|Fentanyl|20mcg/demand dose with an 8 minute lock out
215117078|NCT01582139|DEVICE|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
215117079|NCT00970112|PROCEDURE|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
215117080|NCT00060632|DRUG|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
215028655|NCT06642701|BEHAVIORAL|chest physiotherapy|Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
214439136|NCT06959238|OTHER|Temel beden farkındalığı terapisi|Individuals in the TBFT group will receive a total of 16 exercise sessions, with individual exercises 2 days a week for the first 2 weeks and group exercises 2 days a week for the next 6 weeks. The purpose of the individual sessions is to aim for the participant to learn the TBFT exercises and to prepare the participant for the group sessions. In individual sessions, the person learns body scanning and develops awareness about their own body. The participant continues the exercises they learned in the individual session at home. At this stage, the participant is assigned a notebook and is asked to write down their experiences of the exercises they do at home in this notebook. The participant who completes the individual sessions continues with the group sessions. The purpose of the group sessions is to provide interaction within the group and to establish a bond of trust between the individuals in the group with the interaction obtained. The fact that the participants do exercises toge
214439137|NCT05590169|OTHER|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
214439138|NCT02991807|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
214439139|NCT02991807|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
214439140|NCT06430658|COMBINATION_PRODUCT|Tislelizumab (BGB-A317) with chemoradiotherapy|Different sequences and methods of treatment to convert surgery
214439141|NCT06834022|DEVICE|Transcranial direct current stimulation|tDCS will be used according to instructions for use in migraine headache (supraorbital and M1 stimulation), 1 mA, 20 min, 10 sessions
214439142|NCT06834022|PROCEDURE|Acupuncture|Acupuncture will be semistandardized, (every patient is stimulated over Li4, St36, Li3 + patient specific acu-points), 10 sessions
214439143|NCT06636500|DRUG|CG001419|Oral doses
214439144|NCT06636500|DRUG|Placebo|Oral doses
214439145|NCT06249412|DEVICE|MI-E with PEP function activated during the pause|PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
214439146|NCT06249412|DEVICE|MI-E without PEP function activated during the pause|The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
214439147|NCT06397625|OTHER|Percutaneous electrical neurostimulation (Placebo)|"Group I (Control), will be operated with the same procedure but without electric current, and using placebo needles of the same size (Streitberger Placebo-Needle ® , Asiamed, Pullach, Germany)"
214439148|NCT06397625|OTHER|Percutaneous electrical neurostimulation|The Group II and III electrostimulation procedure is called peripheral nerve stimulation and is known as an echo-guided peripheral nerve stimulation technique using a blunt, dry needle (active electrode). The intervention will be performed on the pudendal nerve, in an area where there is no risk of perforating any vascular-nerve bundle. The invasive technique will be performed by a physiotherapist expert in musculoskeletal and peripheral nervous system ultrasound and specialized in invasive techniques, with two years of experience in the sector. The needle will be introduced through the anterior (perineum).
214439149|NCT06818019|DRUG|Stopping dupilumab|Stopping dupilumab with no dose-reducing or interval of time-increasing strategy
214439150|NCT02300298|DRUG|Nintedanib|Nintedanib
214439151|NCT02300298|DRUG|Docetaxel|Docetaxel
214439152|NCT04975087|OTHER|Patients group|Patients will complete the mentioned questionnaires.
214439153|NCT05171985|PROCEDURE|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
214439154|NCT01723267|OTHER|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
214439155|NCT01723267|OTHER|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
214439156|NCT06624371|DRUG|Atovaquone|"Atovaquone oral suspension (750 mg/5mL) will be administered with meals on an outpatient basis.~Patients 13 years and older will receive atovaquone 750 mg PO BID, the standard pediatric dosing for Pneumocystis Jirovecii Pneumonia (PJP) prevention and treatment.~For those aged 2-12 years, atovaquone will be dosed at 30mg/kg once daily. The maximum dose for children under 12 will be 1500 mg."
214439157|NCT06624371|RADIATION|Radiation Therapy|54-60 Gy in 1.8 Gy daily fractions of MRI-guided proton radiotherapy using intensity-modulated pencil-beam scanning technology to match the target will be used.
214439158|NCT05163301|BEHAVIORAL|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
214439159|NCT06533540|BIOLOGICAL|TPX-115(allogeneic fibroblasts)|Intradermal injection of TPX-115(allogeneic fibroblasts)
214439160|NCT05698758|DRUG|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
215028656|NCT03215160|BEHAVIORAL|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
214439161|NCT03576521|COMBINATION_PRODUCT|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
214439162|NCT03576521|COMBINATION_PRODUCT|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
214439163|NCT06088589|BEHAVIORAL|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
214439164|NCT04433078|DRUG|Doxycycline|100 MG Tablet
214439165|NCT04433078|DRUG|Placebo|Placebo Tablet
214439166|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
214439167|NCT03090763|GENETIC|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
214439168|NCT05048914|DRUG|Ibuprofen|treatment of acute migraine attack
214439169|NCT02612844|DRUG|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
214439170|NCT02612844|DRUG|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
214439171|NCT03244449|OTHER|No apply|
214517624|NCT02217891|BEHAVIORAL|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
214517625|NCT03435939|DRUG|Losartan|50 mg/day for 7 days followed by 100 mg/day for 12 weeks
214517626|NCT00946088|DRUG|Progesterone|Progesterone 400 mg per vagina qhs.
214517627|NCT00946088|DRUG|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
214517628|NCT00711776|DRUG|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
214517629|NCT00711776|DRUG|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
214517630|NCT00197262|DRUG|GW685698X Aqueous Nasal Spray|
214517631|NCT05043298|DRUG|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
214517632|NCT05043298|DRUG|IBI 360 Injection Sintilimab|IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
214517633|NCT03977337|PROCEDURE|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
214517634|NCT01244399|DIETARY_SUPPLEMENT|Inositol|
214517635|NCT04883541|BEHAVIORAL|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
214517636|NCT04883541|BEHAVIORAL|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
214517637|NCT03237741|DRUG|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
214517638|NCT03237741|DRUG|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
214517639|NCT03237741|DRUG|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
215028657|NCT01997164|DRUG|REGN910-3|
215028658|NCT01997164|DRUG|REGN910|
215028659|NCT01997164|DRUG|Intravitreal Aflibercept Injection (IAI)|
215028660|NCT01464606|DRUG|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
215028661|NCT01464606|DRUG|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
214439172|NCT01535690|OTHER|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
214439173|NCT02773693|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
214517640|NCT01383616|DEVICE|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
214517641|NCT02841085|GENETIC|Genetic sample|Blood sample or saliva collection
214517642|NCT03948815|OTHER|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
215117081|NCT01220739|DEVICE|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
214439174|NCT02773693|BEHAVIORAL|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
214439175|NCT02773693|BEHAVIORAL|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
214439176|NCT05967429|DIAGNOSTIC_TEST|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
214517643|NCT06194318|BIOLOGICAL|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
214517644|NCT06194318|BIOLOGICAL|placebo|placebo
214517645|NCT06194318|BIOLOGICAL|candidate vaccine, SCB-1019T|The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain. Antigens are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
214517646|NCT06194318|BIOLOGICAL|AREXVY|AREXVY is a FDA-approved respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Developed by GSK, it targets the prefusion F glycoprotein to protect against lower respiratory tract disease caused by RSV.
214517647|NCT01230359|DIETARY_SUPPLEMENT|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
214517648|NCT01230359|OTHER|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
214517649|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide|
214517650|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide + Imiquimod|
214517651|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Imiquimod|
214517652|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 intra nodal injection|
214517653|NCT06361212|DRUG|Ethoximod|Ethoximod is a S1P1 modulator.
214517654|NCT05344209|BIOLOGICAL|UV1|UV1 vaccine
214517655|NCT05344209|DRUG|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
214517656|NCT05344209|DRUG|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
214439177|NCT05967429|DIAGNOSTIC_TEST|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
214517657|NCT04528524|OTHER|Questionnaire|QoR-15Dt
214517658|NCT01567150|DEVICE|Novel Dressing|Topical wound dressing
214517659|NCT03836885|DRUG|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
214517660|NCT03836885|DRUG|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
215028662|NCT01464606|DRUG|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
215028663|NCT01464606|DRUG|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
215028664|NCT01464606|DRUG|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
215117082|NCT01693536|BEHAVIORAL|Lifestyle counselling|as in Arm Description
215117083|NCT00829842|OTHER|oral hygiene|oral hygiene with 0.12% chlorexidine
214439178|NCT03532165|DIAGNOSTIC_TEST|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
214439179|NCT05408572|BIOLOGICAL|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
214439180|NCT04066725|DRUG|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
215117084|NCT00829842|OTHER|placebo|oral hygiene placebo
215117085|NCT01076530|DRUG|vorinostat|
214439181|NCT04066725|DRUG|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
214439182|NCT04066725|DRUG|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
214439183|NCT04508010|OTHER|IVR|Participants will receive an IVR survey
214439184|NCT04508010|OTHER|CATI|Participants will receive a CATI survey
214439185|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
214439186|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
214439187|NCT05634382|DRUG|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
214439188|NCT05634382|PROCEDURE|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
214439189|NCT03217240|PROCEDURE|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
214439190|NCT03217240|OTHER|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
214439191|NCT03217240|OTHER|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
214439192|NCT01073358|PROCEDURE|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
214439193|NCT00175812|DRUG|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
214439194|NCT00175812|DRUG|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
214439195|NCT00175812|DRUG|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
214439196|NCT00792636|DRUG|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
214439197|NCT00792636|DRUG|sumatriptan tablet|sumatriptan 85mg
214439198|NCT00792636|DRUG|naproxen sodium tablet|Naproxen sodium 500mg
214439199|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
214439200|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botox®)|
214439201|NCT05188300|PROCEDURE|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
214439202|NCT05683418|DRUG|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
214439203|NCT06517355|OTHER|In this research, the procedure under study is represented:|"* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.~* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation."
214439204|NCT06359379|DRUG|Ropidoxuridine|Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
214439205|NCT04415060|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
214439206|NCT04415060|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
214439207|NCT00473902|BEHAVIORAL|Training|
214439208|NCT00473902|DRUG|Creatine Monohydrate, Conjugated Linoleic Acid|
214439209|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|Patients in the TEAS group, the acupoints are bilateral neiguan (PC6), Zusanli (ST 36), Hegu (L14) and Waiguan (SJ5) acupoints. The treatment will consist of two phases: a 30-minute stimulation administered 30 minutes before anesthesia induction, and a 30-minute stimulation session once daily on postoperative days 1, 2, and 3. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. Patients in the sham group will receive electrode attachment but without stimulation.
214439210|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
214439211|NCT02244411|BEHAVIORAL|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
214439212|NCT02244411|BEHAVIORAL|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
215117086|NCT01076530|DRUG|temozolomide|
215117087|NCT01076530|OTHER|diagnostic laboratory biomarker analysis|
215117088|NCT01076530|OTHER|pharmacological study|
215117089|NCT03018899|PROCEDURE|paravertebral block|Ultrasound guided two-segment paravertebral block
215117090|NCT03018899|PROCEDURE|epidural anesthesia|thoracic epidural anesthesia
214439213|NCT02244411|BEHAVIORAL|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
214439214|NCT02244411|OTHER|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
214439215|NCT00963404|RADIATION|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
214439216|NCT01602640|DRUG|Morphine infusion|Conventional dose
214439217|NCT01602640|DRUG|Fentanyl and Midazolam infusion|Conventional dose
214517661|NCT04386538|BEHAVIORAL|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
214439218|NCT03268213|BIOLOGICAL|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
214439219|NCT03640195|OTHER|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
214439220|NCT03288753|OTHER|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
214439221|NCT03288753|BEHAVIORAL|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
214439222|NCT03288753|BEHAVIORAL|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
214439223|NCT03288753|BEHAVIORAL|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
214439224|NCT02849054|DEVICE|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
214517662|NCT04386538|BEHAVIORAL|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
214517663|NCT02181881|BEHAVIORAL|DuoPACT|Intervention sessions are administered weekly by a counselor.
214517664|NCT02181881|BEHAVIORAL|Life Steps|Intervention sessions are administered weekly by a counselor.
214517665|NCT03743688|BIOLOGICAL|Influenza Vaccine Recipients|0.5 mL intramuscular injection
214517666|NCT02958722|PROCEDURE|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
214517667|NCT02958722|DRUG|physiological solution|
214517668|NCT02958722|DRUG|carbon dioxide|
215117091|NCT03741504|PROCEDURE|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
215117092|NCT06144879|PROCEDURE|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
214439225|NCT02849054|DEVICE|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
214439226|NCT02849054|DEVICE|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
214439227|NCT02849054|DEVICE|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
214439228|NCT01159275|DRUG|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
214439229|NCT01159275|DRUG|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
214517669|NCT02309892|DRUG|L-DOS47|A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
214517670|NCT02995707|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
214517671|NCT00599625|DRUG|Pravastatin|80mg administered daily for 6 consecutive weeks
214517672|NCT01995292|DEVICE|bronchoscope|
214517673|NCT01995292|DEVICE|Enk Fiberoptic Atomizer|
214517674|NCT05082545|DRUG|SHR-2002 and SHR-1316|Cohort study
214517675|NCT02868086|DEVICE|OCT B-scans|
214439230|NCT06083155|DIAGNOSTIC_TEST|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
214439231|NCT06083155|OTHER|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
214439232|NCT04751838|OTHER|no intervention|no intervention
214517676|NCT02868086|DEVICE|OCT angiography|
215117093|NCT06144879|PROCEDURE|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
215117094|NCT06144879|PROCEDURE|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
214439233|NCT01610297|DRUG|ICL670|Oral dose of ICL670 at 10 mg/kg daily
214439234|NCT02014831|DRUG|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
214439235|NCT02014831|DRUG|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
214439236|NCT00117026|DRUG|Placebo|Placebo for benfotiamine
214439237|NCT00117026|DRUG|Benfotiamine|300mg/day
214517677|NCT01809444|DRUG|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
214517678|NCT01809444|DRUG|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
214517679|NCT01062776|BIOLOGICAL|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
214517680|NCT01062776|BIOLOGICAL|Placebo|No dehydration is induced
214439238|NCT05715437|DRUG|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
214439239|NCT05715437|DRUG|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
214439240|NCT01629316|BEHAVIORAL|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
214439241|NCT01629316|BEHAVIORAL|Standard of care - control arm|The control arm is standard of care for each subject.
214439242|NCT00574834|DRUG|Ramipril|Ramipril 20 mg once daily for 6 months
214439243|NCT00574834|DRUG|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
214439244|NCT00574834|DRUG|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
214517681|NCT03757767|OTHER|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
214517682|NCT01901302|DRUG|CB-5945|
214517683|NCT01901302|DRUG|Placebo|
214517684|NCT01124916|PROCEDURE|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
214517685|NCT01124916|PROCEDURE|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
214439245|NCT01007396|OTHER|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
214439246|NCT04878328|BEHAVIORAL|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
214517686|NCT00995618|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
214517687|NCT00995618|DRUG|Febuxostat|Febuxostat Tablets, 40 mg, QD
214517688|NCT00995618|DRUG|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
214439247|NCT00937131|DRUG|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
214517689|NCT05871489|DRUG|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
214439248|NCT04553458|DEVICE|Radiofrequency ablation|Radiofrequency ablation of the tumour
214439249|NCT04553458|DRUG|Trance-arterial chemoembolization|Trance-arterial chemotherapy
214439250|NCT04553458|PROCEDURE|Liver resection|non-anatomical or anatomical liver resection
214517690|NCT05871489|DRUG|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
214517691|NCT05871489|DRUG|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
214517692|NCT02397226|PROCEDURE|Radiofrequency ablation|
214517693|NCT02397226|PROCEDURE|High ligation/stripping|
214517694|NCT02397226|DEVICE|Radiofrequency ablation catheter|
214517695|NCT02397226|PROCEDURE|Tumescent anesthesia|
214517696|NCT02397226|PROCEDURE|General anesthesia|
214517697|NCT02397226|DEVICE|Vein stripping catheter|
214517698|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
214517699|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
214517700|NCT04997499|BEHAVIORAL|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
214517701|NCT03630653|PROCEDURE|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
214439251|NCT04553458|COMBINATION_PRODUCT|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
214439252|NCT04553458|DRUG|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
214439253|NCT04553458|DRUG|Systemic chemotherapy|Systemic chemotherapy
214439254|NCT04553458|DRUG|Sorafenib|Sorafenib
214439255|NCT04553458|DIETARY_SUPPLEMENT|Viscum|Viscum for HCC
214439256|NCT04553458|DRUG|Symptomatic treatment|Symptomatic treatment
214439257|NCT02590432|DRUG|Linaclotide|Linaclotide capsules, orally, once daily.
214439258|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
214439259|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
214439260|NCT04290819|DIETARY_SUPPLEMENT|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
214517702|NCT03014726|COMBINATION_PRODUCT|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
214517703|NCT05208788|DIAGNOSTIC_TEST|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
214692768|NCT05844345|OTHER|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
215117095|NCT00813189|DEVICE|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
215117096|NCT05193162|OTHER|No any intervention|have no any intervention
215117097|NCT05377424|DRUG|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
215117098|NCT05377424|OTHER|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
215117099|NCT05377424|DRUG|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
215117100|NCT05377424|OTHER|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
215117101|NCT06466486|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
215117102|NCT06466486|DRUG|FE999302|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
215117103|NCT06466486|DRUG|FE999302 Placebo|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
214439261|NCT04290819|DIETARY_SUPPLEMENT|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
214439262|NCT01697059|DRUG|Piperacillin + Amoxicillin|
214439263|NCT04680767|DRUG|LY3502970|Administered orally.
214439264|NCT04680767|DRUG|[¹⁴C]-LY3502970|Administered orally.
214439265|NCT02611609|BIOLOGICAL|MultiStem|
214439266|NCT02611609|BIOLOGICAL|MultiStem|
215117104|NCT05627232|DRUG|Tazemetostat|Given PO
215117105|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215117106|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215117107|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215117108|NCT05627232|DRUG|Palbociclib|Given PO
215117109|NCT05683184|DRUG|[11C]OMAR|For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
215117110|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
214439267|NCT02611609|BIOLOGICAL|Placebo|
214439268|NCT02448576|RADIATION|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
214439269|NCT05875987|DEVICE|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214439270|NCT05243784|BEHAVIORAL|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
214439271|NCT03405714|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"
214439272|NCT05819242|DIAGNOSTIC_TEST|Angulus|Smartphone app
214439273|NCT04172207|OTHER|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
214439274|NCT02530216|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
214439275|NCT01869179|BEHAVIORAL|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
214439276|NCT01869179|BEHAVIORAL|Wait-list control group|
214439277|NCT04351828|PROCEDURE|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
214439278|NCT02740231|DRUG|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
214517704|NCT05469607|DEVICE|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
214439279|NCT02740231|DEVICE|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
214439280|NCT01881412|DRUG|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
214517705|NCT02845921|OTHER|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
214517706|NCT02845921|OTHER|leg wrapping|Esmarch bandage is used to wrap each lower limb
214517707|NCT02845921|OTHER|control|no intervention has been done
214517708|NCT03958305|PROCEDURE|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
214517709|NCT04922359|DRUG|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
214517710|NCT04922359|DRUG|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
214517711|NCT04414865|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
214517712|NCT01029925|DRUG|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
214517713|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
214517714|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
214517715|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
214517716|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
214517717|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
214517718|NCT04508829|DRUG|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
215117111|NCT06260670|DEVICE|Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter|"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."
215117112|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game (Psycho-education Tool) Design|"The narrative-based medication intervention game Healing Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
214517719|NCT01637194|DRUG|everolimus|Given PO
214517720|NCT01637194|BIOLOGICAL|cetuximab|Given IV
214517721|NCT01637194|OTHER|pharmacological study|Correlative studies
214517722|NCT01637194|OTHER|laboratory biomarker analysis|Correlative studies
215117113|NCT01568840|OTHER|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
214439281|NCT01881412|OTHER|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
214439282|NCT00243503|DRUG|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
214439283|NCT04267458|OTHER|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
214439284|NCT04704323|DRUG|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
214439285|NCT04396782|OTHER|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
214517723|NCT05533788|DRUG|ABSK091 tablet|ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
214517724|NCT06095778|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
214517725|NCT03370094|DIAGNOSTIC_TEST|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
214517726|NCT02442102|BEHAVIORAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
214517727|NCT03493906|OTHER|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
214517728|NCT05546177|OTHER|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
214517729|NCT05546177|OTHER|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
215117114|NCT01568840|OTHER|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
215117115|NCT02957734|PROCEDURE|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
214517730|NCT00610194|DRUG|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
215117116|NCT02535455|BEHAVIORAL|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
215117117|NCT01933490|OTHER|high carbohydrate test meal|
215117118|NCT01933490|OTHER|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
215117119|NCT01933490|OTHER|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
215117120|NCT02669459|DRUG|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
215117121|NCT02669459|PROCEDURE|LLETZ|surgical treatment for CIN, current gold standard
214439286|NCT04396782|OTHER|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
214439287|NCT01777009|PROCEDURE|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
214517731|NCT01775878|DEVICE|Telemonitoring Device|Telemonitoring device was installed in patients' homes
215117122|NCT03491826|BIOLOGICAL|rupture of membrane|
215117123|NCT05676307|BEHAVIORAL|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
215117124|NCT01534000|PROCEDURE|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
215117125|NCT00102128|DRUG|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
214439288|NCT03821636|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
214439289|NCT03821636|PROCEDURE|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
214517732|NCT04223674|DIAGNOSTIC_TEST|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
215117126|NCT03534102|DRUG|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
215117127|NCT03534102|BEHAVIORAL|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
215117128|NCT04977284|DEVICE|DS7R, Digitimer, UK|Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
215117129|NCT03738488|DEVICE|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
215117130|NCT03738488|OTHER|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
215117131|NCT02058446|DRUG|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
215117132|NCT01646086|BEHAVIORAL|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
215117133|NCT05450094|BEHAVIORAL|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
214517733|NCT06502067|DRUG|Analgesia mangement group A,B|1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
215117134|NCT05450094|BEHAVIORAL|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically-based implementation supports, including training, coaching, and data-based feedback. Enhancement aim to increase school teams' awareness and understanding of students' mental health well-being and need for intervention. enhancements.
215117135|NCT01142882|BEHAVIORAL|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
215117136|NCT01142882|BEHAVIORAL|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
215117137|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
215117138|NCT05889676|DIAGNOSTIC_TEST|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
215117139|NCT05256966|OTHER|Sauna (steam)|Steam Sauna
215117140|NCT03940300|DIETARY_SUPPLEMENT|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
214517734|NCT01233089|DEVICE|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
214517735|NCT01233089|DEVICE|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
214517736|NCT01233089|DEVICE|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
214517737|NCT01233089|DEVICE|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
214517738|NCT05306483|PROCEDURE|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
214517739|NCT05306483|PROCEDURE|Ventricular septal defect closure catheter|Catheter closure of VSD
214439290|NCT00786513|OTHER|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
215117141|NCT05026359|DEVICE|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
215117142|NCT00644020|DRUG|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
215117143|NCT02773485|RADIATION|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
215117144|NCT02773485|DRUG|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
215117145|NCT05567250|BEHAVIORAL|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
215117146|NCT05782062|DEVICE|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
215117147|NCT05782062|DEVICE|Balloon|Use of balloon for disrupting thrombus.
214439291|NCT00786513|OTHER|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
214439292|NCT06266845|BEHAVIORAL|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
214439293|NCT06266845|BEHAVIORAL|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
214439294|NCT03490045|OTHER|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
214439295|NCT03490045|OTHER|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
214439296|NCT06510595|OTHER|Active Treatment Arm|"Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force."
214439297|NCT06510595|OTHER|Control Treatment Arm|The child will wear a brace as a conservative treatment method.
214439298|NCT04279366|BEHAVIORAL|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
214439299|NCT05295342|BEHAVIORAL|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
214517740|NCT00255268|DRUG|Goserelin|
214517741|NCT00255268|DRUG|Bicalutamide|
214517742|NCT00337246|BIOLOGICAL|rituximab|
214517743|NCT00337246|DRUG|cyclophosphamide|
214517744|NCT00337246|DRUG|fludarabine phosphate|
215117148|NCT04988529|BEHAVIORAL|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
214439300|NCT05295342|BEHAVIORAL|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
214439301|NCT05295342|BEHAVIORAL|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
214439302|NCT00962702|DEVICE|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
214439303|NCT02410018|DEVICE|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
214439304|NCT00829634|DRUG|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
214439305|NCT00829634|DRUG|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
214439306|NCT04162457|DIETARY_SUPPLEMENT|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
214439307|NCT04162457|DIETARY_SUPPLEMENT|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
214439308|NCT04162457|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
214439309|NCT04162457|DIETARY_SUPPLEMENT|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
215117149|NCT02698514|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
215117150|NCT02698514|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
215117151|NCT04708093|DEVICE|whole body vibration training|Oscillating platform
215117152|NCT06006195|OTHER|patients with dysphagia symptoms|patients with dysphagia symptoms examined by high resolution impedance manometry
215117153|NCT06006195|OTHER|patients without dysphagia symptoms|patients without dysphagia symptoms examined by high resolution impedance manometry
215117154|NCT04339829|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
215117155|NCT04448977|DRUG|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
215117156|NCT01592071|OTHER|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
215117157|NCT01100320|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
215117158|NCT01100320|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
215117159|NCT04036981|DRUG|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
215117160|NCT01418430|DRUG|CHOP-daclizumab|
215117161|NCT04005261|DIAGNOSTIC_TEST|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
215117162|NCT05956899|DRUG|Palonosetron|IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia
215117163|NCT05956899|DRUG|Ondansetron|IV ondansetron 0.15mg/kg at the start of wound closure
214439310|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in plasma after DNAse digestion.|Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).
214439311|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in blood or plasma.|HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
214439312|NCT05398055|DRUG|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
214439313|NCT05398055|DRUG|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
214439314|NCT03076515|DEVICE|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
214439315|NCT03076515|DEVICE|Sham Nerivio Migra|electrical stimulation- shame mode
214439316|NCT00933426|DRUG|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
215117164|NCT05993923|OTHER|GPOU|"Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report"
214439317|NCT00933426|DRUG|Paclitaxel|50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
214439318|NCT03348371|OTHER|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
214439319|NCT06067035|OTHER|Imaging|Imaging data from patients with small-vessel liver tumours will be compared with histological data.
214439320|NCT02301208|DRUG|Nedaplatin|Nedaplatin combine with IMRT
214439321|NCT02301208|DRUG|Cisplatin|Cisplatin combine with IMRT
214439322|NCT05004558|OTHER|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
214517745|NCT00337246|DRUG|mitoxantrone hydrochloride|
214439323|NCT05742126|DRUG|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
214517746|NCT01368874|DEVICE|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
214517747|NCT02260726|PROCEDURE|Magnetic resonance imaging|
215117165|NCT03797586|OTHER|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
215117166|NCT03797586|OTHER|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
215117167|NCT03028610|DEVICE|radiofrequency generator|
215117168|NCT04980612|BEHAVIORAL|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
215117169|NCT04980612|BEHAVIORAL|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
215117170|NCT05398094|DRUG|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
215117171|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
215117172|NCT04678414|OTHER|Survey Administration|Complete survey
215117173|NCT05730387|OTHER|Observational only|This is a non-interventional study
215117174|NCT04823442|DRUG|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
215117175|NCT04823442|DRUG|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
215117176|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
215117177|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
215117178|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
215117179|NCT04015206|OTHER|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
215117180|NCT01951651|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
214439324|NCT05742126|DRUG|Placebo|Matching placebo
214439325|NCT05742126|DRUG|Heparin sodium injection|Matching positive control
214439326|NCT05989932|OTHER|Upadacitinib|Real-world on the use of Upadacitinib
214439327|NCT01947790|DRUG|pioglitazone group|
214439328|NCT01947790|DRUG|Metformin group|
214439329|NCT04626180|PROCEDURE|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
214439330|NCT04626180|PROCEDURE|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
214439331|NCT00521755|DEVICE|Seraffix LTB|laser soldering for soft tissue wounds
214517748|NCT02260726|PROCEDURE|Ultrasound|
214517749|NCT05356065|OTHER|survey administration|Outcome Measures
214517750|NCT02648659|DRUG|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
214517751|NCT02648659|DRUG|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
214439332|NCT02216552|DIETARY_SUPPLEMENT|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
214439333|NCT02216552|DIETARY_SUPPLEMENT|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
214439334|NCT01203995|BEHAVIORAL|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
214439335|NCT01203995|BEHAVIORAL|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
214517752|NCT02648659|DRUG|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
214517753|NCT02648659|DRUG|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
214517754|NCT05567302|OTHER|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
214517755|NCT05567302|OTHER|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
214517756|NCT04455542|OTHER|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
214517757|NCT04455542|OTHER|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
214517758|NCT04455542|OTHER|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
214517759|NCT03345199|OTHER|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
214517760|NCT03012490|OTHER|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
214517761|NCT03012490|OTHER|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
214439336|NCT05401513|OTHER|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
214439337|NCT03245424|DRUG|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
214439338|NCT01189331|DEVICE|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
214439339|NCT04192916|DRUG|DOACs|Direct Oral Anticoagulants
214439340|NCT04622722|OTHER|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
214439341|NCT04622722|OTHER|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
214439342|NCT02374307|OTHER|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
214439343|NCT00999167|DRUG|HPN-100|Part B: 6 mL BID for 16 weeks.
214439344|NCT00999167|DRUG|Placebo|Part B: same as experimental arm
214439345|NCT03722316|OTHER|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
214517762|NCT03012490|OTHER|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
214517763|NCT04791917|BEHAVIORAL|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
214517764|NCT04791917|BEHAVIORAL|Concentric Biceps Flexion|Muscle shortening biceps exercise
214439346|NCT03722316|OTHER|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
214439347|NCT03989024|DRUG|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
214439348|NCT03989024|DRUG|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
214439349|NCT00198146|DRUG|Zenapax|
214517765|NCT02746783|DRUG|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
214517766|NCT02746783|DRUG|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
214517767|NCT03391778|BIOLOGICAL|ADP adoptive cell therapy|No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214517768|NCT04729361|GENETIC|CGH array analysis|CGH array analysis
214517769|NCT01643018|PROCEDURE|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
214517770|NCT01643018|PROCEDURE|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
214517771|NCT03733951|DRUG|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
214517772|NCT02790788|DRUG|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
214517773|NCT02790788|DRUG|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
214517774|NCT03249805|DEVICE|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
214517775|NCT03249805|DEVICE|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
215117181|NCT01951651|DRUG|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
215117182|NCT05157126|DRUG|Gentamicin|Liquid gentamicin administered at the open fracture site
215117183|NCT05157126|DRUG|normal Saline|Normal saline administered at the open fracture site
215117184|NCT05556759|PROCEDURE|control|patient will be operated under general anesthesia
214439350|NCT02554786|DRUG|Indacaterol acetate/Mometasone furoate|
214439351|NCT02554786|DRUG|Mometasone furoate|
214439352|NCT02554786|DRUG|Salmeterol xinafoate/fluticasone propionate|
214439353|NCT05293548|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
214439354|NCT05293548|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
214439355|NCT02934789|PROCEDURE|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
214439356|NCT02934789|DRUG|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
214439357|NCT05052996|DRUG|ISL|Capsules administered orally without regard to food
214439358|NCT05052996|DRUG|LEN|Tablets administered orally without regard to food
214439359|NCT05052996|DRUG|B/F/TAF|Tablets administered orally without regard to food
214517776|NCT05245474|COMBINATION_PRODUCT|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
215117185|NCT05556759|PROCEDURE|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
215117186|NCT05556759|PROCEDURE|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
214517778|NCT03837093|DRUG|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
214517779|NCT03837093|DRUG|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
214517780|NCT01840124|PROCEDURE|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
214517781|NCT02222532|DRUG|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
214517782|NCT02222532|DRUG|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
215117187|NCT01383226|PROCEDURE|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
215117188|NCT03088488|DIAGNOSTIC_TEST|fasting venous blood samples|
215117189|NCT05379465|OTHER|No intervention|No intervention was done.
215117190|NCT04589442|BIOLOGICAL|Split thickness skin graft|standard of care graft
215117191|NCT04589442|BIOLOGICAL|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
214439360|NCT05052996|DRUG|ISL/LEN FDC|Tablets administered orally without regard to food
214439361|NCT01485406|BIOLOGICAL|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
214439362|NCT01485406|BIOLOGICAL|Synflorix™|1 dose administered intramuscularly
214439363|NCT04438343|OTHER|Impairment-specific and augmented intervention|Balance and lower extremities strength training
214439364|NCT04438343|OTHER|Conventional physical therapy|Trunk and upper extremity training
214439365|NCT02902471|OTHER|Forced oscillations measure|
214439366|NCT02698813|BIOLOGICAL|umbilical cord mesenchymal stem cells and hyaluronic acid|
214439367|NCT02698813|DRUG|hyaluronic acid|
214439368|NCT04295993|DRUG|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
214439369|NCT04295993|DRUG|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
214439370|NCT01340417|OTHER|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
214439371|NCT03704727|DIETARY_SUPPLEMENT|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
214439372|NCT04743362|DIAGNOSTIC_TEST|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
214439373|NCT04743362|DIAGNOSTIC_TEST|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
214439374|NCT04743362|DIAGNOSTIC_TEST|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
214439375|NCT04743362|DIAGNOSTIC_TEST|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
214439376|NCT04743362|DIAGNOSTIC_TEST|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
214439377|NCT04743362|DIAGNOSTIC_TEST|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
214439378|NCT04743362|DIAGNOSTIC_TEST|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
214439379|NCT04743362|DIAGNOSTIC_TEST|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
214439380|NCT04810767|OTHER|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
214439381|NCT01086813|DRUG|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
214439382|NCT04175405|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
214439383|NCT00475930|DRUG|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
214439384|NCT00475930|DRUG|Comfort Bath cloths (placebo cloths)|self applied three times weekly
214439385|NCT06142786|BEHAVIORAL|Enhancing the individualized upper alpha frequency band and suppressing the lower alpha band.|Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.
214439386|NCT06142786|BEHAVIORAL|Sham neurofeedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
214439387|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
214439388|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214439389|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214439390|NCT03306082|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
214439391|NCT06230744|BEHAVIORAL|Lifestyle|All participants will receive diet and exercise goals and coaching.
214439392|NCT06230744|BEHAVIORAL|Lifestyle II|All participants will receive diet and exercise goals and coaching.
214439393|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.
214439394|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.
214439395|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intramuscularly.
214439396|NCT05370820|OTHER|No intervention|Control group with no administration of Tranexamic Acid.
214439397|NCT04779216|DRUG|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
214439398|NCT04779216|DRUG|Placebo|Placebo Injection monthly for 12 months
214439399|NCT04779216|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
214439400|NCT01083342|DRUG|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
214439401|NCT05499351|BIOLOGICAL|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
214439402|NCT05499351|BIOLOGICAL|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
214439403|NCT05499351|BIOLOGICAL|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
214439404|NCT05499351|BIOLOGICAL|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
214439405|NCT02847780|DEVICE|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
214439406|NCT02847780|DEVICE|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
214439407|NCT06417346|PROCEDURE|Laparoscopic TEP Repair|Laparoscopic TEP Repair performed
214439408|NCT06417346|PROCEDURE|Open Technique (Lichtenstein)|Open Technique (Lichtenstein) performed
214439409|NCT04319874|DRUG|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
214439410|NCT04319874|DRUG|Chemotherapy|Subjects are treated with conventional chemotherapy
214439411|NCT04319874|DRUG|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
215117192|NCT02527590|OTHER|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
214439412|NCT02415140|OTHER|Rate of depression|
214439413|NCT00001017|DRUG|Fluconazole|
214439414|NCT00001017|DRUG|Amphotericin B|
215117193|NCT02527590|OTHER|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
215117194|NCT02527590|OTHER|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
215117195|NCT02527590|OTHER|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
215117196|NCT02527590|OTHER|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
215117197|NCT00264199|DRUG|GLP-1|iv. by weight (1.0 pmol/kg/min )
215117198|NCT00264199|DRUG|placebo|same rate of infusion as GLP-1
214439415|NCT04165967|DRUG|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
214439416|NCT04159493|DRUG|Estriol|Vaginal Application
214439417|NCT04159493|DRUG|Placebo|Vaginal Application
214439418|NCT04244318|BEHAVIORAL|Video-feedback ODISEA 3.0|Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).
214439419|NCT04244318|BEHAVIORAL|ODISEA-DTP: parental therapy|Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).
214439420|NCT04244318|BEHAVIORAL|Treatment as usual|"Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia"
214517783|NCT01072071|DRUG|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
214517784|NCT06540846|OTHER|No intervention|No intervention since this is an observational study
214517785|NCT03927794|OTHER|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
214517786|NCT04153357|DEVICE|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
214517787|NCT04153357|DEVICE|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
215117199|NCT01317251|OTHER|Dietary intervention (without dairy products)|Control diet without dairy products
215117200|NCT01317251|OTHER|Dietary intervention (high milk content)|Diet with a high content of milk (\~1200 mg Ca/d from milk)
215117201|NCT01317251|OTHER|Dietary intervention (high cheese content)|Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
215117202|NCT00209352|DRUG|Acyclovir|
215117203|NCT00596752|DRUG|Alprostadil|"* Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
215117204|NCT00596752|OTHER|Placebo|"* Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
215117205|NCT05357716|DEVICE|HeartWatch|The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
215117206|NCT05357716|DEVICE|Event Recorder|A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
215117207|NCT05357716|DEVICE|Holter Monitor|A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
215117208|NCT00006474|DRUG|O6-benzylguanine|
215117209|NCT00006474|DRUG|temozolomide|
214439421|NCT05628792|DIAGNOSTIC_TEST|CT|Ultra High Resolution CT scan
214517788|NCT01027455|DEVICE|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
214517789|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
214517790|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
214517791|NCT01826994|DEVICE|heart type fatty acid binding protein testing|
215117210|NCT00006474|PROCEDURE|conventional surgery|
215117211|NCT02842294|DRUG|Bevacizumab|
215117212|NCT05820659|BEHAVIORAL|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
215117213|NCT04716946|DRUG|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
214439422|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
214439423|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
214439424|NCT00522951|DRUG|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
214517792|NCT01571947|OTHER|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
214517793|NCT00238745|DRUG|Bazedoxifene|
214517794|NCT00238745|DRUG|Placebo|
214517795|NCT04704856|BEHAVIORAL|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
214517796|NCT00709787|OTHER|Usual Care|Normal care for hypertensive patients with risk factors for CHD
214517797|NCT04048226|DRUG|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
214517798|NCT04048226|DRUG|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
214517799|NCT00134056|DRUG|atrasentan hydrochloride|Given orally
214517800|NCT00134056|DRUG|docetaxel|Docetaxel given IV and prednisone given orally
214517801|NCT00134056|DRUG|prednisone|Docetaxel given IV and prednisone given orally
214517802|NCT00134056|OTHER|placebo|Given orally
215117214|NCT04716946|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
215117215|NCT06223685|DRUG|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
215117216|NCT06223685|DIETARY_SUPPLEMENT|Probiotic|2x1 capsules per day. 12 weeks.
214439425|NCT05429307|OTHER|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
214439426|NCT01576029|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
214439427|NCT01576029|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
214439428|NCT01157663|OTHER|Adapted balance training|during 8 weeks
214517803|NCT01745835|DRUG|2L Coolprep®|\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
214517804|NCT01745835|DRUG|1L Coolprep® and Bisacodyl|"1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
214517805|NCT02111499|DRUG|LAS41004-IMP1|daily topical application
214517806|NCT02111499|DRUG|LAS41004 IMP2|daily topical application
214517807|NCT02111499|DRUG|LAS41004 IMP3|daily topical application
214517808|NCT02111499|DRUG|LAS41004 IMP4|daily topical application
214517809|NCT02111499|DRUG|LAS41004 IMP6|daily topical application
214517810|NCT02111499|DRUG|LAS41004 IMP5|once daily, topical
214517811|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia® bitter|"* ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein"
214517812|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia®|"* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein"
214517813|NCT04876261|DIETARY_SUPPLEMENT|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"* extra virgin olive oil~* 5 mg hydroxytyrosol"
214439429|NCT01157663|OTHER|Balance Training|Balance training with unipedal standing during 8 weeks
214439430|NCT01827917|BIOLOGICAL|rabies vaccine|Injection on day 0、7、21
214517814|NCT02474745|PROCEDURE|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
214517815|NCT02474745|PROCEDURE|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
214517816|NCT01852175|DRUG|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
214517817|NCT01852175|DRUG|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
214517818|NCT06049719|OTHER|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
214439431|NCT06969105|OTHER|Music|Prior to randomization, all participants will pre-select their preferred music genre. If randomized to the music group, their preferred music genre will be played for a 10 minute duration.
214439432|NCT03891316|DIAGNOSTIC_TEST|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
214439433|NCT03895515|DRUG|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
214439434|NCT02794480|DEVICE|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
214439435|NCT02794480|DEVICE|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
214439436|NCT02794480|DEVICE|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
214439437|NCT04368312|OTHER|No intervention|No intervention, just of questionnaire including validated tests
214439438|NCT04251013|DEVICE|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
214439439|NCT04251013|DEVICE|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
214439440|NCT00767559|DRUG|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
214439441|NCT00767559|DRUG|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
214439442|NCT00767559|DRUG|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
214439443|NCT04770649|BIOLOGICAL|COVID-19 vaccine|Any vaccine for COVID-19
214439444|NCT05744596|OTHER|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
214439445|NCT01017146|DRUG|Tazarotene foam|Tazarotene foam once a day application to the face
214439446|NCT01017146|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
214439447|NCT01448512|BEHAVIORAL|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
214439448|NCT01448512|OTHER|Usual Care|4 time matched sessions focused on health education
215117217|NCT05690984|DRUG|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
215117218|NCT05690984|DRUG|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
215117219|NCT05690984|DRUG|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
215117220|NCT05009069|RADIATION|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
214439449|NCT05127681|RADIATION|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
214439450|NCT05127681|BIOLOGICAL|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
214439451|NCT05127681|RADIATION|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
214439452|NCT05127681|OTHER|medical data collection|Data of healthy men is already available
214439453|NCT04850586|OTHER|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
214439454|NCT01771731|DRUG|Cannabis|
214439455|NCT05237453|RADIATION|Photons|MR-guided adaptive radiotherapy
214439456|NCT01747486|BIOLOGICAL|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
214439457|NCT01347892|OTHER|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
214439458|NCT02847013|DRUG|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
214439459|NCT02847013|PROCEDURE|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
214439460|NCT06409117|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
214439461|NCT00220519|DRUG|Lactobacillus GG|
214439462|NCT01230450|PROCEDURE|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
215117221|NCT05009069|DRUG|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
214439463|NCT01230450|OTHER|stand standard mid-urethral sling (TVT-O)|
215117222|NCT05009069|DRUG|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
215117223|NCT05009069|DRUG|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
214517819|NCT00226746|DRUG|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
214517820|NCT03816202|DEVICE|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
215117224|NCT05009069|DRUG|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
215117225|NCT05973006|BIOLOGICAL|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
215117226|NCT05973006|BIOLOGICAL|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
214439464|NCT00010725|DRUG|MAK|
214439465|NCT00010725|DRUG|Vitamin Supplements|
214517821|NCT06133595|BEHAVIORAL|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
214517822|NCT05905068|DRUG|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
215117227|NCT03637569|OTHER|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
215117228|NCT01970267|PROCEDURE|Laser Ablation of Floaters|
215117229|NCT01970267|PROCEDURE|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
215117230|NCT02652351|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
214439466|NCT03251222|DRUG|Dexmedetomidine|Intranasal aplication of dexmedetomidine
214439467|NCT03251222|OTHER|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
214439468|NCT00704314|DRUG|Simvastatin|80 mg Simvastatin daily for 8 weeks
214439469|NCT00704314|DRUG|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
214439470|NCT00087139|DRUG|ixabepilone|Given IV
214439471|NCT03066115|DRUG|L-NMMA|See arm description.
214439472|NCT03066115|DRUG|Ketorolac|See arm description.
214439473|NCT03066115|DRUG|Ascorbic Acid|See arm description.
214439474|NCT03066115|PROCEDURE|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
214439475|NCT03066115|PROCEDURE|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
214439476|NCT00976495|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
214439477|NCT00976495|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
214439478|NCT00976495|DRUG|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
214439479|NCT05821569|OTHER|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
214439480|NCT05821569|OTHER|Biological nurturing|Adoption of biological nurturing approach to breastfeed
214439481|NCT00033098|DRUG|Metyrapone|
214439482|NCT01879189|BEHAVIORAL|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
214439483|NCT05364216|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
214439484|NCT05364216|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
214439485|NCT05364216|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
214439486|NCT05952258|DEVICE|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
214439487|NCT05952258|DEVICE|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
214517823|NCT06407141|BEHAVIORAL|transcranial pulse stimulation|Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
215117231|NCT04215640|DEVICE|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
215117232|NCT04215640|DEVICE|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
215117233|NCT05585840|DEVICE|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
215117234|NCT01714765|DRUG|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
215117235|NCT01714765|DRUG|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
215117236|NCT04661046|DRUG|Traditional Chinese Medicine|Chinese medicine prescription
214439488|NCT01888744|DRUG|GnRH agonist|
214439489|NCT01888744|DRUG|GnRH antagonist|
214439490|NCT01888744|DRUG|hP-hMG|
215117237|NCT04721210|OTHER|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
215117238|NCT03884790|DEVICE|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
215117239|NCT03382990|DEVICE|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
215117240|NCT02726724|OTHER|5 observers|
215117241|NCT02726724|OTHER|1 observer|
215117242|NCT04378270|DEVICE|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
215117243|NCT04944849|DIAGNOSTIC_TEST|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
215117244|NCT05275595|OTHER|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
214439491|NCT01888744|DRUG|Human chorionic gonadotropin|induction of final oocyte maturation
214439492|NCT01888744|DRUG|Progesterone|
215117245|NCT05275595|OTHER|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
215117246|NCT01629173|PROCEDURE|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
214439493|NCT04386772|PROCEDURE|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
214439494|NCT04386772|PROCEDURE|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
214439495|NCT04308083|PROCEDURE|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
214439496|NCT00222924|BEHAVIORAL|weight loss/ exercise|
214439497|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
214439498|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
214439499|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
214439500|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
214439501|NCT02321514|DEVICE|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
214439502|NCT02743910|OTHER|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
214517824|NCT06407141|BEHAVIORAL|Sham TMS|Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
215117247|NCT01629173|PROCEDURE|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
214439503|NCT02743910|OTHER|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
214439504|NCT05336864|OTHER|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
214439505|NCT05336864|OTHER|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL) and C-reactive protein (CRP)"
214439506|NCT05336864|OTHER|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year outcomes).
214439507|NCT05336864|OTHER|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
214517825|NCT05829668|BEHAVIORAL|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
215117248|NCT01629173|PROCEDURE|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
214517826|NCT05242874|DRUG|Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.
214517827|NCT05242874|DRUG|Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
214517828|NCT03997552|PROCEDURE|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
214517829|NCT03997552|PROCEDURE|marginal approach by palatal incision|Periodontal reconstructive surgery
214517830|NCT03997552|PROCEDURE|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
214517831|NCT05028257|BIOLOGICAL|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
214517832|NCT02555397|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
214517833|NCT03994809|OTHER|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
214517834|NCT05750121|BEHAVIORAL|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
214517835|NCT05583331|PROCEDURE|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
214517836|NCT05583331|PROCEDURE|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
215117249|NCT01629173|PROCEDURE|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
215117250|NCT04584437|OTHER|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
215117251|NCT03399630|OTHER|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
215117252|NCT03399630|OTHER|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
215117253|NCT01327599|DRUG|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
215117254|NCT04078347|PROCEDURE|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
215117255|NCT01187485|DRUG|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
214439508|NCT05336864|OTHER|Processed electroencephalogram (pEEG) monitoring|Processed EEG substudy to explore the relationship between processed EEG-derived depth of anesthesia metrics and cerebral autoregulatory function.
214439509|NCT05434962|DEVICE|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms"
214439510|NCT05973461|DEVICE|Exercise and virtual reality|Riding a cycle ergometer while experiencing virtual reality
214439511|NCT05973461|OTHER|Riding a cycle ergometer|Riding on a cycle ergometer without experiencing virtual reality
214439512|NCT05394285|DRUG|Hetrombopag|"The first anti-tumor treatment cycle (multicenter, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd anti-tumor treatment cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after anti-tumor treatment for 14 days."
214439513|NCT05383859|BEHAVIORAL|Intervention|"1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call."
214439514|NCT04128319|DRUG|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
214439515|NCT01038011|DRUG|drug treatment|
214439516|NCT00332917|DRUG|Pardoprunox|12-42 mg
214439517|NCT01859416|DIETARY_SUPPLEMENT|Oral nutritional supplement|
214439518|NCT02032849|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
214439519|NCT02032849|DEVICE|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
214439520|NCT03396900|DRUG|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
214439521|NCT03396900|OTHER|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
214439522|NCT05631210|OTHER|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
214439523|NCT00153569|BIOLOGICAL|Tyrosinase, MAGE-3, GnTV|
214439524|NCT03954210|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
214439525|NCT03954210|BEHAVIORAL|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
214439526|NCT03954301|DIAGNOSTIC_TEST|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
214439527|NCT02058017|DRUG|OPB-51602|
214439528|NCT01130727|OTHER|green tea extract|1.21g of green tea extract (965 mg of flavonols)
214439529|NCT01130727|OTHER|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
214439530|NCT01130727|OTHER|placebo|placebo
214439531|NCT01130727|OTHER|low polyphenol cocoa extract|placebo
214439532|NCT04484935|DRUG|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
214439533|NCT03600051|DEVICE|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
214439534|NCT02219568|PROCEDURE|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
214439535|NCT02219568|DEVICE|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
214439536|NCT04806529|DRUG|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
214439537|NCT04806529|DRUG|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
214439538|NCT04504708|DRUG|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
214439539|NCT00132964|DEVICE|Below knee walking cast|Not required
214439540|NCT00132964|DEVICE|Removable ankle brace|not required
214439541|NCT02190981|DEVICE|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
214439542|NCT00584246|DRUG|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
214439543|NCT00584246|DRUG|Placebo|50 - 150 mg po qhs for 2 months
214439544|NCT01094184|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
214439545|NCT01094184|DRUG|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
214439546|NCT01094184|DRUG|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
214439547|NCT02150967|DRUG|BGJ398 (infigratinib)|Capsule for oral use
214439548|NCT00563446|DRUG|Darbepoetin alfa|
214517837|NCT02850939|BEHAVIORAL|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
215117256|NCT01187485|DRUG|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
215117257|NCT01187485|DRUG|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
215117258|NCT01678378|BEHAVIORAL|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
215117259|NCT04452019|DEVICE|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
214439549|NCT01989741|OTHER|Sleep restriction|4 hours sleep by night during one week
214439550|NCT00868504|OTHER|no intervention|no intervention
214439551|NCT03892564|DRUG|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
214439552|NCT03892564|DRUG|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
214439553|NCT03892564|DRUG|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
215117260|NCT04452019|DEVICE|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
215117261|NCT06966440|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)-based MRD|MRD testing will be performed before the start of the first treatment cycle, and at weeks 8 and 11 of each subsequent cycle. MinerVa Prime is a tumor-informed MRD assay based on a fixed panel spanning 769 cancer-related genes.
214439554|NCT03892564|DRUG|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
214517838|NCT02761317|DRUG|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
215117262|NCT06966440|DRUG|adjuvant chemotherapy regimens|Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1 monotherapy/adjustable S-1 monotherapy, fluorouracil monotherapy/adjustable fluorouracil monotherapy, GEM plus CAP regimen/adjustable GEM plus CAP regimen, mFOLFIRINOX regimen, GEM plus nab-paclitaxel regimen/adjustable GEM plus nab-paclitaxel regimen.
215117263|NCT04457232|PROCEDURE|Computed Tomography|Undergo PET/CT imaging
215117264|NCT04457232|OTHER|Gallium Ga 68 FAPi-46|Given IV
215117265|NCT04457232|PROCEDURE|Positron Emission Tomography|Undergo PET/CT imaging
214439555|NCT03892564|DRUG|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
214439556|NCT07000552|OTHER|EFT intervention|The intervention groups will be followed up for 4 weeks and 4 EFT therapies will be applied, one session per week.
214439557|NCT06676852|BEHAVIORAL|Primary palliative care|Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
214439558|NCT06372067|DEVICE|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
214439559|NCT06372067|DEVICE|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
214439560|NCT04992390|BEHAVIORAL|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
214439561|NCT06920693|DRUG|GB-7624|Study Drug GB-7624
214439562|NCT06920693|DRUG|Placebo|Placebo
214439563|NCT06867445|PROCEDURE|Minimally invasive pelvic exenteration|If all criteria are met, patients are registered. The patient is enrolled before the surgery, at the time of pelvic evaluation under anaesthesia. A diagnostic laparoscopic assessment can be performed before the operation to exclude peritoneal metastasis. The experimental procedure in this protocol involves the use of a minimally invasive approach (robot-assisted or laparoscopic) for performing pelvic exenteration.
215117266|NCT05816083|BEHAVIORAL|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
215117267|NCT02612922|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
215117268|NCT02612922|DRUG|Placebo|Placebo administered orally twice daily for five days
215117269|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
215117270|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
215117271|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
215117272|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
215117273|NCT00310596|DRUG|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
214439564|NCT01456013|DEVICE|RenalGuard Therapy|Induced Diuresis with matched replacement
214439565|NCT01456013|DRUG|Standard Therapy|Standard of care for patients at risk of CIN
214439566|NCT05009862|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
214439567|NCT05009862|DRUG|Placebo|placebo
214439568|NCT05009862|DRUG|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
215117274|NCT00310596|DRUG|Placebo|0,9% saline at 0,6mL/kg at bolus rate
215117275|NCT02240641|DRUG|Lacidipine|
215117276|NCT02240641|DRUG|Diuretics|
215117277|NCT02240641|DRUG|antihypertensive drugs|
215117278|NCT02240641|DRUG|alpha blockers|
214439569|NCT07021872|BEHAVIORAL|Tele-Positive Affect Intervention|A 4-week intervention consisting of eight skills aimed at enhancing positive affect, delivered via telephone by trained facilitators. Participants will learn skills such as gratitude, mindfulness, and positive reappraisal, with sessions held twice a week.
214439570|NCT07021872|BEHAVIORAL|Tele-Behavioral Activation Intervention|A 4-week intervention designed to promote engagement in meaningful activities, delivered through telephone by trained facilitators. The intervention will include behavior monitoring, activity planning, and social skills enhancement, with sessions held twice a week.
214439571|NCT07021872|BEHAVIORAL|Tele-Friendly Visit|An active control condition consisting of telephone-delivered friendly visits. Participants will engage in social conversation and activities to provide companionship without any specific skills training aimed at reducing loneliness. The intervention will be held within 4-week.
214439572|NCT06712004|DRUG|Bevifibatide citrate injection|Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.
214439573|NCT06709859|DRUG|Afatinib plus chemotherapy as conversion treatment|Patients with unresectable EGFR sensitive mutation-positive stage III NSCLC will receive 3-4 cycles of afatinib plus chemotherapy as the conversion treatment, and then surgery will be provided for patients who are suitable for primary tumor resection.
214439574|NCT06716190|DRUG|BI 3731579|BI 3731579
214439575|NCT06716190|DRUG|Placebo matching BI 3731579|Placebo matching BI 3731579
214439576|NCT06716190|DRUG|Midazolam|Midazolam
214517839|NCT02761317|DRUG|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
214517840|NCT02761317|DRUG|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
214517841|NCT00681915|DRUG|AZD7325|Oral
215117279|NCT02240641|DRUG|Angiotensin-Converting Enzyme Inhibitors|
215117280|NCT02240641|DRUG|beta blockers|
215117281|NCT04260646|DEVICE|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
215117282|NCT04260646|DEVICE|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
215117283|NCT06110806|BEHAVIORAL|MBIE|MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
215117284|NCT06047145|DIETARY_SUPPLEMENT|soy isoflavones|1 capsule daily for 84 days
215117285|NCT06047145|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 84 days
215117286|NCT06609226|DRUG|Etavopivat A|Participants will receive an oral dose of Etavopivat A.
215117287|NCT06609226|DRUG|Etavopivat B|Participants will receive an oral dose of Etavopivat B.
214517842|NCT00637104|DEVICE|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
215117288|NCT04903028|DEVICE|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
215117289|NCT04903028|DEVICE|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
215117290|NCT06437964|OTHER|No use of prophylactic antibiotics|In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
215117291|NCT06437964|DRUG|Prophylactic Antibiotics|Intravenous infusion of 2.0g ceftriaxone before endoscopic therapy
215117292|NCT06059989|DRUG|Infliximab subcutaneous|Mono and combination therapy group
215117293|NCT06059989|DRUG|Immunosuppressive Agents|Combination group only
215117294|NCT02989753|DIETARY_SUPPLEMENT|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
215117295|NCT02989753|DIETARY_SUPPLEMENT|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
215117296|NCT02989753|DIETARY_SUPPLEMENT|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
215117297|NCT05073471|BEHAVIORAL|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
215117298|NCT05073471|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
215117299|NCT02193295|BEHAVIORAL|Caloric Restriction|Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
215117300|NCT06324630|OTHER|Produce Prescription Delivery|Fruit and vegetable box delivery
215117301|NCT06324630|OTHER|Healthy Meal Kit Delivery|Ingredients to cook healthy meals delivered to home
215117302|NCT06324630|OTHER|Produce Prescription Mobile Market|Voucher to purchase fruits and vegetables at a mobile market
215117303|NCT03838978|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
214439577|NCT06717906|DIAGNOSTIC_TEST|Endoscopic Ultrasound|If sigmoidoscopy is warranted as per clinical indication, the consenting patients shall undergo endoscopic ultrasound (EUS) using a radial echo-endoscope during the same sitting of sigmoidoscopy without incurring any additional cost to the patient. Total rectal wall thickness in anterior and posterior wall shall be measured in upper, middle and lower rectum with assessment of vascularity (Modified Limberg scale). The maximal wall thickness including maximum mucosal and submucosal thickness shall be noted and compared to total wall thickness measured by transabdominal ultrasound (TAS) and Transperineal ultrasound (TPUS). On sigmoidoscopy, rectal inflammation shall be measured by ulcerative colitis endoscopic index of severity (UCEIS) in rectum. Biopsy seal be taken as standard protocol to document histologic inflammation (measured by Nancy histologic index) which is known to predict future risk of relapse.
215117304|NCT05697341|PROCEDURE|Ultra-Mini-PCNL|treatment to extract or disintegrate renal stones
215117305|NCT05697341|PROCEDURE|Stented SWL|treatment to disintegrate renal stones in the presence of a JJ
215117306|NCT06859476|DRUG|Manzanilla Sophia®|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
215117307|NCT06859476|DRUG|Meticel Ofteno® 0.5%|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
215117308|NCT00921778|DEVICE|Lapcone|Use of Lapcone during LSH
215117309|NCT00921778|PROCEDURE|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
214517843|NCT00637104|DEVICE|Vision Co-Cr stent implant|Implant of the Vision stent
214517844|NCT02981329|DRUG|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
214517845|NCT02981329|BEHAVIORAL|Questionnaires|Questionnaires will be completed to assess the impact quality of life
214439578|NCT06726434|PROCEDURE|Surgical neurotomy (SN)|"Surgical neurotomy will be performed under general anesthesia according to the previous description. Muscle relaxant drugs will not be used in order to prevent any interference with the intraoperative electrical stimulation.~The patient will be placed in a prone position and a vertical cutaneous incision will be made at the popliteal fossa location.~The tibial nerve will be dissected and the motor nerve branches of the soleus, gastrocnemius, tibialis posterior and flexor hallucis longus will be identified with intraoperative tripolar electrical stimulation. The selected motor nerve branches will be partially sectioned over a 5mm length under the microscope. The extent of nerve section will be determined according to the degree of spasticity and to the intraoperative residual muscular contraction under electrical stimulation"
214439579|NCT06726434|PROCEDURE|Cryoneurotomy (CN)|"After the use of an aseptic technique with 2% chlorhexidine, betadine application and a local anesthesia with lidocaine 1% (3ml), percutaneous cryoneurotomy will be performed with METRUM CRYOFLEX device guided by ultrasound with 1.2mm cryoprobe at -89°C placed through a #16 angio guide. Electrical stimulation will be performed to confirm tibial nerve contact at 0.8 mV.~The ice ball will be repositioned to two spots along the nerve. Each lesion will be treated for 2min cryoneurolysis at -89°C, followed by 2min without freezing (passive defreezing period) and 2min of cryoneurolysis at -89°C, based on cryotherapy for pain management."
215117310|NCT05508087|DIAGNOSTIC_TEST|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
215117311|NCT03384641|DRUG|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
214439580|NCT07037927|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
214439581|NCT07045142|DRUG|Atorvastatin|Participants will receive atorvastatin 20 mg daily.
214439582|NCT07045142|DRUG|Metformin|Participants will receive metformin 1000 mg daily.
214439583|NCT07045142|DRUG|Placebo|Participants will receive placebo 1000 mg daily, mimicking the appearance of metformin without containing active ingredients.
214439584|NCT06716112|DEVICE|Vagus Nerve Stimulation (VNS) Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers active VNS stimulation.
214439585|NCT06716112|DEVICE|Sham VNS Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers sham VNS stimulation.
214439586|NCT06716112|BEHAVIORAL|Upper Extremity Rehabilitation|"Rehabilitation training will be functional and activity-based, focusing on six task categories: reaching and grasping objects, gross movements with objects, flipping objects, inserting objects, self-feeding, and opening and closing containers.~Three 90-minute training sessions per week will be administered by a licensed occupational therapist, over two six-week treatment blocks. Sessions will be paired with either active or sham VNS administration."
214439587|NCT04320251|PROCEDURE|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
214439588|NCT07048795|OTHER|No Intervention: Observational Cohort|No intervention
214439589|NCT07048015|OTHER|Hot Water Foot Bath|Hot Water Foot Bath:When the water temperature reached 40 ° C, the elderly person's feet were placed in the foot bath tub. The elderly person's feet were kept in the water for 20 minutes.
214439590|NCT07056803|DRUG|Oral semaglutide|Starting dose 3 mg for a month, followed by 7 mg for a month increased up to 14 mg a month
214517846|NCT00168506|DRUG|SSRI|
214517847|NCT00168506|DRUG|CBT|
214517848|NCT00168506|DRUG|CBT/SSRI|
214517849|NCT02131454|OTHER|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
214517850|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
214517851|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
214517852|NCT05871788|DIAGNOSTIC_TEST|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
214517853|NCT01887002|DRUG|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
214517854|NCT01887002|DRUG|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
214517855|NCT05897307|DRUG|Ropivacaine|dexmedetomidine
214517856|NCT03322449|OTHER|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
214517857|NCT03322449|OTHER|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
214439591|NCT07056803|DRUG|subcutaneous semaglutide|subcutaneous semaglutide can be started at 0,25 mg a week for a month, to be increased at 0,5 mg a week, up to 1 mg a week
214439592|NCT07064486|DRUG|BGM0504|Administered SC
214439593|NCT07064486|DRUG|BGM0504|Administered SC
214439594|NCT07064486|DRUG|Semaglutide|Administered SC
214439595|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
214439596|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
214439597|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
214439598|NCT06834893|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
214439599|NCT06832033|OTHER|Exercise|12 weeks of concurrent training, which is understood as a combination of strength and aerobic exercises, not necessarily in the same training session. The weekly frequency will be 3 times per week. The aerobic component of the session will last between 30 and 50 minutes (increasing as the weeks go by) and the strength work will be made up of 8 exercises (3 upper body and 5 lower body). The intensity of the training will be individualized and always moderate.
214439600|NCT04077086|DEVICE|Spectacles|Intervention group children in middle school Year 1 will receive spectacles in December 2024. Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone 32 months (December 2024 - July 2027) of treatment by the endpoint of the trial.
214439601|NCT06834477|OTHER|Computed Tomography|low-dose CT is taken
214439602|NCT02627508|DRUG|Pregnenolone|orally administered Pregnenolone capsules
214439603|NCT02627508|DRUG|Placebo|orally administered placebo capsules
214439604|NCT02604277|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
214517858|NCT01184105|DRUG|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
215117312|NCT06998563|OTHER|Rotational Profile- Hip Internal and External Rotation Measurement|Hip internal and external rotation angles measurement, hip range of motion evaluations will be performed. Measurements will be performed using a universal goniometer. The children will be positioned in the prone position with their knees flexed 90° and placed on the edge of the bed. The tuberositas tibia will be chosen as the pivot point of the goniometer, and the movable arm will be aligned with the tibial crista. The fixed arm will be placed perpendicular to the floor and the movable arm will be guided by the tibial crista. During hip rotation, it will be ensured that the hip remains stable and the movement occurs only in the hip joint.
214439605|NCT02604277|BEHAVIORAL|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
214439606|NCT02604277|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
214439607|NCT02604277|BEHAVIORAL|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education \& Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education \& Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
214439608|NCT06830447|OTHER|low-frequency fatigue|Low frequency fatigue tested with myocene
214439609|NCT04307381|DRUG|Donidalorsen|Donidalorsen administered SC
214439610|NCT03181477|DEVICE|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
214439611|NCT06292208|BIOLOGICAL|IBD0333|This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
214439612|NCT06829745|OTHER|Laughter Yoga|Laughter yoga is applied to the intervention group patient 2 hours after the burn dressing. It is applied every other day for 30 minutes after dressing for three weeks.
214439613|NCT06791616|PROCEDURE|Colonoscopy|Surveillance colonoscopy
214439614|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
214517859|NCT01184105|DRUG|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
214439615|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
215117313|NCT06998563|OTHER|Rotational Profile- Craig's Test Measurement|The Craig's (Ryder) test, also known as the 'Trochanteric Prominence Angle Test', will be performed on the children included in the study according to the following protocol. The children will be placed in a prone position. The physiotherapist stood on the opposite side of the hip to be tested. The hips of the children will be placed in the extension position and the knee on the side to be tested will be held in the 90° flexion position. The physiotherapist palpated the trochanter major with the left hand and internal rotated the hip with the right hand. At the point where the trochanteric process will be most prominent, the angle between the tibia and the vertical plane will be measured using a goniometer and the femoral anteversion angle will be recorded.
215117314|NCT06998563|OTHER|Rotational Profile- Foot/Thigh Angle Measurement|Foot/thigh angle assessment will be performed by measuring the angle between the long axis of the femur bone and the foot with a goniometer in the prone position. One arm of the goniometer will be placed parallel to the long axis of the femur, while the other arm will be placed so that it passes through the 2nd and 3rd metatarsals. Normally, the thigh-foot angle should be in external rotation between 10-15°. In young children, this angle can be considered normal up to 30°. A decrease in the thigh-foot angle will indicate internal tibial torsion (expressed as a negative value), which is the internal rotation of the tibia. In this case, there is an abnormal internal rotation of the tibia. If the measured foot-thigh angle exceeds 30°, it is considered to be external tibial torsion (external rotation of the tibia).
215117315|NCT06998563|OTHER|Rotational Profile- Heel Bisector Line Measurement|The heel bisector line test is an evaluation method that helps diagnose metatarsus adductus. During the test, the child will be placed in the prone position with the heel between the physiotherapist's fingers. Then, the midpoint of the lines drawn from the malleoli will be determined. From this point, a perpendicular line will be drawn from the heel to the toes along the foot axis with the help of a goniometer. Normally, this line should end between the 1st and 2nd toes. If the line ends at the 3rd, 4th or 5th toes, this may indicate the presence of metatarsus adductus.
214439616|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
214439617|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
214439618|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
214439619|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
214439620|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
214439621|NCT05873062|DRUG|AUT00201|Single oral dose
214439622|NCT05873062|DRUG|Placebo|Single oral dose
214439623|NCT04948489|DRUG|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
214439624|NCT04948489|DRUG|Placebo|Placebo capsule everyday for 12 months
214439625|NCT05559736|DEVICE|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
214439626|NCT03485430|BEHAVIORAL|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
214439627|NCT06173362|DRUG|Abiraterone|Given abiraterone
214439628|NCT06173362|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214439629|NCT06173362|DRUG|Darolutamide|Given darolutamide
214439630|NCT06173362|DRUG|Prednisone|Given prednisone
214439631|NCT01216176|DRUG|Anastrozole|
214439632|NCT01216176|DRUG|AZD0530 (saracatinib)|
214439633|NCT01216176|DRUG|Placebo|
214439634|NCT04631406|BIOLOGICAL|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
214439635|NCT04847479|BEHAVIORAL|COVID-19 self-test|Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.
214439636|NCT04847479|BEHAVIORAL|COVID-19 test referral|Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
214439637|NCT05310019|OTHER|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
214517860|NCT02207140|DIETARY_SUPPLEMENT|HOWARU Restore|
214517861|NCT00247507|DRUG|acetylcysteine|
214517862|NCT00554814|DRUG|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
214517863|NCT00554814|DRUG|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
214517864|NCT00554814|DRUG|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
214517865|NCT01048385|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
214517866|NCT01048385|DIETARY_SUPPLEMENT|Placebo|Treated with capsules containing the vehicle (Sesame oil).
214439638|NCT05310019|OTHER|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
214439639|NCT01285479|DRUG|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
214439640|NCT05225402|DRUG|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
214439641|NCT03725722|DRUG|Delgocitinib cream|Cream for topical application
214439642|NCT03725722|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214439643|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
215117316|NCT06998563|OTHER|Rotational Profile- Q Angle Measurement|The Q-angle is defined as the angle formed between an imaginary line connecting the anterior superior iliac spine of the pelvis to the midpoint of the patella and the proximal projection of the line from the tibial tubercle to the center of the patella. The child will first be placed in a supine position with legs extended and muscles relaxed, and the midpoint of the patella will be marked with a colored pencil. Then, the goniometer will be placed at the midpoint of the patella and care will be taken to fix the movable arm so that it points to the anterior superior iliac spine and the fixed arm so that it follows the tibia and the angle between the two will be recorded. The measurement will be recorded in two different positions, lying and standing. Q angle between 10-15° in boys and 15-20° in girls will be considered normal.
215117317|NCT06998563|OTHER|Rotational Profile- Navicular Drop Test Measurement|The navicular drop test is commonly used in clinics to assess pes planus. It will begin with the child sitting, feet flat on the floor, and no weight bearing. The navicular tubercle will be palpated and marked first, then the distance from the tubercle to the floor will be measured. The child will then stand with equal weight on both feet and the distance will be measured again. Measurements will be taken bilaterally and recorded in millimeters. The difference between the weighted and unweighted measurements will indicate foot posture: 5-9 millimeters is normal (neutral), 10 millimeters or more will indicate pronation (inward rotation), and 4 millimeters or less will indicate supination (outward rotation). This test is important for assessing the degree of pes planus.
215117318|NCT06998563|OTHER|Rotational Profile- Foot Progression Angle Measurement|The foot progression angle will be used as an important parameter in determining potential disorders and alignment errors in the child's walking pattern by reflecting the rotational relationships between the femur, tibia and foot. For this measurement, two chairs will first be placed opposite each other with a distance of 2 m between them. Then, the child will be asked to sit on the chair. In the sitting position, the middle of the heel and the second toe will be marked with colored paint. After the marking, the child will be asked to walk naturally on a flat surface to the chair opposite. The child will stand up from the sitting position and walk approximately 5-6 steps on a flat surface to the chair opposite. Then, the child will be asked to sit on the chair opposite and clean the paint off his foot. This colored marking will be made in a way that will create the child's walking traces. When the child finishes walking, these traces will be measured in degrees using a goniometer.
215117319|NCT06998563|OTHER|Muscle Shortness/Flexibility- Thomas Test Measurement|The Thomas test will be performed to evaluate shortness/tightness in the hip flexor muscle group, especially in the iliopsoas muscle. The child will be placed in the supine position, the lumbar spine will be fixed and the assessment will begin. During the test, while the assessed hip is in knee extension, the opposite hip and knee will be passively flexed by the physiotherapist, and the hip movement of the assessed side will be observed during this time. The Thomas test will be recorded as negative if no flexion movement is observed in the assessed hip. In the presence of shortness/tightness, the assessed hip is seen to be flexed, and in this case, the Thomas test will be recorded as positive.
215117320|NCT06998563|OTHER|Muscle Shortness/Flexibility- Popliteal Angle Measurement|The popliteal angle test will be used to evaluate shortness or tightness of the hamstring muscles. The hip and knee will be placed in a 90° flexion position while the child is in the supine position. While the physiotherapist passively moves the knee joint towards extension, the popliteal angle will be measured using a goniometer. While one arm of the goniometer is placed parallel to the lateral surface of the femur, the other arm is held parallel to the fibula head and the angle will be measured. The knee joint will be extended until it encounters resistance and the angle between the tibia and the vertical plane will be recorded as the popliteal angle.
214517867|NCT06002672|DIETARY_SUPPLEMENT|Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).|Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
214517868|NCT06002672|DIETARY_SUPPLEMENT|Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.|100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
215117321|NCT06998563|OTHER|Muscle Shortness/Flexibility- Silfverskiöld Test Measurement|Gastrocnemius assessment will be evaluated with the Silfverskiold test for all children participating in the study. The assessment will be performed bilaterally in supine positions where the child does not bear weight on their feet. The knee joint will be in full extension and 90° flexion, the subtalar joint will be in a neutral position, and the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles will be recorded in degrees (°). Passive ankle dorsiflexion of ≤ 10° with the knee extended and a minimum of 10° increase in dorsiflexion with the knee flexed will be considered as isolated gastrocnemius muscle shortness.
215117322|NCT06998563|OTHER|Muscle Shortness/flexibility- Ober Test Measurement|The Ober test will be performed to measure the length of the iliotibial band. Both the Ober test and the modified Ober test are widely used and accepted tests to assess iliotibial band length. During the test, the child will be placed in a supine position with the lower leg slightly bent at the hip and knee. The upper leg will be in 90° flexion of the knee. Once positioning is complete, the physiotherapist will hold the ankle of the upper leg with one hand and stabilize the hip with the other hand. The leg will then be abducted and the knee extended and the leg moved until the femur is in line with the body. Finally, the thigh will be allowed to fall towards the surface in this plane and the result of the test will be judged by the amount of adduction of the hip. If the knee hangs in the air, the test is positive. If the knee falls, the test is negative
214439644|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
214439645|NCT04272736|DIETARY_SUPPLEMENT|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
214439646|NCT05678699|BEHAVIORAL|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1\) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries"
214439647|NCT05678699|BEHAVIORAL|Doula|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1. health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~2. care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania."
214439648|NCT05678699|BEHAVIORAL|Standard Care|Participants receive standard care without quality interventions or doula care
214439649|NCT05154825|OTHER|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
214439650|NCT01643070|DRUG|Capecitabine, Oxaliplatin|Induction chemotherapy - Induction XELOX (Capecitabine 1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - XELOX RT (Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.)
214439651|NCT01643070|RADIATION|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
214439652|NCT04389372|BEHAVIORAL|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
214439653|NCT05885529|OTHER|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
214439654|NCT01600014|DRUG|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
214439655|NCT01600014|DRUG|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
214439656|NCT02872025|DRUG|Pembrolizumab|Injected intralesionally
214439657|NCT02872025|BIOLOGICAL|Intralesional mRNA 2752|Injected intralesionally
214517869|NCT03094442|DRUG|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
214439658|NCT05759533|PROCEDURE|Corrected carotid flow time, IVC diameter|Corrected carotid flow time correction: is the carotid systole time, with heart rate correction applied IVC Collapsibility Index measurement is a reliable predictor of intraoperative hypotension within 30 minutes of spinal anesthetic administration
214439659|NCT01976247|DEVICE|High Intensity Focused Ultrasound Device|
214439660|NCT01976247|DEVICE|Noninvasive Cryolipolysis Device|
214439661|NCT06464055|DRUG|Dose Escalation|Drug: GQ1010
214517870|NCT03094442|DRUG|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
214517871|NCT01135719|PROCEDURE|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
214517872|NCT05165420|OTHER|Cosmetic product|RV4941A is a face cream product
214517873|NCT06510751|OTHER|CGRP level|CGRP and substance P levels will be analysed by ELISA method in CSF and blood materials.
214517874|NCT03038490|DIETARY_SUPPLEMENT|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
214517875|NCT04712032|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
214517876|NCT00043459|DRUG|intravenous T900607-sodium|
215117323|NCT06998563|OTHER|Muscle Shortnes/flexibility- Duncan-Ely Test Measurement|The Duncan-Ely test will be used to evaluate the shortness and tightness of the rectus femoris muscle. While the child is lying in the prone position, the hip will be fixed with one hand by the physiotherapist and the hip and knee will be kept in extension. In this position, the knee joint will be passively flexed in order to stretch the rectus femoris muscle on the tested side. If no shortness or tightness is observed in the rectus femoris muscle on the same side during the test and hip extension is maintained, the Duncan-Ely test will be recorded as negative. However, when the knee is flexed and a flexion movement is observed in the hip, the test will be recorded as positive.
215117324|NCT06998563|OTHER|Muscle Shortness/Flexibility- Sit-Reach Test Measurement|The Sit-Reach test will be used to evaluate the flexibility of the hamstring and lower back muscle groups. The S\&R Sit and Reach® table will be used for this test. The child will sit in front of the table with dimensions of 55 centimeters long, 35 centimeters wide, and 30 centimeters high, and his/her feet will be positioned on the foot surface of the table. The child will be asked to place his/her hands on top of each other and stretch forward in a slow and controlled manner, bringing the ruler on the table forward. He/she will be asked to wait 1-2 seconds at the farthest point without stretching forward or backward. Scoring will be done according to the ruler on the table. (On this table, the child's ability to bring the ruler to the tips of his/her toes corresponds to 23 centimeters). The test will be repeated three times for each child to ensure reliability, and the highest value will be recorded in centimeters.
214439662|NCT06464055|DRUG|Dose Expansion1|Drug: GQ1010 dose 1
214439663|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose 2
214439664|NCT06464055|DRUG|Dose Expansion3|Drug: GQ1010 dose 3
214439665|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
214439666|NCT02975505|OTHER|Strict blood pressure control|Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
214439667|NCT05515224|OTHER|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
214439668|NCT05515224|OTHER|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
214439669|NCT05833516|DIAGNOSTIC_TEST|Cardiac Catheterization|"The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study."
214517877|NCT01269307|PROCEDURE|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
214517878|NCT01269307|PROCEDURE|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
214517879|NCT02501694|OTHER|Auscultation|Electronic stethoscope
214517880|NCT03369483|OTHER|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
214517881|NCT01231074|DRUG|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
214517882|NCT06073470|DRUG|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
214439670|NCT05499741|DEVICE|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
214439671|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can effect pain, craving, and anxiety.
214439672|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
214439673|NCT01259401|BEHAVIORAL|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
214439674|NCT01259401|BEHAVIORAL|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
214439675|NCT06248008|DRUG|ASC40|ASC40 tablets orally once daily
214439676|NCT06241482|PROCEDURE|Enhanced recovery after surgery|"The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment"
214439677|NCT06241482|PROCEDURE|Conventional therapy|Conventional therapy in neurocritical care.
214439678|NCT05769595|BIOLOGICAL|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
214439679|NCT05769595|DRUG|Placebo|IV infusion
214517883|NCT00537914|DRUG|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
215117325|NCT06998563|OTHER|Postural Control Assessment with Biodex Balance System (BBS)|Postural stability, limits of stability, and sensory integration of balance will be assessed using the Biodex Balance System®. Biodex Balance System is a validated and reliable device used to evaluate postural stability, limits of stability, and fall risk. It consists of a balance platform, arm supports, a screen, and a printer. The platform can be set to static or dynamic mode (12 levels; level 12 = most stable, level 1 = least stable with up to 20° movement in all directions). Prior to testing, children will be informed about the procedures. The heel and toe positions will be recorded based on medial-lateral (B-J), anterior, and posterior (1-21) axes. Arm support and screen height will be individually adjusted. Child-specific posture and identification data will be entered into the system. Three tests will be performed: postural stability, limits of stability, and sensory integration of balance.
215117326|NCT06998563|OTHER|Muscle Strength Assessment with Micro-FET2|Muscle tests will be performed using the MicroFET 2 digital hand dynamometer according to the device manual. The measurement will be performed in supine, prone, side-lying and sitting positions by preventing compensatory movements. During the test, the arms will be positioned so that they will not receive power from anywhere on/to the side of the body. Measurements will be performed bilaterally. While the child to whom the test is applied is expected to perform the requested movement with all his/her strength, the evaluating physiotherapist will apply resistance in the opposite direction in proportion to the strength. During the evaluation of the same muscle, a 30-second break will be given between repetitions, and a five-minute rest will be given before moving on to the test for a different muscle. Isometric muscle strength of the Iliopsoas, Gluteus Maximus, Gluteus Medius, Quadriceps, Hamstring, Tibialis Anterior, and Gastrosoleus muscles will be evaluated.
214439680|NCT06241794|PROCEDURE|Group M-TAPA|Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.
214439681|NCT06241794|PROCEDURE|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
214439682|NCT05437380|DIAGNOSTIC_TEST|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
214439683|NCT06696534|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
214517884|NCT02312258|DRUG|Placebo|Ixazomib placebo-matching capsules.
214517885|NCT02312258|DRUG|Ixazomib|Ixazomib capsules.
214517886|NCT01217697|DRUG|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
214439684|NCT06696534|OTHER|Survey using a questionnaire.|Experience questionnaire into colorectal cancer screening programme
214439685|NCT05123365|DRUG|N-Acetylcysteine|Given PO
214439686|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
214439687|NCT03481777|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
214439688|NCT03481777|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
214692769|NCT05844345|OTHER|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
214517887|NCT01217697|DRUG|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
214517888|NCT05912998|PROCEDURE|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
214517889|NCT01204879|BEHAVIORAL|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
214692770|NCT03573128|BEHAVIORAL|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
214692771|NCT03573128|OTHER|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
214692772|NCT00663728|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
214439689|NCT02064517|DEVICE|MTA|Creation of a barrier apicale in the MTA
214439690|NCT02064517|DEVICE|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
214517890|NCT01180959|DRUG|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
214517891|NCT01180959|DRUG|Erlotinib|150 mg by mouth once a day.
215117327|NCT06998563|OTHER|Functional Capacity Assessmnet with 6 Minute Walk Test Measurement|"The 6MWT will be done on a flat 30-meter track marked every 3 meters, with clear start and finish lines. Before the test, the child rests 15 minutes while contraindications will be checked. If none, blood pressure, oxygen saturation, pulse, and Borg scale scores for dyspnea and fatigue will be recorded. Medications taken will be noted. The child will be instructed to walk at their own pace for 6 minutes, allowed to stop or rest, and continue until test is over is announced. The test will start with test is started and end with test is over. The timer will run continuously even if paused. The test ends if chest pain, severe breathlessness, cramps, unsteadiness, sweating, pallor, or oxygen saturation \<85% occurs. Afterward, the child will be sits and post-test vitals and Borg scores will be recorded. Distance walked and any complaints during the test will be noted."
214439691|NCT05696080|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214439692|NCT05696080|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
214439693|NCT05696080|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
214439694|NCT05696080|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214439695|NCT00696124|BIOLOGICAL|VM202 2 mg|2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
214439696|NCT00696124|BIOLOGICAL|VM202 4 mg|4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
214439697|NCT00696124|BIOLOGICAL|VM202 8 mg|8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
214439698|NCT00696124|BIOLOGICAL|VM202 16 mg|16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
214439699|NCT02724228|DRUG|BMN 111|BMN 111 will be administered subcutaneously daily.
214439700|NCT05587530|BEHAVIORAL|Treatment engagement and retention intervention for suicidal clients|The manualized behavioral intervention for treatment engagement and retention of suicidal clients will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1). In addition to factors identified by stakeholders, if deemed feasible and acceptable during phase 1, the intervention will include structured phone outreach, shared decision-making, and peer support.
214517892|NCT03730727|BEHAVIORAL|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
214517893|NCT03730727|DIETARY_SUPPLEMENT|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
214517894|NCT03140709|DRUG|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
214517895|NCT00303537|DRUG|metformin|
215117328|NCT06998563|OTHER|Lower Extremity Functional Scale|The Lower Extremity Functional Scale will be used to evaluate the functional ability of the entire lower extremity in individuals with musculoskeletal disorders. This scale will question the difficulty experienced in various daily activities due to the problem in the lower extremity with 20 items. Each item will be scored between 0-4 on a Likert scale (0=extremely difficult/too difficult to do the activity; 4=not difficult at all). The total score varies between 0-80 and the higher the score, the higher the functional level. A validity and reliability study has been conducted for the Turkish version of the scale to be used in evaluating lower extremity functions.
215117329|NCT06998563|OTHER|Pain Assessment with Viusal Analog Scale|"The Visual Analog Scale is a simple and reliable tool that is widely used to assess subjective experiences such as pain. It consists of a 10 cm horizontal line with one end indicating no pain and the other end indicating worst pain imaginable. Individuals will mark the point that reflects their perception of intensity, which will then be measured in millimeters or centimeters to obtain a numerical score. Higher values will indicate greater severity. The Visual Analog scale is valid and reliable in a variety of populations and conditions, including musculoskeletal pain."
215117330|NCT06998563|OTHER|Demographic Information Form|All children's gender, age, body weight, height and dominant side information will be recorded before clinical evaluations. The body mass index (kilogram/meter2) of the child will be calculated and recorded with the recorded body weight (kilogram) and height (meter) values.
215117331|NCT06998563|OTHER|Ankle Joint Dorsiflexion Range of Motion Measurement|Dorsiflexion range of motion with the knee joint in full extension and 90° flexion, the subtalar joint in a neutral position, the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles were recorded in degrees (°). Measurements will be made bilaterally.
214439701|NCT06447129|OTHER|Exercise|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist."
214439702|NCT06447129|OTHER|Neuromuscular electrical stimulation|The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
214439703|NCT05945719|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
214439706|NCT05853822|OTHER|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
214439707|NCT05853822|OTHER|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
214439708|NCT05768373|DEVICE|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
214439709|NCT05768373|DEVICE|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
214439710|NCT05956821|DRUG|SIACI of cetuximab and bevacizumab|Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
214439711|NCT06409026|DRUG|Sotatercept|As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
214439712|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
214439713|NCT05468736|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
214439714|NCT03954184|BEHAVIORAL|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
214439715|NCT06516302|DRUG|GR1802|GR1802 will be administered SC.
214439716|NCT06516302|DRUG|Placebo|The placebo will be administered SC.
215117332|NCT06998563|OTHER|Leg Length Measurement|Leg Length Measurement, the child will be placed in a supine position. The legs will be positioned in extension and the muscles will be relaxed. The physiotherapist will measure and record the child's right leg length from the SIAS bone to the medial malleola with a flexible metal tape measure. Measurements will be made bilaterally.
215117333|NCT04544956|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
214439717|NCT03398200|BIOLOGICAL|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
215117334|NCT04544956|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
214439718|NCT03398200|OTHER|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
214439719|NCT06810687|DRUG|Methenamine Hippurate 1g BD|Antibiotic prophylaxis
214517896|NCT04053491|PROCEDURE|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
214517897|NCT02817386|OTHER|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
215117335|NCT06613802|OTHER|Time|This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023
214439720|NCT06810687|OTHER|Antibiotic prophylaxis|Antibiotic prophylaxis
214439721|NCT04063709|DIAGNOSTIC_TEST|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
214439722|NCT06172933|BEHAVIORAL|Move with Meaning|Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
214439723|NCT04519177|BEHAVIORAL|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
214439724|NCT06398613|DIAGNOSTIC_TEST|extended pelvic lymph node dissection (ePLND)|Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively in both arms of the study. In arm A all patients will undergo ePLND, in arm B only patients with positive PSMA PET/CT will undergo ePLND
214517898|NCT05167578|BEHAVIORAL|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
214517899|NCT05018065|BEHAVIORAL|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
214517900|NCT01735435|OTHER|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
214517901|NCT02696109|BEHAVIORAL|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
214692773|NCT00663728|DRUG|Placebo|Matching placebo
214692774|NCT02594397|OTHER|acupoints combination 1|
214439725|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
214439726|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
214692775|NCT02594397|OTHER|acupoints combination 2|
214692776|NCT02594397|OTHER|sham acupoints combination|
215117336|NCT06870617|OTHER|Practical Geriatric Assessment|The PGA will be administered via the electronic health record (EHR), available for patients to complete independently prior to an initial medical oncology visit, or during the visit with staff assistance. Results from the PGA will be shared automatically with clinical teams via the EHR, including a Best Practice Alert highlighting any identified geriatric impairment(s) and ASCO's recommendation for PGA-adapted care.
215117337|NCT06870617|OTHER|Correlation of body composition PGA and step count with outcomes|Monitoring of step counts (measured via FitBit) and body composition (measured via standard abdominal CT scans)
215117338|NCT06290687|DRUG|Neoadjuvant Chemotherapy|"Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)"
214439727|NCT03744975|DRUG|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
214439728|NCT03744975|DRUG|Placebos|Participants will receive 1oral Placebo capsule
214692777|NCT04395352|DEVICE|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
214692778|NCT01534234|DEVICE|PARADYM RF SONR|SonR CRT Optimization
214692779|NCT01534234|DEVICE|PARADYM RF SONR|Echocardiography Optimization
214439729|NCT05080972|BEHAVIORAL|in-the-kNOW mobile app|"in-the-kNOW is a mobile app with restricted access through a single-use registration code.~The app will be developed with regular input from Black women enrolled in Atlanta Healthy Start Initiative (AHSI).~The app will have culturally- and contextually targeted HIV prevention and optimal sexual health messaging.~Each participant will have 4 months to engage with the app, with e-reminders in time intervals preferred by the participants (a minimum of 3 times per week) via push notifications. During the 4-month study period, participants will receive push notifications to encourage the use of all app domains: My Logger, My Test, My Resources, and My Circle.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
214439730|NCT05080972|BEHAVIORAL|Control|"The control condition will be a one-time virtual women's health counseling session with a healthcare provider. Participants will get information on~1. Sexual Transmitted Infections (STI)/HIV prevention,~2. Family planning, and~3. General health promotion (e.g., exercise and diet).~The control condition provides access to HIV prevention materials that are publicly available but that do not offer the dynamic and individually customized features of the health communication/new media research approach proposed herein.~Control group participants will continue to receive the usual care associated with Atlanta Healthy Start Initiative (AHSI) enrollment.~The control group will not have access to intervention content (e.g. commodity ordering) until after the study has concluded.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
214439731|NCT04793906|OTHER|Iron supplement with a lunch meal containing beef|Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
214439732|NCT04793906|OTHER|Iron supplement with a lunch meal containing plant-based alternative|Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
214439733|NCT05657743|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
214439734|NCT05355168|DRUG|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
214439735|NCT05321381|OTHER|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
214439736|NCT06749652|DEVICE|firm silicone stent insertion|Insertion of firm silicon ureteral stent (Percuflex Plus)
214439737|NCT06749652|DEVICE|Soft silicone ureteral stent insertion|Soft silicone ureteral stent insertion
214439738|NCT06748352|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
214439739|NCT06748352|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
214439740|NCT05672615|OTHER|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
214517902|NCT02696109|BEHAVIORAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
214517903|NCT00123500|BEHAVIORAL|Diet|Diet
215117339|NCT06290687|PROCEDURE|Partial cystectomy with Extended pelvic lymph node dissection|Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.
214439741|NCT05672615|OTHER|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
214439742|NCT05672615|OTHER|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
214439743|NCT05672615|OTHER|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
214439744|NCT05672615|OTHER|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
214439745|NCT01649271|DRUG|Herceptin|3-weekly
214439746|NCT01649271|DRUG|afatinib|at MTD level
214439747|NCT01649271|DRUG|trastuzumab|3-weekly
214439748|NCT01649271|DRUG|Herceptin|weekly
214439749|NCT01649271|DRUG|afatinib|at MTD level
214517904|NCT00123500|BEHAVIORAL|Physical Activity|Physical Activity
214517905|NCT00123500|BEHAVIORAL|Environment|Environment
214439750|NCT01649271|DRUG|afatinib|escalating dose
214439751|NCT03753074|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
214439752|NCT06339801|DEVICE|MiVu|All patients will undergo mucosal impedance (MI) measurement using the MiVu™ Mucosal Integrity Testing System (Diversatek Healthcare, Inc.).
214517906|NCT00123500|OTHER|Control Group|Control Group
214517907|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
214517908|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
214517909|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
214517910|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
214517911|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
214517912|NCT00438048|PROCEDURE|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
214517913|NCT00438048|DRUG|Artificial Saliva|5ml 3 times daily
214439753|NCT05963737|PROCEDURE|PS setting strategy in pressure-support ventilated patients|Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).
214439754|NCT06313788|OTHER|Possession of a customized placebo analgesic band-aid prior to vaccination or injection|Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
214439755|NCT05614934|DRUG|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
214439756|NCT05614934|DRUG|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
214439757|NCT05614934|DRUG|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
214439758|NCT06180967|DRUG|Midazolam Syrup|Administered Orally.
214439759|NCT06180967|DRUG|Midazolam Solution|Administered IV bolus.
214439760|NCT06180967|DRUG|Pirtobrutinib|Administered Orally.
214439761|NCT00540787|DEVICE|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
214439762|NCT00540787|DRUG|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
214439763|NCT00540787|DEVICE|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
214517914|NCT05773872|OTHER|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
214517915|NCT05248672|DRUG|CT1812|Study Drug
214517916|NCT01590056|OTHER|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test"
214517917|NCT00796835|DRUG|ER OROS Paliperidone|
215117340|NCT06290687|DRUG|Adjuvant systemic therapy|Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
214517918|NCT03109899|BEHAVIORAL|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
214517919|NCT06231316|DRUG|Norepinephrine Injection|Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
215117341|NCT00108771|DRUG|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
215117342|NCT00108771|DRUG|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
214439764|NCT02632760|DRUG|Ferric carboxymaltose|treatment for Iron deficient anaemia
214439765|NCT02632760|DRUG|Placebo|placebo - no active drug
214439766|NCT05756075|BEHAVIORAL|Aerobic exercise training|Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
214439767|NCT06017999|DRUG|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
215117343|NCT03275805|OTHER|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
215117344|NCT03275805|OTHER|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
215117345|NCT07020988|DRUG|Staccato Alprazolam|Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.
215117346|NCT07020988|DRUG|Midazolam|Study participants will receive single dose of IV Midazolam at pre-specified time points.
215117347|NCT07020988|DRUG|Diazepam|Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.
214439768|NCT06017999|DRUG|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
214439769|NCT05906264|BEHAVIORAL|Tele-intervention|Tele-intervention every week to check compliance and encourage the rehabilitation
214439770|NCT05686967|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
214439771|NCT05686967|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
214439772|NCT05686967|BEHAVIORAL|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
214517920|NCT04436016|DRUG|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
214517921|NCT04436016|DRUG|Placebo|Mannitol will be encapsulated for adequate blinding.
214439773|NCT04661566|BEHAVIORAL|"Basic Education (Education)"|All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
214517922|NCT02260154|DRUG|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
214517923|NCT02684435|DRUG|Perflutren lipid microsphere|Dosing per approved package label
214517924|NCT02561195|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
214517925|NCT02561195|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
214517926|NCT02394613|DRUG|ANX776|Single intravenous injection
214439774|NCT04661566|BEHAVIORAL|"Narrative Videos (Narratives)"|The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
214439775|NCT04661566|BEHAVIORAL|"Skills Building Videos (Skills)"|The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
214517927|NCT01736449|DRUG|Bevacizumab|
214517928|NCT03905512|DRUG|SEL-212|Administered as specified in the treatment arm
214517929|NCT03905512|DRUG|KRYSTEXXA®|Administered as specified in the treatment arm
214517930|NCT04990388|BIOLOGICAL|UX053|mRNA-based biologic
214517931|NCT04990388|OTHER|Placebo|consists of the same components as the formulation buffer for UX053
214517932|NCT04990388|DRUG|Antipyretic|participants will receive oral premedication prior to infusion
214517933|NCT04990388|DRUG|H2 Blocker|participants will receive oral premedication prior to infusion
214517934|NCT04990388|DRUG|H1 Blocker|participants will receive oral premedication prior to infusion
214517935|NCT03421301|DIETARY_SUPPLEMENT|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
214517936|NCT01778842|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
214517937|NCT01778842|DRUG|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
214517938|NCT04769141|COMBINATION_PRODUCT|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
214517939|NCT00415688|BEHAVIORAL|Low carbohydrate, ketogenic diet|
214517940|NCT00415688|BEHAVIORAL|Low glycemic index, reduced calorie diet|
214517941|NCT02363049|PROCEDURE|Colectomy|
214517942|NCT02363049|DRUG|Chemotherapy|
214517943|NCT00004784|DRUG|methotrexate|
214517944|NCT00004784|DRUG|ursodiol|
214517945|NCT01446718|BIOLOGICAL|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
214517946|NCT00725972|OTHER|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
214517947|NCT00725972|PROCEDURE|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
214517948|NCT05585632|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214517949|NCT05585632|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214517950|NCT05585632|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214517951|NCT05585632|BIOLOGICAL|mRNA-1045|Formulation for injection
214517952|NCT05585632|BIOLOGICAL|mRNA-1230|Formulation for injection
214517953|NCT04536766|BEHAVIORAL|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
214517954|NCT04536766|BEHAVIORAL|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
214517955|NCT02493166|OTHER|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
214517956|NCT00894218|PROCEDURE|Arthroplasty|Hip or knee arthroplasty
215117348|NCT06700525|BEHAVIORAL|Non-Sedentary Behavior Habit Formation|"Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time."
214439776|NCT04661566|BEHAVIORAL|"Interactive Scenarios (Scenarios)"|The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
214439777|NCT04661566|BEHAVIORAL|"Future Life Planning Tool (Future)"|The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
214439778|NCT04661566|BEHAVIORAL|"Epidemiological Risk Scenario (Risk)"|The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
214517957|NCT03762278|DIETARY_SUPPLEMENT|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
215117349|NCT06700525|BEHAVIORAL|Sedentary Screen Time Reduction Smartphone App|The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
214439779|NCT05621889|PROCEDURE|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
214439780|NCT02466815|DRUG|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
214517958|NCT03762278|DIETARY_SUPPLEMENT|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
214517959|NCT03560206|BEHAVIORAL|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
214517960|NCT03560206|BEHAVIORAL|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
214517961|NCT00000492|DRUG|propranolol|
214517962|NCT00783146|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
214517963|NCT00783146|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
214517964|NCT00783146|DRUG|placebo|placebo, once daily for 15 days
214439781|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
214517965|NCT00753259|OTHER|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
214517966|NCT00753259|OTHER|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
214517967|NCT00385866|BEHAVIORAL|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
214517968|NCT00385866|BEHAVIORAL|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
215117350|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
215117351|NCT06702553|DRUG|Nitric Oxide Gas|Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
215117352|NCT06702553|DRUG|Standard Care Arm|Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
215117353|NCT07034261|DEVICE|Blinded Continuous Glucose Monitoring Device|Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.
214439782|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
214517969|NCT05062343|DEVICE|Dilapan-S|Osmotic dilator
214517970|NCT05062343|DEVICE|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
215117354|NCT06722872|OTHER|Laughter therapy|Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.
214439783|NCT06279650|OTHER|Self-hypnosis|The HYlaDo intervention comprises 8 90-minute sessions. Session 1 offers psycho-education on pain and medical hypnosis. Sessions 2 to 7 offer brief introductions followed by hypnosis induction, during which the CBT elements (exposure and cognitive restructuring) to be worked on during the session are introduced. The sessions are aimed at managing: 2- anxiety and mood; 3- pain dramatization; 4- and 5- pain perception; 6- kinesiophobia; 7- future projection and resource mobilization. Session 8 provides feedback and recommendations for independent practice. Each hypnosis follows the same pattern: induction, deepening, CBT-based hypnotic work, post-hypnotic suggestions and return to wakefulness, explanations of the exercise and recommendations for independent practice.
214439784|NCT06279650|OTHER|Psycho-education and cognitive Bahavioral therapy (CBT)|The psychoeducation-CBT intervention for pain and anxiety/depression consists of 8 90-minute sessions. It has already been implemented in HMR's pain clinic, and controls both the effects of time and repetition of measures, as well as non-specific factors including expectations associated with receiving active treatment, therapeutic relationship, frequency of encounters, and participation in a manualized intervention. It is designed to inform participants about pain, its costs, neurophysiology, nature and impact. It includes general information on pain, as well as information tailored to the participants' particular type of pain. The sessions are interactive, with the therapist stimulating discussion of the educational content and its relevance to the participants' lives.
214439785|NCT05265728|DRUG|Natalizumab|Administered as specified in the treatment arm
214439786|NCT04392050|OTHER|Interview|Complete interview
214439787|NCT04392050|OTHER|Focus Group|Attend focus groups
214439788|NCT04392050|OTHER|Questionnaire Administration|Ancillary studies
214439789|NCT03433469|DRUG|Osimertinib|Given PO (orally)
214439790|NCT03433469|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214517971|NCT01138969|DRUG|esomeprazole|esomeprazole 20 mg qd for 6 months
214517972|NCT03138499|BIOLOGICAL|Nivolumab|Specified dose on specified days
214517973|NCT03138499|BIOLOGICAL|Brentuximab vedotin|Specified dose on specified days
214517974|NCT03102892|PROCEDURE|Scaling root planing|Treatment by scaling and root planing alone.
215117355|NCT06726486|DIETARY_SUPPLEMENT|Atémpero|A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.
215117356|NCT06726486|DIETARY_SUPPLEMENT|Control (Standard treatment)|A complete high-protein and high-calorie diet with mixed fibre was administered.
215117357|NCT06725524|BIOLOGICAL|JMT601|intravenous infusion on day 1 once a week
215117358|NCT07060859|DRUG|Topical Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate|A topical combination of dexamethasone (anti-inflammatory), ascorbic acid (antioxidant), and β-sodium glycerophosphate (mineralization support) was applied directly to the implant site during surgery. The intervention aimed to enhance early osseointegration by modulating local biological responses.
215117359|NCT07066540|DRUG|Reamberin® solution for infusion, 1.5 %|Reamberin® in daily dose 10 mL/kg
215117360|NCT07066995|BIOLOGICAL|Mesothelin and Claudin 18.2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, Mesothelin and Claudin 18.2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial Mesothelin and Claudin 18.2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
214517975|NCT03102892|PROCEDURE|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
214517976|NCT05752370|DEVICE|High flow oxygen|Use of HFO
214517977|NCT05752370|OTHER|Usual care|Room air or normal flow oxygen
214517978|NCT03180541|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
214517979|NCT04573218|DRUG|Placebo|The placebo contains glucose
214517980|NCT04573218|DIETARY_SUPPLEMENT|250 mg OPP|250 mg Oil Palm Phenolics
214517981|NCT01334606|DEVICE|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
214439791|NCT04605198|BEHAVIORAL|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.
214439792|NCT04605198|BEHAVIORAL|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
214517982|NCT01334606|DEVICE|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
214517983|NCT01499979|PROCEDURE|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
214517984|NCT01513733|DRUG|tasquinimod|tasquinimod 0.25 mg continuously
214517985|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
214517986|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
214517987|NCT02674399|DRUG|JointStem|
214517988|NCT02674399|DRUG|Synvisc-One|
214517989|NCT01014559|DRUG|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
214517990|NCT01014559|DRUG|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
214517991|NCT02766361|BEHAVIORAL|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
214517992|NCT02766361|OTHER|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
214517993|NCT01342497|DRUG|isoniazide|Tablets, dosing 3 times daily, 12 weeks
214517994|NCT01342497|DRUG|placebo|tablets, dosing 3 times daily, 12 weeks
214517995|NCT05197179|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
214439795|NCT06131541|PROCEDURE|autogenous tooth graft|undemineralized autogenous tooth graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
214439796|NCT06131541|PROCEDURE|autogenous bone graft|autogenous bone graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
214439797|NCT06058000|DRUG|1.5% QLM3003|QLM3003 topical cream
214439798|NCT06058000|DRUG|2% QLM3003|QLM3003 topical cream
214517996|NCT05197179|OTHER|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
214517997|NCT01156454|PROCEDURE|X-ray|surgical specimen taken to radiology and contents x-rayed
214517998|NCT04805008|OTHER|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
214517999|NCT04805008|OTHER|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
214518000|NCT00594282|DEVICE|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
214518001|NCT03226600|DEVICE|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
214518002|NCT03226600|DEVICE|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
214518003|NCT02099188|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
214518004|NCT02099188|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
214518005|NCT02099188|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
214518006|NCT02099188|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
214518007|NCT02099188|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
214518008|NCT02099188|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
214439799|NCT06058000|DRUG|Vehicle (Placebo)|Vehicle topical cream
214439800|NCT06111313|RADIATION|FTLEAD|In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.
214439801|NCT06111313|DRUG|Ultra-Short-Term Androgen Deprivation Therapy with Relugolix|Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.
215117361|NCT07066683|OTHER|CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION|"Tip: Ensure that this name matches the name used in the associated Arm Description.~CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION):~* Perceived fatigue~* Mental functions~* Sensory functions and pain~* Neuromusculoskeletal and movement-related functions~* Functions of the cardiovascular and respiratory systems~  o Exercise stress test~* Fatigability (neuromuscular fatigue)~  * Lower limbs~ * Maximum voluntary strength and power~ * Study of the central and peripheral components of fatigue~ACTIVITIES AND PARTICIPATION~* Mobility~  * Clinical standard tests for balance and walking~ * Quantified motion analysis~* Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls"
215117362|NCT07065487|DEVICE|Intraoral Scanner - Standard Protocol|A full-arch digital impression is obtained using a high-precision intraoral scanner. Scan bodies are placed on multi-unit abutments and scanned without the use of external reference markers or geometric aids. The scan follows the manufacturer-recommended scanning path to capture the complete arch. This serves as a baseline digital technique for comparison with geometric pattern-assisted scanning.
215117363|NCT07065487|DEVICE|Intraoral Scanner with Geometric Reference Pattern|The same intraoral scanner is used, but with an additional geometric reference pattern introduced in the scanning field to improve stitching accuracy and alignment of the digital scan.
215117364|NCT07065487|PROCEDURE|Conventional Splinted Impression Technique|A physical impression is taken using open-tray impression copings splinted with DuraLay resin and polyvinyl siloxane (PVS) material in a custom tray, according to conventional protocols for full-arch implant prostheses.
215117365|NCT06753448|DRUG|Diosmin and Hesperidin Combination|Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
215117366|NCT06523868|OTHER|GRAIL Galleri|A multi-cancer early detection (MCED) blood test.
214439802|NCT06111313|RADIATION|HypoLEAD|In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.
214439803|NCT06111313|DRUG|ADT Standard of Care|Participants will receive ADT as per standard of care (SOC).
214439804|NCT06750237|OTHER|Stable surface and Isometrics|will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week
214518009|NCT02099188|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
214518010|NCT02099188|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
214518011|NCT02099188|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
215117367|NCT07065110|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Blood draw for testing of metabolics.
215117368|NCT07065110|DIETARY_SUPPLEMENT|Skin test panel|Testing of improving the skin hydration and other skin-related parameters.
215117369|NCT07065110|DIETARY_SUPPLEMENT|HA gel|Participants obtained altogether 3 flasks with 500ml of SH60, SH 120 solution. They tooj 15 ml of the SH60 or SH120 aupplements (experimental group) once daily in the morning before breakfast for 3 months.
215117370|NCT07065110|DIETARY_SUPPLEMENT|Xanthan gum|Participants obtained altogether 3 flasks of placebo solution. They took 15 mL of placebo solution (control group) once daily in the morning before breakfast for 3 months.
215117371|NCT06926855|OTHER|CHC-level cluster randomized control trial|"CHW (with clinic champion support) outreach to eligible patients, verbally consent patients, confirm eligibility, conduct social needs screening, make service or resource referrals, plan and support referral completion as needed, follow-up with patients to assess referral completion and outcomes~Implementation supports: financial support for CHW, clinic champion, and CHC administration of trial activities; 12 weeks of preparatory CHW training and coaching; practice coaching and technical support for data collection at all sites; additional support for sites without existing research data infrastructure; CHW Learning Collaborative through intervention and follow-up period for implementation support and cross-training control sites."
214439805|NCT06750237|OTHER|Unstable surface and isometrics|and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
214439806|NCT04038957|DRUG|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
214518012|NCT02099188|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
214518013|NCT02590770|BEHAVIORAL|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
215117372|NCT06902181|BEHAVIORAL|Experimental Group - 100% CXMCI-01 Essential Oil|Participants in the experimental group will inhale 100% CXMCI-01 essential oil twice(CXMCI-01-M in morning, CXMCI-01-N in night) daily for 28 days using an aroma necklace. Each session involves placing 2 drops of the essential oil on a cotton pad inside the necklace. Inhale near the nose for 5 minutes, then wear the aroma necklace and continue inhalation for 60 minutes.
214439807|NCT05641974|BEHAVIORAL|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
214518014|NCT02590770|OTHER|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
215117373|NCT06902181|BEHAVIORAL|Control Group - 0.1% CXMCI-01 Essential Oil (placebo)|Participants in the placebo group will inhale a 0.1% CXMCI-01 essential oil dilution twice (CXMCI-01-M in morning, CXMCI-01-N in night) ) daily for 28 days. The protocol mirrors the experimental group: inhalation near the nose for 5 minutes, followed by wearing an aroma necklace infused with the diluted essential oil for 60 minutes. This group serves as a placebo comparator to evaluate the effectiveness of the experimental intervention.
215117374|NCT06921395|DRUG|Fang Le Shu (Follitrope)|rFSH 150 IU, 225 IU, 300 IU per syringe
214439808|NCT05831189|DRUG|RBX2660|RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
214439809|NCT06026111|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
214439810|NCT06026111|BEHAVIORAL|Moderate-Intensity Continuous Training (MICT)|Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
214518015|NCT06358794|DIAGNOSTIC_TEST|Machine learning-based predictive model|The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
215117375|NCT06921395|DRUG|Guo Na Fen (Gonal-F)|rFSH 450 IU per pen
215117376|NCT06934239|DEVICE|Artificial intelligence (AI) decision-support tool|"The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information).~Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system."
215117377|NCT06935058|OTHER|Chocolade milk|Participants will drink 400 ml of chocolate milk after exercise.
215117378|NCT06935058|OTHER|Water (Placebo)|Participants will drink 400 ml of water after exercise.
215117379|NCT00979927|DRUG|SPC3649|5 weekly doses
215117380|NCT00979927|DRUG|saline|5 weekly doses
215117381|NCT06940609|DEVICE|accelerated intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS), a FDA-approved form of noninvasive neuromodulation, can reduce neuropsychiatric symptoms and modulate inflammation in the thalamus as detected using dMRS, suggesting a potentially effective and efficient treatment approach with a pathophysiological component that is readily quantifiable.
215117382|NCT05275036|DEVICE|early detection test|Blood collection and early detection testing
215117383|NCT06348667|OTHER|Specific ankle stability exercises|Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
215117384|NCT06348667|OTHER|Conventional physiotherapy exercises program|Conventional exercise program performed in the center twice a week, of which all participants are part.
215117385|NCT03834831|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10
215117386|NCT03834831|DIETARY_SUPPLEMENT|Selenium|Selenium
215117387|NCT03057275|DEVICE|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
214439811|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
214439812|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
214439813|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
214439814|NCT03821844|BEHAVIORAL|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
214439815|NCT05983237|DRUG|Fluzoparib Camrelizumab Temozolomide|Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
214439816|NCT04433299|OTHER|no intervention, observational|no intervention, observational
214439817|NCT00319267|DRUG|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
214439818|NCT06402604|BEHAVIORAL|Aerobic exercise training|See above in arm group descriptions.
214439819|NCT06402604|BEHAVIORAL|Mindfulness Based Stress Reduction training|See above in arm group descriptions.
214439820|NCT06748716|DEVICE|Blue-blocking glasses|The investigators hypothesize that blue-blocking glasses (intervention) is more effective than placebo.
214439821|NCT06748716|DEVICE|Clear glasses|Clear-lensed glasses are placebo
214439822|NCT05744245|OTHER|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
214439823|NCT03591770|BIOLOGICAL|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
214439824|NCT05777902|DRUG|Ozanimod Oral Capsule|We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
214439825|NCT04910308|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
215117388|NCT05020210|DRUG|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
215117389|NCT02671097|DRUG|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
215117390|NCT02671097|DRUG|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
214439826|NCT03859830|DEVICE|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
214439827|NCT03859830|DEVICE|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
215117391|NCT02471222|DRUG|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
215117392|NCT02471222|OTHER|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
215117393|NCT01242605|DRUG|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
214439828|NCT05091957|OTHER|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
214518016|NCT02813304|BEHAVIORAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
214518017|NCT02813304|BEHAVIORAL|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
214518018|NCT00054197|DRUG|gemcitabine hydrochloride|
214518019|NCT00054197|DRUG|paclitaxel poliglumex|
214518020|NCT00054197|DRUG|vinorelbine tartrate|
214439829|NCT05091957|OTHER|Usual Care|Participants in both groups will receive a written summary of available resources
215117394|NCT01242605|DRUG|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
214518021|NCT01929161|DRUG|Oxytocin|24 International Units
214518022|NCT01929161|DRUG|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
214518023|NCT01929161|BEHAVIORAL|Lovingkindness Meditation|
214518024|NCT01929161|BEHAVIORAL|Mindfulness Meditation|
214439830|NCT01998984|DRUG|ingenol mebutate|
214518025|NCT04346784|BEHAVIORAL|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
214518026|NCT04346784|BEHAVIORAL|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
215117395|NCT01242605|DRUG|cisplatin|cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
215117396|NCT00308854|PROCEDURE|Photodynamic Therapy|
215117397|NCT00003763|PROCEDURE|radionuclide imaging|
215117398|NCT00003763|RADIATION|indium In 111 folic acid|
215117399|NCT02736344|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent|
215117400|NCT03511157|OTHER|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
215117401|NCT03511157|OTHER|Control Group|See Control group description
215117402|NCT00548145|DRUG|Pitavastatin|2 mg by orally/day Duration: 12 months
215117403|NCT00548145|DRUG|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
215117404|NCT01918280|PROCEDURE|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
215117405|NCT02800980|PROCEDURE|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
214439831|NCT01998984|OTHER|Placebo|
214439832|NCT06306027|BEHAVIORAL|Web-based education|The patient discharged after knee arthroplasty surgery will attend a follow-up appointment 15 days later, and during this visit, they will be granted permission to resume work. The patient will receive detailed information about accessing, entering, and using the web-based training. Scales with pre-test data will be completed by the patient. They will be encouraged to log in at least twice a week, and the patient will be monitored for a total of 1 month (4 weeks). After one month, the patient will be asked to fill out the scales again.
214518027|NCT04346784|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
214518028|NCT04346784|BEHAVIORAL|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
214518029|NCT00007826|BIOLOGICAL|BCG vaccine|
214518030|NCT00007826|BIOLOGICAL|monoclonal antibody 105AD7 anti-idiotype vaccine|
214518031|NCT00007826|DRUG|alum adjuvant|
215117406|NCT02800980|PROCEDURE|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
215117407|NCT03348176|OTHER|Vegetable exposure|Repeated exposure to variety of vegetables
215117408|NCT03348176|BEHAVIORAL|VIPP-Feeding Infants|Promoting responsive feeding practices
215117409|NCT03348176|OTHER|Control|Phone calls with mother about development of child, no advice on complementary feeding
215117410|NCT02119663|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
215117411|NCT02119663|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
215117412|NCT02119663|DRUG|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
215117413|NCT02022163|BIOLOGICAL|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
215117414|NCT02022163|BIOLOGICAL|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
215117415|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
215117416|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
214518032|NCT02128893|DRUG|Isavuconazole|oral
214518033|NCT02128893|DRUG|Esomeprazole|oral
214518034|NCT05558748|PROCEDURE|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
214518035|NCT05558748|PROCEDURE|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
214518036|NCT06501053|RADIATION|Radiotherapy|45/50 Gy (1.8/2 Gy/fraction/5 weeks)
214439833|NCT05649982|BEHAVIORAL|ALVA|Behavioural digital self-help intervention
214439834|NCT06103825|DRUG|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
214439835|NCT06103825|DRUG|Placebo|Placebo :QD，PO，Day 1-Day 84
214439836|NCT05939427|OTHER|NGAGE tool|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
214439837|NCT04122456|RADIATION|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
214439838|NCT04122456|OTHER|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
214518037|NCT06501053|RADIATION|Short-course radiotherapy|25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days
214439839|NCT04354337|BEHAVIORAL|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
214439840|NCT05874570|DRUG|Esomeprazole|Proton pump inhibitor
214518038|NCT06501053|RADIATION|Contact x-ray brachytherapy|90Gy/3 fractions/4 weeks
214518039|NCT06501053|DRUG|Chemotherapy|Capecitabine (900 mg/m2 bid, on radiation days)
214518040|NCT03500276|BEHAVIORAL|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
214518041|NCT03500276|BEHAVIORAL|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
215117417|NCT02022163|BIOLOGICAL|Placebo|Placebo, 2 doses given 21 days apart
214518042|NCT03800368|OTHER|Exercise|Indoor cycling exercise intervention
214518043|NCT03800368|OTHER|Non-exercise|Psycho-education
214518044|NCT02142569|DRUG|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
214518045|NCT02142569|DRUG|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
214518046|NCT02142569|DRUG|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
214518047|NCT02142569|DEVICE|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
214518048|NCT01661972|DRUG|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
214518049|NCT05466630|DIAGNOSTIC_TEST|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
214518050|NCT05466630|DIAGNOSTIC_TEST|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
214518051|NCT05466630|DIAGNOSTIC_TEST|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
215117418|NCT04355793|DRUG|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
215117419|NCT00892775|BIOLOGICAL|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
215117420|NCT00892775|BIOLOGICAL|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
215117421|NCT00242996|BIOLOGICAL|filgrastim|
215117422|NCT00242996|BIOLOGICAL|rituximab|
215117423|NCT00242996|BIOLOGICAL|sargramostim|
214518052|NCT05466630|DIAGNOSTIC_TEST|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
214518053|NCT04267523|BEHAVIORAL|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
214518054|NCT04267523|BEHAVIORAL|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
214518055|NCT01212913|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
214518056|NCT01212913|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
214518057|NCT01212913|DRUG|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
214518058|NCT06357455|DEVICE|Cell Salvage Autotransfusion: SAME™ device|"* Intervention studied: processing of salvaged blood using the SAME™ autotransfusion device~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Treatment group.~All perioperative measures will be performed according to international, national and in-house standards."
214518059|NCT06357455|DEVICE|Cell Salvage Autotransfusion: Autolog™ device|"* Intervention studied: processing of salvaged blood using the Autolog™ (Medtronic) autotransfusion device (in-house standard device).~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Control group~All perioperative measures will be performed according to international, national and in-house standards."
214518060|NCT00051753|DRUG|levofloxacin; amoxicillin/clavulanate|
214518061|NCT04566185|OTHER|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
214518062|NCT04566185|OTHER|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
214518063|NCT04566185|OTHER|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
214518064|NCT04313985|DEVICE|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
214518065|NCT00269022|DRUG|SB-705498|
214518066|NCT01171053|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
214518067|NCT01171053|BEHAVIORAL|Therapist support|Weekly therapist support without CBT-interventions
214518068|NCT01303822|BEHAVIORAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
214518069|NCT01799005|DIETARY_SUPPLEMENT|Flavanol (410 mg)|
215117424|NCT00242996|DRUG|carmustine|
214518070|NCT01799005|DIETARY_SUPPLEMENT|Control (no flavanols)|
214518071|NCT01973361|DEVICE|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
214518072|NCT01973361|DEVICE|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
214518073|NCT00835328|DRUG|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
214518074|NCT00835328|DRUG|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
215117425|NCT00242996|DRUG|cyclophosphamide|
215117426|NCT00242996|DRUG|etoposide|
215117427|NCT00242996|PROCEDURE|adjuvant therapy|
215117428|NCT00242996|PROCEDURE|bone marrow ablation with stem cell support|
215117429|NCT00242996|PROCEDURE|peripheral blood stem cell transplantation|
214518075|NCT01870336|DEVICE|Combined treatment of medial knee osteoarthritis|
215117430|NCT00699660|BEHAVIORAL|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
215117431|NCT00699660|BEHAVIORAL|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
215117432|NCT01586221|OTHER|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
215117433|NCT00064792|DRUG|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
214439841|NCT05874570|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
215117434|NCT00064792|DRUG|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
214439842|NCT05874570|DRUG|Tetracycline|Antibiotics for H. pylori eradication
214439843|NCT05874570|DRUG|Doxycycline|Antibiotics for H. pylori eradication
214439844|NCT05874570|DRUG|Metronidazole|Antibiotics for H. pylori eradication
214439845|NCT05066542|BEHAVIORAL|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
214439846|NCT05066542|BEHAVIORAL|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
214439847|NCT04009005|BEHAVIORAL|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
214439848|NCT05085990|BIOLOGICAL|TARA-002|Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
214439849|NCT04507503|DRUG|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
214439850|NCT03784924|DIAGNOSTIC_TEST|MRI prostate|MRI and laboratory biomarkers
214439851|NCT04925375|DRUG|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
214439852|NCT04925375|OTHER|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
214439853|NCT06282172|DEVICE|Treatment with BTL-785-7|Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
214439854|NCT03532880|DRUG|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
214439855|NCT03532880|DRUG|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
214518076|NCT01425398|DRUG|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
214518077|NCT01425398|DRUG|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
214518078|NCT04917315|DRUG|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
214518079|NCT04917315|DRUG|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
214518080|NCT02384122|DRUG|Octreotide|Two injections of 20 mg will be given monthly.
214439856|NCT03532880|DRUG|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
214518081|NCT03369457|BIOLOGICAL|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
215117435|NCT00002458|BIOLOGICAL|monoclonal antibody 3F8|
215117436|NCT04218539|DRUG|Psilocybin|10mg Psilocybin
215117437|NCT04218539|DRUG|Placebo|25mg Diphenhydramine
215117438|NCT03507010|RADIATION|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
215117439|NCT03507010|OTHER|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
215117440|NCT03301350|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
214518082|NCT00488969|DRUG|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
214518083|NCT00488969|DRUG|Placebo|
214518084|NCT05692245|DRUG|Ondansetron|Administered Medication
214518085|NCT05692245|DRUG|Dexamethasone|Administered Medication
214518086|NCT00704548|DRUG|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
214518087|NCT00704548|DRUG|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
214518088|NCT02644980|DRUG|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
214518089|NCT02644980|DRUG|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
214518090|NCT02644980|DEVICE|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
214518091|NCT02644980|DRUG|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
214518092|NCT02644980|DRUG|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
214518093|NCT02644980|OTHER|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
214518094|NCT05049265|BIOLOGICAL|JS007|JS007 only
214518095|NCT01129375|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
214518096|NCT01129375|DRUG|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
214518097|NCT01129375|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
214518098|NCT04305496|DRUG|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
215117441|NCT03301350|DRUG|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
215117442|NCT03301350|DRUG|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
214518099|NCT04305496|DRUG|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
214518100|NCT04305496|DRUG|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
214518101|NCT02822092|DRUG|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
214518102|NCT06245317|DEVICE|Mechanical Ventilation Mode|Each arm will have a different ventilation mode according to the allocation.
214518103|NCT03191097|DRUG|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
214518104|NCT03191097|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
214518105|NCT04345588|DRUG|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
214518106|NCT05751720|DRUG|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
214518107|NCT02813733|PROCEDURE|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
214518108|NCT01175980|OTHER|Laboratory Biomarker Analysis|Correlative studies
214518109|NCT01175980|DRUG|Vorinostat|Given PO
214518110|NCT01451840|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
214518111|NCT01451840|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
214518112|NCT04913194|BEHAVIORAL|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
214518113|NCT00796575|DRUG|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
214518114|NCT00796575|DRUG|placebo tablets|placebo tablets matching active
214518115|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
214518116|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
214518117|NCT01929616|DRUG|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
214518118|NCT02301286|DRUG|Acetylsalicylic acid|
214518119|NCT02301286|DRUG|Placebo Acetylsalicylic acid|
214518120|NCT02216448|OTHER|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
215117443|NCT03301350|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
215117444|NCT03301350|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
215117445|NCT03301350|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
215117446|NCT03137225|DEVICE|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
215117447|NCT03137225|DEVICE|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
214439857|NCT03532880|DRUG|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
214439858|NCT03532880|DRUG|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
215117448|NCT01487889|OTHER|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
215117449|NCT00390650|DRUG|Saredutant|
215117450|NCT01248949|DRUG|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
215117451|NCT01248949|DRUG|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
215117452|NCT01248949|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
215117453|NCT01248949|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
215117454|NCT01973413|DEVICE|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
215117455|NCT01973413|DEVICE|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
214439859|NCT03532880|DRUG|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
214439860|NCT03532880|RADIATION|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
214439861|NCT01843374|DRUG|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
214439862|NCT01843374|DRUG|Placebo|Placebo is to be administered as an IV solution, followed by observation.
214518121|NCT02216448|OTHER|OR Training|Training on diagnostic knee arthroscopy in the OR
214518122|NCT04445246|DRUG|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
214518123|NCT00267774|DEVICE|Fractional flow reserve|
214518124|NCT00267774|PROCEDURE|Angio-guided PCI|
214518125|NCT00186563|PROCEDURE|Micro-plasmapheresis|
214518126|NCT00071188|DRUG|ZD6474|
214518127|NCT00071188|DRUG|Paclitaxel|
214518128|NCT00071188|DRUG|Carboplatin|
214518129|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
214518130|NCT05029089|DEVICE|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
214439863|NCT06582212|DEVICE|Mymovesmatter mobile application|Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
214439864|NCT03397108|OTHER|The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use|This observational study enrolled women with IBD, and some of them were receiving a treatment with anti-TNF monoclonal antibody, which was prescribed by their responsible prescribers at a standard dose and dosing interval.
214518131|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
214518132|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
214518133|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
214518134|NCT03455725|DEVICE|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
214518135|NCT03455725|OTHER|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
215117456|NCT01973413|DEVICE|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
215117457|NCT00816192|PROCEDURE|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
214439865|NCT02097758|DEVICE|Transcatheter device closure|"Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size"
214439866|NCT05231421|BEHAVIORAL|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
214439867|NCT04649008|DIAGNOSTIC_TEST|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
215117458|NCT03851198|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
215117459|NCT01882530|DRUG|Paracetamol|
215117460|NCT01882530|DRUG|Nefopam|
215117461|NCT01882530|DRUG|Ketoprofen|
215117462|NCT01882530|DRUG|Morphine|
215117463|NCT03915470|DRUG|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
215117464|NCT03915470|DRUG|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
215117465|NCT02150915|OTHER|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
214439868|NCT04649008|DIAGNOSTIC_TEST|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
214439869|NCT04649008|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
214518136|NCT05427942|DRUG|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
214518137|NCT03423992|BIOLOGICAL|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
214518138|NCT03798132|DIAGNOSTIC_TEST|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
215117466|NCT01772732|DRUG|Simotinib Hydrochloride|
215117467|NCT00078247|DRUG|Abacavir|300 mg tablet taken orally twice daily
215117468|NCT00078247|DRUG|Lamivudine|300 mg tablet taken orally daily
215117469|NCT00078247|DRUG|Zidovudine|300 mg tablet taken orally twice daily
215117470|NCT00078247|DRUG|Tuberculosis treatment|Tuberculosis treatment
215117471|NCT02508909|PROCEDURE|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
215117472|NCT00862056|PROCEDURE|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
215117473|NCT06021509|DEVICE|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
215117474|NCT02601833|DEVICE|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
214518139|NCT04167852|BEHAVIORAL|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
214439870|NCT06007495|DEVICE|Investigational full-face mask with expiratory washout|With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation
214439871|NCT06007495|DEVICE|Conventional full-face mask - single-limb|With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation
214439872|NCT06007495|DEVICE|Conventional full-face mask - dual-limb|With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
214439873|NCT06031649|DEVICE|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
214439874|NCT06815042|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP) Injection|Participants will receive autologous PRP injections prepared from their own blood to treat elbow tendinopathy. PRP is a plasma product with a 3-5 times higher platelet concentration than normal blood, containing growth factors such as TGF-β, PDGF, IGF, and EGF, which are known to promote tissue repair and regeneration. The PRP will be injected directly into the affected tendon area to evaluate its clinical effectiveness and the relationship between platelet concentration, growth factors, and treatment outcomes.
214518140|NCT04167852|BEHAVIORAL|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
214518141|NCT05316649|OTHER|Measurement of external blood loss|Measurement of external blood loss
214518142|NCT05316649|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|Serum Hemoglobin concentration
214518143|NCT02893618|DRUG|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
214518144|NCT04664179|BIOLOGICAL|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10\^7 cells/m2
214518145|NCT04664179|BIOLOGICAL|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
215117475|NCT02601833|PROCEDURE|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
215117476|NCT04205734|DIAGNOSTIC_TEST|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
215117477|NCT03245775|BEHAVIORAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
215117478|NCT03245775|BEHAVIORAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
215117479|NCT06433089|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block was performed before surgery
215117480|NCT02401451|DEVICE|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
215117481|NCT02713828|DRUG|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
215117482|NCT02713828|DRUG|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
215117483|NCT04686383|DRUG|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
215117484|NCT00769912|DRUG|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
214518146|NCT04664179|BIOLOGICAL|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
214518147|NCT04664179|BIOLOGICAL|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
214518148|NCT04664179|BIOLOGICAL|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
214518149|NCT03444298|DRUG|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
214518150|NCT03444298|DRUG|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
214518151|NCT01571440|DIETARY_SUPPLEMENT|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
215117485|NCT00769912|DRUG|Placebo (air)|Placebo administration during the intervention
215117486|NCT06294340|OTHER|Exposure to loud pre-recorded road traffic noise|Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
215117487|NCT02762214|DEVICE|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
215117488|NCT02762214|OTHER|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
214439875|NCT06814600|DIAGNOSTIC_TEST|Transient elastometry|"Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) will be measured by transient liver elastometry Fibroscan to evaluate hepatic steatosis and fibrosis in all patients at baseline. Absence of steatosis S0 is defined as CAP \<248 dB/m, mild steatosis S1 with CAP \< 268 dB/m, and moderate to severe steatosis ≥ S2 is defined as CAP \>280 dB/m. Liver fibrosis will be evaluated using the liver stiffness measurement (LSM) in kPa7."
214439876|NCT06581419|DRUG|IAP0971|Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.
214439877|NCT00817037|DRUG|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
214439878|NCT00817037|DRUG|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
214439879|NCT00817037|DRUG|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
214439880|NCT03554265|DRUG|Somatropin|Genotropin given by injection
214439881|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
214439882|NCT06814405|PROCEDURE|Home patient management|with support therapy, Granulocyte growth factor, blood transfusion
214518152|NCT01571440|DIETARY_SUPPLEMENT|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
214518153|NCT04718116|DRUG|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
214439883|NCT06814405|OTHER|Hospital patient management|all procedures and exams needed
214518154|NCT04718116|DRUG|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
214518155|NCT04718116|DRUG|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
214439884|NCT05364944|DRUG|Debio 4126|Intramuscular (IM) injection
214439885|NCT05364944|DRUG|Sandostatin LAR|Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
214518156|NCT02423707|DRUG|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
214518157|NCT02423707|DRUG|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
214518158|NCT01073761|DRUG|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
215117489|NCT01578122|DEVICE|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
215117490|NCT01578122|DEVICE|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
215117491|NCT00145132|PROCEDURE|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
214439886|NCT05364944|DRUG|Somatuline ATG|Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
214439887|NCT05734196|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
214518159|NCT01634165|DRUG|LY2963016|Administered subcutaneously
214518160|NCT01634165|DRUG|Lantus|Administered subcutaneously
214518161|NCT04995588|OTHER|Blood test|Unique blood draw of 45mL for all the participants
214518162|NCT06096727|BEHAVIORAL|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
214518163|NCT06699524|DRUG|in vitro （chemotherapy）|resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.
214518164|NCT06699524|DEVICE|Adjuvant TACE（Adjuvant Transarterial Chemoembolization）|Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
214518165|NCT06700161|OTHER|Obtaining CGF from patients|Periodontal clinical parameters and Annexin and Lipoxin parameters in CGF will be compared between the test and control groups
215117492|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
215117493|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
215117494|NCT01589393|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
215117495|NCT01589393|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
215117496|NCT00434109|DRUG|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
214439888|NCT02944955|DRUG|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
214518166|NCT03686839|BEHAVIORAL|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
214439889|NCT05579743|OTHER|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
214439890|NCT02605837|DRUG|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
214439891|NCT02605837|DRUG|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
214518167|NCT01575704|OTHER|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
214518168|NCT01575704|OTHER|Mental Training|Memorial/ mental training and relaxation, 5 times per week
214518169|NCT06721468|OTHER|Trout|rainbow trout
214518170|NCT06721468|OTHER|Child-centered nutrition phrases|"learn the phrase, trout helps your brain so you can learn and play either through researcher introduction or completing the About Trout! Pond to Plate curriculum"
214518171|NCT06721468|OTHER|Puzzle|presented with a puzzle to solve each week
215117497|NCT00434109|PROCEDURE|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
215117498|NCT02406105|RADIATION|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
215117499|NCT02406105|DRUG|CyberKnife|
215117500|NCT02321553|OTHER|Brown rice|brown rice cake
215117501|NCT02321553|OTHER|White rice|white rice cake
215117502|NCT06241053|OTHER|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
214439892|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
214518172|NCT05512598|DRUG|HB0034|HB0034, a single dose
214518173|NCT03701607|OTHER|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
214518174|NCT03533894|DEVICE|colic capsule|colic polyp diagnosis
214518175|NCT03329547|DRUG|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
214518176|NCT03329547|DRUG|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
214518177|NCT02450123|DRUG|sunitinib|
214518178|NCT02618564|DRUG|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
214518179|NCT03051529|OTHER|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
214518180|NCT01857362|DRUG|Nitisinone 20 mg|Nitisinone 20 mg capsules
214518181|NCT01857362|DRUG|Nitisinone 10 mg|Nitisinone 10 mg capsules
214518182|NCT00664456|DRUG|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
214518183|NCT00664456|DRUG|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
214518184|NCT00664456|RADIATION|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
215117503|NCT06241053|OTHER|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
215117504|NCT05590507|BEHAVIORAL|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
215117505|NCT02420236|BEHAVIORAL|High-intensity resistance training|
215117506|NCT02420236|BEHAVIORAL|General physical activity|
215117507|NCT02420236|BEHAVIORAL|Multidisciplinary rehabilitation program|
215117508|NCT04374240|GENETIC|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"
215117509|NCT05486611|DEVICE|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
215117510|NCT05486611|DEVICE|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
215117511|NCT06060587|DRUG|Docetaxel|75 mg/m2 via IV
215117512|NCT06060587|DRUG|ADT|Prior to randomization as part of standard of care.
215117513|NCT06060587|DRUG|Abiraterone|1000 mg by mouth
215117514|NCT01773187|DRUG|Pacritinib|
215117515|NCT01773187|DRUG|Best Available Therapy|
215117516|NCT00704860|OTHER|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
215117517|NCT02978833|BIOLOGICAL|PRP|
215117518|NCT02978833|BIOLOGICAL|Whole Blood|
215117519|NCT02978833|DEVICE|Ultrasound|
215117520|NCT05296564|DRUG|CYCLOPHOSPHAMIDE and FLUDARABIN|1\. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
215117521|NCT05296564|DRUG|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
215117522|NCT05296564|BIOLOGICAL|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
215117523|NCT05296564|DRUG|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
215117524|NCT00015795|DEVICE|airway interruption test|
215117525|NCT02436538|OTHER|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
215117526|NCT03644667|BIOLOGICAL|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
215117527|NCT03644667|BIOLOGICAL|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
215117528|NCT03644667|DRUG|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
215117529|NCT04688229|DEVICE|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
215117530|NCT04688229|OTHER|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
215117531|NCT05476016|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
214518185|NCT01961453|DRUG|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
214439893|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
214439894|NCT05670002|DIETARY_SUPPLEMENT|Milk supplement|Children will take the milk supplement for a period of 6 months. During the intervention, anthropometry data, Zinc Protoporphyrin levels, dietary intake, any illness will be recorded.
214518186|NCT01961453|DRUG|Placebo capsule|One capsule of placebo administered once daily at 8 am.
214518187|NCT00093743|DRUG|fludarabine phosphate|Given IV
215117532|NCT06428370|PROCEDURE|Damage Control Surgery|Simple resection, drop, and open abdomen in case of Hinchey III-IV
215117533|NCT03410303|DIAGNOSTIC_TEST|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
215117534|NCT00103740|DRUG|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
215117535|NCT00103740|DRUG|placebo to zoledronic acid|5 mL of sterile water for infusion
215117536|NCT00103740|DRUG|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
215117537|NCT00103740|DRUG|Placebo to risedronate|oral capsules
215117538|NCT00103740|DRUG|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
215117539|NCT02503150|BIOLOGICAL|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
215117540|NCT02503150|DRUG|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
215117541|NCT01863329|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
215117542|NCT04224961|DEVICE|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
215117543|NCT02434042|DIETARY_SUPPLEMENT|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
215117544|NCT02434042|OTHER|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
215117545|NCT05460143|OTHER|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
215117546|NCT05460143|OTHER|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
215117547|NCT00461084|DRUG|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
215117548|NCT00461084|DRUG|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
215117549|NCT02982057|DEVICE|the ABSORB:bioresorbable vascular scaffold|
215117550|NCT02982057|DRUG|O.M.T|
215117551|NCT00815893|DRUG|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
215117552|NCT00815893|DRUG|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
215117553|NCT00815893|DRUG|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
214439895|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization
214439896|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
214439897|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
214439898|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
214439899|NCT02652260|DRUG|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
214439900|NCT02652260|DRUG|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
215117554|NCT01643824|RADIATION|Proton Beam Therapy|"\- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~\- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
214439901|NCT02652260|DRUG|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
215117555|NCT01336153|DRUG|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
215117556|NCT01336153|DRUG|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
215117557|NCT01258283|OTHER|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
215117558|NCT03910088|DRUG|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
215117559|NCT03910088|DRUG|Hydrocortisone|Giving drug to relieve post-dural puncture headache
215117560|NCT03910088|DRUG|Acetaminophen|giving a drug to relieve post-dural puncture headache
215117561|NCT03910088|OTHER|oral fluids|giving oral fluids to maintain good hydration
215117562|NCT03910088|DRUG|Caffeine|giving a drug to relieve post-dural puncture headache
214439902|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
214439903|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
214518188|NCT00093743|DRUG|cyclosporine|Given IV or PO
214518189|NCT00093743|RADIATION|total-body irradiation|Undergo TBI
214518190|NCT00093743|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
214518191|NCT00093743|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
214518192|NCT00093743|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
214518193|NCT00093743|DRUG|mycophenolate mofetil|Given PO or IV
214518194|NCT05235997|DIETARY_SUPPLEMENT|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
215117563|NCT03910088|DRUG|Diclofenac|giving a drug to relieve post-dural puncture headache
215117564|NCT03004352|OTHER|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
215117565|NCT03004352|OTHER|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
215117566|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (600 IU)|Daily oral dose for 12 months
215117567|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (2000 IU)|Daily oral dose for 12 months
215117568|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (4000 IU)|Daily oral dose for 12 months
215117569|NCT01992263|OTHER|Placebo|Daily oral dose for 12 months
215117570|NCT02486393|PROCEDURE|Parotid surgery|Surgery of the parotid gland tumours
214518195|NCT05235997|OTHER|Placebo|Placebo look alike the experimental product
215117571|NCT01406977|DRUG|BPS804|
215117572|NCT06060054|DIAGNOSTIC_TEST|Device measurements|Overnight device measurements
215117573|NCT01110031|BIOLOGICAL|Ofatumumab|Anti-CD20 monoclonal antibody
215117574|NCT02888288|BEHAVIORAL|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
215117575|NCT02888288|BEHAVIORAL|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
214439904|NCT06667648|PROCEDURE|cupping session|Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
214439905|NCT05464329|DRUG|Mosunetuzumab|Provided by Genentech.
214439906|NCT05464329|DRUG|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
214439907|NCT05464329|DRUG|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
214439908|NCT06815107|OTHER|questionnary|On day 1 of an ureteral double J stenting, each participant will receive the first USSQ questionnaire, in the French validated version. This questionnaire will be completed at home, one week after the intervention and returned at the following consultation or hospitalization.
214518196|NCT02556541|PROCEDURE|IV puncture guided by ultrasound|
214518197|NCT02024477|DRUG|Saxagliptin|5 mg tablet once daily for 12 weeks
214518198|NCT02024477|DRUG|Placebo|1 tablet daily for 12 weeks
215117576|NCT02776059|DRUG|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
215117577|NCT02776059|DRUG|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
215117578|NCT02771197|DRUG|Fludarabine|
215117579|NCT02771197|DRUG|Melphalan|
215117580|NCT02771197|DRUG|Pembrolizumab|
215117581|NCT04314583|BEHAVIORAL|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
215117582|NCT04314583|BEHAVIORAL|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
215117583|NCT02155920|DRUG|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
215117584|NCT01794260|DRUG|Cream from Zingiber cassumunar Roxb. extract|
215117585|NCT01794260|DRUG|Placebo cream|
215117586|NCT01802710|BEHAVIORAL|Psychological support|
215117587|NCT01802710|OTHER|No intervention|
215117588|NCT05158725|DEVICE|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
215117589|NCT05158725|DEVICE|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
215117590|NCT05158725|DEVICE|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
215117591|NCT00291486|DRUG|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
215117592|NCT00291486|DRUG|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
215117593|NCT03323177|DIETARY_SUPPLEMENT|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
215117594|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
215117595|NCT00681733|DRUG|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
215117596|NCT00681733|DRUG|Pioglitazone|30 mg OD
215117597|NCT00681733|DRUG|Pentoxifylline|1200 mg/d
215117598|NCT01732016|OTHER|Normobaric hypoxia chamber|
215117599|NCT01246336|OTHER|collection of exhaled breath|no intervention
214518199|NCT00090064|DRUG|Midomafetamine HCl|125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
214518200|NCT00090064|DRUG|Lactose placebo pill|125 mg followed by a supplemental half-dose of 62.5 mg
214518201|NCT00090064|BEHAVIORAL|Therapy|Non-directive therapy provided by a team of two co-therapists
214518202|NCT03428009|OTHER|Magnetic Resonance Imaging|Study interventions are minimal risk.
214439909|NCT06815107|OTHER|USSQ survey|if the stent is removed less than 6 months later, the second USSQ survey, in the French validated version will be given to the patient when removing the stent. This questionnaire will be completed at home one week after removal of the stent and return to the referent hospital. If the patient does not return the second questionnaire, our team may contact them by phone to complete it.
214439910|NCT06072378|BEHAVIORAL|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
214439911|NCT02432963|OTHER|Laboratory Biomarker Analysis|Correlative studies
214518203|NCT01904253|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214518204|NCT01904253|DRUG|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
214518205|NCT01904253|DRUG|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
214692780|NCT04972916|OTHER|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
214439912|NCT02432963|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
214439913|NCT02432963|BIOLOGICAL|Pembrolizumab|Given IV
214439914|NCT05235464|OTHER|Standard meal|Standard meal
215117600|NCT06054139|OTHER|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
215117601|NCT04999345|OTHER|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
215117602|NCT04999345|OTHER|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
214439915|NCT05235464|OTHER|High animal protein meal|Meal with high animal protein content
214439916|NCT05235464|OTHER|High plant protein meal|Meal with high plant protein content
214518206|NCT03414515|DEVICE|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
215117603|NCT01590160|DRUG|Ganetespib|IV, Using dose from Phase I
215117604|NCT03314272|DEVICE|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
215117605|NCT00583037|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
215117606|NCT01099397|OTHER|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
214439917|NCT05235464|OTHER|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
214439918|NCT06761755|OTHER|hot pack , K taping , Progressive muscle relaxation|"Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days"
214439919|NCT06760741|GENETIC|Multigene panel|"Germline Genetic Testing: Germline genetic testing will be performed on all patients with pancreatic cancer (PC) using a custom multigene panel. This panel includes 25 candidate genetic variants of interest and 13 clinically recognized genes associated with a higher risk of PC.~DNA Extraction: Germline DNA will be extracted from peripheral blood samples using the QIAamp DNA Blood Kit (Qiagen, Redwood City, CA, USA) following the manufacturer's instructions. The concentration of double-stranded DNA will be measured using a fluorometric method (Qubit, Thermo Fisher Scientific)."
214518207|NCT04962776|DRUG|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
214518208|NCT04962776|DRUG|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
214518209|NCT04962776|OTHER|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
215117607|NCT05463523|DEVICE|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
215117608|NCT00546949|PROCEDURE|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
215117609|NCT00546949|PROCEDURE|Interspinous Process Decompression (IPD)|Interspinous device
214518210|NCT06057701|OTHER|corrective exercises|"corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door"
215117610|NCT02384018|BIOLOGICAL|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
215117611|NCT02717039|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
214439920|NCT06760741|DIAGNOSTIC_TEST|Other|"1. Characterization of Suspected Pancreatic Cancer Lesions:~   Characterization of suspected pancreatic cancer (PC) lesions identified by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) in patients undergoing screening since 2014. This includes lesion type (solid or cystic), rapid cyst growth exceeding 4 mm per year, location, size, potential assessment of resectability, lobulocentric parenchymal atrophy, and Wirsung duct dilation. Clinically relevant suspected lesions will be defined as solid lesions, intraductal papillary mucinous neoplasms (IPMN), cystic lesions ≥10 mm, and cystic lesions with mural nodules.~2. Determination of CA 19-9 and Glycated Hemoglobin:~Measurement of CA 19-9 levels and glycated hemoglobin (HbA1c) as part of the diagnostic and monitoring process."
214439921|NCT06760741|DIAGNOSTIC_TEST|miRNA measurement in blood|"Analysis of miRNA Expression in plasma:~The expression of circulating miRNAs (in plasma) will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The signature includes two miRNAs (miR-33a-3p and miR-320a) combined with CA 19-9."
214439922|NCT06760741|GENETIC|Generation of 3D Pancreatic Organoids|"Generation of 3D Pancreatic Organoids for Complementary Analyses:~3D pancreatic organoids will be generated for complementary analyses involving in vitro functional studies to evaluate the pathogenicity of novel genes (selected based on the results of the multigene panel). These organoids will be developed from surgical samples obtained from five patients undergoing surgery as part of clinical care."
214439923|NCT06315543|DIETARY_SUPPLEMENT|Drink water|Increase drinking water by 1650mL per day (3 bottles of 550mL bottled water)
214439924|NCT06761313|DRUG|Triple combination formula|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks."
214439925|NCT06761313|DRUG|Bimatoprost .03% sterile ophthalmic solution|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate 0.2%(1 drop twice a day), Timolol Maleate 0.5% (1 drop twice a day) and Bimatoprost 0.3% (1 drop at night). At the first visit a complete ophthalmolgical exam which includes ocular surface items (conjunctival hiperemia, keratitis and tear film break up time). Questionnaires are performed (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire) to assess information about ocular surface adverse effects, quality of life and treatment adherence. Glaucoma exams as retinography, perimetry, optic nerve OCT (optical coherence tomography), central corneal thickness are performed on all patients to evaluate disease's control. This procedure will be repeated at all visits: baseline and within 4, 8, 12 weeks."
214439926|NCT06385119|DRUG|Plixorafenib|Oral Tablet
214439927|NCT06385119|DRUG|Cobicistat|Oral Tablet
214439928|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
214439929|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol
214439930|NCT06786390|OTHER|Rehabilitation protocol without FES|Subjects belonging to the control group will follow the rehabilitation protocol without FES
215117612|NCT00959205|DEVICE|CARTO 3D|CARTO (3D Electroanatomic imaging)
215117613|NCT00959205|DEVICE|Angiography|Conventional fluoroscopically guided activation mapping
215117614|NCT01958359|BEHAVIORAL|Short IVR|IVR-based alcohol diary with feedback
215117615|NCT01958359|BEHAVIORAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
214439931|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol
214518211|NCT06057701|OTHER|resisted diaphragmatic breathing exercises|"1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly"
214518212|NCT03284957|DRUG|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
214518213|NCT03284957|DRUG|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
215117616|NCT03421106|BEHAVIORAL|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
215117617|NCT03421106|OTHER|Control Food Pantries|Normal food pantry use
215117618|NCT03027349|OTHER|No intervention are provided|
215117619|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
215117620|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
215117621|NCT01900652|DRUG|Emibetuzumab|Administered IV
215117622|NCT01900652|DRUG|Erlotinib|Administered Orally
215117623|NCT02774148|DRUG|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
215117624|NCT02774148|DRUG|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
215117625|NCT01584362|DRUG|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
215117626|NCT01584362|DRUG|placebo|single oral dose of placebo
215117627|NCT01584362|DRUG|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
215117628|NCT01584362|DRUG|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
215117629|NCT01584362|DRUG|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
215117630|NCT01584362|DRUG|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
215117631|NCT01584362|DRUG|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
215117632|NCT05356585|GENETIC|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
214439932|NCT05663294|RADIATION|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
214518214|NCT03284957|DRUG|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
215117633|NCT00682526|DEVICE|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
215117634|NCT02663622|DRUG|Efprezimod alfa|Acute GVHD prophylaxis
215117635|NCT02663622|DRUG|Methotrexate|Acute GVHD prophylaxis
215117636|NCT02663622|DRUG|Tacrolimus|Acute GVHD prophylaxis
215117637|NCT02663622|DRUG|Placebo|100 ml saline IV infusion.
215117638|NCT01588600|OTHER|Dietary Fiber|Fiber added to breakfast
215117639|NCT00509626|BEHAVIORAL|exercise intervention|
215117640|NCT00509626|OTHER|questionnaire administration|
215117641|NCT00509626|PROCEDURE|CAM exercise therapy|
215117642|NCT00509626|PROCEDURE|management of therapy complications|
215117643|NCT00509626|PROCEDURE|psychosocial assessment and care|
215117644|NCT00509626|PROCEDURE|quality-of-life assessment|
215117645|NCT04813887|OTHER|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
215117646|NCT01792115|DRUG|Vitamin E 200 IU/d|Supplement-low dose
215117647|NCT01792115|DRUG|Vitamin E 400 IU/d|Supplement-intermediate dose
214518215|NCT03284957|DRUG|Everolimus|Pharmaceutical form: tablet
215117648|NCT01792115|DRUG|Vitamin E 800 IU/d|Supplement High Dose
215117649|NCT01792115|BEHAVIORAL|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
215117650|NCT00258167|BEHAVIORAL|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
215117651|NCT06457711|DIETARY_SUPPLEMENT|Free diet Group (FDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
215117652|NCT06457711|DIETARY_SUPPLEMENT|Very low Calorie Ketogenic Diet Group (VLCKDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
215117653|NCT06457711|DIETARY_SUPPLEMENT|Intermittent Fasting Group (IFG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
215117654|NCT02430857|OTHER|OMT|Manuel osteopathic treatment of the spine
215117655|NCT02865902|DEVICE|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
215117656|NCT04869969|PROCEDURE|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
215117657|NCT04869969|PROCEDURE|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
215117658|NCT02112292|DRUG|tetrahydrocannabinol|
215117659|NCT02112292|DRUG|cannabidiol|
215117660|NCT02112292|DRUG|Placebo|
215117661|NCT01571011|BEHAVIORAL|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
214518216|NCT03284957|DRUG|Abemaciclib|Pharmaceutical form: tablet
215117662|NCT03180125|DRUG|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
215117663|NCT03180125|DEVICE|ultrasound|ultrasound guided injection
215117664|NCT03180125|DRUG|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
215117665|NCT03180125|DRUG|Corticosteroid and 1%lidocain|injection in the carpal tunnel
215117666|NCT02745028|DIETARY_SUPPLEMENT|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
215117667|NCT02021630|OTHER|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
215117668|NCT04988750|DEVICE|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
215117669|NCT04479202|DRUG|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
215117670|NCT04479202|DRUG|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
215117671|NCT00008229|BIOLOGICAL|filgrastim|
215117672|NCT00008229|DRUG|melphalan|
215117673|NCT00008229|PROCEDURE|peripheral blood stem cell transplantation|
215117674|NCT00008229|RADIATION|holmium Ho 166 DOTMP|
214439933|NCT05663294|RADIATION|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
215117675|NCT03658824|OTHER|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
215117676|NCT03047421|DIAGNOSTIC_TEST|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
215117677|NCT05325021|DIAGNOSTIC_TEST|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
215117678|NCT05325021|DIAGNOSTIC_TEST|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
215117679|NCT00900029|BIOLOGICAL|No HP802 Treatment|
215117680|NCT00900029|OTHER|No HP802 Vehicle Treatment|
214439934|NCT06068868|DRUG|ABBV-787|Intravenous (IV) Infusion
214439935|NCT05453565|OTHER|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
214439936|NCT05453565|OTHER|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
214439937|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
214439938|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
214439939|NCT05918484|DEVICE|Intermittenly scanned continuous glucose monitoring|"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L \>70%~* Glycemic management index \<7%~* Coefficient of variation \<36%"
214439940|NCT05918484|OTHER|MODY genetic diagnostic test|"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."
214439941|NCT06122844|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K2 and K3. Each lesson lasts for approximately 30-40 minutes.
214439942|NCT05322525|DRUG|ON101 Cream|"Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day"
214439943|NCT05056246|DRUG|AMG 133|Solution for SC injection
214439944|NCT05319431|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
214439945|NCT05319431|DRUG|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
214439946|NCT05319431|PROCEDURE|TACE|On demand TACE
214518217|NCT06005311|DEVICE|Microfluidic chip|The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
214518218|NCT06005311|DEVICE|Density-gradient centrifugation|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
215117681|NCT04308629|OTHER|Transcranial direct current stimulation|
215117682|NCT04266054|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
215117683|NCT00822536|DRUG|Aspirin and Clopidogrel|Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
215117684|NCT00822536|DRUG|Aspirin|Aspirin : \<= 325 mg/j
214439947|NCT04046848|DRUG|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
214518219|NCT05379400|OTHER|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
214518220|NCT05379400|OTHER|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
214439948|NCT03328455|BEHAVIORAL|Inhibitory control training|Cognitive training is inhibitory task-related.
214518221|NCT05480410|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
214518222|NCT03978130|OTHER|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
214439949|NCT03328455|BEHAVIORAL|Knowledge-based training|Training is not inhibitory task-related.
215117685|NCT02744638|OTHER|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
215117686|NCT02744638|OTHER|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
214439950|NCT03894917|OTHER|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
214439951|NCT04647435|DRUG|APSCTC|APSCTC + Toragesic® placebo + Tramal® placebo
214518223|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
214518224|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
214518225|NCT03227458|OTHER|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
215117687|NCT02744638|DRUG|Arilin|2 tablets Arilin 500mg for 7 days
215117688|NCT04787978|OTHER|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
215117689|NCT06414447|DIAGNOSTIC_TEST|Huxley Medical|diagnostic
215117690|NCT01583842|DRUG|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."
215117691|NCT01583842|DRUG|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."
215117692|NCT01583842|PROCEDURE|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
215117693|NCT04309708|DEVICE|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
214439952|NCT04647435|DRUG|Toragesic®|APSCTC placebo + Toragesic® + Tramal® placebo
214439953|NCT04647435|DRUG|Tramal®|APSCTC placebo + Toragesic® placebo + Tramal®
214439954|NCT06784492|BEHAVIORAL|Healthy Living Intervention-1|Participants will receive a text or email each day with instructions about a healthy intervention.
214518226|NCT03227458|OTHER|Placebo|Participants will take placebo daily for 36 weeks.
214439955|NCT06784492|BEHAVIORAL|Healthy Living Intervention-2|Participants will receive a text or email each day with instructions about a healthy intervention.
214518227|NCT03227458|BEHAVIORAL|Exercise|bone-loading exercise on 3 days per week for 38 weeks
214518228|NCT05952908|OTHER|Proficiency-Based Progression simulation training|The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
214518229|NCT05952908|OTHER|Traditional simulation training|The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
215117694|NCT06527326|DIETARY_SUPPLEMENT|Live Combined Bifidobacterium|the Bifidobacterium genus supplement
215117695|NCT06527326|DIETARY_SUPPLEMENT|Placebo|Placebo
215117696|NCT04071197|DEVICE|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
214439956|NCT06414317|PROCEDURE|Assessment of Distress|Undergo psychological distress screening
214439957|NCT06414317|OTHER|Consultation Visit|Attend consultations
214439958|NCT06414317|OTHER|Nutritional Assessment|Undergo malnutrition screening
214439959|NCT06414317|OTHER|Questionnaire Administration|Ancillary studies
214439960|NCT06414317|OTHER|Supportive Care|Receive access to bladder cancer ENST
214518230|NCT05543759|DIETARY_SUPPLEMENT|Ready-To-Use Therapeutic Food (RUTF)|"* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets RUTF/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
214518231|NCT04233411|OTHER|Mycoprotein ingestion|
214518232|NCT01535625|DEVICE|Momo stent|Patients with PCI
214518233|NCT02464306|DRUG|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
214518234|NCT00466856|DRUG|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres"
214518235|NCT00466856|RADIATION|yttrium Y 90 resin microspheres|radiation
214518236|NCT05659745|OTHER|VM-02|VM-02 is a personal care product for vaginal health.
214518237|NCT05659745|DIETARY_SUPPLEMENT|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
215117697|NCT04071197|DEVICE|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
215117698|NCT01594931|DRUG|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
215117699|NCT01310465|DRUG|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
215117700|NCT01310465|DRUG|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
215117701|NCT01555372|DEVICE|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
215117702|NCT01555372|DEVICE|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
215117703|NCT00430105|DRUG|cyclophosphamide|
215117704|NCT05090735|PROCEDURE|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
215117705|NCT05090735|PROCEDURE|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
215117706|NCT03678311|DEVICE|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.
215117707|NCT01372059|OTHER|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
214518238|NCT05659745|OTHER|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
214439961|NCT06414317|OTHER|Supportive Care|Attend virtual support group meetings
214439962|NCT06789926|OTHER|Intervention Group|Attending a 4-hour ACT workshop, and after attending participants will utilize the remaining course time to independently access the LINE platform. The platform will feature pre-recorded guided audio files for relaxation, emotional videos, and psychological cards.
214439963|NCT06783348|DRUG|177Lu-PSMA-617|Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
214439964|NCT06230198|PROCEDURE|retrograde autologous priming (RAP)|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
214439965|NCT06230198|PROCEDURE|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
214439966|NCT05055778|BEHAVIORAL|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
214439967|NCT06784739|OTHER|Blood sampling|Venous blood sampling
214439968|NCT06784739|OTHER|Mucosal sampling|Saliva and nasal secretions
214439969|NCT06784739|DIAGNOSTIC_TEST|PCR-test|RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
214439970|NCT05729256|BEHAVIORAL|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
214439971|NCT05729256|BEHAVIORAL|Brief Advice and Information|Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
214439972|NCT06783439|OTHER|Ultrasound|The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.
214439973|NCT03190174|DRUG|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
214439974|NCT03190174|BIOLOGICAL|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
214439975|NCT06785532|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
214439976|NCT03899961|DRUG|Oxytocin|Oxytocin 2.5 U i.v.
214518239|NCT06429124|BEHAVIORAL|Dietary Intervention|Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
214439977|NCT03899961|DRUG|Carbetocin|Carbetocin 100 µg i.v.
214439978|NCT06787911|DRUG|Donafeib with Sintilimab|Patients receive Donafenib and PD-1 antibody Sintilimab
214439979|NCT06787638|DRUG|full dose of Neostigmine|"• Group A: received 10ml (a full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
214518240|NCT03450018|DRUG|SLC-0111|Oral SLC-0111
214518241|NCT03450018|DRUG|Gemcitabine Injection|1000 mg/m\^2 IV
214692781|NCT04765826|PROCEDURE|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
215117708|NCT01372059|OTHER|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
215117709|NCT01372059|OTHER|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
215117710|NCT06543901|PROCEDURE|Submuscular plating|the patient was fixed with a submuscular plate
215117711|NCT06543901|PROCEDURE|Traction and casting|the patient was placed on a traction with a thomas splint and then was casted with a hip spica
214439980|NCT06787638|DRUG|half dose of Neostigmine|"• Group B: received 10ml (a half dose of Neostigmine (0.04 mg/kg) plus Atropine (20 mic/kg+8ml normal saline).~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
214439981|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
214439982|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
214439983|NCT06791772|DRUG|Placebo|Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
214439984|NCT05607407|DRUG|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
214439985|NCT05607407|PROCEDURE|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
214439986|NCT05607407|DIAGNOSTIC_TEST|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
214439987|NCT05057091|OTHER|Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation|For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure
214439988|NCT05057091|OTHER|Group 2- Side-Lying Lumbar Spinal Manipulation|The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.
214439989|NCT06834711|DRUG|N-Acetyl Cysteine|The root canals were irrigated with 3 mL N-acetyl Cysteine (NAC)(200 mg/ml) in N-acetyl Cysteine group in the final irrigation.
214518242|NCT05704465|BEHAVIORAL|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
214518243|NCT05704465|BEHAVIORAL|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
214518244|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
214518245|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
214518246|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
214518247|NCT02655900|OTHER|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
214518248|NCT00515112|DRUG|AndroGel|Androgel 1%, 10g daily
214518249|NCT00515112|DRUG|placebo|placebo
214518250|NCT00051740|BEHAVIORAL|Cognitive Adaptation Therapy (CAT)|
214518251|NCT00051740|BEHAVIORAL|Minimal Environmental Supports (MES)|
215117712|NCT01064115|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
215117713|NCT01260714|DRUG|Azacitidine|Given SC
215117714|NCT01260714|DRUG|Etoposide|Given IV
215117715|NCT01260714|OTHER|Laboratory Biomarker Analysis|Correlative studies
215117716|NCT01260714|DRUG|Mitoxantrone Hydrochloride|Given IV
215117717|NCT03027622|BEHAVIORAL|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
215117718|NCT02222610|DRUG|0.5 mg ranibizumab|
214439990|NCT06834711|DRUG|Chlorhexidine|The root canals were irrigated with 3 ml %2 chlorhexidine in chlorhexidin group in the final irrigation.
214439991|NCT05656911|DRUG|Zabedosertib (BAY1834845)|Oral administration, two times a day
214439992|NCT05656911|DRUG|Placebo to zabedosertib (BAY1834845)|Oral administration, two times a day
214439993|NCT01229098|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
214439995|NCT04142476|OTHER|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
215117719|NCT02222610|PROCEDURE|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
215117720|NCT02135055|OTHER|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
215117721|NCT02135055|DRUG|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
215117722|NCT02135055|DRUG|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
215117723|NCT02135055|PROCEDURE|Sedation interruption|Sedation interruption is performed at 8 am every morning.
214439996|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
214439997|NCT06835426|OTHER|Single intravenous injection of the radiotracer|"* only in case of 18F-FDG as PET-tracer: blood glucose level is measured;~* single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group:~  * breast cancer group: 0.8 MBq/kg of 18F-FDG~ * prostate cancer group: 1 MBq/kg 18F-PSMA~ * thyroid cancer group: 1 MBq/kg of 18F-FDG~ * parathyroid adenoma group: 1 MBq/kg of 18F-Choline~ * head \& neck cancer group: 1 MBq/kg of 18F-FDG~ * skin cancer group: 4 MBq/kg of 18F-FDG~ * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG~ * genitourinary malignancies group: 1 MBq/kg of 18F-FDG~ * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG~ * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG~ * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F~ * Gastrointestinal group: 1 MBq/kg of 18F-FDG~ * Thoracovascular group: 1MBq/kg of 18F-FDG"
214439998|NCT06835426|DIAGNOSTIC_TEST|Imaging resected specimen using the high-resolution PET-CT specimen imager|"* the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin;~* additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;"
214439999|NCT06833827|DEVICE|Catheter-directed thrombectomy (CDT)|The intervention consists of immediate thrombectomy (thrombectomy with any approved device) without systemic/locally administered thrombolysis. Thrombectomy is performed via jugular or femoral venous access according to the instructions for use for the particular device. The catheter is advanced over a preplaced guidewire across the right heart into the pulmonary arteries to the location of proximal thrombus. Procedural therapeutic anticoagulation with heparin is administered. After removal of the dilator, the thrombus is extracted by controlled volume aspiration through an aspiration catheter using a syringe or dedicated aspiration system, with multiple aspirations performed as needed. Procedural objectives will be clearly stated prior to the intervention and patient's clinical and hemodynamic status and residual thrombus will guide the investigators to determine when to terminate the procedure. Treatment success is defined as clear evidence of right ventricular recompensation.
214440000|NCT06833827|DRUG|thrombolysis therapy|Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated fragmentation of the thrombus by lytic medication given systemically.
214440001|NCT06832176|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic constipation.
214440002|NCT06832176|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
214440003|NCT06835504|DRUG|Ketamine hydrochloride|Sub-dissociative ketamine, IV
214440004|NCT06835504|DRUG|Morphine sulphate|Morphine, IV
214440005|NCT06155292|BEHAVIORAL|Standard Communication Email|This is a standard quarterly email communication without personalized performance metrics.
214440006|NCT06155292|BEHAVIORAL|Personalized Report Card Email|This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.
215117724|NCT02744092|DRUG|Rivaroxaban|Anticoagulation therapy.
214440007|NCT06155292|BEHAVIORAL|Bottom-Up Framing|"The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback."
214440008|NCT06790433|DEVICE|Vibraject|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis. The Vibraject was activated after aspiration to deposit the solution slowly at approximately 50 seconds. Following cartridge deposition, the operator adjusted the participant to an upright seated position
214518252|NCT05644067|BIOLOGICAL|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
214518253|NCT05644067|BIOLOGICAL|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
214518254|NCT01458288|DRUG|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
214692782|NCT03347604|DIAGNOSTIC_TEST|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
214692783|NCT00395408|DRUG|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
214692784|NCT00395408|DRUG|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
215117725|NCT02744092|DRUG|Apixaban|Anticoagulation therapy.
215117726|NCT02744092|DRUG|Edoxaban|Anticoagulation therapy.
215117727|NCT02744092|DRUG|Dabigatran|Anticoagulation therapy.
215117728|NCT02744092|DRUG|Warfarin|Anticoagulation therapy.
215117729|NCT02744092|DRUG|Dalteparin|Anticoagulation therapy.
215117730|NCT02744092|DRUG|Enoxaparin|Anticoagulation therapy.
215117731|NCT02744092|DRUG|Fondaparinux|Anticoagulation therapy.
215117732|NCT04085549|DEVICE|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
215117733|NCT04085549|OTHER|Reference Cream|Commercial refence cream not containing berry and plant oils.
215117734|NCT01885221|BEHAVIORAL|Multimedia Support Intervention|
214440009|NCT06790433|DEVICE|Dentapen|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis (needle placement). The Dentapen was activated after aspiration to deposit the solution at a medium rate (1 mL/60 s) using the ramp-up mode. Following cartridge deposition, the operator adjusted the participant to an upright seated position
214440010|NCT06322706|DRUG|ABSK021|ABSK021 oral
214440011|NCT06322706|DRUG|Omeprazole|Omeprazole oral
214440012|NCT06792214|DRUG|Nirmatrelvir/ritonavir|Paxlovid PO BID for 5 days + standard of care
214440013|NCT06792214|DRUG|Remdesivir|Veklury IV daily for 5 days + standard of care
214440014|NCT05977712|OTHER|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
214440015|NCT05977712|OTHER|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
214440016|NCT05977712|OTHER|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
214440017|NCT05977712|OTHER|Eye examination|Eye fundus photo, OCT and OCT-A exams
214440018|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
214440019|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
214440020|NCT02837510|BEHAVIORAL|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
214440021|NCT05659459|DRUG|KIN001|Oral tablet
214440022|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
214440023|NCT05982132|OTHER|anthropometric measurement|Measurement of weight and other anthropometrics data
215117735|NCT02936635|DRUG|tirasemtiv|Oral
215117736|NCT01365286|DRUG|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
214440024|NCT06436274|BIOLOGICAL|GARDASIL®9|GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
214440025|NCT06436274|BIOLOGICAL|Menveo®/Menactra®|Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
214440026|NCT03088813|DRUG|Irinotecan liposome injection|IV
214440027|NCT03088813|DRUG|Topotecan|IV
214440028|NCT06272435|DIETARY_SUPPLEMENT|Multiplier|Subjects will consume 1 Liter (2 servings) of commercially available Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
215117737|NCT01365286|DRUG|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
215117738|NCT01633788|DRUG|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
214440029|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free|Subjects will consume 1 Liter (2 servings) of experimental Sugar Free Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
214440030|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free with Amino Acids|Subjects will consume 1 Liter (2 servings) of commercially available Sugar Free Hydration Multiplier product that contains amino acids at a rate of 250 milliliters per 7.5 minutes.
214440031|NCT06272435|DIETARY_SUPPLEMENT|Water|Subjects will consume 1 Liter of water at a rate of 250 milliliters per 7.5 minutes.
214440032|NCT05849168|BEHAVIORAL|Exercise training|Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
215117739|NCT01633788|DRUG|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
215117740|NCT01633788|DRUG|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
215117741|NCT01633788|DRUG|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
214440033|NCT06443684|DIAGNOSTIC_TEST|MRD|MRD（LC-10）include 10 lung cancer-related driver gene mutation site
214440034|NCT04070560|PROCEDURE|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
214440035|NCT04070560|PROCEDURE|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
214440036|NCT06292988|PROCEDURE|Total Thyroidectomy|Total thyroidectomy
214440037|NCT05411744|DRUG|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
214440038|NCT06393699|PROCEDURE|composite restoration|different types of resin composite restorations will be used to restore NCCL
215117742|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
215117743|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
215117744|NCT06263374|BEHAVIORAL|Motor imagery of the jaw|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the experimental group, which involves practicing motor imagery in addition to a self-rehabilitation program and physiotherapy. Patients will be guided to visualize three sets of jaw movements three times a day. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers as the study is multicentric.
214518255|NCT01498406|DIETARY_SUPPLEMENT|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
214518256|NCT06462768|OTHER|Blood sample|Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
214518257|NCT02802176|DEVICE|INVOcell device|intra-vaginal culture of embryos using INVOcell device
214518258|NCT02802176|OTHER|Traditional IVF|traditional culture of embryos in-vitro
214440039|NCT05183542|DRUG|Bone scan|Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale \< 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
214440040|NCT04345016|DEVICE|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
214440041|NCT05113264|DEVICE|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
214518259|NCT00304278|DRUG|Erlotinib (Tarceva)|150 mg daily X 7 weeks
214518260|NCT00304278|DRUG|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
214518261|NCT00304278|RADIATION|Radiation Therapy (RAD)|5 days per week X 7 weeks
214518262|NCT03490747|BEHAVIORAL|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
214518263|NCT03490747|BEHAVIORAL|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
215117745|NCT06263374|BEHAVIORAL|Control task (Sudoku or Crossword puzzle)|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the control group, which involves practicing a control task (completion of Sudoku or crossword puzzles) in addition to a self-rehabilitation program and physiotherapy. Patients will be instructed to engage in the task for approximately 10 minutes per day, equivalent to the duration of motor imagery practice in the group 1. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers, as the study is multicentric.
215117746|NCT00741975|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
215117747|NCT00741975|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
215117748|NCT03536585|DEVICE|Vulvovaginal treatment|"* Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
215117749|NCT03536585|DEVICE|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
215117750|NCT00310011|DRUG|cisplatin|
215117751|NCT00310011|DRUG|gemcitabine hydrochloride|
215117752|NCT00310011|DRUG|paclitaxel|
215117753|NCT00310011|PROCEDURE|conventional surgery|
214518264|NCT05018455|OTHER|Fall prevention program training based on Otago principles|balance and strength exercises
214518265|NCT00409006|DRUG|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
214518266|NCT00409006|DRUG|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
214518267|NCT00409006|DRUG|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
214692785|NCT00004816|DRUG|monoclonal antibody M-T412|
215117754|NCT00215111|BEHAVIORAL|Low carbohydrate, reduced glycemic load, and a control diet|
215117755|NCT03686735|OTHER|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
214518268|NCT05065099|DEVICE|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
214440042|NCT06032208|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 5 and ending at the end of dialysis week 28. This will allow us to compare patient reported symptoms in weeks 1-4 on their usual dialyzer with with their symptoms on the Theranova dialyzer.
214440043|NCT05864118|DIAGNOSTIC_TEST|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
214440044|NCT05864118|DIAGNOSTIC_TEST|COVID-19 antibody test|COVID-19 antibody test
214440045|NCT06025994|OTHER|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
214440046|NCT03172624|DRUG|Nivolumab|nivolumab 3 mg/kg every 2 weeks
214440047|NCT03172624|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
214440048|NCT06029426|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
214518269|NCT01732055|BEHAVIORAL|Partner-Assisted Interpersonal Psychotherapy|
215117756|NCT03686735|OTHER|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
215117757|NCT03686735|OTHER|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
214440049|NCT06029426|DRUG|Placebo|Placebo will be administered orally
214440050|NCT05910554|DRUG|Metformin|Patients randomized to metformin will be assigned the active arm.
214440051|NCT05910554|DRUG|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
214440052|NCT03503344|DRUG|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
214440053|NCT03503344|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214440054|NCT02780388|DRUG|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
214440055|NCT02780388|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
214440056|NCT04527146|OTHER|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
214440057|NCT04527146|OTHER|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the Penn Chart/Epic electronic medical record dashboard.
214440058|NCT04527146|OTHER|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
214440059|NCT05236582|DRUG|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
214440060|NCT05254509|OTHER|Occupational Therapy|Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
214692786|NCT05903937|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion (HAI)
214692787|NCT05903937|DRUG|Melphalan|Administered via isolated hepatic perfusion
214692788|NCT05903937|DRUG|Interleukin-2|low-dose, administered s.c.
214692789|NCT06258135|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|Single 7g dose daily for 28 days
214692790|NCT06258135|DIETARY_SUPPLEMENT|Maltodextrin|Single 7g dose daily for 28 days
215117758|NCT03686735|OTHER|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
215117759|NCT01929226|BIOLOGICAL|ETI-204|Monoclonal Antibody
215117760|NCT01929226|OTHER|Placebo|Placebo for ETI-204
215117761|NCT05802589|PROCEDURE|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
214440061|NCT05254509|OTHER|Occupational Therapy +Virtual Reality|The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
214440062|NCT05107401|BEHAVIORAL|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
214440063|NCT06707337|OTHER|Brief Self-compassion Program|Brief Self-compassion Program will be held in a face-to-face hospital environment for the patients with colorectal cancer in the experimental group. This training program has been developed based on the concepts of Mindfulness-Based Compassionate Living and Mindfulness-Based Stress Reduction Programs. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the mindfulness-based model. The training program was created in a certain flow, based on the introduction to a short self-compassion program (1 sessions), the importance of self-compassion and self-care in the cancer experience (1 sessions), a self-compassionate approach to challenging emotions and situations (1 sessions). There are 3 sessions in the program and the frequency of sessions is 3 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 patients with colorectal cancer in the experimental group.
214440064|NCT06328751|DEVICE|Case group|Meditation will be taught through a video played on a Samsung® gear VR virtual reality glasses with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
214440065|NCT06328751|BEHAVIORAL|Active control group|Meditation will be taught through a video played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
214440066|NCT06328751|BEHAVIORAL|Passive control group|Meditation will be taught through a audio played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
214440067|NCT02379520|GENETIC|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10\^7 cells/m2, DL2-3×10\^7 cells/m2, and DL3-1×10\^8 cells/m2, DL4- 2 to 3×10\^8 cells/m2, DL5- 0.8 to 1×10\^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion \& nivolumab \& HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) \& no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
214440068|NCT02379520|DRUG|Cytoxan|500mg/m\^2/day x 3 days (on days -4, -3 and -2)
214440069|NCT02379520|DRUG|Fludarabine|30mg/m\^2/day x 3 days (on days -4, -3, and -2)
214440070|NCT02379520|BIOLOGICAL|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
214518270|NCT01732055|OTHER|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
214518271|NCT03310372|RADIATION|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
214518272|NCT03310372|DRUG|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
214518273|NCT04397822|BIOLOGICAL|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
215117762|NCT05802589|PROCEDURE|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
214518274|NCT00695149|PROCEDURE|Transplantation of bone marrow stromal cell|
214518275|NCT02652299|BIOLOGICAL|Synovial biopsy|Synovial tissue for analysis and biobank.
214518276|NCT00518310|DRUG|Placebo|
214518277|NCT00518310|DRUG|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
214518278|NCT03334071|BEHAVIORAL|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
215117763|NCT05802589|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
215117764|NCT04734886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 + vitamin D|1 \* 10\^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
215117765|NCT04734886|DIETARY_SUPPLEMENT|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
214440071|NCT06347211|DEVICE|Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm|"Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
215117766|NCT03164811|PROCEDURE|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
215117767|NCT03164811|OTHER|Controlled|standard fluid treatment by an anesthesiologist
214440072|NCT06133322|BEHAVIORAL|Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
214440073|NCT01865110|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
214440074|NCT01865110|DRUG|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
214440075|NCT01865110|DRUG|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
214440076|NCT01865110|DRUG|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
214440077|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
214440078|NCT04713982|DRUG|Deutetrabenazine|Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
214440079|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
214440080|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
214440081|NCT04184089|DEVICE|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
214440082|NCT04184089|DEVICE|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
214440083|NCT04184089|DEVICE|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
214440084|NCT04910776|DRUG|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
214440085|NCT03363854|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
214440086|NCT03363854|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
214440087|NCT00977691|PROCEDURE|PBSC Transplant|PBSC transplant
214440088|NCT00977691|DRUG|Alemtuzumab|alemtuzumab
214440089|NCT00977691|DRUG|Sirolimus|sirolimus
214440090|NCT00977691|DRUG|Cyclophosphamide|cyclophosphamide
214440091|NCT00977691|PROCEDURE|Low Dose Irradiation|low dose irradiation
214440092|NCT01903811|DRUG|Carfilzomib|Given IV
214440093|NCT01903811|DRUG|Dexamethasone|Given IV
214440094|NCT01903811|OTHER|Laboratory Biomarker Analysis|Correlative studies
214440095|NCT06734923|OTHER|Questionnaire (28 questions)|demographic data, information-seeking behavior, platform use and online consultation habits, trust and impact, and interest in additional resources
214440096|NCT06745856|DRUG|5-fluorouracil|Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.
214440097|NCT06745856|DRUG|placebo|Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
214440098|NCT05600972|PROCEDURE|FSH priming|Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
214440099|NCT06745154|PROCEDURE|Biospecimen Collection|Undergo nasal swab collection
214440100|NCT06745154|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
214440101|NCT06745154|OTHER|Interview|Ancillary studies
214440102|NCT06745154|DRUG|Nicotine Replacement|Given nicotine patches, gum, or lozenges
214440103|NCT06745154|BEHAVIORAL|Smoking Cessation Intervention|Receive access to the Ohio Tobacco Quit Line
214440104|NCT06745154|OTHER|Survey Administration|Ancillary studies
215117768|NCT02492178|DRUG|Intrarectal artesunate|
215117769|NCT02492178|DRUG|Intravenous artesunate|
215117770|NCT02492178|DRUG|Intravenous quinine|
215117771|NCT00881738|DRUG|Clarithromycin 250 mg Tablets (Geneva, USA)|
215117772|NCT00881738|DRUG|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
215117773|NCT04804683|GENETIC|Genetic dissection of Fibromuscular Dysplasia|Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
214440105|NCT06745154|OTHER|Tobacco Cessation Counseling|Participate in counseling sessions
214518279|NCT03533803|DRUG|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
214518280|NCT03533803|PROCEDURE|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
214518281|NCT04389996|OTHER|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
214518282|NCT04285151|PROCEDURE|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
214518283|NCT05157464|DRUG|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
214518284|NCT04851444|DRUG|SI-F019|Single dose is administered IV.
215117774|NCT04804683|OTHER|Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia|Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
214440106|NCT05651659|OTHER|TIME model in the prevention and treatment of crises in frail community-dwelling people|TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
214440107|NCT02645487|RADIATION|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
214440108|NCT04468776|DRUG|Zolpidem|Zolpidem, as prescribed by physician
214440109|NCT04468776|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
214440110|NCT04468776|DRUG|Trazodone|Trazodone, as prescribed by physician
214518285|NCT05855499|DEVICE|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
214518286|NCT04221308|DEVICE|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
214518287|NCT04631341|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg every night, for one year
214518288|NCT03709056|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
214518289|NCT03709056|DRUG|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
215117775|NCT03667755|PROCEDURE|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
215117776|NCT00687180|DRUG|Treatment with mycophenolat mofetil|
215117777|NCT00687180|DRUG|Treatment with azathioprin|
215117778|NCT02102295|DRUG|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
215117779|NCT02102295|DRUG|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
215117780|NCT03601260|DRUG|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
214440111|NCT04003948|DRUG|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
214440112|NCT02690064|DIETARY_SUPPLEMENT|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
214440113|NCT02690064|DIETARY_SUPPLEMENT|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
214440114|NCT02690064|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
214440115|NCT03569176|DEVICE|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
214440116|NCT05766878|DEVICE|implants placement|The intervention will consist of placement of two types of short implants (one with traditional machined collar and one with anodized collar). After their healing period, the prosthetic rehabilitation will be made.
214518290|NCT02615041|DRUG|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
214518291|NCT02615041|DRUG|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
215117781|NCT05062005|DRUG|Induction Chemotherapy|Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
215117782|NCT05062005|DRUG|Concurrent Chemotherapy|Cisplatin 100 mg/m², Q3w.
215117783|NCT05062005|RADIATION|Definitive Radiotherapy|For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
215117784|NCT06056492|BEHAVIORAL|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
215117785|NCT00001499|DRUG|paclitaxel|
215117786|NCT00001499|DRUG|cisplatin|
214440117|NCT02865668|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
214440118|NCT02865668|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
214440119|NCT02865668|DRUG|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
214440120|NCT04731467|DRUG|CM-24 and Nivolumab - Dose Escalation|Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
214518292|NCT02615041|DRUG|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
214518293|NCT00228813|DRUG|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
214518294|NCT01179659|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
214518295|NCT03769129|DRUG|Pembrolizumab|Pembrolizumab
214518296|NCT03769129|PROCEDURE|microwave ablation|microwave ablation
215117787|NCT00001499|PROCEDURE|chest radiotherapy|
215117788|NCT04084717|DRUG|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
215117789|NCT04391114|PROCEDURE|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
214440121|NCT04731467|DRUG|CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
214440122|NCT04731467|DRUG|CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
214440123|NCT04731467|DRUG|Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
214440124|NCT04731467|DRUG|Nivolumab and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
214440125|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
214440126|NCT04440176|BIOLOGICAL|Saline|Placebo
214518297|NCT02941432|OTHER|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
214518298|NCT00006006|BIOLOGICAL|recombinant interferon alfa|
214518299|NCT00006006|DRUG|thalidomide|
214518300|NCT06379763|OTHER|diaphragmatic breathing exercise|15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
215117790|NCT04391114|PROCEDURE|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
214440127|NCT03079024|DEVICE|Targeted Cognitive Training|"1. Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an \~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~2. Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory."
214440128|NCT03079024|DEVICE|General Cognitive Exercises|The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
214440129|NCT03079024|OTHER|Coordinated Specialty Care for First Episode Psychosis|Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
214440130|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant function|Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
214440131|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of auditory function|The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
214440132|NCT04817462|PROCEDURE|Liver biopsy|The study population is patients with either haemophilia A or B who have previously been administered gene therapy treatment in one of three specific gene therapy clinical trials. In this study they will have a liver biopsy performed to take up to 3 samples for laboratory analysis.
214440133|NCT05471908|BEHAVIORAL|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
214440134|NCT05471908|BEHAVIORAL|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
214518301|NCT06379763|OTHER|conventional physiotherapy exercise|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
214518302|NCT01741636|OTHER|educational intervention|Undergo Survivorship Care Planning
214518303|NCT01741636|OTHER|questionnaire administration|Ancillary studies
214518304|NCT01741636|PROCEDURE|quality-of-life assessment|Ancillary studies
214518305|NCT00674258|BIOLOGICAL|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214518306|NCT01520285|DRUG|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
214518307|NCT01520285|DRUG|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
214518308|NCT00507429|DRUG|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
214518309|NCT00507429|DRUG|paclitaxel|200mg/m squared on Day 1
214518310|NCT00507429|DRUG|carboplatin|6 AUC on Day 1 following paclitaxel
214518311|NCT02230709|OTHER|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
214518312|NCT02230709|OTHER|"TENS and dry needling"|Application of TENS current after dry needling technique
214518313|NCT01053897|BIOLOGICAL|GBT009|Intradermal Injection following surgery
214518314|NCT01053897|BIOLOGICAL|Placebo|Intradermal Injection following surgery
214518315|NCT05046652|BIOLOGICAL|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
214518316|NCT00086723|BIOLOGICAL|recombinant tissue plasminogen activator|
214518317|NCT00086723|DRUG|captopril|
214518318|NCT05070234|GENETIC|Blood collection for genetic analysis|Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
214518319|NCT04025762|DEVICE|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
214440135|NCT06475261|DEVICE|Tissue Oximetry with ForeSight|Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer
214440136|NCT05176366|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214440137|NCT06819930|OTHER|Physical Assessments, Questionnaires, and Accelerometry for Fibromyalgia evaluation|This study involves a combination of functional tests, questionnaires, and activity measurement using accelerometers. The functional tests include the six-minute walk test (6MWT), handgrip strength dynamometry, and the 8-foot up \&amp; go test. Participants will also complete validated questionnaires assessing symptoms, quality of life, and psychosocial impact. Additionally, accelerometers will be used to objectively measure physical activity levels throughout the study period
214440138|NCT06819605|DRUG|Dabrafenib and trametinib (combination)|"This clinical study investigates the combination of Dabrafenib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) and Trametinib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) as a treatment for \[specific condition\]. The treatment will be administered until disease progression or intolerable toxicities occur. Both medications should be taken at least 1 hour before or 2 hours after a meal, at the same time each day. If a dose is missed, it should be taken within 12 hours of the scheduled time. If less than 12 hours remain before the next dose, the missed dose should not be taken. Both medications should be taken in combination with the scheduled dose of Dabrafenib at either morning or evening and must not be chewed or crushed.~Each treatment cycle lasts 30 days. At the end of each cycle, follow-up assessments will include clinical examination, laboratory tests to evaluate drug safety, and imaging studies to a"
214440139|NCT03612648|RADIATION|Three Fraction Accelerated Partial Breast Irradiation|"* TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
214440140|NCT03612648|PROCEDURE|Partial mastectomy|-Standard of Care
214440141|NCT06425796|DIETARY_SUPPLEMENT|Adiposity and Iron Requirements in Pregnancy (ADIPREG)|"Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered."
214440142|NCT06133062|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
214518320|NCT04025762|DEVICE|Sensor augmented pump therapy|Sensor augmented pump therapy
214518321|NCT05691218|DEVICE|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
214518322|NCT05691218|DEVICE|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
214692791|NCT03767296|DRUG|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)"
214692792|NCT03767296|DRUG|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)"
215117791|NCT02196935|OTHER|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
215117792|NCT01387841|BEHAVIORAL|yoga|Postures,relaxation techniques
215117793|NCT01387841|BEHAVIORAL|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
215117794|NCT02619474|OTHER|Whiteboard|"1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
215117795|NCT00254319|DRUG|Avastin, Alimta|
215117796|NCT04510649|DRUG|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
215117797|NCT04510649|DRUG|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
215117798|NCT04722874|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
215117799|NCT04722874|DEVICE|RLRL|RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
214440143|NCT06133062|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
214440144|NCT06133062|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
214440145|NCT05142618|OTHER|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
214440146|NCT05142618|OTHER|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
214440147|NCT05887700|DEVICE|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
214440148|NCT06787534|OTHER|No Interventions|
214440149|NCT06785987|DRUG|Continuous Lidocaine Infusion|Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
214440150|NCT06785987|DRUG|intermittent fentanyl infusion|Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
214440151|NCT06785987|DRUG|Continuous remifentanil Infusion|Maintained with sevoflurane and continuous remifentanil infusion under dosage: 3-5μg /kg/hr
214440152|NCT06790654|BEHAVIORAL|Text-message based motivational interviewing|Participants will receive weekly text messages during the pilot study period, initiated and managed by MItrained interviewers. Each text message exchange will begin with a short, MI-consistent prompt developed with input from focus groups of mothers who have previously breastfed. These prompts will address common breastfeeding barriers. Following the initial prompt, MI-trained trainers will engage with participants through text exchanges that utilize the core MI OARS skills (open-ended questions, affirmations, reflections, or summaries) to facilitate change talk.
214440153|NCT05929976|OTHER|No intervention|No intervention
214440154|NCT06163989|DRUG|TheaLoz Duo Eyedrop|TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
214440155|NCT06789848|DRUG|Ligufalimab|Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
215117800|NCT00524277|BIOLOGICAL|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
215117801|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
214440156|NCT06789848|DRUG|Cadonilimab|Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
214440157|NCT03982082|PROCEDURE|Physical Therapy|Undergo physical therapy
214440158|NCT03982082|OTHER|Questionnaire Administration|Ancillary studies
214440159|NCT03982082|PROCEDURE|Ultrasound|Undergo ultrasound via MuscleSound technology
214440162|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 10 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
214440163|NCT05254002|DRUG|Empagliflozin|oral administration, once daily
214440164|NCT05254002|DRUG|Empagliflozin Placebo|Matching placebo to empagliflozin oral administration, once daily
214440165|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 20 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
214440166|NCT05254002|DRUG|Finerenone Placebo|Matching Placebo to Finerenone oral administration once daily
214440167|NCT04393532|DEVICE|Su2ura Approximation Device|the use of the study device during a laparoscopic surgery
214440168|NCT04393532|PROCEDURE|Laparoscopic hernia repair surgery|repairing primary umbilical hernia in a laparoscopic procedure using the study device.
214440169|NCT01704079|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
214440170|NCT01704079|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
214440171|NCT05422924|BEHAVIORAL|Web-based platform. (My Viva Plan)|Participants will use a web-based platform (i.e. My Viva Plan®) to improve physical function, nutrition and mindfulness.
214440172|NCT04763356|OTHER|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
215117802|NCT00524277|BIOLOGICAL|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
215117803|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
215117804|NCT02788344|OTHER|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
214440173|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab|Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
214518323|NCT05691218|DEVICE|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
214440174|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy with or without Bevacizumab|Bevacizumab, 15mg/kg，every 21 day
214440175|NCT06775249|BEHAVIORAL|ICE Mindfulness Program|The ICE Mindfulness Program is a tailored, self-paced intervention designed for crew members in isolated and confined environments. It includes a three-week pre-departure online course with videos, audio, and cognitive exercises promoting mindfulness, flexibility, and creativity, requiring 15-30 minutes daily. Delivered via email, it blends elements from Mindfulness-Based Stress Reduction and the Langerian approach. Participants receive new content daily, focusing on stress reduction and adaptation in extreme settings. Pre-departure, the PI leads a 1.5-hour interactive session with group meditation. During the mission, bi-weekly booster sessions are conducted by the ESA MD, supplemented by ongoing access to training materials. Exercises include meditations, mindful discussions, and cognitive tasks, with flexibility to fit participant schedules. The program will be available in Italian, French, and English.
214440176|NCT00003042|BIOLOGICAL|filgrastim|
214440177|NCT00003042|DRUG|cisplatin|
214440178|NCT00003042|DRUG|cyclophosphamide|
214518324|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
214518325|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
214518326|NCT02791009|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
214518327|NCT02791009|OTHER|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
214518328|NCT02791009|OTHER|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
214518329|NCT02791009|OTHER|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
214518330|NCT02791009|OTHER|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
214518331|NCT02791009|OTHER|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
214518332|NCT01593137|DRUG|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
214518333|NCT01593137|DRUG|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
214518334|NCT00873626|DRUG|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
214518335|NCT03241121|BEHAVIORAL|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
214518336|NCT03241121|BEHAVIORAL|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
214518337|NCT03241121|DEVICE|Eating patterns|Data collection on eating patterns via the smartphone app
214518338|NCT03488498|OTHER|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
215117805|NCT03973216|BEHAVIORAL|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
214440179|NCT00003042|DRUG|doxorubicin hydrochloride|
214440180|NCT00003042|DRUG|melphalan|
214440181|NCT00003042|DRUG|mesna|
214440182|NCT00003042|DRUG|paclitaxel|
214440183|NCT00003042|DRUG|tamoxifen citrate|
214440184|NCT00003042|PROCEDURE|bone marrow ablation with stem cell support|
214440185|NCT00003042|PROCEDURE|conventional surgery|
214440186|NCT00003042|PROCEDURE|peripheral blood stem cell transplantation|
214440187|NCT05041556|OTHER|Case-control study of clinical outcomes|A case-control questionnaire will be administered at the home of cases and controls
214440188|NCT05041556|OTHER|Case-control study of mortality outcome|A case-control questionnaire will be administered at the home of cases and controls
214518339|NCT06233422|OTHER|No intervention involved|No intervention involved
214692793|NCT05197478|OTHER|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
215117806|NCT01322100|DEVICE|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
214440189|NCT04605913|COMBINATION_PRODUCT|Modified GCN+TTF treatment|The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
214440190|NCT06490809|OTHER|Physiotherapy|Parkinson\&#39;s upper extremity rehabilitation generally consists of stretching, strengthening, coordination, recreational activities and skill activities. Exercises will be prescribed by the clinical specialist physician and physiotherapist.
214440191|NCT06844474|DRUG|SHR-1826；Adebrelimab；SHR-8068；Bevacizumab|"Drug:~Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks.~Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks."
214440192|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
214440193|NCT06846944|OTHER|Breathing/relaxation intervention|"Ladybug TECHNIQUE is a breathing/relaxation intervention performed in children aged 5 to 10 years and consists of telling the story of a ladybug performing 4 moves and visualizing and performing breathing techniques independently. Afterwards, a drawing is invited.~SUNRISE TECHNIQUE is a breathing/relaxation intervention performed in children aged 10 to 15 years and consists of having the child imagine a favorite place. Then they are invited to reflect on the experience either verbally or through writing or drawing."
214440194|NCT06846580|PROCEDURE|brachiobasilic AVF|perform 2 stage brachiobasilic AVF in hemodialysis patients with central venous stenosis
214440195|NCT00560599|DRUG|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
214440196|NCT00560599|BEHAVIORAL|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
214440197|NCT00560599|DRUG|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
214440198|NCT06793956|DRUG|Sintilimab and Linperlisib Combination Treatment|Sintilimab administered via intravenous infusion; Linperlisib administered orally.
214692794|NCT01397305|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
215117807|NCT01322100|DRUG|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
215117808|NCT04844736|PROCEDURE|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
215117809|NCT00610402|OTHER|blood sample tear drop sample|blood sample tear drop sample
215117810|NCT05539885|PROCEDURE|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
215117811|NCT05539885|PROCEDURE|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
215117812|NCT00003575|BIOLOGICAL|filgrastim|
215117813|NCT00003575|BIOLOGICAL|recombinant interleukin-12|
215117814|NCT00003575|DRUG|etoposide|
215117815|NCT00003575|DRUG|ifosfamide|
214440199|NCT06848127|OTHER|Self-questionnaires|All subjects (healthy volunteers and all patients) will complete a battery of self-questionnaires, assessing emotional dysregulation, traumatic symptoms, alteration of the sense of self, sensitivity to social rejection, dissociative symptoms, child abuse, functional repercussions of the disorders, depressive and anxiety symptoms and Impulsivity.
214692795|NCT01397305|DRUG|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
214692796|NCT00698061|BIOLOGICAL|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
214692797|NCT00698061|BIOLOGICAL|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
214692798|NCT01536002|DRUG|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
214692799|NCT00050986|DRUG|Temozolomide|Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
214440200|NCT06848127|OTHER|Cognitive assessment|Completion of cognitive assessment, consisting of verbal fluency tasks , emotional Hayling, a dissociative associative memory retrieval task, a negative priming task and a heart rhythm detection task. The tasks of associative-dissociative memory retrieval, negative priming and heart rhythm detection will be coupled with a physiological recording, via a Biopac, to measure the change in skin conductance, body temperature and heart rate. The negative priming task will also be associated with the recording of eye movements allowing an indirect measurement of attentional orientation.
214440201|NCT06848127|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed (between visits V1 and V2 for all subjects and between V3 and V4 for the 4 groups of patients) in order to assess emotional and symptomatic dynamics in a daily life context through a connected wath. During 7 days, subjects will be invited, via their smartphone, to carry out daily semi-random readings (indicated by smartphone notifications) of their subjective emotional experiences (10 once/day), but also spontaneous (by reporting emotions deemed intense immediately afterwards that they take place).
214440202|NCT06848127|OTHER|Semi-structured interviews ITI and DSCID-II|"ITI International Trauma Interview is a semi-structured interview consisting of one part allocated to the description of a traumatic event and two parts addressing the symptoms of PTSD (i.e. reliving, avoidance and alteration of wakefulness) and the symptoms of the disturbance of self-organization.~The SCID-II Structured Clinical Interview for DSM-IV Personality Disorder is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-IV."
214440203|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
214440204|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
214440205|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
214440206|NCT00710294|DEVICE|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
214440207|NCT01771484|DEVICE|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
214440208|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
214440209|NCT02845466|BIOLOGICAL|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
214440210|NCT02845466|DEVICE|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
214518340|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
214518341|NCT05434559|DRUG|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
214518342|NCT03077958|PROCEDURE|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
214518343|NCT00608959|DRUG|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
214518344|NCT00608959|DRUG|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
214518345|NCT00028600|BIOLOGICAL|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
214518346|NCT00028600|BIOLOGICAL|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
214440211|NCT02845466|DEVICE|Placebo Dressing|Inactive wound dressing.
214440212|NCT06613906|DEVICE|Healsea Children nasal spray|dosage: 1 puff in each nostril twice daily during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
214440213|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
214440214|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
214440215|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
214440216|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
214440217|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
214440218|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
214440219|NCT03285763|DRUG|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
214440220|NCT04419857|DIETARY_SUPPLEMENT|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
214440221|NCT03624972|BEHAVIORAL|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
214440222|NCT03624972|BEHAVIORAL|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
214440223|NCT00086359|DRUG|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
214440224|NCT00086359|DRUG|Lamivudine/zidovudine|one pill twice daily
214440225|NCT00086359|DRUG|Lopinavir/ritonavir|four pills twice daily
214518347|NCT00028600|DRUG|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
214518348|NCT00028600|DRUG|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
214692800|NCT00050986|DRUG|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
214440226|NCT06158204|BEHAVIORAL|Lifestyle Intervention|"Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day"
214440227|NCT05193552|DRUG|Hizentra|subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
214440228|NCT03456076|DRUG|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
214440229|NCT03456076|DRUG|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
214440230|NCT03456076|DRUG|Vinorelbine|Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
214440231|NCT03456076|DRUG|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
214440232|NCT03456076|DRUG|Pemetrexed|"Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
214518349|NCT00028600|DRUG|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
214518350|NCT00028600|DRUG|methotrexate|5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
214518351|NCT00028600|DRUG|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
214518352|NCT00416442|DRUG|RSV604|
214518353|NCT05034237|DEVICE|ND;YAG 1064NM LASER|laser hair removal sessions
214518354|NCT04351243|DRUG|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
214518355|NCT04351243|DRUG|Placebo|Normal saline
214518356|NCT03616522|OTHER|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
214518357|NCT01156194|DRUG|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
214518358|NCT01156194|DRUG|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
214518359|NCT01156194|DRUG|Placebo|globule identical to true homeopathy comparators
214518360|NCT01707563|PROCEDURE|skin punch biopsy and molecular biology|
214518361|NCT01707563|OTHER|fibroblast culture and molecular biology|
214518362|NCT02568059|DRUG|Sahastara remedy alcoholic extract|comparison of different dose of drug
214440233|NCT03456076|DRUG|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
214440234|NCT05685108|DEVICE|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
214440235|NCT05685108|DEVICE|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
214440236|NCT06491017|DEVICE|MI-E Intervention protocol|"The endotracheal tube cuff will be inflated to 40 cmH2O and MI-E device will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set.~Before initiation of the MI-E intervention protocol, the investigators will carry out a short-period test to find the appropriate MI-E settings to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min. Concretely, inspiratory and expiratory time will always be set at 4 seconds and 2 seconds, respectively, and inspiratory flow will always be in slow mode. Once the appropriate inspiratory pressure will be found, the expiratory pressure will be initially set to exceed in 30 cmH2O the inspiratory pressure and, if required, this will be increased by 5 cmH2O until achieving a PEF ≥80 L/min with a maximum expiratory pressure of 70 cmH2O."
214440237|NCT06491017|DEVICE|Standard MI-E setting|"Cough Assist E70 device (Philips Respironics, USA, Andover, Massachusetts) will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set. During the 1-minute pause between sets, the patient will be reconnected to the ventilator to avoid desaturation and de-recruitment during procedures. PEEP will remain stable during the protocol.~The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause."
214440238|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Neutral-Relaxing)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).
215117816|NCT05120427|DIETARY_SUPPLEMENT|Lipid based nutrient Supplements (LNS):|LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
215117817|NCT05120427|DEVICE|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
214440239|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Drug)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.
214440240|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Non-Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.
214440241|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
214440242|NCT05261828|BEHAVIORAL|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
214440243|NCT05261828|BEHAVIORAL|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
214440244|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
214440245|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
214440246|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
214440247|NCT04136535|DRUG|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
214440248|NCT04136535|DRUG|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
214440249|NCT04136535|DRUG|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
214440250|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
214440251|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
214440252|NCT03517917|OTHER|Tumour tissue collection|Collection of tumour tissue and blood
214440253|NCT03716336|OTHER|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
214440254|NCT03716336|OTHER|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
214440255|NCT03716336|DIETARY_SUPPLEMENT|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
214440256|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
214440257|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
214440258|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
214440259|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
214440260|NCT03772652|OTHER|Observation|Soft tissue implant measurements
214440261|NCT04481074|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
214440262|NCT06564753|DRUG|Drug: Placebo daily and orally|• Placebo comparator
214518363|NCT03751761|DRUG|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
214518364|NCT01005602|OTHER|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
214440263|NCT06564753|DRUG|NA-931, dose 1, daily and orally|"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
214440264|NCT06564753|DRUG|NA-931, dose2, daily and orally|"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
214440265|NCT06564753|DRUG|NA-931 dose 3, daily and orally|"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
214440266|NCT06564753|DRUG|NA-931 dose 4, daily and orally|"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
214440267|NCT03086863|DEVICE|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
214440268|NCT03086863|DEVICE|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
214440269|NCT01675999|OTHER|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
214518365|NCT01005602|DRUG|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
215117818|NCT00799682|DRUG|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
214518366|NCT04967014|DRUG|HIP2101|Test drug
214518367|NCT04967014|DRUG|RLD2101|Reference drug
214518368|NCT01248715|DRUG|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
214518369|NCT06280599|BEHAVIORAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
214440270|NCT01675999|OTHER|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
214518370|NCT01707277|OTHER|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
214518371|NCT01707277|OTHER|Usual care|Usual pahramacological treatment
214518372|NCT04507347|DRUG|TRC041266|TRC041266 sachet 1500 mg strengths
214518373|NCT04507347|DRUG|Placebo|TRC041266 sachet 1500 mg matching placebo
215117819|NCT00799682|DRUG|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
214440271|NCT01675999|OTHER|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
214440272|NCT00088738|DRUG|[18F] SPA-RQ|
215117820|NCT02727218|PROCEDURE|Chest tube removal|chest tube removal post thoracoscopic surgery
215117821|NCT00731419|DEVICE|SEMS|Comparing plastic and metal stents
215117822|NCT04473209|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
215117823|NCT03464747|DEVICE|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
214440273|NCT03424499|PROCEDURE|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
214518374|NCT06559072|DRUG|Atorvastatin|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
214518375|NCT03741985|BEHAVIORAL|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
214518376|NCT03741985|BEHAVIORAL|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
214518377|NCT05530239|OTHER|Blood sample collection|Blood sample collection
214518378|NCT04440956|DRUG|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
214518379|NCT03486756|BEHAVIORAL|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
214518380|NCT05986851|DRUG|Azeliragon|Oral capsule
214518381|NCT05080556|DRUG|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
215117824|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
214518382|NCT04727463|PROCEDURE|Sphincteroplasty|Overlapping sphincteroplasty
215117825|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
215117826|NCT04208308|DIETARY_SUPPLEMENT|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
215117827|NCT04208308|DIETARY_SUPPLEMENT|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
215117828|NCT04183374|OTHER|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
215117829|NCT00723307|DRUG|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
215117830|NCT00723307|DRUG|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
214440274|NCT03424499|PROCEDURE|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
214518383|NCT02364674|RADIATION|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
214518384|NCT02529176|BEHAVIORAL|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
214518385|NCT03771300|BEHAVIORAL|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
214518386|NCT03771300|BEHAVIORAL|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
215117831|NCT04424667|OTHER|donor milk|pasteurized donor milk
215117832|NCT04709042|PROCEDURE|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
214440275|NCT03424499|DIAGNOSTIC_TEST|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
214440276|NCT00321152|OTHER|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
214440277|NCT05882617|OTHER|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
214440278|NCT00006786|BIOLOGICAL|bevacizumab|
214440279|NCT00006786|DRUG|fluorouracil|
214440280|NCT00006786|DRUG|irinotecan hydrochloride|
214440281|NCT00006786|DRUG|leucovorin calcium|
214440282|NCT04710849|DIAGNOSTIC_TEST|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
214440283|NCT02543125|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
214440284|NCT02543125|DEVICE|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
214440285|NCT04556539|DRUG|SC10914|400mg TID, oral admination on fasting condition
214440286|NCT00439413|DRUG|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
214440287|NCT00439413|DRUG|Placebo|Matching placebo via transdermal system
214440288|NCT00439413|BEHAVIORAL|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
214440289|NCT05857930|DRUG|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
214440290|NCT05857930|DRUG|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
214440291|NCT03556085|DEVICE|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
214518387|NCT03771300|BEHAVIORAL|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
214518388|NCT01330953|DRUG|Placebo|Single intravenous placebo dose.
214518389|NCT01330953|DRUG|LY2928057|Single intravenous dose.
214518390|NCT01861509|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
214518391|NCT04888208|BEHAVIORAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
214518392|NCT04400045|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
214518393|NCT04072809|OTHER|No intervention|This study does not involve any interventions.
214518394|NCT05901688|OTHER|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord"
214440292|NCT03614273|DRUG|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
214440293|NCT03614273|DRUG|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
214440294|NCT02054923|PROCEDURE|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
214440295|NCT02054923|BEHAVIORAL|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
214440296|NCT04930406|OTHER|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
214518395|NCT03409276|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
214518396|NCT03409276|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
214440297|NCT04164784|BEHAVIORAL|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
214440298|NCT00621634|DIETARY_SUPPLEMENT|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
214440299|NCT00621634|DIETARY_SUPPLEMENT|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
214440300|NCT05363449|DRUG|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
214440301|NCT05363449|DRUG|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
214440302|NCT04687293|DEVICE|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
214440303|NCT05387044|RADIATION|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
214440304|NCT03636334|BEHAVIORAL|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
214440305|NCT00933712|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
214440306|NCT00265200|DRUG|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
214440307|NCT06450366|DRUG|Enlicitide Decanoate|Administered orally.
214440308|NCT06450366|DRUG|Ezetimibe|Administered orally.
214440309|NCT06450366|DRUG|Bempedoic Acid|Administered orally.
214440310|NCT06450366|OTHER|Placebo for Enlicitide Decanoate|Administered orally.
214440311|NCT06450366|OTHER|Placebo for Ezetimibe|Administered orally.
214440312|NCT06450366|OTHER|Placebo for Bempedoic Acid|Administered orally.
214440313|NCT05660356|DRUG|Growth Hormone|Pfizer provided GH therapy
214440314|NCT05660356|DRUG|Placebo|Pfizer provided placebo
214518397|NCT03409276|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
214518398|NCT03409276|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
214440315|NCT03706521|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
214440316|NCT04579250|BIOLOGICAL|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
214518399|NCT02440698|BEHAVIORAL|Genetic test for personalized nutrition|
214518400|NCT03362853|DRUG|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
214518401|NCT03362853|DRUG|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
214518402|NCT03362853|DRUG|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
214518403|NCT03362853|DRUG|Placebo oral capsule|Receive a single dose in a fasting state
214518404|NCT04109209|BEHAVIORAL|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
214518405|NCT04109209|BEHAVIORAL|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
214440317|NCT02437422|BIOLOGICAL|SANGUINATE|Single two-hour infusion of SANGUINATE
214440318|NCT04059042|BEHAVIORAL|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
214440319|NCT04264013|BEHAVIORAL|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
214440320|NCT04264013|BEHAVIORAL|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
214440321|NCT06272058|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
214518406|NCT03605745|DEVICE|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
214518407|NCT03262753|PROCEDURE|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
214518408|NCT03262753|PROCEDURE|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
214518409|NCT03262753|PROCEDURE|Stent|Primary stent dilation treatment of coarctation of the aorta
214518410|NCT02891018|DEVICE|paclitaxel controlled release balloon catheter Vasoguard TM|
214518411|NCT02891018|DEVICE|paclitaxel release coronary balloon catheter SeQuent Please|
214440322|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
214440323|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
214440324|NCT05990738|DRUG|BI 764532|BI 764532
214518412|NCT01279447|DRUG|0.25% Bupivacaine|10cc, single dose, US guided injection
214518413|NCT01279447|DRUG|Normal Saline|10cc, single dose, US guided injection
214518414|NCT03991052|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
214518415|NCT03991052|DEVICE|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
214518416|NCT05967377|DRUG|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
214518417|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
214518418|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
214518419|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
215117833|NCT04709042|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
215117834|NCT04377217|OTHER|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
215117835|NCT04303481|OTHER|normal diet|Control
215117836|NCT04303481|OTHER|weight loss program kit|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
215117837|NCT04303481|OTHER|weight loss program kit with A. muciniphila prebiotics|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
215117838|NCT05347836|DIAGNOSTIC_TEST|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
215117839|NCT00233766|DEVICE|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
214518420|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
214518421|NCT05967377|DRUG|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
214518422|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
214518423|NCT05967377|DRUG|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
214518424|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
214518425|NCT03338491|BEHAVIORAL|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
214518426|NCT03338491|BEHAVIORAL|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
214518427|NCT00233142|BEHAVIORAL|Expressive writing|Writing as therapeutic intervention
214518428|NCT00233142|BEHAVIORAL|Neutral writing|Non-expressive writing
214518429|NCT04566120|DRUG|cinnamon extract mouthwash|cinnamon extract mouthwash
214440325|NCT05990738|DRUG|Topotecan|Topotecan
214440326|NCT05990738|DRUG|Single agent chemotherapy|single agent chemotherapy
214440327|NCT05672095|PROCEDURE|Biopsy|Undergo needle or core biopsy
214440328|NCT05672095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214440329|NCT05672095|DRUG|Niraparib|Given PO
214440330|NCT05672095|OTHER|Questionnaire Administration|Ancillary studies
214518430|NCT04566120|DRUG|chlorohexidine based mouthwash|chlorohexidine based mouthwash
214518431|NCT01215253|DRUG|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
214518432|NCT02025023|DRUG|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
214440331|NCT05672095|DIETARY_SUPPLEMENT|Selenium|Given IV
214440332|NCT06122688|BEHAVIORAL|Navigator Plus App Intervention|Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
214518433|NCT02025023|DRUG|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
214518434|NCT02025023|PROCEDURE|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
214518435|NCT02025023|DRUG|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
214518436|NCT05612113|BEHAVIORAL|Live Supervision + Session Goal Formulation|"Read under Arms"
215117840|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/rilpivirine|
214440333|NCT06050317|DRUG|Sintilimab Plus mFFN or NALIRIFOX and Radiation|Sintilimab Plus mFFN or NALIRIFOX and Radiation
214440334|NCT04711135|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
214440335|NCT06341088|PROCEDURE|unilateral suture sacro-hysteropexy|patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.
214518437|NCT05612113|OTHER|Session Goal Formulation|"Read under Arms"
214518438|NCT05702892|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
214518439|NCT05746585|BEHAVIORAL|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
214518440|NCT04929444|OTHER|Training on vertigo|"Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study"
214440336|NCT06341088|PROCEDURE|bilateral suture sacro-hysteropexy|patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable suture and bilaterally suspended to the anterior longitudinal ligament.
214440337|NCT03708627|DRUG|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
214518441|NCT05667740|BIOLOGICAL|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
214518442|NCT05667740|BIOLOGICAL|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
214518443|NCT05667740|BIOLOGICAL|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
214518444|NCT05667740|DRUG|Placebo|Saline
215117841|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/efavirenz|
215117842|NCT02041507|OTHER|Air insufflation method.|Air insufflation colonoscopy.
215117843|NCT02041507|OTHER|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
214518445|NCT00674609|DRUG|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
214518446|NCT00674609|DRUG|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
214518447|NCT00674609|DRUG|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
214518448|NCT05728619|DRUG|HTMC0435|Oral administration.
214518449|NCT05728619|DRUG|Temozolomide|Oral administration.
214518450|NCT04352894|DIAGNOSTIC_TEST|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
214518451|NCT02174315|BEHAVIORAL|Contingency Management|
214518452|NCT03785756|DRUG|Ibuprofen 300 mg Oral Tablet|2 × 300 mg tablets at Hours 0 and 12
214518453|NCT03785756|DRUG|Ibuprofen 200 mg Oral Tablet|2 × 200 mg tablets at Hours 0, 8, and 16
214518454|NCT03785756|DRUG|Placebo of PR tablet|2 tablets up to four times in 24 hours
214518455|NCT03785756|DRUG|Placebo of IR tablet|2 tablets up to four times in 24 hours
214518456|NCT05229549|OTHER|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
214518457|NCT05229549|OTHER|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
214518458|NCT05214248|OTHER|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
214692801|NCT01170117|DRUG|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
215117844|NCT02041507|OTHER|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
215117845|NCT05640440|DIAGNOSTIC_TEST|Executive function testing|Assessment of executive function subdivision
215117846|NCT04365712|DEVICE|Piezoelectric tool|
215117847|NCT04365712|DEVICE|Oscillating Saw|
215117848|NCT01934491|BEHAVIORAL|Cognitive Training A|
215117849|NCT01934491|BEHAVIORAL|Cognitive Training B|
215117850|NCT01473732|DRUG|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
215117851|NCT01473732|DRUG|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
214440338|NCT05903495|DEVICE|Deep Brain Stimulation|randomized, sham-controlled, partial crossover study investigating DBS, targeting the nucleus accumbens (NAc) and ventral internal capsule (VC), for participants with severe, treatment refractory OUD.
214440339|NCT03594396|DRUG|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
214440340|NCT03594396|DRUG|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
214440341|NCT05241041|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
214440342|NCT05241041|DEVICE|auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously.
214440343|NCT05241041|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
214440344|NCT06006611|DRUG|Azvudine|Received antiviral treatment with azvudine
214440345|NCT02709304|DRUG|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
214440346|NCT02709304|DRUG|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
214440347|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
214692802|NCT01170117|DRUG|Placebo|Control Group will receive placebo pill
215117852|NCT01473732|DRUG|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
215117853|NCT00005961|DRUG|O6-benzylguanine|
215117854|NCT00005961|DRUG|carmustine|
215117855|NCT03087695|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
215117856|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
215117857|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
215117858|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
215117859|NCT03271424|DIAGNOSTIC_TEST|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
215117860|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
215117861|NCT01798966|DEVICE|SENSIMED Triggerfish|
215117862|NCT04811742|OTHER|bathing|immerson bathing and showering
215117863|NCT01165983|DRUG|Placebo|0mg tablet, taken orally for 12 weeks daily
215117864|NCT01165983|DRUG|Aliskiren|150mg tablet, taken orally for 12 weeks daily
215117865|NCT02246595|BIOLOGICAL|CaCP29|
215117866|NCT02246595|BIOLOGICAL|Placebo|
215117867|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
215117868|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
215117869|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
215117870|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
215117871|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
215117872|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
215117873|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
215117874|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
215117875|NCT01217944|DRUG|Ranibizumab|0.5 mg ranibizumab intravitreal injection
215117876|NCT01217944|DRUG|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
215117877|NCT01217944|DRUG|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
215117878|NCT01217944|DRUG|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
215117879|NCT03579940|DRUG|Lasmiditan|Administered orally.
215117880|NCT03579940|DRUG|Placebo|Administered orally.
215117881|NCT03524482|BEHAVIORAL|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
214518459|NCT03788941|PROCEDURE|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
214440348|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
214518460|NCT01706055|BIOLOGICAL|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
214518461|NCT03821285|PROCEDURE|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
214518462|NCT05500313|BEHAVIORAL|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
214518463|NCT05500313|BEHAVIORAL|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
214518464|NCT01131325|DRUG|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
214518465|NCT02192645|DRUG|Sanfujiu|
214518466|NCT02192645|DRUG|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
214518467|NCT05851521|DEVICE|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
214518468|NCT05851521|DEVICE|Indwelling catheter|Placement of indwelling catheter
214518469|NCT01996514|DIETARY_SUPPLEMENT|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
214518470|NCT01996514|DIETARY_SUPPLEMENT|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
214518471|NCT01996514|BEHAVIORAL|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
214518472|NCT01996514|BEHAVIORAL|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
214518473|NCT06053983|DEVICE|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
214518474|NCT06053983|DRUG|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
214518475|NCT06053983|DRUG|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
214692803|NCT06459622|DIAGNOSTIC_TEST|Serum IL_25 and eosinophils in nasal polyp tisuee|Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids
214692804|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
215117882|NCT03524482|BEHAVIORAL|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
215117883|NCT00257426|DRUG|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
215117884|NCT00671034|DRUG|Calaspargase Pegol-mknl|Given IV
215117885|NCT00671034|DRUG|Cyclophosphamide|Given IV
215117886|NCT00671034|DRUG|Cytarabine|Given IV, IT, PO, or SC
215117887|NCT00671034|DRUG|Daunorubicin Hydrochloride|Given IV
215117888|NCT00671034|DRUG|Dexamethasone|Given PO or IV
215117889|NCT00671034|DRUG|Doxorubicin Hydrochloride|Given IV
215117890|NCT00671034|OTHER|Laboratory Biomarker Analysis|Correlative studies
215117891|NCT00671034|DRUG|Mercaptopurine|Given PO
215117892|NCT00671034|DRUG|Methotrexate|Given IV, IT, or PO
215117893|NCT00671034|DRUG|Pegaspargase|Given IV
215117894|NCT00671034|OTHER|Pharmacological Study|Correlative studies
215117895|NCT00671034|DRUG|Prednisone|Given IV or PO
215117896|NCT00671034|RADIATION|Radiation Therapy|Some patients undergo RT
214440349|NCT05486052|OTHER|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
214440350|NCT03110549|DRUG|TMB-607|
214440351|NCT03110549|DRUG|Placebo|
214440352|NCT01370330|DRUG|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Jubilant DraxImage (Quebec, Canada) with specific activities of 9-18 Ci/mmole, or at Progenics with specific activity of 2,500 mCi/mg. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25-50 ml of normal saline for either preparation, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present.If Azedra is used, the dose will be infused over 30-60 minutes; the low specific activity preparation from Draximage will be infused over 90-120 minutes. For patients with pheochromocytoma or paraganglioma, the recommended maximum dose is 500 mCI or 12 mCi/kg.
214440353|NCT03276403|DEVICE|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
214440354|NCT01077986|DRUG|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
214440355|NCT01077986|DRUG|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
214440356|NCT01077986|DRUG|Everolimus|Everolimus will be administered daily, starting on day 1.
214440357|NCT00764335|PROCEDURE|total hip arthroplasty one side|unilateral total hip arthroplasty
214440358|NCT00764335|PROCEDURE|total hip arthroplasty both sides|bilateral total hip arthroplasty
214440359|NCT02621086|DIETARY_SUPPLEMENT|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
214518476|NCT03884478|BEHAVIORAL|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
214518477|NCT05516511|DIAGNOSTIC_TEST|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
214518478|NCT01272388|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
214518479|NCT01272388|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
214518480|NCT00874172|DRUG|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
214518481|NCT00874172|DRUG|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
214518482|NCT02788708|DRUG|Lenvatinib Mesylate|Given PO
214518483|NCT02788708|DRUG|Paclitaxel|Given IV
214440360|NCT00998881|DRUG|Teneligliptin 20 mg|
214518484|NCT02788708|OTHER|Pharmacological Study|Correlative studies
214440361|NCT00998881|DRUG|Placebo|
214440362|NCT02283749|BIOLOGICAL|Xofigo|This is a radio-isotope
214440363|NCT02954211|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
214518485|NCT02213094|DRUG|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
214518486|NCT02213094|DRUG|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
214518487|NCT00150852|DRUG|Vancomycin|
214518488|NCT01807234|DRUG|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
214518489|NCT01807234|DRUG|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
214518490|NCT01807234|DRUG|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
214518491|NCT06232941|PROCEDURE|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
214518492|NCT04458376|BEHAVIORAL|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
214518493|NCT00538629|OTHER|no intervention|no intervention
214440364|NCT02954211|BEHAVIORAL|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
214440365|NCT00818246|DEVICE|Sham light|
214440366|NCT00818246|DEVICE|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
214440367|NCT05293808|DRUG|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
214440368|NCT05293808|DRUG|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
214518494|NCT00538629|OTHER|no intervention|no intervention
214440369|NCT05293808|DRUG|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
214440370|NCT00002446|DRUG|Posaconazole|
214518495|NCT06544226|DEVICE|UH100|"This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task."
214518496|NCT01803958|RADIATION|partial breast irradiation|
214518497|NCT01803958|RADIATION|whole breast irradiation|
214518498|NCT03536520|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214518499|NCT03536520|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214518500|NCT02301299|BEHAVIORAL|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
214518501|NCT04054245|DRUG|LOXL2 Inhibitor PAT-1251|Given PO
214518502|NCT04054245|OTHER|Quality-of-Life Assessment|Ancillary studies
214440371|NCT00002446|DRUG|Fluconazole|
214518503|NCT04054245|OTHER|Questionnaire Administration|Ancillary studies
214518504|NCT03071172|DRUG|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
214440372|NCT00364117|BEHAVIORAL|Timely Discharge (Remote Presence Technology)|
214440373|NCT03128359|DRUG|Busulfan|Given IV
214440374|NCT03128359|DRUG|Cyclophosphamide|Given IV
214440375|NCT03128359|DRUG|Fludarabine Phosphate|Given IV
214440376|NCT03128359|PROCEDURE|Hematopoietic Cell Transplantation|Undergo PBSC HCT
214440377|NCT03128359|OTHER|Laboratory Biomarker Analysis|Correlative studies
214440378|NCT03128359|DRUG|Melphalan Hydrochloride|Given IV
214518505|NCT03071172|DRUG|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
214518506|NCT03071172|DRUG|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
214518507|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
214518508|NCT00555620|DRUG|oxaliplatin|Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
214518509|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
214440379|NCT03128359|DRUG|Mycophenolate Mofetil|Given IV or PO
214440380|NCT03128359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
214440381|NCT03128359|OTHER|Quality-of-Life Assessment|Ancillary studies
214518510|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
214518511|NCT00555620|DRUG|cisplatin|Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
214518512|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
214518513|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
214518514|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
214518515|NCT03276806|BEHAVIORAL|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
214440382|NCT03128359|DRUG|Tacrolimus|Given IV
214440383|NCT03128359|RADIATION|Total-Body Irradiation|Undergo TBI
214440384|NCT01408524|DRUG|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
214440385|NCT01408524|DRUG|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
214440386|NCT05439395|DEVICE|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
214440387|NCT06107023|BEHAVIORAL|Action observation training|6 weeks, three days a week.
214440388|NCT06107023|BEHAVIORAL|sham action observation training|6 weeks, three days a week.
214440389|NCT02006758|DEVICE|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
214440390|NCT00000749|BIOLOGICAL|rgp120/HIV-1 SF-2|
214440391|NCT00426829|DRUG|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
214518516|NCT03276806|BEHAVIORAL|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
214518517|NCT03276806|OTHER|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
214518518|NCT03276806|OTHER|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
215117897|NCT00671034|DRUG|Thioguanine|Given PO
214440392|NCT00426829|RADIATION|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
214440393|NCT03399604|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
214440394|NCT04788641|DRUG|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
214440395|NCT04788641|DRUG|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
214518519|NCT00005771|DEVICE|Visual utrasound feedback|
214518520|NCT00005771|PROCEDURE|Abdominal Hollowing Exercise|
215117898|NCT00671034|DRUG|Vincristine Sulfate|Given IV
215117899|NCT04044469|BEHAVIORAL|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
215117900|NCT04044469|BEHAVIORAL|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
215117901|NCT04044469|BEHAVIORAL|Control group|This group receives no further information after watching the videotaped doctor's report.
215117902|NCT03609086|OTHER|Melatonin analysis|Measurement of 6-hydroxymelatonin
215117903|NCT02656355|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
215117904|NCT02656355|OTHER|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
215117905|NCT01789684|OTHER|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
215117906|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
215117907|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
215117908|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
215117909|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
214518521|NCT03472118|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
214518522|NCT00035919|GENETIC|Mx-dnG1 Retroviral Vector|
214518523|NCT01726634|OTHER|Elastic Tapping|
214518524|NCT02659488|DRUG|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
214518525|NCT02854709|BEHAVIORAL|Sleep extension|Sleep extension by 1 hour for 2 weeks
215117910|NCT06095219|OTHER|Non- contrast Magnetic Resonance Imaging (MRI) of the hip|Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.
215117911|NCT06095219|OTHER|Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent|The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
215117912|NCT01751984|DRUG|ETC-1002|Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
214518526|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
215117913|NCT01751984|DRUG|Placebo|Placebo once daily for 8 weeks
215117914|NCT01119469|BEHAVIORAL|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
215117915|NCT01699230|DIETARY_SUPPLEMENT|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
215117916|NCT00545090|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
214440396|NCT04788641|DRUG|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
214440397|NCT01291446|DIETARY_SUPPLEMENT|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
214440398|NCT05459233|PROCEDURE|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
214440399|NCT05459233|PROCEDURE|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
214440400|NCT03283371|DRUG|Natalizumab|As specified in the treatment arm.
214440401|NCT03283371|OTHER|Placebo|As specified in treatment arms.
214440402|NCT01596296|DEVICE|Transcervical foley catheter|16 French foley catheter insertion
214440403|NCT01596296|DRUG|Dinoprostone 10mg|Dinoprostone vaginal insertion
214440404|NCT05015608|DRUG|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
214440405|NCT05015608|DRUG|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
214440406|NCT02462759|DRUG|Nusinersen|Administered by intrathecal injection.
214440407|NCT02462759|PROCEDURE|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
214440408|NCT02612142|BEHAVIORAL|physical exercise|endurance-training or stretching (sham exercise)
214692805|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
215117917|NCT01797263|OTHER|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
215117918|NCT01797263|OTHER|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
214440409|NCT05371275|DRUG|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
214440410|NCT00093015|DRUG|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
214440411|NCT00093015|DRUG|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
214440412|NCT03220100|OTHER|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
214440413|NCT02561702|OTHER|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
214440414|NCT02561702|DRUG|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
214440415|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
214440416|NCT06635902|OTHER|Placebo|Isotonic normal saline
214440417|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
214440418|NCT04600752|DRUG|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
214440419|NCT03814369|DEVICE|AmplifEYE|AmplifEYE colonoscopy
214440420|NCT06800040|BEHAVIORAL|Memory training|Memory training
214440421|NCT02462499|DRUG|Inspra (eplerenone)|
214440422|NCT07063381|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 6 months.
214440423|NCT07063433|DRUG|Gluma Desensitizer|Each sensitive tooth will be cleaned with a polishing paste, rinsed with water and air dried. Two coats of Gluma Desensitizer will be applied using a disposable brush applicator following the manufacturer's instructions and left untouched for 30-60 minutes.
214440424|NCT07063433|DRUG|Bioactive glass|The NSK Prophymate Neo will be utilized to dispense Sylc dry powder, which comprises calcium sodium phosphosilicate, onto the sensitive areas. The air stream will be carefully adjusted to 40-46 psi in accordance with the manufacturer's instructions. The handpiece will be maintained at a constant distance of 3-4 mm from the tooth surface, positioned at 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth, using a circular motion.
214440425|NCT07063433|DRUG|Fluoride varnish|The application of a single dose of Bifluorid 10 (by VOCO) will be carried out using a micro brush. A thin coat of varnish will be applied to the tooth surface, and it will be left in place for 10-20 seconds before being air-dried.
214692806|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
214440426|NCT06774612|OTHER|ChatGPT-4o|OpenAI's ChatGPT-4o large language model with chat interface.
214440427|NCT07071844|DRUG|Trifluridine/tipiracil|35 mg/m², orally
214440428|NCT07071844|DRUG|Bevacizumab|5 mg/kg, intravenous route
214440429|NCT07070544|DEVICE|Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on|"Electromagnetic Field Therapy:~* Frequency: 50 Hz~* Intensity: 5-30 mT~* Duration: 30 minutes/session~* Frequency: 3 sessions/week for 8 weeks~Customized Foot Insoles:~* Individually tailored based on foot pressure mapping and deformity.~* Designed to offload pressure points and support foot arches.~Standard Care:~• Wound care, glycemic control, and patient education as per institutional protocol."
214440430|NCT07071740|DEVICE|ventral hernia repair|Robotic-assisted incisional or primary ventral hernia repair with the DEXTER robotic surgery system
215117919|NCT02045095|DRUG|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
214518527|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
214518528|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
214518529|NCT05203822|DRUG|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
214518530|NCT05203822|DRUG|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
214518531|NCT03366233|OTHER|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
214518532|NCT03366233|OTHER|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
214518533|NCT00993590|BEHAVIORAL|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
214518534|NCT00365599|DRUG|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
214518535|NCT00365599|DRUG|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
214518536|NCT03843333|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
214518537|NCT03843333|BEHAVIORAL|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
214518538|NCT03843333|OTHER|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
215117920|NCT04879693|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
215117921|NCT04320017|DIAGNOSTIC_TEST|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"* 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
214440431|NCT07070817|DRUG|Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection|"Ultrasound-guided injection of BoNT-A (specific dosage, e.g., 100 units) into target salivary glands ( parotid and submandibular glands) at baseline."
214518539|NCT03843333|OTHER|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
214518540|NCT00399945|DRUG|Tobramycin|
214518541|NCT02632630|DRUG|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
215117922|NCT00202761|BEHAVIORAL|PIH|Intensified training
215117923|NCT02318966|DIETARY_SUPPLEMENT|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
214440432|NCT07070817|DRUG|Control (Normal saline)|"Intervention: Participants receive routine swallowing rehabilitation training only.~Details of training: The training includes standard techniques to improve swallowing function, such as oral motor training, empty swallowing exercises, and ice stimulation. The frequency and duration of training are consistent across all participants in this arm to ensure standardization."
214440433|NCT07071831|DEVICE|RetroPerc®|The RetroPerc® will be used to obtain renal access.
214440434|NCT07070388|DEVICE|end-effector robotic training|For the robotic training sessions, a haptic wrist robot known as the Wristbot was used (ReWing, Genova, Italy). The training protocol consisted of an eccentric contraction-based exercise. Participants trained 3x per week for 4 consecutive weeks for approximately 25-mins per session.
214440435|NCT07066267|OTHER|Experimental|Autologous adipose stem cell mitochondrial transfer to mature oocytes along with intracytoplasmic sperm injection (ICSI). The intervention is also termed as Adipose Stem Cell ENergy Transfer (ASCENT).
214440436|NCT07064148|BEHAVIORAL|Self-Myofascial Release (SMR) Program|The intervention involves a structured 6-week Self-Myofascial Release (SMR) program using foam rollers and massage balls. Participants perform standardized SMR exercises targeting major muscle groups relevant to golf performance, including the calves, hamstrings, glutes, back, shoulders, and thoracic spine. The intervention is conducted three times per week, with each session lasting approximately 30 minutes. Exercises are demonstrated and monitored by certified instructors. The control group continues regular physical activities without SMR.
214518542|NCT02632630|DIETARY_SUPPLEMENT|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
214518543|NCT02632630|DRUG|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
214518544|NCT02632630|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
214518545|NCT01345253|DRUG|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
214518546|NCT01345253|DRUG|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
214518547|NCT05747352|OTHER|closed-loop hybrid insulin administration|observational non-interventional study
214440437|NCT07064148|BEHAVIORAL|Golf-Related Video Viewing (Attention Control)|Participants in the control group did not receive any self-myofascial release (SMR) intervention. They followed the same daily training schedule, accommodation, and meals as the SMR group. Instead of engaging in SMR exercises, participants in the control group engaged in supervised viewing of golf-related instructional videos or documentaries three times per week, approximately 30 minutes per session, after 7:00 PM in a designated classroom. This viewing schedule was matched in timing and frequency to the SMR group's intervention sessions. No flexibility, mobility, or soft tissue techniques were included in the control group's activities. The sessions were conducted collectively in the same setting and at the same time as the SMR group to control for attention and environmental bias. Attendance and compliance were closely monitored by supervisors to ensure adherence.
214518548|NCT05819177|OTHER|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
214518549|NCT05437328|BIOLOGICAL|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
214518550|NCT00224913|PROCEDURE|Neuromuscular electrical stimulation|
214518551|NCT00224913|PROCEDURE|Voluntary exercise|
214518552|NCT05910879|BEHAVIORAL|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, …a time when you felt successful and proud of yourself. …You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will… a)…think about things I value about myself, b)…remember things that I have succeeded in, c) …think about what I stand for, or d)…think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
214518553|NCT05910879|BEHAVIORAL|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
214518554|NCT03420040|DEVICE|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
214518555|NCT03420040|DEVICE|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
214440438|NCT06893016|DRUG|RAY1225|RAY1225 will be administered SC
214440439|NCT06893016|DRUG|Placebo|Placebo will be administered SC.
214440440|NCT07070024|DRUG|Vitamin C|Topical ascorbic acid powder, (1,000 mg/mL) mixed with saline will be applied over the gingiva for 10 minutes.
214440441|NCT07070024|DEVICE|Microneedling|MN will be achieved using a Dermapen device. c) The device allows for adjustable penetration depth, ranging from 0.2 mm to 3 mm, based on the gingival thickness. d) The needle tip comprises 12 to 24 needles arranged in rows, providing six-speed modes that span from 412 cycles/min at the lowest speed to 700 cycles/min at the highest speed. e) The Dermapen will be positioned perpendicular to the gingival surface, and microneedling will be executed horizontally, vertically, and diagonally approximately four to five times f) Across the entire hyperpigmented gingival surface until subtle microbleeding and mild erythema became evident Each individual will be undergoing a total of three treatment sessions of microneedling, spaced out by 10 days
214440442|NCT07070024|DEVICE|Diode laser|"Energy output, pulse duration, and focal distance will be determined based on manufactures instruction. b) Patient, doctor and assistant will wear protective glass before starting the procedure. c) Depigmentation will be carried out using semiconductor Sirolaser Blue With proper isolation, depigmentation procedure will be done. e) Laser ablation will be started from the mucogingival junction toward the free gingival margin, including interdental papilla. f) The laser beam will be applied using the brush technique, as described by Tal (Tal et al.,2003) and the tip will be kept in motion all the time. g) Remnants of the ablated tissue will be removed using sterile gauze dampened with saline solution"
214518556|NCT02788435|BEHAVIORAL|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
214518557|NCT04775732|BIOLOGICAL|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
214518558|NCT03603691|DIAGNOSTIC_TEST|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
214518559|NCT03603691|DIAGNOSTIC_TEST|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
214518560|NCT03603691|DIAGNOSTIC_TEST|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
214518561|NCT03603691|DIAGNOSTIC_TEST|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
214518562|NCT03603691|DIAGNOSTIC_TEST|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
215117924|NCT01544725|DRUG|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
214518563|NCT03603691|DIAGNOSTIC_TEST|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
214518564|NCT04050514|DEVICE|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
214518565|NCT02043652|DRUG|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
214518566|NCT02043652|DRUG|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
214518567|NCT02073214|OTHER|Probiotic|Standard treatment plus probiotic
214518568|NCT02073214|OTHER|Placebo|Standard treatment plus placebo
214518569|NCT03129009|DRUG|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
214518570|NCT03129009|DRUG|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
214518571|NCT04095338|OTHER|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
214692807|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
214692808|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
214692809|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
214440443|NCT07070024|PROCEDURE|scalpal|Employing surgical blade number 15c, the gingival epithelium in the pigmented area will be excised. c) The blade will be oriented roughly parallel to the elongated axis of the teeth. d) A meticulous assessment of the revealed connective tissue surface will be performed, and any residual tissue tags will be removed with surgical scissors. e) Hemorrhage control will be managed by applying a pressure pack, and after achieving hemostasis, a periodontal dressing (a non-eugenol zinc oxide dressing) will be administered to cover the wound for one week.
214440444|NCT07071168|BEHAVIORAL|hearing-physical activity training|In this study, the intervention was designed to span 10 weeks. Based on our previous study, participants will attend hearing training 30 minutes/day, 5 days/week, The physical activity program will be performed at moderate intensity, 60 min/day, 3 days/week.39
214440445|NCT07071155|DRUG|Momelotinib|The investigators will randomize the first 10 patients to receive 200 mg momelotinib (MMB) monotherapy for first 3 cycles with addition of HMA starting cycle 4 (Arm A, n=5) versus starting with MMB-HMA combination both starting in cycle 1 (Arm B, n=5). The regimen used for the next 8 patients (Arm C- expansion) will be determined after an interim analysis of Arms A and B at week 12 after the first 10 participants have been randomized.
214440446|NCT07071155|DRUG|Azacitidine|75 mg/m2, days 1-5 in a 28-day cycle
214440447|NCT07071155|DRUG|Decitabine|20mg/m2, days 1-5 in a 28-day cycle
214440448|NCT07069790|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|Baseline measurements of neuromuscular function and hemodynamic responses will be performed. Baroreflex sensitivity will be assessed using a neck collar applying positive and negative pressures to stimulate the carotid baroreceptors, thereby modulating baroreflex activity in a dose-dependent manner. Mechanoreflex activation will then be evaluated using the passive leg movement (PLM) technique. After the PLM, participants will perform four fatigue tasks, each followed by 2 minutes of post-exercise circulatory occlusion (PECO). Tasks involve isometric quadriceps contractions at 20% of maximal voluntary contraction (MVC) during 1 min (block 1), 2 min (blocks 2 and 3) and until failure (block4). Neuromuscular function will be assessed through MVC changes and quadriceps twitch responses. Mean arterial pressure (MAP) will be recorded continuously. Metaboreflex activity will be determined by plotting post-PECO changes in peripheral fatigue against the change in MAP during PECO phases.
214440449|NCT07079046|DIETARY_SUPPLEMENT|Intervention 1: Satisens®|A dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers.
214440450|NCT07079046|DIETARY_SUPPLEMENT|Intervention 2: Placebo|Identical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch.
214440451|NCT07078370|DEVICE|ATEV with ESS|Patients will be implanted with a single Acellular Tissue Engineered Vessel with External Support Structure bypass (single proximal and distal anastomoses) to the second or third coronary artery bypass target
214440452|NCT07077538|DRUG|Amino acid peritoneal dialysis solution|After breakfast daily, use a bag of amino acid (15) peritoneal dialysis solution (2L), followed by treatment with glucose peritoneal dialysis solution (lactate).
214440453|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
214518572|NCT04095338|OTHER|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
214518573|NCT04095338|OTHER|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
214518574|NCT00870168|DRUG|chemotherapy|
214518575|NCT00870168|GENETIC|gene expression analysis|
214518576|NCT00870168|OTHER|laboratory biomarker analysis|
214518577|NCT00870168|PROCEDURE|breast biopsy|
214518578|NCT02089425|DRUG|K-103-IP|
215117925|NCT01544725|DRUG|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
215117926|NCT03430778|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
214518579|NCT02089425|DRUG|Placebo|Placebo comparator
214692810|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
215117927|NCT03430778|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
215117928|NCT02246959|BEHAVIORAL|Process Incentive|Daily sweepstake conditional on daily medication adherence
215117929|NCT02246959|BEHAVIORAL|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
215117930|NCT01900158|DRUG|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
215117931|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
214440454|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
214440455|NCT07077941|OTHER|Integrative care|Joint care of mother and child by just one healthcare professional
214440456|NCT06948578|DEVICE|Thread embedding-acupuncture|TEA is performed once at bilateral ST36 (perpendicular insertion) and BL13 (oblique insertion toward EX-B1) using absorbable PDO thread (CARA® 30G × 38 mm). Standard aseptic procedures are followed. Bleeding is controlled, and insertion sites are covered. Participants continue their routine pharmacological COPD treatment.
214440457|NCT06948578|DEVICE|Sham thread-embedding acupuncture|Sham TEA involves taping needles onto the surface of bilateral ST36 and BL13 without skin penetration or thread insertion. The direction toward EX-B1 is mimicked without actual insertion. All procedures, including marking and aseptic preparation, are performed identically to maintain blinding. Participants continue their routine pharmacological COPD treatment.
214440458|NCT00012454|DRUG|E-Selectin nasal spray|
214440459|NCT06955234|DIETARY_SUPPLEMENT|Berbevis supplement|This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
214440460|NCT03760744|PROCEDURE|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
214440461|NCT03760744|PROCEDURE|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
214440462|NCT04694339|OTHER|Survey|Survey
214440463|NCT03620786|DEVICE|Sonablate HIFU device|In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
214440464|NCT03398148|DRUG|risankizumab IV|risankizumab intravenous (IV) infusion
214440465|NCT03398148|DRUG|placebo for risankizumab|placebo for risankizumab
214440466|NCT03398148|DRUG|risankizumab SC|risankizumab subcutaneous (SC) injection
214440467|NCT06113640|DRUG|levodopa-carbidopa|Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
214440468|NCT06113640|DRUG|Montelukast|Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
214440469|NCT04690322|DRUG|Eloctate|Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
214440470|NCT04690322|DRUG|Adynovate|Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
214440471|NCT04690322|DRUG|Emicizumab|Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
214440472|NCT05583708|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
214440473|NCT05583708|DRUG|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
214440474|NCT02400359|DRUG|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
214440475|NCT02400359|DRUG|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
214440476|NCT05923944|BEHAVIORAL|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
214518580|NCT04019301|OTHER|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
214518581|NCT04019301|OTHER|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
214692811|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
214692812|NCT03927248|DRUG|Nivolumab|See description in Arms/Groups section
215117932|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules containing 9000 FCC of acid lactase
215117933|NCT01593631|DIETARY_SUPPLEMENT|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
214440477|NCT05923944|BEHAVIORAL|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
214440478|NCT02791230|DRUG|Tafamidis|Soft gel capsules administered once a day for 60 months
214440479|NCT06439537|OTHER|Semi-structured questionnaire|All patients recruited to the study will undergo a semi-structured questionnaire within 36 hours of admission
214440480|NCT06439537|OTHER|Post-operative interview|All patients recruited to the study will undergo a semi-structured interview once they have reached post-operative day 7 or over
214440481|NCT06190899|DRUG|Gedatolisib|Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
215117934|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
214440482|NCT06190899|DRUG|Darolutamide|Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
214440483|NCT02049034|OTHER|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
215117935|NCT01593631|DIETARY_SUPPLEMENT|Placebo|Capsules containing di-calcium-phosphate
215117936|NCT01302717|DEVICE|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
215117937|NCT01302717|DEVICE|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
215117938|NCT01057849|DRUG|risperidone|3-6 mg per day
215117939|NCT01057849|DRUG|olanzapine|5-20 mg per day
215117940|NCT01057849|DRUG|Aripiprazole|10-30 mg per day
215117941|NCT03658005|OTHER|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).
215117942|NCT05962866|OTHER|I and II. Performing Leopold Maneuvers by the pregnant|24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
215117943|NCT00558116|DEVICE|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
215117944|NCT06143267|OTHER|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
215117945|NCT06504316|DEVICE|CRRT filter|The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
215117946|NCT01576432|BEHAVIORAL|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
215117947|NCT03070535|OTHER|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
215117948|NCT05659368|DRUG|Tirzepatide|tirzepatide once weekly
215117949|NCT01210898|BIOLOGICAL|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
214440484|NCT02049034|OTHER|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
214440485|NCT05138393|OTHER|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
214440486|NCT05138393|OTHER|Observation|Non-specific physical activity 60 minutes per day.
214440487|NCT05233098|DEVICE|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
214440488|NCT05698329|DRUG|AIV007|Periocular injection
214440489|NCT04076293|DRUG|HM15912|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
214440490|NCT04076293|DRUG|Placebo|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
215117950|NCT02150447|DRUG|Proton pump inhibitor|Lansoprazole 30 mg, daily
214440491|NCT04107948|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
214440492|NCT04107948|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
214440493|NCT05281718|DRUG|Factor IX|Factor IX is on of the substrates of emicizumab.
214440494|NCT05810051|BEHAVIORAL|Cardiac rehabilitation|"The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training."
214440495|NCT04039841|DIAGNOSTIC_TEST|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
214440496|NCT05777759|DEVICE|Restylane Lyft with Lidocaine|hyaluronic acid
214440497|NCT05777759|DEVICE|Juvederm Voluma XC|hyaluronic acid
214440498|NCT06381427|OTHER|Interdisciplinary decision-making for perioperative care|Interdisciplinary decision-making for perioperative care involving a cardiologist, anesthesiologist, and surgeon in collaboration with the primary care physician. Decisions include determining whether surgery is feasible or if patient optimization is necessary first. Subsequently, targeted postoperative visits by a heart failure nurse and appropriate postoperative care, also after discharge from the hospital, through the primary care physician.
214440499|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
214440500|NCT06497712|OTHER|Hypnosis|Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
214440501|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
215117951|NCT02150447|DRUG|Placebo|Placebo, daily
215117952|NCT01764555|DRUG|acetaminophen 2 g|
215117953|NCT04516109|DEVICE|Modified hip capsule side fixed slotted cannula|Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
215117954|NCT04516109|DEVICE|Modified bone graft delivery tool set|Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
214440502|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
214440503|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
214440504|NCT04201834|DRUG|Risperidone|capsule or tablet, 0.5 mg
214440505|NCT04201834|DEVICE|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
214440506|NCT06536270|OTHER|A validation and reproducibility study with a cross-sectional component|The primary intervention in this study involves adapting and validating the eNutri web-based Food Frequency Questionnaire and Diet Quality Score for the Turkish population.
214518582|NCT01686724|BEHAVIORAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
214518583|NCT01686724|OTHER|Business As Usual|
214518584|NCT03067870|BIOLOGICAL|Stem Cell Transplantation|"* Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints."
214518585|NCT01352026|DRUG|Metformin|
214518586|NCT03967457|DIAGNOSTIC_TEST|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
215117955|NCT02951494|OTHER|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
215117956|NCT00277550|DRUG|Tegaserod and Placebo|
215117957|NCT05740943|DRUG|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
215117958|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
214440507|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.
214518587|NCT03967457|DIAGNOSTIC_TEST|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
214518588|NCT03967457|DIAGNOSTIC_TEST|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
214518589|NCT03967457|DIAGNOSTIC_TEST|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
214692813|NCT02324842|DRUG|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
214692814|NCT02324842|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
215117959|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
215117960|NCT02682368|DIAGNOSTIC_TEST|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
215117961|NCT02682368|DIAGNOSTIC_TEST|Radiology report|Radiologist report compared to the point of care ultrasound impression.
215117962|NCT02682368|PROCEDURE|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
215117963|NCT03513276|DRUG|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
215117964|NCT03513276|DRUG|Saline Solution|Multimodal analgesia + Saline solution
215117965|NCT03513276|DRUG|Adrenaline 10mcg/ml|
215117966|NCT03158194|BEHAVIORAL|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
214692815|NCT05808998|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
215117967|NCT01450761|BIOLOGICAL|Ipilimumab|
215117968|NCT01450761|BIOLOGICAL|Placebo matching Ipilimumab|
215117969|NCT01450761|DRUG|Etoposide|
215117970|NCT01450761|DRUG|Cisplatin|
215117971|NCT01450761|DRUG|Carboplatin|
215117972|NCT06493058|OTHER|Prone positioning|The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
215117973|NCT03101501|DRUG|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
215117974|NCT03101501|DEVICE|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
215117975|NCT06440941|OTHER|chatbot-based mindfulness-based stress reduction|During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
215117976|NCT05732675|BEHAVIORAL|"Vina-STEAM (Skills to Empower Affirmative Men)"|The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
215117977|NCT03257124|DRUG|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
215117978|NCT04792021|DRUG|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
215117979|NCT01329237|OTHER|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
215117980|NCT00171171|DRUG|deferasirox|
215117981|NCT02256566|BEHAVIORAL|emotional memory training exercise|
215117982|NCT02256566|BEHAVIORAL|memory training exercise|
215117983|NCT05236608|DRUG|Nivolumab|Administered together with ADG106 via intravenous infusion.
215117984|NCT05236608|DRUG|ADG106|Administered as an intravenous infusion over 90 minutes.
215117985|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
215117986|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
215117987|NCT04934501|DIAGNOSTIC_TEST|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
215117988|NCT04934501|DIAGNOSTIC_TEST|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
215117989|NCT03531086|DRUG|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
215117990|NCT04880096|OTHER|eDOL|e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
215117991|NCT02442440|DRUG|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
215117992|NCT06139744|DRUG|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
215117993|NCT06139744|DRUG|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
215117994|NCT01769963|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
214518590|NCT06498232|OTHER|Active Video Based Exercises|Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.
215117995|NCT02636205|DEVICE|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
214440508|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle
214440509|NCT04082637|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
214440510|NCT06402318|DEVICE|A&M Breathalyzer PROTECT Kiosk|The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.
214440511|NCT00212355|DRUG|NPC-02|zinc acetate
214440512|NCT05624606|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5410|Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
214440513|NCT05624606|BIOLOGICAL|Quadrivalent Recombinant Influenza vaccine RIV4|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
214440514|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza Standard Dose QIV-SD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
214440515|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose QIV-HD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
214440516|NCT04349826|DRUG|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
214440517|NCT04349826|DRUG|Cefixime|cefixime 20-30 mg/kg/day for 7 days
214440518|NCT04349826|DRUG|Placebo|cefixime-matched placebo for 7 days
214440519|NCT03661359|OTHER|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
214440520|NCT05947344|DRUG|STI-8591|Four dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg, 60mg and 80mg. Expansion is planned in two dose groups of 40mg and 60mg.
214440521|NCT05629936|OTHER|Digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups
214440522|NCT05757206|DIAGNOSTIC_TEST|Syn-One Test|Participating subjects will have three small skin punch biopsies.
214440523|NCT01923506|RADIATION|stereotactic body radiation therapy|Undergo SBRT
215117996|NCT00096434|DRUG|sorafenib tosylate|Given orally
214440524|NCT01923506|PROCEDURE|quality-of-life assessment|Ancillary studies
214440525|NCT01923506|OTHER|laboratory biomarker analysis|Correlative studies
214440526|NCT06515418|DRUG|Oral Azelaprag (BGE-105)|Capsules
214440527|NCT06515418|DRUG|Oral Placebo for Azelaprag (BGE-105)|Capsules
214440528|NCT06515418|DRUG|Tirzepatide|Subcutaneous Injection
214440529|NCT06515418|DRUG|Tirzepatide Placebo|Subcutaneous Injection
215117997|NCT00096434|OTHER|laboratory biomarker analysis|Correlative studies
214440530|NCT04418115|OTHER|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
214440531|NCT06453005|PROCEDURE|SMART Hall Technique or procedure|"The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure."
214440532|NCT04310735|BEHAVIORAL|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
214440533|NCT04104321|DRUG|Aramchol free acid|Aramchol 300 mg BID
214440534|NCT04104321|DRUG|Placebo|Placebo BID
214440535|NCT04747314|DRUG|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
215117998|NCT00004936|DRUG|iodinated contrast dye|
215117999|NCT00004936|PROCEDURE|computed tomography|
215118000|NCT00004936|PROCEDURE|magnetic resonance imaging|
215118001|NCT00004936|RADIATION|gadopentetate dimeglumine|
215118002|NCT04800601|OTHER|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
215118003|NCT04800601|OTHER|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
215118004|NCT00688584|BEHAVIORAL|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
215118005|NCT00688584|BEHAVIORAL|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
214440536|NCT04747314|OTHER|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
214440537|NCT05152784|DEVICE|Octaray catheter|A high density diagnostic catheter used for substrate and activation mapping.
214440538|NCT05152784|DEVICE|Standard of care|VT ablation guided by substrate-mapping alone.
214440539|NCT05557370|BIOLOGICAL|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
214440540|NCT05361187|DEVICE|BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device|The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
214440541|NCT04013555|DRUG|N-acetylcysteine (NAC)|Flavored effervescent formulation
214440542|NCT04013555|DRUG|Placebo|Flavored effervescent formulation designed to mimic NAC
215118006|NCT02753426|DRUG|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
215118007|NCT02753426|DRUG|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
215118008|NCT00337207|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
215118009|NCT05755139|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
214440543|NCT04013555|DRUG|Tryptophan|Oral slurry form
215118010|NCT03573323|DRUG|Ixekizumab|Administered SC
215118011|NCT03573323|DRUG|Guselkumab|Administered SC
214440544|NCT04219696|OTHER|Reactive balance training|A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
214440545|NCT05605015|BEHAVIORAL|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
214440546|NCT04608045|DRUG|CPX-POM|CPX-POM
214440547|NCT00999193|PROCEDURE|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
214440548|NCT00999193|PROCEDURE|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
214440549|NCT00999193|OTHER|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
214440550|NCT04906213|DRUG|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
214440551|NCT04906213|DRUG|Placebo|10Mg Placebo Tab
214440552|NCT04781959|DRUG|Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
214440553|NCT04781959|DRUG|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
214440554|NCT05307835|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
214440555|NCT05307835|BIOLOGICAL|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
214440556|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
214440557|NCT04420078|PROCEDURE|Catheter Ablation|Ventricular fibrillation substrate
215118012|NCT03573323|DRUG|Placebo|Administered SC
215118013|NCT04354662|DRUG|Toripalimab|240mg d1
215118014|NCT04354662|DRUG|Docetaxel|50mg/m2, d1;
215118015|NCT04354662|DRUG|Fluorouracil|2600 mg/m², d1
215118016|NCT04354662|DRUG|Leucovorin|200 mg/m², d1
215118017|NCT04354662|DRUG|Oxaliplatin|85 mg/m², d1
215118018|NCT05669547|DEVICE|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
215118019|NCT04024696|DRUG|Abexinostat|Abexinostat Tosylate Tablets
214440558|NCT02209350|PROCEDURE|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
215118020|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
215118021|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
214440559|NCT02209350|PROCEDURE|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
214440560|NCT02209350|DRUG|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
214440561|NCT05831683|OTHER|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
214440562|NCT06755203|OTHER|Operating Room Simulation Training|"The intervention involves high-fidelity OR simulations focusing on critical areas of patient safety, including:~Communication Skills: Emphasizing clear communication during surgical procedures.~Stress Management: Training participants to manage stress effectively in high-pressure situations.~Protocol Adherence: Practicing adherence to the WHO Surgical Safety Checklist. Risk Assessment: Identifying and mitigating potential safety risks in simulated scenarios"
214440563|NCT03517553|DEVICE|EMS users in ESRD|use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
214440564|NCT03271151|DRUG|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
214440565|NCT03271151|OTHER|Placebo|Placebo to compare outcomes against Duloxetine
214440566|NCT03575052|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
214440567|NCT03575052|DRUG|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
214440568|NCT05052281|BEHAVIORAL|Mothers and Babies (MB) Course|The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.
214440569|NCT05052281|BEHAVIORAL|Just in Time Intervention (JITI) Content|"Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day."
214440570|NCT05052281|DEVICE|Biostamp nPoint Device|During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
214440571|NCT05631574|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
214440572|NCT05872919|OTHER|SMS reminder massages about adherence|SMS three-times per week in the first six weeks and twice per week in the second six weeks reminding the patient about adherence to prescribed medication
214440573|NCT06273683|OTHER|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
214440574|NCT06273683|OTHER|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
214440575|NCT06772519|DEVICE|green colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
215118022|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
215118023|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
215118024|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
215118025|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
215118026|NCT03209531|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
214440576|NCT06772519|DEVICE|blue colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
214518591|NCT06498232|OTHER|Stabilization and Strengthening Exercises|Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.
215118027|NCT03209531|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
215118028|NCT03209531|DEVICE|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
215118029|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
214440577|NCT06772519|DEVICE|colorless (transparent) lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
214440578|NCT06773663|COMBINATION_PRODUCT|Al18F-NOTA-Pentixafor PET/CT|"Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability."
215118030|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
215118031|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
215118032|NCT05981547|DEVICE|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
215118033|NCT05585710|OTHER|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
215118034|NCT05585710|PROCEDURE|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
215118035|NCT05585710|PROCEDURE|Bilateral or unilateral mastectomy|Standard of care
215118036|NCT05585710|DEVICE|Tissue expander|Standard of care
215118037|NCT05585710|OTHER|Acellular dermal matrix|Standard of care
215118038|NCT04502290|DEVICE|Combined Non-invasive brain stimulation and functional electrical hand stimulation|Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
215118039|NCT01138488|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
215118040|NCT02303249|OTHER|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
215118041|NCT00837213|DRUG|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
215118042|NCT00837213|DRUG|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
215118043|NCT02545218|PROCEDURE|Perineorraphy|Surgery for improperly healed perineal tear
215118044|NCT02545218|OTHER|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
214440579|NCT06775236|DRUG|SYS6010 jnjection|SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
214692816|NCT04767256|DRUG|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
215118045|NCT02293798|DEVICE|silk surgical scaffold|surgical implant
215118046|NCT06226038|OTHER|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
215118047|NCT06226038|OTHER|Stainless steel|For control
215118048|NCT01004926|DEVICE|Echelon foot|One Echelon foot for each subject, for a period of a month.
215118049|NCT00835250|PROCEDURE|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
215118050|NCT00835250|PROCEDURE|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
215118051|NCT01944124|BEHAVIORAL|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
215118052|NCT01944124|BEHAVIORAL|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
215118053|NCT01558947|DRUG|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
214440580|NCT06775236|DRUG|monotherapy chemotherapy|Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
215118054|NCT01558947|DRUG|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
215118055|NCT01931306|DRUG|Afatinib|BIBW2992 low to medium dose once daily
215118056|NCT02396706|DRUG|Ivy Leaves Cough Liquid|
215118057|NCT02396706|DRUG|Placebo|
215118058|NCT03202563|DRUG|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
215118059|NCT03202563|DRUG|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
215118060|NCT03202563|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
215118061|NCT03202563|DEVICE|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
215118062|NCT03202563|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
215118063|NCT01865227|BEHAVIORAL|Group Counseling|
215118064|NCT00825201|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
214440581|NCT06775236|DRUG|SYH2051 tablets|SYH2051 is a Selective ATM protein kinase inhibitor
215118065|NCT00825201|OTHER|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
214440582|NCT03103321|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
214440583|NCT03103321|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
214440584|NCT03103321|OTHER|Best Practice|Undergo usual care
214440585|NCT03103321|OTHER|Quality-of-Life Assessment|Ancillary studies
214440586|NCT03103321|OTHER|Questionnaire Administration|Ancillary studies
214440587|NCT03103321|OTHER|Survey Administration|Ancillary studies
214440588|NCT03103321|OTHER|Laboratory Biomarker Analysis|Correlative studies
214440589|NCT04247542|DRUG|Ibezapolstat|Investigational antibacterial agent
214440590|NCT04247542|DRUG|Vancomycin|Active comparator
214440591|NCT05784935|DEVICE|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
214440592|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
214440593|NCT04517357|DRUG|Fluzoparib|Fluzoparib monotherapy
214440594|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
214440595|NCT06799130|OTHER|instrument-assisted soft tissue mobilization|instrument-assisted soft tissue mobilization
214440596|NCT06799130|OTHER|Muscle energy technique|Muscle energy technique
214518592|NCT06498232|OTHER|Waiting List-Spine protection principles training|Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
215118066|NCT00825201|OTHER|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
215118067|NCT00825201|OTHER|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
215118068|NCT00825201|OTHER|laboratory biomarker analysis|Correlative studies
215118069|NCT06363734|DRUG|Osimertinib plus Dalpiciclib|osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
214440597|NCT04153162|DEVICE|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
214440598|NCT05514002|BIOLOGICAL|Fluzone Quadrivalent|Intramuscular
214440599|NCT05514002|BIOLOGICAL|Flublok Quadrivalent|Intramuscular
214440600|NCT06779760|PROCEDURE|parathyroidectomy|"The FLUOBEAM® LX apparatus consists of a camera with a built-in light emitter (750-800 nm) and detector (800-830 nm) connected to a processor with an indication-oriented software (Fluosoft®). The processor captures the emitted light, allowing display of PTG images in real time. The camera is placed in a sterile sheath and is held perpendicularly at 8 cm from the target tissue with operating lights, all background lights, and any ambient light being extinguished. The reported depth of tissue penetration of near-infrared light is limited to a maximum of 3 mm only with no observed differences between superior and inferior PTGs \[10\]. This highlights the importance of a major surgical technical point reaching the correct plane of dissection namely, the pre-vertebral fascia to maximize the chances of eliciting an adequate signal from parathyroid tissue. The correct application of the technology has demonstrated a success rate of signal elicitation of 90%-100% \[11\]. The ability of near-infr"
214440601|NCT06781944|DRUG|Cyclophosphamide (CTX)|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min"
214440602|NCT06781944|DRUG|Glucocorticoids|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days."
214440603|NCT06781073|DRUG|Nimotuzumab|Nimotuzumab in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
214440604|NCT06781073|DRUG|Paclitaxel|175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
214440605|NCT06781073|DRUG|Cisplatin|50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
214440606|NCT06781073|DRUG|Placebo|Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
214440607|NCT06779916|DIAGNOSTIC_TEST|Blood test|"16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit.~At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken."
214440608|NCT06779916|DIAGNOSTIC_TEST|Urine test|Urine samples will be taken at the inclusion visit and at each follow-up visit.
215118070|NCT05543902|BEHAVIORAL|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
214440609|NCT06779786|OTHER|Group 1 (Aromatherapy Groups):|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of eucalyptus sttriodora (Group 1) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% eucalyptus sttriodora (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
214440610|NCT06779786|OTHER|Group 2 (Aromatherapy Groups):|Group 2(Aromatherapy Groups): Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of medicanal lavandula (Group 2) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% medicanal lavandula (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
214518593|NCT01799603|DRUG|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
214518594|NCT02142478|BEHAVIORAL|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
215118071|NCT06117241|BEHAVIORAL|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
214440611|NCT06779786|OTHER|Group 3 (Placebo Control Group)|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of sesame oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the earlobe from top to bottom with the thumb and index finger for four minutes, and again apply 2 ml of sesame oil into the palm. The group was given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands together with the drops.
214518595|NCT02142478|BEHAVIORAL|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
214518596|NCT00547456|DRUG|Oxygen|Oxygen 2-3L Nasal cannula
214518597|NCT03645213|DEVICE|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
214518598|NCT03645213|DEVICE|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
214518599|NCT03451903|DRUG|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
214518600|NCT03451903|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
214518601|NCT05852197|DRUG|anticoagulant or antiplatelet drugs|combination of anticoagulant or antiplatelet drugs
214518602|NCT00648895|DRUG|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
214518603|NCT00648895|DRUG|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
214518604|NCT01164319|PROCEDURE|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
214518605|NCT03873376|BEHAVIORAL|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
214518606|NCT03873376|BEHAVIORAL|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
214518607|NCT03873376|BEHAVIORAL|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
214518608|NCT04733573|DEVICE|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
214518609|NCT03003715|PROCEDURE|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
214518610|NCT03003715|PROCEDURE|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
215118072|NCT05646537|BEHAVIORAL|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
215118073|NCT02432417|DRUG|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
215118074|NCT05802446|OTHER|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
214518611|NCT03003715|PROCEDURE|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
214518612|NCT03003715|OTHER|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
214518613|NCT05542589|OTHER|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
214518614|NCT05542589|OTHER|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
214518615|NCT04862507|OTHER|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
214518616|NCT04862507|DIAGNOSTIC_TEST|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
214440612|NCT04118452|BEHAVIORAL|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR (Electronic Medical Record) by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
214518617|NCT06301945|DIAGNOSTIC_TEST|Artificial Intelligence Diagnostics|AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
214518618|NCT06301945|DIAGNOSTIC_TEST|Recurrence Prediction Tool|This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
214518619|NCT01241994|OTHER|AASD dialysis technique|
214518620|NCT02838888|DEVICE|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
214518621|NCT04610606|BEHAVIORAL|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
214518622|NCT01134497|DRUG|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
214518623|NCT01134497|DRUG|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
215118075|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
215118076|NCT05566769|DEVICE|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
215118077|NCT03508934|DEVICE|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
215118078|NCT03508934|OTHER|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
214518624|NCT03180788|PROCEDURE|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
215118079|NCT00133042|DRUG|omalizumab|
215118080|NCT05303623|OTHER|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
214518625|NCT03180788|PROCEDURE|Traditional ESD|Endoscopic submucosa dissection
214518626|NCT00363389|DRUG|misoprostol and cervical ripening|
214692817|NCT04767256|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
214440613|NCT06803368|BIOLOGICAL|baseline anti-HBs titer|Patients with baseline anti-HBs titer\<100 mIU/ml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.
214518627|NCT02865083|DEVICE|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
214518628|NCT02152111|DIETARY_SUPPLEMENT|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
214518629|NCT02152111|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months.
214518630|NCT02699398|BEHAVIORAL|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
214518631|NCT02699398|BEHAVIORAL|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
214518632|NCT04436965|OTHER|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
214518633|NCT04436965|DRUG|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
214440614|NCT06803693|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
214518634|NCT04436965|RADIATION|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
214518635|NCT04430673|OTHER|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
214518636|NCT04527679|DRUG|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
214518637|NCT03796364|DRUG|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
214518638|NCT03796364|DRUG|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
214518639|NCT01290471|DRUG|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
214518640|NCT00444730|PROCEDURE|Radical Prostatectomy|Surgical procedure for prostate cancer.
215118081|NCT05303623|OTHER|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
215118082|NCT05303623|OTHER|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
215118083|NCT04555460|PROCEDURE|Hemicraniectomy|Large hemicraniectomy and duraplasty
215118084|NCT04555460|OTHER|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
215118085|NCT01910415|DRUG|Lumacaftor|
215118086|NCT01910415|DRUG|Lumacaftor Placebo|
215118087|NCT01910415|DRUG|Ivacaftor|
214440615|NCT06803693|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
215118088|NCT01910415|DRUG|Ivacaftor Placebo|
214440616|NCT06803693|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214440617|NCT06803693|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214440618|NCT06803693|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
214440619|NCT06803693|DRUG|Zanubrutinib|Zanubrutinib PO will be administered as per the schedule specified in the respective arm.
214440620|NCT06803693|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
215118089|NCT01910415|DRUG|moxifloxacin hydrochloride|
214518641|NCT00444730|PROCEDURE|InterStim Implantation|surgical placement of the interstim
214518642|NCT00444730|PROCEDURE|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
214518643|NCT00841321|DRUG|Ginkgo biloba|120 mg orally twice a day for 12 weeks
214518644|NCT00841321|DRUG|Placebo|One capsule orally twice a day for 12 weeks
214518645|NCT05795283|DRUG|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
214518646|NCT05795283|DRUG|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
214518647|NCT04434222|DEVICE|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
214518648|NCT01363206|BIOLOGICAL|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
214518649|NCT01363206|BIOLOGICAL|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
214518650|NCT05057767|DRUG|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
214518651|NCT05860218|OTHER|advices|"The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
215118090|NCT02698826|OTHER|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
215118091|NCT02545608|DEVICE|Restylane Vital|
215118092|NCT02526602|PROCEDURE|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
215118093|NCT02526602|PROCEDURE|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
215118094|NCT00490958|DRUG|telmisartan|
215118095|NCT01540357|BEHAVIORAL|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
215118096|NCT01540357|BEHAVIORAL|Treatment after waiting time|Treatment was performed after completion of the active arm.
215118097|NCT03311165|OTHER|no intervention|no intervention was given
215118098|NCT00934765|BEHAVIORAL|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
215118099|NCT04774263|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
215118100|NCT05947864|BIOLOGICAL|Biological samples (blood and oral fluid)|"For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)"
215118101|NCT05783336|BEHAVIORAL|Stepping Stones and Creating Futures Plus (SSCF+)|Group-based intervention delivered to small friendship networks, by a facilitator.
215118102|NCT01436786|OTHER|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
215118103|NCT04161937|BEHAVIORAL|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
214518652|NCT05860218|OTHER|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):"
214518653|NCT00292409|DRUG|Aripiprazole|
214518654|NCT05256758|DRUG|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
214518655|NCT05256758|DRUG|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
215118104|NCT05594407|DRUG|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
215118105|NCT05594407|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
215118106|NCT05565703|OTHER|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
215118107|NCT05565703|OTHER|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
215118108|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
215118109|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
215118110|NCT02949999|DRUG|Voclosporin|
215118111|NCT00452868|DRUG|Donepezil|Donepezil 5 milligrams a day for 6 weeks
215118112|NCT01567111|PROCEDURE|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
215118113|NCT03610191|DIAGNOSTIC_TEST|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
215118114|NCT03610191|BEHAVIORAL|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
214440621|NCT06803693|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
214440622|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 single dose as oral suspension.
214440623|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 multiple doses daily as oral suspension.
214440624|NCT06368440|DRUG|Placebo|Participants will receive matching doses of placebo as oral suspension.
214440625|NCT04077567|DRUG|TS-152|30mg,80mg
214440626|NCT05086744|DRUG|Iptacopan|Iptacopan 200 mg BID given orally (capsule)
214440627|NCT06787820|BEHAVIORAL|Music intervention|The musical intervention conducted at the senior home focused on the development of rhythmic and vocal skills, as well as the creation of educational experiences that promoted the acquisition of these competencies. To achieve this, both conventional percussion instruments, such as claves, tambourines, woodblocks, and triangles, and unconventional elements, such as buckets played with drumsticks, sheets of paper, spoons, ribbons, elastic bands, and a parachute, were used to mark the rhythm during the singing sessions. The selected songs were chosen based on the musical styles mentioned by the participants during the pre-intervention interview. Furthermore, participants were given the opportunity to showcase their progress at the end of the activity, with the aim of sharing these achievements with family and friends at the home.
214440628|NCT06787157|OTHER|Prediction Model Construction|
214440629|NCT06785363|OTHER|pumped technique for ilio-lumbar ligament release|Patient position: the patient lying supine or side lying Therapist position: standing on one side of patient. Hand grip: one hand placed on posterior region of iliac crest (close to attachment of ilio-lumbar ligament) while other hand stabilize the medial part of thigh. Therapist force: therapist pulling patient's thigh posteriorly.
214440630|NCT06785363|OTHER|Hot Packs|postnatal women will be treated by hot packs for 20 minutes three times per week for 8 weeks.
214518656|NCT03455153|OTHER|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
214440631|NCT06792058|DEVICE|"Mechanomiograph: The gold standard of quantitative monitoring"|"The gold standard of quantitative monitoring is mechanomyography (MMG), which measures the force of contraction of the adductor pollicis muscle following ulnar nerve stimulation. MMG responses are accurate and reproducible. However, the complex and bulky devices are only suitable for research use, are not suitable for clinical use and are not commercially available."
214440632|NCT06792058|DEVICE|Electromiograph|Another type of monitor is the electromyograph, which can be seen as an alternative to mechanomyography because of its accuracy. This technique measures muscle activity as a summation of the action potentials of muscle fibres. This activity is proportional to the strength of the muscle contraction. The most commonly innervated nerve is also the ulnar nerve, which innervates the abductor digiti minimi and the first dorsalis interosseus muscles. During the measurements, electrical signals from these muscles are detected. EMG has several advantages over other monitoring techniques. It does not require immobilisation of the hand, thumb immobility is not a problem, no preload is required, and hypothermia does not affect the hand as much as other neuromuscular monitors. The TetraGraph (Senzime AB, Sweden) is a portable EMG-based neuromuscular minitor for which the manufacturers received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
214440633|NCT06789458|PROCEDURE|Professional mechanical plaque control|"thisThe first step in therapy is aimed at guiding behavior change by motivating the patient to undertake successful removal of supragingival dental biofilm and risk factor control and may include the following interventions:~* Interventions to improve the effectiveness of oral hygiene \[motivation, instructions (oral hygiene instructions, OHI)~* Professional mechanical plaque removal (PMPR), which includes the professional interventions aimed at removing supragingival plaque and calculus, as well as possible plaque-retentive factors that impair oral hygiene practices.~* Adjustment of faulty restoration and polishing~* The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques."
214440634|NCT06100237|DRUG|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
214440635|NCT06100237|DRUG|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
214440636|NCT06100237|DRUG|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
214440637|NCT06783049|BEHAVIORAL|Cerebrovascular Disease Secondary Prevention Smart Management System|The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.
214440638|NCT04300231|DRUG|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
214440639|NCT04300231|DRUG|Liposomal bupivacaine|20 ml
214440640|NCT04300231|DRUG|bupivacaine 0.125%|40 mL
214440641|NCT04300231|DRUG|bupivacaine 0.5%|60 mL
214440642|NCT04300231|DRUG|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
214440643|NCT04300231|DRUG|injectable saline|40 mL
214518657|NCT04029727|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
215118115|NCT03610191|PROCEDURE|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
214440644|NCT03068663|OTHER|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
214518658|NCT04029727|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
215118116|NCT05375227|OTHER|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
214518659|NCT02379078|OTHER|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
215118117|NCT03641040|DIAGNOSTIC_TEST|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
215118118|NCT03641040|DIAGNOSTIC_TEST|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
214518660|NCT02379078|OTHER|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
214518661|NCT02379078|OTHER|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
214518662|NCT05957822|DRUG|TXA|Tranexamic acid injection 8-10mg/kg
214518663|NCT05957822|DIAGNOSTIC_TEST|TEG6|performing thromboelastography (TEG6)
214518664|NCT03476577|DRUG|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
214518665|NCT04908488|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
214518666|NCT04908488|DEVICE|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
215118119|NCT04764513|BIOLOGICAL|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10\^6、 1×10\^7 and 5×10\^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
215118120|NCT01828229|BEHAVIORAL|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
214518667|NCT02627534|PROCEDURE|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
215118121|NCT01828229|BEHAVIORAL|inactivity|inactivity for 2 weeks
214518668|NCT02627534|PROCEDURE|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
214518669|NCT00003755|DRUG|MKC-1|
214518670|NCT05426655|OTHER|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
214518671|NCT06423976|OTHER|Sequencing study|Sequencing of tumour samples for microbiome analysis and molecular charcterisation.
214518672|NCT04881045|BIOLOGICAL|PF-07257876|CD47-PDL-1 bispecific antibody
214518673|NCT03921164|PROCEDURE|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
214518674|NCT03921164|PROCEDURE|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
214518675|NCT03921164|PROCEDURE|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
214518676|NCT00598156|DRUG|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
214518677|NCT00598156|DRUG|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
214518678|NCT02853188|OTHER|venous thromboembolism|
214518679|NCT00098514|DRUG|talotrexin ammonium|
214518680|NCT04822025|BIOLOGICAL|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
214518681|NCT04822025|BIOLOGICAL|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
215118122|NCT01828229|BEHAVIORAL|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
215118123|NCT01828229|BEHAVIORAL|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
214518682|NCT00212888|BIOLOGICAL|Remune and ALVAC|"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
214518683|NCT01894620|DEVICE|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
214518684|NCT01894620|DEVICE|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
214518685|NCT03268850|OTHER|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
215118124|NCT01828229|BEHAVIORAL|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
215118125|NCT01964417|DRUG|Colonoscopy after bowel cleansing|
215118126|NCT05988879|DRUG|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
215118127|NCT02641431|PROCEDURE|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
215118128|NCT02641431|DRUG|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
215118129|NCT02641431|PROCEDURE|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
215118130|NCT02641431|PROCEDURE|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
214518686|NCT03268850|BEHAVIORAL|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
214440645|NCT05273723|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: You planned to walk today in the park at 3pm."
214440646|NCT04959838|BEHAVIORAL|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
214440647|NCT05523882|DIAGNOSTIC_TEST|point-of-care ultrasound|"All participants will receive the same ultrasound education through attendance of the ultrasound course arranged by PLO-e. The educations intervention consists of three teaching seminars delivered over three months, a curriculum of 10 POCUS applications, an online learning platform providing educational support before, during, and after the teaching sessions (see Figure 2).~The online platform includes videos demonstrating the performance of POCUS, suggestions for additional literature, assignments to support the development of skills, self-quizzes to focus attention of learning outcomes and specific actioncards for each of the 10 POCUS applications framing the examinations in the clinical context. In addition, the online platform provides participants access to webinars and communication with other participants and teachers"
214518687|NCT03268850|BEHAVIORAL|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
214518688|NCT02683317|DIETARY_SUPPLEMENT|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
214518689|NCT02683317|DIETARY_SUPPLEMENT|sunflower oil|Sunflower similar to the excipient used in experimental group
215118131|NCT00904735|DRUG|hydroxyurea|Given orally
215118132|NCT00904735|DRUG|imatinib mesylate|Given orally
214518690|NCT02457078|DIETARY_SUPPLEMENT|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
214518691|NCT02457078|DIETARY_SUPPLEMENT|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
214518692|NCT03563131|DEVICE|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
214518693|NCT00957918|DRUG|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
214518694|NCT00957918|OTHER|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
214692818|NCT04767256|OTHER|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
215118133|NCT04869540|OTHER|Usual care|Evidence based care for transition-aged youth (TAY) with ASD.
215118134|NCT04869540|OTHER|'Got Transition' toolkit and resources|Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.
215118135|NCT04869540|BEHAVIORAL|PSE intervention|A family-based problem solving education (PSE) intervention.
215118136|NCT03655041|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
215118137|NCT03655041|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
215118138|NCT01300312|DRUG|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
215118139|NCT01300312|DRUG|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
215118140|NCT01450865|DRUG|flupirtine|Potassium channel opener (SNEPCO)
215118141|NCT02691559|DEVICE|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
215118142|NCT01669486|OTHER|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
214440648|NCT04965181|BEHAVIORAL|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
214440649|NCT04965181|DRUG|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
214440650|NCT04965181|BEHAVIORAL|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
214440651|NCT04965181|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
214440652|NCT04827979|BIOLOGICAL|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant"
214440653|NCT04827979|BIOLOGICAL|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
214440654|NCT04827979|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
214440655|NCT05986565|BEHAVIORAL|Families Moving Forward (FMF) Teacher adapted training|The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
214440656|NCT04500301|OTHER|Preemptive Pharmacogenomic Testing|The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
214440657|NCT06798311|BEHAVIORAL|SUPPORT workbook|"The SUPPORT workbook contains a template for how pelvic floor physical therapy is delivered in the typical in-person setting with a combination of education, bladder re-training exercises, pelvic floor stretching and core strengthening. To aid in the demonstration of physical therapy exercises, the workbook includes QR-coded links to videos of a physical therapist performing the exercises in an ideal form. The videos include audio instruction to ensure that patients can learn the concepts in either visual, auditory or written form. The cognitive behavioral therapy (CBT) portion of the workbook is adapted from the standardized CBT protocol and includes short introductions and exercises pertaining to cognitive flexibility, behavioral activation and social support. The total time commitment for the program is 2-hours per week.~Patients also will be given access to a custom programmed GPT trained on the SUPPORT workbook and given instructions on empathetic communication techniques."
214440658|NCT06772259|DEVICE|Palm Stimulator|The apparatus is 1.6 cm in diameter and 4 cm long. It has a cylindrical, non-slippery and easy-to-grasp structure for maximum contact with the palm
214440659|NCT06772259|OTHER|Cartoon|The cartoon was projected on a blank wall in the intervention room with a projection device. The cartoon was played in preparation for the PIK procedure and children were allowed to watch it until the procedure was completed.
214440660|NCT06754839|DEVICE|Percutaneous left ventricular assist device(Ventiflow LP)|The PCI will be completed with the support of percutaneous left ventricular assist device(Ventiflow LP).
214440661|NCT06754839|DEVICE|VA-ECMO|The PCI will be completed with the support of Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
214518695|NCT02787135|BEHAVIORAL|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
215118143|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
214518696|NCT00141336|DRUG|Pregabalin|
214518697|NCT03395873|DRUG|Avelumab|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
215118144|NCT00166829|DRUG|sirolimus, tacrolimus, mycophenolate mofetil|
215118145|NCT01185015|DRUG|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
215118146|NCT02316418|DEVICE|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
215118147|NCT05282771|DRUG|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
214440662|NCT05056545|BEHAVIORAL|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
214440663|NCT04164472|BEHAVIORAL|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
214440664|NCT06444529|DRUG|Apraclonidine Hydrochloride Ophthalmic Solution|Investigational ophthalmic solution applied topically to the eye with a dropper bottle
214440665|NCT06444529|DRUG|Vehicle|Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
214440666|NCT04795856|DRUG|[11C] acetate|PET Tracer
214440667|NCT04431050|DIAGNOSTIC_TEST|Point of care testing of respiratory viruses.|Single use point of care diagnostic device.
214440668|NCT04234217|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
214440669|NCT04234217|OTHER|Niacin|Suppression of lipolysis by niacin infusion
214440670|NCT03755141|DRUG|Herzuma|Herzuma + Treatment of Physician's Choice
214440671|NCT03399292|DRUG|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
214440672|NCT05842057|BIOLOGICAL|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
214440673|NCT05842057|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
214440674|NCT03812874|DRUG|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
214440675|NCT03812874|DRUG|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
214440676|NCT01697930|DRUG|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of \[18F\] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the \[18F\] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
214440677|NCT03206372|OTHER|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
214518698|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA+)|Six cooking classes + enhanced elements, such as diabetes-specific nutrition and cooking information, and online educational information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. This arm will have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up. Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
214518699|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA)|Participants will attend cooking and educational sessions once per week for 6 weeks. In addition, they will receive recipes and produce boxes with instructions to prepare the recipe at some point prior to their next class. They will also be invited to the online Google Classroom site where all intervention materials will be housed for their convenience. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up (kits provided at the final cooking class, for a total of 6 fecal samples per participant). Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
214518700|NCT06550024|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
214518701|NCT06550024|DRUG|Corticosteroid Injection|Corticosteroid injection in the knee
214440678|NCT03206372|OTHER|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
214440679|NCT02058108|DRUG|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
214440680|NCT02058108|DRUG|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
214518702|NCT00649402|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
214518703|NCT00649402|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
214518704|NCT05791786|OTHER|Patient|affected individuals diagnosed with AFE
214518705|NCT01442766|DRUG|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
214518706|NCT01442766|DRUG|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
214518707|NCT06000371|DEVICE|Vacuum assisted Closure application|Vacuum assisted Closure Application in Diabetic Foot Ulcers
214518708|NCT00570622|DRUG|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
214518709|NCT00570622|DRUG|Placebo|Patients receive placebo once a day orally for 9 days
214518710|NCT01068977|DRUG|bevacizumab|Repeating intravenous dose
214518711|NCT01068977|DRUG|MetMAb|Repeating escalating intravenous dose
214518712|NCT01068977|DRUG|MetMAb|Repeating intravenous dose
214518713|NCT03122314|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
214518714|NCT03122314|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
214518715|NCT03792178|OTHER|Bulk fill composite|Composite resin dental material
215118148|NCT05282771|DRUG|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
215118149|NCT05282771|DRUG|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
215118150|NCT03645733|PROCEDURE|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
215118151|NCT00671424|DRUG|Hydrochlorothiazide (HCTZ)|
215118152|NCT00671424|DRUG|Remogliflozin etabonate (GSK189075)|
215118153|NCT00671424|DRUG|Furosemide|
215118154|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
215118155|NCT03862183|OTHER|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
214440681|NCT02109601|OTHER|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
214440682|NCT02109601|OTHER|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
214440683|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
214440684|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
214518716|NCT03792178|OTHER|Nano resin composite|Dental composite material
214518717|NCT04685395|DRUG|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
214518718|NCT05584306|DRUG|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
214518719|NCT05584306|DRUG|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
214518720|NCT05584306|DRUG|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
214518721|NCT05584306|OTHER|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
215118156|NCT03869554|DIAGNOSTIC_TEST|Detection of Fabry disease|Systematic detection of Fabry disease
215118157|NCT05497089|DRUG|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
215118158|NCT05497089|DRUG|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
215118159|NCT05649007|DEVICE|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
214440685|NCT04602975|BIOLOGICAL|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
214440686|NCT04602975|BIOLOGICAL|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
214518722|NCT05584306|OTHER|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
214518723|NCT05584306|OTHER|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
214518724|NCT03213587|DRUG|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214440687|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
214440688|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
214440689|NCT01154192|DRUG|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
214440690|NCT01154192|DRUG|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
214440691|NCT03746613|DEVICE|HEARO|Robotic system for otological procedures
214440692|NCT02380105|BEHAVIORAL|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
214440693|NCT02380105|DEVICE|Interocclusal Appliances|Patients were treated using interocclusal appliances
214440694|NCT00054210|DRUG|carboplatin|
214440695|NCT00054210|DRUG|paclitaxel|
214518725|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
214518726|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
214518727|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
214440696|NCT00054210|DRUG|paclitaxel poliglumex|
214440697|NCT06221137|PROCEDURE|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
214440698|NCT06221137|PROCEDURE|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
214518728|NCT00657709|BIOLOGICAL|Infanrix Hexa|Routine vaccination
214518729|NCT00657709|BIOLOGICAL|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
214518730|NCT00657709|BIOLOGICAL|Prevenar|Routine vaccination
214518731|NCT02634593|BEHAVIORAL|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
214518732|NCT03276286|DEVICE|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
214518733|NCT04885140|BEHAVIORAL|Feedback-based health education|This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.
214692819|NCT04767256|OTHER|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
215118160|NCT03692039|PROCEDURE|M-pro files in rotating motion|An endodontic file that has controlled memory properties
215118161|NCT03692039|PROCEDURE|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
215118162|NCT03351517|DRUG|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
215118163|NCT03351517|DRUG|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
215118164|NCT04663503|OTHER|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
215118165|NCT01388569|OTHER|flow cytometry|
215118166|NCT01388569|OTHER|immunologic technique|
215118167|NCT01388569|OTHER|laboratory biomarker analysis|
215118168|NCT04946890|DRUG|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
214518734|NCT04885140|BEHAVIORAL|Routine health education|Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
214518735|NCT01051648|DRUG|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
214518736|NCT03073902|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
214440699|NCT04587505|PROCEDURE|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
214440700|NCT04587505|DRUG|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
214518737|NCT00879827|BIOLOGICAL|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
214518738|NCT00879827|BIOLOGICAL|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
214518739|NCT01941706|BEHAVIORAL|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
214518740|NCT00901459|DEVICE|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
214518741|NCT00901459|DEVICE|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
214518742|NCT00901459|DEVICE|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
214518743|NCT04478409|BIOLOGICAL|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
214518744|NCT05602272|PROCEDURE|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
214518745|NCT01373723|OTHER|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
215118169|NCT01434173|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
215118170|NCT01434173|DRUG|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
215118171|NCT04982939|DRUG|Sintilimab|Sintilimab, 200mg IV d1 Q3W
215118172|NCT04982939|DRUG|S-1|S-1, 40-60mg BID d1-14 Q3W
215118173|NCT04982939|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
215118174|NCT04499495|OTHER|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
215118175|NCT05254106|DEVICE|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
215118176|NCT01380795|BIOLOGICAL|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
215118177|NCT04410094|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
215118178|NCT04410094|DRUG|Itraconazole|Itraconazole capsules will be administered orally.
215118179|NCT04410094|DRUG|Rifampin|Rifampin capsules will be administered orally.
214440701|NCT04587505|PROCEDURE|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
215118180|NCT03274908|OTHER|regular medical treatment|regular medical treatment
215118181|NCT01257516|DRUG|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
215118182|NCT01257516|DRUG|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
214440702|NCT04587505|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
214440703|NCT00537212|OTHER|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
214440704|NCT00537212|OTHER|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
214440705|NCT00537212|OTHER|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
214440706|NCT01432106|DRUG|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
214440707|NCT00411151|DRUG|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
214518746|NCT05668845|OTHER|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
214518747|NCT05668845|OTHER|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>
214518748|NCT04433052|BEHAVIORAL|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
214518749|NCT01755130|PROCEDURE|Photoacoustic Imaging|Undergo LOUISA 3D
214518750|NCT01196286|BEHAVIORAL|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
214518751|NCT01196286|BEHAVIORAL|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
214518752|NCT02633228|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
214518753|NCT02627586|OTHER|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
214692820|NCT05903300|OTHER|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
215118183|NCT02929030|DEVICE|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
215118184|NCT01522716|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
215118185|NCT03062514|DEVICE|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
215118186|NCT04941495|OTHER|conventional physiotherapy|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying."
214440708|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
215118187|NCT04941495|OTHER|Cervical proprioceptive training|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted."
215118188|NCT04064749|BEHAVIORAL|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
215118189|NCT00216671|DRUG|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
215118190|NCT00216671|DRUG|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
215118191|NCT03214354|DRUG|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
215118192|NCT03214354|RADIATION|Total Body Irradiation|TBI 300 cGy on Day -2
215118193|NCT03214354|DRUG|Sirolimus|Sirolimus is used for GVHD prophylaxis
214440709|NCT02191085|PROCEDURE|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
214440710|NCT02686528|OTHER|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
214440711|NCT02686528|OTHER|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
214440712|NCT06271356|BEHAVIORAL|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
214440713|NCT03684980|DRUG|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
214440714|NCT03684980|DRUG|Rituximab|Patients will be treated with rituximab 500 mg/m\^2.
214440715|NCT03684980|DRUG|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
214440716|NCT03684980|DRUG|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
214440717|NCT04192422|OTHER|no intervention|This is a cohort study no intervention
214440718|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (40 -80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
214440719|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
214440720|NCT01875744|DRUG|Polyethylene glycol 4000|
214440721|NCT03953001|DEVICE|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
214440722|NCT03953001|DRUG|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
214440723|NCT03953001|DRUG|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
214440724|NCT02949375|DRUG|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
214440725|NCT02949375|DRUG|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
214440726|NCT02949375|DRUG|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
214440727|NCT02612233|DRUG|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
214440728|NCT03261908|GENETIC|detection of genotype|detection of genotype by next generation sequencing
214440729|NCT06517459|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
214440730|NCT02320877|DEVICE|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
214440731|NCT01896310|DEVICE|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
214440732|NCT03083067|DRUG|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
214440733|NCT03083067|DRUG|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
214518754|NCT02627586|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
214440734|NCT05172323|DEVICE|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
214440735|NCT05172323|OTHER|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
214440736|NCT01121991|DRUG|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
214440737|NCT01104675|DRUG|ENMD-2076|275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
214440738|NCT02848794|DRUG|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
214440739|NCT00017472|BIOLOGICAL|apolizumab|Given IV
214440740|NCT00017472|OTHER|laboratory biomarker analysis|Correlative studies
214440741|NCT00017472|OTHER|pharmacological study|Correlative studies
214518755|NCT04970459|BIOLOGICAL|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
214518756|NCT04765046|DEVICE|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
215118194|NCT05938075|BIOLOGICAL|VXCO-100|Sterile suspension for injection
215118195|NCT05938075|BIOLOGICAL|COVID-19 mRNA vaccine|Sterile suspension for injection
215118196|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
215118197|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
215118198|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
214440742|NCT01409824|OTHER|CDSS|Clinical Decision Support System
214440743|NCT05565508|PROCEDURE|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
214440744|NCT05565508|PROCEDURE|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
214440745|NCT00692042|DRUG|AZD1704|One dose, by mouth
215118199|NCT03605108|DIETARY_SUPPLEMENT|Probiotic|"• Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
214440746|NCT00409838|DRUG|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
214440747|NCT00409838|DRUG|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
214440748|NCT00409838|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
214440749|NCT00409838|DRUG|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
214440750|NCT00409838|DRUG|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
214440751|NCT01964534|DRUG|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
214440752|NCT01964534|DRUG|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
214440753|NCT01964534|DRUG|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
214440754|NCT04498234|PROCEDURE|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
214518757|NCT05334225|OTHER|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
214518758|NCT02085824|DRUG|Enoxaparin|
214518759|NCT02085824|DRUG|rivaroxaban|
214518760|NCT02085824|DRUG|dabigatran|
214518761|NCT05520411|DIETARY_SUPPLEMENT|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
215118200|NCT03605108|OTHER|Placebo|Rice flour only
215118201|NCT04683003|BIOLOGICAL|TAK-755|TAK-755 IV infusion
215118202|NCT06215261|DRUG|Methylone|Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)
215118203|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of quadrivalent hemagglutinin nanoparticle influenza vaccine(qNIV2), SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
214518762|NCT03210025|DRUG|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
214518763|NCT03210025|DRUG|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
214440755|NCT05057936|BIOLOGICAL|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
214440756|NCT01541436|DEVICE|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
214518764|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
214518765|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
214518766|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
214518767|NCT00668057|DRUG|Placebo|5 mg matching placebo
214518768|NCT00668057|DRUG|Placebo|10 mg matching placebo
214518769|NCT00668057|DRUG|Placebo|20 mg matching placebo
214518770|NCT00233545|DRUG|miltefosine|
215118204|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
215118205|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
215118206|NCT00664885|OTHER|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
215118207|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
215118208|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
215118209|NCT04192266|BEHAVIORAL|Prolonged Exposure (PE) therapy|There will be an introductory Prolonged Exposure (PE) therapy session, followed by 5 imaginal exposure sessions, such that there will be 2 sessions per week conducted for a total of 6 sessions over 3 weeks. The PE sessions are 60 minutes long and consist of imaginal exposure. Specifically, the patient is instructed to imagine the trauma and recount it aloud for about 25-30 minutes. In the following 15 minutes, the patient processes her reactions to revisiting the traumatic event by discussing related thoughts and feelings. The session ends with in vivo exposure homework to be completed that same day as the session. In the last session, imaginal exposure is conducted one last time for the same duration as previous sessions. The therapist and patient review treatment progress and discuss applications of treatment principles to daily life.
214440757|NCT02847715|DEVICE|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
214440758|NCT05358457|BEHAVIORAL|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
214440759|NCT00643188|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
214518771|NCT00233545|DRUG|antimony|
214518772|NCT01634802|OTHER|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
214518773|NCT01634802|OTHER|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
215118210|NCT00851279|DEVICE|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
215118211|NCT01843023|DRUG|Extended Release Naltrexone|naltrexone for extended release injectable suspension
215118212|NCT01843023|BEHAVIORAL|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
214518774|NCT03204773|DIAGNOSTIC_TEST|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
214518775|NCT03204773|DIAGNOSTIC_TEST|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
214518776|NCT03204773|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|Testing for pain
214518777|NCT03204773|DIAGNOSTIC_TEST|Becks Depression Inventory (BDI)|Screening for depression
214518778|NCT03204773|DIAGNOSTIC_TEST|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
214692821|NCT06371872|PROCEDURE|total transfixing injury to the rotator cuff|develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
214692822|NCT03673748|DRUG|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
214692823|NCT03673748|DRUG|Placebo|Endovenous injection of saline solution without cells
214440760|NCT00643188|OTHER|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
214440761|NCT05106075|PROCEDURE|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
214440762|NCT01619410|BIOLOGICAL|Linezolid|Linezolid 600 mg every 12 hours for 7 days
214440763|NCT01619410|BIOLOGICAL|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
214518779|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~1. Normal result~2. Ultralow or Dysbiotic result~3. Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
214518780|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
214518781|NCT00694902|DRUG|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
214518782|NCT00694902|DRUG|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
214518783|NCT03256305|DEVICE|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
214518784|NCT03256305|DEVICE|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
214518785|NCT03277391|PROCEDURE|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
214518786|NCT03277391|DEVICE|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
214518787|NCT02741297|DEVICE|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
214518788|NCT01875016|PROCEDURE|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
214518789|NCT03463122|DEVICE|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
214518790|NCT03463122|OTHER|conventional therapy|conventional therapy for stroke rehabilitation
214518791|NCT02718456|BEHAVIORAL|Expedited CD4 testing|
214440764|NCT05957731|OTHER|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
214518792|NCT02718456|BEHAVIORAL|Supplemental peer counseling|
214518793|NCT02350426|OTHER|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
214518794|NCT02350426|OTHER|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
214518795|NCT02350426|OTHER|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
214518796|NCT01212809|DEVICE|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
214518797|NCT01212809|DEVICE|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
214518798|NCT00423215|DRUG|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
214692824|NCT05122650|DRUG|JZP385|JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
214440765|NCT05957731|OTHER|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
214440766|NCT05957731|OTHER|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
214440767|NCT00143949|DRUG|enalapril|
214440768|NCT00143949|DRUG|losartan|
214440769|NCT03237975|BEHAVIORAL|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
214440770|NCT03237975|OTHER|Routine health education|The control group will receive routine health education.
214440771|NCT01864889|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
214440772|NCT02586090|BEHAVIORAL|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
214518799|NCT01345708|DRUG|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
214440773|NCT02586090|BEHAVIORAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
214440774|NCT02755259|DRUG|Acetazolamide|
214440775|NCT02755259|DRUG|Placebo|
214440776|NCT01250769|DEVICE|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
214440777|NCT01250769|DEVICE|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
214440778|NCT01766154|DRUG|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
214440779|NCT05960994|OTHER|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
214440780|NCT02538900|BEHAVIORAL|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
214440781|NCT02538900|OTHER|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
214440782|NCT04110054|DRUG|S-600918|Tablets for oral administration
214440783|NCT04110054|DRUG|Placebo to S-600918|Tablets for oral administration
214440784|NCT02011854|DEVICE|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
214440785|NCT02011854|DEVICE|Acupuncture|
214440786|NCT05021341|DIETARY_SUPPLEMENT|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
214518800|NCT05383586|OTHER|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
214518801|NCT00963105|DRUG|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
214518802|NCT00458510|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
214518803|NCT02885610|BIOLOGICAL|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
214518804|NCT02885610|BIOLOGICAL|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
214518805|NCT02885610|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
214518806|NCT02885610|BIOLOGICAL|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
214692825|NCT05122650|OTHER|Placebo|Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
214440787|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
214518807|NCT04680559|BEHAVIORAL|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
214518808|NCT04680559|BEHAVIORAL|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
214518809|NCT05031052|DEVICE|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
214518810|NCT05031052|PROCEDURE|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
214518811|NCT00171652|DRUG|Diclofenac sodium gel 1%|
214518812|NCT03687554|DRUG|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
214518813|NCT04099576|OTHER|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
214518814|NCT04099576|OTHER|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
214518815|NCT02858206|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
214518816|NCT02858206|DRUG|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
214518817|NCT02858206|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
214518818|NCT02858206|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
214518819|NCT02858206|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
214518820|NCT01429168|DRUG|Etoricoxib|One 60-mg tablet orally daily
214518821|NCT01429168|DRUG|Placebo for etoricoxib|One 60-mg tablet orally daily
214692826|NCT04118998|BEHAVIORAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
214692827|NCT04118998|BEHAVIORAL|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
214692828|NCT06973005|DRUG|AZD2389|Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.
214692829|NCT06973005|DRUG|Midazolam|"Single oral dose on:~* Day 1 (co-administered with caffeine)~* Day 14 (co-administered with caffeine and AZD2389)"
214518822|NCT06179719|DRUG|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
214692830|NCT06973005|DRUG|Caffeine|"Single oral dose on:~* Day 1 (co-administered with midazolam)~* Day 14 (co-administered with midazolam and AZD2389)"
214692831|NCT06973005|DRUG|Bupropion|"Single oral dose on:~* Day 2 (alone)~* Day 15 (co-administered with AZD2389)"
214692832|NCT04725370|OTHER|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
214692833|NCT01385423|DRUG|Preparative Regimen|Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
214692834|NCT01385423|BIOLOGICAL|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
214692835|NCT06406777|DIAGNOSTIC_TEST|Spirometry|Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.
214692836|NCT06406777|DIAGNOSTIC_TEST|Contrast Lung Computed Tomography (CT) Scan|CT scan of the lungs using contrast
214440788|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
214440789|NCT05021341|DIETARY_SUPPLEMENT|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
214440790|NCT04363866|DRUG|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
214692837|NCT06406777|DIAGNOSTIC_TEST|Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan|MRI will be taken while subject is lying on their back breathing 100% oxygen.
214692838|NCT06406777|DRUG|129Xe MRI scans|MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
215118213|NCT01843023|DRUG|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
215118214|NCT00003967|DRUG|etoposide|
215118215|NCT00003967|DRUG|topotecan hydrochloride|
215118216|NCT05381363|DRUG|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
215118217|NCT05381363|OTHER|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
215118218|NCT00748371|DRUG|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
215118219|NCT00748371|DRUG|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
215118220|NCT00748371|DRUG|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
214440791|NCT04363866|DRUG|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
214440792|NCT00004840|DRUG|thyrotropin-releasing hormone|
214440793|NCT02711865|BIOLOGICAL|IGF1R antibody MK0646|
214440794|NCT02711865|OTHER|Saline solution|
214440795|NCT05790863|DEVICE|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
214440796|NCT02874534|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
214440797|NCT02874534|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
214440798|NCT02935998|DRUG|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
214440799|NCT03836378|PROCEDURE|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
214440800|NCT01261052|DEVICE|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
215118221|NCT03305770|DEVICE|verofilcon A contact lenses|Daily disposable soft contact lenses
215118222|NCT03305770|DEVICE|delefilcon A contact lenses|Daily disposable soft contact lenses
215118223|NCT03539601|DRUG|Crisaborole ointment, 2%|Applied twice a day (BID)
215118224|NCT03539601|DRUG|Hydrocortisone butyrate cream, 0.1%|Applied BID
215118225|NCT03539601|DRUG|Pimecrolimus cream, 1%|Applied BID
215118226|NCT03539601|DRUG|Crisaborole Vehicle|Applied BID
215118227|NCT06062329|DEVICE|Symphony Thrombectomy System|The Symphony Thrombectomy System will be used to restore blood flow to the pulmonary arteries by removing thrombus/embolus/clot using aspiration and mechanical clot engagement.
214440801|NCT01261052|DEVICE|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
215118228|NCT04875091|BEHAVIORAL|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
215118229|NCT01970306|DEVICE|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
214518823|NCT06179719|BEHAVIORAL|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
214518824|NCT00183209|BEHAVIORAL|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
214518825|NCT02793752|OTHER|Age|Maternal Age
214440802|NCT06635564|DIAGNOSTIC_TEST|Viscoelastic testing|viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
214440803|NCT04508972|DEVICE|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
214518826|NCT03507452|DRUG|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
214518827|NCT03507452|DRUG|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
214518828|NCT01662804|DRUG|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
214518829|NCT00634348|DRUG|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
214518830|NCT00634348|DRUG|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
214518831|NCT04930263|BEHAVIORAL|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
214518832|NCT04930263|BEHAVIORAL|control group|control group received routine care and a manual on healthy living
215118230|NCT05433025|DEVICE|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
214440804|NCT06314763|DRUG|Rivaroxaban 20mg|Single dose on day 1 and day 16
214440805|NCT06314763|DRUG|Sotorasib 960mg|Daily dose from day 3 till day 16
214440806|NCT02781623|PROCEDURE|MRI|
214518833|NCT05285592|OTHER|Fecal Transplantation|Fecal Transplantation
214518834|NCT05285592|DRUG|Standard Medical Treatment|Standard Medical Treatment
215118231|NCT02348996|OTHER|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
215118232|NCT02348996|OTHER|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
214518835|NCT04267549|DRUG|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
214518836|NCT04267549|DRUG|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
214518837|NCT04267549|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
214518838|NCT04267549|DRUG|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
214518839|NCT04239976|DEVICE|FitBit|Wear FitBit for gait assessment test
214518840|NCT04239976|OTHER|Gait Assessment Test|Undergo gait assessment test
214518841|NCT04239976|OTHER|MC5-A Scrambler Therapy|Undergo scrambler therapy
214518842|NCT04239976|OTHER|Quality-of-Life Assessment|Ancillary studies
214518843|NCT04239976|PROCEDURE|Quantitative Sensory Testing|Undergo quantitative sensory test
214518844|NCT04239976|OTHER|Questionnaire Administration|Ancillary studies
215118233|NCT01005498|DIETARY_SUPPLEMENT|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
215118234|NCT01005498|DIETARY_SUPPLEMENT|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
214440807|NCT06796543|RADIATION|Consolidative radiation therapy (cRT)|Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.
214440808|NCT04140526|DRUG|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
214440809|NCT04140526|DRUG|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
214440810|NCT04140526|DRUG|Docetaxel|Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
214440811|NCT05008315|OTHER|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
214440812|NCT05008315|OTHER|Direct focused scar release technique|Direct focused scar release technique
214440813|NCT05008315|OTHER|Direct manipulations to visceral structures|Direct manipulations to visceral structures
214518845|NCT04815135|OTHER|Observational study|Observational study, the study did not involve any interventions
214518846|NCT00297713|DRUG|ALTU-238|
214518847|NCT02314000|DEVICE|Precision or Precision Spectra Spinal Cord Stimulator System|
214518848|NCT01628939|OTHER|MRI of the lumbar spine|standard protocol, approximately 30 minutes
214518849|NCT01628939|OTHER|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
214440814|NCT05008315|OTHER|pelvic anatomy education|pelvic anatomy education
214440815|NCT05008315|OTHER|sham|sham
214440816|NCT03450434|DRUG|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
214440817|NCT03450434|DRUG|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
214440818|NCT02923180|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
214440819|NCT05471128|PROCEDURE|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
214440820|NCT05673434|BIOLOGICAL|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
214440821|NCT06271616|PROCEDURE|Echocardiography Test|Undergo echocardiography
214440822|NCT06271616|DRUG|Ibrutinib|Given PO
214518850|NCT01417923|DRUG|vitamin D|P.O.4000 units Vit D per day for 6 weeks
214518851|NCT03239353|DRUG|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
214440823|NCT04579211|DIAGNOSTIC_TEST|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
214440824|NCT06230055|DEVICE|Ommaya reservoir|Intrathecal chemotherapy through Ommaya reservoir
214440825|NCT06230055|DRUG|Systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, iv), DS8201(5.4mg/kg, d1, q3w), SG(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w).
214440826|NCT05493969|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
214440827|NCT05493215|DRUG|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
214440828|NCT05370794|DRUG|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
214440829|NCT05370794|DRUG|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
214440830|NCT05090813|DEVICE|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
214440831|NCT05713526|BEHAVIORAL|Telehealth service|Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
214518852|NCT02558803|BEHAVIORAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
214440832|NCT01188369|DRUG|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
214440833|NCT01188369|DRUG|placebo drug|Intravenous infusion, colour identical to levosimendan
214518853|NCT04619823|OTHER|Blood sample collection|Blood sample collection Mosquito collection at home
214518854|NCT04099186|PROCEDURE|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
214518855|NCT00732316|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
214440834|NCT02769819|DEVICE|Flexible fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
214440835|NCT03928522|DRUG|hand mixed vancomycin|hand mixed vancomycin powder into cement
214440836|NCT03928522|DRUG|hand mixed tobramycin|hand mixed tobramycin into cement
214440837|NCT03928522|DEVICE|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
214518856|NCT00732316|PROCEDURE|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
214518857|NCT02649478|DRUG|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
214518858|NCT02649478|DRUG|Placebo|
215118235|NCT01444885|DRUG|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
215118236|NCT01819155|BIOLOGICAL|Adjuvanted seasonal trivalent inactivated influenza vaccine|
214518859|NCT02649478|DRUG|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
214518860|NCT02011789|DIETARY_SUPPLEMENT|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
214518861|NCT02011789|DIETARY_SUPPLEMENT|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
214518862|NCT03528356|BEHAVIORAL|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
215118237|NCT01819155|BIOLOGICAL|Seasonal trivalent inactivated influenza vaccine|
215118238|NCT01819155|BIOLOGICAL|Saline (bacteriostatic 0.9% sodium chloride for injection)|
214518863|NCT02619045|OTHER|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
214518864|NCT04112563|PROCEDURE|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
214518865|NCT04112563|PROCEDURE|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
214518866|NCT06443736|PROCEDURE|Standardized perineal massage|Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
214518867|NCT06443736|BEHAVIORAL|Primary prevention|Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
214518868|NCT04471298|DRUG|Qishenyiqi dripping pills, 6 bags|28 consecutive days
215118239|NCT00226811|DRUG|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
214440838|NCT05444426|OTHER|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
214440839|NCT05350904|OTHER|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
214518869|NCT04471298|DRUG|Qishenyiqi dripping pills, 9 bags|28 consecutive days
215118240|NCT05747742|DEVICE|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
215118241|NCT02741635|DEVICE|New Nasal Pillows Mask|Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
215118242|NCT01470456|DRUG|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
215118243|NCT01470456|DRUG|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
215118244|NCT03136289|BEHAVIORAL|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
215118245|NCT06465004|DIETARY_SUPPLEMENT|Consumption of protein - rich drink|The participants will drink on of three protein - rich drinks
215118246|NCT06498206|OTHER|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
215118247|NCT06498206|OTHER|Patching|Conventional patching therapy.
215118248|NCT00982826|DRUG|ABT-072|See Arms information for a detailed description.
215118249|NCT00982826|DRUG|Placebo|See Arms information for a detailed description.
215118250|NCT01427933|BIOLOGICAL|Ramucirumab (IMC-1121B)|Administered intravenously
214440840|NCT06464393|DRUG|ketamine-lidocaine-dexmedetomidine|Patients will be administered 0,8 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations just before induction of anesthesia.
214440841|NCT06464393|DRUG|fentanyl|Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
214440842|NCT02885636|DRUG|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
214440843|NCT02885636|OTHER|Saline placebo|Saline inhaled through a nebulizer as a single dose
214440844|NCT01150916|PROCEDURE|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
214440845|NCT04287985|DRUG|Dose-Placebo|Unit Dose Strength - 0.9%.
214440846|NCT04287985|DRUG|Low Dose-VIS649|Dose Level = Low
214440847|NCT04287985|DRUG|Medium Dose-VIS649|Dose Level = Medium
215118251|NCT01427933|DRUG|Eribulin|Administered intravenously
215118252|NCT01633541|DRUG|AT-101|Patients will receive AT-101 40 mg orally two times a day.
215118253|NCT01633541|DRUG|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
215118254|NCT01633541|DRUG|Cisplatin|Cisplatin 100 mg/m2
214440848|NCT04287985|DRUG|High Dose-VIS649|Dose Level = High
214440849|NCT01571804|DRUG|Placebo|to receive two identical placebo capsules 1 hr before surgery
214440850|NCT01571804|DRUG|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
214440851|NCT01571804|DRUG|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
214440852|NCT01737489|BEHAVIORAL|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
214440853|NCT01737489|BEHAVIORAL|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
214440854|NCT04953273|OTHER|Vigitrauma|Case management algorithm using early phone contact
214440855|NCT03762772|DRUG|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
214440856|NCT05751785|OTHER|Physical Therapy|All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
215118255|NCT01633541|DRUG|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
214440857|NCT05751785|DEVICE|Shockwave Therapy|A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
214440858|NCT05751785|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm\^2 that is applied in a serpentine manner over the site of injury.
214440859|NCT04400734|OTHER|No intervention, observational study|no intervention
214518870|NCT04471298|DRUG|Qishenyiqi dripping pills, 12 bags|28 consecutive days
214518871|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
214518872|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
214518873|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
215118256|NCT00806039|OTHER|Early Renal Involvement|Renal Consultation
215118257|NCT01643382|DRUG|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
215118258|NCT01643382|DRUG|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
215118259|NCT00491127|DRUG|gemcitabine|
215118260|NCT00491127|DRUG|cisplatin|
215118261|NCT00491127|DRUG|dexamethasone|
215118262|NCT03507205|DEVICE|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
215118263|NCT03507205|DEVICE|Xience Prime|Durable polymer-coated everolimus-eluting stents
215118264|NCT03507205|DEVICE|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
215118265|NCT03507205|DEVICE|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
214440860|NCT02988089|DRUG|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
214440861|NCT02988089|DRUG|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
214440862|NCT02988089|DRUG|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
214440863|NCT02988089|DRUG|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
214440864|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
214440865|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
214440866|NCT03248505|DEVICE|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
214440867|NCT03248505|DEVICE|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
214440868|NCT03248505|OTHER|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
214440869|NCT03248505|DEVICE|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
214440870|NCT03248505|DEVICE|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
214518874|NCT04550455|DRUG|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
214518875|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
214518876|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
214518877|NCT01899183|PROCEDURE|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
214518878|NCT01942551|DRUG|Tadalafil|
214518879|NCT01942551|DRUG|Dutasteride|
214518880|NCT00606723|BIOLOGICAL|Hematopoietic stem cells from bone marrow or peripheral blood|\> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
214518881|NCT04237987|DRUG|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
214518882|NCT04237987|DRUG|ciclosporin and corticosteroid|ciclosporin and corticosteroid
214518883|NCT03296176|BIOLOGICAL|blood sample|blood sample for metabolome analyse
214440871|NCT03248505|OTHER|Placebo TENS|TENS device turned on, but with zero amplitude.
214440872|NCT05673746|PROCEDURE|Acupuncture|acupuncture administration
214440873|NCT05673746|DRUG|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
214518884|NCT06328322|PROCEDURE|Percutaneous Coronary Intervention in Left Main Artery Disease|To investigate and assess the effectiveness and safety of percutaneous coronary intervention in left main coronary artery disease in sitting of acute coronary syndromes.
214518885|NCT03073122|DIAGNOSTIC_TEST|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
214518886|NCT00001280|DRUG|itraconazole|
214518887|NCT04794439|DRUG|Dentifrices|Dentifrice on plaque
214518888|NCT02835196|DEVICE|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
214518889|NCT02835196|OTHER|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
215028665|NCT06642766|DIETARY_SUPPLEMENT|Fiber supplement|"Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary."
214518890|NCT01323244|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
214518891|NCT06412809|OTHER|Combined Land- and Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented both on land and in water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~Land-based exercise:~1. Plank exercise~2. Russian twist~3. Push-up~4. Goblet squat~5. Kettle bell swing~Water-based exercise:~1. Flutter kicks~2. Isometric core crunches~3. Jump lunges~4. Kicks~5. Resisted knee flexion"
214440874|NCT00920972|DRUG|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
214440875|NCT00920972|DRUG|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
214440876|NCT00920972|DRUG|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
214518892|NCT06412809|OTHER|Land-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented on land. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Plank exercise~2. Russian twist~3. Dead bug~4. Push-up~5. Goblet squat~6. Nordic hamstring curl~7. Lunges~8. Kettle bell swing~9. Calf raises~10. Bird dog"
214518893|NCT06412809|OTHER|Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented in the water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Core pulls~2. Flutter kicks~3. Water cycling~4. Isometric core crunches~5. Seated push-up~6. Jump squats~7. Jump lunges~8. Kicks~9. Ankle jumps~10. Resisted knee flexion"
214518894|NCT04534699|DRUG|KBP-5074|KBP-5074 tablet
214518895|NCT05226728|DRUG|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
214518896|NCT00850993|DRUG|Stannsoporfin|Stannsoporfin administered as a single IM injection
214518897|NCT00850993|OTHER|Placebo|Placebo (sterile saline solution) administered as a single IM injection
214518898|NCT00850993|OTHER|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
214518899|NCT00521807|PROCEDURE|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
214518900|NCT03839355|DRUG|Apixaban|Dosage either 5mg or 2.5mg for 2 years
214518901|NCT03839355|DRUG|Warfarin|Dosage assessed by your treating physician for 2 years
214692839|NCT06621979|PROCEDURE|Bypass surgery type one anastomosis gastric bypass|Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention.
214692840|NCT05514366|PROCEDURE|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
214692841|NCT05514366|PROCEDURE|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) \< 97% is detected."
214692842|NCT05514366|PROCEDURE|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs \> 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is \>10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
214692843|NCT06131346|OTHER|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
214692844|NCT00003648|GENETIC|DNA stability analysis|
214692845|NCT00003648|GENETIC|gene rearrangement analysis|
214440877|NCT00920972|DRUG|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
214518902|NCT00297089|DRUG|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
214518903|NCT00297089|DRUG|pemetrexed|Standard pemetrexed every 21 days
214518904|NCT00297089|DRUG|placebo|Placebo daily for 14 days every 21 days
214440878|NCT04802382|DRUG|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
214440879|NCT04802382|DIAGNOSTIC_TEST|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
214440880|NCT04802382|PROCEDURE|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
214440881|NCT04802382|PROCEDURE|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
214440882|NCT04802382|DIAGNOSTIC_TEST|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
214440883|NCT04802382|DIAGNOSTIC_TEST|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
214518905|NCT00470990|DRUG|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
214518906|NCT00324571|DRUG|Sevelamer hydrochloride|
214518907|NCT00324571|DRUG|Calcium-based phosphate binder|
214518908|NCT05607147|DEVICE|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
214518909|NCT00003778|DRUG|dolastatin 10|
214518910|NCT01589380|DRUG|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
214518911|NCT01589380|DRUG|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
214518912|NCT04566744|OTHER|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
215118266|NCT03507205|DEVICE|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
215118267|NCT06453967|DIAGNOSTIC_TEST|blood glucose levels|measurement of blood glucose level at admission ,during ICU admission and at discharge for patients with acute decompensated heart failure
215118268|NCT03472326|DRUG|GS-9131|Tablet(s) administered orally once daily
214440884|NCT04802382|OTHER|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
214518913|NCT03959579|DIAGNOSTIC_TEST|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
214692846|NCT06983028|DRUG|Atacicept|Atacicept 150 mg SC QW via pre-filled syringe
214692847|NCT01429987|DRUG|plecanatide|Subjects receive experimental study drug for 12 weeks.
214692848|NCT01429987|OTHER|Placebo|Subjects receive experimental study drug for 12 weeks.
214692849|NCT04136561|DEVICE|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
214692850|NCT04826224|BIOLOGICAL|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
215118269|NCT03472326|DRUG|BIC|Tablet(s) administered orally once daily
215118270|NCT03472326|DRUG|TAF|Tablet(s) administered orally once daily
215118271|NCT03472326|DRUG|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
215118272|NCT03472326|DRUG|DRV|Tablet(s) administered orally once daily
215118273|NCT03472326|DRUG|RTV|Tablet(s) administered orally once daily
214440885|NCT04802382|DIAGNOSTIC_TEST|PK test|PK test will be performed on day 1 only (only in Brazil sites)
214440886|NCT04802382|DIAGNOSTIC_TEST|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
214440887|NCT04802382|DIAGNOSTIC_TEST|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
214440888|NCT04802382|OTHER|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
214440889|NCT04802382|DIAGNOSTIC_TEST|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
214440890|NCT04802382|PROCEDURE|ECG|patients will undergo an ECG examination on days 1, and day 28
214440891|NCT04802382|OTHER|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
214440892|NCT04802382|DRUG|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
214440893|NCT04802382|DRUG|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
215118274|NCT01010971|DRUG|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
215118275|NCT01010971|DRUG|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
215118276|NCT01010971|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily
215118277|NCT03994666|BIOLOGICAL|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
215118278|NCT03994666|BIOLOGICAL|Placebo (NaCl)|Placebo injection
214440894|NCT02922088|DEVICE|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
214440895|NCT05165459|DEVICE|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
214440896|NCT01763853|DRUG|4% albumin|
214440897|NCT02776475|PROCEDURE|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
214440898|NCT01132560|GENETIC|RNA analysis|
214440899|NCT01132560|GENETIC|gene expression analysis|
214440900|NCT01132560|GENETIC|reverse transcriptase-polymerase chain reaction|
214440901|NCT01132560|OTHER|laboratory biomarker analysis|
214518914|NCT02504034|PROCEDURE|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
214518915|NCT02504034|DEVICE|6-French sheath|
214518916|NCT02504034|DEVICE|22-gauge chiba needle|
214518917|NCT02504034|DEVICE|260-cm-long stiff shaft wire|
214440902|NCT01340066|DRUG|UISH001|sublingual dosing, 1 drop 3 times a day
214440903|NCT01340066|DRUG|matching placebo|sublingual dosing,1 drop 3 times a day
214440904|NCT02789020|DRUG|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
214440905|NCT02789020|OTHER|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
214440906|NCT02789020|DEVICE|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
214440907|NCT02789020|DEVICE|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
214518918|NCT02504034|DEVICE|Balloon catheter|
214518919|NCT02504034|DEVICE|Bare metal stent|
214518920|NCT02504034|DEVICE|Covered stent|
214518921|NCT01320514|DRUG|Fibrin Sealant (Artiss)|
214518922|NCT06058130|DRUG|Anticoagulant Oral|Anticoagulation alone
215118279|NCT04728386|OTHER|curcumin solution|2 % curcumin solution as root canal irrigant
215118280|NCT04728386|OTHER|sodium hypochlorite|2.5% sodium hypochlorite solution as root canal irrigant
215118281|NCT00550017|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
215118282|NCT00745537|OTHER|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
215118283|NCT02426736|DRUG|Dexamethasone|
215118284|NCT02426736|DRUG|Bupivacaine|
215118285|NCT02426736|PROCEDURE|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
215118286|NCT03826238|DIAGNOSTIC_TEST|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
214440908|NCT02789020|OTHER|Physical Function Performance Test|This test will be performed at baseline and one year.
214440909|NCT06530628|BEHAVIORAL|Adult patients resident in Pavillon C of the Pierre Garraud Hospital|"Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents."
214440910|NCT04523688|BIOLOGICAL|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
214440911|NCT04523688|DRUG|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
214440912|NCT00468702|DEVICE|CoaguChek S|
214440913|NCT01145729|BEHAVIORAL|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
214440914|NCT05334199|DEVICE|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
214440915|NCT06521944|BIOLOGICAL|RSV Vaccine|RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation
214518923|NCT06058130|DRUG|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
214440916|NCT06521944|OTHER|Non-exposure to RSV Vaccine|Pregnant individuals who are not exposed to the RSV vaccine
214440917|NCT02395978|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
214440918|NCT02395978|DRUG|placebo|Placebo contained corn starch.
214440919|NCT00011986|DRUG|Paclitaxel|Given IV
214440920|NCT00011986|DRUG|Carboplatin|Given IV
214440921|NCT00011986|DRUG|Gemcitabine Hydrochloride|Given IV
214440922|NCT00011986|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|
214440923|NCT00011986|DRUG|Topotecan Hydrochloride|Given IV
214440924|NCT00011986|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214440925|NCT03771352|DEVICE|RxSight RxLAL|The patients will be assessed for 6 months
214440926|NCT06105125|DEVICE|Rigenera + bone substitute|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. A small punch of connective tissue will be harvested from the palate in the premolar region. Then the graft will be mechanically dissociated using the Rigenera Machine System rotating speed to 80 rpm, in 1.0 ml sterile physiologic solution. After dissociation, the cellular suspension will be passed through a disposable grid with 100 hexagonal blades filtering cells and components of extracellular matrix with a cut-off of 50 um in an average time of 90 s. Finally, part of the suspension containing AMGs will be seeded on the scaffold material and subsequently compacted within the defect. Flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
214440927|NCT06105125|DEVICE|Bone substitute alone|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. The defect will be filled with the same bone substitute employed in the test group. Finally, flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
214440928|NCT02331745|DRUG|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
214440929|NCT02331745|DRUG|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
214440930|NCT05422742|PROCEDURE|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
214440931|NCT05422742|PROCEDURE|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
214440932|NCT06220123|DRUG|SHR-2004|Investigational product arm: SHR-2004
214692851|NCT02843373|DEVICE|TMS|
214440933|NCT06220123|DRUG|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
214440934|NCT02754115|OTHER|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
214440935|NCT05875974|DRUG|JZP258 (XYWAV)|"Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect.~IH Cohort: Initiate dosage per XYWAV label and titrate to effect.~Narcolepsy \>9-Gram Cohort: XYWAV titrated to a dosage of \>9 to 12 grams."
215118287|NCT04811846|DEVICE|Bipolar transurethral resection of bladder tumor (TURBT)|Standard resection in piecemeal technique with standard bipolar cutting loop. (Storz medical, 27040 GP1)
215118288|NCT04811846|DEVICE|Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)|Vaporization of bladder tumor with standard bipolar vaporization electrode. (Storz medical, 27040 NB)
215118289|NCT02951078|PROCEDURE|Thulium Laser en Bloc Resection of bladder tumor|
215118290|NCT02951078|PROCEDURE|Electrical transurethral resection of bladder tumor|
215118291|NCT00652795|DRUG|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
214440936|NCT06484595|OTHER|Best Practice|Receive SOC supportive care services
214440937|NCT06484595|BEHAVIORAL|Patient Navigation|Receive clinical trial navigator guide services
214440938|NCT03915964|DRUG|Baricitinib|Administered orally.
214440939|NCT03915964|DRUG|TNF Inhibitor|Administered SC
214440940|NCT06216535|DRUG|Escitalopram|Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
214440941|NCT06216535|DRUG|Placebo|Inactive placebo comparator
214440942|NCT04421235|BEHAVIORAL|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
214518924|NCT02033343|RADIATION|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
214518925|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
214518926|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
214518927|NCT01502839|OTHER|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
214440943|NCT06964256|BEHAVIORAL|Abdominal breathing exercises|"Control group: conventional rehabilitation treatment. Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks Experimental group: Conventional rehabilitation treatment sEMG monitoring of lower abdominal breathing training.~The conventional rehabilitation treatment method is the same as above; The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder befor"
214440944|NCT06964256|OTHER|Control group: intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks
214440945|NCT06964256|BEHAVIORAL|Experimental group: intermittent catheterization|Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks. The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder before training, the patient to take a supine position, hip and knee flexion 60 degrees (for those who cannot maintain hip and knee flexion in the lower limbs, family members can assist), at the same time, the electrodes are attached to both
214518928|NCT02499497|DRUG|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
214518929|NCT02499497|DRUG|Placebo|The participants will receive pills containing no active drug.
214518930|NCT02471872|BEHAVIORAL|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
214518931|NCT02471872|OTHER|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
214518932|NCT02349802|DRUG|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
214518933|NCT02349802|DRUG|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
214518934|NCT00860509|OTHER|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
214518935|NCT06244394|RADIATION|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
214518936|NCT02826954|OTHER|Upper airway assessment, including nasal biopsy|
214518937|NCT03547167|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
214518938|NCT03547167|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
214692852|NCT00696865|DRUG|AZD2624|oral suspension, 3 doses
214692853|NCT00696865|DRUG|Placebo|
214692854|NCT01759329|DIETARY_SUPPLEMENT|test coffee|test coffee with higher alkyl pyridine content
214692855|NCT01759329|DIETARY_SUPPLEMENT|control coffee|control coffee with regular alkyl pyridine content
214692856|NCT06862791|DRUG|AZD9550|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP
214692857|NCT06862791|DRUG|AZD6234|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
215118292|NCT00652795|DRUG|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
215118293|NCT04783909|PROCEDURE|Phacoemulsification cataract surgery|All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
215118294|NCT03360643|DIAGNOSTIC_TEST|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
215118295|NCT03360643|DIAGNOSTIC_TEST|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
214440946|NCT06964256|OTHER|Control group and experimental group: acupuncture treatment|Acupuncture treatment uses acupuncture to act on the acupuncture points in the lower abdomen and lumbosacral region to improve the patient's urination function
214518939|NCT03547167|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
214518940|NCT03629366|BEHAVIORAL|Supported Employment (SE)|Supported Employment
214440947|NCT03772561|DRUG|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
214440948|NCT06190197|DRUG|Prophylactic antibiotics postoperatively.|Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
214440949|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
214440950|NCT03380390|DRUG|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
214440951|NCT03380390|DEVICE|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
214440952|NCT05097417|COMBINATION_PRODUCT|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
214440953|NCT05097417|PROCEDURE|ablation|Patients will be treated with ablation in the primary tumor sites
214440954|NCT00374959|DRUG|ceftriaxone|
214440955|NCT00374959|DEVICE|Endotracheal tube for aspiration of subglottic secretions.|
214440956|NCT03205436|OTHER|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
214440957|NCT04552509|RADIATION|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
214440958|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
214440959|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
214440960|NCT05069974|DRUG|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
214440961|NCT05069974|DRUG|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
214518941|NCT03629366|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual
214518942|NCT02502019|DEVICE|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
214518943|NCT01317966|DRUG|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
214518944|NCT03266419|DRUG|Deep NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
214518945|NCT03266419|DRUG|Moderate NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
214518946|NCT00100009|DRUG|TAC-PF|
214518947|NCT00100009|DRUG|Triamcinolone Acetonide|
214518948|NCT01501825|DEVICE|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
214692858|NCT06862791|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once weekly.
214692859|NCT03803761|DRUG|Copanlisib|Given IV
214692860|NCT03803761|DRUG|Fulvestrant|Given IM
214518949|NCT01501825|DEVICE|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
214518950|NCT02068053|DRUG|[14C] BMS-986020|
214518951|NCT01383785|OTHER|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
214518952|NCT01383785|OTHER|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
214692861|NCT00720239|OTHER|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
214440962|NCT03037892|DRUG|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
214440963|NCT03037892|DRUG|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
214440964|NCT03037892|DRUG|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
214440965|NCT00015067|DRUG|Methylphenidate|
214440966|NCT02241070|BEHAVIORAL|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
214440967|NCT01886729|OTHER|transcranial direct current stimulation (tDCS)|
214440968|NCT05643456|PROCEDURE|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
214518953|NCT01383785|OTHER|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
214518954|NCT05735379|DRUG|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
214440969|NCT01172418|DRUG|Alemtuzumab|Alemtuzumab used as part of combined Induction.
214440970|NCT01172418|DRUG|Daclizumab|Daclizumab used as part of combined induction.
214518955|NCT05675748|DRUG|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
214518956|NCT02868983|OTHER|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
214692862|NCT01333982|OTHER|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
214440971|NCT01172418|DRUG|Thymoglobulin|Thymoglobulin used as part of combined induction.
214440972|NCT02184806|PROCEDURE|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
214440973|NCT02184806|PROCEDURE|heterotopic graft|"1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen"
214440974|NCT05171777|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
214440975|NCT02538341|BIOLOGICAL|Herpes Zoster (HZ) Vaccine|
214440976|NCT02538341|DRUG|Placebo|
214440977|NCT02809989|DRUG|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
214440978|NCT02522312|OTHER|No Intervention|No drug is administered in this study
214440979|NCT06045208|OTHER|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
214440980|NCT06045208|OTHER|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
214440981|NCT05344807|DIAGNOSTIC_TEST|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
214440982|NCT04405921|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
214440983|NCT04405921|DRUG|Azithromycin 250 MG|orally or via gastric tube
214440984|NCT01306500|PROCEDURE|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
214518957|NCT03270098|BEHAVIORAL|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
214518958|NCT03270098|BEHAVIORAL|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
214518959|NCT02009865|DRUG|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
214518960|NCT02009865|DRUG|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
214692863|NCT01333982|OTHER|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
214692864|NCT01515176|DRUG|Dinaciclib|Given IV
214440985|NCT04434742|OTHER|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
214518961|NCT01760876|DEVICE|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
214518962|NCT02290548|DEVICE|high flow nasal cannula|High flow nasal cannula used in postextubation patients
214518963|NCT05777772|BEHAVIORAL|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
214518964|NCT04979702|BEHAVIORAL|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
214440986|NCT04434742|OTHER|Usual care|Social call was given to this group.
214440987|NCT00092300|DRUG|MK0966, rofecoxib|
214440988|NCT00092300|DRUG|Comparator: valdecoxib|
214440989|NCT00632749|DRUG|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
214440990|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
214440991|NCT00632749|DRUG|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
214440992|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
214518965|NCT04979702|BEHAVIORAL|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
214518966|NCT04115670|BEHAVIORAL|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
214518967|NCT04115670|BEHAVIORAL|Control group|The control group will follow its normal course of activity
214440993|NCT00339131|DRUG|Ultratrace iobenguane I 131|
214440994|NCT01645033|OTHER|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
214518968|NCT03155035|DRUG|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
214518969|NCT03155035|DIETARY_SUPPLEMENT|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
214518970|NCT00255749|BIOLOGICAL|epoetin alfa|
214518971|NCT02135666|PROCEDURE|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
214518972|NCT04023266|DRUG|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
214518973|NCT01517282|BIOLOGICAL|MOR103|Anti-GM-CSF monoclonal antibody
214518974|NCT01517282|OTHER|Placebo|Placebo to anti-GM-CSF monoclonal antibody
214518975|NCT03153423|PROCEDURE|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
214518976|NCT01078051|PROCEDURE|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
214518977|NCT01078051|DRUG|optimal medical therapy|optimal medical therapy
214440995|NCT01645033|OTHER|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
214440996|NCT03548857|OTHER|Lung transplantation|Single or double lung transplantation in patients with COPD
214518978|NCT02275351|DRUG|SM04554|Topical solution, applied once a day
214518979|NCT02275351|DRUG|Vehicle|Topical solution, applied once a day
214518980|NCT05925751|DIAGNOSTIC_TEST|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
214518981|NCT00525915|DRUG|5-Fluorouracil|"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."
214518982|NCT00525915|DRUG|Oxaliplatin|"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"
214518983|NCT00525915|RADIATION|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
214518984|NCT00525915|PROCEDURE|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
214518985|NCT01328223|RADIATION|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
214692865|NCT01515176|OTHER|Laboratory Biomarker Analysis|Correlative studies
214692866|NCT01515176|BIOLOGICAL|Ofatumumab|Given IV
214692867|NCT01515176|OTHER|Pharmacological Study|Correlative studies
214518986|NCT04429672|BEHAVIORAL|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
214518987|NCT04429672|BEHAVIORAL|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
214518988|NCT02529735|OTHER|efficiency study|Blood pressure values measured for comparative lower limb and arm
214518989|NCT04251845|DIETARY_SUPPLEMENT|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
214518990|NCT04251845|OTHER|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
214518991|NCT03368300|OTHER|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
214518992|NCT06428799|DEVICE|Carebot AI MMG|"Carebot AI MMG is a software solution that utilizes artificial intelligence methods, specifically deep learning and computer vision algorithms, to evaluate and localize suspicious regions of potential lesions during the interpretation of digital breast x-rays as part of standard mammography screening procedures. The Carebot AI MMG medical device is not intended for use in diagnostic mammography. The Carebot AI MMG is intended for use in women over the age of 18.~The predictive outputs of the Carebot AI MMG medical device are intended to aid decision-making in screening clinical practice, always in conjunction with other relevant patient information and based on the professional judgment of the examining clinician. The Carebot AI MMG is specifically designed to provide a supporting layer of analysis that helps in evaluating or prioritizing mammography images with additional patient information and the professional judgment of the examining physician."
214518993|NCT04817293|OTHER|Questionnaire|Questionnaire SSD-12 and EQ5D5L
214518994|NCT04817293|OTHER|medical consultation|Medical consultation during the visit with data collection
214518995|NCT00760877|DRUG|Nilotinib|Supplied in 200 mg capsules
214518996|NCT00760877|DRUG|Imatinib|Supplied in 100 mg and 400 mg capsules
214518997|NCT03829072|OTHER|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
214518998|NCT03829072|OTHER|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
214518999|NCT01605435|DRUG|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
214519000|NCT01605435|DRUG|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
214519001|NCT05488002|BEHAVIORAL|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
214692868|NCT00454064|BEHAVIORAL|cognitive-behavioral treatment|
214692869|NCT02371759|DRUG|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
214440997|NCT05452525|DRUG|CKD-379 I|1 tablet administration under fed condition
214440998|NCT05452525|DRUG|CKD-379 II|1 tablet administration under fed condition
214440999|NCT05452525|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
214441000|NCT01859559|PROCEDURE|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
214441001|NCT01859559|PROCEDURE|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
214441002|NCT03373448|DEVICE|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
214441003|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
214441004|NCT04386356|DEVICE|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
214441005|NCT05783570|BIOLOGICAL|EU307 CAR-T Cell|"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"
214441006|NCT02662894|DRUG|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
214441007|NCT02662894|DRUG|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
214441008|NCT02662894|DRUG|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
214692870|NCT02371759|DRUG|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
215118296|NCT06056661|BEHAVIORAL|WMR|Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
215118297|NCT01011543|PROCEDURE|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
215118298|NCT02770989|PROCEDURE|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
214441009|NCT02662894|DRUG|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
214441010|NCT02258815|DRUG|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
214441011|NCT00839241|DEVICE|Bellovac ABT|Bellovac ABT (autologous blood)
214441012|NCT00839241|PROCEDURE|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
214441013|NCT01551953|BEHAVIORAL|Tai chi|12 week tai chi class
214441014|NCT01551953|BEHAVIORAL|Mind-body breathing|12 week breathing class
214441015|NCT01551953|BEHAVIORAL|Education|12 week education class
214441016|NCT00854191|DEVICE|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
214441017|NCT06554756|OTHER|Saliva, serum and GCF sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
214441018|NCT00686504|DRUG|AZD2066|single dose of oral dose, 3 times per subject
214441019|NCT00686504|DRUG|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
214441020|NCT05925920|DRUG|ENT-03|single dose of active drug
214441021|NCT05925920|DRUG|Placebo|single dose of placebo comparator
214441022|NCT01231802|DRUG|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
214441023|NCT01231802|DRUG|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
214441024|NCT01231802|DRUG|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
214441025|NCT01231802|DRUG|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
214441026|NCT01216722|OTHER|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
214441027|NCT00268671|DRUG|Docetaxel|
214692871|NCT02371759|DRUG|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
214692872|NCT02371759|DRUG|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
214692873|NCT04676750|BEHAVIORAL|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
214692874|NCT04933305|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
214692875|NCT02159963|OTHER|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
214441028|NCT03072914|PROCEDURE|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
214441029|NCT05508243|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
214519002|NCT04284592|PROCEDURE|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
214519003|NCT00711555|DRUG|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
214441030|NCT03407846|PROCEDURE|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
214441031|NCT03067142|OTHER|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
214441032|NCT05075486|BEHAVIORAL|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
214441033|NCT05004597|OTHER|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
214441034|NCT01404182|BIOLOGICAL|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
214441035|NCT01203813|OTHER|Electronic Decision Support|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
214441036|NCT04156789|DIAGNOSTIC_TEST|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
214441037|NCT00550823|DEVICE|Cardiac CT 0BRILLIANT 64|Cardiac CT
215118299|NCT00421057|BEHAVIORAL|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
214441038|NCT02332577|DRUG|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
214441039|NCT02332577|DRUG|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
214441040|NCT02332577|DRUG|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
214519004|NCT00466622|DRUG|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
214519005|NCT00466622|DRUG|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
215118300|NCT00421057|BEHAVIORAL|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
215118301|NCT01523418|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
214692876|NCT02159963|OTHER|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
214692877|NCT02159963|OTHER|Optional training|8 weeks of optional home based, unsupervised training.
214692878|NCT02159963|OTHER|Control|8 weeks of control period. Participants are doing daily living.
214692879|NCT03072017|BEHAVIORAL|MBAT|Breathing-based intervention
214441041|NCT02332577|DRUG|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
214441042|NCT01189942|DRUG|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
214519006|NCT04705883|DRUG|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
214441043|NCT03988842|DRUG|Alteplase|Lyophilized powder for reconstitution in 50mg vials
214441044|NCT03988842|DRUG|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
214441045|NCT03988842|DRUG|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
214441046|NCT03988842|DRUG|Apixaban|Apixaban tablet
214441047|NCT03055689|BEHAVIORAL|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
214441048|NCT03055689|BEHAVIORAL|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
214441049|NCT04355221|PROCEDURE|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
214441050|NCT03306368|BEHAVIORAL|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
214441051|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
214519007|NCT03538223|OTHER|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
214519008|NCT03538223|RADIATION|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
214519009|NCT02880306|OTHER|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
214441052|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
214441053|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
214441054|NCT06220149|DIAGNOSTIC_TEST|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
214441055|NCT01093820|DRUG|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
214519010|NCT00470041|DRUG|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
214441056|NCT00352976|DRUG|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
214441057|NCT00352976|DRUG|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
214441058|NCT00352976|PROCEDURE|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
214441059|NCT00352976|PROCEDURE|Bone Marrow Transplantation|A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
214441060|NCT00352976|DRUG|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
214441061|NCT00352976|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
214441062|NCT05708144|DIAGNOSTIC_TEST|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
214519011|NCT05737797|PROCEDURE|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
214519012|NCT06331533|DRUG|Botulinum toxin A|Intradermal botulinum toxin A was applied to the treatment side
214519013|NCT06331533|DRUG|Placebo|NaCl was injected into the placebo side
214519014|NCT01052870|DRUG|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
214519015|NCT00329017|PROCEDURE|Fine needle aspiration|Fine needle aspiration
214519016|NCT00946998|DRUG|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
214519017|NCT00946998|DRUG|placebo|Placebo tablet will be identical and matched to sertraline tablet.
214519018|NCT00801086|DRUG|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
214441063|NCT06257680|BIOLOGICAL|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
214441064|NCT01227265|DRUG|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
214441065|NCT01227265|DRUG|Placebo|Preladenant-matching placebo oral tablet taken twice daily
214441066|NCT04497766|DRUG|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
214441067|NCT04497766|DRUG|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
214441068|NCT05166070|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
214441069|NCT04659018|BIOLOGICAL|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
214441070|NCT01449617|DRUG|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
214441071|NCT04758416|PROCEDURE|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
214441072|NCT04758416|DRUG|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
214441073|NCT06520306|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
214519019|NCT00801086|DRUG|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
214519020|NCT04841811|DRUG|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
214519021|NCT04584359|OTHER|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
215118302|NCT05990634|DEVICE|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
215118303|NCT02733523|BEHAVIORAL|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
215118304|NCT03670563|OTHER|Short foot exercise protocol|Exercises that target intrinsic foot muscles
215118305|NCT03670563|OTHER|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
214441074|NCT00752453|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
214441075|NCT00752453|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
214441076|NCT00752453|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
214441077|NCT03197116|OTHER|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
214441078|NCT03197116|OTHER|No other|No additional reminder will be offered
214692880|NCT03975868|OTHER|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
214692881|NCT00540553|DRUG|placebo|
214692882|NCT00540553|DRUG|GSK971086|
215118306|NCT03386721|DRUG|simlukafusp alfa|simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
214441079|NCT03060317|BEHAVIORAL|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
214441080|NCT06235541|DRUG|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
214441081|NCT01279668|DRUG|Montelukast|10mg tablets, once per day for 28 days.
214441082|NCT01279668|DRUG|Placebo|tablets, once per day for 28 days.
214441083|NCT00070694|DRUG|MDL100.907|
214692883|NCT05128253|OTHER|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
214441084|NCT04668638|OTHER|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
214441085|NCT06696716|DRUG|ONO-4059|Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
214441086|NCT06696716|DRUG|ONO-4059 placebo|Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
214441087|NCT01448681|OTHER|No Interventions|
214441088|NCT04325685|DRUG|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
214441089|NCT04325685|DRUG|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
214441090|NCT04325685|DRUG|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
214441091|NCT04144595|DIAGNOSTIC_TEST|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
214441092|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
214441093|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
214519022|NCT04584359|OTHER|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
214519023|NCT04584359|OTHER|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
214519024|NCT05826405|OTHER|No intervention|No intervention, it's an observational study
215118307|NCT03386721|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
215118308|NCT03386721|DRUG|Gemcitabine|Single-agent treatment administered as per approved protocol.
215118309|NCT03386721|DRUG|Vinorelbine|Single-agent treatment administered as per approved protocol.
215118310|NCT02003092|DRUG|RX-5902|escalating doses (mg)
215118311|NCT04223713|PROCEDURE|TriRec|Trileaflet Reconstruction of the Aortic Valve
215118312|NCT04223713|PROCEDURE|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
215118313|NCT03081884|DRUG|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
215118314|NCT01696370|DRUG|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
214441094|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
214441095|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
214441096|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214441097|NCT05324943|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
214441098|NCT04944407|PROCEDURE|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
214441099|NCT04944407|PROCEDURE|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
214519025|NCT06080919|DEVICE|Drug coated-balloon percutaneous coronary intervention.|Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.
214519026|NCT06080919|DEVICE|Angiography-derived coronary physiology (IMRangio)|Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
214441100|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
214519027|NCT01357447|DRUG|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
214519028|NCT01357447|DRUG|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
214519029|NCT00678132|DRUG|AZD 2281|
214519030|NCT00678132|DRUG|Cisplatin|
214519031|NCT00678132|DRUG|Gemcitabine|
214519032|NCT01234025|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
214519033|NCT01234025|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
214519034|NCT01234025|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
214519035|NCT01234025|DRUG|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
214519036|NCT01234025|DRUG|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
214519037|NCT05593016|BEHAVIORAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
214519038|NCT05593016|BEHAVIORAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
214519039|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
214519040|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
214519041|NCT04630873|DRUG|Botulinum toxin|The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
214519042|NCT04630873|DIAGNOSTIC_TEST|gait analysis|The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
214519043|NCT06305416|DRUG|Ranibizumab 10mg/ml Injection|Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
214441101|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
214519044|NCT06305416|DRUG|Lucentis|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
214519045|NCT05655715|RADIATION|Stereotactic body radiotherapy|8 Gray x 3
214519046|NCT05655715|DRUG|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
214519047|NCT05655715|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
214519048|NCT05655715|PROCEDURE|Biopsies|From soft tissue metastases.
214519049|NCT05776979|DRUG|Isatuximab|Given by vein over about 75 minutes
214519050|NCT05776979|DRUG|lenalidomide|Given by PO
214519051|NCT05306613|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
214519052|NCT05306613|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
214519053|NCT03020914|DEVICE|Audiovisual Distraction|watching a movie using video glasses and headphones
214519054|NCT04789096|DRUG|Tucatinib|Oral tablet
214519055|NCT04789096|DRUG|Pembrolizumab|Intravenous
214519056|NCT04789096|DRUG|Trastuzumab|Intravenous
214519057|NCT04789096|DRUG|Capecitabine|Oral tablet
214519058|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox]|
214519059|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
215118315|NCT01696370|OTHER|Placebo capsule|one capsule three times per day for 3 months
215118316|NCT03676972|DEVICE|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
215118317|NCT02552134|OTHER|exercise training|
215118318|NCT02552134|OTHER|recommendation to be active|
215118319|NCT05717816|DEVICE|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
215118320|NCT03948334|DRUG|ZPL389 30mg|30mg of ZPL389; once daily
215118321|NCT03948334|DRUG|ZPL389 50mg|50mg of ZPL389; once daily
215118322|NCT03948334|DRUG|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
214441102|NCT02568826|DRUG|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
214441103|NCT06864065|BEHAVIORAL|Emotion regulation task (fNIRS recording during the emotional regulation task)|No drugs were used in this study. All participants perform an emotion regulation task. More precisely, they have to down regulate negative emotions elicited by negative pictures using a cognitive reaprasal strategy. To this end, they have to change the meaning of the picture they are watching in order to decrease motional intensity.
214441104|NCT06990789|BEHAVIORAL|effective self-applied ear massage|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
214441105|NCT06990789|BEHAVIORAL|Sham Comparator|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
214441106|NCT06242236|OTHER|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
214441107|NCT06676501|PROCEDURE|ExAblate|Transcranial focused ultrasound thalamotomy
214441108|NCT06676683|DRUG|Usage of Statin in diabetic patients|The use of statin in diabetic patients not known to have Atherosclerotic cardiovascular disease in a low income community
214441109|NCT06676215|DIETARY_SUPPLEMENT|IAA mix supplement|The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.
214441110|NCT06676215|OTHER|Complementary food comprised of rice and legumes|Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
214441111|NCT06677255|DRUG|VUM02 Injection (UC-MSCs)+BAT|"The dose-escalation phase (phase I):~Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week.~The dose-expansion phase (phase II):~-Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses."
214441112|NCT06677255|OTHER|The control group with Best Available Therapy (BAT)|According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
214441113|NCT06675136|PROCEDURE|Biopsy|Undergo tumor biopsy
214441114|NCT06675136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214441115|NCT06675136|PROCEDURE|Computed Tomography|Undergo CT
214441116|NCT06675136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214441117|NCT06675136|OTHER|Medical Device Usage and Evaluation|Given PIPAC
214441118|NCT06675136|DRUG|Nab-paclitaxel|Given IP
214519060|NCT01246232|DRUG|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
214441119|NCT06675136|DRUG|Paclitaxel|Given IV
214441120|NCT06675136|OTHER|Questionnaire Administration|Ancillary studies
214441121|NCT06675136|BIOLOGICAL|Ramucirumab|Given IV
214441122|NCT07008287|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
214441123|NCT07005063|DEVICE|FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
214519061|NCT01246232|DRUG|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
215118323|NCT06312202|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
215118324|NCT02169986|BEHAVIORAL|electronic reminders|
215118325|NCT00598936|DEVICE|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
214441124|NCT05676827|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
214441125|NCT05676827|DIAGNOSTIC_TEST|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, Gamma-aminobutyric acid (GABA), Tumor Necrosis Factor α (TNF-α), CGRP, SERT, interleukin 1B, interleukin 6, interleukin 8, interleukin 10 and interleukin 17A.
214519062|NCT03763682|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
214519063|NCT05995340|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
214519064|NCT05995340|OTHER|Saline Active Control|Intradermal Injections
214519065|NCT02416102|DRUG|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
214441126|NCT06871397|OTHER|Biopsychosocial Cognitive Behavioral Intervention|"The study intervention is based on a biopsychosocial approach (considers the interaction between: biological factors such as physical health, fetal development and physiological changes; psychological factors such as stress management, emotions and thoughts; and social factors such as couple relationships, social support and the maternal role) with cognitive-behavioral strategies designed to promote comprehensive well-being during pregnancy and the postpartum. Techniques such as psychoeducation, reflection and self-observation, cognitive restructuring, problem solving, stress inoculation, progressive muscle relaxation, guided visualizations and mindfulness are applied.~The program consists of 10 modules focused on different areas: introduction to the study, mindfulness and breathing techniques, physical and mental health at different stages of pregnancy, fetal development and prenatal attachment, couple relationship, preparation for childbirth and postpartum, and care of the newborn."
214441127|NCT07011940|BEHAVIORAL|Along With Me|Along With Me is a therapeutic app that delivers cognitive behavior therapy and mindfulness-based psychoeducation and skills, grief normalization, and exercises to address perinatal grief and to reduce trauma symptoms related to the experience of perinatal loss. The Along With Me only arm will deliver the app-based intervention only.
214519066|NCT02416102|DRUG|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
214519067|NCT02162823|PROCEDURE|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
214519068|NCT05049174|BEHAVIORAL|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
214519069|NCT01659697|BEHAVIORAL|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
214519070|NCT04102605|DEVICE|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
215028666|NCT06639139|BEHAVIORAL|CogFun RG occupational therapy|21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
214519071|NCT04102605|DEVICE|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
214519072|NCT02518802|DRUG|Gefitinib|Gefitinib 250mg per day for 2 years.
214519073|NCT02518802|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
214519074|NCT02422355|DEVICE|FNS|Surgical intervention using the FNS
214519075|NCT06437327|PROCEDURE|Electrotherapy|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
214519076|NCT06437327|PROCEDURE|Active release technique|Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
214519077|NCT06437327|PROCEDURE|Hold relax technique|This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
214519078|NCT00540800|DRUG|docetaxel|given in combination with epirubicin or capecitabine
214519079|NCT00540800|DRUG|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
214519080|NCT00540800|DRUG|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
214519081|NCT04516980|OTHER|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
214519082|NCT00958971|DRUG|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
214519083|NCT04065685|OTHER|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
214519084|NCT04065685|OTHER|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
214519085|NCT00668746|DRUG|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
214519086|NCT03671356|OTHER|risk score|risk score
214519087|NCT02109172|DRUG|TD-4208|
214519088|NCT02109172|DRUG|Placebo|
214519089|NCT02011568|OTHER|Therapeutic Hypothermia|
214519090|NCT03539237|OTHER|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
214519091|NCT03591263|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
214519092|NCT05725447|OTHER|Validity and reliability study|Face-to-face questionnaire study
214441128|NCT07011940|BEHAVIORAL|Peer Guide|The peer guide will provide light touch reminders, opportunities to debrief, and resource navigation support, similar to community health navigator interventions provided remotely through insurers.
214441129|NCT04605783|DIETARY_SUPPLEMENT|Travelan®|Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
214441130|NCT04605783|OTHER|Placebo|Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
214441131|NCT06384963|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
214441132|NCT06384963|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
214441133|NCT06872593|PROCEDURE|CPAP-withdrawal|7-day-long CPAP-withdrawal
214441134|NCT06872593|DIAGNOSTIC_TEST|Test Sequence|Test Sequence M or D as specified in arm description
214441135|NCT06696066|BEHAVIORAL|PRS Program|The Peer Recovery Support program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
214441136|NCT00976105|DRUG|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
214441137|NCT00976105|DRUG|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
214519093|NCT03536637|DRUG|DMT310|Topical Powder
214519094|NCT03536637|DRUG|Hydrogen Peroxide|Liquid Diluent
214519095|NCT03536637|DRUG|Placebo|Placebo Topical Powder
214519096|NCT00368823|DEVICE|Electronic point-of-care delivery system|
215118326|NCT05114473|OTHER|Workshops|Several face-to-face workshops given by a researcher
215118327|NCT05114473|OTHER|Online-accessed material|Access to a website containing the educational program
215118328|NCT00497757|BIOLOGICAL|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
215118329|NCT05897229|OTHER|Analysis of costs with patient care during hospitalization|Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
214441138|NCT07023380|DIAGNOSTIC_TEST|Assay directed diet change|Functional T cell assay(s) will be performed on research subjects' peripheral blood using four foods known to commonly cause Eosinophilic esophagitis - milk, soy, egg, and wheat. Response magnitude to foods in vitro will influence whether a subject's physician chooses to recommend the subject AVOID the food or continue to CONSUME the food. Disease response to the diet changes will be evaluated in standard-of-care follow up endoscopy.
214441139|NCT07032259|DEVICE|BioXclude Amnion Chorion Membrane|A resorbable allograft membrane derived from dehydrated human amnion and chorion tissue. The membrane is placed over peri-implant bony defects during guided bone regeneration to act as a biological barrier and promote tissue healing.
214441140|NCT07032259|DEVICE|Collagen Membrane|A resorbable xenograft membrane derived from porcine collagen. The membrane is placed over peri-implant bony defects during guided bone regeneration to support space maintenance and facilitate bone regeneration.
214441141|NCT06309134|BEHAVIORAL|Healthy Families Bright Futures Program|Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
214519097|NCT04415580|OTHER|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
214519098|NCT04415580|OTHER|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
214519099|NCT00557518|DRUG|Alagebrium|200 mg bid
214519100|NCT00557518|DRUG|Placebo|bid
214519101|NCT03867656|OTHER|GLP-2|GLP-2 injection
214519102|NCT03867656|OTHER|GIP|GIP injection
214519103|NCT03867656|OTHER|Placebo|Placebo injection
214519104|NCT01906073|DRUG|intranasal fentanyl spray|
214519105|NCT01906073|DRUG|slow release morphine|
214519106|NCT01880359|DRUG|Cisplatin|
214519107|NCT01880359|RADIATION|Radiotherapy|
214519108|NCT01880359|DRUG|Placebo|
214519109|NCT01880359|DRUG|Nimorazole|
214519110|NCT00166075|PROCEDURE|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
214519111|NCT01641848|DEVICE|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
214519112|NCT02232009|DEVICE|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
214519113|NCT04184609|OTHER|Control|In this condition, the participants will not receive any medications or drugs before exercise
214519114|NCT04184609|DRUG|Albuterol|180 mcg of Albuterol will be administered before exercise
215028667|NCT06639763|DIAGNOSTIC_TEST|Questionnaire|Questionnaire containing a combination of basic epidemiological questions, questions regarding recent sexual activity, questions regarding sexual preference and sexual activity, questions regarding the use of different types of erectile aids, questions regarding satisfaction with the use of these different erectile aid and questions regarding the satisfaction with sexual functioning and the partner relation. Al patients at least 6 months after primary genital gender-affirming surgery and who are sexually active are eligible.
215028668|NCT06641596|DIETARY_SUPPLEMENT|Placebo|2 capsules of Placebo, once daily after breakfast for 12 weeks
215028669|NCT06641596|DIETARY_SUPPLEMENT|Cr-400|1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks
215028670|NCT06641596|DIETARY_SUPPLEMENT|Cr-800|2 capsules of Cr-400, once a day after breakfast for 12 weeks
215028671|NCT06641596|DIETARY_SUPPLEMENT|PE-500|1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks
214519115|NCT04177849|PROCEDURE|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
214519116|NCT04177849|PROCEDURE|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
214519117|NCT04780906|OTHER|Wrist taping|Wrist taping as used as standard in CrossFit practice
214519118|NCT04910399|DIETARY_SUPPLEMENT|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
214441142|NCT07048223|BEHAVIORAL|Expiratory Muscle Training|"In the expiratory muscle training group, participants will receive a respiratory exercise program consisting of breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, expiratory muscle training (EMT) will be performed using the POWERbreathe EX1 device at 50% of each participant's measured maximal expiratory pressure (MEP).~Participants will be instructed to perform 25 repetitions per session, structured as 5 cycles of 5 breaths with 1-minute rest intervals between each cycle. The training will be performed daily at home for a duration of 8 weeks. Compliance will be monitored through exercise tracking forms.~To ensure progressive loading, MEP will be reassessed every 10 days, and the resistance of the device will be adjusted accordingly. Participants will be invited for in-person interim evaluations at these 10-day intervals to update their training parameters."
214441143|NCT07048223|BEHAVIORAL|Sham Expiratory Muscle Training|"In the sham expiratory muscle training group, participants will perform a respiratory exercise program including breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, sham expiratory muscle training will be administered using the POWERbreathe EX1 device set at 10% of the participant's measured maximal expiratory pressure (MEP), providing minimal resistance.~Participants will be instructed to perform the exercises daily at home for a period of 8 weeks. Compliance will be monitored through exercise tracking forms. No progressive loading or resistance adjustments will be made during the intervention period."
214441144|NCT07054658|PROCEDURE|Allogenic Bone Ring Graft With Simultaneous Implant Placement|A surgical procedure involving vertical ridge augmentation using an allogenic bone ring combined with simultaneous dental implant placement in the posterior mandible. The technique allows one-stage treatment of vertical bone defects without the need for autogenous bone harvesting.
214441145|NCT06788886|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214441146|NCT06788886|OTHER|Exercise Intervention|Participate in walking routines
214441147|NCT06788886|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214519119|NCT04910399|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
214519120|NCT00164021|PROCEDURE|Physiotherapy, exercise, percutaneous gastrostomy feeds|
214519121|NCT00164021|DRUG|Anti-reflux pharmacotherapy|
214519122|NCT00006428|DRUG|Amitriptyline|
214519123|NCT00674791|BIOLOGICAL|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
214519124|NCT04232410|DIAGNOSTIC_TEST|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
214519125|NCT04232410|DIAGNOSTIC_TEST|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
214519126|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
214519127|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
214692884|NCT05807334|OTHER|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
214441148|NCT06788886|OTHER|Questionnaire Administration|Ancillary studies
214441149|NCT06788886|PROCEDURE|Respiratory Therapy|Participate in breathing sessions
214441150|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
214441151|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
214441152|NCT06567743|DRUG|Cretostimogene Grenadenorepvec|Respective Cohort
214441153|NCT06884722|BEHAVIORAL|Behavioral task of social perception (stage 1)|Patients with Parkinson disease and healthy volunteer are engaged in a social perception behavioral task.
214519128|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
214519129|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
214519130|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
214519131|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
214519132|NCT00629447|DRUG|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
214519133|NCT02962622|OTHER|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
214519134|NCT03131271|OTHER|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
215028672|NCT06641596|DIETARY_SUPPLEMENT|PE-1000|2 capsules of PE-500, once a day after breakfast for 12 weeks
215028673|NCT06222684|OTHER|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
214441154|NCT06884722|OTHER|Functional magnetic resonance imaging: 3 Tesla magnetic resonance imaging (stage 2)|"Patients with Parkinson disease and healthy volunteer are assessed by functional magnetic resonance imaging while they are engaged in a social perception behavioral task.~2 times for patients with Parkinson disease (during ON-levodopa and OFF-levodopa) Once for healthy volunteer"
214441155|NCT06884722|OTHER|Neurological and neuropsychological assessments|Patients with Parkinson disease and healthy volunteer will undergo a neurological and neuropsychological assessment with several evaluations: weight, height, medical history, global cognitive performance (MoCA and BREF score), apathy (LARS score), depression (BDI-II score), social cognition (mini-SEA), and quality of life (PDQ39 self-questionnaire).
214441156|NCT06884722|OTHER|Neurological assessments of Parkinson's disease symptoms and caregiver burden|Patients with Parkinson disease will undergo a neurological assessment of motor and non-motor symptoms of Parkinson's disease (MDS-UPDRS III \& IV scale and MDS-NMS scale) and caregiver burden (Zarit scale).
214441157|NCT06751225|DEVICE|One week replacement soft contact lenses|One week replacement soft contact lenses
214441158|NCT07059221|DRUG|SHR-A2102|Administration by intravenous infusion
214441159|NCT07059221|DRUG|Adebrelimab|Administration by intravenous infusion
214441160|NCT07059221|DRUG|Cetuximab|Administration by intravenous infusion
214441161|NCT07066020|BEHAVIORAL|Telehealth-delivered Physical Activity Program for Children with ASD|This is a 16-week, theory-driven (Social Cognitive Theory \& Self-Determination Theory) behavioral intervention delivered remotely to caregivers of children with ASD. The program is facilitated by trained therapists via videoconference in small groups and consists of weekly 45-minute sessions. Core components include personalized exercise prescription, collaborative goal-setting, behavior change support, and safety education. Caregivers are coached to guide their child in three 30-40 minute physical activity sessions per week. To provide individualized support, therapists conduct two 10-minute one-on-one phone consultations per family based on biweekly activity logs submitted by caregivers.
214519135|NCT01680315|BEHAVIORAL|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
214441162|NCT07066020|BEHAVIORAL|In-Person Supervised Physical Activity Program|This is a 16-week, structured, in-person physical activity intervention for children with ASD. The program consists of three 40-minute sessions per week delivered on-site at a partner school by certified physical education instructors. The curriculum is manualized and includes an Individualized Motor Protocol, Structured Group Sessions, and Behavior Change Support. Instructors provide direct, hands-on correction and feedback during sessions, adjusting task difficulty in real-time to match each child's individual capabilities and needs.
214441163|NCT07066020|OTHER|General Health Education Materials|This is a minimal intervention control. Participants in this group do not receive a structured or guided physical activity program. At the beginning of the study, caregivers are provided with a one-time, webinar-style session on general pediatric health topics (e.g., nutrition, sleep hygiene) and an exercise guidance manual. These materials are for optional, independent use by the caregivers, and no active monitoring or follow-up is provided by the research team regarding their use.
214519136|NCT01680315|BEHAVIORAL|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
214519137|NCT03371849|DRUG|montelukast and levocetirizine FDC|HCP1102
214519138|NCT03371849|DRUG|Singulair + xyzal|HGP0813 + HGP1408
214519139|NCT01461434|DEVICE|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
214519140|NCT01816165|DRUG|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
214519141|NCT01816165|DRUG|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
214519142|NCT04694300|DRUG|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
214519143|NCT04694300|DRUG|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
214519144|NCT04694300|DRUG|Tramadol|50 mg by mouth every 6 hours as needed for pain
214519145|NCT03443739|OTHER|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
214519146|NCT02829099|DRUG|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
214519147|NCT05285696|DRUG|CSB-111|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
214519148|NCT03877133|DEVICE|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
214519149|NCT01573741|DRUG|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
214519150|NCT03337204|BEHAVIORAL|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
214519151|NCT03337204|BEHAVIORAL|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
214441164|NCT07070167|DRUG|Intratracheal administration of surfactant|Intratracheal administration of pulmonary surfactant with any of the approved methods: (a) via endotracheal tube in a mechanically-ventilated infant, (b) with the INSURE method (intubation-surfactant-extubation), or (c) with LISA method (through a thin catheter inserted intratracheally in a spontaneously breathing infant, supported with CPAP)
214441165|NCT07071727|RADIATION|Preoperative radiotherapy|preoperative radiotherapy
214441166|NCT07071220|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
214441167|NCT07071220|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
214441168|NCT07071480|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
214441169|NCT07071480|DEVICE|Sham device|Sham headband-style device. Participants assigned to use this device will be told they are receiving therapy for 30 minutes. However, no therapy is being provided.
214441170|NCT07070141|DIAGNOSTIC_TEST|Diagnostic work up|None intervention
214441171|NCT07070791|OTHER|Upper Extremity Aerobic Exercise Training|12 weeks of upper extremity aerobic exercise training, 3 sessions per week, 25 minutes per session.
214441172|NCT07070791|OTHER|Upper Extremity Progressive Resistance Exercise Training|Upper extremity progressive resistance training was gradually increased over 12 weeks using elastic resistance bands.
214441173|NCT07070986|PROCEDURE|RESC|"If randomized in the RESC group, interventional group, patient will receive a 20 minutes session of cutaneous resonance stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale (VAS) at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery).~During the RESC session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
214441174|NCT07070986|OTHER|NSCS|"If randomized in the NSCS group, interventional group, patient will receive a 20 minutes session of non-specific cutaneous stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery)~During the NSCS session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
214519152|NCT03792945|DRUG|local injection|In addition to the local injection, carpal tunnel brace will be given.
214519153|NCT03792945|DEVICE|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
214519154|NCT00295100|DRUG|Tamoxifen|
214519155|NCT02018159|DRUG|menotropin|
214519156|NCT02366455|PROCEDURE|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
214519157|NCT02366455|PROCEDURE|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
214519158|NCT01411176|DRUG|Menthol|20 mL NPO-11 in a prefilled plastic syringe
214519159|NCT01411176|DRUG|Placebo|The placebo is included same additives as active comparator.
214519160|NCT05619445|OTHER|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
214519161|NCT05619445|OTHER|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
214519162|NCT05569265|PROCEDURE|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
214519163|NCT05082441|DRUG|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
214519164|NCT05082441|DRUG|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
214519165|NCT05906056|DEVICE|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
214519166|NCT05906056|OTHER|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
214519167|NCT05906056|DRUG|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
214519168|NCT04750447|DEVICE|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
214519169|NCT01495754|OTHER|coffee|Comparison of different amounts of coffee
214519170|NCT02637362|PROCEDURE|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
215118330|NCT03843086|DEVICE|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
215118331|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
215118332|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
215118333|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
215118334|NCT01128426|OTHER|No Intervention|No Intervention
215118335|NCT03087136|DIAGNOSTIC_TEST|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
215118336|NCT03087136|DIAGNOSTIC_TEST|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
214441175|NCT07070960|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
214441176|NCT07070921|DEVICE|Foley catheter|Drainage of urine from the bladder by transurethral catheterization with an indwelling Foley catheter of patients in need of a Foley catheter for 3 to 14 days.
214441177|NCT07070999|BIOLOGICAL|GB221|GB221
214441178|NCT07069868|OTHER|Telehealth|During cycle one, participants will be asked about fevers, mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Symptoms will be graded according to Common Terminology Criteria for Adverse Events. A new adverse event of grade one or higher will be reported to a provider. An adverse event grade two or higher above baseline and/or experiencing cancer related symptoms above baseline, the findings will be reported to a Provider.
214441179|NCT07071272|OTHER|breast-MRI and CEM|Participants will undergo a breast MRI followed by CEM for local breast cancer staging
215118337|NCT04104737|DEVICE|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
214441180|NCT07071129|DEVICE|Virtual Reality Stimulation|VR 1 hour sessions will consist of an exposure to a non-invasive visual stimulation where the subject will be sitting wearing a VR headset.
214692885|NCT05807334|OTHER|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
214692886|NCT03828006|DIETARY_SUPPLEMENT|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
215118338|NCT03796065|BEHAVIORAL|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
215118339|NCT02120066|PROCEDURE|Vitrectomy for submacular hemorrhage|
214441181|NCT07069946|OTHER|traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of traditional physical therapy program : Includes: Strengthening, Stretching, Balance, Postural Control, Functional Mobility and Gait Training.~* 30 minutes of seven different weight-bearing exercises program of exercises with three of those being repeated on the left and right sides to make a total of ten exercises, each held for 3 minutes, the exercises include: hamstring stretch, calf stretch, half kneeling balance, static squat, bridge, four point kneeling and four point kneeling with leg extension the exercises include: : Hamstring stretch,Calf stretch , Half kneeling balance , Static Squat, Bridge, Four point kneeling with leg extension, and Four point kneeling."
214441182|NCT07069946|OTHER|neuromuscular electrical stimulation , traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of the same traditional physical therapy as the control group.~* 30 minutes of the same weight-bearing exercises program as the control group adding to it the neuromuscular electrical stimulation on: Tibialis anterior, Quadriceps, Paraspinal muscles.~* NMES Parameters :~  * Device: Everyway-EV-906.~ * Frequency: 30-35 Hz (to optimize muscle endurance and motor unit recruitment).~ * Pulse Width: 250-300 µs.~ * Intensity: Adjusted to elicit visible muscle contraction without discomfort (submaximal, (25-30 mA).~ * Electrode Placement:~    * Lower Limb: Tibialis anterior (for dorsiflexion) and quadriceps (for knee stability) during weight-bearing (El-Shamy and El Kafy, 2021).~   * Trunk: Paraspinal muscles (for postural control) during static squats and bridging"
214441183|NCT07071701|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine
214441184|NCT07071701|BIOLOGICAL|Influenza vaccine|Influenza vaccine
214441185|NCT07070362|OTHER|None-placebo|This observational cohort study is non-interventional. Perioperative treatment plans are made based on model - suggested results and anesthesiologists' thought processes, without adding new medicines for patients.
214441186|NCT07070375|DRUG|HRS-8427|HRS-8427
214441187|NCT07069959|OTHER|Early assessment of quadriceps muscle strength|Patients will undergo non-invasive assessment of quadriceps muscle strength using manual dynamometry and 3D ultrasound. These assessments will be conducted regularly during their ICU stay to evaluate early recovery. The intervention is part of routine patient care and does not involve additional treatments or procedures.
214441188|NCT07070713|DRUG|FOLFOXIRI + QL1706 + Bevacizumab|FOLFOXIRI(Irinotecan 165mg/m², iv, d1; Oxaliplatin 85mg/m², iv, d1; (Levo) Folinic Acid (200) 400mg/m², iv, d1; total 5-FU 2400mg/m², iv gtt (continuous for 48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Bevacizumab (5mg/kg, i.v., Q2W)
214441189|NCT07070713|DRUG|FOLFOX+QL1706+Cetuximab|FOLFOX (Oxaliplatin 85mg/m², iv gtt (for 2h), d1; (Levo) Folinic Acid (200) 400mg/m², iv gtt (for 2h), d1; 5-FU 400mg/m², iv, followed by 2400mg/m², iv gtt (continuous for 46-48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Cetuximab (500mg/m², i.v., Q2W).
214441190|NCT07071506|DRUG|Active drug for chronic migraine treatment.|Standard dose of Fremanezumab, 225 mg (Ajovy) injected subcutaneously
214441191|NCT07071506|DRUG|Placebo Subcutaneous injection|Inactive placebo (saline) injected subcutaneously in the same volume as the active drug
214519171|NCT02637362|PROCEDURE|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
214519172|NCT02637362|PROCEDURE|Metatarsal block|A metatarsal block will be performed using a standardised technique
215118340|NCT02120066|DRUG|subretinal injection of tissue-plasminogen activator|
215118341|NCT02442024|BEHAVIORAL|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
215118342|NCT02442024|BEHAVIORAL|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
215118343|NCT04483726|PROCEDURE|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
215118344|NCT04483726|PROCEDURE|open distal pancreatectomy|open distal pancreatectomy
215118345|NCT04807933|BEHAVIORAL|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
215118346|NCT02472574|DEVICE|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
215118347|NCT02472574|DRUG|rt-PA|Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
215118348|NCT00775996|DRUG|Clorazepate Dipotassium 15mg Tablets|
214441192|NCT07071025|BEHAVIORAL|Preventing Postpartum Onset Distress (P-POD)|P-POD contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules are designed to educate pregnant women about perinatal anxiety (psychoeducation), teach women to change their thinking patterns (cognitive restructuring), and guide women through testing their dysfunctional beliefs and fears (behavioral experiments). Each of these modules engage the pregnant woman in various self-guided exercises to consolidate the lessons learned. In addition, three partner-directed modules are designed to educate partners about perinatal anxiety, coach partners on providing emotional and social supports to pregnant women at risk for perinatal anxiety, and prepare partners for developmentally normative changes in their relationships following birth. Modules are designed to be completed weekly during the second trimester.
214441193|NCT07071025|BEHAVIORAL|Anxiety Education (ANX-ED)|ANX-ED educates women and their partners about seven anxiety and related disorders. ANX-ED contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules and three partner-directed modules will educate participants about generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobia, obsessive-compulsive disorder, and posttraumatic stress disorder. Specifically, modules will include the diagnostic criteria, prevalence, and etiology of the disorders. They will also include animated examples of mothers experiencing the disorders described in each module. Each module engages the pregnant woman (or partner) in various self-guided exercises to consolidate the material learned.
214441194|NCT07071818|PROCEDURE|Colpocleisis Group|Participants will undergo colpocleisis surgery as part of routine clinical care. The study involves transperineal ultrasound (TPUS) to measure the vesicourethral angle preoperatively and postoperatively, along with assessments for de novo stress urinary incontinence, POP-Q staging, PFDI-20 questionnaire, and stress testing.
214441195|NCT05091580|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.
214441196|NCT05091580|BEHAVIORAL|Enhanced treatment as usual|Depression screening and referral (as needed)
214441197|NCT07071935|DEVICE|Non-invasive ventilation|Non-invasive ventilation will be started earlier than usual respiratory care guidelines for ALS in the United States.
214441198|NCT07069816|RADIATION|Scintigraphy|non invasive method in which the test meals and acquisition procedures have been standardized and the results are largely operator independent
215118349|NCT00818792|DEVICE|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
215118350|NCT00869752|BIOLOGICAL|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
215118351|NCT00869752|DRUG|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
215118352|NCT00869752|DRUG|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
215118353|NCT03976388|DEVICE|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
215118354|NCT03976388|OTHER|Small-Group Discussion|Small group discussion led by a physician.
215118355|NCT01104896|DRUG|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
215118356|NCT01104896|DRUG|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
215118357|NCT02214641|BEHAVIORAL|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
215118358|NCT02214641|BEHAVIORAL|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
214441199|NCT07069816|RADIATION|Scintigraphy|Non invasive method in which the test meals and acquisition procedures have been standardized
214441200|NCT07064863|DRUG|Gemcitabine + BCG|Patients will receive a single intravesical instillation of gemcitabine (2000 mg) at week 0 followed by weekly BCG (50 mg of TICE strain) for a total of 5 instillations. Biopsy will be conducted within three months of completing the induction phase.
214441201|NCT07064863|DRUG|BCG (TICE strain)|Patients will receive intravesical BCG (50 mg, TICE strain) at weekly intervals for a total of 6 instillations. Biopsy will be performed within 3 months of completing the induction phase.
214441202|NCT07070154|BEHAVIORAL|text-messaging based intervention|The 6-week, culture specific, text-messaging based cessation intervention for young adults in Hong Kong consists of 6 sessions: 1) Programme overview, 2) Psychoeducation on the health risks, 3) Social support, 4) Stress management, 5) Craving and withdrawal symptoms management, and 6) Summary and relapse prevention.
214441203|NCT05028582|DRUG|Roflumilast Foam 0.3%|Roflumilast foam 0.3%
214519173|NCT02637362|PROCEDURE|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
214519174|NCT06537570|BEHAVIORAL|Guided Imagery Practice|"Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up."
214519175|NCT05807555|OTHER|Ambulatory ECG|24h ECG monitoring
214519176|NCT05807555|BIOLOGICAL|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
214519177|NCT00005843|DRUG|tipifarnib|
214519178|NCT06164119|OTHER|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
214519179|NCT06164119|OTHER|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
214519180|NCT06164119|OTHER|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
215118359|NCT01027715|OTHER|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
215118360|NCT01698385|OTHER|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
215118361|NCT00550953|DRUG|telmisartan+amlodipine|
215118362|NCT00550953|DRUG|telmisartan|
215118363|NCT01936714|PROCEDURE|cataract surgery|
214441204|NCT05028582|DRUG|Vehicle Foam|Vehicle foam matched to roflumilast 0.3% foam.
215118364|NCT06262100|DEVICE|Carragelose|Application of Carragelose containing eye drops
215118365|NCT03890237|BEHAVIORAL|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
214441205|NCT07070687|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Low-frequency electrical stimulation (800Hz) applied at CV2/S3 regions twice daily for 7 days using MMK520i device
214441206|NCT07071246|DRUG|Rituximab Injection|low dose of rituximab intravenously
214441207|NCT07071610|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% BID
214441208|NCT07071610|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% BID
214519181|NCT04712786|OTHER|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
214519182|NCT00648271|DRUG|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
214519183|NCT00648271|DRUG|Lopressor® Tablets 50 mg|1x50mg, single dose fed
214519184|NCT04605471|DRUG|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
214519185|NCT05815771|PROCEDURE|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
214519186|NCT05815771|PROCEDURE|Bone Marrow stem cells aspirate|stem cells
214692887|NCT03828006|OTHER|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
214692888|NCT02608437|DRUG|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
214692889|NCT02608437|DRUG|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
214692890|NCT01689207|DRUG|Avibactam (AVI)|PART A: AVI IV infusion
215118366|NCT03890237|BEHAVIORAL|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
215118367|NCT03890237|BEHAVIORAL|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
215118368|NCT03890237|BEHAVIORAL|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
214441209|NCT07071610|DRUG|Vehicle|vehicle BID
214441210|NCT07070297|DRUG|XKH001 Injection|Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.
214441211|NCT07077564|DRUG|Sac-TMT|Sacituzumab govitecan 5 mg/kg every 2 weeks on Day 1 of each cycle（IV）
214441212|NCT07078110|PROCEDURE|Material: Filtek Z250 (3M ESPE, USA)|"Group I (Incremental Technique):~Material: Filtek Z250 (3M ESPE, USA) Applied in 2 mm incremental layers, light-cured for 40 seconds per increment."
214441213|NCT07078110|PROCEDURE|Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA|"Group II (Bulk-Fill Technique):~Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA Applied in a single increment (up to 4 mm) and light-cured for 40 seconds."
214441214|NCT07077486|DRUG|Methylprednisolone (Corticosteroid)|In addition to conventional treatment (methyl-40mg or less /d), the treatment group also received hydroxychloroquine (100mg-200mg each time twice a day), and thalidomide (50mg-100mg each time once a day) could be added as appropriate.
214441215|NCT07077486|DRUG|Immunosuppressant other than CYC|The control group only received conventional treatment (methyl 40 mg/d or less), and other traditional immunosuppressants (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine, etc.). No more than 3 types of immunosuppressant should be added during the whole treatment period, and the dose should not exceed 30% from the baseline period)
214441216|NCT07077486|DRUG|Telitacicept Freeze-dried powder Injection 80mg|Telitacicept is a TACI-Fc fusion protein, a type of drug used to treat autoimmune diseases. It works by targeting two key proteins, BLyS and APRIL, which are involved in the development and function of B cells, a type of white blood cell. By blocking these proteins, telitacicept can help to reduce B cell activity and suppress the immune system's overactivity in autoimmune diseases. Subcutaneous injection dose ranges from 80mg once a week to 160mg once a week.
214441217|NCT07077486|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide iv injection is used for severe complications of systemic lupus erythematosus 400mg twice a week
214441218|NCT07078188|BEHAVIORAL|PEG training|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0, 1, and 3 months.). The intervention group will be trained on PEG use before discharge at the first interview.
214441219|NCT07078188|OTHER|Control|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0.,1. ve 3. monts).
214441220|NCT07077759|OTHER|Online self-compassion intervention|Participants in the intervention group will receive five consecutive weekly sessions, with each session lasting 2 hours (totaling 10 hours). Each session will include an introduction, guided exercises, group discussions and home practice.
214441221|NCT07078318|OTHER|Pelvic floor rehabilitation|Participants in this group will receive standard pelvic floor rehabilitation. This includes education about pelvic floor anatomy and function, supervised pelvic floor muscle training (Kegel exercises), relaxation techniques, and manual release of trigger points if necessary. The aim is to improve muscle strength, coordination, and reduce pelvic floor hypertonicity contributing to dyspareunia.
214441222|NCT07078318|OTHER|Diaphragmatic Breathing Exercises|In addition to the standard pelvic floor rehabilitation, participants in this group will practice diaphragmatic breathing exercises. These exercises focus on deep, slow nasal inhalation using the diaphragm, encouraging abdominal expansion while minimizing chest movement. Sessions are performed twice daily for 10 minutes. This technique is aimed at promoting parasympathetic activation, reducing anxiety, and improving autonomic regulation.
214441223|NCT07078318|OTHER|Diaphragm Manual Therapy|an additional manual therapy intervention targeting the diaphragm. Diaphragm manual therapy involves hands-on techniques applied to the thoracic and abdominal regions to reduce fascial restrictions, improve diaphragmatic mobility, and support deeper, more effective breathing. The therapy is delivered for 15 minutes at the start of each weekly session by a trained physiotherapist.
214441224|NCT07078539|OTHER|Kaltenborn Mobilization Group|"Participants in this group will receive Kaltenborn mobilization techniques applied to the talocrural and subtalar joints. Mobilizations will be performed as Grade III passive accessory glides for 10 repetitions per joint, each sustained for 15 seconds with a 10-second rest interval~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
214692891|NCT01689207|DRUG|Aztreonam (ATM)|PART A: ATM IV infusion
214441225|NCT07078539|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan mobilization with movement (MWM) techniques applied to the talocrural and subtalar joints. Mobilizations will be applied as 3 sets of 10 repetitions per joint with 1-minute rest between sets.~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
214441226|NCT07069881|DEVICE|Sonic-Activated Irrigation|Sonic-activated irrigation was performed using the polymer tip (Eddy™, VDW, Germany) activated by an airscaler handpiece.
214519187|NCT04283058|DRUG|Ketamine|d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
214519188|NCT03030053|DIETARY_SUPPLEMENT|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
214519189|NCT03030053|DIETARY_SUPPLEMENT|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
214519190|NCT05464992|OTHER|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
214441227|NCT07069881|DEVICE|Passive Ultrasonic Irrigation|Passive ultrasonic irrigation was performed using the ultrasonic tip (ACTEON, France) attached to an ultrasonic device (P5 Newton™, ACTEON, France)
214519191|NCT05729152|OTHER|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
214519192|NCT02577848|DRUG|GLP-1|GLP-1 were taken daily for 7 days
214519193|NCT02577848|DRUG|Placebo|Placebo were taken daily for 7 days
214519194|NCT01642030|DRUG|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214519195|NCT01642030|DRUG|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214519196|NCT01642030|DRUG|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214519197|NCT00999271|OTHER|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes"
214519198|NCT00977340|BEHAVIORAL|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
214519199|NCT00977340|BEHAVIORAL|confrontation|Confrontation
214519200|NCT00977340|BEHAVIORAL|imagination|Imagination
214519201|NCT01322347|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
214519202|NCT01322347|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
215118369|NCT06137586|OTHER|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
215118370|NCT04515758|OTHER|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
215118371|NCT04515758|OTHER|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
215118372|NCT04311255|PROCEDURE|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
214519203|NCT06247878|DEVICE|Skiin underwear chest band|Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
214519204|NCT01665014|RADIATION|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
214519205|NCT00070161|DIETARY_SUPPLEMENT|EGb761|
214519206|NCT00070161|DRUG|donepezil hydrochloride|
214519207|NCT00070161|PROCEDURE|cognitive assessment|
214519208|NCT02519270|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein.
214519209|NCT05580302|OTHER|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
215118373|NCT03948841|OTHER|magnetic resonance imaging|
215118374|NCT06164834|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
214441228|NCT07078240|OTHER|Falls risk - Artificial Intelligence Recommender (FAIR)|"FAIR is an alert system built into the hospital's electronic medical record system. It is an adaptation of a machine learning model for fall risk calculation built in another hospital in Singapore. FAIR combines multiple patient-specific variables to identify if a patient is at increased risk of falling during their inpatient stay, marking them as a 'falls risk'.~Based on the 'flag' raised, the nurse will be instructed to prioritise her falls risk assessment of the patient (If deemed 'high risk') or to do so subsequently as a lower priority once other pressing patient care issues are resolved (if deemed 'low risk').~That way, it ensures the requirements of each patient receiving a falls risk assessment as scored through mWHeFRA are still met, with FAIR allowing nurses to better prioritise their focus and attention on the patient that most needs the assessment at point of admission,"
214519210|NCT01388621|DRUG|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
214519211|NCT01388621|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
214519212|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
214519213|NCT01388621|DRUG|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
214519214|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
214519215|NCT01388621|DRUG|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
214519216|NCT01840696|DRUG|Regadenoson|Vasodilator stress testing
214519217|NCT00608387|BEHAVIORAL|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
214519218|NCT00896389|PROCEDURE|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
214519219|NCT00896389|DRUG|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
214519220|NCT02612116|DRUG|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
214519221|NCT02612116|DRUG|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
215118375|NCT06164834|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
215118376|NCT06164834|DRUG|Esomeprazole 20mg|Esomeprazole 20 mg tablet
215118377|NCT06182969|DRUG|APG-2575|Take orally once daily (QD) for 12 weeks.
215118378|NCT06182969|OTHER|Placebo|Take orally once daily (QD) for 12 weeks.
214519222|NCT02612116|DRUG|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
214692892|NCT01689207|DRUG|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
214692893|NCT01689207|DRUG|Placebo|PART A, PART B, PART C: matching placebo IV infusions
215118379|NCT01922141|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
215118380|NCT01922141|DRUG|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
215118381|NCT01922141|DRUG|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
215118382|NCT01922141|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
215118383|NCT04528719|BIOLOGICAL|mRNA-1345|Formulation for injection
215118384|NCT04528719|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
215118385|NCT03314064|DRUG|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
214441229|NCT07078240|OTHER|modified Western Health Falls Risk Assessment Tool (mWHeFRA)|The mWHeFRA is the hospital's standard falls risk assessment tool. All nurses are expected to be proficient in its use to guide their risk assessment of patients
214441230|NCT07076901|BEHAVIORAL|Psychological Support|A structured psychological intervention aimed at alleviating preoperative anxiety. It included one-on-one counseling, providing detailed information about the surgical procedure, introducing relaxation techniques and music therapy, and sharing success stories from previous patients to boost confidence. Support was provided via phone or WeChat video by a qualified psychological counselor.
214441231|NCT07076901|BEHAVIORAL|Supervised Exercise Program|A daily guided exercise regimen including two components: 1) General physical conditioning consisting of at least 40 minutes of moderate-intensity aerobic and resistance training (e.g., brisk walking, jogging, cycling). 2) Respiratory function training consisting of abdominal breathing (5 times/hour) and balloon-blowing exercises (10 times/day). Patient adherence was monitored daily via a WeChat group.
214441232|NCT07076901|BEHAVIORAL|Lifestyle and Dietary Modification|Focused on optimizing preoperative habits. Nutritional guidance involved a high-protein, high-vitamin diet with six smaller, frequent meals per day to adapt to post-surgery conditions. Lifestyle guidance included advising smoking and alcohol cessation and ensuring 6-8 hours of sleep per night. Daily dietary and sleep status were reported and monitored via a WeChat group.
214441233|NCT07076901|OTHER|Routine Perioperative Care|Consisted of standard care practices before, during, and after surgery. Preoperative care included health education and fasting instructions. Intraoperative care included body temperature maintenance and vital signs monitoring. Postoperative care included 12-hour ECG monitoring, gradual reintroduction of a clear liquid diet 24 hours post-surgery, encouragement of early mobilization, and standard nursing for catheters and wounds.
214441234|NCT07076628|DRUG|Propofol|Propofol infusion with remifentanil
214441235|NCT07076628|DRUG|Remimazolam|Remimazolam infusion with remifentanil
214441236|NCT07076771|OTHER|Coronary Angiography|All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
214441237|NCT07076771|OTHER|Syntax Score|The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
214441238|NCT07077161|DRUG|Cabozantinib|For patients using 40mg the experimental regimen consists of 60mg once daily for 2 days followed by 1 skipping day (60-60-0 mg). For patients using 20mg the experimental regimen consists of 60mg once daily for 1 day followed by 2 skipping days (60-0-0 mg).
214441239|NCT07078357|BIOLOGICAL|StrepIncor|This arm will include 25/50/100/200 µg compared to placebo
214441240|NCT07078357|OTHER|Placebo|A placebo (aluminum adjuvant) will be administered and compared to the other study arms
215118386|NCT02446717|DRUG|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
215118387|NCT02446717|DRUG|ribavirin (RBV)|Tablet
215118388|NCT02446717|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
215118389|NCT02905266|BIOLOGICAL|Nivolumab|-Specified dose on specified days
214441241|NCT07076550|DRUG|[225Ac]Ac-A9-3408|Administered IV
214441242|NCT07076550|DIAGNOSTIC_TEST|[68Ga]Ga-A9T-3202|Administered IV
214441243|NCT07076732|OTHER|Coronary Angiography|Coronary angiograms will be acquired digitally for quantification.
214441244|NCT07076732|OTHER|SYNTAX Score|Upon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions.
214441245|NCT07077356|BIOLOGICAL|HBV mRNA vaccine|HBV mRNA vaccine
214441246|NCT06894680|OTHER|Stepped care|"It is a systematic, staged approach to delivering care based on the severity of a condition and the patient's response to treatment. In this model, less intensive interventions are provided first, and only those who do not improve progress to more intensive treatments.~In clinical research, stepped-care is classified as an adaptive intervention, where treatment is adjusted based on pre-specified criteria, making it patient-centered and resource-efficient."
214441247|NCT06894680|OTHER|Treatment as usual|Clients that are considered to be depressed are offered counselling by the Nurses who are the first point of contact. Depending on the severity of symptoms the client are then referred to the medical officer at the HIV clinic for assessment and offered counselling services by the counsellors. if symptoms are severe and considered to need specialist care the medical officer will refer to a specialist(psychiatrist) outside the HIV care facility.
214441248|NCT06826859|DRUG|Daily aspirin (ASA)|162mg aspirin taken daily
214441249|NCT06826859|DRUG|Split dose aspirin (ASA)|81mg aspirin q12hours
214441250|NCT07077265|DRUG|Norepinephrine (0.1 μg/kg/min)|The patients will receive norepinephrine infusion at a rate 1 mL/kg/hour of 6 mcg/mL solution.
214441251|NCT07077265|DRUG|Norepinephrine (0.07 μg/kg/min)|The patients will receive NE infusion at a rate 1 mL/kg/hour of 4.2 mcg/mL solution.
214441252|NCT07076667|OTHER|Benson's relaxation technique|effects of Benson's relaxation technique 5 days per week for 45 minutes for 8 weeks
214441253|NCT07076667|OTHER|Tai Chi|Tai Chi 5 days per week for 45 minutes for 8 weeks
214441254|NCT07078916|BEHAVIORAL|Motor-Cognitive Training Group (OLBA + BlazePod™)|Arm 1 participant will receive the One-leg-balance activity using visual feedback BlazePod technology as a dual motor-cognitive task training.
214441255|NCT07078916|BEHAVIORAL|Motor Training Group (OLBA Only)|Arm 2 participant will receive a the One-leg-balance activity as a single motor task.
215028674|NCT06561243|DRUG|BTK inhibitor (Ibrutinib or Acalabrutinib)|Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
215118390|NCT02905266|BIOLOGICAL|Ipilimumab|-Specified dose on specified days
215028675|NCT05905146|OTHER|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
215028676|NCT06642259|RADIATION|Echocardiography|ECHO
215028677|NCT06439810|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
215118391|NCT00442728|DEVICE|ELECTRICAL STIMULATION|
215118392|NCT04871425|DRUG|Ketamine|IV ketamine
215118393|NCT04871425|DRUG|Fentanyl|IV fentanyl
215118394|NCT03149172|DEVICE|Equimatrix®|Ridge preservation bone grafting after tooth extraction
215118395|NCT03149172|DEVICE|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
215118396|NCT03149172|DEVICE|Endobon®|Ridge preservation bone grafting after tooth extraction
215118397|NCT05801666|OTHER|Acupuncture|Acupuncture 5 points
214519223|NCT02351609|BEHAVIORAL|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
214519224|NCT02351609|OTHER|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
214519225|NCT01369147|DRUG|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
214519226|NCT01369147|DRUG|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
214519227|NCT01369147|DRUG|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
214519228|NCT01369147|DRUG|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
214519229|NCT01369147|DRUG|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
214519230|NCT03265262|DIAGNOSTIC_TEST|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
214519231|NCT06644235|OTHER|Cold Application|Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
214519232|NCT00586742|PROCEDURE|labral repair|labral repair with suture anchors
214519233|NCT00586742|PROCEDURE|biceps tenodesis|biceps tenodesis with suture anchor
215118398|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
215118399|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
214519234|NCT00586742|PROCEDURE|diagnostic arthroscopy|diagnostic arthroscopy
214519235|NCT05633849|DIETARY_SUPPLEMENT|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
214441256|NCT07078851|DEVICE|Fractional Picosecond Laser Treatment|Compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval Number: H20063466) was applied to the face. After 60 minutes, it was cleaned thoroughly in preparation for treatment. The subjects lay flat on the treatment bed, and the face was disinfected twice. Treatment was performed using the Picsure Focus Lens (Cynosure, USA, Registration Certificate Number: National Medical Device Import 20153242702) with the following parameters: 6mm spot size, focus filter, 755nm wavelength, energy of 6.0J/cm², and 2Hz frequency. The endpoint response was skin flushing and mild edema. Immediately after the operation, recombinant human epidermal growth factor (Kanghesu, 20000IU/4ml/vial, Shanghai Haohai Biological Technology Co., Ltd.) was applied externally, followed by wet compresses with saline gauze combined with cold spray for 30 minutes. The subjects were required to apply recombinant human epidermal growth factor to the entire facial skin twice a day (one vial each
214441257|NCT07078851|DEVICE|gold microneedle treatment|The face was topically anesthetized with compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval No. H20063466). After 60 minutes, the cream was cleaned off thoroughly to prepare for treatment. The subject was positioned supine on the treatment bed, and the face was disinfected twice. Gold microneedle radiofrequency treatment was performed using the NDPRD00009-E 3DEEP Phased RF治疗仪 (Eedy Med, Israel). The gold microneedle handpiece was disinfected with 95% medical ethanol. Under sterile conditions, the microneedle tips were installed, and the treatment parameters were set as follows: Cheeks mode with Intensif method, microneedle length 0.8-2.0 mm (length \<1.5 mm for forehead, temporal region, and zygomatic bone prominences); RF output time 180 ms; RF power 6-16 W. The operator held the device vertically and applied it evenly across the treatment area in a grid pattern, ensuring gentle contact with the skin to avoid excessive pressure. Any untreated gaps
214441258|NCT07077408|OTHER|iCanCope-NF Youth app|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth.
214441259|NCT07077408|OTHER|iCanCope-NF Youth app + CM|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth. In addition to the standardized orientation and push notifications, this app will also allow users to earn incentives aligned with their program engagement.
214519236|NCT05633849|DIETARY_SUPPLEMENT|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
214441260|NCT07078669|DEVICE|Polyglactin 910 (Dyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture dyed (violet) with colorants such as D\&C Violet No. 2 present.
214441261|NCT07078669|DEVICE|Polyglactin 910 (Undyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture Undyed
214441262|NCT05774483|PROCEDURE|Sentinel Node Biopsy|The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
214441263|NCT05774483|PROCEDURE|Limited Elective Neck Dissection|Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
215118400|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
214519237|NCT06315621|DEVICE|Scanning using intraoral scanner with markers|Scanning different types of nasal defects using intraoral scanner with skin markers.
214519238|NCT06315621|DEVICE|Scanning using intraoral scanner without markers|Scanning different types of nasal defects using intraoral scanner without skin markers.
214519239|NCT06315621|DEVICE|Physical Impression|Recording different types of nasal defects using physical impressions
214519240|NCT02755948|BIOLOGICAL|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
214519241|NCT02755948|BIOLOGICAL|Influenza A/California/04/2009-likw (H1N1)|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
214519242|NCT02755948|BIOLOGICAL|Influenza A/Belgium/4217/2015 (H3N2)|Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
214519243|NCT01488240|PROCEDURE|pulsed dye laser|laser energy
214519244|NCT02411175|OTHER|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
214519245|NCT02411175|DRUG|20% ethanol|
214519246|NCT02041897|PROCEDURE|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
214519247|NCT02883985|RADIATION|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
214519248|NCT05055141|OTHER|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
214519249|NCT03419806|DRUG|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
214519250|NCT03419806|DRUG|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
214441264|NCT07077694|PROCEDURE|Root Canal Retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
214441265|NCT07077551|DRUG|NALIRIFOX|A cycle will be repeated every 14 days. G-CSF prophylaxis will be allowed after each cycle. Patients will undergo re-staging studies every 8 weeks. Patients will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
214441266|NCT06815926|DIETARY_SUPPLEMENT|Probiotic|"Food supplement based on probiotics in capsule format. Dose: 1 capsule/day.~The active capsules contain probiotic strains at ≥1×10\^9 cfu/dose and excipient."
214519251|NCT03419806|DRUG|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
214519252|NCT05146479|PROCEDURE|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
214519253|NCT00379210|BEHAVIORAL|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
214519254|NCT00379210|BEHAVIORAL|Nutrition Education course|8-week course in nutrition
214519255|NCT01598454|DRUG|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
214519256|NCT02637947|DEVICE|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
214441267|NCT06815926|DIETARY_SUPPLEMENT|Placebo|"Food supplement in capsule format. Dose: 1 capsule/day.~The placebo capsules contain only excipient (probiotics are not included)."
215118401|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
215118402|NCT00760955|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
215118403|NCT00760955|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
215118404|NCT00760955|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
215118405|NCT00760955|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
215118406|NCT06251310|DRUG|SW-682|SW-682 tablet administered orally
215118407|NCT06251310|DRUG|Combination Therapy|Appropriate combination therapy
215118408|NCT05947058|PROCEDURE|Arthroplasty|The type of hip prothesis (hemi or total; cemented or uncemented) will be at the discretion of the treating surgeon.
215118409|NCT05947058|PROCEDURE|Internal Fixation|Both fixed angle devices and multiple screws will be permitted for the internal fixation group.
215118410|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
215118411|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
215118412|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
215118413|NCT06725563|PROCEDURE|Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures|We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \&lt;6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.
215118414|NCT06725485|DRUG|Low-Dose Lidocaine|Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
215118415|NCT07049432|DRUG|N803|N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles.
215118416|NCT07053956|OTHER|Chewing Gum|Patients admitted to our outpatient clinic for bronchial asthma undergo regular FeNO measurements. If the value is ≥ 25 ppb (elevated), the patients are randomized into two groups after obtaining their consent. In the control group, a FeNO measurement is performed again after 15 minutes. In the second group, the FeNO measurement is measured again after 15 minutes of consuming sugar-free, antioxidant-containing chewing gum. The following data are then collected and documented from the patients: age, gender, height, weight, smoking status, current medication, other illnesses, whole body lung function test, and laboratory tests (eosinophils, IgE). Participation in the study will not change the course of the patient's stay in our clinic.
214441268|NCT06907485|DRUG|Aminolevulinic acid hydrochloride|Pediatric patients diagnosed with a new or recurrent brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal will receive aminolevulinic acid hydrochloride prior to surgery for resection of the brain tumor.
214441269|NCT01959698|DRUG|Carboplatin|Given IV
214441270|NCT01959698|DRUG|Carfilzomib|Given IV
214441271|NCT01959698|DRUG|Etoposide|Given IV
214441272|NCT01959698|DRUG|Ifosfamide|Given IV
214441273|NCT01959698|OTHER|Laboratory Biomarker Analysis|Correlative studies
214441274|NCT01959698|OTHER|Pharmacological Study|Correlative studies
214441275|NCT01959698|BIOLOGICAL|Rituximab|Given IV
214441276|NCT07070947|DIAGNOSTIC_TEST|sEMG|The spectral characteristics in the amplitude domain will be recorded through the root mean square (RMS, unit: μV) or the mean power frequency (MPF, unit: Hz) of the musculature to be evaluated by means of EMGs, with the electrodes placed parallel to the muscle fibers of the temporal, masseter, and suprahyoid muscles. Standardized EMGs will be recorded and compared in resting position and during maximum voluntary clenching
214441277|NCT07071077|BEHAVIORAL|Web-Based Storytelling Intervention|The Web-based storytelling group will access stories and educational materials on the study website.
214441278|NCT07071077|BEHAVIORAL|Group-Based Storytelling Plus Intervention|The storytelling plus group will watch the stories in a group setting, share their experiences and have educational sessions led by a health coach.
215118417|NCT07056946|OTHER|Fascia Iliaca Nerve Block|With the patient in the proper position, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. After a skin wheal is made, the needle is inserted in-plane
214441279|NCT07071753|BEHAVIORAL|Video tutorial|At the onset of the intervention, all participants will receive tutorial videos via text, covering Instacart account setup, online item selection, and SNAP-eligible stores, aiming to improve digital literacy in grocery shopping. The video was developed by our team, reviewed by SNAP-Ed partners, and available in English and Spanish. Despite being considered helpful during the pilot, nearly half of the participants reported not receiving or watching the tutorial video. To address this, we will call all participants within the trial's first week to provide technical assistance, including step-by-step instructions on redemption of the free delivery membership. Phone follow-ups were well-received during the pilot. Also, an intervention package will be mailed to all participants as material to be referred to in the calls and throughout the intervention. Those receiving the grocery list component will receive shopping lists and recipes printed and via SMS, to aid online grocery ordering in si
214441280|NCT07071753|BEHAVIORAL|Delivery fee waiver|All participants will receive a 12-week Instacart+ Membership e-gift card, eliminating the online delivery fee for orders \>$35.
215118418|NCT07056946|OTHER|Caudal Block Anesthesia|The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view, two hyperechoic lines will appear between the sacral cornu the superficial line is the sacrococcygeal ligament
215118419|NCT02777827|DRUG|Abediterol 0.156 μg|Dry powder for inhalation
215118420|NCT02777827|DRUG|Abediterol 2.5 μg|Dry powder for inhalation
215118421|NCT02777827|DRUG|Abediterol 0.05 μg|Pressurised metered-dose inhaler
215118422|NCT02777827|DRUG|Abediterol 0.156 μg|Pressurised metered-dose inhaler
214441281|NCT07071753|BEHAVIORAL|Texting|Participants randomized to this component will receive 2 text messages weekly via EZ text to enhance their perception of behavioral control and trust in online grocery services. Text messages, deemed acceptable during our pilot, will be actionable, informed by constructs of the Theory of Planned Behavior, and tailored to assist shoppers using Instacart delivery services. We will deliver 24 short text messages (\<160 characters), on Friday afternoons and Mondays, each with one or more of the purposes rooted in behavior change techniques: increasing salience of the benefits of online grocery, modeling steps in behavior change, giving facts to address mistrust or improve control, asking questions to promote engagement, adding anonymized quotations from the pilot participants to reinforce social norms.
214441282|NCT07071753|BEHAVIORAL|Financial incentive|"Participants randomized to this component (alone or in combination with another experimental condition) will receive $1 for each dollar spent on fresh, frozen, or canned FVL loaded onto Instacart Fresh Funds, verified based on the submitted online grocery receipt or data from Instacart. The incentive applies to online purchases only and will not be earned for in-store transactions. A maximum weekly matched incentive will be set to $10, following the local FV incentive NYC (Get the Good Stuff). Fresh Funds earned, supported by Instacart Health, is an infrastructure integrated with retailer payment systems. Incentives will only be used for purchases of healthier foods (FVL) predetermined by the research team, as it has been used by FV prescription programs."
214441283|NCT07071753|BEHAVIORAL|Grocery list with instant shoppable SNAP-Ed recipes|Participants randomized to this component will receive weekly SNAP-Ed-based meal plans with instant shoppable grocery lists tailored to household size, dietary, and cultural preferences. All recipes will emphasize FVL-based eating patterns with Hispanic cuisine influences that have FVL as primary ingredients. Grocery lists organized by store department and recipe, will reflect the nearest available in-store unit. For example, if one recipe calls for 1 cup of flour, a small flour bag will be added to the list. Weekly meal plans will be shared via text as a photo and mailed as hard copies, with instant shoppable lists generated through Instacart's List feature as a hyperlink. Links to the instant shoppable list will be shared via text. Upon clicking, grocery items will be pre-filled automatically in the participant's online shopping cart. Participants can modify items and quantities before checking out.
214519257|NCT02637947|DEVICE|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
214519258|NCT01292499|BEHAVIORAL|Psychotherapy|10 sessions (50 min)
214519259|NCT01292499|BEHAVIORAL|Psychoeducation|7 sessions + 7 phone calls
214519260|NCT01292499|BEHAVIORAL|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
215118423|NCT02777827|DRUG|Abediterol 2.5 μg|Pressurised metered-dose inhaler
215118424|NCT02777827|OTHER|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
215118425|NCT03160898|DRUG|Reldesemtiv|Oral tablet
215118426|NCT03160898|DRUG|Placebo|Oral tablet
215118427|NCT04441255|DRUG|TAK-788|TAK-788 Capsule.
215118428|NCT04527367|PROCEDURE|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
215118429|NCT00474214|BEHAVIORAL|Early hospital discharge facilitated by close nurse practitioner follow-up|
215118430|NCT04511858|OTHER|maximum effort test on a cycloergometer|5 h test on cycloergometer
215118431|NCT04511858|OTHER|maximum effort test on a treadmill|5 h test on treadmill
215118432|NCT00003917|DRUG|topotecan hydrochloride|
215118433|NCT01920308|DEVICE|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
215118434|NCT03840954|OTHER|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
215118435|NCT01250041|PROCEDURE|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
215118436|NCT01250041|PROCEDURE|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
215118437|NCT03360799|OTHER|Questionnaire Administration|Complete questionnaires
215118438|NCT01023724|DRUG|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
215118439|NCT01023724|DRUG|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
214441284|NCT03996239|BEHAVIORAL|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
214441285|NCT03996239|OTHER|plasma samples|Plasma samples will be obtained at baseline.
214441286|NCT03996239|OTHER|blood draw|fasting blood
214441287|NCT06917404|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous injection, 2 mg/kg twice weekly for 6 weeks
214441288|NCT06917404|DRUG|Placebo|Placebo, subcutaneous injection, twice weekly for 6 weeks
214441289|NCT05333471|DRUG|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
214441290|NCT06919692|BEHAVIORAL|Left lateral recumbent positioning|Left-lateral position is the recommended position of resting in pregnancy. The participants in the intervention group will be advised to practice this position with an intermittent 10-minute stretching after every hour of resting, with no more than 4-hours of this intervention per day.
214441291|NCT06915194|BEHAVIORAL|Text message|Participants receive a text message encouraging glycemic screening
214441292|NCT06915194|BEHAVIORAL|Patient portal message|Participants receive a patient portal message encouraging glycemic screening
214441293|NCT06915194|BEHAVIORAL|Mailed letter|Participants receive a mailed letter encouraging glycemic screening
214441294|NCT06920498|DRUG|PF-07941944|Oral formulation
214441295|NCT06920498|DRUG|Placebo|Oral formulation
214441296|NCT06920498|DRUG|Midazolam|Oral formulation
214441297|NCT06929663|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
214441298|NCT06164275|PROCEDURE|Biopsy|Undergo tumor biopsy
214441299|NCT06164275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214441300|NCT06164275|PROCEDURE|Computed Tomography|Undergo CT scan
214519261|NCT05711745|PROCEDURE|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
214519262|NCT02867332|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
214519263|NCT02867332|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
215118440|NCT00289926|DRUG|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
214441301|NCT06164275|DRUG|Dacarbazine|Given IV
214441302|NCT06164275|DRUG|Doxorubicin|Given IV
214441303|NCT06164275|PROCEDURE|Echocardiography|Undergo echocardiography
214441304|NCT06164275|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214441305|NCT06164275|BIOLOGICAL|Pembrolizumab|Given IV
214441306|NCT06164275|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214441307|NCT06164275|DRUG|Vinblastine|Given IV
214441308|NCT06937866|DRUG|Zanzalintinib|Three zanzalintinib doses of 40mg, 60mg or 100mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuously for 28 day cycles.
214441309|NCT06937866|DRUG|Etoposide Capsule|Oral daily for 21 days of each 28 day cycle.
214441310|NCT06937814|DIETARY_SUPPLEMENT|Humiome ® Post LB|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
214441311|NCT06937814|OTHER|Placebo|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
214441312|NCT04680065|BIOLOGICAL|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
214441313|NCT04680065|PROCEDURE|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
214441314|NCT04402294|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Participants undergo resting-state and task-based fMRI to identify individualized transcranial magnetic stimulation (TMS) targets and determine optimal and sub-optimal stimulation frequencies. Additional fMRI scans are performed after each neuromodulation phase to assess changes following three days of stimulation at the optimal and sub-optimal frequencies.
214441315|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants first receive multiple rTMS frequencies during an fMRI scan to assess brain responses and determine individualized optimal and sub-optimal stimulation frequencies. They then complete two neuromodulation intervention periods, receiving rTMS at the identified optimal and sub-optimal frequencies. Each frequency is administered over three consecutive days, with the order of conditions randomized and counterbalanced.
214441316|NCT03482245|OTHER|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 442 nm) such that it produces 1700 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject. Those subjects assigned to blue light will be asked to shine this small portable blue enriched light on themselves from 0800 to 2000 for 3 days."
214519264|NCT02867332|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
215118441|NCT00289926|DRUG|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
215118442|NCT02696759|OTHER|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
215118443|NCT02632357|OTHER|Spinal Manipulation|
215118444|NCT03314311|BEHAVIORAL|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
214519265|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
214519266|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
215118445|NCT03064971|BEHAVIORAL|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
215118446|NCT03064971|BEHAVIORAL|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
215118447|NCT03064971|BEHAVIORAL|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
215118448|NCT03658447|DRUG|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
214441317|NCT06946186|BEHAVIORAL|Virtual Senior Center - GrandPad|The Virtual Senior Center engages older adults in programs and services online with the help of a GrandPad.
214441318|NCT06946186|BEHAVIORAL|Virtual Senior Center - No GrandPad|Participants will be given information to access the website when they are able from their own phone, tablet, or computer.
214519267|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
214519268|NCT03917342|DEVICE|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
214519269|NCT04530721|OTHER|no intervention|we don't do any intervention
215118449|NCT03658447|DRUG|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
215118450|NCT02870608|OTHER|lung and liver elastography measurement of fetus|
215118451|NCT02519205|OTHER|Survey|
215118452|NCT01996280|BEHAVIORAL|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
215118453|NCT01996280|BEHAVIORAL|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
215118454|NCT02424175|BIOLOGICAL|Fecal Microbiota Transplantation|
215118455|NCT03722394|BEHAVIORAL|Pain Neuroscience Education|15 minute verbal one-on-one education session
215118456|NCT04424342|OTHER|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
215118457|NCT04424342|OTHER|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
215118458|NCT04638426|DRUG|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
215118459|NCT04638426|DRUG|Placebo of HL237 tablet|Placebo of HL237, twice a day
215118460|NCT04178720|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
215118461|NCT04178720|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
215118462|NCT04178720|DEVICE|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
215118463|NCT05482841|DIAGNOSTIC_TEST|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
215118464|NCT01813448|DRUG|Fidaxomicin|oral
215118465|NCT01813448|DRUG|Placebo|oral
214441319|NCT06951594|DEVICE|Robotic|The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It provides surgeons with consistent insertion speed and force. The system consists of a drive unit connected to a touch screen control console and foot pedal interface. The surgeon secures the base to the skull with two pre-loaded self-drilling bone screws. The drive unit is placed into the base and the adjustable drive head is coupled to a CI electrode. Before insertion begins, the surgeon selects the desired speed of insertion. the surgeon controls the electrode insertion forward and reverse motion via foot pedal while guiding the electrode array into the cochlea with standard CI instrumentation. Upon the completion of electrode array insertion, the drive head and unit are uncoupled from the electrode lead and removed from the patient for disposal.
214441320|NCT06426134|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)|1x50g ingestion of pure dGK
214519270|NCT03811743|BEHAVIORAL|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
214441321|NCT06426134|OTHER|Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride|Isocaloric carbohydrate control (active control)
214519271|NCT03811743|BEHAVIORAL|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
214441322|NCT03416088|BEHAVIORAL|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
215118466|NCT00724204|DIETARY_SUPPLEMENT|follow on formula without probiotics|A follow on formula without probiotics
214441323|NCT03416088|BEHAVIORAL|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
214441324|NCT03416088|BEHAVIORAL|Body motion|Exercise or body postural changes
214441325|NCT06785935|DEVICE|Needle knife|ultrasonography-guided percutaneous A1 pulley release using a needle knife
214441326|NCT06785935|DRUG|Corticosteroid: Betamethasone|ultrasonography-guided corticosteroid injection under the A1 pulley
214441327|NCT04932122|PROCEDURE|Dorsal wrist ganglion alone (DWG)|Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
214441328|NCT04932122|PROCEDURE|DWG/PIN|Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
214441329|NCT06702527|PROCEDURE|Mitral transcatheter edge-to-edge repair|Mitral transcatheter edge-to-edge repair with the PASCAL system
214441330|NCT06118788|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
214441331|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
214441332|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
214441333|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
214441334|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
214519272|NCT03811743|BEHAVIORAL|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
214519273|NCT00847223|DRUG|ZARNESTRA (Tipifarnib)|
214519274|NCT01525875|DRUG|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
214519275|NCT01525875|DRUG|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
214519276|NCT02509754|PROCEDURE|Atrial fibrillation catheter ablation|
214519277|NCT02509754|PROCEDURE|Rate control|Composite of optimal medical therapy and device implantation
214519278|NCT01762345|DEVICE|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
214441335|NCT06780696|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
214441336|NCT06831877|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
215118467|NCT00724204|DIETARY_SUPPLEMENT|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
215118468|NCT03209856|DRUG|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
214441337|NCT06831877|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
214519279|NCT00062270|DRUG|cisplatin|
214519280|NCT00062270|DRUG|docetaxel|
214519281|NCT00062270|DRUG|gefitinib|
214519282|NCT00062270|DRUG|gemcitabine hydrochloride|
215118469|NCT04689789|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
215118470|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
215118471|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
215118472|NCT03690895|OTHER|Retrospective survival analysis|Kaplan-Meier model
215118473|NCT03145259|DRUG|Diclofenac Epolamine Patch|patch
215118474|NCT03145259|DRUG|diclofenac sodium solution|solution
215118475|NCT02966561|BEHAVIORAL|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
214441338|NCT06833398|PROCEDURE|Arthroscopic Simple Biceps Tenotomy:|"Arthroscopic Simple Biceps Tenotomy: This procedure involves an arthroscopic release of the LHB tendon from its attachment at the superior glenoid labrum. It is a quick and simple technique that does not require implants or extensive postoperative rehabilitation. The main drawback is the potential for developing a Popeye deformity, where the biceps muscle bulges due to distal migration, as well as occasional muscle cramps."
214441339|NCT06833398|PROCEDURE|Anchor Tenotomy Technique:|Anchor Tenotomy Technique: This is a novel arthroscopic method where, after releasing the LHB tendon, it is anchored in place to prevent distal migration. The goal of this technique is to avoid the Popeye deformity and improve cosmetic outcomes while maintaining functional integrity. This procedure is technically more challenging and may involve a longer operative time compared to simple tenotomy.
214441340|NCT06475677|DEVICE|OrthoCor Advanced System|The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
214519283|NCT00062270|PROCEDURE|conventional surgery|
214519284|NCT00062270|PROCEDURE|neoadjuvant therapy|
214519285|NCT00062270|RADIATION|radiation therapy|
215118476|NCT02966561|BEHAVIORAL|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
215118477|NCT02966561|OTHER|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
215118478|NCT00781833|DEVICE|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
215118479|NCT04270539|BEHAVIORAL|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
214519286|NCT01358175|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
214519287|NCT01358175|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
214519288|NCT01358175|DRUG|Placebo|Placebo
214519289|NCT05398042|DIETARY_SUPPLEMENT|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
215118480|NCT04301544|BEHAVIORAL|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
214519290|NCT05398042|DIETARY_SUPPLEMENT|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
214519291|NCT02831088|DRUG|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
214519292|NCT02831088|DRUG|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
214441341|NCT04956341|DEVICE|Auricular acupuncture|Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.
214441342|NCT04956341|OTHER|Standard treatment|Standard treatment from Primary Care Manager (PCM) or Mental Health or both
214441343|NCT06160882|OTHER|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
214519293|NCT02831088|DRUG|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
214519294|NCT01815255|DRUG|tenofovir (TDF)|
214519295|NCT04172571|BIOLOGICAL|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
214519296|NCT04172571|DRUG|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
215118481|NCT04301544|BEHAVIORAL|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
215118482|NCT04301544|BEHAVIORAL|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
215118483|NCT02361008|DEVICE|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
215118484|NCT02361008|PROCEDURE|Surgery repair with CBP|Traditional surgery repair under the CBP.
214519297|NCT01541176|OTHER|Absence of corticotherapy post-transplantation|No study treatment
214519298|NCT01541176|DRUG|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day."
214519299|NCT00427544|DRUG|PRA-027|
214519300|NCT05072795|BEHAVIORAL|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
214519301|NCT00138645|BEHAVIORAL|MicroDiet|MicroDiet
214519302|NCT00138645|BEHAVIORAL|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
214519303|NCT05394727|DEVICE|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.
214519304|NCT05394727|DEVICE|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
214519305|NCT01263275|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
214441344|NCT06160882|PROCEDURE|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
214441345|NCT04175639|BEHAVIORAL|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
214519306|NCT01107912|DRUG|prasugrel|administered orally, daily for 12 days
214519307|NCT01107912|DRUG|clopidogrel|Administered orally, daily for 12 days
214519308|NCT01601821|DRUG|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
214519309|NCT01601821|DRUG|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
214519310|NCT02771184|DEVICE|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
215118485|NCT04177212|DEVICE|MRZF111|MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
215118486|NCT00278746|DRUG|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
215118487|NCT00278746|DRUG|ORS only|Promoted routine management of diarrhea in underfive with ORS
215118488|NCT00897455|GENETIC|DNA analysis|
214519311|NCT00834483|DEVICE|Knotless suture for wound closure|Angiotech Quill SRS
214519312|NCT00834483|DEVICE|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
214519313|NCT06150222|OTHER|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
214519314|NCT04301063|OTHER|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
214519315|NCT02158793|PROCEDURE|Craniomaxillofacial allotransplantation|Transplantation of donor face
214519316|NCT03925519|OTHER|Supervised aerobic exercise|
215118489|NCT00897455|GENETIC|mutation analysis|
215118490|NCT00897455|GENETIC|polymorphism analysis|
215118491|NCT00897455|OTHER|laboratory biomarker analysis|
215118492|NCT00897455|PROCEDURE|evaluation of cancer risk factors|
215118493|NCT00946543|RADIATION|hypofractionated radiation therapy|
215118494|NCT00946543|RADIATION|intensity-modulated radiation therapy|
215118495|NCT04725500|DEVICE|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
214519317|NCT03476525|DRUG|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
214519318|NCT06451224|OTHER|Questionnaire|Online Questionnaire
215118496|NCT04979611|DRUG|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
215118497|NCT00554047|OTHER|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
215118498|NCT00554047|OTHER|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
215118499|NCT00718692|DRUG|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
215118500|NCT01412788|PROCEDURE|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
215118501|NCT01412788|PROCEDURE|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
215118502|NCT00857857|DRUG|GW870086X|Investigational product
215118503|NCT00857857|DRUG|FP|Positive control
214519319|NCT01958346|OTHER|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
214519320|NCT01958346|OTHER|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
214519321|NCT01958346|DEVICE|Fiberoptic Intubation|
214519322|NCT01130077|BIOLOGICAL|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
214519323|NCT01130077|BIOLOGICAL|Poly-ICLC|Vaccine given every 3 weeks
215118504|NCT00857857|DRUG|Placebo|Placebo control
215118505|NCT03163901|OTHER|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
215118506|NCT02333786|OTHER|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
215118507|NCT02333786|OTHER|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
215118508|NCT05675501|DRUG|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
215118509|NCT00277784|PROCEDURE|Ultrasound examination|one ultrasound examination
215118510|NCT02023684|DRUG|control saline|Surgical bed irrigation with saline 40ml
215118511|NCT02023684|DRUG|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
215118512|NCT02023684|DRUG|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
215118513|NCT04618744|DRUG|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
214519324|NCT02562521|BEHAVIORAL|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
214519325|NCT02562521|DRUG|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
215118514|NCT04618744|OTHER|Placebo|Matching Placebo
215118515|NCT01505816|DEVICE|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
215118516|NCT02797392|BEHAVIORAL|Lifestyle intervention|1\) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
215118517|NCT00930930|DRUG|cisplatin|Given IV
215118518|NCT00930930|DRUG|everolimus|Given orally
214519326|NCT02562521|DRUG|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
215118519|NCT00930930|DRUG|paclitaxel|Given IV
215118520|NCT00930930|OTHER|placebo|Given orally
214519327|NCT02562521|BEHAVIORAL|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
215118521|NCT00930930|PROCEDURE|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
215118522|NCT02647424|DRUG|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
215118523|NCT02647424|DRUG|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
215118524|NCT02709330|DRUG|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
215118525|NCT02709330|OTHER|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
215118526|NCT04206735|OTHER|Interprofessional Education (IPE)|We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.
215118527|NCT04206735|OTHER|Usual care|Usual care of patients hospitalized with severe COPD exacerbation
215118528|NCT05234047|PROCEDURE|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
215118529|NCT05234047|PROCEDURE|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
214519328|NCT00072670|DRUG|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
215118530|NCT06394986|PROCEDURE|Hemodialysis session|Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
214519329|NCT05790317|PROCEDURE|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
214519330|NCT01259219|DRUG|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
214519331|NCT02845609|DRUG|Sialic Acid-Extended Release|Oral drug of Sialic acid
214519332|NCT02627794|DEVICE|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
214519333|NCT02627794|DEVICE|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
214519334|NCT03636958|DRUG|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
214519335|NCT03636958|DRUG|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
214519336|NCT06285578|DIETARY_SUPPLEMENT|Probiotics supplementation|Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
215118531|NCT03321084|OTHER|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
215118532|NCT03321084|OTHER|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
215118533|NCT02098798|PROCEDURE|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
215118534|NCT02098798|PROCEDURE|HD Colonoscopy + iSCAN|
215118535|NCT02098798|PROCEDURE|HD Colonoscopy + dye spray|
215118536|NCT02568761|PROCEDURE|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
215118537|NCT02568761|OTHER|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
214441346|NCT05275959|OTHER|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
214441347|NCT02977819|OTHER|Meditation practice|18 months
214441348|NCT02977819|OTHER|Learning English as a foreign language|18 months
214519337|NCT06285578|BEHAVIORAL|HIIT training|HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
214519338|NCT06285578|DIETARY_SUPPLEMENT|Placebo supplementation|Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
214519339|NCT01026441|DEVICE|Vela100 (Aesthetic)|6 treatments once a week
215118538|NCT01914263|BIOLOGICAL|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
214441349|NCT00186992|RADIATION|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
214519340|NCT03218085|DRUG|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
215118539|NCT03468244|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
215118540|NCT04809571|OTHER|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
215118541|NCT03368365|DEVICE|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
215118542|NCT03767946|DIAGNOSTIC_TEST|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
215118543|NCT01172535|DRUG|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
214441350|NCT05840055|BEHAVIORAL|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
214441351|NCT03150914|DRUG|Sirolimus|mTOR inhibitor or placebo
214441352|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)|Comparison of these micro RNAs with the micro RNAs extracted from oral swabs (in Fetal Alcohol Spectrum Disorder group)
214441353|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from bucal swabs (act added for research).|Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group
214441354|NCT06380153|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
214441355|NCT05540938|DRUG|Wangbi granules|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
214441356|NCT05540938|DRUG|Wangbi granules simulant|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
214441357|NCT06515080|DIAGNOSTIC_TEST|Near Red Infrascopy|Monitor of regional cerebral oxygen saturation
214441358|NCT06257472|DEVICE|Virtual Reality Headset|Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
214441359|NCT06106451|BEHAVIORAL|Standard of Care plus Enhanced Patient Education|Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
214441360|NCT06106451|BEHAVIORAL|Motivational Interviewing Intervention|Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
214441361|NCT06106451|BEHAVIORAL|Home-Based Activity Program plus Motivational Interviewing Intervention|Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
214441362|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
214519341|NCT03218085|DRUG|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
215118544|NCT05487222|DEVICE|ICON|hemodynamics variability in response to different fluid regiemens
215118545|NCT04157777|OTHER|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
215118546|NCT04371575|DRUG|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
215118547|NCT03008161|DRUG|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
214441363|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
214441364|NCT06313671|DIAGNOSTIC_TEST|Perfusion index|"The perfusion index (PI) is derived from the plethysmography signal and represents the ratio of pulsatile to non-pulsatile light absorbance of the plethysmography signal.~PPG signal."
214441365|NCT05609552|COMBINATION_PRODUCT|18F-Pretomanid PET/CT|A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
214441366|NCT05152394|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
214441367|NCT06474611|BEHAVIORAL|Patient nudge|Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
214441368|NCT06472414|BEHAVIORAL|Individualized Counselling Sessions|Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
215118548|NCT03008161|DRUG|Placebo|Placebo
215118549|NCT05800223|DRUG|Almonertinib|The dosage is 110 mg/day (2 tablets/day) orally once a day
214441369|NCT06472414|BEHAVIORAL|Educational Women-Focused Sessions|Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.
214441370|NCT06472414|BEHAVIORAL|Supervised Exercise Training Sessions|Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
214441371|NCT05189418|DEVICE|Ambulatory blood pressure monitoring (ABPM)|Periodic (quarterly) 48h ABPM evaluation during follow-up
214441372|NCT05189418|DEVICE|Home blood pressure monitoring (HBPM)|Periodic (monthly) 7-day HBPM, both during awake and sleep spans, during follow-up
215118550|NCT05800223|RADIATION|SBRT|SRT, 27Gy-40Gy/3-5f
215118551|NCT06006650|DRUG|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
215118552|NCT04977440|DIETARY_SUPPLEMENT|Whey protein|"Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given"
215118553|NCT05754723|BEHAVIORAL|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
215118554|NCT01683799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
215118555|NCT04256824|DRUG|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
215118556|NCT04256824|DRUG|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
215118557|NCT00988598|DRUG|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
215118558|NCT00988598|DRUG|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
215118559|NCT04591938|DEVICE|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
214441373|NCT04343703|BEHAVIORAL|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
214441374|NCT04343703|BEHAVIORAL|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
214519342|NCT03610984|OTHER|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
215118560|NCT02347397|DEVICE|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem
215118561|NCT02347397|DEVICE|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
215118562|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR)|Imagery rescripting (IR) is a technique where the individual is instructed to imagine a negative memory or image as vividly as possible, and to change it in a direction that he/she desires. IR seems particularly efficient because it is based on the experienced emotions during perceptual information processing, thereby eliciting stronger emotional responses than verbal processing.
215118563|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR) and Targeted Memory Reactivation (TMR) during sleep|Targeted Memory Reactivation (TMR) is a technique used to strengthen a memory trace during sleep. TMR is used to modify memory formation through the application of cues during sleep. In this TMR protocol, an olfactory cue is associated with the imagery rescripting (IR) during the day, and then administered during sleep. In that way, the replay of the associated memory and its corresponding neural representation in memory networks are artificially promoted, a procedure which usually strengthens memory consolidation. Previous studies have shown that TMR in sleep reduces emotional arousal, making it a promising technique for insomnia.
215118564|NCT06335784|BEHAVIORAL|Sleep Hygiene|Sleep hygiene education includes modifications in the behavior (e.g., exercise, coffee, alcohol intake) and environment (e.g., light, noise, temperature conditions) that offer to the individual the foundation for healthy sleep. Sleep hygiene is an important component in treating ID, but insufficient and less effective than CBT-I when offered alone.
215118565|NCT06335784|BEHAVIORAL|Sleep Hygiene + Odor|Sleep hygiene instructions will be applied in the presence of an odor, which will be also used during the night.
215118566|NCT06335784|OTHER|"Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention"|Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.
214441375|NCT04343703|BEHAVIORAL|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
214441376|NCT04343703|BEHAVIORAL|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
214441377|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
214441378|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
214441379|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
214441380|NCT05868330|PROCEDURE|Interscalene Catheter|Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol
214441381|NCT05868330|PROCEDURE|Exparel Single Shot Interscalene Block|Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
214441382|NCT03769168|DRUG|Secukinumab|Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.
214441383|NCT05215756|DEVICE|transcutaneous vagal nerve stimulation|The tVNS device will be attached to the left concha of the ear to stimulate the auricular branch of the vagal nerve. Each stimulation will last for 2 minutes.
214441384|NCT06418321|DEVICE|Investigational device|The participants' hearing status will be evaluated using the investigational device.
214441385|NCT06418321|OTHER|Audiometer|Participants' hearing thresholds are tested with an audiogram.
214441386|NCT06418321|DEVICE|Otomicroscopy|The status of the participants' ear canals and tympanic membranes are checked.
214441387|NCT06418321|OTHER|REM (Real Ear Measurements)|The acoustic properties of the participants' ears will be measured during the interventions.
214441388|NCT05849012|OTHER|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
214441389|NCT05849012|OTHER|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
214441390|NCT06144827|DEVICE|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
214441391|NCT06144827|DEVICE|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
214441392|NCT05369299|DEVICE|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
214441393|NCT05369299|DEVICE|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
214519343|NCT00378456|DRUG|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
215118567|NCT03974386|DEVICE|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
214519344|NCT00378456|DRUG|Folinic acid|
214519345|NCT00378456|DRUG|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
214519346|NCT00378456|DRUG|Placebo|
214519347|NCT05202444|PROCEDURE|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
215118568|NCT02233972|DRUG|Midazolam|
215118569|NCT02233972|DRUG|Ginkgolides Meglumine Injection|
215118570|NCT02233972|DRUG|placebo|
214519348|NCT05590026|DRUG|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
214519349|NCT03000725|BEHAVIORAL|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
215118571|NCT04316559|OTHER|Placebo|Placebo capsule
214519350|NCT03000725|BEHAVIORAL|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
214519351|NCT01448928|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
214519352|NCT00442559|DRUG|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
215118572|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
215118573|NCT02938208|DEVICE|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
215118574|NCT02393937|DRUG|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
215118575|NCT02393937|DRUG|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
215118576|NCT02393937|DRUG|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
215118577|NCT04393402|PROCEDURE|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
214441394|NCT05938296|DRUG|BS006 Injection|BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
214441395|NCT03117751|DRUG|Prednisone|Given orally (PO).
214441396|NCT03117751|DRUG|Vincristine|Given intravenously (IV).
214441397|NCT03117751|DRUG|Daunorubicin|Given IV.
214441398|NCT03117751|DRUG|Pegaspargase|Given IV or intramuscularly (IM) .
214441399|NCT03117751|DRUG|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
214441400|NCT03117751|DRUG|Cyclophosphamide|Given IV.
214441401|NCT03117751|DRUG|Cytarabine|Given IV or by subcutaneous injection (SQ).
214441402|NCT03117751|DRUG|Mercaptopurine|Given PO.
214441403|NCT03117751|DRUG|Dasatinib|Given PO.
214441404|NCT03117751|DRUG|Methotrexate|Given IV.
214441405|NCT03117751|DRUG|Blinatumomab|Given IV.
214441406|NCT03117751|DRUG|Ruxolitinib|Given PO.
214441407|NCT03117751|DRUG|Bortezomib|Given IV or subcutaneously (SQ).
214441408|NCT03117751|DRUG|Dexamethasone|Given PO.
214441409|NCT03117751|DRUG|Doxorubicin|Given IV.
214441410|NCT03117751|DRUG|Etoposide|Given IV.
214441411|NCT03117751|DRUG|Clofarabine|Given IV.
214441412|NCT03117751|DRUG|Vorinostat|Given PO.
214441413|NCT03117751|DRUG|Idarubicin|Given IV.
214441414|NCT03117751|DRUG|Nelarabine|Given IV.
214519353|NCT00442559|DRUG|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
214441415|NCT03117751|DRUG|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
214441416|NCT03117751|DRUG|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
214441417|NCT03117751|DRUG|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
214441418|NCT01698840|DIETARY_SUPPLEMENT|Vitamin D|
214441419|NCT01698840|DIETARY_SUPPLEMENT|Placebo|
214441420|NCT05093179|PROCEDURE|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
214441421|NCT05093179|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
214441422|NCT06517771|OTHER|Online aerobic exercise|Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
214441423|NCT05344378|BEHAVIORAL|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
214441424|NCT06083064|DIAGNOSTIC_TEST|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
214441425|NCT06083064|OTHER|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
214441426|NCT06083064|OTHER|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
214441427|NCT05478525|DRUG|GLY-200|0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
214441428|NCT05478525|DRUG|GLY-200|1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
214441429|NCT05478525|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
214441430|NCT05478525|DRUG|Placebo|1 placebo capsule BID for 14 days (n=4)
214441431|NCT05478525|DRUG|Placebo|2 placebo capsules BID for 14 days (n=4)
214441432|NCT05478525|DRUG|Placebo|4 placebo capsules BID for 14 days (n=4)
214441433|NCT06129409|DRUG|NT-0796|Orally administered capsules
214441434|NCT04375605|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
214441435|NCT04375605|DRUG|Calcium folinate|Day 1 q2w: 200 mg/m² IV over 2 hours
214441436|NCT04375605|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
214441437|NCT04375605|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 2 hours
214441438|NCT04375605|RADIATION|Radiation|25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy
214441439|NCT04375605|DRUG|Oxaliplatin during radiotherapy|Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours
214519354|NCT02267122|PROCEDURE|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
214519355|NCT02267122|PROCEDURE|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
214519356|NCT02296307|OTHER|Blood test: CA-125 biomarker|"* CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6."
214519357|NCT02296307|OTHER|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
214519358|NCT02296307|OTHER|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
214519359|NCT01645241|DRUG|gonadotropins plus GnRH antagonists|
215118578|NCT03859271|BEHAVIORAL|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
215118579|NCT03859271|BEHAVIORAL|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
214441440|NCT04375605|DRUG|5-Fluorouracil during radiotherapy|day 1 - 33: 225 mg/m²/day IV continuously
214519360|NCT01645241|DRUG|ganirelix|
215118580|NCT00038064|DRUG|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
215118581|NCT00038064|DRUG|rHuEPO|150 IU/kg TIW
215118582|NCT00659074|DRUG|Ondansetron|ODT, single-dose, fasting
215118583|NCT00659074|DRUG|Zofran|ODT, single-dose, fasting
214441441|NCT05647252|DRUG|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
215118584|NCT06434181|DIETARY_SUPPLEMENT|Beetroot Juice|Beet-It Sports Shot, 70mL, containing 6.5 mmol nitric oxide (taking two shots per day in active group)
214441442|NCT05647252|BEHAVIORAL|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
214519361|NCT01318356|BEHAVIORAL|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
214441443|NCT01489813|DRUG|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
214441444|NCT01489813|DRUG|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
214519362|NCT01318356|DRUG|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
214519363|NCT01318356|DRUG|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
214519364|NCT05780957|OTHER|MCED|multi-cancer early detection (MCED) test
214519365|NCT02617459|DRUG|Levobetaxolol eye drops|one drop per time; twice daily
214519366|NCT02617459|DRUG|Betaxolol eye drops|one drop per time; twice daily
215118585|NCT06434181|DIETARY_SUPPLEMENT|Placebo Control|Beet-It Placebo Shot, 70mL (taking two shots per day in placebo group)
215118586|NCT02916901|DRUG|CKD-519 200mg|
215118587|NCT02916901|DRUG|Placebo|
215118588|NCT01034930|PROCEDURE|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
215118589|NCT00137514|DRUG|chloroquine|
215118590|NCT00137514|DRUG|amodiaquine|
215118591|NCT04818970|DEVICE|Narrow Band ultraviolet B-Band Light|Daily doses of NB-UVB for 8 consecutive days.
215118592|NCT04818970|DEVICE|non Narrow Band ultraviolet B-Band Light|Daily doses of non-NB-UVB for 8 consecutive days.
215118593|NCT02203695|DRUG|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
215118594|NCT02203695|RADIATION|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
215118595|NCT04317040|DRUG|Efprezimod alfa|Efprezimod alfa is given on Day 1.
215118596|NCT04317040|DRUG|Placebo|Placebo is given on Day 1.
214441445|NCT06138093|DEVICE|Sealing device|Intratracheal tracheostomy sealing
214441446|NCT06138093|DEVICE|No device|Open tracheostomy wound
214441447|NCT05644002|BEHAVIORAL|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
214441448|NCT05644002|BEHAVIORAL|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
214441449|NCT04913870|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers treatment for 2 years.
215118597|NCT03918421|OTHER|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
215118598|NCT01177007|DEVICE|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
215118599|NCT06531486|OTHER|XS-02 capsules|Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.
215118600|NCT00004092|BIOLOGICAL|filgrastim|Given IV or subcutaneously
215118601|NCT00004092|DRUG|carboplatin|Given IV
214441450|NCT04913870|OTHER|Placebo|Placebo administration for 2 years.
214441451|NCT04842500|BEHAVIORAL|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
214519367|NCT05343936|OTHER|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
214519368|NCT01579955|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
215118602|NCT00004092|DRUG|cyclophosphamide|Given IV
215118603|NCT00004092|DRUG|doxorubicin hydrochloride|Given IV
215118604|NCT00004092|DRUG|paclitaxel|Given IV
215118605|NCT00004092|DRUG|thiotepa|Given IV
215118606|NCT00004092|PROCEDURE|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
215118607|NCT02509923|DRUG|Z-215 10mg|Z-215 10mg, capsules
215118608|NCT02509923|DRUG|Z-215 20mg|Z-215 20mg, capsules
214441452|NCT05636553|OTHER|Massage|Individualised treatment using massage techniques such as longitudinal gliding, transverse gliding, digital ischemic pressure, transverse frictions, and transverse gliding.
214441453|NCT05532059|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
214441454|NCT05532059|DRUG|gemcitabine and cisplatin|gemcitabine and cisplatin
214519369|NCT02699619|DEVICE|Pinloc|3 hook pins interlocked in plate.
214519370|NCT02699619|DEVICE|2 Hansson pins|2 isolated hook pins.(Without plate)
214519371|NCT05224388|DRUG|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
214519372|NCT05224388|DRUG|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
214519373|NCT03379597|DRUG|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
214519374|NCT03379597|DIETARY_SUPPLEMENT|Dietary fiber|dietary fiber compound powder 30g bid
214519375|NCT01049815|DRUG|sevelamer hydrochloride|800-3200 mg with each meal
214519376|NCT01049815|DRUG|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
215118609|NCT02509923|DRUG|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
215118610|NCT02509923|DRUG|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
214441455|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
214441456|NCT06493851|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel."
214441457|NCT06582589|DEVICE|Healsea Children|Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
214441458|NCT03396341|OTHER|Salvia sample|salvia sample
214441459|NCT03396341|BEHAVIORAL|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
214519377|NCT04151030|PROCEDURE|PEG placement|Push PEG placement
214519378|NCT02754375|PROCEDURE|rTMS|
215118611|NCT05083533|BEHAVIORAL|tele-rehabilitation exercise|"Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Treatment program planned to stretch the muscles of individuals with short hamstring muscle group.~Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions."
214519379|NCT00175253|DRUG|alemtuzumab|
215118612|NCT05083533|BEHAVIORAL|Home exercise|All participants received home exercise for 8 weeks. The exercise program includes stretching exercises Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.
215118613|NCT00059345|PROCEDURE|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
215118614|NCT00059345|PROCEDURE|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
215118615|NCT00059345|OTHER|Usual Care|Usual care for knee osteoarthritis
215118616|NCT01961271|DRUG|Buprenorphine transdermal patch|Please see Arm Description.
215118617|NCT01732276|DRUG|gefitinib|
215118618|NCT00002043|DRUG|Dapsone|
214441460|NCT05978414|OTHER|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
215118619|NCT05376631|PROCEDURE|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
215118620|NCT05376631|PROCEDURE|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
215118621|NCT02186574|DRUG|Tenofovir disoproxil|
215118622|NCT02186574|DRUG|Placebo Oral Tablet|
215118623|NCT04603261|DIAGNOSTIC_TEST|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
215118624|NCT04800458|BIOLOGICAL|Blood samples|"* Thrombopoietin : 7 ml whole blood.~* Anti-platelet antibodies free : 14 ml whole blood.~* Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
215118625|NCT02962167|BIOLOGICAL|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
215118626|NCT02962167|BIOLOGICAL|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
215118627|NCT03782233|DRUG|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
215118628|NCT03782233|DRUG|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
215118629|NCT04917965|OTHER|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
215118630|NCT02738749|DEVICE|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
215118631|NCT00755495|DRUG|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
214441461|NCT05978414|OTHER|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
214441462|NCT06564610|PROCEDURE|Transversus abdominis block|The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
214519380|NCT00175253|PROCEDURE|islet transplant|
214519381|NCT01508117|DRUG|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
214519382|NCT01508117|RADIATION|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
214519383|NCT00882856|DRUG|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
214519384|NCT00882856|DRUG|Placebo|placebo
214519385|NCT02618876|DRUG|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
214519386|NCT02618876|DRUG|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
214519387|NCT01597856|BEHAVIORAL|SBIRT|"SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback."
214519388|NCT01979211|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
214519389|NCT01979211|RADIATION|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
215118632|NCT00755495|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
214519390|NCT03944889|DRUG|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
214519391|NCT03944889|DEVICE|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
214519392|NCT03944889|DEVICE|Cadwell Sierra Wave|Intramuscular EMG recording machinery
214519393|NCT03944889|DEVICE|Sonosite Ultrasound Machine|Ultrasound System
214519394|NCT03944889|DEVICE|Goniometer|A device to measure angular position
214519395|NCT00579020|DRUG|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
214519396|NCT00579020|DRUG|Moxifloxacin ophthalmic solution 0.5%|
215118633|NCT00755495|DRUG|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
215118634|NCT00755495|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
214519397|NCT00579020|DRUG|Dexamethasone phosphate solution, 0.1%|
215118635|NCT00335400|DRUG|Anesthetic Dilating Gel|
215118636|NCT00311935|PROCEDURE|method of hernia repair|
214441463|NCT06564610|PROCEDURE|Erector spinae block|The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
214441464|NCT06564610|PROCEDURE|Bariatric surgery|Laparoscopic bariatric procedure will be performed
214441465|NCT06564610|DEVICE|Endotracheal intubation|An endotracheal tube will be inserted as a part of general anesthesia to all patients
214441466|NCT06564610|DRUG|Propofol|The patients will receive propofol for induction of anesthesia
214441467|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
214441468|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
214441469|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
214441470|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
214441471|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
214519398|NCT02531061|DEVICE|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
215118637|NCT01204749|DRUG|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
215118638|NCT01204749|DRUG|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
215118639|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
215118640|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
215118641|NCT02996149|PROCEDURE|Endoscopic lung volume reduction coil treatment|
214441472|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
214441473|NCT04799197|BEHAVIORAL|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
214441474|NCT04032535|DRUG|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
214519399|NCT05978089|DRUG|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
214519400|NCT05978089|DRUG|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
214519401|NCT03956771|BEHAVIORAL|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
214519402|NCT03956771|BEHAVIORAL|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
214519403|NCT00509314|BEHAVIORAL|melanocyte self-assembly and functional analysis|
214519404|NCT04347889|DRUG|Hydroxychloroquine|Oral loading dose followed by once weekly dosing
214519405|NCT04347889|OTHER|Vitamin C|Once daily vitamin C 1 gm
214519406|NCT00753896|DRUG|exenatide|subcutaneous injection, 2.0mcg, once weekly
214519407|NCT04927949|DRUG|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
214519408|NCT04927949|PROCEDURE|standard PCI|primary PCI without cangrelor
214519409|NCT02959866|OTHER|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
214519410|NCT00149565|DRUG|IFN-α2b|
214519411|NCT00952523|DRUG|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
214519412|NCT00952523|DRUG|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
214519413|NCT00416585|DRUG|isotretinoin (Roaccutane)|
214519414|NCT05718492|PROCEDURE|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
214519415|NCT05718492|DRUG|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
214519416|NCT05540951|DRUG|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
214519417|NCT05540951|DRUG|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
214519418|NCT05771272|DIAGNOSTIC_TEST|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
214519419|NCT05771272|DIAGNOSTIC_TEST|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
214519420|NCT03708744|DRUG|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
214519421|NCT03708744|DRUG|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
214519422|NCT03708744|DRUG|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
215118642|NCT04775563|OTHER|COVID-19 vaccine hesitancy scale in rheumatic diseases|The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
214441475|NCT06521840|DEVICE|Masimo RAD 67|This is an observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture). The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone.
214519423|NCT03708744|DRUG|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
215118643|NCT04775563|OTHER|COVID-19 vaccine hesitancy associated factors|The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
215118644|NCT02650765|OTHER|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
215118645|NCT03097965|DIETARY_SUPPLEMENT|PROGRAM|
214519424|NCT02391766|BEHAVIORAL|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
215118646|NCT03097965|OTHER|DIET|
214519425|NCT02391766|BEHAVIORAL|usual care|
214519426|NCT00512265|DRUG|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
214519427|NCT00512265|DRUG|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
214519428|NCT05993247|COMBINATION_PRODUCT|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
214519429|NCT05993247|COMBINATION_PRODUCT|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
214519430|NCT03404440|OTHER|L.Reuteri|
214519431|NCT05541341|OTHER|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
214519432|NCT02158845|DRUG|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
214519433|NCT02158845|DRUG|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
214519434|NCT03405480|OTHER|Rehabilitation|Rehabilitation
214519435|NCT06211751|DRUG|TQB3909 tablets|TQB3909 is a protein inhibitor.
214519436|NCT06211751|DRUG|TQB3702 tablets|TQB3702 is a kinase inhibitor.
214441476|NCT05943743|OTHER|Google form|"* Self-administrated Questionnaire will be used for online survey. A pilot study was conducted on 30 sample size to check the reliability of questionnaire via statistical test.~* A Five-point Likert scale (strongly disagree, disagree somewhat, Neutral, agree somewhat, strongly agree)"
214441477|NCT06815484|OTHER|Intervention group with physical activity programme|Programme comprising active breaks to be incorporated into daily life, supervised group physical activity sessions with personalised advice and a motivational interview with a physical activity professional to encourage regular physical activity.
215118647|NCT06264739|DRUG|esp Dexmedetomidine (dekstomid)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
214441478|NCT06815484|OTHER|Recommendations of the World Health Organisation|The World Health Organisation's recommendations on physical activity, which recommend at least 150 minutes a week of moderate-intensity activity or 75 minutes of high-intensity activity, and highlight the importance of limiting sedentary behaviour.
214441479|NCT06815393|OTHER|Intratechal Morphine|Prior to induction, the patient will be positioned seated, and morphine will be slowly injected intrathecally at a dose of 5 μg/kg, adjusted to the L4-L5 or L3-L4 intervertebral space using a 27G pencil point spinal needle. The injection will be administered over approximately 10 seconds
214441480|NCT06815393|OTHER|Transversalis Fascia Plane Block|Prior to induction, patients will be positioned supine, and bilateral transversus abdominis plane (TAP) block will be performed with the aid of ultrasound. As the blocking agent, 20 cc of 0.25% bupivacaine will be used bilaterally.
214441481|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Standard of care targeted therapy
214441482|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Second-line targeted therapy
214441483|NCT04437498|DEVICE|sham stimulation|non invasive vagal nerve stimulation
215028678|NCT02957240|BEHAVIORAL|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
214441484|NCT04437498|DEVICE|nVNS|active vns stimulation
214441485|NCT02347995|OTHER|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
214441486|NCT02347995|OTHER|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
214441487|NCT05104697|DEVICE|Transcranial Magnetic Stimulation|All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
214441488|NCT06320743|DEVICE|NIRS ,Ventilation parameters|"NIRS ,Ventilation parameters :~Until the patient is taken to the operating table and leaves the operating table routine monitoring parameters, BIS values ,cerebral and peripheral NIRS values, until the patient is intubated and extubated ventilation parameters These parameters; 0. min (before induction), 1. min after induction, pre-post intubation, 5. min, 10. min, 20. min, 30. min, 45. min, 60. min, 90. min after connecting to the ventilator. It will then be noted at 1 hour intervals, and finally at the 5th minute after extubation."
214441489|NCT06320743|DEVICE|Oxygen concentration|"Oxygen concentration :~Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%"
214441490|NCT06390163|OTHER|Sensory-Motor Integration Training|An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
215118648|NCT06264739|DRUG|esp remifentanyl (ultiva)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
214519437|NCT02951806|DRUG|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
214519438|NCT02951806|DRUG|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
214441491|NCT06755294|PROCEDURE|Vestibular incision subperiostal tunnel technique|"The VISTA (Vestibular Incision Subperiosteal Tunnel Access) technique is a minimally invasive surgical approach for root coverage. A single vertical incision is made, often at the labial frenulum for optimal access, reaching the periosteum to elevate a subperiosteal tunnel. This tunnel is extended beyond the mucogingival junction and interproximally under each papilla to enable tension-free coronal repositioning of the gingiva.~An autologous connective tissue graft, harvested and de-epithelialized from the palate, is introduced into the tunnel. Before placement, teeth are etched (orthophosphoric or hydrofluoric acid depending on surface type). Sutures (6-0 polypropylene) stabilize the graft, with additional composite fixation on treated teeth. The vertical incision is closed using 5-0 sutures, ensuring proper stabilization and healing. This approach minimizes trauma, promotes healing, and achieves effective root coverage."
214519439|NCT01891006|DEVICE|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
214519440|NCT01891006|OTHER|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
215118649|NCT01440088|DRUG|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
215118650|NCT01440088|DRUG|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
214519441|NCT04904731|OTHER|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
215118651|NCT01978496|DRUG|Placebo|matching placebo
215118652|NCT01978496|DRUG|Eletriptan 20 mg|20mg oral
215118653|NCT01978496|DRUG|Eletriptan 40 mg|40mg oral
215118654|NCT01978496|DRUG|Eletriptan 80 mg|80mg oral
215118655|NCT02470520|PROCEDURE|CRRT|continuous renal replacement therapy
215118656|NCT01231919|DRUG|Akt inhibitor MK2206|Given PO
215118657|NCT01231919|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
215118658|NCT01231919|OTHER|pharmacological study|Correlative studies
215118659|NCT05505344|DEVICE|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
215118660|NCT04308941|DIAGNOSTIC_TEST|Intraocular pressure|The intraocular pressure will be measured using one of three devices
215118661|NCT02883803|BIOLOGICAL|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
215118662|NCT02883803|BIOLOGICAL|Injection of albumin alone|Injection of albumin alone
214519442|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
214519443|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
214519444|NCT04945616|DRUG|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
214519445|NCT03529942|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
214519446|NCT05656937|PROCEDURE|internal jugular venous cannulation|internal jugular venous cannulation
214519447|NCT03236727|DRUG|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
214519448|NCT00002094|DRUG|Atevirdine mesylate|
215118663|NCT02133898|OTHER|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
215118664|NCT03703544|OTHER|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
215118665|NCT03703544|OTHER|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
214441492|NCT06755294|PROCEDURE|CAF|"The Coronally Advanced Flap (CAF) is an effective technique for root coverage in single or multiple gingival recession cases with adequate apical keratinized tissue thickness and height. Following the De Sanctis and Zucchelli protocol (2007), two horizontal incisions are made 3 mm apart, with placement 1 mm apical to the recession height. Vertical beveled incisions extend into the alveolar mucosa, and a flap is elevated in three stages: partial thickness at the papilla, full thickness to the buccal bone table, and apical partial thickness to release muscle fibers for mobility.~An autologous connective tissue graft (≥1 mm thick) is harvested from the palatal or retromolar area, de-epithelialized, and shaped to the recession size. The anatomical papillae are de-epithelialized, and the graft is sutured apically to the CEJ using 6-0 Polyglactin 910. Sling sutures (6-0 polypropylene) stabilize the flap 2 mm coronally to the CEJ, ensuring optimal positioning and healing."
214441493|NCT06765096|OTHER|Educational Virtual Reality Model|Participants will receive one session on educational virtual reality (VR) model for pelvic floor anatomy.
214441494|NCT06785584|DRUG|Ensartinib|receive neoadjuvant treatment with ensartinib 225 mg once a day, po. for 2 consecutive cycles (56 days) to evaluate possibility of surgery, or discontinue the treatment because of disease recurrence or intolerable toxicity
214519449|NCT03684499|OTHER|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
214519450|NCT03684499|OTHER|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
214519451|NCT02570971|DRUG|Mannitol|
215118666|NCT05437523|OTHER|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
215118667|NCT05437523|OTHER|Standard of care without constipation action plan|Standard of care without constipation action plan
215118668|NCT01366326|DRUG|Methylnaltrexone bromide|Subcutaneous MNTX
215118669|NCT06369974|DRUG|Antisense oligonucleotide treatment (ASO)|Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
215118670|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
215118671|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
215118672|NCT00195949|PROCEDURE|Laparoscopic pyloromyotomy|
215118673|NCT02332174|DRUG|rufinamide|comparison of different doses, sex and medication conditions
215118674|NCT03133507|BEHAVIORAL|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
215118675|NCT03133507|BEHAVIORAL|Reassurance Condition|Children will be reassured by the experimenter .
215118676|NCT03133507|BEHAVIORAL|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
215118677|NCT04252131|DRUG|cassia seed tablet|traditional Chinese herbs
215118678|NCT02059226|BEHAVIORAL|cognitive behavioural therapy|Internet-based CBT
215118679|NCT02059226|OTHER|Internet-based resource page|Static webpage
215118680|NCT01207258|BEHAVIORAL|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
215118681|NCT03740659|DRUG|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
214441495|NCT03845465|BEHAVIORAL|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
214441496|NCT03845465|BEHAVIORAL|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
214441497|NCT06782503|OTHER|Mind-Body Medicine Training Program|"The 4-day training includes lectures and small group participation. Lecture topics cover information on a variety of mind--body techniques and the small groups allow participants to practice the techniques. The 2-day practicum will teach staff the ways in which they can share the skills they have learned one-on-one with parolees and families of parolees. The practicum lectures will provide a review of the mind-body skills and examples of practical applications. The practicum will also include breakout sessions to allow participants to practice their skills. The four 2-hour group consultation sessions will allow time for the trained staff to share their experiences as they teach these skills to others and ask any questions that may arise. These consultations will support the ongoing sharing of mind-body medicine skills with the parolees and the families of parolees.~Edit"
214441498|NCT02939573|DRUG|Colchicine|Randomized to colchicine 0.6 mg x 2/day
214441499|NCT02939573|DRUG|Dapsone|Randomized to dapsone 150 mg/day
214441500|NCT02939573|DRUG|Azathioprine|Randomized to azathioprine 2 mg/kg/day
214441501|NCT06411574|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
214441502|NCT06834737|OTHER|ecological sampling method|6-item diary, twice a day, over the course of 2 months.
214441503|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
214441504|NCT06829511|OTHER|Questionnaire and Physical Exam|Cardiac Self-Efficacy Scale (CSES) 36-Item Short Form Survey (SF-36) Symptom Distress Scale (SDS)
214441505|NCT06783517|PROCEDURE|cerabone|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone graft (cerabone®,Botiss biomaterial) will be added to the implant
214441506|NCT06783517|PROCEDURE|cerabone®plus|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone substitute with sodium hyaluronate graft (cerabone®plus,Botiss biomaterial) will be added to the implant
214441507|NCT06214351|OTHER|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
214441508|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
214441509|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
214441510|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
214441511|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
214441512|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
214441513|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
214441514|NCT06789575|DRUG|Bupivacaine|the patients will receive the content of a syringe (10 ml of bupivacaine 0.25%)
214441515|NCT06789575|DRUG|Adrenaline|the patients will receive the content of a syringe 15 μg adrenaline
214441516|NCT06789575|DRUG|Lidocaine (drug)|the patients will receive the content of a syringe 70 ml Lidocaine .
214441517|NCT06792032|OTHER|peer mentoring with mobile application|peer mentoring with mobile application
214441518|NCT06791785|OTHER|Before Application|All groups will be asked to fill out forms before the application (Westside test anxiety scale, burdon attention test, descriptive information form)
214441519|NCT06791785|OTHER|Before the 1st Written Exam|Fill out forms before the 1st written exam (Westside test anxiety scale, burdon attention test, descriptive information form)
214441520|NCT06791785|OTHER|End of Term|Fill out forms at the end of the term (Westside test anxiety scale, burdon attention test, descriptive information form)
214519452|NCT00956527|BEHAVIORAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
214519453|NCT04449445|DIETARY_SUPPLEMENT|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
214519454|NCT04449445|DIETARY_SUPPLEMENT|Nestle IMPACT AR|Dietary supplement
215118682|NCT03740659|DRUG|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
215118683|NCT03740659|DRUG|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
215118684|NCT06502548|PROCEDURE|Endometriosis|"Anatomopathology waste will be recovered, i.e. the remainder of the endometriosis lesions and the remainder of the endometrial biopsy.~A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up."
215118685|NCT06502548|PROCEDURE|Tubal ligation or Hysterectomy|During surgery, an endometrial biopsy will be taken for research purposes. A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.
215118686|NCT04438395|DEVICE|Cardiac ablation via catheter|Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
214519455|NCT04364035|BIOLOGICAL|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
214519456|NCT04364035|BIOLOGICAL|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
214519457|NCT04364035|DRUG|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
214441521|NCT06792097|DIAGNOSTIC_TEST|Ga-68 Dolacga PET scan|"Contrast Name: Nuclear Medicine Dolacga (Lyophilized product for the preparation of gallium Ga68 Dolacga injection).~Active Ingredient, Dosage, Route: NOTA-Hexa lactoside (INER038), 40 micrograms, IV injection.~PET Imaging Schedule: Before radiofrequency ablation therapy, one month after ablation therapy, and follow-up every three months thereafter."
214441522|NCT05256862|OTHER|Data collection|"Data collection~* on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~* on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
214441523|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
214441524|NCT06029179|DRUG|sodium zirconium cyclosilicate (SZC)|60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
214519458|NCT04364035|BIOLOGICAL|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
214519459|NCT04364035|DRUG|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
214519460|NCT04379310|DRUG|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
214519461|NCT03466645|DRUG|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
214519462|NCT03466645|DRUG|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
214519463|NCT01483131|OTHER|Exercise training|12 weeks of resistance training twice a week.
214519464|NCT01483131|OTHER|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
214519465|NCT02163850|DEVICE|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
214519466|NCT02163850|DEVICE|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
214519467|NCT01586494|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
214519468|NCT01586494|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
214519469|NCT00538499|DRUG|Fentanyl citrate|
215118687|NCT04579341|DIETARY_SUPPLEMENT|probiotics|probiotics administration
215118688|NCT02114463|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
215118689|NCT02114463|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
215118690|NCT02114463|DRUG|ropivacaine|0.2% ropivacaine
215118691|NCT02114463|DRUG|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
215118692|NCT00366951|PROCEDURE|Foley catheter only|
215118693|NCT00366951|PROCEDURE|Extraamniotic saline infusion|
214441525|NCT06029179|DRUG|sodium polystyrene sulfonate|60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
214519470|NCT00538499|DRUG|Bupivacaine hydrocloride|
214519471|NCT00538499|PROCEDURE|videothoracoscopy|
214519472|NCT06475326|DRUG|Adebrelimab|Adebrelimab ,20mg/Kg per time, Q4W
214519473|NCT06475326|DRUG|Oxaliplatin 100 MG|Oxaliplatin: 60mg/m2, Q2W
214519474|NCT06475326|DRUG|Irinotecan liposome|Irinotecan Liposome: 50mg/m2, Q2W
214519475|NCT06475326|DRUG|Calcium Folinate|Calcium Folinate: 400mg/m2, Q2W
214519476|NCT06475326|DRUG|Fluorouracil|Fluorouracil: 2400mg/m2, Q2W
214519477|NCT01989156|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
214519478|NCT01989156|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
214519479|NCT01989156|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
215118694|NCT02625792|DRUG|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
214441526|NCT05073302|PROCEDURE|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
214441527|NCT05650554|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
214441528|NCT05650554|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
214441529|NCT05650554|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
214441530|NCT05650554|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
214441531|NCT06829173|DRUG|XRD-0394|Administered orally; small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-PK.
214441532|NCT06829173|RADIATION|Radiation Therapy|"For Cohort A and Cohort B, the neoadjuvant boost radiation dose is 1400cGy delivered over 7 fractions, and the adjuvant radiation dose is 5000cGy delivered over 25 fractions for a total dose of 6400cGy over 32 fractions, accounting for the treatment break between boost and adjuvant RT.~For Cohort C, the radiation dose is 3500cGy delivered over 10 fractions."
214519480|NCT06309771|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a random order (6 predetermined order). Each module will be composed on 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
214519481|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
214519482|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
214519483|NCT05321576|PROCEDURE|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
214519484|NCT04543032|OTHER|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
214519485|NCT00349713|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
214519486|NCT00349713|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
214519487|NCT03652792|DRUG|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
214519488|NCT03652792|DRUG|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
214441533|NCT06829173|PROCEDURE|Surgical Resection|Resection of tumor tissue.
214441534|NCT04661501|DEVICE|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
214441535|NCT04661501|DEVICE|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
214441536|NCT04661501|DEVICE|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
214519489|NCT03573375|BEHAVIORAL|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
214519490|NCT00082576|DRUG|Azithromycin/Chloroquine|
214519491|NCT00082576|DRUG|Mefloquine|
214519492|NCT01738087|DRUG|NEXThaler 100/6 mcg DPI|
214519493|NCT01738087|DRUG|Flixotide Accuhaler 500 mcg|Active comparator
214519494|NCT01738087|DRUG|NEXThaler 200/6 mcg DPI|
214519495|NCT01738087|DRUG|NEXThaler placebo|Placebo comparator
214441537|NCT04661501|DEVICE|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
214441538|NCT05599789|DRUG|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
214441539|NCT06787027|PROCEDURE|Manual Lymphatic Drainage technique|Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.
214441540|NCT06787027|PROCEDURE|Conventional Treatment group|patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.
214441541|NCT06822179|OTHER|Education for self-management|Education program performed online including information, recommendations and guidance for promoting self-management
214441542|NCT06822179|OTHER|Personalised exercise program|Individualized exercise that includes progressive load adapted to each patient. It includes making flexible adjustments to their exercise (up or down as needed) to help them gradually improve their physical abilities while staying within their energy limits
214441543|NCT06822179|OTHER|Usual Care|Usual care these patients may receive out from the clinical trial.
214441544|NCT06389201|DRUG|HCQ|HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
214441545|NCT06389201|OTHER|Placebo|Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.
214519496|NCT01596634|OTHER|questionnaire administration|Ancillary studies
214519497|NCT01596634|PROCEDURE|quality-of-life assessment|Ancillary studies
215028679|NCT02957240|BEHAVIORAL|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
215028680|NCT06642493|BIOLOGICAL|Fresh frozen plasma|"Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion."
215028681|NCT00655655|DRUG|everolimus|Given orally
215028682|NCT00655655|DRUG|vatalanib|Given orally
215028683|NCT00655655|OTHER|pharmacological study|Correlative study (Cohort IIA only)
215028684|NCT00655655|OTHER|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
215028685|NCT00655655|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
215028686|NCT00655655|PROCEDURE|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
215028687|NCT06562829|DEVICE|Virtual reality technology|Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
214441546|NCT06829992|DEVICE|Kinesio Taping|"KT will be applied by a physiotherapist with experience in the Kinesio Taping method by Kenzo Kase. Three I-shaped Kinesio tapes will be used, 5 cm wide, covering the T-11 and T-12 dermatomes. The first tape will be applied vertically between the navel and pubis, with the participant in an orthostatic position with slight trunk extension.~The second tape, with the same length as the first, will be applied with its central region over the middle zone of the first, perpendicularly. The third tape will be applied horizontally to the lower back, covering the spines posterosuperior iliac muscles, with the participant in an orthostatic position, performing light trunk flexion."
214441547|NCT06829992|DEVICE|Placebo Group|The quantity of tapes, type, size and region of application will be the same as the group KT, however, in this group the tapes will be applied without tension and with procedure different from that recommended, first starting to adhere a side anchor into the skin, followed by the center and then the other side anchor.
214519498|NCT01596634|OTHER|laboratory biomarker analysis|Correlative studies
214519499|NCT01596634|DIETARY_SUPPLEMENT|bovine lactoferrin|Given PO
214519500|NCT02418286|OTHER|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
214519501|NCT05588297|DRUG|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
214519502|NCT05588297|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
214519503|NCT05588297|DRUG|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
214519504|NCT01709630|DRUG|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
214519505|NCT03542604|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
214519506|NCT03542604|BEHAVIORAL|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
214519507|NCT06277011|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
214519508|NCT01176409|DRUG|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
214519509|NCT01176409|DRUG|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
214519510|NCT00635323|DRUG|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
214519511|NCT01721109|DRUG|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
214519512|NCT03933241|BEHAVIORAL|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
214519513|NCT01171950|DEVICE|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
214519514|NCT05760417|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214692894|NCT03744780|BEHAVIORAL|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
214519515|NCT01145326|DRUG|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
214519516|NCT01145326|DRUG|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
214519517|NCT03563989|DEVICE|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
214519518|NCT05968898|DEVICE|Optellum Virtual Nodule Clinic|The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
214519519|NCT04362176|BIOLOGICAL|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
214519520|NCT04362176|BIOLOGICAL|Placebo|Lactated Ringer's solution with multivitamins
214519521|NCT01803945|DRUG|AVE8112|
214519522|NCT01803945|DRUG|Placebo|
214519523|NCT02472808|OTHER|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
214692895|NCT02058927|DRUG|Measles vaccine|measles revaccination administered at 12 months from start of ART
214692896|NCT03705962|DRUG|Tobramycin|
214692897|NCT03705962|OTHER|Placebo: normal saline|
214692898|NCT05959772|RADIATION|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
214692899|NCT02624401|DRUG|Dexmedetomidine|Intravenous infusion
214692900|NCT02624401|DRUG|Propofol|Intravenous infusion
214692901|NCT02624401|DRUG|S-ketamine|Intravenous infusion
214441548|NCT05247242|BEHAVIORAL|Lakeshore Online Fitness (Online)|Online physical activity program delivered to residents of Tarrant, AL via teleconferencing technology to a local community center. Instructors from Lakeshore will lead the physical activity program. This intervention will last six weeks.
214441549|NCT05247242|BEHAVIORAL|Get Active with Virtual Reality (VR)|Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
214441550|NCT05328661|DIAGNOSTIC_TEST|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
214441551|NCT03746769|BIOLOGICAL|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
214441552|NCT03746769|DRUG|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
214441553|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
214441554|NCT06820840|OTHER|SHOFU Block HC Hard|Cementation of hybrid ceramic onlay (SHOFU Block HC Hard) on carious molars.
214441555|NCT06820840|OTHER|SHOFU Ceramage|Cementation of hybrid resin composite onlay (SHOFU Ceramage) on carious molars.
214441556|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
214441557|NCT06783634|DRUG|Dexamethasone|Group 2 (dexamethasone group) single intra venous high dose of dexamethasone 1mg/kg with maximum dose of 100 mg.
214441558|NCT06783634|DRUG|Placebo|Group 1 (Control group) will receive normal saline as a placebo.
214441559|NCT06829446|PROCEDURE|Extra-PV extensive ablation|Extra-PV extensive ablation
214441560|NCT06829446|PROCEDURE|Repeat same PVI and linear ablation as the first procedure|Repeat same PVI and linear ablation as the first procedure
214441561|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
214441562|NCT06786741|BEHAVIORAL|AER for Stronger Communities|3 week rapid intervention aimed at reducing stress.
214441563|NCT06786741|OTHER|Placebo Comparator|3 week short video program (control)
214441564|NCT06831435|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
214441565|NCT05710263|PROCEDURE|bariatric embolization|bariatric or left gastric artery embolization
214441566|NCT05997186|PROCEDURE|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
214441567|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh used:1. Parietex™ Composite Mesh (Medtronic, USA): A multifilament polyester mesh with an anti-adhesive collagen barrier to minimize visceral adhesions."
214519524|NCT02472808|OTHER|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
214692902|NCT02624401|DRUG|Sevoflurane|Inhalation
214519525|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
214519526|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
214519527|NCT06266494|DEVICE|Long-Acting silver dressings|Mepilex Transfer Ag
214519528|NCT06266494|OTHER|Aloe Vera|Dermaid Aloe Vera
214519529|NCT06266494|DRUG|Dalbavancin|1500mg IV dose
214519530|NCT00742560|BIOLOGICAL|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
214692903|NCT02624401|DRUG|Placebo|Intravenous infusion of saline (Ringer's Acetate)
214692904|NCT02884817|DRUG|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
214441568|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh use Synecor™ Hybrid Mesh (BD, USA): A macroporous mesh combining polypropylene with a bioresorbable layer that degrades over time, leaving a durable support structure to promote tissue integration."
214519531|NCT00742560|DRUG|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
214519532|NCT00742560|DRUG|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
214519533|NCT00742560|DRUG|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
215118695|NCT05458206|OTHER|mulligan snag mobilization and diaphragmatic release|"The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement"
215118696|NCT04626375|DRUG|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
214519534|NCT03223935|OTHER|Corn nuts|Roasted corn nut snack
215118697|NCT04626375|DRUG|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
215118698|NCT02366195|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
215118699|NCT01153126|BEHAVIORAL|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
215118700|NCT05520632|DIAGNOSTIC_TEST|Brainstem Auditory Evoked Potentials|Performing Brainstem Auditory Evoked Potentials under sedation
214519535|NCT03223935|OTHER|Chickpeas|Roasted chickpea snack
214519536|NCT03223935|OTHER|Yellow peas|Roasted yellow pea snack
214519537|NCT03223935|OTHER|Pinto beans|Roasted pinto bean snack
214519538|NCT03223935|OTHER|Soybeans|Roasted soybean snack
214519539|NCT03223935|OTHER|Almonds|Roasted almond snack
214519540|NCT00928265|DEVICE|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
214519541|NCT01426217|DEVICE|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
214519542|NCT04928235|DIAGNOSTIC_TEST|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
214519543|NCT06203717|DEVICE|Alpha-Stim AID cranial electrotherapy stimulation|Cranial electrotherapy stimulation using a modified square, bipolar waveform of 0.5 Hz at 100 μA to be used for four weeks on off-duty days.
214519544|NCT00768911|DRUG|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
214519545|NCT00768911|DRUG|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
214519546|NCT00768911|PROCEDURE|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
214519547|NCT04057677|BEHAVIORAL|Bed Rest Intervention|The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.
215028688|NCT06562829|OTHER|different timing of lidocaine injection|Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
215028689|NCT06561776|OTHER|Physical Evaluations of individuals|Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
215028690|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave once a week
215118701|NCT04830930|DRUG|CKD-381|single-dose, oral administration of CKD-381 1 tablet
215118702|NCT01562080|DIETARY_SUPPLEMENT|Armolipid Plus|one tablet per day during 12 weeks
214441569|NCT06833723|OTHER|Retrospective Data Collection and Analysis|This is a retrospective study involving the collection and analysis of existing clinical data from breast cancer patients who received immunotherapy or neoadjuvant immunotherapy between January 1, 2015, and September 30, 2023. No new interventions are administered as part of this study. The data includes diagnostic puncture tissue, residual tumor tissue post-surgery, blood samples, and imaging data. These samples are analyzed using multi-omics approaches (proteomics, transcriptomics, metabolomics) and advanced imaging techniques (imaging mass cytometry and spatial transcriptomics) to build a predictive model for immunotherapy efficacy.
214441570|NCT06830408|DRUG|radionuclide therapy with 177Lu-PSMA-I&T|Standard PSMA RLT with 7-8 GBq i.v. infusion of 177Lu-PSMA-I\&T performed every 6-8 weeks for 4-6 cycles, or until progression or complete response.
214441571|NCT06831955|OTHER|Exercise Therapy|The exercise regimen consists of a non-linear aerobic exercise program of 3-4 sessions per week. During days of FMD no exercise will be prescribed.
214441572|NCT06831955|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet|The FMD is a plant-based, low-carbohydrate, low-caloric diet of 4 days , with the fourth day being the day of chemo/immunotherapy. A total of 6 FMD cycles will be administered over the treatment period of 20 weeks.
214519548|NCT04057677|BEHAVIORAL|Exercise Program|During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.
214519549|NCT01536795|DRUG|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
214519550|NCT01536795|DRUG|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
214519551|NCT00582985|DRUG|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
214519552|NCT00574301|PROCEDURE|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
214519553|NCT01812837|DEVICE|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
214519554|NCT01812837|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
214519555|NCT01812837|RADIATION|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
214519556|NCT05266157|OTHER|Manual lymph drainage|Manual lymph drainage
214519557|NCT05266157|OTHER|Usual care|skin care, exercise and compression stocking
214519558|NCT04469517|OTHER|hypoxic induced factors|hypoxic induced factors analyzed in blood sample
214519559|NCT04889833|BEHAVIORAL|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
215028691|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave twice a week
215028692|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave once a week
215028693|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave twice a week
215028694|NCT06563739|PROCEDURE|Focused low energy shock wave|Receive focused low energy shock wave once a week
215028695|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave once a week
215028696|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave twice a week
215028697|NCT06563739|PROCEDURE|Non-exposed group|Traditional rehabilitation assessment and training guidance
215028698|NCT06564922|OTHER|Counselling|Counselling was given for treatment group.
215028699|NCT03535129|BEHAVIORAL|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
215028700|NCT06641921|DEVICE|Seerlinq haemodynamically-guided heart failure treatment|Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
215028701|NCT06642064|BEHAVIORAL|Intervention group|"• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes."
215028702|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+8Gy x 3f|Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
215028703|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+16Gy x 1f|Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
215028704|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+2.67Gy x 15f|Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
214692905|NCT02884817|OTHER|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
214692906|NCT02884817|OTHER|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
215028705|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f|Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
214441573|NCT06831955|DRUG|SOC|Four cycles of an intravenous infusion of pembrolizumab (200 mg) once every 3 weeks plus paclitaxel (80 mg per square meter of body-surface area once weekly) plus carboplatin (at a dose based on an area under the concentration-time curve of 1.5 mg per milliliter per minute) once weekly in the first 12 weeks, followed by four cycles of epirubicin (90 mg per square meter) plus cyclophosphamide (600 mg per square meter) once every 2 weeks plus pembrolizumab 400mg every 6 weeks or pembrolizumab 200mg every 3 weeks in the subsequent 8 weeks.
214441574|NCT06790888|COMBINATION_PRODUCT|Ripertamab/Eltrombopag|Ripertamab, a novel anti-CD20 monoclonal antibody, in combination with Eltrombopag . Ripertamab is administered intravenously at a dose of 375 mg/m² BSA on Day 1 . If the participant remains in remission at the 3-month mark, an additional intravenous dose of 375 mg/m² Ripertamab is administered. Eltrombopag are given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
214441575|NCT06790888|DRUG|Eltrombopag|Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
214441576|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
214441577|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
214441578|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine|2.7 mg.kg IV every 4 weeks
214441579|NCT05551117|DRUG|Abiraterone|1000 mg once daily
214441580|NCT05551117|DRUG|Enzalutamide|160 mg daily
214441581|NCT05860816|OTHER|Survey|Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
214441582|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
214441583|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
214441584|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
214441585|NCT06783790|DRUG|Avapritinib, azacitidine, Venetoclax|"A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles"
214441586|NCT06787014|OTHER|Histopathological review|Histopathological review
214441587|NCT06835114|PROCEDURE|CABG|CABG
214441588|NCT06835114|PROCEDURE|LIMA on lay patch|Left internal mammary artery harvesting with on lay patch on left anterior descending coronary artery
214441589|NCT06835114|PROCEDURE|Safenous vein patch|Safenous vein patch on left anterior descending artery
214441590|NCT06786169|OTHER|psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
214441591|NCT03188796|DRUG|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
214441592|NCT03188796|DRUG|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
214441593|NCT04740775|DEVICE|LiquiBand Exceed|Cyanoacrylate glue for closure of surgical wounds
214441594|NCT04740775|DEVICE|LiquiBand Rapid|Cyanoacrylate glue for closure of surgical wounds
214441595|NCT05155137|DRUG|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
214692907|NCT04261634|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
215028706|NCT05231915|GENETIC|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
215028707|NCT00841815|DRUG|Amlodipine Besylate|10 mg Tablet
215028708|NCT00841815|DRUG|Norvasc®|10 mg Tablet
215118703|NCT01562080|DIETARY_SUPPLEMENT|placebo|one tablet per day during 12 weeks
214441596|NCT05155137|BEHAVIORAL|Stroke Riskometer|Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
214441597|NCT05205174|DEVICE|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
214441598|NCT05419505|DRUG|CCH-aaes|Administered by subcutaneous injection.
214441599|NCT05419505|DRUG|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
214441600|NCT03358875|DRUG|Tislelizumab|Tislelizumab administered by intravenous (IV) infusion
214441601|NCT03358875|DRUG|Docetaxel|Docetaxel administered as an IV infusion over 1 hour
214441602|NCT03599648|BEHAVIORAL|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
214441603|NCT03599648|BEHAVIORAL|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
214441604|NCT06230640|DIAGNOSTIC_TEST|In vitro medical diagnostic device TEG6s® Platelet Mapping|"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."
214441605|NCT05191667|DRUG|AN0025|250 mg or 500 mg Q.D., oral administration
214441606|NCT04256798|DRUG|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
214441607|NCT04256798|DRUG|Oxygen|Oxygen 80-100%
214441608|NCT04256798|DRUG|Oxygen|Oxygen 21-30 %
214441609|NCT05530551|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
214441610|NCT03860805|PROCEDURE|Laparoscopic tubal ligation|Laparoscopic tubal ligation
214441611|NCT03860805|PROCEDURE|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
215118704|NCT05865626|OTHER|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
214441612|NCT05169489|BIOLOGICAL|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
214441613|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
214441614|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
214519560|NCT06426511|DRUG|Toripalimab+Chemotherapy|After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
214692908|NCT04261634|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
214692909|NCT05130333|OTHER|No intervention|No intervention
214692910|NCT01515306|BIOLOGICAL|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
215118705|NCT02921659|DIETARY_SUPPLEMENT|Niagen™|nicotinamide riboside chloride, 250mg capsules
215118706|NCT02921659|DIETARY_SUPPLEMENT|Placebo|silicified microcrystalline cellulose, vegetarian capsule
215118707|NCT01721863|OTHER|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
215118708|NCT00202007|DRUG|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
215118709|NCT00202007|DRUG|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
215118710|NCT01527968|DRUG|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
214692911|NCT01515306|DRUG|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
214441615|NCT04887259|BIOLOGICAL|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
214692912|NCT06417931|BEHAVIORAL|Patient education and counselling|The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
214692913|NCT02460926|PROCEDURE|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
214692914|NCT04567966|PROCEDURE|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
214692915|NCT04567966|PROCEDURE|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
214692916|NCT00086957|BIOLOGICAL|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
214692917|NCT00086957|DRUG|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
214692918|NCT00086957|DRUG|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
215118711|NCT01527968|DRUG|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
215118712|NCT01527968|DRUG|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
215118713|NCT01338818|DRUG|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
214441616|NCT04887259|BIOLOGICAL|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
214441617|NCT03212404|DRUG|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
214441618|NCT05008926|DRUG|Naloxegol|Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
214692919|NCT00634244|DRUG|alvocidib|Given IV
214692920|NCT00634244|DRUG|mitoxantrone hydrochloride|Given IV
214692921|NCT00634244|DRUG|carboplatin|Given IV
214692922|NCT00634244|DRUG|cytarabine|Given IV
214692923|NCT00634244|DRUG|sirolimus|Given PO
214692924|NCT00634244|DRUG|etoposide|Given IV
214692925|NCT00634244|DRUG|topotecan hydrochloride|Given IV
214692926|NCT02626104|DIETARY_SUPPLEMENT|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
214692927|NCT02626104|DIETARY_SUPPLEMENT|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
214692928|NCT00908206|DRUG|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
215118714|NCT05695807|DEVICE|Carboxytherapy|Device generating CO2 gas
215118715|NCT04508426|DRUG|[14C]AR882|Single dose of \[14C\]AR882
215118716|NCT03391661|BEHAVIORAL|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
215118717|NCT03391661|BEHAVIORAL|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
215118718|NCT00740207|DRUG|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
215118719|NCT00740207|DRUG|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
215118720|NCT02107066|BEHAVIORAL|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
215118721|NCT02507388|DRUG|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
215118722|NCT02507388|DRUG|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
215118723|NCT02980471|DEVICE|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
215118724|NCT03943641|OTHER|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
215118725|NCT05423314|PROCEDURE|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
215118726|NCT04445142|PROCEDURE|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
215028709|NCT04805593|DEVICE|WaveLight EX500 excimer laser system|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
215028710|NCT04805593|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
215028711|NCT01148771|DRUG|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
215028712|NCT01148771|DRUG|ertapenem|1 gram 30 minute infusion q24h for 3 days
215028713|NCT00901914|BIOLOGICAL|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
215028714|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
215028715|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
215028716|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
215028717|NCT03787615|DEVICE|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
215028718|NCT05870111|DRUG|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
215028719|NCT05870111|DRUG|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
215028720|NCT04550728|COMBINATION_PRODUCT|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
215028721|NCT04550728|COMBINATION_PRODUCT|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
215028722|NCT02994719|DRUG|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
215028723|NCT02994719|DEVICE|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
215028724|NCT06554639|DRUG|MK-5684|Administered via oral tablet per dosing regimen.
215028725|NCT06554639|DRUG|Prednisone|Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
215028726|NCT06554639|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
215028727|NCT06554639|DRUG|Diltiazem hydrocholoride|Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
215028728|NCT03464461|DRUG|Ketorolac|IV drug
215028729|NCT06771024|BEHAVIORAL|Physical Exercise|The intervention include a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. International/national exercise prescription guidelines will be applied for each clinical condition (cardio/cerebrovascular disease/risk, diabetes mellitus and osteoarthritis).
215028730|NCT06642467|DEVICE|BGEM|BGEM is an ai driven model to predict blood glucose using ppg sensor
215028731|NCT06640283|DIAGNOSTIC_TEST|ctDNA test|ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.
215028732|NCT06640283|DRUG|Pembrolizumab|Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
215028733|NCT06638008|DRUG|perineural injection|perineural intervention of placental growth factor in one group and PRP in other group
215028734|NCT06639529|DIAGNOSTIC_TEST|Tests of the expression of CXCL3 in various tissues|1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
215029225|NCT06055283|OTHER|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
214441619|NCT05008926|DRUG|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
214441620|NCT02380612|DEVICE|ReCell Treatment|
214519561|NCT06426511|DRUG|Toripalimab+Chemotherapy followed by consolidation toripalimab|"After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians."
214519562|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
214519563|NCT05866887|BEHAVIORAL|Sleep ALL Night|Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
214519564|NCT04089748|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
214519565|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
214519566|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
214519567|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
214519568|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
214519569|NCT05834829|DEVICE|Low-intensity focused ultrasound neuromodulation|ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.
214519570|NCT05834829|DEVICE|Sham Low-intensity focused ultrasound|sham application of ultrasound using blocking of the ultrasound waves of the transducer.
214441621|NCT02380612|PROCEDURE|Skin Graft|
214441622|NCT05846984|BEHAVIORAL|Learning Skills Together Intervention|Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.
214519571|NCT05008224|BIOLOGICAL|Pembrolizumab|"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
214519572|NCT05008224|DRUG|Doxorubicin|"25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age)."
214519573|NCT05008224|DRUG|Vinblastine|6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
214519574|NCT05008224|DRUG|Dacarbazine|375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
214519575|NCT05008224|DRUG|Bleomycin|10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519576|NCT05008224|DRUG|Etoposide|200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519577|NCT05008224|DRUG|Cyclophosphamide|1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519578|NCT05008224|DRUG|Vincristine|1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519579|NCT05008224|DRUG|Procarbazine|100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519580|NCT05008224|DRUG|Prednisone|40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
214519581|NCT03198481|BEHAVIORAL|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
214519582|NCT03198481|BEHAVIORAL|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
214519583|NCT05897450|OTHER|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
214519584|NCT05897450|OTHER|Local anesthetic infiltration|Local anesthetic infiltration was applied to the trocar sites with the same volume.
215029226|NCT05538728|DEVICE|poly-l-lactic acid (Sculptra)|Sculptra
215029227|NCT00203606|DRUG|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
215029228|NCT05100992|PROCEDURE|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
215029229|NCT04706325|OTHER|ACUTE KIDNEY INJURY|KDIGO LEVELS
215029230|NCT03616340|DRUG|Shoulder injection|intra articular or subacromial shoulder injection
215029231|NCT03616340|DRUG|knee injection|intra-articular knee injection
215029232|NCT01655056|DRUG|YM150|oral
215029233|NCT01655056|DRUG|Placebo|oral
215029234|NCT01827020|DRUG|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
215029235|NCT01827020|DRUG|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
215029236|NCT01827020|DRUG|Saline|12 mL saline (0.9% isotonic solution)
214692929|NCT02166021|BIOLOGICAL|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
214692930|NCT01850784|DIETARY_SUPPLEMENT|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
214692931|NCT01850784|DIETARY_SUPPLEMENT|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
214692932|NCT01864759|BIOLOGICAL|ICOVIR-5|
214692933|NCT02674737|DRUG|dexmedetomidine, tramadol and flurbiprofen|
214692934|NCT02674737|DRUG|tramadol and flurbiprofen|
214441623|NCT05846984|BEHAVIORAL|Caregiver Healthy Living Intervention|Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
214441624|NCT06486597|DIETARY_SUPPLEMENT|Meal|Liquid meal
214441625|NCT06274879|DRUG|Gemcitabin, Cisplatin and Durvalumab|CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
214692935|NCT05950477|DIAGNOSTIC_TEST|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
214692936|NCT02335216|DEVICE|Implantation with the commercially available Axium neurostimulator|
214692937|NCT02427477|DEVICE|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
215028735|NCT06641583|BEHAVIORAL|LEGO|"The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models."
214692938|NCT02427477|DEVICE|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
214692939|NCT04369430|DRUG|AKST4290|Oral AKST4290
214692940|NCT04369430|DRUG|Placebo|Oral Placebo
214692941|NCT06552559|DRUG|Selinexor|Combination chemotherapy
214692942|NCT04279379|DRUG|Sintilimab|200mg d1,ivdrip, repeated every 3 weeks
215028736|NCT06641583|OTHER|Controllo|This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
215028737|NCT06644664|BEHAVIORAL|Health Education|Receive control MMS messages
215028738|NCT06644664|OTHER|Interview|Ancillary studies
215028739|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive AR MMS messages
215028740|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive RR MMS messages
215028741|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resources
215028742|NCT06644664|OTHER|Survey Administration|Ancillary studies
215028743|NCT06644664|OTHER|Text Message-Based Navigation Intervention|Receive check-in text message
215029237|NCT05274477|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
215029238|NCT05274477|DRUG|Placebo|no active component
215029239|NCT00388609|DRUG|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
215029240|NCT00388609|DRUG|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
215029241|NCT04016610|DEVICE|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
215029242|NCT05450237|BEHAVIORAL|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
215029243|NCT06565351|OTHER|eGFR estimated from creatinine and cystatin C|eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
215029244|NCT00629603|GENETIC|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
215029245|NCT00629603|GENETIC|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
215029246|NCT00629603|GENETIC|cytokine polymorphism|fibrosis-relating cytokine polymorphism
215029247|NCT04124419|DEVICE|Treatment with Evolve System|EMS and RF Treatment
215029248|NCT01481103|PROCEDURE|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
215029249|NCT02208167|BIOLOGICAL|HXTC infusion|
215029250|NCT04463927|OTHER|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
214441626|NCT06274879|PROCEDURE|Biliary Radiofrequency Ablation|Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks
214441627|NCT06274879|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography with stenting|ERCP with stenting are applied at baseline and as clinically indicated
214441628|NCT03433911|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
214441629|NCT03433911|PROCEDURE|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
214519585|NCT06443099|OTHER|Different methods used after intramuscular injection|Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
214519586|NCT05234632|DEVICE|PICO 14 single-use Negative Pressure Wound Therapy System|The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
214519587|NCT03347084|DEVICE|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
214519588|NCT03347084|DEVICE|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
214519589|NCT04546360|PROCEDURE|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
215118727|NCT00855244|OTHER|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
215118728|NCT00158717|DRUG|Hepsera|
214441630|NCT05796492|DEVICE|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
214441631|NCT05796492|DEVICE|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
214441632|NCT05626725|DEVICE|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
214441633|NCT02214381|DRUG|Myocet|
214519590|NCT03970304|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
214519591|NCT03643770|COMBINATION_PRODUCT|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
214519592|NCT05770570|BEHAVIORAL|Counseling|In-person individual diet and physical activity (PA) counseling
214519593|NCT05770570|BEHAVIORAL|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
214519594|NCT05770570|BEHAVIORAL|Phone calls|Weekly telephone support
214519595|NCT05770570|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools
214519596|NCT06139419|RADIATION|definitive radiotherapy|Participants were treated with definitive thoracic radiotherapy
214519597|NCT06139419|DRUG|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
214519598|NCT06139419|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
214519599|NCT06139419|DRUG|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
214441634|NCT02214381|DRUG|Cyclophosphamide|
214519600|NCT06139419|DRUG|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
214519601|NCT06286618|BEHAVIORAL|Psychosocial Intervention|Psychosocial intervention is an intensive behavioral therapy intervention to address dietary behaviors. Each intervention session is a one-on-one interaction that focuses on setting individualized dietary goals and following up on them and is delivered by trained personnel. Sessions are delivered in 3 modalities which include face-to-face, phone call, and telehealth delivery. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Face-to-face; Telehealth; Phone Call 2) Telehealth; Phone Call; Face-to-face 3) Phone call; Face-to-face; Telehealth.
215118729|NCT06579963|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
215118730|NCT03349658|OTHER|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
215118731|NCT03349658|OTHER|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
214441635|NCT02214381|DRUG|Paclitaxel|
214441636|NCT05333978|DEVICE|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
214441637|NCT05333978|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
214692943|NCT04279379|DRUG|Decitabine|10mg d1-5, ivdrip,repeated every 3 weeks
215118732|NCT03232996|OTHER|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
215118733|NCT05144100|PROCEDURE|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
214441638|NCT04975178|BIOLOGICAL|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
214441639|NCT04975178|BIOLOGICAL|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
214441640|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214441641|NCT01293357|DRUG|LEO 90105|Ointment
214519602|NCT06286618|OTHER|Structural Intervention|The structural intervention is designed to supplement the diet with food resources via three modalities: voucher-based or F/V prescription, home meal delivery, or food bank box program. The voucher-based model includes a weekly $50 gift card with a prescription for having to eat more fruits and vegetables. The home meal delivery model includes a meal subscription that supplements the diet with two meals for two people each week (four total servings worth $65 including shipping). The food bank box program consists of participants picking up a box of food weekly from a food pantry located in the outpatient clinic. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Voucher; Meal Delivery; Food Box 2) Meal Delivery; Food Box; Voucher 3) Food Box; Voucher; Meal Delivery.
214519603|NCT06286618|OTHER|Traditional Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in a referral-based fashion in which participants will receive referral at enrollment visit.
214519604|NCT06286618|OTHER|Integrated Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in an integrated fashion in which participants will receive immediate onboard at enrollment visit.
214519605|NCT00658632|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
214519606|NCT00658632|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
214519607|NCT05712356|DRUG|certepetide|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
214519608|NCT05712356|DRUG|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
214519609|NCT05712356|DRUG|Cisplatin|cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
214519610|NCT05712356|DRUG|Gemcitabine|gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
214519611|NCT05712356|DRUG|FOLFOX regimen|"The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)"
214519612|NCT05712356|DRUG|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
214519613|NCT01524211|DEVICE|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
214519614|NCT01524211|DEVICE|Terumo Arch Branch|The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
214519615|NCT01202344|OTHER|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
214692944|NCT06554925|PROCEDURE|Cardiac surgery|The difference in males and females undergoing cardiac surgery of all types
214692945|NCT00654511|DRUG|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
214692946|NCT00654511|DRUG|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
214692947|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
214692948|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
214441642|NCT03356990|DIETARY_SUPPLEMENT|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
214441643|NCT01064440|BIOLOGICAL|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
214441644|NCT01064440|BIOLOGICAL|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
214441645|NCT01064440|OTHER|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
214441646|NCT05332236|DIAGNOSTIC_TEST|Parent-Adolescent Communication Scale (questionnaire)|Observational psychometric validation study
214441647|NCT05568069|DEVICE|Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)|An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
214441648|NCT06009653|BEHAVIORAL|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
214441649|NCT06009653|BEHAVIORAL|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
214441650|NCT06009653|DRUG|Placebo|Participants will receive placebo subcutaneous injections.
214441651|NCT06009653|DRUG|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
214441652|NCT03429803|DRUG|DAY101|28 day cycle, oral, once per week
214441653|NCT03206320|DRUG|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
214519616|NCT02215447|DRUG|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
214519617|NCT02215447|DRUG|Carboplatin|
214692949|NCT01720615|DRUG|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
215118734|NCT05144100|RADIATION|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
214692950|NCT01720615|DRUG|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
214692951|NCT02368340|OTHER|Pulmonary function test|Pulmonary function testing performed
214692952|NCT02368340|OTHER|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
214441654|NCT04656925|BEHAVIORAL|Contingency management|Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
214441655|NCT05294809|BEHAVIORAL|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
214441656|NCT05294809|BEHAVIORAL|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
214441657|NCT05294809|BEHAVIORAL|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
214441658|NCT05322590|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
214441659|NCT05322590|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
214441660|NCT05720338|DEVICE|19 French Blake Drain|19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
214441661|NCT04759443|OTHER|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
214519618|NCT05656404|DEVICE|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
214519619|NCT05487131|BEHAVIORAL|electrical stimulation|different types of weak electrical stimulation will be used
214519620|NCT06400511|DRUG|Pimecrolimus 0.3% Ophthalmic Ointment|Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
214519621|NCT06400511|DRUG|Placebo Ophthalmic Ointment|Placebo will be applied twice a day to both eyelid margins.
214519622|NCT05486819|DRUG|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
214519623|NCT06153355|DRUG|LY3839840|Administered orally.
214519624|NCT06153355|DRUG|Placebo|Administered orally.
214519625|NCT06153355|DRUG|Midazolam|Administered orally
214692953|NCT02368340|OTHER|Sample collection|Blood and urine sample collections
214692954|NCT03828084|DRUG|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
215118735|NCT05144100|DRUG|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
215118736|NCT05212558|OTHER|Placebo respiratory muscle training|Unloaded respiratory muscle training plus conventional respiratory exercises
215118737|NCT05212558|OTHER|Inspiratory muscle training|Inspiratory muscle training plus conventional respiratory exercises
214441662|NCT03176498|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
214441663|NCT03176498|DRUG|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
215118738|NCT05212558|OTHER|Combined inspiratory and expiratory muscle training|Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
215118739|NCT04976686|OTHER|Diet modification|Participants will reduce their carbohydrate consumption to 80g daily
214441664|NCT04609553|BEHAVIORAL|Usual care including ROR|Usual care which includes ROR.
214441665|NCT04609553|BEHAVIORAL|Text messages|3 text messages per week and one interactive text per month.
214441666|NCT04609553|BEHAVIORAL|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
214441667|NCT05945537|DRUG|INI-822 (A)|Different dose levels of INI-822
214441668|NCT05945537|OTHER|Placebo (B)|Matching placebo to INI-822
214519626|NCT05361954|DRUG|STI-1386|Second generation oncolytic virus
214519627|NCT03800602|DRUG|Metformin|Given PO
214519628|NCT03800602|BIOLOGICAL|Nivolumab|Given IV
214519629|NCT02900937|DEVICE|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
214519630|NCT05904704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214519631|NCT05904704|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
214519632|NCT04819204|DRUG|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
214519633|NCT04819204|DRUG|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
214519634|NCT02991456|DRUG|Rolapitant|single 180 mg dose by mouth
214519635|NCT02991456|DRUG|Ondansetron|8 mg by mouth daily
214519636|NCT02264444|OTHER|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
214519637|NCT04420351|DRUG|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
214519638|NCT04420351|DRUG|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
214519639|NCT02255526|DEVICE|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
214692955|NCT05929144|OTHER|MRI sequences testing|Testing different MRI sequences in order to optimize them
214441669|NCT03837977|DRUG|Liposomal Irinotecan|Arm I
214692956|NCT01590680|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
214692957|NCT02227329|DRUG|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
214441670|NCT03837977|DRUG|Fluorouracil|Arm I
214441671|NCT03837977|DRUG|Folinic Acid|Arm I
214441672|NCT03837977|DRUG|Docetaxel|Arm II
214519640|NCT06318364|OTHER|NO Intervention|NO Intervention
214519641|NCT06970366|OTHER|Cold pack application|Cold pack application
214519642|NCT06970366|OTHER|Cold spray application|Cold spray application
214519643|NCT01699178|DRUG|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
214519644|NCT01699178|DRUG|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
214519645|NCT06008080|DEVICE|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
214519646|NCT03448783|DRUG|Apixaban|Patients are tested for their normal prescription apixaban medication
214441673|NCT06194214|DRUG|Pirtobrutinib|Administered Orally.
214441674|NCT06194214|DRUG|Digoxin|Administered Orally.
214441675|NCT06231381|DRUG|HB0034|Anti-IL-36R antibody
214441676|NCT06231381|OTHER|Placebo|non-biologically active drug
214441677|NCT06331130|DIAGNOSTIC_TEST|Computed Tomography|Computed Tomography done according to Clinical Practice to assess mesenteric involvment
214441678|NCT04273555|DRUG|[18F]-FDG|\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
214441679|NCT05982769|BEHAVIORAL|Endurance Training 3 times per week|endurance training will be performed from home 3 times per week under the supervision of the research team.
214441680|NCT05982769|BEHAVIORAL|Resistance Exercise|resistance training will be performed from home 2 times per week under the supervision of the research team.
214441681|NCT05982769|BEHAVIORAL|Standard of Care|continue usual activity
214519647|NCT06494176|BEHAVIORAL|neVR Fear the Dentist|neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
214692958|NCT02227329|DRUG|Heparin Lock|3 mL of 100 U/ml heparin
214692959|NCT02227329|DRUG|Normal Saline|
214692960|NCT05594680|DRUG|Cilostazol|Cilostazol 50 MG
214692961|NCT05594680|DRUG|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
214692962|NCT05594680|DRUG|Placebo|Placebo
214692963|NCT05228444|BEHAVIORAL|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
214692964|NCT00161980|DRUG|Fibrin Sealant VH S/D|
214441682|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
214441683|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
214441684|NCT04377932|GENETIC|AGAR T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2 DL2: 1x10\^8/m2 DL3: 3x10\^8/m2 DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214692965|NCT00161980|PROCEDURE|Surgical intervention alone without Fibrin Sealant VH S/D application|
214441685|NCT06309693|PROCEDURE|Quadratus Lumborum (QL) Block|The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
215029251|NCT00959049|BIOLOGICAL|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
215118740|NCT00556998|DRUG|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
215118741|NCT04314986|DRUG|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
215118742|NCT04314986|DRUG|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
214441686|NCT06309693|PROCEDURE|Enhanced Recovery After Surgical (ERAS) Protocol|Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
214441687|NCT05551403|DEVICE|Eyes-closed rest-EEG registration|Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions
214441688|NCT05551403|DEVICE|Transcranial Magnetic Stimulation during EEG and EMG registrations|Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols
214441689|NCT05551403|DEVICE|Photic stimulation during eyes-closes EEG registration|Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
214441690|NCT06463795|DEVICE|tDCS|active anodal tDCS
214441691|NCT06463795|DEVICE|Sham tDCS|sham anodal tDCS
214441692|NCT05328557|DRUG|CUG252|CUG252 will be administered by subcutaneous (SC) injection
214441693|NCT05328557|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection
214519648|NCT06646783|DRUG|[68Ga]Ga-NODAGA-SNA014|Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
214519649|NCT04928196|OTHER|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
214519650|NCT00690079|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
214519651|NCT00690079|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
214519652|NCT00317928|DRUG|Metformin|
214519653|NCT05485025|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
214519654|NCT05485025|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
214519655|NCT05396573|BIOLOGICAL|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
215029252|NCT00959049|BIOLOGICAL|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
215029253|NCT01661673|DRUG|EVP-0962|Arms: 1,2,3,4
215029254|NCT01661673|DRUG|Placebo|Arm 5
215029255|NCT00726479|DRUG|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
215029256|NCT02963818|OTHER|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
215029257|NCT02963818|OTHER|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
215118743|NCT04314986|DRUG|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
215118744|NCT04314986|DRUG|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
215118745|NCT00947271|BEHAVIORAL|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health
214441694|NCT04335643|BEHAVIORAL|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
214441695|NCT05874102|OTHER|Sidelying|Position sidelying then Upright
214441696|NCT05874102|OTHER|Upright|Position upright then sidelying
214441697|NCT05124925|BIOLOGICAL|Ianalumab|Ianalumab VAY736 150mg/1ml Solution for injection
214441698|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
214441699|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
214441700|NCT03494504|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
214441701|NCT03719924|DRUG|Onivyde|onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
214441702|NCT03719924|DRUG|Paclitaxel|Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
214441703|NCT05523635|DEVICE|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
214441704|NCT05923125|BEHAVIORAL|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
214441705|NCT06221930|BEHAVIORAL|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
214441706|NCT04640441|OTHER|Sit-to-stand care|"1. Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20\~30 min, once daily.~2. Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20\~30min, once daily.~3. Stepping exercise and sit-to-stand exercise, 20\~30min, once daily."
214441707|NCT05612789|BEHAVIORAL|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
214441708|NCT05612789|BEHAVIORAL|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
214441709|NCT06782763|DEVICE|Repetitive transcranial magnetic stimulation device|Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
214519656|NCT05396573|BIOLOGICAL|Comirnaty|A single dose of 30 μg/0.3 mL
214519657|NCT00515892|DRUG|Immunotoxin therapy|
214519658|NCT00515892|DRUG|CAT-8015 Immunotoxin|
214441710|NCT06819397|OTHER|post isometric relaxation|the athlete will be given instructions to perform a 7-second isometric contraction in the direction of horizontal abduction at about 25% of peak effort, while the examiner will apply an opposing force at the distal humerus.
214441711|NCT06819397|OTHER|cross friction soft tissue mobilization|by identifying the fascia restriction, patients in group B will be treated with the cross friction soft tissue mobilization approach, which comprised applying a low load and prolonged stretch through the knuckles or elbows to the constricted fascia. The therapist will then give the contralateral side of rotation resistance for ten seconds
214441712|NCT06477900|OTHER|SMS reception|reception of 72 SMS encouraging physical activity and nutritional advice
214441713|NCT03938168|DIAGNOSTIC_TEST|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
215118746|NCT00947271|BEHAVIORAL|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
215118747|NCT03314701|DEVICE|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
215118748|NCT03314701|DEVICE|Airway Pressure Release Ventilation (APRV)|"* high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second"
215118749|NCT02838758|DEVICE|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
215118750|NCT02838758|DRUG|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
215118751|NCT02838758|DRUG|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
215118752|NCT05887557|OTHER|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
215118753|NCT05887557|OTHER|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
215118754|NCT05887557|OTHER|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
215118755|NCT05887557|OTHER|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
215118756|NCT05887557|OTHER|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
215118757|NCT05887557|OTHER|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
215118758|NCT05887557|OTHER|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
215118759|NCT05887557|OTHER|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
214441714|NCT04934176|OTHER|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
214441715|NCT04934176|OTHER|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
215118760|NCT05887557|OTHER|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
215118761|NCT05887557|OTHER|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
215118762|NCT05887557|OTHER|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
215118763|NCT05887557|OTHER|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
215118764|NCT00490269|DRUG|Placebo|
215118765|NCT00490269|DRUG|Dronabinol|
215118766|NCT03707301|OTHER|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
215118767|NCT02864121|OTHER|all patients included in IDAHO study|
215118768|NCT02320916|PROCEDURE|23Gauge|Arterial puncture will be made using a 23Gauge needle
214519659|NCT00515892|PROCEDURE|Biological therapy|
214519660|NCT00515892|PROCEDURE|Antibody Therapy|
214519661|NCT00515892|PROCEDURE|Monoclonal Antibody Therapy|
214519662|NCT04636515|DRUG|F520|200mg，Q3W
214519663|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
214519664|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
214519665|NCT03159494|OTHER|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
214519666|NCT04093050|DRUG|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
214519667|NCT01664806|DEVICE|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
214519668|NCT00312806|DRUG|Pantoprazole|Pantoprazole 40 mg o.d.
214519669|NCT05772338|DRUG|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
214519670|NCT05772338|OTHER|Placebo|Placebo. Up to six applications per day.
215118769|NCT02320916|PROCEDURE|25Gauge|Arterial puncture will be made using a 25Gauge needle
215118770|NCT04694690|OTHER|Self adhesive resin cement|Self adhesive resin cement
214519671|NCT02265120|BEHAVIORAL|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
214519672|NCT02327442|RADIATION|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
214519673|NCT00980616|DRUG|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
214519674|NCT00738400|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
214519675|NCT00738400|DRUG|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
215118771|NCT04694690|OTHER|Resin cement|Resin Cement system used after surface treatment
215118772|NCT04400058|BIOLOGICAL|Octagam 10%|Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
215118773|NCT04400058|OTHER|Saline Solution|Placebo
215118774|NCT04493853|DRUG|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
214519676|NCT02211872|DRUG|BI 2536 BS, intravenous|
214519677|NCT00624637|OTHER|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
214519678|NCT02312245|BIOLOGICAL|Bevacizumab|Given IV
214519679|NCT02312245|DRUG|Gemcitabine Hydrochloride|Given IV
214519680|NCT02312245|DRUG|Paclitaxel|Given IV
214519681|NCT02312245|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214519682|NCT02312245|DRUG|Topotecan Hydrochloride|Given IV
214519683|NCT03249857|BEHAVIORAL|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
214519684|NCT03249857|BEHAVIORAL|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
214519685|NCT00508144|DRUG|Alimta|500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
214441716|NCT04881162|DEVICE|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
214692966|NCT01370096|DRUG|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
214692967|NCT01370096|DRUG|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
214692968|NCT00368134|DRUG|Vildagliptin|
214692969|NCT06115434|PROCEDURE|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
214692970|NCT04748224|DRUG|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
214692971|NCT04748224|DRUG|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
214692972|NCT03679663|DEVICE|Ultrasound|Use of ultrasound to identify pre-puncture site
214692973|NCT05913934|BEHAVIORAL|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
214441717|NCT05954962|DRUG|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
214441718|NCT05954962|DRUG|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
214692974|NCT04827836|PROCEDURE|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
214692975|NCT02635737|DEVICE|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
214692976|NCT00937768|DRUG|Goserelin Acetate|Given SC
214692977|NCT00937768|OTHER|Laboratory Biomarker Analysis|Correlative studies
214692978|NCT00937768|DRUG|Leuprolide Acetate|Given IM
215118775|NCT04493853|OTHER|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
215118776|NCT04493853|DRUG|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
214692979|NCT00937768|OTHER|Quality-of-Life Assessment|Ancillary studies
214692980|NCT06273657|OTHER|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
214692981|NCT03769935|DRUG|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
214692982|NCT00077337|DRUG|romidepsin|
214692983|NCT05420688|OTHER|Heart Failure Group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
214692984|NCT05833893|DRUG|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
215118777|NCT05416216|BEHAVIORAL|WELL|The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
214441719|NCT06508801|OTHER|Blood flow restriction training|The BFR Intervention will consist of 75 repetitions; reps (set 1: 30 reps, sets 2 - 4: 15 reps with 30 s of rest between sets and 1 minute between exercises) at 20-30% of 10 repetition maximum (RM). BFR training will be performed during toe raises, lunges and single leg stance exercises on unstable surfaces (i.e., foam, Dyna disc, balance disc, and BOSU-ball®) as tolerated by the participant.
214441720|NCT06508801|OTHER|Instability Resistance Training|The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
214441721|NCT04832360|BEHAVIORAL|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
214692985|NCT03342482|OTHER|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
214692986|NCT01687413|RADIATION|Intensity-modulated radiation therapy (IMRT)|
214692987|NCT01687413|DRUG|Cisplatin|
214692988|NCT04115696|DEVICE|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
214692989|NCT02276235|DEVICE|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
215029258|NCT02963818|OTHER|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
214441722|NCT01631214|BIOLOGICAL|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
214441723|NCT01631214|DRUG|Alendronate|Alendronate 70 mg tablet taken once a week
214519686|NCT00552591|BEHAVIORAL|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
214441724|NCT01631214|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
214441725|NCT01631214|DRUG|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
214441726|NCT06065995|DEVICE|StoMakker|A mobile application that offers age dependent information, a peer support platform and a game
214441727|NCT05833789|DEVICE|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
214441728|NCT03805594|DRUG|Lutetium Lu 177-PSMA-617|Given IV
214519687|NCT00442507|DRUG|Erlotinib|
214519688|NCT00442507|DRUG|Avastin|
214519689|NCT03900988|DRUG|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
214519690|NCT03900988|DRUG|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
214519691|NCT02159794|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
214519692|NCT03542695|PROCEDURE|Computed Tomography|Undergo PET/CT
214519693|NCT03542695|DRUG|Copper Cu-64-DOTA-alendronate|Given IV
214519694|NCT03542695|OTHER|Pharmacokinetic Study|Correlative studies
214519695|NCT03542695|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214519696|NCT03838575|DRUG|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
214519697|NCT03838575|DEVICE|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
214519698|NCT03838575|DEVICE|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
214519699|NCT03838575|OTHER|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
214519700|NCT00230269|PROCEDURE|PET-CT|
214519701|NCT05420584|PROCEDURE|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
214519702|NCT05420584|DRUG|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
214519703|NCT05420584|DRUG|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
214519704|NCT05420584|DIAGNOSTIC_TEST|Pelvic MRI|Pelvic MRI to evaluate efficacy
214519705|NCT05420584|PROCEDURE|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
214441729|NCT03805594|BIOLOGICAL|Pembrolizumab|Given IV
214441730|NCT05476575|OTHER|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
214441731|NCT05650411|DEVICE|LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).|Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
214441732|NCT05650411|DRUG|P2Y12 inhibitor-based SAPT after short DAPT|Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
214441733|NCT05650411|DRUG|Conventional DAPT|6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
214441734|NCT05369182|DIAGNOSTIC_TEST|Invasive physiologic assessment|"All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.~In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed."
215118778|NCT04468581|BEHAVIORAL|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
215118779|NCT03030417|DRUG|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
215118780|NCT03030417|OTHER|Ondansetron|Anti-emetic for nausea or vomiting.
214441735|NCT05369182|DIAGNOSTIC_TEST|Intravascular imaging|By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS \[Boston Scientific, Natick, Massachusetts, USA\] or OCT \[Abbott Vascular\], St. Paul, MN, USA\]).
214441736|NCT05788848|BEHAVIORAL|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
215118781|NCT03030417|OTHER|Olanzapine|Persistent nausea or vomiting.
215118782|NCT03030417|OTHER|Lorazepam|Persistent nausea or vomiting.
215118783|NCT03030417|OTHER|Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate|Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.
214441737|NCT06753825|DEVICE|Radiofrequency|radiofrequency treatment
214441738|NCT06753825|DRUG|flunarizine|flunarizine oral treatment
214441739|NCT05103033|BEHAVIORAL|Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)|The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
214441740|NCT05103033|BEHAVIORAL|Attentional Placebo Control|Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
214441741|NCT03229811|OTHER|ESRD education + conservative kidney management and ACP education|Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
214441742|NCT04093362|DRUG|Futibatinib|Oral tablets
214441743|NCT04093362|DRUG|Cisplatin|IV infusion
214441744|NCT04093362|DRUG|Gemcitabine|IV infusion
214441745|NCT01338389|DIETARY_SUPPLEMENT|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
214441746|NCT01338389|DIETARY_SUPPLEMENT|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
214441747|NCT05795634|BEHAVIORAL|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
214441748|NCT06419777|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
214441749|NCT05896878|DIETARY_SUPPLEMENT|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
214519706|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
214519707|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
214519708|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
214519709|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
214519710|NCT04432415|DEVICE|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
214519711|NCT04432415|DEVICE|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
214519712|NCT04432415|DEVICE|Placebo|biannual application of artificial saliva
214519713|NCT02954783|BEHAVIORAL|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
214519714|NCT02954783|BEHAVIORAL|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
214519715|NCT03982797|BIOLOGICAL|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
214519716|NCT01768585|DRUG|Ivabradine|Please see description of Intervention Arm
214441750|NCT06776627|OTHER|Adapted physical activity (APA)|Adapted program: aerobic capacity, strength, endurance, flexibility, balance and proprioception tests. APA sessions take place over 12 weeks. There will be 2 to 3 sessions per week. Course of a session: - Warm-up: 10-15min: cycling or walking. - Moderate-intensity endurance activity: cycling, walking or swimming: 10min, the duration will be increased gradually up to a minimum of 30min at the end of the program. - Muscle strengthening: with polyarticular or monoarticular exercises targeting the upper limbs or lower limbs in alternation and sheathing. At the beginning: 8 exercises per session and 8 repetitions, 1 time per week. Objective will be to increase the number of repetitions and then integrate other exercises to reach 10 exercises with 12 repetitions, 2 times per week. - Stretching and balance: learning to stretch the muscle groups worked and then working on proprioception (bipodal, monopodal station, then double task). - Quiet time: relaxation through breathing 5 min.
214441751|NCT04047810|BIOLOGICAL|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
214519717|NCT01768585|DRUG|Placebo|
214441752|NCT06777160|PROCEDURE|Collecting data from patients who underwent arthroplasty and cement was used|Collecting data that may change in cement reaction before, during and after surgery from patients who underwent arthroplasty and cement use and taught it to artificial intelligence.
214519718|NCT04572165|DRUG|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214519719|NCT04572165|DRUG|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214519720|NCT04572165|DRUG|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214519721|NCT01204502|BIOLOGICAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
214519722|NCT06199011|DRUG|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
214519723|NCT06199011|DRUG|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
214519724|NCT05823714|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
214519725|NCT00397098|DRUG|SR58611A|
214519726|NCT06506409|DEVICE|Smart-Video Based Game Therapy|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
214519727|NCT06506409|OTHER|Otago Based Structured Exercise|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
214519728|NCT06506409|OTHER|No intervention|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
214519729|NCT02070640|DRUG|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
214519730|NCT02070640|DEVICE|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
214519731|NCT04453930|DRUG|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
214519732|NCT04453930|DRUG|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
214519733|NCT04453930|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
215029259|NCT05341843|DRUG|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
215029260|NCT05341843|DRUG|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
215029261|NCT03514940|DIAGNOSTIC_TEST|ultrasound|second trimester us scan will be made to pregnant women
215029262|NCT01498809|DRUG|Midodrine|Single 10 mg dose
215029263|NCT03218475|OTHER|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
215029264|NCT02704884|DIETARY_SUPPLEMENT|probiotic soy milk|
214441753|NCT05890183|BEHAVIORAL|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
214441754|NCT05890183|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
215118784|NCT03030417|OTHER|Loperamide|Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.
214441755|NCT05890183|BEHAVIORAL|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.
214441756|NCT05890183|BEHAVIORAL|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.
214441757|NCT05890183|BEHAVIORAL|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
214441758|NCT06781567|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
214441759|NCT04998123|DEVICE|SeizureStop Device|Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
214519734|NCT04453930|DRUG|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
215118785|NCT03030417|OTHER|Diphenhydramine|Diphenhydramine 50 mg intravenous (IV) for allergic reaction.
214519735|NCT02731950|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
214519736|NCT03609450|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
214519737|NCT03609450|BEHAVIORAL|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
214519738|NCT04095897|PROCEDURE|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
214519739|NCT04490694|DRUG|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
215029265|NCT04835259|DRUG|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
215029266|NCT02033408|DRUG|AB (antibiotics)|"1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
215118786|NCT03030417|OTHER|Steroid|For allergic reaction at discretion of principal investigator.
215029267|NCT02033408|DRUG|CS (corticosteroids) Only|"1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
215029268|NCT05858931|PROCEDURE|vaginal repair|vaginal repair
215029269|NCT06456892|DRUG|Pucotenlimab|Pucotenlimab Combined with Standard Chemotherapy Regimen
215029270|NCT05880524|DRUG|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
215029271|NCT05880524|DRUG|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
215029272|NCT02692534|OTHER|Urine cocaine negative|Preoperative urine cocaine negative
215029273|NCT02692534|OTHER|Urine cocaine positive|Preoperative urine cocaine positive
214441760|NCT06763211|PROCEDURE|Chlorhexidine Hair Bath|Intervention group 1 will have a hair bath with 5 ml of chlorhexidine gluconate solution 2 times consecutively. Intervention group 2 will first be given a hair bath using the patient's soap or shampoo. Afterwards, the hair will be bathed 2 times consecutively with 5 ml chlorhexidine gluconate solution. Hair bath will be given to the control group using the patient's own soap or shampoo. Surgical site infection follow-up form, laboratory findings form, vital signs form, culture follow-up form will be filled out before and after banyadon. Additionally, cultures will be taken from the surgical area with hair immediately after bathing, on the 2nd post-operative day, and on the day the stitches are removed.
214441761|NCT05330130|DRUG|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
215029274|NCT02673021|PROCEDURE|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
214519740|NCT04490694|PROCEDURE|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
214519741|NCT01074281|DRUG|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
214519742|NCT01858909|DRUG|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
214519743|NCT02223078|BIOLOGICAL|G17DT|
214519744|NCT02223078|BIOLOGICAL|Placebo Comparator|
214519745|NCT00021996|DRUG|valdecoxib|
214519746|NCT03886207|OTHER|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
214519747|NCT03886207|OTHER|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
214519748|NCT01005563|OTHER|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
214519749|NCT01005563|OTHER|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
214519750|NCT05272202|DRUG|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
214519751|NCT05272202|DEVICE|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
214519752|NCT05272202|DEVICE|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
214519753|NCT00253552|BIOLOGICAL|filgrastim|
214519754|NCT00253552|DRUG|busulfan|
214519755|NCT00253552|DRUG|cyclophosphamide|
214519756|NCT00253552|DRUG|cyclosporine|
214519757|NCT00253552|DRUG|etoposide|
214519758|NCT00253552|DRUG|methotrexate|
214519759|NCT00253552|PROCEDURE|allogeneic bone marrow transplantation|
214519760|NCT00253552|RADIATION|radiation therapy|
214519761|NCT05629806|DRUG|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
214519762|NCT05629806|DRUG|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
214519763|NCT03657745|DEVICE|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
214519764|NCT03813602|DRUG|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
214441762|NCT05330130|DRUG|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
214441763|NCT03217006|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
214692990|NCT02276235|DEVICE|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
214519765|NCT05815459|DEVICE|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
214519766|NCT00453440|PROCEDURE|Cheek swab & blood test|Cheek swab \& blood test
214519767|NCT04139486|PROCEDURE|combined EMBOTRAP II or III and Contact Aspiration|refer to title
214519768|NCT04139486|PROCEDURE|Contact Aspiration alone|refer to title
214519769|NCT02409407|DRUG|Misoprostol , Prostaglandins E1 analogue|
215118787|NCT03030417|OTHER|Epinephrine|For allergic reaction at discretion of principal investigator.
214692991|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
215028744|NCT06644508|OTHER|Strict adherence to European guidelines|"The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met."
215029275|NCT00674102|DRUG|ASA404|
215118788|NCT03843892|DRUG|OFEV|twice daily
214519770|NCT01045057|DEVICE|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
214519771|NCT03122548|BIOLOGICAL|CRS-207|Administered by IV infusion over 1 hour.
214519772|NCT03122548|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over 30 minutes.
214519773|NCT03600207|OTHER|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
214519774|NCT03600207|OTHER|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
214519775|NCT01170936|DRUG|canakinumab|Single dose of canakinumab 300mg s.c. injection
214519776|NCT06147115|OTHER|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
214519777|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
214519778|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
214519779|NCT03677986|BEHAVIORAL|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
215029276|NCT02595515|OTHER|Chiropractic treatment|Procedure: chiropractic treatment.
215029277|NCT02595515|OTHER|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
215029278|NCT01280669|DRUG|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
215029279|NCT01280669|DRUG|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
215029280|NCT05930639|OTHER|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
215029281|NCT06392425|OTHER|caspase 3 and ADAM 17 biomarkers|Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
215029282|NCT00000684|DRUG|Dextran sulfate|
214441764|NCT03217006|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
214441765|NCT05778656|BEHAVIORAL|Cardiovascular Risk Prevention with a Mediterranean Dietary Pattern Reduced in Saturated Fat|Eight-week behavioral intervention consisting of a Mediterranean dietary pattern with elimination of red and processed meat
214441766|NCT06456866|OTHER|interpretation|interpretation of blood gases samples
214441767|NCT06737406|DRUG|Topical 5% fluorouracil cream|Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)
214441768|NCT06737406|DRUG|Topical 0.005% calcipotriol ointment|Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
214441769|NCT06737406|DRUG|Placebo|A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.
214441770|NCT06737406|DRUG|Placebo|A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
214441771|NCT06739824|DIAGNOSTIC_TEST|Conventional Treatment(CI)|Patients receive a corticosteroid injection followed by conventional treatment, such as standard physical therapy exercises focused on range of motion and strengthening, without the specific manual techniques of the Spencer method.
214441772|NCT06739824|COMBINATION_PRODUCT|Spencer Technique (CI)|Patients receive a corticosteroid injection followed by the Spencer technique, which involves a series of specific manual mobilization maneuvers aimed at improving shoulder mobility and reducing pain.
214441773|NCT04670081|DRUG|Psilocybin|25 mg, p.o.
214441774|NCT04670081|DRUG|Psilocybin|5 mg, p.o.
214441775|NCT04670081|DRUG|Nicotinamide|100 mg, p.o.
214441776|NCT03717415|DRUG|Rebastinib|Administered orally
214441777|NCT03717415|DRUG|Carboplatin|Administered by IV infusion
214441778|NCT06102460|DIETARY_SUPPLEMENT|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
214441779|NCT06102460|DIETARY_SUPPLEMENT|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
214441780|NCT06102460|DIETARY_SUPPLEMENT|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
215118789|NCT01423968|BIOLOGICAL|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
214441781|NCT06102460|DIETARY_SUPPLEMENT|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
214441782|NCT03401853|OTHER|Laboratory Biomarker Analysis|Correlative studies
214441783|NCT03401853|BIOLOGICAL|Pembrolizumab|Given IV
214441784|NCT03401853|BIOLOGICAL|Rituximab|Given IV
215118790|NCT01423968|OTHER|saline|
215118791|NCT04724915|PROCEDURE|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
215118792|NCT04724915|PROCEDURE|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
215118793|NCT05335876|BIOLOGICAL|onasemnogene abeparvovec|Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
215118794|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
214441785|NCT03401853|BIOLOGICAL|Obinutuzumab|Given IV
214441786|NCT05937425|OTHER|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
214441787|NCT05097599|DRUG|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
214441788|NCT05097599|DRUG|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
214441789|NCT05097599|DRUG|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
214441790|NCT05097599|DRUG|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
214441791|NCT05097599|DRUG|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
214441792|NCT05097599|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
214441793|NCT05097599|DRUG|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
215118795|NCT01684202|DRUG|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
214441794|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
214441795|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
214441796|NCT06795061|BEHAVIORAL|Peer-Supported Exercise with Professional Guidance|Participants will engage in small, peer-supported exercise groups (4-6 individuals) to coordinate weekly sessions (e.g., running, cycling, yoga). A professional coach provides knowledge-based guidance remotely, focusing on safe exercise techniques, injury prevention, basic nutrition, and motivation strategies, but does not conduct in-person training sessions. The aim is to improve adherence to physical activity and enhance mental well-being through peer accountability and evidence-informed coaching.
214441797|NCT05998278|PROCEDURE|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction\_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
214519780|NCT03187249|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
214519781|NCT03187249|BEHAVIORAL|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
214519782|NCT03187249|BEHAVIORAL|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
214519783|NCT04529200|OTHER|electrotherapy treatment|physical therapy management like EMS IFT
214519784|NCT02332889|BIOLOGICAL|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
214692992|NCT01458509|BEHAVIORAL|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
215118796|NCT00191308|DRUG|pemetrexed|500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
215118797|NCT00191308|DRUG|cisplatin|75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
215118798|NCT00191308|PROCEDURE|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
215118799|NCT06583629|BEHAVIORAL|Emotional Freedom Technique|EFT is a self-help technique that incorporates conscious awareness of thoughts and feelings with a gentle touch involving tapping with fingertips on acupuncture/acupressure points on the face, hands, and body. EFT also helps relieve primary physical and emotional symptoms. Gary Craig created EFT, which involved lightly tapping on the body on 12 acupressure sites (also known as acupoints). This acupoints are situated along the body's meridians, or virtual energy channels
215118800|NCT05651906|PROCEDURE|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
215118801|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
215118802|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
215118803|NCT02376972|DRUG|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
215118804|NCT02376972|DRUG|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
215118805|NCT00779025|DEVICE|PD-F-5254|Female Personal Lubricant (MINE)
215118806|NCT00779025|DEVICE|10855-096|Male Personal Lubricant (YOURS)
215118807|NCT03008694|DEVICE|PET/CT|pet/ct is used as radiotherapy simulation
215118808|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
215118809|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
214441798|NCT06444724|COMBINATION_PRODUCT|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
214441799|NCT05744960|BEHAVIORAL|Communication training|Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
214441800|NCT05744960|BEHAVIORAL|financial Incentive|Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
215028745|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of nano-crystalline putty hydroxyapatite.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
215118810|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
215118811|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
215118812|NCT01522300|OTHER|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
214441801|NCT06480981|DRUG|Noribogaine|Noribogaine capsules
214441802|NCT04123379|DRUG|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
214441803|NCT04123379|DRUG|BMS-813160|300mg oral twice a day for 28 days
214441804|NCT04123379|DRUG|BMS-986253|2400mg once by injection
214441805|NCT06583135|OTHER|Sleep hygiene education and motivational interviewing|The intervention group, will receive face-to-face sleep hygiene training and then 4 online motivational interviews will be held within 6 weeks. The online motivational interviews will be implemented in the 1st week (interview 1), 2nd week (interview 2), 4th week (interview 3), and 6th week (interview 4).
214519785|NCT02332889|DRUG|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
215118813|NCT01522300|OTHER|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
215118814|NCT04332718|DEVICE|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
214441806|NCT06583135|OTHER|face-to-face sleep hygiene training|The control group receive face-to-face sleep hygiene training
214441807|NCT04073290|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
214441808|NCT04073290|DRUG|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
214441809|NCT04073290|DRUG|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
214441810|NCT06436157|OTHER|Enhanced education|"In addition to the education conducted as part of usual care, the nurse will: 1) provide basic education on GCT; and 2) if the patient is eligible and agreeable to GCT, place a referral to GCT (if not already ordered).~Patients will also be provided with written materials reinforcing the key messages of GCT education, designed to be understandable to individuals without a medical background. Nurses will also conduct a follow-up nudge by sending an in basket message via electronic medical record to ensure that the referrals are processed by the referral coordinators."
214441811|NCT06436157|OTHER|Usual care education|"A brief introduction to GCT will be provided in accordance with the information covered in the chemo education binder, which is the current standard of care at Enloe Regional Cancer Center. As per the usual care, referrals for genetic testing will be clinician-initiated without the proactive involvement of the RN."
214519786|NCT06200818|PROCEDURE|Diode laser|
214519787|NCT06200818|PROCEDURE|Er:CrYSGG|
214519788|NCT06200818|PROCEDURE|Formocresol|
214441812|NCT06495190|DIETARY_SUPPLEMENT|Blueberry|50 g/d blueberry powder supplement
214519789|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
214441813|NCT06495190|BEHAVIORAL|Walking|Five 45-min walking sessions per week
215118815|NCT03710642|DRUG|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
214441814|NCT06495190|DIETARY_SUPPLEMENT|Placebo|50 g/d placebo powder supplement
214441815|NCT06495190|BEHAVIORAL|Stretching|Five 45-min stretching sessions per week
214441816|NCT06170580|DIAGNOSTIC_TEST|Conventional duplex|Conventional carotid duplex measurement
214441817|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
214441818|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
214441819|NCT05869656|BEHAVIORAL|Fluid restriction|Oral fluid restriction of 1000ml per day
214441820|NCT05869656|BEHAVIORAL|Free fluids|Continue care without any oral fluid restriction
214441821|NCT06453824|DRUG|MDI-2517|study drug
214441822|NCT06453824|OTHER|Placebo|matching placebo
214441823|NCT05792137|OTHER|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
214441824|NCT05792137|OTHER|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
214441825|NCT06799806|DEVICE|virtual reality device|20 minutes session with virtual reality device
214441826|NCT05504226|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily for 52 weeks.
214519790|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
214519791|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
214519792|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
214519793|NCT01381198|PROCEDURE|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
215118816|NCT03710642|DRUG|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
214441827|NCT05504226|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.
214441828|NCT05368662|OTHER|Quality of life and sleep questionnaire|Evaluation of quality of life and quality of sleep by questionnaires
214441829|NCT05288283|DRUG|GWP42003-P|oral solution
214441830|NCT05288283|DRUG|Placebo|oral solution
214441831|NCT05765344|DRUG|Bulevirtide|Administered via subcutaneous injections.
214441832|NCT05002647|OTHER|NO intervention|There is no intervention
214441833|NCT03511118|DRUG|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441834|NCT03511118|DRUG|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441835|NCT03511118|DRUG|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441836|NCT03511118|DRUG|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441837|NCT03511118|DRUG|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441838|NCT03511118|DRUG|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441839|NCT03511118|DRUG|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441840|NCT03511118|DRUG|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441841|NCT03511118|DRUG|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441842|NCT03511118|DRUG|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441843|NCT03511118|DRUG|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441844|NCT03511118|DRUG|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441845|NCT03511118|DRUG|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441846|NCT03511118|DRUG|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441847|NCT03511118|DRUG|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441848|NCT03511118|DRUG|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441849|NCT03511118|DRUG|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214692993|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
214692994|NCT01458509|BEHAVIORAL|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
214441850|NCT03511118|DRUG|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441851|NCT03511118|DRUG|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441852|NCT03511118|DRUG|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214519794|NCT01946256|DRUG|Amoxicillin|
214519795|NCT01946256|DRUG|Erythromycin|
214692995|NCT03122028|DEVICE|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
214441853|NCT03511118|DRUG|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214519796|NCT06812247|OTHER|Therapy dog visits|2-3 ten-minute visits by a trained therapy dog and the dog's handler
214519797|NCT06812247|OTHER|Dog handler visits|2-3 ten-minute visits by a dog handler
214519798|NCT02569294|BEHAVIORAL|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
214519799|NCT02569294|BEHAVIORAL|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
214692996|NCT01767194|BIOLOGICAL|Dinutuximab|Given IV
214441854|NCT03511118|DRUG|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441855|NCT03511118|DRUG|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441856|NCT03511118|DRUG|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441857|NCT03511118|DRUG|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441858|NCT03511118|DRUG|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441859|NCT03511118|DRUG|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441860|NCT03511118|DRUG|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214692997|NCT01767194|DRUG|Irinotecan Hydrochloride|Given IV
214692998|NCT01767194|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214692999|NCT01767194|BIOLOGICAL|Sargramostim|Given SC or IV
214693000|NCT01767194|DRUG|Temozolomide|Given PO
214693001|NCT01767194|DRUG|Temsirolimus|Given IV
214693002|NCT00001439|BIOLOGICAL|gp100 human melanoma peptide|
214693003|NCT02474667|DRUG|ANG-3777|
214693004|NCT02474667|OTHER|Placebo|
214693005|NCT05846997|DIAGNOSTIC_TEST|Liquid biopsy and imaging|Liquid biopsy and imaging
214693006|NCT04072354|DRUG|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
214693007|NCT04072354|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
214693008|NCT04072354|DRUG|Placebo|Placebo tablet dosed once daily
214693009|NCT05165576|BEHAVIORAL|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
214693010|NCT02920684|OTHER|Passive legs mobilisation|A physiotherapist performs a passive leg movement
214693011|NCT02920684|OTHER|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
214693012|NCT02920684|OTHER|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
214441861|NCT03511118|DRUG|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441862|NCT03511118|DRUG|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214519800|NCT02569294|BEHAVIORAL|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
214519801|NCT02995447|OTHER|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
214693013|NCT02920684|OTHER|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
214693014|NCT01444495|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
214693015|NCT01444495|PROCEDURE|Surgery|Total mesorectal excision of rectal cancer
215118817|NCT02240771|PROCEDURE|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
215118818|NCT02240771|DRUG|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days"
214441863|NCT03511118|DRUG|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441864|NCT03511118|DRUG|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214519802|NCT05283876|DEVICE|Excimer light|Excimer light sessions
214519803|NCT05459584|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
214519804|NCT01647802|DEVICE|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
214519805|NCT01647802|DEVICE|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
214519806|NCT01647802|DEVICE|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
214519807|NCT05688605|DRUG|MRG003+HX008|Administered intravenously
214693016|NCT00495664|DEVICE|Titan stent and Taxus-Liberte stent|
214693017|NCT02946710|BIOLOGICAL|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
214693018|NCT05831059|RADIATION|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
214693019|NCT05831059|OTHER|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
214441865|NCT03511118|DRUG|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441866|NCT03511118|DRUG|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441867|NCT03511118|DRUG|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441868|NCT03511118|DRUG|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441869|NCT03511118|DRUG|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214693020|NCT02764632|PROCEDURE|Digital facilitation|
214693021|NCT06679621|BEHAVIORAL|Telehealth intervention|This telehealth intervention will be made using human centered design methods
214693022|NCT07006584|OTHER|Experimental|Group B participated in the same workshops and additionally completed functional gait training using the SSM Fisior® program. The intervention period lasted 12 weeks for both groups, with 2 additional weeks allocated for baseline and post-intervention assessments (T1 and T2).
214693023|NCT07006584|OTHER|Active Comparator #1|Group A attended only the physical activity workshops offered by Centro Integral del Adulto Mayor (CIAM), consisting of one weekly class each of gymnastics, dance, swimming, and Tai Chi, held on different days of the week.
214441870|NCT03511118|DRUG|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
214441871|NCT04709380|OTHER|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
214441872|NCT04709380|DRUG|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
214519808|NCT05127902|DIAGNOSTIC_TEST|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG\_max) for comparison with normalization signal processing program in Noraxon System."
214519809|NCT05977985|DRUG|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
214519810|NCT05977985|DRUG|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
214519811|NCT02815800|DIETARY_SUPPLEMENT|ETHNODYNE VISIO|
214519812|NCT02871245|PROCEDURE|Laparoscopic Surgery|
214519813|NCT02871245|DEVICE|Acupuncture treatment|
214519814|NCT00424502|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
214519815|NCT00424502|DRUG|Methotrexate|10-25mg po/week
214519816|NCT06826326|DRUG|Escitalopram 10mg|oral administration of escitalopram 10 mg
214519817|NCT06826326|DRUG|Placebo|Placebo
214519818|NCT04448561|DRUG|ASP8082|oral
214519819|NCT04448561|DRUG|morphine|oral
214519820|NCT04448561|DRUG|Placebo|oral
214519821|NCT07009054|BEHAVIORAL|Nutrition Education and Exercise|A 6-week intensive randomized controlled trial will be conducted with a total of 60 participants. Thirty participants will be assigned to the intervention group and thirty to the control group through simple randomization using a table of random numbers. The intervention group will receive one weekly theoretical-practical nutrition education session in Urdu and one physical activity session based on Nordic walking per week, for a total of six nutrition sessions and six physical activity sessions over the 6-week period.
214519822|NCT07009054|BEHAVIORAL|Usual Care Group|The control group will participate in 2 theoretical sessions of nutrition education and 2 of physical exercise.
214519823|NCT02010086|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
214519824|NCT02010086|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
214519825|NCT07009249|BEHAVIORAL|Pelvic floor muscle training|"Women in this group will undergo pelvic floor muscle training (PFMT) using the NeuroTrac MyoPlus 4 PRO EMG biofeedback device. Prior to the training, diaphragmatic breathing will be taught to all participants in this position to facilitate relaxation and prepare for PFMT. During the training, participants will perform pelvic floor muscle contractions while observing the real-time feedback of slow and fast contractions, as well as relaxation phases, on the computer screen connected to the device. Concurrently, the physiotherapist will guide the participants with verbal cues such as squeeze-lift-release. Participants will be instructed to avoid holding their breath, pulling in their abdomen, straining, contracting the thigh or gluteal muscles, or moving the pelvis during the exercises. The PFMT protocol will follow the principles of motor learning stages to ensure proper skill acquisition."
214693024|NCT05104099|DRUG|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
214693025|NCT04973228|DRUG|Roflumilast Foam|Roflumilast 0.3% foam for topical application
214693026|NCT04973228|DRUG|Vehicle Foam|Vehicle foam for topical application
214441873|NCT05653258|OTHER|Lifestyle Intervention|"1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
214441874|NCT05653258|DRUG|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
214441875|NCT05653258|DRUG|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
214441876|NCT05653258|DRUG|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
214441877|NCT05653258|PROCEDURE|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
214441878|NCT03388775|OTHER|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
214441879|NCT05227144|DRUG|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
214441880|NCT04367506|BEHAVIORAL|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
214441881|NCT04367506|BEHAVIORAL|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
214441882|NCT06790732|DRUG|Saline|Patients received sham PENG block (just 1mL saline).
214441883|NCT06790732|DRUG|Bupivacaine + Dexamethasone|Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
214441884|NCT06784596|OTHER|Teleconsulting supported training|Patients in this group will be provided with training the day before surgery, on the morning of surgery and on the day of discharge, and will receive teleconsulting services at the 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th and 12th weeks after discharge. will be given.
214441885|NCT02488863|OTHER|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
214441886|NCT02488863|OTHER|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
214441887|NCT02488863|OTHER|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A\&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
214441888|NCT02488863|OTHER|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
214441889|NCT06792435|DRUG|XNW27011|"Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.~An accelerated titration scheme will be used for the first two dose levels (0.6 mg/kg and 1.2 mg/kg) starting from 0.6 mg/kg dose as follows:~The first patient will be enrolled for 0.6 mg/kg dose. If the subject shows no significant toxicity in cycle 1 (DLT observation period), the second patient will be enrolled for 1.2 mg/kg.~3 + 3 dose escalation:3 patients will be enrolled to the dose cohort first，If 1 of 3 patients experiences a DLT, up to 3 more patients will be enrolled in the same dose cohort.. If none of the additional 3 patients experiences a DLT, dose escalation will continue to the next dose.Dose escalation will be stopped when 2 or more patients out of 3 to 6 patients at the same dose level experience a DLT."
214693027|NCT02490150|DRUG|Corifollitropin alfa|
214693028|NCT03532555|DIETARY_SUPPLEMENT|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
215118819|NCT04633928|BIOLOGICAL|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
214441890|NCT06792435|DRUG|XNW27011|Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
214441891|NCT06763133|OTHER|Cold Water Spray Application|Cold water spray application after endonasal endoscopic surgery.
214441892|NCT06763133|OTHER|Clinical routine practice|The process of giving 2 cc of water to patients with a syringe as a clinical routine practice.
214693029|NCT03532555|OTHER|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
214693030|NCT04237207|DEVICE|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
214693031|NCT04237207|DEVICE|301-M062 sound processor & software|New cochlear implant sound processor
215118820|NCT02289638|DEVICE|Intubrite|Video-Laryngoscopy
215118821|NCT02289638|DEVICE|MIL|Direct-Laryngoscopy
214693032|NCT06421246|BEHAVIORAL|Staff-facing screen|Activity will be monitored before and after the introduction of a staff-facing screen
215118822|NCT06140706|BEHAVIORAL|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
215118823|NCT00530738|DRUG|Lipoplus|i.v. fat emulsion for parenteral nutrition
214441893|NCT05654922|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
214693033|NCT07010822|BIOLOGICAL|nOPV2|nOPV2 will be administered at birth and Wk 14 of age depending on the study arm.
214693034|NCT06681623|DRUG|Ublituximab|Drug: ublituximab
214693035|NCT06625723|PROCEDURE|Standard postoperative care|This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
215118824|NCT00530738|DRUG|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
215118825|NCT05034419|DEVICE|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
215118826|NCT05034419|DEVICE|Sham stimulation|Sham stimulation
215118827|NCT02992574|RADIATION|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
215118828|NCT06154707|DRUG|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
214441894|NCT05654922|OTHER|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
214441895|NCT05306509|BEHAVIORAL|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
214441896|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
214441897|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
214441898|NCT01615393|DRUG|ribavirin [Copegus]|Single oral dose of 400 mg tablets
214441899|NCT01615393|DRUG|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
214441900|NCT05128968|PROCEDURE|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
214441901|NCT03069859|DRUG|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
214441902|NCT03069859|DRUG|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
214441903|NCT01046136|DRUG|guaifenesin (Mucinex)|bid 7 days
214441904|NCT01046136|DRUG|placebo|bid 7 days
214441905|NCT04759833|DRUG|Prucalopride|Prucalopride oral solution or oral tablets.
214441906|NCT04759833|OTHER|Placebo|Prucalopride-matching placebo oral solution or oral tablets.
214441907|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
214441908|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
214441909|NCT02664558|DRUG|ubenimex|
214693036|NCT06625723|DEVICE|Surgical Recovery Systems Sleep Aid|Sleep assistive device
214693037|NCT06684535|DRUG|Dexmedetomidine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
214693038|NCT06684535|DRUG|Saline|Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
214693039|NCT06684431|BIOLOGICAL|N-pVAX1|Crimean Congo Hemorrhagic Fever Vaccine
214693040|NCT06684626|DRUG|Sodium Hyaluronate|Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
215118829|NCT06154707|OTHER|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
215118830|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
215118831|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
215118832|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
215118833|NCT04649515|OTHER|0.9% saline|Placebo
215118834|NCT01079416|DEVICE|Capsule endoscopy, Esophagogastroduodenoscopy|
214441910|NCT02664558|OTHER|placebo|
215118835|NCT00782717|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
214441911|NCT01408849|DRUG|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
214441912|NCT01408849|DRUG|Omeprazole|Standard therapy
215118836|NCT00782717|OTHER|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
215118837|NCT00782717|DRUG|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
214441913|NCT01989455|DRUG|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
214441914|NCT01989455|DRUG|Placebo|Placebo: normal saline solution.
214441915|NCT00980473|PROCEDURE|Argon Laser Iridoplasty|
214441916|NCT00980473|DRUG|Travatan/ Timolol/Azopt|
214441917|NCT04421469|DRUG|Triprilimab(JS001)|"1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment."
214519826|NCT07009249|BEHAVIORAL|Dynamic neuromuscular stabilization|Women in this group will be instructed in exercises based on the principles of Dynamic Neuromuscular Stabilization (DNS). Prior to the exercises, intra-abdominal pressure regulation through breathing techniques will be demonstrated. In this study, the Core 360 belt with OhmTrack sensors will be used. Both breathing exercises and DNS exercises will be taught with the belt in place. In a corrected posture, participants will be instructed to gently press the abdominal wall toward the sensors and to maintain expansion of the abdominal wall during both inspiration and expiration, while keeping the spine in a neutral position. The exercise program will begin with a preparatory training phase, which includes fascial mobilizations applied to the feet and hands. DNS exercises will start with the 4.5-month supine developmental position for sagittal stabilization. As the program progresses, exercises will be advanced according to developmental kinesiology positions.
214519827|NCT07008079|PROCEDURE|Flapless punch|use of flapless puch surgery to place dental implants
214693041|NCT06684626|DRUG|Levofloxacin 500mg|Treatment typically involves fluoroquinolones alone, such as levofloxacin.
214441918|NCT00632203|DRUG|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
214693042|NCT07013890|DRUG|FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium|"FICOXPEA® is a phytoterapic compound made of:~* phycocyanin (spirulina platensis extract) 250 mg~* palmitoylethanolamide 200 mg~* L-selenometionine 11 mg"
214693043|NCT00755352|DRUG|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
215118838|NCT03016065|DIETARY_SUPPLEMENT|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
214441919|NCT02095171|DRUG|PRX002|
214441920|NCT02095171|OTHER|Placebo|
214441921|NCT02574442|DEVICE|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
214441922|NCT05771350|PROCEDURE|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
214441923|NCT05771350|PROCEDURE|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
214441924|NCT05771350|PROCEDURE|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
214441925|NCT01411631|DIETARY_SUPPLEMENT|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
214441926|NCT02641912|OTHER|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
214441927|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
214441928|NCT05327049|OTHER|no intervention|treatment of deep carious lesions
214441929|NCT05327049|DEVICE|diode laser|laser light for cavity disinfection
214441930|NCT05327049|DIETARY_SUPPLEMENT|Aloe Vera|herbal dietary supplement for treatment of deep carious lesions
214441931|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
214441932|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
214441933|NCT05588817|GENETIC|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
214441934|NCT05490524|DEVICE|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
214441935|NCT02129283|BEHAVIORAL|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
215118839|NCT03016065|DIETARY_SUPPLEMENT|Control|Baked goods (2 snacks) without added fiber
214693044|NCT00755352|DRUG|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
214693045|NCT04883580|DEVICE|Navigation and Positioning System for Orthopedic Surgeries|"Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation"
215118840|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
215118841|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
214519828|NCT07008079|PROCEDURE|Flapless mini-incision|Use of a flapless mini-incision to place a dental implant
214519829|NCT07008079|PROCEDURE|Conventional flap|Use of a conventional surgical flap to place a dental implant
214519830|NCT06870578|OTHER|Diet modification|In Study 2 only, children will be provided all meals for a 7-day period. Meals will consist of nutritious foods, calories provided will exceed the child's estimated daily caloric need, and children will be asked to consume meals ad libitum.
214519831|NCT04447586|OTHER|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
214693046|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
215028746|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade without vertical releasing incision.~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of nano-crystalline putty hydroxyapatite..~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
215118842|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
215118843|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
215118844|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
215118845|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
215118846|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
215118847|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
215118848|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
215118849|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
215118850|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
215118851|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
215118852|NCT00241722|DRUG|Alvimopan|
215118853|NCT00241722|DRUG|Placebo|
215118854|NCT01669317|OTHER|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
215118855|NCT01669317|OTHER|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
215118856|NCT06312657|BEHAVIORAL|Drug Cue|Individualized drug cues paired with choice options reinforced by $0.25
215118857|NCT06312657|BEHAVIORAL|Money|Two money values will be tested ($0.25 and $4.00)
215118858|NCT06312657|DRUG|Withdrawal|Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
215118859|NCT03291483|OTHER|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
215118860|NCT03291483|OTHER|plyometric training|Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
215118861|NCT03796117|DEVICE|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
214441936|NCT02746549|OTHER|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
214441937|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention|"A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month."
214441938|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention|The Enhanced TCBD/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
214441939|NCT06413693|DRUG|PF-07293893|A single dose of PF-07293893 administered orally as tablets
214441940|NCT06413693|DRUG|Placebo|A single dose of Placebo administered orally as tablets that look the same as PF-07293893
214441941|NCT03358693|DRUG|Anti-TNF|Subject receives anti-TNF antibodies open-label as per guidelines
214441942|NCT03358693|DRUG|Anti-IL12/23|Subject receives anti-IL12/23 antibodies open-label as per guidelines
214441943|NCT03358693|DRUG|Anti-IL17|Subject receives anti-IL17 antibodies open-label as per guidelines
214441944|NCT03358693|DRUG|Dupilumab|Subject receives Dupilumab open-label as per guidelines
214441945|NCT03358693|DRUG|Anti-IL23|Subject receives anti-IL23 antibodies open-label as per guidelines
214441946|NCT03358693|DRUG|Baricitinib|Subject receives Baricitinib open-label as per guidelines
214441947|NCT03358693|DRUG|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
214441948|NCT03358693|DRUG|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
214441949|NCT03358693|DRUG|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
214519832|NCT04447586|OTHER|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
214519833|NCT05356130|BEHAVIORAL|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
214519834|NCT05356130|BEHAVIORAL|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
214519835|NCT03141177|BIOLOGICAL|Nivolumab|Specified dose on specified day
214519836|NCT03141177|DRUG|Cabozantinib|Specified dose on specified days
214519837|NCT03141177|DRUG|Sunitinib|Specified dose on specified days.
214519838|NCT03141177|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214519839|NCT04798898|DEVICE|RFA (radiofrequency ablation)|Preoperative RFA-induced partial necrosis of the liver metastasis
214519840|NCT03535376|DRUG|Valsartan|Patients are tested for their normal prescription valsartan medication
214519841|NCT05569525|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
214519842|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)
214519843|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
215118862|NCT03796117|DEVICE|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
215118863|NCT02292719|DRUG|OBV/PTV/r|Tablet
215118864|NCT02292719|DRUG|Sofosbuvir|Tablet
215118865|NCT02292719|DRUG|Ribavirin (RBV)|Tablet
214441950|NCT03358693|DRUG|Lebrikizumab|Subject receives Lebrikizumab open-label as per guidelines
214441951|NCT03358693|DRUG|Nemolizumab|Subject receives Nemolizumab open-label as per guidelines
215118866|NCT02538042|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
215118867|NCT02538042|DRUG|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
215118868|NCT02538042|BEHAVIORAL|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
214441953|NCT05064735|DRUG|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
214441954|NCT05064735|DRUG|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
214519844|NCT02031055|DRUG|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
214519845|NCT06226545|DRUG|LASN01|Low dose of LASN01 will be administered intravenously.
215118869|NCT02538042|BEHAVIORAL|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
215118870|NCT04936061|DEVICE|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
215118871|NCT04936061|DEVICE|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
214441955|NCT02886286|DRUG|Bupivacaine|Patient-activated intrathecal bolus for incident pain
214441956|NCT02886286|DRUG|Opioid|Patient-activated intrathecal bolus for incident pain
214441957|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
215118872|NCT03026881|DRUG|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
215118873|NCT03026881|DRUG|Apatinib|Oral
215118874|NCT03026881|DRUG|Paclitaxel|Intravenous injection
215118875|NCT04676620|PROCEDURE|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
215118876|NCT00034294|DRUG|GT160-246|
215118877|NCT01187628|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
215118878|NCT01059734|GENETIC|DNA analysis|
215118879|NCT01059734|GENETIC|RNA analysis|
215118880|NCT01059734|GENETIC|mutation analysis|
215118881|NCT01059734|GENETIC|polymerase chain reaction|
215118882|NCT01059734|GENETIC|polymorphism analysis|
215118883|NCT01059734|OTHER|laboratory biomarker analysis|
215118884|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
215118885|NCT03136016|BEHAVIORAL|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
215118886|NCT03136016|BEHAVIORAL|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
214441958|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
214519846|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
214519847|NCT06226545|DRUG|Placebo|Placebo will be administered intravenously.
214519848|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
214519849|NCT02680314|DRUG|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
214519850|NCT06720064|DEVICE|Chlorhexidine Dressing|Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
214519851|NCT06719908|DRUG|AFA-281 is a small molecule, orally available|This is a study to evaluate the interaction of AFA-281 with alcohol
214519852|NCT06719908|OTHER|Alcohol (Ethanol)|Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
215118887|NCT03136016|BEHAVIORAL|nudging + educational activities|Group 4 will receive both interventions
215118888|NCT04931069|OTHER|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
215118889|NCT02220829|DRUG|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
215118890|NCT02220829|DRUG|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
214441959|NCT02009813|PROCEDURE|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
214441960|NCT00044564|DRUG|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
214441961|NCT00831688|DEVICE|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
214441962|NCT00831688|DEVICE|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
214441963|NCT02376790|DRUG|Etanercept|Etanercept was administered by subcutaneous injection once a week
214441964|NCT02376790|DRUG|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
214441965|NCT02376790|DRUG|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
215118891|NCT03575728|OTHER|MyChart-MHT|All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
215118892|NCT06821607|BEHAVIORAL|In-Clinic Physical Therapy|Patients in this group will receive all PT sessions in-clinic with a trained physical therapist. Treatment provided for this group will be consistent with evidence-based guidelines that recommend patient education, exercise instruction, manual therapy interventions, and psychosocial interventions. Specific interventions to be provided within each of these categories: Education, Exercise, Manual Therapy, and Psychosocial interventions. Components of the intervention will be determined by the treating therapist based on patients' symptoms, examination findings, and patients' preferences and goals.
214441966|NCT02376790|DRUG|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
214441967|NCT05056077|OTHER|Counseling|Receive support person coaching
214441968|NCT05056077|OTHER|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with a history of cancer
214441969|NCT05056077|BEHAVIORAL|Health Education|Receive health coaching
214441970|NCT05056077|OTHER|Health Promotion and Education - Direct Text Messaging|Receive text messages
214441971|NCT05056077|OTHER|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
214441972|NCT05056077|OTHER|Questionnaires|Quality of Life and Behavioral Questionnaires
214519855|NCT03523897|PROCEDURE|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
215028747|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
214441973|NCT02023710|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
214519856|NCT03523897|PROCEDURE|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
215118893|NCT06821607|BEHAVIORAL|Telehealth Physical Therapy (Telerehabilitation)|Those randomized to telerehabilitation will receive all PT care, including the initial evaluation and 7 follow-up sessions, via real-time video conferencing technology. Like the interventions provided to those receiving in-clinic PT, treatments provided in the telerehabilitation group will be consistent with evidence-based guidelines, adapted for delivery via real-time video visits. Consistent with the in-clinic group, specific interventions will be selected by the treating physical therapist based on patients' symptoms, examination findings, and preferences and goals. There will be an emphasis: Open-ended questions to allow patients to describe the participant's impairments and limitations; Review patient-reported measures of disability and pain intensity to help identify functional impairments; and Clinical examination of spinal movements and impairments in strength, flexibility, and joint mobility.
214441974|NCT02023710|DRUG|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
214441975|NCT02023710|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
214441976|NCT00901901|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
214519857|NCT03188887|DRUG|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
214519858|NCT03188887|DRUG|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
214519859|NCT05349123|BEHAVIORAL|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
214441977|NCT00901901|DRUG|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
214441978|NCT00901901|DRUG|Placebo|Matching erlotinib placebo 150 mg once daily
214441979|NCT01942018|PROCEDURE|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
214441980|NCT01739270|PROCEDURE|supraclavicular brachial plexus block|
215118894|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
214441981|NCT02272816|DRUG|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
214441982|NCT06440642|DEVICE|tonopen|Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
214441983|NCT03624335|PROCEDURE|ECC|Early clamping of the umbilical cord
214441984|NCT03624335|PROCEDURE|DCC|Delayed clamping of the umbilical cord
214441985|NCT03624335|PROCEDURE|Blood Test 6hours|Blood Test 6hours
214441986|NCT03624335|PROCEDURE|Blood Test 24hours|Blood Test 24hours
214441987|NCT03624335|PROCEDURE|Blood Test 48hours|Blood Test 48hours
214441988|NCT03624335|PROCEDURE|Blood Test 28days|Blood Test 28days
214441989|NCT06364683|OTHER|Survey study|The data collection tools to be used in the study will be filled. It does not include any invasive or non-invasive intervention.
214441990|NCT03947684|DEVICE|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
214441991|NCT01136876|DRUG|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
214441992|NCT01136876|DRUG|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
214441993|NCT03281616|BEHAVIORAL|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
214441994|NCT01241916|DEVICE|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
214441995|NCT01241916|DEVICE|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
214441996|NCT01320657|DEVICE|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
214441997|NCT00251576|DRUG|A-Phase: tirofiban; Z-Phase simvastatin|
214441998|NCT00251576|DRUG|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
214441999|NCT00251576|DRUG|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
214442000|NCT00251576|DRUG|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
214442001|NCT00251576|DRUG|Duration of Treatment: Z-Phase, 2 years.|
214442002|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
214442003|NCT00976937|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214442004|NCT00976937|DRUG|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214442005|NCT00976937|DEVICE|Pen auto-injector|
214442006|NCT00976937|DRUG|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
214519860|NCT05349123|BEHAVIORAL|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
214442007|NCT00976937|DRUG|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
214442008|NCT00976937|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
215118895|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
215118896|NCT06367257|PROCEDURE|App Usage|Conducting patient surveys with app
215118897|NCT06367257|OTHER|Standard of Care|supportive care during and after radio(chemo)therapy according to hospial standards
215118898|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
214442009|NCT02317965|OTHER|Maternal Blood Draw|Maternal Blood Draw
214442010|NCT05506436|DEVICE|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
214442011|NCT05506436|OTHER|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
214442012|NCT05640180|DRUG|Finerenone (Kerendia, BAY94-8862)|Retrospective cohort analysis using randomized clinical trials data.
214442013|NCT05640180|DRUG|Sodium-glucose cotransporter-2 inhibitors (SGLT2i)|Retrospective cohort analysis using United States Optum Electronic Health Records data.
214442014|NCT01011946|DEVICE|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
214442015|NCT04222946|OTHER|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
214442016|NCT00826657|DIETARY_SUPPLEMENT|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
214442017|NCT00826657|DIETARY_SUPPLEMENT|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
214442018|NCT03427034|DEVICE|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
214442019|NCT04818931|DRUG|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
214442020|NCT01644916|PROCEDURE|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
214442021|NCT01644916|PROCEDURE|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
214442022|NCT04705311|OTHER|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
214442023|NCT04705311|BEHAVIORAL|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
214442024|NCT04820686|DRUG|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
214442025|NCT04820686|DRUG|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
214442026|NCT04820686|DRUG|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
214442027|NCT05278533|DIETARY_SUPPLEMENT|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
214442028|NCT05278533|DIETARY_SUPPLEMENT|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
214442029|NCT01424670|DRUG|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
214442030|NCT01424670|DRUG|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
214442031|NCT00099931|DRUG|vildagliptin|
214442032|NCT03169894|DRUG|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
214442033|NCT04156204|OTHER|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
214442034|NCT04156204|DRUG|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
214442035|NCT02789215|BEHAVIORAL|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
214442036|NCT00640549|DRUG|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
214442037|NCT00640549|DRUG|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
214442038|NCT05136157|DRUG|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
214442039|NCT00580918|OTHER|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
214442040|NCT01460667|DRUG|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
214442041|NCT01460667|DRUG|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
214519861|NCT03968276|OTHER|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
215118899|NCT05842070|PROCEDURE|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
214442042|NCT05527912|DRUG|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
215118900|NCT05842070|PROCEDURE|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
214442043|NCT02891915|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
214442044|NCT02891915|DRUG|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
214442045|NCT02891915|DRUG|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
214442046|NCT02891915|OTHER|Placebo|Placebo
214442047|NCT00753480|DRUG|D4064A|
214442048|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
214442049|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
214442050|NCT01967836|DEVICE|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
214442051|NCT03452982|OTHER|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
214442052|NCT03481816|BIOLOGICAL|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
214442053|NCT03481816|BIOLOGICAL|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
214442054|NCT03481816|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
215028748|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and ALB-PRF membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing"
215028749|NCT06643429|DIAGNOSTIC_TEST|colorectal cancer|Patients diagnosed with colorectal cancer by pathological biopsy.
215118901|NCT02586727|DRUG|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
215118902|NCT04382885|DRUG|Cariprazine|Oral Solution
215118903|NCT03784677|DRUG|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
215118904|NCT00096980|DRUG|Raptiva (efalizumab)|
215118905|NCT00079560|DRUG|dronabinol|dronabinol to prevent development of marijuana withdrawal
215118906|NCT02478099|DRUG|MPDL3280A|Anti-PD-L1 antibody
215118907|NCT01377662|DRUG|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
214442055|NCT01704196|DRUG|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
214442056|NCT01704196|DRUG|Placebo|
214442057|NCT04943419|DIAGNOSTIC_TEST|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
214442058|NCT04223258|DEVICE|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
215118908|NCT01377662|OTHER|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
214442059|NCT04223258|OTHER|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
214442060|NCT04393389|DEVICE|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
214442061|NCT01811394|RADIATION|protons|Treatment is performed using 16 x 4 GyE protons
214442062|NCT01811394|RADIATION|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
214442063|NCT00750620|DRUG|YM178|oral
214442064|NCT02362867|DEVICE|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
214442065|NCT04185636|DEVICE|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
214442066|NCT03298074|DRUG|Apatinib|Apatinib, 500mg,po qd for continuous administration
214442067|NCT03298074|DRUG|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
214693047|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
215028750|NCT06643429|DIAGNOSTIC_TEST|colorectal neoplasm|Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
215118909|NCT02481297|DRUG|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
215028751|NCT05935150|PROCEDURE|Omit SLNB|All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
214442068|NCT01091168|DRUG|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
214442069|NCT01091168|DRUG|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
214442070|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
214442071|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
214442072|NCT06528925|OTHER|Virtual reality goggles|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggle (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) that is compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system and minimizes sound loss in the supine position. With the virtual reality glasses, nature landscapes with relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
214442073|NCT03640949|DRUG|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
214442074|NCT03640949|DRUG|Methylprednisolone|40 mg methylprednisolone once
214442075|NCT03640949|DRUG|NaCl|Placebo
214442076|NCT01627652|OTHER|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
214442077|NCT02778659|DRUG|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
214442078|NCT02778659|DRUG|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
214442079|NCT06345404|DRUG|Soquelitinib|Tablets
214442080|NCT06345404|DRUG|Placebo|Soquelitinib matching placebo tablets
214442081|NCT04873869|DRUG|NBI-921352|Administered orally
214442082|NCT04873869|DRUG|Placebo|Administered orally
214693048|NCT03394170|OTHER|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
215028752|NCT06644339|DEVICE|Voice assistant|"Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease.~Follow-up and management of disease provided by specialists at participating institutions."
215028753|NCT06644365|OTHER|Acupresure mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
215028754|NCT06644365|OTHER|Basic mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
215028755|NCT06643949|DIAGNOSTIC_TEST|Echocardiography|The registry will focus on the diagnostic and prognostic value of of echocardiographic features of patients with takotsubo syndrome
214693049|NCT04357379|BEHAVIORAL|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
214519862|NCT04339543|OTHER|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
214519863|NCT01038206|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
214693050|NCT01574313|PROCEDURE|stellate ganglion block|stellate ganglion block
214693051|NCT01574313|DRUG|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
214519864|NCT01671371|OTHER|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
214519865|NCT01364545|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
214519866|NCT01364545|DIETARY_SUPPLEMENT|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
214519867|NCT04127695|DRUG|ABBV-0805|ABBV-0805 administered by IV infusion.
214519868|NCT04127695|DRUG|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
214519869|NCT01631318|PROCEDURE|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
214519870|NCT01631318|DEVICE|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
214519871|NCT01631318|DEVICE|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
214519872|NCT01631318|DRUG|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
214519873|NCT02155218|OTHER|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
214519874|NCT02155218|OTHER|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
214519875|NCT02155218|OTHER|gadolinium contrast|
214519876|NCT01564134|BIOLOGICAL|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
214519877|NCT05450705|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
214519878|NCT03261713|DEVICE|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
214519879|NCT03261713|DEVICE|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
214519880|NCT05693480|DEVICE|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
214519881|NCT02001389|DRUG|EVP-6308|Arms 1, 2, 3, 4
214519882|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
214693052|NCT01574313|DRUG|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
214442083|NCT05375162|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
214442084|NCT05375162|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
214693053|NCT01574313|DRUG|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
214693054|NCT00306917|DEVICE|non-coated femoral hip stem|total hip replacement
214693055|NCT00306917|DEVICE|coated femoral hip stem|total hip replacement
214519883|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
214693056|NCT02318914|DRUG|gevokizumab|
214519884|NCT02367664|BIOLOGICAL|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
214519885|NCT05618509|DEVICE|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
214519886|NCT05618509|OTHER|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
214519887|NCT05618509|OTHER|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
214519888|NCT05618509|DEVICE|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
214693057|NCT02708043|OTHER|Flexible-Laryngeal Mask Airway|
215118910|NCT02481297|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
215118911|NCT00180388|PROCEDURE|endoscopic vein harvesting|
215118912|NCT00180388|PROCEDURE|open vein harvesting|
215118913|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
214519889|NCT05001802|PROCEDURE|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
215118914|NCT01593553|OTHER|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
215118915|NCT00834262|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215118916|NCT00834262|DRUG|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215118917|NCT00834262|DRUG|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215118918|NCT03967054|DRUG|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
215118919|NCT03967054|DRUG|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
215118920|NCT01815827|DRUG|inclacumab|single intravenous doses
215118921|NCT04345562|PROCEDURE|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
215118922|NCT04747899|OTHER|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
215118923|NCT04747899|OTHER|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
215118924|NCT02316496|DRUG|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
215118925|NCT02316496|DRUG|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
214442085|NCT05375162|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
214442086|NCT05375162|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
214442087|NCT05375162|BEHAVIORAL|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
214442088|NCT05646329|BEHAVIORAL|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
214442089|NCT06611059|DEVICE|PSG|Two replicas of each scapula are made. The scapulae are drilled with a commercial guide and with an in-house guide separately
214442090|NCT02113176|DRUG|Minocycline|
214442091|NCT06877273|BEHAVIORAL|CIRCuiTS-MS|The intervention is a blended treatment combining therapist support with carrying out tasks in CIRCuiTS™ digital cognitive remediation software. This software provides opportunities to practice a range of cognitive tasks and adaptively adjusts task difficulty. CIRCuiTS™ is much used in psychosis. Based on collaborative workshops with people with MS, participants for this trial will be asked to attend two 1-hour therapy sessions (in person or on MS Teams) and 1 hour of independent tasks each week for 12 weeks. Participants with reduced ability to operate a mouse quickly or dexterously will be offered a modified programme omitting tasks that require these abilities. The therapist will be an Assistant Psychologist trained in CIRCuiTS™ delivery and in appropriate adjustments to the needs of people with MS. They will follow a manualised template and will receive weekly supervision from an experienced clinical psychologist.
214442092|NCT06885710|BIOLOGICAL|LioCyx-M|Each patient will receive LioCyx-M infusion every one or two weeks, while continuing their existing nucleos(t)ide analog treatment.
214442093|NCT07042347|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
214442094|NCT07042347|DEVICE|Electronic platform|Electronic platform to collect data
214693058|NCT00319852|BIOLOGICAL|DTaP-IPV combined vaccine|0.5 mL, IM
214693059|NCT00319852|BIOLOGICAL|DTaP vaccine|0.5 mL, IM
215118926|NCT00899756|GENETIC|molecular diagnostic method|
215118927|NCT00899756|GENETIC|mutation analysis|
215118928|NCT05747703|COMBINATION_PRODUCT|Ria Treatment Platform|combined medication, coaching, education, and monitoring
215118929|NCT01112397|DRUG|AZD1480|continuous daily oral capsule
215118930|NCT06308419|DRUG|Gemcitabine|Given by IV
215118931|NCT06308419|DRUG|Nab-Sirolimus|Given by IV
215118932|NCT04628780|BIOLOGICAL|PF-07209960|PD-1 targeted IL-15 mutein
215118933|NCT04346329|DRUG|Hydroxychloroquine|Treated group
215118934|NCT04346329|DRUG|Placebo oral tablet|Placebo Group
215118935|NCT03410524|DRUG|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
215118936|NCT03410524|DRUG|Water|3 mL of water as placebo added to the bowel preparation
215118937|NCT05315479|DRUG|N1539|Once daily
215118938|NCT02732964|OTHER|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
215118939|NCT02732964|OTHER|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
215118940|NCT00773162|DRUG|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
215118941|NCT00773162|DRUG|Sugar Pill|Sugar pill to match seroquel
215118942|NCT00273273|PROCEDURE|blood draw|
215118943|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 6 hours|catheter placement for 6 hours beginning in the morning at around 8 a.m.
215118944|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 12 hours|catheter placement for 12 hours in the evening at around 8 p.m.
215118945|NCT00858624|DRUG|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
215118946|NCT02977858|OTHER|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
214442095|NCT06729567|OTHER|Spinal block level analysis|Relation of the dose of hyperbaric bupivacaine to resulting spinal block level is to be assessed. Conventional dose cases (more than 9mg and less than 13mg) will be included in analysis.
214442096|NCT06729567|OTHER|data collection|Intervention is to acquire and analyse anonymous perioperative data. After identification of the eligible cases, statistical analysis will be performed.
214442097|NCT03582722|DRUG|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
214442098|NCT03582722|DRUG|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
214442099|NCT03582722|DIETARY_SUPPLEMENT|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
214442100|NCT07055854|BEHAVIORAL|Mindful After Cancer Program|The Mindful After Cancer Program provides education, mindfulness training, and peer support to help cancer survivors navigate sexual and body image concerns.
214442101|NCT07056049|BEHAVIORAL|High dosage, high intensity motor rehabilitation|Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks.
214519890|NCT05001802|PROCEDURE|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
214519891|NCT03362294|DRUG|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
214519892|NCT03362294|DRUG|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
214519893|NCT01918852|DRUG|Capecitabine|
214519894|NCT01918852|DRUG|Teysuno|
214519895|NCT01918852|DRUG|Bevacizumab|
214519896|NCT01469442|PROCEDURE|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
214519897|NCT01107717|DRUG|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
214519898|NCT01107717|DRUG|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
214519899|NCT01242345|DEVICE|Capnography|Monitoring of the capnography curve for early detection of apnea
214519900|NCT02645578|DEVICE|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
214519901|NCT03696342|DRUG|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
214442102|NCT06619912|DRUG|Dexmedetomidine nasal spray|Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 30 minutes before induction.
214519902|NCT03696342|DRUG|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
214519903|NCT01125956|BEHAVIORAL|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
214519904|NCT01125956|BEHAVIORAL|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
214519905|NCT03875794|OTHER|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
214519906|NCT02187120|DRUG|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
214519907|NCT02187120|DRUG|Placebo|
214519908|NCT00310024|DRUG|bortezomib|Given IV
214519909|NCT00310024|DRUG|vorinostat|Given orally
214519910|NCT00310024|OTHER|laboratory biomarker analysis|Correlative studies
214519911|NCT00310024|OTHER|pharmacological study|Correlative studies
214519912|NCT02823171|DRUG|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
214519913|NCT02823171|DRUG|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
214519914|NCT05340426|DEVICE|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
214519915|NCT04726319|OTHER|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
214693060|NCT06688032|OTHER|Jarlsberg cheese|Jarlsberg cheese contains Propionebacterium freudenreichii (PF) producing the K2-vitamer MK-9(4H) and DHNA in addition to the K2-vitamers found in Norvegia cheese
215118947|NCT02977858|OTHER|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
215118948|NCT04323059|DIETARY_SUPPLEMENT|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
214442103|NCT07061301|DEVICE|Usual Care group|Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
214442104|NCT07061301|DEVICE|Technological group|Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
214442105|NCT07059910|DIAGNOSTIC_TEST|Search for thyroid disorders|TSH , FT3 , FT4
214442106|NCT07059910|DIAGNOSTIC_TEST|Laboratory test|Search for anti thyroid antibodies
214519916|NCT04077437|BEHAVIORAL|Therapy|Standardized non-directive therapy performed by therapist team.
214519917|NCT04077437|DRUG|Midomafetamine|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
214519918|NCT04077437|DRUG|Placebo|Administration of placebo with therapy during three experimental sessions
214519919|NCT05361304|DEVICE|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
214519920|NCT05361304|DEVICE|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
214519921|NCT03456830|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
214519922|NCT03456830|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
214519923|NCT03754686|DRUG|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
214519924|NCT03754686|DRUG|Paracetamol|Best medical care and oral paracetamol twice daily for five days
214519925|NCT02877745|OTHER|Stratification, no intervention|
214442107|NCT07059910|DRUG|Steroid and eltrombopage|See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?
214442108|NCT07059507|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
214442109|NCT07057219|OTHER|Exercise|SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
214442110|NCT07057219|OTHER|Exercise|The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
214519926|NCT00781209|PROCEDURE|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
214519927|NCT05798754|PROCEDURE|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
214519928|NCT05798754|DEVICE|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
214519929|NCT02469493|DEVICE|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
214519930|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
214693061|NCT06688032|OTHER|Norvegia|Cheese with different content of K2 vitamers
214693062|NCT06691100|BEHAVIORAL|Aerobic Exercise|30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).
214693063|NCT06691308|COMBINATION_PRODUCT|WL276 CAR-T cells|This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
215118949|NCT02934165|BEHAVIORAL|Family Safety 123|Theoretically-based injury prevention videos for families
215118950|NCT02934165|BEHAVIORAL|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
215118951|NCT04415814|PROCEDURE|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
215118952|NCT04415814|PROCEDURE|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
215118953|NCT03622814|BEHAVIORAL|Partners at Meals|The focus of the intervention was to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals. Families recorded three meals including behavior at home each month.
214442111|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Lactulose.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
214442112|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Sodium phosphate.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
214442113|NCT06758206|BEHAVIORAL|Flywheel Resistance Training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
214442114|NCT06758206|BEHAVIORAL|Traditional resistance training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 to 12 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at moderate and high intensities (6 to 10 on the OMNI-RES scale).
214442115|NCT07071922|OTHER|No intervention|Observational one-time questionnaire study without intervention
214442116|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO)|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO air purifiers in households for two weeks.
214442117|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO) + filters|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO and filters air purifiers in households for two weeks, to understand the effects comparing with PCO.
214442118|NCT07071870|PROCEDURE|Stent-screw Assisted Internal Fixation (SAIF)|Implanting vertebral body stents (VBS), followed by insertion of percutaneous, fenestrated, cement-augmented pedicular screws
214442119|NCT07071870|PROCEDURE|Surgical stabilization|Spinal fixation with cement augmented pedicle screws bridging the fractured vertebra
214442120|NCT07070401|DEVICE|Commercial AR/VR Headset with Calming App|Commercial AR/VR Headset with Calming App in addition to Pharmacologic Standard of Care
214442121|NCT07070401|OTHER|Pharmacologic Standard of Care Alone|Pharmacologic Standard of Care Alone
214442122|NCT07070804|OTHER|None-placebo|No interventions performed
214442123|NCT07070570|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray, clinical visit and questionnaires at 10 years after surgery
214442124|NCT07070570|OTHER|Active Check-Up on Demand (ACOD)|X-ray, clinical visit and questionnaires at 10 years after surgery when requested by the patient or healthcare provider.
214442125|NCT07070570|OTHER|Passive Check-Up on Demand (PCOD)|X-ray and clinical visit (without questionnaires) at 10 year when requested by the patient or healthcare provider.
214442126|NCT07071636|DRUG|Peg-IFN α-2b combined with NAs|Peg-IFN α-2b (1.5 μg/kg/week) combined with NAs
214442127|NCT07066410|BIOLOGICAL|intervention 1: endocem|EndoCem, a premixed calcium silicate-based cement (Maruchi, Korea), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, EndoCem is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of EndoCem, followed by immediate restoration with FUJI II ensure a coronal seal.
214519931|NCT06049758|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
214519932|NCT06049758|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
214519933|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
214519934|NCT01746199|DRUG|cotrimoxazole daily prophylaxis|
214519935|NCT01746199|DRUG|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
214519936|NCT05716971|PROCEDURE|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
214519937|NCT05974371|OTHER|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
214519938|NCT02797795|DRUG|NEV801|Dose Escalation
214519939|NCT04914520|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
214519940|NCT04914520|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
214519941|NCT01560962|DRUG|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
214519942|NCT01560962|OTHER|No Intervention|
214519943|NCT01560962|DRUG|Azithromycin|
214519944|NCT01560962|DRUG|tobramycin-dexmethasone|
214519945|NCT01560962|OTHER|warm soaked eyelid wash|
214519946|NCT02898350|DEVICE|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
214519947|NCT02898350|DEVICE|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
214442128|NCT07066410|BIOLOGICAL|Intervention 1: biodentine|Biodentine, a tricalcium silicate-based cement (Septodont, France), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, Biodentine is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of Biodentine, followed by immediate restoration with FUJI II to ensure a coronal seal.
214442129|NCT07066514|BEHAVIORAL|AI-Supervised Mobile Exercise Program|This intervention involves the use of an artificial intelligence (AI)-supported mobile application that delivers a personalized exercise program to patients with knee osteoarthritis. The app supervises exercise execution in real time using the device's camera and AI algorithms to track movements, count repetitions, and assess form accuracy. The program includes stretching, strengthening, and range of motion exercises performed 3-4 times per week for 4 weeks. The app provides instructional videos, personalized feedback, reminders, and records user performance. No video or personal images are stored; only anonymized motion data are collected and securely stored.
214519948|NCT02898350|DEVICE|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
214519949|NCT02898350|DEVICE|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
215118954|NCT03622814|BEHAVIORAL|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites received training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month.
215118955|NCT06242301|OTHER|The collective person-centered dialogue intervention|"* Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
215118956|NCT02907151|OTHER|Survey|Complete a survey prior to the consultation and a questionnaire after
215118957|NCT05306587|DRUG|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
215118958|NCT01867762|DRUG|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
215118959|NCT01867762|DRUG|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
215118960|NCT01862536|DRUG|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
215118961|NCT01862536|DRUG|placebo|Daily use in double blind study.
215118962|NCT00503269|PROCEDURE|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
215118963|NCT00503269|PROCEDURE|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
215118964|NCT01288989|BIOLOGICAL|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
215118965|NCT00921349|PROCEDURE|Ligation of varices|all varices are ligated until obliteration
215118966|NCT00921349|DRUG|Nadolol|Nadolol (beta-blocker)
215118967|NCT03602365|DEVICE|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
215118968|NCT01156714|BEHAVIORAL|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
215118969|NCT01156714|BEHAVIORAL|Memory training with computerized memory program|memory testing and training on computer program
214519950|NCT01469429|OTHER|placebo|Receive lozenge placebo PO
214519951|NCT01469429|OTHER|laboratory biomarker analysis|Correlative studies
214519952|NCT01469429|OTHER|questionnaire administration|Ancillary studies
214519953|NCT01469429|DRUG|chemoprevention|Receive LBR lozenge PO
214519954|NCT01469429|DRUG|chemoprevention|Receive LBR Saliva Substitute PO
214519955|NCT01469429|OTHER|placebo|Receive Saliva Substitute placebo PO
214519956|NCT02956915|PROCEDURE|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
214519957|NCT00600223|BEHAVIORAL|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
214519958|NCT03364556|OTHER|No intervention|
214519959|NCT04038723|BEHAVIORAL|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
214519960|NCT04884282|DRUG|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
215118970|NCT01156714|BEHAVIORAL|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
215118971|NCT00747084|PROCEDURE|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
215118972|NCT06359613|DIETARY_SUPPLEMENT|nutrient rich food product|Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
214442130|NCT07066514|BEHAVIORAL|Booklet-Guided Home Exercise Program|This intervention provides patients with a standardized home exercise program in printed booklet format. The program includes the same evidence-based stretching, strengthening, and range of motion exercises used in the mobile application group, performed 3-4 times per week for 4 weeks. Participants receive one-time in-person instruction on proper form but no ongoing supervision or feedback during the program. Adherence and technique are self-monitored.
214442131|NCT06024174|DRUG|BMS-986466|Specified dose on specified days
214519961|NCT04884282|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
214519962|NCT04884282|DRUG|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
214519963|NCT02409732|DRUG|aminolevulinic acid hydrochloride|
215118973|NCT06359613|DIETARY_SUPPLEMENT|food product|Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
214519964|NCT02409732|PROCEDURE|Photodynamic therapy with blue light|
215118974|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
214442132|NCT06024174|DRUG|Adagrasib|Specified dose on specified days
214519965|NCT01233193|BEHAVIORAL|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
214519966|NCT01167816|DRUG|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
214519967|NCT05884671|DRUG|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
214519968|NCT05884671|DRUG|Placebo|All participants will receive placebo during one of the sessions.
214519969|NCT00306735|DRUG|Palonosetron|
214519970|NCT01982266|DEVICE|GRADION™ Hip Total Cartilage Replacement (TCR)™|
215118975|NCT01132313|DRUG|BI 201335|40 weeks, QD
214442133|NCT06024174|DRUG|Cetuximab|Specified dose on specified days
214442134|NCT06900764|DRUG|CAR-T cell|CAR-T cell
214519971|NCT05234476|BEHAVIORAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
214519972|NCT05234476|BEHAVIORAL|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
214519973|NCT02478762|PROCEDURE|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
214519974|NCT02478762|PROCEDURE|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
214519975|NCT01810640|PROCEDURE|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
214519976|NCT02099656|DRUG|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
214519977|NCT02099656|DRUG|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
215118976|NCT01132313|DRUG|BI 207127|4 weeks, low dose TID
214519978|NCT02099656|DRUG|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
214519979|NCT02099656|DRUG|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
214519980|NCT03015961|DRUG|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
214519981|NCT03015961|DRUG|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
214519982|NCT05579587|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
214519983|NCT00376259|DRUG|telbivudine|600mg/day oral tablet for 96 weeks
214519984|NCT00376259|DRUG|adefovir dipivoxil|10 mg of adefovir by mouth once daily
214519985|NCT03734588|GENETIC|SPK-8016|adeno-associated viral vector
215118977|NCT01132313|DRUG|BI 201335|24 weeks, QD
215118978|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
215118979|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
215118980|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
215118981|NCT01132313|DRUG|BI 207127|40 weeks, high dose, TID
215118982|NCT01132313|DRUG|BI 207127|24 weeks, very high dose, BID
215118983|NCT01132313|DRUG|BI 207127|16 weeks, standard dose, BID
215118984|NCT01132313|DRUG|BI 201335|24 weeks, QD
215118985|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
214442135|NCT06901011|PROCEDURE|continuous renal replacement therapy|"Intervention Arm: Effluent dose schedule of 10-20 ml/kg/h after 48 hours of starting dose of 25-35 ml/kg/h, until completing 96 hours~Control Arm Effluent dosage schedule of 25-35 ml/kg/h fixed for 96 hours"
214442136|NCT07071896|OTHER|16 weeks remotely exercise program|16 weeks, twice per week, remotely exercise program
214442137|NCT07070050|DRUG|Ibuprofen continuous infusion|"1. The first bolus: ibuprofen 400 mg diluted in 0,9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Continuous infusion:~   * Ibuprofen 1200 mg diluted in 0,9% NaCl 300 ml is intravenous injected on the first day with the speed of 1 mg/kg/h (for the ideal body weight) during the remaining 23 hours.~  * On the second day the intravenous infusion of ibuprofen 1600 mg diluted in 0,9% NaCl 400 ml with the speed of 1 mg/kg/h is continued during the 24 hours.~3. Imitation of bolus: Every 8 hours placebo (0, 9% NaCl 200 ml) is intravenous injected to create an imitation of bolus injection. Placebo is injected during the first hour."
214442138|NCT07070050|DRUG|Ibuprofen bolus injection|"1. The first bolus: ibuprofen 400 mg diluted in 0, 9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Bolus injection:~   * Every 8 hours a intravenous bolus of ibuprofen 800 mg diluted in 0,9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~  * On the second day the every 8 hours intravenous bolus of ibuprofen 800 mg diluted in 0, 9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~3. Placebo continuous infusion:~Between the boluses a placebo (0,9% NaCl) continuous intravenous infusion is performed with the speed imitating the speed of ibuprofen infusion in the experimental group."
214442139|NCT07071545|BEHAVIORAL|Regular physical activity|Moderate-to-vigorous physical activity at least three times per week.
214442140|NCT07071545|BEHAVIORAL|No regular physical activity|The group that did not engage in physical activity according to the guidelines
214442141|NCT07071233|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
214442142|NCT07071233|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
214442143|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
214442144|NCT06884826|PROCEDURE|Desarda technique|Patients will undergo Desarda technique.
214442145|NCT07070752|DRUG|GP40321|GP40321, solution for subcutaneous injection, 100 U/mL (GEROPHARM LLC, Russia)
214442146|NCT07070752|DRUG|Apidra® SoloStar®|Apidra® SoloStar®, solution for subcutaneous injection, 100 U/mL (Sanofi-Aventis Deutschland GmbH, Germany)
214442147|NCT07070752|DRUG|RinGlar®|Patients also receive long-acting basal insulin therapy (insulin glargine 100 U/mL) throughout the study
214442148|NCT06440135|DRUG|Ziftomenib|Taken orally once per day
214442149|NCT07074730|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia with local anesthetic infiltration.
214442150|NCT07074730|OTHER|General anesthesia|Patients will receive general anesthesia.
214442151|NCT07071597|PROCEDURE|Renal Biopsy|Renal biopsy is performed to clarify the renal pathology.
214519986|NCT05953818|DIAGNOSTIC_TEST|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
214519987|NCT00002401|DRUG|Indinavir sulfate|
214519988|NCT00002401|DRUG|Delavirdine mesylate|
214442152|NCT07077057|DIAGNOSTIC_TEST|AI-assisted ECG interpretation (PMcardio)|Participants in the experimental arm will undergo 12-lead ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical, Slovakia). The AI algorithm analyzes ECG data in real time to detect patterns suggestive of occlusion myocardial infarction (OMI), including cases not meeting traditional ST-elevation myocardial infarction (STEMI) criteria. In the experimental arm, the AI output is provided immediately to the treating clinician and used as an adjunct to standard ECG interpretation to support timely diagnosis and management decisions.
214442153|NCT07078526|OTHER|Otago Exercise Program|The Otago Exercise Program is a structured, progressive exercise regimen focusing on lower limb strengthening and balance retraining. It is performed twice weekly for six weeks under physiotherapist supervision, complementing standard physiotherapy care.
214442154|NCT07078526|OTHER|Neuromuscular Exercise|The neuromuscular exercise intervention involves functional, proprioceptive, and balance exercises delivered twice weekly for six weeks under supervision, in addition to standard physiotherapy care.
214442155|NCT07078227|OTHER|No intervention is used.|No intervention is used.
214519989|NCT00002401|DRUG|Lamivudine|
214519990|NCT00002401|DRUG|Zidovudine|
214519991|NCT05423171|OTHER|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
214519992|NCT00841165|DEVICE|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
214519993|NCT00841165|DEVICE|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
214519994|NCT02376322|RADIATION|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
214519995|NCT02331771|DRUG|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
214519996|NCT02331771|DRUG|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
214519997|NCT01877720|DEVICE|noninvasive respiratory support with NAVA mode and PSV|
214519998|NCT03331276|OTHER|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
214519999|NCT03331276|OTHER|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
214520000|NCT04283396|COMBINATION_PRODUCT|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
214520001|NCT01084408|DEVICE|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
214442156|NCT07077876|PROCEDURE|Hysteroscopic Resection and Hormonal Therapy|Patients underwent hysteroscopic resection of atypical endometrial hyperplasia (AEH) or grade 1-2 endometrial adenocarcinoma (EAC) using a 15 Fr mini-resectoscope. Depending on the case, the procedure included visual D\&C or a combined technique. At the end of the procedure, a 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) was inserted. In patients with EAC G2 or poor prognostic markers (e.g., MMR deficiency), oral progestin therapy with Megestrol Acetate (160 mg daily) was added. Follow-up included hysteroscopic endometrial biopsy at 3, 6, and 12 months to assess response.
214442157|NCT07077577|PROCEDURE|Holistic Birth Approach|Holistic Birth Approach involves use of non pharmacological techniques for better labor process management with less experience of pain, fear and maternal satisfaction to women delivering the baby through normal delivery method.
214442158|NCT07078253|OTHER|Produce box program|Each week during the 20-week study period, participants will pick up a box of fresh vegetables. All produce will be provided to the participants at no cost as part of the client choice pantry program. Participants will take home approximately 6 different types of vegetables each week. Participants will choose which vegetables they want from a variety of options.
214442159|NCT07076745|DIAGNOSTIC_TEST|High-sensitivity C-reactive protein|High-sensitivity C-reactive protein will be done.
214442160|NCT07076745|OTHER|Stiffness Measurement|"Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:~* β-stiffness index.~* Peterson's elastic modulus (Ep).~* Distensibility coefficient (DC).~* Compliance coefficient (CC).~* Strain."
215118986|NCT01132313|DRUG|Ribavirin|40 weeks, according to label
214520002|NCT01084408|DEVICE|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
214520003|NCT04667442|DIAGNOSTIC_TEST|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
215118987|NCT01132313|DRUG|BI 207127|16 weeks, high dose, TID
215118988|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
215118989|NCT01132313|DRUG|BI 201335|28 weeks, QD
215118990|NCT01132313|DRUG|BI 201335|16 weeks, QD
215118991|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
215118992|NCT01132313|DRUG|BI 201335|24 weeks, QD
215118993|NCT01132313|DRUG|BI 201335|28 weeks, QD
214442161|NCT07079202|OTHER|kinetic control|Kinetic Control uses the Movement Control Rating System based on motor tests, the purpose of which is to identify the place and direction of uncontrolled movements and exercises to re-educate motor control
214442162|NCT07079202|OTHER|Conventional physical therapy.|This group received only conventional physical therapy. ( TENS, hot backs, Ultrasound,Nerve mobilization ) three sessions per week for 6 weeks.
214442163|NCT07076784|DRUG|Icariin|Topical application of 3% icariin solution
214442164|NCT07076784|DRUG|Vehicle Control|Topical application of 3% ethanol solution
214442165|NCT07078721|RADIATION|Total Marrow Irradiation|\- TMI 4 Gy qd on Day -2;
214442166|NCT07078721|DRUG|Fludarabine (FLU)|Flu 30 mg/m² × 5 days on Days -6, -5, -4, -3, -2;
214442167|NCT07078721|DRUG|Melphalan (Mel)|Mel 100 mg/m² qd on Day -1.
214442168|NCT07076602|OTHER|Gait and energy expenditure|"SESSION 1:~Physiotherapy assessment: clinical parameters, length of limb segments, range of motion of the lower limbs, muscle strength of each lower limb joint and trunk.~Measurement of energy expenditure:~6-minute walking test with prosthesis, at a constant submaximal speed, with portable gas exchange analyzer to measure oxygen consumption and a connected device to calculate the Physiological Cost Index.~* During test: recording of heart rate at the start, each minute, at the end then 5 minutes after the end, recording of the effort perceived by the child each minute (Borg scale)~* At the end : questionnaire to assess child level of acceptability regarding the measurement of the O2 (Oxygen) consumption~SESSION 2:~Measurement of kinematic parameters by gait analysis: the child will be requested to walk with their prosthesis and shoes at spontaneous speed and at maximal gait speed.~The second measurement of energy expenditure will be conducted using the same procedure as the first."
214442169|NCT07077720|PROCEDURE|genicular nerve block|genicular nerve block with a total of 15 mL of 0.25% bupivacaine preoperatively
214442170|NCT07077720|PROCEDURE|periarticular injection|periarticular injection prepared by the surgical team containing 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin, and 110 mg bupivacaine.
214442171|NCT07077720|PROCEDURE|Addukctor canal block|Addukctor canal block with 15ml %0.25 bupivacaine
214442172|NCT07077720|PROCEDURE|Spinal Anesthesia with Bupivacaine and Morphine|Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
214520004|NCT00447499|DRUG|Somatuline Autogel (lanreotide acetate)|Injections
214520005|NCT00447499|BEHAVIORAL|Home administration|Questionnaire
214520006|NCT01325519|OTHER|video decision aid|video
214520007|NCT04891536|PROCEDURE|Salvage cryoablation of the prostate (SCAP)|Cryotherapy of the prostate through transperineal freeezing needles
214520008|NCT05465499|PROCEDURE|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
214520009|NCT02068352|DRUG|OPA-15406|OPA-15406 topical ointment
214520010|NCT02068352|DRUG|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
214520011|NCT01286870|DEVICE|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
215118994|NCT01132313|DRUG|BI 207127|24 weeks, standard dose, BID
215118995|NCT01132313|DRUG|BI 201335|24 weeks, QD
215118996|NCT01132313|DRUG|BI 201335|16 weeks, QD
215118997|NCT01132313|DRUG|BI 207127|16 weeks, high dose, BID
215118998|NCT01132313|DRUG|BI 201335|24 weeks, QD
215118999|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
215119000|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
214442173|NCT07078084|BEHAVIORAL|Laterality Training|Participants complete a structured laterality training session using a tablet-based application that presents images of hands or feet. Depending on their pain location (shoulder or knee), participants identify whether each image shows a left or right body part. The session consists of 5 one-minute training bouts with 60-second rest intervals between each. The task is designed to engage and retrain cortical body maps associated with the painful region, based on principles of graded motor imagery. Participants are instructed to prioritize accuracy over speed.
214520012|NCT01286870|DEVICE|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
214520013|NCT00079599|DRUG|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
214520014|NCT00079599|OTHER|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
214520015|NCT04967092|DRUG|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
214693064|NCT07017595|BEHAVIORAL|Visual-acoustic biofeedback: experimental|Visual-acoustic biofeedback treatment incorporates elements of traditional voice training, including auditory models, verbal descriptions of articulator placement, and cues for repetitive motor practice using images and diagrams of the vocal tract as visual aids. Our experimental software will provide several options for visualizing the fundamental frequency of the voice (for targets involving vocal pitch) and for visualizing vocal tract resonances. Custom targets for pitch and resonance will be created for each participant based on their baseline voice characteristics and personal voice goals. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments influence the proximity of their output to the target.
215119001|NCT01132313|DRUG|BI 207217|28 weeks, high dose BID
214520016|NCT04967092|OTHER|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
214520017|NCT00841945|DRUG|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
214520018|NCT00841945|DRUG|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
214520019|NCT00841945|DRUG|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
214520020|NCT00841945|DRUG|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
215119002|NCT01132313|DRUG|BI 201335|16 weeks, QD
215119003|NCT01132313|DRUG|BI 207127|24 weeks, high dose, TID
215119004|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
215119005|NCT01132313|DRUG|BI 207127|4 weeks, high dose, TID
215119006|NCT01132313|DRUG|BI 201335|28 weeks, QD
215119007|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
214442174|NCT07078084|OTHER|Sham (No Treatment)|Participants in this arm will complete a non-therapeutic cognitive activity by working independently on a standard word-based crossword puzzle for 10 minutes. This task is designed to match the duration and engagement level of the laterality training without influencing sensorimotor processing or cortical body maps. It serves as a sham comparator to help isolate the specific effects of the laterality training intervention.
214520021|NCT00841945|PROCEDURE|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
214520022|NCT06963281|DRUG|IBI3020|Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection
214520023|NCT03960437|DRUG|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
215119008|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
215119009|NCT04041934|DIETARY_SUPPLEMENT|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
215119010|NCT03104179|DEVICE|Cytosorb Adsorber|Cytokine adsorption during CPB
215119011|NCT04203836|DRUG|LEO 152020 Tablet|film-coated tablet
215119012|NCT05932797|OTHER|Multimodal intervention in Long Covid19|The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
215119013|NCT05113446|DIAGNOSTIC_TEST|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
215119014|NCT03609996|DEVICE|Panretinal Photocoagulation|Laser treatment for PDR
215119015|NCT03609996|DRUG|Lucentis|Intraviteral injection
215119016|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
215119017|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
215119018|NCT02052752|DRUG|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
214442175|NCT07072403|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
214693065|NCT07017023|DRUG|Losartan with BA|7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA
214520024|NCT01732419|BEHAVIORAL|Home-based training|Home-based exercise training for cardiac patients.
214693066|NCT07017023|OTHER|Placebo with BA|7-day placebo (oral; microcellulose in identical capsules) with 7-day BA
215119019|NCT02052752|DRUG|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
214442176|NCT07077603|OTHER|A12 week, twice weekly, small group, online yoga program|A 12 week, twice weekly, small group, online yoga program
214520025|NCT01732419|BEHAVIORAL|Centre-based training|Usual exercise training in an outpatient setting.
214520026|NCT02332096|DEVICE|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
214520027|NCT00249847|DRUG|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
214520028|NCT00249847|DRUG|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
214520029|NCT00073788|PROCEDURE|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
214520030|NCT05893693|OTHER|Biological|CT0594CP
214520031|NCT02320045|DRUG|ITCA 650 (Exenatide in osmotic mini pump)|
215119020|NCT02052752|DRUG|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
215119021|NCT03946748|DRUG|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
215119022|NCT00178568|BEHAVIORAL|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
215119023|NCT03830359|OTHER|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
215119024|NCT02715609|DRUG|Disulfiram|
214442177|NCT06215664|BEHAVIORAL|Singularities Game|Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.
214442178|NCT06215664|BEHAVIORAL|Food4Thought|Food4Thought is an attention control condition in which we provide participants with similar amounts of research team contact and program contact as the intervention. Participants will play the game Pick Your Plate! A Global Guide to Nutrition, developed by the Smithsonian Science Education Center. Participants are instructed to build healthy meals using cuisine from around the world while ensuring they stick to a budget and meet all their nutritional needs. Food4Thought will be delivered via Qualtrics.
214442179|NCT07076225|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
214442180|NCT07076225|DRUG|Sitafloxacin (S)|200mg once daily
214442181|NCT07076225|DRUG|Linezolid (L)|600mg once daily
214520032|NCT00473512|DRUG|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
214520033|NCT00473512|DRUG|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
214520034|NCT00473512|DRUG|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
214520035|NCT01598688|OTHER|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
214693067|NCT07020273|BEHAVIORAL|ELEVATE|ELEVATE uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools).
214693068|NCT07020273|BEHAVIORAL|ELEVATE-S|ELEVATE-S uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools) and implementation strategies to support patients with chronic care model-informed self-management support (patient centered flexible goals and patient-generated health data).
214693069|NCT05030285|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
214693070|NCT02678780|DRUG|Lenvatinib|
214693071|NCT04478682|OTHER|Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application|Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
214693072|NCT02034357|OTHER|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
215119025|NCT02715609|DRUG|Copper Gluconate|
215119026|NCT02715609|PROCEDURE|Surgery|
215119027|NCT02715609|RADIATION|Radiation|
215119028|NCT02715609|DRUG|Temozolomide|
215119029|NCT06567041|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
215119030|NCT06567041|DRUG|Placebo|Placebo will be administered subcutaneously.
214442182|NCT07076225|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
214442183|NCT07076225|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
214442184|NCT07076225|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
214442185|NCT07076225|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
214442186|NCT07078162|OTHER|Photogramety Orbital Prosthesis|Using 2D photographs to abtain 3D model of orbital defect anatomy
214442187|NCT07078162|OTHER|Conventional impression prosthesis|Conventional impression to an orbital defect then scaning the impression using desktop scanner
214442188|NCT06842303|DEVICE|Magnetic resonance elastography (MRE).|Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure
214442189|NCT06842303|DEVICE|High-resolution diffusion sequence in MRI|High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.
214520036|NCT01598688|OTHER|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
214520037|NCT05280522|OTHER|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
214520038|NCT05280522|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
214520039|NCT05280522|DEVICE|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
214520040|NCT02551471|OTHER|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
214520041|NCT02551471|OTHER|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
214520042|NCT02551471|OTHER|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
214520043|NCT03809858|OTHER|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
214520044|NCT03602547|DRUG|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
214520045|NCT03239171|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
214520046|NCT03239171|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214442190|NCT04567615|BIOLOGICAL|Nivolumab|Specified dose on specified days
214442191|NCT04567615|BIOLOGICAL|Relatlimab|Specified dose on specified days
214442192|NCT06912087|DRUG|Zanzalintinib|Experimental receptor tyrosine kinases (RTKs)
214442193|NCT06912087|DRUG|Cetuximab|Food and Drug Administration (FDA) approved monoclonal antibody directed against the epidermal growth factor (EGFR).
214442194|NCT06912087|DRUG|Pembrolizumab|FDA approved monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1)
214442195|NCT06918275|PROCEDURE|Laparoscopic isthmocele repair using V-LocTM 180 barbed suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
214442196|NCT06918275|OTHER|Laparoscopic isthmocele repair using Polyglactin 910 vicryl suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
215119031|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (low dose)|Participants are administered 25 µg of vilanterol + fluticasone furoate
214520047|NCT05686343|DIAGNOSTIC_TEST|Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy|Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
214520048|NCT06027424|OTHER||observational study, no intervention
214520049|NCT02519829|PROCEDURE|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
214520050|NCT02519829|PROCEDURE|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
214520051|NCT02519829|PROCEDURE|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
214520052|NCT02519829|PROCEDURE|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
214520053|NCT02665806|DRUG|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
214520054|NCT02665806|DRUG|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
214520055|NCT03924596|DRUG|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
214520056|NCT03924596|DRUG|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
214520057|NCT00267956|DRUG|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
214520058|NCT00267956|DRUG|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
214520059|NCT00494416|OTHER|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
214520060|NCT05121649|OTHER|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
214520061|NCT01262794|BIOLOGICAL|CDP6038|100 mg/mL solution for injection, single dose
214520062|NCT01262794|BIOLOGICAL|Placebo|0.9% sodium chloride for injection Single-dose
214520063|NCT01263223|DRUG|LY2216684|Administered orally
214520064|NCT01263223|DRUG|Placebo|Administered orally
214520065|NCT00028509|PROCEDURE|management of therapy complications|
214520066|NCT02705456|PROCEDURE|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
214520067|NCT02705456|PROCEDURE|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
214520068|NCT00847847|PROCEDURE|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
214520069|NCT02246647|DIAGNOSTIC_TEST|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
214693073|NCT02034357|OTHER|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
214693074|NCT06108427|OTHER|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
215119032|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (high dose)|Participants are administered 100 µg of vilanterol + fluticasone furoate
215119033|NCT06066606|DRUG|Placebo|Participants are administered placebo
214520070|NCT02246647|PROCEDURE|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
214520071|NCT02246647|PROCEDURE|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
214520072|NCT00026078|DRUG|docetaxel|
214520073|NCT00026078|DRUG|ifosfamide|
214520074|NCT01844362|PROCEDURE|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
214693075|NCT01805700|OTHER|Caffeine enhanced energy drink|Comparison of different energy drinks
214693076|NCT01805700|OTHER|Glucose drink|Glucose drink (containing 84mg glucose alone)
215119034|NCT02114229|DRUG|alisertib|Alisertib will be administered orally at 80 mg/m\^2 per day for enteric coated tablet formulation and 60 mg/m\^2 per day for oral solution formulation.
215119035|NCT02114229|DRUG|methotrexate|Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
214442197|NCT07077200|OTHER|Intranasal dexmedetomidine|"This intervention is distinguished by the use of intranasal dexmedetomidine at a standardized dose of 3 mcg/kg, administered non-invasively upon the child's arrival in the preoperative holding area. Unlike other pharmacological methods that often require intravenous access or oral administration, this approach minimizes procedural stress and discomfort, which is particularly advantageous in pediatric populations.~Dexmedetomidine is a selective alpha-2 adrenergic agonist known for its anxiolytic, sedative, and analgesic properties, without causing significant respiratory depression-a key concern with agents like benzodiazepines or opioids. Its intranasal delivery provides a rapid onset of action while maintaining hemodynamic stability, which is critical during the preoperative period.~This intervention is also notable for its comparison with a non-pharmacological strategy-short video viewing-making the study unique in evaluating the relative efficacy of a low-risk pharmacologic option"
214442198|NCT06932679|OTHER|Assessment of Gait and Visual Exploration|Participants will perform walking tasks involving obstacle crossing while their gait and visual exploration patterns are recorded using wearable sensors and eye-tracking glasses. This is a non-invasive observational study with no therapeutic intervention.
214442199|NCT04914247|DRUG|Selexipag|
214442200|NCT07071207|BEHAVIORAL|Text message reminders|daily 8am text messages reminding patients to perform Kegel exercises as per their standard-of-care post-operative discharge instructions.
214442201|NCT06347939|DIAGNOSTIC_TEST|Mediastinal lymph nodes cryobiopsies|EBUS Mediastinal lymph nodes cryobiopsies
214442202|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
214442203|NCT05755672|DRUG|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
214442204|NCT05755672|PROCEDURE|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
214442205|NCT05755672|PROCEDURE|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
214520075|NCT03869411|BEHAVIORAL|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
214520076|NCT01636700|DRUG|Tramadol 2mg/kg|2mg/kg
214520077|NCT01636700|DRUG|Saline solution|saline solution- 1 dose
214520078|NCT04597047|DIAGNOSTIC_TEST|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
214520079|NCT04597047|DIAGNOSTIC_TEST|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
214520080|NCT00195416|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
214520081|NCT05769361|BEHAVIORAL|UNST|Strength and balance training using different destabilizing devices
214520082|NCT05769361|BEHAVIORAL|ST|Strength and balance training over firm surfaces
214520083|NCT01621087|OTHER|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
214520084|NCT04387773|DRUG|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
214520085|NCT05667688|DRUG|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
214520086|NCT00095251|DRUG|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
214520087|NCT00095251|DRUG|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
214520088|NCT03144076|OTHER|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
215119036|NCT02114229|DRUG|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m\^2 IV infusion.
215119037|NCT02114229|DRUG|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
215119038|NCT02114229|DRUG|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
214442206|NCT05755672|PROCEDURE|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
214520089|NCT01847599|OTHER|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
214520090|NCT04983147|OTHER|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
215119039|NCT02114229|DRUG|etoposide|"Etoposide will be given 100 mg/m\^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
215119040|NCT02114229|DRUG|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL\*hr.
215119041|NCT02114229|DRUG|vincristine|Vincristine will be given 1 mg/m\^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
215119042|NCT02114229|PROCEDURE|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
215119043|NCT02114229|RADIATION|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age \> 36 months.
215119044|NCT02657304|BEHAVIORAL|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
215119045|NCT02657304|OTHER|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
215119046|NCT05950698|DEVICE|Holter Faros 360° EKG (Bittium Corporation)|Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.
215119047|NCT05950698|DIAGNOSTIC_TEST|Beck Depression Inventory (BDI)|The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
215119048|NCT05950698|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scales - HADS|The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
215119049|NCT05950698|DIAGNOSTIC_TEST|Three Factor Eating Questionnaire-R21 - TFEQ-R21|The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
214442207|NCT06408233|OTHER|Performance Coaching|Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
214442208|NCT05933707|BEHAVIORAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
214442209|NCT03481660|DRUG|Brolucizumab|Intravitreal injection
214442210|NCT03481660|DRUG|Aflibercept|Intravitreal injection
214442211|NCT06789783|DRUG|Lithium Carbonate Capsule|10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
214442212|NCT06241664|DEVICE|AEYE-DS Software|An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
214442213|NCT04927234|DEVICE|geko™ therapy|Neuro-muscular electrical stimulation of the peroneal nerve
214442214|NCT02314481|DRUG|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
214442215|NCT02314481|DRUG|Vemurafenib|Film coated tablet
214442216|NCT02314481|DRUG|Alectinib|capsule
214442217|NCT02314481|DRUG|Trastuzumab emtansine|Powder for concentrate for solution for infusion
214442218|NCT02950051|DRUG|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
214442219|NCT02950051|DRUG|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
214442220|NCT02950051|BIOLOGICAL|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
214442221|NCT02950051|DRUG|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
214442222|NCT02950051|DRUG|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
214520091|NCT04983147|OTHER|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
214442223|NCT02950051|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
214442224|NCT02950051|DRUG|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
214442225|NCT03388788|RADIATION|PET Imaging|Positron Emission Tomography (PET) imaging for research.
214442226|NCT03388788|BEHAVIORAL|Circadian Study Protocol|5-day circadian study schedule
214442227|NCT03388788|DRUG|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
214442228|NCT03388788|DRUG|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
214442229|NCT03388788|DRUG|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
214442230|NCT05206747|DEVICE|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
214442231|NCT05206747|DEVICE|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
214442232|NCT03012841|DEVICE|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
214442233|NCT05665725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214442234|NCT05665725|PROCEDURE|Computed Tomography|Undergo CT scan
214520092|NCT01852851|BEHAVIORAL|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
214520093|NCT01012999|DRUG|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
214520094|NCT03557307|BIOLOGICAL|Benralizumab|Benralizumab subcutaneous injection
214693077|NCT06116435|BEHAVIORAL|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
214693078|NCT06116435|BEHAVIORAL|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
215119050|NCT05950698|DIAGNOSTIC_TEST|hort-Form Health Survey-36 itens - SF-36|he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
215119051|NCT00310089|BIOLOGICAL|filgrastim|
215119052|NCT00310089|BIOLOGICAL|pegfilgrastim|
215119053|NCT00310089|DRUG|cediranib maleate|
215119054|NCT00310089|DRUG|cyclophosphamide|
215119055|NCT00310089|DRUG|docetaxel|
215119056|NCT00310089|DRUG|doxorubicin hydrochloride|
215119057|NCT00310089|OTHER|laboratory biomarker analysis|
215119058|NCT00310089|PROCEDURE|conventional surgery|
214442235|NCT05665725|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214442236|NCT05665725|BIOLOGICAL|Siltuximab|Given IV
214442237|NCT03683069|DRUG|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
214442238|NCT00353483|PROCEDURE|Peripheral blood draw|
214442239|NCT00353483|PROCEDURE|Breast tissue collection|
214442240|NCT00353483|PROCEDURE|Bone marrow biopsy|
215119059|NCT00310089|PROCEDURE|neoadjuvant therapy|
215119060|NCT06458452|OTHER|Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support|Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
215119061|NCT03449719|RADIATION|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
215119062|NCT03449719|DRUG|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
215119063|NCT03201419|DRUG|FE 201836|Oral solution for daily intake
215119064|NCT03201419|DRUG|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
215119065|NCT03201419|DRUG|Placebo oral solution|Manufactured to mimic experimental drug
215119066|NCT03201419|DRUG|Placebo ODT|Manufactured to mimic experimental drug
215119067|NCT01123616|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
215119068|NCT04219241|BIOLOGICAL|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
215119069|NCT01307436|BIOLOGICAL|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
214442241|NCT05932212|DRUG|AK104|AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
215119070|NCT01307436|BIOLOGICAL|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
215119071|NCT04854694|DEVICE|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
215119072|NCT04854694|DEVICE|conventional surgical N95 respirator|standard N95 respirator
215119073|NCT05280353|OTHER|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
215119074|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
215119075|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
215119076|NCT06261905|DRUG|[11C]-PHNO|PHNO is used as a tracer for in-vivo imaging.
215119077|NCT06261905|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.
215119078|NCT06261905|OTHER|Placebo Control|A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.
215119079|NCT06261905|PROCEDURE|PET Scan|A high resolution PET Scan performed using a NeurExplorer CT scanner.
215119080|NCT06263829|OTHER|Use of Tappt App|Use of Tappt, a novel digital medication companion solution
215119081|NCT05421013|DRUG|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
214442242|NCT05932212|DRUG|AK104+ Paclitaxel+Cisplatin or Carboplatin|AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
214442243|NCT04543903|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
215119082|NCT06813417|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. Following infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance3.
215119083|NCT06599593|DIETARY_SUPPLEMENT|SQ-LNS|CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories).
215119084|NCT06599593|OTHER|Integrated Nutritional Screening|In conjunction with SMC administration, CHWs screen children for MUAC. CHW refers children with MUAC \&lt;12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.
215119085|NCT06672042|DEVICE|CHAMP App|"CHAMP® App is a proprietary, downloadable, mobile Software Application and software platform designed and developed by the Children's Mercy Hospital of Kansas City (CMH), that permits parents and caregivers to transmit to the care team data to permit remote monitoring of the patient's condition. The parent or caregiver enters into the CHAMP App data including vital signs, intake and output, video, and images of patients (collectively, CHAMP® Data), which operates on computers, mobile devices, and handheld computers. The CHAMP® App is intended to be used in the clinical care of pediatric patients in the home setting that are followed by specialty health care teams to improve patient self-management through the use of asynchronous data. Videos and data related to the patient are entered by the parent and sent electronically to the Clinical Care Team as recommended by the clinical team."
215119086|NCT05199545|DIETARY_SUPPLEMENT|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
215119087|NCT05199545|OTHER|Placebo|Placebo of the dietary supplement
215119088|NCT03265236|DIAGNOSTIC_TEST|Anti - modified citrullinate vimentin|patients with early and late RA
215119089|NCT05907395|DRUG|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
215119090|NCT05907395|DRUG|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
215119091|NCT03671226|OTHER|Questionnaire Administration|Given questionnaire
215119092|NCT06999330|DEVICE|Theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 90%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Session length: 10 min; Time between sessions: 50 minutes.
215119093|NCT06999330|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
215119094|NCT07009509|BEHAVIORAL|YES-CAN! program|Youth Engaged Strategies to Change Adolescent Norms
215119095|NCT04342429|RADIATION|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
215119096|NCT06683599|PROCEDURE|Apneic oxygenation|1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
215119097|NCT07013136|DRUG|Folic Acid 5 MG|In this study, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen. In a rat model of AKI with ischaemia-reperfusion, intraperitoneal injection of 5-methyltetrahydrofolate (5-MTHF) at 3 μg/kg body weight twice (30 min before ischaemia and 3 h after reperfusion) improved kidney function and alleviated oxidative stress within 24 hours. The average body weight is around 60 kg for Chinese. Considering the oral route often requires larger doses than injection to produce the same effect, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen to test its effect on AKI. Depending on the clinical condition, the therapeutic dose of folic acid varies. For foetal support during pregnancy, daily doses of 1 mg of folic acid are recommended; for lowering homocysteine, up to 5 mg daily are generally used.
214442244|NCT05383079|DRUG|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
214442245|NCT05383079|DRUG|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
214442246|NCT04620239|DRUG|padeliporfin VTP|During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
214442247|NCT02204098|BIOLOGICAL|Mammaglobin-A DNA Vaccine|
214442248|NCT02204098|PROCEDURE|Optional biopsy|
214442249|NCT04941287|BIOLOGICAL|Atezolizumab|Given IV
214442250|NCT04941287|PROCEDURE|Biopsy|Undergo tumor biopsy
214442251|NCT04941287|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214442252|NCT04941287|DRUG|Cobimetinib|Given PO
214442253|NCT04941287|PROCEDURE|Computed Tomography|Undergo a CT scan
214442254|NCT04941287|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214442255|NCT04941287|DRUG|Varlilumab|Given IV
214442256|NCT06023719|DEVICE|DISC Care|Medical device to prevent disc herniation recurrence
214442257|NCT06375044|DRUG|SIM0500|Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
214442258|NCT05431270|DRUG|Mavrostobart (PT199)|Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
214442259|NCT05431270|DRUG|Tislelizumab|Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
214442260|NCT05431270|DRUG|Gemcitabine + nab-Paclitaxel|Dosing is per Standard of Care.
214442261|NCT05431270|DRUG|Docetaxel|Dosing is per Standard of Care.
214442262|NCT05431270|DRUG|Pemetrexed|Dosing is per Standard of Care.
214442263|NCT05431270|DRUG|Gemcitabine|Dosing is per Standard of Care.
214442264|NCT05431270|DRUG|Carboplatin + Pemetrexed|Dosing is per Standard of Care.
214442265|NCT05431270|DRUG|Pembrolizumab + Carboplatin + Pemetrexed|Dosing is per Standard of Care.
214442266|NCT04209985|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
214442267|NCT04735627|DEVICE|Levodopameter|There are several minimally-invasive sensors being developed that can detect levodopa levels in the capillary blood, sweat, and interstitial fluid.
214442268|NCT05874206|DEVICE|Cratos™ Stent Graft|Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
214442269|NCT04555967|DEVICE|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
214442270|NCT04065048|OTHER|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
214442271|NCT04065048|OTHER|Non-soy based diet|Diet of identical composition to the soy diet with the exception of soy.
214442272|NCT05904470|DRUG|Bemnifosbuvir|550 mg administered orally once a day (QD) for 8 weeks
214442273|NCT05904470|DRUG|Ruzasvir|180 mg administered orally once a day (QD) for 8 weeks
214442274|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
214442275|NCT05423106|DRUG|Placebo|Placebo will be administered as an oral formulation.
214442276|NCT05423106|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
214442277|NCT05423106|DRUG|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
214442278|NCT05423106|DRUG|Entecavir (ETV)|ETV tablet will be administered orally.
214442279|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
214442280|NCT06530641|DRUG|Custodiol Htk Soln|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Custodiol crystalloid cardioplegia.
214442281|NCT06530641|DRUG|Buckberg Cardi-Braun|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Buckberg blood cardioplegia.
214442282|NCT01688076|PROCEDURE|Botulinum Toxin A|Forehead will be injected with Botox.
214442283|NCT05400200|DIAGNOSTIC_TEST|questionnary administration|questionary
214442284|NCT04280523|DRUG|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
215119098|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
214442285|NCT04592523|OTHER|No Intervention|This is a non-interventional study.
214442286|NCT05923463|BEHAVIORAL|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
215119099|NCT04664634|DEVICE|Aria Sensor|The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.
215119100|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
215119101|NCT05393661|OTHER|inpatient physical therapy poststroke|routine care
214442287|NCT05923463|BEHAVIORAL|standard feedback email messages|Providers receive metrics in a common format.
214442288|NCT06783595|OTHER|intraoral scan|Device that scans the mouth with by taking numerous pictures of the mouth and stitches them together to form a three-dimensional copy of the patient teeth.
214442289|NCT06787404|DRUG|Ephedrine|5 milligrams of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
214442290|NCT06787404|DRUG|Noradrenalin|5 micrograms of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
214442291|NCT06783192|DRUG|MK-8527|MK-8527 capsule taken by mouth
214442292|NCT06783192|DRUG|LNG/EE|LNG/EE combination tablet taken by mouth.
214442293|NCT06286293|OTHER|Neuropsychological assessment, driving simulator task|Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
214442294|NCT06788483|BEHAVIORAL|An self-regulated flipped classroom strategy|The self-regulated flipped classroom strategy was developed based on the self-regulated learning theory (Zimmerman, 2002) and the flipped classroom model (Bishop \& Verleger, 2013).
214442295|NCT06791447|OTHER|AI-assisted Predictive Model for Dialysis Outcomes|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, dialysis treatment details, and clinical observations, to predict outcomes for dialysis patients. The model employs deep learning algorithms to predict mortality risk, intermediate outcomes such as anemia, blood pressure control, nutrition, and calcium-phosphate metabolism, and helps identify early signs of deterioration. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting patient outcomes and optimizing treatment strategies to improve overall health and survival rates for dialysis patients.
214520095|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
215119102|NCT07029724|DEVICE|TrueCPR Multisensory Feedback Device|TrueCPR (Physio-Control, Inc., Redmond, WA, USA) is a real-time CPR feedback device that provides both visual and auditory cues to support the delivery of high-quality chest compressions. The system consists of two pads (chest and back) that measure compression depth using electromagnetic signal transmission. The device offers auditory rate guidance via a metronome and visual feedback through a color display indicating the adequacy of compression depth and recoil. Performance data-including compression depth, rate, ratio, and the percentage of compressions that are too shallow or too deep-are recorded and analyzed using dedicated software. TrueCPR delivers multisensory feedback (auditory and visual) for both professional rescuers and trainees.
215119103|NCT07029724|DEVICE|Ambu Smartman ALS Pro+ (AW301) Simulation Manikin|The Ambu SmartMan ALS Pro+ (AW301) is an advanced simulation manikin designed to support training in both Basic and Advanced Life Support (BLS and ACLS). It features multiple operational modes, including feedback, skills, code, and application modules, with or without manikin dependency. The manikin provides real-time auditory feedback through an integrated metronome and allows online monitoring by instructors. It records performance metrics such as compression depth and rate, compression-to-decompression ratio, hand position accuracy, and number of compressions with leaning.
215119104|NCT07029724|DEVICE|Metronome|The Ambu SmartMan ALS Pro+ (AW301), which is an advanced simulation manikin, offers real-time auditory feedback via an integrated metronome function. Devices that provide only a fixed auditory tempo-such as a metronome-are generally classified as coaching devices, because they do not measure or analyze the user's actions during CPR.
215119105|NCT02728154|OTHER|Blood Sample|One tablespoon of blood will be drawn once during the study.
215119106|NCT02728154|OTHER|Stool Sample|One stool sample will be collected.
215119107|NCT06725251|BEHAVIORAL|Art Therapy|Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
215119108|NCT06726031|DEVICE|wearing VR glass|The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
215119109|NCT06726421|RADIATION|Stereotactic body radiotherapy (SBRT)|The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.
215119110|NCT06726421|DRUG|axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib|Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
214442296|NCT04491968|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
214442297|NCT04491968|OTHER|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
214442298|NCT04185532|OTHER|Rebound ACL brace and physioterapy|Usage of rebound ACL brace and physioterapy supervised by physioterapist
214442299|NCT04185532|OTHER|Physioterapy|Physioterapy supervised by physioterapist
214442300|NCT01885676|DEVICE|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
214442301|NCT01885676|OTHER|Saline Solution|Saline Solution mesotherapy micro injection
214442302|NCT06789068|OTHER|lactose free regimen|lactose free formula and solid foods that lack lactose for infants above 6 months, ensuring adequate macro and micronutrients intake according to recommended daily allowances (RDA) for age and sex.
214520096|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
214520097|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
214520098|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
214520099|NCT01737034|OTHER|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
214520100|NCT03937076|PROCEDURE|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
215119111|NCT06725355|DRUG|IN-R00002|Single administration of IN-R00002 60mg
215119112|NCT06725355|DRUG|IN-G00002|Single administration of IN-G00002 60mg
215119113|NCT06726252|DEVICE|FFR measurement and intravascular imaging|Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement, and intravascular imaging, including IVUS and integrated OCT-IVUS using a single cathete to assess the accurary of OUFR, using wire-based FFR measurement as the gold standard.
215119114|NCT06727149|OTHER|Control Group|No intervention was performed to reduce pain, fear and anxiety in the control group
215119115|NCT06727149|OTHER|Virtual Reality Group|The children in the VR group were informed about the virtual reality glasses and told that they could remove the glasses at any time if they felt uncomfortable during the procedure
215119116|NCT07048483|BEHAVIORAL|Nutrition Education|This intervention uses curated audio-visual messages through videos and films to engage participants in learning about healthy eating behaviors, followed by structured, brief discussions designed to reflect on the content and relate it to personal dietary habits. The intervention leverages narrative-based media to increase self-efficacy for healthy eating.
214442303|NCT05678400|BEHAVIORAL|Hypopressive abdominal techniques|Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.
214442304|NCT05678400|BEHAVIORAL|Stretching of proprioceptive neuromuscular facilitation|Stretching of proprioceptive neuromuscular facilitation
214442305|NCT06789094|OTHER|Ain Shams University Cognitive Assessment (ASCA) tool|The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.
214442306|NCT05534581|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
214442307|NCT05534581|DEVICE|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
214442308|NCT06785376|BEHAVIORAL|DIY (Do It Yourself)|DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
214442309|NCT06785376|BEHAVIORAL|TRUST|TRUST is a single-session HIV self-testing training with facilitator
214442310|NCT06785376|BEHAVIORAL|SOC|standard of care single-session, low threshold peer/near-peer navigation to PrEP.
214520101|NCT03508882|DRUG|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
214520102|NCT03508882|DRUG|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
214520103|NCT03043950|DRUG|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
214520104|NCT04175834|DRUG|cetrizine|prophylaxis
214520105|NCT04175834|DRUG|diphenhydramine|prophylaxis
214520106|NCT00212979|OTHER|non intervention study|
214520107|NCT01037829|OTHER|Non-intervention observational study|Non-intervention observational study
214520108|NCT04158453|DRUG|AUT00201|Oral dose of AUT00201
214520109|NCT04158453|DRUG|Placebo|Oral dose of placebo
214520110|NCT01509599|PROCEDURE|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
214520111|NCT01509599|PROCEDURE|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
214693079|NCT06116435|BEHAVIORAL|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
215119117|NCT07048483|OTHER|control group|Educational materials about food and healthy in the form of handouts will be provided to participants to review.
215119118|NCT05283564|OTHER|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
215119120|NCT07065513|DIAGNOSTIC_TEST|Normal diet|Normal diet (control group, 20 participants: 10 boys and 10 girls).
215119121|NCT07065513|COMBINATION_PRODUCT|Normal diet plus nutritional protein-based bar|: Normal diet plus nutritional protein-based bar (intervention group, 20 participants: 10 boys and 10 girls). The participants will consume 3 servings of 14g each per day, providing 6.8g protein and 283 kcal
214442317|NCT05791071|DEVICE|Floreo VR Building Social Connections|Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
215119122|NCT07064941|BEHAVIORAL|Exercise|Exercise for 30 min a day 5x a week with a choice between Aerobic or strength training. Subjects will choose an aerobic activity to perform 3x/week (e.g. brisk walking, hiking, jogging). They will start at 15-20 min/day depending on fitness level and build up by 5 min intervals/week as tolerated to 50 min/day or 150 min/week by 12 weeks. Subjects will choose strength exercises to perform 2x/week, on days separate from aerobic activity. They will start with 1-2 exercises (e.g. squats, lunges, planks with and without resistance) and gradually add exercises to include all muscle groups (arms, legs, chest, back, abdomen). Start with 2 sets of 10 reps, and work up to 3 sets of 15 reps of given exercises.
215119123|NCT07066956|DEVICE|ATLAS 2030 Exoskeleton|They underwent intensive training with 4 weekly sessions during 6 weeks with the ATLAS 2030 exoskeleton, a wearable device that provides gait assistance through eight degrees of freedom, four for each leg, including hip, knee, and ankle rotations. During training sessions, participants were fitted with the exoskeleton and performed 25 minutes of automatic forward walking, 15 minutes of active forward walking, 15 minutes of automatic forward walking, 5 minutes of automatic backward walking, 5 minutes of active backward walking, and exoskeleton removal. During the walk, therapeutic activities based on therapeutic objectives were carried out according to the participants' abilities.
215119124|NCT07065214|DEVICE|APC|For the surgical procedure for ovarian endometrioma treatment APCapplicator will be used
215119125|NCT07065214|DEVICE|Lap bipolar forceps|For ovarian endometrioma treatment the standard of care treatment will be performed.
215119126|NCT07065955|OTHER|Longevity diet alone or in combination with fasting mimicking diet|The longevity diet generally consists of three isocaloric meals and one snack (for normal-weight individuals) or slightly hypocaloric meals (in the case of overweight or obesity). The diet consists of 50-60% of calories from complex carbohydrates, 30-35% of calories from mostly unsaturated fats, and 10-11% of calories from proteins, primarily from plant sources and fish, and occasionally from eggs, dairy, and meat, especially for those over 65. The diet is formulated to provide all necessary nutrients, including vitamins and minerals. The fasting-mimicking diet is a dietary intervention in which normal food is replaced with a standardized, highly hypocaloric vegan diet for a limited period of 5 consecutive days. This diet is designed to stimulate the same processes normally activated during fasting while minimizing the side effects of total food deprivation.
215119127|NCT07065123|OTHER|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery
215119128|NCT07065708|DIAGNOSTIC_TEST|Visual biofeedback using transperineal ultrasound|Transperineal ultrasound with visual biofeedback
215119129|NCT07065708|DIAGNOSTIC_TEST|Transperineal ultrasound without visual biofeedback|Transperineal ultrasound without visual biofeedback
215119130|NCT07066150|OTHER|Apply a cream containing 0.05% marula oil-derived ceramide NPs|The participants were requested to apply a cream containing 0.05% marula oil-derived ceramide NPs on their faces twice daily for 28 consecutive days.
214442318|NCT05791071|DEVICE|Sham|This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.
214442319|NCT05857644|DRUG|PF-07923568|One time dose of 4 capsules taken orally.
214520112|NCT03425045|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
214520113|NCT03425045|PROCEDURE|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
215119131|NCT04896593|BEHAVIORAL|Smartphone App|Smartphone app teaching suicide prevention skills.
215119132|NCT03718897|DIAGNOSTIC_TEST|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
215119133|NCT00564213|DRUG|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
215119134|NCT01376414|OTHER|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
215119135|NCT06941415|DRUG|Bumetanide|Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
215119136|NCT06941415|DRUG|Furosemide|Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders
215119137|NCT06477419|DRUG|Sacituzumab govitecan-hziy|After enrollment, participants will receive SG until disease progression or intolerable toxicity.
215119138|NCT06169111|BIOLOGICAL|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
215119139|NCT00293618|DEVICE|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
215119140|NCT00293618|OTHER|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
215119141|NCT00293618|OTHER|Feedback|Feedback about the physician's personal performance on prevention of PONV
215119142|NCT00369577|DRUG|Inhaled Placebo|Inhaled Placebo, single dose
215119143|NCT00369577|DRUG|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
215119144|NCT00369577|DRUG|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
215119145|NCT03471780|DIAGNOSTIC_TEST|ultrasound|Transperineal us are made to pregnant ladies in labour
215119146|NCT02850380|OTHER|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
214442320|NCT04646200|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
214442321|NCT04646200|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
214442322|NCT06459739|PROCEDURE|sacral ESPB|sacral ESPB
214442323|NCT04765865|OTHER|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
214442324|NCT05479994|DRUG|BGB-11417|Administered orally
214442326|NCT05096819|OTHER|Patients Using the 6MWT App in the Community|Patients under the care of the cardiovascular clinics in Oxford, who used the Timed Walk app to perform 6MWT in their community during the CODIV19 pandemic period
214442327|NCT05096819|OTHER|Volunteers for 6MWT distance comparison|Volunteers (cardiac patients and hospital staff) who performed 10 6MWT using the TimedWalk app and a trundle wheel simultaneously. Five tests were performed following instructions and 5 were performed introducing errors. Aim is to measure app accuracy under different circumstances.
214442328|NCT05307978|DRUG|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
214442329|NCT05307978|DRUG|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
214520114|NCT03425045|DRUG|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
214520115|NCT06136325|PROCEDURE|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
214520116|NCT05229848|PROCEDURE|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
214520117|NCT05229848|PROCEDURE|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
215119147|NCT05761002|BIOLOGICAL|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
215119148|NCT00352430|DRUG|Nitric Oxide/INP Pulse Delivery|
215119149|NCT00352430|DRUG|Nitric Oxide/INO Pulse Delivery|
214693080|NCT06116435|BEHAVIORAL|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
214693081|NCT06116435|BEHAVIORAL|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
214693082|NCT02100748|DRUG|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
214693083|NCT02100748|DRUG|Morphine|Morphine 4 mg will be administered every 4 hours
214442330|NCT03324984|DRUG|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
214693084|NCT02100748|DRUG|Placebo|Placebo will be administered every 4 hours
215119150|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
215119151|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
215119152|NCT05551611|OTHER|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
214442331|NCT03324984|DRUG|0.75% bupivacaine|Bupivacaine is used on label
214442332|NCT06199700|DRUG|Esketamine hydrochloride|Intravenous infusion of Ketamine
214442333|NCT05454774|GENETIC|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
214442334|NCT04661683|OTHER|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
214520118|NCT02430935|BEHAVIORAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
214520119|NCT02430935|BEHAVIORAL|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
214520120|NCT04013347|PROCEDURE|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
214520121|NCT03852381|DEVICE|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
214520122|NCT03278808|DRUG|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
214520123|NCT03278808|DRUG|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
214520124|NCT03278808|DRUG|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
214520125|NCT05935683|OTHER|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
214520126|NCT00494286|BEHAVIORAL|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
214520127|NCT00494286|BEHAVIORAL|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
214520128|NCT05149976|DIAGNOSTIC_TEST|Voice recording before and after dietary intake|"* A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
214520129|NCT05413954|OTHER|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
215119153|NCT05551611|OTHER|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
215119154|NCT03250208|DIETARY_SUPPLEMENT|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
215119155|NCT03250208|OTHER|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
214442335|NCT04661683|OTHER|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
214442336|NCT04661683|OTHER|Clean Room Air|Exposure to room air for a duration of 60 minutes.
214442337|NCT06831578|PROCEDURE|seratuse anterior plane block|after patient consenting, induction of anathesia Under sterile conditions, and while the patients will be still on the lateral position with the diseased side up after induction of anesthesia, a linear ultrasound transducer (10-12 MHz) will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage. Then counting down ribs till the seventh rib will be identified in the mid-axillar\]y line. The following muscles will be identified overlying the sixth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle . Under continuous ultrasound guidance, 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter.
214442338|NCT06831578|PROCEDURE|paravertebral plane block|after concenting patient, induction of anathesia Paravertebral plan block will be performed while the patient is still in lateral position and a linear ultrasound transducer (10-12 MHz) will be used for ultrasound guidance. A sagittal or transverse image can be obtained at the appropriate vertebral level. After image optimization, the Tuohy needle is advanced in plane until the tip rests in the thoracic paravertebral space. Injection of small amounts of fluid (hydrodissection) will aid in needle tip location. Saline or local anesthetic is injected through the Tuohy needle. The endpoint for a successful block is anterior displacement of the pleura. 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter. The catheter is threaded through the Tuohy needle and its position is confirmed by injecting local anesthetic or small air bubbles. Pleural depression should agai
214442339|NCT06382220|DRUG|Bupivacain|drug injection
214442340|NCT06461676|DRUG|Ventrix Bio Extracellular Matrix|VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
214442341|NCT06789757|DRUG|Memantine Hydrochloride|Memantine (5mg) is an N-methyl-D-aspartate (NMDA) receptor antagonist given in 21-day cycles over six months in combination with Bevacizumab and Atezolizumab. Each week memantine will be escalated by 5mg as tolerated
214442342|NCT06789757|DRUG|Bevacizumab|Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.
215119156|NCT03192761|PROCEDURE|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
214442343|NCT06789757|DRUG|Atezolizumab|Atezolizumab (1200mg) is a programmed death-ligand 1 (PD-L1) blocking antibody given in 21-day cycles over six months in combination with Memantine and Bevacizumab
214442344|NCT06788730|BEHAVIORAL|Transtheoretical Model Based Healthy Internet Use Programme Intervention Supported by Mindfulness Exercise Applied to Adolescents|Transtheoretical Model Based Healthy Internet Use Programme Supported by Mindfulness Exercise will be carried out as one session per week for 8 weeks. The training programme will be carried out by dividing the students into 2 groups (the first group is 18 and the second group is 19 people). The training programme will be applied to the groups two days in the same week at the times determined by the guidance teacher. Interventions will be applied to the intervention group with trainings, homework applications and interventions to increase healthy internet use.
214442345|NCT06785558|DRUG|Anticholinergic therapy|Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
214520130|NCT05413954|OTHER|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
214520131|NCT00010322|DRUG|atamestane|
214520132|NCT00010322|DRUG|toremifene|
214520133|NCT00516178|DRUG|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
214520134|NCT00516178|DRUG|Saline|3 infusions, perioperative or post-PTCA
214520135|NCT03227432|DRUG|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
214520136|NCT03227432|DRUG|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
214520137|NCT03227432|DRUG|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
215119157|NCT03192761|PROCEDURE|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
215119158|NCT03192761|PROCEDURE|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
215119159|NCT01839812|DRUG|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
214442346|NCT00404196|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
214442347|NCT06318507|COMBINATION_PRODUCT|Fecal microbial diversity|Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
214520138|NCT03227432|DRUG|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
214520139|NCT00483171|DRUG|CP-945,598|CP-945,598
214520140|NCT00483171|BEHAVIORAL|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
214520141|NCT00483171|BEHAVIORAL|Low Calorie Diet|Low calorie diet
214520142|NCT00205205|BEHAVIORAL|peer mentoring|
214520143|NCT04092699|DEVICE|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
214520144|NCT01378533|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
214442348|NCT06373211|DRUG|Immunoglobulins IV (CLAYRIG)|"Patients will be treated with cycles of :~\- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"
214442349|NCT06373211|DRUG|Cyclophosphamide IV|"Patients will be treated with cycles of :~\- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"
214442350|NCT06373211|DRUG|Methylprednisolone IV|"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"
214442351|NCT06782516|DEVICE|System of Care - combination of algorithm and Brief Contact Intervention|Case managers see the Native-RISE algorithm classification and Clinical Providers receive a risk notification. A resource card is provided to the participant.
214442352|NCT06782516|BEHAVIORAL|Active Comparator - Provider notification of risk status|Clinical Providers receive a risk notification and a resource card is provided to the participant.
214442353|NCT06558201|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
214442354|NCT06787170|DIAGNOSTIC_TEST|MRI habitat imaging|Habitat imaging, a data-driven image processing technique that divides the entire lesion into multiple sub-regions without assuming anything prior, has capacity to noninvasively evaluate the intratumoral heterogeneity.
214442355|NCT01536886|DRUG|LEO 90100|
214442356|NCT01536886|DRUG|Betamethasone plus calcipotriol|
214442357|NCT01536886|DRUG|Ointment vehicle|
214442358|NCT01536886|DRUG|LEO 90100 vehicle|
214442359|NCT06787287|PROCEDURE|Modified compression method|In the experimental group, an improved compression method was adopted. A thick gauze block of 9cm\*16cm\*8mm was folded three times and placed at the puncture site of the patient's radial artery, and a spiral radial artery hemostatic device was placed above it. The control group was treated with traditional compression method, and the spiral radial artery hemostat was applied directly at the radial artery puncture
214442360|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
214442361|NCT05938101|BEHAVIORAL|Behavioral therapy|Behavioral therapy and psychotherapy
214442362|NCT04533386|BEHAVIORAL|Multi-component intervention strategy|Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
214442363|NCT04607044|DEVICE|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
214442364|NCT04705779|BEHAVIORAL|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
214442365|NCT04705779|BEHAVIORAL|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
214520145|NCT02399982|OTHER|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
214520146|NCT02399982|OTHER|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
214520147|NCT04538534|DRUG|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
214520148|NCT03184519|DIAGNOSTIC_TEST|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
214520149|NCT01613573|DRUG|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
214442366|NCT02611180|PROCEDURE|Skin punch biopsy|
214442367|NCT02611180|PROCEDURE|Peripheral blood draw|
214442368|NCT06334562|DRUG|SUGAMMADEX SODIUM 100 Mg in 1 mL|The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
214442369|NCT06334562|DRUG|Neostigmine|Neostigmine is 50 μg/kg
214442370|NCT05075408|DRUG|Nemolizumab|Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
214442371|NCT05075408|DRUG|Nemolizumab|Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
214520150|NCT01613573|DRUG|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
214442372|NCT05075408|DRUG|Placebo|Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
214442373|NCT06785727|DRUG|Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)|"The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual)."
214442374|NCT06832657|DRUG|JMKX003948 Ophthalmic Suspension|JMKX003948 Ophthalmic Suspension with formulation 1% (15 mg/1.5 mL), 2% (30 mg/1.5 mL), 3% (45 mg/1.5 mL), 5% (75 mg/1.5 mL)
214442375|NCT06832657|DRUG|Placebo|JMKX003948 Ophthalmic Suspension placebo
214520151|NCT02404012|DIETARY_SUPPLEMENT|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
214693085|NCT04215081|DEVICE|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
214442376|NCT06784869|DEVICE|Scaling and root surface debritment|Patients with 4-6 mm pocket depth were participated in this study; clinical periodontal parameters (BOP, PLI, PPD, CAL) were recorded at the baseline visit. To ensure sampling accuracy, From the site two papers with GCF were sampled. Following sample collecting for GCF, Every patient received comprehensive mouth supragingival scaling with an ultrasonic scaler (WoodpEEKer® UDS-K) along with dental hygiene recommendations. One week later, the sites were irrigated with normal saline after being scaled and root planed (ScRp) with Gracey curette. Following completion of subgingival instrumentation, each patient returned to the clinic following 1 and 3 months for periodontal parameter recording and GCF collection. Throughout these sessions, every patient received reinstruction to engage in self-oral hygiene practices.
214442377|NCT04701437|BEHAVIORAL|Peer mentor|Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
214442378|NCT04701437|BEHAVIORAL|Standard of care|Passive referral to a HCV provider
214442379|NCT01727518|OTHER|As the LEAD study is an observational cohort study, there is no intervention to report.|As the LEAD study is an observational cohort study, there is no intervention to report.
214442380|NCT05683392|DEVICE|t:slim X2 insulin pump with Control-IQ technology 2.0|t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
214442381|NCT04878354|DRUG|Tree SLIT-tablet|Sublingual allergy immunotherapy tablets
214442382|NCT04878354|DRUG|Placebo SLIT-tablet|Placebo
214442383|NCT05149534|BEHAVIORAL|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
214442384|NCT05149534|DEVICE|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
214442385|NCT05792540|DRUG|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
214442386|NCT05792540|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
214442387|NCT05792540|DRUG|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
214442388|NCT05666167|BEHAVIORAL|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
214442389|NCT03513939|COMBINATION_PRODUCT|Sernova Cell Pouch|"The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 5 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter)."
214442390|NCT04637594|DRUG|Pembrolizumab|Given IV
214442391|NCT04637594|DRUG|Nivolumab|Given IV
214442392|NCT04637594|DRUG|Atezolizumab|Given IV
214442393|NCT04637594|DRUG|Durvalumab|Given IV
214442394|NCT04637594|DRUG|Avelumab|Given IV
214442395|NCT04615819|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
214442396|NCT04615819|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
214442397|NCT05241613|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
214442398|NCT02281097|OTHER|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
214442399|NCT02281097|OTHER|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
214442400|NCT04247165|DRUG|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
214442401|NCT04247165|DRUG|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
214442402|NCT04247165|DRUG|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
214442403|NCT04247165|DRUG|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
214442404|NCT04247165|RADIATION|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~* Prescription dose shall be according to the following specifications:~* A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~* Pauses are accepted but the treatment should be delivered within 10 calendar days.~* PTV should be covered by 95% isodose (PTV D99% \>95%)."
214442405|NCT03067467|DRUG|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
214442406|NCT03067467|DRUG|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
214442407|NCT06763770|BEHAVIORAL|Managing Your Health (MYH)|The Managing Your Health intervention consists of six weekly videoconference calls with a peer mentor and five self-management educational modules within a mobile application. The first call is to get to know each other, share survivorship stories, identify self-management strengths and weaknesses, and select goals for participation in the intervention. The remaining five weekly calls cover a self-management topic each week, including understanding your survivorship care plan, navigating the healthcare system and insurance, managing the emotional aspects of survivorship, negotiating family and significant other involvement in care, and engaging in healthy lifestyle behaviors.
214442408|NCT06763770|BEHAVIORAL|The Usual Care + Educational Control|The Usual Care + Educational Control group will receive weekly emails with links to the Health Links developed by the Children's Oncology Group for use in survivorship care. Access to these Health Links reflects the current state of clinical care available to survivors. These Health Links were developed as patient education materials to cover relevant self-management and survivorship care topics. The weekly messages will align with the content of the modules from Managing Your Health to provide similar information, including Introduction to Long-Term Follow-Up (Module 1), Finding and Paying for Healthcare (Module 2), Emotional Issues (Modules 3 and 4), Educational Issues, Diet and Physical Activity, Skin Health, Reducing the Risk of Second Cancers, and Male/Female Health Issues (Module 5).
214442409|NCT06763042|DEVICE|Mindfulness-based Life Management Social Robots|Mindfulness-based life management contents for pediatric patients operated by Social Robots
214442410|NCT02707120|DRUG|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
214442411|NCT02707120|DRUG|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
214442412|NCT05587036|DRUG|Rifaximin|Rifaximin oral tablet, 550 mg, twice daily, two-weeks
214520152|NCT05417685|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
214520153|NCT05417685|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
214693086|NCT06693622|BEHAVIORAL|Patient survey|To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
215119160|NCT02210260|PROCEDURE|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
215119161|NCT02210260|PROCEDURE|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
214442413|NCT05587036|DIETARY_SUPPLEMENT|Placebo|Placebo oral tablet, twice daily, two-weeks
214442414|NCT04847999|DIETARY_SUPPLEMENT|Dark chocolate|Dark chocolate
214693087|NCT06686914|DRUG|Cannabidiol (CBD) Oil 300mg|Cannabidiol (CBD) Oil 300mg, 1 dose
214693088|NCT06686914|DRUG|Cannabidiol (CBD) Oil 150mg|Cannabidiol (CBD) Oil 150mg, 1 dose
214693089|NCT06686914|DRUG|Placebo Oil|Placebo Oil, 1 dose
214442415|NCT06358339|OTHER|TEEM|The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
214693090|NCT06874595|OTHER|Cycling exercise at 65% of HRR for 20 minutes followed by HD-tDCS (exercise + HD-tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
214693091|NCT06874595|OTHER|Cycling exercise at 65% of HRR exercise followed by sham HD-tDCS (exercise + sham tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a sham High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
215119162|NCT02210260|DRUG|Bupivacaine|
215119163|NCT02210260|DRUG|Diamorphine|500mcg
215119164|NCT02210260|DEVICE|A Painbuster® catheter|
215119165|NCT02210260|DEVICE|25G Whitacre needle|
215119166|NCT00543777|DIAGNOSTIC_TEST|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
215119167|NCT00543777|DIAGNOSTIC_TEST|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
215119168|NCT04239651|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
215119169|NCT04239651|OTHER|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
215119170|NCT00848783|DRUG|Irinotecan|
214442416|NCT02879448|DEVICE|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
214442417|NCT02879448|DEVICE|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
214442418|NCT03433339|DEVICE|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
214442419|NCT03433339|DEVICE|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
214442420|NCT04999202|DRUG|BAY2416964|Oral, twice or three times daily
215119171|NCT00848783|DRUG|Cisplatin|
215119172|NCT00848783|PROCEDURE|Surgery|
215119173|NCT00848783|DRUG|Floxuridine|
215119174|NCT00848783|DRUG|Capecitabine|
215119175|NCT03388047|DEVICE|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
215119176|NCT01205971|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
215119177|NCT01205971|BEHAVIORAL|Dental Preventive Services|Written oral health educational materials
215119178|NCT04239690|OTHER|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
215119179|NCT04840212|OTHER|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
215119180|NCT02937558|DRUG|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
215119181|NCT02937558|OTHER|Placebo|Isotonic saline
215119182|NCT02360228|DEVICE|tACS (alpha)|
215119183|NCT02360228|DEVICE|tDCS|
214442421|NCT04999202|DRUG|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
214442422|NCT04999202|DRUG|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
214442423|NCT06223659|DRUG|Eutectic Mixture of Local Anesthetics|Apply topically to skin
214442424|NCT06223659|DRUG|Placebo Administration|Apply topically to skin
214442425|NCT06223659|OTHER|Questionnaire Administration|Ancillary studies
214442426|NCT06267586|DIETARY_SUPPLEMENT|PeptiSleep|Plant protein hydrolysate
214442427|NCT06267586|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
214442428|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
214442429|NCT03525288|RADIATION|PSMA -PET/CT simulation|"* PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
214442430|NCT03525288|RADIATION|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
214442431|NCT05952076|DIETARY_SUPPLEMENT|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
214442432|NCT05952076|DIETARY_SUPPLEMENT|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
214442433|NCT02915575|OTHER|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (\<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
214442434|NCT02915575|OTHER|Usual Care|Participants will be discharged as per usual ward discharge protocols.
214520154|NCT05417685|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
214520155|NCT04501354|DRUG|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
215119184|NCT00745043|DRUG|bronchodilator response|
215119185|NCT04160663|DIAGNOSTIC_TEST|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
215119186|NCT01668225|PROCEDURE|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
215119187|NCT06444815|DRUG|VET3-TGI|Oncolytic vaccinia virus engineered with immunomodulatory transgenes
215119188|NCT06444815|DRUG|Pembrolizumab|anti-pd1 antibody
215119189|NCT02755220|DEVICE|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
215119190|NCT04280731|DIETARY_SUPPLEMENT|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
215119191|NCT01429181|DRUG|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
215119192|NCT02769221|DEVICE|Rigid video stylet|
215119193|NCT02769221|DEVICE|Video laryngoscope|
214442435|NCT06739070|OTHER|Plyometric|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
214442436|NCT06739070|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
214442437|NCT06739070|OTHER|Control group (no intervention)|In control group no intervention would be given. Initial test would be performed at 4th and 8th week and then results would be compared with experimental group.
214520156|NCT05395754|DEVICE|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
214520157|NCT06434571|BEHAVIORAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
214520158|NCT06434571|BEHAVIORAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
214442438|NCT05332340|DRUG|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
214520159|NCT06434571|BEHAVIORAL|Treatment as usual (TAU)|They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
215119194|NCT05846373|DRUG|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
215119195|NCT05846373|DRUG|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
215119196|NCT05846373|OTHER|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
215119197|NCT00516256|BEHAVIORAL|CHESS System|Internet-based computer program for 6 months.
215119198|NCT00516256|BEHAVIORAL|Cancer Information Mentor|Phone calls to the patient for 6 months.
215119199|NCT01188304|DRUG|aleglitazar|repeated daily doses
214442439|NCT06328504|COMBINATION_PRODUCT|Cashew immunotherapy|Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
214442440|NCT06738381|BEHAVIORAL|Digital intervention and motivational counselling|A single sesstion of motivational interviewing and access to a digital plattform for a six months period
214520160|NCT00156975|DRUG|Capecitabine|
214520161|NCT00156975|DRUG|Oxaliplatin|
215119200|NCT01188304|DRUG|aspirin|repeated daily doses
215119201|NCT01188304|DRUG|placebo|repeated daily doses
215119202|NCT05650281|OTHER|NO INTERVENTION|NO INTERVENTION
215119203|NCT03316703|PROCEDURE|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
215119204|NCT03316703|PROCEDURE|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
215119205|NCT05019534|DRUG|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
215119206|NCT05019534|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
215119207|NCT05019534|DRUG|Camrelizumab|Camrelizumab 200mg Q2W
215119208|NCT03539575|OTHER|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
215119209|NCT01059318|DRUG|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
215119210|NCT04266925|BEHAVIORAL|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
214442441|NCT06736652|OTHER|Parabolic flight|Preflight each individual was exposed to the 3 Other Interventions and monitored for changes in behavioral performance and neurophysiological responses. In-flight the same monitoring was conducted during partial-gravity (0.25, 0.5. 0.75g) and microgravity (\~0g).
214442442|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
214442443|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
214442444|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
214442445|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment and application of H42® hydrogel to the peri-implant pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
214442446|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of periodontal pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant.
214442447|NCT06740123|PROCEDURE|Non-surgical periodontal treatment and application of H42® hydrogel to the periodontal pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
214442448|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of peri-implant pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant.
214442449|NCT06739928|DRUG|Irinotecan liposome (II) combined with adebrelimab and carboplatin|Irinotecan liposome (II) + adebrelimab + carboplatin
214442450|NCT06739928|DRUG|etoposide combined with adebrelimab and carboplatin|etoposide + adebrelimab + carboplatin
214520162|NCT04010981|OTHER|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
214520163|NCT04010981|OTHER|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
214520164|NCT02067455|OTHER|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
214520165|NCT01092936|OTHER|Rating Scale administration|Movement Disorder Society\_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
214520166|NCT03456089|DIAGNOSTIC_TEST|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
215119211|NCT04266925|OTHER|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
215119212|NCT02082600|OTHER|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
215119213|NCT02082600|OTHER|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
214442451|NCT06738615|DIAGNOSTIC_TEST|Pressure volume loop evaluation|During the left heart catheterization there are catheters which are introduced into the left ventricle to measure left ventricular pressures and into the coronary arteries to assess their patency. This study will require the placement of an additional specialized catheter made into the left ventricle to measure the change of pressure and volume during the cardiac cycle. This will allow the measurement of heart muscle stiffness.
215119214|NCT06327828|DEVICE|Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)|Semi-automated computer-aided treatment based on a mathematical model
214442452|NCT06738615|DIAGNOSTIC_TEST|cardiovascular magnetic resonance imaging|Patients will undergo standard cardiovascular magnetic resonance imaging of their heart to measure their heart size, heart function, and severity of mitral regurgitation. In addition, contrast will be administered and heart tissue will be assessed for scarring or fibrosis.
214442453|NCT06738615|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|A CPET will be performed to objectively measure a patient ability to perform exercise.
214442454|NCT06738615|DIAGNOSTIC_TEST|Kansas City Cardiomyopathy Questionairre|This is a short questionnaire which objectively quantifies symptom burden
214442455|NCT06738433|DIETARY_SUPPLEMENT|ABB i5|Prebiotic ABB i5 (NextDext®, 5g)
214442456|NCT06738433|DIETARY_SUPPLEMENT|ABB C24|ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
214442457|NCT04544969|DRUG|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
214442458|NCT06351137|OTHER|Intravenous administration|Analgesia is administered intravenously.
214442459|NCT06351137|OTHER|Intranasal administration|Analgesia is administered intranasally using an atomizer.
214442460|NCT01718743|DRUG|Ixazomib Citrate|Given PO
214442461|NCT01718743|DRUG|Lenalidomide|Given PO
214442462|NCT01718743|OTHER|Questionnaire Administration|Ancillary studies
214442463|NCT00082186|DRUG|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
214442464|NCT05566925|OTHER|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
214442465|NCT06787768|OTHER|Technology Enriched Rehabilitation Gym|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants attend a minimum of two times per week and can attend daily for the two hour group based circuit class.
214442466|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
214442467|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
214442468|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
214442469|NCT03425201|DRUG|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
214442470|NCT05183763|BEHAVIORAL|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
214442471|NCT05183763|BEHAVIORAL|Medication reminder tools|Medication-taking reminder app and pillbox
214520167|NCT03282877|BEHAVIORAL|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
215119215|NCT06327828|PROCEDURE|Usual care|Guiding methimazole therapy based on the treating physician's decision
215119216|NCT02700828|DRUG|Hydrocortisone|4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
215119217|NCT02700828|DRUG|Placebo|4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
215119218|NCT00559221|DRUG|FLAG+IDA|Fludarabine, cytarabine, G-CSF
215119219|NCT04186871|DRUG|branebrutinib|Specified dose on specified days
215119220|NCT04186871|DRUG|abatacept|Specified dose on specified days
215119221|NCT04186871|DRUG|branebrutinib placebo|Specified dose on specified days
215119222|NCT01557907|DEVICE|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
214442472|NCT06221150|DRUG|Bilateral two level serratus anterior block|A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
214442473|NCT06221150|OTHER|Control group|Intraoperative opioids without regional block
214442474|NCT01276600|DRUG|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
214442475|NCT06310200|DRUG|Lidocaine Topical 4% Topical Solution|Intranasal administration
214442476|NCT06310200|DRUG|Bitrex|Bittering agent
214442477|NCT06310200|DRUG|normal saline|Placebo
214442478|NCT05942391|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
214442479|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
214442480|NCT05798585|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
214442481|NCT06030609|DRUG|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
214442482|NCT06030609|DRUG|Normal saline|The patient will receive NSS with D5W as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
214442483|NCT06752382|DRUG|Experimental drug|Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
214442484|NCT03148743|BIOLOGICAL|Fecal microbiota|fecal microbiota transplantation
214442485|NCT05485922|DEVICE|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
214442486|NCT05485922|DEVICE|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
214693092|NCT06874595|OTHER|No exercise followed by HD-tDCS (no exercise + HD-tDCS).|No exercise but a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
214442487|NCT06792929|DEVICE|virtual reality glasses group|Patients will wear virtual reality glasses throughout the ultrasound-guided fine needle aspiration biopsy procedure.
214520168|NCT02775175|BEHAVIORAL|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
214520169|NCT05329129|DEVICE|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
214693093|NCT06874595|OTHER|State Anxiety Inventory|"A widely used psychological assessment tool designed to measure both state and trait anxiety. 40 self-report items rated on a 4-point Likert scale (1 = Almost Never to 4 = Almost Always). Higher scores indicate higher levels of anxiety. Scores are compared to normative data to determine if they fall within the range of typical or clinical anxiety."
214693094|NCT06874595|OTHER|Visual Analog Scale for Anxiety|"The Visual Analogue Scale for Anxiety (VASA) is a 100-millimeter line that helps people measure how anxious they feel. The scale has a mark on the left end that indicates not at all anxious and a mark on the right end that indicates very anxious."
215119223|NCT01557907|DEVICE|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
215119224|NCT01013857|BEHAVIORAL|Health coaching|Calling patients every week to discuss medication adherence
214442488|NCT03927131|BIOLOGICAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
214442489|NCT03927131|BIOLOGICAL|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
214442490|NCT03927131|BIOLOGICAL|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
214442491|NCT03927131|BIOLOGICAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
214442492|NCT03927131|BIOLOGICAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
214442493|NCT03927131|BIOLOGICAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
214442494|NCT06831773|RADIATION|Carbon ion combined with photon radiotherapy|PTV1 was first treated with photon radiotherapy (started within 30 days after surgery), with a total dose of 50Gy, 25 times; After photon radiotherapy, PTV2 carbon ion radiotherapy was started, the total dose was 24.8Gy(RBE), 8 times. 3.1Gy(RBE)/fx; 1fx/ day, 5 days/week.
214442495|NCT06792877|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Intervention is an adapted form of Mindfulness-based stress reduction (MBSR) training virtual class that meets for 10 weeks. The class involves mindfulness training using awareness and focused attention, group discussion of the experience, and mindful movement. The Mindfulness Intervention also includes daily home practice using mindfulness recordings.
214442496|NCT06792877|BEHAVIORAL|Waitlist then mindfulness|Participants in this arm will first wait 10 weeks and then complete a mindfulness course with outcome measures assessed at baseline, after 10 weeks wait list and then after mindfulness course.
214520170|NCT05972109|OTHER|Workplace SSB sales ban|Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.
214693095|NCT05998616|BEHAVIORAL|Exercise Training Program|The intervention group will be encouraged to complete aerobic and resistance training exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment for monitoring walking and complete resistance training will be provided to the intervention group. The exercise training prescription involves 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and resistance training consisting of 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.
214693096|NCT05998616|BEHAVIORAL|Flexibility Program|The control group will be encouraged to complete stretching and range of motion exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment (yoga mat) for monitoring walking and complete flexibility training will be provided to the control group. The flexibility training prescription involves stretches from the Stretching for People with MS: An Illustrated Manual from the National MS Society.
214693097|NCT05650450|DEVICE|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
214693098|NCT00808327|DRUG|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
215119225|NCT01013857|BEHAVIORAL|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
215119226|NCT03419988|BEHAVIORAL|Exercise Intervention|24 sessions of aerobic exercise
215119227|NCT02464410|BEHAVIORAL|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
215119228|NCT02464410|BEHAVIORAL|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
215119229|NCT02464410|OTHER|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
215119230|NCT04386642|DRUG|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
215119231|NCT04386642|DRUG|Placebo|normal saline solution in a clear 50-ml syringe
214442497|NCT06837844|DRUG|Intrathecal Dexmedetomidine|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
214442498|NCT06837844|DRUG|Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
214442499|NCT06837844|DRUG|Intrathecal Dexmedetomidine + Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
214442500|NCT04973657|DRUG|VK0214|API in capsule
214520171|NCT05972109|BEHAVIORAL|Brief Intervention|Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
214520172|NCT04239911|BEHAVIORAL|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
214520173|NCT04239911|BEHAVIORAL|Virtual training course|Virtual training course on heart failure for home health aides.
214693099|NCT00808327|DRUG|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
215119232|NCT04891354|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
214442501|NCT04973657|OTHER|Placebo|API in capsule
214442502|NCT05065138|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
214442503|NCT05827055|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
214442504|NCT05827055|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
214442505|NCT05827055|DRUG|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
214442506|NCT05827055|DRUG|Placebo|Placebo given in vegan. capsules orally three times a day
214442507|NCT03739996|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
214442508|NCT03739996|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs were not provided by the study. Participants obtained NRTIs outside of the study through routine care.
214442509|NCT03739996|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
215119233|NCT04891354|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
214442510|NCT03739996|BIOLOGICAL|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
214520174|NCT05485441|OTHER|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
215119234|NCT01971385|DRUG|Squaric Acid solution|
215119235|NCT01971385|DRUG|Placebo solution|
214442511|NCT03739996|DRUG|Standard of Care (SOC) ART|SOC ART was not provided by the study. Participants obtained SOC ART outside of the study through routine care.
214442512|NCT06827483|OTHER|Neurocognitive Component|A neurocognitive component will be added to the Y Balance Test
214442513|NCT03471650|DRUG|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
214442514|NCT01673984|DRUG|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
214442515|NCT01673984|DRUG|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
214442516|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
214442517|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
214520175|NCT01839032|DRUG|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
214520176|NCT00720161|DRUG|Metformin|daily 850 mg
214520177|NCT00720161|DRUG|Placebo|placebo
214520178|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (A) for oral administration
214520179|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (B) for oral administration
214520180|NCT03478306|DRUG|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
214693100|NCT06696365|DEVICE|TMS|The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. MagVenture MagPro X100 is available commercially and has been FDA approved to treat major depressive disorder and obsessive-compulsive disorder.
214693101|NCT02959710|DRUG|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
214442518|NCT04667663|DRUG|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
214520181|NCT00234585|DEVICE|Renal Artery Stent with Protective Device/Drug|
214520182|NCT02188745|DRUG|17B-estradiol|Anti-estrogen
214442519|NCT04667663|DRUG|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
214442520|NCT04667663|DRUG|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
214520183|NCT02188745|DRUG|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
214520184|NCT02188745|DRUG|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
214520185|NCT02188745|DRUG|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
214520186|NCT01927484|DRUG|25 mg/week oral methotrexate tablets|active oral methotrexate drug
214520187|NCT01927484|DRUG|25mg/week oral placebo tablets|placebo comparator oral drug
214442521|NCT04667663|DRUG|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
214442522|NCT03044613|DRUG|Nivolumab|240mg or 1 mg/kg administered IV
214442523|NCT03044613|DRUG|Relatlimab|80mg administered IV
214442524|NCT03044613|DRUG|Carboplatin|standard care dose
214442525|NCT03044613|DRUG|Paclitaxel|standard care dose
214442526|NCT03044613|RADIATION|Radiation|standard care dose
214442527|NCT01521052|DEVICE|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
214520188|NCT03823794|OTHER|No intervention|Observational analysis of usual care only
214520189|NCT00680654|DRUG|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
214693102|NCT02959710|DRUG|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
214693103|NCT02959710|DRUG|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
214442528|NCT06243757|OTHER|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
214442529|NCT02553642|DRUG|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~\- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
214442530|NCT02553642|DRUG|Nivolumab plus Ipilimumab|"Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
214442531|NCT05555888|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
214520190|NCT04285645|OTHER|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
214693104|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
214693105|NCT07023757|PROCEDURE|Socket preservation|After tooth extraction, the extraction socket will be filled with a collagen plug in one group or a platelet-rich fibrin plug in the other.
215119236|NCT01810718|DRUG|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
215119237|NCT04352023|PROCEDURE|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
215119238|NCT04342117|DRUG|duvelisib|25 mg BID, 15 mg BID
215119239|NCT04342117|DRUG|PI3K inhibitor|FDA approved PI3K inhibitors
215119240|NCT05209373|BEHAVIORAL|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
215119241|NCT05209373|BEHAVIORAL|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
215119242|NCT04880369|DIETARY_SUPPLEMENT|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
215119243|NCT04880369|DIETARY_SUPPLEMENT|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
215119244|NCT04880369|DIETARY_SUPPLEMENT|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
215119245|NCT04131075|PROCEDURE|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
215119246|NCT03209466|DRUG|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
215119247|NCT03209466|DRUG|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
215119248|NCT01100359|DRUG|carboplatin|
215119249|NCT01100359|DRUG|liposome-encapsulated doxorubicin citrate|
215119250|NCT01100359|OTHER|laboratory biomarker analysis|
214442532|NCT05555888|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
214442533|NCT05555888|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214442534|NCT05555888|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
214442535|NCT06844630|OTHER|Preoperative block application (İntersclane Block)|Before surgery, patients will receive a unilateral interscalene block under ultrasound guidance.
214442536|NCT06844630|OTHER|Preoperative block application (Infraspinatus-teres minor interfascial block)|Before surgery, patients will receive a unilateral infraspinatus-teres minor interfascial block under ultrasound guidance.
215119251|NCT01100359|PROCEDURE|quality-of-life assessment|
215119252|NCT05254483|BEHAVIORAL|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
215119253|NCT05254483|BEHAVIORAL|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
214442537|NCT06847412|DEVICE|Escalating PEEP|Typically, an initial PEEP of 5 cm H₂O, then PEEP is increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).
214442538|NCT06847412|DEVICE|Sustained inflation|Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.
214442539|NCT06844929|OTHER|Podcast Group|Providing breastfeeding education via podcast
214442540|NCT06844929|OTHER|Brochure Group|Providing standard breastfeeding education using brochures
214442541|NCT06846749|DIETARY_SUPPLEMENT|F75 milk feeds|Standard 'F75' (75 kcal/100 ml) 95 kcal/kg/day 12.05 mg/kg/min glucose
214442542|NCT06846749|DIETARY_SUPPLEMENT|F50 milk feeds|Reduced caloric 'F50' (50kcal/100ml) 63 kcal/kg/day 8.03mg/kg/min glucose
214442543|NCT06846749|DIETARY_SUPPLEMENT|F35 milk feeds|"Reduced caloric 'F35' (35 kcal/100ml)~* 47 kcal/kg/day~* 5.62 mg/kg/min glucose"
214442544|NCT04437433|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
214442545|NCT05036408|OTHER|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
214442546|NCT05036408|OTHER|Educational Intervention|Attend educational session
214442547|NCT05036408|PROCEDURE|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
214442548|NCT05036408|BEHAVIORAL|Occupational Therapy|Participate in occupational therapy
214442549|NCT05036408|OTHER|Physical Activity|Participate in physical activity
214442550|NCT05036408|PROCEDURE|Physical Therapy|Participate in physical therapy
215119254|NCT05254483|DEVICE|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
214442551|NCT05036408|OTHER|Questionnaire Administration|Ancillary studies
215119255|NCT01149915|DRUG|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
215119256|NCT02989883|OTHER|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
215119257|NCT05994027|BEHAVIORAL|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
214442552|NCT01544855|DIETARY_SUPPLEMENT|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
214442553|NCT02155010|DRUG|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
214442554|NCT02155010|DRUG|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
214442555|NCT03484416|DRUG|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
214442556|NCT04364139|OTHER|MAP goal less than or equal to 92 mm Hg|Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
214442557|NCT04364139|OTHER|MAP goal 102-107 mm Hg|Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
214442558|NCT04364139|DRUG|Ramipril|An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
214442559|NCT04364139|DRUG|Amlodipine|A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
214442560|NCT04364139|DRUG|Metoprolol|A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
214442561|NCT00894543|DRUG|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
214442562|NCT00894543|OTHER|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
214442563|NCT04048681|BEHAVIORAL|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
214442564|NCT04048681|BEHAVIORAL|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
214442565|NCT04048681|BEHAVIORAL|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
214442566|NCT05413889|BEHAVIORAL|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
214442567|NCT01264289|DRUG|Finasteride|Finasteride Tablets 5 mg
214442568|NCT01532388|BEHAVIORAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
214442569|NCT04570072|DIETARY_SUPPLEMENT|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
214442570|NCT04570072|DIETARY_SUPPLEMENT|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
214442571|NCT03111160|PROCEDURE|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
215119258|NCT06029569|PROCEDURE|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
215119259|NCT06029569|PROCEDURE|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
215119260|NCT00970229|DRUG|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
215119261|NCT04705506|DRUG|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
214442572|NCT03111160|PROCEDURE|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
214442573|NCT01421407|DEVICE|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
214442574|NCT02919449|BIOLOGICAL|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
214442575|NCT02919449|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered every 3 weeks
214442576|NCT01278420|DEVICE|Tecnis MF|30 subjects will be implanted with the Tecnis MF
214442577|NCT01278420|DEVICE|ReSTOR|30 subjects will be implanted with ReSTOR
214442578|NCT03862963|BEHAVIORAL|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
214442579|NCT03862963|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
214442580|NCT00727909|DEVICE|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
214442581|NCT04824274|DRUG|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
214520191|NCT00584909|DRUG|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
214520192|NCT02869230|PROCEDURE|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
214520193|NCT02869230|PROCEDURE|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
214520194|NCT05835856|DEVICE|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
214520195|NCT05835856|DEVICE|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
214520196|NCT05835856|DEVICE|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
214693106|NCT06693440|DRUG|PD-1 Inhibitors|Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
214693107|NCT06692712|GENETIC|MELPIDA|Gene Therapy agent
215119262|NCT03024125|OTHER|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
214693108|NCT06693102|BEHAVIORAL|Digital intervention targeting cancer-related cognitive impairments|The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.
214693109|NCT06693102|BEHAVIORAL|Crossword and sudoku taks|Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.
215119263|NCT03024125|OTHER|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
214442582|NCT04824274|DRUG|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
214442583|NCT04824274|PROCEDURE|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
214442584|NCT04824274|PROCEDURE|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
214442585|NCT00942487|DRUG|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
214442586|NCT00942487|DRUG|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
214442587|NCT00257075|DRUG|Risperidone, oral tablets|
214442588|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
214442589|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
214442590|NCT02022800|OTHER|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
214442591|NCT03056183|BEHAVIORAL|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
214520197|NCT05835856|DEVICE|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
214442592|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
214442593|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
214442594|NCT02731846|DRUG|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
214442595|NCT02731846|DEVICE|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
214442596|NCT02731846|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
214442597|NCT02018900|DIETARY_SUPPLEMENT|Ecologic 825/scFOS|
214442598|NCT02018900|DIETARY_SUPPLEMENT|Placebo|
214442599|NCT00051792|BEHAVIORAL|yoga|
214442600|NCT05223959|BEHAVIORAL|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
214442601|NCT01652820|DRUG|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
214520198|NCT05835856|OTHER|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
214442602|NCT01652820|DRUG|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
214442603|NCT05023993|OTHER|Exercise Intervention|Complete home exercise
214442604|NCT05023993|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Given PO
214442605|NCT06555744|DRUG|ZW191|Administered intravenously
214442606|NCT06456944|OTHER|stretching exercises|stretching exercises of the plantar fascia, gastrocnemius and soleus
214442607|NCT06456944|DEVICE|ultrasound|therapeutic ultrasound upon the most painful point on the medial calcaneal tubercle. The parameters involved a pulsed mode (duty cycle 50%) using an intensity of 1.5 W/cm2 and a 1 MHz of frequency for 5 minutes
214442608|NCT06456944|OTHER|rigid tape|low-dye tapping will be done to provide mechanical correction to plantar fascia and medial longitudinal arch
214442609|NCT06456944|OTHER|mobilization|mobilization techniques for the talocrural joint in weight bearing and non-bearing positions and subtalar joint
214442610|NCT06456944|OTHER|myofascial release|deep tissue release of the plantar fascia and flexor hallucis longus in a stretched position of the plantar fascia
214442611|NCT06456944|OTHER|strengthening exercise|strengthening exercise of the plantar intrinsic muscles using short foot exercise and strengthening of the Achilles tendon and windlass mechanism using unilateral heel raise exercises
214520199|NCT03345407|DRUG|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
214520200|NCT03345407|DRUG|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
214693110|NCT06692062|RADIATION|Hypofractionated Radiation Therapy|R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
214693111|NCT01344811|PROCEDURE|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
214442612|NCT05782816|DRUG|Oxytocin|Low dose oxytocin
214442613|NCT05782816|DRUG|Oxytocin|High dose oxytocin
214693112|NCT01344811|OTHER|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
214693113|NCT06112314|DRUG|Brenetafusp|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
214693114|NCT06112314|DRUG|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
214442614|NCT06445075|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion.
214442615|NCT06445075|DRUG|Placebo|Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo was administered every 4 weeks by intravenous (IV) infusion.
214442616|NCT06445075|DRUG|Tirzepatide|Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide was administered every week by subcutaneous injection.
215119264|NCT03024125|OTHER|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
215119265|NCT02800525|DEVICE|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
215119266|NCT02800525|DEVICE|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
215119267|NCT03141632|DRUG|Dulaglutide|Evaluation visit with assessment of fluid intake
214442617|NCT04686253|OTHER|not appliable|not appliable
214442618|NCT05152264|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
214442619|NCT05152264|OTHER|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
214442620|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
214442621|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
214693115|NCT06112314|DRUG|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 16 mg/mL.
214693116|NCT07034963|DRUG|Determine the ED50 and ED95 of esketamine|According to Dixon's up-and-down sequential design, esketamine will be initiated at 0.3 mg∙kg-1 intravenously, followed by dose adjustments (0.02 mg∙kg-1 increments/decrements) based on somatic responses to cervical dilation (positive: any movement; negative: no movement). The tests will continued until six crossover pairs are achieved.
214693117|NCT07034963|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
215119268|NCT03141632|OTHER|Placebo|Evaluation visit with assessment of fluid intake
214693118|NCT07034963|DRUG|Intravenous remifentanil 1μg∙kg-1|The control group will be injected with remifentanil 1μg∙kg-1.
215119269|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
215119270|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
214442622|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
214442623|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
214442624|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
214442625|NCT00510302|BEHAVIORAL|Questionnaire|Questionnaire regarding melanoma risk-reduction.
214442626|NCT00510302|BEHAVIORAL|Interview|Interview via telephone about topics related to melanoma risk-reduction.
214442627|NCT02523716|OTHER|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
214442628|NCT02523716|OTHER|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
214442629|NCT03338868|OTHER|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
214520201|NCT03345407|DRUG|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
214520202|NCT03345407|DRUG|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
214442630|NCT03338868|OTHER|Physical activity level|assessed by the International Physical Activity Questionnaire-7
214442631|NCT03338868|OTHER|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
214520203|NCT03345407|DRUG|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
214520204|NCT03345407|DRUG|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
214520205|NCT03345407|DRUG|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
214520206|NCT03345407|DRUG|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
214520207|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Micro-coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
214520208|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Enteric coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
214442632|NCT03338868|OTHER|Quality of life|assessed by the Nottingham Health Profile
214442633|NCT03338868|OTHER|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
214442634|NCT03338868|DIAGNOSTIC_TEST|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
214442635|NCT03578536|DEVICE|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
214442636|NCT03749785|OTHER|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
214442637|NCT03749785|OTHER|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
215119271|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
215119272|NCT01270815|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
214442638|NCT05736185|DEVICE|PEEP selection|Electric impedance tomography-guided PEEP titration
215119273|NCT00761826|DEVICE|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
215119274|NCT03858374|DEVICE|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
215119275|NCT03858374|DEVICE|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
214442639|NCT02916862|DIETARY_SUPPLEMENT|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
215119276|NCT03858374|DEVICE|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
215119277|NCT01600079|BIOLOGICAL|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
214442640|NCT02916862|COMBINATION_PRODUCT|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
214520209|NCT00065611|DRUG|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
214520210|NCT00545922|BEHAVIORAL|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
214442641|NCT02916862|DIETARY_SUPPLEMENT|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
214442642|NCT02916862|COMBINATION_PRODUCT|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
214520211|NCT00545922|BEHAVIORAL|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
214520212|NCT02256553|BIOLOGICAL|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
214442643|NCT01582646|DRUG|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
214442644|NCT04217746|DEVICE|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
214442645|NCT05198310|DRUG|KPL-404|Humanized monoclonal antibody
214442646|NCT05198310|DRUG|Placebo|Matching placebo
215119278|NCT00176462|DRUG|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119279|NCT00176462|DRUG|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119280|NCT00176462|DRUG|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
214442647|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
214442648|NCT04436107|DRUG|Lenalidomide|Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.
214442649|NCT06276374|DRUG|Patients who are scheduled to undergo carotid artery stenting|"* Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  \- 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)"
214442650|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
214520213|NCT02256553|BIOLOGICAL|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
214520214|NCT02256553|DRUG|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
215119281|NCT00176462|DRUG|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
214442651|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
214442652|NCT00294840|DEVICE|PET-CT|
214442653|NCT05036070|DEVICE|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
214442654|NCT05036070|DEVICE|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
214442655|NCT05749523|BEHAVIORAL|Exercise|Exercise vs non-exercise
214442656|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
214442657|NCT00809939|DRUG|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
214442658|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
214442659|NCT00809939|DRUG|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
214442660|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
214442661|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
214442662|NCT03144518|OTHER|Positive Affect Intervention|See Previous Description
214442663|NCT03144518|OTHER|Neutral Control Intervention|See Previous Description
214442664|NCT03144518|BIOLOGICAL|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
214442665|NCT03773835|DRUG|HSK3486|Mmanual IV bolus injection completed in 1 minute.
214442666|NCT00448669|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
214442667|NCT00448669|DRUG|Placebo Oral Tablet|
214442668|NCT00039234|BIOLOGICAL|aldesleukin|
214442669|NCT00039234|DRUG|histamine dihydrochloride|
214442670|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
214442671|NCT05205798|BEHAVIORAL|Washout period|No interventional food consumption for 1 week
214442672|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
214520215|NCT02385539|DRUG|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
214520216|NCT00003634|BIOLOGICAL|oregovomab|
215119282|NCT00176462|DRUG|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119283|NCT00176462|DRUG|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
214442673|NCT02638337|DRUG|Ospemifene|60 mg tablet
214442674|NCT02638337|DRUG|Placebo|Tablet identical to the ospemifene tablet without drug
214520217|NCT05007002|DEVICE|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
214520218|NCT00600366|DRUG|biphasic insulin aspart|
214520219|NCT06475690|OTHER|Psychological interventions|Psychological interventions is used for intervention group
214520220|NCT02092909|DRUG|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
214520221|NCT03151109|DIAGNOSTIC_TEST|CT Scan|CT scan at minimum 1 year post op
214520222|NCT03436797|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
215119284|NCT00176462|DRUG|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119285|NCT00176462|DRUG|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
214442675|NCT04762238|OTHER|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
214442676|NCT06436326|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear."
214442677|NCT06436326|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
214442678|NCT06436326|OTHER|Blood glucose meters (BGM)|"Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
214442679|NCT00578916|DRUG|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
214442680|NCT02614235|DEVICE|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
214442681|NCT04317885|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
214442682|NCT01691079|DRUG|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
214442683|NCT01691079|DRUG|Placebo|Inhaled placebo administered before exercise.
214442684|NCT03794024|DEVICE|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
214442685|NCT03794024|DEVICE|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
214442686|NCT00806169|DRUG|triamcinolone and bevacizumab|
214442687|NCT03438903|DEVICE|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
214442688|NCT00445315|DRUG|PF-00868554|300 mg BID
214520223|NCT05721898|DIAGNOSTIC_TEST|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
214520224|NCT05924971|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
214520225|NCT01767025|DRUG|Oxytocin|
215119286|NCT00176462|DRUG|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119287|NCT00176462|DRUG|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
215119288|NCT00176462|DRUG|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
215119289|NCT00176462|DRUG|Leucovorin|
215119290|NCT06064383|DEVICE|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
215119291|NCT04486872|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
214442689|NCT00445315|DRUG|PF-00868554|450 mg BID
214442690|NCT00445315|DRUG|PF-00868554|100 mg BID
214442691|NCT00445315|DRUG|PF-00868554|300 mg TID
214442692|NCT00445315|DRUG|Placebo|Placebo
214442693|NCT02376530|BEHAVIORAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
214442694|NCT02376530|BEHAVIORAL|Price Changes|Price changes will be present during shopping session.
214442695|NCT03338816|DRUG|Givosiran|Givosiran by SC
214442696|NCT03338816|DRUG|Placebo|Matching placebo (normal saline \[0.9% NaCl\]) by SC
214442697|NCT05990816|DIAGNOSTIC_TEST|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
214442698|NCT02986984|OTHER|There is no intervention|There are no interventions
214442699|NCT06124911|OTHER|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
214442700|NCT06124911|OTHER|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
214442701|NCT05917275|DRUG|Amlodipine|4 weeks of Amlodipine
214442702|NCT05917275|DRUG|Olmesartan|4 weeks of Olmesartan
214442703|NCT05917275|DRUG|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
214442704|NCT05917275|DRUG|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
214442705|NCT03092726|DRUG|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
214442706|NCT03092726|DRUG|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
214442707|NCT04403711|OTHER|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
214520226|NCT01767025|DRUG|Sea water|
214520227|NCT02376062|OTHER|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
214442708|NCT04403711|OTHER|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
214442709|NCT04718350|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
214442710|NCT04718350|DRUG|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
214442711|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
214442712|NCT04656210|RADIATION|MRI|Non conventional MRI (35 minutes)
214442713|NCT04656210|OTHER|neuropsychological tests|Standardized and quantified neuropsychological assessment
214442714|NCT06241456|DRUG|FT825|FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
214442715|NCT06241456|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
214442716|NCT06241456|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
214442717|NCT06241456|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
214442718|NCT06241456|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion at planned dose levels.
214442719|NCT06241456|DRUG|Cisplatin|Cisplatin will be administered as an IV infusion at planned dose levels.
214442720|NCT06241456|DRUG|Cetuximab|Cetuximab will be administered as an IV infusion at planned dose levels.
214442721|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
214442722|NCT04950127|DRUG|Linerixibat|Participants will receive linerixibat.
214520228|NCT04782570|DEVICE|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
214520229|NCT04782570|DEVICE|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
214520230|NCT02936609|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
214520231|NCT04463485|PROCEDURE|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
215119292|NCT05168228|PROCEDURE|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
215119293|NCT01797913|DRUG|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
215119294|NCT00002913|DRUG|paclitaxel|Given IV
215119295|NCT00002913|DRUG|cisplatin|Given IV
214442723|NCT04950127|DRUG|Placebo|Participants will receive placebo.
214442724|NCT03999853|DRUG|BKR-017|BKR-017
214442725|NCT04094168|DRUG|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
214442726|NCT04094168|DRUG|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
214442727|NCT03032406|DRUG|Hydroxychloroquine|Hydroxychloroquine
214442728|NCT03032406|DRUG|Everolimus|Everolimus
214442729|NCT03833167|BIOLOGICAL|Pembrolizumab|400 mg IV infusion
214442730|NCT03833167|DRUG|Placebo|Placebo-matched IV infusion
214442731|NCT03997864|DRUG|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
214442732|NCT03997864|DRUG|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
214442733|NCT05187442|OTHER|questionnaire, interview|The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited.
214442734|NCT05329194|DRUG|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
214520232|NCT00083148|DRUG|capecitabine|
214520233|NCT00083148|DRUG|irinotecan hydrochloride|
214520234|NCT00275418|DRUG|beta carotene from Dunaliella algae|
215119296|NCT00002913|DRUG|topotecan hydrochloride|Given IV
215119297|NCT00002913|BIOLOGICAL|filgrastim|Given SC
215119298|NCT01725594|DRUG|CAT 2003|
215119299|NCT01725594|DRUG|Placebo|
215119300|NCT04010591|DEVICE|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
215119301|NCT01640444|DRUG|FOLFIRI + bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
214442735|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
214442736|NCT06501911|DRUG|Bicalutamide|Participants will receive daily oral bicalutamide for six (6) months. The dose will be determined by the cohort to which the participant is enrolled as well as the toxicities experienced by previously enrolled cohorts.
214442737|NCT06501911|RADIATION|Intensity-modulated radiation therapy (IMRT)|Participants will receive 35 Gy delivered in 10 fractions, administered once daily on weekdays.
214442738|NCT06040710|DEVICE|POSEIDON size estimation software with the EndoMind polyp detection system|Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
214442739|NCT03606837|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
214442740|NCT03606837|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
214442741|NCT06430281|OTHER|Manual therapy|A manual force will be applied to a manikin positioned on a chiropractic treatment table. The force exerted during the manual therapy must align with the trial label indicated on the Manual Therapy Force Perception \[MTFP\] scale.
214520235|NCT02955225|DEVICE|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
214520236|NCT02955225|DEVICE|Passive shoe insole|A deactivated insole measures shoe pressure only.
214520237|NCT00118937|DRUG|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
214520238|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
214520239|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
214520240|NCT00241475|DRUG|Gefitinib|
214520241|NCT05224596|DIAGNOSTIC_TEST|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
215119302|NCT01640444|DRUG|FOLFIRI + cetuximab|"* Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
215119303|NCT05581069|BEHAVIORAL|STEPS|STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
215119304|NCT05745519|OTHER|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
215119305|NCT05745519|DEVICE|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
215119306|NCT04284475|DIAGNOSTIC_TEST|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
214520242|NCT03317509|PROCEDURE|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
214520243|NCT03969251|DEVICE|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
214520244|NCT03969251|DEVICE|Sham (SS)|repetitive sham rTMS
214520245|NCT00161434|DRUG|valacyclovir|1 gram daily for 8 weeks
214520246|NCT00161434|DRUG|placebo|matching placebo for 8 weeks
214520247|NCT04626128|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
214520248|NCT04626128|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
214520249|NCT01182285|DRUG|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
215119307|NCT04284475|DIAGNOSTIC_TEST|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
215119308|NCT04284475|DIAGNOSTIC_TEST|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
215119309|NCT03452709|BEHAVIORAL|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
214520250|NCT01182285|DRUG|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
214520251|NCT00741689|DRUG|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
214520252|NCT02122042|BIOLOGICAL|HBOT|
214520253|NCT03985228|DIETARY_SUPPLEMENT|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
214442742|NCT05261620|DIETARY_SUPPLEMENT|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity \[DPPH (2,2-diphenyl-1-picrylhydrazyl) test\] and phenolic profiles \[HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis\] will be performed for wine selection for the clinical trial.
214442743|NCT01948661|DIETARY_SUPPLEMENT|Mirtoselect® + Meriva®|
214442744|NCT01948661|DIETARY_SUPPLEMENT|Placebo|
214442745|NCT03894566|OTHER|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
214442746|NCT04471974|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214442747|NCT04471974|DRUG|Enzalutamide|Given PO
214442748|NCT04471974|BIOLOGICAL|Pembrolizumab|Given IV
214442749|NCT06049459|DEVICE|Optical Correction|Optical correction (if needed)
214442750|NCT06049459|DEVICE|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
214520254|NCT03985228|DIETARY_SUPPLEMENT|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
215119310|NCT03452709|DEVICE|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
215119311|NCT00185575|DRUG|duloxetine|
214442751|NCT03271489|DRUG|Elagolix|Film-coated 300 mg tablets
214442752|NCT03271489|DRUG|Estradiol /norethindrone acetate (E2/NETA)|Estradiol 1 mg/norethindrone acetate 0.5 mg capsules
214442753|NCT03271489|OTHER|E2/NETA Placebo|Placebo capsules
214442754|NCT03271489|OTHER|Elagolix Placebo|Film-coated placebo tablets
214442755|NCT05445466|DEVICE|High-Definition Transcranial Electrical-Current Stimulation|Non-frequency dependent transcranial electrical stimulation condition for 5 days of twice a day treatment
214442756|NCT05445466|DEVICE|High-Definition Transcranial Alternate-Current Stimulation|Active-control stimulation condition will target alpha (10 Hz) for 5 days of twice a day treatment
214442757|NCT05445466|DEVICE|High-Definition Personalized Beta-Gamma Electrical Stimulation|Personalized beta-gamma electrical stimulation for 5 days of twice a day treatment
214442758|NCT06288230|BIOLOGICAL|vesemnogene lantuparvovec|Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
214442759|NCT02860130|DRUG|Prismocitrate 18|Modality of CVVHDF
214442760|NCT02860130|OTHER|No Anticoagulation|Modality of CVVHDF
214442761|NCT06148142|BEHAVIORAL|Pharmacy based health promotion|This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; third at 12 months and , end-line survey at 18 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
214442762|NCT06779474|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy
214442763|NCT06488261|BIOLOGICAL|AVR-RD-02|No study drug is administered in this study. Subjects who received AVR-RD-02 in a separate parent trial will be evaluated in this trial for long-term safety.
214442764|NCT06041802|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab and berahyaluronidase alfa for SC administration.
214442765|NCT03238755|OTHER|Cardiac MRI/MRS|whole blood, plasma, and serum
214442766|NCT06181617|OTHER|Quality of life assessment|Quality of life assessment
214520255|NCT02137603|OTHER|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
214520256|NCT05145088|BEHAVIORAL|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
214520257|NCT01951105|DRUG|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
214693119|NCT06712420|DRUG|neoadjuvant chemotherapy|NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0. PAtients will undergo curative surgery after neoadjuvant chemotherapy
215119312|NCT05465291|PROCEDURE|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
215119313|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation group|"* Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
215119314|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
215119315|NCT03108417|DEVICE|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
214442767|NCT06010342|DRUG|TL118 Capsule|Oral administration
214442768|NCT03330795|BIOLOGICAL|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection, and cryopreserved for later marrow transplantation. BMT conditioning and transplantation will start at least 8 weeks or more post lung transplant - once the participant is clinically judged suitable to undergo BMT conditioning and transplantion.
214442769|NCT04069013|PROCEDURE|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
214442770|NCT06347003|DRUG|Plozasiran Injection|ARO-APOC3 Injection
214442771|NCT06347003|DRUG|Placebo|sterile normal saline (0.9% NaCl)
214442772|NCT06828705|OTHER|datscan scintigraphy|Semi-quantitative analysis on Datscan imaging scintigraphy
214442773|NCT06034548|BEHAVIORAL|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
214520258|NCT01951105|DRUG|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
214520259|NCT01951105|DRUG|Placebo|Take two placebo capsules three times a day for 12 weeks.
214520260|NCT03209492|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
214520261|NCT05943379|DRUG|RC48-ADC in Combination with gemcitabine|RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
214520262|NCT02177058|OTHER|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
214520263|NCT02177058|OTHER|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
214520264|NCT05340439|DRUG|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
214520265|NCT04034602|OTHER|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
214520266|NCT04034602|OTHER|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
214520267|NCT06351917|DRUG|PlexoZome® Levagen® topical spray solution|PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump
214520268|NCT06351917|DRUG|Placebo topical spray solution|Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
214520269|NCT03490006|PROCEDURE|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
214693120|NCT06712420|PROCEDURE|curative surgery|Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification
214693121|NCT05838833|DRUG|INV-001|Patient will be assigned to one of three arms.
215119316|NCT05268172|DRUG|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
215119317|NCT00915707|OTHER|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
214442774|NCT06364644|BEHAVIORAL|Community Champions|The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
214442775|NCT06364644|BEHAVIORAL|Homegrown Heroes|Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
214442776|NCT06456242|BEHAVIORAL|CounsCM+MedCM (Health Rewards)|Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
214442777|NCT06104319|DRUG|GSK4532990|GSK4532990 will be administered
214442778|NCT06062966|DRUG|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
214442779|NCT05018910|OTHER|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
215119318|NCT00915707|OTHER|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
215119319|NCT00915707|OTHER|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
214442780|NCT03361215|OTHER|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
214442781|NCT03954678|BEHAVIORAL|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
214442782|NCT03954678|DIETARY_SUPPLEMENT|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
214520270|NCT03490006|PROCEDURE|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
214520271|NCT05270096|OTHER|Advice|non-interventional study
214520272|NCT00933634|PROCEDURE|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
214520273|NCT00933634|DRUG|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
215119320|NCT01408459|DIETARY_SUPPLEMENT|Tomato Product|Motivational Telephone Counseling weekly
215119321|NCT01408459|DIETARY_SUPPLEMENT|Control|No Motivational telephone Counseling
215119322|NCT03801226|DRUG|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
215119323|NCT03801226|DRUG|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
215119324|NCT01994044|PROCEDURE|Cervical fusion|
214442783|NCT05435963|BEHAVIORAL|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
214442784|NCT03709199|DIAGNOSTIC_TEST|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
214442785|NCT03709199|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
214442786|NCT03709199|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
214442787|NCT03709199|DIAGNOSTIC_TEST|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
214442788|NCT03709199|DIAGNOSTIC_TEST|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
214442789|NCT03709199|DIAGNOSTIC_TEST|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
214520274|NCT02846142|DRUG|PTI-428|
214520275|NCT02846142|OTHER|Placebo|
214520276|NCT02846142|DRUG|ethinyl estradiol and levonorgestrel|
214520277|NCT04463004|DRUG|Mavrilimumab|Treatment infusion
214520278|NCT04463004|DRUG|Placebos|Placebo infusion
214520279|NCT00731913|OTHER|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
214520280|NCT02913898|BEHAVIORAL|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
215119325|NCT00930878|DEVICE|Cardiac Stenting|Drug Eluting stent
215119326|NCT04166097|OTHER|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
215119327|NCT04842383|DRUG|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
215119328|NCT02499705|DIETARY_SUPPLEMENT|Sucralose|2 packets
215119329|NCT02499705|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
215119330|NCT02499705|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
215119331|NCT01939184|DRUG|WC3055|12.5, 25, 50 or 75 mg dose
215119332|NCT01939184|OTHER|Placebo|Placebo
215119333|NCT04119232|BEHAVIORAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
214442790|NCT03709199|DIAGNOSTIC_TEST|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
214442791|NCT03709199|DIAGNOSTIC_TEST|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
215119334|NCT00839644|DEVICE|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
215119335|NCT00839644|DEVICE|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
215119336|NCT00839644|OTHER|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
214520281|NCT02913898|BEHAVIORAL|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
214520282|NCT03677856|PROCEDURE|Paravertebral blockade|Type of anaesthesia
214520283|NCT03677856|PROCEDURE|Thoracic epidural block|Type of anaesthesia
214520284|NCT01912521|BEHAVIORAL|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
214520285|NCT01474265|DRUG|Varenicline|0.5-2 mg per day, oral use
214520286|NCT01474265|DRUG|Placebo|1-2 tablets per day, oral use
214520287|NCT01474265|DRUG|Nicorette TX|10-15 mg per day, transdermal use (patches)
214520288|NCT01625494|DRUG|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
214520289|NCT01625494|DRUG|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
214520290|NCT01625494|DRUG|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
214520291|NCT01625494|DRUG|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
214520292|NCT03137732|DEVICE|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
215119337|NCT01657292|DRUG|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
215119338|NCT01657292|DEVICE|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
215119339|NCT05658705|PROCEDURE|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
214442792|NCT03709199|DIAGNOSTIC_TEST|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
214442793|NCT03709199|DIAGNOSTIC_TEST|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
214442794|NCT03709199|DIAGNOSTIC_TEST|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
214693122|NCT07036952|DRUG|Omega 3 fatty acids|1gm tab twice daily.
215119340|NCT05658705|PROCEDURE|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
215119341|NCT00931775|DRUG|Pindolol|Pill orally administered. 15 mg/day t.i.d.
215119342|NCT01559051|PROCEDURE|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
215119343|NCT04269876|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
215119344|NCT04269876|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
215119345|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
215119346|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
214520293|NCT02604199|DRUG|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
214520294|NCT02604199|OTHER|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
214520295|NCT02604199|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
214520296|NCT02604199|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
214520297|NCT02604199|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
214520298|NCT00749840|BEHAVIORAL|Questionnaire|Questionnaire taking 60-90 minutes.
214520299|NCT00765791|PROCEDURE|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
214520300|NCT00765791|PROCEDURE|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
214693123|NCT07036952|DRUG|Omega -3 fatty acids|1gm tablet twice daily.
214693124|NCT06687161|DEVICE|Transcranial Magnetic Stimulation (TMS) therapy|Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC
215119347|NCT05112003|DEVICE|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
214442795|NCT03709199|DIAGNOSTIC_TEST|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
215119348|NCT01696890|DEVICE|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
214442796|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
214442797|NCT06965712|DEVICE|Point-of-Care Ultrasound (POCUS)|Participants assigned to this group will receive Point-of-Care Ultrasound (POCUS) evaluations of the lungs and inferior vena cava (IVC) during their hospital stay. The ultrasound will be performed twice: once within 24 hours of hospital admission and once prior to hospital discharge. The POCUS findings will be used to guide clinical management decisions regarding fluid status and decongestion therapy in patients with decompensated heart failure. The procedure is non-invasive, radiation-free, and performed at the bedside.
214442798|NCT06286774|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
214442799|NCT06782243|DRUG|Moderate-Intensity Statins|Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.
214442800|NCT06782243|DRUG|High-Intensity Statins|Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.
214520301|NCT04182451|DEVICE|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
214520302|NCT01315418|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
214520303|NCT01315418|OTHER|2-Non fermented dairy product (control)|
214520304|NCT05614141|DEVICE|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
215119349|NCT01696890|DEVICE|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
214520305|NCT05614141|OTHER|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
214520306|NCT02812706|DRUG|Isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
214520307|NCT03500796|PROCEDURE|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
214442801|NCT04164459|DRUG|Xalost S|One drop one times a day in study eye
214442802|NCT04164459|DRUG|Xalatan|One drop one times a day in study eye
214442803|NCT04164459|DRUG|Taflotan-S|One drop one times a day in study eye
214442804|NCT03459677|BEHAVIORAL|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
214442805|NCT03459677|OTHER|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
214442806|NCT05030272|DEVICE|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
214442807|NCT05030272|BEHAVIORAL|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
214442808|NCT05030272|DRUG|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
214520308|NCT03500796|PROCEDURE|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
214520309|NCT03834909|DRUG|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
214520310|NCT03834909|DRUG|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
214520311|NCT01276080|DRUG|Donepezil|10 mg tablets
214520312|NCT01532830|DEVICE|n-VNS|
214520313|NCT04150419|OTHER|Group 1|Attentional training to avoid threatening, negative or pain-related information.
214520314|NCT04150419|OTHER|Group 2|Attention training for vigilance for positive emotional information.
214520315|NCT04150419|OTHER|Group 3 (control group)|Neutral attentional training (control group).
214520316|NCT03785041|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
215119350|NCT00650845|DRUG|Dotarem®-enhanced MRI|Single IV administration before MRI exam
215119351|NCT00650845|OTHER|non-enhanced MRI|non injected MRI
215119352|NCT00917839|DRUG|lamotrigine|100 mg, once daily, 12 months
214693125|NCT06687161|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)
214442809|NCT05030272|BEHAVIORAL|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
214442810|NCT05030272|DRUG|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
214693126|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
214442811|NCT05030272|DRUG|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
214442812|NCT05766969|DRUG|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
214442813|NCT05766969|DRUG|Placebo|An inactive compound.
214442814|NCT01127373|RADIATION|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
214520317|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fed state
214520318|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fasted state
214693127|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
214520319|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as oral solution
214520320|NCT03014024|OTHER|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
214520321|NCT03014024|OTHER|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
214520322|NCT00101062|DRUG|celecoxib|
214520323|NCT00101062|DRUG|letrozole|
214693128|NCT06517953|DRUG|Icotinib|An orally first-generation EGFR inhibitior.
214520324|NCT05989243|DEVICE|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
214693129|NCT06517953|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
214693130|NCT07039942|DEVICE|Omnipod 5|"The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.~The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems."
214693131|NCT06720922|PROCEDURE|Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
214693132|NCT06720922|PROCEDURE|Open Surgery|Traditional Open Surgery
214693133|NCT06715709|DRUG|Dexamethasone IV|Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.
215119353|NCT01003652|PROCEDURE|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
215119354|NCT04371601|DRUG|Oseltamivir|Oseltamivir capsules
215119355|NCT04371601|DRUG|hormones|a moderate amount of hormone
215119356|NCT04371601|DEVICE|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
215119357|NCT04371601|PROCEDURE|mesenchymal stem cells|mesenchymal stem cells
215119358|NCT06130592|DIAGNOSTIC_TEST|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
215119359|NCT03932760|BEHAVIORAL|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
215119360|NCT03932760|BEHAVIORAL|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
215119361|NCT01698723|DRUG|Ribavirin|
215119362|NCT01698723|DRUG|Placebo|
215119363|NCT01301833|DRUG|teneligliptin|
215119364|NCT01301833|DRUG|glinide|
215119365|NCT01301833|DRUG|biguanide|
215119366|NCT01301833|DRUG|alpha-glucosidase inhibitor|
215119367|NCT03922620|DRUG|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
215119368|NCT03922620|DRUG|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
214442815|NCT01127373|BEHAVIORAL|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
214442816|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
214442817|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
214442818|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
214442819|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
214520325|NCT05989243|DEVICE|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
214520326|NCT04247256|DRUG|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
214520327|NCT04247256|DRUG|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
214520328|NCT02961283|DRUG|ASN003 ascending doses|
214520329|NCT02961283|DRUG|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
214520330|NCT02465632|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
215119369|NCT04797351|BEHAVIORAL|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
215119370|NCT02373774|DEVICE|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
215119371|NCT00983385|DRUG|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
215119372|NCT00983385|OTHER|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
215119373|NCT00983385|DRUG|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
214442820|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
214442821|NCT01620684|DRUG|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
214442822|NCT01620684|DRUG|placebo|placebo capsules
214442823|NCT02218060|PROCEDURE|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
214442824|NCT02218060|PROCEDURE|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
214442825|NCT02290613|DRUG|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
214442826|NCT02290613|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
214442827|NCT02713126|DRUG|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
214442828|NCT02713126|DRUG|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
215119374|NCT00513435|DRUG|saracatinib|Given PO
214442829|NCT02713126|DEVICE|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
214520331|NCT02465632|DRUG|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
214520332|NCT02465632|DRUG|Placebo|
214520333|NCT05428215|DRUG|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
214693134|NCT06715709|DRUG|Dexamethasone IV+Oral|Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
215119375|NCT00513435|OTHER|laboratory biomarker analysis|Correlative studies
215119376|NCT03707470|DEVICE|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
214442830|NCT02713126|OTHER|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
215119377|NCT03707470|DEVICE|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
215119378|NCT03707470|PROCEDURE|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
215119379|NCT06337708|BEHAVIORAL|Smart Walk|Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
215119380|NCT06337708|BEHAVIORAL|Fitbit|This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.
215119381|NCT00648557|DRUG|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
214442831|NCT03750539|RADIATION|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
214442832|NCT03750539|RADIATION|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
214442833|NCT03750539|PROCEDURE|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
214442834|NCT00100698|DRUG|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
214442835|NCT00100698|DRUG|placebo|placebo subcutaneously once a day, 18 months
214442836|NCT02909192|DEVICE|Light Therapy Device|
214520334|NCT06646146|PROCEDURE|Fat grafting combine with hair transplantation|Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
214520335|NCT06646146|PROCEDURE|Hair transplantation|Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
215119382|NCT00648557|DRUG|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
215119383|NCT05686291|BEHAVIORAL|Hybrid volunteer training programme|The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
215119384|NCT01695356|DRUG|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
215119385|NCT01695356|DRUG|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
214442837|NCT01426412|DRUG|LY3015014 IV|Administered IV over 30-90 minutes
214442838|NCT01426412|DRUG|Placebo IV|Administered IV only over 30-90 minutes
214442839|NCT01426412|DRUG|LY3015014 SC|Administered SC
214442840|NCT01426412|DRUG|Placebo SC|Administered SC
215119386|NCT01825967|OTHER|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
215119387|NCT05311930|DRUG|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
214442841|NCT01420458|DRUG|Experimental|Bioequivalence of two drug formulations
214442842|NCT05950867|DIAGNOSTIC_TEST|ECG + echocardiography|Electrocardiogram and echocardiography
214442843|NCT05950867|OTHER|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
214442844|NCT01362153|DRUG|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
214442845|NCT01362153|DRUG|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
214442846|NCT02941575|OTHER|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
214520336|NCT01648491|PROCEDURE|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
214520337|NCT01648491|BIOLOGICAL|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
214520338|NCT06155123|DRUG|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
214520339|NCT04135872|OTHER|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
214520340|NCT00481156|BEHAVIORAL|Cognitive Remediation|
214520341|NCT00481156|BEHAVIORAL|Cognitive Behavioral Social Skills Training|
214442847|NCT02941575|OTHER|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
214442848|NCT05406765|DRUG|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
214442849|NCT02035904|DRUG|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
214442850|NCT02035904|DRUG|saline|patient controlled infusion from the 2nd day after surgery
214442851|NCT02035904|DRUG|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
214442852|NCT02035904|DEVICE|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
214442853|NCT02035904|DRUG|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
214442854|NCT02035904|DRUG|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
214442855|NCT05450458|DRUG|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
214442856|NCT03459989|DIAGNOSTIC_TEST|Ultrasound|Samsung H60 Ultrasound
214442857|NCT02371395|OTHER|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
214442858|NCT04974567|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
214442859|NCT05607199|DRUG|AUR103|Twice Daily
214442860|NCT04452201|BEHAVIORAL|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
214442861|NCT02240420|BEHAVIORAL|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
214442862|NCT04381832|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
214442863|NCT04381832|DRUG|Zimberelimab|Zimberelimab is an anti-PD-1 antibody
214442864|NCT04381832|DRUG|Quemliclustat|Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
215119388|NCT01918956|BIOLOGICAL|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
215119389|NCT05269108|PROCEDURE|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
214442865|NCT04381832|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor
214442866|NCT04381832|DRUG|Docetaxel|Docetaxel is type of chemotherapy
214442867|NCT04381832|DRUG|SG|Sacituzumab govitecan is an antibody-drug conjugate
214442868|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
214442869|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
214442870|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
214442871|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
214442872|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
214442873|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
214442874|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
214442875|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
214442876|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
214442877|NCT03819465|DRUG|AZD2936|AZD2936 IV
214442878|NCT04157348|BIOLOGICAL|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
214442879|NCT04157348|BIOLOGICAL|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
214442880|NCT04157348|BIOLOGICAL|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
214520342|NCT00481156|OTHER|Retest in Health Controls|Pre/Post test performance and neuroimaging only
215119390|NCT05269108|PROCEDURE|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
215119391|NCT04523883|RADIATION|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
215119392|NCT04523883|DRUG|JS001|JS001 240mg every three week
215119393|NCT01411956|OTHER|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
214442881|NCT04157348|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
214442882|NCT06376058|DRUG|Chloroprocaine 1% Injectable Solution|• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
215119394|NCT01411956|OTHER|Placebo video|The control group watched a 25-minute patient education video on depression.
215119395|NCT01050244|DIETARY_SUPPLEMENT|Whole soybean soymilk powder|
214442883|NCT06376058|DRUG|Ropivacaine 0.75% Injectable Solution|• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
214442884|NCT06966934|DEVICE|NPA|After sedation, the nasopharyngeal airway (NPA) is inserted when the patient's breathing becomes slightly slow but stable and the eyelash reflex disappears.
214442885|NCT06971835|DEVICE|NMP|"The study product is Induce Biologics NMP Fibers and NMP Micro Particulates however, this is observational research that involves standard of care.~NMP is regulated as a human cellular or tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and in 21 CFR Part 1271. Under this regulation it did not require clinical evaluation before it could be used commercially. It is indicated for use as a bone void filler for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the boney structure."
214442886|NCT05306938|BEHAVIORAL|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
214442887|NCT04968405|DEVICE|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
214442888|NCT06285786|OTHER|Ergonomic Training on Patient Handling Techniques|"Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory."
214442889|NCT06287736|DEVICE|Spinal Cord Stimulator Implantation (SCS)|Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
215119396|NCT01050244|DIETARY_SUPPLEMENT|Whole milk powder|
215119397|NCT01646606|PROCEDURE|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
215119398|NCT01646606|PROCEDURE|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
214442890|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
214442891|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
215119399|NCT01356446|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
214442892|NCT05633719|OTHER|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
214442893|NCT03865056|DEVICE|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
214520343|NCT01403922|DRUG|TC-5214|Tablet oral bid days 1 to 7
214520344|NCT01403922|DRUG|TC-5214|Tablet oral bid days 8 to 14
214520345|NCT00004578|DRUG|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
214520346|NCT00004578|DRUG|Lamivudine|150 mg, every 12 hours
214520347|NCT00004578|DRUG|Stavudine|40 mg every 12 hours
214520348|NCT02299011|DEVICE|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
214520349|NCT02299011|DRUG|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
214520350|NCT06169878|DEVICE|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
214520351|NCT02784145|DIETARY_SUPPLEMENT|Resistant starch|
214520352|NCT02784145|OTHER|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
215119400|NCT00000706|DRUG|Quinine sulfate|
214442894|NCT03865056|DEVICE|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
214442895|NCT02965846|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
214442896|NCT02965846|DRUG|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
214442897|NCT03818100|RADIATION|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
214442898|NCT03818100|DRUG|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
214442899|NCT03818100|PROCEDURE|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
214693135|NCT06715709|DRUG|Dexamethasone IV+Oral 2 Day|Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
214693136|NCT02472548|BIOLOGICAL|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
215119401|NCT00000706|DRUG|Probenecid|
215119402|NCT00000706|DRUG|Zidovudine|
215119403|NCT00672906|BEHAVIORAL|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
214520353|NCT00005971|DRUG|alvocidib|
214520354|NCT06119802|DIAGNOSTIC_TEST|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
214520355|NCT01349699|DRUG|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
214520356|NCT01349699|DRUG|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
214520357|NCT01349699|DRUG|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
214520358|NCT01349699|DRUG|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
214520359|NCT01116830|DRUG|Placebo|Orally daily for 6 weeks
214520360|NCT01116830|DRUG|RO4917838|10 mg daily orally for 6 weeks
214693137|NCT02472548|BIOLOGICAL|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
214693138|NCT02472548|OTHER|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
215028756|NCT06644807|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
215119404|NCT00672906|BEHAVIORAL|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
215119405|NCT01279681|BIOLOGICAL|bevacizumab|Given IV
215119406|NCT01279681|DRUG|capecitabine|Given PO
215119407|NCT01279681|DRUG|fluorouracil|Given IV
214442900|NCT04914442|DIAGNOSTIC_TEST|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
214442901|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.
214442902|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention on healthy lifestyle choices|The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
214442903|NCT00262301|DRUG|recombinant human C1 inhibitor|IV
214442904|NCT00262301|DRUG|Placebo|IV
214442905|NCT05042375|DRUG|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
214520361|NCT01116830|DRUG|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
215119408|NCT01279681|DRUG|leucovorin calcium|Given IV
215119409|NCT01279681|DRUG|oxaliplatin|Given IV
215119410|NCT00125320|DRUG|RSD1235|
215119411|NCT04948853|BEHAVIORAL|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
215119412|NCT03793348|DEVICE|MCD|Micro coring skin removal with automated coring device
215119413|NCT00195936|DRUG|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
215119414|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
215119415|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
215119416|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
214442906|NCT05042375|DRUG|pembrolizumab|pembrolizumab 200 mg.
214442907|NCT05042375|DRUG|camrelizumab|Camrelizumab for injection, 200 mg.
214442908|NCT00677391|DRUG|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
214442909|NCT00677391|DRUG|Placebo|Capsules, once daily
215119417|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
214442910|NCT06338540|OTHER|Black color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the black caries color related to history of pain , ICDAS , pulp exposed and microbial load
214442911|NCT06338540|OTHER|dark brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the dark brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
214442912|NCT06338540|OTHER|light brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the light brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
214442913|NCT06338540|OTHER|yellow color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the yellow caries color related to history of pain , ICDAS , pulp exposed and microbial load
214442914|NCT05608213|PROCEDURE|Lenvatinib Plus I-125 Seed Brachytherapy|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients. Iodion-125 seeds will be implanted into the the target lesions (viable intrahepatic tumor and/or vascular tumor thrombus) under CT guidance according to the pre-operative planning within 7 days after lenvatinib administration. Iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
214442915|NCT05608213|DRUG|Lenvatinib|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
214442916|NCT01084707|DRUG|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
214442917|NCT01084707|DRUG|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
214442918|NCT01084707|DRUG|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
214442919|NCT05512052|DEVICE|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
214693139|NCT04207567|BEHAVIORAL|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
214693140|NCT05475262|DEVICE|Active white noise|Active white noise of 57 dB - 60 dB from 10 pm to 6 am
215119418|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
215119419|NCT04265014|OTHER|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
215119420|NCT04265014|OTHER|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
215119421|NCT01454791|DRUG|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
215119422|NCT01454791|OTHER|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
215119423|NCT04934371|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
215119424|NCT04934371|DEVICE|Sham TDCS|Sham control will be administered to the same area as active TDCS
215119425|NCT06371105|OTHER|10-week water-based aerobic training|The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
215119426|NCT01467505|DRUG|Telaprevir|Tablet
215119427|NCT01467505|DRUG|Ribavirin|Tablet
215119428|NCT01467505|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
215119429|NCT01467505|DRUG|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
215119430|NCT02807623|DRUG|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
215119431|NCT02807623|BEHAVIORAL|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
214442920|NCT05512052|DEVICE|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
214442921|NCT05512052|DEVICE|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
214520362|NCT01717755|OTHER|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
215119432|NCT02807623|DRUG|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
215119433|NCT00425724|DRUG|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
214693141|NCT05475262|DEVICE|Inactive white noise|Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
215119434|NCT01229189|DIETARY_SUPPLEMENT|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
215119435|NCT01229189|DIETARY_SUPPLEMENT|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
215119436|NCT00239239|DRUG|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
215119437|NCT02213835|OTHER|Specific Carbohydrate diet (SCD)|
215119438|NCT03870295|DIAGNOSTIC_TEST|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
215119439|NCT06027203|PROCEDURE|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
215119440|NCT04092686|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
215119441|NCT04092686|DRUG|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
215119442|NCT04092686|DRUG|Placebo|Placebo tablet dosed once daily
215119443|NCT03826121|DIETARY_SUPPLEMENT|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
214442922|NCT04747561|DRUG|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
215119444|NCT03826121|DIETARY_SUPPLEMENT|placebo|placebo for 12 weeks.
215119445|NCT06261177|DEVICE|Functional Electrical Stimulation (FES)|45 mins per day for the duration of 4 weeks (20 sessions).
215119446|NCT06261177|DEVICE|Sham FES|Sham FES
215119447|NCT02953522|OTHER|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
215119448|NCT02953522|OTHER|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
215119449|NCT00972192|BEHAVIORAL|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
215119450|NCT00972192|BEHAVIORAL|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
215119451|NCT00792012|RADIATION|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
215119452|NCT00792012|DRUG|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
214442923|NCT02035631|BEHAVIORAL|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
214442924|NCT02035631|BEHAVIORAL|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
214442925|NCT02035631|BEHAVIORAL|Minimal diet intervention|Some basic diet recommendations
214520363|NCT04485793|DIETARY_SUPPLEMENT|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
214520364|NCT04485793|OTHER|Placebo|Oral administration: 1 tablet/day at evening meal
214520365|NCT02042170|DRUG|human growth hormone self-injection|
214520366|NCT00687128|BEHAVIORAL|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
214520367|NCT00687128|BEHAVIORAL|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
214520368|NCT00687128|BEHAVIORAL|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
214520369|NCT02232958|OTHER|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
214520370|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
214520371|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
214520372|NCT03166215|DRUG|TAK-935|TAK-935 tablets.
214520373|NCT03166215|DRUG|Placebo|TAK-935 placebo-matching tablets.
214520374|NCT00472368|DRUG|LBH589|
214520375|NCT00927316|BIOLOGICAL|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
214520376|NCT05903573|BEHAVIORAL|Cognitive Training|The intervention group will receive cognitive training that provides specific training tasks directed at essential cognitive domains tied to the project's aims and hypotheses (processing speed and working memory) that correspond with the neurocognitive and functional neuroimaging measures to be studied.
214520377|NCT05903573|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
214520378|NCT00208832|PROCEDURE|Graphic medication schedule (Pill card)|
214520379|NCT00208832|PROCEDURE|Refill reminder postcard|
214442926|NCT02035631|BEHAVIORAL|Minimal physical activity intervention|Some basic recommendations on physical activity
214442927|NCT03052335|DEVICE|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
214442928|NCT03052335|PROCEDURE|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
214520380|NCT06451705|DRUG|PECS II block|Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
215119453|NCT03056417|BEHAVIORAL|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
215119454|NCT05272371|COMBINATION_PRODUCT|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
215119455|NCT02098746|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
214442929|NCT03514836|BIOLOGICAL|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
214442930|NCT03514836|DRUG|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
214442931|NCT00715884|DEVICE|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
214442932|NCT00715884|DEVICE|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
214442933|NCT00154011|DRUG|rosiglitazone (drug)|
214442934|NCT04870749|DIAGNOSTIC_TEST|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
214442935|NCT00215787|DRUG|lansoprazole|Lansoprazole 30 mg BID for 1 year
215119456|NCT06115616|BEHAVIORAL|Morning exercise|Exercise before noon in the morning
215119457|NCT06115616|BEHAVIORAL|Afternoon exercise|Exercise in the late after noon
215119458|NCT05777044|BEHAVIORAL|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
215119459|NCT04053257|OTHER|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
215028757|NCT06644807|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
215119460|NCT04126694|BEHAVIORAL|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
214442936|NCT01954836|BEHAVIORAL|initial fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
214442937|NCT01954836|BEHAVIORAL|Secondary fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
214442938|NCT02369289|OTHER|bone mineral density test|
214442939|NCT04351932|BIOLOGICAL|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
214442940|NCT04351932|BIOLOGICAL|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
214442941|NCT04351932|BIOLOGICAL|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
214442942|NCT06334107|BEHAVIORAL|Exercise|Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
214442943|NCT05192980|OTHER|No Intervention NA|Additional blood sampling (not mandatory)
214442944|NCT02412748|BEHAVIORAL|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
214520381|NCT06451705|DRUG|LIA|Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
214520382|NCT06585189|DRUG|Pembrolizumab|
214520383|NCT06585189|DRUG|Pemetrexed|
214442945|NCT02412748|BEHAVIORAL|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
214442946|NCT04065113|PROCEDURE|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
214442947|NCT04065113|PROCEDURE|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
214442948|NCT03069313|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
214520384|NCT06585189|DRUG|Cisplatin|
214520385|NCT06585189|DRUG|Carboplatin|
214520386|NCT06057870|OTHER|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
214520387|NCT05584761|DRUG|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
214520388|NCT03942276|OTHER|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
214520389|NCT03942276|OTHER|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
214520390|NCT03942276|OTHER|Control|Consist of performing no exercise training.
214520391|NCT04435821|DRUG|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
214520392|NCT04332367|DRUG|Carboplatin|Carboplatin IV
214520393|NCT04332367|DRUG|Paclitaxel|Paclitaxel IV
214520394|NCT04332367|DRUG|Ramucirumab|Ramucirumab IV
214442949|NCT06211556|BEHAVIORAL|Very-low calorie diet|\~800 kcal/day delivered via commercially available diet plan (NUPO).
214442950|NCT01577225|DEVICE|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
214442951|NCT01577225|DEVICE|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
214693142|NCT02532595|PROCEDURE|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
214693143|NCT02532595|PROCEDURE|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
215028758|NCT06644807|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
215119461|NCT00217425|BIOLOGICAL|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
215119462|NCT00217425|DRUG|cyclophosphamide|IV infusion per institutional guidelines.
214442952|NCT00664404|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
214442953|NCT00763152|OTHER|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
214442954|NCT05297851|DRUG|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
214442955|NCT05297851|DRUG|Control|Standard treatment accordind to the routine clinical practice
214442956|NCT01296334|DRUG|morphine LO|intravenous infusion, 10 mg, once, 4 hours
214442957|NCT01296334|DRUG|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
214442958|NCT01296334|DRUG|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
214442959|NCT01296334|DRUG|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
214442960|NCT01296334|OTHER|saline|intravenous infusion, 0.9% saline, once, 4 hours
214442961|NCT01052259|DRUG|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
214442962|NCT04243980|DEVICE|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
214442963|NCT04856826|DEVICE|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
214442964|NCT02351310|DRUG|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
214442965|NCT02351310|GENETIC|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
214442966|NCT05088954|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
214442967|NCT00003542|BIOLOGICAL|pegylated interferon alfa|
214442968|NCT04313205|DRUG|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
214442969|NCT00168649|DRUG|Vitamin A|
214442970|NCT01872078|DRUG|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
214442971|NCT01872078|DRUG|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
214442972|NCT01494922|DRUG|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
214442973|NCT00972439|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|
214442974|NCT00972439|DRUG|Oral Contraceptive: Ovcon Fe®|
214442975|NCT06071494|OTHER|Tropical fruits|papaya, mango, banana, orange
214442976|NCT00068198|BIOLOGICAL|Dryvax|
214520395|NCT03749837|DEVICE|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
215119463|NCT00217425|DRUG|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
214442977|NCT06377358|DEVICE|Tecar Therapy|Tecar Therapy at 1Mhz radiofrequency by the use of a C-400 device. The duration of the treatment will be 5 weeks, where 10 sessions will be carried out, 2 per week
214442978|NCT06872320|DRUG|Lactobacillus Rhamnosus|Lactobacillus Rhamnosus (Lactobacillus Rhamnosus, MoProbi-LR Capsules, Drug permit license 052531); Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
214442979|NCT06872320|DRUG|Placebo|Maltodextrin comparable in color. Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
214442980|NCT06871839|DRUG|Lecanemab treatment group|"Lecanemab treatment group: Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.~All subjects in the Lecanemab treatment group receive Lecanemab infusion therapy at a frequency of once every two weeks for a continuous period of 12 months."
214442981|NCT06871839|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
214442982|NCT07008781|BEHAVIORAL|Youth-led cancer screening intervention|High school students will be trained as health advocates and then facilitate discussions about cancer screening recommendations and risk factors with adults in their community. High school students (15-18 years old) from the local community will be recruited for this study, and each student will recruit adults that they live with or are part of their community (i.e. parent) who are eligible for cancer screening. The adult plus youth dyads will all undergo the same youth-led intervention in which the youth will utilize motivational interviewing to discuss cancer screening recommendations and risk factors with their adults and help their adults enroll in cancer screening through ScreenNJ, a community organization that aims to increase cancer screening in New Jersey, reduce cancer mortality rates, and reduce disparities.
214442983|NCT06626425|OTHER|Healthy Minds Program App|An 8-week meditation-based well-being training containing content for each of the four pillars of the training program: Awareness, Connection, Insight, and Purpose.
215119464|NCT00217425|DRUG|prednisone|Prednisone is taken orally.
215119465|NCT00217425|DRUG|vincristine|IV push using extravasation precautions.
215119466|NCT02589054|OTHER|Monitoring|
215119467|NCT03273673|OTHER|Biofeedback Intervention|Visual and Tactile Biofeedback
214442984|NCT06626425|OTHER|Hydro Coach App|The Hydro Coach app (HC). A smartphone-based wellness app to ensure proper hydration.
214442985|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique|"This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery"
214442986|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with double-tract reconstruction|This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
214442987|NCT03730051|DRUG|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
214442988|NCT03730051|DRUG|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
214442989|NCT01837927|DRUG|NVA237|Once daily for 52 weeks
214442990|NCT01837927|DRUG|Tiotropium Respimat®|Once daily for 52 weeks
214442991|NCT07013214|BEHAVIORAL|Dual-Task Exercise|This intervention consists of exercises that integrate motor tasks (e.g., balance training, walking) with concurrent cognitive tasks (e.g., counting, verbal fluency, decision-making tasks). The progression of exercises will be tailored to the individual's abilities, gradually increasing the difficulty of both the motor and cognitive components.
214442992|NCT07013214|BEHAVIORAL|Standard Rehabilitation|This intervention consists of conventional exercises aimed at improving balance, gait, posture, and flexibility, without the integration of simultaneous cognitive tasks. The program will focus on established physical therapy techniques for Parkinson's disease.
214442993|NCT05928624|DEVICE|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
214442994|NCT05928624|OTHER|Standard of Care|Standard of Care
215028759|NCT06644807|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
215119468|NCT01907464|OTHER|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
215119469|NCT01907464|OTHER|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
215119470|NCT01907464|OTHER|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
215119471|NCT01907464|OTHER|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
215119472|NCT00086047|BEHAVIORAL|Coping Skills Training|8 weekly sessions of behavioral treatment
215119473|NCT00086047|BEHAVIORAL|Education|8 weekly sessions of fibromyalgia education
215119474|NCT00096421|BEHAVIORAL|Tight control of blood glucose levels|
215119475|NCT00096421|BEHAVIORAL|Conventional control of glucose levels|
215119476|NCT03558542|OTHER|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
214442995|NCT05300958|DRUG|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
214442996|NCT07022132|OTHER|Diaphragmatic myofascial release (DMR)|The physiotherapist, positioned on the head side of the supine patient, makes bilateral contact with the pisiform, hypothenar region and the underside of the 7th-10th costal cartilages with the last three fingers. During the inspiration phase, he/she pulls the contact points cephalically and slightly laterally with both hands, accompanying the elevation of the costae. During expiration, it deepens the contact towards the inner costal margin, maintaining resistance. In subsequent breathing cycles, it gradually increases the depth of contact inside the costal margin. The application is performed in 2 sets of 10 deep breaths with 1 minute between them.
215119477|NCT03868033|DRUG|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
215119478|NCT03868033|DRUG|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
215119479|NCT06295861|OTHER|no different intervention between the two cohort.|no different intervention between the two cohort.
215119480|NCT03754348|RADIATION|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
215119481|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
215119482|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
215119483|NCT02471014|DRUG|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
215119484|NCT02471014|OTHER|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
215119485|NCT02471014|OTHER|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
214442997|NCT07022132|OTHER|Abdominal hypopressive exercise (AHE)|Each session consists of 6 hypopressive abdominal exercises with a 2-minute recovery period in between, and each exercise is repeated 3 times. This manoeuvre consists of expelling all air until the reserve volume is reached, then holding the breath (expiratory apnoea) and pulling the abdominal wall inwards and cranially by opening the costae without allowing air to enter. Exercises are performed in 6 different positions.
214442998|NCT07022132|OTHER|Conservative treatment|It consists of lumbar flexion and extension, stretching and strengthening exercises for the waist, back and abdominal region.
214442999|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
214443000|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
214443001|NCT02274142|PROCEDURE|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
214443002|NCT02274142|PROCEDURE|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
214443003|NCT02274142|DEVICE|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
214443004|NCT02274142|DEVICE|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
214443005|NCT07050225|OTHER|Digital Cognitive Training|This digital cognitive training program uses gamified tasks in order to enhance cognitive skills in an engaging manner using machine learning AI algorithms to target the intervention to individual cognitive skill deficits. It consists of personalized gamified cognitive tasks that target individual cognitive deficits associated with ADHD including attention, impulsivity, working memory, and cognitive flexibility.
214443006|NCT07050225|OTHER|Digital Non-cognitive Training Intervention|This is a gamified computer platform lacking cognitive training components.
214443007|NCT07048379|DEVICE|Orthosis|A resting orthosis will be preferred because it keeps the wrist in a neutral position.
214443008|NCT07048379|OTHER|Physical Therapy|Participants will undergo physical therapy for three weeks, including hot packs, TENS, tendon-nerve sliding exercises, stretching and strengthening exercises.
214443009|NCT07060781|PROCEDURE|Posterior Lumbar Spine Decompression|Patients undergoing elective posterior lumbar spine decompression.
214443010|NCT06898970|BIOLOGICAL|Vusolimogene Oderparepvec (VO)|Given intratumorally
214520396|NCT03749837|DEVICE|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
214520397|NCT01807845|DIETARY_SUPPLEMENT|enriched skimmilk with VD|enriched skimmilk with VD
214520398|NCT01807845|DIETARY_SUPPLEMENT|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
214520399|NCT01807845|DIETARY_SUPPLEMENT|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
214520400|NCT02632045|DRUG|LEE-011|600 mg capsule (3x 200 mg capsules)
214520401|NCT02632045|DRUG|Fulvestrant|500 mg injection
214520402|NCT02632045|DRUG|Placebo|600 mg capsule (3x 200 mg capsules)
214520403|NCT04276142|BEHAVIORAL|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
215119486|NCT04551118|DEVICE|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
214443011|NCT06898970|DRUG|Pembrolizumab|Given IV
214443012|NCT07067112|BIOLOGICAL|Blood sampling, questionnaire and phone call|The blood sample will drawn after a fasting period of at least 8 hours, and the questionnaire will be auto-administered
214443013|NCT07071467|OTHER|Scaling and root planing with sodium hypochlorite and hyaluronic acid|Sodium hypochlorite gel was applied first for 30 seconds, then followed by subgingival instrumentation of the site. Then, 1.8% hyaluronic acid (1.6% cross-linked, 0.2% natural hyaluronic acid ) was applied subgingivally into the periodontal pocket to seal the site.
214443014|NCT07071467|PROCEDURE|Scaling and root planing|Pockets were treated with sub-gingival scalling and root planning alone.
214443015|NCT07071389|DIETARY_SUPPLEMENT|Zyxelle|Patients in the study group receive Zyxelle dietary supplement along with the oral contraceptive
214443016|NCT07071389|DRUG|Oral contraceptive|Patients in the study group receive daily dose of estroprogestinic oral contraceptive
214443017|NCT07070492|DEVICE|cataract surgery|cataract surgery receiving Vivity IOL or standard mono focal controls
214520404|NCT04276142|BEHAVIORAL|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
214443018|NCT07070492|PROCEDURE|retinal surgery|Retinal surgery for visually significant epiretinal membrane
214520405|NCT00006229|DRUG|carboplatin|
214520406|NCT00006229|DRUG|paclitaxel|
214443019|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
214520407|NCT00006229|DRUG|rebimastat|
215119487|NCT04551118|DEVICE|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
215119488|NCT04551118|DEVICE|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
214443020|NCT07066631|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
214443021|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
214443022|NCT07064954|BIOLOGICAL|Autologous Cold-Stored Platelets|Two units of autologous platelets will be collected via an apheresis machine that draws blood from an intravenous (IV) line over 1-2 hours, isolates and leukoreduces the platelets by centrifugation and returns the remaining blood back to the patients. Collected autologous platelets will be stored at 1-6℃ without agitation until they are needed during or after surgery or 14 days have elapsed since their collection, after which they will be destroyed as per standard institutional procedures for expired blood products. For the first two platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients will receive their autologous cold-stored platelets. For the third and subsequent doses, patients in the intervention group will receive allogeneic room temperature-stored platelets (standard of care).
214443023|NCT07064954|BIOLOGICAL|Allogeneic Room Temperature-Stored Platelets (Standard of Care)|Allogeneic platelets will be collected by Canadian Blood Services as per their standard operating procedures. Room temperature stored platelets will be stored at 20-24°C with constant agitation for up to 7 days as per current practices. For any platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients in the control group will receive allogeneic platelets as per usual care.
214443024|NCT07072429|PROCEDURE|Gastric cancer resection|Any kind of surgical gastric cancer resection
214443025|NCT06894745|DRUG|89-zr-dfo-star polyethylene glycol (StarPEG)|Given intravenously (IV)
214443026|NCT06894745|PROCEDURE|Whole Body Positron Emission Tomography (PET)|Imaging procedure
214443027|NCT06894745|PROCEDURE|Specimen Collection|Urine and blood specimens will be collected for correlative studies
214443028|NCT07075588|BEHAVIORAL|iTHRIVE intervention|"Integration of three traditionally siloed components:~1. Digitally enabled food access~2. Personalized nutrition support~3. Clinical care-rision of home blood pressure device with app"
214443029|NCT07075588|BEHAVIORAL|Active comparator|"Active comparator arm will receive enhanced usual care that consists of:~1. Standard produce bag~2. Home blood pressure Device without app~3. General dietary advice"
214443030|NCT07069855|OTHER|Almond Snack Intervention for Gestational Diabetes|This intervention involves daily consumption of 43 g of whole almonds, split into two portions (afternoon and evening), for 28 days in pregnant women diagnosed with gestational diabetes who habitually consume evening snacks.
214443031|NCT07069855|OTHER|Control (placebo) group|This control involves the daily consumption of a nut-free snack (2 portions) that reflects a 'typical snack' choice among pregnant women with gestational diabetes. It serves as a comparison to assess the specific impact of almond-based evening snacking on overnight glucose regulation.
214443032|NCT07075718|DRUG|Gen 2 Travoprost Intracameral Implant|travoprost
214443033|NCT07075718|DRUG|Timolol eye drops 0.5%|timolol 0.5%
214443034|NCT07075718|PROCEDURE|Sham Procedure|sham implant administration
214520408|NCT06416540|OTHER|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program|"Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient."
214520409|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Program|Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
214520410|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
214443035|NCT07075718|OTHER|Placebo eye drops|artificial tears
215119493|NCT06065618|OTHER|Without intervention|Without intervention
215119494|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
215119495|NCT01409876|RADIATION|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
214443036|NCT07077330|OTHER|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.~Drug: fludarabine and cyclophosphamide Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg"
214443037|NCT07078487|DEVICE|Pacemaker and defibrillator|Setting the pacemaker base rate at a pre-defined base rate
214693144|NCT02687594|DRUG|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
215119496|NCT06344299|OTHER|potential predictors|Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
214443038|NCT07076641|PROCEDURE|rachi morphine anesthesia|Morphine spinal anesthesia is administered before general anesthesia, just after the patient has been admitted to the operating room.
214443039|NCT07076641|PROCEDURE|laparotomy|major digestive or abdominal surgery by laparotomy
214520411|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
214520412|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
215119497|NCT00592904|DRUG|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
215119498|NCT04881617|BEHAVIORAL|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
215119499|NCT04881617|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
215119500|NCT02089594|DRUG|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
214443040|NCT07076641|DRUG|Lidocaine IV|KABI 20 mg/mL solution for injection (ready-to-use ampoule, no dilution). Each ml of solution contains 20 mg lidocaine hydrochloride (monohydrate form), corresponding to 16.22 mg lidocaine.
214443041|NCT07076641|DRUG|Placebo|Sodium chloride (NaCl) FRESENIUS 0.9% solution for infusion. Each ml contains 9 mg sodium chloride.
214443042|NCT07076641|DRUG|MORPHINE|The auxiliary drug on which both experimental strategies are based is MORPHINE: Morphine hydrochloride AGUETTANT 0.1 mg/mL Solution for injection (ready-to-use ampoule) for rachi anesthesia.
214443043|NCT07076953|OTHER|Cherry Seed Massage Group|In the third stage of labor, a cherry pit massage was applied for 15 minutes in the first and second hours. Cherry pits were added to a silk bag to prevent damage to the skin during the massage. The massage application steps were applied as indicated in the hand massage
214520413|NCT05642702|OTHER|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
214693145|NCT05741593|OTHER|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
214693146|NCT06724172|BEHAVIORAL|Self-Management|We will universally offer social needs supports (grocery, physical activity, transportation support) widely in use in clinical settings. Patients may elect to receive all, some, or none of the supports. The patient-directed, structured self-management intervention will be provided through mobile health technology (mHealth) and/or mailings, according to patient preference. Participants will receive health information to support health education and behavior change.
214443044|NCT07076953|OTHER|Manual Breast Massage|"Manual massage was applied for 15 minutes during the third stage of labor, first and second hour.Manual breast massage steps; Step 1: The breast tissue under and near the armpit is compressed and released like a water pump.~Step 2: Pressure is applied to the breast tissue. Step 3: The breasts are massaged using the fingers and pressed with small circular movements. It is moved clockwise and counterclockwise around the breast and towards the areola with light touches.~Step 4: Both hands are placed under the breast; the breast is moved up and down, left and right, forward and backward.~Step 5: One hand is placed under the breast and the other hand is on the breast; the hands are moved in the opposite direction and a rolling motion is applied to the breast."
214443045|NCT07076576|OTHER|Yoga Training|The children in the experimental group underwent yoga training for a total of 16 sessions consisting of 45 minutes each session, 2 times a week for 8 weeks.
214443046|NCT07078279|DEVICE|immersive virtual reality intervention with Meta Quest 3|"The intervention consists of a rehabilitation program based on Immersive Virtual Reality (IVR), specifically designed to improve functional balance in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~The Meta Quest 3 device will be used, a standalone, wireless, high-definition immersive virtual reality system. This device allows the user to fully immerse themselves in interactive virtual environments, blocking out external stimuli and offering an immersive, motivating, and controlled experience."
214443047|NCT07078279|OTHER|Intervention with Conventional Balance Physical Therapy|"The Control Group (CG) will receive a standardized conventional physical therapy program focused on balance training, with the goal of improving postural and functional control in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~This treatment is based on traditional exercises recognized within pediatric physical therapy for balance training and is designed to be comparable in time, frequency, and intensity to the experimental group (virtual reality), but without the use of immersive technology."
214443048|NCT07076381|BEHAVIORAL|Brief and solutions-therapy intervention|"Parents will receive three phone counseling sessions over Zoom of 45-60 minutes each from a counselor when their baby is 4-6 weeks old; 10-12 weeks old, and 16-20 weeks old. The date and time of the sessions will be coordinated by phone or e-mail between the parent and their counselor in the week preceding the call. Following their session, parents in this group will receive a brief satisfaction survey over e-mail (Appendix E) that they will be asked to complete within 72 hours."
214443049|NCT07076212|DRUG|Liposomal Irinotecan|50 mg/m2 will be administered on Day 1 of a 2-week cycle
214443050|NCT07076212|DRUG|Oxaliplatin|60 mg/m2 will be administered on Day 1 of a 2-week cycle
214443051|NCT07076212|DRUG|5-Fluorouracil|5-fluorouracil (2400 mg/m2 over 46 hours) will begin administration on Day 1 of a 2-week cycle
214443052|NCT07076212|DRUG|Leucovorin|400 mg/m2 will be administered on Day 1 of a 2-week cycle
214443053|NCT07076212|DRUG|Gemcitabine (mg/m²)|1000 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
214443054|NCT07076212|DRUG|Nab-paclitaxel|125 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
214443055|NCT07076212|DRUG|Cisplatin|25 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
214443056|NCT07077018|DIETARY_SUPPLEMENT|Fasting-mimicking diet (FMD) Group|The FMD will consist of a triweekly 4-day regimen of a plant-based, calorie-restricted (827± 100 kcal on day 1；637 ± 100 kcal on days 2-4), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles. Participants receive the FMD for 2 days prior to and on the day and one day after each cycle of chemotherapy.
214520414|NCT05642702|OTHER|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
214520415|NCT06415825|BEHAVIORAL|Standard advice and Preliminary muscle contraction|The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.
214520416|NCT06415825|BEHAVIORAL|Standard advice|Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
214520417|NCT04867044|OTHER|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
214520418|NCT04867044|OTHER|Control|healthy woman volunteers
214520419|NCT06080802|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
214520420|NCT05534230|DRUG|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
214520421|NCT05534230|DRUG|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
215119501|NCT02089594|DRUG|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
215119502|NCT04268108|BIOLOGICAL|liquid tumor infiltrating lymphocytes|Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
215119503|NCT02686385|DRUG|Prednisolone|
215119504|NCT02686385|DRUG|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
215119505|NCT04012580|BEHAVIORAL|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
215119506|NCT03706443|OTHER|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
215119507|NCT03706443|OTHER|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
215119508|NCT02056795|DEVICE|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
214443057|NCT07077785|PROCEDURE|Epidural Analgesia|After informed consent and exclusion of contraindications, an epidural catheter will be placed at the L3-L4 interspace in the sitting position using a Tuohy needle. A test dose of 2 mL lidocaine will be administered to confirm correct catheter placement under continuous monitoring of vital signs. Once cervical dilatation reaches 5 cm, 5 mL of 0.2% bupivacaine combined with 25 mcg fentanyl will be administered via the epidural catheter. Additional boluses will be given as needed based on pain assessment. The catheter will be removed 24 hours postpartum.
214443058|NCT07077525|COMBINATION_PRODUCT|Dapagliflozin + Metformin|70 patients with T2DM were treated once daily with Dapa plus Met combination (Dapavildactin plus®, Liptis Pharmaceuticals, Egypt) in a dose titrated from 5 mg Dapa and 1000 mg Met up to a maximum of 10 mg Dapa and 2000 mg metformin as per the standard of care in a physician's practice
214443059|NCT07077525|COMBINATION_PRODUCT|Vildagliptin + Metformin|126 patients with T2DM were treated with Vilda plus Met combination (Gliptus plus®, EVA pharma, Egypt ) in initial daily dose of 50 mg Vilda and 500 mg Met . The medication is titrated gradually up to Vilda 50 mg and metformin 1000 mg twice daily as per the standard of care in a physician's practice
214443060|NCT07078552|OTHER|ptosis|no intervention
214520422|NCT04209322|PROCEDURE|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
214520423|NCT04209322|PROCEDURE|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
214520424|NCT05860894|DEVICE|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
214520425|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|3 capsules daily.
214520426|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|2 capsules twice daily.
214520427|NCT04928937|PROCEDURE|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
214520428|NCT06032156|DIETARY_SUPPLEMENT|Low Dose β-OHB|Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
214520429|NCT06032156|DIETARY_SUPPLEMENT|High Dose β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
214520430|NCT06032156|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
214520431|NCT00777309|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
214520432|NCT00777309|DRUG|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
214520433|NCT00777309|DRUG|Placebo|The placebo is provided as a capsule
214520434|NCT01613599|DRUG|Rituximab|Participants received rituximab at the discretion of their treating physicians.
214520435|NCT02091102|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
214520436|NCT00228657|DRUG|4% Albumin / 0.9% Sodium Chloride|
214520437|NCT01049633|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
214520438|NCT01049633|DRUG|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
214520439|NCT01049633|BIOLOGICAL|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
214520440|NCT01049633|DRUG|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
214520441|NCT01049633|DRUG|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
214520442|NCT01049633|DRUG|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
214520443|NCT01049633|DRUG|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
214520444|NCT01049633|DRUG|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
214520445|NCT01049633|DRUG|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
215119509|NCT02056795|DEVICE|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
215119510|NCT01860833|DRUG|Ibuprofen|time of treatment 14 days
215119511|NCT01860833|DRUG|Celecoxib|time of treatment 14 days
215119512|NCT01860833|DRUG|Diclofenac|time of treatment 14 days
215119513|NCT02939586|PROCEDURE|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
215119514|NCT02939586|PROCEDURE|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
215119515|NCT06106802|DRUG|Lazertinib|Lazertinib 240mg/day
215119516|NCT06106802|DRUG|Tepotinib|Tepotinib 500mg/day
215119517|NCT04688749|DIAGNOSTIC_TEST|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
215119518|NCT04883866|BEHAVIORAL|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
214520446|NCT01049633|DRUG|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
214520447|NCT01049633|DRUG|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
214520448|NCT01049633|DRUG|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
214520449|NCT02003885|DRUG|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
214520450|NCT02705729|DEVICE|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
214520451|NCT02705729|DEVICE|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
214520452|NCT01075815|DRUG|Recombinant human luteinizing hormone (rhLH)|
214520453|NCT01075815|DRUG|Recombinant follicle-stimulating hormone (rFSH)|
214520454|NCT04937309|DEVICE|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
215119519|NCT04883866|BEHAVIORAL|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
215119520|NCT01225094|DRUG|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
215119521|NCT01225094|OTHER|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
215119522|NCT01770574|DEVICE|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
214443061|NCT07078409|BEHAVIORAL|Nudge|When the clinician who ordered the imaging that led to randomization receives the test results, a pre-checked referral order to gynecologic oncology for surgical evaluation will appear in the EHR alongside a brief educational explanation. This will constitute the opt-out default referral order (Figure 3). Clinicians will have the option to unclick the referral to opt out and will be asked to indicate the reason from a pre-populated list of choices; if they do not opt out, the referral to gynecologic oncology will proceed. Imaging findings and referral will be communicated to the patient in keeping with the clinician's usual practice. In keeping with routine practice, referred patients will be contacted by gynecologic oncology's new patient coordinators within 72 hours and offered an appointment within 2 weeks at their preferred location.
215119523|NCT01770574|PROCEDURE|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
214443062|NCT07078149|DEVICE|Robotic-assisted TKA (RATKA).|RATKA was performed using the ROSA® Knee System.
214443063|NCT07078149|PROCEDURE|Conventional manual TKA (mTKA)|mTKA was performed without robot assistance.
215119524|NCT02707146|BEHAVIORAL|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
214443064|NCT07078006|OTHER|Platelet Rich Fibrin|Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
215119525|NCT02707146|OTHER|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
215119526|NCT02707146|DEVICE|iPad|
215119527|NCT03191630|BEHAVIORAL|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
214443065|NCT07078006|OTHER|Platelet Rich Plasma|Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
214443066|NCT07078799|PROCEDURE|LASIK|Wavefront-guided LASIK is being performed in one eye and Ray-tracing guided LASIK is being performed in the fellow eye
214443067|NCT07078799|PROCEDURE|LASIK|Ray-tracing guided LASIK is being performed in one eye and Wavefront-guided LASIK is being performed in the fellow eye.
214520455|NCT04937309|DRUG|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
214520456|NCT04937309|DEVICE|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
214520457|NCT00003049|DRUG|fluorouracil|
214520458|NCT00003049|DRUG|leucovorin calcium|
214520459|NCT00003049|PROCEDURE|conventional surgery|
214443068|NCT07076368|DRUG|Ropivacaine + Fentanyl|A standard epidural admixture - 0.1% Ropivacaine + 2 mcg/ml fentanyl - will be used.
214520460|NCT00003049|RADIATION|radiation therapy|
214520461|NCT06500169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214520462|NCT06500169|PROCEDURE|Discussion|Ancillary studies
214520463|NCT06500169|OTHER|Exercise Intervention|Complete golf related exercises
214520464|NCT06500169|OTHER|Interview|Ancillary studies
214520465|NCT06500169|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
214520466|NCT06500169|PROCEDURE|Physical Examination|Ancillary studies
214520467|NCT06500169|OTHER|Physical Performance Testing|Ancillary studies
214520468|NCT06500169|OTHER|Questionnaire Administration|Ancillary studies
214520469|NCT06500169|OTHER|Recreational Therapy|Participate in golf program
215119528|NCT03191630|BEHAVIORAL|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
215119529|NCT05829954|OTHER|questionnaire|All questionnaire were obtained via online survey system.
214443069|NCT07076823|DRUG|Canagliflozin|Low-dose cohort: 100 mg qd, taken before the first meal of the day. High-dose cohort: Starting dose of 100 mg qd for 1 week. If tolerated, the dose will escalate to 300 mg qd, taken before the first meal of the day.
214443070|NCT07077668|DRUG|A sterile aqueous solution of RAG - 17 preparation (sodium salt)|Patients who meet the inclusion and exclusion criteria are required to come to the hospital at the following time points to complete the intrathecal bolus injection of RAG - 17 for 150 mg: baseline, 60 ± 3 days, 120 ± 3 days, 180 ± 3 days, 240 ± 3 days, 300 ± 3 days, 360 ± 3 days, 450 ± 3 days, 540 ± 3 days.
214443071|NCT07078201|DRUG|Dexmedetomidine|patients received 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL diluted in 12.5 ml preservative-free normal saline, 0.5 ml had been withdrawn).
214520470|NCT00617708|BIOLOGICAL|cixutumumab|Given IV
214520471|NCT00617708|DRUG|erlotinib hydrochloride|Given PO
214520472|NCT00617708|DRUG|gemcitabine hydrochloride|Given IV
214520473|NCT02058992|DRUG|Ramelteon|Ramelteon 8 mg tablets
214520474|NCT03796585|BEHAVIORAL|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
214520475|NCT03796585|BEHAVIORAL|Informational flyer|Informational flyer with ImmPRINT contact information
214520476|NCT01794273|DRUG|ephedrine and phenylephrine|
214520477|NCT00002045|DRUG|Zidovudine|
214520478|NCT03503188|DEVICE|Littmann ®|electronic stethoscope
214520479|NCT02512315|DRUG|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
214520480|NCT02512315|DRUG|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
214520481|NCT02512315|RADIATION|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
214520482|NCT03867396|DEVICE|CROS|Advanced Bionics CROS
214520483|NCT03867396|DEVICE|Hearing Aid|Advanced Bionics Naida hearing aid
214520484|NCT03867396|OTHER|Cochlear Implant Alone|No hearing device on contralateral ear
214520485|NCT05456061|DRUG|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
214520486|NCT05456061|PROCEDURE|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
214520487|NCT06119256|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
214520488|NCT00046488|DRUG|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
214520489|NCT04172974|OTHER|eHealth intervention|Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
214520490|NCT04172974|OTHER|Usual Care|Treatment according to national clinical guideline (referral to GP)
214520491|NCT00293085|DRUG|Docetaxel|
214520492|NCT00293085|DRUG|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
214520493|NCT03747575|DRUG|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
214520494|NCT03747575|DRUG|Placebo|Participants will receive SC placebo
214520495|NCT03031223|RADIATION|low-level laser therapy|low-level laser therapy
215119530|NCT00724178|DIETARY_SUPPLEMENT|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
215119531|NCT02884388|PROCEDURE|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
215119532|NCT02884388|PROCEDURE|general anesthesia|Patients in this group were assigned to receive general anesthesia.
215119533|NCT03573141|OTHER|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
215119534|NCT01468740|DRUG|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119535|NCT01468740|DRUG|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
214443072|NCT07078201|DRUG|fentanyl|patients received 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
214443073|NCT07077304|OTHER|observational study|observational study
214443074|NCT07077772|DRUG|Furosemide intravenous titration based on natriuresis|"Furosemide IV, 20 mg starting dose, titrated every 6 hours based on urinary sodium measured by the LAQUAtwin NA-11 device.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~If natriuresis is \< 70 mmol/L, the furosemide dose will be doubled, with a maximum limit of 200 mg per bolus.~If natriuresis is ≥ 70 mmol/L, the current dose will be maintained.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
214443075|NCT07077772|DRUG|Furosemide intravenous titration based on clinical examination|"Furosemide IV, 20 mg starting dose, titrated every 6 hours clinical evaluation.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~The furosemide dosage will be adjusted based on urine output with a maximum bolus dose of 200 mg. Dose adjustments will be reassessed every 6 hours throughout the study period.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
214693147|NCT06724172|BEHAVIORAL|Community-Based|As is currently in use broadly by community health workers, participants will complete a detailed social needs assessment and active assistance with referrals to evidence-based home visiting programs; maternal child health services to promote social support and resource access; and services to improve social determinants of health including active enrollment assistance for WIC, SNAP, healthcare and insurance, legal support, housing, job training, mental health and others. Community health workers will deliver group and individual physical activity support and assistance with behavioral goal setting.
215119536|NCT01468740|DRUG|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
215119537|NCT01468740|DRUG|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
215119538|NCT01468740|DRUG|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119539|NCT01468740|DRUG|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119540|NCT01468740|DRUG|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119541|NCT01468740|DRUG|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119542|NCT01468740|DRUG|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
215119543|NCT05206812|DRUG|durvalumab|"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
215119544|NCT02459119|DRUG|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
214443076|NCT07076693|PROCEDURE|Radiotherapy or Surgery|Metastatic lesions were treated with surgical resection or radiotherapy. Surgical duration was determined by investigator assessment and metastatic or primary lesions were resected with palliative intent. Radiation dose and fractionation are 30\~50Gy. Radiation dose, fractionation regimen, and treatment sites for metastatic lesions were determined at the investigator's discretion based on clinical indications.
215119545|NCT02649140|DIETARY_SUPPLEMENT|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
215119546|NCT04353245|OTHER|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
214443077|NCT07076693|DRUG|Standard Medical Therapy|Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or ivonescimab.
214520496|NCT03522844|OTHER|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
214520497|NCT03522844|DRUG|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
214520498|NCT06198452|PROCEDURE|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
214443078|NCT07077824|PROCEDURE|Stellate Ganglion Block Injection with Bupivicaine|Patients will receive left stellate ganglion block US guided after induction of anesthesia and intubation and after insertion of Rt IJV CVL and before skin incision
214520499|NCT02086071|PROCEDURE|re biopsy|re biopsy depending on the location of the pathology
214520500|NCT01015794|DRUG|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
214520501|NCT01015794|DRUG|ephedrine hydrochloride|single dose of 1 mg/kg body weight
214520502|NCT00321555|DRUG|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
214520503|NCT01107795|PROCEDURE|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
214520504|NCT04407442|DRUG|Azacitidine|Given IV
214520505|NCT04407442|BIOLOGICAL|Daratumumab|Given SC
214443079|NCT07078474|OTHER|Topical Hyaluronic Acid|Hyaluronic acid was applied topically to the facial skin of healthy participants once daily for a period of 3 weeks. Two application methods were used: on dry skin and on pre-moistened skin. Skin measurements were performed at baseline and after each week of intervention (Week 1, Week 2, and Week 3) to assess hydration and other skin parameters.
214443080|NCT07078032|DIAGNOSTIC_TEST|Prediction Model Arm|Lung cancer risk stratification via prediction model integrating: advanced age, lung cancer family history, personal cancer history, childhood coal exposure, asthma history, and food allergy history. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
214443081|NCT07078032|DIAGNOSTIC_TEST|Standard Screening Arm|Participants are screened based on NCCN guideline criteria. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
214520506|NCT04407442|DRUG|Dexamethasone|Given IV or PO
214520507|NCT04296409|OTHER|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
214520508|NCT00003245|DRUG|irinotecan hydrochloride|
214520509|NCT02907489|OTHER|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
214520510|NCT03988855|DRUG|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
215119547|NCT00763646|DRUG|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
215119548|NCT05665010|OTHER|Genetic susceptibility|Genetic susceptibility increases the risk of ovarian injury
215119549|NCT05572866|OTHER|COVID-19 pandemic|To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
215119550|NCT05282069|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
214443082|NCT07078305|DRUG|Regorafenib and tislelizumab|Tislelizumab: 200mg, iv, d1, Q3W; Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
214443083|NCT07078305|DRUG|Regorafenib|Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
214443084|NCT07077005|OTHER|Exercise training|Supervised, combined endurance and resistance training
214443085|NCT05226780|DRUG|NBI-921352|Administered orally
214443086|NCT06754124|OTHER|Pilates Group|Pilates training will be given individually for approximately 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all participants will be taught the basic elements of Pilates in 1 session. Pilates training will begin with standing exercises for warming up and centering in the supine position. Training will continue with upper and lower extremity movements. The intensity of the exercises will be increased by using different positions and elastic bands. Stretching exercises and posture exercises will be used during the cool-down period. All exercises will start with 10 repetitions and will be increased to 20 later. Each movement will be shown by the physiotherapist first so that the patients can do the movements correctly. The movements that the patients cannot do will be modified appropriately and applied.
214443087|NCT06754124|OTHER|Control Group|No exercise will be allowed for 8 weeks and routine medication will continue.
214443088|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy \* 3-10 fractions) for pulmonary lesions, lymph node lesions and visceral lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity is intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
214443089|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
215119551|NCT05282069|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
215119552|NCT05282069|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
214520511|NCT02066389|DRUG|Placebo|Tablets for oral administration
214520512|NCT02066389|DRUG|Upadacitinib|Tablets for oral administration
214520513|NCT05724576|BIOLOGICAL|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
214520514|NCT01287624|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214520515|NCT01287624|DRUG|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
214520516|NCT01892982|BEHAVIORAL|Problem Solving Education tailored to NICU|
214520517|NCT06452888|BEHAVIORAL|Clinical decision support system.|The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.
214520518|NCT06452888|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
214520519|NCT06585761|DRUG|SGLT2 inhibitor|patients with HF are subjected to regular dose of SGLT2I member according to patient status.
214520520|NCT06585761|DEVICE|echo cardiogram|the patients are subjected to ECHO to determine their EF prior to and post the study
214520521|NCT06584877|OTHER|sample collection|Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
215119553|NCT05282069|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
215119554|NCT05282069|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
215119555|NCT02148523|BEHAVIORAL|Comparison to peers|
215119556|NCT02148523|BEHAVIORAL|Adherence feedback|
215119557|NCT02148523|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
215119558|NCT05103826|DRUG|SHR6390、Famitinib|SHR6390, oral;Famitinib, oral.
214520522|NCT06584877|OTHER|Seeking consent and assent|Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
214520523|NCT02122822|BIOLOGICAL|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
214520524|NCT00374673|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
214520525|NCT06376006|BEHAVIORAL|EMR STAT - Survey|Surveys are completed before and after Advanced Fellow Training.
214520526|NCT00762853|DRUG|Fluoride|Brush half mouth once with assigned study treatment
215119559|NCT03170700|BEHAVIORAL|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
215119560|NCT03170700|BEHAVIORAL|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
215119561|NCT02054585|OTHER|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
215119562|NCT02054585|OTHER|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
215119563|NCT04589871|OTHER|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
215119564|NCT04589871|OTHER|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
214443090|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and bone metastatic lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
214443091|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
215119565|NCT06383832|DRUG|Dapagliflozin|Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
215119566|NCT01367834|DRUG|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
215119567|NCT02917135|DEVICE|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
215119568|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
215119569|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
214520527|NCT00762853|DRUG|Fluoride and triclosan|Brush half mouth once with assigned study treatment
214520528|NCT02114502|DRUG|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
215119570|NCT00240461|OTHER|Placebo|crystalline substance 200 mg twice daily for 6 months
214520529|NCT02114502|DRUG|SAHA|1,000 mg by mouth on Days -8 to -3.
214520530|NCT02114502|DRUG|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
214520531|NCT02114502|DRUG|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
214520532|NCT02114502|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
214520533|NCT02114502|PROCEDURE|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
214520534|NCT02114502|DRUG|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
214520535|NCT02114502|DRUG|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
214520536|NCT02114502|DRUG|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
214520537|NCT02114502|DRUG|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
214520538|NCT02114502|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
214520539|NCT06407193|OTHER|MRI and scintigraphy|Gastric emptying measured with MRI and scintigraphy
214520540|NCT01783379|DRUG|micafungin|100mg/day infusion in 1 hour
214520541|NCT05757622|DRUG|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
214520542|NCT05757622|DRUG|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
214520543|NCT03639545|DRUG|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
214520544|NCT03639545|DRUG|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
214520545|NCT03639545|DRUG|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
214520546|NCT03639545|DRUG|Placebos|The patients receive for 12 weeks.
214520547|NCT00964756|GENETIC|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
214520548|NCT00964756|DRUG|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
214520549|NCT02659176|PROCEDURE|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
214520550|NCT02659176|PROCEDURE|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
214520551|NCT06079047|PROCEDURE|group Dexamethasone|Adductor canal block with dexamethasone
214520552|NCT06079047|PROCEDURE|group Controle|Adductor canal block with saline solution
215119571|NCT05104307|DEVICE|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
215119572|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
215119573|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
215119574|NCT00556907|RADIATION|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
215119575|NCT00556907|DEVICE|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
215119576|NCT01284517|DRUG|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
215119577|NCT01284517|DRUG|Placebo|Equivalent to Lurasidone dosing
215119578|NCT03626792|OTHER|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
215119579|NCT03626792|OTHER|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
215119580|NCT01677325|DRUG|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
215119581|NCT04504981|BEHAVIORAL|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
215119582|NCT03686904|DRUG|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
215119583|NCT03686904|OTHER|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
215119584|NCT03686904|PROCEDURE|Debridement|Removing dead tissue from infected wound (in clinic)
215119585|NCT03686904|DRUG|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
215119586|NCT03686904|OTHER|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
215119587|NCT00040443|DRUG|CX516|
215119588|NCT00040443|DRUG|Placebo|
214443092|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and bone metastatic lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
214443093|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
214443094|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
214443095|NCT06951399|DRUG|Pembrolizumab (KEYTRUDA®)|IV Pembrolizumab 200 mg combined with pemetrexed and platinum (investigator's choice of cisplatin or carboplatin) every 3 weeks
214443096|NCT07077928|DEVICE|Pacemaker upgrade|CRT upgrade
214443097|NCT07078708|DIETARY_SUPPLEMENT|vitamin D (cholecalciferol) supplementation|Vitamin D supplementation at a dose of 50,000 IU every two weeks along with a daily intake of 1,000 mg of calcium for 12 weeks
214443098|NCT07078708|OTHER|Placebo|Placebo was given for 12 weeks
214443099|NCT06480578|BEHAVIORAL|ISS-SBDOH arm|Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
214443100|NCT06261502|DRUG|CBD Oral Solution|Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
214443101|NCT06261502|DRUG|Placebo|Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
214443102|NCT00572169|DRUG|Velcade|Will be given in central venous catheter
214443103|NCT00572169|DRUG|Thalidomide|Capsule taken by mouth
214443104|NCT00572169|DRUG|Dexamethasone|A pill taken by mouth
214443105|NCT00572169|DRUG|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
214443106|NCT00572169|DRUG|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
214443107|NCT00572169|DRUG|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
214693148|NCT04645017|BEHAVIORAL|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
214693149|NCT06926192|COMBINATION_PRODUCT|Surgery combined with secukinumab|Surgery combined with secukinumab
214693150|NCT00443339|DRUG|Darbepoetin|
214443108|NCT00572169|DRUG|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
215119589|NCT04457765|DRUG|Povidone-Iodine (PVP-I)|1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
215119590|NCT01759043|PROCEDURE|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
215119591|NCT01759043|PROCEDURE|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
215119592|NCT03129867|DRUG|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
215119593|NCT00170872|DRUG|Lumiracoxib|
215119594|NCT00269672|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
214443109|NCT04263025|BIOLOGICAL|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
214443110|NCT04263025|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
214443111|NCT04927819|DEVICE|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
214443112|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
214443113|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
214443114|NCT06395181|BEHAVIORAL|Whole Food Plant-Based Diet|A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
214443115|NCT04921501|DEVICE|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
214443116|NCT04921501|DEVICE|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
214443117|NCT00643656|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
214443118|NCT00643656|DRUG|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
214443119|NCT06785077|PROCEDURE|buccal cells|custom myeloid gene panel (Myelo-Panel) to identify germline mutations predisposing to cancer development (Thermo Fisher Scientific)
214443120|NCT06785077|PROCEDURE|bone marrow cells|"Bone marrow cells (optional, for comparison, only in a limited number of patients):~* morphological analysis~* immunophenotype~* cytogenetics/FISH~* analysis of CHIP by custom gene panel and high sensitivity NGS"
214443121|NCT06785077|PROCEDURE|peripheral blood cells|analysis of CHIP by custom gene panel and high sensitivity NGS
214443122|NCT06785077|PROCEDURE|bone marrow biopsy|"Bone marrow biopsy (optional, for comparison, only in a limited number of patients):~* histology~* immunohistochemistry"
214693151|NCT06889870|PROCEDURE|Pectoral Nerve Block|In the PEC group, the PECS II block will be performed by the same anesthesiologist and will be performed before the skin incision, using the technique described by Blanco at al, 2012. 10 ml of ropivacaine solution (0.3%) will be administered into the fascia between the pectoralis major and pectoralis minor muscles and 20 ml of the same anesthetic solution between the pectoralis minor and serratus muscles.
214693152|NCT06889870|PROCEDURE|Local Anesthesia|In the LOC group, local infiltration will be carried out by the surgeon before the surgical incision. Adrenaline 1:20000 will be added to the anesthetic solution in the LOC group for the surgeon's convenience in order to better control per operative bleeding. In the PEC group, a solution of adrenaline in the same concentration in 0.9% saline will be infiltrated, also just to control bleeding in the surgical field.
214443123|NCT03102125|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
214443124|NCT06829472|DRUG|melphalan|conditioning regimen with melphalan, busulfan and fludarabine
214443125|NCT05690386|BIOLOGICAL|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
215119595|NCT01020786|DRUG|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
215119596|NCT01020786|DRUG|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
215119597|NCT06185517|DIAGNOSTIC_TEST|Questionnaire translation and validation|Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
215119598|NCT02939365|DRUG|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
215119599|NCT04021095|DEVICE|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
215119600|NCT02366351|DRUG|SHR3824|Once daily, 12 weeks
214443126|NCT05690386|DRUG|Somatropin|Once-daily subcutaneous injection of Somatropin
214443127|NCT04096014|DIETARY_SUPPLEMENT|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
214443128|NCT04096014|OTHER|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
214443129|NCT03236441|DEVICE|RIPC|Remote ischemic preconditioning
214443130|NCT03236441|DEVICE|Sham-RIPC|Control
214443131|NCT05076448|PROCEDURE|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
215119601|NCT02366351|DRUG|Placebo|Once daily, 12 weeks
215119602|NCT05189548|BIOLOGICAL|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
215119603|NCT02058953|PROCEDURE|Craniotomy scheduled|Resection of affected brain tissue
215119604|NCT02058953|PROCEDURE|Collection for non-craniotomy|CSF, Blood, biopsy
215119605|NCT00115440|RADIATION|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
215119606|NCT02959593|DEVICE|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
215119607|NCT05792813|DRUG|LGYY|LGYY = Linggui Yangyuan paste
215119608|NCT05792813|DRUG|LGYY mimetic|LGYY = Linggui Yangyuan paste
215119609|NCT05792813|DRUG|WZYZ|WZYZ= Wuzi Yanzong oral solution
215119610|NCT05792813|DRUG|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
215119611|NCT05470335|PROCEDURE|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
214520553|NCT01755598|BIOLOGICAL|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
214520554|NCT01755598|BIOLOGICAL|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
214520555|NCT03612999|DEVICE|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
215119612|NCT05616923|DRUG|Trametinib|Topical cream containing 0.1 mg/g trametinib
214520556|NCT03612999|DEVICE|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
214520557|NCT03612999|BEHAVIORAL|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
214520558|NCT03612999|BEHAVIORAL|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
214443132|NCT05076448|PROCEDURE|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
214443133|NCT05076448|PROCEDURE|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
214443134|NCT06832462|BEHAVIORAL|Acceptance and Commitment Therapy|"A one-day Acceptance and Commitment Therapy (ACT) will be held with three (3) sessions. The sessions start with ice breaking, and follow by,~The first session will build a therapeutic relationship and icebreaking, using animated video (unwanted guest) presentations to explain how ACT can help manage issues.~The second session will focus on acceptance and defusion concepts, emphasizing the importance of letting go of unproductive emotion-control techniques by using animated video (response ability)~The third session, 'Show Up', will increase awareness of undesirable thoughts and feelings through structured mindfulness exercises and observing surroundings. The therapist will explain the metaphor of dropping the anchor and emphasize the"
214443135|NCT04714840|OTHER|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
214443136|NCT04714840|OTHER|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
214443137|NCT04714840|OTHER|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
214443138|NCT01025089|DRUG|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
214443139|NCT00833872|DRUG|LEO 22811|First-in-man
214443140|NCT00833872|DRUG|placebo solution|
214520559|NCT03671499|BEHAVIORAL|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
214520560|NCT00422786|DRUG|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
214520561|NCT02574910|DRUG|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
214520562|NCT02423447|DEVICE|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
214520563|NCT02423447|DEVICE|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
214520564|NCT04443881|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
214693153|NCT06728566|DEVICE|Inmersive virtual reality|"In addition to conventional training, IVR training aims to provide a detailed preview of the tasks and procedures required in the standard training with selected virtual scenarios:~Scenario 1: Inspection and Use of Personal Protective Equipment (PPE):~In this scenario, the worker will inspect the equipment to ensure it is in good condition and properly used: Harness, Helmet, Lanyards, Carabiners, Lifelines, Energy Absorbers~Scenario 2: Working on an Elevated Metal Structure:~Structure Ascent: Ascent Method: Use specific ascent systems, ensuring you are always connected to an anchor point.~Positioning on the Structure: Secure Anchorage: Once the working position is reached, secure the anchor to a fixed and reliable point.~Structure Descent: Unanchoring and Reanchoring: Unanchor and re-anchor at secure points as you descend.~Additional Safety Measures: Weather Conditions, signage and delimitation:~Scenario 3: Rescue at Heights: Accessing the Person in Danger, rescue Techniques."
214520565|NCT04528875|DEVICE|Ultrasound imaging|Imaging of low back with ultrasound
214520566|NCT05983991|OTHER|Biological samples (blood and bone marrow samples).|For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
214520567|NCT06415695|BEHAVIORAL|Education sessions|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
214520568|NCT06559098|DEVICE|Vibrotactile coordinated reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
214520569|NCT06563310|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
214693154|NCT06728566|OTHER|Conventional training|"The working at heights training provided by the National Learning Service (SENA) in Colombia includes key steps to ensure safety and proper equipment use:~* Harness Use: Inspect for damage, wear it like a vest, and ensure correct orientation. Adjust shoulder and leg straps for comfort and secure the chest strap.~* Final Check: Verify D-rings are correctly positioned, and all buckles are securely fastened.~* Helmet: Inspect for damage and adjust for a secure fit.~* Lanyards: Select in good condition, connect properly, keep tension, and avoid overloading.~* Carabiners: Use certified carabiners with functioning locks, connected to proper points.~* Lifelines and Energy Absorbers: Install and tension lifelines properly; check energy absorbers before use.~* Climbing/Descending: Maintain three contact points and secure tools to avoid accidents."
215119613|NCT02537249|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
214443141|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
214443142|NCT00214695|DRUG|Experimental Peritoneal Dialysis Solution|
214443143|NCT02152137|DRUG|efatutazone|Given PO
214443144|NCT02152137|DRUG|paclitaxel|Given IV
214443145|NCT04422652|DRUG|Bupropion|Bupropion is an anti-depressant medication.
214443146|NCT04422652|BEHAVIORAL|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
214443147|NCT04422652|DRUG|Placebo|Double-blind placebo.
214443148|NCT04422652|OTHER|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
215119614|NCT02537249|DRUG|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
215119615|NCT00000526|DRUG|encainide|
215119616|NCT00000526|DRUG|flecainide|
214443149|NCT06434714|DEVICE|Auricular percutaneous nerve field stimulator|Percutaneous nerve field stimulator device placed on the ear for 5 days
214443150|NCT06434714|DEVICE|Sham auricular percutaneous nerve field stimulator|Non-functioning percutaneous nerve field stimulator device placed on the ear for 5 days
215119617|NCT00000526|DRUG|moricizine|
215119618|NCT01165541|DRUG|Mirtazapine|mirtazapine (7.5-45mg)
215119619|NCT01165541|DRUG|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
215119620|NCT06217107|BEHAVIORAL|Micro-learning content|This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
215119621|NCT06217107|BEHAVIORAL|Health360x app|The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
215119622|NCT06217107|BEHAVIORAL|Culturally congruent coaching|The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
214443151|NCT05834660|BEHAVIORAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
214443152|NCT05510232|DEVICE|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
214443153|NCT05510232|DEVICE|A treatment group that will have headset on and will watch a non-VR video|"Oculus headset will deliver VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-14. The selected videos will be the same for both the cast and suture/pin removal groups."
214520570|NCT06563310|OTHER|fMRI with Sham-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
214520571|NCT06969612|DRUG|Tislelizumab|200 mg, intravenously on Day 1, every 3 weeks
214520572|NCT06969612|DRUG|Pemetrexed|administered via IV infusion
214520573|NCT06969612|DRUG|Cisplatin|administered via IV infusion
214520574|NCT06969612|DRUG|Carboplatin|administered via IV infusion
214520575|NCT06969612|DRUG|Paclitaxel|administered via IV infusion
214520576|NCT06969612|DRUG|Albumin Paclitaxel|administered via IV infusion
214520577|NCT06969612|DRUG|Golidocitinib|75mg, once a day orally
214520578|NCT02924051|BEHAVIORAL|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
214520579|NCT02924051|BEHAVIORAL|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
214520580|NCT05786911|OTHER|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
215119623|NCT05851196|OTHER|Proprioceptive training|A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
215119624|NCT02289664|DEVICE|MAC|Direct-Laryngoscopy
215119625|NCT02289664|DEVICE|Coopdech|Video-Laryngoscopy -1
215119626|NCT02289664|DEVICE|CoPilot|Video-Laryngoscopy -2
214520581|NCT00828178|DRUG|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
214520582|NCT00828178|DEVICE|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
214520583|NCT00828178|OTHER|corn starch|3 capsules qd for 12weeks
214520584|NCT03967197|DRUG|Saline spray|Physiologic saline spray
214520585|NCT03967197|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
214520586|NCT03234010|OTHER|FT21092|An electronic cigarette
214520587|NCT03234010|OTHER|FT21093|An electronic cigarette
214520588|NCT03234010|OTHER|FT21096|An electronic cigarette
214520589|NCT03234010|OTHER|FT21097|An electronic cigarette
215119627|NCT02289664|DEVICE|Intubrite|Video-Laryngoscopy -3
215119628|NCT05413668|DRUG|RVP-001|Intravenous administration of RVP-001
215119629|NCT05413668|DRUG|Placebo|Intravenous administration of saline placebo
215119630|NCT05404087|DEVICE|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
215119631|NCT04072913|OTHER|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
215119632|NCT00138593|DRUG|vildagliptin|
215119633|NCT00130858|DRUG|Topotecan|
214520590|NCT06153706|DRUG|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
215119634|NCT00130858|DRUG|Carboplatin|
215119635|NCT03498950|OTHER|laser therapy|laser irradiation on the taste papillae
215119636|NCT03705052|OTHER|Questionnaire|Patients and caregivers were asked to complete a questionnaire
215119637|NCT04706949|DRUG|Pyrotinib combined with pemetrexed plus carboplatin|"1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min."
215119638|NCT03512834|DRUG|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
215119639|NCT03512834|DRUG|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
215119640|NCT02745171|OTHER|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
215119641|NCT03912012|DRUG|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
215119642|NCT03912012|DEVICE|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
215119643|NCT03912012|DEVICE|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
215119644|NCT03912012|BIOLOGICAL|Blood sampling|37 mL of blood sample will be performed at Day 1
215119645|NCT03912012|BIOLOGICAL|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
215119646|NCT03912012|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
215119647|NCT03912012|RADIATION|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
215119648|NCT02095470|DEVICE|video laryngoscope|newly developed innovatory device
215119649|NCT02095470|DEVICE|traditional laryngoscope|traditional way for intubation
215119650|NCT06421584|DEVICE|Surgical telementoring|The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
215119651|NCT03787550|DRUG|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
215119652|NCT05356832|DIAGNOSTIC_TEST|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
215119653|NCT05292716|DEVICE|MitraClip|MitraClip
215119654|NCT02152176|DEVICE|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
215119655|NCT04637737|DEVICE|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
215119656|NCT04637737|BEHAVIORAL|Conventional therapy|The control group received the usual gait training.
214520591|NCT06153706|OTHER|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
215119657|NCT06263894|OTHER|Experimental group|Alexander technique will be applied to the experimental group.
215119658|NCT06091150|PROCEDURE|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
215119659|NCT02598440|DRUG|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
215119660|NCT02598440|DRUG|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
215119661|NCT01588561|DRUG|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
215119662|NCT01588561|OTHER|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
215119663|NCT04837573|BEHAVIORAL|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
214693155|NCT06889025|OTHER|Experimental: tASC/CBTp: gamma band electric stimulation for 20 minutes at the beginning of the CBTp session|For the transcranial stimulation we will use the tES device from NeuroMyst,. The gamma pulses are delivered to a study participant via stimulating electrodes positioned at participant's head according to the required technique. The tACS will be applied the first 20 minutes from the classic CBTp session for the experimental group.
214693156|NCT06889025|OTHER|Sham Comparator|For the Sham group the investigators will use the same tES device from NeuroMyst. The Sham stimulation will be applied only for a few seconds in Sham group. The CBTp will follow the same protocol for both arms.
214693157|NCT04614545|DRUG|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
214693158|NCT04614545|BEHAVIORAL|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
214693159|NCT04614545|BEHAVIORAL|Exercise program|Patients will be provided with a personalized exercise program
214693160|NCT01454401|DEVICE|LeucoPatch treatment|weekly
214693161|NCT07044362|DEVICE|HistoSonics Edison® System|Histotripsy is a novel, totally non-invasive, non-ionizing, and non-thermal ablation technique that mechanically disrupts tumors through precisely controlled acoustic cavitation. Histotripsy is administered via HistoSonics Edison® System.
214693162|NCT07044362|DRUG|Chemotherapy|Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).
214693163|NCT06734702|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.
215119664|NCT05318404|DIETARY_SUPPLEMENT|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
214443154|NCT05510232|DEVICE|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Oculus headset will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities.
214520592|NCT05307302|DIAGNOSTIC_TEST|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
214520593|NCT05307302|DIAGNOSTIC_TEST|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
214520594|NCT05307302|DIAGNOSTIC_TEST|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
214693164|NCT06734702|RADIATION|Hypo-RT and concurrent chemotherapy|Definitive dose of hypofractionated thoracic radiotherapy with concurrent chemotherapy
214693165|NCT06734702|RADIATION|CFRT and concurrent chemotherapy|Definitive dose of conventionally fractionated thoracic radiotherapy with concurrent chemotherapy
214693166|NCT06734702|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
214693167|NCT06891781|DEVICE|Deep Brain Stimulation|AlphaDBS System
214693168|NCT04183842|DIETARY_SUPPLEMENT|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6)."
215119665|NCT01634776|DIETARY_SUPPLEMENT|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
215119666|NCT01634776|DIETARY_SUPPLEMENT|corn oil|
215119667|NCT01818596|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
215119668|NCT04197349|BIOLOGICAL|ALD1910|Single Dose IV infusion
215119669|NCT04197349|BIOLOGICAL|Sumatriptan|Single dose subcutaneous injection
215119670|NCT04197349|BIOLOGICAL|ALD1910|Single dose subcutaneous injection
215119671|NCT01366482|DEVICE|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
215119672|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
215119673|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
215119674|NCT02050009|DRUG|metformin hydrochloride|Given PO
214443155|NCT02721381|BEHAVIORAL|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
214443156|NCT05708911|DEVICE|Pharyngeal exerciser|Pharyngo-esophageal manometry during lateral fluoroscopy
214443157|NCT03854903|DRUG|Palbociclib|Palbociclib is taken orally.
214520595|NCT05307302|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
214520596|NCT05307302|DIAGNOSTIC_TEST|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
215119675|NCT02050009|DRUG|carboplatin|Given IV
215119676|NCT02050009|DRUG|paclitaxel|Given IV
215119677|NCT02050009|OTHER|laboratory biomarker analysis|Correlative studies
215119678|NCT03801174|BEHAVIORAL|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
215119679|NCT03801174|BEHAVIORAL|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
214520597|NCT01596777|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
214520598|NCT01596777|DRUG|Loperamide placebo|200 ml apple juice
215119680|NCT00268840|DRUG|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
214520599|NCT01596777|DRUG|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
214520600|NCT01596777|DRUG|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
214520601|NCT01596777|DRUG|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
214520602|NCT01596777|DRUG|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
214520603|NCT01596777|DEVICE|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
215119681|NCT00268840|DRUG|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
215119682|NCT01740414|DRUG|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
214443158|NCT03854903|DRUG|Bosutinib|Bosutinib is taken orally.
214443159|NCT03854903|DRUG|Fulvestrant|Fulvestrant is given as an intramuscular injection.
214443160|NCT05243836|DEVICE|S.T.O.P® F2|Ocufilcon D, 55% water
214443161|NCT05243836|DEVICE|S.T.O.P® DT|Ocufilcon D, 55% water
214443162|NCT05243836|DEVICE|MiSight®|Omafilcon A (60% water)
214443163|NCT04231708|DRUG|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
214520604|NCT01596777|DRUG|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
214520605|NCT05642663|DEVICE|Stapler|Stapling performed with ALTUS Powered Stapler
214520606|NCT03819647|DRUG|stiripentol (Diacomit)|Administration of stiripentol per os
215119683|NCT01740414|DRUG|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
215119684|NCT01337336|DRUG|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
215119685|NCT01337336|DRUG|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
215119686|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
214443164|NCT04231708|DEVICE|Active rTMS|10Hz rTMS over the left dlPFC
214443165|NCT04231708|DRUG|Placebo|lactose (inside capsule)
214443166|NCT04231708|DEVICE|Sham rTMS|inactive stimulation over the left dlPFC
214693169|NCT04183842|OTHER|Placebo|"Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~\- Carrot juice"
214443168|NCT03600155|BIOLOGICAL|Ipilimumab|Given IV
214443169|NCT03600155|BIOLOGICAL|Nivolumab|Given IV
214443170|NCT06594419|BEHAVIORAL|Healthy Mother Healthy Baby Toolkit|Customized bowl with markings to indicate the recommended amount of food that participants should consume in pregnancy and while exclusively breastfeeding in the first 6 months, as well as how much they should feed their babies at 6-8 months, 9-12 months, and 1-2 years respectively. The toolkit also includes a spoon used to test and ensure adequate thickness of the meals fed to infants \>6mos and a counseling card that indicates the frequency of meals, recommended food groups for meeting daily nutrient needs, and hand hygiene and hygienic food preparation
214443171|NCT06594419|OTHER|Standard of care|The Ethiopian government and Saving Little Lives Initiative (SLL) standard of care includes maternal and infant nutrition education and counseling, iron and folic acid supplementation, as well as training on effective Kangaroo Mother Care (KMC), primarily defined as exclusive breastfeeding and skin-to-skin contact ≥ 8 hours per day-in the event of Low birth weight (LBW) or preterm delivery.
214443172|NCT06545123|BEHAVIORAL|Concurrent exercise training|The experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists
214520607|NCT04430153|OTHER|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
214520608|NCT00176319|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
214520609|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
214443173|NCT04337372|BEHAVIORAL|Effects of shared book reading: Labels|Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
214520610|NCT00003088|DRUG|cyclophosphamide|given IV
214520611|NCT00003088|DRUG|doxorubicin hydrochloride|given IV
214520612|NCT00003088|DRUG|paclitaxel|given IV
214520613|NCT02944981|DRUG|Gabapentin|Single oral dose
214693170|NCT04980846|OTHER|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
215119687|NCT03954067|BIOLOGICAL|ASP9801|Administered by intratumoral injection
214443174|NCT05394662|DEVICE|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
214443175|NCT06039267|OTHER|Gut Microbiome Testing|Stool microbiome testing using shotgun metagenomic sequencing
214443176|NCT06051305|BEHAVIORAL|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
214443177|NCT05461781|PROCEDURE|distal radial access|primary percutaneous coronary intervention via distal radial access
214520614|NCT02944981|DRUG|Placebo|Single oral dose
214520615|NCT02356874|BEHAVIORAL|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
215119688|NCT03954067|COMBINATION_PRODUCT|Pembrolizumab|Administered by Intravenous Infusion
215119689|NCT05694039|DEVICE|Hearing Aids|The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
215119690|NCT05817565|DEVICE|Ultrasound (Phyaction 190 I); with a frequency of 3 MHz was used|Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position.
215119691|NCT01939847|OTHER|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
215119692|NCT00673582|DRUG|Rosuvastatin|10 mg/day rosuvastatin
215119693|NCT00673582|DRUG|Placebo|Placebo, 10 mg a day for 96 weeks
215119694|NCT02915263|DRUG|IGIV-C|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
215119695|NCT02915263|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
214443178|NCT05461781|PROCEDURE|conventional transradial access|primary percutaneous coronary intervention via conventional transradial access
214443179|NCT04240756|BEHAVIORAL|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
214443180|NCT04240756|DRUG|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
214443181|NCT05808504|OTHER|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
214443182|NCT05808504|OTHER|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
215119696|NCT02289313|BEHAVIORAL|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
214443183|NCT05808504|OTHER|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
214520616|NCT05811338|BEHAVIORAL|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
214520617|NCT05811338|BEHAVIORAL|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
214520618|NCT05811338|BEHAVIORAL|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
214520619|NCT04453982|OTHER|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
214520620|NCT01434732|PROCEDURE|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
214520621|NCT01434732|PROCEDURE|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
214520622|NCT03005106|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
214520623|NCT03005106|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
214520624|NCT02342652|DRUG|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
214520625|NCT02342652|DRUG|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
214520626|NCT04594525|OTHER|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
214520627|NCT01837368|OTHER|observational research|It is a observational research, no intervention are performed
214520628|NCT05716425|DRUG|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
215119697|NCT01403493|BEHAVIORAL|Patient education|
215119698|NCT01310764|PROCEDURE|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
214443184|NCT05808504|PROCEDURE|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
214443185|NCT05808504|PROCEDURE|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
214520629|NCT05716425|DRUG|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
214520630|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
214693171|NCT05167500|DRUG|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
214693172|NCT05431140|DEVICE|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
214693173|NCT07053670|DRUG|CAR T cells|chimeric antigen receptor T cells
214693174|NCT07054060|PROCEDURE|carotid endarterectomy|Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke due to carotid artery stenosis. During an endarterectomy, the surgeon opens the artery and removes the plaque.
214520631|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
214693175|NCT07054060|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an endovascular procedure in which a stent is deployed in the lumen of the carotid artery to treat narrowing of the carotid artery and reduce the risk of stroke.
214693176|NCT07060300|OTHER|Agree to Pharmacogenetic Testing|Caregivers agree to receive pharmacogenetic testing for their child.
214693177|NCT00544128|DRUG|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
214520632|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
214693178|NCT00544128|DRUG|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
214693179|NCT04748783|OTHER|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
214693180|NCT04748783|OTHER|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
214693181|NCT04748783|DRUG|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
214693182|NCT04748783|OTHER|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
215119699|NCT03986203|DEVICE|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
215119700|NCT05184517|DRUG|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
215119701|NCT05184517|DRUG|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
215119702|NCT01295593|DRUG|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
215119703|NCT00671489|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
215119704|NCT02309008|DRUG|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
214693183|NCT05800444|DRUG|BAY3283142|Oral administration as tablet.
215119705|NCT02309008|OTHER|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
215119706|NCT03962179|DEVICE|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
214520633|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
214520634|NCT03163472|PROCEDURE|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
214520635|NCT03163472|PROCEDURE|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
214520636|NCT03288688|OTHER|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
214520637|NCT06509295|OTHER|Calcium Hypochlorite as Root Canal Irrigant|Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
214520638|NCT01691404|DIETARY_SUPPLEMENT|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
214443186|NCT05307783|DEVICE|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
214443187|NCT04883645|DRUG|Imiquimod 5% Cream|Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
214520639|NCT01691404|DIETARY_SUPPLEMENT|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
214520640|NCT01691404|DIETARY_SUPPLEMENT|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
214520641|NCT01636726|DRUG|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
214520642|NCT03310255|DIAGNOSTIC_TEST|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
214520643|NCT00488267|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
214520644|NCT00488267|DRUG|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
214520645|NCT00488267|DRUG|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
214520646|NCT05836844|DEVICE|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
214520647|NCT00512902|DRUG|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
214520648|NCT00512902|DRUG|Imatinib|Up to 600 mg QD PO for up to 1 year.
214520649|NCT00246350|PROCEDURE|massage|8 light massage treatments and hot pack
214520650|NCT00246350|PROCEDURE|massage|16 light massage treatments and hot packs
214520651|NCT00246350|PROCEDURE|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
214520652|NCT00246350|PROCEDURE|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
214520653|NCT04847180|PROCEDURE|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
214520654|NCT01829594|OTHER|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
214520655|NCT04780152|DEVICE|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
214520656|NCT04780152|DEVICE|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
214520657|NCT04780152|DRUG|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
214520658|NCT01540305|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
214520659|NCT01540305|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
214693184|NCT05800444|OTHER|Placebo|Oral administration as tablet.
214693185|NCT00521092|DRUG|sunitinib malate|Given orally
214693186|NCT00521092|PROCEDURE|laboratory biomarker analysis|Correlative study
214693187|NCT00521092|PROCEDURE|pharmacological study|Correlative study
214693188|NCT05468944|PROCEDURE|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
214693189|NCT05468944|PROCEDURE|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
215119707|NCT02602522|DRUG|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
215119708|NCT02602522|DRUG|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
215119709|NCT06097663|DRUG|MAS825|Active MAS825 single dose
215119710|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
215119711|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
215119712|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
214443188|NCT06522022|BEHAVIORAL|Culturally Responsive SBIRT for OB|"SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools"
214443189|NCT06522022|BEHAVIORAL|Brief Screening for PTSD|This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
214443190|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
214443191|NCT05847543|OTHER|Stool diaper data and sample collection|Stool diaper data and sample collection
214443192|NCT06005662|DRUG|Psilocybin|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
214443193|NCT05240807|DIAGNOSTIC_TEST|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
214443194|NCT04536116|DEVICE|Virtual Reality headset|MRI simulation with a Virtual Reality headset
214443195|NCT00979576|DRUG|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2
214443196|NCT00979576|DRUG|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
214443197|NCT00979576|DRUG|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
214443198|NCT00979576|DRUG|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
214520660|NCT06656663|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
214520661|NCT06656663|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
214520662|NCT05347849|DRUG|BPL-003|A single dose of BPL-003 will be administered intranasally
214520663|NCT05347849|OTHER|Placebo|A single dose of placebo will be administered intranasally
214520664|NCT05172648|OTHER|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
214520665|NCT05172648|OTHER|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
214520666|NCT00635609|DRUG|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
214443199|NCT00979576|DRUG|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
214443200|NCT06182371|BEHAVIORAL|Disengage the breathing circuit|Disengage the breathing circuit when the position of the patient undergoing thoracic surgery changes
214443201|NCT05175352|DRUG|Cendakimab|Specified dose on specified days
214443202|NCT05175352|DRUG|CYP substrates|Specified dose on specified days
214443203|NCT05601219|DRUG|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
214443204|NCT05601219|DRUG|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
214520667|NCT00635609|DRUG|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
214520668|NCT02646098|PROCEDURE|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
214520669|NCT01795313|BIOLOGICAL|HLA-A2 restricted synthetic tumor antigen|
214520670|NCT01795313|DRUG|Imiquimod|
214520671|NCT01795313|OTHER|enzyme-linked immunosorbent assay|
214520672|NCT01795313|OTHER|flow cytometry|
214520673|NCT01795313|OTHER|immunohistochemistry staining method|
214520674|NCT01795313|OTHER|laboratory biomarker analysis|
214520675|NCT01754389|DRUG|Tacrolimus|
214520676|NCT01754389|DRUG|Methotrexate|
214520677|NCT01754389|DRUG|Bortezomib|
214520678|NCT01754389|DRUG|Sirolimus|
214443205|NCT05662787|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
215119713|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration|After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
215119714|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration|After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
214520679|NCT01730118|BIOLOGICAL|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
215119715|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
215119716|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
215119717|NCT01474941|DRUG|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
215119718|NCT01879683|DRUG|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
215119719|NCT00238979|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
215119720|NCT01618669|DRUG|Regadenoson|Administered as an intravenous (IV) bolus
215119721|NCT01618669|PROCEDURE|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
215119722|NCT02577692|OTHER|Oxygen|breathing oxygen
215119723|NCT02577692|OTHER|Ambient|breathing ambient air
215119724|NCT05711134|BEHAVIORAL|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
215119725|NCT03896321|DRUG|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
215119726|NCT03896321|DRUG|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
215119727|NCT05617144|OTHER|Aromatherapy treatment|60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
214443206|NCT05687903|DRUG|TAK-861|TAK-861 oral tablets
215119728|NCT02241148|DRUG|Acetaminophen 500mg|500 mg, tablets every 8 hours
215119729|NCT02241148|DEVICE|Kinesio taping|Taping will be changed every week.
215119730|NCT04226508|OTHER|Physical exercise|"The patients can choose between three modality of EX:~1. Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~2. Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~3. Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
215119731|NCT05802043|BEHAVIORAL|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
215119732|NCT01951560|DRUG|Valproic Acid|By infusion over 1 hour
215119733|NCT01951560|DRUG|Isotonic saline solution|By infusion over 1 hour
214443207|NCT05687903|DRUG|Placebo|Placebo oral tablets matching TAK-861
214443208|NCT06614907|DRUG|QL2108 injection|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
214443209|NCT06614907|DRUG|Dupixent®|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
214520680|NCT00924599|BEHAVIORAL|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
214520681|NCT00924599|BEHAVIORAL|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
215119734|NCT05010980|OTHER|CMR|clinical indication
215119735|NCT05010980|OTHER|scintigraphy|clinical indication
215119736|NCT02518386|OTHER|No intervention|No intervention is planned
215119737|NCT00226486|OTHER|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
215119738|NCT00226486|OTHER|Usual care|No intervention, but ususal care after an accidental fall.
215119739|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
214443210|NCT06424132|OTHER|Cold Vest Exposure Period|A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.
214443211|NCT06424132|OTHER|Rewarming Exposure Period|Following cold exposure, the cold vests will be removed, and participants will be offered a warm blanket to ease the transition from cold back to warm temperatures. Participants will then be moved to an adjacent warm room maintained at 30 degrees celsius and asked to return to the resting position of their choice. Participants will then engage in reading and/or digital entertainment for a 3-hour warm exposure period.
214520682|NCT03707418|DRUG|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
214520683|NCT03707418|DRUG|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
215119740|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
215119741|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
215119742|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
215119743|NCT04914026|OTHER|Biomarker analysis|Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
215119744|NCT02186613|BEHAVIORAL|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
215119745|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 1 tablet of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
215119746|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 2 tablets of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
214443212|NCT06424132|OTHER|Fasting|Participants will be requested to refrain from food and caloric drinks for 12 hours (starting at 8pm) prior to the study visit. Blood will then be drawn the following morning (between 8 and 9am) 30mins later following a breakfast meal (9:30am- 10am). Participants will be housed in a room with ambient temperature at 25 degrees celsius between the two blood draws.
214443213|NCT04855760|DRUG|REL-1017|REL-1017 tablet
214520684|NCT05545319|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
214520685|NCT05545319|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
214520686|NCT05545319|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
214520687|NCT00816621|BEHAVIORAL|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
214520688|NCT00816621|BEHAVIORAL|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
215119747|NCT01954641|OTHER|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
215119748|NCT01954641|OTHER|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
215119749|NCT01680666|PROCEDURE|central line placement|central line placement
215119750|NCT01680666|DEVICE|Ultrasound|Ultrasound guided central venous access
215119751|NCT02179411|OTHER|tilt test|
215119752|NCT00003619|BIOLOGICAL|filgrastim|
215119753|NCT00003619|DIETARY_SUPPLEMENT|vitamin E|
215119754|NCT00003619|DRUG|busulfan|
215119755|NCT00003619|DRUG|cytarabine|
215119756|NCT00003619|DRUG|etoposide|
215119757|NCT00003619|DRUG|fludarabine phosphate|
215119758|NCT00003619|DRUG|isotretinoin|
215119759|NCT00003619|DRUG|topotecan hydrochloride|
215119760|NCT00003619|PROCEDURE|bone marrow ablation with stem cell support|
215119761|NCT00003619|PROCEDURE|peripheral blood stem cell transplantation|
215119762|NCT03259087|DRUG|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
215119763|NCT04351217|BEHAVIORAL|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
215119764|NCT04351217|BEHAVIORAL|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
215119765|NCT00356044|PROCEDURE|Coronary angioplasty|
214443214|NCT05613205|BIOLOGICAL|TYP04A Low Dose without Alum investigational vaccine|2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
214443215|NCT05613205|BIOLOGICAL|TYP04B Full Dose without Alum investigational vaccine|2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
214443216|NCT05613205|BIOLOGICAL|TYP03A Low Dose with Alum investigational vaccine|2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
214443217|NCT05613205|BIOLOGICAL|TYP03B Full Dose with Alum investigational vaccine|2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
214520689|NCT04163185|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
215119766|NCT04333368|BIOLOGICAL|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
215119767|NCT04333368|OTHER|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
215119768|NCT05066386|OTHER|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
215119769|NCT04043559|OTHER|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
215119770|NCT04043559|OTHER|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
215119771|NCT04950465|OTHER|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste containing 0.454% SnF2.
214443218|NCT05613205|BIOLOGICAL|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
215119772|NCT04950465|OTHER|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.
215119773|NCT04950465|OTHER|Sensodyne Repair and Protect|Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
215119774|NCT00006252|DRUG|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
214443219|NCT05613205|BIOLOGICAL|GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
214443220|NCT05159791|DIAGNOSTIC_TEST|Invasive coronary blood flow assessment and simulations and fluid dynamic patient specific simulation|The coronary blood flow and its distribution between the anomalous and normal artery will be measured by invasive coronary catheterization. Coronary artery flow will be calculated based on intravascular ultrasound (IVUS) and pressure difference measurements. After the IVUS assessment, a pressure transducer (FFR/iFR probe) will be inserted in the coronary artery for pressure measurements. The measurements will be done in the anomalous and normal coronary arteries in each patient to determine coronary flow distribution. Patient's specific heart parameters will be retrieve from CT, MRI and other diagnostic tests and integrated in the simulation module.
214520690|NCT04163185|DRUG|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
214520691|NCT03323983|OTHER|data collection|data collection
214520692|NCT03154827|DRUG|BL-8040|Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
214520693|NCT03154827|DRUG|Atezolizumab|Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
214520694|NCT04208542|DRUG|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
215119775|NCT00006252|DRUG|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
215119776|NCT00006252|BIOLOGICAL|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
215119777|NCT00006252|DRUG|G-CSF|5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5
215119778|NCT00006252|BIOLOGICAL|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
215119779|NCT03263273|DRUG|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
215119780|NCT03263273|DRUG|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
215119781|NCT03263273|OTHER|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
215119782|NCT05277376|DRUG|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
215119783|NCT03820882|DEVICE|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
215119784|NCT03820882|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
214443221|NCT06126913|OTHER|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
214443222|NCT01689935|DRUG|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
214443223|NCT01689935|DEVICE|Red light only|Red Light therapy
214443224|NCT01689935|DEVICE|Blue light only|Blue light only
214520695|NCT04212897|OTHER|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
214520696|NCT05624086|BEHAVIORAL|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
214520697|NCT00489489|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
215119785|NCT03356275|BEHAVIORAL|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
215119786|NCT00483691|BEHAVIORAL|Home Visit|Homw visits scheduled weekly for one year.
215119787|NCT01854970|DRUG|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
214443225|NCT05335421|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
214443226|NCT06267183|DRUG|SV001|SV001 ： single-dose
214443227|NCT06267183|DRUG|Placebo|Placebo ： single-dose
214443228|NCT04537247|PROCEDURE|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
214443229|NCT04036188|DRUG|Triamcinolone|Triamcinolone 0.1% daily
214443230|NCT04036188|DIETARY_SUPPLEMENT|Vitamin D3|40,000 IU Vitamin D3 daily
214443231|NCT04036188|DRUG|Placebo|Placebo daily
214443232|NCT04990349|DRUG|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
214443233|NCT05470205|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
214443234|NCT05470205|DRUG|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
214443235|NCT06409754|DEVICE|Functional Electrical Stimulation Therapy coupled to a P-300 based Brain-Computer Interface|The intervention involves a BCI control strategy based on a modified version of the classic P300 Donchin Speller Interface, where the matrix of letters and symbols is replaced by a set of pictures including five hand gestures and wrist orientations: hand opening, grasping, pinching, pronation, and supination. This BCI approach is based on the oddball paradigm, relying on conscious recognition by the user of the intensification of a particular target movement picture, within a sequence of other, non-target, random visual stimuli. This process should evoke the P300 component in the event related potential. The aim of the training sessions is to link an action observation/target selection task, mediated by the P300-based BCI, with the practice of a FES-assisted functional task involving the target movement picture selected. Users will be instructed to synchronize their voluntary movements with the ones induced by FES, to achieve the functional target goal.
214520698|NCT00489489|DRUG|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
214520699|NCT00489489|DRUG|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
214520700|NCT06091982|PROCEDURE|Renal Replacement Therapy (RRT)|Renal Support therapy which consist of procedure of intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration/hemodialysis/hemodiafiltration (CVVH/CVVHD/CVVHDF)
214520701|NCT03859700|BIOLOGICAL|DBV712 250 mcg|DBV712 250 mcg, once daily
214520702|NCT04553029|OTHER|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
214520703|NCT03698305|DRUG|ASP5354|Intravenous
214520704|NCT03698305|DRUG|Placebo|Intravenous
214520705|NCT04309006|PROCEDURE|CTG and customized healing abutment|screw- retained customized healing abutment
215119788|NCT00207311|DRUG|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
215119789|NCT00207311|BEHAVIORAL|Xenicare Program|Xenicare program for 36 weeks.
215119790|NCT02134860|OTHER|Bed rest|8 days of full bed rest
214443236|NCT06409754|OTHER|Conventional Physical Therapy|Conventional physical and occupational therapy will include sessions of joint mobility, muscle strength, task-specific training, sensitivity reeducation and coordination exercises directed by an experienced professional therapist.
214443237|NCT05195970|OTHER|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
214443238|NCT05794763|BEHAVIORAL|Peer Led Group Intervention|A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
214443239|NCT04869982|BIOLOGICAL|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
215119791|NCT02134860|OTHER|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
214443240|NCT04869982|DRUG|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
214443241|NCT05569967|OTHER|Spinal stabilization training through telerehabilitation|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
214443242|NCT05569967|OTHER|Spinal stabilization training face-to-face|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
214443243|NCT00152698|DRUG|Irbesartan|
214443244|NCT02611505|DRUG|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
214443245|NCT05139316|GENETIC|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
214443246|NCT05139316|OTHER|Placebo|Normal Saline infusion
214443247|NCT05139316|DRUG|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
214443248|NCT05139316|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
214443249|NCT05004610|DRUG|Sodium Lactate Solution|continuous intravenous infusion of molar sodium lactate
214443250|NCT03378739|PROCEDURE|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
214443251|NCT05348863|BEHAVIORAL|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
214443252|NCT05145452|DIETARY_SUPPLEMENT|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
214443253|NCT01558804|OTHER|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
214443254|NCT05931861|DEVICE|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
214520706|NCT04309006|PROCEDURE|CTG and conventional healing abutment|conventional healing abutment
214520707|NCT05583864|DEVICE|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
214520708|NCT05583864|DEVICE|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
214443255|NCT04112316|DRUG|Liothyronine|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
214520709|NCT04851587|BEHAVIORAL|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
214520710|NCT06010368|DRUG|Tranexamic acid injection|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
215119792|NCT02134860|OTHER|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
215119793|NCT02134860|OTHER|Cognitive testing|Daily testing of memory and concentration using standardized tests
215119794|NCT02134860|OTHER|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
215119795|NCT02134860|OTHER|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
215119796|NCT02134860|OTHER|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
215119797|NCT02072863|DRUG|Oprozomib|Study subjects will receive oprozomib administered orally.
215119798|NCT02072863|DRUG|Melphalan|Study subjects will receive melphalan 9 mg/m2.
215119799|NCT02072863|DRUG|Prednisone|Study subjects will receive prednisone 60 mg/m2.
214443256|NCT04112316|OTHER|Placebo|A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.
214443257|NCT05806814|BIOLOGICAL|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
214443258|NCT06476847|BEHAVIORAL|PrEP persistence|A light touch, once off, low cost. lay counsellor led intervention, designed to focus decision making around HIV prevention addressing present bias, salience and over optimism. The intervention package consists of evidence informed reminders, commitment pledges and planning prompts.
214443259|NCT02945072|PROCEDURE|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
214443260|NCT02945072|PROCEDURE|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
214443261|NCT05863546|OTHER|Traditional treatment|The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
214443262|NCT05863546|DEVICE|Therapeutic ultrasound|US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
214520711|NCT06010368|DRUG|Oxytocin|the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
214443263|NCT06261801|OTHER|Medication Group|Participants in the medication group would take 150-mg pregabalin capsules (manufactured by Pfizer Pharmaceuticals Co., Ltd) orally twice daily (total daily dose, 300 mg) for 4 weeks.
214520712|NCT04588246|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214520713|NCT04588246|PROCEDURE|Computed Tomography|Undergo CT
215119800|NCT05416866|PROCEDURE|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
215119801|NCT05416866|PROCEDURE|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
215119802|NCT05416866|PROCEDURE|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
214520714|NCT04588246|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214520715|NCT04588246|DRUG|Memantine|Given PO
215119803|NCT06271434|DIETARY_SUPPLEMENT|THYROX (Atlantic krill oil|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
215119804|NCT06271434|DIETARY_SUPPLEMENT|Placebo|The control capsules will be made of olive oil of equal size and color.
214443264|NCT06261801|OTHER|EA Group|Acupoints selection: Ashi acupoint, Sibai acupoint (ST2), Xiaguan acupoint (ST7), and Dicang acupoint (ST4) on the affected side. Acupoints for the diseased branches (all taken from the affected side): eye branch and Tongziliao point (GB1), the maxillary branch is taken from the Quanliao point (SI18), and the mandibular branch is taken from the Jiache point (ST6).Shenting point (DU24), Baihui point (DU20), Hegu point (LI4), Waiguan point (TE5), Yanglingquan point (GB34), and Taichong point (LR3) on the affected side Operation: The EA apparatus will be applied on the Ashi point and (LI4 - TE5). The treatment will last for 30 minutes and the electrical stimulation will be set as 2/100Hz in frequency.
214520716|NCT04588246|OTHER|Quality-of-Life Assessment|Ancillary studies
214520717|NCT04588246|OTHER|Questionnaire Administration|Ancillary studies
214520718|NCT04588246|RADIATION|Stereotactic Radiosurgery|Undergo SRS/fSRS
214520719|NCT04588246|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
214520720|NCT06721702|BEHAVIORAL|Motivational interviewing|Motivational interviews were administered as the intervention of the research. Motivational interviewing consists of two stages. In the first stage, the four principles of motivational interviewing (developing contradiction, showing empathy, supporting self-efficacy, and resolving resistance) are aimed at providing motivation in individuals. The second stage is strengthening the commitment to change.
214443265|NCT06261801|OTHER|EA+Medication Group|Participants in the EA+Medication group would receive both EA and medical treatement. The acupoints and their location, needles, the settings of the EA device are the same as EA Group's; in the meanwhile, the medication and its dosage is the same as Medication Group's.
214443266|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool|Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
214520721|NCT03697837|BEHAVIORAL|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
214520722|NCT01034683|DRUG|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
214520723|NCT04428983|DIETARY_SUPPLEMENT|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
215119805|NCT06021639|DIETARY_SUPPLEMENT|The last 24 hours will consume low fiber food.|White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
214443267|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT)|iCBT, as described above, using only the traditional, detailed therapist manual.
214443268|NCT05518903|PROCEDURE|Computed Tomography|Undergo CT
214443269|NCT05518903|DRUG|Gallium Ga 68 FAPi-46|Given IV
214520724|NCT04483791|COMBINATION_PRODUCT|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
214520725|NCT04701073|DEVICE|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
214443270|NCT05518903|PROCEDURE|Positron Emission Tomography|Undergo PET
214443271|NCT06539156|OTHER|DVT prophyllaxis|VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations
214443272|NCT04947553|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
214443273|NCT04947553|DRUG|Placebo|Placebo tablets, taken twice daily
214520726|NCT01764204|DRUG|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
214520727|NCT04568304|BIOLOGICAL|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
214520728|NCT04568304|DRUG|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
214520729|NCT04568304|DRUG|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
214520730|NCT04568304|DRUG|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
214520731|NCT05196256|PROCEDURE|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
215119806|NCT02172638|PROCEDURE|Fast-Track Protocol|
215119807|NCT02172638|PROCEDURE|Usual management|
214520732|NCT05196256|PROCEDURE|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
215119808|NCT00548600|PROCEDURE|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
215119809|NCT00548600|RADIATION|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
215119810|NCT00931931|BIOLOGICAL|HSV1716|
215119811|NCT02988778|DRUG|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
215119812|NCT02988778|DRUG|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
215119813|NCT01599000|DRUG|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
215119814|NCT01788566|DRUG|Necitumumab|Administered IV
215119815|NCT01788566|DRUG|Gemcitabine|Administered IV
215119816|NCT01788566|DRUG|Cisplatin|Administered IV
215119817|NCT03485066|BEHAVIORAL|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
215119818|NCT01544426|PROCEDURE|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
215119819|NCT01544426|PROCEDURE|Office hysteroscopy|Office hysteroscopy
215119820|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
215119821|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
215119822|NCT06281535|DEVICE|Implant loading|Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
215119823|NCT06332066|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
215119824|NCT01379183|DRUG|Erythromycin|200 mg suspension
215119825|NCT01379183|DRUG|Placebo|200 mg suspension
215119826|NCT01379183|PROCEDURE|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
215119827|NCT01379183|OTHER|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
214443274|NCT05891782|BEHAVIORAL|HAPA-based Multidomain Fall Risk Management|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 stages.~Stage 1: The main format will be group lectures and scenario simulation, each intervention will have a duration of 30 to 45 minutes. Intervention content will utilize BCT \[5.1, 5.3, 5.5, 5.6, 9.3, 15.1\] .~Stage 2: This stage will utilize mostly group lectures or one-to-one interviews, to provide an action and coping plan to participants for fall risk management. This will apply BCT \[1.1-1.4, 4.1\] at week 4.Firstly, individualized targets will be established. Secondly, professionals and participants will collaborate to develop an implementation plan.~Stage 3:Recovery self-efficacy will be implemented as group discussions, with each intervention lasting 15-30 minutes. Maintenance will be implemented in one-to-one interviews, with each intervention lasting 15-30 minutes.Finally, the consolidation and outlook will provide the foundation for the habit formation of healthy behaviors."
214520733|NCT05196256|PROCEDURE|Epidural analgesia|Epidural analgesia
215119828|NCT00329888|PROCEDURE|Endoscopic papillary balloon dilatation|
215119829|NCT00329888|PROCEDURE|Endoscopic sphincterotomy|
215119830|NCT05142605|BEHAVIORAL|Meaning-Centered Grief Therapy|Meaning-Centered Grief Therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in participants' life after participants' loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
215119831|NCT05142605|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy will help participants cope with participants' loss by giving them a place to express participants' feelings and providing participants with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
215119832|NCT05142605|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of participants' standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
215119833|NCT02591940|PROCEDURE|Surgery or Treatment by Heart Catheter|
215119834|NCT00259714|DRUG|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
215119835|NCT00259714|DRUG|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
215119836|NCT04726683|PROCEDURE|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
215119837|NCT04726683|PROCEDURE|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
215119838|NCT04726683|PROCEDURE|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
215119839|NCT04726683|PROCEDURE|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
215119840|NCT05973734|BIOLOGICAL|Infusion of recipient T regulatory cell|Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
215119841|NCT05973734|BIOLOGICAL|Infusion of concomitant Donor Derived Vertebral Bone Marrow|The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
215119842|NCT03116711|OTHER|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
214520734|NCT05196256|DRUG|Sufentanyl/Levobupivacaine|Epidural analgesia
214520735|NCT00437086|DRUG|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
215119843|NCT03116711|OTHER|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
215119844|NCT03116711|OTHER|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
215119845|NCT03116711|OTHER|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
214443275|NCT05891782|BEHAVIORAL|Regular health education lectures|Weeks 1-4 will be provided with fall-related regular health education lectures. Weeks 5-16 will have regular activities according to the daily arrangement of the nursing home. Meanwhile, telephone, WeChat, or face-to-face interviews will be conducted fortnightly, to understand the needs of the participants. During the process, staff will provide usual care such as vital signs monitoring, disease treatment, medication prescription, and health record maintenance.
215119846|NCT04416048|DRUG|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
215119847|NCT04416048|OTHER|Standard Of Care (SOC)|Standard of care treatment
214443276|NCT02338947|OTHER|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
214520736|NCT02101554|DRUG|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
215119848|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
215119849|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
215119850|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
215119851|NCT01620086|DEVICE|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
215119852|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
215119853|NCT00738335|DRUG|erlotinib hydrochloride|
215119854|NCT00738335|OTHER|immunoenzyme technique|
215119855|NCT00738335|OTHER|laboratory biomarker analysis|
215119856|NCT00738335|OTHER|liquid chromatography|
214520737|NCT02101554|DRUG|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
214520738|NCT00324363|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
215119857|NCT00738335|OTHER|mass spectrometry|
215119858|NCT00738335|OTHER|pharmacological study|
215119859|NCT00738335|RADIATION|stereotactic radiosurgery|
215119860|NCT00952458|DEVICE|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
215119861|NCT02633670|DEVICE|Hemopatch|
215119862|NCT02633670|DEVICE|No Hemopatch|
215119863|NCT01695135|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
215119864|NCT01695135|DRUG|Placebo|Placebo (4 tablets) taken orally once daily
215119865|NCT01695135|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
215119866|NCT02576223|DRUG|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
215119867|NCT02576223|DRUG|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
215119868|NCT02576223|DRUG|PCA-pump|"PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes."
215119869|NCT04664374|OTHER|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
215119870|NCT01488526|DRUG|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
214520739|NCT00324363|DRUG|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
214520740|NCT02236299|PROCEDURE|Right Coronary Artery Percutaneous Coronary Intervention|
214520741|NCT02236299|OTHER|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
214520742|NCT02236299|OTHER|GLP-1 Infusion|30 minute infusion GLP-1
214520743|NCT01350102|DRUG|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
214520744|NCT01350102|DRUG|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
214520745|NCT01350102|DIETARY_SUPPLEMENT|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
214520746|NCT00158886|DRUG|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
214520747|NCT00158886|RADIATION|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
215119871|NCT03067428|DIETARY_SUPPLEMENT|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
215119872|NCT03067428|DIETARY_SUPPLEMENT|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
215119873|NCT02696265|PROCEDURE|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
214443277|NCT02338947|OTHER|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
214443278|NCT05944809|DRUG|rhTPO|"Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)"
214443279|NCT05361447|DRUG|Diazepam|5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
214443280|NCT03857620|OTHER|Best Practice|Receive usual care
214443281|NCT03857620|OTHER|Informational Intervention|Receive OPTI-Surg program materials
214443282|NCT03857620|OTHER|Questionnaire Administration|Ancillary studies
215119874|NCT02696265|PROCEDURE|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
214443283|NCT03857620|OTHER|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
215119875|NCT03775798|DRUG|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
214443284|NCT02473250|DRUG|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
214443285|NCT02473250|DRUG|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
214443286|NCT04450797|DEVICE|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
214443287|NCT04450797|DEVICE|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
214443288|NCT06353178|BEHAVIORAL|Cancer Connect Program|Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.
214443289|NCT03054623|PROCEDURE|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
214443290|NCT05229900|DRUG|SGN-ALPV|Given into the vein (IV; intravenously)
214443291|NCT04172233|BIOLOGICAL|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
214443292|NCT04172233|BIOLOGICAL|placebo|matching placebo
214443293|NCT05748834|DRUG|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
214443294|NCT05748834|DRUG|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
215119876|NCT02166892|OTHER|Specially designed plates|
215119877|NCT01844453|PROCEDURE|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
215119878|NCT02562716|DRUG|Fluorouracil|Given IV
214443297|NCT05014087|DRUG|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
214443298|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
214443299|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
214443300|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
214443301|NCT02861430|PROCEDURE|Immunochemistry and molecular biology on sentinel lymph node specimen|
214443302|NCT04798651|BIOLOGICAL|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
215119879|NCT02562716|DRUG|Gemcitabine Hydrochloride|Given IV
215119880|NCT02562716|DRUG|Irinotecan Hydrochloride|Given IV
214520748|NCT03624023|DRUG|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
214520749|NCT00003934|DRUG|tretinoin|Given orally
214520750|NCT00003934|DRUG|daunorubicin hydrochloride|Given IV
215119881|NCT02562716|DRUG|Oxaliplatin|Given IV
215119882|NCT02562716|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
215119883|NCT02562716|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
215119884|NCT00684996|DRUG|etaracizumab|Given IV
215119885|NCT00684996|BIOLOGICAL|bevacizumab|Given IV
215119886|NCT04064658|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
214443303|NCT04798651|BIOLOGICAL|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
214443304|NCT03059069|DRUG|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
214443305|NCT03059069|DRUG|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
214443306|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
214443307|NCT04246151|DRUG|Vancomycin|Vancomycin capsules
214443308|NCT04246151|DIETARY_SUPPLEMENT|Culturelle|Culturelle capsules
214443309|NCT04246151|DRUG|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
214443310|NCT04246151|DRUG|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
214443311|NCT06426706|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Before the induction of general anesthesia, under aseptic conditions, serratus posterior superior intercostal plane block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
214520751|NCT00003934|DRUG|cytarabine|Given IV
214520752|NCT00003934|DRUG|mercaptopurine|Given IV
214520753|NCT00003934|DRUG|methotrexate|Given IV
214520754|NCT00003934|DRUG|arsenic trioxide|Given IV
214520755|NCT04061317|OTHER|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
214520756|NCT05465278|DRUG|Alirocumab|18 months treatment with alirocumab
215119887|NCT04064658|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
215119888|NCT04064658|PROCEDURE|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
215119889|NCT06217848|DRUG|Saxenda|Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide\_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
215119890|NCT01775371|DEVICE|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
215119891|NCT01775371|OTHER|Usual Care|Usual opioid analgesia determined by the provider
215119892|NCT00651339|DRUG|botox|botox injection
215119893|NCT03015168|RADIATION|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
215119894|NCT01145846|DRUG|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
215119895|NCT01166841|PROCEDURE|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
215119896|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
215119897|NCT06290596|DRUG|Vasopressin|Hemostatic drug.
215119898|NCT06290596|DRUG|Tranexamic acid|Hemostatic drug.
215119899|NCT06290596|OTHER|Saline|Placebo
214443312|NCT06426706|PROCEDURE|Paravertebral Block|Before the induction of general anesthesia, under aseptic conditions, paravertebral block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
215119900|NCT02385851|DRUG|CHS-1701|
215119901|NCT02385851|DRUG|Pegfilgrastim|
214443313|NCT06461858|OTHER|cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks
214443314|NCT06461858|OTHER|conventional therapy|Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
214443315|NCT05000073|OTHER|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
215119902|NCT04787107|DEVICE|Mechanical Chair Massage|Healthcare staff will be placed into either massage or break intervention
215119903|NCT02446184|PROCEDURE|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
215119904|NCT02446184|PROCEDURE|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
215119905|NCT02729220|OTHER|Bronchoscopy|Sampling of airways
215119906|NCT03090477|BEHAVIORAL|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
215119907|NCT01078441|DRUG|liposomal doxorubicin|Given IV
215119908|NCT01078441|DRUG|bortezomib|Given subcutaneously.
215119909|NCT01078441|DRUG|dexamethasone|Given orally
215119910|NCT01078441|DRUG|cyclophosphamide|Given IV
215119911|NCT01068522|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
215119912|NCT01068522|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
215119913|NCT01425801|DRUG|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
215119914|NCT01425801|DRUG|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
215119915|NCT01425801|DRUG|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
215119916|NCT01425801|DRUG|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
215119917|NCT01425801|DRUG|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
215119918|NCT01425801|DRUG|Salbutamol placebo|Pressurized inhalation, once-daily
215119919|NCT01425801|DRUG|LAS100977 placebo|Dry powder inhalation, once-daily
215119920|NCT02868554|DEVICE|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
215119921|NCT02868554|DEVICE|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
215119922|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Squamous NSCLC
215119923|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Non-Squamous NSCLC
215119924|NCT06434896|OTHER|ctDNA analysis after surgery|ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
215119925|NCT02553057|DEVICE|mechanical ventilation|
215119926|NCT02864693|DEVICE|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
215119927|NCT02864693|DEVICE|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
215119928|NCT03546946|BEHAVIORAL|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
215119929|NCT03546946|BEHAVIORAL|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
215119930|NCT01864343|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
215119931|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
215119932|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
215119933|NCT05225129|OTHER|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
215119934|NCT05546034|DIAGNOSTIC_TEST|Standard nutrition screening tools to be compared with routine blood tests|None other than completion of questionnaires one of which would be done in routine practice
215119935|NCT00001944|DRUG|Vinorelbine|
215119936|NCT00001944|DRUG|XR9576|
215119937|NCT05001035|OTHER|Time of assessment|Immediate and after one month and after two months
215119938|NCT02950909|PROCEDURE|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
215119939|NCT02950909|PROCEDURE|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
214443316|NCT05000073|OTHER|dialysis|dialysis
215119940|NCT02950909|PROCEDURE|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
215119941|NCT02950909|PROCEDURE|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
215119942|NCT06322888|BEHAVIORAL|Exercise Training Program|A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
214443317|NCT01822652|GENETIC|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
215119943|NCT04915729|DRUG|tenecteplase|tenecteplase
215119944|NCT04915729|DRUG|alteplase|alteplase
214443318|NCT01822652|GENETIC|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
214443319|NCT01822652|DRUG|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
214443320|NCT01822652|DRUG|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
214443321|NCT01822652|DRUG|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
214520757|NCT04565392|DRUG|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
214520758|NCT04945356|OTHER|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
214520759|NCT00092378|DRUG|MK0966, rofecoxib|
214520760|NCT00092378|DRUG|Comparator: diclofenac sodium, placebo|
214520761|NCT02721628|PROCEDURE|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
214520762|NCT02721628|PROCEDURE|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
214520763|NCT02721628|DEVICE|Femtosecond laser|Use in the epic-keratoplasty surgery
214520764|NCT00155376|DRUG|morphine and glucagon|
214520765|NCT00717925|DRUG|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
214520766|NCT05219747|OTHER|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
214520767|NCT05219747|OTHER|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
214520768|NCT05221684|PROCEDURE|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
215119945|NCT03301493|OTHER|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
215119946|NCT04690530|PROCEDURE|mechanical ventilation|mechanical vantilation will be performed
215119947|NCT04690530|DRUG|Sedation|sedation wil be performed
215119948|NCT01960582|BEHAVIORAL|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
215119949|NCT06138626|BEHAVIORAL|Alert|An alert that appears when anesthetic fresh gas flow is excessive
215119950|NCT05919823|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
215119951|NCT05919823|DRUG|Placebo|Placebo Capsules
215119952|NCT02451995|DEVICE|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
215119953|NCT02451995|DEVICE|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
215119954|NCT03292068|COMBINATION_PRODUCT|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
215119955|NCT03292068|DIETARY_SUPPLEMENT|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
215119956|NCT03292068|OTHER|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
214693190|NCT06897826|OTHER|Proprioceptive neuromuscular facilitation|The reason for choosing the proprioceptive neuromuscular facilitation technique is that it increases the hip flexion angle more than static stretching. Participants first lay down on the stretcher in a supine position. Then, the participant's lower extremity was lifted straight until the physiotherapist felt resistance. After reaching this position, the participant was asked to try to extend his lower extremity straight with half of his strength. After 10 seconds, the participant was given time to relax and after the participant relaxed, the lower extremity was brought to the new range of motion. This process was applied 3 times.
215119957|NCT04146350|PROCEDURE|PPV+/-Cat|pars plana vitrectomy+/-cataract
215119958|NCT04146350|PROCEDURE|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
215119959|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
214443322|NCT01822652|GENETIC|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
214443323|NCT05945797|DRUG|Dexamethasone 4mg|An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
214443324|NCT00567398|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
214443325|NCT00567398|DRUG|Physioneal|Physioneal 40 or Physioneal 35
215119960|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
215119961|NCT04146350|PROCEDURE|PSR|posterior scleral reinforcement
215119962|NCT04146350|PROCEDURE|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
215119963|NCT04146350|PROCEDURE|Gas|gas tamponade alone
215119964|NCT01915043|OTHER|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
215119965|NCT05282927|OTHER|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
215119966|NCT05282927|OTHER|Implementation Strategy: Enhanced REP (enREP)|The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
215119967|NCT05370131|OTHER|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
215119968|NCT02727907|DRUG|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
214443326|NCT00567398|DRUG|Extraneal|Extraneal - 7.5% Icodextrin
214443327|NCT00567398|DRUG|Nutrineal|Nutrineal - 1.1% Amino Acids
214443328|NCT06386913|OTHER|Training|Measurement-Based Care Training
214443329|NCT03933384|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
214443330|NCT03933384|DRUG|Entecavir|Entecavir 0.5mg/tab once daily
214520769|NCT02650453|PROCEDURE|Deep venous reconstruction|PTA \& stenting with/without endophlebectomy and/or arteriovenous fistula creation
214520770|NCT00612716|DRUG|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
214520771|NCT00612716|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
214520772|NCT00612716|BIOLOGICAL|Stem cell infusion|Infused on Day 0
214520773|NCT00612716|RADIATION|Total body irradiation|165 cGy morning and evening on days -4 through -1.
214520774|NCT05809245|PROCEDURE|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
214520775|NCT05736445|BEHAVIORAL|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
214443331|NCT01985139|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
214443332|NCT01985139|BIOLOGICAL|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
214443333|NCT05051813|DEVICE|ANTERION|3 repeat measurements on each of the 3 ANTERION devices and 3 reference devices.
214520776|NCT05461092|DRUG|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
215119969|NCT02727907|DRUG|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
214693191|NCT06897462|DIETARY_SUPPLEMENT|SRW Ndo1|The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).
214693192|NCT06899347|PROCEDURE|Total Thyroidectomy + Central Compartment Neck Dissection|"Thyroidectomy will be performed with the patient in the supine position with the neck hyperextended. A 3 to 6 cm transverse cervicotomy, two fingers above the sternal notch, will be performed, and the midline will be opened. After the inferior laryngeal nerve and parathyroids are visualized, the thyroidectomy will be achieved.~When performed, pCCND will aim at removing the nodes of Level VI, which has been reported to contain the thyroid gland and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the brachiocephalic artery, and laterally on each side by the carotid sheaths"
214693193|NCT05612672|OTHER|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
214693194|NCT06899243|DIETARY_SUPPLEMENT|CL22205|200 mg, Route : Oral, One capsule a day after breakfast for 360 days
214693195|NCT06899243|OTHER|Placebo|Route : Oral, One capsule a day after breakfast for 360 days
214693196|NCT07063316|DRUG|SGLT2 inhibitor|SGLT2 inhibitor
214693197|NCT07062588|DRUG|AGA2115|Subcutaneous injection
215119970|NCT02727907|DRUG|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
215119971|NCT02085018|DRUG|Omeprazole|Drug
215119972|NCT02085018|DRUG|Matched placebo|Matched placebo
215119973|NCT00135317|DRUG|darbepoetin alfa|
215119974|NCT04800146|PROCEDURE|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
215119975|NCT00721240|DRUG|montelukast|5mg montelukast once daily for 12 weeks
214443334|NCT06775925|OTHER|Unilateral robot-assisted therapy (RT)|RT will be performed as an add-on therapy to the clinical routine therapy scheme for 3 x 30 minutes per week for 6 weeks. RT is applied using the ArmeoSpring, an exoskeleton that provides adjustable antigravity weight support for the arm through a system of springs (no actuators).
214693198|NCT07062588|OTHER|Placebo|Subcutaneous injection
214693199|NCT07067749|DIAGNOSTIC_TEST|multiparametric magnetic resonance imaging (mpMRI) of the bladder|"This study will investigate the role of bladder mpMRI as a tool to expedite treatment in patients with muscle invasive bladder cancer.~mpMRIs will be investigated as a possible replacement of standard TURBt, a planned surgical procedure for cancer local staging.~mpMRis will be reported according to the Vesical Imaging - Reporting and Data System Stanrdars (VI-RADS) to provide a score indicating probability of muscle invasion."
214693200|NCT07067749|PROCEDURE|Transurethral resection of bladder tumour (TURBt)|This is a planned endoscopic surgical procedure consisting in resection of the bladder tumour through a electrified loop manouvred with an endoscope. In muscle invasive bladder cancer, this procedure allows histological confirmation of presence of detrusor muscle invasion.
214693201|NCT07067749|GENETIC|Circulating tumour DNA levels assessment|"Blood samples will be collected from each enrolled patient at pre-planned time points:~1. Cystoscopy, both arms~2. mpMRI (experimental arm) or TURBt (control arm)~3. Definite cancer treatment, both arms~ctDNA levels will be measured on the collected blood samples."
214693202|NCT04604249|DIAGNOSTIC_TEST|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
214443335|NCT06775925|OTHER|Unilateral conventional occupational therapy (OT)|The OT is applied as add-on therapy for 3 x 30 minutes per week for 6 weeks. OT comprises strengthening exercises (concentric and eccentric) with and without resistance, grasping exercises, fine motor training, peg games, and activity-based tasks which are unilaterally doable.
215119976|NCT00458120|BIOLOGICAL|rDEN1delta30|Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
215119977|NCT00458120|BIOLOGICAL|rDEN2/4delta30(ME)|Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
215119978|NCT00458120|BIOLOGICAL|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
215119979|NCT06500637|DRUG|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
215119980|NCT04958889|OTHER|No intervention|(observational study)
214443336|NCT06775535|DEVICE|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
214443337|NCT06752824|DEVICE|ANALGESIA NOCICEPTION INDEX MONITORING|INTRACRANIAL SURGERY
214443338|NCT05016700|DIAGNOSTIC_TEST|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
215119981|NCT02294058|DRUG|Ozanimod|Capsules for oral administration once a day
215119982|NCT02294058|DRUG|Interferon beta-1a|Administered by intramuscular injection once a week
215119983|NCT02294058|DRUG|Placebo to ozanimod|Matching placebo capsules administered orally once a day
215119984|NCT02294058|DRUG|Placebo to interferon beta-1a|Placebo intramuscular injection once a week
215119985|NCT03923894|DIETARY_SUPPLEMENT|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
214443339|NCT04122469|RADIATION|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
214443340|NCT04703101|DRUG|Capecitabine|Given IV
214443341|NCT04703101|DRUG|Fluorouracil|Given IV
214443342|NCT04703101|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215119986|NCT03923894|DIETARY_SUPPLEMENT|Placebo|Placebo 2.07 g/day for 8 weeks.
215119987|NCT04891380|DEVICE|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
215119988|NCT04891380|OTHER|Hypotension|measurement of physiological parameters
215119989|NCT04891380|OTHER|Intensive care transport|Measurement of physiological parameters
215119990|NCT04932239|OTHER|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
214693203|NCT05911009|DRUG|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
215119991|NCT04617067|DRUG|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
215119992|NCT04617067|DRUG|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
215119993|NCT04827888|PROCEDURE|Orthopaedic surgery|One of the 25 most common orthopedic surgeries reported in the database which are the following as per surgical types: spine surgery (CPT codes 63030, 63047, 22612, 22551 or 22558), trauma (CPT codes 27236, 27125, 27244, 27814, or 27792), sports medicine injuries (CPT codes 29881, 29827, 29880, 29888, 29826, 29877, 29807, or 23412), or joint arthroplasty (CPT codes 27447, 27130, 23472, 27487, 27134, 27446, or 27486).
215119994|NCT05210491|OTHER|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
215119995|NCT03564613|DRUG|DTG|Subjects with DTG exposure during any trimester will be included
215119996|NCT02904733|OTHER|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
215119997|NCT05771766|OTHER|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
215119998|NCT05771766|OTHER|Postural Drainage|Postural Drainage
215119999|NCT05357027|BIOLOGICAL|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
215120000|NCT05357027|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
215120001|NCT05357027|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
215120002|NCT05357027|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
215120003|NCT00298974|DRUG|hydrocodone / acetaminophen extended release|2 tablets twice daily
215120004|NCT00298974|DRUG|Placebo|2 tablets twice daily
215120005|NCT00250341|DRUG|QVAR|480 mcg
215120006|NCT00250341|DRUG|Advair|250/50 mcg
215120007|NCT00250341|DRUG|Servent Diskus|50 mcg
215120008|NCT03934606|BEHAVIORAL|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
215120009|NCT05006261|DEVICE|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
215120010|NCT03575403|DRUG|Alcohol|In each arm and during sessions, subjects will receive doses of alcohol designed to raise breath alcohol levels (BAL) to 0.03 g/dl.
215120011|NCT03575403|DRUG|Placebos|Subjects will receive oral placebo capsules.
215120012|NCT03575403|DRUG|Duloxetine (60 MG)|Subjects will receive 60-mg of oral duloxetine capsules.
215120013|NCT03575403|DRUG|Methylphenidate|Subjects will receive methylphenidate capsules.
215120014|NCT03575403|DRUG|Duloxetine (30 MG)|Subjects will receive 30-mg of oral duloxetine capsules.
215120015|NCT05326711|BEHAVIORAL|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
215120016|NCT01223729|DRUG|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
214443343|NCT04703101|DRUG|Leucovorin|Given IV
215120017|NCT01223729|OTHER|placebo|placebo twice per day
215120018|NCT00657644|DRUG|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
215120019|NCT06276426|OTHER|Soy foods|Soy milk, soy yogurt, tofu, tempeh, soy nuts, edamame, soy protein bar, and soy-based frozen meat substitutes.
215120020|NCT06276426|OTHER|Non-Soy Plant-Based Foods|Pea milk, almond milk yogurt, chickpeas, chickpea chips, lentil chips, non-soy protein bar, and non-soy based frozen meat substitutes.
215120021|NCT01683539|BEHAVIORAL|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
215120022|NCT01683539|BEHAVIORAL|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
215120023|NCT01094535|DRUG|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
215120024|NCT02330055|PROCEDURE|Forty-five degrees elevated upper body position|
215120025|NCT02330055|PROCEDURE|non-elevated upper body position|
215120026|NCT02330055|DEVICE|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
215120027|NCT02330055|OTHER|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
215120028|NCT02330055|OTHER|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
215120029|NCT02330055|OTHER|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
215120030|NCT02330055|OTHER|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
215120031|NCT01509235|PROCEDURE|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
215120032|NCT05607524|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and twice a day
215120033|NCT05607524|DIETARY_SUPPLEMENT|placebo|Eat a capsule for once, and twice a day
215120034|NCT02976935|OTHER|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
215120035|NCT00746616|DEVICE|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
215120036|NCT00963391|OTHER|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
215120037|NCT02151188|DIETARY_SUPPLEMENT|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
215120038|NCT02151188|DEVICE|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
215120039|NCT00540072|DRUG|daptomycin|
215120040|NCT04544358|BEHAVIORAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
215120041|NCT05432713|DRUG|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
215120042|NCT05432713|DRUG|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
214443344|NCT04703101|DRUG|Oxaliplatin|Given IV
214443345|NCT04703101|OTHER|Quality-of-Life Assessment|Ancillary studies
214443346|NCT04703101|BEHAVIORAL|Surveillance|Undergo NOM
214443347|NCT04703101|PROCEDURE|Total Mesorectal Excision|Undergo TME
214443348|NCT06273137|BEHAVIORAL|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
214443349|NCT06273137|BEHAVIORAL|Supportive psychotherapy (SUP)|Supportive psychotherapy provides a time, attention, and social support control that is similar to a placebo but likely to be perceived as relevant to this population.
214443350|NCT04229056|BEHAVIORAL|Computer-based cognitive rehabilitation (CBCR)|CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
214443351|NCT04229056|BEHAVIORAL|General computer-based cognitive stimulation|For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.
214520777|NCT05461092|DIAGNOSTIC_TEST|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
214520778|NCT05461092|OTHER|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
214520779|NCT05461092|OTHER|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
214520780|NCT05461092|OTHER|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
214520781|NCT05461092|OTHER|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
215120043|NCT02521922|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
215120044|NCT02521922|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
215120045|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
215120046|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
215120047|NCT03233113|BEHAVIORAL|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
215120048|NCT03359174|DRUG|All-trans retinoic acid|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
215120049|NCT01180686|DEVICE|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
215120050|NCT01180686|DEVICE|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
215120051|NCT04889183|DRUG|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
215120052|NCT04889183|DRUG|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
215120053|NCT02591108|DEVICE|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
215120054|NCT02591108|DEVICE|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
215120055|NCT00239733|DRUG|Anti-D|30-minute infusion administered in an outpatient setting
215120056|NCT03715803|DEVICE|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
214443352|NCT05580536|BEHAVIORAL|Project Dulce + Dulce Digital|"Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic.~The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes.~The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. .~Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic."
214520782|NCT05461092|OTHER|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
214520783|NCT05461092|OTHER|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
214520784|NCT05461092|OTHER|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
214520785|NCT05461092|OTHER|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
214520786|NCT05461092|OTHER|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
214520787|NCT05461092|OTHER|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
214520788|NCT05461092|OTHER|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
214520789|NCT05461092|OTHER|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
214520790|NCT05461092|OTHER|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
214520791|NCT05461092|OTHER|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
214520792|NCT05461092|OTHER|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
215120057|NCT03715803|DEVICE|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
215120058|NCT04714164|BEHAVIORAL|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
215120059|NCT03055117|BEHAVIORAL|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
215120060|NCT03055117|BEHAVIORAL|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
215120061|NCT03055117|BEHAVIORAL|Home exercise|Supervised home exercise
215120062|NCT06024486|DIAGNOSTIC_TEST|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
215120063|NCT06301451|DEVICE|General dietary guidance and hydrogen water prepared by portable hydrogen rich water machine|The trial group drink the hydrogen water prepared by the experimental equipment on the basis of receiving general dietary guidance.
215120064|NCT06527118|OTHER|ACTIVITIES TO LEARN SELF CARE SKILLS|This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
215120065|NCT00420862|PROCEDURE|Spiral Computed Tomography|
214443353|NCT06540781|PROCEDURE|wet cupping therapy|"The cupping (WCT) procedure consists of five phases:~Primary suction: Using a manual suction pump, air was drawn from glass cups that were positioned on the chosen locations. The skin and subcutaneous tissue swelled as a result of the cups' five minutes of skin contact.~Area disinfection: After disinfecting the cupped areas with povidone-iodine, they were wiped with sterile gauze.~Scarification: Using a sterile number 11 surgical blade, superficial incisions measuring 20-30 gauge in length and 1-2 mm in depth were made on the skin.~Bloodletting and secondary suction: Once again applied to the scarified areas, the previously removed cups created suction using the manual pump which was previously mentioned. In order to fill the cups, blood was drawn from the skin's and subcutaneous tissue's capillaries.~Removing and dressing: After 10 minutes, the cups filled with blood were removed. The application areas were wiped with sterile gauze, and dressings were applied."
215120066|NCT05570266|DIAGNOSTIC_TEST|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
215120067|NCT02416739|DRUG|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
215120068|NCT03678701|DIETARY_SUPPLEMENT|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
215120069|NCT06212557|DEVICE|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
215120070|NCT06212557|BEHAVIORAL|KIOS App education|Educational tools provided to participants with opioid use disorder
215120071|NCT06212557|BEHAVIORAL|Treatment as usual|Behavioral counseling in clinic
215120072|NCT04154046|PROCEDURE|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
214443354|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).
215120073|NCT00424944|BIOLOGICAL|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
215120074|NCT00424944|BIOLOGICAL|GMZ2 malaria vaccine|100 micrograms of GMZ2
215120075|NCT00424944|BIOLOGICAL|Verorab vaccine|Anti-rabies vaccine
215120076|NCT02677935|OTHER|Community education programs|
214520793|NCT05461092|OTHER|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
215120077|NCT05986786|DEVICE|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
215120078|NCT06368258|DIETARY_SUPPLEMENT|Red yeast rice|Red yeast rice 160 mg (total monacolins 2.8 mg)
215120079|NCT06368258|OTHER|Placebo|Placebo
215120080|NCT04868955|OTHER|Oral screen training|Oral screen training (IQoro®) during 13 weeks.
215120081|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
214520794|NCT02061215|OTHER|CMV viral load|
214520795|NCT04613219|DRUG|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
214520796|NCT06363409|OTHER|Cereal Bar as a recovery food snack|Cereal bar as a recovery snack food
214520797|NCT06363409|OTHER|Almond|Almond as a recovery snack food
214520798|NCT01521689|DRUG|Rituximab|Low doses of sub cutaneaous rituximab
215120082|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
215120083|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
215120084|NCT01611038|DIETARY_SUPPLEMENT|Methylselenocysteine|Methylselenocysteine capsule given daily
215120085|NCT01611038|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given daily
214520799|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
214693204|NCT06809166|DRUG|Contrave|"CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule).~Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events."
215120086|NCT02677168|DEVICE|cNEP|continuous negative external pressure
215120087|NCT03568240|DIAGNOSTIC_TEST|Patients suffering from Sleep apnea|PSG test
215120088|NCT01332994|DRUG|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
215120089|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
215120090|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
215120091|NCT00354380|DRUG|Methylene blue|
215120092|NCT00354380|DRUG|Artesunate|
215120093|NCT00354380|DRUG|Amodiaquine|
214443355|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).
214443356|NCT06182124|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
214443357|NCT06182124|BIOLOGICAL|Licensed pneumococcal comparator vaccine|A licensed pneumococcal comparator vaccine
214520800|NCT06747637|OTHER|Skill-building classes|Unidos en el Cuidado is a manualized, multi-family group intervention provided at no cost vis-à-vis videoconferencing or on-site by trained facilitators Sessions are held weekly for 1.5 hours. Class components include caregiver role identity; skills-building; knowledge attainment; attitudinal changes; resource-sharing; practice/role-plays; homework; videos, handouts. Classes will be provided online with some classes offered in the community, if available
214520801|NCT06747637|OTHER|Wait list control group|The intervention is the same; the wait period is longer to receive the intervention described in Group A.
214520802|NCT00535795|RADIATION|Radiation Therapy|Radiation Therapy
214520803|NCT05482295|BIOLOGICAL|In-House Recombinant Hepatitis B (Bio Farma) vaccine|3 doses of In-House Recombinant Hepatitis B (Bio Farma) vaccine
215120094|NCT01154868|PROCEDURE|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
215120095|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
215120096|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)|Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
215120097|NCT03360123|DRUG|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
215120098|NCT03360123|DRUG|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
215120099|NCT04651868|OTHER|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
215120100|NCT04651868|OTHER|Placebo|A 210 mins intravenous infusion with isotonic NaCl
215120101|NCT04651868|OTHER|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)
215120102|NCT04651868|OTHER|Placebo|A 180 mins intravenous infusion with isotonic NaCl
214443358|NCT06401213|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
214443359|NCT06401213|OTHER|Placebo|Matching Placebo-- Normal Saline
214520804|NCT05482295|BIOLOGICAL|Registered Hepatitis B vaccine recombinant (Engerix-B)|3 doses of Registered Hepatitis B vaccine recombinant (Engerix-B)
214693205|NCT06809166|DRUG|Placebo|"Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention.~Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave."
214520805|NCT05854056|PROCEDURE|Accelerated rehabilitation protocol|See Arms section
214693206|NCT06809166|BEHAVIORAL|Diet Program|All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.
215120103|NCT06470997|BIOLOGICAL|Blood sample collection|6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)
214520806|NCT05854056|PROCEDURE|Conservative rehabilitation protocol|See Arms section
214520807|NCT04388917|PROCEDURE|Patial nephrectomy|Partial nephrectomy assisted with robot to remove kidney cancer
214520808|NCT02178878|GENETIC|Progress, Pain|Progress, Pain
214520809|NCT02176512|DRUG|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
215120104|NCT06470997|PROCEDURE|Liver biopsy|1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.
215120105|NCT06061081|DRUG|VH3739937|VH3739937 will be administered.
215120106|NCT06061081|DRUG|Placebo|Placebo will be administered.
215120107|NCT05496296|DEVICE|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
214520810|NCT02176512|DRUG|BIBR 277 SE|Treatment B - Monocomponent
214520811|NCT02176512|DRUG|HCTZ|Treatment B -Monocomponent
214520812|NCT01748578|DRUG|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
214520813|NCT01748578|DRUG|EBI-005-1 Placebo|
215120108|NCT03863756|RADIATION|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
215120109|NCT04255589|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
215120110|NCT04255589|DRUG|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
215120111|NCT04255589|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
215120112|NCT04255589|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
215120113|NCT00994526|OTHER|Ham|Ham : 180 g per day during 4 days
215120114|NCT00994526|OTHER|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
215120115|NCT00994526|OTHER|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
214520814|NCT01709643|DIETARY_SUPPLEMENT|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
215120116|NCT05528393|DIAGNOSTIC_TEST|Blood sampling|blood sampling
215120117|NCT04428229|OTHER|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
215120118|NCT02531724|DRUG|Levosimendan|
215120119|NCT02531724|DRUG|Placebo|Sodium chloride
215120120|NCT05733052|OTHER|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
214520815|NCT01709643|DIETARY_SUPPLEMENT|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
214520816|NCT03246256|OTHER|Group 1|
214520817|NCT01562587|DRUG|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
214520818|NCT01562587|DRUG|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
214520819|NCT04320810|OTHER|no intervention|It's only observational study. No interventions.
214520820|NCT00438230|DRUG|Warfarin|
214520821|NCT06136507|DRUG|FRSW107|experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
214520822|NCT05016674|DEVICE|LipoLife system|Abdominal Laser-Assisted Liposuction
214520823|NCT01808898|PROCEDURE|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
214520824|NCT05893017|OTHER|Virtual Reality Exercises|Virtual Reality Exercises will be apply for muscle strengthening
214520825|NCT05893017|OTHER|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
214520826|NCT05893017|OTHER|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
214520827|NCT03598803|OTHER|Survey|Urinary Incontinence Survey
214520828|NCT02896335|DRUG|Palbociclib|Administered orally once per day on days 1-21 of 28-day cycles.
214520829|NCT02896335|DRUG|Pembrolizumab|Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
214520830|NCT04815707|PROCEDURE|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
214520831|NCT01252199|DRUG|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
214520832|NCT01252199|DRUG|Placebo|Placebo administered over 1 hour + standard of care
214520833|NCT05993832|OTHER|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
214520834|NCT06458309|PROCEDURE|spine surgery|"AO Classification6 It classifies thoracolumbar fractures into 3 major groups, based on the mechanism of injury.and each of them subdivided to 3 subgroups.~A. Compression B. Distraction C. multi-directional with translation Thoracolumbar AO spine injury score"
214520835|NCT01883297|BIOLOGICAL|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
214520836|NCT01883297|BIOLOGICAL|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
214520837|NCT01883297|DRUG|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
214520838|NCT02136797|BIOLOGICAL|CMVpp65 Specific T-cells|
214520839|NCT05428839|DIAGNOSTIC_TEST|Pharyngeal width measurement|A simple, non-invasive measurement of the pharyngeal width inside each subjects mouth
214520840|NCT06415383|DRUG|Vitamin B6 100 MG|Vitamin B6 in for the form of pyridoxal phosphate (PLP)
214520841|NCT06415383|OTHER|Placebo|Placebo tablet containing microcrystalline cellulose
214520842|NCT06520020|DEVICE|Transcutaneous Spinal Cord Stimulation (Tc-SCS)|This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.
214520843|NCT06552910|PROCEDURE|Nerve Block|Since this study was conducted retrospectively, the choice of anesthesia method was made based on our own experience. For every patient undergoing LEA under PNB, a popliteal sciatic nerve block was carried out. A saphenous nerve block was also carried out if the procedure was on a level that was close to the metatarsal bone. In some circumstances (distal surgery, such as the metatarsal bone), a sensory block on the surgical site was tried following the popliteal sciatic nerve block to demonstrate that the saphenous nerve's anatomic abnormalities required an additional saphenous nerve block. The related block was later carried out, if needed. Under ultrasound guidance, every PNB was finished.
215029283|NCT01128517|BEHAVIORAL|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
214443360|NCT05265312|OTHER|START diabetes prevention clinical pathway|"The diabetes prevention clinical pathway will focus on the following steps:~1. Screen/test - testing of eligible patients for prediabetes/diabetes~2. Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~3. Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~4. Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~5. Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes."
214443361|NCT06319144|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
214443362|NCT06319144|OTHER|0.9% sodium chloride solution|Patients in the control group were infused intravenously with 0.9% sodium chloride solution in the PACU.
214443363|NCT04468399|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214443364|NCT04468399|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
214520844|NCT05017883|DRUG|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
214520845|NCT03162523|RADIATION|High-Dose Rate Brachytherapy|
214520846|NCT00040521|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|
214520847|NCT01903928|BIOLOGICAL|ASP0113|injection
215120121|NCT02309801|DIETARY_SUPPLEMENT|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
214520848|NCT05610254|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
215120122|NCT02309801|DIETARY_SUPPLEMENT|Alcohol|Alcohol single oral dose
214520849|NCT00371696|DRUG|diclofenac|
214520850|NCT00371696|DRUG|paracetamol|
214520851|NCT00371696|DEVICE|heat retaining knee support|
214520852|NCT00371696|DEVICE|standard knee support|
214520853|NCT04523571|BIOLOGICAL|BNT162b1|Intramuscular injection
214520854|NCT04523571|OTHER|Placebo|Intramuscular injection
214520855|NCT06549270|DRUG|MAbs|Monthly or quarterly mAbs administration
214520856|NCT00589745|OTHER|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
214520857|NCT00155662|BEHAVIORAL|work-hardening program|
214520858|NCT06584838|PROCEDURE|ACL reconstruction|Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
214520859|NCT01810328|OTHER|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
214520860|NCT01810328|OTHER|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
215029284|NCT01128517|BEHAVIORAL|Education|Maternal education on complementary food
215029285|NCT00337168|DRUG|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
215029286|NCT00337168|DRUG|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
215029287|NCT03253237|DEVICE|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
214443365|NCT06161753|BEHAVIORAL|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
215120123|NCT03565536|DRUG|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
215120124|NCT03565536|PROCEDURE|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
215120125|NCT03565536|RADIATION|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
215120126|NCT00279916|DRUG|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
214443366|NCT06826287|OTHER|7T MR exam|a 7 Tesla MRI scan, with a functional and anatomical dedicated protocol
214520861|NCT06313099|OTHER|Survey|Participants' musculoskeletal system disorders were assessed using the Cornell Musculoskeletal Disorders Questionnaire (CMDQ), fatigue levels were measured using the Fatigue Severity Scale (FSS), sleep quality was evaluated using the Visual Analog Scale (VAS), depression levels were assessed using the Beck Depression Inventory (BDI), and quality of life was measured with the Nottingham Health Profile (NHP). Google Forms was used to create the data collection tools, which were then sent to the participants' email addresses and collected online.
214520862|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
214520863|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
214520864|NCT04925245|OTHER|Clinical Reminder|Clinical reminder in the electronic medical record
214520865|NCT05669287|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
214520866|NCT02039297|OTHER|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
214520867|NCT06127485|PROCEDURE|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
214520868|NCT06127485|PROCEDURE|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
214520869|NCT03466775|DIAGNOSTIC_TEST|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
214520870|NCT03466775|DIAGNOSTIC_TEST|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
214520871|NCT03466775|OTHER|Allograft survival|
214520872|NCT03466775|OTHER|Allograft rejection appearance|
214520873|NCT02585752|DEVICE|Noninvasive ventilation|Expiratory pressure modulation
214520874|NCT02041845|RADIATION|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
214520875|NCT02041845|RADIATION|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
214520876|NCT06342635|DEVICE|Hydra Transcatheter Aortic Valve (THV) Series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
214520877|NCT05670678|DIETARY_SUPPLEMENT|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
214520878|NCT05670678|DIETARY_SUPPLEMENT|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
214520879|NCT02910336|OTHER|Quantitative Sensory Testing|sensory testing profile
214520880|NCT02201992|OTHER|Clinical Observation|Undergo observation
214520881|NCT02201992|DRUG|Crizotinib|Given PO
215029288|NCT03901040|DEVICE|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
214443367|NCT06826287|OTHER|clinical assessment|A comprehensive clinical assessment before the MRI exam.
215029289|NCT00760760|DRUG|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
214443368|NCT04256707|DRUG|Selinexor 100 mg|"100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)"
214443369|NCT04256707|DRUG|Docetaxel|75 mg/m\^2 IV
214443370|NCT04256707|DRUG|Pembrolizumab|200 mg IV
214443371|NCT04256707|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV"
214443372|NCT04256707|DRUG|Selinexor 40 mg|\- 2 × 20-mg tablets (Tablet A)
214520882|NCT02201992|OTHER|Laboratory Biomarker Analysis|Correlative studies
214520883|NCT00139308|DEVICE|high frequency stimulation|
215029290|NCT00760760|DRUG|control|equivalent amount of fat as butter
215029291|NCT01318681|DRUG|cetirizine 10 mg|cetirizine 10 mg over encapsulated
215029292|NCT01318681|DRUG|fluticasone furoate|nasal spray 25ug per dose
215029293|NCT01318681|DRUG|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
215029294|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
214443373|NCT04256707|DRUG|Selinexor 80 mg|\- 4 × 20-mg tablets (Tablet A)
214443374|NCT04256707|DRUG|Selinexor 60 mg|\- 3× 20-mg tablets (Tablet A)
214443375|NCT06098677|DIETARY_SUPPLEMENT|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
214443376|NCT06098677|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
214443377|NCT06789536|OTHER|training nurses to prescribe nicotine substitutes, to adapt doses and to transmit to the outpatient physician and/or nurse nurse to facilitate the continuation of treatment|Nurses will undergo training sessions provided by the smoking cessation team to learn how to prescribe nicotine replacement therapy, adjust dosages, and forward a referral letter to the patient's primary care physician and/or community nurse for continuity of care. They will receive a dosage adjustment guide to share with patients. Upon completing the training, nurses will be authorized to prescribe nicotine replacement therapy using the hospital's prescription software.
214443378|NCT05938465|BIOLOGICAL|EXE-346|EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
214443379|NCT05938465|OTHER|Placebo|Placebo contains excipients maltose and silicon dioxide.
214443380|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
214443381|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
214443382|NCT05524649|DIETARY_SUPPLEMENT|Placebo|5 drops/day for 3 months of sunflower oil
214443383|NCT06769178|OTHER|Virtual Reality based|Participants will receive treatment by a specialist physiotherapist for a total of 16 sessions, 2 days a week on non-consecutive days for 8 weeks. Both groups will receive neurodevelopmental treatment (NGT) for 16 sessions. While the control group will receive traditional balance training in each session, the VR group will play virtual reality-based games.
214443384|NCT06789133|OTHER|PNF exercises and Body weight supported treadmill gait training|"PNF Exercises:~.Proprioceptive neuromuscular facilitation exercises include D1 Flexion and D1 Extension of lower limb ,D2 flexion D2 extension of lower limb .rhythmic initiation ,hold relax ,pelvic pattern and contract relax technique . subjects will perform each exercise for 30sec with resting interval of 30 to 60 seconds Will be provided after completion of each exercise. 3 sessions will be held per week, For 8 weeks~Gait training:~Body weight supported treadmill gait training for 20 minutes 3 sessions per week.~In total all PNF exercises with gait training will be held for 40-45 minutes."
214520884|NCT03782545|DEVICE|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
214693207|NCT06814340|DEVICE|ECMO + near apneic ventilation|"Near apneic ventilation will be use during the first 3 days of ECMO. Patients will be ventilated in BIPAP/APRV or pressure-controlled ventilation. PEEP will be set to maintain the same mean airway pressure obtained during the standardized ventilation period pre-randomization to prevent lung derecruitment (PEEP ≥15cmH2O). If BIPAP/APRV is used, an RR of 2-4/min will be set with high pressure set at 30cmH20 for 3 sec. If pressure-controlled ventilation is selected, a respiratory rate of two sigh breaths/min with 30 cmH2O plateau pressure will be applied. Each sigh breath will be of three seconds duration.~Neuromuscular blockade and sedation could be used at the discretion of the attending physician. After 3 days on ECMO, apneic ventilation could be pursued (at the physician's discretion). If not, ultra-protective lung ventilation will be applied (i.e standard of care). Prone positioning on ECMO will be left to the physicians' discretion."
215029295|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
215029296|NCT01189760|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
215029297|NCT00003794|PROCEDURE|psychosocial assessment and care|
215029298|NCT00003794|PROCEDURE|quality-of-life assessment|
215029299|NCT00269581|OTHER|Educational CD-rom|Educational CD-Rom
214443385|NCT06789133|OTHER|Body weight supported treadmill gait training and Routine physical therapy|"Body Weight Supported Treadmill Training (BWSTT):~This will include body weight supported treadmill gait training. 10 % BWSTT or 20% BWSTT. The session will of 20 minutes .3 sessions will be Held per week.~Routine physical therapy:~Stretching and strengthening of lower extremities In total all BWSTT along with routine physical therapy protocol will be held for 40-45minutes .3 sessions will be held per week."
214443386|NCT06785337|DRUG|Inhaled nitroglycerin|Inhaled nitroglycerin
214443387|NCT05805774|PROCEDURE|Distal Femur Replacement|Knee surgery to remove the lower part of the femur and knee joint (where the broken bones are) and will replace them with an artificial knee joint (prosthesis).
214443388|NCT05805774|PROCEDURE|Surgical fixation|Knee surgery to fix the fracture, that can use wires, nails, screws, pins or plates to health and fix the bones together.
214443389|NCT05190991|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
214520885|NCT01837199|DRUG|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
214520886|NCT00966888|PROCEDURE|standard follow-up care|No intervention
214520887|NCT00966888|RADIATION|radiation therapy|Chest wall radiotherapy
214520888|NCT00560209|DRUG|ONO-1101|placebo for 1 minute IV
214520889|NCT00560209|DRUG|ONO-1101|0.06 mg/kg for 1 minute IV
214520890|NCT00560209|DRUG|ONO-1101|0.125 mg/kg for 1 minute IV
215029300|NCT00269581|OTHER|Headstrong CD-rom|Headstrong CD-rom
215029301|NCT05963126|OTHER|No intervention.|No intervention.
215029302|NCT04373200|BIOLOGICAL|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
215120127|NCT00279916|DRUG|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
215120128|NCT01068574|OTHER|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
215120129|NCT01807598|DRUG|Brentuximab vedotin|
215120130|NCT01648972|DRUG|Gastrografin|
215120131|NCT01648972|DRUG|Placebo|
215120132|NCT04311762|DRUG|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
215120133|NCT01895595|BEHAVIORAL|Guided Imagery|
215120134|NCT01895595|BEHAVIORAL|Digital Storytelling|
215120135|NCT03554928|DIAGNOSTIC_TEST|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
215120136|NCT03055520|OTHER|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
215120137|NCT03055520|OTHER|placebo|nonspecific recreation including befriending and free simple activities.
214443390|NCT05236595|OTHER|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
214443391|NCT06766435|DEVICE|i-STAT TBI Test|The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.
215120138|NCT03822767|BIOLOGICAL|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
215120139|NCT03822767|BIOLOGICAL|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
215120140|NCT04514822|DIAGNOSTIC_TEST|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
215120141|NCT03203083|OTHER|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
215120142|NCT04417608|PROCEDURE|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
215120143|NCT04090411|DRUG|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
215120144|NCT04090411|DRUG|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
214443392|NCT06766019|DRUG|Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV|"1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles"
214443393|NCT06766058|OTHER|Carrier oil|Inhaler stick containing 2 drops of carrier oil.
214443394|NCT06766058|OTHER|Asian plant extract blend|Inhaler stick containing 2 drops of Asian plant extract blend.
214443395|NCT02088060|DRUG|Cannabidiol|Cannabidiol capsules
214520891|NCT03694210|DEVICE|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
214443396|NCT02088060|DRUG|Olanzapine|Olanzapine capsules
214443397|NCT02088060|DRUG|Placebo Cannabidiol|Placebo cannabidiol capsules
214520892|NCT01581476|DRUG|Statin|10mg daily for a minimum period of 2 years
214443398|NCT02088060|DRUG|Placebo Olanzapine|Placebo olanzapine capsules
214443399|NCT04409639|DRUG|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
214443400|NCT06766799|DEVICE|Rebound and Applanation Tonometer|Measurement of Intraocular Pressure
214520893|NCT01581476|DRUG|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
214520894|NCT01581476|DRUG|Placebo|Participants receive statin placebo and ACEI placebo
214520895|NCT01581476|DRUG|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
215120145|NCT04090411|DRUG|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
215120146|NCT04090411|OTHER|Induction- Placebo SC Q4W|0 mg Placebo
215120147|NCT04090411|DRUG|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
215120148|NCT04090411|DRUG|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
215120149|NCT04090411|DRUG|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
215120150|NCT00756418|DRUG|montelukast|montelukast 5 mg QD 4-weeks.
215120151|NCT00756418|DRUG|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
215120152|NCT02699320|OTHER|Complications|Not involved
215120153|NCT04370613|BEHAVIORAL|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
215120154|NCT03612336|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
215120155|NCT03612336|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
215120156|NCT05581459|OTHER|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
214443401|NCT04060160|OTHER|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
214443402|NCT04060160|OTHER|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
214443403|NCT05593328|DRUG|Onvansertib|Oral capsule
214443404|NCT05593328|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
214443405|NCT05593328|DRUG|Bevacizumab|IV infusion
215029303|NCT04373200|OTHER|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
215029304|NCT01230060|DEVICE|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
215029305|NCT06312215|OTHER|Closed-system catheter|Closed-system catheters was applied
215029306|NCT03901586|OTHER|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
215029307|NCT03901586|OTHER|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
215029308|NCT03901586|OTHER|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
215029309|NCT00931281|DRUG|ABT-450|capsules, QD or BID, 14 days, ascending doses
215029310|NCT00931281|DRUG|ritonavir|capsules, QD or BID, 14 days, ascending doses
215029311|NCT00931281|DRUG|Placebo for ABT-450|capsule, QD or BID, 14 days
215029312|NCT00931281|DRUG|Placebo for ritonavir|capsule, QD or BID, 14 days
215029313|NCT03226691|DRUG|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
215029314|NCT01052779|DRUG|Ferumoxytol|IV Ferumoxytol
215029315|NCT01052779|DRUG|Iron Sucrose|IV Iron Sucrose
215029316|NCT02059447|OTHER|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
215029317|NCT02059447|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
215029318|NCT02059447|BEHAVIORAL|Relaxation Therapy|
215029319|NCT00243035|DRUG|bortezomib|Given IV
215029320|NCT00243035|DRUG|tipifarnib|Given orally
215029321|NCT00243035|OTHER|laboratory biomarker analysis|Correlative studies
215029322|NCT00303407|DRUG|nadroparin|
215029323|NCT03723473|DEVICE|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
215029324|NCT04932148|OTHER|Incremental HD|Starting haemodialysis at twice weekly frequency
215029325|NCT04932148|OTHER|Conventional HD|Starting haemodialysis at thrice weekly frequency
215029326|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
215029327|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
215029328|NCT03663582|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
215029329|NCT03663582|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
215029330|NCT03663582|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
215029331|NCT03663582|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
215029332|NCT04388228|OTHER|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
215029333|NCT00780585|DRUG|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
215029334|NCT03505060|BIOLOGICAL|DNA CON-S env|Administered by intramuscular injection in the deltoid.
215029335|NCT03505060|BIOLOGICAL|IHV01|Administered by intramuscular injection in the deltoid.
215029336|NCT03505060|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
214443406|NCT04170946|OTHER|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
214693208|NCT06814340|DEVICE|ECMO + ultra-protective lung ventilation|"Ultra-protective lung ventilation will be used up to the ECMO weaning. This group will receive ultra-protective lung ventilation with BIPAP/APRV or VCV mode setting a PEEP \>10 cmH2O, ΔP 14-15 cmH2O, RR 15-20/min, Vt 3-4ml/kg and lowest FiO2 to maintain SpO2\>92%.~The use of prone positioning during ECMO will be left at the physician's discretion."
215120157|NCT05581459|OTHER|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
214693209|NCT06898203|DEVICE|SkinScan3D|A handheld, simple, low-cost, and user-friendly technology that combines liquid lens technology and artificial intelligence (AI).
214693210|NCT07070063|DEVICE|Virtual Reality Therapy|Eight sessions of virtual reality therapy will be administered over a two-week period (four sessions per week, each lasting 20 minutes). The intervention will be delivered using the VRTierOne device (Stolgraf®), which employs a head-mounted display to create a fully immersive environment. Through the integration of visual, auditory, and kinesthetic stimuli, the therapy provides a multi-sensory experience that can have calming and mood-enhancing effects, as well as support psychological engagement and motivation in the rehabilitation process. The virtual environment-designed as a therapeutic garden-is rich in symbols and metaphors derived from Ericksonian psychotherapy. The central element of this environment is the Garden of Revival, a metaphor for the patient's health. Once vibrant and full of life, the garden is now neglected and requires care and effort to be restored. Throughout the therapeutic process, the patient is guided by a symbolic narrative reflecting their individual
214693211|NCT07070063|DEVICE|Pelvic Floor Muscle Electrostimulation with EMG Biofeedback|Eight sessions of pelvic floor muscle electrostimulation combined with EMG biofeedback will be provided over a two-week period (four sessions per week). The intervention will be delivered using a specialized EMG-Biofeedback electrostimulation device equipped with a screen for real-time signal visualization. Vaginal electrodes will be used to ensure precise stimulation and accurate detection of pelvic floor muscle activity. During each 30-minute session, patients will receive symmetrical biphasic rectangular electrical impulses at a frequency of 50 Hz, with a 5-second stimulation phase followed by a 10-second rest period. The intensity of the stimulation will be individually adjusted to ensure both safety and comfort. The integrated biofeedback system will allow participants to observe their muscle activation patterns on the screen, enhancing their awareness and control of pelvic floor function and supporting the learning of correct activation during voluntary contractions.
215120158|NCT05581459|OTHER|Sham vibration|Handheld device was applied to the participants without any vibrations.
215120159|NCT00365924|DRUG|Forteo|Open label single arm study with Forteo as an intervention
215120160|NCT01833559|DIETARY_SUPPLEMENT|Dietary control|
215120161|NCT01833559|DRUG|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
215120162|NCT02717494|BIOLOGICAL|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
215120163|NCT02717494|BIOLOGICAL|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
215120164|NCT02717494|OTHER|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
215120165|NCT03915314|DIAGNOSTIC_TEST|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
215120166|NCT00214981|DRUG|Modafinil|
215120167|NCT02053636|DRUG|lucitanib|
215120168|NCT04791618|BEHAVIORAL|Health360x plus health coach|Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
215120169|NCT04791618|BEHAVIORAL|Health360x only (High tech)|All participants will have access to Helath360x with reminders generated for goal setting.
215120170|NCT03117855|DRUG|Capecitabine|Given PO
215120171|NCT03117855|OTHER|Laboratory Biomarker Analysis|Correlative studies
215120172|NCT03117855|RADIATION|Radioembolization|Undergo yttrium Y-90 radioembolization
215120173|NCT00217217|DEVICE|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
215120174|NCT05799131|DEVICE|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
214443407|NCT03830177|DRUG|Natural Treatment|Participants will receive a topical treatment formulated with natural ingredients (Lactobacillus sp., honey, and turmeric) and a kit containing all necessary materials, including an instruction handout. The treatment is applied to the scalp, left for roughly 5 minutes, and rinsed off.
214443408|NCT04497129|DEVICE|ROMTech PortableConnect|ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.
214443409|NCT04497129|DEVICE|Traditional Rehabilitation and CPM Device|Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
214443410|NCT04627948|DIAGNOSTIC_TEST|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
214443411|NCT03137771|RADIATION|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
214443412|NCT03137771|DRUG|Docetaxel|Given IV
214443413|NCT03137771|DRUG|Gemcitabine|Given IV
214520896|NCT04107844|DIAGNOSTIC_TEST|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
214520897|NCT03050372|DEVICE|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
214520898|NCT03050372|DEVICE|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
215029337|NCT04433195|DIAGNOSTIC_TEST|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
214443414|NCT03137771|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
214443415|NCT03137771|DRUG|Pemetrexed Disodium|Given IV
214443416|NCT03137771|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
214443417|NCT03137771|DRUG|Erlotinib Hydrochloride|Given PO
214443418|NCT03137771|DRUG|Pembrolizumab|Given IV
214443419|NCT03087032|DRUG|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
214443420|NCT03087032|DRUG|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
214443421|NCT03602014|DRUG|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
214443422|NCT03602014|OTHER|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
214443423|NCT06782204|DRUG|Paracetamol|At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have blood and urine samples collected 2 hours after administration.
214443424|NCT01898494|PROCEDURE|Transoral surgery|Undergo transoral surgical resection
214443425|NCT01898494|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
214443426|NCT01898494|DRUG|cisplatin|Given IV
214443427|NCT01898494|DRUG|carboplatin|Given IV
214443428|NCT06478030|DIAGNOSTIC_TEST|questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)|The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
215029338|NCT04931576|PROCEDURE|no drainage tube applied|No drainage tube implacement after TOETVA
214443429|NCT03289039|DRUG|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
214443430|NCT03289039|DRUG|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
214443431|NCT06780657|BEHAVIORAL|Online hypopressive exercise training program|The hypopressive exercises were based on recommendations from the literature and consultation with an expert in the field. Each session will be held twice a week for 20-25 minutes. Participants will perform each exercise 10 times during these sessions.
214443432|NCT05540002|DEVICE|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
215029339|NCT00336206|DRUG|Alemtuzumab|
215029340|NCT04118101|DRUG|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
215029341|NCT04118101|OTHER|control|no ESPB will be given.
215029342|NCT05994430|OTHER|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
215029343|NCT05280054|DRUG|AV-101|360 mg capsules
215029344|NCT05280054|DRUG|Probenecid|1000 mg oral
215029345|NCT00480532|DRUG|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
215029346|NCT00480532|DRUG|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
215029347|NCT00480532|DRUG|Oracea|40-mg tablet daily for 84 days
215029348|NCT00480532|DRUG|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
215029349|NCT00480532|DRUG|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
214443433|NCT05540002|DEVICE|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
214520899|NCT04916847|OTHER|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
214520900|NCT01863537|BEHAVIORAL|Multimedia Connect|
214443434|NCT04621357|RADIATION|Brain MRI|Brain MRI will include differents sequences.
214443435|NCT04621357|BIOLOGICAL|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
214443436|NCT04732494|BIOLOGICAL|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
214443437|NCT04732494|BIOLOGICAL|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
214520901|NCT01863537|BEHAVIORAL|Traditional Connect|
214520902|NCT04723784|OTHER|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
214520903|NCT04723784|OTHER|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
215029350|NCT00480532|DRUG|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
215029351|NCT00480532|DRUG|placebo daily|Placebo daily for the first 84 days of the study
215029352|NCT06183970|DEVICE|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
215029353|NCT06183970|DEVICE|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
215029354|NCT05860985|DEVICE|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
215029355|NCT06318546|DRUG|Dexmedetomidine Injection [Precedex],,,|patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
215029356|NCT06318546|DRUG|Fentanyl|will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
214443438|NCT04732494|DRUG|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
214443439|NCT06798285|PROCEDURE|Pars Plana Vitrectomy Standard|Group I: PPV with endoillumination set at 3.2 Lm.
214443440|NCT06798285|PROCEDURE|Pars Plana Vitrectomy 3D|Group II: PPV with endoillumination set at 0.5 Lm.
214443441|NCT06218368|BEHAVIORAL|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
214443442|NCT04939844|DRUG|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
214443443|NCT04023669|DRUG|Prexasertib|IV
214443444|NCT04023669|DRUG|Cyclophosphamide|IV
214520904|NCT04723784|OTHER|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
214520905|NCT03687918|OTHER|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~* To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
214693212|NCT07072455|OTHER|Scales|"This observational study consists of data collection using a structured questionnaire based on an e-CRF, distributed by e-mail.~Four questionnaires were administered : the Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS) and the State-Trait Anxiety Inventory (STAI-Y).~Socio-demographic and treatments were collected."
214443445|NCT04023669|DRUG|Gemcitabine|IV
214443446|NCT04023669|BIOLOGICAL|filgrastim|Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.
214443447|NCT04023669|BIOLOGICAL|peg-filgrastim|Given subcutaneously (SQ). Alternatively, filgrastim may be given.
214520906|NCT00161954|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
214520907|NCT00572299|DRUG|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
214520908|NCT01347099|BEHAVIORAL|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
214520909|NCT01347099|BEHAVIORAL|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
214443448|NCT05541666|BEHAVIORAL|The Emotional Freedom Technique|The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
214520910|NCT05418335|OTHER|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
214693213|NCT07072455|OTHER|High Intellectual Potential Scale|For participants with High Intellectual Potential, the total Intelligence Quotient (IQ) or General Ability Index (GAI), along with the index scores from the Wechsler scales (Verbal Comprehension Index, Perceptual Reasoning Index, Working Memory Index, and Processing Speed Index), will be extracted from the cognitive assessment previously completed by the participant prior to study enrollment.
214443449|NCT05906030|DIAGNOSTIC_TEST|Diaphragm ultrasound|Diaphragm ultrasound will be used pre- and postoperatively. Diaphragm dysfunction will be diagnosed using the measurements diaphragm thickening fraction, diaphragm excursion and diaphragm density.
215120175|NCT04671264|DEVICE|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
215120176|NCT00292019|PROCEDURE|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
215120177|NCT01374633|DRUG|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
214443450|NCT01007383|DRUG|LEO 27847|First in man
214693214|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
214443451|NCT04514497|PROCEDURE|Biopsy|Undergo tumor biopsy
214443452|NCT04514497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214443453|NCT04514497|PROCEDURE|Computed Tomography|Undergo CT
215120178|NCT00731679|DRUG|Rifaximin|
214443454|NCT04514497|DRUG|Elimusertib|Given PO
214520911|NCT05358184|DEVICE|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
214520912|NCT01404377|PROCEDURE|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
215120179|NCT00731679|DRUG|Placebo|
214443455|NCT04514497|DRUG|Irinotecan Hydrochloride|Given IV
214443456|NCT04514497|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214443457|NCT04514497|DRUG|Topotecan Hydrochloride|Given IV
214443458|NCT03897686|DEVICE|"hydrous biopolymer with silver ions Argiform"|2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml
214443459|NCT03897686|DEVICE|saline solution|2 once-weekly intra-articular injections of saline solution 4 ml
214443460|NCT04680897|BEHAVIORAL|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
214520913|NCT03519906|DRUG|Metoprolol|Patients are tested for their normal prescription metaprolol medication
215120180|NCT00330122|PROCEDURE|fore locked plate|
214520914|NCT02510404|BIOLOGICAL|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
214443461|NCT04680897|BEHAVIORAL|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
214520915|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
214520916|NCT04385849|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214693215|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
214693216|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
214693217|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
214693218|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
214693219|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
215120181|NCT00330122|PROCEDURE|external radiocarpal fixer|
214443462|NCT05579327|DRUG|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
214443463|NCT05579327|DRUG|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
214443464|NCT05214482|DRUG|AK112|IV infusion,Specified dose on specified days
214443465|NCT05214482|DRUG|AK117|IV infusion,Specified dose on specified days
214443466|NCT05214482|DRUG|Chemotherapy|IV infusion,Specified dose on specified days
214443467|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
214443468|NCT04889430|DRUG|Iptacopan|Iptacopan 200mg twice daily oral
214443469|NCT05986864|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
214443470|NCT05695131|DEVICE|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
214443471|NCT06415474|PROCEDURE|Lymphocyte Phenotyping Procedure|"For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture."
214443472|NCT06798038|DEVICE|radiofrequency ablation|35 Patients will be undergo for radiofrequency ablation which will be applied to each genicular nerve.
214443473|NCT06798038|DRUG|phenol neurolysis|35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
214443474|NCT06798038|DRUG|alcohol neurolysis|35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
214443475|NCT04995835|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
214443476|NCT06083233|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
215120182|NCT01598922|BEHAVIORAL|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
215120183|NCT01940835|PROCEDURE|Upper endoscopy with small bowel biopsies and brushings.|
214443477|NCT06083233|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
214520917|NCT04385849|OTHER|Saline|Sterile saline solution
214520918|NCT06373367|OTHER|Illustration based application|Illustrations regarding the cause, risks, and warning signs of preeclampsia
214520919|NCT06373367|OTHER|Text based application|Standard preeclampsia discharge instructions
214520920|NCT05530928|OTHER|Reproductive life plan counseling|The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
214520921|NCT05991947|OTHER|No intervention|No intervention measures are needed.
214520922|NCT06291220|DRUG|Obinutuzumab|Intravenous Infusion
214520923|NCT06291220|DRUG|ABBV-453|Oral; Tablet
214520924|NCT01584999|BIOLOGICAL|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
214520925|NCT01375777|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214520926|NCT01375777|DRUG|Ezetimibe|Administered orally once a day
214520927|NCT01375777|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
215120184|NCT01940835|OTHER|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
215120185|NCT01940835|OTHER|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
214693220|NCT07074964|OTHER|Autonomic nervous system intervention|Manual therapy applied to structures adjacent to the vagus nerve along its pathway. Head: CV4 tecnique and Jugular foramen tecnique; Neck: stretching and mobilization of the superficial and deep layers; Thorax: Longitudinal and transverse translations of the mediastinum; Diaphragm tecniques, Abdomen: Stretching of the gastro-phrenic ligament with lowering of the stomach and general treatment of the small intestine and the mesentery. Stretching, compression and traction movements will be carried out on these structures.
214693221|NCT07074964|OTHER|Slight finger pressure|The hands will be placed on areas similar to those in the intervention group, with the fingertips in contact with the skin of the area. A slight finger pressure will be applied, which would not have the same effect as the proposed techniques, since those techniques require a greater intensity of manipulation of the described tissues and structures.
214693222|NCT07075848|PROCEDURE|vaginal delivery|follow up of progress of labour
215120186|NCT03724929|PROCEDURE|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
214443478|NCT06083233|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
214443479|NCT06083233|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
214443480|NCT06083233|PROCEDURE|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
214443481|NCT06083233|PROCEDURE|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
214443482|NCT06083233|PROCEDURE|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
214443483|NCT06083233|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
214443484|NCT06787118|DRUG|CBD oil|Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
214443485|NCT06787118|DRUG|Placebo|Patients will receive placebo for a total of 12 weeks.
214443486|NCT06820424|BIOLOGICAL|Anti-CDH17 CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-CDH17 CAR-T Cells after lymphodepleting therapy.
214443487|NCT06787898|OTHER|Group R: retrolaminar block performed group|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®) was injected posterior to each lamina (T9, T10), totalling 20 mL
214520928|NCT04807452|OTHER|Strength and balance training|Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.
214520929|NCT04807452|OTHER|Aerobics training|"After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down ."
214520930|NCT05500872|OTHER|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
214693223|NCT05563298|DEVICE|Neuro RX Gamma device|The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
214693224|NCT05563298|DEVICE|Sham Neuro RX Gamma device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
215120187|NCT03724929|DEVICE|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
214693225|NCT07076966|DEVICE|3D device|Use 3D machine to generate the 3D image
215120188|NCT02488005|DEVICE|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
215120189|NCT02964000|DEVICE|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
215120190|NCT02964000|DEVICE|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
215120191|NCT02964000|DEVICE|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
215120192|NCT03286452|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
215120193|NCT05980585|DEVICE|CPM Device|Daily use of the CPM wearable device
215120194|NCT03127293|DIAGNOSTIC_TEST|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
215120195|NCT05431478|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
214443488|NCT06787898|OTHER|Group C - Placebo|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®)was injected posterior to each lamina (T9, T10), totalling 20 mL.
214443489|NCT06788054|OTHER|intradialysis exercise|moderate intensity aerobic and muscular resistance exercise protocol lasting 12 weeks
214443490|NCT06791733|OTHER|Passive static stretching|the intervention consists of passive static stretching of agonist or antagonist muscles between sets
214443491|NCT06792487|PROCEDURE|skin biopsy|punch biopsy (6 mm) of lesional psoriasis skin
214443492|NCT06792110|DEVICE|Artificial Intelligence Integrated Hearing Aid Use|Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
214443493|NCT06792110|DEVICE|Phonak Infineo Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
214443494|NCT06792110|DEVICE|Oticon Real Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
214443495|NCT06785610|DIETARY_SUPPLEMENT|Capsulase®|Capsulase® supplement daily administration after surgery
214443496|NCT06782568|DIAGNOSTIC_TEST|Ultrasound Scan|Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
214443497|NCT06787092|PROCEDURE|bladder cycling|started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 250 cc of sterile saline for 2 hours.
214443498|NCT06318403|DRUG|Transdermal estrogen|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
214443499|NCT06318403|PROCEDURE|Rotator Cuff Repair Surgery|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
214443500|NCT04978597|DRUG|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
214443501|NCT04978597|DRUG|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
214520931|NCT05500872|OTHER|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
214520932|NCT00512473|DRUG|Saline infusion|0.9 % NaCl
214520933|NCT00512473|DRUG|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
214520934|NCT00512473|DRUG|Pegvisomant|30 mg Somavert administered at t = - 36 hours
214520935|NCT05135845|DRUG|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
214520936|NCT05135845|DRUG|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
214520937|NCT00211926|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
214520938|NCT00211926|BIOLOGICAL|placebo|single dose of placebo
214520939|NCT05587907|DEVICE|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
214520940|NCT02334202|BEHAVIORAL|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
214520941|NCT02334202|OTHER|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
214520942|NCT05163678|OTHER|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
214443502|NCT06784219|DIAGNOSTIC_TEST|Hindi version of self reported oral health questionnaire|The original 8-item CDC/AAP questionnaire as well as other selected periodontal disease surveillance questions will be translated into Hindi through forward translation, backward translation, and expert committee process to reach a consensus and produce a prefinal version. The prefinal version questionnaire will be pilot tested on a sample of 20 patients to evaluate the overall comprehension by non-professionals. On the basis of responses and evaluation from the participants, the questionnaire will be further refined to build the final version. The final version of the questionnaire will be administered to patients seeking care from out-patient department of department of Periodontics at PGIDS, Rohtak. The participants will be required to fill the questionnaire by themselves prior to periodontal examination, without any help from others.
214443503|NCT06785519|BIOLOGICAL|CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection|Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion
214443504|NCT06792149|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions .
214443505|NCT06792149|OTHER|Adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
214443506|NCT06792149|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience
214443507|NCT06784570|DRUG|levosemindan|In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
214443508|NCT06784570|DRUG|adrenaline,noreadrenaline,dopamine and doputamine|adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
214443509|NCT06472089|BEHAVIORAL|BMT-CARE|Therapist-delivered psychosocial intervention comprised of 6 sessions
214443510|NCT06472089|BEHAVIORAL|Usual Care|Meeting a transplant social worker prior to HCT and as needed for extra visits
214520943|NCT05747872|BEHAVIORAL|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~1. The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~2. Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~3. Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
214520944|NCT05650437|DEVICE|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
214520945|NCT05650437|BEHAVIORAL|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
215120196|NCT05431478|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
215120197|NCT05431478|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
215120198|NCT02326597|OTHER|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
215120199|NCT02326597|OTHER|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
215120200|NCT02369913|OTHER|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
214520946|NCT05650437|DIETARY_SUPPLEMENT|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A\&B)
214520947|NCT00198666|DRUG|Zinc|Elemental Zinc
214520948|NCT02855892|OTHER|Placebo|
214520949|NCT02855892|DRUG|GV1001|
215120201|NCT01158781|BEHAVIORAL|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
214520950|NCT02665624|DRUG|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
214520951|NCT02665624|DRUG|Senna alone|comparison of bowel cleansing and patient comfort.
215120202|NCT02286921|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
215120203|NCT02286921|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
214443511|NCT06629454|DEVICE|Adherence to digital incentive spirometer in the postop period after major chest surgery.|Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
215120204|NCT02286921|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
215120205|NCT05192993|OTHER|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
214443512|NCT04999306|BEHAVIORAL|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
214443513|NCT04999306|BEHAVIORAL|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
214443514|NCT04905407|DRUG|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
214443515|NCT04905407|DRUG|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
214443516|NCT04905407|DRUG|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
214443517|NCT05946109|BEHAVIORAL|ACTIVE-AGE@home|"functional, homebased training program offering basic functional exercises connected to meaningful activities, lifestyle coaching and motivational interviewing; derived from evidence-based training principles . Through a precise application of the FITT-VP\* guidelines, a progressive and balanced program was designed and piloted in different proof-of-concept studies. The uniqueness of the program lies in the multi-component approach which brings together functional exercises for (1) muscle strength/muscle endurance, (2) aerobic endurance, (3) flexibility, motor ability and balance and (4) meaningful daily activities, in a home-based environment.~The frail participants are visited three times a week during 24 weeks with in total 72 sessions. Each session is 1 hour in duration. Thus they receive 72 training hours.~\*(Frequency, Intensity, Time, Type of exercises, Volume and Progression)"
214520952|NCT03598023|DEVICE|Cytal® Burn Matrix|Cytal® Burn Matrix
214520953|NCT03598023|DEVICE|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
214520954|NCT05851170|OTHER|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
214520955|NCT05851170|OTHER|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
214520956|NCT00000940|DRUG|Ritonavir|
214520957|NCT00000940|DRUG|Abacavir sulfate|
214520958|NCT00000940|DRUG|Amprenavir|
214520959|NCT00000940|DRUG|Lamivudine|
214520960|NCT00000940|DRUG|Stavudine|
214520961|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
214520962|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
214520963|NCT05554991|DIETARY_SUPPLEMENT|HMO|Composition comprising of HMO
214520964|NCT05554991|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
214520965|NCT05554991|BEHAVIORAL|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
214520966|NCT03886688|DRUG|HEC53856|oral administration
214520967|NCT03886688|DRUG|placebo|oral administration
214520968|NCT02791685|BEHAVIORAL|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
214520969|NCT02791685|BEHAVIORAL|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
214520970|NCT02791685|BEHAVIORAL|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
214520971|NCT00042510|BIOLOGICAL|Treatment group|
214520972|NCT05734235|DIETARY_SUPPLEMENT|Vitamin C|Two Vitamin C tablets daily for 8 days.
214520973|NCT05734235|DIETARY_SUPPLEMENT|Vitamin E|One Vitamin E tablet daily for 8 days.
214520974|NCT03635801|DEVICE|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
215120206|NCT05192993|OTHER|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
214443518|NCT03434509|OTHER|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
214443519|NCT04639518|OTHER|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
214443520|NCT04639518|OTHER|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
214443521|NCT05178810|DRUG|FAB122|Daily dose 100 mg
214443522|NCT05178810|DRUG|Placebo|Daily dose
214443523|NCT04423250|OTHER|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|\- Failure to trace, Lack of product information, absence of product in the operating room
214443524|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
214443525|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
214443526|NCT01485575|PROCEDURE|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
214443527|NCT03969446|DRUG|Decitabine|Given IV
214520975|NCT05444231|BEHAVIORAL|Brain Training A|Interventions may include education, exercises, and/or strategies to support brain health
214520976|NCT05444231|BEHAVIORAL|Brain Training B|Interventions may include education, exercises, and/or strategies to support brain health
214520977|NCT05444231|BEHAVIORAL|Brain Training C|Interventions may include education, exercises, and/or strategies to support brain health
214520978|NCT04639752|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
214520979|NCT04639752|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
214520980|NCT06561412|BEHAVIORAL|Produce Prescription|Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. These vouchers are sponsored by The Food Trust.
214520981|NCT05911191|OTHER|Exercise based prehabilitation|A peripheral muscle strengthening program
214520982|NCT02169089|DRUG|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
214520983|NCT02169089|DRUG|Placebo|Placebo
214520984|NCT05791552|DIAGNOSTIC_TEST|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
214520985|NCT04004663|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
214520986|NCT04357522|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
214520987|NCT04357522|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
215120207|NCT05192993|OTHER|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
215120208|NCT05661279|PROCEDURE|general anesthesia|general anesthesia
214520988|NCT01838499|BIOLOGICAL|MEDI8968|SC injection at baseline, Week 4 and Week 8
214520989|NCT01838499|BIOLOGICAL|Saline|SC injection at baseline, Week 4 and Week 8
214520990|NCT00036309|DRUG|Duloxetine Hydrochloride|
214520991|NCT00788632|BEHAVIORAL|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
214443528|NCT03969446|BIOLOGICAL|Pembrolizumab|Given IV
214443529|NCT03969446|DRUG|Venetoclax|Given PO
214520992|NCT00788632|BEHAVIORAL|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
214520993|NCT00788632|BEHAVIORAL|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
214520994|NCT01939483|DRUG|irinotecan hydrochloride|Given IV
214520995|NCT01939483|OTHER|laboratory biomarker analysis|Correlative studies
214443530|NCT06159985|PROCEDURE|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
214443531|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
214443532|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
214443533|NCT05629169|OTHER|No intervention applied - observational study only|Observational study only. All head impacts will be assessed using video footage.
215120209|NCT05661279|PROCEDURE|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
214520996|NCT02977468|DRUG|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
214520997|NCT02977468|RADIATION|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
214520998|NCT02368691|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
215120210|NCT05661279|PROCEDURE|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
214520999|NCT01502202|DRUG|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
215120211|NCT03642652|BEHAVIORAL|SMS|Text reminders to mobile telephone
214521000|NCT01502202|DRUG|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
214521001|NCT01502202|DRUG|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
214521002|NCT06228417|OTHER|Adaptive digital intervention|Participants received reminder for medication intake on daily basis. Also, short message regarding hypertension, medication and lifestyle changes
214521003|NCT00313963|DRUG|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
214521004|NCT00313963|DRUG|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
214521005|NCT04513535|OTHER|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
214521006|NCT04513535|OTHER|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
214521007|NCT04513535|OTHER|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
215120212|NCT05937061|BIOLOGICAL|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
215120213|NCT05937061|OTHER|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
214443534|NCT05066009|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consistent contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
215120214|NCT05937061|RADIATION|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
214443535|NCT05066009|DEVICE|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
214521008|NCT04513535|OTHER|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
214521009|NCT04581772|DRUG|DNL343|Multiple oral doses
214521010|NCT04581772|DRUG|Placebo|Single oral dose
214521011|NCT04581772|DRUG|DNL343|Single oral dose
214521012|NCT01854164|DIETARY_SUPPLEMENT|HGE (hydrolyzed ginseng extract)|
214521013|NCT01854164|DIETARY_SUPPLEMENT|Placebo|
214521014|NCT03863184|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
214521015|NCT03863184|DRUG|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
214521016|NCT03863184|DRUG|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
214521017|NCT03863184|DRUG|Obinutuzumab|Obinutuzumab on days 1, 8, 15 of cycle 1, day 1 of cycles 2-6, then every 2 cycles
214521018|NCT00675519|BEHAVIORAL|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
214521019|NCT00895297|DRUG|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
214521020|NCT01459523|PROCEDURE|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
214521021|NCT01459523|PROCEDURE|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
214521022|NCT01459523|PROCEDURE|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
214521023|NCT01459523|PROCEDURE|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
214693226|NCT07078747|BEHAVIORAL|To compare the effectiveness of video- and model-based training methods in improving Leopold maneuver skills among midwifery students.|"This study involves two educational interventions aimed at improving Leopold maneuver skills among midwifery students. Both intervention groups receive a standardized 2-hour theoretical lecture about the purpose, application, and clinical relevance of the Leopold maneuvers.~In the Video-Based Training Group, students watch an instructional video developed by the research team that visually demonstrates each step of the maneuver.~In the Model-Based Training Group, students perform the maneuvers on anatomical models under the supervision of an instructor.~These interventions are conducted in separate sessions to prevent cross-group contamination."
214693227|NCT04941378|DRUG|OTL38|One time infusion of OTL38
214443536|NCT05066009|OTHER|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
214443537|NCT04906200|OTHER|Best Practice|Receive usual care
214521024|NCT00550927|BIOLOGICAL|bevacizumab|
214521025|NCT00550927|DRUG|enzastaurin hydrochloride|
214521026|NCT00550927|OTHER|diagnostic laboratory biomarker analysis|
214521027|NCT00550927|OTHER|pharmacological study|
214521028|NCT00287183|DRUG|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
214521029|NCT00287183|OTHER|Placebo|Placebo
215120215|NCT05937061|OTHER|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
215120216|NCT00203489|DEVICE|KERLIX A.M.D. Gauze|
215120217|NCT04089761|DEVICE|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214443538|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
214443539|NCT04906200|OTHER|Survey Administration|Complete survey
214443540|NCT03263026|DRUG|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
214443541|NCT03263026|OTHER|R-CHOP + placebo|R-CHOP + placebo
214521030|NCT05716152|DIAGNOSTIC_TEST|Morning blood sample and skin punch biopsy of 4 mm diameter.|"1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
214521031|NCT03314233|PROCEDURE|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
214521032|NCT02029027|DEVICE|GYNEFFIK(R)|Vaginal electro-stimulation medical device
214521033|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
214521034|NCT03003832|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
214521035|NCT01114217|DRUG|Ferumoxytol|IV Ferumoxytol
214521036|NCT03224689|DEVICE|PEEK-Optima Femoral Component|TKA Surgery
214521037|NCT01930877|DRUG|Lidocaine|Lidocaine iv bolus followed by infusion
214521038|NCT01930877|OTHER|Placebo (normal saline)|Normal saline bolus followed by infusion
214521039|NCT06642376|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
214521040|NCT05685511|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
214521041|NCT05685511|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
214521042|NCT05685511|OTHER|Usual care resources|List of resources that the patient can explore on their own
214521043|NCT01183013|DRUG|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
214521044|NCT01183013|DRUG|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
214521045|NCT01183013|DRUG|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
214521046|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
214521047|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
214521048|NCT01183013|DRUG|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
214443542|NCT05253833|DRUG|AR882 Dose 1|Solid Oral Capsule
214443543|NCT05253833|DRUG|AR882 Dose 2|Solid Oral Capsule
214443544|NCT05253833|DRUG|Allopurinol Tablet|Solid tablet
214443545|NCT02661893|DRUG|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
214443546|NCT02661893|DRUG|Rifampin|Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
214443547|NCT05769660|DRUG|BEY1107|Administer twice daily, PO, 4-week continuous dose.
214443548|NCT05769660|COMBINATION_PRODUCT|Temozolomide|Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
214443549|NCT06301997|DIETARY_SUPPLEMENT|ZAX.1400.P03|ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
214443550|NCT06301997|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
214443551|NCT06151535|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
214443552|NCT06153056|DIAGNOSTIC_TEST|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
214521049|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
214521050|NCT00209222|DRUG|Rituximab|antibody
214521051|NCT00209222|DRUG|Cyclophosphamide|chemotherapy
214521052|NCT00209222|DRUG|Doxorubicin|chemotherapy
214521053|NCT00209222|DRUG|Vincristine|chemotherapy
214521054|NCT00209222|DRUG|Prednisone|corticosteroide
214521055|NCT00209222|DRUG|Cisplatinum|chemotherapy
214521056|NCT00209222|DRUG|Ara-C|chemotherapy
214521057|NCT00209222|DRUG|Dexamethasone|corticosteroide
214521058|NCT00209222|DRUG|BCNU|chemotherapy
214521059|NCT00209222|DRUG|Melphalan|chemotherapy
214521060|NCT00209222|DRUG|Etoposide|chemotherapy
214521061|NCT00209222|DRUG|G-CSF|growth factor
214521062|NCT00209222|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
214521063|NCT00209222|PROCEDURE|chemotherapy: R-DHAP|immuno-chemotherapy
214521064|NCT00209222|PROCEDURE|chemotherapy: Dexa-BEAM|chemotherapy
214521065|NCT00209222|PROCEDURE|stem cell harvest|procedure
214521066|NCT00209222|PROCEDURE|total body irradiation|radiation
214521067|NCT00209222|PROCEDURE|high-dose chemotherapy: Cyclophosphamide|chemotherapy
214443553|NCT06797167|DEVICE|Injections of a filler gel containing cross-linked hyaluronic acid|"Vaginal Filler will be administered according to Investigator's judgment and Instruction For Use (IFU) to correct hypotrophy, improve the shape and increase the volume of the female external genital areas (labia majora). Vaginal Filler is a resorbable medical device available in packages containing 2 sterile pre-filled mono-use syringes of 1 ml with pre-assembled plunger rod and backstop, containing 25 mg/g cross-linked hyaluronic acid.~The injection is performed by medical personnel at visit V0 in one or both sides of the superficial subcutaneous layer of the labia majora, along its longitudinal axis.The dosage to be used for the individual case is at the doctor's discretion. An anesthetic may be applied (lidocaine 2% injection only in the cannula access point) to the affected area before the IP injection.~In order to maintain the results achieved, an eventual touch-up could be performed one months after the first treatment in the same areas of the first injection, at visit V2."
214443554|NCT06789224|DEVICE|CATUVAB|inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates
215120218|NCT06245733|OTHER|Compassion-Based Education Program Adapted for Adults|Training will be given once a week. This training will last 10 weeks in total.
214443555|NCT06685601|DEVICE|tPBM（active）|During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.
214443556|NCT06685601|DEVICE|tPBM（sham）|During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.
214443557|NCT05070013|DEVICE|Deep Brain Stimulation|All participants will undergo three 1-week interventions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
214443558|NCT06794528|OTHER|RehbeCa mobile application|The system consists of a mobile application (to be used by patients) and a web application (to be used by physiotherapists) that allows monitoring of the patient's performance without the need for attendance, thus facilitating telerehabilitation. The mobile application consists of a serious game that aims to induce the patient to perform neck exercises, adapting to their capacity and evolution at all times through artificial intelligence. The patient's interaction with the mobile application is based on the integration of a vision-based head-tracker to track the movements of the patient's head. The web application aims to provide professionals with a tool to monitor the evolution of their patients through the data captured by the mobile application.
214443559|NCT06794528|OTHER|Home exercise program|Set of therapeutic exercises to be carried out at home. They are taught face-to-face, and also printed on a leaflet that is delivered to the participant.
214443560|NCT06795477|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
214443561|NCT06795477|BEHAVIORAL|Interpretable MI|Participants receive interpretable machine intelligence assistance to complete the medication verification tasks.
214443562|NCT06795477|BEHAVIORAL|Uninterpretable MI|Participants receive uninterpretable (i.e., black-box) machine intelligence assistance to complete the medication verification tasks.
214443563|NCT05139914|DRUG|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
214443564|NCT05139914|OTHER|Placebo|Placebo capsule for 6 weeks
214443565|NCT06792669|OTHER|Simulation training to evaluate the participants' manual skill improvement|
214443566|NCT06830655|OTHER|Fatigue Protocol|"After the warm-up, each participant will be assigned the easiest route of their skill level on the Kilter Board with a 15-degree wall incline. Participants will start the route from the initial holds and finish it with the need to touch the top hold with both hands. They will be instructed to climb as quickly and smoothly as possible. After reaching the last hold, they will descend along the same route to the initial holds without touching the ground. The procedure will be repeated until the participant reports fatigue that prevents further climbing. Any stoppage by the participant during the protocol will not be allowed to last longer than 5 seconds, will be recorded, and categorized as either isometric contraction or rest time, depending on the nature of the stoppage, which will be established during records analyzing."
214521068|NCT00209222|PROCEDURE|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
214521069|NCT03379779|DIAGNOSTIC_TEST|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
214521070|NCT05114161|OTHER|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
214443567|NCT06797219|DEVICE|Low Level Laser Therapy for Intraventricular Hemorrhage of Prematurity|The experimental arm will be administered treated with the study device. It will be 10 mW/cm\^2 of 650nm laser through use of a novel laser device given for 5 minutes twice daily for 12 days.
214521071|NCT03185910|BEHAVIORAL|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
214521072|NCT03185910|BEHAVIORAL|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
215120219|NCT01553019|RADIATION|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
215120220|NCT01553019|DRUG|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
215120221|NCT05721521|OTHER|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
215120222|NCT05721521|OTHER|Control|30 minute completing seated activities (e.g., wordsearches)
214443568|NCT06837532|DRUG|Ultrasound-guided rectus sheath block|Patients will receive ultrasound-guided rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the end of surgery.
214693228|NCT04941378|DEVICE|intraoperative imaging camera system|intraoperative imaging camera system
214693229|NCT07083700|BEHAVIORAL|Frame Access|FRAME™ provides a collaborative care platform that connects patients with evidence-based resources, education and support from a dedicated care team throughout their reproductive health care journey. More specifically, for patients exploring fertility treatment. Frame supplements the patient experience by providing patients with direct contact to board-certified fertility coaches and resources that can be accessed between appointments in a web-based application. Regular use of Frame's platform may help patients make lifestyle changes that can improve their fertility outcomes as well as boost their emotional health throughout the treatment process and reduce feelings of overwhelm and loneliness which can lead to patients dropping out of care.
214443569|NCT06837532|DRUG|Surgical rectus sheath block|Patients will receive a surgical rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the time of closure.
214443570|NCT06837532|DRUG|Local anesthesia infiltration|Patients will receive local anesthesia infiltration at the end of surgery.
214443571|NCT04434209|DEVICE|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
214521073|NCT05317377|OTHER|Exercise Therapy|Structured exercises focused on hand functionality
214443572|NCT04434209|OTHER|Standard of Care|Standard of Care patient management
214443573|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
214693230|NCT07082595|OTHER|TASS Intervention (Sham)|Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. No auditory stimuli will be delivered.
214693231|NCT07082595|OTHER|TASS Intervention (Verum)|TASS: Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. Auditory stimuli will be delivered through the integrated headphones when non-rapid-eye-movement (NREM) sleep is detected during the night to induce TASS.
214443574|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
214443575|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
214521074|NCT05317377|DEVICE|Leap Motion Based Exergame|Appropriate games from Leap Motion Based Exergame system focused on hand functionality
214521075|NCT06003868|OTHER|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
215120223|NCT03467711|OTHER|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
215120224|NCT03467711|OTHER|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
215120225|NCT04485546|DRUG|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
214443576|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
214693233|NCT07084701|DEVICE|Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD)|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
214693234|NCT07084701|DEVICE|sham-intervention treatment|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
214693235|NCT07082764|DRUG|Brimonidine gel|TAR-0520 gel
214693236|NCT07082764|OTHER|No intervantion|No treatment
214443577|NCT05018793|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
214443578|NCT05018793|BIOLOGICAL|AlloRx|Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal injection for
214443579|NCT05183490|DRUG|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"
214443580|NCT04255979|DRUG|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
215120226|NCT04366661|DIAGNOSTIC_TEST|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
215120227|NCT06303596|OTHER|Hippotherapy|Hippotherapy: Hippotherapy in psychiatry is not concerned only about the patient sitting on a horse and the horseback movement influencing the physical condition of the patient and his functional and postural disorders. This therapy is concerned with positive effects on a patient's mental state and use mainly contact with the horse, work with the horse from the ground and riding on horseback. It aims for enjoyment, social communication, and the development of cognitive and executive functions.
214443581|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
214521076|NCT06003868|OTHER|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
215120228|NCT06303596|OTHER|Standard psychiatric treatment|Standard psychiatric treatment: Standard psychiatric treatment includes medication and routine activities provided by the Community Mental Health Center.
214521077|NCT06011642|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter, digitale Version (Kinder-eDIPS)|The Kinder-eDIPS is a digital, structured interviews which assesses the most frequent psychological disorders. It exists in a parent and a child version. It can be delivered by trained clinicians and takes between 60 and 120 minutes.
214521078|NCT04114903|OTHER|Study A: Single use of cannabis flower product|Participants are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
214521079|NCT04114903|OTHER|Study B: Ad libitum cannabis use for four weeks or no cannabis use|Participants choose whether to use a cannabis flower product ad libitum for four weeks or to not use cannabis for four weeks. Participants who choose to use cannabis are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
214443582|NCT00441298|DRUG|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
214443583|NCT00441298|DRUG|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
214521080|NCT04503772|PROCEDURE|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
214521081|NCT01189994|PROCEDURE|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
214443584|NCT00599469|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
214443585|NCT02421380|DRUG|Hyperpolarized Pyruvate|
214443586|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
214521082|NCT01189994|BEHAVIORAL|Orientation|Orientation sessions focusing in fibromyalgia
214521083|NCT04232202|DEVICE|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
214521084|NCT04232202|PROCEDURE|Standard extraction|Standard extraction procedure
214521085|NCT01358201|DRUG|vINCRISTINE|
214521086|NCT01358201|DRUG|Dexamethasone|
214521087|NCT01358201|DRUG|Methotrexate|
214521088|NCT01358201|DRUG|Cytosine arabinoside|
214521089|NCT01605084|DRUG|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
214521090|NCT01605084|DRUG|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
214521091|NCT01605084|DRUG|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
214521092|NCT01605084|DRUG|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~\- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine"
214521093|NCT01525888|PROCEDURE|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
214521094|NCT03352570|DEVICE|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
214521095|NCT05655689|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
214521096|NCT05655689|DRUG|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
215120229|NCT01817439|DRUG|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
215120230|NCT00099138|BEHAVIORAL|Caloric Restriction (CR)|
215120231|NCT00099138|BEHAVIORAL|Exercise|
215120232|NCT00895115|DIETARY_SUPPLEMENT|vitamin E|Given once daily
215120233|NCT00895115|PROCEDURE|sham intervention|No supplementation
215120234|NCT03036020|RADIATION|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
215120235|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
214693237|NCT07082179|DRUG|Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum (cisplatin/carboplatin)|"Induction therapy regimen：Iparomlimab and Tuvonralimab 5 mg/kg, every 3 weeks (q3w), administered via intravenous infusion. Paclitaxel polymer micelles in combination with platinum: In cycle 1, paclitaxel polymer micelles 230 mg/m² administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min. In cycle 2, if the patient's nadir neutrophil count is ≥1.0×10⁹/L and the nadir platelet count is ≥80×10⁹/L after cycle 1, and no grade II-IV non-hematologic toxicities have occurred, then paclitaxel polymer micelles 300 mg/m² will be administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min.~The local treatment regimen is either surgery or standard radiotherapy. The consolidation therapy regimen consists of Iparomlimab and Tuvonralimab for 1 year , with the decision to combine with chemotherapy left to the discretion of the treating physician on an individual basis."
214693238|NCT07082985|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 14 days (4 capsules per day)
214693239|NCT07082985|OTHER|Maca (Maca trial)|The Maca capsule supplement was taken for 14 days, with a daily dosage of 1600 mg of Maca (equivalent to 4 capsules per day, each containing 400 mg of Maca).
215120236|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
215120237|NCT04739436|DEVICE|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
215120238|NCT06162026|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
215120239|NCT00676013|PROCEDURE|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
215120240|NCT00676013|PROCEDURE|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
214443587|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
214693240|NCT07082478|DEVICE|in-ear device measuring blood flow|"A small in-ear wearable device will be placed to monitor the blood flow to the head. The investigators will make sure it fits comfortably and show the participant how to use it properly.~Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin of the abdomen to monitor sensor sugar levels.~These sensors will be placed during visit one and will be worn together for 10 days. A followup visit (visit 2) will occur remotely at 4-6 days later. A final visit will occur after 10 days when the device will be removed."
214693241|NCT07082647|BEHAVIORAL|Mixed feedback method|Feedback (technical correction) method in which both visual and verbal feedback are predominantly used in the feedback given to the participants throughout the training program.
214693242|NCT07082647|BEHAVIORAL|Visual feedback method|Feedback (technical correction) method in which visual feedback is predominantly used in the feedback given to gymnasts throughout the training program.
215120241|NCT00676013|PROCEDURE|Homograft|Grafting using homograft as a skin substitute
215120242|NCT00676013|PROCEDURE|Autograft|grafting using patients own skin from a separate donor site
215120243|NCT06056583|DRUG|Cimetidine 200 MG|Cimetidine will serve as the probe drug
215120244|NCT00428948|DRUG|Tolvaptan|Tolvaptan was supplied as tablets.
215120245|NCT00428948|DRUG|Placebo|Placebo was supplied as tablets.
215120246|NCT01926834|DRUG|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
215120247|NCT01926834|DRUG|placebo|normal saline, 500ml,i.v.,qd, for 7 days
215120248|NCT04215809|DRUG|Lisaftoclax|Lisaftoclax investigation drug in ramp up dosing
214443588|NCT05802706|OTHER|No intervention.|No intervention.
214443589|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
214443590|NCT06064916|DIAGNOSTIC_TEST|Visual Acuity|Monocular and binocular measurement of distance, intermediate, and near visual acuity
214443591|NCT06064916|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
214443592|NCT06064916|OTHER|Intraocular Lens Satisfaction (IOLSAT) Questionnaire|Self-reported post-operative patient satisfaction with vision after surgery
214443593|NCT06064916|OTHER|Quality of Vision After Surgery (QUVID) Questionnaire|Self-reported post-operative patient vision quality after surgery
214443594|NCT06064916|OTHER|Visual Disturbance Questionnaire|Questionnaire of self-reported visual disturbances of patients
214443595|NCT06064916|DIAGNOSTIC_TEST|Topography and Tomography|Topography and tomography measurements with Atlas, iTrace, and/or Pentacam
214443596|NCT02697136|DRUG|CER-001|Recombinant human apoA-I/phospholipid complexes
215120249|NCT05313087|BIOLOGICAL|COVID-19 vaccine|assess response to vaccine
215120250|NCT04248699|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
215120251|NCT01552070|BEHAVIORAL|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
215120252|NCT01552070|OTHER|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
215120253|NCT01835821|DEVICE|prosthetic crowns|prosthetic crowns
214443597|NCT02697136|DRUG|Placebo|0.9% Sodium Chloride Injection, USP
214443598|NCT05468489|DRUG|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
214443599|NCT05468489|DRUG|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
214443600|NCT03829852|DRUG|Regorafenib|Treatment was performed based on physician's discretion
214521097|NCT05655689|DRUG|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
214521098|NCT05655689|DRUG|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
214521099|NCT05655689|DRUG|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
214521100|NCT05655689|DRUG|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
214521101|NCT05655689|DRUG|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
215120254|NCT04639544|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
214521102|NCT05655689|DRUG|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
215120255|NCT04639544|DIETARY_SUPPLEMENT|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
215120256|NCT03449758|DRUG|SARILUMAB|Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
215120257|NCT03449758|DRUG|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
215120258|NCT03449758|DRUG|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
214443601|NCT05672147|BIOLOGICAL|Anti-CD33 CAR T-cells|Given IV
214443602|NCT05672147|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
214443603|NCT01095796|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
214443604|NCT01095796|DRUG|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
214443605|NCT01095796|DRUG|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
214443606|NCT01095796|DRUG|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
214443607|NCT02926911|OTHER|Surgery|Surgery +/- radiation choice for endocrine therapy
214693243|NCT07082647|BEHAVIORAL|Verbal feedback method|Feedback (technical correction) method in which verbal feedback is predominantly used in the feedback given to gymnasts throughout the training program.
214693244|NCT07083739|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
215120259|NCT03449758|DRUG|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
214443608|NCT02926911|OTHER|Active Monitoring|Choice for endocrine therapy
214443609|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
214443610|NCT06420570|PROCEDURE|Thoracic Surgery|Patients will either undergo thoracic surgery, specifically thoracotomy (traditional method of chest surgery using a large surgical incision) or video-assisted thoracic surgery (minimally invasive method using video cameras)
214443611|NCT04116736|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
215120260|NCT03449758|DRUG|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
215120261|NCT03449758|DRUG|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
215120262|NCT03449758|DRUG|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
215120263|NCT02326285|DRUG|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
214443612|NCT04116736|DEVICE|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
214443613|NCT04349072|DRUG|Mavacamten|Mavacamten Capsules Other names: MYK-461
214443614|NCT04349072|DRUG|Placebo|Placebo
214443615|NCT01363492|BIOLOGICAL|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
214443616|NCT03285386|BEHAVIORAL|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
214443617|NCT03285386|BEHAVIORAL|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
214443618|NCT05998863|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
215120264|NCT02326285|DRUG|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
215120265|NCT02326285|DRUG|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
214443619|NCT05998863|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
214443620|NCT04820894|OTHER|Electronic Medical Record|Medical records are reviewed
214443621|NCT04820894|OTHER|Survey Administration|Complete surveys
214443622|NCT04985812|DRUG|JNJ-67484703|Participants will receive JNJ-67484703.
214443623|NCT04985812|DRUG|Placebo|Participants will receive placebo to JNJ-67484703.
214443624|NCT05953623|BIOLOGICAL|Albumin|In the first phase of the study, a 3 + 3 dose-escalation study with 7 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg, 0.55g/kg, 0.60g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation. In the second phase of the study, at the maximum safe dose determined in the first phase, an additional 15 to 20 patients will be enrolled for intra-arterial albumin infusion.
214443625|NCT03341156|DRUG|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
214443626|NCT03341156|DRUG|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
214443627|NCT05512962|DRUG|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
214443628|NCT05512962|DEVICE|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
214443629|NCT03401879|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
214443630|NCT03401879|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
214443631|NCT03401879|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
214521103|NCT01952002|OTHER|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
214521104|NCT03249961|DEVICE|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
214521105|NCT03249961|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
214521106|NCT03249961|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
214521107|NCT01373359|DRUG|Misoprostol|400 µg sublingual misoprostol
214521108|NCT01373359|DRUG|Oxytocin|10 IU IM
214521109|NCT05785975|OTHER|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
214521110|NCT03490188|BEHAVIORAL|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
214521111|NCT04692441|DIETARY_SUPPLEMENT|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
214521112|NCT02074709|DRUG|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
214521113|NCT02074709|DRUG|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
214521114|NCT06458296|OTHER|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
214521115|NCT06458296|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
214443632|NCT03401879|DEVICE|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
214443633|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
214443634|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
214443635|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
214443636|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
214521116|NCT00004276|DRUG|thalidomide|
214521117|NCT05064475|DIAGNOSTIC_TEST|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
214443637|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
214443638|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
214443639|NCT03490864|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
214521118|NCT02722278|DRUG|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
214521119|NCT02722278|DRUG|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
214521120|NCT04993976|OTHER|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs \[eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises\], one to three sets each) for 20-60 minutes five days a week.
214521121|NCT04993976|OTHER|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
214521122|NCT04162977|BEHAVIORAL|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
214521123|NCT04175392|DRUG|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
214521124|NCT04175392|DRUG|Placebos|Placebos capsule 1 capsule Once daily
214521125|NCT02153697|DEVICE|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
214521126|NCT02153697|DRUG|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
214521127|NCT03469089|DRUG|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
214521128|NCT03469089|DRUG|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
214521129|NCT03469089|DRUG|Modafinil|Modafinil tablet 100 mg placed in a capsule
214521130|NCT03469089|DRUG|Placebo for ketamine|0.9 % NaCl infusion solution
214521131|NCT03469089|DRUG|Placebo for modafinil|Placebo capsule for modafinil capsule
214521132|NCT02251405|BEHAVIORAL|One bag, stainless container|
214521133|NCT01289197|BEHAVIORAL|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
214521134|NCT02727998|DRUG|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
214521135|NCT02727998|DRUG|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
214521136|NCT01725087|DRUG|Matching Placebo|
214521137|NCT01725087|DRUG|Low Dose GRT6005|
214521138|NCT01725087|DRUG|Medium Dose GRT6005|
214443640|NCT03490864|DIETARY_SUPPLEMENT|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
214521139|NCT01725087|DRUG|High Dose GRT6005|
214521140|NCT01725087|DRUG|Tapentadol|
214521141|NCT02105688|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
214521142|NCT02105688|DRUG|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
214521143|NCT03423537|DRUG|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
214443641|NCT03490864|OTHER|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
214521144|NCT03423537|DRUG|Placebo|100IU per day containing N/S 0.9% will be injected
214521145|NCT02274350|RADIATION|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
215120266|NCT02326285|PROCEDURE|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
214443642|NCT03490864|OTHER|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
214443643|NCT00662519|DRUG|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
214443644|NCT00662519|DRUG|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
214521146|NCT04734171|BEHAVIORAL|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
214521147|NCT04734171|BEHAVIORAL|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
214521148|NCT04734171|BEHAVIORAL|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
214521149|NCT05237856|DEVICE|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
214521150|NCT00731276|DRUG|irinotecan hydrochloride|
214521151|NCT00731276|OTHER|pharmacogenomic studies|
214521152|NCT00731276|OTHER|pharmacological study|
214521153|NCT00329771|OTHER|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
214521154|NCT03553459|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
214521155|NCT00308009|PROCEDURE|Vaginal Repair for prolapse, TVT procedure|"1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair"
214521156|NCT00308009|PROCEDURE|TVT and Prolapse surgery|"1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery"
214443645|NCT00662519|DIETARY_SUPPLEMENT|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
214521157|NCT00942799|DRUG|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
214521158|NCT00942799|DRUG|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
214521159|NCT04994314|DRUG|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
214521160|NCT04994314|DRUG|Control primer|Conventional orthodontic primer
214521161|NCT00464932|DRUG|Vasoactive Intestinal Peptide (VIP)|
214521162|NCT02010021|DRUG|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
214693245|NCT07074236|DRUG|QLC7401 injection|QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.
214693246|NCT07074236|DRUG|RBD7022 injection|RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.
215120267|NCT03864939|DRUG|dHAM|A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
214443646|NCT00662519|OTHER|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
214443647|NCT00662519|OTHER|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
214443648|NCT04790357|OTHER|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
214443649|NCT04790357|OTHER|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
214521163|NCT03456206|OTHER|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
214521164|NCT03456206|OTHER|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
214521165|NCT00537758|BEHAVIORAL|Cognitive Behavior Therapy|
214521166|NCT00537758|BEHAVIORAL|CBT and BWL|
214521167|NCT00537758|BEHAVIORAL|Behavioral Weight Loss Treatment|
214521168|NCT06575998|OTHER|Training|A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
214521169|NCT06575998|OTHER|Pro-active identification|Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
214521170|NCT01757171|DRUG|Cabazitaxel|20mg IV over 1 hour every 3 weeks
214521171|NCT05080803|DRUG|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
214521172|NCT00103116|BIOLOGICAL|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
214521173|NCT02419664|DRUG|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
214521174|NCT01551121|OTHER|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
214521175|NCT05469867|DEVICE|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
214521176|NCT00887471|PROCEDURE|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
214521177|NCT03322475|DEVICE|PiQo4 laser system|The PiQo4 laser system
214521178|NCT04391218|OTHER|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
214521179|NCT04130373|PROCEDURE|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
214521180|NCT04130373|PROCEDURE|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
214521181|NCT05878522|DRUG|sisunatovir|6 capsules administered Q12 hours for 5 doses
214521182|NCT05878522|DRUG|placebo|6 capsules administered Q12 hours for 5 doses
214521183|NCT05878522|DRUG|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
214521184|NCT05878522|DRUG|sisunatovir|7 capsules administered Q12 hours for 5 doses
214521185|NCT05122559|DRUG|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
214521186|NCT05122559|DRUG|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
214521187|NCT05272254|DRUG|10% povidone iodine + FV|applied to children's teeth
214443650|NCT05617742|DIAGNOSTIC_TEST|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
214693247|NCT07075874|OTHER|PDPH|Observational analysis of preoperative inflammatory markers (e.g., NLR, PLR, SIRI) in relation to PDPH development following spinal anesthesia.
214443651|NCT00879333|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
214443652|NCT00879333|DRUG|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
214443653|NCT00879333|DRUG|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
214693248|NCT07077187|DIAGNOSTIC_TEST|computerized dynamic posturography|Patients in each arm will have computerized dynamic posturography performed at baseline prior to taking first tablet as well as at 4 weeks and 8 weeks. In the adjuvant therapy arm, subjects will be evaluated on rasagiline but in a functional OFF state for their other Parkinson disease medications.
215120268|NCT03864939|DRUG|No dHAM|A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
215120269|NCT06233188|PROCEDURE|orthogantic surgery|surgery that correcting the maxilla and mandible related with each other
214443654|NCT02672033|RADIATION|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
214443655|NCT02672033|RADIATION|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
214443656|NCT02672033|OTHER|Laboratory Biomarker Analysis|Correlative studies
214443657|NCT02672033|PROCEDURE|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
214443658|NCT02634450|DEVICE|Alere q|
214443659|NCT02671435|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
214443660|NCT02671435|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
214443661|NCT02671435|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
214443662|NCT02671435|DRUG|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
214443663|NCT02671435|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
214443664|NCT06286085|OTHER|Lung function tests|Pulmonary function tests
214443665|NCT06000813|BEHAVIORAL|REACH-Es|REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.
214443666|NCT06000813|BEHAVIORAL|ETAU|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
214443667|NCT03547999|DRUG|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
214443668|NCT03547999|BIOLOGICAL|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
214443669|NCT03547999|BIOLOGICAL|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
214443670|NCT03547999|DRUG|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
215120270|NCT05036174|DRUG|Diphenhydramine 5%|Diphenhydramine 5% ointment
215120271|NCT05036174|DRUG|Placebo|Placebo matched to diphenhydramine 5% ointment
215120272|NCT02942758|DRUG|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
215120273|NCT02942758|DRUG|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
215120274|NCT02942758|DRUG|ATRA|ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
215120275|NCT02942758|DRUG|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
215120276|NCT06344728|DRUG|Brensocatib Oral Solution|Brensocatib solution
215120277|NCT06344728|DRUG|Brensocatib Oral Tablet|Brensocatib tablet
215120278|NCT06138769|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day
214443671|NCT00573482|BEHAVIORAL|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
214443672|NCT00573482|BEHAVIORAL|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
215120279|NCT00215358|DRUG|Formoterol Fumarate|
215120280|NCT00028483|DRUG|cBR96-doxorubicin immunoconjugate|
215120281|NCT00028483|DRUG|docetaxel|
215120282|NCT05599308|DEVICE|OMRON blood pressure monitor with AFib screening feature|Blood pressure measurement by an oscillometric blood pressure monitor
214443673|NCT00738023|DRUG|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
214443674|NCT00738023|DRUG|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
214443675|NCT00738023|DRUG|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
214443676|NCT05998252|DEVICE|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
214443677|NCT00761189|DRUG|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
214443678|NCT01392638|OTHER|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
214443679|NCT01392638|DRUG|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
214443680|NCT00498511|PROCEDURE|upper gastrointestinal endoscopy, colonoscopy|
214521188|NCT05272254|OTHER|Placebo +FV|applied to children's teeth
214521189|NCT03147430|OTHER|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
214521190|NCT04707924|DEVICE|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
214521191|NCT06178471|DIAGNOSTIC_TEST|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
214521192|NCT05846932|BEHAVIORAL|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
214521193|NCT05846932|BEHAVIORAL|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
215120283|NCT05599308|DEVICE|Microlife WatchBP Home A|Blood pressure measurement by an oscillometric blood pressure monitor
215120284|NCT04773119|PROCEDURE|PVI only|Patients in this group receive PVI only
215120285|NCT04773119|PROCEDURE|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
215120286|NCT00948753|DRUG|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
215120287|NCT00948753|DRUG|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
215120288|NCT00948753|DRUG|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
214443681|NCT00873613|PROCEDURE|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
214443682|NCT02759016|DRUG|BI 836826|
214443683|NCT02759016|DRUG|Ibrutinib|Standard of Care
214443684|NCT03608787|BEHAVIORAL|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
214443685|NCT06077851|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
214443686|NCT04005482|OTHER|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
214443687|NCT05838677|BEHAVIORAL|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
214443688|NCT05838677|OTHER|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
214521194|NCT04855708|OTHER|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
214521195|NCT04855708|OTHER|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
214521196|NCT02252172|DRUG|Daratumumab IV|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
214521197|NCT02252172|DRUG|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
214521198|NCT02252172|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
214521199|NCT02252172|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
214443689|NCT03692780|DRUG|Careseng 1370|4,000mg granules in sachet
214443690|NCT03692780|DRUG|Placebo|4,000mg granules in sachet
214443691|NCT02444858|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.
214443692|NCT02444858|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
214443693|NCT01910896|DEVICE|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
214443694|NCT04103723|PROCEDURE|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
214443695|NCT03828968|DIAGNOSTIC_TEST|bladder scan|Measurement of vesical volume by bladder scan
214443696|NCT02226536|BEHAVIORAL|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
214443697|NCT05237752|DRUG|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
214443698|NCT02300675|BEHAVIORAL|therapeutic education program|
214443699|NCT03939312|DRUG|Atogepant|Atogepant Tablets
214443700|NCT02119650|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
214443701|NCT02119650|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
214443702|NCT02119650|DRUG|Pemetrexed|500 mg/m\^2 administered as an intravenous infusion over 10 minutes
214521200|NCT04441983|DIAGNOSTIC_TEST|7 Tesla MRI of the foot|7 Tesla MRI
214521201|NCT06084260|DIETARY_SUPPLEMENT|Diet group|Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
214521202|NCT06084260|BEHAVIORAL|Self-compassion group|Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
214521203|NCT03985020|OTHER|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
214521204|NCT03985020|OTHER|Water Intervention|Bottled Water
214521205|NCT03690011|GENETIC|CD7.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2"
214521206|NCT04563026|DRUG|DUR-928 30 mg|IV infusion
214521207|NCT04563026|DRUG|DUR-928 90 mg|IV infusion
214443703|NCT02119650|DRUG|Cisplatin|75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
214443704|NCT06111924|OTHER|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
214443705|NCT06111924|OTHER|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
214443706|NCT03081611|DEVICE|Ram cannula|Ventilatory support for preterm infants using Ram cannula
214443707|NCT03081611|DEVICE|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
214443708|NCT04362046|PROCEDURE|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
214443709|NCT02179268|DRUG|sertraline|50mg, 50-150mg/d,qd for one year
214443710|NCT02179268|DRUG|citalopram|20mg, 20-40mg/d,qd,for one year
214443711|NCT02179268|DRUG|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
214443712|NCT02179268|DRUG|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
214443713|NCT02179268|BEHAVIORAL|control|50min, every week for three months, every month, for nine months
214443714|NCT02210442|BEHAVIORAL|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
214443715|NCT02210442|OTHER|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
214443716|NCT04749784|DIETARY_SUPPLEMENT|High Dose Arterin Cholesterol|240mg active ingredient daily
214521208|NCT04563026|DRUG|Placebo+ Standard of Care (SOC)|IV infusion
214521209|NCT01483885|DEVICE|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
214521210|NCT01483885|DEVICE|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
214521211|NCT01483885|PROCEDURE|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
214521212|NCT00375388|DRUG|Metformin on top of intensive insulin therapy|
214521213|NCT05680597|OTHER|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
214521214|NCT06529809|RADIATION|Hypofractionated external beam radiation|Central pelvis (19.05 Gy in 15 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
214521215|NCT06529809|DRUG|Chemotherapy|Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
214443717|NCT04749784|DIETARY_SUPPLEMENT|Low Dose Arterin Cholesterol|120mg active ingredient daily
214443718|NCT04749784|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
214521216|NCT06529809|RADIATION|Image-guided brachytherapy|HDR boost 7.3 Gy x 6 fractions
214521217|NCT03696147|DEVICE|Magnetic resonance imaging|Diffusion weighted sequence of MRI
214693249|NCT07077187|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral tablet daily will be administered to study participants.
215120289|NCT00269971|DRUG|epoetin alfa|
214443719|NCT01721291|DRUG|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
214443720|NCT05871112|OTHER|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
214443721|NCT03336905|OTHER|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
214443722|NCT03136042|OTHER|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
214443723|NCT03136042|OTHER|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
214443724|NCT03136042|OTHER|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
214443725|NCT05035446|PROCEDURE|single-incision plus one-port laparoscopic surgery|The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
214443726|NCT05035446|PROCEDURE|conventional laparoscopic surgery|It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
214443727|NCT02113267|DRUG|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
214443728|NCT02113267|DRUG|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
214443729|NCT05007587|DRUG|Lenvatinib|8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) QD
214521218|NCT00629161|DRUG|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
214521219|NCT00629161|DRUG|placebo|12 months period of placebo plus 1 month period without placebo
214521220|NCT01482871|DRUG|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
214521221|NCT01482871|DRUG|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
214521222|NCT01482871|DRUG|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
214521223|NCT01482871|DRUG|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
214521224|NCT05740371|DRUG|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
214521225|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
214521226|NCT05499117|DEVICE|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
214521227|NCT05499117|DEVICE|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
214443730|NCT05007587|DRUG|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
214443731|NCT05007587|DRUG|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
214443732|NCT05325931|DEVICE|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
214443733|NCT05325931|DEVICE|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
214443734|NCT02183506|DRUG|Metformin|
214521228|NCT04021277|DRUG|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
214521229|NCT04021277|DRUG|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
214521230|NCT04021277|DEVICE|Ultrasound|Ultrasound activation and enhancement
214521231|NCT04425837|BIOLOGICAL|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
214521232|NCT04425837|OTHER|Standard care|Standard care according to guidelines and national regulations
214443735|NCT02183506|DRUG|BI 1356 BS|
214443736|NCT05400161|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
214443737|NCT05400161|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
214443738|NCT02261649|DEVICE|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
214443739|NCT02261649|PROCEDURE|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
214443740|NCT02261649|DEVICE|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
214443741|NCT02261649|OTHER|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
214443742|NCT03642106|BEHAVIORAL|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
214521233|NCT05155553|DEVICE|QIAstat-Dx® Meningitis/Encephalitis (ME) Panel|The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.
214521234|NCT05766566|PROCEDURE|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
214521235|NCT00021099|DRUG|ixabepilone|Given IV
214521236|NCT04485975|DEVICE|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
214521237|NCT03868202|DRUG|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
214521238|NCT04734236|DIAGNOSTIC_TEST|New technique vs Xpert|New technique vs Xpert
214521239|NCT02391389|PROCEDURE|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
215120290|NCT00893958|DRUG|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
215120291|NCT01867749|BEHAVIORAL|Group Interpersonal Psychotherapy (IPT-G)|
215120292|NCT01867749|BEHAVIORAL|Coping with Depression (CWD)|
215120293|NCT04201665|DRUG|Carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
215120294|NCT04201665|DRUG|Oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
214443743|NCT01260870|DEVICE|Cotavance Paclitaxel Coated Balloon|
214443744|NCT01260870|DEVICE|Standard balloon angioplasty|
214443745|NCT06375876|BEHAVIORAL|Single-session intervention (SSI)|The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
214521240|NCT03145909|DRUG|ABBV-176|Intravenous infusion
214521241|NCT03583034|PROCEDURE|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
214521242|NCT02288572|DIETARY_SUPPLEMENT|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
214521243|NCT02288572|DIETARY_SUPPLEMENT|Placebo|Taking dietary supplement on a daily basis for 3 months.
214521244|NCT02672345|DRUG|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
214521245|NCT00745069|DRUG|tapentadol HCl|
214521246|NCT02488733|PROCEDURE|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
214693250|NCT07077187|DRUG|Placebo|Placebo 1 mg oral tablet daily will be administered to study participants.
215120295|NCT03279029|BIOLOGICAL|blood samples|blood samples
215120296|NCT03279029|BIOLOGICAL|biopsy|biopsy of aortic valve
215120297|NCT00313417|DIETARY_SUPPLEMENT|Creatine monohydrate|Up to 10 grams
215120298|NCT00313417|OTHER|Placebo|Placebo will be given in the same way and appearance as the active treatment
215120299|NCT04327102|BEHAVIORAL|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
214443746|NCT06067984|DEVICE|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
214443747|NCT03000101|OTHER|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
214443748|NCT03000101|OTHER|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
214443749|NCT03707236|BEHAVIORAL|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
214443750|NCT00859794|OTHER|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
214443751|NCT00859794|OTHER|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
214443752|NCT00859794|OTHER|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
214521247|NCT02488733|DRUG|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
214521248|NCT04878861|BEHAVIORAL|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
214521249|NCT03979144|BEHAVIORAL|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
214521250|NCT06585007|RADIATION|Radiotherapy|Progression-directed therapy (stereotactic body radiation therapy)
214521251|NCT06585007|PROCEDURE|metastasectomy|Progression-directed therapy (metastasectomy)
214521252|NCT03831698|DRUG|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
214521253|NCT03010878|OTHER|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
214521254|NCT03010878|OTHER|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
214521255|NCT02444195|BEHAVIORAL|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
214521256|NCT00125723|OTHER|PI Discretion|PI Discretion
214521257|NCT05441293|PROCEDURE|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
214521258|NCT00227422|BIOLOGICAL|Mencevax ACWY|
214521259|NCT01151397|DRUG|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
214521260|NCT01151397|DRUG|Peg + Ribavirin|Peg+ Ribavirin for 6 months
214521261|NCT02502136|PROCEDURE|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
214521262|NCT02502136|PROCEDURE|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
214521263|NCT02877524|OTHER|Adaptive support ventilation|ASV during NIV
214521264|NCT02877524|OTHER|Pressure support ventilation|PSV during NIV
214521265|NCT00523458|DRUG|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
214521266|NCT00272415|DRUG|INO-1001|Intravenous repeating dose
214521267|NCT00272415|DRUG|temozolomide|Oral repeating dose
214693251|NCT07083882|BIOLOGICAL|freezedried autologous encapsulated fecal microbiota transplantation|The freezedried autologous encapsulated microbiota transplantation increases the exposure of the small intestine to the microbiota residing in the colon. Prior evidence was found that this has strong immunomodulatory effects leading to potential preservation of beta cell function in type 1 diabetes.
214693252|NCT07083882|OTHER|placebo matching capsule without microbial content|this is the matching placebo capsule that looks from the outside identical to the actual treatment but does not contain the fecal microbiota.
215120300|NCT05751746|DRUG|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
215120301|NCT05217160|DRUG|KeraStat® Gel with Morphine application|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes."
215120302|NCT05217160|DRUG|KeraStat® Gel application|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes."
215120303|NCT00922623|DEVICE|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
214521268|NCT01374152|OTHER|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
214521269|NCT06380959|OTHER|Art Based Activity|"Art Based Activity Module consists of 3 art-based activities under the titles My Life Journey, The Power Within Me and Letter to the Future. Each activity consists of three stages. In the first stage, the participants were made to practice breathing exercises. At this stage, the participant was expected to become aware of himself and his ideas. In the second stage, art activity was carried out. In the final stage, the revealed art object was concretized by the participants with a verbal expression. The materials used in the activities (dry paint, pastel paint, watercolor) are dermatologically tested and consist of anti-allergen products."
214521270|NCT01654198|RADIATION|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
214521271|NCT00634998|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C capsules orally twice daily
214521272|NCT00634998|DIETARY_SUPPLEMENT|Placebo|1000mg Placebo capsules orally twice daily for 90 days
214521273|NCT02632188|PROCEDURE|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
214521274|NCT02632188|BIOLOGICAL|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
214521275|NCT03019289|DRUG|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
214521276|NCT03039556|BEHAVIORAL|Normal Daily Steps|Complete normal daily ambulation for one week
214521277|NCT03039556|BEHAVIORAL|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
214521278|NCT03039556|BEHAVIORAL|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
214521279|NCT05606796|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
215120304|NCT01088334|OTHER|screening|CT-Chest/abdomen and mammography in women
214521280|NCT04873544|PROCEDURE|ERAS protocols for TKA|ERAS protocols for TKA
214521281|NCT06393855|PROCEDURE|single-step Trans-PRK|Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.
214521282|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
214521283|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
214693253|NCT07083141|OTHER|Peer Mentoring Program|A 13-week peer mentoring program in which trained third-year midwifery students supported first-year students through regular meetings aimed at enhancing academic adaptation, confidence, and professional understanding.
214693254|NCT07084584|DRUG|GB3226|GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles
214693255|NCT07082517|OTHER|Percentage analysis|Analysis the percentage of the population with risk factors that may lead to a PAD.
214443753|NCT00859794|OTHER|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
214443754|NCT04430634|OTHER|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
214443755|NCT04430634|OTHER|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
214443756|NCT04430634|OTHER|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
214443757|NCT04430634|OTHER|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
214521284|NCT01779089|DRUG|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
214693256|NCT07082855|DRUG|Minocycline 100mg|Capsules Minocycline 100mg po per day and placebo 100mg po per day for 12 months
214693257|NCT07082855|DRUG|Minocycline 200mg|Capsules Minocycline 100mg po twice a day for 12 months
214693258|NCT07082855|DRUG|Placebo|Capsules placebo 100mg po twice a day for 12 months
214693259|NCT07083466|DIAGNOSTIC_TEST|complete blood count|blood test
214693260|NCT07083466|DIAGNOSTIC_TEST|serum albumin|blood test
215120305|NCT01402817|DRUG|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
215120306|NCT00314639|DRUG|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
215120307|NCT01179581|DRUG|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
214521285|NCT01779089|DRUG|placebo|
214521286|NCT04327349|BIOLOGICAL|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
214521287|NCT02389894|DEVICE|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
214521288|NCT02389894|DEVICE|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
214693261|NCT07083674|BEHAVIORAL|Multi-level communication intervention|The intervention will target multiple levels (provider, unit, hospital) and will respond to identified modifiable communication challenges. Aim 2 intervention mapping will finalize the specific intervention; we anticipate it will involve training and education of staff members and new unit protocols for communication.
214693262|NCT07083609|DRUG|Dabigatran|Dabigatran will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
214693263|NCT07083609|DRUG|Rivaroxaban|Rivaroxaban will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
215120308|NCT01179581|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
215120309|NCT01179581|DRUG|GLPG0634|multiple dose, capsule, 10 days
214443758|NCT04430634|OTHER|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
214443759|NCT04430634|OTHER|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
214443760|NCT04430634|OTHER|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
214443761|NCT04430634|OTHER|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
214443762|NCT02436317|DEVICE|Point Of Care Ultrasound|Examination with an ultrasound machine
214443763|NCT02523443|OTHER|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
214443764|NCT02523443|OTHER|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
214443765|NCT06985303|COMBINATION_PRODUCT|Investigational Combination Product|This investigational therapy combines a proprietary, human-derived cell-based component with a unique blend of small molecules and an enzyme. The components are designed to work synergistically to address the complex pathology of white matter injury. The therapy aims to provide a source for cellular regeneration, support the survival of existing cells, enhance the potential for myelin repair, and modify the inhibitory environment of glial scar tissue. This multi-pronged biological intervention is designed to promote neural regeneration and functional recovery in patients with PVL.
214693264|NCT07084415|OTHER|Postural correction exercise|Each participant will be given cervical thoracic spine correction exercises in the form of thoracic Roll Stretching Exercises, shoulder Bracing (Shoulder Retraction), superman Pose, chin Tuck (Cervical Retraction), five days a week for 4 weeks
215120310|NCT01179581|DRUG|placebo|multiple dose, capsule, 10 days
215120311|NCT03708107|DEVICE|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
215120312|NCT03708107|OTHER|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
215120313|NCT04820244|OTHER|No intervention|No intervention
215120314|NCT00003425|BIOLOGICAL|filgrastim|
215120315|NCT00003425|DRUG|amifostine trihydrate|
215120316|NCT00003425|DRUG|cyclophosphamide|
215120317|NCT00003425|DRUG|melphalan|
214443766|NCT04772300|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
214443767|NCT04772300|DEVICE|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
214443768|NCT06987539|DRUG|Inebilizumab|Inebilizumab will be administered IV.
214443769|NCT06987097|DRUG|Ambrisentan|After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced to 5 mg/day. If the study drug has reached the maximum allowable dose (two tablets/day) and the patient shows signs of worsening PAH or right heart failure, the clinician may decide to add diuretics (with the type and dosage left at the referring physician's discretion). The number and percentage of patients requiring diuretic combination therapy in both groups will be recorded. Other baseline treatment medications will remain unchanged through follow-up duration.
214443770|NCT06987097|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.
214443771|NCT06988098|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
214443772|NCT06014866|DEVICE|Cardiac pacing|Patient's previously implanted with the INGEVITY+ lead located in the LBBA
214443773|NCT01840566|DRUG|Carmustine|
214443774|NCT01840566|DRUG|Etoposide|
214443775|NCT01840566|DRUG|Cytarabine|
214443776|NCT01840566|DRUG|Melphalan|
214443777|NCT01840566|BIOLOGICAL|Pegfilgrastim|
214443778|NCT01840566|BIOLOGICAL|19-28z T CELLS|
214443779|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
214521289|NCT02440256|OTHER|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
214521290|NCT06222086|OTHER|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.
214521291|NCT06222086|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
214521292|NCT00106405|DRUG|Memantine HCl|
214521293|NCT03473275|DIAGNOSTIC_TEST|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
215120318|NCT00003425|PROCEDURE|peripheral blood stem cell transplantation|
215120319|NCT00181363|DEVICE|Mamma board|use of mamma board during radiotherapy
215120320|NCT03310723|DEVICE|Face Mask preoxygenation|Standard face mask preoxygenation.
215120321|NCT03310723|DEVICE|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
215120322|NCT06071949|DRUG|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214443780|NCT06986343|DEVICE|Hyrax|Children in this group are going to use only the Hyrax device.
214521294|NCT03473275|DIAGNOSTIC_TEST|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
214521295|NCT06337903|BEHAVIORAL|Self-compassion intervention (the Mindful Self-Compassion course)|An online 8-week mindful self-compassion course with weekly sessions.
214521296|NCT05436041|BEHAVIORAL|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
214443781|NCT06986343|DEVICE|Hyrax and Uplocker Vacuum Device|Children in this group are going to use the Hyrax device and Up-Locker vacuum activator.
214443782|NCT03651505|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
214443783|NCT04534400|RADIATION|thoracic CT-scan|Automated measurement
214443784|NCT06998043|BIOLOGICAL|BX004|Bacteriophage
215120323|NCT06071949|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
215120324|NCT01599975|DRUG|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
215120325|NCT01599975|DRUG|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
215120326|NCT01599975|DRUG|Matched placebo|2 tablets of matched placebo daily by mouth
214443785|NCT06998043|OTHER|Placebo|Placebo
214443786|NCT03922035|OTHER|Best Practice|Receive standard peri-/post-transplant supportive care
214443787|NCT03922035|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
214443788|NCT06679959|DRUG|ASC30 Injection, for subcutaneous use or placebo|Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
214443789|NCT07003139|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
214443790|NCT06866938|DRUG|[177Lu]Lu-PSMA-617 (Pluvicto, Novartis)|"Patients will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis).~One injection every 6 weeks at the dose of 7.4 GBq (±10%)"
214443791|NCT06878417|DRUG|CBD|The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
214443792|NCT06878417|DRUG|THC|The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
214443793|NCT06878417|DRUG|Placebo|The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
214521297|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 500 ml alginate beverage per meal test
214521298|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 330 ml alginate beverage per meal test
214521299|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 500 ml placebo beverage per meal test
214521300|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 330 ml placebo beverage per meal test
214521301|NCT04453137|BIOLOGICAL|Adalimumab originator|Subcutaneous injection every other week
214521302|NCT04453137|BIOLOGICAL|Adalimumab biosimilar|Subcutaneous injection every other week
214521303|NCT03258034|DRUG|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
214521304|NCT04451720|DRUG|Risankizumab|Subcutaneous (SC) injection
214521305|NCT04451720|DRUG|Placebo|Subcutaneous (SC) injection
214521306|NCT04168450|OTHER|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
214521307|NCT04168450|OTHER|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
214521308|NCT01670942|OTHER|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
214521309|NCT02228889|PROCEDURE|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
214521310|NCT02228889|OTHER|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
214521311|NCT02228889|OTHER|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
214521312|NCT02228889|OTHER|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
214521313|NCT02228889|OTHER|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
214521314|NCT02228889|OTHER|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
214521315|NCT02228889|OTHER|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
214521316|NCT02228889|OTHER|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
214521317|NCT02228889|OTHER|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
214521318|NCT02228889|OTHER|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
214521319|NCT02228889|OTHER|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
214521320|NCT02228889|OTHER|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
214521321|NCT02228889|OTHER|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
214521322|NCT02228889|OTHER|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
214521323|NCT02228889|OTHER|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
214521324|NCT02228889|OTHER|Assess overall complications at 30 days postoperatively|
214521325|NCT02228889|OTHER|Assess overall complications at 1 year postoperatively|
214521326|NCT02228889|PROCEDURE|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
214521327|NCT02228889|DEVICE|Strattice|Strattice mesh
214521328|NCT02228889|DEVICE|XenMatrix|Xenmatrix mesh
214521329|NCT00145496|DRUG|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
214521330|NCT00145496|DRUG|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
214521331|NCT06232005|DRUG|Mitomycin c|injection of antifibrotic drugs in urethral strictures after internal urethrotomy
214521332|NCT04912726|DRUG|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
214521333|NCT04896827|OTHER|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
214521334|NCT06101069|PROCEDURE|MRF in conjunction with IVIM MRI without contrast|MRF in conjunction with IVIM MRI scan, without contrast.
215120327|NCT05087771|DRUG|injectable naltrexone|360 mg dose to be given prior to hospital discharge
214443794|NCT07034885|BEHAVIORAL|Mindfulness-Based Self-Efficacy Development Program|"Mindfulness-Based Self-Efficacy Development Program is a unique intervention model that integrates mindfulness-based practices with self-efficacy theory, structured for postmenopausal women. With the implementation of this research, a holistic and evidence-based intervention model will be presented for physical, psychological and social problems frequently encountered in the postmenopausal period. This program processes mindfulness-based skills such as observing thoughts, body awareness, regulating emotions, coping with stress and developing self-compassion in the axis of self-efficacy development with 8-week structured sessions. In this context, it is anticipated that the study will contribute to scientific knowledge and practices.~In addition, the Mindfulness-Based Self-Efficacy Development Program developed in the study aims not only at symptom management, but also at increasing the individual's perception of control over their own lives, recognizing their internal resources and"
214443795|NCT06711627|BEHAVIORAL|Standard of Care (SoC)|Standard recommended nutrition and gestational weight gain counseling.
214443796|NCT06711627|BEHAVIORAL|Food Provision|Standard recommended nutrition and gestational weight gain counseling plus food provision.
214443797|NCT07041905|PROCEDURE|Total Caries Removal|"Arm 1: Total caries removal (complete excavation to hard dentin)"
214443798|NCT07041905|PROCEDURE|Selective Caries Removal|Partial removal leaving affected dentin near pulp.
214443799|NCT06703814|OTHER|Intraoperative flow-controlled ventilation strategy|"In the FCV group, intraoperative ventilation will be provided with the EVONE (IES Ventinova Medical).PEEP and Ppeak are titrated guided by dynamic compliance, as follows: Starting from a default setting of 5 cmH2O of PEEP and 15 cmH2O of Ppeak, PEEP and Ppeak are equally increased by 1 cmH2O steps and the PEEP value with the highest VT and thus highest dynamic compliance is defined as best PEEP. Subsequently, Ppeak is stepwise (+1 cmH2O) increased until there is no further over-proportional increase in tidal volume (VT) (i.e. measured VT \> expected VT according to measured dynamic compliance), defined as best driving pressure. No recruitment maneuvers are carried out during FCV. With the I:E ratio set to 1:1, flow is adjusted to establish normocapnia (target etCO2 4.5 to 5.8 kPa). FiO2 is adjusted to maintain oxygen saturation (SpO2) \> 92%."
214443800|NCT06703814|OTHER|Intraoperative pressure-controlled ventilation strategy|In the PCV group, intraoperative ventilation will be provided by a standard anesthesia ventilator in use in the respective participating centers. Patients will be ventilated in PCV mode, at the lowest inspired oxygen fraction (FiO2), to maintain oxygen saturation (SpO2) \> 92%. It is left to the discretion of the attending anesthesiologist to use a higher fraction of FiO2. Inspiratory to expiratory ratio is set at 1:1 to 1:2, respiratory rate will be adjusted to target normocapnia (target etCO2 4.5 to 5.8 kPa. VT will be set at 7 to 9 ml/kg predicted body weight (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. Ventilation starts with 5 cm H2O PEEP, and can be increased to 10 cm H2O PEEP.
214443801|NCT07040514|OTHER|Questionnaires of Patient understanding of Pathologist input|"* Benefit Self-Rating Total Score (assessing patient's perceptions of anticipated and actual extent to which they benefitted from the meeting with the pathologist)~* Knowledge Questionnaire Total Score (assessing accuracy of knowledge of their own diagnosis and the diagnostic process in general)~* State-Trait Anxiety Inventory Form Y (Total Scores for state (current) and trait (general) anxiety)"
214443802|NCT06704074|DEVICE|virtual reality (VR) head mounted display|The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.
214443803|NCT06886659|DRUG|Trastuzumab (proposed Trastuzumab biosimilar)|6 mg/kg single intravenous infusion of Trastuzumab of Incepta Pharmaceuticals Ltd
214443804|NCT06886659|DRUG|Herclon|6 mg/kg single intravenous infusion of Trastuzumab of Roche
214443805|NCT06729710|PROCEDURE|Prism adaptation test|Prism Adapation test for 1 hour in one group, and 4 hours in second group
214521335|NCT05667597|DIAGNOSTIC_TEST|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
214521336|NCT00474409|DRUG|Merislon|
214521337|NCT05536869|PROCEDURE|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
214521338|NCT05621902|OTHER|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
214521339|NCT02076594|DRUG|Docetaxel|Powder for solution for infusion
214521340|NCT02076594|DRUG|Epirubicin|Solution for infusion
214521341|NCT02076594|DRUG|Oxaliplatin|Powder for solution for infusion
214521342|NCT02076594|DRUG|Capecitabine|Film coated tablets
214521343|NCT01991275|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
214521344|NCT01991275|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
214521345|NCT00927849|PROCEDURE|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
214521346|NCT00927849|DRUG|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
214521347|NCT00927849|DRUG|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
214521348|NCT01549951|DRUG|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
214521349|NCT02843100|OTHER|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
214521350|NCT02843100|OTHER|Crohn's Disease Exclusion Diet|a limited whole food diet
214521351|NCT02843100|OTHER|Partial Enteral Nutrition|25-50% of Energy from formula
214521352|NCT02843100|OTHER|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
214443806|NCT06729710|PROCEDURE|other|Surgery based on prism adaptation test of 1 hour in one group and 4 hours in second group
214443807|NCT07044531|BEHAVIORAL|Training-as-Usual (TAU)|Participants receive the standard Peer Recovery Supporter (PRS) training currently offered by CCAR. This training follows existing certification requirements and does not include any digital modules or facilitated teleconferencing components.
214521353|NCT04732611|OTHER|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
214521354|NCT04732611|OTHER|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
214521355|NCT05503407|PROCEDURE|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
214521356|NCT05503407|PROCEDURE|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
214443808|NCT07044531|BEHAVIORAL|TDPP-A (Asynchronous Platform)|Participants engage with the Thrive Digital Peer Platform (TDPP), a fully asynchronous, self-paced online training program. The content includes 11 interactive modules structured using the Connect → Grow → Apply (CGA) learning framework, featuring peer stories, behavioral exercises, and scenario-based assessments.
214443809|NCT07044531|BEHAVIORAL|TDPP-Z (Asynchronous + Zoom)|Participants use the same asynchronous TDPP platform as the TDPP-A group, with the addition of three live, facilitator-led Zoom sessions. These synchronous group sessions provide opportunities for applied learning, discussion, and skill reinforcement.
214443810|NCT07046767|OTHER|IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap|BioLab Membrane Wrap LiteTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Membrane Wrap LiteTM is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
214443811|NCT07046767|OTHER|IP2: BioLab Tri-Membrane Wrap|BioLab Tri-Membrane WrapTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Tri-Membrane WrapTM is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
214443812|NCT06888687|BEHAVIORAL|Dietetic support|Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
214443813|NCT06888687|DEVICE|Continuous glucose monitoring|Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor.
214443814|NCT06733922|DEVICE|ETNATM-ProgMS|To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
214443815|NCT06887491|OTHER|Conventional physiotherapy program|Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.
214443816|NCT06887491|OTHER|Conventional physiotherapy program + Dual task program|"Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.~Dual task program: Walking 10 meters (Single task) and basic dual task introduction. Simple motor-motor tasks (e.g., holding a ball while walking). Carrying a half-full water bottle in each hand while walking. Placing or carrying objects accompanied by exercises requiring balance. Counting Counting backwards while walking. Solving simple math problems while walking Complexification of motor-motor and cognitive-motor tasks.~Dual tasks similar to activities of daily living"
214443817|NCT06737510|BEHAVIORAL|Informational brochure on household emergency preparedness|"An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones ."
215120328|NCT05087771|DRUG|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
215120329|NCT03816735|DEVICE|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
215120330|NCT03816735|DEVICE|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
215120331|NCT04062110|DEVICE|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
215120332|NCT01410890|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
214521357|NCT02735005|OTHER|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
214521358|NCT06170125|OTHER|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
214521359|NCT05813522|DRUG|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
214521360|NCT02452567|OTHER|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
214521361|NCT06034444|OTHER|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
215120333|NCT01467141|DRUG|insulin aspart|Injected s.c. (under the skin) three times a day
215120334|NCT01467141|DRUG|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
215120335|NCT01467141|DRUG|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
215120336|NCT05001334|BEHAVIORAL|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
215120337|NCT00247403|DRUG|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
215120338|NCT00938184|DRUG|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
215120339|NCT00938184|DRUG|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
215120340|NCT00938184|DRUG|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
215120341|NCT04699565|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Evaluate the predictive value of myocardial viability measured with cardiac magnetic resonance for the identification of LV REM 6 months after STEMI
215120342|NCT01033539|OTHER|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
215120343|NCT01889823|OTHER|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
214521362|NCT03958526|DEVICE|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
214521363|NCT03958526|DEVICE|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
214521364|NCT03902626|OTHER|Physiotherapy students|
214521365|NCT03902626|OTHER|Medical students|
214521366|NCT00003240|DRUG|cisplatin|
214521367|NCT00003240|DRUG|ifosfamide|
214521368|NCT00003240|DRUG|mitomycin C|
214521369|NCT00003240|DRUG|vinblastine sulfate|
214521370|NCT00003240|DRUG|vindesine|
214521371|NCT00003240|DRUG|vinorelbine tartrate|
214521372|NCT00003240|PROCEDURE|conventional surgery|
214521373|NCT00003240|RADIATION|radiation therapy|
214521374|NCT04251455|PROCEDURE|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
214521375|NCT01123200|DEVICE|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
214521376|NCT05000359|BEHAVIORAL|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
214521377|NCT02034188|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
214521378|NCT06157684|BEHAVIORAL|Postprandial ambulation|See arm description
214521379|NCT00193102|DRUG|Thalidomide|Thalidomide
214521380|NCT00193102|DRUG|Capecitabine|Capecitabine
214521381|NCT04971902|OTHER|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
214521382|NCT05972161|DEVICE|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
214521383|NCT04202822|OTHER|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
214521384|NCT00780988|BIOLOGICAL|Autologous tumor cell + CpG vaccine|
215120344|NCT01889823|OTHER|Hyperoxia|Subjects will be breathing 100% oxygen
215120345|NCT01230463|DRUG|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
215120346|NCT01230463|DRUG|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
215120347|NCT03749759|PROCEDURE|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
215120348|NCT04608721|OTHER|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
215120349|NCT01121146|DEVICE|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
215120350|NCT01499615|DEVICE|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
215120351|NCT03833869|PROCEDURE|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
215120352|NCT02987465|DRUG|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
214443818|NCT06737510|BEHAVIORAL|Phone-based household emergency preparedness|A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
214443819|NCT07052045|OTHER|One Stop Management|Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.
214443820|NCT07052045|OTHER|Usual care management|Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.
214443821|NCT07060846|PROCEDURE|Endoscopic lumbar discectomy|Patients will undergo endoscopic lumbar discectomy.
215120353|NCT02987465|DRUG|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
214443822|NCT07060846|PROCEDURE|Open lumbar discectomy|Patients will undergo an open lumbar discectomy.
214443823|NCT07070869|BEHAVIORAL|Serious game|"Participation in the serious game SPAMLO-3.0."
214521385|NCT00780988|PROCEDURE|Autologous hematopoietic and immune cell rescue (transplantation)|
214521386|NCT06261515|PROCEDURE|Active periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
215120354|NCT02987465|DRUG|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
215120355|NCT02987465|DRUG|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
215120356|NCT03723369|DEVICE|accupuncture|accupuncture
215120357|NCT05156788|DRUG|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
214521387|NCT05497167|OTHER|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
214521388|NCT01234584|PROCEDURE|spk|implants using SPK Abutments
214521389|NCT01234584|PROCEDURE|CPK Abutments|implants using CPK Abutments
214521390|NCT06446726|DRUG|Tislelizumab|Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
214521391|NCT06446726|RADIATION|Low-dose radiotherapy|Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
214521392|NCT06446726|DRUG|Nab-paclitaxel|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
214521393|NCT06446726|DRUG|Cisplatin|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
214521394|NCT02239614|BIOLOGICAL|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
215120358|NCT03464409|OTHER|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
215120359|NCT03464409|OTHER|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
215120360|NCT03464409|OTHER|SF-36|A health-related quality of life (QoL) self-reported survey.
215120361|NCT01227980|DRUG|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
215120362|NCT01227980|DRUG|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
215120363|NCT03818750|DEVICE|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
215120364|NCT03818750|BEHAVIORAL|Alcohol Use Disorders Identification Test|Questionnaire
215120365|NCT00329368|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
214443824|NCT07072871|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum DAD-13|A probiotic supplement (Vipilac®) containing Lactiplantibacillus plantarum DAD-13 administered orally via nasogastric tube, 2 capsules daily for 4 days, intended to modulate immune response and support gut microbiota in ICU sepsis patients.
214443825|NCT07072871|DRUG|Placebo|Placebo capsules containing maltodextrin administered via nasogastric tube (NGT), identical in appearance and schedule to the probiotic group (2 capsules/day for 4 days), alongside standard sepsis care.
214521395|NCT02239614|BIOLOGICAL|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
214521396|NCT02168855|DRUG|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
215120366|NCT00329368|BIOLOGICAL|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
215120367|NCT00329368|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
215120368|NCT00329368|DRUG|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
215120369|NCT00329368|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
215120370|NCT00974753|DRUG|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
214443826|NCT07076719|DIAGNOSTIC_TEST|Trophectoderm (TE) Biopsy|"* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):~  * Good: AA or AB.~ * Fair: BA, BB, BC.~ * Poor: CB or CC.~* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.~* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.~* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015)."
215120371|NCT00974753|OTHER|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
215120372|NCT00155493|PROCEDURE|obtain surgical specimen for analysis|
215120373|NCT00809900|DIETARY_SUPPLEMENT|Experimental|Administration of of 480 mL cranberry juice
215120374|NCT06528951|OTHER|Control Phase ( 6Weeks)|The participants will perform a control phase of six weeks of resistance training using the same volume for the upper (160 repetitions) and lower limbs (230 repetitions), with relative intensities ranging from 40% to 70% of 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 5-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 5-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 6-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 5-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
214443827|NCT07076719|DIAGNOSTIC_TEST|Non-invasive Preimplantation Genetic Diagnosis|"* DNA Contamination Minimization:~  o SCM was harvested after embryo culture with care taken not to include cellular material.~* Sample Storage:~* Processing for Genetic Analysis:~  6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH)~* Chromosomal Assessment:~* BAC-chip Slides:~* Labeling and Hybridization:~* Scanning and Data Acquisition:~* Data Processing and Analysis:~  8\. Validation and Quality Control~* Robust quality control measures included:"
214443828|NCT07078617|OTHER|Proprioceptive Neuromuscular Facilitation|PNF technique given for 3-4 days/week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
214443829|NCT07078617|OTHER|Soft Tissue Mobilization along with exercise|Soft tissue mobilization along with facial exercise 3- days/ week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
214521397|NCT02168855|BEHAVIORAL|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
214521398|NCT06473194|PROCEDURE|general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum|this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
214521399|NCT02037009|OTHER|Health care organization (anesthetic surveillance)|
214521400|NCT02991573|DEVICE|Prime & Bond Universal|Prime \& Bond Universal
214521401|NCT02991573|DEVICE|Ceram X|
214521402|NCT02991573|DEVICE|Prime & Bond XP|Control
214521403|NCT02991573|PROCEDURE|technique 1|
214521404|NCT02991573|PROCEDURE|technique 2|
215120375|NCT06528951|OTHER|15% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 15% (upper limbs - 184 repetitions; lower limbs - 268 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 4-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 3-8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
214443830|NCT07078513|OTHER|Active release Technique|Active Release Technique (ART) is a hands-on manual therapy that targets soft tissue restrictions by combining precise pressure with patient-assisted movement. It helps break down adhesions, improve mobility, and reduce pain by restoring normal tissue function.
214521405|NCT00121589|DRUG|Lutein|
214521406|NCT01217645|RADIATION|150 mg [14C] AZD6765|
214521407|NCT02411188|BEHAVIORAL|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
214521408|NCT03998956|PROCEDURE|CPVI|Circumferential PV isolation only
214521409|NCT03998956|PROCEDURE|CPVI+BOX|Circumferential PV and BOX isolation
214521410|NCT03998956|PROCEDURE|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
214521411|NCT03436537|OTHER|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
214521412|NCT05757063|OTHER|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
214521413|NCT05757063|OTHER|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
214521414|NCT04604899|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
214521415|NCT03807947|PROCEDURE|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
215120376|NCT06528951|OTHER|30% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
215120377|NCT06528951|OTHER|One group that performed 15% more volume and increased to 30% (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed a 15% volume will now increase more by 15% and perform 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
215120378|NCT06528951|OTHER|One group that performed 30% more volume and increased to 45% (10 Weeks).|The participants will perform 10 weeks of resistance training. The group that performed a 30% volume will now increase more by 15% and perform 45% (upper limbs - 232 repetitions; lower limbs - 334 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 2-3 sets of 8 repetitions in the sit-to-stand exercise, v) 2-3 sets of 8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
215120379|NCT06528951|OTHER|Control group ( 29 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
215120380|NCT01742195|PROCEDURE|Oral EBUS insertion|
215120381|NCT01742195|PROCEDURE|Nasal EBUS insertion|
215120382|NCT01487135|DRUG|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
214443831|NCT07078513|OTHER|Strain counter strain tecnhnique|Strain-Counterstrain is a gentle, passive manual therapy that relieves muscle tension by positioning the body in a pain-free, comfortable posture. The therapist holds this position for about 90 seconds while applying light pressure to tender points, allowing the muscle and fascia to relax and reset.
214443832|NCT07077096|DIAGNOSTIC_TEST|PRISM PCR panel|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
214443833|NCT07077096|DIAGNOSTIC_TEST|Conventional bacterial culture|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
214443834|NCT07076836|DEVICE|Acupuncture|The electroacupuncture parameters were set as follows: frequency at 10 Hz, current intensity at 0.5 mA, pulse width at 50 μs, and each session lasted 30 minutes. On the first day of chemotherapy, electroacupuncture was administered 1-2 hours prior to chemotherapy initiation. From Day 2 to the final day of chemotherapy, electroacupuncture sessions were conducted daily between 2:00 PM and 4:00 PM.
214443835|NCT07076836|DEVICE|sham acupuncture|The sham electroacupuncture group referenced the same acupoints as the electroacupuncture group, but the false acupoint shallow needling method and false electrode method are used, and the treatment time and course are the same as the electroacupuncture group.
214443836|NCT07077473|DRUG|real word drugs|real word drugs
214443837|NCT07076290|DRUG|R-3750|R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)
214443838|NCT07077343|PROCEDURE|AI-Assisted Navigated Hematoma Aspiration|By leveraging AI algorithms for real-time hematoma segmentation, volume calculation, and trajectory optimization, this approach enhances the accuracy of minimally invasive catheter placement and facilitates efficient clot removal under image-guided navigation.
214443839|NCT07077343|PROCEDURE|Conservative Treatment|Compared to surgical hematoma aspiration, conservative treatment relies on medical stabilization and the body's natural clearance mechanisms, and remains the standard of care in many cases of moderate or deep-seated ICH without signs of clinical deterioration.
214443840|NCT07078123|PROCEDURE|Laparoscopic Donor Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
214443841|NCT07078058|DEVICE|Low level laser|Patients in the low level laser group will be irradiated with visible and near-infra-red lasers at a pulsed mode with a frequency of 35 Hz, peak power of 100 mW, and a spot diameter of 5 mm. The 15-minute sessions were performed three times a week for two months, with each laser having a power density of 0.35 mW/cm2 and an energy density of 32.08 J/cm2.
214443842|NCT07078058|DEVICE|Transcutaneous auricular Vagus nerve stimulation|Patients will receive 30 minutes of transcutaneous vagus nerve stimulation for 2 months, with 5 sessions per week. The antihelix and cymba concha will be sterilized with 75% alcohol, and the electrode will be attached. The device parameters include a wave width of 0.2 ms ± 30%, pulse frequency of 20 Hz, gradually increasing intensity to a tolerable intensity (4-6 mA), and duration of 30 minutes.
214443845|NCT07078214|OTHER|Foot Sole Surface Area Measurements|The child's TWB was measured using the BTS P-Walk platform \[2440x740x8 mm, 12,000 sensors\] with an additional 500mm sensor-free mat for accurate start/end measurements. The system focused on foot-ground contact surface area data.Before measurements, the child familiarized herself with the platform through play. All walks were barefoot, with at least 3 attempts per assessment and the clearest data selected. To encourage platform crossing, the child carried a small object to her mother waiting opposite. To prevent upper extremity interference with gait, only return walks (without object) were analyzed for measurement.
214443846|NCT07078214|OTHER|Walking Exercise Program and Implementation Process|The backward walking exercise program was performed on a treadmill at 1±0.2 km/h speed, conducted 5 days per week between 14:00-15:00 hours when the child was most alert according to maternal reports. Initially planned for minimum 5-minute sessions with gradual increases, but the child's short attention span and unfamiliarity with backward walking limited sessions to 3 minutes during first two days. Favorite cartoons displayed via tablet during sessions successfully enabled gradual time increases. Week 1 progressed from 3-5 minutes daily. Weeks 2-5 showed progressive increases to 6-9 minutes with sessions increased to 2 daily, separated by 10-15 minute play breaks. From week 6 onwards, two 10±0.2 minute sessions continued daily. Starting week 3, sessions were restructured as 5 minutes backward + 1 minute forward + 2-7 minutes backward walking to combat attention deficits after 5 minutes, improving exercise efficiency.
214443847|NCT07078968|DEVICE|Tri-Membrane Wrap™|Membrane Wrap™
214443848|NCT07078968|DEVICE|Membrane Wrap™|Membrane Wrap™
214443849|NCT07078968|DEVICE|Membrane Wrap-Hydro™|Membrane Wrap-Hydro™
214443850|NCT07078968|OTHER|Standard of Care|Basic care involves debridement, along with local wound care depending on the wound needs. Debridement involves removal of fibrin and devitalized tissue from the base and the borders of the ulcer which is necessary in all treatment plans to reduce the risk of infection and promote healing.
214443851|NCT07077252|DRUG|SCTB39G|SCTB39G,IV
214443852|NCT07076511|OTHER|"Scenario unexpected difficult airway"|"Participants are asked to solve a scenario unexpected difficult airway using a manikin in accordance with current guidelines. The scenario aims for participants to try 3 different techniques in securing the airway before performing emergency front of neck access."
214443853|NCT07079007|OTHER|Water|Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.
214443854|NCT07076316|BEHAVIORAL|Structured Early Rehabilitation Nursing Pathway|A multi-component, phased nursing intervention focused on early and progressive mobilization, respiratory exercises, and psychological support.
214443855|NCT07076316|BEHAVIORAL|Routine Care|Standard nursing care for severe acute pancreatitis patients in the ICU, including monitoring and passive limb mobilization.
214443856|NCT07078422|DEVICE|Encora Pulse|"The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.~This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration."
214443857|NCT07078929|BIOLOGICAL|CD19-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a CD19-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
214443858|NCT07077967|PROCEDURE|Phacoemulsification with EDOF IOLs|Uneventful pseudophakic presbyopic correction with EDOF IOLs
214443859|NCT07077837|OTHER|Study Group|received perceptual learning using plantar hardness discrimination and conventional treatment
214443860|NCT07077837|OTHER|Control|received conventional treatment (balance exercise functional care training
214443861|NCT07079137|OTHER|History, examination, bite documentation, SSS scoring,Baseline labs as per institutional protocol|"Following enrollment, an initial clinical assessment will be conducted in the Emergency Department (ED). This includes history taking, physical examination, documentation of bite characteristics, and calculation of the Snakebite Severity Score (SSS) at presentation. Baseline laboratory investigations will be performed as per institutional protocol.~All participants will undergo serial clinical and laboratory monitoring as per institutional protocol. The development of syndrome-specific core outcomes, including neurotoxicity, haemotoxicity, coagulopathy, local tissue damage, acute kidney injury, and hypotension (Annexure) would be followed-up and evaluations will be conducted at the following time points:~At presentation, Within 3 hours of ED admission, Within 6 hours of ED admission, Within 12 hours of ED admission"
214443862|NCT07076537|DIETARY_SUPPLEMENT|Placebo|Placebo
214443863|NCT07076537|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium, L-theanine and lemon balm extract
214443864|NCT07078565|OTHER|Modified-Otago Exercises|Intervention is administered 3 times per week for 4 weeks, with the same baseline therapy as the Tai Chi group.
214443865|NCT07078565|OTHER|Tai Chi|Intervention is administered 3 times per week for 4 weeks, along with baseline therapy (TENS + heating pad).
214521416|NCT03807947|PROCEDURE|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
214521417|NCT04047303|DRUG|CC-90010|CC-90010
215120383|NCT01487135|DRUG|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
215120384|NCT01487135|DRUG|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
215120385|NCT05338034|DRUG|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
215120386|NCT05338034|DRUG|Placebo|Capsule
215120387|NCT02724098|DRUG|Dexmedetomidine|
214693265|NCT07084415|DEVICE|Laser acupuncture|"A dermatograph pencil (COLOURED®) will be used to draw circles with diameters of 2 cm around the application points. Each point will be stimulated for 30 seconds.~The laser will be placed at the specific acupuncture points in shoulder and cervical regions.~Each woman in the study group will be treated by laser acupuncture for 7 minutes twice a week for 4 weeks.~Acupuncture points of the neck:~B10 (Tianzhu), GB 20 (Fengchi), GB 21 (jianjing), and EX-HN15 (jianzhongsgu). Acupuncture points of shoulder: LI 14 (Binao), LI 15 (Jianyu), TE 14 (Jianlio), LI 4 (Hegu),LI16 (Jugu), ST 38 (Tiaoko), SI 10 (Naoshu),LI 11 (Quchi),TE 15 (Tianliao),LU 1 (Zhongfu),~Parameter of laser:~wavelength: 808\[nm\], Operating mode: Continuous wave, Output power: 100 \[mW\], Power density: 333\[mW/cm\], area irradiated:0.3 cm2, Total time per point: 30\[s\], Angle of application:90 degree."
214693266|NCT07078344|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|The oil-based supplements will include the Ultra Omega-3 product that delivers 683 mg EPA and 252 mg DHA (as ethyl esters) per capsule. A daily dose will provide 2.8 g of EPA+DHA (as ethyl esters). This product is part of the Nature Made line manufactured by Pharmavite (see Letter of Support). Three capsules will be self-administered orally by study participants, preferably at a single mealtime.
214693267|NCT07078344|OTHER|Placebo|Safflower oil (placebo) that delivers 70-80% oleic acid and 10-14% LA. The placebo is identical in appearance and shape to the active study agent. Three capsules will be self-administered orally by study participants, preferably at mealtimes.
214693268|NCT07083622|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
214443866|NCT07078864|OTHER|Nursing Care Decision Support System|Phase Two involves implementing the Nursing Care Decision Support System. Data will be collected using a Descriptive Information Form, the Nurse Decision-Making Scale (pre-test), and a Semi-Structured Interview Form to explore nurses' views. Nurses will receive two training sessions (totaling 4 hours) covering system use, importance, challenges, and solutions. Training will be held in two groups based on shift schedules. A one-week trial will follow, with the researcher answering questions and providing support via a WhatsApp group. Nurses must use the system for at least 15 days (maximum 30 days due to dissertation timeline). Fifteen days after use ends, the Nurse Decision-Making Scale (post-test) and interviews will assess the system's effectiveness and areas for improvement.
214443867|NCT07077590|BEHAVIORAL|Open Label Placebo|Any woman who arrive to the labor room is connected to fluids (Hartman's solution), as part of routine care. The study intervention (open placebo) is based on injection of placebo into an infusion bag accompanied by a verbal suggustion. The placebo is 5 ml NaCl 0.9%.
214693269|NCT07083622|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
214693270|NCT07083128|DEVICE|Parasternal intercostal thickening|Temporal change in parasternal intercostal thickening fraction at initiation and 30 minutes of spontaneous breathing trial
214693271|NCT07082907|OTHER|intervention group|Before using the nebulizer, children were given 2 fish in a bowl accompanied by their parents. The child patient was in the fowler/semifowler position, the movements of the fish were monitored during the nebulization period, and the fish was fed by the child during this process (Communication was provided for at least 5 minutes.)
214693272|NCT07074704|DEVICE|Hi-tACS|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
215120388|NCT00997035|DRUG|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
215120389|NCT00997035|DRUG|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
215120390|NCT04702412|OTHER|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
215120391|NCT02375035|DEVICE|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
215120392|NCT04045379|PROCEDURE|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
215120393|NCT04045379|PROCEDURE|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
215120394|NCT04045379|DRUG|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
214443868|NCT07076485|RADIATION|Ultrahypofractionated radiation|Given by infusion
214443869|NCT07076485|RADIATION|Moderately hypofractionated radiation|Given by infusion
214693273|NCT07074704|DEVICE|Sham Comparison|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
214693274|NCT07075900|OTHER|Dynamic Neuromuscular Stabilization Training|"According to the principles of Dynamic Neuromuscular Stabilization (DNS), proper activation of the integrated spinal stabilization system requires that the abdominal muscles expand not only in the caudal direction but also posteriorly and laterally.Therefore, firstly, the physiotherapist will assess the expansion of the entire abdominal wall and teach the patient to regulate intra-abdominal pressure through correct breathing techniques. During training and exercises, a belt will be used. Participants will be instructed to maintain abdominal expansion toward the belt during exercises performed in positions supported by proper alignment. A four-phase exercise protocol based on developmental kinesiology principles will be implemented for the DNS group, beginning with supine-position exercises appropriate for the 3-month developmental stage.~They will be instructed to repeat the exercises at least three times per day.Patients will record their home exercise program using an exercise diary."
214693275|NCT07075900|OTHER|Pelvic Floor Muscle Training|"Participants in the PFMT group will undergo a structured pelvic floor muscle training program supervised by a physiotherapist. The training will include verbal and manual instructions to ensure correct identification and isolated activation of the pelvic floor muscles without compensatory movements from the gluteal, abdominal, or thigh muscles using a NeuroTrac Simplex EMG-Biofeedback device.~The exercise protocol will consist of both slow and fast contractions, focusing on endurance, strength, and coordination.~The exercises will be performed in various positions (e.g., supine, sitting, standing) and will gradually progress in intensity and complexity over time, following the principles of motor learning stages. They will be instructed to repeat the exercises at least three times per day. Patients will record their home exercise program using an exercise diary."
214693276|NCT07083037|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)|The BRIDGE intervention includes 12 weeks of 20-60-minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use).
214443870|NCT07076303|DEVICE|Direct Selective Laser Trabuloplasty|Eligible participants will undergo the DSLT procedure to facilitate controlled aqueous outflow. DSLT will consist of 120 shots, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2.4 seconds
214693277|NCT07082023|PROCEDURE|V-NOTES Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via vaginal natural orifice transluminal endoscopic surgery (V-NOTES).
214693278|NCT07082023|PROCEDURE|Laparoscopic Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via conventional laparoscopy.
214693279|NCT07083921|DEVICE|plantar pressure|Healthy individuals carry loads with their dominant and non-dominant hands.
214693280|NCT07082153|DEVICE|the coronary sinus balloon pump|The coronary sinus balloon pump comprises a coronary sinus balloon pump catheter system and a coronary sinus balloon pump therapeutic device. This product is indicated for the treatment of ST-segment elevation myocardial infarction (STEMI) with or without coronary microvascular dysfunction (CMD), by intermittently occluding coronary sinus blood flow during percutaneous coronary intervention (PCI) procedures to reduce myocardial infarction size.
214693281|NCT07083505|DRUG|HB1801|HB1801 \[administered according to the clinical trial protocol\]
214693282|NCT07083505|DRUG|Taxotere®|Taxotere® 75 mg/ m\^2 \[administered according to the clinical trial protocol\]\]
214693283|NCT06929897|PROCEDURE|Pulmonary Vein Isolation|"1. Pulmonary vein isolation (PVI) is performed as the primary procedure.~2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group.~3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization."
214693284|NCT06929897|PROCEDURE|Additional Left Atrial Posterior Wall Ablation|"1. Additional left atrial posterior wall ablation is performed.~2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved).~3. Post-procedural rhythm monitoring follows the study protocol."
214693285|NCT06929897|PROCEDURE|Non-PV trigger test|"1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed.~2. Post-procedural rhythm monitoring follows the study protocol."
214693286|NCT06926179|DRUG|neoadjuvant immunotherapy|"Patients in the cohort received neoadjuvant immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors, as part of routine clinical care. The specific regimens included monotherapy or combination with chemotherapy. The agents used may include nivolumab, camrelizumab, sintilimab, atezolizumab, or others.~This is a retrospective observational study. All interventions (neoadjuvant immunotherapy ± chemotherapy, surgery, or other treatments) were determined by treating physicians as part of standard care. The study aims to evaluate perioperative and survival outcomes across different treatment paths in real-world clinical settings."
214693287|NCT06929546|DIAGNOSTIC_TEST|Anti-phospholipid antibodies|Serum samples will be obtained for determination of IgG and IgM isotypes of 4 anti-phospholipid antibodies including anti-cardiolipin (aCL), anti-phosphatidylserine (aPS), anti-phosphatidic acid (aPA) and anti-phosphatidylcholine (aPC) with in-house ELISAs.
214693288|NCT04634240|PROCEDURE|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
214693289|NCT06930950|OTHER|Cashew nut oral immunotherapy|Cashew nut oral immunotherapy (OIT) where the aim is desensitizing individuals with cashew nut allergies. The approach involves the gradual administration of increasing doses of cashew nut protein. The goal of OIT is to increase the threshold of tolerance to cashew nuts, thereby reducing the risk of severe allergic reactions upon accidental exposure
214443871|NCT07077083|DRUG|89Zr-Girentuximab|89Zr-Girentuximab PET
214443872|NCT07078383|DEVICE|Rapidlink|The Rapidlink implant is comprised of a Gelweave graft section (gelatin-sealed woven polyester) attached to a stented section (which utilizes nitinol ring stents), with a 'cuff'' feature joined to the stented section of the implant. The implant is supplied pre-loaded in a single use delivery system which compacts the stented section within a polytetrafluoroethylene (PTFE) sheath at the front of the system.
214443873|NCT07076589|PROCEDURE|FURS|FURS using traditional UAS \& FANS
215120395|NCT04049708|OTHER|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
215120396|NCT02919644|BIOLOGICAL|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate
214443874|NCT07077512|DRUG|Autoleucel (Relmacabtagene Autoleucel)|Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).
215120397|NCT02919644|DRUG|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
215120398|NCT00089596|PROCEDURE|Expansion of umbilical cord stem cells|
215120399|NCT00468026|DEVICE|ProstaPlant Stent|
214443875|NCT07077512|DRUG|Sintilimab (PD-1 inhibitor)|Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.
214443876|NCT07077291|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|A group intervention delivered by a psychiatrist and two assistants. Sessions were 120 minutes, once per week, for 12 weeks. Content included mindfulness exercises such as 3-minute breathing space, body scanning, mindfulness walking, meditation, and cognitive therapy techniques to observe connections between thoughts, emotions, and behavior.
214443877|NCT07077291|DRUG|Escitalopram Hydrobromide|Oral administration of escitalopram hydrobromide tablets, 20mg once daily (qd) for the entire 12-week study duration.
214443878|NCT07076940|OTHER|Mindfulness-based Training Program|The mindfulness-based training program was completed in a total of five sessions (one day per week, 60 minutes, for a total of five consecutive weeks).
214443879|NCT07076940|OTHER|Psychoeducational Program|"The Psychoeducational Program, themed around stress, well-being, and mindfulness, was completed in two sessions (two sessions over five weeks, each lasting 60 minutes)."
214443880|NCT07077044|DEVICE|The transcutaneous posterior tibial nerve stimulation device|In addition to their conventional treatment, subjects in both TTNS groups will complete eight weeks of home TTNS treatment (3 sessions per week), and each session will last for 20 minutes. Stimulation will be provided by a portable device (Chattanooga®, ContinuumTM, Hixson, TN, USA). The device will be pre-programmed to apply a bi-phasic squared wave with a pulse width of 200μsec, and a pulse frequency of 20 Hz. These are default settings for TTNS that have been used in previous studies for urinary and fecal incontinence59,62,67. Two self-adhesive electrodes (5 x 5 cm) will be placed over the ankle area, one approximately 3 to 4 cm above the medial tibial malleolus and a second electrode just below the medial malleolus of the same leg.
214443881|NCT07077044|OTHER|PSUS|Handheld US
214443882|NCT07077369|BIOLOGICAL|WGc-0201 injection|WGc-0201 injection
214443883|NCT07077369|DRUG|Tislelizumab|Tislelizumab, 200mg
214443884|NCT07077798|DRUG|Sintilimab|Patient receives first adjuvant sintilimab 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 8 cycles
214443885|NCT07077798|DRUG|Lenvatinib|lenvatinib is initiated orally(12 mg for body weight \&gt;= 60kg, 8 mg for body weight \&lt; 60kg daily), 2-4 weeks postoperatively for 6 months.
214443886|NCT07079059|OTHER|Virtual Reality Training|One hour of virtual reality training to be included in students' Anesthesia training prior to the start of their Anesthesia rotation.
214443887|NCT06902272|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* During Neoadjuvant Therapy: Approximately once after four cycles of standard of care Pembrolizumab and platinum doublet therapy.~* Approximately once two weeks before surgery.~* Approximately once three weeks after surgery.~* During Adjuvant Therapy: Approximately once every 12 weeks during standard of care, adjuvant Pembrolizumab therapy.~* Follow-up Period: Approximately once every three months for up to one year."
214443888|NCT06902272|DRUG|Pembrolizumab|Participants will receive standard of care, neoadjuvant Pembrolizumab therapy intravenously (IV) on Day 1 of each three-week cycle, for up to four cycles prior to standard of care surgery. After surgery, low-risk participants may continue standard of care, adjuvant Pembrolizumab therapy for up to six months; high-risk participants may receive standard of care, adjuvant Pembrolizumab therapy for up to 12 months.
214443889|NCT06902272|DRUG|Platinum Doublet Chemotherapy|Participants will receive neoadjuvant platinum doublet chemotherapy intravenously (IV) per standard of care on Day 1 of each three-week cycle for up to four cycles, prior to standard of care surgery. Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine. Participants receiving Gemcitabine therapy will be administered Gemcitabine, per standard of care, on Day 8 of each three-week cycle.
214521418|NCT03689452|DEVICE|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
214521419|NCT03689452|DRUG|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
214521420|NCT02879669|BIOLOGICAL|ONCOS-102|
214521421|NCT02879669|DRUG|Pemetrexed/cisplatin (carboplatin)|
214521422|NCT02879669|DRUG|Cyclophosphamide|
214521423|NCT00136851|DRUG|amlodipine besylate/benazepril hydrochloride|
215120400|NCT01067378|OTHER|Peer-led debriefing|
215120401|NCT01067378|OTHER|Expert instructor debriefing|
215120402|NCT00242671|PROCEDURE|Isocapnic Hyperponea|
215120403|NCT01380769|DRUG|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
215120404|NCT01380769|OTHER|Best Supportive Care|best supportive care
215120405|NCT03172312|PROCEDURE|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
215120406|NCT05514600|PROCEDURE|closure of parastomal hernia fascial defect|For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
215120407|NCT02919774|DRUG|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
215120408|NCT02919774|DRUG|placebo|matching placebo tablets
215120409|NCT01934257|OTHER|Marketed milk-based lactose-containing infant formula|
215120410|NCT01934257|OTHER|Marketed milk-based lactose-free infant formula|
215120411|NCT01934257|OTHER|Marketed soy-based lactose-free infant formula|
215120412|NCT01944540|PROCEDURE|Optimized ESD with snaring|
214443890|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
215120413|NCT01944540|PROCEDURE|Conventional ESD|
215120414|NCT01361646|DRUG|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
215120415|NCT05291793|DRUG|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
215120416|NCT05291793|DRUG|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
215120417|NCT05291793|DRUG|Saline|2ml sterile saline administered intraarticularly
215120418|NCT01156220|DRUG|Furosemide|Injection, 40 mg, single dose over 5 min
215120419|NCT01156220|DRUG|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
215120420|NCT02564133|DEVICE|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
215120421|NCT03064646|OTHER|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
215120422|NCT05491408|DEVICE|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure \[4,5\].
215120423|NCT04899622|BEHAVIORAL|MBSR|Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
215120424|NCT04899622|BEHAVIORAL|Exercise|"Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises."
215120425|NCT04899622|BEHAVIORAL|Online Self-Management Guide|Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
215120426|NCT05045261|DRUG|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
214443891|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
214443892|NCT07076758|OTHER|Transthoracic echocardiography|Transthoracic echocardiography will be done for all patients during their cardiac care unit stay including two-dimensional and color Doppler echocardiography studies. It will be performed in the left lateral position using the parasternal and apical transducer positions. All studies will be technically adequate for scoring endocardial regional wall motion. The following views will be obtained: long-axis parasternal, short-axis parasternal, apical four chamber, apical two-chamber and apical five-chamber views. All the measurements taken will be according to the criteria of the American Society of Echocardiography
214443893|NCT07076654|DRUG|Caffeine (200 mg)|Oral caffeine will be given as 200 mg before spinal anesthesia
214443894|NCT07076654|DRUG|Placebo|Patient at this arm will receive placebo
214443895|NCT03559049|DRUG|Pembrolizumab|200mg IV every 21 days
214443896|NCT03559049|DRUG|Pemetrexed|500mg/m\^2 IV every 21 days
214443897|NCT03559049|DRUG|Carboplatin|AUC 5 IV every 21 days
214443898|NCT03559049|DRUG|Rucaparib|600mg PO, BID days 1-21 of each 21 day cycle
214521424|NCT01383590|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
214521425|NCT02704637|DEVICE|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
215120427|NCT05045261|DRUG|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
215120428|NCT03445884|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
215120429|NCT01314001|DRUG|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
214693290|NCT07082140|OTHER|Social media based education|"Participants in the intervention group will be required to follow the Instagram account created specifically for the training. The Instagram account will be made private to prevent women in the control group from accessing Instagram posts. The training provided via Instagram will last 2 weeks, including the process of sharing all posts and videos. After the completion of the training, the Healthy Lifestyle Behaviors Scale and the Preconceptional Knowledge and Attitude Scale will be applied as a post-test."
214693291|NCT06930469|BEHAVIORAL|structured team model with shared decision-making|Structured team model based on shared decision-making model: ① Maternal Critical Care Review: Pre-hospital (prenatal checkup): Obstetricians and nurses conduct regular prenatal checkups for mothers, identify high-risk mothers, and set up high-risk maternal health records. Referral: Critically ill pregnant women establish a green channel for timely referral to the obstetrics department or ICU, and contact the relevant personnel of the structured management team. Assessment: The multidisciplinary team conducts a comprehensive assessment of the extent of the maternal condition, vital signs, and laboratory test results. Identification: Identify the main causes of critical maternal illness and potential risks, such as hemorrhage, infection, and organ failure. Rescue plan: according to the assessment results, formulate a personalized rescue plan and clarify the responsibilities and tasks of each department. Monitoring: real-time monitoring of maternal vital signs and changes in condition, a
214693292|NCT06930469|BEHAVIORAL|conventional multidisciplinary resuscitation care|"The observation group implemented a structured team model based on a shared decision-making model, which operated as follows:~(1) Constructing a structured management team: multidisciplinary medical and nursing staff, including obstetricians, ICU doctors, obstetric nurses, ICU nurses, head nurses, anesthesiologists, ultrasonographers, and family members of the patient's main companions, are divided into small teams according to their functions, and each small team has a team leader who is responsible for the coordination of the overall situation and the rapid coordination of information. Obstetricians and ICU doctors are responsible for life support, obstetric evaluation, condition monitoring and development of resuscitation plan for critically ill mothers. Anesthesiologists are responsible for anesthesia management, pain control and intraoperative resuscitation support. The nurse manager coordinates the nursing team to ensure the standardization of rescue care. Obstetrician and ICU nu"
214693293|NCT06929364|DIETARY_SUPPLEMENT|Omni Biotic Stress|Multistrain probiotic formulation (Omni Biotic Stress), 1 sachet daily for 8 weeks
214693294|NCT06929364|OTHER|Placebo|Inert powder identical in appearance and taste to probiotic, 1 sachet daily for 8 weeks
214443899|NCT07077135|DEVICE|stimulated group|Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days. Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20).
214443900|NCT07077135|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
214693296|NCT07083167|OTHER|No Interventions.|No interventions.
214693297|NCT06930612|BIOLOGICAL|CM512|Administered subcutaneous injection
214693298|NCT06930612|DRUG|Placebo|Administered subcutaneous injection
214693299|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 1.~Subject will receive placebo at dose level 1."
215120430|NCT01314001|DRUG|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
215120431|NCT01314001|DRUG|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
215120432|NCT02485561|BEHAVIORAL|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
215120433|NCT02485561|BEHAVIORAL|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
215120434|NCT04347863|OTHER|Group swallowing disorder diet preparation program|This program included food properties, select food, type of cooking, using thickener and tasting
215120435|NCT00082498|DRUG|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
215120436|NCT00082498|DRUG|Placebo|Patients in Group 1 will receive placebo.
214443901|NCT07078734|OTHER|Foam roller technique|In this intervention group, the patient is given back and forth oscillations using his or her own weight using a foam roller under the supervision of a physiotherapist.
214443902|NCT07078734|OTHER|Mulligan Straight Leg Raise Technique|This intervention consists of the mulligan straight leg raise technique applied to the patient by a physiotherapist.
214443903|NCT07076563|DIETARY_SUPPLEMENT|Functional Ice Cream with Cimarrón Bean Extrudate|"Ice cream containing 10 g of Cimarrón bean extruded (Phaseolus vulgaris L., local variety Cimarrón) 100 g per portion. Participants consume 100 g daily (two 50 g portions, \~2 hours after a main meal) for 4 weeks."
214443904|NCT07076563|DIETARY_SUPPLEMENT|Placebo Ice Cream|Ice cream without Cimarrón bean extrudate, matched in appearance, taste, and texture to the functional ice cream. Participants consume 100 g daily (two 50 g portions) for 4 weeks.
214443905|NCT06816693|BEHAVIORAL|tele-CR program|Following the completion of basic characteristics assessment prior to discharge, a 12 weeks tele-CR program was implemented for all participants. The tele-CR program is divided into three parts: motivational interview, App delivery, and self-management and tracking. The motivational interviewing during hospitalization, which involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR App (approximately 30-60 minutes per session). After discharge, the researchers monitored App usage and conducted four follow-up sessions via LINE or telephone at 1, 4, 8, and 12 weeks post-discharge. These follow-ups, lasting approximately 5-15 minutes each, aimed to assess patients' living conditions, resolve any issues promptly, and provide encouragement or praise based on their engagement with the App.
214443906|NCT06828835|OTHER|Reach for Equity in Pediatric Obstructive Sleep Evaluation (REPOSE)|The REPOSE intervention consists of a centralized patient navigator who (1) identifies and addresses dynamic individual barriers, (2) provides support for parent-child dyads, and (3) facilitates bidirectional SDB care coordination between clinical teams and parents to achieve evidence-based care. The goals of the REPOSE intervention are to systematically address barriers to care, develop parental self-efficacy to enhance healthcare utilization (e.g., receipt of recommended care and adherence to evidence-based care), and to improve symptom severity and quality of life.
214521426|NCT04997408|DEVICE|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
214521427|NCT04997408|OTHER|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
214521428|NCT01964118|OTHER|Intermittent Fasting group|Intermittent fasting for 12 months
214521429|NCT01964118|OTHER|control group|usual diet for 6 months and intermittent fasting for other 6 months
214521430|NCT02676778|DRUG|E7777|
214521431|NCT00732498|DRUG|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
215120437|NCT04048486|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
214521432|NCT00732498|DRUG|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
214693300|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 2.~Subject will receive placebo at dose level 2."
214693301|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 3.~Subject will receive placebo at dose level 3."
214693302|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 4.~Subject will receive placebo at dose level 4."
214693303|NCT07084194|OTHER|Chitosan Nanoparticles Irrigant|using Chitosan Nanoparticles irrigant as a final irrigation solution.
215120438|NCT04048486|OTHER|Physical development and General Health|Physical development and General health examination
215120439|NCT04048486|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
215120440|NCT01969006|DRUG|Marcaine ½%|
214521433|NCT00732498|DRUG|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
214521434|NCT00732498|DRUG|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
214521435|NCT00732498|DRUG|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
214521436|NCT00732498|DRUG|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
214521437|NCT00732498|DRUG|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
214521438|NCT03000829|OTHER|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
214693304|NCT07084194|OTHER|aloe vera nanoparticles irrigant|using Aloe Vera Nanoparticles irrigant as a final irrigation solution.
214693305|NCT07084194|DEVICE|Diode Laser Activation|activation of nanoparticles irrigants using diode laser
214693306|NCT07084194|DEVICE|ultrasonic activator|activation of nanoparticles irrigants using ultrasonic activator
214693307|NCT07082491|BEHAVIORAL|Mindfulness-based stress reduction|The intervention consists of 8 in-person sessions over a period of 8 weeks, with each session lasting about three hours, once per week, with an intensive full-day practice session lasting 7 hours. The instructors provide audio recordings at each session to be used as daily practice. The MBSR program is an introductory pathway to mindfulness practices that works through the systematic and continuous cultivation of specific mental states that foster a different relationship with stress.
215120441|NCT01969006|PROCEDURE|Needle prick|
215120442|NCT02526277|DEVICE|MMF07 Foot Massager|
215120443|NCT02526277|DEVICE|Heat Therapy|
215120444|NCT02753946|DRUG|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
214443907|NCT06828835|OTHER|Usual Care|Usual care is defined by standard clinical care delivered without a protocolized intervention (e.g., the ordinary course of care).
214443908|NCT07079150|DRUG|Peg IFN-α-2b|In the treatment of Peg IFNα-2b combined with NAs (Peg IFN combined treatment group), the treatment of Peg IFNα-2b should be no less than 48 weeks. The initial therapeutic dose of Peg IFNα-2b and the subsequent adjusted dose will be individualized determined by clinicians based on the specific condition of the patients. In the NAs monotherapy group, entecavir (ETV), tenofovir fumarate disoproxil (TDF), tenofovir propofol fumarate (TAF), and emitenofovir (TMF) were used for treatment for no less than 48 weeks, and Peg IFN was not added or switched for treatment.
214443909|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
214521439|NCT03000829|OTHER|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
214693308|NCT07083570|BEHAVIORAL|Active scapular repositioning|The examiner will first passively position the participant's scapula in a neutral position on the posterior chest wall. The participant will then be instructed to actively maintain that position.
214693309|NCT07083570|PROCEDURE|Passive scapular repositioning|The examiner will passively position and hold the participant's scapula in a neutral position.
214693310|NCT07083570|PROCEDURE|Sham scapular repositioning|The examiner will perform gentle shoulder girdle movements that do not alter scapular positioning.
214443910|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
214443911|NCT06896136|DRUG|VENBETA6890|Part A will consist of 1 sentinel dosing group of 2 subjects randomized 1:1 to receive VENBETA6890 and will evaluate VENBETA6890 at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
214693311|NCT07082660|DEVICE|High-Frequency Capacitive-Resistive Diathermic Current Therapy (TECAR)|20 minutes per session, 3 times per week for 4 weeks
214443912|NCT06896136|DRUG|Placebo|Part A Placebo (saline) will be administered at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
214443913|NCT06896799|OTHER|Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.|Participants who are randomised to eat the protein/fat-based component (scrambled egg) of the meal before the carbohydrate-based component (wholemeal toast) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
214521440|NCT04992494|BEHAVIORAL|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
214443914|NCT06896799|OTHER|Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.|Participants who are randomised to eat the carbohydrate-based component (wholemeal toast) of the meal before the protein/fat-based component (scrambled egg) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
214693312|NCT07082660|BEHAVIORAL|Lumbal Stabilization Exercise Program|3 sessions per week for 4 weeks, each session includes core stabilization and lumbar control exercises (12 sessions total).
214693313|NCT07074314|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
214693314|NCT07079163|DEVICE|Obturator block|A manually fabricated obturator using a preoperative maxillary cast, retained with clasps and wire. Delivered immediately after maxillectomy.
215120445|NCT02753946|DRUG|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
215120446|NCT00016497|PROCEDURE|bilateral myringotomy|
215120447|NCT00016497|PROCEDURE|bilateral myringotomy and tubes|
214693315|NCT07079163|DEVICE|Obturator block|A digitally designed obturator based on fused CBCT and intraoral scan data. Fabricated in resin using 3D-printing, and retained with 3D-printed clasps and palatal screws. Delivered immediately post-maxillectomy
214693316|NCT07079163|DEVICE|Obturator block|A digitally designed and 3D-printed obturator fabricated in metal, using CBCT and intraoral scan data. Retention is provided by metal clasps and palatal screws. Delivered during or immediately after surgery.
215120448|NCT00016497|PROCEDURE|adenoidectomy|
214443915|NCT04764357|DEVICE|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
214443916|NCT04764357|OTHER|Alopecia Assessments|Photographs will be taken prior to the use of the scalp cooling system and once at the end of the study. Patients with solid tumors will have additional photographs taken after every 2 cycles of chemotherapy.
214443917|NCT04764357|OTHER|Patient Reported Outcomes Questionnaires|"* Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, after every 2 cycles of chemotherapy, 4 week follow up and end of study.~* Tolerability Questionnaire each time the cooling cap is used and at the end of study"
214443918|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by an interventionist.
215120449|NCT06039709|COMBINATION_PRODUCT|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given \~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
214443919|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
214443920|NCT07077954|DRUG|Rivaroxaban|Rivaroxaban used to treat DVT
214521441|NCT04992494|BEHAVIORAL|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
214521442|NCT04904354|DEVICE|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
214521443|NCT04168437|OTHER|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
214521444|NCT01430299|DEVICE|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
214521445|NCT01430299|DEVICE|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
214521446|NCT03394508|DRUG|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
214443921|NCT07077954|DRUG|Warfarin|warfarin used for DVT
214443922|NCT07078890|PROCEDURE|bone augmentation simultaneous to implant removal|Placement of bone substitutes in the socket simultaneous to implant removal, and reimplantation is performed after 6 months of healing.
214443923|NCT03576274|BEHAVIORAL|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
214443924|NCT03576274|BEHAVIORAL|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
214443925|NCT03576274|BEHAVIORAL|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
214443929|NCT06915324|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial direct current stimulation (tDCS) is delivered by a device that has a user-friendly interface and a large-button keypad, making it is easy to use at home. The device delivers a weak electrical current of 2.0 mA that is transmitted through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are easily placed through a headset.~The active stimulation session lasts 30 minutes.~The inactive (sham) stimulation session will also last 30 minutes."
214443930|NCT06915324|BEHAVIORAL|Cognitive training|The cognitive training tasks are administered via a computer-based program BrainHQ (Posit Science). There are 20 sessions, each 30 minutes a day, conducted over approximately 4 weeks. The BrainHQ adaptive cognitive training tasks have been previously associated with improved processing speed in other populations.
214521447|NCT03394508|DRUG|ALK diluent 0,3% human albumin|Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
214521448|NCT01107171|DRUG|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
214521449|NCT01107171|DRUG|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
214521450|NCT01107171|DRUG|Placebo|Tang-min-Ling pills analogue 6g,tid,po
214521451|NCT01288729|DEVICE|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
214521452|NCT01288729|DEVICE|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
214521453|NCT03214198|DRUG|Vonoprazan|Vonoprazan tablets
215120450|NCT06342908|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
215120451|NCT06342908|BIOLOGICAL|Dendritic Cell Therapy|Given PpDC vaccine ID
215120452|NCT06342908|PROCEDURE|Leukapheresis|Undergo leukapheresis
215120453|NCT06342908|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215120454|NCT06342908|DRUG|Poly ICLC|Given IM
215120455|NCT03074565|DEVICE|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
215120456|NCT03074565|DEVICE|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
215120457|NCT02519439|DRUG|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
215120458|NCT05054998|RADIATION|Fludeoxyglucose F-18|Given IV
215120459|NCT05054998|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
215120460|NCT05054998|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
215120461|NCT02703298|DRUG|TRX-818 capsules|
214443931|NCT06919783|BEHAVIORAL|Health at Every Size in Obstetrics|Individuals are invited to participate in 5 group sessions during pregnancy and the postpartum period. The sessions will last 2-2.5 hours each and will include education on pregnancy, mental health, nutrition, movement, and self-advocacy. The sessions will be administered by an OBGYN/MFM physician and psychologist and include discussion with doulas, registered dieticians with pregnancy and disordered eating experience, and prenatal yoga instructors.
214443932|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
214443933|NCT06924346|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
214443934|NCT06924346|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
214443935|NCT07079215|DEVICE|Neurostimulation|Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.
214443936|NCT07079215|DEVICE|Sham stimulation|"Control Group (Sham Stimulation, n=12):~Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group."
214443937|NCT06924021|OTHER|Retinal Imaging|"Eligible participants will undergo one retinal imaging session of both eyes for the following:~* Single field stereo color fundus photography (cFP) - pre and post dilation~* Macular spectral domain-optical coherence tomography (SD-OCT)"
214443938|NCT06942221|OTHER|usual care|"Patients in the usual care group will be followed up according to the local practice until the end of the study."
214443939|NCT06942221|OTHER|guideline-directed medical therapy|Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.
214443940|NCT03436485|DRUG|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
214521454|NCT03726528|DIAGNOSTIC_TEST|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
214443941|NCT03436485|DRUG|Midazolam|orally
214693317|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
214693318|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
214521455|NCT02254200|OTHER|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
214521456|NCT02254200|OTHER|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
214521457|NCT06168994|DRUG|Eplerenone|Amiodarone vs eplerenone in AF
214693319|NCT00488618|DRUG|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
214693320|NCT00488618|DRUG|Placebo|Dose-matched placebo oral administration, once per day.
214443942|NCT06931483|DEVICE|Transcranial temporal interference stimulation (tTIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
214693321|NCT07083661|BEHAVIORAL|Mindfulness-based intervention on parent empowerment in reducing children's screen time (MORE)|Participants will receive a 6-week MORE group training by integration of mindfulness-based component into a modified Hands-on Parent Empowerment-20 (HOPE-20) programme.
214443943|NCT06931483|DEVICE|Sham transcranial temporal interference stimulation (tTIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.
214443944|NCT06942039|DRUG|Cytarabine IT|Age-based dosing as a part of double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
214521458|NCT04552444|DRUG|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
214521459|NCT02779972|OTHER|Echo stress test|Echo stress test
214521460|NCT02774876|DEVICE|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
214521461|NCT02774876|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
214443945|NCT06942039|DRUG|hydrocortisone|Double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
214443946|NCT06942039|DRUG|Cisplatin|Intravenous CISplatin given on Day 1 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
214693322|NCT07082205|BIOLOGICAL|Antimalarial monoclonal antibodies|L9LS Antimalarial monoclonal antibodies (mMAbs)
214693323|NCT07082205|DRUG|Dihydroartemisinin - Piperaquine (DP)|Post-Discharge Malaria Chemoprevention
214693324|NCT07082205|BIOLOGICAL|Placebo mMAB|Placebo anti malarial monoclonal antibody (placebo mMAB) which is Normal saline
214693325|NCT07082205|DRUG|Placebo PDMC|Placebo PDMC course which comprises placebo DP oral tablets
214693326|NCT07082062|DIETARY_SUPPLEMENT|GLP-1 formula Group|Participants in the intervention group will consume a single dose of GLP-1 formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
215120462|NCT05183945|DEVICE|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
215120463|NCT05183945|DEVICE|Coil|A coil which is used for preoperative localization of lung nodules.
214693327|NCT07083687|DRUG|Lorlatinib 100 mg|After enrollment, patients will receive 100 mg of lorlatinib orally once daily until disease progression, unacceptable toxicity, or withdraw study .
214443947|NCT06942039|DRUG|Vincristine|Intravenous VinCRIStine given on Days 1, 8 \& 15 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
214443948|NCT06942039|DRUG|Etoposide|"Induction: Intravenous Etoposide given on Days 1, 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, cyclophosphamide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Etoposide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Cyclophosphamide and Temozolomide."
214443949|NCT06942039|DRUG|Cyclophosphamide|"Induction: Intravenous high-dose Cyclophosphamide given on Days 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, etoposide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Cyclophosphamide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Etoposide and Temozolomide."
215120464|NCT02412228|DRUG|Ixazomib|"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
215120465|NCT02412228|DRUG|Cyclophosphamide|"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"
215120466|NCT02412228|DRUG|Dexamethasone|"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
215120467|NCT04112966|PROCEDURE|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
215120468|NCT04112966|OTHER|the health education|The health education for lymphedema prevention.
215120469|NCT01365728|PROCEDURE|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
215120470|NCT05568628|DEVICE|ultrasound|screening of breast lesions by ultrasonography
214443950|NCT06942039|DRUG|Mesna|Induction: Intravenous Mesna given at hour 0 of Cyclophosphamide delivery and 3, 6, 9 \& 12 hours post-dose during induction (3 cycles, 1 cycle = 21 days).
214521462|NCT02774876|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
214521463|NCT02774876|OTHER|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
214521464|NCT02966197|PROCEDURE|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
214521465|NCT02966197|DEVICE|Prophylactic internal iliac artery balloon|
214521466|NCT02966197|RADIATION|Radiology operation|
214521467|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
215120471|NCT04143685|DRUG|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
214443951|NCT06942039|DRUG|Filgrastim|"Induction: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hrs after last dose of chemotherapy and/or as per institutional guidelines until count recovery.~Consolidation: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hours after last stem cell infusion and/or per institutional guidelienes until count recovery."
214443952|NCT06942039|DRUG|carboplatin|Consolidation: Intravenous Carboplatin given on days -3 \& -2 during consolidation alongside thiotepa and filgrastim.
214443953|NCT06942039|DRUG|Thiotepa|Consolidation: Intravenous Thiotepa given on days -3 \& -2 during consolidation alongside carboplatin and filgrastim.
215120472|NCT04143685|DRUG|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
215120473|NCT04358302|BEHAVIORAL|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
214693328|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria of weaning from mechanical ventilation|Patients will be weaned after fulfilling the conventional clinical criteria of weaning from mechanical ventilation by using spontaneous breathing trials
215120474|NCT05032482|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
215120475|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
215120476|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
215120477|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
215120478|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
215120479|NCT01739036|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
215120480|NCT01126723|OTHER|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
215120481|NCT01126723|OTHER|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
215120482|NCT03668002|PROCEDURE|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
215120483|NCT03668002|PROCEDURE|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
215120484|NCT00837200|DRUG|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
215120485|NCT04369313|PROCEDURE|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
215120486|NCT04369313|PROCEDURE|early cord clamping|umbilical cord clamping within 15 seconds after birth
215120487|NCT05897008|BIOLOGICAL|CMAB007|for subcutaneous injection only
215120488|NCT05897008|BIOLOGICAL|Xolair|for subcutaneous injection only
215120489|NCT06108154|BEHAVIORAL|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
215120490|NCT05402514|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with subacromial shoulder pain consist of two daily distributed and progressively adaptable exercises there are delivered through the app as videos with subtitles. Patient education is provided 2-3 times per week as short lessons in the app with a quiz following the text to ensure that the information is properly understood by the patients. An individual physical therapist is assigned to each patient with compulsory telephone or video consultations at the start of the treatment, at 6 weeks and at 3 months. An asynchronous chat function with the physical therapist is available during the treatment period as well as a peer support chat.
215120491|NCT03107260|OTHER|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
214693329|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria and ultrasonic criteria for weaning|Patients will be weaned using the conventional clinical criteria and ultrasonic criteria for weaning.
214693330|NCT07082933|OTHER|Standard medical treatment|Standard medical treatment
214693331|NCT04315649|OTHER|3D movie viewing|3D movie viewing
214693332|NCT07083388|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
214443954|NCT06942039|DRUG|Topotecan IT|"Maintenance A (for low-risk patients): IT Topotecan on Day 1 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and ISOtretinoin.~Maintenance B (for high-risk patients): IT Topotecan every 4 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside ISOtretinoin, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
214443955|NCT06942039|DRUG|Tamoxifen|Maintenance A (for low-risk patients): Oral Tamoxifen twice daily, Days 1-28 (max 12 cycles, 1 cycle = 28 days) alongside ISOtretinoin and IT Topotecan.
214443956|NCT06942039|DRUG|ISOtretinoin|"Maintenance A (for low-risk patients): Oral ISOtretinoin twice daily on Days 15-28 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and IT Topotecan.~Maintenance B (for high-risk patients): Oral ISOtretinoin twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
214443957|NCT06942039|DRUG|Celecoxib|Maintenance B (for high-risk patients): Oral Celecoxib twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Temozolomide.
214443958|NCT06942039|DRUG|etoposide phosphate|During Induction and Maintenance B (for high-risk patients), etoposide phosphate may be given for subsequent doses to patients who have experienced etoposide allergic reactions.
214443959|NCT06942039|DRUG|Temozolomide|Maintenance B (for high-risk patients): Oral Temozolomide daily on Days 1-21, every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Celecoxib.
214693333|NCT07083388|DRUG|Dapagliflozin 10 mg|Orally administered once per day
215120492|NCT05318261|PROCEDURE|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
215120493|NCT04247230|DRUG|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
215120494|NCT04247230|OTHER|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
215120495|NCT04247230|DRUG|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
215120496|NCT02239159|OTHER|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
215120497|NCT03805802|OTHER|active product|Once daily consumption over the period of the study
215120498|NCT03805802|OTHER|reference product|Once daily consumption over the period of the study
215120499|NCT01541046|BIOLOGICAL|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
215120500|NCT01541046|BIOLOGICAL|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
215120501|NCT01539759|DEVICE|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
215120502|NCT04376307|PROCEDURE|minimal flow anesthesia|Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
215120503|NCT03790722|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
214443960|NCT07078071|DEVICE|ECG|Each participant undergoes testing with both the investigation device and the control device simultaneously. The results of the investigation device, which are obtained through pulse wave data analysis at the wrist, are compared to the investigator's interpretation of the ECG.
214443961|NCT07077811|PROCEDURE|pulsed field ablation|Medtronic Pulse Select pulsed field ablation
214443962|NCT07077811|DRUG|antiarrhythmic drug|treated with class I or class III antiarrhythmic drugs
214443963|NCT06153537|DRUG|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
214443964|NCT04790175|DRUG|Tolvaptan (SAMSCA)|The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.
214443965|NCT03744312|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
214443966|NCT03744312|DRUG|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
214443967|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214443968|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
214443969|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
215120504|NCT03790722|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
215120505|NCT03402334|BEHAVIORAL|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
215120506|NCT05917613|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
215120507|NCT03901144|DRUG|2% urea/20% glycerol cream|Moisturizing cream for topical application
215120508|NCT03901144|DRUG|Miniderm® 20% cream|Moisturizing cream for topical application
215120509|NCT03901144|DRUG|Diprobase® cream|Emollient cream for topical application
214443970|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
214443971|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
214443972|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
214443973|NCT05181709|DRUG|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
214443974|NCT05181709|BIOLOGICAL|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
214443975|NCT05181709|BIOLOGICAL|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
214443976|NCT05181709|BIOLOGICAL|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
214443977|NCT05181709|BIOLOGICAL|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
214443978|NCT05134337|DRUG|LOXO-305|Oral LOXO-305
215120510|NCT04894032|PROCEDURE|Combination of Laparoscopic Uterosacral Ligament and Round Ligament Plication.|Laparoscopic Uterosacral Ligament Plication, Fixation of PVC fascia and the combination with round ligament plication
215120511|NCT01031719|BIOLOGICAL|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
214443979|NCT05134337|DRUG|Itraconazole|Oral itraconazole
214443980|NCT05134337|DRUG|Rifampin|Oral rifampin
215120512|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
215120513|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
215120514|NCT02491983|DRUG|Palbociclib|
215120515|NCT02491983|DRUG|Fulvestrant|
215120516|NCT02491983|DRUG|Letrozole|
215120517|NCT05163262|OTHER|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
215120518|NCT05724407|OTHER|Diagnostic assistance tool|"Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months."
215120519|NCT02714569|DRUG|LY3202328|Administered orally
215120520|NCT02714569|DRUG|Placebo|Administered orally
215120521|NCT02714569|DRUG|Atorvastatin|Administered orally
215120522|NCT02714569|DRUG|Simvastatin|Administered orally
214443981|NCT03850015|DIAGNOSTIC_TEST|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
214443982|NCT03850015|OTHER|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
214443983|NCT05461352|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
214693334|NCT07083388|DRUG|Pioglitazone 30 mg|Orally administered once per day
214693335|NCT07083388|DRUG|Metformin HCl 1000 mg|Orally administered once per day
214443984|NCT05461352|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
214443985|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
214443986|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
214443987|NCT04592198|DRUG|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
214443988|NCT03591133|DRUG|TS-143|
214443989|NCT03591133|DRUG|Placebo|
214443990|NCT05834920|DEVICE|Transcranial pulse stimulation (TPS)|Participants will be treated with the TPS device NEUROLITH (Storz Medical AG). Treatments will be administered for up to 12 sessions within 4 weeks, each session consisting of 6000 TPS pulses of 0.2 mJ/mm².
214693336|NCT06825884|BIOLOGICAL|Extracellular micro vesicles (EV)|Extracellular micro vesicles (EV) as direct perilesional injection into the diabetic chronic foot ulcers (DFU) which have not healed after using standard of care.
214521468|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
214521469|NCT03363009|DEVICE|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
215120523|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
215120524|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
215120525|NCT03532126|DEVICE|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
215120526|NCT05275374|DRUG|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
214693337|NCT07083934|DEVICE|Peripheral nerve stimulator|Peripheral nerve stimulator along with ultrasound
215120527|NCT05275374|DRUG|Trametinib|Trametinib will be administered 2mg orally once a day.
215120528|NCT04383457|DEVICE|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
215120529|NCT00190723|DRUG|Enzastaurin|
215120530|NCT02067936|DRUG|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
215120531|NCT02067936|DRUG|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
215120532|NCT02067936|DRUG|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
215120533|NCT02067936|DRUG|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
215120534|NCT05932472|DRUG|Aspirin|Aspirin at currently prescribed dose
215120535|NCT01361893|OTHER|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
215120536|NCT00587678|DRUG|Simvastatin|40mg each night
215120537|NCT00587678|DRUG|Ezetimibe|10mg daily
215120538|NCT00587678|DRUG|Simvastatin/Ezetimibe|40mg/10mg each night
215120539|NCT04736381|DRUG|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
215120540|NCT06333379|OTHER|Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF|Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.
214693338|NCT07083934|DEVICE|No peripheral nerve stimulator|No peripheral nerve stimulator with ultrasound. Only ultrasound will be used
214693339|NCT07083180|OTHER|Recreative activity|Patients practice a leisure activity before surgery (20 minutes)
214693340|NCT07083180|OTHER|Medical Hypnosis by virtual reality|Patients benefit from a medical hypnosis session using virtual reality (20 minutes)
214693341|NCT07082413|OTHER|Nutritional Intervention|This study will follow a randomized controlled trial design aimed at evaluating the impact of nutritional intervention on personal satisfaction and perceived quality of life. The protocol includes two assessment points: a baseline measurement at the start of the intervention (Day 0) and a second measurement after a follow-up period (Day 90), allowing for the analysis of with-in-subject changes associated with the intervention.
215120541|NCT03552497|DIAGNOSTIC_TEST|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
215120542|NCT03468361|OTHER|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
215120543|NCT03468361|OTHER|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
215120544|NCT00104650|GENETIC|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
215120545|NCT00104650|DRUG|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
215120546|NCT00104650|GENETIC|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
215120547|NCT03390465|DRUG|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
215120548|NCT05820854|OTHER|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
215120549|NCT00990743|DRUG|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
215120550|NCT06393075|BEHAVIORAL|combined care guidance|Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
214443991|NCT05834920|DEVICE|Neurofeedback|Participants will engage in a neurofeedback game designed to increase the ratio of theta/beta frequency bands in electroencephalography measurement. This intervention will be delivered for up to 12 sessions within 4 weeks.
215120551|NCT06393075|BEHAVIORAL|general care guidance|general care guidance
214443992|NCT05170269|DRUG|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
215120552|NCT03413124|DRUG|MGL-3196 Tablet|MGL-3196 in Tablet form
215120553|NCT03413124|DRUG|MGL-3196 Capsule|MGL-3196 in Capsule form
215120554|NCT03353805|BEHAVIORAL|questionnaire|questionnaire
214443993|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
214443994|NCT05607121|DEVICE|intermittent theta burst stimulation|transcranial magnetic stimulation
214443995|NCT05607121|DEVICE|continuous theta burst stimulation|transcranial magnetic stimulation
214443996|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
214443997|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
215120555|NCT01431781|DRUG|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
215120556|NCT01431781|OTHER|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
214443998|NCT05498376|DEVICE|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
214443999|NCT05498376|DEVICE|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
214444000|NCT06694948|DRUG|pimicotinib capsules|pimicotinib capsules
214444001|NCT02991625|OTHER|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
214444002|NCT02991625|OTHER|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
214444003|NCT02991625|OTHER|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
214444004|NCT06830122|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
215120557|NCT02111330|DRUG|PBF-509|
214444005|NCT06830122|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
215120558|NCT02111330|DRUG|Placebo|
215120559|NCT04311684|DEVICE|hybrid Brillouin-Raman spectroscopy|Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
215120560|NCT04470635|DIAGNOSTIC_TEST|ELISA|Saliva sample collection
215120561|NCT00189839|DRUG|tacrolimus|Immunosuppression
215120562|NCT02722226|OTHER|Simulation|High fidelity simulation based sedation learning program
215120563|NCT02722226|DEVICE|Airway management|Workshop on using airway management and oxygenation devices.
215120564|NCT02722226|BEHAVIORAL|Crisis resource management|Learning crisis resource management principles
215120565|NCT04642391|DRUG|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
215120566|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
215120567|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
215120568|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
214444006|NCT05954130|OTHER|Education|Sexual Health in Pregnancy
215120569|NCT03903419|DIAGNOSTIC_TEST|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
215120570|NCT03763019|PROCEDURE|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
215120571|NCT03763019|PROCEDURE|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
215120572|NCT03407755|PROCEDURE|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
215120573|NCT02946034|DRUG|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
214444007|NCT05310539|OTHER|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
214444008|NCT06833450|OTHER|Transabdominal intestinal ultrasound|Transabdominal intestinal ultrasound
214444009|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
215120574|NCT02946034|DRUG|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
214444010|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
214444011|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
214444012|NCT03152786|OTHER|Survey Administration|Ancillary studies
214444013|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
214444014|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
214444015|NCT06575335|OTHER|Triphala Tooth Wipe|The wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned.
215120575|NCT00500188|DRUG|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
215120576|NCT04661436|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
215120577|NCT02728089|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
215120578|NCT01849406|DRUG|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
215120579|NCT01849406|DRUG|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
214444016|NCT06575335|OTHER|Chlorhexidine Tooth Wipe|Same as triphala tooth wipe
214444017|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying Breath Test|13C-Spirulina GEBT (Cairn Diagnostics) is non-radioactive, non-invasive breath based test validated against scintigraphy for the measurement of gastric emptying. Patients will be mailed test kits to be done in their homes remotely along with telehealth assistance from the study team. After overnight fast and providing duplicate pre-meal breath samples, the patient consumes 27 grams of re-hydrated, precisely formulated, pasteurized scrambled egg mix containing a dose of 43 mg of 13C (provided by approximately 100 mg of 13C-Spirulina), 6 saltine crackers and 6 ounces (180 mL) of potable water. The caloric value of the meal is approximately 230 kCal.Patient will provide breath samples into provided glass tubes before and after test meal administration which are then mailed back to a central laboratory for analysis by gas isotope ratio mass spectrometry.
214444018|NCT05274568|DRUG|[18F]UCB-2897|"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."
214521470|NCT03363009|DEVICE|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
214521471|NCT00363090|BIOLOGICAL|alemtuzumab|
214521472|NCT00363090|DRUG|cyclophosphamide|
214521473|NCT00363090|DRUG|doxorubicin hydrochloride|
214521474|NCT00363090|DRUG|prednisone|
214521475|NCT00363090|DRUG|vincristine sulfate|
214521476|NCT00363090|OTHER|flow cytometry|
214521477|NCT00363090|OTHER|pharmacological study|
214521478|NCT03401099|PROCEDURE|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
214521479|NCT03401099|PROCEDURE|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
214521480|NCT02395406|DEVICE|Orotracheal intubation with Totaltrack|
214521481|NCT02395406|DEVICE|Orotracheal intubation with Airtraq|
214521482|NCT04650763|BIOLOGICAL|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
215028760|NCT06644859|DEVICE|Daily Activity Patterns Using Wearable Tri-Axial Sensors|This intervention uniquely focuses on the prediction of injurious falls by combining daily life gait (DLG) measures (e.g., gait speed, cadence, variability) with daily life physical activity (DLPA) measures (e.g., activity levels, activity fragmentation). Unlike other studies, this analysis leverages data from a large cohort of older women (n=17,466) enrolled in the Women's Health Study (WHS), where participants wore a tri-axial accelerometer for 1 week. Additionally, the study links accelerometer data to long-term health outcomes, specifically fall-related injuries from Centers for Medicare \&amp; Medicaid Services (CMS) records. This is the first study to explore whether combining DLG and DLPA measures, derived from wearable technology, can predict fall-related injuries in an aging population, applying advanced machine learning techniques to this large, anonymized dataset.
214444019|NCT06073717|BEHAVIORAL|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
214444020|NCT06073717|BEHAVIORAL|Motor-cognitive Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
214444021|NCT06073717|BEHAVIORAL|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
214444022|NCT03618160|DRUG|JNJ-64565111|Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
214444023|NCT03618160|DRUG|Placebo|Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
214521483|NCT04650763|DEVICE|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
214693342|NCT07083258|DEVICE|Progressive Inspiratory Muscle Training (IMT)|The intervention involves the application of inspiratory muscle training using the POWERbreathe Plus device. Training will be conducted at an initial intensity of 50% of the individual's MIP and will be increased weekly by 10%, reaching 80% by week four. Sessions will take place 5 days per week and consist of 2 sets of 30 repetitions per day, with 2-minute rest intervals between sets. This training aims to improve inspiratory muscle strength and endurance, as well as core stability, respiratory function, dynamic balance, and trunk isokinetic strength.
214693343|NCT07083258|OTHER|Placebo Training|The placebo group will perform identical training sessions using the same device but with a constant minimal resistance set at 15% of the initial MIP, insufficient to induce a physiological training effect. This intervention is designed to control for placebo response. Assessment protocols will be identical to those in the experimental group.
214693344|NCT07082348|BEHAVIORAL|Herbs and Spices Nutrition Education Program|Participants will attend two group visits at the UNLV Nutrition Center (weeks 0 and 3 of the 6-week intervention), where trained RDs will deliver the HSNP, covering the principles and health benefits of the Dietary Guidelines for Americans (DGA), recommended food group intake, and practical, budget-friendly strategies for incorporating herbs and spices into the diet. Sessions will include education, supporting materials, and a sensory evaluation of 20 foods (spanning fruits, vegetables, grains, dairy, and proteins) prepared with various herbs and spices, rated using a 9-point hedonic scale to identify preferred flavor profiles and promote long-term DGA adherence through enhanced taste and acceptability.
214693345|NCT07083544|BEHAVIORAL|Written Sleep Hygiene Strategies (W-SHS)|Participants assigned to the W-SHS group received a printed handout containing general sleep hygiene strategies. These strategies were designed to improve sleep quality and included recommendations on maintaining a consistent sleep-wake schedule, minimizing light exposure before bedtime, avoiding screens and heavy meals in the evening, optimizing the sleep environment (e.g., room temperature, noise), and managing nap timing. Participants were instructed to apply these strategies consistently for 10 consecutive days. No individual guidance was provided.
215028761|NCT02873052|DEVICE|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
215028762|NCT03658304|DRUG|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
214444024|NCT05166954|PROCEDURE|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
215028763|NCT05773482|BEHAVIORAL|Breathing and Attention Training (BAT)|BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
215120580|NCT04298437|BEHAVIORAL|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
215120581|NCT00798525|DRUG|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
215028764|NCT05773482|BEHAVIORAL|Breathing Control|Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
214444025|NCT05166954|PROCEDURE|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
214444026|NCT04924062|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
214444027|NCT04924062|DRUG|Gemcitabine|Gemcitabine by IV infusion
214444028|NCT04924062|DRUG|Cisplatin|Cisplatin by IV infusion
214444029|NCT04924062|DRUG|Placebo|Placebo to pembrolizumab
214444030|NCT03980509|DRUG|Curcumin|Curcumin is an extract from turmeric
214444031|NCT04499950|DRUG|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
214444032|NCT04499950|BEHAVIORAL|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
214444033|NCT04281134|DEVICE|Summit RC+S System|"Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger."
214444034|NCT04281134|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
214444035|NCT04732052|DEVICE|Transcranial Direct Current Stimulation|non-invasive brain stimulator
214521484|NCT04246099|OTHER|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
214521485|NCT02154893|DEVICE|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
214521486|NCT02154893|DEVICE|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
214521487|NCT02154893|DEVICE|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
214521488|NCT04295499|DEVICE|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
214521489|NCT05681611|DRUG|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
214521490|NCT06277206|DIAGNOSTIC_TEST|18F-FAPI PET/CT|Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.
214521491|NCT02135445|DRUG|TAK-385|TAK-385 tablet
214521492|NCT02135445|DRUG|Degarelix|Degarelix injection
214521493|NCT05771688|DEVICE|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
214521494|NCT06989866|DRUG|Bupivacaine|Bupivicaine injection post operatively
214521495|NCT06989866|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline injected to control group
214521496|NCT06598891|PROCEDURE|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
214521497|NCT06598891|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
214521498|NCT06994611|PROCEDURE|MOSE application|The length of the tissue strips was judged using the specimen table and photographed for record. If the MVC of the first needle sample was ≥10mm, the tissue strip was placed into bottle A formalin for fixation. A second needle of tissue strip was pushed directly into the B-bottle formalin. If the first needle sample MVC was \< 10mm, the puncture was continued until the total length of sample MVC was ≥10mm, and all samples were placed into bottle A formalin.
214521499|NCT06994611|PROCEDURE|Conventional processing|Two needles were punctured and all tissue strips were placed into bottle A formalin.
214521500|NCT07008651|BEHAVIORAL|Digital parenting education|"Description: The digital parenting training to be given to mothers consists of 8 sessions of 20 minutes each. In the first week of the training process, a meeting will be held with the mothers in the experimental group and a brief introduction will be made to the subject. In the second week, information will be provided on the following topics: Definition and Roles of Digital Parenting, How Does the Use of Information Technologies Affect the Parent-Child Relationship?, How Does the Use of Information Technologies Affect Children's Behavior?, How Should Social Media Be Used Properly?, What are the Opportunities and Risks of Information Technologies for Parents and Children?, and What Should Parents Pay Attention to in the Use of Information Technologies? in the sixth week. In the eighth week, Question and Answer/Closing will be conducted to collect post-test data and end the training session."
215028765|NCT06371352|DEVICE|iTBS|Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
215028766|NCT06371352|DEVICE|cTBS|Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
215028767|NCT06371352|DEVICE|Sham|Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
215028768|NCT04886856|BEHAVIORAL|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
214693346|NCT07083544|BEHAVIORAL|Verbal Sleep Hygiene Strategies (V-SHS)|Participants in the V-SHS group received the same general sleep hygiene strategies as the W-SHS group, but delivered through a one-on-one verbal education session. A trained researcher in sleep and sport science conducted a 40-minute session with each athlete, explaining each strategy and offering personalized clarifications and suggestions. Participants were then instructed to implement these strategies over a 10-day period.
214693347|NCT07083401|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
214693348|NCT07083401|DRUG|Dapagliflozin 10 mg|Orally administered once per day
214693349|NCT07083401|DRUG|Pioglitazone 30 mg|Orally administered once per day
214693350|NCT07083401|DRUG|Metformin HCl 1000 mg|Orally administered once per day
214693351|NCT05185882|OTHER|Single leg squat|Single leg squat exercise in different circumstances
214693352|NCT07082426|DEVICE|Balloon expandable TAVI|Prospective, single-arm, multi-center early experience study.
214693353|NCT07084324|BEHAVIORAL|Unstuck and On Target|Children will receive the Unstuck and On Target (Unstuck) curriculum, a manualized cognitive-behavioral intervention that teaches executive functioning (EF) skills such as flexibility, emotional regulation, and goal-setting. Caregivers will attend concurrent Spanish-language sessions focused on understanding EF challenges and learning strategies to support their child's skills at home. Weekly home practice sheets in Spanish summarize each session and provide practical tips and activities. The program is designed to be neurodiversity-affirming and accessible to Spanish-speaking families.
214693354|NCT06930404|OTHER|facial scans, videos and heart rate variability measurements|Ignite app to collect data (videos, photos and heart rate variability)
214693355|NCT00992446|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214693356|NCT00992446|DRUG|Bortezomib|Given IV
214693357|NCT00992446|DRUG|Carmustine|Given IV
214693358|NCT00992446|DRUG|Cytarabine|Given IV
214693359|NCT00992446|DRUG|Etoposide|Given IV
214693360|NCT00992446|DRUG|Melphalan|Given IV
214693361|NCT00992446|DRUG|Rituximab|Given IV
214693362|NCT00992446|DRUG|Vorinostat|Given PO
214693363|NCT04562064|DEVICE|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
214693364|NCT06390982|RADIATION|Radiotherapy|45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
214693365|NCT06390982|DRUG|Tislelizumab|200 mg IV on Day 1 of each 21-day cycle.
214693366|NCT06390982|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
214693367|NCT06390982|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
214693368|NCT06390982|DRUG|Capecitabine|825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
214693369|NCT01468727|DIETARY_SUPPLEMENT|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
214693370|NCT01468727|DIETARY_SUPPLEMENT|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
214693371|NCT02222012|DEVICE|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
215028769|NCT04886856|BEHAVIORAL|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
215028770|NCT06571890|DEVICE|Narcotrend bispectral index anaesthesia monitor|A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
215028771|NCT06571890|DEVICE|Mdoloris Anaesthesia Nociception Monitor|A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
215028772|NCT01179555|BEHAVIORAL|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
215028773|NCT01179555|BEHAVIORAL|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
215028774|NCT03685149|DRUG|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
215028775|NCT03685149|DRUG|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
215028776|NCT04318938|DRUG|Brigatinib|Treatment with Brigatinib
215028777|NCT04318938|DRUG|Tyrosine kinase inhibitor|Treatment with any TKI
215028778|NCT04506437|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
215028779|NCT04506437|BEHAVIORAL|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
215028780|NCT02609503|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
215028781|NCT02609503|RADIATION|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
215028782|NCT06162507|BIOLOGICAL|CM310|CM310 injection
215028783|NCT06293287|DRUG|Subcutaneous enoxaparin sodium|Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
215028784|NCT06293287|DRUG|Placebo|placebo (0.9% saline solution)
215028785|NCT02808611|DRUG|propranolol|Reduction of the ANS response
215028786|NCT02808611|DRUG|Placebo|
215028787|NCT01810172|DEVICE|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
215120582|NCT00798525|DRUG|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
215120583|NCT01451385|DRUG|COV795|COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
215120584|NCT01887184|DRUG|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranasally
214444036|NCT04981977|BEHAVIORAL|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
214444037|NCT04981977|BEHAVIORAL|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
214444038|NCT04981977|OTHER|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
214444039|NCT00667030|BEHAVIORAL|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
214521501|NCT07008937|OTHER|Balneotherapy|"For balneotherapy, patients will be treated in a thermal pool for 15-20 minutes daily, with full-body immersion, for a total of 15 days.~For control, Volunteers in the control group will only receive a home exercise program. They will be called in for a check-up every five days to confirm that the home program is being followed correctly. In this way, the volunteers in the control group will not be left completely without treatment."
214521502|NCT07008937|OTHER|home exercise program|home exercise program
214521503|NCT07007754|PROCEDURE|Voice recording playback|Voice recordings were created from a text containing 12 standardised messages common to both the patient's relatives and the researcher and expert opinion was obtained in terms of the applicability of the created text. Before the intervention, the postoperative patient's suitability was determined by the patient's statement and the researcher's observations. No intervention was performed if the patient had nausea/vomiting, pain or agitation before the intervention. Kingboss 8 Gb+ 650 hours uninterrupted digital voice recorder and headphones were used for voice recording. When the voice recorder and headphones were to be used in a different patient, they were wiped with 70% alcohol and used after waiting for 2 minutes in accordance with the manufacturer's instructions. The voice of one of the family members was recorded for Intervention group-1 patients and the voice of one of the researchers was (nötr voice) recorded for intervention group-2.
214521504|NCT07008300|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
214521505|NCT07008833|PROCEDURE|Radiochemotherapy|Maximum TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m². After 2-6 weeks of neoadjuvant chemotherapy, patients will receive radiotherapy for 4 weeks, with concomitant cisplatin at a dose of 40 mg/m² weekly.
214521506|NCT07008833|PROCEDURE|Radical cystectomy|TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m², followed by radical cystectomy, bilateral pelvic lymphadenectomy, and reconstruction with either a Bricker procedure or a neobladder.
214693372|NCT02222012|DEVICE|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
214521507|NCT07008066|OTHER|Bicycle ergometer excercise|Patients will undergo a symptom-limited ergometer cycling test under medical supervision. If the atrial fibrillation is not converted to sinus rhythm during the exercise test, the patients will be electrically converted.
214521508|NCT07008066|PROCEDURE|Standard care with electrical cardioversion|Standard care with planned electrical cardioversion without exercise intervention.
214693373|NCT03257163|DRUG|Capecitabine|Given PO
215120585|NCT01887184|DRUG|Placebo|Intranasal saline was given
215120586|NCT03960112|DEVICE|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
215120587|NCT00056004|DRUG|zileuton|
215120588|NCT00531635|DRUG|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
214444040|NCT05711602|OTHER|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
214444041|NCT05872932|PROCEDURE|gastric balloon implantation|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
214444042|NCT05872932|PROCEDURE|botulinum toxin A injection|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
214444043|NCT06761365|DEVICE|LuSeed Aneurysm Embolization System|a permanent intrasaccular implant used for treatment of unruptured intracranial saccular aneurysms (IA) in adult patients according to international guidelines who are indicated for non-emergent endovascular embolization of saccular IAs at the time of presentation.
214444044|NCT05704296|PROCEDURE|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
214444045|NCT05704296|PROCEDURE|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
214444046|NCT05549362|OTHER|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
214444047|NCT06702891|OTHER|Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing|The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
214444048|NCT06261593|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
214444049|NCT06527521|PROCEDURE|Traumatologic surgery|Patients undergoing trauma surgery
214444050|NCT02428192|BIOLOGICAL|Ipilimumab|Given IV
214444051|NCT02428192|OTHER|Laboratory Biomarker Analysis|Correlative studies
214444052|NCT02428192|BIOLOGICAL|Nivolumab|Given IV
214444053|NCT06783582|OTHER|Motivational interviewing based on Pender's health promotion model|In addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
214444054|NCT04562480|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214444055|NCT04562480|OTHER|Quality-of-Life Assessment|Ancillary studies
214521509|NCT07007650|DRUG|High-concentration Ropivacaine|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
214444056|NCT04562480|OTHER|Questionnaire Administration|Ancillary studies
214444057|NCT04562480|PROCEDURE|Resection|Undergo surgical resection
214444058|NCT05426213|DEVICE|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
214444059|NCT06788639|BIOLOGICAL|Lisocabtagene maraleucel|According to the United States Prescribing Information
214444060|NCT06784258|PROCEDURE|General Anesthesia (control group)|The patient will undergo conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/kg BB. After that the patient will be intubated
214521510|NCT07007650|DRUG|Low concentration ropivacaine group|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
214521511|NCT00997750|DRUG|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
214521512|NCT06700395|DRUG|TQB2029 injection|TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
214521513|NCT06719570|DRUG|MK-8591A|Fixed dose combination tablet
214521514|NCT06719570|DRUG|Islatravir|Oral capsule
214521515|NCT06719570|DRUG|Doravine|Oral tablet
214521516|NCT03167645|DRUG|Human albumin|Substitution according to pre-specified dosage
214521517|NCT00116233|DEVICE|REPEL-CV|
214521518|NCT00826956|PROCEDURE|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
214521519|NCT01064505|DRUG|QPI-1007 at various doses|Single Intravitreal Injection
214521520|NCT01886391|BEHAVIORAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
214693374|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
214693375|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
214444061|NCT06784258|PROCEDURE|General Anesthesia combined with epidural anesthesia|The patient will undergo epidural anesthesia first with an epidural catheter inserted through a Tuohy needle and ensuring that the length of the multihole epidural catheter that enters the epidural space is 5-6 cm. After that, the patient underwent conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/ kg BW. After that the patient will be intubated. The patient will be given local anesthesia Bupivacaine 0.25% in increments to the desired volume according to the desired height of the segmental block. Local anesthetic medication will be given intermittently every 2 hours
215120589|NCT05348200|DRUG|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
214444062|NCT06782958|DRUG|50mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
214444063|NCT06782958|DRUG|100mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
214444064|NCT06782958|DRUG|150 mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
214444065|NCT06782958|DRUG|200 mg FHND1002（fasting）|Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
214444066|NCT06782958|DRUG|250mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
214444067|NCT06782958|DRUG|200mg FHND1002(postprandial)|Participants will receive a one-time dose (200 mg) under postprandial conditions
214693376|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
215120590|NCT05348200|DRUG|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
215120591|NCT05348200|DRUG|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
215120592|NCT05348200|DRUG|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
215120593|NCT05348200|DRUG|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
215120594|NCT00209859|DRUG|Methotrexate|
215120595|NCT00209859|DRUG|Intraarticular betamethasone|
215120596|NCT00209859|DRUG|Cyclosporine/placebo-cyclosporine|
215120597|NCT01550809|OTHER|iBolus|Insulin bolus calculated from data obtained through CGM
215120598|NCT01550809|OTHER|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
215120599|NCT01736371|DRUG|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
215120600|NCT01736371|DRUG|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
215120601|NCT01736371|DRUG|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
215120602|NCT02386449|DRUG|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
215120603|NCT02386449|DRUG|mannitol|
215120604|NCT02386449|DRUG|Bisacodyl|
215120605|NCT04740697|OTHER|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
215120606|NCT06315946|DEVICE|Pixie® skin tag|The skin tag is treated by treatment with the cryogenic device. To protect the surrounding skin, a protective foam plaster is applied before the device is used on the skin tag. The skin tag is treated for 20 seconds after loading the device for 2 seconds.
215120607|NCT06315946|DEVICE|Wortie® Skin Tag Remover|The skin tag is treated by treatment with the cryogenic device. The frozen metal nib is applied on the skin tag for 40 seconds.
215120608|NCT00003811|BIOLOGICAL|bleomycin sulfate|
215120609|NCT00003811|DRUG|amifostine trihydrate|
215120610|NCT00003811|DRUG|cisplatin|
215120611|NCT00003811|DRUG|etoposide|
215120612|NCT00003811|PROCEDURE|conventional surgery|
215120613|NCT01440855|OTHER|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
215120614|NCT01440855|OTHER|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
215120615|NCT00018967|DRUG|glucarpidase|
215120616|NCT03893032|DRUG|Modafinil 200mg|single 200 mg dose
215120617|NCT03893032|DRUG|mixed amphetamine salts|single 10 mg dose
215120618|NCT03893032|DRUG|Placebo|single oral-administration placebo tablet
215120619|NCT04334993|DRUG|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
215120620|NCT01428908|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
214521521|NCT01407302|OTHER|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
214521522|NCT00349648|PROCEDURE|acromioplasty|
215120621|NCT01428908|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
214444068|NCT04373226|BEHAVIORAL|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
215120622|NCT01428908|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
215120623|NCT01428908|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
214444069|NCT06830954|DRUG|Group A|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg).
214444070|NCT06830954|DRUG|Reference Group|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg).
214444071|NCT05173818|DRUG|Hyperbaric oxygen at 1.5 ATA|Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
214444072|NCT05173818|DRUG|Sham treatment|"Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent"
214444073|NCT06780592|DRUG|Vebreltinib + Temozolomide|Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
214444074|NCT06780592|DRUG|Temozolomide|Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
214444075|NCT06785779|OTHER|Secukinmab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
214444076|NCT05968677|DIETARY_SUPPLEMENT|FSMP|Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
214444077|NCT05968677|OTHER|Nutritional counseling|Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
214444078|NCT04955717|OTHER|Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert|Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
214521523|NCT06584786|COMBINATION_PRODUCT|Jing Si herbal tea (JSHT)|JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
215120624|NCT02209701|DRUG|Porfiromycin|
214521524|NCT06584786|OTHER|Placebo|Placebo of JSHT
214521525|NCT04557735|DRUG|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
214693377|NCT06829381|PROCEDURE|Tailored BPL length|Total bowel length measure and BPL will be 40% of total bowel length ensuring at least 250 cm common channel
215120625|NCT04702841|DRUG|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
215120626|NCT04603118|PROCEDURE|Optic ultrasonography|
215120627|NCT04603118|PROCEDURE|Lumbar puncture|
215120628|NCT03607942|DIETARY_SUPPLEMENT|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
214521526|NCT04557735|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
214521527|NCT05727553|RADIATION|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
214521528|NCT03016364|DEVICE|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
214521529|NCT02132598|DRUG|cabozantinib|
214521530|NCT02904291|DRUG|Amlodipine|Patients are tested for their normal prescription amlodipine medication
214521531|NCT06386263|DRUG|Trastuzumab deruxtecan|This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.
215120629|NCT03607942|DIETARY_SUPPLEMENT|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
215120630|NCT03117985|OTHER|no drug|Stopping antiretroviral therapy
215120631|NCT02690350|DRUG|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
215120632|NCT00917761|DRUG|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
215120633|NCT00917761|DRUG|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
215120634|NCT00917761|DRUG|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
215120635|NCT01758913|DRUG|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
215120636|NCT03374540|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
214444079|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan, to use with individuals with Down syndrome, that combines two treatment approaches: Cycles Phonological Remediation Approach and Script training, while adapting each to prioritize use of practice words with low vowels given research findings that the low vowels /ɑ/ as in 'hot' and /æ/as in 'hat' are less intelligible than the high vowels /i/ as in 'heat' and /u/ as in 'boot'; also, vowel acoustic analyses that revealed word-intelligibility to improve when the production of the low vowels /ɑ/ and /æ/ had more distinctive second formants/vocal tract resonances (a measure that is associated with tongue front-back movement). Each intervention session will include 40-50 minutes of the adapted 'Cycles Phonological Remediation Approach' focusing on articulatory/phonological training at the syllable/word level, and 10-20 minutes of the adapted Script program for motor training at the sentence level.
215120637|NCT03374540|DRUG|Vitamin K antagonist (VKA)|Individually adjusted dose
214444080|NCT05695053|DEVICE|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
214444081|NCT05695053|OTHER|Placebo|Placebo
214444082|NCT05514769|PROCEDURE|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
214444083|NCT06095050|DEVICE|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
215120638|NCT06149208|BEHAVIORAL|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
215120639|NCT05922371|DIAGNOSTIC_TEST|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
215120640|NCT03384940|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
215120641|NCT01668849|DIETARY_SUPPLEMENT|Grape extract|Grape extract self-administered by mouth daily for 35 days
215120642|NCT01668849|DRUG|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
215120643|NCT05206149|DRUG|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
215120644|NCT05206149|DRUG|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
215120645|NCT02497183|DEVICE|ultrasound|A repeat ultrasound exam following oral contrast material consumption
215120646|NCT02497183|OTHER|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
215120647|NCT05682742|DEVICE|Robotic-assisted Surgery|Subjects scheduled to undergo robotic-assisted surgery
215120648|NCT03308708|DRUG|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
215120649|NCT05211427|PROCEDURE|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
215120650|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
215120651|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
215120652|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
215120653|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215120654|NCT01242592|DRUG|Anti-Tuberculosis Treatment|
215120655|NCT04981379|DRUG|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
215120656|NCT04981379|DRUG|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
215120657|NCT04981379|DRUG|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
215120658|NCT04981379|DRUG|Placebo|Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
215120659|NCT00786318|DRUG|ziprasidone|ziprasidone 20mg IM
215120660|NCT00786318|DRUG|Standard therapy|Haldol 5mg/ Ativan 2mg IM
215120661|NCT04184297|DRUG|Tiotropium and Olodaterol (Tio+Olo)|drug
215120662|NCT04184297|DRUG|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
215120663|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI|
214444084|NCT06095050|OTHER|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
214444085|NCT05403801|BEHAVIORAL|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
215120664|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 1|
215120665|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 2|
215120666|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI replicate|
215120667|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
215120668|NCT03078894|DIAGNOSTIC_TEST|Zika|Zika Diagnostic test
215120669|NCT03078894|DIAGNOSTIC_TEST|Chikagunya|Chikagunya Diagnostic test
215120670|NCT03078894|DIAGNOSTIC_TEST|Dengue|Dengue Diagnostic test
215120671|NCT06281093|OTHER|questionary|Parental questionnaire on pregnancy history and environmental exposure
215120672|NCT06281093|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (1 week) by positioning a dosimeter close to the incubator
215120673|NCT06281093|OTHER|Follow-up of daily infants clinical parameters|Follow-up of daily infants clinical parameters
215120674|NCT06281093|OTHER|recording of cerebral (EEG)|recording of cerebral (EEG)
214444086|NCT05091476|DEVICE|OPTiC System|OPTiC System procedure
214521532|NCT06538831|OTHER|Diet N-P-|Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)
214444087|NCT06794476|BEHAVIORAL|Milieu Teaching-AV|In Milieu Teaching-AV, coaches will teach caregivers to engage the child in play or routines around a standardized set of toys, follow the child's attention or communication lead around these toys, and respond to the infant's communication acts by modeling and expanding those communication acts into more sophisticated strategies. While responding to infant communication acts, coaches will slowly move the referent of the infant's lead near the face at approximately the level of the mouth, wait for the infant to shift his/her gaze towards the new referent position if necessary, and provide all models, prompting, and expanding while maintaining placement of the referent near the mouth.
214444088|NCT06823362|DRUG|Pentoxifylline|400 mg
214444089|NCT06823362|DRUG|Pentoxifylline|400 mg
214521533|NCT06538831|OTHER|Diet N+P-|Rich in SFAs, free sugar and sodium; Low in UPFs
214521534|NCT06538831|OTHER|Diet N-P+|Low in SFAs, free sugar and sodium; High in UPFs
214693378|NCT06829381|PROCEDURE|Control - BPL 180 cm|Total bowel length measure and BPL will be180 cm
215120675|NCT06281093|OTHER|autonomic nervous (ECG) activity|autonomic nervous (ECG) activity
215120676|NCT02732548|OTHER|Negative Pressure Wound Therapy (NPWT)|
214521535|NCT06538831|OTHER|Diet N+P+|Rich in SFAs, free sugar and sodium; High in UPFs
215120677|NCT02732548|OTHER|MIRODERM Application(s)|
215120678|NCT02732548|OTHER|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
215120679|NCT02412098|DRUG|Eleclazine|Eleclazine tablets administered orally
215120680|NCT03089580|DEVICE|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
215120681|NCT03089580|PROCEDURE|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
215120682|NCT03764644|BEHAVIORAL|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
215120683|NCT03764644|BEHAVIORAL|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
214444090|NCT04619680|DRUG|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
214444091|NCT04619680|DRUG|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
214444092|NCT06216080|OTHER|D-FF-OCT analysis of CVC|Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
214444093|NCT06168162|OTHER|titated PEEP to best static compliance|the Intraoperative PEEP will be titrated to best static compliance for each patient
214444094|NCT06835374|PROCEDURE|Per oral endoscopy myotomy (Per oral endoscopy myotomy)|POEM is the procedure to reduce the symptoms of dysphagia, regurgitation.
214444095|NCT06835374|PROCEDURE|Endoscopy procedure|Endoscopy procedure is required to rule out type of reflux disease
214444096|NCT03888989|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
214444097|NCT06622226|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally.
214444098|NCT03224767|DRUG|Vemurafenib|Given PO
214444099|NCT03224767|DRUG|Cobimetinib|Given PO
214444100|NCT03224767|OTHER|Laboratory Biomarker Analysis|Correlative studies
214444101|NCT03224767|OTHER|Quality-of-Life Assessment|Ancillary studies
214444102|NCT06566040|DEVICE|Wheelchair|Wheelchairs provided to hospital inpatients
214444103|NCT04894110|BIOLOGICAL|EO2002|EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
214444104|NCT04894110|BIOLOGICAL|EO2002 low dose|Low dose of EO2002 (magnetic human corneal endothelial cells)
214444105|NCT04894110|BIOLOGICAL|EO2002 mid dose|Mid dose of EO2002 (magnetic human corneal endothelial cells)
214521536|NCT03451292|DRUG|Albutein 20%|Injectable solution
214521537|NCT03451292|OTHER|SMT|Participants received SMT according to institution standards for the management of decompensated cirrhosis.
214693379|NCT07082751|BEHAVIORAL|Lifestyle Guidance|Lifestyle Guidance
214693380|NCT07083492|DIAGNOSTIC_TEST|non-invasive measurement of zink protoporphyrin|validation of non-invasive measurement of zink protoporphyrin
214693381|NCT02931695|OTHER|evaluation of QT interval duration|ECG to evaluation of QT interval duration
214693382|NCT02931695|OTHER|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
214444106|NCT04894110|BIOLOGICAL|EO2002 high dose|High dose of EO2002 (magnetic human corneal endothelial cells)
214444107|NCT06789939|OTHER|Train the trainer program for MPCC professionals|The intervention will consist on a train the trainer program. 3 professionals from each MPCC will be trained by an educational team. They will then have to implement an IPEP (knowledge of the MPCC, participation in interprofessional MPCC activities, etc.) for students on placement in their MPCC.
214444108|NCT05903794|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
214693383|NCT06922552|PROCEDURE|Giomer pit and fissure sealant with etching applied on Permanent Molars Affected by MIH|"* Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel An adequate amount of primer will be dispensed on the enamel surface of the pit and fissure using a brush then will be left undisturbed for 5sec. Gentle air blow for 3 sec and then dryness with stronger stream of air until a thin and uniform bonding layer is obtained.~* The giomer sealant (BeautiSealant, Shofu, Kyoto, Japan) will be applied into the occlusal fissures applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow."
214693384|NCT06922552|PROCEDURE|Resin based sealant applied on Permanent Molars Affected by MIH|"Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel~* The resin sealant (UltraSeal XT™ hydro™) will be applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow into the pit and fissures. Photo - curing for the sealant will be done for 20 seconds using LED light curing unit. The tip of the light will be held as close as possible to the sealant, without actually touching the sealant.~the surfaces will be checked with an explorer to ensure that no voids were present."
214444109|NCT06834763|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth. PSP provides site-specific placement success prediction scores \[i.e., client's likelihood of success per placement based on machine learning models\] for each youth.
214444110|NCT06270758|DIAGNOSTIC_TEST|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
214444111|NCT06834503|DRUG|Rivotril®|Rivotril® 2 mg
214444112|NCT06834503|DRUG|Clonazepam TQ 2 mg|Test
214444113|NCT06834243|PROCEDURE|Intermittent Bolus PENG Block|Patients received intermittent bolus administration of the Pericapsular Nerve Group (PENG) Block via a catheter. A researcher manually administered 20 mL of 0.25% bupivacaine every 4 hours over a 24-hour period.
214444114|NCT06834243|PROCEDURE|Continuous Infusion PENG Block|Patients received continuous infusion of the Pericapsular Nerve Group (PENG) Block via a catheter. A pump delivered 5 mL/hour of 0.25% bupivacaine continuously over a 24-hour period.
214444115|NCT06835686|BEHAVIORAL|Health Literacy and Culturally Tailored Materials|Participants will receive health literacy-appropriate written information on community resources and weight management
214444116|NCT06835686|BEHAVIORAL|Community-Engaged Health Coaching and Navigation|Participants will receive virtual coaching sessions over a 6-month period from trained Community Health Workers (CHWs). Coaching will include culturally competent information and strategies for weight management, and linking participants to community wellness resources identified in Community Asset Mapping (see below). Coaches will also remotely monitor patients' weight loss and physical activity via online portals to provide patients with tailored support during coaching sessions.
214444117|NCT06835686|BEHAVIORAL|Self-Monitoring and Remote Patient Monitoring of weight and physical activity|Participants will self-monitor weight and physical activity during the 6-month health coaching protocol using a cellular-connected digital weight scale and a Bluetooth-connected wrist-worn fitness tracking device (e.g., Fitbit). Participants will be instructed to weigh themselves and wear a fitness tracker (e.g., Fitbit) daily. Health coaches will remotely monitor weight and physical activity data logged by these devices to incorporate into health coaching sessions.
214444118|NCT06835686|OTHER|Community Asset Mapping (CAM)|The CHW from each intervention community clinic will convene a team of community members, including but not limited to CONNECT participants, that will meet regularly to identify and describe community assets that enable, support, and promote healthy lifestyles related to weight loss and management (e.g., healthy eating and physical activity resources). Community teams will be supported to design and implement Community Action Projects to promote the utilization of community resources identified in the map.
214444119|NCT06835686|OTHER|Primary Care Provider Training|Education sessions will be provided to FQHC providers. The training curriculum is designed to increase healthcare providers' knowledge of evidence-based and guideline-concordant obesity management strategies in primary care settings.
214444120|NCT06835686|OTHER|Obesity Toolkit for Primary Care Providers|We will provide FQHC providers with a toolkit containing additional obesity management resources and information and the community resource guides given to participants to support obesity management.
214444121|NCT06833710|OTHER|Auricular Acupressure|In the experimental group, the Shenmen point (MA-TF1) and Xin point (Xin MA) on both ears were treated with Wangbuliuxing seeds. Initially, the seeds were applied to the left ear for seven days, after which they were switched to the corresponding acupoints on the right ear. Following application, the seeds were pressed daily, once after each meal, with each acupoint being stimulated for 1 minute
214444122|NCT06833996|DRUG|Bakuchiol|Apply bakuchiol cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
214444123|NCT06833996|DRUG|Vehicle|Apply vehicle cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
214444124|NCT06832423|DIETARY_SUPPLEMENT|Creatine monohydrate|Powder mixed with flavoured water
214444125|NCT06832423|DIETARY_SUPPLEMENT|Placebo|Powder mixed with flavoured water
214693385|NCT06923501|DEVICE|Tools for Coping with Cancer Calm Health mobile app program|"Participants will be asked to use a 13-session self-management program Tools for Coping with Cancer within the Calm Health mobile app."
214444126|NCT03157323|BEHAVIORAL|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
214444127|NCT06830343|DRUG|SYH9017|subcutaneous injection once time in SAD and four times in MAD
214444128|NCT06830343|DRUG|Placebo|subcutaneous injection once time in SAD and four times in MAD
214444129|NCT06830343|DRUG|Wegovy ®|subcutaneous injection once a week
214444130|NCT06833112|DRUG|Secukinumab|The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.
214444131|NCT06833112|DRUG|Adalimumab|The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.
214444132|NCT06825741|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
214521538|NCT05030467|BEHAVIORAL|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
214521539|NCT03943771|OTHER|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
214521540|NCT06047795|OTHER|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
214521541|NCT06047795|OTHER|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
215120684|NCT03087513|DRUG|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
215120685|NCT03087513|DRUG|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
215120686|NCT00977626|DRUG|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
215120687|NCT00977626|DRUG|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
215120688|NCT00977626|DRUG|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
215120689|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
215120690|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
215120691|NCT05529693|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
215120692|NCT03871699|DRUG|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
215120693|NCT06346015|PROCEDURE|Gamma Entrainment Stimulation|"Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）"
215120694|NCT05590975|BEHAVIORAL|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
215120695|NCT00083525|DRUG|WX-UK1 in combination with Capecitabine|
215120696|NCT02739399|DRUG|Phenylephrine|Intravenous administration
215120697|NCT01462240|DEVICE|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
215120698|NCT06169553|OTHER|Holistic injection-related injection treatment|Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
215120699|NCT00770601|DRUG|Canakinumab|
215120700|NCT03779698|OTHER|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
215120701|NCT03779698|DRUG|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
215120702|NCT00878748|DRUG|Effexor XR|
215120703|NCT00878748|OTHER|Effexor XR discontinue|
214444133|NCT06833918|GENETIC|blood sampling|"The followings markers will be investigated in plasma samples:~1. LIPCAR, STAT3 and DDIT3 using quantitative real-time polymerase chain reaction (qRT-PCR)~2. α-SMA using western blot analysis~3. Troponin T using ELISA expression~4. Serum levels of fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C), oxidized low-density lipoprotein (ox-LDL) using chemical methods (spectrophotometry). The Friedewald formula was used to compute low-density lipoprotein cholesterol (LDL-C): LDL-Cholesterol =Total cholesterol- (HDL-Cholesterol +Triglycerides/5)."
214444134|NCT05097950|DRUG|Administration of 1 gr paracetamol I.V|Administration of 1 gr paracetamol I.V
214444135|NCT03651895|DRUG|Metformin|The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.
214444136|NCT03651895|DRUG|Placebo|Placebo
214521542|NCT03716947|PROCEDURE|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
214521543|NCT03716947|PROCEDURE|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
214521544|NCT03716947|PROCEDURE|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
215120704|NCT04119674|DRUG|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
215120705|NCT04119674|DRUG|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
215120706|NCT04119674|RADIATION|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
215120707|NCT04693559|PROCEDURE|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
215120708|NCT04693559|PROCEDURE|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
214444137|NCT06791746|DRUG|compound Staphylococcal lysostaphin mouthrinse|Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.
214444138|NCT06791746|DRUG|chlorhexidine mouthrinse|Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.
214444139|NCT01447758|DRUG|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
214444140|NCT01447758|DRUG|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
214444141|NCT06030544|DIETARY_SUPPLEMENT|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
214444142|NCT06030544|DIETARY_SUPPLEMENT|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
214444143|NCT06787729|DEVICE|mHealth|The experimental design is composed of three phases: baseline, intervention, and retention. During the first two weeks (baseline), subjects will wear sensors, but no additional features (e.g., feedback, goal-setting, and weekly Zoom calls with clinicians) will be provided. For the next four weeks (intervention), subjects will wear sensors and have access to all intervention features, including weekly Zoom calls and goal-setting with clinicians. They will be encouraged to use the more impaired arm as much as possible. In the final two weeks (retention), the mobile intervention and clinician interactions will be removed, while subjects continue to wear sensors to examine the effects of withdrawing feedback.
214444144|NCT03127722|PROCEDURE|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
214444145|NCT03127722|DEVICE|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
214444146|NCT03127722|PROCEDURE|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
214444147|NCT04309461|BEHAVIORAL|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
214444148|NCT04309461|BEHAVIORAL|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
214444149|NCT05741333|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.
214444150|NCT04576286|PROCEDURE|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
214521545|NCT06837155|DRUG|TS-172 20 mg|oral administration of TS-172 20 mg
214521546|NCT06837155|DRUG|TS-172 90 mg|oral administration of TS-172 90 mg
214521547|NCT06837155|DRUG|Moxifloxacin|oral administration of moxifloxacin 400 mg
214693386|NCT06923241|BEHAVIORAL|menu labelling type|Participants will be given a restaurant's menu with calorie information or a menu with calorie information and NS labelling.
214693387|NCT06920719|DRUG|YHP2406|Test drug: YHP2406, Comparator: YHR2501
214693388|NCT06920719|DRUG|YHR2501|Test drug: YHP2406, Comparator: YHR2501
214693389|NCT06924879|OTHER|Mindfulness-Based Pregnancy Stress Reduction Program|Mindfulness-Based Pregnancy Stress Reduction Program Training Content Session 1 Introduction to the program Course preparation Orientation process Session 2 Introduction to Mindfulness practices Session 3 Focusing on the moment Session 4 Coping with thoughts Connecting with pregnant women's bodies Becoming aware of their thoughts, feelings and bodily senses Session 5 Releasing emotions and thoughts Session 6 Awareness Session 7 Keeping distance from thoughts Session 8 Accepting Awareness
214693390|NCT06926374|PROCEDURE|Robotic surgery using the Sentire Surgical System|Robotic surgery using the Sentire Surgical System
214693391|NCT06929767|OTHER|biomarker-guided decision making|-recommendations for antibiotic and steroid Rx provided to study physician based on bio-marker (serum CRP, blood eosinophils, sputum colour) results.
214693392|NCT06929767|OTHER|GOLD recommendations|Recommendations provided to study physician for Rx of antibiotics and steroids based on current GOLD recommendations
214693393|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
214693394|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
214693395|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
214693396|NCT05809011|DRUG|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
214693397|NCT05809011|DRUG|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
214693398|NCT05104671|OTHER|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:"
214693399|NCT05104671|OTHER|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
215120709|NCT04693559|PROCEDURE|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
215120710|NCT00181662|DRUG|Curcumin|
214521548|NCT06837155|DRUG|Placebo|oral administration of placebo
214521549|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
214521550|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
214521551|NCT05878990|BEHAVIORAL|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
214521552|NCT05878990|BEHAVIORAL|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
215028788|NCT01810172|DEVICE|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
215028789|NCT01555424|DIETARY_SUPPLEMENT|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
215028790|NCT01555424|DIETARY_SUPPLEMENT|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
215028791|NCT03647137|OTHER|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
214444151|NCT02525692|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
214444152|NCT02396199|DEVICE|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
214444153|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
214444154|NCT04898023|DRUG|zinc-green tea extract-ascorbic acid|Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
214444155|NCT04898023|DRUG|Placebo|Compounded capsules containing microcrystalline cellulose.
214444156|NCT05716165|DEVICE|proprioceptive knee braces|The patient will perform the tests with the knee braces.
214444157|NCT05716165|DEVICE|No knee brace|The patient will perform the tests without the knee brace.
214444158|NCT01395732|DRUG|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
214444159|NCT05323175|DRUG|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
214444160|NCT05323175|OTHER|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
214444161|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
214444162|NCT06055387|BEHAVIORAL|Frailty intervention measures|"Providing specialized guidance:~* Physical Function and Fall History:~  * Prioritizing home safety for those with physical impairments.~ * Arranging rehab consultations when necessary.~* Nutrition:~  * Assessing diets and offering education.~ * Pre-treatment nutritionist assessments.~ * Monitoring weight, intervening if \>5-10% loss, or \>10% loss.~* Social Support:~  * Evaluating the needs of those without family support.~ * Referring to social services and introducing care resources.~* Cognition:~  * Detecting cognitive issues, addressing reversible causes.~ * Assessing decision-making and medication self-administration.~ * Refer to specialists when needed.~* Polypharmacy and Comorbidity:~  * Collecting medication data, ensuring adherence.~ * Noting chronic illnesses.~ * Collaborating with specialists or pharmacists for complex cases.~* Psychological:~  * Providing weekly support for psychological concerns.~ * Refer to specialists for assessments and treatment options."
214444163|NCT01563341|DEVICE|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
214444164|NCT03938532|DEVICE|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
214444165|NCT03938532|DEVICE|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
214444166|NCT05432765|OTHER|Phenotypic Personalized Medicine Dosing|Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
214444167|NCT05432765|OTHER|Standard of Care Dosing|Providers will decide on the combination of drug doses needed based on their overall assessment per standard of care.
214444168|NCT05871177|DEVICE|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight \[32 mg (HHA) + 32 mg (LHA) / 2 ml\]
214444169|NCT02349412|OTHER|Early palliative care|
214444170|NCT03918720|BEHAVIORAL|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
214444171|NCT05925595|DEVICE|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
214521553|NCT05878990|BEHAVIORAL|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
214521554|NCT05878990|BEHAVIORAL|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
214521555|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
214444172|NCT03587688|PROCEDURE|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
215028792|NCT05713838|DRUG|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
215028793|NCT05713838|DRUG|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
214444173|NCT05179200|PROCEDURE|Plasmapheresis|Plasma donation
214444174|NCT05179200|PROCEDURE|Whole blood donation|Blood donation
214444175|NCT03611153|DRUG|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
214521556|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
215028794|NCT05713838|DRUG|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
215028795|NCT05713838|RADIATION|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
214444176|NCT03611153|DRUG|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
214444177|NCT04642599|DEVICE|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
214444178|NCT05754034|DEVICE|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
214444179|NCT05754034|OTHER|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
214444180|NCT02945904|PROCEDURE|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
214444181|NCT05214820|BIOLOGICAL|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
214444182|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
214444183|NCT06157099|DRUG|Atorvastatin|Given PO
214444184|NCT06157099|DRUG|Placebo Administration|Given orally (PO)
214444185|NCT06157099|PROCEDURE|Computed Tomography|Undergo CT
214444186|NCT06157099|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214444187|NCT06157099|OTHER|Electronic Health Record Review|Ancillary studies
214521557|NCT03119051|BEHAVIORAL|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
214521558|NCT03119051|BEHAVIORAL|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
214521559|NCT02543294|DEVICE|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
214521560|NCT02543294|DEVICE|Electrocardiogram|Electrocardiogram performed at baseline.
214521561|NCT02543294|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
214693400|NCT05104671|OTHER|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
214693401|NCT06930690|DRUG|Dexamethasone Sodium Phosphate Injection|One time dose of dexamethasone sodium phosphate given intravenously at the time of surgery
214444188|NCT04719988|BIOLOGICAL|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
214444189|NCT04719988|PROCEDURE|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
214444190|NCT06744998|DEVICE|Hemopatch® (Baxter)|HEMOPATCH® is an absorbable collagen pad intended for sealing and hemostasis
214444191|NCT05030831|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
214444192|NCT05027763|BEHAVIORAL|high-fiber/low fat|high fiber/low fat preoperative diet
214444193|NCT05027763|BEHAVIORAL|fermented|fermented preoperative diet
214521562|NCT02543294|BEHAVIORAL|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
214693402|NCT04940936|BEHAVIORAL|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
214693403|NCT06930911|BIOLOGICAL|Antibiotic therapy|Evaluating antibiotic exposure in premature infants before 35 weeks in a tertiary care neonatal unit
215028796|NCT01628952|DRUG|Transversus Abdominis Plane|PIA coelioscopic
215028797|NCT01628952|DRUG|Curare|IAP coelioscopic
214521563|NCT03258788|PROCEDURE|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
215028798|NCT00938080|BIOLOGICAL|AG013|Mouth rinse once a day for 14 days
215028799|NCT00938080|BIOLOGICAL|AG013|Mouth rinse three times a day for 14 days
215028800|NCT00938080|BIOLOGICAL|AG013|Mouth rinse six times a day for 14 days
215028801|NCT00938080|OTHER|Placebo|Mouth rinse once a day for 14 days
215028802|NCT00938080|OTHER|Placebo|Mouth rinse three times a day for 14 days
215120711|NCT06141863|OTHER|questionnaire|Neck Disability Index, The Fonseca Anamnestic Index (FAI) and Visual Analogue Scale (VAS)
215120712|NCT02569684|DIETARY_SUPPLEMENT|Prebiotic fibers: oligofructose and inulin|
215120713|NCT02569684|DIETARY_SUPPLEMENT|Maltodextrin|
215120714|NCT03441087|DEVICE|Transvaginal ultrasound|
215120715|NCT03441087|DEVICE|Hysteroscopy|
215120716|NCT02094651|DRUG|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
214444194|NCT06218836|OTHER|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
214444195|NCT06218836|OTHER|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
214521564|NCT00799188|DRUG|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
214521565|NCT05206552|OTHER|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
214521566|NCT03622242|DEVICE|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
214521567|NCT03622242|DEVICE|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
214521568|NCT02181192|DEVICE|PET/CT|PET/CT
215120717|NCT02094651|OTHER|Placebo|The placebo is an inactive substance that looks like the active drug.
215120718|NCT02160652|PROCEDURE|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
215120719|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
215120720|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
214444196|NCT04048850|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
214444197|NCT03377543|DRUG|Aspirin|81mg aspirin pill daily at bedtime over a 25 day period
214444198|NCT03377543|DRUG|Placebo|81mg non-active pill that looks like aspirin
214521569|NCT02181192|RADIATION|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
214521570|NCT02181192|RADIATION|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
214521571|NCT00722514|BEHAVIORAL|patient education|"* complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* Patient education 6 x 90 Minutes"
214521572|NCT00722514|BEHAVIORAL|Standard Care|"* complex individual antiinflammatory rehabilitation program during inpatient~* complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
214521573|NCT01092585|DRUG|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
215120721|NCT05373849|DIETARY_SUPPLEMENT|essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
215120722|NCT05373849|DIETARY_SUPPLEMENT|no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
215120723|NCT03387865|PROCEDURE|tissue biopsies|additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.
215120724|NCT03387865|PROCEDURE|blood sampling|additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)
215120725|NCT03387865|GENETIC|DNA banking|constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation
215120726|NCT03761186|BEHAVIORAL|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
215120727|NCT03761186|BEHAVIORAL|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
215120728|NCT03761186|BEHAVIORAL|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
215120729|NCT05659771|BEHAVIORAL|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
215120730|NCT02862873|PROCEDURE|Spinal anaesthesia|
215120731|NCT02862873|DRUG|Ondansetron|
215120732|NCT02862873|OTHER|saline solution|
215120733|NCT02506634|DRUG|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
215120734|NCT00854880|DRUG|PDC339|
214444199|NCT04791228|DEVICE|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
214444200|NCT04791228|DRUG|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
214444201|NCT05864248|DEVICE|Supira System|The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.
214444202|NCT02294799|OTHER|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization
214444203|NCT02294799|OTHER|Placebo group|Nonspecific Mandibular Movement.
214444204|NCT04830592|BIOLOGICAL|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
214444205|NCT04830592|BIOLOGICAL|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
214444206|NCT05817344|BEHAVIORAL|Written Exposure Therapy - Integrated|A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
214444207|NCT04656158|OTHER|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
214444208|NCT05468008|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
214444209|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
214444210|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
215120735|NCT00854880|DRUG|Placebo|
214444211|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
214444212|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
214444213|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
214444214|NCT04460352|DRUG|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
214444215|NCT04460352|DRUG|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
215120736|NCT00943930|DRUG|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
215120737|NCT03899298|BIOLOGICAL|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
215120738|NCT02518763|DRUG|Vitamin D3, 100 000 IU weekly, 4 times|
215120739|NCT02518763|BIOLOGICAL|25 OH vitamin D serum concentration measurements|
215120740|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
215120741|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
215120742|NCT05267886|DRUG|Dobutamine|Dobutamine administered according to its clinical dose stage for cardiogenic shock
215120743|NCT05267886|DRUG|Milrinone|Milrinone administered according to its clinical dose stage for cardiogenic shock
215120744|NCT05267886|DRUG|Normal Saline|Normal saline running at a standardized rate
214693404|NCT06930547|OTHER|Experimental|"In this study, the experimental group will undergo a smoking cessation training program consisting of eight sessions over four weeks, conducted twice a week. Each session is planned to last approximately 40-45 minutes.~During the program, before each session, the previous session will be reviewed to reinforce learning and establish continuity between sessions. Feedback will be collected to ensure engagement and comprehension. At the end of each session, a summary of the session's agenda will be provided.~Before each session, both the experimental and control groups will be evaluated using a smoking cessation status form to assess their progress. Additionally, follow-up assessments will be conducted one month and three months after the program to test the retention of the training's effectiveness."
214444216|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
214444217|NCT05769478|DRUG|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
214444218|NCT04188665|DRUG|MASL|Patients treated with MASL lozenge
214444219|NCT04188665|OTHER|Placebo|Patients treated with placebo lozenge
214444220|NCT04840199|DRUG|Letermovir Oral Tablet|480 mg administered orally once daily with or without food
214444221|NCT01983241|BIOLOGICAL|Alpha-1 MP|
214444222|NCT01983241|OTHER|0.9% Sodium Chloride for Injection, USP|
214444223|NCT05746871|DEVICE|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
214521574|NCT02403414|DEVICE|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
214521575|NCT01133600|DRUG|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
214521576|NCT01133600|DRUG|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
215120745|NCT04892082|BEHAVIORAL|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
215120746|NCT04892082|OTHER|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
215120747|NCT00776971|OTHER|Sugar-sweetened soft drink|500mL as a preload drink
215120748|NCT00776971|OTHER|Aspartame-sweetened soft drink|500mL as a preload drink
215120749|NCT00776971|OTHER|Semi-skimmed milk|500mL as a preload drink
215120750|NCT00776971|OTHER|Water|500mL as a preload drink
214444224|NCT05746871|OTHER|standard care|Subjects will continue with their standard care for 5 weeks
214444225|NCT05418972|DRUG|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
214444226|NCT06443645|DRUG|Anthracycline|as standard of care
214444227|NCT05747651|BIOLOGICAL|Blood sample|Total volume of blood (on each sampling occasion): 54,5mL.
214444228|NCT05747651|BIOLOGICAL|Urine sample|Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.
214444229|NCT05747651|BIOLOGICAL|Saliva sample|Saliva: will be collected in special container for saliva microbiome and methylation.
214444230|NCT05747651|BIOLOGICAL|Stool sample|Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.
214444231|NCT05747651|BIOLOGICAL|Tissue sample|"Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
214521577|NCT01686256|DRUG|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
214521578|NCT01648075|DIETARY_SUPPLEMENT|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
214521579|NCT04231175|DIAGNOSTIC_TEST|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
214521580|NCT03205345|DRUG|Emricasan (25 mg)|25 mg emricasan
214693405|NCT06929637|DRUG|Infusion Therapy|Infusion of amino acids once daily - dose 1g/kg, maximum 100 g daily for 3 consecutive days starting D1 after kidney transplantation procedure
214444232|NCT06377761|DRUG|Qishen Granules|One package per time, twice a day, 90 days of treatment
214444233|NCT06377761|DRUG|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
214693406|NCT06929637|DRUG|Saline solution infusion|Infusion of saline solution a s standard rehydration therapy after kidney transplantation
214521581|NCT03205345|DRUG|Emricasan (5 mg)|5 mg emricasan
214521582|NCT03205345|DRUG|Placebo|Matching Placebo
214521583|NCT05744505|PROCEDURE|1565nm Non-ablative Fractional Laser|Every 3 weeks
214521584|NCT05744505|PROCEDURE|placebo|Every 3 weeks
214521585|NCT04403815|PROCEDURE|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
214521586|NCT03015415|PROCEDURE|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
214521587|NCT03015415|PROCEDURE|Non-surgical intervention|Rehabilitation with splinting protocols
214693407|NCT06929793|DIETARY_SUPPLEMENT|Multiple Micronutrients|"1. Multiple micronutrient~2. Calcium Carbonat 766 mg~3. Vitamin D3 5000 IU~4. DHA 300 mg"
214693408|NCT06929793|DRUG|Standard Antenatal Vitamin|Standard Antenatal Vitamin given in Community Health Centers
214521588|NCT00647452|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
214521589|NCT03672188|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214693409|NCT06930378|PROCEDURE|Nerve Suture|"Sensory nerve coaptations will be performed~1. either by suturing the donor to the recipient nerve immediately (1 coaptation)~2. or by interposing an autograft originating from the zone of the flap to be discarded (2 coaptations). The anterior cutaneous branch (ACB) of the 3rd or 4th intercostal nerve (ICN) will be connected to the sensory branch of the 10th, 11th or 12th ICN of the flap."
214693410|NCT06929078|OTHER|Protective lung ventilation methods with different positive end-expiratory pressure during Laparoscopic Surgeries|Protective lung ventilation methods with positive end-expiratory pressure help in prevention of atelectasis and improvement of intraoperative ventilator parameters e.g low driving pressure and improved dynamic compliance resulting in better oxygenation of lungs ere will be three groups in this study. Individualized positive end-expiratory pressure with recruitment maneuver and fixed positive end-expiratory pressure will be interventional groups. They will be compared with conventional ventilation group in which no additional positive end-expiratory pressure will be applied. The effects on respiratory parameters and oxygenation of patients will be compared for each group. This study will determine which method of positive end-expiratory pressure is superior and how it differs from conventional ventilation for prevention of atelectasis induced by pneumoperitonium and improvement of respiratory mechanical parameters and oxygenation in Mechanical ventilation during laparoscopic surgeries.
215028803|NCT00938080|OTHER|Placebo|Mouth rinse six times a day for 14 days
215028804|NCT02306252|OTHER|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
215028805|NCT04363892|OTHER|Optical and infrared imaging|Acquiring images (photographs) of the skin
215028806|NCT03697447|PROCEDURE|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
214444237|NCT04432454|DRUG|Lasofoxifene and abemaciclib (VERZENIO (R)).|Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
214444238|NCT06217718|OTHER|Telenursing Interventions|Patient follow-up with phone calls and text messages
214444239|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
214444240|NCT06174285|OTHER|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
214444241|NCT06174285|OTHER|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
214444242|NCT04309565|BEHAVIORAL|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
214521590|NCT03672188|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
214521591|NCT05159037|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
214521592|NCT05159037|BEHAVIORAL|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
214521593|NCT03676400|OTHER|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
214521594|NCT03676400|OTHER|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
214521595|NCT04595110|OTHER|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
215028807|NCT04956016|DEVICE|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
215028808|NCT04956016|DEVICE|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
215028809|NCT06564935|DRUG|Heptaminol Hydrochloride|heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
214444243|NCT04309565|BEHAVIORAL|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
214444244|NCT06393400|DRUG|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant"
214444245|NCT06393400|DRUG|PEG3350|"Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX"
214521596|NCT00984334|DRUG|Naloxone SR 5 mg capsules|
214521597|NCT00984334|DRUG|Placebo|
214521598|NCT00984334|DRUG|Naloxone SR 10 mg capsules|
214521599|NCT00984334|DRUG|Naloxone SR 20mg capsules|
214521600|NCT00984334|DRUG|Naloxone SR 2.5 mg capsules|
214521601|NCT02655536|DRUG|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
214521602|NCT02655536|DRUG|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
214521603|NCT00396409|DRUG|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
214521604|NCT00396409|DRUG|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
214521605|NCT00396409|DRUG|Placebo|Placebo given during the 2006 core study
214521606|NCT04006652|DRUG|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
214521607|NCT01730261|BEHAVIORAL|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
214521608|NCT00001079|DRUG|Testosterone enanthate|
214521609|NCT00001079|DRUG|Megestrol acetate|
214521610|NCT00071929|DRUG|oxaliplatin|
215120751|NCT04385186|DRUG|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
215120752|NCT04385186|DRUG|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
215120753|NCT00063778|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
215120754|NCT00063778|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
215120755|NCT01952886|DRUG|Granisetron|
215120756|NCT01952886|DRUG|Ondansetron|
215120757|NCT02132819|OTHER|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
214444246|NCT06393400|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Gemzar"
214444247|NCT06393400|DRUG|nab-Paclitaxel|"nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Abraxane"
214444248|NCT06151080|DRUG|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
214444249|NCT05274425|OTHER|Enerzair 150/50/80 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
214444250|NCT05274425|OTHER|Enerzair 150/50/160 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
214444251|NCT06776913|DEVICE|Colonoscopy|Standard Colonoscopy with photo documentation and the recording of procedure timing.
214521611|NCT04564222|DIETARY_SUPPLEMENT|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
214521612|NCT04564222|DIETARY_SUPPLEMENT|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
214521613|NCT01763502|OTHER|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
214444252|NCT06026527|DRUG|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
214444253|NCT06026527|DRUG|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
214444254|NCT06755190|DIAGNOSTIC_TEST|Diagnostic Test: AI-Based Diagnostic and Prognostic Model for Ocular Diseases|This intervention involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. It integrates multi-modal data, including fundus photography, optical coherence tomography (OCT), and patient clinical records, to provide real-time, precise, and personalized diagnostic support. Unlike other models, this system utilizes a longitudinal patient dataset to predict disease progression and treatment outcomes.Key distinguishing features include: 1. Multi-Modal Data Integration: Combines imaging, clinical, and genetic data for comprehensive analysis. 2. Predictive Capability: Offers advanced prognostic predictions, enabling personalized treatment plans. 3. Deep Learning Framework: Employs state-of-the-art deep learning algorithms for improved diagnostic accuracy and efficiency. 4. Real-World Validation: Validated using a large cohort of diverse patient data, ensuring generalizability and robustness.
214444255|NCT05827523|DRUG|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
214444256|NCT05736744|DRUG|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
214444257|NCT05736744|DRUG|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
214444258|NCT05550207|DRUG|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
214444259|NCT06510491|DRUG|Epcoritamab|Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
214444260|NCT05857553|OTHER|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
214444261|NCT05857553|OTHER|No Direct Cash Transfer|No intervention
214444262|NCT06038656|DIETARY_SUPPLEMENT|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
214521614|NCT01763502|OTHER|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
214521615|NCT00244426|DRUG|indobufen|Indobufen capsules 100 and 200mg
214521616|NCT00244426|DRUG|aspirin|Acetylsalicylic acid capsules 300mg
214521617|NCT06436612|RADIATION|Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy|stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
215120758|NCT02132819|OTHER|feeding during transfusion|The feeding process will be continued during the transfusion
215120759|NCT05940701|COMBINATION_PRODUCT|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
215120760|NCT05940701|OTHER|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
214444263|NCT00753090|DEVICE|Vanguard™ Deep Dish Rotating Platform Knee|Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee
214444264|NCT00753090|DEVICE|Vanguard™ Cruciate Retaining Knee|Total knee replacements with the Vanguard Cruciate Retaining Knee
214521618|NCT00079235|DRUG|temsirolimus|Given IV
214521619|NCT00079235|OTHER|laboratory biomarker analysis|Correlative studies
214521620|NCT01309802|DRUG|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
214521621|NCT05599230|DRUG|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
215120761|NCT06087484|BEHAVIORAL|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
215120762|NCT00762047|DEVICE|Durasphere FI|Durasphere Injection
215120763|NCT00762047|DEVICE|Sham|Sham injection with anesthesia
215120764|NCT04321070|DRUG|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
215120765|NCT04321070|DRUG|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
215120766|NCT04321070|DRUG|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
215120767|NCT05065788|OTHER|data collection|data collection
215120768|NCT04706481|PROCEDURE|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
215120769|NCT02745834|OTHER|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
214444265|NCT03747042|DRUG|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
214444266|NCT06776601|BEHAVIORAL|Full process digital therapy intervention package|Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
214444267|NCT06244641|OTHER|Auto-questionnaires, hetero-questionnaires and Evoked-potentials|Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
214444268|NCT06777394|OTHER|High intensity interval training|"The HIIT program begins with a warm-up, followed by high-intensity repetitions separated by moderate-intensity recovery intervals. High-intensity exercises are performed near maximum effort, while moderate-intensity periods are maintained at 50% effort. HIIT exercises, involving low-skill movements in short bursts, enhance blood sugar regulation and fat-burning capacity.~The HIIT protocol has four phases:~Warm-Up: 10 minutes, gradually increasing to about 60% of maximum heart rate. Intervals: 4 minutes at 85-95% maximum heart rate. Relief/Recovery: 3 minutes at 60% maximum heart rate, repeated four times. Cool Down: 5 minutes, bringing the heart rate down to around 50% of maximum. Three key components determine the success of HIIT: intensity, duration, and recovery period. Exercises include dumbbell and kettlebell exercises, push-ups, squats, jump training, and stationary cycling"
214444269|NCT06777394|OTHER|Routine treatmet|"outine physical therapy includes stretching exercises, exercises to maintain a normal range of motion, and low-intensity and aerobic exercises for the patients.~Low-Intensity Exercise: The effects of low-intensity exercise become noticeable after about 20 minutes, providing a metabolic boost during the activity. Generally, a longer exercise duration further enhances metabolism."
214444270|NCT06776120|DIAGNOSTIC_TEST|Fecal chemical test (FIT)|Eligible participants will be instructed to collect their two stool samples within seven days prior to undergoing bowel preparation. These stool samples will be then submitted for a quantitative FIT (OC-SENSOR, EIKEN CHEMICAL, Japan). Colonoscopic observations and histopathological findings will be employed as the definitive reference standards for diagnosis.
214444271|NCT03654573|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
214444272|NCT05038345|PROCEDURE|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
214444273|NCT04623424|DIAGNOSTIC_TEST|intestinal microbiota|Stoll samples will be tested for different bacteria
214444274|NCT02201108|DRUG|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
214444275|NCT02201108|DRUG|Placebo|Pharmaceutical form:tablet, Route of administration: oral
214444276|NCT04843865|DIETARY_SUPPLEMENT|Chinese Herbs|Chinese Herbs
214521622|NCT05179096|BEHAVIORAL|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
214521623|NCT02161393|BEHAVIORAL|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
214521624|NCT02161393|BEHAVIORAL|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
215120770|NCT06189924|DIAGNOSTIC_TEST|Proteomic analysis of exhaled breath condensate|Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.
215120771|NCT04712370|PROCEDURE|Conventional caudal block|Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
215120772|NCT04712370|PROCEDURE|Ultrasound-guided caudal block|Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
214444277|NCT05193227|DRUG|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
214444278|NCT05193227|DRUG|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
214444279|NCT04110977|DEVICE|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
214444280|NCT04871490|DIAGNOSTIC_TEST|Blood test for HPV DNA|All participants will have blood tested for HPV DNA.
214521625|NCT02873442|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
214693411|NCT06929611|OTHER|Combined continous caudal epidural with general anaesthesia|"A 17- or 18-gauge Tuohy-type needle will be inserted in the midline into the caudal canal. An initial dose of 20 ml of 0.25% bupivacaine will be injected in the caudal canal in order to perform sensory block and spare motor power. Then a dose of 10 ml 0.25% bupivacaine will be injected through the epidural catheter every 1-hour intra operatively and at 0-hour and 1-hour post operative then the catheter will be removed 1 hour post operative.~-The following factors will be assessed:~1. Intra operative heart rate and blood pressure.~2. Post operative pain assessment according to numeric pain scale score.~3. Time to rescue analgesia (intravenous analgesia administered after surgery).Patients with numeric pain scale score ≥ 3 at any point of time, will receive intravenous morphine 5mg.~4. Estimated blood loss and surgeon satisfaction of surgical field.~5. Total intra operative and post operative analgesia.~6. Common complications."
214521626|NCT02873442|BIOLOGICAL|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~\+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
214521627|NCT01690871|DRUG|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
214693412|NCT06930807|OTHER|Adaptive postoperative management based on minimal residual disease|participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.
214693413|NCT06930859|DRUG|Ribociclib|CDK4/6 inhibitor
214693414|NCT06930859|DRUG|Letrozole|Aromatase inhibitor
215120773|NCT04712370|PROCEDURE|Ultrasound guided erector spinae plane Block|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
215120774|NCT00546546|DRUG|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
215120775|NCT04751318|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
215120776|NCT04751318|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
214444281|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
214444282|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 1 and 15
214444283|NCT03535727|DRUG|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
214444284|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 1 and 15
214444285|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 1 and 15
214444286|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
214444287|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 4 and 11
214444288|NCT03535727|DRUG|Capecitabine|PO BID; Days 1- 14
214444289|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 4 and 11
214521628|NCT04203199|DEVICE|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
214521629|NCT04203199|DEVICE|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
215120777|NCT00679835|DRUG|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
215120778|NCT06357039|DEVICE|Sleep tracking device|In addition to polysomnography, a device containing EEG+PPG sensors for sleep classification was placed on the forehead, and another device containing PPG and accelerometer sensors was placed on the wrist. The wrist to which the device is attached is randomly assigned.
215120779|NCT04924595|BEHAVIORAL|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
215120780|NCT00991653|PROCEDURE|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
215120781|NCT06310616|DRUG|VH4524184|VH4524184 will be administered.
215120782|NCT06310616|DRUG|Loestrin|Loestrin will be administered.
215120783|NCT00213499|PROCEDURE|non invasive ventilation|
215120784|NCT05112562|BEHAVIORAL|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
214444290|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 4 and 11
214444291|NCT05046444|DIAGNOSTIC_TEST|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
214444292|NCT06781320|DEVICE|stabilization splint|"the patients will receive a stabilization splint fabricated using a fully digital workflow includes:~Intraoral scanning of maxillary and mandibular arches to create a digital model.~Jaw tracking using the Zebris JMA system to record mandibular movements. CAD design of the splint using Exocad software. Fabrication of the splint via 3D printing technology. The FD-SS is designed to provide optimal occlusal stabilization, reduce TMJ stress, and minimize enamel wear over 6 months.~Or the patient will receive stabilization splint fabricated using conventional methods. The intervention includes:~Taking alginate impressions of maxillary and mandibular arches to create plaster casts.~Jaw registration using a Lucia jig and semi-adjustable articulator for proper occlusal adjustment.~Manual fabrication of the splint using polymethyl methacrylate (PMMA) resin. The C-SS is designed to achieve occlusal stabilization and symptom relief for TMD patients over 6 months."
214444293|NCT04031677|PROCEDURE|Surgery|Large en-bloc curative-intent surgery
214444294|NCT04031677|DRUG|Preoperative chemotherapy|"* High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same."
214521630|NCT06090253|BEHAVIORAL|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
214521631|NCT06090253|BEHAVIORAL|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
214521632|NCT06090253|BEHAVIORAL|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
214521633|NCT06090253|BEHAVIORAL|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
214521634|NCT06090253|BEHAVIORAL|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
214693415|NCT06930859|DRUG|Anastrozole|Aromatase inhibitor
214693416|NCT05366413|OTHER|Early Referral|Directing a patient for a pain specialist consult earlier than standardly occurs.
214693417|NCT05366413|OTHER|Pain Management Strategies|Specialized plan with procedures to ease pain
214693418|NCT05511753|DEVICE|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
214693419|NCT06940388|DRUG|Tislelizumab|During ChemoImmunotherapy: Patients in the investigational arm will receive 8 cycles of tislelizumab 150 mg IV on Day 1, followed by mFOLFOX6 (Q2W).
214693420|NCT06940388|DRUG|Total neoadjuvant therapy (TNT)|Patients will be treated with 6 weeks of capecitabine-based CRT followed 4 weeks later by 16 weeks of chemotherapy with mFOLFOX6, Q2W.
214693421|NCT06939140|PROCEDURE|Bipolar prostatectomy|Endoscopic transurethral bipolar enucleation or reaction of the prostate
214693422|NCT06939062|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Endoscopic transurethral enucleation of the prostate using bipolar energy
215120785|NCT05112562|BEHAVIORAL|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
215120786|NCT00306085|GENETIC|Autologous bone marrow cells|
215120787|NCT00306553|BIOLOGICAL|CYT004-MelQbG10|
215120788|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
215120789|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
215120790|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
215120791|NCT06454383|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215120792|NCT06454383|DRUG|Cholestyramine|Given PO
215120793|NCT06454383|PROCEDURE|Computed Tomography|Undergo CT
215120794|NCT06454383|PROCEDURE|Diagnostic Imaging|Undergo imaging scans
215120795|NCT06454383|DRUG|Gemcitabine|Given IV
215120796|NCT06454383|DRUG|Leflunomide|Given PO
215120797|NCT06454383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215120798|NCT02053090|BEHAVIORAL|Group Education and Stretching|
215120799|NCT02053090|PROCEDURE|Group Acupuncture|
215120800|NCT06823908|OTHER|Reuse of surgical waste|Heathly donnors will be received in the plastic surgery department as part of routine care. They will be informed of the study and their surgical waste (adipose tissue) will be recovered specifically for this research.
215120801|NCT06823908|OTHER|Reuse of biological samples|Patients included in the cellcordes 2 trial who have given their consent for the re-use of their biological samples (Stromal Vascular Fraction) in other clinical research projects, and who have been informed of the cellcordes bio study.
214521635|NCT02035488|DRUG|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
214521636|NCT03964545|BEHAVIORAL|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
214521637|NCT00317317|PROCEDURE|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
215120802|NCT06122506|PROCEDURE|Laparoscopic cerclage|Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
215120803|NCT06122506|PROCEDURE|Vaginal cerclage|Transvaginal cerclage in pregnant women.
215120804|NCT06281925|DEVICE|Cryotherapy Gloves|All patients in the intervention group will receive cryotherapy with cold packs enclosed in a fabric envelope (gloves). The fabric envelope (gloves) will be patient specific.
214521638|NCT01810406|PROCEDURE|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
215028810|NCT06564935|DRUG|Placebo|Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
215120805|NCT02784171|DRUG|Cisplatin|
215120806|NCT02784171|DRUG|Pemetrexed|
215120807|NCT02784171|DRUG|Pembrolizumab|
215120808|NCT06362824|BEHAVIORAL|De Pie Intervention|Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.
215120809|NCT06362824|OTHER|Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)|Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
215120810|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
215120811|NCT03842033|BEHAVIORAL|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
215120812|NCT03842033|BEHAVIORAL|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
215120813|NCT03842033|BEHAVIORAL|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
215120814|NCT04290897|DRUG|Anhydrous Enol-oxaloacetate|Given PO
215120815|NCT04290897|OTHER|Questionnaire Administration|Ancillary studies
215120816|NCT06431633|DRUG|Zimberelimab|"Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells.~Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL.~No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle."
215120817|NCT06431633|DRUG|Sacituzumab govitecan|"Sacituzumab govitecan (SG) is an ADC composed of the following 3 components:~o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers.~o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38.~Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer."
215120818|NCT06431633|DRUG|Cisplatin|"Cisplatin-based adjuvant chemotherapy~Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation."
215120819|NCT06431633|DRUG|Carboplatin|Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02
215120820|NCT00539162|BEHAVIORAL|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
215120821|NCT06308666|DEVICE|Delefilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
215120822|NCT01748097|DRUG|sodium bicarbonate 4.2%|
214521639|NCT01810406|PROCEDURE|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
214521640|NCT02367339|OTHER|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
214521641|NCT03320941|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
214521642|NCT03320941|DRUG|Placebo|Placebo will be supplied as tablets to be taken daily orally.
214521643|NCT03174470|DEVICE|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
215028811|NCT03191331|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
214444295|NCT06764784|PROCEDURE|Freehand Implant Surgery|This intervention involves implant placement performed manually by the surgeon without the use of specialized guides. The procedure relies on the surgeon's clinical judgment and experience to determine the implant's positioning, angulation, and depth.
214444296|NCT06764784|PROCEDURE|Pilot-Drilled Implant Surgery|This intervention utilizes a pilot drill to create an initial guide hole for the implant. The pilot-drilled pathway improves accuracy while still allowing the surgeon flexibility during the procedure. The final implant is placed following sequential drilling.
214444297|NCT06764784|PROCEDURE|Fully Guided Implant Surgery|This intervention employs computer-aided surgical templates created from preoperative imaging data, such as CBCT scans. These guides ensure precise implant positioning, angulation, and depth based on preoperative planning. The approach minimizes variability and enhances accuracy.
214444298|NCT06781086|DRUG|Nimotuzumab|Patients will receive 3 cycles of neoadjuvant treatment with Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
214444299|NCT06781086|DRUG|AG regimen|Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
214693423|NCT06939062|PROCEDURE|Bipolar transurethral resection of the prostate (B-TURP)|Endoscopic transurethral resection of the prostate using bipolar energy
215120823|NCT06624163|BEHAVIORAL|OHWL Clinic Activities (Standard of Care)|Following a directed history and physical at the initial visit, the OHWL Care provider (OCP) develops a medical and weight management plan, which includes laboratory testing (such as for Hemoglobin A1C (HbA1c), consultant referrals (e.g. sleep, heart failure clinics) and referral to nutritionists and physical therapy (PT). The OCP begins the process of establishing patient goals, which will be followed up by the coach. The OCP reviews patient progress with the goals during face-to-face visits (some by telehealth) at two, four and six months. As part of the standard initial clinic evaluation, a medical assistant evaluates grip strength (using a hand dynamometer) the timed up and go mobility test; these are repeated at the 6-month visit.
214444300|NCT06781086|DRUG|Placebo|Patients will receive 3 cycles of neoadjuvant treatment with placebo (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant therapy (placebo 400 mg on days 1, 8, and 15 of a 21-day cycle).
214444301|NCT03902223|DIAGNOSTIC_TEST|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
214444302|NCT03902223|DIAGNOSTIC_TEST|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
214444303|NCT06780436|DEVICE|3D Transcranial Ultrasound Brain Imaging|The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.
214521644|NCT00987155|DEVICE|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
214521645|NCT05829278|PROCEDURE|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
214521646|NCT03800745|DRUG|Colace 100Mg Capsule|Prescribed to Arm B
214521647|NCT03800745|DRUG|Miralax|Prescribed to Arm C
214521648|NCT01489163|BEHAVIORAL|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
214521649|NCT03881267|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
214521650|NCT03881267|OTHER|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
214521651|NCT03881267|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
214521652|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
214521653|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
214521654|NCT03083600|DIETARY_SUPPLEMENT|Placebo|Cellulose Placebo for 12-weeks
214521655|NCT06113822|DEVICE|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
214521656|NCT03967093|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
214521657|NCT00274976|BIOLOGICAL|alemtuzumab|
214521658|NCT01440699|BIOLOGICAL|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
214444304|NCT06781918|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|"DHA \&amp; Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.~Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17."
214444305|NCT06781918|BEHAVIORAL|Psychosocial stimulation|"The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.~During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.~Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation."
214444306|NCT03571945|DEVICE|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
214444307|NCT03571945|DEVICE|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
214444308|NCT06781346|PROCEDURE|Rhomboid Intercostal Block|In RI block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the medial border of the scapula between the 4th and 5th rib of the patients in the RIB group. In the ultrasound image, the trapezius muscle, rhomboid muscle, intercostal muscles,pleura, and lung were identified. Under the aseptic condition, inserted laterally in the plane of the T5 level guided by an ultrasound probe with an in plane technique. The intravascular injection should be confirmed negative through aspiration, and 1-3 ml of normal saline was injected to divide the rhomboid and intercostal muscle, and a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected After negative aspiration of blood or air, injected into the deep layer of the rhomboid muscle.
214444309|NCT06781346|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards.
214444310|NCT06022029|DRUG|ONM-501|Intratumoral injection
214693424|NCT06937775|OTHER|Periodontal measurements (plaque index, gingival index and probing pocket depth scores )|Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.
214693425|NCT06937775|OTHER|Biochemical Sample Supply (Collection of serum and saliva samples)|"Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses.~For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day.~Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes."
214693426|NCT06937775|PROCEDURE|Rapid maxillary expansion with Hyrax appliance|Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.
214693427|NCT04321694|DRUG|KHK2455|
215120824|NCT06624163|BEHAVIORAL|Coach Activities|A patient coach follows patients outside of clinic to ensure adherence with referral appointments and use of recommended community services. The coach assesses the participant at baseline, 3 months, and 6 months using the Patient-Specific Functional Scale and follows up with patients via phone over 6 months. The coach utilizes S.M.A.R.T. (Specific, Measurable, Achievable, Relevant, Time-bound) goals to facilitate, for example, transportation, barriers to scheduling, etc. The coach follows up on specialist referral recommendations, physical therapy, and nutrition program, as well as social work recommendations. Barriers and facilitators to program adherence are identified and addressed.
214693428|NCT06951672|DEVICE|This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.|The ability to deploy the annuloplasty ring in a percutaneous fashion affords an improved safety profile for surgical candidates, as well as surgical style solution for those patients that are at elevated risk for surgery due to comorbidities and advanced age. This early feasibility study allows treatment of higher risk surgical candidates with a surgical- level annuloplasty repair therapy by the AMEND™ Implant.
215120825|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in DDP
215120826|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in HT
215120827|NCT03546972|OTHER|Questionnaire Administration|Ancillary studies
214444311|NCT06022029|DRUG|Cemiplimab|Intravenous administration of 350 mg
214444312|NCT06780020|OTHER|Effects of different interventions using boxing|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component BOX and a 10-minute cool-down with static flexibility exercises.
214444313|NCT06780020|OTHER|Effects of different interventions using taekwondo|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component TKD and a 10-minute cool-down with static flexibility exercises.
214444314|NCT06780020|OTHER|Effects of different interventions using Elastic Band|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component Elastic Band and a 10-minute cool-down with static flexibility exercises.
214444315|NCT04835831|OTHER|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
214444316|NCT06780410|DRUG|Bempedoic Acid Tablet|Once daily, oral
214444317|NCT06780410|DRUG|Placebo|Once daily, oral
214444318|NCT05937776|OTHER|Fludeoxyglucose F-18|Given IV
214444319|NCT05937776|OTHER|Gadoterate Meglumine|Given IV
214444320|NCT05937776|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
214444321|NCT05937776|PROCEDURE|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
214444322|NCT06157216|DRUG|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
214444323|NCT06268041|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
215120828|NCT04965688|DRUG|Biopsy-Guided Therapy Selection|"All enrolled participants will undergo a tumor biopsy, which will be analyzed for genomic and transcriptomic alterations using FoundationOne (DNA) and Fulgent (RNA). Based on the genomic findings, participants will receive one of the following therapy standard-of-care treatment options:~PI3K inhibitor + anti-estrogen therapy ( alpelisib + fulvestrant)~MTOR inhibitor + anti-estrogen therapy (everolimus + exemestane)~Anti-estrogen therapy alone (fulvestrant monotherapy)~Cytotoxic chemotherapy (capecitabine)"
215120829|NCT05864586|BEHAVIORAL|Vaping study EC A|Vaping two puffs using the study EC device
215120830|NCT05864586|BEHAVIORAL|Vaping study EC B|Vaping two puffs using the study EC device
215120831|NCT05864586|BEHAVIORAL|Vaping study EC C|Vaping two puffs using the study EC device
215120832|NCT05864586|BEHAVIORAL|Vaping study EC D|Vaping two puffs using the study EC device
215120833|NCT05864586|BEHAVIORAL|Vaping study EC E|Vaping two puffs using the study EC device
215120834|NCT05864586|BEHAVIORAL|Vaping study EC F|Vaping two puffs using the study EC device
214444324|NCT06268041|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
214444325|NCT03055377|DRUG|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
214444326|NCT03055377|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
214444327|NCT06763666|DRUG|Cladribine|Given IV
214444328|NCT06763666|DRUG|Cytarabine|Given IV
214444329|NCT06763666|DRUG|G-CSF|Given SC
214444330|NCT06763666|DRUG|Venetoclax|Given PO
214444331|NCT06764836|DRUG|IMM27M|Intravenous injection
214444332|NCT06764836|DRUG|IMM2510|Intravenous injection
214444333|NCT06078696|DRUG|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
214444334|NCT06078696|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
214444335|NCT06078696|PROCEDURE|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
214444336|NCT06078696|PROCEDURE|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
214444337|NCT06078696|DRUG|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).
214444338|NCT06078696|DRUG|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
215120835|NCT05864586|BEHAVIORAL|Vaping study EC G|Vaping two puffs using the study EC device
215120836|NCT05864586|BEHAVIORAL|Vaping study EC H|Vaping two puffs using the study EC device
215120837|NCT05864586|BEHAVIORAL|Vaping study EC I|Vaping two puffs using the study EC device
214693429|NCT06954025|DRUG|High-intensity inpatient MDMA-assisted psychotherapy|"Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg~Psychotherapy: manualized psychotherapy"
214693430|NCT05170659|DRUG|Relatlimab|
214693431|NCT02503176|DRUG|KCT-0809 ophthalmic solution|
214693432|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
214693433|NCT03744546|DRUG|ABBV-8E12|Solution for infusion
214693434|NCT07082452|DRUG|Venetoclax|Venetoclax 400 mg orally once Daily
215120838|NCT05864586|BEHAVIORAL|Vaping study EC J|Vaping two puffs using the study EC device
215120839|NCT06848348|DRUG|Halneuron|Halneuron for Subcutaneous Injection
215120840|NCT06848348|DRUG|Placebo|Placebo for Subcutaneous Injection
215120841|NCT05044962|DRUG|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
215120842|NCT05044962|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
215120843|NCT05044962|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
215120844|NCT05044962|DRUG|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
215120845|NCT05044962|DRUG|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
214693435|NCT07082452|DRUG|Azacitidine|75 mg/m2 Subcutaneous (SC) or intravenous (IV) Daily with a continuous 7-day scheme or on a 5-on/2-off \[weekend\]/2-on schedule (5-0-2) in 28-day cycle
214693436|NCT07082400|PROCEDURE|right heart catheter|measurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction
215120846|NCT03151733|PROCEDURE|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
215120847|NCT03151733|PROCEDURE|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
215120848|NCT06156735|OTHER|Passive Music Therapy (P)|Music Therapy Intervention
215120849|NCT06156735|OTHER|Active Music Therapy (A)|Music Therapy Intervention
215120850|NCT06156735|OTHER|Standard Care Control Condition (C)|Without any intervention
214693437|NCT07082634|PROCEDURE|Socket shield concept and immediate implant placement|"Tooth Sectioning: The tooth will be sectioned mesiodistally using a fissure bur, preserving the buccal segment.~Palatal fragment extraction: carefully after sectioning the tooth , the palatal fragment is luxated and extracted with the most important factor is taking care of the buccal part not to become loose , the extraction is done using a periotome to be minimally invasive and to preserve the bone from major damage.~Shield Preparation: The buccal fragment is reduced to bone level using a round bur, a beveled edge is created using a diamond football bur, and the shield is thinned to maintain structural integrity.~Implant Site Preparation: Sequential osteotomy performed under copious irrigation, ensuring primary stability.~Implant Placement: A Megagen implant is inserted"
214444339|NCT06078696|DRUG|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
214444340|NCT06078696|DRUG|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
214521659|NCT04260100|BEHAVIORAL|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
214693438|NCT06085924|DRUG|SoC|COVID-19 treatment as per government guidance
214693439|NCT06085924|OTHER|Disease description|No intervention
214693440|NCT03906344|DRUG|INCB052793|
214693441|NCT03675737|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
214693442|NCT03675737|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
214693443|NCT03675737|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
214693444|NCT03675737|DRUG|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
214693445|NCT03675737|DRUG|capecitabine|Administered orally BID on Days 1 to 14 Q3W
214693446|NCT03675737|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
214693447|NCT05841680|BEHAVIORAL|SSI Module|Single Session Intervention (SSI) module for youth with anxiety disorders and their parents. The SSI module will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI module will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts.
214693448|NCT06337812|DIETARY_SUPPLEMENT|Potato Starch|"Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study."
215120851|NCT00466531|BIOLOGICAL|therapeutic autologous lymphocytes|
214693449|NCT05487417|DRUG|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
214693450|NCT04252612|DRUG|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
214693451|NCT04141852|DEVICE|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
215120852|NCT00466531|DRUG|cyclophosphamide|
215120853|NCT05721170|DRUG|Beta blocker|Investigation on beta-blockers in TAVI and brief post-TAVI period.
215120854|NCT05628103|DRUG|SEP-363856|SEP-363856 will be flexibly dosed for 8 weeks.
215120855|NCT05769023|BEHAVIORAL|Intervention test|behavioral sessions to promote vaccines
215120856|NCT05003674|DEVICE|Focused stimulation strategy|Investigational focused stimulation strategy
215120857|NCT05003674|DEVICE|ACE stimulation strategy|Standard of care stimulation strategy
215120858|NCT02313584|DRUG|dabigatran|
215120859|NCT02313584|DRUG|placebo|
215120860|NCT01458483|DEVICE|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
215120861|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
214693452|NCT05483621|DRUG|Beta-hCG|Treatment of spermatogenesis
214693453|NCT00128700|DRUG|temozolomide|
215120862|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
214693454|NCT00128700|DRUG|vatalanib|
215120863|NCT04000061|OTHER|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
214444341|NCT06763003|OTHER|Music Therapy|The music therapy session described follows a structured and engaging approach, aimed at enhancing the patient's cognitive skills during neurorehabilitation. Here's a summary of the session components: Relaxation Phase, Song Selection, Instrument Selection and Familiarization, Rhythmic Training, Progression and Adjustment, Session Frequency and Customization. This individualized approach aims to enhance patient engagement and recovery by integrating music, rhythm, and therapeutic interaction into the neurorehabilitation process.
214444342|NCT06763003|OTHER|Standard Care (in control arm)|In the control group, participants will receive the standard neurorehabilitation program prescribed by the rehabilitation team, without the addition of music therapy. This will provide a baseline to compare outcomes with the intervention group and evaluate the feasibility and preliminary effects of the music therapy intervention. The usual cognitive rehabilitation program during the subacute stroke period focuses on restoring cognitive abilities such as attention, memory, executive functions, and communication. The control group's daily rehabilitation sessions will last for 45 minutes, mirroring the music therapy group's session duration, ensuring a fair comparison of outcomes across both groups. This comparison will help assess the unique contributions of music therapy on cognitive functions like attention, memory, and executive functions in stroke patients.
214521660|NCT00357747|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
214521661|NCT00357747|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
214521662|NCT05865782|BEHAVIORAL|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
214521663|NCT02589678|BIOLOGICAL|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
214521664|NCT02589678|BIOLOGICAL|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
214521665|NCT04695249|BEHAVIORAL|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
214693455|NCT00128700|PROCEDURE|adjuvant therapy|
214693456|NCT00128700|RADIATION|radiation therapy|
215028812|NCT00837135|OTHER|Screening|"A. SCREENING~1. Consent~2. Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~3. Physical Exam, History, Blood Tests~4. Skin Test (for allergy to saccaromyces cerevisiae) yeast.~5. Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~1. Consent~2. Chemotherapy~3. GI-4000 Vaccine #1 + Prevnar + Activated T Cells~4. GI-4000 Vaccine #2~5. Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
214521666|NCT00391521|DRUG|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
214693457|NCT04538092|OTHER|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
215028813|NCT00837135|BIOLOGICAL|GI-4000 Vaccine|"1. Chemotherapy and Radiation~2. GI-4000 Vaccine #3~3. GI-4000 Vaccine #4"
215028814|NCT00837135|BIOLOGICAL|GI-4000 Vaccine + Activated T Cells|"1. Apheresis #2~2. Chemoradiation~3. Activated T Cells + GI-4000 Vaccine #3~4. GI-4000 Vaccine #4"
215028815|NCT00837135|BIOLOGICAL|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
215028816|NCT02226653|DRUG|Evacetrapib|Administered orally
215120864|NCT04000061|OTHER|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
215120865|NCT04485416|DRUG|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
215120866|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
215120867|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
215120868|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
215120869|NCT06662058|OTHER|Interview|Ancillary studies
215120870|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
215028817|NCT05554731|DEVICE|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
215028818|NCT05554731|DEVICE|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
214444347|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
214444348|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
214444349|NCT03215030|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
214444350|NCT03215030|DRUG|Dexamethasone|Dexamethasone.
214444351|NCT06789900|DRUG|Everolimus (Afinitor®)|Oral dose of everolimus 5 mg once a week for 24 weeks
214444352|NCT06789900|OTHER|Football Fitness Concept|"Structured hybrid exercise training via the football fitness concept organized as a super-vised group training at the University of Southern Denmark, Department of Sports Science and Clinical Biomechanics. Football Fitness concept is designed for participants with little prior experience with football and it is multifaceted training incorporating endurance training, high-intensity interval training (HIIT) and strength training. The training session lasts 60 minutes, and participants will receive two training sessions per week for 24 weeks. Each session is composed of 4 elements: a 15 min warm-up that includes strength and balance exercises, a 15 min period with technical pair-based drills, and a 30-min period with small-sided football drills"
215028819|NCT02529956|DRUG|UCB4940|"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"
215028820|NCT02529956|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"
215028821|NCT01522274|BEHAVIORAL|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
215028822|NCT01522274|BEHAVIORAL|Health education|Videos
215028823|NCT05007639|OTHER|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
215028824|NCT05007639|OTHER|No public Health intervention programme|
215028825|NCT05208437|BEHAVIORAL|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
215028826|NCT05208437|BEHAVIORAL|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
215028827|NCT00767208|OTHER|oral glucose load|oral ingestion of 13C labeled glucose
215028828|NCT04876391|DRUG|Spesolimab 1200 mg|Participants in the 1368-0052 PoCC trial's placebo arm received a 1200 mg intravenous (i.v.) loading dose at Visit 1, then 600 mg s.c. every two weeks for 12 weeks.
215028829|NCT04876391|DRUG|Spesolimab 600 mg|Participants in the 1368-0052 PoCC trial's active arm received a 600 mg subcutaneous (s.c.) loading dose of spesolimab at Visit 1, followed by 600 mg s.c. every two weeks for 12 weeks.
214444353|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
214444354|NCT06788418|PROCEDURE|Wavelight Plus Alcon system|Wavelight Plus Alcon system guided surgery for myopia
214444355|NCT06788418|PROCEDURE|SMILE|Small Incision Lenticule Extraction surgery for myopia
215120871|NCT04904536|DRUG|Atorvastatin|40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
214444356|NCT06788418|PROCEDURE|ICL|Implantable Collamer Lens surgery for myopia
214444357|NCT06300658|DRUG|Stellate ganglion block|Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
214521667|NCT00391521|DRUG|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
214521668|NCT00391521|DRUG|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
214444358|NCT05304468|RADIATION|IMRT|Patients in experimental group received reduced dose IMRT
214444359|NCT05304468|DRUG|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
214444360|NCT05304468|DRUG|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
214444361|NCT06093126|DRUG|Lemborexant 5 MG|The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
214444362|NCT06766942|OTHER|structured sherborne developmental movement program with sensory integration program|In addition to the sensory integration therapy they receive at the rehabilitation center for 45 minutes, two days a week for 12 weeks, the Structured Sherborne Developmental Movement Program will be applied.
214444363|NCT06766942|OTHER|sensory integration program group|Sensory integration therapy programmed according to the individual's needs and disabilities will be applied to this group by an occupational therapist at the rehabilitation center for 45 minutes, 2 days a week for 12 weeks.
214444364|NCT06766942|OTHER|control group|This group will not participate in any activities outside of the standard special education program.
214444365|NCT04274478|DEVICE|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
214521669|NCT00819676|OTHER|analysis of exhaled breath by biosensors|
214521670|NCT00819676|OTHER|measurement of exhaled nitric oxide|
214521671|NCT04871932|BIOLOGICAL|Recently Vaccination|
214521672|NCT04369547|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
214521673|NCT04369547|DRUG|Roflumilast|Roflumilast 250mcg
214521674|NCT04369547|DRUG|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
214521675|NCT03234049|OTHER|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
214521676|NCT00556296|DRUG|NRP104|NRP104 30mg capsule once daily in a.m.
214521677|NCT00556296|DRUG|NRP104|NRP104 50mg capsule once daily in a.m.
214521678|NCT00556296|DRUG|NRp104|NRP104 70mg capsule once daily in a.m.
214521679|NCT00556296|DRUG|Placebo|Placebo
214521680|NCT03236818|DRUG|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
214521681|NCT01125735|DEVICE|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
214521682|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
214521683|NCT02775123|DEVICE|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
214521684|NCT00992654|DRUG|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
214521685|NCT02183961|OTHER|Restech|
214521686|NCT02183961|OTHER|Peptest|
214521687|NCT02183961|OTHER|Detection of pepsin in adenoid specimen|
214521688|NCT04968314|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
214521689|NCT03336684|BEHAVIORAL|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
214521690|NCT05364047|BIOLOGICAL|Low-dose of LVRNA009|25μg/person
214521691|NCT05364047|BIOLOGICAL|Middle-dose of LVRNA009|50μg/person
214521692|NCT05364047|BIOLOGICAL|High-dose of LVRNA009|100μg/person
214521693|NCT05364047|OTHER|Placebo|0.5ml/person
214521694|NCT03990909|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
214521695|NCT03990909|DIETARY_SUPPLEMENT|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
214521696|NCT03990909|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
214444366|NCT06769906|OTHER|Individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will apply continuous glucose monitoring system and receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires.
214444367|NCT06764901|BEHAVIORAL|Online Therapy Chat Service (TCS)|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer).
214444368|NCT06765551|DIAGNOSTIC_TEST|Neuromuscular Ultrasound|Non-invasive ultrasound of peripheral muscles of the upper and lower extremities with additional artificiall intelligence processing of ultrasound images.
214444369|NCT06766006|PROCEDURE|Venoarterial extracorporeal life support (VA ECLS) implant|Implantation of venoarterial extracorporeal life support implant for refractory cardiogenic shock or cardiac arrest of any cause.
214444370|NCT06766955|OTHER||
214444371|NCT06285604|PROCEDURE|Blood transfusion|Transfusion of designated red blood cell products to anemic neonates.
214444372|NCT06767215|OTHER|Ice Compress|Ice compress will be applied 5 minutes before butulinium injection
214444373|NCT06767215|OTHER|No ice compress|No ice compress will be applied .
214444374|NCT05845424|DRUG|Guideline directed statin therapy|At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
214444375|NCT05845424|DRUG|High intensity statin plus ezetimibe therapy|Rosuvastatin 20 mg + Ezetimibe 10 mg
214444376|NCT06799858|DEVICE|Breast cancer localisation with magnetic seed Sirius Pintuition|Patients with histologically proven non-palpable breast cancer or with histologically proven pathological lymph node will be localised by a magnetic seed Sirius Pintuition.
214444377|NCT03701113|DIETARY_SUPPLEMENT|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
214444378|NCT03701113|DIETARY_SUPPLEMENT|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
214444379|NCT05215847|DRUG|ARD-101|Twice daily, oral administration
214444380|NCT06678737|OTHER|CBIT +cTBS|10 daily sessions of CBIT plus cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
214444381|NCT06678737|OTHER|CBIT +sham cTBS|10 daily sessions of CBIT plus sham cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
214521697|NCT01523678|DRUG|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
214521698|NCT01523678|DRUG|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
214444382|NCT04330326|DRUG|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
214444383|NCT04330326|DRUG|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
214444384|NCT06479785|OTHER|Educational Intervention Program for machine workers|A detailed Educational Intervention Program for marble factory workers working on Machines.
214521699|NCT01523678|DRUG|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
214521700|NCT03614923|BIOLOGICAL|Etokimab|Administered by subcutaneous injection
214444385|NCT06479785|OTHER|Educational Intervention Program for manual workers|A detailed Educational Intervention Program for marble factory workers working manually.
214444386|NCT05744401|DRUG|AL002|Administered via intravenous (IV) infusion
214444387|NCT06091215|DEVICE|Sciton Joule System|Sciton Joule System
214444388|NCT02961660|DRUG|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
214444389|NCT05739175|DEVICE|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
214444392|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
214521701|NCT03614923|BIOLOGICAL|Placebo|Administered by subcutaneous injection
214693458|NCT03000374|DRUG|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
214693459|NCT03000374|DRUG|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
214693460|NCT03000374|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
214693461|NCT03000374|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
214693462|NCT02567617|DIETARY_SUPPLEMENT|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
214693463|NCT02567617|DIETARY_SUPPLEMENT|Placebo controlled|Starch capsules
214693464|NCT01672021|PROCEDURE|PET/MRI|PET/MRI
214444393|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
214521702|NCT03614923|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
214521703|NCT03959930|DEVICE|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
214521704|NCT02246387|PROCEDURE|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
214521705|NCT06505408|DIETARY_SUPPLEMENT|Multivitamin|4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks
214521706|NCT06505408|DIETARY_SUPPLEMENT|Placebo|4 placebo capsules consumed daily for 12 weeks
214521707|NCT01107353|DRUG|Imipramine Pamoate|75 mg capsule
214521708|NCT04286893|DIAGNOSTIC_TEST|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
214521709|NCT04286893|DIAGNOSTIC_TEST|High resolution ECG|Measurement HRV using high resolution ECG
215120872|NCT04904536|OTHER|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
215120873|NCT06719804|DRUG|Propranolol|Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
215120874|NCT06722677|DEVICE|VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
215120875|NCT06722677|DEVICE|Sham VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
214444394|NCT05752747|OTHER|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
214444395|NCT05752747|OTHER|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
214521710|NCT04286893|DIAGNOSTIC_TEST|Blood withdrawal|Measurement of endothelial inflammation markers
214521711|NCT00082784|DRUG|Bortezomib|Given IV
214521712|NCT00082784|DRUG|Alvocidib Hydrochloride|Given IV
214521713|NCT00082784|OTHER|Pharmacological Study|Correlative studies
214521714|NCT00185848|RADIATION|[18F]FHBG|\< 7mCi and 2 ug, iv
215120876|NCT06722677|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke.
214521715|NCT00527696|PROCEDURE|transvaginal obturator tape|
214521716|NCT01943370|OTHER|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
214521717|NCT01943370|OTHER|Routine Irrigation|Routine initiation of saline irrigation
214521718|NCT03321188|PROCEDURE|HIPEC|HIPEC with cisplatin
214521719|NCT03321188|DRUG|Carboplatin|Adjuvant IV chemotherapy
214521720|NCT03321188|DRUG|Paclitaxel|Adjuvant IV chemotherapy
214521721|NCT03068676|BEHAVIORAL|Space from Depression|internet-delivered CBT
214521722|NCT03068676|BEHAVIORAL|Space from Anxiety|internet-delivered CBT
214521723|NCT04143802|DRUG|LY3437943|Administered SC
214521724|NCT04143802|DRUG|Dulaglutide|Administered SC
215120877|NCT06460142|DIAGNOSTIC_TEST|Aortic/ cardiac magnetic resonance imaging|MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
214521725|NCT04143802|DRUG|Placebo|Administered SC
214521726|NCT02988245|DRUG|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
214521727|NCT02988245|DRUG|JNC-8|Using JNC-8 guidelines to guide therapy
214521728|NCT04223661|DRUG|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
214521729|NCT04223661|DRUG|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
214444396|NCT06110442|DEVICE|IbexBH Software|A software application applied to radiographs
214521730|NCT04223661|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
214521731|NCT01136733|DRUG|Lenvatinib|taken orally, once a day
214521732|NCT01136733|DRUG|Everolimus|taken orally, once a day
214521733|NCT00113334|DRUG|ABT-510|100 mg subcutaneously twice daily
214521734|NCT01343147|OTHER|Microwave diathermy|Deep tissue heating via microwave diathermy
214521735|NCT01343147|OTHER|Superficial hyperthermia|Superficial heating via hot pack application
214521736|NCT02201368|DRUG|Triheptanoin (SpezialölÒ 107®)|"* Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
214444397|NCT05909982|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
214444398|NCT05034354|DEVICE|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A\&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A\&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
214444399|NCT06789029|DRUG|perineural Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg perineural Dexamethasone
214444400|NCT06789029|DRUG|intravenous Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg intravenous Dexamethasone
214444401|NCT06788366|DRUG|Immunotherapy|First-line regimen according to clinical practice
214444402|NCT06788366|DRUG|Chemotherapy|First-line regimen according to clinical practice
214444403|NCT05873426|DRUG|[14C] ZSP1273|600 mg suspension containing 50μCi of \[14C\]ZSP1273
214444404|NCT05552326|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214444405|NCT05552326|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
214444406|NCT06096532|OTHER|75 gm oral glucose load|Consumption of 75 gm oral glucose load in order to test nutrient responsiveness
214444407|NCT05150795|DRUG|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
214444408|NCT05150795|DRUG|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
214444409|NCT06148818|OTHER|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
214521737|NCT02201368|DIETARY_SUPPLEMENT|MCT (Medium-Chain Triglycerides)|"* Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months"
214521738|NCT05267249|PROCEDURE|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
214521739|NCT03360071|DRUG|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
214521740|NCT03360071|DRUG|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
214444410|NCT06148818|OTHER|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
214444411|NCT04477681|OTHER|Data collection|In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, compassionate use/ off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
214444412|NCT06790134|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
214444413|NCT03157167|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214444414|NCT06791070|DRUG|Disitamab Vedotin combined with Toripalimab|Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
214521741|NCT03586739|PROCEDURE|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
214521742|NCT03586739|PROCEDURE|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
214521743|NCT03586739|DEVICE|Duplex-scan|a Duplex-scan will be performed during patient follow up.
214521744|NCT03586739|DEVICE|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
214521745|NCT03586739|DEVICE|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
214521746|NCT03586739|OTHER|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
214521747|NCT01642888|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
214521748|NCT01642888|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
214521749|NCT03490942|DRUG|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
214521750|NCT03490942|DRUG|Placebo|The placebo solution is a non-active formulation containing excipients only.
214444415|NCT02688712|DRUG|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
214521751|NCT03293329|OTHER|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
214444416|NCT02688712|DRUG|Capecitabine|Antimetabolite chemotherapy
214444417|NCT02688712|DRUG|Fluorouracil|Antimetabolite chemotherapy
214444418|NCT02688712|PROCEDURE|Tumor specific mesorectal excision|Tumor specific mesorectal excision
214444419|NCT05701072|PROCEDURE|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
214444420|NCT05701072|PROCEDURE|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
214444421|NCT05587582|OTHER|Survey Administration|Complete a survey
214444422|NCT04079868|BEHAVIORAL|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
214444423|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplemnt|Hair growth supplement for women ages 18 - 44.
214444424|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70.
214521752|NCT03293329|OTHER|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
214521753|NCT03293329|OTHER|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
214444425|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.
214521754|NCT02459132|BEHAVIORAL|High-intensity aerobic interval exercise|See arm/group description
214521755|NCT02078947|BEHAVIORAL|High Intensity Exercise|
214521756|NCT02078947|BEHAVIORAL|Moderate Continuous Exercise|
214521757|NCT02078947|BEHAVIORAL|Usual Care|
214521758|NCT02266589|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
214521759|NCT01330719|PROCEDURE|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
214521760|NCT01330719|PROCEDURE|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
214521761|NCT01585597|DEVICE|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
214444426|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
214444427|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Men's Hair Growth Supplement|Hair growth supplement for men ages 25 - 50.
214444428|NCT05847855|DIAGNOSTIC_TEST|Blood collection|Blood collection for fragmentomic profiles of plasma cell-free DNA
214521762|NCT06641128|DRUG|MTX SC or IM|IM or SC Methotrexate
214521763|NCT06641128|DRUG|Empagliflozin 25mg tab|Empa tablets 25 mg once daily for 3 months.
214521764|NCT00740298|OTHER|sucrose|sweet taste
214521765|NCT00740298|OTHER|warmth|warmth
214521766|NCT05264506|DRUG|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
214521767|NCT01504178|DRUG|duloxetine|administration during 28 days
214521768|NCT01504178|DRUG|placebo of duloxetine|administration during 28 days
214521769|NCT01504178|DRUG|injection of apomorphine|injection performed at D28
214521770|NCT01504178|DRUG|injection of placebo of apomorphine|performed at D28
214521771|NCT01504178|DRUG|L-Dopa|performed at D28
214521772|NCT01504178|DRUG|injection of placebo of L-Dopa|performed at D28
214521773|NCT02072889|OTHER|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
215028830|NCT04876391|DRUG|Placebo matching 600 mg Spesolimab|Participants from the placebo arm of the 1368-0052 PoCC trial will receive a subcutaneous (s.c.) administration of placebo matching 600 mg spesolimab at Visit 1.
214521774|NCT00266136|DRUG|Cytarabine|see protocol
214521775|NCT00266136|DRUG|Thioguanine|see protocol
214444429|NCT06786156|BEHAVIORAL|Pecha Kucha Education|"After the first interviews, the participants will be given face-to-face training to count fetal movements in the first stage. The training will last 30-45 minutes. The training content includes a comfortable environment and a suitable position for pregnant women, how to count and what to look for before counting fetal movements. Then, the training will be sent to the pregnant women via WhatsApp. A form will be given to count the fetal movements, and training will be applied using the Pecha Kucha method using smartphones once a week for 4 weeks. Pecha kucha is a presentation method developed to attract and maintain the attention of the audience throughout a series of different presentations. Pecha kucha (P-K), derived from the word meaning chat in Japanese, is to help present creative works with visual images. Pecha kucha training includes position, how to count and what to look for before counting fetal movements. This training will be delivered via WhatsApp with a practical presenta"
214444430|NCT05064813|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR Intervention|MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.
214444431|NCT05064813|BEHAVIORAL|Stress Education Control Condition (SE)|Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
214444432|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214444433|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
214521776|NCT00266136|DRUG|Daunorubicin|see protocol
214521777|NCT00266136|DRUG|Cyclophosphamide|see protocol
214521778|NCT00266136|DRUG|G-CSF|see protocol
214521779|NCT00266136|PROCEDURE|Autologous stem cell transplantation|for details see protocol
214521780|NCT00266136|PROCEDURE|Allogeneic stem cell transplantation|for details see protocol
214521782|NCT05640947|DEVICE|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
214521783|NCT04639076|BEHAVIORAL|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
215028831|NCT04876391|DRUG|Placebo matching 1200 mg Spesolimab|Participants from the active arm of the 1368-0052 PoCC trial will receive an intravenous (i.v.) infusion of placebo matching 1200 mg spesolimab at Visit 1
215028832|NCT04007549|BEHAVIORAL|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
215028833|NCT05781685|DRUG|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
214444434|NCT06447519|DRUG|Ca(OH)2 as intracanal medicament|Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
214444435|NCT06784583|DEVICE|transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception), and one-hour timing. Next, begin the stimulation.~3. Stimulation end: After an hour, the device will be automatically switched off. And the procedure is finished."
214444436|NCT06784583|DEVICE|sham transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception). Next, turn off the stimulation，and one-hour timing.~3. Stimulation end: After an hour, the device will be removed and the procedure is finished."
214444437|NCT06784297|BIOLOGICAL|IMM01-STEM|The individuals receiving expanded access will receive a treatment identical to the most convenient regimen in the current clinical trial (STEM-META). The treatment will consist of one i.m. injection per week containing 2 mg of total protein in 2 mL, for a total of 4 weeks (4 injections). As more efficacy information accumulates, the treatment plan will be adjusted accordingly to maximize the potential benefit.
214444438|NCT06032793|OTHER|Breathing exercises|Pursed lip breathing, Diaphragmatic breathing and powered breathing
215120878|NCT06460142|DIAGNOSTIC_TEST|Vascular ultrasound|Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
214444439|NCT06787547|DEVICE|IVL(Sonico-CX)|SONICO-CX® balloon matched 1:1 to the reference vessel diameter, was advanced to the target lesion to pretreat
214444440|NCT05873868|OTHER|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
214444441|NCT05873868|OTHER|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
214444442|NCT05873868|OTHER|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
214521784|NCT04639076|BEHAVIORAL|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
214521785|NCT05858047|DRUG|Placebo|Administered orally, once daily (QD)
214521786|NCT05858047|DRUG|SYHX1901|Administered orally, once daily (QD)
214521787|NCT02829411|BEHAVIORAL|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
214521788|NCT02829411|BEHAVIORAL|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
214521789|NCT02504502|OTHER|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
214521790|NCT05453292|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
214521791|NCT04264416|DEVICE|WB-EMS|16 weeks of WB-EMS
214521792|NCT03741283|OTHER|Optimisation of nutrition and medication|"1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
214521793|NCT03761134|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214521794|NCT03761134|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214521795|NCT03761134|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214521796|NCT03761134|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
215028834|NCT05781685|OTHER|Placebo Syrup|Oil-based sublingual product.
215028835|NCT04717739|DEVICE|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
214444443|NCT06045234|OTHER|Urine sampling|"Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
214693465|NCT00444509|DRUG|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
214693466|NCT00444509|DRUG|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
214444444|NCT06791798|OTHER|Ventilator Hyperinflation|In ventilator hyperinflation volume control mode, the ventilator will be set to eight breaths per minute, and the tidal volume will be increased to deliver hyperinflation breaths that are 15 ml/kg, as will be calculated using the predicted body weight. Tidal volume will be increased in 150-ml increments until a peak airway pressure of 40 cmH2O is achieved. Once this pressure is reached, eight mechanical breaths will be delivered to the patient. After this, the ventilator will be reset to pretreatment variables, and the patient will be rested for 30 s. The sequence will be repeated. The treatment will consist of five sets of eight ventilator hyperinflation breaths.
214693467|NCT05138783|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
215120879|NCT06460142|DIAGNOSTIC_TEST|Transorbital Ultrasound|Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
215120880|NCT06460142|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
214444445|NCT06791798|OTHER|Vibrocompression|Vibrocompression will be performed by the physical therapist to produce vibration and will be combined with compression of the patient's chest in the expiratory phase. Every vibrocompression will be interrupted at the end of each expiratory phase to allow free inspiration.
215120881|NCT06460142|DIAGNOSTIC_TEST|Optical coherence tomography angiography|OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
215120882|NCT06460142|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
215120883|NCT06460142|DIAGNOSTIC_TEST|Fundus autofluorescence|This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
215120884|NCT06460142|DIAGNOSTIC_TEST|Color Fundus Photography|Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
215120885|NCT06460142|DIAGNOSTIC_TEST|Cell-based ex-vivo assay with high-content analysis|This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
215120886|NCT06460142|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
214444446|NCT06791798|OTHER|Traditional Chest Physical Therapy Program|Percussion, Postural Drainage, and Suction
214444447|NCT06784245|BEHAVIORAL|TeleActivate|Each session will consist of a warm-up activity (5-10 min), main exercise activity (30-40 min), and cool-down activity (5-10 min) following the guidelines of multicomponent exercise program Vivifrail. Exercise intensity will be controlled based on the Rating of Perceived Exertion (RPE) on the Borg scale and heart rate measured with a smartwatch before, during, and after each exercise session according to the guidelines of the American College of Sports Medicine (ACSM), as explained below. The warm-up and cool-down activities will include stretching and walking in place (9≤RPE≤10 and 40\<55% maximum Heart rate (HRmax). While the main exercise activity will consist of strength, resistance exercise, cardiovascular exercises, and balance exercises (to avoid falls) performed using dumbbells, colour-coded resistance bands (Thera-Band; Hygenic Corp.) and a chair (11\<RPE≤15 and 55\<70 HRmax).
214444448|NCT02785042|DEVICE|Heidelberg Spectralis OCT|OCT imaging
214693468|NCT05138783|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214693469|NCT03746223|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
214693470|NCT03746223|DRUG|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
214693471|NCT03746223|DRUG|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
214693472|NCT05731843|DRUG|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
214693473|NCT05731843|DRUG|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
215120887|NCT06460142|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
214444449|NCT06349564|DEVICE|Pico 4 Enterprise headset with noise cancelling headphones|The device includes a computer tablet and virtual reality headset.
214444450|NCT06471751|OTHER|Inspiratory and Oropharyngeal Muscle Strengthening|"Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device."
214444451|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
214444452|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
215120888|NCT06460142|DIAGNOSTIC_TEST|Flow cytometry|Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
215120889|NCT06460142|DIAGNOSTIC_TEST|Laboratory assessment:|Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
214444453|NCT06065189|BIOLOGICAL|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
214444454|NCT03527433|PROCEDURE|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
214444455|NCT05441696|DEVICE|ezCVP measurement|"* Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
214444456|NCT06592547|DRUG|Intravenous metoprolol tartrate|An intravenous beta-blockers, recieved FDA approval
214444457|NCT06592547|OTHER|Standard Care (in control arm)|Standard care according to surviving sepsis campaign
214444458|NCT01939275|RADIATION|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
214444459|NCT01939275|DEVICE|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
214444460|NCT01939275|OTHER|laboratory biomarker analysis|Correlative studies
214444461|NCT01939275|PROCEDURE|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
214444462|NCT06132048|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
214444463|NCT03526835|DRUG|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
214444464|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
214444465|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFIRI|MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
214444466|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFOX|MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
214444467|NCT05145257|DIETARY_SUPPLEMENT|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
214444468|NCT06799884|DRUG|Ethinyl Estradiol / Levonorgestrel Oral Tablet|Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel
214521797|NCT03369652|BEHAVIORAL|Medication review|Conducted by the pharmacist and discussed with hospital physician
214521798|NCT00692250|DRUG|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
214521799|NCT03771183|OTHER|Patients in long response during Halaven® treatment|Data collection
215120890|NCT06460142|DIAGNOSTIC_TEST|Immunohistochemistry of Temporal Artery Biopsies|Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
214521800|NCT00748488|OTHER|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
214521801|NCT00748488|OTHER|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
215120891|NCT06460142|DIAGNOSTIC_TEST|Functional assessment questionnaires|The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
214444469|NCT06799884|DRUG|Aprocitentan|Film-coated tablet of aprocitentan 25 mg
214444470|NCT04598854|DEVICE|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
214444471|NCT04598854|DEVICE|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
214444472|NCT06137170|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
215120892|NCT06506942|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
215120893|NCT05503862|DEVICE|YoSperm|The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
215120894|NCT06725641|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
214444473|NCT06557538|DEVICE|Automatic Ankle Brachial Pressure Index device assessment|The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).
214444474|NCT06557538|DEVICE|Manual Ankle Brachial Pressure Index assessment|The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
214444475|NCT06479590|DEVICE|tDCS|The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)
214444476|NCT06479590|OTHER|Sham tDCS|sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application
214444477|NCT05511298|BEHAVIORAL|Relationship Smarts Combo|The intervention is a combination of Mind Matters, Relationship Smarts 4.0, and Money Habitudes curricula, developed by the Dibble Institute
214444478|NCT03442101|DRUG|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
214444479|NCT05186818|DRUG|Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)|Aficamten tablets were administered orally once daily.
214444480|NCT05186818|DRUG|Placebo to match aficamten|Placebo tablets were administered orally once daily.
214444481|NCT05837936|OTHER|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
214444482|NCT05837936|OTHER|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
214444483|NCT06023082|DIETARY_SUPPLEMENT|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
214444484|NCT03694002|DRUG|Carboplatin|Given IV
214444485|NCT03694002|DRUG|Paclitaxel|Given IV
214444486|NCT03694002|BIOLOGICAL|Ramucirumab|Given IV
214444487|NCT04823611|DRUG|Part A:Placebo|Placebo solution
214444488|NCT04823611|DRUG|Part A:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
214444489|NCT04823611|DRUG|Part B:Placebo|Placebo solution
214444490|NCT04823611|DRUG|Part B:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
214444491|NCT04823611|DRUG|Part C: Placebo|Placebo solution
214444492|NCT04823611|DRUG|Part C: AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
214444493|NCT06796322|DEVICE|non-invasive blood glucose meter|Blood glucose were detected by non-invasive glucose meter at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
214444494|NCT06796322|DEVICE|fully automatic laboratory biochemical analyzer|Blood glucose were detected by fully automatic laboratory biochemical analyzer using plasma sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
214444495|NCT06796322|DEVICE|fingertip capillary blood glucose meter|Blood glucose were detected by fingertip capillary blood sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
214444496|NCT05637307|PROCEDURE|Sentinel node procedure|Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
214444497|NCT05664516|DRUG|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
214444498|NCT05664516|DRUG|Placebo|Nasal solution without oxytocin
214444499|NCT05568225|DRUG|Etavopivat|400 mg once daily
214444500|NCT06420869|DIAGNOSTIC_TEST|Assessment|A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.
215120895|NCT06725641|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）|Cholinergic agonists
215120896|NCT06748001|DRUG|Avapritinib|Avapritinib will be administered in accordance with the parent study protocol.
215120897|NCT06921265|BEHAVIORAL|Training with Speech Language Therapy|"The SLT will consist of an online intervention performed through a web-based platform.~The SLT training of the SLT group will consist of 2 cycles of training lasting 1 (rest) + 5 (training) weeks, 3 times per week, 1 hour each session, separated by a 12-week washout period."
214444501|NCT03933059|OTHER|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
214444502|NCT02531841|DRUG|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
214444503|NCT02531841|DRUG|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
214444504|NCT02306954|BIOLOGICAL|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
214444505|NCT02306954|RADIATION|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
214444506|NCT02610673|DEVICE|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
214444507|NCT06005961|BEHAVIORAL|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
214444508|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 1|The study foresees the intake of 1 capsule per day during 56 days
214444509|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 2|The study foresees the intake of 1 capsule per day during 56 days
214444510|NCT06571409|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
214444511|NCT05444192|DEVICE|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
214444512|NCT04522713|BEHAVIORAL|Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material|Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
214444513|NCT05634070|DEVICE|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
214444514|NCT02746510|GENETIC|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
214444515|NCT06525311|DRUG|K-808|K-808 single or multi dose extended-release tablets
214444516|NCT05568017|DRUG|peptide receptor radionuclide therapy with Y-90-DOTATOC|Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
214444517|NCT05092113|DRUG|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
214444518|NCT06338319|BEHAVIORAL|Book-Sharing for Toddlers with Clefts (BOOST)|BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
214444519|NCT01540318|PROCEDURE|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
214444520|NCT02686398|BIOLOGICAL|Fluad|
214444521|NCT02686398|BIOLOGICAL|Agrippal|
214444522|NCT04238910|BEHAVIORAL|Maximizing Energy|The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
214444523|NCT04238910|BEHAVIORAL|Health Education|The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
214444524|NCT05623345|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214444525|NCT05623345|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214693474|NCT02294318|BEHAVIORAL|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
215120898|NCT06921265|DEVICE|Standard rTMS|Stimulation of DLPFC; rTMS will be administered as high-frequency (20Hz) in 2 second trains (40 pulses per train) with an inter-train interval of 22 seconds for a total of 50 trains (2000 pulses per session) at 120% of the patient's resting motor threshold. Patients will undergo an induction with 20-minutes rTMS protocol for 5 consecutive days, then they will start a maintenance phase where rTMS will be performed 3 days a week per 20 minutes preceding the SLT session, for a total of 20 sessions (of whom 15 combined with SLT).
214444528|NCT01385176|DEVICE|Implant of investigational device system|Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
214444529|NCT01385176|PROCEDURE|Titration during the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
214521802|NCT05476770|DRUG|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
214521803|NCT05476770|DRUG|Fludarabine|"30 mg/m\^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
214521804|NCT05476770|DRUG|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
214521805|NCT05476770|DRUG|Dexamethasone|"* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~* Any oral formulation of dexamethasone is acceptable.~* IV may be given if oral formulation is not tolerated"
214444530|NCT01385176|PROCEDURE|Titration after the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
214444531|NCT01385176|DIAGNOSTIC_TEST|Blood Draw|Blood draw before implant and 6 months after implant at the end of the randomization phase.
214444532|NCT02336217|OTHER|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
214521806|NCT05476770|DRUG|Vincristine|"* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~* Infusion will start 30 minutes after start of tagraxofusp on day 8."
214521807|NCT05476770|DRUG|Azacitidine|"* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
214521808|NCT05476770|DRUG|Methotrexate|"Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age"
214521809|NCT05476770|DRUG|Cytarabine IT|"Give intrathecally:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
214521810|NCT05476770|DRUG|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
214521811|NCT06099119|DRUG|creon 35.000 Ph.U (R)|Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
214521812|NCT06099119|OTHER|Best Standarard of Care|Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
214521813|NCT00222209|BEHAVIORAL|Experimental heat pain model|
215120899|NCT06921265|DEVICE|Targeted rTMS|The protocol will be the same as standard STIM. The site of stimulation will be defined using EEG/fMRI recordings of language tasks (syntax production for nfvPPA; silent naming for svPPA and lvPPA) to evidence the areas of higher activation/connectivity of the language network. We will define the area of higher fMRI activation; then, we will use fMRI-EEG connectivity and spectral activity to select the site of stimulation, among the areas with the highest fMRI activation and the highest Beta/Gamma frequencies.
215120900|NCT06921265|DEVICE|Standard rTMS (first cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will firstly undergo the standard rTMS in the first 6 week of training after the baseline visit
214444533|NCT02336217|OTHER|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
214444534|NCT05384730|OTHER|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
214521814|NCT01014013|DRUG|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
215120901|NCT06921265|DEVICE|Standard rTMS (second cycle)|Patients of the SLT + STIM (targeted rTMS + standard rTMS) will secondly undergo the standard rTMS after 12 week washout period
215120902|NCT06921265|DEVICE|Targeted rTMS (first cycle)|Patients of the SLT + STIM (targeted rTMS + standardTMS) will firstly undergo the targeted rTMS in the first 6 weeks of training after the baseline visit
214521815|NCT01014013|DRUG|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
214521816|NCT04949113|DRUG|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
214521817|NCT04949113|DRUG|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
214444535|NCT05744271|DEVICE|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
214444536|NCT01772472|DRUG|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
214444537|NCT01772472|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
214444538|NCT05774626|BEHAVIORAL|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
214444539|NCT02913196|DRUG|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
214444540|NCT02913196|DRUG|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"
214444541|NCT02913196|DRUG|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"
214693475|NCT02294318|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
214444542|NCT02913196|DRUG|Prednisone|Dose: 5 mg BID
214444543|NCT04804202|OTHER|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
214444544|NCT04909619|PROCEDURE|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
214521818|NCT05990075|BEHAVIORAL|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
214521819|NCT04299698|BEHAVIORAL|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
214521820|NCT03359187|OTHER|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
214521821|NCT03359187|OTHER|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
214521822|NCT03359187|OTHER|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
214521823|NCT00316121|DEVICE|HEALOS and Leopard Cage|Placement in interbody space
214521824|NCT00316121|DEVICE|Leopard Cage and Autograft|Placement in the interbody space
214521825|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
214521826|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
214521827|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
214521828|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
214521829|NCT03419754|DIETARY_SUPPLEMENT|Glucose|Glucose
214521830|NCT03419754|BEHAVIORAL|Fidgetting|low intensity physical activity (fidgetting)
214521831|NCT00547885|DRUG|Dihydrocodeine|"Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting"
214521832|NCT02305797|DRUG|Extended-release lorazepam|Extended-release lorazepam capsules
214521833|NCT02305797|DRUG|Placebo|Placebo capsules
214521834|NCT05802498|DEVICE|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
214521835|NCT05404802|DEVICE|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
214693476|NCT03187912|DRUG|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
214693477|NCT06394518|DRUG|TNP-2092 for injection|The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
214693478|NCT06394518|DRUG|placebo|The placebo for TNP-2092 active drug
214693479|NCT02723266|BEHAVIORAL|STOPPING-GDM|Educational counseling and skills building Intervention
214444545|NCT04909619|PROCEDURE|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
214521836|NCT05404802|DEVICE|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
214521837|NCT06337045|BEHAVIORAL|Complex prevention and rehabilitation intervention|The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
214521838|NCT01630239|PROCEDURE|Laser ablation|Laser ablation of hepatic tumors
214521839|NCT02473549|DEVICE|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
214521840|NCT02473549|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
214693480|NCT06019936|DRUG|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
214693481|NCT06019936|DRUG|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
214693482|NCT00078559|DRUG|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
215120903|NCT06921265|DEVICE|Targeted rTMS (second cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will secondly undergo the targeted rTMS after 12 week washout period
214444546|NCT05663931|OTHER|DM Discharge Toolkit|"The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content."
214521841|NCT02473549|DEVICE|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
214693483|NCT00078559|DRUG|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
214693484|NCT00078559|DRUG|Tacrolimus|2mg orally twice daily, on days 1-60
214693485|NCT00078559|PROCEDURE|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
214693486|NCT00078559|DRUG|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
215120904|NCT06920875|BEHAVIORAL|Imagery and Breathing Exercises|Participants performed daily imagery and breathing exercises before bedtime for 10 weeks. The protocol involved a 4-second inhale through the nose and a 4-second exhale through the mouth while visualizing a 200-meter freestyle swim with detailed attention to technique and performance. A 6-day training period was provided to teach the techniques, and participants received daily reminders and feedback via a WhatsApp group.
215120905|NCT06921694|BEHAVIORAL|Runner group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (running), a schedule of gradually intensifying strengthening exercises and flexibility exercises
214521842|NCT02473549|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
214521843|NCT00065247|BEHAVIORAL|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
214521844|NCT03674476|DRUG|BMS-986036|Specified dose on specified days
214521845|NCT01115153|OTHER|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
214693487|NCT00078559|DRUG|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
214693488|NCT00078559|DRUG|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
214693489|NCT00078559|DRUG|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
214693490|NCT00078559|DRUG|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
214693491|NCT00078559|DRUG|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
214693492|NCT00078559|DRUG|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
214693493|NCT00078559|DRUG|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
214444547|NCT04057456|OTHER|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
214521846|NCT01115153|OTHER|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
214521847|NCT03075475|BEHAVIORAL|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
214521848|NCT04891263|PROCEDURE|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
214521849|NCT04891263|DEVICE|Surgical suture|Suture used for closure during septoplasty surgery.
214521850|NCT02100189|OTHER|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
214521851|NCT02100189|PROCEDURE|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
214521852|NCT02100189|OTHER|Laboratory Biomarker Analysis|Correlative studies
214521853|NCT00245505|DRUG|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
214521854|NCT01351597|DRUG|docetaxel/ oxaliplatin|"1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
214521855|NCT01894750|BEHAVIORAL|group-based skill building self-care program|
214521856|NCT00460577|DRUG|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
214521857|NCT00460577|DRUG|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
214521858|NCT01702688|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
214521859|NCT01702688|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
214521860|NCT01628822|BEHAVIORAL|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
214521861|NCT01628822|BEHAVIORAL|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
214521862|NCT06570954|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
214521863|NCT02469051|DEVICE|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
214521864|NCT02469051|DEVICE|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
214521865|NCT02469051|DEVICE|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
214521866|NCT01306409|DRUG|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
214521867|NCT01306409|DRUG|ESA|Sequential application of three different ESA
214521868|NCT04698499|OTHER|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
214444548|NCT04057456|OTHER|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
214521869|NCT00441493|DRUG|fluvastatin|
214521870|NCT02526199|DRUG|Bupivacaine|Sciatic nerve block
214521871|NCT02526199|DRUG|Epinephrine|Adjuvant to perinerual block
214521872|NCT02526199|DRUG|Dexamethasone|Adjuvant to perinerual block
214521873|NCT01827176|OTHER|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
214521874|NCT03316248|OTHER|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
214521875|NCT03316248|OTHER|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
214521876|NCT02213458|BEHAVIORAL|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
214521877|NCT02653066|OTHER|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
214521878|NCT02653066|OTHER|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
215120906|NCT06921694|BEHAVIORAL|Swim/Cycle Group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (swim/cycle), a schedule of gradually intensitfing strengthening exercises and flexibility exercises
214444549|NCT04057456|DRUG|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
214444550|NCT04057456|OTHER|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
214444551|NCT02842424|DRUG|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
214444552|NCT02571725|DRUG|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
214444553|NCT02571725|DRUG|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
214444554|NCT03295734|BEHAVIORAL|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
214444555|NCT03295734|DRUG|Perindopril|4 mg qd titrated to 8 mg qd perindopril
214444556|NCT03295734|DRUG|Losartan|50 mg qd titrated to 100 qd losartan
214444557|NCT03295734|DRUG|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
214444558|NCT03926819|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
214444559|NCT05777486|BEHAVIORAL|TikTok Ads - With Food|TikTok posts from influencers promoting food.
214444560|NCT05777486|BEHAVIORAL|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
214444561|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|"* Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.~* Home programme with parental coaching"
214444562|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|\- Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
215120907|NCT06920810|DRUG|viscum album|"Active Ingredient: Viscum album Excipients: Ascorbic acid, disodium phosphate dihydrate, monosodium phosphate monohydrate Formulation: Injectable solution contained in a colorless ampoule; the solution is colorless to pale yellow and clear.~Manufacturer: LB Abnoba Co., Ltd. Dosage and Administration: Administered subcutaneously three times per week, with dose escalation according to the following protocol."
214444563|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
214444564|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
214444565|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
214444566|NCT03299322|DRUG|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
214444567|NCT03299322|DRUG|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
214444568|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
214444569|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
214521879|NCT00489151|DRUG|adefovir dipivoxil|
214521880|NCT00489151|DRUG|lamivudine|
214521881|NCT00910871|DRUG|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
214521882|NCT00910871|DRUG|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
214521883|NCT00787345|OTHER|simulation based training|simulation based training in aseptic techniques that included specified AT categories
214521884|NCT03759262|DRUG|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
214521885|NCT02606617|DRUG|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
215120908|NCT03739346|BEHAVIORAL|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
215120909|NCT03739346|BEHAVIORAL|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
215120910|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
215120911|NCT06103994|OTHER|Placebo|Placebo
214444570|NCT04431726|DRUG|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
214444571|NCT06194578|OTHER|Sterile Saline|Sterile saline will be administered subcutaneously.
214444572|NCT03552562|DEVICE|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
215120912|NCT04845763|OTHER|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
215120913|NCT04254601|DEVICE|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
214444573|NCT03746535|DRUG|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
214444574|NCT01748110|BEHAVIORAL|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
214444575|NCT01748110|BEHAVIORAL|TRIMM|text message intervention.
214444576|NCT06389435|PROCEDURE|Patients will be randomized to undergo TKR or RTKR|Total knee replacement (control group)
214444577|NCT02623894|OTHER||No intervention study is an observational study
214444578|NCT00731341|PROCEDURE|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
214444579|NCT00186849|DRUG|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
214444580|NCT00186849|PROCEDURE|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
214444581|NCT06212843|OTHER|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
214521886|NCT02606617|DRUG|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
214521887|NCT03343509|DRUG|Metronidazole Oral|Oral Metronidazole
214521888|NCT03343509|DRUG|Metronidazole Ointment|Metronidazole Ointment
214521889|NCT03343509|DRUG|Placebo Oral Tablet|Placebo Tablet
214521890|NCT03343509|DRUG|Placebo Ointment|Placebo Ointment
214521891|NCT03045549|DEVICE|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
214521892|NCT03045549|OTHER|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
214444582|NCT06212843|OTHER|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
214521893|NCT01878253|DEVICE|Sidus Stem-Free Total Shoulder Arthroplasty System|
214521894|NCT01224509|DRUG|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
214444583|NCT05869331|PROCEDURE|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
214444584|NCT05869331|PROCEDURE|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
215120914|NCT04254601|DRUG|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
215120915|NCT03213834|PROCEDURE|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
214444585|NCT02168829|DRUG|Rivaroxaban|
214521895|NCT01224509|OTHER|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
214521896|NCT04608006|DRUG|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
214521897|NCT04043806|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
215120916|NCT03213834|PROCEDURE|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
215120917|NCT03213834|DRUG|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
215120918|NCT03213834|DRUG|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
215120919|NCT00791908|PROCEDURE|Electrodessication|Treatment applied to a third of the torso at each study visit.
215120920|NCT00791908|PROCEDURE|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
215120921|NCT00791908|PROCEDURE|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
215120922|NCT06330259|DIAGNOSTIC_TEST|menstrual cycle monitoring|frequent serum sampling and 3D ultrasound
214444586|NCT02168829|DRUG|Acetylsalicylic acid|
214521898|NCT04043806|DRUG|IVA|Tablet for oral administration.
214521899|NCT00852345|DRUG|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
214521900|NCT03985826|OTHER|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
214521901|NCT01856647|PROCEDURE|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
214521902|NCT01622088|DRUG|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
214521903|NCT04673071|OTHER|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
214693494|NCT00078559|DRUG|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
215120923|NCT01902121|DRUG|Technosphere® Insulin 10U + 20U|Inhaled Insulin
215120924|NCT01902121|DRUG|Technosphere® Insulin 30U|Inhaled Insulin
215120925|NCT04742114|DEVICE|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
215120926|NCT04742114|DEVICE|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
214444587|NCT06020495|DRUG|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
214444588|NCT06020495|DRUG|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
214444589|NCT06538857|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
214444590|NCT06538857|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
215120927|NCT05901402|BEHAVIORAL|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
214444591|NCT03771105|DRUG|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
214444592|NCT05256745|DRUG|TTP488|Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
214444593|NCT05256745|DRUG|ddAC/ddT|Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
214444594|NCT05256745|DRUG|TC|Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
214521904|NCT04673071|OTHER|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
214521905|NCT00396721|DRUG|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
214521906|NCT00396721|DRUG|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
214521907|NCT03327688|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
214521908|NCT02351388|DEVICE|Transcranial Direct Current Stimulation|
214521909|NCT02351388|OTHER|Sham Stimulation|
214521910|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
214521911|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
214521912|NCT02035345|DRUG|Carboplatin|
214693495|NCT04202718|DIAGNOSTIC_TEST|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
215120928|NCT02812927|DEVICE|Edelvaiss Multiline-8|Optimised infusion line
215120929|NCT02812927|DEVICE|Standard infusion line|
215120930|NCT06525142|BEHAVIORAL|Audiovisual Intervention|"【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person."
215120931|NCT03205176|DRUG|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
214444595|NCT05256745|DRUG|TCHP|Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
214444596|NCT05256745|DRUG|Chemotherapy regimen that includes ddAC|can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
214444597|NCT03022708|DEVICE|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
214444598|NCT06232447|OTHER|Cigarette Type Switching|Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of four weeks
214521913|NCT04868734|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
214521914|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
215120932|NCT03205176|DRUG|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
214521915|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
214521916|NCT00881972|BEHAVIORAL|Exercise|walking/running/cycling
214521917|NCT02948686|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214444599|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
214444600|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
214444601|NCT06475937|DRUG|DM001|Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
214444602|NCT01724242|DRUG|Vaginal DHEA|
215120933|NCT00319254|DRUG|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
215120934|NCT02410239|BIOLOGICAL|Mesenchymal Stem Cells|
214444603|NCT01724242|DRUG|Placebo|
214444604|NCT04093752|DRUG|Tirzepatide|Administered SC
215120935|NCT03075358|DRUG|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
215120936|NCT03075358|OTHER|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
215120937|NCT01505374|PROCEDURE|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
215120938|NCT01505374|PROCEDURE|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
214444605|NCT04093752|DRUG|Insulin Glargine|Administered SC
214444606|NCT04826978|BEHAVIORAL|Auditory environment|Auditory environment
214444607|NCT01101451|DRUG|Cisplatin|Given IV
214444608|NCT01101451|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
214444609|NCT01101451|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
214444610|NCT01101451|OTHER|Laboratory Biomarker Analysis|Correlative studies
214444611|NCT01101451|OTHER|Quality-of-Life Assessment|Ancillary studies
214444612|NCT01101451|OTHER|Questionnaire Administration|Ancillary studies
214444613|NCT03176888|BEHAVIORAL|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
214444614|NCT03176888|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
214444615|NCT00004257|DRUG|fluorouracil|
214444616|NCT00004257|DRUG|oxaliplatin|
214444617|NCT00004257|PROCEDURE|conventional surgery|
214444618|NCT00004257|RADIATION|radiation therapy|
214444619|NCT06835907|OTHER|Questionnaires|Questionnaires include: the Alcohol Use Disorder Identification Test (AUDIT), Composite Autonomic Symptom Score (COMPASS-31), Depression Anxiety Stress Scale (DASS-21), Drug Desire Questionnaire (DDQ), Drinking Motives Questionnaire short form (DMQ-SF), Mini International Neuropsychiatric Interview (MINI), PROMIS-alcohol, Timeline Follow Back (TLFB) and Visual Analog Scale for craving (VAS).
214521918|NCT02948686|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214521919|NCT02948686|OTHER|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
214521920|NCT02948686|OTHER|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
214521921|NCT05165563|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
214521922|NCT04143100|OTHER|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
214521923|NCT06268600|RADIATION|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
214521924|NCT01095237|DEVICE|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
214521925|NCT06226896|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily plus RAS inhibitor
214444620|NCT00004559|BEHAVIORAL|dietary polyunsaturated fatty acid|
214444621|NCT05586971|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
214444622|NCT05586971|DRUG|Allopurinol|Xanthine Oxidase Inhibitor
214444623|NCT05586971|DRUG|Placebo|Matching placebo
214444624|NCT05568381|DEVICE|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
214444625|NCT05568381|OTHER|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
214444626|NCT06568341|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Outcome Expectations For Yoga (OEY) Scale
214444627|NCT04854096|DRUG|NS-018|Experimental
214444628|NCT04854096|DRUG|Best Available Therapy|Active Comparator
214444629|NCT06095440|OTHER|Hepatorenal Syndrome outcome in Patients at Methodist Health systems|1.2.1. To perform a retrospective analysis of patients with HRS with the aim of comparing various treatment modalities such as vasoconstrictors, albumin, CRRT, Molecular Adsorbent Recirculating System (MARS), and TIPS.
214521926|NCT06355271|PROCEDURE|Fentanyl 1|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl
214521927|NCT06355271|PROCEDURE|Fentanyl2|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl
214521928|NCT06355271|PROCEDURE|Fentanyl 3|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
214521929|NCT06124599|OTHER|Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
214521930|NCT06124599|OTHER|Identification of symptoms of menstrual in control patient in the last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
214693496|NCT01689402|DEVICE|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
215120939|NCT03809494|DEVICE|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
215120940|NCT03809494|OTHER|Saline|Normal (0.9%) saline
215120941|NCT04177979|BEHAVIORAL|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
215120942|NCT02095080|DIETARY_SUPPLEMENT|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
215120943|NCT03308994|OTHER|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
214444630|NCT06409884|DEVICE|T-cell activation test using intracellular markers|A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
214444631|NCT04398745|DRUG|Belantamab mafodotin|Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.
214444632|NCT03647956|DRUG|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
214444633|NCT03647956|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
214521931|NCT03519893|DRUG|Losartan|Patients are tested for their normal prescription losartan medication
214521932|NCT04967521|DRUG|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
214521933|NCT04967521|DRUG|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
214521934|NCT05004740|OTHER|Vaccinated Pregnant or Lactating persons|vaccinated lactating persons from Sinai Health System or the general public
214693497|NCT00000255|DRUG|Nitrous oxide|
214693498|NCT04977154|OTHER|Primary prevention|The primary prevention that the trainers put in place for the hockey players
215120944|NCT03308994|OTHER|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
214444634|NCT03647956|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
214444635|NCT03647956|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
214444636|NCT04093895|DRUG|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
214444637|NCT04757610|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
214693499|NCT05015166|BEHAVIORAL|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
214444638|NCT04757610|BIOLOGICAL|0.5 mg ranibizumab|intravitreal injection
214521935|NCT03623776|DRUG|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
214521936|NCT03623776|DRUG|Pemetrexed|Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
214693500|NCT05015166|BEHAVIORAL|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
214693501|NCT02753036|DRUG|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
214693502|NCT01682499|DRUG|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
214693503|NCT05297656|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
214693504|NCT05297656|OTHER|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
214693505|NCT05297656|OTHER|Home exercises programe|Only Home exercises programe
214444639|NCT04757610|PROCEDURE|Sham|intravitreal injection
214521937|NCT03623776|DRUG|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
214693506|NCT05484180|OTHER|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
214693507|NCT00866892|PROCEDURE|Irrigation|irrigation
214693508|NCT00866892|PROCEDURE|No irrigation|no irrigation
214693509|NCT05958758|DRUG|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
215120945|NCT01079494|OTHER|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
214444640|NCT02752659|PROCEDURE|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
214444641|NCT05747196|DEVICE|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
214444642|NCT04814719|DRUG|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
214444643|NCT04814719|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
214444644|NCT06500780|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
214444645|NCT04683315|DRUG|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
214444646|NCT04683315|DRUG|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
214521938|NCT03623776|PROCEDURE|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
214521939|NCT03476603|DRUG|Irbesartan|Patients are tested for their normal prescription irbesartan medication
214521940|NCT06471842|OTHER|MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire|The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
214521941|NCT04799587|OTHER|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
214521942|NCT04799587|OTHER|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
214521943|NCT04387916|DRUG|KC1036|Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
214444647|NCT04683315|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
214444648|NCT04275908|DEVICE|MHSAFE app|App to detect presence of mental state
214444649|NCT02892214|PROCEDURE|Pelvic floor physical therapy|
214444650|NCT02892214|DRUG|estriol cream (ovestin)|
214444651|NCT02892214|PROCEDURE|Low-level-laser therapy|
214444652|NCT04524494|OTHER|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
214444653|NCT04524494|OTHER|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
214444654|NCT04524494|OTHER|urine collection|Midstream Urine collection
214444655|NCT03767452|DRUG|Xiaflex® 0.58 mg|0.25 mL injections.
214444656|NCT02622984|BEHAVIORAL|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
214444657|NCT02622984|BEHAVIORAL|SBIRT|"Face to face standard intervention considered treatment as usual."
214444658|NCT00252369|DRUG|Infliximab|
214521944|NCT04798833|DEVICE|Integrated Newborn Care Kit (iNCK)|"Contents of the integrated newborn care kit:~* Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~* 3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~* 4% CHX solution (15 mL)~* Sunflower oil emollient (50 mL)~* Temperature monitoring strip or sticker~* Fleece blanket for the newborn~* Click to heat warmer~* Pictorial guide that illustrates how and when to use each kit component~* Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit"
214521945|NCT05651347|OTHER|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
214521946|NCT05651347|DRUG|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
214521947|NCT05492721|DEVICE|2-Octylcyanoacrylate|Incisions on left will have one glue and on right will have the other glue
215120946|NCT02315534|DRUG|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
215120947|NCT02315534|DRUG|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
215120948|NCT06267222|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
215120949|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
214444659|NCT00252369|PROCEDURE|Instillation of fibrin glue|
214444660|NCT00073749|DRUG|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
214444661|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
214444662|NCT03304834|DEVICE|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
214444663|NCT02253459|DRUG|UTD1 Injection plus capecitabine|
214444664|NCT02253459|DRUG|Capecitabine|
214444665|NCT00226018|DEVICE|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
214444666|NCT00226018|DEVICE|Placebo|placebo
214444667|NCT06489041|GENETIC|"Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx"|Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
215120950|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
215120951|NCT02452424|DRUG|PLX3397|PLX3397 capsules, 200 mg
215120952|NCT02452424|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 200 mg, IV
215120953|NCT03977766|PROCEDURE|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
214444668|NCT04099875|DIAGNOSTIC_TEST|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
214444669|NCT00785915|DRUG|AZD6765|single administration and once daily for 5 days
214444670|NCT00785915|DRUG|Placebo|single administration and once daily for 5 days
214444671|NCT03592732|OTHER|Blood sample|Blood sample
214444672|NCT03788200|PROCEDURE|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
214444673|NCT03788200|PROCEDURE|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
214444674|NCT05858580|BEHAVIORAL|Bennett Kids PowerUP Project|Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
214444675|NCT04154384|BEHAVIORAL|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
214444676|NCT04154384|OTHER|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
214444677|NCT04154384|BEHAVIORAL|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
214444678|NCT02256254|DRUG|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
214521948|NCT05492721|DEVICE|N-butyl-2-cyanoacrylate|Incisions on left will have one glue and on right will have the other glue
214521949|NCT05341960|BEHAVIORAL|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
214521950|NCT05341960|OTHER|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
214521951|NCT00515281|DRUG|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
214521952|NCT00515281|DRUG|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
214521953|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
214521954|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
214521955|NCT01996098|DRUG|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
214521956|NCT01996098|DRUG|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
214521957|NCT06233682|OTHER|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
214521958|NCT04374435|PROCEDURE|MKTP with Surgical blade|In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
214521959|NCT04374435|DEVICE|MKTP with Negative Pressure Instrument|In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
214521960|NCT04374435|DEVICE|Suction blister grafting without cell dissociation|In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
214521961|NCT05542004|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
214521962|NCT06408194|DRUG|CD22CART infusion|CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
214521963|NCT06408194|DRUG|Tisagenlecleucel|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
214521964|NCT05488678|DRUG|VNRX-7145|single oral dose
214444679|NCT02256254|DRUG|Placebo|2 placebo capsules every evening for 14 days
214444680|NCT05048186|BEHAVIORAL|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
215120954|NCT01647776|OTHER|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
214444681|NCT05430880|DIAGNOSTIC_TEST|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
214444682|NCT04301596|OTHER|Collection of data|different set of data will be collected over a 6 months period
214444683|NCT00951379|DRUG|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
214444684|NCT00951379|OTHER|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
214444685|NCT00951379|OTHER|laboratory biomarker analysis|Correlative studies
215120955|NCT01647776|PROCEDURE|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
214444686|NCT02467166|DEVICE|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
214444687|NCT04218266|DRUG|BAY2433334|Tablet, taken orally once a day.
214444688|NCT04218266|DRUG|Apixaban|Capsule, taken orally twice a day.
215120956|NCT01647776|OTHER|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
214444689|NCT04218266|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
215120957|NCT01463306|DRUG|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
215120958|NCT00048698|PROCEDURE|TMS|
214444690|NCT04218266|OTHER|Apixaban matching placebo|Capsule, taken orally twice a day.
215120959|NCT00048698|PROCEDURE|EEG|
214444691|NCT02755415|DEVICE|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
215120960|NCT05594628|OTHER|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
215120961|NCT04205721|BEHAVIORAL|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
214444692|NCT02755415|OTHER|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
214444693|NCT02742519|DRUG|ivacaftor|
214444694|NCT02742519|DRUG|Placebo|
214444695|NCT06345586|DRUG|Drospirenone|4 mg tablet once daily
214444696|NCT03452085|DEVICE|artificial saliva spray (AS)|cross over design
214444697|NCT03452085|OTHER|maritime throat spray (TT)|cross over design
214521965|NCT05488678|DRUG|Ceftibuten|single oral dose
214521966|NCT04929236|DRUG|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
215120962|NCT06061835|OTHER|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
215120963|NCT06061835|OTHER|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
215120964|NCT02444325|BEHAVIORAL|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
215120965|NCT01903629|DEVICE|MCE|MCE first, followed by standard gastroscopy
215120966|NCT01903629|DEVICE|Standard gastroscopy|
214521967|NCT03613363|DEVICE|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
215120967|NCT00345618|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
215120968|NCT00345618|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
214521968|NCT06312566|DRUG|brivaracetam (BRV) tablet|Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.
214521969|NCT06312566|DRUG|brivaracetam (BRV) dry syrup|Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
214521970|NCT05208255|OTHER|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
215028836|NCT03097640|OTHER|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
215120969|NCT00345618|DRUG|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
215120970|NCT00345618|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
214444698|NCT01035034|PROCEDURE|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
214444699|NCT01035034|PROCEDURE|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
214521971|NCT06562244|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens (PLH)|The PLH program is the core intervention and will be delivered over 6 sessions with adolescents and caregivers, focusing on building positive parent-child relationships, problem-solving skills, stress management, effective limit-setting, and emotional regulation. There will also be a pre-program visit with the facilitator and families prior to the group sessions. Sessions will include both separate and joint activities between adolescents and caregivers. Engagement boosters will be provided during the PLH sessions and are part of the PLH intervention.
214521972|NCT06562244|BEHAVIORAL|Helping Adolescents Thrive comics|UNICEF's Helping Adolescents Thrive (HAT) comics will be used to guide adolescents through content on improving relationships, handling conflict, understanding emotions, and problem solving. These sessions will be group-based and cover the content in the HAT manual with the adolescents in an interactive format.
214521973|NCT06562244|BEHAVIORAL|I Support My Friends|"An adapted version of UNICEF's I Support My Friends program will be provided to adolescents by a facilitator in a group-based workshop format over the course of 1 day."
214521974|NCT05010031|RADIATION|Palliative radiotherapy|An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
214521975|NCT02430597|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
214521976|NCT02430597|DEVICE|NanoKnife|
214521977|NCT06281938|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
214521978|NCT06281938|OTHER|Standard care weight estimation|Standard care (unspecified) will be used to determine weight-based dosing and other management.
214521979|NCT04736472|DEVICE|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
214444700|NCT00035308|DRUG|Abetimus sodium (LJP 394)|
214444701|NCT05335642|PROCEDURE|EVAR|Endovascular repair of abdominal aortic aneurysms
214444702|NCT04377308|DRUG|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
214521980|NCT02116582|DRUG|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
214521981|NCT04476849|DRUG|fezolinetant|Oral
215028837|NCT02621944|DRUG|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
215028838|NCT02621944|OTHER|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
215028839|NCT02621944|OTHER|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
215028840|NCT02621944|BEHAVIORAL|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
215028841|NCT02510248|DRUG|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
215028842|NCT02510248|DRUG|Placebo|Placebo to match AL-704
214444703|NCT00840229|DRUG|Triamcinolone hexacetonide|20 mg
214444704|NCT00840229|DRUG|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
214444705|NCT03580369|BIOLOGICAL|Ligelizumab|Liquid in vial
214444706|NCT03580369|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
214444707|NCT03580369|OTHER|Placebo|Liquid in vial
214444708|NCT00224445|DRUG|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
214444709|NCT00224445|DRUG|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
214444710|NCT00224445|DRUG|Ritonavir|Ritonavir 100 mg capsule administered orally QD
214444711|NCT04881175|DEVICE|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
215028843|NCT04519567|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
215028844|NCT04519567|BIOLOGICAL|Placebo|Placebo Comparator
215028845|NCT01310751|DRUG|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
215028846|NCT01310751|DRUG|distilled water|2 ml per session
215028847|NCT03524066|DRUG|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
215028848|NCT03524066|DRUG|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
215028849|NCT03524066|OTHER|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
214444712|NCT02824458|DRUG|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
214444713|NCT02824458|DRUG|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
214444714|NCT02824458|DRUG|Placebo|
214444715|NCT00006198|DRUG|thalidomide|
215120971|NCT00345618|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
215120972|NCT00345618|DRUG|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
214444716|NCT00006198|PROCEDURE|chemoembolization with doxorubicin/collagen|
214444717|NCT03189472|DEVICE|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
214444718|NCT03189472|DEVICE|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
214444719|NCT04664270|BEHAVIORAL|e-CBT|e-CBT + Mindfulness + Problem Solving
214444720|NCT04319913|DEVICE|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
214444721|NCT02173717|DRUG|Dabigatran etexilate|150 mg Dabigatran etexilate
214444722|NCT02173717|DRUG|Rifampicin|600 mg Rifampicin
214444723|NCT03041064|OTHER|50/100|SPF
214521982|NCT06012305|OTHER|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
214521983|NCT05626920|DRUG|Disulfiram 250 mg|Disulfiram treatment
214521984|NCT05626920|DRUG|Placebo|Placebo treatment
214521985|NCT01533896|BEHAVIORAL|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
214521986|NCT02978235|DRUG|TAS4464|Intravenous (IV) Infusion
214521987|NCT02465944|DRUG|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
215028850|NCT04426357|DRUG|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
214444724|NCT03041064|OTHER|100/50|SPF
214444725|NCT02886195|DRUG|pemetrexed|500mg/m2 ivgtt d1, per three weeks
214444726|NCT02886195|DRUG|cisplatin|80mg/m2 ivgtt d1, per three weeks
214444727|NCT02886195|DRUG|Erlotinib|150mg po. every day
214444728|NCT03894436|COMBINATION_PRODUCT|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
214444729|NCT03242148|DEVICE|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
214444730|NCT06987877|OTHER|No flushing of the nephrostomy|Subjects allocated to the study intervention group will not flush their nephrostomy tube during the duration of the research study
214444731|NCT06987877|OTHER|Flushing of nephrostomy|Subjects assigned to this cohort will flush their nephrostomy catheter once daily with 10 mL of normal saline
214444732|NCT06677424|DEVICE|NeuroCatch® Platform 2|The NeuroCatch® Platform 2, a medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information. The device is approved as a medical device by Health Canada.
214444733|NCT06699680|DRUG|PRX019|Specified dose on specified days
214444734|NCT06699680|DRUG|Placebo|Placebo
214521988|NCT02465944|DRUG|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
214521989|NCT04895202|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
214521990|NCT03861078|OTHER|Own Brand Cigarette|Effects of own brand cigarette use.
214521991|NCT03861078|OTHER|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
214521992|NCT03861078|OTHER|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
214521993|NCT03861078|OTHER|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
215028851|NCT02071732|DEVICE|real repetitive Transcranial Magnetic Stimulation|
215028852|NCT02071732|DEVICE|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
215028853|NCT06186284|DIAGNOSTIC_TEST|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
215028854|NCT06186284|DIAGNOSTIC_TEST|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
215028855|NCT06186284|DIAGNOSTIC_TEST|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
215028856|NCT06186284|DIAGNOSTIC_TEST|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
215028857|NCT02871440|DRUG|Omega 3|
215028858|NCT02871440|DRUG|Optive Advanced|
215028859|NCT02871440|DRUG|Optive|
215028860|NCT06541587|BEHAVIORAL|mindfulness based virtual reality|mindfulness based virtual reality
215028861|NCT06541587|BEHAVIORAL|mindfulness based audio practice|mindfulness based audio practice
215028862|NCT00159445|DRUG|gemcitabine, capecitabine|
215028863|NCT06407011|OTHER|Control|The CON group did not have any intervention but usual care.
214444735|NCT07043738|PROCEDURE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation (aiTBS) will be administered under the supervision of a physician with TMS expertise.
214444736|NCT07048418|OTHER|Mailing and completing CLEFT-Q and NOSE questionnaires|Mailing and completing CLEFT-Q and NOSE questionnaires
214444737|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
214444738|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
214444739|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
214444740|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
214444741|NCT04774237|DRUG|BRIMOCHOL™|A single drop in each eye at a visit.
214444742|NCT04774237|DRUG|BRIMOCHOL™ F|A single drop in each eye at a visit.
214444743|NCT04774237|DRUG|Carbachol|A single drop in each eye at a visit.
214444744|NCT06898606|OTHER|Psilocybe cubensis and Fluoxetina|Intervention group receiving treatment with fluoxetine associated with a psychotherapy session assisted by a single dose of 3 g of Psilocybe cubensis mushrooms
214444745|NCT06898606|OTHER|Psilocybe cubensis and placebo|control group, which will receive the same treatment with mushrooms, but will use a daily placebo
214444746|NCT07058727|DRUG|Sodium Hypochlorite 2,5%|2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping
214444747|NCT07058727|DRUG|Chlorhexidine|2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group
214444748|NCT07058727|DRUG|Cold Saline|Hemostasis via 4°C saline (1 Min), then standardized pulp capping
214444749|NCT06827379|OTHER|IMT-S (strength)|Composed of 3 sets of 1 minute of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 3 minutes of IMT. The initial load will be individualized according to the MIP, with the load equivalent to 60% of the MIP.
214521994|NCT03861078|OTHER|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
214521995|NCT06315647|PROCEDURE|DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation|comparison between different technique in difficult CBD cannulation
214521996|NCT03074097|DRUG|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
214521997|NCT02950870|DRUG|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
214521998|NCT02950870|DRUG|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
214521999|NCT02950870|DRUG|Ribavirin|Patients will be treated with ribavirin if necessary.
214522000|NCT06339385|BEHAVIORAL|PADIS assessment|Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
214522001|NCT03627130|DRUG|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
214522002|NCT03627130|DRUG|Potassium Chloride|Potassium Chloride capsules for 5 days
214522003|NCT04050319|DIAGNOSTIC_TEST|Screening and diagnosis if injured|physical therapy
214522004|NCT00955565|PROCEDURE|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
214522005|NCT00955565|PROCEDURE|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
214522006|NCT02038114|BEHAVIORAL|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
214522007|NCT02971683|DRUG|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
214522008|NCT02971683|DRUG|Placebo|Placebo of Abatacept subcutaneous
215028864|NCT06407011|OTHER|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
215028865|NCT06407011|OTHER|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
215028866|NCT04647357|DRUG|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
214522009|NCT05692232|OTHER|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
215028867|NCT00255502|DRUG|metoprolol succinate|
215028868|NCT04481841|DRUG|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
214444750|NCT06827379|OTHER|IMT-R (resistance)|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT. The load will also be individualized according to the MIP, with the load equivalent to 30% of the MIP.
214444751|NCT06827379|OTHER|Sham - IMT|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT with a minimum load of 3cmH2O.
214444752|NCT03413982|OTHER|Registry|Patient registry
214444753|NCT07067671|OTHER|Internal Thoracic Impedance|Internal Thoracic Impedance is a non-invasive an imaging technique which use low alternative current through electrodes placed on a belt positioned at the level of the patient's rib cage. Images are constructed according to conductivity measured.
214444754|NCT06767566|DRUG|Ketamine (Ketalar)|Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
214444755|NCT07072416|OTHER|Aquatic Exercise|Aquatic exercise or hydrotherapy, involving the performance of physical exercise in water, has been determined to have an assortment of beneficial health impacts on healthy individuals and those with chronic diseases. Aquatic exercise has been determined to enhance strength, balance, flexibility, and the quality of life, particularly among groups like postmenopausal women, patients with osteoarthritis, Parkinson's disease, and type 2 diabetes
214444756|NCT07072416|OTHER|Mirror Therapy|Mirror therapy is a type of rehabilitation where visual feedback is employed to induce movement and recovery in an affected limb by asking the patients to observe the reflection of their healthy limb in a mirror, giving the illusion that both limbs are moving normally.
214522010|NCT05692232|OTHER|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
214522011|NCT05692232|OTHER|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
214522012|NCT06169774|OTHER|Educational video|Watch the 17-minute educational video as many times as needed within a 12-month period.
215120973|NCT04679974|BEHAVIORAL|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
214444757|NCT07072416|OTHER|Designed physical therapy program.|The program will start with 10 minutes of poolside exercises including warming up, active range of motion and stretching followed by 20 minutes of aquatic exercise in the pool. The pool session consists of 20 minutes of active range of motion, stretching and strengthening exercises
214444758|NCT05527093|RADIATION|MRI 3T and MRI 7T|MRI 3T and MRI 7T before and post epilepsy surgery
214444759|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
214522013|NCT03408821|OTHER|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
215120974|NCT04921228|BEHAVIORAL|Heart rate variability biofeedback|"* 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
214522014|NCT04206501|DEVICE|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
214522015|NCT02713776|DRUG|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
214522016|NCT02713776|DRUG|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
214522017|NCT00067925|BEHAVIORAL|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
214522018|NCT02451553|DRUG|Afatinib Dimaleate|Given PO
214522019|NCT02451553|DRUG|Capecitabine|Given PO
214522020|NCT02451553|OTHER|Laboratory Biomarker Analysis|Correlative studies
214522021|NCT02268526|BIOLOGICAL|CSJ148|CSJ148 IV q 4weeks
214522022|NCT02268526|DRUG|Placebo|Placebo IV q 4weeks
214522023|NCT00023621|DRUG|celecoxib|
214444760|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
214444761|NCT06847139|DRUG|Zinc Sulfate 50 Mg Tab|experimental group will get zinc sulfate
214444762|NCT06847139|DRUG|Folic Acid 5 Mg Oral Tablet|control group will get folic acid
214444763|NCT06754930|DRUG|SHR-1826|SHR-1826 for injection.
214444764|NCT06754930|DRUG|SHR-1316|SHR-1316 for injection.
214444765|NCT06754930|DRUG|SHR-9839|SHR-9839 for injection.
214444766|NCT06754930|DRUG|SHR-8068|SHR-8068 for injection.
214444767|NCT06754930|DRUG|Ametinib mesylate|Ametinib mesylate.
214444768|NCT06754930|DRUG|BP-102|BP-102 for injection.
214444769|NCT06754930|DRUG|Carboplatin|Carboplatin for injection.
214444770|NCT07078266|DEVICE|Magnetocardiography examination|"Magnetocardiography (MCG) is a non-invasive, risk-free, and contactless technology that characterizes the local magnetic field signals generated by the electrical activity of the heart.~the magnetic signals used in magnetocardiograms can pass through the body with almost no interference. Therefore, magnetocardiography theoretically offers more clinically useful information, with the advantages of being non-invasive, safe, and fast, enabling earlier and more accurate diagnoses of potential heart diseases."
214444771|NCT07077148|BEHAVIORAL|Facilitated tucking|The upper and lower extremities of the newborns are taken to the midline and positioned in the womb.
214444772|NCT07077148|BEHAVIORAL|Swaddling|The baby is swaddled using the cloths used in the neonatal intensive care unit.
214444773|NCT07078097|OTHER|Traditional Sape' Dayak Music Listening|This intervention is distinguished by its use of the Sape' Dayak, a specific traditional musical instrument from East Kalimantan, Indonesia, known for its gentle, contemplative, and culturally significant sounds. The music utilizes pentatonic melodies that foster a serene and emotionally relaxing environment. Its distinct rhythm (80-85 beats per minute) is also a key feature. The intervention also incorporates a gentle abdominal massage and imagining the infant.
214444774|NCT07078097|OTHER|Brahms' Lullaby Music Therapy|This intervention is distinguished by its use of a globally popular and well-known lullaby composed by Johannes Brahms. The lyrics typically revolve around themes of love and affection, expressing mothers' love and tenderness for their fetuses. Unlike the Sape' Dayak, the specific lullaby will be preselected by the researcher to ensure a homogeneous intervention, with personal lullaby preferences ignored to avoid bias. Participants also engage in gentle abdominal touching and reflection on their unborn children.
214444775|NCT07079176|DRUG|etomidate combined with propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All patients underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the EP group, patients received 50 μg fentanyl, followed by a slow intravenous injection of a propofol-etomidate mixture (10 mL:20 mg etomidate + 10 mL:100 mg propofol) at 0.1-0.2 mL/kg. Supplemental doses of 0.05 mL/kg were administered as needed to maintain sedation throughout the procedure.
214522024|NCT01565031|PROCEDURE|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
214522025|NCT00596960|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
214522026|NCT00596960|BEHAVIORAL|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
214522027|NCT01158716|OTHER|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
214522028|NCT03147742|DRUG|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
214522029|NCT00801151|DRUG|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
215028869|NCT06563778|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
215028870|NCT06563778|DRUG|Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody|Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
215028871|NCT00209131|DRUG|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
215028872|NCT00209131|DRUG|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
215028873|NCT03925467|OTHER|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
215028874|NCT04347967|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
215028875|NCT03770611|DIETARY_SUPPLEMENT|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
215028876|NCT03770611|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic fiber is Agave inulin
214693510|NCT05766228|OTHER|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
214693511|NCT03945032|OTHER|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
214444776|NCT07079176|DRUG|propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the P group, 50 μg fentanyl was administered, followed by a slow intravenous injection of propofol (1-2 mg/kg) after 3 minutes. Supplemental doses of 0.5 mg/kg were administered as needed to maintain sedation throughout the procedure.
214444777|NCT07076914|DRUG|Experimental (Health Canada Approved Proton Pump Inhibitors)|The intervention uses a proton pump inhibitor as a preventative measure
214444778|NCT07076888|OTHER|Aerobic Exercises|"1. Timing of Exercise:~   Aerobic exercises were performed on non-dialysis days. This scheduling avoids post-dialysis fatigue and hypotensive effects, optimizing patient safety and performance.~2. Frequency:~   Patients was engaged in aerobic exercise 3 times per week on non-consecutive days, to allow sufficient recovery time between sessions.~3. Duration of Each Session:~   * Total Duration: Each exercise session was last between 20 to 45 minutes.~  * Warm-Up: 5-10 minutes of low-intensity activity (e.g., slow walking).~  * Main Exercise: 15-30 minutes of moderate-intensity aerobic exercise.~  * Cool-Down:\*5-10 minutes of gradual reduction in intensity.~4. Exercise Modality:~   * Options: Patients may choose between treadmill walking or using a stationary bike, depending on their preference, physical condition.~  * Variety: To maintain engagement and reduce monotony, patients can alternate between treadmill and bike exercises.~5. Intensity:~Use moderate-intensity exercise, aiming for 60-70% of the p"
214444779|NCT07076888|OTHER|Conventional Program|"1\. Breathing Exercises~\- Diaphragmatic Breathing: Instruct patients to place one hand on their chest and the other on their abdomen. They should inhale deeply through their nose, allowing the abdomen to rise, and then exhale slowly through their mouth. This breathing technique has been shown to reduce stress, improve respiratory efficiency, and enhance relaxation . For optimal benefits, patients should practice this for 5-10 minutes, 2-3 times a day.~Stretching Exercises Hamstring Stretch: Instruct patients to sit with one leg extended straight out in front of them and the other leg bent. They should reach towards the toes of the extended leg while keeping their back straight. Hold the stretch for 20-30 seconds and repeat the stretch 2-3 times per leg.~Lower Limb Circulatory Exercises Ankle Pumps: While lying down or seated, instruct patients to alternately point and flex their feet to stimulate circulation and improve lower leg mobility. Perform 20-30 pumps per foot, 2-3 times a day"
214693512|NCT01225757|DEVICE|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
214693513|NCT04706169|DEVICE|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
214522030|NCT05689424|DRUG|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
214522031|NCT01305837|DRUG|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
214522032|NCT00231166|DRUG|HCD122|
214522033|NCT03874091|PROCEDURE|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
214522034|NCT03874091|PROCEDURE|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
214522035|NCT03874091|DRUG|Morphine PCA pump|Morphine given postoperatively.
214522036|NCT04258306|DIETARY_SUPPLEMENT|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
214522037|NCT04258306|DIETARY_SUPPLEMENT|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
214693514|NCT05321095|DIAGNOSTIC_TEST|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
214693515|NCT05321095|DIAGNOSTIC_TEST|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
214693516|NCT05321095|DIAGNOSTIC_TEST|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
214693517|NCT03725202|DRUG|Upadacitinib|Administered orally once a day
215028877|NCT03770611|DIETARY_SUPPLEMENT|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
215028878|NCT03770611|DIETARY_SUPPLEMENT|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
215028879|NCT05360784|DRUG|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
215028880|NCT05360784|DRUG|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
215120975|NCT05042583|PROCEDURE|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
215120976|NCT04713956|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
215120977|NCT04713956|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
215120978|NCT04713956|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
214444782|NCT07077499|DEVICE|Pulsed Vacuum Cleaning and Disinfection Device|After manual pre-treatment, instruments were placed into the pulsed vacuum cleaning and disinfection machine (Shandong Xinhua Medical, Model PC-150L). The automated program included pulsed vacuum cleaning, rinsing, thermal disinfection (93°C for 2.5 minutes), and vacuum drying.
214444783|NCT07077499|DEVICE|Vacuum Ultrasonic Cleaner|After manual pre-treatment, instruments were cleaned in a vacuum ultrasonic cleaner (Shandong Xinhua Medical, Model super-6000) with a multi-enzyme solution for a minimum of 5 minutes. This was followed by a separate process in a spray cleaning and disinfection machine for rinsing and drying.
214444784|NCT07076875|OTHER|Questioner interview|The 2 questionnaires were translated from English to standard Arabic comprised of three sections, general information, including data and sociodemographic factors such as region of residence, parental education level, child age, child sex, and child order between siblings, Barriers to oral health care needs, including frequency and reasons for dental visits, any previous dental treatment, barriers to treatment such as fear of dentist, distance from the dental clinic, expense of an appointment due to health ban, responsibilities towards family members, not being familiar with appointment booking, and no available appointments, and Comprising of interviewer-administered questionnaires with a five-point Likert scale (strongly agree, agree, uncertain, disagree, strongly disagree) to assess the level of patients' satisfaction with the dental services provided.
214522038|NCT00916318|BEHAVIORAL|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
215120979|NCT04713956|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
215120980|NCT04713956|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
214444785|NCT07078331|DEVICE|OsteoAdapt DE (0.8 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (0.8 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
214444786|NCT07078331|DEVICE|OsteoAdapt DE (2.0 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (2.0 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
214444787|NCT07078331|DEVICE|Xenograft Bone Graft|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted xenograft bone graft by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
214522039|NCT01117532|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
214522040|NCT04201275|DRUG|HEC74647PA capsule|Capsule administered orally once daily
214522041|NCT04201275|DRUG|placebo|HEC74647PA capsule matching placebo administered orally once daily
214522042|NCT05945979|DIETARY_SUPPLEMENT|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
214444788|NCT05606406|OTHER|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
214444789|NCT05208814|DRUG|TPN171H single dose|10 mg TPN171H taken once
214444790|NCT01722916|DRUG|Hyaluronidase|
214444791|NCT05297734|OTHER|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
214444792|NCT05297734|BEHAVIORAL|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
214444793|NCT06494618|DEVICE|Radial Extracorporeal Shockwave Therapy|1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
214522043|NCT03307993|DRUG|Idalopirdine|Idalopirdine 60-120 mg daily dose
214522044|NCT05910788|DEVICE|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
214522045|NCT00459433|PROCEDURE|Biopsychosocial intervention|Psychosocial versus usual care
214522046|NCT02303613|OTHER|Mapping|Mapping of current triage situation regarding 30 days mortality
214522047|NCT05404178|OTHER|Type 2 diabetes group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
214522048|NCT05360134|DRUG|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
214522049|NCT05360134|OTHER|Placebo|Placebo will be given in a similar manner
214444794|NCT05828953|DRUG|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
214444795|NCT05828953|DRUG|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
214444796|NCT06829524|DRUG|Satralizumab|Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.
214444797|NCT05746117|DEVICE|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
214444798|NCT05746117|DEVICE|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
214444799|NCT06629714|OTHER|Exposure: emotional distress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
214444800|NCT04333290|DRUG|[11C]MeDAS|PET radiotracer
214444801|NCT05088590|DIETARY_SUPPLEMENT|Enfagrow® Neuropro Toddler Nutritional Drink|Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
214444802|NCT05088590|DIETARY_SUPPLEMENT|Pediasure® Grow & Gain Protein Shake for Kids|Pediasure® Grow \& Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
214444803|NCT06829706|DEVICE|Conventional olfactory training device|Conventional olfactory training was designed by Hummel et al. They performed OT using four odors (phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronella, lemon; and eugenol, cloves), which are representative of four odor categories on the odor prism proposed by Henning.
214444804|NCT06829706|DEVICE|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. Its bidirectional airflow and unidirectional pressure characteristics significantly increased the deposition rate of olfactory odors in the olfactory cleft area, making the patient feel stronger in the nasal cavity during olfactory training.
214522050|NCT02303509|DRUG|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
214522051|NCT02303509|DRUG|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
214522052|NCT02303509|OTHER|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
214522053|NCT00327314|PROCEDURE|Transplantation|
214522054|NCT00327314|PROCEDURE|Hematopoietic cell transplantation|
214522055|NCT04400214|BEHAVIORAL|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
214522056|NCT04400214|OTHER|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
214522057|NCT03941769|BIOLOGICAL|Recombinant Interleukin-7|Given IM or SC
214522058|NCT06646978|DRUG|Imatinib (STI571)|Imatinib-based regimen
215120981|NCT01142622|DRUG|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
215120982|NCT01142622|DRUG|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
215120983|NCT03878680|OTHER|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis."
215120984|NCT03094533|DRUG|TIVA|total intravenous anesthesia with propofol
215120985|NCT03094533|DRUG|VIMA|volatile induction and maintenance anesthesia with sevoflurane
214444805|NCT06829706|DEVICE|Conventional olfactory training device with placebo|Based on the traditional olfactory training device, four olfactory odors are replaced by placebo。
214444806|NCT04923347|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered
214444807|NCT04923347|DEVICE|ELLIPTA|Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
214444808|NCT05196815|OTHER|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
214444809|NCT05196815|PROCEDURE|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
214444810|NCT05196815|PROCEDURE|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
214444811|NCT05196815|RADIATION|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
214444812|NCT05196815|DRUG|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
214444813|NCT05105360|PROCEDURE|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
214444814|NCT05105360|PROCEDURE|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
214444815|NCT05014165|OTHER|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
214444816|NCT05014165|OTHER|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
214444817|NCT05014165|OTHER|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
214522059|NCT06646315|BEHAVIORAL|Early Intervention|The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
214522060|NCT03722602|OTHER|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
214522061|NCT06247761|DEVICE|Skin closure at end of hand surgery|skin closure with vicryl rapide suture
214522062|NCT00872404|DRUG|CP-751,871|20mg/kg/3 weeks
214522063|NCT01601925|OTHER|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
214522064|NCT00658177|DRUG|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
214522065|NCT00658177|DRUG|Placebo|Matching placebo
214522066|NCT03109600|BIOLOGICAL|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
214522067|NCT03109600|BIOLOGICAL|Vi polysaccharide vaccine|Vi polysaccharide vaccine
214522068|NCT03109600|BIOLOGICAL|Influenzae vaccine|1 dose of Influenzae vaccine
214522069|NCT03109600|BIOLOGICAL|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
214444818|NCT05563636|DEVICE|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
214522070|NCT00441571|DRUG|177Lu-CYT-500|
214522071|NCT00336375|DRUG|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
214522072|NCT02241980|OTHER|Patient survey|
214522073|NCT02241980|OTHER|Physician survey|
214522074|NCT01292005|DRUG|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
214522075|NCT01292005|DRUG|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
214522076|NCT03293147|OTHER|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
214522077|NCT03293147|OTHER|Standard care|Standard care for hypertensive patients
214522078|NCT04140422|OTHER|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
214522079|NCT04140422|OTHER|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
214522080|NCT01060163|DRUG|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
214522081|NCT01060163|DRUG|Saline|Saline served as placebo
214444819|NCT05563636|DEVICE|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
214444820|NCT06251986|OTHER|ofatumumab|This is an observational study, there is no treatment allocation.
214444821|NCT04032899|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
215120986|NCT03658733|DRUG|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
214444822|NCT04032899|DIETARY_SUPPLEMENT|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
214444823|NCT05481658|DRUG|Diphencyprone (DPCP)|topical immunomodulator
215120987|NCT03658733|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
214522082|NCT00347425|DRUG|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
214522083|NCT00347425|DRUG|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
215120988|NCT03478033|DRUG|Rifampicin|Rifampicin capsules, 150mg
215120989|NCT03478033|DRUG|Rifabutin|Rifabutin capsules, 150mg
215120990|NCT01568294|DRUG|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
214444824|NCT05673499|DEVICE|NIRS/EEG monitoring|The study intervention will be monitoring NIRS and EEG for one hour before surgery, during surgery, and up to 8-24 hours after surgery.
214444825|NCT06186206|BEHAVIORAL|Social media interventions for vaccine uptake|"Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates."
214444826|NCT06335641|DEVICE|External active conductive head cooling|Cooling is applied during the endovascular thrombectomy procedure for a maximum of 120 minutes
214444827|NCT05163899|PROCEDURE|Release of filum terminale|Surgery will be offered to section the filum terminale
214444828|NCT04341376|BEHAVIORAL|Enhanced First Connections|Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
214444829|NCT06366451|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
214522084|NCT00347425|DRUG|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
214522085|NCT00347425|DRUG|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
214522086|NCT00347425|DRUG|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
214522087|NCT00347425|DRUG|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
215120991|NCT02679287|DEVICE|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
215120992|NCT02956187|BEHAVIORAL|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
214444830|NCT06366451|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
214444831|NCT06366451|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
214444832|NCT06366451|BIOLOGICAL|AZD9592|Intratumoral microdose injection by the CIVO device.
214444833|NCT06366451|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214444834|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Rilvegostomig|Intratumoral microdose injection by the CIVO device.
214444835|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Volrustomig|Intratumoral microdose injection by the CIVO device.
214444836|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Sabestomig|Intratumoral microdose injection by the CIVO device.
214444837|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214522088|NCT00347425|DRUG|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
214522089|NCT00347425|DRUG|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
215120993|NCT02956187|DIETARY_SUPPLEMENT|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
214444838|NCT06710002|BEHAVIORAL|Pelvify: Menopause and dyspareunia treatment|"Topics addressed in the Asynchronous Online Telerehabilitation Program would be:~1. What it is and why it hurts during sex. What is dyspareunia?~2. How to recover vaginal elasticity.~3. Massage~4. Self-palpation.~5. Stretching of the pelvic floor muscles.~6. Use of vaginal dilators.~7. Moisturizers and lubricants.~8. Sexual pleasure.~9. Communication with the partner."
214444839|NCT06710002|OTHER|Face to Face Physical Therapy Protocol|"Physical Therapy Protocol will be based on:~1. Health education:~2. CMRF: INDIBA® ACTIV CT8 will be used to apply the radiofrequency~3. Manual therapy: it will be based on performing the Thiele's massage.~4. Vaginal dilators: FEMINAFORM® vaginal dilators will be used."
214444840|NCT06710002|OTHER|Face to Face Protocol Combined With an Asynchronous Telerehabilitation Program|Both, the face to face protocol and the Asynchronous Telerehabilitation Program will be carried on on this group.
215029357|NCT04832659|BEHAVIORAL|CEASE|The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
215120994|NCT03963648|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
214444841|NCT06737822|COMBINATION_PRODUCT|TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment|"TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment."
214444842|NCT06737822|COMBINATION_PRODUCT|Surgery and Adjuvant Treatment|Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
214444843|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
214444844|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
214444845|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
214444846|NCT03166150|OTHER|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
214444847|NCT03166150|OTHER|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
214444848|NCT06739161|RADIATION|Sintilimab combined with chemotherapy and local treatment|"Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable."
214522090|NCT00347425|DRUG|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
214522091|NCT00347425|DRUG|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
214522092|NCT00138814|PROCEDURE|Radiotherapy (boost versus no boost)|
214522093|NCT05811000|DRUG|PM012|PM012 650 mg tablet drug
214522094|NCT05811000|DRUG|PM012 Placebo|PM012 tablet placebo
214522095|NCT05811000|DRUG|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
214522096|NCT05811000|DRUG|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
214522097|NCT00930319|OTHER|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
214522098|NCT06576037|DRUG|CBP-1019|Given by vein (IV)
214522099|NCT06576037|DRUG|Oxaliplatin|Given by vein (IV)
214522100|NCT06576037|DRUG|Leucovorin|Given by vein (IV)
214522101|NCT06576037|DRUG|5-FLUOROURACIL|Given by vein (IV)
214522102|NCT06576037|DRUG|Bevacizumab|Given by vein (IV)
215120995|NCT01840345|DRUG|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
215120996|NCT04793113|OTHER|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
215120997|NCT02699710|DRUG|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
215120998|NCT02699710|DRUG|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
214522103|NCT06576037|DRUG|Pembrolizumab|Given by vein (IV)
214522104|NCT06576037|DRUG|Enzalutamide|Given by mouth
214522105|NCT04682483|DRUG|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
214522106|NCT04682483|DRUG|Inotrope|Inotropes include dobutamine and milrinone.
214522107|NCT04682483|DEVICE|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
214522108|NCT02130401|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
214522109|NCT01270906|DRUG|CHIR-258 (TKI258)|
214522110|NCT01731210|DEVICE|implantation of the new LV lead: NANO system.|
215120999|NCT02699710|DRUG|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
214444849|NCT06739161|COMBINATION_PRODUCT|Sintilimab combined with chemotherapy only|"Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."
214444850|NCT02960230|BIOLOGICAL|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
214444851|NCT02960230|DRUG|Nivolumab|anti-programmed cell death protein 1 (PD-1) monoclonal antibody
214444852|NCT02216864|PROCEDURE|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
214444853|NCT06066541|BEHAVIORAL|Scorecard|"Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score."
214444854|NCT06066541|BEHAVIORAL|Social norms|Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).
214444855|NCT06066541|BEHAVIORAL|Messenger effects|Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.
214444856|NCT06066541|BEHAVIORAL|Processing fluency|"Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring."
214444857|NCT06779838|OTHER|Group Emotion Focused Therapy Intervention|The EFT group intervention: Taming the Inner Critic: Emotion-Focused Group Therapy for Eating and Body Concerns. This group is a 10-12 week (number of participants=8-10 +2 sessions) closed therapy group for students seeking support regarding issues related to eating and/or body concerns. Working one-to-one and within the group, group members will be facilitated to recognise and explore some of the difficult emotions underlying and driving eating and/or body related issues. In particular, the group will focus on 'taming' the inner critic, that part of ourselves that criticises or chastises us for not being good enough. By identifying the critic in ourselves and by witnessing it in others, group members will be better positioned to figure out what they really need from themselves at times of difficulty, and thus better able to access self-compassion and self-assertion. There will be some psychoeducation, both around eating and emotions, but this will be largely in a handout format, with
214444858|NCT06779838|OTHER|Treatment as Usual (TAU)|Treatment that would otherwise be offered by the university counselling service (one on one counselling, a group, or signposting to external support).
214522111|NCT05693428|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
214522112|NCT05693428|DRUG|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
214522113|NCT05693428|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
214522114|NCT01667159|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
215028881|NCT05218083|BEHAVIORAL|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation \& personalized instruction \& coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities \& general resistance exercises for major muscle groups.~Balance incorporates static \& dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward \& backward starting within base of support \& progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
214444859|NCT06780839|DRUG|Ensartinib|Patients will receive Ensartinib 225mg QD by MRD test guided, if MRD test shows negative, only ensartinib will be given. if MRD test turns from negative to posive, patients will receive step-up treatment, which is ensartibe plus platinum - based doublet chemotherapy no more than 4 cycles. If MRD test turns from posive to negative, only ensartinib will be given. if MRD test constantly shows positive, MDT will determine the next step ensartib-based therapy.
214444860|NCT04714671|OTHER|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
214444861|NCT05281484|DRUG|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
214522115|NCT01667159|BEHAVIORAL|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
214522116|NCT03612388|PROCEDURE|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
214444862|NCT06782126|BEHAVIORAL|BreeZe (Brandwonden en Zelfmanagement)|BreeZe is a self-management support program designed to enhance burn survivors' intrinsic motivation and self-efficacy for self-management after discharge. The intervention is based on the Self-Regulation Theory framework. Key strategies include evidence-based techniques such as goal setting and pursuit, Solution-Focused Brief Therapy, and Motivational Interviewing. The program takes a positive approach to boost motivation and self-efficacy, promoting sustainable behavior change in burn aftercare. BreeZe will be implemented through various strategies, including educating healthcare professionals on self-management, training them in communication skills (e.g., motivational interviewing), and providing materials such as a decision aid tool (self-management web) and a workbook tailored to burn survivors. Burn survivors will use the web to identify and prioritize problems, set personalized goals with their healthcare professional, and create an action plan for goal attainment.
214693518|NCT03725202|DRUG|Corticosteroid (CS)|At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
214444863|NCT05276063|DRUG|Linsitinib|Study medication taken twice daily by mouth
214444864|NCT05276063|DRUG|Placebo|Placebo taken twice daily by mouth
214522117|NCT05414825|OTHER|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
214522118|NCT06012214|PROCEDURE|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
214522119|NCT00388856|DRUG|Vitamin C 1000mg and E 400IU|
214522120|NCT05410717|BIOLOGICAL|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
215028882|NCT05142306|BIOLOGICAL|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
215121000|NCT02699710|DRUG|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
214444865|NCT06164197|DEVICE|Lokomat|Robot Assisted Gait Training
214444866|NCT06164197|DEVICE|Thera Trainer Balo|Virtual Reality Based Balance Training Device
214444867|NCT06164197|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
214522121|NCT01400997|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
214522122|NCT00936065|DRUG|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
214522123|NCT00936065|DRUG|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
214522124|NCT00936065|DRUG|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
214693519|NCT03725202|OTHER|Placebo|Administered orally once a day
214693520|NCT02557386|DRUG|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
214693521|NCT02557386|DRUG|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
214693522|NCT02557386|DRUG|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
214693523|NCT02557386|DRUG|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
214693524|NCT02557386|DRUG|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
215028883|NCT01143441|BIOLOGICAL|DAC-HYP|
215028884|NCT02251041|DRUG|Antithrombin-III|
215028885|NCT02251041|DRUG|Infliximab|
215028886|NCT02251041|DRUG|Apotransferrin|
215028887|NCT02251041|DRUG|Human recombinant erythropoietin|
215028888|NCT02251041|DRUG|C1-Inhibitor|
215028889|NCT02251041|DRUG|Glutathione|
215028890|NCT02251041|DRUG|Alfa-tocopherol|
215028891|NCT02251041|DRUG|Melatonin|
215028892|NCT02251041|DRUG|Epoprostenol|
215028893|NCT02251041|DRUG|Sodium chloride solution|
215028894|NCT03779620|DEVICE|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
215028895|NCT06395220|OTHER|Detection of donor-specific anti-HLA antibody (DSA)|"Detection methods~1. . Morphology: using microscope to observe the morphology of bone marrow.~2. . Immunophenotyping: using multi-color flow cytometry (MFC) to detect immunophenotype of leukemia cells and leukemia-associated immunophenotype of bone marrow samples.~3. . Cytogenetics analysis: G-band and/or fluorescence in situ hybridization (FISH) analysis are used in this study~4. . Molecular detection: Real-time quantitative RT-PCR (RQ-PCR) and/or next generation sequencing techniques are used to detect the molecular marker, such as: PML/RARA, AML-ETO, BCR/ABL, and WT1.~5. . HLA-Typing: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined according to the literatures published by our group \[Huo MR, et al. Bone Marrow Transplant. 2018;53(5):600-608\]..~6. . Other analyses: Detection of minimal residual diseases were performed using MFC and RQ-PCR according to the methods reported by our group \[Li SQ, et al. Blood,2022;140(5):516-520\]."
215028896|NCT06332755|DRUG|LB-LR1109|intravenous administration
215028897|NCT05681078|BEHAVIORAL|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
215121001|NCT00374933|DRUG|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
215121002|NCT00374933|DRUG|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
215121003|NCT00374933|DRUG|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
215121004|NCT04408040|BIOLOGICAL|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
215121005|NCT06356051|DEVICE|Echocardiography|cardiovascular evaluation
215121006|NCT02628353|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
215121007|NCT02628353|DIETARY_SUPPLEMENT|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
215121008|NCT05481489|DRUG|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
215121009|NCT02679170|DRUG|Crizotinib|Treatment with crizotinib following routine clinical practice
215121010|NCT05331586|BEHAVIORAL|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
215121011|NCT04966949|PROCEDURE|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
215121012|NCT00992459|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
214444868|NCT06552468|DEVICE|AF monitoring by a smartwatch with PPG|The device we used for intervention is a smartwatch (JKwear 1, Chengdu CVhealth Science and Technology Co., Ltd, CN) for collecting watch-recorded-PPG (W-PPG).
214522125|NCT06505252|PROCEDURE|enoscopic Myringoplasty|"general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat"
214522126|NCT06124170|PROCEDURE|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
214522127|NCT06124170|PROCEDURE|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
214522128|NCT06124170|PROCEDURE|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
214693525|NCT02557386|DRUG|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
214693526|NCT00376987|DIETARY_SUPPLEMENT|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
214693527|NCT04093817|DEVICE|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
214693528|NCT06157879|DEVICE|WVI-MIS-01-2022|Microwave scans
215121013|NCT00992459|DRUG|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
215121014|NCT02154841|BEHAVIORAL|Questionnaire, taste test, visual food test|
215121015|NCT01166204|RADIATION|Radiotherapy|Radiotherapy
215121016|NCT04219904|OTHER|Fludeoxyglucose F-18|Given IV
215121017|NCT04219904|DRUG|Gadobutrol|Given IV
215121018|NCT04219904|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
215121019|NCT04219904|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
215121020|NCT00543387|DRUG|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
215121021|NCT00543387|DRUG|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
215121022|NCT04627207|DRUG|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
215121023|NCT04627207|DRUG|CKD-333 1 Tab|Other names: Test
214444869|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
214444870|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
214444871|NCT05728489|DRUG|BI 765250|BI 765250
214444872|NCT05728489|DRUG|Placebo|placebo
214444873|NCT05698017|BIOLOGICAL|hOMSC300|Human Oral Mucosa Stem Cells
215121024|NCT03611673|OTHER|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
215121025|NCT04201613|DEVICE|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
215121026|NCT04201613|BEHAVIORAL|Usual Care|This group will receive standard care with no additional therapy.
215121027|NCT05109923|DIETARY_SUPPLEMENT|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
215121028|NCT05109923|DIETARY_SUPPLEMENT|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
214522129|NCT01584596|BEHAVIORAL|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
214522130|NCT01584596|BEHAVIORAL|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
215121029|NCT04532905|OTHER|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
215121030|NCT00083005|DRUG|docetaxel|
215121031|NCT00083005|DRUG|estramustine phosphate sodium|
215121032|NCT00083005|DRUG|thalidomide|
215121033|NCT04532775|DRUG|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
214522131|NCT00070317|DRUG|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
214522132|NCT00070317|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping
215121034|NCT04532775|DRUG|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
214444874|NCT00984321|BEHAVIORAL|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
214522133|NCT00070317|PROCEDURE|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
214693529|NCT05975775|PROCEDURE|Laparoscopic radical prostatectomy|Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
214693530|NCT03130023|DEVICE|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
214693531|NCT04987983|OTHER|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
214693532|NCT04987983|OTHER|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
214693533|NCT00735124|DRUG|Gabapentin|1200 mg single dose gabapentin
214693534|NCT00735124|OTHER|placebo|Injection of placebo/sham
214693535|NCT01060735|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
215121035|NCT04532775|DRUG|Bupivacaine Hydrochloride|local anesthetic drug
215121036|NCT04532775|DRUG|saline 0.9%|solution for intravenous and epidural injection
215121037|NCT04520399|OTHER|none intervention|there is no intervention in this study
215121038|NCT02742545|BEHAVIORAL|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
215121039|NCT05429398|DRUG|Linperlisib Tablet|"1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
215121040|NCT00169156|DRUG|Rituximab|375 mg/m2 D1
215121041|NCT00169156|DRUG|Prednisone|40 mg/m2 D1 to D5
215121042|NCT00169156|DRUG|Doxorubicine|50 mg/m2 D1
215121043|NCT00169156|DRUG|Cyclophosphamide|750 mg/m2 D1
215121044|NCT00169156|DRUG|Vincristine|1,4 mg/m2 D1
215121045|NCT01904045|OTHER|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
215121046|NCT01904045|OTHER|tacrolimus Prograf|intake of Prograf twice daily for 3 months
215121047|NCT02903498|DRUG|UFT|UFT 360mg/m2 qd po d1-14, q3w
215121048|NCT00940498|DRUG|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
215121049|NCT04826939|DEVICE|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
215121050|NCT03683953|OTHER|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
215121051|NCT03683953|DRUG|0.9% sodium chloride|0.9% sodium chloride in control group
214444875|NCT00984321|BEHAVIORAL|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
214444876|NCT00984321|BEHAVIORAL|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
214522134|NCT00070317|DRUG|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
215121052|NCT00256802|DEVICE|MR-angiography, GTN|
215121053|NCT02457676|BEHAVIORAL|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
215121054|NCT02425059|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
215121055|NCT02425059|DEVICE|NanoKnife|
215121056|NCT03589027|DRUG|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
215121057|NCT03589027|DRUG|Rilpivirine|Oral ripilvirine 25mg once daily
215121058|NCT03589027|DRUG|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
214444877|NCT05807711|DRUG|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
215121059|NCT00158041|DRUG|Amifostine administered subcutaneously|
215121060|NCT01047982|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
215121061|NCT01047982|OTHER|folic acid 400 mcg|2 pills a day
215121062|NCT03160820|BIOLOGICAL|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
214522135|NCT00070317|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
215121063|NCT03963843|BEHAVIORAL|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
214522136|NCT00070317|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
214522137|NCT00070317|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
214522138|NCT00070317|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical hysterectomy
214522139|NCT00309439|PROCEDURE|ALA-rich diet|
214522140|NCT01429285|DRUG|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
214522141|NCT01429285|DRUG|Usual care|Attending administers any IV opioid in any dose he chooses
214522142|NCT01885559|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
214522143|NCT01885559|DRUG|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
214522144|NCT01885559|DRUG|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
214522145|NCT03120936|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
214522146|NCT03120936|BEHAVIORAL|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
214522147|NCT02791295|OTHER|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
214522148|NCT01399606|DRUG|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
214693536|NCT01247220|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
214693537|NCT01247220|PROCEDURE|Peripheral Laser|Angiography-directed peripheral laser
214444878|NCT05733715|DRUG|Pembrolizumab infusion|100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
214444879|NCT05733715|DRUG|Lenvatinib tablet|10mg and 4mg daily for 21 days
214693538|NCT06133647|PROCEDURE|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
214693539|NCT02783794|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
214444880|NCT04022343|DRUG|Cabozantinib|Given PO
214444881|NCT04128904|PROCEDURE|IVF|"Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description."
214444882|NCT04128904|PROCEDURE|ICSI|"Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description."
214522149|NCT05703412|BEHAVIORAL|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
214522150|NCT05703412|BEHAVIORAL|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
214522151|NCT04373291|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
214522152|NCT04373291|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
214522153|NCT03382704|DIAGNOSTIC_TEST|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
214522154|NCT01443572|DRUG|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
214522155|NCT01443572|DRUG|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
214522156|NCT06510400|OTHER|OMNICHROMA|supra nano filled composite
214522157|NCT06510400|OTHER|Ceram. x spectra|nano hybrid composite resin
214522158|NCT05366478|DRUG|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
214522159|NCT04981431|DRUG|Elinzanetant (BAY3427080)|Oral administration
214522160|NCT04981431|DRUG|Placebo|Oral administration
214522161|NCT02680145|DEVICE|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
214693540|NCT02783794|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
214693541|NCT01328249|DRUG|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
215121064|NCT03963843|OTHER|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
215121065|NCT00791752|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
215121066|NCT00791752|DRUG|Placebo|Placebo
215121067|NCT03944512|DRUG|Pravastatin|20 mg Pravastatin taken daily
215121068|NCT03944512|OTHER|Placebo|Identical appearing placebo pill
215121069|NCT04499625|PROCEDURE|Sinus floor elevation|
215121070|NCT04499625|DEVICE|Sinus floor elevation using an ultrasonic device|
215121071|NCT00927212|DRUG|AS101 ointment|Twice daily topical application
214444883|NCT03055858|DEVICE|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
214444884|NCT04586920|DRUG|LY3509754|Administered orally
214444885|NCT04586920|DRUG|Placebo|Administered orally
214444886|NCT04586920|DRUG|Itraconazole|Administered orally
214444887|NCT04586920|DRUG|Midazolam|Administered orally
214522162|NCT02827110|DEVICE|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
214522163|NCT02827110|DEVICE|pentax-airway scope|Tracheal intubation using pentax-AWS
214693542|NCT03226080|DRUG|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
214693543|NCT03226080|DRUG|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
214693544|NCT03226080|DRUG|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
214522164|NCT02827110|PROCEDURE|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
214522165|NCT02694107|OTHER|Proprioceptive exercises|
214522166|NCT02694107|OTHER|Control|
214522167|NCT06189898|DIAGNOSTIC_TEST|Re Staging FDG-PET|Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).
214522168|NCT06519448|DRUG|Empagliflozin 10 miligrams (mg)|Use of empagliflozin 10 mg daily for 12 months.
214522169|NCT01542502|DRUG|Anakinra|Anakinra 100 mg daily subcutaneous injection
214522170|NCT01542502|DRUG|Placebo|Placebo daily subcutaneous injection
214522171|NCT03410680|BEHAVIORAL|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
214522172|NCT06459167|OTHER|The position adopted when patients undergoing procedure or surgery|For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
214522173|NCT01052714|BEHAVIORAL|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
214522174|NCT00631202|DRUG|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
214522175|NCT01389791|DRUG|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
214693545|NCT06054022|DEVICE|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
214693546|NCT06054022|DEVICE|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
214693547|NCT01215734|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
214693548|NCT01215734|BIOLOGICAL|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
214693549|NCT02294409|BEHAVIORAL|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
214693550|NCT02294409|BEHAVIORAL|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
214693551|NCT05476185|BEHAVIORAL|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
215028898|NCT04918771|DRUG|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
215028899|NCT04918771|DRUG|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
215028900|NCT04331951|DIAGNOSTIC_TEST|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
215028901|NCT01046669|DEVICE|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
214522176|NCT01389791|DRUG|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
214522177|NCT01389791|DRUG|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
214522178|NCT02168153|OTHER|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
215028902|NCT01046669|OTHER|Standard medical care for septic shock|Standard medical care for septic shock
215121072|NCT03053843|DIETARY_SUPPLEMENT|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
214444888|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
214444889|NCT04761302|DRUG|Intravenous ketorolac and oral acetaminophen|ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group
214444890|NCT04761302|DRUG|Intravenous morphine and oral oxycodone|Morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
214444891|NCT06473844|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg once daily from recruitment to hospital discharge
214444892|NCT06473844|DRUG|Placebo|Placebo single tablet once daily from recruitment to hospital discharge
214444893|NCT03281902|PROCEDURE|Biopsy|Undergo tumor biopsy
214444894|NCT03281902|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
214444895|NCT03281902|OTHER|Laboratory Biomarker Analysis|Correlative studies
214444896|NCT02697123|OTHER|antepartum and postpartum|This is a prospective observational cohort study.
214444897|NCT05620641|DRUG|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
214444898|NCT05620641|DRUG|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
214444899|NCT04052516|DRUG|Icosabutate|Icosabutate oral capsule once daily
214522179|NCT02168153|OTHER|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
214522180|NCT04623996|DRUG|TP-0184|Oral dose
214522181|NCT02355106|DEVICE|PolarStart System|Atrial flutter Ablation
214522182|NCT00380809|PROCEDURE|Rotational Atherectomy + PES|
214522183|NCT00380809|PROCEDURE|Standard Treatment (PES without Rotational Atherectomy)|
214522184|NCT03584282|BEHAVIORAL|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
215121073|NCT02380911|OTHER|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
215121074|NCT01453010|OTHER|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
214444900|NCT04052516|DRUG|Placebo|Matching placebo oral capsule
214444901|NCT05790707|PROCEDURE|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
214444902|NCT05790707|DRUG|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
214522185|NCT03584282|BEHAVIORAL|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
215121075|NCT01091012|DRUG|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
214522186|NCT02492126|OTHER|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
215028903|NCT02062684|DRUG|Blisibimod|
215028904|NCT02062684|DRUG|Placebo|
215028905|NCT03434899|BEHAVIORAL|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
215028906|NCT03434899|BEHAVIORAL|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
215028907|NCT00200239|BEHAVIORAL|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
214444903|NCT05679297|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~2. Thermal pain threshold~3. Mechanical detection thresholds for touch~4. Mechanical pain threshold for pinprick stimuli~5. Stimulus-response functions~6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~7. Vibration detection threshold~8. Pressure pain threshold"
214444904|NCT05679297|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
214444905|NCT05679297|OTHER|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
214444906|NCT05679297|OTHER|Follow-up interview|"Structured telephone interview with 3 Questionnaires~1. The german pain questionnaire~2. Questionnaire regarding clinical development since the last visit designed by the investigators~3. German translation of 12-item-allodynia symptom checklist (ASC-12)"
214444907|NCT04684108|DRUG|SG301|Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
214444908|NCT06792344|OTHER|anti-CD19 CAR-T cells|Intravenous injection the targeting CD19 CAR T cell
214444909|NCT06792344|DRUG|anti-CD19 CAR-T cells|CD19-targeting CAR-T cells
214444910|NCT05753410|BEHAVIORAL|Mindful Courage|Self-guided online intervention
214444911|NCT06087614|RADIATION|DE-HyART|The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
214444912|NCT06087614|RADIATION|Standard Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
214444913|NCT06087614|DRUG|Cisplatin injection|Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
214444914|NCT06087614|RADIATION|Standard fractionation (Radiation Oncology preference)|Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
214444915|NCT03625323|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
214444916|NCT03625323|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
214444917|NCT03948763|BIOLOGICAL|V941|V941 administered IM, Q3W for 9 3-week cycles
214444918|NCT03948763|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
214522187|NCT05871502|DEVICE|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
214522188|NCT00605605|DRUG|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
215028908|NCT02915601|DRUG|Sodium bicarbonate|
215028909|NCT02915601|DRUG|Placebo|
214444919|NCT05415436|OTHER|Propofol slow administration|Propofol will be slowly administered over 120 seconds by anesthesia provider
214444920|NCT06188247|DEVICE|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
214444921|NCT01745965|DRUG|T-DM1|
215028910|NCT03794726|PROCEDURE|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
215028911|NCT03794726|PROCEDURE|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
215028912|NCT00680914|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
215028913|NCT00680914|BIOLOGICAL|Prevenar|3 doses administered intramuscularly.
215028914|NCT00680914|BIOLOGICAL|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
215028915|NCT02848027|BIOLOGICAL|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
214444922|NCT01745965|DRUG|Trastuzumab|
214444923|NCT06269744|BEHAVIORAL|Proactive Screening Outreach|Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
214444924|NCT06170489|BIOLOGICAL|JS004 in combination with Toripalimab|Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
214444925|NCT06170489|DRUG|Bendamustine or gemcitabine|Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
214444926|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
214444927|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
214444928|NCT05563857|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214444929|NCT05563857|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214444930|NCT03537586|DRUG|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
214444931|NCT03537586|DRUG|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
214444932|NCT03537586|DRUG|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
214444933|NCT03537586|DEVICE|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
214444934|NCT03537586|DEVICE|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
214444935|NCT04362839|BIOLOGICAL|Ipilimumab|Given IV
214444936|NCT04362839|BIOLOGICAL|Nivolumab|Given IV
214444937|NCT04362839|DRUG|Regorafenib|Given PO
214444938|NCT05508763|GENETIC|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
214444939|NCT04962126|DRUG|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
214444940|NCT04962126|DRUG|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
214444941|NCT04962126|RADIATION|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
214444942|NCT00753987|DRUG|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
214522189|NCT01853904|PROCEDURE|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
214522190|NCT01853904|PROCEDURE|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
214693552|NCT05658185|BEHAVIORAL|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:"
214444943|NCT06800001|OTHER|Physical Activity|Physical Activity is an 8-week practical intervention for managing the stereotyped behavior \& anxiety. Week 1: Introduction - Build engagement with the help of rapport building. Learn \& practice ball-tapping exercise with warm up \& cool down relaxation exercise. Week 2: Calmness- Practice jumping in trampoline exercise and learn balloon breathing exercise that give calmness. Week 3: Focus enhancement-Learn skills of jumping exercise to increase focus and improve impulse. Week 4: Strength, balance, and stress relief -explore the gym ball exercise in different directions that improves emotional regulation. Week 5: self control - Learn strategies for specific jumping patterns that improves impulse control and focus in children with ASD. Week 6: Reduce Stereotyped Behaviors - Learn complex trampoline exercises. Week 7: Skill Reinforcement- Review exercises, increasing speed or direction changes. Week 8: Integration -Encourage playful interaction to maintain engagement \& consolidate skills.
214693553|NCT01406847|OTHER|Spinal Manipulation|High velocity low amplitude joint-biased intervention
214693554|NCT01406847|OTHER|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
214693555|NCT01406847|OTHER|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
214693556|NCT00623454|BEHAVIORAL|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
214693557|NCT00748553|DRUG|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
214693558|NCT00748553|DRUG|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
214444944|NCT06417996|OTHER|Digital Group|Once patients are ready for discharge, patients in the digital group will be sent home with the Biobeat digital monitoring kit with written \& oral instructions on how it will be used in maintaining continuity of care which will track ECG (electrocardiogram), HR, NIBP, SPO2, and pain scores. A continuous recording and two-lead ECG patch will be applied and activated at the time of discharge to identify any paroxysmal atrial fibrillation.
214444945|NCT06785285|DRUG|Dexmedetomidine|To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
214444946|NCT06436755|PROCEDURE|no intervention,this is a observational studies|no intervention,this is a observational studies
214444947|NCT05103904|OTHER|Laboratory Biomarker Analysis|Correlative studies
214444948|NCT05103904|DRUG|Lenvatinib|Given PO
214444949|NCT06782607|DIAGNOSTIC_TEST|Pneumonia Panel by FilmArray|The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
214444950|NCT04634435|COMBINATION_PRODUCT|BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2|Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
214444951|NCT05586542|COMBINATION_PRODUCT|DERMASEAL|a novel skin substitute formulated as planar, thin film
214444952|NCT05586542|BIOLOGICAL|Plasma Film|a planar, thin film made from human plasma
214693559|NCT03273205|DEVICE|Anodal tDCS|This group gets a real stimulation
214693560|NCT03273205|DEVICE|Sham tDCS|This group gets a sham stimulation
214693561|NCT01852097|BEHAVIORAL|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
214693562|NCT00315705|DRUG|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
215121076|NCT04436172|PROCEDURE|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
215121077|NCT04489472|DIETARY_SUPPLEMENT|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
215121078|NCT03212534|OTHER|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
214444953|NCT05586542|OTHER|Standard of Care|standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
214444954|NCT06783543|OTHER|Comprehensive detumescence treatment with education video|Comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low elastic bandaging and functional exercise four steps
214444955|NCT06783543|OTHER|Comprehensive detumescence treatment|Three to five times a week, one hour each time
214444956|NCT04505774|DRUG|theraputic heparin|increased dose of heparin above standard of care.
214444957|NCT04505774|DRUG|prophylactic heparin|standard of care dose of heparin
214444958|NCT04505774|DRUG|P2Y12|added P2Y12 inhibitor
214444959|NCT04505774|DRUG|Crizanlizumab Injection|crizanlizumab injection
214444960|NCT04505774|DRUG|SGLT2 inhibitor|sglt2 inhibitor
214444961|NCT06786273|GENETIC|Small RNA sequencing|The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
214444962|NCT06792474|DRUG|Lidocaine in Saline|Lidocaine infusion 1.5 mg/kg/hr
214444963|NCT06792474|DRUG|Normal saline|Normal saline infusion
214693563|NCT00315705|DRUG|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
215121079|NCT01943591|DEVICE|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
215121080|NCT02829580|PROCEDURE|Echocardiography|Measures by Doppler and study of endothelial function
215121081|NCT03320720|OTHER|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
215121082|NCT03320720|OTHER|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
215121083|NCT01081899|OTHER|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
215121084|NCT05830175|OTHER|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
214693564|NCT00315705|DRUG|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
214693565|NCT06254105|OTHER|HANDY programme|The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
214444964|NCT06789276|BEHAVIORAL|Supine position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in either the supine position.
214444965|NCT06789276|BEHAVIORAL|lateral decubitus position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in the lateral decubitus position with the puncture side up.
214522191|NCT01821222|DEVICE|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
214444966|NCT05653674|BEHAVIORAL|Acceptance and commitment approach-based psychoeducation|The psychoeducation based on acceptance and commitment approach reducing psychological distress in nursing students; It has been prepared to increase psychological flexibility, mindfullness and level valuing. A potential approach that has been shown to be effective in reducing psychological distress is one of the third generation cognitive behavioral therapies; acceptance and commitment therapy. Acceptance and commitment-based approaches encourage participants to change their relationship with their thoughts and physical sensations through acceptance, mindfullness, and value-based action mechanisms.
214522192|NCT04779463|DIAGNOSTIC_TEST|Parasternal intercostal muscles thickness ultrasound indicies|"Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration."
214522193|NCT05209256|DRUG|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
214522194|NCT05209256|DRUG|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
214522195|NCT02408978|DRUG|OXP005|
214522196|NCT02408978|DRUG|Naproxen|
214693566|NCT01021605|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
215028916|NCT05385289|BEHAVIORAL|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
215028917|NCT04832152|OTHER|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
214444967|NCT06799923|PROCEDURE|laser electrode|A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).
214444968|NCT06782724|DRUG|Psilocybin therapy|Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
214444969|NCT06782841|DEVICE|GMA-TULIP Laryngeal Mask|After the anesthesia induction, use the GMA-TULIP laryngeal mask as the airway ventilation device.
214444970|NCT06782841|DEVICE|i-gel Laryngeal Mask|After the anesthesia induction, use the i-gel laryngeal mask as an airway ventilation device.
214444971|NCT06782841|DEVICE|BlockBuster Laryngeal Mask|After the anesthesia induction is over, use the BlockBuster laryngeal mask as the airway ventilation device.
214444972|NCT06788470|DRUG|MSC|Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
214444973|NCT06784609|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
214444974|NCT06787456|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.
214444975|NCT06787456|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.
214444976|NCT06787456|OTHER|epidemiological information survey|epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.
214444977|NCT06787456|OTHER|Clinical examinations for high-risk participants|nasopharyngoscopy, head and neck MRI.
214444978|NCT06787456|OTHER|EBV and human genetic sequencing|EB virus and human genetic sequencing for plasma, etc.
214444979|NCT06787885|DRUG|Levofloxacin + clindamycin|Group 1
214444980|NCT06787885|DRUG|Levofloxacin + cefipime|Group 2
214444981|NCT06787885|DRUG|Moxifloxacin + meronam|Group 3
214444982|NCT02815813|BEHAVIORAL|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
214444983|NCT02815813|BEHAVIORAL|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
214444984|NCT06786871|PROCEDURE|IVF treatment|Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
214444985|NCT06790511|OTHER|bioactive highly filled injectable flowable composite|bioactive highly filled injectable flowable composite
214444986|NCT06790511|OTHER|highly filled injectable flowable composite|highly filled injectable flowable composite
214444987|NCT06789471|DIETARY_SUPPLEMENT|psyllium husk|Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
214444988|NCT06782893|BEHAVIORAL|Non-pharmacological cough control therapy|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about chronic cough, introduction to cough suppression and goal setting. Session 2 will cover education about chronic cough in ILD, cough triggers and training in cough suppression techniques. Session 3 will focus on hydration techniques, laryngeal hygiene, and breathing exercises to control coughing. Session 4 will reinforce all aspects of non-pharmacological cough control treatment, and session 5 will explore the sustainability of cough control strategies after the program using real-life case scenarios.
214444989|NCT06782893|BEHAVIORAL|Healthy lifestyle|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about exercise and physical activity. Session 2 will cover education about diet. Session 3 will focus on stress management. Session 4 will cover relaxation techniques, and session 5 will reinforce all aspects previously considered.
214444990|NCT05568537|DRUG|Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)|Piflufolastat F18 will first be given intravenously over about 5 seconds.
214522197|NCT05700656|DRUG|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
214522198|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
214522199|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
214522200|NCT02338505|DEVICE|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
214444991|NCT06782061|OTHER|DSM17938+Routine clinical treatment|Lactobacillus reuteri DSM17938，5 drops per day by mouth (containing at least 100 million CFU of Lactobacillus reuteri DSM17938)，Routine clinical treatment
214444992|NCT06799871|DEVICE|Dental implant|There is no intervention in the study. The participants have already received dental implant treatment and data will be collected retrospectively regarding the procedure
214444993|NCT06786598|DIAGNOSTIC_TEST|Cholesterol|Qimica/kit
214522201|NCT05799534|OTHER|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
214522202|NCT00147394|DRUG|Risperidone|
215121085|NCT05830175|OTHER|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
215121086|NCT05641636|DIAGNOSTIC_TEST|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
215121087|NCT03662594|OTHER|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
215121088|NCT02566694|PROCEDURE|Implant|orthopaedic implant
215121089|NCT01043991|DRUG|Darbepoetin alfa|
215121090|NCT01043991|DRUG|Placebo|
215121091|NCT04019899|DIETARY_SUPPLEMENT|control group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
215121092|NCT04019899|DIETARY_SUPPLEMENT|study group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
215121093|NCT01361971|PROCEDURE|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
215121094|NCT02302365|DEVICE|Spectra Optia® Apheresis System|White Blood Cell Depletion
215121095|NCT00227721|DRUG|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
215121096|NCT00227721|DRUG|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
214444994|NCT05734066|DRUG|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
214444995|NCT06139081|OTHER|Oxygen delivery mode|After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
214444996|NCT01780883|DRUG|melatonin|
214444997|NCT01780883|DRUG|Placebo|Placebo tablets of Circadin®
214444998|NCT04869436|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
214522203|NCT02521337|OTHER|observation|observation
214522204|NCT03662009|OTHER|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
214522205|NCT01748058|BEHAVIORAL|Exercise based on active video gaming|
214522206|NCT06181968|DIAGNOSTIC_TEST|Cardiothoracic ultrasound protocol|Combined echocardiography and lung ultrasound for guiding therapy
214522207|NCT03455751|GENETIC|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
214522208|NCT02836184|DRUG|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
214522209|NCT02836184|DRUG|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
214522210|NCT04572425|OTHER|Guided imagery|10 minutes of guided imagery experience delivered on tablet
214444999|NCT06112171|PROCEDURE|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
214445000|NCT06112171|PROCEDURE|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
214445001|NCT03842826|DIAGNOSTIC_TEST|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
214445002|NCT01901094|PROCEDURE|Axillary Lymph Node Dissection (ALND)|
214445003|NCT01901094|RADIATION|Nodal Radiation Therapy|
214445004|NCT01901094|RADIATION|Axillary Radiation Therapy|
214445005|NCT05243069|PROCEDURE|Imaging Technique|Undergo 3D scanning
214445006|NCT04563793|DEVICE|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
214522211|NCT04572425|OTHER|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
214522212|NCT02131792|PROCEDURE|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
214522213|NCT02115945|OTHER|DN4 test|The DN4 test was used to evaluate neuropathic pain.
214522214|NCT02115945|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
214522215|NCT02115945|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
214522216|NCT02115945|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
214522217|NCT02115945|PROCEDURE|femoral block|
214522218|NCT02115945|PROCEDURE|epidural block|
215121097|NCT01848665|DRUG|Indomethacin|
215121098|NCT01848665|DRUG|Placebo|
215121099|NCT00431561|DRUG|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
215121100|NCT00431561|DRUG|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
215121101|NCT00431561|DRUG|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
215121102|NCT00431561|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
214445007|NCT02597946|DRUG|afatinib|
214445008|NCT02597946|DRUG|paclitaxel|
214445009|NCT06779071|DEVICE|NPNP-001|Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.
214445010|NCT06779071|DEVICE|Conjuran|Description: Conjuran 2ml per injection, once a week for 5 injections.
214445011|NCT06366373|OTHER|A mental health art exhibition|"The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health."
214445012|NCT06366373|OTHER|printed or online education materials|The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
214445013|NCT06294158|OTHER|Brightness measurement|Measurement of ambience brightness using lux meters
214445014|NCT06294158|OTHER|Sound level measurement|Measurement of ambience sound levels using sound level meters
214445015|NCT04487587|DRUG|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
214522219|NCT02984787|PROCEDURE|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
214522220|NCT02984787|PROCEDURE|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
214522221|NCT00329186|DRUG|desvenlafaxine SR|
214522222|NCT00329186|DRUG|venlafaxine ER|
214522223|NCT04889820|DRUG|Neoadjuvant chemotherapy|In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
214522224|NCT04889820|DRUG|Adjuvant chemotherapy|After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
214522225|NCT04889820|PROCEDURE|Curative resection|After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
214522226|NCT05190289|OTHER|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
214693567|NCT02551198|DRUG|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
214693568|NCT02551198|DRUG|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
214693569|NCT05094921|OTHER|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
215121103|NCT00431561|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
214693570|NCT05094921|PROCEDURE|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
214693571|NCT05130164|RADIATION|CBCT|Cone beam computed tomographic images selected for age estimation
214693572|NCT03761043|BEHAVIORAL|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
214693573|NCT01642524|BIOLOGICAL|hypertonic saline mixed Dextran|single dose administered intravenously
214693574|NCT01642524|BIOLOGICAL|Saline solution|placebo - saline solution
214693575|NCT05099146|BEHAVIORAL|pictures|pictures with brushing technique demonstrated technique for proper brushing
214693576|NCT05099146|BEHAVIORAL|video|video of brushing technique demonstrated technique for proper brushing
214693577|NCT05099146|BEHAVIORAL|control|oral hygiene instructions provided
214693578|NCT03233412|PROCEDURE|Control|Exertion of the cervix transformation zone
214693579|NCT03233412|DRUG|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
214693580|NCT02260908|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
214693581|NCT02260908|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
214445016|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
214693582|NCT02140359|BEHAVIORAL|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
214693583|NCT01716533|PROCEDURE|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
214693584|NCT01716533|OTHER|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
214693585|NCT05591599|DIAGNOSTIC_TEST|calponin 2|serum calponin 2 level
214693586|NCT02701803|DEVICE|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
214693587|NCT05900193|DIETARY_SUPPLEMENT|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
214693588|NCT05948371|OTHER|High Intensity interval Training|"High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
214693589|NCT05948371|OTHER|Continuous Aerobic training|"Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling."
214694196|NCT01769690|OTHER|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
214445017|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
215121104|NCT02608658|OTHER|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test"
214445018|NCT04995484|DRUG|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
214445019|NCT05135949|OTHER|Patient Reported Outcomes|Satisfaction, Disabilities of the Shoulder, Arm and Hand
215121105|NCT05699850|OTHER|ARTIFICIAL INTELLIGENCE (AI)|ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINE
215121106|NCT05324111|DEVICE|Kardia 6L|The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
215121107|NCT02568735|DRUG|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
214445020|NCT05135949|OTHER|Strength Test|Handheld dynamometer to measure tricep extension
214445021|NCT06301919|OTHER|Clinical data|Collecting data from the medical record.
214693590|NCT06552611|COMBINATION_PRODUCT|Transcutaneous electrical spinal cord stimulation + therapy|A two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand therapy sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin as cathodes to stimulate the cervical spinal cord at two vertebral levels. An additional pair of electrodes will be symmetrically positioned over either the iliac crests or shoulders, functioning as anodes. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will range from 0 to 120 milliamperes (mA), with incremental increases of 5 mA until reaching the level that facilitates voluntary movement. The stimulation amplitude will be fine-tuned for each specific activity based on the therapist's observation.
214445022|NCT06301919|OTHER|Imaging data|Collecting data from the medical record.
215121108|NCT02568735|DRUG|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
215121109|NCT04974255|OTHER|Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples|Examination of pathology specimen and laboratory measuring
215121110|NCT05298202|BIOLOGICAL|Capsaicin|application of capsaicin gel from shoulder to wrist and mid thigh to ankle
215121111|NCT05298202|BIOLOGICAL|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
214445023|NCT06301919|OTHER|Biological data|Collecting data from the medical record.
215121112|NCT05298202|OTHER|Exercise|treadmill walking 3.5 mph at 5% grade
214445024|NCT06086171|DRUG|Methadone Hydrochloride|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
214445025|NCT06086171|OTHER|Placebo|Saline solution
214445026|NCT05212220|BEHAVIORAL|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
215121113|NCT05298202|OTHER|Hot environment|38°C, 60% relative humidity
214445027|NCT05212220|BEHAVIORAL|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
214445028|NCT04255303|OTHER|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
214445029|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
214445030|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
214445031|NCT06072404|BIOLOGICAL|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
214445032|NCT02582125|DRUG|ONO-4538|
214445033|NCT05818228|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
214445034|NCT04659031|DRUG|ABC008|ABC008
214522227|NCT06471153|BEHAVIORAL|Empowerment Program Based on BASNEF Model|Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
214522228|NCT06471153|BEHAVIORAL|Routine Health Education|Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
214522229|NCT06490497|OTHER|Interview|individual interviews semi-directive
214522230|NCT01184755|BEHAVIORAL|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
215121114|NCT06053853|BIOLOGICAL|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~1. Perform sensitivity tests, and desensitization if necessary.~2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~3. The recommended DAT treatment dosage ranges (pediatric and adult) are:~   * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~  * Nasopharyngeal disease 40,000 - 60,000 unit~  * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~  * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
214522231|NCT01184755|DEVICE|RESPeRate|
214522232|NCT00318591|DEVICE|SpeediCath|hydrophilic coated urinary intermittent catheter
214522233|NCT00318591|DEVICE|Conveen Uncoated|Uncoated urinary intermittent catheter
215121115|NCT03190395|PROCEDURE|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
215121116|NCT03190395|PROCEDURE|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
215121117|NCT04862325|OTHER|Multimodal Prehabilitation|"1. High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~2. Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~3. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
215121118|NCT01875159|DRUG|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
215121119|NCT03943615|DRUG|Voxelotor|
215121120|NCT01029184|OTHER|commercialized complete cereals|complete cereals suitable for the weaning period
214445035|NCT06422052|OTHER|Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）|H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
214445036|NCT04935320|DRUG|HTL0016878.HCl Solution 10 mg|Oral solution fasted
214445037|NCT04935320|DRUG|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
214445038|NCT04058639|PROCEDURE|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
214445039|NCT04058639|PROCEDURE|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
214445040|NCT02485834|PROCEDURE|FDG-PET|
214445041|NCT02485834|PROCEDURE|surgery|
214445042|NCT02485834|DRUG|5-FU|200 mg/m\^2/day IV
214445043|NCT02485834|DRUG|capecitabine|oral 800 mg/m\^2 BID
214522234|NCT04911322|DEVICE|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
214693591|NCT06552611|OTHER|Occupational Therapy|The hand therapy program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each training session. Activities are chosen according to the participant's ability, interests, and needs and are modified as function progresses over time.
214522236|NCT06976502|PROCEDURE|Blood Draw|Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.
214522237|NCT06976502|PROCEDURE|Tissue Collection|If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.
215028918|NCT01321905|DIETARY_SUPPLEMENT|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
215028919|NCT05888233|DRUG|Allopurinol|Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
215028920|NCT05745961|RADIATION|TSPO PET scan (11C-PBR28)|PET scan
214445044|NCT02485834|DRUG|docetaxel|30 mg/m\^2 IV
214445045|NCT02485834|DRUG|Irinotecan|50 mg/m\^2 IV
215028921|NCT04297774|BEHAVIORAL|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
215028922|NCT04297774|BEHAVIORAL|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
215028923|NCT04297774|BEHAVIORAL|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
215028924|NCT05570162|OTHER|Diabetes educational program|30-minute long diabetes educational program
215028925|NCT03918291|OTHER|Addition of whole-body vibration to squat training|
215028926|NCT03918291|OTHER|Squat training|squatting exercises for 12 weeks, 3x/week
215121121|NCT01029184|OTHER|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
214445046|NCT02485834|RADIATION|3D-CRT|
214445047|NCT02485834|RADIATION|IMRT|
215121122|NCT03462108|BIOLOGICAL|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
215121123|NCT03462108|OTHER|Placebo|Placebo contains 30% sucrose in DMEM
215121124|NCT02575755|DRUG|Azithromycin plus piperaquine phosphate|
215121125|NCT02575755|DRUG|Sulfadoxine-pyrimethamine|
215121126|NCT00361192|PROCEDURE|biopsy of temporal artery|
215121127|NCT06525415|DIAGNOSTIC_TEST|DCE MRI|the recruited patients should complete pre- and post-operative DCE MRI workshops
215121128|NCT00408122|PROCEDURE|PET/CT scan and EUS|
214693592|NCT02474524|BEHAVIORAL|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
214445048|NCT03711110|OTHER|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
214445049|NCT03711110|OTHER|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
214445050|NCT05796648|BEHAVIORAL|RN-CHeFRx|The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
214445051|NCT05058391|BIOLOGICAL|Elaprase|Elaprase IV infusion.
214445052|NCT05721989|DRUG|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
214445053|NCT05721989|DRUG|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
214522238|NCT06976502|PROCEDURE|DNA Collection|Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.
214522239|NCT06976502|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the participant's medical record.
214522240|NCT03507699|RADIATION|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
214522241|NCT03507699|DRUG|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
214522242|NCT03507699|DRUG|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
214522243|NCT03507699|DRUG|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
214693593|NCT02474524|BEHAVIORAL|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
214693594|NCT03355937|PROCEDURE|Sperm Chip|Sperm selection using by conventional or with sperm chip
214693595|NCT00982241|DIETARY_SUPPLEMENT|water|drinking water / normal dietary fluids for oral intake
214693596|NCT02529241|DRUG|Group 1:LCB01-0371|"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"
214693597|NCT02529241|DRUG|Group 2:LCB01-0371|"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"
214445054|NCT05721989|DRUG|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
214445055|NCT04080128|DEVICE|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
214445056|NCT05622799|BEHAVIORAL|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
214522244|NCT03577054|BEHAVIORAL|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
214522245|NCT03577054|BEHAVIORAL|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
214522246|NCT03987698|BIOLOGICAL|SHR-1210|SHR-1210 injection
214522247|NCT03987698|BIOLOGICAL|CIK cells|CIK cells injection
214522248|NCT06290453|DIAGNOSTIC_TEST|micro RNA 27- FLP1 gene expression|"From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined"
214693598|NCT02765178|OTHER|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
215121129|NCT03840863|DIETARY_SUPPLEMENT|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
215121130|NCT01253642|PROCEDURE|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
215121131|NCT01253642|DRUG|Docetaxel|Given IV
215121132|NCT01253642|OTHER|Laboratory Biomarker Analysis|Correlative studies
215121133|NCT01253642|DRUG|Phenelzine Sulfate|Given PO
214693599|NCT02765178|OTHER|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
214522249|NCT06290453|DIAGNOSTIC_TEST|The Expanded Disability Status Scale (EDSS)|"The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients."
215121134|NCT02498301|DRUG|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
214445057|NCT06024096|DRUG|Atorvastatin|"Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination."
214445058|NCT06024096|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
214693600|NCT02765178|OTHER|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
214693601|NCT02765178|OTHER|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
214693602|NCT02765178|OTHER|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
214445059|NCT06772961|OTHER|Transcutaneous electrical acupoint stimulation|In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
214445060|NCT06772961|OTHER|Conventional care plan|Conventional care plan
214522250|NCT06290453|DIAGNOSTIC_TEST|Electrophysiological assessment:|Electromyography and nerve conduction velocity will be performed for all MS patients.
215121135|NCT02498301|DRUG|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
215121136|NCT01412164|DEVICE|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
214522251|NCT06290453|DIAGNOSTIC_TEST|MRI examination MRI brain:|will be done on all MS patients to detect the number, the site, and the enhancement of lesions
214445061|NCT05220514|DRUG|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
214522252|NCT06359483|OTHER|Meal Frequency Manipulation|The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
214693603|NCT02330549|DRUG|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
214693604|NCT02330549|DRUG|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
214693605|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
215121137|NCT04480840|DRUG|PLN-74809|PLN-74809
215121138|NCT04480840|DRUG|Placebo|Placebo
215121139|NCT06086509|OTHER|Music|Children were played music during computerized tomography.
215121140|NCT01456286|DRUG|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
215121141|NCT01916135|RADIATION|[18F]-SKI-249380|
215121142|NCT01916135|PROCEDURE|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
214445062|NCT05220514|DRUG|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
215121143|NCT01916135|OTHER|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic \& metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
215121144|NCT01389882|PROCEDURE|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
215121145|NCT03923257|DRUG|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
215121146|NCT03923257|PROCEDURE|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
215121147|NCT00436995|DRUG|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
215121148|NCT03014739|OTHER|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
215121149|NCT00567450|DRUG|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
215121150|NCT00567450|DRUG|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
215121151|NCT03095079|DRUG|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
214445063|NCT02662309|DRUG|MPDL3280A|Intravenous infusion
214445064|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
214445065|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
214445066|NCT05136404|DRUG|Selpercatinib|Administered orally
214445067|NCT06149598|BEHAVIORAL|Coughing at the time of biopsy|Patients are asked to cough or not to cough during cervical biopsy.
214445068|NCT05847920|DRUG|SHR-2010 Injection|SHR-2010 Injection
214445069|NCT05847920|DRUG|Placebo|Placebo
214445070|NCT04133948|DRUG|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
214445071|NCT04133948|DRUG|Nivolumab|2 courses nivolumab 240 mg q3weeks
214445072|NCT04133948|DRUG|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
214445073|NCT04853212|PROCEDURE|Biopsy|Biopsy during recto-coloscopy
214445074|NCT03584516|DRUG|Itacitinib|In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
214445075|NCT03584516|DRUG|Placebo|In Part 2, participants will receive matching placebo.
214445076|NCT03584516|DRUG|Methylprednisolone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
214445077|NCT03584516|DRUG|Prednisone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
214445078|NCT01954992|DRUG|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
215121152|NCT03074409|DRUG|oxytocin|self-administration of oxytocin (nasal spray)
215121153|NCT03074409|DRUG|placebo|self-administration of placebo (nasal spray)
215121154|NCT03685955|BIOLOGICAL|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
215121155|NCT04640233|BIOLOGICAL|Gam-COVID-Vac|Vaccine for intramuscular injection
215121156|NCT04640233|OTHER|Placebo|Placebo comparator
215121157|NCT00107692|BEHAVIORAL|Physical activity and diet|
214445079|NCT01954992|DRUG|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
214445080|NCT01236287|DRUG|Voclosporin|Subjects will receive voclosporin capsules, twice daily
214445081|NCT06112795|OTHER|Non-Interventional Study|Non-interventional study
214445082|NCT06262919|DRUG|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
214445083|NCT00448240|DRUG|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
214445084|NCT04187040|PROCEDURE|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs"
214522253|NCT03854032|BIOLOGICAL|Nivolumab|Given IV
214522254|NCT03854032|BIOLOGICAL|IDO1 Inhibitor BMS-986205|Given PO
214445085|NCT04187040|PROCEDURE|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
214445086|NCT04868110|BEHAVIORAL|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
214445087|NCT06754397|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Three most important sequences included axial T2 weighted scan from liver to ampullary region followed by T2 weighted 3D FSE sequence acquired in coronal oblique plane using respiratory triggering by tying bellows over abdomen. After this breath hold HASTE sequence is acquired in coronal plane. Maximum intensity projection (MIP) and thick slab images are also used for interpretation. US, CECT and MRCP scans are interpreted by radiologists blinded to other imaging findings
214445088|NCT06088732|OTHER|Exercise Session|30 min cycling on bicycle ergometer at 60% peak power output
214445089|NCT06088732|DRUG|Ibuprofen 800 mg|A single oral dose of Ibuprofen
214445090|NCT06088732|OTHER|Rest|Resting for 30 min in chair
214445091|NCT06088732|DRUG|Placebo|Matched placebo
214522255|NCT03854032|PROCEDURE|Therapeutic Conventional Surgery|Undergo Surgery
214522256|NCT03854032|OTHER|Questionnaire Administration|Ancillary studies
214522257|NCT06592664|DRUG|certepetide|certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
214522258|NCT06592664|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
214445092|NCT03379168|DEVICE|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
214445093|NCT03379168|DRUG|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
214445094|NCT03379168|DRUG|Saline|Sterile saline injection will act as a placebo group.
214445095|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
214445096|NCT06106178|OTHER|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
214522259|NCT06592664|DRUG|gemcitabine|gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
214522260|NCT06592664|DRUG|placebo matching certepetide|placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
214522261|NCT06592664|DRUG|certepetide|certepetide given as two IV pushes over 1 minute when standard treatment(s) are given
214522262|NCT06592664|DRUG|placebo matching certepetide|placebo given as an IV infusion over 4 hours when standard treatment(s) are given
214522263|NCT06592664|DRUG|placebo matching certepetide|certepetide given as a slow IV push over 1 minute when standard treatment(s) are given
215028927|NCT04564014|BEHAVIORAL|ISSS|The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
214522264|NCT06596915|DRUG|BA1302|BA1302 administered intravenously
214522265|NCT06600204|OTHER|lung scintigraphy|Use the SPECT/CT to predict pulmonary function
214522266|NCT06034145|OTHER|No intervention|No intervention
215028928|NCT04564014|OTHER|Education Materials|Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
214522267|NCT00955097|DRUG|Definity®|Definity® injections given both pre-ablation and post-ablation
214522268|NCT00794274|DRUG|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
214522269|NCT02854982|PROCEDURE|therapeutic management of the prostate Cancer as usual|
214522270|NCT04187378|DEVICE|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
214522271|NCT04187378|DEVICE|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
214445097|NCT06465511|BEHAVIORAL|Supportive clinic|During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.
214445098|NCT06465511|BEHAVIORAL|Control: Self-management|Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
214445099|NCT05701215|DRUG|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
214445100|NCT06787859|OTHER|Showing a nature view curtain to type 2 diabetic patients during insulin injection|a nature view curtain
214522272|NCT05746026|BEHAVIORAL|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~* Session 1: introduction and basic information about Climate Change~* Session 2: causes and factors that contribute to climate change by humans and nature~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
214522273|NCT03346590|BEHAVIORAL|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
214522274|NCT05816798|DEVICE|Photobiomodulation|PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.
214445101|NCT04082624|BEHAVIORAL|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
214445102|NCT04082624|BEHAVIORAL|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
214445103|NCT04082624|BEHAVIORAL|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
215028929|NCT00539500|DRUG|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
215028930|NCT00539500|DRUG|Etoposide|300 mg/m\^2 by vein over 24 hours for 4 days
215028931|NCT00539500|DRUG|Melphalan|70 mg/m\^2 Intravenous Bolus for 3 Days
215028932|NCT00539500|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
215028933|NCT00539500|DEVICE|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
215028934|NCT00804232|BEHAVIORAL|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
215028937|NCT03376282|OTHER|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
215028938|NCT01287208|DEVICE|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
215028939|NCT01287208|DEVICE|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
215028940|NCT02252510|OTHER|HALOSPERM|
215028941|NCT00003158|DRUG|carboplatin|
215028942|NCT00003158|DRUG|etoposide|
215028943|NCT00003158|DRUG|paclitaxel|
215028944|NCT00003158|RADIATION|radiation therapy|
215028945|NCT04037137|OTHER|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
215028946|NCT02839928|DRUG|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
215028947|NCT02839928|DEVICE|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
215028948|NCT02839928|DRUG|EMLA|
215028949|NCT01299961|DRUG|abatacept|125 mg once a week up to 12 months.
215028950|NCT04898179|OTHER|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
215028951|NCT04898179|OTHER|Control group|Usual care
215028952|NCT05143411|OTHER|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
215028953|NCT02904096|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
215028954|NCT04403685|DRUG|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
215121158|NCT06151548|DRUG|THYROX (Atlantic krill oil).|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
215121159|NCT06151548|DRUG|Placebo|The control capsules will be made of olive oil of equal size and color.
214445104|NCT04082624|BEHAVIORAL|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
214445105|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
214445106|NCT03895541|DIAGNOSTIC_TEST|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
214445107|NCT06788327|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.
214445108|NCT06788327|DEVICE|Blood Flow Restriction Therapy|"Participants will perform three exercises of the standard exercises protocol with BFRT. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. Each BFRT session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 50% of the maximum occlusion pressure in the first stage and 60% in stages II and III. The participant will perform 75 repetitions per BFRT exercise divided into 4 sets (30, 15, 15, and 15 repetitions). The load intensity during the BFRT exercises will be set near to 3 out of 10 on the Borg's CR10 scale (weak), which corresponds to 30% of a 1RM effort. After each exercise, the cuff will be deflated, and the patient will rest for two minutes."
214445109|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
214522275|NCT05816798|OTHER|Standard Physiotherapy Tretament|standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
214445110|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
214522276|NCT05816798|DEVICE|Photobiomodulation Placebo|The same interventions described of Photobiomodulation Group bu device will be turned off
214522277|NCT03202056|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
214445111|NCT06793189|DRUG|Obinutuzumab and Orelabrutinib|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).
214445112|NCT06793189|DRUG|Obinutuzumab, Orelabrutinib and Lenalidomide|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).
214445113|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
214445114|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
214522278|NCT03202056|OTHER|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
214522279|NCT06985433|DEVICE|Vaginal light therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
214522280|NCT06985433|DEVICE|Vaginal Light Therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
215121160|NCT03042117|OTHER|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
215121161|NCT01120366|DRUG|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
215121162|NCT01120366|DRUG|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
214522281|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
215121163|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
215121164|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
215121165|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
215121166|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
215121167|NCT03871062|PROCEDURE|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
215121168|NCT03871062|PROCEDURE|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
215121169|NCT03306940|DRUG|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
215121170|NCT02343393|DRUG|Hydralazine|
215121171|NCT02343393|DRUG|Isosorbide Dinitrate|
215121172|NCT05620095|DEVICE|drug-coated balloon|To evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.
215121173|NCT06134219|OTHER|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
214445115|NCT05982678|DRUG|Trastuzumab deruxtecan|T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
214445116|NCT06797739|OTHER|Nutritional counselling|Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.
214445117|NCT06797739|OTHER|Diet|Patients will be asked to follow Mediterranean Diet only
214445118|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
214445119|NCT04998981|DRUG|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
214445120|NCT04998981|DRUG|Placebo tablet|Placebo tablet x 2 twice daily
214445121|NCT04998981|DRUG|Placebo capsule|Placebo capsule once daily
214445122|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
214445123|NCT04998981|DRUG|Placebo tablet|Placebo tablet twice daily
214445124|NCT04172402|DRUG|TS-1|Intervention is administered to patients in this Arm.
214445125|NCT04172402|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
214445126|NCT04172402|DRUG|Nivolumab|Intervention is administered to patients in this Arm.
214445127|NCT06793436|PROCEDURE|chest wall blocks|The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.
214522282|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
214522283|NCT06232395|DIAGNOSTIC_TEST|DNA test|circulating DNA test
214522284|NCT06598774|OTHER|Assessment of head posture:|Head posture was assessed using photographic methods and craniovertebral angle
214522285|NCT06598774|OTHER|Assessment of Cervical Pain Pressure Threshold|The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
215121174|NCT06134219|OTHER|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
215121175|NCT04738981|DRUG|UC-MSC|UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
215121176|NCT04738981|DRUG|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
215121177|NCT04513756|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
215121178|NCT00381004|DRUG|Cyclophosphamide|Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
215121179|NCT00381004|DRUG|Fludarabine|Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
215121180|NCT00381004|DRUG|Sargramostim|Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10
215121181|NCT00381004|DRUG|Rituximab|Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
215121182|NCT05414890|DIAGNOSTIC_TEST|CBA-TSA|Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
214445128|NCT05890300|DEVICE|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
214445129|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
214445130|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
214445131|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
214445132|NCT06840912|OTHER|Pharmacological in addition to electroencephalographic (EEG) biofeedback|Patients with heroin use disorder diagnosed according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition), treated by pharmacological in addition to electroencephalography (EEG) biofeedback after 3 months of abstinence.
214445133|NCT06840912|DRUG|Pharmacotherapy|Patients with heroin use disorder taken as control group matching with patients group treated only by pharmacotherapy
215121183|NCT03973359|BEHAVIORAL|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
215121184|NCT02966808|BEHAVIORAL|cognitive and behavioural questionnaires|
215121185|NCT00637065|DRUG|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
215121186|NCT00637065|DRUG|Placebo|Placebo tables - identical to active drug but without the active ingredient -
215121187|NCT04903782|DIAGNOSTIC_TEST|Family-based whole genome sequencing|"1. Germline whole-genome family-based sequencing and variant identification.~2. Multidisciplinary Meeting case discussion.~3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling.~4. Psychosocial study to analyse the impact of germline sequencing on families."
215121188|NCT03036410|DEVICE|standard telephone setting|without streaming function
215121189|NCT03036410|DEVICE|DECT|cordless telephone (streaming to both hearing devices)
215121190|NCT03036410|DEVICE|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
215121191|NCT03036410|DEVICE|DuoPhone|streaming function, which provides the speech signal to both ears
214445134|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
214445135|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
214445136|NCT03849534|DEVICE|Soft occlusal appliance|According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition
214445137|NCT03849534|BEHAVIORAL|Jaw exercises|The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch
214445138|NCT03849534|BEHAVIORAL|Counseling|The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
214445139|NCT04268888|DRUG|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
214445140|NCT04268888|PROCEDURE|TACE/TAE|TACE/TAE (as per local practice)
214445141|NCT05867966|BEHAVIORAL|psychoeduc/self-care/self-hypnosis group|See arm description.
214445142|NCT02915198|DRUG|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
214445143|NCT02915198|DRUG|Placebo|"For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
214445144|NCT06793254|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
214445145|NCT05526534|DEVICE|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
215121192|NCT02620982|DEVICE|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
215121195|NCT06514872|OTHER|prevalance and determinants of home accidents|home accidents among Turkish older
214445146|NCT05526534|DEVICE|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
214445147|NCT06788951|DIETARY_SUPPLEMENT|administration of oral carbohydrate solution to patients before coronary artery bypass graft surgery|Oral carbohydrate solution will be administered to patients before coronary artery bypass graft operation and its effects on postoperative nausea-vomiting, hunger, thirst, physiological parameters and recovery will be evaluated.
214445148|NCT06788951|OTHER|giving flavored water to patients before coronary artery bypass graft surgery|The effects of flavored water given to patients before coronary artery bypass graft operation on postoperative nausea-vomiting, hunger and thirst,
214445149|NCT06796153|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214445150|NCT06796153|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
215121196|NCT02329470|PROCEDURE|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
215121197|NCT04839016|DRUG|SHR-1314|SHR-1314
215121198|NCT04839016|DRUG|Placebo|Placebo
215121199|NCT01579435|DEVICE|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
215121200|NCT01116401|DRUG|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
215121201|NCT02893241|DRUG|Cafedrine/theodrenaline|
215121202|NCT02893241|DRUG|Ephedrine|
215121203|NCT01560286|BIOLOGICAL|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
215121204|NCT01957878|BIOLOGICAL|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
215121205|NCT01957878|BIOLOGICAL|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
215121206|NCT01521026|BEHAVIORAL|Cognitive Training|12-week compensatory cognitive training in group format
215121207|NCT01545726|DRUG|QAW039|QAW039 was supplied as capsules for oral administration.
215121208|NCT01545726|DRUG|Placebo|Placebo was supplied as capsules for oral administration.
214522286|NCT06598774|OTHER|Assessment of general cervical mobility|Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
215121209|NCT03654183|DIAGNOSTIC_TEST|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
215121210|NCT02171221|DRUG|Oral DFP-11207|
215121211|NCT00746070|OTHER|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
214445151|NCT05343390|BEHAVIORAL|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)
214445152|NCT05343390|BEHAVIORAL|Standard implementation package|Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
214445153|NCT06312709|BEHAVIORAL|teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)|teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.
214445154|NCT06312709|OTHER|Health Education|Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
214445155|NCT02253251|GENETIC|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
214445156|NCT06792851|DEVICE|Kosmos Bladder Volume Algorithm|Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.
214445157|NCT04286282|BEHAVIORAL|Group Pyschotherapy|Group psychotherapy
214445158|NCT04286282|OTHER|Depression Standard of Care|Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
214522287|NCT06598774|OTHER|Assessment of upper cervical mobility|It will be assessed using the CROM device and the flexion-rotation test.
214445159|NCT04286282|OTHER|HIV Standard of Care|Standard clinical care for HIV
214445160|NCT06792565|DEVICE|hemodializer|Fresenius Helixone FX5 (61346 Bad Homburg, Germany)
214445161|NCT06792565|DEVICE|hemofilter|Medica (741036 Medolla, Italy)
214445162|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from three national service dog providers, including K9s For Warriors, Canine Companions, and America's VetDogs. All three providers have an established track record of training and providing service dogs for PTSD, as well as collaborating with the investigative team in research.
214522288|NCT06598774|OTHER|Assessment of Body Awareness|Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
214522289|NCT06037057|OTHER|no intervention name|no intervention description
214522290|NCT01533194|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214522291|NCT01533194|BIOLOGICAL|Wild-type Reovirus|Given IV
214522292|NCT03028961|OTHER|Stanford Letter|Receive and complete the Stanford Letter
214522293|NCT03028961|OTHER|Interview|Undergo semi-structured, research staff-led interview
214522294|NCT03028961|OTHER|Questionnaire Administration|Ancillary studies
214522295|NCT03028961|OTHER|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
214522296|NCT06456164|DEVICE|Cook Cervical Ripening Balloon|The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
214522297|NCT06993129|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
214693606|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
214693607|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
214693608|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
214693609|NCT01393171|DEVICE|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
214693610|NCT01393171|PROCEDURE|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
214693611|NCT01393171|PROCEDURE|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
214693612|NCT02696915|DRUG|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
214693613|NCT02696915|DRUG|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
214693614|NCT02696915|DEVICE|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
214693615|NCT02696915|DRUG|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
214693616|NCT03408951|OTHER|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
214693617|NCT02295735|DEVICE|Mepilex® Border Sacrum and Mepilex® Border Heel|
214693618|NCT01794819|DEVICE|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
214693619|NCT05590741|BEHAVIORAL|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
214693620|NCT01490749|DRUG|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
214693621|NCT01490749|DRUG|XELOX|Patients will receive two cycles of XELOX.
215121212|NCT06317571|BEHAVIORAL|fertility support education|In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
215121213|NCT03955835|DEVICE|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
215121214|NCT00443417|DRUG|SK-PC-B70M|dosage, frequency
214445163|NCT06796920|PROCEDURE|Spinal cord stimulation|Upon completion of the initial assessments, a lumbar spinal cord nerve stimulator and pulse generator will be implanted. Following surgery, based on the patient's recovery status, the patient will be transferred to the respective center for rehabilitation within one to two weeks. Afterward, electrical stimulation therapy will be initiated. Stimulation should be applied at least three days per week. Each day, the total stimulation time should be between 4 and 8 hours. Stimulation Modes: Continuous Stimulation: For example, if 6 hours of stimulation are prescribed, the stimulator will run uninterrupted for 6 hours. Intermittent Stimulation: For instance, a cycle of 40 seconds on and 20 seconds off. If a total of 6 hours of active stimulation is needed, the stimulator must remain on for 9 hours in total to accommodate rest intervals.The ranges for each parameter are as follows:Stimulation Frequency: 2 Hz - 2000 Hz, Pulse Width: 20 μs - 1000 μs, Stimulation Amplitude:Voltage: 0 V - 10 v
214445164|NCT05417932|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
214445165|NCT05806788|BEHAVIORAL|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
214445166|NCT06222593|DRUG|Bicalutamide in combination with Sunitinib|Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
214693622|NCT01490749|DRUG|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
215121215|NCT05842759|PROCEDURE|Monitoring|Continuous blood pressure monitoring
215121216|NCT05842759|PROCEDURE|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
215121217|NCT05842759|PROCEDURE|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
215121218|NCT05842759|PROCEDURE|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
214693623|NCT01490749|RADIATION|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
214693624|NCT01809418|DEVICE|keePAP|
214693625|NCT03242083|OTHER|quality of life questionnaire|quality of life questionnaire
214693626|NCT00745368|DRUG|Raltegravir|400 mg tablets twice daily during duration of trial
214693627|NCT00003444|BIOLOGICAL|recombinant interferon alfa|
214693628|NCT00003444|RADIATION|radiation therapy|
214693629|NCT02052843|BEHAVIORAL|Steps to Success|
214693630|NCT02052843|BEHAVIORAL|Traditional Healthy Families|
214693631|NCT00495495|DEVICE|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
214693632|NCT00495495|DEVICE|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
214693633|NCT00862316|DEVICE|Oxford Unicompartmental Knee|Knee Arthroplasty
214693634|NCT06554834|PROCEDURE|CV4 + RR|Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
214693635|NCT06554834|PROCEDURE|CV4|Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
214693636|NCT06554834|DEVICE|sham ultrasound transducer|Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
214445167|NCT06838715|DRUG|Dexamethasone|Assessing the relation between the level of cytokines (interleukins and tumor necrosis factor alpha) and the development of cardiac complications associated with scorpion envenomation among pediatric patients. and Evaluating the role of the use of Dexamethasone and/or extended anti-venom administration on cardiac function and outcome in pediatric cases.
214445168|NCT04511702|BIOLOGICAL|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
215121219|NCT05842759|PROCEDURE|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
214445170|NCT01894061|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
214445171|NCT01894061|DEVICE|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
214445172|NCT01894061|OTHER|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
214445173|NCT06424561|BEHAVIORAL|Psychological Intervention Group|"The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers."
214445174|NCT06793904|DRUG|Aromatase inhibitor Letrozole|2.5 mg tab twice daily from the 3rd day of the cycle for 5 days
214445175|NCT06788704|DRUG|Tadalafil 5mg|Patient recive tadalafil 5mg once daily early post turp
214522298|NCT06988540|OTHER|Personalized Health Planning Program Administration|The T2D PHP program is 8 hour-long sessions offered over 16 weeks. The program includes development of a personal health plan supported by a patient-provider health risk assessment; group session structure supplemented by educational, video sessions; lessons, discussions, and activities based on behavioral modification, health engagement, and diabetes distress; goal progress tracking; social support; mindful awareness practices and qualitative health evaluations via surveys and a one-on-one consultation with a personal health coach. Participants will be provided a group participant notebook that provides information discussed during the program. The T2D PHP program is a complement to routine care.
214445176|NCT06788704|DRUG|Placebo|Patient recive placebo once daily early post turp
214522299|NCT06988540|OTHER|Usual Care|Patients will be encouraged to see their diabetes provider. Patients will not participate in the T2D PHP program but will complete laboratory tests and surveys as listed in the section on outcomes.
214522300|NCT06913777|DRUG|Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib|The backbone is chemotherapy which will be used in the control group. The precision group will add targeted therapy agents which were determined according to SNF classification: the SNF2 subtype add adebrelimab combined with famitinib, the SNF3 subtype receives fluzoparib, and the SNF4 subtype receives apatinib.
214522301|NCT06913777|DRUG|Chemotherapy (wP-EC)|Chemotherapy : weely nab-P \* 12- EC \* 4
215121220|NCT02416843|OTHER|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
214445177|NCT05202860|BIOLOGICAL|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
214445178|NCT05202860|BIOLOGICAL|PLACEBO vaccine|Isotonic saltwater sham vaccine
214445179|NCT04452864|DEVICE|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
214445180|NCT04452864|DEVICE|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
214445181|NCT06790940|OTHER|No intervention|This is an observational study, no intervention will be implemented.
214445182|NCT06796972|OTHER|Semi-structured interviews with a psychologist|Semi-directed interviews using an interview guide on different themes
214445183|NCT06790043|OTHER|Patient-selected visual art in hospital room|Patient-selected visual art placed in patient's antepartum hospital room
214445184|NCT06790043|OTHER|Routine care|Patient will receive routine care, and will not select, nor have, visual art in their antepartum hospital room.
214445185|NCT06834334|DEVICE|MM780G|SmartGuard in Medtronic Minimed 780G advaced hybrid closed-loop
214445186|NCT06834334|DEVICE|TTSX2|Control-IQ in Tandem T Slim X2 advanced hybrid closed-loop
214445187|NCT06834334|DEVICE|CamAPS|CamAPS Fx in Ypsopump advanced hybrid closed-loop
214445188|NCT05243862|DRUG|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
214445189|NCT05243862|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
214445190|NCT05653232|OTHER|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
214445191|NCT05653232|OTHER|Transmit and Treat (T&T)|For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
214445192|NCT04659993|BEHAVIORAL|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
214445193|NCT06395636|DEVICE|Infection-Prediction Algorithm|This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
214445194|NCT05996744|DRUG|Obeldesivir|Tablet administered orally with or without food
214445195|NCT06840301|BEHAVIORAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
214445196|NCT06840301|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214445197|NCT06840301|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
214445198|NCT06840301|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214445199|NCT06840301|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
214445200|NCT06840301|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants"
214522302|NCT06614582|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|"The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit."
214522303|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
214522304|NCT00555932|PROCEDURE|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
214522305|NCT05913609|DEVICE|Yaari Extractor|The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
215121221|NCT05275816|OTHER|Comparing the appropriateness of our practice and the usability of the AUC through comparing the actual management provided at our institution with that recommended by the AUC.|"The AUC application for carpal tunnel syndrome management requires four patients' variables to generate appropriateness ratings for six different treatment options. Each procedure is rated as appropriate, maybe appropriate, or rarely appropriate. The six procedures include splint, steroid injection, carpal tunnel release, oral steroids or Ketoprofen phonophoresis, investigation of alternative diagnoses, and further investigation using an electro-diagnostic study.~To judge the usability of the AUC for the management of carpal tunnel syndrome, the required parameters of each patient were collected and entered into the AUC application by two independent authors to generate the appropriateness rating of the provided treatment for each patient. Afterwards, the agreement between the AUC recommendations and the actual treatment that was provided at our institution was assessed."
214693637|NCT06554834|DEVICE|Ultrasound Transducer Sham Procedure|Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
214693638|NCT06554834|DEVICE|EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System|Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
214445201|NCT06840301|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
214445202|NCT06840301|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
214445203|NCT04827563|DEVICE|EndoPAT|An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
214445204|NCT04827563|DEVICE|Blood Pressure Cuff|A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
214445205|NCT04827563|DIAGNOSTIC_TEST|Echocardiogram|A test used to conduct an ultrasound of participant's heart.
214445206|NCT04827563|OTHER|Quality of Life Assessment|A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
214445207|NCT04827563|OTHER|Blood Tests|Routinely collected for all participants who begin carfilzomib treatment.
214445208|NCT06839586|DRUG|CMTS4520 (dietary fiber and probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
214522306|NCT06999382|BEHAVIORAL|Active Dissemination and Implementation|This intervention is designed to accelerate the uptake of evidence-based interventions that help maximize the impact of the addition or renovation of public open spaces on their utilization for active recreation among community members, ultimately effective physical activity levels in communities. The intervention targets implementation partners: local stakeholders/decision makers and community leaders, to increase their awareness of these evidence-based approaches for place-activation, and their willingness to adopt and implement them in their neighborhood settings. Intervention components include capacity building workshops, newsletters, targeted messaging and access to a knowledge broker and implementation support for 1-year.
214522307|NCT06999382|BEHAVIORAL|Passive Dissemination|Delivery of booklet with menu of evidence-based interventions for place-activation; and of pamphlet summarizing importance of healthy lifestyle promotion.
214693639|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
215121222|NCT05661812|DIAGNOSTIC_TEST|Quationnaires and symptom registration|Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
215121223|NCT05661812|DIAGNOSTIC_TEST|PNIF and spirometry|To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
214445209|NCT06839586|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
214445210|NCT02840474|BIOLOGICAL|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
214693640|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
214693641|NCT01511835|DRUG|Folic Acid|Folic Acid 400mcg; 1 cp/die
214445211|NCT02840474|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
214445212|NCT06838312|OTHER|Reuse or dispose a polyp trap|Participant hospitals will be separated into two groups, according to their standard clinical practice: A) reuse or B) dispose polyp traps after a colonoscopy with polypectomy. Centres will participate with their current method of using polyp traps. Work dynamics will not change as patients will be recruited from centers that routinely reuse or dispose polyp traps.
215121224|NCT05661812|DIAGNOSTIC_TEST|SPT, spesific IgE, pBAT and NPT|To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
215121225|NCT02599363|DRUG|Ribociclib (LEE011)|
215121226|NCT02599363|DRUG|Paclitaxel|
215121227|NCT01174407|OTHER|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
214445213|NCT06228755|BEHAVIORAL|Integrative Medicine Group Visit|Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
214522308|NCT06999447|OTHER|ChatGPT-Supported Case-Based AI Education (C-CASE)|In the intervention group (C-CASE), after informed consent and pretest completion (including a sociodemographic form and CDMNS), the case scenario was introduced by the course instructor. Students were divided into small groups, and each group selected a representative who accessed ChatGPT-4.0 Premium via credentials provided by the research team. Using a collaborative problem-solving format, each group worked through a structured case scenario involving pediatric surgical emergencies. Questions were distributed sequentially, with 5-minute intervals allocated per question. Students used ChatGPT to support reasoning and clinical decision-making within their group. After each interval, responses were submitted, and the next question was handed out. Sessions were proctored by research assistants, and the full implementation, including discussion, lasted approximately two hours. The intervention aimed to foster decision-making, teamwork, and AI literacy in a clinical nursing education.
214522309|NCT06999447|OTHER|Standard Education|In the control group (Standard Education), students followed the same structured case-based learning session as the intervention group, without access to AI tools. After providing informed consent and completing the pretest (sociodemographic form and CDMNS), the case scenario was introduced by the instructor. Students were divided into small groups and selected a representative to use a personal computer during the session. To ensure no access to AI-based tools, the Mobile Guardian app was installed to block websites such as ChatGPT. Students were allowed to use only academic databases and the university's online library. Each group answered a series of timed case questions (5 minutes per item), submitting responses before receiving the next question. Research assistants monitored the session in both classrooms to ensure standardization and prevent external support. The session concluded with a class-wide case discussion, led by the course instructor.
214522310|NCT03991416|BEHAVIORAL|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
214522311|NCT03991416|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
214522312|NCT03543982|DIETARY_SUPPLEMENT|Oral probiotic product|Once per day (QD), 28 days
214522313|NCT07004036|BEHAVIORAL|Occupation-based Self-Regulation Intervention Program|The intervention includes both group and individual applications. It has a large occupation/activity pool that can be selected in a person-centered manner. The activities are focused on supporting and developing the areas of influence in the sensory processing skills of individuals or the areas in executive functions, and providing occupations that will replace the screen and shape life in children for the screen abuse. It shapes the will, habits and routines necessary for the child to prefer alternative activities instead of the screen. For this purpose, an intervention program has been shaped to ensure that the child gains in the areas of daily life activities, productivity activities and leisure activities with the right developing skills, the child's wishes, the family's wishes, social expectations. As far as we know, it is the first flood regulation intervention program applied to children with screen addiction from an occupational therapy perspective.
214522314|NCT07004036|BEHAVIORAL|Family Awareness Training|Family awareness training on the harms of screen addiction and prolonged exposure to the screen, as a one-time event.
214522315|NCT07008729|DEVICE|Heart monitoring tools (data revision)|data collected by the devices will be reviewed by the treating physician in the intervention group
214522316|NCT07008729|OTHER|Control (Standard treatment)|Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations
215121228|NCT00956917|DEVICE|Akern USA EFG|Impedance measurement device
215121229|NCT00956917|DEVICE|RJL Impedance analyzer|Impedance analyzer
215121230|NCT05448339|COMBINATION_PRODUCT|PVHA or TACE|PVHA or TACE
215121231|NCT00359996|BEHAVIORAL|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
215121232|NCT00359996|OTHER|No additional educational sessions|
215121233|NCT00859547|BIOLOGICAL|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
215121234|NCT01302483|DRUG|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
215121235|NCT01302483|DRUG|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
215121236|NCT01364584|DRUG|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
215121237|NCT01364584|DRUG|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
214445214|NCT06228755|OTHER|Implementation Strategies|"Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity."
214445215|NCT06428903|DRUG|ADC189 tablet|ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
215121238|NCT05162183|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference group.
214522317|NCT07008573|OTHER|probiotics in soybean concentrate|treatment with topical probiotics on DFU
214522318|NCT07009223|BEHAVIORAL|Mediterranean Diet|Participants will receive only the educational intervention about the Mediterranean diet. The program consists of 4-5 online sessions conducted by a nutritionist.
214522319|NCT07009223|BEHAVIORAL|Physical Activity|In addition to educational sessions on the Mediterranean diet, there will be 2-3 weekly personalized exercise sessions, followed by a dedicated personal trainer at a partner gym. The treatment will last 12 weeks.
214522320|NCT07009223|BEHAVIORAL|Cognitive Training|In addition to educational sessions on the Mediterranean diet, there will be one weekly cognitive training session in groups, supervised by qualified staff at the IRCCS FBF. The treatment will last for 12 weeks.
214522321|NCT07008053|DRUG|BR+OR|Patients who meet the inclusion criteria will enter the treatment period, which consists of an induction phase followed by a maintenance phase. During the induction treatment period, a combined treatment of 3 cycles of the BR regimen and 3 cycles of the OR regimen will be administered, every 28-day cycle for 6 cycles. After the induction treatment, the efficacy assessment will determine whether patients with CR or PR proceed to the maintenance treatment period. Orelabrutinib monotherapy will used as maintenance therapy, every 28-day cycle for up to 24 cycles, or until disease progression/recurrence, unacceptable toxicity, death or consent withdrawal.
214522322|NCT07007845|BEHAVIORAL|CVT Support intervention|The CVT Emergency Aid program focused on optimising the work on the diaphragm was conducted in 3 steps. Step 1 related to establishing diaphragmatic breathing by feeling expansion around lower ribs at inhalation. Step 2 related to establishing connection between pulmonary pressure and subtotal pressurisation by invoking inwards abdominal movements on controlled exhaled voiceless exercises (ssss-sound) Step 3 related to establishing dynamic control of subglottal pressure by performing fricative voice sounds (vvvf- and zzz-sounds) while contracting the abdominal wall inwards and thereby pressurising the pulmonary space leading to increased subglottal pressure on accents and extended pitch accents.
214522323|NCT07007845|PROCEDURE|Dooming Diaphragm|Osteopathic treatment: Dooming Diaphragm. The inferior costal margin was contacted with the hands, allowing the thumbs to rest just below the ribcage anteriorly. Care was taken to avoid contact with the xiphoid process, as this could cause discomfort for the patient. The patient was instructed to breathe deeply, and as they exhaled, gentle pressure was applied superiorly and laterally with the thumbs, rolling them underneath the ribcage as far as was comfortable. This process was repeated for 3-5 breath cycles or until no tension was felt in the thumbs during exhalation.
214522324|NCT07008872|BIOLOGICAL|CD7 CART|For intravenous infusion
214522325|NCT07009405|DEVICE|non-invasive thermal infusion site monitoring NTISM device|Non-invasive thermal infusion site monitoring NTISM device for detecting extravasation and infiltration events using thermal anisotropy measurements
214522326|NCT07008690|DIAGNOSTIC_TEST|MRI|This exploratory study will longitudinally image patients diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 18 months using 3T MRI.
214522327|NCT07008690|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|For comparison, this exploratory study will image patients that are not diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 4 weeks.
214522328|NCT04344236|DRUG|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
214522329|NCT04344236|DRUG|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
214522330|NCT04344236|DRUG|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
215121239|NCT05162183|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
215121240|NCT01758809|PROCEDURE|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
215121241|NCT01758809|PROCEDURE|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
215121242|NCT01480960|OTHER|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
215121243|NCT05460455|DRUG|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
214445216|NCT06428903|DRUG|ADC189 granules|ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
214445217|NCT06428903|DRUG|ADC189 180mg|ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
214445218|NCT06106672|DRUG|CNP-106|CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
214445219|NCT06106672|OTHER|Placebo|CNP-106 Placebo
214445220|NCT06796556|DEVICE|virtual reality exposition|emotional response triggered by exposure to sensory stimuli presented in virtual reality.
214445221|NCT06793930|BEHAVIORAL|A tailored, optimised, and person-centred critical pathway to promote sustainable lifestyle modification|The TOP-S programme is a nurse-led intervention promoting the maintenance of lifestyle modification
214445222|NCT06793930|OTHER|Brief advice|once-off brief lifestyle advice lasting for 15 minutes
214445223|NCT05037526|DEVICE|Dexcom G System|Continuous glucose monitoring system
214445224|NCT05037526|DEVICE|Self monitoring blood glucose|Standard Care
214445225|NCT04626596|COMBINATION_PRODUCT|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
214445226|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of sevoflurane and opioid.
214445227|NCT04443517|BEHAVIORAL|Emergence from anesthesia with Dexmedetomidine|Infusion of .05 mcg/kg/h of propofol during the final 10-20 minutes of surgery.
214445228|NCT06790472|BEHAVIORAL|Online Lifestyle Intervention|The Metabolic Wellness Program (MWP) is an established 8-week program that provides participants with health education videos and webinars that focus on evidence-based nutrition, fitness, sleep, and stress intervention, including with CGM, allowing participants to monitor their real-time glucose data and to learn which lifestyle choices are best for their glycemic control and personal metabolic health. The program is also intended to help healthy participants maintain their metabolic health and lower their potential risk of developing cardiometabolic disease, as well as at-risk and pre-diabetic participants preventing the progression to T2D and people with established T2D reverse their condition.
214522331|NCT07008755|DRUG|Peginterferon α-2b injection|During the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 45 μg per administration, to be delivered on Day 1 and Day 3.
214522332|NCT07008755|DRUG|Peginterferon α-2b injection|CoDuring the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 90 μg per administration, to be delivered on Day 1 and Day 3.
214522333|NCT07009314|BEHAVIORAL|Implementation package (training, facilitation, electronic health record nudge)|"Training will consist of an initial presentation on S.A.F.E. Firearm by the study team, informational resources to support program delivery, and recommendations for self-guided continuing medical education programs.~Facilitation will last 6 months at each site. It may involve 1) a readiness assessment for each clinic to identify implementation barriers and develop relationships with constituents; 2) kick-off meetings at trial launch, at which staff will identify how to implement S.A.F.E. Firearm in the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain the program for future years.~A clinician decision support (nudge), designed to align with best practices within each health system, will be deployed in the EHR workflow to remind clinicians to deliver S.A.F.E. Firearm and offer a cable lock."
214522334|NCT02244775|DEVICE|SR™MCP|
214522335|NCT01613807|DRUG|Insulin LISPRO|Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
214522336|NCT01613807|DRUG|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
214522337|NCT04226651|DEVICE|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
214522338|NCT04226651|DEVICE|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
214522339|NCT01612221|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
214522340|NCT01612221|OTHER|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
214522341|NCT03015844|DRUG|131-I-meta-iodobenzylguanidine|
214522342|NCT03460327|DRUG|Candesartan|Patients are tested for their normal prescription candesartan medication
214522343|NCT01823926|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
214522344|NCT01823926|DEVICE|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
214522345|NCT01823926|DEVICE|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
214522346|NCT00468884|DRUG|Increasing doses of GLP-1|
214522347|NCT00468884|DRUG|PYY3-36|
215121244|NCT01161186|DRUG|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
215121245|NCT00491465|BEHAVIORAL|Intensive Physical activity|
214445229|NCT06790472|DEVICE|Continuous Glucose Monitoring|"CGM measurements begin at enrollment with training provided digitally Participants will be asked to live life as usual whilst wearing the device with initial 10-14 day readings providing baseline data. Participants will participate in the online lifestyle program, which the investigators refer to as the intervention stage. Participants will also receive questionnaires on behavior change at the beginning of week 5. During the final two weeks of the program (weeks 7-8), the final 10-14 days of CGM will be used as comparison data with baseline information."
214445230|NCT06797648|OTHER|data analysis|follow up after 15 months
214445231|NCT06795425|DIETARY_SUPPLEMENT|Postbiotic Active Lifestyle Blend|The active intervention, Postbiotic Active Lifestyle Blend, containing a heat-treated blend of bacterial strains; 2 capsules per day.
215121246|NCT00491465|BEHAVIORAL|Control- regular physical activity|
215121247|NCT03919539|DIAGNOSTIC_TEST|5hmc testing|NGS
215121248|NCT02944214|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
215121249|NCT02944214|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
214445232|NCT06795425|OTHER|Placebo|The placebo intervention contains no active ingredients and consists of maltodextrin as an inactive ingredient. The capsule matches the appearance and dosage form of the active intervention.
214445233|NCT04172506|DRUG|AK105|Anti-PD-1 antibody
214445234|NCT06840938|BEHAVIORAL|physiological maneuver|Group A will be subjected to physiological and postural trainings (traditional)
214445235|NCT06840938|DEVICE|Surface Electrical Stimulation|Group B will be subjected to Surface Electrical Stimulation through the use of electrodes and stimulators.
214445236|NCT06840938|COMBINATION_PRODUCT|Surface Electrical Stimulation|Group C will be subjected to both physiological and Surface Electrical Stimulation supports.
214445237|NCT06841003|DRUG|Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin|Peritoneal antibiotic lavage using a solution of gentamicin/clindamycin in NaCl 0.9%.
214522348|NCT04764864|PROCEDURE|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
215121250|NCT01919944|DRUG|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
215121251|NCT01919944|DRUG|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
214445238|NCT04020978|DIAGNOSTIC_TEST|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
215121252|NCT01773486|DRUG|Hesperidin|Citrus polyphenol, hesperidin
215121253|NCT01773486|DRUG|Placebo|Placebo matching hesperidin
214445239|NCT06834581|DEVICE|Vibrating mesh nebuliser|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128 kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled.
214445240|NCT06834581|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
214445241|NCT06795074|COMBINATION_PRODUCT|Optilume|Dilatation with drug-coated balloon
214445242|NCT06795074|DEVICE|UroMax Ultra|Dilatation with non-coated balloon
214445243|NCT06271512|OTHER|No Intervention|This is non-interventional study.
214445244|NCT06839690|PROCEDURE|Isometric training of thumb muscles|Isometric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using manual resistance and progress with training against resistance of elastic band and theraband.I
214445245|NCT06839690|PROCEDURE|Eccentric training for thumb muscles|In Group B, eccentric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using unweighted and weighted hammer curls and progress with training using elastic band, dumbbell and theraband.
214445246|NCT06839690|PROCEDURE|Ultrasound|Therapeutic ultrasound for symptom management
214445247|NCT06797804|OTHER|Information Technology-Assisted Horticultural Therapy Program|The intervention involves technology-assisted horticultural therapy sessions conducted once a week, lasting 120 minutes per session, over a total period of 8 weeks
214445248|NCT06176469|OTHER|No intervention|No intervention
214522349|NCT04764864|PROCEDURE|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
214522350|NCT00644332|DRUG|Ranolazine|Oral dosage form.
214522351|NCT01654445|DRUG|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
214522352|NCT01896921|DRUG|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
214522353|NCT00185783|DRUG|Hydrocortisone Administration (Standard of Care Therapy)|
214522354|NCT01319227|PROCEDURE|Hip replacement|Hip arthroplasty with uncemented components
214522355|NCT00627523|DRUG|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
214522356|NCT00627523|DRUG|Control-no treatment|Control-no treatment
214522357|NCT02603861|DRUG|LY3154207|LY3154207 administered orally.
214522358|NCT02603861|DRUG|Placebo|Placebo administered orally.
214522359|NCT02603861|DRUG|Modafinil|Modafinil administered orally.
214522360|NCT00702338|DRUG|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
214522361|NCT00702338|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
214522362|NCT00702338|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
214445249|NCT04953780|DRUG|Calaspargase pegol-mknl|Calaspargase pegol-mknl
214445250|NCT06840223|OTHER|Traditional stroke rehabilitation|Personalized traditional stroke rehabilitation programme including spasticity inhibition, sensory-perceptual-motor integration techniques, core stabilization and strengthening exercises, balance training i.e. applied as needed for stroke patients approximately for 45 minutes
214445251|NCT06840223|OTHER|Thoracolumbar fascia release|Thoracolumbar fascia release was performed by physiotherapist for one session. Supine Pelvic Rotation, Supine Arm Elevation, Bending Forward in Sitting Position and Sitting Crossed Arm and Knee Positions were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
214445252|NCT06840223|OTHER|Respiratory exercise|Respiratory exercises were performed by physiotherapist for one session. Pursed-Lip Breathing, Deep Breathing Exercise, Diaphragm Strengthening Exercise and Thoracic Expansion Exercises were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
214522363|NCT00702338|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
214522364|NCT06829979|BEHAVIORAL|Access to napping/relaxation room|During the night shift, study participants will have access to the hospital unit's napping/relaxation room with a sound machine, diffusers for aromatherapy, a massage chair that can be used for napping, and snacks.
214522365|NCT06829979|OTHER|Blue and green light blocking glasses|During the night shift, participants will be asked wear study-provided blue and green light blocking glasses.
214522366|NCT02344602|DRUG|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
214522367|NCT04607889|OTHER|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
214522368|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
214522369|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
214522370|NCT00734253|DRUG|Placebo|Placebo capsules taken twice a day for 1-year
214522371|NCT05399667|OTHER|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
214522372|NCT05399667|OTHER|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
214522373|NCT00266305|BEHAVIORAL|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
215121254|NCT01727596|OTHER|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
214445253|NCT06838923|COMBINATION_PRODUCT|Light Paraffin Oil|Embryos in this group will be cultured under conditions using light paraffin oil as an overlay in in vitro fertilization (IVF). The oil serves to protect the culture media from evaporation and temperature fluctuations. Key outcomes, including embryo development, blastocyst formation rate, and pregnancy rate, will be assessed.
214445254|NCT06838923|COMBINATION_PRODUCT|Heavy Paraffin Oil|Embryos in this group will be cultured under conditions using heavy paraffin oil as an overlay in in vitro fertilization (IVF). This study aims to compare the effects of heavy paraffin oil to light paraffin oil in embryo culture, assessing embryo development, blastocyst formation, and pregnancy rates.
214445255|NCT06736249|DIAGNOSTIC_TEST|Sarcopenic group|The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.
214445256|NCT06736249|OTHER|Muscle harvesting|A piece of discarded muscle during surgery will be collected
214445257|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
214522374|NCT01236963|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
214522375|NCT01236963|DEVICE|Dental Floss|
214522376|NCT00355784|OTHER|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
214522377|NCT00355784|DRUG|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
214522378|NCT04768491|DRUG|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
214522379|NCT02794441|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
214522380|NCT02794441|OTHER|Placebo|Matched oral solution
214522381|NCT02181751|OTHER|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
214522382|NCT00406276|DRUG|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
214522383|NCT00406276|DRUG|Docetaxel|In combination with RAD001
214522384|NCT05681390|DRUG|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
214522385|NCT03602053|BIOLOGICAL|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
214522386|NCT03602053|BIOLOGICAL|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
214522387|NCT03602053|BIOLOGICAL|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
214522388|NCT00575900|BEHAVIORAL|dietary intervention|12 weeks of dietary intervention
215121255|NCT04220216|OTHER|H4H fitness program|4 weekly, 1 hour exercise sessions
215121256|NCT05710055|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
214445258|NCT06735937|OTHER|Low flow anesthesia|Anesthesia management by using low flow anesthesia
214445259|NCT06645379|OTHER|Platelet-Rich Plasma (PRP) Injections|Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
214445260|NCT06813079|DRUG|Cobimetinib|"Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway.~Participants will take cobimetinib by mouth (orally), once a day on days 1 to 21 followed by a 7-day break of each cycle. A cycle will be 28 days in length."
214445261|NCT06813079|DRUG|Ponatinib|"Ponatinib is a type of drug called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that act as chemical messengers to stimulate cancer cells to grow. Ponatinib blocks and interferes with a number of protein kinases. It is called a multi kinase inhibitor.~Participants will take ponatinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days."
214445262|NCT06813079|DRUG|Brigatinib|"Brigatinib is a type of cancer growth blockers called a tyrosine kinase inhibitor (TKI). It blocks chemical signals (enzymes) from tyrosine kinase proteins. Tyrosine kinases help to send growth signals in cells, so blocking them stops the cell growing and dividing.~Participants will take brigatinib by mouth (orally), once a day for the first 7 days. If participants are able to tolerate the dose during the first 7 days, they will take the doubled dose orally, once a day until end of the cycle (day 8 to day 28). Each cycle will be 28 days in length."
214445263|NCT06813079|DRUG|Colchicine|"Colchicine is an alkaloid that affects the way the body responds to uric acid crystals, and reduces swelling and pain.~On the first day, participants will take two tablets of colchicine by mouth (orally), then one tablet orally one hour later. Starting the second day, participants will take one tablet of colchicine once or twice a day, every day of each cycle. A cycle will be 28 days in length. The study doctor will decide whether participants will take colchicine once or twice a day."
214445264|NCT06813079|DRUG|Selinexor|"Selinexor blocks a protein called CRM1, a protein within the cell, and may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor.~Participants will take selinexor by mouth (orally), once a week on days 1, 8, 15, and 22 of each cycle. A cycle will be 28 days in length."
214522389|NCT06381297|DIAGNOSTIC_TEST|Hearing test|Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
214522390|NCT06381297|DIAGNOSTIC_TEST|Speech in noise discrimination test|Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
214522391|NCT06381297|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale|Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
214522392|NCT06381297|DIAGNOSTIC_TEST|Symbol Number Modalities Test (SDMT)|Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
214522393|NCT05051488|PROCEDURE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
214522394|NCT05051488|DEVICE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
214522395|NCT00160537|DRUG|Levocetirizine|
214522396|NCT06375317|DRUG|PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets|"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."
214522397|NCT02219529|DEVICE|MCE|
214522398|NCT02219529|DEVICE|Standard gastroscopy|
214522399|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
214522400|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
214522401|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
214693642|NCT06004141|BEHAVIORAL|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
214693643|NCT05494541|OTHER|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
214693644|NCT00173251|PROCEDURE|obtain surgical specimen for analysis|
214445265|NCT06813079|DRUG|Abemaciclib|"Abemaciclib belongs to a class of medications called kinase inhibitors. Abemaciclib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.~Participants will take abemaciclib by mouth (orally), twice a day, every day of each cycle. A cycle will be 28 days in length."
214445266|NCT06813079|DRUG|Neratinib|"Neratinib is a targeted cancer drug that works on a protein called human epidermal growth factor receptor 2 (HER2). HER2 proteins make cells divide and grow. Some cancers have large amounts of HER2 proteins which can cause cancer cells to divide and grow faster. Neratinib works by locking onto the HER2 on the cancer cells. So it stops the cells from growing.~Participants will take neratinib by mouth (orally), once a day, every day of each cycle. Dose will increase weekly, until week 3. On week 3 and onward, participants will take the same dose. A cycle will be 28 days in length."
214445267|NCT06813079|DRUG|Doxorubicin|"Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2. Cancer cells need this enzyme to divide and grow.~Participants will receive doxorubicin by vein (intravenous infusion or IV) in clinic, over 60-90 minutes, once every cycle. A cycle will be 21 days in length. Participants may receive 6-8 cycles of study drug."
214445268|NCT06813079|DRUG|Etoposide|"Etoposide is a chemotherapy drug that destroys quickly dividing cells, such as cancer cells.~Participants will receive etoposide by mouth (orally), twice a day, on days 1 to 7 of every cycle. On days 8 to 21, there will be no dosing. A cycle will be 21 days in length."
214445269|NCT06813079|DRUG|Ceritinib|"Ceritinib is a tyrosine kinase inhibitor. It works by blocking an enzyme called anaplastic lymphoma kinase (ALK). Ceritinib only works in cancer cells that have an overactive version of ALK.~Participants will take ceritinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days in length."
214445270|NCT06840275|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|Two intravenous infusions of C2C\_ASC110 1 month apart. The C2C\_ASC110 product contains 110 million cells.
214445271|NCT06840275|OTHER|Cryostor CS10|Two intravenous infusions of CryoStor CS10 1 month apart.
214445272|NCT06838754|OTHER|Whole body vibration therapy|Experimental group will get whole body vibrations. WBV will be performed by the patient while seated on the vibrating plate's base. Five series with a 30-second wait will make up each session. Five minutes and thirty seconds will be spent on vibration, and twenty minutes and thirty seconds will be spent on exercise. 5 Hz will be the frequency utilized. Over the course of two months, 16 classes will be held twice a week.
214445273|NCT06838754|OTHER|Routine physical therapy|Group B will only get routine physical therapy. Walking in all directions, advancing past the point of stability in a variety of positions, including half-kneeling, standing on both soft and hard surfaces, stepping up and down, walking and standing simultaneously, and standing on one leg with eyes open and closed were all part of the postural control exercise. There will be a 20-minute session.As each participant's functional improvement progresses, the intensity of the workout program will progressively rise. There will be 16 sessions in total (two days a week), with 8 sessions for each group.
214445274|NCT04745299|BIOLOGICAL|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
214445275|NCT04745299|DRUG|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
214445276|NCT04745299|DRUG|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
214445277|NCT00890006|PROCEDURE|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
214445278|NCT06789640|OTHER|Vitamin C|"Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups"
214693645|NCT01827059|DRUG|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
214693646|NCT01827059|DRUG|Placebo|
214445279|NCT06789640|OTHER|Placebo|"Placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls"
214445280|NCT04249947|BIOLOGICAL|P-PSMA-101 CAR-T cells|P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).
214445281|NCT04249947|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated
214445282|NCT04411823|DEVICE|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
214445283|NCT05141903|DIETARY_SUPPLEMENT|Antibiotic|Vancomycin (250 mg/dose), Metronidazole (500 mg/dose)
214693647|NCT03153735|DEVICE|CMDHA0101|Maximum injection dose : 22 ml
214693648|NCT03153735|DEVICE|PowerFill®|Maximum injection dose : 22 ml
214693649|NCT03061370|PROCEDURE|Esophagectomy or Gastrectomy|Surgical resection
214693650|NCT02536170|DRUG|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
214693651|NCT02536170|DRUG|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
214693652|NCT02536170|OTHER|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
214693653|NCT04923919|DRUG|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
214693654|NCT04774679|PROCEDURE|Endosonographic fine needle aspiration biopsy|An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
214445284|NCT05141903|DIETARY_SUPPLEMENT|HMO Concentrate|Concentrated milk fortifiers from donor human milk
214445285|NCT05141903|DIETARY_SUPPLEMENT|Probiotic|B. infantis
214445286|NCT05141903|DIETARY_SUPPLEMENT|Food Supplement|Synthetic powder containing 2'-fucosyllactose (2'-FL) and lactoneotetraose (LNnT)
214445287|NCT06833151|DEVICE|Ultrasound Respiratory Assessment|For lung ultrasound analysis, we selected ultrasound recordings of the right lower lung apex at the costophrenic angle along the right mid-axillary line. Using the open-source image processing tool ImageJ 1.4, the pleural line corresponding to the right lower lung apex was enhanced and its terminal coordinates extracted. During respiration, the right lower lung apex moves with the breathing cycle, and the pleural line exhibits corresponding motion. The terminal coordinates of the pleural line also shift during respiration, and a plot of this displacement against time is generated to create the pleural line sliding displacement curve.
214445288|NCT04140721|DRUG|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
214445289|NCT04140721|DRUG|Moxonidine Pill|Moxonidine pill administered for 4 weeks
214445290|NCT06202872|DEVICE|Gamma (40 Hz) tACS at the precuneus region|40 Hz tACS applied at a current of 3.2 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
214445291|NCT06202872|DEVICE|Sham tACS at the precuneus region|Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
214445292|NCT04494048|OTHER|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
214445293|NCT04452877|DRUG|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
214522402|NCT01291524|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
214522403|NCT01038128|DRUG|Memantine|Drug: Memantine, 10-40 mg daily
214522404|NCT04851288|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
214522405|NCT04851288|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
214522406|NCT01769352|DRUG|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
214522407|NCT02144116|OTHER|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
214522408|NCT02144116|OTHER|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
214522409|NCT05955222|DEVICE|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
214522410|NCT05955222|DEVICE|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
214522411|NCT05955222|DEVICE|Traditional|Participants receiving splints from vacuum forming system
214522412|NCT05770193|OTHER|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
214693655|NCT05172193|BIOLOGICAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
214693656|NCT03331666|DRUG|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
214693657|NCT03230162|DRUG|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
214693658|NCT03230162|DRUG|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
215121257|NCT05710055|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
215121258|NCT05710055|DIETARY_SUPPLEMENT|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
214445294|NCT04452877|DRUG|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
214445295|NCT05461417|DEVICE|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
214445296|NCT06364371|OTHER|Medical examination|Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
214445297|NCT05805384|DEVICE|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
214445298|NCT06050070|OTHER|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
214445299|NCT06050070|OTHER|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
214445300|NCT06391177|DRUG|Vonoprazan|Oral tablet.
214445301|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
214522413|NCT05770193|OTHER|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
214522414|NCT05770193|OTHER|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
214693659|NCT02581566|DRUG|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
214693660|NCT02581566|DRUG|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
214693661|NCT02581566|DRUG|Bupivacaine|Intrathecal Bupivacaine
214693662|NCT02326467|DRUG|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
214693663|NCT05811767|OTHER|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
214693664|NCT00681967|DRUG|Gefitinib|250 mg; oral
214693665|NCT00681967|DRUG|Gefitinib|250mg; oral
214693666|NCT00091143|BIOLOGICAL|gp100 antigen|
214693667|NCT00091143|BIOLOGICAL|incomplete Freund's adjuvant|
214693668|NCT00091143|BIOLOGICAL|keyhole limpet hemocyanin|
214693669|NCT00091143|DRUG|fludarabine phosphate|
214693670|NCT00091143|PROCEDURE|peripheral blood stem cell transplantation|
214693671|NCT03695640|DRUG|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
214693672|NCT03695640|PROCEDURE|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
214693673|NCT00434512|BIOLOGICAL|HIV vaccine 732461|
214693674|NCT01063816|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
214693675|NCT01063816|DRUG|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
214693676|NCT01063816|DRUG|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
214693677|NCT02526758|DRUG|beclomethasone|
214693678|NCT02526758|DRUG|formoterol|
214693679|NCT02526758|DRUG|budesonide|
214693680|NCT00745186|DRUG|Glucagen|0.2 mg or 1 mg Glucagen single injection
214693681|NCT00745186|DRUG|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
214693682|NCT03570034|DEVICE|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
214693683|NCT03472235|DEVICE|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
214693684|NCT00199134|DRUG|Letrozole|Size of the tumor is followed
214693685|NCT03489616|BIOLOGICAL|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
214693686|NCT03489616|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
214693687|NCT03489616|RADIATION|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
215121259|NCT05710055|DIETARY_SUPPLEMENT|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
215121260|NCT05161416|BEHAVIORAL|Bubble Blowing|Active Distraction Methods
214693688|NCT03489616|DRUG|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
215121261|NCT05161416|BEHAVIORAL|Cartoon Watching|Passive Distraction Methods
214445302|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
214445303|NCT06384651|DRUG|Intraosseous Vancomycin Injection|"* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus."
214445304|NCT06384651|DRUG|Intravenous Vancomycin|• Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
214445305|NCT04582708|DEVICE|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
214445306|NCT03911388|BIOLOGICAL|G207|Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
214445307|NCT04490720|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
214445308|NCT04490720|DIETARY_SUPPLEMENT|Buckwheat husk extract|consume 1 sachet per day for 2 months
214445309|NCT03764137|DRUG|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
214445310|NCT03089398|PROCEDURE|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
214445311|NCT03089398|DEVICE|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
214522415|NCT05770193|OTHER|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50\_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 \_75% tension and the tails will be applied toward the ribs."
214522416|NCT04769219|OTHER|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
214522417|NCT05450939|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
214522418|NCT04554615|DRUG|Insulin|insulin infusion to control postoperative hyperglycemia
214522419|NCT03639649|DIAGNOSTIC_TEST|STHLM3|
214522420|NCT00487253|DRUG|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
214522421|NCT00487253|DRUG|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
214522422|NCT00800917|DRUG|Temsirolimus|25 mg weekly IV
214522423|NCT00800917|DRUG|Bevacizumab|10 mg/kg every 2 weeks
215028955|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
214445312|NCT03089398|DEVICE|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
214445313|NCT02519452|DRUG|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
214445314|NCT02519452|DRUG|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
214445315|NCT06847061|BEHAVIORAL|Pulmonary rehabilitation program|"Participants are expected to engage in the home-based pulmonary rehabilitation routine at least 24 minutes a day, five to six days a week for the entire 12-week study period.~The pulmonary rehabilitation routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time again is 24 minutes, followed by a 4-minute mindful breathing meditation/cool down"
214522424|NCT03292744|DRUG|Alfacalcidol|alfacalcidol 0,5 mcg
214522425|NCT06055478|PROCEDURE|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block|"Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline.~Low fixed dose patient controlled analgesia (PCA) were done in the two group."
214522426|NCT04958434|DRUG|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
214445316|NCT06074614|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
214693689|NCT00014378|DRUG|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
214693690|NCT00797797|DRUG|No Treatment Added|No added treatment
214445317|NCT06074614|DIAGNOSTIC_TEST|Respiratory related evoked potential|The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
214693691|NCT00797797|DRUG|Milnacipran Added|Milnacipran 100 mg/d added
214445318|NCT06074614|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
214445319|NCT05062265|DEVICE|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
214445320|NCT05062265|DEVICE|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
214445321|NCT04626037|BEHAVIORAL|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
214445322|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
214445323|NCT06400433|PROCEDURE|Ultrasound-guided median nerve hydrodissection|Injected wrist will be supinated and slightly dorsiflexed. The transducer of the ultrasound will be placed transversely at the proximal carpal inlet. After sterile preparation, a 22 gauge needle will be inserted using the short-axis technique, in-plane ulnar approach. During hydrodissection, separation of either between the median nerve and flexor retinaculum or between the median nerve and the underlying flexor tendons will be visually confirmed.
214445324|NCT05677334|DRUG|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
214522427|NCT02871453|DEVICE|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
214522428|NCT02871453|OTHER|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
214522429|NCT00003541|BIOLOGICAL|filgrastim|
214522430|NCT00003541|DRUG|CHOP regimen|
214522431|NCT00003541|DRUG|carboplatin|
214522432|NCT00003541|DRUG|cyclophosphamide|
214522433|NCT00003541|DRUG|doxorubicin hydrochloride|
214522434|NCT00003541|DRUG|etoposide|
214522435|NCT00003541|DRUG|ifosfamide|
214522436|NCT00003541|DRUG|prednisone|
214522437|NCT00003541|DRUG|vincristine sulfate|
214522438|NCT00003541|PROCEDURE|peripheral blood stem cell transplantation|
214522439|NCT00003541|RADIATION|radiation therapy|
214522440|NCT04203225|DRUG|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
214522441|NCT04399798|DRUG|Baricitinib|4 mg/day for 7 days
214522442|NCT04457245|PROCEDURE|Computed Tomography|Undergo whole body PET/CT
214522443|NCT04457245|OTHER|Fluorine F 18 DCFPyL|Given IV
214522444|NCT04457245|PROCEDURE|Positron Emission Tomography|Undergo whole body PET/CT
214522445|NCT04457245|RADIATION|Radiation Therapy|Undergo standard of care definitive radiation therapy
214522446|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
214522447|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
214522448|NCT00301730|BIOLOGICAL|aldesleukin|
214522449|NCT00301730|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214522450|NCT00301730|BIOLOGICAL|trastuzumab|
214522451|NCT00301730|DRUG|paclitaxel|
214522452|NCT00301730|PROCEDURE|conventional surgery|
214522453|NCT06388876|OTHER|Exercise|Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
214693692|NCT05133193|DRUG|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
214693693|NCT03144583|BIOLOGICAL|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
214693694|NCT01575197|BIOLOGICAL|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
214693695|NCT02233205|DEVICE|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
214693696|NCT02233205|DRUG|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
214445325|NCT05677334|DEVICE|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
214445326|NCT06388590|OTHER|Dragons|The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.
214445327|NCT06388590|OTHER|Standard of Care|Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
214445328|NCT06846216|DEVICE|Treatment with BTL-785F and HPM-6000UF Devices|Three treatment sessions will consist of the consecutive application of the BTL-785F and HPM-6000UF devices, delivered 5-10 days apart. Three sessions will consist of the standalone application of the HPM-6000UF device, delivered 2-4 days apart. The treatments with BTL-785 device equipped with BTL-785-3 applicator will last 2-10 minutes and with HPM-6000UF 28 minutes.
214445329|NCT06847659|DIAGNOSTIC_TEST|intraoperative body temperature|Body temperature measurement with esophageal probe
214445330|NCT06373835|DRUG|Emodepside|5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
214445331|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
214445332|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
214445333|NCT06845956|OTHER|Is it coronary artery embolism|"This observational study categorizes patients with acute myocardial infarction (AMI) into three distinct groups based on their clinical characteristics:~1. Group 1: Patients with atrial fibrillation (AF) and coronary artery embolism (CAE).~2. Group 2: Patients with AF but non-coronary artery embolism myocardial infarction (non-CAE MI).~3. Group 3: Patients without AF and non-coronary artery embolism myocardial infarction (non-CAE MI without AF).~A key innovation of this study compared to previous research is its expanded eligibility criteria for AMI patients. Earlier studies typically focused exclusively on ST-segment elevation myocardial infarction (STEMI). In contrast, this investigation encompasses a broader spectrum of acute myocardial infarction, including both STEMI and non-ST-segment elevation myocardial infarction (NSTEMI). This comprehensive approach enhances the generalizability and applicability of the findings by capturing a wider range of clinical scenarios."
214445334|NCT05275075|OTHER|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
214522454|NCT06388876|OTHER|lifestyle advice|At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
214522455|NCT05222178|DRUG|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
214522456|NCT03445507|OTHER|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
214522457|NCT03445507|OTHER|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
214522458|NCT03364283|PROCEDURE|Surgical position|
214522459|NCT00128908|DRUG|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
214522460|NCT00128908|DRUG|Rapidly Cycled HAART|
214445335|NCT06845111|OTHER|Therapeutic play|In this context, the pre-school teachers in the container area were contacted and the sessions were held every Wednesday-Thursday (8 sessions in total) for 5 weeks, taking into account their availability hours. Children were included in the programme in groups of 12. Before data collection, the necessary materials were provided and stored in an empty container. It was found appropriate to complete the trainings in kindergartens located in the container city (4). A total of 3 evaluations were carried out: a post-test immediately after the end of the programme and a retention test at the end of the first month.
214445336|NCT03107520|DIAGNOSTIC_TEST|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
214445337|NCT03107520|DRUG|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
214445338|NCT06357130|OTHER|Questionnaire|A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
214522461|NCT01193283|DRUG|Cyclophosphamide|30 my/kg for 4 days
214522462|NCT01193283|DRUG|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
214522463|NCT00784771|BEHAVIORAL|Hypnotherapeutic Olfactory Conditioning (HOC)|
214522464|NCT02936193|PROCEDURE|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
214522465|NCT02936193|PROCEDURE|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
214522466|NCT01745718|OTHER|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
214522467|NCT00830284|PROCEDURE|Recruitment maneuver|"Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
214522468|NCT05980325|BEHAVIORAL|Nordic Walking|A 12-week Nordic Walking exercise programme supervised twice weekly
214522469|NCT05980325|BEHAVIORAL|Aquatic Exercise|A 12-week water-based exercise training programme supervised twice weekly
214522470|NCT05980325|BEHAVIORAL|Functional Exercise Training|A 12-week circuit-based exercise training programme supervised twice weekly
214693697|NCT01726413|DRUG|GRC 17356|
214693698|NCT01726413|DRUG|Matching Placebo|
214693699|NCT04253834|DEVICE|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
214693700|NCT04253834|DEVICE|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
214445339|NCT06843915|OTHER|Moderate intensity aerobic exercise|Participants in the MIAE group engaged in a 40-minute supervised session using the StepOne-SCIFIT recumbent stepper machine. The session included a 5-minute warm-up at 25 watts, followed by 30 minutes of moderate-intensity exercise, main-taining a stepping rate of 90-100 steps per minute. The workload was adjusted to keep the participant's heart rate within the target heart rate range (THRR), calculated using the Karvonen formula. During the first three weeks, the exercise intensity was set at 50-59% of heart rate reserve (HRR), and for the remaining three weeks, it was increased to 60-69% of HRR. Polar heart rate monitors were used to assess heart rate before and after each session. Participants kept weekly exercise logs to monitor compliance.
214445340|NCT06843915|OTHER|Home Exercise Program|Home Exercise Program
214522471|NCT00952016|DRUG|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
214522472|NCT01537900|DRUG|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
214522473|NCT02281214|OTHER|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
214693701|NCT01630096|DRUG|Nu-Lytely|Bowl prep solution.
214693702|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
214522474|NCT04950790|DRUG|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
214522475|NCT04950790|DRUG|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
214693703|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
214693704|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
214693705|NCT05151679|DRUG|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
214693706|NCT05151679|DRUG|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
214693707|NCT03481127|BEHAVIORAL|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
214693708|NCT03481127|OTHER|Surveys|"* NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey"
214693709|NCT03481127|PROCEDURE|Blood draw|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment"
214693710|NCT03481127|PROCEDURE|Fresh tissue from ovary|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery"
214693711|NCT02694627|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
214693712|NCT02737735|DRUG|standard chemotherapy medicine combined with Chinese herbs|
214693713|NCT02737735|DRUG|standard chemotherapy medicine|
214522476|NCT04950790|DRUG|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
214693714|NCT01527227|OTHER|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
214693715|NCT00132236|DRUG|nicotine sublingual tablets|
214522479|NCT05304884|COMBINATION_PRODUCT|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
214522480|NCT01838447|DIETARY_SUPPLEMENT|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
214693716|NCT00132236|BEHAVIORAL|low and high behavior support|
215121262|NCT02431988|PROCEDURE|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
214693717|NCT04615702|DIAGNOSTIC_TEST|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis"
214445341|NCT06844253|PROCEDURE|INTERVENTION GROUP; TRAINING WITH EXERGAMING|RANDOMIZED CONTROL TRIAL EXERGAMING KINECT 20,000 LEAKS , KINECT BUBBLE POP, KINECT RALLY BALL GROUP 2: TASK ORIENTED TRAINING TRANSFERRING OBJECTS FROM ONE SIDE TO OTHER SIDE OF TABLE CATCHING AND THROWING BALLSIN DIFFERENT DIRECTIONS PICKING UP OBJECTS FROM LESS HIGHTED TABLES.
214693718|NCT04615702|DEVICE|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
214693719|NCT04615702|DEVICE|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
214693720|NCT04615702|DIAGNOSTIC_TEST|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
214693721|NCT04615702|DEVICE|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
214693722|NCT04615702|DRUG|Ringer lactate|"The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
215121263|NCT02431988|DRUG|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
214445342|NCT06844253|PROCEDURE|Task oriented training|"The participant will receive task oriented training consisting of different tasks in sitting and standing position.~week1-2 sitting position: throwing and catching balls standing position: picking up glass from less heighted table . week 3-4 sitting position: transferring the plastic rings from one corner of table to another.~standing position: catching balls from multiple directions. wee5-6 sitting position: picking objects from floor standing position: opening drawer from less heighted tables week 7-8 standing position: picking up and transferring bottles, jars at different locations on table standing position: removing stickers from wall time of session: 15-20 reps, 2 sets. 30 minutes of session with 5 minutes rest in between. the intervention will be given for 30 minutes , 3 days a week for total 8 weeks of time period."
214445343|NCT06842797|OTHER|Weighted Blanket|Participants will lie down and be covered with a weighted blanket.
214445344|NCT06842797|OTHER|Non Weighted Blanket|Participants will lie down and be covered with normal weight blanket (non-weighted blanket)
214445345|NCT05233527|PROCEDURE|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
214445346|NCT00909961|DRUG|Zoledronic acid|
214445347|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
214445348|NCT05341661|DEVICE|Butterfly Prostatic Retraction Device|Implantation of the Butterfly device
214445349|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
214445350|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
214693723|NCT04615702|COMBINATION_PRODUCT|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
215121264|NCT02431988|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
215121265|NCT02431988|BIOLOGICAL|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg"
215121266|NCT05449184|PROCEDURE|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
214445351|NCT03902951|DRUG|Abiraterone Acetate|Given PO
214445352|NCT03902951|DRUG|Apalutamide|Given PO
214445353|NCT03902951|DRUG|Leuprolide Acetate|Given SC
214445354|NCT03902951|OTHER|Quality-of-Life Assessment|Ancillary studies
214445355|NCT03902951|OTHER|Questionnaire Administration|Ancillary studies
214445356|NCT03902951|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214445357|NCT05784740|OTHER|12-week precision exercise training|The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
214522481|NCT05164133|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
214522482|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
214522483|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
214522484|NCT01120561|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
214522485|NCT00168805|DRUG|enoxaparin|40 mg once daily
214522486|NCT00168805|DRUG|dabigatran etexilate|150 mg once daily
214445358|NCT06450704|OTHER|Physical Exercise|"Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes."
214445359|NCT03490825|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
214445360|NCT03490825|DIETARY_SUPPLEMENT|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
214445361|NCT03490825|OTHER|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
214445362|NCT03490825|OTHER|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
214445363|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
214522487|NCT00168805|DRUG|dabigatran etexilate|220 mg once daily
214522488|NCT00302406|DRUG|methylphenidate hydrochloride|
214693724|NCT04615702|COMBINATION_PRODUCT|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"* Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given."
214693725|NCT04615702|DIETARY_SUPPLEMENT|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs"
214693726|NCT04615702|DEVICE|nasogastric tube|in case of ileus or vomiting
214693727|NCT04615702|PROCEDURE|retroperitoneal necrosectomy|"* General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
215121267|NCT05449184|PROCEDURE|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
214445364|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
214445365|NCT03737058|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
214445366|NCT02682316|OTHER|dry gauze|
214445367|NCT02682316|DEVICE|The Prevena Incision Management System|
214522489|NCT00302406|DRUG|OROS methylphenidate hydrochloride (CONCERTA)|
214522490|NCT03199261|DRUG|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
214522491|NCT03199261|DRUG|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
214522492|NCT01910740|OTHER|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
214445368|NCT06172699|DEVICE|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
215028956|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
214445369|NCT04715399|OTHER|No intervention|No intervention
214445370|NCT05938803|BEHAVIORAL|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
214522493|NCT01910740|OTHER|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
214522494|NCT01910740|OTHER|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
214522495|NCT03998423|BIOLOGICAL|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
214522496|NCT00161408|BEHAVIORAL|cognitive behavioural therapy|
214522497|NCT00161408|BEHAVIORAL|psychoeducation|
214522498|NCT06571019|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
214522499|NCT05804981|OTHER|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
214522500|NCT01655862|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
214522501|NCT00426218|DRUG|ACZ885|
214522502|NCT01033123|DRUG|BSI-201|IV infusion, 5.6 mg/kg
214522503|NCT05236218|OTHER|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
214522504|NCT05236218|OTHER|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
214522505|NCT00845286|BEHAVIORAL|Munich Marathon|42,195 km marathon run
214522506|NCT02782273|DRUG|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
214522507|NCT02782273|DRUG|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
214522508|NCT01090856|PROCEDURE|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
214522509|NCT05971199|DRUG|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
214522510|NCT05971199|DRUG|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
214522511|NCT05971199|DEVICE|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
214522512|NCT03363100|BEHAVIORAL|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
214522513|NCT05438745|OTHER|Copenhagen Burnout Inventry|Questionnaire
214522514|NCT03460444|DIETARY_SUPPLEMENT|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
214522515|NCT06384859|DEVICE|ESWT|Receive ESWT once a week for 4 weeks
214522516|NCT06384859|BIOLOGICAL|PRP|Receive PRP injection at week 5
214522517|NCT02093078|BEHAVIORAL|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
214522518|NCT00967915|PROCEDURE|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
214522519|NCT00967915|OTHER|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
214522520|NCT04554316|DEVICE|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
215121268|NCT01102088|RADIATION|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
214445371|NCT05693610|DEVICE|Portable OSP|The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
214445372|NCT05693610|DEVICE|Cloud-based OSP|The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
214445373|NCT05927753|DEVICE|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
214445374|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
214522521|NCT04117711|DRUG|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
214522522|NCT04117711|DRUG|Placebo|Matching placebo will be administered once in the morning before breakfast
214522523|NCT01029418|DRUG|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
214522524|NCT04320433|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
214522525|NCT02878720|DEVICE|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
215121269|NCT03685630|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection"
215121270|NCT05563610|DRUG|Amoxicillin 500mg|Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
214445375|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
214445376|NCT04781621|DEVICE|Robotic Gait Training|Participants will wear an exoskeleton suit and receive robotic gait training with a physical therapist for 90 minutes each week. Robot gait training will include standing and walking activities while wearing the The Ekso Bionics Ekso GT™ robotic exoskeleton. Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor.
214445377|NCT04781621|OTHER|Usual Care Gait Training|Participants receive usual care gait training with a physical therapist for 90 minutes each week. Usual care gait training includes standard gait training involving standing and walking activities such as conventional overground walking, body weight-supported treadmill training (BWSTT), overground body weight-supported overground system, and various assistive devices (e.g., BWSTT, overground with braces, walker, etc.). Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor and number of steps.
214445378|NCT00051545|DRUG|Seocalcitol|
214445379|NCT03915379|DRUG|JNJ-67571244|JNJ-67571244 will be administered.
214522526|NCT02394171|BEHAVIORAL|Group Cohesion|See description in arm/group above
214522527|NCT02324088|DRUG|Docetaxel|
214522528|NCT02324088|DRUG|Cyclophosphamide|
214522529|NCT02324088|DRUG|Epirubicin|
214522530|NCT00682344|DRUG|Levobupivacaïne|1,75mg/kg
214522531|NCT00472199|DRUG|Pramipexole|
214522532|NCT00472199|DRUG|Placebo|
214522533|NCT00312871|DRUG|Epoetin alfa|
214522534|NCT01406899|BEHAVIORAL|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
214445380|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
214445381|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
214445382|NCT04452084|RADIATION|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
214445383|NCT04452084|RADIATION|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
214445384|NCT06580548|DEVICE|CHW-supported telerehabilitation|Participants will receive the Mobile Rehab mobile software, which allows participants to be prescribed personalized rehabilitation strengthening video regimens electronically based on respondent-indicated mobility and activities of daily living functionality
214445385|NCT06580548|OTHER|Usual Care|Participants will be provide a list of local social services resources, including mental health, that participants can use . A callback number will be provided if they have any questions about the services.
214445386|NCT00000958|BIOLOGICAL|MTP-PE/MF59|
214522535|NCT00367445|DRUG|Inhaled Human Insulin (Exubera)|
214693728|NCT04615702|PROCEDURE|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
215121271|NCT04675385|DRUG|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
215121272|NCT04562181|OTHER|Bispectral index and qCON/qNOX monitoring|This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
215121273|NCT00210717|DRUG|paliperidone palmitate|
215121274|NCT04890379|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
215121275|NCT04890379|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
215121276|NCT00000801|DRUG|Filgrastim|
214445387|NCT00000958|BIOLOGICAL|Env 2-3|
214445388|NCT01988935|BEHAVIORAL|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
214445389|NCT01988935|BEHAVIORAL|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
214445390|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
214445391|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
214445393|NCT05912556|DEVICE|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
214445394|NCT05912556|DEVICE|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
214445395|NCT05521984|DRUG|Dapagliflozin|Commercially available
214445396|NCT05521984|DRUG|Carmustine|Standard of care
214445397|NCT05521984|DRUG|Topotecan|Standard of care
214522536|NCT00367445|DRUG|Insulin Glargine (Lantus)|
214522537|NCT01540071|DRUG|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
215121277|NCT00000801|DRUG|Vincristine sulfate|
214522538|NCT03635242|OTHER|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
214445398|NCT05521984|DRUG|Cyclophosphamide|Standard of care
214445399|NCT03630328|DIETARY_SUPPLEMENT|Cogni.Q|AGN
214445400|NCT03630328|OTHER|Placebo|Placebo
214445401|NCT06388980|OTHER|Validated questionnaires and ad hoc questions|validated questionnaires and open questions online through the institution's intranet anonymous
214445402|NCT05832983|BEHAVIORAL|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
214445403|NCT05832983|OTHER|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
214445404|NCT05497453|DRUG|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
214445405|NCT05497453|DRUG|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
214445406|NCT05497453|DRUG|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
214445407|NCT05497453|DRUG|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
214445408|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm."
214445409|NCT00150813|DRUG|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
214445410|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
214445411|NCT06166927|DEVICE|Cuffed endotracheal tube|Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
214445412|NCT06166927|DEVICE|UnCuffed ETT|Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
214445413|NCT06351046|DEVICE|Virtual Reality-based Pain Self-management program|The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
214445414|NCT05349370|OTHER|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
214693729|NCT04615702|PROCEDURE|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
214693730|NCT04615702|PROCEDURE|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
214693731|NCT04615702|PROCEDURE|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
214445415|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
214445416|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
214445417|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
215121278|NCT00000801|DRUG|Doxorubicin hydrochloride|
214445418|NCT06030388|OTHER|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
214445419|NCT06030388|OTHER|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
214445420|NCT00268723|DRUG|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
214445421|NCT00268723|DRUG|Placebo|Placebo MDI QID
214693732|NCT04615702|PROCEDURE|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
214445422|NCT05143931|BEHAVIORAL|Home food environment and grocery delivery (AVOID)|Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices
214445423|NCT05143931|BEHAVIORAL|Inhibitory control training (RESIST)|Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
214445424|NCT05143931|BEHAVIORAL|WW|Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
214445425|NCT06783101|BEHAVIORAL|Use of smart inhaler to enhance asthma inhaler proficiency|The application of the smart inhaler technology to enhance asthma inhaler proficiency
214522539|NCT03635242|OTHER|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
214522540|NCT03024593|BEHAVIORAL|Health- and illness-related internet use|
214693733|NCT01938690|DEVICE|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
214693734|NCT03137121|DRUG|Olanzapine|Olanzapine is used as an anti-emetic.
214693735|NCT03137121|OTHER|Placebo|The placebo is a non-anti-emetic.
214693736|NCT03448978|BIOLOGICAL|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
214693737|NCT03448978|DRUG|Fludarabine|intravenous fludarabine
214693738|NCT03448978|DRUG|Cyclophosphamide|intravenous cyclophosphamide
214693739|NCT00380211|BIOLOGICAL|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
214693740|NCT00380211|BIOLOGICAL|Fluarix|
214445426|NCT05344963|DRUG|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
214522541|NCT04132388|OTHER|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
214522542|NCT04132388|DRUG|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
214693741|NCT06226688|PROCEDURE|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
214693742|NCT06226688|PROCEDURE|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
214693743|NCT02236728|DRUG|Pramipexole|
214693744|NCT01290445|DRUG|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
214693745|NCT01290445|BEHAVIORAL|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
214693746|NCT01290445|OTHER|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
214693747|NCT05210205|DIETARY_SUPPLEMENT|EAA|EAA-enhanced protein snack bars
214693748|NCT05210205|DIETARY_SUPPLEMENT|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
214693749|NCT05210205|DIETARY_SUPPLEMENT|Control|Low energy dense snack bars (same calories in a greater volume of food)
214693750|NCT00414778|DRUG|LHT344|
214693751|NCT00048399|DRUG|Fludarabine|
214693752|NCT00048399|DRUG|CAMPATH 1H|
214693753|NCT00048399|DRUG|FK506|
214693754|NCT00048399|PROCEDURE|Stem Cell Transplantation|
214693755|NCT00111475|DRUG|Romiplostim|Administered by subcutaneous injection
214693756|NCT00111475|DRUG|Placebo|Administered by subcutaneous injection
214693757|NCT02178293|DRUG|Benzidamine hydrochloride|
214693758|NCT02178293|DRUG|Ketoprofen lysine salt|
214693759|NCT02863367|DRUG|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
214693760|NCT02863367|DRUG|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
214445427|NCT06236607|DEVICE|Device specific training|Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.
214445428|NCT06236607|OTHER|Study clinician/educator visit|Participants will receive insulin dose and other diabetes management guidance.
214693761|NCT03303092|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
214693762|NCT03303092|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
214693763|NCT03303092|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
214693764|NCT01062568|DRUG|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
214693765|NCT01062568|DRUG|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
214693766|NCT01308723|DRUG|RO5323441|escalating doses iv
214693767|NCT01308723|DRUG|RO5323441|iv every 2 weeks
214693768|NCT01308723|DRUG|sorafenib|400 mg orally twice daily to once every other day
214694197|NCT01769690|OTHER|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
215121279|NCT00000801|DRUG|Cyclophosphamide|
215121280|NCT00000801|DRUG|Cytarabine|
215121281|NCT00000801|DRUG|Dexamethasone|
215121282|NCT01317758|DRUG|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
215121283|NCT01317758|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
215121284|NCT01317758|BIOLOGICAL|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
215121285|NCT03689023|OTHER|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
215121286|NCT05331560|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
215121287|NCT00669214|DRUG|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
215121288|NCT00669214|DRUG|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
215121289|NCT04643626|DEVICE|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
215121290|NCT00075712|DRUG|carboplatin|
215121291|NCT00075712|DRUG|paclitaxel|
215121292|NCT00075712|PROCEDURE|adjuvant therapy|
215121293|NCT00075712|PROCEDURE|conventional surgery|
215121294|NCT00075712|PROCEDURE|neoadjuvant therapy|
215121295|NCT06601062|DEVICE|Tele-BE|Clinicians and their patients use the newly developed telehealth tool to support their use of CBT during session
214445429|NCT05799781|DEVICE|MPC closed-loop system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled.
214445430|NCT05799781|DEVICE|t:slim X2 pump with Dexcom G6 CGM and Control IQ|The t:slim pump is a hybrid closed-loop system available to consumers for automated insulin delivery. Control IQ technology automatically adjusts insulin levels based on continuous glucose monitoring (CGM) readings from Dexcom G6.
214445431|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
214445432|NCT06133439|BEHAVIORAL|Colorectal Screen rates with implementation of evidence-based intervention|Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
215121296|NCT02063204|DRUG|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
215121297|NCT03453905|DIAGNOSTIC_TEST|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
215121298|NCT03453905|OTHER|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
215121299|NCT00754377|OTHER|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
215121300|NCT00837915|DRUG|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
215121301|NCT02362321|DRUG|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
215121302|NCT02362321|OTHER|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
215121303|NCT05487521|DRUG|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
215121304|NCT03636217|OTHER|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
215121305|NCT03636217|OTHER|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
215121306|NCT03636217|OTHER|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
215121307|NCT04957446|DEVICE|Sculptra Aesthetic|Injectable implant containing microparticles of poly-L-lactic acid (PLLA)
215121308|NCT04957446|OTHER|Placebo|Saline solution
215121309|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
215121310|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
214522543|NCT01370161|PROCEDURE|TIPS treatment|"1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
214522544|NCT01370161|DRUG|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
214522545|NCT00475436|DRUG|GSK573719|
214522546|NCT02357355|DEVICE|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
214522547|NCT02446912|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
214522548|NCT02446912|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
215121311|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
215121312|NCT04257201|OTHER|Yellow Oyster -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
215121313|NCT04257201|OTHER|Yellow Oyster -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
215121314|NCT04257201|OTHER|White button -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
215121315|NCT04257201|OTHER|White button -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
215121316|NCT04257201|OTHER|Control|Participants will consume the standardized test day salad only
215121317|NCT02075112|DRUG|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
215121318|NCT02075112|RADIATION|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
215121319|NCT02075112|DRUG|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
214522549|NCT00015171|DRUG|Buprenorphine/naloxone|
214522550|NCT01268488|DEVICE|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
215121320|NCT04026321|DRUG|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
215121321|NCT04026321|DRUG|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
215121322|NCT04026321|DRUG|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
215121323|NCT04026321|DRUG|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
215121324|NCT04026321|DRUG|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
214445433|NCT06341179|BEHAVIORAL|Sleep extension|Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
214522551|NCT01670032|DRUG|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
214522552|NCT01670032|DRUG|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
214693769|NCT04498819|BEHAVIORAL|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
214693770|NCT05258708|BIOLOGICAL|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
215121325|NCT04058444|COMBINATION_PRODUCT|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
215121326|NCT06111417|OTHER|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire"
214522553|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
214693771|NCT04350229|DRUG|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
214693772|NCT04350229|OTHER|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
214693773|NCT02512744|PROCEDURE|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
215121327|NCT06111417|OTHER|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
215121328|NCT01276639|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
215121329|NCT01276639|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
215121330|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
215121331|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
214522554|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
214522555|NCT03853642|OTHER|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
214522556|NCT00517270|DRUG|Rabeprazole 20mg twice daily|
214522557|NCT01879488|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
214522558|NCT01879488|DEVICE|Vibrating-mesh nebulizer|
214522559|NCT01879488|OTHER|Gamma scintigraphy|
214522560|NCT01879488|OTHER|Preoperative spirometry|
214522561|NCT00266747|DRUG|SR58611A|
214693774|NCT02512744|DEVICE|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
214693775|NCT01026389|DRUG|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
214693776|NCT01026389|DRUG|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
214693777|NCT00836277|DRUG|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
214693778|NCT00836277|DRUG|Irinotecan|125mg/m2 IV Day 1 and Day 8
214693779|NCT01995136|DRUG|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
214693780|NCT04627116|DRUG|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
215121332|NCT05271916|DRUG|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
215121333|NCT05271916|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
215121334|NCT01982123|DIAGNOSTIC_TEST|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
214693781|NCT06079957|PROCEDURE|Ergonomic training|"1\. Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
214693782|NCT06079957|PROCEDURE|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
214693783|NCT06215222|OTHER|Microbiota Sampling|We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
214693784|NCT03402152|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
214693785|NCT03402152|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
214693786|NCT03402152|DRUG|Placebo|Placebo oral capsule
214445434|NCT06281028|DEVICE|SOLACEA-H/HYDROLINK-NVU|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
214445435|NCT06281028|DEVICE|HYDROLINK-NVU/SOLACEA-H|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
214522562|NCT02210949|DRUG|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
214522563|NCT00828542|DRUG|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
214522564|NCT00828542|DRUG|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
214522565|NCT02551926|BEHAVIORAL|mobile text messages|
214522566|NCT02551926|BEHAVIORAL|virtual community|
215121335|NCT01982123|PROCEDURE|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
215121336|NCT01982123|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
215121337|NCT01982123|DRUG|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
215121338|NCT05590052|DEVICE|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
214522567|NCT02551926|BEHAVIORAL|brochures|
215121339|NCT05590052|DEVICE|Thermocautery|achievement of hemostasis using thermocautery
215121340|NCT02046707|OTHER|initial evaluation|
214522568|NCT02551926|OTHER|Usual care|
214522569|NCT02551926|DEVICE|mobile phone|
214522570|NCT00147745|DRUG|Colesevelam|Colesevelam 3.8g for 12 weeks
214522571|NCT00147745|DRUG|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
214522572|NCT00147745|DRUG|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
214522573|NCT02658032|BEHAVIORAL|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
214522574|NCT02658032|BEHAVIORAL|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
214522575|NCT02658032|OTHER|standard care|
214522576|NCT05223283|OTHER||
214522577|NCT05430607|BEHAVIORAL|Running therapy|A 9-week running program.
214522578|NCT04212559|OTHER|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
214522579|NCT00003057|DRUG|loperamide hydrochloride|
214522580|NCT00003057|DRUG|octreotide acetate|
214522581|NCT04257786|PROCEDURE|1ry cyto-reductive surgery|1ry surgery then chemotherapy
214693787|NCT01480492|DRUG|Telbivudine|600mg,1/d,one year
214693788|NCT01791699|DRUG|Moxonidine|
214693789|NCT01791699|DRUG|Placebo|
214693790|NCT00012896|BEHAVIORAL|Telephone Care + Educational (AV Materials)|
214693791|NCT04410198|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
214522582|NCT04257786|COMBINATION_PRODUCT|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
214522583|NCT05903118|BIOLOGICAL|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
214522584|NCT05903118|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
214522585|NCT03151161|DRUG|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
214522586|NCT03151161|DRUG|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
214522587|NCT02409823|DRUG|Atypical Antipsychotics|any atypical antipsychotic
214522588|NCT05966623|OTHER|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
214693792|NCT03222076|BIOLOGICAL|Ipilimumab|Given IV
214693793|NCT03222076|BIOLOGICAL|Nivolumab|Given IV
215121341|NCT02046707|OTHER|Period of cardiac rehabilitation|
215121342|NCT02046707|OTHER|final evaluation|
214522671|NCT06329011|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215121454|NCT06100679|BEHAVIORAL|Responsible Engaged and Loving (REAL) Fathers Initiative|REAL Fathers is a multilevel norms-shifting intervention among: young fathers (ages 16-25 whose oldest child is under the age of 3); couple dyads (fathers and wives); mentoring dyads and groups; and communities. Respected men in the community are identified by participating young fathers, their partners and community members to become mentors. Mentors participate in a training and mentor young fathers through home and group sessions on conflict resolution, non-violent discipline, family planning, and couple communication. Mentoring is supplemented with a monthly poster campaign designed to reinforce messages from the home and group mentoring sessions and a community celebration. REAL Fathers aims to build positive partnerships and parenting practices among young fathers to: 1) reduce incidence of intimate partner violence; 2) reduce harsh physical punishment of children; 3) improve early childhood development; 4) decrease unmet need for family planning.
215121455|NCT04095182|DRUG|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
215121456|NCT04095182|DRUG|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
215121457|NCT04095182|DRUG|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)
215121458|NCT04095182|DRUG|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
215121459|NCT04095182|DRUG|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
215121460|NCT04095182|DRUG|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
215121461|NCT05569447|PROCEDURE|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
215121462|NCT05575362|OTHER|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
215121463|NCT05575362|OTHER|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
215121464|NCT00972335|DRUG|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
215121465|NCT00972335|DRUG|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
215121466|NCT01391624|DRUG|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
215121467|NCT01391624|DRUG|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
215121468|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
215121469|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
215121470|NCT01988675|RADIATION|Whole Brain Irradiation|
215121471|NCT01988675|RADIATION|Partial Brain Irradiation|
215121472|NCT01988675|BEHAVIORAL|Neuropsychological Testing|
215121473|NCT01988675|BEHAVIORAL|Quality of Life Questionnaire|
215121474|NCT01988675|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
215121475|NCT03852017|BEHAVIORAL|Audio Program|
215121476|NCT02544503|DEVICE|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
215121477|NCT02544503|DEVICE|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
215121478|NCT02544503|DEVICE|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
215121479|NCT02544503|DEVICE|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
215121480|NCT04041271|OTHER|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
215121481|NCT04041271|OTHER|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
214522672|NCT06329011|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
215121482|NCT04041271|OTHER|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
215121483|NCT04041271|OTHER|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
214522673|NCT06329011|BEHAVIORAL|Placebo Transcranial direct current stimulation|The Transcranial direct current stimulation will be performed without being turned on.
214522674|NCT05923554|OTHER|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
215121484|NCT04041271|OTHER|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
214522675|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
215121485|NCT00068341|BIOLOGICAL|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
215121486|NCT00068341|DRUG|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
215121487|NCT00068341|DRUG|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
215121488|NCT00068341|BIOLOGICAL|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
215121489|NCT05561023|DRUG|Hawthorn red pigment|"For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme"
215121490|NCT06528236|DIAGNOSTIC_TEST|Artificial intelligence model|Using the artificial intelligence model to diagnosis benign, borderline, and malignant ovarian masses.
215121491|NCT05960981|BEHAVIORAL|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
215121492|NCT00726648|DRUG|CDP323|50mg capsules, 100mg bid for 4 weeks
215121493|NCT00726648|DRUG|CDP323|250mg capsules, 500mg bid for 4 weeks
215121494|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg bid for 4 weeks
215121495|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg daily for 4 weeks
214522676|NCT00348283|BIOLOGICAL|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
215121496|NCT00726648|DRUG|Placebo|placebo capsules for 4 weeks
215121497|NCT01080807|DRUG|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
215121498|NCT01080807|DRUG|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
215121499|NCT01513408|OTHER|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
215121500|NCT05237349|DRUG|Envafolimab|300mg,sc,d1,Q3W
214522677|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
214522678|NCT04453709|BEHAVIORAL|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~1. Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~2. Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~3. Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~4. Strengthening Social Support: Social skills session and practice exercise to identify social support.~5. Staying Well: Make a plan that helps to create supportive family environment."
215121501|NCT05237349|DRUG|Oxaliplatin|130mg/m2, iv,d1,Q3W
214522679|NCT04453709|BEHAVIORAL|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
214522680|NCT05337722|BEHAVIORAL|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
214522681|NCT05337722|BEHAVIORAL|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
214522682|NCT03590847|BEHAVIORAL|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
214522683|NCT06961591|BEHAVIORAL|Weight Loss Plus Cooking|"Participants in the eSLD+Chef-ID group will follow a healthy eating plan using the enhanced stoplight diet, meet with a health coach once a month on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~In addition, they will attend in-person cooking classes-twice a month during the first 6 months and once a month for the next 12 months. In these 60-minute classes, instructors will teach cooking skills, and participants will practice on their own or with a partner, depending on their comfort level. They will learn how to safely use kitchen tools and appliances (like ovens, blenders, knives, and measuring cups) and prepare simple meals or snacks."
214522684|NCT06961591|BEHAVIORAL|Traditional Weight Loss|"Participants in the eSLD group will follow a healthy eating plan using the enhanced stoplight diet, meet once a month with a health coach on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~They will also receive short (2-minute) video messages from their coach-twice a month during the first 6 months and once a month after that. These videos will include feedback on their progress, reminders about their goals, and tips to help them stay on track with healthy eating and exercise."
215121502|NCT05237349|DRUG|S1|40mg/m2, op,bid,d1-14,Q3W
215121503|NCT05583487|OTHER|Nurse-led progressive mobility protocol|The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.
215121504|NCT05583487|OTHER|Standard of Care|For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
214522685|NCT05073835|DRUG|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
214522686|NCT05073835|DRUG|Placebo|Placebo
214522687|NCT05039047|OTHER|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
214522688|NCT05977699|DRUG|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
214522689|NCT05977699|DRUG|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
214522690|NCT05977699|OTHER|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
214568438|NCT04208490|OTHER|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
215121505|NCT01219309|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|3 capsules bid orally
215121506|NCT01219309|DIETARY_SUPPLEMENT|Placebo (olive oil)|3 capsules bid orally
214708544|NCT03700970|DRUG|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
214522691|NCT05837650|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
215121507|NCT03637777|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
214522692|NCT04372186|DRUG|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
215121508|NCT00458380|PROCEDURE|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
214522693|NCT04372186|DRUG|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
215121509|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
215121510|NCT02430090|DRUG|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
215121511|NCT02430090|DRUG|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
215121512|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
215121513|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
215121514|NCT01425502|BEHAVIORAL|DQIP Intervention|"The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives"
215121515|NCT03512171|DRUG|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
215121516|NCT03512171|DRUG|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
215121517|NCT03512171|DIAGNOSTIC_TEST|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
215121518|NCT03512171|DIAGNOSTIC_TEST|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
215121519|NCT00202514|DRUG|divalproex sodium extended release|
215121520|NCT04645446|DRUG|Pro-ocular gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
215121521|NCT04645446|DRUG|Placebo gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
215121522|NCT05923879|DRUG|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
215121523|NCT03253042|OTHER|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
215121524|NCT03253042|OTHER|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
215121525|NCT04908085|BEHAVIORAL|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
215121526|NCT01072188|DEVICE|Arginine/Calcium Carbonate|One time treatment
215121527|NCT01072188|DEVICE|Nupro - Fluoride Free|Brush twice daily
215121528|NCT00725777|DRUG|artemether-lumefantrine|Standard artemether-lumefantrine treatment
215121529|NCT05404243|DRUG|phenolization|In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
214522694|NCT06435520|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.
214708545|NCT03700970|DRUG|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
215121530|NCT05404243|PROCEDURE|Conventional surgery|In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
215121531|NCT03922581|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
215121532|NCT02464436|DRUG|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
215121533|NCT00168441|DRUG|Botulinum Toxin Type A|
215121534|NCT04955171|DRUG|BEOVU intravitreal injection|BEOVU intravitreal injection
215121535|NCT04472611|DRUG|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
215121536|NCT00566423|OTHER|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
215121537|NCT04419831|DIAGNOSTIC_TEST|Yale Stress Pain Test (YSPT)|Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
215121538|NCT03917849|BEHAVIORAL|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
215121539|NCT05757752|BEHAVIORAL|Problem Solving Therapy and Integrated Care|The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
215121540|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
215121541|NCT04685798|DEVICE|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
214522695|NCT06435520|BEHAVIORAL|Structured Medication Tapering|A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
214522696|NCT04614558|DRUG|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
214522697|NCT01765439|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
215121542|NCT04685798|DEVICE|FDG PET/CT|Standard of care
215121543|NCT05480683|DIAGNOSTIC_TEST|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
215121544|NCT06427031|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
215121545|NCT06427031|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
214522698|NCT04946656|PROCEDURE|sphenopalatine ganglion block|The sphenopalatine ganglion will be blocked with bupivacaine for this study
215121546|NCT04093713|PROCEDURE|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
215121547|NCT03205124|PROCEDURE|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
215121548|NCT03205124|PROCEDURE|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
214522699|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
214522700|NCT04391803|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
214522701|NCT03621683|PROCEDURE|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
215121549|NCT06521710|PROCEDURE|Intraoperative Somatic-Autonomic Nerve Grafting|A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
215121550|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
214522702|NCT03621683|DIETARY_SUPPLEMENT|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
214708546|NCT02396342|GENETIC|AAV5-hFIX|AAV5hFIX gene therapy
215121551|NCT05706922|OTHER|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
215121552|NCT06236919|BEHAVIORAL|VR cognitive training|The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
215121553|NCT06236919|BEHAVIORAL|VR nature exposure relaxation|The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
215121554|NCT00002306|DRUG|Fluconazole|
215121555|NCT04867746|OTHER|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
214445464|NCT05632562|DRUG|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
214445465|NCT03803904|OTHER|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
214445466|NCT01044069|BIOLOGICAL|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
214445467|NCT00212433|DRUG|Tagitol V, Lo So, Readi-Cat 2|
215121556|NCT04867746|OTHER|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
215121557|NCT04867746|OTHER|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 \* 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
214522703|NCT04060641|GENETIC|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
214522704|NCT06128330|DRUG|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
214522705|NCT06128330|DRUG|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
214522706|NCT06128330|DRUG|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
214522707|NCT06128330|DRUG|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
214522708|NCT02060071|OTHER|Blood test|Blood test
215121558|NCT04867746|OTHER|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
215121559|NCT04867746|OTHER|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
215121560|NCT02223715|OTHER|CDI Pts|
215121561|NCT03316144|BIOLOGICAL|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
214445468|NCT06067698|DRUG|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
214445469|NCT06067698|DRUG|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
214522709|NCT06646757|BEHAVIORAL|APP|1\) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
214522710|NCT06646757|BEHAVIORAL|CBT|"2\) Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
214522711|NCT06646757|BEHAVIORAL|HELP|3\) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
215121562|NCT03956550|DRUG|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
214522712|NCT06646757|BEHAVIORAL|PEER|4\) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
214522713|NCT01445379|DRUG|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
214708547|NCT00434499|DRUG|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
215121563|NCT03956550|DRUG|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
215121564|NCT04198480|DRUG|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
215121565|NCT00150267|DRUG|Xalacom|
215121566|NCT00006591|DRUG|Ritonavir|
214445470|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
215121567|NCT00006591|DRUG|Amprenavir|
215121568|NCT02776111|OTHER|Blood Sample|A one time blood sample will be provided.
215121569|NCT01574508|DRUG|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
215121570|NCT01574508|DRUG|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
215121571|NCT05768412|PROCEDURE|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
215121572|NCT00984308|PROCEDURE|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
215121573|NCT00172263|PROCEDURE|blood sampling|
215121574|NCT03965494|DRUG|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
215121575|NCT03965494|DRUG|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
215121576|NCT03901131|DRUG|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
215121577|NCT02405156|DRUG|Letrozole|
215121578|NCT02405156|DRUG|Placebo|
215121579|NCT02405156|DRUG|Misoprostol|
214445471|NCT04820855|BEHAVIORAL|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
214445472|NCT04820855|OTHER|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
214522714|NCT00763919|BEHAVIORAL|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
214522715|NCT00763919|BEHAVIORAL|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
214522716|NCT00763919|BEHAVIORAL|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
215121580|NCT03056677|DIETARY_SUPPLEMENT|Control|200mls water will be given prior to a mixed carbohydrate meal
215121581|NCT03056677|DIETARY_SUPPLEMENT|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
215121582|NCT03056677|DIETARY_SUPPLEMENT|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
215121583|NCT01620229|DRUG|brentuximab vedotin|Given IV
215121584|NCT01620229|OTHER|laboratory biomarker analysis|Correlative studies
214522717|NCT00763919|BEHAVIORAL|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
214522718|NCT05253066|DRUG|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
214708548|NCT04362904|OTHER|acupressure|
215121585|NCT01620229|OTHER|pharmacological study|Correlative studies
215121586|NCT02471235|BEHAVIORAL|Physiotherapy|Pulmonary rehabilitation
215121587|NCT01971541|BEHAVIORAL|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
215121588|NCT01971541|BEHAVIORAL|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
215121589|NCT01011374|DRUG|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
215121590|NCT05005663|OTHER|surgical management of incisional hernia|surgical repair of the incisional hernia
215121591|NCT00605124|OTHER|Knee muscle exercises|Home exercises three times a week, control every three months
215121592|NCT02635607|DRUG|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
215121593|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
215121594|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.
215121595|NCT02635607|DRUG|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
215121596|NCT02635607|DRUG|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
215121597|NCT04331717|DEVICE|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
215121598|NCT04331717|BEHAVIORAL|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
214445473|NCT06530407|OTHER|Static streching exercise|Static stretching exercises were applied to the M. Gastrocnemious and M. Hamstring muscle groups for both groups. The exercises were applied as a set, with three repetitions for 15 seconds on each leg, with a 20-second rest between repetitions. Static stretching was applied by slowly stretching the relevant muscle group to the point of sensitivity, without straining the pain threshold, and waiting in that position. All stretching exercises lasted an average of 6 minutes.
215121599|NCT04331717|DRUG|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
215121600|NCT02602093|PROCEDURE|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
215121601|NCT02602093|PROCEDURE|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
215121602|NCT03520985|DRUG|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
215121603|NCT03520985|DRUG|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients \> 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
215121604|NCT01745367|DRUG|Tivozanib Hydrochloride|
215121605|NCT01745367|DRUG|paclitaxel|
215121606|NCT01745367|DRUG|Placebo|
215121607|NCT03648294|OTHER|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
215121608|NCT04001348|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121609|NCT04001348|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
214445474|NCT04179149|BEHAVIORAL|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of environmental enrichment: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
214445475|NCT04260230|DEVICE|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
214522719|NCT05253066|DRUG|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
214445476|NCT05657106|BEHAVIORAL|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
214445477|NCT06466148|DEVICE|JessieHug|Assessment of JessieHug device when placed on infants.
214445478|NCT06625489|DRUG|Part A: Placebo|Placebo will be administered.
214445479|NCT06625489|DRUG|Nintedanib|Nintedanib will be administered.
214445480|NCT06625489|DRUG|GSK3915393|GSK3915393 will be administered.
214445481|NCT06739902|DIAGNOSTIC_TEST|Traditional Physiotherapy Group|Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.
214445482|NCT06739902|COMBINATION_PRODUCT|VR + Traditional Physiotherapy Group|Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
214445483|NCT05244915|OTHER|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
214445484|NCT05244915|OTHER|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
214445485|NCT05244915|OTHER|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
214445486|NCT06771687|BEHAVIORAL|High intensity interval training|A 12-week high intensity interval training program, with 30 minutes of exercise three times a week. The trainings can be completed at home and will be digitally supervised.
214445487|NCT04249713|DRUG|Brodalumab|Interleukin 17 Receptor A Antagonist
214445488|NCT06637163|DRUG|Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy|Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
214445489|NCT06637163|DRUG|Paclitaxel + Carboplatin + Radiotherapy|Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
214445490|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
214445491|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
214445492|NCT05452239|DRUG|Eptinezumab|Solution for infusion
214445493|NCT05452239|DRUG|Placebo|Solution for infusion
214445494|NCT04058626|DIAGNOSTIC_TEST|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
214445495|NCT04058626|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
214445496|NCT04058626|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
214445497|NCT04058626|DIAGNOSTIC_TEST|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
214445498|NCT04058626|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
214445499|NCT01904188|DEVICE|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)|The Gene Z device (no longer in use) and now using In-Dx created in our lab, and other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
214445500|NCT03392181|DRUG|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
214445501|NCT02994316|OTHER|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
214445502|NCT02558972|DRUG|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
214445503|NCT02558972|DRUG|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
214522720|NCT02884622|OTHER|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
214445504|NCT02558972|DRUG|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
215121610|NCT04001348|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121611|NCT04001348|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121612|NCT04001348|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
214522721|NCT02884622|OTHER|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
214522722|NCT06030999|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
214522723|NCT06030999|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
214522724|NCT06030999|DIETARY_SUPPLEMENT|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
214522725|NCT02816645|PROCEDURE|Magnetic Resonance Imaging (MRI)|
215121613|NCT04001348|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121614|NCT04001348|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121615|NCT04001348|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121616|NCT04001348|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121617|NCT04001348|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121618|NCT04001348|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121619|NCT04001348|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121620|NCT04001348|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121621|NCT04001348|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121622|NCT04001348|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121623|NCT04001348|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
215121624|NCT00896298|DRUG|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
215121625|NCT00896298|DRUG|Placebo|Sugar pill
215121626|NCT00287222|DRUG|Bevacizumab|15 mg/KG I.V. every 21 days
215121627|NCT00287222|DRUG|Erlotinib|150 mg orally every day
215121628|NCT05220085|DRUG|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
215121629|NCT06238440|OTHER|Splint and taping methods|"In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape"
215121630|NCT01392131|DIETARY_SUPPLEMENT|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
215121631|NCT01392131|OTHER|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
215121632|NCT00824473|DRUG|Placebo|Placebo
215121633|NCT00824473|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
215121634|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
215121635|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
215121636|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
215121637|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
214445505|NCT02558972|DRUG|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
214445506|NCT04828590|OTHER|No intervention|Due to observational study
215121638|NCT06423313|PROCEDURE|maintenance of anesthesia|Types used to maintain anesthesia
215121639|NCT05576922|OTHER|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
215121640|NCT05576922|OTHER|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
215121641|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
215121642|NCT03845647|PROCEDURE|contralateral central lymph node dissection|contralateral central lymph node dissection
215121643|NCT06462183|DRUG|RGT-61159|Oral MYB inhibitor
215121644|NCT01359904|OTHER|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
215121645|NCT04372420|DRUG|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
215121646|NCT04372420|PROCEDURE|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
215121647|NCT05534399|PROCEDURE|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
215121648|NCT03539718|DRUG|Taurolidine heparin|Taurolock-hep 500 at end of session
215121649|NCT03539718|DRUG|Heparin Sodium|Heparin sodium 5000 at end of session
215121650|NCT01396213|DRUG|Larazotide Acetate|gelatin capsule
215121651|NCT01396213|DRUG|placebo|gelatin capsule
215121652|NCT02660853|DIAGNOSTIC_TEST|FEV1|Participants have FEV1 test
215121653|NCT04601012|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
215121654|NCT01576289|OTHER|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
215121655|NCT06149455|OTHER|Duration of antibiotics|Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
215121656|NCT00302341|DRUG|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
215121657|NCT00302341|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
215121658|NCT05912764|OTHER|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
215121659|NCT06129279|OTHER|EFT group|"Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed."
215121660|NCT00997958|DRUG|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
215121661|NCT04168658|COMBINATION_PRODUCT|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
215121662|NCT04168658|BEHAVIORAL|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
215121663|NCT02525588|DEVICE|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
215121664|NCT01837277|DRUG|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
215121665|NCT01837277|DRUG|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
215121666|NCT02408133|OTHER|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
215121667|NCT03018691|DRUG|OPA-15406|
215121668|NCT03018691|DRUG|Placebos|
215121669|NCT02339753|DRUG|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
215121670|NCT03992079|PROCEDURE|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
215121671|NCT01433016|DRUG|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
215121672|NCT03369418|DEVICE|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
215121673|NCT03369418|DEVICE|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
215121674|NCT00358397|DRUG|Clostridium novyi-NT spores|
215121675|NCT03586713|DIAGNOSTIC_TEST|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
215121676|NCT01094678|DEVICE|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
215121677|NCT02702466|OTHER|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
215121678|NCT04955457|OTHER|Healthy women active teachers|The neuropsychological testing data, psychometric measure, demographic, clinical and lifestyle information and blood samples were collected at similar time points. This group not received any intervention.
214445507|NCT01198366|BIOLOGICAL|AERAS-402 1.5 x 10^10 vp|
214445508|NCT01198366|BIOLOGICAL|AERAS-402 3.0 x 10^10 vp|
214445509|NCT01198366|BIOLOGICAL|AERAS-402 1.0 x 10^11 vp|
214445510|NCT01198366|BIOLOGICAL|Placebo|
214445511|NCT03851367|PROCEDURE|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
214445512|NCT03851367|PROCEDURE|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
214522726|NCT02374476|DEVICE|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
214522727|NCT00751088|PROCEDURE|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
214522728|NCT00751088|PROCEDURE|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
215121679|NCT05048173|PROCEDURE|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
215121680|NCT05048173|PROCEDURE|Lymphadenectomy|Conventional lymphadenectomy
215121681|NCT01064934|PROCEDURE|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
215121682|NCT01064934|OTHER|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
215121683|NCT04762732|DEVICE|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
214445513|NCT00650104|DRUG|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
214445514|NCT00931710|DRUG|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
214445515|NCT00931710|DRUG|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
214445516|NCT06500533|DEVICE|rTMS combined with tDCS|"The intervention will last 30 days per patient, where rTMS will be administered on odd numbered days (study day 1, 3, 5, 7, ..29) and tDCS on even numbered days (study day 2, 4, 6, 8, … 30). All patients will start with TMS and finish with home-based tDCS treatment. Both rTMS and tDCS treatments will be administered during working days, from Monday to Friday.~rTMS treatment will be administered by the experienced nurses of the rTMS clinic of each department. The rTMS treatment will profit from ongoing supervision by the Clinical Directors of each TMS clinic, which is in line with treatment as usual.~tDCS will be performed at home by the patients."
214445517|NCT02182479|DRUG|Berodual® via Respimat®, high dose|
214445518|NCT02182479|DRUG|Berodual® via Respimat®, low dose|
214445519|NCT02182479|DRUG|Berodual® via MDI, high dose|
214445520|NCT02182479|DRUG|Placebo Respimat®|
214445521|NCT02182479|DRUG|Placebo MDI|
214708549|NCT02246023|DEVICE|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
214708550|NCT02246023|DEVICE|Oxygen saturation|Continuous measurement of oxygen saturation;
214708551|NCT02246023|DEVICE|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
215121684|NCT04762732|DEVICE|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
215121685|NCT00834665|BIOLOGICAL|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
215121686|NCT00834665|BIOLOGICAL|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
215121687|NCT06166940|OTHER|ROTEM Guided Management|ROTEM guided management of hemostasis after CPB
215121688|NCT03335410|OTHER|Non- interventional|Non- interventional
215121689|NCT04067934|BEHAVIORAL|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
215121690|NCT03487991|BEHAVIORAL|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
215121691|NCT03415282|DRUG|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
215121692|NCT00952029|BIOLOGICAL|bevacizumab|
215121693|NCT00952029|DRUG|FOLFIRI regimen|
215121694|NCT00952029|DRUG|fluorouracil|
215121695|NCT00952029|DRUG|irinotecan hydrochloride|
215121696|NCT00952029|DRUG|leucovorin calcium|
214445522|NCT06151314|PROCEDURE|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
214445523|NCT03471559|DRUG|Cannabidiol|single or multiple dosing
214445524|NCT01376700|BIOLOGICAL|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
214522729|NCT00751088|PROCEDURE|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
214522730|NCT00751088|PROCEDURE|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
214522731|NCT03795792|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
215121697|NCT01495286|DEVICE|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
215121698|NCT05892601|OTHER|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
215121699|NCT02218645|DRUG|WE 941 OD tablets|
215121700|NCT02218645|DRUG|Brotizolam|
215121701|NCT00796666|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
215121702|NCT00796666|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
215121703|NCT05701007|DRUG|abiraterone|mCRPC
215121704|NCT05701007|DRUG|enzalutamide|mCRPC
215121705|NCT05701007|DRUG|docetaxel|mCRPC
215121706|NCT05701007|DRUG|apalutamide|mCRPC
215121707|NCT05701007|DRUG|cabazitaxel|mCRPC
215121708|NCT05701007|DRUG|Radium-223|mCRPC
215121709|NCT05701007|DRUG|Lutetium-177|mCRPC
215121710|NCT05701007|DRUG|degarelix|mCSPC
215121711|NCT05701007|DRUG|goserelin|mCSPC
215121712|NCT05701007|DRUG|leuprorelin|mCSPC
215121713|NCT05701007|DRUG|triptorelin|mCSPC
215121714|NCT03174366|DRUG|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
215121715|NCT00638534|DRUG|Telithromycin (HMR3647)|
215121716|NCT05502913|DRUG|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
215121717|NCT05502913|OTHER|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
215121718|NCT03169166|DRUG|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
215121719|NCT02882594|BEHAVIORAL|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
215121720|NCT06328673|DRUG|DM919|Anti-MICA/MICB monoclonal antibody
215121721|NCT06328673|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
215121722|NCT00670280|BEHAVIORAL|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
214522732|NCT03795792|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Will be provided in capsules.
214445525|NCT02217514|DRUG|Midazolam|
214445526|NCT02217514|DRUG|BI 44370 low dose|
214445527|NCT02217514|DRUG|BI 44370 medium dose|
214445528|NCT02217514|DRUG|BI 44370 high dose|
214445529|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
214445530|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
214445531|NCT05124613|OTHER|Survey|"Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
214445532|NCT02488148|BEHAVIORAL|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
214522733|NCT06585735|DIETARY_SUPPLEMENT|Proteolytic enzyme fortified protein supplement|Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
214522734|NCT06545669|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
214522735|NCT06545669|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
214522736|NCT06545669|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
214522737|NCT06545669|OTHER|Lung Cancer Screening|After participating in shared decision-making, eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
215121723|NCT00670280|BEHAVIORAL|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
215121724|NCT00670280|BEHAVIORAL|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
215121725|NCT03959059|DEVICE|Mixed Reality technology|combine image with real body
215121726|NCT05003375|BEHAVIORAL|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures"
215121727|NCT02418039|DIETARY_SUPPLEMENT|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
215121728|NCT02418039|DIETARY_SUPPLEMENT|Normal protein|A normal protein diet will be administrated in patients with MHE.
215121729|NCT01226225|BEHAVIORAL|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
215121730|NCT01226225|BEHAVIORAL|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
215121731|NCT03871426|PROCEDURE|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
215121732|NCT02845817|OTHER|Qualitative research|Semi-structured interviews
214522738|NCT06584578|OTHER|Whole-Body Electromyostimulation|Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
214522739|NCT06584578|OTHER|Pilates|Pilates exercise twice weekly for 12 weeks
214522740|NCT06584578|OTHER|Tai Chi|Pilates exercise twice weekly for 12 weeks
215121733|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
215121734|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
214445533|NCT02488148|BEHAVIORAL|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
214445534|NCT06518915|DEVICE|baroloop system|Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
215121735|NCT02894671|OTHER|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
215121736|NCT04934566|OTHER|ECMO flow|Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
215121737|NCT04205526|DEVICE|Active rTMS|Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
215121738|NCT04205526|DEVICE|Sham TMS|For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
215121739|NCT00002963|DRUG|aminolevulinic acid hydrochloride|
215121740|NCT00002963|PROCEDURE|conventional surgery|
215121741|NCT00057863|DRUG|Paclitaxel|Given IV
215121742|NCT00057863|DRUG|Oxaliplatin|Given IV
215121743|NCT02316561|RADIATION|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
215121744|NCT02461381|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
215121745|NCT00182039|DRUG|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
215121746|NCT00182039|DRUG|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
215121747|NCT01521507|DEVICE|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
215121748|NCT01521507|DEVICE|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
215121749|NCT06117735|DEVICE|Transjugular Intrahepatic Portosystemic shunt|The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
214445535|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
214445536|NCT04752163|DRUG|DS-1594b|Given DS-1594b PO
215121750|NCT04764474|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
215121751|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
215121752|NCT05597033|BEHAVIORAL|Control|seated rest
215121753|NCT03073239|GENETIC|ALS patients genetic characterization|Genetic findings in ALS patients
214522741|NCT06584578|OTHER|Nutritional counseling|Nutritional counseling for 12 weeks
214445537|NCT04752163|DRUG|Azacitidine|Given IV or SC
214445538|NCT04752163|DRUG|Cyclophosphamide|Given IV
214445539|NCT04752163|DRUG|Cytarabine|Given IT
214445540|NCT04752163|DRUG|Dexamethasone|Given PO or IV
214708552|NCT02246023|DEVICE|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
215121754|NCT03073239|OTHER|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
215121755|NCT00184795|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
215121756|NCT00184795|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
215121757|NCT00184795|DRUG|placebo|Placebo tablets for 24 weeks
215121758|NCT03171337|DEVICE|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
215121759|NCT03171337|DEVICE|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
215121760|NCT03171337|DEVICE|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
215121761|NCT02731495|DIETARY_SUPPLEMENT|EGCG|EGCG (Epigallocatechin -3-gallate)
214445541|NCT04752163|BIOLOGICAL|Filgrastim|Given SC
214445542|NCT04752163|DRUG|Leucovorin|Given IV or PO
214445543|NCT04752163|DRUG|Mesna|Given IV
214445544|NCT04752163|DRUG|Methotrexate|Given IT
214445545|NCT04752163|DRUG|Prednisone|Given PO
214445546|NCT04752163|BIOLOGICAL|Rituximab|Given IV
214445547|NCT04752163|DRUG|Venetoclax|Given PO
215121762|NCT02731495|DIETARY_SUPPLEMENT|Placebo (deionized water)|
215121763|NCT06279455|OTHER|Pelvic Floor Muscle Exercise|A 12-week pelvic floor muscle exercise program was applied to pregnant women.
215121764|NCT01479868|DRUG|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
215121765|NCT01479868|DRUG|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
215121766|NCT01479868|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
215121767|NCT00354146|DRUG|tipifarnib (R115777)|
215121768|NCT03266133|BEHAVIORAL|Sleep Education for Pregnancy|Sleep education specific to pregnancy
215121769|NCT01292187|DRUG|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
215121770|NCT01292187|DRUG|Oral placebo at dinnertime|Oral placebo at dinnertime.
215121771|NCT01292187|DRUG|Oral calcitonin at bedtime|Oral calcitonin at bedtime
215121772|NCT01292187|DRUG|Oral placebo at bedtime|Oral placebo at bedtime
215121773|NCT04161742|DEVICE|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
215121774|NCT00195039|DRUG|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
215121775|NCT03904212|PROCEDURE|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
215121776|NCT03904212|PROCEDURE|saline|injection with saline
215121777|NCT04539600|DRUG|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
215121778|NCT00804700|BEHAVIORAL|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
214445548|NCT04752163|DRUG|Vincristine|Given IV
214445549|NCT04063514|OTHER|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
215121779|NCT00531258|DEVICE|rTMS|Bilateral rTMS
215121780|NCT00531258|DEVICE|Sham rTMS|sham rTMS
215121781|NCT00113841|DRUG|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
215121782|NCT00113841|DRUG|Bioperine|5 mg (Tablets) orally twice daily
215121783|NCT00348985|DRUG|belinostat|
215121784|NCT00348985|DRUG|bortezomib|
215121785|NCT00348985|OTHER|pharmacological study|
215121786|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
215121787|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
215121788|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
215121789|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
215121790|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
215121791|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
215121792|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
215121793|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
215121794|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
214522742|NCT06584994|OTHER|sample collection|Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
215121795|NCT02296567|OTHER|Control Group|Control group Subjects will no previous anti-VEGF treatment
215121796|NCT03170726|DRUG|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
215121797|NCT03170726|DRUG|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
215121798|NCT03170726|OTHER|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
215121799|NCT05362123|OTHER|non interventional|Online google form questioner
215121800|NCT02530021|OTHER|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
215121801|NCT03178383|BEHAVIORAL|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
215121802|NCT03178383|BEHAVIORAL|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
215121803|NCT02867735|DRUG|LKA651|Interventional
215121804|NCT02867735|OTHER|Sham Comparator|
215121805|NCT05505448|DRUG|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
215121806|NCT05505448|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
215121807|NCT04230317|DIAGNOSTIC_TEST|Chest CT|Low dose CT taken with three different protocols
215121808|NCT01557426|OTHER|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
215121809|NCT03997526|DEVICE|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
215121810|NCT05038865|OTHER|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
215121811|NCT00488488|DRUG|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
215121812|NCT04173806|OTHER|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
215121813|NCT04173806|OTHER|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
215121814|NCT02721875|DRUG|Volasertib|
215121815|NCT02721875|DRUG|Volasertib|
215121816|NCT02721875|DRUG|Azacitidine|
215121817|NCT01207375|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
215121818|NCT01207375|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
215121819|NCT01485159|PROCEDURE|Spirometry|assessment of lung function by spirometry
215121820|NCT06473220|BEHAVIORAL|Narrative nursing|Narrative nursing is an intervention mode of psychological nursing.
215121821|NCT02647307|DRUG|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
215121822|NCT00376129|DRUG|Alefacept|15 mg i.m. once weekly for 12 weeks
215121823|NCT00430716|DRUG|Sildenafil citrate|oral, 20 mg, tid
215121824|NCT00430716|DRUG|Sildenafil citrate|oral 1 mg, tid
215121825|NCT00430716|DRUG|Sildenafil citrate|oral 5 mg, tid
215121826|NCT00430716|DRUG|Sildenafil citrate|oral 20 mg, tid
215121827|NCT01433172|BIOLOGICAL|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
215121828|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
215121829|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
215121830|NCT00773513|DRUG|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
215121831|NCT00773513|DRUG|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
215121832|NCT00773513|DRUG|Epoetin Beta|Epoetin beta will be administered as per approved label.
214522743|NCT04847284|RADIATION|Intraoperative radiotherapy|Intraoperative radiotherapy application immediately following resection of brain metastases.
215121833|NCT00773513|DRUG|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
215121834|NCT00991991|GENETIC|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
214522744|NCT03305458|BEHAVIORAL|TFCBT|treatment as usual
214522745|NCT03305458|BEHAVIORAL|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
214522746|NCT05431543|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
214522747|NCT05431543|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
215121835|NCT00991991|GENETIC|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
215121836|NCT00991991|GENETIC|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
215121837|NCT00991991|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
215121838|NCT00991991|OTHER|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
214522748|NCT05431543|DRUG|Vehicle proprietary ophthalmic solution|Proprietary Vehicle ophthalmic solution
215121839|NCT05864222|OTHER|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
215121840|NCT04789915|DRUG|Memantine|Add on treatment with memantine to aripiprazole.
215121841|NCT04789915|DRUG|Placebo|Placebo add on to aripiprazole
215121842|NCT02436616|DEVICE|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
215121843|NCT00804466|DEVICE|OncoE6|HPV oncoprotein assay
215121844|NCT00804466|DEVICE|EVA System|low-cost colposcope
215121845|NCT03593057|OTHER|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
215121846|NCT03593057|OTHER|Control group|Advice on self-care and body awareness.
215121847|NCT02645292|DEVICE|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
215121848|NCT02645292|DEVICE|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
215121849|NCT05910216|OTHER|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
215121850|NCT05910216|OTHER|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
215121851|NCT03890588|OTHER|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
215121852|NCT05122728|OTHER|Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment|"Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)"
215121853|NCT06096636|OTHER|Study participants|Participants will complete study survey and dietary assessment.
215121854|NCT05774938|PROCEDURE|Standard Endovascular aneurysm repair (sEVAR)|Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).
215121855|NCT05774938|PROCEDURE|Complex Endovascular Aneurysm Repair (cEVAR)|Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
214522749|NCT00796497|DRUG|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
214522750|NCT00440037|BIOLOGICAL|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
214522751|NCT00498797|DRUG|Zactima (vandetanib)|
215121856|NCT04502563|OTHER|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
215121857|NCT04502563|OTHER|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
215121858|NCT04699383|DRUG|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
215121859|NCT06552650|BEHAVIORAL|Exercise|Four supervised exercise interventions after surgery: One exercise education session per week from postoperative day 5 through 1 month Subsequent home-based exercise: Home-based exercise recommendations from 1 month to 3 months post-surgery
215121860|NCT06552650|OTHER|Usual Care|The full spectrum of patient care practices in which clinicians have the opportunity (which is not necessarily seized) to individualize care
215121861|NCT03642509|DEVICE|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
215121862|NCT03642509|DRUG|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
215121863|NCT04991662|DRUG|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
215121864|NCT04991662|DRUG|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
215121865|NCT04991662|DRUG|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
215121866|NCT00214539|PROCEDURE|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
215121867|NCT00214539|DRUG|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
215121868|NCT04494620|DIAGNOSTIC_TEST|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
215121869|NCT02033434|DRUG|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
215121870|NCT05873608|OTHER|Educational video|Testing an educational video
215121871|NCT05873608|OTHER|Interview|Participate in interview
215121872|NCT05873608|OTHER|Observation|Undergo observation
215121873|NCT02306798|DRUG|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
215121874|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
215121875|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
215121876|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
215121877|NCT05938894|OTHER|online games with various food images|Participant will play a series of online games with various food images.
215121878|NCT05938894|OTHER|online games with images of flowers and songbirds|Participant will play a series of online games with images of flowers and songbirds.
215121879|NCT05684276|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
215121880|NCT05684276|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
215121881|NCT05684276|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
214445550|NCT01549899|BEHAVIORAL|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education \& hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
215121882|NCT06665828|DRUG|REGN9533|Administered per the protocol
214522752|NCT00498797|DRUG|Docetaxel|
215121883|NCT06665828|DRUG|Matching Placebo|Administered per the protocol.
215121884|NCT06805331|BEHAVIORAL|Intervention group(Pelvic Floor Muscle Exercise Training)|The intervention will involve educating participants on pelvic floor muscle exercises, using the health belief model. The goal is to evaluate improvements in incontinence severity, quality of life, and pelvic floor muscle exercise self-efficacy
215121885|NCT06805331|OTHER|control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
215121886|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
215121887|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
215121888|NCT04659317|DRUG|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
215121889|NCT04659317|DRUG|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
215121890|NCT04674722|DRUG|Injection of 99mTc-NM-02|A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
215121891|NCT04674722|DRUG|Injection of 188Re-NM-02|A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
215121892|NCT05846815|DEVICE|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
215121893|NCT05846815|OTHER|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
215121894|NCT06420323|DEVICE|Treatment with NovoX® Cup|NovoX® Cup treatment
215121895|NCT06420323|DEVICE|Treatment with Omnistrip®|Omnistrip® treatment
215121896|NCT03116685|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
215121897|NCT03116685|OTHER|Placebo|Placebo
215121898|NCT01200303|PROCEDURE|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
214522753|NCT00498797|DRUG|Prednisolone|
215121899|NCT01564563|DRUG|standard therapy|Standard treatment of bleeding
215121900|NCT01564563|DRUG|placebo|Placebo
215121901|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
214522754|NCT05840822|DRUG|Cannabidiol (CBD) Capsule 75mg|Cannabidiol (CBD) capsule containing 75mg CBD
214522755|NCT05840822|DRUG|Placebo|Placebo capsule without cannabidiol
214522756|NCT02852499|OTHER|Urine sampling|
214522757|NCT02852499|OTHER|Carry a GPS and BET|
214522758|NCT02852499|OTHER|Carry pollution sensor|
214522759|NCT02852499|OTHER|Sampling at the maternity|
214522760|NCT02852499|OTHER|Self-questionnaires|
214522761|NCT02852499|OTHER|Sampling in partum period|Meconium and a strand of hair.
214522762|NCT05386706|BEHAVIORAL|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
214522763|NCT05386706|DRUG|Metformin|Traditional metformin monotherapy.
214445551|NCT01549899|BEHAVIORAL|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
215121902|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
215121903|NCT06623890|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
215121904|NCT07022262|BEHAVIORAL|Progressive resistance training plus impact loading|The structure of the exercise sessions will be: 1) warm up; 2) progressive resistance training plus impact loading; 3) cool down. Briefly, the warm-ups will be based on RAMP methodology (i.e., raise, activate, mobilise and potentiate) in order to maximize middle-term performance of the main exercises. Exercises focused on the brace, squat, lunge or jump patterns will be included in the first part of the session. The main part of the session will consist of 9 sets of 10-12 jumps, 9 sets of 10-12 repetitions of lower body resistance exercise and 3 sets of 10-12 repetitions of upper resistance exercise. Each set will be performed with approximately 15-30 seconds of rest for jumps and 2-3 minutes of rest for resistance exercises. Finally, participants will perform a cool down including guided static stretching and relaxing exercises.
215121905|NCT06726330|PROCEDURE|Fimbriectomy Followed by Delayed Oophorectomy (F-DO)|"This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis"
215121906|NCT06726330|PROCEDURE|Bilateral Salpingo-Oophorectomy|This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
215121907|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2
215121908|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2
215121909|NCT06431243|DRUG|A group Purinostat Mesylate 6mg/m2|Purinostat Mesylate 6mg/m2 + FS 500mg
215121910|NCT06431243|DRUG|A group Purinostat Mesylate 8.4mg/m2|Purinostat Mesylate 8.4mg/m2 + FS 500mg
215121911|NCT06431243|DRUG|A group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + FS 500mg
215121912|NCT06431243|DRUG|A group Purinostat Mesylate 15 mg/m2|Purinostat Mesylate 15 mg/m2 + FS 500mg
215121913|NCT06431243|DRUG|B group Purinostat Mesylate 6 mg/m2|Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg
215121914|NCT06431243|DRUG|B group Purinostat Mesylate 8.4 mg/m2|Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
215121915|NCT06431243|DRUG|B group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
215121916|NCT06431243|DRUG|B group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg
215121917|NCT06921564|OTHER|Combined training|During the 6-week intervention period, the combined training group performed 2 sessions per week of lower-body strength training and 2 sessions per week of small-sided games training in different formats. The strength training was performed on Tuesdays and Thursdays. This training was finished at least one hour before the team's technical and tactical soccer training. The strength training program is designed to include movements for bilateral hip dominant, bilateral knee dominant, unilateral hip dominant, unilateral knee dominant and calf muscles. The exercises were selected to allow players to perform them on the field with minimal equipment, without the need for machines. In addition, small field games training was practiced two days a week. Repetitions in reserve and resistance training-specific ratings of the perceived exertion scale were used to determine training intensity and load.
214445552|NCT00601900|BIOLOGICAL|Bevacizumab|Given IV
214445553|NCT00601900|OTHER|Laboratory Biomarker Analysis|Correlative studies
214445554|NCT00601900|DRUG|Letrozole|Given PO
214445555|NCT00601900|OTHER|Questionnaire Administration|Ancillary studies
214445556|NCT00601900|DRUG|Tamoxifen Citrate|Given PO
214445557|NCT05873751|BIOLOGICAL|Trumenba Vaccine|Trumenba vaccine given as standard of care
214445558|NCT05873751|BIOLOGICAL|MenACWY Vaccine|MenACWY Vaccine given as standard of care
214445559|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
214445560|NCT05638308|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
214445561|NCT00596336|DRUG|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
214445562|NCT00596336|DRUG|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
214445563|NCT00972049|DRUG|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
214445564|NCT00972049|DRUG|Placebo|Capsule administered once orally
215121918|NCT06921564|OTHER|Small-sided games alone|The small-sided games group performed 2 sessions per week of small-sided games training program in different formats, without participating in any strength training. The small-sided games training was conducted twice a week on Wednesdays and Fridays (8:00-10:00 p.m.) for 6 weeks. These training sessions started before the team's technical and tactical training. Extra balls are placed at the goals and along the field boundary lines, allowing play to restart immediately after the ball leaves the field. During the games, the offside rule was not applied. The game started with the foot when the ball left edge of the field. Other rules in the games were kept similar to those of official soccer. During the games, the coaches encouraged the players to exert maximum effort. The number of defenders, midfielders, and attackers in the teams was kept as equal as possible.
215121919|NCT06921226|OTHER|Psychological Processes|"* The sense of thwarted belonging and perceived burden will be measured using the Interpersonal Needs Questionnaire (INQ; Van Orden et al., 2012). The back-translated French version by Landrault et al. (2019) will be used. This scale is based on a seven-point Likert scale, ranging from 1 (not at all true for me) to 7 (very true for me).~* To assess impulsivity, we will use the short version of the UPPS validated in French by Billieux and colleagues (2012). It comprises 20 items divided into 5 dimensions (negative urgency, positive urgency, lack of premeditation, lack of perseverance and sensation seeking). Participants were asked to respond on a Likert scale from 1 (I strongly agree) to 4 (I strongly disagree).~* We will use the French version of the SRS (Suicidal Rumination Scale, Rogers et al., 2022), back-translated for this study. This eight-item scale assesses suicidal ruminations."
215121920|NCT06921226|OTHER|Risk-taking variables|"* One of the behavioral tasks based on a real-life model of risky decision-making is BART (Lejuez et al., 2002, 2007). It is based on a conceptual framework of balance between reward and loss potential (Leigh, 1999; Lejuez et al., 2002).~* We will measure one of the cognitive aspects of risk-taking behavior, especially the general cognitive decision-making styles (GDMS, from Scott and Bruce, 1995; Gerard et al., 2016).~* We will measure negative (NRTB , Duell et al., 2020) and positive (PRTB, Fryts et al., 2024) self-reported risk-taking behaviour."
215121921|NCT06921226|OTHER|Suicidal ideation and behavior|"Suicidal ideation and behavior were measured using the screening grid, the Columbia Suicide Severity Rating Scale (C-SSRS screen version, Posner, Brown, Stanley et al., 2011). It is composed of 6 questions, which take into account the potential method of suicide, the presence of suicidal intent and/or ideation with a plan or intention. This scale has high reliability and validity in general paediatric emergencies (Scudder et al., 2023) and psychiatric samples (Campos et al., 2023).~It classifies people as being at low or high risk of suicide, based on the presence or absence of significant active suicidal ideation in the last three months."
215121922|NCT06937437|OTHER|Teletherapy|A teletherapy patient presenting with stammering (stuttering) is a person receiving speech therapy remotely, using technology like video conferencing, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
215121923|NCT06937437|OTHER|Traditionally speech therapy|This type of intervention is traditional speech therapy that will be given to stammering adults, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
215121924|NCT02617654|DRUG|Liraglutide|Treatment with liraglutide for 52 weeks
215121925|NCT02617654|DRUG|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
215121926|NCT01060852|BEHAVIORAL|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
215121927|NCT03867643|BIOLOGICAL|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
215121928|NCT01284023|OTHER|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
215121929|NCT04374045|OTHER|ECG-Holter|Patient will have a ECG-Holter recording during all their hospitalization.
215121930|NCT01192308|DRUG|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
215121931|NCT06407245|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
215121932|NCT06407245|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
214445565|NCT02345720|DEVICE|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
215121933|NCT01045694|DRUG|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
215121934|NCT01045694|DRUG|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
215121935|NCT01045694|DRUG|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
214445566|NCT06239792|BEHAVIORAL|Sleep Promotion Program|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
214445567|NCT02317783|DRUG|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
214445568|NCT02317783|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
214445569|NCT02317783|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
214445570|NCT05464810|DRUG|Letrozole|Given PO
214445571|NCT05464810|DRUG|Simvastatin|Given PO
214445572|NCT04362501|BIOLOGICAL|dupilumab|300mg dupixent SC every two weeks for six months
214445573|NCT04362501|DRUG|placebo|placebo SC injection every two weeks for six months
214445574|NCT01837394|PROCEDURE|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
214522764|NCT02531997|BEHAVIORAL|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
215121936|NCT02226887|PROCEDURE|MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit."
215121937|NCT02226887|PROCEDURE|NO MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~\- Hospital discharge after verification of normal digestive transit"
215121938|NCT02226887|RADIATION|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
215121939|NCT02226887|RADIATION|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
215121940|NCT02226887|OTHER|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
215121941|NCT04957797|PROCEDURE|round tunnel|reamed with round tunnel
215121942|NCT04957797|PROCEDURE|flat tunnel|reamed with flat tunnel
215121943|NCT02954107|OTHER|MRI|
215121944|NCT02954107|OTHER|24h-EEG + video|
215121945|NCT02954107|OTHER|Neuropsychological tests|
215121946|NCT04533724|DRUG|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
215121947|NCT03303326|BEHAVIORAL|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
214445575|NCT01837394|PROCEDURE|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
214522765|NCT02531997|BEHAVIORAL|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
214522766|NCT04677985|COMBINATION_PRODUCT|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
214522767|NCT06585163|DRUG|Hydrocodone Bitartrate|Hydrocodone bitartrate oral suspension
215121948|NCT02182323|DRUG|BI 201335 NA|
215121949|NCT02182323|DRUG|Placebo solution|
215121950|NCT00428766|DRUG|MORAb-003|
215121951|NCT05244616|OTHER|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
215121952|NCT02719171|DRUG|risankizumab|Risankizumab administered by SC injection
214445576|NCT01837394|DRUG|Paracetamol|
214522768|NCT06585163|DRUG|Doxapram Hydrochloride|Doxapram hydrocholoride oral suspension
215121953|NCT02719171|DRUG|placebo for risankizumab|Placebo for risankizumab administered by SC injection
214445577|NCT01837394|DRUG|Morphine|5 mg as needed
214445578|NCT01837394|DRUG|Ondansetron|4 mg i.v. as needed in the PACU
214445579|NCT01837394|DRUG|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
214445580|NCT01762059|DEVICE|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
214445581|NCT01762059|OTHER|Usual care|
214445582|NCT04216381|DIAGNOSTIC_TEST|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
214445583|NCT02140645|DRUG|linagliptin|non-randomized
214445584|NCT00525954|DRUG|A-002|
214445585|NCT05170620|PROCEDURE|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
214445586|NCT06107751|OTHER|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
214445587|NCT06107751|OTHER|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
214445588|NCT04678895|DRUG|Naltrexone|Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
214445589|NCT04678895|DRUG|Placebo|Naltrexone matched placebo capsule.
214445590|NCT06718569|DRUG|Biological or targeted synthetic DMARD|All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases
214445591|NCT06969053|BEHAVIORAL|Mindfulness Intervention Therapy plus Sleep Hygiene Education|Participants will receive a 6-week program combining Mindfulness Intervention Therapy (MIT) and Sleep Hygiene Education (SHE). MIT includes body scan, mindful breathing, breathing space exercises, mindful walking, sitting meditation, loving-kindness meditation, and development of a personalized mindfulness practice plan. Sessions are conducted daily for 50 minutes. SHE provides structured guidance on optimizing sleep schedules, bedroom environment, and reducing stimulants such as caffeine and alcohol.
214445592|NCT06969053|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
214522769|NCT05419921|DIAGNOSTIC_TEST|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, \& did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
214522770|NCT05978947|DEVICE|ZyMōt Multi 850µL device|The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
214522771|NCT05978947|DEVICE|Density Gradient Centrifugation Method|Density gradient centrifugation is a laboratory technique used to separate and isolate different types of cells or particles based on their density. It is commonly used in various applications, including cell biology, immunology, and assisted reproductive technology (ART).
214522772|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
215121954|NCT05822882|PROCEDURE|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
215121955|NCT02963454|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
215121956|NCT02963454|DRUG|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
214522773|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
214522774|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
215121957|NCT02963454|DRUG|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
215121958|NCT05927038|OTHER|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
215121959|NCT05927038|OTHER|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
215121960|NCT01013129|GENETIC|DNA analysis|saliva samples will be collected from men (probands) who join the study.
215121961|NCT01013129|GENETIC|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
215121962|NCT01013129|OTHER|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
215121963|NCT01013129|OTHER|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
215121964|NCT01013129|OTHER|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
214445593|NCT03419572|OTHER|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
214445594|NCT02318901|DRUG|Pembrolizumab|
214445595|NCT02318901|DRUG|Trastuzumab|
214445596|NCT02318901|DRUG|ado-trastuzumab emtansine|
214445597|NCT02318901|DRUG|Cetuximab|
214445598|NCT01484353|BEHAVIORAL|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
215121965|NCT01013129|PROCEDURE|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
215121966|NCT01013129|PROCEDURE|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
215121967|NCT06133335|OTHER|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
215121968|NCT00333021|DRUG|Fondaparinux sodium|
215121969|NCT00333021|DRUG|GSK576428|
215121970|NCT02828371|DEVICE|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
215121971|NCT02828371|OTHER|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
215121972|NCT06079385|OTHER|Acupuncture treatment|Acupuncture treatment with needles
215121973|NCT00908453|DRUG|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
215121974|NCT03921827|DEVICE|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
215121975|NCT02796677|DRUG|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
215121976|NCT02796677|DRUG|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
215121977|NCT02796677|DRUG|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
215121978|NCT02796677|OTHER|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
215121979|NCT02796677|DRUG|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
215121980|NCT02796677|OTHER|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
215121981|NCT04921566|DRUG|Torasemide tablet 10 mg|Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.
215121982|NCT04921566|DRUG|Toradiur® tablet 10 mg|Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
215121983|NCT01103765|PROCEDURE|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
215121984|NCT01103765|PROCEDURE|stent deployment without post-dilatation|stent deployment without systematic post dilatation
215121985|NCT01532947|PROCEDURE|post placement|placement of an endocanalar post
215121986|NCT03372785|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
215121987|NCT03372785|DEVICE|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
214522775|NCT02954276|DRUG|Omexa Sublingual Sumatriptan tablet|75 mg
214522776|NCT02954276|DRUG|Imitrex Oral Product|100 mg
214522777|NCT03658395|PROCEDURE|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
214522778|NCT03658395|PROCEDURE|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
214708553|NCT02246023|DEVICE|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
214708554|NCT00854555|OTHER|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
214708555|NCT00854555|OTHER|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
215121988|NCT04147689|DEVICE|DESIRIAL® PLUS|"DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study."
215121989|NCT00515151|DRUG|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
215121990|NCT00515151|DRUG|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
215121991|NCT01319669|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
215121992|NCT00961181|DEVICE|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
215121993|NCT05532865|OTHER|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
215121994|NCT05532865|OTHER|Stool samples|A stool sample for collection of digestive microbiota at inclusion
215121995|NCT05532865|OTHER|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
215121996|NCT05532865|OTHER|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
215121997|NCT05532865|OTHER|Skin biopsies|At inclusion and 18 months
215121998|NCT04914780|BEHAVIORAL|Education|Education intervention with mobile application for 4 weeks
214694260|NCT06898619|BEHAVIORAL|Crisis Management Training for Third-Year Nursing Students|"Crisis management is essential for nurses, who often work on the front lines during emergencies. This training program for third-year nursing students equips them with the skills and knowledge required to handle crises effectively. The program includes nine stages: raising awareness, assessing baseline knowledge, reinforcing foundational concepts, introducing advanced techniques, practicing through simulations, reflecting on learning, providing feedback, summarizing key points, and enhancing learning with additional resources.~Participants explore critical topics such as disaster response, triage, communication strategies, and teamwork. Simulated scenarios help develop practical skills like decision-making and prioritization under pressure. Feedback and reflective discussions reinforce learning, while additional resources encourage ongoing professional growth.~By bridging theoretical knowledge with practical application, the training prepares nursing students to respond confidently t"
214708556|NCT06287944|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
215121999|NCT01045967|DRUG|Lansoprazole|30 mg delayed-release Capsule
215122000|NCT01045967|DRUG|Prevacid®|30 mg delayed-release Capsule
215122001|NCT01525836|DRUG|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 29th day)
215122002|NCT01525836|DRUG|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
215122003|NCT03314493|DRUG|Spironolactone 25Mg Tablet|Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
215122004|NCT05582486|BEHAVIORAL|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
215122005|NCT01804478|BEHAVIORAL|Mild pneumatic compression|
215122006|NCT01863381|DEVICE|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
215122007|NCT01863381|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
215122008|NCT02654886|OTHER|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
215122009|NCT01248195|DRUG|Amisulpride open label|4-week open label amisulpride treatment
215122010|NCT01248195|DRUG|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
215122011|NCT01248195|DRUG|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
215122012|NCT01248195|DRUG|12-week clozapine open-label treatment|12-week clozapine open-label treatment
215122013|NCT01248195|BEHAVIORAL|Psychosocial intervention|Psychosocial intervention
215122014|NCT04541407|DRUG|Temozolomide plus Osimertinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
215122015|NCT04541407|DRUG|Temozolomide plus Lorlatinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
215122016|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
215122017|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
215122018|NCT00754702|DRUG|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
215122019|NCT00754702|DRUG|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
215122020|NCT02875379|PROCEDURE|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
215122021|NCT00769886|DRUG|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
215122022|NCT00769886|DRUG|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
215122023|NCT00769886|DRUG|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
215122024|NCT00769886|DRUG|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
214445599|NCT06094231|BEHAVIORAL|Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor|The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
214522779|NCT04964297|DEVICE|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
214522780|NCT03312621|BEHAVIORAL|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
214694261|NCT06898879|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
215122025|NCT04581486|OTHER|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
215122026|NCT04581486|OTHER|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
215122027|NCT05219331|PROCEDURE|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
215122028|NCT00481819|DRUG|FK506MR|oral
215122029|NCT00481819|DRUG|Prograf|oral
215122030|NCT00481819|DRUG|Mycophenolate Mofetil|oral
215122031|NCT00481819|DRUG|Methylprednisolone|oral
215122032|NCT00481819|DRUG|Prednisolone|oral
215122033|NCT01841905|OTHER|Observational Study|Observational Study
215122034|NCT04796363|PROCEDURE|Erector Spinae Plane Block with Bubivacaine|Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
215122035|NCT04796363|PROCEDURE|Standard General Anaesthesia|Standard General Anaesthesia without ESPB
215122036|NCT04662359|DIAGNOSTIC_TEST|Ultrasound Assessment|Patients will undergo an ultrasound scan to assess the severity of their rheumatoid arthritis.
215122037|NCT04601935|BIOLOGICAL|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
215122038|NCT05077930|BIOLOGICAL|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
215122039|NCT05077930|DRUG|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
215122040|NCT05313035|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
215122041|NCT05313035|BIOLOGICAL|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
215122042|NCT03967145|BEHAVIORAL|Determining quality of life|Quality of Life
215122043|NCT06527898|DRUG|hypofractionated radiotherapy with immunotherapy|hypofractionated radiotherapy with Adebrelimab consolidation
215122044|NCT03255135|DEVICE|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
215122045|NCT03833024|DRUG|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
215122046|NCT03833024|DRUG|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
215122047|NCT01794988|BEHAVIORAL|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
215122048|NCT01794988|BEHAVIORAL|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
215122049|NCT01794988|BEHAVIORAL|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
215122050|NCT01794988|BEHAVIORAL|NO TIVR|Control - no intervention
215122051|NCT03471247|DEVICE|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
215122052|NCT03471247|OTHER|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
215122053|NCT01729286|DEVICE|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
214522781|NCT01855399|BEHAVIORAL|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
214522782|NCT01855399|BEHAVIORAL|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
214522783|NCT02084615|DRUG|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
214522784|NCT01753674|DIETARY_SUPPLEMENT|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
214522785|NCT01753674|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
215122054|NCT01729286|OTHER|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
214522786|NCT03953079|DRUG|Drug: GB-102|Intravitreal injection of GB-102
215122055|NCT02960516|DEVICE|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
215122056|NCT03018444|DRUG|Atorvastatin|Atorvastatin tablet
215122057|NCT03018444|OTHER|Placebo|Placebo tablet
215122058|NCT06381934|OTHER|Standard Care|Standard diagnosis and therapy procedures at physician's discretion.
215122059|NCT06381934|OTHER|aSID/ChU Guided Therapy|"Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization."
215122060|NCT03477396|DRUG|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
215122061|NCT03477396|OTHER|Laboratory Biomarker Analysis|Correlative studies
215122062|NCT03477396|OTHER|Pharmacokinetic Study|Correlative studies
215122063|NCT03477396|OTHER|Questionnaire Administration|Ancillary studies
215122064|NCT03477396|DRUG|Ribociclib|Given PO
215122065|NCT00254137|DRUG|capecitabine|
215122066|NCT00254137|DRUG|irinotecan|
215122067|NCT00254137|DRUG|oxaliplatin|
214522787|NCT03953079|DRUG|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
214522788|NCT05550441|DRUG|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
214522789|NCT05550441|DRUG|Placebo|The Placebo group received placebo for 1 year.
215122068|NCT00254137|DRUG|cetuximab|
215122069|NCT00028704|PROCEDURE|conventional surgery|
215122070|NCT00028704|RADIATION|radiation therapy|
215122071|NCT03030469|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
215122072|NCT01372969|DRUG|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
215122073|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
215122074|NCT06173583|DIAGNOSTIC_TEST|Detection/screening|Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
215122075|NCT03373929|DEVICE|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
215122076|NCT03373929|DEVICE|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
215122077|NCT06166966|OTHER|Flipped Education Model|The effect of the Inside Out Education Model on the course success of nursing students.
215122078|NCT04467086|DRUG|Propranolol Hydrochloride|"Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min."
215122079|NCT01485094|DRUG|GRT6010|Oral solution given once daily.
215122080|NCT01485094|DRUG|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
215122081|NCT01485094|DRUG|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
215122082|NCT02576639|DRUG|CNP520|
215122083|NCT02576639|DRUG|Placebo|Matching placebo to CNP520 was supplied in capsules.
215122084|NCT06129643|DRUG|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
215122085|NCT06129643|DEVICE|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
215122086|NCT06129643|COMBINATION_PRODUCT|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
215122087|NCT02125084|DRUG|Everolimus|
215122088|NCT02125084|DRUG|Enzalutamide|
214445600|NCT00593489|OTHER|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
214445601|NCT03898310|DIETARY_SUPPLEMENT|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
214445602|NCT03898310|DIETARY_SUPPLEMENT|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
215122089|NCT01880658|DRUG|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
215122090|NCT06032169|OTHER|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
215122091|NCT01380223|DRUG|placebo|I.V. infusion of placebo for 8 hr
215122092|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
215122093|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
215122094|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
215122095|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
215122096|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
215122097|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
215122098|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
215122099|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
215122100|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
215122101|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
215122102|NCT01503008|DEVICE|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
215122103|NCT01503008|DRUG|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
215122104|NCT00367939|DRUG|valsartan + amlodipine|
214445603|NCT04414826|BEHAVIORAL|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
215122105|NCT03188107|OTHER|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
214445604|NCT04414826|BEHAVIORAL|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
215122106|NCT03228771|DRUG|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
215122107|NCT03228771|DRUG|ATV gel|Atorvastatin loaded in methyl cellulose gel
215122108|NCT04610047|DRUG|Norketotifen|Oral capsule
215122109|NCT04610047|DRUG|Placebo|Oral capsule
214445605|NCT05694442|OTHER|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
214445606|NCT00611559|BIOLOGICAL|Infanrix™ penta|Subjects received a booster dose
214445607|NCT00611559|BIOLOGICAL|Infanrix™ hexa|Subjects received a booster dose
214445608|NCT04073953|DRUG|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
214445609|NCT04073953|DRUG|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
214522790|NCT03370588|DRUG|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
215122110|NCT03074071|BEHAVIORAL|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
215122111|NCT03531671|DEVICE|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
215122112|NCT02093507|OTHER|parents manipulation|parents perform manipulation the child foot to correct the deformity
215122113|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
215122114|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
215122115|NCT02079038|DEVICE|Totalis|
215122116|NCT02079038|PROCEDURE|Comparator Surgical Procedure|
215122117|NCT05605626|OTHER|the better retaining of skills|identify which teaching program has the better retaining of skills
215122118|NCT05424016|DRUG|Propranolol|120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
215122119|NCT05424016|OTHER|follow-up|routine follow-up (neurosurgical consultation and an MRI every six months)
214445610|NCT04073953|DRUG|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
214445611|NCT02629679|BEHAVIORAL|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
215122120|NCT05206175|OTHER|Affect Treatment Program for Methamphetamine Use Disorder|Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
214445612|NCT02629679|BEHAVIORAL|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
215122121|NCT05712070|BEHAVIORAL|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
215122122|NCT05712070|BEHAVIORAL|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
215122123|NCT02333357|BEHAVIORAL|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
214445613|NCT05838469|OTHER|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
215122124|NCT02333357|BEHAVIORAL|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
215122125|NCT04113317|DRUG|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
215122126|NCT02478463|DRUG|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
215122127|NCT02478463|DRUG|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
215122128|NCT01290614|OTHER|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
215122129|NCT01290614|OTHER|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
215122130|NCT01358825|PROCEDURE|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
214445614|NCT05865834|OTHER|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
214522791|NCT03370588|DRUG|Normal saline|Group B: Saline infusion during same time period.
214522792|NCT04394624|DRUG|SAR408701|Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
214522793|NCT04394624|DRUG|ramucirumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
214522794|NCT04394624|DRUG|pembrolizumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
214522795|NCT01466556|OTHER|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
214522796|NCT04019925|DEVICE|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
214522797|NCT05888285|PROCEDURE|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
214522798|NCT05888285|PROCEDURE|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
214708557|NCT06287944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215122131|NCT02036047|DEVICE|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
215122132|NCT02036047|DEVICE|Regular polypectomy snare (Snare Master, SD-210U-10)|
215122133|NCT00152893|DRUG|chromium nicotinate|
215122134|NCT00152893|DRUG|Placebo|
215122135|NCT04079595|DEVICE|Head immobilization mask|Immobilization
215122136|NCT02081157|DEVICE|GalaFlex Mesh|
215122137|NCT03406637|DEVICE|BPK-S Integration|primary total knee endoprosthesis
215122138|NCT01825187|DEVICE|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
214445615|NCT05865834|OTHER|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
214445616|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
214445617|NCT06450405|DRUG|Testosterone Cypionate 50 MG/ML Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
214445618|NCT05297136|PROCEDURE|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
214445619|NCT05297136|PROCEDURE|No Stent|No preoperative stenting with distal pancreatectomy alone
214445620|NCT05662124|OTHER|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
214445621|NCT06821152|DEVICE|Miss Liberty Condom|The Miss Liberty female condom is manufactured by Zhejiang Rui Bo 001 High Polymer Co, Ltd. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The sheath, are made of polyurethane. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. Miss Liberty measures 180mm in length and 78mm in lay-flat width. The device is pre-lubricated with silicone oil. This condom is a similar design (material, length, width) to the USFDA approved FC1 female condom which was discontinued and replaced by FC2.
214445622|NCT06821152|DEVICE|FC2 condom|The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark of the European Union. The FC2 is pre-qualified by the WHO. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 170mm in length and 80mm in lay-flat width. The device is pre-lubricated with silicone oil. This FC is available in the public health sector in South Africa.
214445623|NCT02412683|OTHER|oxaliplatin|
214522799|NCT04005248|DIAGNOSTIC_TEST|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
214522800|NCT03147222|BEHAVIORAL|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
214522801|NCT01002209|PROCEDURE|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
214708558|NCT06287944|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
215122139|NCT01825187|DEVICE|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
215122140|NCT01825187|OTHER|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
215122141|NCT01508169|DEVICE|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
215122142|NCT03744767|DRUG|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
215122143|NCT02364141|OTHER|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
214445624|NCT02814383|OTHER|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
215122144|NCT02364141|OTHER|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
215122145|NCT01225614|DEVICE|Bilevel pressure ventilator|Nocturnal home ventilation
215122146|NCT04117204|OTHER|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
215122147|NCT04832932|BIOLOGICAL|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
215122148|NCT06155461|PROCEDURE|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
215122149|NCT02558855|OTHER|Thrust Joint Manipulation of the Lumbar Spine|
215122150|NCT02558855|OTHER|Non-thrust Joint Manipulation of the Lumbar Spine|
215122151|NCT03501472|BEHAVIORAL|text-only PWL|
215122152|NCT03501472|BEHAVIORAL|low-emot PWL|
215122153|NCT03501472|BEHAVIORAL|high-emot PWL|
215122154|NCT03501472|BEHAVIORAL|immed posttest|
215122155|NCT03501472|BEHAVIORAL|delay posttest|
215122156|NCT04035252|DIAGNOSTIC_TEST|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
215122157|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
215122158|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
215122159|NCT01725490|DRUG|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
215122160|NCT00076414|DRUG|Acetylcholine|
215122161|NCT00076414|DRUG|L-NMMA|
215122162|NCT01584310|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
214694262|NCT06898879|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation, befriending, and Veteran to Veteran support. Each session is 60 minutes long.
214694263|NCT06899321|OTHER|Cosmetic product M68|Cosmetic skin brightening product to be applied to defined test site
215122163|NCT01584310|OTHER|No STAMP using|No intervention
215122164|NCT02952599|DRUG|Edoxaban|Prescribed according to approved label
215122165|NCT02116881|PROCEDURE|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
215122166|NCT01533506|DRUG|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
215122167|NCT03600740|DEVICE|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
215122168|NCT05233592|DEVICE|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
215122169|NCT00814450|DEVICE|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
215122170|NCT04440748|DEVICE|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
215122171|NCT04440748|OTHER|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
215122172|NCT01749306|BIOLOGICAL|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
214445625|NCT06986850|DEVICE|FeelSync mobile application|Ecological Momentary Intervention focused on cognitive reappraisal for distressing autobiographical memories, with a possibility to choose between distancing and positive reappraisal.
214445626|NCT06986850|DEVICE|Ecological Momentary Assessment mobile application|Ecological Momentary Assessment used for self-monitoring of emotional states.
214445627|NCT06988085|OTHER|Blood sampling|Before and after fludarabine infusion
214445628|NCT06987851|BIOLOGICAL|Divozilimab|Intravenous infusion of BCD-132 every 24 weeks
214445629|NCT06987760|PROCEDURE|flexible ureteroscope urolithiasis|Using flexible ureteroscope combine with urethral access sheath to treatment urolithiasis
214445630|NCT06987994|OTHER|control group( physical therapy)|"Participants will receive conventional physiotherapy 3 times per week for 4 weeks. The treatment includes:~Standing exercises: multidirectional stepping, single- and double-leg stance~Walking exercises: forward, backward, and lateral walking~Weight-shifting exercises: lunges, half-squats, leaning, and reaching"
214445631|NCT06987994|OTHER|Experemental group|In this group the number of Participants are 15 . The experment by using VR sessions will last 30 minutes per session, 3 times per week for 4 weeks . In addition to the same physiotherapy program used in the control group, this group will receive Virtual Reality (VR) training using a Meta Quest 2 headset . Patients will interact with immersive environments designed to stimulate movement and functional tasks.
214522802|NCT01002209|PROCEDURE|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
214522803|NCT05832489|DRUG|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
215122173|NCT01749306|OTHER|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
215122174|NCT03653858|DEVICE|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
215122175|NCT01814527|DIETARY_SUPPLEMENT|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
215122176|NCT01814527|DRUG|Placebo|5 capsules that are identical to the treatment.
215122177|NCT04524858|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
215122178|NCT02414685|DRUG|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
215122179|NCT02414685|DRUG|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
215122180|NCT02414685|DRUG|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
215122181|NCT03571204|BIOLOGICAL|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
215122182|NCT03571204|BIOLOGICAL|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
215122183|NCT06522789|PROCEDURE|corneal cross-linking procedure|Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
214445632|NCT06988319|DRUG|Psilocybin (Usona Institute)|Single dose of pharmaceutical grade psilocybin (25 mg) combined with psychotherapy sessions
214522804|NCT05832489|DRUG|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
214522805|NCT01285856|OTHER|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
214694264|NCT06899321|OTHER|Cosmetic product Z15|Cosmetic skin brightening product to be applied to defined test site
215122184|NCT02396212|BIOLOGICAL|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
214445633|NCT06988436|DIAGNOSTIC_TEST|Ultrasound|All the participants were scanned using B mode sonography to determine the fetal biometric parameters (BPD, HC, AC and FL). The machine automatically calculated the estimated fetal weight using the Headlock formula. umbilical artery pulsatility index (UAPI) and pulmonary vein pulsatility index (PVPI) were measured in the study
214445634|NCT06987019|OTHER|3D motion capture, wearable devices, and functional outcome measures|Gait evaluation, Hill and Stair Assessment Indices, 6 minute walk test, AMPPro, Timed Up and Go
214445635|NCT06987227|BEHAVIORAL|Intelligent intervention to enhance parent-child connection|"The Intelligent Intervention to Enhance Parent-Child Connection support program is mainly carried out through web pages, Figma software, cloud files and official Line accounts. It can be divided into: the first stage is to provide parents with care knowledge and skills during the hospitalization of premature infants, provide parents with physical and mental support, and encourage parents to establish parent-child connections and prepare for discharge. The second stage is after discharge, continuing to provide premature infants' families with the care guidance needed to respond to the different stages of development of premature infants, including interpersonal support, sleep schedule establishment, crying comfort, premature infant nutrition and couple relationship management, etc., and continue to provide family support, answer questions and track its implementation status."
214445636|NCT06987227|OTHER|Routine care|Premature infants receive routine care during their hospitalization, and general nursing guidance for premature infant discharge care is provided before discharge.
214445637|NCT06987955|OTHER|Biocoat Pit and fissure sealant|Application of Biocoat
215122185|NCT03479086|DRUG|Topiramate|200mg/day 100mg b.i.d
215122186|NCT03479086|DRUG|Naltrexone|50mg/day
215122187|NCT02461654|OTHER|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
215122188|NCT05932108|BEHAVIORAL|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
215122189|NCT05932108|OTHER|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
215122190|NCT04612166|BEHAVIORAL|Medication Action Plan and Patient Empowerment (MAP-PE )|"Intervention patients (after consenting) will meet with a study health coach for an in-person meeting where the health coach will review the pharmacists Medication Action Plan (MAP) for deprescription of high-risk medication. The MAP will have previously been approved by both the patient and the patient's primary care physician. If the patient is on more than one high risk medication, the medication that puts them at the highest risk will be deprescribed first and only one medication will be decreased at a time. During this initial meeting, the health coach will use motivational interviewing and distribute materials to empower and support the patient in the reduction of the medication as outlined on their MAP. The health coach will then follow up with the patient on a schedule determined~by the type and dosage of medication being reduced. Follow ups will decrease in frequency over time (starting with at least once a week). The patients will be followed for up to 12 months."
215122191|NCT01363700|DRUG|DE-114 ophthalmic solution|
215122192|NCT01363700|DRUG|Placebo ophthalmic solution|
215122193|NCT01363700|DRUG|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
215122194|NCT00114816|DRUG|capecitabine|
215122195|NCT00114816|DRUG|docetaxel|
215122196|NCT01999296|DEVICE|Use of Thunderbeat (TM) in laparoscopic surgery|
215122197|NCT01187940|BEHAVIORAL|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
215122198|NCT01155336|DRUG|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
215122199|NCT01155336|DRUG|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
214445638|NCT06987955|OTHER|Fissurit FX Pit and fissure sealant|Application of Fissurit FX
214445639|NCT06986356|DIETARY_SUPPLEMENT|Test product: Yoghurt|High protein spoonable yoghurt
214445640|NCT06986356|DIETARY_SUPPLEMENT|Placebo|Placebo Jelly
214694265|NCT06899321|OTHER|Cosmetic product R52|Cosmetic skin brightening product to be applied to defined test site
214445641|NCT06988397|BEHAVIORAL|Physical activity after different type of meals|Standardized physical activity (walking) after consuming one of three meal types (vegetable-based, meat-based, dairy-based). Ultrasound of gastric volume will be performed at 3 and 6 hour between walking sessions.
214445642|NCT06987214|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
214445643|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
214445644|NCT01945762|DRUG|Vandetanib 300 mg|Vandetanib commercial tablets
214445645|NCT06275919|DRUG|Regorafenib 40 MG Oral Tablet|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
214445646|NCT06275919|DRUG|Local Standard of Care|In this setting there are not drugs with indication. Every site will treat patients as per their experience.
214445647|NCT03109197|OTHER|Biospecimin Collection|
214445648|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
215122200|NCT03449966|DEVICE|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
215122201|NCT03449966|DEVICE|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
215122202|NCT06106113|DRUG|GST-HG171 Tablets|150mg GST-HG171 Tablets
215122203|NCT02360826|DRUG|Pravastatin|
215122204|NCT02360826|DRUG|Simvastatin|
215122205|NCT06020157|OTHER|Simple Suture Technique|The half of the full arch flap will be closed by the simple suture technique.
215122206|NCT06020157|OTHER|Continuous Suture Technique|The half of the full arch flap will be closed by the continuous suture technique.
215122207|NCT01274026|DRUG|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
215122208|NCT00669890|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
215122209|NCT00669890|DRUG|Busulfan|Conditioning Regimen
215122210|NCT00669890|DRUG|Cyclophosphamide|Conditioning Regimen
215122211|NCT00669890|DRUG|Thymoglobulin|(Unrelated Donors only)
215122212|NCT00669890|DRUG|Tacrolimus|GVHD Prophylaxis
215122213|NCT00669890|DRUG|Mycophenolate Mofetil|GVHD Prophylaxis
215122214|NCT00669890|DRUG|Methotrexate|GVHD Prophylaxis
215122215|NCT00504088|PROCEDURE|Bypass|
215122216|NCT00504088|PROCEDURE|Silverhawk Plaque Excision|
215122217|NCT03788174|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
215122218|NCT03788174|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
215122219|NCT02119871|PROCEDURE|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
215122220|NCT02119871|PROCEDURE|Right Pleura Open|Right pleura open Left ventricular apical drainage
215122221|NCT03790566|DRUG|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
215122222|NCT03214107|OTHER|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
215122223|NCT03214107|OTHER|Snack|Full snack or Distributed snack
215122224|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
215122225|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
215122226|NCT04494035|DEVICE|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
215122227|NCT01809821|BEHAVIORAL|Online Sleep Education|
215122228|NCT03167333|DRUG|platelet rich plasma|The amount of PPR was about 4-5 cc
215122229|NCT03167333|DRUG|Hyaluronic acid|HA was 2.5cc
214445649|NCT04393558|DEVICE|ADAM Sensor|ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
214522806|NCT05832320|DRUG|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
214694266|NCT06899321|OTHER|Cosmetic product J61|Cosmetic skin brightening product to be applied to defined test site
215122230|NCT06150950|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.
215122231|NCT06150950|OTHER|Usual care|For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.
215122232|NCT05003037|DRUG|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
215122233|NCT05065905|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
215122234|NCT02414308|DRUG|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
215122235|NCT01933308|OTHER|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
215122236|NCT01933308|OTHER|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
215122237|NCT01933308|OTHER|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
215122238|NCT02789059|OTHER|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
215122239|NCT03408197|DEVICE|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
215122240|NCT03408197|DEVICE|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
215122241|NCT05202418|BEHAVIORAL|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
215122242|NCT01671163|PROCEDURE|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
215122243|NCT03287401|DEVICE|Electroencephalography|Patients electroencephalogram will be recorded
215122244|NCT05770817|OTHER|N/A: SKyRoCKeT is an observational study|None; this is an observational study
215122245|NCT06396234|DEVICE|Safe VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
215122246|NCT06396234|PROCEDURE|Endotracheal intubation using video laryngoscope|Endotracheal intubation (size 7.0 mm) using video laryngoscope
215122247|NCT06396234|DEVICE|SaCo VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
215122248|NCT00006000|DRUG|cisplatin|
215122249|NCT00006000|DRUG|irinotecan hydrochloride|
215122250|NCT00006000|DRUG|semaxanib|
215122251|NCT04507243|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
215122252|NCT04507243|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
215122253|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
214522807|NCT05832320|DRUG|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
214708559|NCT06287944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215122254|NCT05663203|OTHER|Interview|Complete interview
215122255|NCT05663203|OTHER|Survey Administration|Complete survey
215122256|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
215122257|NCT02949609|OTHER|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
215122258|NCT02949609|OTHER|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
215122259|NCT05309902|DRUG|Soticlestat|Soticlestat tablet.
215122260|NCT05309902|DRUG|Placebo|Soticlestat placebo-matching tablet.
215122261|NCT05309902|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
215122262|NCT05309902|DRUG|Placebo|Moxifloxacin placebo-matching capsule.
215122263|NCT03482622|DIAGNOSTIC_TEST|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
215122264|NCT00804726|DEVICE|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
215122265|NCT02146417|PROCEDURE|Low pressure pneumoperitoneum|
215122266|NCT02146417|PROCEDURE|Normal pressure pneumoperitoneum (12 mmHg)|
214445650|NCT03949881|BIOLOGICAL|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
214445651|NCT05188469|DRUG|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
214445652|NCT05188469|DRUG|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
214445653|NCT05188469|DRUG|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
214445654|NCT05188469|DRUG|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
214445655|NCT05188469|DRUG|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
214445656|NCT04333706|DRUG|Capecitabine|Capecitabine 1000 mg BID
214445657|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg or 200 mg plus Capecitabine|Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
214522808|NCT04222400|DIAGNOSTIC_TEST|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
214522809|NCT05618717|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
214522810|NCT01034774|DRUG|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
215122267|NCT02146417|PROCEDURE|Deep neuromuscular block|
215122268|NCT04392817|BEHAVIORAL|Arabic Articulatory Error Remediation software program|A speech therapy computerized intervention
214445658|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg plus Capecitabine|Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
214445659|NCT03424811|DEVICE|Mobile Health Intervention|Mobile health intervention to promote healthy eating.
214445660|NCT06134479|DRUG|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
214522811|NCT01034774|DRUG|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
214522812|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
214522813|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
214522814|NCT02790645|OTHER|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
214522815|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
214522816|NCT00959634|DRUG|ABT-126|Dose administered twice daily on Study Days 1-10
214694267|NCT06899321|OTHER|Cosmetic product U36|Cosmetic skin brightening product to be applied to defined test site
214522817|NCT00959634|DRUG|Placebo|Dose administered twice daily on Study Days 1-10
214694268|NCT06898684|BEHAVIORAL|Exercise|Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.
214694269|NCT07063030|GENETIC|LX107 Injection|Subjects will receive subretinal injection of LX107 on Day 0.
214708560|NCT06287944|PROCEDURE|Computed Tomography|Undergo CT
215122269|NCT03855696|BIOLOGICAL|MG1113|MG1113
215122270|NCT03855696|OTHER|Placebo of MG1113|Placebo of MG1113
215122271|NCT05339360|PROCEDURE|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
214522818|NCT04306081|DRUG|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
214708561|NCT06287944|BIOLOGICAL|Daratumumab|Given IV
214708562|NCT06287944|PROCEDURE|Echocardiography|Undergo echocardiography
214708563|NCT06287944|DRUG|Fludarabine|Given IV
214445661|NCT06134479|DRUG|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
214445662|NCT04455035|OTHER|Comparator: Retrospective Group(Control)|The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.
215122272|NCT03803189|BEHAVIORAL|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
214522819|NCT04306081|OTHER|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
215122273|NCT05918185|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215122274|NCT05918185|OTHER|Comprehensive Geriatric Assessment|Undergo cGA
215122275|NCT05918185|OTHER|Electronic Health Record Review|Medical records are reviewed
214445663|NCT04455035|DEVICE|Prospective Group|"The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles."
214522820|NCT04004806|DEVICE|Hill Rom tracking device|Location tracking devices from Hill Rom company.
214522821|NCT05431426|DRUG|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
214522822|NCT06036485|DEVICE|Kerecis Omega 3|Decellularized intact fish skin developed for the management of chronic wounds
215122276|NCT05918185|OTHER|Survey Administration|Complete surveys
215122277|NCT01335776|BEHAVIORAL|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
214522823|NCT06036485|PROCEDURE|Surgical debridement|Superficial sharp surgical debridement technique
214522824|NCT01165944|DRUG|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
215122278|NCT01335776|BEHAVIORAL|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
214522825|NCT03460366|DRUG|Enalapril|Patients are tested for their normal prescription enalapril medication
214522826|NCT06550674|GENETIC|Constitutional exome analysis|"For each patient included:~* A family tree is drawn up, reporting personal and family histories of cancer. The patient's anatomopathological reports, related to his or her tumor lesions, are retrieved, in order to confirm/clarify individual or family diagnoses.~* A blood sample and a jugal smear are taken to enable constitutional genetic exome analysis for research purposes."
215122279|NCT00675909|DRUG|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
215122280|NCT00675909|DRUG|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
214522827|NCT01026207|DEVICE|Polysomnography|Sleep study polysomnography compared with portable monitoring
215122281|NCT00675909|DRUG|Oral midazolam|oral midazolam 0.5mg/kg
215122282|NCT01329978|DRUG|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
215122283|NCT01329978|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
215122284|NCT01329978|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
215122285|NCT04950244|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
215122286|NCT02677194|DEVICE|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
215122287|NCT02677194|OTHER|Control device|Device without any LED exposition
214522828|NCT04236700|OTHER|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
214445664|NCT06135298|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
214522829|NCT00733174|DRUG|Rosiglitazone|tablet
215122288|NCT02952365|DRUG|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
215122289|NCT03811444|DEVICE|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
215122290|NCT03811444|DEVICE|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
215122291|NCT03811444|DEVICE|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
215122292|NCT03324802|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215122293|NCT03324802|OTHER|Quality-of-Life Assessment|Ancillary studies
215122294|NCT03324802|RADIATION|Radiation Therapy|hypofractionated radiation therapy
215122295|NCT05984043|BEHAVIORAL|Biofeedback|Heart-rate Variability Biofeedback
215122296|NCT05984043|OTHER|Waitlist|Waitlist control group
215122297|NCT01887132|DRUG|Donepezil|
215122298|NCT01887132|DRUG|Placebo|
215122299|NCT02598206|DRUG|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
215122300|NCT03293030|DRUG|Dupilumab|Dupilumab treatment
215122301|NCT00287716|DRUG|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
214522830|NCT00733174|DRUG|Placebo|
214522831|NCT04617574|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
214522832|NCT04617574|DEVICE|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
214522833|NCT00254241|DRUG|Seroquel and Risperidone|
214522834|NCT00998517|DIETARY_SUPPLEMENT|Soy/peanut fortified spread|75kcal/kg/day
215122302|NCT00287716|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
215122303|NCT00924248|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
215122304|NCT05277558|OTHER|Observational|Investigators are observing brain health over time (21 months) in these groups
215122305|NCT02782286|DRUG|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
215122306|NCT02782286|DRUG|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
215122307|NCT00821496|DRUG|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
215122308|NCT03579706|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
215122309|NCT03579706|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
215122310|NCT01587144|DRUG|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
215122311|NCT01587144|DRUG|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
215122312|NCT01587144|RADIATION|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
215122313|NCT01587144|DRUG|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
215122314|NCT03015636|BEHAVIORAL|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
214522835|NCT00998517|DIETARY_SUPPLEMENT|Milk fortified corn/soy blend|75 kcal/kg/day
214522836|NCT00998517|DIETARY_SUPPLEMENT|Supplementary Plumpy®|75 kcal/kg/day
214522837|NCT06186349|GENETIC|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
214522838|NCT03742882|DRUG|CC-90001|CC-90001
215122315|NCT03015636|OTHER|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
215122316|NCT00900055|GENETIC|microarray analysis|
215122317|NCT00900055|GENETIC|polyacrylamide gel electrophoresis|
215122318|NCT00900055|GENETIC|polymerase chain reaction|
215122319|NCT00900055|GENETIC|protein expression analysis|
215122320|NCT00900055|GENETIC|reverse transcriptase-polymerase chain reaction|
215122321|NCT00900055|GENETIC|western blotting|
215122322|NCT00900055|OTHER|chromatography|
215122323|NCT00900055|OTHER|high performance liquid chromatography|
215122324|NCT00900055|OTHER|immunoenzyme technique|
215122325|NCT00351754|DRUG|Isovue|
215122326|NCT01214005|BEHAVIORAL|smoking abstinence|3 days of biologically-confirmed smoking abstinence
215122327|NCT04394065|DEVICE|ultrasensitive positron emission tomography|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
215122328|NCT00393211|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
215122329|NCT00393211|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
215122330|NCT01950403|DRUG|linaclotide acetate|Given PO
215122331|NCT01950403|OTHER|placebo|Given PO
215122332|NCT01950403|OTHER|pharmacological study|Correlative studies
215122333|NCT01950403|OTHER|laboratory biomarker analysis|Correlative studies
215122334|NCT02864563|PROCEDURE|Blood sampling|"* Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
215122335|NCT04725253|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide, 1,5 gr per day for 7 days.
215122336|NCT04725253|OTHER|Placebo tablets|Placebo tablets, 1 per day for 7 days.
215122337|NCT00485017|DRUG|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
214522839|NCT00561249|PROCEDURE|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
214522840|NCT01992276|BIOLOGICAL|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
214522841|NCT01992276|BIOLOGICAL|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
214522842|NCT01992276|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
214522843|NCT04439591|OTHER|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
214522844|NCT00372476|DRUG|Imatinib and Vinorelbine|
214708564|NCT06287944|PROCEDURE|Hematopoietic Cell Transplantation|Undergo SCT
215122338|NCT00485017|DRUG|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
215122339|NCT06303921|DRUG|11C-M503 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
215122340|NCT06303921|DIAGNOSTIC_TEST|Brain MRI|MRI scan of brain.
215122341|NCT06303921|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB
215122342|NCT06303921|BEHAVIORAL|Neurological assessments|Neurological assessments, including a video interview.
215122343|NCT06731088|DRUG|Midazolam|Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
215122344|NCT06731088|DRUG|Remazolam besylate|Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
214522845|NCT02648555|BEHAVIORAL|Daily walking|Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.
214708565|NCT06287944|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
214708566|NCT06287944|DRUG|Melphalan|Given IV
215122345|NCT01824550|OTHER|home-based exercise training condition|Home based endurance exercise training
215122346|NCT06581653|BEHAVIORAL|Phone-based PERT education intervention|Participants who allocate to the intervention group will receive regular phone-based PERT education intervention by professional team.
215122347|NCT02021669|DRUG|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
215122348|NCT02021669|DRUG|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
215122349|NCT03219502|OTHER|Best Practice|Receive standard of care
215122350|NCT03219502|OTHER|Quality-of-Life Assessment|Ancillary studies
215122351|NCT03219502|OTHER|Questionnaire Administration|Ancillary studies
215122352|NCT03219502|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
215122353|NCT03219502|PROCEDURE|Sham Intervention|Undergo sham rTMS
215122354|NCT05300776|DIAGNOSTIC_TEST|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
215122355|NCT05244746|PROCEDURE|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
215122356|NCT04593524|DIETARY_SUPPLEMENT|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
215122357|NCT04593524|OTHER|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
215122358|NCT02733445|DRUG|dasatinib|
215122359|NCT02733445|DRUG|nilotinib|
215122360|NCT04170543|DRUG|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
215122361|NCT04170543|DRUG|Placebo|Placebo
215122362|NCT04170543|DRUG|Dapagliflozin|Dapagliflozin 10 mg
215122363|NCT05668910|GENETIC|whole genomic methylation and fragmentation profile analysis of cfDNA|The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
215122364|NCT06361589|DRUG|Lorlatinib|lolatinib 100mg qd po
215122365|NCT00041379|DRUG|beta alethine|
215122366|NCT03627871|BEHAVIORAL|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
215122367|NCT03627871|BEHAVIORAL|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
215122368|NCT03627871|BEHAVIORAL|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
215122369|NCT03627871|BEHAVIORAL|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
215122370|NCT03627871|BEHAVIORAL|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
215122371|NCT00599066|DEVICE|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
215122372|NCT01152528|DEVICE|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
215122373|NCT03635749|DRUG|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
215122374|NCT03635749|DRUG|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
214522846|NCT02648555|BEHAVIORAL|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
214522847|NCT00504205|DRUG|multitargeted receptor tyrosine kinase inhibitor MP470|
215122375|NCT03635749|DRUG|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
214522848|NCT00504205|OTHER|laboratory biomarker analysis|
215122376|NCT03635749|DRUG|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
215122377|NCT03115762|BIOLOGICAL|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
215122378|NCT03115762|BIOLOGICAL|ASKB1202|
214522849|NCT00504205|OTHER|pharmacological study|
214522850|NCT00504205|PROCEDURE|positron emission tomography|
214522851|NCT00448344|BEHAVIORAL|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
214708567|NCT06287944|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215122379|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Resource Energy|Carbohydrate Supplement
215122380|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
215122381|NCT04303559|DRUG|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
215122382|NCT04303559|DRUG|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
215122383|NCT05809609|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
215122384|NCT05809609|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
215122385|NCT00421681|BEHAVIORAL|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
215122386|NCT00592488|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
215122387|NCT05367570|BEHAVIORAL|Cross-sectional observational study|The first work package of this project is an explanatory cross-sectional study with no intervention.
215122388|NCT02534363|DRUG|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
215122389|NCT02534363|DRUG|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
215122390|NCT02534363|DRUG|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
214522852|NCT00448344|BEHAVIORAL|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
215122391|NCT02534363|BEHAVIORAL|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
215122392|NCT05355064|DRUG|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
215122393|NCT05246371|DRUG|Propofol, dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
215122394|NCT05246371|DRUG|Desflurane|Patients will receive maintenance of general anesthesia by desflurane.
215122395|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
215122396|NCT00774293|DRUG|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
215122397|NCT00774293|DRUG|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
215122398|NCT00398658|DRUG|gentamycin and clindamycin|
215122399|NCT02408588|OTHER|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
215122400|NCT02238119|DRUG|Tiotropium + formoterol combination|
215122401|NCT02238119|DRUG|Tiotropium|
215122402|NCT02238119|DRUG|Formoterol|
215122403|NCT05279287|OTHER|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
215122404|NCT00893061|DRUG|anastrozole|Given orally
215122405|NCT00893061|DRUG|exemestane|Given orally
215122406|NCT00893061|DRUG|letrozole|Given orally
215122407|NCT00893061|DRUG|tamoxifen citrate|Given orally
215122408|NCT04648319|DRUG|BMS-936558|BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
215122409|NCT05557344|DRUG|Acetaminophen IV|An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
215122410|NCT05557344|DRUG|Acetaminophen|A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
215122411|NCT04662008|BEHAVIORAL|Tele-coaching|This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
215122412|NCT04662008|BEHAVIORAL|Website|This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
214522853|NCT04728100|OTHER|LQT|Patients with LQT syndrome diagnosis.
215122413|NCT01826656|PROCEDURE|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
215122414|NCT01826656|RADIATION|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
215122415|NCT01826656|RADIATION|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
214522854|NCT00410150|DRUG|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
214522855|NCT00410150|DRUG|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
214522856|NCT00097409|DRUG|Ispinesib|
214522857|NCT04806659|DRUG|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
214522858|NCT05143099|DRUG|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
215122416|NCT01826656|RADIATION|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
215122417|NCT00748345|DRUG|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
215122418|NCT06009094|DRUG|VC005|VC005 group with Local topical application
215122419|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
215122420|NCT04655573|PROCEDURE|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
215122421|NCT02173106|DRUG|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
214708568|NCT06287944|PROCEDURE|Radionuclide Imaging|Undergo nuclear scan
214708569|NCT06287944|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT scan
214708570|NCT06287944|DRUG|Sirolimus|Given sirolimus
215122422|NCT04140630|OTHER|No intervention|No intervention; 1 week observational study
215122423|NCT04807686|DEVICE|Auditory simulation|Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.
215122424|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
215122425|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
215122426|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
214445665|NCT06135298|DRUG|Zoledronic acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
215122427|NCT04037891|DRUG|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.
215122428|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
215122429|NCT04037891|DRUG|rVA576|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
215122430|NCT06654440|DRUG|SHR-A2102 for injection|SHR-A2102 for injection
215122431|NCT05441267|DRUG|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
215122432|NCT05441267|DRUG|Placebo oral tablet|Placebo oral semaglutide
214445666|NCT06135298|DEVICE|CERAMENT BONE VOID FILLER (BVF)|In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
214445667|NCT06286189|DRUG|Placebo oral tablet|Placebo capsule taken 30 min before sleep
214445668|NCT06286189|DRUG|Trazodone Hydrochloride|Trazodone 100 mg 30 min before sleep
214445669|NCT06434610|DRUG|B013|B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
214522859|NCT04413188|OTHER|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
214522860|NCT00886548|PROCEDURE|Ultrasound performed|Nurse-driven ultrasound performed
214522861|NCT03478072|DEVICE|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
214445670|NCT06434610|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
214445671|NCT06434610|DRUG|Placebo|Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
214445672|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
214445673|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
215122433|NCT06598475|OTHER|Facilitator-driven provider- and practice-level implementation strategies for influencing provider recommendations and practice-level HPV vaccination rates|"The practice facilitator (UTHealth research staff) will implement the following 4 strategies with providers and immunization navigators at each practice:~* Facilitator-driven provider education: The practice facilitator will conduct one provider education module (5 total modules) over three months with health care providers using a booklet and resource binder.~* Facilitator-driven clinical practice plan: The practice facilitator will assist the implementation team in creating their clinical practice in two additional modules and encourage providers to identify strategies to increase HPV vaccination.~* Training and education for staff (Immunization Navigators): The facilitator will train immunization navigators to implement the plan, and practice immunization navigators will implement the plan.~* Technical assistance plus assessment and feedback: During implementation of the plan, the facilitator will provide technical assistance, ongoing assessment and feedback, and booster trainings."
214445674|NCT01927744|DRUG|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
214445675|NCT01927744|DRUG|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
214445676|NCT01927744|OTHER|Placebo|150 mg by mouth daily continuously until the day before surgery.
215122434|NCT06654882|DRUG|TNFi (Tumor Necrosis Factor inhibitor) medication|"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"
215122435|NCT06654882|DRUG|Abatacept|"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"
215122436|NCT06654882|DRUG|Tocilizumab|"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"
215122437|NCT06654882|DRUG|Tofacitinib|"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"
215122438|NCT04166071|DRUG|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
215122439|NCT04166071|DRUG|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
214445677|NCT01927744|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
214445678|NCT01927744|BEHAVIORAL|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
214445679|NCT01927744|DRUG|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
214445680|NCT04871100|BEHAVIORAL|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
214445681|NCT04871100|BEHAVIORAL|Usual care|referrals to VA care for SUD and anxiety
214445682|NCT00477958|OTHER|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
214445683|NCT00477958|PROCEDURE|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
214445684|NCT00477958|PROCEDURE|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
214445685|NCT02728557|BEHAVIORAL|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
214522862|NCT03471884|PROCEDURE|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
214522863|NCT03471884|PROCEDURE|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
214522864|NCT00449254|DRUG|oleoyl-estrone (MP-101)|
214522865|NCT04526132|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
215122440|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
215122441|NCT06824051|DRUG|Orforglipron|Administered orally
215122442|NCT06824051|DRUG|Placebo|Administered orally
215122443|NCT06817031|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
215122444|NCT06817031|DRUG|Placebo|Enteric Capsules filled with approximately 400mg of Microcrystalline Cellulose (bulking agent)
215122445|NCT06817031|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
215122446|NCT02472717|DRUG|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
215122447|NCT02472717|OTHER|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
214445686|NCT02728557|BEHAVIORAL|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
214445687|NCT03948490|DEVICE|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
214445688|NCT03948490|DEVICE|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
214708571|NCT06287944|DRUG|Tacrolimus|Given tacrolimus
214708572|NCT06287944|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
215122448|NCT03446313|BEHAVIORAL|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
215122449|NCT05274958|BEHAVIORAL|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
215122450|NCT06670755|BIOLOGICAL|ID93/GLA-SE|"ID93/GLA-SE is a protein-adjuvant vaccine which has been purposefully designed to elicit a diverse immune response against M.tb bacterial antigens, improve treatment outcomes and prevent TB disease in people already infected with M.tb.~ID93/GLA-SE will be administered intramuscularly."
215122451|NCT06670755|BIOLOGICAL|BCG Danish|"BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.~For the challenge, aerosol BCG will be administered via nebulizer."
215122452|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
215122453|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
215122454|NCT06991010|DEVICE|Suction-Activated Patent Hemostasis (SAPH) Device|A compression device intended to achieve patient hemostasis of the radial artery
215122455|NCT04927650|DIAGNOSTIC_TEST|HPV testing|Undergo collection of cervical samples for HPV testing
215122456|NCT04927650|OTHER|Questionnaire Administration|Complete questionnaires
215122457|NCT06611527|DEVICE|PS+PEEP group|Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%
215122458|NCT06611527|DEVICE|CPAP group|Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.
215122459|NCT06174987|DRUG|T-DXd|T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
215122460|NCT06610214|OTHER|IMPACT-care intervention|1, Training of Healthcare Staff; 2, Development of Medication Summary; 3, Information Package for Patient and/or Caregiver; 4, Discharge Coaching; 5, Post-Discharge follow-Up call
215122461|NCT06538662|DRUG|FID 123320 Ophthalmic Solution|Investigational sterile aqueous solution
215122462|NCT06538662|DRUG|Vehicle|FID 123320 Ophthalmic Solution inactive ingredients
215122463|NCT06699602|DRUG|Cemiplimab|cemiplimab IV flat
215122464|NCT06699602|DRUG|Fianlimab|fianilmab IV flat
215122465|NCT03191266|DEVICE|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
215122466|NCT03191266|DEVICE|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
215122467|NCT05118139|OTHER|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
214522866|NCT04526132|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
214708573|NCT00729313|DRUG|Lanreotide microparticles|
214708574|NCT00729313|DRUG|Placebo|
215122468|NCT05118139|OTHER|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
215122469|NCT05118139|OTHER|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
215122470|NCT05118139|OTHER|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
215122471|NCT05118139|OTHER|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
215122472|NCT05118139|OTHER|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
215122473|NCT05118139|OTHER|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
215122474|NCT05118139|OTHER|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
215122475|NCT05118139|OTHER|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
215122476|NCT05118139|OTHER|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
215122477|NCT05118139|OTHER|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
215122478|NCT05118139|OTHER|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
215122479|NCT05118139|OTHER|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
215122480|NCT05118139|OTHER|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
215122481|NCT05118139|OTHER|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
215122482|NCT05118139|OTHER|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
215122483|NCT06922071|OTHER|REMINDER4Care|"REMINDER4Care was an adapted version of the original REMINDER program, tailored to the characteristics, needs, and interests of older adults in RDF.~The REMINDER4Care intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). Social support and emotion regulation strategies (like attention management, positive cognitive reappraisal, and reframing speech) were included to address psychosocial risk factors like stress, social isolation, and depression."
214445689|NCT03948490|BEHAVIORAL|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
214445690|NCT03948490|BEHAVIORAL|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
214445691|NCT04415788|DEVICE|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
214445692|NCT04415788|DEVICE|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
214445693|NCT04415788|DEVICE|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
214445694|NCT03416010|BEHAVIORAL|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
214445695|NCT05743621|DRUG|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
214445696|NCT05743621|DRUG|Enzalutamide|160 mg daily PO
214445697|NCT05573828|PROCEDURE|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
214708575|NCT02556593|RADIATION|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
215122484|NCT06920771|BIOLOGICAL|PURETHAL Mites 50,000 AUeq/ml|"Biological/Vaccine: Placebo~Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals"
215122485|NCT06920771|BIOLOGICAL|Biological/Vaccine: Placebo|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
215122486|NCT07009015|OTHER|The oral health education intervention program|The intervention program will be designed to improve oral health knowledge, attitudes, and behaviors among students over a one-month school term, carefully scheduled to avoid disrupting regular academic activities. The program consists of initial sessions focused on building students' understanding and appreciation of oral health and healthy eating habits, followed by sessions aimed at developing practical behavioral skills. The effectiveness of the program will be evaluated at three points-before the intervention, two months after, and four months post-intervention-using a closed-ended questionnaire to assess changes in knowledge, attitudes, and practices.
214445698|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
214445699|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
214445700|NCT06798792|OTHER|PechaKucha technique|The Discharge Education course was taught using the PechaKucha technique.
214445701|NCT06798792|OTHER|TeachBack technique|The Discharge Education course was taught using the TeachBack technique.
214445702|NCT05574426|BEHAVIORAL|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
214445703|NCT06790342|DRUG|Cystine|Used for smoking cessation and alcohol reduction
214445704|NCT06790342|BEHAVIORAL|Positively Smoke Free|An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
214445705|NCT06790342|OTHER|Placebo|Matched to cystine
214445706|NCT06790342|OTHER|Standard of Care|Standardized brief advice to quit smoking (standard of care)
214522867|NCT01644604|DEVICE|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
214708576|NCT02556593|RADIATION|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
215122487|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
215122488|NCT05481359|DEVICE|Electrographic Flow™ (EGF) mapping and ablation|"Electrographic Flow™ (EGF) mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF algorithm (Ablamap® Software). Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity levels exceeding the recommended threshold are deemed significant and are targeted for ablation. The success of the ablation is confirmed through an EGF remap, where elimination of the source is defined as reduction of EGF source activity below the threshold."
215122489|NCT05404048|OTHER|89Zr-atezolizumab PET-imaging|89Zr-atezolizumab tracer injection + PET/CT-scan
215122490|NCT06870422|DRUG|Esflurbiprofen Topical System|TK-254RX will be applied for one day
214445707|NCT06783556|DEVICE|The Ear Electroacupuncture of Battlefield Acupuncture (BFA) and paracetamol intravenous therapy|"Electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle insertion was performed perpendicularly at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture uses continuous waves of 2 Hz frequency with an intensity that can be tolerated by the patient for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
214522868|NCT06272526|OTHER|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
214522869|NCT05953025|BEHAVIORAL|Questionnaire|No intervention on care- questionnaire to see effect of standard care treatment on symptoms
215122491|NCT07015125|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Use of TENS device for 1 hour during each migraine episode.
215122492|NCT06689878|BEHAVIORAL|Mobile Cognitive Behavioral App|"A mobile cognitive behavioral therapy (CBT) app called Maya that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke."
215122493|NCT05516953|DRUG|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
215122494|NCT03066063|DEVICE|iCare|The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.
215122495|NCT03066063|BEHAVIORAL|Amblyopia standard of Care|The amblyopia standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily
215122496|NCT03066063|BEHAVIORAL|CI standard of Care|A dosage-matched CI standard of Care group will be prescribed pencil pushups for 20 minutes per day, five days per week.
215122497|NCT04588116|BEHAVIORAL|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
215122498|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
214522870|NCT06173167|DEVICE|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).
214522871|NCT06173167|DEVICE|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
215122499|NCT03189537|DRUG|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
215122500|NCT03189537|DRUG|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
215122501|NCT04757116|DEVICE|iTind|The iTind is implemented for 5-7 days
214522872|NCT03480815|DEVICE|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
214522873|NCT03480815|OTHER|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
214708577|NCT02556593|DRUG|erlotinib|erlotinib 150mg daily
214708578|NCT03838770|DEVICE|Active tDCS|Active target 2.0mA tDCS (n=60)
214708579|NCT03838770|DEVICE|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
215122502|NCT04757116|PROCEDURE|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
215122503|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~\- TDF/3TC/DOR)"
215122504|NCT06695546|OTHER|VExUS evaluation ultrasound|"VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity."
215122505|NCT06631183|BEHAVIORAL|Self-help information based on principles of behavioral activation|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on behavioral activation and physical activity.
215122506|NCT06631183|BEHAVIORAL|Self-help information based on principles of cognitive restructuring|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on cognitive restructuring.
215122507|NCT06693089|OTHER|MIT-ED|The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
215122508|NCT06419062|DEVICE|Frontier X2|Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
215122509|NCT06713330|DEVICE|BioFLX crown|Device: BioFLX crown
214445708|NCT06783556|DEVICE|The sham electroacupuncture and paracetamol intravenous therapy|"Sham electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle only attached using plester (not inserted) at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture device is not turned on. The therapy is carried out for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
214445709|NCT04030130|BEHAVIORAL|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
214445710|NCT06792409|DEVICE|Minimally invasive breast augmentation procedure with a trans-axillary approach.|Minimally invasive breast augmentation procedure with a transaxillary approach using Motiva Ergonomix2 Diamond®, Motiva Injector® and Motiva® Inflatable Balloon.
214445711|NCT03819686|BEHAVIORAL|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching \~20-minutes of videos from the website)
214445712|NCT03819686|BEHAVIORAL|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
214445713|NCT06396260|OTHER|Diffusion Kurtosis Imaging (DKI)|Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
214445714|NCT06396260|OTHER|Resting State Magnetoencephalography|Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
214522874|NCT05080348|PROCEDURE|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
214522875|NCT05080348|PROCEDURE|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
214522876|NCT04281355|PROCEDURE|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
214522877|NCT04281355|RADIATION|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
214522878|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
215122510|NCT06713330|DEVICE|3M Stainless Steel Crown|3M Stainless Steel Crown
214445715|NCT06784102|OTHER|Damon Clear Debonding Plier (the primary intervention being tested in this study).|This clinical trial evaluates two types of orthodontic debonding pliers: the Damon Clear Debonding Plier and the traditional Bracket Remover Debonding Plier. The Damon Clear plier features a third wedging arm, which applies an additional lingual or palatal force in addition to the standard occluso-gingival force. The study is designed to assess and compare pain levels and debonding forces between the two pliers. A total of 40 patients, aged 17-25, were treated with both devices using a split-mouth design. The Damon Clear Plier is tested on one side of the mouth while the Bracket Remover Plier is used on the opposite side. Pain perception was measured immediately after the debonding procedure using the Numerical Rating Scale (NRS), and the forces applied during debonding were measured with a force-sensitive prototype. The study aims to identify the device that provides effective debonding with less pain.
214522879|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
215122511|NCT06706141|BEHAVIORAL|PowerPoint presentation.|The training included topics such as breast anatomy; breast cancer incidence in Somalia, mortality, morbidity rates; breast cancer risk factors, importance of screening methods; The messages on breast self-examination, health belief models, breast cancer awareness, confidence for BSE, and perceived barriers/benefits for BSE were presented in a PowerPoint presentation. The procedure for performing breast self-examination was described using the English edition of Bristol-Myers Squibb Oncology. In the movie, BSE was made simpler with schematics showing the breast area that needed to be covered. Simple directions on which fingers to use and how to move them over the breast were provided. After the film, the emphasis shifted to helping students gain more self-assurance in their ability to accurately complete each BSE step. Students were encouraged to use proper palpation technique to find lumps by performing a breast examination on a silicone breast model.
215122512|NCT06727422|DRUG|rifaximin 66mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
214522880|NCT00141271|DRUG|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
215122513|NCT06727422|DRUG|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
215122514|NCT06727422|DRUG|Placebo|placebo three times daily
215122515|NCT06725043|DEVICE|Therapeutic ultrasound|Pulsed therapeutic ultrasound (1 MHz , 50% duty cycle and intensity gradually increased till the patient felt a deqi sensation).Each point was stimulated by ultrasound for 5 minutes at bilateral acupuncture points of PC6, PC7, BL60 and KI1(3 times / week for 4 weeks).
215122516|NCT06725043|DEVICE|Placebo therapeutic ultrasound|patients were received placebo therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI.
215122517|NCT06725043|OTHER|Traditional physical therapy program|Strengthing exercise, balance training, stretching exercises and home exercise program and education
215122518|NCT06725914|BEHAVIORAL|kangaroo care|Transport practice with paternal kangaroo care in preterm infants
215122519|NCT06725407|BEHAVIORAL|Cesarean section|In the study, the participants' postoperative hypothermia development status was monitored.
215122520|NCT06727201|DRUG|Ondansetron (Zofran)|Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.
215122521|NCT06727201|DRUG|Saline (NaCl 0,9 %) (placebo)|normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia
214522881|NCT00816205|DRUG|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
215122522|NCT06725758|DRUG|ODM-212|ODM-212 5mg and/or 40mg tablets
215122523|NCT06725745|OTHER|Survey|Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
215122524|NCT06727383|PROCEDURE|peripheral blood collection|standard blood test procedures
215122525|NCT06727383|PROCEDURE|leukapheresis|"Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma."
215122526|NCT06725511|BEHAVIORAL|Opt-out framing|Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.
214445716|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
214522882|NCT01249144|DEVICE|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
214522883|NCT00079222|DRUG|itraconazole|
214522884|NCT00079222|DRUG|voriconazole|
215122527|NCT06725511|BEHAVIORAL|Opt-in framing|Eligible participants are invited to enroll
215122528|NCT06725498|DRUG|Tislelizumab-jsgr|200mg, Q3W
214522885|NCT00104442|DRUG|Rivastigmine|
214522886|NCT06176131|OTHER|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
215122529|NCT06725498|DRUG|Cisplatin|60-75 mg/㎡, Q3W
215122530|NCT06725498|DRUG|Albumin-Bound Paclitaxel|260 mg/㎡, Q3W
215122531|NCT06725498|RADIATION|Radiotherapy|Radical Radiotherapy or adjuvant Radiotherapy per guidelines.
215122532|NCT06726798|PROCEDURE|Endoscopic submucosal dissection with EndoRobotics traction device|All patients received robotic ESD under general anesthesia or monitored anaesthetic care at the endoscopy center of Prince of Wales Hospital. The targeted lesion would first be localized and pre-injected using a mixture of normal saline, indigocarmine, epinephrine and sodium hyaluronate. The robotic endoscopic traction device was then inserted to reach the target. Mucosal incision first started from the anal side followed by lifting with the grasper\[Figure 1; Video 1\]. Vio 3 diathermy system (ERBE, Germany) was used with endocut Q effect 3 and forced coagulation effect 3. Further submucosal dissection would be performed by electrocautery knife with traction achieved via EndoRobotics traction. Upon completion, the specimen would be retrieved upon withdrawal of the whole system.
215122533|NCT06726603|PROCEDURE|Assisted Reproductive Technology|Assisted Reproductive Technology for the purposes of this study include IVF and IVF+ICSI. Ovulation induction methods are not considered Assisted Reproductive Technology
215122534|NCT06921122|DEVICE|IOWA ORAL PERFORMANCE INSTRUMENT|"In the first session all protocols and assessments will be carried out as a way of observing the responses and previous measures of all participants. The group in this study must appear weekly for six weeks to verify if necessary, reinsufflate the bulb, carry out force measurement and lingual press with the IOPI, as well as receive or reinforce the guidance provided at the beginning of the treatment.~The participants in the group will study that will have a mobile phone and an instant message application will receive weekly, on scheduled days, a letter containing the following text message: Here is the day of performing the last exercise by the Speech Pathologist. Participants who do not have a mobile phone will be notified through a telephone connection or contact with a responsible family member/caregiver.~After the end of the sixth week of training, patients will be subjected to the last set of data on the two protocols and evaluations proposed in this study."
215122535|NCT06921122|DEVICE|Placebo Group - Without Treatment|"The group in study, without treatment, supported by the same schedule of the patients treated, will represent the natural progression of failure disorders in PD. A decision was made not to include a false treatment, in order to adhere to the principle of balance and not to place an undue burden of time and effort on patients who receive a treatment with low therapeutic potential. Furthermore, the researchers considered that given the questions regarding the adequacy of simulations as comparators of treatment in behavioral studies, research in this work between the group in the study and the placebo group (without treatment) can provide more useful contrasts than a group with therapeutic simulation.~If the intervention clearly aims to provide direct benefits to the participants, this group will be contacted to carry out the same intervention later."
215122536|NCT06921109|BEHAVIORAL|Experimental: Relaxation training with VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment integrated into various virtual environments. Homework exercises will be assigned to them after each session.
214445717|NCT06787443|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for five weeks
214445718|NCT06787443|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for five weeks
214445719|NCT06785740|DRUG|Statin|Statin use
214445720|NCT06788873|OTHER|Data comparison|"For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit."
214445721|NCT06784908|OTHER|Yale Pain Stress Task (YPST)|Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.
214445722|NCT04296162|DRUG|Vinorelbine|Vinorelbine chemotherapy (oral)
214445723|NCT04296162|DRUG|Capecitabine|Capecitabine chemotherapy (oral)
214445724|NCT04296162|DRUG|Trastuzumab|Trastuzumab target therapy
214445725|NCT05466890|DRUG|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
214445726|NCT05466890|DRUG|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
214445727|NCT05454215|DEVICE|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
214445728|NCT05454215|DEVICE|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
214445729|NCT06783920|PROCEDURE|music|music will be played during the copper IUD insertion
214445730|NCT06783920|PROCEDURE|no music|IUD insertion will be done as usual without music
214708580|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
214445731|NCT06783764|PROCEDURE|PECS II block and transverse thoracic plane block|will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
214445732|NCT06783764|PROCEDURE|Erector Spinae Plane Block|ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)
214522887|NCT01720407|DRUG|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
214522888|NCT01720407|DRUG|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
214522889|NCT00990314|DRUG|Beraprost Sodium Modified Release|
214522890|NCT04749641|BIOLOGICAL|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
214522891|NCT03139045|BIOLOGICAL|Venous puncture in elderly patients|Venous puncture in elderly patients
214522892|NCT02978040|DRUG|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
214522893|NCT02978040|DRUG|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
214522894|NCT02978040|DRUG|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
214522895|NCT00587405|PROCEDURE|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
214522896|NCT00587405|PROCEDURE|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
214522897|NCT02704156|DEVICE|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
215122537|NCT06921109|BEHAVIORAL|Experimental: Relaxation training without VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment displayed on a computer screen. Homework exercises will be assigned to them after each session.
215122538|NCT06921109|BEHAVIORAL|No Intervention: Control group|This group will benefit from 8 psychoeducation sessions delivered through video modules sent to their homes.
215122539|NCT06921187|BEHAVIORAL|Psychoacoustic test|Natural sounds will be presented at different decibels (dB), and the subject will be asked to rate the pleasantness/unpleasantness of the sound heard on a visual analogue scale, as well as the loudness (subjective intensity) of the sound heard.
214445733|NCT06783764|DRUG|bupivacaine 0.25 % injection|injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
214522898|NCT02704156|DEVICE|Cyberknife plus Gemcitabine|Radiation therapy plus drug
214522899|NCT03430362|DRUG|Hyoscine N Butylbromide|7\. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
214522900|NCT03430362|DRUG|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
215122540|NCT06921187|OTHER|semi-structured interviews|interview, designed under the supervision of a psychologist and using the methodology of micro-phenomenological interviews the aim of these interviews is to gain access to the participants' experiences, as they describe them in the first person, during misophonic episodes
215122541|NCT06921187|OTHER|Exposure to unpleasant sounds|"Home exposure is a practice whereby participants voluntarily subject themselves to SMs in a controlled environment.~Participants will be asked to complete two tasks: firstly, they will have to expose themselves to all 10 sounds at least twice a week; secondly, they will have to record the annoyance felt for each sound and the subjective loudness (loudness) of each SM using VAS."
215122542|NCT06922513|DEVICE|digital health (Application and Smart Measuring Tape)|For lymphedema management, we use a smart measuring tape to measure arm circumference and provide analysis results along with self-management strategies.
215122543|NCT06921161|DEVICE|TongueFit|"TongueFit is a newly orofacial manometer. This device is specifically developed for children to measure and improve tongue strength and endurance which includes a complementary application. Participants will do a series of tongue exercise therapy using TongueFit. The exercise therapy will be performed once per day, three times a week, for eight weeks."
215122544|NCT06921161|OTHER|OSMS|Patients will receive OSMS therapy, conducted for 15 minutes per session, three times a week, over a duration of eight weeks.
215122545|NCT06922045|DRUG|STSP-0601 for Injection|Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors
215122546|NCT02466932|DEVICE|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
215122547|NCT06726083|BEHAVIORAL|Nutrition Intervention|Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
215122548|NCT06726083|BEHAVIORAL|Contact Control|Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
214445734|NCT06783764|DRUG|bupivacaine 0.25 % injection|30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
214445735|NCT06786208|DRUG|Sunvozertinib|sunvozertinb, a EGFR-TKI, 300mg QD oral
214445736|NCT06791902|DEVICE|Adaptive DBS|Adapting DBS stimulation based on locomotor states
214445737|NCT06790264|PROCEDURE|68Ga-FAPi-46 PET/CT|Study participants will undergo baseline assessments at enrollment with 68Ga-FAPi-46 PET/CT
214445738|NCT06790550|OTHER|Music Therapy|Music will be played during the insulin injection process
214445739|NCT06349174|PROCEDURE|bronchoscopic lung volume reduction surgery using endobronchial valve|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
214445740|NCT06791395|DIAGNOSTIC_TEST|Artificial intelligence platform for endocytoscopy|The detected lesions are predicted by artificial intelligence
214445741|NCT06785155|OTHER|Chatbot group|Participants explored the topics using the AI chatbot platform.
214445742|NCT06785155|OTHER|website assisted|Participants explored the topics using the website platform
214445743|NCT06785974|DRUG|Atorvastatin|Daily 20mg atorvastatin.
214445744|NCT06785974|DRUG|Placebo|Daily Placebo in combination with ICI-therapy
214445745|NCT06783465|DEVICE|Digital therapeutics session|During the digital therapeutics session, the patient performs tasks by handling objects according to instructions displayed by the device. A camera records the task performance, and the system analyzes the task performance.
214522901|NCT05111340|BEHAVIORAL|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
215122549|NCT00451971|DRUG|LEFLUNOMIDE|
214445746|NCT04788537|BEHAVIORAL|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
214445747|NCT06037382|OTHER|Mood Triggers App|"The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction."
214445748|NCT06322615|PROCEDURE|Acupressure Therapy|Undergo acupressure
214445749|NCT06322615|OTHER|Educational Intervention|Receive education session about using acupressure at home
214445750|NCT06322615|OTHER|Electronic Health Record Review|Ancillary studies
214445751|NCT06322615|OTHER|Questionnaire Administration|Ancillary studies
214445752|NCT05648786|BEHAVIORAL|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
214445753|NCT05648786|BEHAVIORAL|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
214445754|NCT06785896|PROCEDURE|Angle Class II unilateral, treated by carriere motion appliance|This treatment was unilateral, with dental composite bites ramps behind canines
214522902|NCT01798537|DRUG|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
214522903|NCT00255242|DRUG|Simvastatin treatment for 28 days|40 mg / day
215122550|NCT06726629|OTHER|Version Of The New Knee Society Knee Scoring System|All patients will be subjected to the same clinical and radiographic checks, the data of which will be collected in the different centres
215122551|NCT05648188|BIOLOGICAL|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
215122552|NCT06897202|DRUG|MET097 Injection|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
215122553|NCT06897202|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
214445755|NCT06783816|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
214445756|NCT06307873|DIAGNOSTIC_TEST|pre and post operative POP-Q results|Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
215122554|NCT07064980|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Performed under intravenous anesthesia. A duodenoscope was advanced to the major duodenal papilla. After cannulation and cholangiography, purulent bile was aspirated. Biliary sphincterotomy was performed in most patients (95.2%), followed by stone extraction using a balloon catheter or basket. A 7-10 Fr nasobiliary tube was placed for drainage in all patients. Prophylactic rectal indomethacin (100mg) was also administered.
215122555|NCT07064980|PROCEDURE|Percutaneous Transhepatic Biliary Drainage|Performed under general anesthesia with endotracheal intubation and ultrasound guidance. An 18G needle was used to puncture a dilated intrahepatic bile duct. After guidewire placement, an 8-10 Fr drainage catheter was inserted for either internal-external drainage (if the guidewire could pass into the duodenum) or purely external biliary drainage.
215122556|NCT07066969|GENETIC|Sophia DDM|Germline panel for patients with tumoral BRCA alteration in EC
215122557|NCT06795490|BEHAVIORAL|Online program|Families in Balance Online is a 6-week online program that includes 6 weekly group discussions and 3 individual support sessions, all held over Zoom. Program activities will focus on improving parent and child self-regulation as a means to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
215122558|NCT06795490|BEHAVIORAL|Control Condition|Families in Balance is an asynchronous program in which participants will be sent materials weekly over 6 weeks to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
215122559|NCT06901583|OTHER|Mindfulness-oriented psycho-education|The program, consisting of six sessions and developed by evaluating studies in the literature, covers topics such as mindfulness, anger, and interpersonal relationships
215122560|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
215122561|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
215122562|NCT06915246|DRUG|VI-0609|Carmustine with Propylene Glycol
215122563|NCT06915246|DRUG|BiCNU|Carmustine with Ethanol
215122564|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215122565|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
215122566|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
215122567|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
214445757|NCT06307873|BEHAVIORAL|pre and post operative PİSQ-12 results|Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
214445758|NCT06790745|PROCEDURE|Epidural blood patch|Patients will receive epidural blood patch injection
214445759|NCT06790745|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma rich fibrin injection by Racz catheter
214445760|NCT04035174|DIAGNOSTIC_TEST|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
214522904|NCT05568277|BEHAVIORAL|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
215122568|NCT06917755|OTHER|Virtual Reality Training in Thyroid Surgery|Participants will use an application in an Immersive Virtual Reality environment. In this module, the participant will be the chief surgeon and will be guided to accomplise the first steps of thyroidectomy: from neck incision until continious neuromonitoring device placement in vagus nerve.
215122569|NCT06917755|OTHER|Convetional Training|This intervation consists of traditional methods of training. Participants will read specific chapters of a technical book specialised in Endocrine Surgery (Atlas of Thyroid Surgery- Alexander Shifrin). Also, they will be provided with videos of the clinic's archive which will support them with specific surgical steps : neck incision up to Continious Neuromonitoring Device placement on Vagus nerve.
215122570|NCT06921044|DRUG|R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone|Rituximab ：375 mg/m2，ivgtt，d0； Mitoxantrone Liposome ： The first dose level: 6mg/m2, ivgtt, d1; The second dose level: 8mg/m2, ivgtt, d1; The third dose level: 10mg/m2, ivgtt, d1; Cyclophosphamide :400 mg/m2，ivgtt，d1； Vincristine :1mg（，ivgtt，d1； Prednisone:40 mg/m2，po.，d1-5； Q3W
215122571|NCT06922422|BEHAVIORAL|Sensory-Motor Integration Exercises|A structured sensory-motor integration program based on sensory play activities designed to enhance sensory processing and balance. Each session lasted 45 minutes, conducted four times per week, for a total of 64 sessions over 16 weeks. Activities targeted multiple sensory modalities, including tactile, proprioceptive, and vestibular inputs.
214445761|NCT04035174|DIAGNOSTIC_TEST|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
214445762|NCT03654053|DRUG|Placebo Oral Tablet|Placebo taken once nightly at bed time.
214445763|NCT03654053|DRUG|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
214445764|NCT05863273|DRUG|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
214522905|NCT04999722|BEHAVIORAL|Traditional mode of management|Traditional model management of Diabetes Mellitus patients
214522906|NCT04999722|BEHAVIORAL|Mobile APP management|Management of diabetic patients with mobile phone APP
215122572|NCT06922422|BEHAVIORAL|Conventional therapy group|Conventional therapy sessions consisting of Applied Behavior Analysis (ABA) and massage therapy without specific sensory-motor integration activities. Each session lasted 45 minutes, conducted four times weekly, for a total of 64 sessions over 16 weeks.
215122573|NCT06920966|OTHER|Cold Water Immersion (CWI)|Participants undergo five intermittent immersions of 2 minutes each in cold water (11°C), with 2-minute rest periods in between.
215122574|NCT06920966|OTHER|Hot water immersion (HWI)|Participants undergo a continuous immersion of 18 minutes in hot water (38°C)
215122575|NCT06920966|OTHER|Thermography-Guided Immersion (TI)|Based on thermographic assessments, participants with a hypothermic profile (decreased temperature) receive hot water immersion, while those with a hyperthermic profile (increased temperature) receive cold water immersion.
215122576|NCT06920758|DIETARY_SUPPLEMENT|USPlus DERM Bioactive Fatty Acids 160 mg Softgels|"USPlus® DERM Bioactive Fatty Acids (160 mg) Ingredient List (Per Softgel)~Active: 100% Concentrated Lipidosterolic Extract of Saw Palmetto (Serenoa repens).~Shell: Bovine Gelatin, Glycerin, Water"
215122577|NCT06920758|OTHER|Placebo softgel|"Placebo Ingredient List:~Palm oil Gelatin Glycerin Water Caramel color"
215122578|NCT06921096|OTHER|Tai Chi|The Tai chi group practiced 24-form simplified Tai Chi for 12 weeks, 3 times/week, 60 minutes/session (including 5-minute warm-up and 5-minute cool-down) at our university's track, under professional coaching, from 8:00-9:10 AM. The first 4 weeks were for learning, and the next 8 for consolidation.
215122579|NCT06922136|DEVICE|Hyalo Gyn Vaginal Gel|Hyalo Gyn® is uniquely formulated with Hydeal-D®, a proprietary HA derivative component manufactured by Fidia Farmaceutici S.p.A.
215122580|NCT06922136|OTHER|Placebo|Placebo
215122581|NCT06920979|OTHER|(semi)continue monitoring of patients at risk for sepsis at home|(semi)continue monitoring of patients at risk for sepsis at home
215122582|NCT06921421|DIAGNOSTIC_TEST|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging captures at specific timepoints.
215122583|NCT06922084|DEVICE|Clareon PanOptix|Bilateral Clareon PanOptix IOL implantation
215122584|NCT06922084|DRUG|Clareon PanOptix PRO|Bilateral Clareon PanOptix PRO IOL implantation
215122585|NCT06922084|DRUG|Mix-and-Match PanOptix/Vivity|Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye
215122586|NCT06921343|DRUG|Iron (III) Hydroxide Polymaltose (50 mg/5 mL)|"Participants randomized to the intervention group will receive oral iron supplementation in addition to a gluten-free diet. The specific iron formulation used in this study is Iron (III) Hydroxide Polymaltose (50 mg/5 mL) at a dosage of 6 mg/kg/day, up to a maximum of 100 mg/day, for 3 months.~The iron supplement will be given once daily, preferably on an empty stomach or with vitamin C-containing foods to enhance absorption. Parents/caregivers will be instructed on proper administration, and adherence will be monitored through weekly self-reported intake logs and pharmacy dispensing records.~This intervention is specifically targeted at children with newly diagnosed celiac disease and iron deficiency without anemia.~The study follows a non-inferiority design, comparing the effect of iron supplementation versus a gluten-free diet alone on ferritin levels."
215122587|NCT06921343|OTHER|Gluten-free diet|Participants in the control group will follow a strict gluten-free diet, the standard-of-care treatment for celiac disease. No iron supplementation will be given. Compliance will be monitored through self-reported adherence and TTG antibody levels at follow-up.
215122588|NCT06921902|DEVICE|FreeStyle Libre 3|Abbott Sensor Based Glucose Monitoring System (FreeStyle Libre 3 System)
215122589|NCT06921291|DRUG|Salbutamol (Ventolin®)|Randomized controlled trials
215122590|NCT06922487|PROCEDURE|Karolinska Sleepiness Scale, KSS|Assessment of sleepiness during resection using KSS
215122591|NCT06920823|PROCEDURE|antegrade (proximal entry) fixation|In the antegrade headless cannulated screw fixation technique, a small incision was made on the extensor aspect of the fractured metacarpal at the level of the carpometacarpal joint.
214522907|NCT01490047|DRUG|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
214708581|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
214708582|NCT03522272|OTHER|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
215122592|NCT06920823|PROCEDURE|retrograde (distal entry) fixation|In the fixation technique with retrograde headless cannulated screw, a small incision was made on the extensor side of the fractured metacarpal at the level of the metacarpophalangeal joint.
215122593|NCT06921798|OTHER|mHealth|This mHealth intervention is designed to provide health education, and to notify study participants when their result is ready and it is time for them to return to the healthcare clinic for follow up.
214522908|NCT01490047|DRUG|Liposomal doxorubicin|Infusion over 60 minutes
214522909|NCT01490047|DRUG|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
214522910|NCT01490047|DRUG|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
214708583|NCT01871896|DEVICE|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
215122594|NCT06921642|DEVICE|Echocardiography images|Addition of a recording loop during routine ultrasound, during which the patient is in simplified standardized ventilation
215122595|NCT06920862|BEHAVIORAL|Multi-Modal Digital Intervention|"Participants in this group will receive a multi-modal digital intervention designed to enhance healthy weight control behaviors among overweight and obese adolescents.~1. The intervention integrates AI-driven coaching, interactive platforms, gamified applications, and real-time feedback mechanisms.~2. Participants will complete biweekly intervention sessions (2 hours each) over a 3-month period.~3. The intervention is grounded in the Theory of Planned Behavior (TPB) to target attitudes, subjective norms, and perceived behavioral control regarding weight control behaviors.~4. Participants will have access to the Virti platform, where they will receive personalized guidance and feedback."
215122596|NCT06939712|BEHAVIORAL|Online Positive Psychology Intervention|A 6-week online psychological support program, held once a week, primarily organized by a facilitator, with patient-led discussions and communication.
215122597|NCT06939712|OTHER|Routine Care|A 6-week program of health education provided by IBD specialists and nurses during patient follow-ups, tailored to individual patient circumstances and needs. Topics include IBD disease knowledge, medication management, diet, exercise, lifestyle, psychological support, and follow-up care. Patients in this group will also join a control group WeChat group for study-related communication.
215122598|NCT01603485|DRUG|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
215122599|NCT01603485|DRUG|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
214445765|NCT00588185|DRUG|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
214445766|NCT06786468|OTHER|Early palliative care integration|The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits
215122600|NCT01603485|DRUG|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
215122601|NCT01603485|DRUG|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
215122602|NCT01603485|DRUG|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
215122603|NCT02154256|BEHAVIORAL|Increasing incentives|Offer incentives that increase over time.
214445767|NCT06786468|DRUG|Standard systemic treatment for advanced lung cancer|Standard systemic treatment for advanced lung cancer
214445768|NCT06789380|BEHAVIORAL|Schema therapy|Schema therapy (ST) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bamelis et al., 2014; Sempértegui et al., 2013; Arntz et al., 2022). Eligible programs must adhere to the minimum standards described in the evidence-based literature. ST is an integrative treatment method, originally rooted in cognitive theory, but with additional influences from Gestalt, psychodynamic, and experiential methods. Schema therapy programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions and/or a duration of 12 to 24 months. In addition, in order to be eligible, a schema therapy program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
214445769|NCT06789380|BEHAVIORAL|Mentalization-based treatment|Mentalization-based treatment (MBT) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bateman \& Fonagy, 2008; Bateman \& Fonagy, 2009; Laurenssen et al., 2018; Juul et al., 2023). MBT is rooted in psychodynamic and attachment theory and aims to alter personality pathology by improving mentalizing and enhancing epistemic trust. Eligible programs must adhere to the minimum standards described in the evidence-based literature. MBT programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions or a duration of 12 to 24 months. In additon, in order to be eligible, an MBT program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
214522911|NCT03829566|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
214522912|NCT03829566|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
215122604|NCT02154256|BEHAVIORAL|Decreasing incentives|offer incentives that decrease over time
215122605|NCT02154256|BEHAVIORAL|stable incentives|offer incentives that are stable over time, but higher than usual care
215122606|NCT06937658|DEVICE|Alert-based care|Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators
215122607|NCT06937658|DEVICE|Guideline-based care|Guideline-based care is the current typical standard for longitudinal management of patients with wireless pacemakers and implantable defibrillators
215122608|NCT04491136|DRUG|ACEI/ARB|Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
215122609|NCT04491136|DRUG|ARNI|Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
215122610|NCT00587717|DRUG|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
215122611|NCT00587717|DRUG|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
215122612|NCT03929107|BIOLOGICAL|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
215122613|NCT01611194|DRUG|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
215122614|NCT01611194|DRUG|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
215122615|NCT01857297|BIOLOGICAL|Enzira® vaccine|
215122616|NCT04323072|PROCEDURE|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
215122617|NCT04323072|PROCEDURE|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
215122618|NCT03731091|DRUG|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
215122619|NCT03731091|DRUG|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
215122620|NCT03731091|OTHER|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
215122621|NCT00452790|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
215122622|NCT00452790|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
215122623|NCT04346992|OTHER|no intervention|no intervention
215122624|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
215122625|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
215122626|NCT02517697|DRUG|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
214445770|NCT06789380|BEHAVIORAL|Guideline-informed treatment for personality disorders|GIT-PD is a non-theoretical and non-methodological approach, based upon principles derived from common factors across evidence-based treatments for PD. GIT-PD has a flexible approach, enabling tailoring treatment to clinical needs of different types of patients. The treatment duration (start-end) is 12- 18 months. The treatment consists of three distinct phases. First, an assessment phase. Second, a modular treatment phase that offers either group or individual interventions. Third, a follow-up phase with limited treatment and focus on relapse prevention. In order to be eligible, GIT-PD should be less intensive than specialist psychotherapies offered in the control arm at the same location (i.e. MBT or ST). GIT-PD will not include evidence-based psychotherapy for personality disorders as described in previous RCTs.
214445771|NCT06790862|DRUG|SHR0302Base gel|SHR0302Base gel.
214445772|NCT06790862|DRUG|SHR0302Base gel placebo|SHR0302Base gel placebo.
214445773|NCT06789991|DEVICE|electromyography|electromyographic activity of posterior oblique sling muscles will be measured
214445774|NCT05616273|OTHER|Mixed Meal Tolerance Test (MMTT)|At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.
214445775|NCT05616273|OTHER|Arginine Stimulation Test (AST)|At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.
214445776|NCT05616273|OTHER|Home Finger Prick Sample|Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
214445777|NCT06791629|DEVICE|Pulsed Field Ablation|Patients will be treated with pulsed field ablation for atrial fibrillation.
214445778|NCT06791629|DEVICE|Radiofrequency Ablation|Patients will be treated with radiofrequency ablation for atrial fibrillation.
214445779|NCT06785662|DRUG|The budesonide nasal irrigation|The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
214445780|NCT06785662|DRUG|The budesonide nasal spray|The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
214445781|NCT06627231|DRUG|TEV-56286|Oral capsule
214445782|NCT06627231|DRUG|[14C]-TEV-56286|Oral capsule
214445783|NCT06313827|BEHAVIORAL|Exercise plus Monitoring Group (TG-2)|Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
214522913|NCT03829566|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
214522914|NCT03829566|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
214522915|NCT03829566|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
215122627|NCT02517697|DRUG|Placebo|oral formulation of matching placebo three times daily for 12 weeks
215122628|NCT00882960|DRUG|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
215122629|NCT00882960|DRUG|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
215122630|NCT03999060|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
215122631|NCT02918357|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
215122632|NCT05075590|DIAGNOSTIC_TEST|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
215122633|NCT05080530|DRUG|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
215122634|NCT03046030|OTHER|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
215122635|NCT03046030|OTHER|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
215122636|NCT03046030|OTHER|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
215122637|NCT03046030|OTHER|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
215122638|NCT01679873|OTHER|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
215122639|NCT06040944|DRUG|antipsychotic drugs inducing hyperprolactinemia|not exposed
215122640|NCT05639257|DRUG|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
215122641|NCT05639257|DRUG|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
214522916|NCT03829566|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
215122642|NCT05525650|DRUG|House Dust Mite Extract, Dermatophagoides Farinae|"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
215122643|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
215122644|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
214522917|NCT03829566|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
214522918|NCT03829566|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
214522919|NCT00561275|BIOLOGICAL|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
214522920|NCT00604461|DRUG|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
214522921|NCT04126993|DRUG|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
214522922|NCT04126993|DRUG|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
214522923|NCT01844063|GENETIC|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
215122645|NCT05371912|DEVICE|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
215122646|NCT04231604|BEHAVIORAL|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
215122647|NCT04231604|BEHAVIORAL|Waiting list control|Control group placed on a twelve-week waiting list.
214445784|NCT06313827|BEHAVIORAL|Exercise plus monitoring and follow-up group (TGF-3)|"Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week."
215122648|NCT04887753|OTHER|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
215122649|NCT05533424|OTHER|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
214445785|NCT06313827|BEHAVIORAL|Exercise Group (CG-1)|Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
214522924|NCT01844063|GENETIC|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
215122650|NCT05533424|OTHER|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
215122651|NCT01756404|DRUG|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
215122652|NCT01756404|DRUG|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
215122653|NCT01405612|DRUG|Midazolam|Single oral administration on Day 1 or Day 5
215122654|NCT01405612|DRUG|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
214522925|NCT01844063|DRUG|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
214522926|NCT00504101|DRUG|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
214522927|NCT00504101|DRUG|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
214522928|NCT00504101|DRUG|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
214522929|NCT00504101|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
214522930|NCT05125614|OTHER|No adjuvant chemotherapy|There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
215122655|NCT05396144|DRUG|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
215122656|NCT00120965|DEVICE|AutoPulse|Standard device settings
215122657|NCT00120965|OTHER|Manual CPR|Manual CPR
215122658|NCT01579890|DRUG|Diclofenac|diclofenac topical lotion
215122659|NCT04393168|COMBINATION_PRODUCT|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
214522931|NCT02619578|OTHER|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
214522932|NCT02619578|OTHER|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
215122660|NCT00079573|BEHAVIORAL|Atkins diet (extremely low carbohydrate)|
215122661|NCT00079573|BEHAVIORAL|Zone diet (low carbohydrate, high protein)|
215122662|NCT00079573|BEHAVIORAL|Ornish diet (very low fat)|
215122663|NCT04505332|PROCEDURE|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
215122664|NCT04623840|OTHER|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
215122665|NCT04623840|DRUG|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
215122666|NCT03577678|PROCEDURE|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
215122667|NCT02669992|PROCEDURE|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
215122668|NCT02669992|PROCEDURE|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
215122669|NCT03062293|DEVICE|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
215122670|NCT00685789|DEVICE|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
215122671|NCT00685789|DEVICE|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
214445786|NCT05950165|DRUG|CHO-H01|"Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
214445787|NCT05950165|DRUG|CHO-H01 at RP2D|"Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
214445788|NCT05950165|DRUG|Lenalidomide|Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
214445789|NCT06062030|DRUG|DWJ1609|Drug of test group
214445790|NCT06062030|DRUG|DWC202304|Drug of control group
214445791|NCT06783335|DEVICE|Cordella PA Sensor System|"* Patients who receive the Cordella PA Sensor System for monitoring chronic heart failure~* These patients will be monitored for 2 years after receiving the device~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
214445792|NCT06783335|DRUG|Standard of Care Pharmacologic Therapy|"* Patients with chronic heart failure who receive standard medical care without PA pressure monitoring~* These patients will be monitored for 2 years~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
214445793|NCT06786442|OTHER|EFFACLAR DUO+M CREAM|twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)
214445794|NCT06310356|DEVICE|Freestyle Libre 3|CGM
214522933|NCT02619578|DRUG|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
214445795|NCT06310356|DEVICE|Glucometer|SMBG
214445796|NCT03233399|DEVICE|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
214445797|NCT03233399|DEVICE|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
214522934|NCT02619578|OTHER|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
214445798|NCT03233399|DEVICE|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
214445799|NCT00837369|DRUG|Regadenoson|400ug IV bolus injection, single dosage
214445800|NCT03995641|DRUG|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
214445801|NCT04176783|DRUG|Opioids|narcotic pain medicine
214445802|NCT04176783|DRUG|Opioid-Free|non narcotoc pain medication
214445803|NCT05160480|DIAGNOSTIC_TEST|Total-body PET imaging|Total-body PET imaging at different timepoints
214445804|NCT02778685|DRUG|Fulvestrant|
214445805|NCT02778685|OTHER|Laboratory Biomarker Analysis|Correlative studies
214445806|NCT02778685|DRUG|Letrozole|Given PO
214445807|NCT02778685|DRUG|Palbociclib|Given PO
214522935|NCT06201000|DRUG|SGLT2 inhibitors (Dapagliflozin and Empagliflozin)|10 mg of dapagliflozin or empagliflozin
214522936|NCT04834167|DEVICE|OneDoc Picopulse|Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
214522937|NCT02995278|OTHER|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
215122672|NCT00293995|PROCEDURE|Repair of unilateral inguinal hernia|
215122673|NCT04359485|PROCEDURE|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
215122674|NCT04359485|OTHER|Saline|Sodium chloride
214522938|NCT04578691|DEVICE|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
214522939|NCT04578691|DEVICE|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
214522940|NCT02932124|DEVICE|mechanical chest compression device|
214522941|NCT00992693|DRUG|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1\) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
214522942|NCT04158323|DEVICE|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
214522943|NCT01177644|DRUG|PDS 1.0|
214522944|NCT00267865|DRUG|Methotrexate|6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
214522945|NCT00267865|DRUG|Rituximab|375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
214522946|NCT00267865|DRUG|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
214522947|NCT04119778|BEHAVIORAL|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
214522948|NCT03115619|DRUG|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
214522949|NCT03640078|OTHER|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
214445808|NCT02778685|BIOLOGICAL|Pembrolizumab|Given IV
214445809|NCT01523171|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214445810|NCT06778824|DRUG|Takepron|Participants are expected to take a proton-pump inhibitor (PPI) for 12 weeks, with a dosage of 30 mg taken once a day.
214445811|NCT06778824|DRUG|Zoloft 50Mg Tablet|Participants are expected to take a selective serotonin reuptake inhibitor (SSRI) for 12 weeks, with a dosage of 50 mg taken once a day.
214445812|NCT06778824|DRUG|Imipramine Pill|Participants are expected to take tricyclic antidepressants (TCA) for 12 weeks, with a dosage of 25 mg taken twice a day.
214445813|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
214445814|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
214445815|NCT06029257|DRUG|Tildrakizumab|As provided in real-world clinical practice.
214445816|NCT02669069|DEVICE|PS1|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
214445817|NCT02669069|DEVICE|PS2|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
214445818|NCT02669069|DEVICE|PS3|Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
214445819|NCT06444477|OTHER|ITP and cancer|ITP and cancer
214445820|NCT06203821|DRUG|NP137|NP137 for the Treatment of Resectable Pancreatic Cancer
214522950|NCT03556059|OTHER|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
214522951|NCT05866289|OTHER|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
214522952|NCT02973035|DRUG|Amlodipine|
214522953|NCT02973035|DRUG|Valsartan|
214522954|NCT06267326|PROCEDURE|debridment|resection of dead bone
214522955|NCT00857909|DRUG|Amiloride|1 tablet twice a day
214522956|NCT00857909|DRUG|Spironolactone|1 tablet twice a day
214522957|NCT00857909|DRUG|Placebo|Placebo
214445821|NCT04899115|DRUG|Placebo|Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
214445822|NCT04899115|DRUG|VE303|"Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules."
214445823|NCT04899115|DRUG|oral vancomycin|All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
214522958|NCT00857909|DRUG|Placebo and spironolactone|5mg twice daily
214522959|NCT00857909|DRUG|Spironolactone|25mg twice daily
214522960|NCT01923935|DRUG|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
214445824|NCT05926024|BEHAVIORAL|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
215122675|NCT05890469|COMBINATION_PRODUCT|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
215122676|NCT05890469|COMBINATION_PRODUCT|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
215122677|NCT06267534|DEVICE|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
215122678|NCT02345213|DRUG|E2020|E2020 tablets will be orally administered once daily after breakfast
215122679|NCT02345213|DRUG|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
215122680|NCT01712204|DRUG|Placebo|Placebo Capsule BID for 16 Weeks
215122681|NCT01712204|DRUG|AC-201|AC-201 50mg Capsule BID for 16 Weeks
215122682|NCT01712204|DRUG|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
215122683|NCT01290744|DRUG|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
215122684|NCT01290744|DRUG|Placebo|Daily for 12 months
215122685|NCT02051322|DEVICE|Jet Nebulizer|
215122686|NCT02051322|DEVICE|Trunk Mask Nebulizer|
215122687|NCT02051322|DEVICE|Aerobika Nebulizer|
215122688|NCT03580681|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
215122689|NCT03580681|DIETARY_SUPPLEMENT|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
215122690|NCT02110095|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
215122691|NCT03833414|PROCEDURE|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
215122692|NCT04360837|PROCEDURE|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
215122693|NCT01166425|DRUG|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
215122694|NCT01166425|DRUG|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
214445825|NCT05926024|BEHAVIORAL|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
214445826|NCT05926024|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
214445827|NCT05926024|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
214445828|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
214522961|NCT01923935|DRUG|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
214522962|NCT03603275|DRUG|New FVIII products|Kovaltry or Jivi prescribed by the treating Physician
214522963|NCT03853525|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
215122695|NCT00386243|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
215122696|NCT00386243|BEHAVIORAL|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
215122697|NCT00386243|DRUG|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
215122698|NCT00386243|DRUG|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
215122699|NCT02781610|DRUG|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
215122700|NCT03143504|DIAGNOSTIC_TEST|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
215122701|NCT03051308|COMBINATION_PRODUCT|NPT and UW Solution|Tissue preservation solutions for transplantation
215122702|NCT03015935|PROCEDURE|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
215122703|NCT03015935|PROCEDURE|Veress entry|First trocar entry will be performed with Veress
214445829|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
214445830|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
215122704|NCT04718493|PROCEDURE|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
215122705|NCT04718493|PROCEDURE|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
215122706|NCT06399237|DEVICE|Foot Orthoses|Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
215122707|NCT00284219|DEVICE|Transcranial Magnetic Stimulation 10Hz|3\. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
215122708|NCT00284219|DEVICE|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
215122709|NCT04190732|BEHAVIORAL|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
215122710|NCT05701696|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
214445831|NCT05926024|BEHAVIORAL|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
214522964|NCT03853525|OTHER|Semisolid vaseline|Product is applied to one side of the inguinal region.
215122711|NCT05701696|DIAGNOSTIC_TEST|Widespread pain index|Total the number of painful body areas
215122712|NCT05701696|DIAGNOSTIC_TEST|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
215122713|NCT05701696|OTHER|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
215122714|NCT05701696|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
215122715|NCT05701696|DIAGNOSTIC_TEST|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
215122716|NCT04740216|BEHAVIORAL|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
215122717|NCT04740216|BEHAVIORAL|exercise therapy|the control group performed 20-minute stretching exercises each time.
215122718|NCT05276921|OTHER|ultrasound|Quadriceps and abdominal muscle ultrasonography
215122719|NCT01150097|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
215122720|NCT01150097|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
215122721|NCT01150097|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
214445832|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
214445833|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
214445834|NCT05926024|DIAGNOSTIC_TEST|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
214445835|NCT03139305|DRUG|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
214445836|NCT03139305|DRUG|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
214445837|NCT03139305|DRUG|Placebo|Intravenous infusion of saline for 72 hours
214445838|NCT04845945|BIOLOGICAL|PCV15|Blood draw after the vaccination
214445839|NCT05710900|OTHER|Dietary intervention|Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
214445840|NCT06795256|BEHAVIORAL|Percussion and position change in retrograde intrarenal surgery|To evaluate the effectiveness of this homework on stone clearance rates after RIRC by giving instructions to the patient in the home environment and suggesting percussion (tapping) and movement/position changes to help spontaneous stone passage.
214445841|NCT04046445|DRUG|ATP128|5-6 SC injections
214445842|NCT04046445|DRUG|BI 754091|≥ 7 IV infusions
214445843|NCT04046445|DRUG|VSV-GP128|1 single IV injection
214445844|NCT05286554|DRUG|gonadotropin releasing hormone-agonist|subcutaneous injection
214445845|NCT05286554|DRUG|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
214445846|NCT03697070|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
214445847|NCT03697070|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
214445848|NCT03311152|DIAGNOSTIC_TEST|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
214445849|NCT04383951|OTHER|Dietary consult for participants in the ketogenic diet arm|An initial consultation with the providers of medically supervised weight loss clinic will be arranged. Participants in the ketogenic diet group will be educated on the concepts of the diet and will be provided with recipes to be utilized at home that adhere to this diet. In addition to the initial consultation, participants in this arm receive additional consultations with these providers with a frequency as determined by the provider.
214445850|NCT04383951|OTHER|Dietary consult for participants in the standard of care arm|For participants in the standard of care arm, an initial consultation with the providers of medically supervised weight loss clinic will be arranged and the discussion will center around portion control using a balanced diet. Participants will receive only one additional consultation with the provider 16 weeks later just prior to the conclusion of the study.
214445851|NCT05161715|DRUG|Obicetrapib|10mg obicetrapib
214445852|NCT05548088|BIOLOGICAL|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6,3E6,6E6,1E7 cells/kg
214522965|NCT03686176|OTHER|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
214522966|NCT04546178|BEHAVIORAL|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
215122722|NCT01150097|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
215122723|NCT01150097|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
215122724|NCT01150097|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
215122725|NCT02815423|BIOLOGICAL|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
215122726|NCT02815423|BIOLOGICAL|Percutaneous|Percutaneous injection
215122727|NCT03383510|OTHER|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
215122728|NCT03383510|OTHER|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
215122729|NCT03383510|OTHER|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
215122730|NCT03383510|OTHER|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
215122731|NCT04872699|DIAGNOSTIC_TEST|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
215122732|NCT03483493|BEHAVIORAL|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
215122733|NCT03483493|OTHER|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
215122734|NCT01966913|DRUG|Bevacizumab|
215122735|NCT01966913|DRUG|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
215122736|NCT05238545|OTHER|gluten-free diet|Diet excluding foods containing gluten.
215122737|NCT02919072|DRUG|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
215122738|NCT02919072|DRUG|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
214445853|NCT05445700|DEVICE|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
214522967|NCT04546178|OTHER|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
214445854|NCT06752317|DRUG|Dexamethasone|patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
214445855|NCT06752317|DRUG|Dexmedetomidine|patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
214522968|NCT02400372|DEVICE|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
214522969|NCT00391794|BEHAVIORAL|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
214522970|NCT00391794|BEHAVIORAL|Educational Seminar|4 hour education session led by trained facilitators
214522971|NCT04882956|DRUG|intravitreal injection|Brolucizumab-Dbll intravitreal injection
215122739|NCT05286502|DEVICE|fundus photography|color fundus photography
215122740|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
215122741|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
215122742|NCT06400953|OTHER|Kinetic Brain Exercises and Core Stabilization Exercises|Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.
215122743|NCT06400953|OTHER|Core Stabilization Exercises|Core Stabilization Exercise Program in groups of 8-10 people, for 40 minutes, 2 days a week, for 8 weeks.These exercises included a 5-minute active warm-up, a 30-minute Core Stabilization exercise that included upper and lower extremity movements, and immediately followed by a 5-minute cool-down exercise.The exercises are pilates-based and in the first stage of the program. Movements were performed in standing and sitting positions.Movements were started with 6-8 repetitions, increased by 1-2 repetitions each week, and in the last week, 12-15 repetitions were performed, with contraction times increasing from 5 seconds to 10 seconds. As the exercises progressed from easy to difficult, from simple movements to complex movements, the movements were continued by adding an elastic band and 0.5 kg weight.While advancing the exercise program, the exercises were personalized by taking into account the individual's strain levels.
214445856|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
215122744|NCT00748423|DRUG|Nitric Oxide|NO in inhalation for 3 days
215122745|NCT00748423|DRUG|Placebo|Placebo in inhalation for 3 days
214445857|NCT04913064|OTHER|Questionnaire Administration|Ancillary studies
214445858|NCT04913064|DRUG|White Button Mushroom Extract|Given PO
214445859|NCT05635786|DRUG|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
214445860|NCT05635786|DRUG|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
215122746|NCT03019094|DEVICE|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
215122747|NCT00549445|DRUG|Azithromycin|250 mg daily
215122748|NCT00549445|DRUG|Placebo|Daily
215122749|NCT06379776|OTHER|Education through a 3D model|Training through a 3D model of the spine fractures
215122750|NCT06379776|OTHER|Education through a traditional pedagogical support|Training through a traditional pedagogical support
215122751|NCT04958174|DEVICE|web-application|web application for monitoring children's development
215122752|NCT02761382|OTHER|Mindfulness-based psychological treatment|
215122753|NCT02761382|OTHER|Non-specific psychological treatment|
215122754|NCT02458833|BEHAVIORAL|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
215122755|NCT02865655|PROCEDURE|Hysteroscopic|
215122756|NCT02748395|DRUG|Triamcinolone|
215122757|NCT02748395|OTHER|Placebo|
215122758|NCT02748395|DRUG|Lidocaine|
215122759|NCT00890110|BIOLOGICAL|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
215122760|NCT00559247|DRUG|BMS-650032 or Placebo|Oral, Once daily, Single Dose
214445861|NCT03743636|DRUG|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
214445862|NCT03743636|DRUG|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
214445863|NCT03743636|OTHER|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
214445864|NCT04502446|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
214522972|NCT04882956|DRUG|intravitreal injection|Aflipercept intravitreal injection
214522973|NCT01823458|BEHAVIORAL|Lottery Insurance|
215122761|NCT01925547|DIETARY_SUPPLEMENT|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
215122762|NCT01925547|DIETARY_SUPPLEMENT|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
215122763|NCT01065038|DRUG|Anagrelide|
215122764|NCT01065038|DRUG|Hydroxyurea|
215122765|NCT02168114|OTHER|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
215122766|NCT02168114|PROCEDURE|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
215122767|NCT04437485|BEHAVIORAL|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
215122768|NCT04437485|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
215122769|NCT04437485|DRUG|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
215122770|NCT04437485|OTHER|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
215122771|NCT04049487|OTHER|Exercise|Both groups will participate in group exercise as previously described
215122772|NCT02602535|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
215122773|NCT02602535|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
214445865|NCT05979584|DEVICE|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
214522974|NCT01823458|BEHAVIORAL|Standard Lottery|
214445866|NCT05979584|DEVICE|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
214445867|NCT06772636|PROCEDURE|music group|In the music group, the music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
214445868|NCT06772636|PROCEDURE|non music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
214522975|NCT00515879|DRUG|D-cycloserine|50 mg
214522976|NCT00515879|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
214522977|NCT00515879|DRUG|Placebo|Same dosage as active pill
214522978|NCT04880135|OTHER|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
214445869|NCT01938547|DRUG|clevidipine|
214445870|NCT05844332|OTHER|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
214445871|NCT05707897|DRUG|TS-142 10 mg|Single-dose of 10 mg of TS-142
215122774|NCT04324671|DEVICE|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP\*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
215122775|NCT00110539|BEHAVIORAL|Complementary and alternative medicine education|
215122776|NCT04260893|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
215122777|NCT04456634|DRUG|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
215122778|NCT04456634|OTHER|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
215122779|NCT05588349|OTHER|Dry needling|Dry needling + stretching exercise
215122780|NCT05588349|OTHER|Stretching exercise|Stretching exercise only
215122781|NCT06139549|OTHER|Gross motor development group session|Group session for gross motor development
214445872|NCT06774469|DEVICE|assigned|Group II: (Normal-US Group): The rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power, for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 30 days. Group V: (Osteoarthritis-US group) after two weeks of chemical induction of osteoarthritis, the rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 44 days.
214445873|NCT06774469|DRUG|Injection, Solution|"Group III: (Osteoarthritis-induced group): For studying the histological changes of the articular knee joint after osteoarthritis induction in the right knee joint before recovery occur. The patellar ligament will be palpated below the patella and a single intra-articular injection of (MIA lateral to the ligament using an insulin syringe will be performed).~The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL). Saline acts as a vehicle for MIA. The rats will be sacrificed after 14 days of MIA injection (1st day of the experiment).~Group IV: (Osteoarthritis-Recovery group): The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL), Saline acts as a vehicle for MIA and will not receive any medication. The rats will be sacrificed after 44 days of MIA injection (1st day of the experiment)."
214445874|NCT06774469|DEVICE|ultrasound|Group I:Sham Comparator (Control group): for studying the normal histological structure of the articular knee joint.
214445875|NCT06786949|OTHER|Questionnaire|All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer
214445876|NCT06786949|DIAGNOSTIC_TEST|Blood samples for biomarker measurement|Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample
214445877|NCT06785831|OTHER|Psyllium|Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.
214445878|NCT06785831|OTHER|Sauerkraut|Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.
214445879|NCT06785831|OTHER|Fresh apples|Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.
214445880|NCT06785831|OTHER|Dried apples|Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.
214445881|NCT04497012|DRUG|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
214522979|NCT04880135|OTHER|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
214522980|NCT01636778|DRUG|SB-497115-GR|TPO receptor agonist to increase platelet count
214522981|NCT01434355|OTHER|Laboratory Biomarker Analysis|Correlative studies
214522982|NCT01434355|OTHER|Questionnaire Administration|Ancillary studies
214445882|NCT04497012|DRUG|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
214522983|NCT03458416|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
215122782|NCT01848158|DEVICE|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
215122783|NCT01848158|DEVICE|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
215122784|NCT03790111|DRUG|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
214522984|NCT06479499|OTHER|Pilates Exercises|Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
215122785|NCT01432405|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
215122786|NCT01432405|DRUG|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
215122787|NCT02467179|DEVICE|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
215122788|NCT02467179|DEVICE|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
215122789|NCT02494960|BEHAVIORAL|The brief smoking cessation AWARD model|"* Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
215122790|NCT02494960|BEHAVIORAL|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
215122791|NCT03798717|DIAGNOSTIC_TEST|Heating|Warm water immersion
215122792|NCT00942903|DEVICE|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
215122793|NCT02752880|DRUG|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
215122794|NCT02752880|DRUG|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
215122795|NCT01686334|BIOLOGICAL|DC vaccine|Autologous WT1 mRNA-electroporated DCs
215122796|NCT06142539|RADIATION|CT Radiation Doses|Obtaining Low CT Radiation Doses by Adjusting Dose Levels
215122797|NCT05314868|DEVICE|PhotoFix|Surgical repair with patch.
215122798|NCT01777308|BIOLOGICAL|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
214445883|NCT04163536|DRUG|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
214445884|NCT04163536|DRUG|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
214445885|NCT06766253|DEVICE|GMA-TULIP|Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
215122799|NCT01799707|BEHAVIORAL|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
215122800|NCT01799707|BEHAVIORAL|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
215122801|NCT04381858|DRUG|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction."
215122802|NCT04381858|DRUG|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
215122803|NCT03410628|DEVICE|gammaCore|Non-invasive vagal nerve stimulator
214445886|NCT04547413|BEHAVIORAL|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
215122804|NCT03212326|DRUG|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
215122805|NCT02942212|BEHAVIORAL|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
215122806|NCT02942212|BEHAVIORAL|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
215122807|NCT02942212|OTHER|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
215122808|NCT02942212|DRUG|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke \>10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
215122809|NCT02942212|BEHAVIORAL|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
215122810|NCT02942212|BEHAVIORAL|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
215122811|NCT02942212|BEHAVIORAL|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
215122812|NCT04333914|DRUG|Autophagy inhibitor (GNS651)|Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
215122813|NCT04333914|OTHER|Standard of care|"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest."
215122814|NCT04333914|DRUG|Avdoralimab|Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
215122815|NCT04333914|DRUG|Monalizumab|Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
215122816|NCT03533673|BIOLOGICAL|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
215122817|NCT03430791|DRUG|Nivolumab 240 mg IV|Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
215122818|NCT03430791|DRUG|Nivolumab 3 mg/kg|Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
215122819|NCT03430791|DRUG|Ipilimumab 1 mg/kg|Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
215122820|NCT03430791|DEVICE|NovoTTF200A (Optune)|A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
214445887|NCT00607776|DRUG|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
214445888|NCT00607776|DRUG|Systane|Drops
214445889|NCT05820477|BEHAVIORAL|FAMS-T1D|Behavioral FAMS-T1D FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.
215122821|NCT02016976|DRUG|EMLA Analgesic Cream|
215122822|NCT02016976|DRUG|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
214445890|NCT05820477|BEHAVIORAL|Digital resources for diabetes|Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
214445891|NCT05096767|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
215122823|NCT05581602|DEVICE|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
215122824|NCT00791063|OTHER|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
215122825|NCT02918617|DRUG|Control toothpaste containing Novamin® technology|
215122826|NCT02918617|DRUG|Control toothpaste containing 1500 ppm fluoride as MFP|
215122827|NCT02918617|DRUG|Test toothpaste with nano-HAP (high concentration)|
215122828|NCT02918617|DRUG|Test toothpaste with nano-HAP (low concentration)|
215122829|NCT02918617|DRUG|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
215122830|NCT02918617|DRUG|Control toothpaste without nano-HAP|
215122831|NCT02918617|DRUG|Test toothpaste with nano-HAP (medium concentration)|
215122832|NCT02918617|DRUG|Test cream with nano-HAP (higher concentration)|
215122833|NCT02918617|DRUG|Control cream without nano-HAP|
215122834|NCT05390372|OTHER|human milk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
215122835|NCT05390372|OTHER|Routine care group|cream applied as part of hospital routine practice
215122836|NCT04456023|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of 0.6 - 6.0×10\^8 CAR positive viable T cells.
214445892|NCT04474847|DRUG|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
215122837|NCT05441826|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
215122838|NCT02964221|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
215122839|NCT03840317|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
215122840|NCT05118646|DEVICE|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
215122841|NCT05118646|DEVICE|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
215122842|NCT05317104|OTHER|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
215122843|NCT05062122|OTHER|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
215122844|NCT05062122|OTHER|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
215122845|NCT05062122|OTHER|control group|Manual dexterity was assessed before and after traditional physiotherapy.
215122846|NCT02937337|DEVICE|Laryngeal mask insertion with videostylet guided technique|
215122847|NCT02937337|DEVICE|Laryngeal mask insertion with standard blind technique|
215122848|NCT06453408|PROCEDURE|Punción seca con aguja retráctil|"The placebo dry needling protocol will be performed in the same position, with identical antiseptic measures and the same number of simulated incisions as the real dry needling protocol, using DONGBANG AcuPrime® 0.30 x 30mm blunt-tipped placebo needles with a retractable handle. These needles simulate the sensation of needle contact without penetrating the skin. The therapist will hold the needle and guide tube, pressing the tube against the skin and simulating needle manipulation. Changes in pressure direction will mimic the real technique. The protocol will end with compression using an alcohol swab and an upper trapezius stretch.~Participants in both groups will receive the same information about the sensations of the dry needling procedure. At the beginning, they will be informed that they may or may not feel the needle insertion. They will also be told that the physiotherapist will manually manipulate the needle multiple times during the procedure."
215122849|NCT06453408|PROCEDURE|Punción seca con aguja normativa.|To perform the actual SP, patients shall be asked to lie prone with arms close to the body. The dry needling shall be performed with a 0,30 × 30 mm DN needle (APS Regular Agupunt) with a guide tube. The therapist shall first clean the area with alcohol. The trapezius muscle is then firmly grasped with a clamp between the thumb and index finger, so that the needle is directed deep into the index finger until the tip of the needle is felt to be approaching (33). This procedure involves an approximate insertion of the needle to a depth of 30 mm and ensures the intramuscular penetration necessary for dry needling. Puncture of the PGM shall be performed using the Hong technique (34), performing up to 12 inlets and outlets, at a frequency of 1 Hz. When the needle is withdrawn, the area is firmly compressed with cotton wool for 60 seconds. Finally, the upper trapezius muscle is stretched, following the technique originally described by Simons (35).
215122850|NCT04471519|BIOLOGICAL|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
215122851|NCT04471519|BIOLOGICAL|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
215122852|NCT04471519|BIOLOGICAL|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
214445893|NCT04474847|DRUG|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
214445894|NCT05038566|DEVICE|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
215122853|NCT04471519|BIOLOGICAL|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
215122854|NCT04471519|BIOLOGICAL|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
215122855|NCT04471519|BIOLOGICAL|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
214445895|NCT06793267|DRUG|Metoclopramide (Maxolon)|Participants will receive 0.15 mg/kg of metoclopramide administered intravenously. The drug will be diluted in 2 ml of solution prior to administration.
214445896|NCT06793267|DRUG|Saline|patients will recive normal saline 0.9% 2ml intravenous
215122856|NCT02754973|BEHAVIORAL|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
215122857|NCT02754973|BEHAVIORAL|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
215122858|NCT00291616|DRUG|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
215122859|NCT00291616|DRUG|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
215122860|NCT04849208|OTHER|Presentation of fast and slow trials|"In each task trial participants will solve a reasoning problem. Half of the trials will be traditional Slow trials in which participants get ample time to deliberate (i.e., 20 s). The other half of the trials will be Fast trials in which people do not get sufficient time to deliberate (i.e., 4 s deadline) and need to rely on intuitive processing"
215122861|NCT02763306|DEVICE|Dermal Cooling System|Treatment with dermal cooling system.
215122862|NCT06244004|DRUG|Antiandrogen Therapy|Undergo SOC ADT
215122863|NCT06244004|PROCEDURE|Bone Scan|Undergo bone scan
215122864|NCT06244004|PROCEDURE|Computed Tomography|Undergo CT
215122865|NCT06244004|DRUG|Cytotoxic Chemotherapy|Receive SOC cytotoxic chemotherapy
215122866|NCT06244004|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
215122867|NCT06244004|RADIATION|Radiation Therapy|Undergo MDRT
215122868|NCT04839510|DRUG|MRG002|Administrated intravenously
215122869|NCT04239001|DRUG|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
215122870|NCT00985673|BIOLOGICAL|GSK2340274A|Two intramuscular injections
215122871|NCT00985673|BIOLOGICAL|GSK2340273A|Two intramuscular injections
215122872|NCT00985673|BIOLOGICAL|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
215122873|NCT00985673|BIOLOGICAL|Saline placebo|Single intramuscular injection
215122874|NCT03715517|PROCEDURE|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
215122875|NCT03715517|PROCEDURE|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
215122876|NCT03715517|DRUG|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
215122877|NCT03715517|DRUG|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
214445897|NCT04970888|OTHER|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
215122878|NCT03715517|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
215122879|NCT03715517|DRUG|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
215122880|NCT03715517|DRUG|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
215122881|NCT05736874|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
215122882|NCT05736874|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215122883|NCT03065322|OTHER|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
215122884|NCT04314908|PROCEDURE|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
215122885|NCT04314908|PROCEDURE|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
215122886|NCT04314908|PROCEDURE|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
215122887|NCT04314908|PROCEDURE|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
215122888|NCT02805686|DEVICE|spectral domain optical coherence tomography|
215122889|NCT02805686|DEVICE|multifocal electroretinogram|
215122890|NCT03194906|DRUG|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
215122891|NCT03194906|OTHER|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
215122892|NCT03194906|OTHER|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
215122893|NCT00984256|DRUG|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
215122894|NCT00984256|OTHER|Procedure - malaria challenge|2\) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
215122895|NCT01500590|DRUG|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
215122896|NCT01500590|DRUG|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
215122897|NCT00002682|DRUG|Amoxicillin|
215122898|NCT00002682|DRUG|Bismuth Subsalicylate|
215122899|NCT00002682|DRUG|Clarithromycin|
215122900|NCT00002682|DRUG|Metronidazole Hydrochloride|
215122901|NCT00002682|DRUG|Omeprazole|
215122902|NCT00002682|DRUG|Tetracycline Hydrochloride|
215122903|NCT03057496|DEVICE|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
215122904|NCT05245435|DIAGNOSTIC_TEST|FDHT-PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
215122905|NCT05245435|DIAGNOSTIC_TEST|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
215122906|NCT05587816|DEVICE|Validation of the PortionSize app|The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
214694270|NCT02725073|PROCEDURE|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
215122907|NCT03033277|BIOLOGICAL|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
215122908|NCT03033277|BIOLOGICAL|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
215122909|NCT01033981|DRUG|Sunitinib|Treatment for mRCC as indication approved and physician criterium
215122910|NCT01925885|PROCEDURE|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
215122911|NCT01925885|PROCEDURE|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
215122912|NCT05254665|DRUG|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
215122913|NCT06440473|DRUG|Roflumilast|Roflumilast 0.3% cream
215122914|NCT06440473|OTHER|Vehicle (Roflumilast 0.3% vehicle cream)|Vehicle (Roflumilast 0.3% vehicle cream)
215122915|NCT02136979|DRUG|Propofol|group of patients with propofol-based anesthesia
215122916|NCT02136979|DRUG|Sevoflurane|group of patients with sevoflurane-based anesthesia
215122917|NCT06136364|BIOLOGICAL|CAR-T|CAR-T immunotherapy targeting CD7+
215122918|NCT00280917|DRUG|CF101|
215122919|NCT02264275|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
215122920|NCT03684616|DRUG|Statin|continuous statin treatment for 3 months prior to cardiac arrest
215122921|NCT01307319|DRUG|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
215122922|NCT01307319|DRUG|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
215122923|NCT03689582|DRUG|68Ga-PSMA|"Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
215122924|NCT05348902|OTHER|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
215122925|NCT03189186|DRUG|Pembrolizumab Injection [Keytruda]|Same as arm description
215122926|NCT03189186|PROCEDURE|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
215122927|NCT03189186|PROCEDURE|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
215122928|NCT03991312|DRUG|itraconazole|Participants will receive an oral solution as described in the arm description.
215122929|NCT03991312|DRUG|rifampin|Participants will receive oral capsule(s) as described in the arm description.
215122930|NCT03991312|DRUG|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
215122931|NCT04895254|DEVICE|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
215122932|NCT04895254|PROCEDURE|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
215122933|NCT00333008|DRUG|Doxil|
215122934|NCT00333008|DRUG|Cyclophosphamide|
215122935|NCT00333008|DRUG|Vincristine|
214694271|NCT02362711|DRUG|NPC-16 Standard Dosing Regimen Group|
214694272|NCT02362711|DRUG|NPC-16 Continuous Dosing Regimen Group|
214694273|NCT02362711|DRUG|Placebo Group|
215122936|NCT00333008|DRUG|Prednisone|
215122937|NCT00333008|DRUG|Rituximab|
215122938|NCT00333008|DRUG|Pegfilgrastim|
215122939|NCT01982734|DIETARY_SUPPLEMENT|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
215122940|NCT04059510|PROCEDURE|rectovaginal swab|Self taken rectal and vaginal swab
215122941|NCT04059510|PROCEDURE|pregnancy test|Urine pregnancy test
215122942|NCT04059510|PROCEDURE|Menstrual cup|Menstrual cup vaginal fluid collection
215122943|NCT04059510|PROCEDURE|Blood test|Venous blood sample
215122944|NCT04059510|OTHER|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
215122945|NCT00035789|DRUG|Entecavir|
215122946|NCT02372877|DEVICE|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
215122947|NCT02700308|DEVICE|Kyphoplasty|Placement and inflation of balloon prior to cement injection
215122948|NCT02700308|DEVICE|Conventional vertebroplasty|Conventional vertebroplasty
215122949|NCT05638932|DRUG|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
215122950|NCT01866371|PROCEDURE|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
215122951|NCT01963195|DRUG|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
215122952|NCT02436525|DEVICE|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
215122953|NCT02436525|DEVICE|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
215122954|NCT02436525|DEVICE|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
215122955|NCT00955214|DEVICE|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
215122956|NCT05408962|OTHER|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
215122957|NCT03909893|RADIATION|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
215122958|NCT04985929|DRUG|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
215122959|NCT04985929|DRUG|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
215122960|NCT01731912|DRUG|Degarelix|Given SC
214445898|NCT04970888|OTHER|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
214522985|NCT06479499|OTHER|Aerobic Exercises|Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
215122961|NCT01731912|RADIATION|External Beam Radiation Therapy|Undergo standard EBRT
215122962|NCT01731912|OTHER|Laboratory Biomarker Analysis|Correlative studies
215122963|NCT04213300|OTHER|Low carbohydrate diet|"Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) ."
215122964|NCT02757144|DRUG|DWP14012|DWP14012 tablets
215122965|NCT02757144|DRUG|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
214522986|NCT04288440|PROCEDURE|Surgery|Removal of epiretinal membrane and ILM
215122966|NCT02757144|DRUG|Esomeprazole|Nexium®
215122967|NCT04507607|DRUG|Tenofovir Alafenamide 25 MG|TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
215122968|NCT02339311|OTHER|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
215122969|NCT03200119|BEHAVIORAL|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
215122970|NCT02222558|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
215122971|NCT00127023|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
215122972|NCT03400852|DRUG|MNK-1411|MNK-1411 (1 mg/mL suspension) for subcutaneous injection
215122973|NCT03400852|OTHER|Placebo|Placebo suspension for subcutaneous injection
215122974|NCT06144463|DIAGNOSTIC_TEST|lung ultrasound-guided fluid resuscitation|For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion
215122975|NCT05134558|RADIATION|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
215122976|NCT02528708|DRUG|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
215122977|NCT02528708|DRUG|Placebo|0.9% saline solution
215122978|NCT06268054|DRUG|DEH113|Tablets
215122979|NCT06268054|DRUG|Placebo Comparator|Tablets
215122980|NCT06288555|DIAGNOSTIC_TEST|Ipswich touch test|"Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses."
215122981|NCT05551858|DRUG|Proglumide|(CAS: 6620-60-6.)
215122982|NCT05551858|DRUG|Placebo|Avicel fiber filled capsule taken by mouth three times daily
215122983|NCT03421522|OTHER|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
215122984|NCT01762553|BEHAVIORAL|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
215122985|NCT03493555|BEHAVIORAL|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
215122986|NCT01169948|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
215122987|NCT02759757|OTHER|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
215122988|NCT02759757|OTHER|Placebo|A micropore tape will be used as placebo
215122989|NCT02621112|BIOLOGICAL|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
215122990|NCT02621112|BIOLOGICAL|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
215122991|NCT02621112|BIOLOGICAL|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
215122992|NCT05724940|OTHER|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~1. Thorough medical history of the patients~2. Full clinical examination including:~   1. General examination and vital signs.~  2. Complete rheumatological examination.~  3. SLE disease activity index SLEDAI (ref).~  4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~4. Renal investigations:~   1. Kidney functions~  2. Urine analysis~  3. 24 hours protein in urine and/or A/C ratio~  4. Renal biopsy if indicated.~5. ANA (Antinuclear Antibodies)test.~6. ANA profile for the most common 19 autoantibodies by immunoblot."
214445899|NCT04970888|OTHER|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
214445900|NCT05438329|DRUG|DB-1305/BNT325|Administered Injection of Vein (I.V.)
215122993|NCT00974649|BEHAVIORAL|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
215122994|NCT00502554|PROCEDURE|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
215122995|NCT04033744|PROCEDURE|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
215122996|NCT04019353|GENETIC|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
215122997|NCT02436018|DEVICE|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
215122998|NCT02436018|DEVICE|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
214445901|NCT05438329|COMBINATION_PRODUCT|Pembrolizumab|Administered I.V.
214445902|NCT05438329|DRUG|BNT327|Administered I.V.
215122999|NCT05977400|DRUG|Ampicillin|Intravenous Ampicillin
215123000|NCT05977400|DRUG|Gentamicin|Intravenous Gentamicin
215123001|NCT05977400|DRUG|Placebo|Intravenous Normal Saline
215123002|NCT05874284|DRUG|Gelofusin|In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
215123003|NCT04945187|OTHER|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
214445903|NCT04111458|DRUG|BI 1701963|Tablet
215123004|NCT00936702|DRUG|carboplatin|Given IV
215123005|NCT00936702|DRUG|everolimus|Given PO
215123006|NCT00936702|DRUG|paclitaxel|Given IV
215123007|NCT01636635|OTHER|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
215123008|NCT02532465|DEVICE|Air-Q|
215123009|NCT02532465|DEVICE|i-gel|
215123010|NCT00793858|DRUG|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
215123011|NCT03915171|DIAGNOSTIC_TEST|Next generation sequencing|NGS can provide genetic and MSI test for patients
215123012|NCT04567641|DIETARY_SUPPLEMENT|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
215123013|NCT02938195|RADIATION|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
215123014|NCT02938195|PROCEDURE|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
215123015|NCT02019732|OTHER|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
215123016|NCT06421038|OTHER|Thyme honey|Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days
215123017|NCT06421038|DRUG|Kenalog|kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)
215123018|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
215123019|NCT00622505|DRUG|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
215123020|NCT04322188|OTHER||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
215123021|NCT02935530|DRUG|s-LMWH|2125KU, subcutaneous injection of 5-10 days
215123022|NCT02935530|DRUG|LMWH|4250KU, subcutaneous injection of 5-10 days
215123023|NCT02935530|DRUG|Argatroban|20mg, injection for 5-10 days
215123024|NCT04979676|BEHAVIORAL|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
215123025|NCT04979676|BEHAVIORAL|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
215123026|NCT04979676|BEHAVIORAL|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
215123027|NCT00980356|DRUG|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
215123028|NCT04105049|OTHER|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
215123029|NCT02361333|BEHAVIORAL|Teaching Intervention|Patients will be taught how to install and use a remote monitor
214445904|NCT04111458|DRUG|Trametinib|Tablet
215123030|NCT00411749|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
215123031|NCT00411749|BIOLOGICAL|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
214445905|NCT06790524|DEVICE|One-piece dental implants with MUA|one-piece dental implants with multi-units abutment mounted on the implants as a single piece provided with different abutment angulation utilizing these implants for All-On-Four prothesis
214522987|NCT04288440|DEVICE|Vitrectomy machine|Pars plana vitrectomy
214522988|NCT02286297|DEVICE|McGRATH® MAC|video-laryngoscopy-1
214522989|NCT02286297|DEVICE|AirTraq|video-laryngoscopy-2
214522990|NCT02286297|DEVICE|GlideScope|video-laryngoscopy-3
214522991|NCT02286297|DEVICE|Miller|Direct laryngoscopy
214694274|NCT06597734|DRUG|Olutasidenib|Given by PO
215123032|NCT02768493|DRUG|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
215123033|NCT02768493|DRUG|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
215123034|NCT01648634|DRUG|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
215123035|NCT01648634|DRUG|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
215123036|NCT02373488|OTHER|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
215123037|NCT02373488|OTHER|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
215123038|NCT02373488|OTHER|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
215123039|NCT05963620|OTHER|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
215123040|NCT03560336|DRUG|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
215123041|NCT04006093|DRUG|Apixaban Oral|one Tablet 5mg
215123042|NCT06273150|OTHER|Positive genetic test for pathological expansion in ATN1|Positive genetic test for pathological expansion in ATN1
215123043|NCT01809522|PROCEDURE|Posterior reconstruction of the rhabdosphincter|
215123044|NCT04869865|DIETARY_SUPPLEMENT|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
215123045|NCT03444493|OTHER|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
215123046|NCT00295191|PROCEDURE|high-flux membrane|high-flux dialyser
215123047|NCT00295191|PROCEDURE|low-flux membrane|low-flux dialyser
215123048|NCT00295191|PROCEDURE|conventional dialysate|conventional dialysate
215123049|NCT00295191|PROCEDURE|ultrapure dialysate|ultrapure dialysate
215123050|NCT01865760|DIETARY_SUPPLEMENT|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
215123051|NCT01865760|DIETARY_SUPPLEMENT|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
215123052|NCT01865760|DRUG|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
215123053|NCT05913830|OTHER|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
215123054|NCT00882232|DEVICE|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
215123055|NCT02817126|PROCEDURE|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
215123056|NCT02817126|PROCEDURE|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
215123057|NCT05888675|DRUG|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
215123058|NCT03656029|DRUG|Cannabis|Participants will smoke as much of the cigarette as they wish
215123059|NCT03656029|DRUG|Placebo|Participants will smoke a placebo cigarette
215123060|NCT00998465|OTHER|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
215123061|NCT00998465|OTHER|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
215123062|NCT00998465|OTHER|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
215123063|NCT00998465|RADIATION|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
215123064|NCT00998465|RADIATION|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
215123065|NCT00998465|RADIATION|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
215123066|NCT00998465|OTHER|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
215123067|NCT00998465|OTHER|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
215123068|NCT00998465|DIETARY_SUPPLEMENT|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
215123069|NCT04581265|DRUG|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
215123070|NCT03153514|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
215123071|NCT02506712|DEVICE|SmartDrive assisting device|oxygen consumption
215123072|NCT02506712|DEVICE|Standard manuel wheelchair|oxygen consumption
215123073|NCT03433963|DIETARY_SUPPLEMENT|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
215123074|NCT03433963|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
215123075|NCT00585117|PROCEDURE|PET-imaging with CuATSM|imaging with CuATSM
215123076|NCT00585117|PROCEDURE|PET Imaging|Imaging with CuATSM
215123077|NCT00585117|PROCEDURE|PET CuATSM|Imaging with CuATSM
215123078|NCT00585117|PROCEDURE|PET imaging|imaging with CuATSM
215123079|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
215123080|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
215123081|NCT02398305|DEVICE|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
215123082|NCT02398305|DEVICE|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
215123083|NCT00176774|DRUG|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
215123084|NCT00176774|DRUG|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
215123085|NCT00176774|DRUG|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
215123086|NCT00176774|DRUG|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
215123087|NCT00965081|DRUG|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
215123088|NCT00965081|DRUG|Placebo|QD po at the same time each day for 12 weeks
215123089|NCT00964496|DRUG|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
215123090|NCT00964496|DRUG|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
215123091|NCT02060435|OTHER|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
215123092|NCT00896766|GENETIC|loss of heterozygosity analysis|
215123093|NCT00896766|GENETIC|microarray analysis|
215123094|NCT00896766|GENETIC|polymorphism analysis|
215123095|NCT00896766|GENETIC|tumor replication error analysis|
215123096|NCT01263964|PROCEDURE|coronary angiogram|coronary angiogram
215123097|NCT00350571|BEHAVIORAL|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
215123098|NCT00350571|BEHAVIORAL|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
215123099|NCT00350571|BEHAVIORAL|standard care follow up|routine counselor phone calls and letters
215123100|NCT02497924|DRUG|GBT440|GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
215123101|NCT02736058|DEVICE|Trans- abdominal sonography|
215123102|NCT02736058|DEVICE|Trans-vaginal sonography|
215123103|NCT02736058|PROCEDURE|post-operative pathological specimen examination|
215123104|NCT02961959|PROCEDURE|Surgery|Arthrodesis of SI-joints, Physiotherapy
215123105|NCT02961959|OTHER|Non-surgery|Physiotherapy
215123106|NCT01246427|DRUG|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
215123107|NCT01246427|DRUG|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
215123108|NCT05665894|DEVICE|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
215123109|NCT03687788|BEHAVIORAL|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
215123110|NCT02727829|DEVICE|pefusion index measurement|perfusion index measurement using massimo radical 7 device
215123111|NCT02541812|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
215123112|NCT05555966|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
215123113|NCT02159066|DRUG|LGX818|Combination of LGX818 and MEK162 (Part I)
215123114|NCT02159066|DRUG|MEK162|Combination of LGX818 and MEK162 (Part I)
215123115|NCT02159066|DRUG|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
215123116|NCT02159066|DRUG|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
215123117|NCT02159066|DRUG|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
215123118|NCT02159066|DRUG|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
215123119|NCT01147666|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arms.
215123120|NCT01147666|DRUG|Epoetin Alfa|Epoetin Alfa will be administered per dose and schedule specified in the arms.
215123121|NCT01147666|OTHER|Placebo|Placebo matching to roxadustat will be administered per schedule specified in the arm.
215123122|NCT05878834|DIETARY_SUPPLEMENT|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
215123123|NCT05878834|DIETARY_SUPPLEMENT|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
215123124|NCT02750774|BEHAVIORAL|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
215123125|NCT02750774|OTHER|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
215123126|NCT05220878|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
215123127|NCT05220878|BIOLOGICAL|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
215123128|NCT00217932|DRUG|Divalproex Sodium (Depakote)|
215123129|NCT00462007|DRUG|Stalevo|Oral 3-4 daily doses for 6 weeks
215123130|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
215123131|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
215123132|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
214445906|NCT06790524|DEVICE|Two-piece dental implants|"Surgical and immediate loading procedures:~On the day of implant placement, patients will receive two-piece implant. After crestal incision and full-thickness flap elevation, the implant sites will be prepared aided by a surgical template. 4 implants will be placed, two aligned in an axial orientation and two will be distally aligned (17 degrees). The standard placement procedure as recommended by the manufacturer will be used. The surgical drills with increasing diameters will be used to prepare the implant sites. Implants will be ideally placed at bone level (or 1 mm deeper depending on the soft tissue thickness). After 3 months as a healing phase, a definitive prosthesis will be fabricated using the same abutments, and the marginal bone loss after the osseointegration phase will be assessed."
214445907|NCT06797817|DIETARY_SUPPLEMENT|tributyrin|Participants will receive 1 capsule per day for 12 weeks. Each capsule contains 450 mg of tributyrins. The capsules will have a gelatin coating. In the market, formulations are available with dosages ranging from 200 to 500 mg.
215123133|NCT05768100|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
215123134|NCT05768100|DIETARY_SUPPLEMENT|Placebo|Isovolumic placebo
215123135|NCT04266808|DEVICE|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
215123136|NCT04266808|BEHAVIORAL|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
215123137|NCT00130169|DRUG|E7974|Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
215123138|NCT01203735|DRUG|Valproic acid|800mg per day for entire period of RT
215123139|NCT02299726|DRUG|Spironolactone|
215123140|NCT02299726|OTHER|Placebo|Matching placebo
215123141|NCT01744249|DRUG|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
215123142|NCT01744249|DRUG|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
215123143|NCT01744249|DRUG|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
214445908|NCT06797817|OTHER|Placebo|The placebo will consist of potato starch encapsulated under identical conditions to those used for the tributyrin capsules, ensuring adequate blinding of the study.
214445909|NCT06794034|DEVICE|Intervention|taVNS 25Hz+routine treatment, three times daily, 30 mins
214445910|NCT06794034|DEVICE|Sham Comparator|taVNS 1Hz+routine treatment, three times daily, 30 mins
214445911|NCT04842643|BIOLOGICAL|IGSC 20% infusion|IGSC 20% infusion,
214522992|NCT02501876|OTHER|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
214522993|NCT02371278|DIETARY_SUPPLEMENT|Leucine|5 g leucine with sucrose and maltodextrin
214522994|NCT02371278|DIETARY_SUPPLEMENT|Placebo|5 g glycine with sucrose and maltodextrin
215123144|NCT05716061|PROCEDURE|Sacral ESPB|Cadaver study
215123145|NCT01630915|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
215123146|NCT01712126|DRUG|Irbesartan and Hydrochlorothiazide|
215123147|NCT01712126|DRUG|Avalide|
215123148|NCT00301626|BEHAVIORAL|smoking reduction intervention (including NRT)|
215123149|NCT01658007|DRUG|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
215123150|NCT03145740|OTHER|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
215123151|NCT03145740|OTHER|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
215123152|NCT06015386|OTHER|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
215123153|NCT06015386|OTHER|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
215123154|NCT02171507|DRUG|Dabigatran etexilate|
215123155|NCT02171507|DRUG|Diclofenac|
214445912|NCT06839482|DEVICE|Robotic Assisted Upper Limb Rehabilitation|"The EG will follow a mixed rehabilitation approach for the upper limb, combining Robotic Assisted Upper Limb Rehabilitation and conventional physical therapy (PT) and/or occupational therapy (OT) with a total daily duration of 90 minutes. The Robotic Assisted UL Rehabilitation's session will last 30 minutes, with the following procedure provided:~* First week: alternate between passive mobilization exercises, bilateral mode, and therapist-driven mode.~* Second week: alternate between therapist-driven mode and active-assisted mobilization.~* Third week: alternate between active-assisted mobilization and active mobilization.~* Fourth week: alternate between active-assisted mobilization and active mobilization.~* Fifth week: exclusively perform active mobilization. However, if this proposed progression does not match the patient's motor capabilities, the therapist will optimize the therapeutic program by selecting personalized exercises, following a progressive difficulty approach."
215123156|NCT00474955|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
215123157|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
215123158|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
215123159|NCT01135134|DRUG|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
215123160|NCT01135134|DRUG|Placebo|"MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
215123161|NCT00282139|DRUG|Aripiprazole|
215123162|NCT05490862|BEHAVIORAL|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
215123163|NCT05490862|BEHAVIORAL|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
215123164|NCT06018948|DRUG|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
215123165|NCT06018948|DRUG|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
215123166|NCT06018948|DRUG|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
215123167|NCT01496235|DIETARY_SUPPLEMENT|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
215123168|NCT01496235|DIETARY_SUPPLEMENT|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
215123169|NCT02255916|OTHER|Music|live sound-bed music intervention
215123170|NCT02174991|DRUG|Rho-Kinase Inhibitor (AR-12286)|
215123171|NCT04163029|PROCEDURE|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
215123172|NCT00631358|DRUG|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
215123173|NCT00631358|OTHER|No treatment|Healthy normal control group receiving no treatment
215123174|NCT04013607|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
215123175|NCT02289677|DEVICE|ATMOS Scope|Video-laryngoscopy 1
215123176|NCT02289677|DEVICE|COOPDECH|Video-laryngoscopy-1
215123177|NCT02289677|DEVICE|AirTraq|Optical-laryngoscopy
215123178|NCT00802516|DIETARY_SUPPLEMENT|stanol ester|enriched margarine
215123179|NCT00802516|DIETARY_SUPPLEMENT|sterol ester|enriched margarine
215123180|NCT00802516|DIETARY_SUPPLEMENT|No intervention|placebo margarine
215123181|NCT05646134|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
215123182|NCT05646134|DEVICE|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
215123183|NCT05951946|DRUG|BR3006-1|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
215123184|NCT05951946|DRUG|BR3006-2|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
214445913|NCT06839482|OTHER|Control Group (CG)|The CG will follow a conventional occupational therapy (OT) and physical therapy (PT) program for upper limb rehabilitation, with a total daily duration of 90 minutes. Upper limb rehabilitation exercises will be performed with a therapist who will tailor the treatment according to the patient's clinical characteristics and needs. Specifically, upper limb treatment will consist of motor exercises (shoulder, elbow, wrist, and hand) through a mix of individual sessions with both passive and active interventions where possible.
215123185|NCT05951946|DRUG|BR3006-3|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
215123186|NCT01915160|BEHAVIORAL|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
215123187|NCT01915160|BEHAVIORAL|TF-CBT|Treatment as usual.
215123188|NCT00407186|DRUG|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
214445914|NCT06791681|DRUG|ESO-T01|ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.
215123189|NCT00407186|RADIATION|radiotherapy|45 Gy in 25 fracions (5 days/week)
215123190|NCT00407186|DRUG|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
215123191|NCT00067184|DEVICE|Toitu 320/325|Fetal monitor
215123192|NCT05283551|DRUG|Famciclovir|Famciclovir (500mg BD)
215123193|NCT04692623|DRUG|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
215123194|NCT04692623|DRUG|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
214694275|NCT05943938|OTHER|Epic Sepsis Model Version - 1|The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
214694276|NCT05943938|OTHER|Epic Sepsis Model Version - 2|The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
214445915|NCT02226341|DRUG|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
214694277|NCT05943938|OTHER|Emory Sepsis Model|Emory internal algorithm
214694278|NCT06854627|PROCEDURE|Daily prone position sessions|Prone position sessions will be extended at least 16 hours, but no longer than 24 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
215123195|NCT06376630|DRUG|Esmolol Hcl 10Mg/Ml Inj|"the loading dose of 500 mkg/kg for 1 minute, followed by the initial rate of 50 mkg/kg/min. Individual titration depending on the desired hemodynamical effect (to the heart rate of 60 bpm or to the maximum tolerated dose maintaining stable hemodynamics) every 5-15 minutes (the maximum allowed rate of administration is 300 mkg/kg/min) for 6 hours.~Thereafter patients in both treatment arms - the IV esmolol arm and the placebo arm, will be administered oral β-adrenergic blockers, if decided so by the treating physician and unless contraindicated."
215123196|NCT03334032|OTHER|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
215123197|NCT02037139|OTHER|Screening|Standard care screening
215123198|NCT02037139|OTHER|Brochure|Participants are given an illustrated educational brochure
215123199|NCT02037139|BEHAVIORAL|Education|Participants undergo a in-person educational intervention
215123200|NCT00614679|DRUG|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
215123201|NCT01083823|OTHER|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
215123202|NCT02610582|DRUG|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
215123203|NCT02668458|PROCEDURE|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
215123204|NCT02668458|PROCEDURE|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
215123205|NCT02254473|OTHER|Wedge Insert|
215123206|NCT02254473|OTHER|Flat Insert|
214445916|NCT02226341|DRUG|ACTHar gel|"Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response."
214445917|NCT06179901|PROCEDURE|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
214445918|NCT06179901|PROCEDURE|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
214522995|NCT04081818|OTHER|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
214522996|NCT05910359|DIAGNOSTIC_TEST|Ultrasound|transabdominal and transperineal ultrasound by expert sonographers
214522997|NCT00991133|DRUG|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
214522998|NCT01154699|DEVICE|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
214522999|NCT01154699|OTHER|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
215123207|NCT00256724|DEVICE|Impedance Threshold Device|Active impedance threshold device
215123208|NCT00256724|DEVICE|sham ITD|sham impedance threshold device
214523000|NCT01154699|OTHER|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
215123209|NCT03955614|OTHER|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
215123210|NCT03955614|OTHER|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
215123211|NCT03955614|OTHER|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
215123212|NCT03159559|DRUG|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
215123213|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
215123214|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
215123215|NCT02241564|OTHER|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
215123216|NCT02241564|DRUG|Switch from calcineurin inhibitor to an mTOR inhibitor|
215123217|NCT05724992|GENETIC|Saliva swab testing|41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
215123218|NCT03725631|DIAGNOSTIC_TEST|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
215123219|NCT06192849|DRUG|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
215123220|NCT01685775|PROCEDURE|Transvaginal/transumbilical|
215123221|NCT01685775|PROCEDURE|Needlescopic with 3 trocars|
215123222|NCT04262726|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
215123223|NCT04262726|BEHAVIORAL|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
215123224|NCT02956343|DEVICE|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
215123225|NCT01908686|BEHAVIORAL|Pivotal Response Training|Behavioral intervention for autism
215123226|NCT00706446|DRUG|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
215123227|NCT00706446|DRUG|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
215123228|NCT00706446|DRUG|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
215123229|NCT00706446|DRUG|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
215123230|NCT00706446|DRUG|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
214445919|NCT06794281|OTHER|Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result|"O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result.~O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care.~O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation.~O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs.~O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices."
215123231|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
215123232|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
215123233|NCT04004910|DRUG|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
215123234|NCT01569841|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
215123235|NCT01569841|DRUG|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
214445920|NCT06796010|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214445921|NCT06796010|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
214445922|NCT06796881|OTHER|Instrument assisted soft tissue mobilization|The group will undergo Instrument assisted soft tissue mobilization using M2Tblade, applying it for 40-120 seconds until hyperemia occurs. After treatment, ice packs will be applied for 5 minutes to reduce hyperemia. The therapist will ensure comfort through continuous communication and reporting any discomfort.
214445923|NCT06796881|OTHER|Myofascial release|The therapist will use a cross-hand release technique to release the lumbar spine, ensuring the patient is prone and suitable. They will lean into the patient to the tissue depth barrier, wait, and follow each release, avoiding force or slipping. The technique will be applied for 5 minutes on each side.
214445924|NCT06796881|OTHER|The conventional exercise program|Patients will undergo a 12-session exercise program for 6 weeks, consisting of straight leg raising, bridging exercise, prone hip extension exercise, and abdominal curl exercise. The exercises will be done 3 sets, 10 repetitions each, with 1 minute rest between each set. The abdominal curl exercises involve supine or hook-lying positions with the lumbar spine neutral, with the patient performing a drawing in maneuver to stabilize the abdominal muscles. The progression involves lifting the shoulders, changing arm positions, and holding a weight or medicine ball. The patient's position is hook-lying, maintaining a neutral spinal position.
214445925|NCT02122562|DRUG|Ketamine|Treatment
214445926|NCT06796621|BEHAVIORAL|Building Respectful Online Space (BROS)|Session 1 (40 minutes to 50 minutes): Respectful online relationship (Psychoeducation) using face-to-face approach with 40 minutes to 50 minutes online serious game Session 2 (40 minutes to 50 minutes): Navigating the online world (Psychoeducation) using face-to-face approach with 20 to 30 minutes online music therapy Session 3 (40 minutes to 50 minutes): Behaviour specific cognitions and reflection using face-to-face approach
214445927|NCT06796621|BEHAVIORAL|Healthy diet education program|Session 1 (40 - 50 minutes): Healthy Diet Pyramid (Psychoeducation) using face-to-face approach Session 2 (40 - 50 minutes): Mindful Eating and Healthy Weight Management (Psychoeducation) using face-to-face approach Session 3 (40 - 50 minutes): Healthy Eating Habits for Life (Psychoeducation)using face-to-face approach
214445928|NCT06792890|OTHER|Use Nabla AI Scribe tool provided|"AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.~Nabla leverages its proprietary speech-to-text to transform the conversation into a written context, combined with HIPAA compliant Large Language Models (LLM) like Azure OpenAI's GPT-4. Nabla does not store any audio."
214445929|NCT06792890|OTHER|Use AI Scribe tool provided by Vendor B|AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.
214445930|NCT06792864|DEVICE|OsteoprintCR|Hybrid technique of 3D printed bone matrix based on polycaprolactone with tricalcium beta phosphate
214445931|NCT06792864|DEVICE|SMAR SET GMV Endurance Gentamicin|"Patient undergoing cranioplasty with conventional technique using polymethylmethylmethacrylate-based surgical cement brand SMAR SET GMV Endurance Gentamicin."
214445932|NCT06796179|OTHER|Visible Light Exposure - Treated zones with sunscreen products|The treated zones with sunscreen products were exposed to Visible Light to induce skin pigmentation (144 J/cm²), 15 to 30 minutes after application.
214523001|NCT00559195|BIOLOGICAL|epoetin beta|
214523002|NCT00559195|PROCEDURE|quality-of-life assessment|
214523003|NCT00083122|DRUG|cisplatin|Given IV
214523004|NCT00083122|DRUG|alvocidib|Given IV
214523005|NCT00083122|DRUG|cisplatin/flavopiridol|Given IV
214523006|NCT00642499|DRUG|Dronabinol|2.5 mg to 40 mg
214523007|NCT00642499|DRUG|Placebo|placebo
214523008|NCT00449917|DRUG|lutein|
214523009|NCT00449917|DRUG|DHA|
214523010|NCT00449917|DRUG|vitamins|
215123236|NCT04821258|DIETARY_SUPPLEMENT|MICODIGEST 2.0 supplement|MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes
215123237|NCT04821258|DIETARY_SUPPLEMENT|Placebo supplement|Placebo
215123238|NCT00876161|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
215123239|NCT00876161|DRUG|Lactose|
215123240|NCT02327676|DRUG|Emtricitabine|emtricitabine were given to each patients for 48 weeks
215123241|NCT05783206|DRUG|MIR 19 ®|"MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs."
215123242|NCT05783206|COMBINATION_PRODUCT|Standard therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
215123243|NCT00172211|DRUG|Physioneal|
215123244|NCT05010096|DRUG|Copanlisib|Given IV
215123245|NCT05010096|DRUG|Elimusertib|Given PO
215123246|NCT03728543|DRUG|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
215123247|NCT02907762|DEVICE|Endovascular aneurysm repair EVAR|
215123248|NCT02041481|DRUG|MEK inhibitor MEK162|Given PO
215123249|NCT02041481|DRUG|leucovorin calcium|Given IV
215123250|NCT02041481|DRUG|fluorouracil|Given IV
215123251|NCT02041481|DRUG|oxaliplatin|Given IV
215123252|NCT02041481|OTHER|pharmacological study|Correlative studies
215123253|NCT02041481|OTHER|Laboratory Biomarker Analysis|Correlative Studies
215123254|NCT02539641|RADIATION|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
215123255|NCT02539641|OTHER|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
215123256|NCT00644046|BEHAVIORAL|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
215123257|NCT01859923|DRUG|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
215123258|NCT01859923|DRUG|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
215123259|NCT01859923|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
215123260|NCT03148613|DEVICE|Carbon Monoxide Breath Sensor System (COBSS)|Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
215123261|NCT03148613|DEVICE|Bedfont - Micro+™ Smokerlyzer®|Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
215123262|NCT03544021|BIOLOGICAL|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
215123263|NCT00429949|DRUG|Dasatinib|
215123264|NCT03787186|DRUG|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
215123265|NCT03787186|DRUG|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1690
215123266|NCT03787186|DRUG|[14C]-GLPG1690 capsules|single oral dose of \[14C\]-GLPG1690
215123267|NCT04474678|OTHER|"My Logbook! - I know my way around!"|"Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment."
215123268|NCT04479826|DEVICE|Advanced hybrid closed loop system|Free living follow-up of meal handelling
215123269|NCT04486534|OTHER|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
215123270|NCT00764361|DRUG|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
215123271|NCT00764361|DRUG|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
215123272|NCT00547651|DRUG|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
215123273|NCT00547651|DRUG|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
215123274|NCT05238389|DEVICE|AI-based upper limb robotic therapy|"Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years)."
214708584|NCT03203889|BEHAVIORAL|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
215123275|NCT02090426|OTHER|Link2Care|
215123276|NCT03393234|RADIATION|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
215123277|NCT02462148|DRUG|Dexamethasone|Used in nerve block mixture
215123278|NCT02462148|DRUG|Bupivacaine|Used in nerve block mixture
215123279|NCT02462148|DRUG|Epinephrine|Used in nerve block mixture
215123280|NCT02462148|PROCEDURE|Saphenous Peripheral Nerve Block|Peripheral nerve block.
215123281|NCT03471273|PROCEDURE|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
215123282|NCT05923814|DRUG|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
215123283|NCT03572452|BEHAVIORAL|McKenzie Method|Treatment according to the Mechanical Diagnosis and Therapy Approach
215123284|NCT03572452|BEHAVIORAL|Advice to saty active|Physiotherapy councelling advicing to stay normally active
215123285|NCT00106314|DRUG|Dehydroepiandrosterone [DHEA]|
215123286|NCT04521322|DRUG|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
215123287|NCT02456155|PROCEDURE|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
215123288|NCT02456155|PROCEDURE|placing nasal jejunal tube endoscopically|
215123289|NCT04143867|DEVICE|Nolix Device|For temporary management of SUI
215123290|NCT03882892|DRUG|Ezetimibe|Ezetimibe 10 mg tablets
215123291|NCT03882892|DRUG|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
214445933|NCT06796179|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
215123292|NCT03882892|DRUG|Placebo|Placebo tablets matched to ezetimibe
215123293|NCT04503746|DRUG|ALH-L1005 600mg/day|ALH-L1005 300mg 2 tablet and placebo 2 tablet
215123294|NCT04503746|DRUG|ALH-L1005 1,200mg/day|ALH-L1005 300mg 4 tablet
214445934|NCT06832072|OTHER|MR-BLS|In MR group, students attended a 32 minutes course, in groups of four students with one teacher. The course included 22 minutes of individual MR training using headset (HTC Vive Focus 3®) and 10 minutes of debriefing. The individual MR training contained a step-by-step BLS reminder, including chest compression practice. Then, students engaged in a standardized virtual scenario where they interacted with both virtual characters and a physical manikin torso. The headset overlaid digital elements onto the real world, allowing the students to perform BLS while receiving real-time feedback. The feedback system provided visual cues indicating whether their chest compression rate and depth were correct. The teacher-to-student ratio was 1:4
214445935|NCT06839404|DRUG|fluid challenge|Fluid bolus of 500 mL of crystalloids given at a constant rate between 10 and 15 minutes
215123295|NCT04503746|DRUG|Placebo|Placebo 4 tablet
215123296|NCT02719496|DRUG|IBEROGAST|
215123297|NCT05771649|BEHAVIORAL|Mindfulness-based intervention|A mindfulness instructor will guide focused attention meditations that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
215123298|NCT05771649|BEHAVIORAL|Physical exercise|An instructor will guide to running with mental association strategies that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
215123299|NCT06457061|OTHER|Survey Study|"Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers."
215123300|NCT05201508|PROCEDURE|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
215123301|NCT05201508|PROCEDURE|Sutures only|Traditional hiatal closure with non-absorbable sutures.
215123302|NCT03986996|DRUG|amoxicillin, metronidazole and doxycycline|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
215123303|NCT03986996|DRUG|amoxicillin and doxycyclin|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
215123304|NCT01952132|DRUG|OMS643762|
215123305|NCT01952132|DRUG|Placebo|
215123306|NCT01141712|PROCEDURE|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
215123307|NCT01141712|DRUG|BCNU|Participants will receive BCNU 300 mg/m\^2 Day -6
215123308|NCT01141712|DRUG|Etoposide|Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
215123309|NCT01141712|DRUG|Cytarabine|Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
215123310|NCT01141712|DRUG|Melphalan|Participants will receive Melphalan 140 mg/m\^2 Day -1
215123311|NCT01308736|DRUG|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
215123312|NCT01308736|DRUG|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
215123313|NCT03634085|DRUG|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
215123314|NCT06409910|RADIATION|Radiotherapy|Non-institutional-standard radiotherapy
215123315|NCT05698680|DRUG|Prednisolone 30 mg Tablet|"See treatment arm Prednisolone"
215123316|NCT05698680|DRUG|Colchicine 0.5 mg Oral Tablet|"See treatment arm Colchicine"
215123317|NCT03841422|PROCEDURE|video-assisted nasal self-packing|video-assisted nasal self-packing
215123318|NCT06161597|BEHAVIORAL|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
215123319|NCT03269149|OTHER|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
215123320|NCT03269149|BEHAVIORAL|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
214445936|NCT06794242|OTHER|Body representation|All the participants (controls and patients) in the study will follow the same experimental procedure, which consists of a single virtual reality session involving the estimation of leg length and an object.
215123321|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
215123322|NCT06138548|DEVICE|Ossiofiber® Trimmable Fixation Nail|OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*
215123323|NCT06386523|DIAGNOSTIC_TEST|Passage of olfactory tests|test TODA2 and Sniffin Stick Test
215123324|NCT04458909|DRUG|Carboplatin|Given IV
215123325|NCT04458909|DRUG|Cisplatin|Given IV
215123326|NCT04458909|DRUG|Gemcitabine|Given IV
215123327|NCT04458909|BIOLOGICAL|Nivolumab|Given IV
215123328|NCT04458909|OTHER|Questionnaire Administration|Ancillary studies
215123329|NCT03246789|BEHAVIORAL|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
214445937|NCT03749421|OTHER|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
214445938|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs alone (20 g of protein equivalent)|cGMP-AAs alone (20 g of protein equivalent)
214708585|NCT03203889|BEHAVIORAL|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
214445939|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
214708586|NCT02415439|DRUG|VBP15|
214708587|NCT02415439|DRUG|Placebo|
215123330|NCT03246789|BEHAVIORAL|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
215123331|NCT05258136|DRUG|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
215123332|NCT01867736|DEVICE|Passeo-18 Lux DRB|
215123333|NCT01867736|DEVICE|Standard PTA (POBA)|
215123334|NCT01175863|DEVICE|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
215123335|NCT01175863|DEVICE|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
215123336|NCT05754294|DIAGNOSTIC_TEST|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
215123337|NCT04561895|GENETIC|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
214694279|NCT06854627|PROCEDURE|Prolonged prone position sessions|Prone position sessions will be extended at least 48 hours AND until PaO2/FiO2 ratio is ≥ 200, but no longer than 120 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
215123338|NCT02055326|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
215123339|NCT02055326|BEHAVIORAL|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
215123340|NCT02055326|BEHAVIORAL|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
215123341|NCT05369663|DEVICE|mask use|face mask use
215123342|NCT00296816|DRUG|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
215123343|NCT00296816|DRUG|Docetaxel (Taxotere®)|75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
215123344|NCT00296816|DRUG|Oxaliplatin (Eloxatin®)|85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
215123345|NCT01889875|DRUG|"ALK Grazax 75,000 SQ-T Phleum pratense"|
215123346|NCT01889875|DRUG|"ALK AluTard 225 Phleum pratense"|
215123347|NCT01556451|BIOLOGICAL|Zoster Vaccine Live|Zoster vaccine live
215123348|NCT06420947|OTHER|atomizer|Participants received 2% lidocaine by atomizer.
215123349|NCT02624440|DRUG|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
215123350|NCT02624440|DRUG|Clarithromycin|P.o. clarithromycin 250 mg twice daily
214445940|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
214445941|NCT06794385|DRUG|dinoprostone vaginal delivery system|Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
214445942|NCT06794385|DRUG|low dose peroral misoprostol|Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours
214445943|NCT06813716|OTHER|Neoprene elastic knee sleeve|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
214445944|NCT06813716|OTHER|Neoprene elastic knee sleeve with metal supports|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
214445945|NCT06839716|PROCEDURE|Arm I (Ropivacaine-Poloxamer 407 hydrogel group)|Patients receive intraoperative application of Ropivacaine-Poloxamer 407 hydrogel at the incision site. A mixture of 0.75% Ropivacaine (22.5 mg, 3 mL) and Poloxamer 407-based gel (Welpass, 6 mL) is prepared. The hydrogel is applied as 4 mL between the peritoneum and fascia, and 2 mL is injected subcutaneously around the incision before skin closure. This intervention aims to provide sustained local anesthesia for up to 72 hours.
215123351|NCT02624440|DRUG|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
215123352|NCT02624440|DRUG|Observation|Observation without prophylactic antibiotic
215123353|NCT02152709|BIOLOGICAL|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
215123354|NCT02152709|BIOLOGICAL|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
215123355|NCT03030001|BIOLOGICAL|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
215123356|NCT00945282|DRUG|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
215123357|NCT00945282|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
215123358|NCT00945282|DRUG|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
215123359|NCT00945282|DRUG|Placebo|Placebo is a capsule with no drug in it.
215123360|NCT00945282|DRUG|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
215123361|NCT03494920|OTHER|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
215123362|NCT03494920|OTHER|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
215123363|NCT00941408|PROCEDURE|Diagnostic tumor core biopsy|
215123364|NCT00808093|DRUG|GSK256073|GSK256073 100 mg study drug
215123365|NCT00854230|DRUG|Naltrexone|Naltrexone dose 25-100mg
215123366|NCT02018081|DRUG|Levofloxacin|8 blood sampling by patients between the 48th and 60th
215123367|NCT03694717|DRUG|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
215123368|NCT02744365|OTHER|Observational|"All women of the biobank have provided:~1. blood samples (plasma, serum and Buffy-coat)~2. urine samples~3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~4. mean arterial blood pressure~5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
215123369|NCT01729299|DRUG|Exendin (9-39)|
215123370|NCT01729299|DRUG|acyl ghrelin|
215123371|NCT01729299|DRUG|saline|
215123372|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
215123373|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
215123374|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
215123375|NCT05364463|PROCEDURE|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
215123376|NCT02486536|DRUG|polyethylene glycol|
215123377|NCT02486536|DEVICE|capsule endoscopy|
215123378|NCT04872192|OTHER|transversus thoracic muscle plane block|transversus thoracic muscle plane block by injection of 15 ml of bupivacaine 0.25% on each side combined with general anaesthesia
215123379|NCT04872192|OTHER|general anaesthesia|transversus thoracic muscle plane block by injection of 15 ml of saline on each side combined with general anaesthesia
215123380|NCT05064371|DRUG|Eptinezumab|Concentrate for solution for IV infusion
215123381|NCT00423839|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
215123382|NCT01410513|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
215123383|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
215123384|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
215123385|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
215123386|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
215123387|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
215123388|NCT01594320|BIOLOGICAL|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 \& Day 21
215123389|NCT01153737|OTHER|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
215123390|NCT01153737|OTHER|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
215123391|NCT02345473|GENETIC|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
215123392|NCT00509470|DRUG|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
215123393|NCT00509470|DEVICE|Amlodipine|
215123394|NCT05944406|OTHER|Educational training of ER Nurses|educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
215123395|NCT03101566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV
215123396|NCT03101566|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV
215123397|NCT03101566|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV
215123398|NCT03101566|DRUG|Nivolumab|Nivolumab 360 mg or 240 mg IV
215123399|NCT00985465|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
215123400|NCT04390126|OTHER|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
215123401|NCT04390126|OTHER|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
215123402|NCT05922189|OTHER|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
215123403|NCT05922189|OTHER|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
215123404|NCT04648813|DRUG|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
215123405|NCT04648813|DRUG|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
215123406|NCT05775016|BEHAVIORAL|Exercise|12 week resistance and cardiovascular exercise program
214445946|NCT06839716|PROCEDURE|Arm II (TAP block group)|"Patients undergo ultrasound-guided subcostal transversus abdominis plane (TAP) block before anesthesia emergence. A total of 30 mL of 0.375% Ropivacaine (15 mL per side) is injected bilaterally between the internal oblique and transversus abdominis muscles. TAP block is a regional anesthesia technique known for effective postoperative pain control, typically lasting 24 to 48 hours.~Both groups receive standardized postoperative analgesia, including IV acetaminophen, fentanyl via patient-controlled analgesia (PCA), and rescue pethidine as needed."
215123407|NCT02397304|OTHER|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
215123408|NCT04703426|DRUG|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
214445947|NCT04189445|DRUG|Futibatinib|Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle
215123409|NCT04703426|DRUG|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
215123410|NCT02150278|BEHAVIORAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
215123411|NCT05375591|OTHER|Non-Interventional Study|First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
215123412|NCT00986843|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
215123413|NCT05373446|DRUG|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
215123414|NCT05373446|DRUG|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
215123415|NCT05373446|DRUG|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
214708588|NCT04557254|DEVICE|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
214445948|NCT06839417|BEHAVIORAL|Exercise|using squash exercise
214708589|NCT01917110|DEVICE|omafilcon A|
214708590|NCT01917110|DEVICE|Spectacle|
214708591|NCT05912920|PROCEDURE|gastric band|gastric band
214445949|NCT06839508|OTHER|Radio chemotherapy|The task involves identifying similarities in biopsy samples (prior to radio-chemotherapy treatment) to predict a hypothetical complete response.
215123416|NCT02564458|BEHAVIORAL|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
215123417|NCT01897363|OTHER|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
215123418|NCT00828230|DRUG|budesonide|One application of 2mg budesonide once daily for 8 weeks
215123419|NCT00828230|DRUG|Placebo foam|One application of placebo foam once daily for 8 weeks
215123420|NCT05441631|DRUG|Insulin|"* Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)"
215123421|NCT05441631|DRUG|Subcutaneous Insulin|"* Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine"
215123422|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
215123423|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
215123424|NCT00756431|DEVICE|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
215123425|NCT00756431|DEVICE|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
215123426|NCT00314743|DRUG|Ondansetron|
215123427|NCT00314743|DRUG|Dexamethasone|
215123428|NCT00314743|DRUG|Aprepitant|
215123429|NCT04701333|DRUG|Cabergoline 1 MG|Dopamine agonist
215123430|NCT04701333|DRUG|Placebo|Placebo
215123431|NCT01012258|BIOLOGICAL|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
215123432|NCT05266612|DRUG|VG2025|"1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15"
215123433|NCT05266612|DRUG|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
215123434|NCT03457376|DIAGNOSTIC_TEST|Hand Grip Force|Hand Grip Force
215123435|NCT03457376|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
215123436|NCT03457376|DIAGNOSTIC_TEST|Maximal Expiratory Pressure|Maximal Expiratory Pressure
215123437|NCT03865082|DRUG|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
214445950|NCT06837623|DRUG|Colchicine Tablets|"Oral colchicine tablets. The dosing regimen is as follows:~* Patients weighing \>70 kg: 0.5 mg twice daily (BID)~* Patients weighing ≤70 kg: 0.5 mg once daily (OD) Administered for 3 months"
215123438|NCT03865082|DRUG|Nivolumab|Specified dose on specified days.
215123439|NCT03865082|DRUG|Ipilimumab|Specified dose on specified days.
215123440|NCT00962637|DRUG|Androxal|12.5 mg once daily
215123441|NCT00962637|DRUG|Androxal|25 mg once daily
215123442|NCT00962637|DRUG|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
215123443|NCT00962637|DRUG|Placebo|1 capsule daily
215123444|NCT01749969|DRUG|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
215123445|NCT01749969|DRUG|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
214445951|NCT06796478|OTHER|Tailored Egoscue Excercises|A. Elbow curls on the wall with abduction B. Elbow curls on the wall with adduction C. Overhead extension D. Open Up arm and chest E. Upper spinal twist. F. Spinal Twist G. Pelvic tilts H. Static back alone and static back with breathing I. Static wall. J. Air Bench Abdominal contraction in the static back position. K. Resisted Abduction L. Abductor press M. Supine groin progression
214445952|NCT06796478|OTHER|Core stabilization excercises|A. Cat Pose \& Camel pose B. Pelvic tilt C. Hip flexor stretches D. Hamstring stretches E. Piriformis stretch F. Prone on elbow
214708592|NCT02102984|DEVICE|covered biliary stents|endoscopic placement of covered biliary stents
215123446|NCT01749969|DRUG|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
214708593|NCT02102984|DEVICE|uncovered biliary stents|endoscopic placement of uncovered biliary stents
214445953|NCT06797661|DIAGNOSTIC_TEST|Functional MRI|"11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2).~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
215123447|NCT03062020|DEVICE|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
215123448|NCT03921034|DRUG|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
215123449|NCT03921034|DRUG|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
215123450|NCT03742973|DRUG|Baricitinib|Administered orally.
215123451|NCT03742973|DRUG|Placebo|Administered orally.
215123452|NCT02996630|PROCEDURE|Sonography|Fetal Ultrasound exploration
215123453|NCT02996630|DEVICE|Magnetic Resonance Imaging|Fetal MRI for brain study
215123454|NCT02996630|OTHER|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
215123455|NCT02996630|PROCEDURE|Surgical intervention|Congenital Heart Disease repair
215123456|NCT02996630|PROCEDURE|Brain monitoring|EEG and continuous brain oximetry before surgery.
215123457|NCT02996630|PROCEDURE|cord blood sample|Cord blood samples will be taken after birth in both groups.
215123458|NCT06423469|DEVICE|Noninvasive ICP monitoring|The brain4care system is a FDA approved noninvasive device for surrogate intracranial pressure monitoring. Serial monitoring sessions were performed in included patients. Information recorded was for study purposes only and did not affect any therapy planned for the attending teams.
215123459|NCT02109640|DRUG|Targinact|Post-operative analgesia
215123460|NCT02109640|DRUG|Oxycodone|Postoperative analgesia
215123461|NCT02109640|PROCEDURE|Laparoscopic segmental colectomy|
215123462|NCT03980249|DRUG|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
215123463|NCT03155126|OTHER|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
214445954|NCT06797661|DIAGNOSTIC_TEST|FDG-PET|"Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg.~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
214445955|NCT06797661|DIAGNOSTIC_TEST|Structural MRI|"Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight .~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
214523011|NCT03949699|OTHER|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
214523012|NCT04988958|PROCEDURE|hydatid cyst resection|radical resection of hydatic cyst
214708594|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
215123464|NCT02230566|DRUG|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
215123465|NCT02230566|OTHER|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
215123466|NCT03061357|BEHAVIORAL|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
215123467|NCT03563820|BEHAVIORAL|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
215123468|NCT04361734|OTHER|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
215123469|NCT03507036|DEVICE|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
215123470|NCT04283305|OTHER|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
215123471|NCT04283305|OTHER|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
215123472|NCT03746626|BEHAVIORAL|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
215123473|NCT06461663|DEVICE|Breast Cancer Locator Guided Breast Conserving Surgery|Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
215123474|NCT02749539|DEVICE|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
215123475|NCT02749539|PROCEDURE|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
215123476|NCT04731389|BEHAVIORAL|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
215123477|NCT04731389|BEHAVIORAL|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
215123478|NCT00230646|BEHAVIORAL|Exercise counseling|
215123479|NCT00580723|OTHER|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
215123480|NCT03223402|OTHER|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
215123481|NCT06350188|OTHER|experimental|15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month
215123482|NCT06350188|OTHER|traditional|15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
215123483|NCT03258307|OTHER|Preoperative level|Blood sample
215123484|NCT00148759|DRUG|LPV/r|LPV/r 800/200 mg once daily
215123485|NCT03776695|BIOLOGICAL|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
215123486|NCT03776695|OTHER|Placebo|0.9% Saline
215123487|NCT01454596|BIOLOGICAL|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
215123488|NCT01454596|DRUG|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
215123489|NCT01454596|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
215123490|NCT01454596|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
215123491|NCT06023940|DIETARY_SUPPLEMENT|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
214523013|NCT02951416|OTHER|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
215123492|NCT04735874|OTHER|Evaluate vascular disease risk factors in children with Down Syndrome|We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw \[lipid panel with subfractions (NMR), insulin, glucose, and CRP\].
215123493|NCT04735874|OTHER|Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome|We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
215123494|NCT04221724|OTHER|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
215123495|NCT05035758|OTHER|Transcendental Meditation|"In the beginning, the patients from group B will receive an introductory lecture about transcendental meditation (TM) which includes general information, the procedure itself and other techniques of relaxation and personal development.~In this first session the method is learned by practice, in the following 3 meetings additional instructions are given about the correct practice of the TM technique; TM is practiced twice a day for 20 minutes. The method is easy to learn and effortless. To guarantee the right performance of TM by the patients, there will be two group meetings per week and one individual personal meeting with the TM teacher.After discharge from the rehabilitation program (after 4 weeks) there will be meetings offered according to the patients need. This will then be arranged individually."
215123496|NCT05035758|OTHER|Yoga|"In addition to the standard rehabilitation exercise training, the patients in this group will receive a 20-minute workshop where they learn how to do the yoga exercise. The initial yoga workshop will be held by Dr. Gilda Wüst who is a yoga expert with a lot of experience based in St. Radegund.~After this, yoga sessions will be included (additionally to the regular/standard exercise) into their daily timetable. Two yoga sessions will be done every day, one in the morning (6:30-6:50) and one in the evening (16:30-16:50) and will last for about 20 minutes."
215123497|NCT04924335|PROCEDURE|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
215123498|NCT02426515|DEVICE|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
215123499|NCT00240058|DRUG|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
215123500|NCT00857285|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
215123501|NCT00857285|DRUG|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
215123502|NCT02376764|PROCEDURE|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
215123503|NCT03154385|DRUG|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
215123504|NCT05716074|OTHER|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
215123505|NCT05716074|OTHER|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
215123506|NCT00895284|PROCEDURE|Robotic hysterectomy|Robotic hysterectomy.
215123507|NCT00895284|PROCEDURE|Standard Hysterectomy|Standard hysterectomy.
215123508|NCT06116734|DRUG|Grastofil®|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
215123509|NCT06116734|DRUG|Lapelga|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
215123510|NCT02483806|PROCEDURE|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0-\>5-\>10, 0-\>10-\>5, 5-\>10-\>0, 5-\>0-\>10, 10-\>5-\>0, 10-\>0-\>5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
215123511|NCT02573766|PROCEDURE|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
215123512|NCT02573766|PROCEDURE|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
215123513|NCT02573766|BEHAVIORAL|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
215123514|NCT02573766|BEHAVIORAL|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
215123515|NCT04532034|BEHAVIORAL|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
215123516|NCT01987102|DRUG|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
215123517|NCT01987102|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
215123518|NCT00643968|DRUG|EFV+TDF|
215123519|NCT00643968|DRUG|EFV+3TC+TDF|
215123520|NCT00419731|DRUG|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
215123521|NCT00419731|DRUG|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
215123522|NCT06342817|BEHAVIORAL|online mindfulness based meditation program|Participants in the intervention group will attend 8 weekly online meetings lasting approximately 60 minutes each (generally structured in an initial 10 minutes for questions about the practices, 15-20 minutes of exposition on the central theme of the meeting, 5-10 minutes for class practice, 10-15 minutes for post-practice inquiry, 5 minutes for explanation of the week's informal practice and audios for daily practice). Audio in mp3 of the practice carried out at each meeting will be provided to maintain daily individual practice during the week. An online questionnaire related to weekly practices will also be left at the beginning of each meeting.
215123523|NCT00110500|GENETIC|hVEGF-A|
215123524|NCT03904121|PROCEDURE|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
215123525|NCT01236521|DRUG|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
215123526|NCT01236521|BEHAVIORAL|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
215123527|NCT05524779|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
215123528|NCT05730582|BEHAVIORAL|Parkland Diabetes Detection Program (PDDP) Screening Invitation|"The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days."
215123529|NCT06603558|DRUG|Atogepant|Oral Tablet
215123530|NCT05974098|OTHER|Observational study|This study intends to use correlation analysis and mediation analyses to assess the mediating effects of self-efficacy, coping, depression and anxiety on the quality of life of patients with paroxysmal atrial fibrillation.
215123531|NCT04947696|DIAGNOSTIC_TEST|Blood sampling|Blood sampling preoperatively and sequentially up to 30 days post op
215123532|NCT04232241|DRUG|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
215123533|NCT04183205|DIAGNOSTIC_TEST|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
215123534|NCT04183205|DRUG|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
215123535|NCT04183205|DRUG|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
214523014|NCT05219409|DRUG|Sitagliptin|The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
215123536|NCT06304207|COMBINATION_PRODUCT|Onsite Maintenance Exercise Training|Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.
215123537|NCT06304207|COMBINATION_PRODUCT|Telehealth Maintenance Exercise|Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
215123538|NCT06720857|DIAGNOSTIC_TEST|Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium|Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
215123539|NCT06725550|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
215123540|NCT06725550|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
215123541|NCT06725368|DRUG|PCC|"PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death."
215123542|NCT06756490|DRUG|HY-2003 (10 mg/ml), BELKYRA and placebo|Participants received HY-2003 (10 mg/ml), or BELKYRA, or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments.
215123543|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (5 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
215123544|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.
214445956|NCT04188327|PROCEDURE|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
215123545|NCT03492125|DRUG|MS-553|Oral, multiple dose levels
215123546|NCT03492125|DRUG|MS-553|Oral recommended phase 2 dose of MS-553
215123547|NCT03492125|DRUG|acalabrutinib|Oral
215123548|NCT03492125|DRUG|venetoclax|Oral
214445957|NCT04188327|PROCEDURE|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
214445958|NCT06014034|OTHER|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
214523015|NCT05219409|DEVICE|Professional CGM|The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
214523016|NCT04117256|DEVICE|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
214523017|NCT04117256|DEVICE|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
214523018|NCT00563433|DRUG|ofloxacin|400 mg twice a day for 14 days
214523019|NCT00563433|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
215123549|NCT03492125|DRUG|Rituximab|IV
215123550|NCT03492125|DRUG|obinutuzumab|IV
215123551|NCT02756572|DRUG|Cladribine|Given IV
215123552|NCT02756572|DRUG|Cyclosporine|Given PO
215123553|NCT02756572|DRUG|Cytarabine|Given IV
215123554|NCT02756572|BIOLOGICAL|Filgrastim|Given SC
215123555|NCT02756572|DRUG|Fludarabine Phosphate|
215123556|NCT02756572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
215123557|NCT02756572|OTHER|Laboratory Biomarker Analysis|Correlative studies
215123558|NCT02756572|DRUG|Melphalan|Given IV
215123559|NCT02756572|DRUG|Mitoxantrone Hydrochloride|Given IV
215123560|NCT02756572|DRUG|Mycophenolate Mofetil|Given PO
215123561|NCT02756572|OTHER|Questionnaire Administration|Ancillary studies
215123562|NCT02756572|DRUG|Sirolimus|Given PO
215123563|NCT02756572|RADIATION|Total-Body Irradiation|Undergo TBI
215123564|NCT02756572|DRUG|Melphalan Hydrochloride|Given IV
215123565|NCT06231979|DRUG|Dexmedetomidine|1 μg/kg Dexmedetomidine per side in erector spinae block
215123566|NCT06231979|DRUG|Bupivacain|18 mL of bupivacaine 0.25 % per side in erector spinae block
215123567|NCT06231979|DRUG|Normal saline|2 ml normal saline 0.9% per side in erector spinae block
215123568|NCT02404818|PROCEDURE|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
215123569|NCT02404818|PROCEDURE|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
214445959|NCT06839781|OTHER|Retirement education|This initiative is structured as a six-week training program designed to support individuals in adapting to the retirement process. By addressing various aspects of retirement, the program aims to ensure that participants transition into this phase of life in a well-prepared and informed manner. The first week will serve as an introduction, providing general information and initiating physical transition training. The second week will focus on health protection and development training. The third week will address social transition training. The fourth week will be dedicated to spiritual transition training. The fifth week will focus on financial transition training. The sixth and final week will bring together previously retired individuals and current participants. This program adopts a holistic approach, aiming to facilitate both the physical and psychosocial adaptation of individuals to the retirement process.
214445960|NCT06173310|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
214445961|NCT06322381|PROCEDURE|Reinsertion achilles tendon|Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.
214445962|NCT06322381|PROCEDURE|Zadek osteotomy|lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
214445963|NCT06791993|DRUG|Placebo Capsule|Participants will receive an inert placebo capsule that matches the probiotic capsule in size, shape, and color. The placebo will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
214445964|NCT06791993|DIETARY_SUPPLEMENT|Probiotic with Human Milk Oligosaccharides (HMO)|Participants will receive a dual-strain probiotic containing Human Milk Oligosaccharides (HMO) in capsule form. The probiotic will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
214445965|NCT06794398|DEVICE|V-CPR inside a room when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
214445966|NCT06794398|DEVICE|V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
214445967|NCT06795620|DRUG|Adipose tissue derived mesenchymal Stroma/stem Cells transplantation|Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
214523020|NCT01846988|DEVICE|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
214523021|NCT01237509|DEVICE|Hypo device|
214708595|NCT05901285|COMBINATION_PRODUCT|Nivolumab or pembrolizumab|VAX014 will be given in combination with Investigator's choice of nivolumab or pembrolizumab.
215123570|NCT02623621|DRUG|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
215123571|NCT05633888|DEVICE|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
215123572|NCT03009799|DRUG|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
215123573|NCT03009799|DRUG|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
215123574|NCT03628976|OTHER|tVNS|Intervention
215123575|NCT03628976|OTHER|Motor training|Same finger training for both arms
215123576|NCT03583970|DEVICE|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
215123577|NCT05235542|DRUG|AK104|IV infusion,Specified dose on specified days
215123578|NCT05235542|DRUG|AK117|IV infusion,Specified dose on specified days
215123579|NCT05235542|DRUG|Capecitabine tablets|Oral,Specified dose on specified days
215123580|NCT05235542|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
215123581|NCT05235542|DRUG|Cisplatin|IV infusion,Specified dose on specified days
215123582|NCT05235542|DRUG|Paclitaxel|IV infusion,Specified dose on specified days
215123583|NCT05235542|DRUG|Irinotecan|IV infusion,Specified dose on specified days
215123584|NCT05235542|DRUG|Docetaxel|IV infusion,Specified dose on specified days
214523022|NCT01441258|BEHAVIORAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
214523023|NCT01441258|BEHAVIORAL|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
214523024|NCT01441258|BEHAVIORAL|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
215123585|NCT05235542|DRUG|5-FU|IV infusion,Specified dose on specified days
215123586|NCT06288074|DIAGNOSTIC_TEST|Multi-omics tests|Biological sample collection for Multi-omics tests
214523025|NCT01843699|DRUG|Topiramate flexible dosage|
214523026|NCT01843699|DRUG|Placebo matching tablets|
215123587|NCT01612130|DRUG|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
215123588|NCT01612130|DRUG|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
215123589|NCT05858372|DIETARY_SUPPLEMENT|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
215123590|NCT05858372|OTHER|Placebo|Placebo
215123591|NCT02648568|BEHAVIORAL|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
215123592|NCT02648568|BEHAVIORAL|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
215123593|NCT04730856|DRUG|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
214445968|NCT06796569|DIAGNOSTIC_TEST|systemic immune inflammatory index|Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.
214445969|NCT06504342|DEVICE|Blue-blocking glasses|These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.
214445970|NCT06504342|BEHAVIORAL|Time-restricted eating|Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m
214445971|NCT06504342|DEVICE|Lightly tinted glasses|These lenses block shorter wavelengths of light, mainly ultraviolet light.
214445972|NCT00739648|DRUG|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
214445973|NCT00739648|DRUG|Placebo|same frequency as study drug using the same method of delivery
214445974|NCT03495297|PROCEDURE|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
214445975|NCT06792786|DIAGNOSTIC_TEST|ctDNA detection|"dynamically monitor the changes of ctDNA in patients with esophageal cancer Radiation: Radiotherapy 95% PTV50-50.4Gy/25-28fractions, 1.8-2Gy/1 fractions; 5 days a week; 6 weeks. Chemotherapy:weekly paclitaxel (50mg/m²) in combination with carboplatin (AUC=2) chemotherapy, a total of 4-5 cycles.~Other Names:~Intensity-modulated radiotherapy (IMRT) Drug: Toripalimab Toripalimab (240 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision~Other Names:~Immunotherapy ctDNA detection: The first tissue and blood ctDNA test (T0) before treatment is based on next generation sequencing (NGS) technology, and ctDNA test is based on tumor- prior analysis informed assays method. Blood ctDNA testing after chemoradiotherapy was performed every 3 months"
214445976|NCT05870995|DRUG|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
214523027|NCT01843699|BEHAVIORAL|4-session gambling cognitive restructuring|
214523028|NCT03875599|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
214523029|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
214523030|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
214523031|NCT03663699|BEHAVIORAL|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
214523032|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
215123594|NCT04340453|OTHER|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
215123595|NCT04340453|OTHER|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
215123596|NCT04340453|OTHER|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
215123597|NCT00475189|DRUG|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
215123598|NCT00475189|DRUG|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
215123599|NCT00788788|DRUG|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
215123600|NCT04057521|OTHER|Care Coordination|Comprehensive care coordination.
215123601|NCT03928795|PROCEDURE|elective caesarean section|elective caesarean section
215123602|NCT02416154|PROCEDURE|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
215123603|NCT04368780|OTHER|Effect of Progressive Muscle Relaxation Combined With Music|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
215123604|NCT04277065|PROCEDURE|BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection|Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
215123605|NCT04277065|PROCEDURE|cotton tourniquet|cotton tourniquet
215123606|NCT04371965|DRUG|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
215123607|NCT03111303|DEVICE|mechanical ventilation|Connection to mechanical ventilator
215123608|NCT04154436|OTHER|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
215123609|NCT04154436|OTHER|Water (H2o)|Alkaline Solution
215123610|NCT03910504|DRUG|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.
215123611|NCT03910504|DRUG|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
215123612|NCT06182878|BEHAVIORAL|Tender loving care intervention|Receiving weekly prenatal care counseling messages
215123613|NCT00032669|DRUG|HAART|
215123614|NCT02582528|BEHAVIORAL|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
215123615|NCT02582528|BEHAVIORAL|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
214523033|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
214523034|NCT05746676|DRUG|Insulin|in treatment of periodontal defects
214523035|NCT05746676|DRUG|Hyaluronic acid|in treatment of periodontal defects
214523036|NCT01033097|DRUG|DNK333 5 mg|5 mg oral
215123616|NCT04921202|OTHER|Metabolic syndrome and meniscus injuries|Metabolic syndrome
215123617|NCT00051870|DEVICE|Magstim Rapid Magnetic Stimulator|
215123618|NCT03588663|DEVICE|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
215123619|NCT03588663|OTHER|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
215123620|NCT03588663|OTHER|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
215123621|NCT03588663|OTHER|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
215123622|NCT00058396|BIOLOGICAL|lumiliximab|
215123623|NCT04760756|OTHER|Fragility Fracture Integrated Rehabilitation Management|"* At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)"
215123624|NCT04519736|DEVICE|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
215123625|NCT02252146|DRUG|IMO-8400|MO-8400 given subcutaneously twice weekly
214445977|NCT06792201|DIAGNOSTIC_TEST|SARC-F, Handgrip test, Chair stand test|The SARC-F questionnaire is a simple to use questionnaire consisting of five questions about daily actions.To test the force will be used: Hand-grip test and Chair stand test. The tool used for the hand-grip test is the GRIP-A (Takei). The test is performed on the dominant limb and repeated three times. The position taken by the patient will be: sitting with shoulders and elbows flexed, forearms in neutral position. The Chair stand test measures the time it takes for a patient to get up five times from a sitting position without the help of her upper limbs. The test will be timed.The measurement of lean mass will be carried out by means of a bio impedance meter. This instrument does not measure muscle mass directly but estimates it based on the electrical conductivity of the whole body. Bioimpedance is a method that is easy and safe for the patient to use.
214445978|NCT06792604|DEVICE|Anal self-sampling (smear)|Anal self-sampling (smear) at M12, M24 and M36 (each year) for HPV16+ patients at M0 and anal self-sampling (smear) at M36 for HPV16- at M0
214445979|NCT06792604|BEHAVIORAL|HPV questionnaire|HPV questionnaire at each visit M0, M12, M24 and M36 for HPV16-positive patients at M0 and HPV questionnaire at each visit M0, 4 and M36 for HPV16-negative patients
214445980|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3|
214445981|NCT01728571|DIETARY_SUPPLEMENT|fish oil|
214445982|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
214445983|NCT01728571|DIETARY_SUPPLEMENT|Fish oil placebo|
214445984|NCT06794450|DRUG|Sugammadex 1 mg/kg|Patient in experimental arms will receive i.v. sugammadex 1 mg/kg at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
214445985|NCT06794450|DRUG|Neostigmine + Atropine|Patient in active comparators arms will receive i.v. neostigmine 60 mcg/kg along with 0.4 mg of atropine sulfate per 1 mg of neostigmine at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
214445986|NCT01757665|DEVICE|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
214445987|NCT06789549|DRUG|epinephrine nasal drops|Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
214523037|NCT01033097|DRUG|Placebo to 5 mg|5 mg placebo oral
214523038|NCT01033097|DRUG|DNK333 25 mg|25 mg oral
214523039|NCT01033097|DRUG|Placebo to 25 mg|25 mg placebo oral
214523040|NCT01033097|DRUG|DNK333 100 mg|100 mg oral
214523041|NCT01033097|DRUG|Placebo to 100 mg|100 mg placebo oral
215123626|NCT04034368|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
215123627|NCT00531284|DRUG|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
215123628|NCT00531284|DRUG|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
215123629|NCT00433641|DRUG|sibutramine|placebo
215123630|NCT00433641|DRUG|sibutramine|oral 15 mg sibutramine once per day
215123631|NCT00433641|DRUG|sibutramine|oral sibutramine 10 mg once per day
215123632|NCT05904158|BIOLOGICAL|Platelet-Rich Fibrin during Standard ACL reconstruction surgery|Plateleth-rich fibrin was obtained from patients own blood (40 cc) and applied to the tunnels which were drilled for ACL graft
214445988|NCT06789549|DRUG|oxymetazoline nasal drops|Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
214445989|NCT05333263|DEVICE|Treadmetrix|Programmable treadmill that delivers controlled postural disturbances
214445990|NCT05597176|OTHER|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
214523042|NCT01033097|DRUG|Betamethasone 4 mg|4 mg oral
214523043|NCT01033097|DRUG|DNK333 1mg|1 mg oral
214523044|NCT01033097|DRUG|Placebo to 1mg|1 mg placebo oral
214523045|NCT03530345|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
214523046|NCT03530345|DRUG|Placebo|Glass vials with matching placebo.
215123633|NCT05904158|OTHER|Standard ACL reconstruction surgery|This was a control group where patients received Standard ACL reconstruction surgery
215123634|NCT00291135|DRUG|letrozole|Letrozole 2.5 mg daily
215123635|NCT02219464|DEVICE|Nasopharyngeal catheter|
215123636|NCT02219464|DEVICE|Nasal Cannula|
215123637|NCT02219464|PROCEDURE|Oxygen Supplementation|Initially set at 3 liters/minute
215123638|NCT02219464|PROCEDURE|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
215123639|NCT01909895|OTHER|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
214523047|NCT04652050|DRUG|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
215123640|NCT01909895|OTHER|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
215123641|NCT01909895|OTHER|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
215123642|NCT01909895|OTHER|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
215123643|NCT04834180|DIETARY_SUPPLEMENT|Hypocaloric diet plan|The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
215123644|NCT04834180|OTHER|Auricular Acupuncture|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
215123645|NCT04834180|OTHER|Acupressure|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
215123646|NCT03695224|DIAGNOSTIC_TEST|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
215123647|NCT01493193|OTHER|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
215123648|NCT01493193|OTHER|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
214523048|NCT01095809|DRUG|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
214523049|NCT01095809|DRUG|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
214523050|NCT03392688|OTHER|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
214523051|NCT03392688|DIAGNOSTIC_TEST|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
215123649|NCT01493193|OTHER|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
215123650|NCT05525377|BEHAVIORAL|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
215123651|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
215123652|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
215123653|NCT02040623|OTHER|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
215123654|NCT00259545|DRUG|Retarded Release Phosphatidylcholine (rPC)|
214523052|NCT03392688|OTHER|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
214523053|NCT03282071|BEHAVIORAL|Joyful Parenting Intervention|"* Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
215123655|NCT00786383|BIOLOGICAL|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
215123656|NCT00786383|BIOLOGICAL|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
215123657|NCT00786383|BIOLOGICAL|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
215123658|NCT00786383|BIOLOGICAL|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
215123659|NCT00786383|BIOLOGICAL|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
215123660|NCT01512134|DEVICE|Deep Brain Stimulation Device|Deep brain stimulation surgery
215123661|NCT02383563|DRUG|metformin extended release|
215123662|NCT01447654|DRUG|Losartan|100 mg for 12 months.
215123663|NCT01447654|DRUG|Placebo|100 mg for 12 months.
215123664|NCT06074848|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
215123665|NCT06074848|BEHAVIORAL|Motor Training|Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
215123666|NCT06074848|BEHAVIORAL|Cognitive Training|an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
215123667|NCT03270943|BEHAVIORAL|MFY|Mindful Self-Compassion course for teens
215123668|NCT03270943|BEHAVIORAL|HLG|Healthy Lifestyles course for teens
215123669|NCT03342586|DIAGNOSTIC_TEST|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
215123670|NCT03342586|OTHER|Auditory Attention and Executive Functions Test|"* Trail Making Test (Parts A \& B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~* Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~* Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
215123671|NCT03342586|OTHER|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
214445991|NCT06795737|BEHAVIORAL|Exercise rehabilitation|The experimental group's protocol consists of two stages: in-hospital Phase I and post-discharge self-training. For Phase I, cardiac and rehab specialists assess NYHA classification, muscle strength, and mobility to create an exercise plan, supervised by therapists and nurses. Phase II involves twice-weekly outpatient rehab for 24 sessions and weekly remote guidance with WeChat and wristbands to track vitals, totaling 12 remote sessions. Exercise prescriptions are customized based on 6MWTD outcomes, with ongoing support from rehab staff and nurses.
214445992|NCT06795737|BEHAVIORAL|Conventional rehabilitation|"Health Education: Nurses provide manuals on heart failure causes, treatment, diet, exercise (detailing frequency, intensity, duration, types, and safety), and self-monitoring to control group patients.~Outpatient Follow-up: Post-discharge, heart failure patients have follow-ups at 2 weeks, 1 month, 2 months, and 3 months. A multidisciplinary team of doctors, pharmacists, and nurses handles these, with doctors for assessment, pharmacists for medication education, and nurses for self-care assessment and education."
214445993|NCT06839378|PROCEDURE|intravenously inject with 5-FU (400 mg/m2)|5-FU (400 mg/m2) will be injected IV bolus before operation. After CRS, the patients will be treated with cisplatin or cisplatin + docetaxel HIPEC respectively. The tumor tissue samples of patients will be collected before and after HIPEC treatment. The tumor tissue samples before and after HIPEC treatment will be sequenced by Flura-seq using high-throughput sequencing technology, and the changes of newly generated transcripts in tumor tissue during HIPEC will be analyzed. The differentially expressed genes in the cisplatin group and the cisplatin + docetaxel group will be compared to evaluate the effect of different HIPEC regimens on the transient transcriptome of PMP tumor.
214445994|NCT06840197|DIAGNOSTIC_TEST|NG-TestⓇ Monkeypox virus kit|Evaluation of the performance of the rapid diagnostic test (RDT) for the detection of the Mpox virus (NG-TestⓇ Monkeypox virus kit) and comparision with PCR result (reference test)
215030430|NCT03135067|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
215030431|NCT01613586|DRUG|ASP3652|Oral
215123672|NCT03342586|OTHER|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
215123673|NCT03342586|OTHER|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
215123674|NCT05980728|OTHER|No Intervention|No Intervention
215123675|NCT02981368|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
215123676|NCT02981368|DIAGNOSTIC_TEST|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
215030432|NCT01613586|DRUG|Placebo|Oral
215030433|NCT05196620|OTHER|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
215030434|NCT04198402|BIOLOGICAL|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
215030435|NCT02100826|DRUG|Cephalexin|Administered orally.
215123677|NCT06059235|OTHER|pharmaceutical care|"consultation with a pharmacist performing advanced pharmaceutical care : Package of clinical pharmacy activities including :~Medication history (during assessment consultation) Medication review and consultation with the geriatrician Therapeutic education (during results consultation) Shared decision (at results consultation) One-week follow-up call + usual care"
215123678|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
215123679|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
215123680|NCT01459588|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
215123681|NCT01459588|DRUG|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
215123682|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
215123683|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
215123684|NCT00860873|DIETARY_SUPPLEMENT|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
215123685|NCT00860873|DIETARY_SUPPLEMENT|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
215123686|NCT02544321|DRUG|Bromocriptine|
215123687|NCT02544321|OTHER|Placebo|
214445995|NCT06793228|DRUG|Nanocrystalline Megestrol Acetate|Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
214445996|NCT06793228|DRUG|Tislelizumab|Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
214445997|NCT06793228|DRUG|PTOC|Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
214445998|NCT05262374|PROCEDURE|Procedure/Surgery: Laparoscopic|Surgeon
214523054|NCT01221532|BEHAVIORAL|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
214523055|NCT04117386|DIAGNOSTIC_TEST|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
214523056|NCT04117386|DIAGNOSTIC_TEST|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
214523057|NCT00212459|BEHAVIORAL|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
215123688|NCT01584232|DRUG|LY2189265|
215123689|NCT01584232|DRUG|Insulin glargine|
215123690|NCT01584232|DRUG|Sulfonylureas (SU)|
215123691|NCT01584232|DRUG|Biguanide (BG)|
215123692|NCT01810484|DEVICE|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
214523058|NCT00212459|BEHAVIORAL|Control|No more contacts are made with control patients after the initial counseling session.
214523059|NCT01377545|PROCEDURE|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
215123693|NCT01810484|DEVICE|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
215123694|NCT01810484|DEVICE|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
215123695|NCT04554420|BEHAVIORAL|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
215123696|NCT02099240|DRUG|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
215123697|NCT02099240|PROCEDURE|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
215123698|NCT05308992|DEVICE|HydroGlyde Condom|The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
214445999|NCT05262374|PROCEDURE|Robotic|Versius system.
214446000|NCT06408051|PROCEDURE|Injection of onabotulinumtoxinA into the bladder wall|BTX was injected into the detrusor muscles at 20 sites
214446001|NCT06793241|BIOLOGICAL|CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection|Each subject receive CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells by intravenous infusion
214446002|NCT06835439|BEHAVIORAL|STEPPT Pilot|The pilot STEPPT intervention, which includes (1) education of providers and staff on disparities in referrals and the benefits of physical therapy for spine pain, (2) modifications to the EHR to automate physical therapy referral and delivery of culturally tailored patient education materials related to the physical therapy referral, and (3) enhanced patient health navigation to educate patients on physical therapy and address barriers to attending physical therapy for Hispanic patients with spine pain. Patient education materials were developed using evidence-based guidelines and were culturally and linguistically adapted for Hispanic patients with spine pain.
214446003|NCT06835439|BEHAVIORAL|Standard Care (Control)|Usual care (3-month baseline) includes no provider education, physician-initiated referrals and delivery of standard educational materials, and scheduling for physical therapy by the clinic referrals specialists using standard processes.
214446004|NCT06830616|DIAGNOSTIC_TEST|7T MRI brain|A very detailed MRI scan of the brain using a 7T MRI scanner.
215123699|NCT04412577|DRUG|TQB3473|TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
215123700|NCT01138423|DRUG|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
215123701|NCT01138423|DRUG|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
215123702|NCT01138423|DRUG|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
215123703|NCT01138423|DRUG|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
215123704|NCT01138423|DRUG|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
215123705|NCT03327909|BEHAVIORAL|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
215123706|NCT01414894|OTHER|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
215123707|NCT01414894|OTHER|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
215123708|NCT01913951|DRUG|vosaroxin|Given IV over 10 minutes on Day 1 and 4
215123709|NCT01913951|DRUG|Azacitidine|Given SC or IV over 15 minutes on days 1-7
215123710|NCT04557540|BEHAVIORAL|Lifestyle Therapy|Receive The WORD lifestyle CER weight loss intervention
215123711|NCT04557540|OTHER|Quality-of-Life Assessment|Ancillary studies
215123712|NCT04557540|OTHER|Questionnaire Administration|Ancillary studies
214446005|NCT04958122|DRUG|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
214446006|NCT04958122|DRUG|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
214446007|NCT03426293|OTHER|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
214446008|NCT06636227|DRUG|Diclofenac 100mg|Diclofenac 100mg
214446009|NCT06636227|DRUG|Diclofenac 75mg|Diclofenac 75mg
214446010|NCT06636227|DRUG|Diclofenac 50mg|Diclofenac 50mg
214446011|NCT06636227|DRUG|Placebo control|Placebo control
215123713|NCT04557540|OTHER|Short-Term Fasting|Receive Fasting WORD intermittent fasting weight loss intervention
215123714|NCT03789916|DRUG|Ticagrelor|90 mg bis in die
215123715|NCT03789916|DRUG|acetylsalicylic acid|100 mg die
215123716|NCT05915845|OTHER|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
215123717|NCT05915845|OTHER|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
215123718|NCT04296656|BEHAVIORAL|The 5 S's infant calming intervention|5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
215123719|NCT01379716|OTHER|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
214523060|NCT01377545|PROCEDURE|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
215123720|NCT00963963|BEHAVIORAL|Healthy Futures parent education|Multi-year audio CD parent education
215123721|NCT04929535|DRUG|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
215123722|NCT02768766|DRUG|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123723|NCT02768766|DRUG|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123724|NCT02768766|DRUG|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123725|NCT02768766|DRUG|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123726|NCT02768766|DRUG|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123727|NCT02768766|DRUG|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
215123728|NCT02564666|OTHER|telephone counseling|regular telephone counseling for compliance and advese event
215123729|NCT01912066|DRUG|Stillen|
215123730|NCT01912066|DRUG|Cytotec (reference drug)|
215123731|NCT01912066|DRUG|NSAID (Aceclofenac)|
215123732|NCT03347123|DRUG|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
215123733|NCT03347123|DRUG|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
215123734|NCT03347123|DRUG|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
215123735|NCT03347123|DRUG|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
214523061|NCT04472715|PROCEDURE|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
215123736|NCT04197830|PROCEDURE|Thrombectomy for stroke|Patients who have had thrombectomy for acute stroke.
215123737|NCT00262496|DRUG|Botox|
214523062|NCT04229940|PROCEDURE|Peritoneal bridging|The defect is covered by peritoneal bridging
214523063|NCT04229940|PROCEDURE|No peritoneal bridging|The defect is left without bridging
214523064|NCT00253851|DRUG|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
215123738|NCT00569712|DRUG|budesonide/formoterol fumarate dihydrate inhalation aerosol|
215123739|NCT00569712|GENETIC|DNA methylation analysis|
215123740|NCT00569712|GENETIC|comparative genomic hybridization|
215123741|NCT00569712|GENETIC|microarray analysis|
215123742|NCT00569712|OTHER|bronchoalveolar lavage|
215123743|NCT00569712|OTHER|immunoenzyme technique|
215123744|NCT00569712|OTHER|laboratory biomarker analysis|
215123745|NCT00569712|PROCEDURE|bronchoscopy|
215123746|NCT00500916|DEVICE|ProSeal LMA|GEB vs digital vs introducer tool
215123747|NCT05346120|BIOLOGICAL|allogeneic marrow stromal cells (MSCs)|stem cell infusion
215123748|NCT05448040|PROCEDURE|Socket preservation|Tooth extraction and preservation with a biomaterial
215123749|NCT00175513|DRUG|Valacyclovir (Valtrex)|
215123750|NCT01132807|BIOLOGICAL|Bleomycin Sulfate|Given IV
215123751|NCT01132807|DRUG|Doxorubicin Hydrochloride|Given IV
215123752|NCT01132807|DRUG|Procarbazine Hydrochloride|Given PO
215123753|NCT01132807|DRUG|Vinblastine Sulfate|Given IV
215123754|NCT01132807|DRUG|Dacarbazine|Given IV
215123755|NCT01132807|DRUG|Cyclophosphamide|Given IV
215123756|NCT01132807|DRUG|Etoposide phosphate|Given IV
215123757|NCT01132807|DRUG|prednisone|Given PO
215123758|NCT01132807|DRUG|Radiation Therapy|Undergo radiation therapy
215123759|NCT01132807|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
215123760|NCT01132807|PROCEDURE|computed tomography|Undergo FDG PET/CT
215123761|NCT01132807|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
215123762|NCT03326804|DEVICE|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
215123763|NCT05625984|DEVICE|Fascigel|The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
215123764|NCT00314730|DEVICE|handheld Personal Digital Assistant (PDA)|
215123765|NCT00763412|DRUG|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
215123766|NCT00763412|DRUG|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
215123767|NCT03908333|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
215123768|NCT03908333|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
215123769|NCT03908333|DRUG|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
215123770|NCT03908333|DRUG|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
215123771|NCT00509184|DRUG|Rituximab|375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap
215123772|NCT02134223|BEHAVIORAL|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
215123773|NCT02134223|OTHER|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
215123774|NCT01198197|DRUG|NOP-1A|
215123775|NCT00178477|PROCEDURE|MRI with breath-holding|Breath holding for diminished tumor motion.
215123776|NCT05681650|BIOLOGICAL|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D
215123777|NCT05681650|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
215123778|NCT05681650|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
215123779|NCT05681650|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
215123780|NCT01624116|DRUG|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
215123781|NCT01624116|OTHER|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
215123782|NCT01624116|DRUG|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
215123783|NCT01624116|DRUG|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
215123784|NCT01624116|DRUG|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
214523065|NCT05360771|DEVICE|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
215123785|NCT02043938|DEVICE|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
215123786|NCT03646877|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
214523066|NCT05360771|DEVICE|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
215123787|NCT03646877|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
215123788|NCT03202407|DRUG|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
215123789|NCT01107951|DRUG|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)"
215123790|NCT06000124|OTHER|Plyometric exercises|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
214523067|NCT04853394|BEHAVIORAL|MASLIHAT|peer educator intervention
214523068|NCT04853394|BEHAVIORAL|TANSIHAT|health education intervention
214523069|NCT06301529|DRUG|Invokana Pill|100 mg and 150 mg doses, taken every day and every-other day, respectively.
214523070|NCT04212299|DEVICE|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
214523071|NCT03537014|BEHAVIORAL|Therapy|Non-directive therapy performed by therapist team
215123791|NCT06000124|OTHER|Regulation Exercises Program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
215123792|NCT04690140|PROCEDURE|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
215123793|NCT04690140|PROCEDURE|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
215123794|NCT03941496|DRUG|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay"
215123795|NCT00248495|DRUG|cisplatin|Given IV
215123796|NCT00248495|DRUG|pemetrexed disodium|Given IV
215123797|NCT00248495|PROCEDURE|adjuvant therapy|Metastasis prevention/control
215123798|NCT00248495|PROCEDURE|conventional surgery|Undergoing tissue removal
215123799|NCT00248495|PROCEDURE|neoadjuvant therapy|Tumor Reduction
214523072|NCT03537014|DRUG|midomafetamine HCl|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions
214523073|NCT03537014|DRUG|Placebo|Administration of placebo during three experimental sessions
215123800|NCT03812380|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
215123801|NCT03812380|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
214523074|NCT00943371|DRUG|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
215123802|NCT00308477|DRUG|dexamethasone|
215123803|NCT03662958|DRUG|Lutrate|a novel leuprolide acetate 3.75mg depot
215123804|NCT03662958|DRUG|Enantone|market reference leuprolide acetate 3.75 mg depot
214523075|NCT00943371|DRUG|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
214523076|NCT00715182|DRUG|TKI258|
214523077|NCT03754166|OTHER|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
214523078|NCT07008339|PROCEDURE|Areola Micropigmentation|Areola micropigmentation performed by trained nurses
215123805|NCT03318835|DRUG|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
215123806|NCT03318835|DRUG|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
215123807|NCT00481702|DRUG|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
215123808|NCT00481702|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
215123809|NCT00481702|DRUG|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
215123810|NCT00992758|BIOLOGICAL|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
215123811|NCT05876481|DRUG|Psilocybin|Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
215123812|NCT01285401|DRUG|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
215123813|NCT01285401|DRUG|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
215123814|NCT01285401|BIOLOGICAL|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
215123815|NCT00659802|DRUG|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
215123816|NCT00659802|DRUG|Placebo|Matching dose of Placebo
215123817|NCT00659802|DRUG|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
215123818|NCT05625698|DRUG|MagTrace only|see information in arm descriptions
215123819|NCT05625698|COMBINATION_PRODUCT|MagTrace and Magseed|see information in arm descriptions
215123820|NCT00494585|DRUG|CEP-701|80 mg orally twice a day for 30 days
214446012|NCT06837467|DIAGNOSTIC_TEST|Immunohistochemistry (IHC)|We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
214446013|NCT06797791|DEVICE|Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation|The experimental stimulation protocol included 3 trains of cTBS with an inter-train interval of 10 min. Each train of cTBS consisted of 600 pulses applied in blocks at the theta frequency (200ms) with a duration of 40 s. A block of pulses consisted of 3 pulses at 50Hz frequency, stimulus intensity being estimated as 80% of the RMT. Stimulation application was performed by positioning the Magventure MMC-140 coil over the vertex (Cz) according to the 10-20 EEG system overlapping bilateral motor and somatosensory cortical areas.
215123821|NCT01359345|DRUG|gadollinum|use of on injection gadollinum Iv for imaging
215123822|NCT01909999|PROCEDURE|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
215123823|NCT01909999|PROCEDURE|Clinical parameters evaluation|"The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
215123824|NCT01909999|PROCEDURE|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
215123825|NCT01909999|PROCEDURE|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
215123826|NCT01909999|PROCEDURE|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
215123827|NCT01909999|DRUG|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
215123828|NCT02161835|OTHER|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
215123829|NCT04557800|DRUG|DNL151|oral dose(s)
215123830|NCT04557800|DRUG|Placebo|oral dose(s)
215123831|NCT00112372|DRUG|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
215123832|NCT02248805|DRUG|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
215123833|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
215123834|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|"ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL"
215123835|NCT01578681|PROCEDURE|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
215123836|NCT01578681|PROCEDURE|Stretching|Patient will be instructed to do muscle stretching of the thorax
215123837|NCT01507688|BEHAVIORAL|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
215123838|NCT04402424|DIAGNOSTIC_TEST|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
215123839|NCT02534415|DRUG|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
215123840|NCT02534415|DRUG|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
215123841|NCT02534415|DRUG|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
215123842|NCT01333228|OTHER|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
215123843|NCT05178199|BEHAVIORAL|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
214446014|NCT04899024|BEHAVIORAL|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
214446015|NCT04899024|BEHAVIORAL|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
214446016|NCT04899024|BEHAVIORAL|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
214446017|NCT06795204|DRUG|HSK3486|Study Drug
214446018|NCT06795204|DRUG|Moxifloxacin Hydrochloride|Positive Control
214446019|NCT06795204|DRUG|Placebo|Negative Control
214523079|NCT07008339|DEVICE|Hyaluronic Acid Filler Injection|Subcutaneous injection of cross-linked hyaluronic acid filler (Juvederm®) for nipple projection.
214523080|NCT07009574|DRUG|anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization|"All patients underwent one intravitreal injection at baseline (0.5 mg ranibizumab or 2.0 mg aflibercept); additional intravitreal injections were administered over the follow-up period based on the above-mentioned activity signs with a pro-re-nata (PRN) treatment protocol. The patients have been followed on a monthly or bimonthly basis. The number of visits and examinations in the 12-month study period will be collected.~Clinical and imaging data of the baseline examination as well as of the 12-month visit (M12) after the first intravitreal injection."
214523081|NCT07009652|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|Extracorporeal cardiopulmonary resuscitation (commonly known as ECPR) is a method of cardiopulmonary resuscitation (CPR) that passes the patient's blood through a machine in a process to oxygenate the blood supply.
214523082|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from reinforced resin|A comprehensive clinical examination with an understanding of patients' chief complaints and needs will be carried out. For each patient, two implants will be placed in the edentulous area, and the patient will receive a screw-retained bridge supported by both implants made of milled monolithic zirconia (Dental Direkt Zirconia, Germany). After 6 months, the zirconia restoration will be replaced with a milled resin-reinforced composite (Nanoska G Plus, USA), allowing the same patient to use the new restoration for another 6 months. Randomization will be performed to determine the sequence of bridge material for each participant. Accordingly, the two restorations will be sequentially delivered to each participant with no gap (wash-up period) between them. Consent will be signed by the selected participants after explaining the detailed information of the trial.
214446020|NCT06237426|DRUG|Methylone|A course of treatment includes 4 weekly doses of TSND-201.
214523083|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia
215123844|NCT05178199|BEHAVIORAL|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
215123845|NCT01514019|DRUG|Acebutolol|Acebutolol
214523084|NCT07008950|OTHER|The Self-Efficacy and Knowledge Trial|The intervention is composed on 8 sessions given over a period of 8 weeks covering topics of emotional regulation, communication, problem management, decision making, self-efficacy and others in relation to sexual reproductive health, family planning, and wellbeing. The intervention package will be delivered by trained non-specialists with at least 12 years of formal education. The package will be administered once a week for a duration of 90 minutes.
214523085|NCT07007871|OTHER|Tutoring and Counselling (1)|During the intervention, students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
214523086|NCT07007871|OTHER|Tutoring and Counselling (2)|Students assigned to the waitlist control group receive the program after the experimental group completes it. Students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
215123846|NCT01514019|DRUG|Placebo|Placebo capsule(Capsules filled up with lactose)
215123847|NCT04966260|OTHER|Standardized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
215123848|NCT04966260|OTHER|Control|This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
215123849|NCT04966260|OTHER|Personalized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
215123850|NCT02163824|DRUG|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
215123851|NCT02163824|DRUG|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
215123852|NCT02163824|DRUG|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
215123853|NCT02163824|DRUG|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
215123854|NCT04110912|OTHER|This is a registry and no interventions are taking place.|
215123855|NCT03470480|DEVICE|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
214523087|NCT07009613|DIAGNOSTIC_TEST|Parasitological tests|The primary outcome was reported based on the technicians' answers collected with a structured questionnaire. The individuals screened underwent testing with the tests detailed above
214523088|NCT07009613|OTHER|Questionnaire|The primary outcome was based on the technicians' evaluation, based on their answers collected in a questionnaire. The individuals screened were tested with assays used for the national control programmes
214523089|NCT07008144|OTHER|Digoxin alarm|A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
215123856|NCT03470480|DEVICE|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
215123857|NCT03470480|BEHAVIORAL|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
215123858|NCT03470480|BEHAVIORAL|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
214523090|NCT07008040|OTHER|Silver dressing|Silver dressing will be applied to the sternotomy and donor site wounds for the CABG patients
214523091|NCT07008196|DRUG|Telitacicept|Telitacicept 160mg qw subcutaneous injection
214523092|NCT07009236|DEVICE|MIGS|Implant MINIject S+ in supraciliary space
214523093|NCT07008703|DRUG|Injection of humanized nerve growth factor (NGF) antibody|Subcutaneous injection, 20mg
214523094|NCT07008820|OTHER|Health-related quality of life questionnaires|"Questionnaires include:~EORTC-QLQ C30 FACT-An PGI-S EQ-5D-5L"
215123859|NCT02366312|DRUG|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
215123860|NCT00790192|DRUG|Lurasidone|Lurasidone 80 mg tablets
215123861|NCT00790192|DRUG|Lurasidone|Lurasidone 4 40 mg tablets
215123862|NCT00790192|DRUG|Quetiapine XR|Quetiapine XR 600mg
215123863|NCT00790192|DRUG|Placebo|Matching Placebo to Lurasidone or Quetiapine
215123864|NCT00354679|BIOLOGICAL|bevacizumab|
215123865|NCT00354679|DRUG|cisplatin|
215123866|NCT00354679|DRUG|irinotecan hydrochloride|
215123867|NCT00354679|GENETIC|proteomic profiling|
215123868|NCT00354679|OTHER|diagnostic laboratory biomarker analysis|
215123869|NCT00354679|OTHER|mass spectrometry|
215123870|NCT00354679|PROCEDURE|adjuvant therapy|
215123871|NCT00354679|PROCEDURE|neoadjuvant therapy|
215123872|NCT00354679|PROCEDURE|therapeutic conventional surgery|
214446021|NCT06510907|BEHAVIORAL|mindfulness based stress reduction program|"Mindfulness training will be delivered through a generic 8-week MBSR. The MBSR will consist of weekly 2-hour classes, in which the techniques to various meditations (e.g., body scan, mindful awareness of breathing, body, sounds, thoughts, emotions, and mindful movements) will be taught and discussed. Participants will be asked to meditate for ≥40 minutes every day during the 8-week program as homework. Besides cultivating attention control and a non-judgemental stance to experience, psychoeducation about psychological stress and stress response will also be discussed during the MBSR classes. The MBSR teacher will discuss any difficulties encountered during homework meditations in every class to enhance adherence.~Each MBSR class can have up to 25 participants. The 8-week program will be taught by a qualified MBSR teacher"
214446022|NCT02387853|DRUG|LEO 90100|
214446023|NCT06061965|BEHAVIORAL|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
214523095|NCT07008820|OTHER|Qualitative interviews|For participants that meet eligibility criteria
214523096|NCT04702191|BEHAVIORAL|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, \& Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
214523097|NCT04702191|BEHAVIORAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
215123873|NCT00354679|RADIATION|radiation therapy|
215123874|NCT04115384|DRUG|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
215123875|NCT02089919|BIOLOGICAL|cancer stem cell vaccine|
215123876|NCT05147376|DRUG|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
215123877|NCT05147376|DRUG|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
215123878|NCT05527665|PROCEDURE|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
215123879|NCT05315102|OTHER|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
215123880|NCT05315102|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
215123881|NCT05315102|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
215123882|NCT03678064|DEVICE|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
215123883|NCT03719131|DRUG|Nivolumab|Receive standard of care nivolumab therapy
215123884|NCT03719131|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV or SC
215123885|NCT03719131|DRUG|Ipilimumab|Receive standard of care ipilimumab therapy
215123886|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
215123887|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
215123888|NCT05870891|OTHER|Food|Food
215123889|NCT03938896|OTHER|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
215123890|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
215123891|NCT03566706|BEHAVIORAL|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
215123892|NCT03566706|BEHAVIORAL|Discussion Tool: Marijuana Use|Parent Discussion Tools
215123893|NCT03566706|BEHAVIORAL|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
215123894|NCT04294602|OTHER|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
214446024|NCT05959733|PROCEDURE|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
214446025|NCT05959733|PROCEDURE|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
214446026|NCT04942431|BEHAVIORAL|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
214446027|NCT04953884|DRUG|wilate|wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
214446028|NCT04523376|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
214446029|NCT04547686|BEHAVIORAL|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
214446030|NCT04547686|BEHAVIORAL|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
214446031|NCT04836728|BIOLOGICAL|CIK cells injection|CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion, d14, Q3W.
214446032|NCT04836728|DRUG|Sintilimab Injection|200 mg, intravenous infusion, d1, every 3 weeks
215123895|NCT04294602|OTHER|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
215123896|NCT04294602|OTHER|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
215123897|NCT04294602|OTHER|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
215123898|NCT00056693|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
215123899|NCT01544920|BIOLOGICAL|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
215123900|NCT01544920|DRUG|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
215123901|NCT01544920|DRUG|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
215123902|NCT01454986|DRUG|ALXN1007|Single dose, IV
215123903|NCT01454986|OTHER|Placebo|Single dose, IV
215123904|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
215123905|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
215123906|NCT00933322|DIETARY_SUPPLEMENT|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
215123907|NCT00466440|DRUG|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
215123908|NCT00466440|DRUG|placebo|Loading dose, then po QD until unblinding
215123909|NCT00466440|DRUG|docetaxel|75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
215123910|NCT00466440|DRUG|prednisone|5 mg po BID, six 21-day cycles
215123911|NCT01135615|DRUG|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
215123912|NCT01135615|DRUG|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
215123913|NCT06262308|BEHAVIORAL|Psychological intervention along Cognitive Behavioural Therapy principles|Women who have PPROM will be offered a series of 6 sessions with a Clinical Psychologist
215123914|NCT00250237|DRUG|Haloperidol|Haloperidol 1mg twice daily during 72hours
215123915|NCT00250237|DRUG|placebo|Placebo 1mg twice daily during 72hours
215123916|NCT00637078|OTHER|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
215123917|NCT03029468|BEHAVIORAL|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
215123918|NCT03029468|BEHAVIORAL|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
215123919|NCT01839058|OTHER|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
215123920|NCT03494296|DRUG|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
215123921|NCT01395576|DEVICE|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
215123922|NCT00414141|BIOLOGICAL|Grass MATA MPL|4 subcutaneous injections
215123923|NCT00414141|BIOLOGICAL|Placebo|4 subcutaneous injections
215123924|NCT05663021|DIAGNOSTIC_TEST|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
215123925|NCT05734755|BEHAVIORAL|The Individualized Dietary Behavioural Change Programme (IDBC)|The first three weekly face-to-face sessions will be during the 'goal initiation' and 'planning' phases. The remaining seven face-to-face sessions will be offered once to twice per month between weeks 4 and 24 during the program at the 'action execution' phase. Family members will be encouraged to join the dietary consultations. Strategies will be discussed with the family members to facilitate the participant's adherence to the recommended diet regimen.Phase I Goal Initiation is aimed at motivating the participants to actively manage their sarcopenic obesity. Phase II Plan Formulation is aimed at guiding the participants in transforming their (sub-) goals into detailed individualized action plans.Phase III Action Execution is aimed at encouraging the participants to continually execute the action plan. The IDBC guidebook will be given to the participants to guide them on how to gradually adopt our dietary recommendations in their daily life.
214446033|NCT04836728|DRUG|Pemetrexed|500 mg/m\^2, intravenous infusion, d1, every 3 weeks
214446034|NCT04836728|DRUG|Albumin paclitaxel|260 mg/m\^2, intravenous infusion, d1, every 3 weeks
214446035|NCT04836728|DRUG|Carboplatin|AUC 5, intravenous infusion, d1, every 3 weeks
214446036|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Enhanced)|Interactive routine is based on tailoring to the participants type of pain and personality.
214446037|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Standard)|Interactive routine is a basic interaction with the voice assistant.
214446038|NCT05710406|DRUG|Encorafenib|Given PO
214446039|NCT05710406|BIOLOGICAL|Cetuximab|Given IV
214446040|NCT05710406|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214446041|NCT05710406|PROCEDURE|Computed Tomography|Undergo CT
214446042|NCT05710406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214446043|NCT05710406|OTHER|Patient Observation|Undergo observation per usual care
214446044|NCT06347666|BEHAVIORAL|Caregiver coaching|Speech language pathologists will meet with caregivers to talk through strategies to promote child development.
214446045|NCT03679611|DRUG|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
215123926|NCT05734755|BEHAVIORAL|The Exercise Training|The group size will be \< 10. They will be used in the resistance exercise in this study to improve muscle strength (20 mins). Brisk walking (20 mins) will be employed in the aerobic exercise in this study. Each session will include 10 minutes of warm-up and cool-down exercises at the beginning and at the end. A YouTube video and a pamphlet describing the different types of exercises used in this programme will be disseminated to all participants to encourage them to continually practise their exercises at home for 30 minutes at least 5 times per week.
215123927|NCT01412528|OTHER|Allergen extracts|
215123928|NCT03294590|OTHER|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
215123929|NCT03294590|OTHER|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
215123930|NCT01844388|DRUG|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
215123931|NCT01844388|DRUG|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
215123932|NCT03292224|DIAGNOSTIC_TEST|- Microscopic examination and culture of collected specimens|"1. Unstained wet mount with 10%-20% KOH.~2. Wet mounts stained with:~   * Lactophenol cotton blue.~  * India ink~  * Gram stain Culturing on Sabouraud´s dextrose agar ."
215123933|NCT06396819|DRUG|collagen-povidone solution|Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
215123934|NCT00819936|PROCEDURE|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
214446046|NCT03679611|DRUG|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
214446047|NCT01815749|BIOLOGICAL|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
214446048|NCT01815749|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
214446049|NCT01815749|OTHER|laboratory biomarker analysis|Correlative studies
214446050|NCT02395367|PROCEDURE|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
214446051|NCT02395367|RADIATION|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
214446052|NCT02395367|DRUG|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
214523098|NCT07009158|DRUG|Ketamine Infusion|Ketamine hydrochloride (DIN: 02246795, 02246796) will be administered over 40-min intravenous (IV) infusion twice per week on non-consecutive days for the first two weeks of study treatment (four treatment sessions in total). We will use a standard dose of 0.5mg/kg which has demonstrated efficacy in safety in individuals with PTSD.
215123935|NCT00819936|PROCEDURE|backward walking|physiotherapy with use a backward walking type of physiotherapy
214446053|NCT04534933|DEVICE|Evone|Airway ventilation device
214568443|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
215123936|NCT00651781|DRUG|Bortezomib|2 times per week of Velcade administration.
215123937|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
215123938|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
215123939|NCT01061970|DRUG|Fispemifene|once daily for 4 weeks
215123940|NCT01645254|DRUG|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
215123941|NCT02820454|DRUG|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
214446054|NCT04534933|DEVICE|Primus|Airway ventilation device
214446055|NCT03391466|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
214446056|NCT03391466|DRUG|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
214446057|NCT03391466|DRUG|Cyclophosphamide|Administered intravenously
214446058|NCT03391466|DRUG|Fludarabine|Administered intravenously
214446059|NCT06518135|OTHER|SLNB group|After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
215123942|NCT02820454|RADIATION|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
215123943|NCT02088450|DRUG|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
215123944|NCT05762497|OTHER|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
215123945|NCT01509755|DRUG|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
215123946|NCT01509755|DRUG|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
215123947|NCT01509755|DRUG|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
215123948|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years"
215123949|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years"
215123950|NCT02304900|OTHER|white implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
215123951|NCT02304900|OTHER|yellow implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
215123952|NCT02426463|DRUG|propofol|
215123953|NCT02426463|DRUG|oxycodone|
215123954|NCT02532608|OTHER|Acute sleep deprivation|Participants will stay awake for 36 hours
215123955|NCT03287999|DIAGNOSTIC_TEST|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
215123956|NCT03287999|DIAGNOSTIC_TEST|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
215123957|NCT00001716|DRUG|Nitric Oxide|
215123958|NCT00001716|DRUG|Nitroglycerin|
215123959|NCT04713488|BIOLOGICAL|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
215123960|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
215123961|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
214446060|NCT03655132|BEHAVIORAL|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
214446061|NCT05568004|BEHAVIORAL|Combined exercise|aerobic plus resistance exercise
214446062|NCT05568004|BEHAVIORAL|Aerobic exercise|Only aerobic exercise
214446063|NCT02478892|OTHER|Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen|Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.
214446064|NCT02478892|OTHER|Blood sample collection for research|Up to 40mL of blood may be collected for analysis at each screening examination.
214446065|NCT06157437|DEVICE|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
214446066|NCT05813496|DRUG|Alpha-Lipoic Acid (ALA)|Oral tablet
214446067|NCT05813496|DRUG|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
215123962|NCT02513121|OTHER|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
215123963|NCT05703750|PROCEDURE|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
215123964|NCT01936571|OTHER|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
215123965|NCT02609308|OTHER|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
215123966|NCT02609308|PROCEDURE|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
215123967|NCT02451085|BEHAVIORAL|training with video therapy|training with video therapy
215123968|NCT02451085|BEHAVIORAL|conventional exercise|training in conventional way
215123969|NCT04555395|OTHER|survival rates|survival rates
215123970|NCT03116516|DRUG|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
214446068|NCT04972513|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215123971|NCT03116516|DRUG|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
215123972|NCT00815217|PROCEDURE|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
215123973|NCT00815217|OTHER|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
215123974|NCT03367858|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
215123975|NCT03367858|BEHAVIORAL|Brief Adolescent Mindfulness (BAM)|Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
215123976|NCT03211468|BEHAVIORAL|Clinical intervention program to prevent eating disorders|See previous
215123977|NCT05180695|DRUG|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
215123978|NCT05180695|DRUG|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
215123979|NCT00984984|DRUG|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
215123980|NCT00984984|DRUG|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
214446069|NCT04972513|PROCEDURE|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
214446070|NCT04972513|PROCEDURE|Oscillometry|Undergo airwave oscillometry
214446071|NCT04972513|PROCEDURE|Spirometry|Undergo spirometry
214446072|NCT04972513|OTHER|Survey Administration|Complete survey
214446073|NCT04972513|PROCEDURE|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
214446074|NCT05678959|DRUG|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
214446075|NCT05678959|DRUG|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
214446076|NCT05797376|DRUG|Rivaroxaban 2.5mg|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
214446077|NCT05777447|PROCEDURE|Mycotic aortic-iliac aneurysms and in situ reconstruction|Surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction
214446078|NCT06297447|OTHER|PNE4Adults - pain science education|Is formerly described under arm descriptions
214446079|NCT06297447|OTHER|Usual care|Is formerly described under arm descriptions
214446080|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
214446081|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
214446082|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
214446083|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
214446084|NCT02764138|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
214446085|NCT05919082|DRUG|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
214446086|NCT05919082|DRUG|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
214446087|NCT03479476|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
215030436|NCT05348421|PROCEDURE|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
214446088|NCT03479476|DRUG|Metformin|Active medication.
214446089|NCT03946527|DRUG|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
214446090|NCT05153915|DRUG|Tacrolimus granules|Oral
214446091|NCT05153915|DRUG|Tacrolimus granules|Oral
214446092|NCT05586737|DRUG|Rituximab|1 gram rituximab twice with two weeks interval
214446093|NCT06781203|BEHAVIORAL|Digitally delivered CBTI (eCBTI)|Based on the existing consensus concerning non-pharmacological treatment of insomnia, Hvil® includes the following treatment components: sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. Intervention duration is approximately six to nine weeks.
214446094|NCT03237702|DIETARY_SUPPLEMENT|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
214446095|NCT05268094|DEVICE|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
214446096|NCT05268094|PROCEDURE|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
214446097|NCT06780514|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|To our knowledge, this is the first study to perform CPET's in Turner Girls aged \<18 years
215030437|NCT05348421|PROCEDURE|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
215030438|NCT01676870|BEHAVIORAL|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
215030439|NCT01676870|BEHAVIORAL|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
215030440|NCT01676870|BEHAVIORAL|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
215030441|NCT00877656|BIOLOGICAL|HuMax-CD4|Active treatment
215030442|NCT00894881|PROCEDURE|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
215030443|NCT03429088|BEHAVIORAL|Motivational interviewing telephone counseling|
215030444|NCT06466642|BEHAVIORAL|Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©|The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
215030445|NCT05105724|BIOLOGICAL|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
215030446|NCT00019448|DRUG|gp100 antigen|
215030447|NCT00019448|DRUG|interleukin-2|
215030448|NCT05189678|OTHER|No intervention|No intervention
215030449|NCT03316430|OTHER|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
215030450|NCT06048042|BIOLOGICAL|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
215030451|NCT06048042|BIOLOGICAL|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
215030452|NCT00967499|DRUG|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
215123981|NCT06104085|DIAGNOSTIC_TEST|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
215123982|NCT01119053|DEVICE|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
214446098|NCT06261346|PROCEDURE|Endothelial keratoplasty|"Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes."
215123983|NCT01119053|DEVICE|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
215123984|NCT02800616|OTHER|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
215123985|NCT02800616|BEHAVIORAL|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
215123986|NCT02928315|DRUG|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
214446099|NCT06261346|BIOLOGICAL|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~PRGF incubation lasts 15 minutes. It is a one-time procedure performed on the tissue that will be done in the operating room prior to endothelial keratoplasty."
214446100|NCT06781658|OTHER|Structured rehabilitation intervention|Participants will be prescribed a multi-component SRI which will include education, cervical range of motion exercises, progressive neck strengthening exercises, individualised scapular and upper limb strengthening, task specific hand function training and a physical activity behavioural change intervention. The TIDieR checklist has been used to provide a comprehensive description of this complex intervention. (17).
214446101|NCT06781658|OTHER|Clinical Surveillance|Participants assigned to the clinical surveillance control group will be invited to attend a single, one to one education session which will be supplemented with a written patient information booklet after which they will be scheduled for a 12 week follow up.
214446102|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
214446103|NCT04578171|DRUG|Mepolizumab|100 mg subcutaneous injections every four weeks
214446104|NCT03992664|OTHER|Educational training program|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
214446105|NCT03444701|DRUG|E7130|Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
214568444|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
215123987|NCT02928315|OTHER|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
215123988|NCT06375213|DIAGNOSTIC_TEST|Plasma tau phosphorylated at Thr217|Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.
215123989|NCT06375213|OTHER|Neurocognitive examination|Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.
215123990|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
215123991|NCT01303939|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
215123992|NCT00623324|DRUG|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
215123993|NCT00623324|DRUG|Placebo|Placebo tablets to match the number of active tablets
214446106|NCT03444701|DRUG|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
214446107|NCT05482789|DRUG|Exenatide|10 microgram injected sub-cutaneously once
215123994|NCT06009367|PROCEDURE|Fascial Manipulation by Stecco method|Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
215123995|NCT01018277|OTHER|Mobilization (walking)|25 meters twice
215123996|NCT01217463|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
215123997|NCT04619615|OTHER|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
215123998|NCT04619615|OTHER|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
215123999|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
214446108|NCT06139172|BEHAVIORAL|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
215124000|NCT01250366|DRUG|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
215124001|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
215124002|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
215124003|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
215124004|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
215124005|NCT01250366|DRUG|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
215124006|NCT01250366|DRUG|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
215124007|NCT01250366|DRUG|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
214523099|NCT07009158|BEHAVIORAL|Mindfulness-based cognitive therapy|The Mindfulness-based cognitive therapy (MBCT) will be an 8-week group program adapted from a protocol developed to treat PTSD to include psychoeducation about chronic pain and mutual maintenance factors through which chronic pain and PTSD facilitate each other. The MBCT group will be delivered by trained professionals in weekly 2-hour sessions through Microsoft Teams. The 8-week program will include 1) mindfulness techniques; 2) psychoeducation regarding chronic pain, PTSD and stress responses; 3) psychoeducation on mutual maintenance factors that contribute to negative interactions between pain and PTSD symptoms, 4) promoting mindful awareness of these factors' impact on daily life and 5) feedback and supportive group discussion of exercises. Participants will be asked to complete daily mindfulness exercises between sessions to practice skills learned for a recommended minimum of 20 minutes per day.
215124008|NCT01285817|DRUG|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
214523100|NCT06634199|DRUG|Durvalumab|Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
215124009|NCT03836768|DRUG|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
215124010|NCT05371925|DRUG|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
215124011|NCT06375070|PROCEDURE|PFO closure|PFO closure
215124012|NCT06375070|DRUG|anticoagulant|rivaroxaban
215124013|NCT00005674|DRUG|Creatine|
215124014|NCT03148366|DRUG|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
215124015|NCT03148366|DRUG|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
215124016|NCT02028442|BIOLOGICAL|Enadenotucirev|Oncolytic virus
215124017|NCT01505959|DEVICE|CPAP treatment|Usual CPAP treatment
215124018|NCT01505959|DEVICE|CPAP treatment|CPAP treatment with telemedicine system
215124019|NCT03515525|DIAGNOSTIC_TEST|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
215124020|NCT01082692|BIOLOGICAL|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
215124021|NCT06437262|DRUG|0.20% CHX gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
215124022|NCT06437262|DRUG|0.20% CHX and Cymenol gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
215124023|NCT06437262|DRUG|0.20% CHX gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
215124024|NCT06437262|DRUG|0.20% CHX and Cymenol gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
215124025|NCT03777761|DRUG|tucatinib|300mg oral dose
215124026|NCT03777761|DRUG|placebo|Matching placebo for tucatinib
215124027|NCT03777761|DRUG|moxifloxacin|400mg single oral dose
215124028|NCT01818102|DEVICE|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
215124029|NCT01818102|DEVICE|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
214446109|NCT06139172|OTHER|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
214446110|NCT03793465|DIETARY_SUPPLEMENT|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
214523101|NCT06721806|PROCEDURE|PRP & bone regeneration|PRP effect on bone healing
215124030|NCT06051669|DEVICE|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
215124031|NCT06051669|DEVICE|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
215124032|NCT04188938|OTHER|Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma|
215124033|NCT04075344|OTHER|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
215124034|NCT03543761|DEVICE|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
215124035|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
215124036|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
215124037|NCT06097065|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Grouping based on detected oral glucose tolerance test results without any other intervention.
215124038|NCT00293917|DRUG|Tacrolimus Cream|
215124039|NCT05222828|DRUG|Carbocaine Injectable Product|One injection per patient
215124040|NCT00226928|BEHAVIORAL|Supportive-Expressive Group Therapy plus education|
215124041|NCT00226928|BEHAVIORAL|Education|
215124042|NCT03096340|DRUG|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
215124043|NCT04404231|RADIATION|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
215124044|NCT04404231|OTHER|No Infrared treatment|This is sham treatment. No light is actually given.
215124045|NCT00006107|DRUG|Taxotere|
215124046|NCT00006107|PROCEDURE|Surgery|
215124047|NCT00006107|RADIATION|radiation therapy|
215124048|NCT02251626|DIETARY_SUPPLEMENT|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
215124049|NCT02251626|DIETARY_SUPPLEMENT|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
215124050|NCT03025646|OTHER|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~1. Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~   Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~2. Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
215124051|NCT00634439|DRUG|atomoxetine|
215124052|NCT00634439|DRUG|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
215124053|NCT00634439|OTHER|No intervention (general population)|
215124054|NCT03117816|DRUG|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
215124055|NCT03117816|OTHER|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
215124056|NCT02104453|PROCEDURE|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
215124057|NCT04592588|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
215124058|NCT04592588|BEHAVIORAL|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
215124059|NCT00806910|DRUG|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
215124060|NCT00806910|OTHER|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
215124061|NCT00141674|PROCEDURE|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
215124062|NCT01623115|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
215124063|NCT01623115|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
215124064|NCT01623115|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
215124065|NCT03827655|DRUG|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
215124066|NCT03827655|DRUG|TAK-954|TAK-954 intravenous infusion.
215124067|NCT05543954|DRUG|68Ga-FAPI-RGD|Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
215124068|NCT05543954|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
215124069|NCT05543954|DRUG|68Ga-FAPI|Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
215124070|NCT05543954|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
215124071|NCT00898963|GENETIC|gene expression analysis|
215124072|NCT00898963|GENETIC|microarray analysis|
215124073|NCT00898963|GENETIC|polymorphism analysis|
215124074|NCT00898963|OTHER|diagnostic laboratory biomarker analysis|
215124075|NCT00898963|OTHER|immunohistochemistry staining method|
214446111|NCT04272619|BEHAVIORAL|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
215124076|NCT00898963|OTHER|immunologic technique|
215124077|NCT03833739|DEVICE|Fixed appliance|
215124078|NCT02587741|DRUG|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
215124079|NCT02587741|DRUG|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
215124080|NCT02587741|DRUG|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
214446112|NCT04495452|DRUG|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
215030453|NCT00967499|DRUG|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
215030454|NCT00091975|DRUG|Zemplar Capsule|
215124081|NCT00961311|PROCEDURE|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
215124082|NCT00961311|DEVICE|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
215124083|NCT03075618|BEHAVIORAL|Questionnaires|Questionnaires
215124084|NCT04959747|OTHER|acupuncture|"Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
215124085|NCT02670486|OTHER|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
215124086|NCT03930693|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice shot (70mL containing 400mg inorganic nitrate)
215124087|NCT01473290|DIETARY_SUPPLEMENT|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
215124088|NCT01473290|OTHER|placebo|Given PO
215124089|NCT01721161|BIOLOGICAL|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
215124090|NCT01721161|DRUG|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
215124091|NCT01335139|BIOLOGICAL|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
215124092|NCT01335139|BIOLOGICAL|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
215124093|NCT01335139|OTHER|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
215124094|NCT01645072|OTHER|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI \>55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
215124095|NCT01645072|OTHER|Control group|The ongoing anti epileptic drug treatment will be continued without change.
215124096|NCT06063863|DIAGNOSTIC_TEST|Nurse led screening with Optos ultra-widefield retinal-imaging device|The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
215124098|NCT04247386|DRUG|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
215124099|NCT04247386|DRUG|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
215124100|NCT04404868|OTHER|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
215124101|NCT00434226|DRUG|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
215124102|NCT00434226|DRUG|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
215124103|NCT00434226|DRUG|carboplatin|On the first day of each cycle for 4 cycles
215124104|NCT00434226|DRUG|paclitaxel|On the first day of each cycle for 4 cycles
215124105|NCT00115505|OTHER|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
214446113|NCT04496960|DRUG|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
214446114|NCT04496960|OTHER|Placebo|white, round, film-coated tablet
214446115|NCT05078619|PROCEDURE|No PCI|Omission of PCI of significant coronary artery disease prior to TAVI
214446116|NCT05840809|DRUG|First line tuberculosis treatment|This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
214446117|NCT06844149|BEHAVIORAL|CPR; (Cardiac and Psychosocial Rehabilitation) with Cardiac Rehabilitation|This intervention combines an 8-week Cognitive Behavioral Therapy (CBT)-based psychosocial rehabilitation program with a structured Home-Based Cardiac Rehabilitation (CR) program for young adults with Fontan circulation. The CBT component includes weekly 90-minute group sessions focusing on stress management, cognitive restructuring, and social coping skills. The CR component consists of a personalized aerobic exercise plan, starting at 15-30 minutes per session and progressing to 40-60 minutes, with weekly monitoring and adjustments. This combined intervention is provided exclusively to participants in the CPR group
214446118|NCT06844149|BEHAVIORAL|CR; Home-Based Cardiac Rehabilitation|This intervention consists of an 8-week Home-Based Cardiac Rehabilitation (CR) program designed for young adults with Fontan circulation. Participants follow a structured aerobic exercise plan tailored to their cardiopulmonary fitness levels. The program starts with 15-30 minutes of exercise per session, progressing to 40-60 minutes, with intensity set at 60-70% of maximum heart rate. Exercise adherence is monitored through weekly follow-ups, with adjustments made as needed. This intervention is provided to participants in both the CR group and the CPR group but without the Cognitive Behavioral Therapy (CBT) component in the CR-only group.
214446119|NCT06844149|BEHAVIORAL|Usual Care|Participants in the control group received usual care without any additional interventions. They did not participate in the Cognitive Behavioral Therapy (CBT)-Based Psychosocial Rehabilitation or the Home-Based Cardiac Rehabilitation (CR) programs during the study period. After the study was completed, they were given the option to enroll in the CPR program. This group serves as a comparison to evaluate the effectiveness of the interventions in the CPR and CR groups
215124106|NCT00115505|OTHER|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
215124107|NCT02888106|DRUG|Myrcludex B|Lyophilised powder for solution for subcutaneous injection
215124108|NCT02888106|DRUG|PEG IFN alfa-2a|solution for subcutaneous injection, once per week
215124109|NCT02888106|DRUG|Tenofovir|Film-coated tablets, 300 mg, per os, once daily
215124110|NCT05861596|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
215124111|NCT05861596|DEVICE|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
215124112|NCT00017602|BIOLOGICAL|oblimersen sodium|
215124113|NCT00017602|DRUG|dexamethasone|
215124114|NCT03782519|OTHER|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
215124115|NCT03782519|OTHER|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
215124116|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
215124117|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
215124118|NCT00930696|PROCEDURE|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
215124119|NCT00930696|PROCEDURE|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
215124120|NCT05007522|DRUG|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
215124121|NCT05007522|DRUG|Placebo|Matching placebo tablet
215124122|NCT01813916|OTHER|proteomic analysis|
215124123|NCT00694616|DEVICE|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
215124124|NCT00694616|DEVICE|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
215124125|NCT04363203|DRUG|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.
215124126|NCT04363203|DRUG|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
215124127|NCT04363203|DRUG|Placebo oral tablet|Placebo in pill packs identical to study drugs
215124128|NCT02643108|PROCEDURE|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
215124129|NCT02995356|OTHER|Collecting cervical liquid and sera samples|
215124130|NCT04703088|DRUG|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
215124131|NCT04703088|DRUG|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
214446120|NCT06846060|BEHAVIORAL|Mindfulness-Based Self-Compassion Program|Mindfulness-based intervention programs are a program that includes a special session in which body and mind are integrated, and consists of homework for participants on yoga, meditation and a mindfulness-based approach to vital events in order to be aware of the moment. The conscious awareness-based self-compassion program, created in line with the literature, consists of 8 sessions in total, in groups of 5-8 people, on the same day and time every week. There are specific goals and objectives for each session, and each session also has a separate theme along with its subject.
214446121|NCT04905537|OTHER|No intervention|It's only observational study. No interventions.
214446122|NCT06848049|OTHER|Mobile Aplication|In this study, individuals will be monitored for 28 days. They will be asked to fill out the Pressure Injury Information Form and the Pressure Injury Skills Checklist for Caregivers to be informed about pressures throughout the study process. The researcher will fill out the Bates-Jensen Wound Assessment Tool to ensure that their pressures are improving. Individuals who will undergo the intervention will use the mobile application. Face-to-face training will be provided to individuals. Individual-specific audio reminders will be based on daily living activities and will be delivered via the mobile application according to changes in individual dependencies. After 30 days, individuals will be asked to fill out the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist. The Bates-Jensen Wound Assessment Tool will be filled out by the researcher.
215124132|NCT01244685|DEVICE|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
215124133|NCT04033562|DRUG|Lidocaine patch|Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
215124134|NCT04033562|DEVICE|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
215124135|NCT01774032|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
215124136|NCT03262220|RADIATION|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
215124137|NCT06239740|PROCEDURE|Electroacupuncture group|The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.
215124138|NCT06239740|PROCEDURE|Sham acupuncture|participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
215124139|NCT01101399|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
215124140|NCT06491602|DIAGNOSTIC_TEST|renal biobsy|analsis of renal biobsy and decide grade of renal affection
215124141|NCT04265196|OTHER|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
215124142|NCT04265196|OTHER|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
215124143|NCT00006269|DRUG|irinotecan hydrochloride|
215124144|NCT00006269|DRUG|octreotide acetate|
215124145|NCT01069432|OTHER|No Intervention|No Intervention
215124146|NCT00498459|BEHAVIORAL|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
214446123|NCT06848049|OTHER|Control|In this study, individuals will be monitored for 28 days. In order to monitor their knowledge about pressure injuries, individuals will be asked to complete the Pressure Injury Information Form for Caregivers and the Pressure Injury Skills Checklist to monitor their skill levels about pressure injuries throughout the study period. The Bates-Jensen Wound Assessment Tool will be completed by the researcher to perform a physical examination of the patient and to assess the healing of the individual's pressure injury. Individuals in the control group will be interviewed twice by phone. Individuals with pressure injuries will be trained by a team consisting of a physician, nurse, dietician, and physiotherapist. Individuals will be interviewed twice by phone. After 30 days, individuals will be asked to complete the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist.
214446124|NCT06846619|DEVICE|Intra-Oral Scanning Method|"Intervention Description:~The intra-oral scanning method involves capturing digital impressions of the oral cavity directly using the 3Shape scanner. This method eliminates the need for traditional impression materials, providing a more comfortable and precise imaging process. The digital impressions are then utilized to design and fabricate maxillary dentures using 3D printing technology. The intervention focuses on evaluating patient satisfaction with the dentures in terms of comfort, fit, and aesthetics."
214446125|NCT06846619|DEVICE|Extra orally scanned|The extra-oral scanning method involves creating conventional impressions of the oral cavity using traditional impression materials. These impressions are then scanned externally using the 3Shape scanner to produce digital models. The digital models are used to design and fabricate maxillary dentures through 3D printing technology. This intervention aims to assess patient satisfaction with the dentures based on comfort, fit, and aesthetics.
215124147|NCT04035733|DRUG|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
215124148|NCT00860730|DEVICE|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
215124149|NCT04602403|PROCEDURE|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
215124150|NCT05003947|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
215124151|NCT00128895|DRUG|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
215124152|NCT04045327|DRUG|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
214446126|NCT05185856|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
215124153|NCT04045327|DRUG|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
215124154|NCT01324661|BEHAVIORAL|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
215124155|NCT02426840|DIETARY_SUPPLEMENT|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
215124156|NCT02426840|DIETARY_SUPPLEMENT|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
215124157|NCT01894607|PROCEDURE|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
215124158|NCT01894607|DRUG|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
215124159|NCT01894607|BEHAVIORAL|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
215124160|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
215124161|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
215124162|NCT01398371|DRUG|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
215124163|NCT01398371|DRUG|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
215124164|NCT04579471|DIAGNOSTIC_TEST|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
215124165|NCT00431626|DRUG|Dutasteride (Avodart)|
215124166|NCT00431626|DRUG|Placebo|Placebo before and after treatment of TURP
215124167|NCT02673918|OTHER|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
214446127|NCT05185856|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
214446128|NCT06843941|OTHER|Music intervention|"In the music group, MusiCure® compositions, which feature soft rhythmic melodies, were chosen. These musical pieces were composed by Danish composer Niels Eje (MusiCure, 2020) and are therapeutic in nature, designed for physical and mental relaxation within a range of 60-80 bpm (Eje, 2020). Literature reviews indicate that the MusiCure® album has positive effects on conditions such as pain, well-being, and anxiety (Fredriksson et al., 2009; Nilsson et al., 2009). The pieces to be used in this study were selected after communication with Niels Eje, and the recommended pieces were Winter, Early Spring, Equator, and Ocean Echoes (MusiCure, 2020). The music was presented hygienically to the participants through headphones and played for 30 minutes in four tracks via an mp3 player."
214523102|NCT06720129|DEVICE|the modified pressure-reducing fixation protective nasal strip|Materials Preparation consists of one foam dressing, one piece of 3M tape, and two pairs of scissors. 2. Manufacturing Procedure: step 1 Cut the foam dressing into two large rectangles and one little T-shape based on the patient's face shape and size as well as the width of the nasolabial fold. Attach these sections to the nasolabial fold region and both cheeks, respectively . Step 2: Based on the size of the oxygen cannula, set up small, medium, and large fixation patch models. Select the appropriate model according to the patient's condition and make the necessary cuts to properly secure the nasal prongs. Step 3: Check the tightness of the head strap, ensuring it is snug enough to fit one finger beneath it to avoid pressing on the skin around the ears. Ensure proper placement on the patient. See Figure 1 for detailed application.
215124168|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
215124169|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
215124170|NCT03824041|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
215124171|NCT05706948|OTHER|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
215124172|NCT05706948|OTHER|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
215124173|NCT05533996|DIAGNOSTIC_TEST|ultrasound|Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
214446129|NCT03561103|BEHAVIORAL|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
214446130|NCT03709134|DIAGNOSTIC_TEST|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
214446131|NCT05783219|DRUG|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
215124174|NCT05586919|PROCEDURE|Direct Puncture Repair / Ethanol|Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
215124175|NCT05586919|PROCEDURE|Direct Puncture Repair / Polidocanol|Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
215124176|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
215124177|NCT05189470|PROCEDURE|Inforatio technique|Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
215124178|NCT05189470|OTHER|Usual care of the respective outpatient clinics|Usual care of the DFUs includes local wound care and offloading treatment.
214523103|NCT06720129|DEVICE|Standard care alone|standard care plus a hydrocolloid dressing for protection
214523104|NCT06703099|DIETARY_SUPPLEMENT|Magnesium Supplementation|Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning over 8 weeks.
214523105|NCT06720493|DEVICE|echocardiographic assessment of shocked patients to fluid administration|hemodynamic assessment of pediatric shocked patients using different modalities like echocardiography and electrical cardiometry
215124179|NCT00881114|DRUG|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
214446132|NCT05783219|OTHER|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
214446133|NCT03818191|DRUG|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
214446134|NCT03818191|OTHER|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
214446135|NCT06842511|DRUG|open flap debridement and Hyaluronic Acid-Based Gel application|Hyaluronic Acid-based gel as an adjunctive chemotherapeutic agent
214446136|NCT06842511|PROCEDURE|open flap debridement|periodontal surgery technique
214446137|NCT05560815|PROCEDURE|Any surgical procedure|Might differ for substudies.
214446138|NCT05762367|DIAGNOSTIC_TEST|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
214446139|NCT05939193|PROCEDURE|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
214446140|NCT05939193|PROCEDURE|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
214446141|NCT05939193|DRUG|Forced administration of furosemide|Forced administration of furosemide
214446142|NCT05939193|DRUG|Routine administration of furosemide|Routine administration of furosemide
214446143|NCT06469853|DRUG|MBF-015 16 mg oral capsules|MBF-015 oral capsules HDAC inhibitor
215124180|NCT00881114|DRUG|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
215124181|NCT05287828|OTHER|Surgeons CT scan analysis|Surgeons extract indicators using standard methods of analysis
215124182|NCT05287828|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed using PRAEVAorta Suite which is composed of the software PRAEVAorta 2 and PRAEVAorta Web. Indicators extraction is fully automatic.
214446144|NCT05299476|DRUG|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
214446145|NCT06276257|PROCEDURE|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
214446146|NCT06276257|PROCEDURE|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
214446147|NCT02944825|DRUG|Ciprofloxacin|first line prophylactic oral antibiotic
214523106|NCT03476538|DRUG|Gabapentin|Patients are tested for their normal prescription gabapentin medication
214523107|NCT06900140|DRUG|Methylene Blue|Continuous methylene blue infusion at a fixed dose of 0.50 mg/kg/hour (diluted in 500 mL of dextrose 5% in water) over 6 hours once daily, for a total of up to 3 doses.
214523108|NCT06900140|OTHER|Usual Care|Usual guideline-directed care for adult septic shock.
214523109|NCT03728803|DEVICE|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
214523110|NCT05838976|DIAGNOSTIC_TEST|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
214523111|NCT00569036|DRUG|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
215124183|NCT01862913|OTHER|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
215124184|NCT01862913|OTHER|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
215124185|NCT03546582|DRUG|Pembrolizumab|Anti-PD-1 targeted immunotherapy
215124186|NCT03546582|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
215124187|NCT02738554|OTHER|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
215124188|NCT05005975|DRUG|MT-7117|MT-7117
215124189|NCT04998955|BEHAVIORAL|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
215124190|NCT03374579|DIAGNOSTIC_TEST|Fluid challenge|Fluid challenge and measure change in co2 gap
215124191|NCT02927392|DRUG|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
215124192|NCT05184530|DRUG|Evolocumab 140 MG/ML|140 mg per two weeks, subcutaneous injection
215124193|NCT00278733|BEHAVIORAL|Brief intervention (physician advice)|
215124194|NCT04287621|DRUG|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
215124195|NCT03708978|DIAGNOSTIC_TEST|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
215124196|NCT00512876|DRUG|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
215124197|NCT05187078|PROCEDURE|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
215124198|NCT05187078|PROCEDURE|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
215124199|NCT06410014|OTHER|No intervention is performed|The study is observational
215124200|NCT03455738|OTHER|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a \>10% decrease in mean arterial pressure (MAP).
214446148|NCT02944825|DRUG|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
214446149|NCT02944825|DRUG|No Intervention|No intervention
214446150|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
214446151|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
214446152|NCT04703322|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
214446153|NCT05912504|OTHER|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
214523112|NCT01613183|DRUG|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
215124201|NCT03674632|BEHAVIORAL|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
215124202|NCT04083365|DRUG|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
215124203|NCT04083365|DRUG|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
215124204|NCT04083365|DRUG|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
215124205|NCT03342417|BIOLOGICAL|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
215124206|NCT03342417|BIOLOGICAL|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
215124207|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
215124208|NCT01708317|BEHAVIORAL|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
215124209|NCT06164574|OTHER|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
215124210|NCT02493686|DIAGNOSTIC_TEST|audiogram|hearing test
215124211|NCT02401347|DRUG|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
214446154|NCT05592288|OTHER|PREDIABE-TR mobile app.|"* Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
214523113|NCT01613183|OTHER|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
215124212|NCT05037474|PROCEDURE|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
215124213|NCT02843906|PROCEDURE|Lombar Punction|cerebrospinal fluid testing at screening and M36
215124214|NCT02843906|RADIATION|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
215124215|NCT02843906|RADIATION|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
215124216|NCT02843906|OTHER|Psychiatric tests|
215124217|NCT02843906|OTHER|Neuropsychological Tests|done at screening, M12, M24 and M36
215124218|NCT02843906|GENETIC|Apolipoprotein (ApoE) detection|ApoE detection done at screening
215124219|NCT02936674|DEVICE|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
214523114|NCT00705614|BIOLOGICAL|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
215124220|NCT02936674|DEVICE|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
215124221|NCT00363636|DRUG|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
214694280|NCT06864949|DEVICE|AMCOP appliance|"The device measure will be determined with OrthoCad program on digital models, taking the distance between the vestibular cusps of the upper first molars, at the level of the most prominent point. AMCOPs are preformed devices and there are five different measures based on transverse diameter: 1 (45mm), 2 (50mm), 3 (55mm), 4 (60mm), 5 (65mm).~Requiring expansion, we will choose an higher AMCOP measure than the transverse distance measured on the digital models at T0.~The clinical indications for use of the AMCOP device will be as follow:~* in the first week, wear the appliance during the night and for 30 minutes during the day~* from the second week onward, wear the appliance for one hour during the day and throughout the night During this time, every month we will visit patients and we will expand the device by soaking it in hot water at about 70 °C for 30 s and then in cold water to stabilize it in its new shape."
214694281|NCT07075380|BEHAVIORAL|online questionnaire|Online questionnaire assessing physical activity level, completed twice at a 6-month interval.
214694282|NCT00500045|DRUG|nicotinic acid|niacin 1500 mg po qd
214694283|NCT00380354|DRUG|GSK256066|
214523115|NCT00742014|DRUG|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
214523116|NCT01044901|PROCEDURE|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
214523117|NCT05381077|OTHER|MRI|Whole body MRI (ZTE sequence)
214694284|NCT07082114|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 52 weeks
214694285|NCT07082114|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 52 weeks
214694286|NCT07082114|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 52 weeks
214694287|NCT07082114|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg will be provided
215124222|NCT00363636|DRUG|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
215124223|NCT04104386|OTHER|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
215124224|NCT02660164|DEVICE|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
214694288|NCT07083531|OTHER|Healthy volunteers without SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
214694289|NCT07083531|OTHER|Healthy volunteers with SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
214694290|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
214694291|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
215124225|NCT00957879|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
215124226|NCT00957879|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
215124227|NCT01111695|DEVICE|ApisSept|honey and ionic silver based dressing
215124228|NCT02354534|DRUG|Artesunate Suppositories|
214694292|NCT07082192|DRUG|Test drug CB03-154 5mg group|One CB03-154 tablet (5mg/tablet) once daily.
214694293|NCT07082192|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
215124229|NCT00174902|DRUG|inderal (drug), acetylsalicylic acid (drug)|
215124230|NCT00374439|BEHAVIORAL|Cognitive-behavioral|Cognitive-behavioral approach
215124231|NCT00374439|BEHAVIORAL|Interpersonal Therapy|Interpersonal therapy approach
215124232|NCT03169335|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
215124233|NCT03169335|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
215124234|NCT03169335|DRUG|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
215124235|NCT03169335|DRUG|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
215124236|NCT03458312|BEHAVIORAL|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
215124237|NCT06526416|OTHER|Anterior segment optical coherence tomography|Imaging of the anterior segment of the eye using optical coherence tomography
215124238|NCT02972203|BEHAVIORAL|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
215124239|NCT02972203|BEHAVIORAL|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
214446155|NCT03805048|PROCEDURE|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
214446156|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
214446157|NCT06311084|OTHER|Imaginator 2.0|Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
214446158|NCT04870203|DRUG|baricitinib treatment|4 mg daily during 12 months
214446159|NCT04870203|DRUG|anti-TNF therapy|adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history
214446160|NCT04870203|DRUG|Placebo|40 mg every 2 weeks during 6 months only during Period A
214694294|NCT07082192|DRUG|Test drug CB03-154 15mg group|Three CB03-154 tablets (5mg/tablet) once daily.
214694295|NCT07082192|DRUG|Placebo Group|Three Placebo tablets once daily.
214694296|NCT07084311|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
215124240|NCT04469972|OTHER|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
215124241|NCT03259555|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
215124242|NCT03259555|DRUG|Placebo|Administered orally daily for 3 weeks.
215124243|NCT05057663|DRUG|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
215124244|NCT03965013|DRUG|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
215124245|NCT03965013|DRUG|Placebo|A single dose of placebo given in Part 1
215124246|NCT03965013|DRUG|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
215124247|NCT00000346|BEHAVIORAL|counseling|
215124248|NCT03850860|OTHER|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
214523118|NCT00676195|DRUG|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
215124249|NCT01363089|DRUG|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
215124250|NCT01363089|DRUG|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
215124251|NCT05894785|PROCEDURE|External cephalic version|An ECV attempt is made on the study group
215124252|NCT02194595|DRUG|Basal insulin and exenatide|
215124253|NCT02194595|DRUG|Basal insulin only|
215124254|NCT02194595|DRUG|Basal insulin and bolus insulin|
215124255|NCT05943886|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
215124256|NCT05943886|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen.
215124257|NCT02552030|DEVICE|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
215124258|NCT02552030|DEVICE|iPhone 4s|
215124259|NCT02147756|DEVICE|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
215124260|NCT02147756|DEVICE|Repair|
215124261|NCT05772624|DRUG|low dose nivolumab in combination with AVD|Nivolumab as an standard dose of 40mg in combination with AVD.
215124262|NCT04339816|DRUG|Azithromycin|orally or into nasogastric tube for 5 days
215124263|NCT04339816|DRUG|Hydroxychloroquine|orally or into nasogastric tube for 5 days
215124264|NCT04339816|DRUG|Placebo|orally or into nasogastric tube for 5 days
215124265|NCT00583336|DEVICE|ShuntCheck|Thermal dilution test for CSF flow
215124266|NCT03420872|OTHER|Nutrient mixtures|consumption of a mixture of beneficial nutrients
215124267|NCT00148148|DRUG|caspofungin|
215124268|NCT00148148|DRUG|liposomal amphotericin B|
215124269|NCT01190501|DEVICE|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
215124270|NCT05137964|DIAGNOSTIC_TEST|Vitamin D|Serum Biochemical routine lab workup and gynaecological ultra sound AFC
215124271|NCT03392220|PROCEDURE|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
215124272|NCT03392220|PROCEDURE|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
215124273|NCT03406273|RADIATION|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
215124274|NCT03406273|RADIATION|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
215124275|NCT03887013|DRUG|Trimetazidine|Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
214523119|NCT01676883|DEVICE|Bioelectric impedance|removal of calluses and corns by pedicure
214523120|NCT01676883|DEVICE|Air displacement plethysmography|
214523121|NCT00213226|DRUG|dexamethasone|
214523122|NCT00978783|DEVICE|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
214523123|NCT00978783|DEVICE|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
214523124|NCT01414543|OTHER|Information Sheet|Providing the Participant with information regarding the aim of the experiment
215124276|NCT04393493|DRUG|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
215124277|NCT04393493|DRUG|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
215124278|NCT04393493|DRUG|Spironolactone|One 50 mg pill administrated every 24 hours in group B
215124279|NCT02654548|OTHER|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
215124280|NCT00778115|DRUG|Loperamide HCl 2 mg and simethicone 125 mg tablets|
215124281|NCT05416905|DEVICE|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
215124282|NCT05416905|DEVICE|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
215124283|NCT01125800|DRUG|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
215124284|NCT05177614|DIETARY_SUPPLEMENT|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
215124285|NCT05177614|DIETARY_SUPPLEMENT|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
215124286|NCT05177614|DIETARY_SUPPLEMENT|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
215124287|NCT01492205|DRUG|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
215124288|NCT04885335|OTHER|PAS (Pediatric Appendicitis Score) survey|Score ≤ 5: appendicitis unlikely. Score ≥ 6: probable appendicitis. core ≥ 7: very probable appendicitis
215124289|NCT00549315|DEVICE|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
215124290|NCT02687464|OTHER|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
215124291|NCT02687464|PROCEDURE|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
215124292|NCT04528160|OTHER|Pain neuroscience education and exercise|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
214694297|NCT07083973|BEHAVIORAL|Prone position|"Patients were ventilated based on the ARDS-Net recommendations . Patients were kept in a supine position. The process of lung ventilation and perfusion assessment was as follows:~1. PEEP was determined by the attending doctor and was kept the same during the supine and prone period.~2. 3D-EIT was used to monitor the ventilation and perfusion of ARDS patients at three timepoints: T1: supine position, T2: prone position at 30min, T3: prone position over 10 hours."
215124293|NCT04528160|OTHER|Usual Care|Usual care delivered at primary care for older adults with pain.
215124294|NCT02625805|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
215124295|NCT02625805|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
215124296|NCT02625805|DRUG|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
215124297|NCT01876355|DRUG|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
215124298|NCT01876355|DRUG|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
215124299|NCT00055692|BIOLOGICAL|bevacizumab|Given orally
215124300|NCT05774301|BEHAVIORAL|simulation-based training|the training will include a theoretical \& practical parts
215124301|NCT00966615|OTHER|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
215124302|NCT00966615|OTHER|glucose-based dialysis solution|2-L exchange; three times a day
215124303|NCT01168726|BEHAVIORAL|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
215124304|NCT01168726|BEHAVIORAL|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
215124305|NCT01168726|BEHAVIORAL|Alcohol Education|Educational information about harms associated with heavy drinking.
215124306|NCT04332107|DRUG|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
215124307|NCT04332107|DRUG|Placebos|Participants will be shipped a dose of matching placebo
215124308|NCT01908452|DRUG|Pyridoxine|1200 mg/d during 12 weeks
215124309|NCT02348593|DRUG|JZP-110|
215124310|NCT02348593|DRUG|Placebo oral tablet|
215124311|NCT02290015|OTHER|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
215124312|NCT04354324|DRUG|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
215124313|NCT01670721|DRUG|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
215124314|NCT01670721|DRUG|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
215124315|NCT01670721|DRUG|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
215124316|NCT01670721|DRUG|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
215124317|NCT03216408|DRUG|Neuronox|
215124318|NCT03216408|DRUG|Botox|
215124319|NCT00271102|PROCEDURE|anterior vaginal repair (colporrhaphy)|vaginal repair
215124320|NCT00271102|PROCEDURE|abdominal paravaginal defect repair|abdominal repair
215124321|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
215124322|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
215124323|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
215124324|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
215124325|NCT00597688|DRUG|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
215124326|NCT00597688|DRUG|Placebo gel|Oral mucosal application of placebo gel
215124327|NCT06669208|BIOLOGICAL|HydroVax-005 CHIKV|HydroVax-005 CHIKV vaccine
215124328|NCT06669208|OTHER|Placebo|NaCl 0.9%, Normal Saline
215124329|NCT05414292|DRUG|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
215124330|NCT05414292|BEHAVIORAL|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
215124331|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
215124332|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
215124333|NCT01001247|DRUG|TMC278; Omeprazole|
215124334|NCT06216938|BIOLOGICAL|Vusolimogene oderparepvec (RP1)|Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
215124335|NCT06726317|BEHAVIORAL|Early palliative care integration|The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
215124336|NCT06725654|OTHER|Diagnostic Procedures|To evaluation the oral and dental health of orphaned children, DMFT, deft, GI, PI and CPITN indices were used to assess dental caries experience, gingival inflammation, the amount of plaque on the tooth surface and periodontal status, respectively.
214523125|NCT01414543|OTHER|Consent|Providing a consent form for participants. The participant is aware of his or her rights
215124337|NCT06725342|GENETIC|Combined DNA/RNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.|"Dual extractions (DNA/RNA) will be carried out from macrodissected thick unstained FFPE sections; samples will be measured for adequate quality / quantity; libraries will be constructed separately with each panel and samples will be sequenced in the same chip in an Ion Torrent Proton System, according to the manufacturer's instructions.~Sequencing results will be called with the Variant Caller for each panel and submitted for initial analysis and annotation to the Ion Reporter pipeline with each DNA and RNA panel"
215124338|NCT06727175|BEHAVIORAL|non-invasive neuromodulation therapy|Patients with subjective tinnitus were treated using non-invasive neuroregulation therapy. That is, to generate personalized, non-invasive acoustically stimulated neuroregulation regimens for six montns. Each participant was treated three times a day (morning, noon and bedtime) for 30 minutes each time.
214523126|NCT01414543|OTHER|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
214523127|NCT01414543|OTHER|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
214523128|NCT03787719|OTHER|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
214523129|NCT03498885|PROCEDURE|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
214523130|NCT03498885|PROCEDURE|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
214523131|NCT02878590|DEVICE|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
214523132|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
214523133|NCT02661490|DRUG|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
214523134|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
214523135|NCT00185796|PROCEDURE|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
214523136|NCT00185796|PROCEDURE|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
214523137|NCT03448354|PROCEDURE|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
214523138|NCT04999956|PROCEDURE|dynamic navigation surgery|immediate implant placement using dynamic navigation
214523139|NCT04999956|PROCEDURE|freehand surgery|immediate implant placement using freehand surgery
214523140|NCT00019019|DRUG|carboxyamidotriazole|
214523141|NCT00019019|DRUG|paclitaxel|
214523142|NCT04891159|OTHER|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
214523143|NCT05381181|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
215124339|NCT06727175|OTHER|before any intervention|before any intervention
215124340|NCT06921447|OTHER|Clinical Cases|Seven clinical cases that have to be analysed
215124341|NCT06752239|RADIATION|Modified delineation|Modified delineation (MD) of cervical lymphatic drainage areas, sparing the common carotid artery within the clinical target volume (CTV)
214523144|NCT05441371|OTHER|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
214523145|NCT04176926|DIAGNOSTIC_TEST|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
214523146|NCT05918289|BEHAVIORAL|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
214523147|NCT02782598|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
215124342|NCT06752239|RADIATION|Standard delineation|Standard delineation
214523148|NCT02880969|BEHAVIORAL|answering questionnaires|
214523149|NCT02591914|DRUG|Fovista™|Anti-PDGF-B pegylated aptamer
214523150|NCT02591914|DRUG|Lucentis®|Anti-VEGF
214523151|NCT02591914|DRUG|Avastin®|Anti-VEGF
214523152|NCT02591914|DRUG|Eylea®|Anti-VEGF
214523153|NCT01755247|DRUG|Topical Gel Vehicle|
214523154|NCT01755247|DRUG|8% NVN1000 Topical Gel|
214523155|NCT01755247|DRUG|8% NVN1000 Topical Gel and moisturizer|
214523156|NCT00202306|DRUG|lithium carbonate|
214523157|NCT02243436|DRUG|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
214523158|NCT02243436|DRUG|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
214523159|NCT02243436|DRUG|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
214523160|NCT02243436|DRUG|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
214523161|NCT02243436|DRUG|Ara C|Intravenous use, 2g/m2, day 5
214523162|NCT05947708|DEVICE|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
215124343|NCT05657990|DRUG|Tamsulosin|Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
215124344|NCT06906978|PROCEDURE|blood sampling|Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.
215124345|NCT05524220|DEVICE|Standard care with a facemask.|The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
215124346|NCT05524220|DEVICE|SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)|The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
215124347|NCT04088006|DEVICE|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
215124348|NCT00434187|DRUG|ERB-041|
215124349|NCT06910748|BEHAVIORAL|E-training for Medical Professionals On Wellbeing and Effective Resolutions (E.M.P.O.W.E.R.)|The EMPOWER programme aims to help participants acquire problem-solving skills adapted into the context of MPs' workplace and daily life to address their work-related, personal, and interpersonal problems, including self-neglect, work-life imbalance, patient communication problems, as well as stress during emerging public health crises. The session elements include video introduction, metaphors, daily examples, and narrative stories with prototype MP characters depicting the targeted problems to demonstrate how the taught problem-solving skills could be applied in a variety of situations. Brief exercise and homework will be assigned after each session and personalized written feedback will be provided.
215124350|NCT06910748|OTHER|Education Materials|The waitlist control receive education materials covering (1) introduction of mental health problems; (2) signs, symptoms, causes, and consequences of anxiety and depression, and (3) treatment approaches and available community resources.
215124351|NCT06319898|BEHAVIORAL|Lavender aromatherapy sticker|Lavender aromatherapy during procedure, music and dim lighting
215124352|NCT06914544|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
215124353|NCT05321927|DEVICE|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 7 pulses per burst for the last 5 minutes.
215124354|NCT05321927|OTHER|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
215124355|NCT05321927|DEVICE|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
215124356|NCT06914947|BEHAVIORAL|Brain Health Together|Each week, the program included a 1-hour group brain health education class, a 1-hour group Moving Together class, and a 30-minute individual brain health coaching session (total: 2.5 hours/week). Before the first session, participants were asked to complete a brief online survey about lifestyle behaviors and medical conditions related to dementia risk. The first 4 brain health education classes focused on general content to introduce and reinforce the concept that healthy lifestyle behaviors and management of chronic medical conditions can improve cognitive function, delay cognitive decline, and potentially prevent dementia. Another goal was to introduce participants to health coaching and to help participants each set specific, measurable, achievable, realistic, time-limited (SMART) goals to improve brain health. The remaining 8 weeks were adjusted to accommodate participant feedback in the early portion of the pilot study.
215124357|NCT04894669|DEVICE|INVSENSOR00045|Noninvasive sensor will be fitted to the subject's hand, foot, or toe to measure oxygen saturation and pulse rate.
214446161|NCT06770166|OTHER|Physiological serum mouthwash|Physiological serum contains sodium chloride : 0.009 g/ml, sodium 154 (mEq/I), chloride 154 (mEq/I)\].
214446162|NCT06770166|OTHER|Chlorhexidine mouthwash|Chlorhexidine mouthwash contains 0.12% chlorhexidine digluconate and 0.15% benzydamine hydrochloride.
214446163|NCT06770166|OTHER|Chamomile mouthwash|Chamomile mouthwash contains 10% chamomile in physiological serum.
214446164|NCT05470907|DEVICE|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
214446165|NCT04049747|PROCEDURE|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]
214446166|NCT04049747|PROCEDURE|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
214446167|NCT04049747|PROCEDURE|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
214446168|NCT04049747|PROCEDURE|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
214446169|NCT05426668|OTHER|No Intervention|No Intervention
214446170|NCT05671185|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
215124358|NCT06911736|OTHER|Trendelenburg position|In addition to the management described above, the postoperative position was modified in the intervention group (trendelenburg). After admission to the hospital unit (general ward, special care, or intensive care unit), the patient's position was adjusted with a 30° leg elevation and a 10° downward head tilt. Proper positioning was verified with a goniometer. This position was maintained until the drains were removed, and the patient was then positioned according to usual care. If the patient decided to get out of bed, the nurse occluded the drains and reopened them when the patient returned to the position described for each group.
215124359|NCT06922565|DEVICE|acupuncture|Subjects in the acupuncture group received traditional acupuncture. The needles were inserted to induce a sense of 'getting qi' and left in place for 30 minutes.
215124360|NCT06922565|DEVICE|sham acupuncture|Sterile disposable retractable needles and a fake placebo acupuncture device are used for sham acupuncture. The acupuncturist attached the base of the sham acupuncture device to the acupoints, and then inserted sterile disposable blunt-tipped retractable needles into the tubes; when the blunt tips touched the skin, the needles retracted into the handles, and there was no sensation of getting qi.
215124361|NCT06920849|BIOLOGICAL|SRP+iPRF|SRP (scaling and root planing) with iPRF (injectable platelet-rich fibrin)
215124362|NCT06920849|PROCEDURE|SRP|SRP (scaling and root planing)
215124363|NCT06918366|DRUG|Part A - single rising dose 1|Inhaled XQ-001
215124364|NCT06918366|DRUG|Part A - single rising dose 2|Inhaled XQ-001 or Placebo
215124365|NCT06918366|DRUG|Part A - single rising dose 3|Inhaled XQ-001 or Placebo
215124366|NCT06918366|DRUG|Part A - single rising dose 4|Inhaled XQ-001 or Placebo
215124367|NCT06918366|DRUG|Part A - single rising dose 5|Inhaled XQ-001 or Placebo
215124368|NCT06918366|DRUG|Part A - single rising dose 6|Inhaled XQ-001 or Placebo
215124369|NCT06918366|DRUG|Part B - mutiple rising dose 1|Inhaled XQ-001 or Placebo
215124370|NCT06918366|DRUG|Part B - mutiple rising dose 2|Inhaled XQ-001 or Placebo
215124371|NCT06922773|DIAGNOSTIC_TEST|Completion of questionnaires; child psychiatric screening; faecal sample analysis|"Completion of questionnaires:~* FFQ (Food Frequency Questionnaire) - completed by child~* KIDSCREEN-10 - completed by child~* CRIES-13 (Child Revised Impact of Events Scale) - completed by parents/guardian and child~* CTES (Childhood Trust Events Survey) - completed by parents/guardian~* RCADS-25 (Revised Children's Anxiety and Depression Scale) - completed by parents/guardian and child~Child psychiatric screening using SCID-5-Junior - semi-structured interview conducted with child and parent(s)/guardian~Faecal sample analysis:~* Beta-diversity (UniFrac and Bray-Curtis distance index)~* Firmicutes/Bacteroidetes ratio~* Abundance of Prevotella, Lactobacillaceae, Bifidobacteriacae and Lachnospiraceae~* Short-chain fatty acid metabolites"
215124372|NCT06922682|BEHAVIORAL|Training with Sudden Infant Death Syndrome Training Booklet|Sudden Infant Death Syndrome Training Booklet was prepared. Prgenant women who agreed to participate were provided a face-to-face training on the risk factors triggering sudden infant death syndrome through the booklet. Following the educational session, they received the safe sleep handout to use at home and were informed that the researcher would call them two months later to check on their adherence to safe sleep practices. Following the training, participants were re-administered the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire and the training booklet was given to them as a gift. Two months after the training, the pregnant women were contacted via phone and they were required to fill out the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire once again.
215124373|NCT06922500|DEVICE|depth of anesthesia|Time spent within recommended pEEG-levels
215124374|NCT06921252|DRUG|chemotherapy agents|Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
215124375|NCT05688696|DRUG|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
215124376|NCT05688696|DRUG|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
215124377|NCT05688696|DRUG|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
214446171|NCT00392067|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
214446172|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
214446173|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
214446174|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
215124378|NCT06921889|PROCEDURE|Autologous Chondrocyte Implantation (ACI)|ACI is a two-stage process that utilises the patient's own chondrocytes to repair damaged chondral tissue. After a harvesting procedure to obtain the cells, the chondrocytes are cultured and expanded in a specialised laboratory. A second procedure is then performed to implant the cells into the defect to replace and regenerate the injured cartilage. ACI allows the knee to generate durable and hyaline-like repair tissue.
215124379|NCT06922201|OTHER|SmartCoach|Participants will receive a tailored life-skills training program over four months, which includes 2-4 personalized messages per week via Whatsapp. These messages, in the form of microdialogues generated by an automated system, will focus on self-management skills, social skills and substance use resistance skills. The program will use interactive elements such as quiz questions, behavioural plans, message contests and multimedia content (audio testimonials, motivational podcasts, videos, images and links to relevant websites).
215124380|NCT06920927|OTHER|Decision aid|Decision aid for use by physicians and patients with CKD when deciding upon an invasive vs a conservative approach to management of coronary artery disease.
215124381|NCT06919601|BEHAVIORAL|Grief-Informed Healing Circles|Eight one-hour sessions delivered in a group setting
215124382|NCT06921629|OTHER|Menstruatie Educatie Kalender (Menstrution Education Calendar) application (MEK-app)|The MEK-APP is a mHealth application to evaluate menstrual complaints like heavy menstrual blood loss and dysmenorrhea. The MEK-APP is a calendar and facilitates daily monitoring of pain intensity using a Visual Analogue Scale (VAS), the amount of blood loss through a pictorial blood loss assessment chart (PBAC), and the impact of these complaints on daily life. The MEK-APP followed the waterfall methodology for software development and the usability was evaluated by both adults and adolescents(4). Furthermore, the MEK app has been approved by the privacy and security officers of Amsterdam UMC
215124383|NCT06921629|OTHER|Questionnaires|"After registration for this study via www.mijnmenstruatie.nl (which has also been approved by the privacy and security officers of Amsterdam UMC), participants received the first digital questionnaire. This questionnaire consisted of a baseline questionnaire, the electronic self bleeding assessment tool (e-self-BATH) and the Menstrual Health Literacy questionnaire.~After using the MEK-app for at least one month, participants received an e-mail with the second questionnaire. This questionnaire consisted of the Menstrual Bleeding Questionnaire; Period ImPact and Pain Assesment; Pelvic Pain Impact Questionnaire; ENDOPAIN-4D; Endometriosis Health Profile 5 and iMTA Productivity Cost Questionnaire."
215124384|NCT06922253|DRUG|Sacubitril and Valsartan-Test product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
215124385|NCT06922253|DRUG|Sacubitril and Valsartan-Reference product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
215124386|NCT06920732|PROCEDURE|VLNT（Vascularized Lymph Node Transfer）|VLNT is a physiologic surgical procedure in which vascularized lymph nodes are harvested from a donor site (e.g., groin or submental region) and transplanted to the affected limb to restore lymphatic drainage. The transferred lymph nodes are anastomosed to recipient vessels to ensure perfusion, aiming to reconstruct lymphatic flow and reduce lymphedema-related swelling and fibrosis.
215124387|NCT06920732|PROCEDURE|LVA（Lymphaticovenular Anastomosis）|LVA is a supermicrosurgical technique designed to improve lymphatic drainage by creating anastomoses between functional lymphatic vessels and nearby venules. Under high magnification, lymphatic vessels (typically \<0.8 mm) are identified and connected to subdermal venules to bypass obstructed lymphatic pathways, facilitating improved lymph flow and symptom relief in patients with early-stage lymphedema.
215124388|NCT06920732|PROCEDURE|LS（Liposuction）|LS is a volume-reduction procedure used in the management of advanced lymphedema characterized by fibroadipose tissue hypertrophy. Tumescent liposuction is performed to remove excess subcutaneous adipose tissue, thereby reducing limb volume and improving limb contour. This procedure is often combined with physiologic surgical techniques for optimal long-term outcomes.
215124389|NCT06918847|OTHER|Myofacial release|Myofascial release (MFR) for the calf muscle will be administered with the patient in a prone position, holding for 120 seconds. The MFR technique involves allowing the lateral aspect of the therapist's thumb to sink into the central portion of the muscle belly. MFR will be performed for 15 minutes.
215124390|NCT06918847|OTHER|Dynamic cupping therapy|In dynamic cupping therapy, patients will be comfortably positioned in a prone position, ensuring that the lower limb is exposed and accessible for treatment. Appropriately sized cups will be selected and applied to the calf and hamstrings region. Prior to application, a small amount of lubricant or oil will be applied to facilitate the smooth movement of the cups over the skin surface during the therapy. The technique of dynamic cupping will involve compressing the cups and gently situating them onto the area being treated, applying the necessary force to generate negative pressure. The duration of dynamic cupping therapy will be 10 minutes.
215124391|NCT06921369|OTHER|Compassionate Care Education Level|Compassionate Care Education Level
215124392|NCT06921369|OTHER|Question Form Created for Nurses' Compassionate Care Attitudes|Question Form Created for Nurses' Compassionate Care Attitudes
215124393|NCT06921369|OTHER|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model
215124394|NCT05579977|DRUG|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
215124395|NCT05579977|OTHER|Placebo|No drug
215124396|NCT05579977|DRUG|Rybelsus|Oral Semaglutide
215124397|NCT06939296|DRUG|VCT220|A small molecule GLP-1R drug, film coated tablet
215124398|NCT06939296|DRUG|Placebo|Placebo tablets
215124399|NCT06937216|DEVICE|Volara therapy|Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
215124400|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:|In this approach, patients who were treated with rTMS five days per week during their acute episode receive less frequent treatments during a taper period (for example treatment three days per week followed by two sessions per week) with a gradual transition into a maintenance schedule. For example, the maintenance schedule might begin with a single weekly session for one or two months and then the intensity is reduced to one session every two weeks (and possibly then one session every three or four weeks).
215124401|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:|Clustered maintenance rTMS typically involves around 4 TMS sessions applied over 2 days, at 1-month intervals. Our team initially developed this approach based upon preclinical TMS studies (for example (Maeda et al. 2000)) suggesting that rTMS treatment effects may accumulate when applied over multiple sessions in a shorter period of time (Maeda et al. 2000).
215124402|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS|Sham treatment will be administered as either standard or clustered maintenance rTMS for 6 months period using a sham coil. The intervention target will be located via a Brainsight TMS Navigator (Brainsight, Montreal, Canada). For safety reasons, the individual TMS intensity will be limited to 130% of the individual resting motor threshold.
215124403|NCT06939205|DIAGNOSTIC_TEST|Assessment of body surface area and assessment ventricular dilatation prevalence|Estimation of body surface area and quantification of absolute and relative values of echocardiographic variables
214523163|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
215124404|NCT00964652|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
215124405|NCT06939192|OTHER|Intervention Group (APP)|Combination of app-based information and diagnostic screening for parents of premature babies.
215124406|NCT06939192|OTHER|Treatment as usual-Group (TAU)|No intervention. Treatment in the form of usual aftercare service is possible.
215124407|NCT06938789|OTHER|Blood Transfusion|Blood transfusion is given without delay (within 4 hours) in case of hemoglobin below our threshold.
215124408|NCT06938789|OTHER|Standard care|These patients recieve our standard care including blood transfusion as usual. Vital parameters and delirium screening are collected three times a day.
215124409|NCT06938321|DRUG|AK112|Following a predefined dose and date.
215124410|NCT06938321|DRUG|AK130|Following a predefined dose and date.
215124411|NCT04510051|DRUG|Cyclophosphamide|Given IV
215124412|NCT04510051|DRUG|Fludarabine|Given IV
215124413|NCT04510051|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
215124414|NCT06937736|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
215124415|NCT06937671|PROCEDURE|Cold EMR|Cold EMR with cold forceps (regular or jumbo forceps) removal of any visible neoplasia that cannot be ensnared.
215124416|NCT06937671|PROCEDURE|Hybrid EMR|Cold EMR with hot avulsion of any visible residual neoplasia within the resection bed, in addition to precise APC of the fibrotic bands that may harbor invisible neoplasia within the resection bed.
215124417|NCT01755871|DRUG|Fingolimod|0,5mg Fingolimod once a day
214523164|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID DIET|2\. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
215124418|NCT00350844|DRUG|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
215124419|NCT04957121|OTHER|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
215124420|NCT04957121|OTHER|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
215124421|NCT04247737|OTHER|gluten free diet|Participants keep a gluten free diet for six weeks
215124422|NCT00005644|DRUG|gemcitabine hydrochloride|
215124423|NCT00005644|DRUG|paclitaxel|
214523165|NCT02206087|DRUG|PER977|Reversal of heparin-induced anticoagulation
214523166|NCT02206087|DRUG|Placebo|Reversal of heparin-induced anticoagulation
215124424|NCT03004235|DEVICE|Observational data collection|Observational data collection
215124425|NCT01420926|DRUG|Bortezomib|Given SC
215124426|NCT01420926|DRUG|Decitabine|Given IV
215124427|NCT01420926|OTHER|Laboratory Biomarker Analysis|Correlative studies
215124428|NCT01420926|OTHER|Pharmacological Study|Correlative studies
215124429|NCT01420926|OTHER|Quality-of-Life Assessment|Ancillary studies
215124430|NCT01420926|OTHER|Questionnaire Administration|Ancillary studies
215124431|NCT02285387|PROCEDURE|Rhythm control|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
214523167|NCT02206087|DRUG|Heparin Sodium|
214523168|NCT02646189|DRUG|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
215124432|NCT02285387|PROCEDURE|Rate control|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
215124433|NCT00932321|DRUG|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
214523169|NCT02646189|DRUG|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
214523170|NCT02646189|DRUG|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
215124434|NCT00932321|DRUG|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
215124435|NCT05152771|OTHER|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
215124436|NCT00158288|BEHAVIORAL|LAAM|
215124437|NCT02860104|DEVICE|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
215124438|NCT01792037|DRUG|Etomidate|
215124439|NCT01792037|DRUG|Midazolam|
215124440|NCT01792037|DRUG|methylprednisolone|
215124441|NCT02606331|PROCEDURE|Piezosurgery|Corticotomy cuts will be performed by this technique.
215124442|NCT02606331|RADIATION|ER:YAG laser|Corticotomy cuts will be performed by this technique.
215124443|NCT02775916|DRUG|CDZ173|
215124444|NCT02775916|DRUG|Placebo|
215124445|NCT02698150|DEVICE|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
215124446|NCT04027894|DRUG|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
215124447|NCT04027894|DRUG|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
215124448|NCT00294294|BIOLOGICAL|Prevenar|
215124449|NCT00294294|BIOLOGICAL|Infanrix hexa|
215124450|NCT03727815|OTHER|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
215124451|NCT03727815|OTHER|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
214446175|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment|Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
215124452|NCT01151488|OTHER|Resistance Training|RT 3x/wk for 4 months
214446176|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention|Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
214446177|NCT05520983|BEHAVIORAL|Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
214446178|NCT05520983|OTHER|Strengthening Families|The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
214446179|NCT05520983|OTHER|Virtual psycho-educational discussion groups for caregivers and participants|The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
214446180|NCT05520983|OTHER|Maternal Child Health Bureau (MCHB) Care Coordination|MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
214446181|NCT06262594|DRUG|Lemborexant|Drug is administered
214446182|NCT06262594|DRUG|Placebo|Drug is administered
214446183|NCT05249439|OTHER|I-SatPro weight loss programme|I-SatPro weight loss programme: participants advised on I-SatPro dietary change as well as eating patterns, lifestyle change such as exercise, self-care such as advice on sleep and behavioural change strategies.
214446184|NCT05249439|OTHER|Tier 3 weight loss programme|Tier 3 weight loss programme: participants advised to make changes to food choices in accordance with NHS healthy eating advice, eating habits, lifestyle change such as exercise, mindful eating and behavioural change strategies.
214446185|NCT06574178|BEHAVIORAL|Dietary Counseling|A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
214446186|NCT05166694|OTHER|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
214446187|NCT05166694|OTHER|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
214446188|NCT05166694|OTHER|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
214446189|NCT04720313|DRUG|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
214446190|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
214523171|NCT00508859|DRUG|Sertraline|maintenance treatment with sertraline
215124453|NCT03222635|PROCEDURE|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
215124454|NCT02289495|DRUG|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
214523172|NCT00508859|DRUG|placebo|placebo
215124455|NCT02289495|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
215124456|NCT02289495|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
215124457|NCT02614729|OTHER|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
215124458|NCT02614729|OTHER|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
215124459|NCT02614729|OTHER|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
215124460|NCT02614729|OTHER|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
215124461|NCT03984110|DRUG|Ozurdex|Intravitreal injection
215124462|NCT03984110|DRUG|Eylea|Intravitreal injection
215124463|NCT04510714|DEVICE|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
215124464|NCT00034775|DRUG|risperidone|
215124465|NCT06153134|DRUG|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
215124466|NCT06153134|DRUG|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
215124467|NCT03710148|OTHER|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet \& drinking water, and of excessive iodine intake from drinking water
215124468|NCT05489848|DRUG|Paclitaxel|Paclitaxel: paclitaxel dose of 135\~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
215124469|NCT05489848|DRUG|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
215124470|NCT05489848|DRUG|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
215124471|NCT05489848|RADIATION|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
215124472|NCT05489848|RADIATION|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
214446191|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
214523173|NCT04617262|BEHAVIORAL|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
214446192|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
214523174|NCT05530460|DEVICE|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
214523175|NCT05530460|DEVICE|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
214523176|NCT05608408|DEVICE|Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system|Stimulation of site with the Medtronic Percept PC system using low frequency stimulation at 0.5 Hz.
215124473|NCT00602212|BEHAVIORAL|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
215124474|NCT00602212|BEHAVIORAL|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
215124475|NCT02264158|DRUG|Telmisartan high|
215124476|NCT02264158|DRUG|Telmisartan low|
215124477|NCT02264158|DRUG|Lacidipine high|
215124478|NCT02264158|DRUG|Lacidipine low|
215124479|NCT02264158|DRUG|Placebo|
215124480|NCT04393675|DRUG|LT5001|Administered twice daily
215124481|NCT04393675|DRUG|Placebo|Administered twice daily
215124482|NCT05429216|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
215124483|NCT05429216|PROCEDURE|ESD procedure|ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
215124484|NCT06413602|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
215124485|NCT06413602|OTHER|Neuromuscular Electrical Stimulation|During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
215124486|NCT01232868|BIOLOGICAL|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
215124487|NCT00025597|DRUG|carboplatin|
215124488|NCT00025597|DRUG|cyclophosphamide|
215124489|NCT00025597|DRUG|doxorubicin hydrochloride|
214446193|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
214446194|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
214446195|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
214446196|NCT06217068|BEHAVIORAL|Elliptical Activity|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
214446197|NCT06571552|PROCEDURE|Single Plasma Exchange followed by Double Filtration Plasmapheresis|Double Filtration Plasmapheresis followed by Single Plasma Exchange
214446198|NCT06113510|RADIATION|Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography|18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.
214446199|NCT06554301|DRUG|empagliflozin in treatment pulmonary aerterial hypertension|On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
214446200|NCT06554301|DRUG|placebo in treatment pulmonary aerterial hypertension|On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
215124490|NCT00025597|DRUG|etoposide|
215124491|NCT00025597|DRUG|vincristine sulfate|
215124492|NCT00025597|PROCEDURE|conventional surgery|
215124493|NCT01538069|OTHER|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
214446201|NCT06329557|BEHAVIORAL|Intervention 1|Intervention 3
214446202|NCT06569550|DEVICE|Real Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
215124494|NCT01538069|OTHER|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
215124495|NCT01538069|OTHER|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
215124496|NCT04575194|DRUG|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
215124497|NCT04575194|DRUG|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
215124498|NCT00981097|GENETIC|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
215124499|NCT00981097|OTHER|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
215124500|NCT00867516|BIOLOGICAL|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
215124501|NCT00867516|BIOLOGICAL|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
215124502|NCT02619760|DRUG|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
215124503|NCT02619760|DRUG|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
215124504|NCT05644314|DEVICE|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
215124505|NCT00774761|DRUG|fluticasone propionate/formoterol fumarate|inhalation suspension
215124506|NCT00774761|DRUG|fluticasone propionate|inhalation suspension
215124507|NCT00774761|DRUG|formoterol fumarate|inhalation solution
215124508|NCT03128515|DRUG|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
215124509|NCT01316016|DIETARY_SUPPLEMENT|Rose hip|40 g of rose hip powder daily for 6 weeks.
215124510|NCT04589858|OTHER|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
214446203|NCT06569550|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
215124511|NCT04589858|OTHER|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
215124512|NCT03880539|DRUG|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
214523177|NCT05608408|DEVICE|Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system|Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system using standard of care high frequency stimulation parameters.
215124513|NCT03880539|DRUG|Vancomycin Oral|SOC vancomycin pulse/taper
215124514|NCT03564717|OTHER|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
215124515|NCT04532268|DRUG|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
215124516|NCT05872685|DRUG|S1|S-1 orally intake as perioperative chemotherapy
215124517|NCT05872685|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
214523178|NCT02706834|DRUG|TAK-828|TAK-828 oral solution
214523179|NCT02706834|DRUG|Placebo|TAK-828 placebo-matching oral solution
214523180|NCT02653001|OTHER|Stool sample collection|Collection of complete stool sample
214523181|NCT01862614|DRUG|Articaine Hydrochloride + Epinephrine|
214523182|NCT01862614|DRUG|Buffered Articaine Hydrochloride + Epinephrine|
215124518|NCT05872685|DRUG|Serplulimab|Perioperative serplulimab, 300 mg IV infusion
215124519|NCT05872685|DRUG|Placebo|Perioperative placebo, 300 mg IV infusion
215124520|NCT02539797|DEVICE|tDCS|comparing anodal, cathodal, and sham tDCS
215124521|NCT02762695|OTHER|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
215124522|NCT02762695|OTHER|Usual Care|Usual Care at Primary Health Care Center
215124523|NCT05721495|OTHER|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
215124524|NCT05721495|OTHER|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
215124525|NCT05651100|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
215124526|NCT06129526|DIETARY_SUPPLEMENT|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
215124527|NCT06129526|DIETARY_SUPPLEMENT|Corn Oil|Corn Oil
215124528|NCT01475877|DRUG|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
215124529|NCT02742831|BEHAVIORAL|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan."
215124530|NCT02742831|OTHER|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
215124531|NCT02335619|BEHAVIORAL|Early palliative care|
215124532|NCT02495129|DRUG|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
215124533|NCT02495129|DRUG|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
215124534|NCT03741153|DEVICE|slit lamp|"1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma."
215124535|NCT06327698|DRUG|Cadonilimab|Injectable solution
215124536|NCT06327698|DRUG|anlotinib|capsule
215124537|NCT01775644|DRUG|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
215124538|NCT00455299|PROCEDURE|Laparoscopic ventral hernia repair|
215124539|NCT02216669|DRUG|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
215124540|NCT05051748|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
215124541|NCT05051748|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
215124542|NCT05051748|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
215124543|NCT01139814|DEVICE|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
215124544|NCT05091658|DEVICE|LH Urine Test|Test for qualitative detection of LH in urine
215124545|NCT04002960|DEVICE|INVSENSOR00036|Noninvasive regional oximeter
215124546|NCT02529540|OTHER|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
214446204|NCT05257980|DIETARY_SUPPLEMENT|Dietary supplement (ONS)|At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
214446205|NCT06098586|BEHAVIORAL|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
214446206|NCT06098586|PROCEDURE|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
214446207|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
214446208|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
214446209|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
215124547|NCT02529540|OTHER|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
215124548|NCT02529540|OTHER|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
215124549|NCT01250106|DIETARY_SUPPLEMENT|Lactobacillus reuteri|twice daily
215124550|NCT03958175|OTHER|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
215124551|NCT06274463|BEHAVIORAL|Exercise therapy including a trunk stabilization exercise program|All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
215124552|NCT03111563|OTHER|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
215124553|NCT04965142|BEHAVIORAL|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
215124554|NCT00379665|DRUG|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
215124555|NCT04595552|OTHER|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
215124556|NCT02962258|DRUG|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
215124557|NCT02962258|DRUG|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
215124558|NCT06112574|BEHAVIORAL|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
215124559|NCT01815944|DRUG|0.75% Ropivacaine|
215124560|NCT01815944|DRUG|Normal saline|
215124561|NCT01815944|DRUG|Dextrose 5%|
215124562|NCT01649895|DRUG|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
215124563|NCT01649895|DRUG|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
215124564|NCT04277949|DEVICE|Erbium:YAG|Treatment with Erbium:YAG laser
215124565|NCT04277949|DRUG|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
215124566|NCT01609348|DRUG|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
214446210|NCT05731024|DEVICE|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
214446211|NCT05731024|DEVICE|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
215124567|NCT01609348|DRUG|Venlafaxine|225 mg daily for 12 weeks
215124568|NCT01879917|DRUG|Liraglutide|
215124569|NCT01879917|DRUG|Placebo|Saline
215124570|NCT02620501|DRUG|Lidocaine|topical lidocaine
215124571|NCT02620501|DRUG|Placebo|0.45% Normal Saline
215124572|NCT01647165|DRUG|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
215124573|NCT01647165|DRUG|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
215124574|NCT01647165|DRUG|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
215124575|NCT00865345|DEVICE|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
215124576|NCT00383786|DRUG|NK1 Antagoist (GR205171)|
214446212|NCT03752294|DRUG|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
214446213|NCT03752294|DRUG|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
214446214|NCT04230408|DRUG|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
214523183|NCT02062281|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
215124577|NCT00383786|PROCEDURE|Psychophysiology (Trauma Script)|
215124578|NCT00383786|PROCEDURE|Psychophysiology (Verbal Threat)|
215124579|NCT00383786|PROCEDURE|Psychophysiology (Fear Conditioning)|
215124580|NCT00383786|PROCEDURE|Psychophysiology (Affective Modulation)|
215124581|NCT00383786|PROCEDURE|Psychophysiology (Heart rate variability)|
215124582|NCT00383786|PROCEDURE|Lumbar Puncture|
215124583|NCT00383786|PROCEDURE|24-hour plasma sampling|
215124584|NCT00383786|PROCEDURE|MRI|
214446215|NCT01707030|OTHER|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
214446216|NCT01707030|OTHER|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
214523184|NCT02062281|BIOLOGICAL|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
215124585|NCT00894140|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
214446217|NCT05859724|BIOLOGICAL|NM26-2198|IL-4R/IL-31 bispecific antibody for subcutaneous administration
214446218|NCT05859724|OTHER|Placebo|Placebo for NM26-2198
215124586|NCT01100866|DIETARY_SUPPLEMENT|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
215124587|NCT01100866|OTHER|Placebo|placebo capsules
215124588|NCT01722019|DEVICE|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
215124589|NCT01722019|DEVICE|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
215124590|NCT00317551|DEVICE|Aberration controlled contact lens|
215124591|NCT00317551|BEHAVIORAL|Vision training|
215124592|NCT03813888|OTHER|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
215124593|NCT03813888|OTHER|Usual Activity group|Usual after school activities at home.
215124594|NCT01279434|DRUG|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
215124595|NCT01279434|DRUG|Vitamin E|Vitamin E 400 mg BD daily for 12 months
215124596|NCT06525428|DRUG|standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab|"First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT"
215124597|NCT00246519|DRUG|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
215124598|NCT00246519|DRUG|Atenolol|atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
215124599|NCT05720650|OTHER|No intervention|No intervention
215124600|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
215124601|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
215124602|NCT02583919|DRUG|Placebo|once weekly dosing for 26 weeks
215124603|NCT01517750|DEVICE|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
215124604|NCT01517750|DEVICE|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
215124605|NCT01298479|OTHER|Uniject|single use container
215124606|NCT00001572|DRUG|Id-KLH Vaccine|
215124607|NCT00001572|DRUG|QS-21 (Stimulation-QS-21) Drug|
215124608|NCT05549895|DRUG|Dexamethasone|8 mg intrathecally
215124609|NCT05549895|DRUG|Bupivacaine Hydrochloride|0.5 % intrathecally
215124610|NCT02204930|DRUG|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
215124611|NCT04123886|DRUG|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
215124612|NCT02038816|DRUG|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
215124613|NCT02038816|DRUG|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
215124614|NCT00048412|DRUG|FLUDARABINE|
215124615|NCT00048412|DRUG|CAMPATH 1H|
215124616|NCT00048412|DRUG|FK50|
215124617|NCT00048412|PROCEDURE|Stem Cell Collection and Infusion|
215124618|NCT05647135|OTHER|Medical food|enteral formulas with different protein composition
215124619|NCT01626924|DRUG|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
215124620|NCT02723773|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
215124621|NCT06343246|DEVICE|Inspiratory muscle training with device|: A randomized, controlled three-arm study. Forty-five patients with HT randomized three group: Group 1 will receive IMT (7 days/8 weeks) with function and POWERbreathe® Classic LR device, group 2 will reviece only IMT with 50 % maximal inspiratory pressure (MIP), n: 15) and control group will recieve breathing exercises(7 days/8 weeks).
215124622|NCT00003994|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
215124623|NCT00003994|DRUG|cisplatin|Given IV
215124624|NCT00003994|DRUG|vincristine sulfate|Given IV
215124625|NCT00003994|DRUG|fluorouracil|Given IV
215124626|NCT00003994|DRUG|amifostine trihydrate|Given IV
215124627|NCT00003994|DRUG|carboplatin|Given IV
215124628|NCT03629886|BIOLOGICAL|HPV (Types 16, 18) Vaccine, Adsorbed|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
215124629|NCT05401162|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
214446219|NCT02884180|DRUG|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
214446220|NCT02884180|DRUG|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
214446221|NCT04754711|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
215124630|NCT02831621|BEHAVIORAL|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
215124631|NCT00463255|BEHAVIORAL|diet|
215124632|NCT05133024|DIETARY_SUPPLEMENT|concentrated beetroot juice|Nitrate supplementation; natural source of dietary nitrate
215124633|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
215124634|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
215124635|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
215124636|NCT00404651|BIOLOGICAL|DTaP-HBV-IPV vaccine|0.5 mL, IM
215124637|NCT04458155|DEVICE|Siemens® Point-of-care high sensitive troponin I analyzer|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
215124638|NCT00666666|DRUG|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
215124639|NCT00666666|DRUG|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
214523185|NCT02062281|BIOLOGICAL|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
215124640|NCT00666666|OTHER|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
215124641|NCT03300401|DRUG|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
215124642|NCT03300401|DRUG|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
215124643|NCT03300401|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
215124644|NCT03300401|DEVICE|Positron Emission Tomography|Undergo PET/CT
215124645|NCT03300401|DEVICE|Computed Tomography|Undergo CT scan
215124646|NCT03300401|BIOLOGICAL|Yttrium-90 (90Y)|Given IV
215124647|NCT04214223|OTHER|Pre-Anesthesic Consultation|Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
215124648|NCT04214223|OTHER|Pre-Anesthesic Numerical Evaluation|Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
215124649|NCT02343146|BEHAVIORAL|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
215124650|NCT00182169|DRUG|Human recombinant growth hormone|
215124651|NCT05574023|DEVICE|Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|"Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
215124652|NCT05574023|DEVICE|Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia|"in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
215124653|NCT00346216|DRUG|celecoxib|100 to 200 mg twice daily, taken by mouth
215124654|NCT00346216|DRUG|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
215124655|NCT00346216|DRUG|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
215124656|NCT02166099|PROCEDURE|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
215124657|NCT02448277|DEVICE|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
214446222|NCT05065944|BEHAVIORAL|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
214446223|NCT05065944|BEHAVIORAL|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
214446224|NCT03526861|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
214446225|NCT03526861|DRUG|Placebos|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
214446226|NCT04846595|OTHER|self questionnaire|Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
214446227|NCT05713734|DIAGNOSTIC_TEST|Thrombin generation|Measurement of thrombin generation by ST Genesia
214446228|NCT05713734|DIAGNOSTIC_TEST|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
214446229|NCT05713734|DIAGNOSTIC_TEST|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
214446230|NCT05713734|DIAGNOSTIC_TEST|Coated platelets|Measurement of coated platelets by flow cytometry
214446231|NCT04155541|DRUG|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
214446232|NCT05995613|DEVICE|MABOS|The novel pulse oximeter (MABOS) will be placed to acquire two biometrics: blood oxygen saturation and epidermal melanin concentration.
214446233|NCT05995613|DEVICE|Nonin PureSat|An FDA approved pulse oximeter will be placed to acquire blood oxygen saturation.
214523186|NCT02788305|DRUG|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
214523187|NCT03590067|OTHER|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
214523188|NCT05494099|PROCEDURE|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
215124658|NCT02448277|DEVICE|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
215124659|NCT02448277|DEVICE|Glidescope|the device is to assist the nasotracheal tube into trachea
215124660|NCT02568514|DEVICE|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
215124661|NCT05182788|DIETARY_SUPPLEMENT|Placebo pressed candy|consume 2 tablets per day for 8 weeks
215124662|NCT05182788|DIETARY_SUPPLEMENT|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
214523189|NCT05494099|PROCEDURE|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
215124663|NCT05098028|DRUG|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
215124664|NCT05098028|DRUG|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
215124665|NCT05098028|DRUG|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
215124666|NCT05098028|DRUG|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
215124667|NCT05098028|DRUG|Placebo|Placebo Twice Daily
215124668|NCT03301558|DRUG|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
215124669|NCT03301558|DRUG|High dose sodium bicarbonate|3000 mg sodium bicarbonate
215124670|NCT02803736|DEVICE|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
215124671|NCT02484066|DEVICE|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
215124672|NCT02484066|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
215124673|NCT02484066|DEVICE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
215124674|NCT05117736|DRUG|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
214523190|NCT05494099|PROCEDURE|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
214446234|NCT04951921|DRUG|Hyperpolarized 13C Pyruvate|Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
215124675|NCT05117736|DRUG|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
215124676|NCT03617952|BEHAVIORAL|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
215124677|NCT03065777|DEVICE|ONE ENDO|single file rotary system
215124678|NCT03065777|DEVICE|F6 SKYTaper|single file rotary system
215124679|NCT03065777|DEVICE|ProTaper Universal|multi-file rotary system
215124680|NCT01683708|DIETARY_SUPPLEMENT|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
215124681|NCT04319367|DRUG|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
215124682|NCT01572181|DRUG|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"* IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
215124683|NCT03432507|OTHER|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
215124684|NCT05230940|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
214523191|NCT01529853|DRUG|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214446235|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
214446236|NCT04816149|BEHAVIORAL|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
214523192|NCT01529853|DRUG|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214523193|NCT00547716|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
214523194|NCT00547716|DRUG|Placebo comparator|
214523195|NCT02985476|OTHER|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
215124685|NCT05230940|BIOLOGICAL|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
215124686|NCT01418144|PROCEDURE|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
215124687|NCT01418144|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
215124688|NCT03497065|PROCEDURE|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
215124689|NCT01512199|DRUG|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
215124690|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
215124691|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
215124692|NCT01512199|DRUG|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
214523196|NCT00003116|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
214523197|NCT00003116|DRUG|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
214523198|NCT00003116|DRUG|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
214523199|NCT00003116|DRUG|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
214523200|NCT00003116|PROCEDURE|bone marrow ablation with stem cell support|
214523201|NCT00003116|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
215124693|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
215124694|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
214446237|NCT04816149|BEHAVIORAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
214446238|NCT03727061|BIOLOGICAL|Nivolumab|Immunotherapy - Standard of care
214446239|NCT03727061|DRUG|Porfimer Sodium|Given IV
214446240|NCT03727061|PROCEDURE|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
214446241|NCT03727061|OTHER|Quality of Life Assessment|Ancillary Studies
214523202|NCT03658018|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
214523203|NCT03149887|DRUG|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
214523204|NCT03149887|DRUG|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
214523205|NCT05527054|OTHER|Diuretics|Inpatients using diuretics
214523206|NCT01634620|DEVICE|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
215124695|NCT01512199|DRUG|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
215124696|NCT00721448|DRUG|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
215124697|NCT00721448|DRUG|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
214523207|NCT00014235|DRUG|fludarabine phosphate|Given IV
215124698|NCT01220167|DRUG|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
215124699|NCT01220167|DRUG|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
214446242|NCT04618016|DEVICE|UHMWPE with Vitamin E|e.motion Pro (PS and UC) with MXE gliding surface
214446243|NCT04618016|DEVICE|UHMWPE without Vitamin E|e.motion Pro (PS and UC) with β-PE gliding surface
214446244|NCT06347471|DRUG|Artemether-lumefantrine|Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.
214446245|NCT06347471|DRUG|Dihydroartemisinin-Piperaquine|Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
214523208|NCT00014235|RADIATION|total-body irradiation|Undergo TBI
214523209|NCT00014235|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
214523210|NCT00014235|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
214523211|NCT00014235|DRUG|cyclosporine|Given PO or IV
214523212|NCT00014235|DRUG|mycophenolate mofetil|Given IV or PO
214523213|NCT00014235|OTHER|laboratory biomarker analysis|Correlative studies
215124700|NCT01220167|DRUG|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
215124701|NCT02071199|DRUG|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
215124702|NCT02071199|DRUG|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
215124703|NCT02071199|DRUG|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
215124704|NCT04674007|OTHER|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
215124705|NCT00580736|DEVICE|Optical Clearing|Optical Clearing
215124706|NCT03987477|BEHAVIORAL|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
215124707|NCT03987477|BEHAVIORAL|Waiting list|Waiting list procedure for the control group.
215124708|NCT02341235|BEHAVIORAL|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
215124709|NCT02341235|BEHAVIORAL|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
215124710|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
215124711|NCT02726763|BEHAVIORAL|Questionnaires|
215124712|NCT01028417|DEVICE|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
215124713|NCT03324243|DRUG|Crenolanib|66.7 mg/m2 three times a day (TID)
215124714|NCT03324243|DRUG|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
215124715|NCT03324243|DRUG|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
215124716|NCT04222296|DEVICE|Fitting strategy of cohlear implant of hearing aid|To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
215124717|NCT02581306|OTHER|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
215124718|NCT06357702|BEHAVIORAL|Physical Self Regulation Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.
215124719|NCT06357702|BEHAVIORAL|Psycho-education Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
215124720|NCT05651945|OTHER|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
215124721|NCT05682326|DRUG|Daprodustat|Daprodustat will be administered up to Week 52.
215124722|NCT02043158|BEHAVIORAL|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
214446246|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
214446247|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
214446248|NCT06739421|PROCEDURE|NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
214446249|NCT06739421|PROCEDURE|NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
214446250|NCT02305147|OTHER|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
214446251|NCT06840132|PROCEDURE|Exercise|7-station exercise protocol was designed, consisting of motor activities progressing from easy to difficult, with the goal of transforming these activities into permanent skills through meaningful tasks. Each station aimed to gradually improve the patient's motor abilities. Patients were allowed to rest between tasks, and the difficulty of the tasks progressively increased based on each patient's capacity. This 7-station protocol was designed for the first time by our own research team
214446252|NCT06840132|PROCEDURE|Exercise|In addition to the task-oriented training program, the group using plastic static ankle-foot orthoses performed the same 7-station exercise protocol as the task oriented training group. However, participants in this group were required to wear custom-made plastic static ankle-foot orthoses while completing the exercises.
214446253|NCT05573945|BEHAVIORAL|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
214446254|NCT05573945|BEHAVIORAL|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
215124723|NCT02043158|BEHAVIORAL|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
215124724|NCT05200143|DRUG|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
215124725|NCT05200143|DRUG|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
215124726|NCT05200143|DRUG|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
215124727|NCT05599750|PROCEDURE|Incisional hernia repair|Participants will undergo incisional hernia repair
215124728|NCT04811703|DRUG|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
215124729|NCT05400655|DRUG|L9LS|Administered subcutaneously.
215124730|NCT05400655|OTHER|Normal Saline|Administered subcutaneously.
215124731|NCT05257278|DEVICE|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
215124732|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
215124733|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
215124734|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
215124735|NCT05992064|OTHER|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~* Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~* Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
215124736|NCT04748614|OTHER|Cost|ICU cost
215124737|NCT04192955|DRUG|Acetyl Salicylate|Tablets
215124738|NCT03203252|OTHER|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
215124739|NCT03203252|OTHER|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
215124740|NCT03203252|OTHER|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
215124741|NCT00619515|OTHER|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
215124742|NCT00619515|PROCEDURE|implanted fiducial-based imaging|Undergo fiducial placement imaging
215124743|NCT00619515|RADIATION|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
215124744|NCT03140397|DIETARY_SUPPLEMENT|Placebo|
215124745|NCT03140397|DIETARY_SUPPLEMENT|6-prenylnaringenin|
215124746|NCT03140397|DIETARY_SUPPLEMENT|8-prenylnaringenin|
215124747|NCT06189326|PROCEDURE|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
214523214|NCT03416335|DRUG|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
215124748|NCT06189326|PROCEDURE|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
215124749|NCT03482531|OTHER|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
215124750|NCT04034823|BIOLOGICAL|KN035|KN035 5 mg/kg s.c. Q3W
215124751|NCT04034823|BIOLOGICAL|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
215124752|NCT04034823|DRUG|Docetaxel|100 mg/m2 Q3W IV
215124753|NCT04100382|DEVICE|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
215124754|NCT02493036|DRUG|SYN-010|
215124755|NCT02420093|DEVICE|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
215124756|NCT05580822|DRUG|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
215124757|NCT05580822|DRUG|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
215124758|NCT01095432|PROCEDURE|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
215124759|NCT00088140|DRUG|IDN-6556|
215124760|NCT00088140|DRUG|Placebo|
215124761|NCT04862065|DEVICE|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
215124762|NCT05098730|BEHAVIORAL|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
215124763|NCT04499937|BEHAVIORAL|Streak incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
215124764|NCT04499937|BEHAVIORAL|Loss-based incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
214446255|NCT06798844|DEVICE|Spinal Cord Stimulation|SCS is an established treatment for chronic neuropathic pain and the implantation procedure in this study follows the conventional clinical approach. Under local anaesthesia, a lead electrode is positioned in the spinal epidural space at the Th8-Th10 vertebral levels. The electrode is then connected to an external stimulator (implantable pulse generator, IPG), used for the 3-week external trial stimulation. Upon completion of the core trial, the electrode may either be removed or connected to an internal IPG, after extensive counselling and dependent on the FOG outcome and patient's preference. A subsequent long-term open label phase will evaluate the long-term efficacy and safety of SCS on FOG, with a follow-up period of six months. Electrophysiological recordings of the dorsal spinal cord will be conducted at the end of the external trial stimulation and at the 6-month follow-up.
214446256|NCT06798844|OTHER|Spinal electrophysiological recordings|The sole purpose of the control groups in this study, is to facilitate the interpretation of spinal cord electrophysiological characteristics in PD freezers by providing a comparison with individuals without the condition.
214446257|NCT05090826|DEVICE|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
214446258|NCT05147688|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214446259|NCT05795946|DIETARY_SUPPLEMENT|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
214446260|NCT06001177|DRUG|KAN-101|Dose KAN-101 Intravenous (IV) Infusion
214446261|NCT06001177|DRUG|Placebo|Placebo Intravenous (IV) Infusion
214446262|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
214446263|NCT05514496|DRUG|NX-019|NX-019 will be administered orally.
214446264|NCT06182163|BEHAVIORAL|Sedentary time intervention|Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents and young adults (AYAs) with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
214446265|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
214446266|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
214446267|NCT06288412|DRUG|Insulin icodec|Participants will receive insulin icodec subcutaneous (s.c.) once weekly.
214446268|NCT06288412|DRUG|Insulin degludec|Participants will receive insulin degludec s.c. once daily.
214523215|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
214523216|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
215124765|NCT04499937|BEHAVIORAL|Flat-fee control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
215124766|NCT04499937|BEHAVIORAL|Flat-Fitbit control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
215124767|NCT05674058|OTHER|No intervention|According to clinical practice.
215124768|NCT03371472|DEVICE|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
215124769|NCT03103126|BEHAVIORAL|Combined resistance exercise and walking|Combined resistance exercise and walking
215124770|NCT01030029|DEVICE|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
215124771|NCT01030029|DEVICE|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
215124772|NCT02525653|DRUG|albumin-bound paclitaxel|
214446269|NCT04755179|PROCEDURE|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate"
214523217|NCT05129371|OTHER|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
214523218|NCT05129371|OTHER|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
214523219|NCT03034772|DRUG|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
214523220|NCT03034772|OTHER|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
214523221|NCT00411463|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
214523222|NCT00411463|DRUG|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
215124773|NCT02525653|DRUG|gemcitabine|
215124774|NCT00878956|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
215124775|NCT00878956|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
215124776|NCT05459467|OTHER|Exercise|12 weeks high intensity exercise programme
215124777|NCT01507922|DRUG|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
215124778|NCT01507922|DRUG|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
215124779|NCT04365621|OTHER|we enrolled ultra-high risk of psychosis (UHR) patient to describe|there is no intervention because we study only the prevalence of patients meeting UHR criteria
215124780|NCT03170661|DRUG|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
215124781|NCT03244917|BEHAVIORAL|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
214523223|NCT00116584|DRUG|heliox|continuous heliox therapy
215124782|NCT03846050|BEHAVIORAL|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
214446270|NCT04755179|PROCEDURE|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate"
214523224|NCT00116584|DRUG|oxygen|continuous oxygen therapy
214523225|NCT00936195|DRUG|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
214523226|NCT00936195|DRUG|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
214708769|NCT01525940|DEVICE|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
215124783|NCT03846050|BEHAVIORAL|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
215124784|NCT02884024|OTHER|no intervention|there is no intervention in this study
215124785|NCT00269308|PROCEDURE|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
215124786|NCT00269308|PROCEDURE|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
215124787|NCT00269308|BEHAVIORAL|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
215124788|NCT03001557|DRUG|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
215124789|NCT03001557|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablets
215124790|NCT03001557|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablets
215124791|NCT03001557|DRUG|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
215124792|NCT03001557|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
215124793|NCT02646631|OTHER|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
215124794|NCT02646631|BEHAVIORAL|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
215124795|NCT02646631|BEHAVIORAL|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
215124796|NCT02646631|OTHER|Educational Materials|Printed educational materials on the management of epilepsy
214523227|NCT05650580|DRUG|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
214523228|NCT02173249|DRUG|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
215124797|NCT01272232|DRUG|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
215124798|NCT01272232|DRUG|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
215124799|NCT01272232|DRUG|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
215124800|NCT02869399|DIETARY_SUPPLEMENT|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
215124801|NCT02531217|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
215124802|NCT04718207|DEVICE|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
214523229|NCT00591188|DRUG|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
214694298|NCT03752853|BEHAVIORAL|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
214694299|NCT07084753|DRUG|Levobupivacaine|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
214523230|NCT04011995|BEHAVIORAL|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
214523231|NCT04011995|BEHAVIORAL|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
214523232|NCT04011995|BEHAVIORAL|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
214523233|NCT02884921|DRUG|Paracetamol|Paracetamol
214523234|NCT02884921|DRUG|Paracetamol|Paracetamol
215124803|NCT03360435|DIETARY_SUPPLEMENT|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
214694300|NCT07084753|DRUG|Dexamethasone contained in the solution for thoracic paravertebral block|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
215124804|NCT02915666|DRUG|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
215124805|NCT02915666|DRUG|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
215124806|NCT02915666|DRUG|Trametinib|trametinib 2 mg PO daily for 8-week cycles
215124807|NCT01227798|DRUG|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
215124808|NCT01227798|DRUG|Placebo|Normal Saline
215124809|NCT01546558|DRUG|Metformin|Metformin 1000 mg bid on Days 1-10
215124810|NCT01546558|DRUG|Ranolazine|Ranolazine 500 mg bid on Days 6-10
215124811|NCT00425646|BIOLOGICAL|bevacizumab|
215124812|NCT00425646|DRUG|imatinib mesylate|
215124813|NCT02140515|DRUG|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
215124814|NCT02140515|DRUG|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
215124815|NCT04353128|DRUG|Melatonin 2mg|2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
215124816|NCT04353128|DRUG|Placebo oral tablet|Identically looking placebo tablets P.O. before bedtime for 12 weeks
215124817|NCT02386046|OTHER|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
214523235|NCT02884921|DRUG|Placebo|Placebo
214523236|NCT05828602|OTHER|Conventional treatment|Conventional treatment
214694301|NCT07084753|DRUG|Adrenaline|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
214708770|NCT03749798|PROCEDURE|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
215124818|NCT04140396|DRUG|Saline infusion|Normal saline infusion at 10mL/hour
215124819|NCT04140396|DRUG|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
215124820|NCT05114408|OTHER|4 week trimodal prehabilitation course|"trimodal prehabilitation in mixed: stationary and at-home structure"
215124821|NCT05753488|DIAGNOSTIC_TEST|graft function|renal transplantation
215124822|NCT06264011|BEHAVIORAL|Salaat|While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
215124823|NCT06264011|OTHER|Sham comparator|Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
215124824|NCT03076762|DRUG|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
215124825|NCT01007357|DEVICE|Body MR imaging|Body MR imaging will be performed to optimize sequences
215124826|NCT05616468|BIOLOGICAL|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
215124827|NCT05616468|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
215124828|NCT05616468|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
215124829|NCT05711043|DEVICE|Endoscopic sutured gastroplasty with endomina|"Subjects in the intervention group will be treated with an ESG with the endomina ® and TAPES devices (Endo Tools Therapeutics S.A.), both CE-marked for endoscopic gastroplasty. The endomina is a device that can be attached to an endoscope and allows remote actuation of the device during a peroral intervention. Thanks to a therapeutic channel that can be angled perpendicularly to the axis of vision of the endoscope, it allows the possibilities of making transoral full thickness tissue apposition and performing, via a transoral route, large plications with tight serosa to serosa apposition in the stomach. This suturing will be done from the incisura to the upper body of the stomach, along the great curvature with TAPES, a single use needle preloaded with suture.~In addition to the endomina device, any other required endoscopic accessories can be used during the procedure (e.g., grasping forceps, loop cutter)."
215124830|NCT03361085|PROCEDURE|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
215124831|NCT03308916|DIAGNOSTIC_TEST|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
215124832|NCT03308916|DIAGNOSTIC_TEST|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
215124833|NCT03308916|DIAGNOSTIC_TEST|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
215124834|NCT03308916|DIAGNOSTIC_TEST|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
215124835|NCT03308916|DIAGNOSTIC_TEST|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
215124836|NCT03308916|DIAGNOSTIC_TEST|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
215124837|NCT03308916|DIAGNOSTIC_TEST|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
214446271|NCT04755179|PROCEDURE|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
215124838|NCT01122602|DRUG|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
215124839|NCT01122602|DRUG|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
215124840|NCT01122602|DRUG|Placebo|Two placebo tablets
215124841|NCT05313789|DEVICE|Analgesia Nociception Index (ANI)|Monitorization of Analgesia Nociception Index in Intensive Care Patients
215124842|NCT04236102|DIAGNOSTIC_TEST|Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples|Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
215124843|NCT01730521|BEHAVIORAL|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
215124844|NCT05936489|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
215124845|NCT05936489|DRUG|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
214446272|NCT04755179|PROCEDURE|Direct appendectomy|laparoscopic or open appendectomy as described
214446273|NCT04034095|DRUG|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446274|NCT04034095|DRUG|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214523237|NCT05828602|OTHER|TeleRehabilitation|TeleRehabilitation
214523238|NCT05820542|OTHER|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
214523239|NCT05820542|OTHER|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
214523240|NCT05614843|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
214523241|NCT05614843|DEVICE|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
215124846|NCT01960140|DRUG|Baricitinib|Administered orally
215124847|NCT01960140|DRUG|Simvastatin|Administered orally
215124848|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
215124849|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
214523242|NCT01798238|DRUG|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
214523243|NCT01798238|DRUG|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
214523244|NCT02239666|OTHER|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
214523245|NCT03055819|DEVICE|Brow Lift|Minimally Invasive Brow Lift
214523246|NCT01745380|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
214523247|NCT01745380|DRUG|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
215124850|NCT03439501|DRUG|avelumab|"* Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
215124851|NCT01881516|DEVICE|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
214523248|NCT01882088|DRUG|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
214523249|NCT01256645|OTHER|blood transfusion|application of single units of red blood cell transfusions
214523250|NCT04226183|OTHER|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
214523251|NCT01931683|DRUG|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
214523252|NCT01931683|DEVICE|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
214523253|NCT00125619|BEHAVIORAL|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
214523254|NCT01295788|DEVICE|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
214523255|NCT01295788|DEVICE|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
214523256|NCT00803335|DRUG|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
214523257|NCT00803335|DRUG|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
214523258|NCT04297423|DRUG|Plenvu|randomization 1:1
214523259|NCT01116453|PROCEDURE|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
214523260|NCT01116453|PROCEDURE|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
214523261|NCT02503839|DRUG|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
215124852|NCT01881516|DEVICE|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
215124853|NCT00889135|DRUG|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
215124854|NCT01931423|BEHAVIORAL|Placental cord drainage|
215124855|NCT04696081|OTHER|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
215124856|NCT02394535|DRUG|Capecitabine|Given PO
215124857|NCT02394535|OTHER|Laboratory Biomarker Analysis|Correlative studies
214523262|NCT02503839|BIOLOGICAL|H56:IC31|Therapeutic and prophylactic TB vaccine
214523263|NCT02247141|BIOLOGICAL|Subgam® (Human Normal Immunoglobulin Solution)|
214523264|NCT00662415|DEVICE|mirror-box treatment|15 minutes daily for 4 weeks
214523265|NCT00662415|BEHAVIORAL|observation|observation
215124858|NCT02394535|DRUG|Nab-paclitaxel|Given IV
214523266|NCT01521221|OTHER|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
214523267|NCT02473588|DEVICE|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
214523268|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 18%-protein diet|
214523269|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 35%-protein diet|
214523270|NCT02333071|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
215124859|NCT02394535|OTHER|Questionnaire Administration|Ancillary studies
215124860|NCT02394535|RADIATION|Radiation Therapy|Undergo radiation therapy
215124861|NCT00628030|BEHAVIORAL|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
215124862|NCT00628030|OTHER|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
215124863|NCT03392935|DEVICE|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
214523271|NCT02333071|OTHER|Placebo|Placebo
214523272|NCT01048983|DRUG|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
214523273|NCT01048983|DRUG|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
214523274|NCT01048983|DRUG|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
214523275|NCT01048983|DRUG|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
214523276|NCT01048983|BEHAVIORAL|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
214523277|NCT04271514|DRUG|RPT193|Antagonist of the CCR4 chemokine receptor
214523278|NCT04271514|DRUG|Placebo|Matching placebo
214523279|NCT02396550|BEHAVIORAL|Positive Expectations|Give positive expectation of the treatment efficacy to patients
214523280|NCT02396550|PROCEDURE|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
214523281|NCT02325258|OTHER|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
214523282|NCT05990283|PROCEDURE|Socket shield technique|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
214523283|NCT05990283|PROCEDURE|Guided bone regeneration|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
214523284|NCT04348383|DRUG|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
214523285|NCT04348383|DRUG|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
214523286|NCT00201214|DRUG|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
214523287|NCT02133183|OTHER|Laboratory Biomarker Analysis|Correlative studies
215124864|NCT02368665|DRUG|Amlodipine 5mg|\- Daily oral administration for 8 weeks
215124865|NCT02368665|DRUG|Amlodipine 5mg, Candesartan cilexetil 16mg|\- Daily oral administration Amlodipine 5mg for 8 weeks
215124866|NCT02368665|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|\- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
215124867|NCT04122365|OTHER|Chest Wall Mobilization Program|Soft tissue therapy and joints mobilization
215124868|NCT04122365|OTHER|Control|Routine limbs exercises and education
215124869|NCT01295359|OTHER|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
215124870|NCT00105911|BEHAVIORAL|Cognitive Behavioral Therapy|
215124871|NCT01732744|OTHER|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
215124872|NCT01732744|OTHER|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
215124873|NCT01732744|OTHER|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
215124874|NCT01732744|OTHER|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
215124875|NCT01156480|DRUG|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
214446275|NCT04034095|DRUG|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446276|NCT04034095|DRUG|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446277|NCT04034095|DRUG|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446278|NCT04034095|DRUG|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446279|NCT04034095|DRUG|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
214446280|NCT02966613|DEVICE|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
214523288|NCT02133183|OTHER|Pharmacological Study|Correlative studies
214523289|NCT02133183|DRUG|Sapanisertib|Given PO
214694302|NCT07084753|DRUG|Dexmedetomidin|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
214523290|NCT02133183|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214523291|NCT01065493|OTHER|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
214523292|NCT01065493|BEHAVIORAL|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
214523293|NCT04297436|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
215124876|NCT01156480|DRUG|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
215124877|NCT01235013|DRUG|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
215124878|NCT03997461|DEVICE|BPro|BPro and Oscar 2 comparison for 24 hours
215124879|NCT04816084|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|"Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age,~* known risk-factor for Covid-19~* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays"
215124880|NCT01726894|DEVICE|Irreversible Electroporation|
215124881|NCT03301883|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
214446281|NCT06121921|OTHER|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%"
214446282|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
214446283|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
214446284|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
214523294|NCT03800264|DRUG|Bisoprolol|PREVENTIVE DOUBLE BLINDED
214523295|NCT05453877|OTHER|No intervention will be applied.|This is an observational study.
214446285|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
214446286|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
214446287|NCT05395403|DEVICE|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
214446288|NCT04893759|DRUG|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
214446289|NCT05844306|PROCEDURE|Computed Tomography|Undergo \[18F\]-FDG PET-CT
214446290|NCT05844306|OTHER|Fludeoxyglucose F-18|Given via injection
214523296|NCT04420897|PROCEDURE|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
214523297|NCT01797705|DEVICE|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
215124882|NCT03301883|DRUG|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
215124883|NCT03301883|DRUG|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
215124884|NCT03301883|DRUG|MTX|Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
215124885|NCT02271464|DRUG|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~\- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
214523298|NCT05394389|OTHER|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
214523299|NCT05394389|OTHER|social support|ten minutes of conversing.
214523300|NCT05181878|DEVICE|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
214523301|NCT04747847|DRUG|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
214523302|NCT00733577|DRUG|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
215124886|NCT02271464|DRUG|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
215124887|NCT05794035|OTHER|Surgery with additional moderate hypofractionation RT (15 fractions)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed."
215124888|NCT05794035|OTHER|Surgery alone, without radiation post surgery|Arm A: Surgery alone followed by surveillance
215124889|NCT05794035|RADIATION|Surgery with extreme hypo fractionation treatment (HF)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed."
215124890|NCT03890068|DRUG|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
214446291|NCT05844306|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
214446292|NCT05844306|DEVICE|Positron Emission Tomography|Undergo \[18F\]-FDG PET-CT
214446293|NCT03740763|DEVICE|Spinal Cord Stimulation (SCS)|SCS for treatment of neuropathic pain
214446294|NCT03740763|OTHER|Physiotherapy|Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
214446295|NCT05371808|OTHER|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
214446296|NCT05371808|OTHER|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
214446297|NCT05371808|OTHER|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
214446298|NCT06321003|DEVICE|OCT (Optical Coherence Tomography)|OCT diagnosis in oral carcinogenesis
214446299|NCT05569395|OTHER|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
214446300|NCT05569395|OTHER|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
214446301|NCT03728764|OTHER|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
214446302|NCT04835844|DEVICE|CARTO|Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
214446303|NCT04835844|DEVICE|RHYTHMIA|Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
214446304|NCT06398314|RADIATION|Palliative radiotherapy|Hypofractionated radiotherapy
214446305|NCT04121936|OTHER|There will be no intervention|There will be no intervention
214694303|NCT07084753|DRUG|ketamine|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
215124891|NCT00690729|BEHAVIORAL|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
215124892|NCT00690729|BEHAVIORAL|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
215124893|NCT00027625|DRUG|gefitinib|
215124894|NCT00027625|DRUG|temozolomide|
215124895|NCT00430469|DRUG|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
215124896|NCT04210674|OTHER|The traditional medicinal product of Argan spinosa oil|All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
215124897|NCT05377853|BEHAVIORAL|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
215124898|NCT03006146|DRUG|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
215124899|NCT04386369|OTHER|Airway pressure release ventilation|Ventilator management strategy
215124900|NCT03625284|DIETARY_SUPPLEMENT|Placebo|Edible oil
215124901|NCT03625284|DIETARY_SUPPLEMENT|FucoVital|Microalgae oil extract
214446306|NCT00274469|DRUG|fulvestrant|500 mg intramuscular injection
214446307|NCT00274469|DRUG|anastrozole|1 mg oral tablet
214446308|NCT03526354|DRUG|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
214446309|NCT03526354|OTHER|Treatment as Usual|Current antipsychotic medication for 12 weeks
214446310|NCT05720780|OTHER|MS group|"All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training"
214523303|NCT01394783|DEVICE|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
214523304|NCT01394783|DEVICE|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
214523305|NCT01493947|DRUG|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
215124902|NCT05594719|DEVICE|Shorter-wavelength dominant light|Shorter-wavelength dominant light
215124903|NCT05594719|DEVICE|Light similar to the solar spectrum proportion|Light similar to the solar spectrum proportion with no specific wavelength dominant
214446311|NCT05720780|OTHER|C group|All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
214523306|NCT01493947|DRUG|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
214523307|NCT03204045|DRUG|fentanyl|2 mL mixture of fentanyl with isotonic saline
214523308|NCT03204045|DRUG|Oxycodone|2 mL mixture of oxycodone with isotonic saline
214523309|NCT03204045|DRUG|control|isotonic saline 2 mL
215124904|NCT05594719|DEVICE|Longer-wavelength dominant light|Longer-wavelength dominant light
214446312|NCT04025359|DRUG|Dronabinol|Dronabinol 2.5 mg
214446313|NCT04025359|DRUG|Dronabinol|Dronabinol 5 mg
214446314|NCT04025359|DRUG|Placebo|Placebo
214446315|NCT05847894|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
214694304|NCT07084753|DRUG|Lidocain|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
215124905|NCT01176058|DRUG|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
215124906|NCT05745311|DRUG|The KPCXM18 injection|Intravenous infusion
215124907|NCT05745311|DRUG|Placebo|Intravenous infusion
215124908|NCT03762031|DRUG|GC4711 30mg|single dose given via a 15 minute intravenous infusion
215124909|NCT03762031|DRUG|GC4711 60mg|single dose given via a 15 minute intravenous infusion
215124910|NCT03762031|DRUG|GC4711 90mg|single dose given via a 15 minute intravenous infusion
215124911|NCT03762031|DRUG|GC4711 120mg|single dose given via a 15 minute intravenous infusion
215124912|NCT03762031|DRUG|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
215124913|NCT03762031|DRUG|GC4711 75mg|single dose given via a 15 minute intravenous infusion
215124914|NCT03762031|DRUG|GC4711 105mg|single dose given via a 15 minute intravenous infusion
215124915|NCT06248606|DRUG|Adagrasib|Adagrasib 600mg orally
215124916|NCT06248606|RADIATION|Stereotactic Radiosurgery|Delivered as per standard of care
215124917|NCT03363516|DIAGNOSTIC_TEST|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
215124918|NCT02528825|DRUG|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
215124919|NCT05220306|DEVICE|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
215124920|NCT02579213|OTHER|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
215124921|NCT00003815|BIOLOGICAL|bleomycin sulfate|
215124922|NCT00003815|DRUG|carmustine|
215124923|NCT00003815|DRUG|cyclophosphamide|
215124924|NCT00003815|DRUG|cytarabine|
214708771|NCT00716638|BEHAVIORAL|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
215124925|NCT00003815|DRUG|doxorubicin hydrochloride|
215124926|NCT00003815|DRUG|etoposide|
215124927|NCT00003815|DRUG|melphalan|
215124928|NCT00003815|DRUG|prednisolone|
215124929|NCT00003815|DRUG|vincristine sulfate|
215124930|NCT00003815|PROCEDURE|autologous bone marrow transplantation|
215124931|NCT00003815|RADIATION|radiation therapy|
215124932|NCT03992352|DIAGNOSTIC_TEST|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
215124933|NCT00006326|DRUG|Indinavir sulfate|
215124934|NCT00006326|DRUG|Ritonavir|
215124935|NCT00006326|DRUG|Delavirdine mesylate|
215124936|NCT00377793|DRUG|Levitra (Vardenafil, BAY38-9456)|
215124937|NCT00377793|DRUG|Placebo|
215124938|NCT03493295|DRUG|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
215124939|NCT04166812|DIAGNOSTIC_TEST|oscillometry|assessment of peripheral airway resistance using oscillometry
215124940|NCT04166812|DIAGNOSTIC_TEST|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
215124941|NCT04166812|DIAGNOSTIC_TEST|spirometry|assessment of lung function using spirometry
215124942|NCT04166812|DIAGNOSTIC_TEST|body plethysmography|assessment of lung function using body plethysmography
215124943|NCT04166812|DIAGNOSTIC_TEST|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
215124944|NCT04166812|DIAGNOSTIC_TEST|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
215124945|NCT04166812|DIAGNOSTIC_TEST|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])
215124946|NCT04166812|DIAGNOSTIC_TEST|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
215124947|NCT04166812|DIAGNOSTIC_TEST|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
215124948|NCT04276233|DRUG|Mepolizumab|Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
215124949|NCT04276233|DRUG|Salbutamol|Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
215124950|NCT06634875|DRUG|isunakinra|Isunakinra is a potent IL1R1 inhibitor
215124951|NCT05777603|DRUG|aerosolized aztreonam|antibiotic with gram-negative bacteria coverage
215124952|NCT05777603|DRUG|aerosolized vancomycin|antibiotic with gram-positive bacteria coverage
215124953|NCT05777603|DRUG|pembrolizumab|standard of care therapy/monoclonal antibody for patients with advanced NSCLC
215124954|NCT05024435|DEVICE|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
215124955|NCT01946139|PROCEDURE|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
215124956|NCT01946139|OTHER|laboratory biomarker analysis|Correlative studies
215124957|NCT01946139|OTHER|questionnaire administration|Ancillary studies
215124958|NCT01946139|PROCEDURE|quality-of-life assessment|Ancillary studies
215124959|NCT01191723|DRUG|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
215124960|NCT01191723|DRUG|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
215124961|NCT01191723|DRUG|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
215124962|NCT01191723|DRUG|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
215124963|NCT03599206|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
215124964|NCT03599206|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
215124965|NCT00348439|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
215124966|NCT00348439|DRUG|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
215124967|NCT05923840|DIAGNOSTIC_TEST|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
215124968|NCT05923840|DIAGNOSTIC_TEST|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
215124969|NCT05923840|DIAGNOSTIC_TEST|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
215124970|NCT02525471|DRUG|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
215124971|NCT01676987|DRUG|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
215124972|NCT01676987|DRUG|Budesonide|Delivered dry powder inhaler for 12 weeks.
215124973|NCT01722539|DRUG|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
215124974|NCT01722539|DRUG|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
215124975|NCT01722539|DRUG|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
215124976|NCT01722539|DRUG|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
215124977|NCT02354274|RADIATION|Escalated: Inhomogeneous dose plan|
215124978|NCT02354274|RADIATION|Standard: Homogeneous dose plan|
215124979|NCT00890825|DRUG|AZD6244|oral capsules, 75mg twice daily
214446316|NCT05847894|DIAGNOSTIC_TEST|Pulmonary Examination|Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
214446317|NCT05643326|DEVICE|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
214446318|NCT05643326|DEVICE|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
214523310|NCT05036499|BEHAVIORAL|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
215124980|NCT00890825|DRUG|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
214446319|NCT05032261|DRUG|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
214446320|NCT00084396|DRUG|letrozole|
214446321|NCT00084396|PROCEDURE|conventional surgery|
215124981|NCT00890825|DRUG|Placebo|placebo
215124982|NCT00486369|DRUG|Oral salmon calcitonin|
214446322|NCT05562089|DEVICE|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
214446323|NCT06852534|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
214446324|NCT06852534|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
214446325|NCT06647238|OTHER|Pharmacist Intervention in lipid therapy|Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
214523311|NCT03317678|DIETARY_SUPPLEMENT|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
215124983|NCT02977000|DRUG|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
215124984|NCT06124365|OTHER|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
215124985|NCT06124365|OTHER|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
214523312|NCT03317678|DIETARY_SUPPLEMENT|Non-fermented milk|A non-fermented milk drink.
214523313|NCT01533181|OTHER|Laboratory Biomarker Analysis|Correlative studies
215124986|NCT04781166|BEHAVIORAL|Calm program|7 online modules designed to teach cognitive behavioral skills
215124987|NCT03168620|PROCEDURE|Restoration|
215124988|NCT00778778|DRUG|cefprozil 500mg tablets|
215124989|NCT06256172|DEVICE|Medlink|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
214446326|NCT06155721|DEVICE|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
215124990|NCT02544568|OTHER|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
214446327|NCT06175312|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
215124991|NCT04903210|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide supplied as 400mg capsule|NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
215124992|NCT04903210|BEHAVIORAL|Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
215124993|NCT02318563|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
215124994|NCT02318563|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol
215124995|NCT02336607|DRUG|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
214446328|NCT06175312|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
215124996|NCT02336607|DRUG|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
214446329|NCT00000969|DRUG|Zalcitabine|
214446330|NCT00000969|DRUG|Didanosine|
214446331|NCT03706664|OTHER|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
214446332|NCT04095104|DRUG|Phentermine|Phentermine tablet
214446333|NCT04095104|DRUG|Immediate Release Topiramate|Topiramate tablet
214446334|NCT04095104|DRUG|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
214446335|NCT04095104|DRUG|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
214446336|NCT05747716|DRUG|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
214446337|NCT04277936|DRUG|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
214446338|NCT01467375|DRUG|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
214446339|NCT02057939|DRUG|enzalutamide|160 mg orally once daily for six months
214446340|NCT02057939|DRUG|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
214446341|NCT02057939|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
214446342|NCT02709850|DRUG|IONIS ANGPTL3-LRx|
214446343|NCT02709850|DRUG|Placebo|0.9%NaCl, water, riboflavin
214446344|NCT00197613|DRUG|(A) zidovudine, lamivudine and nevirapine|
214446345|NCT00197613|DRUG|(B) zidovudine, lamivudine and efavirenz|
214446346|NCT00197613|DRUG|(C) zidovudine, didanosine, and nevirapine|
214446347|NCT00197613|DRUG|(D) zidovudine, didanosine, and efavirenz|
214446348|NCT00197613|DRUG|(E) stavudine, lamivudine, and nevirapine|
214446349|NCT00197613|DRUG|(F) stavudine, lamivudine and efavirenz|
214446350|NCT00197613|PROCEDURE|Adherence Strategy Standard of Care (SOC)|
214446351|NCT00197613|PROCEDURE|Adherence Strategy Community-Based DOT|
214446352|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
214446353|NCT02160951|DRUG|LGH447|LGH447, QD
214446354|NCT04850768|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
215124997|NCT02336607|DRUG|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
215124998|NCT02336607|DRUG|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
215124999|NCT04748666|BEHAVIORAL|Problem Solving Training|Problem Solving Training (PST) is a metacognitive strategy training approach, grounded in self-management theory, that teaches a simple, systematic method for evaluating problems, generating and selecting solutions, developing specific goals and action plans, and evaluating and revising plans as needed.
215125000|NCT01180335|DRUG|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
215125001|NCT01180335|DRUG|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
215125002|NCT04203511|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
215125003|NCT04203511|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
215125004|NCT04203511|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
215125005|NCT04203511|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
215125006|NCT04203511|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
214446355|NCT04850768|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
214446356|NCT06423534|BEHAVIORAL|Breastfeeding Health Educational Program|Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
214446357|NCT00809497|DRUG|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
214446358|NCT03912831|DRUG|KITE-439|A single infusion of E7 TCR T cells (KITE-439).
214523314|NCT01533181|DRUG|Linsitinib|150 mg given orally (PO) twice a day (BID)
214523315|NCT01533181|OTHER|Pharmacological Study|Correlative studies
215125007|NCT04203511|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
215125008|NCT04203511|DRUG|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
215125009|NCT04203511|RADIATION|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
215125010|NCT04590807|DEVICE|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
215125011|NCT04590807|DEVICE|Anterior vertebral body tethering|Vertebral screws and cable
215125012|NCT04139226|DRUG|CC-11050|CC-11050
214446359|NCT03912831|DRUG|Cyclophosphamide|Administered intravenously.
214446360|NCT03912831|DRUG|Fludarabine|Administered intravenously.
214446361|NCT03912831|DRUG|Interleukin-2|Administered subcutaneously.
214446362|NCT05845177|PROCEDURE|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
214523316|NCT01533181|DRUG|Topotecan Hydrochloride|1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
214523317|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol Env A/B/C|1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
214523318|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol|5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
214523319|NCT01099150|DIETARY_SUPPLEMENT|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
214523320|NCT01099150|DIETARY_SUPPLEMENT|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
214523321|NCT01099150|DIETARY_SUPPLEMENT|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
214523322|NCT02326740|DRUG|gevokizumab|
214523323|NCT02326740|DRUG|Placebo|
215125013|NCT02643459|BEHAVIORAL|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
215125014|NCT04983966|DRUG|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
215125015|NCT04983966|DRUG|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
215125016|NCT02232217|BEHAVIORAL|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
215125017|NCT02232217|OTHER|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
215125018|NCT05022186|DRUG|Cannabidiol Oil|Patients will use it with specific instructions and they will be monitored at least one time in a month
215125019|NCT05022186|DRUG|Homotaurine|Patients will use it with specific instructions and they will be monitored at least one time in a month
215125020|NCT04370158|OTHER|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
215125021|NCT01495208|DRUG|Aflibercept|intravitreal aflibercept injection 2mg
215125022|NCT01167803|DRUG|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
215125023|NCT01167803|DRUG|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
215125024|NCT02489071|BEHAVIORAL|Brain Training Program|
215125025|NCT02489071|BEHAVIORAL|Brain Health Program|
215125026|NCT00744926|DRUG|placebo|sc, once weekly
215125027|NCT00744926|DRUG|taspoglutide|10mg sc, once weekly
214446363|NCT05916001|OTHER|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
214523324|NCT02326740|DRUG|gevokizumab open-label|
214523325|NCT02840175|DRUG|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
215125028|NCT00744926|DRUG|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
215125029|NCT00005952|BIOLOGICAL|filgrastim|
215125030|NCT00005952|DRUG|temozolomide|
215125031|NCT00005952|PROCEDURE|peripheral blood stem cell transplantation|
214446364|NCT05916001|DIETARY_SUPPLEMENT|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
214446365|NCT05916001|PROCEDURE|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
214446366|NCT01522924|OTHER|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
214446367|NCT00276796|DRUG|cisplatin|
214446368|NCT00276796|DRUG|paclitaxel|
214446369|NCT00276796|DRUG|topotecan hydrochloride|
214523326|NCT02840175|DRUG|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
214523327|NCT02840175|DRUG|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
214523328|NCT02840175|DRUG|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
214523329|NCT03730311|DRUG|Elpida|elsulfavirine, capsules
214523330|NCT03730311|DRUG|placebo|placebo
215125032|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
215125033|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
215125034|NCT04079426|OTHER|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
215125035|NCT03780049|PROCEDURE|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
215125036|NCT03780049|DRUG|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
215125037|NCT03780049|DRUG|Placebos|Patients receive normal saline 10ml in each session of HAIC
215125038|NCT05262257|DRUG|Metformin|Take it regularly for 12 weeks
215125039|NCT05262257|DRUG|Dapagliflozin|Take it regularly for 12 weeks
215125040|NCT05262257|BEHAVIORAL|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
215125041|NCT05716555|DEVICE|Deep brain stimulation|Electrical stimulation of lateral habenula
215125042|NCT01338337|DRUG|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
215125043|NCT01658748|DEVICE|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
215125044|NCT01658748|DEVICE|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
215125045|NCT02464618|BEHAVIORAL|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
215125046|NCT04107714|BEHAVIORAL|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure."
215125047|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (Moderate Risk)|Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.
215125048|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (High Risk)|Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
215125049|NCT05706311|OTHER|Standard of Care|Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
215125050|NCT03226717|DRUG|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
214446370|NCT02910713|DEVICE|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
214523331|NCT02213224|DRUG|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
215125051|NCT03093896|DIETARY_SUPPLEMENT|snack mix|commercial cereal mix with bits of beef jerky and coconut
214446371|NCT00145236|DRUG|Nebivolol|
214446372|NCT02808767|DRUG|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
214446373|NCT02808767|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
214446374|NCT00766649|DRUG|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
214446375|NCT04944563|PROCEDURE|Segmentectomy|Patients receive segmentectomy
214446376|NCT04944563|PROCEDURE|Lobectomy|Patients receive lobectomy
214446377|NCT00220038|BEHAVIORAL|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
215125052|NCT03093896|DIETARY_SUPPLEMENT|almonds, 1.5 oz|almonds, 1.5 oz/day
215125053|NCT03093896|DIETARY_SUPPLEMENT|almonds, 3 oz|almonds, 3.0 oz/day
215125054|NCT05028192|OTHER|no intervention|no intervention
215125055|NCT01216202|RADIATION|Preoperative radiotherapy|"Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes."
215125056|NCT06034288|DRUG|Xeomin 100 UNT Injection|intravesical injection
215125057|NCT06034288|DRUG|Botox 100 UNT Injection|intravesical injection
215125058|NCT02091817|DRUG|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
215125059|NCT02091817|DRUG|Placebo|Placebo will be given to control group and experimental group as well.
215125060|NCT04564664|DRUG|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
215125061|NCT05642585|DRUG|MY008211A tablets|Single oral
215125062|NCT05642585|DRUG|Placebo|Single oral
215125063|NCT04968158|DRUG|Etoricoxib 90 mg / Tramadol 50 mg|One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
215125064|NCT04968158|DRUG|Acetaminophen 325 mg / Tramadol 37.5 mg|One tablet, every 8 hours of 325 mg/ 37.5 m
215125065|NCT05055544|DRUG|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
215125066|NCT05055544|DRUG|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
215125067|NCT02191371|DRUG|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
215125068|NCT02191371|DRUG|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
215125069|NCT03196544|BEHAVIORAL|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
215125070|NCT03196544|BEHAVIORAL|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
215125071|NCT02828735|DEVICE|respiration assessment|Respiration Breathing Exercise
214523332|NCT02213224|DRUG|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
214523333|NCT02213224|DRUG|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
215125072|NCT06379165|DRUG|Meloxicam Nanocrystal Injection|30 mg (1 mL), once daily, by intravenous infusion
215125073|NCT06379165|DRUG|Placebo|1 mL Placebo, once daily, by intravenous infusion
215125074|NCT00230126|DRUG|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
214523334|NCT00953342|BEHAVIORAL|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
214523335|NCT00953342|BEHAVIORAL|Usual care|Standard medical care
214694305|NCT07084753|DRUG|Sufentanil|Following three-minute preoxygenation, sufentanil (5 to 15 micrograms), propofol (1 to 2 mg/kg ideal body weight), and rocuronium (0.8 to 1 mg/kg ideal body weight) are administered intravenously during induction of anesthesia. Anesthesia is sustained with sevoflurane maintained at 0.6-1.3 MAC. Sufentanil is added at the assessment of the anesthesiologist in the operating room.
214694306|NCT07084753|PROCEDURE|Opioid free anesthesia based on thoracic paravertebral block|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized without the use of opioids, with general anesthesia and pain blockade using a thoracic paravertebral block
215125075|NCT04836585|OTHER|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~1. Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~2. PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~3. Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
215125076|NCT03767647|BEHAVIORAL|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
215125077|NCT03827135|OTHER|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
215125078|NCT03827135|OTHER|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
214446378|NCT05284071|DEVICE|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
214446379|NCT06541093|BIOLOGICAL|UVAX-1107|Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
215125079|NCT01679496|OTHER|Food items|Food items with different fatty acid composition
215125080|NCT03982641|PROCEDURE|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
215125081|NCT04724408|DEVICE|VieScope|see above
215125082|NCT04724408|DEVICE|Conventional|see above
215125083|NCT05136508|DRUG|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
215125084|NCT05136508|DRUG|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
215125085|NCT04502537|DRUG|Roxadustat|Oral
215125086|NCT04502537|DRUG|erythropoietin|injection
215125087|NCT00408850|DRUG|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
215125088|NCT00408850|DRUG|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
215125089|NCT04757493|DRUG|Prucalopride 2mg|Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
214446380|NCT06541093|BIOLOGICAL|UVAX-1197|Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
214694307|NCT07084753|PROCEDURE|Opioid based Anesthesia|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized with opioids and general anesthesia
215125090|NCT02223780|OTHER|early palliative care|the patients will benefit from an early palliative care consultation
215125091|NCT04113850|DEVICE|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
215125092|NCT01775774|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
215125093|NCT06059365|BEHAVIORAL|Hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward
215125094|NCT06059365|BEHAVIORAL|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
214446381|NCT06541093|OTHER|Placebo|Saline injection
214708772|NCT00716638|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
215125095|NCT00061659|DRUG|ABT-510 - Thrombospondin-1 mimetic|
215125096|NCT05109780|DEVICE|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
215125097|NCT04103359|OTHER|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
215125098|NCT00271375|BEHAVIORAL|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
215125099|NCT00271375|BEHAVIORAL|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
215125100|NCT00271375|BEHAVIORAL|Control|Control group usual care
215125101|NCT03483896|OTHER|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
215125102|NCT02365649|DRUG|Placebo|Oral Dosing
215125103|NCT02365649|DRUG|ABT-494|Oral Dosing
215125104|NCT05312593|OTHER|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
215125105|NCT05312593|OTHER|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
215125106|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 12 g polydextrose|12 g polydextrose
215125107|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
215125108|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
215125109|NCT02314936|DIETARY_SUPPLEMENT|Placebo|12 g Maltodextrin
215125110|NCT04618146|DRUG|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
215125111|NCT04618146|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
215125112|NCT01577017|DRUG|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
215125113|NCT03287921|DRUG|mono bronchodilatation|within indication according to current GOLD recommendation
215125114|NCT03287921|DRUG|dual bronchodilatation|within indication according to current GOLD recommendation
215125115|NCT04001712|DRUG|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
215125116|NCT05052034|OTHER|Music|Through headphones, the patients would listen to different types of music during the intervention.
215125117|NCT00165880|DRUG|E7070|
215125118|NCT04471077|PROCEDURE|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
215125119|NCT01528059|PROCEDURE|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
215125120|NCT03913858|PROCEDURE|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
215125121|NCT03913858|PROCEDURE|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
215125122|NCT03572179|DEVICE|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
215125123|NCT04653480|DRUG|Surufatinib|250mg per oral, once daily
215125124|NCT04653480|DRUG|Toripalimab|3mg/kg IV, once every 2 weeks
215125125|NCT04653480|DRUG|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
214446382|NCT03767517|OTHER|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
214446383|NCT03767517|OTHER|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
215125126|NCT05853146|DEVICE|Oxitone 1000M|World's First FDA-cleared Wrist-Sensor Pulse Oximetry Monitor
215125127|NCT03853330|DEVICE|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
215125128|NCT03853330|DRUG|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
215125129|NCT03853330|DRUG|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
215125130|NCT03476135|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
215125131|NCT03592316|OTHER|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
215125132|NCT00071227|DRUG|Triamcinolone Acetonide (TAC-PF)|
215125133|NCT02307708|DEVICE|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
215125134|NCT02307708|OTHER|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
215125135|NCT00867230|DRUG|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
215125136|NCT00790946|DRUG|Valsartan|Valsartan 80 to 160 mg
215125137|NCT02885688|DIETARY_SUPPLEMENT|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
215125138|NCT02885688|PROCEDURE|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
215125139|NCT00069446|DRUG|rhuMAb VEGF (telbermin)|
215125140|NCT05854355|OTHER|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
215125141|NCT05515731|BIOLOGICAL|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
215125142|NCT04024488|BEHAVIORAL|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
214446384|NCT06987721|DEVICE|Modus ESWT-Focused|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.056 mj/mm, 6 Hz for focused applications. All applications were done with the same device; Modus ESWT.
214446385|NCT06987721|DEVICE|Modus ESWT-Radial|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.1 mj/mm, 10-16 Hz for radial applications. All applications were done with the same device; Modus ESWT.
214446386|NCT06987721|DEVICE|Modus ESWT-Sham|The sham application was made in such a way that the device was set to 0 frequency and power, making only sound. All applications were done with the same device; Modus ESWT.
214446387|NCT04526678|DIETARY_SUPPLEMENT|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
214446388|NCT06710756|DRUG|[203Pb]Pb-PSV359|\[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
214446389|NCT06710756|DRUG|[212Pb]Pb-PSV359|\[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.
214446390|NCT04954898|DEVICE|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
214446391|NCT06710795|DEVICE|MaxTack™ Motorized Fixation Device|All subjects enrolled will receive the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
214446392|NCT06877247|DRUG|[14C] SHR6508 Injection|\[14C\] SHR6508 injection.
214446393|NCT06741020|DRUG|Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin|Chemotherapy drugs including Oxaliplatin, Fluorouracil,Leucovorin and immunotherapy durgs Adebrelimab will infuse to liver by transarterial catheter toward to the lesion.
214446394|NCT06778070|OTHER|Pelvic floor yoga|Pelvic floor yoga
214446395|NCT06778070|OTHER|Physical conditioning|Physical conditioning
214446396|NCT06618274|BEHAVIORAL|Intervention of oncology research navigator embedded in central oncology navigation|The intervention of oncology research navigator or Oncology research navigator (ORN) is embedded in central oncology navigation cancer care delivery.
214523339|NCT06003738|PROCEDURE|fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected."
214694308|NCT07084753|PROCEDURE|Opioid free anesthesia, Opioid free anesthesia based on intravenous dexmedetomidine, ketamine and lidocainedexmedetomidine, ketamine and lidocaine|Patients who are scheduled for laparoscopic gastrectomy will be anesthetized without the use of opioids and under general anesthesia, with analgesia by intravenous administration of dexmedetomidine, ketamine and lidocaine.
214446397|NCT06618274|BEHAVIORAL|Central oncology navigation (SOC)|Central oncology navigation (SOC ) alone.
214446398|NCT06908135|BEHAVIORAL|Independent walking program using walking poles|Participants will independently walk at least 3 times a week for 8 weeks using walking poles
214446399|NCT06908135|BEHAVIORAL|Independent walking program without walking poles|Participants will independently walk at least 3 times a week for 8 weeks without walking poles
214446400|NCT04674306|BIOLOGICAL|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
214446401|NCT04674306|BIOLOGICAL|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
214446402|NCT05792423|DEVICE|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
214523340|NCT06003738|PROCEDURE|pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
214708777|NCT05516160|DIAGNOSTIC_TEST|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
214708778|NCT00454272|DRUG|Teicoplanin|
214708779|NCT00454272|DRUG|Vancomycin|
215125143|NCT04024488|BEHAVIORAL|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
215125144|NCT05150184|OTHER|Non-interventional|observational study, thus no different arm/groups
215125145|NCT06214975|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on stroke related symptoms."
215125146|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
215125147|NCT01847963|DRUG|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
215125148|NCT01847963|DRUG|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
215125149|NCT00334217|BEHAVIORAL|Cognitive Remediation|PSS Cogrehab
215125150|NCT01188772|DRUG|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
215125151|NCT01188772|DRUG|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
215125152|NCT01188772|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
215125153|NCT01188772|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
215125154|NCT05696249|DEVICE|OhmTrak device.|All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
214446403|NCT06931119|DRUG|EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.|"Total Treatment Duration: 1 cycle (1 administration of EMEND® capsules)~* Frequency: Patients will take EMEND® capsules at the start of new ICI.~* Dosing Schedule:~  * Day 1: EMEND® 125 mg, taken orally 1-2 hours before ICI administration.~ * Day 2: EMEND® 80 mg, taken orally in the morning.~ * Day 3: EMEND® 80 mg, taken orally in the morning. During the study period (12 weeks), participant must refrain from using any medications that could potentially interfere with the study's assessment of pruritus symptoms (e.g steroids, antihistamines)~Follow-up 1(7 days after the first capsule of Aprepitant): 12-PSS, safety assessment, QLQ-C30 Follow-up 2: 12-PSS, safety assessment Follow-up 3: 12-PSS, safety assessment Follow-up 4: 12-PSS, QLQ-C30, safety assessment Extended Follow-up: Recurrence of pruritus, long-term safety monitoring, QLQ-C30"
214446404|NCT06927739|DRUG|Orticumab|Orticumab treatment for 24 weeks for post MI population
214446405|NCT06927739|DRUG|Placebo|Placebo for 24 weeks for the post MI population
215125155|NCT05696249|OTHER|Outpatient Physiotherapy|All probands will undergo six-week outpatient therapy once a week for an hour
215125156|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
214446406|NCT06927817|DRUG|hyoscine-n-butylbromide, ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
215125157|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
215125158|NCT01125982|DRUG|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
215125159|NCT01125982|DRUG|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
215125160|NCT00055835|DRUG|carboplatin|\*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
215125161|NCT00055835|DRUG|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
215125162|NCT00055835|DRUG|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 \& 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
215125163|NCT00055835|DRUG|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
214708780|NCT03623425|DRUG|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
215125164|NCT00055835|PROCEDURE|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
215125165|NCT00055835|RADIATION|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
215125166|NCT01366001|DRUG|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
215125167|NCT01366001|DRUG|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
215125168|NCT01366001|DRUG|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
215125169|NCT04388254|DRUG|Simufilam 100 mg oral tablet|Simufilam 100 mg oral tablet for b.i.d. administration
215125170|NCT04388254|DRUG|Placebo|Matching placebo oral tablets
215125171|NCT00066677|DRUG|rhuMAB-VEGF|
215125172|NCT00066677|DRUG|docetaxel|
215125173|NCT00879385|DRUG|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
215125174|NCT00879385|DRUG|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
215125175|NCT05775770|DRUG|Insulin|insulin therapy
215125176|NCT03823183|BEHAVIORAL|Cognitive training|Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
215125177|NCT03823183|BEHAVIORAL|Physical training|Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
215125178|NCT03823183|BEHAVIORAL|Cognitive control|Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
215125179|NCT03823183|BEHAVIORAL|Physical control|Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
215125180|NCT05217277|DIAGNOSTIC_TEST|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
215125181|NCT02840708|DRUG|Sargramostim|
215125182|NCT01212861|DEVICE|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
215125183|NCT02883231|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
215125184|NCT06062654|OTHER|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
215125185|NCT06062654|OTHER|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
215125186|NCT03370718|DRUG|Cabozantinib|Given PO
215125187|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
215125188|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
215125189|NCT05676112|DRUG|nintedanib|nintedanib
215125190|NCT05676112|DRUG|pirfenidone|pirfenidone
215125191|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
215125192|NCT03035799|OTHER|Paleolithic diet|Paleolithic diet
215125193|NCT03035799|OTHER|General Healthful Diet|General Healthful Diet
215125194|NCT04187495|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
215125195|NCT05301517|DRUG|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
215125196|NCT05301517|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
215125197|NCT04106609|OTHER|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
215125198|NCT04106609|OTHER|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
215125199|NCT00200330|BEHAVIORAL|Behavioral weight loss treatment|
215125200|NCT00200330|BEHAVIORAL|Behavioral and home environment weight loss treatment|
215125201|NCT04665271|BEHAVIORAL|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
215125202|NCT03863509|BEHAVIORAL|Cigarettes|smokes daily
215125203|NCT03863509|BEHAVIORAL|E-Cigarettes|E-cigarette usage \>/= 5 days/week
214446407|NCT06927817|DRUG|• hyoscine-n-butylbromide • ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
215125204|NCT03549221|DRUG|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
215125205|NCT05455476|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
215125206|NCT05455476|BEHAVIORAL|CBT for Chronic Pain|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
214446408|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 12.5 mg|1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).
214446409|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 10 mg|2- Reduced dose group: receiving a20% reduced dose of hyperbaric bupivacaine (10 mg hyperbaric bupivacaine + 25 mcg fentanyl).
214446410|NCT07140692|DEVICE|Vitrectomy|In this single-arm, non-comparative study, patients presenting with vitreous opacities affecting daily activities of living will undergo vitrectomy using the single-use vitrector probe of Vista Ophthalmics for the removal of the vitreous opacities.
214446411|NCT06932627|PROCEDURE|ILIB|The treatment group receive an intravenous laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 5 Mw, 30 minutes each time,once every other day for 3 consecutive days each week, for 2 weeks (total 6 times in one course)
215125207|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
215125208|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
215125209|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
214446412|NCT06932627|PROCEDURE|Sham Control|The steps for the control group are the same as the treatment group, exceptthat the output power is adjusted to zero intensity.
214446413|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
214446414|NCT06361758|DRUG|Cadonilimab+Lenvatinib|Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
214446415|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
214446416|NCT06077812|BEHAVIORAL|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
214446417|NCT06077812|BEHAVIORAL|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
214446418|NCT06077812|BEHAVIORAL|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
214446419|NCT06537258|BEHAVIORAL|Biofeedback Enhanced Treatment|"At all 4 assessment points (T1-T4), HRV will be measured using the ECG module of the mobile MindWare system at a sampling rate of 500 Hz, and a Skin Conductance Response (SCR) will be collected at a sampling rate of 10 Hz using eSense for iPad. Electrodes to assess SCR and HRV will be attached to patients during an \~10-minute period.~A 5-minute initial baseline assessment will occur first followed by three 5-minute stress trials.~Stress tasks will be audio recorded to measure study fidelity, and participants will be asked to rate their subjective level of stress with each trial. At all assessment points (T1-T4), participants will be provided with stool collection kits to collect a stool sample within 3 days of the laboratory psychophysiological assessment.~At all assessment points (T1-T4), a blood draw of approximately 3 ml of blood will be collected."
214446420|NCT05938023|DRUG|ATL1102 25mg|Dose and scheduled as specified in the Arm description
214446421|NCT05938023|DRUG|ATL1102 50mg|Dose and scheduled as specified in the Arm description
214708781|NCT03623425|DRUG|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
214446422|NCT05938023|DRUG|Placebo|Dose and scheduled as specified in the Arm description
214446423|NCT05649319|PROCEDURE|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
214446424|NCT06786338|DRUG|SGB-9768|SGB-9768 for subcutaneous (SC) injection
214446425|NCT03116412|PROCEDURE|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
214446426|NCT06833801|DEVICE|Real-Time Blood Data Monitoring System (Device/Software Integration)|"Description: An alert function will be integrated into the hospital's electronic system, allowing healthcare providers to view real-time blood test results of radiation therapy patients. The system will notify both medical staff and patients of abnormal results, prompting timely intervention.~Mode of Delivery: Hospital Information System (HIS) Integration Purpose: Improve treatment safety by reducing delays in managing abnormal blood counts."
214446427|NCT06833801|BEHAVIORAL|Enhanced Patient Education Materials (Behavioral/Educational Intervention)|"Description: Optimized educational pamphlets and multimedia resources will be provided to patients, including clear self-care instructions and guidance on reporting blood test needs during radiation therapy.~Mode of Delivery: Printed materials, multimedia resources, verbal education by medical staff Purpose: Improve patient understanding and engagement in their treatment process."
214708782|NCT02128594|BEHAVIORAL|Serosorting Intervention|Single session, behavioral intervention
215125210|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
215125211|NCT04508049|DEVICE|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
215125212|NCT03971461|DRUG|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
215125213|NCT02912715|DEVICE|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
215125214|NCT05676502|DEVICE|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
215125215|NCT04186767|DIETARY_SUPPLEMENT|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
215125216|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
214446428|NCT06833801|BEHAVIORAL|Internal Warning Signs and Alerts (Behavioral Intervention)|"Description: Physical reminder signs will be placed in high-traffic patient areas (e.g., check-in counters, treatment rooms) to prompt patients to report discomfort or abnormal symptoms, especially related to blood test needs.~Mode of Delivery: Visual reminders placed within the radiation oncology department Purpose: Increase patient awareness and adherence to treatment safety protocols."
214446429|NCT03768440|PROCEDURE|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
214446430|NCT03768440|PROCEDURE|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
214446431|NCT03768440|DRUG|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
214446432|NCT04141774|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
214446433|NCT04141774|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
214446434|NCT04141774|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
214446435|NCT04141774|OTHER|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
214446436|NCT06149104|DRUG|sacubitril/valsartan|sacubiril/valsartan
214446437|NCT06817863|OTHER|Digital|This intervention is a self-help digital treatment, delivered via a smartphone application, for adults with co-morbid binge eating and obesity. The app ChangeBite will integrate principles of evidence based treatments for obesity (behavioral weight loss treatment) and binge eating (cognitive behavioral therapy, acceptance and commitment therapy) into a highly personalized, self-guided, program that leverages an artificial conversational agent and Just-In-Time-Adaptive-Interventions (JITAIs).
214523341|NCT06003738|PROCEDURE|palcebo fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected."
214523342|NCT06003738|PROCEDURE|palcebo pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
214523343|NCT00119756|DRUG|paliperidone palmitate|
214523344|NCT01837719|DRUG|Atazanavir|300-mg capsule
214523345|NCT01837719|DRUG|Cobicistat|150-mg tablet
214523346|NCT01837719|DRUG|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
214523347|NCT01703988|DRUG|Nusinersen|Single IT injection for each dose
214523348|NCT05194813|OTHER|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
214523349|NCT05194813|OTHER|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
214523350|NCT03750305|OTHER|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
214523351|NCT03750305|OTHER|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
214523352|NCT02995733|DRUG|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
214523353|NCT00790777|DRUG|Paliperidone ER|
214523354|NCT03802487|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
214523355|NCT03802487|DRUG|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
214523356|NCT03802487|DRUG|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
214523357|NCT04775173|DRUG|Sirolimus|Use of different doses of the same drug
215125217|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
215125218|NCT06666088|OTHER|Cognitive stimulation and Strength training|"The experimental group will participate in a 12-week program to enhance cognitive functions and physical strength through twice-weekly sessions of 45 minutes to 1 hour. Cognitive stimulation activities will improve memory, attention, processing speed, and executive functions through memory games, recall exercises, and tasks that promote focus and quick thinking. Each session will be led by a neuropsychology or occupational therapy professional who will tailor activities to individual needs.~Strength training will also occur twice a week, focusing on exercises that strengthen major muscle groups, improve balance, and enhance coordination. Participants will use light weights, resistance bands, and bodyweight exercises, with modifications based on their physical levels. A specialized trainer will supervise the program, progressively adjusting exercise intensity to ensure safety and optimize benefits."
215125219|NCT03095248|DRUG|Selumetinib|Continuous twice daily dosing; oral agent
215125220|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by ICG|Use of ICG during the targeted axillary dissection (TAD)
215125221|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by Blue patent|Use of Blue patent during the targeted axillary dissection (TAD)
215125222|NCT06577597|DRUG|GSK3923868|Participants will receive single dose of GSK3923868.
215125223|NCT06577597|DRUG|Placebo|Participants will receive single dose of Placebo.
215125224|NCT01572480|DRUG|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
214523358|NCT04697641|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
214523359|NCT04697641|DRUG|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
214523360|NCT04697641|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
214523361|NCT04697641|DRUG|Levosulpiride|Levosulpiride 25 mg as and when required before meals
214523362|NCT04697641|DRUG|Acotiamide|Acotiamide 100mg as when required before meals
214523363|NCT04697641|DRUG|Itopride|Itopride 50mg as when required before meals
214523364|NCT01916447|DRUG|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214523365|NCT01916447|DRUG|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214523366|NCT01916447|DRUG|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214523367|NCT06353919|OTHER|Yoga Nidra|"Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice."
214523368|NCT06353919|OTHER|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
214523369|NCT00905814|DRUG|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
214523370|NCT00905814|DRUG|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
214523371|NCT05654558|DEVICE|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
215125225|NCT01572480|DRUG|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
215125226|NCT01572480|DRUG|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
215125227|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
215125228|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
215125229|NCT06128304|OTHER|Core Implementation strategies|"Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants"
215125230|NCT06128304|OTHER|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5\. Community engagement using Health Beginning Initiative Model~6\. Smart Cards to facilitate patient engagement"
215125231|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
215125232|NCT06172348|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
215125233|NCT01006759|OTHER|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
215125234|NCT03254199|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
215125235|NCT03254199|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
215125236|NCT05171192|BEHAVIORAL|CMAP Plus LTP|The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
215125237|NCT06468995|OTHER|Surveys completion|Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
215125238|NCT06468995|DRUG|Home administration of CAB+RPV|Drug treatment and follow-up at home (home arm).
215125239|NCT06468995|DRUG|Hospital administration of CAB+RPV|Drug treatment and follow-up in hospital (hospital arm)
215125240|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
215125241|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
215125242|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
215125243|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
215125244|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
215125245|NCT06533280|DRUG|Part A, C and D: VH3739937 500 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions
215125246|NCT06533280|DRUG|Part A: VH3739937 100 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
215125247|NCT06533280|DRUG|Part A and C: Placebo|Oral administration of Placebo in moderate fat/moderate calorie conditions
215125248|NCT06533280|DRUG|Part B: Treatment A|VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
215125249|NCT06533280|DRUG|Part B: Treatment B|VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
215125250|NCT06533280|DRUG|Part B: Treatment C|VH3739937, 500 mg single tablet administered under fasted conditions.
215125251|NCT06533280|DRUG|Part B: Treatment D|VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
215125252|NCT06533280|DRUG|Part B: Treatment E|VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
215125253|NCT06533280|DRUG|Part D: Probe cocktail|Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
215125254|NCT04837833|DIAGNOSTIC_TEST|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
214446438|NCT06790056|PROCEDURE|duodenal ndoscopic bind ligation|"We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion.~By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions.~We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success.~You are requested to come for follow up for 3 months for endoscopy prodecure."
215125255|NCT02378545|DRUG|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
215125256|NCT03458949|OTHER|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
215125257|NCT02825615|PROCEDURE|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
215125258|NCT00191334|DRUG|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
214446439|NCT06120621|PROCEDURE|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
215125259|NCT00191334|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
215125260|NCT02747810|DEVICE|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
215125261|NCT01817504|PROCEDURE|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
215125262|NCT01817504|PROCEDURE|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
214446440|NCT05338086|DRUG|MB09 (denosumab biosimilar)|Pre-filled syringe (PFS) 60 mg/mL solution, administered as subcutaneous injection
214446441|NCT05338086|DRUG|EU-Prolia|PFS 60 mg/mL solution, administered as subcutaneous injection
214446442|NCT05338086|DIETARY_SUPPLEMENT|Elemental Calcium|at least 1000 mg daily
214446443|NCT05338086|DIETARY_SUPPLEMENT|Vitamin D|at least 400 IU daily
214446444|NCT03879343|OTHER|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
214446445|NCT06765330|DRUG|CHX disinfection|Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
214446446|NCT06765330|DEVICE|Laser Disinfection|After the caries removal procedure, the cavity will be disinfected using an Er,Cr: YSGG laser (EPIC X™, BIOLASE, USA) with 940 nm and 0.1 W output power. The laser tip will be a 400 µm tip with an energy density of 138.12 J/cm in non-contact mode (2 mm distance), 5 s/mm2 sweeping motion.
214446447|NCT06765330|PROCEDURE|Tungsten carbide bur|Carious tissue will be completely removed from the surrounding cavity walls with a tungsten carbide bur, leaving at least 2 mm of peripheral intact tooth structure for good adaptation and sealing of the restoration.
214446448|NCT06765330|PROCEDURE|Polymer bur|Access to the lesion will be achieved using a high-speed handpiece with a sterile high-speed bur. The polymer bur will be used with a low-speed handpiece at 5,000-10,000 RPM to remove carious dentin in sizes RA4, RA6, and RA8 according to the size of the caries lesion. The instrument will be used with a circular, light force starting from the center of the carious lesion towards the periphery as recommended by the manufacturer. Caries removal will be stopped when the instrument is macroscopically worn and blunt and can no longer remove tissue. An excavator will be used to verify if any caries remain at the base of the cavity. If necessary, a new polymer bur will be used to remove the remaining decay.
214446449|NCT06366867|DEVICE|VibrantMinds|VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
214446450|NCT02536118|DEVICE|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
214446451|NCT06229613|DEVICE|medical device for exhaled breath aerosols (XBAs) collection|To evaluate the feasibility of XBAs collection and analysis (index test) using the molecular tests currently in use at San Raffaele Hospital for the detection of respiratory pathogens in clinical samples, compared to upper respiratory secretion and sputum samples, that will be collected using standard procedures and analysed using the same kits (comparator tests).
214446452|NCT04996160|DRUG|Palbociclib|Oral
214446453|NCT04996160|DRUG|Dexamethasone|8 mg/m2/day divided BID, PO, NG, or IV
215125263|NCT05957965|DEVICE|Wii fit|Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
215125264|NCT05957965|OTHER|Strengthening, proprioceptive exercises.|"-Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board"
215125265|NCT04266132|PROCEDURE|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
215125266|NCT04266132|PROCEDURE|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
214523372|NCT05654558|DEVICE|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
214523373|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)|0.25 mL per dose.
214523374|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)|0.5 mL per dose
215125267|NCT04266132|PROCEDURE|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
215125268|NCT04266132|DRUG|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
215125269|NCT05396300|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
215125270|NCT02551341|PROCEDURE|higher PEEP ventilation|
215125271|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
215125272|NCT06938815|OTHER|Pigment Balancing Peel|Chemical Peel
214446454|NCT04996160|DRUG|Bortezomib|1.3 mg/m2/dose, IV (preferred) or SC
214446455|NCT04996160|DRUG|Doxorubicin|25 mg/m2/dose IV
214446456|NCT06459141|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
214446457|NCT04533022|DRUG|C21|C21 100 mg BID (twice daily)
214446458|NCT05285007|OTHER|Mobilization with Movement|Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.
214446459|NCT05285007|OTHER|No mobilization with movement and education|Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
214446460|NCT06116409|DRUG|Bupivacain|Bupivacaine was used for postoperative analgesia block.
214446461|NCT06242431|PROCEDURE|Group serratus posterior superior intercostal plane block (SPSIPB)|SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
214523375|NCT06642558|BIOLOGICAL|Placebo (Saline solution)|0.5 mL per dose
214523376|NCT00243633|PROCEDURE|Real-time contrast-enhanced ultrasound sonography|
214523377|NCT02844348|OTHER|Hypnosis session|
214523378|NCT05805033|OTHER|Mucointegration|Placement of abutment on a dental implant to study mucointegration
214523379|NCT04885764|BIOLOGICAL|Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart
214523380|NCT04885764|BIOLOGICAL|Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart
214523381|NCT05675839|OTHER|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI\_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
214523382|NCT02186587|DEVICE|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
215125273|NCT06938815|OTHER|Discoloration Defense Serum|Dark spot correcting serum
215125274|NCT06938815|OTHER|LHA Cleansing Gel|exfoliating gel facial cleanser
215125275|NCT06938815|OTHER|Hydrating B5 Gel|Vitamin B5 serum with hyaluronic acid
215125276|NCT06938815|OTHER|Daily Brightening Sunscreen|daily moisturizing sunscreen SPF 30
215125277|NCT06937515|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
215125278|NCT06938711|DRUG|Elacestrant|Elacestrant 200mg once daily oral dosing in cycles of 28 days.
215125279|NCT06938711|DRUG|Onapristone|Onapristone 40mg twice daily oral dosing in cycles of 28 days.
215125280|NCT00866814|DEVICE|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
215125281|NCT06938360|PROCEDURE|breast-conserving surgery combined with radiotherapy|The experimental group received breast-conserving surgery combined with radiotherapy
215125282|NCT06939387|OTHER|Observational study, no intervention|Observational study, no intervention
215125283|NCT06937567|BIOLOGICAL|CDH17 CAR-T|The initial dose of cell therapy in this clinical study was set at 1.0×106/Kg and the maximum dose was set at 6.0×106/Kg.
215125284|NCT06937151|PROCEDURE|Rocabado approach exercise program 6×6 and manibulation .|Rocabado's approach (Rocabado's 6 × 6 Exercises and manipulation). This program included 6 exercises to be performed 6 times a day, repeated 6 times, and three gliding exercises.
215125285|NCT06937151|PROCEDURE|Arthrocentesis|"Participants in the Control Group underwent arthrocentesis of the affected temporomandibular joint. The procedure was performed as follows:~Anesthesia: Local anesthesia was administered to the area surrounding the TMJ.~Needle Insertion: A 20-gauge needle was inserted into the upper joint space approximately 10 mm anterior to the tragus.~Lavage: The joint was lavaged with lactated Ringer's solution to reduce inflammation and remove debris. The joint was irrigated with lactated Ringer's solution."
215125286|NCT05708456|OTHER|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
215125287|NCT01063153|DRUG|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
215125288|NCT04304872|BEHAVIORAL|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
215125289|NCT04304872|BEHAVIORAL|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
215125290|NCT00411255|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
215125291|NCT02607943|DRUG|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
215125292|NCT02607943|DRUG|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
215125293|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
214446462|NCT06242431|PROCEDURE|Group pectoralis nerve block (PECS-II)|PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
214446463|NCT05050916|DIETARY_SUPPLEMENT|Vitamin D|The High Dose Vitamin D arm will receive 50,000 IU/week of cholecalciferol. The Low Dose Vitamin D arm will receive 4,200 IU/week of cholecalciferol
214446464|NCT05050916|OTHER|Placebo|Cellulose capsule
214446465|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
214446466|NCT02163447|DRUG|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
214446467|NCT02163447|DRUG|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
214446468|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for infants|
214446469|NCT02163447|DRUG|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
214446470|NCT05886517|DEVICE|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
214446471|NCT06048614|PROCEDURE|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
214446472|NCT06048614|DRUG|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
214446473|NCT06641154|DRUG|GT-UGT1A1-AAV8-02|Intravenous infusion, single dose
214446474|NCT06582706|DRUG|Placebo Comparator|a readily available inert placebo will be used
214446475|NCT06582706|DRUG|Extended Release Niacin|500 mg
215125294|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
214446476|NCT03821233|DRUG|ZW49|"* Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study"
214446477|NCT06240091|DEVICE|DISC-MA|DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
214523383|NCT05023941|DRUG|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
214446478|NCT02419014|DEVICE|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
214446479|NCT02419014|DEVICE|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
214446480|NCT06484985|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
214446481|NCT05113966|DRUG|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
214446482|NCT05113966|DRUG|Sacituzumab Govitecan-hziy|10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
214446483|NCT06786910|OTHER|Toothpaste with olive oil, trimethylglycine and xylitol|Composition comprising olive oil, trimethylglycine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
214446484|NCT06786910|OTHER|Toothpaste without olive oil, trimethylglycine nor xylitol|Composition without olive oil, without trimethylglycine and without xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
214446485|NCT06792240|DIETARY_SUPPLEMENT|iron supplementation|"The amount of supplementary iron was decided for patients according to the daily requirement (8- 18 mg / day), according to LARN 2012 and (RDAs) for Iron. (25) . This study took in consideration also, the recommendation of the National Institutes of Health iron dietary supplement fact of sheet as reference to calculate iron dose for our candidates because this dose isn't against LARN and more practical to applicate.~The minimum RDA values is applied, which coincides within the LARN daily requirement limits. (7 mg-18 mg of iron per day). Applying the minimum recommended RDA dose, that can satisfy the daily iron requirement by age, approximating it to be adequate for the clinical dose administered orally once a day (e.g. 1.98 g ==\> 2 g, 1.53 g ==\> 1.5 g"
214446486|NCT06792240|DIETARY_SUPPLEMENT|control group|Non intervension: Only restricted low and controlled Phe diet therapy
214446487|NCT06779201|OTHER|Fasting|One-week fasting without limit of water drink (Participants can feel free to drink water )
214446488|NCT06789744|DEVICE|General Anesthesia (GA)|"Patients will be induced with general anesthesia, consisting of propofol (1.5-2 mg/kg intravenously), rocuronium (1-2 mg/kg intravenously), and fentanyl (1-2 μg/kg intravenously). Anesthesia will be maintained with inhaled sevoflurane or desflurane, adjusted according to BIS values. Remifentanil (0.05-0.2 μg/kg/min) will be administered via continuous infusion, with the infusion rate adjusted to maintain blood pressure and heart rate within ±20% of baseline.~Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode using an Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA). Ventilator settings will be as follows: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and inspired oxygen concentration of 41%."
214446489|NCT06789744|PROCEDURE|Epidural Analgesia( 0.2% ropivacaine)|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine will be administered, followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hour. In pediatric patients, the initial bolus will consist of 0.2% ropivacaine at a dose of 0.5-1 mg/kg, not to exceed 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hour.
214446490|NCT06789744|DEVICE|Paravertebral block ( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For paravertebral blocks, patients will be positioned either sitting or in the lateral decubitus position to fully expose the target area of the spine. The spinous process of the target vertebra will be palpated, and the puncture site identified. Using ultrasound guidance, the paravertebral space will be located. After standard skin preparation, a blunt needle will be advanced perpendicular to the skin. Once the needle tip contacts the transverse process, it will be withdrawn 1-2 mm, and then slightly angled caudally to pass through the paravertebral ligament and enter the paravertebral space. After negative aspiration for blood or cerebrospinal fluid, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 5 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
214446491|NCT06789744|DEVICE|Transversus Abdominis Plane Block (TAP Block)( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For TAP blocks, patients will be positioned supine with the abdomen exposed. Following standard skin preparation, a needle will be advanced perpendicular to the skin using ultrasound guidance, through the external oblique and internal oblique muscles to reach the fascial plane between the transversus abdominis and internal oblique muscles. After negative aspiration for blood, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 10 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
214446492|NCT06789744|PROCEDURE|Intrathecal Morphine|For intrathecal analgesia, adults will receive 0.1-0.2 mg of morphine intrathecally. For pediatric patients, the dose of intrathecal morphine will be 5-10 mcg/kg.
214446493|NCT06789744|DRUG|Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)|For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
214523384|NCT05023941|DEVICE|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
215125295|NCT05154253|OTHER|Standard gait training|Standard gait training without a device.
215125296|NCT05154253|DEVICE|Ankle foot orthosis|Standard ankle foot orthosis
215125297|NCT05154253|OTHER|Standard physical therapy|Physical therapy without a device.
214446494|NCT06784440|GENETIC|Evaluation of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA)|From the blood samples taken, 2 mL of plasma separated from blood will be stored in EDTA frozen at -80°C. This material will later be processed by NGS run using of CareDX kits. The result will be provided by dedicated software as percentage of donor DNA in relation to recipient DNA.
214446495|NCT05386355|BEHAVIORAL|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
214446496|NCT05386355|OTHER|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
214446497|NCT06459583|OTHER|eHealth Platform|The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
214446498|NCT06459583|OTHER|Videoconference Telehealth Platform|Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
214446499|NCT06790576|OTHER|closed-loop-peak|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-peak (each pulse synchronized to person's peak of theta waveform)
214446500|NCT06790576|OTHER|Open-loop|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: open-loop (TMS pulse delivered without regard to EEG)
214446501|NCT06790576|OTHER|closed-loop-trough|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-trough (each pulse synchronized to trough of theta waveform)
214446502|NCT06143670|DRUG|Stannous fluoride toothpaste|0.454% w/w SnF2
214446503|NCT06143670|DRUG|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
214446504|NCT06229964|OTHER|SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
214446505|NCT06229964|OTHER|Sham SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
214446506|NCT06784362|OTHER|No intervention|This is an observational study
214446507|NCT06792591|DEVICE|PEM|Accuracy of PEM in detection of breast cancer
214446508|NCT03373097|BIOLOGICAL|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
214446509|NCT03875573|DRUG|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
214446510|NCT03875573|RADIATION|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
214446511|NCT03875573|DRUG|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
214446512|NCT06789120|OTHER|Instrument-assisted soft tissue mobilization|In the study, the Graston device will be applied to the plantar flexor muscles of the patients. The medial and lateral gastarosoleus muscles and tendon will be applied deeply for 3 minutes, and the soleus muscle will be applied deeply for 90 seconds.
215125298|NCT05154253|OTHER|Standard walking|Walking without a device
215125299|NCT06262724|PROCEDURE|Breast auto-augmentation|Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
215125300|NCT05669859|PROCEDURE|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
215125301|NCT04434079|OTHER|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
215125302|NCT02831764|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
215125303|NCT02831764|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
215125304|NCT02831764|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
214446513|NCT06786182|BEHAVIORAL|PFM Educational Program|A structured telematic educational program covering PFM anatomy, function, and proper activation techniques. Content includes videos, visual guides, and exercises aimed at promoting PFM co-contraction and awareness.
214446514|NCT06789627|OTHER|RPD with PEEK framework|Indirectly CAD/CAM produced PEEK framework
214446515|NCT06789627|OTHER|RPD with metallic framework|Indirectly CAD/CAM produced metallic RPD
214446516|NCT06784531|DIETARY_SUPPLEMENT|Mitoquinone mesylate (MitoQ)|Four 20 mg MitoQ capsules (80 mg total) are ingested orally.
214446517|NCT06784531|DIETARY_SUPPLEMENT|Placebo|Four placebo (microcrystalline cellulose) capsules are ingested orally.
214446518|NCT06784531|OTHER|Cold Water Hand Immersion|Volunteers place one hand in cold (54°F) water for 30 minutes.
214446519|NCT06784531|OTHER|Cold Air Exposure|Volunteers sit in cold (41°F) air for 90 minutes.
214446520|NCT06786065|OTHER|No intervention (observational study)|No intervention (observational study)
214446521|NCT06792526|OTHER|IVIM Imaging MRF Imaging|IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of Head and Neck Cancer undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage. MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
214446522|NCT06316154|PROCEDURE|Echinococcectomy|Echinococcectomy with subsequent pathomorphological analysis of liver parenchyma next to and in the thickness of the fibrous capsule
214446523|NCT06786819|OTHER|ERACS with Digital Platform|The assistance provided to patients in the intervention group will be sequential and prospective. The project will utilize an app based on protocols that prepare patients for rapid recovery (ERAS), starting before surgery and extending up to 30 days post-discharge. This includes pre-operative evaluations (dental, psychological, nutritional, and others), scheduling and confirming hospital admission, and following specific protocols during surgery and intensive care. The app aims to enhance communication and teamwork, improving patient-centered care. It will feature modules for patient and family education, team communication, and activity management through a dashboard. Additionally, it will facilitate interaction with patients through messages and surveys, monitor multidisciplinary team communication, and collect patient-reported outcomes 30 days after the surgical procedure.
215125305|NCT05360927|DRUG|BDB-001 injection|Intravenous injection
214446525|NCT06785233|DEVICE|Non-Adjustable Intragastric Balloon|Weight Loss with a 12-Month Non-Adjustable Intragastric Balloon is More Effective Compared to a 6-Month Balloon.
214446526|NCT06785233|DEVICE|ORBERA365|endoscopic treatment of overweight and mild obesity using a 12-month non-adjustable intragastric balloon
214446527|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
214446528|NCT03747484|DRUG|Avelumab|Given IV
214446529|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
214446530|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
214446531|NCT06332911|DEVICE|Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+|Cracking-not-debulking technique (SHOCKWAVE IVL)
214446532|NCT06776458|OTHER|N/A - Usual Care|Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
214446533|NCT03833245|BEHAVIORAL|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
214446534|NCT06318754|DEVICE|Inari Triever Aspiration Catheter|Inari Triever Aspiration Catheter for portomesenteric venous thrombosis
214446535|NCT03944434|DRUG|Ribociclib|ribociclib 600 mg/day orally
214446536|NCT03944434|DRUG|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
214446537|NCT03944434|DRUG|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
214446538|NCT06751914|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
215125306|NCT05360927|DRUG|Placebo|Intravenous injection
215125307|NCT04564846|DRUG|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
214446539|NCT06751914|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214446540|NCT03775109|DRUG|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
214446541|NCT03775109|DRUG|Placebo|100ml 5% Dextrose
214446542|NCT03347383|DEVICE|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
214446543|NCT03743623|DEVICE|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
214446544|NCT03743623|DEVICE|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
214446545|NCT03029026|OTHER|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
214446546|NCT03029026|PROCEDURE|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
214446547|NCT03029026|PROCEDURE|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
214446548|NCT03029026|RADIATION|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
214446549|NCT03029026|PROCEDURE|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
214446550|NCT03029026|PROCEDURE|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
214446551|NCT03029026|OTHER|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
214446552|NCT06528444|DRUG|Grup 1 placebo|placebo 1 capsule (6 mg) /day for 7 days.
214446553|NCT06528444|DRUG|Grup 2 dexametasona|dexamethasone 1 capsule (6 mg)/day for 7 days
214446554|NCT04030169|DRUG|Midomafetamine HCl|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
214446555|NCT06093295|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
214446556|NCT06534086|DEVICE|Virtual reality (VR) guided meditation therapy|Tripp application on Meta Quest 3 VR headset
214446557|NCT06534086|OTHER|Treatment as usual|No VR, local anesthetic only
214446558|NCT03226808|DEVICE|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
214523385|NCT05023941|DEVICE|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
214523386|NCT04157959|DRUG|SHR4640 dose1|Tablet,dose1,QD
214523387|NCT04157959|DRUG|Febuxostat dose2|Tablet,dose2,QD
214523388|NCT00001077|DIETARY_SUPPLEMENT|Multivitamin and mineral supplements|Oral tablets taken daily
214523389|NCT00001077|DIETARY_SUPPLEMENT|Peptamen|Solution received daily
214523390|NCT00001077|DIETARY_SUPPLEMENT|NuBasics|Solution or dietary bar received daily
214523391|NCT06027697|DEVICE|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
215125308|NCT04564846|OTHER|Placebo|Placebo capsule (Fish Oil)
215125309|NCT06136780|OTHER|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
214523392|NCT00067119|DRUG|Aggrenox|
214523393|NCT00067119|DRUG|Placebo|
214523394|NCT01189370|DRUG|sorafenib|"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."
214523395|NCT03785210|DRUG|nivolumab|480 mg intravenous (IV) every 4 weeks
214523396|NCT03785210|DRUG|tadalafil|10 mg by mouth (PO) daily
215125310|NCT00831961|PROCEDURE|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
215125311|NCT00884364|OTHER|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
214446559|NCT00830557|OTHER|medical chart review|baseline, 12 month and 36 months
214446560|NCT00830557|OTHER|survey administration|baseline, 6 month, 12 month
214446561|NCT00830557|OTHER|biospecimen collection|baseline
214446562|NCT04206826|DEVICE|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
214446563|NCT04206826|DEVICE|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
214446564|NCT04876196|OTHER|Selfapy for Bulimia Nervosa|Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
214446565|NCT06798272|PROCEDURE|dialysisis with and without glucose in the dialysis|there were assessed three consecutive hemodialysis sessions
214446566|NCT05703516|OTHER|Capmatinib|There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
214446567|NCT05090124|DRUG|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
214446568|NCT05090124|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
214446569|NCT05738746|DIETARY_SUPPLEMENT|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
214446570|NCT05738746|DIETARY_SUPPLEMENT|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
214446571|NCT05691452|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
214446572|NCT06546371|DEVICE|Spinal cord stimulator|Electrical stimulation of the dorsal horn to reduce chronic pain.
214446573|NCT06158126|DRUG|Initiating daily oral PrEP during pregnancy|Group 1a will include pregnant women who initiate oral PrEP when already pregnant, at enrollment into the study.
214446574|NCT06158126|DRUG|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
214446575|NCT06158126|DRUG|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) when already pregnant, at enrollment into the study.
215125312|NCT00884364|BEHAVIORAL|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
215125313|NCT04978896|DEVICE|Self-guided program on stress coping|This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.
215125314|NCT04978896|DEVICE|Self-guided program on cooperation|The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
215125315|NCT00675181|DRUG|Melatonin|5mg per os
215125316|NCT00675181|DRUG|Placebo|per os
215125317|NCT01476059|OTHER|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
215125318|NCT01476059|OTHER|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
215125319|NCT02735239|DRUG|Durvalumab|Anti PD-L1 antibody
215125320|NCT02735239|DRUG|Tremelimumab|Anti CTLA-4 antibody
215125321|NCT02735239|DRUG|Oxaliplatin|IV administered chemotherapy
215125322|NCT02735239|DRUG|Capecitabine|orally-administered chemotherapy
215125323|NCT02735239|RADIATION|Radiotherapy|
215125324|NCT02735239|DRUG|Paclitaxel|IV administered chemotherapy
215125325|NCT02735239|DRUG|Carboplatin|IV administered Chemotherapy
215125326|NCT02735239|DRUG|5-fluorouracil (5-FU)|IV administered chemotherapy
215125327|NCT02735239|DRUG|Leucovorin|chemo-protective agent
215125328|NCT02735239|DRUG|Docetaxel|IV administered chemotherapy
215125329|NCT02041325|DRUG|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
214446576|NCT06158126|DRUG|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis and enrollment into the study.
214446577|NCT06314087|OTHER|Placebo + conventional treatment including radiotherapy|Placebo + conventional treatment including radiotherapy
214446578|NCT06314087|COMBINATION_PRODUCT|Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine|The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
214446579|NCT03169777|BIOLOGICAL|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
214446580|NCT03169777|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
214446581|NCT03169777|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214446582|NCT03169777|BIOLOGICAL|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
214446583|NCT03169777|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214446584|NCT03169777|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214446585|NCT03169777|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
214446586|NCT03169777|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214446587|NCT03169777|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214446588|NCT03169777|BIOLOGICAL|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
214446589|NCT03169777|DRUG|Lovaza|Omega-3-acid ethyl esters
215125330|NCT02041325|DRUG|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
215125331|NCT00318084|DRUG|Esomeprazole|
215125332|NCT00318084|PROCEDURE|Ambulatory 24-hour esophageal pH-monitoring|
214446590|NCT03169777|DRUG|oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214446591|NCT03169777|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
214446592|NCT03169777|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
214446593|NCT03169777|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
214446594|NCT03169777|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
214446595|NCT03169777|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214446596|NCT03169777|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
214446597|NCT03169777|BIOLOGICAL|GI-4000|RAS yeast vaccine
214446598|NCT03169777|BIOLOGICAL|GI-6207|CEA yeast vaccine
214446599|NCT03169777|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214446600|NCT03169777|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
214446601|NCT04582760|OTHER|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
214446602|NCT05128838|OTHER|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
214446603|NCT03564600|OTHER|Aging Back Clinics management|Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
214446604|NCT05839717|PROCEDURE|Blood sampling|A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
215125333|NCT06523335|OTHER|Neuromuscular coordination-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
215125334|NCT06523335|OTHER|Force strengthening-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
215125335|NCT01179724|DRUG|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
215125336|NCT01179724|DRUG|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
215125337|NCT02038153|OTHER|Laboratory Biomarker Analysis|Correlative studies
215125338|NCT02038153|DRUG|Lenalidomide|Given PO
215125339|NCT02155634|DRUG|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
215125340|NCT05228665|BEHAVIORAL|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
215125341|NCT02018341|OTHER|homeopathic remedy in 30C potency|
214446605|NCT06241209|OTHER|PowerPoint program visual stimulation|Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
214446606|NCT06839313|DRUG|Kenacort A Orabase® pomad , Bristol-Myers Squibb İlaçları Inc. İstanbul , Türkiye|Apply to the injured area 4 times a day
214446607|NCT06839313|COMBINATION_PRODUCT|Hyaluronic acid, Aftamed ® Oral jel , AktiFarma . İstanbul, Türkiye|Apply to the injured area 4 times a day
214446608|NCT06839313|COMBINATION_PRODUCT|St. John's wort oil, Zade Vital; Health&Fitness, Developed With Ege Üniversiesi Argefar|Apply to the injured area 4 times a day
214446609|NCT05457998|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
214446610|NCT05457998|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
214446611|NCT05457998|DIAGNOSTIC_TEST|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
214446612|NCT06472219|DRUG|Prednisolone 30 mg|This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
214446613|NCT06472219|DRUG|Placebo|This a tablet identical to prednisolone.
214446614|NCT06833671|OTHER|Apple juice|A preoperative carbohydrate load was done two hours before the operation using a10 ml/kg, with a maximal volume of 250 ml of commercial brand of apple juice (glucose 28 g in 250 ml).
214446615|NCT06833671|DRUG|Anhydrous glucose|A preoperative carbohydrate load was done using 1.75mg/kg/dose of anhydrous glucose (Alpha Chmika).
214446616|NCT06833671|OTHER|Water|Patients received water.
214446617|NCT06792630|BEHAVIORAL|laughter therapy intervention|"In addition, patients in the intervention group were given laughter therapy intervention from the 1st day of HSCT, with the mnemonic hihihi (pinyin spelling), hahahaha, eggplant eggplant eggplant, qixi qixi qixi qixi, hahahahahahahahaha, 30 times of the mnemonic as a training session, once a day, from the beginning of the transplantation transfusion +1d to the end of the transplantation transfusion +1d, and then to the end of the transplantation. Patients were discharged from the warehouse, and after discharge, patients were centralized on-line laughter therapy intervention, 1 time/week, repeating 30 times of mnemonics, until 1 year after transplantation."
214446618|NCT05822193|OTHER|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
214446619|NCT06833866|DRUG|Hydroxytyrosol|"Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression.~The prescribed FOLFIRI/FOLFOX administer as: Irinotecan 180 mg/m² intravenously (IV) over 90 minutes concurrently with Leucovorin 400 mg/m² IV over 120 minutes, followed by Fluorouracil 400-500 mg/m² IV bolus then 2400-3000 mg/m² IV infusion over 4-6 hours with or without, the designated Biologics, a standard dose of Cetuximab or Bevacizumab will be administered in 2-week cycles until disease progression or un-tolerated toxicity"
214446620|NCT06519669|BIOLOGICAL|GT201 injection|GT201 injection to treat Advanced lung cancer
214446621|NCT06407856|OTHER|conventional therapy|The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks
214446622|NCT06407856|OTHER|Dual Task Training|Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
214446623|NCT06828874|DRUG|Levornidazole Disodium Phosphate for Injection|1g，once daily, intravenously guttae for 4 to 7 days
214523397|NCT03785210|DRUG|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
214523398|NCT01599377|DRUG|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
214523399|NCT01599377|DRUG|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
215125342|NCT02018341|OTHER|Placebo|
215125343|NCT00942565|DRUG|tramadol/acetaminophen|
215125344|NCT00942565|DRUG|acetaminophen|
215125345|NCT04098523|DIAGNOSTIC_TEST|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
215125346|NCT01772966|PROCEDURE|Spinal manipulation|
215125347|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-01|1 capsule after breakfast once a day
215125348|NCT05952232|DIETARY_SUPPLEMENT|MK-GH-04|1 capsule after breakfast once a day
215125349|NCT05952232|DIETARY_SUPPLEMENT|TSH-GH-03|1 capsule after breakfast once a day
215125350|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-02|1 capsule after breakfast once a day
215125351|NCT03985241|DIAGNOSTIC_TEST|Functional Assessment of Myocardial Ischemia by icECG|
215125352|NCT02472860|BEHAVIORAL|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
215125353|NCT02472860|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition
215125354|NCT01288755|DRUG|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
215125355|NCT01288755|DRUG|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
215125356|NCT01757314|BEHAVIORAL|ultrasound technique|instruction in the ultrasound technique
215125357|NCT01757314|OTHER|palpation technique|placement of a line via palpation technique
215125358|NCT04497649|DRUG|Sofosbuvir|Sofosbuvir once daily
215125359|NCT04497649|DRUG|Daclatasvir|daclatasuvir once daily
215125360|NCT02313259|OTHER|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
214446624|NCT06828874|DRUG|Ornidazole and Sodium Chloride Injection|0.5g at a time , 2 times per day, intravenously guttae for 4 to 7 days
214446625|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
214446626|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
215125361|NCT02313259|BEHAVIORAL|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
215125362|NCT04354792|DIAGNOSTIC_TEST|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
214446627|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Dasatanib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
214446628|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
214446629|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
214523400|NCT02615834|PROCEDURE|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
214523401|NCT03952728|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
215125363|NCT04057066|BEHAVIORAL|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
214446630|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
214446631|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
214446632|NCT06347536|COMBINATION_PRODUCT|Supported rescue pack|1\) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
214446633|NCT06837376|OTHER|Education|One 45 minute educational session on the role of carbohydrate in exercise
214523402|NCT03952728|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
214523403|NCT01021202|PROCEDURE|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
214523404|NCT02946450|DRUG|Other: Not applicable-observational study|
214523405|NCT05598138|BIOLOGICAL|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
214523406|NCT04042259|DEVICE|Abthera|Negative Pressure Wound Therapy Device
214523407|NCT04042259|PROCEDURE|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
214446634|NCT06837376|OTHER|Metabolic Testing (Exercise) with shared interpreted results|One 20-30 minute session. Treadmill, warm-up, then at increasing intensities for 3-minute intervals wearing a mouthpiece for measurement of respiratory gasses (oxygen consumption, carbon dioxide production). Testing starts with a 3-minute warm-up at 3.4 mph, 1% grade, increasing every 3 minutes until a respiratory exchange ratio of 1.0 is reached or volitional exhaustion
214446635|NCT06791941|BIOLOGICAL|Culture of organoids|Culture of organoids prepared from both the primary tumor and the respective relapse, using the material from the prospective part of the study, the response to treatment will be carried out by macroscopic analysis, evaluating the size and number of organoids before and after treatment,
215125364|NCT04057066|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
215125365|NCT04956536|OTHER|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
215125366|NCT01573546|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression \> 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
215125367|NCT01573546|BEHAVIORAL|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
215125368|NCT01573546|OTHER|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
215125369|NCT04796597|DEVICE|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
215125370|NCT03016312|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
215125371|NCT03016312|DRUG|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
215125372|NCT03088891|OTHER|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
215125373|NCT03088891|OTHER|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
215125374|NCT01050634|DRUG|Aromasin (exemestane)|25mg oral tablet, daily, for \>1yr
215125375|NCT05947188|OTHER|prostate cancer diagnosis|prostate cancer diagnosis
214446636|NCT06518681|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
214446637|NCT06289491|PROCEDURE|Hydrus Microstent|Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
214446638|NCT06289491|PROCEDURE|Incisional goniotomy|Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
214523408|NCT05354726|OTHER|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
214523409|NCT00574626|PROCEDURE|PBSCT|Peripheral Blood Stem Cell Transplant
215125376|NCT00900510|PROCEDURE|Incision and drainage|
215125377|NCT00900510|DRUG|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
215125378|NCT00900510|DRUG|Placebo|
215125379|NCT01840007|DRUG|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
215125380|NCT01089686|PROCEDURE|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
214446639|NCT06289491|PROCEDURE|Excisional goniotomy|Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
214446640|NCT05670366|DEVICE|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
214446641|NCT05670366|DEVICE|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
214446642|NCT06795828|BEHAVIORAL|Emotional support group|Women who met the inclusion criteria and volunteered to participate in the study and were provided emotional support were administered the Personal Information Form, Visual Analog Scale, State Anxiety Inventory and Surgical Fear Scale via face-to-face interview method on the first day of their hospitalization before the caesarean section (pre-test). This application lasted 15-20 minutes. Enter a brief, descriptive title for this arm of the study.
215125381|NCT01089686|PROCEDURE|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
215125382|NCT02356445|OTHER|Cytotoxic drug|Observe patients versus treatment type
215125383|NCT05982990|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
215125384|NCT05982990|DRUG|ADVAIR DISKUS® 250/50|2 inhalations in one study period
215125385|NCT01239069|DRUG|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
215125386|NCT01239069|DRUG|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
215125387|NCT01239069|OTHER|Placebo|DE-110 ophthalmic suspension vehicle;QID
215125388|NCT05884086|OTHER||no intervention is necessary. Clinical observation and clinical examination only.
214446646|NCT06839703|DRUG|Dinutuximab beta|Dinutuximab beta is added in different dosages to the standard chemotherapy
215125389|NCT03880292|PROCEDURE|Document intraoperative Maneuvers|Monitoring procedure during surgery
215125390|NCT00496015|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
214446647|NCT06839443|DIAGNOSTIC_TEST|Retinopathy group|OCT scans and Retinai algorithm will be performed
214446648|NCT06839443|DIAGNOSTIC_TEST|Control group|OCT scans and Retinai algorithm will be performed
215125391|NCT00496015|BIOLOGICAL|Infanrix hexa.|1 intramuscular injection.
215125392|NCT00496015|BIOLOGICAL|Meningococcal vaccine GSK134612.|1 intramuscular injection.
215125393|NCT00496015|DRUG|Paracetamol.|Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
215125394|NCT02632292|DEVICE|Absorb GT1|Bioresorbable vascular scaffold
215125395|NCT02632292|DEVICE|Promus|Everolimus-eluting stent
214446649|NCT06203340|OTHER|Core stabilizasyon and lumbal back school|Lumbal back schooL
214446650|NCT05414136|DRUG|BAT1006|Intravenous fluids
215125396|NCT00675402|OTHER|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
215125397|NCT03004729|OTHER|CoMiSS questionnaire|
215125398|NCT00190437|DRUG|Amoxicillin-clavulanic|Amoxicillin-clavulanic
215125399|NCT04792736|DIAGNOSTIC_TEST|Blood lactate level|Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
215125400|NCT00043719|DRUG|Nitroglycerin ointment|
215125401|NCT00043719|DRUG|Calcium supplement with vitamin D|
215125402|NCT00527735|DRUG|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
215125403|NCT00527735|DRUG|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
215125404|NCT00527735|DRUG|Paclitaxel|175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
215125405|NCT00527735|DRUG|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
215125406|NCT01911611|DRUG|RO6870868|Single ascending doses
215125407|NCT01911611|DRUG|placebo|Single ascending doses
215125408|NCT02916966|OTHER|Patient Registry|Patient Registry
215125409|NCT00472225|DRUG|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
215125410|NCT04759235|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Anatomical (T2W) and functional MRI (DWI) at a 3.0T Siemens or Philips scanner Three MRI scan series (before, during, after nCRT) Measurements: change in apparent diffusion coefficient (ADC)
215125411|NCT04759235|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT)|PET-CT scan at diagnosis and 4-6 weeks after nCRT before operation Measurements: change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value)，MTV（Metabolic tumor volume）
215125412|NCT04759235|DIAGNOSTIC_TEST|Blood and urine metabolic biomarker|Blood and urine specimens are collected before radiotherapy, the third week of radiotherapy, and at the end of radiotherapy.
215125413|NCT04851626|OTHER|Hypnotic intervention for persistent pelvic pain.|Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
215125414|NCT04851626|OTHER|Control group persistent pelvic pain no intervention.|Control group no hypnotic intervention. Waitlist control.
215125415|NCT01535807|DEVICE|CorMatrix extra cellular matrix (ECM)|"* Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
215125416|NCT01590979|DRUG|Ranolazine|1000mg, two times a day, 12 hour intervals
215125417|NCT01590979|DRUG|Placebo|two times a day, 12 hour intervals
215125418|NCT04319952|DEVICE|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
215125419|NCT00138749|DRUG|SS-RBX|
215125420|NCT05198817|DRUG|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
215125421|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
215125422|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
214446651|NCT06636058|BEHAVIORAL|vCare Intervention (6-month active treatment followed by 6-month maintenance)|"During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks."
214523410|NCT00574626|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant
215125423|NCT02533414|DEVICE|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
215125424|NCT02533414|DEVICE|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
215125425|NCT02730728|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
215125426|NCT02730728|DRUG|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
215125427|NCT02730728|DRUG|5ml bolus of 0.5% ropivicaine|Local anesthetic
215125428|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
215125429|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
215125430|NCT03614117|DIETARY_SUPPLEMENT|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
215125431|NCT03354117|DRUG|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
215125432|NCT01153165|DRUG|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
215125433|NCT01153165|DRUG|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
215125434|NCT04531761|BEHAVIORAL|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
215125435|NCT03148535|DRUG|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
215125436|NCT03148535|DRUG|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
215125437|NCT01548274|DRUG|Sarpogrelate|Sarpogrelate 300mg/day
215125438|NCT01855412|OTHER|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
215125439|NCT01293825|DRUG|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
215125440|NCT05004831|DRUG|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
215125441|NCT06340022|OTHER|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.
215125442|NCT06340022|OTHER|Face Image Scale (FIS) scoring system|Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.
215125443|NCT06340022|OTHER|Visual Analogue Scale (VAS)|In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.
215125444|NCT06340022|OTHER|pulse rate|Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
214446652|NCT06636058|BEHAVIORAL|vCare Intervention (active treatment after 6 months)|During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
214446653|NCT06836466|OTHER|Google Form-based questionnaire|All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire includes introductory personal, academic, and work experience data about the physicians as gender, age, current specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience.
214446654|NCT04847544|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
214446655|NCT04847544|DRUG|Placebo|Placebo administered orally BID for up to 28 days.
214446656|NCT06797479|PROCEDURE|Blood samples for the analysis of sildenafil in plasma|To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
214446657|NCT06830694|DRUG|Atezolizumab, Etoposide, Carboplatin, Tarlatamab|Cycle 1\~4 : Atezolizumab 1200 mg IV, carboplatin AUC 5.0 IV, Etoposide 100 mg/m2 IV Cycle 5\~ : Atezolizumab 1200 mg IV, Tarlatamab 1 or 10mg IV
214446658|NCT02404896|DRUG|Metreleptin|Metreleptin open-label treatment
214446659|NCT06827158|OTHER|validity and reliability of the Turkish version of the Dexterity Questionnaire 24 (DextQ-24|"Permission for the Turkish translation and validation of the DextQ-24 questionnaire was obtained from its developer, Tim Vanbellingen. The original English version will be translated into Turkish by two independent translators and then back into English by two native English speakers. After review, the finalized version will be used in the study.~Patients diagnosed with Parkinson's disease (aged 40-80) will complete consent and demographic forms. The Mini-Mental State Examination (MMSE) will exclude those scoring ≤24. Disease staging will follow the Hoehn and Yahr Scale (stages I-IV included). The MDS-UPDRS (sections II and III) will assess disease severity, while the Nine-Hole Peg Test and Hand Dexterity Scale-36 will evaluate hand function. Participants will complete the Turkish DextQ-24, with 30 randomly selected patients retaking it after two weeks for reliability testing. Data collection per participant will take approximately 30 minutes."
214446660|NCT05577858|OTHER|Meat based|Omnivorous diet following dietary guidelines
214446661|NCT05577858|OTHER|Pulse based|Lacto-ovo-vegetarian pulse-based diet following dietary guidelines
214446662|NCT06537739|OTHER|Lumbar manipulation|Participant lies in the supine position, a physiotherapist faces the participant's side that will be manipulated. The participant interlocks their fingers behind their neck. Then the physiotherapist turns the participant on their side and performs a short thrust across the participant's pelvis in a posterior and inferior direction. The manipulation will be carried out on the symptomatic side, based on the participant's indication of the painful side. If the participant is unable to indicate the more symptomatic side, the physiotherapist performing the procedure will select the side. If no audible cavitation occurs during the manipulation, the physiotherapist will attempt to manipulate the opposite side. A maximum of 2 attempts per side will be allowed.
214446663|NCT06537739|OTHER|Positive communication - placebo|"Participants from Group A who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is a very effective method of treating spinal disorders, which will significantly reduce the low back pain you are experiencing (positive communication - placebo)."
214523411|NCT04636021|DIAGNOSTIC_TEST|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
214523412|NCT06306677|DIAGNOSTIC_TEST|AI-clincial-based hybrid system for radiographic image analysis|The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
214523413|NCT00210964|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
215125445|NCT00665665|DRUG|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
214523414|NCT00210964|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
214523415|NCT05303415|OTHER|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
215125446|NCT00665665|DRUG|placebo|Placebo for s.c. injection
215125447|NCT00665665|DRUG|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
215125448|NCT00665665|DRUG|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
214446664|NCT06537739|OTHER|Negative communication - nocebo|"Participants form Group B who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is not an effective method of treating spinal disorders, thus it may temporarily increase the low back pain you are experiencing (negative communication - nocebo)."
214446665|NCT06537739|OTHER|Neutral communication|"Participants from Group C who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation has not been verified for its effectiveness in affecting your level of low back pain (neutral communication)."
214446666|NCT06821503|DRUG|LM-108 injection|LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.
214523416|NCT02879539|DEVICE|MP3000 sound coding strategy or ACE strategy with lower stimulation|
215125449|NCT00665665|DRUG|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
215125450|NCT02932137|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
215125451|NCT03068871|OTHER|ACT|Psycho-educational group
215125452|NCT03068871|OTHER|CET|Psycho-educational group
214523417|NCT06539325|DIAGNOSTIC_TEST|Diagnosis algorithm according to the delay between travel and consultation|Tests : RT-PCR for the most common arboviruses (Dengue, Zika, Chikungunya, and West Nile virus) and serology for dengue infection (NS1 antigen, and IgM and IgG), serologies for chronic viral infections (HIV, HBV and HCV) and schistosomiasis, Blood cultures and Innovativ Diagnostics : panel Dragonfly and two metagenomic analyses
215125453|NCT02122679|DRUG|Tranexamic Acid|
215125454|NCT02122679|DRUG|placebo|
215125455|NCT00911248|DRUG|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
215125456|NCT01292941|DEVICE|Intermittent catheterisation|Speedicath, Intermittent catheterisation
215125457|NCT01292941|DEVICE|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
215125458|NCT01292941|DEVICE|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
215125459|NCT01292941|DEVICE|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
215125460|NCT05261555|DEVICE|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
215125461|NCT02723812|BIOLOGICAL|GCFLU® Influenza vaccine (Split virion, Inactivated)|
215125462|NCT02785185|DRUG|IDP-122 Vehicle Lotion|Vehicle
214446667|NCT06821503|DRUG|Penpulimab injection|Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.
214446668|NCT06821503|DRUG|Paclitaxel for injection (albumin bound)|Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug
215125463|NCT02785185|DRUG|IDP-122 Vehicle Cream|Vehicle
215125464|NCT02785185|DRUG|IDP-122 Lotion|Lotion
215125465|NCT02785185|DRUG|Ultravate Cream|Cream
215125466|NCT02028377|PROCEDURE|PET/MRI|PET/MRI
215125467|NCT00420485|DRUG|gimatecan|
215125468|NCT02539771|OTHER|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
215125469|NCT03041948|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
215125470|NCT03041948|PROCEDURE|Caudal-epidural nerve block|See arm description
214446669|NCT06821503|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.
214446670|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
214446671|NCT04517903|OTHER|eye rubbing questionnaire|eye rubbing questionnaire at baseline and 15 days later for exploratory phase; at baseline and then validation by a Group Nominal
214446672|NCT04716634|DRUG|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
214446673|NCT04716634|DRUG|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
214446674|NCT05134779|PROCEDURE|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
214446675|NCT03729180|PROCEDURE|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
214446676|NCT03729180|DIAGNOSTIC_TEST|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
214446677|NCT03729180|OTHER|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
214446678|NCT06793059|DEVICE|SHIELD|Pipeline SHIELD device under study
214446679|NCT03096054|DRUG|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
214446680|NCT06787677|PROCEDURE|PRF|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the PRF group received PRF treatment in automatic mode for 360 s, at a maximum of 42°C, pulse frequency of 2 Hz, and pulse width of 20 ms.
214446681|NCT06787677|PROCEDURE|NB|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the NB group received nerve block with a mixture of 40 mg of triamcinolone and 2 ml of 0.75% bupivacaine with 2 ml of normal saline and 1:100000 epinephrine.
214523418|NCT05135741|DEVICE|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
214523419|NCT04879823|DRUG|Dexamethasone|IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
215125471|NCT03041948|DRUG|Acetaminophen|See arm description
215125472|NCT03041948|DRUG|Sevoflurane|See arm description
215125473|NCT03041948|DRUG|Remifentanil|See arm description
215125474|NCT03041948|DRUG|Propofol|See arm description
215125475|NCT03041948|DRUG|Morphine|See arm description
215125476|NCT03041948|DRUG|Ondansetron|See arm description
215125477|NCT03041948|DRUG|Dexamethasone|See arm description
215125478|NCT03041948|DRUG|Ketorolac|See arm description
215125479|NCT02495701|PROCEDURE|Hip arthroscopic surgery|Hip arthroscopic surgery
215125480|NCT04535635|OTHER|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
215125481|NCT04535635|OTHER|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
215125482|NCT04004897|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
215125483|NCT00072007|BIOLOGICAL|filgrastim|filgrastim
215125484|NCT00072007|BIOLOGICAL|rituximab|rituximab
215125485|NCT00072007|DRUG|CHOP regimen|CHOP regimen
215125486|NCT00072007|DRUG|cladribine|cladribine
215125487|NCT00072007|DRUG|cyclophosphamide|cyclophosphamide
215125488|NCT00072007|DRUG|doxorubicin hydrochloride|doxorubicin hydrochloride
215125489|NCT00072007|DRUG|prednisone|prednisone
215125490|NCT00072007|DRUG|vincristine sulfate|vincristine sulfate
215125491|NCT04998071|DRUG|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
215125492|NCT04569877|DRUG|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
215125493|NCT04569877|OTHER|Placebo nebuliser solution|Placebo nebulised seven times within 7 days via rapid nebuliser system
215125494|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
214446682|NCT06789952|BEHAVIORAL|Mindfulness-Based Stress Reduction|"MBSR is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. It is a practice that is embedded in mind/body and integrative medicine, it combines formal and informal practices of mindfulness.~The formal practices include body scanning, gentle hatha yoga - movements, sitting meditation and walking, meditation. Informal practices include mindfulness of daily activities, such as eating, driving, washing dishes, showering, etc. A variety of other exercises will be used as a support for developing proficiency in the practice of mindfulness. This class places strong emphasis on experiential learning. Each session will include:~* guided instruction while engaging in practices of mindfulness~* opportunity to reflect on experiences and ask questions~* discussion of topics related to the practice of mindfulness as a strategy for reducing stress"
214446683|NCT06789952|BEHAVIORAL|Lifestyle Intervention|"The lifestyle sessions will include the following topics:~Movement -passive stretches and dynamic stretches, cardio HIIT exercise, flexibility and strength, and core and balance.~Nutrition Body - Include healthy eating with whole, clean, and nutritionally balanced meals; menu planning/prepping, snacking and noticing cravings and feelings of fullness or satiety.~Sleep - Include routine for evening, and morning for optimal sleep, logging routines and quality of sleep, tools to aid in falling asleep, and returning to sleep during the night, eating and sleep patterns Nature/Culture/Arts (with Kemper Museum of Contemporary Art - which will also take place during ½ day retreat) includes spending time in nature and journal experiences, reconnecting with the sun, and surround self with nature.~Financial - Focus on financial wellbeing, budgets/adjustments to budgets, and buying/spending patterns.~Cooking - Include healthy foods, smoothies, juices, kitchen appliances."
214446684|NCT06795971|DEVICE|Continuous Positive Airway Pressure|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was delivered to the patient through a face mask connected to an ICU ventilator.~2. PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. PEEP and FiO2 were titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. CPAP was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
214446685|NCT06795971|DEVICE|High-flow nasal oxygen|"1. Oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 50 liters per minute and an FiO2 of 0.5 at initiation. HFNO heating temperature was prespecified at 37°C.~2. FiO2 will be titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. HFNO was applied for at least 2 calendar days."
214446686|NCT06795971|DEVICE|Non-invasive ventilation|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was also delivered to the patient through a face mask connected to an ICU ventilator. The mask most appropriate for the patient will be selected and adjusted to minimize leakage and pressure points.~2. The inspiratory positive airway pressure (pressure support plus PEEP) was initiated between 12 and 14 cm H2O, PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. FiO2 was titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. NIV was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
215125495|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
215125496|NCT00934635|OTHER|PET Scan|PET Scan
215125497|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
215125498|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
215125499|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
215125500|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
215125501|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
215125502|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
215125503|NCT03104296|DIAGNOSTIC_TEST|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
214523420|NCT04879823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
215125504|NCT00793195|DRUG|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
215125505|NCT00793195|DRUG|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
215125506|NCT02463916|OTHER|Exercise|8 week structured exercise programme
215125507|NCT00952302|DRUG|Iron sucrose|Single intravenous infusion of iron 200 mg
215125508|NCT00952302|DRUG|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
215125509|NCT00952302|PROCEDURE|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
215125510|NCT00952302|DRUG|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
215125511|NCT00952302|DRUG|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
215125512|NCT03624673|PROCEDURE|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
215125513|NCT03624673|PROCEDURE|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
215125514|NCT06143358|DRUG|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
215125515|NCT06143358|OTHER|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
215125516|NCT01755364|BIOLOGICAL|AdimFlu-V|
215125517|NCT05332600|OTHER|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
215125518|NCT02126722|PROCEDURE|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
215125519|NCT02126722|DEVICE|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
215125520|NCT02126722|OTHER|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
215125521|NCT02126722|OTHER|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
215125522|NCT04243694|BEHAVIORAL|Mindfulness training|Participants of the intervention group will receive 6-weeks of mindfulness training.
215125523|NCT04662567|DRUG|acetaminophen|compare the postoperative pain 1 hour and \~24h post surgery
215125524|NCT01668459|DRUG|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
215125525|NCT01668459|OTHER|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
215125526|NCT00170508|BIOLOGICAL|Fluzone®|
215125527|NCT01702974|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
215125528|NCT01702974|DRUG|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
214446687|NCT05265000|DEVICE|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
214446688|NCT02839291|OTHER|quality of life questionaries|
214446689|NCT02839291|DRUG|intravenous or oral bone antiresorptive treatments|
214446690|NCT02959229|DRUG|Lactoferrin|
214446691|NCT02959229|DRUG|Placebo (for Lactoferrin)|placebo in form of distilled water
214446692|NCT02793687|DRUG|Mexidol|50 mg/ml IV solution, 125 mg tablet
214446693|NCT02793687|OTHER|Placebo|Placebo IV solution, Placebo tablet
214446694|NCT03467542|DEVICE|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
214446695|NCT06451354|OTHER|Erector spinae plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
214446696|NCT06451354|OTHER|Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
214446697|NCT06451354|OTHER|Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
215125529|NCT04300985|DRUG|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
214446698|NCT05550324|PROCEDURE|Blood draw|One time intravenous blood draw
214446699|NCT03022656|DEVICE|Active Brace system|
214446700|NCT06429618|DIETARY_SUPPLEMENT|Low carbonhydrate diet|Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
214446701|NCT04077762|PROCEDURE|Radial Access|Radial Access
214446702|NCT04077762|PROCEDURE|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
214446703|NCT04077762|PROCEDURE|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
214446704|NCT05739825|OTHER|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
215125530|NCT04300985|DRUG|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
215125531|NCT04300985|DRUG|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
215125532|NCT04895449|BIOLOGICAL|MVA-SARS-2-ST|i.m. vaccine administration
215125533|NCT03446755|DEVICE|intra uterine Cook balloon|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
215125534|NCT03752138|DRUG|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
215125535|NCT03752138|DRUG|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
215125536|NCT03752138|DRUG|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
215125537|NCT03752138|DRUG|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
215125538|NCT03752138|DRUG|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
215125539|NCT03752138|DRUG|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
215125540|NCT03752138|DRUG|Part 2: TK216|Recommended dose from Part 1.
215125541|NCT00917930|BEHAVIORAL|physical training|intensive cardiac rehabilitation program
215125542|NCT01702844|DRUG|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
215125543|NCT05979948|DRUG|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
214446705|NCT05421390|OTHER|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
214446706|NCT05421390|OTHER|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
214446707|NCT04271358|BEHAVIORAL|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
214446708|NCT04905446|OTHER|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
215125544|NCT05979948|DRUG|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
215125545|NCT05979948|DRUG|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
215125546|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
215125547|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
214446709|NCT04905446|PROCEDURE|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
215125548|NCT01062750|BIOLOGICAL|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
215125549|NCT00721006|BIOLOGICAL|MESENDO|40 subcutaneous injections of biological product
215125550|NCT00721006|BIOLOGICAL|Placebo|40 subcutaneous injections of placebo
215125551|NCT00702858|DRUG|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
215125552|NCT00702858|DRUG|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
215125553|NCT04118465|PROCEDURE|external cephalic version|external cephalic version
215125554|NCT02123134|DRUG|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
215125555|NCT02123134|DRUG|Placebo|Phosphate buffered saline placebo for injection
215125556|NCT02458716|PROCEDURE|Robotic Assisted Radical Prostatectomy|Undergo RARP
215125557|NCT02458716|PROCEDURE|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
215125558|NCT02458716|OTHER|Laboratory Biomarker Analysis|Correlative studies
215125559|NCT02458716|OTHER|Quality-of-Life Assessment|Ancillary studies
215125560|NCT02458716|DRUG|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
214446710|NCT04905446|PROCEDURE|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
214446711|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
214446712|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
215125561|NCT04761601|DRUG|UCT-01-097|Orally available kinase inhibitor
215125562|NCT04761601|DRUG|Gemcitabine|Gemcitabine injection for intravenous use.
215125563|NCT04761601|DRUG|Paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
215125564|NCT03431441|DEVICE|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
215125565|NCT00904813|RADIATION|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
215125566|NCT00904813|RADIATION|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
215125567|NCT00024336|DRUG|tamoxifen citrate|
215125568|NCT00024336|RADIATION|radiation therapy|
215125569|NCT01475435|PROCEDURE|non- surgical periodontal treatment|scaling and root planning
215125570|NCT01475435|PROCEDURE|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
215125571|NCT00914186|DRUG|TS022|Lotion
215125572|NCT00914186|DRUG|Vehicle|Lotion
215125573|NCT00505557|PROCEDURE|Transaxillary dual plane technique|
215125574|NCT02271698|DRUG|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
215125575|NCT02271698|OTHER|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
215125576|NCT01038141|PROCEDURE|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
215125577|NCT02834481|DEVICE|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
215125578|NCT00764699|DRUG|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
215125579|NCT06415318|DRUG|Paclitaxel + Ifosfamide + Cisplatin & Toripalimab|Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
215125580|NCT02050113|DEVICE|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
215125581|NCT03788057|OTHER|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
214446713|NCT03323463|DIAGNOSTIC_TEST|F-FMISO PET/CT Scan|All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
215125582|NCT03985761|BEHAVIORAL|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
215125583|NCT01320189|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
215125584|NCT01052155|OTHER|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
215125585|NCT00151385|PROCEDURE|single blood draw|
215125586|NCT03011281|DRUG|Tofacitinib|
215125587|NCT05580523|DRUG|75 mg acetylsalicylic acid|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
215125588|NCT05580523|DRUG|1.5g Metformin|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g
215125589|NCT05580523|DRUG|150 mg acetylsalicylic acid|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
215125590|NCT05580523|DRUG|Placebo of acetylsalicylic acid and Metformin|Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
215125591|NCT05905094|OTHER|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
215125592|NCT00303823|DRUG|placebo|Given orally
215125593|NCT00303823|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
215125594|NCT00303823|OTHER|laboratory biomarker analysis|Correlative studies
214446714|NCT03323463|RADIATION|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
214446715|NCT03323463|DRUG|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
214446716|NCT03323463|DRUG|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
214446717|NCT03323463|DRUG|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
214446718|NCT03323463|RADIATION|Proton Therapy|Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
214446719|NCT04925388|OTHER|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
214446720|NCT04925388|OTHER|conventional method analysis|peritoneal samples will be analysed using conventional method
214446721|NCT06738147|OTHER|pelvic floor muscle training|pelvic floor muscle training (PFMT) for 30 min., 3 sessions/ week in addition to traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
215125595|NCT02322281|DRUG|Rociletinib|
215125596|NCT02322281|DRUG|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
215125597|NCT03354949|OTHER|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
215125598|NCT02925897|BEHAVIORAL|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
215125599|NCT01826396|DRUG|Irinotecan|Comparison of standard and high dose irinotecan
215125600|NCT03002441|DEVICE|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D\&E procedure
215125601|NCT03002441|DEVICE|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D\&E procedure
215125602|NCT05432492|DRUG|AK112|IV infusion, specified dose on specified days
215125603|NCT05925946|DIETARY_SUPPLEMENT|CURE-DM|"1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
215125604|NCT01492790|PROCEDURE|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
215125605|NCT01492790|PROCEDURE|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
215125606|NCT05757648|DRUG|Non-buffered Anesthetic|non-buffered LA, 2% lidocaine with epinephrine 1:100,000
215125607|NCT05757648|DRUG|Buffered Anesthetic|A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
215125608|NCT05757648|DEVICE|Onset|"The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge."
214446722|NCT06738147|OTHER|balance exercises|traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
214446723|NCT06554951|OTHER|Patients who are candidates for CAR-T cell therapy for hematologic malignancy|This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
214446724|NCT06737198|OTHER|without interventios.|without interventios.
214446725|NCT04676373|DRUG|ALGLUCOSIDASE ALFA|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214446726|NCT06238960|OTHER|Telerehabilitation|the patient will undergo 10 session of tele rehabilitation in continuity with traditional physiotherapy
214446727|NCT06238960|OTHER|Traditional rehabilitation|the patient will undergo 16 session of outpatient physiotherapy rehabilitation
214446728|NCT06518759|OTHER|traditional chest techniques|patients will receive traditional chest techniques in the form of percussion and vibration, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks
214446729|NCT06518759|OTHER|Glossopharyngeal breathing exercise|patients will receive Glossopharyngeal breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
214446730|NCT06518759|OTHER|Diaphragmatic breathing exercise|patients will receive diaphragmatic breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
214446731|NCT05000827|DEVICE|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
214446732|NCT05000827|OTHER|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
214446733|NCT05783401|OTHER|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
214446734|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
214446735|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
214446736|NCT03484884|DIAGNOSTIC_TEST|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
214446737|NCT04958967|DRUG|Furmonertinib 240mg|treated subjects will receive Furmonertinib 240mg/day
214446738|NCT04958967|DRUG|Furmonertinib 160mg|treated subjects will receive Furmonertinib 160mg/day
214446739|NCT03915886|DRUG|JNJ-0440|JNJ-0440 tablets will be administered orally.
214446740|NCT03915886|DRUG|Placebo|Matching placebo tablets will be administered orally.
214446741|NCT04941989|DRUG|HTL0022562|HTL0022562
214446742|NCT04941989|DRUG|Placebo|Placebo
215125609|NCT02249936|DRUG|AZD1722|
215125610|NCT02249936|DRUG|Omeprazole|
215125611|NCT00395655|DRUG|Hydralazine and magnesium valproate administration|
215125612|NCT00395655|PROCEDURE|Core-needle biopsy of the breast|
214446743|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
214446744|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
214446745|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
214446746|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
214446747|NCT06776029|BIOLOGICAL|Fecal Microbiota Transplantation Capsule|FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.
214446748|NCT06512155|DRUG|Pregabalin|Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
214446749|NCT06512155|DRUG|Zolpidem|Take zolpidem 10mg qn from two days before surgery to three days after surgery
214446750|NCT04225455|DEVICE|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~\[Green: 5-15 mmol/L; Amber: 4 to \<5mmol/L and \>15 to 20mmol/L; Red: \<4mmol/L and \>20mmol/L\]"
214446751|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
214446752|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
214446753|NCT04593472|BEHAVIORAL|Sharing Healthcare Wishes in Primary Care (SHARE)|SHARE is a multicomponent communication intervention to proactively engage family members or friends to support advance care planning in primary care.
214446754|NCT04593472|BEHAVIORAL|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
214446755|NCT05402592|DIETARY_SUPPLEMENT|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
214446756|NCT05402592|OTHER|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
214446757|NCT06323889|BEHAVIORAL|Modified Alternate Day Fasting|Participants are instructed to fast every other day.
214446758|NCT06323889|BEHAVIORAL|Time-Restricted Eating|Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
214446759|NCT06323889|BEHAVIORAL|Weight-loss counseling|Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
214446760|NCT06489600|OTHER|No Rays, Thanks Mineral sunscreen|"Wash your face with standard facewash and apply a pea size amount on the face in the morning.~Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical"
214446761|NCT02736448|DRUG|Capecitabine|oral low dose of capecitabine
214523421|NCT04879823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214523422|NCT04879823|DRUG|Placebo|An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
214446762|NCT02736448|DRUG|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
214446763|NCT02736448|DRUG|SS-LAR|long acting octreotide or lanreotide
214446764|NCT03940950|BIOLOGICAL|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
214446765|NCT03940950|DRUG|Placebo|Saline control that contains no active ingredient
214446766|NCT02770859|PROCEDURE|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the LES for the treatment of achalasia
214523423|NCT05313178|DIETARY_SUPPLEMENT|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
214523424|NCT04047225|DEVICE|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
215125613|NCT03518294|BEHAVIORAL|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
215125614|NCT04254224|PROCEDURE|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
215125615|NCT03077191|OTHER|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
215125616|NCT05789745|DRUG|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
215125617|NCT05789745|OTHER|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
215125618|NCT04493138|DRUG|Azacitidine|Given SC or IV
215125619|NCT04493138|DRUG|Quizartinib|Given PO
215125620|NCT05555329|DRUG|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
215125621|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
215125622|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
215125623|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
215125624|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
215125625|NCT03777943|PROCEDURE|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
215125626|NCT04533919|PROCEDURE|Biospecimen Collection|Undergo collection of dorsal root ganglia
215125627|NCT04410172|DIAGNOSTIC_TEST|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
215125628|NCT03242694|DIAGNOSTIC_TEST|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
215125629|NCT03242694|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
215125630|NCT03232346|DRUG|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
214446767|NCT06847802|OTHER|Survey|The survey will include statements related to the Domains Addressing healthcare workers/trainees, Critical Care (CC) Academic meetings, At the Workplace, CC Academia, Education of CC Trainees, Professionalism and Misconduct, Administration and Governance in the Workplace and in CC Societies, Environmental and logistic facilities, Publication of Gender metrics, Committee/working group for gender-balance The statements related to the domains will be drafted in the form of a 7-point Likert scale (strongly agree, agree, somewhat agree, neither agree nor disagree, somewhat disagree, disagree, strongly disagree) Statements that achieved consensus and stability will be used to issue the position. The results of the Delphi rounds, position statements, and the manuscript will be reviewed and approved by the panelists before submission for publication
214446768|NCT06099795|DEVICE|eBAM Cov Testing|Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
214446769|NCT06846411|DRUG|Empagliflozin 10 mg|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
214446770|NCT06846411|DRUG|Metformin|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
214446771|NCT06843811|DRUG|Sirolimus|Sirolimus will be given at a starting dose of 0.8 to 1.3 mg/m2 twice daily, depending on subject age and weight.
214446772|NCT06845254|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.
214446773|NCT06845254|DRUG|placebo capsule|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.
214446774|NCT03006913|BEHAVIORAL|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
214446775|NCT03006913|BEHAVIORAL|By phone|Patients in the phone arm will receive a scheduled call at their home.
215125631|NCT03232346|DRUG|Buprenorphine|5-week buprenorphine taper
215125632|NCT00327106|DRUG|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
215125633|NCT00327106|DRUG|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
214446776|NCT03006913|BEHAVIORAL|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
215125634|NCT06299449|PROCEDURE|free-hand socket shield|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
215125635|NCT06299449|PROCEDURE|AI/guided socket shield|"The patient specific guides will be placed at the pre-planned positions at the labial buccal mucosa.~using artificial intelligence the socket shield approach will be planned to keep the buccal shield and using surgical guide the shield will be preciesly prepared followed by guided implant placement and whole tooth grafting of the jumping gap"
215125636|NCT00139074|DRUG|Quetiapine fumarate|oral variable dose
215125637|NCT00139074|DRUG|sodium valproate|oral
215125638|NCT00218504|DRUG|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
215125639|NCT04380389|DIAGNOSTIC_TEST|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
215125640|NCT00639470|OTHER|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
215125641|NCT04852861|DIAGNOSTIC_TEST|immunogenicity after first and second dose|Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
215125642|NCT04087980|DEVICE|Poseidon System|Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
215125643|NCT04258878|PROCEDURE|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
215125644|NCT00754585|DEVICE|Logic Back Grahl Duo Back Model DB11-01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
215125645|NCT04122326|BEHAVIORAL|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
215125646|NCT03898726|BIOLOGICAL|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
215125647|NCT03041571|BEHAVIORAL|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
215125648|NCT03041571|BEHAVIORAL|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
215125649|NCT00134303|DRUG|Metformin|Metformin is used.
215125650|NCT04291846|DRUG|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
215125651|NCT04291846|DRUG|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
215125652|NCT00677404|BIOLOGICAL|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
215125653|NCT03650088|BEHAVIORAL|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
215125654|NCT01877512|DRUG|Change in daily dosage of Growth Hormone|
215125655|NCT03111836|BEHAVIORAL|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
215125656|NCT03111836|BEHAVIORAL|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
215125657|NCT03111836|BEHAVIORAL|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
215125658|NCT01425034|OTHER|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
215125659|NCT01425034|OTHER|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
215125660|NCT06216067|DEVICE|CALLISTO eye|Cataract toric lens placement tool
214446777|NCT04236856|DEVICE|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
214446778|NCT03816631|DRUG|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.
214446779|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET CT|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
214446780|NCT06120049|DIAGNOSTIC_TEST|[18F]-FE-PE2I PET CT or PET MRI|"\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
214446781|NCT06120049|DIAGNOSTIC_TEST|[123I]-MIBG SPECT CT|"\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
214523425|NCT03897075|DRUG|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
214523426|NCT03897075|DRUG|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
215125661|NCT06216067|DEVICE|Wavetec AnalyzOR|Cataract toric lens placement tool
215125662|NCT03679065|DRUG|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
215125663|NCT03679065|DRUG|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
215125664|NCT03679065|DRUG|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
215125665|NCT00304174|BEHAVIORAL|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
215125666|NCT00732823|DEVICE|Placebo - No device worn|
215125667|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
215125668|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
215125669|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
215125670|NCT01900795|DRUG|V117957|V117957 4.5 mg suspension taken orally after surgery.
215125671|NCT01900795|DRUG|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
215125672|NCT01900795|DRUG|Placebo|Placebo taken orally after surgery.
215125673|NCT01344902|DRUG|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
215125674|NCT02486575|OTHER|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
215125675|NCT02486575|OTHER|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
215125676|NCT03568981|RADIATION|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
214446782|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET dosimetry scans|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
214523427|NCT04468633|DEVICE|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
214523428|NCT04468633|DEVICE|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
214523429|NCT05653050|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
214523430|NCT05653050|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Freestyle Libre 3 CGM
215125677|NCT03568981|RADIATION|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
215125678|NCT03326778|PROCEDURE|AVR and CABG|Combined AVR with CABG
215125679|NCT01536717|DRUG|Articaine hydrochloride 2% solution|"* 4 ml/h periosteal wound infusion~* duration of 72 h"
215125680|NCT01536717|DRUG|Sodium Chloride|Placebo Sodium chloride 0,9%
215125681|NCT00887302|PROCEDURE|Gastric Band|Places a band over the upper portion of the stomach.
215125682|NCT00887302|PROCEDURE|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
215125683|NCT00887302|PROCEDURE|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
215125684|NCT06457724|DIETARY_SUPPLEMENT|Levilactobacillus brevis CNCM I-5566|Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
215125685|NCT06457724|DIETARY_SUPPLEMENT|Placebo|Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
215125686|NCT06159452|DRUG|SAR153191-P3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
215125687|NCT06159452|DRUG|SAR153191-P2 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
215125688|NCT06159452|DRUG|SAR153191-C1F3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
215125689|NCT02470221|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
215125690|NCT02470221|OTHER|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
215125691|NCT03268785|DIAGNOSTIC_TEST|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
215125692|NCT03571139|DEVICE|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
215125693|NCT02976337|DRUG|Naloxone|active drug infusion
215125694|NCT02976337|DRUG|Normal Saline|placebo comparator
214523431|NCT00142532|PROCEDURE|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
215125695|NCT02414815|DEVICE|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
215125696|NCT05470387|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
215125697|NCT05470387|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
215125698|NCT05034913|OTHER|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
215125699|NCT04826172|DRUG|IMB-1018972|Modified release (MR) oral tablet
215125700|NCT04826172|DRUG|Placebo|Matching oral tablet
215125701|NCT03567772|DEVICE|Wiifit Nintendo video game|
215125702|NCT03567772|OTHER|Pulmonary rehabilitation program|
215125703|NCT03309566|DRUG|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
215125704|NCT03275740|DRUG|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
214523432|NCT00142532|PROCEDURE|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
215125705|NCT03275740|DRUG|Placebo intravenous healthy participant|Placebo comparator
215125706|NCT03275740|DRUG|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
215125707|NCT03275740|DRUG|Placebo subcutaneous healthy participant|placebo comparator
215125708|NCT03275740|DRUG|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
215125709|NCT05648266|DRUG|Continous SAPB (Ropivacain)|postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
215125710|NCT05648266|OTHER|institutional standard of care pain medication protocol|institutional standard of care pain medication protocol
215125711|NCT01388517|DRUG|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
215125712|NCT01388517|DRUG|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
215125713|NCT01388517|DRUG|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
215125714|NCT03880058|DRUG|SLI-F06|Active treatment
214523433|NCT05185089|DRUG|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
215125715|NCT03880058|DRUG|Formulation buffer|Placebo treatment
215125716|NCT00750724|DRUG|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
215125717|NCT00750724|DRUG|normal saline,2 ml., intraarticular weekly for 5 weeks|
215125718|NCT04179006|DIETARY_SUPPLEMENT|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
215125719|NCT00002164|DRUG|Nelfinavir mesylate|
215125720|NCT03018236|DRUG|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
215125721|NCT03018236|DRUG|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
215125722|NCT03018236|DRUG|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
215125723|NCT03018236|DRUG|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
215125724|NCT03142529|DRUG|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
215125725|NCT02498288|DRUG|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
215125726|NCT02498288|DRUG|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
215125727|NCT02498288|DRUG|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
215125728|NCT05413746|DEVICE|Reoxcare antioxidant dressing|After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
215125729|NCT00687401|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
214523434|NCT05185089|DRUG|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
214523435|NCT02592902|PROCEDURE|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
214523436|NCT02592902|PROCEDURE|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
214523437|NCT04344886|PROCEDURE|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
215125730|NCT03639363|DRUG|4% chlorhexidine gluconate soap-like solution|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
215125731|NCT03639363|OTHER|standard soap|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
215125732|NCT03178435|OTHER|Measures to prevent AKI among critically ill patients|"1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary"
215125733|NCT02604446|DRUG|Tapentadol|
215125734|NCT02604446|DRUG|Oxycodone|
215125735|NCT02604446|DRUG|Placebo|
215125736|NCT02604446|DRUG|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
215125737|NCT04711785|BEHAVIORAL|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
215125738|NCT05806320|OTHER|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
215125739|NCT05806320|OTHER|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
214523438|NCT04344886|PROCEDURE|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
215125740|NCT02920892|DRUG|AFQ056|12.5 mg - 100 mg oral suspension (liquid)
215125741|NCT02920892|DRUG|Placebo|Placebo oral suspension (liquid)
215125742|NCT02920892|OTHER|Language Intervention|"All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children."
215125743|NCT06410898|DEVICE|Punch Biopsy 5mm|Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
215125744|NCT03306966|DEVICE|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
215125745|NCT02474563|DRUG|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
215125746|NCT02474563|DRUG|Melphalan|Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.
215125747|NCT02474563|DRUG|Prednisone|Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
215125748|NCT05016466|OTHER|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
215125749|NCT05016466|OTHER|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
215125750|NCT05591092|PROCEDURE|Computed Tomography|Undergo a SPECT/CT scan
215125751|NCT05591092|RADIATION|Iodine I-123|Given PO
215125752|NCT05591092|PROCEDURE|Planar Imaging|Undergo planar imaging
215125753|NCT05591092|PROCEDURE|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
215125754|NCT04486235|BEHAVIORAL|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
214523439|NCT04344886|PROCEDURE|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
214523440|NCT04344886|PROCEDURE|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
214523441|NCT06398015|PROCEDURE|Surgical reconstruction of hip abductor tendon tear|"If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied."
214523442|NCT06398015|PROCEDURE|Sham surgery of hip abductor tendon tear|If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
214523443|NCT00003732|DRUG|carboplatin|
214523444|NCT00003732|DRUG|paclitaxel|
214523445|NCT00003732|DRUG|topotecan hydrochloride|
214523446|NCT00289952|DRUG|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
215125755|NCT01715168|DRUG|DOXIL/CAELYX|
215125756|NCT01715168|DRUG|ATI-0918|
215125757|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
214523447|NCT00289952|DRUG|HAART|As per standard of care.
215125758|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
215125759|NCT00451672|DRUG|bromocriptine|
214523448|NCT01843920|DRUG|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
214523449|NCT01843920|DRUG|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
214523450|NCT01086514|PROCEDURE|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
214523451|NCT00244556|DRUG|Methotrexate plus ENBREL or ENBREL alone|
214523452|NCT03398889|DIAGNOSTIC_TEST|Plasma levels of metabolites|plasma levels of metabolites
215125760|NCT02124733|PROCEDURE|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
215125761|NCT00495729|DRUG|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
215125762|NCT00495729|DRUG|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
215125763|NCT00495729|DRUG|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
214523453|NCT03398889|BEHAVIORAL|Dietary questionnaire|Harvard food frequency questionnaire
214523454|NCT03398889|DIAGNOSTIC_TEST|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
214523455|NCT02216994|DRUG|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
215125764|NCT00881517|DRUG|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
215125765|NCT00881517|DRUG|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
215125766|NCT00213512|DRUG|Mabthera|
215125767|NCT01622621|PROCEDURE|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
215125768|NCT01622621|RADIATION|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
215125769|NCT01009658|DIETARY_SUPPLEMENT|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
215125770|NCT01009658|DIETARY_SUPPLEMENT|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
215125771|NCT04641845|OTHER|Cork inlay wedge|
215125772|NCT03935126|DIAGNOSTIC_TEST|Diagnostics|Diagnostics
215125773|NCT00343265|DRUG|Vaginal progesterone gel|Vaginal gel once daily
215125774|NCT00343265|DRUG|Placebo gel|once daily
215125775|NCT02604381|DIETARY_SUPPLEMENT|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
215125776|NCT02604381|OTHER|Placebo|
215125777|NCT05058807|OTHER|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
214523456|NCT02216994|BEHAVIORAL|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
214523457|NCT02216994|DRUG|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
214523458|NCT00460434|DEVICE|TVT|Prophylactic TVT
214523459|NCT00460434|OTHER|Sham|Sham TVT
214523460|NCT04391439|DRUG|Intravenous Methylprednisolone|
214523461|NCT03426709|BEHAVIORAL|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
214523462|NCT02292056|BEHAVIORAL|1-on-1 counseling|"1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
214523463|NCT01381185|DRUG|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
214523464|NCT03593798|OTHER|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
214523465|NCT04653987|PROCEDURE|Percutaneous biliary drainage|
214523466|NCT00604344|DRUG|insulin detemir|
214523467|NCT00604344|DRUG|insulin NPH|
214523468|NCT05481996|OTHER|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
214523469|NCT05481996|OTHER|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
214523470|NCT01940913|DIETARY_SUPPLEMENT|Probiotic capsules|
214523471|NCT01940913|DIETARY_SUPPLEMENT|Placebo capsules|
215125778|NCT05058807|OTHER|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
214523472|NCT00490243|DRUG|budesonide and montelukast|
214523473|NCT00490243|DRUG|budesonide and formoterol|
214523474|NCT00490243|DRUG|montelukast|
214523475|NCT00490243|DRUG|budesonide|
215125779|NCT02520726|DRUG|Sertraline|\< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
215125780|NCT02520726|DRUG|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
215125781|NCT03649217|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
215125782|NCT01092728|DRUG|Dasatinib|100 mg daily.
214523476|NCT00490243|DRUG|placebo|
214523477|NCT02465866|DRUG|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
214523478|NCT02465866|DRUG|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
214523479|NCT02465866|DRUG|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
214523480|NCT02465866|DRUG|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
214523481|NCT03180086|OTHER|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
214523482|NCT00203502|DRUG|Bevacizumab|IV 15mg/kg 21 days
214523483|NCT00203502|DRUG|Cyclophosphamide|500mg per meter squared, IV every 21 days
214523484|NCT00203502|DRUG|Docetaxel|60 mg per meter squared, IV every 21 days
215125783|NCT01092728|PROCEDURE|Surgical Resection|Complete surgical resection of tumor(s).
215125784|NCT00646685|PROCEDURE|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
214523485|NCT02607293|DRUG|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
214523486|NCT02607293|DRUG|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
214523487|NCT02607293|DRUG|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
214523488|NCT00801905|DRUG|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
214523489|NCT00801905|OTHER|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
214523490|NCT02699437|OTHER|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
214523491|NCT06181123|OTHER|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
215125785|NCT00646685|PROCEDURE|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
215125786|NCT00734435|DRUG|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
215125787|NCT00734435|DRUG|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
215125788|NCT00339586|DRUG|Erlotinib|
215125789|NCT03744728|DIAGNOSTIC_TEST|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
215125790|NCT03744728|DIAGNOSTIC_TEST|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
215125791|NCT02763423|PROCEDURE|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
215125792|NCT02552966|DEVICE|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
215125793|NCT00721396|BIOLOGICAL|rMenB+OMV NZ|
215125794|NCT00721396|BIOLOGICAL|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
215125795|NCT00721396|BIOLOGICAL|Pneumococcal vaccine|
215125796|NCT00510159|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
215125797|NCT00510159|DRUG|Praziquantel|
215125798|NCT06187259|DEVICE|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
215125799|NCT06187259|DEVICE|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
214523492|NCT00935129|DEVICE|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
215125800|NCT01521130|DRUG|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
214523493|NCT00935129|DEVICE|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
214523494|NCT00653419|DRUG|buspirone HCl|Tablets, 30 mg, single-dose
214523495|NCT00653419|DRUG|Buspar|Tablets, 30 mg, single-dose
215125801|NCT00226590|DRUG|Gemcitabine|Induction Chemotherapy.
215125802|NCT00226590|DRUG|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
215125803|NCT00226590|DRUG|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
215125804|NCT00226590|PROCEDURE|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
215125805|NCT06136429|PROCEDURE|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
215125806|NCT04506541|OTHER|Kangaroo Care|Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
215125807|NCT05806463|BEHAVIORAL|Mother's Time|Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
215125808|NCT02394314|DRUG|MEDI0382|MEDI0382 administered subcutaneously
215125809|NCT02394314|DRUG|Placebo|Placebo administered subcutaneously
215125810|NCT01091675|DRUG|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
215125811|NCT01054105|DRUG|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
215125812|NCT00614380|DRUG|telmisartan/amlodipine 40/5 mg fixed combination|
215125813|NCT00614380|DRUG|telmisartan/amlodipine 80/5 mg fixed combination|
215125814|NCT02714192|OTHER|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
215125815|NCT05384340|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|On the first day, an acute test will be carried out with beet juice rich in nitrate, in which two units of juice will be provided, totaling 140 ml (800 mg of nitrate) for each protocol. That is, each participant will receive 2 units of juice bottles. From the second to the seventh day, participants will receive 6 units of vials of the juice corresponding to the first intervention on the first visit to the laboratory and will drink one vial a day for a week. Of the 8 units (100%), six bottles (75%) will be provided for the participants to take home. On the seventh day of the intervention, the participants will return to the laboratory for the consumption of the seventh and last bottle of juice. Between one protocol and another, a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
215125816|NCT02161796|DRUG|FG-4592|Oral
215125817|NCT02161796|DRUG|Placebo|Oral
215125818|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
215125819|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
215125820|NCT03938935|PROCEDURE|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
214446783|NCT04538417|DEVICE|Cooled Radiofrequency Ablation|RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
214446784|NCT01981031|DRUG|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
214446785|NCT01981031|DRUG|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
214446786|NCT04514757|DEVICE|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
214446787|NCT04514757|DEVICE|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
214446788|NCT06273228|BEHAVIORAL|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
214446789|NCT04746677|DEVICE|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
214446790|NCT03394846|BEHAVIORAL|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
214446791|NCT05714397|DEVICE|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
214446792|NCT06332482|DEVICE|Implant supported screw retained prosthesis|All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
214523496|NCT03597542|OTHER|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
214523497|NCT06431360|OTHER|hyperthermia|hyperthermia (using a heater, 44℃for 15 min)
214523498|NCT03856294|DRUG|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
214523499|NCT03856294|DRUG|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
214523500|NCT04284722|DRUG|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
215125821|NCT03591926|DRUG|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
214446793|NCT05836883|BIOLOGICAL|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
214446794|NCT05836883|OTHER|Local injection of normal saline|Placebo
214446795|NCT02375204|DRUG|paclitaxel|IV
214446796|NCT02375204|DRUG|ifosfamide|IV
214446797|NCT02375204|DRUG|cisplatin|IV
214446798|NCT02375204|DRUG|pegylated G-CSF|IV
214446799|NCT02375204|DRUG|G-CSF|IV
214446800|NCT02375204|DRUG|carboplatin|IV
214446801|NCT02375204|DRUG|etoposide phosphate|IV
214523501|NCT00993018|DRUG|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
214523502|NCT00993018|DRUG|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
214523503|NCT00993018|DRUG|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
214523504|NCT00993018|DRUG|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
214523505|NCT00049751|DRUG|Adalimumab|
214523506|NCT02869308|DRUG|stannous pyrophosphate|Injection of 1ml Angiocis
214446802|NCT02375204|PROCEDURE|stem cell reinfusion|surgical procedure
214446803|NCT05018832|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214523507|NCT02869308|DRUG|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
214523508|NCT02869308|DEVICE|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
214523509|NCT02869308|DEVICE|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
214523510|NCT03366727|DEVICE|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
214523511|NCT03366727|DEVICE|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
214523512|NCT03992599|PROCEDURE|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
214523513|NCT02686983|DRUG|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
215125822|NCT03435185|PROCEDURE|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
215125823|NCT03435185|PROCEDURE|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
215125824|NCT05612308|OTHER|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
215125825|NCT04142034|BEHAVIORAL|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
215125826|NCT04142034|BEHAVIORAL|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
215125827|NCT04142034|OTHER|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
215125828|NCT04142034|OTHER|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
215125829|NCT03865446|DRUG|Dacomitinib|anti-cancer agent
215125830|NCT03111238|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
215125831|NCT03111238|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
215125832|NCT01562808|DRUG|Aripiprazole|single oral administration of aripiprazole
215125833|NCT02304744|OTHER|Observational study, no intervention.|Observational study, no intervention.
214446804|NCT04128566|PROCEDURE|walking stress test|walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
214523514|NCT04501107|DRUG|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
215125834|NCT04508946|DRUG|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
215125835|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
215125836|NCT05195307|OTHER|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
214523515|NCT04501107|DRUG|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
214523516|NCT04501107|DRUG|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
214523517|NCT04501107|DRUG|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
214523518|NCT05382390|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
214523519|NCT05382390|DRUG|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
214523520|NCT00291928|DRUG|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
214523521|NCT00291928|DRUG|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
214523522|NCT04301947|OTHER|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
214523523|NCT04301947|OTHER|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
214523524|NCT02884219|DRUG|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
215125837|NCT00111514|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
215125838|NCT01207635|PROCEDURE|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
215125839|NCT03523884|OTHER|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
215125840|NCT03523884|OTHER|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
214446805|NCT06130995|DRUG|Relugolix and Enzalutamide|"Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily"
214446806|NCT06494293|OTHER|Data Collection|Collection of medical data from MICU intervention file and patient medical files from participating centres
214446807|NCT06110208|DRUG|CLL1 and CD38 dual-target CAR-T injection|CLL1 and CD38 dual-target CAR-T injection
214446808|NCT06550596|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214446809|NCT06550596|OTHER|Axolotl DualGraft + SOC|Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214446810|NCT02094365|DRUG|ALS-008176|
214446811|NCT02094365|DRUG|vehicle|
214446812|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
214446813|NCT04681105|DRUG|Acetaminophen|Given PO
214446814|NCT04681105|DRUG|Dexamethasone|Given IV
215125841|NCT03434730|RADIATION|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
214446815|NCT04681105|DRUG|Diphenhydramine|Given IV or PO
214446816|NCT04681105|BIOLOGICAL|Flotetuzumab|Given IV
214446817|NCT04681105|DRUG|Ibuprofen|Given PO
214446818|NCT04681105|DRUG|Ranitidine|Given IV
214446819|NCT04273828|PROCEDURE|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
214446820|NCT02218996|OTHER|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
214446821|NCT06275269|PROCEDURE|Ultrasound-Guided|Ultrasound-Guided Triamcinolone Injection
214446822|NCT06275269|PROCEDURE|Translaryngeal Endoscopic Mucosal Injection|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
214446823|NCT04549168|DRUG|Lemborexant|Lemborexant 10 mg tablet.
214446824|NCT04549168|DRUG|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
214523525|NCT02884219|OTHER|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
214523526|NCT02884219|DRUG|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
215125842|NCT03434730|DRUG|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
215125843|NCT03434730|DRUG|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
215125844|NCT03434730|DRUG|Tocilizumab|For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
214446825|NCT03262779|BIOLOGICAL|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
214446826|NCT04856332|OTHER|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
214446827|NCT05803993|PROCEDURE|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
214523527|NCT02301871|DEVICE|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
214523528|NCT02301871|PROCEDURE|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
214523529|NCT02301871|PROCEDURE|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
214446828|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
214523530|NCT01403805|BIOLOGICAL|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
214523531|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
214523532|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
214523533|NCT01403805|OTHER|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
214523534|NCT03082196|DRUG|Test varnish|Topical application of test varnish to the teeth 4 times per year.
214446829|NCT06787261|OTHER|saliva sample|saliva sample
214446830|NCT06787261|OTHER|carious tissue samples|carious tissue samples
214446831|NCT06786897|OTHER|Questionnaire and Physical Exam|Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
214446832|NCT06553235|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
214446833|NCT06553235|BEHAVIORAL|Sleep hygiene education|\- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
214446834|NCT04897438|PROCEDURE|Kidney allograft biopsy depending on donor-derived cell-free DNA levels|Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
214446835|NCT04868227|DIETARY_SUPPLEMENT|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
214523535|NCT03082196|DRUG|Standard varnish|Topical application of test varnish to the teeth 4 times per year
214523536|NCT01103141|DEVICE|Micropuncture needle set|Groin access for vascular intervention
214523537|NCT01103141|DEVICE|Standard gauge-18 needle set|Groin access for vascular intervention
214523538|NCT01747616|DEVICE|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
214523539|NCT01747616|OTHER|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
214523540|NCT01695993|DEVICE|Acupressure bands|Bilateral acupressure wrist bands
214523541|NCT01695993|OTHER|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
214523542|NCT01695993|BEHAVIORAL|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
214523543|NCT01695993|OTHER|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
214523544|NCT01695993|BEHAVIORAL|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
214523545|NCT00669149|DRUG|clopidogrel + aspirin|
214523546|NCT00669149|DRUG|heparin + clopidogrel + aspirin|
214523547|NCT00669149|DRUG|enoxaparin + clopidogrel + aspirin|
214446836|NCT06078384|DRUG|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
214523548|NCT00669149|DRUG|bivalirudin + clopidogrel + aspirin|
214523549|NCT01699802|OTHER|Inhaled anaesthetic agent|
214523550|NCT00465699|DRUG|Topical B12 0.07%|
214523551|NCT02250911|OTHER|webcasts|
214523552|NCT02250911|BEHAVIORAL|Assessments|
214446837|NCT06078384|DRUG|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
214523553|NCT02250911|OTHER|Usual care|
214446838|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
214446839|NCT02475434|DIETARY_SUPPLEMENT|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
215125845|NCT03434730|DRUG|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
215125846|NCT05646498|PROCEDURE|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
215125847|NCT05646498|DEVICE|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
215125848|NCT00461006|DRUG|Actos|45mg po daily
215125849|NCT00461006|DRUG|aleglitazar|0.6mg po daily
215125850|NCT00139230|DRUG|Taxotere|
215125851|NCT00139230|DRUG|Cisplatin|
215125852|NCT00139230|DRUG|5-Fluorouracil|
215125853|NCT00139230|DRUG|Leucovorin|
215125854|NCT00139230|DRUG|G-CSF|
215125855|NCT00139230|DRUG|Ciprofloxacin|
215125856|NCT04067323|DIETARY_SUPPLEMENT|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
215125857|NCT04067323|DIETARY_SUPPLEMENT|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
215125858|NCT05474352|DEVICE|Allon System|Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
215125859|NCT05532644|OTHER|AD drugs|AD drugs
215125860|NCT04894721|DRUG|Ivermectin|0,6mg/kg of weight orally on days 1 and 7
215125861|NCT04894721|OTHER|Placebo|A substance with similar physical characteristics as ivermectin, without the active drug ingredient
214446840|NCT04749446|OTHER|Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)|"This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures"
214446841|NCT05426629|DEVICE|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
214446842|NCT06008392|GENETIC|Pan-genomic Testing|Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).
214446843|NCT03833622|OTHER|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
214446844|NCT06327061|BEHAVIORAL|Network overdose prevention|Participants are taught overdose prevention methods with network members.
214446845|NCT06327061|BEHAVIORAL|Standard of care health education|Participants will receive the standard of care for overdose prevention.
214694309|NCT07084753|DEVICE|Ultrasound guided thoracic paravertebral block|"Patients are positioned prone, with the identification of the 1st rib achieved using a convex XX Hz ultrasound probe. The left and right transverse processes of the 5th, 7th, and 9th thoracic vertebrae are marked accordingly. TPVB is executed in a paramedian sagittal oblique scan utilizing an in-plane needle insertion approach at the Th5, Th7, and Th9 levels bilaterally. An insulated echogenic needle, sized between 10-15 cm and 22-20 G, is employed. The skin and subcutaneous tissue at each level are infiltrated with 1.5 ml of 1% lidocaine.~Ultrasound guidance combined with nerve stimulation (dual monitoring) is utilized at each corresponding paravertebral space. Verification of the paravertebral space is established through visualization of pleural displacement, as observed via the ultrasound probe following the injection of 1 ml of 5% glucose, as well as via a motor response at a current intensity of 0.3-0.5 mA."
215125862|NCT02021565|BEHAVIORAL|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
215125863|NCT02021565|OTHER|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
215125864|NCT01307826|OTHER|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
215125865|NCT01307826|OTHER|massage|classical massage (Swedish massage)
214446846|NCT03840603|DIAGNOSTIC_TEST|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
214446847|NCT06386783|DRUG|Dexmedetomidine Injection [Precedex]|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
214446848|NCT06386783|DRUG|Fentanyl HCl|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
214446849|NCT03946410|DIAGNOSTIC_TEST|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
214446850|NCT04983108|OTHER|No Intervention|No intervention. This is an observational Study
214446851|NCT04795362|BIOLOGICAL|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
214446852|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
214446853|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
214446854|NCT06048484|DRUG|Quemliclustat|100 mg IV
214446855|NCT06048484|DRUG|Etrumadenant|150 mg orally
214446856|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
214446857|NCT05582993|BIOLOGICAL|Vonicog Alfa|Vonicog Alfa administered by intravenous injection.
214446858|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
214446859|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
214446860|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
214446861|NCT05859698|DRUG|Valbenazine|Valbenazine capsules for oral administration
214446862|NCT06315088|OTHER|Einkorn Diet|Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
214446863|NCT06315088|OTHER|Intermediate oral microbiota|Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
214446864|NCT06315088|OTHER|Periodontal health status|Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
214446865|NCT06315088|OTHER|General health status|Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
214523554|NCT03035149|OTHER|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
214523555|NCT02243488|DEVICE|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
214523556|NCT03341754|BIOLOGICAL|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
214523557|NCT03341754|BIOLOGICAL|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
214523558|NCT03341754|OTHER|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
214523559|NCT05257434|BEHAVIORAL|inbody|Body fluid composition
214523560|NCT02548052|DRUG|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
214523561|NCT02548052|DRUG|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
215125866|NCT03318549|DIAGNOSTIC_TEST|Visual Performance tests|Participants came to the clinic in person for 2 hours for visual performance tests once every 6 months for up to 5 years. These tests included virtual reality tests and tests on a computer screen to investigate performance during simulated daily life activities, such as driving, situations of low contrast and glare.
215125867|NCT03318549|DEVICE|Brain-computer interface|The brain-computer interface (BCI) consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle. The test is done in person and may take up to 30 minutes, once every 6 months for up to 5 years.
215125868|NCT04415372|DIAGNOSTIC_TEST|MRI|The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
215125869|NCT04415372|DIAGNOSTIC_TEST|Neuropsychological Testing|A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
215125870|NCT05924945|DEVICE|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
215125871|NCT05924945|DEVICE|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
215125872|NCT04320355|OTHER|Soft tissue manual therapy|The intervention is a type of massage.
215125873|NCT00997802|DEVICE|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
215125874|NCT04970875|OTHER|Questionnaire|QoL questionnaire
215125875|NCT02202239|DRUG|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
215125876|NCT02202239|DRUG|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
215125877|NCT02202239|DRUG|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
215125878|NCT02202239|DRUG|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
215125879|NCT02202239|DRUG|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
215125880|NCT02202239|DRUG|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
215125881|NCT02202239|DRUG|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
215125882|NCT02202239|DRUG|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
214523562|NCT02548052|DRUG|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
214694310|NCT07084753|DEVICE|Nerve stimulator for peripheral nerve blocks|During the application of the thoracic paravertebral block, verification of the distance of the insulated echogenic needle tip from the thoracic spinal nerve is monitored using via a motor response at a current intensity of 0.3-0.5 mA.
215125883|NCT03309423|DIAGNOSTIC_TEST|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
215125884|NCT02303093|BIOLOGICAL|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
215125885|NCT02303093|BIOLOGICAL|Panzyga|Panzyga
214523563|NCT02548052|DRUG|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
214694311|NCT07084753|DRUG|Metoclopramide 10mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and metoclopramide (10 mg) intraoperatively
214694312|NCT07084753|DRUG|Ondasetron 4mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intraoperatively.
215125886|NCT02798250|OTHER|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
215125887|NCT02798250|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
215125888|NCT02798250|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
215125889|NCT02798250|DEVICE|Dexcom G4 Platinum glucose sensor|
215125890|NCT02798250|DEVICE|Accu Chek Combo insulin pump|
215125891|NCT02021942|DRUG|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
215125892|NCT01490775|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
215125893|NCT01490775|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
215125894|NCT00510835|PROCEDURE|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
215125895|NCT00510835|PROCEDURE|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
215125896|NCT00510835|PROCEDURE|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
215125897|NCT05061511|OTHER|Analysis of inflammasome expression|RNA isolation, spectrophotometric quantification, reverse transcription to cDNA and relative quantification of gene expression using a quantitative reverse transcription polymerase chain reaction (qRT-PCR). Specific inflammasome-related transcripts will be investigated, including ASC, caspase-1, IL-1beta, IL-18, NLRP3, NLRP2, AIM2, POP1, POP2, CARD16, CARD18, TRIM16, and TRIM20. A qRT-PCR System (e.g. StepOne Plus, Applied Biosystems) will be used for the amplification and analysis of the PCR products. Expression data will be reported as the ratio between each investigated target gene and GAPDH (used as housekeeping endogenous control).
215125898|NCT05061511|OTHER|Histological analysis|"gingival tissue samples will be prepared for paraffin inclusion and different stains will be used to evaluate the histological features of the tissues, distribution of inflammatory cells and alignment of collagen fibers.~Moreover, a trained examiner will assess semi-quantitatively the inflammatory infiltrate under light microscopy.~The expression of inflammatory/immune-related proteins such as NLRP3, ASC-2, IL-1beta and IL-18 protein expressions will be compared among the three groups by immunodetection methods"
215125899|NCT02870283|DRUG|Lithium|
215125900|NCT02870283|DRUG|Valproic Acid|
215125901|NCT02870283|DRUG|Carbamazepine|
215125902|NCT06483724|PROCEDURE|cervical tourniquet|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-An assistant slides a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix 4-The bladder peritoneum is isolated from the uterus 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
215125903|NCT06483724|PROCEDURE|uterine artery ligation|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-The bladder peritoneum is isolated from the uterus 4-The uterine vessels were ligated in continuity at the level of the utero-vesical fold on each side 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
215125904|NCT03123666|DRUG|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
215125905|NCT03123666|OTHER|Placebo|Placebo identical to GMCSF will be given
215125906|NCT00323141|DEVICE|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
215125907|NCT05839171|BEHAVIORAL|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
215125908|NCT06028997|BEHAVIORAL|Behavioral and Sleep Hygiene Education with Mindfulness Intervention|Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
215125909|NCT06426472|OTHER|Web-based support program|Web-based support program for infertile women with failed IVF experience
215125910|NCT00607087|DRUG|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
214523564|NCT02548052|DRUG|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
215125911|NCT00607087|DRUG|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
214523565|NCT02548052|DRUG|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
214694313|NCT07084753|DRUG|Thiethylperazine|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and thiethylperazine (6.5 mg) intravenously.
214523566|NCT03011554|DEVICE|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
215125912|NCT00607087|DRUG|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
214523567|NCT06086665|DRUG|Niraparib|Niraparib
214523568|NCT04057937|DRUG|Apremilast|Apremilast
214523569|NCT04057937|DRUG|Placebo|Placebo
214523570|NCT04301609|DIETARY_SUPPLEMENT|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
215125913|NCT05455528|DIAGNOSTIC_TEST|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
215125914|NCT04451499|OTHER|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
215125915|NCT01597336|PROCEDURE|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
215125916|NCT01597336|PROCEDURE|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
215125917|NCT02647437|DRUG|Levetiracetam|
215125918|NCT02647437|DRUG|Placebo|
215125919|NCT04423055|DRUG|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
215125920|NCT00700440|DRUG|C225 (cetuximab)|one week before and then weekly during radiotherapy
215125921|NCT01673997|DRUG|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
215125922|NCT00650767|DRUG|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
215125923|NCT00650767|DRUG|Placebo; oral|matching placebo
215125924|NCT05396053|OTHER|Physical therapy exercises|Three times a week for 12 weeks.
215125925|NCT05396053|OTHER|Mirror therapy|Three times a week for 12 weeks.
215125926|NCT05396053|OTHER|Constraint Induced Movement Therapy|Three times a week for 12 weeks.
215125927|NCT02273661|DRUG|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
215125928|NCT02273661|DRUG|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
215125929|NCT05944679|RADIATION|No Xray|Just one Xray 12 months after the intervention
215125930|NCT05944679|RADIATION|Xray|Xray at 1, 3, 6 and 12 months after intervention
215125931|NCT00387296|DEVICE|functional microarray|functional microarray application
215125932|NCT01774799|BEHAVIORAL|Advance care planning intervention|
215125933|NCT01774799|OTHER|Control group|
215125934|NCT04761133|DRUG|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
215125935|NCT02386982|DRUG|HMS5552|
215125936|NCT00295542|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
214523571|NCT04301609|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
214523572|NCT02103816|DEVICE|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
214523573|NCT05584709|BIOLOGICAL|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
214523574|NCT04388514|PROCEDURE|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
214523575|NCT05256914|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
214523576|NCT05256914|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
215125937|NCT00295542|PROCEDURE|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
215125938|NCT00295542|DRUG|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
215125939|NCT00295542|DRUG|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
215125940|NCT00295542|DRUG|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
215125941|NCT00295542|DRUG|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
215125942|NCT00295542|PROCEDURE|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
215125943|NCT02504489|DRUG|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
215125944|NCT02504489|DRUG|Docetaxel (D)|Docetaxel 75 mg/m2 IV
215125945|NCT02418052|PROCEDURE|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
214523577|NCT06379451|DRUG|NKG2D Chimeric Antigen Receptor NK Cell Injection|Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
214523578|NCT02461719|DRUG|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
215125946|NCT02586623|DRUG|Droxidopa capsules|100, 200 or 300 mg
215125947|NCT02586623|DRUG|Placebo capsules|
215125948|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (active treatment)|
214446866|NCT06162871|BEHAVIORAL|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
214446867|NCT05839119|DRUG|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
214446868|NCT05839119|COMBINATION_PRODUCT|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
214446869|NCT03988634|DRUG|sacubitril/valsartan|Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
214446870|NCT03988634|DRUG|valsartan|Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
214446871|NCT03988634|DRUG|sacubitril/valsartan matching placebo|Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
214446872|NCT03988634|DRUG|valsartan matching placebo|Valsartan matching placebo was available as tablet form to be taken orally, twice daily
214446873|NCT06311357|DIETARY_SUPPLEMENT|Ensure|Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
214446874|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
214446875|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
214446876|NCT06799910|PROCEDURE|continuous renal replacement therapy (CRRT)|The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups.
214446877|NCT06799910|OTHER|Free UF Prescription|The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition.
214523579|NCT02461719|DRUG|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
215125949|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (placebo treatment)|
215125950|NCT03631342|OTHER|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
215125951|NCT03631342|OTHER|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
215125952|NCT03631342|OTHER|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
215125953|NCT03631342|OTHER|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
214446878|NCT01728402|PROCEDURE|blood draw, bone marrow procedure, or tissue biopsy|
214446879|NCT04725240|DRUG|Setmelanotide|Setmelanotide for SC injection
214446880|NCT05643599|DIETARY_SUPPLEMENT|Mad Honey|mad honey (80 mg/kg); (n:6)
214446881|NCT05643599|DIETARY_SUPPLEMENT|Normal Honey|normal honey (80 mg/kg),(n:6)
214446882|NCT05643599|DIETARY_SUPPLEMENT|Control|Control
214694314|NCT07084753|DRUG|Dexamethasone, 8 mg intravenously|To prevent postoperative nausea and vomiting (PONV), patients receive intraoperatively dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intravenously.
214694315|NCT07083752|DRUG|Botulinum toxin application|Hemiplegic stroke patients who received upper extremity botulinum toxin will be evaluated retrospectively. Information regarding upper extremity motor recovery, spasticity levels, and muscle thickness measured by ultrasound before and one month after botulinum toxin administration will be obtained from file records.
214446883|NCT05780385|DEVICE|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
215125954|NCT03631342|OTHER|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
215125955|NCT06278792|PROCEDURE|Diuretic protocol|Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result
215125956|NCT06278792|PROCEDURE|Standard of Care|Diuretic therapy at the discretion of the physician
215125957|NCT00704366|DRUG|AZD0530|oral, tablet, once daily, dose will be variable
215125958|NCT05041335|OTHER|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
215125959|NCT05041335|OTHER|Microsieve|A microsieve used for tissue preparation
215125960|NCT05041335|OTHER|No heparin flush|The needle not prepped
215125961|NCT05041335|OTHER|No microsieve|The tissue is placed into formalin
215125962|NCT05705466|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
215125963|NCT05705466|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
214523580|NCT06164041|BEHAVIORAL|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
214523581|NCT00862225|DRUG|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
214523582|NCT00862225|DRUG|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
214523583|NCT00862225|DRUG|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
214523584|NCT06446531|DRUG|Placebo|Oral tablet administered once daily
214523585|NCT06446531|DRUG|Rybelsus Tablet|Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
214523586|NCT06446531|DRUG|Jardiance 25Mg Tablet|Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
214523587|NCT06446531|DRUG|Metformin|Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
214523588|NCT06446531|DRUG|Actos|Oral tablet dosed at 15mg once daily
214523589|NCT00420797|DRUG|10% Phenylephrine hydrochloride gel|
214523590|NCT02146300|BIOLOGICAL|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
214523591|NCT04236622|OTHER|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
214523592|NCT00427297|DRUG|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
214694316|NCT07083089|OTHER|Thorough Hearing assessment|Otoscopy Tympanometry Tonal audiometry (air and bone conduction) Vocal audiometry (in silence and in noise) Distorsion Products of OtoAcoustic Emissions (DPOAE) Middle Ear Muscle Reflex (MEMR) Auditory Brainstem Response (ABR) Electrocochleography (EcochG)
215125964|NCT05705466|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
215125965|NCT00003419|PROCEDURE|antiviral therapy|
215125966|NCT01603589|PROCEDURE|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
214523593|NCT00427297|DRUG|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
214523594|NCT00427297|DRUG|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
214523595|NCT00427297|DRUG|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
214523596|NCT00427297|DRUG|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
214523597|NCT00427297|DRUG|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
214523598|NCT00427297|DRUG|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
214523599|NCT04340726|PROCEDURE|One time abutment|
214523600|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
214523601|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
215125967|NCT01603589|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
215125968|NCT00376792|DRUG|docetaxel|
214523602|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
215125969|NCT00376792|OTHER|active surveillance|
214523603|NCT00001436|DRUG|OncoLAR® (Registered Trademark)|
214523604|NCT00001436|DRUG|tamoxifen|
214523605|NCT01890798|DRUG|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
215125970|NCT00376792|PROCEDURE|adjuvant therapy|
215125971|NCT02910466|DRUG|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
215125972|NCT04037865|DRUG|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
215125973|NCT04816474|BEHAVIORAL|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
215125974|NCT04154475|DIETARY_SUPPLEMENT|yogurt diet|500 g yogurt/day
215125975|NCT04154475|DIETARY_SUPPLEMENT|dairy diet|500 g non-yogurt dairy products
215125976|NCT04154475|DIETARY_SUPPLEMENT|standard diet|500 g soya-yogurt
215125977|NCT04184570|OTHER|Observational Trial|Observational Trial
215125978|NCT00965250|DRUG|IMC-12|20 mg/kg intravenously once every three weeks
215125979|NCT01163526|PROCEDURE|CT perfusion|
215125980|NCT04387513|PROCEDURE|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
215125981|NCT02221869|DRUG|Xyrem|
215125982|NCT01808196|DRUG|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
215125983|NCT05297591|OTHER|assessment of UL function and prognostic factors|clinical assessments and questionnaires
214523606|NCT02230423|PROCEDURE|Nasal surgery|
214523607|NCT05610943|PROCEDURE|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
214523608|NCT05610943|PROCEDURE|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
214523609|NCT01689285|DRUG|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
214523610|NCT01689285|DRUG|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
215125984|NCT01366989|DEVICE|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
215125985|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
215125986|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
215125987|NCT00479713|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
215125988|NCT00479713|DRUG|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
215125989|NCT00479713|DRUG|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
215125990|NCT00479713|DRUG|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
215125991|NCT02664662|OTHER|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
215125992|NCT02226718|OTHER|Administration of questionnaire|
215125993|NCT02952885|DRUG|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
215125994|NCT00141102|DRUG|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
215125995|NCT00141102|DRUG|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
215125996|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
215125997|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
215125998|NCT06579950|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
215125999|NCT04315233|DRUG|Ribociclib|Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28
215126000|NCT04315233|DRUG|Belinostat|"Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules."
215126001|NCT06807151|PROCEDURE|Extracorporeal Treatment|Extracorporeal treatments in our study included hemoperfusion and continuous veno-venous hemodiafiltration.
215126002|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
215126003|NCT06311292|DEVICE|Volara System|Intrapulmonary percussive ventilation for mobilizing mucus.
215126004|NCT06347978|DEVICE|Deep Brain Stimulation|"Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks."
215126005|NCT05247086|DEVICE|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
215126006|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
215126007|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
215126008|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
214446884|NCT05780385|DEVICE|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
214446885|NCT06282289|BEHAVIORAL|Magnetoencephalography (MEG)|Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
214446886|NCT06282289|OTHER|Cognition development questionnaire|Computerised questionnaires completed by parents
214446887|NCT00102921|DRUG|CCX282-B|
214446888|NCT05767229|DRUG|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
214523611|NCT01998997|BEHAVIORAL|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
214523612|NCT04044820|DRUG|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
215126009|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
214523613|NCT05657418|DRUG|JS107|JS107, i.v., q3w
215126010|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
215126011|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
215126012|NCT04726722|BEHAVIORAL|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
215126013|NCT03009851|BEHAVIORAL|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
215126014|NCT05626530|DRUG|Letermovir|Open label 480 mg given daily for 60 days
215126015|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
215126016|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
214523614|NCT05657418|COMBINATION_PRODUCT|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
214694317|NCT06509789|DEVICE|Transcranial magnetic stimulation (TMS) - Theta burst stimulation (TBS) protocol|This procedure uses magnetic fields to stimulate nerve cells in the brain involved in various neurological functions, such as motor control. Theta burst stimulation is a patterned form of TMS protocol.
214694318|NCT05617898|BEHAVIORAL|Motivational Interviewing|Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
215126017|NCT05233033|DRUG|KT-413|KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
215126018|NCT03400475|DRUG|Simvastatin|One topical application in peri-implant gingival crevice
214523615|NCT02411253|DRUG|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
214523616|NCT02411253|DRUG|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
214523617|NCT05099978|GENETIC|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
214523618|NCT04075097|BEHAVIORAL|Aerobic exercise|1 session
214523619|NCT04075097|BEHAVIORAL|Iyengar yoga|1 session
214523620|NCT05319756|DRUG|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
214523621|NCT05319756|DRUG|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
214523622|NCT05319756|DRUG|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
214523623|NCT05319756|DRUG|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
214523624|NCT05319756|DRUG|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
214523625|NCT05319756|DRUG|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
214694319|NCT05617898|BEHAVIORAL|Nutrition Didactic Training|The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
214694320|NCT00228969|DRUG|RWJ-333369|
215126019|NCT03400475|OTHER|Placebo|One topical application in peri-implant gingival crevice
215126020|NCT00966511|PROCEDURE|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
215126021|NCT06915207|DIETARY_SUPPLEMENT|Counselling, behavioural, nutrition|integrative medical care delivered by one physician and referral to other health professionals as appropriate
215126022|NCT06867289|DEVICE|EEG|EEG monitoring will be performed in addition to the usual practice, before DEX administration and for 20 minutes before NMRI, to enable calculation of the PSI sedation score (at 0, 10, 20 minutes). Sedation will also be assessed by the PSSS clinical score at 0, 10, 20 minutes after DEX administration, as well as at 150 minutes after DEX.
215126023|NCT06613724|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
215126024|NCT01347528|BEHAVIORAL|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
215126025|NCT06692140|DEVICE|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)|Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
215126026|NCT06692140|DEVICE|PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
215126027|NCT06727435|DRUG|non-sedation strategy|Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
215126028|NCT06726564|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
215126029|NCT06726967|DIAGNOSTIC_TEST|vitamin D 25(OH)D|Thyroid functions (thyroid-stimulating hormone (TSH), serbest triiodothyronine (fT3), serbest thyroxine (fT4)); Thyroid antibodies (Anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG))
215126030|NCT06725628|DIAGNOSTIC_TEST|Thy_CLNM_multi_omics|Surgery
215126031|NCT06726005|DEVICE|functional appliance twin block|3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
215126032|NCT06725836|PROCEDURE|Implantation of electrodes into the epidural space for spinal cord stimulation|Under X-ray guidance and with neurophysiological supervision, the electrode is implanted. The stimulator is surgically placed in a pocket formed in the iliac crest area on the left side, where it is secured. The generator is connected to an electrode array positioned on the dorsal epidural surface of the spinal cord at the appropriate level (sacral-lumbar/cervical region), as confirmed by intraoperative fluoroscopy.
214446889|NCT06005129|BEHAVIORAL|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
214446890|NCT05228197|DIAGNOSTIC_TEST|Biopsy & Imaging|H\&E stained prostate biopsy slides from standard of care treatment
214446891|NCT01918683|RADIATION|TACE transarterial chemoembolization|
214446892|NCT01918683|RADIATION|stereotatic body radiotherapy (SBRT)|
214446893|NCT05555290|COMBINATION_PRODUCT|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
214446894|NCT05555290|COMBINATION_PRODUCT|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
214446895|NCT03235271|DEVICE|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
214446896|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214446897|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214446898|NCT06572618|DRUG|Nemtabrutinib|Given PO
214446899|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
214446900|NCT06572618|BIOLOGICAL|Rituximab|Given IV
214446901|NCT04422899|DRUG|AIV007|intravitreal
214446902|NCT02249949|DRUG|efatutazone|Given PO
214446903|NCT04256759|DRUG|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
214523626|NCT06399003|BIOLOGICAL|SIBP MMR Vaccine|This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.
214523627|NCT06399003|BIOLOGICAL|GSK MMR Vaccine (PRIORIX)|PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.
215126033|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for spastic syndrome suppression|During the selection of the optimal stimulation program for spasticity suppression, spinal cord stimulation (SCS) is performed at various sites on the electrode array. Stimulation is initiated at a specific site with a frequency of 60 Hz, and the intensity is gradually increased until the spasticity is alleviated (i.e., the limb can flex and extend without restriction). If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is again adjusted from 0 to comfortable values. Stimulation is sequentially applied at different sites, and those sites where muscle spasticity is most effectively suppressed are selected.
215126034|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for volitional motor control|Over the course of two weeks, the configuration of the electrodes and the intensity of the stimulation are adjusted to ensure optimal voluntary muscle control. A systematic approach is used to determine the most suitable settings. First, the anodes and cathodes on the electrode array are identified. The desired frequency range is 20-40 Hz. The pulse width is determined empirically. The adjustment begins at 20 Hz, with the stimulation intensity gradually increased. If unpleasant sensations (such as muscle spasms or pain) occur, the intensity is reduced to comfortable values. If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is adjusted again from 0 to comfortable levels. Stimulation is sequentially applied at different sites, with the sites that provide the most effective voluntary muscle control being selected.
215126035|NCT06725836|DIAGNOSTIC_TEST|Resting electroencephalography for identifying neurocorrelates of spinal cord stimulation.|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. Initially, the participant is recorded in a resting state before the implantation of the stimulator for 20 minutes (5 minutes with eyes open, followed by 5 minutes with eyes closed). After the surgery, the participant is recorded in the same manner before the first activation of the stimulator. After selecting the programs, the participant is recorded without stimulation (eyes open, then closed), followed by recordings with the spinal cord stimulator (SCS) activated (eyes open, then closed). The stimulation is then turned off again, and recording is conducted with eyes open and closed. Before discharge, the participant is recorded in a resting state for 20 minutes with the stimulation program active.
215126036|NCT06725836|DIAGNOSTIC_TEST|Electroencephalography within the motor imagery paradigm|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. During the experiment, with the stimulator turned off, the participant views a fixation cross on a computer screen. Then, they hear an auditory signal and see a sign indicating a specific movement (complete flexion and extension of the left arm, complete flexion and extension of the right arm, complete flexion and extension of the left leg, complete flexion and extension of the right leg). The participant imagines the movements according to the auditory and visual signals on the screen. Subsequently, the participant performs the same movements in the same order. The motor control stimulation program is then activated, and the entire sequence is repeated (first imagining the movement, then performing the imagined movements). The timing of the command presentations is recorded with marker placements.
215126037|NCT06725381|DRUG|SKB571|SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
215126038|NCT06705543|GENETIC|multi-omics genetic analyses included exome|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit. These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study.~* Trio exome study (parents-fetus)."
215126039|NCT06705543|GENETIC|multi-omics genetic analyses|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit; These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study."
215126040|NCT05776251|DEVICE|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
215126041|NCT06718543|DRUG|AK112 with SCRT and CapeOX|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally).
215126042|NCT06718543|DRUG|AK112 with SCRT|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion).
215126043|NCT06726525|DEVICE|HPMC+GlicoPro eyedrops|HPMC+GlicoPro eyedrops, artificial tears for dry eye disease
215126044|NCT06726525|DEVICE|Hydroxypropyl-methylcellulose|Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease
215126045|NCT06727019|DEVICE|low-level red-light|650-nm low-level red-light
215126046|NCT06727019|DRUG|Atropine (0.01%)|Atropine eye drops at concentration of 0.01%
214523628|NCT06399003|BIOLOGICAL|Yellow Fever Vaccine (Stamaril)|This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
214523629|NCT06214754|PROCEDURE|PCI|The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
214523630|NCT03324048|OTHER|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
214523631|NCT00002792|DRUG|busulfan|
214523632|NCT00002792|DRUG|cyclophosphamide|
214523633|NCT00002792|DRUG|cyclosporine|
214523634|NCT00002792|DRUG|methotrexate|
214523635|NCT00002792|DRUG|tacrolimus|
214446904|NCT06374979|BIOLOGICAL|Ixekizumab|Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
214446905|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
214523636|NCT00002792|PROCEDURE|allogeneic bone marrow transplantation|
214523637|NCT00002792|PROCEDURE|peripheral blood stem cell transplantation|
214523638|NCT05574244|PROCEDURE|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
214523639|NCT05574244|PROCEDURE|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
215126047|NCT06885879|RADIATION|Temporal change of fragmentomics of Circulating tumour DNA undergoing Stereotactic Body Radiation Therapy investigation|"Patients will have blood taking for Circulating tumour DNA (ctDNA) (20cc each) at Week 0 (before radiotherapy), Week 1 (during radiotherapy), Week 2 (after radiotherapy), Week 12 and Week 24.~Radiological assessment will be performed before radiotherapy, Week 12 (approximately 3 months post treatment) and Week 24-26 (approximately 6 months post treatment)."
214446906|NCT06477263|DEVICE|Neurocytotron|Neuronal regeneration treatment
214446907|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
214446908|NCT01783626|DEVICE|Evodial|
214446909|NCT01783626|DEVICE|Evodial+ Condition B1|
214446910|NCT01783626|DEVICE|Evodial+ Condition B2|
214446911|NCT01783626|DEVICE|Evodial+ Condition C|
214446912|NCT06298006|OTHER|Follow-up|Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
214446913|NCT04713683|DEVICE|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
214446914|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
214446915|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
214446916|NCT02867384|DRUG|Obinutuzumab|B cell depletion
214446917|NCT02867384|DRUG|Placebo|Placebo
214446918|NCT06011733|OTHER|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
214523640|NCT01803828|DRUG|Tadalafil|20 mg/die (1 capsule)
215126048|NCT02647723|DIETARY_SUPPLEMENT|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
215126049|NCT02647723|DIETARY_SUPPLEMENT|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
215126050|NCT06760364|DRUG|CHT102|CHT 102 : MSLN UCAR-T.
215126051|NCT01806142|OTHER|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
215126052|NCT01806142|OTHER|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
214446919|NCT06011733|DRUG|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
214446920|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
214523641|NCT01803828|DRUG|Placebo|Placebo 20 mg/die (1 capsule)
214523642|NCT00422162|DRUG|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
214523643|NCT00422162|DRUG|Placebo|placebo capsule by mouth
214523644|NCT00393185|BIOLOGICAL|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
214523645|NCT03562702|OTHER|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
214523646|NCT03562702|OTHER|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
214523647|NCT03703999|DEVICE|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
214523648|NCT00003697|DRUG|vadimezan|
214523649|NCT05159726|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
214523650|NCT02064335|BEHAVIORAL|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
214523651|NCT00144937|DRUG|Stepwise therapy for dyslipidemia, hypertension and diabetes|
214523652|NCT00144937|BEHAVIORAL|Dietary recommendations|
214523653|NCT00144937|BEHAVIORAL|Increase in physical activity|
214523654|NCT00144937|BEHAVIORAL|Smoking cessation|
214523655|NCT00038376|DRUG|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
214523656|NCT00038376|DRUG|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
214523657|NCT05048407|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
214523658|NCT00075699|DRUG|cisplatin|
214523659|NCT00075699|DRUG|mitomycin C|
214523660|NCT00075699|DRUG|vincristine sulfate|
214523661|NCT00075699|DRUG|vinorelbine tartrate|
214523662|NCT00075699|PROCEDURE|pain therapy|
214523663|NCT00075699|PROCEDURE|psychosocial assessment and care|
214523664|NCT00075699|PROCEDURE|quality-of-life assessment|
214523665|NCT05658445|OTHER|evacuation|after complete evacuation of uterus follow abortion
214523666|NCT03803488|DEVICE|DropSafe safety pen needle|
214523667|NCT00640354|DEVICE|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
214523668|NCT00640354|DEVICE|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
214523669|NCT06249594|PROCEDURE|targeted sensory reinervation|targeted sensory reinnervation (TSR) in hand amputation by using and reactivation of existing nerves to treat and prevent phantom pain
214523670|NCT05142553|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
214523671|NCT05142553|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
214523672|NCT06645691|DRUG|Hyperpolarized 13C-pyruvate|Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner
214523673|NCT05815693|BEHAVIORAL|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
214523674|NCT00950430|DRUG|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
214523675|NCT00950430|DRUG|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
214523676|NCT00950430|DRUG|Tau (18-F-AV-1451)|"1. PIB PET scan, Tau PET scan and/or FDG PET scan~2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
214523677|NCT02468037|PROCEDURE|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
214523678|NCT03245996|DEVICE|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
214523679|NCT03245996|DEVICE|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
214523680|NCT03245996|DEVICE|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
214523681|NCT03245996|DRUG|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
214523682|NCT03245996|DRUG|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
214523683|NCT03245996|DRUG|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
214523684|NCT06647368|OTHER|PET with 18-FDG|The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
214523685|NCT03287947|DRUG|nintedanib|Oral nintedanib, taken twice daily
214523686|NCT04609579|DRUG|SNX281|SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
214523687|NCT04609579|DRUG|pembrolizumab|pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
214523688|NCT03873922|OTHER|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
214523689|NCT06472882|DEVICE|tDCS targeting DLPFC|The anodic electrode will be placed on the left DLPFC (area F3) and the cathode on the right orbitofrontal cortex (area Fp2). Participants will receive 20 minutes of tDCS at 2 mA while seated.
214523690|NCT06472882|DEVICE|tDCS targeting M1|The anodes will be placed over C3 and C4 (according to EEG 10-20 system), and the cathodes over the ipsilateral shoulders. Participants will receive 20 minutes of tDCS at 2 mA while seated.
214523691|NCT06472882|DEVICE|SHAM tDCS|The electrodes will be placed as in the other conditions, but the stimulation will be switched off after 30 seconds, providing an initial stinging sensation without continuous stimulation.
214523692|NCT01973296|BEHAVIORAL|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
214523693|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
215126053|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
215126054|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
215126055|NCT06908044|DRUG|Bryophyllum|Bryophyllum Pinnatum - tablets, for 6 Months
215126056|NCT06921525|DRUG|Tea Tree Oil Topical Application Oil|Tea tree oil (TTO), derived from the leaves of Melaleuca alternifolia,
215126057|NCT06921525|DRUG|Azithromycin Ophthalmic Solution|Azithromycin has demonstrated efficacy in improving meibomian gland function and reducing inflammation and improving symptoms of dryness of the eye
215126058|NCT06922721|OTHER|Focus group|"The Well-Being Coffee Group intervention is implemented in two formats: in person and others via videoconference, all facilitated by the same psychologist throughout the study. Across all formats, participation is voluntary and follows an information phase and the signing of an informed consent form. Participants will complete standardized evaluation questionnaires at multiple time points. The discussion groups are designed to create a supportive and open environment that encourages free expression. Their goal is to provide participants with a space to share their thoughts, emotions, and personal experiences, as well as to reflect on those emerging from group discussions. Topics explored include identity, substance use, migratory experiences, and mental health, fostering meaningful dialogue and mutual support."
214446921|NCT05061095|OTHER|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
214446922|NCT05061095|OTHER|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
214446923|NCT02386735|DRUG|Placebo|Three days prednisone 40mg, two days placebo
214446924|NCT02386735|DRUG|Prednisone|Five days prednisone 40mg.
214446925|NCT06051292|OTHER|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
214446926|NCT06051292|OTHER|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
214446927|NCT03414814|DRUG|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
214446928|NCT05050279|DRUG|Delgocitinib capsule|oral capsule
214446929|NCT05050279|DRUG|Placebo capsule|oral capsule
214446930|NCT05219487|DRUG|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
214446931|NCT03607513|DRUG|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
214446932|NCT03607513|DRUG|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
214446933|NCT06319716|BEHAVIORAL|Video-Based Diabetes Self-Management Education and Support (DSMES)|The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.
214523694|NCT05797116|OTHER|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
214523695|NCT03556345|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
214523696|NCT04933188|DIAGNOSTIC_TEST|Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure|Baseline and follow-up examination of echocardiography is to be performed on study subjects.
215126059|NCT06921005|OTHER|Exercise|Recovery with vascular occlusion or active recovery in soccer players.
214446934|NCT06319716|BEHAVIORAL|Community Health Worker (CHW) Support|CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.
214523697|NCT01436604|OTHER|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
214523698|NCT04074304|OTHER|I-HoME|A multi-component technology-based care intervention.
214523699|NCT04303598|DRUG|FNC|3mg, 1 tablet，QD
214446935|NCT05912569|PROCEDURE|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
214446936|NCT04716712|DRUG|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
214523700|NCT04303598|DRUG|3TC|300mg, 1 tablet，QD
215126060|NCT06921577|COMBINATION_PRODUCT|antimicrobial agent|Adding nanoparticles to 3Dprinted denture base resin improve the properties of the material
215126061|NCT06914011|DRUG|Tislelizumab|"* Participants who underwent upfront surgery without prior neoadjuvant therapy:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for one cycle~ * Concurrent radiotherapy (25 fractions of 1.8 Gy each, with 5 fractions per week) with Tislelizumab 200 mg iv D1, D22, Paclitaxel 50 mg/m2 iv D1, 8, 15, 22, 29, and Carboplatin AUC 2 mg/mL/min D1, 8, 15, 22, 29~ * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for 1 cycle~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles~* For participants who underwent neoadjuvant chemoradiotherapy followed by surgery will receive adjuvant chemoimmunotherapy in the following sequence:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for four cycles~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles"
215126062|NCT06920589|BEHAVIORAL|"Safe and Protected Sex intervention targeting HPV"|"This study used the Safe and Protected Sex intervention (Báez et al., 2019), adapted and validated from an HIV prevention program to focus on HPV. The intervention consists of a single module with two stages aimed at increasing HPV knowledge by enhancing personal (self-determination) and social (controlled behavior) motivation.~Module 1: Nursing Consultation on HPV This structured, planned process follows Corona and Kaltmeier's (2012) horizontal methodology, promoting self-care through social support and trust in nurse-patient dialogue. The goal is to provide counseling on HPV prevention and responsible sexual behavior while acknowledging participants' prior knowledge.~Stage 1: A 4.21-minute educational video, HPV Fun Facts, uses persuasive narrative to explain HPV transmission, symptoms, complications, and prevention.~Stage 2: A 45-minute Friendly Educational Guidance session uses open-ended questions to explore participants' experiences."
214446937|NCT04716712|DRUG|Placebo|Matching identical placebo in packaging, appearance, and taste.
214446938|NCT05340816|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
214446939|NCT05340816|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
214446940|NCT03218904|DIETARY_SUPPLEMENT|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
214446941|NCT03218904|DIETARY_SUPPLEMENT|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
214446942|NCT03994627|DRUG|Olaratumab|Administered intravenously (IV)
214446943|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
214446944|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
214446945|NCT04044690|DRUG|human immunoglobulin G|human immunoglobulin G administered subcutaneously
214446946|NCT04044690|DRUG|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
214446947|NCT05766371|DRUG|Pembrolizumab|Given IV
214446948|NCT05766371|DRUG|177Lu-PSMA-617|Given IV
214446949|NCT05196061|OTHER|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~1. Age~2. Sex~3. Race~4. Ethnicity"
214523701|NCT04303598|DRUG|TDF|300mg, 1 tablet，QD
214523702|NCT04303598|DRUG|EFV|200mg, 1 tablet，QD
214523703|NCT04303598|DRUG|FNC placebo|1 tablet，QD
214523704|NCT04303598|DRUG|3TC placebo|1 tablet，QD
214523705|NCT06014788|DEVICE|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
214523706|NCT06014788|DEVICE|Conventional NPWT|Conventional NPWT
214523707|NCT00214162|BEHAVIORAL|Comprehensive Health Enhancement Support System|Full CHESS
214523708|NCT00214162|BEHAVIORAL|computer with internet|computer with internet use x 1 year
214523709|NCT06244888|BEHAVIORAL|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
214523710|NCT06244888|BEHAVIORAL|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
214523711|NCT06244888|BEHAVIORAL|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
214523712|NCT06244888|BEHAVIORAL|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
214523713|NCT06266065|DEVICE|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
214523714|NCT04872465|DEVICE|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
215126063|NCT06920589|BEHAVIORAL|Diptych of the Secretary of Health in Mexico|a brochure is provided with general information about the human papilloma virus in men, including the form of contagion, diagnosis, treatment and the use of condoms for prevention.
215126064|NCT06922058|DEVICE|Virtual Reality Glasses|Virtual reality glasses haven\&#39;t used in orthodontics in another clinical study.
215126065|NCT01446627|OTHER|There is no intervention for this study|None, no intervention made.
215126066|NCT06151522|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
214523715|NCT04872465|DEVICE|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
215126067|NCT06151522|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
215126068|NCT06200753|PROCEDURE|Mechanical Thrombectomy|"Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury."
215126069|NCT06938178|OTHER|Mindfulness treatment|The Mindfulness treatment will consist of a series of 8 weekly meetings in small groups . An experienced therapist will guide patients and during the sessions they will be encouraged to close their eyes, assume a relaxed posture, focus on breathing and the present moment in order to improve awareness of mental and bodily sensations. Patients will also be encouraged to add a regular, practice at home of about 10 minutes to the group treatment. If necessary, patients in both groups can take the medication they normally take for acute events. These occurrences will be reported in the headache diary given to each subject. Before conducting the study protocol, the investigator will explain the study to each participant and collect a signed copy of the written informed consent. All participants will undergo a clinical, neurophysiological and neuropsychological evaluation before the first session and after the last. In both groups, the usual drug therapies in case of crisis will be allowed.
215126070|NCT06938087|DEVICE|3D printed prosthesis foot|Energy storage and restoration 3D printed prosthesis foot
215126071|NCT06938087|DEVICE|Current prosthesis foot|Energy storage and restitution prosthesis foot made in carbon fibers blades
215126072|NCT00002609|BIOLOGICAL|lintuzumab|
215126073|NCT00002609|DRUG|cytarabine|
215126074|NCT00002609|DRUG|idarubicin|
215126075|NCT02135510|DRUG|metoclopramide|
215126076|NCT02135510|DRUG|dexamethason|
215126077|NCT02135510|DRUG|palonosetron|
215126078|NCT00932581|OTHER|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
215126079|NCT00932581|OTHER|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
214523716|NCT01860222|PROCEDURE|SR|
214523717|NCT01860222|PROCEDURE|PLAT|
214523718|NCT03959735|OTHER|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
215126080|NCT03226925|DIAGNOSTIC_TEST|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
215126081|NCT03226925|DIAGNOSTIC_TEST|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
215126082|NCT03226925|DIAGNOSTIC_TEST|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
215126083|NCT05899374|BEHAVIORAL|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
215126084|NCT03787797|DIAGNOSTIC_TEST|Echocardiography|Assessment of epicardial adipose tissue thickness
215126085|NCT02817243|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
215126086|NCT02817243|DRUG|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
215126087|NCT06449495|DEVICE|NIRVANA|"NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection."
215126088|NCT05354271|OTHER|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
215126089|NCT05354271|OTHER|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
214446950|NCT05196061|OTHER|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
214446951|NCT05196061|OTHER|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
214446952|NCT05196061|OTHER|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
214446953|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214446954|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
214446955|NCT01351805|OTHER|placebo pill|placebo
214446956|NCT05006430|BIOLOGICAL|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
214446957|NCT05006430|OTHER|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
214446958|NCT05911100|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
214446959|NCT05911100|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
214446960|NCT05911100|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
214446961|NCT05911100|DIAGNOSTIC_TEST|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
214446962|NCT05911100|OTHER|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
214446963|NCT05911100|DIAGNOSTIC_TEST|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
214446964|NCT05911100|OTHER|Indicators characterizing the severity of the underlying disease|"* Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~* Medications taken."
214446965|NCT06208657|DRUG|Paxalisib, Irinotecan, Temozolomide|Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
214523719|NCT05990309|DIAGNOSTIC_TEST|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
214523720|NCT03022747|DRUG|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
214523721|NCT03022747|DRUG|Standard treatment|Oral 6-mercaptopurine and methotrexate
214523722|NCT04004169|DEVICE|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
214523723|NCT04004169|DEVICE|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
214523724|NCT04004169|DEVICE|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
214523725|NCT00639639|BIOLOGICAL|tetanus toxoid|Given by injection
214523726|NCT00639639|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
214523727|NCT00639639|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214523728|NCT03981120|PROCEDURE|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
214523729|NCT05074004|OTHER|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
214523730|NCT05199597|DRUG|0.01% atropine|0.01%, room temp, Lab A
214523731|NCT05199597|DRUG|0.05% atropine|0.05%, room temp, Lab A
214523732|NCT05199597|DRUG|0.05% atropine|0.05%, refrigerated, Lab A
214523733|NCT05199597|DRUG|0.05% atropine|0.05%, room temperature, Lab B
214523734|NCT04390971|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
214523735|NCT00448786|DRUG|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
214523736|NCT00448786|DRUG|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
214523737|NCT00448786|DRUG|AMG 706|AMG 706 125 mg daily continuously (Arm A)
214523738|NCT03078699|RADIATION|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
214523739|NCT05255276|DRUG|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
214523740|NCT05255276|DRUG|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
214523741|NCT05255276|DRUG|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
214523742|NCT05255276|DRUG|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
214523743|NCT00166361|DEVICE|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
214523744|NCT00166361|DEVICE|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
214523745|NCT02623101|DEVICE|Reflectance confocal microscopy|Non-invasive imaging of the lesion
214523746|NCT02623101|PROCEDURE|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
214523747|NCT02623101|PROCEDURE|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
214523748|NCT01047306|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
214523749|NCT05390697|OTHER|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
214523750|NCT01304953|DRUG|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
215126090|NCT01871519|DEVICE|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
215126091|NCT05160896|DRUG|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
215126092|NCT05160896|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
215126093|NCT05160896|DRUG|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
215126094|NCT05160896|DRUG|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
215126095|NCT00056953|BEHAVIORAL|Peer mentoring program|
214523751|NCT01304953|DRUG|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
214523752|NCT01304953|DRUG|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
214446966|NCT04646707|DRUG|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
214446967|NCT04646707|DRUG|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
214446968|NCT06238323|BEHAVIORAL|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
214446969|NCT05183477|OTHER|fast track|short cut for the request of xrays directly at triage
214446970|NCT05183477|OTHER|normal pathway|x-ray would be required according to doctor's clinical evaluation.
214446971|NCT05328531|DRUG|Genakumab for Injection|150 mg/1ml/bottle
214446972|NCT05328531|DRUG|Placebo for Genakumab for Injection|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
214446973|NCT05142423|DRUG|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
214446974|NCT05650710|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
214446975|NCT06146218|BEHAVIORAL|Contemplative-Based Resilience Training (CBRT)|The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
214446976|NCT05581173|DEVICE|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
214446977|NCT03468426|DRUG|BI 836880|intra-venous infusion
214446978|NCT03468426|DRUG|ezabenlimab|intra-venous infusion
214446979|NCT05119985|PROCEDURE|Peripheral vein cannulation|The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance
214446980|NCT05119985|PROCEDURE|Cannulation without ultrasound|Cannulation is done the conventional way without any ultrasound use.
214446981|NCT06267742|DIAGNOSTIC_TEST|Complete Blood Count (CBC) with Differential|CBC with Differential including Monocyte Distribution Width (MDW)
214446982|NCT04221750|BEHAVIORAL|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
214446983|NCT04221750|DRUG|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
214446984|NCT04221750|DRUG|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
214446985|NCT04221750|BEHAVIORAL|Healthy Lifestyle|Group educational sessions that focus on healthy diet, exercise, and social support once a month
214446986|NCT02158858|DRUG|Pelabresib (CPI-0610)|
214446987|NCT02158858|DRUG|Ruxolitinib|
214446988|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
214446989|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
214446990|NCT05500508|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
214446991|NCT05500508|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
214523753|NCT01304953|DRUG|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
214523754|NCT01543009|OTHER|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
215126096|NCT00794950|DRUG|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
215126097|NCT02485704|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
215126098|NCT02485704|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
215126099|NCT02187068|DRUG|Dexmedetomidine|Dexmedetomidine administered intravenously
214523755|NCT00652496|DRUG|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
214523756|NCT00652496|DRUG|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
214523757|NCT00652496|DRUG|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
214523758|NCT00652496|DRUG|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
214523759|NCT00652496|DRUG|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
214523760|NCT03664271|BEHAVIORAL|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
214523761|NCT03664271|BEHAVIORAL|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
214523762|NCT03856424|PROCEDURE|Modality 1|Pressure support ventilation (PSV) modality
214523763|NCT03856424|PROCEDURE|Modality 2|T-Piece modality
214523764|NCT03856424|PROCEDURE|Modality 3|High-flow oxygen
215126100|NCT05065151|OTHER|Stimulation on|Stimulation from Percept DBS will be on while the patient is playing a decision-making game on a computer-based application.
215126101|NCT05065151|OTHER|Stimulation off|Stimulation from Percept DBS will be off while the patient is playing a decision-making game on a computer-based application.
214523765|NCT01452204|OTHER|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
214523766|NCT03613571|DRUG|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
214523767|NCT02259296|PROCEDURE|Lower eGFR for AVF construction|Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
214523768|NCT02259296|PROCEDURE|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
214523769|NCT05742256|DRUG|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
214523770|NCT05742256|DRUG|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
214523771|NCT05742256|DRUG|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
214523772|NCT02538055|BEHAVIORAL|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
214523773|NCT02538055|BEHAVIORAL|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
214523774|NCT02053402|DRUG|Vitamin D|Vitamin D daily for six months
214523775|NCT04627259|OTHER|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
215126102|NCT05065151|BEHAVIORAL|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
215126103|NCT02806453|DIETARY_SUPPLEMENT|thickened formula|
215126104|NCT02806453|DIETARY_SUPPLEMENT|Mg alginate|
214446992|NCT03405740|DEVICE|Remote Patient Management|"1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access"
214446993|NCT03405740|DEVICE|Standard of Care|No intervention
214446994|NCT06637137|DRUG|Iron|Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
214446995|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Sham|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.
214446996|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
214446997|NCT05310253|DRUG|Fludrocortisone|pill of fludrocortisone
214446998|NCT05310253|DRUG|Placebo|placebo pill
214446999|NCT05310253|BEHAVIORAL|Trier Social Stress Test (TSST)|psychosocial stress induction
214447000|NCT05310253|BEHAVIORAL|Placebo Trier Social Stress Test (P-TSST)|control condition
214447001|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
214447002|NCT03705403|DRUG|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
214447003|NCT03705403|RADIATION|Radiation|Radiotherapy
214447004|NCT04941157|PROCEDURE|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
214447005|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
214447006|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
214447007|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
214447008|NCT03822845|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
214447009|NCT06527313|BEHAVIORAL|Movement Mobilization Concept, Exercise and Tape|Mulligan Concept MWM Mulligan Taping Mulligan Self Home Workout
214447010|NCT06527313|BEHAVIORAL|Sham Movement Mobilization Concept, Exercise and Tape|The technique will be applied to cases in the sham group with only hand contact, without any slippage or rotation in any direction. Then, rigid taping will be applied without any tension or direction, and home exercises will be given.
214447011|NCT06527313|BEHAVIORAL|Special Exercises|"Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips"
214523776|NCT03097458|BEHAVIORAL|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
214523777|NCT00722488|DRUG|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
214447012|NCT03705741|BEHAVIORAL|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
214447013|NCT05633407|DRUG|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
214447014|NCT05633407|DRUG|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
214447015|NCT02500758|PROCEDURE|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
214447016|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
214523778|NCT04038034|DIETARY_SUPPLEMENT|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
214523779|NCT04038034|DIETARY_SUPPLEMENT|Placebo|Placebo
214523780|NCT00538616|DRUG|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
215126105|NCT02806453|BEHAVIORAL|reassurance with lifestyle changes|
215126106|NCT01706523|DRUG|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
215126107|NCT00902460|DRUG|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
215126108|NCT00902460|DRUG|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
215126109|NCT06128577|COMBINATION_PRODUCT|3-month intensive intervention|"Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week."
215126110|NCT04737018|OTHER|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
215126111|NCT04737018|OTHER|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
215126112|NCT04737018|OTHER|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
215126113|NCT04737018|OTHER|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
215126114|NCT04737018|OTHER|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
215126115|NCT04737018|OTHER|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
215126116|NCT04737018|DEVICE|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
215126117|NCT04737018|OTHER|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
215126118|NCT04737018|OTHER|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
215126119|NCT04936633|OTHER|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~\- Intervention contents~1. Diet, exercise pattern~2. Causes of hypoglycemia~3. Causes of hyperglycemia~4. Causes of glycemic variability~5. Counseling for improvement plans for the cause~6. Counseling to strengthen lifestyle modification~7. Counseling for insulin administration~8. Counseling for Insulin dose adjustment (adjusted dose)~9. Counseling for how to use a FSGM"
215126120|NCT04776512|PROCEDURE|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
215126121|NCT04776512|PROCEDURE|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
215126122|NCT05144139|BIOLOGICAL|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
215126123|NCT03522792|OTHER|Neurotensin|Intravenous infusion of neurotensin
215126124|NCT03522792|OTHER|Saline|Intravenous infusion of saline
215126125|NCT03522792|OTHER|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
215126126|NCT03522792|OTHER|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
215126127|NCT00727792|PROCEDURE|MRI -Clinical|MRI done is standard of care
215126128|NCT00727792|PROCEDURE|MRI-Research|MRI includes extra sequences
215126129|NCT05309148|BEHAVIORAL|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
215126130|NCT05309148|BEHAVIORAL|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
214523781|NCT00538616|DRUG|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
214523782|NCT06009770|DEVICE|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
214523783|NCT06009770|BEHAVIORAL|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
214523784|NCT00000121|DEVICE|Prisms in Eyeglasses|
214523785|NCT00274846|BIOLOGICAL|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
215126131|NCT05309148|BEHAVIORAL|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
215126132|NCT04382742|BEHAVIORAL|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
215126133|NCT06009055|DRUG|Remimazolam|0.3mg/kg，injection completed in 30 seconds
215126134|NCT06009055|DRUG|Propofol|2mg/kg，injection completed in 30 seconds
215126135|NCT03603483|PROCEDURE|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
215126136|NCT02649556|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
214523786|NCT00274846|BIOLOGICAL|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
214523787|NCT00274846|DRUG|cyclophosphamide|Days -5 and -4: 60 mg/kg
214523788|NCT00274846|DRUG|fludarabine phosphate|Days -5 through -2: 25 mg/m\^2
214523789|NCT00274846|PROCEDURE|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
214523790|NCT03770299|BIOLOGICAL|Nivolumab|Specified dose on specified days
214523791|NCT03770299|DRUG|Vinorelbine|Specified dose on specified days
214523792|NCT03770299|DRUG|Gemcitabine|Specified dose on specified days
214523793|NCT03770299|DRUG|Docetaxel|Specified dose on specified days
214447017|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
214523794|NCT03770299|DRUG|Pemetrexed|Specified dose on specified days
214523795|NCT03770299|DRUG|Cisplatin|Specified dose on specified days
214523796|NCT03770299|DRUG|Carboplatin|Specified dose on specified days
214523797|NCT03770299|DRUG|Paclitaxel|Specified dose on specified days
214523798|NCT03770299|OTHER|Observation|Observation by the investigator
214523799|NCT00187122|DRUG|Vincristine|See Detailed Description section for description of treatment plan.
214523800|NCT00187122|PROCEDURE|Radiation Therapy|See Detailed Description section for description of treatment plan.
214523801|NCT00187122|DRUG|Daunomycin|See Detailed Description section for description of treatment plan.
215126137|NCT02649556|OTHER|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
215126138|NCT02866227|DRUG|TOL-463|TOL-463 vaginal gel
214447018|NCT05308069|DEVICE|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
214447019|NCT05308069|DEVICE|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
214523802|NCT00187122|DRUG|L-Asparaginase|See Detailed Description section for description of treatment plan.
214523803|NCT00187122|DRUG|Cytarabine|See Detailed Description section for description of treatment plan.
214523804|NCT00187122|DRUG|Methotrexate|See Detailed Description section for description of treatment plan.
214523805|NCT00187122|DRUG|Mercaptopurine|See Detailed Description section for description of treatment plan.
214523806|NCT00187122|DRUG|Etoposide|See Detailed Description section for description of treatment plan.
214523807|NCT00187122|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
214523808|NCT00187122|DRUG|Prednisone|See Detailed Description section for description of treatment plan.
214523809|NCT00187122|DRUG|Dexamethasone|See Detailed Description section for description of treatment plan.
214523810|NCT05168696|OTHER|Virtual Reality Glasses|Virtual Reality Glasses
214523811|NCT03027999|OTHER|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7"
214523812|NCT05416970|BEHAVIORAL|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
214523813|NCT01670747|RADIATION|Chest computed tomography|
214523814|NCT05788406|OTHER|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
214523815|NCT02578628|OTHER|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
214523816|NCT01001637|DIETARY_SUPPLEMENT|Curcumin Formulation|2000mg or 3000mg daily BID
214523817|NCT01001637|DIETARY_SUPPLEMENT|Placebo|Placebo
214523818|NCT02524951|DRUG|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
215126139|NCT02866227|DRUG|TOL-463|TOL-463 vaginal insert
215126140|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
215126141|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
215126142|NCT01209429|DRUG|GH hormone infusion|Norditropin 30 ng/kg/min
215126143|NCT01209429|BEHAVIORAL|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
215126144|NCT01209429|BEHAVIORAL|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
215126145|NCT03656991|OTHER|Bicycle intervention|
214523819|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
215126146|NCT02753166|DRUG|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
215126147|NCT03974048|DIAGNOSTIC_TEST|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
215126148|NCT01773681|DRUG|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
215126149|NCT01773681|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
215126150|NCT01773681|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
215126151|NCT00585481|PROCEDURE|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
215126152|NCT00585481|PROCEDURE|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
214447020|NCT05961020|DEVICE|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
214447021|NCT05961020|OTHER|moderate restricted diet|moderate restricted diet
214447022|NCT03979235|DIAGNOSTIC_TEST|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
214447023|NCT03007030|DRUG|Brentuximab Vedotin|Given IV
214447024|NCT03007030|OTHER|Laboratory Biomarker Analysis|Correlative studies
214447025|NCT05378256|OTHER|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
214447026|NCT06137560|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
214447027|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
214447028|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
214447029|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
214523820|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
214523821|NCT06035003|BEHAVIORAL|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214523822|NCT05582421|DRUG|Diclofenac Sodium|intracanal medication
214447030|NCT06137560|DEVICE|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
214523823|NCT01248663|PROCEDURE|antecolic reconstruction|see study arm description
214523824|NCT01248663|PROCEDURE|retrocolic reconstruction|see study arm description
214447031|NCT00530153|BEHAVIORAL|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
214447032|NCT00530153|DIETARY_SUPPLEMENT|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
214447033|NCT06217692|OTHER|nutrition education|nutrition education
214447034|NCT02498717|DEVICE|GameReady|Cryotherapy and compression
214447035|NCT02498717|OTHER|RICE|SOC ice and elevation
214447036|NCT06969040|OTHER|CBTI + tACS|CBTI + tACS group method: CBTI for about 50 minutes each time, for a total of 6 weeks: ① first interview: enrolment assessment; ② second interview: treatment initiation; ③ third interview: sleep titration and sleep hygiene; ④ fourth interview: sleep titration; ⑤ fifth-seventh interview: sleep titration; ⑥ eighth interview: sleep titration (end of standardised CBTI treatment. tACS true stimulation) : Transcranial alternating current therapy (tACS) was operated during the same period of CBTI, with 3 electrodes, placed in the prefrontal lobe and bilateral mastoid; the stimulation intensity was 77.5 Hz, 15 mA, 40 min each time, once a day, 5 days a week, for 6 weeks.
214447037|NCT06969040|OTHER|CBTI + Sham tACS|CBTI+sham tACS group method: CBTI treatment method was the same as before. tACS pseudo-stimulation: the electrode placement position, stimulation frequency, and time settings were the same as the real stimulation, and the stimulation process only had the output of gradual rising and falling current at the beginning and the last 10s, respectively, so as to make the subjects produce the same subjective feelings as the real stimulation.
214447038|NCT04575961|DRUG|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
214447039|NCT06967922|BEHAVIORAL|Analytic-Integrative Cognitive Behavioural Therapy|Analytic-Integrative Cognitive-Behavioural Approach: Initial Interview for Information Gathering: comprehensive collection of patient information; Assessment: collection of multidimensional factors; Diagnosis: insomnia and co-morbidities; Analytic-Integrative Analysis for Treatment Decision Making.
214447040|NCT06967922|OTHER|Sleep hygiene education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
215126153|NCT02836912|OTHER|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
214447041|NCT05269472|PROCEDURE|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
214523825|NCT01995253|DEVICE|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
214523826|NCT01995253|DEVICE|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
214523827|NCT04409132|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
215126154|NCT00670553|DRUG|panobinostat|
215126155|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
215126156|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
215126157|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
215126158|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
215126159|NCT04481243|BIOLOGICAL|Pneumovax 23- pneumococcal polysaccharide|PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
215126160|NCT04481243|PROCEDURE|Blood draw|6 ml blood draw at baseline and 6 months post immunization
215126161|NCT01131988|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
215126162|NCT02191462|DIETARY_SUPPLEMENT|Niagen 100mg|
215126163|NCT02191462|DIETARY_SUPPLEMENT|Niagen 300mg|
215126164|NCT02191462|DIETARY_SUPPLEMENT|Niagen 1000mg|
215126165|NCT00004858|BIOLOGICAL|B43-genistein immunoconjugate|
215126166|NCT00157885|DRUG|Amodiaquine plus artesunate; Artekin|
215126167|NCT02718079|BIOLOGICAL|Plasma Exchange|
215126168|NCT02718079|OTHER|Management of cerebral edema/intracranial hypertension:|
215126169|NCT02718079|OTHER|Transfer to Intensive Care Unit|
215126170|NCT02718079|DRUG|Prophylactic Antibiotics|
215126171|NCT02718079|OTHER|Intubation of trachea|
215126172|NCT02718079|OTHER|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
215126173|NCT02718079|OTHER|Volume Replacement|
215126174|NCT02718079|OTHER|Pressor Support|
215126175|NCT02718079|DRUG|N-acetyl-L-cysteine|
215126176|NCT02718079|OTHER|Correction of metabolic parameters|
215126177|NCT02718079|DIETARY_SUPPLEMENT|Correction of nutrition|
215126178|NCT01017484|OTHER|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
214523828|NCT02633345|DIETARY_SUPPLEMENT|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
215126179|NCT02152306|DRUG|Fimasartan and Amlodipine|
215126180|NCT02152306|DRUG|Fimasartan|
215126181|NCT05481775|DRUG|Anlotinib|Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
215126182|NCT05481775|DRUG|Chemotherapy|Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
215126183|NCT05481775|RADIATION|Radiotherapy|Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
214523829|NCT02633345|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214523830|NCT00812825|DRUG|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
214523831|NCT00812825|DRUG|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
214523832|NCT00812825|DRUG|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
214523833|NCT00812825|DRUG|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
214523834|NCT00812825|DRUG|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
214523835|NCT02971995|DEVICE|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
215126184|NCT05481775|DRUG|Immunotherapy|consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
215126185|NCT02153593|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
215126186|NCT02153593|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
215126187|NCT02153593|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
215126188|NCT03622008|DRUG|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
215126189|NCT03622008|OTHER|Placebo|Placebo IV
214523836|NCT02971995|DEVICE|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
214523837|NCT02860858|BIOLOGICAL|Intravitreous aflibercept injection|
215126190|NCT02321241|DRUG|Aflibercept (EYLEA, BAY-86-5321)|"1. st year: 3 monthly injections followed by 1 injection every two months~2. nd year and following: injection according the visual and anatomical results observed the 1st year"
214523838|NCT00737997|DRUG|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
214523839|NCT00737997|OTHER|Saline|10 ml saline alone
214523840|NCT03653689|DIETARY_SUPPLEMENT|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
215126191|NCT02413918|DRUG|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
215126192|NCT04813588|OTHER|Pantomiming|Pantomiming with fluency shaping techniques
215126193|NCT04813588|OTHER|Easy onset|Easy onset method with breathing exercises
215126194|NCT05697783|DRUG|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
215126195|NCT04985526|OTHER|Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)|Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
215126196|NCT04309292|DIETARY_SUPPLEMENT|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
215126197|NCT04309292|DIETARY_SUPPLEMENT|Protein supplement|commercially available protein supplementation with high leucine content
215126198|NCT04309292|DIETARY_SUPPLEMENT|Maltrodextrin (placebo)|Starchy substance
215126199|NCT02173769|DRUG|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
215126200|NCT02173769|DRUG|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
215126201|NCT00434538|DEVICE|BST-DermOn|
215126202|NCT04397510|DRUG|Heparin|Nebulized Heparin
215126203|NCT04397510|DRUG|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
215126204|NCT04388111|DRUG|Morphine|10mg of Morphine delivered Intraosseously
215126205|NCT00928486|DRUG|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
215126206|NCT00928486|DRUG|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
215126207|NCT00008008|BIOLOGICAL|filgrastim|
215126208|NCT00008008|BIOLOGICAL|sargramostim|
215126209|NCT00008008|DRUG|cyclophosphamide|
215126210|NCT00008008|DRUG|thiotepa|
215126211|NCT00008008|PROCEDURE|autologous bone marrow transplantation|
215126212|NCT00008008|PROCEDURE|bone marrow ablation with stem cell support|
215126213|NCT00008008|PROCEDURE|peripheral blood stem cell transplantation|
215126214|NCT01342913|DRUG|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
215126215|NCT01342913|DRUG|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
215126216|NCT06552273|BEHAVIORAL|Emotional Reasoning bias correction training|Emotional Reasoning Bias correction training involves 12 daily self-applied sessions focusing on psychoeducation about emotions and identifying ER biases and their impact on behaviour.
215126217|NCT06552273|BEHAVIORAL|Module of Mindfulness of the Transdiagnostic treatment|Module based on mindfulness using techniques for training in awareness and acceptance of experiences, observing experiences as they arise without judgment.
215126218|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
214447042|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
215126219|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
215126220|NCT05295849|BEHAVIORAL|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
215126221|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
215126222|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy combined with the local treatment of FES-negative lesions|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
215126223|NCT06195709|COMBINATION_PRODUCT|Chemotherapy|Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
215126224|NCT02701517|DRUG|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
214447043|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
214447044|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
214447045|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
214447046|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
214447047|NCT01309932|BIOLOGICAL|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
215126225|NCT02701517|DRUG|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
215126226|NCT03388034|PROCEDURE|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
215126227|NCT03388034|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
214447048|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
214447049|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
214447050|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
214447051|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
214523841|NCT03653689|DIETARY_SUPPLEMENT|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
215126228|NCT01105910|OTHER|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
215126229|NCT01105910|OTHER|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
215126230|NCT02682381|DRUG|Teduglutide 0.05mg/kg|0.05 mg/kg
215126231|NCT02682381|DRUG|Teduglutide 0.025 mg/kg|0.025 mg/kg
215126232|NCT02682381|OTHER|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
215126233|NCT05227456|DRUG|Etonogestrel 68mg implant|Implant will be inserted
215126234|NCT05227456|DEVICE|Etonogestrel 68mg implant|Implant will be inserted
214447052|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
214447053|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
214447054|NCT01309932|DRUG|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
214447055|NCT01309932|DRUG|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
214447056|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
214447057|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
214447058|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
214447059|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
214447060|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
214447061|NCT05386069|DRUG|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
214447062|NCT04999592|DRUG|Standard of care without prophylaxis|Administer antibiotics in response to infection
214447063|NCT04999592|DRUG|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
214523842|NCT03653689|DIETARY_SUPPLEMENT|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
214523843|NCT03681002|BEHAVIORAL|structured lifestyle program|Intensive Lifestyle counseling during one year
214523844|NCT01063127|OTHER|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
214523845|NCT01063127|OTHER|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
214523846|NCT05070637|PROCEDURE|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
215126235|NCT02300792|DIETARY_SUPPLEMENT|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
215126236|NCT02300792|DIETARY_SUPPLEMENT|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
214447064|NCT03162497|DRUG|Azithromycin|Azithromycin 15mg/g eyedrops
214447065|NCT03162497|DRUG|Doxycycline|Doxycycline 100 mg per os
214447066|NCT04756440|BEHAVIORAL|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
214447067|NCT03580200|OTHER|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
214447068|NCT00903474|OTHER|questionnaire administration|
214447069|NCT00903474|OTHER|study of socioeconomic and demographic variables|
214447070|NCT00903474|PROCEDURE|CAM exercise therapy|
214447071|NCT00903474|PROCEDURE|psychosocial assessment and care|
214523847|NCT05070637|PROCEDURE|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
214447072|NCT00903474|PROCEDURE|quality-of-life assessment|
214523848|NCT05070637|PROCEDURE|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
214523849|NCT01463397|DRUG|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
214523850|NCT01463397|DRUG|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
215126237|NCT00387881|DRUG|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
215126238|NCT00387881|DRUG|Placebo|Placebo to match Treximet tablets
215126239|NCT05490017|DRUG|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
215126240|NCT05490017|DRUG|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
215126241|NCT00436150|BEHAVIORAL|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
214447073|NCT00903474|PROCEDURE|stress management therapy|
214447074|NCT06074354|BEHAVIORAL|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
214447075|NCT06074354|BEHAVIORAL|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
214447076|NCT05179395|DEVICE|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
214447077|NCT05486598|DRUG|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
214447078|NCT01388777|DEVICE|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
214447079|NCT01388777|PROCEDURE|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
214447080|NCT01388777|PROCEDURE|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
214447081|NCT00084552|RADIATION|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
214447082|NCT02421159|BEHAVIORAL|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
214447083|NCT02421159|BEHAVIORAL|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
214447084|NCT00616031|DRUG|carboplatin|
214523851|NCT03710850|DIETARY_SUPPLEMENT|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
214447085|NCT00616031|DRUG|nitroglycerin|
214447086|NCT00616031|DRUG|paclitaxel|
214447087|NCT04092205|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
214447088|NCT00000675|DRUG|CD4-IgG|
214447089|NCT06589258|BIOLOGICAL|Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding|Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
214447090|NCT05110053|DEVICE|Spinal Cord Stimulation|"Spinal Cord stimulation. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
214447091|NCT05413629|OTHER|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
214447092|NCT06097702|DRUG|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
214447093|NCT06097702|DRUG|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 4 sequential days in one of the three doses based on body weight and followed up for 14 days.
214447094|NCT06097702|DRUG|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
214447095|NCT06988189|DIAGNOSTIC_TEST|12-lead ECG|12-lead ECG from a conventional ECG machine
214447096|NCT06988189|DIAGNOSTIC_TEST|Continuous long term ambulatory ECG monitoring|Continuous long term ambulatory ECG monitoring using wearable ECG or cardiac monitor
214523852|NCT05703477|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
214447097|NCT06988189|DIAGNOSTIC_TEST|Ultra-high-frequency ECG|Ultra-high-frequency ECG acquired using specific acquisition equipment
214447098|NCT06987292|DRUG|IL-17i|IL-17 inhibitors
214447099|NCT06987669|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
214523853|NCT02933996|DEVICE|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
214447100|NCT06986681|OTHER|Big toe muscles strengthening exercises|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol
214523854|NCT02933996|DEVICE|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
214523855|NCT05310058|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
214523856|NCT01357564|OTHER|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
215126242|NCT00436150|BEHAVIORAL|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
215126243|NCT04283617|BEHAVIORAL|Intensification of insulin regimen/Nutrition|The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
215126244|NCT00659412|DRUG|Alefacept|Intramuscular
215126245|NCT00659412|DRUG|Methotrexate|Oral
215126246|NCT00659412|DRUG|Placebo|Intramuscular
215126247|NCT05301985|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
215126248|NCT00453154|DRUG|Carboplatin|Given IV
214447101|NCT06986681|OTHER|Big toe muscles strengthening exercises with neuromuscular training|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises and neuromuscular training protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol.
214447102|NCT06987617|DEVICE|Menopause App|The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a (peri-)menopausal disorder, through tools such as a symptom diary and guided interactive exercises.
214447103|NCT06986824|DEVICE|Pelvic wand|Use of a pelvic wand to perform perineal massage
214447104|NCT06987279|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
214447105|NCT06987279|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
214523857|NCT01357564|OTHER|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
214523858|NCT06286592|BEHAVIORAL|Ultra-brief mindfulness intervention video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
214523859|NCT06286592|BEHAVIORAL|Forgiveness video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
215126249|NCT00453154|DRUG|Cisplatin|Given IV
215126250|NCT00453154|DRUG|Etoposide|Given IV
215126251|NCT00453154|OTHER|Laboratory Biomarker Analysis|Correlative studies
215126252|NCT00453154|OTHER|Placebo Administration|Given PO
215126253|NCT00453154|DRUG|Sunitinib Malate|Given PO
214447106|NCT06987552|DEVICE|Da Vinci SP Surgical System|Da Vinci SP Surgical System
214447107|NCT06988111|DEVICE|BIPAP|The second arm (NIV group) will be managed by BIPAP device for post-operative respiratory failure
215126254|NCT01275352|DRUG|Eplerenone|Eplerenone 50 mg/day
215126255|NCT01275352|DRUG|placebo|placebo
215126256|NCT00461617|DRUG|Mitiglinide|10mg tablet, 10mg TID
214447108|NCT06988111|DEVICE|Vapotherm|The first arm (HVNC group) will be managed by Vapotherm device for post-operative respiratory failure
214523860|NCT06286592|BEHAVIORAL|ACT values video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
214523861|NCT04978688|DRUG|Relugolix|Administered as an oral tablet once daily.
214523862|NCT04978688|DRUG|E2/NETA|Administered as an oral tablet once daily.
214523863|NCT00398749|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length
214523864|NCT01648699|DRUG|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
214523865|NCT04958629|OTHER|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
214523866|NCT02038803|DRUG|TOBIpodhaler|
214523867|NCT06802991|OTHER|ERAS 3.0 (Enhanced Recovery After Surgery)|Nutritional support at discharge and home visits which include comprehensive geriatric assessment, nutritional guidance by dietitian, and instructions on exercise and physical activity.
214523868|NCT06369987|DEVICE|Deleficon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia.
214523869|NCT06369987|DEVICE|Senofilcon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia
214523870|NCT02588027|DRUG|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
214523871|NCT02588027|DRUG|Placebo|Pharmacy formulated placebo
214523872|NCT05476601|BEHAVIORAL|CMAP Plus|The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
214523873|NCT04848064|DRUG|Cyclophosphamide|Given IV
214523874|NCT04848064|DRUG|Fludarabine|Given IV
214523875|NCT04848064|BIOLOGICAL|Mogamulizumab|Given IV
214523876|NCT04848064|BIOLOGICAL|Natural Killer Cell Therapy|Given via infusion
214523877|NCT04848064|OTHER|Quality-of-Life Assessment|Ancillary studies
214523878|NCT04848064|OTHER|Questionnaire Administration|Ancillary studies
214523879|NCT05144854|DRUG|ONO-4538|Specified dose on specified days
215126257|NCT04558177|DEVICE|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
215126258|NCT00060645|DRUG|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
214523880|NCT05144854|DRUG|Ipilimumab|Specified dose on specified days
214523881|NCT05144854|DRUG|Oxaliplatin|Specified dose on specified days
214523882|NCT05144854|DRUG|Capecitabine|Specified dose on specified days
214523883|NCT05144854|DRUG|S-1|Specified dose on specified days
214523884|NCT03219216|DRUG|Glecaprevir/Pibrentasvir|Film-coated tablet
214523885|NCT02332824|DRUG|TAK-272|TAK-272 tablets
214523886|NCT02332824|DRUG|TAK-272 Placebo|TAK-272 placebo-matching tablets
214523887|NCT02332824|DRUG|Candesartan cilexetil|Candesartan cilexetil tablets
214523888|NCT02332824|DRUG|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
214523889|NCT04950010|BEHAVIORAL|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.
215126259|NCT01790594|BIOLOGICAL|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
215126260|NCT01790594|DRUG|methylprednisolone|
215126261|NCT01790594|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|
215126262|NCT01790594|DRUG|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
215126263|NCT01790594|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
215126264|NCT06217965|OTHER|survey|The study will involve patients completing a questionnaire on a secure online platform (such as RedCap)
215126265|NCT03392103|DRUG|Raltitrexed|concurrent chemotherapy
215126266|NCT03392103|RADIATION|postoperative radiotherapy|concurrent postoperative radiation therapy
215126267|NCT04578275|OTHER|diagnostic strategy using ECGI|"Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.~ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure."
215126268|NCT03011008|DRUG|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
215126269|NCT03011008|DRUG|Insulin|Receive insulin following clinician's instruction.
215126270|NCT03636659|DRUG|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
215126271|NCT03636659|DRUG|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
215126272|NCT06305702|DRUG|inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
215126273|NCT02907034|PROCEDURE|Virtual reality experimentation sequency (VR)|
215126274|NCT02907034|PROCEDURE|Classical narrative approach (CN)|
215126275|NCT01772446|BEHAVIORAL|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
215126276|NCT04803383|OTHER|Tele-yoga|Tele-yoga training 3 days a week for 8 weeks
214447109|NCT06987188|OTHER|Modified Pilate Exercises|Modified Pilates exercises are gentle adaptations of traditional Pilates movements, designed to accommodate various fitness levels, physical limitations, or specific health conditions. These exercises focus on core strength, flexibility, posture, and controlled breathing while reducing strain on joints and muscles. Often recommended for beginners, seniors, or individuals recovering from injury or surgery, modified Pilates may involve the use of props like pillows, resistance bands, or chairs to support proper alignment and ease of movement. By emphasizing slow, mindful motions and personalized adjustments, modified Pilates helps individuals safely build strength, improve mobility, and enhance overall body awareness without the risk of overexertion.
215126277|NCT01473771|BEHAVIORAL|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
215126278|NCT05528705|BIOLOGICAL|LAENNEC|Subacromial spatial administration
215126279|NCT05528705|OTHER|0.9% normal saline|Subacromial spatial administration
215126280|NCT00617786|PROCEDURE|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
215126281|NCT04842903|OTHER|Therapeutic Touch|Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
215126282|NCT00445081|DRUG|Prednisolone|
215126283|NCT00445081|DRUG|Ciclosporine A|
215126284|NCT02823509|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68\_R84-089)
215126285|NCT02439697|OTHER|Darbepoetin alfa|Conversion from Aranesp® to NESP®
215126286|NCT03758781|DRUG|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
215126287|NCT03758781|DRUG|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
215126288|NCT03291067|DRUG|MT-8554 1mg|MT-8554 1mg QD, oral, 12 weeks
215126289|NCT03291067|DRUG|MT-8554 5mg|MT-8554 5mg QD, oral, 12 weeks
215126290|NCT03291067|DRUG|MT-8554 10mg|MT-8554 10mg QD, oral, 12 weeks
215126291|NCT03291067|DRUG|Placebo|Placebo QD, oral, 12 weeks
215126292|NCT02680522|OTHER|Exercise|exercise training with virtual reality in videogame
215126293|NCT00121563|DRUG|Thalidomide, Ibuprofen or Diazepam|
215126294|NCT02598401|OTHER|observation|Observational study with no intervention
215126295|NCT00197314|BEHAVIORAL|circular muscle exercises versus pelvic floor exercises|
215126296|NCT04796714|DRUG|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
215126297|NCT04796714|DRUG|Aspirin|One sachet of aspirin 160 mg per day during 3 months
215126298|NCT04796714|DEVICE|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
215126299|NCT04796714|OTHER|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
215126300|NCT05270668|DRUG|Tulisokibart|Tulisokibart administered at timepoints as directed by the protocol
215126301|NCT05270668|DIAGNOSTIC_TEST|Companion diagnostic ( CDx)|CDx+ or CDx-
215126302|NCT05270668|DRUG|Placebo|Placebo
215126303|NCT05844891|BEHAVIORAL|Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)|TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (when possible), featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
215126304|NCT05844891|BEHAVIORAL|Enhanced Care (EC)|Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
215126305|NCT05747443|OTHER|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
215126306|NCT05747443|OTHER|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
215126307|NCT05730725|DRUG|BMS-986322|Specified dose on specified days
215126308|NCT05730725|OTHER|Placebo|Specified dose on specified days
214447110|NCT06987188|OTHER|General Physiotherapy Plan|A general physiotherapy plan for improving trunk control and balance focuses on enhancing core stability, postural alignment, and coordinated movement through targeted exercises and functional activities. The plan typically begins with gentle activation of deep core muscles such as the transverse abdominis and pelvic floor, progressing to dynamic tasks that challenge balance and coordination, like seated weight shifts, bridging, and reaching tasks in various positions (sitting, kneeling, or standing). Balance training may include exercises on unstable surfaces, gait training, and proprioceptive activities to improve body awareness and stability. The physiotherapy approach is individualized, gradually increasing in complexity and intensity as the patient gains strength and confidence, with consistent emphasis on proper technique, breathing, and safety to support overall mobility and independence.
214447111|NCT06988293|PROCEDURE|inguinal hernia repair|İnguinal hernia repair quality of life index
215126309|NCT04275323|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
215126310|NCT04275323|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
215126311|NCT05861466|DRUG|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
215126312|NCT05861466|PROCEDURE|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
215126313|NCT02152631|DRUG|Abemaciclib|Administered orally
215126314|NCT02152631|DRUG|Erlotinib|Administered orally
214447112|NCT06987578|OTHER|OMT vs. Ibruprofen|OMT vs. Standard Therapy in the Management of Acute Neck and Low Back Pain in the Emergency Department
214464428|NCT06548022|BEHAVIORAL|Rare Group Problem Management Plus|The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.
215126315|NCT05473026|BEHAVIORAL|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
215126316|NCT05672329|OTHER|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
215126317|NCT05672329|OTHER|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
214523890|NCT04950010|BEHAVIORAL|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
214523891|NCT03840148|DRUG|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
215126318|NCT05672329|OTHER|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
215126319|NCT05672329|OTHER|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
215126320|NCT05624476|DIAGNOSTIC_TEST|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
215126321|NCT00359463|DRUG|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
215126322|NCT03006380|DRUG|oxytocin|Ecbolic used to reduce blood loss
215126323|NCT03776747|DRUG|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
215126324|NCT03776747|DRUG|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
215126325|NCT03776747|DIAGNOSTIC_TEST|Vitals|
215126326|NCT03776747|DIAGNOSTIC_TEST|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
215126327|NCT03776747|DIAGNOSTIC_TEST|Initial protocol MRI scan|Initial scan to determine placement
215126328|NCT02071966|DRUG|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
215126329|NCT02071966|DRUG|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
215126330|NCT05327179|OTHER|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
215126331|NCT05327179|OTHER|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
215126332|NCT03487731|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
215126333|NCT03487731|DRUG|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
215126334|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
215126335|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
215126336|NCT04909489|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
215126337|NCT05686785|DIAGNOSTIC_TEST|Transient elastography|Transient elastography measures liver stiffness in kPa
215126338|NCT05877755|DEVICE|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
215126339|NCT00905450|DRUG|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
215126340|NCT00905450|DRUG|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
215126341|NCT05084313|OTHER|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
214464429|NCT05138822|DRUG|GSK3882347|GSK3882347 will be administered on each dosing day.
214464430|NCT05138822|DRUG|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
214464431|NCT05138822|DRUG|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
214464432|NCT05641441|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery
214464433|NCT04527029|OTHER|No interventions|It is an observational study. No interventions.
214464434|NCT05880966|BEHAVIORAL|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
214464435|NCT03936959|DRUG|LY3434172|Administered IV
214464436|NCT05984433|DEVICE|Auricular acupuncture|Electro auricular acupuncture
215126342|NCT05084313|OTHER|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
215126343|NCT05084313|OTHER|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
215126344|NCT01529073|DRUG|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
215126345|NCT06330740|OTHER|Clinical Decision Support|Upon ordering antibiotics the provider will be prompted to utilize an indication-based order set which guides the clinician to the appropriate empiric antibiotic choice.
215126346|NCT04149249|OTHER|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
215126347|NCT04149249|OTHER|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
215126348|NCT03683173|BEHAVIORAL|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
215126349|NCT04258930|OTHER|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
215126350|NCT04258930|DEVICE|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
215126351|NCT04258930|DEVICE|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
215126352|NCT05279352|DRUG|FBR-002|Administration on D1 and D3
215126353|NCT05279352|DRUG|Placebo|Administration on D1 and D3
215126354|NCT03567031|PROCEDURE|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
215126355|NCT00363532|DRUG|infusion of calcitonin gene related peptide (CGRP)|
215126356|NCT01934959|DRUG|Bifico|
215126357|NCT01057953|GENETIC|Blood drawn|Blood drawn for patient
215126358|NCT00547274|DRUG|MK0767|
215126359|NCT00276510|DRUG|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
215126360|NCT00276510|OTHER|Placebo|1 tablet twice a day, oral route, during 5 years.
215126361|NCT05661786|OTHER|Observation|Monitor every 6 months
215126362|NCT05661786|OTHER|Antiviral treatment|Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
215126363|NCT05631561|DEVICE|Endovascular denervation System (Generator and Catheter )|All patients receive endovascular denervation (EDN) treatment
215126364|NCT01320475|DRUG|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
215126365|NCT01320475|DRUG|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
214464437|NCT06027567|DRUG|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
215126366|NCT02210000|DRUG|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
215126367|NCT02210000|DRUG|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
215126368|NCT01378988|DRUG|Dexmedetomidine|For sedation according to protocol
215126369|NCT01329263|OTHER|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
215126370|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
215126371|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
215126372|NCT05343858|DIETARY_SUPPLEMENT|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
215126373|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
215126374|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
215126375|NCT02790996|DRUG|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
214464438|NCT06027567|DIETARY_SUPPLEMENT|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
214464439|NCT06027567|BEHAVIORAL|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
214523892|NCT03840148|DRUG|Meropenem|Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
215126376|NCT04369378|BEHAVIORAL|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
215126377|NCT02076607|PROCEDURE|Arthrodesis|Posterior approach to toracolumbar spine fusion.
215126378|NCT02076607|DEVICE|Brace|Toracolumbar imobilization
215126379|NCT00308139|DRUG|exenatide, long acting release|
215126380|NCT00308139|DRUG|exenatide|
215126381|NCT02152826|DEVICE|Potassium oxalate|Professional application
215126382|NCT04051398|OTHER|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
215126383|NCT03960216|PROCEDURE|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
215126384|NCT03960216|PROCEDURE|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
215126385|NCT02093884|OTHER|Text Messaging Intervention|
214447113|NCT06987929|PROCEDURE|Hydrodilatation injection|During the procedure, the patient lie supine on an examination couch, with the affected arm in the modified Crass position. All injections were done under image guidance using a Philips EPIQ ultrasound machine with an L18-12 MHz linear array transducer, performed consecutively by 2 rheumatologists or 1 pain medicine anaesthetist, all trained in MSK US. Aseptic technique was used. The transducer was placed at the short axis of the supraspinatus tendon, and the rotator cuff interval and coracohumeral ligament (CHL) were identified. Local anaesthetic (1% lignocaine) was injected subcutaneously to the skin. The therapeutic medication consisted of a mixture of 40 mg triamcinolone (10 mg/ml concentration) and 5ml 1% lignocaine, which was diluted with sterile normal saline into a total of 20mls suspension. The injection was administered using a 22-G 2-inch needle (Stimuplex A) introduced below the CHL adjacent to the long head of biceps tendon, in the in-plane view under US guidance.
214447114|NCT06987929|PROCEDURE|Intra-articular steroid injection (IAI)|Intra-articular corticosteroid injection was performed as a control group. The posterior shoulder approach was used. The patient was positioned in the lateral decubitus or semi-prone position with the affected shoulder at the uppermost position, elbow semi-flexed and the ipsilateral arm resting on a pillow for comfort and stability. The ultrasound transducer is positioned over the long axis of the myotendinous junction of the infraspinatous tendon to view the contours of the posterior glenoid labrum and posterior portion of the humeral head. The injectate was administered using a 21-G hypodermic needle. 40 mg triamcinolone (10 mg/ml concentration) mixed with 1ml of 1% lignocaine was injected into the posterior glenohumeral joint, under ultrasound-guidance. Any adverse reaction that occurred during the procedure was recorded. Following the procedure, the patient was advised to avoid overuse of the injected joint for 24 hours as part of post-injection care.
214447115|NCT06987565|DEVICE|Active vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated. Patients will be followed through day 57 to assess durability of the intervention.
214523893|NCT03615404|BIOLOGICAL|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
214708783|NCT00643344|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
214708784|NCT00259246|DRUG|Peptide YY infusion|
215126386|NCT02093884|OTHER|Standard Referral|
215126387|NCT00833040|DRUG|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
215126388|NCT02313766|OTHER|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
215126389|NCT02313766|OTHER|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
215126390|NCT04739826|DRUG|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
215126391|NCT04739826|DRUG|Nilotinib Pill|Nilotinib Capsules 300mg bid
215126392|NCT03723148|DRUG|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
215126393|NCT01893801|DRUG|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
215126394|NCT01893801|DRUG|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
215126395|NCT01893801|DRUG|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
215126396|NCT04907734|OTHER|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
215126397|NCT01045486|DRUG|ATP mixed probiotics|\- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
215126398|NCT01045486|DRUG|Placebo|\- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
215126399|NCT01290107|GENETIC|DNA analysis|
215126400|NCT01290107|GENETIC|gene rearrangement analysis|
215126401|NCT01290107|GENETIC|microarray analysis|
214523894|NCT03615404|BIOLOGICAL|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
214523895|NCT00455715|DRUG|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
214523896|NCT01774929|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
214523897|NCT01845337|DRUG|Teysuno|
214523898|NCT01845337|DRUG|Capecitabine|
214523899|NCT00939211|DRUG|AZD9164|Solution for inhalation through nebulization, single dose
214523900|NCT00939211|DRUG|Tiotropium|Dry powder for inhalation, single dose
214694321|NCT06195501|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)|"Flexible Endoscopic Evaluation of Swallowing (FEES):~FEES is performed for analysis of swallowing ability according to the same methodology as in the initial trial: one day before a TEE and max. 4 hours after TEE. Before the FEES anticongestive nose drops are applied and the nostrils are anaesthetized by applying a lidocaine gel via cotton sticks. During the FEES examination the participants sit upright and are asked to swallow various consistencies: FEES is aborted in case of aspiration of any of the consistencies during the examination.~Transesophageal Ecocardiography (TEE):~For the TEE anesthesia is applied via intravenous injection of propofol or a combined anesthesia, through intravenous application of propofol and local anesthesia, using lidocaine spray. All patients undergoing a TEE are sober before and at least two to four hours after TEE."
215126402|NCT01290107|GENETIC|polymerase chain reaction|
215126403|NCT01290107|OTHER|immunological diagnostic method|
214523901|NCT00939211|DRUG|Placebo|Placebo
214523902|NCT04943614|OTHER|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
214523903|NCT04943614|OTHER|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
214694322|NCT00755846|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
214694323|NCT00755846|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
214694324|NCT00755846|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
215126404|NCT01290107|OTHER|laboratory biomarker analysis|
215126405|NCT03255239|PROCEDURE|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
215126406|NCT04273607|DRUG|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
215126407|NCT03167385|DRUG|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
215126408|NCT02211053|DRUG|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
215126409|NCT02211053|DRUG|placebo|
215126410|NCT02193776|DRUG|PA-824|oral
215126411|NCT02193776|DRUG|bedaquiline|oral
215126412|NCT02193776|DRUG|moxifloxacin|oral
215126413|NCT02193776|DRUG|pyrazinamide|oral
215126414|NCT02193776|DRUG|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
215126415|NCT02971423|DRUG|ETX2514|
215126416|NCT02971423|DRUG|Placebo|matching placebo infusion
215126417|NCT02971423|DRUG|Sulbactam|
215126418|NCT02971423|DRUG|Imipenem/Cilastatin|
215126419|NCT01139502|BEHAVIORAL|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
215126420|NCT01139502|BEHAVIORAL|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
215126421|NCT01635231|OTHER|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
215126422|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Acute DVT
215126423|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Chronic DVT
215126424|NCT00379847|DRUG|conivaptan|IV
215126425|NCT03290443|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
215126426|NCT06028919|DEVICE|Temperature controlled DiamondTemp (DT) ablation catheter|The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
215126427|NCT06028919|DEVICE|Tacticath/Tactiflex (TF) ablation catheter|The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
215126428|NCT02064946|DIETARY_SUPPLEMENT|vitamin D|50,000IU/week of vitamin D3
215126429|NCT02064946|DIETARY_SUPPLEMENT|Placebo|
215126430|NCT02602769|DIAGNOSTIC_TEST|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
215126431|NCT04718623|DIAGNOSTIC_TEST|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
215126432|NCT01458639|DRUG|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
215126433|NCT01458639|DRUG|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
215126434|NCT01169129|OTHER|surgery|resection of brain metastases
214447116|NCT06987565|DEVICE|Sham vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated, however, the vagus nerve will not be stimulated. Patients will be followed through day 57 to assess durability of the intervention.
214447117|NCT06987331|OTHER|haptonomy|"Haptonomy involves a combination of skills taught in 4-8 sessions of 45-60 minutes between 20 and 36 weeks of gestation. An important stage of the three-step haptonomy application is the attachment of the parents to the foetus by touching the foetus in the 20-36th weeks of pregnancy.~Mindfullnes is a mbsr application done in 8 sessions"
214447118|NCT06987331|BEHAVIORAL|Haptonomy application|breastfeeding status
214447119|NCT06987331|BEHAVIORAL|Mindfulness|breastfeeding status
214447120|NCT06986746|OTHER|Hypertension Crisis Awareness Program|Education materials-consist of description about hypertension crisis, symptoms, causes and preventive measures (emphasizing on healthy lifestyle and physical activity) with pictorial presentation.
214447121|NCT06987253|DEVICE|OROXID® forte oral solution|Patients will use OROXID® forte oral solution two to three times daily for 14 days as an adjunct to standard care.
214447122|NCT06987253|DEVICE|OROXID® sensitive oral solution|Patients will use OROXID® sensitive oral solution two to three times daily for 14 days as an adjunct to standard care.
214447123|NCT06987253|OTHER|Standard of Care (SOC)|Patients will receive standard of care meaning proper tooth brushing without the use of any mouthwash or other products aimed at reducing bacteria in the oral cavity.
214447124|NCT06823856|DRUG|Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated table
214447125|NCT06823856|DRUG|Synjardy 12.5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 12.5 mg/1000 mg filmcoated tablets
214447126|NCT05803798|DEVICE|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
214447127|NCT06988007|DEVICE|Whole body MRI|Whole body MRI (ZTE sequence)
214447128|NCT03164486|DRUG|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
214694325|NCT00755846|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
214694326|NCT00755846|DRUG|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
215126435|NCT01169129|RADIATION|radiosurgery|radiosurgery to brain metastases
215126436|NCT02870998|OTHER|Active learning|1-day continuing education activity consisting of a lecture on patient education.
215126437|NCT02870998|OTHER|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
215126438|NCT03900507|PROCEDURE|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
215126439|NCT00317993|DRUG|ezetimibe|
215126440|NCT00317993|DRUG|simvastatin|
214464440|NCT06507735|DIETARY_SUPPLEMENT|Mannose|Mannose is a sugar monomer that is important in the glycosylation of many proteins. The concentration of mannose in mammalian plasma is \~50-100 μM, which is primarily derived from N-glycan processing. Taking dietary mannose supplements can raise the levels of plasma mannose by 3- to 5-fold. There are currently no known adverse effects of mannose supplementation in humans.
214464441|NCT05345015|DEVICE|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
215126441|NCT00317993|DRUG|ezetimibe plus simvastatin|
215126442|NCT02946281|BEHAVIORAL|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
215126443|NCT01262807|OTHER|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
215126444|NCT06381804|OTHER|shotblocker|shotblocker device
215126445|NCT06381804|OTHER|palm stimulator|palm stimulator
215126446|NCT04622111|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
215126447|NCT04622111|DRUG|Placebo|matching placebo tablet
215126448|NCT04622111|DRUG|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
215126449|NCT04072926|DRUG|BioRoot|Influence of biomaterial BioRoot on periapical healing
215126450|NCT03921749|DEVICE|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
215126451|NCT05101447|DRUG|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
214447129|NCT05358925|OTHER|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 4-10 minutes long, for a total of \~72 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: symptoms, basic factors about BPD, the naturalistic long term course of BPD, prevalence of BPD and its common comorbid disorders, key principles for recovery, available psychotherapeutic treatment options for BPD, common factors amongst treatments, medications, the interpersonal hypersensitivity model of BPD, and a review of the top 10 tips."
214447130|NCT05358925|OTHER|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from the first two time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
215126452|NCT06528366|DIETARY_SUPPLEMENT|Chlorella pyrenoidosa|Functional food, organically pressed into tablets (Registration with Anvisa/MS/Brazil: 6.7273.000)
215126453|NCT06528366|DEVICE|High Definition Transcranial Direct Current Stimulation|Neuromodulation Technics, non invasive, target and safety
214447131|NCT05358925|OTHER|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, coping, self-compassion and self-care, stress and anxiety, depression, and healthy sleep habits.
214447132|NCT04937842|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
214447133|NCT06987006|OTHER|Jigsaw education|The Jigsaw Technique (JT) is used as a teaching technique where each student creates pieces of an academic and instructional puzzle, specializes in puzzle groups, and teaches the subject they specialize in to other group members.
214447134|NCT06987006|OTHER|Classical Education Technique|In the classical education method, students listen to the lesson explained by the educator in a classroom environment.
214523904|NCT04553627|DEVICE|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
215126454|NCT05241262|DRUG|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
214523905|NCT01855672|DEVICE|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
215126455|NCT04744675|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
215126456|NCT04744675|DRUG|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
215126457|NCT04744675|DRUG|Bupivacaine|Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
215126458|NCT06304961|BIOLOGICAL|Tozorakimab|Tozorakimab will be administered as a single SC dose on Day 1.
214523906|NCT06509269|PROCEDURE|intraoral scanning|Intraoral Scanning of edentulous Jaw
214523907|NCT06509269|PROCEDURE|Desktop scanning|Desktop scanning of definitive impression
215126459|NCT05416138|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be performed at either peaks or troughs of ongoing prefrontal theta oscillations (3-7 Hz) concurrently with the cognitive test at the beginning of every test trial. Theta oscillations will be monitored in real-time at the left dorsolateral prefrontal cortex using electroencephalography (EEG).
215126460|NCT06296589|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Behavioral therapy for trauma related guilt and shame
215126461|NCT06296589|BEHAVIORAL|Prolonged Exposure Therapy|Behavioral exposure therapy for PTSD
215126462|NCT05191394|DIAGNOSTIC_TEST|Evolution of antibodies titre|For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.
215126463|NCT04148534|DRUG|Rocroniom, Non Depolarizing Muscle Relaxant|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
215126464|NCT03604211|RADIATION|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
215126465|NCT02246049|BIOLOGICAL|Bevacizumab|Given IV
215126466|NCT02246049|DRUG|5-fluorouracil|Given IV
215126467|NCT02246049|DRUG|Irinotecan hydrochloride|Given IV
215126468|NCT02246049|DRUG|Leucovorin calcium|Given IV
215126469|NCT02246049|DRUG|Oxaliplatin|Given IV
215126470|NCT02520817|DIETARY_SUPPLEMENT|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
215126471|NCT02520817|DIETARY_SUPPLEMENT|Lactulose|
215126472|NCT05510063|DRUG|Humira (Adalimumab)|Subcutaneous (SC) injection
215126473|NCT05510063|DRUG|SB5 (Adalimumab Biosimilar)|Subcutaneous (SC) injection
215126474|NCT02818868|DRUG|apixisaban|
215126475|NCT01865422|OTHER|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
215126476|NCT01884077|DEVICE|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
215126477|NCT01884077|DEVICE|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
214447135|NCT06988475|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
214447136|NCT06986629|DEVICE|pulsed electromagnetic therapy|We will use the ASTAR Physio MG 827, a generator and 75 cm solenoid couch, in a pulsed electromagnetic field group. Participants will be placed comfortably in the solenoid, and the device will be turned on and programmed for 20 guesses for 10 minutes, 7 Hz, three times per week for 8 weeks.
214447137|NCT06986629|DEVICE|Photobiostimulation|The therapy will be performed using an ASTAR PhysioGo -As low level laser therapy device with a wavelength of 830 nm, 30 mW power output, and 1 J energy dose. Patients will be supine and wear laser safety goggles. The laser will be applied to six locations over the maxillary or frontal sinuses, administered in a continuous manner for 33 seconds per spot, totaling 198 seconds and 6 J per session
214523908|NCT00312546|DRUG|Enfuvirtide|90 mg subcutaneously twice daily
214523909|NCT00312546|DRUG|Valproic acid|500 to 750 mg, taken orally twice daily
214523910|NCT04937049|OTHER|EMAeHealth digital tool|eHealth intervention to support Maternal Education
214523911|NCT05384808|BEHAVIORAL|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
214523912|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
215126478|NCT04078802|PROCEDURE|VNOTES/VH|same as above
215126479|NCT01755234|DRUG|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
215126480|NCT01755234|DRUG|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
215126481|NCT04508881|DEVICE|Ahmed Glaucoma Valve|To compare the prevalence of postoperative hypotony between the 2 arms
215126482|NCT00981149|DRUG|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
215126483|NCT00981149|DRUG|Placebo|Placebo match duloxetine for 6 week period.
215126484|NCT06135961|DEVICE|eCTG monitoring with the NFMS|Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
215126485|NCT02648204|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
215126486|NCT02648204|DRUG|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
215126487|NCT06159088|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
215126488|NCT06159088|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
215126489|NCT06159088|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
215126490|NCT04722900|OTHER|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
215126491|NCT02634333|PROCEDURE|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
214447138|NCT06986629|OTHER|Self-sinus massage technique|Participants are instructed to perform self-massage to their frontal and maxillary sinuses at home twice daily, in the morning and evening. For the frontal sinus, place the fingers above the eyebrows on either side of the forehead, and gently circular outward massage for three sets of 30 seconds, repeated twice a day.
214447139|NCT06988280|DIAGNOSTIC_TEST|Ultrasound-guided transvaginal aspiration of cystic pelvic lesions.|Ultrasound-guided transvaginal aspiration is a minimally invasive procedure used to drain cystic pelvic lesions, such as adnexal cysts or pelvic abscesses. A thin needle is inserted through the vaginal wall under ultrasound guidance to aspirate fluid from the cyst, reducing its size.
215126492|NCT02634333|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
215126493|NCT02634333|PROCEDURE|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
215126494|NCT02634333|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
215126495|NCT05513339|DEVICE|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
215126496|NCT01794000|DRUG|Prasugrel|Administered orally
215126497|NCT01794000|DRUG|Placebo|Administered orally
215126498|NCT02748863|DRUG|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
215126499|NCT02748863|DRUG|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
215126500|NCT02748863|DRUG|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
215126501|NCT06171958|DRUG|Iodine-containing Contrast Media|Patients will receive or not receive ICM depending on their medical need.
215126502|NCT04537793|DRUG|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
215126503|NCT04537793|DRUG|IVA|Granules for oral administration.
215126504|NCT01255423|DRUG|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
215126505|NCT01255423|DRUG|Placebo|Placebo, 4 times daily
215126506|NCT00006275|DRUG|calcitriol|
214447140|NCT03671811|DRUG|Megestrol Acetate|Given PO
214447141|NCT03671811|BIOLOGICAL|Pterostilbene|Given PO
214447142|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214447143|NCT04913805|DRUG|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
214447144|NCT04913805|DRUG|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
214447145|NCT04913805|OTHER|Potassium Chloride|Active control
214523913|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
214523914|NCT01990183|DEVICE|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
214523915|NCT01990183|OTHER|Standard Care|Current care advices in the management of preterm infants in the first months of life
214694327|NCT00755846|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
215126507|NCT05655884|OTHER|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
215126508|NCT05655884|OTHER|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
215126509|NCT03022877|DRUG|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
215126510|NCT02638766|DRUG|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
215126511|NCT00543257|OTHER|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
215126512|NCT00543257|OTHER|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
215126513|NCT06313983|DRUG|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
215126514|NCT06313983|DRUG|Lapatinib+Capecitabine|Take the pills according to the instructions
215126515|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
214447146|NCT06863337|DEVICE|CGM|"Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.~Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.~In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation."
214447147|NCT06856551|BEHAVIORAL|Minimal contact control|Participants in the control group received a pamphlet about general dietary and physical activity guidelines.
214523916|NCT04716283|OTHER|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
214694328|NCT00786032|DEVICE|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
215126516|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
215126517|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
214694329|NCT03835000|PROCEDURE|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
215126518|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
215126519|NCT01994642|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
215126520|NCT01994642|DRUG|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
214447148|NCT06856551|BEHAVIORAL|Promotion and Prevention Interventions|regulatory focus groups, participants completed a 1-hour educational information session with study staff and received a packet which contained information about energy balance, healthy food choices, exercise recommendations, strategies for weight control, goal setting, and responding to lapses. Participants were encouraged to track their food intake and exercise with a provided log book or free apps (Lose It!; MyFitnessPal). The informational content and intervention procedures were identical except for the framing of messages and tasks. The prevention messages emphasized protecting one's health (e.g., failing to regularly exercise can undermine your weight control program and lead to poor health; if you do not vigilantly follow these behaviors, you will not fulfill your weight control goals or protect your health and well-being; not eating fruits and vegetables results in failure to supply the body with the nutrients it needs). The promotion messages emphasized promoting one's health
214447149|NCT06864468|BEHAVIORAL|Health promotion curricula|3-day summer camp and 9-month health promotion curriculum that focuses on physical activity and nutrition
214447150|NCT06673095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214447151|NCT06673095|PROCEDURE|Excision|Undergo narrow margin excision
214447152|NCT06673095|PROCEDURE|Excision|Undergo wide margin excision
214447153|NCT06673095|OTHER|Survey Administration|Ancillary studies
214447154|NCT03242616|DRUG|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)"
214447155|NCT03242616|DRUG|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
214447156|NCT04150887|DRUG|Cusatuzumab|Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
214447157|NCT04150887|DRUG|Azacitidine|Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
214447158|NCT04150887|DRUG|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
214447159|NCT06188091|BEHAVIORAL|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
214447160|NCT05924256|DRUG|SHR-A1811|SHR-A1811
214447161|NCT05924256|DRUG|SHR 3680 + leuprolide|SHR 3680 + leuprolide
214447162|NCT05924256|DRUG|SHR-A1921|SHR-A1921
214447163|NCT05924256|DRUG|SHR-A1811|SHR-A1811
214447164|NCT06870175|DEVICE|Electronic-Textile-based Electrocardiographic Monitoring|Participants will be invited to wear the Skiin chest band for up to 14 days, as prescribed by their physician. Participants will wear the Skiin chest band in a similar capacity to a conventional Holter monitor.
214447165|NCT06310837|DRUG|Adalimumab Biosimilars Injection|Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
214447166|NCT06310837|DRUG|Corticosteroid|Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
215126521|NCT01994642|DRUG|Placebo Sterile Otic Suspension|
215126522|NCT04562454|OTHER|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
215126523|NCT00363844|DRUG|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
215126524|NCT02308956|BEHAVIORAL|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
215126525|NCT02308956|BEHAVIORAL|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
215126526|NCT04684264|OTHER|Heart Failure Prevention Clinic|Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
215126527|NCT00574808|OTHER|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
215126528|NCT01612975|DRUG|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
215126529|NCT01612975|DRUG|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
215126530|NCT03831477|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
215126531|NCT04598022|OTHER|cross-sectional observation|observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester
215126532|NCT04598022|OTHER|cross-sectional follow-up observation|follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
215126533|NCT00429559|DRUG|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
215126534|NCT00429559|DRUG|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
215126535|NCT06316908|DRUG|Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.
214447167|NCT06310837|DRUG|Immunosuppressive Agents|Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
215126536|NCT06316908|DRUG|Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
214447168|NCT06873776|DEVICE|A&L cycling|Participants will complete simultaneous arms and legs cycling for 60min of active cycling. Targeted exercise intensity is 70-85% of the age-predicted maximum heart rate. Cycling resistance will be modified for continuous challenge. A target speed 10% above the highest speed at which each study participant is able to cycle voluntarily without motor, FES, or tSCS assistance will be selected during the first session and maintained throughout all training sessions. Once a participant can complete 60 minutes of continuous cycling at a specific resistance for two consecutive training sessions, the resistance will be increased to the next setting level at the mid-point of the subsequent session. Upon completion of each session, the physical therapists/researcher will complete skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
215126537|NCT00232622|DRUG|Streptokinase|Accelerated infusion of streptokinase
215126538|NCT00232622|DRUG|Streptokinase|Standard dose streptokinase
214447169|NCT06873776|DEVICE|Body weight supported treadmill training (BWSTT)|The physical therapists/researchers will assist the patient with donning any necessary lower extremity braces and a padded walking harness. The patient will be assisted onto the treadmill via a ramp while seated in a wheelchair or by ambulation with physical assistance, clipped into the body weight support system, assisted to stand, and provided the appropriate amount of body weight support to allow for successful stepping for 60 minutes of active walking. During BWSTT, physical therapists/trainers will adjust treadmill speed or incline and the degree of body weight support to challenge participants. Participants will be instructed to exercise with a targeted intensity of 70-85% of the age-predicted maximum heart rate. Upon completion of each session, the harness will be doffed with skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
214447170|NCT02619786|DRUG|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
215126539|NCT05948241|OTHER|Online psychological support group|"1. st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~2. nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments"
215126540|NCT05948241|OTHER|Standard multidisciplinary care|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
215126541|NCT03407898|OTHER|intubation time|intubation attempt number and intubation time
215126542|NCT00657046|DRUG|Droxidopa|Capsules containing 200 mg droxidopa
214447171|NCT04053816|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
214447172|NCT06300892|OTHER|No intervention|samples from the incision site and GI tract collected
214447173|NCT06693817|DEVICE|Wireless skin sensors vital sign monitoring system|The wireless monitoring system will be applied to the newborn and consist of a chest sensor (Anne Arc by Sibel Inc.) and a RAD-7 (Masimo)pulse oximeter limb sensor.
214523917|NCT06212596|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
215126543|NCT00657046|DRUG|Placebo|Capsules with mannitol substituted for droxidopa
215126544|NCT05353595|DIETARY_SUPPLEMENT|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
215126545|NCT05353595|BEHAVIORAL|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
214523918|NCT06212596|DRUG|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
214523919|NCT06212596|DRUG|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
214523920|NCT01599221|DEVICE|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
215126546|NCT00546624|DRUG|MK0777|
215126547|NCT01022021|DRUG|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
215126548|NCT01022021|DRUG|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
215126549|NCT04138303|OTHER|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
215126550|NCT04138303|OTHER|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
215126551|NCT04138303|OTHER|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
215126552|NCT05775068|RADIATION|Radiotherapy|Radiotherapy
215126553|NCT02278926|OTHER|Ultrasound|Ultrasound measurements
214523921|NCT01394263|DRUG|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
214523922|NCT01394263|DRUG|Zoladex goserelin implant|goserelin implant injection.
215126554|NCT02278926|OTHER|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
215126555|NCT01212562|PROCEDURE|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
215126556|NCT02757989|OTHER|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
215126557|NCT06079333|DRUG|dabrafenib/trametinib|braf/mek-inhibition
215126558|NCT04540965|DRUG|Telaglenastat|Glutaminase inhibitor
215126559|NCT04540965|DRUG|Famotidine|Histamine-H2 Receptor Antagonist
215126560|NCT04540965|DRUG|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
215126561|NCT01858363|DEVICE|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
215126562|NCT01858363|DEVICE|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
215126563|NCT03004365|DRUG|C16G2 Varnish|Antimicrobial Peptide
215126564|NCT03004365|DRUG|Placebo Varnish|Placebo
215126565|NCT02197117|DEVICE|Remote ischemic conditioning|
215126566|NCT02197117|DEVICE|Control|
214447174|NCT06693817|DEVICE|Wired vital sign monitoring system|A standard ECG and SpO2 monitoring device will be applied suing the Infinity M540 monitor (Draeger, Germany). The chest sensor will be placed as per standard of care on the newborn's chest and abdomen, and the SpO2 sensor on their hands or feet.
214447175|NCT00909025|DRUG|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
214523923|NCT05531136|OTHER|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
214523924|NCT06330363|OTHER|Laser therapy|The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
214523925|NCT06330363|OTHER|Sham|The laser device has sham light option that will be used.
214523926|NCT06645522|DRUG|Edaravone dexborneol|Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
215126567|NCT00491413|DRUG|epoetin|
215126568|NCT05418322|BEHAVIORAL|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
215126569|NCT01619839|DRUG|NKTR-181|
215126570|NCT01619839|DRUG|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
215126571|NCT00508326|DRUG|Paclitaxel|Starting dose 150 mg/m\^2 HAI once every 4 weeks
215126572|NCT00596986|DRUG|Duloxetine|Duloxetine 30mg up to 120mg per day.
215126573|NCT00596986|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
215126574|NCT03480152|BIOLOGICAL|National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine|Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
215126575|NCT06072326|DRUG|Sotagliflozin|200 mg/day as a tablet
215126576|NCT06072326|DRUG|Ambrisentan|2.5 mg/day as a tablet
215126577|NCT06072326|DRUG|Ambrisentan and Sotagliflozin|2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet
215126578|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
214694330|NCT00775502|DRUG|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
214694331|NCT00133900|PROCEDURE|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
214694332|NCT03924141|BEHAVIORAL|Training in de-escalation|Will receive one hour of de-escalation training
214447176|NCT06699264|OTHER|Blood Flow Restriction Training|Pressure cuff is applied to the leg during training for low-load strength training with simultaneous restiction of blood flow
214447177|NCT06699264|OTHER|Training without BFR|Strength training according to experimentral group without simultaneous restriction blood flow
214447178|NCT06146959|DEVICE|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
214447179|NCT06146959|OTHER|Home exercise program|Intrinsic foot strengthening and stretching exercises
214447180|NCT04208126|DEVICE|ECMO|ECMO implantation immediately after ICU admission
214447181|NCT06692543|OTHER|Active population|1 blood withdraw, questionnaire and tests
214447182|NCT06692543|OTHER|Inactive population|1 blood withdraw, questionnaire and tests
214523927|NCT06645522|DRUG|Placebo|Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
214447183|NCT06641141|PROCEDURE|Induction of Labour|"Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a failed IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia."
214447184|NCT05242640|OTHER|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
214447185|NCT05242640|OTHER|Exercise|Participants will complete a moderate-intensity walking program
214447186|NCT05242640|OTHER|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
214447187|NCT06733012|DEVICE|Splanchnic nerve block|Catheter based ablation on the right greater splanchnic nerve
214447188|NCT06733012|OTHER|Sham-control procedure|Sham-control ablation procedure
214447189|NCT06743997|DRUG|Test Drug (Eutropin Catridge, 48IU/Cartridge)|Liqid somatropin
214447190|NCT06743997|DRUG|Reference Drug (Eutropin, 4 IU/vial)|Lyophilized somatropin
214447191|NCT06892665|DEVICE|Hypotension prediction index|HPI and other haemodynamics parameters, is available to the anaesthetist to view and act upon
214447192|NCT06892665|DEVICE|Non invasive Blood Pressure Monitoring|Anaesthetist will respond to hemodynamic variables using NIBP
214447193|NCT06747234|OTHER|Oat bran group|Patients consume 28 grams of oat bran daily for two months in addition to their usual medical treatment.
214447194|NCT06747234|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
214447195|NCT05976165|OTHER|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
214447196|NCT06900946|OTHER|gluten|The intervention group will receive 3 grams of gluten powder daily
214447197|NCT06900946|OTHER|cornstarch|The control group will receive 3 grams of cornstarch powder daily
214447198|NCT06781892|OTHER|Anterior-lateral pad positioning|Defibrillation pads positioned anterior-lateral
214447199|NCT06781892|OTHER|Anterior-posterior pad positioning|Defibrillation pads positioned anterior-posterior
214447200|NCT06781892|OTHER|Double-sequential defibrillation|Combination of anterior-lateral and anterior-posterior pad positioning for a total of 4 pads and 2 shocks.
214447201|NCT06754683|BEHAVIORAL|8 weeks Self-compassion based psycho-education|The Self-compassion psychoeducational intervention will be utilized as the intervention in this study will be delivered by the first investigator and supervised by the Principal investigator, who has experience in mindfulness and self-compassion practices. It will consist of eight weekly 1.5 hours of face-to-face sessions and 1 hour each week of online sessions. Each session will be according to a specific topic that will cover the objectives of the study, incorporating the concept of self-compassion interventions based on the research literature and input from experts in the field, taking into consideration the needs of the participants. Participants will be required to have at least 80% of attendance for intervention completion.
214523928|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
214523929|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
214523930|NCT05876013|PROCEDURE|ACL reconstruction|Randomized between hamstring and patellar tendon graft
214447202|NCT04890249|DEVICE|Investigational IOL Model C1V000|IOL replaces the natural lens removed during cataract surgery.
214447203|NCT04890249|DEVICE|Investigational IOL Model C2V000|IOL replaces the natural lens removed during cataract surgery.
214447204|NCT04890249|DEVICE|Control IOL Model ICB00|IOL replaces the natural lens removed during cataract surgery.
214447205|NCT06792331|PROCEDURE|vNOTES high uterosacral ligament suspension|Following the entry into the peritoneal cavity via apical colpotomy, a transvaginal retractor was inserted through the vaginal vault and the vaginal access platform was established. The ureters and uterosacral ligaments (USL) were identified via laparoscopic view. Bilateral nonabsorbable sutures were placed by the intermediate portions of the USL at the level of the ischial spines making up a total of 4 stitches (Figure 1). Then, the sutures were slightly weighed to verify proper placement. Then, the V-notes platform was removed and the peritoneum was closed. The aforementioned sutures were fixed to the ipsilateral cardinal ligament stump and the pubocervical fascia on the anterior wall. Finally, the previously mentioned nonabsorbable sutures were attached to the vaginal cuff and tied. Routine postoperative cystoscopy was performed.
214447206|NCT06792331|PROCEDURE|Laparoscopic lateral suspension|The polypropylene mesh used had a width of 2.5 cm and a length of 25 cm. The vaginal cuff was suspended. Blunt dissection was applied to develop vesicovaginal and rectovaginal spaces. The middle part of the mesh was placed flatly in the vesicovaginal space, and fixed with non-absorbable sutures. An atraumatic laparoscopic instrument was inserted through skin incisions of approximately 2-3 mm approximately 3 cm above and 4 cm lateral to the anterior superior iliac spine, followed by perforation only of the aponeurosis of the external oblique muscle and retroperitoneal advancement of the instrument through the lateral abdominal wall. Under laparoscopic visualization, the instrument moved through the bilateral tension-free retroperitoneal tunnels created. The lateral arms of the mesh were secured bilaterally to the aponeurosis of the external oblique muscle and behind the anterior superior iliac spine. Finally, the peritoneum was closed.
214447207|NCT06781879|DRUG|Mitomycin c|Chemoablation
214447208|NCT03432832|BEHAVIORAL|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
214447209|NCT03432832|BEHAVIORAL|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
214447210|NCT06754579|OTHER|High-Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
214447211|NCT06754579|OTHER|Low Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
214447212|NCT06728176|DRUG|MT1988|Active Drug
214447213|NCT06728176|DRUG|Placebo|Placebo comparator
214694333|NCT04436809|PROCEDURE|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
214694334|NCT04436809|PROCEDURE|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
215126579|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
215126580|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
215126581|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
215126582|NCT06306170|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
215126583|NCT03776799|DEVICE|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
215126584|NCT03776799|DEVICE|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
215126585|NCT03281928|DIETARY_SUPPLEMENT|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
214447214|NCT06926686|PROCEDURE|Autologous tarsus|Surgical implantation of autologous tarsus to the lower eyelid
214447215|NCT06926686|PROCEDURE|Acellular dermal matrix|Surgical implantation of acellular dermal matrix to the lower eyelid
214523931|NCT04453969|OTHER|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
214523932|NCT01275911|DRUG|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
215126586|NCT03281928|DIETARY_SUPPLEMENT|Placebo|Sodium without Potassium Citrate
215126587|NCT00970918|PROCEDURE|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
215126588|NCT00970918|BIOLOGICAL|Blood sample testing for hs-CRP|one time, blood sample taking
215126589|NCT05154084|BEHAVIORAL|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
215126590|NCT02110563|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
215126591|NCT00101686|DRUG|Modified Bolus 5-FU/LV with Irinotecan|Day 1 \& 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID \[two times a day\] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
214447218|NCT04839302|DRUG|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
214447219|NCT06902506|BEHAVIORAL|Augmented Music|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
214447220|NCT06902506|BEHAVIORAL|Non-Augmented Music|Same melodic theme without the augmentation.
214447221|NCT06930989|DEVICE|Positive airway pressure (PAP)|Intervention as part of routine clinical care. Data from national registries.
214447222|NCT06762548|DRUG|DA-007|Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine
214447223|NCT06762548|DRUG|Placebo|Topical placebo solution
214447224|NCT06785688|DEVICE|Protective gear irradiated by infrared rays|irradiated by infrared rays back brace
214447225|NCT06751329|DRUG|DM002|An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
214447226|NCT04036097|OTHER|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
214447227|NCT04036097|OTHER|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
214523933|NCT01275911|DRUG|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
214523934|NCT03133572|DEVICE|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
214523935|NCT03133572|DEVICE|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
214523936|NCT00105222|DRUG|Sodium Nitrite|
215126592|NCT00101686|DRUG|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID \[two times a day\] oral Every 2 weeks"
214447228|NCT06904495|OTHER|Survey of sleep quality and associated factors|Sleep quality and associated factors (anxiety, depression, and pain) will be evaluated through an online survey on the Reseau Morphee platform, through an self-administered evaluation of the patients' pain and sleep difficulties, and a precarity scale.
214447229|NCT06234267|BEHAVIORAL|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
214447230|NCT06467864|PROCEDURE|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
214447231|NCT06919458|DRUG|Prednisolone 40 mg|Patients will be screened for infection till 90 days from the day of initiation of prednisolone. the three patient arms will be compared for severity scores of the disease, rate and severity of infections, diabetic control, post-treatment outcomes, and mortality.
214447232|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Experimental drug: Nanokine 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Nanogen Biopharmaceutical JSC.~Arm 1 (22 volunteers): Nanokineinjection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex® injection 4000 IU will be administered subcutaneously on Day 29."
214447233|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Comparator drug: Eprex® 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Janssen-Cilag Ltd~Arm 2 (22 volunteers): Eprex® injection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex injection 4000 IU will be administered subcutaneously on Day 29.~Total: 44 participants will be recruited in the trial."
214447234|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
214447235|NCT06920069|BIOLOGICAL|sIPV|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose
214447236|NCT06920069|BIOLOGICAL|DTaP|Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose
214447237|NCT06920069|BIOLOGICAL|bOPV 1,3|Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose
214447238|NCT06920069|BIOLOGICAL|MMR Vaccine|Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose
214447239|NCT06923683|BEHAVIORAL|Treatment for social cognition disorders (T-ScEmo)|T-ScEmo is an evidence-based, multifaceted treatment protocol for poor social cognition and emotion regulation impairments in patients with ABI. T-ScEmo is implemented as standard practice in the Netherlands. In total, the treatment consists of 20 1-hour sessions. The treatment is divided into extended psychoeducation for patient and proxy and 3 modules, including emotion perception (module 1), perspective taking and understanding social information (module 2), and goal-directed social behavior (module 3). These three modules are interdependent and strengthen each other. Therefore, the developers strongly recommend to offer all three modules. The presence of a proxy is required in the first psycho-education session and during the third module. The first and second modules are invariant (10 sessions together), but in the third module, therapists can adjust the content to individual needs and personal goals.
214447240|NCT06931795|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
215126593|NCT00101686|DRUG|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV \*over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID \[two times a day\] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID \[two times a day\] continues daily without interruption Every 3 weeks
215126594|NCT00101686|DRUG|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID \[two times a day\](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
214447241|NCT06931795|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
214523937|NCT04711018|DIAGNOSTIC_TEST|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
214523938|NCT05652985|BEHAVIORAL|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
214523939|NCT01217294|PROCEDURE|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
214523940|NCT01217294|PROCEDURE|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
214523941|NCT05473468|DRUG|Famitinib|a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
215126595|NCT00101686|DRUG|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
215126596|NCT02008123|DRUG|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
215126597|NCT04390451|BEHAVIORAL|Whole Health STEPS|A peer-delivered package of Whole Health services.
215126598|NCT05904197|OTHER|Gamified Cards about Nephrotic Syndrome|"* The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication…etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child."
215126599|NCT02907424|DIETARY_SUPPLEMENT|2 months of treatment|standard 2 months of treatment
215126600|NCT00391482|BEHAVIORAL|Peer Mentoring Intervention for HCV-Infected IDUs|
215126601|NCT03044366|OTHER|general anesthesia management of preterm infants|general anesthesia management of preterm infants
214447242|NCT06931912|BEHAVIORAL|MENBS clinical interventions|"* Monitor: Continuously monitor health-related indicators through regular follow-up.~* Education: Provide health education to improve cognition of patients and their families.~* Nutrition: Assess patients' nutritional risks and develop personalized diet plans.~* Behavior: Recommend appropriate exercise plans to promote physical development.~* Support: Conduct home visits, offer free clinics and establish a support network."
214447243|NCT06932653|OTHER|SurgPASS - intervention|SurgPASS consists of a preoperative surgical passport used for any patients requiring emergency laparotomy, a simulation training course and local clinical champions.
214447244|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active|Transcranial focussed ultrasound to target site
214447245|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Sham|Transcranial focussed ultrasound off
214447246|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active control|Transcranial focussed ultrasound on to control
214447247|NCT05478213|DEVICE|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
214447248|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
214447249|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
214447250|NCT04222660|DIETARY_SUPPLEMENT|Blackmores Omega Daily (4 1g capsules per day)|Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
214447251|NCT05385965|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
214447252|NCT04075903|BEHAVIORAL|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
214523942|NCT00065663|GENETIC|GAM501|
214523943|NCT02577315|DRUG|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
214523944|NCT02577315|DRUG|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
214523945|NCT02577315|DRUG|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
214523946|NCT02577315|DRUG|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
214523947|NCT05773599|OTHER|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
214694335|NCT01820078|DRUG|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
215126602|NCT06188507|DRUG|GSK4347859|GSK4347859 will be administered
215126603|NCT06188507|DRUG|Placebo|Placebo will be administered
215126604|NCT00867165|DRUG|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
215126605|NCT00867165|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
215126606|NCT04138992|DRUG|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
215126607|NCT04138992|DRUG|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
215126608|NCT04138992|DRUG|Docetaxel|used in neoadjuvant chemotherapy
215126609|NCT04138992|RADIATION|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
215126610|NCT02351765|DRUG|Acelarin|First-in-class nucleotide analogue
215126611|NCT02351765|DRUG|Cisplatin|Platinum-compound chemotherapy drug
215126612|NCT02183857|DEVICE|Ultrasound|
215126613|NCT02183857|OTHER|Landmark|
215126614|NCT04125043|DIAGNOSTIC_TEST|Direct ophthalmoscope|Red reflex test
214523948|NCT00986661|DRUG|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
214523949|NCT05711017|DRUG|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
214523950|NCT05711017|DRUG|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
214523951|NCT04758156|DRUG|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
215126615|NCT04441411|DEVICE|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
215126616|NCT05120414|OTHER|balanace exercises|Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
215126617|NCT05120414|OTHER|Balance Exercises plus Ankle strategy|ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
214523952|NCT04758156|DRUG|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
214523953|NCT03885622|DEVICE|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
214523954|NCT05200299|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
214523955|NCT05200299|DRUG|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
214523956|NCT06072352|OTHER|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
214523957|NCT06072352|OTHER|Normal saline|Perineal cleansing using normal saline
215126618|NCT02738008|DRUG|ARC-520 Injection|IV injection
215126619|NCT02738008|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
215126620|NCT02738008|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
214523958|NCT01945086|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
214523959|NCT01945086|DRUG|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
214523960|NCT01945086|OTHER|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
215126621|NCT02738008|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
215126622|NCT03781661|OTHER|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
215126623|NCT04912778|OTHER|Filling in an online survey|Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
215126624|NCT03550378|DRUG|MEDI0382|Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
215126625|NCT03550378|DRUG|Placebo|Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
215126626|NCT00017511|DRUG|cevimeline hydrochloride|
214447253|NCT06835829|DEVICE|Transradial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance transradial access hemostasis
214447254|NCT06835829|DEVICE|Distal radial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance distal radial access hemostasis
214447255|NCT06835829|PROCEDURE|Ultrasound-guidance|Ultrasound guidance for distal radial access
214447256|NCT06835829|PROCEDURE|Conventional guidance|Conventional guidance for distal radial access
214447257|NCT06784388|DEVICE|Deep Brain Stimulation(DBS)|During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
215126627|NCT04283071|DEVICE|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
215126628|NCT00468299|DRUG|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
215126629|NCT00468299|DRUG|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
215126630|NCT04827108|OTHER|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
215126631|NCT00586859|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
215126632|NCT02205996|DRUG|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
215126633|NCT02205996|DEVICE|Euglycaemic Hypoglycaemic Insulin clamp|
215126634|NCT03546621|DRUG|Myrcludex B|2 mg, once daily, subcutaneously
215126635|NCT03546621|DRUG|Myrcludex-B|5 mg, once daily, subcutaneously
215126636|NCT03546621|DRUG|Myrcludex-B|10 mg, once daily, subcutaneously
215126637|NCT03546621|DRUG|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
215126638|NCT00646646|DRUG|propofol|sedative
214447258|NCT06784388|DRUG|Esketamine|SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
214447259|NCT06721741|OTHER|Nusmile bioflex crowns|The Bioflex crown is a new synthetic crown that has been introduced in pediatric practice. This crown is believed to offer better adaptation, durability, and ease of handling, along with improved aesthetic properties when compared to conventional crowns
214447260|NCT06721741|OTHER|Stainless steel crowns|Preformed metal crowns are a popular and affordable option as a treatment for dental caries. They offer full crown coverage and help to prevent recurrent caries. However, their aesthetic limitation is a notable drawback
214447261|NCT06787079|OTHER|Kinesio Tape|Kinesio tape is a non-invasive therapeutic approach that does not involve any medication. It is often used to support tissue and reduce pain.
214447262|NCT06787079|OTHER|Pilates|Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
214447263|NCT06787079|OTHER|Placebo|Placebo taping will be applied in the same way as kinesio taping, but with plaster tape.
214447264|NCT05460416|DRUG|Acetylsalicylic acid|160mg once a day
214447267|NCT02520063|DRUG|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
215126639|NCT00646646|DRUG|dexmedetomidine|Sedative
215126640|NCT00646646|DRUG|Midazolam|sedative
214447268|NCT02520063|DRUG|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
214447269|NCT02520063|DRUG|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
214447270|NCT05005221|BEHAVIORAL|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
214447271|NCT06782659|DRUG|ASP-001|Oral liquid suspension of sildenafil
214447272|NCT06782659|DRUG|Viagra|Sildenafil film-coated tablet
214447273|NCT06782659|DEVICE|ASP-001|Bottle/pump containing ASP-001 suspension
214447274|NCT05612477|PROCEDURE|Autotransfusion|blood is collected from the surgical field, washed, processed and transfused back into the patient
214447275|NCT06477107|DEVICE|Soterix® 4x1HD-TDCS|Is intended for inducing cortical neuromodulation for research and treatment purposes.
214523961|NCT04644692|OTHER|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
214523962|NCT00507702|PROCEDURE|phlebotomy|Standard of care
214523963|NCT03852485|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
215126641|NCT00646646|DRUG|saline placebo|saline placebo
215126642|NCT03901495|OTHER|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
215126643|NCT00377520|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
215126644|NCT02111447|DRUG|Propofol|Propofol infusion with nasal oxygen
215126645|NCT02111447|DRUG|Propofol|Propofol infusion with an LMA
215126646|NCT02111447|DRUG|Sevoflurane|Sevoflurane with an LMA
215126647|NCT02111447|DRUG|Isoflurane|Isoflurane with an LMA
215126648|NCT03476200|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
215126649|NCT06045312|OTHER|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
215126650|NCT06304116|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
215126651|NCT06304116|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215126652|NCT06304116|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215126653|NCT01145742|BEHAVIORAL|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
215126654|NCT01746303|DIETARY_SUPPLEMENT|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
215126655|NCT01746303|DIETARY_SUPPLEMENT|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
215126656|NCT01746303|OTHER|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
215126657|NCT01746303|OTHER|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
215126658|NCT00799201|DRUG|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
215126659|NCT00407771|DRUG|Tirofiban|
215126660|NCT04002076|BEHAVIORAL|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
215126661|NCT04002076|BEHAVIORAL|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
214447276|NCT06477107|DEVICE|Soterix® 1x1 tDCS|At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.
215126662|NCT06185465|DEVICE|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
215126663|NCT06185465|DEVICE|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
215126664|NCT05081895|DEVICE|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
214523964|NCT01019824|DRUG|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
214523965|NCT01556087|BEHAVIORAL|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
214523966|NCT01556087|BEHAVIORAL|Health Education|7 individual sessions with didactic health education information
214447277|NCT06477107|BEHAVIORAL|Cognitive training program|Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation
214447278|NCT04880226|DEVICE|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
214447279|NCT03940703|DRUG|Tepotinib|Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
214447280|NCT03940703|DRUG|Osimertinib|Participants received Osimertinib at a dose of 80 mg orally once daily.
214447281|NCT06407973|DEVICE|OMNI Surgical System|The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
215126665|NCT05081895|OTHER|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
215126666|NCT03291938|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
215126667|NCT03291938|OTHER|Pharmacodynamic Study|Correlative studies
215126668|NCT03291938|OTHER|Pharmacokinetic Study|Correlative studies
215126669|NCT06110663|DRUG|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
214523967|NCT06416189|DEVICE|Fixed appliances|MBT Brackets 0.022 inch
215126670|NCT06110663|DRUG|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
215126671|NCT01847352|DRUG|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
215126672|NCT01847352|OTHER|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
215126673|NCT04362436|RADIATION|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
215126674|NCT06012682|DRUG|Metformin Hydrochloride|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
215126675|NCT06012682|DRUG|Placebo|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
215126676|NCT00258141|DRUG|Rupatadine|
215126677|NCT00258141|DRUG|Placebo|
215126678|NCT02570503|DRUG|Ropivacaine|Ropivacaine (5mg/ml)-50ml
215126679|NCT02570503|DRUG|Ketorolac|ketorolac (30mg/ml)- 1 ml
215126680|NCT02570503|DRUG|Clonidine|clonidine (0.1mg/ml)- 0.8ml
215126681|NCT02570503|DRUG|Epinephrine|epinephrine (1mg/ml)-1ml
215126682|NCT02570503|DRUG|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
215126683|NCT01464086|OTHER|whole body MRI|whole body MRI at inclusion, one and two years
215126684|NCT04296760|DIAGNOSTIC_TEST|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
215126685|NCT04296760|DIAGNOSTIC_TEST|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
215126686|NCT06141707|OTHER|Arabic pediatric sleep questionnaire|Pediatric Sleep Questionnaire (PSQ) developed and validated by chervil et al. (2000) is a 22 item questionnaire which had been shown to have a sensitivity of 81% and specificity of 87% for SRBD.These scales for childhood SRBDs, snoring, sleepiness, and behavior are valid and reliable instruments that can be used to identify SRBDs or associated symptom-constructs in clinical research when polysomnography is not feasible.
215126687|NCT03797846|PROCEDURE|combined glaucoma surgery|combined procedure with trabeculectomy and cataract removal
215126688|NCT00462306|PROCEDURE|Survey: Berlin questionnaire|Completion of questionnaire
215126689|NCT04236674|DEVICE|Buzzy thermomechanical device|Buzzy thermomechanical device placed near intervention site.
215126690|NCT04236674|BEHAVIORAL|Music Selection|Patient specified procedural music
215126691|NCT01623479|DRUG|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
214447282|NCT06407973|DRUG|Latanoprost plus adjunctive glaucoma medication|"* Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator"
214447283|NCT05560529|BEHAVIORAL|DBT|Applying DBT modules in group format over 20 weeks
214447284|NCT05560529|DRUG|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
214523968|NCT02056925|OTHER|Echocardiography|
214447285|NCT05560529|DIAGNOSTIC_TEST|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
214523969|NCT03962127|OTHER|no intervention|no intervention
214447286|NCT06788652|BIOLOGICAL|Lisocabtagene maraleucel|According to US Prescribing Information
214523970|NCT07009145|DRUG|QL1706|QL1706 (Iparomlimab and Tuvonralimab) is administered at a dose of 5 mg/kg via intravenous infusion on Day 1 of each 3-week cycle (Q3W).
215126692|NCT05839574|DRUG|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
215126693|NCT05839574|DRUG|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
215126694|NCT05101434|DIAGNOSTIC_TEST|Periodontal Probing|with the help Michigan probe, periodontal pocket measurement was done.
215126695|NCT04808817|DIAGNOSTIC_TEST|calorimetry, impedance measurement at baseline and after 3 months of treatment|biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
215126696|NCT02173080|OTHER|PLD-Q|polycystic liver disease questionnaire
214447287|NCT06783504|DEVICE|PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION|The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
214447288|NCT06783504|DEVICE|Sham percutaneous electrical nerve field stimulation|SHAM (no electrical charge)
214447289|NCT06789562|DEVICE|F-18FDG PET/CT and CT|compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
214447290|NCT06791434|DRUG|"Fixed Dose Combination Etoshine MR tablets"|Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
214447291|NCT06791434|PROCEDURE|Dry needling|Thin needle insertion
214447292|NCT06791434|OTHER|Physiotherapy|Exercises
214447293|NCT06790849|DIETARY_SUPPLEMENT|Active 1 ETAS®|300 mg ETAS®
214447294|NCT06790849|DIETARY_SUPPLEMENT|Active 2 ETAS®|1500mg ETAS®
214523971|NCT07009145|DRUG|Bevacizumab|Bevacizumab is administered at a dose of 7.5 mg/kg every 3 weeks (Q3W) via intravenous (iv) infusion.
214523972|NCT07008508|DRUG|Cyclin-dependent Kinase 4/6 Inhibitor|Planned new line of Cyclin-dependent Kinase 4/6 Inhibitor
214523973|NCT07007910|DRUG|HSK46575|co-administered with glucocorticoid and fludrocortisone, orally daily
214523974|NCT07008521|PROCEDURE|Universal exercise unit|universal exercise unit (UEU) for study groip (A)
214523975|NCT07008521|PROCEDURE|Rebound Therapy|rebound therpay for study group (B)
215126697|NCT03499093|OTHER|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
215126698|NCT00154297|DRUG|Everolimus (RAD001)|
214447295|NCT06790849|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule
214447296|NCT04662112|DRUG|NASOX|Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
214447297|NCT06778148|OTHER|Ambient AI for clinician documentation|Ambient AI for clinician documentation
214447298|NCT05815173|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
214447299|NCT05815173|DRUG|Ladarixin|"Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles."
214447300|NCT05760261|DRUG|Midazolam|Midazolam will be administered.
214447301|NCT05760261|DRUG|GSK3882347|GSK3882347 will be administered.
214447302|NCT02972372|PROCEDURE|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
214447303|NCT02972372|PROCEDURE|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
214523976|NCT07008521|PROCEDURE|Traditional physical therapy program|traditional physical therapy program for contrl group
214523977|NCT05022472|BEHAVIORAL|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
214694336|NCT01820078|OTHER|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
215126699|NCT06544174|OTHER|Percutaneous Coronary Intervention of CTO|CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
215126700|NCT01302353|DRUG|Emulsified Isoflurane|
214523978|NCT05022472|BEHAVIORAL|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
214523979|NCT05022472|BEHAVIORAL|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
214523980|NCT05022472|BIOLOGICAL|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
214523981|NCT06720649|OTHER|isokinetic test|Bilateral strength will be measured using a Contrex ® dynamometer equipped with an exercise table. Each subject will perform isokinetic tests of the right and left knee extensors and flexors. Subjects will be stabilized by straps during testing and the joint rotation axis will be aligned with the input shaft of the dynamometer.
214523982|NCT06720649|OTHER|Ballistic test|ballistic squat jumps performed in the supine position on a frictionless sled at a resistance between 0% of body weight (BW)
214523983|NCT06720649|OTHER|K-STARTS test|"The K-STARTS (Knee Health Athletic Return To Sport) test brings together a set of 7 tests validated in the scientific literature to assess the control and neuromuscular capacities of the lower limb when performing dynamic movements as well as apprehension when resuming activity.~Test in 30 minutes with physical exercises and questionnaire."
215126701|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
215126702|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
215126703|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
215126704|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
215126705|NCT02548208|DEVICE|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
215126706|NCT02548208|DEVICE|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
215126707|NCT01111617|PROCEDURE|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
215126708|NCT00930085|OTHER|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
215126709|NCT06005181|BEHAVIORAL|Music listening|Daily music listening
214447304|NCT05925270|BEHAVIORAL|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
214447305|NCT05925270|BEHAVIORAL|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
214447306|NCT04521478|DRUG|BI 1358894|BI 1358894
214447307|NCT04521478|DRUG|Placebo|Placebo
214447308|NCT04521478|DRUG|Quetiapine|quetiapine
214447309|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
214447310|NCT05023928|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
214447311|NCT04578912|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
214447312|NCT04578912|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
214447313|NCT04578912|DEVICE|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
214447314|NCT00216879|DRUG|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
214447315|NCT04210596|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
214523984|NCT06720649|OTHER|Questionnaires|KOOS (Knee Injury and Osteoarthritis Outcome Score) Questionnaire
214523985|NCT04113187|DRUG|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
215126710|NCT06005181|BEHAVIORAL|Piano training|Daily piano practice
215126711|NCT05546775|DIAGNOSTIC_TEST|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~* To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~* To assess the growth parameters in patients with CGD."
215126712|NCT00187863|BEHAVIORAL|pain perception|pain perception
215126713|NCT01619371|DEVICE|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
215126714|NCT05051579|DRUG|LY3502970|Administered orally
214523986|NCT04113187|DRUG|Placebo|per os, twice a day (morning and evening) during three months
214523987|NCT04728217|DRUG|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
214523988|NCT04414254|DRUG|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
214523989|NCT00657475|DRUG|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
214523990|NCT00657475|DRUG|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
214523991|NCT01414725|OTHER|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
214523992|NCT01414725|OTHER|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
214523993|NCT01414725|OTHER|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
215126715|NCT05051579|DRUG|Placebo|Administered orally
215126716|NCT05055024|DRUG|Mazindol|Drug: NLS-2
214694337|NCT06412419|DIAGNOSTIC_TEST|Magnifying Endoscopy and Endoscopic Ultrasonography|The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
214694338|NCT00311181|DEVICE|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
214447316|NCT06549829|OTHER|Nutritional optimization-led triple prehabilitation Intervention|The nutritional status of the patients was assessed together with the clinical nutritionist to develop an individualized nutritional plan. The experimental group used ordinary dietary supplementation + transoral nutritional supplementation, and the control group used ordinary dietary supplementation. The target energy was basal energy metabolism level \* physical activity level, physical activity level was male: 1.55 female: 1.56; basal energy level was basal metabolism standardized value \* body weight (basal metabolism standardized value for obese patients was 25; basal metabolism standardized value for normal or emaciated patients was 30). Add 600kcal capacity supplement to this. Exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance. Specialized psychological interventions.
214447317|NCT06549829|OTHER|Conventional triple prehabilitation Intervention|Conventional triple prehabilitation: ordinary dietary supplementation; exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance; specialized psychological interventions.
214447318|NCT04351685|BIOLOGICAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
214447319|NCT04351685|BIOLOGICAL|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
214447320|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
214447321|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
214447322|NCT03170141|BIOLOGICAL|Antigen-specific IgT cells|Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3
214447323|NCT00159406|OTHER|Registry and Database|Data Collection
214447324|NCT06776718|PROCEDURE|vNOTES|vNOTES for benign hysterectomy
214447325|NCT06776718|PROCEDURE|vaginal hysterectomy|vaginal hysterectomy for benign hysterectomy
214447326|NCT05636358|OTHER|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
214523994|NCT01239537|DRUG|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
214694339|NCT02669862|DRUG|A-101 Solution 40|
214694340|NCT02669862|DRUG|A-101 Solution 45|
214694341|NCT02669862|DRUG|Vehicle Solution|
214694342|NCT01907984|DRUG|Diclofenac|
214694343|NCT01907984|DRUG|Midazolam|
215126717|NCT06262893|PROCEDURE|Shoulder arthroscopy blocks|Effect of dexamethasone adjuvant in combined supraclavicular block and suprascapular block versus Interscalene block in patients undergoing shoulder arthroscopy.
215126718|NCT02108249|DEVICE|Annex™ Adjacent Level System|
214523995|NCT06309849|OTHER|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique)|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique) strengthening exercises for neck muscles, ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2.
215126719|NCT03333707|BEHAVIORAL|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
215126720|NCT04477161|DIETARY_SUPPLEMENT|Ketone Ester Elite endurance Nutrition Drink|Subjects will take one bottle four times daily for four weeks
215126721|NCT04477161|OTHER|Stool Sample|Subjects will provide a stool sample at 2 timepoints.
215126722|NCT00001118|DRUG|Enfuvirtide|
215126723|NCT04608565|DEVICE|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
215126724|NCT02356913|DRUG|Nicotine gum|
215126725|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
215126726|NCT04657874|OTHER|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
214708785|NCT03194620|OTHER|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
215126727|NCT04657874|OTHER|Placebo|Oral tablet without the active principle
215126728|NCT02872246|DRUG|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214447327|NCT04081714|DRUG|CNM-Au8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.
214447328|NCT05215067|DRUG|AK104|IV infusion,Specified dose on specified days
214447329|NCT05215067|DRUG|Docetaxel|IV infusion,Specified dose on specified days
214447330|NCT04867395|BEHAVIORAL|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
214447331|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
214447332|NCT06459310|DRUG|Metformin Hydrochloride tablet|Extended release oral tablets, 1000 mg/day, single dose
214447333|NCT06459310|DRUG|Placebo|Oral tablets, 1000 mg/day, single dose
214447334|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
214447335|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
214447336|NCT04982224|DRUG|REGN5093-M114|Administered by intravenous (IV) infusion
214447337|NCT04982224|DRUG|Cemiplimab|Administered by IV infusion
214447338|NCT05642156|PROCEDURE|isolated Ultrafiltration (iso-UF)|isolated Ultrafiltration
214447339|NCT04712994|OTHER|PrEP Optimization Interventions|A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
214447340|NCT03684109|DEVICE|3T MRI Scanner|3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
214447341|NCT06763575|DEVICE|Surgical Glove-Compression Therapy|In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
214447342|NCT06763575|DEVICE|non-compressive plastic gloves|In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
214447343|NCT06763406|OTHER|Exercise|Due to the limited research on exercise approaches for pectus excavatum, further investigation in this field is needed. This study aims to explore the impact of Schroth-based exercise therapy on adolescents with pectus excavatum.
214523996|NCT04389918|OTHER|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
214523997|NCT01151878|DIETARY_SUPPLEMENT|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
214523998|NCT01151878|DIETARY_SUPPLEMENT|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
215126729|NCT02872246|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
215126730|NCT00012103|OTHER|bronchoalveolar lavage|
215126731|NCT00012103|OTHER|screening questionnaire administration|
215126732|NCT00012103|OTHER|sputum cytology|
215126733|NCT00012103|PROCEDURE|bronchoscopic and lung imaging studies|
215126734|NCT00012103|PROCEDURE|bronchoscopy|
215126735|NCT00012103|PROCEDURE|computed tomography|
215126736|NCT00012103|PROCEDURE|study of high risk factors|
215126737|NCT05100615|PROCEDURE|surgery|applying the graft inside bony defect after surgery
215126738|NCT05054140|DRUG|IMU-838|IMU-838 tablets
214447344|NCT06762925|OTHER|No Interventions|No Interventions
214447345|NCT06772441|DRUG|Androgen deprivation therapy (ADT)|"* Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant"
214447346|NCT02692807|PROCEDURE|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
214447347|NCT04985695|DRUG|Epidural analgesia|All patients received local anesthesia (3-5 ml of 2% Lidocaine). During the preoperative induction of anaesthesia a catheter was inserted 4cm into the epidural space. The catheter will be load during the intervention (0.1 ml/kg/h). In postoperative situation, a patient controlled epidural analgesia was introduced with a debit adapted to the arterial pressure.
214447348|NCT04985695|DRUG|Bilateral rectus sheath block|Bilateral rectus sheath block was performed Under general anesthesia and with ultrasound guidance. Rectus sheath block was inserted on each side of the abdomen. All patients received ropivacaine through elastomeric pump
214447349|NCT04985695|PROCEDURE|Laparotomy|A midline sub or supra umbilical laparotomy or xypho-pubian laparotomy
214447350|NCT05567705|OTHER|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
214447351|NCT06784115|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
214447352|NCT05246657|PROCEDURE|EUS-guided Entero-biliary Anastomosis|EUS-guided Entero-biliary Anastomosis
214447353|NCT06332599|DRUG|BQT|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
214447354|NCT06332599|DRUG|PBM4M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
214447355|NCT06332599|DRUG|PBM3M3|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
214447356|NCT06332599|DRUG|PBM2M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
214447357|NCT06332599|DRUG|PBM2M3|PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
214447358|NCT05332379|DIAGNOSTIC_TEST|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
214447359|NCT06190678|DRUG|Pirtobrutinib|Administered orally
214447360|NCT06525740|DRUG|Hydromorphone|Given IT
214447361|NCT06525740|DRUG|Methadone|Given IV
214447362|NCT06525740|OTHER|Questionnaire Administration|Ancillary studies
214447363|NCT05911932|OTHER|Biosample collection.|Blood draw.
214447364|NCT06764953|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
214447365|NCT06764953|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
214447366|NCT04974892|DIAGNOSTIC_TEST|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
214523999|NCT03950596|OTHER|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
215126739|NCT05054140|DRUG|Placebo matching IMU-838|Placebo matching IMU-838 tablets
215126740|NCT04161885|DRUG|Venetoclax|Tablet; Oral
215126741|NCT04161885|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
215126742|NCT04161885|OTHER|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
215126743|NCT04849130|PROCEDURE|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
215126744|NCT04849130|PROCEDURE|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
215126745|NCT04744961|OTHER|SCAR-Q survey|Telephone survey
215126746|NCT05609942|DRUG|BLU-263|BLU-263 Oral Tablets
215126747|NCT05609942|DRUG|Azacitidine|Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
215126748|NCT06542133|DEVICE|AVEIR remote care system|In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
215126749|NCT05577923|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
215126750|NCT05577923|DRUG|pyrotinib|Pyrotinib 320mg, PO daily, continuously
215126751|NCT05577923|DRUG|Dalpiciclib|Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
215126752|NCT05577923|DRUG|fulvestrant|Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
215126753|NCT00990106|DRUG|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
215126754|NCT00990106|DRUG|placebo|placebo
215126755|NCT05152459|DRUG|Tazemetostat|Given PO
215126756|NCT05152459|BIOLOGICAL|Ublituximab|Given IV
215126757|NCT05152459|DRUG|Umbralisib|Given PO
215126758|NCT06067503|DRUG|18F-fluorofuranylnorprogesterone|The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
215126759|NCT06067503|DEVICE|Liquid Biopsy|20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
215126760|NCT06067503|DEVICE|Positron Emission Tomography/Computed Tomography|FFNP drug in combination with PET/CT scans to image participant
215126761|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
215126762|NCT00052585|DRUG|irinotecan hydrochloride|Given IV
215126763|NCT00052585|DRUG|gefitinib|Given orally
215126764|NCT00052585|DRUG|leucovorin calcium|Given IV
215126765|NCT00052585|DRUG|fluorouracil|Given IV
215126766|NCT06763055|DRUG|Colchicine 0.5 mg|The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.
215126767|NCT06763055|DRUG|Deferoxamine Mesylate|The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
215126768|NCT06763055|OTHER|Control (Standard treatment)|The group will not receive deferoxamine mesylate or colchicine
215126769|NCT00410956|BIOLOGICAL|bevacizumab|
214447367|NCT05320432|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
214447368|NCT05320432|DEVICE|Sham|No current applied through pads.
214447369|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
214447370|NCT04767568|DIAGNOSTIC_TEST|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
214447371|NCT04767568|OTHER|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
214447372|NCT04767568|OTHER|stool collection|In cohort B: Stool sample n°1 collected before surgery. Stool sample n°2 collected 1 month after surgery
214447373|NCT04827953|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
214447374|NCT04827953|DRUG|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
214447375|NCT04827953|DRUG|NLM-001|NLM-001 will be administered three cycles consecutively followed by two rest cycles.
214447376|NCT04827953|DRUG|Zalifrelimab|Zalifrelimab administration each 6 weeks.
214524000|NCT03950596|BEHAVIORAL|Background Questionnaire|Background questionnaire will be filled out by participants
215126770|NCT00410956|DRUG|dexamethasone|
215126771|NCT00410956|DRUG|floxuridine|
215126772|NCT00410956|GENETIC|protein expression analysis|
215126773|NCT00410956|OTHER|flow cytometry|
215126774|NCT00410956|OTHER|immunoenzyme technique|
215126775|NCT00410956|OTHER|immunohistochemistry staining method|
215126776|NCT00410956|OTHER|immunologic technique|
215126777|NCT00410956|OTHER|laboratory biomarker analysis|
215126778|NCT00410956|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
215126779|NCT01194037|DRUG|recombinant variant of interferon-alpha 2b|SC, Weekly
214447377|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Left hemi-back|The treated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214447378|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Right hemi-back|The treated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214524001|NCT03950596|OTHER|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
214524002|NCT03950596|GENETIC|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
214524003|NCT03950596|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
215126780|NCT01194037|DRUG|Peginterferon alfa-2a|SC Weekly
215126781|NCT01194037|DRUG|Ribavirin|Oral administration (The daily dose of ribavirin(RBV) was 1000mg for subjects weighing \< 75 kg or 1200 mg for subjects weighing ≥ 75 kg)
215126782|NCT04418258|DEVICE|Capillary Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter\[#CSL2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
215126783|NCT04418258|DEVICE|Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter\[#2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
215126784|NCT06920888|BEHAVIORAL|Cognitive restructuring|CR drawn from classic CBT
215126785|NCT06920888|BEHAVIORAL|Attention allocation|AA drawn from contemporary CBTs
215126786|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
215126787|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
215126788|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
215126789|NCT02783196|DRUG|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
215126790|NCT02783196|DRUG|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
215126791|NCT06726226|OTHER|Standard care for preterm infants|Standard care for preterm infants according to the institutional protocol
215126792|NCT04388683|DRUG|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
215126793|NCT06725472|PROCEDURE|Open Heart Surgery|This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.
215126794|NCT06725771|DRUG|Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline|Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
215126795|NCT06725771|DRUG|Sertraline Hydrochloride Tablets|Sertraline are given to patients simultaneously
215126796|NCT06726642|DIAGNOSTIC_TEST|Cell-free DNA analysis|Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).
215126797|NCT06921135|DIETARY_SUPPLEMENT|supplementation, food|Supplementation of fresh foods
215126798|NCT06922578|PROCEDURE|NeoPUTTY MTA pulpotomy|Neoputty MTA pulpotomy performed in vital primary molars with symptomatic irreversible pulpitis
215126799|NCT06922578|PROCEDURE|Endoflas pulpectomy|Endoflas pulpectomy in vital primary molars with symptomatic irreversible pulpitis
215126800|NCT06921811|OTHER|Intact chickpeas|Salad meal containing intact chickpeas
215126801|NCT06921811|OTHER|Broken chickpeas|Burger meal containing chickpea flour
215126802|NCT00880698|BIOLOGICAL|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose
215126803|NCT00880698|BIOLOGICAL|Placebo|2 mL solution
215126804|NCT06726980|DRUG|dextrose 5%|patients will receive 5 % dextrose infusion
215126805|NCT06726980|DRUG|Dextrose 10%|patients will receive 10 % dextrose infusion (25gm/ 250 mL)
215126806|NCT06726980|DRUG|0.9% saline|patients will receive infused IV 0.9 % saline
215126807|NCT06727162|PROCEDURE|Contrast-Enhanced Ultrasound|"Participants are scanned in a supine position with the neck fully exposed. A routine ultrasound examination is first performed to assess the cervical lymph nodes. Assessment includes: number, size, location (zones I-VII), structure, echogenicity, margin, shape, hilum, calcification, and vascular distribution.~After the routine ultrasound scan, the ultrasound system is switched to dual contrast-enhanced ultrasound mode. Sonazoid (GE Healthcare) is then administered intravenously through the antecubital vein at a dose of 0.015 mL/kg, followed by an injection of 5 mL of physiological saline. A timer is started after the injection, and video recording is made during the vascular phase from 5 to 60 seconds."
215126808|NCT06705075|DRUG|Perfluten|Use of UCA Definity to evaluate uterine fibroids by contrast-enhanced ultrasound (CEUS) and subharmonic-aided pressure estimation (SHAPE) pre and post-uterine artery embolization (UAE).
215126809|NCT06726291|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
215126810|NCT06890702|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including urine, feces, cerebrospinal fluid, blood, plaques, emboli, drainage fluid, bone marrow, lymph nodes and brain tissue etc al) of ischemic cerebrovascular disease
215126811|NCT06727461|OTHER|Home-based Feeding EnhancEment in Dementia (Feed@home)|"The FEED@home program is an 8-week initiative led by a speech therapist (ST) and nurse team through teleconsultations and home visits:~* Within 3 days after discharge, a nurse teleconsultation with the family caregiver to assess the patient's mealtime behaviors and provide feeding strategy recommendations and educational materials.~* Two to three home visits by STs during mealtime (depending on the mastery of feeding techniques) to assess swallowing and cognitive feeding issues, providing tailored interventions and proper training of feeding techniques.~* Two teleconsultations by nurses to assess the caregiver's techniques and provide additional training.~* One additional home visit during mealtime by a nurse to assess the caregiver's mastery of the feeding techniques through observation.~* The program lasts 8 weeks, regardless of readmissions, unless the patient converts to tube feeding, moves to a care home, passes away, or withdraws from study."
214447379|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Left hemi-back|The untreated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
215126812|NCT00004164|BIOLOGICAL|filgrastim|
215126813|NCT00004164|DRUG|cisplatin|
215126814|NCT00004164|DRUG|docetaxel|
215126815|NCT00004164|DRUG|fluorouracil|
215126816|NCT00004164|DRUG|leucovorin calcium|
215126817|NCT00004164|RADIATION|radiation therapy|
214524004|NCT03950596|DIAGNOSTIC_TEST|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
214524005|NCT00312364|DRUG|MRE0094|
215126818|NCT05935592|BEHAVIORAL|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
215126819|NCT05935592|BEHAVIORAL|Didactic health information|Web-based newsletters (for child and parent) by email and/or text
215126820|NCT06576934|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
215126821|NCT06755281|OTHER|Direct Oral challenge|Patients will receive a 1-step or 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be instructed to contact the hospital after the drug provocation test to inquire delayed allergic reactions.
215126822|NCT06755281|OTHER|standard of care|The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.
215126823|NCT06785207|DEVICE|3D-printed scoliosis brace|"Scoliosis brace will be 3D printed using a Filament Innovations Icarus printer and the material CPX. There will be corrugations where extra strength is needed. The brace will be made using the same shape as the participant's current brace to minimize variables at play.~According to Sec. 890.3490 of the Code of Federal Regulations Title 21, scoliosis braces are Class I devices, requiring only general controls. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records and § 820.198, regarding complaint files."
215126824|NCT06777784|OTHER|Product A|Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette
215126825|NCT06777784|OTHER|Product B|Modern Nicotine Oral Product Cool Mint 6 mg Nicotine
215126826|NCT06777784|OTHER|Product C|Modern Nicotine Oral Product Cool Mint 12 mg Nicotine
215126827|NCT06777784|OTHER|Product D|Modern Nicotine Oral Product Cool Mint 15 mg Nicotine
215126828|NCT06777784|OTHER|Product E|Modern Nicotine Oral Product Smooth 6 mg Nicotine
215126829|NCT06777784|OTHER|Product F|Modern Nicotine Oral Product Wintergreen 6 mg Nicotine
215126830|NCT06777784|OTHER|Product G|Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine
215126831|NCT06777784|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
215126832|NCT06188767|DRUG|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
215126833|NCT06607523|DIETARY_SUPPLEMENT|Inulin|Inulin, 4g twice daily for 42 days
215126834|NCT06770023|DEVICE|Protek Solo Transseptal Cannula|The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.
215126835|NCT04846387|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
215126836|NCT04846387|DIAGNOSTIC_TEST|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
214447380|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Right hemi-back|The untreated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
214447381|NCT06300944|DRUG|saline|A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
214447382|NCT06300944|DRUG|Esketamine|A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
214524006|NCT04693650|DEVICE|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
214524007|NCT04809298|DEVICE|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
215126837|NCT04846387|DIAGNOSTIC_TEST|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
215126838|NCT04846387|BEHAVIORAL|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
215126839|NCT05107908|BEHAVIORAL|Active Implicit Priming|Approximately 10-minute behavioral intervention
215126840|NCT05107908|BEHAVIORAL|Control Implicit Priming|Approximately 10-minute behavioral intervention
215126841|NCT05107908|BEHAVIORAL|Food Exposure Task|Approximately 10-30 minute behavioral intervention
215126842|NCT03929159|PROCEDURE|Biospecimen Collection|Undergo blood biospecimen collection
215126843|NCT06911216|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution once daily (QD) (9AM ± 60 min), one drop for each eye
215126844|NCT06922396|OTHER|Parameters on admission|"A: Parameters on admission:~* Age.~* Sex.~* Comorbidities (DM, HTN, CKD, IHD, Liver Disease)~* Mode of trauma.~* Laboratory data (RBS, INR, AST, ALT, Urea, Creatinine, WBC ,HB, CK, Myoglobin).~* Ct brain findings.~* Scoring system (GCS, RTS, APACHE II).~B: Parameters after 2 weeks:~* Days on Mechanical Ventilation.~* Medical or surgical management.~* Complications (Pneumonia, DVT, septic shock, Pulmonary embolism, ARDS)."
215126845|NCT06920784|DEVICE|PRISMATIC ADAPTATION|"The experimental treatment includes a session of prismatic adaptation, in which patients, wearing priasmatic lenses, performs pointing exercises using an 11'' tablet. The visual target is represented by a black squares randomly presented in one of three spatial positions of the tablet's screen (in the centre of the screen or at 21° to the right or to the left space). Taking into account the type of lesion resulting from traumatic brain injury, the prismatic deviation induced by the lenses will be changed alternately from right to left. Then patients will wear rightward prism lenses for 5 days and leftward prism lenses for other 5 days. The prismatic deviation will be randomized.~Following these prismatic adaptation, lasting 10 minutes, cognitive training with serious games will be performed, for the remaining 30 minutes."
215126846|NCT06920784|DEVICE|Serious games|patients receiving the same serious games for 10 days over a span of 2 weeks, withouth prismatic adaptation session.
215126847|NCT06913166|OTHER|Online quiz competition|Students in the intervention and control arm will participate in an online quiz game on tobacco or diet related topics respectively. Each day, students could answer a maximum of 10 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 5 days.
215126848|NCT06922370|DIAGNOSTIC_TEST|conventional radiograph or computed tomography|patients with gitelman syndrome evaluated with conventional radiograph or computed tomography
215126849|NCT06665438|DRUG|Normal Saline (Placebo)|the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
215126850|NCT06665438|DRUG|Bupivacaine 0.25%|the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
215126851|NCT06665438|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
215126852|NCT06939348|DEVICE|The Brainsonix BX Pulsar 1002 was designed to deliver low-intensity focused ultrasound pulsations (LIFUP) to the human brain.|The BX Pulsar 1002 consists of two main elements: the transducer and the ultrasound console. The transducer itself and the housing for it went through several iterations in order to be compatible with an MRI environment. Currently, the transducer and its housing are deemed MR-conditional at 3T with SAR ≤ 2W/kg. The design includes a solid acoustic coupling gel pad attached to the front of the transducer to provide good acoustic transmission into the scalp. An outer housing was designed to attach the transducer firmly to the head above the temporal window, and to allow it to be moved side to side to accurately target intended structures.
215126853|NCT06939231|BEHAVIORAL|Living Lab approach to improve sustainable and healthy dietary behaviours|Living Lab baseline data collection measures, plus invitations to Study 1-3 and events/ activities (optional), and LL endpoint data collection measures.
215126854|NCT06938334|GENETIC|Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA|The intervention is intended for newly diagnosed T1D patients with residual beta-cell function, who can receive the Drug Product (DP) within 180 days from the first insulin administration. Mobilized autologous HSPCs, collected by leukapheresis, are ex vivo transduced with a LVV encoding for hPD-L1 and formulated in a cryopreservation medium containing DMSO (DP). After release, the DP is thawed and administered to the patient at a dose ranging between 5 and 20 million of cells per kilogram of body weight. The intervention plans for a single DP injection.
215126855|NCT06939452|DRUG|anlotinib +TQB2450 + Oxaliplatin+S-1|"Anlotinib: 10mg, po, d1-14,q3w,until disease progression or unacceptable toxicity.~TQB2450: 1200mg, iv, d1, q3w,until disease progression or unacceptable toxicity. Oxaliplatin: 130mg/㎡, iv, d1,6 cycles.~S-1:40mg, po, bid, d1\~14,6 cycles."
215126856|NCT06939179|OTHER|Class III Malocclusion|Class III malocclusion treatment
215126857|NCT06939179|OTHER|Class III Malocclusion|non treated Class III malocclusion
215126858|NCT06937697|DRUG|Test toothpaste|A commercially available fluoride toothpaste
214447383|NCT06796166|BEHAVIORAL|AI-Supported Preoperative Education|This intervention involves the use of a pre-trained AI-powered education platform designed to provide preoperative information to patients undergoing mastectomy. The program delivers structured, interactive education that includes details about the surgical process, postoperative care, and emotional coping strategies. The pre-trained AI system offers standardized responses to patient questions, ensuring consistency and clarity in the information provided, with the goal of reducing fear and anxiety.
214447384|NCT06796166|BEHAVIORAL|Standard Preoperative Education|This intervention consists of standard preoperative education provided by healthcare professionals. Patients receive general information about the surgical procedure, postoperative care, and strategies to manage fear and anxiety. The education is delivered in a traditional, face-to-face format without the use of AI or digital tools.
214447385|NCT06793280|PROCEDURE|intraoperative ICG angiography|Intraoperative ICG angiography to evaluate colonic perfusion
215126859|NCT06937697|DRUG|Control toothpaste|A commercially available fluoride toothpaste
214447386|NCT06793280|PROCEDURE|No intraoperative ICG angiography|Visual evaluation of colonic perfusion
215126860|NCT06938919|DEVICE|routine care without electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%.
215126861|NCT06938919|DEVICE|routine care with electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%; and refer to the following electronic breath sound abnormalities to maintain sedation depth: Maintain respiratory rate (RR) at 12-20 bpm; avoid partial airway obstruction
215126862|NCT06937489|DEVICE|Hydrogel conventional toric lenses with -10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
215126863|NCT06937489|DEVICE|Hydrogel conventional toric lenses with +10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
215126864|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 0.5 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
215126865|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 1.0 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
215126866|NCT00765804|DRUG|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
215126867|NCT00765804|DRUG|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
215126868|NCT02001935|DRUG|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
215126869|NCT02145117|BEHAVIORAL|MBSR|Behavioral
215126870|NCT00001146|DRUG|Ethyl Eicosapentaenoic Acid|
215126871|NCT00001146|DRUG|OmegaBrite|
215126872|NCT01663012|DRUG|Etirinotecan pegol|
215126873|NCT05929625|DEVICE|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
215126874|NCT05929625|DEVICE|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
215126875|NCT01202630|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
215126876|NCT01202630|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
215126877|NCT05030168|DRUG|Ketosteril|ketoanalogues of essential amino acid
215126878|NCT04886713|DIAGNOSTIC_TEST|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
215126879|NCT04886713|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and \> 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume"
214447387|NCT06793865|OTHER|Russian Current Stimulation for Anterior Tibial Group|"Parameters were adjusted as the following frequency of 2.5 kHz and 50 bursts per second with 50 pulses per burst. The stimulus was applied for a 10 seconds on period followed by a 10 seconds off period for total treatment time 20 minutes."
214447388|NCT06793865|OTHER|Placebo Russian Current Stimulation for Anterior Tibial Group|Placebo Russian current stimulation was applied to the anterior tibial group without active current for 20 minutes.
214447389|NCT06793865|OTHER|Selected physical therapy exercise for both limbs|The selected physical therapy exercise for both limbs was applied for 40 minutes, including passive, active assisted and active range of motion exercises, stretching of spastic muscles, strengthening of weak muscles (anterior tibial group), and finally functional mobility exercises.
215126880|NCT04886713|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
215126881|NCT00862693|DRUG|Calcitriol|0.5ug/Biw
215126882|NCT00751803|DRUG|BI 44370 TA Low Dose|
215126883|NCT00751803|DRUG|Eletriptan|
215126884|NCT00751803|DRUG|Placebo|
215126885|NCT00751803|DRUG|BI 44370 TA Medium Dose|
215126886|NCT02907684|DIETARY_SUPPLEMENT|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
215126887|NCT02907684|DIETARY_SUPPLEMENT|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
214447390|NCT05641753|DRUG|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
215126888|NCT03177928|DEVICE|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
215126889|NCT03186027|DIETARY_SUPPLEMENT|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
215126890|NCT03186027|DIETARY_SUPPLEMENT|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
215126891|NCT00206843|DEVICE|Triage BNP Test|
214447391|NCT05641753|DRUG|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
215126892|NCT01667653|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule once daily
215126893|NCT01667653|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
215126894|NCT00519051|OTHER|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
215126895|NCT03374033|DIETARY_SUPPLEMENT|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
215126896|NCT03374033|BEHAVIORAL|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
215126897|NCT05954000|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
215126898|NCT02458053|BEHAVIORAL|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
215126899|NCT02458053|BEHAVIORAL|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
215126900|NCT02458053|BEHAVIORAL|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
215126901|NCT02458053|BEHAVIORAL|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
215126902|NCT02458053|OTHER|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
215126903|NCT02458053|BEHAVIORAL|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
215126904|NCT00880295|PROCEDURE|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
215126905|NCT00880295|PROCEDURE|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
214447392|NCT05641753|DRUG|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
214447393|NCT05641753|DRUG|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
215126906|NCT06546046|DEVICE|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
215126907|NCT06482541|COMBINATION_PRODUCT|5 billion exosomes and saline solution microneedling|Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
215126908|NCT06482541|COMBINATION_PRODUCT|50 billion exosomes and saline solution microneedling|Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
215126909|NCT00006133|DRUG|estradiol|
215126910|NCT00006133|DRUG|ethinyl estradiol|
215126911|NCT00006133|DRUG|medroxyprogesterone|
215126912|NCT00006133|DRUG|norethindrone|
215126913|NCT02360891|OTHER|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
215126914|NCT04767503|DRUG|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
215126915|NCT04767503|DRUG|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
215126916|NCT01344083|DRUG|T1210|2 drops T1210 once a day
215126917|NCT01344083|DRUG|Olopatadine hydrochloride|2 drops once a day Olopatadine
215126918|NCT01385657|DRUG|Placebo|A total of 4 doses were administered.
215126919|NCT01385657|DRUG|Dupilumab|A total of 4 doses were administered.
215126920|NCT01385657|OTHER|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
214694344|NCT02264899|OTHER|in Memento-VASCOD|"* Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement"
214694345|NCT02566252|DRUG|PUL-042 Inhalation Solution|PUL-042
214694346|NCT02566252|DRUG|Cromolyn Sodium|Pre-treatment
214694347|NCT02566252|DRUG|Albuterol sulfate|Pre-treatment
214694348|NCT00878631|DRUG|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
214694349|NCT00878631|DRUG|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
215126921|NCT01154777|BEHAVIORAL|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
215126922|NCT04480658|DRUG|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
215126923|NCT00556816|BEHAVIORAL|on demand clinic|Outpatient on demand clinic
215126924|NCT00556816|BEHAVIORAL|Control|conventional outpatient clinic
215126925|NCT05958849|DRUG|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
215126926|NCT01630291|DEVICE|Electrode device|Lacrimal gland stimulation
215126927|NCT06422013|DIETARY_SUPPLEMENT|GTB1|oral administration of GTB1 powder packet once daily
215126928|NCT06422013|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo powder packet once daily
215126929|NCT02756117|DRUG|L-Lysine|
215126930|NCT02756117|DRUG|Normal (0.9%) Saline|
215126931|NCT04384055|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
215126932|NCT03607955|DRUG|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
215126933|NCT03607955|DRUG|Paclitaxel|Commercially available
215126934|NCT03607955|DRUG|Carboplatin|Commercially available
215126935|NCT03607955|PROCEDURE|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
215126936|NCT03607955|PROCEDURE|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
215126937|NCT03607955|PROCEDURE|Interval Debulking|"* Standard of Care~* Research tissue samples will be collected"
215126938|NCT03607955|PROCEDURE|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
215126939|NCT03607955|PROCEDURE|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
215126940|NCT01582399|DRUG|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
214694350|NCT05890118|DRUG|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
215126941|NCT05842018|DRUG|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
215126942|NCT01041820|BEHAVIORAL|Exercise|Children will be exposed to a 10-week exercise intervention
215126943|NCT01855360|DRUG|Tauroursodeoxycholic Acid and Doxycycline|
215126944|NCT02947737|OTHER|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
215126945|NCT02947737|OTHER|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
215126946|NCT03703089|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
215126947|NCT03703089|DRUG|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
215126948|NCT04168671|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
215126949|NCT01060696|DRUG|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
215126950|NCT00955396|DRUG|GSK1014802|Tablets
215126951|NCT00955396|DRUG|Placebo|Tablets
215126952|NCT01252706|BEHAVIORAL|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
215126953|NCT04631848|DEVICE|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
215126954|NCT00502788|DRUG|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
215126955|NCT00502788|DRUG|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
215126956|NCT04158583|DRUG|RO7296682|RO7296682 will be administered by the schedules specified in the respective arms.
215126957|NCT05545683|BIOLOGICAL|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
215126958|NCT00044473|DRUG|levofloxacin|
215126959|NCT03232866|OTHER|Pilates exercise|Pilates methods exercises
215126960|NCT00320515|DRUG|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
215126961|NCT00320515|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
215126962|NCT02779647|BEHAVIORAL|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
215126963|NCT06154356|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
215126964|NCT06154356|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
215126965|NCT04221646|DEVICE|BTL-899|Treatment with study device.
215126966|NCT02717052|DRUG|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
215126967|NCT02717052|DRUG|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
215126968|NCT02717052|DRUG|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
215126969|NCT02717052|DRUG|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
215126970|NCT02717052|OTHER|PILOT Study II: PET1|\[11C\]DASB PET
214447394|NCT05641753|DEVICE|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
214447395|NCT05641753|DEVICE|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
214447396|NCT05641753|DEVICE|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
214447397|NCT06793631|OTHER|Participants will be interviewed qualitatively about experience of providing/receiving financial support for living costs|There is no intervention for participants. Participants will receive qualitative interviews to explore their experience of financial insecurity
214447398|NCT03875625|PROCEDURE|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
214447399|NCT03875625|BEHAVIORAL|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
214447400|NCT03875625|BEHAVIORAL|Conventional care (control)|receive routine care
214447401|NCT03919981|OTHER|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
214447402|NCT06796725|DEVICE|rTMS|(1) The patient undergoes pseudo stimulus intervention in the first week and real stimulus intervention afterwards, which is blind to the patient. (2) Starting from the second week, true stimulation intervention will be conducted for 4 weeks, with each patient making an appointment for 1 month. On Day 7 after the patient intervention, Day 14, Day 30, Day 60, Day 90, Day 180 scales were used to evaluate follow-up.
214447403|NCT06796725|DRUG|Sibelium|Sibelium 10mg is taken orally every night for 4 weeks each course of treatment. Patients were evaluated and followed up with a scale based on medication intervention, including Day 7, Day 14, Day 30, Day 60, Day 90, and Day 180
214447404|NCT06794567|DIAGNOSTIC_TEST|Genetic Testing|Early access to genetic testing.
214447405|NCT06360575|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214447406|NCT06360575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214447407|NCT06360575|DRUG|Crizotinib|Given PO
214447408|NCT06360575|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
214447409|NCT03963453|OTHER|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
215126971|NCT02717052|OTHER|PILOT Study II: PET2|\[11C\]DASB PET
215126972|NCT02717052|OTHER|Main Study: PET1|\[11C\]DASB PET
215126973|NCT02717052|OTHER|Main Study: PET2|\[11C\]DASB PET
215126974|NCT02717052|OTHER|PILOT Study I: PET1|\[11C\]DASB PET
214447410|NCT05717621|DRUG|VTD-101 ointment|Self-administration of VTD-101 ointment (Decitabine ointment)
215126975|NCT02717052|OTHER|PILOT Study I: PET2|\[11C\]DASB PET
214694351|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
214447412|NCT05561725|DRUG|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
214447413|NCT05561725|DRUG|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
214447414|NCT04155398|PROCEDURE|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
214447415|NCT06796816|OTHER|Bioelectrical Impedance Vector Analysis (BIVA)|"Bioelectrical Impedance Vector Analysis (BIVA) both in total body mode (Total Body Water) and segmental mode. The device used is the BIA 101 Anniversary by Akern. The BIVA exam will be performed in total body and segmental modes.~For total body mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 4 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the right foot (metatarsal). The cable connected to your instrument will then be connected to the electrodes. After the instrument is switched on, the variables are read and then analysed. For segmental mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 8 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the left hand, 2 on the right foot (metatarsal) and 2 on the left foot."
214447416|NCT06794424|DIAGNOSTIC_TEST|Ziwig Endotest®|Saliva sampling for Endometriosis diagnostic
214447417|NCT06796634|DEVICE|J-plasma|"* Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP.~* Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations:~  * 15 W, 30W, or 45W~ * 2, 5, or 10 seconds.~* The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry."
214447418|NCT05541861|BIOLOGICAL|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214447419|NCT05541861|BIOLOGICAL|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214447420|NCT05541861|BIOLOGICAL|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214447421|NCT05541861|BIOLOGICAL|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214447422|NCT05541861|BIOLOGICAL|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214447423|NCT05541861|BIOLOGICAL|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214524008|NCT04809298|DEVICE|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
214524009|NCT05964270|DEVICE|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
214524010|NCT01178281|DRUG|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
214524011|NCT01178281|DRUG|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
214524012|NCT01178281|DRUG|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
214694352|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
214694353|NCT02429258|DRUG|Farxiga|Farxiga 10mg/day
214694354|NCT02429258|DRUG|Placebo|Placebo
214694355|NCT02429258|DRUG|Metformin|Metformin background therapy \>/= 1500mg/day
214694356|NCT02429258|DRUG|Insulin|Insulin \>/= 30 units
214694357|NCT02397694|DRUG|BIC|75 mg tablet administered orally once daily
215126976|NCT02717052|DRUG|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
215126977|NCT02717052|DRUG|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
215126978|NCT02717052|OTHER|PILOT Study III: PET1|\[11C\]DASB PET
215126979|NCT02717052|OTHER|PILOT Study III: PET2|\[11C\]DASB PET
215126980|NCT01777776|DRUG|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
215126981|NCT01777776|DRUG|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
215126982|NCT00851786|BIOLOGICAL|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
215126983|NCT00851786|BIOLOGICAL|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
215126984|NCT06225687|OTHER|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
215126985|NCT01524146|PROCEDURE|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
215126986|NCT03698123|OTHER|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
215126987|NCT03488277|OTHER|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
215126988|NCT02987270|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
215126989|NCT01743443|OTHER|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
215126990|NCT03095729|OTHER|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
214447424|NCT06333691|DRUG|Calcium Gluconate|to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
215126991|NCT02741622|BEHAVIORAL|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
215126992|NCT02741622|BEHAVIORAL|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
215126993|NCT00786292|OTHER|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
215126994|NCT01638455|DEVICE|Noninvasive device|Noninvasive device
214447425|NCT06789796|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg , every 3 weeks
214524013|NCT00541840|DRUG|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
214524014|NCT00329498|DRUG|L-Ascorbic Acid|
214524015|NCT05017688|PROCEDURE|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
214447426|NCT06789796|DRUG|placebo for QL1604|every 3 weeks
214447427|NCT06789796|DRUG|QL1604|200mg, every 3 weeks
214524016|NCT00826371|DRUG|ranibizumab 0.5 mg|
214524017|NCT02440646|RADIATION|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
214694358|NCT02397694|DRUG|F/TAF|200/25 mg FDC tablet administered orally once daily
214694359|NCT02397694|DRUG|DTG|50 mg tablet administered orally once daily
214447428|NCT06789796|DRUG|placebo for Iparomlimab and Tuvonralimab (QL1706)|every 3 weeks
214447429|NCT06791317|OTHER|Checklist|A checklist for the intubation procedure was organised into the categories physiological optimisation, equipment and drugs, team line-up, and contingency plan. This checklist was implemented in the clinic.
214447430|NCT06797349|DIETARY_SUPPLEMENT|First Reference product|dextrose (containing 25 grams of carbohydrates)
215126995|NCT02933788|DRUG|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
215126996|NCT02933788|DRUG|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
215126997|NCT04745364|BEHAVIORAL|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
215126998|NCT00471692|DRUG|Ropivicaine|
215126999|NCT04967976|PROCEDURE|TiLoop Bra mesh in expander-implant breast reconstrution|The tissue expander is inserted with TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral.
215127000|NCT04967976|PROCEDURE|sub-pectoral expander-implant breast reconstruction|The tissue expander is inserted without TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
214524018|NCT02440646|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
214524019|NCT04488978|DRUG|Irbesartan/Amlodipine|QID
214524020|NCT00549861|PROCEDURE|Cardiac Magnetic Resonance study|Cardiac MRI study
214447431|NCT06797349|DIETARY_SUPPLEMENT|Second reference product|dextrose (containing 25 grams of carbohydrates)
214524021|NCT03586141|DIAGNOSTIC_TEST|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
214524022|NCT03292198|OTHER|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
214524023|NCT03292198|OTHER|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
214524024|NCT05451641|BEHAVIORAL|Blood flow restriction resistance training|The participants will receive a 2-week exercise training program (3 times per week). Each training session will consist of 3 resistance training exercises with two blood flow restriction devices (wide-rigid cuff and narrow-elastic band). For both arms, the participants will perform the same exercise with different BFR devices.
215127001|NCT03306667|DRUG|FYU-981|Oral single dosing
215127002|NCT04633668|BEHAVIORAL|CBT for parasomnias (CBT-p)|Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
215127003|NCT04633668|BEHAVIORAL|Self-Monitoring|Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
215127004|NCT06237582|PROCEDURE|epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
215127005|NCT02574403|DRUG|eculizumab|eculizumab discontinuation
215127006|NCT04277559|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
215127007|NCT04277559|OTHER|Classical music|Patients will listen to classical music through headphones before surgery.
215127008|NCT04277559|OTHER|No music|Patients will not listen to music.
215127009|NCT00027170|DEVICE|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
214447432|NCT06797349|DIETARY_SUPPLEMENT|Third reference product|dextrose (containing 25 grams of carbohydrates)
214447433|NCT06797349|DIETARY_SUPPLEMENT|First Concept product|Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)
214447434|NCT06797349|DIETARY_SUPPLEMENT|Second Concept product|Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)
214447435|NCT06797349|DIETARY_SUPPLEMENT|Third Concept product|Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)
214447436|NCT06797349|DIETARY_SUPPLEMENT|Fourth Concept product|Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)
214447437|NCT06797349|DIETARY_SUPPLEMENT|Fifth Concept product|Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates
214694360|NCT02397694|DRUG|BIC Placebo|Tablet administered orally once daily
214694361|NCT02397694|DRUG|DTG Placebo|Tablet administered orally once daily
214694362|NCT02397694|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
215127010|NCT05195229|DEVICE|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
215127011|NCT00708292|DRUG|AUY922|
215127012|NCT00708292|DRUG|Bortezomib|
215127013|NCT00708292|DRUG|Dexamethasone|
215127014|NCT04380506|PROCEDURE|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
215127015|NCT00908986|DRUG|Rituximab|375mg/m2 q week x 4; repeated in 6 months
215127016|NCT02454790|RADIATION|Radiotherapy|
214447438|NCT06797349|DIETARY_SUPPLEMENT|Sixth Concept product|Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates
215127017|NCT02908022|DEVICE|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
215127018|NCT02908022|DEVICE|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
215127019|NCT02893566|BEHAVIORAL|Mi Band Step Challenge|
215127020|NCT06211439|DEVICE|real transcranial alternating current stimulation|The alternating current was non-invasively delivered using an M×N five-channel high-definition transcranial electrical current stimulator (Soterix Medical). A BrainCap (Brain Vision) embedded with high-definition plastic holders consisted of five 12-mm-diameter Ag/AgCl ring electrodes, filled with conductive gel. During real HD-tACS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
215127021|NCT06211439|DEVICE|sham transcranial alternating current stimulation|For the sham condition(sham HD-tACS), the same electrode placement was used as in the stimulation condition, but the current was only applied during the first and last 30 seconds of the entire 20-minute stimulation period.
215127022|NCT05359172|DRUG|Tranexamic acid|preoperative intravenous infusion
215127023|NCT03900494|DEVICE|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
215127024|NCT03900494|DEVICE|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
215127025|NCT04822675|PROCEDURE|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
215127026|NCT04822675|PROCEDURE|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
215127027|NCT03737123|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
215127028|NCT03737123|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
215127029|NCT03737123|DRUG|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
215127030|NCT03737123|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
215127031|NCT00633971|OTHER|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
215127032|NCT01715181|OTHER|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
215127033|NCT05914948|DEVICE|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
215127034|NCT05385666|OTHER|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
215127035|NCT00500617|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
215127036|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
215127037|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
215127038|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
215127039|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
215127040|NCT02386020|DRUG|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
215127041|NCT02386020|DRUG|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
215127042|NCT04607486|DIAGNOSTIC_TEST|3DfUS and IPSA of leg muscles|"1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
215127043|NCT03460886|DEVICE|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
215127044|NCT03460886|DEVICE|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
215127045|NCT03460886|OTHER|Walking on treadmill|walking on treadmill for 10 minutes
215127046|NCT00273338|DRUG|calcitriol|
215127047|NCT00273338|DRUG|docetaxel|
215127048|NCT00282763|DRUG|MK0686|
215127049|NCT04931940|DIETARY_SUPPLEMENT|Usual Care|Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU
215127050|NCT04931940|DIETARY_SUPPLEMENT|Higher Protein/Amino Acid Group|Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
215127051|NCT01102686|DRUG|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
215127052|NCT01102686|DRUG|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
215127053|NCT01218334|DEVICE|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
215127054|NCT03250637|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
214524025|NCT03163836|PROCEDURE|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
214524026|NCT03163836|PROCEDURE|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
215127055|NCT04290039|DRUG|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
215127056|NCT04290039|DRUG|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
215127057|NCT01411826|BEHAVIORAL|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
215127058|NCT01411826|BEHAVIORAL|Information Only|Information from CDC website on colon cancer screening.
215127059|NCT06411717|DEVICE|Microstructure lens A|Subjects randomized to Trial Group A will be required to wear microstructural lens A (microstructural design type with low defocus ratio) for 12 months
215127060|NCT06411717|DEVICE|Microstructure lens B|Subjects randomized to Trial B will be required to wear microstructural lens B (high defocus ratio microstructural design type) for 12 months
215127061|NCT06411717|OTHER|Control group|Subjects randomized to the control group will be required to wear aspherical single-light lenses for 12 months
215127062|NCT00825292|PROCEDURE|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
215127063|NCT00825292|PROCEDURE|colon polyp removal|identify and remove polyp
215127064|NCT00825292|PROCEDURE|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
215127065|NCT00055302|DRUG|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
215127066|NCT02598726|DRUG|Curcumin|Given PO
214447439|NCT06797349|DIETARY_SUPPLEMENT|Seventh Concept product|High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates
214447440|NCT06839040|OTHER|Group 1: ExVerbPsy|A multidisciplinary intervention will be carried out, consisting of an initial phase of individual physiotherapy based on specific active muscle training of the pelvic floor (EMSP). This will be followed by a group-based multi-component physical exercise program with instructions on pelvic floor contraction during the exercises, and psychoeducation sessions to help cope with the fear of increased likelihood of falls and urinary incontinence as a result of aging.
214524027|NCT00192322|BIOLOGICAL|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
214524028|NCT00192322|BIOLOGICAL|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T \<10\^5
214524029|NCT00192322|BIOLOGICAL|Placebo|a single intranasal 0.2 mL dose of placebo
215127067|NCT02598726|OTHER|Laboratory Biomarker Analysis|Correlative studies
215127068|NCT02598726|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
215127069|NCT02598726|OTHER|Quality-of-Life Assessment|Ancillary studies
215127070|NCT02149914|DEVICE|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
214447441|NCT06839040|OTHER|Group 2: ExVerb|The same procedure as experimental group 1 ExVerbPsy will be performed except for the psychoeducation sessions.
214447442|NCT06839040|OTHER|Group 3: Ex|The same procedure as experimental group 1 ExVerbPsy will be performed but without verbal instructions and psychoeducation sessions.
214524030|NCT00192322|BIOLOGICAL|TIV|commercially available TIV injected intramuscularly
214524031|NCT01860495|PROCEDURE|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
214524032|NCT01860495|PROCEDURE|G2|tradetional occlusive collagen membrane
215127071|NCT02149914|DEVICE|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
215127072|NCT02149914|DEVICE|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
214524033|NCT01984853|OTHER|OBSERVATIONAL REGISTRY|
214524034|NCT00672672|BIOLOGICAL|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
214524035|NCT06047379|DRUG|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
214524036|NCT06047379|DRUG|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
214694363|NCT04274166|DRUG|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
214694364|NCT00887146|DRUG|concomitant temozolomide (TMZ)|75 mg/m\^2, orally daily
215127073|NCT02149914|OTHER|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
215127074|NCT02149914|DRUG|PPI|
214524037|NCT06047379|DRUG|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
214524038|NCT06047379|DRUG|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
215127075|NCT04634097|OTHER|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
215127076|NCT04634097|OTHER|standrad group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
215127077|NCT02397577|OTHER|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
215127078|NCT04046328|DRUG|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
215127079|NCT04046328|DRUG|Placebo|Enteric-Coated Delayed Release Placebo Capsules
215127080|NCT02172430|DRUG|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
215127081|NCT02172430|DRUG|Tersigan®|2 puffs of oxitropium three times daily via MDI
215127082|NCT04032067|DRUG|GV1001 placebo|0.9 % Normal Saline
215127083|NCT04032067|DRUG|Proscar placebo|PO
215127084|NCT01816217|DEVICE|Intubation with The McGrath Mac videolaryngoscope|
215127085|NCT02374697|DEVICE|During tele-expertise|
215127086|NCT02861612|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
215127087|NCT03237793|PROCEDURE|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
215127088|NCT03237793|PROCEDURE|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
215127089|NCT02167308|DEVICE|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
215127090|NCT05111860|DRUG|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
215127091|NCT04104256|BEHAVIORAL|Nudge #1: Alert highlighting the safety/potential harms to patients of undergoing pre-op tests|"Nudge 1:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-op tests do NOT increase patient safety and go AGAINST local and national guidelines Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
215127092|NCT04104256|BEHAVIORAL|Nudge #2: Alert highlighting the financial harms to the patient experiencing pre-op tests|"Nudge #2:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can increase the patient's out-of-pocket costs without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Nudge includes hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
215127093|NCT04104256|BEHAVIORAL|Nudge #3: Alert highlighting potential psychological harms to the patient of experiencing pre-op tests|"Nudge 3:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can cause aggravation and psychological stress for the patient without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
215127094|NCT04104256|OTHER|Usual Care|Patients will receive usual care from their physicians.
214524039|NCT06047379|DRUG|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
214524040|NCT06047379|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
214524041|NCT06047379|DRUG|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
214694365|NCT00887146|RADIATION|radiotherapy|
214524042|NCT06047379|DRUG|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
214524043|NCT06047379|DRUG|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
215127095|NCT03080857|OTHER|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
215127096|NCT03080857|DEVICE|AliveCor Heart Monitor|A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
215127097|NCT01650298|OTHER|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
215127098|NCT00699036|DRUG|avandia|4 mg twice daily
215127099|NCT00699036|DRUG|metformin|500 mg twice daily for 48 weeks
215127100|NCT00699036|DRUG|losartan|losartan 50 mg once daily
215127101|NCT00579774|OTHER|Low AGE Diet|Diet
215127102|NCT00579774|OTHER|Regular Diet|Diet
215127103|NCT04752267|PROCEDURE|Computed Tomography|Undergo PET/CT
214447443|NCT05126901|DRUG|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
214447444|NCT05126901|DRUG|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
214447445|NCT05694988|DEVICE|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
214447446|NCT01918527|DRUG|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
214524044|NCT02228083|DRUG|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
214524045|NCT00156377|DRUG|Mupirocin|
214524046|NCT03562897|DIETARY_SUPPLEMENT|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
214694366|NCT00887146|DRUG|procarbazine|Days 8-21: 60 mg/m\^2 orally
215127104|NCT04752267|DRUG|18F-FMAU|Given IV
215127105|NCT04752267|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
215127106|NCT04752267|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215127107|NCT02217163|DRUG|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
214447447|NCT01918527|DRUG|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
214447448|NCT06483880|DRUG|Albendazole|Patients will receive albendazole therapy at the recommended dosage.
214447449|NCT06483880|DRUG|Placebo|Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.
214447450|NCT06794502|DRUG|Herbal medicine|Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
214447451|NCT06794502|OTHER|Tuberculosis (TB) treatment|The patients in anti-TB monotherapy group (Group 2) were given a regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months. This group did not receive any additional therapy.
214447452|NCT05535062|DEVICE|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
214447453|NCT06794710|DRUG|diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids|Patients in this group will receive pharmacological treatment for heart failure.
214447454|NCT06794710|BEHAVIORAL|Close follow-up|High risk patients receive close follow-up
214694367|NCT00887146|DRUG|adjuvant temozolomide (TMZ)|150 or 200 mg/m\^2 orally
215127108|NCT04233801|DRUG|Empagliflozin|Empagliflozin
215127109|NCT04233801|DRUG|Placebo|Placebo
215127110|NCT00761475|PROCEDURE|mesh supported closure|onlay mesh supported closure midline laparotomy
215127111|NCT00761475|PROCEDURE|primary closure|primary closure of the midline
215127112|NCT00761475|PROCEDURE|mesh supported closure|sublay mesh supported closure midline laparotomy
215127113|NCT03441438|DIETARY_SUPPLEMENT|Water|Serum and urine markers will be obtained after drinking 5 oz of water
215127114|NCT03441438|DIETARY_SUPPLEMENT|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
215127115|NCT03441438|DIETARY_SUPPLEMENT|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
215127116|NCT03382886|DRUG|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
214524047|NCT06164769|PROCEDURE|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
215127117|NCT03382886|DRUG|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
215127118|NCT06032065|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
215127119|NCT06032065|BEHAVIORAL|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
214447455|NCT06794710|BEHAVIORAL|early rehabilitation guidance|Early rehabilitation guidance such as cardiopulmonary exercise tests and cardiac rehabilitation therapy
214447456|NCT06790238|OTHER|gastric surgery and ERAS protocol|Patients under gastric surgery in an ERAS protocol
214447457|NCT03285321|DRUG|Nivolumab|480mg
214447458|NCT03285321|DRUG|Nivolumab|240mg
214447459|NCT03285321|DRUG|Ipilimumab|1mg/kg
214447460|NCT05194969|DEVICE|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
214447461|NCT05194969|DEVICE|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
214447462|NCT05408611|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
214447463|NCT05408611|OTHER|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
214447464|NCT03924973|BEHAVIORAL|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
214447465|NCT06838910|DRUG|Experimental: tislelizumab+anlotinib|All patients will receive tislelizumab 200mg on Day1 every 3-week plus anlotinib 12mg or 10mg or 8mg on Day 1-14 every 3-week (Q3W) until disease progression.
215127120|NCT06032065|DIETARY_SUPPLEMENT|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
215127121|NCT01589796|PROCEDURE|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
215127122|NCT01722305|DRUG|Dexamethasone|Given PO
215127123|NCT01722305|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215127124|NCT01722305|OTHER|Pharmacological Study|Optional correlative studies
214447466|NCT06793982|DEVICE|Platelet Rich Plasma Joint Injection|Magellan Autologous Concentration System, ISTO Biologics
214447467|NCT06793982|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
214447468|NCT06795594|PROCEDURE|cheek acupuncture|Cheek Acupuncture
214694368|NCT00887146|DRUG|CCNU|Day 1: 110 mg/m\^2 orally
214694369|NCT00887146|DRUG|vincristine|Days 8 and 29: 1.4 mg/m\^2 IV
214694370|NCT04478149|DEVICE|SafelyYou|technology to detect and prevent falls
214694371|NCT04478149|OTHER|Control|technology present but not activated
214694372|NCT04765436|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
214694373|NCT04765436|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
215127125|NCT01722305|DRUG|Pomalidomide|Given PO
215127126|NCT01860664|DRUG|hydrocortisone ophthalmic ointment 0.5%|"* Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
215127127|NCT01860664|DRUG|placebo|Mineral oil and white petrolatum
215127128|NCT04175249|OTHER|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
215127129|NCT06428110|OTHER||
214447469|NCT06795594|DRUG|sufentanil 2 µg/kg + ondansetron 0.2 mg/kg|The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.
215127130|NCT01026545|DRUG|PF-04287881|500 mg once daily for 10 days
215127131|NCT01026545|DRUG|Placebo|To match 500 mg dose once daily for 10 days
215127132|NCT01026545|DRUG|PF-04287881|750 mg once daily for 10 days
215127133|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
215127134|NCT01026545|DRUG|PF-04287881|1100 mg once daily for 10 days
215127135|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
215127136|NCT01026545|DRUG|PF-04287881|Optional cohort with dose not greater than 1100 mg
214447470|NCT06083597|OTHER|Qualitative interview|Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.
215127137|NCT01026545|DRUG|Placebo|Optional cohort to match dose not greater than 1100 mg
215127138|NCT01026545|DRUG|PF-04287881|750 mg dose once daily for 10 days
215127139|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
215127140|NCT01026545|DRUG|PF-04287881|1100 mg dose once daily for 10 days
215127141|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
215127142|NCT01447589|DRUG|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
215127143|NCT01447589|RADIATION|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
215127144|NCT05477615|DRUG|Lazertinib|\- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
214447471|NCT06838728|DEVICE|Head Mounted Magnifying Glasses|This study was divided into an experimental group and a control group based on whether a head mounted magnifying glass was used.
214464442|NCT05345015|DEVICE|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
214708786|NCT03194620|OTHER|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
215127145|NCT05477615|DRUG|Pemetrexed|\- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
215127146|NCT05477615|DRUG|Carboplatin|\- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
215127147|NCT00923923|BEHAVIORAL|stress|compare levels of stress
214708787|NCT03194620|OTHER|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
214708788|NCT03194620|OTHER|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
214464443|NCT06360328|DEVICE|video laryngoscopy|The residents used video laryngoscopy for endotracheal intubation
214464444|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
215127148|NCT04013386|DRUG|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
215127149|NCT04013386|DRUG|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
215127150|NCT04013386|DRUG|Dexamethasone|Dexamethasone 8 mg IVI
215127151|NCT03481894|DRUG|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
214524048|NCT04890483|DEVICE|Transcranial direct current stimulation|tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
214524049|NCT06529783|OTHER|Shockwave Therapy|The proposed model for radial shockwave therapy at Clínica Osteopática Dr. David Ponce is the DolorClast® by EMS, made in Nyon, Switzerland. Treatment parameters include 2500 impulses, 0.2 mJ/mm² energy density, and 15 pulses per second, using a 15 mm diameter applicator with ultrasound gel applied to the treatment area. The patient will be positioned laterally on the table with specific leg positions to ensure comfort and effectiveness.
214524050|NCT06529783|OTHER|Therapeutic Exercises|The exercise protocol was followed daily, with continuous physiotherapist supervision to ensure correct execution and avoid improper postures. The protocol includes four exercises: bilateral low-load supine abduction, unilateral isometric hip abduction in medial rotation, hip abduction with sliding, and bilateral supported glute bridge. A maximum of 4/10 on the VAS pain scale is allowed during exercise; exceeding this threshold means skipping exercises for that day.
215127152|NCT03481894|DRUG|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
215127153|NCT02137863|DRUG|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
215127154|NCT02137863|DRUG|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
215127155|NCT02137863|DRUG|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
215127156|NCT04066439|OTHER|specimen|Immunohistochemistry analysis
215127157|NCT02719535|OTHER|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
215127158|NCT02423850|DEVICE|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
215127159|NCT00282035|RADIATION|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
215127160|NCT00282035|RADIATION|Whole breast irradiation|Whole breast irradiation
215127161|NCT03573934|OTHER|GLP-2|GLP-2
215127162|NCT03573934|OTHER|GIP|GIP
215127163|NCT03573934|OTHER|GLP-2+GIP|GLP-2+GIP
215127164|NCT03573934|OTHER|Placebo|Placebo
215127165|NCT04674891|OTHER|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
215127166|NCT04674891|OTHER|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
215127167|NCT03932877|OTHER|MMP-14 and s-ENG levels|Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
215127168|NCT02718521|PROCEDURE|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
215127169|NCT02718521|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
215127170|NCT02718521|DRUG|0.9% sodium chloride ﬂuid administration|
215127171|NCT02718521|DRUG|isosorbide dinitrate|
215127172|NCT05193214|DRUG|Recombinant anti-PD-1 humanized monoclonal antibody injection|Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
215127173|NCT00703456|BEHAVIORAL|Balance Training|balance training three days per week for 4 weeks during single limb standing
215127174|NCT02324946|OTHER|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
215127175|NCT03902691|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
215127176|NCT03902691|DRUG|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
215127177|NCT04781010|DEVICE|MRI|MRI pattern in children with Leukodystrophy
215127178|NCT01169103|DRUG|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
215127179|NCT01169103|DRUG|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
215127180|NCT04552522|OTHER|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
215127181|NCT06800261|BIOLOGICAL|Sinovac PCV24|Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.
215127182|NCT06800261|BIOLOGICAL|Prevnar®|Prevnar® (0.5 mL) is administered intramuscularly according to different immunization schedules.
215127183|NCT06065488|DEVICE|ankle kinesio tap|Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
215127184|NCT05968274|DEVICE|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
215127185|NCT05968274|DEVICE|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
215127186|NCT06130254|DRUG|Adagrasib|Given by PO BID
215127187|NCT06130254|DRUG|Olaparib|Given by PO BID
215127188|NCT04705662|DIAGNOSTIC_TEST|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
215127189|NCT04705662|OTHER|Stool sample|Participants will provide a stool sample pre and post iron supplementation
215127190|NCT04705662|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
215127191|NCT04705662|OTHER|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
215127192|NCT04705662|DIETARY_SUPPLEMENT|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
214447472|NCT06795919|PROCEDURE|: delayed surgical repair of alveolar cleft using particulate cortico-cancellous anterior iliac bon|skin incision was marked 2-4 cm from the crest to anterior iliac spine height. This is done to avoid pain at the beltline if the incision is made directly over the anterior ilium. As well as avoid injury to the lateral femoral cutaneous nerve. After the anatomical marking are drawn using betadine solution, the site is injected with local anesthesia at the subcutaneous level. The skin incision line is made parallel to the iliac crest and posterior to the anterior iliac spine. Scalpel blade number 10 is used. The incision of the skin and subcutaneous fat was performed. Blunt dissection is carried out at the level of subcutaneous tissues to separate the fascia from fat. Cautery is used to control any hemorrhage. Using a number 15 blade, fascia was incised which covers the iliac spine. A hypo vascular plane was identified. It is located over the anterior iliac spine, as well as between the insertions of tensor fascia laterally and the external and the transverse abdominal muscles medially
214708789|NCT03194620|OTHER|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
215127193|NCT05518643|PROCEDURE|ERAS protocol|ERAS protocol as described above
215127194|NCT04608617|DEVICE|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
215127195|NCT04608617|OTHER|Baseline Effectiveness Cohort|No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
215127196|NCT04125563|DRUG|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
215127197|NCT04125563|DRUG|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
215127198|NCT04755816|BEHAVIORAL|Sodium intervention|The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.
215127199|NCT04755816|BEHAVIORAL|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
215127200|NCT04755816|BEHAVIORAL|Educational content|Standard heart failure educational information and a daily symptom survey.
215127201|NCT05072418|BEHAVIORAL|Eye-opened and Eye-closed|The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
215127202|NCT04306614|PROCEDURE|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
215127203|NCT03049761|DEVICE|Water Flosser|Power interdental cleaner
215127204|NCT03049761|DEVICE|String Floss|Mechanical interdental cleaner
215127205|NCT03049761|DEVICE|Manual Toothbrush|ADA standard soft bristle toothbrush
215127206|NCT02792231|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
215127207|NCT02792231|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
215127208|NCT02792231|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
215127209|NCT02792231|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
215127210|NCT05196828|DEVICE|NTX100 Neuromodulation System|Active Noninvasive peripheral nerve stimulation device programmed to active mode
215127211|NCT02005367|BEHAVIORAL|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
215127212|NCT02005367|BEHAVIORAL|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
215127213|NCT03866655|DEVICE|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
215127214|NCT02469623|DEVICE|Dipole Density Mapping with AcQMap followed by ablation|
214708790|NCT03194620|OTHER|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
214708791|NCT03194620|OTHER|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
215127215|NCT04073186|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
215127216|NCT01270178|DRUG|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
215127217|NCT01096316|BEHAVIORAL|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
215127218|NCT02763644|DRUG|LFG316 active drug|LFG316
215127219|NCT02763644|OTHER|Standard of care treatment|SoC (site specific)
215127220|NCT02461667|DRUG|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
215127221|NCT02461667|DRUG|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
215127222|NCT02461667|DRUG|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
215127223|NCT01028989|DIETARY_SUPPLEMENT|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories"
215127224|NCT01028989|DIETARY_SUPPLEMENT|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories"
215127225|NCT01719796|PROCEDURE|Regional analgesia infusion|
215127226|NCT01772628|BEHAVIORAL|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
215127227|NCT01772628|BEHAVIORAL|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
215127228|NCT01772628|BEHAVIORAL|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
214708792|NCT03194620|OTHER|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
215127229|NCT01772628|BEHAVIORAL|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
215127230|NCT02836652|DEVICE|HeartMate II (HMII)|Left Ventricular Assist Device
214524051|NCT06529783|OTHER|Ultrasound-Guided Percutaneous Neuromodulation:|"This technique was applied only to the experimental group before shockwave therapy. An ultrasound-guided approach to the superior gluteal nerve used a 7-12 MHz linear probe from Esaote MyLab™Alpha and Physio Invasiva® equipment. The needle length varied with patient anatomy, with a typical safety reference from 0.30 x 60 to 0.35 x 70 mm. A biphasic current with 10 Hz frequency and 240 μs pulse width was used, with intensity adjusted for a visible but non-painful motor response, following the 10-10-10 protocol.~To locate the superior gluteal nerve, a longitudinal scan of the lateral iliac crest identified the nerve between the gluteus minimus and medius. The procedure used a short-axis approach at 80º to target the nerve's perineurium, with the area disinfected with chlorhexidine before needle insertion."
214524052|NCT06846463|DRUG|Zanubrutinib|Investigational Agent Administration. Zanubrutinib will be first administered on Cycle 2 Day 1 of rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP). It is up to the discretion of the treating physician how many cycles of R-CHOP the treatment would require, but it is not to exceed 6 cycles of R-CHOP and 5 cycles of zanubrutinib. The number of cycles of R-CHOP should be per standard of care, with the number of zanubrutinib cycles being 1 less than the number of total R-CHOP cycles.
215127231|NCT02836652|DRUG|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
215127232|NCT02836652|DRUG|acetylsalicylic acid (ASA) therapy|(81mg/day)
215127233|NCT01474525|DEVICE|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
215127234|NCT00473434|DRUG|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
215127235|NCT03536013|OTHER|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
215127236|NCT03647930|DEVICE|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
215127237|NCT02349633|DRUG|PF-06747775|
215127238|NCT02349633|DRUG|Palbociclib|
215127239|NCT02349633|DRUG|Avelumab|
215127240|NCT00558246|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
215127241|NCT00558246|DEVICE|Suture|Topical Suturing
215127242|NCT06366178|DEVICE|BONFIX system|"The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide."
215127243|NCT05478421|PROCEDURE|Collagen sponge|The bone cavity will be filled with collagen sponge.
215127244|NCT05478421|PROCEDURE|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
215127245|NCT05478421|PROCEDURE|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
215127246|NCT01160276|DRUG|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
215127247|NCT01160276|DRUG|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
215127248|NCT03820609|BEHAVIORAL|Digital Intervention|This digital application for sexual assault prevention can be completed on a tablet computer.
215127249|NCT02760940|DRUG|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
214524053|NCT05335005|DRUG|MK-2060|MK-2060 administered via IV infusion
215127250|NCT05233865|BEHAVIORAL|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
215127251|NCT05233865|BEHAVIORAL|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
215127252|NCT06359158|DEVICE|Digital stethoscope use|In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
215127253|NCT05548517|BEHAVIORAL|Time Restricted Eating (TRE)|9-hour eating window
215127254|NCT05548517|BEHAVIORAL|Calorie Restriction|daily calorie restriction
215127255|NCT03315520|DRUG|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
215127256|NCT01008943|BIOLOGICAL|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
215127257|NCT05590481|DEVICE|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
215127258|NCT05590481|BEHAVIORAL|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
215127259|NCT05552027|DEVICE|CCS System- Prototype|Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
215127260|NCT05552027|DEVICE|CCS System- Control|The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
215127261|NCT05428332|DEVICE|Tri-Compartment Unloader Brace|Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
215127262|NCT02455245|DRUG|Carboplatin and Vincristine|Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
214524054|NCT04050722|DRUG|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
214524055|NCT04050722|DRUG|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
214524056|NCT04462653|DEVICE|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
214524057|NCT04462653|DEVICE|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
215127263|NCT02455245|DRUG|Carboplatin|Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
214464445|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
215127264|NCT04218968|DRUG|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
215127265|NCT04765371|DRUG|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
215127266|NCT04765371|DRUG|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
215127267|NCT06532643|GENETIC|anti-CD20/CD30-CAR-T cells|"Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed."
215127268|NCT06532643|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
215127269|NCT06532643|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
215127270|NCT02370329|OTHER|Laboratory Biomarker Analysis|Correlative studies
215127271|NCT02370329|OTHER|Quality-of-Life Assessment|Ancillary studies
214464446|NCT06215430|DRUG|Caffeine Tablet|Administered orally.
214524058|NCT01316809|DRUG|AZD8055|Patients will start at 120 mg once daily
214524059|NCT01181206|PROCEDURE|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
214524060|NCT04245878|OTHER|gastric ultrasound|gastric ultrasound for measurement of the antral area
215127272|NCT02370329|BIOLOGICAL|Ropeginterferon Alfa-2B|Given SC
215127273|NCT06580587|DRUG|MK-8527|Oral administration
215127274|NCT04327206|DRUG|BCG Vaccine|"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection"
215127275|NCT04327206|DRUG|0.9%NaCl|0.9% Sodium Chloride Injection
214524061|NCT00527371|DEVICE|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
214524062|NCT00527371|PROCEDURE|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
214524063|NCT03194789|DEVICE|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
215127276|NCT06016686|OTHER|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
215127277|NCT06016686|OTHER|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
215127278|NCT04960969|OTHER|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
215127279|NCT02181309|DRUG|Meloxicam, low dose|
215127280|NCT02181309|DRUG|Meloxicam, medium dose|
215127281|NCT02181309|DRUG|Meloxicam, high dose|
215127282|NCT00571155|DRUG|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
215127283|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
215127284|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
215127285|NCT01453140|DRUG|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
215127286|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
214447473|NCT03930199|OTHER|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
214447474|NCT06784284|OTHER|Glasgow Outcome Scale -Extended (GOSE)|Questionnaire to cotate the neurological deterioration following mild head trauma. Score from 1 to 8, the higher the number the better the outcome
214524064|NCT03194789|OTHER|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
215127287|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
215127288|NCT01453140|DRUG|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
215127289|NCT04824469|OTHER|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
215127290|NCT05223270|OTHER|wound dressing under the NIMV mask|wound dressing under the NIMV mask
215127291|NCT00925262|BEHAVIORAL|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
215127292|NCT00925262|BEHAVIORAL|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
214524065|NCT05664711|DRUG|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
215127293|NCT00925262|BEHAVIORAL|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
215127294|NCT00641004|DRUG|Rebamipide and Esomeprazole|"1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
215127295|NCT02147743|BEHAVIORAL|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
215127296|NCT02147743|BEHAVIORAL|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
215127297|NCT05734599|DEVICE|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
215127298|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) lecture|OHEM via lecture will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
215127299|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) exhibition|OHEM via exhibition will be delivered to the mothers who will be instructed to teach their children.
215127300|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) demonstration|OHEM via demonstration will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
215127301|NCT00557921|DRUG|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
215127302|NCT00557921|DRUG|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
215127303|NCT01003158|DRUG|AZD8931|Tablet Oral bid
215127304|NCT01003158|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off
215127305|NCT02750189|OTHER|Direct cost|Money spent to treat COPD in medical institute based on HIRA
215127306|NCT02750189|OTHER|Indirect cost|extra-expanses excluding hospital fees
215127307|NCT00325715|DRUG|AGN 201904|
215127308|NCT00325715|DRUG|esomeprazole|
215127309|NCT05788055|DIAGNOSTIC_TEST|Stool Analysis|Stool Analysis to detect H.Pylori Antigen in Stool
215127310|NCT06403462|PROCEDURE|transversalis fascial plane block|ultrasound guidance transversalis fascial plane block after iliac bone graft
215127311|NCT06403462|PROCEDURE|transversus abdominis plane block|ultrasound guidance lateral transversus abdominis plane block after iliac bone graft
215127312|NCT02383875|BEHAVIORAL|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
215127313|NCT03003052|PROCEDURE|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
215127314|NCT00005992|BIOLOGICAL|PSA prostate cancer vaccine|
215127315|NCT00005992|BIOLOGICAL|therapeutic autologous dendritic cells|
215127316|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
215127317|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
214524066|NCT00231517|DRUG|topical opiod|
214524067|NCT00231517|DRUG|morphine sulphate in intrasite gel|
215127318|NCT03936608|DEVICE|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
215127319|NCT03936608|DEVICE|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
215127320|NCT03214861|OTHER|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
215127321|NCT01332123|DEVICE|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
215127322|NCT04379063|OTHER|COVID-19 pandemic|Currently practicing during the COVID-19 pandemic
214464447|NCT06215430|DRUG|Omeprazole capsule|Administered orally.
214464448|NCT06215430|DRUG|Warfarin tablet|Administered orally.
214464449|NCT06215430|DRUG|Pirtobrutinib|Administered orally.
215127323|NCT05850949|DIETARY_SUPPLEMENT|Konjac Grain|Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
215127324|NCT00423657|DRUG|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
215127325|NCT00423657|DRUG|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
215127326|NCT00423657|DRUG|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
215127327|NCT00730977|DRUG|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
215127328|NCT04538937|OTHER|no intervention|no intervention
215127329|NCT05289843|OTHER|Rosmarinus Officinallis|Root canal Irrigants
215127330|NCT02795117|DRUG|Ivermectin|
215127331|NCT02795117|DRUG|Ivermectin (reference)|
215127332|NCT02795117|DRUG|Placebo|
215127333|NCT03700801|DRUG|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
215127334|NCT03700801|DRUG|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
215127335|NCT01059409|PROCEDURE|Meniscal Allograft|Meniscal Allograft
215127336|NCT02653326|DEVICE|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
215127337|NCT02653326|PROCEDURE|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
215127338|NCT02653326|BEHAVIORAL|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
215127339|NCT02653326|OTHER|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
215127340|NCT02653326|DRUG|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
215127341|NCT02422498|RADIATION|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
214524068|NCT01828593|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
214524069|NCT01828593|OTHER|Placebo|Matching placebo
214524070|NCT02411695|DRUG|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
214524071|NCT02028234|DRUG|Pantoprazole,|os, 20 mg, once per day, for 30 days
215127342|NCT02422498|DRUG|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
215127343|NCT02422498|PROCEDURE|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
215127344|NCT05507307|BEHAVIORAL|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
215127345|NCT02305030|DRUG|BIA 9-1067|
215127346|NCT02305030|DRUG|Warfarin|
215127347|NCT03206216|DIAGNOSTIC_TEST|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
215127348|NCT04958824|DIAGNOSTIC_TEST|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
215127349|NCT03438617|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
215127350|NCT06270069|OTHER|Excercise-based therapy|An individual 60-min motor training sessions twice a week for eight-week outpatient program, that included exercises aimed at improving postural control, strengthening and stabilizing the back muscles, and stretching
215127351|NCT06279858|DIETARY_SUPPLEMENT|Probiotics|Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
215127352|NCT01353404|DRUG|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
215127353|NCT01353404|DRUG|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
215127354|NCT01353404|DRUG|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
215127355|NCT01353404|DRUG|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
215127356|NCT01353404|DRUG|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
215127357|NCT01353404|DRUG|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
215127358|NCT04394923|PROCEDURE|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
215127359|NCT04394923|PROCEDURE|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
215127360|NCT04504422|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
215127361|NCT04177706|DRUG|Ketamine Hydrochloride|Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
215127362|NCT04177706|DRUG|Placebo|Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
215127363|NCT01387217|DRUG|GSK2018682|GSK2018682
215127364|NCT01387217|DRUG|Placebo|Matched Placebo
215127365|NCT00217958|BEHAVIORAL|SHS reduction intervention based on social cognitive learning theory|
215127366|NCT03243695|OTHER|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
215127367|NCT03243695|OTHER|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
215127368|NCT03642977|DIAGNOSTIC_TEST|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
215127369|NCT00388986|DRUG|GK Activator (2)|100mg po bid
215127370|NCT00388986|DRUG|Glyburide|10-20mg po daily
215127371|NCT01415271|OTHER|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
215127372|NCT01936675|OTHER|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
215127373|NCT02016196|DRUG|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~\--------------------------------------------------------------------------------"
215127374|NCT02016196|DRUG|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
215127375|NCT04772703|DIAGNOSTIC_TEST|COMET ASSAY|The description in the detailed description of the study
215127376|NCT02251015|PROCEDURE|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
215127377|NCT02251015|PROCEDURE|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
214524072|NCT02028234|DRUG|Omeprazole|os, 20 mg, once per day, for 30 days
214524073|NCT00725036|DRUG|inhaled human insulin|
214524074|NCT00725036|DRUG|insulin aspart|
214524075|NCT00725036|DRUG|insulin NPH|
214524076|NCT01580462|OTHER|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
214447475|NCT06839573|OTHER|Experience with virtual reality glasses|"If the group belongs to GE (teaching with in-person simulation in the classroom and teaching with VR headsets), they will also receive the two training sessions described for GC:~30 minutes of individual training through VR (headsets and controllers to perform actions while receiving immediate feedback through VR) before the in-person simulation."
215127378|NCT01467544|OTHER|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
215127379|NCT05220722|DRUG|SD-101|SD-101 doses will be delivered via HAI using the PEDD method of administration.
215127380|NCT05220722|BIOLOGICAL|Pembrolizumab|During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
215127381|NCT05220722|BIOLOGICAL|Nivolumab|During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
215127382|NCT05220722|BIOLOGICAL|Ipilimumab|During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
215127383|NCT04782063|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
215127384|NCT05246774|BIOLOGICAL|Biological sample collection|"The following biological samples will be collected on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* fecal sample~* urinary sample~* blood sample (22 ml at each occasion)"
214447476|NCT05770947|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
214447477|NCT05770947|BEHAVIORAL|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
214447478|NCT04173663|BEHAVIORAL|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
214447479|NCT03931291|DRUG|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
214447480|NCT06247631|OTHER|STOP BANG|The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
214524077|NCT03353649|BEHAVIORAL|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
214524078|NCT03353649|DEVICE|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
214524079|NCT06487897|DEVICE|Optimal laser keratoplasty|Laser
214524080|NCT02848885|OTHER|Active TDCS|Participants will receive active tDCS stimulation.
214524081|NCT02848885|OTHER|Sham TDCS|Participants will receive sham tDCS stimulation
215127385|NCT05246774|OTHER|Questionnaires|"The following questionnaires will be filled by the patients on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* CTCAE Radiation Adverse Event Questionnaire~* Lower Urinary Tract Disorders Questionnaire (IPSS Score)~* Quality of Life Questionnaire (FACT-P)~* Physical Activity Questionnaire (IPAQ)"
215127386|NCT03273335|DEVICE|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
215127387|NCT05806437|DIETARY_SUPPLEMENT|sideremil vita cp|assunzione per 30 giorni dell'integratore
215127388|NCT04428736|BEHAVIORAL|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
215127389|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures|All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
215127390|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures|All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding…
215127391|NCT04354376|DRUG|Loop diuretics, thiazides, dihydropyridines|Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
215127392|NCT04354376|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
215127393|NCT05852080|BEHAVIORAL|multilevel system intervention based on information platform|"1. Standardized templates of medical record~2. Continuous medical quality control and feedback system: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the percentage of stroke of undetermined cause.~3. Team collaboration based on video conferencing: hospitals will receive corresponding suggestions for their improvement from experts online.~4. Enhanced feedback incentives"
215127394|NCT06802406|OTHER|Food Bags|Participants will receive bags of shelf-stable food for 2-3 days for one individual twice a week in clinic. They will also receive recipes, handouts, and videos to help with education and food preparation.
215127395|NCT01054456|DRUG|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
215127396|NCT00611689|DRUG|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in \< 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
215127397|NCT00003239|BIOLOGICAL|Recombinant Interferon Alfa|Daily by subcutaneous injection.
215127398|NCT00003239|DRUG|Cytarabine|Daily by subcutaneous injection.
215127399|NCT00003239|DRUG|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
215127400|NCT03212118|BEHAVIORAL|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
215127401|NCT03212118|BEHAVIORAL|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
215127402|NCT03212118|BEHAVIORAL|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
215127403|NCT00290173|DRUG|efficacy of oral ritodrine in maintaining uterine quiescence|
215127404|NCT05513352|DEVICE|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
215127405|NCT05513352|DEVICE|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
214447481|NCT06792656|OTHER|standardized Forest Therapy session (120 min)|standardized, 2-hrs Forest Therapy session following the INFTA Forest Therapy Guiding Sequence
214447482|NCT04604977|BEHAVIORAL|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
214447483|NCT05745350|DRUG|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
214447484|NCT05441670|BEHAVIORAL|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
214524082|NCT01602003|DRUG|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
214447485|NCT05441670|BEHAVIORAL|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
214447486|NCT03900780|PROCEDURE|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
214447487|NCT03900780|PROCEDURE|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
214447488|NCT03503955|OTHER|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
214447489|NCT03503955|OTHER|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
215127406|NCT05513352|DEVICE|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
215127407|NCT00507169|DRUG|SVT-40776|
215127408|NCT04438694|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
215127409|NCT04438694|DRUG|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
215127410|NCT05555875|BEHAVIORAL|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
215127411|NCT04951830|DIAGNOSTIC_TEST|MRI|MRI of TMJ
215127412|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
215127413|NCT00004925|BIOLOGICAL|trastuzumab|
215127414|NCT00004925|DRUG|pegylated liposomal doxorubicin hydrochloride|
215127415|NCT03143530|PROCEDURE|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
214447490|NCT06839612|PROCEDURE|Two-point method|In the two-point method, the distal end of the drainage tube was passed over the duodenal and intestinal lumen of the common bile duct during PTCD operation. In the process of sinus dilation, guide wire was sent into the intestinal lumen through the drainage tube, and then the drainage tube was inserted into the intestinal lumen with the extract forceps under the duodenoscope in reverse order to drag the drainage tube into the intestinal lumen before being sent into the guide wire.Clamp the guide wire with the access pliers and slowly draw out the guide wire through the mouth. Expand the outer inlet skin.When the skin was 6mm, the epigastric PTCD tube was removed, the percutaneous nephrostomy dilator was placed through the guide wire, and the patient was instructed to be drawn by the assistant.The mouth end of the guide wire, the surgeon pulls the other end of the guide wire, so that the two ends of the guide wire fix in vitro to form a higher tension to Expand the skin.
214447491|NCT06839612|PROCEDURE|Conventional PTCS|PTCS can be divided into three steps: PTCD, sinus dilation, and lithotomy. In PTCD, we first performed intraoperative fluoroscopy, and punctured the biliary tract at a relatively straight Angle with the target biliary tract as far as possible. The distal end of the indenture drainage tube was inserted into the duodeno-intestinal cavity through the end of the common bile duct. The PTCD drainage tube was indwelled for 3-5 days.When the sinus was mature, we used dilated sheath tubes to dilate the sinus to 14-18Fr at a time, and used the working channel established by the choledochoscope to carry out net basket stone extraction. If large diameter stones were difficult to be extracted through the net basket, mechanical lithotomy was adopted to solve the problem, and conventional anti-inflammation was adopted in all patients after surgery. Cholangiography or epigastric CT were used to confirm complete removal of the stones after lithotomy.
214447492|NCT05093972|DRUG|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
214447493|NCT06506760|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
214708793|NCT05367557|PROCEDURE|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
215127416|NCT03143530|DRUG|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
215127417|NCT03143530|DRUG|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
215127418|NCT01735448|OTHER|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
214524083|NCT01602003|DRUG|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
215127419|NCT01735448|OTHER|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
215127420|NCT01735448|OTHER|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
215127421|NCT03145311|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|
215127422|NCT04129502|DRUG|TAK-788|TAK-788 capsule
215127423|NCT04129502|DRUG|Pemetrexed|Pemetrexed IV infusion
215127424|NCT04129502|DRUG|Cisplatin|Cisplatin IV infusion
215127425|NCT04129502|DRUG|Carboplatin|Carboplatin IV infusion
215127426|NCT02519023|DRUG|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
215127427|NCT02519023|DRUG|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
215127428|NCT02519023|DEVICE|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
215127429|NCT02519023|DRUG|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
214524084|NCT01602003|DRUG|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
214524085|NCT05641155|DEVICE|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
215127430|NCT02519023|DRUG|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
215127431|NCT02519023|DRUG|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
214524086|NCT03497143|DRUG|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
214524087|NCT06584643|DIAGNOSTIC_TEST|gasdermin d|evaluation of serum gasdermin d in vitligo patients and healthy controls
215127432|NCT02519023|DRUG|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
215127433|NCT05196607|OTHER|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
215127434|NCT04916574|OTHER|Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum|Concentration of active substance on nasal mucosal surface in time
215127435|NCT04590014|DEVICE|Conventional Precision Flow|Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
215127436|NCT04590014|DEVICE|HVNI HVT2.0 Device|Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
215127437|NCT01667289|RADIATION|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
215127438|NCT01667289|DRUG|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
215127439|NCT05931757|DRUG|Olverembatinib|Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
215127440|NCT05841368|DIAGNOSTIC_TEST|CAM-ICU|Delirium in adult patients will be screened according to CAM-ICU
215127441|NCT05841368|DIAGNOSTIC_TEST|pCAM-ICU|Delirium in adult patients will be screened according to pCAM-ICU
215127442|NCT03741465|PROCEDURE|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
215127443|NCT03741465|PROCEDURE|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
215127444|NCT04337424|DIAGNOSTIC_TEST|Sampling salivary|Collection of 1 to 2 ml of saliva
215127445|NCT03298802|DRUG|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
215127446|NCT03298802|DRUG|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
215127447|NCT05355103|OTHER|Educational tool about epidural analgesia|See arm description
215127448|NCT02253225|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
215127449|NCT02313701|OTHER|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
215127450|NCT01096836|OTHER|macronutrient and energy manipulation|
215127451|NCT04907981|DIAGNOSTIC_TEST|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
215127452|NCT00128739|DRUG|Budesonide|
215127453|NCT01944007|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
215127454|NCT01111708|PROCEDURE|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
215127455|NCT04139655|DRUG|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
215127456|NCT04139655|DRUG|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
215127457|NCT00521287|OTHER|Immune profiling and DC vaccine|"1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression."
214447494|NCT06506760|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training). Thirty minutes of ergotherapy. Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
214447495|NCT06160050|BEHAVIORAL|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
214447496|NCT06839768|PROCEDURE|Standard endoscopic enucleation of the prostate (EEP)|Stabdard EEP will be nerformed using 26 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
214447497|NCT06839768|PROCEDURE|MiLEP|Minimally-invasive laser EEP will be nerformed using 22 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
214447498|NCT06835868|PROCEDURE|Spinal cord stimulation|implantation of electrode which is linked to an implantable impulse generator for the treatment of chronic pain syndromes.
214447499|NCT06839534|BEHAVIORAL|Structured Maternal Voice Program (SMVP)|"Pre-recorded maternal voice messages played via an MP3 player integrated into the infant's incubator. The recordings include recognition messages (I'm so glad to have you) and soothing messages (Rest well, little one, you're safe with me). The intervention is delivered three times daily for five minutes per session over a four-day period."
214447500|NCT06749223|DIAGNOSTIC_TEST|D-dimer test|Blood sample collection for D-dimer testing
214447501|NCT06487910|DEVICE|3D scan measurment|"patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process."
214447502|NCT04009343|DRUG|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
214524088|NCT03684356|PROCEDURE|socket shield technique|immediate implant placement with buccal part of the root is retained
214524089|NCT03684356|PROCEDURE|xenograft|immediate implant placement with filling the buccal gap with xenograft
215127458|NCT01506271|DRUG|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
215127459|NCT01506271|DRUG|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
215127460|NCT01506271|DRUG|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
215127461|NCT01506271|DRUG|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
215127462|NCT04169958|OTHER|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
215127463|NCT00292240|BEHAVIORAL|Brief motivational substance use intervention|
215127464|NCT04389359|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
215127465|NCT04802330|OTHER|Questionnaire|Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
215127466|NCT05444556|DRUG|Imlunestrant|Administered orally.
215127467|NCT05444556|DRUG|Repaglinide|Administered orally.
215127468|NCT05444556|DRUG|Omeprazole|Administered orally.
215127469|NCT05444556|DRUG|Dextromethorphan|Administered orally.
215127470|NCT05444556|DRUG|Quinidine|Administered orally.
214524090|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
215127471|NCT05444556|DRUG|Rosuvastatin|Administered orally.
215127472|NCT05444556|DRUG|Digoxin|Administered orally.
215127473|NCT05640323|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
215127474|NCT01071681|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
214447503|NCT04009343|DRUG|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
214447504|NCT06791148|RADIATION|Low-dose radiotherapy|2Gy/f，q3w，×4f
214447505|NCT06791148|DRUG|albumin-bound paclitaxel|100-120mg/m2,i.v.,d2,d9,q3w
214447506|NCT06791148|DRUG|AK112|20mg/kg, i.v., d2, q3w
214447507|NCT06796426|DRUG|Plozasiran|25 mg ARO-APOC3 by sc injection administered by healthcare professional
214447508|NCT06796504|PROCEDURE|Procedure/Surgery: Implant Procedure|The SetPoint System (study device)contains a miniaturized stimulator (implnat) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
214447509|NCT06796504|DRUG|Disease-Modifying Therapies (DMTs)|All subjects will continue treatment with standard of care disease-modifying therapies for he duration of the study.
214447510|NCT06796504|DEVICE|Device: Active stimulation|Active stimulation for 1 minute once per day
214447511|NCT06796504|DEVICE|Device: Non-active stimulation|Non-active stimulation for 1 minute once per day
214447512|NCT04271085|OTHER|Observational study|No intervention involved
214447513|NCT06838650|DRUG|Dexmedetomidine|patients will recive of low-dose (0.5 µg/kg) intravenous Dexmedetomidine before general anathesia
214447514|NCT06838650|DRUG|Saline|patients will recive saline
214447515|NCT05491122|BEHAVIORAL|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
214447516|NCT05971810|DIETARY_SUPPLEMENT|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
214447517|NCT05971810|OTHER|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
214447518|NCT06793150|DRUG|Remifentanil|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
215127475|NCT02922530|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|
215127476|NCT02922530|OTHER|Commercially available computerized training|
215127477|NCT04771832|PROCEDURE|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
215127478|NCT04410185|BEHAVIORAL|Meditation|Meditation sessions will take place over 12 weekly sessions of 1.5 hours
214447519|NCT06793150|DRUG|dexmedetomidin|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
214447520|NCT06838741|PROCEDURE|otago exercises|"A walking program is given to participants, with the goal of including two 30-minute walking sessions each week (which can be divided into shorter segments, like three ten-minute blocks).~Exercises Start exercises with 10 repetition maximum STRENGTH Knee extensor Hold for 3-5 seconds Knee flexor Hold for 3-5 seconds Hip adductor Hold for 3-5 seconds Ankle planter-flexion Calf raises Ankle dorsiflexion Toe raise BALANCE Knee bends Backwards walking Upto 30 minutes Walking and turning around 5-10 minutes Sideways walking Tandem stance Heel to toe stand Tandem walk One leg stand Heel walking Toe walk Heel toe walking backwards Sit to stand Stair walking"
214447521|NCT06838741|DEVICE|virtual reality|Begin with 20-30 minutes per session and extend to 30-45 minutes as tolerance and endurance improve throughout the program. Exercise sessions will be done for 3 sessions per week.
214447522|NCT06841042|BIOLOGICAL|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.
214447523|NCT05512975|DIETARY_SUPPLEMENT|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
214447524|NCT05512975|DIETARY_SUPPLEMENT|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
214447525|NCT05512975|DIETARY_SUPPLEMENT|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
214447526|NCT06839742|OTHER|Deep Posterior Gluteal Compartment Block|Deep Posterior Gluteal Compartment Block will be performed under USG guidance before neuraxial anesthesia.
214447527|NCT06839742|OTHER|Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block will be performed under USG guidance before neuraxial anesthesia.
215127479|NCT01043172|DRUG|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
215127480|NCT03290846|DRUG|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
215127481|NCT03290846|DRUG|Saline Solution|Randomized, single-blinded saline infusion.
215127482|NCT03290846|OTHER|Cold exposure|All subjects will undergo a cold exposure PET scan.
215127483|NCT03040141|DRUG|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
214524091|NCT04335695|BEHAVIORAL|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
214524092|NCT00443755|DRUG|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
214524093|NCT00443755|DRUG|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
214524094|NCT00443755|DRUG|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
214524095|NCT01588171|DRUG|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
214524096|NCT01588171|DRUG|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
215127484|NCT03040141|DRUG|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
215127485|NCT03040141|DRUG|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
215127486|NCT04345341|DRUG|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
214708794|NCT00926666|DRUG|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
215127487|NCT01944137|OTHER|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
214447528|NCT03025763|OTHER|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
214447529|NCT03025763|OTHER|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
214447530|NCT03025763|PROCEDURE|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
214447531|NCT03025763|PROCEDURE|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
214447532|NCT03025763|PROCEDURE|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
214447533|NCT03025763|PROCEDURE|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
214447534|NCT03025763|PROCEDURE|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
214447535|NCT06791421|OTHER|AI-Predictng Model|The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans). The AI model is trained to predict a patient's genotype based on these non-genetic data sources. This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing. There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
214524097|NCT03759132|PROCEDURE|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
214524098|NCT03637621|OTHER|ORIF|open reduction internal fixation of the distal humerus
214524099|NCT05499247|OTHER|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
215127488|NCT02823769|DEVICE|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
215127489|NCT02823769|DEVICE|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
215127490|NCT05534217|BIOLOGICAL|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
215127491|NCT03826940|DRUG|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
215127492|NCT03826940|DRUG|Placebos|60 MG Placebo per day for 3 consecutive days
214524100|NCT04739462|BEHAVIORAL|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
214524101|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
214524102|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
214524103|NCT04611048|DIAGNOSTIC_TEST|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
214524104|NCT01291043|OTHER|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
215127493|NCT05093439|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
215127494|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
215127495|NCT06114186|DEVICE|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
215127496|NCT06114186|OTHER|standard of care|self reported HbA1C or GMI
215127497|NCT02692937|PROCEDURE|Neurolysis|
215127498|NCT02692937|OTHER|Traditional neck-specific exercise program|
215127499|NCT06073808|DEVICE|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
215127500|NCT06073808|DEVICE|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
215127501|NCT04138641|DRUG|Cangrelor|Cangrelor intravenous
215127502|NCT03612778|BEHAVIORAL|Plant-based diet|Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
215127503|NCT03612778|BEHAVIORAL|Mediterranean diet|Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
215127504|NCT01391663|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
215127505|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
215127506|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
215127507|NCT02721602|BEHAVIORAL|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
215127508|NCT03997669|OTHER|Collection of pleural effusion|Detection of pleural effusion
215127509|NCT01693549|DRUG|Cabazitaxel|
215127510|NCT03515824|BIOLOGICAL|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
215127511|NCT01451489|DRUG|FK506|FK506:0.05-0.1mg/kg/d
215127512|NCT01451489|DRUG|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
214524105|NCT05811455|OTHER|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
215127513|NCT00920855|DRUG|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
215127514|NCT00920855|DRUG|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
215127515|NCT01384734|DRUG|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
215127516|NCT01384734|DRUG|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
214524106|NCT05811455|OTHER|Progressive muscle relaxation|progressive muscle relaxation exercises.
214524107|NCT01792583|DRUG|Modafinil/armodafinil|
214524108|NCT03932422|DIAGNOSTIC_TEST|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
214708795|NCT01632176|BEHAVIORAL|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
215127517|NCT01384734|DRUG|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
215127518|NCT01384734|DRUG|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
215127519|NCT01384734|DRUG|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
215127520|NCT01384734|DRUG|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
215127521|NCT01384734|DRUG|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
215127522|NCT01384734|DRUG|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
215127523|NCT02650089|OTHER|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
215127524|NCT02650089|OTHER|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
215127525|NCT02650089|OTHER|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
215127526|NCT01528930|DRUG|Amikacin|500 mg, once daily for 2 years
215127527|NCT04215536|DRUG|Empagliflozin|Empagliflozin dispensing claim is exposure
215127528|NCT04215536|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
215127529|NCT01484210|DRUG|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
215127530|NCT03070080|PROCEDURE|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
215127531|NCT03070080|PROCEDURE|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
214524109|NCT01695525|OTHER|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
214524110|NCT00678899|DEVICE|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
214524111|NCT00159341|PROCEDURE|Nasal lavage|Nasal lavage was carried out at specified timepoints
214524112|NCT00159341|PROCEDURE|Nasal filter paper|Nasal filter paper was placed at specified timepoints
214524113|NCT00159341|PROCEDURE|Blood sampling|Blood sampling was performed as a routine safety check
214524114|NCT01543906|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
214524115|NCT05681845|DRUG|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
214524116|NCT06402123|DRUG|zagociguat 15mg|Once-daily oral tablets
214524117|NCT06402123|DRUG|zagociguat 30mg|Once-daily oral tablets
214524118|NCT06402123|DRUG|Placebo|Once-daily oral tablets
214524119|NCT02160496|BEHAVIORAL|Weight loss interventional study with 20% protein-diet|
214524120|NCT02160496|BEHAVIORAL|Weight loss interventional study with 27% protein-diet|
214524121|NCT02160496|BEHAVIORAL|Weight loss interventional study with 35% protein-diet|
214524122|NCT03932253|OTHER|FCN-159|Administered orally once a day
214524123|NCT01243086|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
214524124|NCT01243086|DRUG|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
214524125|NCT01093976|DRUG|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
214524126|NCT00376935|DRUG|Palifermin|Keratinocyte growth factor administered via injection
214524127|NCT00376935|DRUG|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
214524128|NCT00840788|PROCEDURE|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
214524129|NCT00840788|PROCEDURE|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
214524130|NCT01217723|BIOLOGICAL|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
214524131|NCT01217723|OTHER|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
214524132|NCT00084409|DRUG|iloprost|Given orally
214524133|NCT00084409|OTHER|placebo|Given orally
214524134|NCT00936364|OTHER|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
215127532|NCT00811525|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
215127533|NCT04480268|DRUG|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~* nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~* cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~* capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~* gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
215127534|NCT02371824|OTHER|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
214524135|NCT00936364|OTHER|Modified fast|Minimal caloric intake on days -2 and -1
214524136|NCT00936364|OTHER|Fasting|Day -1
214524137|NCT00936364|OTHER|Fasting|Days -2 and -1
214524138|NCT00936364|OTHER|Fasting|Days -3, -2, and -1
214524139|NCT00936364|OTHER|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
214524140|NCT06344494|DEVICE|Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system|Novel ICE catheter and combined ultrasound system
214524141|NCT06344494|DEVICE|SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system|Commercially available devices
214524142|NCT01124656|DRUG|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
214524143|NCT05129592|BEHAVIORAL|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
214524144|NCT03296423|BIOLOGICAL|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
215127535|NCT00102765|DRUG|fluticasone propionate/salmeterol powder|
215127536|NCT00102765|DRUG|fluticasone propionate powder|
214524145|NCT03296423|BIOLOGICAL|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
214524146|NCT03321175|OTHER|subcutaneous saline irrigation|200 cc saline irrigation
214524147|NCT03003884|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
214524148|NCT03003884|DRUG|Propofol|Initial dose plus supplemental doses as necessary.
214524149|NCT06181019|DRUG|50 mg of mirabegron|Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
214524150|NCT06181019|COMBINATION_PRODUCT|acupuncture combined with mirabegron.|Patients in the treatment group were treated with acupuncture combined with mirabegron.
214524151|NCT04422509|BIOLOGICAL|lanadelumab|single dose, or two doses administered iv
214524152|NCT04422509|OTHER|regular care|no lanadelumab administration, treated according to regular care
214524153|NCT02339506|DRUG|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
214524154|NCT02339506|DRUG|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
214524155|NCT05099068|BIOLOGICAL|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
214524156|NCT01257386|DRUG|Asacol®|400mg tablets
214524157|NCT01257386|DRUG|Mesalazine|400mg tablets
214524158|NCT01572493|BIOLOGICAL|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
214524159|NCT01572493|BIOLOGICAL|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
215127537|NCT00567853|DEVICE|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
215127538|NCT02634385|PROCEDURE|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
215127539|NCT02634385|PROCEDURE|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
215127540|NCT00186225|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
215127541|NCT02991638|DRUG|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
215127542|NCT01290523|DEVICE|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
215127543|NCT00346125|BIOLOGICAL|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
215127544|NCT00346125|DRUG|doxorubicin hydrochloride|65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
215127545|NCT00346125|DRUG|ifosfamide|9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
215127546|NCT00346125|DRUG|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
215127547|NCT00346125|PROCEDURE|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
214447536|NCT06676332|OTHER|motor imagery training|"Children in the study group will receive multisensory motor imagery training program 45 minutes. The training protocol consists of several parts that will be run through every training session according to Kumar et al. (2016):~* Watching videos of selected multisensory motor skills for 10 minutes.~* Mental rehearsal of these motor skills 10 minutes.~* Overt practice of the multisensory motor skills for 25 minutes. On the videos, the performance of the skill by a child aged 8-12 years will be shown. All the exercises will be looped to repeat for six to seven times. While projecting the video on the laptop screen, it will be ensured that the children are in a comfortable seating position and the screen is in their visual field. Repetition of the exercises was based on their ability which could be a minimum of five repetitions per session to a maximum of ten repetitions per exercise session."
214447537|NCT06676332|OTHER|traditional physical therapy|traditional physical therapy training program
214447538|NCT06797570|OTHER|Communication Strategy for Side Effect Counseling in ADHD Treatment|One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.
214447539|NCT04571970|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
214447540|NCT06780332|DRUG|RDD to Palynziq|Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
214447541|NCT05930431|BEHAVIORAL|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
214447542|NCT05930431|BEHAVIORAL|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
214447543|NCT06839209|DEVICE|Toxclean 1g|1 g of Toxclean once or twice daily for 28 days
214447544|NCT06835478|BEHAVIORAL|EPURE + : EPURE program|EPURE program will be tested.
214447545|NCT06835478|BEHAVIORAL|EPURE - : Standard practices|This group will receive standard practices to prevent the use of screens in child under 3
214447546|NCT06839183|DEVICE|integrated interactive self-care APP|integrated interactive self-care APP
214447547|NCT06795698|DRUG|Enoxaparin|enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
215127548|NCT00346125|RADIATION|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
214524160|NCT00609245|DRUG|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
214524161|NCT00609245|DRUG|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
214524162|NCT01234675|DRUG|Milnacipran|50 mg twice daily
215127549|NCT00539994|DRUG|retapamulin|200mg BID retapamulin 3 days
214524163|NCT01234675|DRUG|Placebo|50 mg twice daily
214524164|NCT00454545|DRUG|Atorvastatin|
215127550|NCT00539994|DRUG|Retapamulin|200mg BID retapamulin 5 days
215127551|NCT00539994|DRUG|Placebo|200mg BID placebo 5 days
215127552|NCT04428346|BEHAVIORAL|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
215127553|NCT04871659|OTHER|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
215127554|NCT03071263|DRUG|Patiromer|2 packets/day starting dose, administered orally
214447550|NCT06840847|BEHAVIORAL|Sexual Coercion|This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.
214447551|NCT06839677|OTHER|semi-structured interview on Microsoft Teams|Data will be collected through a single semi-structured interview on Microsoft Teams, audio recorded and transcribed in full, and analysed using NVivo V1.6.2.32. Participants' statements will be categorised into semantic categories and subsequently refined into sub-themes and themes through an iterative process.
214447552|NCT06640933|DRUG|BIIB091|Administered as specified in the treatment arm.
214447553|NCT06839547|DRUG|Radiotherapy + Novel Anti-tumor Drug|"1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\]~2. Radiotherapy"
214447554|NCT03485547|DRUG|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
214447555|NCT05547958|OTHER|Focus group and online survey|"Focus group with parents of children with disabilities or chronic condition will be organized to identify hypotheses regarding their needs in terms of informations exchange with pediatric rehabilitation professionals about the rehabilitation care of their children.~Then, an online survey will be proposed to parents of children with disabilities or chronic condition in France to identify their needs regarding the development of apps that offer the feature to share informations with rehabilitation professionals."
214447556|NCT06091098|OTHER|Dynamic CO2|2% inspired CO2 for 2-4 breaths
214447557|NCT06091098|OTHER|Sham CO2|Air
214447558|NCT06223503|BEHAVIORAL|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
214524165|NCT05673421|OTHER|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
214524166|NCT05673421|OTHER|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
214524167|NCT04183803|PROCEDURE|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
214524168|NCT06422559|DEVICE|Transmagnetic stimulation|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
214524169|NCT06422559|DEVICE|TMS|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
214524170|NCT06275906|OTHER|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
214524171|NCT02746497|PROCEDURE|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
215127555|NCT03071263|DRUG|Placebo|2 packets/day starting dose, administered orally
214447559|NCT06794801|DEVICE|Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）|In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.
214524172|NCT00331799|DRUG|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
214524173|NCT04107688|OTHER|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
214524174|NCT04107688|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
214524175|NCT02889809|DRUG|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
214524176|NCT02889809|DRUG|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
215127556|NCT03071263|DRUG|Spironolactone|25 mg tablet/day starting dose, administered orally
215127557|NCT02763839|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
215127558|NCT02763839|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
215127559|NCT02763839|DRUG|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
215127560|NCT05549011|OTHER|PENG Block|PENG block for analgesic purposes performed before hip surgery
215127561|NCT05549011|OTHER|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
215127562|NCT05549011|DIAGNOSTIC_TEST|Numeric Rating Scale|Self-reported pain intensity score between 0-10
215127563|NCT05549011|DIAGNOSTIC_TEST|Angle of sitting|Measurement of sitting angle in degrees with a protractor
215127564|NCT05569902|DEVICE|active tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
215127565|NCT05569902|DEVICE|sham tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
215127566|NCT00002781|DRUG|boronophenylalanine-fructose complex|
215127567|NCT01437280|BIOLOGICAL|CGTG-102|"VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
215127568|NCT04840446|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Sensor
215127569|NCT01665469|DIETARY_SUPPLEMENT|Tomato extracted lycopene|
215127570|NCT01665469|DIETARY_SUPPLEMENT|Placebo|
215127571|NCT04163575|BIOLOGICAL|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
215127572|NCT00154856|BEHAVIORAL|Detect the variation of limb lengthening|
214524177|NCT02889809|DRUG|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
214524178|NCT02889809|DRUG|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
214524179|NCT05065918|BEHAVIORAL|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
214524180|NCT05065918|BEHAVIORAL|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
215127573|NCT03084796|DRUG|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
215127574|NCT03084796|DRUG|Placebo|Placebo Control
215127575|NCT03084796|DRUG|Tiotropium Bromide 18 µg Inhalation Capsule|Active Control
215127576|NCT05470985|DRUG|Ozanimod|Specific dose on specific days
215127577|NCT02266355|DRUG|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
215127578|NCT03651037|BEHAVIORAL|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
215127579|NCT02854046|OTHER|Calcific Uremic Arteriolopathy|
215127580|NCT01917747|BEHAVIORAL|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
215127581|NCT01917747|BEHAVIORAL|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
215127582|NCT02640638|BEHAVIORAL|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
215127583|NCT03487926|RADIATION|[18F]FEPPA|up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI
215127584|NCT02374151|DEVICE|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
215127585|NCT02741245|DRUG|Ezetimibe 10 mg|
215127586|NCT02741245|DRUG|Rosuvastatin 2.5 mg|
215127587|NCT02741245|DRUG|Placebo for Ezetimibe|
215127588|NCT02741245|DRUG|Placebo for Rosuvastatin|
215127589|NCT00603330|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
215127590|NCT01685567|DEVICE|MICHI NPS+f|Cerebral protection with carotid flow reversal
215127591|NCT03692559|OTHER|full aseptic dressing|Replacement of the central venous catheters in the dressing process
215127592|NCT00093210|DRUG|rFIX|
215127593|NCT00093210|DRUG|rFIX-R|
215127594|NCT02997501|PROCEDURE|T790M+ Testing|The patient will need to have T790M+ testing
215127595|NCT02997501|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
215127596|NCT02997501|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
215127597|NCT02997501|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
215127598|NCT02997501|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
215127599|NCT02997501|PROCEDURE|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
215127600|NCT05057481|DRUG|Mycophenolate Mofetil 500mg|MMF 2gram/day orally for 12 weeks
215127601|NCT05057481|DRUG|Rituximab|375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
215127602|NCT00415285|DRUG|Docetaxel|
215127603|NCT00415285|DRUG|Capecitabine|
215127604|NCT00415285|DRUG|Docetaxel/Capecitabine|
215127605|NCT03195283|OTHER|Meal service|The type of meal service in the hospital (usual care)
215127606|NCT02023307|DEVICE|V-Loc Suture|
215127607|NCT00415948|DEVICE|Biomarkers|
215127608|NCT02429635|BEHAVIORAL|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
215127609|NCT04632888|OTHER|Telephone support for breastfeeding follow-up|The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
215127610|NCT00152503|DRUG|Seletracetam (UCB44212)|"* Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration"
215127611|NCT03375034|DRUG|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
215127612|NCT03375034|DRUG|NDMC60mg|Oral administration of three NDMC 20mg capsules
215127613|NCT03375034|DRUG|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
215127614|NCT03375034|DRUG|Placebo|Oral administration of three Placebo capsules
215127615|NCT04361435|PROCEDURE|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
215127616|NCT00874146|GENETIC|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
215127617|NCT02922725|DRUG|5-hydroxytryptophan and Creatine|
215127618|NCT02922725|OTHER|Placebo control|
215127619|NCT01300234|DRUG|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
215127620|NCT01300234|DRUG|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
215127621|NCT04140968|DRUG|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
215127622|NCT03253679|DRUG|Adavosertib|Given PO
215127623|NCT02944409|DEVICE|total knee prothesis VEGA System|total knee replacement
215127624|NCT00895635|BEHAVIORAL|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
215127625|NCT00895635|BEHAVIORAL|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
215127626|NCT00895635|BEHAVIORAL|Usual Care|Usual care for PAD
215127627|NCT02584179|DEVICE|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
215127628|NCT05660772|DEVICE|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
215127629|NCT05660772|DRUG|Corticosteroid|intra-articular knee injection of corticosteroid
215127630|NCT03692702|BEHAVIORAL|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
215127631|NCT03902314|DRUG|Lidocaine Iv|Intravenous infusion
215127632|NCT03902314|DRUG|Saline Solution|Intravenous infusion
215127633|NCT04816214|DRUG|Capmatinib|Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).
215127634|NCT04816214|DRUG|Osimertinib|Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)
215127635|NCT04816214|DRUG|Pemetrexed|Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
215127636|NCT04816214|DRUG|Cisplatin|Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.
215127637|NCT04816214|DRUG|Carboplatin|Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
215127638|NCT00625079|DRUG|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
215127639|NCT00550407|DRUG|lamotrigine|lamotrigine 100mg/day or 200mg/day
215127640|NCT00550407|DRUG|Placebo|placebo once daily
215127641|NCT05647590|PROCEDURE|Chemotherapy|3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
215127642|NCT05647590|PROCEDURE|Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)|"* RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks … maintenance"
215127643|NCT05647590|PROCEDURE|Maintenance chemotherapy|Maintenance chemotherapy will follow 3-6 weeks after RT.
215127644|NCT01640782|DRUG|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"* Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
215127645|NCT01640782|DRUG|Leucovorin, 5-Fluorouracil|"* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
214447560|NCT06794801|DEVICE|Conventional Drug coated balloon (DCB)|In the control arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successful lesion preparation (residual stenosis ≤ 30%, no type C dissections, no significant residual plaque burden, no dissection involving the media or adventitia, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no location at the stent distal end, no hematoma, TIMI thrombus burden grade ≤ 2) will be treated with a conventional DCB coated with 3 μg/mm2 paclitaxel. If angiographic and intravascular imaging results are unsatisfactory, a bailout DES will be implanted.
214447561|NCT06795750|PROCEDURE|neural therapy|Neural therapy (NT) is a therapeutic intervention that uses local anesthetics to alleviate persistent musculoskeletal pain. NT targets the underlying autonomic dysfunction by modulating the autonomic nervous system. The enhancement of autonomic dysfunction leads to controlled microcirculation, the elimination of pain mediators, and the attainment of an anti-inflammatory effect. NT focuses on painful regions, specific segments of these areas, and trigger points, encompassing both local and segmental treatment
214447562|NCT06795750|OTHER|Exercise|The second group received a home exercise program consisting of stretching, strengthening, and aerobic exercises for 30 minutes, three times per week, for a duration of five weeks.
214447563|NCT06084910|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
214447564|NCT06084910|BEHAVIORAL|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
214447565|NCT06839456|DEVICE|Phase 1 Dose Level 1|Patients in the first dose level for the CD45RA depleted addback will receive 1 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
214447566|NCT06839456|DEVICE|Phase 1 Dose Level 2|Patients in the second dose level for the CD45RA depleted addback will receive 2 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
214447567|NCT06839456|DEVICE|Phase 1 Dose Level 3|"Patients in the third and final dose level for the CD45RA depleted addback will receive 5 X 10\^6 CD45RO+ T cells/kg. All patients in this dose group will be evaluated for acute GVHD at day 100. Based on these findings, the maximum tolerated dose (MTD) will be determined.~Once MTD for the addback cell dose has been determined in Phase 1, subjects with mismatched related donors will then enroll in Phase 2."
215127646|NCT04014283|DIETARY_SUPPLEMENT|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
215127647|NCT04014283|OTHER|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
215127648|NCT04014283|OTHER|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
215127649|NCT06296485|BEHAVIORAL|SAGE Group Sessions|Participants enroll in 3 educational group sessions and receive CGMs
215127650|NCT06296485|OTHER|Usual Care|Participants continue to receive usual care (Control Arm)
215127651|NCT02151669|BEHAVIORAL|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
215127652|NCT04364828|GENETIC|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
215127653|NCT04364828|GENETIC|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
215127654|NCT04364828|GENETIC|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
215127655|NCT00584415|DEVICE|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
215127656|NCT04852939|OTHER|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
215127657|NCT04852939|OTHER|Conventional physical therapy|"* Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
215127658|NCT03741686|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)
215127659|NCT03741686|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
215127660|NCT02935647|DRUG|Diprivan|
215127661|NCT03624842|DRUG|Trappsol (R) Cyclo (TM)|
215127662|NCT02650180|DEVICE|Soberlink Cellular Device|Alcohol Breath Analyzer
215127663|NCT06524128|DEVICE|Dreeft wheels (EPPUR company)|The braking system (Dreeft wheels) is installed directly on the participant's wheelchair, by a trained occupational therapist. The Dreeft wheels are supplied for a period of 1 month.
215127664|NCT02338544|DRUG|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
215127665|NCT01788917|DIETARY_SUPPLEMENT|Linseed oil|Dietary supplement: 10 mL linseed oil per day
215127666|NCT04487106|DRUG|Azacitidine|Given IV or SC
214447568|NCT06839456|DEVICE|Phase 2 Maximum Tolerated Dose determined in Phase 1|Patients with mismatched related donors will receive the CD45RA depleted addback at the maximum tolerated dose determined in the Phase 1 portion of the study.
214447569|NCT06839456|DEVICE|Phase 2 Established Dose from prior study, NCT03810196|Patients with unrelated donors will receive the CD45RA depleted addback at the dose 5 X 10\^6 CD45RO+ T cells.
214447570|NCT06839651|COMBINATION_PRODUCT|uc-msc secretome intra cavernous injection|"UC-MSC secretome was obtained from UC-MSC cultures with 80% confluence in serum-free medium after 24 hours of incubation The VEGF level in the secretome given was 1400 pg/ml.~The intervention was the administration of 0.5 mL/site of secretome injection injected intra-cavernous to all subjects using a 22-gauge needle according to a sterile protocol. The same volume was given at bilateral sites of the penile shaft. The intra-cavernous injection sites were in the right and left dorsolateral regions of the penis. After the intervention, tolerability was assessed by observing and questioning the subjects regarding pain during injection."
214447571|NCT06797102|OTHER|Neuromuscular Exercises|Patients in this group received a neuromuscular training protocol along with general treatment for 10 minutes. This included hot packs, lumbar stretches, and ergonomic posture correction divided over 6 weeks The exercises performed included squatting, single leg stance, and balance reach leg and arm exercises with 10 repetitions each. They also did lunge exercises with five repetitions bilaterally, step up and down exercises with 10 repetitions, single leg standing on a balance mat with 10 repetitions and a 10-second hold, single board exercises, and single leg stance with weights and eyes closed for five minutes with a 10-second hold. Additionally, they stood on a wobble board with eyes closed five times with a 10-second hold. The protocol included running on a treadmill and trampoline for five minutes per day, running figure-of-eight patterns, and agility drills at a slow speed for five minutes each.
214447572|NCT06797102|OTHER|Close Chain Exercises|Patients in this group received closed chain exercises for core strengthening along with general treatment for 10 minutes, including hot packs, lumbar stretches, and ergonomic posture correction, divided over 6 weeks. The exercises included sets of squats, lunges, leg presses, wall squats, standing heel raises on a single leg, and single leg dead lifts. Each treatment session lasted 60 minutes, incorporating a warm-up and cool-down period of 10 minutes.
214524181|NCT03934944|DEVICE|Phone application|Weekly foot alerts and educational video
214524182|NCT03934944|OTHER|Usual care|Usual routine of diabetic foot education
215127667|NCT04487106|DRUG|Trametinib|Given PO
215127668|NCT04487106|DRUG|Venetoclax|Given PO
215127669|NCT00391300|PROCEDURE|bioelectric field imaging|
215127670|NCT00391300|PROCEDURE|biopsy|
215127671|NCT00391300|PROCEDURE|histopathologic examination|
215127672|NCT06374953|DIAGNOSTIC_TEST|Ultrasound-based viscoelastic hemostasis analysis|Adding recombinant tissue plasminogen activator (rtPA) and/or Tranexamic acid （TXA）to blood in vitro, and fibrinolysis capacity is assessed using ultrasound-guided viscoelastic coagulation testing.
215127673|NCT02447614|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy
215127674|NCT02447614|OTHER|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
215127675|NCT02447614|OTHER|no treatment|just regular follow-up
215127676|NCT01271556|DRUG|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
215127677|NCT01271556|PROCEDURE|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
215127678|NCT01271556|OTHER|Placebo|placebo, inhalatory (MDI) once
215127679|NCT05397769|DRUG|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
215127680|NCT06389578|DRUG|Teprotumumab|SC administration and IV infusion
215127681|NCT06155422|DRUG|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
215127682|NCT00717249|DEVICE|galyifilcon A control lens|Marketed daily wear contact lens
215127683|NCT00717249|DEVICE|galyfilcon A with a silver additive|Investigational daily wear contact lens
215127684|NCT05742477|DRUG|Antibiotic|role of antibiotics in treatment of neonatal sepsis
215127685|NCT00876616|DRUG|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
215127686|NCT00876616|DRUG|Cyclophosphamide|CTX 0.75g/m2 BSA
215127687|NCT00360412|DRUG|E2007|
215127688|NCT03318588|PROCEDURE|Vitrectomy|Pars plana vitrectomy
215127689|NCT01205100|BEHAVIORAL|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
215127690|NCT01205100|DRUG|Placebo|
215127691|NCT00043043|DRUG|celecoxib|
215127692|NCT05430958|DRUG|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
215127693|NCT05430958|DRUG|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
215127694|NCT05430958|DEVICE|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
215127695|NCT00967317|DRUG|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
215127696|NCT00967317|DRUG|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
215127697|NCT04874935|DRUG|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
215127698|NCT04874935|DRUG|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
215127699|NCT00798616|DRUG|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
215127700|NCT00798616|DRUG|placebo|oral or IV placebo
215127701|NCT03952013|OTHER|To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure|All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
215127702|NCT05094726|RADIATION|photobiomodulation|Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.
215127703|NCT05094726|OTHER|placebo intervention by photobiomodulation device|placebo intervention while the photobiomodulation device is on the off mode
215127704|NCT00871871|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
215127705|NCT00871871|DRUG|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
215127706|NCT00871871|DRUG|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
215127707|NCT00871871|DRUG|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
215127708|NCT02093793|DEVICE|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
215127709|NCT03082248|OTHER|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
215127710|NCT03082248|PROCEDURE|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
215127711|NCT02107833|DRUG|OPRX-106|
215127712|NCT04065139|DRUG|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
215127713|NCT04065139|DRUG|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
215127714|NCT01568489|DRUG|HL-009 Liposomal Gel|Topical adenosylcobalamin gel
215127715|NCT01568489|DRUG|Placebo|Placebo gel
215127716|NCT01041313|DRUG|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
215127717|NCT01041313|DRUG|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
214524183|NCT05707585|DIAGNOSTIC_TEST|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
215127718|NCT00001114|DRUG|Interferon alfa-2b|
215127719|NCT00001114|DRUG|Didanosine|
215127720|NCT01381393|DRUG|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
215127721|NCT03067246|DEVICE|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
215127722|NCT03067246|DEVICE|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
215127723|NCT05662085|OTHER|No intervention|According to clinical practice.
214447573|NCT06796855|DEVICE|Selective Bladder Denervation via Radiofrequency Ablation|Participants in this arm will undergo a single session of selective bladder denervation using radiofrequency ablation (RFA). The procedure is performed under general anesthesia using the Apro Korea AK-F200 system, which delivers radiofrequency energy at four submucosal points in the bladder trigone area. The energy is applied at 25 watts per site for 60 seconds, targeting nerve pathways involved in overactive bladder symptoms. The procedure is conducted using a 19 Fr. rigid cystoscope in lithotomy position, ensuring precise electrode placement. Patients are discharged on postoperative day 1 following urinary ultrasound and post-void residual (PVR) assessment. Follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
214447574|NCT06796855|DRUG|Intravesical Onabotulinum Toxin A Injection|Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19 Fr. rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
214447575|NCT06830876|DEVICE|Chattanooga Continuum Device|The Chattanooga Continuum (Enovis, Wilmington, DE) is an FDA-approved, multi-functional, dual-channel electrotherapy device that offers adjunctive rehabilitation therapies, including muscle re-education (NMES), pain control, and stimulation of local blood circulation. The device provides a treatment duration of up to 60 minutes, allowing for cycled or continuous therapy. It offers symmetrical and asymmetrical waveform types, adjustable pulse rates of up to 150 Hz, and pulse width durations of up to 400 μs. The device also features off times, channel ramp times, and on time settings. Additionally, the Continuum is equipped with a data and parameter logger, enabling the monitoring of patient usage. It incorporates an automatic lock function to prevent accidental changes in intensity by preventing unintended pressing of the control buttons. The device operates on two AA rechargeable NiMH batteries, and a battery charger and extra batteries are included with the device.
214447576|NCT04675892|PROCEDURE|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
214447577|NCT04675892|PROCEDURE|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
214447578|NCT05557864|DEVICE|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
214447579|NCT06797141|OTHER|Vestibular Rehabilitation and Dual task Training and Traditional Physical Therapy|Group A will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 30 minutes and Dual Task Training for 20 minutes along with routine physical therapy of 10 minutes. Treatment session will be given 5 days per week for 8 weeks. Patients will be instructed to perform 2 sets of 5 repetition each Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Dual Task exercises comprising of primary and secondary tasks Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down
214447580|NCT06797141|OTHER|Vestibular Rehabilitation and Traditional Physical Therapy|"Group B will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 5 days per week for 8 weeks.~Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down"
214524184|NCT00599599|BEHAVIORAL|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
215127724|NCT00116012|DRUG|rNAPc2|
215127725|NCT05990192|DRUG|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
215127726|NCT05990192|RADIATION|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
215127727|NCT02511379|OTHER|Propylene Glycol 0.6% eye drops|
215127728|NCT00285909|BEHAVIORAL|Alcohol: 25 gday (white wine)|
215127729|NCT06604130|DIAGNOSTIC_TEST|Prostate cancer screening decision|The subjects would receive serum PSA test.
215127730|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
215127731|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
215127732|NCT06868511|PROCEDURE|Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase|Neuronavigation-assisted stereotactic minimally invasive puncture will enhances catheter placement precision, reducing complications and improving hematoma evacuation and neurological outcomes. TNK, a third-generation thrombolytic will offers advantages over alteplase (rt-PA), including a longer half-life for rapid bolus administration and effective thrombolytic effects to dissolve clots and promote hematoma clearance.
215127733|NCT06868511|DRUG|Standard medical treatment|The standard medical treatment for this group of patients will be provided according to the optimal care standards defined by the American Heart Association (AHA) guidelines for intracerebral hemorrhage management
215127734|NCT05937399|BEHAVIORAL|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
215127735|NCT05937399|BEHAVIORAL|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
215127736|NCT06703567|BEHAVIORAL|Standard Policy|Patients will receive information about the GEP test by clinical teams
215127737|NCT06703567|BEHAVIORAL|Standard Policy + GEP Information Film|Patients will receive information about the GEP test by clinical teams and, after consultation with physician, they will be sent a link to view the film regarding OncotypeDX
215127738|NCT06703671|DEVICE|electroacupuncture group|"According to the acupuncture prescription, the acupuncture doctor carried out acupuncture and lifting and twisting, and qi appeared under the needle. Select waist Jiaji point and Shenshu point on the same side to connect a set of electronic needle therapy instrument, the positive pole (red clip) connected to Shenshu point, the negative pole (white clip) connected to waist Jiaji point, after confirming that the electric current intensity of the electric needle instrument returns to zero, open the electronic needle therapy instrument, select continuous wave, 2Hz, current intensity 2mA. During the process of needle retention, the other points were injected every 15 minutes and retained for 30 minutes.The investigators have developed detailed acupoint positioning and operation rules."
215127739|NCT06703671|DEVICE|sham-acupuncture group|The investigators fixed the foam pad with one hand and inserted a comfort needle with the other, making sure the needle only touched the surface of the skin and did not penetrate the point. After the completion of all acupoint operations, the operator selected the simulated needle insertion points of Jiaji point on the waist and Shenshu point on the same side. An electroacupuncture treatment device designed to connect a circuit interrupt treatment is operated with the electroacupuncture group, a process that ensures that the participant does not experience any perceptible stimulation
215127740|NCT06726382|DRUG|Esketamine Nasal Spray|1 x 28 mg dose
215127741|NCT06726382|DRUG|Esketamine 28 mg|1 x 5,6 ml p.o.
214447581|NCT03805464|OTHER|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
214447582|NCT06829628|BEHAVIORAL|chatbot teaching strategies|Chatbot-Based Learning
214447583|NCT05534750|DRUG|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
214447584|NCT05534750|DRUG|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
214447585|NCT05534750|DRUG|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
214447586|NCT02989935|PROCEDURE|Ventilation|Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
214447587|NCT02989935|PROCEDURE|Parasternal EMG|Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.
214447588|NCT02989935|PROCEDURE|Phrenic magnetic stimulation|Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
214447589|NCT04762641|DRUG|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
214524185|NCT01062854|OTHER|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
214524186|NCT05208593|BEHAVIORAL|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
215127742|NCT06726382|DRUG|Cobicistat 150 MG|1 x 150 mg tablet
215127743|NCT06726356|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
214447590|NCT00804453|DEVICE|Cartridge blood set|Once a week
215127744|NCT06725875|OTHER|White Noise Group|During the procedure, a mobile white noise (WN) application called Noise: White, Pink, Brown will be played via over-the-ear headphones to provide the individual with a sense of comfort. The intensity of the white noise will be determined using sound samples for patient comfort. The mobile WN application will be played to the patient by selecting white from among the color options. The sound level will be adjusted below 50 dB using a measuring device to prevent possible hearing damage (12). At the end of the procedure, the listening process will be terminated and the headphones will be removed. At the end of the procedure, the outer and inner surfaces of the headphones will be cleaned with disposable disinfectant wipes to prevent decontamination when used by another patient.
215127745|NCT06725875|OTHER|Earplug group|2\. Earplug group: An earplug that prevents patients from hearing outside sounds will be used during the procedure. Features: Smooth, dirt-resistant surface provides better hygiene. Earplugs are easy to roll for quick and easy insertion. Conical design fits comfortably in ear canals. Soft polyurethane foam is hypoallergenic. Similar earplugs were used in a previous study
215127746|NCT03288571|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
215127747|NCT03741088|DEVICE|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
215127748|NCT06727188|DIAGNOSTIC_TEST|Laboratory as cbc crp|Using laboratory and imaging investigations to help in diagnosis and follow up the cases
214447591|NCT00804453|DEVICE|Standard blood line|Once a week
215127749|NCT01810770|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
215127750|NCT06705634|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the multifidus of the C5-C6 cervical muscles. Once the needle has been inserted, the needle will be pistoned in an up and down motion within the multifidus muscle at approximately 1Hz for 10 seconds and then left in-situ for 5 minutes.
214447592|NCT06204237|DRUG|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
214447593|NCT06204237|RADIATION|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
214447594|NCT06826963|OTHER|Aerobic eccentric intervention|This arm will participate in a supervised eccentric cycling training program for three months. The intervention will include two training sessions per week in the first month, increasing to three sessions per week in the following two months. Each session will consist of a warm-up (5 minutes), a main training phase (20-30 minutes), and a cool-down (5-10 minutes). The intensity of training will be gradually adjusted to maintain a perceived exertion rating (RPE) between light and moderate with a target heart rate zone (57-76% of HRmax). Pre- and post-training assessments will evaluate physical function through several tests, body composition and anthropometric indices, muscle strength of upper and lower limbs, questionnaires related to the overall health improvement. Finally, participants will also be monitored for daily physical activity through wearable sensors to track mobility and autonomy.
214447595|NCT06836804|OTHER|Sociodemographic Data Form|After inquiring about participants' sociodemographic characteristics, such as name, contact information, age, gender, marital status, education level, income, and place of residence, measurements of height, weight, and waist circumference will be obtained. Then, participants' CVD, psychiatric and other medical conditions, CVD risk factors, health history, and medications they are using will be queried. This information will be recorded in the sociodemographic data form. The sociodemographic data form has been prepared by the researchers.
214524187|NCT05208593|BEHAVIORAL|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
214524188|NCT05208593|BEHAVIORAL|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
214524189|NCT05208593|BEHAVIORAL|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
215127751|NCT03064490|DRUG|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
214524190|NCT02502188|DRUG|CC-90005|
214524191|NCT02502188|DRUG|Placebo|
215127752|NCT06912698|RADIATION|Reduced dose radiation|Reduced dose group would receive 61.48Gy radiation.
214524192|NCT05324527|OTHER|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
214524193|NCT01090076|DIETARY_SUPPLEMENT|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
214524194|NCT01680302|BEHAVIORAL|High intensity exercise|
214524195|NCT01680302|BEHAVIORAL|Moderate intensity exercise|
214524196|NCT01680302|BEHAVIORAL|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
215127753|NCT06912698|RADIATION|Standard dose radiation|Standard dose group would receive 69.96Gy radiation.
215127754|NCT06922331|DRUG|Upadacitinib|A selective Janus kinase (JAK) 1 inhibitor used for the treatment of refractory inflammatory bowel disease.
215127755|NCT06932861|BIOLOGICAL|mRNA Tumor Vaccine Therapy|personalized mRNA vaccines
215127756|NCT06938165|OTHER|Fecal Microbiota Transplant (FMT)|FMT in patients with refractory GVHD
215127757|NCT06937905|DRUG|Standard of Care Chemotherapy|Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX, FOLFIRI or alkylating-based chemotherapy in primary digestive tumors.
215127758|NCT06937905|DRUG|Tarlatamab|Tarlatamab 10 mg every 2 weeks
215127759|NCT06938958|OTHER|Video and Motion Analysis|"1. Measurements of joint angle, body segment position, static and dynamic postures and posture duration.~2. Video of Surgeon and Procedure."
215127760|NCT06937450|DEVICE|CLR Irrigator|All enrolled patients will have their hemothorax treated with a CLR device that allows for easy suction and irrigation through indwelling catheters,
215127761|NCT06937450|PROCEDURE|Serial Lavage and Drainage|The current protocol is to do a singular lavage and drainage, this study will investigate the benefits of daily lavage.
215127762|NCT06937450|DEVICE|28 Fr Open Chest Tube|Patients will have a standard 28 Fr open chest tube or a percutaneous 14Fr chest tube placed.
215127763|NCT06937450|DEVICE|Percutaneous 14Fr Chest Tube|Patients will have a standard 28 Fr open chest tube, or a percutaneous 14Fr chest tube placed.
215127764|NCT06938126|DIETARY_SUPPLEMENT|L-Arginine and Citrulline-Malate Supplementation|L-Arginine and Citrulline Malate supplementation was consumed as a liquid one single time to examine the acute effects on sport performance
215127765|NCT06938126|DIETARY_SUPPLEMENT|Placebo consumption|Consumption of placebo as a liquid
215127766|NCT06937684|BEHAVIORAL|Early Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 1 hour after anesthesia.
215127767|NCT06937684|BEHAVIORAL|Traditional Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 2 hours after anesthesia.
215127768|NCT06939270|BIOLOGICAL|CD73/AXL.HypoSti.CAR-T cells|Dose escalation: Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg); Dose expansion: RP2D.
215127769|NCT06939270|DRUG|Albumin-Bound Paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5 .
215127770|NCT06939270|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2 .
215127771|NCT06939270|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2.
215127772|NCT06937554|OTHER|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters
215127773|NCT06938490|PROCEDURE|Anterior rectal resection with D3-lymphatic dissection|"This study aims to determine the incidence of anastomosis failure in the group with first SA and LCA preservation in order to identify the feasibility of manipulation.~The study is unique in that there is only one study in the world that evaluates the incidence of anastomosis failure with preservation of the first sigmoid and there is no study comparing the groups described in this study."
215127774|NCT06937411|DRUG|LY4100511|Administered orally
214447596|NCT06836804|OTHER|Short Form Health Survey|SF-36 is a self-assessment scale and can be completed in five minutes. SF-36 can evaluate both the negative and positive aspects of health. The scale consists of 36 items which are used to assess different health dimensions in 8 subscales: Physical functioning (10 items), social functioning (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items).
214447597|NCT06836804|OTHER|Hospital Anxiety and Depression Scale|The HADS was designed in 1983 to identify anxiety and depression in individuals with physical illnesses. The HADS is a self-reported scale consisting of seven items each for the anxiety and depression subscales. Each item is scored from 0 to 3, and the total score for the anxiety and depression subscales is 21 points. The overall HADS score is obtained by summing the points from both subscales. A total subscale score between 0-7 indicates a normal test result, 8-10 indicates mild anxiety or depression, 11-15 indicates moderate anxiety or depression, and 16-21 indicates severe anxiety or depression. Higher scores represent higher levels of anxiety or depression, and the total HADS score reflects an overall measure of psychological distress. The survey can be completed in 2-5 minutes.
214447598|NCT06836804|OTHER|Illness Intrusiveness Ratings Scale|The IIRS is an easy-to-administer scale designed to predict the psychosocial impact of chronic illness and to document and compare the effectiveness of therapeutic interventions. It consists of 13 questions which are completed by the patient. The scale measures how the limitations imposed by chronic and life-threatening diseases hinder participation in regular activities across 13 important aspects of life: Health, diet, work, active recreation (sports), passive recreation (reading, listening to music), finances, relationships with partners, sexual life, family relationships, other social relationships, self-expression/development, religious expression, and community and civic participation.
214524197|NCT01323335|DRUG|IV Uric Acid|
214524198|NCT01323335|DRUG|IV Rasburicase|
214524199|NCT03104309|DEVICE|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
215127775|NCT06938256|OTHER|Suboccipital Muscle Inhibition|With the patient in the supine position and the eyes closed, the therapist sits behind the subject's head and place the palms of his/her hands beneath it, resting the pads of his/her fingers on the projection of the posterior arch of the atlas. Pressure is exerted upward and toward the therapist. The pressure is maintained for 2 minutes until tissue relaxation had been achieved. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
215127776|NCT06938256|OTHER|Rocabado 6x6 Exercises|"Rocabado created 6X6 program for the management of CGH which includes 6 fundamental components, one session under supervision and remaining five sessions by the subject at home.~These components are:~* Rest position of the tongue~* Control of TMJ rotation~* Rhythmic stabilization technique~* Stabilized head flexion~* Axial extension of the neck~* Shoulder posture"
215127777|NCT03842670|BEHAVIORAL|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
215127778|NCT03842670|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
215127779|NCT01800591|BEHAVIORAL|Financial incentive|
215127780|NCT05692544|PROCEDURE|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
215127781|NCT01332383|DRUG|Naratriptan|
215127782|NCT01456065|BIOLOGICAL|Procure|The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
215127783|NCT01456065|BIOLOGICAL|Procure|The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
215127784|NCT02843841|OTHER|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
215127785|NCT02459444|DEVICE|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
214447599|NCT06836804|OTHER|Cardiac Depression Scale|CDS was designed to identify depression in individuals with CVDs. It consists of 26 items across 7 subscales. The subscales address issues such as sleep, uncertainty, mood, hopelessness, immobility, anhedonia, and cognition. The CDS is rated on a 7-point Likert scale, with seven items being reverse-coded. Based on patient feedback and clinical experience, two short forms were developed, each consisting of five questions. Both short forms showed good consistency with the original CDS. The first short form includes questions from the original CDS numbered 12, 24, 21, 10, and 9. The second short form includes questions from the original CDS numbered 12, 4, 25, 21, and 7.
214447600|NCT06500104|DIETARY_SUPPLEMENT|Kefir peptide|Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
214447601|NCT06500104|DIETARY_SUPPLEMENT|Placebo|Glucose powder
214447602|NCT03413592|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
214447603|NCT03413592|OTHER|Car-following test|Driving with simulator program for DCV measurement
214447604|NCT03413592|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
214447605|NCT06836024|DIETARY_SUPPLEMENT|Actazin chewable tablet|Actazin tablets are tableted non-GMO, freeze-dried, green kiwifruit powder from 100% New Zealand-grown green kiwifruit. Currently, kiwifruit extracts (such as Actazin), are marketed in Canada as a natural supplement. It is safe, bioavailable, and has been previously shown to be well tolerated at doses up to 2400 mg.
214447606|NCT06836024|DRUG|PEG 3350|a commonly used over the counter laxative in north America. A stool softener.
214447607|NCT06836024|OTHER|Chewable Tablet|Sorbitol-based placebo chewable tablets made by Pharma NZ. Those tablets will have a similar appearance to active Actazin but will not taste the same. This is because the taste of Actazin is a non-altered natural kiwi taste. They will be administered in the same dose and manner as the active Actazin oral chewable tablets.
214447608|NCT06836024|OTHER|Maltodextrin (Placebo)|Maltodextrin powder, administered in the same doses and manner as active PEG 3350 group.
214447609|NCT04850807|BEHAVIORAL|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
214447610|NCT05505513|DEVICE|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
214447611|NCT06836518|DIAGNOSTIC_TEST|serum sialic acid|measurement of serum sialic acid to evaluate its efficacy in the diagnosis of hepatocellular carcinoma
214524200|NCT03807271|DEVICE|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
215127786|NCT02459444|OTHER|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
215127787|NCT04561440|DIAGNOSTIC_TEST|molecular karyotyping|performed by NGS or CMA chip
215127788|NCT01928927|DRUG|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
215127789|NCT06284083|DIAGNOSTIC_TEST|taking a blood sample|Blood samples collected from patienst, only 7 mL
214447612|NCT06835413|PROCEDURE|1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice 2-Strength and Balance Exercises A- Sit-to-stand B- Heel r|"1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice A- Standing with a decreased base B- Graded reaching in standing~* Feet together and level.~* Semi-tandem stance.~* Tandem stance.~* Stand on one leg.~* Maintain position for longer~* Close eyes.~* Stand on different surfaces e.g. foam rubber mat.~* Minimize hand support \& Aim to increase time without hand support. • Feet placement- narrower, step standing~* Reaching further.~* Reaching in different directions.~* Reaching down to a stool or the floor.~* Reaching for heavier objects.~* Reaching for a full cup of water.~* Standing on a softer surface eg foam rubber mat.~* Stepping while reaching. C- Stepping in different directions D- Walking Practice~* Narrow foot position.~* Longer steps.~* Faster steps.~* Step over objects.~* Choice component e.g. step forward with left foot.~* Incorporate pivoting on the non-stepping foot.~* Use different color"
215127790|NCT03369977|DEVICE|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
215127791|NCT03369977|OTHER|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
215127792|NCT02171442|DRUG|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
215127793|NCT02171442|DRUG|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
215127794|NCT01756196|DRUG|Spinal Steroid Injection|Steroid Injection
215127795|NCT02557737|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
215127796|NCT03043885|DEVICE|FDBA|Graft material used to graft extraction socket
215127797|NCT03043885|DEVICE|PRF|Autologous blood product used to graft extraction socket
215127798|NCT03043885|PROCEDURE|Blood Clot|Surgical treatment of extraction socket without addition of graft material
215127799|NCT01063647|DRUG|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
215127800|NCT01063647|DRUG|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
215127801|NCT01063647|DRUG|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
215127802|NCT00284700|DRUG|Iron|
214447613|NCT06793969|PROCEDURE|Swartz sheath with Angioplasty Guidewire-Assisted Technique for PFO tunnel passage|"The angioplasty guidewire is advanced into the left atrium and left superior pulmonary vein (LSPV). The Swartz sheath is then delivered to the left atrium along the 0.014 guidewire through the PFO. Next, the Runthrough guidewire is changed to a 0.035 J-tipped guidewire, which is advanced into the LSPV. Finally, the delivery sheath for the PFO closure device is introduced to the left atrium along the guidewire, and all other toolkits are withdrawn."
214447614|NCT06793969|PROCEDURE|Conventional technique to pass the PFO tunnel|In the conventional group, the PFO closure procedure is performed with a multi-functional catheter and guided by intraprocedural fluoroscopy and ICE
214447615|NCT06795867|BEHAVIORAL|acceptance and commitment therapy|a 'third wave behavioral management
215127803|NCT05914090|PROCEDURE|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
215127804|NCT02707627|DEVICE|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
215127805|NCT03439280|DRUG|Mezagitamab|Mezagitamab subcutaneously.
215127806|NCT03439280|DRUG|Pomalidomide|Pomalidomide orally.
215127807|NCT03439280|DRUG|Dexamethasone|Dexamethasone orally.
215127808|NCT01147042|DRUG|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
215127809|NCT05821985|PROCEDURE|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
215127810|NCT05821985|PROCEDURE|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
215127811|NCT06409806|OTHER|ECOG Array|"The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment.~Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference.~Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain."
215127812|NCT06343831|PROCEDURE|2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)|The study participant will be requested to stand upright with hands comfortably behind their back and turn 45 degrees and 90 degrees in either direction for standard anteroposterior (AP), oblique and lateral photos. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers. The photographs will be acquired using a commercially available camera or study iPad device.
215127813|NCT06343831|PROCEDURE|3-Dimensional (3-D) Photographs (Visit 1- 6)|3-Dimensional surface scans of the participant's torso will be acquired using a commercially available handheld camera scanning device that offers texture, geometry, and color acquisition from any complex surface using white light technology, which is safe for exposure to skin and eyes. Prior to imaging, a pattern of lines and dots will be marked on the patient's breasts using a washable marker. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member moves around their torso with the handheld scanner. The exam room table will then be reclined to a lay-flat position such that the patient is laying supine, and breast imaging will be repeated. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers.
215127814|NCT06343831|PROCEDURE|Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)|The images will be acquired using a commercially available handheld ultrasound scanning device. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member obtains images of the specific area of the breast of chest wall to be grafted (V1) and that which was grafted (V4-6). Images usually take 5-10 minutes to acquire depending on the number of areas grafted.
214447616|NCT06795269|DEVICE|Cryotherapy Compression Machine|The Cryo Pro is a simple to use cold compression therapy product that requires only ice, water and power. It's unique design is convenient to use, provides pain relief and reduces swelling and inflammation, making recovery faster.
214524201|NCT00553800|DRUG|bevacizumab|
215127815|NCT06343831|PROCEDURE|Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)|An MRI of the breast will be obtained around visit 1 and visits 4-6 timepoints. The images will be acquired in collaboration with the Breast Imaging Core and the Magnetic Resonance Research Imaging Center. Dr. Abe (co-investigator, radiology) will review the images to assess volume of the overall breast, the specific areas of the breasts that were grafted.
214447617|NCT06795269|OTHER|Conservative treatment|Strength and stretch exercises for hip and knee large groups of muscles.
215127816|NCT06343831|PROCEDURE|BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)|"The BREAST-QTM measures three satisfaction domains and three quality of life (QoL) domains.6 For BREAST-QTM, each domain has a score range from 0 - 100. A difference in score, either positive or negative, of 10 points is considered clinically important; a difference of 20 points is considered clinically very important. This survey will be administered to participants via iPad during visit 1 and visits 4-6 and takes approximately 10-20 minutes to complete."
215127817|NCT05607810|GENETIC|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
215127818|NCT04772872|OTHER|Assessment by Brazelton neonatal behavior for group A,Band C|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
215127819|NCT01419795|DRUG|lenalidomide|Given PO
214447618|NCT06740656|OTHER|No Interventions|no intervention
214447619|NCT06831799|OTHER|Non applicable, is a patient registry|Non applicable, is a patient registry
214447620|NCT06835153|OTHER|Monthly Performance Feedback with Dashboards (Automated Audit and Feedback)|"Hospital services in the intervention group will receive monthly automated dashboards that provide detailed performance metrics. These include:~The proportion of patients with a discharge letter generated on the day of discharge, The proportion of discharge letters validated on the day of discharge, Median delays for generating discharge letters, Median delays for validating discharge letters. The dashboards are shared with all physicians, nurse managers, and secretarial staff in each service. A designated quality improvement officer is available to assist teams in interpreting the data and implementing organizational changes based on the feedback. The intervention uses real-time data extraction from the hospital's electronic health record system to generate these insights."
214447621|NCT06793319|OTHER|educational app|State Anxiety Inventory was filled out before the training. Atrial Fibrillation training was provided. After the training, the Situationality Anxiety Inventory was filled out again. It was aimed to evaluate the effect of education on anxiety.
214447622|NCT01868269|DRUG|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
214447623|NCT01868269|DRUG|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
214447624|NCT01868269|DRUG|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
214447625|NCT06643832|OTHER|Rubbing Distraction|gently touching on proximal part of the IV injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.
214447626|NCT06643832|DRUG|Lidocaine (drug)|lidocaine will be used by mixing it with the propofol before intravenous injection
214447627|NCT06643832|OTHER|Saline|intravenous propofol will be given without mixing with any drug (except for 2 ml saline to ensure blindness of the outcome assessor).
214524202|NCT00553800|DRUG|Erlotinib|
215127820|NCT01419795|BIOLOGICAL|rituximab|Given IV
215127821|NCT01419795|OTHER|pharmacological study|Correlative studies
215127822|NCT01419795|OTHER|laboratory biomarker analysis|Correlative studies
214447628|NCT06796803|DRUG|camrelizumab combined with rivoceranib and HAIC|systemic therapy combined with locoregional theraphy as conversion therapy
214447629|NCT06796803|DRUG|camerlizumab + rivoceranib|systemic therapy
214447630|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
214447631|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
214447632|NCT06191991|DRUG|Atorvastatin|40 mg
214447633|NCT06191991|DRUG|ALG-055009|0.9 mg
214447634|NCT06191991|DRUG|Rosuvastatin|10 mg
214524203|NCT00907699|GENETIC|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
214524204|NCT00907699|GENETIC|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
215127823|NCT04355754|DEVICE|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
215127824|NCT00367250|DRUG|Cetuximab|weekly i.v.
215127825|NCT00367250|DRUG|Trastuzumab|weekly i.v.
215127826|NCT01391364|DEVICE|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
215127827|NCT01391364|DEVICE|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
215127828|NCT02490436|DRUG|Cetuximab|Randomized cross-over between cetuximab and placebo
215127829|NCT02490436|DRUG|Placebo|Randomized cross-over between cetuximab and placebo
215127830|NCT03118414|OTHER|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
214447635|NCT06795347|BEHAVIORAL|Online VIPP-SD|The Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is delivered online in this study. VIPP-SD is a manualized parenting intervention. The online version consists of 12 individual sessions, where the first and hereafter every second session consists of video recordings of mother and child in pre-defined everyday situations. The recordings are reviewed and discussed with the mother/parents during subsequent video-feedback sessions, where positive sequences in the interaction are pointed out by the intervener and form the basis of a discussion of pre-defined themes regarding child signals, attachment, child development, limit setting and sensitive parenting. The 12 sessions are conducted within five months from randomization with weekly or bi-weekly intervals.
214447636|NCT06795347|BEHAVIORAL|Care As Usual|Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.
214447637|NCT06023134|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
215127831|NCT03118414|OTHER|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
215127832|NCT03118414|OTHER|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
215127833|NCT02421172|BIOLOGICAL|CJM112|CJM112 Fully human IgG1 monoclonal antibody
215127834|NCT02421172|DRUG|Placebo|
215127835|NCT05959044|DRUG|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
215127836|NCT05959044|OTHER|Placebo|orally 5mg two times daily for 8weeks
215127837|NCT03534609|DEVICE|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
214447638|NCT06023134|DIAGNOSTIC_TEST|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
214447639|NCT01653535|BEHAVIORAL|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
214447640|NCT06796244|OTHER|Croq'Santé nutrition education program|The Croq'Santé program aims to develop food literacy in children aged 8 to 11 years. It is based on the creation or adaptation of a recipe chosen by the children. The program is designed to run over the course of one school year, with approximately ten sessions. These sessions are delivered in schools by teachers, following a 3-hour training course. Teachers receive an intervention kit that includes a guide for conducting the different sessions, food images, and a mascot, which children can accessorize as they complete sessions and challenges. The sessions are organized around four stages: discover, invent, cook, and taste. Challenges are to be completed at the end of each stage with the child's family. At the end of the program, children are invited to cook and taste their recipe in a dedicated environment.
215127838|NCT02832544|DRUG|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
215127839|NCT02832544|DRUG|Vitamin K antagonists (VKA)|
215127840|NCT06196385|DEVICE|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
215127841|NCT04128137|DRUG|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
215127842|NCT04128137|OTHER|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
215127843|NCT02660177|DRUG|Metamizole|metamizole IV administration
215127844|NCT04715620|DRUG|Niraparib|Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
215127845|NCT00132574|BEHAVIORAL|Minimization of milk and dairy products in the diet|
215127846|NCT03478540|DRUG|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
215127847|NCT02426333|OTHER|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
215127848|NCT00915954|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
215127849|NCT00915954|DIAGNOSTIC_TEST|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
214694374|NCT03617133|RADIATION|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
214694375|NCT03617133|RADIATION|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
214694376|NCT03617133|RADIATION|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
214694377|NCT03617133|RADIATION|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
215127850|NCT00915954|DIAGNOSTIC_TEST|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
214447641|NCT06472453|DEVICE|Allograft/Xenograft|"Alveolar ridge preservation of a single extraction socket site with a mixture of demineralized cortical bone substitute vallos® and xenograft Bio-Oss®."
214447642|NCT06472453|DEVICE|Allograft|Alveolar ridge preservation of a single extraction socket site with vallos® (mineralized cortico-cancellous bone substitute)
215127851|NCT05723224|PROCEDURE|elective endoscopic gallbladder treatment|Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
215127852|NCT03872375|DIETARY_SUPPLEMENT|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
214447643|NCT04634643|OTHER|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
214447644|NCT05457699|RADIATION|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
214447645|NCT05457699|OTHER|no RT|no SABR, continued systemic therapy per SOC
214447646|NCT03667404|DIETARY_SUPPLEMENT|Resistant maltodextrin|Resistant maltodextrin powder
214447647|NCT03667404|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin powder
214447648|NCT06466122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214447649|NCT06466122|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214447650|NCT06466122|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214447651|NCT06466122|PROCEDURE|Computed Tomography|Undergo CT
214447652|NCT06466122|DRUG|Pirtobrutinib|Given PO
214447653|NCT06466122|DRUG|Venetoclax|Given PO
214447654|NCT04814420|DEVICE|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
214447655|NCT06363994|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
214447656|NCT06363994|DRUG|Bendamustine Injection|Eligible patients will receive Bendamustine by injection as per the protocol
214447657|NCT06363994|DRUG|Rituximab|Eligible patients will receive Rituximab by injection as per the protocol
214447658|NCT06363994|DRUG|Orelabrutinib Placebo|Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
214447659|NCT04862975|DRUG|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
214447660|NCT04862975|DRUG|Lamivudine|Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
214447661|NCT04862975|DRUG|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
214447662|NCT04862975|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
214447663|NCT06352866|DRUG|Siltuximab|Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system
214447664|NCT06352866|DRUG|Teclistamab(FDA-approved)|Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
214447665|NCT04223570|DEVICE|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
214447666|NCT04580225|PROCEDURE|Four-Corner Arthrodesis|Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.
214447667|NCT04580225|PROCEDURE|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision|Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
214447668|NCT02278562|DRUG|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
214447669|NCT02278562|DRUG|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
214447670|NCT02278562|OTHER|placebo|placebo capsules and injection
214447671|NCT02187003|DRUG|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
214447672|NCT02187003|OTHER|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
214447673|NCT06028529|DEVICE|Exoskeleton|lightweight ground exoskeleton
214447674|NCT05360264|DRUG|Decitabine 50 MG [Dacogen]|DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.
214447675|NCT05816551|OTHER|Hyperthermia Trial|"Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol."
214447676|NCT05816551|OTHER|Control Trial|"Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol."
214447677|NCT04020276|RADIATION|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
214447678|NCT02475148|DRUG|JNJ 54175446|
214447679|NCT02475148|DRUG|Placebo|
214447680|NCT02475148|OTHER|High fat/high Calorie Breakfast|
214447681|NCT04825275|DRUG|Posaconazole Pill|300 mg (three 100 mg tablets) orally
214447682|NCT06128681|PROCEDURE|Intraairway ultrasound-guided mediastinal opening technique|Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses
214447683|NCT05361993|DRUG|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
214447684|NCT05361993|DEVICE|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
214447685|NCT04311996|OTHER|Friend and target|random assignment to Friend and Target Both condition
214447686|NCT04311996|OTHER|Friend support|random assignment to Friend Provides Support condition
214447687|NCT04311996|OTHER|unfamiliar peer and target|random assignment to Unfamiliar Peer and Target condition
214447688|NCT04311996|OTHER|alone|random assignment to Alone condition
214447689|NCT05481515|DEVICE|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
214447690|NCT05481515|DEVICE|Spectrophotometry|Spectrophotometry will be used to measure skin tone
214447691|NCT05139420|OTHER|lifestyle intervention with meal replacement program|participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
214447692|NCT02379156|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
214447693|NCT02379156|OTHER|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
214447694|NCT02630823|DRUG|MK-3475|
214447695|NCT02630823|PROCEDURE|Surgical resection (standard of care)|
214447696|NCT02630823|DRUG|Paclitaxel (standard of care)|
214524205|NCT00907699|GENETIC|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214524206|NCT00907699|GENETIC|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214524207|NCT00907699|GENETIC|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214524208|NCT00907699|GENETIC|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214447697|NCT02630823|DRUG|Carboplatin (standard of care)|
214447698|NCT02630823|RADIATION|Radiation (standard of care)|
214447699|NCT02630823|PROCEDURE|Endometrial biopsy|
214694378|NCT03617133|RADIATION|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
214694379|NCT03617133|RADIATION|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
215127853|NCT03872375|BEHAVIORAL|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
215127854|NCT02122835|BEHAVIORAL|aerobic exercise training|12 weeks of supervised aerobic exercise training
215127855|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
215127856|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
214447700|NCT02630823|PROCEDURE|Peripheral blood draw|
215127857|NCT00683878|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
215127858|NCT00683878|DRUG|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
215127859|NCT06445543|BEHAVIORAL|MFeast ENHANCED|The intervention group will initially receive 10 weekly prepared heart-healthy meals from MFeast; Lactation nutritional snack bundles to boost milk supply + structural support for breastfeeding/ pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (medically tailored via study team-crafted virtual grocery store) for 16 more weeks.
215127860|NCT06445543|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive 10 weekly prepared heart-healthy meals from MFeast."
214447701|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
214447702|NCT05713994|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
214447703|NCT05713994|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
214447704|NCT05713994|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
214447705|NCT05713994|DRUG|Lenvatinib|8mg; p.o.; q.d.
214447706|NCT05713994|DRUG|Sorafenib|400mg; p.o. bid
214447707|NCT05713994|DRUG|Donafenib|200mg; p.o. bid
214447708|NCT05713994|DRUG|Regorafenib|160 mg; p.o.; q.d.
214447709|NCT05713994|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
215127861|NCT02474797|DEVICE|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7)."
214447710|NCT05713994|DRUG|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
214524209|NCT00907699|GENETIC|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214524210|NCT00907699|OTHER|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
214524211|NCT03388021|PROCEDURE|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
214524212|NCT05576727|OTHER|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
214524213|NCT00501111|DRUG|AZD3480|3 oral doses
214524214|NCT00501111|DRUG|Donepezil|
214524215|NCT00721019|OTHER|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
214524216|NCT00721019|OTHER|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
214524217|NCT04096261|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
215127862|NCT03112681|DRUG|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
215127863|NCT03112681|DRUG|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
215127864|NCT03112681|DRUG|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
215127865|NCT06048302|DRUG|Obicetrapib|1 single dose of obicetrapib
215127866|NCT02869633|DRUG|Ibrutinib|Given by mouth
214447711|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
214447712|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
214447713|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
214447714|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
214447715|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
214447716|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
214447717|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
214447718|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
214447719|NCT05994742|DRUG|Rifampicin|Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
214447720|NCT05994742|DRUG|Azithromycin|Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
214447721|NCT05994742|DRUG|Isoniazid|Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
214447722|NCT05994742|DRUG|Pyridoxine Hydrochloride|Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
214524218|NCT01317771|PROCEDURE|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
214524219|NCT00319670|DRUG|MiraLax|
214524220|NCT00158236|DRUG|Buprenorphine|
214524221|NCT00158236|DRUG|Buprenorphine and Naloxone|
214524222|NCT00158236|DRUG|Hydromorphone|
215127867|NCT02869633|OTHER|Laboratory Biomarker Analysis|Correlative studies
215127868|NCT04024891|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
215127869|NCT04024891|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
215127870|NCT03832348|DEVICE|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
215127871|NCT02773186|OTHER|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
215127872|NCT03959163|DIAGNOSTIC_TEST|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
215127873|NCT02372578|DRUG|ASP3662|oral
215127874|NCT02372578|DRUG|pregabalin|oral
215127875|NCT02372578|DRUG|ASP3662 placebo|oral
215127876|NCT02372578|DRUG|pregabalin placebo|oral
215127877|NCT05655663|OTHER|Vascular investigation|Measure of of carotid stiffness
215127878|NCT05626166|DRUG|Placebo|placebo tablets twice daily
215127879|NCT05626166|DRUG|Diosmin|diosmin 600 mg twice daily
215127880|NCT05412147|DIETARY_SUPPLEMENT|RECO-18|4 pills daily, oral
215127881|NCT05412147|DIETARY_SUPPLEMENT|Multi-vitamins|one tablet daily, oral
214447723|NCT05994742|BEHAVIORAL|The Friendship Bench|The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
214447724|NCT05994742|BEHAVIORAL|Care for Child Development|Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
214447725|NCT05994742|BEHAVIORAL|Educational and behaviour-change modules|Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
214447726|NCT05994742|DIETARY_SUPPLEMENT|Reformulated Ready to Use Therapeutic Food|A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
214447727|NCT05994742|OTHER|Standard Care|All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
214447728|NCT05130450|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214447729|NCT05013645|OTHER|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
214447730|NCT05013645|OTHER|Placebo|Gel control product
214447731|NCT05897021|BEHAVIORAL|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
215127882|NCT05439044|OTHER|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
215127883|NCT01421017|RADIATION|Radiation|
215127884|NCT01421017|DRUG|Imiquimod|
215127885|NCT01421017|DRUG|Cyclophosphamide|
215127886|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
215127887|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
215127888|NCT04189367|DRUG|Traditional Chinese Medicine|"One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks."
215127889|NCT04189367|DRUG|Western medicine|"Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks"
215127890|NCT06079788|DRUG|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion."
215127891|NCT06079788|DRUG|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
215127892|NCT02849379|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
215127893|NCT02849379|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
215127894|NCT05572008|BEHAVIORAL|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
215127895|NCT01972581|OTHER|Reaction Time Training|
215127896|NCT05917912|DRUG|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
215127897|NCT05917912|DRUG|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
215127898|NCT03422029|DRUG|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
215127899|NCT03489863|DRUG|Prasugrel|Maintenance dose will be maintained for 10±3 days.
215127900|NCT03489863|DRUG|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
215127901|NCT02984488|PROCEDURE|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
215127902|NCT02984488|PROCEDURE|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
214447732|NCT05897021|BEHAVIORAL|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
214447733|NCT05416515|DRUG|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
214447734|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
214447735|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
214447736|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
214447737|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
214447738|NCT06755489|OTHER|Placebo|530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day
214447739|NCT06755489|OTHER|GABA|530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day
214447740|NCT04975516|DRUG|Chemotherapy|Given chemotherapy
214447741|NCT04975516|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214447742|NCT04975516|PROCEDURE|Computed Tomography|Undergo CT
214447743|NCT04975516|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214447744|NCT04975516|PROCEDURE|Biospecimen Collection|Undergo blood collection
214447745|NCT04975516|OTHER|Questionnaire Administration|Ancillary studies
214524223|NCT02332122|PROCEDURE|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
215127903|NCT04636281|OTHER|Active and passive static stretching exercises|Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
215127904|NCT03598179|BIOLOGICAL|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10\^6 Acute lymphocytic leukemia 2×10\^6 Chronic lymphocytic leukemia 10×10\^6
214447746|NCT04178733|DRUG|LY3493269 - SC|Administered SC
214447747|NCT04178733|DRUG|Placebo - SC|Administered SC
214447748|NCT04178733|DRUG|LY3493269 - IV|Administered IV
214447749|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
214447750|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
215127905|NCT02754570|DRUG|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
215127906|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
215127907|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
215127908|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
215127909|NCT00530413|DRUG|Phenobarbital|Phenobarbital will be given based on weight range
215127910|NCT00530413|OTHER|Placebo|Placebo group
214447751|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
214447752|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
214447753|NCT02730039|BEHAVIORAL|workshop|
214447754|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
214447755|NCT02730039|BEHAVIORAL|assessments|
214447756|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
214447757|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
214447758|NCT05159583|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
214447759|NCT05159583|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
214447760|NCT05037266|BIOLOGICAL|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
214447761|NCT03708224|BIOLOGICAL|Atezolizumab|Given intravenously (IV)
214447762|NCT03708224|BIOLOGICAL|Tocilizumab|Given IV
214447763|NCT03708224|BIOLOGICAL|Tiragolumab|Given IV
214447764|NCT03169764|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214447765|NCT03169764|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
214447766|NCT03169764|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214447767|NCT03169764|BIOLOGICAL|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
214447768|NCT03169764|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214447769|NCT03169764|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214447770|NCT03169764|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214447771|NCT03169764|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
214447772|NCT03169764|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214447773|NCT03169764|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214447774|NCT03169764|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
214447775|NCT03169764|DRUG|Lovaza|Omega-3-acid ethyl esters
214447776|NCT03169764|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
214447777|NCT03169764|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\]
214447778|NCT03169764|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen (CEA) vaccine
214447779|NCT03169764|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 (HER2) vaccine
214447780|NCT03169764|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214447781|NCT03169764|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1) vaccine
215127911|NCT00182130|PROCEDURE|Quality Initiative in Rectal Cancer (QIRC) strategy|
214447782|NCT03169764|BIOLOGICAL|GI-4000|Ras yeast vaccine
214447783|NCT03169764|BIOLOGICAL|GI-6207|CEA yeast vaccine
214447784|NCT03169764|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214447785|NCT03169764|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
214447786|NCT06147830|OTHER|None (Observational study)|Not Applicable since Observational Study
214447787|NCT06494683|DRUG|Pueraria lobata radix|The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
214447788|NCT03512314|DRUG|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
214447789|NCT05126862|BEHAVIORAL|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
215127912|NCT03467321|OTHER|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
215127913|NCT03447002|DIAGNOSTIC_TEST|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
215127914|NCT00629226|BIOLOGICAL|cetuximab|Given IV
215127915|NCT00629226|DRUG|bortezomib|Given IV
215127916|NCT00629226|DRUG|cisplatin|Given IV
215127917|NCT00629226|RADIATION|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
215127918|NCT00737113|DRUG|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
215127919|NCT00454714|DRUG|single dose Sildenafil|Application of a single dose Sildenafil
215127920|NCT00454714|DRUG|Single dose placebo|Application of a single dose placebo
215127921|NCT03936114|BEHAVIORAL|SMART|SMART program mindfulness training program
214447790|NCT06443320|OTHER|patient included in experimental groupe will view the video excerpt, a playtime, a drawing activities|Patients included in the videodrama arm will participate in a total of 18 videodrama sessions, with one session per week. Each session will include a patient welcome period, the viewing of a video excerpt (in slow motion or not), a playtime, a drawing period, and a group closing session. For the play and drawing activities, the same materials will be provided in each department and for each group, including small figurines, animals, shapes (such as cubes, triangles, circles), small plush toys, markers, colored pencils, and A4 white sheets of paper.
214447791|NCT06333340|DRUG|Oxytocin|Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
214447792|NCT06333340|DRUG|Carbetocin|Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
214447793|NCT05956145|DRUG|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
214447794|NCT05956145|OTHER|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
214447795|NCT06392997|DIAGNOSTIC_TEST|Saliva sample|Saliva sample
214447796|NCT03454750|DRUG|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
214447797|NCT04119284|DEVICE|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
214447798|NCT04995068|RADIATION|Head CT to determine presence of traumatic intracranial lesion|Head CT to determine presence of traumatic intracranial lesion
214447799|NCT04782544|OTHER|Buttermilk Powder|Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
214447800|NCT04782544|OTHER|Anhydrous Milk Fat|Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
214447801|NCT06348849|DEVICE|Low-level laser therapy|Wavelength 980nm (SmartM, Lasotronix, Poland)
214447802|NCT06348849|DRUG|Nanosilver fluoride|Optimized synthesis of Nanosilver Fluoride
214447803|NCT06334952|DEVICE|transcranial direct current stimulation|Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
214447804|NCT05531643|DEVICE|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
214447805|NCT05531643|DEVICE|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
214447806|NCT05313334|BEHAVIORAL|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
214447807|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
214447808|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
214447809|NCT05175547|DRUG|Clevidipine|Blood pressure management with Clevidipine
214447810|NCT06115161|DEVICE|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
214447811|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
214447812|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
214447813|NCT04847648|PROCEDURE|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
214447814|NCT04847648|PROCEDURE|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
214447815|NCT04286607|DRUG|Topical roflumilast|Active treatment
215127922|NCT00962208|DEVICE|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
215127923|NCT00962208|DEVICE|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
215127924|NCT03729648|BEHAVIORAL|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
215127925|NCT02867267|DRUG|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
215127926|NCT02867267|OTHER|Placebo|Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
215127927|NCT00285896|DRUG|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
215127928|NCT00285896|DRUG|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
215127929|NCT00888693|DRUG|ABT-288|See Arm Description for details.
215127930|NCT00888693|DRUG|Placebo|See Arm Description for details.
215127931|NCT00935181|BEHAVIORAL|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
215127932|NCT06733467|OTHER|Stimulus properties: remembered feature|The feature used to determine which stimulus feature to remember to will be varied across trials using a letter cue (M = remember-motion; C = remember-color; 0 = remember nothing)
214447816|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
215127933|NCT02904798|DRUG|Polypodium Leucotomos|\- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
214447817|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
215127934|NCT00791388|DRUG|Placebo|oral capsule, 2x/day for 14 days
215127935|NCT00791388|DRUG|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
215127936|NCT00791388|DRUG|PG-760564|oral capsule, 100mg, 2x/day for 14 days
215127937|NCT00791388|DRUG|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
215127938|NCT00791388|DRUG|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
215127939|NCT05084040|OTHER|90 days interval between catheter maintenance|Length of time between catheter maintenances extended from 60 days to 90 days
215127940|NCT03930836|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
215127941|NCT03930836|BEHAVIORAL|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
215127942|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
214447818|NCT06340347|DRUG|Osivelotor|"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"
214447819|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
215127943|NCT00498914|DRUG|YM155|Continuous IV infusion
215127944|NCT03090308|OTHER|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for \> 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
215127945|NCT04375917|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
214447820|NCT05380583|BEHAVIORAL|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
215127946|NCT04133558|OTHER|tracheal aspirate during routine care|tracheal aspirate during routine care
215127947|NCT03416855|DRUG|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
215127948|NCT02995980|DEVICE|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
215127949|NCT02995980|DEVICE|digital mammography|routine digital mammography
215127950|NCT05718973|OTHER|short, animated storytelling video (intervention video)|Participants in the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital.
215127951|NCT05718973|OTHER|short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
215127952|NCT01173016|DRUG|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
215127953|NCT02291146|BEHAVIORAL|LA Sprouts intervention|see arm 1 description
215127954|NCT03274323|DEVICE|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
215127955|NCT03274323|PROCEDURE|Trabeculectomy|Standard trabeculectomy
215127956|NCT02719548|DEVICE|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield"
215127957|NCT02719548|DEVICE|Modified PF breast shield - Soft edge oval - Hard oval|"1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield"
215127958|NCT02719548|DEVICE|Hard oval - Soft edge oval - Modified PF breast shield|"1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield"
215127959|NCT04277728|DIAGNOSTIC_TEST|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
215127960|NCT04441359|OTHER|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
215127961|NCT04441359|OTHER|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
215127962|NCT00657540|DRUG|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
215127963|NCT00657540|DRUG|Saline|50 mL of saline infused over 10 minutes
215127964|NCT03714178|DEVICE|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
215127965|NCT03296917|DRUG|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
215127966|NCT03296917|DRUG|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
214447821|NCT05380583|BEHAVIORAL|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
214447822|NCT04637763|GENETIC|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
214447823|NCT04637763|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214447824|NCT04637763|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214447825|NCT05471479|DRUG|Activated Charcoal|Activated charcoal
214447826|NCT05471479|OTHER|No activated charcoal|No activated charcoal
214447827|NCT03442413|DRUG|2-[18F]-FA PET/CT|2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
214447828|NCT03442413|DRUG|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
214447829|NCT03077776|PROCEDURE|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
214447830|NCT03077776|PROCEDURE|Biopsy (optional)|\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
214447831|NCT03077776|PROCEDURE|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
214447832|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
214447833|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
214447834|NCT06781541|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
214447835|NCT06781541|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
214447836|NCT06781541|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, a total of 12 weeks. Participants used professional Bungy Pump Pole.
214447837|NCT06781541|BEHAVIORAL|Daily life|The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.
215127967|NCT00555412|DRUG|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
215127968|NCT00555412|DRUG|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
215127969|NCT00555412|DRUG|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
215127970|NCT00555412|DRUG|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
215127971|NCT05979740|DRUG|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection \[2.0 mg/kg, Q2W, iv\] and Toripalimab injection \[3mg/kg, Q2W, iv\] for 1\~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
215127972|NCT05440877|BEHAVIORAL|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
215127973|NCT05440877|BEHAVIORAL|Tutorial guide|A tutorial guide including description of the smokers' cases
215127974|NCT03852602|DRUG|Preemptive Analgesics|Analgesic application15 minutes before the treatment
215127975|NCT03852602|DRUG|Control|Analgesic application15 minutes before the end of the treatment
214524224|NCT02332122|PROCEDURE|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.
214524225|NCT02332122|OTHER|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
214524226|NCT02650388|BEHAVIORAL|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
214524227|NCT05127122|DRUG|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
214524228|NCT05127122|OTHER|Saline|Placebo Saline
214524229|NCT04905511|BIOLOGICAL|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
214524230|NCT05872984|DIAGNOSTIC_TEST|adjustment of dry weight based on absolute blood volume measurement|adjustment of dry weight based on absolute blood volume measurement
214524231|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
214524232|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
214447838|NCT06781541|BEHAVIORAL|Functional general conditioning training|Training sessions were supervised by a certified instructor. Training was carried out at home with individually adjusted resistance depending on age and health. Participants typically performed 10-13 repetitions of a given exercise. 30-second rest intervals were used between exercises. As intended, the training was comprehensive, i.e. including muscles of the arms, legs, trunk, abdomen, chest, balance and flexibility exercises. Basic training equipment was used during the training.
214447839|NCT04149288|DIETARY_SUPPLEMENT|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
214447840|NCT04149288|DIETARY_SUPPLEMENT|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
215127976|NCT03536156|OTHER|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
215127977|NCT03010527|DRUG|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
214447841|NCT05004285|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
214447842|NCT06780527|OTHER|15% Grape seed extract as dentin pretreatment|using proanthocyanidin-rich grape seed extract as a biomodifier for dentin improved the mechanical properties of dental collagen by cross-linking and dehydrating fibrils. This made the collagen substrate more suitable for hybridization. It also acted as a non-specific MMP-inhibitor, protecting exposed collagen fibrils from biodegradation from dentin proteases.
214524233|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
214524234|NCT01116440|DRUG|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
214524235|NCT01116440|DRUG|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
214447843|NCT03744936|OTHER|Feedback|Study team members will conduct interviews with subjects to gather feedback on Atrial Fibrillation experiences
214447844|NCT06419972|OTHER|multimodal physiotherapy programme|The intervention to which the climacteric women will be subjected will consist of a combined program of education and general strength and pelvic floor muscles exercises of 8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min, except for the first one, which will be 90 min.
214447845|NCT04022746|PROCEDURE|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
214447846|NCT04022746|PROCEDURE|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
214447847|NCT06521658|PROCEDURE|Timing of retroflexion|The intervention is the timing of the retroflexion/looping of the colonoscope in the rectum
214447848|NCT04214990|DRUG|Aspirin 100mg|Daily aspirin 100 mg for 5 years
214447849|NCT04214990|DRUG|Placebo oral tablet|Daily placebo for 5 years
214447850|NCT03328702|DEVICE|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
214447851|NCT05789537|DRUG|SerpinPC|Administered as SC injection.
214524236|NCT02630147|OTHER|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
214524237|NCT03591328|DIAGNOSTIC_TEST|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
214524238|NCT05279417|DRUG|ATI-450 50 mg oral tablet BID|Oral, small molecule MK2 inhibitor
215127978|NCT03010527|OTHER|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
215127979|NCT04458506|PROCEDURE|Maxillary expansion|Correction of the unilateral posterior cross bite in children
215127980|NCT03092583|OTHER|Blood sample|35 mL, 7 tubes
215127981|NCT01793428|OTHER|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
215127982|NCT06269224|OTHER|Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.|The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
215127983|NCT02656017|DRUG|Metformin|Monitoring of tolerability and symptoms.
215127984|NCT02656017|OTHER|Placebo|Monitoring of tolerability and symptoms.
215127985|NCT00823862|DRUG|SD-101|Intramuscular (IM)
215127986|NCT00823862|DRUG|ribavirin|oral, 2 times per day, for 2 months
215127987|NCT00400777|DRUG|Valsartan, hydrochlorothiazide and amlodipine|
215127988|NCT05656339|DIETARY_SUPPLEMENT|CHO+WP|Oral supplement containing carbohydrates plus whey protein
215127989|NCT05656339|DIETARY_SUPPLEMENT|CHO|Oral supplement containing carbohydrates
215127990|NCT05656339|DIETARY_SUPPLEMENT|Fast|Fast condition of 12 hours
215127991|NCT05400135|BEHAVIORAL|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
215127992|NCT04245111|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
215127993|NCT02547311|BEHAVIORAL|Team Clinic|
215127994|NCT02197312|DEVICE|NobelProcera Bridge Shaded Zirconia|
215127995|NCT05767008|OTHER|Sunscreen -R43|Long wear metal oxide particles
215127996|NCT01442246|DRUG|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
214447852|NCT06845657|OTHER|Hip Abductor Strengthening Exercises|Hip Abductor Strengthening Exercises .1.side lying leg raise 2.clam shell(Frequency: 3 sets 10 reps in session 1-5) 3.standing hip abduction.4.pelvic lift training (Frequency: 3 sets 10 reps in session 6-9) .Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions).total duration is 3 sessions per week for 3 consecutive weeks.
214447853|NCT06845657|OTHER|Conventional Treatment|Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions). Total duration is 3 sessions per week for 3 consecutive weeks
214447854|NCT06844760|DEVICE|Hyaluronic Acid (HA)|Subjects will be treated with 2cc of Perleux body at baseline. After 4 weeks, a touch-up injection will be performed to achieve optimal improvement.
214447855|NCT06846294|BEHAVIORAL|Diet|Individualised dietary intervention
214447856|NCT06846294|BEHAVIORAL|Diet and physical activity|Obesity prevention: Diet, Diet and physical activity and standard care
214447857|NCT06846229|OTHER|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of diseases. Patients in this cohort will undergo standard examinations, with clinical decisions guided by the recommendations generated by the AI system.
214524239|NCT05279417|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
214524240|NCT05279417|DRUG|Methotrexate|15 mg to 25 mg weekly
214524241|NCT05279417|DRUG|ATI-450 20 mg oral tablet BID|Oral, small molecule MK2 inhibitor
215127997|NCT05356377|DRUG|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
215127998|NCT04210648|DEVICE|Mobile app|Mobile app for self-managing emotional dysregulation
215127999|NCT06720415|DRUG|Oral methadone, immediately prior to transport|Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room
215128000|NCT06720415|DRUG|Intravenous methadone|Patients will receive 0.3mg/kg IV methadone after induction of general anesthesia
215128001|NCT03087396|DEVICE|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
215128002|NCT00269178|BEHAVIORAL|Peer Health Education Programme|
215128003|NCT06112665|DRUG|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
215128004|NCT06304103|DRUG|AND017|Administer AND017 once per day (QD)
215128005|NCT03650621|DEVICE|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
215128006|NCT03650621|DEVICE|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
215128007|NCT04580238|DRUG|Botox 200 UNT Injection|"Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites"
215128008|NCT04580238|COMBINATION_PRODUCT|Non Botox based Standard of Care Treatments for Headache/Migraine|Control Group will receive normal standard of care Non-Botox based interventions.
215128009|NCT05952349|DRUG|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
215128010|NCT05952349|DRUG|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
214447858|NCT06844292|DEVICE|MINIject with Cataract Surgery|Patients will be randomized to receive either a MINIject implant or a Hydrus Microstunt in conjunction with cataract surgery. If randomized to MINIject, the device will be implanted into the supraciliary space with a minimally invasive ab interno approach. It is designed to be implanted with its head in the anterior chamber and its body in the supraciliary space, leading to improved natural uveoscleral outflow by directing aqueous humor from the anterior chamber to the sub-scleral space. Cataract surgery will be performed with phacoemulsification.
215128011|NCT05957679|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
215128012|NCT05957679|PROCEDURE|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
215128013|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
215128014|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
215128015|NCT04543396|OTHER|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
215128016|NCT04935957|DEVICE|GLUCUBE device|device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
214447859|NCT06844292|DEVICE|Hydrus Microstent with Cataract Surgery|"Patients will be randomized to receive either a Hydrus Microstunt or a MINIject implant in conjunction with cataract surgery. If randomized to Hydrus Microstent, the device will be implanted into Schlemm's canal through the trabecular meshwork in order to dilate and restore the natural aqueous outflow pathway through Schlemm's canal, leading to a reduction of intraocular pressure.~Cataract surgery will be performed with phacoemulsification."
214447860|NCT04833777|DRUG|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
214447861|NCT04833777|DRUG|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
214447862|NCT05672186|BEHAVIORAL|Full-service market intervention|Full-service mobile market implementation: the market will visit intervention sites weekly. The market will carry items from all food groups including fresh, frozen and canned fruits and vegetables, whole grains, dairy/ dairy substitutes, proteins (e.g., frozen meat/fish, beans, eggs), and dry goods (e.g., cooking oil, spices). Prices on the market are affordable, approximately 10% lower than grocery stores.
214447863|NCT05672186|OTHER|No intervention|No intervention
214447864|NCT05687279|BIOLOGICAL|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
214447865|NCT05687279|OTHER|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
214447866|NCT06845839|DRUG|CAY001|Polyphosphate (PolyP) - silica nanoparticle (SNP) complex
214447867|NCT06845839|OTHER|Placebo|Vehicle - aqueous solution
214447868|NCT05959785|PROCEDURE|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
214524242|NCT06963138|DEVICE|Visual Acuity|VA will be measured for near and distance vision with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
214524243|NCT06963138|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
214524244|NCT06963138|DEVICE|Standard Subjective refraction|Standard subjective refraction for distance vision will be performed with Vision-R™
214524245|NCT06963138|DEVICE|Near vision examination and determination of additions|"Near vision examination and determination of additions will be performed with Vision-R™. The following objective and subjective measurement methods will determine the values of the various additions:~1. Determination of addition using the retinoscopy method (Add\_OBJ)~2. Randomization and administration of addition determination tests: FCC; R/G; PRA-NRA"
214524246|NCT06963138|DEVICE|Binocular vision tests|"The following measurements will be taken in trial glasses equipped with the final addition:~1. Stereoscopic acuity measurement~2. Measurement of the Near Point of Accommodation (PPA)~3. Measurement of the Near Point of Convergence (PPC)~4. Measurement of fusion reserves~5. Measurement of prismatic rock~6. Subjective questionnaire on the different methods used"
215128017|NCT05963672|DEVICE|EEG-guided sleep protection|"The tablet will display a specific picture prioritize sleep or prioritize care depending on the patient status determined by the algorithm. When the picture favor/prioritize sleep is displayed, all caregivers and visiting family are asked to follow the sleep protection rules: refrain to enter the room for not urgent reasons, switch off television, reduced light in the room/corridor, reduce noise in front of the door, close curtain (if any), and delay non urgent care…etc; if caregivers have to enter the room, headlight and/or additional light will be favored. All these rules will be established collegially by nurses and doctors. Obviously, urgent care and reactions to alarms are maintained.~When the picture favor/prioritize care is displayed, all caregivers and visiting family are invited to perform non urgent care, cleaning, restocking perfusion needles, comfort care, visiting."
215128018|NCT05963672|OTHER|Control condition|the recording device will be placed on the patient to record sleep but the tablet will be masked and placed face down on the bench in the room, invisible from the door.
215128019|NCT03093922|DRUG|Atezolizumab|1200 mg/m\^2
215128020|NCT03093922|DRUG|Gemcitabine|1000 mg/m\^2
215128021|NCT03093922|DRUG|Cisplatin|70 mg/m\^2
215128022|NCT04467073|BEHAVIORAL|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
215128023|NCT04736888|OTHER|extended-reality CPR training|extended-reality technologies based CPR training module
215128024|NCT04736888|OTHER|conventional CPR training|conventional CPR training with video
215128025|NCT03895333|OTHER|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
215128026|NCT02314663|DEVICE|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
215128027|NCT05288647|PROCEDURE|TMJ injection|four sodium hyaluronate injections in superior TMJ space
215128028|NCT03309878|BIOLOGICAL|Mogamulizumab|Given IV
215128029|NCT03309878|BIOLOGICAL|Pembrolizumab|Given IV
215128030|NCT06474624|OTHER|Cardio Rehabilitation program|A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.
214524247|NCT06963138|DEVICE|Extended trial of addition|"The following measurements will be performed using trial glasses equipped with the final addition:~1. Submission of the CISS questionnaire and distance adaptation~2. Initial measurements of accommodative positioning and phorias~3. Completion of three smartphone tasks: reading, memorization, and video viewing~4. Final measurements of accommodative positioning and phorias~5. Submission of the QoL questionnaire regarding visual discomfort during the trial."
215128031|NCT06474624|OTHER|Cycling for 20-30 minutes|Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.
215128032|NCT06474624|OTHER|Cycling a total of 4 cycles|Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
215128033|NCT03679975|DRUG|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
215128034|NCT00038753|PROCEDURE|Vision Screening|
215128035|NCT03992053|OTHER|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
215128036|NCT04870658|PROCEDURE|Dental implant treatment|Patients who receive one o more dental implant treatment to restore oral function.
215128037|NCT00010400|DRUG|Cyclophosphamide|
214524248|NCT00119314|DRUG|capecitabine|
214524249|NCT00119314|DRUG|docetaxel|
214524250|NCT00119314|DRUG|gemcitabine hydrochloride|
214524251|NCT00119314|PROCEDURE|positron emission tomography|
214524252|NCT02245971|PROCEDURE|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
214524253|NCT02245971|PROCEDURE|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
214524254|NCT01100593|PROCEDURE|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
214524255|NCT06048471|OTHER|HiTop|High tone transcutaneous electrical stimulation
214524256|NCT00203788|BEHAVIORAL|Individual Placement and Support|Supported education/employment
215128038|NCT00010400|DRUG|filgrastim|
214524257|NCT00203788|BEHAVIORAL|Workplace Fundamentals Module|Group skills training on job/school topics
214524258|NCT00203788|BEHAVIORAL|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
214524259|NCT00203788|DRUG|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
214524260|NCT00203788|BEHAVIORAL|Skills training group|Group social skills training that did not focus primarily on work situations
214524261|NCT04809545|OTHER|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
214524262|NCT04809545|OTHER|Treatment as usual|Usual care provided on the Specialized Dementia Unit
214524263|NCT01604499|BEHAVIORAL|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
214524264|NCT01604499|BEHAVIORAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
214524265|NCT02894385|DRUG|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
214524266|NCT01239225|DEVICE|Abdominal ultra-sound|
215128039|NCT03608319|DRUG|A4250|9.6 mg
214524267|NCT01239225|PROCEDURE|Abdominal ultrasound|
214524268|NCT01870999|DRUG|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
214524269|NCT01870999|DRUG|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
214524270|NCT01518127|OTHER|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
214524271|NCT00940914|DRUG|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
214524272|NCT00148499|DRUG|Ambroxol hydrochloride (Mucoangin?)|
214524273|NCT00148499|DRUG|benzocaine|
214524274|NCT02064361|OTHER|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
214524275|NCT05939349|OTHER|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
214524276|NCT03491774|BEHAVIORAL|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
214524277|NCT00555334|PROCEDURE|RFA|radiofrequency ablation
214524278|NCT00555334|DRUG|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
214524279|NCT01523028|OTHER|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter"
214524280|NCT06003478|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
215128040|NCT06034210|DEVICE|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
214524281|NCT01636258|BEHAVIORAL|Stress Management|Every other week
214524282|NCT01636258|BEHAVIORAL|Diet|Every other week
214694380|NCT03617133|RADIATION|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or \>2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
214708796|NCT01178723|DIETARY_SUPPLEMENT|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
214708797|NCT00105755|DEVICE|personal dermal thermometer (DT)|
214708798|NCT00105755|DEVICE|Device|
214524283|NCT01636258|BEHAVIORAL|Exercise|Every week
214524284|NCT01636258|BEHAVIORAL|Culinary education|Every other week
215128041|NCT06085599|BEHAVIORAL|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
215128042|NCT06007534|OTHER|Samples|Blood samples, urine samples and oropharyngeal swabs before taking 200mg of doxycycline and then 2h, 24h, 48h, 7 days, 14 days, 60 days and 90 days after the single dose of doxycycline Hair samples: at the time of doxycycline administration, 1 month and 3 months after the single dose of doxycycline
215128043|NCT06518824|DEVICE|DBS On|The DBS device will be turned on while the patient undergoes the working memory task.
215128044|NCT06518824|DEVICE|DBS Off|The DBS device will be turned off while the patient undergoes the working memory task.
215128045|NCT05471544|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
215128046|NCT05471544|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
215128047|NCT05323695|BEHAVIORAL|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
215128048|NCT03192176|DRUG|Fezolinetant|Oral Capsule
215128049|NCT03192176|DRUG|Placebo|Oral Capsule
215128050|NCT05685043|DEVICE|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients \> 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
215128051|NCT04498221|PROCEDURE|Imaging procedure|During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
215128052|NCT04498221|PROCEDURE|Surgical procedure|Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
215128053|NCT05671692|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
215128054|NCT05671692|DRUG|Placebo|Same as active comparator, except placebo dispensed.
215128055|NCT06362850|OTHER|Tele-support|via real-time audio-video connection through an experienced physician
215128056|NCT05188586|OTHER|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
215128057|NCT05533385|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
215128058|NCT00667628|DRUG|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
215128059|NCT00667628|DRUG|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
215128060|NCT01725906|DRUG|empirical therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
215128061|NCT01725906|DRUG|Genotypic resistance guided therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
215128062|NCT06580496|BEHAVIORAL|Mightier|Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
215128063|NCT06509659|DIAGNOSTIC_TEST|Methacholine Challenge Test|MCT with IOS alone versus MCT IOS and FEV1 combined
215128064|NCT04244253|DRUG|OPC-64005 20 mg , Once-daily|Active, High Dose
215128065|NCT04244253|DRUG|OPC-64005 10 mg , Once-daily|Active, Low Dose
215128066|NCT04244253|DRUG|Placebo, Once-daily|Placebo
214524285|NCT00582192|OTHER|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
214524286|NCT01406171|DRUG|Isavuconazole|oral
214524287|NCT01406171|DRUG|Midazolam|Oral
214524288|NCT01763346|DRUG|Metformin|metformin 1000 mg bid
214524289|NCT01763346|DEVICE|gastric banding|LAP-BAND
214524290|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
214524291|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
214524292|NCT01418599|DRUG|Torrent's Alfuzosin Extended Release Tablet|
214524293|NCT03360227|DEVICE|implantation of cardiac devices|implantation of cardiac devices
214524294|NCT02798861|DEVICE|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
214524295|NCT02547025|DRUG|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
214524296|NCT02547025|DRUG|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
214524297|NCT02547025|DRUG|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
214524298|NCT01968083|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
214524299|NCT01968083|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
214524300|NCT01785797|DEVICE|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
214524301|NCT02186015|DRUG|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
215128067|NCT05222958|DEVICE|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
215128068|NCT04663321|DRUG|MK-1942|MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
215128069|NCT04663321|DRUG|Placebo|Dose matched placebo capsules BID orally over 4 weeks.
215128070|NCT01874197|DEVICE|B-TEVAR device|Implantation of the Branched Thorcoabdominal aortic anerysm device
215128071|NCT05108246|BEHAVIORAL|Dual-Task Exercise Training|Simultaneous cognitive-motor training
215128072|NCT05983458|PROCEDURE|Transaortic valve replacement|"TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view."
215128073|NCT05833958|DRUG|GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin|As described previously
215128074|NCT05833958|DRUG|Metformin|As described previously - Experimental Arm, 175mg at night
215128075|NCT05833958|DRUG|Metformin|As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
215128076|NCT03532542|DRUG|Casimersen|Casimersen solution for IV infusion
214524302|NCT05952583|DIAGNOSTIC_TEST|Ultrasound|Additional ultrasound measurements during pregnancy
215128077|NCT03532542|DRUG|Golodirsen|Golodirsen solution for IV infusion
215128078|NCT02982902|BIOLOGICAL|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
215128079|NCT03121508|BEHAVIORAL|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
215128080|NCT05097820|DEVICE|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
215128081|NCT01962441|DRUG|SOF|400 mg tablet administered orally once daily
215128082|NCT01962441|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214524303|NCT00907517|DRUG|MK-8776|IV infusion
214524304|NCT00907517|DRUG|Cytarabine|IV infusion
214524305|NCT00733551|DRUG|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
214524306|NCT00733551|DRUG|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
214524307|NCT00355602|DRUG|Cefuroxime|
214524308|NCT00355602|DRUG|Ciprofloxacin|
214524309|NCT00355602|DRUG|Clarithromycin|
214524310|NCT00355602|DRUG|Cotrimoxazole|
214524311|NCT00355602|DRUG|Coamoxiclav|
214524312|NCT00355602|DRUG|metronidazole|
214524313|NCT00355602|DRUG|neomycin|
214708799|NCT02347462|DEVICE|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
214708800|NCT02347462|OTHER|Standard care|Standard care according to the hospital severe asthma protocol
214524314|NCT00355602|DRUG|rifaximin|
214524315|NCT00355602|DRUG|Vancomycin|
214524316|NCT00355602|DRUG|Doxycycline|
214708801|NCT06066359|DRUG|Fludarabine phosphate|Given by (IV) vein
214708802|NCT06066359|DRUG|Cyclophosphamide|Given by (IV) vein
214708803|NCT06066359|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
215128083|NCT01962441|DRUG|Peg-IFN|180 µg administered via subcutaneous injection once weekly
215128084|NCT04787224|OTHER|immediate implant with vestibular socket therapy|A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
214524317|NCT03467802|BIOLOGICAL|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
214524318|NCT03467802|DEVICE|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
215128085|NCT05294315|PROCEDURE|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
214524319|NCT02660034|BIOLOGICAL|Tislelizumab|
214524320|NCT02660034|DRUG|Pamiparib|
214524321|NCT03377283|BIOLOGICAL|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
214524322|NCT03377283|OTHER|organ perfusion with saline|
214524323|NCT00571558|DRUG|aminolevulinic acid hydrochloride|Given PO
215128086|NCT05294315|PROCEDURE|Single level erector spinae block|erector spinae block at 4th transverse process
215128087|NCT03166514|DIETARY_SUPPLEMENT|Commercially Available Food Bar|
215128088|NCT03166514|DIETARY_SUPPLEMENT|Placebo|
214524324|NCT00571558|DRUG|photodynamic therapy|Undergo photodynamic therapy
215128089|NCT02055898|DRUG|Sodium Oxybate|
215128090|NCT02055898|OTHER|placebo (fresh potable water)|
215128091|NCT06139341|DRUG|BI 765845|BI 765845
215128092|NCT06139341|DRUG|Placebo|Placebo
215128093|NCT06389526|BIOLOGICAL|CHS-1000|Specified dose on specified days
215128094|NCT06389526|BIOLOGICAL|Toripalimab|Specified dose on specified days
215128095|NCT03802578|BEHAVIORAL|HAND EXERCISE|
214524325|NCT00571558|OTHER|laboratory biomarker analysis|Correlative studies
214524326|NCT00618384|DRUG|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
214524327|NCT03340818|OTHER|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
214524328|NCT03340818|OTHER|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
214708804|NCT01226589|PROCEDURE|MRS|
214708805|NCT02098499|DRUG|Haloperidol|5mg IV
215128096|NCT03604367|DEVICE|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
215128097|NCT05072392|DEVICE|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
215128098|NCT03847766|BEHAVIORAL|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
215128099|NCT03847766|BEHAVIORAL|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
215128100|NCT01349517|PROCEDURE|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
215128101|NCT01349517|PROCEDURE|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
215128102|NCT01349517|PROCEDURE|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
215128103|NCT01349517|PROCEDURE|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
214524329|NCT00220441|BEHAVIORAL|Aerobic exercise|
214524330|NCT01333137|DRUG|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
214708806|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
214708807|NCT02098499|DRUG|Diphenhydramine|25mg IV
214708808|NCT05979233|PROCEDURE|staged managment|staged management
214708809|NCT05979233|PROCEDURE|one session ERCP then LC|one session ERCP then LC
214708810|NCT05979233|PROCEDURE|one session LC then ERCP|one session LC then ERCP
215128104|NCT01441843|DRUG|Lorazepam|Once 1mg \<75kg body weight, 1.5mg 75kg and \>75kg body weight, IV, before surgery
215128105|NCT01441843|DRUG|NaCl 0.9% (Sodium Chloride)|Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
215128106|NCT00103168|DRUG|imatinib mesylate|400 mg/day for 2 years
215128107|NCT02302768|DIETARY_SUPPLEMENT|Selenomethionine|
215128108|NCT02302768|OTHER|Placebo|
215128109|NCT01500772|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
215128110|NCT01500772|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
214447869|NCT05959785|PROCEDURE|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
214447870|NCT03636503|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment
214447871|NCT03636503|DRUG|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
214524331|NCT01333137|DRUG|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
214524332|NCT03919318|OTHER|Root Canal Filling Sealers|Root Canal Obturation
214524333|NCT02030847|BIOLOGICAL|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
214524334|NCT02030847|BIOLOGICAL|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
214524335|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
214524336|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
214524337|NCT02908412|DRUG|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
214524338|NCT04193397|BEHAVIORAL|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
214524339|NCT02431832|DRUG|Augmentin tab|
214524340|NCT01074437|DRUG|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
215128111|NCT01500772|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
215128112|NCT01733875|DRUG|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
215128113|NCT01733875|DRUG|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
215128114|NCT01733875|DRUG|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
215128115|NCT01733875|DRUG|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
215128116|NCT01733875|DRUG|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
215128117|NCT01733875|DRUG|Placebo|A single dose of placebo will be administered orally once a day.
215128118|NCT01733875|DRUG|CC-220|CC-220 4 mg will be administered orally once a day
215128119|NCT01733875|DRUG|CC-220|CC-220 6 mg will be administered orally once a day
215128120|NCT01733875|DRUG|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
215128121|NCT02040649|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
215128122|NCT02040649|OTHER|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
215128123|NCT02418871|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
215128124|NCT02418871|PROCEDURE|Cataract surgery|Performed using standard microsurgical techniques
215128125|NCT06468098|DRUG|IBI363 + chemotherapy|In this group, patients will receive IBI363 and chemotherapy
215128126|NCT06468098|DRUG|IBI363 + Investigator's Choice SOC|In this group, patients will receive IBI363 and Investigator's Choice SOC
214524341|NCT01074437|DRUG|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
214524342|NCT01074437|DRUG|Placebo|Liquid placebo will be given during the two month treatment trial.
214524343|NCT04265911|BIOLOGICAL|ASP3772 (subcutaneous)|Subcutaneous injection
214524344|NCT04265911|BIOLOGICAL|ASP3772 (intramuscular)|Intramuscular injection
214524345|NCT04265911|BIOLOGICAL|PPSV23 (subcutaneous)|Subcutaneous injection
214524346|NCT04265911|BIOLOGICAL|PPSV23 (intramuscular)|Intramuscular injection
214524347|NCT00449202|DRUG|oleoyl-estrone (MP 101)|
214524348|NCT03185845|DRUG|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
214524349|NCT04134221|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
214708811|NCT01320956|BEHAVIORAL|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
215128127|NCT00153036|DRUG|rt-PA 0.9 mg/kg verum or placebo Intravenous|
215128128|NCT02338635|DRUG|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
215128129|NCT00466232|DRUG|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
214524350|NCT02222844|OTHER|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
214708812|NCT01320956|OTHER|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
214708813|NCT00873288|OTHER|Usual care mailing intervention|routine colposcopy reminder letter
215128130|NCT00466232|DRUG|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
215128131|NCT00127634|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
215128132|NCT00127634|DRUG|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
215128133|NCT00127634|DRUG|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
215128134|NCT04926649|PROCEDURE|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
215128135|NCT04315155|DRUG|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
215128136|NCT04315155|DRUG|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
215128137|NCT04315155|DRUG|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
215128138|NCT04315155|DRUG|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
214524351|NCT04542200|BIOLOGICAL|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
214524352|NCT04238559|OTHER|Self-report questionnaire|Fill in the SWAMECO questionnaire
214524353|NCT01475019|DRUG|Orlistat|Tablet, 120 mg, three times daily, for six months
214524354|NCT01475019|DRUG|Sibutramine|Tablet, 10 mg, once daily, for six months
214524355|NCT01475019|BEHAVIORAL|Diet and physical exercise|Hypocaloric diet and regular physical exercise
214524356|NCT05286008|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214524357|NCT05286008|DRUG|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214524358|NCT05286008|DRUG|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214524359|NCT04466397|DEVICE|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
214524360|NCT02343978|DRUG|KWA-0711|
214524361|NCT01189318|DRUG|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
214524362|NCT06640075|OTHER|Community co-produced action|"Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening."
214708814|NCT00873288|OTHER|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
215128139|NCT04315155|DRUG|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
214524363|NCT06640075|OTHER|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
214524364|NCT03743987|PROCEDURE|control group|a procedure used to prevent or resolves apical periodontitis.
214524365|NCT03743987|PROCEDURE|MTA group|a procedure used to prevent or resolves apical periodontitis.
214524366|NCT03743987|PROCEDURE|PRF group|a procedure that is used for wound healing
214524367|NCT03743987|PROCEDURE|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
214524368|NCT05885841|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
214524369|NCT06247488|DRUG|Placebo|Participant will receive oral dose of placebo.
214524370|NCT06247488|DRUG|Oxycodone 20 mg|Participant will receive oral dose of oxycodone 20 mg.
214694381|NCT03617133|DRUG|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
215128140|NCT02314052|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
215128141|NCT03701139|PROCEDURE|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
215128142|NCT03701139|PROCEDURE|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
215128143|NCT02558517|DRUG|prednisone discontinuation|randomization
215128144|NCT00965666|DRUG|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
215128145|NCT00117637|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
215128146|NCT00117637|DRUG|Interferon|Interferon
215128147|NCT01618032|OTHER|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
215128148|NCT01618032|OTHER|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
215128149|NCT01618032|OTHER|placebo|Manual contact during a period of time similar of teh other interventions
215128150|NCT01654926|PROCEDURE|blood ultrafiltration|
215128151|NCT02417883|DRUG|Furosemide|Evaluate urinary excretion rate fo furosemide
215128152|NCT02432326|DRUG|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
215128153|NCT02432326|DRUG|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
215128154|NCT04215926|OTHER|No intervention; cross-sectional study|No intervention; cross-sectional study
215128155|NCT01476007|DRUG|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
215128156|NCT01476007|DRUG|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
214524371|NCT06247488|DRUG|GE-IR 200 mg|Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
214524372|NCT06247488|DRUG|GE-IR 450 mg|Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
214524373|NCT02749175|DEVICE|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
214524374|NCT02749175|DEVICE|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
214524375|NCT05550077|DIAGNOSTIC_TEST|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
214524376|NCT05550077|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
214524377|NCT05942573|DRUG|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
214524378|NCT05942573|DRUG|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
214524379|NCT00000236|DRUG|Buprenorphine/naloxone|
214524380|NCT00316459|DRUG|ERB-041|
214524381|NCT06545721|OTHER|Adjusting dietary structure + exercise + behavioral intervention|Adjusting to a healthy diet involves consuming low GI and low-fat foods, avoiding sugary drinks, increasing dietary fiber intake, reducing saturated fat while increasing omega-3 unsaturated fat intake, and limiting trans fat consumption. A weight loss program includes a high-protein diet, exercise, and behavioral intervention with daily total energy needs calculated based on ideal body weight (kg) x 15-20 kcal/kg/d; developing a daily meal plan with regular protein supplementation; limiting salt intake to ≤5 g/d; ensuring adequate water consumption at 2-3L/d; aiming for a dietary fiber intake of 25-30g/d; recommending micronutrient supplementation as needed; maintaining daily aerobic exercise (40 minutes at 70-80% HRmax) along with resistance training (20 minutes); establishing an early bedtime before 11pm and an early wake-up time.
214524382|NCT00352963|BIOLOGICAL|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
214524383|NCT02720198|DRUG|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
214524384|NCT02720198|DRUG|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
214524385|NCT00641797|DRUG|Meclizine|medication administration 25mg PO one time
214524386|NCT00641797|OTHER|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
215128157|NCT03431298|BEHAVIORAL|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training"
215128158|NCT03431298|BEHAVIORAL|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down"
215128159|NCT04688658|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
215128160|NCT04688658|DRUG|Duvelisib|Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
215128161|NCT01028105|OTHER|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
215128162|NCT03881839|OTHER|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
215128163|NCT05740488|DRUG|Apalutamide|240mg, po, qd
215128164|NCT05740488|DRUG|89Sr|100\~150MBq(based on weight), iv, q90d
215128165|NCT05740488|DRUG|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
214524387|NCT00641797|DRUG|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
214524388|NCT00641797|DRUG|Diphenhydramine|25 - 50mg PO/IV once prn
214524389|NCT00641797|DRUG|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
214524390|NCT04596917|BEHAVIORAL|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
214524391|NCT04596917|BEHAVIORAL|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
214524392|NCT03890692|PROCEDURE|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
214524393|NCT00908193|DEVICE|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
214524394|NCT00908193|PROCEDURE|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
215128166|NCT00537602|DRUG|miglustat|
215128167|NCT00537602|DRUG|placebo|
215128168|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
215128169|NCT00956735|OTHER|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
215128170|NCT01620060|DRUG|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
215128171|NCT02180581|DIETARY_SUPPLEMENT|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months
215128172|NCT02180581|DIETARY_SUPPLEMENT|Placebo|Placebo for 6 months
215128173|NCT06378034|DIETARY_SUPPLEMENT|Lactium|300 mg per day, taken 30 min to 60 min before bedtime
215128174|NCT06378034|DIETARY_SUPPLEMENT|Placebo|300 mg per day, taken 30 min to 60 min before bedtime
215128175|NCT03016572|BEHAVIORAL|Standard of Care|Follow-Up Calls, Questionnaires
214694382|NCT03617133|OTHER|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (\>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
214524396|NCT00183235|DRUG|aripiprazole (up to 15 mg/day) for 8 days|
214524397|NCT05038319|PROCEDURE|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
214694383|NCT03136133|DIETARY_SUPPLEMENT|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
214694384|NCT04859335|RADIATION|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
214694385|NCT05454202|DEVICE|ANI|Pain measurement during care procedures in palliative care
214694386|NCT01796262|DIETARY_SUPPLEMENT|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
214694387|NCT01796262|DIETARY_SUPPLEMENT|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
214694388|NCT02168933|DEVICE|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
215128176|NCT03016572|BEHAVIORAL|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
215128177|NCT03016572|BEHAVIORAL|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
215128178|NCT01402401|DRUG|AUY922|
215128179|NCT01402401|DRUG|Trastuzumab|
215128180|NCT00743002|DRUG|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
215128181|NCT00743002|DRUG|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
215128182|NCT06349694|OTHER|Transcutaneous MPN stimulation (T-MPNS)|Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
215128183|NCT06349694|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
215128184|NCT06349694|OTHER|BT (Control group)|Conventional bladder training
215128185|NCT04522453|OTHER|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
214524398|NCT05591456|RADIATION|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
214524399|NCT02295293|DRUG|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
214524400|NCT02295293|DRUG|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
214524401|NCT01562288|GENETIC|DNA analysis|
214524402|NCT01562288|GENETIC|gene expression analysis|
214524403|NCT01562288|GENETIC|polymerase chain reaction|
214524404|NCT01562288|OTHER|enzyme-linked immunosorbent assay|
214524405|NCT01562288|OTHER|laboratory biomarker analysis|
214524406|NCT02023099|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
214524407|NCT02023099|DRUG|Placebo|Tablet
214524408|NCT02450279|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
214524409|NCT02450279|DEVICE|Vibrating-mesh nebulizer|
214524410|NCT02450279|DEVICE|Jet Nebulizer|
214694389|NCT02168933|DEVICE|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
214694390|NCT01483898|BIOLOGICAL|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
214694391|NCT01483898|OTHER|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
214694392|NCT04689594|COMBINATION_PRODUCT|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
214708815|NCT01029015|PROCEDURE|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
214708816|NCT01029015|PROCEDURE|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
215128186|NCT04522453|OTHER|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
215128187|NCT00367575|PROCEDURE|Internet personalized alcohol feedback (PAF)|
215128188|NCT04985721|DRUG|Pamiparib|40 mg orally twice a day
215128189|NCT04985721|DRUG|Tislelizumab|200 mg IV every 21 days
215128190|NCT01361022|DRUG|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
215128191|NCT01361022|DRUG|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
215128192|NCT05218369|DRUG|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
215128193|NCT01792310|DRUG|LAM561|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
215128194|NCT05976516|DIAGNOSTIC_TEST|CXCL2/CXCL8|Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
215128195|NCT01582061|DRUG|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
215128196|NCT03153774|DIAGNOSTIC_TEST|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
215128197|NCT00354016|BIOLOGICAL|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
215128198|NCT05924061|OTHER|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
215128199|NCT00231777|DRUG|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
215128200|NCT00231777|DRUG|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
215128201|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
215128202|NCT05425602|DRUG|MAX-40279-01: 50mg/70mg|\[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
214447872|NCT03636503|DRUG|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
214447873|NCT03636503|DRUG|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
214447874|NCT06847646|OTHER|bioflex crown using hall technique|crowns assessment
214447875|NCT06847646|OTHER|stainless steel crown using hall technique|crown assessment
214447876|NCT06843746|DEVICE|Commercial thermoplastic|The participants received a commercial thermoplastic splint material for splint fabrication.
214447877|NCT06843746|DEVICE|Newly developed low-cost thermoplastic|The participants received a newly developed low-cost thermoplastic splint material for splint fabrication.
214447878|NCT04525950|PROCEDURE|Navio|New generation computer navigation with haptics and robotics
214447879|NCT04525950|PROCEDURE|Conventional|Total knee arthroplasty using conventional instruments
214447880|NCT03223961|DRUG|EPREX|60 000 U/week for at least 12 weeks
214447881|NCT05126147|DRUG|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
214524411|NCT02450279|OTHER|Planar scintigraphy|
214524412|NCT02450279|OTHER|Preoperative spirometry|
214447882|NCT06844513|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed using the Da Vinci Xi and the HUGO RAS platform
214447883|NCT06844513|PROCEDURE|Partial nephrectomy|partial nephrectomy (PN) using either the Da Vinci Xi platform or the HUGO™ RAS platform
214447884|NCT03475108|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
214447885|NCT06201962|OTHER|Massage|Massage applications will be performed for 15 minutes every morning and evening for two days.
214524413|NCT00597779|DEVICE|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
215128203|NCT03573414|OTHER|raspberry powder, milled flaxseed and soy milk|"* The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples"
214447886|NCT06201962|OTHER|Foot Reflexology|In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
214447887|NCT06201962|OTHER|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
214447888|NCT06845410|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
214447889|NCT06845410|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
214447890|NCT06845410|DRUG|Immunosuppressive Therapy|Glucocorticoids and/or immunosuppressive agents
214447891|NCT06845410|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
214447892|NCT06845410|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
215128204|NCT02787928|DRUG|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
215128205|NCT05308875|BIOLOGICAL|PD1-BCMA-CART|Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
215128206|NCT00297219|DRUG|Low dialysate calcium|1.25 mmol/L dialysate calcium
215128207|NCT00297219|DRUG|high dialysate calcium|1.75 mmol/L dialysate calcium
215128208|NCT00702468|DRUG|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
215128209|NCT00702468|DRUG|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
215128210|NCT05650008|DRUG|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
215128211|NCT05858086|OTHER|Novel same-day discharge protocol after total joint arthroplasty|Preoperative gait/stair training with physical therapy, then postoperative ambulation with nursing after total joint arthroplasty
215128212|NCT05858086|OTHER|Conventional postoperative physical therapy clearance|Physical therapy evaluation and clearance after total joint arthroplasty
215128213|NCT04458636|DRUG|Prednisolone|Oral
215128214|NCT02190136|OTHER|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
215128215|NCT02190136|OTHER|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
215128216|NCT02190136|OTHER|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
215128217|NCT05691881|DRUG|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
215128218|NCT02053012|DEVICE|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
215128219|NCT02579668|OTHER|Language Therapy|
215128220|NCT03308344|BEHAVIORAL|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
215128221|NCT05089006|PROCEDURE|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
215128222|NCT01615250|BIOLOGICAL|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
215128223|NCT02928068|BEHAVIORAL|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
215128224|NCT02190526|DRUG|Mesalazine(asacol 800 mg)|
215128225|NCT02190526|DRUG|Amitriptyline|
215128226|NCT02190526|DRUG|placebo like asacol|
214447893|NCT06846346|DRUG|Ivonescimab|Ivonescimab 20 mg/kg by intravenous (IV) infusion once every 2 weeks until disease progression.
214447894|NCT06846346|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion, every two weeks for 8 cycles followed by 5FU as maintenance therapy until disease progression.
214447895|NCT06846346|DRUG|Irinotecan|180 mg/ m2 IV over 90 min infusion every two weeks for a minimum of 4 cycles
214447896|NCT06846346|DRUG|Paclitaxel|80 mg/m2 IV at D1, D8 and D15, every four weeks (D1=D28)
214447897|NCT06846255|DRUG|Dexamethasone Cyclophosphamide Pulse therapy|33 patients were enrolled in DCP group. They were given Dexamethasone Cyclophosphamide pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
215128227|NCT02190526|DRUG|placebo like amitriptyline|
215128228|NCT02780843|OTHER|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
215128229|NCT02780843|OTHER|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
215128230|NCT05225038|OTHER|Exercise|Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.
215128231|NCT05225038|DIETARY_SUPPLEMENT|Nutritional|Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.
214524414|NCT02916524|BEHAVIORAL|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
214524415|NCT01071720|DRUG|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
214524416|NCT02592434|DRUG|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg."
214524417|NCT02592434|OTHER|placebo|matching placebo tablet or solution for tofacitinib
214524418|NCT01088347|DRUG|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
215128232|NCT05225038|BEHAVIORAL|Behavioral Medicine|"Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support."
215128233|NCT05225038|BEHAVIORAL|Smoking Cessation|Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
215128234|NCT05975255|DRUG|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
215128235|NCT05961267|BEHAVIORAL|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
215128236|NCT03839368|PROCEDURE|fixation of angle fracture|open reduction and internal fixation of angle fracture
215128237|NCT04698343|DEVICE|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
215128238|NCT02931019|PROCEDURE|Intubation|
215128239|NCT05256680|OTHER|Gardening Activities|"In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home."
215128240|NCT06094920|DRUG|Empagliflozin 10 MG|Oral administration
215128241|NCT06094920|DRUG|Finerenone|"Oral administration.~Finerenone treatment may be initiated if serum potassium levels are ≤5.0 mmol/L. Conversely, if serum potassium levels are \>5.0 mmol/L, the initiation of finerenone treatment should be avoided. In such cases, a second serum potassium measurement will be performed two days later. If serum potassium levels are ≤5.0 mmol/L, these patients can still be considered for inclusion. However, if serum potassium levels are \>5.0 mmol/L again, these patients will be excluded, and an assessment of the underlying cause(s) of hyperkalaemia will be conducted.~The recommended initial dose of finerenone is determined based on eGFR, which will be assessed prior to the commencement of the trial. If eGFR is ≥60 mL/min/1.73m2, the dose will be set at 20 mg once daily. If eGFR is ≥25 to \<60, the dose will be set at 10 mg once daily. Participants with an eGFR \<25 are not advised to undergo finerenone treatment and will be excluded from the study."
214524419|NCT01088347|DRUG|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
214524420|NCT01088347|RADIATION|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
214694393|NCT05915494|OTHER|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
214694394|NCT05915494|OTHER|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
214694395|NCT01554839|BEHAVIORAL|"Family of Heroes"|One hour online educational tool
215128242|NCT06094920|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 40 days. Three consecutive measurements are taken."
215128243|NCT06094920|DEVICE|Withings Body|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 49 days."
215128244|NCT06094920|DIAGNOSTIC_TEST|PeeSpot Urine Collection Device|Biochemical urine data will be collected using first-morning void urine samples. Participants will obtain urine samples with the PeeSpot device, a validated tool designed for the collection and preservation of small urine volumes. This device comprises a urine absorption pad, a holder, a tube, and a lid. Patients can void directly onto the absorption pad while it is placed in the holder. Following voiding, the pad and holder are inserted into the tube, sealed with the lid, and stored in a refrigerator until they are sent to the laboratory using a biological materials envelope (PolyMed, DaklaPack, Europe). Through the incorporation of an inert hygroscopic polymer, the pad efficiently absorbs 1.2 mL of urine, and with the addition of various preservatives, the urine remains stable for up to four days. The investigators will employ the PeeSpot to determine the first-morning void levels of albumin, creatinine, sodium, potassium, glucose, urea, and osmolality once daily on 28 days.
215128245|NCT06094920|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 17 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, potassium, hsCRP, haematocrit, cystatin C, and fasting plasma glucose.
215128246|NCT06094920|BEHAVIORAL|Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies|Participant perspectives regarding the feasibility of participating in a home-based trial will be evaluated using a digital questionnaire. This questionnaire includes inquiries adapted from the validated Telehealth Usability Questionnaire, supplemented with additional questions employed in prior studies that assessed the feasibility of decentralized clinical trials. The web application Research Electronic Data Capture 10.0.23 (REDCap - www.projectredcap.org) will facilitate the administration of these digital questionnaires. Participants will receive a link to access the digital questionnaires via email. Weekly telephone calls will be conducted to evaluate adherence to study procedures and monitor the occurrence of adverse events.
215128247|NCT05583916|PROCEDURE|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
215128248|NCT03488836|PROCEDURE|reciproc|rotary reciprocating protocol
215128249|NCT03488836|PROCEDURE|race rotary|race rotary group protocol
215128250|NCT02756338|DEVICE|BioMonitor 2 Insertable Cardiac Monitor|
215128251|NCT00961155|DRUG|cyklezonid|160 mcg once daily
215128252|NCT00961155|DRUG|montelukast sodium|5 or 10 mg according to age once daily
215128253|NCT00961155|DRUG|placebo|fluticasone placebo twice daily, montelukast placebo once daily
214447898|NCT06846255|DRUG|Dexamethasone Azathioprine Pulse therapy|33 patients were enrolled in DAP group. They were given Dexamethasone Azathioprine pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
214447899|NCT03178760|DIAGNOSTIC_TEST|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~1. Age~2. Gender~3. Weight~4. Length~5. Waist Circumference~6. Body mass index"
214524421|NCT05147545|OTHER|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
214524422|NCT05147545|OTHER|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
214524423|NCT05147545|OTHER|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
214524424|NCT05147545|DIAGNOSTIC_TEST|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
214524425|NCT01469819|DRUG|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
214524426|NCT04061772|DRUG|Bortezomib|Bortezomib injection
215128254|NCT00961155|DRUG|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
215128255|NCT06160232|DRUG|Psilocybin (high dose)|Psilocybin-assisted therapy
215128256|NCT06160232|DRUG|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
215128257|NCT00483613|BEHAVIORAL|Cognitive-behavioral therapy of Meichenbaum|
215128258|NCT00219063|DRUG|aliskiren|
215128259|NCT03395899|DRUG|Atezolizumab|PD-L1 antibody
215128260|NCT03395899|DRUG|Cobimetinib|Highly selective small-molecule inhibitor of MEK1 and MEK2
214524427|NCT04061772|DRUG|Etoposide|Etoposide injection
215128261|NCT03395899|DRUG|Ipatasertib|Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
215128262|NCT03395899|DRUG|Bevacizumab|Highly specific humanized monoclonal antibody that targets VEGF
214524428|NCT04061772|DRUG|Cyclophosphamide|Cyclophosphamide injection
214524429|NCT04061772|DRUG|Pharmorubicin|Pharmorubicin injection
214524430|NCT04061772|DRUG|Prednisone|Prednisone tablet
215128263|NCT03688815|DIAGNOSTIC_TEST|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
214524431|NCT05005338|DRUG|BIIB122 (DNL151)|Oral doses
214524432|NCT05005338|DRUG|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
214524433|NCT00176969|DRUG|Capsaicin|
214524434|NCT00219635|DRUG|UK-390,957|
214524435|NCT04714697|DRUG|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
214524436|NCT05697822|OTHER|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
215128264|NCT04309110|DEVICE|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
215128265|NCT02181465|BIOLOGICAL|G17DT|
214447900|NCT06846112|PROCEDURE|Robotic partial nephrectomy|Robotic partial nephrectomy (RPN) is the treatment of choice for organ-confined renal tumors. For to improve functional outcomes, we designed an off-clamp and suture-free approach (SL) to limit the ischemic damage and destruction of the renal parenchyma caused, respectively, by temporary closure of the vessels of the renal hilum and by renorrhaphy (RR) (i.e. by the juxtaposition of the margins of resection of the enucleation bed, which is commonly performed at the end of tumor exeresis using suture threads stopped by surgical clips)
214447901|NCT01508312|DRUG|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
214447902|NCT01508312|DRUG|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
214447903|NCT06844370|OTHER|Non-invasive ventilation|Providing ventilation support through non-invasive means
214447904|NCT06848036|BEHAVIORAL|smart integrated care services|"Provide integrated care services through the 'Hunan Province Integrated Healthcare and Elderly Care Intelligent Service Platform,' including home-based care, mobile medical visits, and remote diagnosis and treatment services."
214447905|NCT04627766|DEVICE|Monitoring with VT-Patch (Connected device manufactured by VitalTracer)|Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
214694396|NCT01554839|BEHAVIORAL|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
214694397|NCT01480479|DRUG|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
214694398|NCT01480479|DRUG|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
214694399|NCT01480479|DRUG|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
214694400|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
214694401|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
214694402|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
214694403|NCT00518921|DRUG|Placebo|Placebo, double dummy
214694404|NCT01235169|DEVICE|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
215128266|NCT02334930|OTHER|Biopsy|
214447917|NCT05252754|DRUG|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
214524437|NCT02029521|DIETARY_SUPPLEMENT|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
214524438|NCT02029521|DIETARY_SUPPLEMENT|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
214524439|NCT02739841|OTHER|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
214524440|NCT02739841|OTHER|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
214524441|NCT00281983|BIOLOGICAL|alemtuzumab|
214447918|NCT05252754|DRUG|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
214447919|NCT05252754|DRUG|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
214447920|NCT06407817|PROCEDURE|Spencer technique|No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)
214447921|NCT06407817|PROCEDURE|reverse distraction technique|No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)
214447922|NCT06847945|PROCEDURE|Sham acupuncture|Patients in the non-meridian and non-acupoint group received sham acupuncture treatment at the position 2cm apart from the sensitized acupoint, once every other day for 30min each time, a total of 3 times for 1 week.
214524442|NCT00281983|BIOLOGICAL|anti-thymocyte globulin|
214524443|NCT00281983|BIOLOGICAL|filgrastim|
214524444|NCT00281983|BIOLOGICAL|rituximab|
215128267|NCT03654794|BIOLOGICAL|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
215128268|NCT00088530|DRUG|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
215128269|NCT00088530|DRUG|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
214447923|NCT06847945|PROCEDURE|Acupuncture|Patients in acupoint sensitization group were treated with pseudoacupuncture at the sensitized points once every other day for 30min each time, a total of 3 times for 1 week.
214447924|NCT06843798|OTHER|Survey|Participants will answer questions of different evaluation surveys via online survey. Sociodemographic information, ergonomic information, musculoskeletal pain etc. will be questioned.
214447925|NCT05345639|DRUG|LRA Loco-regional anesthesia|"Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator."
214447926|NCT05345639|PROCEDURE|Standardized post-operative analgesia protocol|"The pain management protocol in intensive care is as follows:~* paracetamol 1g x 4 per day systematically (apart from the usual contraindications), IV then PO;~* PCA (Patient Controlled Analgesia) with oxycodone or morphine: 1mg bolus, 7min refractory period, maximum 4h dose 20mg.~The PCA is usually maintained until 24-48h after the intervention then relayed by oxycodone 5mg every 4h if EVA \> 3 sublingual and addition of oxycodone LP 10mg x 2 per day if daily intake on PCA \> 20mg.~Remedy molecules in case of ineffective analgesia:~ketoprofen 100mg q12h IV, or 50mg q8h PO; nefopam 20mg every 6h IV or PO; ketamine 1 to 1.5 mg/kg/24H IVSE."
214447927|NCT06053125|PROCEDURE|Adipose Tissue Biopsy|Fat sample collected from abdomen before exercise, immediately after exercise, and 3 hours after exercise
214447928|NCT06053125|BEHAVIORAL|Exercise|30 minutes of exercise on a cycle ergometer exercise machine
214447929|NCT06844695|OTHER|Art Therapy (Virtual Museum Visit)|Virtual Reality (VR) is a technology that creates simulated settings in which users can interact and experience as if they were physically there.Virtual Reality typically involves the use of a headset or glasses that display the virtual environment, as well as other input devices such as controllers or gloves that allow users to interact with the virtual world
214447930|NCT06843876|OTHER|"digital vaccine platform TM VAX application"|Physicians and healthcare providers and Patients will use the TM-VAX system for at least one week. Investigators will distribute the online questionnaire via Jotform through the LINE application at day 7, which will take around 10-15 minutes to complete. If participants have any questions or encounter any issues with the questionnaire, the research team will provide assistance and answer questions via the LINE application or in-person
214524445|NCT00281983|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214524446|NCT00281983|DRUG|busulfan|
214524447|NCT00281983|DRUG|cyclophosphamide|
214524448|NCT00281983|DRUG|cyclosporine|
214524449|NCT00281983|DRUG|fludarabine phosphate|
214524450|NCT00281983|DRUG|methotrexate|
214524451|NCT00281983|DRUG|mycophenolate mofetil|
214524452|NCT00281983|PROCEDURE|peripheral blood stem cell transplantation|
214524453|NCT00281983|RADIATION|radiation therapy|
214524454|NCT03660254|BEHAVIORAL|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
214524455|NCT02686359|BIOLOGICAL|sample|
214524456|NCT02389725|DEVICE|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
214524457|NCT02389725|DEVICE|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
215128270|NCT04864249|DEVICE|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
214524458|NCT00428441|DRUG|Warfarin|tablets, based on INR levels, according to D-dimer levels
214524459|NCT03912298|OTHER|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
214524460|NCT00724750|DEVICE|Gauze suction (G-SUC)|Negative pressure wound therapy
214524461|NCT00724750|DEVICE|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
214524462|NCT05269303|DEVICE|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
214524463|NCT03410953|BIOLOGICAL|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
215128271|NCT04864249|OTHER|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
215128272|NCT02724332|DRUG|Rapamycin|2mg,po,bid
215128273|NCT05107544|OTHER|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
215128274|NCT01858792|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
215128275|NCT01858792|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
215128276|NCT01858792|OTHER|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
215128277|NCT00300755|DRUG|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
215128278|NCT00276263|DRUG|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
215128279|NCT05532826|OTHER|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
215128280|NCT04442542|OTHER|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
214447931|NCT06845982|OTHER|ultrasound-guided transuterine vaginal biopsy (BVTE)|A BVTE is performed under general anaesthetic in the operating theatre on the scheduled day of myomectomy or hysterectomy. It will be directed to the centre of the uterine smooth muscle tumour in question via an exclusively transuterine route to avoid any peritoneal spread. At least 4 to 5 samples will be taken per uterine smooth muscle tumour, with a maximum of 3 tumours to limit the risk of confusion. The woman will then be operated on as planned during the same operation. All surgical specimens will be sent to the Anatomopathology Department of La Timone for anatomopathological diagnosis after immediate formalin embedding during surgery. Surgical specimens will be analysed as usual.
215128281|NCT04442542|OTHER|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
215128282|NCT00325455|DRUG|MK0859|
215128283|NCT03284606|DEVICE|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
214447932|NCT04076735|PROCEDURE|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
214447933|NCT04076735|PROCEDURE|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
214447934|NCT06843538|DRUG|Tamsulosin|This intervention will investigate if tamsulosin will decrease postoperative urinary retention. Subjects will be directed to start taking the medication 5-7 days prior to their procedure; as previous studies have shown, this is when tamsulosin reaches its steady state. Patients will continue to take their assigned pills for 7 days postoperatively.
214447935|NCT06843538|DRUG|Placebo|This intervention will ensure blinding and an accurate measure of the real effect of tamsulosin.
214524464|NCT00510783|DRUG|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
214694405|NCT02616185|BIOLOGICAL|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
214524465|NCT00510783|DRUG|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
214524466|NCT00510783|DRUG|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
214524467|NCT02744898|DRUG|Carboplatin AUC|
214524468|NCT02744898|DRUG|Abraxane|100mg/m2
214524469|NCT01285596|DRUG|Mirabegron|oral
214524470|NCT02237456|PROCEDURE|Comparison of OCT scans|
214524471|NCT02237456|PROCEDURE|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
214524472|NCT06207084|BEHAVIORAL|asynchronous content only|Receives asynchronous exercise content and no live training
214524473|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
214524474|NCT06207084|BEHAVIORAL|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
214524475|NCT06207084|BEHAVIORAL|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
214694406|NCT02616185|BIOLOGICAL|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
215128284|NCT03284606|PROCEDURE|Common rehabilitation|Common rehabilitation for hemiplegic patients
215128285|NCT04481412|DRUG|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
215128286|NCT04481412|DRUG|Placebo|96% ethanol that will be applied once daily.
215128287|NCT04481412|DRUG|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
215128288|NCT02333461|DIETARY_SUPPLEMENT|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
215128289|NCT02333461|DIETARY_SUPPLEMENT|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
215128290|NCT02333461|DIETARY_SUPPLEMENT|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
215128291|NCT02333461|DIETARY_SUPPLEMENT|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
215128292|NCT02333461|DIETARY_SUPPLEMENT|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
215128293|NCT02503592|OTHER|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
215128294|NCT03547778|DRUG|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
215128295|NCT03547778|DRUG|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
215128296|NCT03192826|DRUG|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
215128297|NCT03192826|DRUG|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
214524476|NCT06207084|BEHAVIORAL|asynchronous content and group training|receives asynchronous content and live group training
214524477|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
214524478|NCT01973478|DEVICE|DBS|
215128298|NCT03192826|DRUG|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
214524479|NCT01973478|DEVICE|SHAM|
214524480|NCT02896556|DEVICE|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
214524481|NCT03955341|DEVICE|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
214524482|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
214524483|NCT05487209|DIAGNOSTIC_TEST|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
214524484|NCT02391714|PROCEDURE|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
214524485|NCT02391714|DRUG|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
214524486|NCT02391714|DRUG|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
214524487|NCT02391714|OTHER|Oxygen|100% oxygen via nasal mask.
214524488|NCT02391714|OTHER|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
215128299|NCT02694744|DRUG|patiromer|8.4 g/day starting dose, administered orally
215128300|NCT01379417|DIETARY_SUPPLEMENT|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
215128301|NCT05224115|OTHER|[11C]CHDI-00485180-R|Mutant huntingtin aggregate binding PET radioligand.
215128302|NCT05224115|OTHER|[11C]CHDI-00485626|Mutant huntingtin aggregate binding PET radioligand.
215128303|NCT01842802|DEVICE|Diode Laser|Diode Laser for treatment of subcutaneous fat
215128304|NCT01842802|DEVICE|YAG laser|YAG laser for treatment of subcutaneous fat
215128305|NCT00686777|BIOLOGICAL|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
215128306|NCT00686777|DRUG|Ribavirin|Ribavirin 400 mg/day orally
215128307|NCT06012123|PROCEDURE|Aortoiliac angioplasty and stenting|Covered endovascular reconstruction of aortic bifurcation (CERAB) in patient with aorto-iliac occlusive disease
215128308|NCT04297865|DRUG|A dose as CJ-15314|A dose as CJ-15314, 1 capsule
215128309|NCT04297865|DRUG|B dose as CJ-15314|B dose as CJ-15314, 1 capsule
215128310|NCT04297865|DRUG|C dose as CJ-15314|C dose as CJ-15314, 1 capsule
215128311|NCT04297865|DRUG|D dose as CJ-15314|D dose as CJ-15314, 2 capsules
215128312|NCT04297865|DRUG|E dose as CJ-15314|E dose as CJ-15314, 1 capsule
215128313|NCT04297865|DRUG|F dose as CJ-15314|F dose as CJ-15314, 2 capsules
215128314|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
215128315|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
215128316|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
215128317|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
215128318|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
214447936|NCT06846892|PROCEDURE|Exercise|Both groups were given a total of 12 sessions of Williams exercises, two days a week, in 20-minute sessions, accompanied by a physiotherapist. Williams back exercises are an exercise method that aims to increase lumbar flexion and strengthen the abdominal and gluteal muscles. The exercise program included pelvic tilts, single and double knee pulls, partial crunches, hamstring stretches, hip flexor stretches and squats. In addition, the patients continued their Williams exercises at home three days a week.
214447937|NCT06845592|RADIATION|total marrow/lymphoid irradiation|Combination of 20 Gy TMLI with Treg/Tcon adoptive immunotherapy in allogeneic cell transplantation
214447938|NCT06844422|DRUG|Ivonescimab|"1. Phase Ib (Dose Escalation):~   In this phase, patients will receive Ivonescimab in escalating doses, with the aim of determining the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended Phase II dose (RP2D). The dose-escalation process will follow a 3+3 design over a 4-week period to establish the RP2D of Ivonescimab.~2. Phase II (Efficacy Evaluation):~After establishing the RP2D, patients will receive Ivonescimab combined with SBRT and modified FOLFIRINOX chemotherapy."
214447939|NCT06844994|OTHER|Manual Diaphragmatic Technique|The intervention will be given 3 days per week for up to 6 weeks starting assessment with modified Borg scale questionnaire will be asked from the patient to evaluate the patient's dyspnea level. The patient at first will be asked to do 5-6 diaphragmatic breathing in upright position and then will be asked to breathe with the breather device after complete inhalation the patient will blow hard in the device. The patient will be asked to inhale and then hold for 2-3 second and breathe out through the device with the 3 sets with each set including 8 repetitions same cycle with relaxed diaphragmatic breathing between each set
214447940|NCT06844994|OTHER|Lateral Coastal Breathing|The group B will be the lateral coastal breathing that will be given 2 times a day, 3 days per week for up to 6 weeks. The patient will be asked by practitioner to perform 4 to 5 times lateral coastal breathing in suitable sitting or lying position
214524489|NCT05324384|DRUG|Sirolimus|Use of different doses of the same drug
214524490|NCT05289778|OTHER|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
214524491|NCT06646367|OTHER|Conventional therapy|All participants in the two groups will receive conventional therapy in the form of TENS and moist heat for 5 weeks.TENS will be applied 5 times a week for 5 weeks at a frequency of 80Hz with 10- to 30-mA intensity for 25 minutes. Four surface electrodes (5x5 cm each) were situated over the painful region in the neck (two electrodes will be placed in either side of the spine high on neck, just underneath the skull and the other two electrodes will be placed about 5cm underneath them) with intensity in the tactile sensation threshold. The hot packs will be applied for 30 minutes on the cervical area, 5 times per week for 5 weeks.
214694407|NCT02616185|DEVICE|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
214694408|NCT02616185|BIOLOGICAL|Tremelimumab|PF-06753388 will be administered every 28 days.
214694409|NCT02616185|BIOLOGICAL|PF-06801591|PF-06801591 will be administered every 28 days.
214694410|NCT02616185|BIOLOGICAL|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
215128319|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
215128320|NCT00516113|DRUG|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
215128321|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
215128322|NCT01370902|DRUG|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
215128323|NCT01370902|DRUG|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
215128324|NCT01370902|DRUG|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
215128325|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
215128326|NCT01370902|DRUG|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
215128327|NCT03803306|COMBINATION_PRODUCT|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
215128328|NCT03803306|OTHER|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
215128329|NCT01808859|DEVICE|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
215128330|NCT01945021|DRUG|Crizotinib|
215128331|NCT01320358|DRUG|ECMPS-IEM|ECMPS-IEM
215128332|NCT03707353|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
215128333|NCT03582215|DRUG|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
215128334|NCT03582215|DRUG|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
214524492|NCT06646367|OTHER|Alexander technique|Women in the experimental group will attend 10 Alexander Technique classes (60 minutes each, twice a week for 5 weeks). The Alexander Technique focuses on body awareness, reducing muscle tension, and improving coordination through three principles: enhanced awareness, purposeful inhibition, and mental imagery. Participants will learn to release habitual muscle tension and explore alternative movement patterns, covering biomechanics and ergonomics of the neck, spine, and limbs. The sessions involve hands-on guidance, verbal instruction, and group activities. Daily practice in a semi-supine position is encouraged to improve posture, coordination, and overall well-being.
214524493|NCT01112163|DEVICE|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
214524494|NCT05165303|DRUG|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
214524495|NCT03158519|BEHAVIORAL|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
214524496|NCT06647212|OTHER|introducing breathing exercises with the harmonica|In addition to regular breathing exercises, participants will perform harmonica exercises
214524497|NCT04002856|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
214524498|NCT05741866|DEVICE|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
215128335|NCT03582215|DRUG|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
215128336|NCT03582215|DRUG|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
215128337|NCT03582215|DRUG|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
215128338|NCT03582215|DRUG|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
215128339|NCT03582215|DRUG|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
215128340|NCT03582215|DRUG|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
215128341|NCT01911715|DRUG|MDV3100|Oral
215128342|NCT03604952|DIAGNOSTIC_TEST|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
215128343|NCT02163902|DRUG|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
215128344|NCT02163902|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
215128345|NCT06403007|BEHAVIORAL|Phonics plus morphology|This intervention trains teachers to teach phonics plus morphology to at-risk poor readers
215128346|NCT06403007|BEHAVIORAL|Phonics plus set-for-variability|This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
214524499|NCT05741866|DEVICE|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
214524500|NCT05082493|DRUG|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
214524501|NCT05680415|BIOLOGICAL|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
215128347|NCT04730908|OTHER|DENTIFRICE|GEL -DENTIFRICE FOR BRUSHING TEETH
215128348|NCT02319330|BEHAVIORAL|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
215128349|NCT02319330|BEHAVIORAL|Treatment as Usual|Routine HIV clinic-based counseling
215128350|NCT05238077|PROCEDURE|Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy|Patients will have different kinds of light shined on different areas
215128351|NCT03636581|BEHAVIORAL|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
215128352|NCT04127721|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
215128353|NCT04127721|DRUG|Busulfan|Given IV
215128354|NCT04127721|DRUG|Fludarabine|Given IV
215128355|NCT04127721|DRUG|Itacitinib|Given PO
215128356|NCT04127721|DRUG|Methotrexate|Given IV
215128357|NCT04127721|DRUG|Tacrolimus|Given IV and PO
215128358|NCT05665036|COMBINATION_PRODUCT|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
215128359|NCT04785222|DRUG|dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine|Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
215128360|NCT03119259|BEHAVIORAL|ABC Clinical Program|"The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary."
215128361|NCT03119259|BEHAVIORAL|BCN|"BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others."
215128362|NCT00983346|DRUG|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
215128363|NCT01032616|OTHER|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
215128364|NCT01032616|OTHER|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
215128365|NCT03267368|BEHAVIORAL|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
215128366|NCT05868603|OTHER|Remineralization gel|Remineralization gel
215128367|NCT02262585|DRUG|BIBR 277 tablet|
214524502|NCT03779776|OTHER|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
214524503|NCT03779776|OTHER|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
215128368|NCT02262585|DRUG|BIBR 277 capsule|
215128369|NCT02050438|PROCEDURE|Total Knee Arthroplasty|
215128370|NCT01286675|DRUG|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
215128371|NCT03293615|OTHER|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
215128372|NCT00003468|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
215128373|NCT06560203|PROCEDURE|Mechanical thrombectomy|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
215128374|NCT00655265|DRUG|Colesevelam hydrochloride film-coated tablets|tablets
215128375|NCT00655265|DRUG|Placebo|Tablets
215128376|NCT01893996|DRUG|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
215128377|NCT01893996|DRUG|Placebo|
214524504|NCT03538457|DRUG|Paracetamol|Patients are tested for their normal prescription paracetamol medication
214524505|NCT05271799|DRUG|Gepotidacin|Gepotidacin will be administered
214694411|NCT05610917|COMBINATION_PRODUCT|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
215128378|NCT04892641|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
215128379|NCT04892641|DRUG|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
215128380|NCT01723241|DRUG|XAF5, concentration A|
214447941|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
214447942|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
214447943|NCT04714034|DIAGNOSTIC_TEST|to develop and validate a scale measuring problematic online dating app (ODA) use in sexual minorities|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of scores in the problematic ODA use scale with sexual health and mental health outcomes."
214447944|NCT06845696|OTHER|kinesiotaping|Before applying the tape, the treated area was cleaned and shaved. A Y strip of the tape was used to facilitate muscle contraction of the semispinalis capitis with 15 -25% tension in elongated muscle position and three I strip are used in it to release tight upper trapezius, facilitate middle trapezius and to correct posture. 3 days a week for 4 weeks
214447945|NCT06845696|OTHER|Brugger relief exercise|This protocol includes that the patient is positioned on edge of a chair with his hips abducted, feet externally rotated, his head up, his forearms supinated, and wrists and fingers extended. the participants were instructed to perform scapular retraction with chin tucked in, shoulder external rotation, elbow extension, shoulder abduction, and extension. While actively moving their arms and spreading their fingers externally, patient exhaled through lips 12 reps 4 set for 3 days a week Intervention will be given for 4 weeks
214447946|NCT04820933|DRUG|Doravirine 100 Mg|Doravirine 100 Mg orally dail
214694412|NCT05610917|COMBINATION_PRODUCT|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
214694413|NCT02366741|RADIATION|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
215128381|NCT01723241|DRUG|XAF5, concentration B|
215128382|NCT01723241|DRUG|XAF5, concentration C|
215128383|NCT01723241|DRUG|Placebo|
215128384|NCT04056416|DEVICE|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
215128385|NCT05478642|OTHER|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
215128386|NCT05356416|OTHER|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
214447947|NCT06846372|DEVICE|occluscence|"The OccluSense handheld is a battery powered device which uses your local wireless network to transmit the recorded data to the OccluSense-iPad-App.~The inductive charger provides wireless power transfer. Fully charged batteries allow up to 4 hours usage of the device."
214447948|NCT06846372|OTHER|patient satisfaction|"• patient satisfaction will be evaluated by using (VAS score) on a line from 0 to 100mm (0 mm is very bad /100 mm is excellent).~Are you satisfied with the esthetic outcome of the treatment? Does the treatment answer to your expectations? Would you choose the same treatment again? Is your ability to chew improved after placement of the implant prothesis? Did you find the complete treatment time too prolonged?"
214447949|NCT06844968|OTHER|Physical effort|The examined rowers will be subjected to an effort on a rowing ergometer, consisting of covering a designated distance in the shortest possible time.
214694414|NCT03871140|OTHER|diagnosis|therre is no intervention diagnosis or treatment for patients
214694415|NCT01346371|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|
214694416|NCT01346371|DRUG|Bepreve 1.5% Ophthalmic Solution|
214694417|NCT04913961|OTHER|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
214694418|NCT04913961|OTHER|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
214694419|NCT00200252|DRUG|oxytocin|
215128387|NCT05356416|OTHER|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
215128388|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
215128389|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
215128390|NCT04986163|DEVICE|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
215128391|NCT04430920|OTHER|Intensive intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 80 mmHg.
215128392|NCT04430920|OTHER|Conventional intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
215128393|NCT03796273|OTHER|Best Practice|Undergo standard surgery
215128394|NCT03796273|DRUG|Ketoconazole|Given PO
215128395|NCT05648253|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
215128396|NCT05837390|DEVICE|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
215128397|NCT05837390|OTHER|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
215128398|NCT05837390|OTHER|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
214447950|NCT06844136|OTHER|No intervention|No intervention
214447951|NCT06847919|DIETARY_SUPPLEMENT|Probiotic yogurt group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
214447952|NCT06847919|DIETARY_SUPPLEMENT|Yogurt control group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
214447953|NCT06847841|PROCEDURE|Double J Stent Placement|Patient in whom a DJS will be placed for post op drainage
214447954|NCT06847841|PROCEDURE|Percutaneous Feeding Tube Placement|Patient in whom a PrcFT will be placed for post op drainage
214447955|NCT06847555|RADIATION|Radiation|Tumor radiotherapy is a method of treating malignant tumors by using radioactive rays such as alpha, beta, gamma rays produced by radioactive isotopes and x-rays, electron rays, proton beams and other particle beams produced by various x-ray therapy machines or accelerators.
214524506|NCT01920399|DRUG|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
214524507|NCT01920399|DRUG|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
214524508|NCT04789616|DRUG|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
214524509|NCT04789616|BEHAVIORAL|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
214524510|NCT04789616|OTHER|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
214694420|NCT04224896|DIAGNOSTIC_TEST|UPPER ENDOSCOPY|UPPER ENDOSCOPY
214694421|NCT02320695|DRUG|Saline|
214694422|NCT02320695|DRUG|Isopropyl Alcohol|
214694423|NCT02320695|DRUG|Pain Relieving Cream|
214694424|NCT02320695|DRUG|Antibiotic/Pain Relieving Ointment|
214694425|NCT02320695|DRUG|Original Ointment|
214694426|NCT02320695|DRUG|Pain Relief Ointment|
215128399|NCT05346575|BEHAVIORAL|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
215128400|NCT05346575|BEHAVIORAL|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
215128401|NCT06063161|BEHAVIORAL|Music therapy intervention|Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.
215128402|NCT06063161|OTHER|Non-guided music listening|Participants will listen to generic music playlists.
215128403|NCT06063161|OTHER|Standard of care|placebo arm, routine standard of care
215128404|NCT06054607|DIETARY_SUPPLEMENT|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
215128405|NCT06054607|OTHER|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
215128406|NCT05622604|BEHAVIORAL|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
215128407|NCT05622604|BEHAVIORAL|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
215128408|NCT03693521|DEVICE|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
215128409|NCT03693521|OTHER|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
215128410|NCT01745926|DEVICE|MECHANICAL CHEST COMPRESSION|
215128411|NCT06085534|DRUG|LNK01001|Capsules for oral use
215128412|NCT06085534|DRUG|Placebo|Capsules for oral use
214447956|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
215128413|NCT02083471|DIETARY_SUPPLEMENT|Specific Oral Tolerance Induction with Egg or Cow's milk|
215128414|NCT04484558|DRUG|Actilyse|Infusion
215128415|NCT02903160|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
214447957|NCT06846424|BIOLOGICAL|SCT-001 CAR-T cells|SCT-001 CAR-T cells are autologous-derived CAR-T cell products, which transduce second-generation CAR targeting TAG-72 into patient autologous T cells by lentiviral transfection, and knock out immunosuppressive related genes by CRISPR/Cas9 technology to enhance the anti-tumor function of CAR-T cells.
214447958|NCT05461131|BIOLOGICAL|BPZE1|Live attenuated vaccine
214447959|NCT05461131|BIOLOGICAL|Placebo|Placebo
214694427|NCT01432197|OTHER|ADL intervention|1\) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
214694428|NCT02456545|OTHER|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
214694429|NCT02456545|OTHER|depressive syndrome|in- and outpatients with depressive syndrome
215128416|NCT02903160|DRUG|Prednisone|5 mg PO twice a day
215128417|NCT02903160|DRUG|Radium-223 dichloride|50 kBq/kg IV monthly
215128418|NCT02903160|DRUG|cabazitaxel|25 mg/m2 IV every 3 weeks
215128419|NCT02903160|DRUG|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
215128420|NCT02903160|DRUG|Enzalutamide|160 mg PO daily
215128421|NCT01838317|DRUG|Pioglitazone|
215128422|NCT01664910|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
215128423|NCT01664910|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
215128424|NCT01664910|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214447960|NCT05461131|DRUG|Azithromycin|Antibiotic
215128425|NCT01664910|DRUG|Bendamustine Hydrochloride|Given IV
215128426|NCT01664910|DRUG|Fludarabine Phosphate|Given IV
215128427|NCT01664910|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
215128428|NCT01664910|DRUG|Methotrexate|Given IV
215128429|NCT01664910|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
215128430|NCT01664910|BIOLOGICAL|Rituximab|Given IV
215128431|NCT01664910|DRUG|Tacrolimus|Given IV or PO
215128432|NCT02203877|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
215128433|NCT02203877|DIETARY_SUPPLEMENT|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
215128434|NCT00274248|DRUG|MLN518|
215128435|NCT01009541|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
215128436|NCT01009541|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
215128437|NCT01009541|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
215128438|NCT01009541|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
215128439|NCT03272750|DIETARY_SUPPLEMENT|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
215128440|NCT03272750|DIETARY_SUPPLEMENT|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
215128441|NCT03272750|DIETARY_SUPPLEMENT|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
215128442|NCT03236896|BEHAVIORAL|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
215128443|NCT03236896|BEHAVIORAL|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
215128444|NCT02006316|PROCEDURE|Microsurgical subinguinal varicocelectomy|
215128445|NCT00302809|DIETARY_SUPPLEMENT|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
215128446|NCT02374164|DRUG|Febuxostat XR|Febuxostat XR capsules
215128447|NCT06112483|BEHAVIORAL|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn \& Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
215128448|NCT04376216|DRUG|Prednisone|60 mg with dose tapering over 2 months
215128449|NCT01082250|DRUG|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
215128450|NCT01127243|PROCEDURE|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
215128451|NCT01127243|PROCEDURE|inpatient LSH|patients discharged home the day after the operation
215128452|NCT04969029|DRUG|Tirelizumab|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
215128453|NCT00730158|DRUG|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
215128454|NCT00730158|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
215128455|NCT00730158|DRUG|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
215128456|NCT04678115|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.
215128457|NCT04678115|DEVICE|Kinesiotape Frontalis Sling (KTFS)|Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
215128458|NCT01051674|OTHER|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
215128459|NCT01012986|OTHER|Assessment of reading skills|
215128460|NCT01055561|OTHER|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
215128461|NCT04034303|GENETIC|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
215128462|NCT05757986|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
215128463|NCT01459484|DRUG|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
214694430|NCT02456545|OTHER|ADHD|in- and outpatients with ADHD
215128464|NCT01459484|OTHER|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
215128465|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
215128466|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
215128467|NCT01168349|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
215128468|NCT01757106|DRUG|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
215128469|NCT01757106|DRUG|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
215128470|NCT02257034|OTHER|Taichi|
215128471|NCT02257034|OTHER|Dance|
215128472|NCT02185703|DEVICE|Chordate System S020 in treatment mode|
215128473|NCT02185703|DEVICE|Chordate System S020 in placebo mode|
214447961|NCT05461131|OTHER|Bordetella Pertussis Challenge Strain|Challenge Strain
214447962|NCT01518556|DRUG|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
214447963|NCT03896516|OTHER|Placebo|Participants receive Placebo orally twice daily.
214447964|NCT03896516|DRUG|GLWL-01|GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
214447965|NCT06845059|OTHER|"11 For Health"|"Participants will participate in the 11 For Health program, consisting of 11 sessions over 11 weeks. The program combines football skills with health education to promote overall health and well-being."
214447966|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
214447967|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
214447968|NCT04700111|DEVICE|DOT Pattern|DOT Pattern Spectacle Lens
214447969|NCT04700111|DEVICE|Control Spectacles|Control lens
214447970|NCT06412016|BEHAVIORAL|Peer Nutritional Counseling + Urban Gardening|Peer nutritional counseling and urban gardens
214447971|NCT00186927|BIOLOGICAL|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
214447972|NCT04172441|DRUG|dasiglucagon|Glucagon analogue
214447973|NCT04172441|DRUG|Placebo|Placebo for dasiglucagon
214447974|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
214447975|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
214447976|NCT03687528|RADIATION|CT-scanner|After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
214447977|NCT06845033|OTHER|LEAP2 infusion|The LEAP2 infusion is a hormone infusion that is different from the placebo (saline) infusion
215128474|NCT04485897|DEVICE|icare HOME device (Icare Oy, Vanda, Finland)|icare HOME device versus hospital based measurements
215128475|NCT04059549|BEHAVIORAL|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
215128476|NCT04059549|BEHAVIORAL|A-CHESS|A-CHESS control group
214447978|NCT06845033|OTHER|Placebo|Placebo infusion (saline) is different from the LEAP2 infusion
214447979|NCT06847607|DRUG|Iptacopan|Iptacopan
214524511|NCT04789616|DEVICE|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
214524512|NCT04789616|BEHAVIORAL|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
214524513|NCT01391533|DRUG|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
214524514|NCT04277273|OTHER|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
214524515|NCT02944526|DRUG|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
214524516|NCT02944526|DRUG|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
214524517|NCT03252899|OTHER|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
214524518|NCT03252899|OTHER|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
214694431|NCT06238245|DRUG|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
214694432|NCT00239187|DRUG|E1 and G1|
214694433|NCT00074724|PROCEDURE|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
214694434|NCT00074724|DRUG|Modern medical management|Therapies with evidence-based recommendations.
214694435|NCT00074724|DEVICE|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
214694436|NCT00074724|DRUG|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
214694437|NCT04004559|OTHER|No interventions|As this is a patient registry, there are no interventions.
214708817|NCT05037669|BIOLOGICAL|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
215128477|NCT04676295|BEHAVIORAL|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
215128478|NCT02639494|DEVICE|Self-Centering Guide Catheter|
215128479|NCT04581226|DIAGNOSTIC_TEST|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
215128480|NCT03195816|BEHAVIORAL|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
215128481|NCT00988884|BIOLOGICAL|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
215128482|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
215128483|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
215128484|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
215128485|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
215128486|NCT00752050|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
214447980|NCT06844578|OTHER|Experimental Group|"specific intervention programme in the experimental group, which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. The programme will be aimed at improving various functional capacities, through specifically designed exercises, including:~* Unipodal stability: Exercises focused on strengthening balance by maintaining a posture on one foot, which is key to preventing falls and improving postural stability.~* Gait re-education: Activities aimed at correcting and adjusting gait technique, promoting an efficient and safe movement pattern.~* Muscle strength: Exercises aimed at muscle strengthening, especially in the lower limbs, to increase endurance and stability during daily activities.~* Stationary walking: Practices that simulate stationary walking, improving cardiovascular endurance and motor coordination."
214447981|NCT06844578|OTHER|Active comparator Group|"which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. Participants who will exclusively receive an intervention based on gerontogymnastics.~This programme will include a series of exercises adapted to the needs of the older adult population, with an emphasis on improving balance, muscle strength, flexibility and motor coordination. These include:~* Shoulder raises~* Hip flexion~* Knee flexion~* Trunk rotations~* Ankle dorsiflexion"
214447982|NCT06396611|BEHAVIORAL|Exercise Training as Intervention|Supervised Exercise Training as an Intervention using Resistance Training.
214447983|NCT06847178|DIETARY_SUPPLEMENT|Placebo twice daily in blinding|Administered placebo twice-daily for 12 weeks in blinding
214447984|NCT06847178|DRUG|Low-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
214447985|NCT06847178|DRUG|High-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
214447986|NCT06847178|DRUG|High-dose LCZ300-1 twice daily in open-label|Administered high-dose LCZ300-1 twice-daily for 12 weeks in open-label
214447987|NCT06846437|DRUG|JSKN003|Administered intravenously according to protocol.
214708818|NCT03385499|BIOLOGICAL|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
214708819|NCT04777474|DIAGNOSTIC_TEST|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
215128487|NCT00752050|DRUG|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
215128488|NCT01632020|DRUG|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
215128489|NCT01632020|DRUG|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
215128490|NCT04368260|DEVICE|Control swab|FDA-cleared nasopharyngeal swab
215128491|NCT04368260|DEVICE|Prototype swab|Injection molded polypropylene flocked nylon nasopharyngeal swab
215128492|NCT05553795|PROCEDURE|Early removal of chest drain|Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.
215128493|NCT05553795|PROCEDURE|Chest drain|The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
215128494|NCT02906423|OTHER|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
215128495|NCT00420576|DRUG|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
215128496|NCT01239966|DEVICE|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
215128497|NCT01929590|DRUG|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
215128498|NCT01929590|DRUG|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
215128499|NCT01929590|DRUG|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
215128500|NCT00763113|DEVICE|Vanguard PS Knee|Vanguard PS Knee
215128501|NCT00763113|DEVICE|Vanguard CR Knee|Vanguard CR Knee
214447988|NCT06846437|DRUG|Trastuzumab emtansine (T-DM1)|Administered intravenously according to the approved label.
214524519|NCT01825018|BEHAVIORAL|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
214524520|NCT01825018|BEHAVIORAL|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
214524521|NCT03606863|DRUG|Perioperative peripheral parenteral nutrition|
214524522|NCT04241380|DRUG|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
214524523|NCT04241380|OTHER|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
214524524|NCT04241380|DRUG|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
215128502|NCT01861626|DRUG|V0057 - A mg|Single oral administration
215128503|NCT01861626|DRUG|Isotretinoin|Single oral administration
215128504|NCT05311735|PROCEDURE|Freeze-Dried Bone Allograft control|Bone grafting to prevent alveolar ridge collapse after tooth removal
215128505|NCT05311735|PROCEDURE|Mineralized Dentin Graft|Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
215128506|NCT05311735|PROCEDURE|Partial-Demineralized Dentin Graft|Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
215128507|NCT01362348|DRUG|pazopanib eye drops|10 mg/mL (1 drop) four times daily
215128508|NCT01021735|DRUG|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
215128509|NCT01021735|DRUG|Rituximab|1g x2 by IV infusion repeated every 5 months or more
215128510|NCT02266316|DEVICE|Air warming mask|Mask that warms air at the mouth
215128511|NCT06020898|DRUG|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
215128512|NCT06020898|DRUG|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
215128513|NCT06011408|OTHER|TDtect|Collecting video data on abnormal movement
215128514|NCT02851303|DRUG|Morphine|Morphine wean protocol as described in arm description
215128515|NCT02851303|DRUG|Methadone|Methadone wean protocol as described in arm description
215128516|NCT06451302|DRUG|cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide|The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
215128517|NCT01747512|DRUG|C-PERT|Patients with thyroid and Head and Neck cancer
215128518|NCT01747512|DRUG|G-PERT|Patients with thyroid and Head and Neck cancer
215128519|NCT03168477|OTHER|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
215128520|NCT03168477|OTHER|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
215128521|NCT03168477|OTHER|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
215128522|NCT03168477|OTHER|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
215128523|NCT03168477|OTHER|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
215128524|NCT04954508|DIAGNOSTIC_TEST|The hug-up test|It is a new physical test used to detect supraspinatus tear
215128525|NCT04954508|DIAGNOSTIC_TEST|EC test|It is a traditional physical test used to detect supraspinatus tear
215128526|NCT04954508|DIAGNOSTIC_TEST|FC test|It is a traditional physical test used to detect supraspinatus tear
215128527|NCT04954508|DIAGNOSTIC_TEST|Neer impingement sign|It is a traditional physical test used to detect supraspinatus tear
215128528|NCT04954508|DIAGNOSTIC_TEST|Hawkins-Kennedy impingement sign|It is a traditional physical test used to detect supraspinatus tear
215128529|NCT04954508|DIAGNOSTIC_TEST|diagnostic arthroscopy|The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (\>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
215128530|NCT02866058|PROCEDURE|Cesarean Section|
215128531|NCT05239481|DEVICE|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
215128532|NCT05239481|DEVICE|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
215128533|NCT00934453|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
215128534|NCT00934453|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
215128535|NCT01301807|DRUG|Carfilzomib|Given IV
215128536|NCT01301807|DRUG|Panobinostat|Given PO
215128537|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
214524525|NCT04194671|BIOLOGICAL|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
215128538|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
215128539|NCT05724732|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
215128540|NCT05993663|BEHAVIORAL|Arts in health group intervention|12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
215128541|NCT00647296|DRUG|Placebo|Placebo: 2 tablets taken orally twice daily
215128542|NCT00647296|DRUG|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
215128543|NCT00647296|DRUG|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
215128544|NCT00647296|DRUG|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
214524526|NCT04194671|OTHER|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
214524527|NCT05118737|DRUG|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
215128545|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
215128546|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
215128547|NCT05753839|OTHER|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
214524528|NCT02453971|OTHER|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
215128548|NCT01787461|DIETARY_SUPPLEMENT|Imedeen|Two tablets per day for 6 months
215128549|NCT01787461|DIETARY_SUPPLEMENT|Placebo|Two tablets per day for 6 months
215128550|NCT02304939|PROCEDURE|changeover|
214524529|NCT06493448|OTHER|observation|This is an observational study.
214524530|NCT01348763|DRUG|Maraviroc|Maraviroc 150 mg daily
214524531|NCT01348763|DRUG|Truvada|daily until 10. day then stop
215128551|NCT02304939|DEVICE|use of automatic infusion pump|
215128552|NCT02304939|BEHAVIORAL|datas collection|
215128553|NCT03679728|BEHAVIORAL|First trimester|Analysis of sensorimotor outcomes
215128554|NCT03679728|BEHAVIORAL|Second trimester|Analysis of sensorimotor outcomes
215128555|NCT04582786|DRUG|Morphine|Repeated bolus according to pain score
215128556|NCT04582786|DRUG|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
215128557|NCT04582786|DRUG|STR-324|Infusion of solution for intravenous administration
215128558|NCT01736111|BEHAVIORAL|one way text|
215128559|NCT01736111|BEHAVIORAL|Personal feedback|
215128560|NCT00359255|BEHAVIORAL|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
215128561|NCT00359255|BEHAVIORAL|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
215128562|NCT01034514|DEVICE|Real-time Position Management system|Standard of Care
215128563|NCT01034514|DEVICE|Discovery ST multislice PET/CT scanner|Standard of Care
215128564|NCT01034514|DEVICE|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
215128565|NCT01034514|DEVICE|Pinnacle3 treatment planning system|Standard of Care
215128566|NCT01034514|DEVICE|SKYLight nuclear camera|Standard of Care
215128567|NCT01034514|DRUG|DTPA|1 mCi; inhalation
215128568|NCT01034514|DRUG|TECHNETIUM TC 99M MAA|3 mCi; iv
215128569|NCT02609061|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
215128570|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
215128571|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
215128572|NCT00720590|DRUG|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
215128573|NCT00720590|DRUG|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
214447989|NCT06845137|OTHER|Tactile-Kinesthetic Stimulation (TKS) and Soft Tissue Manipulation (STM)|"Tactile-Kinesthetic Stimulation (TKS): TKS involves the application of tactile (touch) and kinesthetic (movement) stimuli to various parts of the body. This technique aims to enhance sensory awareness and motor control. TKS can include gentle tapping, brushing, or vibration on the skin, joints, or muscles. The sensory input provided through TKS helps in proprioceptive feedback, which is essential for improving body awareness, coordination, and movement patterns. It is often used in neurological rehabilitation to facilitate neuromuscular re-education and in pediatric therapy to promote sensory integration.~Soft Tissue Manipulation (STM): STM involves various manual techniques applied to the soft tissues of the body, including muscles, tendons, ligaments, and fascia. These techniques can range from gentle stretching and mobilization to deeper techniques such as myofascial release, trigger point therapy, and deep tissue massage. STM aims to alleviate muscle tension, improve flexibility,"
214524532|NCT01348763|DRUG|Darunavir|daily until 10. day then stop
214524533|NCT01078571|BIOLOGICAL|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
214524534|NCT00574106|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
214524535|NCT02595593|DEVICE|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
214524536|NCT00029276|PROCEDURE|Prefrontal transcranial magnetic brain stimulation|
214524537|NCT01132378|PROCEDURE|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
214524538|NCT03647709|OTHER|opioids|dosage frequency and duration
214524539|NCT05068687|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
214708820|NCT04777474|DIAGNOSTIC_TEST|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
214708821|NCT04777474|DIAGNOSTIC_TEST|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
215128574|NCT00720590|DRUG|Placebo|Daily dose of placebo for 4 weeks
215128575|NCT05743803|OTHER|Sensititization campaign on preoperative fasting rules|"* Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~* Reminder display in surgical wards and consults.~* Individualized fasting cards for patients.~* Short message service reminder on pre-operative fasting rules for patients.~* Medical fasting prescription with clear fasting times."
215128576|NCT02537717|DEVICE|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
215128577|NCT02537717|DEVICE|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
215128578|NCT03133247|DRUG|SHR-1316|PD-L1
215128579|NCT00005617|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
215128580|NCT00005617|PROCEDURE|leukapheresis|Patients require a single leukapheresis to obtain 2x10\^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
214447990|NCT06845137|OTHER|Standard Therapy|Nursing care for preterm neonates involves a higher level of monitoring and specialized support due to their underdeveloped physiological systems. Nurses focus on maintaining thermal regulation through incubators or radiant warmers to prevent hypothermia, as preterm infants are more vulnerable to temperature instability. Respiratory support is critical, often requiring continuous positive airway pressure (CPAP) or mechanical ventilation to assist with immature lungs. Nutritional support is provided through intravenous fluids or gavage feeding (tube feeding) if the infant is not yet able to breastfeed or bottle-feed. Nurses also monitor for complications such as hypoglycemia, infection, and jaundice and administer antibiotics, vitamin K, and eye prophylaxis as needed. Developmentally supportive care is emphasized, including minimizing sensory overload and encouraging kangaroo care (skin-to-skin contact) to support bonding, promote growth, and help regulate the neonate's heart rate, temp
214447991|NCT06846632|DEVICE|PEEK|placement of PEEK after maxillary sinus lifting
214447992|NCT06846632|DEVICE|titanium meshwork|placement of titanium meshwork after maxillary sinus lifting
214447993|NCT06846593|DEVICE|Semiconductor Embedded Therapeutic Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
214447994|NCT06846593|DEVICE|Placebo Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
214447995|NCT06846593|OTHER|Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections|patients will choose or opt out of these standard of care injections.
215128581|NCT01014130|RADIATION|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
215128582|NCT01014130|RADIATION|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
215128583|NCT00064363|DRUG|talampanel|
215128584|NCT00251459|DRUG|rhuFab V2 (ranibizumab)|
215128585|NCT05195567|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
215128586|NCT05195567|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
215128587|NCT03471312|DRUG|Magnesium|magnesium therapy
215128588|NCT02515734|DRUG|fluorouracil|
215128589|NCT02515734|DRUG|Leucovorin|
215128590|NCT02515734|DRUG|irinotecan|
214447996|NCT06468501|BEHAVIORAL|Price reduction on healthier foods|Price reduction (10%) on healthier foods based on the UK NPM
214447997|NCT06468501|BEHAVIORAL|Price increase to less healthy foods|Price increase (10%) on less healthy foods based on the UK NPM
214447998|NCT06468501|BEHAVIORAL|Combination of price reduction on healthier foods and price increase on less healthy foods|Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
214447999|NCT06468501|BEHAVIORAL|Control|Existing price structure
214448000|NCT06522464|OTHER|Group A: mCIMT with cross-education|"For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands (18). We'll utilize weight cuffs for every activity."
214448001|NCT06522464|OTHER|Group B: mCIMT without cross-education|For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
214448002|NCT04674358|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
214448003|NCT04674358|DRUG|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
214524540|NCT04007822|BEHAVIORAL|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
214524541|NCT04018534|BEHAVIORAL|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
214524542|NCT04018534|BEHAVIORAL|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
215128591|NCT02515734|DRUG|oxaliplatin|
215128592|NCT02515734|BIOLOGICAL|bevacizumab|
215128593|NCT02515734|BIOLOGICAL|cetuximab|
215128594|NCT01259180|PROCEDURE|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
215128595|NCT01259180|PROCEDURE|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
215128596|NCT00951366|OTHER|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
215128597|NCT03416140|OTHER|Therapeutic Exercise|30 minutes per day of therapeutic exercise
215128598|NCT05009277|DEVICE|Device|LINDA thermal device
215128599|NCT01673828|DRUG|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
215128600|NCT01673828|DRUG|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
214448004|NCT06180694|OTHER|Reminiscence therapy|Reminiscence therapies will be applied to individuals with dementia in 45-minute sessions once a week for 8 weeks.
214448005|NCT06502444|BEHAVIORAL|Moving Forward Together Activity Intervention|The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
214448006|NCT05276492|DRUG|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
214448007|NCT05276492|DRUG|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
214448008|NCT05276492|OTHER|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
214448009|NCT05276492|DRUG|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
214448010|NCT03648840|BEHAVIORAL|Aversive Cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
214448011|NCT03648840|BEHAVIORAL|Neutral Cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
214524543|NCT04018534|BEHAVIORAL|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
214524544|NCT05915884|OTHER|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
214524545|NCT05045638|DRUG|Rosuvastatin|Oral dose
215128601|NCT06811727|DRUG|Continuos ceftazidime/avibactam infusion|Continuous infusion will include a loading dose of 2 g/0.5 g administered over 2 hours, followed by continuous infusion of 6 g/1.5 g over 24 hours, equivalent to 0.25 g of ceftazidime per hour. The drug reconstitution and dilution process are shown in Figure 2. The final volume of solution of CZA will be 50 mL, which gives concentration of ceftazidime of 40 mg/mL, with 4:1 concentration ratio for avibactam (10 mg/mL). The solution will be administered via an infusion syringe, with an infusion rate of 6.25 mL/h. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula
215128602|NCT06811727|DRUG|Intermitent dosing as per SMPC|Intermittent dosing, as outlined in the SmPC, consists of 2 g/0.5 g administered by prolonged infusion over 2 hours every 8 hours. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula.
215128603|NCT06784349|DRUG|ALN-APOC3|Administered as per the protocol
215128604|NCT06784349|DRUG|Matching Placebo|Administered as per the protocol
215128605|NCT06462053|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
215128606|NCT06462053|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg d1 q3w
215128607|NCT06462053|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
214448012|NCT06060626|DRUG|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
214448013|NCT06060626|DRUG|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
214524546|NCT05045638|DRUG|Sotorasib|Oral dose
214524547|NCT03802513|OTHER|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
214708822|NCT00329394|DRUG|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
215128608|NCT06462053|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
215128609|NCT06462053|DRUG|Capecitabine|Xeloda
215128610|NCT06727071|PROCEDURE|Hyperglycemic clamp|A continuous infusion of 20% dextrose will be maintained throughout the procedure, while a variable rate of insulin infusion will be used to control participants blood glucose level.
215128611|NCT06928571|BEHAVIORAL|Connect4Health Engage|Intervention focused on motivating and guiding patients to use empirically supported, freely available online tools for weight loss.
215128612|NCT06928571|BEHAVIORAL|Connect4Health Discover|Educational control - information about healthy eating and physical activity
215128613|NCT01403623|PROCEDURE|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
215128614|NCT01403623|PROCEDURE|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
215128615|NCT06937606|BEHAVIORAL|Self-compassion training|Online group intervention: led by a certified mindfulness teacher for mindful self-compassion and additional qualification in self-compassion in healthcare communities (duration: 6 weekly appointments of 90 min each);
215128616|NCT06938880|BIOLOGICAL|ZGGS18 for Injection|Intravenous infusion
215128617|NCT06938880|BIOLOGICAL|ZG005 for Injection|Intravenous infusion
215128618|NCT06939218|BEHAVIORAL|Countermovement Jump (CMJ)|Participants perform a vertical jump starting from a standing position, bending their knees to 90 degrees, and then jumping as high as possible. The height of the jump is measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
215128619|NCT06939218|BEHAVIORAL|Repeated Jump Test|Participants perform repeated vertical jumps for 20 seconds, with the height of each jump measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
215128620|NCT06939218|BEHAVIORAL|Repeated Sprint Ability (RSA) Test|articipants perform six 30-meter sprints with 20 seconds of rest between each sprint. Sprint times are measured using photocell timing gates (RaceTime, Microgate, Bolzano, Italy).
215128621|NCT06939218|BEHAVIORAL|Maximum Sprint Test|Participants perform three maximum effort sprints over 40 meters. Sprint times and speeds are measured using 1080 motion analysis
215128622|NCT06939218|BEHAVIORAL|Change of Direction (COD) Test|Participants perform a sprint with a change of direction, running 5 meters in one direction and then 5 meters at a 90-degree angle. The time to complete the test is measured.
215128623|NCT06939218|BEHAVIORAL|Shooting Test|Participants perform a shooting test, aiming to hit a target with maximum speed. The speed of the shot is measured using radar.
215128624|NCT06939218|BEHAVIORAL|Small side game test|Participants engage in a 5v5 small-sided game on a 600 m² field to simulate match conditions and assess performance in a game-like scenario.
215128625|NCT06939218|BEHAVIORAL|Performance and Comfort Perception Questionnaire|Participants complete a questionnaire to assess their perception of performance and comfort on the surface, using a Visual Analogue Scale (VAS).
215128626|NCT06939218|BEHAVIORAL|Perceived Exertion Questionnaire|Participants complete a questionnaire to assess their perceived exertion during the tests, using the Borg scale
215128627|NCT01704027|RADIATION|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)"
215128628|NCT01704027|DRUG|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
215128629|NCT06525285|PROCEDURE|Connective tissue graft wall technique|Harvested connective tissue graft will be placed over the exposed root surface like a wall to cover the gingival recession
215128630|NCT06173830|OTHER|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
215128631|NCT06173830|OTHER|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
215128632|NCT00432484|DRUG|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
215128633|NCT01519323|DRUG|vemurafenib|Cohort 1 (participants \>=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
215128634|NCT02493439|BEHAVIORAL|Best Possible Self|
215128635|NCT02493439|BEHAVIORAL|Daily Activities|
215128636|NCT04325971|OTHER|Neuroimaging|MR, EEG recordings
215128637|NCT05498610|DRUG|NNC0480 0389|"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
215128638|NCT05498610|DRUG|Semaglutide|"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
214524548|NCT02382913|BIOLOGICAL|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
214524549|NCT02382913|BIOLOGICAL|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
215128639|NCT05354661|DEVICE|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
215128640|NCT03908801|BEHAVIORAL|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
215128641|NCT01572207|BEHAVIORAL|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
215128642|NCT01572207|BEHAVIORAL|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
215128643|NCT00379535|DRUG|potassium iodide|per os
215128644|NCT00379535|DRUG|placebo|per os
215128645|NCT03658421|DRUG|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
214524550|NCT02382913|BIOLOGICAL|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
215128646|NCT03658421|PROCEDURE|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
215128647|NCT03658421|DEVICE|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
215128648|NCT03658421|PROCEDURE|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
215128649|NCT00383552|DRUG|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
215128650|NCT00383552|DRUG|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
214448014|NCT03739450|BEHAVIORAL|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
215128651|NCT00383552|DRUG|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
215128652|NCT00383552|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
215128653|NCT01590030|PROCEDURE|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
215128654|NCT01925560|OTHER|Agave Inulin|3x3 Latin square with 3 periods
215128655|NCT01925560|OTHER|Placebo|control- 0 (zero) grams/day inulin
215128656|NCT00002328|DRUG|Azithromycin|
215128657|NCT05738135|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
214448015|NCT03739450|BEHAVIORAL|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
214448016|NCT05688410|OTHER|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
214448017|NCT05688410|BEHAVIORAL|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
214524551|NCT03623308|OTHER|Fiber cereal|Whole grain and bran cereal
215128658|NCT05738135|DRUG|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
215128659|NCT00232765|DEVICE|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
215128660|NCT00232765|DEVICE|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
215128661|NCT05574686|BEHAVIORAL|Telehealth Blood Pressure Monitoring and Food Insecurity|Telehealth Blood Pressure Monitoring and Food Insecurity
215128662|NCT03096834|BIOLOGICAL|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
215128663|NCT03096834|BIOLOGICAL|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
215128664|NCT00242268|DRUG|Simvastatin|
215128665|NCT02669953|DRUG|Aflibercept|
215128666|NCT00433173|PROCEDURE|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
215128667|NCT00433173|DRUG|testosterone|transdermal 7.5 g/per day for 3 months
215128668|NCT00433173|DRUG|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
215128669|NCT00433173|DRUG|goserelin acetate implant|single depot injection 10.8 mg 3 months
215128670|NCT00433173|PROCEDURE|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
215128671|NCT00433173|PROCEDURE|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
215128672|NCT00433173|PROCEDURE|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
215128673|NCT00433173|PROCEDURE|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
215128674|NCT00433173|PROCEDURE|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
215128675|NCT00433173|PROCEDURE|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
215128676|NCT01043068|DRUG|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
215128677|NCT04085575|DRUG|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
215128678|NCT00966654|DRUG|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
215128679|NCT00966654|DRUG|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
215128680|NCT04890860|OTHER|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
215128681|NCT06290115|OTHER|Questionnaires set 1|Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
215128682|NCT06290115|OTHER|Questionnaires set 2|Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
215128683|NCT06290115|OTHER|Questionnaires set 3|Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
215128684|NCT00575185|DRUG|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
215128685|NCT00575185|DRUG|placebo|Placebo tablets orally twice daily for 21 days.
215128686|NCT02156843|DRUG|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
215128687|NCT02156843|DRUG|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
215128688|NCT04416204|OTHER|glycogen loading|Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
215128689|NCT04416204|OTHER|No Glycogen Loading|Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
215128690|NCT02516280|DEVICE|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
215128691|NCT02516280|DEVICE|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
215128692|NCT02372604|DRUG|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))"
214448018|NCT04381130|DRUG|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
214448019|NCT05930600|DEVICE|Ultrasonography of Internal Jugular Vein|Non invasive monitoring of fluid responsiveness
214448020|NCT05930600|DEVICE|Doppler Echocardiograhy|Non invasive monitoring of fluid responsiveness
214448021|NCT06527586|DEVICE|soft contact lens|Vision Correction
214448022|NCT06076837|DRUG|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
215128693|NCT02372604|DRUG|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet"
215128694|NCT04892498|RADIATION|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
215128695|NCT04892498|DRUG|PD-1 inhibitor|q3w, until PD
215128696|NCT04892498|DRUG|GM-CSF|200μg, D1-D7, ≥8 cycles
215128697|NCT04892498|DRUG|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
215128698|NCT03858049|DRUG|Crinone|Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
215128699|NCT03858049|DRUG|Duphaston|Participants received 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoign pregnancy was confirmed up to Day 63.
215128700|NCT04456504|BIOLOGICAL|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
215128701|NCT05718947|DIAGNOSTIC_TEST|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
215128702|NCT02429323|DRUG|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
215128703|NCT04017221|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
215128704|NCT04017221|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
214448023|NCT06076837|DRUG|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
215128705|NCT04017221|DRUG|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
215128706|NCT03472625|DIAGNOSTIC_TEST|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
215128707|NCT04617782|COMBINATION_PRODUCT|Donepezil TDS|Transdermal Delivery System
215128708|NCT04617782|DRUG|Aricept|Oral
215128709|NCT00490087|DEVICE|Levonorgestrel intrauterine device (IUD)|
215128710|NCT00251524|DRUG|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
215128711|NCT03571230|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
214448024|NCT06076837|DRUG|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
214448025|NCT06076837|DRUG|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
214448026|NCT06076837|DRUG|Nab paclitaxel|microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
214448027|NCT06076837|DRUG|Gemcitabine|a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer
214448028|NCT06076837|DRUG|Cisplatin|platinum-based drug indicated for the treatment of advanced cancers
214448029|NCT03219697|BEHAVIORAL|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
214448030|NCT04318197|OTHER|Personalized rehabilitation program with electrostimulation|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.
214448031|NCT04318197|OTHER|Global rehabilitation program|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
214448032|NCT05007613|DRUG|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
214694438|NCT02123563|OTHER|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
214694439|NCT02123563|OTHER|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
214694440|NCT05140954|DRUG|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
215128712|NCT03571230|DRUG|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
215128713|NCT03571230|DRUG|one proton pump inhibitor(PPI)|All the patients need this drug.
215128714|NCT03571230|DRUG|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
215128715|NCT03571230|DRUG|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
214448033|NCT05007613|DRUG|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
214448034|NCT06336785|DEVICE|Restylane line of soft tissue fillers and Dysport neuromodulator|Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
214448035|NCT06259396|BEHAVIORAL|The 8x5 Diet|A virtual, dietitian-counselled, healthy dietary pattern defined by its fat intake, its daily eating pattern, keeping adequately hydrated, having a variety of whole grains, fruit and vegetables, and use of certain plant fibres.
214448036|NCT05119972|DRUG|ZSP1603|ZSP1603 administered orally
214448037|NCT05119972|DRUG|Placebo|Placebo administered orally
214448038|NCT05382936|DRUG|SL-901|Patients took study medication daily, with dosage based on their assigned cohort and regimen.
214448039|NCT06068075|OTHER|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
214448040|NCT03175666|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214448041|NCT03175666|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
214448042|NCT03175666|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214448043|NCT03175666|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214448044|NCT03175666|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214448045|NCT03175666|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214448046|NCT03175666|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214448047|NCT03175666|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214448048|NCT03175666|DRUG|Lovaza|omega-3-acid ethyl esters)
214448049|NCT03175666|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
214448050|NCT03175666|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
214524552|NCT00730496|PROCEDURE|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
214524553|NCT05570578|DEVICE|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
214524554|NCT03788421|DEVICE|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
214524555|NCT03788421|PROCEDURE|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
214524556|NCT04727190|PROCEDURE|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
214524557|NCT04727190|PROCEDURE|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
214524558|NCT01803789|DEVICE|Single Kirschner Wire|
214524559|NCT01803789|DEVICE|Double Kirschner Wire|
214524560|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
214524561|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
215128716|NCT00972413|RADIATION|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
215128717|NCT00972413|RADIATION|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
215128718|NCT00972413|RADIATION|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
215128719|NCT01405768|DRUG|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
215128720|NCT01405768|DRUG|Non-buffered lidocaine|
215128721|NCT05383469|OTHER|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
215128722|NCT05383469|OTHER|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
215128723|NCT05383469|OTHER|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
215128724|NCT05383469|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
215128725|NCT03692208|BEHAVIORAL|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
215128726|NCT06377176|OTHER|Massage therapy|the intervention group underwent ten sessions of twice-weekly mother and infant massage therapy for five weeks.
214524562|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
214524563|NCT04739293|DRUG|ON123300|ON 123300 hard gelatin capsules
214524564|NCT02619279|OTHER|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
214524565|NCT00006747|DRUG|carmustine|IV
214524566|NCT00006747|DRUG|melphalan|IV
214524567|NCT00006747|DRUG|etoposide|IV
214524568|NCT00006747|DRUG|cytarabine|IV
214524569|NCT00006747|DRUG|tacrolimus|IV
215128727|NCT03338777|BIOLOGICAL|Suicide plus immunogene therapy|"1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
215128728|NCT05041049|DEVICE|Comparing Visual Reality to High-fidelity mannequin Stimulation|"This is a prospective, randomized, non-inferiority study. VR will be compared to HFS, which will be considered the a priori gold standard for residents simulation training.~The study will be divided into two phases. In the pre-test phase, participants will be randomly allocated to receive either a VR or HFS scenario (scenario 1, see below). In the post-test phase, all participants (regardless the initial grouping) will undergo a HFS scenario (scenario 2, see below).~All scenarios have been chosen from critical events published by the Society of Pediatric Anesthesia48 and adult sources49.~The study will be conducted at the McGill University Health Center - Research Institute (MUHC-RI)."
214524570|NCT00006747|DRUG|methotrexate|IV
214524571|NCT00006747|DRUG|sargramostim|IV
214524572|NCT00006747|PROCEDURE|transplant|
214524573|NCT02032420|BEHAVIORAL|STAR|
214524574|NCT02032420|BEHAVIORAL|ART|
214524575|NCT03451994|OTHER|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
214524576|NCT03869541|OTHER|Mobilization|Physical rehabilitation
214524577|NCT01171885|DRUG|0.9% saline|20 ml of 0.9% saline
214524578|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.25%.
214524579|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.5%.
214524580|NCT03126721|DRUG|midazolam|a single oral dose of 2 mg midazolam
215128729|NCT05664321|OTHER|Observational, case-control study|obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].
215128730|NCT04935996|DEVICE|Pleuropulmonary echography|Pleuropulmonary echography is performed, in addition of the chest X-ray already performed in routine care
215128731|NCT04889846|PROCEDURE|SAFE early intervention approach|SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
215128732|NCT01992796|DRUG|Irbesartan|75 mg/per os/for 15 days
215128733|NCT03424564|DRUG|Perampanel|Oral Tablet
215128734|NCT03415321|DEVICE|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
215128735|NCT02125396|OTHER|Transarterial chemoembolization|Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
215128736|NCT02125396|OTHER|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
215128737|NCT01412177|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
215128738|NCT01412177|DRUG|Placebo|Single intratympanic injection of placebo
215128739|NCT00005984|DRUG|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
215128740|NCT00005984|DRUG|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
215128741|NCT00005984|DRUG|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
215128742|NCT00005984|PROCEDURE|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
215128743|NCT00005984|PROCEDURE|radiation therapy|total body irradiation twice a day on days -4 through -1
215128744|NCT04848675|OTHER|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
215128745|NCT04848675|OTHER|Brisk walking|Participants will perform brisk walking.
215128746|NCT01690052|DRUG|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
215128747|NCT01690052|DRUG|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
215128748|NCT01866332|OTHER|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
215128749|NCT01866332|DEVICE|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
215128750|NCT00173407|PROCEDURE|immunohistochemical, methylation, gene transfection|
215128751|NCT02249806|OTHER|PH target therapy according to physician|Patients receiving PH target therapy
215128752|NCT06043024|DEVICE|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
214524581|NCT03126721|DRUG|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
214524582|NCT03045302|DRUG|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
214524583|NCT00447356|DRUG|recombinant interferon alfa|
214524584|NCT05287178|BEHAVIORAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
215128753|NCT05787340|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation.
215128754|NCT03397264|BIOLOGICAL|Aflibercept|Intravitreal injection
214524585|NCT01102985|BEHAVIORAL|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
214524586|NCT01102985|BEHAVIORAL|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
214524587|NCT01889277|DRUG|MT-3995-Low|
214524588|NCT01889277|DRUG|MT-3995-High|
214524589|NCT01889277|DRUG|Placebo|
214694441|NCT01396993|PROCEDURE|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
215128755|NCT03397264|BIOLOGICAL|OPT-302|Intravitreal Injection
215128756|NCT03397264|OTHER|Sham intravitreal injection|Sham (mock) intravitreal injection
215128757|NCT01777035|OTHER|early PT OT|"1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
215128758|NCT02003235|DEVICE|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
215128759|NCT06453148|OTHER|Non-interventions|Usual care evaluations
215128760|NCT00210535|DRUG|Topiramate; Placebo|
215128761|NCT04355234|DIAGNOSTIC_TEST|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
215128762|NCT04355234|BIOLOGICAL|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
214448051|NCT03175666|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
214448052|NCT03175666|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214448053|NCT03175666|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)
214448054|NCT03175666|BIOLOGICAL|GI-4000|RAS yeast vaccine
215128763|NCT00599872|BIOLOGICAL|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
215128764|NCT00599872|BIOLOGICAL|Placebo|Placebo, sublingual oral
215128765|NCT00126035|DEVICE|Migraid|
215128766|NCT01474317|DEVICE|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
215128767|NCT03177902|DRUG|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
215128768|NCT03629964|DEVICE|Wiersma Head Stabilizer|Experimental device attached to treatment table.
215128769|NCT03629964|DEVICE|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
215128770|NCT05621330|DRUG|QL0911|The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
215128771|NCT05621330|DRUG|Placebo comparator|The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
215128772|NCT03665636|DRUG|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
214694442|NCT01396993|PROCEDURE|Breast Surgery|Breast conserving therapy without defect correction
214694443|NCT02207478|PROCEDURE|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
215128773|NCT02946437|DRUG|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
215128774|NCT02946437|DRUG|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
215128775|NCT02946437|DRUG|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
214448055|NCT03175666|BIOLOGICAL|GI-6207|CEA yeast vaccine
214448056|NCT03175666|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214448057|NCT03175666|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
215128776|NCT02946437|DEVICE|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
215128777|NCT00132743|DEVICE|Stent|Stent
215128778|NCT00132743|BEHAVIORAL|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
215128779|NCT00132743|DRUG|Cilostazol|Cilostazol, 100 mg twice a day
215128780|NCT05951114|DIAGNOSTIC_TEST|Maximum inspiratory/Expiratory manoeuvre for patients can follow the order|Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre
215128781|NCT01381016|DRUG|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
214524590|NCT02037750|BEHAVIORAL|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
215128782|NCT01381016|DRUG|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
215128783|NCT01381016|DRUG|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
215128784|NCT03298360|OTHER|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
215128785|NCT01314196|OTHER|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
215128786|NCT01314196|OTHER|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
215128787|NCT04428398|DIAGNOSTIC_TEST|Analysis of urine samples with flow cytometry|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
215128788|NCT02107417|DEVICE|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
214448058|NCT03143374|DRUG|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
214448059|NCT04584632|DEVICE|Efemoral Vascular Scaffold System (EVSS)|Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
214448060|NCT03703700|DRUG|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
214448061|NCT03703700|DRUG|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
214448062|NCT05400317|DRUG|AD-218|PO, Once daily(QD), 12weeks
214448063|NCT05400317|DRUG|AD-218A|PO, Once daily(QD), 12weeks
214448064|NCT03085004|DRUG|Ethanol|The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
214448065|NCT03085004|DRUG|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
214448066|NCT03085004|DRUG|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
214448067|NCT04437654|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
214448068|NCT05673304|RADIATION|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
214694444|NCT02207478|PROCEDURE|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
214694445|NCT02998424|DRUG|Propofol|Continuous infusion
215128789|NCT02107417|DEVICE|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
214448069|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
214448070|NCT06311864|DRUG|Daridorexant 50 mg|As indicated by the physician
214448071|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
214448072|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
215128790|NCT05883969|BEHAVIORAL|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
215128791|NCT05883969|BEHAVIORAL|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
215128792|NCT01693029|DRUG|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
215128793|NCT01693029|DRUG|US-licensed epoetin alfa|Solution for subcutaneous injection.
215128794|NCT05822934|DRUG|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
215128795|NCT01494948|OTHER|allergen challenge|nasal challenges with antigen to which they are sensitive to
215128796|NCT02647281|DRUG|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
215128797|NCT02647281|DRUG|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
214448073|NCT06467123|OTHER|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
214448074|NCT06467123|OTHER|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
214448075|NCT05697211|DRUG|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
214448076|NCT05271578|DEVICE|Standardized Electronic Research Cigarette|Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)
214448077|NCT05271578|DEVICE|Nicotine Research Cigarette|Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
214448078|NCT06105463|OTHER|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
214448079|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
214448080|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
214448081|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
214448082|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
214524591|NCT05817864|DIAGNOSTIC_TEST|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level \> 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
214524592|NCT04979234|DEVICE|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
215128798|NCT05801991|DEVICE|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
215128799|NCT05801991|DEVICE|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
215128800|NCT00972101|RADIATION|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
215128801|NCT00972101|DRUG|Melphalan|140 mg/m\^2 by vein over 30 minutes as a single dose on Day -8
215128802|NCT00972101|DRUG|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
215128803|NCT00972101|DRUG|Fludarabine|40 mg/m\^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
215128804|NCT00972101|DRUG|Rituximab|"Regimen 1:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
215128805|NCT00972101|DRUG|Etoposide|60 mg/m\^2 by vein over 1-2 hours as a single dose on Day -3.
215128806|NCT00972101|DRUG|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
215128807|NCT00972101|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
215128808|NCT00972101|DRUG|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
215128809|NCT00972101|PROCEDURE|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
215128810|NCT00972101|DRUG|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is \> 2.5 x 10e\^9/L.
215128811|NCT00972101|PROCEDURE|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e\^5 T cells/kg on Day 14+.
214448083|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
214448084|NCT06129214|PROCEDURE|Prepectoral|Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
214448085|NCT06129214|PROCEDURE|Subpectoral|No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
214448086|NCT05130879|BEHAVIORAL|BRAW|"Sessions~1. Happiness and positivity Understanding strengths and resilience and positive attitude~2. Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~3. Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~4. Emotion regulation Preventing and managing conflict Emotion regulation abilities~5. Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~6. Problem solving Problem-solving work-life problems Work-life balance Bringing it together"
214448087|NCT03572335|DIAGNOSTIC_TEST|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
214448088|NCT01351545|DRUG|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
214448089|NCT05095740|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
214448090|NCT05095740|DEVICE|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
214448091|NCT05130840|DIAGNOSTIC_TEST|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
214448092|NCT05130840|DIAGNOSTIC_TEST|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
214524593|NCT04979234|BEHAVIORAL|Diet|Multidisciplinary follow up
214524594|NCT01592565|OTHER|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
214524595|NCT01107249|DEVICE|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
215128812|NCT00414856|DRUG|AFQ056|
215128813|NCT05019690|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
215128814|NCT05019690|DRUG|Albumin-Bound Paclitaxel|Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
214524596|NCT00254722|DRUG|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
215128815|NCT03684174|DEVICE|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
214694446|NCT02998424|DEVICE|Pupillary diameter measurement|Instantaneous measure
215128816|NCT03450863|DRUG|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
215128817|NCT00467077|BIOLOGICAL|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
215128818|NCT00467077|DRUG|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
215128819|NCT05183061|DRUG|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
215128820|NCT02539004|OTHER|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
215128821|NCT01274481|DRUG|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
215128822|NCT02454738|RADIATION|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
215128823|NCT03671941|DRUG|D578|D578 Tab.1T single oral administration under fasting condition
215128824|NCT03671941|DRUG|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
215128825|NCT05635656|DEVICE|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
215128826|NCT02761226|PROCEDURE|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
215128827|NCT02761226|PROCEDURE|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
215128828|NCT01316523|DRUG|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
215128829|NCT01316523|DRUG|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
215128830|NCT03498807|DEVICE|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
215128831|NCT03498807|DEVICE|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
215128832|NCT05937763|OTHER|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
215128833|NCT01451723|DRUG|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
215128834|NCT01451723|OTHER|Placebo|Matching placebo capsules
215128835|NCT05682755|DRUG|Chidamide|initial time：platelet count ≥50×10\^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10\^9/L-increased by 5 mg 20×10\^9/L≤ platelet count \<50×10\^9/L-remains unchanged platelet count \<50×10\^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
214448093|NCT05054374|DRUG|Mirdametinib|Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
214448094|NCT05054374|DRUG|Fulvestrant|"The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant"
214524597|NCT06296797|BEHAVIORAL|Control arm: Existing educational website|Information about tubal sterilization currently provided on the Planned Parenthood website
214524598|NCT06296797|BEHAVIORAL|Advancing Access Website|A website comparing tubal sterilization to long-acting reversible contraceptives informed by recent patient centered outcomes research.
214694447|NCT03711006|OTHER|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
215128836|NCT04507022|DRUG|Estradiol Valerate|2mg three times daily
215128837|NCT04507022|DRUG|Progesterone|100 mg daily intramuscular
215128838|NCT04507022|DRUG|Aromatase inhibitor|2.5 mg twice daily for 5 days
215128839|NCT04897217|DRUG|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
215128840|NCT04897217|DRUG|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
215128841|NCT02136966|OTHER|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
214694448|NCT03586245|DIETARY_SUPPLEMENT|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
214448095|NCT05909111|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI weekly during the radiation treatment course (5 RMI added to the standard care)
215128842|NCT01631435|OTHER|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
215128843|NCT01631435|DEVICE|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
214448096|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
214448097|NCT02813460|DRUG|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
214448098|NCT02813460|DRUG|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
214448099|NCT02813460|DRUG|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
214448100|NCT02813460|DRUG|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
214448101|NCT02813460|DRUG|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
214448102|NCT02813460|DRUG|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
214448103|NCT02813460|DRUG|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
214448104|NCT02813460|DRUG|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
214448105|NCT02813460|DRUG|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
214448106|NCT02813460|DRUG|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
214448107|NCT02813460|DRUG|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
214448108|NCT02813460|DRUG|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
214448109|NCT04303377|BIOLOGICAL|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
214448110|NCT06522178|OTHER|Patient' ages|Patients were divided into two groups according to their ages.
214448111|NCT01571570|DRUG|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
214448112|NCT01571570|DRUG|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
214448113|NCT01571570|DRUG|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
214448114|NCT01571570|DRUG|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
214448115|NCT01571570|DRUG|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
214448116|NCT03206151|DRUG|CMAB009|for injection only
214448117|NCT03206151|DRUG|Irinotecan|for injection only
214448118|NCT03206151|DRUG|Folinic acid|for injection only
214448119|NCT03206151|DRUG|5-fluorouracil|for injection only
214448120|NCT06986382|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
214448121|NCT06986382|DRUG|Prednisone/Methylprenisolone|Administered as part of the HSCT conditioning regimen
214448122|NCT06986382|DRUG|Palifermin|Administered as part of the HSCT conditioning regimen
214448123|NCT06986382|DRUG|ATG|Administered as part of the HSCT conditioning regimen
214448124|NCT06986382|DRUG|Clofarabine|Administered as part of the HSCT conditioning regimen
214448125|NCT06986382|DRUG|Melphalan|Administered as part of the HSCT conditioning regimen
214448126|NCT06986382|RADIATION|Total Body Irradiation|200 cGy, administered as part of the HSCT conditioning regimen
214448127|NCT06986382|DRUG|Rituximab|Administered as part of the HSCT conditioning regimen
214448128|NCT06987799|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR; CALM-Chicago Study)|This clinical trial will evaluate the effectiveness of the culturally adapted intervention, CALM-Chicago, in a community setting. CALM-Chicago has been previously used in a clinical setting.
214694449|NCT03586245|DIETARY_SUPPLEMENT|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
214694450|NCT03586245|DIETARY_SUPPLEMENT|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
214694451|NCT00970528|DRUG|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
214694452|NCT00970528|DRUG|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
214694453|NCT00214968|DRUG|Modafinil|maximum dosage 400 mg/day (4 tablets)
214694454|NCT00084942|DRUG|capecitabine|
214524599|NCT00802334|DRUG|generic lopinavir/ritonavir|"1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
214448129|NCT06986499|DEVICE|Hearing Aid Widex SmartRIC MRRLD 440|Receiver in Canal (RIC) hearing aid
214524600|NCT04064840|DRUG|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
214524601|NCT04064840|DRUG|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
215128844|NCT06447558|BEHAVIORAL|palatal stimulation with a finger in premature infants|Oral administration of breast milk droplets, palatal stimulation with a finger in premature infants
215128845|NCT04750291|DRUG|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
215128846|NCT04750291|OTHER|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
215128847|NCT00793988|PROCEDURE|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
214448130|NCT06986499|DEVICE|Own hearing aid|subjects' own hearing aids, any brand, any model
214448131|NCT06986655|OTHER|Augmented Reality|In this intervention children will play an augmented reality game during the allergy testing procedure. The game will be used as a distraction method to potentially reduce pain and fear, and enhance care satisfaction.
214448132|NCT06986538|PROCEDURE|Clearance with the left side of the SMV as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMV as the medial boundary
214448133|NCT06986538|PROCEDURE|Clearance with the left side of the SMA as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMA as the medial boundary
214448134|NCT06986408|DEVICE|Earplugs and Eye Masks|"The patients in the experimental group will be given the Informed Consent Form before surgery and the Patient Introduction Form will be applied after permission is obtained. Patients will be given eye masks and earplugs on the nights following surgery and they will be ensured to use them correctly. The General Comfort Scale and the Quality of Recovery Questionnaire (Qor-40) will be applied 24 and 48 hours after surgery."
214448135|NCT05428384|DEVICE|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
214448136|NCT06988137|DEVICE|Kinesio Taping|Elastic therapeutic tape was applied using the ligament correction technique. The tape was reapplied at Day 3 and Day 21 under supervision
214524602|NCT04064840|DRUG|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
214524603|NCT04064840|DRUG|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
214524604|NCT05859529|DRUG|JS002|The drug was administered by a single subcutaneous injection
214524605|NCT01248143|DIETARY_SUPPLEMENT|Green tea|9 gram per day
214694455|NCT00084942|DRUG|gemcitabine hydrochloride|
214708823|NCT05905601|BEHAVIORAL|"NORTH Full"|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
215128848|NCT00793988|PROCEDURE|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
215128849|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
215128850|NCT01373463|DRUG|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
215128851|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
214448137|NCT06988137|PROCEDURE|Buddy Taping|Buddy taping involved strapping the injured finger to an adjacent digit using medical tape. Early motion was restricted.
214448138|NCT06988137|DEVICE|Splinting|A custom-molded thermoplastic splint was applied to restrict joint movement and maintain alignment. Patients remained immobilized until Week 3.
214448139|NCT06988072|OTHER|blood sampling|At BKPyV reactivation, at 1 month, 3 months and 12 months
214448140|NCT06988072|OTHER|blood sampling|once
214448141|NCT06988072|OTHER|blood sampling|once
214448142|NCT06987942|BIOLOGICAL|Varicella vaccine+TIV|"* Varicella vaccine: lyophilized powder, subcutaneous injection~* TIV: Inactived, split virion, containing H1N1, H3N2 and BV strains."
214448143|NCT06987942|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous
214448144|NCT06987942|BIOLOGICAL|TIV|Inactived, split virion, containing H1N1, H3N2 and BV strains.
215128852|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
215128853|NCT01373463|DRUG|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
215128854|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
215128855|NCT01373463|PROCEDURE|Lobectomy|Surgery
215128856|NCT01373463|PROCEDURE|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
214708824|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
215128857|NCT00367328|DEVICE|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
215128858|NCT04443634|PROCEDURE|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
214448145|NCT06332209|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT; Cohen et al., 2017) is an evidence-based, manualized treatment protocol designed to treat posttraumatic stress and co-occurring symptoms such as depression and anxiety in trauma-exposed children and youth and their supportive and non-offending caregivers. TF-CBT is divided into nine cognitive and behavioral components, all of which incorporate gradual exposure to trauma memories and reminders
214448147|NCT06677177|DIETARY_SUPPLEMENT|Nano-water, Tamsulosin Dutasteride|Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
214448148|NCT06677177|DRUG|Regular water, tamsulosin, Dutasteride|Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
214448149|NCT06986941|BEHAVIORAL|Ballet-Based Dance Therapy|An 8-week ballet-based dance therapy program designed to improve balance, flexibility, peripheral muscle strength, cognitive functions, and overall functional capacity in Parkinson's disease patients. The therapy will be conducted twice a week, with each session lasting approximately 60 minutes. The exercises will be adapted to the participants' physical abilities and will focus on enhancing motor coordination, strength, and stability through ballet-inspired movements.
214448150|NCT06986941|OTHER|Standard Care with Exercise Counseling|Participants in the control group will receive standard care for Parkinson's disease, including pharmacological management and routine clinical follow-up. Additionally, they will receive a one-time exercise counseling session and an informational brochure outlining general home-based exercises appropriate for individuals with Parkinson's disease. No supervised or structured exercise sessions will be conducted.
214448151|NCT06678828|OTHER|ClarityDX Prostate|The ClarityDX Prostate report will be shared with the healthcare team of participants randomized into ClarityDX Prostate arm before the healthcare team decides whether to perform an MRI/advanced imaging and/or biopsy.
214448152|NCT06678828|OTHER|ClarityDX Prostate, blinded|ClarityDX Prostate will be run for the control participants. Participants (and healthcare team) in the control arm will be blinded to the ClarityDX Prostate results and will be considered for prostate MRI/advanced imaging and/or biopsy based on standard of care criteria. The result of the ClarityDX Prostate will be unblinded to study teams at the 12 months follow-up visit (± 2 months). The study team will then share the test results with the participant's health care team to assess whether there is a need to change the participant's care path.
214448153|NCT06676774|DRUG|Oxytocin nasal spray|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.
214448154|NCT06676774|OTHER|Placebo|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.
214448155|NCT06702852|DEVICE|NIRS imaging in addition to SOC|The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
214448156|NCT06926348|BEHAVIORAL|Digital Health Technology for Chronic Insomnia|A mobile application designed to support chronic insomnia management through digital self-monitoring of sleep patterns, personalized sleep hygiene education, cognitive strategies, relaxation and mindfulness exercises, and chatbot interactions. Users receive tailored notifications and educational content to encourage healthy sleep behaviors over an 8-week period. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged
214524606|NCT01248143|DIETARY_SUPPLEMENT|FPP|2 sachets twice daily
214524607|NCT01662661|DRUG|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
214524608|NCT01662661|DRUG|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
214524609|NCT04788472|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
214708825|NCT05172037|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
215128859|NCT04443634|PROCEDURE|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
215128860|NCT04443634|PROCEDURE|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
215128861|NCT04443634|DRUG|Bupivacaine 20 ml|20ml bupivacaine 0.5%
215128862|NCT04443634|DRUG|Bupivacaine 30ml|30ml bupivacaine 0.5%
215128863|NCT04443634|DRUG|Bupivacaine 10ml|10ml bupivacaine 0.5%
215128864|NCT01638663|DRUG|Tolvaptan|15 mg pr day for 1 day
215128865|NCT01638663|DRUG|Placebo|1 tablet Unikalk 1 pr day for 1 day
215128866|NCT04085419|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|denosumab 60 mg subcutaneously every 6 months
215128867|NCT04085419|DRUG|Zoledronic Acid|zoledronic acid 5 mg intravenously once a year
214448157|NCT06926348|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive standard sleep hygiene recommendations via a printed educational booklet. They maintain printed sleep diaries for daily self-monitoring throughout the 8-week intervention. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged.
214448158|NCT06733324|BEHAVIORAL|SCERTS (Social Communication, Emotional Regulation, Transactional Support)|"The SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention is a comprehensive, multidisciplinary approach specifically tailored to address the unique needs of children with Autism Spectrum Disorder (ASD) aged 3-6 years. Unlike traditional behavioral therapies such as Applied Behavior Analysis (ABA), SCERTS emphasizes a developmental framework, focusing on enhancing social communication, emotional regulation, and environmental support. It incorporates family involvement and integrates strategies into naturalistic settings, ensuring skill generalization across home, school, and community environments.~This intervention is distinguished by its individualized goals based on each child's developmental profile and its emphasis on fostering meaningful interactions rather than relying on compliance-based methods. SCERTS also incorporates transactional supports, such as modifying the physical and social environment to promote engagement and reduce stress, w"
214448159|NCT06733324|BEHAVIORAL|Behavioral Treatment, Speech Therapy|The control group will be the treatment as usual group receiving conventional behavior therapy and speech therapy
214448160|NCT06791382|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.
214448161|NCT06915727|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
214448162|NCT06915727|PROCEDURE|Near Infrared Imaging|Undergo NIR fluorescent imaging
214448163|NCT06915727|DRUG|Pafolacianine Sodium|Given IV
214448164|NCT06915727|PROCEDURE|Surgical Procedure|Undergo SOC surgery
214448165|NCT06920524|DEVICE|Intervention group IM-IM|The intervention group (IM-IM) will receive a tablet and headphones to listen to music during the toxin injections. Then, during the waiting time, the patient, with or without assistance, will choose the music they wish to listen to, according to their musical tastes. The duration of the music can be modulated according to the duration of the medical procedure to follow.
214448166|NCT06931886|OTHER|Inspiratory Muscle Strength Training|Participants will be asked to inhale against a resistance. This resistance will be set to \~55% of their maximal inspiratory ability. Participants will complete 5 sets of 6 breaths (30 total) a day for 5 days a week for 6 weeks.
214448167|NCT06931340|DRUG|Androgen Therapy|Given ADT
214448168|NCT06931340|DRUG|Apalutamide|Given PO
214448169|NCT06931340|DRUG|Docetaxel|Given IV
214448170|NCT06931340|PROCEDURE|Computed Tomography|Undergo CT
214448171|NCT06931340|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214448172|NCT06931340|PROCEDURE|Bone Scan|Undergo Bone Scan
214448173|NCT06931340|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
214448174|NCT06931340|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214448175|NCT06931340|OTHER|Questionnaire Administration|undergo Questionnaire Administration
214448176|NCT05519007|OTHER|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
214448177|NCT05519007|OTHER|Saline irrigation|The surgical site will be irrigated with Saline
214448178|NCT05045183|DEVICE|SoC Adhesive Bandage|On the randomized wound site, a SoC adhesive bandage will be applied.
214448179|NCT05045183|DRUG|Antibiotic Ointment|On the randomized wound site, a antibiotic ointment will be applied.
214448180|NCT05045183|DRUG|Antiseptic Wash|On the randomized wound site, a antiseptic wash will be applied.
214448181|NCT05045183|DEVICE|Hydrocolloid Pad|On the randomized wound site, hydrocolloid pad will be applied.
214448182|NCT03818802|DIETARY_SUPPLEMENT|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
215128868|NCT02780401|OTHER|Laboratory Biomarker Analysis|Correlative studies
214524610|NCT02261675|DRUG|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
215128869|NCT02780401|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
215128870|NCT02780401|BIOLOGICAL|Sargramostim|Given ID
215128871|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
215128872|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
215128873|NCT00621374|BEHAVIORAL|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
215128874|NCT00621374|BEHAVIORAL|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
215128875|NCT02542046|DRUG|Barium|Administration of barium oral contrast agent prior to CT scan
215128876|NCT02542046|DRUG|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
215128877|NCT02542046|DRUG|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
215128878|NCT01179321|OTHER|Early referral to Dietitian for assessment and nutrition support|
215128879|NCT03443141|DRUG|Vitamin E|The applied dressing will be embebbed in Vitamin E
215128880|NCT03443141|DRUG|Standard dressing|The applied dressing is a normal one without adding any product to it.
215128881|NCT02208102|PROCEDURE|Radio-frequency catheter ablation|
215128882|NCT01103167|BEHAVIORAL|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
215128883|NCT04233008|DEVICE|Foley catheter length|see arm description
215128884|NCT01479101|OTHER|MammaPrint 70-gene expression profile|
215128885|NCT01479101|OTHER|BluePrint 80 gene expression profile|
215128886|NCT06260566|DRUG|N-Acetylcysteine|"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."
215128887|NCT01005251|DRUG|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
215128888|NCT01005251|DRUG|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
215128889|NCT01005251|DRUG|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
215128890|NCT01005251|DRUG|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
215128891|NCT01005251|DRUG|Placebo|oral,capsules, bid for 4 w
215128892|NCT01019187|PROCEDURE|Quality-of-Life Assessment|Ancillary Studies
214524611|NCT01956955|DRUG|enoxaparin ,alteplase, unfractionated heparin|
214708826|NCT05172037|BIOLOGICAL|Placebo|Saline
215128893|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
215128894|NCT01019187|OTHER|Placebo|Given orally
215128895|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
215128896|NCT01019187|PROCEDURE|Sleep Disorder Therapy|
215128897|NCT01019187|DRUG|Armodafinil|Given orally
215128898|NCT01019187|PROCEDURE|Quality-of-life assessment|Ancillary studies
215128899|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
215128900|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
215128901|NCT01019187|PROCEDURE|Management of Therapy|
215128902|NCT01019187|PROCEDURE|Sleep disorder therapy|
215128903|NCT01019187|PROCEDURE|cognitive assessment|
215128904|NCT01019187|PROCEDURE|Quality of Life assessment|Ancillary Studies
215128905|NCT01019187|OTHER|Questionnaire Administration|Ancillary studies
215128906|NCT01019187|OTHER|Placebo|Given orally
215128907|NCT01019187|PROCEDURE|Fatigue assessment and management|
215128908|NCT01019187|PROCEDURE|Management of therapy and complications|
215128909|NCT01019187|PROCEDURE|Sleep disorder therapy|
215128910|NCT01019187|DRUG|Armodafinil|Given orally
215128911|NCT01019187|PROCEDURE|Cognitive Assessment|
215128912|NCT01019187|PROCEDURE|Quality of Life Assessment|Quality of Life Assessment
215128913|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
215128914|NCT01019187|PROCEDURE|Fatifue assessment and management|
215128915|NCT01311817|BIOLOGICAL|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
215128916|NCT01776658|DRUG|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
214694456|NCT03969043|OTHER|MRI|"The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
215128917|NCT01776658|DRUG|Placebo|Ocular topical administration of placebo for 10 consecutive days
215128918|NCT06473064|OTHER|Benelli technique for nipple sparing mastectomy in surgical treatment of grade 3 and 4 gynecomastia|".The Nipple areola complex (NAC )margins on both sides are marked as circular. -Around the initial circle, a second circle (external) was drawn 1 cm broader than the boundary.~* The skin was resected, with deepithelialization between the two circles.~* A transdermal incision was made through the border of the external circle.~  -. The breast tissue around the pedicle was lifted over the pectoral fascia and excised by preserving the NAC and the underlying breast pedicle~* The base of the mammary pedicle under the NAC was infixed at the farthest end of the mastectomy area by using 3/0 absorbable multifilament suture material~  * Hence, the space formed after mastectomy was filled with a breast pedicle located posterior to the NAC.~ * The closure of the circular deepithelialized area around the NAC with a diameter of 1 cm accomplished by using 4/0 absorbable monofilament suture material and the surgery was completed"
215128919|NCT03387670|DRUG|Simvastatin|"* One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months"
215128920|NCT03387670|DRUG|Placebo|"* One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months"
215128921|NCT05357625|BEHAVIORAL|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
215128922|NCT05297877|OTHER|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
215128923|NCT05297877|OTHER|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
215128924|NCT01393275|OTHER|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
215128925|NCT01393275|OTHER|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
215128926|NCT00443040|DRUG|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
215128927|NCT00443040|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
215128928|NCT02222571|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
215128929|NCT02222571|BEHAVIORAL|Supervision for Safety|group-based safety intervention for parents
214524612|NCT01658176|DRUG|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
214524613|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
214524614|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
214694457|NCT01593163|DRUG|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
214708827|NCT02693327|OTHER|Biological Sample|A one time sample will be collected.
215128930|NCT04678583|PROCEDURE|Resection of colorectal liver metastases|Comparison of two liver surgery methods
215128931|NCT02681809|DRUG|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
215128932|NCT02681809|DRUG|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
215128933|NCT02681809|DRUG|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
215128934|NCT04479397|PROCEDURE|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
214524615|NCT06200480|OTHER|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
214524616|NCT00002405|DRUG|Amprenavir|
214524617|NCT06574503|DRUG|GP681 40mg|2X20mg tablets taken orally
214524618|NCT06574503|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
214524619|NCT05563961|DRUG|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
214524620|NCT05563961|DRUG|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
215128935|NCT04479397|PROCEDURE|No sling in postoperative care|No sling will be used in postoperative care.
215128936|NCT00435409|DRUG|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
215128937|NCT00435409|DRUG|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
215128938|NCT01666249|BIOLOGICAL|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
215128939|NCT04271852|DEVICE|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
215128940|NCT04392739|DRUG|Tpoxx|oral antiviral
215128941|NCT04875325|OTHER|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
215128942|NCT02159586|DEVICE|gastric electrical stimulator|
215128943|NCT06400069|OTHER|Evaluation of serum NLRP6 levels|intervention: Evaluation of serum NLRP6 levels control: Evaluation of serum NLRP6 levels
214524621|NCT05959837|OTHER|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
214524622|NCT00603278|DRUG|GW685698X|GW685698X
214524623|NCT00603278|DRUG|placebo|placebo
214524624|NCT04617197|DEVICE|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
215128944|NCT06147843|OTHER|Blood sample|Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss
215128945|NCT06790121|DRUG|Lunsekimig|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
215128946|NCT06790121|DRUG|Placebo|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
215128947|NCT06785467|OTHER|eDoula App|eDoula is an app that will give patients reading material and videos to watch based on their due date. It also provides helpful postpartum device.
215128948|NCT06539884|OTHER|Observational|Evaluating whether the 2005 SIRS - Sepsis diagnostic and grading criteria, pSOFA, PRISM III and PELOD scores are compatible and to compare their prognostic predictive power.
215128949|NCT03661723|DRUG|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
215128950|NCT03661723|DRUG|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
215128951|NCT03661723|RADIATION|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
215128952|NCT05765682|OTHER|Mepivacaine Spinal|spinal block using 60mg of mepivacaine
215128953|NCT05765682|OTHER|Bupivacaine Spinal|spinal block using 10mg of bupivacaine
215128954|NCT05757843|DIAGNOSTIC_TEST|Signatera ctDNA test|The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. ctDNA testing will be repeated approximately every 4 weeks until two consecutive negative analyses occur. ctDNA testing will be otherwise discontinued after progressive disease or after up to 1 year of consolidation treatment per standard medical practice is considered complete, whichever occurs first.
215128955|NCT05757843|DRUG|Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Durvalumab will be stopped after two consecutive negative ctDNA analyses occur.
215128956|NCT05791253|OTHER|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
215128957|NCT03122639|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
215128958|NCT03122639|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
215128959|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
215128960|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
215128961|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
215128962|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
215128963|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
215128964|NCT00001917|DRUG|O15|
215128965|NCT00001917|DRUG|[F-18] FP-TZTP|
215128966|NCT04175730|DEVICE|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
215128967|NCT04175730|DEVICE|Ultrasound|A single subsequent ultrasound guided prostate biopsy
215128968|NCT05932277|DRUG|BMS-986419|Specified dose on specified days
215128969|NCT05932277|DRUG|Caffeine|Specified dose on specified days
214448183|NCT03818802|DIETARY_SUPPLEMENT|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
214448184|NCT05872022|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
214448185|NCT06275529|PROCEDURE|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
214448186|NCT05701748|OTHER|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
214448187|NCT05865899|PROCEDURE|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
214448188|NCT06782581|BEHAVIORAL|Contribution to Caregivers Well-Being|Contribute to caregiver's well-being via household tasks.
214448189|NCT06782581|BEHAVIORAL|Control|factually describe either (1) immediate environment, (2) the weather, or (3) organization of closet
214448190|NCT06783972|BEHAVIORAL|Touching|In the second stage of birth, when the baby's head crowns, the mother is allowed to touch the baby's head as much as she wants and with as many fingers as she wants.
214448191|NCT06790498|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
214448192|NCT06770309|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
214448193|NCT06770309|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
214448194|NCT05439772|DRUG|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
214448195|NCT03803332|BEHAVIORAL|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
214448196|NCT03803332|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
214448197|NCT06208462|DRUG|Adebrelimab|1200mg，i.v. , q3w
214448198|NCT06208462|DRUG|Lenvatinib|8mg,qd
214448199|NCT06208462|DRUG|Gemcitabine|800 mg/m2，q3w
214448200|NCT06208462|DRUG|Oxaliplatin|85 mg/m2，q3w
215128970|NCT05932277|DRUG|Bupropion|Specified dose on specified days
215128971|NCT05932277|DRUG|Flurbiprofen|Specified dose on specified days
215128972|NCT05932277|DRUG|Omeprazole|Specified dose on specified days
215128973|NCT05932277|DRUG|Midazolam|Specified dose on specified days
215128974|NCT05932277|DRUG|Fexofenadine|Specified dose on specified days
215128975|NCT05854108|DIAGNOSTIC_TEST|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
215128976|NCT05854108|DIAGNOSTIC_TEST|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
215128977|NCT00883779|DRUG|Placebo|po on days 15-28 of each 4 week cycle until disease progression
215128978|NCT00883779|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
215128979|NCT00883779|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
215128980|NCT00883779|DRUG|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
215128981|NCT00499681|DRUG|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
215128982|NCT00499681|DRUG|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
215128983|NCT00499681|OTHER|placebo|Given once daily for 2 weeks
215128984|NCT03397979|BEHAVIORAL|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
215128985|NCT02793726|PROCEDURE|NMR|NMR
215128986|NCT04942587|BEHAVIORAL|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
214448201|NCT00922870|DEVICE|Cascade|Cascade treatment over 48h
214448202|NCT00922870|OTHER|Standard treatment|Standard therapy
214448203|NCT02829060|DRUG|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
214448204|NCT02829060|DRUG|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
215128987|NCT03159416|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
215128988|NCT00380237|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
215128989|NCT03186612|BEHAVIORAL|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
215128990|NCT05566535|DRUG|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
215128991|NCT05842317|DRUG|Lenvatinib Plus Tislelizumab|Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
214448205|NCT02829060|DRUG|Ampicillin 2g|Peri-operative dose: 2 grams, IV
214448206|NCT02829060|DRUG|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
215128992|NCT05842317|DEVICE|Transarterial Chemoembolization(TACE)|A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
215128993|NCT04757207|OTHER|survey|International Physical Activity Questionnaire (short form)
215128994|NCT06036277|OTHER|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
215128995|NCT06036277|OTHER|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
215128996|NCT02832648|DIETARY_SUPPLEMENT|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
215128997|NCT00572377|DRUG|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
215128998|NCT00572377|DRUG|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
215128999|NCT03961334|DRUG|Dabigatran|150mg 2x/d
215129000|NCT03961334|DRUG|Apixaban|5mg 2x/d
215129001|NCT03961334|DRUG|Edoxaban|60mg 1x/d
215129002|NCT03961334|DRUG|Aspirin|100mg 1x/d
214448207|NCT02829060|DRUG|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
214448208|NCT02829060|DRUG|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
214448209|NCT02926859|DRUG|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
214448210|NCT02926859|DRUG|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
215129003|NCT03961334|DRUG|Clopidogrel|75mg 1x/d
215129004|NCT04383509|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
215129005|NCT04383509|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
214448211|NCT01220154|DRUG|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
214448212|NCT01220154|DRUG|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
214448213|NCT01220154|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
214448214|NCT03360838|OTHER|CogCheck|Performance of study participants in the application
214448215|NCT02643667|DRUG|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
214448216|NCT02643667|PROCEDURE|Radical prostatectomy|-Standard of care
214448217|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
214448218|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
214448219|NCT04562389|OTHER|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
214448220|NCT04562389|DRUG|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
214448221|NCT03326310|DRUG|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
214524625|NCT00729170|DIETARY_SUPPLEMENT|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
214524626|NCT02406859|BEHAVIORAL|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
214524627|NCT02406859|BEHAVIORAL|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
214524628|NCT05024578|DEVICE|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
214524629|NCT05024578|DEVICE|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
214524630|NCT04374253|DRUG|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
214524631|NCT04374253|DRUG|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
214524632|NCT01207453|DRUG|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
214524633|NCT01207453|DRUG|Placebo|
214524634|NCT02020551|DRUG|Lidocaine Spray|
214524635|NCT02020551|DRUG|Placebo|
214524636|NCT05556070|OTHER|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
214524637|NCT05556070|OTHER|Arm 2|Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
214524638|NCT05556070|OTHER|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
214524639|NCT05556070|OTHER|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
214524640|NCT03784222|DRUG|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
214694458|NCT01593163|DRUG|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
215129006|NCT03313869|DIETARY_SUPPLEMENT|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
215129007|NCT03313869|DIETARY_SUPPLEMENT|control diet|habitual diet to be followed
215129008|NCT02174731|DRUG|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
215129009|NCT02174731|DRUG|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
215129010|NCT03792659|OTHER|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
215129011|NCT00079040|DRUG|cisplatin|Given IV
215129012|NCT00079040|DRUG|etoposide|Given IV
215129013|NCT00079040|BIOLOGICAL|bevacizumab|Given IV
215129014|NCT00079040|OTHER|laboratory biomarker analysis|Correlative studies
215129015|NCT02640274|BEHAVIORAL|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
215129016|NCT02640274|OTHER|Usual care|
215129017|NCT01140308|DRUG|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
215129018|NCT01140308|DRUG|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
215129019|NCT02345135|PROCEDURE|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
215129020|NCT02345135|PROCEDURE|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
214524641|NCT03784222|OTHER|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
214524642|NCT03455140|DRUG|PEG- BCT-100|PEGylated recombinant human arginase 1
214524643|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
214694459|NCT03480607|DRUG|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
215129021|NCT02345135|BEHAVIORAL|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
215129022|NCT05371769|OTHER|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
215129023|NCT05371769|OTHER|No intervention|No intervention will be made.
215129024|NCT02715739|OTHER|No intervention|
214448222|NCT03326310|DRUG|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
214448223|NCT06476418|BEHAVIORAL|distraction|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
214448224|NCT05975385|DEVICE|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
214448225|NCT04775589|BEHAVIORAL|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
214448226|NCT06039644|DIETARY_SUPPLEMENT|Probiotic|Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
214448227|NCT06039644|OTHER|Placebo|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
214448228|NCT02790931|OTHER|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
214448229|NCT03059121|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|
214448230|NCT05148780|DIAGNOSTIC_TEST|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
214448231|NCT05705440|BIOLOGICAL|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
214448232|NCT05705440|OTHER|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
214448233|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
214448234|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
214448235|NCT06110689|OTHER|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
214448236|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
214448237|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
214448238|NCT06066944|OTHER|Thai Foot Massage|It is the application of Massage through specific techniques and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Thai foot massage is often based on traditional Thai massage techniques. The researcher is duly certified for the administration of Thai Foot Massage.
214448239|NCT01526798|DEVICE|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
214448240|NCT01526798|DEVICE|Conventional high-flux dialyzer|
214448241|NCT03576989|DIETARY_SUPPLEMENT|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
214448242|NCT03576989|OTHER|placebo|placebo contains mineral oil
214448243|NCT06495294|BIOLOGICAL|Whole Blood|2 units of whole blood administered by Ornge AAS
214448244|NCT06495294|BIOLOGICAL|RBC + plasma|2 units of RBC + 2 units of plasma administered by Ornge AAS
214448245|NCT03176225|PROCEDURE|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
214448246|NCT03176225|DEVICE|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
214448247|NCT03176225|DEVICE|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
214524644|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
215129025|NCT00739401|DEVICE|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
215129026|NCT01663870|BEHAVIORAL|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
215129027|NCT01663870|BEHAVIORAL|Focus Group Session|Focus group session taking 60-90 minutes.
215129028|NCT01663870|OTHER|Website Session|10-15 minute session with the HealthATM website.
215129029|NCT01663870|BEHAVIORAL|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
215129030|NCT00580619|OTHER|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
215129031|NCT00580619|OTHER|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
215129032|NCT00580619|DRUG|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
215129033|NCT00580619|DRUG|methyldopa|Aldomet oral twice a day for 12 weeks
215129034|NCT04575155|BEHAVIORAL|TEAM Strategy|"1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
215129035|NCT04701008|DRUG|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
215129036|NCT03740022|PROCEDURE|ACL plasty|standard ligamentoplasty by Kenneth Jones
215129037|NCT03740022|PROCEDURE|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
215129038|NCT05748275|DIAGNOSTIC_TEST|Argos|Biometry measurements first with the Argos device, then the IOLMaster 700 device.
215129039|NCT05748275|DIAGNOSTIC_TEST|IOLMaster 700|Biometry measurements first with the IOLMaster 700 device, then the Argos device.
215129040|NCT05655598|DRUG|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
215129041|NCT05655598|DRUG|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
215129042|NCT05655598|DRUG|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
215129043|NCT05655598|DRUG|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
215129044|NCT03023202|OTHER|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
215129045|NCT03886506|BIOLOGICAL|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
215129046|NCT06547437|DRUG|Papaverine|papaverine a smooth muscle relaxant
215129047|NCT06547437|DRUG|normal saline|normal saline 0.9% 100 cc
215129048|NCT00467740|DRUG|BI 1744 CL|
215129049|NCT02737007|DRUG|[14C]-GSK3191607|\[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
215129050|NCT01892670|OTHER|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
215129051|NCT05675319|DRUG|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
215129052|NCT05675319|DRUG|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
214448248|NCT05601726|DRUG|ABD-3001|"Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m²."
214448249|NCT05601726|DRUG|ABD-3001|"For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days."
215129053|NCT05675319|DRUG|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
215129054|NCT05675319|DRUG|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
215129055|NCT05675319|DRUG|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
215129056|NCT05675319|DRUG|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
215129057|NCT05675319|DRUG|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
215129058|NCT05675319|DRUG|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
215129059|NCT05675319|DRUG|Autologous Stem Cells|Autologous Stem Cell Transplantation
215129060|NCT05675319|DRUG|daratumumab/pomalidomide/dexamethasone (DPD)|triple regimen for first relapse should be applied according to latest SmPC version
215129061|NCT05675319|DRUG|isatuximab/carfilzomib/dexamethasone (Isa-KD)|triple regimen for first relapse should be applied according to latest SmPC version
215129062|NCT05675319|DRUG|selinexor/bortezomib/dexamethasone (SVD)|triple regimen for first relapse should be applied according to latest SmPC version
215129063|NCT04421170|BEHAVIORAL|smartphone app for smoking cessation|Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
215129064|NCT04249856|DIAGNOSTIC_TEST|Dynamic Spectral Imaging (DYSIS)|Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
215129065|NCT01368250|PROCEDURE|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
215129066|NCT04538638|PROCEDURE|Mesenteric sparing ileocolic resection|Mesentery left in situ
215129067|NCT04538638|PROCEDURE|Central mesenterectomy ileocolic resection|Mesentery is taken up to the level of the ileocolic trunk
215129068|NCT03535974|DIETARY_SUPPLEMENT|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
215129069|NCT03535974|DIETARY_SUPPLEMENT|Placebo|Placebo administration for 6 weeks bid
215129070|NCT02068326|BEHAVIORAL|Mentalization Based Treatment|
215129071|NCT02068326|BEHAVIORAL|Treatment As Usual|Treatment As Usual
215129072|NCT05011227|DRUG|Camrelizumab|2 cycles Camrelizumab before endoscopic surgery and one year after
215129073|NCT05011227|DRUG|Chemotherapy|2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
215129074|NCT05011227|PROCEDURE|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
215129075|NCT02663011|OTHER|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
214524645|NCT04725552|BEHAVIORAL|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
214524646|NCT04927806|DEVICE|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli"
215129076|NCT02678351|DRUG|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
214694460|NCT03480607|DRUG|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
215129077|NCT02678351|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
215129078|NCT02678351|PROCEDURE|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
215129079|NCT00741052|DRUG|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
214694461|NCT02152670|DRUG|Methylphenidate|
214694462|NCT02152670|DRUG|Alpha Methyl Para Tyrosine (AMPT)|
214694463|NCT02152670|OTHER|[11C]PHNO|
214694464|NCT02152670|OTHER|[11C]raclopride|
214708828|NCT02693327|OTHER|Blood Sample|A one time blood sample will be collected.
215129080|NCT00741052|DRUG|Azithromycin|1 gm Azithromycin single dose
215129081|NCT01919229|DRUG|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
215129082|NCT01919229|DRUG|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
215129083|NCT03806621|PROCEDURE|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
215129084|NCT00700596|DRUG|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
215129085|NCT00700596|DRUG|Placebo|Control or Placebo SA (30 % ethanolic solution)
215129086|NCT02828761|DEVICE|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
215129087|NCT02828761|PROCEDURE|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
215129088|NCT03225235|RADIATION|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
215129089|NCT05406011|DIETARY_SUPPLEMENT|Pelleted sour cherry (anthocyanin) containing chewing gum usage.|Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).
215129090|NCT05406011|DIETARY_SUPPLEMENT|Pelleted chewing gum for stimulated saliva sampling.|Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.
215129091|NCT05406011|PROCEDURE|Scaling|Scaling after a 1-week control period without chewing the sour cherry gum.
215129092|NCT03022396|BIOLOGICAL|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
215129093|NCT03022396|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
215129094|NCT00803283|DRUG|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
215129095|NCT00803283|DRUG|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
215129096|NCT02028533|DRUG|Oxytocin|
215129097|NCT02028533|DRUG|Placebo|
215129098|NCT00184223|BEHAVIORAL|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
215129099|NCT00184223|OTHER|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
215129100|NCT03630835|OTHER|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
215129101|NCT04886323|DEVICE|Cold atmospheric plasma treatment device|Treat with cold atmospheric plasma treatment device.
215129102|NCT04886323|DRUG|Itraconazole Capsules|Treat with Itraconazole capsules
214448250|NCT04869098|DIETARY_SUPPLEMENT|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
214448251|NCT04869098|DIETARY_SUPPLEMENT|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
214448252|NCT05549726|DRUG|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
215129103|NCT03326388|DRUG|Selumetinib|Selumetinib Intermittent Dosing
215129104|NCT03477734|DEVICE|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
215129105|NCT03502837|OTHER|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
215129106|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
214694465|NCT02607254|DRUG|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
215129107|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
215129108|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
215129109|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 30 mg (2\*15 mg) oral capsules.
215129110|NCT04999839|OTHER|Placebo|Placebo matched to NDI-034858 oral capsules.
215129111|NCT00371592|DRUG|Acyclovir|800 mg tablet taken orally twice daily
215129112|NCT00371592|DRUG|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
215129113|NCT03963765|PROCEDURE|Group I (Standard DL-PDT)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
215129114|NCT03963765|PROCEDURE|Group II (DL-PDT with microneedles)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
215129115|NCT03963765|PROCEDURE|Group III (DL-PDT with CO2 laser)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass
215129116|NCT03963765|PROCEDURE|Group IV (DL-PDT with microdermabrasion)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
215129117|NCT04320004|BEHAVIORAL|Education|Subject receives education
215129118|NCT04320004|BEHAVIORAL|Education with Reminder|Subject receives education with reminder
215129119|NCT04320004|BEHAVIORAL|Education + Disposal Bag|Subject receives education and disposal bag
215129120|NCT04320004|BEHAVIORAL|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
215129121|NCT01651481|DRUG|HCP1102|
215129122|NCT01651481|DRUG|Singulair and Xyzal|
215129123|NCT00399516|DEVICE|Precision|
215129124|NCT00120016|BEHAVIORAL|dietary counseling|telephone counseling
215129125|NCT02631096|DRUG|ARB-001467|An IV infusion of ARB-001467
215129126|NCT02631096|OTHER|Placebo|An IV infusion of placebo
215129127|NCT02572323|DRUG|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
214694466|NCT02607254|DRUG|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
214694467|NCT01057069|DRUG|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
214694468|NCT01057069|DRUG|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
215129128|NCT06262789|OTHER|"Return-to-work after cancer consultation"|"The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation."
214448253|NCT05549726|OTHER|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
214448254|NCT05549726|OTHER|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
214448255|NCT06794268|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
214448256|NCT05989984|DIETARY_SUPPLEMENT|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
214448257|NCT05989984|DIETARY_SUPPLEMENT|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
214448258|NCT06792916|PROCEDURE|spermidine and minimally invasive non surgical tecnique|minimally non surgical periodontal therapy will be performed with the adjunct of spermidine based gel
214448259|NCT06792916|OTHER|peridontal therapy (minimally invasive non surgical tecnique)|subgingival instrumentation will be performed according to MINST
214448260|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
214448261|NCT06796517|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
214448262|NCT06796517|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
214448263|NCT06796517|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
215129129|NCT02967146|DEVICE|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
215129130|NCT05887986|OTHER|hand-held fan airflow stimulation|"Outcome dyspnea measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the dyspnea level will be evaluated.~Outcome comfort measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the comfort level of the patients will be evaluated."
215129131|NCT04361071|DEVICE|stent|stent
215129132|NCT04361071|DEVICE|plaque excision system|plaque excision system
215129133|NCT01067677|DRUG|Metaclopramide|0.5 mg/kg for rescue after PONV
215129134|NCT01067677|DRUG|Ondansetron|0.1 mg/kg (max 4 mg0
215129135|NCT01067677|DRUG|diphenhydramine|0.25 mg/kg (max 25 mg)
215129136|NCT01067677|DRUG|Saline|equal volume (5 ml)as experimental rescue medications
215129137|NCT03367728|DRUG|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
215129138|NCT03367728|DRUG|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
215129139|NCT03761927|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
215129140|NCT03761927|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
214448264|NCT06796517|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
214448265|NCT06796517|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
214448266|NCT06796517|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
214448267|NCT06794749|OTHER|Action Observation Therapy|Patients received general physiotherapy in addition to action observation therapy (AOT) via telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face to face for 45 minutes.
215129141|NCT03761927|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
215129142|NCT05670522|DEVICE|Transcranial direct current stimulation|"Transcranial direct-current stimulation (tDCS), over the motor cortex, is a potential therapy option for motor control deficits in children with CP. The application of tDCS involves positioning 2 rubber electrodes sheathed in saline-soaked pads onto the scalp, held in place by a rubber strap. Low-intensity, direct-current, of 1 to 2 mA, is delivered to cortical areas from the device.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
214448268|NCT06794749|OTHER|Control|Patients received general physiotherapy in addition to action observation therapy (AOT) via face-to-face telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face-to-face for 45 minutes.
214448269|NCT06788158|DRUG|Incobotulinum Toxin A|will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
214448270|NCT06788158|DRUG|Glucocorticoid|Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
214448271|NCT03320707|DRUG|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
214448272|NCT03320707|DRUG|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
214448273|NCT03320707|DRUG|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
214448274|NCT03484702|DRUG|JCAR017|Specified dose on specified days
214448275|NCT01226979|RADIATION|High-dose endorectal brachytherapy (HDRBT)|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
214448276|NCT06838975|DEVICE|VR Training|Participants in the VR Training Group will undergo a virtual reality-based rehabilitation program designed to improve cognitive, emotional, social, and motor functions. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), using immersive and non-immersive VR systems tailored to individual needs. The program integrates interactive exercises, real-time feedback, and task-oriented training to enhance motor function, cognitive abilities, and patient engagement. Neurophysiological changes will be monitored through EEG, MRI, and motion analysis to assess brain plasticity and functional improvements.
214448277|NCT06838975|OTHER|traditional cognitive and motor rehabilitation following standard clinical practices|Participants in the Active Control Group will receive traditional cognitive and motor rehabilitation following standard clinical practices. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), focusing on conventional physical therapy, cognitive training, and task-oriented exercises to enhance motor function and cognitive abilities. This group serves as a comparison to evaluate the effectiveness of VR-based rehabilitation. Neurophysiological changes will be monitored using EEG, MRI, and motion analysis to assess functional improvements.
214448278|NCT06836570|BIOLOGICAL|Platalet Rich Plasma|Platelet-rich plasma (PRP) is a preparation of autologous human platelet concentration enriched in a small amount of plasma produced by centrifuging a patient's own blood. It is applied to the extraction socket after the extraction of an impacted wisdom tooth.
214448279|NCT06836570|OTHER|Low Level Laser Therapy|Low-level laser therapy is a technology that has been used since the mid-1960s to treat a variety of conditions requiring healing stimulation, pain and inflammation relief, and restoration of function. A single 940 nm diode laser was applied intraorally for 120 seconds (BIOLASE) immediately after the extraction and suturing of an impacted wisdom tooth.
214448280|NCT06794944|DRUG|Vancomycin (POC)|Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. Patients will receive 125mg PO every 6 hours for 10 days.
214448281|NCT06794944|DRUG|Fidaxomicin|Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. Patients will receive 200mg PO twice daily for 10 days.
214448282|NCT06796530|PROCEDURE|Cardiopulmonary exercise test (CPET)|Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).
214448283|NCT06796530|PROCEDURE|High-intensity circuit training|The patients will undergo a 10-minute warm-up, followed by \~30 high intensity exercise circuit.
214448284|NCT06794957|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
214524647|NCT05374967|BEHAVIORAL|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
214524648|NCT05374967|OTHER|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
214524649|NCT01794351|DIETARY_SUPPLEMENT|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
214694469|NCT01057069|DRUG|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
214524650|NCT01794351|OTHER|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
214524651|NCT01959009|OTHER|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
214524652|NCT05022953|OTHER|Education, dijital storytelling|Digital story
214524653|NCT01150305|BIOLOGICAL|blood sample|Peripheral whole blood sample, 5 ml
215129143|NCT05670522|DEVICE|Virtual reality|"Virtual reality rehabilitation is an emerging therapy for motor rehabilitation of children with CP. The therapy is provided through a computer-simulated environment where they interact with real-world-like objects and events through sight, sound, and touch. The Wii Remote was used as the interactive interface, and standard computer/television screens were used as the display hardware. Therefore, VR therapy was of the non-immersive type.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
215129144|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
215129145|NCT03389022|DRUG|Saline|Intravenous injection given pre-incisional in the operating room.
215129146|NCT03389022|DRUG|Ketamine|0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
215129147|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.
214448286|NCT05947071|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
214448287|NCT05947071|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
214448288|NCT02780128|PROCEDURE|Biopsy|Needle or incisional tumor biopsy
214448289|NCT02780128|GENETIC|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
214448290|NCT02780128|PROCEDURE|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
214524654|NCT02313077|BIOLOGICAL|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
214524655|NCT02313077|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
214524656|NCT02313077|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
215129148|NCT03389022|DRUG|Ketamine|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
215129149|NCT03626259|DRUG|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
215129150|NCT03626259|DRUG|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
215129151|NCT02787395|PROCEDURE|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
214524660|NCT02097316|DEVICE|JewelPump|
214524661|NCT02097316|DEVICE|usual insulin pump|
214524662|NCT05928520|DRUG|Tramadol 5%|Topical tramadol 5%
214524663|NCT05928520|DRUG|Lidocaine 2%|Topical Lidocaine 2%
214524664|NCT05224245|DEVICE|ACURATE Prime XL Transfemoral Aortic Valve System|ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
214524665|NCT02195180|DRUG|ERY001|
214524666|NCT02195180|DRUG|Gemcitabine|
214524667|NCT02195180|DRUG|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
214524668|NCT00389285|DRUG|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
214524669|NCT00389285|DRUG|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
215129152|NCT02050477|PROCEDURE|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
215129153|NCT01329302|PROCEDURE|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
215129154|NCT00526292|BIOLOGICAL|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
215129155|NCT00526292|DRUG|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
215129156|NCT00526292|DRUG|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
215129157|NCT03899714|OTHER|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
215129158|NCT05918796|DRUG|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
215129159|NCT05918796|DRUG|Dexamethasone|dexamethasone
215129160|NCT02278406|OTHER|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
214524670|NCT01558245|DRUG|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
214524671|NCT03640793|DEVICE|Implantation|Implantation of 6 PPIS implants
214524672|NCT02703519|PROCEDURE|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
214524673|NCT03994185|DEVICE|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
214524674|NCT01305551|DRUG|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
214524675|NCT01305551|DRUG|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
214524676|NCT01305551|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
214524677|NCT01469884|DRUG|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
214524678|NCT01469884|DRUG|Cyclosporine|Trough level should be between 100 and 200ng/ml.
214524679|NCT01469884|DRUG|Tacrolimus|Trough level should be between 5 and 10ng/ml.
214524680|NCT02274116|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
214524681|NCT02274116|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
214524682|NCT04867499|OTHER|No intervention|Descriptive study. No intervention.
214524683|NCT01895868|OTHER|Simulation-based ultrasound training|
214524684|NCT05301725|OTHER|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
214524685|NCT05301725|OTHER|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
214524686|NCT03984734|PROCEDURE|Pancreatoduodenectomy with antrectomy|
214524687|NCT03984734|PROCEDURE|Pylorus-preserving pancreatoduodenectomy|
214524688|NCT01425697|OTHER|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
214524689|NCT01425697|OTHER|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
214694470|NCT05617404|DIAGNOSTIC_TEST|CT scan|Polytrauma patients with thoracic CT-scan
214524690|NCT04992884|DEVICE|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
214524691|NCT02226029|OTHER|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions"
214524692|NCT03879252|DEVICE|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
214524693|NCT03879252|DRUG|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
215129161|NCT00756106|DRUG|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
215129162|NCT00756106|OTHER|Imaging biomarker analysis|MRI
215129163|NCT00756106|RADIATION|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
215129164|NCT03918616|DRUG|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
215129165|NCT03418155|DRUG|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
214524694|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
214524695|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
214524696|NCT00683371|PROCEDURE|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
214524697|NCT00683371|PROCEDURE|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
214524698|NCT05058547|DEVICE|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
214524699|NCT06319924|DRUG|Simethicone combined with Macrogol 4000 (PEG)|bowel preparation product for colonoscopy as part of CRC screening
214524700|NCT06085859|DEVICE|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
214524701|NCT06085859|DEVICE|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
214524702|NCT05333133|DIETARY_SUPPLEMENT|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
214524703|NCT03761979|DIETARY_SUPPLEMENT|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
215129166|NCT03418155|DRUG|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
215129167|NCT05818488|OTHER|Experimental mind-body intervention|A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
215129168|NCT01718379|DRUG|Lenalidomide|Lenalidomide:10 mg per day during 21 days
215129169|NCT01718379|DRUG|Epoetin beta|Epoetin beta: 60,000 Units/week.
215129170|NCT00171379|DRUG|Enteric-Coated Mycophenolate Sodium|
215129171|NCT02263469|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
214524704|NCT01432223|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
214524705|NCT00782353|DRUG|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
214524706|NCT00782353|DRUG|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
214524707|NCT00782353|DRUG|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
214524708|NCT05208021|BEHAVIORAL|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
214524709|NCT02199171|DRUG|carboplatin|Given via HIPEC
214524710|NCT00990821|DRUG|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
215129172|NCT04980534|DIETARY_SUPPLEMENT|Viusid and Asbrip|Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
215129173|NCT04980534|DRUG|COVID-19 Standard Therapy|Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
214524711|NCT00990821|DRUG|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
215129174|NCT04069559|OTHER|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
215129175|NCT04077021|DRUG|CCW702|Investigational immunotherapy for prostate cancer
215129176|NCT00837902|DRUG|Atenolol (β-blocker)|25 mg tablet
215129177|NCT03072446|DEVICE|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
214524712|NCT00990821|DRUG|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
214524713|NCT00990821|DRUG|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
214524714|NCT00990821|DRUG|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
214524715|NCT00990821|DRUG|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
214524716|NCT00990821|DRUG|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
214524717|NCT00990821|DRUG|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
214524718|NCT00990821|DRUG|Placebo|Placebo matching MK-0517
214524719|NCT00990821|DRUG|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
214524720|NCT00990821|DRUG|125 mg Aprepitant|Aprepitant oral tablet, single dose
215129178|NCT04888624|DEVICE|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
215129179|NCT04888624|DEVICE|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
215129180|NCT04013308|PROCEDURE|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
215129181|NCT00900978|BIOLOGICAL|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
215129182|NCT03806192|BEHAVIORAL|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
215129183|NCT03806192|OTHER|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
215129184|NCT03806192|OTHER|Questionnaire Administration|Ancillary studies
214524721|NCT00990821|DRUG|2 mg Midazolam|Midazolam oral tablet, single dose
214524722|NCT05306223|DRUG|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
214524723|NCT05306223|DRUG|Levofloxacin|Levofloxacin filmcoated will be administered orally
214524724|NCT05306223|DRUG|Linezolid|Linezolid tablets will be administered orally
214524725|NCT05306223|DRUG|Cycloserine|Cycloserine capsules will be administered orally.
214524726|NCT05306223|DRUG|Clofazimine|Clofazimine capsules will be administered orally.
214524727|NCT05306223|DRUG|Pyrazinamide|Pyrazinamide tablets will be administered orally.
214524728|NCT05306223|DRUG|Protionamide|Protionamide enteric-coated tablets will be administered orally.
214524729|NCT02862158|DEVICE|FDT visual field|
214524730|NCT02862158|DEVICE|Standard HVF|
214524731|NCT05781984|PROCEDURE|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
214524732|NCT01631799|DEVICE|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
214524733|NCT01631799|DEVICE|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
214524734|NCT03468387|PROCEDURE|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
214524735|NCT03468387|PROCEDURE|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
214524736|NCT00469352|DRUG|Ranibizumab|Ranibizumab as needed
214524737|NCT06269796|DIAGNOSTIC_TEST|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
214524738|NCT06269796|DIAGNOSTIC_TEST|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
214708829|NCT02001363|DRUG|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
214524739|NCT01328483|PROCEDURE|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
214448291|NCT02780128|PROCEDURE|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
214448292|NCT02780128|OTHER|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
214448293|NCT02780128|OTHER|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
214448294|NCT02780128|OTHER|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
214448295|NCT02780128|OTHER|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
214448296|NCT02780128|BEHAVIORAL|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
214448297|NCT02780128|OTHER|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
214448298|NCT02780128|OTHER|Echocardiogram|The participant will have an Echocardiogram (ECHO), an ultrasound of the heart, taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
214448299|NCT02780128|DRUG|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
214448300|NCT02780128|DRUG|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
214448301|NCT06790186|BEHAVIORAL|Perceive, Recall, Plan and Perform intervention Interventions:|The PRPP is a standardized system which determines the impact of information processing on performance of everyday activities. It is a method for assessment of performance mastery, and efficient use of cognitive strategies, as well as a model of intervention to train mastery and cognitive strategy use, in everyday activities. The PRPP assess task performance mastery, as well as cognitive strategy application
214448302|NCT04929899|BEHAVIORAL|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
214708830|NCT02001363|DRUG|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
214448304|NCT06839391|DRUG|Hyaluronidase|Effect of hyaluronidases in different doses added to bupivacaine on quality of ultrasound-guided TAB block during CS ,
214448305|NCT06840704|DIETARY_SUPPLEMENT|Oral immunonutrition|Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.
214448306|NCT03604263|DEVICE|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
214448307|NCT04533061|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
214448308|NCT06840925|DRUG|PRAX-628|Once daily oral
214448309|NCT06797115|DRUG|SGLT-2 inhibitor|T2D patients for whom, in addition to administering any existing antidiabetic regimen, the treating physician decided to initiate SGLT-2 inhibitor therapy (empagliflozin or dapagliflozin) based on standard clinical indications.
214448310|NCT06736288|DRUG|BUCCALIN®|"Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach."
214448311|NCT06736288|OTHER|Placebo|Gastro-resistant tablets containing only excipients). The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
214524740|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
214524741|NCT00308113|DRUG|Prednisone|Prednisone 0/75 mg/kg/day.
214448312|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
214448313|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
214448314|NCT02651324|DRUG|Ketamine|
214448315|NCT02651324|OTHER|Placebo|
214448316|NCT05789147|DEVICE|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
214448317|NCT05789147|DEVICE|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
214524742|NCT00308113|DIETARY_SUPPLEMENT|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
215129185|NCT03327493|DIAGNOSTIC_TEST|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
215129186|NCT03180385|DEVICE|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
215129187|NCT03180385|DEVICE|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
215129188|NCT04338282|DRUG|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
215129189|NCT05403996|BEHAVIORAL|Activa-Mente|Active break program
215129190|NCT03324776|DRUG|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
215129191|NCT00441623|BEHAVIORAL|observational|effect of protein-bound uremic retention solutes
215129192|NCT03139760|BEHAVIORAL|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
215129193|NCT03289793|OTHER|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
215129194|NCT03289793|OTHER|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
215129195|NCT03289793|OTHER|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
215129196|NCT05096624|OTHER|DD-TENS system|Use of DD-TENS system
215129197|NCT05096624|OTHER|Gold Standard|Gold standard
215129198|NCT05096624|OTHER|Digital Denture system|Use of Digital Denture system
215129199|NCT03630796|DRUG|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
215129200|NCT03630796|DRUG|TIVA|Total intravenous anesthesia
215129201|NCT05249023|OTHER|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
214448318|NCT01974245|DRUG|Cholecalciferol|100,000 IU/week for 12 weeks
214448319|NCT01974245|DRUG|Placebo|100 drops/ week for 12 weeks
214448320|NCT06782334|DRUG|AMT-116|AMT-116 is an antibody Drug Conjugate (ADC)
215129202|NCT04274816|DRUG|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
215129203|NCT01406301|DRUG|fondaparinux|fondaparinux
215129204|NCT04480320|PROCEDURE|pericapsular nerve group block|Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
214448321|NCT06781216|BEHAVIORAL|Motivational interviewing|It is emphasized that motivational interviewing is a feasible intervention that can be used by various health professionals to optimize clinical outcomes in cancer patients and survivors, helping individuals to better cope with the stress they experience related to cancer and improve their quality of life. Considering the benefits of motivational interviewing on individuals diagnosed with cancer, it is anticipated that the intervention planned in the study will improve coping strategies, reduce post-traumatic stress symptoms, and increase the level of post-traumatic growth in women with endometrial cancer.
214524743|NCT05563987|BEHAVIORAL|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
214524744|NCT05563987|BEHAVIORAL|DE|DE
214524745|NCT05986799|DIETARY_SUPPLEMENT|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
214524746|NCT05986799|DIETARY_SUPPLEMENT|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
215129205|NCT03944928|OTHER|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
215129206|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
215129207|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
215129208|NCT03678272|PROCEDURE|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
215129209|NCT03678272|PROCEDURE|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
215129210|NCT03735836|OTHER|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
215129211|NCT00531765|OTHER|sodium bicarbonate infusion|short infusion of sodium bicarbonate
214448322|NCT06122285|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
214448323|NCT02560805|PROCEDURE|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
214448324|NCT02560805|BEHAVIORAL|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
214448325|NCT02560805|PROCEDURE|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
214448326|NCT02560805|PROCEDURE|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.
214448327|NCT02560805|DRUG|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
214448328|NCT02560805|DRUG|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
214448329|NCT02560805|DRUG|Losartan|Losartan will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
214448330|NCT02560805|DRUG|Atenolol|Atenolol will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
214448331|NCT02560805|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) is administered using the gammaCore (ElectroCore) TENS device. The gammaCore device is a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and two buttons to power on the device and for operator control of the stimulation intensity (range 0-40). A small amount of conductive gel is applied to the pair of stainless steel round discs on the device are placed vertically on the skin with the gel. The stimulation is increased until there is a strong vibration and slight muscle contraction in the lower face or neck (usual intensity 15-25). Then the dose is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes of treatment. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
214448332|NCT02560805|DEVICE|Sham Transcutaneous Vagal Nerve Stimulation (tVNS)|A sham device that is identical to the gammaCore device will be provided to participants. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
214524747|NCT04282863|PROCEDURE|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
214524748|NCT04282863|PROCEDURE|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
215129212|NCT04839939|OTHER|Conventional physical therapy|Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
215129213|NCT04839939|OTHER|Ankle Foot Orthosis|Solid prescribed AFO with a wearing schedule of 6-12 hours per day
215129214|NCT04839939|OTHER|Combination Taping|Combination between elastic and inelastic taping
215129215|NCT05313113|BEHAVIORAL|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
215129216|NCT01152658|BIOLOGICAL|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
215129217|NCT01152658|OTHER|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
215129218|NCT00539981|BIOLOGICAL|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
215129219|NCT00539981|BIOLOGICAL|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
215129220|NCT02675907|DRUG|N1539|
215129221|NCT02675907|DRUG|Intravenous Placebo|
215129222|NCT05298488|BEHAVIORAL|Home office|Working from home
215129223|NCT05298488|BEHAVIORAL|Office|Working at the office
215129224|NCT01611792|OTHER|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
214448333|NCT04559256|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
214448334|NCT06172764|DIETARY_SUPPLEMENT|Vitamin D supplements along with behavioral modification|"Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
214448335|NCT06172764|COMBINATION_PRODUCT|Topical fluoride application and Vitamin D supplements along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
214448336|NCT06172764|PROCEDURE|Topical fluoride application along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
214448337|NCT05581758|DRUG|AMG 510|Oral Tablet
214448338|NCT06847620|PROCEDURE|Supraclavicular Brachial Plexus Block|The block will be performed using a portable ultrasound system (sonosite M-turbo USA) with linear high-frequency transducer (12HZ) to get the sonographic anatomy of brachial plexus in the transverse and longitudinal planes.
214448339|NCT06847620|DRUG|Bupivacaine 0.25% 20ml alone|will receive 20 ml of plain bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml of normal saline.
214448340|NCT06847620|DRUG|bupivacaine 0.25% And verapamil|will receive 20 ml of bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml verapamil (equivalent to 5 mg
214448341|NCT03465592|DRUG|Nivolumab|Administered IV
214448342|NCT06135974|DRUG|LC106|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
214448343|NCT06135974|DRUG|LC115|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
214448344|NCT06135974|DRUG|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
214448345|NCT06135974|DRUG|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
214448346|NCT06304077|OTHER|Forest|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
214448347|NCT06304077|OTHER|Urban|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
214448348|NCT06304077|OTHER|Rural|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
214448349|NCT06847789|DEVICE|Tensi+|Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
214448350|NCT06146348|BEHAVIORAL|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
214524749|NCT06983808|OTHER|Digital Cardiac Prehabilitation|Digital Cardiac Prehabilitation - A combined telehealth and app-based preparation for cardiac surgery
214524750|NCT06983808|OTHER|Control (Standard treatment)|Standard preparation for surgery as per Melbourne Health hospital procedures and processes. This may include information sessions, pamphlets, and meetings with clinicians. This does not include a prehabilitation program.
214524751|NCT05351411|OTHER||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
214524752|NCT01307540|DEVICE|phototherapy|low level light therapy, broad band light wavelengths.
214524753|NCT07007975|BEHAVIORAL|Web based training|This group will receive information about healthy lifestyle behaviors and gynecological cancer awareness.
215129225|NCT01611792|OTHER|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
215129226|NCT00896714|DEVICE|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
215129227|NCT05252546|DRUG|pyrotinib tablet|single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
215129228|NCT05252546|DRUG|Montmorillonite Power|3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
215129229|NCT05252546|DRUG|Loperamide|4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
215129230|NCT04326920|DRUG|Sargramostim|Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
215129231|NCT04326920|OTHER|Control|Standard of care
215129232|NCT02313220|DRUG|Dapagliflozin|Oral use
215129233|NCT02313220|DRUG|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
215129234|NCT02313220|DRUG|Placebo|Oral and Subcutaneous use.
215129235|NCT03920345|DEVICE|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
215129236|NCT04896528|DRUG|Avatrombopag|"* Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment."
215129237|NCT02693808|PROCEDURE|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
215129238|NCT02693808|PROCEDURE|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
215129239|NCT04931264|DIAGNOSTIC_TEST|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
215129240|NCT01222845|DRUG|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
215129241|NCT02898454|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
215129242|NCT02898454|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
215129243|NCT02898454|DRUG|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension~Route of administration: Intranasal"
215129244|NCT00148902|DRUG|lapatinib|lapatinib
215129245|NCT00148902|DRUG|docetaxel|docetaxel
215129246|NCT00701285|DRUG|pitavastatin|pitavastatin 4mg once daily
215129247|NCT00701285|DRUG|pravastatin|pravastatin 10mg once daily
215129248|NCT03144739|OTHER|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
215129249|NCT03144739|OTHER|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
215129250|NCT01476423|DRUG|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
215129251|NCT05823402|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
215129252|NCT00106847|DRUG|Infliximab|
214448351|NCT06847880|DRUG|1: Vitamin C Supplementation|• Vitamin C (Ascorbic Acid): This intervention involves the administration of vitamin C, which is known for its antioxidant properties. The concentration will be 120 mg in 1.2 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.2 ml (20 mg) of the vitamin C. It is hypothesized to accelerate orthodontic tooth movement by reducing oxidative stress and promoting collagen synthesis.
214448352|NCT06847880|DRUG|Vitamin E Supplementation|• Vitamin E (Tocopherol Acetate): This intervention uses vitamin E, another antioxidant, thought to reduce inflammation and support tissue repair, potentially improving the effectiveness of orthodontic treatment by enhancing tissue recovery and reducing side effects. The concentration will be 60 mg in 0.4 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.07 ml (10 mg) of the vitamin E.
214448353|NCT06847880|OTHER|Saline Solution (Control)|Saline Solution (Control): The control group will receive a saline solution, which is a placebo, allowing for the comparison of the effects of vitamin C and vitamin E on orthodontic tooth movement without the influence of additional nutrients.
214448354|NCT06847048|PROCEDURE|Thermophore pad warming group|Thermophore pad waa using heel warming
214448355|NCT06847048|PROCEDURE|Warm towel warming group|In this group, to warm the heel, the heel area where the blood would be taken was wrapped with a previously heated towel before heel prick.
214448356|NCT06847048|OTHER|Control group|in this group, heel prick intervention was performed in line with the routine interventions of the clinic.
214448357|NCT03062319|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
214448358|NCT03062319|DRUG|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
214448359|NCT05315167|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
214448360|NCT06584032|DRUG|fruquintinib|Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
214448361|NCT06584032|BIOLOGICAL|sintilimab|Sintilimab will be intravenously administrated on Day 1 every three weeks.
214448362|NCT06584032|DRUG|paclitaxel|175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
214524754|NCT05843695|BEHAVIORAL|iTCBT-I|Individual format over 2 weeks
214524755|NCT05843695|BEHAVIORAL|iTCBT-G|Group format over 2 days
214524756|NCT05843695|BEHAVIORAL|TAU|Standard care
214524757|NCT07009028|COMBINATION_PRODUCT|Storigami figure|Combination Produc: The origami figure that will be formed as a result of the process will be used as a distraction method
214524758|NCT07007728|DRUG|Iparomlimab/Tuvonralimab|5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days). Duration: 3 or 6 cycles
214524759|NCT07007728|DRUG|Bevacizumab + CAPEOX|"Bevacizumab: 7.5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days).~Capecitabine: 1000 mg/m2 twice daily orally on Day 1-14 of each cycle (every 21 days).~Oxaliplatin: 130 mg/m2 intravenous infusion on Day 1 of each cycle (every 21 days).~Duration:~Conversion therapy phase: 3 or 6 cycles; Postoperative follow-up phase (for patients with successful conversion surgery ): 3 or 6 cycles (a total perioperative duration of 9 cycles); Maintenance phase (for patients without successful conversion surgery ): Continuous therapy until disease progression, intolerable adverse events, withdrawal of consent, loss to follow-up, death, or study termination."
214524760|NCT07007728|PROCEDURE|Surgical resection ± ablation or stereotactic radiotherapy (if applicable)|After 3 or 6 cycles of conversion therapy, surgical resection ± ablation or stereotactic radiotherapy will be provided if applicable.
214448363|NCT06584032|DRUG|doxorubicin|60mg/m\^2 via IV infusion, on Day 1 every three weeks.
214448364|NCT05410353|BEHAVIORAL|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing \< 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
214524761|NCT07007546|DRUG|ABSK061|A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.
214524762|NCT07007546|DRUG|ABSK061|A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.
215129253|NCT02953600|DIETARY_SUPPLEMENT|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
215129254|NCT02953600|OTHER|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
215129255|NCT02953600|DIETARY_SUPPLEMENT|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
215129256|NCT02764463|DEVICE|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
215129257|NCT00002998|DRUG|cisplatin|
215129258|NCT00002998|DRUG|gemcitabine hydrochloride|
215129259|NCT00649844|DRUG|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
215129260|NCT00649844|DRUG|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
215129261|NCT01622959|PROCEDURE|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
215129262|NCT01601535|DRUG|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
215129263|NCT01601535|DRUG|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
215129264|NCT01601535|DRUG|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
215129265|NCT06021925|OTHER|Obstetrical history|Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.
215129266|NCT06021925|OTHER|Anti-HLA Antibody tests|Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.
214448365|NCT05410353|BEHAVIORAL|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
214448366|NCT05216250|BIOLOGICAL|BOTOX|Intramuscular injection
214448367|NCT05216250|DRUG|Placebo for BOTOX|Intramuscular injection
214524763|NCT07007546|DRUG|ABSK061|Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).
214524764|NCT05827549|DRUG|Reinduction(4weeks)|Prednisolone 60 mg/m2/day tid days 1-28, Vincristine 1.5 mg/m2 on days 1, 8, 15, 22, L-asparaginase 6,000 IU/m2(days 2-4 start, total 9 doses for 3 weeks), Idarubicin 10 mg/m2 on days 1, 8, (15\~17), IT Ara-C on days 1, IT MTX on days 8, 29
214524765|NCT05827549|DRUG|Cosolodation 1st(3weeks)|Ifosfamide: 1.8 g/m2 (days 1, 2, 3, 4, 5), Etoposide: 100 mg/m2 (days 1, 2, 3, 4, 5), IT MTX on day 1
214524766|NCT05827549|DRUG|Consolidation 2nd(3weeks)|MTX: 500 mg/m2 over 30 min followed by 1,000 mg/m2 over 23.5 hr (day 1), Ara-C: 3,000 mg/m2/dose (day 2, 3), IT MTX on day 1
214524767|NCT05827549|DRUG|Blinatumomab 1st(High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), Dexamethasone 5 mg/m2/dose on Day 1, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
215129267|NCT05539066|DEVICE|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
215129268|NCT03151629|OTHER|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
215129269|NCT01917383|DRUG|Trabodenoson|Ophthalmic eye drop
215129270|NCT01917383|DRUG|Latanoprost|Ophthalmic eye drop
215129271|NCT01917383|DRUG|Timolol|Ophthalmic eye drop
215129272|NCT04520607|DRUG|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
215129273|NCT04520607|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
215129274|NCT01777074|OTHER|Data collection|Questionnaire, Vaccination book
215129275|NCT05009498|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
215129276|NCT05009498|OTHER|Placebo|Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
215129277|NCT03596502|DRUG|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
215129278|NCT03596502|DRUG|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
215129279|NCT00352677|DRUG|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
214524768|NCT05827549|DRUG|Blinatumomab 2nd (High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
215129280|NCT06123078|BEHAVIORAL|CaCBT|Culturally adapted Self help guide and modules total eight 80 hour session per week
215129281|NCT06313216|PROCEDURE|duoteck membrane|the dehisced bone defect will be covered with duoteck membrane
215129282|NCT06313216|PROCEDURE|autogenous demineralized tooth graft|the dehisced bone defect will be covered with autogenous demineralized tooth graft
215129283|NCT06313216|PROCEDURE|autogenous demineralized tooth graft and plate|the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
214448368|NCT03873467|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
214448369|NCT03873467|OTHER|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
214448370|NCT04533555|GENETIC|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
214448371|NCT04533555|GENETIC|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
214448372|NCT06847334|DRUG|HLX17|HLX17 will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
214448373|NCT06847334|DRUG|US-sourced Keytruda®|US-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed. After 24 weeks, all subjects in the US-Keytruda® group will receive HLX17 in combination with Pemetrexed until loss of clinical benefit or up to 1 year.
214448374|NCT06847334|DRUG|EU-sourced Keytruda®|EU-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
214448375|NCT05926804|DRUG|Lansoprazole|14 days of Lansoprazole (30 mg BID) (days 1-14)
214448376|NCT05926804|DRUG|Amoxicillin|7 days of Amoxicillin (1000 mg BID) (days 1-7)
214448377|NCT05926804|DRUG|Clarithromycin|7 days of Clarithromycin (500 mg BID) (days 8-14)
214448378|NCT05926804|DRUG|Metronidazole|7 days of Metronidazole (500 mg BID) (days 8-14)
214448379|NCT06846970|OTHER|Experimental|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, TENS, ultrasound and balneotherapy, five days a week and once a day for four weeks. Exercise, hot pack, TENS, ultrasound therapy, and balneotherapy will be performed under the supervision of a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
214448380|NCT06846970|OTHER|Active Comparator|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, tens and ultrosound therapy five days a week and once a day for four weeks. It was planned to perform exercise, hot pack, tens, ultrasound therapy accompanied by a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
214448381|NCT06844279|OTHER|Control Group: Standard Hemodynamic Monitoring|Anesthesia depth monitoring based on hemodynamic values without additional processed EEG guidance.
214448382|NCT06844279|DEVICE|Processed Electroencephalogram (BIS Index)|Anaesthesia depth monitoring according to numeric BIS index values.
214448383|NCT06844279|DEVICE|Processed Electroencephalogram (DSA Mode)|Anaesthesia depth monitoring according to density spectral array functions
214448384|NCT04915495|DIAGNOSTIC_TEST|LuViva Advanced Cervical Scan|Multimodal hyperspectral device
214448385|NCT05988203|BIOLOGICAL|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
215129284|NCT06124963|DRUG|WX390|WX390 tablet, 0.9 mg once a day
215129285|NCT06124963|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
215129286|NCT01019070|DRUG|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
215129287|NCT05120362|DRUG|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
215129288|NCT02928575|DRUG|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
215129289|NCT02928575|DRUG|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
215129290|NCT02928575|RADIATION|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
215129291|NCT02911974|DEVICE|Acquire EUS Biopsy Device|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
215129292|NCT02911974|DEVICE|Expect EUS Aspiration Needle|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
215129293|NCT05287386|DRUG|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
215129294|NCT03292380|OTHER|No intervention was included|
215129295|NCT03649074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
214524769|NCT05827549|DRUG|Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks|Blinatumomab 9 mcg/day(Weight ≥ 45kg) or 5 mcg/m²/day(Weight \< 45kg) on 1-7 days, 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 8-28 days, Dexamethasone 5 mg/m2/dose on day 1 and day 8, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
214524770|NCT05827549|DRUG|Blinatumomab-Salvage 2nd (Very High Risk Group)_4 Weeks|Blinatumomab 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 1-28 days, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
215129296|NCT01943812|DRUG|Estradiol and progeterone|Estradiol and progesterone
215129297|NCT00795704|DRUG|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
215129298|NCT00795704|DRUG|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
215129299|NCT03980730|DRUG|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
215129300|NCT03980730|DRUG|Placebo|Matching placebo capsule administered orally, once daily
215129301|NCT00775099|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
215129302|NCT00775099|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
215129303|NCT05864417|OTHER|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
215129304|NCT05864417|OTHER|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
215129305|NCT00556894|DRUG|CF101|orally q12h
215129306|NCT00556894|DRUG|Placebo|orally q12h
215129307|NCT01949974|DRUG|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
215129308|NCT01949974|OTHER|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
215129309|NCT02331186|PROCEDURE|bariatric surgery|bariatric surgery for obese women
215129310|NCT01189474|DEVICE|Blephasteam|Eye lid warming goggles
214448386|NCT05622955|OTHER|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
214524771|NCT05827549|DRUG|Intensification course|"\<Intensification 1st(3 Weeks)\> Etoposide: 100 mg/m2 on day 1, 2, 3, Ifosfamide 3.4 g/m2 on day 1, 2, 3~\<Intensification 2nd(2 Weeks)\> Oral 6-mercaptopurine 50 mg/m2/day PO (days 1-14), Methotrexate: 25 mg/m2 on day 1, 8, TIT on day 1~\<Intensification 3rd(3 Weeks)\> Ara-C 1.0 g/m2 (days 1-3), Idarubicin: 5mg/m2 (days 1- 3)~\<Intensification 4th(2 Weeks)\> Dexamethasone 8 mg/m2/day on days 1-14, Vincristine 2 mg/m2 on days 1 and 8, L-asparaginase 10,000 IU/m2 on days 1 and 8"
214524772|NCT05827549|DRUG|Maintenance(12 Weeks/Cycle)|Prednisolone: 15 mg/m²/dose(Days 1-5, 29-33, 57-61), Vincristine: 1.5 mg/m²/dose(Day 1, 29, 57), Oral 6-mercaptopurine: 50 mg/m²/dose (Days 1-84), Methotrexate: 20 mg/m²/dose (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78), Intrathecal methotrexate (Day 1)
214524773|NCT05827549|PROCEDURE|Stem Cell Transplantation|All matters related to hematopoietic stem cell transplantation are subject to each institution's practice.
214524774|NCT02304289|DRUG|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
215129311|NCT06070792|OTHER|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
215129312|NCT06070792|OTHER|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
215129313|NCT05092672|BEHAVIORAL|Exercise|Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
215129314|NCT00361881|DRUG|ME-609|Cream, dose 5 times daily during 5 days.
215129315|NCT00361881|DRUG|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
215129316|NCT00361881|DRUG|Vehicle|Dose 5 times daily for 5 days
215129317|NCT02341352|DRUG|fluoride varnish|Sodium fluoride 50mg/ml
215129318|NCT02341352|BIOLOGICAL|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
215129319|NCT02341352|DIETARY_SUPPLEMENT|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
215129320|NCT01603303|BEHAVIORAL|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
215129321|NCT01603303|OTHER|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
215129322|NCT01603303|OTHER|Luvena|Use vaginally 2 or 3 times a week.
215129323|NCT01603303|OTHER|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
215129324|NCT01603303|OTHER|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
215129325|NCT01603303|BEHAVIORAL|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
214524775|NCT06697431|DRUG|Anakinra|"Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase."
214524776|NCT06697431|DRUG|Intravenous Immunoglobulins, Human|see previous section
214524777|NCT04300478|BEHAVIORAL|REx Condition First|REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.
214524778|NCT04300478|BEHAVIORAL|Sedentary Control Condition First|Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
214524779|NCT06720116|OTHER|sustained natural apophysial glide|"The patients will be in the sitting position and asked to move their head in the direction that particularly produces their symptoms. As the participant moves their head, the physiotherapist gently glides the painful vertebra anteriorly and sustains the glide through the movement.~During the application of the glide, the participant should stay symptom free and is instructed to stop moving if any PAIN is produced. This movement was repeated for 10 times for 3 sets, The interval between the sets was 15 to 20 seconds.After mobilization subject had to perform same exercises as conventional group plus conventional physical therapy"
214524780|NCT06720116|OTHER|instrument assisted soft tissue mobilization|"The subject will be in comfortable sitting position leaning on a treatment table with the arm crossed to rest the head. After cleaning the skin of the subject and the blade with alcohol swabs, a lubricant (Vaseline) was applied, and a sweeping technique was used to apply a deep yet comfortable soft tissue mobilization on the upper trapezius from origin to insertion for approximately 3 min.~First, M2T blade will be utilized to locate the precise locations of limitation in the affected muscles. Second, the M2T blade was put at 45 degree angle by using convex surface to apply gentle strokes along the muscle. Subjects were instructed that slight hyperemia on the skin is a normal feeling and should subside before the next session."
214524781|NCT06720116|OTHER|conventional physical therapy|the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
214524782|NCT06721546|OTHER|Nursing interventions|"The data collection process took place between March and June 2024. The implementation process took place between July 9 and October 24, 2024. In this process, education, reminder messages and telephone counseling for individuals with type 2 diabetes continued for 12 weeks.~Introduction and Preliminary Preparation: Before randomization, both oral and written informed consent form and pretest forms (Personal Information Form, Nutrition Habits, Functional Foods Information Form, Functional Foods Consumption Form, Diabetes Self-Efficacy Scale, Healthy Lifestyle Behaviors II Scale Application) were administered by the researcher to individuals with type 2 diabetes who agreed to participate in the study between March and June 2024. After reaching the sample size (n=86), randomization was performed. Appointments were made for the intervention group for training at KEAH via telephone on Tuesday-Thursday of the week in groups."
214524783|NCT06721546|OTHER|reminder messages|Reminder messages: Address and telephone numbers of individuals with Type 2 diabetes in the intervention group were obtained after obtaining their informed consent at the first meeting. After the group training, the messages were sent to the groups (groups A, B, C and D) on Tuesdays and Thursdays during daylight hours every week on the 2nd (July 23-August 15) and 6th (August 20-September 12) weeks. The message was a reminder to the participants about healthy nutrition and consumption of functional foods.
214524784|NCT06721546|OTHER|Telephone counseling|Telephone counseling: After the group trainings applied to the intervention group, in the 4th (August 6-August 29) and 8th (September 3-September 26) weeks of each week on Tuesdays and Thursdays during daylight hours, individuals with diabetes mellitus were questioned about 'the obstacles they encounter during healthy eating and functional food consumption and whether they have the belief that they can overcome these obstacles and whether there is a change in their healthy eating and functional food consumption behaviors'. Reinforcement was made with reminder questions. In this process, the importance of functional food consumption was emphasized. The first telephone interview with 43 individuals with type 2 diabetes lasted 575 minutes in total and the second telephone interview lasted 495 minutes in total.
214524785|NCT05420701|PROCEDURE|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
215129326|NCT01603303|BEHAVIORAL|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
215129327|NCT03477045|DIETARY_SUPPLEMENT|Single dose fish oil|Fish oil consumed within a single high fat test meal
215129328|NCT03477045|DIETARY_SUPPLEMENT|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
215129329|NCT03477045|DIETARY_SUPPLEMENT|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
215129330|NCT03477045|DIETARY_SUPPLEMENT|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
215129331|NCT00569140|DRUG|E10030|Intravitreal injection
215129332|NCT00622037|DRUG|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
215129333|NCT00622037|DRUG|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
214448387|NCT06221176|BEHAVIORAL|Being Brave|Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
214448388|NCT04639401|OTHER|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
214448389|NCT05956288|DEVICE|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
214448390|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
214448391|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
214448392|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
214448393|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
214448394|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
214448395|NCT04807218|BEHAVIORAL|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
214448396|NCT06285409|DRUG|Carbetocin|Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
214448397|NCT06285409|DRUG|Oxytocin|Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
214448398|NCT06285409|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
214448399|NCT06285409|DRUG|Oxytocin|Increasing concentrations of oxytocin from 10-10 M to 10-5 M
214448400|NCT06285409|DRUG|Ergonovine|Increasing concentrations of ergometrine from 10-10 M to 10-5 M
214448401|NCT06285409|DRUG|Carboprost|Increasing concentrations of carboprost from 10-10 M to 10-5 M
214448402|NCT03886311|DRUG|Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]|Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
214448403|NCT03886311|DRUG|Nivolumab IV Soln 100 MG/10ML|NIVOLUMAB 240 mg IV over 30 min q 2 weeks
214448404|NCT03886311|DRUG|Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution|TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
214448405|NCT04700969|OTHER|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
214448406|NCT01195831|DRUG|Xamiol® gel|Once daily application
214448407|NCT01195831|DRUG|Calcipotriol scalp solution|Twice daily application
214448408|NCT04916236|DRUG|RMC-4630|"* SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week"
214448409|NCT04916236|DRUG|LY3214996|"* ERK inhibitor~* Powder in capsule~* Administered every day"
214448410|NCT01857934|DRUG|cyclophosphamide|Given intravenously (IV)
214448411|NCT01857934|DRUG|topotecan|Given IV
214448412|NCT01857934|BIOLOGICAL|hu14.18K322A|Given IV
214448413|NCT01857934|PROCEDURE|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
214448414|NCT01857934|PROCEDURE|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
214448415|NCT01857934|DRUG|cisplatin|Given IV
214448416|NCT01857934|DRUG|etoposide|Given IV
214448417|NCT01857934|DRUG|doxorubicin|Given IV
214448418|NCT01857934|DRUG|vincristine|Given IV
214448419|NCT01857934|DRUG|busulfan|Given IV
214448420|NCT01857934|DRUG|melphalan|Given IV
214448421|NCT01857934|BIOLOGICAL|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
214448422|NCT01857934|BIOLOGICAL|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
215129334|NCT06152510|OTHER|Virtual Reality Rehabilitation System|In a single session to evaluate postural control, both children with ASD and typically developing peers will participate in an activity utilizing the Virtual Reality Rehabilitation System (VRRS) in conjunction with a stabilometric balance platform. During the assessment task, participants will stand on the balance platform with their eyes open, focusing on a fixed point displayed on the VRRS screen for a duration of one minute. This process will be repeated three times for each participant. The combined use of VRRS and the stabilometric balance platform aims to provide a comprehensive evaluation of postural control abilities in both groups, allowing for the observation and measurement of potential differences in stability and balance performance between children with ASD and their neurotypical counterparts.
215129335|NCT00395356|BEHAVIORAL|calorie controlled diet|
215129336|NCT06173414|OTHER|No intervention measures|No intervention measures
215129337|NCT00880620|DRUG|Placebo|Placebo
214448423|NCT01857934|RADIATION|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
215129338|NCT00880620|DRUG|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
215129339|NCT00880620|DRUG|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
215129340|NCT00880620|DRUG|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
215129341|NCT00880620|DRUG|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
215129342|NCT02536898|OTHER|Fracture Liaison Service|
215129343|NCT02536898|OTHER|Current treatment|
215129344|NCT03125226|DEVICE|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
215129345|NCT01467011|DRUG|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
215129346|NCT03883581|DRUG|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
215129347|NCT05006235|DRUG|Epinephrine Inhalation Solution|
215129348|NCT05006235|DRUG|Salbutamol|
215129349|NCT05006235|DRUG|Saline Inhalants|
215129350|NCT02624271|OTHER|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
215129351|NCT04612725|BIOLOGICAL|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
215129352|NCT04612725|BIOLOGICAL|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
215129353|NCT03659318|PROCEDURE|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
215129354|NCT03659318|PROCEDURE|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
214524786|NCT06721780|DEVICE|Participants randomised to wear AR headset|Participants will use an AR headset that employs a distraction game specifically designed for children and young adults undergoing painful procedures.
214524787|NCT06721780|DEVICE|Participants randomised to wear VR headset|Participants will utilise a VR headset, running a calming virtual environment or an interactive game during the dressing change.
215129355|NCT04712955|OTHER|Bloodflow restricted exercise|Low-intensity bloodflow restricted resistance exercise is conducted as traditional knee extension exercise with a load corresponding to 30% of 1 repetition maximum (RM), with concurrent partial occlusion of the circulation by means of inflatable pneumatic cuffs wrapped around the proximal part of the thighs. Cuffs are inflated to a pressure corresponding to 50% of the arterial occlusion pressure, which only compromises venous but not arterial blood flow.
215129356|NCT06313229|PROCEDURE|implant placement 6 months after ridge augmentation|the deficient ridge was grafted first followed by implant placement after 6-monthes
215129357|NCT06313229|PROCEDURE|implant placement Simultaneously with ridge augmentation|the deficient ridge was grafted and followed by implant placement simultaneously
215129358|NCT04854785|OTHER|[18F]FEPPA PET scan|One \[18F\]FEPPA PET for TSPO VT, and one MRI scan
214448424|NCT01857934|BIOLOGICAL|GM-CSF|Given subcutaneously (SQ)
214448425|NCT01857934|BIOLOGICAL|G-CSF|Given subcutaneously (SQ)
214448426|NCT01857934|DRUG|mesna|Given IV
214448427|NCT01857934|DRUG|levetiracetam|Given IV
214448428|NCT01857934|BIOLOGICAL|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
214448429|NCT01857934|DRUG|Isotretinoin|Given orally (PO)
214524788|NCT06717503|OTHER|data collection|data will be collected from data sheets of acute spinal cord injury patients (Patients' demographic and epidemiological ,Mode of trauma, Cause of injury, Method of arrival to hospital, Time passed between trauma and arrival at hospital,How to deal with the TSI patients from the time of the injury until arrival at hospital, Examination findings, Imaging findings, Type and level of the injury, Sequels, Hospital stay period and operations)
214524789|NCT04264884|DRUG|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
215129359|NCT04854785|OTHER|[11C]SL25.1188 PET scan|One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
215129360|NCT06848881|PROCEDURE|Cryoablation|The eligible patient will be randomized to cryoablation group to receive cryoablation.
215129361|NCT06848881|PROCEDURE|Thoracoscopic Surgery|The eligible patient will be randomized to thoracoscopic surgery group to receive surgery.
214524790|NCT06892587|BEHAVIORAL|An 8-week virtual group intervention designed to promote sustainable health behavior changes in participants|"The Healthy YOU Program is an 8-week virtual group intervention designed to help participants make lasting health behavior changes, focusing on diet and physical activity. Delivered via confidential Zoom sessions, it offers flexibility and support in a group setting. Participants engage in facilitated discussions, interactive activities, and expert guidance.~Participants receive a structured curriculum with a printed workbook, covering evidence-based topics like nutrition, exercise, and well-being. Learning methods include:~Weekly Newsletters: Provide health tips, resources, and reflections to support behavior change.~Facilitated Group Discussions: Live sessions to share experiences, ask questions, and support each other.~Applied Activities: Hands-on tasks like meal planning and goal-setting to build confidence.~Demonstrations: Live sessions on healthy cooking, home exercises, and overcoming barriers.~The program encourages goal setting, progress tracking, and self-regulation."
214524791|NCT06892587|BEHAVIORAL|Standard of care Nutritional Information|The standard of care will involve providing participants with 8 weeks of nutrition information through printed handouts. These handouts will be generic, similar to materials typically provided by healthcare providers or available on public-facing health/nutrition websites. While they will cover the same topics as the experimental group, the handouts will contain only basic, publicly available nutritional information and will not include guidance for application. These handouts are also included in the Healthy YOU curriculum as background material for weekly class preparation. Participants will be instructed to review and utilize the handout information in a self-paced manner over the 8-week period.
215129362|NCT00456404|DRUG|peppermint water|
214448430|NCT01857934|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
215129363|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
215129364|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
215129365|NCT04699656|DRUG|Plazomicin Injection|single dose of plazomicin
215129366|NCT02354235|DRUG|Teneligliptin|
215129367|NCT02354235|DRUG|Canagliflozin|
215129368|NCT02354235|DRUG|Placebo|
215129369|NCT06443372|OTHER|Clinical periodontal measurements, GCF sampling|"Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
215129370|NCT06148207|RADIATION|[18F]BF3-BPA Injection for PET Imaging|Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
215129371|NCT05931367|DRUG|Retatrutide|Administered SC
215129372|NCT05931367|DRUG|Placebo|Administered SC
215129373|NCT06051578|OTHER|Abdominal wall tension measurement|"All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
215129374|NCT05790460|OTHER|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
215129375|NCT05135377|OTHER|Observational|Not applicable - observational study
215129376|NCT04750642|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
215129377|NCT04750642|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
215129378|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
215129379|NCT06532084|DRUG|Sorafenib|Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
214448431|NCT05617872|DRUG|Vinegar 20ml|Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
214448432|NCT05617872|DRUG|Saline (NaCl 0,9 %) (placebo)|Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
214448433|NCT05617872|DRUG|Vinegar 40ml|Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
214448434|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
215129380|NCT01800097|DRUG|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
215129381|NCT01800097|DRUG|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
215129382|NCT04440826|OTHER|Whole Food Meal|Whole foods meal
215129383|NCT04440826|OTHER|Processed Food Meal|Processed food meal
214448435|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
215129384|NCT04440826|OTHER|Gluten-free and lactose-free|Gluten-free and lactose-free food meal
215129385|NCT02210728|DRUG|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
215129386|NCT02210728|BEHAVIORAL|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
215129387|NCT05245201|OTHER|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
215129388|NCT05245201|OTHER|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
215129389|NCT05986370|PROCEDURE|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
215129390|NCT05986370|PROCEDURE|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
215129391|NCT05986370|PROCEDURE|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
215129392|NCT05568446|BEHAVIORAL|Social virtual reality|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
215129393|NCT05568446|BEHAVIORAL|Traditional social skills|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
214448436|NCT05293041|DRUG|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
214448437|NCT05293041|DRUG|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
215129394|NCT04273334|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
214448438|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
214448439|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
214448440|NCT06220864|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
214448441|NCT04383314|BEHAVIORAL|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
214448442|NCT05164367|DRUG|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
214448443|NCT06241950|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
214448444|NCT06241950|BIOLOGICAL|imlifidase|IV infusion of Imlifidase
214524792|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
214524793|NCT06736600|BEHAVIORAL|Goal Attainment Scaling (GAS)|Goal-setting tele-coaching and the well-studied Patient Priorities Care framework will assist participants with bothersome CIPN identify their most important health goals and scale them into specific, measurable, achievable, relevant, and time-bound (SMART) goals
214524794|NCT05262244|DRUG|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
214448445|NCT06784986|DEVICE|The Conventional Insufflation System|The Conventional Insufflation System employs standard CO2 insufflation techniques for maintaining intra-abdominal pressure during laparoscopic and robotic surgeries. It serves as the base for comparison with the AirSeal® System.
215129395|NCT00663364|DRUG|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
214448446|NCT06784986|DEVICE|AirSeal® System|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple-lumen filtered tube set, and a valve-free trocar (AirSeal® Access Port). This innovative system allows peritoneal access and pneumoperitoneum maintenance without a mechanical seal, reducing CO2 usage and associated complications.
214524795|NCT02026583|DRUG|Simvastatin|
215129396|NCT04959396|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
215129397|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
215129398|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
214524796|NCT02630927|DRUG|AG-519|AG519 will be tested.
214524797|NCT02630927|DRUG|Placebo|Placebo will be tested.
214524798|NCT01651650|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
215129399|NCT02728180|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
215129400|NCT02728180|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
215129401|NCT06667089|OTHER|Povidone-Iodine|The povidone-iodine group will receive a 10% povidone-iodine solution or gel applied directly to the wound after gentle cleaning, with the treatment applied according to a set frequency, typically twice daily. This antiseptic will be left on the wound for a brief period to enhance its antimicrobial action.
215129402|NCT06667089|OTHER|Chlorhexidine|The chlorhexidine group will receive a chlorhexidine solution, usually at a concentration of 0.5% to 2%, applied similarly after cleaning the wound. This solution will remain on the wound according to protocol guidelines, also typically applied twice daily. Both groups will be monitored for adverse reactions, signs of infection, and the overall effectiveness of wound healing throughout the treatment period.
215129403|NCT05913908|DEVICE|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
215129404|NCT06674642|OTHER|Traditional Indigenous Foods diet|A diet composed of traditional indigenous foods will be given to participants.
215129405|NCT04902339|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
215129406|NCT04902339|OTHER|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
214524799|NCT04233333|DEVICE|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
214524800|NCT06086522|DRUG|QN-302|Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
214524801|NCT01503437|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
214524802|NCT01802892|DRUG|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
214524803|NCT01802892|DRUG|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
214524804|NCT01802892|DRUG|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
214524805|NCT00874484|DRUG|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
214524806|NCT04983225|DRUG|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
215129407|NCT04902339|BEHAVIORAL|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
215129408|NCT06689241|DRUG|Enoxaparin|40mg
215129409|NCT06689241|DRUG|rivaroxaban|10mg
215129410|NCT06727097|DIAGNOSTIC_TEST|Posturography|"Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns."
215129411|NCT06727097|DIAGNOSTIC_TEST|Walking Speed|The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.
215129412|NCT06727097|DIAGNOSTIC_TEST|Instrumented 7M Timed UP and GO|This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.
215129413|NCT06727097|OTHER|Fall Event Records|A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.
215129414|NCT06727097|DIAGNOSTIC_TEST|MRI (3T)|Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
215129415|NCT06895928|DRUG|SHR-A2102|SHR-A2102 for injection.
215129416|NCT06895928|DRUG|Bevacizumab Injection|Bevacizumab injection.
215129417|NCT06895928|DRUG|Adebelimab Injection|Adebelimab injection.
215129418|NCT06895928|DRUG|Ametinib Mesylate Tablets|Ametinib mesylate tablets.
215129419|NCT06895928|DRUG|Osimertinib Mesylate Tablets|Osimertinib mesylate tablets.
215129420|NCT06841731|DRUG|HRS-8427|HRS-8427 for injection.
215129421|NCT06841731|DRUG|Meropenem|Meropenem for injection.
214448447|NCT06786975|DEVICE|Silver Diamine Fluoride|"Tooth will be isolated with cotton rolls, the oral cavity will be dried with small cotton balls and the gingiva around the tooth, and surrounding structures, will be protected with vaseline. Then the silver diamine fluoride solution will be applied to cavitated caries lesions with a micro applicator for one minute approximately. If necessary the solution excess should be removed with a gauze.~Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears."
214448448|NCT06786975|PROCEDURE|Atraumatic Restorative Treatment|Participants will be treated with Atraumatic Restorative Treatment (ART) technique. Glass ionomer will be used for cavity filling (Ketac MolarTM, 3M ESPETM) according to manufacter specifications and will be applied with a spatula, followed by finger pressure using vaseline for a few seconds; for occluso-proximal cavities, a matrix band will be used. The restoration will be protected with vaseline and then the occlusion will be checked with articular paper after the initial adjustment (approximately 5 minutes). Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
214448449|NCT06786403|DIETARY_SUPPLEMENT|Bromelain|Dietary Supplement: Bromelain 1000 mg/day
214448450|NCT06786403|DIETARY_SUPPLEMENT|Placebo|Placebo (1000 mg/day)
214448451|NCT06783270|BIOLOGICAL|TIL therapy|Compared to traditional TIL-therapy, this study will include silencing of the PD-1 coding gene in the TILs using non-viral CRISPR-Cas9 prior to the rapid expansion protocol.
214448452|NCT06784960|BEHAVIORAL|Messages|We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.
214448453|NCT05595629|BEHAVIORAL|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
214448454|NCT05595629|BEHAVIORAL|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
214524807|NCT04983225|OTHER|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
214524808|NCT00439348|BEHAVIORAL|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
214524809|NCT00439348|BEHAVIORAL|Prescription|Patients receive a prescription for a specific over-the-counter medication.
214524810|NCT00747721|DRUG|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
214524811|NCT05347121|DIAGNOSTIC_TEST|difficult airway|ultrasonography of airway
215129422|NCT06928376|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75 mg/m2/day, days 1 to 7). Cytarabine (75-100 mg/m2 bid, days 1 to 5). Aclacinomycin(20 mg/day, days 1,3,5). Chidamide (30 mg/day , days 1,4,8,11). Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
215129423|NCT06928376|DRUG|"3+7"|"IA regimen:~Idarubicin (8-10 mg/m2) for 3 days . Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~Daunorubicin(60 mg/m2) for 3 days. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
215129424|NCT06938620|OTHER|Bottle with a flow restrictor|Flow restrictors added to liquid medicine bottles to determine whether they limit accessibility of liquid bottle contents to young children compared with control bottles without flow restrictors.
215129425|NCT06938620|OTHER|Control bottle|Traditional bottle either no cap or an incompletely-closed child-resistant cap
215129426|NCT06938204|DRUG|INV-101|SAD MAD
215129427|NCT06938204|DRUG|INV-101 Placebo|SAD MAD
215129428|NCT06937424|OTHER|Dry cotton pellet group|The contaminated dentine surface was scrubbed with a dry cotton pellet until no visible sealer remnants were observed
215129429|NCT06937424|OTHER|Ethanol-saturated cotton pellet 7 seconds group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet for 7 seconds
215129430|NCT06937424|OTHER|Ethanol-saturated cotton pellet visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed.
215129431|NCT06937424|DEVICE|Ethanol-saturated cotton Pellet + air polishing group|After the contaminated dentine surface scrubbing with an 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed, air polishing was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Sodium bicarbonate powder (Velopex) was applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
215129432|NCT06937424|OTHER|Microbrush 7 sec group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush for 7 seconds
215129433|NCT06937424|OTHER|Microbrush visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush until no visible sealer remnants were observed.
215129434|NCT06937424|DEVICE|Air abrasion group|Air abrasion was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Aluminium oxide particles (53 µm, Velopex) were applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
215129435|NCT06938139|OTHER|None-placebo|None, observational study
215129436|NCT06938217|DEVICE|Low-flow ECMO|low-flow ECMO, defined as 1-2.5 L of blood flow/min.
215129437|NCT06937112|OTHER|PET-CT examination|Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination
215129438|NCT06938659|DRUG|Emicizumab Injection|Emicizumab 0.8-1.5mg/kg weekly for 4 weeks as loading dose. Then 0.8-1.5mg/kg 4-weekly for 24 weeks will be used in Emicizumab group-I and Emicizumab Group- WI
215129439|NCT06938659|DRUG|Factor VIII (FVIII)|10-15 unit/Kg thrice weekly (for conventional half-life products) or twice weekly (for extended half-life products) for 28 weeks. Inj. Factor VIII is available in 250U, 500U, 750U \& 1,000 IU vail sizes. Dose will be round up to full nearest full vail strength.
215129440|NCT06938243|DEVICE|Vagus Nerve Stimulation in early stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
215129441|NCT06938243|DEVICE|Vagus Nerve Stimulation in late stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
215129442|NCT06938737|BEHAVIORAL|laughter yoga|Laughter yoga sessions begin with gentle warm-up techniques that include stretching and flexing movements, songs, applause and body movements. These techniques aim to break down any inhibitions against laughter and develop childlike playfulness. Breathing exercises prepare the lungs for laughter and are combined with a series of laughter exercises that follow.
215129443|NCT06937632|BEHAVIORAL|sleep hygiene intervention|sleep program was done three times a week for 2 weeks for the study group (6 sessions in total). It took roughly 30 minutes for each session. sessions were demonstrated during the first 3 sessions, re-demonstration of all the 3 of other sessions. Over a course of two sessions, the older adults in the intervention group were taught how to perform sleep program. The telephone number of each subject was taken to check their consistency with the proposed nursing interventions.
215129444|NCT06937528|BIOLOGICAL|Extracellular vesicles|Intra-articular extravascular vesicles injection.
214448455|NCT06785259|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
215129445|NCT06938893|OTHER|Exercise|Cardiac output (CO) was measured after exercise intervention in patients with normal cardiac function
215129446|NCT06937268|DIAGNOSTIC_TEST|DOTATATE-PET scan|DOTATATE tracer PET scan for meningioma
214448456|NCT05373615|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
214448457|NCT06786845|OTHER|Treatment lege artis|Adequate treatment of sleep disorders at Sleep clinic
214524812|NCT05990270|BEHAVIORAL|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
214524813|NCT06244030|OTHER|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
215129447|NCT06938750|DEVICE|SECHOLD DEVICE|PLACEMENT OF A MULTIPLE THERAPY GRIPPING DEVICE TO FIX THE DRIPPER SYSTEMS ALONG ITS PATH TO SOME SURFACE OR SPACE, AVOIDING IT TO REMAIN IN THE AIR, WITHOUT MARKING OR LABELING AND FAVORING ITS ORGANIZATION. SECHOLD is a vascular access fixation device designed for critical clinical environments such as ICU and operating rooms. It allows the simultaneous connection of 3-6 parenteral therapies to the same vascular access, ensuring clear and protocolized identification of each drug by means of labels with name, concentration and infusion range, in addition to a universal color code. This reduces the risk of drug administration errors and facilitates optimal visualization of essential information. SECHOLD also organizes infusion systems connected to the same vascular access, preventing knots and pulls that can compromise catheter integrity in case of accidental infusion bag drops.
215129448|NCT06939374|DEVICE|Intracoronary Cryotherapy|Intracoronary cryotherapy for stabilization of High-risk coronary plaque
215129449|NCT06938503|DRUG|AG regimen|Patients will receive 4 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
215129450|NCT06938503|DRUG|Nimotuzumab|Patients will receive 4 cycles of Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
215129451|NCT06937190|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.
215129452|NCT06937190|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.
214524814|NCT04826419|OTHER|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
214524815|NCT00445861|BIOLOGICAL|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
215129453|NCT06939400|PROCEDURE|Photodynamic therapy (PDT)|GBM patients recevied surgical combination photodynamic therapy
215129454|NCT06939400|PROCEDURE|GBM patients recevied traditional treatment options|GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
215129455|NCT06938451|OTHER||This is an observational study and does not involve an intervention
215129456|NCT06937645|DRUG|Hyaluronic Acid (HA)|hyaluronic acid PRP preparation used to wash the endometrium on the day of oocytes retrieval
215129457|NCT06937645|DRUG|platlet rich plasma (PRP)|PRP preparation used to wash the uterine cavity on the day of oocytes retrieval
215129458|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
215129459|NCT00187252|DEVICE|Atrial Overdrive Pacing|Pacemaker/ ICD implant
215129460|NCT01308697|PROCEDURE|Operative fixation of flail chest|Plate fixation
215129461|NCT01308697|OTHER|Non Operative management|Non Operative treatment of Flail Chest
215129462|NCT02926638|DRUG|Erlotinib Hydrochloride|Given PO
215129463|NCT02926638|OTHER|Laboratory Biomarker Analysis|Correlative studies
215129464|NCT02926638|BIOLOGICAL|Rilotumumab|Given IV
215129465|NCT05542654|OTHER|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
215129466|NCT00361556|BEHAVIORAL|The Back Book|A book on how to prevent back pain
215129467|NCT00361556|BEHAVIORAL|The Back Guide|A guide for the prevention of back pain.
215129468|NCT00361556|BEHAVIORAL|General health book|A book on general health
215129469|NCT04373928|PROCEDURE|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
215129470|NCT02965430|DEVICE|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
215129471|NCT05389033|DIETARY_SUPPLEMENT|Probiotic bacteria|28 days daily supplementation with active probiotic
215129472|NCT05389033|OTHER|Placebo Capsule|28 days daily supplementation with placebo
215129473|NCT06085508|BEHAVIORAL|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
214448458|NCT06327295|DRUG|ATB1651-102- Cohort 1|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
214448459|NCT06327295|DRUG|ATB1651-102- Cohort 2|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
214448460|NCT06327295|DRUG|ATB1651-102- Cohort 3|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
214448461|NCT06327295|DRUG|ATB1651-102- Cohort 4|Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
214448462|NCT06327295|DRUG|Placebo|participants will receive matching placebo across cohorts 1-4 of the study.
215129474|NCT04124640|OTHER|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
215129475|NCT05164393|DRUG|AVX001|Topical gel treatment for once daily application
215129476|NCT05461859|PROCEDURE|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
215129477|NCT00675714|PROCEDURE|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
214448463|NCT06520384|DEVICE|Radiofrequency|Patients will receive radiofrequency.
214448464|NCT06520384|DRUG|Alcohol 30%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
214448465|NCT06520384|DRUG|Alcohol 50%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
214448466|NCT06520384|DRUG|Alcohol 70%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
214448467|NCT03108846|DRUG|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
214448468|NCT03108846|DRUG|Placebo|Masked placebo
214448469|NCT05097001|OTHER|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
214448470|NCT03713086|BIOLOGICAL|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
214448471|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
214448472|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
214448473|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
214448474|NCT04242602|DEVICE|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
214448475|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID then MMF QD|Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
214448476|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID|Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
214448477|NCT06354179|DRUG|LCP-tacrolimus QD + MMF QD then MMF QD|Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
214448478|NCT06354179|DRUG|LCP-tacrolimus QD + MMF BID|Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
214448479|NCT05652777|DEVICE|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
214448480|NCT06525766|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214448481|NCT06525766|PROCEDURE|Bone Scan|Undergo bone scan
214448482|NCT06525766|DRUG|Capecitabine|Given PO
214448483|NCT06525766|PROCEDURE|Computed Tomography|Undergo CT
214448484|NCT06525766|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214448485|NCT06525766|OTHER|Questionnaire Administration|Ancillary studies
214448486|NCT05736068|PROCEDURE|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
214448487|NCT05736068|PROCEDURE|Surgical treatment|Closed reduction with or without fixation
214448488|NCT06503237|DRUG|Anti-CD19 CART cells will be given IV at split doses.|Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
214448489|NCT05649956|DRUG|Letrozole|Letrozole 2.5 mg PO daily
214448490|NCT05942495|BEHAVIORAL|short-term schema focused group therapy|There are two intervention phases. The first concerns the pre-treatment phase, which consists of five online sessions and three face-to-face sessions. The second intervention phase is the short-term SFGT. The SFGT consists of 17 weekly group sessions.
214448491|NCT05837325|PROCEDURE|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
214448492|NCT05837325|PROCEDURE|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
214448493|NCT05837325|PROCEDURE|ICSI|One oocyte injected at a time.
214448494|NCT05837325|PROCEDURE|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
214448495|NCT05837325|GENETIC|Biopsy|One embryo per culture drop.
214448496|NCT05837325|PROCEDURE|Vitrification|One embryo per vitrification straw.
214448497|NCT05837325|PROCEDURE|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
214448498|NCT05837325|PROCEDURE|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
214448499|NCT05818033|DEVICE|CARE1.02|Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
214448500|NCT05818033|DEVICE|Single-vision spectacle lens|Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.
214448501|NCT04143516|DIAGNOSTIC_TEST|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
214448502|NCT04143516|PROCEDURE|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
214448503|NCT04143516|DIAGNOSTIC_TEST|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
214448504|NCT03650764|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
214448505|NCT03650764|DRUG|Pembrolizumab|Pembrolizumab is commercially available
214448506|NCT03650764|OTHER|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
214448507|NCT03650764|OTHER|FACT H&N|-Screening, start of cycle 2, start of cycle 5
214448508|NCT03650764|PROCEDURE|Peripheral blood|-Baseline
214448509|NCT01447147|DRUG|Placebo|Placebo capsules once daily
214448510|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
214448511|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
214448512|NCT03494569|DRUG|Fludarabine|Given IV
214448513|NCT03494569|OTHER|Laboratory Biomarker Analysis|Correlative studies
214448514|NCT03494569|DRUG|Melphalan|Given as per City of Hope Standard Operating Procedure
214448515|NCT03494569|RADIATION|Total Marrow Irradiation|Undergo TMLI
214448516|NCT04992728|OTHER|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
214448517|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
214448518|NCT04889911|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
214524816|NCT00445861|BIOLOGICAL|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
214448519|NCT04889911|OTHER|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
214448520|NCT03869372|DEVICE|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
214448521|NCT01582711|BEHAVIORAL|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
214448522|NCT01582711|BEHAVIORAL|SMS reminders|Short Message Service (SMS) text reminders
214448523|NCT01582711|DRUG|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
214448524|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
214524817|NCT00445861|BIOLOGICAL|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
214448525|NCT04876183|OTHER|Selfapy for Binge Eating Disorder|Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
214448526|NCT05413525|PROCEDURE|ultrasound-guided manual vacuum aspiration (USG- MVA)|USG-MVA was carried out as an outpatient day procedure. Women was given a 400μg oral misoprostol tablet 2-3 hours before the procedure. All patients will be given 500mg naproxen orally an hour before the procedure. During the USG-MVA, all the women were placed in the lithotomy position and aseptically dressed. Speculum was performed to visualize the cervix with PCB performed. USG-MVA was performed using a 60ml charged syringe with a flexible curetteattached to it. Transabdominal USG during MVA was performed. During the procedure, local lidocaine gelwas applied to the cervical canal and over the end of the MVA catheter tip during the insertion.The USG-MVA was stopped as soon as USG confirmed that the uterine cavity was empty, defined as a thin endometrial lining with no evidence of retained products of conception.
214448527|NCT03860961|OTHER|Questionnaire Administration|Ancillary studies
214448528|NCT03860961|OTHER|Survivorship Care Plan|Given survivorship care plan
214448529|NCT03860961|OTHER|Treatment Plan|Given treatment plan
214448530|NCT06480968|DRUG|CTH120|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition)."
214448531|NCT06480968|OTHER|Placebo|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD."
214448532|NCT06500364|DEVICE|LoopLoc Arm|Patients in this intervention will have had a capsular closure performed using a LoopLoc device after their hip arthroscopy.
214448533|NCT06500364|DEVICE|Control Arm|Patients in this intervention will have not had a capsular closure using a LoopLoc device after their hip arthroscopy.
214448534|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
214448535|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
214448536|NCT06103500|OTHER|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
214448537|NCT05473923|DRUG|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
214448538|NCT05670821|DRUG|Spesolimab|Spesolimab
214448539|NCT05780814|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
214448540|NCT05780814|BEHAVIORAL|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
214448541|NCT04199182|BEHAVIORAL|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
214524818|NCT00445861|PROCEDURE|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
214524819|NCT05490147|PROCEDURE|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.
214524820|NCT05490147|PROCEDURE|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
214524821|NCT06008106|DRUG|tunlametinib|12mg BID
215129478|NCT00675714|PROCEDURE|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
215129479|NCT00675714|PROCEDURE|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
215129480|NCT00675714|DRUG|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
215129481|NCT00675714|DRUG|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
215129482|NCT00675714|DRUG|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
215129483|NCT00675714|DRUG|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
215129484|NCT00675714|DRUG|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
215129485|NCT00675714|DRUG|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
215129486|NCT00675714|DRUG|Placebo|placebo to be given once a day for up to two years post burn injury.
215129487|NCT00675714|BEHAVIORAL|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
215129488|NCT00675714|BEHAVIORAL|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
214448542|NCT04199182|OTHER|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
215129489|NCT03496493|DEVICE|All patients|Peripheral arterial oxygen saturation recording with both study devices
215129490|NCT03293602|DEVICE|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
215129491|NCT04590274|DRUG|Hydroxychloroquine|Hydroxychloroquine
215129492|NCT04590274|DIETARY_SUPPLEMENT|Vitamins and Minerals|elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
214448543|NCT02662062|DRUG|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
214448544|NCT02662062|DRUG|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
214448545|NCT02662062|RADIATION|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
214448546|NCT04032418|BIOLOGICAL|Pembrolizumab|Given IV
214448547|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
214448548|NCT06623656|DRUG|Cemiplimab|Intravenously
214448549|NCT06623656|DRUG|Platinum based chemotherapy|Intravenously
214448550|NCT06623656|RADIATION|Stereotactic body radiation therapy|8 Gy times 3 treatment days (Days 1-3)
214448551|NCT06770790|OTHER|strain echocardiography|HR, MAP, SBP, and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Two transthoracic 2D echocardiographic examinations will be performed immediately before and 15 minutes after TEA. The examinations include apical four-, two-, and three-chamber projections, mitral and aortic Doppler flow velocities. Standard measurements of left ventricular systolic function include left ventricular volumes (indexed to body surface area, BSA), left ventricular ejection fraction (LVEF) according to the modified Simpson rule, time and velocity integral in the left ventricular outflow tract (TVI-LVOT), and stroke volume (SV) (= π x LVOT radius2 x TVI-LVOT). Stroke volume index (SVI) will be calculated as SV/BSA. Mitral and aortic Doppler flow profiles, left ventricular isovolumetric relaxation time, maximum flow velocity will be recorded for m
214448552|NCT06772857|DRUG|Metformin|Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
215129493|NCT04590274|DRUG|Azithromycin|Azithromycin
215129494|NCT00644423|DRUG|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
215129495|NCT00644423|DRUG|Placebo|Matching Placebo
215129496|NCT01769742|BEHAVIORAL|Early mobility bundle|
215129497|NCT04936906|BEHAVIORAL|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
215129498|NCT04936906|OTHER|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
215129499|NCT03335384|DIAGNOSTIC_TEST|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
215129500|NCT03335384|DIAGNOSTIC_TEST|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
215129501|NCT03335384|DIAGNOSTIC_TEST|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
214448553|NCT06397612|OTHER|Low Dose|Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
215129502|NCT00182026|BEHAVIORAL|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
215129503|NCT05974241|DRUG|Methylphenidate, aripiprazole, and combination|Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
215129504|NCT02657096|PROCEDURE|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
215129505|NCT02657096|PROCEDURE|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
215129506|NCT01647789|DRUG|CFG920|
214448554|NCT02396459|DRUG|Triac|Triac, individually titrated dose
214448555|NCT03836261|DRUG|Acalabrutinib|Acalabrutinib,
214448556|NCT03836261|DRUG|Venetoclax|Venetoclax
214448557|NCT03836261|DRUG|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
214448558|NCT03836261|DRUG|Obinutuzumab|Obinutuzumab
214448559|NCT06351332|DRUG|Azenosertib|WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
214448560|NCT06351332|DRUG|Carboplatin|Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
214448561|NCT06351332|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
214448562|NCT04600323|DRUG|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
214448563|NCT04600323|DRUG|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
214448564|NCT04883775|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
214448565|NCT04883775|DRUG|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
214448566|NCT06310070|DEVICE|3D Printed Personalized Ostomy Appliance|Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
214448567|NCT06329297|DEVICE|CGM monitor|blood glucose sensor used to monitor interstitial glucose
214448568|NCT05654519|DRUG|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
214448569|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
214448570|NCT06065384|OTHER|experimental group: intensive motor training|Intervention group: receive an extra 6 hours of motor training each week (distributed over the week) for 8 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
214448571|NCT06065384|OTHER|usual care|usual rehabilitation
215129507|NCT04406298|PROCEDURE|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
215129508|NCT04406298|PROCEDURE|Large Volume Paracentesis|Large Volume Paracentesis \> 5litres
215129509|NCT01893463|DEVICE|iTClamp50|
215129510|NCT03189368|DEVICE|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~* Interpolar distance for the first left ventricular pulse \>30mm (i.e. non-sequential poles used)~* Nearly simultaneous (Δt=5msec) second left ventricular pulse and~* Threshold of ≤3.5V@0.5msec"
215129511|NCT02426580|BEHAVIORAL|wechat|The wechat model of dietary education every 1 month by cellphone
214448572|NCT03841669|BEHAVIORAL|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
214448573|NCT03841669|BEHAVIORAL|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
214448574|NCT05081492|BIOLOGICAL|Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody|Given IT
214448575|NCT05406921|BEHAVIORAL|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
214524822|NCT06008106|DRUG|paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin|according to investigators' suggestion
214524823|NCT03618927|BEHAVIORAL|Daily physical activity intervention|
214524824|NCT06347029|PROCEDURE|Urine sampling|Urine sampling
214524825|NCT06347029|PROCEDURE|Blood sampling|Blood sampling
214524826|NCT06347029|DEVICE|Flow mediated dilatation test|The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
214524827|NCT00598117|BEHAVIORAL|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS"
214524828|NCT00002519|DRUG|chemotherapy|
214524829|NCT00002519|DRUG|paclitaxel|
215129512|NCT02686372|BIOLOGICAL|TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
215129513|NCT02686372|BIOLOGICAL|No intervention and TCR-T (at crossover)|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
215129514|NCT00445549|DRUG|Vandetanib|300 mg daily dose, 28 day cycle
214524830|NCT00002519|RADIATION|radiation therapy|
215129515|NCT05378685|PROCEDURE|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
215129516|NCT04070781|DRUG|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
214448576|NCT03222128|DEVICE|TAVR|Implantation of the SAPIEN 3
214448577|NCT05414812|BEHAVIORAL|Multi-component oncofertility care intervention|"The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
214448578|NCT05464225|DEVICE|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
215129517|NCT04070781|DRUG|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
215129518|NCT03901170|DRUG|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
215129519|NCT05433246|BEHAVIORAL|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
215129520|NCT05041231|DEVICE|Photobiomodulation therapy (PBT)|"Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm)."
214448579|NCT05464225|DEVICE|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
215129521|NCT05041231|DEVICE|Sham Photobiomodulation therapy (Sham PBT)|Similar to active PBT, however, the device will not provide the active electromagnetic waves)
215129522|NCT04687657|DRUG|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
215129523|NCT03707795|DRUG|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
214448580|NCT05209100|PROCEDURE|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
214448581|NCT06233838|DEVICE|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
214448582|NCT05412602|PROCEDURE|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
214524831|NCT02872818|DRUG|17β estradiol hemihydrate|4mg/kg/day for 20 days
214524832|NCT02872818|DRUG|Metformin|50 mg/kg/day last 10 days
214524833|NCT02872818|DRUG|medroxyprogesterone acetate|1mg/kg/day last 10 days
214524834|NCT01913288|OTHER|Biological Maternal Sounds|
214524835|NCT03945097|BEHAVIORAL|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
214524836|NCT00925288|BIOLOGICAL|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
214524837|NCT00770640|DRUG|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
214524838|NCT00770640|DRUG|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
214524839|NCT00092365|DRUG|MK0966, rofecoxib|
214524840|NCT00092365|DRUG|Comparator: celecoxib, placebo|
215129524|NCT01235091|BEHAVIORAL|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
215129525|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
214448583|NCT05250544|OTHER|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
214448584|NCT05146388|OTHER|EHR-Based Approach|The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of \<= 1mL, optimal tool is 1 mL syringe, 2) for \>1 mL to 5 mL, use a 5 mL syringe, 3) for \>5mL to 10mL, use 10 mL syringe.
214448585|NCT04299009|DEVICE|Bright light therapy glasses|Bright light therapy delivered through glasses
214448586|NCT06272994|DIAGNOSTIC_TEST|MRSA Nasal Swab PCR|For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
214448587|NCT06154408|DIETARY_SUPPLEMENT|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
214448588|NCT06154408|DIETARY_SUPPLEMENT|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
214448589|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
214448590|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
214448591|NCT06272630|DRUG|DWJ1464|DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
214448592|NCT06272630|DRUG|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
214448593|NCT06428071|OTHER|standard physical therapy|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks to all the participants
214448594|NCT06428071|OTHER|knee Decompression|continuous mechanical decompression using 20% of the body weight as a traction force for 15 minutes.
214448595|NCT06428071|OTHER|hot pack|hot pack over the treated knee joint will be applied for 20 minutes. this application will be performed while the patient is receiving the decompression session
214448596|NCT04631276|DRUG|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
214448597|NCT05891860|OTHER|Participation in virtual rounds|Virtual participation in daily ICU team rounds
214448598|NCT05251389|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
214448599|NCT04608357|DIAGNOSTIC_TEST|Needle Core Biopsies|Not an interventional study
214448600|NCT03905876|OTHER|Questionnaire|Questionnaire to evaluate psychological experience
214448601|NCT04480853|DRUG|Fingolimod|Fingolimod 0.5 mg QD, oral
214448602|NCT05981105|DEVICE|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
214448603|NCT05981105|DEVICE|ambIT pump with sham catheter|sham catheter with no infusion
214448604|NCT04795440|PROCEDURE|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
214448605|NCT05391178|OTHER|Lumiton yarn sleeve|Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
214448606|NCT05391178|OTHER|Lumiton yarn hat|Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
214448607|NCT05391178|OTHER|Lumiton yarn shirt|Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
214448608|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
214448609|NCT05557123|DEVICE|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
214448610|NCT06108544|DRUG|TAK-279|Specified drug on specified days.
214448611|NCT06108544|DRUG|Placebo|Specified drug on specified days.
214448612|NCT06108544|DRUG|Apremilast|Specified drug on specified days.
214448613|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
214448614|NCT05792735|DRUG|Cadonilimab Injection|Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.
214448615|NCT05792735|RADIATION|Short-course radiotherapy|Preoperative short-course radiotherapy (5x5 Gy)
214448616|NCT05792735|DRUG|Consolidation chemotherapy|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
214448617|NCT00676715|DRUG|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
214448618|NCT00676715|DRUG|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
215129526|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
215129527|NCT01991392|DEVICE|Nasogastric tube|For nasogastric decompression.
215129528|NCT01991392|DEVICE|No nasogastric tube|For nasogastric decompression.
215129529|NCT04190602|DEVICE|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
215129530|NCT04863170|PROCEDURE|orthognathic surgery|surgical intervention of the maxilla and / or mandible that includes orthodontic treatment before and after surgery
215129531|NCT05448495|OTHER|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
215129532|NCT05448495|OTHER|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane
215129533|NCT03147846|PROCEDURE|delayed cord clamping|delay of cord clamping for 60 seconds
215129534|NCT03147846|PROCEDURE|cord milking|active cord milking 5 times
215129535|NCT03867214|DRUG|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
215129536|NCT03867214|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
214448619|NCT00676715|DRUG|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
214524841|NCT03219255|DRUG|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
214524842|NCT05242913|DIETARY_SUPPLEMENT|Resistant Potato Starch|Unmodified potato starch containing \>60% resistant starch Type 2
214524843|NCT05242913|DIETARY_SUPPLEMENT|Placebo|Fully digestible corn starch
214524844|NCT04346433|BEHAVIORAL|Restricted Sleep|During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
214524845|NCT04346433|BEHAVIORAL|Adequate Sleep|During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
214524846|NCT03322514|DIETARY_SUPPLEMENT|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
214524847|NCT03322514|DIETARY_SUPPLEMENT|Inulin|Inulin
215129537|NCT01095640|DRUG|adapalene 0.3% topical gel|once a day, 84 days
215129538|NCT03876717|DRUG|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
215129539|NCT03876717|DRUG|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
215129540|NCT05987358|DRUG|TQB3454 tablets|TQB3454 is a selective IDH1 mutant enzyme inhibitor.
215129541|NCT05987358|DRUG|TQB3454 tablets matching placebo|Placebo tablets without active substance.
215129542|NCT03546985|DEVICE|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
215129543|NCT03546985|DEVICE|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
215129544|NCT01608711|BIOLOGICAL|AGS-1C4D4|Intravenous Infusion
215129545|NCT01608711|BIOLOGICAL|gemcitabine|Intravenous Infusion
215129546|NCT02660788|OTHER|Standard Reminder Postcard|
215129547|NCT02660788|OTHER|Family Physician Reminder Letter|
214448620|NCT05532137|BEHAVIORAL|e-12HR app|"The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~1. Evaluation of the user's MDSS index.~2. Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups)."
214448621|NCT05456295|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
215129548|NCT03777358|DEVICE|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
215129549|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
215129550|NCT00768989|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
215129551|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
215129552|NCT00768989|DRUG|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
215129553|NCT00768989|DRUG|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
215129554|NCT03675503|OTHER|Fall Prevention Decision Support|Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
215129555|NCT01687361|DIETARY_SUPPLEMENT|branched-chain amino acids (BCAA) supplementation|
214448622|NCT03725735|BEHAVIORAL|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
214448623|NCT06462339|BEHAVIORAL|Experimental: Intervention Group|The group that will receive pilates training via telerehabilitation
214448624|NCT02075684|PROCEDURE|Renal Biopsy|
214448625|NCT01820260|DRUG|Ingenol mebutate gel|
214448626|NCT01820260|DRUG|placebo|
214448627|NCT06032845|DRUG|Tislelizumab|a PD-1 immune check inhibitor
214448628|NCT06032845|DRUG|Lenvatinib|Lenvatinib capsules
214448629|NCT06032845|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
214524848|NCT01184859|DRUG|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
215129556|NCT01687361|DRUG|PLACEBO|
215129557|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
214524849|NCT01184859|DRUG|Placebo|Placebo melt tablet for sublingual administration
214524850|NCT04549142|OTHER|There is no intervention|There is no intervention
214524851|NCT05460429|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
214524852|NCT04041661|OTHER|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
214524853|NCT04041661|OTHER|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
214524854|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 30 grams|Roasted walnuts without salt or sugar.
215129558|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
215129559|NCT01898455|DEVICE|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
215129560|NCT04579991|OTHER|Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel|Topical product, apply small amount on mucosal surface of vulva included clitoris once daily
215129561|NCT04579991|OTHER|Emulgel-only|Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
215129562|NCT02690181|BIOLOGICAL|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
215129563|NCT03976479|OTHER|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
215129564|NCT02326038|DRUG|Methylphenidate|single oral administration of 20 mg tablet
215129565|NCT01909440|BEHAVIORAL|exercise intervention|Receive whole body RT
215129566|NCT01909440|DIETARY_SUPPLEMENT|nutritional supplementation|Given whey protein supplementation PO
215129567|NCT01909440|PROCEDURE|quality-of-life assessment|Ancillary studies
215129568|NCT01909440|OTHER|questionnaire administration|Ancillary studies
215129569|NCT01909440|OTHER|pharmacological study|Correlative studies
215129570|NCT01909440|OTHER|laboratory biomarker analysis|Correlative studies
215129571|NCT01905098|OTHER|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
215129572|NCT01905098|OTHER|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
215129573|NCT06208553|OTHER|QI toolkit implementation|Patients and clinicians will have access to online toolkits of resources (e.g., video, checklist, rehabilitation tracker, quick guides) reflecting quality indicators for rehabilitation care after total hip and knee replacement surgery.
215129574|NCT00003714|DRUG|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
214448630|NCT04190303|OTHER|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
214448631|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
214448632|NCT06555016|BEHAVIORAL|Walking|Overground walking.
214448633|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
215129575|NCT05805631|DRUG|Pemetrexed|Intrathecal Pemetrexed
215129576|NCT03977792|DRUG|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
215129577|NCT03977792|DRUG|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
215129578|NCT00000266|DRUG|Flupenthixol|
215129579|NCT02021201|DRUG|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
215129580|NCT02021201|DRUG|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
215129581|NCT05750251|PROCEDURE|levator muscle resection surgery|conventional ptosis surgery
215129582|NCT05750251|PROCEDURE|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
215129583|NCT05750251|PROCEDURE|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
215129584|NCT04477408|OTHER|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
214448634|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
214448635|NCT04027309|DRUG|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
214448636|NCT04027309|DRUG|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
214448637|NCT06501573|DRUG|SGB-9768|SGB-9768 for sc injection
214448638|NCT06501573|OTHER|Placebo|sterile normal saline (0.9% NaCl) for sc injection
214448639|NCT01280994|DRUG|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
214448640|NCT06211270|BEHAVIORAL|FRESH|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
214448641|NCT06335901|DRUG|Drug:Standard therapy|Percutaneous coronary Intervention
214448642|NCT06394414|DRUG|YL201|YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.
214448643|NCT05942586|DIETARY_SUPPLEMENT|Probiotic capsule (L. reuteri PB-W1™), Placebo sachet|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
214524855|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 60 grams|Roasted walnuts without salt or sugar.
214524856|NCT03220659|DEVICE|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
214524857|NCT03220659|DEVICE|Standard settings|Normal bipolar LV pacing
214524858|NCT00961298|DRUG|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
215129585|NCT01222013|DRUG|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
215129586|NCT03357107|PROCEDURE|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
215129587|NCT01149317|PROCEDURE|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
215129588|NCT01582815|DRUG|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
215129589|NCT01582815|DRUG|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
215129590|NCT02316028|DRUG|Decitabine|"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"
215129591|NCT04532307|BEHAVIORAL|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
215129592|NCT04532307|BEHAVIORAL|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
215129593|NCT04532307|BEHAVIORAL|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
215129594|NCT04532307|BEHAVIORAL|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
215129595|NCT00228280|PROCEDURE|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
215129596|NCT04346095|DRUG|Oral Sedatives with or Without Analgesia|The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
215129597|NCT04346095|DRUG|Intravenous Sedatives with or Without Analgesia|The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
215129598|NCT03070288|OTHER|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
214694471|NCT01705197|DRUG|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
214694472|NCT03117166|DRUG|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
214694473|NCT03117166|DRUG|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
214694474|NCT03712501|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
214694475|NCT01206478|DRUG|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
214694476|NCT01206478|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
214694477|NCT01206478|DRUG|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
214694478|NCT06087042|DIAGNOSTIC_TEST|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
215129599|NCT00965601|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
215129600|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
214448644|NCT05942586|DIETARY_SUPPLEMENT|Prebiotic sachet (Prebiotic Blend), Placebo capsule|Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
214694479|NCT01467648|DRUG|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
214694480|NCT01467648|DRUG|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
215129601|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
215129602|NCT03316196|BEHAVIORAL|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
215129603|NCT03316196|BEHAVIORAL|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
215129604|NCT04247139|OTHER|Kefir|commercial versus traditional kefir
215129605|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
215129606|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
215129607|NCT03405883|OTHER|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
215129608|NCT03856060|OTHER|Questionnaire Administration|Complete questionnaires
214448645|NCT05942586|COMBINATION_PRODUCT|Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
214448646|NCT05942586|DIETARY_SUPPLEMENT|Placebo sachet, Placebo capsule|Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
214448647|NCT04692597|DEVICE|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
214448648|NCT04692597|DEVICE|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
214448649|NCT04356027|PROCEDURE|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
214448650|NCT04356027|PROCEDURE|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
214448651|NCT04356027|PROCEDURE|FFR|FFR will be measured
214448652|NCT04356027|OTHER|VFR Analysis|VFR will be calculated offline using the OCT pullback images
214448653|NCT04786093|RADIATION|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
214448654|NCT04786093|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
214448655|NCT02073994|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
214448656|NCT04193917|DIAGNOSTIC_TEST|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
214448657|NCT05863416|DRUG|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
214448658|NCT06059118|DRUG|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
214524859|NCT06414759|DRUG|Acetazolamide|"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."
214448659|NCT06059118|DRUG|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
214448660|NCT06059118|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
214448661|NCT06059118|DRUG|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
214448662|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
214524860|NCT06414759|DRUG|Metolazone|"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."
215129609|NCT03856060|OTHER|Video|Watch videos of doctor and patient interaction in different settings
215129610|NCT04587947|DRUG|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
215129611|NCT05979064|PROCEDURE|Laparoscopically harvested omental tissue autograft|"1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity."
215129612|NCT04909710|OTHER|Mobile Game System for Potential Treatment of Developmental Delays|Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
215129613|NCT06479343|DEVICE|Liquid Embolic System (Tonbridge)|Endovascular treatment with Liquid Embolic System (Tonbridge).
215129614|NCT06479343|DEVICE|Onyx Liquid Embolic System (Medtronic)|Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
215129615|NCT05318131|OTHER|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
215129616|NCT05318131|OTHER|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
215129617|NCT05846126|BEHAVIORAL|RehabCovid_Telematic|A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
214448663|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
214448664|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
214448665|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
214448666|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
215129618|NCT05846126|BEHAVIORAL|RehabCovid_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
215129619|NCT05846126|BEHAVIORAL|Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
215129620|NCT02455193|BEHAVIORAL|Exercise|
215129621|NCT02455193|BEHAVIORAL|Diet|
215129622|NCT05380973|OTHER|Short fiber resin composite|resin composite reinforced with short glass fibers
215129623|NCT05380973|OTHER|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
215129624|NCT05828862|PROCEDURE|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
215129625|NCT05174247|OTHER|FFRct analysis|Software analysis of Cardiac CT to show extent of pericardial stenoses
215129626|NCT04688359|BEHAVIORAL|Guided Self Determination|Nurse lead intervention in primary care
215129627|NCT02519608|DRUG|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
215129628|NCT02519608|DRUG|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
215129629|NCT02519608|DRUG|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
215129630|NCT04146168|DIAGNOSTIC_TEST|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
214448667|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
214448668|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
214448669|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
214448670|NCT05464433|DRUG|Tislelizumab combined with Liposomal mitoxantrone hydrochloride|"Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle."
214448671|NCT05464433|DRUG|Maintenance of tislelizumab|Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
214448672|NCT03002025|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 as SC injection.
214448673|NCT03002025|DRUG|Placebo|Participants will receive matching placebo to JNJ-64304500 as SC injection.
214448674|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
214448675|NCT04831281|DRUG|ATH-1017|Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
214448676|NCT04831281|DRUG|Placebo|Daily subcutaneous injection of Placebo in a pre-filled syringe
215129631|NCT06271408|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Aerosolized albuterol
215129632|NCT06271408|DEVICE|Vibrating Mesh Nebulizer|A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
215129633|NCT06271408|DEVICE|Metered Dose Inhaler|A metered dose inhaler will be used to deliver aerosolized albuterol
215129634|NCT06271408|DEVICE|Jet Nebulizer|A jet nebulizer will be used to deliver aerosolized albuterol
215129635|NCT02343042|DRUG|Selinexor|Oral tablets
215129636|NCT02343042|DRUG|Dexamethasone|Oral tablets
215129637|NCT02343042|DRUG|Lenalidomide|Oral capsule
215129638|NCT02343042|DRUG|Pomalidomide|Oral tablets
215129639|NCT02343042|DRUG|Bortezomib|Subcutaneous Injection (single use vial)
215129640|NCT02343042|DRUG|Daratumumab|Intravenous Infusion
215129641|NCT02343042|DRUG|Carfilzomib|Intravenous infusion
215129642|NCT02343042|DRUG|Ixazomib|Oral capsule
215129643|NCT02343042|DRUG|Elotuzumab|Intravenous infusion
215129644|NCT02343042|DRUG|Clarithromycin|Tablets
215129645|NCT02343042|DRUG|Belantamab Mafodotin|Intravenous infusion
215129646|NCT02343042|DRUG|Mezigdomide|Oral Capsules
215129647|NCT00718510|DRUG|L-Arginine|3 grams, twice daily, oral administration
215129648|NCT03255902|BEHAVIORAL|Parenting classes|Parenting Classes:The Incredible Years curriculum
215129649|NCT02760966|OTHER|Alcohol 70º|
214448677|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
215129650|NCT02760966|OTHER|Soap|
215129651|NCT04073121|DEVICE|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
215129652|NCT03393585|OTHER|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
215129653|NCT03074708|OTHER|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
215129654|NCT01378559|OTHER|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
215129655|NCT01881191|OTHER|MRI|
215129656|NCT04579146|OTHER|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
215129657|NCT02268149|DRUG|BIIL 284 BS|
215129658|NCT02268149|DRUG|Prednisone|
215129659|NCT02268149|DRUG|Placebo|
215129660|NCT01895075|DRUG|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
215129661|NCT01895075|DRUG|Normal saline|2 ml normal saline by inhalation
215129662|NCT03668795|PROCEDURE|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
215129663|NCT05511181|DEVICE|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
215129664|NCT05511181|DEVICE|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
215129665|NCT04506840|OTHER|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
214694481|NCT03563456|BEHAVIORAL|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
215129666|NCT04056819|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
214448678|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
214448679|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
214448680|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
215129667|NCT05954858|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
215129668|NCT06542029|BEHAVIORAL|Groups 4 Health (G4H)|"Groups 4 Health, G4H, (Ryhmät kuntoon) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention."
215129669|NCT06542029|BEHAVIORAL|The study psychologists' group intervention|University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
215129670|NCT06542029|BEHAVIORAL|Towards better well-being and studying -online course|"Towards better well-being and studying -online course (Kohti parempaa opiskelua) is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion."
215129671|NCT05668234|OTHER|interview|semi-directive interview
215129672|NCT05553509|OTHER|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
214524861|NCT06414759|DRUG|IV Loop Diuretics|IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
214524862|NCT03184142|BEHAVIORAL|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
214448681|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
214524863|NCT03184142|BEHAVIORAL|Video|Student watch a 15-minute intimidation video (see arm description).
214524864|NCT03184142|BEHAVIORAL|Control group|No intervention. The students suture for 70 minutes
214524865|NCT05154539|DIAGNOSTIC_TEST|Remote digital assessment|Remote digital assessment of test group participants
214524866|NCT05154539|DIAGNOSTIC_TEST|Conventional physical assessment|Conventional physical assessment of control group participants
214524867|NCT01778647|DIETARY_SUPPLEMENT|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
214694482|NCT03563456|BEHAVIORAL|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
214694483|NCT05732844|DEVICE|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
214694484|NCT05732844|OTHER|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
214694485|NCT05738694|DRUG|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
214694486|NCT05738694|PROCEDURE|nephrectomy|nephrectomy
215129674|NCT05405920|BEHAVIORAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
214448682|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
214524868|NCT01778647|DRUG|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
214524869|NCT05607485|PROCEDURE|Randomized video numbers|See arm/group description
214694487|NCT03986775|DIETARY_SUPPLEMENT|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
214694488|NCT03986775|DIETARY_SUPPLEMENT|sucrose|conventional beverage with sucrose
214448683|NCT06271694|OTHER|Vestibular Rehabilitation|Standard vestibular rehabilitation
214448684|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
214524870|NCT00260676|PROCEDURE|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
214524871|NCT05189171|DEVICE|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
214694489|NCT02683694|DEVICE|iOCT|the number of subjects that can be peeled without dye are assessed
214694490|NCT04949906|DRUG|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
214694491|NCT04949906|DRUG|No nourishing serum brain granules are used|No nourishing serum brain granules are used
214694492|NCT01493986|DRUG|Ropivacaine|Dosage. Onset time
214694493|NCT05016869|DRUG|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
214694494|NCT03338114|DRUG|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
214694495|NCT01640925|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
214524872|NCT01100268|DRUG|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
215129675|NCT05405920|BEHAVIORAL|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
215129676|NCT03874468|DEVICE|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
215129677|NCT06297187|DEVICE|CUSA (Cavitronic Ultrasonic Surgical Aspirator)|CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
215129678|NCT04133883|PROCEDURE|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
215129679|NCT00590187|DRUG|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
215129680|NCT00590187|DRUG|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
214448685|NCT04793776|BEHAVIORAL|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
214448686|NCT04793776|BEHAVIORAL|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
214448687|NCT04107051|DRUG|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
214448688|NCT05899465|DRUG|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
214524873|NCT01827449|DEVICE|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
214448689|NCT05899465|DRUG|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
214524874|NCT03022110|DEVICE|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
215129681|NCT00590187|DRUG|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
215129682|NCT00590187|DRUG|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
215129683|NCT00590187|DRUG|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
215129684|NCT00590187|DRUG|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
215129685|NCT00590187|DRUG|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
215129686|NCT00590187|DRUG|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
215129687|NCT00590187|DRUG|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
215129688|NCT02428101|GENETIC|polymorphism analysis|
214524875|NCT00317850|DRUG|Gabapentin (Neurontin)|
215129689|NCT05003479|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
214524876|NCT05497037|DEVICE|PRF stimulation|One time 500 kHZ stimulation for 15 min
215129690|NCT05003479|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
215129691|NCT03929185|DIAGNOSTIC_TEST|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
215129692|NCT03929185|DIAGNOSTIC_TEST|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
215129693|NCT02527681|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
215129694|NCT05244512|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
214448690|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
214448691|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
214448692|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
214448693|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
214448694|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
214448695|NCT06231823|OTHER|Extraction|Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
214524877|NCT05497037|DEVICE|Sham stimulation|Sham stimulation for 15 min
214524878|NCT04358614|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
214694496|NCT01640925|OTHER|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
214694497|NCT02343276|DRUG|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
214694498|NCT02343276|OTHER|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
215129695|NCT05244512|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
215129696|NCT04220346|OTHER|Tablet group|Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
215129697|NCT02742961|OTHER|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
215129698|NCT01475591|BEHAVIORAL|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
215129699|NCT00143910|OTHER|observation|
215129700|NCT05241379|DEVICE|Amber UI System|The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
215129701|NCT00844376|DRUG|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
215129702|NCT00844376|DRUG|Lipitor|A single dose of 80 mg Lipitor tablet
215129703|NCT06466694|BEHAVIORAL|Modified Dialectical Behavioural Therapy|The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. To evaluate through a patient lens content of the Dialectical Behavior Therapy (DBT) through the lens of an Indigenous Knowledge Carrier (Elder)
215129704|NCT05354908|OTHER|scientific and academic productivity|Number and quartile of scientific products generated by the group
215129705|NCT01011673|DRUG|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
215129706|NCT01011673|DRUG|Ketorolac|ketorolac 30mg IVSS
215129707|NCT03242629|DRUG|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
215129708|NCT03242629|DRUG|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
215129709|NCT06473415|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography using the Sleep-Profiler device
215129710|NCT04199507|OTHER|physical fitness assessment|assessment
215129711|NCT03550612|DIAGNOSTIC_TEST|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
215129712|NCT03550612|DIAGNOSTIC_TEST|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
215129713|NCT03651635|DIAGNOSTIC_TEST|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1
215129714|NCT00549640|DRUG|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
215129715|NCT00549640|DRUG|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
214448696|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
214448697|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
214448698|NCT05878561|DRUG|Fimasartan + Indapamide|a fixed dose combination
214448699|NCT05878561|DRUG|Fimasartan + Indapamide placebo|a fixed dose combination
214448700|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
214448701|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
214448702|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
214448703|NCT02512523|DRUG|Teneligliptin|
214448704|NCT02512523|DRUG|Sitagliptin|
214448705|NCT06281483|OTHER|platelet-rich plasma|Under aseptic conditions, 20 mL of whole blood will be withdrawn from each patient and will be collected in the centrifuge tube prefilled with Anticoagulant Citrate Dextrose (1.5 mL each). A two-stage centrifugation process (double-spin method) will be employed for the preparation of PRP. The first spin is at 100 relative centrifugal force (RCF) (g) for 10 min, while the second spin is at 400 RCF for 10 min. PRP will be injected into the base of the ulcer and the surrounding skin. Group A: will receive treatment that will include PRP application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
214694499|NCT00003026|DRUG|bicalutamide|
214694500|NCT00003026|DRUG|flutamide|
214694501|NCT00003026|DRUG|triptorelin|
214694502|NCT00003026|RADIATION|radiation therapy|
215129716|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
215129717|NCT01682408|DRUG|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
215129718|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
215129719|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
215129720|NCT01682408|DRUG|Ranitidine|150 mg ranitidine
215129721|NCT00064285|DRUG|alvocidib|
215129722|NCT00064285|DRUG|imatinib mesylate|
215129723|NCT02232035|DRUG|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
214524879|NCT02016664|DRUG|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
215129724|NCT02028481|PROCEDURE|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
215129725|NCT02774980|BEHAVIORAL|Recurrent depression|
215129726|NCT01655758|DRUG|0.5% timolol|
214448706|NCT06281483|OTHER|platelet-rich fibrin|20 ml blood will be drawn from each patient by venipuncture under aseptic precautions in four sterile glass tubes of 5-ml capacity without anticoagulant and immediately centrifuged. A single stage centrifugation process, that is (200 g for 8 min), has been found to produce a fibrin clot with the highest platelet and WBC count and highest overall cumulative growth factor yield. Group B: will receive treatment that will include PRF application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
215129727|NCT01655758|DRUG|timolol-dorzolamide fixed combination|
214448707|NCT06281483|OTHER|Surgical debridement, normal saline washing and dressing coverage|Each patient will receive the same conventional debridement and dressing coverage (After opening the bandage, the ulcer will be irrigated with normal saline and will be prepared for debridement as required to remove dead tissues and hyperkeratotic skin. Then, a second wash with normal saline will be done to remove any debris), but without any PRP nor PRF application.
214448708|NCT02097420|DEVICE|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
214448709|NCT05636709|DEVICE|Adacolumn|Non interventional study
214448710|NCT06057012|DRUG|BRII-296|BRII-296 will be given via intramuscular injection.
214448711|NCT06057012|DRUG|Depo Medrol|Depo Medrol will be given via intramuscular injection.
214448712|NCT05570786|DRUG|Gestrinone|The intradermal gestrinone/placebo pellet will be inserted on the same day as the levonorgestrel intrauterine hormonal device (Kyleena®)
214448713|NCT05570786|DRUG|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol)
214524880|NCT02946307|DEVICE|Restore DEB（dimeter>2.00 mm）|
214448714|NCT05712902|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
214448715|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
214448716|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
214448717|NCT06405633|DRUG|WVE-006|RNA editing oligonucelotide
214524881|NCT02946307|DEVICE|Resolute DES|
214524882|NCT02946307|DEVICE|Restore DEB（dimeter:2.00 mm）|
214524883|NCT02622464|OTHER|micro injection of SVF in vocal cords|
214694503|NCT00731263|DRUG|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
214694504|NCT00180141|DRUG|Elidel-Creme|
215129728|NCT01655758|DRUG|Latanoprost|
215129729|NCT01655758|DRUG|Travoprost|
215129730|NCT01655758|DRUG|Bimatoprost|
215129731|NCT04736914|DRUG|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
215129732|NCT05714267|DEVICE|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
215129733|NCT05714267|DEVICE|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
215129734|NCT05714267|DEVICE|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
214694505|NCT05464862|DRUG|Popliteal Plexus Block with 10 ml|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
214694506|NCT05464862|DRUG|Popliteal Plexus Block with 20 ml|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
215129735|NCT00409071|DRUG|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
215129736|NCT00409071|DRUG|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
215129737|NCT06119126|DRUG|SDF1|Topical SDF application
215129738|NCT06119126|DEVICE|Diode Laser|Irradiating Enamel by Diode laser
215129739|NCT06119126|DRUG|Pit Fissure Sealant|Sealing occlusal pits and fissures
215129740|NCT00664547|BEHAVIORAL|Diet Weight Loss|
215129741|NCT00664547|BEHAVIORAL|Exercise Weight Loss|
215129742|NCT00664547|BEHAVIORAL|Exercise Without Weight Loss|
215129743|NCT04944459|DEVICE|Muse-S headband; InteraXon Inc., RRID:SCR_014418|"Muse-S is used as a technology-supported Mindfulness Training (tsMT) device as a way to introduce meditation as a method for managing chronic pain in individuals as it facilitates the learning process, requires minimal training to use and provides mechanisms to enhance compliance and track progress. The availability of direct feedback data from Muse-S may encourage the participant to perform meditation sessions and may increase time spent in the calm brain state."
215129744|NCT02028923|DRUG|Morphine gel|Topical
215129745|NCT02028923|OTHER|Neutral gel|Topical
215129746|NCT02579460|OTHER|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
214448718|NCT06571903|OTHER|Teaching from videos|Teaching from videos for independent study
214694507|NCT05464862|DRUG|Popliteal Plexus Block with 30 ml|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
214694508|NCT05464862|DRUG|Femoral Nerve Block|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
214694509|NCT05464862|DRUG|Sciatic Nerve Block|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
214694510|NCT01319110|DRUG|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
214694511|NCT01319110|DIETARY_SUPPLEMENT|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
214694512|NCT00442013|DRUG|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
215129747|NCT00332072|DRUG|bimatoprost/timolol fixed combination|
215129748|NCT02644759|BIOLOGICAL|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
215129749|NCT02388581|DRUG|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
215129750|NCT05157295|DRUG|OnabotulinumtoxinA|100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
215129751|NCT02212808|OTHER|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
215129752|NCT02212808|OTHER|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
215129753|NCT06140602|OTHER|Intervention shake|The pecan shake contains 69g of pecans
215129754|NCT04932928|DEVICE|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
215129755|NCT04932928|DEVICE|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
215129756|NCT04335617|DRUG|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
215129757|NCT04335617|OTHER|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
215129758|NCT05620316|DRUG|BOTOX® Injection|100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
215129759|NCT05620316|OTHER|Prick skin|patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.
215129760|NCT00660192|DRUG|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
215129761|NCT00660192|OTHER|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
215129762|NCT04482517|OTHER|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
215129763|NCT04482517|OTHER|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
215129764|NCT04482517|OTHER|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
215129765|NCT04482517|OTHER|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
215129766|NCT02734693|DRUG|dasotraline 4mg|dasotraline 4mg/day
215129767|NCT02734693|OTHER|Placebo|placebo/day
215129768|NCT05966649|OTHER|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
214448719|NCT04092387|OTHER|Varying the nicotine content of cigarettes|1\) Altering the nicotine content of the tobacco research cigarettes
214448720|NCT04092387|OTHER|E-Cigarettes|Comparing effects of combining RC2 with EC 1 versus EC2
214448721|NCT06080178|DRUG|Plasma-lyte (static group)|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
214448722|NCT06080178|DRUG|Norepinephrine (static group)|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
214448723|NCT06080178|DRUG|Plasma-lyte (dynamic group)|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
214448724|NCT06080178|DRUG|Norepinephrine (dynamic group)|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
214448725|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
214448726|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
214448727|NCT04564495|BEHAVIORAL|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
214448728|NCT02193958|DRUG|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle (Cohorts 1-6), Days 1-21 of a 28-say cycle (Cohort 7), Days 1-28 of a 28-day cycle (Cohort 8) or Days 1-21 of a 28-say cycle (Cohort 9). The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
214448729|NCT03457675|DEVICE|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
215129769|NCT05966649|OTHER|Placebo|Matching placebo
215129770|NCT02719808|DRUG|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
215129771|NCT02719808|DRUG|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
215129772|NCT02719808|DRUG|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
215129773|NCT02719808|DRUG|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
215129774|NCT00040586|DRUG|Monoclonal Antibody J591|
215129775|NCT00040586|DRUG|Recombinant Interleukin-2|
215129776|NCT03207126|DIAGNOSTIC_TEST|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
215129777|NCT06163963|DIAGNOSTIC_TEST|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
215129778|NCT06163963|DIAGNOSTIC_TEST|charcoal injection to uterus to map sentinel lymph nodes|During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
215129779|NCT02730481|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
214448730|NCT03457675|OTHER|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
214448731|NCT06097975|DRUG|Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
214448732|NCT06097975|PROCEDURE|Neurosurgery and intracavitary injection nivolumab and ipililumab|The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
214448733|NCT06097975|DRUG|Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary|Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
214448734|NCT06495632|DRUG|Motrin and narcotic|See described earlier
214448735|NCT05664074|DRUG|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
214448736|NCT05664074|DRUG|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
214448737|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
214524884|NCT05611489|PROCEDURE|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
214524885|NCT05611489|PROCEDURE|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
214524886|NCT02475005|BEHAVIORAL|pain self management app on smartphone|
214524887|NCT03540615|DRUG|BAY1830839|Dose escalation in healthy male subjects
214524888|NCT03540615|DRUG|Placebo|Matching placebo
214524889|NCT03867552|PROCEDURE|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
214524890|NCT03867552|PROCEDURE|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
214524891|NCT01537120|DRUG|Vildagliptin|
214524892|NCT01537120|DRUG|Placebo|
214524893|NCT05899621|DRUG|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
214448738|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
214448739|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
214524894|NCT05899621|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
214524895|NCT05899621|DRUG|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
214524896|NCT05899621|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214524897|NCT05899621|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214524898|NCT05899621|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
214524899|NCT05899621|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
214694513|NCT00442013|DRUG|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
215129780|NCT03121859|OTHER|Neck stabilization exercise|Exercise
215129781|NCT03121859|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS)
215129782|NCT03121859|OTHER|IFC|Interferential current therapy(IFC)
215129783|NCT05837338|DRUG|BXP154|BXP154 will be self-administered topically following wound induction
215129784|NCT05837338|DRUG|Placebo|Placebo will be self-administered topically following wound induction
215129785|NCT05647681|DRUG|Douloff|topic gel
215129786|NCT05647681|DRUG|paracetamol|tablets
215129787|NCT03957148|BEHAVIORAL|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
215129788|NCT00000214|DRUG|Buprenorphine|
215129789|NCT03740048|OTHER|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
215129790|NCT03740048|DRUG|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
214524900|NCT02657421|PROCEDURE|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
214524901|NCT00392704|DRUG|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
214524902|NCT00392704|DRUG|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
214448740|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
214524903|NCT00392704|DRUG|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
214524904|NCT00392704|DRUG|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
214694514|NCT01523314|DRUG|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
215129791|NCT00348712|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
215129792|NCT00348712|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
215129793|NCT00348712|DRUG|metformin|Tablets, 2000 mg/day.
215129794|NCT01476722|DEVICE|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
215129795|NCT02337868|BIOLOGICAL|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
214524905|NCT00392704|RADIATION|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
214524906|NCT03628183|OTHER|Hydrolysate Infant Formula 1|Feed ad lib
214524907|NCT03628183|OTHER|Hydrolysate Infant Formula 2|Feed ad lib
214524908|NCT05854121|DIAGNOSTIC_TEST|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
214694515|NCT01523314|OTHER|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
214694516|NCT05836519|OTHER|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
215129796|NCT02337868|OTHER|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
215129797|NCT01985295|DRUG|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
214448741|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
214524909|NCT05854121|DIAGNOSTIC_TEST|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
214524910|NCT05098756|OTHER|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
214524911|NCT00282828|DRUG|Sertraline|
214524912|NCT00282828|DRUG|Venlafaxine|
214524913|NCT00282828|DRUG|Placebo|
214524914|NCT00282828|DRUG|Clonazepam|
214524915|NCT05992662|BEHAVIORAL|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up"
214524916|NCT03390270|OTHER|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
214524917|NCT01532583|OTHER|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
214524918|NCT00945178|DRUG|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
214524919|NCT00945178|DRUG|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
214524920|NCT00945178|DRUG|Naproxen|Tablet, single oral dose, 500mg
214524921|NCT00945178|DRUG|Placebo for Naproxen|Tablet, single oral dose
214524922|NCT03695198|DRUG|LY3361237 - SC|LY3361237 administered SC
214524923|NCT03695198|DRUG|LY3361237 - IV|LY3361237 administered IV
214524924|NCT03695198|DRUG|Placebo - SC|Placebo administered SC
214694517|NCT02025491|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
215129798|NCT05901701|RADIATION|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
215129799|NCT05901701|DEVICE|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
215129800|NCT04123522|PROCEDURE|anterior approach|anterior approach
215129801|NCT04123522|PROCEDURE|posterior appraoch|posteiror appraoch
215129802|NCT05095961|DRUG|Prednisone|5 day course of oral prednisone pre-operatively. 30mg per day.
214524925|NCT03695198|DRUG|Placebo - IV|Placebo administered IV
214524926|NCT04966936|OTHER|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
214524927|NCT04966936|OTHER|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
214694518|NCT03145194|DRUG|Ticagrelor|2 x 90mg Ticagrelor tablets
215129803|NCT04499755|DRUG|Nucleo CMP Forte|Nucleo CMP Forte twice daily for 6 weeks
215129804|NCT00737646|BEHAVIORAL|Usual care|No intervention will be conducted in this arm of the study.
215129805|NCT00737646|BEHAVIORAL|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
214524928|NCT04966936|OTHER|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
214524929|NCT05698199|DRUG|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
214524930|NCT00944996|DRUG|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
214524931|NCT01503515|DRUG|Caspofungin Acetate|Given IV
214524932|NCT01503515|DRUG|Fluconazole|Given IV or PO
214524933|NCT01503515|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214524934|NCT01503515|DRUG|Voriconazole|Given IV or PO
214524935|NCT03690336|DRUG|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
214524936|NCT01007617|DEVICE|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
214524937|NCT01563445|DRUG|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
215129806|NCT00737646|BEHAVIORAL|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
215129807|NCT02097862|PROCEDURE|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
215129808|NCT05603117|BEHAVIORAL|Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)|CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
215129809|NCT03261336|DRUG|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
215129810|NCT00647179|PROCEDURE|Transsphenoidal adenomectomy|Surgery
215129811|NCT01155713|DRUG|TKI258|
215129812|NCT01480661|DRUG|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
215129813|NCT01480661|DRUG|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
215129814|NCT01480661|RADIATION|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
215129815|NCT05478408|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
215129816|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
215129817|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
215129818|NCT02306681|OTHER|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
215129819|NCT02528084|PROCEDURE|yoga|patients watch and follow an online yoga video.
214448742|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
214448743|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
214448744|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
214448745|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
214448746|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
214448747|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
214448748|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
215129820|NCT02528084|PROCEDURE|standard exercises|patients watch and follow an online standard exercises video.
214694519|NCT03145194|OTHER|Placebo|2 x matching placebo tablets
214694520|NCT05597059|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
215129821|NCT03901417|DEVICE|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
215129822|NCT03901417|DEVICE|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
215129823|NCT01798693|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|
215129824|NCT01798693|DIETARY_SUPPLEMENT|Multi-nutrient Blend|
214448749|NCT06354543|DEVICE|Cemented joint arthroplasty|Joint replacement with cemented prosthetic components
214448750|NCT05938712|DRUG|Dapagliflozin 10 MG|Semaglutide subcutaneous once weekly for 12 weeks.
214448751|NCT05938712|DRUG|Semaglutide, 1.0 mg/mL|Dapagliflozin oral once daily for 12 weeks.
214448752|NCT06219707|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
214448753|NCT03161379|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
214448754|NCT03161379|DRUG|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
214448755|NCT03161379|DRUG|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
214448756|NCT03161379|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
214448757|NCT06455605|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
214524938|NCT01563445|DRUG|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
215129825|NCT04816448|OTHER|cervical mobilization (Headache SNAG)|For cervical mobilization the patient's position is sitting on a chair in the erect posture. The therapist handled C2 spinous process with the middle phalanx of one hand. With the other hand, he performed ventral glide asked the patient to move neck in all directions (Flexion, Extension, Side bending and rotation) one by one and then slowly move the neck back to its starting position while the therapist maintained the ventral glide.
215129826|NCT04816448|OTHER|Sub-occipital myofascial release|"For the application of the technique , the patient position is supine lying with the head fully supported on therapist's hands and therapist places 3 middle fingers just inferior to the nuchal line, lifts the fingers tips towards the ceiling while resting the head on the table and then therapist will apply a gentle upward pull. This procedure done for 2 to 3 minutes and 5 to 7 repetitions, 3 sessions per week on alternate days were given for 6 weeks.~Evaluation was done before treatment, during treatment at 4th week and after treatment at 6th week. Outcomes will be measured by NDI, PNRS and Universal Goniometer."
215129827|NCT06060236|DRUG|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
214524939|NCT00515697|BIOLOGICAL|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
215129828|NCT06060236|DRUG|Dexketoprofen|Dexketoprofen 50 Mg İV
215129829|NCT00562367|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
215129830|NCT02462044|DRUG|240 mg Iodine|
215129831|NCT02462044|DRUG|300 mg Iodine|
215129832|NCT02462044|DRUG|370 mg Iodine|
215129833|NCT01869738|DEVICE|MGuard Prime|
215129834|NCT01869738|DEVICE|(BMS/DES)|
215129835|NCT03174353|DRUG|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
215129836|NCT02710656|DEVICE|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
215129837|NCT02710656|DEVICE|Standard PTA|Percutaneous angioplasty performed with a standard balloon
215129838|NCT01069484|OTHER|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
215129839|NCT06240637|OTHER|Telemonitoring|A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
215129840|NCT02296164|DRUG|Valchlor|Valchlor gel 0.016%
215129841|NCT01052792|DRUG|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
215129842|NCT02848469|DIETARY_SUPPLEMENT|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
215129843|NCT00683111|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
215129844|NCT00683111|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
215129845|NCT00292942|DRUG|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
215129846|NCT00292942|DRUG|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
214448758|NCT06455605|DRUG|2141 V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
214448759|NCT02432560|DRUG|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
214448760|NCT02432560|DRUG|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
214448761|NCT06150664|DRUG|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
214448762|NCT03992430|DRUG|Eteplirsen|Solution for intravenous (IV) infusion.
214448763|NCT05483764|DEVICE|Ultrasonographic evaluations|"Ultrasonographic evaluations of the talar cartilage will be performed with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) by the same physiatrist according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS).~Ultrasonographic evaluations of the Achilles tendon will be performed by the same physiatrist with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS)."
214448764|NCT02728076|RADIATION|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
214448765|NCT05344534|BEHAVIORAL|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
214448766|NCT04353869|BIOLOGICAL|Bio collection|venous blood sampling and collection of urine
214448767|NCT03820830|DRUG|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
215129847|NCT05975723|BEHAVIORAL|MIND diet education|An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).
215129848|NCT05975723|BEHAVIORAL|Routine follow-up and general advice|Routine follow-up administered by trained staff.
215129849|NCT02282852|DEVICE|Wireless Capsule Endoscopy|
215129850|NCT02282852|DEVICE|Magnetically steerable capsule endoscopy|
215129851|NCT02027012|DEVICE|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
215129852|NCT00644358|DRUG|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
215129853|NCT04976985|PROCEDURE|Osteopathic Manipulative Therapy (OMT)|"Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~1. Occipital- Alanto release~2. Muscle energy and soft tissue to mid trapezius muscle~3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~5. Soft tissue to cervical paraspinal muscles~6. Myo-fascial release of frontal forehead~7. CV4 cranial technique"
215129854|NCT04976985|OTHER|Standard of care|Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
214448768|NCT03820830|DRUG|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
214448769|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted
214448770|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted.
214448771|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
214448772|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
214448773|NCT06311656|DRUG|Placebo|Administered orally.
214448774|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
214448775|NCT04456920|OTHER|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
214448776|NCT04456920|OTHER|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
214448777|NCT04456920|OTHER|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
214448778|NCT04456920|OTHER|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
214448779|NCT02384317|DRUG|CCX168|CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
214448780|NCT05463341|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
214448781|NCT03667716|DRUG|COM701|COM701 monotherapy.
214524940|NCT04462497|OTHER|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
214524941|NCT05599516|BIOLOGICAL|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
214524942|NCT05599516|BIOLOGICAL|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
215129855|NCT02141087|DRUG|Pirfenidone|
214448782|NCT03667716|DRUG|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
214448783|NCT04140708|BEHAVIORAL|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
214524943|NCT05599516|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
215129856|NCT00079326|BIOLOGICAL|trastuzumab|Given IV
215129857|NCT00079326|DRUG|ixabepilone|Given IV
215129858|NCT00079326|OTHER|laboratory biomarker analysis|Correlative studies
215129859|NCT03191617|DIETARY_SUPPLEMENT|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
215129860|NCT05476445|PROCEDURE|Control|Root canal treatment
214448784|NCT03817021|BEHAVIORAL|ECE Provider|Provide online training for Head Start educators
214448785|NCT03817021|BEHAVIORAL|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
214448786|NCT03817021|BEHAVIORAL|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
214448787|NCT06394037|PROCEDURE|Active surveillance|Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
214448788|NCT03088852|DRUG|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
214448789|NCT04160546|DRUG|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
214448790|NCT04160546|DRUG|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
214524944|NCT03087851|DRUG|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
215129861|NCT05476445|PROCEDURE|Laser|Root canal treatment+Laser application
215129862|NCT05476445|PROCEDURE|Cryotherapy|Root canal treatment + Cryotherapy application
215129863|NCT03496259|DEVICE|On-Q pump|Type of pain control device used
215129864|NCT03496259|DEVICE|Epidural catheter|Type of pain control device used
215129865|NCT03045367|PROCEDURE|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
215129866|NCT02151487|DRUG|Ropivacaine|Ropivacaine alone
215129867|NCT02151487|DRUG|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
215129868|NCT02151487|DRUG|Ropivacaine and clonidine|Ropivacaine combination with clonidine
214524945|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery
214524946|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
214524947|NCT05341063|BEHAVIORAL|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
214524948|NCT05341063|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
215129869|NCT02151487|DRUG|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
215129870|NCT06389630|OTHER|video-assisted training group|This group will be taught subcutaneous insulin injection through video-supported training.
215129871|NCT06389630|OTHER|low fidelity simulation model group|This group will be taught subcutaneous insulin injection on a low-fidelity simulation model.
215129872|NCT00049023|RADIATION|90Y-DOTA-tyr3-OCTREOTIDE|
215129873|NCT02774460|DRUG|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
215129874|NCT02774460|DRUG|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
215129875|NCT02774460|DRUG|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
215129876|NCT02774460|DRUG|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
215129877|NCT02774460|DRUG|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
214448791|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
214448792|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
214448793|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
214448794|NCT03997968|DRUG|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
214448795|NCT03997968|DRUG|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
214694521|NCT04624035|PROCEDURE|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
214694522|NCT04624035|PROCEDURE|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
215129878|NCT02774460|DRUG|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
215129879|NCT02774460|DRUG|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
214694523|NCT03372668|OTHER|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
215129880|NCT02929953|OTHER|chart review|data from charts and from registries will be compared
215129881|NCT02826746|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
214694524|NCT00192439|BEHAVIORAL|High Risk Respiratory Disease|
215129882|NCT02826746|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
215129883|NCT00651924|BEHAVIORAL|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
215129884|NCT01269866|DRUG|Cymbalta|Cymbalta 60 to 120 mg PO QD
215129885|NCT01356160|DRUG|GS-5885|tablet, 30 mg QD
215129886|NCT01356160|DRUG|GS-9451|tablet, 200 mg QD
214448796|NCT03997968|DRUG|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
214448797|NCT03997968|DRUG|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
215129887|NCT01356160|BIOLOGICAL|peginterferon alfa-2a|(solution for injection) 180 µg/week
214448798|NCT04997473|BEHAVIORAL|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
214448799|NCT06628895|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
214448800|NCT06289374|OTHER|Biosample collection|Collection of saliva, urine, blood, breath and quality of life questionnaires.
215129888|NCT01356160|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
215129889|NCT01356160|DRUG|GS-9451 Placebo|Placebo to match GS-9451 QD
215129890|NCT05405010|OTHER|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
215129891|NCT05405010|OTHER|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
215129892|NCT05405010|OTHER|Seated control|Seated control
215129893|NCT04400357|PROCEDURE|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
215129894|NCT04400357|PROCEDURE|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
215129895|NCT00960063|DRUG|Temozolomide|
215129896|NCT00960063|DRUG|Vincristine|
215129897|NCT00960063|DRUG|Ifosfamide|
215129898|NCT00960063|DRUG|Irinotecan|
215129899|NCT00960063|BIOLOGICAL|Robatumumab|
215129900|NCT00960063|DRUG|Doxorubicin|
214448801|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
214448802|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
214448803|NCT05975047|DRUG|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
215129901|NCT00960063|DRUG|Cyclophosphamide|
215129902|NCT00960063|DRUG|Etoposide|
215129903|NCT02859922|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
215129904|NCT02859922|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
215129905|NCT01672645|BIOLOGICAL|NIC7-001|Intramuscular, multiple dose
215129906|NCT01672645|BIOLOGICAL|NIC7-003|Intramuscular, multiple dose
215129907|NCT01672645|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
215129908|NCT03341416|DEVICE|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
215129909|NCT03341416|DEVICE|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
214524949|NCT01742949|DEVICE|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
214524950|NCT01742949|DEVICE|No Humidification|Heated Humidification (ThermoSmart) Turn Off
214524951|NCT02515500|BEHAVIORAL|Gradual Cessation|
214524952|NCT02515500|BEHAVIORAL|Gradual Cessation w/ Quitbit|
214524953|NCT03520088|PROCEDURE|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
214524954|NCT03520088|PROCEDURE|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
214524955|NCT04225247|DRUG|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
214524956|NCT04225247|DRUG|Bifluorid 12|it is a fluoride varnish by VOCO.
214694525|NCT03604237|DIAGNOSTIC_TEST|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
215129910|NCT03655145|OTHER|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
215129911|NCT03655145|OTHER|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
215129912|NCT00771914|DRUG|Aspirin|Aspirin 81mg tablet
215129913|NCT00771914|DRUG|Lovaza|Lovaza 4 grams
214448804|NCT05975047|DRUG|Placebo|Participants will receive matching placebo across Part A and B of the study
214448805|NCT05404880|DEVICE|EDWARDS INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
214448806|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
214448807|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
215129914|NCT00771914|DRUG|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
215129915|NCT00771914|OTHER|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
215129916|NCT03771755|DRUG|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
215129917|NCT03771755|DRUG|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
214448808|NCT05734625|DRUG|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
214448809|NCT05734625|DRUG|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
214448810|NCT04975633|DEVICE|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
214448811|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
214448812|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
214524957|NCT04225247|DRUG|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
214524958|NCT06159933|PROCEDURE|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
214524959|NCT06159933|PROCEDURE|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
214524960|NCT06159933|PROCEDURE|Late pronation|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
214524961|NCT04782505|DRUG|DWJ1248|Camostat mesylate Tablet from Daewoong
214524962|NCT05849571|OTHER|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
214524963|NCT04441996|BIOLOGICAL|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
215129918|NCT01636765|DRUG|No Intervention|No intervention.
215129919|NCT02654782|DRUG|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
215129920|NCT02654782|DRUG|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
215129921|NCT01386164|BIOLOGICAL|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
215129922|NCT01386164|BIOLOGICAL|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
215129923|NCT00976131|DRUG|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
215129924|NCT00976131|OTHER|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
215129925|NCT00976131|DRUG|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
215129926|NCT00976131|DRUG|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
215129927|NCT00752700|OTHER|Conventional resistance training|Conventional resistance training program (CRT)
215129928|NCT00752700|OTHER|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
215129929|NCT02978417|DRUG|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
215129930|NCT02978417|DRUG|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
215129931|NCT04102397|PROCEDURE|Vojta therapy after standard therapy|Vojta Therapy \~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
215129932|NCT04102397|PROCEDURE|Standard therapy|"\~50 minutes/session:~* TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~* Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~* Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~* Cryotherapy (5 minutes)."
215129933|NCT03111875|DEVICE|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
214448813|NCT02504905|DEVICE|TMS|single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
214448814|NCT00797719|OTHER|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
214448815|NCT03568487|OTHER|Intensive scapula-focused approach|scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
214448816|NCT03568487|OTHER|Control Therapy|not have any physical training but is encouraged to stay active as usual.
214448817|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
214524964|NCT04441996|OTHER|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
214524965|NCT05289375|DRUG|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
214524966|NCT05289375|DRUG|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
215129934|NCT03111875|DEVICE|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
215129935|NCT03975010|DRUG|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
215129936|NCT01361555|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
215129937|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
214694526|NCT04785079|PROCEDURE|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
214694527|NCT01836744|DEVICE|Survival rate dental implant (OsseoSpeed™)|
215129938|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
215129939|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
215129940|NCT03273426|PROCEDURE|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
215129941|NCT03273426|PROCEDURE|wide excision|Surgical wide excision of the biopsied area.
215129942|NCT05083351|DEVICE|MightySat|Noninvasive pulse oximeter
215129943|NCT05604846|DIETARY_SUPPLEMENT|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
215129944|NCT00871767|DRUG|AZD5672|40 mg tablet (Test formulation)
215129945|NCT00871767|DRUG|AZD5672|40 mg tablet (Reference formulation)
214448818|NCT04089371|DEVICE|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
214448819|NCT04089371|DEVICE|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
214448820|NCT03222102|DEVICE|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
214448821|NCT06477783|DRUG|Teclistamab|Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
214448822|NCT05595447|DRUG|Brentuximab Vedotin 50 MG [Adcetris]|Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
214448823|NCT05826717|OTHER|Apple|20g fructose in \[x\] g of apple
214448824|NCT05826717|OTHER|Mashed apple|20g fructose in \[x\] g of mashed apple
214448825|NCT05826717|OTHER|Apple juice|20g fructose in \[x\] ml apple juice
214448826|NCT05826717|OTHER|Fructose powder in water|20g fructose in \[x\] ml water
214448827|NCT06399094|OTHER|Lung sound recordings|The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
214448828|NCT05479643|DEVICE|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
214448829|NCT05355298|DRUG|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
214448830|NCT05355298|DRUG|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
214448831|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
214448832|NCT05641948|OTHER|MRI scan|Participants will undergo brain MRI scan at 3 intervals
214448833|NCT04240990|OTHER|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~* TB contact history~* Suggestive TB symptoms in the previous 4 weeks~* Physical examination~* Clinical, anthropometric and biochemical assessment of malnutrition~* Clinical assessment for other non-dietary causes of malnutrition~* Digitalized CXR~* Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~* Mycobacterial culture performed on two GAs~* Abdominal ultrasonography~* QuantiFERON®-TB Gold IGRA~* Monocyte-to-Lymphocyte Ratio (MLR)~* C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
214448834|NCT06501170|OTHER|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes
214448835|NCT03652428|DRUG|Gemcitabine|see arm description
214448836|NCT03652428|RADIATION|Hypofractionated Ablative Proton Therapy|see arm description
214448837|NCT05581992|DRUG|AMG 510|Oral Tablet
214448838|NCT05581992|DRUG|Omeprazole|Capsule
214448839|NCT05938283|DEVICE|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
214448840|NCT06262334|BEHAVIORAL|The Fade to Fitness Program|The Fade to Fitness Program is a group-based and barbershop-based behavioral intervention to improve health-related quality of life among African American men. The program is unique because it is culturally targeted and individually tailored. The culturally targeted content was developed following barbershop-based focus groups. The Fade to Fitness Program targets four behaviors strongly linked to health-related quality of life among African American men - physical activity, healthy eating, stress management, and depression management. During the group-based portion of the program, Motivational Interviewing is used by the facilitator as a conversational approach to enhance participants\&#39; motivation and commitment towards positive behavior change. The goal is to foster intrinsic motivation among participants to engage in these behaviors. It is individually tailored by encouraging participants to identify personal values and linking them to health promoting behaviors.
214694528|NCT02353039|DRUG|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
214694529|NCT02353039|DRUG|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
215129946|NCT00871767|DRUG|AZD5672|100 mg tablet (Test formulation)
215129947|NCT00871767|DRUG|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
215129948|NCT03485924|DIAGNOSTIC_TEST|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
215129949|NCT03485924|DIAGNOSTIC_TEST|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
215129950|NCT02522247|PROCEDURE|UPP|surgery with cold steel in general anesthesia
214524967|NCT06141694|DEVICE|The LIBERTY® Robotic System|"The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures."
214524968|NCT04009902|BEHAVIORAL|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
215129951|NCT03297957|DEVICE|Hands-free goggle system|-Manufactured at Washington University
215129952|NCT05890248|PROCEDURE|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
215129953|NCT04937985|OTHER|Performance Tests|Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
215129954|NCT01792700|DRUG|esomeprazole|
215129955|NCT01792700|DRUG|tripotassium dicitrate bismuthate|
215129956|NCT01792700|DRUG|metronidazole|
215129957|NCT01792700|DRUG|tetracycline|
215129958|NCT01792700|DRUG|moxifloxacin|
215129959|NCT01792700|DRUG|amoxicillin|
215129960|NCT00467246|DRUG|Levemir|
215129961|NCT03360903|DRUG|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline"
215129962|NCT03360903|DRUG|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate"
215129963|NCT01402440|DRUG|AEB071|
215129964|NCT04097431|BEHAVIORAL|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
215129965|NCT00259909|OTHER|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
214448841|NCT06224517|OTHER|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
215129966|NCT00259909|OTHER|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
215129967|NCT00259909|OTHER|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
214448842|NCT06512194|DRUG|Psilocybin|The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
214448843|NCT06512194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
214524969|NCT02080143|DEVICE|Thermal Adhesion Patch|
214524970|NCT02080143|DEVICE|Thermal Adhesion Patch|
215129968|NCT00259909|OTHER|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
215129969|NCT01759420|DRUG|Ondansetron|4mg of intravenous ondansetron
215129970|NCT01998256|DEVICE|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
215129971|NCT00166218|DEVICE|near-infrared spectroscopy|
214524971|NCT05921929|DRUG|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
214524972|NCT01763489|BEHAVIORAL|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
214524973|NCT00122707|DEVICE|catheters|
214524974|NCT03110640|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
214524975|NCT03110640|DRUG|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
214524976|NCT03110640|DRUG|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
214524977|NCT02112799|DRUG|NVR 3-778|
215129972|NCT05389098|OTHER|Hand-Eating|eat-hands type food mode
215129973|NCT05389098|OTHER|Control|Usual eating mode
215129974|NCT05106127|DRUG|EG-007|A Repurposed Drug
215129975|NCT05106127|DRUG|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
215129976|NCT05106127|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
215129977|NCT03561675|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
215129978|NCT03561675|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
215129979|NCT04325802|DRUG|Naltrexone|50mg Naltrexone daily
215129980|NCT04325802|OTHER|Placebo|Placebo (Mannitol) daily
215129981|NCT01422161|DRUG|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
215129982|NCT01422161|DRUG|Placebo|The control group will receive a placebo injection.
215129983|NCT01129622|DRUG|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
215129984|NCT02970799|DEVICE|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
215129985|NCT00004838|DRUG|succimer|
215129986|NCT04040374|DIAGNOSTIC_TEST|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
215129987|NCT04040374|DIAGNOSTIC_TEST|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
215129988|NCT05597202|DRUG|Semaglutide, 2.0 mg/mL|Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
215129989|NCT00960375|BEHAVIORAL|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
215129990|NCT00960375|BEHAVIORAL|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
215129991|NCT01416818|DRUG|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
215129992|NCT01416818|DRUG|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
215129993|NCT01416818|DRUG|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
215129994|NCT04842708|DIAGNOSTIC_TEST|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
215129995|NCT02900794|DEVICE|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
215129996|NCT02900794|PROCEDURE|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
215129997|NCT05046223|PROCEDURE|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
215129998|NCT05046223|PROCEDURE|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
215129999|NCT02733263|DIETARY_SUPPLEMENT|15 g RMD|15 grams of resistant maltodextrin
215130000|NCT02733263|DIETARY_SUPPLEMENT|25 g RMD|25 grams of resistant maltodextrin
214448844|NCT06512194|DEVICE|Sham taVNS|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
215130001|NCT02733263|DIETARY_SUPPLEMENT|0 g RMD|0 grams of resistant maltodextrin
215130002|NCT04256694|DIAGNOSTIC_TEST|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
214524978|NCT02112799|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
214524979|NCT02112799|DRUG|Pegasys|
214524980|NCT03694249|DRUG|Ifetroban Sodium|Given by mouth
214524981|NCT03694249|OTHER|Placebo|Given by mouth
214524982|NCT02232919|DEVICE|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
214448845|NCT04494555|DEVICE|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
214524983|NCT05166317|OTHER|This is an observational study|This is an observational study
214524984|NCT05834647|DRUG|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
215130003|NCT02949349|DRUG|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
215130004|NCT02949349|DRUG|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
215130005|NCT02949349|DRUG|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
214448846|NCT04494555|DEVICE|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
214448847|NCT04494555|DEVICE|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
214448848|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
215130006|NCT00002814|BIOLOGICAL|filgrastim|
215130007|NCT00002814|DRUG|paclitaxel|
215130008|NCT00002814|DRUG|topotecan hydrochloride|
215130009|NCT03585478|DRUG|Latiglutenase|Latiglutenase administered orally (daily)
215130010|NCT03585478|OTHER|Placebo|Placebo administered orally (daily)
215130011|NCT04364477|PROCEDURE|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
214448849|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
214448850|NCT06839807|DEVICE|AtMoves Knee System|The AtMoves Knee Stystem is a loading device that is able to exert force in varus and valgus. when these forces are applied during a CT-scan micromotions of the tibial component of the total knee prosthesis can be detected.
214448851|NCT06099184|DRUG|EYP-1901|Intravitreal Injection
214448852|NCT06099184|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
214448853|NCT06794814|BEHAVIORAL|oral exercise|The oral exercise protocol included several physical components, namely neck and shoulder stretching, cheek puffing exercises, tongue exercises, salivary gland massage, and oral diadochokinesis.
214448854|NCT06795503|DRUG|Docetaxel plus cyclophosphamide|Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.
214448855|NCT06795503|DRUG|Epirubicin, cyclophosphamide plus paclitaxel|Patients in the control group received the EC-P regimen chemotherapy, with a cycle length of 21 days, for a total of 8 cycles. The specific treatment was as follows: Epirubicin (E) at a dose of 90 mg/m² and Cyclophosphamide (C) at a dose of 600 mg/m² were administered intravenously on Day 1 of each cycle for the first 4 cycles. This was followed by Paclitaxel (P) at a dose of 80 mg/m², administered intravenously on Days 1, 8, and 15 of each cycle for the subsequent 4 cycles.
214694530|NCT02353039|DRUG|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
215130012|NCT03101280|DRUG|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
215130013|NCT03101280|DRUG|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
215130014|NCT00591006|DRUG|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
215130015|NCT00591006|DRUG|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
215130016|NCT00591006|DRUG|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
215130017|NCT05329844|DRUG|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
215130018|NCT01204099|DRUG|Docetaxel|
215130019|NCT01204099|DRUG|PX-866|
215130020|NCT04368026|OTHER|No intervention (survey study for medical doctors).|No intervention
215130021|NCT00054392|DRUG|carboplatin|
215130022|NCT00054392|DRUG|gemcitabine hydrochloride|
215130023|NCT00054392|DRUG|paclitaxel|
215130024|NCT03576508|DRUG|CNTX-4975-05|1 mg (2mL) IA injection
215130025|NCT03576508|DRUG|Qutenza|8% topical patch
215130026|NCT03576508|DRUG|Lidocaine (without epinephrine)|15 mL IA injection of 2% lidocaine (without epinephrine)
215130027|NCT04207034|PROCEDURE|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
215130028|NCT04207034|PROCEDURE|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
215130029|NCT05213832|DRUG|Isoflurane Inhal Soln|Administration of isofluorane in patients with severe SAH
215130030|NCT01064063|DEVICE|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
215130031|NCT01064063|DEVICE|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
215130032|NCT01334060|BIOLOGICAL|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
215130033|NCT06091696|OTHER|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
215130034|NCT06091696|OTHER|Aerobic exercises|Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).
214448856|NCT06245746|BIOLOGICAL|umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)|UCMSC-Exo will be infused intravenously.
214448857|NCT04807738|DEVICE|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The outpatients will be randomized into groups: Individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in the interventional group, uses virtual reality and the new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
214464450|NCT06564948|OTHER|Treatment as usual (TAU)|"TAU patients will be identified using targeted limited chart review methods used in our prior studies, scraping clinical notes in the EHR for criminal justice involvement. Initial Identification terms, police, arrest, court, summons, jail, and crime will be used to identify candidates for police involvement, downloading the sentence in which the keyword appeared and the sentence before and after. Next, an iterative process of editing of the search terms will be conducted to remove patients with negation of the keyword (did not commit a crime), and other sentence characteristics that generate false positives (cardiac arrest). Samples of the resulting dataset will be taken, accuracy assessed by examining the surrounding sentences, leading to further iterations and repetition of the process until a high level of accuracy is achieved."
215130035|NCT03009786|OTHER|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
215130036|NCT03400618|OTHER|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
215130037|NCT03400618|OTHER|Higher carbohydrate diet|50 E % carbohydrates included in the diet
214524985|NCT05834647|DRUG|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
214524986|NCT03997409|OTHER|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
214694531|NCT02353039|DRUG|Placebo|Administer placebo t.i.d for 2 weeks
215130038|NCT05594459|PROCEDURE|Mini invasive analgesic technique|patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
215130039|NCT05594459|DRUG|high opioids dosages|patients will be treated with high opioids dosages
215130040|NCT01434277|OTHER|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
215130041|NCT00689390|BIOLOGICAL|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
215130042|NCT00689390|BIOLOGICAL|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
214448858|NCT04807738|OTHER|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will undergo physical therapy with physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
215130043|NCT00689390|BIOLOGICAL|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
215130044|NCT00689390|DRUG|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
215130045|NCT00689390|OTHER|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
215130046|NCT02343263|DRUG|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
215130047|NCT02343263|BIOLOGICAL|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
214448859|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
214448860|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
215130048|NCT04068402|DEVICE|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
215130049|NCT03174184|DRUG|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
215130050|NCT03174184|DRUG|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
215130051|NCT03174184|DRUG|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
215130052|NCT03174184|DRUG|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
214448861|NCT06582758|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
214448862|NCT06582758|BEHAVIORAL|Mindful Pain Management|In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.
214524987|NCT04463888|OTHER|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
215130053|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
215130054|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
215130055|NCT00973752|DRUG|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
215130056|NCT00973752|DRUG|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
215130057|NCT00973752|DRUG|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
215130058|NCT00973752|DRUG|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
215130059|NCT00973752|DRUG|Cytarabine|Intrathecally during Induction and CNS therapy
215130060|NCT00973752|DRUG|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
215130061|NCT00973752|DRUG|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
215130062|NCT00973752|DRUG|Clofarabine|Intravenously during Consolidation 1 Therapy
215130063|NCT00973752|DRUG|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
215130064|NCT02023424|DRUG|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
215130065|NCT01723735|DRUG|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
215130066|NCT01723735|DRUG|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
215130067|NCT01723735|DRUG|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
215130068|NCT01723735|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
215130069|NCT01780116|BEHAVIORAL|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
215130070|NCT04872361|PROCEDURE|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
215130071|NCT04872361|PROCEDURE|High PEEP|PEEP of 10 cm H2O will be applied
215130072|NCT04872361|PROCEDURE|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
214524988|NCT02581826|DRUG|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
214524989|NCT02581826|DRUG|Placebo|No column specified.
214524990|NCT04975646|BEHAVIORAL|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
214524991|NCT01975259|DRUG|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
214524992|NCT01975259|DRUG|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
214524993|NCT01975259|DRUG|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
215130073|NCT04872361|DEVICE|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
215130074|NCT01713959|DEVICE|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
215130075|NCT01713959|DEVICE|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
215130076|NCT05668832|DIETARY_SUPPLEMENT|UVB-exposed button mushrooms|Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
215130077|NCT00392392|DRUG|nab-paclitaxel|ABI-007
215130078|NCT00392392|DRUG|Bevacizumab|Bevacizumab
215130079|NCT00392392|DRUG|Trastuzumab|Trastuzumab
215130080|NCT05334368|DRUG|Depemokimab|Depemokimab will be administered.
215130081|NCT05334368|OTHER|Placebo|Matching placebo will be administered.
214524994|NCT01975259|DRUG|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
214694532|NCT02325947|DEVICE|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
214694533|NCT02325947|DEVICE|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
215130082|NCT00931034|BEHAVIORAL|South Beach Diet with South Beach Diet Products|
215130083|NCT00931034|BEHAVIORAL|American Diabetes Association Diabetes Meal Plan|
215130084|NCT03153696|BEHAVIORAL|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
215130085|NCT06519812|PROCEDURE|Combined Intrarenal Surgery and percutaneous nephrolithotomy|A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
215130086|NCT01682733|DRUG|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
214694534|NCT03173482|OTHER|questionnaire|asking about details of indication of cesarean section
215130087|NCT01682733|DEVICE|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
215130088|NCT03495466|PROCEDURE|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
214524995|NCT01975259|DRUG|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
215130089|NCT00663013|OTHER|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
215130090|NCT06306209|OTHER|Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management|All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.
215130091|NCT03494270|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
215130092|NCT03494270|DRUG|Monorova|Rosuvastatin 20mg
215130093|NCT00394199|DRUG|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
215130094|NCT00394199|DRUG|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
215130095|NCT00394199|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
215130096|NCT02416999|DRUG|Ultra-low dose Bevacizumab|
215130097|NCT02416999|DRUG|Temozolomide|
215130098|NCT01176734|DEVICE|tVNS-Device|Active treatment with the t-VNS device.
215130099|NCT04604041|DIAGNOSTIC_TEST|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
215130100|NCT00085163|DRUG|celecoxib|
215130101|NCT00085163|DRUG|fluorouracil|
215130102|NCT00085163|DRUG|leucovorin calcium|
215130103|NCT00085163|PROCEDURE|adjuvant therapy|
215130104|NCT02066766|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
214448863|NCT06349213|RADIATION|FDOPA injection before PET imaging|Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.
214448864|NCT06349213|BEHAVIORAL|Time perception tasks|The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations
214448865|NCT06349213|DEVICE|fMRI imaging|Imaging of brain structure during the completion of the time perception task
214448866|NCT06349213|DEVICE|EEG imaging|Recording of neural dynamics during the completion of the time perception task
214448867|NCT06349213|BEHAVIORAL|3 year follow-up|Behavioral and EEG follow-up (for older adults only)
215130105|NCT05606666|OTHER|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
214694535|NCT05024877|DRUG|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
214694536|NCT05024877|DRUG|Stanozolol Tablets|Stanozolol would be given 2mg tid.
214694537|NCT02875821|DRUG|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
215130106|NCT05833529|BEHAVIORAL|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
215130107|NCT05833529|OTHER|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
215130108|NCT05833529|BEHAVIORAL|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
215130109|NCT05869435|DEVICE|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
215130110|NCT01112137|DRUG|Clopidogrel|
215130111|NCT01112137|DRUG|Clopidogrel|
215130112|NCT01112137|DRUG|Clopidogrel|
214448868|NCT06490705|OTHER|tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises|"6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board."
214448869|NCT05703672|DRUG|Varenicline Tartrate|0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
214448870|NCT05703672|DRUG|Placebo|One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
215130113|NCT01112137|DRUG|Clopidogrel|
214448871|NCT05703672|OTHER|Electronic cigarette|Nicotine salt pod based e-cigarette in 5% nicotine
214694538|NCT02875821|DRUG|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
214694539|NCT00332514|BEHAVIORAL|telephone call by a pharmacist|
214694540|NCT03397277|BEHAVIORAL|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
214694541|NCT03397277|BEHAVIORAL|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
214694542|NCT04586114|DRUG|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
214694543|NCT00357526|DRUG|OCPs|
215130114|NCT02316730|DRUG|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
215130115|NCT02316730|DRUG|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
215130116|NCT00409539|DRUG|Placebo|Placebo, 2 week duration.
215130117|NCT00409539|DRUG|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
215130118|NCT00409539|DRUG|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
215130119|NCT03324490|PROCEDURE|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected."
215130120|NCT03324490|PROCEDURE|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure."
215130121|NCT03324490|DRUG|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
215130122|NCT03324490|DRUG|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
215130123|NCT03324490|DRUG|Fentanyl|Neuro-axially injected
215130124|NCT03324490|DRUG|Dexmedetomidine|Neuro-axially injected
215130125|NCT00689312|DRUG|Enfalyte|Each patient will receive one 250 ml dose.
214694544|NCT00357526|DEVICE|vaginal ring|
215130126|NCT00689312|DRUG|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
215130127|NCT00689312|DRUG|Pedialyte|Each patient will receive one 250 ml dose.
215130128|NCT06293521|PROCEDURE|Pulpotomy|After the chamber is deroofed and coronal pulp is amputated using a round-end fissure bur in a high-speed handpiece with adequate water spray and light pressure until canal orifices were reached, The access cavity is flushed with sterile normal saline solution. Saline-wetted cotton pellets were placed for about 5 minutes over amputation sites applying moderate pressure to control pulpal hemorrhage. After discarding the pellets, blood oozing was present, MTA+ Cerkamed will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by application of glass ionomer cement.
215130129|NCT06293521|PROCEDURE|Partial Pulpectomy|"Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of Zinc oxide and eugenol.~The tooth with then be restored with stainless steel crown"
215130130|NCT00073658|DRUG|Citalopram|
215130131|NCT00073658|DRUG|Risperidone|
215130132|NCT03179566|BEHAVIORAL|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
215130133|NCT03179566|BEHAVIORAL|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
215130134|NCT03034486|DRUG|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
215130135|NCT00877136|DEVICE|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
215130136|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
215130137|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
215130138|NCT00629044|BIOLOGICAL|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
215130139|NCT00466063|DRUG|Deferasirox|
215130140|NCT01130753|DRUG|Erlotinib|Erlotinib 150mg per day for 8 weeks
215130141|NCT02662972|DRUG|Botulinum Toxin Type A|
214448872|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
214448873|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
214448874|NCT06371209|PROCEDURE|Modified Amputation|Modified amputation procedure
214448875|NCT06371209|PROCEDURE|Standard Amputation|Standard amputation procedure
214448876|NCT06395038|DRUG|Abatacept plus Aldesleukin|CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
214448877|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
214448878|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
214448879|NCT05898854|DRUG|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
214448880|NCT06028672|DRUG|Toripalimab|200mg q2w intravenous
215130142|NCT02600481|PROCEDURE|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
215130143|NCT02600481|PROCEDURE|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
215130144|NCT05118191|OTHER|OOLER|Following the baseline block (first four weeks), participants will use the OOLER device to power a cooling mattress pad each night during sleep for four weeks.
215130145|NCT05118191|OTHER|EmbrWave|Following the baseline block (first four weeks), participants will use the Embr Wave 2 device to provide pulsed warm sensations to the inner wrist each night during sleep for four weeks.
215130146|NCT01239511|DRUG|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
215130147|NCT03841110|DRUG|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
215130148|NCT03841110|DRUG|Nivolumab|Immune Checkpoint Inhibitor
214448881|NCT06028672|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
214694545|NCT04400409|OTHER|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
215130149|NCT03841110|DRUG|Pembrolizumab|Immune Checkpoint Inhibitor
215130150|NCT03841110|DRUG|Atezolizumab|Immune Checkpoint Inhibitor
215130151|NCT03841110|DRUG|Cyclophosphamide|Lympho-conditioning agent
215130152|NCT03841110|DRUG|Fludarabine|Lympho-conditioning agent
215130153|NCT03841110|DRUG|IL-2|Biologic response modifier
215130154|NCT00356681|DRUG|AMG 706 placebo|Blinded placebo
215130155|NCT00356681|DRUG|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
215130156|NCT00356681|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
215130157|NCT00356681|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
214694546|NCT04400409|OTHER|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
215130158|NCT00525512|DRUG|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
215130159|NCT00525512|DRUG|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
215130160|NCT01863459|DRUG|Lisdexamfetamine Dimesylate|
215130161|NCT01863459|DRUG|placebo|
215130162|NCT04905550|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
215130163|NCT04905550|RADIATION|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
215130164|NCT04268186|DEVICE|Direct tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
215130165|NCT04268186|DEVICE|Indirect tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
215130166|NCT04268186|DEVICE|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
215130167|NCT04268186|DEVICE|Sham tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
215130168|NCT03133611|OTHER|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
215130169|NCT03133611|OTHER|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
214448882|NCT05610878|BIOLOGICAL|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
214448883|NCT05610878|BIOLOGICAL|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
214448884|NCT05610878|OTHER|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
214448885|NCT04936035|DRUG|Placebo|Placebo administered by SC injection
214448886|NCT04936035|DRUG|ALN-AGT01|ALN-AGT01 administered by SC injection
214448887|NCT02808676|DIETARY_SUPPLEMENT|Vitamin D3|Dose: 10000 IU, three times per week, orally.
215130170|NCT01596803|PROCEDURE|Taking of blood|Taking venous blood samples to analyse oxidant stress
215130171|NCT01596803|DIETARY_SUPPLEMENT|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
215130172|NCT01596803|DIETARY_SUPPLEMENT|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
215130173|NCT01596803|DIETARY_SUPPLEMENT|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
215130174|NCT01383603|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
215130175|NCT02609958|DRUG|Varlitinib|"varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID"
215130176|NCT00809016|RADIATION|3-dimensional conformal radiation therapy|
214448888|NCT02808676|OTHER|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
214448889|NCT02808676|OTHER|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
214448890|NCT02808676|OTHER|placebo D3|matching placebo for Vitamin D3
214448891|NCT02808676|OTHER|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
214448892|NCT02808676|OTHER|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
214448893|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
214448894|NCT04493125|DRUG|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
214448895|NCT04493125|DRUG|Placebo|Placebo
214448896|NCT04521699|DEVICE|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
214448897|NCT06527833|PROCEDURE|Non Packing of perianal abscess cavity after drainage|"* All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity."
214448898|NCT06527833|PROCEDURE|Packing of perianal abscess cavity after drainage|an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
214448899|NCT04970511|BEHAVIORAL|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
214448900|NCT04970511|BEHAVIORAL|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
214448901|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
214448902|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
214448903|NCT04418245|DIAGNOSTIC_TEST|Imaging by thoracic scanner|Low-dose computed tomography
214524996|NCT01975259|DRUG|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
215130177|NCT00809016|RADIATION|fludeoxyglucose F 18|
215130178|NCT00809016|RADIATION|intensity-modulated radiation therapy|
215130179|NCT04228263|DRUG|Hydroxychloroquine|400mg
215130180|NCT04228263|DRUG|Folic Acid|5 mg
215130181|NCT04228263|DRUG|Low-dose aspirin|75 mg
215130182|NCT01439516|BEHAVIORAL|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
215130183|NCT04809012|BIOLOGICAL|STI-3031|STI-3031 is an anti-PD-L1 antibody
215130184|NCT03289208|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
215130185|NCT05110638|DRUG|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
215130186|NCT01784991|DRUG|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
215130187|NCT01784991|DRUG|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
215130188|NCT00662207|DEVICE|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
215130189|NCT00662207|PROCEDURE|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
214448904|NCT05775835|OTHER|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
214448905|NCT05775835|OTHER|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
214448906|NCT05775835|OTHER|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
214448907|NCT06849674|BIOLOGICAL|Platelet rich plasma (PRP)|Hair grafts will be immersed in autologous Platelwt-richh plasma(PRP) before transplantation.
214448908|NCT06849674|OTHER|Saline|Hair grafts will be immersed in normal saline solution before transplantation.
214448909|NCT06849297|BEHAVIORAL|Aromatherapy during labor|Use of essential oils (diffusion, massage, or infused cloths) during labor to promote relaxation and pain relief.
214448910|NCT05530057|DRUG|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
214448911|NCT05530057|DRUG|Eribulin Mesylate|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
214448912|NCT03978871|BEHAVIORAL|Growth Mindset|Growth emotion mindset induction
214448913|NCT03978871|BEHAVIORAL|Brain Education|Brain education
214524997|NCT01975259|OTHER|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
215130190|NCT00632216|DRUG|Risedronate Sodium|
215130191|NCT04264858|DRUG|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
215130192|NCT04264858|DRUG|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
215130193|NCT05256485|BEHAVIORAL|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
215130194|NCT06435208|OTHER|Subgingival instrumentation|All the participants will undergo scaling and root planning with hand scalers, curettes and ultrasonic scaler.
215130195|NCT00798200|OTHER|Exercise program|All exercise programs will include endurance and strength exercises.
215130196|NCT01169025|DRUG|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
214524998|NCT01975259|OTHER|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
214524999|NCT01975259|OTHER|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
214525000|NCT01975259|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
214525001|NCT00562926|PROCEDURE|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
214525002|NCT04730570|BEHAVIORAL|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
214525003|NCT05734976|DEVICE|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
214525004|NCT05115721|OTHER|no intervention|It's only observational study. No interventions.
214448914|NCT04450342|DEVICE|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
215130197|NCT01169025|DRUG|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
215130198|NCT02249416|DRUG|Tipranavir (TPV) low|
215130199|NCT02249416|DRUG|Ritonavir (RTV) low|Norvir®
215130200|NCT02249416|DRUG|Tipranavir (TPV) high|Retrovir®
214448915|NCT04450342|PROCEDURE|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
214525005|NCT04067206|OTHER|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
215130201|NCT02249416|DRUG|Ritonavir (RTV) high|
215130202|NCT02249416|DRUG|Zidovudine|
215130203|NCT02530346|DRUG|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
215130204|NCT02530346|DRUG|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
215130205|NCT01259141|DRUG|Moxifloxacin|0.4 Qd for 7days
215130206|NCT01259141|DRUG|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
215130207|NCT00457717|DRUG|0.25 % atropine|
215130208|NCT00457717|DRUG|0.5 % atropine|
215130209|NCT00457717|PROCEDURE|0.25 % atropine+auricular acupoints|
215130210|NCT02507765|OTHER|Laboratory Biomarker Analysis|Correlative studies
215130211|NCT02507765|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215130212|NCT02507765|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
215130213|NCT06296186|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy for PTSD
215130214|NCT03353675|BIOLOGICAL|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
215130215|NCT03353675|DRUG|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
215130216|NCT03353675|DRUG|Nivolumab|360 mg IV administration every 3 weeks
214525006|NCT04067206|OTHER|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
214525007|NCT04067206|OTHER|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
214525008|NCT03300661|BEHAVIORAL|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
214525009|NCT01753323|DRUG|KAF156|KAF156 was supplied as tablets for oral use.
215130217|NCT04670341|OTHER|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
215130218|NCT04670341|OTHER|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
215130219|NCT01938079|DRUG|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
215130220|NCT01938079|OTHER|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
215130221|NCT05354817|DRUG|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
215130222|NCT03649542|OTHER|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
215130223|NCT05075330|BEHAVIORAL|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
215130224|NCT05449821|DIAGNOSTIC_TEST|Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum and saliva samples will be collected from both groups for biochemical analysis.
214448916|NCT04450342|DEVICE|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
214448917|NCT05871346|BEHAVIORAL|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
214525010|NCT01657071|DRUG|YH14659|YH14659 capsule by oral
214525011|NCT01657071|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
214525012|NCT02115542|DRUG|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
214525013|NCT01110161|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
214525014|NCT00224198|PROCEDURE|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
214525015|NCT03199170|DRUG|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
214525016|NCT03199170|DRUG|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
214525017|NCT03199170|DRUG|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
214525018|NCT05959109|DRUG|Peresolimab|Administered SC
214525020|NCT05750017|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
214525021|NCT05750017|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
214525022|NCT05750017|DRUG|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
214525023|NCT00276783|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
215130225|NCT03524430|PROCEDURE|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at \~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
215130226|NCT03217708|DEVICE|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
215130227|NCT04028713|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
215130228|NCT04028713|PROCEDURE|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
215130229|NCT04028713|DRUG|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
215130230|NCT01078610|BIOLOGICAL|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
215130231|NCT02025179|DRUG|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
215130232|NCT02025179|DEVICE|Vibration|Vibration 10 min/day for 12 months
215130233|NCT02362724|DEVICE|Sapphire|silicone hydrogel contact lens
215130234|NCT02362724|DEVICE|Pearl|silicone hydrogel contact lens
215130235|NCT00402168|DRUG|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
215130236|NCT00402168|DRUG|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
215130237|NCT00402168|DRUG|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
214525024|NCT04015128|DEVICE|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
215130238|NCT03146611|DIAGNOSTIC_TEST|nCD64|neutrophil CD64
215130239|NCT03146611|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
215130240|NCT01854359|DRUG|Idebenone|
215130241|NCT02961608|DRUG|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
215130242|NCT00656929|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
215130243|NCT00656929|OTHER|Placebo|Placebo tablets
215130244|NCT05853341|DRUG|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
215130245|NCT05853341|DRUG|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
215130246|NCT02435004|DEVICE|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
215130247|NCT01128049|BEHAVIORAL|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
215130248|NCT01128049|PROCEDURE|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
215130249|NCT01128049|DRUG|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
214525025|NCT00788879|BEHAVIORAL|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
214694547|NCT04400409|OTHER|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
215130250|NCT05182723|PROCEDURE|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
215130251|NCT02783365|BEHAVIORAL|Photo-elicitation and online group support|See above information.
215130252|NCT04234620|DRUG|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
215130253|NCT00707785|DIETARY_SUPPLEMENT|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
215130254|NCT06042959|OTHER|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
214525026|NCT00788879|BEHAVIORAL|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
214525027|NCT06167915|BIOLOGICAL|30μg dose of LYB002V14|30μg dose of LYB002V14 vaccine IM, on day 0
214525028|NCT06167915|BIOLOGICAL|60μg dose of LYB002V14|60μg dose of LYB002V14 vaccine IM, on day 0
215130255|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
215130256|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
215130257|NCT03243136|OTHER|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
215130258|NCT02338726|OTHER|Gynecological examination|Comparison of questionnaires and gynecological examination
215130259|NCT00358930|DRUG|ARQ 501|
215130260|NCT03847844|BIOLOGICAL|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
215130261|NCT03847844|OTHER|Placebo|Normal saline
215130262|NCT03073421|OTHER|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
215130263|NCT01102036|OTHER|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
215130264|NCT01102036|OTHER|Yoghurt without probiotics|Yoghurt without probiotics
215130265|NCT00928902|DRUG|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
215130266|NCT00928902|BIOLOGICAL|melanoma vaccine|six melanoma vaccines given over a 6-week period
215130267|NCT04406766|DEVICE|Connected nutrition pump system|"For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution."
215130268|NCT01315171|DIETARY_SUPPLEMENT|Medium chain triglycerides|4 tablespoons/day for 2 weeks
215130269|NCT04070365|DEVICE|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
214525029|NCT06167915|BIOLOGICAL|placebo|placebo IM, on day 0
214525030|NCT02186496|DRUG|CKD-330 8/5mg|
214525031|NCT02186496|DRUG|Candesartan 8mg and Amlodipine 5mg|
214525032|NCT00168714|DRUG|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
214525033|NCT06516562|DRUG|Optimal treatment|Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
214525034|NCT04240418|OTHER|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
214525035|NCT01498445|DRUG|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
214525036|NCT01498445|DRUG|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
214525037|NCT01498445|DRUG|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
214525038|NCT04636463|PROCEDURE|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
214525039|NCT04196517|OTHER|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
214525040|NCT04196517|OTHER|WebMD|WebMD is a widely used educational platform for health information.
214525041|NCT02305667|DEVICE|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
215130270|NCT00855621|PROCEDURE|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
215130271|NCT00395746|DRUG|sulfonylurea|SU agent
215130272|NCT00395746|DRUG|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
215130273|NCT00395746|DRUG|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
214448918|NCT06495359|OTHER|immunization education program|The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
214448919|NCT00220740|DRUG|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
214448920|NCT00220740|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
214448921|NCT01433315|BEHAVIORAL|sleep restriction|restricted sleep
214448922|NCT03314324|DRUG|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
214448923|NCT03314324|DRUG|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
214448924|NCT06309264|DEVICE|Phonak Lumina P90|FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
214448925|NCT06041139|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
214448926|NCT06041139|DIAGNOSTIC_TEST|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
215130274|NCT02982564|BEHAVIORAL|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
214448927|NCT06041139|DIAGNOSTIC_TEST|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
214448928|NCT06041139|OTHER|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
214525042|NCT02305667|DEVICE|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
214525043|NCT02305667|DEVICE|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
214694548|NCT04400409|OTHER|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
215130275|NCT02982564|BEHAVIORAL|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
215130276|NCT05279859|DRUG|ERAS-007|Administered orally
215130277|NCT05279859|DRUG|ERAS-601|Administered orally
215130278|NCT05279859|DRUG|Gilteritinib|Administered orally
215130279|NCT02804334|PROCEDURE|Psychiatric Questionnaires|
215130280|NCT02804334|PROCEDURE|Blood draw|
215130281|NCT00871910|DRUG|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
215130282|NCT00871910|DRUG|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
215130283|NCT00871910|DRUG|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
215130284|NCT00871910|DRUG|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
215130285|NCT00871910|DRUG|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
215130286|NCT00871910|DRUG|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
215130287|NCT00871910|DRUG|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
215130288|NCT06524102|DEVICE|Magnetic Activated Cell Sorting|"The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use."
215130289|NCT04903561|DEVICE|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
215130290|NCT02747186|DRUG|Lidocaine|Intraoral maxillary field block
215130291|NCT00582361|PROCEDURE|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
215130292|NCT00582361|DEVICE|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
215130293|NCT02365155|OTHER|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
215130294|NCT02365155|OTHER|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
215130295|NCT02365155|OTHER|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
215130296|NCT02365155|OTHER|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
215130297|NCT02365155|OTHER|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
215130298|NCT02365155|OTHER|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
215130299|NCT00016328|DRUG|temsirolimus|Given IV
215130300|NCT00016328|OTHER|laboratory biomarker analysis|Correlative studies
215130301|NCT00016328|OTHER|pharmacological study|Correlative studies
215130302|NCT03137992|DRUG|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
215130303|NCT03137992|DRUG|Test Product (tiotropium bromide inhalation powder)|Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
215130304|NCT03137992|DRUG|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
215130305|NCT06025006|OTHER|alternative to incarceration|place of respite with housing plus intensive follow-up
215130306|NCT02370420|BIOLOGICAL|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
215130307|NCT02370420|BEHAVIORAL|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
215130308|NCT03077542|PROCEDURE|haploidentical stem cell transplant|haploidentical stem cell transplant
214448929|NCT06501989|DRUG|Biweekly 5-FLUOROURACIL (5-FU)|5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
214448930|NCT06501989|DRUG|Biweekly Modified FOLFOX6|Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
214448931|NCT06501989|DRUG|Biweekly FOLFIRI|"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."
214448932|NCT06501989|DRUG|mFOLFOXIRI|Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
214448933|NCT05052021|OTHER|Public or Private Sector Patients|No intervention will be done. Two groups of patients will be recruited: patients receiving surgery in the Private Healthcare Sector, and patients receiving surgery in the Public Healthcare Sector
214448934|NCT05472792|RADIATION|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
214525044|NCT02305667|DEVICE|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
214525045|NCT00113009|DRUG|VLTS-934|
214525046|NCT03199456|DEVICE|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
214525047|NCT03199456|DEVICE|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
214525048|NCT04441073|DRUG|Lignocaine|preoperative nebulization of lignocaine
214525049|NCT04441073|DRUG|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
214525050|NCT00083473|DRUG|Pivanex|
214525051|NCT00605384|DRUG|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
214525052|NCT00605384|DRUG|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
214525053|NCT01526850|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
214525054|NCT01526850|DRUG|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
215130309|NCT03077542|DRUG|Sirolimus|conditioning regimen
215130310|NCT03077542|DRUG|Alemtuzumab|conditioning regimen
215130311|NCT03077542|DRUG|Pentostatin|conditioning regimen
214525055|NCT03599440|OTHER|Pressure line extensions|"Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line"
214525056|NCT01876719|DRUG|AR08|
214525057|NCT01876719|DRUG|Placebo|
215130312|NCT03077542|DRUG|Cyclophosphamide|conditioning regimen
215130313|NCT03077542|DRUG|Hydroxyurea|conditioning regimen
215130314|NCT03077542|DRUG|Filgrastim|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
215130315|NCT01333293|DRUG|injections|subcutaneous injections
215130316|NCT00236353|DRUG|risperidone|
214525058|NCT06376344|OTHER|myofascial release with tennis ball|Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
214525059|NCT05414435|BEHAVIORAL|Reading of informed consent form|Patients that adequately read informed consent forms
214525060|NCT00730925|DRUG|BIBW2992|tablet BIBW high dose
214525061|NCT00730925|DRUG|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
214525062|NCT02261519|DRUG|NaBen®|500 mg twice daily (1000 mg total)
214525063|NCT02261519|OTHER|Placebo|0 mg twice daily (0 mg total)
214525064|NCT04479137|DIAGNOSTIC_TEST|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
214525065|NCT02668796|DRUG|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
214525066|NCT02668796|DRUG|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
214525067|NCT02668796|DRUG|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
214525068|NCT02366702|DEVICE|Lower Limb Powered Knee-Ankle Prosthesis|
214525069|NCT00561678|DRUG|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
214525070|NCT00561678|DRUG|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
214525071|NCT04051190|DIETARY_SUPPLEMENT|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
215130317|NCT05983419|PROCEDURE|ESD|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
215130318|NCT00286585|DRUG|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
215130319|NCT00286585|DRUG|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
215130320|NCT01300728|DRUG|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
215130321|NCT01300728|OTHER|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
215130322|NCT05161923|PROCEDURE|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
215130323|NCT02392806|DEVICE|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
215130324|NCT02392806|DEVICE|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B\&B Bubbler at time of extubation
215130325|NCT03798613|DEVICE|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
215130326|NCT03798613|DEVICE|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
215130327|NCT00301808|DRUG|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
215130328|NCT00301808|DRUG|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
215130329|NCT00301808|DRUG|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
215130330|NCT00301808|RADIATION|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
215130331|NCT06102096|BEHAVIORAL|Culturally Adapted iCBT|A culturally adapted iCBT targeting mild to moderate mental health problems among Arabic-speaking refugee and migrant youth.
215130332|NCT04494074|OTHER|External Cooling|External Cooling
215130333|NCT02620839|DRUG|Alpelisib|Given PO
215130334|NCT02620839|DRUG|Cisplatin|Given IV
215130335|NCT05971550|OTHER|Absence of antibiotic treatment|Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
215130336|NCT05971550|DRUG|Ceftriaxone|Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
214448935|NCT05472792|DRUG|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
214448936|NCT04659811|DRUG|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
214448937|NCT04659811|PROCEDURE|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
214448938|NCT05517278|OTHER|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
214448939|NCT05517278|OTHER|Standard of Care|The control group will receive standard of care.
214448940|NCT05609812|DRUG|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
214448941|NCT05609812|DRUG|Placebo|placebo
214448942|NCT03423758|OTHER|Blood sample|Blood sample
214448943|NCT06144905|OTHER|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
214448944|NCT04314895|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
214448945|NCT06627530|DRUG|Darolutamide Oral Tablet|darolutamide 600 mg PO BID for 24 weeks
214448946|NCT06627530|DRUG|leuprorelin|leuprorelin depot 22.5 mg SC every 12 weeks
214694549|NCT04131517|DRUG|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
215130337|NCT03212898|OTHER|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
214448947|NCT03941860|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214448948|NCT03941860|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
214448949|NCT03941860|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214694550|NCT04131517|DRUG|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
214694551|NCT02576457|BIOLOGICAL|BMS-936559|
214694552|NCT02576457|OTHER|Placebo|
215130338|NCT03332459|DRUG|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
215130339|NCT03332459|DRUG|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
215130340|NCT02186275|DRUG|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"* Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
215130341|NCT02186275|DRUG|Vitamin D3 800 UI/day then 800 UI/day|"* Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
215130342|NCT03444610|BIOLOGICAL|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
215130343|NCT05924880|DRUG|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
215130344|NCT00194805|BEHAVIORAL|Telehealth for Diabetes Self Management|
215130345|NCT00194805|OTHER|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
215130346|NCT05893862|DRUG|MK-8189|Oral Tablet
215130347|NCT05893862|DRUG|Moxifloxacin|Oral Tablet
215130348|NCT05893862|DRUG|Placebo|Oral Tablet
215130349|NCT05915299|DEVICE|OCS Heart|"The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
215130350|NCT02429830|DEVICE|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
215130351|NCT04306263|DIETARY_SUPPLEMENT|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
215130352|NCT04306263|DIETARY_SUPPLEMENT|Standard formula|Infants receiving a standard infant formula.
215130353|NCT04306263|DIETARY_SUPPLEMENT|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
215130354|NCT04875052|DEVICE|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
214448950|NCT03941860|PROCEDURE|Computed Tomography|Undergo CT scan
214448951|NCT03941860|DRUG|Ixazomib Citrate|Given PO
214448952|NCT03941860|DRUG|Lenalidomide|Given PO
214448953|NCT03941860|OTHER|Placebo Administration|Given PO
214448954|NCT03941860|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214448955|NCT03941860|OTHER|Quality-of-Life Assessment|Ancillary studies
214448956|NCT03941860|OTHER|Questionnaire Administration|Ancillary studies
214448957|NCT05876546|DEVICE|Liquid bandage|The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.
214448958|NCT05876546|DEVICE|Saline Solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
214448959|NCT06532227|OTHER|No intervention|No intervention excepted data collection
214448960|NCT04789486|DRUG|AGuIX|Injected gadolinium-based nanoparticles
215130355|NCT04875052|DEVICE|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
215130356|NCT04875052|OTHER|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
214448961|NCT04789486|RADIATION|Radiotherapy|Stereotactic magnetic resonance-guided adaptive radiation therapy
214448962|NCT05242432|BIOLOGICAL|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
214448963|NCT05242432|OTHER|Placebo|Matching Placebo will be administered as an IM injection
214448964|NCT04166565|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
214448965|NCT04166565|DRUG|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
214448966|NCT04166565|DRUG|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
215130357|NCT00379015|BIOLOGICAL|trastuzumab|
215130358|NCT00379015|DRUG|cyclophosphamide|
215130359|NCT00379015|DRUG|docetaxel|
215130360|NCT00379015|DRUG|epirubicin hydrochloride|
215130361|NCT00379015|PROCEDURE|conventional surgery|
215130362|NCT00379015|PROCEDURE|neoadjuvant therapy|
215130363|NCT00286858|DEVICE|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
215130364|NCT02772601|DRUG|Caffeine|
215130365|NCT02772601|DRUG|Warfarin|
215130366|NCT02772601|DRUG|Omeprazole|
215130367|NCT02772601|DRUG|Metoprolol|
215130368|NCT02772601|DRUG|Midazolam|
215130369|NCT02772601|DRUG|Risankizumab|
215130370|NCT03306914|OTHER|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
215130371|NCT03306914|OTHER|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
215130372|NCT03306914|DRUG|Albumin 5%|Infusion of Albumin 5% intra-operatively
215130373|NCT03306914|DRUG|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
215130374|NCT04187118|OTHER|Quality of life|Quality of life one year post chemo-therapy
215130375|NCT01733420|DRUG|Biodentine pulpotomy|
215130376|NCT01733420|DRUG|White MTA pulpotomy|
215130377|NCT01733420|DRUG|Tempophore pulpotomy|
215130378|NCT04864522|DRUG|SLAMF7 FPBMC|Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
215130379|NCT02254811|BIOLOGICAL|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
215130380|NCT02649413|DRUG|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
215130381|NCT00101231|DRUG|alvocidib|Given IV
215130382|NCT02607059|OTHER|Registry|
215130383|NCT05246917|PROCEDURE|Handsewn anastomosis|To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
215130384|NCT01456637|BEHAVIORAL|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
215130385|NCT03363737|BEHAVIORAL|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
215130386|NCT05036096|DEVICE|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
215130387|NCT05036096|DEVICE|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
215130388|NCT01319708|PROCEDURE|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
215130389|NCT01319708|PROCEDURE|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
215130390|NCT01329315|BEHAVIORAL|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
215130391|NCT01329315|BEHAVIORAL|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
215130392|NCT06223334|OTHER|No intervention|observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
215130393|NCT00002327|DRUG|Cidofovir|
214448967|NCT04166565|DRUG|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
214448968|NCT06611397|DEVICE|Discogen Low pulsed ultrasound treatment|"The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.~The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.~The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge"
214448969|NCT06611397|DEVICE|Discogen Sham Treatment|The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week
214448970|NCT05328648|BEHAVIORAL|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
214448971|NCT05328648|BEHAVIORAL|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
214448972|NCT05190705|DRUG|Loncastuximab Tesirine|Administered by intravenous infusion
214448973|NCT05190705|DRUG|Dexamethasone|Taken orally or administered by intravenous infusion
215130394|NCT02031575|BEHAVIORAL|Interactive Treatment|Mobile phone text messaging service about reproductive health
215130395|NCT02031575|BEHAVIORAL|Basic Treatment|Mobile phone text messaging service about reproductive health
215130396|NCT02031575|OTHER|Control, comparator arm|
215130397|NCT01441999|DEVICE|Less rigid rod|Titanium rod with semi rigid end
214448974|NCT04192981|DRUG|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
214448975|NCT04192981|RADIATION|whole brain radiation therapy radiation|30Gy in 10 fractions
215130398|NCT01441999|DEVICE|Rigid Rod|Rigid Titanium rods
215130399|NCT04172584|BEHAVIORAL|correct use of the contraceptions|know the emergency contraception and how to use
215130400|NCT01908426|DRUG|Cabozantinib tablets|
215130401|NCT01908426|DRUG|Placebo tablets|
215130402|NCT00100035|PROCEDURE|Polarity therapy|
215130403|NCT00007592|DRUG|Chlorthalidone|
215130404|NCT00007592|DRUG|Furosemide|
215130405|NCT03346434|DRUG|Dupilumab|Solution for injection, subcutaneous (SC)
215130406|NCT03346434|DRUG|Matching placebo|Solution for injection, subcutaneous (SC)
215130407|NCT05717361|DRUG|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
215130408|NCT05717361|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
214448976|NCT06099457|BEHAVIORAL|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
214448977|NCT06932978|DEVICE|Provision of smart glasses for environmental control use|To the authors knowledge there has not been a clinical trial that includes the use of smart glasses with environmental controls. The smart glasses were used with environmental control systems that had a USB-C display output.
214525072|NCT04051190|PROCEDURE|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
215130409|NCT03991221|OTHER|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
215130410|NCT03991221|OTHER|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
215130411|NCT03991221|OTHER|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
215130412|NCT00297310|DRUG|tacrolimus|
215130413|NCT04697667|OTHER|Exercise|Supervised exercise program
215130414|NCT04697667|BIOLOGICAL|PRP|Intra-articular PRP injections to knee joint
215130415|NCT03011320|DRUG|EC1456|intravenous (IV) bolus dose
215130416|NCT03011320|DRUG|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
215130417|NCT03240601|DEVICE|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
215130418|NCT01782898|DRUG|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
214525073|NCT04051190|PROCEDURE|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
214525074|NCT03263104|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
214525075|NCT03263104|DIETARY_SUPPLEMENT|Maltodextrin|
214525076|NCT00718744|OTHER|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
215130419|NCT01782898|DRUG|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
215130420|NCT00034307|DRUG|sitaxsentan sodium|
215130421|NCT06077721|DRUG|Milrinone|giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
214525077|NCT00840918|DRUG|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
214525078|NCT00840918|OTHER|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
214525079|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
214525080|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
214525081|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
214525082|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
214525083|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
214525084|NCT01942538|DEVICE|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
215130422|NCT01414634|BIOLOGICAL|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
215130423|NCT00489996|DRUG|gemcitabine|
215130424|NCT00489996|DRUG|cisplatin|
215130425|NCT03046186|DIAGNOSTIC_TEST|Mixed meal test with double tracer technique|
215130426|NCT05515965|OTHER|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
215130427|NCT05515965|OTHER|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
214525085|NCT01942538|DEVICE|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
215130428|NCT02202421|BEHAVIORAL|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
215130429|NCT00836368|DIETARY_SUPPLEMENT|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
214525086|NCT04479176|PROCEDURE|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
215130430|NCT01052727|PROCEDURE|Laparoscopic Cholecystectomy|
215130431|NCT03470688|BIOLOGICAL|Originator|Originator anti-TNF agents
214525087|NCT02899676|OTHER|neuropsychological testing|
214525088|NCT02899676|OTHER|functional magnetic resonance imaging|
214525089|NCT02899676|OTHER|simple arithmetic operations|
214525090|NCT01072396|DRUG|Tiotropium|double blind randomized crossover
214694553|NCT05917626|BEHAVIORAL|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
214694554|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
214694555|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
214694556|NCT06168071|DEVICE|taVNS|Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
214694557|NCT05480787|DRUG|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
214694558|NCT05480787|DRUG|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
214694559|NCT05480787|DRUG|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
214694560|NCT02909673|BEHAVIORAL|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
214694561|NCT04149899|DRUG|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
214694562|NCT04149899|DRUG|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
215130432|NCT03470688|BIOLOGICAL|Biosimilar|Biosimilar anti-TNF agents
214525091|NCT01072396|DRUG|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
214525092|NCT03635047|BIOLOGICAL|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
214525093|NCT03635047|OTHER|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
215130433|NCT04436354|PROCEDURE|vaginoscopic office hysteroscopy|comparison of procedural time and pain scores of patients in different gynecologycal positions
215130434|NCT01183689|BEHAVIORAL|Small Behavior Changes|"The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level."
214525094|NCT01007851|DRUG|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
214525095|NCT01007851|DRUG|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
215130435|NCT01183689|BEHAVIORAL|Large Behavior Changes|"The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking."
215130436|NCT00546806|OTHER|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
215130437|NCT01419236|DRUG|Testosterone Solution 2%|Administered topically
215130438|NCT01419236|DRUG|Placebo Solution|Administered topically
215130439|NCT01140529|DRUG|Dexmedetomidine|Bolus and continuous infusion
215130440|NCT01140529|DRUG|Haloperidol|Bolus doses
215130441|NCT01140529|DRUG|Saline|Bolus and continuous infusion
215130442|NCT00001483|DRUG|buproprion (Wellbutrin)|
215130443|NCT00001483|DRUG|sertraline (Zoloft)|
215130444|NCT00001483|DRUG|venlafaxine (Effexor)|
215130445|NCT00896857|GENETIC|RNA analysis|
215130446|NCT00896857|GENETIC|polymerase chain reaction|
215130447|NCT00896857|GENETIC|protein expression analysis|
215130448|NCT00896857|GENETIC|reverse transcriptase-polymerase chain reaction|
215130449|NCT00896857|GENETIC|western blotting|
215130450|NCT00896857|OTHER|immunoenzyme technique|
215130451|NCT00896857|OTHER|immunohistochemistry staining method|
215130452|NCT00896857|OTHER|laboratory biomarker analysis|
215130453|NCT00896857|PROCEDURE|breast duct lavage|
215130454|NCT04326972|DEVICE|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
215130455|NCT06078241|DRUG|Intravenous lidocaine infusion|Intravenous lidocaine infusion
215130456|NCT06078241|OTHER|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
215130457|NCT06078241|OTHER|Intravenous infusion of normal saline|Intravenous infusion of normal saline
215130458|NCT06078241|OTHER|ESPB with normal saline|Unilateral ESPB with normal saline
215130459|NCT03998306|DIETARY_SUPPLEMENT|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
215130460|NCT03998306|OTHER|No intervention|No intervention
215130461|NCT06378229|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
215130462|NCT02649582|BIOLOGICAL|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle"
215130463|NCT04149912|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
215130464|NCT04901793|BEHAVIORAL|Virtual Reality Headset and handheld remote control.|Brand name: Oculus Quest
214694563|NCT04149899|DRUG|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
214694564|NCT04149899|DRUG|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
215130465|NCT00591682|DRUG|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
215130466|NCT01964651|DRUG|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
215130467|NCT01964651|DRUG|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
215130468|NCT01964651|DRUG|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
215130469|NCT01964651|DRUG|Placebo|Matching placebo orally administered once daily for 10 days.
215130470|NCT02849418|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
215130471|NCT02849418|DRUG|Placebo|Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
215130472|NCT04874025|DRUG|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
215130473|NCT01869608|PROCEDURE|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
215130474|NCT04621981|DRUG|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
215130475|NCT04621981|DRUG|Normal Saline|This group was treated with normal saline.
215130476|NCT03413007|DIAGNOSTIC_TEST|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
215130477|NCT00747903|DRUG|aminolevulinic acid hydrochloride|
215130478|NCT03245203|PROCEDURE|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4\~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4\~8 weeks.
215130479|NCT03245203|PROCEDURE|CRT|total dose of radiotherapy was 40\~50Gy, a subdose of 1.8\~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
215130480|NCT04292275|DEVICE|Biobeat Wrist Watch|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.
215130481|NCT04292275|OTHER|Standard of Care|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
215130482|NCT02476149|PROCEDURE|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
215130483|NCT01254253|DEVICE|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
215130484|NCT06390722|DRUG|Upadacitinib|Oral Tablet
215130485|NCT06390722|DRUG|Placebo for Upadacitinib|Oral Tablet
215130486|NCT01372709|DEVICE|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
215130487|NCT00762359|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
215130488|NCT00762359|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
215130489|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
214448978|NCT03461978|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
214448979|NCT02677051|DRUG|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
214448980|NCT02677051|DRUG|Placebo|
214448981|NCT05920304|DEVICE|virtual Hospital at Home (vHaH)|"Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app."
214525096|NCT05128227|BEHAVIORAL|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
215130490|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
215130491|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
215130492|NCT06077656|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
215130493|NCT01453049|DRUG|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
215130494|NCT01453049|DRUG|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
215130495|NCT04734639|BEHAVIORAL|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
214525097|NCT05128227|BEHAVIORAL|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
214525098|NCT02592044|PROCEDURE|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
215130496|NCT04734639|BEHAVIORAL|Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.|Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
215130497|NCT04734639|BEHAVIORAL|Def-EI. Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
215130498|NCT06301958|DRUG|Dextrose prolotherapy|A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
215130499|NCT02685319|PROCEDURE|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
215130500|NCT01366768|OTHER|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
215130501|NCT01366768|OTHER|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
215130502|NCT00882440|DRUG|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
215130503|NCT00882440|DRUG|Placebo|Placebo capsule to losartan
215130504|NCT00882440|DRUG|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
215130505|NCT05300503|BEHAVIORAL|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
215130506|NCT02773381|DRUG|semaglutide|Oral administration once-daily.
214448982|NCT04075539|OTHER|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
214448983|NCT04075539|OTHER|usual care|A prescription of 6 sessions of outpatient physiotherapy
214694565|NCT05154149|OTHER|Neck Disability Pain Index|Single time collection of the data
214694566|NCT00312884|DEVICE|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
215130507|NCT02773381|DRUG|placebo|Oral administration once-daily.
215130508|NCT00213616|PROCEDURE|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
215130509|NCT05366335|DRUG|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
215130510|NCT05366335|DRUG|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
215130511|NCT05366335|DRUG|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
215130512|NCT00828243|DRUG|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
215130513|NCT03287791|DRUG|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
215130514|NCT03287791|DRUG|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
215130515|NCT03287791|DRUG|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
215130516|NCT03287791|OTHER|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
215130517|NCT03287791|OTHER|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
215130518|NCT03287791|OTHER|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
215130519|NCT03287791|OTHER|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
215130520|NCT03010917|DRUG|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
215130521|NCT03010917|DRUG|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
214448984|NCT02669771|DRUG|enzalutamide|oral
214448985|NCT05359653|DRUG|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
214448986|NCT05359653|DRUG|Placebo|Matched sugar tablet
214448987|NCT03643900|DEVICE|pancreatic duct stenting|Place the pancreatic duct stent
214448988|NCT03643900|DRUG|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
214694567|NCT00882726|DRUG|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
215130522|NCT03441477|DEVICE|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
215130523|NCT03441477|DEVICE|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
215130524|NCT03441477|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
215130525|NCT05529108|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits everyday during intervention period.
215130526|NCT05529108|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
215130527|NCT05529108|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
215130528|NCT01512485|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
215130529|NCT02474446|DIETARY_SUPPLEMENT|Vitamin D|150,000 IU of Vitamin D3 Oral solution
215130530|NCT01048879|PROCEDURE|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
215130531|NCT01048879|PROCEDURE|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
215130532|NCT05482308|DRUG|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
215130533|NCT05482308|DRUG|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
215130534|NCT05011981|DEVICE|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
215130535|NCT05397327|OTHER|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
215130536|NCT05020821|PROCEDURE|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
215130537|NCT05020821|PROCEDURE|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
215130538|NCT05690139|PROCEDURE|Pre-operative LSG patients|Baseline
215130539|NCT05690139|PROCEDURE|Post-operative patients 1st month|1 month after surgery
215130540|NCT05690139|PROCEDURE|Post-operative patients 3rd month|3 months after surgery
215130541|NCT05690139|PROCEDURE|Post-operative patients 6th month|6 months after surgery
215130542|NCT03820596|DRUG|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
215130543|NCT03820596|DRUG|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
214448989|NCT06575816|BEHAVIORAL|Augmented Reality Video Intervention|This intervention involves a video intervention using augmented reality (AR) technology to reduce the pain, anxiety and fear children experience during the blood collection process. During the intervention, children watch AR videos to distract and relax them from the blood collection process. These videos are equipped with a variety of entertaining and engaging content and aim to reduce children's psychological stress.
214448990|NCT06374394|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
214448991|NCT06374394|BIOLOGICAL|COVID-19 mRNA vaccine|1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
215130544|NCT02760459|DRUG|Dexamethasone|
215130545|NCT02760459|DRUG|Normal saline solution|
215130546|NCT03156101|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
215130554|NCT00656357|DRUG|SYN117 Placebo|Placebo
215130555|NCT00656357|DRUG|SYN117 80 mg|SYN117 80 mg
215130556|NCT00656357|DRUG|SYN117 160 mg|SYN117 160 mg
215130557|NCT00656357|DRUG|Cocaine 10mg|IV Cocaine 10mg
214448992|NCT04655677|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
214448993|NCT05184036|DIAGNOSTIC_TEST|Low Vision|"* The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~* The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~* The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
214448994|NCT02990234|PROCEDURE|Capsular Repair|
214448995|NCT02990234|PROCEDURE|No Capsular Repair|
214448996|NCT03902132|OTHER|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
215130558|NCT00656357|DRUG|Cocaine 20mg|IV Cocaine 20mg
215130559|NCT00656357|DRUG|Cocaine 40mg|IV Cocaine 40mg
215130560|NCT00656357|DRUG|Saline|IV Cocaine Placebo
215130561|NCT06285435|DIAGNOSTIC_TEST|prothrombin fragment 1+2|Blood sample
215130562|NCT05034367|DIAGNOSTIC_TEST|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
215130563|NCT00520949|DRUG|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
215130564|NCT00520949|DRUG|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
215130565|NCT00520949|DRUG|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
215130566|NCT00520949|DRUG|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
215130567|NCT01760057|BEHAVIORAL|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
215130568|NCT01760057|BEHAVIORAL|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
215130569|NCT00817297|DEVICE|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
215130570|NCT03893396|DEVICE|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
215130571|NCT05851651|BEHAVIORAL|Antenatal milk expression and breastfeeding self-efficacy enhancement|A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
214448997|NCT03902132|OTHER|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
214448998|NCT00226889|DRUG|bosentan|
214448999|NCT05119543|OTHER|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
214449000|NCT04866810|BEHAVIORAL|Intervention Arm|High fiber, plant based diet + exercise prescription with ACT sessions
214449001|NCT04866810|BEHAVIORAL|Control|Standard diet and exercise recommendations
214449002|NCT03396588|DRUG|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
214449003|NCT03396588|DRUG|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
214449004|NCT06648850|DRUG|DA-001|Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution
214449005|NCT06648850|OTHER|Placebo|Placebo Topical Solution
214449006|NCT06648850|DRUG|Phenylephrine|Phenylephrine Topical Solution
214449007|NCT06648850|OTHER|Intact5|Cosmetic formulation containing bitter orange extract
214449008|NCT02675959|DRUG|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
214449009|NCT00812461|DRUG|Placebo|as-needed use, tablets, orally, 6 months
214449010|NCT00812461|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
214694568|NCT00882726|DRUG|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
215130572|NCT02250326|DRUG|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
215130573|NCT02250326|DRUG|CC-486|Oral CC-486
214694569|NCT00882726|DRUG|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
214694570|NCT00882726|DRUG|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
214449011|NCT06810427|DEVICE|CervImage device|"CervImage™, developed by Pensievision, Inc., is an accessible, simple, cost-effective, early detection imaging technology for preventing cervical cancer deaths caused by a lack of screening.~The novel device is a simple-to-operate, point-of-care, all-focus, 3D-imaging device, with clinical relevance to early-stage detection and prevention of cervical cancers. CervImage's proprietary 3D-rendering software, incorporating strategies previously used for high resolution imaging with NASA telescopes, can quantify tissue color, volume and shape. Virtual navigation tools and all-focus imaging enable straightforward use by minimally trained personnel; expert personnel can also benefit from shorter setup times.~The research procedure and evaluation will be incorporated into the scheduled annual pap smear exam or colposcopic gynecologic exam that involves using a vaginal speculum."
214694571|NCT00279968|DEVICE|ICD|
214694572|NCT01935687|DEVICE|Using of instrumented wheel|Using of instrumented wheel
214694573|NCT01935687|DEVICE|Using of ergometer roller|Using of ergometer roller
214694574|NCT05337527|DIETARY_SUPPLEMENT|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
214694575|NCT04115046|DEVICE|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
214694576|NCT04115046|DEVICE|FibroScan|manufactured by Echosens
215130574|NCT02250326|DRUG|Duravalumab|
215130575|NCT04156061|OTHER|Delivery of CT scan results|Method of results delivery - verbal or visual.
215130576|NCT05195164|OTHER|No intervention|There was no intervention
215130577|NCT05150028|BEHAVIORAL|Patient participation|Questionnaire
215130578|NCT05150028|OTHER|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
215130579|NCT05596136|DIAGNOSTIC_TEST|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
215130580|NCT01109264|DRUG|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
214449012|NCT00495885|DRUG|volinanserin (M100907)|oral, one tablet taken around bedtime
214449013|NCT00495885|DRUG|Placebo|oral, one tablet taken around bedtime
214449014|NCT04408872|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
214449015|NCT04408872|DIAGNOSTIC_TEST|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
214449016|NCT03448510|DEVICE|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
214449017|NCT03448510|DRUG|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
214449018|NCT06975670|OTHER|multimedia consent tool|The multimedia consent tool is new and developed for this particular study
214449019|NCT06978907|DEVICE|Monnalisa Touch® Laser Therapy|Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.
214449020|NCT06978907|COMBINATION_PRODUCT|Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)|Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.
214449021|NCT06655402|BEHAVIORAL|CARE-CITE|"CARE-CITE is a post-stroke family education program, to support care partners (CPs) in aiding stroke survivors (SS) during rehabilitation. Utilizing autonomy-supportive strategies, CARE-CITE emphasizes empathy, choice, and problem-solving while minimizing controlling language.~The program features a user-friendly web-based platform with interactive videos that guide CPs in providing support for SS. Over four weeks, CPs engage in two virtual home visits and two phone check-ins. During the initial visit, CPs review online modules, set collaborative goals, and co-create a home exercise plan targeting upper extremity (UE) activities. The second and third weeks involve structured phone calls to discuss autonomy-supportive strategies and address challenges.~The final visit reinforces strategies, assesses SS progress, and adjusts rehabilitation goals. Each module is designed to foster motivation and effective practice in daily activities."
214449022|NCT06655402|BEHAVIORAL|Attention Control Group|"Over a similar 4-week period, the SS and CP will receive the same number of structured virtual weekly visits as the CARE-CITE group without the review of CARE-CITE modules.~The CP will receive a brochure with general caregiving information and website resources. At week 1, a separate control group intervention therapist will deliver a 2-hour virtual home visit to evaluate SS UE function and assess safety concerns. Based on SS impairments, a home exercise program will be prescribed for flexibility, strength, and coordination (6-8 exercises, 2 sets of 10 reps). SS will be encouraged to practice daily (targeting 30 min/day). Weeks 2 and 3: CP Phone check-ins \[15-minute\]. The intervention therapist will review safety, assess adverse events, and CP's use of web resources. Week 4 Virtual Home visit (2 hours). Review SS's progress with the UE activity home exercise program, discuss safety concerns, and progress UE exercises as appropriate."
214449023|NCT06655402|OTHER|Actigraph GT3X+|Accelerometry data will be collected using Actigraph GT3X+ wearable sensors, approved by the FDA. The device does not collect or store individually identifiable health information (IIHI), private health information (PHI), or sensitive data. It is not intended for diagnosing, treating, or preventing diseases. These small, wrist-worn monitors document physical movement for physiological monitoring, including tracking movement during sleep. They can analyze circadian rhythms and assess activity in situations where quantifiable analysis of physical motion is needed.
214694577|NCT04115046|DEVICE|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
215130581|NCT01109264|DRUG|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
215130582|NCT02292108|BEHAVIORAL|dietetic counselling|
215130583|NCT02292108|BEHAVIORAL|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
215130584|NCT06593483|BEHAVIORAL|Motivational Interview with Self-Talk Video|Participants will engage in an interview based in motivational interviewing techniques and then record a self talk video discussing their goals and reasons for reducing their drinking.
215130585|NCT06593483|BEHAVIORAL|Motivational Interviewing|Participants will engage in an interview based in motivational interviewing
215130586|NCT05691894|DRUG|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
215130587|NCT05691894|DRUG|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
214449024|NCT06986889|PROCEDURE|Conventional radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized conventional radial access for cardiac catheterization.
214449025|NCT06986889|PROCEDURE|Distal radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized distal radial access for cardiac catheterization.
214449026|NCT06987396|DIETARY_SUPPLEMENT|1000 mg Betaglucans (daily)|Patients in the experimental group receive betaglucans supplement in capsule form, administered orally
214449027|NCT06988046|DEVICE|Cover spine orthosis (CSO)|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
214449028|NCT06988046|DEVICE|Semi-rigid thoracolumbar orthosis|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
214449029|NCT06987084|COMBINATION_PRODUCT|Bryophyllum pinnatum tea|24 g of B. pinnatum leaves boiled in 250 mL of water for 61 minutes sweetened with 1/2 teaspoon of sugar
214449030|NCT06987084|COMBINATION_PRODUCT|Placebo tea|250 mL of water boiled with 3 g of wheat-bran for 5 minutes sweetened with 1/2 teaspoon of sugar
214449031|NCT06986902|PROCEDURE|Laparoscopic Nissen Fundoplication|a 360° total wrap of the gastric fundus around the esophagus.
214449032|NCT06986902|PROCEDURE|Laparoscopic Toupet fundoplication|a 270° posterior partial wrap of the gastric fundus around the esophagus.
214449033|NCT06987123|DRUG|Toripalimab|Toripalimab 240 mg, administered on the first day, Q3W × 17 cycles
214449034|NCT06987123|DRUG|Capecitabine|Capecitabine 650 mg/m2 twice a day, oral administration, d1-21, Q3W × 17 cycles
214449035|NCT06987123|PROCEDURE|salvage surgery|"The specific steps of high-frequency electrosurgical knife treatment for localized recurrent nasopharyngeal carcinoma are as follows:~1. It must be performed under general anesthesia, with the complete resection of the nasopharyngeal tumor and its sufficient safe boundary through both nasal cavities under the guidance of nasal endoscopy. When marking the surgical margin, the anterior margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper margin can reach about 0.5-1cm to the upper margin of the posterior nostril. The lateral and lower margins are designed individually based on the size and location of the tumor. The basic principle is to ensure a safe margin of 0.5-1.0cm, and then use low-temperature plasma ablation. Ablate the tumor tissue and the normal tissue at the resection margin layer by layer from the upper resection margin to the lower resection margin until no obvious tumor residue was observed with the naked eye.~2. Rinse the surgical c"
214449036|NCT06987266|OTHER|no intervention|no ntervention
214449037|NCT06855186|BEHAVIORAL|Symptom-Targeted Approach to Rehabilitation for Concussion|This study is looking at a shortened version of a therapist-direct cognitive rehabilitation intervention, known as STAR-C. STAR-C is focused on strategy use, and for strategy use to become a habit the person must have the opportunity for high-dose spaced practice. Thus, in STAR-C each session includes opportunities for repeated practice and participants schedule practice times between sessions. Sometimes a new strategy requires learning new facts, in which case the clinician chooses ingredients such as self-quizzing or comparing and contrasting outcomes, which are effective for learning new facts and concepts.
214449038|NCT06676748|DRUG|Benzydamine Hydrochloride|The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
214449039|NCT06677450|OTHER|Pain neuoroscience education|Pain neurosicence education will be applied 1 day / 6 weeks at the beginning of one of the weekly exercise sessions in addition to the exercise program. The educations will include the definition and general characteristics of pain, pain physiology, peripheral neuropathic pain, the role of the brain in pain perception, tissue healing, peripheral and central sensitization, the effects of emotional, psychological and social factors on the pain process and pain coping strategies.
214449040|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
214449041|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
214449042|NCT05297864|DRUG|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
214449043|NCT04634019|BEHAVIORAL|Financially incentivized knowledge assessments|We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
214525099|NCT02592044|PROCEDURE|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
215130588|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
215130589|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Audio-track.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
215130590|NCT05478941|BEHAVIORAL|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
215130591|NCT04758702|BIOLOGICAL|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
215130592|NCT04758702|BIOLOGICAL|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
214449044|NCT06718244|BIOLOGICAL|single dose of Inaticabtagene autoleucel|"Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.~If the quantity of CAR-T cells of the patient is sufficient, after the patient receives the first CAR-T transfusion 5\~6 months，they will receive a second CAR-T cell transfusion. The aim of the second transfusion is to prolong the duration of CAR-T in the patient's body and prolong the patient's DOR. The dose and procedures of the second transfusion are the same as those for the first transfusion. After the second infusion, the patient will receive evaluation based on the day of the second transfusion as Day0."
214449045|NCT06725615|OTHER|Regular Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
214449046|NCT06725615|OTHER|High Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
215130593|NCT04758702|DEVICE|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
215130594|NCT05835765|DEVICE|Dynamic Elastometric Body in Preterm Newborns|The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
215130595|NCT04388592|OTHER|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
215130596|NCT00268918|DRUG|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
215130597|NCT00268918|DRUG|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
215130598|NCT03242486|DEVICE|toric intraocular lens|
215130599|NCT03635463|DEVICE|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
215130600|NCT03635463|DEVICE|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
215130601|NCT00205335|DEVICE|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
215130602|NCT00205335|DEVICE|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
215130603|NCT05363553|DIETARY_SUPPLEMENT|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
215130604|NCT05363553|DIETARY_SUPPLEMENT|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
215130605|NCT02867410|OTHER|No intervention|
215130606|NCT00416624|DRUG|darbepoetin alfa|
215130607|NCT00416624|DRUG|epoetin alfa|
215130608|NCT00416624|PROCEDURE|fatigue assessment and management|
215130609|NCT00416624|PROCEDURE|quality-of-life assessment|
215130610|NCT04463472|BIOLOGICAL|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
215130611|NCT04463472|BIOLOGICAL|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
214449047|NCT06725615|OTHER|Low Umami exposure|This group will receive the basic diet without added MSG.
214449048|NCT06725615|OTHER|one-week run-in period|During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
214449049|NCT06780709|BEHAVIORAL|Wellness Program and Behavioral Counseling|The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.
214525100|NCT02592044|PROCEDURE|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
214525101|NCT02467049|DEVICE|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
214525102|NCT02467049|DEVICE|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
215130612|NCT04098822|DEVICE|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
215130613|NCT03924622|DEVICE|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
215130614|NCT03924622|DEVICE|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
215130615|NCT01753622|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
215130616|NCT02870777|COMBINATION_PRODUCT|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
215130617|NCT04673214|DRUG|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
215130618|NCT04673214|DRUG|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
215130619|NCT03684863|DRUG|Capecitabine|observation
215130620|NCT01077635|DRUG|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
215130621|NCT06420882|OTHER|The experimental group.|In the experimental group, in addition to home exercises, patella mobilization, muscle strengthening exercises, range of motion exercises and home exercises will be performed 3 days a week for 3 sessions with a therapist.
215130622|NCT06420882|OTHER|The home exercise group|Participants in both groups will be included in a 3-week treatment programme.
215130623|NCT03743441|OTHER|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
215130624|NCT03743441|OTHER|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
215130625|NCT03743441|OTHER|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
215130626|NCT03743441|OTHER|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
215130627|NCT04426929|OTHER|Conventional exercise therapy|Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.
215130628|NCT04426929|OTHER|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
215130629|NCT04426929|OTHER|Video Based Exercise Group|Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
215130630|NCT00937352|DRUG|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
215130631|NCT02743585|DEVICE|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in \< 1 - 1.5 hours
215130632|NCT02743585|DEVICE|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
215130633|NCT06215534|DIETARY_SUPPLEMENT|first reference product series 1|dextrose (containing 25 grams of carbohydrates)
215130634|NCT06215534|DIETARY_SUPPLEMENT|second reference product seies 1|dextrose (containing 25 grams of carbohydrates)
215130635|NCT06215534|DIETARY_SUPPLEMENT|third reference product series 1|dextrose (containing 25 grams of carbohydrates)
215130636|NCT06215534|DIETARY_SUPPLEMENT|first concept product series 1|Standard tube feed (containing 25 grams of carbohydrates)
215130637|NCT06215534|DIETARY_SUPPLEMENT|second concept product series 1|Tube feed with added fibers (containing 25 grams of carbohydrates)
215130638|NCT06215534|DIETARY_SUPPLEMENT|third concept product series 1|Tube feed with extra energy (containing 25 grams of carbohydrates)
215130639|NCT06215534|DIETARY_SUPPLEMENT|4th concept product seris 1|Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)
215130640|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 1|Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates
215130641|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 1|Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates
215130642|NCT06215534|DIETARY_SUPPLEMENT|1st reference product series 2|dextrose (containing 25 grams of carbohydrates)
215130643|NCT06215534|DIETARY_SUPPLEMENT|2nd reference product series 2|dextrose (containing 25 grams of carbohydrates)
215130644|NCT06215534|DIETARY_SUPPLEMENT|3rd reference product series 2|dextrose (containing 25 grams of carbohydrates)
215130645|NCT06215534|DIETARY_SUPPLEMENT|1st concept product series 2|High energy plant based tube feed (containing 25 grams of carbohydrates)
215130646|NCT06215534|DIETARY_SUPPLEMENT|2nd concept product series 2|High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)
215130647|NCT06215534|DIETARY_SUPPLEMENT|3rd concept product series 2|High protein tube feed (containing 25 grams of carbohydrates)
215130648|NCT06215534|DIETARY_SUPPLEMENT|4th concept product series 2|High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)
215130649|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 2|Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)
215130650|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 2|Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)
215130651|NCT02855008|BEHAVIORAL|STEPS|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius. We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.
215130652|NCT02855008|BEHAVIORAL|Food for Life|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
215130653|NCT06472284|DEVICE|TetraGraph|etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
215130654|NCT00141453|DRUG|olmesartan medoxomil|Tablets 10, 20, or 40 mg
215130655|NCT00141453|DRUG|Placebo Tablets|Matching placebo tablets
215130656|NCT02568969|DEVICE|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
215130657|NCT05506540|DRUG|ENN0403 1mg|ENN0403 capsules for oral use
215130658|NCT05506540|DRUG|ENN0403 4mg|ENN0403 capsules for oral use
215130659|NCT05506540|DRUG|ENN0403 10mg|ENN0403 capsules for oral use
215130660|NCT05506540|DRUG|ENN0403 20mg|ENN0403 capsules for oral use
215130661|NCT05506540|DRUG|ENN0403 30mg|ENN0403 capsules for oral use
215130662|NCT05506540|DRUG|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
215130663|NCT05506540|DRUG|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
215130664|NCT05506540|DRUG|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
215130665|NCT05506540|DRUG|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
215130666|NCT05506540|DRUG|Placebo|Placebo capsules for oral use
214525103|NCT04557332|BEHAVIORAL|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
214525104|NCT00005908|DRUG|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
214525105|NCT00005908|DRUG|Anastrozole|1 mg orally daily for five years
214525106|NCT00005908|DRUG|cyclophosphamide|600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
214525107|NCT00005908|DRUG|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
214525108|NCT00005908|DRUG|Doxorubicin hydrochloride|60 mg/m\^2 will be administered as a slow intravenous push on day 1
214525109|NCT00005908|DRUG|Tamoxifen Citrate|20 mg/day orally for five years
214525110|NCT00005908|DRUG|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
214525111|NCT00005908|DRUG|Capecitabine - Dose A|capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
214525112|NCT04260282|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
214525113|NCT04260282|DIAGNOSTIC_TEST|Induced sputum microbiome|Microbiome in induced sputum
214525114|NCT01938209|OTHER|seated thoracic manipulation|seated general thoracic spine manipulation
215130667|NCT04773392|DRUG|Twice-daily Tacrolimus|Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.
214449050|NCT06885047|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
215130668|NCT04773392|DRUG|Once-daily envarsus XR|Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
215130669|NCT04773392|DRUG|Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)|Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.
215130670|NCT04773392|DRUG|Methylprednisolone, prednisone|Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.
215130671|NCT04773392|DRUG|Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)|Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
215130672|NCT04773392|DRUG|Azathioprine|Azathioprine (1-3 mg/kg) will be administered once a day.
215130673|NCT00005567|BEHAVIORAL|Parental knowledge and beliefs about infant sleep position|
215130674|NCT06425861|DRUG|THB335 single dose|Single dose as oral capsule
215130675|NCT06425861|DRUG|Single dose placebo|Single dose as oral capsule
214449051|NCT06885047|BEHAVIORAL|Treatment as usual|TAU consists of eclectic brief treatments, including some CBT or psychodynamic strategies that are applied with adolescents or in conjunction with the caregiver. In all cases, psychoeducation is provided to adolescents and their caregivers. Occasionally, they may be referred to some family therapy intervention. All treatments are brief therapy, provided by clinical psychologists and are intended to address the cognitive, emotional, and family factors that affect the adequate psychosocial functioning of the adolescent.
214449052|NCT06782321|BEHAVIORAL|modified Cognitive Behavioral Therapy (mCBT)|"The theoretical model underling Cognitive Behavioral Therapy (CBT) explains the interaction of thoughts, feelings, and behaviors during life situations. This model suggests that a person's thoughts/feeling/behaviors affect their functioning during life situations. This contrasts with a common belief that one's functioning during life situations is the only way to effect thoughts/feelings/behaviors. Applied to stroke, this model suggests that the stroke survivor can alter his/her functioning during life situations by altering his/her thoughts/feelings/behaviors. The purpose of CBT is to empower the person with the skills to alter his/her thoughts/feelings/behaviors in order to positively affect function in life situations.~The mCBT intervention includes 4 elements: psychoeducation, education about unhelpful thinking, behavioral activation therapy, education on sleep hygiene, and relaxation training."
214449053|NCT06782321|BEHAVIORAL|Occupational or Speech Therapy|"If the participant demonstrates aphasia of any severity level on the Revised Western Aphasia Battery (WAB-R) assessment given at the PRE session, the subject will receive ST, provided by a Speech Language Pathologists (SLP), stroke telerehabilitation. If there is no aphasia, the subject will receive OT stroke telerehabilitation.~The OT and ST stroke telerehabilitation sessions will utilize a similar metacognitive strategy training approach which is focused on enabling the stroke survivor to re-engage with meaningful life activities. In the Occupational Therapy literature this approach is called Cognitive Orientation to Occupational Performance (CO-OP) and in the Speech Language Pathology Literature this approach is called the Life Participation Approach to Aphasia (LPAA).~Telerehabilitation CO-OP and LPAA within the OT or ST session include three common elements: Shared decision-making for goal setting, guidance/coaching from the therapist, and self-evaluation."
214525115|NCT01938209|OTHER|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
215130676|NCT06425861|DRUG|THB335 fasted/fed|Single dose fasted and fed as oral capsule
215130677|NCT06425861|DRUG|Placebo fasted/fed|Single dose fasted and fed as oral capsule
215130678|NCT06425861|DRUG|THB335 multiple dose|Multiple ascending doses oral capsule
215130679|NCT06425861|DRUG|Multiple dose placebo|Multiple doses oral capsule
215130680|NCT03824223|DIAGNOSTIC_TEST|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
215130681|NCT00184834|BEHAVIORAL|quality of life|
215130682|NCT01393834|PROCEDURE|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
215130683|NCT01393834|PROCEDURE|Milking of the cord|Milking of the cord 4 times in 10 seconds
215130684|NCT04522895|DRUG|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
215130685|NCT06705647|OTHER|Chronic Obstructive Pulmonary Disease (COPD)|The base line acoustic and mel frequency ceprtum coefficients will be analysed statistically between COPD voices and healthy control groups to highlight the correlation between COPD and its effects on voice production.
215130686|NCT02724358|PROCEDURE|TACE|iodized oil (5ml) + Pirarubicin (20mg)
215130687|NCT02724358|DRUG|Rg3|20mg, BID, maintained though Month 12.
215130688|NCT02724358|OTHER|TACE + Rg3|
215130689|NCT02724358|PROCEDURE|protective therapy|standard liver protective therapy
215130690|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
215130691|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
215130692|NCT04375150|DRUG|Tyrosine kinase inhibitor (TKI)|TKIs
215130693|NCT04375150|DRUG|Immuno-oncology (IO)|IOs
215130694|NCT03793751|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
215130695|NCT00301795|BIOLOGICAL|oblimersen sodium|Given IV
215130696|NCT00301795|BIOLOGICAL|rituximab|Given IV
215130697|NCT00301795|OTHER|laboratory biomarker analysis|Correlative studies
215130698|NCT06073613|DIAGNOSTIC_TEST|oral health status|"* CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions"
215130699|NCT03779542|PROCEDURE|cataract surgery|phacoemulsification and intraocular lens implantation
215130700|NCT00925834|BEHAVIORAL|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
215130701|NCT02230735|DRUG|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
215130702|NCT02230735|DRUG|Normal Saline|(placebo for bupivacaine)
214449054|NCT03964350|DRUG|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
214449055|NCT03964350|OTHER|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
214449056|NCT06790758|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma-rich fibrin epidural injection by Racz catheter in post-dural puncture headache-guided optic nerve sheath diameter.
214449057|NCT06575686|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214449058|NCT06575686|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214449059|NCT06575686|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214449060|NCT06575686|BIOLOGICAL|Epcoritamab|Given SC
214449061|NCT06575686|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214449062|NCT06575686|DRUG|Tazemetostat|Given PO
214449063|NCT06832644|BEHAVIORAL|Lifestyle Management|All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I.
214449064|NCT06922799|DIAGNOSTIC_TEST|Saliva-Check Buffer test and periodontal charting|Saliva-Check buffer test will be used to perform evaluations on saliva pH, quantity and quality
214449065|NCT06928038|BEHAVIORAL|Positioned group|applied a side-lying position (20 minutes) on the occiput side and a prostrate position (15 minutes).
215130703|NCT06527170|PROCEDURE|Sleeve gastrectomy|Each patient undergoes bariatric surgery. Each patient is diagnosed before surgery for erectile dysfunction. Similar tests are done 1 year after
215130704|NCT01906333|OTHER|Exercise|
214449066|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
214449067|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
214449068|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
214525116|NCT00475787|PROCEDURE|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
214525117|NCT00475787|PROCEDURE|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
214525118|NCT04562571|OTHER|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
215130705|NCT01906333|OTHER|Glucose|
215130706|NCT01906333|OTHER|Fasted|
215130707|NCT04393415|COMBINATION_PRODUCT|stem cells|giving stem cells to patients with covid - 19
215130708|NCT04498078|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate (20 g per day)
215130709|NCT01233596|DEVICE|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
215130710|NCT04310111|PROCEDURE|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
215130711|NCT05252897|PROCEDURE|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
215130712|NCT05252897|PROCEDURE|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
215130713|NCT05161897|OTHER|Individualized Nutrition Therapy|Explained in arm/group description.
215130714|NCT06181526|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
215130715|NCT06181526|DEVICE|intravenous injection|According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping
214449069|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
214449070|NCT04661293|BIOLOGICAL|Autologous Muscle Derived Cells (AMDCs)|
214449071|NCT06840691|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
214449072|NCT06840691|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
214449073|NCT06793384|BEHAVIORAL|Virtual reality based Cognitive Stimulation Therapy (VR-CST)|In the VR-CST condition, participants wore a head-mounted display (HMD; model: DPVR P1 Pro Headset) for the themed activities in every session except sessions 1 and 14. In these two sessions, group physical activities (such as passing a ball from one participant to another) were conducted, so no HMDs were used. In other sessions, panoramic images (e.g., wet market) and videos (e.g., the neighborhood surroundings) prepared by the project team were mainly used, supplemented by 2-dimensional images /videos in which preparing panoramic images/videos was deemed impossible. Such a situation occurred in Session 5 (current affairs), in which news clips or captions from newspaper websites served as more appropriate content for discussion than self-created panoramic images/videos.
214449074|NCT06793384|BEHAVIORAL|Conventional Cognitive Stimulation Therapy (Conventional CST)|In the conventional CST group, 2-dimensional images/videos illustrating content identical to the VR-CST condition were displayed via tablet computers (see Table 2 for details) in which participants could manipulate the size of the image depicted or the pace of the videos with the help of the facilitator/therapy assistant.
214449075|NCT06792643|DRUG|Cangrelor|Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.
214449076|NCT06789081|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
214449077|NCT06792838|DEVICE|Confocal Laser Endomicroscopy|"1. The Endo microscope probe will be prepped in channel #1 and normal saline (30 ml) will be flushed into the duodenal mucosa through channel # 2 which will serve as a control. Inject 1-3ml fluorescein 10% intravenously.~2. The duodenal mucosa is assessed at a minimum of four sites (20 seconds each~3. The first potential allergen will be sprayed via catheter onto the mucosa.~4. After 2 minutes, three different areas of of duodenum will be assessed with the gastroflex probe for fluorescein leakage and cell shedding. If fluorescein leakage and cell shedding are visualized that is considered a positive test,no further allergy testing can be conducted. If the first allergen test is negative, irrigate and repeat steps for the next potential allergen for a maximum of three allergens per patient."
214525119|NCT05983328|DRUG|HUYPS-1 one tablet|After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
214525120|NCT05983328|DRUG|HUYPS-1 nine tablets|After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
214525121|NCT03253783|BEHAVIORAL|Pulse|
214525122|NCT01827202|OTHER|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
214525123|NCT01827202|DRUG|Aliskiren|
214525124|NCT01827202|DRUG|Candesartan|
214525125|NCT01651416|DRUG|Artemether-lumefantrine combination|
214694578|NCT06288776|DIAGNOSTIC_TEST|Herbal based mouthwash|Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
214525126|NCT01651416|DRUG|Dihydroartemisinin Piperaquine combination|
214525127|NCT01651416|DRUG|Amodiaquine plus sulphadoxine-pyrimethamine combination|
214694579|NCT04137276|DRUG|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
214525128|NCT04745819|BEHAVIORAL|1. The Child Behavior Checklist (CBCL), parent form|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
214525129|NCT01481701|DRUG|Oxaliplatin|85 mg/m² / 14days
214525130|NCT01481701|DRUG|oxaliplatin|oxaliplatin
214525131|NCT03748680|DRUG|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
214525132|NCT03748680|OTHER|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
214525133|NCT00072826|DRUG|Oxypurinol|
214525134|NCT00072826|DRUG|L-NMMA|
214694580|NCT04137276|DRUG|vitamin B1|thiamine 200 mg/12 hours for 3 days
214694581|NCT01818050|OTHER|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
214694582|NCT05094999|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
214694583|NCT05094999|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
215130716|NCT06181526|DEVICE|intrathecal injection|According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.
215130717|NCT05306626|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
215130718|NCT05510089|DRUG|Etoposide|D1\~D2: 75mg/m\^2
215130719|NCT05510089|DRUG|Cytarabine|D1\~D2: 300mg/m\^2, q12h
215130720|NCT05510089|DRUG|PEG-rhG-CSF|D6: 6mg
215130721|NCT04051359|OTHER|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)
215130722|NCT00866177|OTHER|Laboratory Biomarker Analysis|Correlative studies
215130723|NCT00866177|DRUG|Selumetinib|Given orally
215130724|NCT03798106|DRUG|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
215130725|NCT03549975|DRUG|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
215130726|NCT02745197|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
215130727|NCT02745197|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
214525135|NCT00072826|DRUG|Acetylcholine|
214525136|NCT02690025|DRUG|ZP1848|
214525137|NCT03779126|DEVICE|Electrical stimulation|1\) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
214525138|NCT00340184|DRUG|paclitaxel, carboplatin|
215130728|NCT05267080|DEVICE|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
215130729|NCT01778790|DEVICE|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
215130730|NCT01157702|BIOLOGICAL|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
215130731|NCT01323023|BEHAVIORAL|varies by project|
215130732|NCT03065816|DRUG|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
215130733|NCT03065816|DRUG|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
215130734|NCT06325059|OTHER|Study of renal progenitors|Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
215130735|NCT01308541|DRUG|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
215130736|NCT01308541|DRUG|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
215130737|NCT01308541|DRUG|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
215130738|NCT05025839|OTHER|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
215130739|NCT03585660|PROCEDURE|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
214525139|NCT02884336|OTHER|No intervention|
214525140|NCT05113212|DEVICE|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
214525141|NCT05113212|DEVICE|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
214694584|NCT04474899|DRUG|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
215130740|NCT03585660|PROCEDURE|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
215130741|NCT03585660|DEVICE|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
215130742|NCT02253914|DRUG|BILR 355 BS, solution|
215130743|NCT02253914|DRUG|BILR 355 BS, tablet|
215130744|NCT02253914|DRUG|Ritonavir|
215130745|NCT02253914|DRUG|Placebo|
215130746|NCT00204152|BEHAVIORAL|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
215130747|NCT00116103|DRUG|Tacrolimus Inhalation Aerosol|
215130748|NCT05836441|RADIATION|Exposure to white patches|Exposure to white patches
215130749|NCT05836441|RADIATION|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
215130750|NCT02039115|DRUG|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
215130751|NCT02039115|DRUG|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
215130752|NCT04084158|DRUG|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
215130753|NCT04084158|DRUG|Paclitaxel, Albumin-Bound|Paclitaxel
215130754|NCT04084158|RADIATION|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
215130755|NCT04084158|DRUG|Platinum-Based Drug|carboplatin
215130756|NCT01553656|DRUG|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
215130757|NCT01553656|DRUG|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
215130758|NCT05635461|DRUG|CVN424|150 mg of either tablet or suspension formulation
215130759|NCT04794855|DIAGNOSTIC_TEST|laboratory tests|routine laboratory tests and biomarkers tests
215130760|NCT05322798|PROCEDURE|High-frequency SCS|Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
215130761|NCT05322798|PROCEDURE|Low-frequency SCS|Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
215130762|NCT03860649|OTHER|Nordic Walking|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
215130763|NCT03860649|OTHER|Jogging|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
215130764|NCT03860649|OTHER|Dance|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
215130765|NCT03860649|OTHER|Pilates Training|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
215130766|NCT04581278|DIAGNOSTIC_TEST|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
215130767|NCT03519074|DRUG|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
215130768|NCT06052475|DEVICE|Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
215130769|NCT06052475|DEVICE|Continued RV Pacing (Right Ventricular Pacing)|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
215130770|NCT03753334|COMBINATION_PRODUCT|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
215130771|NCT03753334|DIETARY_SUPPLEMENT|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
215130772|NCT04436991|DIAGNOSTIC_TEST|Blood sampling|"At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day)."
215130773|NCT04436991|DIAGNOSTIC_TEST|Sputum sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
215130774|NCT04436991|DIAGNOSTIC_TEST|Hemoculture|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
215130775|NCT04436991|DIAGNOSTIC_TEST|Urine sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
215130776|NCT05884554|DRUG|PF-07817883|Experimental
215130777|NCT05344950|BEHAVIORAL|Audio + Radio (AURA)|Participants will receive personalized self-care information based on their symptoms and signs of complications (e.g., fatigue) from interacting with our voice assistant device, connected to a system that integrating the patient-reported outcome and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home.
215130778|NCT04474470|DRUG|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
215130779|NCT04474470|DRUG|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
215130780|NCT04474470|DRUG|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
215130781|NCT05070936|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
215130782|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
214449078|NCT06797310|DRUG|Baricitinib|This study evaluates the use of baricitinib 4 mg once daily for 16 weeks in patients with acute alopecia areata (AA) experiencing active hair shedding. Unlike prior studies focusing on chronic AA with extensive hair loss (SALT ≥ 50), this intervention targets the acute phase, aiming to halt shedding within 4-6 weeks-faster than conventional treatments like corticosteroids. Patients meeting the primary endpoint (iSARS-AA ≤ 20 at week 16) will taper to 2 mg daily for an additional 16 weeks. Scheduled follow-ups at weeks 0, 4, 8, 12, 16, 24, 32, 36, 44, and 52 ensure comprehensive monitoring, distinguishing this study from others with shorter follow-ups or less frequent assessments.
214694585|NCT04474899|DRUG|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
215130783|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
215130784|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
215130785|NCT01853020|DRUG|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
215130786|NCT01853020|DRUG|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
215130787|NCT05953532|OTHER|A1Control|diabetes self-management and diabetes technology education software
215130788|NCT02498925|BEHAVIORAL|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
215130789|NCT06092749|OTHER|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
215130790|NCT06092749|OTHER|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
215130791|NCT03891706|DRUG|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
215130792|NCT03891706|DRUG|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
215130793|NCT05511259|OTHER|exercise|Square stepping exercise
215130794|NCT02592291|DEVICE|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
215130795|NCT05517135|OTHER|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
215130796|NCT05517135|OTHER|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
215130797|NCT05517135|OTHER|Arm 3|"IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)"
215130798|NCT05517135|OTHER|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
215130799|NCT05517135|OTHER|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
215130800|NCT05208476|PROCEDURE|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
215130801|NCT06114121|PROCEDURE|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
215130802|NCT06114121|DRUG|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
215130803|NCT06114121|DRUG|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
215130804|NCT06114121|DRUG|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
215130805|NCT05272683|DRUG|GLPG3667|On day 1 and day 8, participants will receive a single dose
215130806|NCT05272683|DRUG|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
215130807|NCT06288581|OTHER|Traditional toothbrush group|Children in this group will use a traditional brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a U shaped brush with a traditional toothpaste for another 30 days.
215130808|NCT06288581|OTHER|U shaped toothbrush group|Children in this group will use a U shaped brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a traditional brush with a traditional toothpaste for another 30 days.
215130809|NCT05120830|BIOLOGICAL|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
215130810|NCT05120830|OTHER|Normal Saline IV Administration|The administration of IV normal saline
215130811|NCT05083273|OTHER|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
215130812|NCT04218721|OTHER|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
214449080|NCT06788210|OTHER|Multiprofessional Geriatric Emergency Team applied front-door CGA to identify patients who require inpatient care and those who can safely be discharged.|"In comparison to the precedent studies, this project is characterised by some innovative aspects as regards to the design of intervention:~1. the participation of both a geriatrician and a nurse expert in transitional care, with the consultancy of a social worker when needed, in the management of the elderly patient within ED, adds to the project a greater operational capacity of the multidimensional assessment (CGA) of planning the best care setting for the patient.~2. The proposed CGA model is complete in the analysis of the different domains (social, clinical, functional, cognitive-affective) and achievable in this particular urgent setting.~3. The program examines, unlike other studies, much more variables that can help to define the effectiveness of the intervention.~4. The involvement in the network program of three main hospitals of the Emilia Romagna with a pool of elderly patients afferent to ED of about 20,000 elderly/year per hospital (2019 data prior of Sars Cov2 pandemic)"
214449081|NCT05548426|DRUG|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
214449082|NCT05548426|DRUG|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
214449083|NCT06840639|PROCEDURE|Dentoalveolar surgery|Surgery to extract teeth
214449084|NCT06795321|PROCEDURE|Spinal anesthesia|Patients who preferred spinal anesthesia were included in this group.
214449085|NCT06795321|PROCEDURE|General anesthesia|Patients who preferred spinal anesthesia were included in this group
214449086|NCT05328427|OTHER|Stopping|Discontinuation of nucleoside analogue
214449087|NCT06797752|DEVICE|OCTA Scan|Optical Coherence Tomography Angiography before and after receiving the stellate ganglion nerve block.
214449088|NCT06793332|DRUG|Ivonescimab Combined With TROP2 ADC|Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
214449089|NCT06839950|OTHER|Calm room|"The calm room combines the effects of music, light, and videos designed with natural atmospheres. Four themes are offered in the calm room: Comfort, Optimism, Freshness, and Lullaby. These themes feature nature videos, combining relaxing images with calm musical ambiance. The lighting can be adjusted by the user, who can choose from a varied color palette. The available lights have a low glare level, and the light intensity can also be adjusted by the user.~They can be used by patients any time they want and for as long as they want."
215130813|NCT04101968|DIAGNOSTIC_TEST|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
214449090|NCT06054529|PROCEDURE|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
214449091|NCT06054529|OTHER|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
214449092|NCT06789393|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.5 mcg/kg).
214449093|NCT06789393|DRUG|Bupivacaine|Penile block with bupivacaine 0.25% (0.2 ml/kg)
214449094|NCT06789887|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy (WET) is a 5-session, trauma-focused intervention in which individuals write about their traumatic experience following scripted instructions.
215130814|NCT04101968|DIAGNOSTIC_TEST|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
215130815|NCT06790420|DRUG|Rituximab Pfizer|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
215130816|NCT06790420|DRUG|Rituxan|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
215130817|NCT05749146|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
215130818|NCT06366737|DEVICE|KILBON Appliance|palatal TAD assissted lingual appliance for en-mass retraction
215130819|NCT06366737|DEVICE|CAT appliance|palatal TAD assissted clear aligner
215130820|NCT04371783|PROCEDURE|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
215130821|NCT04371783|PROCEDURE|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
215130822|NCT03760029|OTHER|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
215130823|NCT06445348|DEVICE|Cervical pedicle screw|cervical pedicle screw
215130824|NCT05973942|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
215130825|NCT05804838|OTHER|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
215130826|NCT05941793|DRUG|MBS-COV|MBS-COV for inhalation
215130827|NCT05941793|DRUG|Placebo|Placebo for inhalation
215130828|NCT03137654|OTHER|Affective Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
215130829|NCT03137654|OTHER|Neutral Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
215130830|NCT06384066|OTHER|GetWell Mobile Application|GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.
214449095|NCT06789887|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
214449096|NCT06796205|OTHER|Treated zones exposed with Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214449097|NCT06796205|OTHER|Untreated zone exposed with Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
214449098|NCT06791954|OTHER|Exercise|Clinical pilates program
214449099|NCT06163014|BEHAVIORAL|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~1. Symptom explanations and facts about frequent symptoms including brief animated explanations~2. Physical energy (sleep, diet and activity)~3. Working with resources and strain in everyday life~4. Values and choices (meaning and existential issues)~5. Thoughts~6. Feelings (emotion regulation)~7. Self-care (attention incl. mindfulness and audio exercises)~8. Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
214449100|NCT06839339|DRUG|AL-001|Administered via suprachoroidal space injection.
214449101|NCT06839339|DRUG|Aflibercept|Intravitreal injection
214449102|NCT06795360|OTHER|discontinuation of weight loss medication|Participants will be studied right before their injectable weight loss medication runs out, and 3 months later
214449103|NCT05831709|OTHER|Exercise program|The intervention consists of a supervised exercise program
214449104|NCT04534127|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214449105|NCT01803438|DEVICE|cryoballoon ablation system|
214449106|NCT01803438|DRUG|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
214449107|NCT02868268|OTHER|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
215130831|NCT06384066|OTHER|Standard of Care|Office Based Pathway
215130832|NCT04890652|BEHAVIORAL|Digital intervention|All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
214694586|NCT05148585|OTHER|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
215130833|NCT02969122|PROCEDURE|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
215130834|NCT02969122|PROCEDURE|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
215130835|NCT02969122|PROCEDURE|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
215130836|NCT02969122|OTHER|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
215130837|NCT02969122|OTHER|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
215130838|NCT06025916|DRUG|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
215130839|NCT04237467|OTHER|No intervention|There was no intervention.
215130840|NCT04806724|BEHAVIORAL|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
215130841|NCT04806724|BEHAVIORAL|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
215130842|NCT02542657|DRUG|Clarithromycin|Given PO
215130843|NCT02542657|DRUG|Dexamethasone|Given PO
215130844|NCT02542657|DRUG|Ixazomib Citrate|Given PO
215130845|NCT02542657|DRUG|Pomalidomide|Given PO
215130846|NCT05195710|DRUG|Yttrium-90 (Y-90) resin microspheres|Given by scan
215130847|NCT06510933|DEVICE|Heel cups in different BMI index and its correlation to physical activity in children|Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
215130848|NCT06797024|DRUG|JY231 Injection|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion. A total of 3 dose groups were established to conduct a 3+3 dose-escalation study. The doses were divided into two categories: non-lymphodepletion and lymphodepletion pretreatment. The three dose groups for lymphodepletion included: 2×10\^8 TU, 4×10\^8 TU, and 8×10\^8 TU. The three dose groups for non-lymphodepletion included: 2×10\^9 TU, 4×10\^9 TU, and 8×10\^9 TU. The decision to perform lymphodepletion was based on the lymphocyte count and function during the patient screening period.
215130849|NCT04108364|BEHAVIORAL|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
215130850|NCT05972278|DRUG|Obicetrapib|1 tablet daily
215130851|NCT00493493|PROCEDURE|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
215130852|NCT03474614|DRUG|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
215130853|NCT03474614|GENETIC|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
215130854|NCT01324817|DEVICE|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
215130855|NCT01324817|DEVICE|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
215130856|NCT02905097|PROCEDURE|Knee Replacement|Surgical replacement of arthritic knee with an implant
215130857|NCT00271635|DRUG|Placebo|Placebo 4 capsules b.i.d. during 1 year
215130858|NCT00271635|DRUG|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
215130859|NCT01207700|BEHAVIORAL|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
215130860|NCT04149834|PROCEDURE|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
215130861|NCT04149834|PROCEDURE|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
215130862|NCT03663829|OTHER|Non-Interventional|Non-Interventional
215130863|NCT03663829|OTHER|Non-Interventional|Non-Interventional
215130864|NCT06306833|OTHER|Surface Electromyography (sEMG) Biofeedback|Biofeedback sEMG therapy through the use of virtual aids like digital therapeutics would help reduce chronic low back pain in patients by overcoming their psychophysiological manifestations. All participants in the intervention group will receive sEMG biofeedback as an alternative therapy.
215130865|NCT03274284|COMBINATION_PRODUCT|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
215130866|NCT06072911|BEHAVIORAL|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
215130867|NCT06072911|BEHAVIORAL|General exercise|A general progressive resistance exercise program
215130868|NCT06072911|BEHAVIORAL|Physical Activity Counseling|Advice on increasing physical activity
215130869|NCT04891614|DEVICE|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
215130870|NCT01199354|PROCEDURE|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
215130871|NCT01029496|PROCEDURE|different time of umbilical cord clamping|"1. for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~   control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~2. for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
215130872|NCT00524485|DRUG|aminolevulinic acid|
215130873|NCT00524485|PROCEDURE|laser therapy|
215130874|NCT05320081|BIOLOGICAL|CD30 CAR-T|"Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10\^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition."
215130875|NCT05320081|DRUG|Camrelizumab|Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
214449108|NCT06832514|BIOLOGICAL|Serogroup B meningococal vaccine|The 4CMenB vaccine will be administered via two intramuscular (IM) injections in the non-dominant upper arm, with a one month interval.
214449109|NCT06489418|OTHER|Dew Restore Barrier Repair Cream|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical"
214449110|NCT04402489|DRUG|Placebo|Placebo
214449111|NCT04402489|DRUG|MT-7117 Low Dose|MT-7117 Low Dose
214449112|NCT04402489|DRUG|MT-7117 High Dose|MT-7117 High Dose
214449113|NCT05926102|GENETIC|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
214449114|NCT05926102|OTHER|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
214449115|NCT06840990|DEVICE|CXC-SP|Standard therapy plus sterile Isotonic ophthalmic solution based on CX-CMC and silk protein, istilled six time a day until complete healing.
214449116|NCT06840990|DEVICE|CTRL|Standard therapy plus sterile ophtalmic isotonic solution for six time a day until complete healing.
214449117|NCT05949060|BEHAVIORAL|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
214449118|NCT06838403|OTHER|Oro motor excercise to study arms and controoled arms|Each child in both groups will receive OME program for 30 minutes three times per week for 6 months.
214449119|NCT06840184|BEHAVIORAL|Cognitive Behavioral Therapy based Intervention|"Session 1: Introduction of CBT, Relationship between events, thoughts and behavior.~Session 2: Psychoeducation about the vicious circle of inactivity and depression, Ladder technique for task management.~Session 3: Problem solving techniques and discussion about them, Decision making techniques through Advantages/ Disadvantages chart.~Session 4: Identifying positive and negative emotions, Cognitive errors were explained.~Session 5: Identifying negative thoughts through Socratic questioning, Finding evidence for and against the thoughts, Challenging negative thought, Cracking firm irrational beliefs.~Session 6: Cognitive restructuring techniques, Finding alternative thoughts."
214449120|NCT06840184|OTHER|No intervention|No intervention was provided to the control group, except for a few members who requested for the therapy, that too after the post assessment.
214449121|NCT06796023|OTHER|Stretching and strengthening exercises for back muscles|Stretching and strengthening exercises for back muscles
214449122|NCT06796023|OTHER|Lumbar stabilization Exercises|Lumbar stabilization Exercises
214694587|NCT05148585|OTHER|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
214694588|NCT05524441|OTHER|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
214694589|NCT03535038|DIAGNOSTIC_TEST|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
214449123|NCT06796023|OTHER|Lumbar Manipulation|Lumbar Manipulation
214449124|NCT05048628|OTHER|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
214449125|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
214449126|NCT05902793|DEVICE|Investigational device: V.A.C. VERAFLO™ Dressing Kit|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
214449127|NCT05902793|DEVICE|Comparator device: Negative pressure wound drainage material|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
214449128|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
214449129|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
214449130|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
214449131|NCT06173804|OTHER|Adapted Look Ahead Lifestyle Intervention|Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
214449132|NCT06830317|PROCEDURE|Endoscopic Radiofrequency treatment|Treatment with RFA will carried out with focal RFA with a TTS catheter at 12 Joule/cm2 to all visible areas of GAVE under conscious sedation or propofol sedation by experienced team of endoscopists and anesthetists
214449133|NCT06830317|OTHER|QoL EQ5D questionaire|Quality of Life EQ5D (by EuroQol Group) before every RFA treatment and at Follow up visits (3, 6 and 12 months after the first procedure). QoL questionnaire EQ5D The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state
214449134|NCT06125587|DRUG|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
214449135|NCT06125587|DRUG|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
214449136|NCT06780956|OTHER|Conventional|conventional drilling protocol using full sequence
214449137|NCT06780956|OTHER|simplfied|3 burrs for implant placment
214449138|NCT05602506|DRUG|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
214449139|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
214449140|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
214449141|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
214449142|NCT03676582|DIAGNOSTIC_TEST|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
214449143|NCT06302361|PROCEDURE|Lymphovenous anastomosis (LVA)|Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
214694590|NCT03535038|DIAGNOSTIC_TEST|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
215130876|NCT00474123|DRUG|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
215130877|NCT00474123|DRUG|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
215130878|NCT04306471|DRUG|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
214449144|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
214449145|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
214449146|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
214449147|NCT06845943|DRUG|HCR-188|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
214449148|NCT06845943|DRUG|Placebo|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
214449149|NCT03775096|DRUG|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
214449150|NCT03158805|DRUG|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
214449151|NCT03158805|OTHER|Placebo|Placebo injection
214449152|NCT06225492|DRUG|DaxibotulinumtoxinA 15 units|Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band
214449153|NCT06225492|DRUG|DaxibotulinumtoxinA 20 units|Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band
214449154|NCT05418296|DEVICE|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
214525142|NCT06255899|BEHAVIORAL|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
214525143|NCT06255899|BEHAVIORAL|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
214525144|NCT01106586|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
214525145|NCT01106586|DRUG|ATV|Atazanavir 300 mg capsule administered orally once daily
214525146|NCT01106586|DRUG|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
214525147|NCT01106586|DRUG|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
214525148|NCT01106586|DRUG|Stribild Placebo|Placebo to match Stribild administered orally once daily
214525149|NCT01106586|DRUG|ATV Placebo|Placebo to match ATV administered orally once daily
214694591|NCT02233400|DRUG|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
214694592|NCT02961712|BIOLOGICAL|NK cells|single intravenous injection of NK cells (0.9\~1\*10\^9)
214449155|NCT04035824|DRUG|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
214449156|NCT04035824|DRUG|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
214525150|NCT01106586|DRUG|RTV Placebo|Placebo to match RTV administered orally once daily
214694593|NCT02961712|BIOLOGICAL|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
215130879|NCT04306471|OTHER|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
215130880|NCT00456053|DRUG|FG2216|
215130881|NCT00738998|BEHAVIORAL|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
215130882|NCT00738998|OTHER|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
215130883|NCT05475249|OTHER|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
214449157|NCT05568134|DIAGNOSTIC_TEST|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
214449158|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
214449159|NCT01567800|OTHER|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
214449160|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
214449161|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
215130884|NCT02767271|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
215130885|NCT06404814|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|(TENS) is a method of pain relief involving the use of a mild electrical current
214525151|NCT01106586|DRUG|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
215130886|NCT06404814|DIAGNOSTIC_TEST|Muscle Energy Technique|n Spencer's technique, there are seven steps as follows: shoulder extension along with elbow flexion, shoulder flexion with elbow extension, circumduction with compression, circumduction with distraction, shoulder abduction and internal rotation with elbow flexion, shoulder adduction and external rotation with elbow
215130887|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
214449162|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
214525152|NCT05312190|DRUG|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
214694594|NCT05012852|DEVICE|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
214525153|NCT05312190|DRUG|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
214525154|NCT01379521|DRUG|everolimus|
214525155|NCT01379521|DRUG|everolimus placebo|
214525156|NCT03894280|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
214694595|NCT06371014|DRUG|Ondansetron oral membrane|A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
214694596|NCT00003353|BIOLOGICAL|filgrastim|
214694597|NCT00003353|DRUG|melphalan|
214694598|NCT00003353|PROCEDURE|bone marrow ablation with stem cell support|
215130888|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
215130889|NCT02084485|DRUG|PH-797804|30 MG Single dose
215130890|NCT02084485|DRUG|Placebo|matching placebo
215130891|NCT03439306|DEVICE|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
215130892|NCT06013735|DRUG|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
215130893|NCT06013735|DRUG|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
215130894|NCT06013735|DRUG|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
215130895|NCT06013735|OTHER|Distilled water|placebo distilled water
215130896|NCT03028233|BEHAVIORAL|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
215130897|NCT03028233|BEHAVIORAL|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
215130898|NCT03584750|OTHER|Floating|Floating in specialized tank with full floatation and sensory deprivation.
215130899|NCT03584750|OTHER|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
215130900|NCT06512064|DIAGNOSTIC_TEST|AWARE|AWARE testing to estimate lung function and aid in disease diagnosis
215130901|NCT01841879|BEHAVIORAL|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
215130902|NCT01841879|BEHAVIORAL|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
215130903|NCT06184633|DRUG|Semaglutide 3.2 MG/ML|Intervention arm receives semaglutide in addition to combined lifestyle intervention
215130904|NCT06184633|DRUG|Placebo|Control arm receives placebo in addition to combined lifestyle intervention
215130905|NCT04189705|DRUG|MCT-SR|Rebamipide 150mg
215130906|NCT04189705|DRUG|Mucosta Tab.|Rebamipide 100mg
214449163|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
214449164|NCT05807841|PROCEDURE|percutaneous coronary intervention|IVUS-guided stent implantation
214449165|NCT02829814|DRUG|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
214449166|NCT02829814|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
214449167|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
214449168|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
214449169|NCT06445010|OTHER|Creating Musical Playlist|Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
214694599|NCT00003353|PROCEDURE|peripheral blood stem cell transplantation|
214449171|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
214449172|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
214525157|NCT03894280|DRUG|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
214525158|NCT03894280|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
214525159|NCT02502721|DRUG|DWC20151|
214525160|NCT02502721|DRUG|DWC20152|
214525161|NCT00938041|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
214449173|NCT01441687|OTHER|laboratory biomarker analysis|Correlative studies
214449174|NCT01441687|PROCEDURE|transrectal prostate biopsy|Undergo prostate biopsy
214449175|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
214449176|NCT03705104|BEHAVIORAL|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
214449177|NCT00616967|DRUG|carboplatin|Given IV
214449178|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214449179|NCT00616967|DRUG|vorinostat|Given orally
214449180|NCT00616967|OTHER|placebo|Given orally
214449181|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
214449182|NCT05171855|DRUG|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
214449183|NCT06004531|BEHAVIORAL|Prompting open-ended question promoting sustainability|This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
214694600|NCT05856825|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
214694601|NCT00150670|DRUG|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
214694602|NCT00150670|DRUG|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
215130907|NCT04780165|DEVICE|Blephademodex|During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
215130908|NCT05684458|PROCEDURE|Reiki|Reiki, a non-invasive, free and safe complementary therapy method, is practiced with a series of hand positions held on the patient's body to help balance the life force energy.
215130909|NCT01416402|DRUG|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
215130910|NCT01416402|DRUG|Febuxostat|80 mg once daily orally for 5 weeks
215130911|NCT01416402|DRUG|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
215130912|NCT04629755|BEHAVIORAL|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
215130913|NCT00006053|DRUG|imatinib mesylate|
214449184|NCT06004531|BEHAVIORAL|Sustainability Passage|This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
214449185|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
214449186|NCT05380570|RADIATION|Occupational radiation exposure|Ionizing radiation in workplaces
215130914|NCT05062174|DRUG|Mifepristone 200 MG|Orally, one time dosage of 200 mg
215130915|NCT05062174|PROCEDURE|Prophylactic mastectomy|Planned prophylactic mastectomy (having one or both breasts removed).
215130916|NCT06527014|PROCEDURE|Pulse Radiofrequency to the suprascapular nerve|Pulse radiofrequency ablation to the Suprascapular nerve
215130917|NCT06249685|DEVICE|Bilateral hearing devices|Three week trial while wearing bilateral hearing devices.
214449187|NCT05059262|DRUG|Vimseltinib|Administered orally
214449188|NCT05059262|DRUG|Placebo|Administered orally
214449189|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
214449190|NCT06571227|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
214525162|NCT04464434|PROCEDURE|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
214525163|NCT01026103|DEVICE|Tri Staple Technology stapler|This is a single arm study.
214525164|NCT00105521|DRUG|Sarizotan|Sarizotan will be administered twice daily.
214525165|NCT00105521|DRUG|Placebo|Placebo matching to sarizotan will be administered twice daily.
214525166|NCT03103178|OTHER|Quality of life questionnaire|Measurement of quality of life
214525167|NCT06401447|RADIATION|Radiotherapy|Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
214694603|NCT02919124|DEVICE|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
214694604|NCT02542917|DEVICE|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
214694605|NCT05596903|OTHER|EMDR 2.0 group protocol|EMDR 2.0 group protocol
215130918|NCT00947375|DRUG|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
215130919|NCT00947375|DRUG|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
215130920|NCT00287898|BEHAVIORAL|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
215130921|NCT00287898|BEHAVIORAL|Usual Care|subjects will receive standard in-person genetic counseling
215130922|NCT01099371|OTHER|exercise|progressive resistance training
214449191|NCT05426408|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging to study coronary microvascular dysfunction|Myocardial perfusion mapping will be investigated after administration of adenosine
215130923|NCT00667888|RADIATION|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
215130924|NCT00667888|RADIATION|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
215130925|NCT02753803|DRUG|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
215130926|NCT02753803|DRUG|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
215130927|NCT02753803|DRUG|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
214449192|NCT06569719|OTHER|Complex decongestive therapy|Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
214449193|NCT06570278|DIAGNOSTIC_TEST|WGS coupled with MCM|Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
215130928|NCT02753803|DRUG|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
215130929|NCT02753803|DRUG|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
214449194|NCT04970836|BIOLOGICAL|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
214449195|NCT04864912|OTHER|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
214525168|NCT03698721|PROCEDURE|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
214525169|NCT03999697|DRUG|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
214525170|NCT03053908|PROCEDURE|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
214525171|NCT03053908|PROCEDURE|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
214525172|NCT05128539|DRUG|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
215130930|NCT02753803|DRUG|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
215130931|NCT02684773|PROCEDURE|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
215130932|NCT02684773|PROCEDURE|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
215130933|NCT04859322|DRUG|Glucagon|Pancreatic clamp
215130934|NCT03796507|DRUG|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
215130935|NCT04978883|OTHER|No intervention|No intervention
214449196|NCT04675541|BIOLOGICAL|Afstyla®|Solution for injection
214449197|NCT06385834|OTHER|Morning aerobic exercise|Patients were randomly assigned to morning aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
215130936|NCT05936112|OTHER|Fecal calprotectin dosage|Dosing calprotectin in infants' feces + questionnaire/interview with parents
215130937|NCT05936112|OTHER|Questionnaire and interview with parents|Dosing calprotectin in infants' feces + questionnaire/interview with parents
215130938|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
215130939|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
215130940|NCT02140047|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
215130941|NCT05101590|DEVICE|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
215130942|NCT01665196|DRUG|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
214525173|NCT03347773|DIETARY_SUPPLEMENT|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
214525174|NCT00826527|DRUG|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
215130943|NCT01754103|OTHER|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
215130944|NCT01264341|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
215130945|NCT01264341|DRUG|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
215130946|NCT01983475|DRUG|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
214449198|NCT06385834|OTHER|Evening aerobic exercise|Patients were randomly assigned to evening aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
214449199|NCT03970278|OTHER|No intervention|No intervention
214449200|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
214449201|NCT04846478|DRUG|Talazoparib|capsule, taken by mouth, once a day
214449202|NCT04846478|DRUG|Tazemetostat|orally as a tablet twice daily.
214449203|NCT04977180|DRUG|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
215130947|NCT01983475|DRUG|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
215130948|NCT01904409|DRUG|Placebo|
215130949|NCT01904409|DRUG|Rifaximin SSD 40 mg IR tablet|
214449204|NCT05449795|DEVICE|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
214449205|NCT06370091|OTHER|Gum of Xylitol|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
214449206|NCT06370091|OTHER|Gum of sugar free|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
214449207|NCT06370091|OTHER|Gum of sugar|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
214449208|NCT06370091|OTHER|Paraffin wax|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
214449209|NCT06077591|OTHER|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
214449210|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
214525175|NCT02286427|DEVICE|Amniotic Membrane|
214525176|NCT00885859|DEVICE|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
214525177|NCT05051696|DRUG|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
214525178|NCT05800483|BEHAVIORAL|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
214525179|NCT00482417|DRUG|MK0359|
214694606|NCT05596903|OTHER|Mhgap stress module|Mhgap stress module
215130950|NCT01904409|DRUG|Rifaximin SSD 80 mg IR tablet|
215130951|NCT01904409|DRUG|Rifaximin SSD 40 mg SER tablet|
215130952|NCT01904409|DRUG|Rifaximin SSD 80 mg SER tablet|
215130953|NCT01904409|DRUG|Rifaximin SSD 80mgIR/80mgSER tablet|
215130954|NCT00003464|DRUG|temozolomide|
215130955|NCT00003464|RADIATION|radiation therapy|
215130956|NCT00659061|DIETARY_SUPPLEMENT|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
214525180|NCT05202327|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
214525181|NCT05202327|DRUG|Placebo|The placebo contained corn starch.
214525182|NCT05876364|BIOLOGICAL|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
214525183|NCT05876364|BIOLOGICAL|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
215130957|NCT00659061|BEHAVIORAL|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
215130958|NCT00605852|DRUG|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
215130959|NCT00605852|DRUG|Placebo|Placebo will be given to subjects.
215130960|NCT01277744|PROCEDURE|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
215130961|NCT01277744|DRUG|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
215130965|NCT03688269|DRUG|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
215130966|NCT03688269|DRUG|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
215130967|NCT03688269|DRUG|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
215130968|NCT04694222|DEVICE|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
214525184|NCT05876364|BIOLOGICAL|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
214525185|NCT00495261|BEHAVIORAL|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
214525186|NCT00495261|BEHAVIORAL|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
214525187|NCT02578667|DEVICE|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
214525188|NCT00002471|DRUG|asparaginase|
214525189|NCT00002471|DRUG|cyclophosphamide|
214525190|NCT00002471|DRUG|cytarabine|
215130969|NCT02341560|DRUG|QPI-1007 Injection - 1.5 mg|
215130970|NCT02341560|DRUG|QPI-1007 Injection - 3.0 mg|
215130971|NCT02341560|OTHER|Sham Injection Procedure|Sham Procedure
215130972|NCT06329908|DRUG|LG002|Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
214525191|NCT00002471|DRUG|daunorubicin hydrochloride|
214525192|NCT00002471|DRUG|dexamethasone|
214525193|NCT00002471|DRUG|etoposide|
214525194|NCT00002471|DRUG|leucovorin calcium|
214525195|NCT00002471|DRUG|methotrexate|
214525196|NCT00002471|DRUG|methylprednisolone|
214525197|NCT00002471|DRUG|therapeutic hydrocortisone|
214525198|NCT00002471|DRUG|thiotepa|
214525199|NCT00002471|DRUG|vincristine sulfate|
214525200|NCT01014663|BEHAVIORAL|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
214694607|NCT04379219|DRUG|Methotrexate|giving methotrexate at least 1 w week before surgery
214694608|NCT06195826|PROCEDURE|Gravity infusion|hysteroscopic myomectomy with the gravity infusion method
214694609|NCT06195826|PROCEDURE|Pump infusion|hysteroscopic myomectomy with the pump infusion method
215130973|NCT06493760|DRUG|SSGJ-707|bispecific antibody
215130974|NCT06493760|DRUG|Bevacizumab|VEGF antibody
215130975|NCT06493760|DRUG|Oxaliplatin|chemotherapy
215130976|NCT06493760|DRUG|Capecitabine|chemotherapy
215130977|NCT06493760|DRUG|Calcium Folinate|chemotherapy
215130978|NCT06493760|DRUG|5-fluorouracil|chemotherapy
215130979|NCT04459143|BEHAVIORAL|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
215130980|NCT00325897|DRUG|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
215130981|NCT00325897|DRUG|Placebo|Placebo taken on a daily basis
215130982|NCT04418791|BEHAVIORAL|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
215130983|NCT04418791|BEHAVIORAL|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
215130984|NCT03380728|DRUG|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
215130985|NCT05781178|DIETARY_SUPPLEMENT|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
215130986|NCT02366494|DRUG|Bicalutamide|ANDROGEN BLOCKADE
215130987|NCT02366494|DRUG|Leuprolide|ANDROGEN BLOCKADE
215130988|NCT02366494|DRUG|Goserelin|ANDROGEN BLOCKADE
215130989|NCT02366494|DRUG|Triptorelin|ANDROGEN BLOCKADE
215130990|NCT02366494|DRUG|Docetaxel|Chemo hormonal therapy
215130991|NCT02366494|DRUG|Abiraterone|Chemo hormonal therapy
215130992|NCT02366494|DRUG|Apalutamide|Nonsteroidal antiandrogen medication
215130993|NCT02366494|DRUG|Enzalutamide|Nonsteroidal antiandrogen medication
215130994|NCT04991649|BEHAVIORAL|Acceptance and Commitment Therapy-based Asthma Management Training Program|In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
215130995|NCT04991649|BEHAVIORAL|Treatment-as-usual Group|Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
215130996|NCT03870919|DRUG|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
215130997|NCT03870919|OTHER|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
215130998|NCT06172452|BEHAVIORAL|Project Body Neutrality SSI|Online, 30-minute self-guided intervention for youth ages 13-17
215130999|NCT06172452|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-guided activity for youth ages 13-17
215131000|NCT03915717|DEVICE|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
215131001|NCT03915717|DEVICE|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
215131002|NCT03093909|DRUG|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
214449211|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
214694610|NCT03298152|PROCEDURE|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
214694611|NCT03298152|PROCEDURE|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
214694612|NCT04899713|OTHER|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
214694613|NCT01006720|DRUG|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
214694614|NCT01006720|DRUG|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
214694615|NCT01006720|DRUG|Saline|Saline 0.9% (Saline)
215131003|NCT05954468|OTHER|standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social \& health psychology
215131004|NCT03808090|DIETARY_SUPPLEMENT|Normal Individuals|"Controlled Dietary phase: Low oxalate fixed diet~4 days of fixed normal calorie diet with low oxalate (\< 60 mg/day), normal calcium (800-1200 mg/day)"
215131005|NCT04737512|BEHAVIORAL|Mindfulness-Based ADHD Treatment for Children|MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
215131006|NCT04737512|BIOLOGICAL|Goal-Standard Medication (Treatment as Usual)|"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."
214449212|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
214449213|NCT05312892|DRUG|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
214449214|NCT05312892|DRUG|Moxonidine|Moxonidine
214449215|NCT05312892|DRUG|Placebo|Placebo
214449216|NCT06317064|DRUG|Ibuprofen and Aprepitant|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
214449217|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
214449218|NCT05616026|BEHAVIORAL|Intervention|6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
214449219|NCT05616026|BEHAVIORAL|Attention Control|6 months of texts for general health promotion
214525201|NCT01014663|BEHAVIORAL|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
214525202|NCT01504919|BEHAVIORAL|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
215131007|NCT03748823|COMBINATION_PRODUCT|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
215131008|NCT03748823|BIOLOGICAL|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
215131009|NCT06120712|BIOLOGICAL|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
214449220|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
214449221|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
214449222|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
214525203|NCT01504919|BEHAVIORAL|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
214525204|NCT01504919|BEHAVIORAL|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
214525205|NCT01504919|DRUG|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
214525206|NCT06170931|PROCEDURE|posterior cruciate ligament-retaining prostheses|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
214525207|NCT06170931|PROCEDURE|posterior cruciate ligament-substituting prostheses|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
215131010|NCT03345251|DEVICE|Hydrotubation|
215131011|NCT02149381|BEHAVIORAL|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
215131012|NCT02149381|BEHAVIORAL|Befriending|Social support intervention, sessions once per week
215131013|NCT02149381|OTHER|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
215131014|NCT04479085|OTHER|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
214449223|NCT06508541|PROCEDURE|ICG Guided surgery|In ICG guided surgery group,Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
214449224|NCT06508541|PROCEDURE|conventional surgery|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose
214449225|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
214449226|NCT04902846|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
214449227|NCT04902846|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
214449228|NCT04501861|DRUG|Vasopressin|Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
214449229|NCT04501861|DRUG|Norepinephrine|Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
214464451|NCT06564948|OTHER|Family and Social Justice|Documentation and follow-up by the Cambridge Police Department (CPD) for all mental health-related police calls, including involuntary and voluntary Emergency Department admissions; Established partnerships with city departments, healthcare systems, clergy, courts, businesses, and mental health advocates to ensure timely engagement in mental health treatment and community-based services; Required 40 hours of officer crisis intervention training (CIT), and additional sessions on trauma- informed policing, mental health, procedural justice, race, and crisis negotiation; and Staffing of sworn and civilian staff including specially-trained officers designated to work with individuals living with mental illness, homelessness, and substance abuse.
214525208|NCT04360642|OTHER|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
214525209|NCT06123819|DEVICE|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
214525210|NCT02475733|DRUG|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
215131015|NCT00984477|DRUG|AZD5122|A single dose of oral suspension
215131016|NCT00984477|DRUG|Placebo|A single dose of oral suspension
215131017|NCT00984477|DRUG|AZD5122|A single intravenous infusion
215131018|NCT04730765|PROCEDURE|left elective colectomy (Surgical Experimental Group)|Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.
215131019|NCT04730765|DRUG|antibiotic therapy (medical Control Group)|Antibiotic treatement for 10 days by oral or intravenous administration
215131020|NCT01754974|BIOLOGICAL|Peginterferon Lambda-1a|
215131021|NCT01754974|DRUG|Ribavirin|
215131022|NCT01754974|BIOLOGICAL|Peginterferon alfa-2a|
215131023|NCT04272346|BEHAVIORAL|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
214525211|NCT02475733|DRUG|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
214525212|NCT02475733|DRUG|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
214525213|NCT00404547|DRUG|Ciclesonide|Asthma Care with Alvesco
215131024|NCT04272346|BEHAVIORAL|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
215131025|NCT04272346|BEHAVIORAL|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
215131026|NCT04958499|BEHAVIORAL|Bio-healthy Park|Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
215131027|NCT03833492|BEHAVIORAL|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
215131028|NCT00626275|DRUG|ADL5859|
215131029|NCT00626275|DRUG|Naproxen|
215131030|NCT00626275|DRUG|Placebo|
215131031|NCT00626275|DRUG|ADL5859|
215131032|NCT00626275|DRUG|Placebo|
214449230|NCT00959140|DEVICE|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10\^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10\^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
214449231|NCT04807868|PROCEDURE|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
214449232|NCT04807868|OTHER|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
214449233|NCT04807868|OTHER|Biospecimen Collection|Blood and urine will be collected.
214449234|NCT06173219|COMBINATION_PRODUCT|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
214525214|NCT00404547|DRUG|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
215131033|NCT02760615|DRUG|Caffeine|Caffeine tablets
215131034|NCT02760615|DRUG|Losartan|Losartan tablets
214525215|NCT00880152|BEHAVIORAL|Mindfulness-based stress reduction|An 8-week course in mindfulness training
214525216|NCT00094497|DRUG|Etoposide|
214525217|NCT00094497|DRUG|Doxorubicin|
214525218|NCT00094497|DRUG|Cisplatin|
214525219|NCT00094497|DRUG|Streptozotocin|
214525220|NCT00094497|DRUG|Mitotane|
214525221|NCT00917631|PROCEDURE|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
215131035|NCT02760615|DRUG|Omeprazole|Omeprazole capsules
215131036|NCT02760615|DRUG|Dextromethorphan|Dextromethorphan capsules
215131037|NCT02760615|DRUG|Midazolam|Midazolam syrup
215131038|NCT02760615|DRUG|Vedolizumab|Vedolizumab solution for IV infusion
215131039|NCT01476670|OTHER|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
215131040|NCT00790426|DRUG|TKI258|
215131041|NCT06387823|DRUG|Sivelestat sodium|Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
215131042|NCT06387823|DRUG|Dexamethasone|Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)
214449235|NCT05893173|BEHAVIORAL|Sleep Deprivation|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation.
214449236|NCT04773457|OTHER|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
214449237|NCT06498973|DRUG|Azacitidine|Given IV
214449238|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214449239|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214449240|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214449241|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
214449242|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
215131043|NCT06387823|DRUG|Sivelestat sodium placebo|Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
215131044|NCT06387823|DRUG|Dexamethasone placebo|Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
214449243|NCT00741728|OTHER|Spider flash ECG, high-precision carotid echo-tracking, step test|cardiac rhythm recorded during health check up, vascular aging parameters and baroreflex sensitivity recorded during carotid echotracking of the right common carotid artery , step test during 2 minutes
214449244|NCT04031456|BIOLOGICAL|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
214449245|NCT04031456|BIOLOGICAL|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
214525222|NCT05143437|BEHAVIORAL|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
214525223|NCT03892122|DRUG|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
214694616|NCT04687605|PROCEDURE|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
214694617|NCT01592409|DRUG|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
214694618|NCT01592409|DRUG|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
214694619|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
215131045|NCT05485740|OTHER|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
214449246|NCT05830721|DEVICE|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
214449247|NCT05830721|DEVICE|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
215131046|NCT05485740|OTHER|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
215131047|NCT00056095|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215131048|NCT00056095|DRUG|cyclophosphamide|
215131049|NCT00056095|DRUG|cyclosporine|
215131050|NCT00056095|DRUG|fludarabine phosphate|
215131051|NCT00056095|PROCEDURE|allogeneic bone marrow transplantation|
215131052|NCT00056095|PROCEDURE|peripheral blood stem cell transplantation|
215131053|NCT00086866|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
215131054|NCT00086866|BIOLOGICAL|SB-AS02B adjuvant|
215131055|NCT00086866|BIOLOGICAL|SB-AS15 adjuvant|
215131056|NCT00697502|DRUG|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
214449248|NCT05830721|OTHER|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
214449249|NCT02312960|OTHER|Data Collection|No study treatment will be provided in this long term follow up study.
214449250|NCT06007976|DEVICE|Erchonia® Trident|Low-level laser therapy
214449251|NCT06473688|PROCEDURE|Cholecystectomy|Robotic-assisted and laparoscopic cholecystectomy
214449252|NCT04461821|DIAGNOSTIC_TEST|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
214449253|NCT04461821|DIAGNOSTIC_TEST|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
214449254|NCT04461821|DIAGNOSTIC_TEST|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
214449255|NCT04461821|DIAGNOSTIC_TEST|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
214449256|NCT04461821|DIAGNOSTIC_TEST|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
214449257|NCT06024304|DEVICE|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
214449258|NCT06024304|DEVICE|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
214449259|NCT03636230|DEVICE|Remote Monitoring|Remote Monitoring only + VIRTUES
214449260|NCT03636230|OTHER|Standard of care|In-Clinic visits only
214449261|NCT05978531|DRUG|Monomethyl Fumarate|95 mg oral capsule, 190 mg (2 x 95 mg) twice daily
214449262|NCT04301778|DRUG|Durvalumab|"1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV"
214449263|NCT04301778|DRUG|SNDX-6352|"1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV"
214449264|NCT05164744|DIAGNOSTIC_TEST|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
214449265|NCT05164744|DIAGNOSTIC_TEST|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
214449266|NCT05164744|DIAGNOSTIC_TEST|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
214449267|NCT05164744|DIAGNOSTIC_TEST|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
214449268|NCT05862688|OTHER|antimicrobial therapy|antimicrobial therapy
214525224|NCT03892122|DRUG|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
214525225|NCT00415883|DRUG|Valsartan|
214525226|NCT06480851|PROCEDURE|Ecoguided Percutaneous Neuromodulation|Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
214525227|NCT05262218|DRUG|PBF-680 10mg|PBF-680 10mg administered orally once a day
215131057|NCT00646139|DRUG|Src kinase inhibitor KX2-391|
215131058|NCT00646139|OTHER|immunoenzyme technique|
215131059|NCT00646139|OTHER|pharmacological study|
214449269|NCT05410743|DRUG|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
214449270|NCT05410743|DRUG|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.33GBq （90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
215131060|NCT02367573|PROCEDURE|2D laparoscopic TAPP inguinal hernia repair|
215131061|NCT02367573|PROCEDURE|3D laparoscopic TAPP inguinal hernia repair|
215131062|NCT02934802|DEVICE|Total Knee prothesis e motion PS Pro|
215131063|NCT06317558|DRUG|Neoadjuvant immunotherapy|Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.
215131064|NCT06317558|DRUG|Other drugs for neoadjuvant treatment|Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
215131065|NCT01140841|DRUG|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
214449271|NCT05410743|DRUG|177Lu-LNC1010 3|The patients were intravenously injected with single dose 4.99GBq (135 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
214449272|NCT05410743|DRUG|177Lu-LNC1010 4|Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
214525228|NCT05262218|DRUG|Placebo|Placebo administered orally once a day
214525229|NCT00530049|OTHER|questionnaire administration|
214525230|NCT00530049|PROCEDURE|assessment of therapy complications|
214525231|NCT00530049|PROCEDURE|psychosocial assessment and care|
214525232|NCT00530049|PROCEDURE|quality-of-life assessment|
214525233|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
214694620|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
214694621|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
214694622|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
214694623|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
214694624|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
214694625|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
215131066|NCT01140841|DRUG|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
215131067|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
214449273|NCT00214721|DRUG|Experimental Peritoneal Dialysis Solution|
215131068|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
214525234|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
214525235|NCT04973332|DEVICE|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
214525236|NCT03732950|BIOLOGICAL|Pembrolizumab|Given IV
214525237|NCT03047278|PROCEDURE|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
214525238|NCT03047278|PROCEDURE|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
214525239|NCT03047278|DRUG|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
214525240|NCT03047278|DRUG|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
214525241|NCT00206609|PROCEDURE|Oxygen and air administration|
214525242|NCT00666991|DRUG|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
214525243|NCT02131155|DRUG|Placebo|Once daily
214525244|NCT02131155|DRUG|Afatinib|Once daily
214525245|NCT00452985|DRUG|Docetaxel|60-75 mg/m²
214525246|NCT00452985|DRUG|Carboplatin|AUC 5
214525247|NCT04147091|OTHER|ApaCare & Repair|Initial cariuos lesions were treated.
214525248|NCT01249599|PROCEDURE|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
214694626|NCT05311644|OTHER|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
214694627|NCT04168593|PROCEDURE|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
215131069|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
215131070|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
215131071|NCT02319941|DRUG|ticagrelor|
215131072|NCT02319941|DRUG|clopidogrel|
215131073|NCT01046565|DRUG|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
215131074|NCT01046565|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
215131075|NCT02179008|DRUG|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
215131076|NCT02179008|DRUG|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
215131077|NCT02179008|DRUG|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
215131078|NCT02179008|DRUG|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
215131079|NCT02179008|DRUG|DE-117 High Dose ophthalmic solution|High Dose DE-117
215131080|NCT02179008|DRUG|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
214525249|NCT04427397|OTHER|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
215131081|NCT03295435|OTHER|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural \& Prosthetic units present Group C: No natural units present"
215131082|NCT02098330|DRUG|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
215131083|NCT02098330|DRUG|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
215131084|NCT01918124|RADIATION|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
215131085|NCT01918124|DRUG|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
215131086|NCT01918124|DRUG|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
215131087|NCT01918124|DRUG|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
214449274|NCT04015765|PROCEDURE|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
214449275|NCT06038630|DRUG|Hyperpolarized Xe129|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
215131088|NCT01650558|DRUG|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
215131089|NCT01650558|DRUG|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
215131090|NCT01998230|DIETARY_SUPPLEMENT|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
215131091|NCT01110824|DRUG|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
215131092|NCT03395483|OTHER|Haemodynamic monitoring|see Group description
215131093|NCT04722614|OTHER|Music|Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property
215131094|NCT04722614|OTHER|Essential oil|Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.
215131095|NCT04722614|OTHER|Control|The routine intensive care unit sedation protocol
215131096|NCT01815723|DRUG|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
214449276|NCT06038630|OTHER|Oxygen Administration|Oxygen administration
214525250|NCT00411177|PROCEDURE|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
215131097|NCT01815723|DRUG|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
215131098|NCT01815723|DRUG|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
215131099|NCT01815723|DRUG|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
214449277|NCT04251806|DIAGNOSTIC_TEST|neonatal polysomnography|This procedure will allow the detection of sleep-disordered breathing in the neonatal period.
214449278|NCT04251806|DIAGNOSTIC_TEST|2-year Bayley Exam|This procedure will evaluate neurodevelopmental outcomes.
214449279|NCT04251806|DIAGNOSTIC_TEST|2-year polysomnography|This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
214449280|NCT04660435|DIAGNOSTIC_TEST|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
215131100|NCT03062735|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
215131101|NCT03062735|OTHER|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
215131102|NCT02578407|OTHER|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
215131103|NCT05919407|DRUG|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
215131104|NCT05919407|DRUG|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
215131105|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
215131106|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
215131107|NCT05330013|DRUG|Dapagliflozin|Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).
215131108|NCT05330013|DEVICE|MRI scan|For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).
215131109|NCT05330013|DEVICE|CMR imaging|Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
215131110|NCT00002643|BIOLOGICAL|filgrastim|
215131111|NCT00002643|DRUG|amifostine trihydrate|
215131112|NCT00002643|DRUG|cyclophosphamide|
214449281|NCT02104063|PROCEDURE|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
214449282|NCT06219538|DEVICE|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery or D \& C,
215131113|NCT00002643|DRUG|doxorubicin hydrochloride|
215131114|NCT00002643|DRUG|etoposide|
214449283|NCT01823562|DRUG|lyophilized black raspberry confection|Given PO
214449284|NCT01823562|OTHER|laboratory biomarker analysis|Correlative studies
214449285|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low polyphenol diet
214449286|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low ellagitannin diet
214449287|NCT01823562|PROCEDURE|quality-of-life assessment|Ancillary studies
214449288|NCT01823562|OTHER|questionnaire administration|Ancillary studies
214449289|NCT06580418|OTHER|Additional biopsies and blood samples|During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
214449290|NCT04775602|DRUG|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
214449291|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
214449292|NCT06163482|OTHER|Mixed meal|Each individual will ingest 5 mL/kg of Boost energy drink.
214449293|NCT04936191|DEVICE|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
214449294|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
214449295|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
214449296|NCT03437005|DRUG|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
214449297|NCT03437005|DRUG|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
215131115|NCT00002643|DRUG|ifosfamide|
215131116|NCT00002643|DRUG|topotecan hydrochloride|
215131117|NCT00002643|DRUG|vincristine sulfate|
214449298|NCT04193787|OTHER|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
215131118|NCT00002643|PROCEDURE|conventional surgery|
215131119|NCT00002643|RADIATION|low-LET cobalt-60 gamma ray therapy|
214525251|NCT00411177|PROCEDURE|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
214525252|NCT01887418|DRUG|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
214525253|NCT01887418|DRUG|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
214525254|NCT01887418|DRUG|Delatestryl 200 mg IM Treatment C|Standard of care
215131120|NCT00002643|RADIATION|low-LET electron therapy|
215131121|NCT00002643|RADIATION|low-LET photon therapy|
215131122|NCT03597815|DRUG|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
215131123|NCT03597815|DIAGNOSTIC_TEST|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
215131124|NCT03597815|DEVICE|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
215131125|NCT01893541|PROCEDURE|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
215131126|NCT01893541|DRUG|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
215131127|NCT01893541|DEVICE|a multiband ligation device|
215131128|NCT05769296|DEVICE|Headpulse measurements|Placement of headset on subject
215131129|NCT02843269|BEHAVIORAL|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
215131130|NCT03829085|OTHER|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
215131131|NCT01599156|PROCEDURE|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
215131132|NCT02478008|DEVICE|CardiAQ TMVI System (Transapical DS)|
215131133|NCT05605808|OTHER|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
215131134|NCT05605808|OTHER|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
215131135|NCT06276062|PROCEDURE|Distal radius fracture fixation in pediatrics.|using double short titanium elastic nails in treatment of pediatric distal radius fractures.
215131136|NCT02732600|OTHER|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
215131137|NCT03032562|DIAGNOSTIC_TEST|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
215131138|NCT03669614|DRUG|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
215131139|NCT03669614|DRUG|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
214449299|NCT06202053|PROCEDURE|Type of surgical incision|"The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest."
214449300|NCT02634645|PROCEDURE|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
214449301|NCT02634645|PROCEDURE|Esophagectomy|The esophagus is surgically removed
214449302|NCT02634645|DRUG|Chemotherapy|Chemical substances are used to treat cancer
214449303|NCT02634645|RADIATION|Radiation|Cancer cells are destroyed by radiation therapy.
215131140|NCT01616628|BEHAVIORAL|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
214525255|NCT04770740|DIETARY_SUPPLEMENT|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
214525256|NCT04770740|DIETARY_SUPPLEMENT|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
214525257|NCT04171258|DRUG|Botulinum toxin type A injection|Experimental
215131141|NCT00528957|DRUG|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
215131142|NCT00528957|DRUG|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
215131143|NCT00528957|DRUG|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
215131144|NCT00549692|DRUG|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
215131145|NCT04565626|OTHER|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
214449304|NCT06579872|OTHER|plantar pressure|foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases
214449305|NCT05259787|DRUG|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
214449306|NCT05259787|DRUG|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
214449307|NCT05464758|OTHER|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
214449308|NCT05329883|PROCEDURE|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
214449309|NCT05702853|DRUG|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
215131146|NCT03624881|DEVICE|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
215131147|NCT03590444|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
215131148|NCT03521349|OTHER|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
215131149|NCT03521349|OTHER|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
215131150|NCT05255523|DRUG|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
215131151|NCT06430697|DRUG|paracetamol administration|Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
215131152|NCT01969708|DRUG|aflibercept|
215131153|NCT01969708|DRUG|bevacizumab|
215131154|NCT04387448|DRUG|GFB-887|Investigational Medicinal Product (IMP)
215131155|NCT04387448|DRUG|Placebo|Matching
215131156|NCT05633563|DRUG|Trimetazidine|Oral intake of capsules
215131157|NCT05633563|DRUG|Placebo|Oral intake of capsules
215131158|NCT00724841|DRUG|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
215131159|NCT00724841|DRUG|Temozolomide|
215131160|NCT02892994|OTHER|ultrasound|
215131161|NCT04386200|OTHER|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
214449310|NCT05702853|DRUG|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
214449311|NCT05702853|BIOLOGICAL|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
214449312|NCT05168605|OTHER|Home visit|Patients receiving home Visits
214449313|NCT06360419|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
214449314|NCT06360419|DRUG|Placebo|Placebo tablets, taken once daily
214449315|NCT05987033|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
214449316|NCT05204589|BIOLOGICAL|Aerosolized Ad5-nCoV|Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
214449317|NCT05204589|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine|Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
214449318|NCT06464341|OTHER|Observational study no intervention|Observational study no intervention
214449319|NCT04288375|RADIATION|Intensity-modulated radiation therapy (IMRT)|The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
214449320|NCT06375200|OTHER|No intervention|Observational one-time questionnaire study without intervention
214449321|NCT05544084|BEHAVIORAL|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
214449322|NCT06470100|DRUG|0.9% Sodium Chloride Injection|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
215131162|NCT04386200|BEHAVIORAL|traditional approach|"traditional face-to-face educational approach"
215131163|NCT00000547|DRUG|enalapril|
215131164|NCT02553213|OTHER|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
215131165|NCT02553213|OTHER|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
214449323|NCT06470100|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
214525258|NCT04171258|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
215131166|NCT02553213|OTHER|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
215131167|NCT02553213|OTHER|easy digestible diet|
215131168|NCT04050046|DEVICE|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
215131169|NCT04050046|BEHAVIORAL|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
215131170|NCT03740256|BIOLOGICAL|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
215131171|NCT06268652|OTHER|Organoid-guided personalized treatment|After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
215131172|NCT06268652|DRUG|Gemcitabine|1000mg/m2，IV, days 1, 8, q3w
215131173|NCT06268652|DRUG|Capecitabine|1000mg/m² , PO, bid, days1-14, q3w
215131174|NCT06268652|DRUG|Vinorelbine|25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
215131175|NCT06268652|DRUG|Eribulin|1.4mg/m², IV, days 1 and 8, q3w
215131176|NCT00490464|DRUG|Nicardipine and Nipride|
215131177|NCT02897648|DRUG|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
215131178|NCT01863823|DRUG|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
215131179|NCT01863823|DRUG|Mouth washing|Two time washing mouth per day
215131180|NCT05255471|DRUG|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
215131181|NCT05255471|DRUG|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~* Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~* Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~* Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
215131182|NCT01859234|DRUG|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
215131183|NCT04608981|DRUG|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
215131184|NCT04608981|DRUG|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
215131185|NCT04608981|DRUG|Placebo|Starch
215131186|NCT03383861|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
215131187|NCT04258423|DRUG|Tacrolimus|Low dose Tacrolimus
215131188|NCT04258423|DRUG|Everolimus|Everolimus
215131189|NCT03980015|OTHER|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
215131190|NCT04129593|BEHAVIORAL|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
215131191|NCT04129593|BEHAVIORAL|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
215131192|NCT02361359|OTHER|Psychological questionnaires|
215131193|NCT02584946|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
215131194|NCT02372643|OTHER|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
215131195|NCT06262386|DRUG|Cisplatin based chemottherapy|adjuvant therapy for high risk patient
215131196|NCT05345457|DRUG|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
215131197|NCT05345457|DRUG|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
215131198|NCT06630494|DRUG|Recombinant human thrombopoietin for injection (rhTPO)|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
214525259|NCT04787718|OTHER|Almond|2.0 oz of raw, shelled, unsalted almonds
215131199|NCT03852134|PROCEDURE|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
215131200|NCT03852134|PROCEDURE|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
214525260|NCT04787718|OTHER|Control group|an isocaloric amount of unsalted pretzels
215131201|NCT06612879|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
214525261|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
214525262|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
215131202|NCT01586949|BEHAVIORAL|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
215131203|NCT06039553|PROCEDURE|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
215131204|NCT06726694|DEVICE|class II molar relation correction by advanced molar distalization appliance|correction of class II molar relation by a novel miniscrews distalizer
215131205|NCT05229484|OTHER|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
215131206|NCT06750458|DRUG|Dapagliflozin placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative
215131207|NCT06750458|DRUG|Placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
215131208|NCT06750458|DRUG|DexamethasoneGroup III (n=25) (Dexamethasone group)|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
215131209|NCT06894342|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonographic evaluation of the masseter muscle
215131210|NCT05086705|DEVICE|EMBr Wave|Use EMBr Wave
215131211|NCT05086705|OTHER|Questionnaire Administration|Ancillary studies
215131212|NCT06881342|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|The first-stage intervention is eSMHP Plus in the intervention arm and eSMHP in the control arm. In the intervention arm, adolescents receive eSMHP Plus from teachers and non-specialists, while in the control arm, they receive eSMHP from teachers. eSMHP, based on developmental, behavioral, social, and cognitive theories, enhances teachers' mental health literacy, training them in early identification, basic counseling, life skills, positive discipline, parental engagement, referrals, and teacher well-being. The second-stage intervention is a CBT-based self-help app. At six weeks, adolescents scoring ≥28 on PSC in both arms (indicating psychosocial distress) are re-randomized to continue their initial treatment (eSMHP Plus or eSMHP) or receive a step-up, CBT-based guided self-help app for two months.
214449324|NCT06470100|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
214449325|NCT03514329|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
214449326|NCT05695989|DEVICE|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
214449327|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
214525263|NCT01248078|DRUG|saline solution|100cc administered before skin incision
214525264|NCT05819983|DRUG|Ivermectin Tablets|Ivermectin 200µg/kg BW
214525265|NCT05819983|DRUG|Permethrin Cream|Permethrin cream 5%
214525266|NCT03255785|DEVICE|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
214525267|NCT00369239|DRUG|risperidone long acting injectable|
214449328|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
214449329|NCT04856176|DRUG|pemetrexed|500mg/m2
214449330|NCT04856176|DRUG|Paclitaxel|200mg/m2
214525268|NCT01614899|DRUG|SM-13496 40mg|once daily orally
215131213|NCT06922006|PROCEDURE|Percutaneus nephrolithotomy (PCNL)|Percutaneus nephrolithotomy (PCNL) for removal of large kidney stones
214449331|NCT04856176|DRUG|Carboplatin|AUC 5/6
214449332|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
214525269|NCT01614899|DRUG|SM-13496 80mg|once daily orally
214525270|NCT01614899|DRUG|Placebo|once daily orally
215131214|NCT06939010|DEVICE|3d-interlocking miniplate|3d-interlocking miniplate
215131215|NCT06939010|DEVICE|Conventional miniplates|double miniplates in the conventional configuration
215131216|NCT06937359|OTHER|Reiki healing|Each client received four treatments with Healing Space Reiki Therapy: a foundation of Reiki, combined with a fully customized treatment with trauma processing and adjustments in diet and lifestyle at Dojo In Reiki treatments. In the Dojo In, there were 8 futons, with two Reiki Therapists at each futon treating one client. During these sessions, participants receive 4 Reiki treatments, each lasting about an hour, over 4 consecutive weeks. During these days, 2 trained and/or still training Reiki Therapists per treatment table provide a Reiki treatment under the supervision of the founders of Healing Space.
215131217|NCT06937138|PROCEDURE|AI-Assisted Screw Path Planning|The trajectory for screw placement during femoral neck fracture fixation will be guided by an AI algorithm based on intraoperative X-ray imaging. The system will automatically suggest the screw entry point and trajectory on the robotic navigation platform. The surgeon will proceed with the operation after confirming the feasibility of the AI-generated plan. In principle, surgeons are advised not to modify the AI-recommended trajectory unless necessary, to preserve the independent evaluative value of the AI-assisted plan. If significant disagreement arises between the surgeon's judgment and the AI-recommended trajectory, a third-party orthopedic specialist-blinded to group allocation-will conduct an independent postoperative assessment of the screw placement's appropriateness and accuracy.
215131218|NCT06937138|PROCEDURE|Surgeon-Directed Screw Path Planning|The screw trajectory will be entirely determined manually by the operating surgeon, based on personal experience and under guidance from the robotic navigation system and intraoperative fluoroscopy, without reliance on any AI recommendation module.
215131219|NCT06938542|BEHAVIORAL|Family Centered pediatric palliative care for family caregivers of children with rare diseases.|Child with rare disease who is unable to participate in medical decision making/family caregiver/support person triads will be randomized at a 1:1 ratio to one of two study arms, either the 3 session FACE-Rare intervention or the enhanced Treatment as Usual. Assessments will be completed at baseline, 3, 6 and 12 month outcomes.
214449333|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
214449334|NCT04259580|PROCEDURE|Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures
214449335|NCT04709432|PROCEDURE|ECMO|ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
214449336|NCT06178861|DEVICE|Group wearing a radiotherapy bra|Group wearing a radiotherapy bra
214449337|NCT04234204|DRUG|Fezolinetant|Oral
214449338|NCT04234204|DRUG|Placebo|Oral
214449339|NCT05153226|DRUG|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
214449340|NCT05153226|BIOLOGICAL|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
214449341|NCT05299138|BEHAVIORAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
214525271|NCT02350127|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
214525272|NCT02350127|BEHAVIORAL|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
215131220|NCT06939244|DIETARY_SUPPLEMENT|Krill oil|Krill oil supplement
215131221|NCT06938425|OTHER|intratissue percutaneous electrolysis|Using fine needles guided by ultrasound to apply electrical stimulation directly to the affected tissue (for example, damaged muscles or tendons).
215131222|NCT06938425|OTHER|deep dry needling|Insertion of fine needles into muscle trigger points (without injection of drugs) to relieve muscle pain and release tension.
215131223|NCT06938425|PROCEDURE|Standard physiotherapy|It includes manual techniques such as therapeutic massage and mobilization, along with stretching and strengthening exercises to improve range of motion and reduce pain.
215131224|NCT06938932|OTHER|High temperature exposure|Subjects will be exposed to 35 degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
215131225|NCT06938932|OTHER|Moderate temperature exposure|Subjects will be exposed to 24degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
215131226|NCT06938633|OTHER|mass spectrometry analysis|The collected urine samples will be analyzed to determine medication adherence during study visits
214449342|NCT06631001|OTHER|Abdominal Massage|Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
214449343|NCT05750212|DIAGNOSTIC_TEST|Tone|Tone is a binary measurement of the pelvic floor muscle on physical examination
214449344|NCT05750212|DIAGNOSTIC_TEST|Tenderness|Tenderness is a binary measurement of the pelvic floor muscle on physical examination
214449345|NCT05750212|DIAGNOSTIC_TEST|Contraction|Contraction is a binary measurement of the pelvic floor muscle on physical examination
214449346|NCT05750212|DIAGNOSTIC_TEST|Relaxation|Relaxation is a binary measurement of the pelvic floor muscle on physical examination
214449347|NCT05750212|DIAGNOSTIC_TEST|Electromyography|Electromyography is a measurement of the pelvic floor muscle in microvolts
214449348|NCT05750212|DIAGNOSTIC_TEST|Transperineal|Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
214449349|NCT05750212|DIAGNOSTIC_TEST|Pressure|Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
214449350|NCT05939934|DEVICE|Mandibular advancement device treatment|a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
214449351|NCT04382898|BIOLOGICAL|BNT112|Intravenous bolus injection
215131227|NCT00673777|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
215131228|NCT02696213|OTHER|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
215131229|NCT02696213|OTHER|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
215131230|NCT01789437|DEVICE|Dexamethasone Intravitreal Implant (Ozuredex)|
215131231|NCT03167775|DRUG|Elemene Injection/Elemene Oral Emulusion|
215131232|NCT02790801|OTHER|observation|observation
215131233|NCT01216137|OTHER|Exercise: Vestibular Rehabilitation|Balance and eye movement training
215131234|NCT01216137|OTHER|Exercise|Bicycle ergometry and stretching
215131235|NCT03125551|DIETARY_SUPPLEMENT|Ginger|Ginger dosage at daily recommended allowance
215131236|NCT03125551|DIETARY_SUPPLEMENT|Garlic|Garlic dosage at daily recommended allowance
215131237|NCT03125551|DIETARY_SUPPLEMENT|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
215131238|NCT03125551|DIETARY_SUPPLEMENT|Ginseng|Ginseng dosage at daily recommended allowance
215131239|NCT03125551|OTHER|Placebo|Daily dosage strategy
215131240|NCT03057015|DRUG|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
215131241|NCT03057015|DRUG|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
215131242|NCT03057015|DRUG|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
215131243|NCT03057015|DRUG|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
215131244|NCT03057015|DRUG|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
215131245|NCT00148278|DRUG|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
214449352|NCT04382898|DRUG|Cemiplimab|Intravenous infusion
215131246|NCT00148278|DRUG|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
215131247|NCT03284710|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
215131248|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
215131249|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection
215131250|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
215131252|NCT06430996|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
215131253|NCT04445285|DRUG|Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
215131254|NCT04445285|DRUG|0.9%sodium chloride|Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
215131255|NCT04446416|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
214449353|NCT05229120|BEHAVIORAL|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
215131256|NCT04446416|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
215131257|NCT02398916|BEHAVIORAL|Music listening|
215131258|NCT06322849|BEHAVIORAL|Psychoeducation|Psychoeducation is a potential active element of Project ABC. In psychoeducation, participants learn about the cognitive model of behavior and how they can take action to change their moods.
214449354|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
215131259|NCT06322849|BEHAVIORAL|Testimonials and Saying is believing exercises|Testimonials and Saying is believing exercises is a potential active element of Project ABC. In this element, participants learn about how others have taken action to improve their mood and complete one exercise where they give advice to a virtual peer who is stuck in a negative spiral.
215131260|NCT06322849|BEHAVIORAL|Action planning|Action planning is a potential active element of Project ABC. In this element, participants plan in detail an action they can take to get out of the negative mood spiral.
215131261|NCT06322849|BEHAVIORAL|Breathing exercise|Participants will be presented with a one-minute breathing exercise.
215131262|NCT04714606|OTHER|Sibling support group|The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.
215131263|NCT04714606|OTHER|None - control condition|The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
215131264|NCT04166422|OTHER|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
215131265|NCT04166422|OTHER|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
215131266|NCT04595968|DEVICE|Vestal DM Active device|Battery powered non-invasive neurostimulation device
215131267|NCT04595968|BEHAVIORAL|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
215131268|NCT04595968|DEVICE|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
215131269|NCT04992312|DRUG|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
214449355|NCT06378359|OTHER|Screening and decolonization for SA carriers with the 3 drug bundle|nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse and CHG soap showers x 5 days and non-SA carriers receive 2 CHG pre-op showers
214449356|NCT06378359|OTHER|No screening for SA|All receive the 3 drug bundle, Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash
214449357|NCT06378359|OTHER|no screening|giving pre-surgical patients the three drug decolonization bundle without screening
214449358|NCT06378359|OTHER|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
215131270|NCT03238716|OTHER|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
215131271|NCT03238716|OTHER|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
215131272|NCT03238716|OTHER|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
215131273|NCT06220214|DIAGNOSTIC_TEST|CEDM|Contrast Enhanced Digital Mammography
215131274|NCT06220214|DIAGNOSTIC_TEST|CEDBT|Contrast-Enhanced Digital Breast Tomosynthesis
215131275|NCT06220214|DRUG|Omnipaque 350mgI/mL Solution for Injection|Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
214449359|NCT06378359|OTHER|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
214449360|NCT04652830|BEHAVIORAL|Naprapathy training|Active training aimed at strengthening the abdominal muscles
214449361|NCT04652830|OTHER|Control group|No change of daily routines in regard to training
214449362|NCT03730922|PROCEDURE|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
214449363|NCT03730922|PROCEDURE|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
214449364|NCT06308874|DRUG|Amg dose administration group|Orally, Amg tablet single administration
214449365|NCT06308874|DRUG|Amg dose administration group- Placebo|Orally, Placebo Amg tablet single administration
214449366|NCT06308874|DRUG|Bmg dose administration group|Orally, Bmg tablet single administration
215131276|NCT02348177|DRUG|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
215131277|NCT02348177|DRUG|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
215131278|NCT02592031|DRUG|XM17|300 IU corresponds to an injection volume of 0.5 mL.
215131279|NCT02592031|DRUG|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
215131280|NCT02592031|DRUG|Zoladex®|3.6 mg
215131281|NCT05941702|BEHAVIORAL|Body Signal Integration Training|Information and protocol uploaded to documents.
215131282|NCT05782868|OTHER|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
214449367|NCT06308874|DRUG|Bmg dose administration group- Placebo|Orally, Placebo Bmg tablet single administration
214449368|NCT05192174|BIOLOGICAL|NIB101|NIB101
214449369|NCT02900924|DEVICE|BioMimics 3D Stent|
214449370|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
214449371|NCT02342782|DRUG|Carmustine|Given IV
214449372|NCT02342782|DRUG|Etoposide|Given IV
214449373|NCT02342782|DRUG|Cytarabine|Given IV
214525273|NCT01050699|DRUG|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
214449374|NCT02342782|DRUG|Melphalan|Given IV
214449375|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
214449376|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
214449377|NCT02342782|OTHER|Pharmacological Study|Correlative studies
214449378|NCT03531463|PROCEDURE|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
215131283|NCT05782868|OTHER|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
215131284|NCT05782868|OTHER|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
215131285|NCT02412306|DRUG|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
214449379|NCT06018987|OTHER|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
215131286|NCT05387083|DRUG|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
215131287|NCT05387083|DRUG|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
214449380|NCT06018987|DEVICE|HAC 20L|Subdermal Injections
214449381|NCT05081596|BEHAVIORAL|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
214449382|NCT02328872|DEVICE|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
214449383|NCT02328872|DEVICE|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
214449384|NCT04950192|DEVICE|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
214449385|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
214449386|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
214449387|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
214525274|NCT01050699|DRUG|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
214525275|NCT02701595|DRUG|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)
214525276|NCT02701595|PROCEDURE|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
215131288|NCT05387083|DRUG|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
215131289|NCT05845385|PROCEDURE|lumbar epidural analgesia with bupivacaine|postoperative analgesic method
215131290|NCT05845385|PROCEDURE|transversus abdominis plane block with bupivacaine|postoperative analgesic method
215131291|NCT05845385|PROCEDURE|wound infiltration with bupivacaine|postoperative analgesic method
215131292|NCT05708196|OTHER|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
215131293|NCT05708196|OTHER|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
215131294|NCT05562128|BEHAVIORAL|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
215131295|NCT05562128|BEHAVIORAL|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
215131296|NCT06345716|DRUG|paracétamol tramadol|Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
215131297|NCT06345716|DRUG|Paracétamol cafeine|Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
215131298|NCT06345716|DRUG|Placebo|Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
215131299|NCT05989126|DRUG|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
215131300|NCT04709068|DEVICE|Current Health|wearable device and tablet used to collect health measures at home
215131301|NCT06314217|DEVICE|Everads Injector|Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector
215131302|NCT03392896|DRUG|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
215131303|NCT03392896|DRUG|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
215131304|NCT04019379|OTHER|High Phosphorus Diet|Controlled research diet of high phosphorus (with low calcium)
215131305|NCT04019379|OTHER|Low Phosphorus Diet|Controlled research diet of low phosphorus (with low calcium)
215131306|NCT04002141|DRUG|Placebo oral tablet|1 tablet oral daily
215131307|NCT04002141|DRUG|Letrozole|5mg oral daily
215131308|NCT04672590|OTHER|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
215131309|NCT04530981|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
215131310|NCT04530981|DRUG|Repaglinide|Oral antihyperglycemic agent
215131311|NCT01489319|DRUG|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
215131312|NCT01489319|DRUG|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
215131313|NCT05871541|BIOLOGICAL|JCXH-105|As IM injection
214449388|NCT04705441|BEHAVIORAL|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
214449389|NCT06798142|PROCEDURE|extracorporeal treatment|Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).
214449390|NCT01086527|DRUG|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
214449391|NCT06170385|BEHAVIORAL|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
214449392|NCT06052150|PROCEDURE|Dental exam and periodontal cleaning if needed|Dental exam and periodontal cleaning if needed
214449393|NCT05549037|DRUG|Pembrolizumab, Sintilimab|One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
214449394|NCT06798493|OTHER|Complex Regional Pain Syndrome (CRPS) Severity Score - Self Report|Self-report tool in a questionnaire format to capture CPRS Severity Score.
214449395|NCT06799507|BEHAVIORAL|Interventions Based on Mindfulness|Affirmation, Relaxation, Mindfulness, Meditation, Healthy Lifestyle, Quality Life
214449396|NCT06799507|OTHER|Routine clinical procedure|Routine clinical procedure
214525277|NCT02765347|DRUG|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
214525278|NCT02765347|DRUG|Insulin|For arm 2, just accept insulin for 24 weeks
214525279|NCT06207747|DIAGNOSTIC_TEST|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
214525280|NCT01446042|DRUG|Testosterone|Intranasal testosterone
214525281|NCT01446042|DRUG|Testosterone|Intranasal testosterone
214525282|NCT03906240|BEHAVIORAL|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
214525283|NCT00720629|DRUG|Visilizumab|3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
214525284|NCT00720629|DRUG|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
215131314|NCT05871541|BIOLOGICAL|Active Control (Shingrix)|As IM injection
215131315|NCT05627271|OTHER|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
215131316|NCT05627271|OTHER|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
215131317|NCT05627271|OTHER|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
215131318|NCT01290458|DIETARY_SUPPLEMENT|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
215131319|NCT05626101|DRUG|BCG|Intravsical induction and maintenance BCG injections.
215131320|NCT05626101|DRUG|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
215131321|NCT02325596|GENETIC|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
214525285|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
214525286|NCT00720629|DRUG|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
214525287|NCT00720629|DRUG|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
215131322|NCT04489316|OTHER|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
215131323|NCT01706458|BIOLOGICAL|sipuleucel-T|Given IV
215131324|NCT01706458|BIOLOGICAL|DNA Vaccine|Given ID
215131325|NCT04006418|OTHER||
215131326|NCT00111046|DRUG|Ibuprofen|
215131327|NCT00111046|DRUG|Tramadol|
215131328|NCT01028443|DRUG|Sandimmune|
215131329|NCT01028443|DRUG|Artelose|
215131330|NCT03228446|BEHAVIORAL|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
215131331|NCT03228446|BEHAVIORAL|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
215131332|NCT03228446|OTHER|no training (control)|no training applied
215131333|NCT03101969|OTHER|Call|not called, not reached, and spoken to
215131334|NCT00702481|DRUG|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
215131335|NCT00702481|DRUG|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
215131336|NCT00702481|RADIATION|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
215131337|NCT01533792|PROCEDURE|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
215131338|NCT01533792|PROCEDURE|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
215131339|NCT04228588|DRUG|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
215131340|NCT04457739|OTHER|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
214449397|NCT06163157|OTHER|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
214449398|NCT03972813|BEHAVIORAL|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
214449399|NCT03972813|BEHAVIORAL|Information about STDs|Caregivers learn that HPV is an STD.
214449400|NCT03972813|BEHAVIORAL|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
214449401|NCT03972813|BEHAVIORAL|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
214449402|NCT03972813|BEHAVIORAL|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
214449403|NCT03972813|BEHAVIORAL|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
214449404|NCT03972813|BEHAVIORAL|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
214449405|NCT03972813|BEHAVIORAL|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
214449406|NCT03836417|DIAGNOSTIC_TEST|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
214449407|NCT05470894|BIOLOGICAL|Approved COVID-19 vaccine|Vaccination for COVI9-19
214449408|NCT06796400|OTHER|General exercises|4 general exercises were done by control group with 10 repetitions and 3 sets, 6 times per week, up to 8 weeks.These exercises are for lower trapzius and serratus anterior mucles strengthing.
214449409|NCT06796400|OTHER|Theraband exerises|5 Thera-band exercises were completed by experimental group with 3 sets and 10 repetitions, 6 times per week, up to 8 weeks. These exercises are for lower trapzius and serratus anterior mucles strengthing.
214449410|NCT05356117|BEHAVIORAL|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
214449411|NCT05356117|BEHAVIORAL|Resistance Training (RT)|Aerobic and resistance exercise
214449412|NCT05356117|BEHAVIORAL|Attention Control (AC|Stretching
215131341|NCT04457739|OTHER|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
215131342|NCT04457739|OTHER|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
215131343|NCT06050265|DEVICE|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
215131344|NCT02956395|OTHER|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
215131345|NCT03359629|DEVICE|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
214525288|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
215131346|NCT03359629|DEVICE|YSI 2300 Stat Plus|Reference commercial glucometer
215131347|NCT05563103|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
215131348|NCT05563103|OTHER|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
215131349|NCT05563103|OTHER|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
214525289|NCT02724423|DRUG|NRL-1|
214694628|NCT06422494|DRUG|hyperinsulinaemic hypoglycaemic clamp|Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
215131350|NCT05563103|OTHER|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
214525290|NCT05624229|DRUG|Proton Pump Inhibitors|PPI infusion continued to use for 5 days in experimental group
214525291|NCT05624229|DRUG|No Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy.
214525292|NCT00730392|DRUG|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
215131351|NCT05820412|OTHER|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
215131352|NCT05131945|OTHER|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
215131353|NCT05131945|OTHER|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
215131354|NCT04310540|PROCEDURE|Biopsy|Undergo biopsy
214449413|NCT05046314|BIOLOGICAL|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
214449414|NCT06798558|DRUG|Lu-17-PSMA-617|Lu-17-PSMA-617 administration
214525293|NCT00730392|DRUG|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
215131355|NCT04310540|PROCEDURE|Computed Tomography|Undergo CT
215131356|NCT04310540|DRUG|Gallium Ga 68 Gozetotide|Given IV
215131357|NCT04310540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215131358|NCT04310540|PROCEDURE|Positron Emission Tomography|Undergo PET
214449415|NCT06638606|BEHAVIORAL|Sleep improvement techniques|Insomniac and hypersomniac individuals are given behavioral counselling to improve sleep.
214449416|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
214449417|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
214449418|NCT05966714|DEVICE|aEEG|amplitude-integrated electroencephalography
214449419|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
214525294|NCT03152409|DRUG|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
214525295|NCT03152409|DRUG|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
215131359|NCT00072462|DRUG|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
215131360|NCT00072462|DRUG|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
215131361|NCT04984031|DIAGNOSTIC_TEST|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
215131362|NCT04349891|DEVICE|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
215131363|NCT04349891|DEVICE|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
214449420|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
214449421|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
214449422|NCT06639269|OTHER|fertility health education program|"The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes."
214449423|NCT05737095|PROCEDURE|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
214449424|NCT05984784|DRUG|Placebo|Drug: Placebo Intravenous Infusion
214449425|NCT05984784|DRUG|IMG-007|Drug: IMG-007 Intravenous Infusion
214449426|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
214449427|NCT02365766|DRUG|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
214449428|NCT02365766|DRUG|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
214449429|NCT02365766|DRUG|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
214449430|NCT02365766|PROCEDURE|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
214449431|NCT06582953|BEHAVIORAL|Turning the Tide Violence Intervention Program (hospital violence intervention program)|TTVIP is already integrated into the regular care of patients who are violently injured and treated at MUSC Charleston. Client advocates provide immediate support, help with communication and provide anti-retaliation messaging to victims of violence and their families, in addition to helping support their healthcare. Patients that opt to be followed for long-term wrap-around services and live in the surrounding 3-county area are supported for months (up to 1 year) after injury and provided mentorship, service referrals (i.e. education, employment, substance abuse, injury recovery, pro-social activities, housing) and mental health services.
214449432|NCT06637319|DEVICE|Ultrasound|Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
214525296|NCT05085015|OTHER|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
214525297|NCT05085015|OTHER|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
214525298|NCT04737499|BEHAVIORAL|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
214525299|NCT04503889|DEVICE|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
214525300|NCT04503889|DEVICE|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
214525301|NCT01532024|OTHER|Microdose of NAP|Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
214694629|NCT06422494|DRUG|Propranolol Hydrochloride 1 MG/ML|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
214694630|NCT06422494|DRUG|Phentolamine|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
215131364|NCT03679247|OTHER|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
215131365|NCT03679247|OTHER|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
215131366|NCT03800095|DRUG|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
215131367|NCT02927301|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
215131368|NCT03028766|DRUG|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
215131369|NCT03028766|DRUG|Cisplatin|Chemotherapy drug
215131370|NCT03028766|RADIATION|Radiotherapy|Intensity Modulated Radiotherapy
215131371|NCT05884307|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
214449433|NCT06121596|BEHAVIORAL|Breathing Exercise|A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
214449434|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
214449435|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
214449436|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
214449437|NCT05652569|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
214449438|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
214449439|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
214449440|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
214449441|NCT03763708|DEVICE|Spinal Cord Stimulation|Programming
214449442|NCT03610815|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
214694631|NCT04431661|PROCEDURE|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
215131372|NCT06526260|BEHAVIORAL|Very Brief Exposure to Facial Expressions|In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
214449443|NCT06452446|DRUG|Selinexor|Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
214449444|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
214449445|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
214449446|NCT06641271|DEVICE|Closed Loop Trans-Auricular Vagus Nerve Stimulation System|A closed loop system that delivers stimulation to the vagus nerve via the ear non-invasively following a trigger event.
214449447|NCT06641271|DEVICE|Placebo|A closed-loop vagus nerve stimulation device that can deliver sham stimulation to the ear to simulate stimulation of the vagus nerve.
215131373|NCT04534244|DEVICE|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
215131374|NCT05796557|BIOLOGICAL|Platelet Transfusion|Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
215131375|NCT06047093|PROCEDURE|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
215131376|NCT06047093|BIOLOGICAL|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
214449448|NCT06638411|BEHAVIORAL|ADHD information workshop|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
214449449|NCT06638411|BEHAVIORAL|ADHD information workshop with nocebo education|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
214449450|NCT06638411|BEHAVIORAL|Sleep workshop|An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
214449451|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
214449452|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
214449453|NCT04895995|BEHAVIORAL|Daylight dCBT Application|Participants will complete up to four modules of digital intervention delivered in a self-paced format.
214449454|NCT06281418|DRUG|Granisetron 1 Mg/mL Intravenous Solution|2mL intraperitoneal adminstration of granisetron (1 mg/mL)
214449455|NCT06281418|OTHER|Normal saline|2 ml IP normal saline (0.9% NaCl)
214525302|NCT00764855|PROCEDURE|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
214449456|NCT06354049|OTHER|Reiki|Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
214449457|NCT04233021|DRUG|Osimertinib|Osimertinib 80 mg/d
214449458|NCT06584539|BEHAVIORAL|Eco-Labels|"Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY."
214449459|NCT05470400|BIOLOGICAL|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214449460|NCT05470400|BIOLOGICAL|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214449461|NCT05470400|BIOLOGICAL|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214449462|NCT05470400|BIOLOGICAL|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214449463|NCT05470400|BIOLOGICAL|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214525303|NCT06645990|DEVICE|Impella|LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
214525304|NCT06645990|DEVICE|IABP|LV unloading with IABP before or within 24 h of ECMO initiation
215131377|NCT06047093|OTHER|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and after the FNA has been performed.
214525305|NCT06647355|OTHER|Effectiveness of physical exercise in preventing pain and improving plantar pressure distribution|At the beginning of the study, the participants underwent a baropodometric and photometric analysis. At the same time, anthropometric data and self-assessed body pain data were collected. For 12 continuous weeks, the participants completed a training programme that included specific exercises designed for each group. At the end, the baropodometry images were analysed again, which led to the final conclusion of the study.
214525306|NCT01979757|OTHER|Puregraft|
214525307|NCT01979757|OTHER|Centrifugation|
215131378|NCT04179097|DIAGNOSTIC_TEST|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
214449464|NCT05470400|BIOLOGICAL|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
214449465|NCT05896254|DRUG|MAR001|Subcutaneous injection
214449466|NCT05896254|DRUG|Placebo|Subcutaneous injection
214449467|NCT06561152|DRUG|Tagraxofusp|Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)
214449468|NCT06561152|DRUG|Cladribine (CLAD)|Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)
215131379|NCT06553092|OTHER|Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey|The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
215131380|NCT05740254|BEHAVIORAL|Early Time Restricted Eating|Early Time Restricted Eating 7 AM to 3 PM
215131381|NCT05740254|BEHAVIORAL|Late Time Restricted Eating|Late Time Restricted Eating 12 PM to 8 PM
215131382|NCT04851691|BEHAVIORAL|EHR CDS|"When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation."
215131383|NCT04851691|OTHER|Usual Care|Patients will receive usual care from their physicians.
215131384|NCT05702463|DRUG|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
215131385|NCT05702463|DRUG|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
215131386|NCT05702463|DRUG|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
215131387|NCT05901298|DEVICE|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
214449469|NCT06561152|DRUG|Cytarabine|Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
214449470|NCT06563167|DIAGNOSTIC_TEST|CXR|CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
214525308|NCT06646393|OTHER|Skin to skin contact|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
215131388|NCT04055220|DRUG|Treatment by Regorafenib|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
215131389|NCT04055220|DRUG|Treatment by Placebo|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
215131390|NCT05642741|OTHER|Response to medical and research questionnaires|Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
215131391|NCT04247347|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
215131392|NCT04247347|OTHER|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
215131393|NCT04247347|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
215131394|NCT05413590|OTHER|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
214449471|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
214449472|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
214449473|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
214449474|NCT05956002|DRUG|Estraimod Immediate Release (IR)|an immediate release tablet
214449475|NCT05956002|DRUG|Etrasimod Mini Tab in water|very small tablet mixed in water
214449476|NCT05956002|DRUG|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
214449477|NCT05956002|DRUG|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
214449478|NCT05956002|DRUG|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
214449479|NCT04933136|DEVICE|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
214449480|NCT02983760|DEVICE|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
214449481|NCT02983760|DEVICE|CTPA-based strategy|Strategy based on pulmonary angiography
215131395|NCT05413590|OTHER|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
214449482|NCT02983760|DEVICE|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
214449483|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
214449484|NCT05974046|DRUG|[14C]IDV184001AN|\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
214449485|NCT02561923|DRUG|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
214449486|NCT02561923|DRUG|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
214694632|NCT04431661|PROCEDURE|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
214449487|NCT02561923|DRUG|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
214449488|NCT02561923|DRUG|Saline|Saline \[Kcentra saline control or TXA saline control\] on Day 4.
214449489|NCT06024239|DRUG|ABBV-932|Capsule; oral
214449490|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
214449491|NCT06756425|BEHAVIORAL|aerobic exercise program|aerobic exercise program for 3 months with nutritional health awearness sessions
214449492|NCT06756425|BEHAVIORAL|nutritional health awareness sessions|lifestyle changes and nutritional awareness sessions for 3 months twice a week for participants and their parents
214449493|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
214449494|NCT06436703|BIOLOGICAL|Influenza ModRNA Vaccine|Intramuscular injection
214449495|NCT06436703|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|Intramuscular injection
214449496|NCT01220583|DRUG|cisplatin|Given IV
214449497|NCT01220583|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
214449498|NCT01220583|RADIATION|intensity-modulated radiation therapy|Undergo radiotherapy
215131396|NCT05413590|OTHER|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
215131397|NCT03066206|DRUG|Poziotinib|Given PO
214449499|NCT04270474|OTHER|Deprescribing of target anticholinergics|The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
214449500|NCT04270474|OTHER|Usual Care|Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
214525309|NCT04842227|PROCEDURE|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
215131398|NCT03562195|DRUG|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
215131399|NCT03562195|DRUG|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
215131400|NCT03562195|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
215131401|NCT05641545|BIOLOGICAL|IVAC|IVAC is a personalized peptide vaccine
214525310|NCT04167150|DIETARY_SUPPLEMENT|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
214525311|NCT00210288|BIOLOGICAL|SC599|
214525312|NCT05834972|DEVICE|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
214525313|NCT04837235|DRUG|Hemay005|oral
214525314|NCT06646744|BIOLOGICAL|mRNA COVID-19 vaccine|Children will be vaccinated according to standard local procedure
214525315|NCT04818918|DEVICE|Absolute coronary flow measurement|Absolute coronary flow will be measured.
214525316|NCT04818918|DEVICE|Microvascular resistance measurement|Microvascular resistance will be measured.
214525317|NCT04818918|OTHER|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
215131402|NCT03949569|BEHAVIORAL|Therapy Dog|Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
215131403|NCT03949569|BEHAVIORAL|Stuffed Toy Dog|Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
215131404|NCT03949569|BEHAVIORAL|5 Minute Puppy Video|Children will watch a 5 minute puppy video.
214525318|NCT06645730|DIAGNOSTIC_TEST|hypertension|diagnosed with hypertension
214525319|NCT06645730|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
214525320|NCT06645730|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver on CT
214525321|NCT06645548|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
215131405|NCT02730858|BEHAVIORAL|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
214449501|NCT04369976|DEVICE|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
214449502|NCT04808843|DRUG|Dienogest (BAY86-5258, Visanne)|Following the physicians' decision.
214449503|NCT04740671|DRUG|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
214449504|NCT04740671|DRUG|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
214449505|NCT05222945|OTHER|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
214449506|NCT02991534|BEHAVIORAL|CV Toolkit Components|"* Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
214449507|NCT01767311|DRUG|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
214449508|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
214449509|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
214525322|NCT00194961|DRUG|Recombinant Human Growth Hormone|
214525323|NCT05148247|BEHAVIORAL|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
214525324|NCT05823051|OTHER|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
215131406|NCT02730858|BEHAVIORAL|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
215131407|NCT06247813|DIETARY_SUPPLEMENT|Inflammation Support Formula|Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).
215131408|NCT06247813|DIETARY_SUPPLEMENT|Nerve Health Formula|Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).
215131409|NCT06247813|DIETARY_SUPPLEMENT|Redox Support Formula|N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).
215131410|NCT05355571|DIETARY_SUPPLEMENT|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
215131411|NCT05355571|DIETARY_SUPPLEMENT|Placebo|Placebo
215131412|NCT05682170|DRUG|ZN-d5 ZN-c3|Oral agent
215131413|NCT05682170|DRUG|ZN-c3|Oral agent
214449510|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
214449511|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
214449512|NCT01767311|DRUG|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
214449513|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
215131414|NCT06068309|OTHER|CareAide App Usage|The study participant uses the CareAide app in addition to prescribed usual therapeutic care
215131415|NCT06639594|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
215131416|NCT02529852|DRUG|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
215131417|NCT02529852|DRUG|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
215131418|NCT02529852|DRUG|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
215131419|NCT02529852|DRUG|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
215131420|NCT02529852|DRUG|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
215131421|NCT02529852|DRUG|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
215131422|NCT04087018|DRUG|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
214449514|NCT04647422|BEHAVIORAL|Analysis of executive functioning and of social cognition processes|"Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes"
214449515|NCT02307565|DRUG|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
214449516|NCT02307565|DRUG|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
214449517|NCT04516278|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
214449518|NCT05688293|PROCEDURE|Connective tissue graft|non-surgical periodontal treatment and connective tissue graft
214449519|NCT05688293|PROCEDURE|Free gingival graft|will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
214449520|NCT05688293|PROCEDURE|Non surgical|non-surgical periodontal treatment only
214449521|NCT05350475|RADIATION|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
214449522|NCT05350475|RADIATION|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
214449523|NCT05574309|DEVICE|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
214449524|NCT05574309|DEVICE|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
214449525|NCT05205928|DRUG|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
214449526|NCT05281406|DRUG|Osimertinib|80 mg daily or reduced dose 40 mg daily
214525325|NCT01385683|DRUG|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
215131423|NCT06585046|PROCEDURE|pancreatic surgery|patients who did pancreas-related surgery
215131424|NCT06408870|DRUG|BI 1015550|BI 1015550
215131425|NCT03839524|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
215131426|NCT03354013|PROCEDURE|AOA|100% ICSI-AOA will be performed.
215131427|NCT03354013|DIAGNOSTIC_TEST|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
215131428|NCT03354013|DIAGNOSTIC_TEST|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
215131429|NCT06235515|OTHER|rehabilitation program|conventional treatment (hotpack and TENS and exercise)
215131430|NCT06235515|OTHER|virtual reality|virtual reality treatment
214449527|NCT05281406|DRUG|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
214449528|NCT05281406|DRUG|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
215131431|NCT04584424|OTHER|The study does not required|The study is prospective multi-center COVID-19 patient cohort
215131432|NCT05512403|DRUG|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction"
215131433|NCT04885569|BEHAVIORAL|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
215131434|NCT04885569|BEHAVIORAL|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
214449529|NCT05281406|DRUG|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
214525326|NCT01385683|DRUG|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
215131435|NCT04885569|BEHAVIORAL|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
215131436|NCT06361563|DRUG|Nivolumab|As per product label
214449530|NCT05767281|BEHAVIORAL|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
214449531|NCT05633472|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
214449532|NCT05633472|OTHER|Placebo|Placebo
214449533|NCT06407050|BEHAVIORAL|4 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
214449534|NCT06407050|BEHAVIORAL|8 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
214449535|NCT06407050|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
214449536|NCT04829604|DRUG|ARX788|The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
214449537|NCT04080180|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
214449538|NCT04080180|BEHAVIORAL|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
214449539|NCT05440734|DRUG|Melatonin|2 Mg Oral Tablet, slow release
214449540|NCT05440734|DRUG|Placebo|placebo pill identical to the treatment pill
214694633|NCT04431661|PROCEDURE|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
214694634|NCT03223857|PROCEDURE|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
215131437|NCT03422835|PROCEDURE|R-TME|Conventional Robotic Total Mesentery Excision
215131438|NCT03422835|PROCEDURE|R-TaTME|Robotic Transanal Total Mesentery Excision
215131439|NCT05125159|PROCEDURE|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
215131440|NCT04179552|DEVICE|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
215131441|NCT02284204|DRUG|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
215131442|NCT02284204|DRUG|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
215131443|NCT02102789|DRUG|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
215131444|NCT02102789|DRUG|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
215131445|NCT05772819|DIAGNOSTIC_TEST|exercise MRI|All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
215131446|NCT02253615|OTHER|Machines exercises|Resistance training in pneumatic machines.
215131447|NCT02253615|OTHER|Elastic exercises|Resistance training with elastic tubes.
215131448|NCT05259345|PROCEDURE|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
214449541|NCT02663219|BEHAVIORAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
215131449|NCT05259345|PROCEDURE|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
215131450|NCT05259345|PROCEDURE|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
215131451|NCT00003663|BIOLOGICAL|rituximab|
214449542|NCT02807805|DRUG|Abiraterone Acetate|Given PO
214449543|NCT02807805|DRUG|Niclosamide|Given PO
214449544|NCT02807805|DRUG|Prednisone|Given PO
214449545|NCT06541639|BIOLOGICAL|EVM16|cancer vaccine
214449546|NCT06541639|DRUG|Tislelizumab|Anti-PD1 antibody
214449547|NCT04954781|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214449548|NCT04954781|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
214525327|NCT02899481|OTHER|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
215131452|NCT00003663|DRUG|dexamethasone|
214449549|NCT06191666|BEHAVIORAL|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
214449550|NCT06191666|BEHAVIORAL|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
214449551|NCT06191666|BEHAVIORAL|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
214449552|NCT06191666|BEHAVIORAL|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
214449553|NCT02589275|DRUG|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
214525328|NCT00176761|DRUG|Interleukin-2 (IL-2)|
214525329|NCT02536729|DRUG|Oral Sodium Phosphate - Normal preparation|
214525330|NCT02536729|DRUG|Oral sodium phosphate - Modified Preparation|
214449554|NCT05337215|BEHAVIORAL|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
214449555|NCT05264714|DRUG|Rimegepant|150 mg oral disintegrating tablet every other day for one week
214525331|NCT02536729|DRUG|polyethylene glycol + Electrolytes|
215131453|NCT06305286|DRUG|AT-1501|AT-1501 is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40.
215131454|NCT01784731|BEHAVIORAL|Willingness to pay|
215131455|NCT00938158|BIOLOGICAL|albiglutide|single dose of subcutaneously injected albiglutide
215131456|NCT03222700|PROCEDURE|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
215131457|NCT04854018|DRUG|Indocyanine green|Intravenous or intraparenchymal injection
215131458|NCT05870514|DRUG|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
215131459|NCT05870514|DRUG|Propofol|Propofol
215131460|NCT04289181|OTHER|Medically Tailored Meals|4 weeks of medically tailored meals
215131461|NCT03564288|DRUG|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
215131462|NCT04694235|DIETARY_SUPPLEMENT|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
215131463|NCT04733326|DRUG|Ketorolac Tromethamine|final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
215131464|NCT04733326|OTHER|Cryotherapy|final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
214449556|NCT02051218|DRUG|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
214449557|NCT02051218|DRUG|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
214449558|NCT05776056|DRUG|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
214449559|NCT05776056|DRUG|Placebo|An inactive pill (placebo) will be taken twice daily.
214449560|NCT03241082|DEVICE|ultrasound|validation of portable ultrasound to measure body composition
214449561|NCT04401800|DRUG|Lenvatinib|Capsules administered orally once daily
214449562|NCT04401800|DRUG|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
214449563|NCT05778266|DIETARY_SUPPLEMENT|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
214449564|NCT05778266|DIETARY_SUPPLEMENT|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
214449565|NCT05778266|OTHER|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
214449566|NCT06177873|OTHER|foot bath|On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
214449567|NCT06118749|DIAGNOSTIC_TEST|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
214449568|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
214449569|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
215131465|NCT04733326|OTHER|Saline|final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
215131466|NCT02222935|BEHAVIORAL|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
215131467|NCT02222935|BEHAVIORAL|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
215131468|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
214449570|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
214449571|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
214449572|NCT04115371|BEHAVIORAL|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
214449573|NCT05334732|BEHAVIORAL|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
214449574|NCT05868772|DEVICE|Active Sentry Handpiece|With low IOP settings
214449575|NCT05868772|DEVICE|Ozil Handpiece|With high IOP settings.
214449576|NCT05336721|DRUG|Chiauranib|25mg/35mg/50mg orally once daily
214449577|NCT05336721|DRUG|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
214449578|NCT03574103|BEHAVIORAL|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
214449579|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
214449580|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
214449581|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
214449582|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
214449583|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
214449584|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
215131469|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
215131470|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
214449585|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
214449586|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
214449587|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
214449588|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
214449589|NCT04804072|OTHER|Primary care|Primary care
214449590|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
214449591|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
214449592|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
214449593|NCT04392401|BIOLOGICAL|Collection of blood samples in order to create a biocollection|Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
214449594|NCT05102591|DRUG|Ketorolac|Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
214449595|NCT05102591|DRUG|Metoclopramide|Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
214449596|NCT05102591|DEVICE|Active Remote Electrical Neuromodulation Device|The REN device is a battery-powered, wirelessly controlled neuromodulation device that attaches via armband to the upper arm. The REN device is controlled by a smartphone application and administers electrical stimulation to the local C and Aδ nociceptive sensory nerves of the upper arm. This stimulation is achieved using a symmetrical, biphasic, square pulse, modulated at a frequency between 100-120 Hz. Each pulse has a width of 400 µs and the user, via the smartphone application, can adjust the output current to apply a maximum of 40 mA. Each stimulation session occurs over 45 minutes and each device can administer up to 12 stimulation sessions.
214449597|NCT05102591|DRUG|Placebo|0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
214449598|NCT05102591|DEVICE|Sham Remote Electrical Neuromodulation Device|The sham REN device is identical to the active REN device but the stimulation parameters are different, administering a modulated symmetrical biphasic square electrical pulse, modulated frequency of \~0.083 Hz and a modulated pulse width of 40-550 µ. These sham parameters are designed to induce a sensation that will be perceptible to participants, similar to stimulation from the active REN device, but at a frequency that is low enough so as to not modulate the nociceptive sensory nerves.
214449599|NCT05455723|PROCEDURE|Inflation-deflation technique|Inflation-Deflation Technique: The tracheal tube cuff will be inflated with 15-20 ml of air (volume of air is depending on the level of larynx). Once the tip of ETT at the laryngeal inlet, the cuff of ETT will be deflated and advanced into the trachea.
214449600|NCT05455723|PROCEDURE|Magill forceps technique|The Magill forceps to guide the ETT tip to pass through the pharynx and glottis into the trachea.
214449601|NCT05202678|DEVICE|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
214449602|NCT06503809|BEHAVIORAL|Ketogenic Diet|Participants will consume a very-low-carbohydrate ketogenic diet for 12 weeks.
214449603|NCT06503809|BEHAVIORAL|Standard Diet|Participants will consume an American Diabetes Association-recommended standard diet for 12 weeks.
214449604|NCT06105788|OTHER|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
214449605|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
214525332|NCT03684434|BEHAVIORAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
215131471|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
215131472|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
215131473|NCT06207786|OTHER|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
215131474|NCT06207786|DIAGNOSTIC_TEST|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
215131475|NCT06207786|DRUG|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
214449606|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
214449607|NCT05629845|PROCEDURE|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
214449608|NCT05629845|PROCEDURE|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
214449609|NCT04768569|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
214449610|NCT04768569|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
214449611|NCT04554953|DRUG|Combination drug containing fimasartan and statins|"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
214449612|NCT02281955|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
214449613|NCT02281955|DRUG|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
214449614|NCT02281955|PROCEDURE|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
214525333|NCT03684434|BEHAVIORAL|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
214525334|NCT02501616|DRUG|Metformin|
215131476|NCT02655328|OTHER|blood sample|blood sample
215131477|NCT02655328|OTHER|urine sample|urine sample
215131478|NCT03296514|BEHAVIORAL|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
215131479|NCT04721678|BEHAVIORAL|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
215131480|NCT05003466|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|"2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose.~Administer as an intramuscular injection into the lateral deltoid of the upper arm."
215131481|NCT05003466|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
214525335|NCT02501616|DRUG|Dapagliflozin|
214525336|NCT02137928|DRUG|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
215131482|NCT01968486|DRUG|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
215131483|NCT01968486|DRUG|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
215131484|NCT01968486|DRUG|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
215131485|NCT00800566|DRUG|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
215131486|NCT04550858|DRUG|Rebamipide|rebamipide use for ttt of h.pylori infection
215131487|NCT00973726|OTHER|Glucose test|Subjects ingest an oral glucose tolerance test.
215131488|NCT03282461|DRUG|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
215131489|NCT05971316|DEVICE|Foam Roller|General Warm-up + Foam Roller
215131490|NCT04401735|DRUG|Polydeoxyribonucleotides|PDRN injection to epidural space
215131491|NCT04401735|DRUG|Normal saline|Normal saline
215131492|NCT02926872|OTHER|There is no intervention in the study|
215131493|NCT01360671|DRUG|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
215131494|NCT03979898|BIOLOGICAL|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10\^7cells/5mL 15kg \~ 25kg : 1x10\^8cells/10mL 25kg over : 1.5x10\^8cells/15mL
214449615|NCT06118775|PROCEDURE|EaDyn Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.
214449616|NCT06118775|PROCEDURE|PAM Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
214449617|NCT02958462|PROCEDURE|Biospecimen Collection|Undergo blood sample, hair follicle, and saliva collection
214449618|NCT02958462|PROCEDURE|Bone Marrow Biopsy|Undergo a bone marrow biopsy
214449619|NCT02958462|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
214525337|NCT02137928|DRUG|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
215131495|NCT02646826|OTHER|Placebo|Subjects are treated with Placebo tablets
215131496|NCT02646826|DRUG|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
215131497|NCT02646826|DRUG|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
215131498|NCT02646826|DRUG|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
215131499|NCT05106881|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
215131500|NCT01752426|OTHER|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
214449620|NCT02958462|PROCEDURE|Buccal Swab|Undergo a saliva or buccal swab
214449621|NCT02958462|OTHER|Clinical Evaluation|Undergo clinical assessment
214449622|NCT02958462|OTHER|Genetic Counseling|Receive genetic counseling
214449623|NCT02958462|OTHER|Quality-of-Life Assessment|Ancillary studies
214449624|NCT02958462|OTHER|Electronic Health Record Review|Ancillary studies
214525338|NCT00296504|DRUG|fosamprenavir (GW433908)|
214525339|NCT00296504|DRUG|ritonavir|
214525340|NCT02815709|DRUG|Oliceridine|
214525341|NCT02815709|DRUG|Placebo|
214525342|NCT02815709|DRUG|Morphine|
214525343|NCT05033158|OTHER|Blood sampling|Blood sampling before and after COVID-19 vaccination
214449625|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
214449626|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
214449627|NCT05148702|DRUG|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
214449628|NCT05148702|DRUG|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
214449629|NCT04830410|DIETARY_SUPPLEMENT|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
214449630|NCT04830410|DIETARY_SUPPLEMENT|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
214449631|NCT05396625|BEHAVIORAL|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
214449632|NCT05396625|BEHAVIORAL|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention, SAFE Children, which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children, such as, separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community. Each session lasts about one to one and a half hours and delivered by facilitator and co-facilitator at the SOS Child and Family Center.
214449633|NCT05396625|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
214449634|NCT05396625|OTHER|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
214449635|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
214525344|NCT06032702|PROCEDURE|tooth alignment|Alignment will be assessed by Little's Irregularity Index
214525345|NCT02200016|PROCEDURE|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
214525346|NCT02200016|PROCEDURE|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
214525347|NCT02200016|DEVICE|B Braun Contiplex S catheter|
214525348|NCT01994135|OTHER|Reference food|Reference food will be used to which test food samples will be compared to.
214525349|NCT01994135|OTHER|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
215131501|NCT01752426|DRUG|PCI-32765|420 mg orally once daily.
215131502|NCT01081691|BIOLOGICAL|CNTO 5825|10 mg/kg single dose IV or matching placebo
215131503|NCT01081691|BIOLOGICAL|CNTO 5825|3 mg/kg single dose IV or matching placebo
215131504|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
215131505|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
215131506|NCT01081691|BIOLOGICAL|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
215131507|NCT01081691|BIOLOGICAL|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
215131508|NCT01081691|BIOLOGICAL|CNTO 5825|1 mg/kg single dose IV or matching placebo
215131509|NCT00941941|PROCEDURE|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
215131510|NCT00941941|PROCEDURE|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
215131511|NCT05853016|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
215131512|NCT03658122|BEHAVIORAL|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
215131513|NCT06401369|PROCEDURE|Lingual brackets|These brackets will be used on the lingual surfaces of the upper and lower teeth.
215131514|NCT06401369|PROCEDURE|Buccal brackets|These brackets will be used on the vestibular surfaces of the upper and lower teeth.
215131515|NCT03965975|DEVICE|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
215131516|NCT03965975|DEVICE|S-There|"Second intervention (assigned to the All participants arm)."
215131517|NCT04365972|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
215131518|NCT04681235|OTHER|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
215131519|NCT04480489|OTHER|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
215131520|NCT04480489|OTHER|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
215131521|NCT03282058|DEVICE|Silastic Stent|The silastic stent is a splint made of silicone.
215131522|NCT05239052|OTHER|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
215131523|NCT05239052|OTHER|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
215131524|NCT02269124|DEVICE|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
215131525|NCT03278314|DRUG|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
215131526|NCT00323323|DRUG|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
215131527|NCT00323323|DRUG|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
215131528|NCT00323323|PROCEDURE|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
215131529|NCT05594550|OTHER|Data collection|"Demographic data:~Age, Sex, weight, height, main history and treatments.~\- Biological data: CRP, PCT, albumin, pre-albumin"
215131530|NCT05594550|OTHER|analysis of thoracic scans|muscle area calculated on the T7 and T12 thoracic slices
215131531|NCT05814185|DEVICE|Periodontal distractor|different activation protocols of periodontal distractor
215131532|NCT04808115|DRUG|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
215131533|NCT03897959|DEVICE|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
215131534|NCT04900012|PROCEDURE|Distal pancreatectomy|We are going to collect all cases
215131535|NCT03776864|BIOLOGICAL|Pembrolizumab|Given IV
215131536|NCT03776864|DRUG|Umbralisib|Given PO
215131537|NCT06524609|DRUG|Epigallocatechin-3-Gallate|After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).
215131538|NCT06524609|DRUG|Alcohol|After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).
215131539|NCT04344808|DEVICE|Dynamic navigation system|The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
215131540|NCT04344808|DEVICE|Freehand implant placement|Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
215131541|NCT00192881|DEVICE|Bx Sonic & Cypher stent from Cordis|
215131542|NCT01950858|BIOLOGICAL|Weight reduction|
215131543|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
215131544|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
215131545|NCT03196908|OTHER|Placebo|Lime juice, water, and cherry flavoring
215131546|NCT06464354|PROCEDURE|The mammary artery harvesting by the pedicle technique|The mammary artery harvesting by the pedicle technique was used in the LIMA pedicle study group.
215131547|NCT06464354|PROCEDURE|The mammary harvesting using the skeletonization technique|The mammary harvesting using the skeletonization technique was used in the LIMA skeletonized study group.
215131548|NCT06464354|PROCEDURE|No intervention|No intervention was used in the control study group.
215131549|NCT00648336|DRUG|Mercaptopurine 50 mg|50mg, single dose fasting
214525350|NCT01994135|OTHER|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
214449636|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1\. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
214708831|NCT01270230|BEHAVIORAL|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
215131550|NCT00648336|DRUG|Purinethol® Tablets 50 mg|50mg, single dose fasting
214449637|NCT05199909|DRUG|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
214449638|NCT02729467|DRUG|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
214449639|NCT02729467|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
214449640|NCT02729467|DRUG|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
214449641|NCT06836492|COMBINATION_PRODUCT|VAC，VAC/VII，CAV/IE|Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP
215131551|NCT03452540|DRUG|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
215131552|NCT00923520|DRUG|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
215131553|NCT02348476|OTHER|No Intervention|No study drug is administered in this study.
215131554|NCT00839189|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
215131555|NCT02571712|DRUG|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
215131556|NCT04790188|DIETARY_SUPPLEMENT|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
214449642|NCT05724160|OTHER|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
215131557|NCT04790188|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin lemon flavor (HSN®).
215131558|NCT02056743|DRUG|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
215131559|NCT02056743|DRUG|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
214449643|NCT05724160|OTHER|Physiotherapy Protocol|Routine physiotherapy protocol
214449644|NCT06365632|DRUG|Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus|An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.
214449645|NCT06365632|PROCEDURE|antegrade appendectomy|An antegrade appendectomy is performed without using Antispike.
214525351|NCT03044951|PROCEDURE|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
214525352|NCT03044951|PROCEDURE|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
214525353|NCT00310050|DRUG|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
215131560|NCT02056743|DIETARY_SUPPLEMENT|Red ginseng|During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
215131561|NCT02056743|DIETARY_SUPPLEMENT|Fermented-red ginseng|During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
215131562|NCT05357573|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
215131563|NCT02913703|DRUG|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
215131564|NCT02913703|OTHER|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
214694635|NCT02311699|BEHAVIORAL|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
214694636|NCT06252259|BEHAVIORAL|Choose to Move|As described under study arm description
214694637|NCT02841319|OTHER|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
215131565|NCT00976846|DEVICE|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
215131566|NCT05075746|DEVICE|enVista Toric|enVista Toric IOL
215131567|NCT05075746|DEVICE|enVista non-Toric (spherical)|enVista non-Toric (spherical) IOL
215131568|NCT01022736|DRUG|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
215131569|NCT04136808|DRUG|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
215131570|NCT04664153|DRUG|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
215131571|NCT04664153|DRUG|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
215131572|NCT01045460|BIOLOGICAL|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
215131573|NCT01045460|BIOLOGICAL|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
215131574|NCT01045460|DRUG|Cyclophosphamide|Administered at 2.5 g/m\^2.
215131575|NCT01045460|BIOLOGICAL|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
214449646|NCT06016621|BEHAVIORAL|Improvisational Music Therapy|The therapist engages with the child by playing and sharing musical instruments, and/or sings while being attuned to the child's behaviour and expression. Various improvisational techniques are employed to engage the child. There are opportunities for pulse, rhythmic, dynamic or melodic patterns, and timbre to be mirrored, reinforced, or complemented, which allows for moments of synchronization between the therapist and the child, giving the child's musical expressions a pragmatic meaning within this context. The therapist may also gently provoke the child by violating expectations or patterns that have been jointly developed in order to elicit specific social communication behaviours. Further, there are opportunities for the child to develop and enhance social communication skills such as joint attention, sharing affect, reciprocity, shared history, scaffolding, imitation and turn-taking. These have been shown to develop social competency and also resilience.
214449647|NCT02966548|DRUG|Relatlimab|Specified dose on specified days
214449648|NCT02966548|DRUG|Nivolumab|Specified dose on specified days
215131576|NCT01045460|PROCEDURE|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
214449649|NCT06008600|DEVICE|Kinocardiography|Smartphone (application with seismocardiography)
214449650|NCT06836648|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
214449651|NCT02457156|PROCEDURE|Blumgart Anastomosis|"1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
214449652|NCT02457156|PROCEDURE|Cattell-Warren Anastomosis|"1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
214449653|NCT02457156|DRUG|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
214449654|NCT06682572|DRUG|Avutometinib (VS-6766) + Defactinib (VS-6063)|combination therapy
214449655|NCT04453189|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
214449656|NCT04453189|DRUG|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
214449657|NCT04453189|DRUG|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
215131577|NCT01045460|DRUG|Melphalan|100 mg/m\^2/day given on Days -2 and -1.
215131578|NCT01045460|BIOLOGICAL|Autologous stem cell transplant|Infused on Day 0.
215131579|NCT06373016|DIETARY_SUPPLEMENT|Glucose|A glucose drink is administered midway through one of the scan sessions.
215131580|NCT06373016|DIETARY_SUPPLEMENT|Ketones|A ketone drink is administered midway through one of the scan sessions.
215131581|NCT01184586|DEVICE|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
215131582|NCT01184586|DEVICE|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
215131583|NCT04356222|DRUG|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
214525354|NCT00310050|DEVICE|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
215131584|NCT04356222|DRUG|methotrexate|Intrathecal chemotherapy specified dose on specified days
215131585|NCT04103216|OTHER|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
215131586|NCT04103216|OTHER|Nitazoxanide|Nitazoxanide with placebo
215131587|NCT01233804|OTHER|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
215131588|NCT00097500|DRUG|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
215131589|NCT00097500|DRUG|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
214449658|NCT06490822|PROCEDURE|Skin biopsy|A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
214449659|NCT03433274|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
215131590|NCT00097500|DRUG|Metformin|Patients usual dosage
215131591|NCT03388346|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
215131592|NCT00335491|BEHAVIORAL|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
215131593|NCT00335491|PROCEDURE|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
215131594|NCT00335491|PROCEDURE|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
215131595|NCT00335491|PROCEDURE|physical therapy|12 weeks of 3x/week training on the eccentron
215131596|NCT05030181|OTHER|kinesiotaping and exercise|kinesiotaping group, ''I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
214449660|NCT03433274|DEVICE|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
214449661|NCT02697396|BEHAVIORAL|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
214449662|NCT02697396|OTHER|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
214449663|NCT02697396|OTHER|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
214449664|NCT05969795|DIAGNOSTIC_TEST|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
214449665|NCT05969795|DIAGNOSTIC_TEST|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
214449666|NCT05969795|DRUG|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
214525355|NCT02162771|BIOLOGICAL|Rituxan|
214525356|NCT02162771|BIOLOGICAL|CT-P10|
214525357|NCT02162771|DRUG|Cyclophosphamide|
214525358|NCT02162771|DRUG|Vincristine|
214525359|NCT02162771|DRUG|Prednisone|
214525360|NCT04893993|DRUG|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
214525361|NCT04893993|DRUG|Placebo|Tablets. Same number of tablets as Thiamine
215131597|NCT05030181|OTHER|exercise|exercise
215131598|NCT03964103|DIETARY_SUPPLEMENT|gQ-lab daily|probiotics
215131599|NCT03964103|DIETARY_SUPPLEMENT|Placebo|powdered skim milk, lactose
215131600|NCT00252421|DRUG|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
215131601|NCT00252421|DRUG|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
214449667|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
215131602|NCT04053335|BEHAVIORAL|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~* Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~* Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~* Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~* Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~* Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
215131603|NCT01692184|DRUG|50 mg AVL-292|
215131604|NCT01692184|DRUG|100 mg AVL-292|
215131605|NCT01692184|DRUG|200 mg AVL-292|
215131606|NCT01692184|DRUG|350 mg AVL-292|
215131607|NCT01692184|DRUG|Placebo capsules|
214449668|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
215131608|NCT00189098|DRUG|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
215131609|NCT00189098|DRUG|Placebo|
215131610|NCT01404507|DRUG|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
215131611|NCT01404507|DEVICE|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
215131612|NCT01404507|OTHER|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
215131613|NCT01600885|DRUG|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
214449669|NCT05969795|PROCEDURE|Embryo transfer|The procedure in which embryo is placed in the uterus.
214449670|NCT05969795|DIAGNOSTIC_TEST|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of \> 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
214449671|NCT05969795|DIAGNOSTIC_TEST|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
214449672|NCT06012708|DRUG|KN510 60mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
214449673|NCT06012708|DRUG|KN510 120mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
214449674|NCT06012708|DRUG|KN510 120mg/day + KN713 90mg/day|Once daily with 28 days (4 weeks) as one cycle.
214449675|NCT06012708|DRUG|KN510 120mg/day + KN713 120mg/day|Once daily with 28 days (4 weeks) as one cycle.
214449676|NCT06850480|DRUG|JP-1366 simulation tablets|qd, last for 4-8 weeks
214449677|NCT06850480|DRUG|Esomeprazole Magnesium (Nexium) simulation tablets|qd, last for 4-8 weeks
214525362|NCT05848102|DRUG|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
214525363|NCT03244202|OTHER|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
215131614|NCT01600885|DRUG|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
215131615|NCT02319200|DRUG|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
215131616|NCT02319200|DRUG|placebo tablet|4 tablets per day for 36 months
215131617|NCT00330577|DRUG|timolol maleate 0.5%|
215131618|NCT00330577|DRUG|latanoprost/timolol fixed combination|
215131619|NCT00330577|DRUG|placebo (artificial tears)|
215131620|NCT00436332|BIOLOGICAL|bevacizumab|
214449678|NCT06495125|DRUG|Avutometinib|Given PO
214449679|NCT06495125|PROCEDURE|Biopsy|Undergo biopsy
214449680|NCT06495125|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214449681|NCT06495125|PROCEDURE|Computed Tomography|Undergo CT
214449682|NCT06495125|DRUG|Defactinib|Given PO
214449683|NCT06495125|BIOLOGICAL|Nivolumab|Given IV
214449684|NCT06495125|PROCEDURE|Positron Emission Tomography|Undergo PET
214449685|NCT05948735|OTHER|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
214449686|NCT05948735|OTHER|Physical Therapy Exercise (PTE) only for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
214449687|NCT02199600|DEVICE|GMK Sphere Knee Replacement|
215131621|NCT00436332|DRUG|erlotinib hydrochloride|
215131622|NCT00987376|DEVICE|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
215131623|NCT00639197|PROCEDURE|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
215131624|NCT00639197|PROCEDURE|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
215131625|NCT05189275|DIETARY_SUPPLEMENT|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
215131626|NCT01457651|PROCEDURE|Alveolar recruitment|"Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)"
215131627|NCT02538744|DRUG|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
215131628|NCT02538744|DRUG|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
215131629|NCT02538744|DRUG|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
214449688|NCT06850467|BEHAVIORAL|Sexual intercourse protocol|The study involved pregnant women who were randomly assigned to 2 groups. The protocol involved engaging in sexual intercourse and nipple stimulation 3 times per day for two consecutive weeks with the consecutive days of sexual intercourse and days of nipple stimulation being different. Patients documented their coital activities as well as the frequency of orgasms in their daily journal. There were no prohibitions regarding or promotions of sexual activities for the control group. The main outcome was the onset of labor, which was defined as the presence of effective uterine contraction with changes of the cervix (Bishop score \> 5) without using the induction treatments during protocol time or until 41 weeks of pregnancy.
214449689|NCT06849167|RADIATION|hypofractionated radiotherapy with immunotherapy|Immunotherapy combined with hypofractionated concurrent chemoradiotherapy followed by consolidation immunotherapy
214449690|NCT06848595|PROCEDURE|spine surgery|spine surgery in prone position
214449691|NCT06848595|DRUG|Magnesium sulfate|Patients will receive loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
214449692|NCT06848595|DRUG|Dexmedetomidine|Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
214449693|NCT06848595|DRUG|Normal Saline (0.9% NaCl)|Patients will receive the same volume of normal saline.
214449694|NCT06390410|DRUG|Simufilam|100 mg PTI-125
214449695|NCT00287235|DEVICE|MARS|
214449696|NCT00287235|DRUG|Standard Medical Therapy|
214449697|NCT04146597|OTHER|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
214449698|NCT06355583|DRUG|EBX-102|EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
214449699|NCT06355583|DRUG|Placebo|The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
215131630|NCT02538744|DRUG|Placebo|
215131631|NCT00472108|RADIATION|Photodynamic Therapy (PDT)|
215131632|NCT00472108|DRUG|Metvix cream|
215131633|NCT00472108|DRUG|Placebo Cream|
214449700|NCT05974462|DRUG|Methylprednisolone 125 MG|125 mg daily for 3 days diluted in saline solution 250 mL
214449701|NCT05974462|OTHER|IV saline solution 0.9%|Saline solution 0.9% 250 mL
214449702|NCT05536128|DRUG|Olaparib|Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
214449703|NCT05536128|DRUG|Fulvestrant|Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
215131634|NCT02910817|DRUG|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
215131635|NCT02910817|OTHER|Placebo|Placebo
215131636|NCT04389775|DRUG|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
215131637|NCT04389775|DRUG|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
215131638|NCT04389775|DRUG|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
215131639|NCT04389775|DRUG|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
215131640|NCT00716963|DRUG|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
215131641|NCT00716963|DRUG|budesonide 400 mcg|budesonide 400 mcg
215131642|NCT00716963|OTHER|Placebo|Placebo
215131643|NCT00642356|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
215131644|NCT00642356|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
215131645|NCT05030025|COMBINATION_PRODUCT|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
215131646|NCT05030025|COMBINATION_PRODUCT|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
215131647|NCT03469752|BEHAVIORAL|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
215131648|NCT03497663|OTHER|VIA Family intervention|Family based intervention
215131649|NCT03497663|OTHER|Treatment As Usual|Treatment As Usual
215131650|NCT01009060|DRUG|GSK239512|Histamine H3 Antagonist
215131651|NCT01009060|DRUG|Placebo|Placebo to match GSK239512
214449704|NCT05141604|OTHER|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
214449705|NCT03480061|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
215131652|NCT01304264|DEVICE|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
215131653|NCT00450970|DRUG|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
215131654|NCT01394055|DRUG|RM-131|100 μg subcutaneously once
214449706|NCT05655403|BEHAVIORAL|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
214449707|NCT03877796|DEVICE|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
214449708|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
214449709|NCT05241418|DIAGNOSTIC_TEST|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
214449710|NCT03042156|RADIATION|Palliative Radiation Therapy|
215131655|NCT01394055|DRUG|Placebo|Matching placebo volume subcutaneously once
215131656|NCT04642625|OTHER|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and \>7cm are the indicators of severe pain."
215131657|NCT04642625|OTHER|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
215131658|NCT01274949|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
215131659|NCT00883363|PROCEDURE|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
215131660|NCT05953545|DRUG|Peginterferon Lambda|Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
215131661|NCT02749396|DRUG|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
215131662|NCT02749396|DRUG|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
215131663|NCT02749396|DRUG|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
214449711|NCT06113939|DEVICE|airway clearance|mechanical suctioning of airway secretions
214449712|NCT04831684|DRUG|Placebo|Participants will be getting placebo for 8 days of dosing.
214449713|NCT04831684|DRUG|GET73|Participants will be getting GET73 for 8 days of dosing.
214449714|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
214449715|NCT05014204|DEVICE|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
214449716|NCT02181257|COMBINATION_PRODUCT|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
214449717|NCT02181257|OTHER|No intervention in the SOC / Retrospective Chart review.|SOC Retrospective chart review similar to a control group
214449718|NCT04761458|DIAGNOSTIC_TEST|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
214449719|NCT04761458|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
214449720|NCT04761458|DIAGNOSTIC_TEST|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
214449721|NCT04761458|DIAGNOSTIC_TEST|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
214449722|NCT04072822|DRUG|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
214449723|NCT04072822|DRUG|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
214449724|NCT04072822|DRUG|Placebos|Matching placebo
214449725|NCT03095274|DRUG|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
214449726|NCT03095274|DRUG|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
214449727|NCT03483246|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
215131664|NCT02749396|DRUG|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
215131665|NCT02749396|DRUG|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
215131666|NCT02749396|DRUG|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
215131667|NCT02749396|OTHER|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
214449728|NCT03483246|DRUG|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
214449729|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
214449730|NCT04513132|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
214449731|NCT04513132|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
214449732|NCT04391894|DRUG|ECF843|Topical ocular eye drop
214449733|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
214449734|NCT06163586|OTHER|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
214449735|NCT01889199|DRUG|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
214449736|NCT01889199|OTHER|Placebo|Placebo orally each 28 day cycle for 6 cycles
214449737|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
215131668|NCT00005906|DRUG|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
215131669|NCT04078841|DIETARY_SUPPLEMENT|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
215131670|NCT04078841|OTHER|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
215131671|NCT01628146|DEVICE|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
214449738|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance elastography (MRE)|Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.
214449739|NCT04591106|DEVICE|Prototype MRE soft flexible passive transducer paddle|The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.
214449740|NCT05689021|DRUG|Abiraterone Acetate/Niraparib|Given PO
215131672|NCT03939546|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
215131673|NCT05323136|DRUG|MT1002 for Injection|single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
215131674|NCT06247917|DRUG|Fludarabine, Busulfan and Melphalan|Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
215131675|NCT01258543|OTHER|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
215131676|NCT02868112|OTHER|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
215131677|NCT02868112|OTHER|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
215131678|NCT00576355|BEHAVIORAL|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
215131679|NCT00576355|BEHAVIORAL|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
215131680|NCT03553901|PROCEDURE|Acupressure|Acupressure was performed before the injection onto GB30 point
215131681|NCT03821896|BEHAVIORAL|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
215131682|NCT03821896|BEHAVIORAL|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
215131683|NCT00174577|DRUG|Risperidone|
215131684|NCT02800538|DIETARY_SUPPLEMENT|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
215131685|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
215131686|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
214449741|NCT05689021|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214449742|NCT05689021|PROCEDURE|Bone Scan|Undergo technetium-99m bone scan
214449743|NCT05689021|PROCEDURE|Computed Tomography|Undergo CT scan
214449744|NCT05689021|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214449745|NCT05689021|DRUG|Prednisone|Given PO
214449746|NCT06581588|DEVICE|THRIVE|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen
214449747|NCT06581588|DEVICE|THRIVE combine nasopharyngeal airway|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
214525364|NCT03244202|OTHER|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
214525365|NCT03154684|OTHER|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active"
215131687|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
215131688|NCT01460212|DRUG|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
215131689|NCT01460212|BEHAVIORAL|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
214525366|NCT03154684|OTHER|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
215131690|NCT00015210|DRUG|Nefazodone|
215131691|NCT00015210|BEHAVIORAL|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
215131692|NCT02264730|DRUG|ClotFoam|Patient has not received blood products between screenings
215131693|NCT05706298|BEHAVIORAL|Active Breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
214525367|NCT00223743|DRUG|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
214525368|NCT04422210|DRUG|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
214525369|NCT04422210|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
214525370|NCT04422210|DRUG|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
214525371|NCT04422210|DRUG|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
214525372|NCT00004311|DRUG|leuprolide acetate|
215131694|NCT04232319|BEHAVIORAL|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
215131695|NCT03334305|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
215131696|NCT03334305|DRUG|Dose-intensified TMZ|After chemoradiation, subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
215131697|NCT03334305|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Prior to chemoradiation, enrolled subjects will undergo a mobilized leukapheresis for collection of PBSCs and PBMCs for generation of DCs. One group will receive recommended dose of \> 2 x 106 CD34+ HSCs/kg. Subjects enrolled in Group B will receive HSCs during TMZ Cycle 6 before receiving DC vaccine and T-cell infusion.
215131698|NCT03334305|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 6 and with DC vaccine #8, an infusion of T-cells will be administered to all subjects.
215131699|NCT03334305|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
215131700|NCT00119847|PROCEDURE|PCI|
215131701|NCT00119847|DRUG|Optimal Medical Therapy|Guideline-directed drug therapies after MI
214449748|NCT04987814|OTHER|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
214449749|NCT04987814|OTHER|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
214525373|NCT00004311|DRUG|spironolactone|
215131702|NCT03043534|OTHER|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
215131703|NCT03043534|OTHER|Brush|All subjects randomized to brush will use the brush with each shave
215131704|NCT06001203|PROCEDURE|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
214525374|NCT03937596|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
214525375|NCT03937596|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
214525376|NCT03937596|DRUG|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
214525377|NCT02732899|DRUG|Sirolimus|
214525378|NCT02732899|DRUG|EYLEA|
214525379|NCT03264599|DEVICE|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
214525380|NCT02233504|DRUG|Exjade® (deferasirox, ICL670)|
214449750|NCT04987814|OTHER|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
215131705|NCT04257890|BEHAVIORAL|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
215131706|NCT04257890|OTHER|Education material about IGD|Printed education material introducing IGD will be distributed.
215131707|NCT04257890|OTHER|Education material about CBT|Printed education material introducing CBT will be distributed.
215131708|NCT02601157|DRUG|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
215131709|NCT02601157|DRUG|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
215131710|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
214449751|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
214449752|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
215131711|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
215131712|NCT00286442|DRUG|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
214449753|NCT02323321|DEVICE|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
214449754|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214449755|NCT00446225|DRUG|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
214449756|NCT00446225|DRUG|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
214449757|NCT00446225|DRUG|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
214449758|NCT00446225|DRUG|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
214449759|NCT00446225|DRUG|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
214694638|NCT06159868|OTHER|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
214449760|NCT05204732|OTHER|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
214449761|NCT05204732|OTHER|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
214449762|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
214449763|NCT03379051|DRUG|Venetoclax|BCL-2 Inhibitor
214449764|NCT03379051|DRUG|Umbralisib|PI3K-Delta Inhibitor
214449765|NCT03379051|BIOLOGICAL|Ublituximab|Glycoengineered Anti-CD20 mAb
214694639|NCT06159868|OTHER|Standard care|Standard ward based care provided by usual care teams
214449766|NCT03379051|DRUG|Lenalidomide|Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
214449767|NCT04353310|DRUG|Curcumin|Curcumin 1500mg PO BID
214449768|NCT04353310|OTHER|Placebo|identical in appearance to curcumin
214694640|NCT04322994|DEVICE|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
215131713|NCT02726620|PROCEDURE|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
215131714|NCT02726620|PROCEDURE|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
215131715|NCT02726620|PROCEDURE|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
214449769|NCT01057433|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
214449770|NCT01057433|DRUG|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
214449771|NCT00910338|DEVICE|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks"
214449772|NCT05670106|DRUG|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
214694641|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
215131716|NCT02726620|PROCEDURE|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
215131717|NCT02726620|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
215131718|NCT02726620|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
215131719|NCT02726620|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
215131720|NCT02726620|DEVICE|Pager system|The mobile pager system through which alerts can be sent
215131721|NCT02726620|PROCEDURE|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
215131722|NCT02726620|PROCEDURE|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
214449773|NCT05670106|OTHER|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
214449774|NCT05670106|DRUG|68Ga-PSMA-11|Administered single intravenous dose of approximately 150 MBq. Administered dose could not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
215131723|NCT02726620|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
215131724|NCT02726620|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
215131725|NCT02726620|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
215131726|NCT02726620|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
215131727|NCT02726620|DRUG|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
215131728|NCT02726620|DRUG|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
215131729|NCT02726620|DRUG|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
215131730|NCT02726620|DRUG|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
215131731|NCT02726620|DRUG|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
215131732|NCT02726620|DRUG|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
215131733|NCT02726620|DRUG|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
215131734|NCT02726620|DRUG|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
215131735|NCT02726620|DRUG|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
215131736|NCT02726620|DRUG|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
215131737|NCT02726620|DRUG|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
214449775|NCT06202976|OTHER|Secondary data collection|clinical data
214449776|NCT05440786|DRUG|Abemaciclib|Orally
215131738|NCT02726620|DRUG|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
215131739|NCT02726620|DRUG|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
215131740|NCT02726620|DRUG|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
215131741|NCT02726620|DRUG|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
215131742|NCT02726620|DRUG|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
215131743|NCT02726620|DRUG|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
215131744|NCT02726620|DRUG|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
215131745|NCT02726620|DRUG|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
215131746|NCT02726620|DRUG|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
215131747|NCT02726620|DRUG|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
215131748|NCT02726620|DRUG|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
214449777|NCT05440786|DRUG|Irinotecan|IV
214449778|NCT05440786|DRUG|Temozolomide|Orally
214449779|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
214449780|NCT02811679|DRUG|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
214449781|NCT06109311|DRUG|Orforglipron|Administered orally.
214449782|NCT06109311|DRUG|Placebo|Administered orally.
214449783|NCT06488144|BEHAVIORAL|Health coach|Health Coaching
214694642|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
215131749|NCT02726620|DRUG|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
215131750|NCT02726620|DRUG|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
215131751|NCT02726620|DRUG|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
215131752|NCT02726620|DRUG|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
215131753|NCT02726620|DRUG|Procaine|Local anesthetic used for central neuraxial anesthesia.
215131754|NCT02726620|DRUG|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
215131755|NCT02726620|DRUG|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
215131756|NCT02726620|DRUG|Articaine|Local anesthetic used for central neuraxial anesthesia.
215131757|NCT02986126|BEHAVIORAL|Resiliency Class|See Arm Description
215131758|NCT02986126|OTHER|Resource for Services (RS)|See Resource for Services (RS) Description
215131759|NCT02441023|BEHAVIORAL|Nutritional therapy and education|"1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
215131760|NCT02441023|BEHAVIORAL|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
215131761|NCT05206721|OTHER|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
214449784|NCT06488144|BEHAVIORAL|Remote Incentive Program|Behavioral incentive program including gamification, social incentivization, and monitoring.
214525381|NCT03317288|DEVICE|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
214525382|NCT03594266|DEVICE|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
214525383|NCT03594266|DEVICE|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
214525384|NCT00449033|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
214525385|NCT00449033|DRUG|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
214525386|NCT00449033|DRUG|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
214525387|NCT00449033|DRUG|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m\^2 IV
214694643|NCT05092737|PROCEDURE|Prone positioning|Prone position during invasive mechanical ventilation
215131762|NCT05259735|COMBINATION_PRODUCT|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
215131763|NCT05259735|OTHER|Comparator|In this arm usual management of T2DM without any clinical guideline
215131764|NCT03113032|OTHER|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
215131765|NCT03113032|OTHER|Normal pre-surgical care|Routine pre-surgical care
215131766|NCT00737776|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215131767|NCT02542865|DIETARY_SUPPLEMENT|Fortified malt based food|Fortified malt based food
215131768|NCT05289115|DEVICE|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
215131769|NCT05289115|DEVICE|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
215131770|NCT00811603|DRUG|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
214449785|NCT03468335|DRUG|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
214525388|NCT06021834|OTHER|rehabilitation|The subjects will be invited to attend the program three times per week.
214525389|NCT04393779|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
214525390|NCT02959255|DRUG|Esomeprazole|dosage difference
214525391|NCT00666913|OTHER|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
214525392|NCT01190228|BIOLOGICAL|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
214525393|NCT01190228|BIOLOGICAL|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
214525394|NCT01567670|DRUG|Naloxone|2 mg x 1-2
214525395|NCT01567670|DRUG|naloxone placebo|h2o placebo spray
214525396|NCT04063345|PROCEDURE|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
214525397|NCT04063345|PROCEDURE|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
214525398|NCT02488070|PROCEDURE|Computed Tomography|Part of PET/CT scan
214525399|NCT02488070|DRUG|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
214525400|NCT02488070|PROCEDURE|Magnetic Resonance Imaging|Part of PET/MRI scan
214525401|NCT02488070|PROCEDURE|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
214694644|NCT05820100|OTHER|Observational|"The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel."
214525402|NCT06645106|DEVICE|Rapid Point of Care (POC) Syphilis testing|Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
214525403|NCT04290416|DIAGNOSTIC_TEST|Microwire electrodes|
214525404|NCT01770509|DEVICE|NMBM|Daily application of NMBM in addition to compression therapy
214525405|NCT01770509|OTHER|Compression garments|Compression garments
214525406|NCT02383121|DRUG|Midodrine|Not appliciable
214525407|NCT02078778|DEVICE|CPAP|3 months of CPAP treatment
214525408|NCT00207935|BEHAVIORAL|Swallow instruction|
214525409|NCT01370564|DRUG|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
214525410|NCT02181400|DEVICE|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
215131771|NCT05644119|DEVICE|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
215131772|NCT05644119|DEVICE|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
215131773|NCT01445444|BEHAVIORAL|Habit Reversal Training|"* 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
215131774|NCT00920751|PROCEDURE|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
215131775|NCT00920751|PROCEDURE|Air insufflation|Conventional air insufflation colonoscopy
215131776|NCT02608944|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
215131777|NCT02608944|DRUG|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
215131778|NCT02608944|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
215131779|NCT02608944|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
215131780|NCT02608944|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
215131781|NCT04055675|DIAGNOSTIC_TEST|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
215131782|NCT01882673|BEHAVIORAL|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
215131783|NCT01882673|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
215131784|NCT05661344|DRUG|BI 1015550|BI 1015550
215131785|NCT02848963|DRUG|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
215131786|NCT05221411|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
215131787|NCT05221411|DRUG|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
215131788|NCT01339689|DRUG|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
215131789|NCT01339689|DRUG|Placebo|capsules, bid, up to 12 weeks
215131790|NCT04260685|DRUG|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
214525411|NCT00511459|DRUG|AMG 386 Placebo|AMG 386 Placebo \[blinded\]
214525412|NCT00511459|DRUG|AMG 386|AMG 386 3mg/kg IV QW \[blinded\]
214525413|NCT00511459|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
214525414|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[Open-Label\]
214525415|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[blinded\]
214525416|NCT00511459|DRUG|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
214525417|NCT01540877|PROCEDURE|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
214525418|NCT01540877|PROCEDURE|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
214525419|NCT01540877|PROCEDURE|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
215131791|NCT04260685|DRUG|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
215131792|NCT02350517|DRUG|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
214525420|NCT01540877|PROCEDURE|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
214449786|NCT05404750|BEHAVIORAL|Harm Reduction|Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
214449787|NCT06365086|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the right hemisphere during brain activity patterns associated with strong and weak corticospinal tract activation. Single-pulse TMS will also be applied to the right hemisphere during random brain activity patterns.
214449788|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
215131793|NCT03188159|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
215131794|NCT02738814|DRUG|propofol|When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
215131795|NCT00188552|DRUG|pentoxifylline|
215131796|NCT00188552|DRUG|α-Tocopherol|
215131797|NCT01299844|BEHAVIORAL|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
215131798|NCT03617562|PROCEDURE|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
215131799|NCT03617562|PROCEDURE|Partial Repair|Rotator cuff is repaired with residual defect remaining.
215131800|NCT04571944|DRUG|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
215131801|NCT04571944|DRUG|Placebo|Suvorexant-matching placebo administered QD via oral tablet
215131802|NCT02360566|BEHAVIORAL|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
215131803|NCT01180465|DRUG|LIPO-102|LIPO-102 High dose
214694645|NCT03664193|RADIATION|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
214694646|NCT03367130|BEHAVIORAL|Mobile phone reminder|Intervention described already in arm/group descriptions.
214449791|NCT05611073|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
214449792|NCT05611073|DIAGNOSTIC_TEST|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
215131804|NCT01180465|DRUG|LIPO-102 Low|LIPO-102 Low dose
215131805|NCT01180465|DRUG|LIPO-102, Placebo|Placebo
215131806|NCT06555185|OTHER|Potentiation warm-up protocol|The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.
214449793|NCT05611073|OTHER|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
214449794|NCT05050929|RADIATION|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
214449795|NCT05888311|DEVICE|Liquid bandage|Liquid elastic collodion- and benzethonium chloride-based topical solution
214694647|NCT05667155|BIOLOGICAL|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
215131807|NCT06555185|OTHER|Usual warm-up protocol|The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
215131808|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
215131809|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
215131810|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
215131811|NCT04187898|BIOLOGICAL|Eflapegrastim|Administered in Cycles 1-4, 30 mins after TC chemotherapy.
215131812|NCT04187898|DRUG|Docetaxel|"75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
215131813|NCT04187898|DRUG|Cyclophosphamide|"600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
215131814|NCT04630665|OTHER|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
215131815|NCT06344871|DEVICE|NeuroLF|NeuroLF Scan
215131816|NCT06344871|DEVICE|Conventional PET scan|Scan on conventional PET system
215131817|NCT03106571|DRUG|Pomaglumetad methionil|Tablets twice daily
215131818|NCT03106571|DRUG|Placebo|1-4 tablets twice daily
215131819|NCT03106571|DRUG|Methamphetamine|intravenous methamphetamine
215131820|NCT02828475|OTHER|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
215131821|NCT02828475|BEHAVIORAL|Standard Care|Previous standard of care based on surgeon judgement alone.
215131822|NCT01150526|DIETARY_SUPPLEMENT|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
215131823|NCT01150526|DIETARY_SUPPLEMENT|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
215131824|NCT01150526|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
214449796|NCT05492916|BEHAVIORAL|Diabetes Prevention Program (DPP)|Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.
214449797|NCT05492916|BEHAVIORAL|Community-Supported Agriculture (CSA)|Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
214449798|NCT06623110|BIOLOGICAL|RP2 Injection|Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
214449799|NCT05147779|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214449800|NCT03361748|BIOLOGICAL|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
214449801|NCT05047224|BEHAVIORAL|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
214449802|NCT05047224|BEHAVIORAL|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
214449803|NCT06011252|DEVICE|Solia S lead with any BIOTRONIK Pacemaker|"* Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III"
214449804|NCT05606575|DEVICE|Nelli|Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.
214449805|NCT01826331|BEHAVIORAL|Incentives for Participation|Participants will receive three smoking cessation programs
214449806|NCT01826331|BEHAVIORAL|Incentives for Cessation|Participants will have access to a smoking cessation program
214525421|NCT05621720|OTHER|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
214525422|NCT05621720|OTHER|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
214525423|NCT03806218|DEVICE|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
215131825|NCT01150526|DIETARY_SUPPLEMENT|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
215131826|NCT04477265|DRUG|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
215131827|NCT04477265|BEHAVIORAL|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
215131828|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
215131829|NCT06092762|DRUG|AK120|subcutaneous injection every 2 weeks
215131830|NCT04740983|OTHER|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
215131831|NCT00966186|PROCEDURE|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
215131832|NCT04139330|DRUG|NPC-06|Infuse NPC-06 intravenously
215131833|NCT04610359|DRUG|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
215131834|NCT00471653|DRUG|temozolomide|
215131835|NCT00471653|GENETIC|comparative genomic hybridization|
215131836|NCT00471653|GENETIC|polymorphism analysis|
215131837|NCT00471653|OTHER|laboratory biomarker analysis|
215131838|NCT00471653|OTHER|pharmacological study|
215131839|NCT00471653|RADIATION|radiation therapy|
215131840|NCT03864835|BEHAVIORAL|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
215131841|NCT03442816|DEVICE|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
215131842|NCT03380897|OTHER|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
215131843|NCT03380897|OTHER|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
215131844|NCT02229058|DRUG|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
215131845|NCT02229058|DRUG|S-1|40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.
214449807|NCT03191981|DRUG|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
214449808|NCT03191981|DRUG|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
214449809|NCT03191981|DRUG|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
214449810|NCT03751449|OTHER|Educational Intervention|Receive nutrition education
215131846|NCT04669808|DRUG|STP705|Dry powder for intra-and peri-lesional injection.
215131847|NCT06005935|OTHER|Survey|Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
215131848|NCT05794425|DRUG|Cyclosporine A|3-5 mg per kilogram per day.
215131849|NCT05794425|BIOLOGICAL|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
215131850|NCT05388786|BEHAVIORAL|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
215131851|NCT02536612|OTHER|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
215131852|NCT02536612|OTHER|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
215131853|NCT04913610|DRUG|ABBV-4083|Oral Capsule
215131854|NCT04913610|DRUG|Placebo for ABBV-4083|Oral Capsule
215131855|NCT04913610|DRUG|Albendazole|Oral encapsulated tablets
215131856|NCT04913610|DRUG|Placebo for Albendazole|Oral Capsule
214525424|NCT03806218|DEVICE|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
215131857|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
215131858|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
214449811|NCT03751449|BEHAVIORAL|Exercise Intervention|Complete home-based aerobic and resistance exercise program
214449812|NCT03751449|OTHER|Quality-of-Life Assessment|Ancillary studies
214449813|NCT03751449|OTHER|Questionnaire Administration|Ancillary studies
214449814|NCT06969079|BEHAVIORAL|Ba Duan Jin Exercise plus Sleep Hygiene Education|Participants will receive Ba Duan Jin exercise combined with Sleep Hygiene Education. The Ba Duan Jin intervention consists of eight traditional Chinese Qigong movements performed daily for 6 weeks, with each session lasting 50 minutes, accompanied by structured sleep hygiene counseling.
214449815|NCT06969079|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
214449816|NCT04986501|DEVICE|MucoPEG|Experimental
214449817|NCT04986501|DEVICE|Biotene|Active Comparator
214525425|NCT03806218|DEVICE|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
214525426|NCT03806218|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
214525427|NCT03867123|DRUG|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
214525428|NCT03867123|RADIATION|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
215131859|NCT03936998|COMBINATION_PRODUCT|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
215131860|NCT03936998|COMBINATION_PRODUCT|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
215131861|NCT06490289|OTHER|Denpro oral gel|Experimental group was given Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan)
215131862|NCT00826644|DRUG|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
215131863|NCT00826644|DRUG|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
214525429|NCT03867123|DRUG|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
214449818|NCT04180059|COMBINATION_PRODUCT|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
214449819|NCT06645925|PROCEDURE|One Step Protocol|FGG will be done simultaneous with implant placement
214449820|NCT06645925|PROCEDURE|Two Steps Protocol|Conventional FGG protocol, prior to implant placement
214525430|NCT04153851|PROCEDURE|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
215131864|NCT00826644|DRUG|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
214525431|NCT02225288|DRUG|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
215131865|NCT05408338|OTHER|Low Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)
214525432|NCT01116700|DRUG|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
214525433|NCT00905255|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
215131866|NCT05408338|OTHER|High Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
215131867|NCT01879111|OTHER|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
215131868|NCT01999452|BEHAVIORAL|Paleolithic diet|
215131869|NCT01999452|BEHAVIORAL|Diabetes diet|
215131870|NCT00771394|DRUG|Tamsulosin hydrochloride|oral
215131871|NCT00771394|DRUG|Solifenacin succinate|oral
215131872|NCT05358236|OTHER|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area"
215131873|NCT00280982|BIOLOGICAL|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
215131874|NCT06066216|DRUG|Cadonilimab|Injectable solution
215131875|NCT06066216|DRUG|Carboplatin|Injectable solution
215131876|NCT06066216|DRUG|Cisplatin|Injectable solution
215131877|NCT06066216|DRUG|Paclitaxel|Injectable solutionS
215131878|NCT01811771|BIOLOGICAL|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
215131879|NCT00231426|DEVICE|ICD|
215131880|NCT03530397|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
215131881|NCT03530397|DRUG|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
215131882|NCT03530397|DRUG|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
215131883|NCT03530397|BIOLOGICAL|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
215131884|NCT03530397|DRUG|Paclitaxel or Nab-Paclitaxel|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
215131885|NCT01210716|DEVICE|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
215131886|NCT06427213|DRUG|Zanubrutinib,Obinutuzumab|"Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease； Obinutuzumab ：Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks，up to 20 doses. 1 cycle = 28 days.~Maintenance: Zanubrutinib, 160mg PO BID"
215131887|NCT06427213|DRUG|Zanubrutinib and R-BAC|"Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression"
215131888|NCT02571426|DRUG|Sevoflurane|anesthetic agent
215131889|NCT02571426|DRUG|propofol|anesthetic agent
215131890|NCT03607214|OTHER|Placebo|"Placebo nasal spray~Film Sequence"
215131891|NCT00329966|BIOLOGICAL|Surface Antigen, Inactivated, Influenza (form.2006-07)|
214525434|NCT00905255|DEVICE|Pen auto-injector|
215131892|NCT03399058|OTHER|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
214449821|NCT03461991|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
215131893|NCT03399058|BEHAVIORAL|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
215131894|NCT03399058|BEHAVIORAL|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
215131895|NCT05602493|DRUG|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
215131896|NCT05602493|DRUG|sterile saline|sterile saline
215131897|NCT01622439|DRUG|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
215131898|NCT01622439|DRUG|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
215131899|NCT01622439|DRUG|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
214449822|NCT03931447|BIOLOGICAL|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
214449823|NCT03931447|BIOLOGICAL|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
214525435|NCT05464082|OTHER|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
214525436|NCT02821572|BIOLOGICAL|blood sample|
215131900|NCT01622439|DRUG|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
215131901|NCT01622439|DRUG|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
214449824|NCT03721913|OTHER|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
215131902|NCT01622439|DRUG|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
215131903|NCT04657679|DRUG|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
214449825|NCT03113422|DRUG|Induction Venetoclax|"1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
214449826|NCT03113422|DRUG|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
214694648|NCT01676402|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
214449827|NCT06624176|DEVICE|Bionix ShotBlocker|This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.
214449828|NCT06624176|OTHER|Swaddling|Standard of care swaddling
214525437|NCT02821572|PROCEDURE|spleen sample|
214525438|NCT00131404|DRUG|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
214525439|NCT00131404|DRUG|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
214525440|NCT05054556|DIAGNOSTIC_TEST|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
214694649|NCT01676402|BIOLOGICAL|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
215131904|NCT05767515|DRUG|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
214449829|NCT06624176|OTHER|Sucrose administration|Standard of care sucrose administration
214449830|NCT06624176|OTHER|Masimo Rad-97 Oximeter probe|Oximeter probe
214694650|NCT02576964|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
214694651|NCT02576964|DRUG|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
214694652|NCT06124547|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
214694653|NCT05034484|DRUG|ALPN-303|Multiple dose levels will be evaluated.
214694654|NCT05034484|DRUG|Placebo|Placebo will be administered
215131905|NCT05343754|DRUG|Hyperbaric oxygen|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
215131906|NCT05343754|OTHER|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
215131907|NCT04418024|DRUG|AG10|TTR stabilizer administered orally twice daily (BID)
215131908|NCT04418024|DRUG|Placebo|Non-active control
215131909|NCT02358473|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered by IV infusion.
215131910|NCT02358473|DRUG|Docetaxel|Docetaxel will be administered by IV infusion.
215131911|NCT06415890|OTHER|4-7-8 Breathing Technique|The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
214449831|NCT04594798|DRUG|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
215131912|NCT05773846|DRUG|Ropivacaine|A long acting formulation of ropivacaine
215131913|NCT04097470|DRUG|Decitabine|Decitabine dosage 20mg/m2 i.v.
215131914|NCT04097470|DRUG|Midostaurin|Midostaurin 50 mg b.i.d.
215131915|NCT05476289|OTHER|No intervention|No intervention
215131916|NCT06178796|DEVICE|Dental implant|Dental implant placement
215131917|NCT02588690|PROCEDURE|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
215131918|NCT02588690|OTHER|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
214449832|NCT04594798|DRUG|Rituximab|IV 375 mg/m2 per cycle
214449833|NCT04594798|DRUG|Cyclophosphamide|IV 400 mg/m2 per cycle
214449834|NCT04594798|DRUG|Doxorubicin|IV 25 mg/m2 per cycle
214449835|NCT04594798|DRUG|Prednisone|PO 40 mg/m2 per cycle
214449836|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
214449837|NCT02374112|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
214449838|NCT02374112|OTHER|Placebo|Placebo supplementation
214449839|NCT04892693|DRUG|Talazoparib Oral Capsule|\- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
214449840|NCT04864158|PROCEDURE|TSA-group|Reverse total shoulder arthroplasty followed by standard rehabilitation.
214694655|NCT00019500|DRUG|raloxifene|
214694656|NCT00019500|PROCEDURE|evaluation of cancer risk factors|
214694657|NCT03241472|DRUG|Letrozole|oral tablets 5 mg
214694658|NCT03241472|DRUG|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
214694659|NCT01157416|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
214694660|NCT01157416|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
214694661|NCT01157416|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
214694662|NCT02345252|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
215131919|NCT02588690|PROCEDURE|Blood pressure measurement|Blood pressure measurement
215131920|NCT06292169|PROCEDURE|Pectoralis Minor Release|The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.
215131921|NCT06292169|PROCEDURE|RSA|RSA is the current Standard of Care (SOC)
215131922|NCT05234411|OTHER|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
215131923|NCT00316537|DRUG|ATG002 (study drug)|
215131924|NCT00002403|DRUG|Zintevir|
215131925|NCT06103396|BIOLOGICAL|Transplantation of autologous MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
214449841|NCT04864158|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
214449842|NCT06977074|DRUG|PD-1 inhibitor|Two to four cycles of tislelizumab at a dose of 200 mg every three weeks, along with a platinum-based chemotherapy doublet based on the result of ctDNA dynamics
214449843|NCT06977074|DRUG|Platinum Doublet|Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² \[adenocarcinoma\] or nab-paclitaxel 260 mg/m² \[squamous/other subtypes\])
214449844|NCT06189534|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
214449845|NCT02814838|DRUG|Ladarixin|Ladarixin oral capsule
214449846|NCT02814838|DRUG|Placebo|Placebo oral capsule
214449847|NCT06649019|DEVICE|ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)|Test Lens
214449848|NCT06649019|DEVICE|Dailies Total 1 for Astigmatism (DT1fA)|Control Lens
214449849|NCT02229721|DRUG|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
214449850|NCT02229721|DRUG|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
214449851|NCT03811366|DRUG|Corticosteroid monotherapy|Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
214449852|NCT06650852|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
214449853|NCT06650852|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
214694663|NCT02345252|DRUG|FTC/RPV/TDF Placebo|Tablets administered orally once daily
214694664|NCT02345252|DRUG|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
214694665|NCT02345252|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
215131926|NCT06103396|BIOLOGICAL|Transplantation of allogeneic MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
215131927|NCT06285487|BEHAVIORAL|Group Program|Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
215131928|NCT01259817|DRUG|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
215131929|NCT01259817|DRUG|Aspirin|81 or 100 mg daily.
215131930|NCT01213394|DRUG|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
214525441|NCT02263859|DEVICE|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
214525442|NCT01624532|BIOLOGICAL|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
214525443|NCT02543307|PROCEDURE|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
214525444|NCT03036722|OTHER|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
214694666|NCT02131948|DRUG|Intranasal insulin|Intranasal spray
214694667|NCT02131948|DRUG|Intranasal placebo|Intranasal spray
214694668|NCT00074841|DRUG|Azithromycin/Chloroquine|
214449854|NCT06650852|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
214449855|NCT06650852|DRUG|Placebo of BRII-179|Placebo of BRII-179 will be given via intramuscular injection
214449856|NCT06650852|DRUG|Placebo of BRII-835|Placebo of BRII-835 will be given via subcutaneous injection
214449857|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
214449858|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
214449859|NCT01361711|BIOLOGICAL|alemtuzumab|Given SC
214449860|NCT01361711|BIOLOGICAL|ofatumumab|Given IV
214449861|NCT01361711|PROCEDURE|biopsy|Correlative studies
214449862|NCT05982717|OTHER|No intervention|As this is an observational study, no intervention will be administered.
214449863|NCT05737160|BIOLOGICAL|Telitacicept|Administered as an SC infusion
214449864|NCT05737160|DRUG|Placebo|Administered as an SC infusion
214449865|NCT02596126|DRUG|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
214449866|NCT02596126|DRUG|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
214449867|NCT01790152|OTHER|Assessment of Therapy Complications|Ancillary studies
214449868|NCT01790152|OTHER|Laboratory Biomarker Analysis|Correlative studies
214449869|NCT01790152|OTHER|Quality-of-Life Assessment|Ancillary studies
214449870|NCT01790152|OTHER|Questionnaire Administration|Ancillary studies
214449871|NCT04923932|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
214449872|NCT04351555|DRUG|Osimertinib|Oral
214449873|NCT04351555|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
214449874|NCT04351555|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
214449875|NCT04351555|DRUG|Placebo|Oral
214449876|NCT04351555|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
214449877|NCT06370793|OTHER|Patient with schizophrenia without intervention|Patients with schizophrenia identified based on exposures of interest to the study
214694669|NCT00074841|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
215131931|NCT01213394|OTHER|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
215131932|NCT05719649|DIETARY_SUPPLEMENT|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
215131933|NCT05719649|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
215131934|NCT04350281|DRUG|Interferon Beta-1B|Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
214449878|NCT03403478|OTHER|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
214449879|NCT03403478|OTHER|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
214449880|NCT03403478|OTHER|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
214449881|NCT03403478|OTHER|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
214449882|NCT01784575|OTHER|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
214449883|NCT05134324|OTHER|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
214449884|NCT05134324|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
214449885|NCT05134324|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
214449886|NCT05134324|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
214449887|NCT06645652|BEHAVIORAL|Training in observational drawing|"* 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing"
214449888|NCT06645652|BEHAVIORAL|Arts engagement through digital galleries|"* 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing"
214449889|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-F8scFv|89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
214449890|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-C9scFv|89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
214449891|NCT06645808|RADIATION|PET/CT scan|IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
214449892|NCT01638026|DRUG|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
214449893|NCT01791816|DRUG|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
214449894|NCT01791816|DRUG|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
214449895|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
214525445|NCT03036722|OTHER|Placebo control porridge|control porridge matched for energy and fat content.
215131935|NCT04350281|DRUG|Hydroxychloroquine|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
215131936|NCT01527123|DRUG|GSK2585823|CLDM1%/BPO3%
215131937|NCT05830708|DIETARY_SUPPLEMENT|Lactobacillus sp. probiotic|The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
214525446|NCT00104845|BIOLOGICAL|human gp100 plasmid DNA vaccine|
214525447|NCT00104845|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
214525448|NCT01245699|BEHAVIORAL|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
214525449|NCT00390806|DRUG|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
214694670|NCT04125797|OTHER|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
214694671|NCT01094730|DEVICE|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
215131938|NCT05830708|BEHAVIORAL|Acceptance and commitment therapy|The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
215131939|NCT05830708|DIETARY_SUPPLEMENT|Placebo|The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
215131940|NCT04262700|DEVICE|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
214694672|NCT01094730|DEVICE|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
215131941|NCT00213863|DEVICE|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
215131942|NCT02483780|BEHAVIORAL|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
215131943|NCT01742273|DRUG|Vitamin K1|Vitamin K1 to slow vascular calcification
215131944|NCT02121379|BEHAVIORAL|pulmonary rehabilitation|
215131945|NCT00523757|DRUG|Spironolactone|
215131946|NCT00523757|DRUG|Placebo|
215131947|NCT06052228|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
215131948|NCT05305352|OTHER|Very low carbohydrate dietary intervention|The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
215131949|NCT06032910|DEVICE|Surgical mesh|Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.
215131950|NCT03028298|DRUG|Low dose sildenafil citrate|
215131951|NCT03028298|DRUG|High dose sildenafil citrate|
215131952|NCT02571114|DIETARY_SUPPLEMENT|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
214525450|NCT00390806|RADIATION|Radiation|Whole brain radiation
214525451|NCT01072734|DRUG|Vaccine|Influenza vaccine
214525452|NCT04685434|OTHER|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
214525453|NCT04661189|BEHAVIORAL|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
214694673|NCT00786136|DRUG|rosuvastatin|rosuvastatin
214694674|NCT02850991|RADIATION|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
214694675|NCT02850991|RADIATION|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
215131953|NCT02571114|DIETARY_SUPPLEMENT|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
215131954|NCT02571114|DIETARY_SUPPLEMENT|Control 1|White bread (serving size = 25 g available carbohydrate)
215131955|NCT02571114|DIETARY_SUPPLEMENT|Control 2|White bread (serving size = 25 g available carbohydrate)
215131956|NCT02812836|DEVICE|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
215131957|NCT00878241|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
215131958|NCT00409643|DRUG|valsartan+amlodipine combination|
214525454|NCT04661189|BEHAVIORAL|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
214525455|NCT05076578|DEVICE|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
214525456|NCT02293278|BEHAVIORAL|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
214525457|NCT04963998|DEVICE|Application of Wound Dressings with Copper Oxide|Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
214525458|NCT00702871|DRUG|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
214525459|NCT00702871|DRUG|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
214525460|NCT05852379|DEVICE|active taVNS|Transcutaneous auricular vague nerve stimulation
214694676|NCT04406051|PROCEDURE|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
215131959|NCT00409643|DRUG|valsartan|
214449896|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
214449897|NCT00912600|OTHER|Intensive Care Unit admission|Intensive Care Unit admission
214525461|NCT05852379|DEVICE|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
214525462|NCT01766323|DRUG|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
214525463|NCT01766323|DRUG|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
214525464|NCT01844908|PROCEDURE|Electroacupuncture|
214694677|NCT04406051|PROCEDURE|norepinephrine infusion and crystalloid co-loading (NOR-CRYST)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
215131960|NCT00409643|DRUG|amlodipine|
215131961|NCT05114824|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
215131962|NCT03201796|DRUG|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
215131963|NCT03201796|DRUG|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
214525465|NCT00593528|DEVICE|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
214525466|NCT00593528|DEVICE|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
214525467|NCT00593528|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
214525468|NCT05507372|DRUG|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
214525469|NCT04363645|OTHER|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
214525470|NCT02135419|DRUG|imiquimod|Applied topically
214525471|NCT02135419|DRUG|fluorouracil|Applied topically
214525472|NCT02135419|DEVICE|infrared photocoagulation therapy|Undergo infrared coagulation
214525473|NCT02135419|DEVICE|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
214694678|NCT02857114|OTHER|massage|
214694679|NCT03363412|DEVICE|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
214694680|NCT02426593|DEVICE|IMED-4|Non-invasive novel lung hydration status sensor.
215131964|NCT00382772|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
214449898|NCT05027386|DRUG|Apatinib, Irinotecan, Temozolomide|"In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 6 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.~In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 6 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred."
214449899|NCT03717506|DRUG|GDC 268 Lotion|GDC 268 is a topical lotion
214449900|NCT03717506|DRUG|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
214694681|NCT00779324|DRUG|Amantadine Hydrochloride|100 mg every morning and noon
215131965|NCT02192515|DRUG|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
215131966|NCT02192515|DRUG|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
215131967|NCT02192515|DRUG|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
215131968|NCT02192515|DRUG|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
215131969|NCT02192515|DRUG|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
215131970|NCT02192515|DRUG|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
215131971|NCT02192515|DRUG|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
215131972|NCT02192515|DRUG|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
215131973|NCT03762408|DEVICE|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
215131974|NCT03762408|DEVICE|Durolane|60 mg HA crosslinked in 3 ml
214449901|NCT03717506|DRUG|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
214449902|NCT06980584|PROCEDURE|Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention|Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
214449903|NCT06980584|PROCEDURE|Pulmonary Vascular Interventional Therapy|According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
214449904|NCT06986369|DRUG|Rivaroxaban 2.5 MG Oral Tablet [Xarelto]|prospective, randomized, 3 months study to clarify the efficacy of rivaroxaban and aspirin versus aspirin in the alone the changes on the number of circulating endothelial cells and endothelial function, and systemic inflammation, platelet and coagulation activation in patients with stable atherosclerotic vascular diseases.
214525474|NCT02135419|DEVICE|laser therapy|Undergo laser therapy
214525475|NCT02135419|OTHER|clinical observation|Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
214525476|NCT02135419|OTHER|laboratory biomarker analysis|Correlative studies
214525477|NCT06311448|DRUG|Single target immunomodulation|Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
214525478|NCT06311448|DRUG|Standard of care|Standard of care during COVID-19 pandemic including steroids.
214525479|NCT00158561|DRUG|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
215131975|NCT00672698|PROCEDURE|SURGERY|ELECTIVE SURGICAL PROCEDURES
215131976|NCT05219357|OTHER|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
215131977|NCT05219357|DRUG|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
215131978|NCT06444035|DRUG|HA35 injection|HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
215131979|NCT04743115|DRUG|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
215131980|NCT02051764|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
215131981|NCT02051764|DRUG|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
215131982|NCT02051764|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
215131983|NCT05919576|DEVICE|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
215131984|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
215131985|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
215131986|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
214449905|NCT06926231|BEHAVIORAL|Protocolized medical hypnosis|Patients who will receive protocolized medical hypnosis before the SBT every day between inclusion and day 7. Medical hypnosis sessions will consist in the administration of a 5-min hypnotic text by a loudspeaker installed in the ICU room, after selection of a hypnotic theme (sea, mountain or animals) by the participant. The hypnosis session will involve an induction phase, a suggestion phase and an emergence phase, along with self-hypnosis tips. The hypnosis session will immediately precede the SBT (\<2h). The intervention is administered before the SBT daily from the randomization to day 7 or until extubation.
214449906|NCT06926231|BEHAVIORAL|Protocolized standard of care|The protocolized standard of care will consist in the description of authorized human/behavioral patient-nurse interactions and patient installation prior to the daily SBT.
214449907|NCT06752902|OTHER|Standard Care Arm|standard care combined with personalised prevention
214449908|NCT06752902|OTHER|standard care combined with personalised prevention|standard care combined with personalised prevention
214449909|NCT06840821|DRUG|MB0151 for injection|In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .
214449910|NCT06909526|BEHAVIORAL|Mindfulness-based stress reduction :MBSR|The intervention consists of 4 weekly virtual sessions and daily mindfulness exercises at home (between 1-5min of duration each, according to the participant's availability. Each session lasts 1 hour (except the first one, which is 1.5 hours due to discussion of the program's logistics). The sessions follow a brief check-in, a lecture on the week's topic, and a guided practice exercise. For the audio guides, participants can select a short version of the daily practice exercise or a longer one, which they will record in the practice logs. Participants also receive information sheets summarizing the weekly sessions.
214449911|NCT06909526|BEHAVIORAL|Usual care|Subjects will continue with their usual healthcare routine and lifestyle. Upon completion of all study visits, subjects will be given access to the audio guides and information sheets for voluntary at-home practice exercises
214694682|NCT00779324|DRUG|Placebo|one placebo tablet every morning and 12 Noon
214694683|NCT05945901|DRUG|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
215131987|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
215131988|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
215131989|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
215131990|NCT00357630|DRUG|gemcitabine hydrochloride|
215131991|NCT00357630|PROCEDURE|quality-of-life assessment|
215131992|NCT03883256|DEVICE|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
215131993|NCT03883256|DEVICE|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
215131994|NCT04303455|DIAGNOSTIC_TEST|blood sampling|sampling serum renin
215131995|NCT00364585|DEVICE|GreenLight Model 120 Laser System|
215131996|NCT02113917|BIOLOGICAL|Identification of biological markers|
215131997|NCT06064630|DEVICE|Automatic continuous positive airway pressure|Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
215131998|NCT03557970|DRUG|Edicotinib|Given PO
215131999|NCT03557970|OTHER|Pharmacokinetic Study|Correlative studies
215132000|NCT03215017|DEVICE|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
215132001|NCT03215017|DRUG|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
214449912|NCT06931873|COMBINATION_PRODUCT|SCRT+Capoex+QL706|Using a short-course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 25 Gy (5 Gy/treatment × 5 treatments); 2 weeks of rest after the end of radiotherapy were followed by 4 cycles of Capoex combined with QL706.
214449913|NCT06931873|COMBINATION_PRODUCT|LCRT+Capoex+QL706|Using a long course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 50 Gy (2 Gy/treatment x 25 treatments); a 2-week break at the end of radiotherapy was followed by 4 cycles of Capoex combined with QL706.
214449914|NCT06932692|OTHER|magnetoencephalography|500 patients with Parkinson's disease and essential tremor will undergo magnetoencephalography
214449915|NCT06925945|PROCEDURE|regional anestesia|Modified thoracoabdominal plane block (M-TAPA) and rectus sheath block with local infiltration analgesia
214449916|NCT06931613|DRUG|Nivolumab|Nivolumab with or without bendamustine is administered to children prior to auto-HSCT
215132002|NCT04055064|DIETARY_SUPPLEMENT|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
215132003|NCT05771103|DEVICE|thermal Radiofrequency neurolysis of Stellate ganglion|Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
215132004|NCT04609098|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
214449917|NCT06942585|DEVICE|Kinesiology Tape|An elastic therapeutic tape applied to the ankle and knee using standard kinesiology taping techniques. The tape is stretched to approximately 10-15% during application and is designed to mimic the properties of human skin. It aims to provide sensory stimulation, improve proprioceptive feedback, and support joint function without limiting range of motion. The application targets muscles and tendons surrounding the knee and ankle, commonly used in both preventive and rehabilitative physiotherapy.
214449918|NCT06942585|DEVICE|Dynamic tape|A biomechanical tape characterized by high elasticity (over 200%) and strong resistance, applied to the ankle and knee to assist movement and absorb load. The tape is applied in a shortened muscle position with maximal stretch across the joint, following the manufacturer's guidelines (GripIt ACTIVETAPE, 5 cm width). This taping method aims to provide both mechanical support and neurosensory input, facilitating muscle activation and improving joint stability during movement. It is used to address both biomechanical and proprioceptive components of lower limb control.
215132005|NCT04609098|DRUG|Tafenoquine 100mg [Arakoda]|Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
215132006|NCT02656277|OTHER|Decision Tool|
215132007|NCT02656277|OTHER|Information on Shoulder Dislocation|
215132008|NCT00976807|OTHER|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
215132009|NCT00786669|DRUG|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
215132010|NCT00786669|DRUG|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
215132011|NCT00786669|DRUG|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
215132012|NCT00786669|DRUG|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
215132013|NCT00786669|DRUG|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
215132014|NCT00300417|DRUG|VRC-WNVDNA020-00-VP|
215132015|NCT04038541|DIETARY_SUPPLEMENT|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
215132016|NCT04038541|DIETARY_SUPPLEMENT|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
215132017|NCT05797012|OTHER|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
215132018|NCT05701293|PROCEDURE|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
215132019|NCT03155724|DEVICE|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
215132020|NCT03633851|DEVICE|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
215132021|NCT03633851|OTHER|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
215132022|NCT04540263|DIAGNOSTIC_TEST|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
215132023|NCT02987725|BEHAVIORAL|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
215132024|NCT02987725|BEHAVIORAL|Attention Control|A 30-minute historical story read by a research clinician.
214449919|NCT04280445|OTHER|Psychological therapy|Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
214449920|NCT06847828|OTHER|QPL|The QPL is in the form of a structured list of questions that caregivers would like to ask. It includes 17 questions on concept communication and 20 questions on end-of-life care. You can check the questions you want to ask and then discuss them with the medical team.
214449921|NCT05993078|DRUG|0.9% NaCl 2000ml|The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
214449922|NCT05993078|DRUG|0.9% NaCl 200-400ml|The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
214449924|NCT05137899|COMBINATION_PRODUCT|Neoadjuvant|Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
215132025|NCT05093816|BEHAVIORAL|Common Elements Toolbox|The Common Elements Toolbox (COMET) is an online single-session intervention. It is entirely self-guided and lasts about 60 minutes. Participants complete a series of reading and writing exercises focused on four modules: cognitive restructuring, behavioral activation, gratitude, and self-compassion. The intervention is entirely unguided and completed in a single sitting.
214449925|NCT06846645|OTHER|No intervention|Patients will receive clinical treatment with no special intervention in this observational study. There is no difference in term of treatment of patients. It only involves one additional blood sampling early after admission.
214449926|NCT05610774|DRUG|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
214449927|NCT05610774|DRUG|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
214449928|NCT06755359|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|Radioactive sources named Alpha DaRT sources: Ra - 224 coated onto titanium tubes inserted into the tumor.
214449929|NCT06217458|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
214449930|NCT06845722|OTHER|Balance training|"* The balance training will be given for 12 weeks (2 sessions/week, 30-35 in each) that included six balance exercises per training session.~* After 5-min warm-up program including general (e.g., neck rolls, shoulder circles, side bends, hip circles, marsh in place) and specific (e.g., two-/one-legged stance on unstable devices, forward/backward beam walking).~* Two sets per balance exercise will be performed for 30s each with a 60s rest period between sets and a 90 s break between exercises. Yet, both groups will execute the same training volume (i.e., number of exercises, number of sets per exercise, and duration per set of exercise).~* Progression during training will be achieved by means of increasing exercise duration (i.e., from 30s over 45s to 60 s), change of stance (i.e., two-legged stance, tandem. stance, one-legged stance) and walking (i.e., forward, backward) condition, manipulation of visual input (e.g., eyes opened vs. closed), and concurrent execution of cognitive"
214449931|NCT06845722|OTHER|Cognitive Rehabilitation:|"* The cognitive rehabilitation will be given for 12 weeks ( 2 sessions/week,30 min each session). The individual sessions for the CR approach will involve an individualized intervention focusing on a personally meaningful goal (e.g., maintaining attention while flipping cards and finding matching pairs, learning to use a cellular phone, remembering the names of people).~* The individual sessions will be consisted of practical strategies and aids, compensation strategies (e.g., using a memory notebook), and the techniques for stress management to improve performance and functioning in relation to goals. The group sessions of CR involved some tasks of cognitive training.~* The group sessions will be focused on practicing time-and-place orientation through paper-and pencil tasks provided by a therapist and use of a calendar and personal memory notebook or cellular phone at the start of each session. (30)~* The group sessions also involved matching faces and names and learning memory"
214449932|NCT06843629|DIAGNOSTIC_TEST|Specific positron imaging agents targeting MSLN|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using specific positron imaging agents targeting MSLN (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
214449933|NCT02694094|DIETARY_SUPPLEMENT|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
214449934|NCT06845189|OTHER|Modified Robbery Exercises|Prescribed set of Modified Robbery exercises will be applied
214449935|NCT06845189|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy Treatment for Frozen Shoulder
214449936|NCT04049539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214449937|NCT03588481|DEVICE|DESyne X2|Novolimus-eluting stent
214449938|NCT06847594|DRUG|ringer lactate (20ml/kg)|ringer lactate 20 ml/kg over the first 90 to 120 minutes after induction intraoperatively
214449939|NCT06847594|DRUG|Dextrose 10%|Dextrose 10% 250 ml over 60 minutes
214525480|NCT03550014|PROCEDURE|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
215132026|NCT00732212|DEVICE|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
215132027|NCT00732212|OTHER|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
215132028|NCT01991808|RADIATION|Radiotherapy|
215132029|NCT00321789|BEHAVIORAL|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
215132030|NCT04970277|OTHER|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
215132031|NCT04970277|OTHER|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
214449940|NCT05777031|DRUG|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
214449941|NCT06848101|DIETARY_SUPPLEMENT|Carotenoid Group|Treatment will contain 20mg free lutein (10mg/softgel), 4 mg free zeaxanthin (2mg/softgel), 40mg maqui berry extract (20mg/softgel), 6 mg astaxanthin (3 mg/softgel), 80mg bilberry extract (40mg/softgel), flaxseed oil (150mg/softgel), and vitamin E (5IU/softgel)
214449942|NCT06848101|DIETARY_SUPPLEMENT|Control (placebo) group|Flaxseed Oil (330mg)
214449943|NCT01525966|DRUG|carboplatin|Given IV
214449944|NCT01525966|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214525481|NCT03550014|PROCEDURE|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
214525482|NCT04150250|DRUG|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
215132032|NCT02588599|DEVICE|Erchonia LUNULA|Active low level laser light therapy
215132033|NCT02346045|PROCEDURE|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
215132034|NCT03243617|OTHER|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
215132035|NCT03243617|OTHER|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
215132036|NCT03053375|DEVICE|MDCure|Battery powered portable pulsed electromagnetic therapy device
215132037|NCT04777617|OTHER|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
215132038|NCT03309020|PROCEDURE|Cataract surgery|Cataract surgery and aqueous humor sampling.
215132039|NCT03770312|DRUG|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
215132040|NCT03770312|DRUG|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
214449945|NCT01525966|OTHER|laboratory biomarker analysis|Correlative studies
214449946|NCT06847672|DIAGNOSTIC_TEST|preoxygenation|The time required to reach EtO2 90% and the time until ORI drops below 0.55
214449947|NCT06845995|DIETARY_SUPPLEMENT|Synbiotic supplement|Daily synbiotic supplement: The synbiotic supplement (contains both probiotic and prebiotic) that will be used in this study is commercially available; Celebrate Balance. The probiotic will be one capsule daily and consists of lactobacillus acidophilus, Bifidobacterium longum, lactobacillus rhamnosus, and lactobacillus gasser at 28,5 Billion CFUs at manufacture / 15 billion CFUs guaranteed at expiration
214449948|NCT04328844|DRUG|IOA-244|IOA-244 will be administered orally once daily (QD)
214449949|NCT04328844|DRUG|Avelumab Injection|Avelumab will be administered IV every 2 weeks
214449950|NCT04328844|DRUG|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
214449951|NCT04328844|DRUG|Cisplatin|Cisplatin will be administered IV every 3 weeks
214449952|NCT04328844|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
214449953|NCT06845787|BEHAVIORAL|Live-music therapy|Children will be offered live-music therapy for 3 consecutive sessions, 30 minute sessions in which 10 to 20 minutes of music is provided by a trained music therapist in the presence of parents. In the sessions, the music therapist will make a tailored plan for each child to avoid overstimulation, which includes choosing the appropriate instrument, determining the child's behavioural state, and continuously monitoring the child (i.e., looking for signs of relaxation but also of overstimulation such as tension, crying movements, hiccups, yawning or frowning). The music therapist will collaborate with parents in constructing a program for the sessions. Parents will be actively involved in the sessions, to stimulate their role as caregiver and empower them. The contents of the live-music is thus constantly evaluated and adapted for the individual child.
214449954|NCT06846983|DEVICE|Peripheral perfusion index pulse oximeter|Masimo pulse oximeter probe for measuring peripheral perfusion index and predicting success of caudal block
214525483|NCT04150250|DRUG|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
214449955|NCT06843837|OTHER|Sweet orange essential oil aromatherapy|The sweet orange essential oil used in the study was prepared by the Food Engineering Department of Fırat University. To obtain the essential oil used for aromatherapy in this study, the peels of Citrus sinensis sweet oranges were utilized. The orange peels were cut into small pieces of approximately 3-5 mm in size, placed into a boiling flask, and distilled water was added. Based on the analysis results, the percentage composition of the total essential oil fatty acids was determined. The chemical composition analysis revealed that D-limonene was the major component, comprising 90% of the total oil. The oil is 100% pure essential oil, containing up to 90% D-limonene, along with citral and linalool. A cotton ball infused with three drops of sweet orange essential oil was held 4 to 5 cm away from the student's nose, and they were instructed to breathe slowly for five minutes. After this, the students were asked to perform IV cannulation on the patient.
214449956|NCT06847451|DIAGNOSTIC_TEST|Prognostic biomarker as Red Cell Distribution Width|Assessment of prognostic value of Red Cell Distribution Width in septic intensive care unit patients for 28 days mortality.
214449957|NCT05085977|BIOLOGICAL|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
214449958|NCT03948373|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
214449959|NCT05197816|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that adapts to patient activity and/or physiology
214449960|NCT05098795|BEHAVIORAL|Behavioral Activation (BA)|BA seeks to increase the positive reinforcement patients experience from their natural environment by promoting prosocial and valued experiences. BA has been found to improve substance use treatment retention and adherence, as well as medication adherence in low-income individuals with HIV/AIDS.
214449961|NCT03554109|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214449962|NCT03554109|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214449963|NCT03554109|DRUG|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
214525484|NCT04150250|OTHER|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
215132041|NCT04254393|BEHAVIORAL|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
215132042|NCT04254393|OTHER|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
215132043|NCT02567981|DIETARY_SUPPLEMENT|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
215132044|NCT02567981|DIETARY_SUPPLEMENT|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
215132045|NCT02567981|DIETARY_SUPPLEMENT|Ferrous sulphate|"Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
215132046|NCT02567981|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
215132047|NCT02106000|DEVICE|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
215132048|NCT00644696|DRUG|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
215132049|NCT01102114|BIOLOGICAL|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
215132050|NCT01102114|BIOLOGICAL|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
214525485|NCT04150250|DRUG|Antibiotics|"Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
214525486|NCT01112371|DRUG|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
214525487|NCT02511847|DRUG|Afatinib|"1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
214525488|NCT01309633|DRUG|12.5mg sunitinib with Cisplatin and Gemcitabine|"1\) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
214525489|NCT01309633|DRUG|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
214525490|NCT01309633|DRUG|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
215132051|NCT04434417|DEVICE|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
215132052|NCT01849601|DEVICE|percutaneous transluminal angioplasty balloon catheter|
214449964|NCT03554109|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214449965|NCT03554109|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
215132053|NCT05563129|OTHER|First aid lessons|The school children will have first aid training
214449966|NCT03554109|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214449967|NCT03554109|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
215132054|NCT03007550|PROCEDURE|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
215132055|NCT03007550|PROCEDURE|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
214449968|NCT03554109|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
215132056|NCT03466385|DEVICE|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
215132057|NCT03466385|DEVICE|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
214449969|NCT03554109|BIOLOGICAL|GI-6207|CEA yeast vaccine
214449970|NCT03554109|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214449971|NCT03554109|DRUG|Avelumab|Avelumab
215132058|NCT03107481|DRUG|Acetaminophen|Acetaminophen 1g IV
214449972|NCT03554109|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
215132059|NCT03107481|DRUG|Hydromorphone|Hydromorphone 1mg IV
214449973|NCT03554109|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
214449974|NCT03554109|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214449975|NCT03554109|DRUG|Doxorubicin HCL|Doxorubicin HCL
214449976|NCT03554109|DRUG|paclitaxel|paclitaxel
214449977|NCT05269160|DRUG|Dermaprazole 1%|Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
214449978|NCT05269160|DRUG|Dermaprazole 2%|Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
214449979|NCT03840421|DRUG|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
214449980|NCT03840421|DRUG|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
214449981|NCT03840421|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
214449982|NCT03840421|DRUG|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
215132060|NCT00000235|DRUG|Buprenorphine|
215132061|NCT04874714|BIOLOGICAL|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
215132062|NCT04874714|BIOLOGICAL|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
215132063|NCT04874714|BIOLOGICAL|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
215132064|NCT04874714|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
214449983|NCT05063994|DRUG|Chronocort|Over-encapsulated hydrocortisone modified-release capsule for oral administration.
214449984|NCT05063994|DRUG|Cortef|Over-encapsulated hydrocortisone immediate-release tablet for oral administration.
214449985|NCT05063994|OTHER|Placebo|Matching placebo
214449986|NCT06245564|DRUG|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
214449987|NCT06245564|DRUG|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
214449988|NCT06245564|DRUG|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
214449989|NCT06245564|OTHER|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
214449990|NCT06245564|OTHER|Histamine|After the cream removal, itch will be induced using histamine in the first session
214449991|NCT06245564|OTHER|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
214525491|NCT01309633|DRUG|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
214525492|NCT05664061|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
214525493|NCT05664061|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
214525494|NCT05664061|DRUG|Placebo|twice daily inhalation throughout the treatment period
214525495|NCT01243658|DRUG|Oxytocin|Oxytocin
214525496|NCT01243658|OTHER|placebo|placebo
215132065|NCT05467241|BEHAVIORAL|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
215132066|NCT04618003|BEHAVIORAL|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
215132067|NCT02859714|OTHER|screening data|
215132068|NCT02501252|PROCEDURE|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
215132069|NCT04435483|DRUG|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
215132070|NCT04435483|DRUG|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
215132071|NCT04435483|DRUG|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
214449992|NCT05570838|DEVICE|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
214525497|NCT01786551|DRUG|Eplerenone|50 mg daily for 14 days
214525498|NCT04247906|DRUG|Narsoplimab|
214525499|NCT03559296|DIAGNOSTIC_TEST|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
214525500|NCT03669965|DRUG|KRT-232|KRT-232, administered by mouth
214525501|NCT03669965|DRUG|Ruxolitinib|Ruxolitinib per approved prescribing label
214525502|NCT03576625|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
214449993|NCT05570838|DEVICE|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
214449994|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
214449995|NCT04516616|DRUG|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
214525503|NCT03576625|DIETARY_SUPPLEMENT|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
214525504|NCT05588739|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
214525505|NCT00692757|DRUG|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
214525506|NCT00692757|DRUG|Iodopovidone|Iodopovidone
214525507|NCT04018521|BEHAVIORAL|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
214525508|NCT04018521|BEHAVIORAL|CSC Usual Care|standard of care provided to youth following first episode of psychosis
214449996|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
214449997|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
214449998|NCT03323554|DEVICE|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
214449999|NCT03323554|DEVICE|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
214450000|NCT03723772|DRUG|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
214450001|NCT03723772|DRUG|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
214450002|NCT04509427|BEHAVIORAL|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
214450003|NCT04509427|BEHAVIORAL|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
214450004|NCT04509427|BEHAVIORAL|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
214450005|NCT04509427|BEHAVIORAL|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
214450006|NCT04509427|BEHAVIORAL|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
214450007|NCT05478837|DRUG|Cyclophosphamide|Given IV
214450008|NCT05478837|DRUG|Fludarabine|Given IV
214450009|NCT05478837|BIOLOGICAL|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
214450010|NCT06757933|COMBINATION_PRODUCT|The Spencer technique|The Spencer technique, which consists of seven different manual movements intended to increase shoulder mobility and lessen pain, was used to treat the participants in this group. The method seeks to improve blood flow, loosen up the shoulder joint and soft tissues, and reduce any tightness or impingement that is causing pain in the sub-acromial area. By re-establishing appropriate shoulder function and movement patterns, the Spencer approach is commonly used to treat disorders including adhesive capsulitis.
214525509|NCT01391234|RADIATION|STAT RT planning and delivery workflow|"* Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
214525510|NCT03852771|DEVICE|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
215132072|NCT06206538|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214525511|NCT05280509|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
215132073|NCT06206538|BEHAVIORAL|Rehabilitation therapy|"he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
215132074|NCT05930119|DRUG|HMPL-453|300 mg HMPL-453
215132075|NCT05930119|DRUG|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
215132076|NCT00003316|DRUG|gemcitabine hydrochloride|
215132077|NCT01319981|DRUG|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
215132078|NCT01319981|DRUG|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
215132079|NCT01319981|DRUG|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
214450011|NCT06757933|COMBINATION_PRODUCT|isotonic workouts|This group's members engaged in isotonic workouts that emphasized forward flexion and extension motions. Both concentric (shortening the muscle) and eccentric (lengthening the muscle) motions were used in these exercises. These exercises were designed to increase shoulder range of motion and strengthen the rotator cuff muscles. People with Adhesive Capsulitis may have less pain and have better shoulder function if they perform isotonic workouts, which increase muscular strength and stability.
214450012|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
214450013|NCT05633446|OTHER|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
214450014|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
214450015|NCT05633446|OTHER|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
214450016|NCT05514730|BEHAVIORAL|Phase-based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children|PBT is a skills-based protocol that primarily works with caregivers to manage problematic behavior and to teach children healthy information about sex and sexuality. It was designed based on the current empirical knowledge regarding the etiology and treatment of childhood problematic sexual behavior. It is delivered in 12 weekly sessions, with each session lasting approximately 50 minutes.
215132080|NCT01319981|DRUG|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
215132081|NCT01319981|DRUG|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
215132082|NCT01319981|DRUG|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
215132083|NCT01319981|DRUG|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
215132084|NCT01319981|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
215132085|NCT01319981|DRUG|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
214525512|NCT05280509|DRUG|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
214525513|NCT05828654|BEHAVIORAL|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
214525514|NCT05828654|BEHAVIORAL|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
214694684|NCT05945901|DRUG|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
215132086|NCT01319981|DRUG|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.
214450017|NCT05514730|BEHAVIORAL|Treatment-as-Usual (TAU)|The TAU intervention designed for this trial relies largely on the delivery of child-focused treatment techniques, particularly on the development of therapeutic rapport through the utilization of non-directive techniques. These sessions are supplemented with educational materials for the caregiver on child behavior and parenting recommendations. This treatment is designed to be administered over 12 weekly sessions, with each session lasting approximately 50 minutes.
215132087|NCT01319981|DRUG|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
215132088|NCT01319981|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
215132089|NCT05039957|OTHER|joint preparation|fixation of fracture with joint preparation
215132090|NCT05039957|OTHER|without joint preparation|fixation of fracture without joint preparation
215132091|NCT00884546|DRUG|BMS-833923|Capsule, Oral, Once daily, 6 months
215132092|NCT00884546|DRUG|Lenalidomide|Capsule, Oral, Once daily, 6 months
215132093|NCT00884546|DRUG|Dexamethasone|Capsule, Oral, Once a week, 6 months
215132094|NCT00884546|DRUG|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
214450018|NCT04581603|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 \& 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
215132095|NCT04527640|DIETARY_SUPPLEMENT|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
214450019|NCT04581603|BEHAVIORAL|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
215132096|NCT04527640|OTHER|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
215132097|NCT02919761|DRUG|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
214450020|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
214525515|NCT00170950|DRUG|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
214525516|NCT00170950|DRUG|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
215132098|NCT02919761|DRUG|Placebo|Matching placebo 1 mL for subcutaneous injection
215132099|NCT06590090|BIOLOGICAL|Natrunix 400 mg|"The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.~Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0."
215132100|NCT06590090|DRUG|Placebo|Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
215132101|NCT06590090|DRUG|Methotrexate (MTX)|Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.
215132102|NCT01231958|BEHAVIORAL|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
214450021|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
214450022|NCT06321042|DEVICE|Knee arthroplasty|Knee arthroplasty surgery with perseus orthokey alignment device
214525517|NCT00170950|DRUG|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
214525518|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
214525519|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
215132103|NCT06593132|PROCEDURE|endoscopic breast conserving surgery|Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.
215132104|NCT00000140|DRUG|Perfluoropropane|
215132105|NCT00000140|DRUG|Sulfur Hexafluoride|
215132106|NCT00000140|DRUG|Silicone Oil|
215132107|NCT01796925|DEVICE|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
214694685|NCT02918487|DRUG|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
214694686|NCT02918487|DRUG|Placebo|Inactive compound that is similar looking as the intervention
214694687|NCT02918188|DRUG|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
214694688|NCT04774042|DIETARY_SUPPLEMENT|Infloran probiotic|Infloran
214694689|NCT04774042|DIETARY_SUPPLEMENT|HAC probiotic|HAc probiotic
214694690|NCT04774042|DIETARY_SUPPLEMENT|Infloran placebo|Infloran placebo
214694691|NCT04774042|DIETARY_SUPPLEMENT|HAC placebo|HAC placebo
214694692|NCT03665350|DRUG|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
214694693|NCT00916123|DRUG|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
214694694|NCT00916123|DRUG|Prednisone|10 mg per day starting on cycle 1, day 1
214694695|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
215132108|NCT06199713|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography|research scan 3-4 weeks after start of immunotherapy
215132109|NCT06699927|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
215132110|NCT06878690|OTHER|Online Questionnaire|Completion of an online questionnaire via the secure RedCap platform
214450023|NCT04630262|DEVICE|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
214450024|NCT04630262|DEVICE|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
214450025|NCT03721497|DRUG|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
214450026|NCT03828994|BEHAVIORAL|Tech-PN|"* text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment"
214450027|NCT05114460|DRUG|Naloxone|Intranasal Naloxone
214450028|NCT05114460|DRUG|Marijuana|Vaped Marijuana
214450029|NCT06351150|DRUG|Angiotensin II Injection|1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.
214450030|NCT06351150|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection, not containing active ingredients.
214450031|NCT01911091|BEHAVIORAL|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
214694696|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
215132111|NCT06704412|BEHAVIORAL|floss band|"The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
215132112|NCT06704412|BEHAVIORAL|Sham (No Treatment)|The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
215132113|NCT06716437|BEHAVIORAL|Prehabilitation|"Patients will undergo a physiotherapy-led digitally-enabled prehabilitation program before lung resection surgery.~The intervention will be delivered through a mobile app and supported by tele-health and will consist of:~i) watching six educational videos embedded on the app on relevant topics to prepare for surgery, such as the importance of physical fitness, breathing exercises after surgery, and pain management.~ii) a physical activity coaching program to increase daily activity with feedback iii) a home-based, unsupervised exercise program consisting of 10 whole body strengthening exercises delivered in a video format iv) an inspiratory muscle training program using a hand-held device to be performed twice daily."
214450032|NCT05432557|PROCEDURE|external oblique intercostal plain block (EOIP)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
214450033|NCT05432557|PROCEDURE|subcostal transversus abdominis plane block (SCTAP)|The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
215132114|NCT06887335|PROCEDURE|Deep Sedation Under Proceduralist Direction with Pre-emptive Endotracheal Intubation|"If an eligible subject consents to participate in the study, deep sedation and preemptive endotracheal intubation will be performed, followed by bronchoscopy. Deep sedation will be administered according to the study protocol, with final approval of sedative administration given by the proceduralist. Oxygen will be supplied at a flow rate of 4-6 L/min via a nasal cannula before sedative administration.~To achieve a deep sedation state (Modified Observer's Assessment of Alertness/Sedation \[MOAA/S\] score ≤ 2, defined as the patient not opening their eyes despite repeated verbal stimuli), an initial dose of 50 mcg fentanyl will be administered, followed by 2.5-5 mg of remimazolam. The sedation depth will be assessed every two minutes using the MOAA/S score. If the patient has not reached deep sedation, an additional 2.5 mg of remimazolam will be administered.~Once deep sedation is achieved, lidocaine will be sprayed onto the trachea and bronchi using a bronchoscope for local anesthe"
214450034|NCT05432557|OTHER|control group|No LA injection
214450035|NCT05883111|DIAGNOSTIC_TEST|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
214450036|NCT05272618|DIAGNOSTIC_TEST|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
214450037|NCT04165941|BIOLOGICAL|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
215132115|NCT06704568|OTHER|exercise|Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group: Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
214450038|NCT05155319|BIOLOGICAL|UFluA 20 µg each antigen/dose|Low dose
214450039|NCT05155319|BIOLOGICAL|UFluA 60 µg each antigen/dose|High Dose
214450040|NCT05155319|BIOLOGICAL|Placebo|Placebo
214450041|NCT03111290|DEVICE|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
214450042|NCT03111290|DEVICE|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
214450043|NCT06340932|DEVICE|Iovera|Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration
214450044|NCT06340932|DRUG|Celecoxib|200mg BID
214525520|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
214525521|NCT00748098|DRUG|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
214525522|NCT00748098|DRUG|Placebo|Placebo
214525523|NCT00488761|DRUG|Tigecycline|
214525524|NCT04070521|OTHER|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
214525525|NCT03136588|DEVICE|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
214694697|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
214450045|NCT06340932|DRUG|Acetaminophen|1000mg q8h
214450046|NCT06340932|DRUG|Oxycodone|As needed
214450047|NCT06340932|DRUG|Tramadol|As needed
214450048|NCT06340932|DRUG|Bupivacaine Hydrochloride|20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK
215132116|NCT06925243|DRUG|Neoadjuvant apatinib combined with sintilimab and perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid) Apatinib: 250mg, po, day1-21, for 3 cycles preoperatively
215132117|NCT06925243|DRUG|Neoadjuvant sintilimab combined with perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)
215132118|NCT06922305|DRUG|HR19042 Capsule, Tarpeyo®, Budenofalk®|In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.
214450049|NCT06340932|DRUG|Acetaminophen 500Mg Cap|500mg q6h prn
215132119|NCT06725082|BIOLOGICAL|Recombinant Humanized Type III Collagen Injection|rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
215132120|NCT06837493|OTHER|Resistance based hand exercises and functional task-oriented hand exercise|The interventions for HEG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
215132121|NCT06837493|OTHER|Cognitive training|The interventions for CTG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
215132122|NCT04721223|DRUG|JAB-3068|JAB-3068 administrated orally as a tablet.
215132123|NCT04721223|DRUG|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
215132124|NCT02231515|DEVICE|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
215132125|NCT02231515|DEVICE|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
215132126|NCT02962401|DRUG|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
215132127|NCT02962401|DRUG|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
215132128|NCT05550779|BEHAVIORAL|Mental Exercise|Participant perform a 10-minute mental exercise
215132129|NCT06551051|DRUG|duloxetine|Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
215132130|NCT03349723|DRUG|BI 1265162|Single rising dose groups
215132131|NCT03349723|DRUG|Placebo|Single rising dose groups
215132132|NCT05482139|PROCEDURE|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
215132133|NCT00684866|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
214525526|NCT01324011|BEHAVIORAL|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
215132134|NCT00684866|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
215132135|NCT02923141|BEHAVIORAL|Neutral Writing|
215132136|NCT02923141|BEHAVIORAL|Expressive Writing|
215132137|NCT02923141|BEHAVIORAL|Contingency Management|
215132138|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
215132139|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
214450050|NCT04975880|DEVICE|SC+ Hemodialysis System|Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
215132140|NCT00399308|DEVICE|Control (compression bandaging)|Multi-layer compression bandaging
215132141|NCT03409796|DIETARY_SUPPLEMENT|Gluten|Gluten powder.
215132142|NCT01679288|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
215132143|NCT04307797|DRUG|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
215132144|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
215132145|NCT04307797|DRUG|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
215132146|NCT04307797|DRUG|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
215132147|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
215132148|NCT04307797|DRUG|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
215132149|NCT06280924|BEHAVIORAL|Supported Exercise|Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.
214450051|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
214450052|NCT03984695|BEHAVIORAL|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
214450053|NCT04638998|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|MRSI is a non invasive imaging technique used to detect neuroinflammation.
214450054|NCT04638998|PROCEDURE|Blood draw|Blood will be drawn to assess systemic inflammation in Gulf War verterans.
214450055|NCT03692676|DEVICE|Spiriva Respimat|soft-mist inhaler
214450056|NCT04491058|DIAGNOSTIC_TEST|SSCT thickness measurement|Thickness measurement with ultrasound
214450057|NCT04044937|DRUG|F-18 Fluoroethyltyrosine (FET)|Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
214450058|NCT04044937|PROCEDURE|Positron Emission Tomography (PET)|All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
214450059|NCT05997589|BEHAVIORAL|Behavioral Intervention|Receive educational materials
214450060|NCT05997589|OTHER|Educational Intervention|Attend financial health educational program
214450061|NCT05997589|OTHER|Questionnaire Administration|Ancillary studies
214450062|NCT05831540|OTHER|Discussion|Participate in focus group
214450063|NCT05831540|OTHER|Educational Activity|Undergo training to use CDS tool
214450064|NCT05831540|BEHAVIORAL|Healthcare Activity|Utilize CDS tool
214450065|NCT05831540|OTHER|Survey Administration|Complete survey
214450066|NCT04507555|PROCEDURE|Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing|"The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist."
214450067|NCT04507555|PROCEDURE|Standard care antidepressant selection and dosing|Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
214450068|NCT03542383|DEVICE|High Definition Transcranial Direct Current Stimulation|Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
214450069|NCT03542383|DEVICE|Sham High Definition Transcranial Direct Current Stimulation|Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
214450070|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
214450071|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
214450072|NCT06024122|OTHER|IRM exam|A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
214450073|NCT05877014|OTHER|questionnaires|EQ-5D-5L and SF-12
214450074|NCT05877014|OTHER|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
214450075|NCT04966104|BEHAVIORAL|ODYSSEE-vCHAT|Automated digital counselling program with social network support
214450076|NCT05831657|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
214525527|NCT06819579|DRUG|1.5% Lidocaine|After successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose
214525528|NCT06819579|DRUG|1.0% Lidocaine|After successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose
214450077|NCT05831657|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
214450078|NCT05519228|DEVICE|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
214450079|NCT01180634|DRUG|Aeroquin|Inhalation Solution
214525529|NCT06819579|DRUG|0.5% Lidocaine|After successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose
214525530|NCT03275467|OTHER|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
214694698|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
214525531|NCT03430440|DEVICE|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
214525532|NCT03430440|DEVICE|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
214525533|NCT02442622|OTHER|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
214525534|NCT02442622|DEVICE|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
214525535|NCT01617889|OTHER|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
214450080|NCT01180634|DRUG|Placebo|Inhalation Solution
214450081|NCT06166004|OTHER|Balance Training|Balance Training device with VR
214450082|NCT06166004|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
214450083|NCT06783725|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) is a structured program designed to help individuals with chronic insomnia improve their sleep patterns through mindfulness practices. It combines mindfulness meditation, cognitive behavioral strategies, and sleep education to address the cognitive and physiological factors that disrupt sleep. The therapy emphasizes present-moment awareness, acceptance of sleep difficulties, and the reduction of sleep-related anxiety to promote better sleep quality and overall well-being.
214450084|NCT06783725|BEHAVIORAL|Wait-list control|The wait-list control group consists of participants who do not receive the intervention during the initial study period but are placed on a waitlist to receive it after the trial concludes. This group serves as a comparison to evaluate the effectiveness of the intervention while ensuring participants eventually have access to the treatment. It helps control for natural changes over time and the psychological effects of expecting future treatment.
214450085|NCT06786221|DEVICE|mini-implant template|"The proposed structure will be made of three main components: a tooth guide part, a gingival guide part, and a steering part. The tooth guide and gingival guide parts are firmly connected by fracture lines. The mini-implant guide part is specifically designed to accommodate the angle and position required for miniscrew insertion. On the basis of the resin guide plate, add a guide hole structure and change it to simulate the patient's actual tooth root condition.~During usage, the guide can be pre-designed in accordance with the desired planting position and direction of the patient's mini-implant, enabling precise guidance during the implantation process. The designed guide's data is inputted into EnvisionTEC Vida 3D printer to create the mini-implant guide. Prior to the implantation of the mini-screw, patients will be informed about the potential risks and required to sign an informed consent form."
214450086|NCT06146842|DRUG|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
214525536|NCT01617889|OTHER|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
214525537|NCT02765867|DRUG|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
214525538|NCT03771261|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
214525539|NCT03771261|DIETARY_SUPPLEMENT|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
214525540|NCT05085678|DEVICE|Co'moon (online website to support women with AET)|"The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
214525541|NCT06987500|DRUG|XNW29016|Oral Medication. The study set 7 dose level cohorts in dose escalation part.
214525542|NCT06987500|DRUG|XNW29016|Oral Medication
214525543|NCT05836753|DRUG|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
214450087|NCT03692611|BEHAVIORAL|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
214450088|NCT03692611|BEHAVIORAL|Comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
214450089|NCT04419168|OTHER|cCBT|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.
214450090|NCT04419168|OTHER|m-Education|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
214450091|NCT06787989|BIOLOGICAL|BCMA-CD19 cCAR T cells|• BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214525544|NCT05836753|DRUG|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
214694699|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
214525547|NCT04890158|OTHER|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
214525548|NCT01946477|DRUG|Pomalidomide|
214525549|NCT01946477|DRUG|Dexamethasone|
214525550|NCT01946477|DRUG|Daratumumab|
214525551|NCT06993181|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
214525552|NCT06993181|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
214525553|NCT06993181|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
214525554|NCT06993181|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
215132150|NCT06280924|BEHAVIORAL|Standard Care|Participants will receive standard care
215132151|NCT02452307|BIOLOGICAL|Peptide vaccine|subcutaneous
215132152|NCT02452307|DRUG|Montanide ISA-51|subcutaneous
215132153|NCT02452307|DRUG|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
215132154|NCT02452307|DRUG|Imiquimod|epicutaneous
215132155|NCT02452307|DRUG|mRNA|subcutaneous
215132156|NCT02452307|DRUG|Protamin|subcutaneous
215132157|NCT02452307|PROCEDURE|local hyperthermia|
215132158|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
215132159|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
215132160|NCT04462640|OTHER|Management of Infant Digestive Disorders and Quality of Life|The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
215132161|NCT03195881|OTHER|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
215132162|NCT01602224|DRUG|Placebo|Administered IV
215132163|NCT01602224|DRUG|Dexamethasone|Administered orally
215132164|NCT01602224|DRUG|Bortezomib|Administered SQ
215132165|NCT01602224|BIOLOGICAL|Tabalumab|Administered IV
214525555|NCT06860763|DRUG|Chinese herbal medicine|The general treatment strategy will follow principles of clearing excess and replenishing deficiency, regulating the internal organs, and balancing yin and yang. Based on the patient's specific syndrome in TCM.
215132166|NCT04299165|DEVICE|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
215132167|NCT04299165|OTHER|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
215132168|NCT06473389|PROCEDURE|Suprascapular nerve pulse radiofrequency ablation|Pulse RF application will be applied to the suprascapular nerve once under US guidance with a TOP-TLG10 STP generator at a maximum temperature of 42 degrees, 2 Hz, 20 ms and 45 V for 2 minutes.
215132169|NCT06473389|PROCEDURE|Suprascapular Nerve Block Group|Suprascapular block will be applied once with a mixture consisting of 5 ml (1 ml betamethasone, 2% lidocaine 2 ml, 0.9% saline 2 ml).
214450092|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
214450093|NCT06185296|DEVICE|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
214450094|NCT06185296|DEVICE|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
214450095|NCT04238364|DRUG|EI-1071|EI-1071 Tablet(s)
214450096|NCT04238364|DRUG|Placebo|Matching Placebo Tablet(s)
214450097|NCT04814082|DEVICE|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
214450098|NCT04814082|DEVICE|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
214694700|NCT02919488|OTHER|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
215132170|NCT06473389|PROCEDURE|Steroid Group|Intra-articular steroid application will be made with a mixture consisting of 5 ml (2 ml of 2% lidocaine, 2 ml of 0.9% saline and 1 ml of betamethasone 5 mg).
215132171|NCT05757713|BIOLOGICAL|teplizumab|CD3-directed humanized monoclonal antibody
215132172|NCT01352117|DRUG|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
215132173|NCT01352117|DRUG|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
214450099|NCT06059144|DRUG|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
214450100|NCT03394079|PROCEDURE|PCI|Percutaneous Coronary Intervention
214450101|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
214450102|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
214450103|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
215132174|NCT00633477|DRUG|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
215132175|NCT00633477|DRUG|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
215132176|NCT00261690|BEHAVIORAL|Virtual Reality Distraction|Using virtual reality distraction during a procedure
215132177|NCT02539823|DRUG|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
214694701|NCT02919488|OTHER|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
215132178|NCT02539823|DRUG|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
215132179|NCT02539823|DRUG|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
215132180|NCT00770653|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
215132181|NCT00770653|DRUG|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
215132182|NCT04505059|PROCEDURE|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
215132183|NCT04505059|PROCEDURE|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
215132184|NCT01024517|DRUG|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
215132185|NCT01024517|DRUG|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
215132186|NCT01417546|DRUG|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
214450104|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
214450105|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
214450106|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
214450107|NCT05151380|DEVICE|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
214450108|NCT04490915|DRUG|Crinecerfont|CRF type 1 receptor antagonist
214450109|NCT04490915|DRUG|Placebo|Non-active dosage form
214694702|NCT06840119|DRUG|IMC-R117C|IV infusion
214450111|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
215132187|NCT04580355|PROCEDURE|One-Stage Full Mouth Debridement|Periodontal debridement
215132188|NCT04580355|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
214525556|NCT06860763|DEVICE|Acupuncture|The acupuncture needles used will be 0.25 mm in diameter and 25 mm in length, inserted quickly with even supplementation and reduction techniques.
214525557|NCT06859775|DRUG|SHR-A1811|SHR-A1811 injection.
214525558|NCT06859775|DRUG|Adebelimab injection|Adebelimab injection.
214525559|NCT06859775|DRUG|Bevacizumab injection|Bevacizumab injection.
214525560|NCT06859775|DRUG|SHR-8068|SHR-8068 injection.
214525561|NCT06859775|DRUG|Cisplatin injection|Cisplatin injection.
214525562|NCT06859775|DRUG|Carboplatin injection|Carboplatin injection.
214694703|NCT06840119|DRUG|Chemotherapy drug|IV infusion
214694704|NCT06840119|DRUG|Chemotherapy drug|oral
214694705|NCT06840119|DRUG|Kinase inhibitor|oral
214694706|NCT06840119|DRUG|Antiangiogenic Agent|IV infusion
214694707|NCT06840119|DRUG|Monoclonal antibody|IV infusion
215132189|NCT04580355|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
215132190|NCT04580355|DRUG|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
215132191|NCT04580355|DRUG|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
214450112|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
214450113|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
214450114|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
214450115|NCT04244656|BIOLOGICAL|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
214694708|NCT02500238|OTHER|Saliva sample|All participants will provide a saliva sample.
214694709|NCT02500238|OTHER|Urine Sample|All participants will provide a urine sample.
214694710|NCT02500238|OTHER|Toe nail clippings|All participants will provide toe nail clippings.
214694711|NCT02500238|OTHER|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
215132192|NCT02217839|DRUG|DG3173|
215132193|NCT02217839|DRUG|DG3173+Octreotide|
215132194|NCT02217839|DRUG|Octreotide|
215132195|NCT02217839|DRUG|DG3173 Placebo|
215132196|NCT02217839|DRUG|DG3173 Placebo+Octreotide Placebo|
215132197|NCT02217839|DRUG|Octreotide+DG3173 Placebo|
215132198|NCT00187291|DEVICE|T-Wave Alternans test|
215132199|NCT01962792|DRUG|Ibrutinib|
215132200|NCT01962792|DRUG|Carfilzomib|
215132201|NCT01962792|DRUG|Dexamethasone|
215132202|NCT04906499|BEHAVIORAL|Physical Activity Promotion|"After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (\<10 days with \<1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day."
215132203|NCT02326623|OTHER|distraction|distraction using an iPad with a selection of child-appropriate games
215132204|NCT02326623|OTHER|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
215132205|NCT02318160|OTHER|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
215132206|NCT01198886|OTHER|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
215132207|NCT01198886|OTHER|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
215132208|NCT01723098|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
215132209|NCT01502748|OTHER|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
214450116|NCT05042388|BEHAVIORAL|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
214450117|NCT05042388|BEHAVIORAL|Treatment-As-Usual|Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
214450118|NCT05220033|OTHER|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
214450119|NCT05220033|OTHER|survey administration|Ancillary studies
214525563|NCT06993714|PROCEDURE|Breast restoration surgery based on 3D printed degradable biological implants|In the experimental group, the surgeon makes an incision on the skin and creates an electrosurgical free flap with a thickness of approximately 3mm. Based on the tumor size simulated by the computer and combined with real-time exploration during the operation, the tumor is resected. The incision margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the resected specimen. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are excluded from the clinical trial). Corresponding surgical treatment is provided. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The wound is soaked and rinsed, hemostasis is thoroughly achieved, the designed 3D printed filler is implanted, and sutured and fixed. After placing the drainage, the skin is sutured layer by layer. The corresponding operation time is recorde.
214525564|NCT06993714|PROCEDURE|Traditional breast-conserving surgery|In the control group undergoing traditional breast - saving surgery, tumor segment resection is performed according to the clinical routine. The resection margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the circumferential specimens after resection. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative resection margin. The volume of the resected part during the intraoperative section is replaced by autologous tissue. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The corresponding operation time is recorded.
214450120|NCT06333964|DRUG|AST-001|AST-001, PO bid for 24weeks (dosage according to weight range)
214694712|NCT00617409|DRUG|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
215132210|NCT03121313|DRUG|tegafur-uracil|
215132211|NCT06465940|DEVICE|Total hip arthroplasty|Replacement of hip joint
215132212|NCT03058120|OTHER|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
215132213|NCT03897426|BEHAVIORAL|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
214450121|NCT06333964|DRUG|Placebo of AST-001|Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
214450122|NCT05380856|DEVICE|Turning ON the neuromodulator|IPG on
214450123|NCT05380856|DEVICE|Turning OFF the neuromodulator|IPG OFF
214450124|NCT05722067|OTHER|calcium ionophore|The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
215132214|NCT04935658|DEVICE|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
214450125|NCT05303714|COMBINATION_PRODUCT|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
214450126|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
214450127|NCT05374837|BEHAVIORAL|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
214450128|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
214450129|NCT03149315|DRUG|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
214450130|NCT00958516|DRUG|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
214450131|NCT05559541|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
214450132|NCT05559541|DRUG|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
214450133|NCT05440383|DRUG|KLH-2109|Oral administration
214450134|NCT05440383|DRUG|Leuprorelin|Subcutaneous administration
214450135|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
214450136|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
214450137|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
214450138|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
214450139|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
214450140|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
214450141|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
214450142|NCT04733495|OTHER|Counseling|Receive group-based behavioral counseling
214450143|NCT04733495|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary counseling
215132215|NCT04935658|DRUG|local anesthesia|standard anesthesic procedure
214450144|NCT04733495|OTHER|Quality-of-Life Assessment|Ancillary studies
214450145|NCT04733495|OTHER|Questionnaire Administration|Ancillary studies
214450146|NCT04733495|OTHER|Resistance Training|Undergo personalized resistance exercises
214450147|NCT05950243|BEHAVIORAL|Questionnaire|Questionnaire survey for data collection
214450148|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
214450149|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
214450150|NCT03786783|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214450151|NCT03786783|DRUG|Carboplatin|Given IV
214450152|NCT03786783|DRUG|Cisplatin|Given IV
214450153|NCT03786783|DRUG|Cyclophosphamide|Given IV
214450154|NCT03786783|DRUG|Dexrazoxane|Given IV
214450155|NCT03786783|BIOLOGICAL|Dinutuximab|Given IV
214450156|NCT03786783|DRUG|Doxorubicin|Given IV
215132216|NCT04862715|DRUG|Ferinject|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
215132217|NCT04862715|OTHER|Placebo: NaCl (sodium chloride 0.9%)|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
214450157|NCT03786783|DRUG|Etoposide|Given IV
214450158|NCT03786783|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214450159|NCT03786783|DRUG|Isotretinoin|Given PO
214450160|NCT03786783|DRUG|Melphalan|Given IV
214450161|NCT03786783|BIOLOGICAL|Sargramostim|Given SC
214450162|NCT03786783|DRUG|Thiotepa|Given IV
214450163|NCT03786783|DRUG|Topotecan|Given IV
214450164|NCT03786783|DRUG|Vincristine|Given IV
214450165|NCT02910583|DRUG|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
214450166|NCT02910583|DRUG|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
214450167|NCT02910583|DRUG|Placebo|placebo capsules to match ibrutinib administered orally once daily
214450168|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
214450169|NCT05401032|DRUG|Tamsulosin|Oral medication, once a day for 6 months.
214450170|NCT05401032|DRUG|5-hidroxitriptophan|Oral medication, 3 times a day for 6 months.
214450171|NCT01331005|DRUG|nepafenac 0.1% drops|One drop three times per day for one year
214450172|NCT01331005|OTHER|Nepafenac Vehicle|Placebo
214450173|NCT04480645|DEVICE|CivaDerm|radioactive bandage
214450174|NCT05825014|OTHER|No intervention|No intervention
214708832|NCT01270230|BEHAVIORAL|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
214450176|NCT04849052|BEHAVIORAL|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
215132218|NCT04478201|OTHER|back sleep positioning|sleeping on the back.
214450177|NCT04849052|BEHAVIORAL|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
214708833|NCT00293150|DRUG|Eplerenone|
215132219|NCT04478201|OTHER|side sleep positioning|sleeping on the side
215132220|NCT03029806|OTHER|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
215132221|NCT03029806|OTHER|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
215132222|NCT03029806|OTHER|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
214450178|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
214450179|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
214450180|NCT06532422|PROCEDURE|Partial or total laparoscopic nephrectomy|Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
214450181|NCT06159608|DRUG|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
214450182|NCT06159608|OTHER|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
214450183|NCT06205615|DRUG|BXP154B|BXP154B will be self-administered topically following wound induction
214450184|NCT06205615|DRUG|Placebo|Placebo will be self-administered topically following wound induction
214450185|NCT06205615|PROCEDURE|Punch Biopsy|Punch biopsy to leg
214450186|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Alpha|Rhythmic alpha stimulation
214450187|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Theta|Rhythmic theta stimulation applied
214450188|NCT06252532|DEVICE|Sham Direct cortical stimulation (DCS)|Arrhythmic stimulation paradigm applied
214450189|NCT06252532|DEVICE|Direct cortical stimulation (DCS) In-Phase Theta|Rhythmic in-phase theta stimulation applied
214450190|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Anti-Phase Theta|Rhythmic anti-phase theta stimulation applied
215132223|NCT04861129|PROCEDURE|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
215132224|NCT04861129|PROCEDURE|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
215132225|NCT05622734|BEHAVIORAL|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
215132226|NCT03432325|DEVICE|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
214450191|NCT06569290|BEHAVIORAL|Primer postcard|Inclusion of a mailed primer post card
214450192|NCT06569290|BEHAVIORAL|Control recruitment letter|a recruitment letter without any behaviorally-informed language
214450193|NCT06569290|BEHAVIORAL|Behavioral theory-informed recruitment letter (prospect theory)|the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.
214450194|NCT06569290|BEHAVIORAL|2 phone calls|2 recruitment phone calls made by the call center
214450195|NCT06569290|BEHAVIORAL|4 phone calls|4 recruitment phone calls made by the call center
215132227|NCT03084211|OTHER|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
214450196|NCT06570525|BEHAVIORAL|NurseNET|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
214450197|NCT06570525|OTHER|PAL|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
214450198|NCT03059407|BEHAVIORAL|Dog therapy only|Canine assisted therapy only during echocardiogram
214450199|NCT03059407|BEHAVIORAL|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
214450200|NCT03059407|BEHAVIORAL|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
214450201|NCT05597891|DEVICE|Hēlo PE Thombectomy System|Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
215132228|NCT03567564|DIAGNOSTIC_TEST|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
215132229|NCT01866540|DRUG|FLUENZ|live attenuated influenza vaccine
214450202|NCT06260774|DRUG|TTX-MC138|The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
214450203|NCT04478734|DRUG|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
214525565|NCT06993714|PROCEDURE|Traditional silicone prosthesis breast reconstruction|In the control group of traditional prosthesis reconstruction, subcutaneous gland resection with nipple and areola preservation combined with prosthesis for concurrent breast reconstruction is carried out according to the clinical routine. The incision method is selected by the surgeon. During the operation, the tissue behind the nipple is sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are considered out of the clinical trial and given corresponding surgical treatment), and the surgeon decides whether to use the patch in combination. The corresponding operation time is recorded.
214525566|NCT06999850|OTHER|Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps;
214708834|NCT04270617|BEHAVIORAL|Yoga program|The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
214450204|NCT04478734|DRUG|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
214450205|NCT04718389|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
214450206|NCT04718389|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
214450207|NCT04718389|BIOLOGICAL|Benralizumab|Benralizumab will be provided in a single-use PFS.
214450208|NCT04718389|BIOLOGICAL|Placebo|Placebo will be a sterile liquid formulation.
214450209|NCT04718389|DRUG|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
214450210|NCT04718389|DEVICE|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
214450211|NCT05800600|DRUG|Venofer|Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
214450212|NCT03205800|DEVICE|Mini-screw|Placement of a mini-screw
214708835|NCT05289076|DRUG|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
215132230|NCT05858541|BEHAVIORAL|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
215132231|NCT05858541|BEHAVIORAL|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
215132232|NCT04027855|PROCEDURE|collection of peripheral blood mononuclear cells from healthy volunteers|"1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
215132233|NCT02722564|BEHAVIORAL|self estimation of breath alcohol content|
215132234|NCT02722564|DEVICE|breath alcohol content as measured by Alco Sensor IV device|
215132235|NCT02722564|OTHER|drink a beer|drink a beer, repeat until breath alcohol content 0.1
215132236|NCT02250742|OTHER|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
215132237|NCT05602298|OTHER|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
214525567|NCT06999850|OTHER|Walk Test|"Assessment of climbing and walking skills through test series:~Borg scale: An evaluation scale for measuring effort perception. The evaluation scale consists of answering some questions at the end of the exercise described above; 10-metre walk test (10MWT): Test to assess walking speed in metres per second over a short distance. Can be used to determine functional mobility, gait and vestibular function. The test consists of walking at a steady speed and safely for 10 metres; 30 second sit to stand test: test for the evaluation of strength and endurance of the legs in the elderly. The test consists in performing the movement of standing up and sitting down from a chair for 30 consecutive seconds; Timed Up \& Go test (TUG): test to assess the risk of falling and balance. During the test, patients wear normal footwear and may use a walking aid if necessary. The patient starts in a sitting position, gets up on the therapist's command, walks in a straight line for a distance of 3 m"
214525568|NCT06999850|OTHER|Repaeted Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps. In this case, the ascent and descent of the stairs must be repeated two times. Between the two trial the IMU units must be repositioned.
214525569|NCT07000305|DRUG|Cetuximabβ combined with Envolimab and mFOLFOX6|Envolimab, 200 mg, sc, day 1; Cetuximabβ 500 mg/m2 IV over 60- 120 min, day 1; chemotherapy mFOLFOX6; with the above regimen every 14 days for 1 treatment cycle. Then patients who did not experience disease progression within 8-12 cycles were entered into maintenance therapy, which consisted of a fluorouracil-based-chemotherapy with Cetuximabβ and Envolimab regimen until progression or unacceptable toxicity.
214525570|NCT07000253|DRUG|Chemotherapy|Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
214525571|NCT07000253|DRUG|Targeted Systemic Therapy|Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
214708836|NCT03712800|OTHER|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
214708837|NCT03712800|BEHAVIORAL|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
215132238|NCT06235372|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph .
215132239|NCT05887869|BEHAVIORAL|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
214525572|NCT07000253|DRUG|Immunotherapy|Biomarker selected patients will recieve checkpoint inhibitors according to standard care
214525573|NCT07000253|PROCEDURE|Surgery|If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
214525574|NCT07000253|RADIATION|Radiotherapy|Metastases may be irradiated
214525575|NCT07002658|PROCEDURE|Harvesting of the saphenous vein graft|"Most existing studies on endoscopic saphenectomy have been conducted in CABG with cardiopulmonary bypass (CBP), whereas most CABG surgeries at the study center are performed without CBP.~The following outcomes will be identified:~* Days of admission or need for hospitalization~* Use of antibiotic therapy for saphenectomy wound infections~* Need for wound dressings due to necrosis and/or wound infection~* Need for analgesic treatment for wound pain"
215132240|NCT00907595|DRUG|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
215132241|NCT00907595|DRUG|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
215132242|NCT02726503|DRUG|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
215132243|NCT03641417|DRUG|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
215132244|NCT03641417|OTHER|Placebo|Same as GLWL-01, but no active ingredient
214450213|NCT06417541|DIAGNOSTIC_TEST|Diseased patients with an indwelling central venous catheter who is referred to autopsy|Photon counting CT is performed and the results are compared to the results of the autopsy
214525576|NCT07001670|OTHER|Tele-Yoga Training|The Tele-yoga group will participate in real-time yoga sessions three times a week for eight weeks, including individual sessions for the first two weeks and small group sessions for the remaining six weeks, with all sessions supervised by a certified instructor. Each session will last approximately 45-60 minutes and include a 5-10 minute warm-up, 15-20 minutes of yoga postures, 15-20 minutes of yogic breathing exercises, and 5-10 minutes of relaxation and meditation.
215132245|NCT03084146|OTHER|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
215132246|NCT01305720|DEVICE|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
215132247|NCT06456567|BIOLOGICAL|Telitacicept|Subcutaneous injection
215132248|NCT06456567|DRUG|Placebo|Subcutaneous injection
215132249|NCT01102335|PROCEDURE|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
215132250|NCT01102335|DRUG|Telbivudine|anti-HBV drug
215132251|NCT05077826|DEVICE|North Coast Medical Activadose II|tES device model Activadose II (North Coast Medical, Morgan Hill, CA, USA) programed to deliver tES.
215132252|NCT02602366|OTHER|HEC Placebo Gel|
215132253|NCT02602366|OTHER|Placebo Vaginal Insert|
215132254|NCT02602366|OTHER|Placebo Vaginal Film|
215132255|NCT02602366|OTHER|Placebo Intravaginal ring (IVR)|
215132256|NCT04445935|DRUG|Bivalirudin Injection|The patients will receive iv Bivalirudin according to the institutional HIT protocol.
215132257|NCT04445935|DRUG|Standard treatment|This group will receive standard anticoagulation with LMWH/UFH
215132258|NCT00805350|DRUG|Eplivanserin|one 5 mg tablet once a day
215132259|NCT00805350|DRUG|Placebo|Placebo of Eplivanserin one tablet once a day
214450214|NCT06417541|RADIATION|Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast|Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
214694713|NCT00617409|BIOLOGICAL|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
214708838|NCT03024255|DRUG|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
215132260|NCT01095185|DRUG|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
215132261|NCT01095185|DRUG|Placebo|Simvastatin placebo
215132262|NCT01273766|DRUG|deferasirox|Given orally
215132263|NCT01273766|OTHER|laboratory biomarker analysis|Correlative studies
215132264|NCT01273766|OTHER|enzyme-linked immunosorbent assay|Correlative studies
215132265|NCT03525444|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
215132266|NCT03525444|DRUG|IVA|Participants received IVA orally once daily in the evening
215132267|NCT03525444|DRUG|Placebo|Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
214450215|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
214450216|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
215132268|NCT01262417|PROCEDURE|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
215132269|NCT01262417|PROCEDURE|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
215132270|NCT00460876|DRUG|Topotecan|
215132271|NCT00262860|DRUG|bortezomib|
215132272|NCT00262860|DRUG|gemcitabine hydrochloride|
215132273|NCT02741128|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
215132274|NCT02741128|BIOLOGICAL|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
215132275|NCT05134688|DRUG|Magnesium sulfate|Tocolytic to stop preterm labor
215132276|NCT01544296|DRUG|KHK6188|
214450217|NCT04969874|OTHER|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
214450218|NCT05492838|PROCEDURE|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
214450219|NCT06320756|BEHAVIORAL|Wysa in Hindi|Wysa in Hindi is a blended digital mental health intervention
214450220|NCT06320756|BEHAVIORAL|Individual and group sessions on topics like motivation, coping, wellbeing|Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team
214450221|NCT06435117|OTHER|Patient Navigation|CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
214450222|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
214450223|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
214450224|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
214450225|NCT03036488|BIOLOGICAL|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
214450226|NCT03036488|DRUG|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
214450227|NCT03036488|DRUG|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
214450228|NCT03036488|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
214450229|NCT03036488|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
214450230|NCT03036488|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
214450231|NCT03036488|DRUG|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
214450232|NCT03036488|BIOLOGICAL|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
214450233|NCT06498791|OTHER|Venipuncture|Blood drawing
215132277|NCT01544296|DRUG|Placebo|
215132278|NCT03589716|OTHER|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
215132279|NCT03589716|OTHER|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
215132280|NCT03589716|OTHER|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
215132281|NCT03589716|OTHER|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
215132282|NCT03589716|OTHER|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
215132283|NCT01404741|PROCEDURE|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
215132284|NCT01404741|PROCEDURE|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
214450234|NCT06498791|OTHER|Questionnaire|Completion of the questionnaire
215132285|NCT02332538|PROCEDURE|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
215132286|NCT02332538|PROCEDURE|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
215132287|NCT02332538|PROCEDURE|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
215132288|NCT05378165|OTHER|Music group|The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The music group listened to Acemasiran-type classical Turkish music.Acemasiran-type music affects the human brain and provides a sense of creativity to people. This musical tone has pain- relieving and antispasmodic
215132289|NCT05378165|OTHER|Stress ball group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
215132290|NCT05378165|OTHER|Video group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Video group allowed to watch a licensed virtual reality application,A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
215132291|NCT05378165|OTHER|Control group|"The study was divided into three stages; (1) before; (2) during; and (3) after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Control group, without any additional intervention."
215132292|NCT04879030|DRUG|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
215132293|NCT04879030|DRUG|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
215132294|NCT01419769|DEVICE|AXIOS Stent & Delivery System|"The AXIOS Stent \& Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
215132295|NCT04391374|PROCEDURE|an arterial reconstructive procedure|
215132296|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
215132297|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
215132298|NCT00878501|DRUG|Placebo|Oral, during 4 weeks
215132299|NCT05410522|DEVICE|EMS Program|Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
215132300|NCT04227808|DRUG|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
215132301|NCT00799786|BEHAVIORAL|Building Better Caregivers Online Workshop|
215132302|NCT04985617|OTHER|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
214450235|NCT06055959|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
214450236|NCT06099613|BIOLOGICAL|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
215132303|NCT01650532|BEHAVIORAL|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
215132304|NCT01650532|BEHAVIORAL|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
214450237|NCT05032105|DEVICE|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
214450238|NCT03219307|COMBINATION_PRODUCT|NOVOCART 3D|Matrix associated autologous chondrocyte implant
214708839|NCT03024255|DRUG|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
214708840|NCT03024255|DRUG|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
215132305|NCT05893745|OTHER|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
215132306|NCT05893745|OTHER|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
215132307|NCT00852683|DRUG|Pregabalin|75 mg twice a day
215132308|NCT00852683|DRUG|Placebo|75 mg twice a day
215132309|NCT05813106|DRUG|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
215132310|NCT05813106|DRUG|normal saline|normal saline
215132311|NCT02941081|DIETARY_SUPPLEMENT|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
215132312|NCT02941081|DIETARY_SUPPLEMENT|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
215132313|NCT02941081|OTHER|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
215132314|NCT00812708|DEVICE|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
215132315|NCT01221896|PROCEDURE|C11-Choline PET/CT|
215132316|NCT01082016|OTHER|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
215132317|NCT02266368|DEVICE|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
214450239|NCT03786796|DRUG|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
214450240|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
214450241|NCT05031026|DRUG|Dexmedetomidine|dexmedetomidine infusion rule in prevention of IRI
214450242|NCT05031026|DRUG|Normal Saline|normal saline infusion as a placebo
214450243|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
214450244|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
214450245|NCT05606965|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214450246|NCT05606965|BIOLOGICAL|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
215132318|NCT01959503|DEVICE|Progel Vascular Sealant|
215132319|NCT01959503|DEVICE|Gelfoam Plus|
214450247|NCT05606965|BIOLOGICAL|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
214450248|NCT05606965|BIOLOGICAL|Inactivated Influenza Vaccine|Sterile suspension for injection
214450249|NCT05606965|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214694714|NCT00617409|DRUG|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
214694715|NCT05583435|BEHAVIORAL|One-on-one professional coaching|One-on-one professional coaching
214694716|NCT05583435|BEHAVIORAL|Small-group professional coaching|Small-group professional coaching
215132320|NCT03960749|DEVICE|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
215132321|NCT03960749|DEVICE|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
215132322|NCT03960749|DEVICE|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
215132323|NCT03960749|DEVICE|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
215132324|NCT03960749|DEVICE|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
215132325|NCT03960749|DEVICE|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
215132326|NCT05641337|DRUG|Insulin Degludec and Insulin Aspart|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
215132327|NCT02675946|DRUG|CGX1321|
215132328|NCT02675946|DRUG|Pembrolizumab|
215132329|NCT02675946|DRUG|encorafenib|
215132330|NCT02675946|DRUG|cetuximab|
215132331|NCT05482997|DIETARY_SUPPLEMENT|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
215132332|NCT05482997|DIETARY_SUPPLEMENT|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
215132333|NCT02857517|DRUG|conbercept|0.05ml conbercept
215132334|NCT01600326|PROCEDURE|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
215132335|NCT01600326|DRUG|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
214450250|NCT05606965|BIOLOGICAL|mRNA-1045|Sterile liquid for injection
214450251|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
214450252|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
214450253|NCT02029443|DRUG|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
214525577|NCT07003256|DRUG|Romiplostim|After transplantation + 6 days, the subcutaneous injection of roprastine 3ug/kg was started, and the number of platelets in the machine-taken platelet suspension was increased by 2 µg/kg per week, and the maximum dose was 10 μg/kg. Discontinued until platelets rose to 100 × 109/L. If platelets ≤ 20 X 109/L were used for + 20 days, roprastine combined with atropopa 25mg was given orally once a day. Patients were given 1 therapeutic dose of fresh machine-taken platelet suspension when platelets were ≤ 20 X 109/L, or when there was active bleeding at 21\~ 50 × 109/L. The number of platelets in the machine-taken platelet suspension per therapeutic dose was \> 2.5 × 1011. If not implanted at + 28 days after transplantation, re-transplantation is required, and roprastine is considered ineffective.
215132336|NCT04504734|DRUG|Bucillamine|100mg tablets
214450254|NCT05139862|DEVICE|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
214450255|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
215132337|NCT04504734|DRUG|Placebo|100mg tablets
215132338|NCT04504734|DRUG|Bucillamine|200mg tablets
215132339|NCT03043014|DRUG|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
215132340|NCT01452906|DRUG|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
214525578|NCT07009392|DIAGNOSTIC_TEST|NGS Analysis|NGS (Next Generation Sequencing) analysis is performed on tissue from ACL
214694717|NCT02507193|PROCEDURE|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
214708841|NCT03024255|DRUG|Vehicle (Placebo)|Placebo, applied once to each axilla daily
215132341|NCT01452906|DRUG|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
215132342|NCT01452906|DRUG|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
215132343|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
215132344|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
215132345|NCT03021785|BIOLOGICAL|TK001|TK001 will be administered intravitreal injection.
215132346|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
214450256|NCT03534947|DRUG|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
214450257|NCT03534947|DRUG|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
214450258|NCT03534947|PROCEDURE|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
214450259|NCT03534947|OTHER|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
214450260|NCT04478318|DEVICE|uEXPLORER/mCT|Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
214450261|NCT04478318|DEVICE|mCT/uEXPLORER|Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
214450262|NCT05290610|OTHER|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
215132347|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg per day
214450263|NCT04722354|OTHER|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
215132348|NCT03484754|BIOLOGICAL|botulinum toxin|injection of botulinum toxina in two different facial sites
215132349|NCT00848809|PROCEDURE|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
215132350|NCT00848809|PROCEDURE|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
215132351|NCT06378944|OTHER|Application of green indocyanine colorant|The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
215132352|NCT06378944|DRUG|Technetium99|Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
215132353|NCT06397170|OTHER|Graded repetitive arm supplementary program|Patients in Group A will receive Graded repetitive arm supplementary program
215132354|NCT06397170|OTHER|Task based training|Patients in Group B will receive Task based training.
215132355|NCT01703910|DRUG|Arm A chemotherapy|
215132356|NCT01703910|DRUG|arm B chemotherapy|
215132357|NCT00077246|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
215132358|NCT06499298|DRUG|Nivolumab|As per product label, as prescribed by treating physician
215132359|NCT03965130|BIOLOGICAL|Glucagon|PINTA study with glucagon
214450264|NCT04722354|PROCEDURE|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
214450265|NCT04722354|DIETARY_SUPPLEMENT|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
214450266|NCT04722354|OTHER|Placebo|Those in this group will receive placebo (300 mg cornstarch)
214694718|NCT02507193|PROCEDURE|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
214694719|NCT05668312|OTHER|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
214694720|NCT05668312|OTHER|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
215132360|NCT03965130|OTHER|Control Study|The same participants will not receive glucagon during the PINTA study
215132361|NCT04912258|DRUG|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
215132362|NCT05734027|DEVICE|Sectional matrix|The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion
215132363|NCT05734027|DEVICE|Circumferential matrix|Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
215132364|NCT02061787|DEVICE|balloon pulmonary angioplasty|patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
215132365|NCT01796340|BEHAVIORAL|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
215132366|NCT01796340|BEHAVIORAL|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
215132367|NCT01131507|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
215132368|NCT02161770|DRUG|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
215132369|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
215132370|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
215132371|NCT04142203|OTHER|23 h surgery|Patients were treated in 23 surgical unit
215132372|NCT05862753|DRUG|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
215132373|NCT06333249|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
215132374|NCT01517399|DRUG|tivantinib|three oral 120 mg tablets administered twice a day
215132375|NCT01517399|DRUG|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
215132376|NCT01517399|DRUG|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
215132377|NCT01517399|DRUG|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
215132378|NCT01517399|DIETARY_SUPPLEMENT|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
215132379|NCT01517399|DRUG|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
215132380|NCT01517399|DRUG|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
215132381|NCT05213975|DEVICE|Kinesio tape|Kinesio taping
215132382|NCT02534376|DRUG|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
215132383|NCT06272240|OTHER|Ovarian Cancer Organoids|To characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
215132384|NCT03177863|PROCEDURE|Expectancy|Clinical monitoring. See arm description
215132385|NCT00149877|DRUG|Tegaserod|
215132386|NCT03694405|BIOLOGICAL|MenACWY-CRM|Booster vaccination with MenACWY-CRM
215132387|NCT03694405|BIOLOGICAL|MenACWY-DT|Booster vaccination with MenACWY-DT
215132388|NCT03694405|BIOLOGICAL|MenACWY-TT|Booster vaccination with MenACWY-TT
215132389|NCT01393158|DRUG|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
215132390|NCT00924521|DIETARY_SUPPLEMENT|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
215132391|NCT00924521|DIETARY_SUPPLEMENT|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
215132392|NCT01716286|DIETARY_SUPPLEMENT|low fat vs. essence yoghurt|
215132393|NCT06333184|OTHER|Food|Fruit ingested in whole form or as either commercially available, or home-made smoothies
215132394|NCT02324881|BEHAVIORAL|Telephone-Based Intervention|Use PSMA
215132395|NCT02324881|OTHER|Questionnaire Administration|Ancillary studies
215132396|NCT04529733|DEVICE|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
215132397|NCT00582439|DEVICE|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
214450267|NCT05747937|DIAGNOSTIC_TEST|Skin biopsy|A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
215132398|NCT02113696|DIETARY_SUPPLEMENT|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
215132399|NCT02113696|DIETARY_SUPPLEMENT|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
215132400|NCT04823403|DRUG|Nivolumab|Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
215132401|NCT04823403|DRUG|Ipilimumab|"Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~* (D1) Starting dose : 50 mg; n=3 to 6~* (D2) 2nd dose-level : 100 mg; n=3 to 6~* (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)"
215132402|NCT03272802|DRUG|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
215132403|NCT03272802|DRUG|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
215132404|NCT02389166|DEVICE|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
215132405|NCT02389166|DEVICE|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
215132406|NCT04419025|DRUG|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
215132407|NCT03224130|OTHER|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
215132408|NCT03224130|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
215132409|NCT02985827|DRUG|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
215132410|NCT02985827|DRUG|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
214450268|NCT05747937|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
214450269|NCT05747937|DIAGNOSTIC_TEST|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
214450270|NCT05747937|DIAGNOSTIC_TEST|Dinamic Sweat Test|Test for the functional assessment of postganglionic sudomotor pathway
214450271|NCT03324464|BEHAVIORAL|Central Executive Training: Working Memory|Computerized working memory training
214450272|NCT03324464|BEHAVIORAL|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
215132411|NCT02198014|OTHER|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
215132412|NCT02198014|OTHER|Educational Physiotherapy|"* Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
215132413|NCT00668421|DRUG|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
214450273|NCT04821154|DEVICE|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
214450274|NCT04469036|OTHER|Virtual Pediatric Trauma Center|Telehealth
214450275|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
214450276|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
214450277|NCT05062369|DEVICE|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
214450278|NCT05062369|BEHAVIORAL|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
214694721|NCT04121429|OTHER|Observation|No intervention will be performed
214694722|NCT02913222|OTHER|Rehabilitation|Comparison of two rehabilitation approaches
215132414|NCT04803318|DRUG|Combination of three inhibitors Trametinib, Everolimus and Lenvatinib|Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
215132415|NCT05119777|DEVICE|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
215132416|NCT05849142|DEVICE|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
215132417|NCT03886285|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
214694723|NCT02776410|BEHAVIORAL|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
215132418|NCT00966836|DRUG|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
215132419|NCT00966836|DRUG|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
215132420|NCT00966836|DRUG|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
215132421|NCT00966836|DRUG|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
215132422|NCT02506543|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
215132423|NCT02506543|BEHAVIORAL|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
215132424|NCT00144807|DRUG|rituximab|
215132425|NCT00144807|DRUG|doxorubicin|
215132426|NCT00144807|DRUG|cyclophosphamide|
215132427|NCT00144807|PROCEDURE|autologous stem cell transplantation|
215132428|NCT00777140|DRUG|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
215132429|NCT03261648|OTHER|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
215132430|NCT03261648|OTHER|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
215132431|NCT05443308|DIAGNOSTIC_TEST|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral \[15O\]H2O PET before and after diamox infusion
215132432|NCT04471714|DRUG|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
215132433|NCT03095651|BIOLOGICAL|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
215132434|NCT03095651|BIOLOGICAL|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
215132435|NCT03095651|BIOLOGICAL|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
215132436|NCT03095651|BIOLOGICAL|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
215132437|NCT03095651|BIOLOGICAL|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
215132438|NCT03095651|BIOLOGICAL|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
215132439|NCT03095651|DRUG|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
215132440|NCT03095651|BIOLOGICAL|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
215132441|NCT00610870|DRUG|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
214450279|NCT05935462|COMBINATION_PRODUCT|Digital Learning Aids|Recruitment is currently underway for special children undergoing outpatient early intervention. Among the recruited participants, five children between the ages of 6 and 9, who are receiving early intervention, were screened. After obtaining their consent to participate in this study, their basic information was recorded, including gender, age, education, diagnosis, Movement Assessment Battery for Children (MABC-2), Visual-Motor Integration (VMI) test, and Children's ABILHAND questionnaire for manual ability. Once the collection of basic information is completed, a trial of digital aids will be conducted, and a trial feedback questionnaire will be administered. The trial period will consist of a 20-minute session and 2-3 sessions (per week) of home (or therapy room) use.
214450280|NCT03393975|BIOLOGICAL|TAK-755|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg TAK-755 ORT during Period 1 and Period 2 and switch to TAK-755 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of TAK-755.
214450281|NCT03393975|BIOLOGICAL|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
214450282|NCT06194721|PROCEDURE|Cold intrapulpal anesthesia|Intrapulpal cold local anesthesia at 4-5 c temperature
214450283|NCT06194721|PROCEDURE|Room temperature intrapulpal anesthesia|Intrapulpal cold local anesthesia at room temperature
214450284|NCT03221036|DRUG|Vedolizumab IV|Vedolizumab IV infusion
214450285|NCT03221036|DRUG|Placebo|Matching-placebo IV infusion
215132442|NCT05132153|DRUG|Milrinone|will be given by nebulization
215132443|NCT05132153|DRUG|Normal saline|will be given by nebuliztion
215132444|NCT02921035|DRUG|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
215132445|NCT01657864|DRUG|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
215132446|NCT00851357|DRUG|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
215132447|NCT00851357|BEHAVIORAL|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
215132448|NCT00851357|DRUG|Placebo|Placebo nicotine patch
214450286|NCT04597411|RADIATION|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
214450287|NCT04597411|RADIATION|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
214450288|NCT04083235|DRUG|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
214450289|NCT04083235|DRUG|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
214450290|NCT04083235|DRUG|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
215132449|NCT00851357|OTHER|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
215132450|NCT00783523|DRUG|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
215132451|NCT02437045|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
214450291|NCT04083235|DRUG|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
214450292|NCT04083235|DRUG|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
214450293|NCT04083235|DRUG|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
214450294|NCT01007591|DRUG|LEO 80190|Applied once daily
214450295|NCT01007591|DRUG|Hydrocortisone|Applied once daily
214450296|NCT04180397|DRUG|Furosemide|Furosemide 10 mg/ml for injection/infusion
214450297|NCT04180397|DRUG|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
214450298|NCT03333200|OTHER|Palliative Care|Collecting information about the natural progression of these diseases
214450299|NCT03333200|BIOLOGICAL|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
214450300|NCT02549339|DRUG|LEO 43204 gel|
214450301|NCT02549339|DRUG|Vehicle gel|
214450302|NCT05890807|DIAGNOSTIC_TEST|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
214450303|NCT06433050|DRUG|Sotagliflozin|Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
214450304|NCT03016169|DEVICE|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
214450305|NCT04537156|BIOLOGICAL|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214450306|NCT04537156|BIOLOGICAL|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214450307|NCT06415422|BIOLOGICAL|Biological samples|Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
214450308|NCT01765140|DRUG|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
214450309|NCT05737030|DRUG|L-ornithine L-aspartate|Amino acid combination
214450310|NCT06489548|DRUG|Foralumab TZLS-401 50 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
214450311|NCT06489548|DRUG|Foralumab TZLS-401 100 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
214450312|NCT03289403|DRUG|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment."
214450313|NCT03289403|DRUG|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"
214450314|NCT06288828|BEHAVIORAL|Aerobic exercise + Nutrition consultant|"Participants in the intervention group will engage in 150 minutes of moderate aerobic exercise weekly for 16 weeks, primarily brisk walking or jogging.~For the initial four weeks, they will visit the hospital weekly for guidance and participate in home-based exercise following a protocol totaling 150 minutes of moderate aerobic exercise in the form of brisk walking or jogging. Healthcare professionals will help adjust exercise intensity based on heart rate (60-80% of maximum) and perceived exertion (RPE 12-15), while monitoring vital signs and adverse events.~After, they will transition to a home exercise program for twelve weeks, recording exercise details in a logbook. Weekly follow-up calls will ensure adherence and monitor adverse events.~They will be provided with nutritional recommendations by a dietitian, the same as the control group."
214450315|NCT06288828|BEHAVIORAL|Nutrition consultant|"Participants will maintain their physical activity at the same level as before enrolling in the study.~However, they will be provided with nutritional recommendations by a dietitian, which include 1.2 grams of protein per kilogram of ideal body weight daily and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day. To assess adherence and make necessary adjustments, participants will complete a 3-day food record at the beginning of the study, at week 8, and at the end of the study at week 16. If participants encounter difficulties adhering to the recommended nutritional intake, the dietitian will provide additional guidance to help them meet the requirements."
214694724|NCT06426199|DRUG|Chitosan-Hyaluronate Gel Mixture|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
215132452|NCT02437045|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
215132453|NCT02847377|OTHER|Injection of [18F]-ODS2004436 radiotracer|
215132454|NCT02714400|DRUG|Venlafaxine|Venlafaxine 50mg before sleep
215132455|NCT02714400|DRUG|Placebo|One piece of placebo before sleep
215132456|NCT05328609|DIETARY_SUPPLEMENT|Semaine Hormonal Imbalance & The Daily|All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
214450316|NCT06257758|DRUG|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
214450317|NCT00302315|OTHER|Physiotherapy|Thoracic expansion exercises and huffing technique Lower limb exercises TENS with frequency of 120 Hz and pulse width of 60 μs was used for 30 min in every session Connective tissue manipulation (CTM) to the sacral and lumbar regions, Education (proper use of body mechanics during baby caring and daily activities; improving posture; anatomy and functions of the pelvic floor and Knack maneouvre)
214450318|NCT04508192|OTHER|Exercise|Both interventions are simple strength exercises without technical equipment
214450319|NCT02207062|DRUG|Ibrutinib|Given PO
214450320|NCT02207062|OTHER|Laboratory Biomarker Analysis|Correlative studies
214450321|NCT04302168|DIETARY_SUPPLEMENT|Choline supplement|Choline 470mg twice daily for 8 weeks.
214450322|NCT04302168|DIETARY_SUPPLEMENT|Placebo|Placebo pill twice daily for 8 weeks
214450323|NCT04559334|DEVICE|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
214450324|NCT04883333|DRUG|LEO 153339|LEO 153339
214450325|NCT04883333|DRUG|Placebo|Placebo
214450326|NCT04895358|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
214450327|NCT04895358|DRUG|paclitaxel|IV infusion
214450328|NCT04895358|DRUG|nab-paclitaxel|IV infusion
214450329|NCT04895358|DRUG|liposomal doxorubicin|IV infusion
214450330|NCT04895358|DRUG|capecitabine|oral administration
214450331|NCT04895358|DRUG|normal saline|IV infusion
214450332|NCT04895358|DRUG|dextrose|IV infusion
214450333|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
214450334|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
214450335|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
214450336|NCT02713607|DRUG|Doxycycline|Given doxycycline to acne subjects
214450337|NCT04843384|OTHER|Reiki|Reiki
214450338|NCT04843384|OTHER|Sham reiki|sham Reiki
214450339|NCT05099315|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
214450340|NCT06310603|OTHER|Low-Processed Food Diet|Participants that receive intervention will be instructed to eat a diet rich in unprocessed/minimally-processed foods, as described by the NOVA food classification system
214450341|NCT06472297|DEVICE|The continuous glucose monitoring system|CGM device worn on back of the arm and glucose readings are shown on the participant's smartphone as a continuous data stream.
214450342|NCT04965753|DRUG|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
214450343|NCT05789212|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A-mindfulness, B-yoga, and C-guided walking.
214450344|NCT05789212|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A-mindfulness, B-yoga, and C-guided walking.
214450345|NCT04961580|DRUG|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
214450346|NCT05687539|DIETARY_SUPPLEMENT|Mastiha water|10ml of mastiha water before every meal for one month
214450347|NCT05687539|DIETARY_SUPPLEMENT|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
214450348|NCT06386757|PROCEDURE|Combined Video Laryngoscopy (VL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.
214450349|NCT06386757|PROCEDURE|Combined Direct Laryngoscopy (DL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation
215132457|NCT03793049|DEVICE|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
215132458|NCT01682239|OTHER|RVAP|In this arm pacemaker leads will be placed in the RV apex.
215132459|NCT01682239|OTHER|RVSP|In this arm pacemaker leads will be placed in the RV septum.
215132460|NCT04006041|DRUG|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
215132461|NCT04006041|DRUG|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
215132462|NCT04006041|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
215132463|NCT04006041|PROCEDURE|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
215132464|NCT03664531|OTHER|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
215132465|NCT03664531|OTHER|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
215132466|NCT03664531|OTHER|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
215132467|NCT02435186|DRUG|p53 gene|p53 gene will be given intraperitoneally.
215132468|NCT02435186|DRUG|Cisplatin|150 mg/m\^2 cisplatin will be given intraperitoneally.
215132469|NCT02435186|DRUG|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
215132470|NCT03623113|BEHAVIORAL|BCC intervention|Structured training and education i basic carbohydrate counting principles
215132471|NCT03623113|BEHAVIORAL|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
214450350|NCT05458011|DRUG|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214450351|NCT05458011|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214450352|NCT06528457|DRUG|ISLA101|ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
214450353|NCT06528457|DRUG|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.
214450354|NCT06528457|OTHER|Placebo|Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
214450355|NCT06426641|DEVICE|Polyethylene|There is no intervention
214450356|NCT05106257|BEHAVIORAL|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
214450357|NCT05106257|BEHAVIORAL|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
214450358|NCT05106257|BEHAVIORAL|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
214450359|NCT05106257|BEHAVIORAL|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
214450360|NCT05106257|BEHAVIORAL|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
214450361|NCT06045078|OTHER|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
214450362|NCT06045078|OTHER|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
215132472|NCT03623113|BEHAVIORAL|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
215132473|NCT00811161|DEVICE|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
215132474|NCT02383381|PROCEDURE|lateral rectus recession|typical surgery for correcting intermittent exotropia
215132475|NCT00543036|DEVICE|H-Coil deep TMS|
215132476|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
215132477|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
215132478|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
215132479|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
215132480|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
215132481|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
214525579|NCT07008625|DEVICE|virtual reality glasses|"Experimental Group (Those who applied virtual reality glasses):~1.Stage: The mothers who will be included in the experimental-application group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the"
214694725|NCT06426199|DRUG|Hyaluronic Acid|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
214694726|NCT01945424|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
214694727|NCT06483516|PROCEDURE|Open repair|Open repair via median laparotomy or lumbotomy
214694728|NCT06483516|PROCEDURE|Endovascular repair|EVAR if AAA simple F-BEVAR if Complex AAA
214694729|NCT04151355|DRUG|Atorvastatin 20mg|atorvastatin (20 mg once daily)
214694730|NCT06400316|DIETARY_SUPPLEMENT|Amino Acid Supplement|The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
214694731|NCT00694954|DEVICE|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
214694732|NCT00694954|OTHER|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
215132482|NCT03866070|OTHER|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
215132483|NCT03866070|OTHER|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
215132484|NCT03976765|OTHER|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
215132485|NCT00167115|DRUG|Alcohol|
215132486|NCT02572544|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
215132487|NCT02237326|PROCEDURE|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
214694733|NCT05038748|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
215132488|NCT02237326|PROCEDURE|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
215132489|NCT05118971|DIAGNOSTIC_TEST|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
215132490|NCT00315835|DRUG|Buprenorphine transdermal delivery system|
215132491|NCT05690451|DIAGNOSTIC_TEST|non-contrast abbreviated MRI|"Liver MRI without contrast injection. The following sequences will be obtained from all of the participants.~* Axial heavily and regular T2 WI~* precontrast fat-suppressed T1 WI~* Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000"
214694734|NCT05038748|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
214694735|NCT05931744|DRUG|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
214694736|NCT05931744|DRUG|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
214694737|NCT05931744|DRUG|Saline|saline intrapolyp injection
215132492|NCT05690451|DIAGNOSTIC_TEST|Contrast enhanced liver CT|"Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained~* precontast, arterial phase, portal venous phase and delayed phase"
215132493|NCT03868215|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
215132494|NCT04620785|OTHER|methylene blue / IPL|therapeutic
215132495|NCT04620785|OTHER|IPL|therapeutic
215132496|NCT04620785|OTHER|saline|placebo
215132497|NCT00208728|DEVICE|PC/SMART cardiopulmonary bypass circuit|
215132498|NCT00208728|DEVICE|PMEA modified cardiopulmonary bypass circuit|
215132499|NCT00208728|DEVICE|Standard of care uncoated cardiopulmonary bypass circuit|
215132500|NCT01751061|BEHAVIORAL|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
215132501|NCT01751061|OTHER|Usual care|usual ICU care
215132502|NCT05427981|DRUG|Belbuca Buccal Product|Buprenorphine Buccal Films
215132503|NCT05427981|OTHER|Placebo|Placebo Buccal Films
215132504|NCT02446977|DRUG|Vitamin B2 Streuli®|4ml IV
215132505|NCT02446977|OTHER|Solution for injection|4ml IV
215132506|NCT01048008|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
215132507|NCT02590796|OTHER|No intervention given to participants|This is an observational study. Participants will receive no intervention.
215132508|NCT00733785|DRUG|Rosiglitazone XR|Rosiglitazone extended release formulation
215132509|NCT02490735|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
215132510|NCT00503750|DRUG|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
215132511|NCT00503750|DRUG|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
215132512|NCT00503750|DRUG|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
215132513|NCT00875186|OTHER|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
215132514|NCT00875186|OTHER|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
215132515|NCT05138302|OTHER|Observation|This study is an observe research
215132516|NCT04834570|BEHAVIORAL|Quality of life in Breast Cancer Survivors|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B"
215132517|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
215132518|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
215132519|NCT03827408|DRUG|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
215132520|NCT03827408|DRUG|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
215132521|NCT03827408|DRUG|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
215132522|NCT01419002|RADIATION|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
215132523|NCT01419002|PROCEDURE|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
215132524|NCT04789252|BIOLOGICAL|Bioinformatics analysis of single cell transcriptomics data|"1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry"
215132525|NCT03972059|OTHER|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
215132526|NCT03972059|OTHER|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
215132527|NCT03972059|OTHER|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
215132528|NCT02226393|BEHAVIORAL|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
215132529|NCT02226393|BEHAVIORAL|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
215132530|NCT06005415|DIETARY_SUPPLEMENT|Wire-cut cookie|Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
214694738|NCT06313177|PROCEDURE|syndesmosis fixation with screws|syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
215132531|NCT04604600|DRUG|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
215132532|NCT01176201|DRUG|SLV337 suspension|400 mg experimental
215132533|NCT01176201|DRUG|SLV337 capsule|5 x 200 mg immediate release capsule
215132534|NCT03869658|BEHAVIORAL|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
215132535|NCT05732298|DEVICE|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
215132536|NCT02367898|OTHER|Lumosity Cognitive Training|adaptive online cognitive training
215132537|NCT02367898|OTHER|Crossword Puzzles|timed online crossword puzzles
215132538|NCT00412009|PROCEDURE|Comprehensive package of activities|
215132539|NCT06297369|DRUG|N acetyl cysteine|N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
215132540|NCT03850379|DRUG|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
215132541|NCT03850379|DRUG|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
215132542|NCT05203614|BEHAVIORAL|Household Contribution|Questionnaires
215132543|NCT05203614|BEHAVIORAL|Outside Contribution|Questionnaires
215132544|NCT05203614|BEHAVIORAL|Control|Questionnaires
215132545|NCT03371498|DRUG|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
215132546|NCT03371498|DRUG|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
215132547|NCT01223534|DRUG|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
214694739|NCT00736866|DRUG|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
215132548|NCT01223534|DRUG|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
215132549|NCT05525897|OTHER|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
215132550|NCT05326087|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
215132551|NCT05326087|DRUG|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
215132552|NCT01194830|DRUG|Linagliptin|Active drug 1 tablet PO QD
215132553|NCT01194830|DRUG|Placebo|1 Tablet PO QD
215132554|NCT00698854|DEVICE|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
215132555|NCT00698854|DEVICE|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
215132556|NCT00061087|DRUG|Methylphenidate|Methylphenidate 80mg/day
215132557|NCT00061087|DRUG|Bupropion|Bupropion 400mg/day
215132558|NCT00061087|OTHER|Placebo|Placebo
215132559|NCT04861597|BEHAVIORAL|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
215132560|NCT04861597|BEHAVIORAL|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
215132561|NCT00162487|DRUG|Albuterol (1,200 μg) through metered-dose inhaler|
215132562|NCT01815918|DRUG|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
215132563|NCT01815918|DRUG|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
215132564|NCT06435936|DRUG|Single Ascending Dose of SAB-176|Single ascending dose
215132565|NCT06435936|DRUG|Single Ascending Dose of Placebo|Single ascending dose
215132566|NCT04682197|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
215132567|NCT01673308|DRUG|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
215132568|NCT04723511|OTHER|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session"
215132569|NCT04723511|OTHER|Kendall exercises|"exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop."
215132570|NCT03154866|DIETARY_SUPPLEMENT|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
215132571|NCT03154866|DIETARY_SUPPLEMENT|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
215132572|NCT05889728|DRUG|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
215132573|NCT00568295|DRUG|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
215132574|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
215132575|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
215132576|NCT02085967|DRUG|rifampin 600 mg|
215132577|NCT02085967|DRUG|itraconazole 200 mg|
215132578|NCT02085967|DRUG|midazolam 2 mg with bupropion 75 mg|
215132579|NCT02085967|DRUG|E2006|
215132580|NCT02814916|DRUG|Dalbavancin|Dalbavancin was administered intravenously over 30 (± 5) minutes.
215132581|NCT02814916|DRUG|Vancomycin|Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
215132582|NCT02814916|DRUG|Oxacillin|Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
215132583|NCT02814916|DRUG|Flucloxacillin|Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
214694740|NCT00736866|DRUG|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
215132584|NCT02814916|DRUG|Cefadroxil|Cefadroxil was administered orally every 12 hours.
215132585|NCT02814916|DRUG|Clindamycin|Clindamycin was administered orally every 8 hours.
214708842|NCT05031429|OTHER|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
214708843|NCT02521298|OTHER|Strength Training|
214708844|NCT02521298|PROCEDURE|Placebo|
214708845|NCT02521298|DRUG|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
214708846|NCT02521298|PROCEDURE|Dry Needling|
214708847|NCT02169804|DRUG|Androxal 25 mg|
215132586|NCT03804840|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.
215132587|NCT03804840|DRUG|Placebo|Placebo
215132588|NCT05626738|DEVICE|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
215132589|NCT04951115|DRUG|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
215132590|NCT04951115|DRUG|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
215132591|NCT04951115|DRUG|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
215132592|NCT04951115|DRUG|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
215132593|NCT04951115|RADIATION|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
215132594|NCT06446921|DIETARY_SUPPLEMENT|Ginger formula|supplement delivering a minimum of 20 mg of gingeroids / d
215132595|NCT06446921|DIETARY_SUPPLEMENT|Placebo|arabic gum
215132596|NCT04335253|DRUG|EOS884448|Multiple Ascending Dose
215132597|NCT04959435|OTHER|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
215132598|NCT04819451|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
215132599|NCT04126798|OTHER|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
215132600|NCT06070779|OTHER|neuro linguistic programming|neuro linguistic programming
215132601|NCT05700669|DRUG|AsiDNA|All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.
215132602|NCT05700669|DRUG|Olaparib|Olaparib is given orally in combination with AsiDNA
215132603|NCT06498583|DRUG|Ropivacaine|0.25 % ropivacaine ( 0.5ml / kg )
215132604|NCT06498583|PROCEDURE|erector spinae plane block|After the operation, unilateral erector spinae plane block was performed at the T5 level under ultrasound guidance.
215132605|NCT06498583|PROCEDURE|Incision infiltration of local anesthesia|After the operation, Incision infiltration of local anesthesia is performed around the surgical incisions.
215132606|NCT05002868|DRUG|RP12146|starting dose of 100 mg QD
215132607|NCT05955612|PROCEDURE|Procalcitonin measurement|Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
215132608|NCT05351944|BEHAVIORAL|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
215132609|NCT05351944|DRUG|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
215132610|NCT00910104|DRUG|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
215132611|NCT05720143|PROCEDURE|Osseodensification|Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
215132612|NCT05720143|PROCEDURE|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
215132613|NCT05720143|PROCEDURE|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
215132614|NCT05835206|DRUG|Microbiome Therapeutic|"Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
215132615|NCT05835206|DRUG|Placebo|"Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
214694741|NCT04356417|OTHER|- Synthetic anti-malarial drugs|Prevalent users will be those with at least one dispensing of AMD or ARBs/ACEi's from 01/01/2019 to 01/01/2020. Exposed users will be those among prevalent users who still received AMD or ARBs/ACEi's on 31/12/2019. The inclusion period will be from 01/01/2019 to 01/01/2020. The study end date will be 30/06/2020. For each treatment AMD or ARB/ACRi's, the persistence of treatment will be defined as the length of time from initiation to discontinuation. Initiation will be the date of the first reimbursement of AMD or ARB/ACRi's during the inclusion period. We will define the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription i.e 30 days. Exposure to a combination of drugs will be defined as a period shorter than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
214694742|NCT06365515|DRUG|Levodopa administration|To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
215132616|NCT04364386|DEVICE|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
215132617|NCT06511973|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
215132618|NCT06511973|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
215132619|NCT06511973|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch
214450363|NCT06278454|DRUG|NRT6008 Injection + Systematic chemotherapy|"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and selected tumor average absorbed dose."
214450364|NCT05274750|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
214450365|NCT05274750|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
214450366|NCT05669989|DRUG|Isatuximab intravenous (IV)|Route of administration: IV infusion; Pharmaceutical form: Vial
214450367|NCT05669989|DRUG|Cemiplimab (SAR439684)|Route of administration: IV infusion; Pharmaceutical form: Vial
214450368|NCT05669989|DRUG|Dexamethasone|Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial
214450369|NCT05669989|DRUG|Lenalidomide|Route of administration: Oral; Pharmaceutical form: Capsules
214450370|NCT05669989|DRUG|Pomalidomide|Route of administration: Oral; Pharmaceutical form: Hard capsules
214450371|NCT05669989|DRUG|Isatuximab subcutaneous (SC)|Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial
214450372|NCT05669989|DRUG|Carfilzomib|Route of administration: IV infusion; Pharmaceutical form: Vial
214450373|NCT02605057|DRUG|LEO 80185 gel|
214450374|NCT02605057|DRUG|Dovobet(r) Ointment|
214450375|NCT05067166|DRUG|Ansuvimab|single infusion 50 mg/kg IV
214450376|NCT04612192|DEVICE|Active luminette|receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
214450377|NCT04612192|DEVICE|Placebo luminette|receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
214450378|NCT03900468|DEVICE|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
214450379|NCT06489314|BEHAVIORAL|LEAD (Learn, Engage, Act, Dedicate)|LEAD is a 5-session behavioral activation (BA) intervention delivered by peer-father counselors. LEAD also incorporates motivational interviewing (MI) and masculinity discussion strategies. This is a task-shifted intervention meaning mental health service tasks are delegated to non-specialist providers, in this case peer-fathers, as opposed to a specialized workforce (e.g., psychiatrists, psychologists).
214450380|NCT02724878|DRUG|Bevacizumab|
214450381|NCT02724878|DRUG|Atezolizumab|
214450382|NCT04793685|DRUG|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
214450383|NCT04793685|BEHAVIORAL|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
214450384|NCT06046573|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
214450385|NCT06046573|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
214450386|NCT06046573|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
214450387|NCT06046573|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
214450388|NCT06385028|BEHAVIORAL|Physical activity promotion|The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
214450389|NCT04207346|DEVICE|TMS 1 hz|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
214450390|NCT04207346|DEVICE|Sham TMS|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
214450391|NCT06093334|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
214450392|NCT06093334|DIAGNOSTIC_TEST|Cardiopulmonary testing|Myocardial function (Strain-Analysis by echocardiography) and spiroergometry, capillary blood gases and lactate
215132620|NCT06511973|DRUG|A solution of 0.2% SLS|0.2% SLS will be dispensed directly on the patch.
214450393|NCT06093334|DIAGNOSTIC_TEST|Pulmonary testing|Lung function (VC%, FEV1%)
215132621|NCT04014829|DIAGNOSTIC_TEST|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
215132622|NCT04014829|DIAGNOSTIC_TEST|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
215132623|NCT04014829|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
215132624|NCT04014829|DIAGNOSTIC_TEST|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
215132625|NCT04014829|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
214450394|NCT06093334|DIAGNOSTIC_TEST|Blood sample|Standard procedures/parameters routinely available in follow-up care after oncological treatment
214450395|NCT05216068|DIAGNOSTIC_TEST|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
214450396|NCT05899998|BEHAVIORAL|Bright IDEAS|Bright IDEAS® (Identify, Define, Evaluate, Act, See) is a problem-solving skills training program that was originally developed to alleviate distress in caregivers of children recently diagnosed with cancer. Intervention materials include instructor and user manuals, a brochure, and worksheets to be completed by the parent caregiver, initially with the help of the interventionist and then with increasing independence.
215132626|NCT04014829|DIAGNOSTIC_TEST|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
215132627|NCT04014829|DIAGNOSTIC_TEST|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
215132628|NCT04014829|DIAGNOSTIC_TEST|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
215132629|NCT04014829|DIAGNOSTIC_TEST|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
215132630|NCT04014829|DIAGNOSTIC_TEST|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
215132631|NCT04014829|DIAGNOSTIC_TEST|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
215132632|NCT06310187|OTHER|High Oxidant Unflavored Little Cigar - Group A|Subjects will be provided with high oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant unflavored little cigar to use for outcome measure data collection in the lab)
215132633|NCT06310187|OTHER|Low Oxidant Unflavored Little Cigar - Group B|Subjects will be provided with low oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant unflavored little cigar to use for outcome measure data collection in the lab)
214525580|NCT07008625|BEHAVIORAL|routine care|"1.Stage: The mothers who will be included in the control group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study, 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the control group were given 1 during the waiting for the next milking time. and 2. r"
215132634|NCT06310187|OTHER|High Oxidant Flavored Little Cigar - Group C|Subjects will be provided with high oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant flavored little cigar to use for outcome measure data collection in the lab)
215132635|NCT06310187|OTHER|Low Oxidant Flavored Little Cigar - Group D|Subjects will be provided with low oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant flavored little cigar to use for outcome measure data collection in the lab)
215132636|NCT06310187|OTHER|Usual Cigarette - Group E|Subjects will use one of their own cigarettes in the collection of outcome measure data in the lab.
215132637|NCT06310187|OTHER|Unlit Little Cigar - Group F|Subjects will be provided with an unlit little cigars to use for outcome measure data collection in the lab. This will be the control group for outcome measure data.
214450397|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
214450398|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
215132638|NCT05953181|PROCEDURE|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
215132639|NCT05976256|OTHER|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
215132640|NCT05976256|OTHER|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
215132641|NCT05976256|OTHER|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
215132642|NCT02081924|OTHER|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
215132643|NCT02081924|OTHER|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
214450399|NCT05749627|DRUG|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
214450400|NCT05749627|DRUG|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
214450401|NCT06075784|OTHER|reiki|placebo reiki
214525581|NCT07008222|COMBINATION_PRODUCT|we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate|Either 3cc of unbuffered lidocaine (control) or 3cc of buffered 1% lidocaine (intervention) will be prepared and administered by the clinician. In a study investigating buffered lidocaine versus unbuffered lidocaine in intrauterine device insertion, investigators prepared 20cc of buffered lidocaine utilizing 18cc of 1% lidocaine (90%) and 2cc of 8.4% sodium bicarbonate (10%). 3 Thus, we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate.
214525582|NCT07008222|OTHER|Unbuffered lidocaine|For the control, 3cc of unbuffered lidocaine will be prepared and administered by the clinician.
214525583|NCT07008547|BIOLOGICAL|Netakimab|Netakimab administered subcutaneously
214525584|NCT07008547|DRUG|Placebo|Placebo administered subcutaneously
214525585|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), stretching will be applied to the ankle joint as described by Tardieu: first at a velocity as slow as possible (V1) for 5 minutes, followed by stretching at the fastest possible velocity (V3), sufficient to elicit a catch, for 10 minutes. A 1-minute rest period will be provided between each stretch. This protocol will be conducted three times per week for four weeks under the supervision of a physiotherapist. Afterward, the exercise will be taught to the families and continued at home as a home-based program for up to six months, without velocity measurement.
215132644|NCT02081924|OTHER|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
215132645|NCT02081924|OTHER|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
215132646|NCT04904692|PROCEDURE|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
215132647|NCT04904692|PROCEDURE|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
215132648|NCT04904692|PROCEDURE|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
215132649|NCT01700413|DRUG|Idarubicin|
215132650|NCT06022861|DRUG|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
215132651|NCT06022861|DRUG|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
215132652|NCT06022861|DRUG|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
215132653|NCT06022861|DRUG|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
214450402|NCT05477602|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
214450403|NCT06296836|DRUG|Metformin|Continuation of home metformin
214525586|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), standard stretching will be applied to the ankle joint three sessions per week. Stretching will be performed for a total of 15 minutes per leg in each session, consisting of 10 repetitions of 60 seconds with 30-second rest intervals. During the 4-week intervention period, the exercises will be taught to the families and continued at home as a home exercise program for up to six months
214694743|NCT06365515|DRUG|Placebo administration|Placebo tablets will be administered as the placebo-controlled condition.
214694744|NCT02652312|DRUG|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
214694745|NCT02652312|DRUG|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
215132654|NCT01349426|DEVICE|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
215132655|NCT05104853|DRUG|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
215132656|NCT05104853|DRUG|Placebo|CNP-104 Placebo
214694746|NCT02652312|PROCEDURE|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
215132657|NCT03960541|DRUG|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
215132658|NCT03960541|DRUG|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
215132659|NCT00936234|DRUG|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
215132660|NCT05179252|DRUG|Shen-Fu injection|Chinese patent medicine made by modern technology
215132661|NCT05179252|DRUG|normal saline|0.9% normal saline, used for sham control
215132662|NCT00872963|BIOLOGICAL|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
215132663|NCT01762696|BEHAVIORAL|MET|Motivational Enhancement Therapy only
215132664|NCT01762696|BEHAVIORAL|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
215132665|NCT05683847|OTHER|User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)|Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
215132666|NCT01885429|DIETARY_SUPPLEMENT|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
214450404|NCT05912478|OTHER|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
214525587|NCT07008846|DRUG|To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis|This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate
214525588|NCT07009275|OTHER|The game-based simulation application developed using 3D animation technology|The intervention group consisted of students using the game-based simulation application developed using 3D animation technology, while the control group consisted of students using traditional learning methods.
214525589|NCT07008092|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of C-reactive protein, white blood cell count and neutrophile count.
214525590|NCT07008092|DIAGNOSTIC_TEST|Urine collection|Urine sample collection for analysis of creatinine and prostaglandin E urinary metabolites
214525591|NCT07008183|OTHER|self-questionnaires|Patients who volunteer to take part in the research will complete self-questionnaires before their appointment with the psychiatrist.
214525592|NCT07007988|DRUG|SIM0388|Abdominal perfusion
214525593|NCT07007988|DRUG|SIM0388|Abdominal perfusion
214525594|NCT05183802|DRUG|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
214525595|NCT06720519|DIAGNOSTIC_TEST|QIAstat-Dx®Meningitis/Encephalite Panel|"The analytical sensitivity of the test is assessed by comparing the results obtained with those known from routine diagnostic tests.~For viruses only, the semi-quantitative value of Ct is also evaluated with the viral load provided by qPCR."
215132667|NCT01885429|DIETARY_SUPPLEMENT|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
215132668|NCT01885429|DIETARY_SUPPLEMENT|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
215132669|NCT01885429|DIETARY_SUPPLEMENT|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
215132670|NCT01885429|DIETARY_SUPPLEMENT|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
215132671|NCT03954639|DRUG|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
215132672|NCT03954639|DRUG|Bupivacaine Hydrochloride|Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
215132673|NCT01706172|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
215132674|NCT01706172|OTHER|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
215132675|NCT00637611|DRUG|Fexofenadine HCl|
214525596|NCT06721819|COMBINATION_PRODUCT|Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention|Preoperative Sleep Hygiene and Brain game followed by post operative IV acetaminophen administration
214525597|NCT06721819|DRUG|Control|Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
214694747|NCT02652312|PROCEDURE|fentanyl|1.5 μg/kg intraoperative
215132676|NCT03080155|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
215132677|NCT04841863|DEVICE|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
215132678|NCT04841863|OTHER|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
215132679|NCT03882294|OTHER|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
215132680|NCT03882294|OTHER|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
215132681|NCT05537753|DEVICE|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
214525598|NCT06720324|DRUG|Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
214525599|NCT06719960|DRUG|Dexmedetomidine group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the dexmedetomidine group, in addition to propofol infusion at the same doses, dexmedetomidine 0.5 μg/kg-1 loading dose was administered within 10 minutes and then continued as infusion at a dose of 0.2-0.7 μg/kg/h.
215132682|NCT05537753|DEVICE|FDA-approved PFO closure device|Chosen by the investigator
215132683|NCT05774353|OTHER|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
215132685|NCT05872737|BEHAVIORAL|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
215132686|NCT05872737|BEHAVIORAL|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
215132687|NCT04739982|DEVICE|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
215132688|NCT05699187|PROCEDURE|Face allotransplantation|Facial allotransplantation
215132689|NCT04984967|DEVICE|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
215132690|NCT04984967|OTHER|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
214450405|NCT05912478|OTHER|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
214450406|NCT04838262|OTHER|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
214525600|NCT06719960|DRUG|Propofol group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the propofol group, propofol loading dose: 0.2-0.5mg/kg, maintenance infusion dose: 0.5-4mg/kg/h was continued.
214450407|NCT03366272|DRUG|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
215132691|NCT00702702|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
215132692|NCT00702702|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
215132693|NCT00702702|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
215132694|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
215132695|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
215132696|NCT05967598|DEVICE|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
215132697|NCT03228108|DRUG|Ciprofloxacin|see study arms.
215132698|NCT03228108|DRUG|Trimethoprim/Sulfamethoxazole|see study arms.
215132699|NCT03228108|DRUG|Fosfomycin|see study arms.
215132700|NCT03228108|DRUG|Pivmecillinam/augmentin|see study arms.
215132701|NCT00373581|DRUG|Vigabatrin|
215132702|NCT00373581|DRUG|Cocaine|
215132703|NCT02240485|BEHAVIORAL|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
215132704|NCT02240485|BEHAVIORAL|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
214450408|NCT03366272|DRUG|Rituximab|eight cycles of R-GemOx in 2-wk intervals
214450409|NCT03366272|DRUG|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
214450410|NCT03366272|DEVICE|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
215132705|NCT00953667|DRUG|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
215132706|NCT03320668|OTHER|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
215132707|NCT04635449|OTHER|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
215132708|NCT02113709|DEVICE|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
215132709|NCT02113709|DEVICE|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
215132710|NCT00436449|DRUG|Avotermin|
215132711|NCT03337230|BEHAVIORAL|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
215132712|NCT03337230|BEHAVIORAL|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
214450411|NCT06188468|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
214450412|NCT06535971|OTHER|Manual therapy combined exercise|"1. Manual therapy included fascia release, progressive passive stretch, mobilization, etc.(depend on subject's current condition)~2. Exercise included muscle strengthening, trunk (spine) stabilization exercise. (depend on subject's current condition)"
215132713|NCT03337230|BEHAVIORAL|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
215132714|NCT05441384|BEHAVIORAL|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
215132715|NCT00391885|DEVICE|Closed-loop anesthesia system|
215132716|NCT04819945|DEVICE|GATT-Patch|Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
215132717|NCT03038321|DRUG|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
215132718|NCT03038321|DRUG|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
215132719|NCT03038321|DRUG|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
215132720|NCT03602677|DEVICE|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
215132721|NCT00475670|DRUG|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
215132722|NCT00475670|DRUG|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
215132723|NCT01961505|DRUG|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
215132724|NCT01961505|DRUG|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
215132725|NCT04239898|OTHER|Red cabbage microgreens|2 cups per day
215132726|NCT04239898|OTHER|Red beet microgreens|2 cups per day
215132727|NCT05407389|DRUG|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
214525601|NCT06752577|DRUG|Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)|Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
214525602|NCT01819233|BEHAVIORAL|Behavioral dietary intervention|Receive caloric restricted dietary intervention
214525603|NCT01819233|PROCEDURE|Therapeutic conventional surgery|Undergo definitive lumpectomy
214525604|NCT01819233|RADIATION|Radiation therapy|Undergo radiation therapy
214525605|NCT01819233|OTHER|Counseling intervention|Receive dietary counseling
214525606|NCT01819233|PROCEDURE|Quality-of-life assessment|Ancillary studies
214525607|NCT06910241|DRUG|Lidocaine|Lidocaine local infiltration
214525608|NCT06910241|DRUG|Diphenhydramine|Diphenhydramine local infiltration
214525609|NCT04701970|PROCEDURE|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
214525610|NCT05144438|DIAGNOSTIC_TEST|Toxseek test|Hair taking
214694748|NCT02652312|PROCEDURE|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
214694749|NCT02652312|PROCEDURE|Atracurium|0.5 mg/kg IV for endotracheal intubation
215132728|NCT06576505|PROCEDURE|peripheral blood sampling, bronchoscopy, upper airway and faeces sampling|"1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml/year but never more than 100 ml/ month.~2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times/year.~3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times/year.~4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment."
215132729|NCT00823251|DEVICE|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
215132730|NCT06175338|DRUG|Rituximab|Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
215132731|NCT06175338|DRUG|MabThera®|MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
215132732|NCT04949191|DRUG|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
215132733|NCT04949191|DRUG|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
215132734|NCT04949191|DRUG|Pembrolizumab|Commercially labeled products
215132735|NCT04494256|DRUG|BIIB105|Administered as specified in the treatment arm.
215132736|NCT04494256|DRUG|Placebo|Administered as specified in the treatment arm.
215132737|NCT01460966|PROCEDURE|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
215132738|NCT01460966|PROCEDURE|Thrombus aspiration catheter|Thrombus aspiration catheter only
215132739|NCT05043350|DRUG|Loratadine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
215132740|NCT05043350|DRUG|Famotidine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
215132741|NCT03659799|DRUG|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
215132742|NCT03659799|DRUG|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
214450413|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
214450414|NCT06289049|OTHER|Experimental|"Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12."
214450415|NCT05617027|OTHER|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
214450416|NCT05617027|OTHER|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
214450417|NCT06142825|OTHER|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
214450418|NCT04742231|DEVICE|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
214450419|NCT05641831|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
214450420|NCT05641831|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
214450421|NCT05641831|DRUG|Canakinumab|Given SC
214450422|NCT05641831|PROCEDURE|Chest Radiography|Undergo chest x-ray
214450423|NCT05641831|PROCEDURE|Echocardiography|Undergo ECHO
214450424|NCT05641831|DRUG|Placebo Administration|Given SC
214694750|NCT02652312|PROCEDURE|diclofenac sodium|1 mg/kg for postoperative analgesia
214694751|NCT02652312|PROCEDURE|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
215132743|NCT03659799|OTHER|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
215132744|NCT03659799|OTHER|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
215132745|NCT04268082|DEVICE|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
215132746|NCT04268082|OTHER|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
215132747|NCT05071170|BEHAVIORAL|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
215132748|NCT06360146|OTHER|Early mobilisation|Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
215132749|NCT01988714|OTHER|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
215132750|NCT01988714|OTHER|(CG) plus evidence-based SE|(CG) plus evidence-based SE
215132751|NCT02913482|DRUG|Risdiplam|Risdiplam will be administered orally.
215132752|NCT03360266|COMBINATION_PRODUCT|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
215132753|NCT03360266|COMBINATION_PRODUCT|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
215132754|NCT03360266|DRUG|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
215132755|NCT06421857|PROCEDURE|suturing|laparoscopic cystectomy for endometrioma and hemostasis was done using suturing
215132756|NCT06421857|PROCEDURE|bipolar electrocoagulation|laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
214450425|NCT05641831|OTHER|Quality-of-Life Assessment|Ancillary studies
214450426|NCT06552689|DEVICE|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System|Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
214450427|NCT05839548|DRUG|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
214450428|NCT05839548|DRUG|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
215132757|NCT04183114|BIOLOGICAL|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
215132758|NCT04183114|BIOLOGICAL|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
215132759|NCT04508166|DRUG|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
215132760|NCT04508166|DRUG|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
214450429|NCT05105802|BEHAVIORAL|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
214525611|NCT02847819|DEVICE|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
214525612|NCT00518583|DRUG|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
214525613|NCT01232569|DRUG|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
214525614|NCT01232569|DRUG|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
214525615|NCT03465085|DRUG|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
214694752|NCT01091987|BEHAVIORAL|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
214694753|NCT05663736|DRUG|Gemigliptin|DPP-4 inhibitor
215132761|NCT04508166|DRUG|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
214450430|NCT05105802|BEHAVIORAL|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
214450431|NCT06046326|BEHAVIORAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
214450432|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
214450433|NCT05081622|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
214450434|NCT03206710|OTHER|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
214450435|NCT03652805|DRUG|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
214450436|NCT06414122|OTHER|mid-frequency whole-body electromyostimulation (WB-EMS)|supervised group training sessions at least once and optionally twice a week, lasting 11-20 minutes, over 12 weeks, 12-24 training sessions in total
214450437|NCT06414122|OTHER|conventional exercise training|supervised group training at least once a week, optional additional home-based training once a week, lasting 40 minutes, over 12 weeks, 12-24 training sessions in total
214450438|NCT06414122|OTHER|nutritional therapy|conventional nutritional counselling with guidelines and digital nutritional coaching
214450439|NCT03113929|RADIATION|MRI|Research MRI
214450440|NCT05150860|BEHAVIORAL|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
214450441|NCT05150860|BEHAVIORAL|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
214450442|NCT05690633|DEVICE|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
214694754|NCT05663736|DRUG|Glimepiride|Glimepiride
214694755|NCT00011713|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
214694756|NCT04385147|OTHER|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
214694757|NCT05917366|OTHER|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
214694758|NCT05917366|OTHER|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
214708848|NCT03583606|BIOLOGICAL|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).
214694759|NCT00809458|DRUG|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
214694760|NCT03585322|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
214694761|NCT00987623|DEVICE|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
214694762|NCT00987623|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
214694763|NCT01611350|OTHER|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
214694764|NCT01611350|OTHER|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
214450443|NCT06237179|BEHAVIORAL|Exercise Training Intervention|5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
214450444|NCT06237179|BEHAVIORAL|Healthy Living Education|During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
214450445|NCT06513299|DEVICE|low tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
214450446|NCT06513299|DEVICE|high tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
214450447|NCT06513299|DEVICE|low driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
214450448|NCT06513299|DEVICE|high driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
214450449|NCT04752319|DEVICE|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
214450450|NCT04752319|DEVICE|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
215132762|NCT04508166|BEHAVIORAL|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
215132763|NCT04532671|OTHER|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
215132764|NCT04532671|OTHER|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
215132765|NCT04532671|OTHER|indirect resin composite|CADCAM resin composite blocks using milling process
214694765|NCT01611350|OTHER|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
214694766|NCT03248947|DRUG|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
214708849|NCT03583606|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).
214708850|NCT03583606|OTHER|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
215132766|NCT01983228|BEHAVIORAL|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
214694767|NCT03248947|OTHER|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
214694768|NCT06301841|OTHER|experimental|"At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days."
214694769|NCT02437448|OTHER|No intervention|
214694770|NCT01496430|DRUG|Placebo|
214694771|NCT01496430|DRUG|Azilsartan medoxomil|
214694772|NCT01496430|DRUG|Azilsartan medoxomil|
214694773|NCT05135130|DRUG|ON101 Cream|Not applicable in this retrospective study
214694774|NCT01100307|DRUG|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
215132767|NCT03155165|DEVICE|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
215132768|NCT04338672|OTHER|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
215132769|NCT04472052|OTHER|appendectomy|Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
215132770|NCT00768612|DRUG|SCA-136 50mg/day|
215132771|NCT00768612|DRUG|SCA-136 150 mg/day|
214694775|NCT01100307|OTHER|sham injection|sham injection every 6 weeks
215132772|NCT00768612|DRUG|SCA-136 300mg/day|
215132773|NCT00768612|DRUG|Risperidone 4mg/day|
215132774|NCT00788463|DRUG|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
215132775|NCT00788463|DRUG|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
215132776|NCT00830544|DRUG|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
214694776|NCT03314558|OTHER|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
214694777|NCT05110040|DRUG|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
214694778|NCT01140854|PROCEDURE|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
214694779|NCT01140854|OTHER|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
214694780|NCT06579196|DRUG|Trabedersen|Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).
214694781|NCT06579196|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
215132777|NCT00830544|DRUG|Chemotherapy|Neoadjuvant chemotherapy
215132778|NCT00830544|DRUG|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
215132779|NCT05622630|PROCEDURE|Four-cell bath|Four-cell bath:Treatment with direct current
215132780|NCT05622630|PROCEDURE|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
215132781|NCT00866424|PROCEDURE|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
215132782|NCT02971917|RADIATION|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
215132783|NCT02971917|RADIATION|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image"
214694782|NCT02509598|DRUG|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
214450451|NCT05669846|DRUG|Healthy Donor Fecal Microbiota Transplant (hdFMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy, or, administered orally in the form of capsules. The FMT consists of introducing normal bacterial flora contained in the stool collected from a healthy donor into the small intestine. In this case, the hdFMT will be administered on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
214450452|NCT05669846|DRUG|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
214450453|NCT06436053|DEVICE|LBBAP with SyncAV|Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.
214450454|NCT06062901|OTHER|Educational Intervention|Receive educational intervention
214450455|NCT06062901|OTHER|Interview|Participate in one-on-one interview
214450456|NCT06062901|OTHER|Survey Administration|Ancillary studies
214694783|NCT02509598|DRUG|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
214694784|NCT02509598|PROCEDURE|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
214694785|NCT03284242|DRUG|Treg|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
215132784|NCT02971917|RADIATION|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
215132785|NCT05860088|OTHER|Beef Diet|Controlled-Feeding Diet Intervention
214450457|NCT06574191|DRUG|Topical Diclofenac gel 1%|Topical NSAID
214450458|NCT05082909|DRUG|Probenecid|Addition of 500mg QDS to oral penicillin.
214450459|NCT05668754|DRUG|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
214450460|NCT05668754|OTHER|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
214450461|NCT06388811|OTHER|Early Osteoarthritis Questionnaire|Self administered questionnaire
214450462|NCT04357574|OTHER|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
214450463|NCT05531604|BEHAVIORAL|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
214450464|NCT02406014|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
214450465|NCT02406014|DRUG|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
214450466|NCT00929084|OTHER|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
214450467|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
214694786|NCT00188877|PROCEDURE|intensity modulated radiation therapy|
215132786|NCT05860088|OTHER|Vegetarian Diet|Controlled-Feeding Diet Intervention
215132787|NCT00443144|DRUG|recombinant human growth hormone|
215132788|NCT04076085|OTHER|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
215132789|NCT02003326|OTHER|Inflammatory markers|
214450468|NCT04539574|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
214450469|NCT04539574|OTHER|Questionnaire Administration|Ancillary studies
214694787|NCT00188877|DRUG|cisplatinium and fluorouracil - standard treatment|
214694788|NCT02196038|BEHAVIORAL|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
214694789|NCT02196038|BEHAVIORAL|Attention Control|Usual care with bi-weekly contact from study staff
214694790|NCT04056455|DRUG|Mobocertinib|Mobocertinib capsule.
214694791|NCT00422838|PROCEDURE|fine-needle aspiration biopsy|aspiration of intrahepatic cells
214694792|NCT02697513|BEHAVIORAL|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
214694793|NCT05931016|DIAGNOSTIC_TEST|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
214694794|NCT05931016|DIAGNOSTIC_TEST|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
214450470|NCT05921448|BIOLOGICAL|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
214450471|NCT05921448|BIOLOGICAL|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
215132790|NCT01813396|OTHER|joint mobilization plus massage|
215132791|NCT01813396|OTHER|joint mobilization/shoulder physical activity guide|
215132792|NCT04400630|OTHER|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
215132793|NCT00918385|DRUG|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
215132794|NCT00918385|DRUG|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
215132795|NCT02005016|BEHAVIORAL|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
215132796|NCT04446637|DRUG|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI|Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
215132797|NCT04446637|DRUG|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI|Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
215132798|NCT04773951|BIOLOGICAL|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
215132799|NCT02843230|RADIATION|Avastin|
215132800|NCT02843230|RADIATION|Lomustine|
214450472|NCT03175029|DRUG|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
215132801|NCT02843230|RADIATION|Temozolomide|
214450473|NCT03175029|DRUG|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
214450474|NCT03164980|DRUG|Trabectidin (Yondelis)|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
214450475|NCT05641623|DRUG|OSU6162|OSU6162
214450476|NCT05641623|DRUG|Placebo|Placebo
214450477|NCT06521164|DEVICE|Haermonics Pure system|pericardial flushing with Haermonics Pure system
214450478|NCT04230499|DRUG|Encapsulated Rapamycin (eRapa)|eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
214450479|NCT06123611|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
214694795|NCT01055808|DRUG|Insulins|Individual dose and frequency and duration as determined by the treating physician
214694796|NCT05621824|DEVICE|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
215132802|NCT02843230|DEVICE|MRI|
215132803|NCT02843230|DEVICE|MRS|
215132804|NCT02843230|DEVICE|DSC|
215132805|NCT05765422|OTHER|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
215132806|NCT05421949|OTHER|Exercise group|Incremental Shuttle Walking Test
215132807|NCT00994552|OTHER|Pressure support ventilation|Pressure support ventilation
215132808|NCT00994552|OTHER|Pressure control ventilation|Pressure control ventilation
215132809|NCT00317473|BIOLOGICAL|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
215132810|NCT00317473|BIOLOGICAL|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
215132811|NCT05288816|DRUG|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
215132812|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
215132813|NCT03184064|DIETARY_SUPPLEMENT|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
215132814|NCT03184064|DIETARY_SUPPLEMENT|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
215132815|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
215132816|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
215132817|NCT05294926|DRUG|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure \< 60 mmHg and heart rate \< 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate \< 40 bpm) are used to prevent hypotension or bradycardia
215132818|NCT05294926|DEVICE|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
215132819|NCT05129748|DRUG|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
214450480|NCT06186336|OTHER|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
215132820|NCT03416868|BEHAVIORAL|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
215132821|NCT01323582|DRUG|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
215132822|NCT01323582|DRUG|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
215132823|NCT03755713|DRUG|ASP0892|Intradermal
215132824|NCT03755713|DRUG|Placebo|Intradermal; normal saline solution
215132825|NCT02848820|DRUG|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
215132826|NCT02848820|PROCEDURE|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
214450481|NCT03381261|DRUG|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
215132827|NCT06313255|DRUG|PegIFNα2b|The patients receive PegIFNα2b therapy
215132828|NCT06313255|DRUG|PegIFNα2b+probiotics|The patients receive both PegIFNα2b and probiotics therapy
215132829|NCT06313255|DRUG|Nucleoside analog|The patients receive nucleoside analog therapy
215132830|NCT06313255|DRUG|Nucleoside analog+probiotics|The patients receive both nucleoside analog and probiotics therapy
214450482|NCT04421079|DIETARY_SUPPLEMENT|Trans-resveratrol|150mg, 300mg, 450mg
214450483|NCT04421079|DIETARY_SUPPLEMENT|Concord grape juice|8 oz, 16 oz, 24 oz
214450484|NCT04421079|DIETARY_SUPPLEMENT|Grape seed polyphenol extract|450mg, 900mg, 1200mg
214450485|NCT04421079|DRUG|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
214694797|NCT05621824|PROCEDURE|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
214694798|NCT02528097|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
215132831|NCT05359458|BEHAVIORAL|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
215132832|NCT00956163|PROCEDURE|magnetic resonance imaging|Undergo whole-body MRI
215132833|NCT00956163|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
215132834|NCT00956163|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
215132835|NCT00956163|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
215132836|NCT00956163|RADIATION|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
215132837|NCT00956163|OTHER|laboratory biomarker analysis|Correlative studies
215132838|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
215132839|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
215132840|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
215132841|NCT01593826|DRUG|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
215132842|NCT01593826|DRUG|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
215132843|NCT01593826|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
215132844|NCT01593826|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
214450486|NCT05434819|PROCEDURE|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
214450487|NCT05226351|DRUG|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
215132845|NCT00083889|DRUG|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
215132846|NCT00083889|DRUG|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
215132847|NCT01486875|DRUG|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
215132848|NCT03844776|DRUG|Co-Amoxiclav|amoxicillin + clavulanic acid orally
215132849|NCT03844776|DRUG|Paracetamol|paracetamol orally
215132850|NCT03844776|DRUG|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
215132851|NCT03844776|DRUG|Normal saline|0.9% normal saline irrigation
215132852|NCT03844776|DRUG|Amoxicillin 500 Mg|Amoxicillin 500 orally
215132853|NCT03844776|DRUG|Metronidazole|metronidazole 500 mg orally
215132854|NCT00388349|DRUG|Gemcitabine|
215132855|NCT00388349|DRUG|Vinorelbine|
215132856|NCT00388349|DRUG|Carmustine|
215132857|NCT00388349|DRUG|Etoposide|
214450488|NCT05226351|DRUG|Placebo|single administration of placebo oral (oily solution)
214450489|NCT05227209|DRUG|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
215132858|NCT00388349|DRUG|Cyclophosphamide|
215132859|NCT00388349|PROCEDURE|Autologous HCT|
215132860|NCT05449418|BEHAVIORAL|Full Intervention|A small group of employees who work at facilities randomized to this arm will be invited to develop tailored COVID-19 vaccination promotion materials in teams with other long-term care staff sharing the same or similar language and/or cultural affinity. These employees will also help promote these materials to all of the employees who work at their facilities.
215132861|NCT05449418|OTHER|Enhanced Usual Care|Employees who work at facilities randomized to this arm will see COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention \[CDC\] or other national organization.
215132862|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
215132863|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
215132864|NCT02854085|BEHAVIORAL|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
215132865|NCT02854085|BEHAVIORAL|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
215132866|NCT03402802|DRUG|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
215132867|NCT00112736|DRUG|erlotinib|Given orally
215132868|NCT00112736|DRUG|temsirolimus|Given IV
215132869|NCT00112736|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
215132870|NCT00112736|OTHER|laboratory biomarker analysis|Correlative studies
215132871|NCT00112736|OTHER|pharmacological study|Correlative studies
215132872|NCT05435339|BIOLOGICAL|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
215132873|NCT01605006|DEVICE|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
214450493|NCT06551922|COMBINATION_PRODUCT|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022)."
214525616|NCT03465085|DRUG|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
214525617|NCT02862652|OTHER|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
214525618|NCT00074178|BIOLOGICAL|filgrastim|
214525619|NCT00074178|BIOLOGICAL|pegfilgrastim|
214525620|NCT00074178|DRUG|cyclophosphamide|
214525621|NCT00074178|DRUG|cytarabine|
214525622|NCT00074178|DRUG|dexamethasone|
214525623|NCT00074178|DRUG|etoposide phosphate|
214525624|NCT00074178|DRUG|methotrexate|
214525625|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
215132874|NCT01283555|DRUG|Tenofovir|Delivered using prefilled and user-filled applicator
215132875|NCT03104881|DEVICE|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
215132876|NCT03104881|DEVICE|2D end-effector type robot|2 dimension end-effector type upper extremity robot
215132877|NCT06222632|OTHER|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
215132878|NCT06222632|OTHER|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 \&amp; 12 of the intervention.
215132879|NCT06222632|OTHER|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
215132880|NCT06342934|DIAGNOSTIC_TEST|Ultrasound|Ultrasound images are collected and stored. The images stored during your preoperative ultrasound will be exported in anonymous format from the ultrasound system, and sent to the coordinating center (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano). There, images will be submet to radiomic analysis through the application of a dedicated software; that will allow to evaluate the intrinsic characteristics of the tissue according to different parameters (shape, intensity, grade of heterogeneity and many others) of the 'pixels' (gray dots) that constitute the ultrasound imag
215132881|NCT00537394|DRUG|Enfuvirtide|90mg subcutaneously twice daily
215132882|NCT00537394|DRUG|Raltegravir|400 mg twice daily
215132883|NCT00537394|DRUG|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
215132884|NCT00537394|DRUG|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
215132885|NCT00537394|DRUG|Etravirine|Two 100-mg tablets twice daily
215132886|NCT00537394|DRUG|Maraviroc|Dosage dependent on regimen in which maraviroc is included
215132887|NCT04468646|DRUG|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
215132888|NCT04712188|DIAGNOSTIC_TEST|Musculoskeletal ultrasonography|The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
215132889|NCT04712188|OTHER|Wheelchair propelling test|Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
215132890|NCT06126614|DRUG|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
214450494|NCT06551922|COMBINATION_PRODUCT|Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022)."
214450495|NCT06202287|OTHER|Balance measurements using the HUR Smart balance device, balance tests, and other surveys.|50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
214525626|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
215132891|NCT06126614|DRUG|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
215132892|NCT06126614|OTHER|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
215132893|NCT06126614|OTHER|Saline|saline for irrigation
215132894|NCT04731636|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
215132895|NCT03473236|DRUG|GB002|Inhaled GB002
215132896|NCT03473236|DEVICE|Generic Dry Powder Inhaler|dry powder inhaler used for inhalation of active drug or placebo
215132897|NCT03473236|DRUG|Placebo|Inhaled placebo
215132898|NCT06406764|OTHER|Plyometric training|Participants undergo a plyometric training program. The plyometric training consists of exercises in the horizontal, lateral, and vertical directions of movement. Exercises are progressively focused on maximal performance with short ground contact (\<250 ms). The training sessions are twice per week.
215132899|NCT06406764|OTHER|Control training|Participants continues their regular sports activities without additional plyometric training. The training sessions are twice per week.
215132900|NCT03756519|BEHAVIORAL|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
215132901|NCT03756519|BEHAVIORAL|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
215132902|NCT03756519|BEHAVIORAL|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
215132903|NCT03756519|OTHER|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
215132904|NCT06221995|DIAGNOSTIC_TEST|Indirect Calorimetry|Resting energy expenditure measurement
215132905|NCT03291496|OTHER|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
215132906|NCT03291496|OTHER|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is \>24 hours old.
215132907|NCT03291496|OTHER|Adult Blood collection|One Time 1 ml of whole blood collected
215132908|NCT04983017|DIETARY_SUPPLEMENT|Dietary supplement|iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
215132909|NCT04983017|OTHER|Placebo|Matched Placebo to Intervention
215132910|NCT05565365|PROCEDURE|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
215132911|NCT05565365|PROCEDURE|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
215132912|NCT00685165|DRUG|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
215132913|NCT00685165|DRUG|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
215132914|NCT05546151|DRUG|BMS-986322|Specified dose on specified days
215132915|NCT05546151|OTHER|Placebo for BMS-986322|Specified dose on specified days
215132916|NCT00506870|DEVICE|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
215132917|NCT00506870|DEVICE|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
215132918|NCT02893709|DRUG|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
215132919|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
215132920|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
215132921|NCT05139043|DRUG|Dexamethasone|Given IV and PO
215132922|NCT00293657|DRUG|Lornoxicam 8 mg|
215132923|NCT00293657|DRUG|Lornoxicam 16 mg|
215132924|NCT00293657|DRUG|Placebo|
214450496|NCT06216548|OTHER|Usual Care and Enhanced Primary Care|"Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice."
214450497|NCT06216548|OTHER|Enhanced Primary Care|The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
214450498|NCT05341986|OTHER|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
214450499|NCT05331170|BIOLOGICAL|Research Grade RG-RV|Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
215132925|NCT05135871|DRUG|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
215132926|NCT00959608|BEHAVIORAL|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
215132927|NCT00959608|BEHAVIORAL|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
215132928|NCT05200065|PROCEDURE|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
215132929|NCT05200065|PROCEDURE|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
215132930|NCT02364908|OTHER|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
215132931|NCT02195908|OTHER|single point Neiguan(PC6) plus antiemetic drug|
215132932|NCT02195908|OTHER|single point Zhongwan(CV12) plus antiemetic drug|
215132933|NCT02195908|OTHER|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
215132934|NCT02195908|DRUG|only antiemetic drug|
215132935|NCT03650491|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
215132936|NCT04924816|PROCEDURE|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
215132937|NCT03140514|DRUG|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
215132938|NCT04217382|OTHER|patient with melanoma pre transplantation|survival time without melanoma recurrence
215132939|NCT00534365|DEVICE|tension-free vaginal tape|Retropubic mid-urethral sling
215132940|NCT00534365|DEVICE|TVT-SECUR device|Mid-urethral mini-sling
215132941|NCT02899936|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
215132942|NCT02899936|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
215132943|NCT02681198|DRUG|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
215132944|NCT02681198|DRUG|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
215132945|NCT00434408|BEHAVIORAL|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
215132946|NCT00434408|BEHAVIORAL|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
215132947|NCT00434408|BEHAVIORAL|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
215132948|NCT04731285|DIAGNOSTIC_TEST|Pressure wire fractional flow reserve|Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
215132949|NCT04731285|DIAGNOSTIC_TEST|CFD-based RuiXin-FFR|"CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour"
215132950|NCT06235866|OTHER|Pulmonary rehabilitation|According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
215132951|NCT01581918|DRUG|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
214450500|NCT06483477|OTHER|Standard skin care|From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
214525627|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
214525628|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
215132952|NCT02931617|OTHER|Chest Physiotherapy|
215132953|NCT02931617|DEVICE|Post-therapy lung volume measurements|In both intervention groups.
215132954|NCT02856412|OTHER|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
215132955|NCT02856412|OTHER|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
215132956|NCT05189743|PROCEDURE|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
215132957|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\_06 Group and ABCWY low dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\_01 Group, ABCWY low doseS\_02 Group and ABCWY low doseS\_06 Group in study Phase II (Sourcing).
215132958|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\_06 Group and ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\_01 Group, ABCWY high doseS\_02 Group and ABCWY high doseS\_06 Group in study Phase II (Sourcing).
215132959|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\_06 Group, ABCWY low dose\_02 Group, ABCWY high dose\_06 Group, ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding).
215132960|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
215132961|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
215132962|NCT06971926|BEHAVIORAL|Home visist|Caregivers and children will receive home visits twice a month delivered by the social assistance service within the PI-SUAS/CF during 12 months
215132963|NCT06483230|DEVICE|Intensive Visual Stimulation Device|The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
215132964|NCT02099864|DRUG|Enzalutamide|Given PO
215132965|NCT05061238|DEVICE|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
214450501|NCT06483477|DEVICE|Reminder App|In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
214450502|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
214450503|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
214450504|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
214450505|NCT06024187|PROCEDURE|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
214450506|NCT06024187|PROCEDURE|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
215132966|NCT06642454|OTHER|Transcutaneous auricular vagus nerve stimulation|"Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz."
215132967|NCT04527796|OTHER|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
215132968|NCT05270057|DRUG|Etoposide|Dose level -2=50 mg/m\^2; dose level -1=50 mg/m\^2; dose level 1=50 mg/m\^2; dose level 2=60 mg/m\^2; dose level 3=72 mg/m\^2; dose level 4=86.4 mg/m\^2; dose level 5=103.7 mg/m\^2; dose level 6=124.4 mg/m\^2; dose level 7=149.3 mg/m\^2
215132969|NCT05270057|DRUG|Doxorubicin|Dose level -2=10 mg/m\^2; dose level -1; dose level -1=10 mg/m\^2; dose level 1=10 mg/m\^2; dose level 2=12 mg/m\^2; dose level 3=14.4 mg/m\^17.3 mg/m\^2; dose level 4=17.3 mg/m\^2; dose level 5=20.7 mg/m\^2; dose level 6=24.8 mg/m\^2; dose level 7=29.8 mg/m\^2.
215132970|NCT05270057|DRUG|Cyclophosphamide|Dose level -2=480 mg/m\^2; dose -1=600 mg/m\^2; dose level 1=750 mg/m\^2; level 2=900 mg/m\^2; level 3=1080 mg/m\^2; level 4=1296 mg/m\^2; level 5=1555 mg/m\^2; level 6=1866 mg/m\^2; level 7=2239 mg/m\^2.
215132971|NCT05270057|DRUG|Rituximab|Level -2 through level 7: 375 mg/m\^2
215132972|NCT05270057|DRUG|Vincristine|Level -2 through level 7: 0.4 mg/m\^2/day
215132973|NCT05270057|DRUG|Prednisone|Level -2 through level 7: 60 mg/m\^2/twice daily (BID)
215132974|NCT05270057|DRUG|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
215132975|NCT05270057|DRUG|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
215132976|NCT05270057|DRUG|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
215132977|NCT01400698|DRUG|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
215132978|NCT01400698|DRUG|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
214450507|NCT03042962|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
214708851|NCT05106595|DEVICE|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
215132979|NCT01400698|OTHER|Observation only|Subjects were only observed.
214450508|NCT03042962|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
214450509|NCT04470726|DRUG|AIV001|Intradermal/intratumoral
214450510|NCT04470726|DRUG|AIV001 suspension|AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
214450511|NCT04950660|DRUG|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
214450512|NCT04950660|DRUG|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
214450513|NCT05177523|DIAGNOSTIC_TEST|MRI|Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
214450514|NCT05177523|OTHER|Neurocognitive examination for healthy subjects|Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
214450515|NCT05177523|OTHER|blood sampling|Each enrolled subject will undergo a blood sampling (10 ml) at baseline
214450516|NCT04166266|OTHER|Blood draw for the laboratory assessment|Blood sampling for the biobank and, in addition, as sub-studies are planned on sub-groups of patients, additional blood samples are planned for the patients in these sub-studies.
214450517|NCT03761537|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
214450518|NCT03761537|OTHER|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
214450519|NCT04786028|OTHER|Isatuximab|Brand name for interventional drug is Sarclisa
214450520|NCT06111846|DRUG|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)
214450521|NCT05359523|DEVICE|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
214450522|NCT05359523|OTHER|fascia injection|Under ultrasound guidance, a local anesthetic and steroid mixture will be injected into the fascia between the trapezius muscle and the rhomboid muscle.
214450523|NCT06159634|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) will be the technique used to remove target lesions.
214450524|NCT06159634|DEVICE|Traction Device|Use of traction device to aid in removing target lesions
214450525|NCT05711173|BIOLOGICAL|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
214450526|NCT05736211|BEHAVIORAL|Organization-level Youth Engagement prevention strategy|Systematically incorporating Youth Engagement into prevention efforts in a community setting
215132980|NCT00751686|PROCEDURE|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
215132981|NCT00751686|OTHER|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
214450527|NCT04268979|BEHAVIORAL|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
214450528|NCT04268979|BEHAVIORAL|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
214450529|NCT05421325|BIOLOGICAL|QBKPN SSI|Site-Specific Immunomodulator
214450530|NCT05421325|OTHER|Normal Saline Placebo|Normal Saline
214450531|NCT04178252|OTHER|mask|investigators will add eye mask to standard treatment
214450532|NCT04178252|OTHER|headset|investigators will add headset to standard treatment
214450533|NCT04178252|OTHER|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
214450534|NCT06246422|DRUG|Tranexamic Acid 500 MG|Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
214450535|NCT06246422|DRUG|Normal saline|Local instillation of 20 ml normal saline in the gall bladder bed
214450536|NCT03169738|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214450537|NCT03169738|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
214450538|NCT03169738|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214450539|NCT03169738|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214450540|NCT03169738|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214525629|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
214708852|NCT00207012|DRUG|BMS-599626|
214450541|NCT03169738|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214450542|NCT03169738|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
214450543|NCT03169738|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214450544|NCT03169738|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214450545|NCT03169738|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
214450546|NCT03169738|DRUG|Lovaza|Omega-3-acid ethyl esters
214450547|NCT03169738|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214450548|NCT03169738|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
214450549|NCT03169738|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
214450550|NCT03169738|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
214450551|NCT03169738|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
214450552|NCT03169738|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214450553|NCT03169738|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
214450554|NCT03169738|BIOLOGICAL|GI-4000|Ras yeast vaccine
214450555|NCT03169738|BIOLOGICAL|GI-6207|CEA yeast vaccine
214450556|NCT03169738|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214450557|NCT03169738|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
214450558|NCT05524233|DEVICE|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
215132982|NCT04566471|OTHER|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
215132983|NCT04190914|OTHER|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
215132984|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
215132985|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
215132986|NCT00756366|OTHER|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
214450559|NCT05443620|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
215132987|NCT02413307|OTHER|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
215132988|NCT00035490|DRUG|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
215132989|NCT00035490|DRUG|placebo|placebo tablet, once daily for one year
215132990|NCT00035490|DRUG|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
214450560|NCT05443620|DEVICE|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
214450561|NCT05134350|DRUG|LOXO-305|LOXO-305 orally.
214450562|NCT05134350|DRUG|Omeprazole|Omeprazole Orally.
214450563|NCT04323774|BEHAVIORAL|AYA-RISE Adolescents and Young Adults Risk Information and Screening Education|A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.
215132991|NCT01740713|DRUG|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
215132992|NCT01740713|DRUG|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
215132993|NCT01740713|DRUG|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
215132994|NCT04084171|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
215132995|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
215132996|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
215132997|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
215132998|NCT06722378|OTHER|Access to medical notes|Inpatient notes shared in real-time on a hospital-owned bedside tablet linked to their child's records.
215132999|NCT06749314|PROCEDURE|Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression|The LE-ULBD: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression is a single portal through lamina with instrument to decompression both side of the spinal canal, giving strength of preserve facet joint, preserve spinal musculature, mitigate the risk of adjacent fusion and lesser bleeding
215133000|NCT06757075|DRUG|Ibuprofen|10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery
215133001|NCT06757075|DRUG|Acetominophen|15 mg/kg/dose of acetominophen will be given every 6 hours for 24 hours post surgery
215133002|NCT06926790|DRUG|Nivolumab & Ipilimumab|This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.
215133003|NCT06887582|PROCEDURE|Free-hand sinus lift augmanted by particulate autologous dentin graft + free-hand implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous free-hand implant placement
215133004|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift augmanted by particulate autologous dentin graft + computer-guided implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
215133005|NCT06887582|PROCEDURE|Free-hand sinus lift with autologous dentin block graft +free-hand immediate implant placement|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous free-hand implant placement
215133006|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift with autologous dentin block graft +computer-guided immediate implant placement.|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
215133007|NCT04785495|OTHER|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
215133008|NCT05376384|DIAGNOSTIC_TEST|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
214450564|NCT04323774|BEHAVIORAL|Standard clinical visit for genetic counseling|Standard clinical visit for genetic counseling and follow up
214450565|NCT06184256|BEHAVIORAL|BfedBwell - Core Curriculum|12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
214450566|NCT06184256|BEHAVIORAL|BfedBwell - 1:1 Counseling|Individual 1:1 counseling sessions with a registered dietitian
214450567|NCT06184256|BEHAVIORAL|BfedBwell - Behavioral Skills|Group-based behavioral skills development sessions
214450568|NCT06184256|BEHAVIORAL|BfedBwell - Group Support|Structured group support sessions
215133009|NCT05376384|PROCEDURE|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
215133010|NCT06350786|OTHER|P-Dragees blue Lichtenstein, Placebo dragees|"In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points:~1. Opioids work by telling the body that participants are not experiencing as much pain;~2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies);~3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid;~4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids."
215133011|NCT06350786|OTHER|Control group (EM)|"In the EM control group, the focus lies on the electronic monitoring (EM) of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points:~1. The collection of EM data allows for greater patients' sense of agency over medication treatment;~2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies);~3. The EM is a useful tool, and daily recording of opioid medication intake should be done;~4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids."
215133012|NCT06932848|DRUG|Curcumin in Nanogels|Participants will apply curcumin nanogels to affected oral areas three times daily for 4 weeks.
215133013|NCT06932848|DRUG|0.1% Fluocinolone Acetonide Oral Paste|Participants will apply 0.1% fluocinolone acetonide oral paste to the affected oral mucosa three times daily for 4 weeks. This corticosteroid paste is the standard treatment for oral lichen planus.
215133014|NCT06937723|OTHER|Device: Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
215133015|NCT06938555|BEHAVIORAL|Prolonged Nightly Fasting|At the start of the intervention (week 1) PNF participants will be asked to engage in fasting (14 hours a night, starting no later than 8pm) six nights a week (for the 8-week study duration). Participants will be asked to track their fasting start/stop times on a tracking sheet provided by study staff. During the nightly fast, participants will be allowed to drink water, coffee or tea (without dairy or sweeteners). Study staff will meet with participants via phone for weekly check-in calls (\~10-15 mins) to collect weekly fasting start/stop dates/times (entered into REDCap); alternately, participants may elect to email or text their fasting start/stop date/times to the study staff.
215133016|NCT06938555|BEHAVIORAL|Health Education Videos|Provision of HED is a retention strategy and can influence outcomes. Thus, all participants will receive HED. Each week, participants will receive hyperlinks to videos focused on health educational content unrelated to fasting, diet and outcome measures. Participants will be asked to view the videos (\~10-15 min) prior to their weekly check-in calls with the study staff (\~5-10 mins for HED-Only Control group). They will receive each week's videos on a Monday, and receive a reminder to view on Friday. Study staff will follow a scripted HED weekly check-in call to ensure consistency of data collected. Weekly topics are as follows: W1: Internet safety, W2: Sun safety, W3: Home safety, W4: Driving safety, W5: Hydration, W6: Dental health, W7: Working environment, W8: Communication. Data collected on electronic forms during all participant/staff check-in calls will be stored in participant-specific ASU Dropbox files.
215133017|NCT06939127|DRUG|Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy|"Eligible patients will start the study treatment (7-14 days between pathological diagnosis and cryoablation). Patients first undergo cryoablation of the primary tumor. Then, 7±3 days after cryoablation, they start treatment with tislelizumab (200 mg) plus platinum-based doublet chemotherapy, given every 3 weeks for 3-4 cycles.~The following platinum-based doublet chemotherapy regimens are allowed in this trial:~* Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)~* Cisplatin/carboplatin + albumin-bound paclitaxel/paclitaxel (squamous NSCLC)"
215133018|NCT06939127|PROCEDURE|Surgery|After completing neoadjuvant therapy, surgery should be performed as soon as possible within 4-6 weeks after the last dose of neoadjuvant therapy.
215133019|NCT06939127|DRUG|Adjuvant tislelizumab|"Patients receiving adjuvant therapy must meet the following criteria:~* ECOG performance status score of 0 or 1~* Recovery from surgery and adequate organ function as determined by the investigator based on laboratory values During the adjuvant phase, patients will receive tislelizumab as adjuvant therapy. The first dose of tislelizumab (cycle 1 of the adjuvant phase) should be administered within 2-8 weeks after surgery. Patients will continue to receive tislelizumab (400 mg, Q6W) as adjuvant therapy every 6 weeks until one of the following events occurs: completion of 8 cycles of tislelizumab adjuvant therapy, disease recurrence, unacceptable adverse events (AEs), death, or decision by the patient and/or investigator to discontinue study treatment."
215133020|NCT03906539|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg per day
215133021|NCT03906539|DIETARY_SUPPLEMENT|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
215133022|NCT03906539|OTHER|Placebo|Placebo capsule - 1 capsule per day
214450569|NCT06184256|BEHAVIORAL|Program delivery|Delivery and evaluation of one or more intervention components
214450570|NCT04441047|DRUG|AlloStim|Living, activated allogeneic Th1-like memory immune cells
214450571|NCT06512025|BEHAVIORAL|WWWT psychoeducative intervention|"What Were We Thinking (WWWT) is a highly structured, interactive, gender-informed, couples-based, psycho-educational program for parents and a first newborn to promote confident parental caretaking, optimize functioning in the intimate partner relationship and improve infant care manageability.~The adaptation of the WWWT programme (Catalan and Spanish version) comprises 2 sessions, each lasting 2 hours, that will be designed for groups of 5-7 families - within the first 6 weeks postpartum -, each consisting of mother, partner (or other caregiver) and their infant(s)."
214450572|NCT03342079|DRUG|Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)|topical anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)
214450573|NCT03342079|DRUG|Placebos|placebo topical anesthetic
214450574|NCT05111405|PROCEDURE|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
214450575|NCT05772130|OTHER|Best Practice|Receive family letter and genomic test report
214450576|NCT05772130|OTHER|Electronic Health Record Review|Ancillary studies
214450577|NCT05772130|BEHAVIORAL|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
214450578|NCT05772130|OTHER|Survey Administration|Ancillary studies
214450579|NCT02530671|DEVICE|Toothbrushing with manual toothbrush|
215133023|NCT05981469|DEVICE|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
214450580|NCT02530671|DEVICE|Toothbrushing with power toothbrush|
214450581|NCT02736409|DRUG|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
214450582|NCT02736409|DRUG|Placebo|Matching Placebo dose
214450583|NCT03465865|DEVICE|optical coherence tomography|optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
214450584|NCT04528355|DRUG|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
214450585|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
214450586|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
214450587|NCT04390048|DEVICE|Anodal tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
214450588|NCT04390048|DEVICE|Sham tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
214450589|NCT02202356|DRUG|ALS-008176|
214450590|NCT02202356|DRUG|Placebo|
214450591|NCT02038569|DRUG|LEO 80185 gel|
214450592|NCT05801913|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
214450593|NCT05801913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214450594|NCT05801913|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214450595|NCT05801913|PROCEDURE|Computed Tomography|Undergo CT
214450596|NCT05801913|PROCEDURE|Leukapheresis|Undergo leukapheresis per SOC
214450597|NCT05801913|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
214525630|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
214525631|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
215133024|NCT05981469|OTHER|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
215133025|NCT00211328|DRUG|anecortave acetate|
215133026|NCT02631980|DRUG|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
214450598|NCT05801913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214450599|NCT05801913|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214450600|NCT05801913|PROCEDURE|Positron Emission Tomography|Undergo PET
214450601|NCT05801913|PROCEDURE|X-Ray Imaging|Undergo x-ray
214450602|NCT05629663|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
214450603|NCT04900363|DRUG|AK112|Subjects receive AK112 intravenously.
214450604|NCT03126019|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food
214450605|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
215133027|NCT02631980|DRUG|IV placebo|Intravenous 0.9% saline (250 ml)
215133028|NCT00003229|BIOLOGICAL|aldesleukin|
215133029|NCT00003229|BIOLOGICAL|gp100 antigen|
215133030|NCT00003229|BIOLOGICAL|tyrosinase peptide|
215133031|NCT00948064|DRUG|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
215133032|NCT00948064|DRUG|Azacitidine|75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
215133033|NCT02022059|DRUG|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
215133034|NCT02022059|DRUG|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
215133035|NCT05016479|DEVICE|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
215133036|NCT02996344|OTHER|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
215133037|NCT02996344|OTHER|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
215133038|NCT01373021|DRUG|Fentanyl|Fentanyl 2500mcg+NS50ml
215133039|NCT01373021|DRUG|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
215133040|NCT00289653|DRUG|Nicoderm|
215133041|NCT02044354|DRUG|Taxotere|
215133042|NCT02044354|DRUG|Jevtana|
215133043|NCT01439789|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
215133044|NCT01439789|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
215133045|NCT05503836|PROCEDURE|abdominal surgeries|abdominal surgeries
215133046|NCT00002044|DRUG|Zidovudine|
215133047|NCT06378021|DRUG|Calcium Chloride|5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft
215133048|NCT06378021|DRUG|Sodium Chloride 0.9% Inj|0.9% sodium chloride injection during on pump during Coronary artery bypass graft
215133049|NCT03323892|OTHER|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
215133050|NCT01288573|DRUG|plerixafor|160 μg/kg subcutaneous (SC) injection
215133051|NCT01288573|DRUG|plerixafor|240 μg/kg subcutaneous (SC) injection
215133052|NCT01288573|DRUG|plerixafor|320 μg/kg subcutaneous (SC) injection
215133053|NCT03449511|OTHER|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
215133054|NCT03449511|OTHER|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
215133055|NCT03449511|OTHER|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
215133056|NCT03449511|OTHER|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
215133057|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (tablet)
215133058|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (capsule)
215133059|NCT00179621|DRUG|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
215133060|NCT00179621|DRUG|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
215133061|NCT00179621|DRUG|Placebo|Placebo, matching to active study drug arms
215133062|NCT00270985|BEHAVIORAL|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
215133063|NCT00270985|BEHAVIORAL|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
215133064|NCT04272918|BEHAVIORAL|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
215133065|NCT04272918|BEHAVIORAL|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
215133066|NCT03422913|PROCEDURE|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still \>5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) \> 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
215133067|NCT00837252|DRUG|Finasteride|Participants received 5mg of oral finasteride daily for three months.
215133068|NCT03896139|DRUG|Kinase inhibitor|Patients treated with kinase inhibitors for cancer or other conditions
215133069|NCT02438163|DEVICE|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
215133070|NCT05000398|OTHER|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
215133071|NCT05000398|OTHER|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
215133072|NCT05000398|OTHER|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
215133073|NCT05000398|OTHER|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
215133074|NCT05000398|OTHER|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
215133075|NCT05000398|OTHER|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
215133076|NCT05000398|OTHER|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
215133077|NCT05000398|OTHER|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
215133078|NCT05000398|OTHER|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
215133079|NCT01649349|DEVICE|two-piece nasogastric tube|one week period
215133080|NCT02973100|DRUG|Dulaglutide|Administered SC
215133081|NCT02973100|DRUG|Placebo|Administered SC
215133082|NCT00960622|DRUG|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
214450606|NCT06205992|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
215133083|NCT00960622|DRUG|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
215133084|NCT00960622|DRUG|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
214450607|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
215133085|NCT03562364|OTHER|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
215133086|NCT04461275|OTHER|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
214450608|NCT06205992|DEVICE|2D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
214450609|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
214450610|NCT04122235|OTHER|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
214450611|NCT04907929|BEHAVIORAL|targeted speech and cognitive therapy|One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
214450612|NCT06435468|GENETIC|Blood sample for genetic analysis|genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
214450613|NCT06435468|OTHER|Blood sample for immunological response assessments|Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
214450614|NCT06435468|OTHER|Blood sample to identify relevant biomarker of the disease|Research biomarkers for diagnosis, prognosis and monitoring of disease activity
214450615|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
214694799|NCT02528097|DRUG|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
215133087|NCT03128294|OTHER|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
215133088|NCT04696120|DRUG|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
215133089|NCT04696120|DRUG|Placebo|All patients who are assigned to placebo group will receive placebo
215133090|NCT05642351|OTHER|Autobiographical reminder|"The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)"
215133091|NCT06046924|OTHER|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
214525632|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
214525633|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
214525634|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
214525635|NCT00123435|DEVICE|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
214525636|NCT04044352|BIOLOGICAL|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
214450616|NCT05123300|DIAGNOSTIC_TEST|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
214450617|NCT06419218|BEHAVIORAL|School meal messages|Messages focused on the benefits of children consuming school lunch and breakfast, using text and images developed based on parent interviews. Participants will view a total of 10 messages.
214450618|NCT06419218|BEHAVIORAL|Control (neutral) messages|Control messages approximately matched to the intervention messages on length and design, but discussing a neutral topic unrelated to school meals (reading). Participants will view a total of 10 messages.
214450619|NCT05159128|DRUG|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
214450620|NCT05159128|OTHER|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
214450621|NCT05665244|PROCEDURE|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
214525637|NCT05572385|BEHAVIORAL|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
214525638|NCT03000647|PROCEDURE|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
214525639|NCT03000647|PROCEDURE|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
214525640|NCT00651937|DRUG|Melphalan|100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
214525641|NCT00651937|PROCEDURE|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0."
214525642|NCT00651937|BEHAVIORAL|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
214525643|NCT00651937|DRUG|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
214525644|NCT00651937|PROCEDURE|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
214525645|NCT05672498|DRUG|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
214450622|NCT05665244|DEVICE|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
215133092|NCT06046924|DRUG|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
215133093|NCT06046924|OTHER|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
214450623|NCT03094663|DRUG|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
214450624|NCT03094663|DRUG|Methylprednisolone|40 mg/ml, 1 ml
214450625|NCT03094663|DRUG|Cefazolin|500 mg in 10 ml
214450626|NCT03094663|DEVICE|8 MHz. Chiba needle|22G/ 4 inches
214525646|NCT05672498|OTHER|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
214525647|NCT06479330|OTHER|Milk Chocolate|Acute intake
214525648|NCT02306213|DRUG|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
214525649|NCT02306213|OTHER|standard volume therapy|
214525650|NCT04282564|OTHER|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
214525651|NCT06399341|DEVICE|Papilocare vaginal gel|Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
214525652|NCT01314898|DRUG|3 mg PF-03882845|3 mg PF-03882845, single oral dose
214525653|NCT01314898|DRUG|10 mg PF-03882845|10 mg PF-03882845, single oral dose
214525654|NCT01314898|DRUG|30 mg PF-03882845|30 mg PF-03882845, single oral dose
214525655|NCT01314898|DRUG|100 mg PF-03882845|100 mg PF-03882845, single oral dose
214525656|NCT01314898|DRUG|Spironolactone|100 mg spironolactone, single oral dose
214525657|NCT00104013|DRUG|xaliproden (SR57746A)|
214525658|NCT03698617|DRUG|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
215133094|NCT06403787|DRUG|Aerobic exercise + Ginkgo Biloba Extract|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
215133095|NCT06403787|DRUG|Aerobic exercise + Calcined magnesia (placebo)|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
215133096|NCT06403787|DRUG|Aerobic exercise + Atorvastatin|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
214450627|NCT03094663|DRUG|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
214450628|NCT03094663|DRUG|Bupivacaine 25cc|25 cc 0.25% bupivacaine
214450629|NCT03094663|DRUG|Bupivacaine 20cc|20cc 0.25% bupivacaine
214450630|NCT03094663|DRUG|Dexamethasone|2 mg IV dexamethasone.
214450631|NCT04804514|DRUG|KH001|The study drug is applied to teeth
214450632|NCT04804514|DRUG|Placebo|The placebo is applied to teeth
214450633|NCT06636734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214450634|NCT06636734|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214450635|NCT06636734|DRUG|Lovastatin|Given PO
214525659|NCT03698617|DRUG|Propofol|For induction of general anesthesia
214525660|NCT01488838|DRUG|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
214525661|NCT01488838|RADIATION|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
214525662|NCT04237519|BEHAVIORAL|SFL training|"The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
214694800|NCT00590018|DRUG|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
214694801|NCT00590018|DRUG|Placebo|Placebo for 5 days intravenously.
215133097|NCT03770234|DRUG|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
215133098|NCT01361230|DEVICE|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
215133099|NCT05471271|OTHER|[18F]AlF-RESCA-IL2 PET scan|Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment
215133100|NCT06131632|PROCEDURE|Breast conserving surgery|Remove only a small part of the breast
215133101|NCT06131632|PROCEDURE|Radical modified mastectomy|Remove all the breast parenchyma, nipple and skin
215133102|NCT00414635|DRUG|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
215133103|NCT05243823|DRUG|Vagifem®|According to local clinical practice - independent of inclusion in this study
215133104|NCT05243823|DRUG|Non-Vagifem® LDVE, Estradiol|According to local clinical practice - independent of inclusion in this study
215133105|NCT01841281|DRUG|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
215133106|NCT01841281|DRUG|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
215133107|NCT05440097|OTHER|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
215133108|NCT00631514|DRUG|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
215133109|NCT00631514|DRUG|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
215133110|NCT00631514|DRUG|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
215133111|NCT05296226|PROCEDURE|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
215133112|NCT01572597|DRUG|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
215133113|NCT01572597|DRUG|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
214450636|NCT06636734|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214450637|NCT06636734|BIOLOGICAL|Pembrolizumab|Given IV
214450638|NCT06636734|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214450639|NCT06641297|BEHAVIORAL|Music video game|The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
214450640|NCT02727972|BEHAVIORAL|Cognitive Testing|Verbal assessments as well as computer testing.
214450641|NCT02727972|OTHER|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
214450642|NCT02727972|RADIATION|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
214450643|NCT06584799|DRUG|Micronized purified flavonoid fraction|"Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months."
214694802|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
215133114|NCT03282656|BIOLOGICAL|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
215133115|NCT04649541|DRUG|MRX-8|novel semi-synthetic polymyxin B analog.
215133116|NCT04649541|DRUG|Placebo|5% dextrose in water
215133117|NCT04785443|DRUG|ICG|"During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months."
215133118|NCT04785443|PROCEDURE|Control group|"During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months."
215133119|NCT03732339|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
215133120|NCT06211920|OTHER|Non-invasive ventilation|The application of NIV will be performed using af a facemask as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.
215133121|NCT03512821|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
215133122|NCT03512821|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
215133123|NCT04427319|DIETARY_SUPPLEMENT|β-alanine|7 days of consumption
215133124|NCT04427319|DIETARY_SUPPLEMENT|wheat semolina|7 days of consumption
215133125|NCT04404426|DIETARY_SUPPLEMENT|L-citrulline|Administration of citrulline enterally for 7 days.
214450644|NCT06584799|DRUG|Diosmin 600|Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
214450645|NCT06584799|DRUG|Hesperidin+Diosmin combination 1000|"A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months"
214450646|NCT06563609|BEHAVIORAL|Intensive physical Therapy|Tailored exercise programs supervised by trained physiotherapists, focusing on improving cardiorespiratory fitness, strength, and functional capacity.
214450647|NCT06563609|DIETARY_SUPPLEMENT|Probiotic treatment|Administration of probiotic yeast Saccharomyces boulardii twice daily
214450648|NCT06563609|BEHAVIORAL|Individualised Nutritional Support|Personalized nutritional plans guided by a dietitian, addressing malnutrition and caloric/protein deficiencies with daily caloric intake adjustments and supplements if necessary based on the EFFORT trial.
214450649|NCT06563609|OTHER|Standard hospital care|Patients will receive standard hospital care
214450650|NCT04918758|DEVICE|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
214450651|NCT04918758|DRUG|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
214450652|NCT04637152|DRUG|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
214450653|NCT06427928|BEHAVIORAL|Explains the perioperative process with pictures|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
214450654|NCT06427928|BEHAVIORAL|The perioperative process is only explained|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
214525663|NCT04237519|BEHAVIORAL|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
214525664|NCT00235014|DRUG|trandolapril|2 mg QD
215133126|NCT04404426|OTHER|Placebo|Administration of placebo (water) enterally for 7 days
215133127|NCT06201260|OTHER|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
215133128|NCT06201260|OTHER|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
215133129|NCT06107777|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
215133130|NCT06107777|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
215133131|NCT01517932|DRUG|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
215133132|NCT01517932|DRUG|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
215133133|NCT00375271|PROCEDURE|perioperative hemodynamic optimization protocol|
214450655|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
214450656|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
214450657|NCT00580515|BEHAVIORAL|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
214450658|NCT06400342|PROCEDURE|TAVR-explant|Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.
214450659|NCT06400342|DEVICE|Redo-TAVR|Repeat transcatheter aortic valve implantation within a failed THV.
214450660|NCT05612048|OTHER|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
214450661|NCT05612048|OTHER|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
214450662|NCT05612048|OTHER|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
214450663|NCT06153563|OTHER|Data collection on patient history and intraoperative results.|Data collection on patient history and intraoperative results.
214694803|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
214525665|NCT00235014|DRUG|trandolapril/verapamil|180/2 mg QD
214694804|NCT04801342|DRUG|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
214525666|NCT00235014|DRUG|placebo|1 tablet QD
214525667|NCT00235014|DRUG|verapamil|SR 240 mg QD
214525668|NCT02589418|PROCEDURE|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
214525669|NCT02589418|PROCEDURE|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
214525670|NCT02589418|PROCEDURE|No Acupuncture|Control intervention: No needle insertion and manipulation
214525671|NCT06475027|OTHER|TBDESJS|Chinese herbal tea TBDESJS
214525672|NCT06475027|OTHER|Acupuncture|acupuncture GB20 or GB20 plus BL2
214694805|NCT01172587|OTHER|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
214694806|NCT01005537|BIOLOGICAL|aldesleukin|Given IV and orally
214694807|NCT01005537|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214694808|NCT01005537|DRUG|cyclophosphamide|Given IV
215133134|NCT00434681|DRUG|paracetamol 4.8% paediatric oral suspension|
215133135|NCT06223711|RADIATION|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
215133136|NCT06223711|DRUG|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
215133137|NCT06223711|RADIATION|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
215133138|NCT06223711|DRUG|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
215133139|NCT03531489|DEVICE|AIR-AD|Non-significant risk medical device as decided by institutional review board
215133140|NCT01865266|DRUG|Ulinaststin for injection|
215133141|NCT01865266|DRUG|placebo|
215133142|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
215133143|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
215133144|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
215133145|NCT00003343|DRUG|endocrine-modulating drug therapy|
215133146|NCT00003343|DRUG|mitoxantrone hydrochloride|
215133147|NCT00003343|DRUG|prednisone|
215133148|NCT00003343|DRUG|prinomastat|
215133149|NCT03600272|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
215133150|NCT03600272|PROCEDURE|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
215133151|NCT04864756|OTHER|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
215133152|NCT01836588|PROCEDURE|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
215133153|NCT02102035|PROCEDURE|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
215133154|NCT02152891|BEHAVIORAL|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
214450666|NCT06173258|DEVICE|Water exchange alone|During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
214694809|NCT03134508|OTHER|treated by antiTNFα|pregnant IBD women treated by antiTNFα
214694810|NCT03134508|OTHER|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
214694811|NCT05519371|DRUG|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
215133155|NCT05260671|DRUG|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
215133156|NCT03246971|DRUG|Wafermine™ 50 mg|Administered as needed for 12 hours
215133157|NCT03246971|DRUG|Wafermine™ 75 mg|Administered as needed for 12 hours
215133158|NCT03246971|DRUG|Placebos|Administered as needed for 12 hours
215133159|NCT03246971|DRUG|Wafermine™ 25 mg|Administered as needed for 12 hours
215133160|NCT01913561|DEVICE|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
215133161|NCT01913561|DEVICE|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
215133162|NCT01941511|DRUG|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
215133163|NCT00308802|PROCEDURE|Kidney transplantation|Participants in this study will have had a kidney transplant
215133164|NCT01046981|PROCEDURE|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
215133165|NCT01046981|PROCEDURE|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
215133166|NCT06169202|DEVICE|fruquintinib|4 mg orally once daily, D1-14, repeated every 3 weeks.
215133167|NCT06169202|DRUG|Irinotecan|180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
215133168|NCT06169202|DRUG|Capecitabine|1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
215133169|NCT01383746|DEVICE|Yttrium microsphere injection|Radiation therapy
215133170|NCT04356495|DIETARY_SUPPLEMENT|Vitamins|2 tablets daily from the first day (day 0) to day 9
215133171|NCT04356495|DRUG|Telmisartan|1 tablet daily from the first day (day 0) to day 9
215133172|NCT04356495|DRUG|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
215133173|NCT04356495|DRUG|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
215133174|NCT00350025|DRUG|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
215133175|NCT00350025|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
215133176|NCT03021057|DRUG|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
215133177|NCT04516746|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
215133178|NCT04516746|BIOLOGICAL|Placebo|Commercially available 0.9% (n/V) saline for injection.
215133179|NCT05809921|DRUG|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
215133180|NCT05809921|DRUG|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
215133181|NCT02629029|PROCEDURE|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
214450667|NCT06173258|DEVICE|Water exchange plus Artificial Intelligence (AI)|Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
214450668|NCT06755970|PROCEDURE|ICOUGH|"After the patient has recovered from postoperative anesthesia and their hemodynamic values have stabilized, the ICOUGH bundle applications mentioned above will be carried out. The patient's pain and nausea levels will be recorded for a period of 48 hours.~Postoperative pain and nausea will be assessed with the help of data collectors, using a numerical rating scale at 2, 4, 8, 12, 24, and 48 hours after surgery.~Considering that postoperative respiratory complications are relatively common and costly, various studies have been conducted to explore ways to reduce the risk of their occurrence. One of these protocols is the ICOUGH bundle, which stands for Incentive Spirometry, Coughing and Deep Breathing, Oral Care, Patient Understanding of the Interventions, Getting Out of Bed, and Head of Bed Elevation."
214450669|NCT04815187|DRUG|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
214450670|NCT04815187|DRUG|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
214450671|NCT05200247|DRUG|spesolimab|solution for infusion
214450672|NCT05085496|BIOLOGICAL|Atezolizumab|Given IV
214450673|NCT05085496|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214694812|NCT05519371|DRUG|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
215133182|NCT02629029|DEVICE|Computed tomography angiography (CTA)|
215133183|NCT00778934|OTHER|Intimate Health Gel|Intimate Health Gel
215133184|NCT00315926|DRUG|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
215133185|NCT00315926|DRUG|Placebo|a mixture of ethanol and physiological saline
215133186|NCT02455921|DRUG|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
215133187|NCT02455921|DRUG|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
215133188|NCT00322777|BEHAVIORAL|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
215133189|NCT02489435|DRUG|VM-1500|VM-1500
215133190|NCT02489435|DRUG|Placebo|Placebo
215133191|NCT02537977|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
215133192|NCT03115359|BEHAVIORAL|Mindfulness Based Therapy|"The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
215133193|NCT03115359|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
215133194|NCT03285724|DEVICE|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
215133195|NCT04739644|DEVICE|Specific wrist rehabilitation by WRISTBOT device|The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
215133196|NCT04739644|OTHER|Specific wrist rehabilitation performed by the physiotherapist|Passive, active and assisted mobilization
215133197|NCT04739644|OTHER|General rehabilitation|Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
214450674|NCT06757322|PROCEDURE|Singel Needle Double Cannula TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991. The single needle technique was developed by Singh and Varghese and introduced in 2013. The single needle method is a more simplified modification of the first method.
214450675|NCT06757322|PROCEDURE|Double Needle TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991.
214450676|NCT05636943|BEHAVIORAL|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
214450677|NCT05636943|BEHAVIORAL|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
214450678|NCT06461689|DRUG|177Lu-PSMA-617|All patients treated with 177Lu-PSMA had a post-therapy 68Ga-PSMA PET scan and a post-therapy 177Lu-PSMA-617 SPECT/CT scan. These scans are available in the CHRU PACS, and patients are informed that their data may be used for research purposes, via posters in the nuclear medicine department or via the welcome booklet,
214708853|NCT00880880|OTHER|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
215133198|NCT02994238|DEVICE|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
215133199|NCT02818309|DRUG|Lesogaberan|120 mg bid
215133200|NCT02818309|DRUG|Placebo|Placebo
215133201|NCT04231669|BEHAVIORAL|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
215133202|NCT00566774|OTHER|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
215133203|NCT00566774|OTHER|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
215133204|NCT06024941|RADIATION|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
215133205|NCT05535946|DRUG|ABX464|Administered once daily, preferably in the morning, with food
215133206|NCT05535946|DRUG|Placebo|Administered once daily, preferably in the morning, with food
215133207|NCT03656003|DEVICE|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
215133208|NCT03656003|DEVICE|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
215133209|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage).|Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.
215133210|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).|Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
215133211|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
215133212|NCT05543265|BEHAVIORAL|Default appointment scheduling|Default primary care appointment scheduling
215133213|NCT05543265|BEHAVIORAL|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
215133214|NCT05543265|BEHAVIORAL|Nudge Reminders|Primary care appointment reminders
215133215|NCT05316597|BEHAVIORAL|Forest bathing|Participants will be seated in a forest environment for an hour-long exposure to the forest
215133216|NCT04776083|DRUG|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
215133217|NCT04776083|RADIATION|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
214450679|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
214450680|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
214450681|NCT03634930|BEHAVIORAL|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
214450682|NCT03940963|DEVICE|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
214450683|NCT03940963|PROCEDURE|Standard Neurectomy|Surgical excision of symptomatic neuroma
215133218|NCT06472661|DEVICE|Echopulse or Echopulse HD|The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.
215133219|NCT06472661|DRUG|PolyICLC|PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
215133220|NCT05526716|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
215133221|NCT05526716|BIOLOGICAL|QIV|Single 0.5 mL IM injection
215133222|NCT05526716|BIOLOGICAL|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
215133223|NCT05763017|OTHER|Relative Motion Splint|Six weeks relative motion splint wear.
214450684|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
214450685|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
214450686|NCT04056897|BIOLOGICAL|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
214450687|NCT04056897|DRUG|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
214450688|NCT04056897|DRUG|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
214450689|NCT04056897|BIOLOGICAL|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
214450690|NCT05262296|PROCEDURE|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
215133224|NCT05763017|OTHER|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
214450691|NCT05262296|PROCEDURE|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
214450692|NCT06440317|DEVICE|Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)|The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.
214450693|NCT06397976|DEVICE|ANTERION investigational|Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
214450694|NCT05354024|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
214450695|NCT05354024|BIOLOGICAL|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
215133225|NCT02997631|DEVICE|MEDi Robot|Distraction therapy using an interactive humanoid robot
215133226|NCT03767933|DRUG|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
215133227|NCT03767933|DRUG|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
215133228|NCT03767933|DRUG|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
214450696|NCT04782687|DRUG|Selinexor|oral drug that comes in 20 mg tablets
214450697|NCT04782687|DRUG|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.
214450698|NCT04782687|DRUG|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
214450699|NCT04782687|DRUG|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
214708854|NCT03101527|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
214708855|NCT05549089|DEVICE|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
214450700|NCT01809691|DRUG|TAK-700|300 mg, PO, twice daily
214450701|NCT01809691|DRUG|Bicalutamide|50 mg, PO, q daily
215133229|NCT03767933|DRUG|Acetaminophen placebo|Oral liquid
215133230|NCT03767933|DRUG|Hydromorphone placebo|Oral liquid
215133231|NCT03541850|DRUG|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
215133232|NCT03541850|OTHER|Quality-of-Life Assessment|Ancillary studies
215133233|NCT03541850|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215133234|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
215133235|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
215133236|NCT06204679|DRUG|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
215133237|NCT04750824|DRUG|Afatinib|Afatinib
215133238|NCT04750824|DRUG|other systemic therapy|other systemic therapy
215133239|NCT05136976|DRUG|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
215133240|NCT05136976|DRUG|Placebo infusion|2 infusions of placebo at a 2 week interval.
215133241|NCT05136976|DRUG|Premedications|"Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
215133242|NCT04204447|OTHER|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
215133243|NCT04204447|OTHER|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
215133244|NCT04024865|DRUG|Domperidone|Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
215133245|NCT04024865|DRUG|No domperidone|Women with no prescription for domperidone during the six months following delivery.
215133246|NCT06512961|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
215133247|NCT06512961|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
215133248|NCT06512961|OTHER|Training Protocol|The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
215133249|NCT03859024|DRUG|Oxycodone|oxycodone tablet
215133250|NCT03859024|DRUG|Acetaminophen|acetaminophen tablet
215133251|NCT03859024|DRUG|Gabapentin|gabapentin tablet
215133252|NCT03859024|DRUG|celebrex|Celebrex tablet
215133253|NCT03859024|DRUG|Bupivacaine|bupivacaine injection
215133254|NCT03859024|DRUG|Ibuprofen 800 mg|ibuprofen tablet
215133255|NCT03859024|DRUG|Dexamethasone|Dexamethasone injection
215133256|NCT05040659|DEVICE|AROMHA Longitudinal Smell Test|The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
215133257|NCT06005194|BEHAVIORAL|InMotion|A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
215133258|NCT04921670|DIAGNOSTIC_TEST|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
215133259|NCT02854072|DRUG|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
215133260|NCT02854072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
215133261|NCT02854072|DRUG|Capecitabine|Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
215133262|NCT03628092|DEVICE|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
215133263|NCT03628092|DEVICE|Placebo|Sham Device
215133264|NCT04645368|DRUG|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
215133265|NCT05095636|DRUG|Apatinib Mesylate|oral Apatinib once everyday
215133266|NCT05095636|DRUG|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
215133267|NCT00701454|OTHER|No intervention|No intervention
215133268|NCT01584869|DEVICE|capsule endoscopy|
215133269|NCT04357717|DIAGNOSTIC_TEST|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
215133270|NCT00176696|DEVICE|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
215133271|NCT04557410|DRUG|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
215133272|NCT04780867|BEHAVIORAL|Delayed vaccination|First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
215133273|NCT03938311|OTHER|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
215133274|NCT00759590|PROCEDURE|CT scan and Pressure volume curve|CT scan
214708856|NCT05549089|DEVICE|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
215133275|NCT02492035|BEHAVIORAL|Lifestyle intervention|
215133276|NCT05500287|OTHER|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
215133277|NCT02570984|DRUG|Omalizumab|anti-ige injection
215133278|NCT02570984|DRUG|Placebo|placebo comparator arm, injection similar to active
215133279|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
215133280|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day after transplant
215133281|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
215133282|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
215133283|NCT00099801|DRUG|FTY720|
215133284|NCT06174246|BEHAVIORAL|Pain self-management program|"Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/"
215133285|NCT06174246|BEHAVIORAL|Additional support for self-management program|"This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program."
215133286|NCT00335699|DRUG|Rosuvastatin|
215133287|NCT01616966|DRUG|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
215133288|NCT01616966|DRUG|propofol|Maintenance of anesthesia with propofol
215133289|NCT04538521|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
215133290|NCT01951443|DIETARY_SUPPLEMENT|Ginseng|400mg of encapsulated Rg3-KRG
215133291|NCT01951443|DIETARY_SUPPLEMENT|Wheat Bran|400mg of encapsulated wheat bran
215133292|NCT00907426|DRUG|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
215133293|NCT00907426|DRUG|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
215133294|NCT03547518|DEVICE|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
215133295|NCT03547518|DEVICE|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
215133296|NCT00375063|PROCEDURE|Percutaneous Coronary Intervention|
215133297|NCT00375063|PROCEDURE|Coronary Artery Bypass Grafting|
214525673|NCT05264064|OTHER|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
215133298|NCT04854135|DEVICE|CGM4Home|FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
215133299|NCT05672654|DIAGNOSTIC_TEST|Blood draw|Blood draw
215133300|NCT04252911|OTHER|Bispectral index score|Bis value from two sites gives similar results
215133301|NCT00360841|PROCEDURE|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
215133302|NCT00360841|PROCEDURE|Sham auricular acupuncture|
215133303|NCT02314468|PROCEDURE|Negative pressure wound therapy|NPWT changed twice a week.
215133304|NCT02314468|PROCEDURE|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
215133305|NCT05989581|DRUG|Labetalol or Nifedipine|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs \<130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP\<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
215133306|NCT04962711|OTHER|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
215133307|NCT04962711|OTHER|Usual care|provided by participants' usual healthcare professional(s)
215133308|NCT05282095|OTHER|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
215133309|NCT06552286|BEHAVIORAL|STRW-T|The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).
215133310|NCT06552286|BEHAVIORAL|PEERS-T|PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
215133311|NCT06396598|OTHER|Educational Activity|Review education materials
215133312|NCT06396598|OTHER|Electronic Health Record Review|Ancillary studies
215133313|NCT06396598|OTHER|Internet-Based Intervention|Participate use the electronic symptom monitoring program to log symptoms
215133314|NCT06396598|OTHER|Media Intervention|Watch a video
215133315|NCT06396598|OTHER|Survey Administration|Ancillary studies
215133316|NCT01154920|DRUG|Paclitaxel|135 mg/m\^2 weekly, Weeks 1 - 6
215133317|NCT01154920|DRUG|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
215133318|NCT01154920|DRUG|Cetuximab|"PCC Arm: 400 mg/m\^2 by vein over about 1-2 hours on Day 1; 250 mg/m\^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
215133319|NCT01154920|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
215133320|NCT01154920|DRUG|Cisplatin|100 mg/m\^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
215133321|NCT01154920|DRUG|Fluorouracil|700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
215133322|NCT01154920|RADIATION|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
215133323|NCT01154920|OTHER|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m\^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
214450702|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
214450703|NCT00974415|PROCEDURE|CO2|CO2 treatment delivered to randomized flank at each study visit
214708857|NCT05549089|DEVICE|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
215133324|NCT06245941|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
215133325|NCT06245941|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
215133326|NCT05817890|DRUG|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
215133327|NCT05253209|DRUG|L-citrulline|Intravenous L-citrulline given for up to 48 hours
215133328|NCT05253209|DRUG|Plasmalyte A|Intravenous Plasmalyte A given for up to 48 hours
215133329|NCT06383858|DIAGNOSTIC_TEST|Screening method|All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
215133330|NCT06383858|DIAGNOSTIC_TEST|Screening method|In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
215133331|NCT06222866|DIAGNOSTIC_TEST|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
215133332|NCT02384551|OTHER|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
215133333|NCT01894139|OTHER|High-Protein/Low-GI Diet|
215133334|NCT01894139|OTHER|Low-protein/High-GI Diet|
215133335|NCT03679923|DIETARY_SUPPLEMENT|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
215133336|NCT03679923|DIETARY_SUPPLEMENT|Placebo|Placebo
214450704|NCT00974415|PROCEDURE|Sham|Sham treatment to other flank at each study visit
214450705|NCT03843151|DRUG|BI 1358894|Oral administration of single dose of 10 milligram (mg) BI 1358894 (2 tablets of 5 mg) with 240 milliliter (mL) of water after an high-fat, high-calorie breakfast on Day 1 of Treatment Period 1.
214450706|NCT03843151|DRUG|Itraconazole|Oral administration of 200 mg itraconazole (20 mL of 10 mg/mL solution) with 240 mL of water after an overnight fast for at least 10 h once daily for 14 days on Days -3 to 11 combined with a single dose of 10 mg BI 1358894 (2 tablets of 5 mg) on Day 1 of Treatment Period 2, 1.5 hours after administration of itraconazole.
214450707|NCT05967273|OTHER|CirrhosisRx CDS|CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
214708858|NCT05402722|DRUG|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
215133337|NCT05442749|DRUG|Niraparib|"Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB \>1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB \>1.5 ULN and up to 3ULN and/or ASAT/ALAT \> 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin \< 1.5ULN) and 2) no grade \>1 related AE are reported."
214450708|NCT01787383|DRUG|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
214450709|NCT01787383|DRUG|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
214450710|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Low - Dose 435 mg/day)|Plant protein hydrolysate
214450711|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Mid - Dose 870 mg/day)|Plant protein hydrolysate
214450712|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (High - Dose 2610 mg/day)|Plant protein hydrolysate
214450713|NCT06440213|DIETARY_SUPPLEMENT|Placebo Microcrystalline Cellulose|Placebo MCC micro-crystalline cellulose
214450714|NCT06414798|DRUG|Drug: ABBV-1088|• Oral Capsule
214450715|NCT06414798|DRUG|Drug: Placebo for ABBV-1088|• Oral Capsule
214450716|NCT06456359|DRUG|Signifor|Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
214450717|NCT03829631|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
214450718|NCT06303271|OTHER|Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Experimental group will received intervention of 30 minutes daily for 4 weeks (16 sessions). Assessment was done at the baseline, after 2 weeks and after 4 weeks. Intervention Group received non-invasive vagus nerve stimulation at left auricle (because of anatomy of vagus nerve as right VN innervate SA node which is regulating heartbeat and left VN innervates AV node which is responsible for controlling timing of heartbeat) of ear. VNS group received vagus nerve stimulation via Med Fit vagus nerve stimulator at auricle of left ear only as stimulation of right auricular branch of vagus nerve can result in bradycardia. Frequency of stimulation was kept between 15-30Hz. Intensity was gradually increased according to patient's tolerance. The participant was able to withdraw from the trial if he could not tolerate the stimulation
214450719|NCT06303271|OTHER|Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will intervention of 30 minutes daily for 4 weeks (16 sessions). Caw Thorne Cooksey exercises were carried out during the stimulation of vagus nerve. Although no adverse effects had been reported during the stimulation of left auricular branch of vagus nerve but a pulse oximeter was used during the stimulation to monitor the heart rate.
214450720|NCT05935748|DRUG|NKT2152|Oral HIF2a inhibitor
214450721|NCT05935748|DRUG|palbociclib|a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
214450722|NCT05935748|OTHER|sasanlimab|an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
214450723|NCT06513104|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
214450724|NCT06513104|DRUG|Levonorgestrel + Ethinylestradiol|Levonorgestrel + Ethinylestradiol will be administered orally.
214450725|NCT06513104|DRUG|Paracetamol|Paracetamol will be administered orally.
214450726|NCT04533347|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
214450727|NCT04533347|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
214450728|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
214450729|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
214450730|NCT05057624|OTHER|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
214450731|NCT05057624|OTHER|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
214450732|NCT05057624|OTHER|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
214450733|NCT06549530|DRUG|MVA-BN|All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
215133338|NCT04230759|DRUG|Chemotherapy|"Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
215133339|NCT04230759|RADIATION|Radiation|PTV\_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV\_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV\_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV\_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
215133340|NCT04230759|DRUG|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
215133341|NCT06211114|DRUG|PD-(L)1 inhibitor|Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks
215133342|NCT06211114|DRUG|Axitinib|axitinib 5mg orally twice daily
215133343|NCT04192565|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
215133344|NCT04742556|DRUG|BI 3011441|BI 3011441
214450734|NCT06156202|OTHER|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
214450735|NCT06156202|OTHER|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
214450736|NCT06274112|DEVICE|TMS|TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.
214525674|NCT04263558|BEHAVIORAL|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
214525675|NCT00511147|BIOLOGICAL|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
214525676|NCT01399684|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
214525677|NCT01399684|DRUG|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
214525678|NCT01399684|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
215133345|NCT02616640|DRUG|Durvalumab|
215133346|NCT02616640|DRUG|Pomalidomide|
215133347|NCT02616640|DRUG|Dexamethasone|
215133348|NCT04601818|PROCEDURE|Experimental: Preserving of Donor Lungs|lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
215133349|NCT03035032|DRUG|Leuprolide|Subcutaneous Injection
214525679|NCT01399684|DRUG|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
214525680|NCT01399684|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
214525681|NCT01399684|DRUG|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
214525682|NCT05804526|DRUG|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
214525683|NCT05804526|DRUG|Sintilimab Injection|Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
215133350|NCT06306105|DIETARY_SUPPLEMENT|Marine Collagen Peptides|consume 1 bottle per day
215133351|NCT06306105|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
215133352|NCT05757505|DEVICE|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
215133353|NCT05757505|DEVICE|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
215133354|NCT06289751|DRUG|Cadonilimab|10 mg/kg (body weight), 60 min, IV. Repeat every 3 weeks for a total of 3 cycles
215133355|NCT06289751|DRUG|Paclitaxel-albumin|260 mg/m2 for 30 min. Repeat every 3 weeks for a total of 3 cycles.
215133356|NCT06289751|DRUG|Cisplatin|75-80 mg/m2, IV, 1 mg/min. Repeat every 3 weeks for a total of 3 cycles.
215133357|NCT06289751|PROCEDURE|Extrafascial hysterectomy|Extrafascial hysterectomy + pelvic lymphadenectomy (or SLN mapping) (For participants who meet ConCerv criteria)
215133358|NCT06289751|PROCEDURE|Radical hysterectomy|Radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy (or SLN mapping) (For participants who do not meet ConCerv criteria)
215133359|NCT06289751|PROCEDURE|Cone biopsy|Cold knife conization (CKC) (For participants with tumor size ≤2 cm after 3 cycles of chemo-immunotherapy)
215133360|NCT04961710|DRUG|Hetrombopag Olamine|Hetrombopag Olamine; once daily
215133361|NCT04961710|DRUG|Placebo|Placebo; once daily
215133362|NCT03486821|RADIATION|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
215133363|NCT06356337|DEVICE|Light goggles|Blue light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks.
215133364|NCT06356337|DEVICE|Orange glasses|Orange glasses that do not provide entrainment will be worn for 1 hour each morning to block morning light for two weeks.
215133365|NCT06581705|PROCEDURE|Video Laryngoscope|Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
215133366|NCT04745910|DRUG|Pegloticase|Given IV
215133367|NCT04745910|DRUG|Rasburicase|Given IV
215133368|NCT06133244|DIAGNOSTIC_TEST|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
215133369|NCT02162550|DRUG|Bydureon|once weekly injection
215133370|NCT02162550|DRUG|placebo|once weekly injection
215133371|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
215133372|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
215133373|NCT03381521|DEVICE|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
215133374|NCT03381521|DRUG|Normal saline|The normal saline was used for injection solution
214450737|NCT06017180|OTHER|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
214450738|NCT06017180|OTHER|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
214450739|NCT06399757|DRUG|APL-5125|APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
214450740|NCT05942001|DRUG|HRS-5041|HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
214450741|NCT06837948|DRUG|PM8002|Specified dose on specified days.
214450742|NCT06837948|DRUG|Sintilimab|Specified dose on specified days.
214450743|NCT06837948|DRUG|Nab-paclitaxel|Specified dose on specified days.
214450744|NCT06837948|DRUG|Carboplatin|Specified dose on specified days.
214525684|NCT00647985|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fed
214525685|NCT00647985|DRUG|Allegra® Tablets 180 mg|180mg, single dose fed
215133375|NCT06227871|PROCEDURE|Exploratory laparotomy|Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
215133376|NCT04982731|OTHER|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
215133377|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
215133378|NCT02201524|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
215133379|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
215133380|NCT02201524|OTHER|Placebo|Subjects will receive placebo for 4 weeks
215133381|NCT05175092|PROCEDURE|Living Donor Liver Transplantation|The LDLT will be performed by the UW Division of Transplantation in accordance with the standard of care for this operation.
215133382|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
215133383|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
215133384|NCT04384809|BIOLOGICAL|Leukocyte rich platelet rich plasma|Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon
215133385|NCT04384809|DEVICE|Percutaneous Tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
215133386|NCT05635344|DRUG|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
215133387|NCT05851118|BEHAVIORAL|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
215133388|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
215133389|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
215133390|NCT04042220|DRUG|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
215133391|NCT00921271|DEVICE|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
215133392|NCT02022137|DIETARY_SUPPLEMENT|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
215133393|NCT02022137|DIETARY_SUPPLEMENT|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
215133394|NCT02022137|DIETARY_SUPPLEMENT|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
215133395|NCT00389948|DRUG|Lanzoprazole|
215133396|NCT02855203|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
215133397|NCT02855203|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
215133398|NCT05404139|DRUG|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
215133399|NCT05404139|OTHER|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
215133400|NCT05036304|OTHER|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
214450745|NCT06837948|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
214450746|NCT06509386|OTHER|Major Depressive Disorder without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
214450747|NCT06509386|OTHER|Major Depressive Disorder with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
214450748|NCT06509386|OTHER|Major Depressive Disorder without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
214450749|NCT06509386|OTHER|Major Depressive Disorder with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
214450750|NCT06509386|OTHER|Schizophrenia without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
214450751|NCT06509386|OTHER|Schizophrenia with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
214450752|NCT06509386|OTHER|Schizophrenia without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
214450753|NCT06509386|OTHER|Schizophrenia with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
214450754|NCT06837363|DEVICE|Home-based Neofect Smart board|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart board, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
214450755|NCT06837363|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
214708859|NCT05402722|DRUG|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
214708860|NCT05337904|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
214708861|NCT05337904|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
214450756|NCT06837922|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
215133401|NCT05036304|OTHER|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park)
215133402|NCT04781478|OTHER|Application of Biorepair Gel|Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
215133403|NCT04781478|OTHER|Irrigation of Chlorhexidine 1.00% gel|Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
215133404|NCT02720393|OTHER|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
215133405|NCT02720393|OTHER|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
215133406|NCT05472935|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
215133407|NCT02182622|DRUG|Docetaxel|
215133408|NCT02182622|DRUG|Prednisone|
215133409|NCT02182622|DRUG|LDE225|
215133410|NCT01261988|DEVICE|VIPER|Comparison of ostomy systems
215133411|NCT01261988|DEVICE|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
215133412|NCT05103007|PROCEDURE|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
215133413|NCT05103007|PROCEDURE|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
215133414|NCT05894460|DEVICE|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
215133415|NCT06385769|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|The TTNS will be conducted unilaterally, with the patient in a supine position, using a surface electrode dual stimulation channel stimulation device. Two self-adhesive round surface electrodes will be positioned with the negative electrode 2 cm behind the medial malleolus and the positive electrode 10 cm proximal to it. The ground electrode will be placed on the ipsilateral limb. Channel 1 will provide active stimulation, while channel 2 will remain inactive.
215133416|NCT06385769|OTHER|Sham Transcutaneous tibial nerve stimulation (TTNS)|Sham TTNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the TTNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
215133417|NCT00006088|DRUG|vinorelbine tartrate|
215133418|NCT03808116|DEVICE|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process."
215133419|NCT01493323|BEHAVIORAL|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
215133420|NCT01493323|BEHAVIORAL|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
215133421|NCT01493323|BEHAVIORAL|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
215133422|NCT01493323|PROCEDURE|Cyber ball game|functional neuroimaging
215133423|NCT01493323|PROCEDURE|Iowa Gambling Task|functional neuroimaging
215133424|NCT01493323|PROCEDURE|Microcomputer|functional neuroimaging
215133425|NCT01493323|PROCEDURE|blood sample|blood sample
214450757|NCT05147155|BIOLOGICAL|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
214450758|NCT06741475|BEHAVIORAL|Caregiver-Assist Strategy Training|CaST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing real-life limitations after stroke. During the intervention, the caregiver not only supervises the participant but also co-participates in the practice by instructing on when and how to be an assistant and facilitator when the stroke survivor executes their practice plan.
214450759|NCT06741475|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequela, and adaptive skills for impaired functions are provided.
214450760|NCT06101862|PROCEDURE|CCTA|Participants will be examined with CCTA during admission.
214450761|NCT06101862|PROCEDURE|Conventional ICA|Patients will be examined with conventional standard-of-care ICA.
214450762|NCT06101862|OTHER|Team-based interventional triage|The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
214450763|NCT06822959|OTHER|Pharmacogenetics, TDM and MedReview|Patients will undergo pharmacogenetics, TDM and MedReview analyses according to the study protocol
214450764|NCT04984291|DEVICE|Alliance Glenoid|Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
214450765|NCT04984291|DEVICE|Identity Stem|Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
214450766|NCT06836999|PROCEDURE|deep sedation|The deep sedation was inducted using atropine 0.5 mg iv administered 15 min before the procedure to avoid aspiration. In the EP lab, anesthesia preparation is performed, including invasive arterial blood pressure monitoring via puncture of the radial artery or brachial artery. Noninvasive BP monitoring every 5 minutes is also permitted. Subsequently, midazolam 1-2mg or accompanied with propofol 0.3-0.5 mg/kg is administered intravenously at the start of the CA procedure (i.e., femoral vein puncture), and fentanyl 25 µg is administered intravenously. Then, continuous titrated infusion of propofol 0.2-0.5mg/kg/h for anesthesia maintenance throughout the CA procedure. An additional iv fentanyl (25-50 µg) is administrated at the beginning of RF applications. Further boluses or additional drugs are administrated as needed to maintain analgesia during the procedure. The anesthesiologist is responsible for administering anesthesia and administering medication.
214450767|NCT06836999|PROCEDURE|Conscious sedation|This protocol is aimed at analgesia, with local infiltration of lidocaine for femoral vein puncture followed by intravenous administration of fentanyl (1-2 ug/kg/h). The operator determines the dose of fentanyl and midazolam. A midazolam 1-5 mg bolus is administrated before electrical cardioversion is performed or when the patient is nervous.
214450768|NCT05947578|DRUG|CLZ-2002|Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
214450769|NCT06031688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214450770|NCT06031688|PROCEDURE|Computed Tomography|Undergo CT scan
214450771|NCT06031688|PROCEDURE|Lymphoscintigraphy|Undergo lymphoscintigraphy scan
214450772|NCT06031688|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214450773|NCT06031688|BIOLOGICAL|Ramucirumab|Given IV
214450774|NCT06031688|DRUG|Tepotinib|Given PO
215133426|NCT02914639|DRUG|SF0166 Topical Ophthalmic Solution|
215133427|NCT01814774|OTHER|No Intervention|No treatment (intervention) was administered.
215133428|NCT04938908|DRUG|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
215133429|NCT04938908|DRUG|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
215133430|NCT04938908|DIETARY_SUPPLEMENT|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
215133431|NCT04938908|DIETARY_SUPPLEMENT|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
215133432|NCT04668469|DRUG|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
215133433|NCT04668469|DRUG|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
215133434|NCT04668469|BEHAVIORAL|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
215133435|NCT06079138|DEVICE|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
215133436|NCT06079138|DEVICE|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
214450775|NCT03737149|OTHER|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
214450776|NCT06294067|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.
214450777|NCT06294067|DIETARY_SUPPLEMENT|soybean oil placebo|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks. The 0mg group will receive only placebos.
214450778|NCT04098640|GENETIC|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
214450779|NCT04595786|DRUG|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
214450780|NCT04595786|DRUG|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
214450781|NCT04755309|BEHAVIORAL|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
214450782|NCT04755309|BEHAVIORAL|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
214450783|NCT02681328|OTHER|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
214450784|NCT02681328|OTHER|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
214450785|NCT02681328|OTHER|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
214525686|NCT05982028|PROCEDURE|Minimally invasive pit-picking surgery|Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
214708862|NCT01511432|DRUG|telaprevir formulation A|A single 1125-mg dose administered orally
214708863|NCT01511432|DRUG|telaprevir Formulation B|A single 1125-mg dose administered orally
214708864|NCT01511432|DRUG|telaprevir Formulation C|A single 1125-mg dose administered orally
214450786|NCT02681328|OTHER|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
214450787|NCT05839041|DRUG|AVD-104|Intravitreal injection
214708865|NCT01511432|DRUG|telaprevir Formulation D|A single 1125-mg dose administered orally
214708866|NCT02189590|DEVICE|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
215133437|NCT06079138|OTHER|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
215133438|NCT05472337|DRUG|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
215133439|NCT04414241|DRUG|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
215133440|NCT03284177|DRUG|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
215133441|NCT03284177|DRUG|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
215133442|NCT03284177|OTHER|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
215133443|NCT01460108|DEVICE|AeriSeal System|20 mL
215133444|NCT03690817|BEHAVIORAL|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
215133445|NCT00495768|BEHAVIORAL|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
215133446|NCT03243851|DRUG|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
215133447|NCT03243851|DRUG|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
215133448|NCT03025425|DEVICE|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
215133449|NCT04392323|DIAGNOSTIC_TEST|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
215133450|NCT01018030|DRUG|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
215133451|NCT01018030|DRUG|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
215133452|NCT01018030|DRUG|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
215133453|NCT05397717|OTHER|observational|Observational, without interfering the patient care of treating doctors
215133454|NCT00524511|DEVICE|Surgical skin staples|Standard method to close abdominal surgical wounds
215133455|NCT00524511|DEVICE|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
215133456|NCT02802306|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
215133457|NCT04277975|OTHER|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
215133458|NCT04277975|OTHER|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
215133459|NCT03617172|DRUG|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
215133460|NCT03617172|OTHER|Placebo|Two capsules twice per day
215133461|NCT04789707|BEHAVIORAL|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
215133462|NCT04205448|BEHAVIORAL|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
215133463|NCT06473727|OTHER|Omnichoroma|Patients with anterior non-carious cervical lesions were treated with Omnichoroma. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
214450788|NCT05839041|DRUG|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
215133464|NCT06473727|OTHER|Charisma Topaz One|Patients with anterior non-carious cervical lesions were treated with Charisma Topaz One. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
215133465|NCT05963334|DRUG|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
215133466|NCT00497458|DRUG|Testosterone|testosterone 40 or 80 mg once a day
215133467|NCT03826706|DEVICE|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
215133468|NCT03826706|DEVICE|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
215133469|NCT00004249|BIOLOGICAL|QS21|
215133470|NCT00004249|BIOLOGICAL|keyhole limpet hemocyanin|
215133471|NCT00004249|DRUG|polysialic acid|
215133472|NCT01089504|DRUG|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
215133473|NCT01089504|DRUG|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
215133474|NCT00068068|DRUG|Talaporfin sodium (LS11)|
215133475|NCT00068068|DEVICE|LED-based light infusion device|
215133476|NCT00068068|DEVICE|Light emitting diodes (LED)|
215133477|NCT00068068|PROCEDURE|Photodynamic therapy|
215133478|NCT00068068|PROCEDURE|Phototherapy|
215133479|NCT00068068|PROCEDURE|Chemotherapy|
215133480|NCT03351842|DRUG|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
215133481|NCT03351842|PROCEDURE|Undergo surgery|Therapeutic conventional surgery, R0 resection
215133482|NCT01924845|DRUG|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
215133483|NCT00062439|DRUG|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes
214694813|NCT01985633|BIOLOGICAL|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
214694814|NCT01985633|BIOLOGICAL|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
214694815|NCT02200471|DEVICE|VeinViewer|
214694816|NCT04877314|OTHER|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
215133484|NCT00062439|DRUG|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
215133485|NCT00062439|DRUG|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
215133486|NCT00062439|PROCEDURE|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
215133487|NCT00062439|RADIATION|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
215133488|NCT06491186|OTHER|Point of Care Ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
215133489|NCT01994252|DEVICE|Optimal Medical therapy plus ICD|
214450789|NCT06270888|RADIATION|Radiation|Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
214525687|NCT05982028|PROCEDURE|Radical surgical excision without suturing|Under the guidance of brilliant green, the cavity of the pilonidal cyst, along with the sinus tracts and fistulas, was marked. A symmetric elliptical incision was made to excise the pits and secondary fistula openings. The pilonidal cyst was removed from the healthy subcutaneous tissue and sacrococcygeal fascia using monopolar electrocautery. The wound was not sutured and was left open to heal by secondary intention. After haemostasis was achieved, the wound was covered with sterile gauze with 10 % povidone-iodine solution.
214525688|NCT01949649|BEHAVIORAL|Peer-Led Group Intervention|
215133490|NCT01994252|DEVICE|Optimal Medical therapy plus CRT/ICD|
215133491|NCT00380939|DRUG|Atorvastatin|
215133492|NCT00380939|DRUG|Pravastatin|
215133493|NCT04424537|DIETARY_SUPPLEMENT|Control diet|Meal replacement beverages made with whey protein
215133494|NCT04424537|DIETARY_SUPPLEMENT|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
215133495|NCT04424537|DIETARY_SUPPLEMENT|Low protein diet|meal replacement beverages(MRBs) containing low protein
215133496|NCT00000376|BEHAVIORAL|Cognitive therapy|
215133497|NCT00000376|DRUG|Desipramine|
215133498|NCT01889667|DRUG|ORMD-0801 Dose # 1|Oral Insulin Formulation
215133499|NCT01889667|DRUG|ORMD-0801 Dose # 2|Oral Insulin Formulation
215133500|NCT01889667|DRUG|Placebo|Oil Capsules
215133501|NCT00001832|DRUG|gp100:209-217 (210M)|"gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
215133502|NCT00001832|DRUG|Montanide ISA-51|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
215133503|NCT00001832|DRUG|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
215133504|NCT00001832|DRUG|MART-1:26-35(27L)|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
215133505|NCT00001832|BIOLOGICAL|Abl cells|Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
214525689|NCT01949649|BEHAVIORAL|Internet-Based Intervention|
214525690|NCT01949649|BEHAVIORAL|Clinician-Led Group Intervention|
215133506|NCT00001832|DRUG|Fludarabine|5x25 mg/m\^2 intravenous
215133507|NCT00001832|DRUG|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
214450790|NCT03669367|DRUG|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
215133508|NCT00001832|BIOLOGICAL|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.
215133509|NCT00001832|PROCEDURE|Apheresis|
215133510|NCT05288309|OTHER|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
215133511|NCT05288309|OTHER|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
215133512|NCT03828032|PROCEDURE|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
215133513|NCT03828032|PROCEDURE|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
215133514|NCT05856877|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
215133515|NCT05856877|OTHER|Placebo|Single dose of placebo solution as nasal spray
215133516|NCT03382132|BEHAVIORAL|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
215133517|NCT03382132|BEHAVIORAL|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
214450791|NCT03669367|DRUG|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
214450792|NCT05575128|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
215133518|NCT02199002|DEVICE|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
215133519|NCT03560297|BEHAVIORAL|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
215133520|NCT03560297|BEHAVIORAL|Delayed Intervention|Participants receive intervention after delay
215133521|NCT05335330|OTHER|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
214450793|NCT05575128|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
214450794|NCT05575128|OTHER|Care as usual|Care as usual, with written resources provided
214525691|NCT01949649|BEHAVIORAL|Education Video|
214525692|NCT03792035|DRUG|Tongxinluo|tid, po.
214525693|NCT03792035|DRUG|Placebos|tid, po.
214525694|NCT04939883|DRUG|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
214525695|NCT04939883|DRUG|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
214525696|NCT03308383|OTHER|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
214525697|NCT04448925|OTHER|inertial-load exercise (ILE)|Length of time between exercise bouts
214525698|NCT02411422|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube
215133522|NCT03909789|DIETARY_SUPPLEMENT|Plant based bioequivalent Nitrate supplementation|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
215133523|NCT03909789|DIETARY_SUPPLEMENT|Placebo|Placebo
215133524|NCT05139680|DRUG|tafamidis|80 or 61 milligrams (mg)
215133525|NCT06184529|BEHAVIORAL|Virtual Reality|The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
215133526|NCT06510660|DRUG|adebrelimab|The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
215133527|NCT05661149|DEVICE|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
215133528|NCT02344654|DRUG|Indocyanine green|
215133529|NCT02344654|DEVICE|Near-infrared illumination|To see the fluorescence from indocyanine green
215133530|NCT02344654|DRUG|Urografin|
215133531|NCT02344654|RADIATION|X-ray|
215133532|NCT04899843|DIETARY_SUPPLEMENT|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
215133533|NCT04899843|DIETARY_SUPPLEMENT|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
215133534|NCT03591718|DRUG|BI 456906|Solution for injection
215133535|NCT03591718|DRUG|Placebo|solution for injection
215133536|NCT01801566|PROCEDURE|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
215133537|NCT01546857|DRUG|Placebo|Normal Saline
215133538|NCT01546857|DRUG|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
215133539|NCT06289933|DRUG|BR3005|One tablet administered alone, Once a day
214450795|NCT04983173|DRUG|Ovarian Stimulation with CC+rFSH|: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
214450796|NCT04983173|DRUG|Ovarian Stimulation with rFSH|rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
214450797|NCT05828719|PROCEDURE|Percutaneous coronary intervention|"Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
214450798|NCT04725695|DRUG|Viscous Lidocaine|The patients will be randomized to either viscous lidocaine or placebo
215133540|NCT06289933|DRUG|BR3005-1|One tablet administered alone, Once a day
215133541|NCT06289933|DRUG|BR3005-2|One tablet administered alone, Once a day
215133542|NCT06322563|DRUG|LTC004+regorafenib|LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
215133543|NCT00154570|DEVICE|EGG, 24 hour esophageal pH monitor|
215133544|NCT04948047|DIAGNOSTIC_TEST|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
215133545|NCT04948047|DIAGNOSTIC_TEST|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
215133546|NCT04361370|DRUG|Olaparib-Pembrolizumab-Bevacizumab|"* Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
214450799|NCT04831216|BEHAVIORAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
214450800|NCT03306173|OTHER|Commercially available cigarette|Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.
214450801|NCT06848478|BEHAVIORAL|Exercise Intervention|In addition to the standard of care, participants engage in exercise coaching and a 12-week exercise program, encompassing three 60-minute supervised sessions per week.
215133547|NCT01469221|DRUG|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
215133548|NCT01469221|DRUG|Placebo|6 weekly multi-instillation of matching placebo in 40mL
214450802|NCT06848478|BEHAVIORAL|Nutritional Intervention|In addition to the standard of care, participants receive dietary coaching and engage in a 12-week daily dietary program enriched with a blend of fruits and vegetables.
214450803|NCT06849505|DEVICE|online rTMS|5 Hz rTMS is applied to the MRI-localized hotspot on the affected hemisphere when the patients are performing motor tasks
214450804|NCT06849505|DEVICE|offline rTMS|The patients perform motor tasks after 5 Hz rTMS applied to the MRI-guided hotspot on the affected hemisphere
214450805|NCT06849505|DEVICE|sham rTMS|Sham rTMS is applied to the M1 on the affected hemisphere when the patients are performing motor tasks.
214525699|NCT02411422|DEVICE|Reinforced endotracheal tube|Reinforced endotracheal tube
215133549|NCT03833323|COMBINATION_PRODUCT|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
215133550|NCT02397798|BEHAVIORAL|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
215133551|NCT02397798|BEHAVIORAL|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
215133552|NCT04749940|OTHER|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
215133553|NCT05005260|DRUG|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
215133554|NCT05005260|DRUG|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
215133555|NCT03882060|DRUG|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
215133556|NCT03882060|DRUG|Normal saline|Control group, no intervention.
215133557|NCT01561014|DRUG|erlotinib hydrochloride|Given PO
215133558|NCT01561014|DRUG|oxaliplatin|Given IV
215133559|NCT01561014|DRUG|fluorouracil|Given IV
215133560|NCT01561014|RADIATION|radiation therapy|Undergo radiotherapy
215133561|NCT01561014|PROCEDURE|conventional surgery|Undergo surgical resection
215133562|NCT01561014|OTHER|immunohistochemistry staining method|Correlative study
215133563|NCT01561014|PROCEDURE|positron emission tomography|Correlative study
214450806|NCT06844175|DRUG|Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol|The intervention group was given budigfovir once a day, the dose was 160ug/7.2ug/4.8ug by inhalation
214450807|NCT04668781|PROCEDURE|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
214450808|NCT04668781|PROCEDURE|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
214450809|NCT04206540|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Electrical stimulation of the vagus nerve around the external ear using a transcutaneous device. Electrical current will be increased in intensity based on subject feedback of a scale 0-10.~Electrical stimulation will be delivered for 2 minutes once the subject reports the maximum comfortable intensity."
214694817|NCT03589105|DRUG|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
214694818|NCT03589105|DRUG|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
215133564|NCT01561014|PROCEDURE|computed tomography|Correlative study
215133565|NCT01561014|PROCEDURE|laboratory biomarker analysis|Correlative study
215133566|NCT01561014|GENETIC|gene expression analysis|Correlative study
215133567|NCT01561014|RADIATION|fludeoxyglucose F 18|Undergo F18 PET and CT scan
215133568|NCT03164668|OTHER|menthol flavored e-cigarette|menthol flavored e-cigarette
215133569|NCT03164668|OTHER|tobacco flavored e-cigarette|tobacco flavored e-cigarette
215133570|NCT01626014|BEHAVIORAL|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
215133571|NCT01626014|BEHAVIORAL|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
215133572|NCT01122641|DRUG|Vildagliptin|Vildagliptin 50mg bid
215133573|NCT01122641|DRUG|Placebo|Matched tablets
215133574|NCT04993651|DEVICE|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
215133575|NCT04706364|BEHAVIORAL|Neuropsychological Testing|Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
215133576|NCT04706364|GENETIC|(Optional) Saliva Collection|"The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes.~Genetic testing is funded by Boston Children's Hospital."
215133577|NCT04706364|DEVICE|Sensory Testing|"Three different tests will be completed:~the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold).~Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist).~The second sensory visit will be another version of the PPI testing involving hearing and sound."
215133578|NCT04706364|DEVICE|Electroencephalogram (EEG)|A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.
215133579|NCT04706364|DEVICE|Transcranial Magnetic Stimulation|"Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex.~There will be two - four identical TMS testing visits."
215133580|NCT03919396|DEVICE|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material."
215133581|NCT06250699|PROCEDURE|Tubeless laparoscopic adrenalectomy|No drainage tube placed after laparoscopic adrenalectomy
215133582|NCT06250699|PROCEDURE|Drainage tube|Placing drainage tubes after laparoscopic adrenalectomy
215133583|NCT01575821|DIETARY_SUPPLEMENT|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
215133584|NCT01575821|DIETARY_SUPPLEMENT|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
215133585|NCT01575821|DIETARY_SUPPLEMENT|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
215133586|NCT01575821|DIETARY_SUPPLEMENT|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
215133587|NCT00790803|DRUG|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
215133588|NCT00176384|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
215133589|NCT03572920|DEVICE|Objective sleep evaluation by actigraphy|Each subject will wear a wrist activity monitor (actigraphy) to detect his/her sleep behaviour during hospitalization.
215133590|NCT03572920|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Each subject will fill twice the Pittsburgh Sleep Quality Index (PSQI), before hospitalization and after the 10th day, to evaluate his/her subjective sleep quality.
215133591|NCT03728907|DEVICE|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
215133592|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
215133593|NCT01363375|PROCEDURE|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
215133594|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
215133595|NCT00301899|BIOLOGICAL|pertuzumab|
215133596|NCT00301899|BIOLOGICAL|trastuzumab|
215133597|NCT02160080|DRUG|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
215133598|NCT04162249|OTHER|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
215133599|NCT04162249|OTHER|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
214525700|NCT03550183|BIOLOGICAL|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
215133600|NCT04162249|OTHER|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
215133601|NCT04162249|DIAGNOSTIC_TEST|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions \<72 hours after ablation.
215133602|NCT03101995|DRUG|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
215133603|NCT02004236|DEVICE|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
215133604|NCT02004236|DEVICE|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
214525701|NCT05335239|OTHER|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
214694819|NCT02991937|DRUG|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
214694820|NCT02991937|PROCEDURE|Surgical Treatment|Appendectomy
215133605|NCT02004236|DEVICE|tRNS with sham|the subjects receive 35 session with sham
215133606|NCT03011788|DRUG|Golytely Oral Solution|Bowel purge prior to,colonoscopy
215133607|NCT04578951|DEVICE|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
215133608|NCT02447965|DRUG|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
215133609|NCT02447965|DRUG|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
215133610|NCT03239834|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
215133611|NCT02707068|BEHAVIORAL|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
215133612|NCT05665439|RADIATION|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
215133613|NCT00405080|DRUG|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
215133614|NCT00405080|DRUG|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
215133615|NCT02987231|PROCEDURE|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
215133616|NCT02987231|DEVICE|ES|Local electric stimulation for 120 seconds, once a day for a week
215133617|NCT02987231|DEVICE|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
215133618|NCT05826483|DRUG|Almonertinib|Almonertinib Mesilate Tablets
215133619|NCT00435916|DRUG|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
215133620|NCT00161200|DRUG|Ranitidine & Pantoprazole|
215133621|NCT00918281|DRUG|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
215133622|NCT05683093|OTHER|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
215133623|NCT04818658|OTHER|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
215133624|NCT03178214|DRUG|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
215133625|NCT00168844|DRUG|Tiotropium Inhalation Solution|
215133626|NCT00168844|OTHER|Placebo|
215133627|NCT04992117|OTHER|NO INTERVENTION|NO INTERVENTION
215133628|NCT02735967|OTHER|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
215133629|NCT02735967|DEVICE|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
215133630|NCT00988832|BIOLOGICAL|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
215133631|NCT05208502|DEVICE|DSA monitor|Next Generation SedLine features an enhanced signal processing engine, which provides processed EEG parameters. This four channel EEG monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan
215133632|NCT05112575|RADIATION|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
215133633|NCT04672642|DEVICE|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
215133634|NCT02267239|DRUG|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
215133635|NCT02267239|DRUG|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
215133636|NCT02267239|DRUG|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
214450810|NCT04206540|PROCEDURE|Vagal Stimulation|"Subjects will be asked to do the following in order to stimulate the vagus nerve:~* Cough 6 to 8 forceful coughs~* Have an ice cold wash cloth placed on their face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor is briefly inserted into the back of the mouth touching the bag of the throat.~* Valsalva maneuver: Subjects will be asked to bear down as if having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a device that measures how hard they are blowing. Alternatively, we can have them blow through the barrel of a 10 ml syringe for 15-20 seconds.~* Eating: Subjects will be asked to drink water and/or Ensure that has 220 calories after fasting overnight."
215133637|NCT02267239|DRUG|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
215133638|NCT02267239|PROCEDURE|professional oral cleaning|scaling and polishing teeth of the volunteers
215133639|NCT02267239|PROCEDURE|Plaster cast|Taking a plaster cast of the volunteers' mouth
215133640|NCT02267239|DEVICE|IDODS|Specific intraoral device which carries six glass disks
215133641|NCT00004380|DRUG|relaxin|
215133642|NCT04828421|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
215133643|NCT04828421|DIETARY_SUPPLEMENT|Placebo|Placebo
215133644|NCT00995761|DRUG|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
215133645|NCT01468285|DRUG|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
214694821|NCT03508635|DRUG|CORT125134|Oral capsules
215133646|NCT01468285|OTHER|placebo|placebo tablets b.i.d., six weeks treatment
215133647|NCT04760847|OTHER|Intermittent Fasting|These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
214450811|NCT05018871|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
214450812|NCT06266130|DEVICE|Treatment Group Digital Bonding Tray|The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.
214450813|NCT06266130|DEVICE|Control Group Direct Bonding|The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.
214694822|NCT03508635|DRUG|Matching Placebo of CORT125134|Placebo
214450814|NCT03526874|DRUG|Lidocaine 4% Topical Application Cream [LMX 4]|Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
214694823|NCT03508635|DRUG|Mifepristone|Active comparator
215133648|NCT04760847|OTHER|No intermittent fasting|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
215133649|NCT05324293|DRUG|HMI-115|Once Every 2 weeks, subcutaneously injection
215133650|NCT05099809|OTHER|Hyperthermia|Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
215133651|NCT03796650|OTHER|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
215133652|NCT03796650|DRUG|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
215133653|NCT01820286|BEHAVIORAL|Positive psychology intervention|
215133654|NCT01820286|BEHAVIORAL|Recollection intervention|
215133655|NCT02172144|DRUG|BI 1744 CL solution for inhalation|
215133656|NCT02172144|DRUG|Placebo matching BI 1744 CL|
214694824|NCT03508635|DRUG|Prednisone|Challenge agent
214694825|NCT03508635|DRUG|Glucose|
215133657|NCT02172144|DRUG|Moxifloxacin (Avalox®)|
215133658|NCT01377584|BEHAVIORAL|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
215133659|NCT01377584|BEHAVIORAL|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
215133660|NCT01377584|DEVICE|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
215133661|NCT01377584|OTHER|No intervention|No intervention will be received.
215133662|NCT06365879|DRUG|CMAB007|300mg, SC, Q4W
215133663|NCT06365879|DRUG|Xolair|300mg, SC, Q4W
215133664|NCT00788307|BIOLOGICAL|Ad5-CMV-NIS|
215133665|NCT00788307|DRUG|liothyronine sodium|
215133666|NCT00788307|GENETIC|reverse transcriptase-polymerase chain reaction|
215133667|NCT00788307|OTHER|laboratory biomarker analysis|
215133668|NCT00788307|RADIATION|iodine I 131|
215133669|NCT00828971|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
215133670|NCT00828971|DRUG|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
215133671|NCT03917797|BIOLOGICAL|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
214450815|NCT03526874|DRUG|Lidocaine Hydrochloride 2 mg/mL Injectable Solution|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
214450816|NCT03526874|DRUG|Normal Saline|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
214450817|NCT05741489|DEVICE|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
214450818|NCT02670109|DRUG|Carmustine|300mg/m2, IV, in 3 hours, during day -4
214450819|NCT02670109|DRUG|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
214450820|NCT02670109|DRUG|Carboplatin|1400/m2, IV, in 1 hour, during day -3
214450821|NCT02670109|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
214450822|NCT02670109|DRUG|Busulfan|16mg/kg, Oral, during day -4
214450823|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
214450824|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 366 in previously dosed participants.
214450825|NCT06630845|DRUG|Fluorodeoxyglucose F18|Given IV as part of routine imaging
214450826|NCT06630845|PROCEDURE|Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)|Imaging procedure
214450827|NCT06630845|PROCEDURE|Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)|Imaging procedure done concurrently with PET/MRI
214450828|NCT06630845|DEVICE|General Electric (GE) SIGNA PET/MR|Imaging device
214450829|NCT04904094|OTHER|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
214450830|NCT04285567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
214450831|NCT04285567|DRUG|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
215133672|NCT03917797|DRUG|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
215133673|NCT03917797|DRUG|Placebo|MSC infusion vehicle
215133674|NCT02579200|DEVICE|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.
215133675|NCT02579200|DEVICE|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
215133676|NCT04729725|BIOLOGICAL|Anti-TGF-beta Monoclonal Antibody SAR-439459|Given IV
215133677|NCT04729725|BIOLOGICAL|Cemiplimab|Given IV
215133678|NCT00849940|DEVICE|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
215133679|NCT00297388|DRUG|Risperidone, long-acting injectable|
215133680|NCT02611973|OTHER|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
214450832|NCT04285567|DRUG|Fludarabine|Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
214450833|NCT04285567|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
214694826|NCT04550611|OTHER|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
215133681|NCT02611973|OTHER|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
215133682|NCT02611973|OTHER|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
215133683|NCT02611973|DRUG|Hydroxyurea treatment (HU)|HU maintenance
214450834|NCT04285567|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
214450835|NCT04285567|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
214450836|NCT06056297|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
215133684|NCT06002620|DIETARY_SUPPLEMENT|CSB+|standard care
215133685|NCT06002620|DIETARY_SUPPLEMENT|Enriched nutrition food (CEF)|enriched cricket flour at 20%
215133686|NCT06002620|BEHAVIORAL|Nutrition education|regular videos, sms reminders and face to face interaction
215133687|NCT06002620|COMBINATION_PRODUCT|Combined nutrition and education|combined enriched cricket flour and nutrition education
215133688|NCT05998122|OTHER|nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
215133689|NCT03142386|OTHER|Osteopathic manipulative treatment|
215133690|NCT03142386|OTHER|Physiotherapy|
215133691|NCT02752594|BIOLOGICAL|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
215133692|NCT02752594|OTHER|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
215133693|NCT01548547|OTHER|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
215133694|NCT04687306|DIAGNOSTIC_TEST|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
215133695|NCT00062712|DRUG|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
214450837|NCT06056297|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
214450838|NCT06538649|DRUG|Rosuvastatin|Rosuvastatin provided at 10 mg start; 5mg for Asians. Dose will be increased to 20 mg for those tolerating and without contraindication.
214450839|NCT06538649|OTHER|Placebo|Placebo tablet(s)
214450840|NCT06803888|PROCEDURE|Bariatric Surgery|Patients receive either RYGB or SG. The surgical risk, the differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
214450841|NCT06803888|DRUG|Semaglutide|"Semaglutide will be initiated at a dose of 0.25 mg once weekly and will be increased during the dose-escalation period to reach a maintenance dose of up to 2.4 mg once weekly by week 16. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Semaglutide is the FDA-approved dosing schedule.~The maintenance dose is 2.4 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 2.4 mg and may stay at the lower maintenance dose level (e.g., 1.7 mg once weekly), if needed."
215133696|NCT04896996|DIETARY_SUPPLEMENT|whole eggs|whole eggs
215133697|NCT04896996|DIETARY_SUPPLEMENT|yolk-free egg substitutes|yolk-free egg substitutes
215133698|NCT02585401|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
215133699|NCT00416208|DRUG|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
215133700|NCT03467347|DRUG|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
215133701|NCT04068701|OTHER|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
215133702|NCT02172963|BIOLOGICAL|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
215133703|NCT00706368|DEVICE|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
215133704|NCT04960449|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
215133705|NCT04261556|DEVICE|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
214450842|NCT06803888|DRUG|Tirzepatide|"Tirzepatide will be initiated at a dose of 2.5 mg once weekly and will be increased by 2.5 mg every week during the dose-escalation period to reach a maintenance dose of up to 15 mg once weekly by week 20. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Tirzepatide is the FDA-approved dosing schedule.~The maintenance dose is 15 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 15 mg and may stay at the lower maintenance dose level (e.g., 10 mg once weekly), if needed."
214450843|NCT05518682|DEVICE|Lenire bimodal stimulation device|The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
214450844|NCT05397561|OTHER|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
214450845|NCT06290635|DIAGNOSTIC_TEST|Breathlessness Assessment Tool|Participants will complete a breathlessness assessment tool (questionnaire) at three timepoints over the study duration, among other validated questionnaires.
214450846|NCT06198972|OTHER|Pelvic Pnf exercises|"Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Pelvic patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
214450847|NCT06198972|OTHER|Strength exercises|"3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down Lower extremity movements~* Hip flexion~* Hip extension~* Hip abduction~* Hip adduction~* Knee flexion~* Knee extension Resistance exercise training"
214450848|NCT06494930|OTHER|F-IMT|A core stabilization exercise protocol including functional respiratory muscle training will be applied to the F-IMT group. IMT will be provided with the red Powerbreath Plus MR exercise device. Initial training intensity will be set at 50% of the MIP value measured at the athlete's first evaluation. Every two weeks, the athlete will be re-evaluated the new MIP value will be measured, and the training intensity will be adjusted to 50% of the newly measured MIP value. After the nose clip is attached, the athlete will be asked to take the device's mouthpiece into his mouth, close his lips tightly, and take a deep, fast, and powerful breath, then exhale slowly and completely with minimal effort. While the athlete does breathing exercises with the device, he will also do core stabilization exercises. Athletes will be asked to train 30 minutes daily, five days a week, for six weeks.
214450849|NCT06494930|OTHER|Core Stabilization Exercise|Only the core stabilization exercise protocol will be applied to the control group. Athletes will be asked to train 30 minutes a day, five days a week, for six weeks.
214450850|NCT06570135|DIAGNOSTIC_TEST|Detecting Brain Activity with Functional Near Infrared Spectroscopy|Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
215133706|NCT04261556|DEVICE|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
215133707|NCT04403334|DRUG|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
215133708|NCT04403334|DRUG|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
215133709|NCT05009875|OTHER|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
215133710|NCT05009875|OTHER|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
215133711|NCT00507013|DEVICE|QuickClose device|
215133712|NCT02864589|BEHAVIORAL|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
215133713|NCT02864589|BEHAVIORAL|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
215133714|NCT03315741|DRUG|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
215133715|NCT06400017|DEVICE|microelectrode stimulation of DBS|"Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour"
215133716|NCT05167435|OTHER|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
215133717|NCT05167435|OTHER|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
215133718|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
215133719|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
215133720|NCT02552914|DEVICE|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
215133721|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
215133722|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
215133723|NCT03991845|DRUG|Vit D|Vit D supplementation was done
215133724|NCT00872235|DRUG|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
215133725|NCT01927497|PROCEDURE|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
215133726|NCT01927497|PROCEDURE|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
214450851|NCT05905640|OTHER|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
214450852|NCT06329583|DIAGNOSTIC_TEST|diaphragmatic breathing|Different positions and techniques for diaphragmatic breathing
214450853|NCT05442671|BEHAVIORAL|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
215133727|NCT04859088|DIETARY_SUPPLEMENT|Partial Enteral Nutrition|Dietary intervention (Liquid food replacement intervention)
215133728|NCT02428777|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
215133729|NCT02428777|DRUG|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
215133730|NCT02428777|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
214694827|NCT04550611|OTHER|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
215133731|NCT04871841|BIOLOGICAL|Sputnik V|Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
214450854|NCT05319860|DRUG|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
214450855|NCT05319860|DRUG|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
215133732|NCT03052790|PROCEDURE|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
215133733|NCT03052790|DEVICE|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
215133734|NCT06265181|BEHAVIORAL|Diabetes coaching|Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.
215133735|NCT03914417|DRUG|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
215133736|NCT04918706|GENETIC|Allogeneic MSC|These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
214450856|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214450857|NCT01247207|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
215133737|NCT04918706|DRUG|Placebo|The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
215133738|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
215133739|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
215133740|NCT01239849|DRUG|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100\~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130\~159 mg/dl is 20 mg, 160\~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol"
215133741|NCT03361137|DRUG|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
215133742|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
215133743|NCT03626727|DRUG|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
215133744|NCT00149968|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
215133745|NCT03201068|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement capsule
215133746|NCT03201068|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
215133747|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
214708867|NCT02189590|DEVICE|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
214450858|NCT02117752|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
214450859|NCT02117752|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
214450860|NCT02117752|DRUG|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
214450861|NCT02117752|DRUG|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
215133748|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
215133749|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
215133750|NCT03009058|BIOLOGICAL|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
215133751|NCT03009058|DRUG|Gemcitabine|Standard of Care chemotherapy
215133752|NCT03009058|DRUG|Nab-paclitaxel|Standard of Care chemotherapy
215133753|NCT03009058|DRUG|Capecitabine|Standard of Care chemotherapy
215133754|NCT03009058|DRUG|Folinic Acid|Standard of Care chemotherapy
215133755|NCT03009058|DRUG|Fluorouracil|Standard of Care chemotherapy
215133756|NCT03009058|DRUG|Irinotecan|Standard of Care chemotherapy
215133757|NCT03009058|DRUG|Oxaliplatin|Standard of Care chemotherapy
215133758|NCT03009058|BIOLOGICAL|cetuximab|Standard of Care immunotherapy
215133759|NCT03009058|BIOLOGICAL|Anti-PD1|Standard of Care immunotherapy
215133760|NCT03009058|BIOLOGICAL|Ipilimumab|Standard of Care immunotherapy
215133761|NCT03009058|DRUG|Cyclophosphamide|Standard of Care chemotherapy
215133762|NCT03401775|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
215133763|NCT02936817|DEVICE|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
215133764|NCT02936817|RADIATION|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
215133765|NCT02956694|BEHAVIORAL|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
215133766|NCT04990258|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.
215133767|NCT05656534|DRUG|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
215133768|NCT05656534|OTHER|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
215133769|NCT02103309|DEVICE|Nelfilcon A contact lenses|
215133770|NCT02103309|DEVICE|Etafilcon A contact lenses|
215133771|NCT02798393|OTHER|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
215133772|NCT02798393|OTHER|Sham|
215133773|NCT01805011|OTHER|minimum 4 months of breastfeeding|
215133774|NCT04818619|DIAGNOSTIC_TEST|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
215133775|NCT03479229|DEVICE|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm\^2
215133776|NCT03479229|DEVICE|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
215133777|NCT03469063|DIETARY_SUPPLEMENT|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
215133778|NCT00821808|DEVICE|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
215133779|NCT00821808|DEVICE|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
215133780|NCT02490449|DRUG|Dexlansoprazole MR|Administration of drug after or before diet
215133781|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
214450862|NCT05841979|BEHAVIORAL|Moodlifters|Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta \& Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.
214450863|NCT05841979|BEHAVIORAL|Physical Activity|Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan \& Karlamangla, 2014; Strasser \& Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).
214450864|NCT05841979|BEHAVIORAL|Nature Experiences|Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.
215133782|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
215133783|NCT00426920|DRUG|Insulin|
215133784|NCT01486966|DRUG|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
215133785|NCT01486966|DRUG|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
215133786|NCT01486966|DRUG|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
215133787|NCT01486966|DRUG|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
215133788|NCT01486966|DRUG|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
215133789|NCT05737914|PROCEDURE|Endoscopic thoracic T3 sympathectomy|Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
215133790|NCT05737914|PROCEDURE|ThoracicT3 radiofrequency ablation|radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
215133791|NCT04983277|OTHER|no intervention|no intervention
215133792|NCT04131023|BEHAVIORAL|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
215133793|NCT01832077|DEVICE|90 D|rural doctors exam eye fundus by 90 D
215133794|NCT01832077|DEVICE|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
215133795|NCT04061122|DIAGNOSTIC_TEST|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
215133796|NCT04350632|DIAGNOSTIC_TEST|Shear wave elastography assessment of the external anal sphincter|"Assessment of the external anal sphincter viscoelastic properties using shear wave elastography technology~* Women in lithotomy position with an empty bladder~* The linear probe is applied on transversal plane on the perineal with a transperineal approach~* The external anal sphincter will be identified in 2D ultrasound using a SL 18-5 linear probe~* Viscoelastic properties of the muscle will be assessed by measuring the shear modulus at rest, Valsalva maneuver and contraction~* Exactly the same investigations will be performed for the two visits planned in the protocol. In the first visit, it will be one single observer and for the second it will be 2 observers.~* Data about the mode of delivery and the occurrence of OASI will be collected into women's medical fil"
215133797|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
215133798|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
215133799|NCT05144373|BEHAVIORAL|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
215133800|NCT06522906|BEHAVIORAL|Muscle Strengthening|Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
215133801|NCT06522906|BEHAVIORAL|General Physical Activity|The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
215133802|NCT06522906|BEHAVIORAL|Education|Administered by a promotora, treatment will include 4 live video educational sessions about OA
214450865|NCT05422014|BEHAVIORAL|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group."
215133803|NCT06219525|DIETARY_SUPPLEMENT|Higher dose of enteral zinc|Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
215133804|NCT06219525|DIETARY_SUPPLEMENT|Standard dose of enteral zinc|Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
215133805|NCT01691794|DRUG|Atazanavir|
215133806|NCT01691794|DRUG|Ritonavir|
215133807|NCT03201588|DIETARY_SUPPLEMENT|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
215133808|NCT04965324|OTHER|Anaesthesia Depth|
215133809|NCT01606072|DRUG|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
214450866|NCT03972657|DRUG|REGN5678|Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration
214450867|NCT03972657|DRUG|Cemiplimab|Administered at the assigned DL by IV
214450868|NCT06221488|DIAGNOSTIC_TEST|TB infection testing|Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
214450869|NCT05981794|DEVICE|Electrical heating pad|A powered heating pad
214450870|NCT05981794|DEVICE|Sham heating pad|A heating pad that is not powered on
214450871|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
214450872|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
214450873|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
214694828|NCT02582021|PROCEDURE|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
215133810|NCT04972786|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
214450874|NCT05736679|DEVICE|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
215133811|NCT01799096|DIETARY_SUPPLEMENT|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
215133812|NCT01799096|DIETARY_SUPPLEMENT|Aspartame|Intensely sweetened soft drink (no energy content)
215133813|NCT00628017|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
215133814|NCT02559102|DRUG|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
215133815|NCT02559102|DRUG|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
215133816|NCT02559102|PROCEDURE|Caudal anaesthesia|single shot caudal anaesthesia
215133817|NCT02559102|PROCEDURE|Inguinal hernia surgery|Infant inguinal hernia repair.
214525702|NCT04614285|PROCEDURE|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
215133818|NCT00844844|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
215133819|NCT04604535|DIETARY_SUPPLEMENT|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
215133820|NCT04604535|DIETARY_SUPPLEMENT|Placebo|70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
215133821|NCT04666285|OTHER|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
215133822|NCT02512549|OTHER|Pulmonary Rehabilitation|
215133823|NCT00532662|DRUG|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
215133824|NCT04778735|PROCEDURE|Liver Transplantation|Liver Transplantation is performed under spesific conditions to increase the life time of patients with liver diseases.
215133825|NCT02893319|BEHAVIORAL|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
215133826|NCT01943344|DEVICE|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
215133827|NCT05903508|OTHER|Functional task training and functional therapy program|Functional task training group this will receive walking and no walking activities
215133828|NCT05903508|OTHER|Functional therapy program Group|Functional therapy program Group this will receive goal directed training
215133829|NCT04809831|OTHER|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
215133830|NCT04809831|OTHER|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
215133831|NCT05998018|DEVICE|pdSTIM System Therapy|Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
214525703|NCT02584075|DRUG|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
214525704|NCT02584075|DRUG|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
214525705|NCT02449837|OTHER|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
214694829|NCT02582021|PROCEDURE|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
214708868|NCT00859989|BEHAVIORAL|behavioral dietary intervention|
215133832|NCT03676842|COMBINATION_PRODUCT|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
215133833|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
215133834|NCT02891447|DRUG|Cisplatin|Given intraperitoneally
215133835|NCT02891447|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
215133836|NCT02891447|DRUG|Mitomycin|Given intraperitoneally
215133837|NCT01071057|DRUG|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
215133838|NCT01071057|DRUG|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
215133839|NCT05638165|DRUG|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
215133840|NCT03081026|DIAGNOSTIC_TEST|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
215133841|NCT03844555|DRUG|Elafibranor|120mg oral single dose
215133842|NCT01591707|BEHAVIORAL|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
214450875|NCT03752671|DEVICE|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
215133843|NCT06651749|DRUG|Propofol injection|hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
215133844|NCT06604221|BEHAVIORAL|Resistance exercise intervention|The exercise prescription, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.
215133845|NCT06604221|BEHAVIORAL|Routine care|"1.Pre-dialysis Assessment:~1. Vital Signs: Monitor blood pressure, heart rate, temperature.~2. Access Care: Check the vascular access site for signs of infection and patency. 2.During Dialysis:~（1）Monitoring: Continuous vital signs and machine settings monitoring. （2）Fluid Management: Control fluid removal based on pre-dialysis weight. 3.Post-dialysis Care:~1. Observation: Monitor for complications like hypotension, cramps, or bleeding.~2. Weight Check: Weigh post-dialysis to verify fluid removal. 4.Education and Support:~（1）Diet: Educate on dietary restrictions (potassium, phosphorus, fluids). （2）Medications: Advise on medication adjustments. 5.Psychosocial Support:~（1）Provide emotional support and counseling."
215133846|NCT00952991|DRUG|LAF237 = vildagliptin|
215133847|NCT03968679|RADIATION|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
215133848|NCT04498715|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
215133849|NCT04498715|DRUG|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
215133850|NCT04498715|DEVICE|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
215133851|NCT03755921|OTHER|bried and intensive therapy|Speech Therapy Exercises
215133852|NCT05136586|OTHER|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
215133853|NCT05136586|OTHER|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
215133854|NCT05136586|OTHER|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
215133855|NCT05136586|OTHER|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
215133856|NCT05472090|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
214694830|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
215133857|NCT05472090|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
215133858|NCT04227470|DRUG|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
215133859|NCT05968716|OTHER|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
215133860|NCT03495661|PROCEDURE|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
215133861|NCT03827434|DEVICE|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
215133862|NCT03827434|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
215133863|NCT06699823|OTHER|Greek version of QoR-15|Greek version of QoR-15
215133864|NCT06705101|DRUG|Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin|In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.
215133865|NCT06705101|OTHER|Placebo Oral Tablet|The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.
215133866|NCT06706089|OTHER|Nurse-led educational intervention|"This nurse-led educational intervention included: a) an oral training session regarding glaucoma by the P.I. lasting 15 minutes, b) provision of printed informational material (leaflet) and c) provision of appropriately selected free informational videos from the World Glaucoma Association on the YouTube -online platform. All of the above mentioned educational methods focused on the disease, its treatment and its long-term management. The oral training session took place in an appropriate, quiet and clean area, respecting the patient's privacy. During this process, study participants had the opportunity and time to ask questions and ask for clarifications or additional information."
215133867|NCT06784154|OTHER|Non-interventional|Non-interventional
215133868|NCT06887595|PROCEDURE|Free-hand linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting
215133869|NCT06887595|PROCEDURE|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided crestal ridge splitting expansion after linear micro perforation osteotomy will be performed using electromagnetic mallet
215133870|NCT05324358|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
215133871|NCT05324358|DRUG|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
215133872|NCT05324358|OTHER|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
214694831|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
214694832|NCT02582021|PROCEDURE|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
215133873|NCT05324358|OTHER|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
215133874|NCT03402737|RADIATION|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy (day 1-4)~* 3x 6-8Gy (day 1-4-7)~* 3x 6-10Gy (day 1-4-7)~* 3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
215133875|NCT05038475|DIAGNOSTIC_TEST|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
215133876|NCT04079361|DIAGNOSTIC_TEST|Blood samples|Bood samples during prenatal and postnatal visits
215133877|NCT06935136|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
215133878|NCT03641937|DEVICE|INVSENSOR00011|INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
215133879|NCT01350999|DRUG|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
215133880|NCT01350999|DRUG|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
215133881|NCT01594619|DRUG|Naloxegol|Oral 25mg tablet
215133882|NCT01594619|DRUG|Diltiazem XR|Oral 240mg tablet
215133883|NCT03593044|DRUG|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
215133884|NCT00263094|DRUG|Rofecoxib|
215133885|NCT02363920|DEVICE|HOF|the addition of high oxygen flow to patients breathing spontaneously
215133886|NCT02363920|DEVICE|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
215133887|NCT01929421|DRUG|Gemcitabine/S-1|
215133888|NCT04450238|BEHAVIORAL|Routine care inpatient treatment|All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
215133889|NCT04230889|OTHER|Usual Diet Group|three main meals and two snacks
215133890|NCT04230889|OTHER|Group 1 Nutritional Shake|2 servings per day
215133891|NCT04230889|OTHER|Group 2 Nutritional Shake|2 servings per day
214708869|NCT00859989|BEHAVIORAL|exercise intervention|
214708870|NCT00859989|BEHAVIORAL|telephone-based intervention|
214708871|NCT00859989|OTHER|counseling intervention|
215133892|NCT00281463|DEVICE|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
215133893|NCT02632799|DEVICE|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
215133894|NCT02632799|DEVICE|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
215133895|NCT02632799|DEVICE|CPAP|Nsal CPAP 5cm H2o by face mask
215133896|NCT02356276|PROCEDURE|D2 lymphadenectomy|
215133897|NCT02356276|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.
215133898|NCT02356276|DRUG|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
215133899|NCT02249663|DRUG|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
215133900|NCT02249663|DRUG|Dymista™|137/50 mcg Nasal Spray
215133901|NCT02249663|OTHER|Placebo|Nasal spray with no pharmaceutically active content
215133902|NCT03693703|DIAGNOSTIC_TEST|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
215133903|NCT03693703|DIAGNOSTIC_TEST|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
214450876|NCT03752671|PROCEDURE|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
214450877|NCT05180162|DRUG|68Ga-FAP-2286|A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
214525706|NCT02423252|BEHAVIORAL|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
215133904|NCT01557153|DRUG|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
215133905|NCT01557153|DRUG|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
214450878|NCT05180162|PROCEDURE|Positron Emission Tomography (PET)|Imaging will begin 50-100 minutes after injection and last about 45 minutes.
214450879|NCT06847035|DIETARY_SUPPLEMENT|Active Comparator|LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide)，once daily for 12 weeks
214450880|NCT06847035|DIETARY_SUPPLEMENT|Placebo Comparator|placebo solid beverage (Maltodextrin with edible flavor)，once daily for 12 weeks
214708872|NCT00859989|OTHER|educational intervention|
214708873|NCT00859989|OTHER|immunoenzyme technique|
214708874|NCT00859989|OTHER|laboratory biomarker analysis|
215133906|NCT00991861|DRUG|LAS41007 o.d.|Once daily, topical application
215133907|NCT00991861|DRUG|LAS41007 b.i.d.|Twice daily, topical application
214450881|NCT05674617|BEHAVIORAL|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
215133908|NCT00991861|DRUG|LAS106521|Twice daily, topical application
215133909|NCT00431990|DRUG|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
215133910|NCT00431990|DRUG|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
215133911|NCT00431990|DRUG|dexamethasone|20mg for 2 days with each dose of bortezomib
215133912|NCT02891174|DRUG|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
215133913|NCT02891174|DRUG|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
215133914|NCT04124939|DRUG|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
215133915|NCT05719103|BEHAVIORAL|With and Without Awake Prone Positioning|"1. HFNC flow at 60 L/min or maximum tolerable flow at supine position~2. HFNC flow at 60 L/min or maximum tolerable flow at prone position~3. CPAP with full face mask at 10 cmH2O at supine position~4. CPAP with full face mask at 10 cmH2O at prone position~5. MC at supine position~6. MC at prone position"
215133916|NCT04235140|DRUG|LUM/IVA|LUM/IVA granules for oral administration
214450882|NCT05674617|BEHAVIORAL|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
214450883|NCT06794931|OTHER|Nutrition|The patient will be instructed to follow the modified Mediterranean diet or his usual diet based on the assigned treatment group.
214450884|NCT06794931|OTHER|Biological samples collection|Additional biological samples will also be collected.
215133917|NCT00945958|DRUG|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
215133918|NCT01192997|BIOLOGICAL|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
215133919|NCT01192997|BIOLOGICAL|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
215133920|NCT04052490|OTHER|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
215133921|NCT05045768|DRUG|(Gelsectan, Devintec Sagl)|Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
215133922|NCT04101071|OTHER|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
215133923|NCT04101071|OTHER|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
215133924|NCT02177695|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
215133925|NCT02177695|DRUG|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
215133926|NCT02177695|DRUG|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
215133927|NCT02177695|DRUG|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
215133928|NCT02177695|DRUG|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
215133929|NCT02177695|DRUG|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
214450885|NCT05009394|PROCEDURE|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
214450886|NCT05009394|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
214450887|NCT05009394|PROCEDURE|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
214708875|NCT00859989|OTHER|questionnaire administration|
215133930|NCT04445961|DIAGNOSTIC_TEST|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
215133931|NCT04445961|DIAGNOSTIC_TEST|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
215133932|NCT00419393|DRUG|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
215133933|NCT02986217|OTHER|regular structured assessment of surgical performance|
215133934|NCT00979901|DRUG|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
215133935|NCT00979901|DRUG|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
215133936|NCT00979901|DRUG|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
214450888|NCT06464445|DEVICE|Monophasic iTBS|"iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
214450889|NCT06464445|DEVICE|Biphasic iTBS|"iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
214450890|NCT06464445|DEVICE|Monophasic-Long iTBS|"iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
215133937|NCT00979901|DRUG|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
215133938|NCT01106599|DRUG|GDC-0623|Repeating oral dose
215133939|NCT00206635|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
215133940|NCT01640002|DRUG|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
214450891|NCT06847932|OTHER|AF-predict AI-ECG alert system guided management|AF-predict AI-ECG alert system
214525707|NCT02423252|OTHER|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
214525708|NCT03009877|DEVICE|Optiflow F&P 850™ System|"Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
214525709|NCT03009877|DEVICE|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
214694833|NCT02582021|PROCEDURE|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
215133941|NCT01640002|DRUG|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
215133942|NCT01718288|DRUG|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
215133943|NCT01718288|DRUG|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
215133944|NCT01672385|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
215133945|NCT00681044|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
214708876|NCT00859989|OTHER|study of socioeconomic and demographic variables|
215133946|NCT00681044|DRUG|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
215133947|NCT00681044|PROCEDURE|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
215133948|NCT06186323|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
215133949|NCT06186323|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
214450892|NCT03057938|DRUG|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
214450893|NCT06324396|DRUG|Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)|A single oral dose of sildenafil will be administered to all study subjects.
214450894|NCT06324396|DRUG|Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)|A single oral dose of pravastatin will be administered to all study subjects.
214450895|NCT03238794|PROCEDURE|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
214525710|NCT03009877|DRUG|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
215133950|NCT06186323|BEHAVIORAL|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
215133951|NCT03888443|DEVICE|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
215133952|NCT03010696|OTHER|No interventions, questionnaire, collect specimen|
215133953|NCT02962700|DEVICE|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
215133954|NCT04236817|BEHAVIORAL|Pre-packed blisters for distribution of medications|
215133955|NCT04236817|BEHAVIORAL|Routine distribution of medications|
215133956|NCT01870206|BIOLOGICAL|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
215133957|NCT01870206|BIOLOGICAL|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
215133958|NCT01190397|DEVICE|Warming goggles|
215133959|NCT01190397|DEVICE|warm and moist compresses|
215133960|NCT02698696|OTHER|ECo program|
215133961|NCT02698696|OTHER|CRT program|
215133962|NCT02698696|OTHER|Supportive psychotherapy|
215133963|NCT01317472|DRUG|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
215133964|NCT01317472|DRUG|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
215133965|NCT02546271|BEHAVIORAL|GPS|
215133966|NCT03078114|OTHER|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
215133967|NCT03078114|OTHER|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
215133968|NCT00628368|GENETIC|gene expression analysis|
215133969|NCT00628368|GENETIC|mutation analysis|
214450896|NCT03238794|OTHER|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
214525711|NCT03009877|DRUG|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
215133970|NCT00628368|GENETIC|polymorphism analysis|
215133971|NCT00628368|OTHER|laboratory biomarker analysis|
215133972|NCT00628368|PROCEDURE|biopsy|
215133973|NCT00628368|PROCEDURE|endoscopic biopsy|
215133974|NCT04340895|OTHER|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
215133975|NCT04340895|OTHER|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
215133976|NCT03985930|DEVICE|Distraction with virtual reality|Distraction content delivered through virtual reality goggles
215133977|NCT03985930|OTHER|Treatment as Usual|Treatment as Usual
215133978|NCT00494182|DRUG|Carboplatin|Given IV
215133979|NCT00494182|DRUG|Paclitaxel|Given IV
214525712|NCT03009877|DRUG|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
215133980|NCT00494182|DRUG|Sorafenib|Given PO
215133981|NCT04096430|BEHAVIORAL|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
215133982|NCT01958372|DIETARY_SUPPLEMENT|soy isoflavones|Given PO
215133983|NCT01958372|DRUG|cisplatin|Given IV
215133984|NCT01958372|DRUG|etoposide|Given IV
215133985|NCT01958372|DRUG|pemetrexed disodium|Given IV
215133986|NCT01958372|RADIATION|radiation therapy|Undergo RT
215133987|NCT03583099|OTHER|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
215133988|NCT03583099|OTHER|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
215133989|NCT06353997|DRUG|Pembrolizumab|Drug will be delivered per standard-of-care as established by trial Keynote-522.
215133990|NCT06353997|DRUG|INBRX-106|INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
215133991|NCT01782027|DRUG|3H-cholesterol bound to albumin|up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
215133992|NCT02050061|OTHER|compression stocking|study the impact of compression stocking
215133993|NCT01489540|DEVICE|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
215133994|NCT02182895|DRUG|Saxagliptin|2.5-5 mg daily
215133995|NCT00006359|DRUG|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
215133996|NCT00006359|DRUG|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
215133997|NCT00006359|RADIATION|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
215133998|NCT00006359|RADIATION|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
215133999|NCT05830812|DIAGNOSTIC_TEST|Invasiveness diagnosis|To predict the invasiveness of patients with small-sized lung adenocarcinoma intraoperatively based on multi-modal information.
215134000|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
215134001|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
215134002|NCT06272799|DRUG|T-DM1 adjuvant|Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
215134003|NCT06572865|OTHER|Screening for depression and anxiety|Parents respond to questionnaires assessing depression and anxiety.
214450897|NCT06367283|DRUG|Metformin|Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
215134004|NCT04592874|DRUG|AL002|Administered via intravenous (IV) infusion
215134005|NCT04592874|DRUG|Placebo|Administered via intravenous (IV) infusion
215134006|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
215134007|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
215134008|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
215134009|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
215134010|NCT04066283|OTHER|No intervention|There was no intervention in this study
215134011|NCT05361395|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
215134012|NCT05361395|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
215134013|NCT05361395|DRUG|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
215134014|NCT05361395|DRUG|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
215134015|NCT05361395|DRUG|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
215134016|NCT04088877|BEHAVIORAL|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
215134017|NCT04088877|BEHAVIORAL|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
215134018|NCT04297904|BEHAVIORAL|Sedentary behaviour|To assess sedentary behaviour each participant will wear an activity monitor (PAL Technologies, Scotland). The resident will wear the monitor on their right thigh for 24 hours per day over seven days continuously.
215134019|NCT04297904|DIAGNOSTIC_TEST|Urinary Incontinence|The presence of IU, assessed by the Minimum Data Set (MDS) version 3.0, and used together with the International Consultation on Incontinence Questionnaire-Short Form to characterize the incontinence.
215134020|NCT04935034|DIETARY_SUPPLEMENT|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
214450898|NCT06367283|DRUG|Placebo|Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
214525713|NCT03009877|DRUG|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
214694834|NCT02582021|PROCEDURE|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
215134021|NCT06579768|DIAGNOSTIC_TEST|different types of computed tomography (CT) scans|For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
215134022|NCT05164120|DRUG|Belnacasan|Oral administration
215134023|NCT05164120|DRUG|Placebo|Tablet containing 0mg of API
215134024|NCT05682625|OTHER|No intervention|No intervention
215134025|NCT03803293|DIAGNOSTIC_TEST|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
215134026|NCT04853173|OTHER|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
215134027|NCT02439853|BEHAVIORAL|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
215134028|NCT04435704|DRUG|Oxytocin|Intravenous Oxytocin
214450899|NCT04675476|BEHAVIORAL|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
214450900|NCT05428618|OTHER|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
215134029|NCT03631940|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
215134030|NCT03631940|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
215134031|NCT03789669|DEVICE|IntraLase iFS femtosecond laser and patient interface|Commercial ophthalmic laser surgical system
215134032|NCT03789669|DEVICE|Cheetah femtosecond laser and cheetah patient interface|Ophthalmic laser surgical system
215134033|NCT04206124|PROCEDURE|Brown Fat Harvest During Anterior Neck Surgery|During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
215134034|NCT06566989|DRUG|[¹⁴C]Opevesostat|Oral solution
215134035|NCT06566989|DRUG|Prednisone|Tablet
215134036|NCT06566989|DRUG|Fludrocortisone|Tablet
215134037|NCT05381948|DRUG|Eyp-1901|Intravitreal Injection
215134038|NCT05381948|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
215134039|NCT04080635|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
215134040|NCT04080635|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
215134041|NCT06123325|PROCEDURE|Clipping|Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
215134042|NCT06123325|PROCEDURE|Endovascular embolization|Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
214450901|NCT05428618|OTHER|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
214525714|NCT03009877|DEVICE|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
214525715|NCT01956071|DEVICE|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
214525716|NCT03326050|DRUG|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
214525717|NCT03326050|DRUG|Ciprofloxacin|cipro 750 tablet twice daily
215134043|NCT06123325|DIAGNOSTIC_TEST|Surveillance imaging|Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
215134044|NCT03122041|DRUG|Sitagliptin|
215134045|NCT03122041|BEHAVIORAL|Lifestyle intervention|
215134046|NCT00836589|DEVICE|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
215134047|NCT00115570|DRUG|Insulin glulisine|Subcutaneous injection
215134048|NCT00115570|DRUG|insulin lispro|Subcutaneous injection
215134049|NCT00115570|DRUG|insulin glargine|Subcutaneous injection once daily
215134050|NCT00115570|DRUG|NPH insulin|subcutaneous injection twice daily
215134051|NCT01105819|PROCEDURE|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
214525718|NCT03326050|DRUG|Rifampicin|Rifampicin 150Mg Capsule twice daily
214525719|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
215134052|NCT01105819|PROCEDURE|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
215134053|NCT02259673|OTHER|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
215134054|NCT02259673|OTHER|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
215134055|NCT00447720|BEHAVIORAL|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
215134056|NCT03326596|DRUG|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
215134057|NCT00003461|PROCEDURE|surgical procedure|
215134058|NCT00003461|RADIATION|astatine At 211 monoclonal antibody 81C6|
215134059|NCT04453865|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
215134060|NCT04453865|OTHER|Online Resources and Referrals|Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
214450902|NCT06846164|OTHER|Supervised progressive strength training including elements of neuromuscular exercise intervention (SNG)|Participants will be randomized to SNG and will perform training sessions (60-70 minutes) twice weekly, over a duration of 12 weeks, commencing 8 exercises for the lower extremities in 3 sets of 10 repetitions with an intensity of 12 repetitions maximum. Individual progression, quality of exercise, number of sets, repetitions, and additional training weights will be monitored
215134061|NCT04637386|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
215134062|NCT04637386|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
215134063|NCT01949935|DRUG|Mupirocin|
215134064|NCT03078322|DRUG|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
215134065|NCT03078322|DRUG|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
215134066|NCT02457390|PROCEDURE|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
215134067|NCT01598935|OTHER|nutrition|protein-based food
215134068|NCT05730296|DEVICE|TMS|10 rTMS sessions combined with cognitive training
214450903|NCT06846164|OTHER|home based low-intensity weight-bearing exercise protocol.|Participants allocated to CON will receive written and verbal instructions regarding 4 home-based (low intensity), weight-bearing exercises for the lower extremities, to be performed twice weekly. This intervention is designed to resemble usual care in cases where persistent knee muscle strength deficits would be discovered and considered a clinical issue.
214450904|NCT04747912|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
214450905|NCT04747912|DRUG|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
214450906|NCT04747912|DRUG|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
214450907|NCT04747912|DRUG|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
215134069|NCT05730296|DEVICE|TMS|10 rTMS sessions
215134070|NCT05730296|DEVICE|TMS|10 sham coils sessions without cognitive training
215134071|NCT02763059|DRUG|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
215134072|NCT02763059|DRUG|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
215134073|NCT02763059|DRUG|Placebo|This group receives 1 hour before surgery placebo.
214450908|NCT04747912|DRUG|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
214450909|NCT04747912|DRUG|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
214450910|NCT04747912|DRUG|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
214708877|NCT00859989|PROCEDURE|evaluation of cancer risk factors|
215134074|NCT02763059|DRUG|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
215134075|NCT00120926|DRUG|Parenteral Nutrition|
215134076|NCT02529917|DIETARY_SUPPLEMENT|Hemp powder|Hemp powder supplement
215134077|NCT02529917|DIETARY_SUPPLEMENT|Soy Powder|Soy powder supplement
215134078|NCT00497029|DRUG|fluoride varnish|
215134079|NCT00497029|BEHAVIORAL|patient education|
215134080|NCT02004730|DEVICE|ABSORB implantation|ABSORB implantation for long (\> 24mm) single vessel disease
215134081|NCT00860808|DRUG|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
214525720|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
214525721|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
214525722|NCT02571283|DRUG|Cocktail|Administered as a single dose injection.
214525723|NCT02571283|DRUG|Exparel|Administered 20 minutes+ before additional medications.
215134082|NCT00628121|DRUG|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
215134083|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
215134084|NCT00746681|DRUG|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
215134085|NCT00746681|DRUG|Placebo|Placebo, Oral, twice daily for 4 weeks
215134086|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
214525724|NCT02571283|DRUG|Marcaine|Administered 20 minutes or more after Exparel is administered.
214525725|NCT02150083|PROCEDURE|OR retrograde fill|
214708878|NCT00859989|PROCEDURE|support group therapy|
214708879|NCT00126581|DRUG|Carboplatin|Given IV
215134087|NCT00746681|DRUG|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
215134088|NCT04935385|OTHER|Collecting blood specimens|Blood samples will be collected from all study participants at different required timelines
215134089|NCT00013572|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
215134090|NCT06406712|OTHER|retroclavicular block|regional anesthesia
215134091|NCT04294121|OTHER|Food marketing on product packaging|Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
215134092|NCT01962935|DRUG|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
215134093|NCT01962935|DRUG|Placebo|Part A - multiple ascending dose daily
215134094|NCT01962935|DRUG|AZD5069|Part B - one dose decided after part A, twice a day
215134095|NCT06366607|OTHER|high-alert medication administration|high-alert medication administration
215134096|NCT03213340|OTHER|Catechin Cohort 1|\- 4 capsules taken with water 1 hour prior to meal
215134097|NCT03213340|OTHER|Curcuminoid Cohort 2|\- 2 capsules taken with water 1 hour prior to meal
215134098|NCT03213340|OTHER|Flavonoid Cohort 3|\- \~ 1 oz. serving consumed 30 minutes before meal
215134099|NCT02571023|PROCEDURE|microscope surgery|
215134100|NCT02571023|PROCEDURE|neuroendoscope surgery|
215134101|NCT03701776|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
215134102|NCT03701776|BEHAVIORAL|Balance Training|Standard of care
215134103|NCT06459375|OTHER|modified otago exercises|patients will receive modified Otago exercises with conventional treatment.
215134104|NCT06459375|OTHER|Action Observation Training|Patients will receive Action Observation Training with conventional treatment.
215134105|NCT02275702|DRUG|Dexamethasone IV|It will be administered at the induction of the anesthesia
215134106|NCT02275702|DRUG|Saline solution|
215134107|NCT01526499|DRUG|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
215134108|NCT01526499|DRUG|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
215134109|NCT00242931|OTHER|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
215134110|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
215134111|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
215134112|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
215134113|NCT00442169|BIOLOGICAL|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
215134114|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
215134115|NCT00442169|BIOLOGICAL|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
215134116|NCT05874674|DRUG|Nafamostat Mesylate|Comparison effect of nafamostat and cnoxan
215134117|NCT03217344|PROCEDURE|conservative treatment|immobilization on sling of the injured arm
215134118|NCT04731701|DIAGNOSTIC_TEST|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
215134119|NCT02595983|DRUG|Revusiran|500mg Revusiran by subcutaneous (sc) injection
215134120|NCT01890343|DRUG|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
215134121|NCT01890343|DRUG|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
215134122|NCT05749341|DIAGNOSTIC_TEST|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
215134123|NCT01149850|BIOLOGICAL|bevacizumab|Given IV
215134124|NCT01149850|DRUG|temozolomide|Given orally
215134125|NCT01149850|OTHER|laboratory biomarker analysis|Correlative studies
214450911|NCT04747912|PROCEDURE|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
214450912|NCT06844084|OTHER|Gardening Activity|In the project, gardening activities will be applied to the participants in the experimental group in the nursing home and greenhouse for 16 weeks (4 months), once a week for 60 minutes. During the implementation phase of horticulture activities, information meetings will be held in the meeting room of the nursing home in one group. In addition, 20 minutes break will be given during the activity in terms of the tolerance of the elderly to gardening activities.
214525726|NCT03461211|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
214525727|NCT01470664|DRUG|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
214525728|NCT01470664|DRUG|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
214525729|NCT01470664|DRUG|FST-100 Vehicle|FST-100 Vehicle
215134126|NCT01149850|OTHER|immunohistochemistry staining method|Correlative studies
215134127|NCT01149850|GENETIC|microarray analysis|Correlative studies
214708880|NCT00126581|DRUG|Erlotinib|Given PO
214708881|NCT00126581|DRUG|Erlotinib Hydrochloride|Given PO
215134128|NCT01149850|GENETIC|DNA methylation analysis|Correlative studies
215134129|NCT04982562|OTHER|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
215134130|NCT03047941|DIAGNOSTIC_TEST|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
215134131|NCT03596216|OTHER|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
215134132|NCT03596216|OTHER|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
215134133|NCT01626326|BEHAVIORAL|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
215134134|NCT05856500|DIETARY_SUPPLEMENT|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
215134135|NCT05856500|DIETARY_SUPPLEMENT|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
215134136|NCT02918370|DRUG|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
215134137|NCT02918370|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
215134138|NCT05817903|DRUG|Axitinib|Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
215134139|NCT05817903|DRUG|Nivolumab|Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
215134140|NCT03550118|DEVICE|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
215134141|NCT02456012|DRUG|oral esomeprazole 20 mg twice daily|for 36 weeks
215134142|NCT02456012|DRUG|oral esomeprazole 20 mg once daily|for 36 weeks
214694835|NCT04100798|PROCEDURE|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
215134143|NCT04156022|OTHER|Dystonia Coalition is an observational study.|This is not an interventional study.
215134144|NCT03908034|OTHER|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
215134145|NCT03908034|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
215134146|NCT06082206|PROCEDURE|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
215134147|NCT06082206|PROCEDURE|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
215134148|NCT04910295|DRUG|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
215134149|NCT04404179|OTHER|COVID-19 FACILITY|A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
215134150|NCT01187017|DRUG|Cyclophosphamide|60 mg/kg
215134151|NCT01187017|DRUG|Fludarabine|125 mg/m squared
215134152|NCT02931188|DRUG|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
215134153|NCT02931188|DRUG|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
215134154|NCT02931188|DRUG|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
215134155|NCT06256185|PROCEDURE|esophagectomy|Resection of esophageal tumor and lymph node dissection
215134156|NCT04107662|DEVICE|Tbit system|Suspected traumatic brain injury with head CT
215134157|NCT05595655|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
215134158|NCT05033197|BEHAVIORAL|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
215134159|NCT04068025|OTHER|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
215134160|NCT03560882|DRUG|Atorvastatin|Atorvastatin tablet, 80mg
215134161|NCT02399215|OTHER|Laboratory Biomarker Analysis|Correlative studies
215134162|NCT02399215|DRUG|Nintedanib|Given PO
215134163|NCT02399215|OTHER|Pharmacological Study|Correlative studies
214694836|NCT04100798|PROCEDURE|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
214694837|NCT00063583|DRUG|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
214708882|NCT00126581|DRUG|Paclitaxel|Given IV
215134164|NCT02399215|OTHER|Quality-of-Life Assessment|Ancillary studies
215134165|NCT00772538|DRUG|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
215134166|NCT00772538|DRUG|placebo|Matching placebo
215134167|NCT03381690|PROCEDURE|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
215134168|NCT04638907|PROCEDURE|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
215134169|NCT02481154|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
215134170|NCT04605601|OTHER|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
215134171|NCT04605601|OTHER|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
215134172|NCT02262936|DRUG|Desmopressin|
215134173|NCT02262936|DRUG|Fesoterodine|
215134174|NCT04863729|BEHAVIORAL|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
215134175|NCT02843724|OTHER|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
215134176|NCT02843724|OTHER|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
215134177|NCT01153386|DRUG|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
215134178|NCT04043910|DEVICE|fNIRS|The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
215134179|NCT04043910|OTHER|Speech intelligibility|Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
215134180|NCT04043910|OTHER|Sound localisation|Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
214450913|NCT06845878|OTHER|chatbot|"Participants will:~* Participate in a baseline session to complete an initial survey and get trained on using the chatbot~* Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback~* Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot~* Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context."
214450914|NCT06847009|OTHER|Acupressure application|Acupressure will be applied to hemodialysis patients within the first two hours of HD and three times a week for four weeks. This intervention aims to evaluate its effects on sleep quality.
214450915|NCT03378219|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
214525730|NCT06395961|PROCEDURE|high ankle block|"The block position is in the middle and lower third of the calf, about 15cm above the inner or outer ankles. 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve. The water separation technique is used and 2ml of physiological saline is injected before blocking to clarify the position of the needle tip and avoid nerve damage. 20 minutes after, the effect was measured using acupuncture by visual analogue scale (VAS) score. If the VAS score is less than 3, the block is considered successful and surgery is immediately performed."
214525731|NCT06395961|PROCEDURE|general anesthesia|intravenous injection of midazolam 0.03-0.05 mg/kg, etomidate 0.15-0.20 mg/kg, cisatracurium 0.15-0.20 mg/kg, and sufentanil 0.3-0.5 μg/kg. Intraoperative anesthesia maintenance using intravenous infusion of remifentanil 0.1-0.3 μg/kg·min, propofol 4-6 mg/kg·h, maintain bispectral index (BIS) value of 40-60, maintain intraoperative blood pressure and heart rate fluctuations within ± 20% of the baseline value, intermittently inject cisatracurium intravenously as needed. After the surgery, the patient was transferred to post-anaesthesia care unit (PACU). After regaining consciousness and regaining autonomous breathing, the tracheal catheter was removed and transferred to the ward when the indications for transfer were met.
215134181|NCT04043910|OTHER|Speech assessments|Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
214450916|NCT06843928|DEVICE|Submucosal debridement|Participants will undergo non-surgical submucosal debridement alone (SD)
214525732|NCT02945007|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
214525733|NCT05171465|DEVICE|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
214450917|NCT06843928|DEVICE|Submucosal debridement + titanium brushes|Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
214450918|NCT05838131|DRUG|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
214450919|NCT06843694|OTHER|video game|The students in the video game group will be given training. The students in this group (n=30) will be divided into 4 groups and each group will have 5 students. The students will be given training about the Video Game (Lifesaver) by the researcher beforehand. The Video Game (Lifesaver-Cankurtaran); is a free video game developed by the Resuscitation Council in English.
214450920|NCT00579124|DEVICE|CliniMACs|T and B Cell depletion
214450921|NCT03854578|DRUG|BI 1358894|Film-coated tablet
214525734|NCT06225986|BEHAVIORAL|LMH-4-DCP|Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
215134182|NCT04043910|OTHER|Quality of Life|Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
215134183|NCT04161859|DIETARY_SUPPLEMENT|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
215134184|NCT05623332|DIAGNOSTIC_TEST|Maraciclatide|Imaging marker that binds to AVB3/5 lesions
215134185|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
214450922|NCT03854578|DRUG|Placebo matching BI 1358894|Film-coated tablet
214450923|NCT03854578|DRUG|Citalopram|Film-coated tablet
214525735|NCT06225986|BEHAVIORAL|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
214525736|NCT06318130|DEVICE|Fixed helix, lumenless pacing lead.|Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.
214525737|NCT06318130|DEVICE|Extendable helix, stylet-driven pacing lead.|Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
214525738|NCT00319878|DRUG|Sirolimus|"Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
214525739|NCT00319878|DRUG|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
215134186|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
215134187|NCT04616755|OTHER|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
215134188|NCT05993806|DRUG|L04RD1|1 tablet of L04RD1
215134189|NCT05993806|DRUG|L04TD3|1 tablet of L04TD3
215134190|NCT01172106|BEHAVIORAL|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
215134191|NCT01172106|BEHAVIORAL|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
215134192|NCT01172106|BEHAVIORAL|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
215134193|NCT00189540|GENETIC|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
215134194|NCT00189540|GENETIC|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
215134195|NCT06061874|DIAGNOSTIC_TEST|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
215134196|NCT05072158|OTHER|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
215134197|NCT06410430|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
215134198|NCT02740946|OTHER|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
215134199|NCT03603782|DIETARY_SUPPLEMENT|2.5% protein|2.5%
215134200|NCT03603782|DIETARY_SUPPLEMENT|protein 5%|5%
215134201|NCT03603782|DIETARY_SUPPLEMENT|protein 10%|10%
215134202|NCT03603782|DIETARY_SUPPLEMENT|protein 15%|15%
215134203|NCT03603782|DIETARY_SUPPLEMENT|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
215134204|NCT03603782|DIETARY_SUPPLEMENT|B2: only breakfast (no product)|only breakfast
215134205|NCT03603782|DIETARY_SUPPLEMENT|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
215134206|NCT03603782|DIETARY_SUPPLEMENT|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
215134207|NCT01101217|DRUG|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
215134208|NCT01101217|DRUG|placebo|placebo daily for 6 weeks
215134209|NCT04410497|OTHER|Porcine xenograft (wound dressings)|commercial porcine xenograft, derived from acellular dermis from porcine.
214450924|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
214450925|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
214450926|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
214450927|NCT06530446|OTHER|one group. observational study|observational study of this group
214450928|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
215134210|NCT04410497|OTHER|Silver foam (wound dressings)|commercial silver containing foam dressing
215134211|NCT05390073|DIAGNOSTIC_TEST|growth hormone level and insulin like growth factor 1|laboratory test
215134212|NCT00298324|DRUG|Myfortic|1440mg twice daily
215134213|NCT00298324|DRUG|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
215134214|NCT00713609|DRUG|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
215134215|NCT00713609|DRUG|Clindamycin gel|1% clindamycin phosphate applied topically once a day
215134216|NCT00713609|DRUG|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
215134217|NCT00713609|DRUG|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
215134218|NCT00713609|DRUG|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
215134219|NCT01903356|DRUG|Trajenta duo|Linagliptin and Metformin
215134220|NCT01824238|DRUG|Anacetrapib|
215134221|NCT01824238|DRUG|Placebo for anacetrapib|
215134222|NCT03488095|BEHAVIORAL|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
215134223|NCT01387828|PROCEDURE|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
215134224|NCT01387828|PROCEDURE|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
215134225|NCT03728868|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
215134226|NCT03728868|DIETARY_SUPPLEMENT|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
214450929|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
214450930|NCT05683041|DEVICE|Hyalobarrier|Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
214450931|NCT05807594|BEHAVIORAL|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
214450932|NCT05807594|BEHAVIORAL|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
215134227|NCT03728868|DIETARY_SUPPLEMENT|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
215134228|NCT03854058|DIAGNOSTIC_TEST|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
215134229|NCT00095693|DRUG|sorafenib tosylate|Given PO
215134230|NCT00095693|OTHER|laboratory biomarker analysis|Correlative studies
215134231|NCT00095693|OTHER|pharmacological study|Correlative studies
215134232|NCT00095693|RADIATION|fludeoxyglucose F 18|Correlative studies
215134233|NCT00095693|PROCEDURE|positron emission tomography|Correlative studies
215134234|NCT00095693|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
215134235|NCT00118183|DRUG|docetaxel|Given IV
215134236|NCT00118183|BIOLOGICAL|cetuximab|Given IV
215134237|NCT00118183|DRUG|bortezomib|Given IV
215134238|NCT00160186|DRUG|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
215134239|NCT00160186|DRUG|Placebo|Placebo
215134240|NCT05026528|OTHER|Digital diabetes self management education and support system|Digital diabetes self management and support system
215134241|NCT04529083|DEVICE|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
215134242|NCT02144181|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
215134243|NCT05366023|BEHAVIORAL|BUD1|10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
215134244|NCT05366023|BEHAVIORAL|BUD2|10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
215134245|NCT05366023|BEHAVIORAL|TDD1|10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
215134246|NCT05366023|BEHAVIORAL|TDD2|10 hours of top-down driven computerized cognitive training designed to improve executive function
215134247|NCT05366023|BEHAVIORAL|CSA10|10 hours of computerized games
215134248|NCT05366023|BEHAVIORAL|CSA20|20 hours of computerized games
215134249|NCT05366023|BEHAVIORAL|CSA30|30 hours of computerized games
215134250|NCT05366023|BEHAVIORAL|CSA40|40 hours of computerized games
215134251|NCT04814303|PROCEDURE|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
215134252|NCT04814303|PROCEDURE|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
215134253|NCT04814303|PROCEDURE|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
215134254|NCT00003989|BIOLOGICAL|ISIS 3521|
215134255|NCT00933699|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
214525740|NCT02912104|BIOLOGICAL|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
215134256|NCT02470286|DRUG|SA001 60mg or Placebo|"* Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)"
215134257|NCT02470286|DRUG|SA001 120mg or Placebo|"* Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
215134258|NCT02470286|DRUG|SA001 180mg or Placebo|"* Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)"
215134259|NCT02470286|DRUG|SA001 240mg or Placebo|"* Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)"
215134260|NCT02470286|DRUG|SA001 300mg or Placebo|"* Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
215134261|NCT02669810|DRUG|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
215134262|NCT02669810|DRUG|Standard Treatment for CHF post AMI|
215134263|NCT04265963|BIOLOGICAL|CD123 CAR-T cells|CD123 CAR-T cell therapy
215134264|NCT06240234|DEVICE|Capnodynamic method|All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
215134265|NCT05399069|DRUG|VGR-R01|Gene Replacement Therapy
215134266|NCT03120884|PROCEDURE|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
214525741|NCT00183599|BEHAVIORAL|5 Minutes of Simple Advice|
214525742|NCT00183599|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
214525743|NCT00183599|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214525744|NCT01827800|BEHAVIORAL|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
214708883|NCT04720495|PROCEDURE|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
215134267|NCT03120884|PROCEDURE|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
215134268|NCT03305666|DRUG|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
215134269|NCT03305666|DRUG|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
215134270|NCT00967564|OTHER|epidemiologic study|QoL assessment
215134271|NCT02990026|BEHAVIORAL|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
215134272|NCT01293903|DRUG|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
215134273|NCT01293903|DRUG|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
215134274|NCT00783159|PROCEDURE|Power Training|Power training, Vitamin D substitution
215134275|NCT00783159|PROCEDURE|Strength Training|Strength training, Vitamin D substitution
215134276|NCT00783159|OTHER|Control|Vitamin D substitution, Lifestyle consultation
215134277|NCT00196547|DRUG|Montelukast (drug)|
215134278|NCT06091475|DRUG|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
215134279|NCT03969485|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser Device
215134280|NCT02739230|DRUG|Exparel|
215134281|NCT02739230|DRUG|On-Q pain intra-articular catheter|
215134282|NCT01615146|OTHER|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
215134283|NCT06540053|OTHER|Active Static Hamstring Stretch Exercise|In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.
215134284|NCT06540053|OTHER|Waiting List|Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
215134285|NCT01434017|DRUG|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
214450933|NCT02662751|OTHER|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
214450934|NCT02662751|DEVICE|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
214450935|NCT06423196|OTHER|Experimental group|In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
214525745|NCT05071378|BEHAVIORAL|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
214525746|NCT01249378|OTHER|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
214525747|NCT04872842|OTHER|Obervation|This study is an observational study without any intervention
214525748|NCT04086576|DEVICE|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
214525749|NCT04086576|DEVICE|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
214525750|NCT04086576|DEVICE|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
214525751|NCT04086576|DEVICE|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
214525752|NCT04086576|DEVICE|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
215134286|NCT01434017|DRUG|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
215134287|NCT01434017|DRUG|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
215134288|NCT02064803|PROCEDURE|Gastro-entero anastomosis only|Gastro-entero anastomosis only
215134289|NCT02064803|PROCEDURE|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
215134290|NCT02005549|DRUG|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
214525753|NCT04086576|DEVICE|Floome|Floome branded smartphone-paired breathalyzer
214525754|NCT04086576|DEVICE|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
214525755|NCT03092323|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
215134291|NCT02005549|DRUG|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
214450936|NCT02966483|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
214450937|NCT02966483|PROCEDURE|LpTME|Conventional Laparoscopic Total Mesorectal Excision
215134292|NCT02005549|DRUG|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
214525756|NCT00578929|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
215134293|NCT03799146|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
215134294|NCT03799146|OTHER|Waiting List|Waiting List control group
214525757|NCT00578929|DRUG|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
214525758|NCT04736602|DRUG|Triptorelin pamoate 15mg|Intramuscular injection (IM)
214525759|NCT04299971|DRUG|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
214525760|NCT04299971|DRUG|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
214525761|NCT00053391|BIOLOGICAL|recombinant CD40-ligand|
214525762|NCT00053391|BIOLOGICAL|therapeutic autologous dendritic cells|
214525763|NCT05987839|PROCEDURE|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
214525764|NCT00317135|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
214525765|NCT00317135|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
214525766|NCT01468025|DRUG|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
214525767|NCT01468025|OTHER|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
215134295|NCT05182086|OTHER|Group physical therapy and dietary improvements|20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
215134296|NCT00521950|GENETIC|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
215134297|NCT00521950|DRUG|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
215134298|NCT06460545|BIOLOGICAL|sIPV (booster dose at 18 months of age)|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose at 18 months of age for the booster one
215134299|NCT06460545|BIOLOGICAL|HepA-L|Freeze-dried/lyophilized live-attenuated hepatitis A virus vaccine, 1.0mL for each dose at 18 months of age
215134300|NCT06460545|BIOLOGICAL|HepA-I|Inactivated hepatitis A virus vaccine, 0.5mL for each dose, two doses at 18 and 24 months of age, respectively
214525768|NCT01468025|DRUG|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
214525769|NCT04893902|DEVICE|medit intra oral scanner|ear scanning with intra oral scanner
214525770|NCT00765921|DRUG|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
215134301|NCT04195646|DEVICE|EndoVigilant CAD Software|The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
215134302|NCT01729741|PROCEDURE|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
215134303|NCT02728115|BIOLOGICAL|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
215134304|NCT02728115|BIOLOGICAL|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
215134305|NCT06092723|DIETARY_SUPPLEMENT|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
215134306|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 1,Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
215134307|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 2,Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
215134308|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
215134309|NCT03188016|BEHAVIORAL|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
215134310|NCT03188016|BEHAVIORAL|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
215134311|NCT04196686|DEVICE|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
215134312|NCT04196686|OTHER|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
215134313|NCT00169182|DRUG|DOCETAXEL|75 mg/m 2 on day 1
215134314|NCT00169182|DRUG|Cisplatin|75 mg/m 2 on day 1
215134315|NCT00169182|DRUG|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
215134316|NCT01166139|DRUG|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
215134317|NCT02051452|DRUG|Methylphenidate|
215134318|NCT02051452|OTHER|Saline|
215134319|NCT04944277|OTHER|ThoughtFullChat Application|A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
215134320|NCT05247372|OTHER|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
215134321|NCT02587221|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
214450938|NCT04263311|BEHAVIORAL|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
214450939|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
214450940|NCT04614233|DIETARY_SUPPLEMENT|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
214525771|NCT03223714|DRUG|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
214525772|NCT03223714|DRUG|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
214525773|NCT01714414|DRUG|FZD|
214525774|NCT01714414|DRUG|3TC|
214525775|NCT01714414|DRUG|EFV|
214525776|NCT01714414|DRUG|AZT|
214525777|NCT03455569|BEHAVIORAL|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
214525778|NCT03455569|BEHAVIORAL|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
215134322|NCT02587221|BIOLOGICAL|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
215134323|NCT04268459|DEVICE|Provox prosthesis exchange|Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
215134324|NCT04665141|BIOLOGICAL|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
214450941|NCT04614233|DRUG|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
214450942|NCT05890729|DRUG|XTMAB-16 or Placebo|Infusion
214525779|NCT00957671|DRUG|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
214525780|NCT05107999|DRUG|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
214525781|NCT05107999|DRUG|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
214525782|NCT04723888|DIETARY_SUPPLEMENT|alpha-ketoglutarate|alpha-ketoglutarate supplements
215134325|NCT04665141|BIOLOGICAL|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
215134326|NCT04665141|BIOLOGICAL|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
215134327|NCT04665141|BIOLOGICAL|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
215134328|NCT04665141|BIOLOGICAL|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
215134329|NCT04558060|OTHER|Virtual Standardized Patient|Computer program that presented a virtual human patient
214450943|NCT04312802|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
214450944|NCT05773573|DEVICE|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
214450945|NCT05773573|DEVICE|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
214450946|NCT05759195|DIAGNOSTIC_TEST|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
214450947|NCT06506604|BEHAVIORAL|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
214450948|NCT06580405|DEVICE|KNP-1000 Apheresis System|sFlt-1 is removed from the participants' plasma through treatment.
214450949|NCT06580912|DRUG|Krill oil|4 grams of krill oil per day
214450950|NCT06580912|DIETARY_SUPPLEMENT|Mixed vegetable oil|4 grams of mixed vegetable oil per day
214450951|NCT06314061|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A continuous glucose monitor which through a sensor in the skin registers glucose levels every 5 minutes. Glucose levels are shown by connecting the sensor to a mobile device or the Dexcom G7 Receiver where realtime alerts on deviating glucose levels will be sent.
215134330|NCT04558060|OTHER|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
215134331|NCT05926817|DEVICE|Placebo-VR headsets|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
214525783|NCT03681171|OTHER|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
214525784|NCT04364022|DRUG|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
214525785|NCT03735641|PROCEDURE|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
215134332|NCT05926817|DEVICE|QTC-VR headsets|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
215134333|NCT03171402|DIAGNOSTIC_TEST|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
215134334|NCT00241384|PROCEDURE|External beam radiation|
215134335|NCT00241384|PROCEDURE|Pd-103|
215134336|NCT05852119|OTHER|Outpatient treatment with standard anticoagulant therapy|All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
214450952|NCT05569174|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
214450953|NCT05569174|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
214450954|NCT05796297|DEVICE|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
214450955|NCT04975139|DEVICE|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
214450956|NCT04595435|PROCEDURE|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
214450957|NCT04595435|RADIATION|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
214450958|NCT02954341|DEVICE|CardioMEMS HF System|
214525786|NCT03556540|OTHER|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
215134337|NCT00517764|DRUG|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
215134338|NCT06227481|PROCEDURE|Scar subcision|"* Subcision will be performed with18 gauge cannula at the margin of the scars on both sides of the face.~* The cannula will be directed in a forward and backward motion producing a tunnel. Then, the it will be passed in sideways in a sweeping action to freeing up the scars from their bases.~* Once finish, the pressure will be applied to reduce the bleeding and swelling. The topical antibiotic will be applied for 3 days."
215134339|NCT06227481|PROCEDURE|Platelet rich plasma injection|• 20 ml of autologous whole blood will be collected into tubes containing acid citrate dextrose and centrifuged at 1500 rpm for 10 minutes in order to get PRP at the top of the test tube. Then, the PRP will be further centrifuged at 3700 rpm for 10 minutes at room temperature of 22°C in order to obtain a platelet count 4.5 times higher than the base line. Platelet-poor plasma (PPP) will be partly removed and partly used to resuspend the platelets. Calcium gluconate will be added as an activator (1:9), i.e., 1 ml of calcium gluconate in 9 ml of PRP
215134340|NCT06227481|PROCEDURE|Polydioxanone mono threads insertion|"* Topical anesthetic cream will be applied for halfan hour on the involved area.~* polydioxanone mono threads (50 mm, 27 G) will be inserted at 1-cm spacing into the dermal layer of the skin; the threads will be arranged in a transverse and vertical line in the form of a mesh similar to cross-hatching technique.~* The total numbers will range from 8 to 10 each side. The skin of the face will be stretched by the non-dominant hand of the physician and the needle will be inserted by the other hand through the required point."
215134341|NCT06227481|DEVICE|Fractional carbon dioxide laser|"* Topical anesthetic cream will be applied for 30 minutes before the procedure.~* BX300 device from AMI inc.,Korea will be used.~* Different settings will be used according to each individual case regarding the type of scar, severity and skin type fluence ranging from 36 to 42 j/cm2 will be used and pulse duration 1.8 ms.~* In an attempt to avoid common side effects that occur with fractional laser treatment, a lower fluence will be used in the first session and depending on the results, the fluence will be increased per treatment session."
215134342|NCT04612335|OTHER|Rate control|Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
215134343|NCT04612335|OTHER|Pharmacological or electrical cardioversion|Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
215134344|NCT04922086|PROCEDURE|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
215134345|NCT04922086|PROCEDURE|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
215134346|NCT02862678|OTHER|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
215134347|NCT02546609|DRUG|Leu-Met-Sil 0.5|NS-0200 low dose
215134348|NCT02546609|DRUG|Leu-Met-Sil 1.0|NS-200 high dose
215134349|NCT02546609|DRUG|Placebo|Placebo
215134350|NCT02944110|DRUG|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
215134351|NCT02944110|DRUG|Placebo|Oral dose of placebo tablets
214450959|NCT05634226|DEVICE|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
214450960|NCT05859620|OTHER|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
214450961|NCT05768295|DEVICE|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
214450962|NCT03945539|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
214450963|NCT03945539|DRUG|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
214450964|NCT03141424|DRUG|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
214450965|NCT04848896|DEVICE|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
214450966|NCT04848896|PROCEDURE|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
214450967|NCT02663193|OTHER|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
214450968|NCT06089577|DRUG|Cangrelor 50 MG|Cangrelor will be administered during PCI
214450969|NCT06467487|OTHER|Traditional Letter|Patients receive a traditional letter.
214450970|NCT06467487|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
214450971|NCT06467487|OTHER|Optimized Letter|Patients receive an optimized letter.
214450972|NCT06467487|OTHER|Direct to Patient Message - Optimized|Patients receive an optimized direct to patient message via the portal.
214450973|NCT05459207|OTHER|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
215134352|NCT02196896|OTHER|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
215134353|NCT02196896|OTHER|Information|The patients receive online information about depression once a week for 90 days.
215134354|NCT05225311|OTHER|Observation|Patients will be followed by the registry for life-long outcomes.
215134355|NCT05711576|OTHER|Placebo mouthwash|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash
215134356|NCT05711576|OTHER|Full mouth disinfection|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
215134357|NCT02517931|PROCEDURE|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
215134358|NCT02517931|PROCEDURE|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
215134359|NCT02616510|PROCEDURE|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
215134360|NCT05132556|OTHER|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
215134361|NCT02905461|BEHAVIORAL|Contraceptive text messages|
215134362|NCT02905461|OTHER|Text messages not about contraception|
215134363|NCT04099563|DRUG|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
215134364|NCT00914849|DRUG|AMD3100|
215134365|NCT00914849|PROCEDURE|Leukopheresis|
215134366|NCT00914849|PROCEDURE|Stem cell transplant|
215134367|NCT04648462|OTHER|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
215134368|NCT02965911|DRUG|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
215134369|NCT02965911|DRUG|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
215134370|NCT01001221|DRUG|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1"
215134371|NCT01001221|DRUG|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1."
215134372|NCT03160638|DRUG|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
215134373|NCT03809728|PROCEDURE|endoscopic biopsy|Per-endoscopic biopsies
215134374|NCT03809728|PROCEDURE|samples of the oral cavity|7 samples of the oral cavity with a swab
215134375|NCT03809728|PROCEDURE|Samples of the resected specimen|if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
215134376|NCT02385929|BEHAVIORAL|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
215134377|NCT00000306|DRUG|Dextroamphetamine|
215134378|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
215134379|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
215134380|NCT03541551|PROCEDURE|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
215134381|NCT03541551|PROCEDURE|Trab Trab|combined trabeculotomy with trabeculectomy
215134382|NCT05612854|PROCEDURE|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
215134383|NCT05612854|DEVICE|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
215134384|NCT05106959|BEHAVIORAL|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
215134385|NCT00080158|DRUG|fluoxetine|
215134386|NCT00080158|DRUG|sertraline|
215134387|NCT00080158|DRUG|citalopram|
215134388|NCT00080158|DRUG|escitalopram|
215134389|NCT00080158|DRUG|bupropion|
215134390|NCT00080158|DRUG|mirtazapine|
215134391|NCT00080158|DRUG|venlafaxine|
215134392|NCT00080158|DRUG|lithium|
215134393|NCT00080158|BEHAVIORAL|Cognitive Behavioral Therapy|
215134394|NCT01559636|BIOLOGICAL|bivalent oral polio vaccine|vaccine given during immunization campaigns
214525787|NCT02238691|PROCEDURE|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
215134395|NCT03558659|DEVICE|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
215134396|NCT02452736|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
215134397|NCT04989751|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
215134398|NCT04989751|DIAGNOSTIC_TEST|IDEAL MRI|Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
214525788|NCT02584218|PROCEDURE|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
214525789|NCT02584218|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
215134399|NCT05274997|DRUG|YY-20394|Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
215134400|NCT01292486|DEVICE|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
215134401|NCT05467059|OTHER|Napping|Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
215134402|NCT05177393|OTHER|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
215134403|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
215134404|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
215134405|NCT04369404|BEHAVIORAL|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
215134406|NCT04369404|BEHAVIORAL|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
215134407|NCT04369404|BEHAVIORAL|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
215134408|NCT04662021|OTHER|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
215134409|NCT04514887|OTHER|mild intraoperative hyperventilation|Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
215134410|NCT03136887|DEVICE|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
215134411|NCT05537909|OTHER|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
215134412|NCT04367727|DEVICE|Light emitting diode|Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
214525790|NCT00475735|DRUG|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
214525791|NCT00475735|DRUG|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
215134413|NCT01995708|BIOLOGICAL|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
215134414|NCT01995708|OTHER|Standard of care|No vaccines
215134415|NCT05906719|OTHER|video recording|Patients' performance of MDS-UPDRS III will be recorded.
214450974|NCT05459207|OTHER|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
214450975|NCT06679036|DRUG|HRS-2189|HRS-2189
214450976|NCT06679036|DRUG|Fluvustat|Fluvustat
214450977|NCT06679036|DRUG|HRS-8080|HRS-8080
214525792|NCT00475735|DRUG|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
214708884|NCT04720495|PROCEDURE|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
215134416|NCT03003026|OTHER|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
215134417|NCT03003026|OTHER|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
215134418|NCT05383118|BEHAVIORAL|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors"
215134419|NCT05383118|BEHAVIORAL|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment"
215134420|NCT03379181|DRUG|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
215134421|NCT06322186|OTHER|Ready-Heat Chemical Heating Blankets|Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.
215134422|NCT06322186|OTHER|Warmed blankets or FAWB|The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
215134423|NCT04197245|DRUG|saline injection therapy in post-acne atrophic scars|saline injection contains 0.9% isotonic sodium chloride solution
215134424|NCT04592939|PROCEDURE|immediate weight bearing after surgery|immediate weight bearing
215134425|NCT04592939|PROCEDURE|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
215134426|NCT04918420|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
215134427|NCT05575453|OTHER|Kvatchii Portal|Online education portal
215134428|NCT00259662|DRUG|atorvastatin|
215134429|NCT04602390|DRUG|ANK-700|Intravenous (IV) infusion
215134430|NCT04602390|DRUG|Placebo|Intravenous (IV) infusion
215134431|NCT06527560|DRUG|Cefuroxime|Intravenous cefuroxime 750 mg every 8 hours
215134432|NCT06527560|DRUG|Cefuroxime Axetil|Oral cefuroxime 500 mg every 12 hours
214450978|NCT06679036|DRUG|HRS-6209|HRS-6209
214708885|NCT01754207|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
214708886|NCT01754207|DEVICE|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
214708887|NCT00251875|DEVICE|online health information journal|
214450979|NCT06679036|DRUG|HRS-1358|HRS-1358
214450980|NCT06636279|PROCEDURE|Gas bubble technique|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
214450981|NCT02639026|RADIATION|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
214450982|NCT02639026|DRUG|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
214450983|NCT02639026|DRUG|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
214450984|NCT05728242|DIAGNOSTIC_TEST|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
214450985|NCT04573725|DRUG|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
214450986|NCT04573725|DRUG|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
214450987|NCT05900700|BEHAVIORAL|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
215134433|NCT04005846|DEVICE|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
215134434|NCT00265564|BEHAVIORAL|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
215134435|NCT00265564|BEHAVIORAL|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
215134436|NCT02641847|DRUG|docetaxel|
215134437|NCT02641847|DRUG|doxorubicin or epirubicin|
214450988|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.
214525793|NCT03132753|BEHAVIORAL|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
215134438|NCT02641847|DRUG|cyclophosphamide|
215134439|NCT02641847|DRUG|gemcitabine|
214450989|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.
215134440|NCT02641847|DRUG|cisplatin|
215134441|NCT04309734|DRUG|AT-777|Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
214450990|NCT05608187|BIOLOGICAL|Placebo|Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
214450991|NCT05493423|DEVICE|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
214450992|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
214450993|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
214525794|NCT00125853|DRUG|Nebivolol|Nebivolol 2.5mg daily
214525795|NCT00125853|DRUG|Atenolol|Atenolol 25mg daily
214525796|NCT01000415|OTHER|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
214525797|NCT03437902|DIETARY_SUPPLEMENT|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
215134442|NCT04309734|DRUG|Placebo|Administered orally, as one or two placebo capsules, depending on the arm.
215134443|NCT04309734|DRUG|AT-527|Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
214525798|NCT03437902|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
215134444|NCT05931081|DEVICE|Thermal imaging in diagnostics of chronic ulcers|atypical: vasculitic or pyoderma gangraenosum ulcers
215134445|NCT06458283|OTHER|hiybrid simulation|The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.
215134446|NCT06458283|OTHER|control grup|low fidelity simulator
215134447|NCT01553084|DRUG|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
215134448|NCT01553084|DRUG|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
214450994|NCT03423953|DEVICE|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
214450995|NCT05086016|DEVICE|Catheterized Stenting|Catheterized stenting of vascular narrowings.
214450996|NCT06074523|BEHAVIORAL|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
214450997|NCT06120036|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
214450998|NCT06120036|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
214450999|NCT02863718|DRUG|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
214451000|NCT02863718|DRUG|Placebo|Placebo 420mg daily
215134449|NCT01553084|DRUG|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
215134450|NCT01452438|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
215134451|NCT03988400|BEHAVIORAL|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
214451001|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
214451002|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
214451003|NCT05465551|COMBINATION_PRODUCT|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
214451004|NCT05776641|DEVICE|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
214451005|NCT04097184|DEVICE|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
214451006|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
214451007|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
214451008|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
214451009|NCT05622448|OTHER|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
214451010|NCT05622448|OTHER|RPD with metallic framework|removable partial denture with cobalt chromium framework
214451011|NCT01426425|DEVICE|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
214451012|NCT04147078|BIOLOGICAL|DC vaccine subcutaneous administration|subcutaneous administration
214451013|NCT04773353|DRUG|Follitropin Delta (FE 999049)|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
215134452|NCT03988400|BEHAVIORAL|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
215134453|NCT00245323|BEHAVIORAL|Smoking status as a routine vital sign|
215134454|NCT04400877|DIAGNOSTIC_TEST|Diagnostic examination for venous thromboembolism|Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
215134455|NCT03448796|PROCEDURE|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
215134456|NCT03448796|OTHER|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
214451014|NCT04773353|DRUG|Follitropin Alfa (GONAL-F)|GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
215134457|NCT05682508|OTHER|Education group|"Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable."
215134458|NCT06369870|DRUG|Levobupivacaine Hydrochloride 0.25 % Injectable Solution|After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
215134459|NCT06369870|DRUG|Sodium chloride 0.9%|Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the intervention description of the IPP-PSP block.
215134460|NCT04201431|BIOLOGICAL|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
215134461|NCT05671107|DIAGNOSTIC_TEST|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
215134462|NCT03941756|DRUG|Indocyanine Green|Given IV
215134463|NCT03941756|PROCEDURE|Lymphangiography|Undergo lymphangiography
214451015|NCT06052176|DRUG|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
214451016|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product A)|Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
214451017|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product B)|Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
214451018|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product C)|Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
214451019|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product D)|Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
214451020|NCT06093659|OTHER|Conventional Cigarette (Product E)|Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
214451021|NCT04558164|DEVICE|Active Theta Burst Stimulation|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
214451022|NCT04558164|DEVICE|Sham Theta Burst Stimulation|Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
214451023|NCT06394765|BEHAVIORAL|Mindful Mapping|Participants in the Mindful Mapping condition will receive a 5-minute, therapist-guided mindfulness intervention for chronic pain. During this training they will learn the 30-second Mindful Mapping technique, which they will be instructed to use each time they experience a painful sensation over the next 2 weeks. The Mindful Mapping technique consists of focusing on five basic characteristics (shape, weight, density, temperature, movement) of the most intense sensation in the body as it emerges in the present moment while remaining equanimous, i.e., preventing the learned reaction.
214451024|NCT06394765|BEHAVIORAL|Serial Sevens|"Participants in the control condition will receive a 5-minute, therapist-guided serial sevens intervention for chronic pain. During this training, participants will be instructed that each time they experience pain, they will count backwards in their heads by 7 from 100 for 30 second."
214451025|NCT01253824|DRUG|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
215134464|NCT03941756|PROCEDURE|Lymphovenous Bypass|Undergo LVB
215134465|NCT03538197|OTHER|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
215134466|NCT03081702|DRUG|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
215134467|NCT03081702|DRUG|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
215134468|NCT01429675|DRUG|bonviva|150mg Ibandronate once a month
215134469|NCT01176032|DRUG|Aliskiren|Aliskiren 300 mg film coated tablets
215134470|NCT01176032|DRUG|Losartan|Losartan 100 mg tablets
215134471|NCT01176032|DRUG|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
215134472|NCT01176032|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
215134473|NCT01074775|BIOLOGICAL|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
215134474|NCT04471350|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
215134475|NCT06478420|BIOLOGICAL|Omicron BA.5 SARS-CoV-2 challenge virus|The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
215134476|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
215134477|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
215134480|NCT00375999|DRUG|Docetaxel and epirubicin|
215134481|NCT05414461|DRUG|Combinations|PD-1 inhibitor-based combinaiton treatment
215134482|NCT00792844|DIETARY_SUPPLEMENT|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
215134483|NCT00792844|DIETARY_SUPPLEMENT|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
215134484|NCT04756310|DIETARY_SUPPLEMENT|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
215134485|NCT04756310|DIETARY_SUPPLEMENT|Theavit|antioxidants micronutrients
215134486|NCT00002088|DRUG|Saccharomyces boulardii|
215134487|NCT03382717|DEVICE|Excilor Forte|1 application per day during 6 months
215134488|NCT03382717|DRUG|Loceryl 5%|1 application per week during 6 months
215134489|NCT04549285|BIOLOGICAL|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10\^6 cells/kg (up to a maximum dose of 100x10\^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
214451026|NCT01253824|DRUG|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
214451027|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
214451028|NCT00512070|DRUG|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
214451029|NCT04679376|DRUG|Atorvastatin|40 mg daily administered orally in tablet or capsule form
214451030|NCT04679376|DRUG|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
215134490|NCT00830999|BEHAVIORAL|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
215134491|NCT00830999|BEHAVIORAL|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
215134492|NCT00830999|BEHAVIORAL|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
215134493|NCT00830999|BEHAVIORAL|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
215134494|NCT00830999|BEHAVIORAL|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
215134495|NCT00534326|PROCEDURE|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
215134496|NCT00534326|PROCEDURE|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
215134497|NCT03667482|DRUG|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
215134498|NCT03667482|DRUG|Cetuximab|Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
215134499|NCT04205240|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
215134500|NCT04205240|DRUG|Cyclophosphamide|Given IV
215134501|NCT04205240|BIOLOGICAL|Daratumumab|Given IV
215134502|NCT04205240|DRUG|Fludarabine|Given IV
215134503|NCT04205240|DRUG|Melphalan|Given IV
215134504|NCT04205240|DRUG|Mycophenolate Mofetil|Given IV or PO
214451031|NCT04910724|OTHER|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
214451032|NCT06411301|DRUG|225Ac-DOTATATE|Two intravenous infusions every 6 weeks (Q6W)
214451033|NCT04885959|BEHAVIORAL|Traditional Asian Diet|The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020). The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
214451034|NCT05826587|BEHAVIORAL|Home-based, m-Health Delivered Physical Function Training|An individualized home exercise physical function training will be prescribed. This would include 5 balance training exercises and 1-2 upper and lower-body muscular conditioning exercises (i.e., wall push-up and chair stand) prescribed 3 days/week over the course of a 6-week period. Subjects will be assigned exercises from 1 of 3 different levels of exercise progression based on performance during the baseline muscular fitness assessment (functional chair stand and static chest throw).
214451035|NCT05826587|BEHAVIORAL|Cardiac Rehabilitation & Exercise Prescription|Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
214451036|NCT05826587|OTHER|Connected mHealth mobile application|Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
214694838|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
215134505|NCT04205240|DRUG|Tacrolimus|Given PO or IV
215134506|NCT03456128|OTHER|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
215134507|NCT01810471|DEVICE|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
215134508|NCT01791244|DRUG|Rebif®|
215134509|NCT01149096|PROCEDURE|Bone Marrow Donation|Undergo bone marrow harvest
215134510|NCT01149096|BIOLOGICAL|Filgrastim|Given subcutaneously
215134511|NCT01149096|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215134512|NCT05783141|DIETARY_SUPPLEMENT|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
215134513|NCT05783141|DIETARY_SUPPLEMENT|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
215134514|NCT06314711|DIAGNOSTIC_TEST|Ultrasound|High-frequency ultrasound of ex vivo specimen
215134515|NCT05854966|DRUG|CPI 613|"For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent."
215134516|NCT05854966|DRUG|Metformin|"For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent"
215134517|NCT05854966|BIOLOGICAL|Blood draws|In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
215134518|NCT05854966|PROCEDURE|Bone marrow biopsy|After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
215134519|NCT03234595|DRUG|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
215134520|NCT06563726|DIAGNOSTIC_TEST|point-of-care milk sodium testing|Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.
215134521|NCT04079296|BIOLOGICAL|ASP7517|Intravenous (IV)
215134522|NCT06561451|PROCEDURE|intracytoplasmic sperm injection and artificial oocyte activation|A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
215134523|NCT06561451|PROCEDURE|intracytoplasmic sperm injection|A single sperm will be injected within 4 hours after the follicular aspiration.
215134524|NCT05182372|BEHAVIORAL|Enhanced dCBT-I|Telehealth Coaching
215134525|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization."
215134526|NCT06280950|DRUG|Tacrolimus (continued reduction)|"* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction"
215134527|NCT06280950|DRUG|Tacrolimus (maintain 50% reduction)|\- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
215134528|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen."
215134529|NCT05992675|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
215134530|NCT05992675|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
215134531|NCT06437301|OTHER|Baseline measure of ETCO2 without mask|Baseline
215134532|NCT06437301|OTHER|Baseline ETCO2 with mask|Mask
215134533|NCT06437301|OTHER|ETCO2 after 200 meter walk with mask|200 meter walk and mask
215134534|NCT06437301|OTHER|ETCO2 after 200 meter walk without mask|200 meter walk
215134535|NCT05068752|DRUG|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
215134536|NCT05068752|DRUG|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
214451037|NCT02506959|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214451038|NCT02506959|DRUG|Busulfan|Given IV
214451039|NCT02506959|DRUG|Gemcitabine Hydrochloride|Given IV
214451040|NCT02506959|DRUG|Melphalan|Given IV
214451041|NCT02506959|DRUG|Panobinostat|Given PO
214451042|NCT02506959|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214451043|NCT02506959|OTHER|Pharmacological Study|Correlative studies
214451044|NCT04736550|BEHAVIORAL|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
214451045|NCT04736550|BEHAVIORAL|Psychotherapy for Pain (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
215134537|NCT06133816|BEHAVIORAL|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
215134538|NCT06133816|BEHAVIORAL|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
215134539|NCT06133816|BEHAVIORAL|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
215134540|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
215134541|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
215134542|NCT06133816|BEHAVIORAL|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
214451046|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
214451047|NCT03610490|DRUG|Cyclophosphamide|Given IV
214451048|NCT03610490|DRUG|Fludarabine|Given IV
214451049|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
215134543|NCT06114537|DRUG|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
215134544|NCT01346358|BIOLOGICAL|IMC-CS4|
215134545|NCT02839096|DRUG|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
215134546|NCT02839096|DRUG|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
215134547|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and placebo (NPL)|Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
215134548|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and ketones (NKE)|Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
215134549|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and placebo (HPL)|Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
214451050|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
214451051|NCT06310590|DRUG|NRT6003 Injection|Selective internal radiation therapy (SIRT) with TareSphere
214451052|NCT03932682|BIOLOGICAL|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
214451053|NCT03932682|BIOLOGICAL|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (NeisVac-C)
214451054|NCT04884412|PROCEDURE|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO\_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
214451055|NCT04884412|PROCEDURE|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
214451056|NCT03775187|BIOLOGICAL|Burosumab|
214451057|NCT05312515|OTHER|Warm Application to Feet|Warm Application to Feet after Cesarean Section
214451058|NCT02945774|RADIATION|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
214451059|NCT06619015|DRUG|Pramlintide Acetate 1 MG/ML|Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.
215134550|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and ketones (HKE)|Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
215134551|NCT05058365|BEHAVIORAL|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
215134552|NCT05687656|DEVICE|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
214451060|NCT06619015|DRUG|Semaglutide Pen Injector|Semaglutide from 0,25mg/week to 2,4mg/week
214451061|NCT06619015|DRUG|Sodium Chloride 0.9% Inj|Placebo
214451062|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
214451063|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
214451064|NCT05838651|DEVICE|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
214451065|NCT05838651|DEVICE|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
214451066|NCT04080531|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
214451067|NCT04080531|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
214525799|NCT02521428|OTHER|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
214525800|NCT03547648|PROCEDURE|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
214451068|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
214451069|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
214708888|NCT03728140|PROCEDURE|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
214525801|NCT03543540|BIOLOGICAL|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
214525802|NCT03543540|BIOLOGICAL|Placebo|Placebo injections: 14 in total at twice weekly intervals
214525803|NCT02525497|DEVICE|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
215134553|NCT04413071|OTHER|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
215134554|NCT02511665|DRUG|Metformin|Given metformin
215134555|NCT02511665|RADIATION|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
215134556|NCT02511665|DRUG|Placebo|Given placebo
215134557|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
215134558|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
215134559|NCT00207155|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
215134560|NCT05345353|BEHAVIORAL|Fat For Fight (FFF), The Aarhus Protocol|A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
215134561|NCT05345353|BEHAVIORAL|The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol|A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
215134562|NCT04148807|BEHAVIORAL|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
215134563|NCT04148807|BEHAVIORAL|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
215134564|NCT06473922|PROCEDURE|Reginal anesthesia|General anesthesia
214451071|NCT05462613|OTHER|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
214451072|NCT05462613|PROCEDURE|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
214451073|NCT05462613|DRUG|Regorafenib|"\- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
215134565|NCT00003605|BIOLOGICAL|rituximab|
215134566|NCT00003605|DRUG|cyclophosphamide|
215134567|NCT03285802|DRUG|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
215134568|NCT03285802|DRUG|Everolimus|Everolimus 10mg daily q 28 days
215134569|NCT03402542|PROCEDURE|Cholecystectomy|Cholecystectomy
215134570|NCT05564949|OTHER|CKD|Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
215134571|NCT06262152|DIAGNOSTIC_TEST|Actigraphy, blood and salivary sample, and sleep evaluation|"* For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment.~* 7 days actigraph recording through wearing of Actiwatch spectrum plus at home~* Standardized sleep questionnaire administration"
214451074|NCT05462613|DRUG|Metronomic chemotherapies|"* Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months"
214451075|NCT05462613|DRUG|Aspirin|75 mg orally and daily during two months
214451076|NCT05462613|DRUG|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
215134572|NCT00818610|DRUG|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
215134573|NCT00818610|DRUG|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
215134574|NCT04038359|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) inhibitor
215134575|NCT05776017|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
215134576|NCT05776017|BIOLOGICAL|Anti-Rabies Vaccine|Control vaccine
215134577|NCT01281618|PROCEDURE|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
215134578|NCT05604040|BEHAVIORAL|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
215134579|NCT03717688|DRUG|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
215134580|NCT03717688|DRUG|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
215134581|NCT03717688|DRUG|Placebos|No treatment
215134582|NCT05123534|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.
215134583|NCT04915846|DRUG|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
215134584|NCT04915846|DRUG|Placebo|placebo comparator
215134585|NCT00703014|DRUG|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
215134586|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
215134587|NCT00703014|DRUG|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
214451077|NCT05462613|DRUG|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
214451078|NCT06084338|RADIATION|stereotactic ablative radiotherapy|Metastasis directed
214451079|NCT06084338|DRUG|Pluvicto|PSMA targeted radiopharmaceutical therapy
215134588|NCT00703014|DRUG|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
215134589|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
215134590|NCT00703014|DRUG|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
215134591|NCT00703014|BIOLOGICAL|hCG|In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
215134592|NCT00703014|BIOLOGICAL|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
215134593|NCT05816811|OTHER|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
215134594|NCT03366545|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
215134595|NCT03484130|DIETARY_SUPPLEMENT|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of \>180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
215134596|NCT03484130|DIETARY_SUPPLEMENT|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
215134597|NCT05983211|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks."
215134598|NCT05549219|DRUG|GLM101|GLM101 IV Infusion
214451080|NCT06084338|DRUG|topical testosterone|Topical testosterone 1.62% gel
214451081|NCT05366647|PROCEDURE|canaloplasty|canaloplasty ab interno with tensioning suture
214451082|NCT05366647|PROCEDURE|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
215134599|NCT06410027|OTHER|Pain Neuroscience Education + Virtual Reality + Therapeutic Exercise|Patients will receive 1-hour pain neuroscience education session + 30-minutes exposure to exercise with virtual reality + therapeutic exercise
215134600|NCT06410027|OTHER|Therapeutic Exercise|Patients will receive therapeutic exercise
215134601|NCT04535843|OTHER|Biomarkers and omics data|To detect disease-related biomarkers and omics data, in this prospective MG cohort.
215134602|NCT05121766|DRUG|Omega-3 (EPA+DHA)|"Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA."
215134603|NCT05121766|DRUG|Placebo|3 Soybean Oil Placebo capsules
214451083|NCT06126822|DRUG|Zabdeno® booster|A single Zabdeno® booster vaccination
214451084|NCT06126822|DRUG|Ervebo® booster|A single Ervebo® booster vaccination
214451085|NCT06095154|RADIATION|CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma|CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
214451086|NCT02339922|DRUG|Ixazomib Citrate|Given PO
214451087|NCT02339922|OTHER|Laboratory Biomarker Analysis|Correlative studies
214451088|NCT02339922|BIOLOGICAL|Rituximab|Given IV
214451089|NCT05508165|DEVICE|Stream Dx|home uroflowmetry device
214451090|NCT05508165|DEVICE|DFree|at home wearable bladder scanner
214451091|NCT05508165|DEVICE|TestCard|mobile urinalysis reader
214451092|NCT05672225|DRUG|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
214451093|NCT05672225|DRUG|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
214525804|NCT02525497|DEVICE|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
214451094|NCT06071884|DEVICE|Bridge Percutaneous Nerve Field Stimulator|The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
214451095|NCT05347472|OTHER|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
214451096|NCT05347472|OTHER|Sham Smartphone application|ham application that includes information and general advice about UI only
214451097|NCT04806594|DEVICE|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
214451098|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
214451099|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
214525805|NCT06292247|BEHAVIORAL|Cognitive behavioral therapy|CBT aims to treat anxiety by restructuring unfavorable beliefs and controlling negative thoughts so as to reduce dental anxiety.
215134604|NCT05574322|OTHER|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology"
215134605|NCT05574322|OTHER|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
215134606|NCT02893293|DRUG|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
215134607|NCT02893293|DEVICE|Magentic Resonance Imaging|Both arms will receive MRI
215134608|NCT03264274|DRUG|Aflibercept|Antiangiogenic
215134609|NCT03264274|PROCEDURE|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
215134610|NCT04325893|DRUG|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
215134611|NCT04325893|DRUG|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
215134612|NCT01579227|DEVICE|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
215134613|NCT01579227|DIETARY_SUPPLEMENT|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
215134614|NCT01579227|DEVICE|Tamoxifen Cream|Tamoxifen cream
214451100|NCT05914155|DRUG|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
214451101|NCT05914155|DRUG|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
214451102|NCT05914155|DRUG|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
214451103|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
214451104|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
214451105|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
214525806|NCT06292247|BEHAVIORAL|Auricular plaster therapy|APT involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect (e.g. reduce anxiety)
214525807|NCT06292247|BEHAVIORAL|Tell Show Do|TSD is composed of 3 phases. The Tell phase involves an age-appropriate explanation of the procedure. The Show phase is used to demonstrate a procedure up to the point where the instrument is performed. The Do phase is then initiated, and the treatment is performed.
214525808|NCT02080117|PROCEDURE|kidney transplantation, living or deceased donor|
214525809|NCT05223452|DEVICE|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
214525810|NCT03219788|DRUG|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
215134615|NCT01579227|DEVICE|Placebo cream|Placebo cream
215134616|NCT01579227|DIETARY_SUPPLEMENT|placebo capsule|placebo capsule
215134617|NCT01224119|DEVICE|Amplex|225 micrograms of B2A per cc of ceramic granules
215134618|NCT01224119|PROCEDURE|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
215134619|NCT01885156|DRUG|Naftin 1% Cream|Topically applied once a day
215134620|NCT01885156|DRUG|Placebo Cream|Topically applied once a day
215134621|NCT02970981|BIOLOGICAL|Nivolumab|
215134622|NCT02970981|BIOLOGICAL|Ipilimumab|
215134623|NCT01404169|DRUG|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
215134624|NCT01404169|DRUG|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
215134625|NCT04281615|OTHER|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
215134626|NCT06279741|BIOLOGICAL|Endotracheopulmonary Instillation, Suspension|"The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant."
215134627|NCT01059097|PROCEDURE|Pancreaticoduodenectomy|
215134628|NCT01033240|DRUG|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
215134629|NCT01033240|DRUG|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
215134630|NCT01033240|DRUG|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
215134631|NCT01033240|DRUG|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
215134632|NCT01033240|DRUG|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
215134633|NCT01033240|DRUG|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
215134634|NCT05123872|DEVICE|tDCS|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
215134635|NCT05468814|PROCEDURE|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
215134636|NCT05468814|PROCEDURE|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
214451106|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214451107|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
214451108|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
214451109|NCT03982160|DRUG|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
214451110|NCT03982160|OTHER|Placebo|Saline
214451111|NCT02312557|DRUG|Enzalutamide|Given PO
214451112|NCT02312557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214451113|NCT02312557|BIOLOGICAL|Pembrolizumab|Given IV
214451114|NCT04827875|DRUG|AIV001|Intradermal
214525811|NCT03219788|DRUG|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
215134637|NCT01773317|OTHER|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
215134638|NCT01773317|OTHER|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
215134639|NCT06107140|OTHER|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
215134640|NCT04396535|DRUG|Bintrafusp Alfa|Given IV
215134641|NCT04396535|DRUG|Docetaxel|Given IV
215134642|NCT05302674|OTHER|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
215134643|NCT02955589|DRUG|HBI-8000|Oral, twice weekly
215134644|NCT04716426|DRUG|Tetracycline hydrochloride 3%|Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
215134645|NCT04716426|DRUG|Placebo|Formulation composed of FDA approved inactive ingredients.
215134646|NCT02494193|OTHER|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
215134647|NCT02494193|OTHER|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
215134648|NCT02494193|OTHER|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
215134649|NCT02494193|OTHER|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
215134650|NCT02494193|OTHER|Definitive restoration|Definite restoration will be performed using composite.
215134651|NCT00551759|DRUG|5-Fluorouracil|given IV
215134652|NCT00551759|DRUG|Oxaliplatin|given IV
215134653|NCT00551759|DRUG|Cetuximab|given IV
215134654|NCT00551759|DRUG|Docetaxel|given IV
215134655|NCT00551759|PROCEDURE|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
214451115|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
214451116|NCT05448651|DRUG|UPB-101|Subcutaneous injection
215134656|NCT00551759|RADIATION|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
215134657|NCT03894488|DIAGNOSTIC_TEST|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
215134658|NCT02655848|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
215134659|NCT02655848|PROCEDURE|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
215134660|NCT02655848|PROCEDURE|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
215134661|NCT00588926|DRUG|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
215134662|NCT00723996|BEHAVIORAL|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
215134663|NCT05035524|DRUG|Sodium Bicarbonate Solution|Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
215134664|NCT05035524|DRUG|Placebo|Placebo
215134665|NCT02960217|DRUG|UX007|liquid for oral (PO) administration
215134666|NCT02960217|DRUG|Placebo|liquid safflower oil for PO administration
215134667|NCT03838185|DRUG|J147|Single oral dose of J147
215134668|NCT03838185|DRUG|Placebo|Single oral dose of corn oil
215134669|NCT00192933|PROCEDURE|NovoSeven treatment according to guideline|
215134670|NCT01182636|DRUG|Adapalene|0.1% Topical Gel
215134671|NCT01182636|DRUG|Differin®|0.1% Topical Gel
215134672|NCT01182636|DRUG|Placebo|Gel Base
215134673|NCT01774201|OTHER|Breathing exercises|Breathing exercises with positive expiratory pressure.
215134674|NCT01228279|OTHER|DIANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
215134675|NCT01228279|OTHER|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
215134676|NCT05167851|DRUG|Lazertinib , a combination group of SBRT|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
214451117|NCT05448651|DRUG|Placebo|Subcutaneous injection
214451118|NCT06258889|BEHAVIORAL|reward-focused intervention|"Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session."
215134677|NCT05167851|DRUG|Lazertinib single administration group|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
214525812|NCT03219788|DRUG|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
214525813|NCT01829685|DRUG|Entecavir, Adefovir|
215134678|NCT02919228|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
215134679|NCT02153268|PROCEDURE|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
215134680|NCT02411630|DRUG|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
215134681|NCT02244541|DRUG|ANAVEX2-73 Oral|
215134682|NCT02244541|DRUG|ANAVEX2-73 Intravenous|
215134683|NCT02244541|DRUG|ANAVEX2-73 Oral|30 mg hard gelatin capsule
215134684|NCT02244541|DRUG|ANAVEX2-73 Oral|50 mg hard gelatin capsule
215134685|NCT06309940|OTHER|Prognostic factors of surgical evacuation of basal ganglionic haemorrhage|Surgical evacuation of basal ganglionic haemorrhage
215134686|NCT00214045|DEVICE|Flexible Cystoscopy|
215134687|NCT00214045|DEVICE|Rigid Cystoscopy|
215134688|NCT06175676|DRUG|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
215134689|NCT06175676|DRUG|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
215134690|NCT06175676|DRUG|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
215134691|NCT00625131|DRUG|Nicotine|Delivered through transdermal nicotine patch
214451119|NCT06258889|BEHAVIORAL|cognitive flexibility intervention|"This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations."
214451120|NCT06258889|BEHAVIORAL|exposure|"All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions)."
214451121|NCT06258889|BEHAVIORAL|Psychoeducation|All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
214451122|NCT05652296|DEVICE|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
214451123|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
214451124|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
214451125|NCT00294242|PROCEDURE|Membrane Sweep|Weekly Membrane Sweep
214451126|NCT00294242|PROCEDURE|No Membrane Sweep|No Membrane Sweep
215134692|NCT00625131|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
215134693|NCT00625131|DRUG|Bupropion Sustained Release (SR)|Antidepressant
215134694|NCT00625131|DRUG|Placebo patch|Pre-treatment placebo transdermal patch
215134695|NCT01003301|DRUG|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
215134696|NCT01003301|DRUG|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
215134697|NCT04279886|OTHER|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
215134698|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
215134699|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
215134700|NCT00801736|DRUG|Cisplatin, Paclitaxel|"* Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1"
215134701|NCT03433937|DEVICE|Negative pressure wound therapy|Wound dressing
215134702|NCT03433937|OTHER|Micropore tape|Wound dressing
215134703|NCT02300207|DEVICE|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
215134704|NCT04604145|DIAGNOSTIC_TEST|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
215134705|NCT05367778|DRUG|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
215134706|NCT04107246|DEVICE|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
215134707|NCT01003808|BIOLOGICAL|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
214451127|NCT02361723|DRUG|BGB-290|
214451128|NCT02361723|DRUG|BGB-290|
214451129|NCT02361723|DRUG|BGB-290|
214451130|NCT02361723|DRUG|BGB-290|
214451131|NCT02361723|DRUG|BGB-290|
214451132|NCT05129969|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
214451133|NCT01415154|DEVICE|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
214708889|NCT02043236|BEHAVIORAL|Healthy bones pamphlet|written educational material
214451134|NCT06332352|BIOLOGICAL|PRP|Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
215134708|NCT04160182|BEHAVIORAL|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
215134709|NCT06491446|DRUG|ABI-2280|"Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered."
215134710|NCT01406886|BEHAVIORAL|Eating rate|
215134711|NCT04945083|OTHER|Experimental Nutritional Pudding|High Calorie, High Protein pudding
215134712|NCT01404039|BEHAVIORAL|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
215134713|NCT01404039|BEHAVIORAL|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
215134714|NCT01404039|BEHAVIORAL|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
215134715|NCT01404039|BEHAVIORAL|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
215134716|NCT01404039|DEVICE|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
215134717|NCT06162988|DRUG|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
215134718|NCT00953602|OTHER|Genetically modified potato|Genetically modified potato
215134719|NCT06230627|OTHER|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
215134720|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
215134721|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
215134722|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
215134723|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
215134724|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
215134725|NCT06593353|OTHER|Systems Analysis and Improvement Approach (SAIA)|SAIA an evidence-based, multi-prong, implementation strategy to improve systems thinking amongst frontline care teams to optimize care quality and continuity. The intervention includes monthly meetings where patient care cascades, process mapping and continuous quality improvement are used to identify bottlenecks and prioritize clinic based solutions.
214451135|NCT05410730|DRUG|SHR-1501|SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
215134726|NCT06665945|DIAGNOSTIC_TEST|Platelet RNA expression|The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.
215134727|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
215134728|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
214451136|NCT05351541|DRUG|Psilocybin therapy with Zolpidem and Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
214451137|NCT05351541|DRUG|Psilocybin therapy with Zolpidem|1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
214451138|NCT05351541|DRUG|Psilocybin therapy with Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
214451139|NCT05351541|DRUG|Psilocybin therapy with Placebo|1-30 mg (oral administration), and placebo (oral administration)
214708890|NCT02043236|BEHAVIORAL|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
215134729|NCT06051435|OTHER|lumbar proprioception training|"a) Sensorimotor training: Sensorimotor training and reconditioning of proprioceptive senses have recently been found to be helpful in increasing motor performance and coordination, muscle strength, sensorimotor abilities, increasing intermuscular control, and improving one's response to sensory information and muscle tone. Reconditioning of proprioceptive senses and sensorimotor training increases one's muscle adjustment ability, maximizes the sensory input in different parts of the body and aids in improving one's motor adjustment ability (Hwang et al ., 2013).~Position Exercise methods as Hollowing exercise: Participants will be asked to contract the abdominal muscles, raising the center of movement toward the navel in a quadruped position."
215134730|NCT06051435|OTHER|Hot packs|hot application in the form of hot packs on the lower abdomen and lower back for a total duration of 30 minutes, once per day, during the first two days of menstruation
215134731|NCT06051435|OTHER|Pelvic rocking exercise|Pelvic rocking exercise
215134732|NCT06599827|RADIATION|moderately hypofractionated radiotherapy|35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.
215134733|NCT06599827|DRUG|chemotherapy|CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
215134734|NCT06599827|DRUG|immunotherapy|Serplulimab 300 mg IV infusion on day 1 every 21 days.
214451140|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
214451141|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
214451142|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
214525814|NCT00719056|DRUG|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
214525815|NCT00719056|DRUG|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
215134735|NCT06599827|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
215134736|NCT05805020|PROCEDURE|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
215134737|NCT01869907|DRUG|Minocycline|100 mg once daily by mouth during 14 days
215134738|NCT01869907|DRUG|placebo|once daily by mouth during 14 days
215134739|NCT01869907|DRUG|Amitriptyline|25mg once daily by mouth during 14 days
215134740|NCT04449913|BEHAVIORAL|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
215134741|NCT04449913|BEHAVIORAL|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
215134742|NCT05183178|DRUG|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
215134743|NCT05183178|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
215134744|NCT03316092|DIAGNOSTIC_TEST|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
215134745|NCT00193336|DRUG|ZD1839|
214451143|NCT06797882|DRUG|Silver diamine fluoride- potassium iodide|SDF , Riva Star, SDI Limited., Australia
214451144|NCT06797882|DRUG|Fluoride varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd.
214451145|NCT06797882|OTHER|0.9 % saline|Standard oral hygiene instructions every 3 months and application of Normal Saline for every 6 months
214525816|NCT02713698|DRUG|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
214525817|NCT03999398|PROCEDURE|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
214525818|NCT01871597|DEVICE|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
214708891|NCT02043236|BEHAVIORAL|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
214451146|NCT04907695|DEVICE|I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700|All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
214451147|NCT05880979|BEHAVIORAL|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
214451148|NCT05880979|BEHAVIORAL|Regular well child care|Participants will receive their regularly scheduled well-child care
214525819|NCT05791305|BEHAVIORAL|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
215134746|NCT04748861|OTHER|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
215134747|NCT01766050|DRUG|Caffeine|
215134748|NCT01766050|DRUG|Losartan|
215134749|NCT01766050|DRUG|Omeprazole|
215134750|NCT01766050|DRUG|Dextromethorphan|
215134751|NCT01766050|DRUG|Midazolam|
215134752|NCT01766050|BIOLOGICAL|Belatacept|
215134753|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
215134754|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
215134755|NCT06349798|DRUG|NaCl 0.9%|50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
215134756|NCT03991780|DRUG|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
215134757|NCT03057093|OTHER|Non interventional study|retrospective noninterventional study
215134758|NCT02361385|OTHER|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
215134759|NCT03577275|DRUG|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
215134760|NCT03577275|DRUG|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
215134761|NCT03577275|DRUG|Moxifloxacin 400mg|Active comparator with known effect on QT interval
215134762|NCT03577275|DRUG|NST-4016 2000mg|Supratherapeutic dose of NST-4016
215134763|NCT04464863|OTHER|Kinematic metrics|kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
215134764|NCT02299596|OTHER|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
215134765|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
214451149|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
214451150|NCT05838183|DIAGNOSTIC_TEST|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
214451151|NCT05285618|DEVICE|Argus II|Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
214451152|NCT00170573|DRUG|Caelyx|40 mg/m² biweekly
214525820|NCT01918943|DEVICE|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
214525821|NCT01400217|DRUG|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
214708892|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
214708893|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
215134766|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
215134767|NCT00782535|DRUG|Placebo|Inhaled solution, single dose of placebo
215134768|NCT05866666|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
215134769|NCT03609645|PROCEDURE|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
215134770|NCT03609645|PROCEDURE|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
215134771|NCT01941485|DEVICE|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
215134772|NCT01941485|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
215134773|NCT03889808|DIAGNOSTIC_TEST|Determination of serum anti-toxin Abs for C. difficile|
215134774|NCT01873937|RADIATION|Red LED|Phototherapy with red LED on temporomandibular area
215134775|NCT01873937|RADIATION|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
215134776|NCT01873937|RADIATION|LASER|Phototherapy with LASER INFRARED on temporomandibular area
215134777|NCT00576706|DRUG|Rebamipide|Rebamipide 100㎎, 12 weeks
215134778|NCT00576706|DRUG|Misoprostol|Misoprostol 200㎍ 12 weeks
215134779|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134780|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134781|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134782|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134783|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134784|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
215134785|NCT00089297|BIOLOGICAL|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
215134786|NCT00089297|DRUG|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
215134787|NCT00089297|DRUG|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
214451153|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
214451154|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
214525822|NCT01400217|DRUG|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
214451155|NCT06789003|OTHER|Adapted exercises|"Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale."
214451156|NCT06789003|OTHER|No intervention|Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.
214451157|NCT06789003|BEHAVIORAL|Quality of Life questionnaire|QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
214451158|NCT06789003|BEHAVIORAL|Questionnaire of Fatigue|Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
214451159|NCT06789003|BEHAVIORAL|Physical activity questionnaire|Questionnaire (IPAQ) at baseline and after transplantation
214451160|NCT06789003|BEHAVIORAL|Physical condition|Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
214451161|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
214451162|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
214451163|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
214451164|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
214451165|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
214451166|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
214451167|NCT06487858|DRUG|BGB-R046|Intravenous administration
214451168|NCT06487858|DRUG|Tislelizumab|Intravenous administration
214525823|NCT06153901|PROCEDURE|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
215134788|NCT00089297|RADIATION|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
214451169|NCT04048304|DRUG|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
214451170|NCT06368570|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery with neuraxial anesthetic
214451171|NCT04556656|DRUG|Pridopidine|Pridopidine hard gelatin capsule
214451172|NCT04556656|DRUG|Placebo|Pridopidine-matching placebo hard gelatin capsule
214451173|NCT05722704|PROCEDURE|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
214708894|NCT03188432|DRUG|Carboplatin|Given IV and IP
214708895|NCT03188432|OTHER|Quality-of-Life Assessment|Ancillary studies
215134789|NCT01414868|DRUG|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
215134790|NCT05493202|DEVICE|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
214451174|NCT05722704|PROCEDURE|Occlusal reduction|Reduction of the functional and non-functional cusps
214451175|NCT06069713|BEHAVIORAL|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
214451176|NCT04876222|PROCEDURE|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
215134791|NCT06486025|DRUG|maintenance magnesium sulphate1g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
215134792|NCT06486025|DRUG|maintenance magnesium sulphate2g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
215134793|NCT00403377|BEHAVIORAL|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
215134794|NCT04432935|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
215134795|NCT04432935|OTHER|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
215134796|NCT05731583|DEVICE|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
215134797|NCT01910285|DRUG|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
214451177|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
214451178|NCT05655325|OTHER|Attention control|Health education and stretching
214525824|NCT04520620|DRUG|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
214525825|NCT04520620|DEVICE|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
214525826|NCT03575572|DRUG|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
214708896|NCT03188432|OTHER|Questionnaire Administration|Ancillary studies
214451179|NCT06555848|DEVICE|CERAMENT G|CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
214451180|NCT05886335|DRUG|Cyclophosphamide|Time of administration
214451181|NCT06286137|OTHER|Listening to music for 1 minute|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 19 minutes before the 1 minute music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
215134798|NCT01910285|DRUG|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
215134799|NCT03270436|BEHAVIORAL|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
215134800|NCT03270436|BEHAVIORAL|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
215134801|NCT02825693|PROCEDURE|Conventional cataract surgery (phacoemulsification)|
215134802|NCT02825693|PROCEDURE|Femtosecond laser assisted cataract surgery|
215134803|NCT02030808|DRUG|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
215134804|NCT02030808|DRUG|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
215134805|NCT03887923|BEHAVIORAL|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
215134806|NCT03406377|DRUG|OPK-88003|OPK-88003 subcutaneous injection
215134807|NCT03406377|DRUG|Placebo|Placebo subcutaneous injection
215134808|NCT02900729|DEVICE|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
215134809|NCT02900729|DRUG|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
215134810|NCT00368888|DEVICE|Urine collection bag for infants|
215134811|NCT03400735|COMBINATION_PRODUCT|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
215134812|NCT03400735|DRUG|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
215134813|NCT03612817|DRUG|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
215134814|NCT03481088|PROCEDURE|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
215134815|NCT04475458|PROCEDURE|Ultrasound-guided dorsal penile nerve block|This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
215134816|NCT02167971|OTHER|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
215134817|NCT02167971|OTHER|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
215134818|NCT02273479|DRUG|Asasantin®|Asasantin® extended release (RAD-SP)
215134819|NCT02273479|DRUG|Placebo|
215134820|NCT04521790|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
215134821|NCT01806441|OTHER|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
215134822|NCT01806441|OTHER|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
215134823|NCT04530617|DRUG|Camostat Mesilate|Tablets
215134824|NCT04530617|DRUG|Artemisia Annua Leaf|Tea bags
214451182|NCT06286137|OTHER|Listening to music for 5 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 15 minutes before the 5 minutes music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
214451183|NCT06286137|OTHER|Listening to music for 20 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 20 minutes through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels.
214451184|NCT06286137|OTHER|Not listening to music|Participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones), for a duration of 20 minutes.
214525827|NCT03127475|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
214525828|NCT01745445|OTHER|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
215134825|NCT02088008|DRUG|cinidipine, valsartan|
215134826|NCT03742076|DIETARY_SUPPLEMENT|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
215134827|NCT03742076|DIETARY_SUPPLEMENT|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
215134828|NCT03742076|DIETARY_SUPPLEMENT|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
215134829|NCT06207591|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
215134830|NCT01910298|PROCEDURE|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
215134831|NCT01910298|PROCEDURE|Two Stage Breast Reconstruction|
215134832|NCT01364896|PROCEDURE|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing"
215134833|NCT00717574|DRUG|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
215134834|NCT00717574|DRUG|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
214451185|NCT06798584|DIETARY_SUPPLEMENT|FeoSol Original Iron Supplement Tablets|325 mg of ferrous sulfate containing 65 mg of elemental iron
214451186|NCT06798584|DIETARY_SUPPLEMENT|21st Century Gelatin Capsules|600 mg
214451187|NCT06799949|DIAGNOSTIC_TEST|ROTEM (TEM Innovations GmbH, Munich, Germany) assay|For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery, during the placement of the arterial line (Start ratio), and another one, at the end, during the completion of the surgical wound closure (Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specific empty coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.
214451188|NCT05118867|BEHAVIORAL|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
214451189|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
214451190|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
214451191|NCT05846451|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
214451192|NCT05846451|DRUG|Oxycodone|Immediate-release oral tablet, 10 mg
214525829|NCT04405089|DEVICE|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
214525830|NCT04405089|DEVICE|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
215134835|NCT06357481|PROCEDURE|Endodontic Retreatment|A single operator procedured in one visit of non-surgical endodontic retreatment. Teeth were anesthetized using articaine hydrochloride with epinephrine 1:200,000 for mandibulary premolar teeth with one root canal. Each tooth was isolated with a rubber dam and then coronal restorations and caries were removed using sterile high-speed burs under water cooling. After preperation of the cavity access and localization of the canal orifice, all microorganisms that may have entered the root canal system are eliminated by removing the old canal filling with the One Flare and MicroMega REMOVER files in the MicroMega retreatment kit.
215134836|NCT03037385|DRUG|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
215134837|NCT00144547|DRUG|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
215134838|NCT01977547|BIOLOGICAL|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
215134839|NCT04058938|BEHAVIORAL|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
215134840|NCT04058938|BEHAVIORAL|Control|Standard patient counseling
215134841|NCT02535481|DEVICE|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
215134842|NCT02535481|PROCEDURE|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
215134843|NCT02130817|DRUG|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
215134844|NCT02130817|DRUG|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
215134845|NCT02130817|PROCEDURE|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
215134846|NCT02130817|DRUG|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
214525831|NCT00179478|DRUG|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
215134847|NCT02130817|DRUG|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
215134848|NCT02130817|DRUG|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
215134849|NCT01195766|DRUG|Ofatumumab|Ofatumumab in addition with ESHAP therapy
215134850|NCT00294450|DEVICE|Fistula Pouching System|3 different sizes of fistula pounching system
215134851|NCT05165771|DRUG|GS-5718|Tablets administered orally
215134852|NCT05165771|DRUG|GS-5718|Tablets administered orally
215134853|NCT05165771|DRUG|Placebo to match GS-5718|Tablets administered orally
215134854|NCT05165771|DRUG|Tofacitinib 5 mg|Tablets administered orally
214451193|NCT03498651|BEHAVIORAL|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
214451194|NCT03498651|BEHAVIORAL|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
215134855|NCT05165771|DRUG|Placebo to match Tofacitinib|Tablets administered orally
214451195|NCT03498651|BEHAVIORAL|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
214451196|NCT05784857|OTHER|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
214451197|NCT05930821|BEHAVIORAL|Aerobic and Resistance Exercise Program (GEMS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
214451198|NCT05930821|BEHAVIORAL|Flexibility and Stretching Program (FLEX-MS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~* Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program."
214451199|NCT06639841|DEVICE|Virtual Reality Psychotherapy|"Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies."
214525832|NCT00412802|DRUG|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
214525833|NCT00412802|DRUG|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
214525834|NCT02328209|DRUG|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
214525835|NCT02217098|PROCEDURE|GIC Restorations|Restorations using Glass Ionomer Cement
214525836|NCT02217098|PROCEDURE|Carbomer Restorations|Restorations using Glass Carbomer
214525837|NCT02217098|PROCEDURE|Compomer Restorations|Restorations using Compomer
214525838|NCT01384916|BEHAVIORAL|Yoga|2x weekly
215134856|NCT02783534|DEVICE|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
215134857|NCT02783534|DEVICE|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
215134858|NCT02783534|BEHAVIORAL|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
214525839|NCT01384916|BEHAVIORAL|Healthy Living Workshop|2x weekly
214525840|NCT00843245|OTHER|No intervention|No intervention
214708897|NCT03188432|PROCEDURE|Cytoreductive Surgery|Undergo CRS
214708898|NCT00698035|DRUG|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
215134859|NCT03915197|DIAGNOSTIC_TEST|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
215134860|NCT05119647|DEVICE|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
215134861|NCT04434482|DRUG|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
215134862|NCT01838694|BIOLOGICAL|Ala-Cpn10|
215134863|NCT01838694|DRUG|Placebo|
214451200|NCT06639841|BEHAVIORAL|Yoga|"The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness."
215134864|NCT00055393|DRUG|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
215134865|NCT00055393|DRUG|Placebo|21 subjects received Placebo.
215134866|NCT00672555|PROCEDURE|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
215134867|NCT03623243|DRUG|Siponimod|Siponimod 2mg tablets taken once daily
215134868|NCT04623788|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with contrast
215134869|NCT06031519|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
215134870|NCT04540185|BIOLOGICAL|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
215134871|NCT04540185|BIOLOGICAL|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
215134872|NCT04540185|DRUG|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
214451201|NCT06643000|DRUG|furmonertinib|furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
214451202|NCT06640361|DRUG|Olverembatinib|Oral administration with meal, QOD, every 28 days for a cycle.
214451203|NCT06479187|DRUG|18F-rhPSMA-7.3|radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.
214451204|NCT06479187|DEVICE|PET/CT|Diagnostic imaging test
214451205|NCT05323084|DIETARY_SUPPLEMENT|Dietary supplement|1 week of each intervention at bedtime with a 2-week washout period in between interventions
214451206|NCT06513559|DEVICE|Anatomic total shoulder replacement|Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
214451207|NCT06513559|DEVICE|Reverse total shoulder replacement|Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
214451208|NCT03311503|BIOLOGICAL|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
215134873|NCT04540185|DRUG|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
215134874|NCT04540185|COMBINATION_PRODUCT|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
215134875|NCT04540185|COMBINATION_PRODUCT|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
215134876|NCT02767817|PROCEDURE|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
215134877|NCT02767817|BIOLOGICAL|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
215134878|NCT02767817|BIOLOGICAL|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
214451209|NCT06261775|OTHER|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
214451210|NCT06261775|OTHER|No meat diet|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
214525841|NCT04370392|PROCEDURE|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
215134879|NCT01011998|DRUG|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
215134880|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
215134881|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
215134882|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
215134883|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
215134884|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
215134885|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
215134886|NCT03904017|OTHER|Oxygen|100% Oxygen air
215134887|NCT03904017|OTHER|placebo|medical air
215134888|NCT04800965|BEHAVIORAL|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
215134889|NCT04800965|BEHAVIORAL|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
215134890|NCT04800965|BEHAVIORAL|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
214451211|NCT04382404|DRUG|Sofosbuvir-Velpatasvir Drug Combination|One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
214451212|NCT05092139|DEVICE|endovascular treatment|all enrolled patients must receive endovascular treatment
214451213|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
214451214|NCT06251258|DIAGNOSTIC_TEST|Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)|Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)
214451215|NCT03587363|DRUG|Erdafitinib|Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
214451216|NCT05102409|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
214451217|NCT05102409|DRUG|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
214451218|NCT02960893|DRUG|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
214451219|NCT02960893|DRUG|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
214451220|NCT02960893|DRUG|Troriluzole|Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
214451221|NCT04951492|DRUG|Olaparib|Given PO
214451222|NCT05691738|OTHER|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
214451223|NCT05691738|OTHER|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
214451224|NCT05279898|DEVICE|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
214451225|NCT05279898|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
214451226|NCT05279898|DRUG|Ketamine|Intraoperative infusion
214451227|NCT05279898|DRUG|Remifentanil|Intraoperative infusion
214451228|NCT05279898|DRUG|Dexmedetomidine|Intraoperative infusion
214451229|NCT05279898|DRUG|Rocuronium|Intraoperative intermittent bolus
214451230|NCT05279898|DRUG|Propofol|Intraoperative infusion
214525842|NCT04028128|DIETARY_SUPPLEMENT|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
214525843|NCT04028128|DIETARY_SUPPLEMENT|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
214708899|NCT00698035|DRUG|Estring|2mg ring inserted vaginally once every 12 weeks
215134891|NCT00555958|DEVICE|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
215134892|NCT05685914|PROCEDURE|endoscopic surgery|Emergency or elective surgery
215134893|NCT02153086|DRUG|Ramelteon|Ramelteon tablets 8 mg
215134894|NCT04953494|DIAGNOSTIC_TEST|Patient information collection, exon sequencing and follow-up.|Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
215134895|NCT04457297|DRUG|trifluridine and tipiracil|Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
215134896|NCT04457297|DRUG|Placebo|Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
215134897|NCT02859220|OTHER|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
214525844|NCT05174988|PROCEDURE|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
215134898|NCT02859220|OTHER|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
215134899|NCT04386304|DRUG|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
215134900|NCT00446849|DRUG|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
215134901|NCT03954366|DRUG|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
215134902|NCT03954366|DRUG|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
215134903|NCT03954366|DRUG|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
215134904|NCT00904943|DRUG|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
215134905|NCT00904943|DRUG|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
215134906|NCT05560477|DRUG|AM3101|Injectable drug product.
215134907|NCT05560477|DRUG|Saline Placebo|2 mL 0.9% normal saline
215134908|NCT04456127|PROCEDURE|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
215134909|NCT03446794|OTHER|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
215134910|NCT05158270|PROCEDURE|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
215134911|NCT05158270|PROCEDURE|Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block|Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
215134912|NCT05158270|OTHER|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
214451231|NCT05989035|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|"Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory."
214451232|NCT05677880|OTHER|Study Procedures|"Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw"
214451233|NCT05687916|DRUG|Placebo|TAK-861 placebo matching tablets.
214451234|NCT05687916|DRUG|TAK-861 2 mg|TAK-861 2 mg tablets.
214451235|NCT05687916|DRUG|TAK-861 2 mg and 5 mg|TAK-861 2 mg and 5 mg tablets.
214451236|NCT05502861|BEHAVIORAL|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
214451237|NCT05502861|BEHAVIORAL|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
214451238|NCT05629182|OTHER|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
214451239|NCT06200259|RADIATION|Spot Delete planning for proton therapy|The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy
214451240|NCT06200259|RADIATION|Traditional proton treatment planning system|In the control arm, the proton spots placed by the treatment planning system are not modified.
214451241|NCT01781338|OTHER|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
214451242|NCT04614909|DRUG|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
214451243|NCT04614909|DRUG|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
214451244|NCT04614909|RADIATION|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
214708900|NCT06198075|OTHER|Control Group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
214708596|NCT05958615|BEHAVIORAL|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
215134913|NCT00023959|DRUG|hydroxyurea|Given orally
215134914|NCT00023959|DRUG|fluorouracil|Given IV
215134915|NCT00023959|BIOLOGICAL|bevacizumab|Given IV
215134916|NCT00023959|RADIATION|radiation therapy|Undergo radiotherapy
215134917|NCT00023959|BIOLOGICAL|filgrastim|Given subcutaneously
215134918|NCT00023959|OTHER|laboratory biomarker analysis|Correlative studies
215134919|NCT04829201|PROCEDURE|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
215134920|NCT05546476|DRUG|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
215134921|NCT05546476|DRUG|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
215134922|NCT02012439|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
215134923|NCT02012439|BEHAVIORAL|Cognitive Therapy|
215134924|NCT04013997|DEVICE|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
215134925|NCT03480048|BEHAVIORAL|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
215134926|NCT06397079|BEHAVIORAL|Electric toothbrush|Teach Bass brushing technique and bursh teeth using electric toothbrush dental hygiene three times a day.
215134927|NCT06397079|BEHAVIORAL|Soft bristle toothbrush|Teach Bass brushing technique and bursh teeth using soft bristle toothbrush dental hygiene three times a day.
215134928|NCT03301311|OTHER|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
215134929|NCT03301311|OTHER|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
215134930|NCT04141605|DEVICE|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
215134931|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
215134932|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
215134933|NCT00807911|DRUG|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
215134934|NCT00807911|DRUG|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
215134935|NCT00642200|PROCEDURE|Lichtenstein hernioplasty|
215134936|NCT00642200|PROCEDURE|Laparoscopic TEP|
215134937|NCT02102646|DRUG|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
215134938|NCT02102646|PROCEDURE|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
214451245|NCT04614909|DRUG|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
214451246|NCT05830929|PROCEDURE|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
214451247|NCT05391906|OTHER|Diffusion-weighted magnetic resonance imaging|Diffusion-weighted magnetic resonance imaging
215134939|NCT01325077|OTHER|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
215134940|NCT06177496|PROCEDURE|local ablation|treatment of HCC
215134941|NCT06177496|PROCEDURE|TACE|treatment of HCC
215134942|NCT06177496|DRUG|Sorafenib|treatment of HCC
215134943|NCT02953652|DRUG|HBI-8000|Orally twice weekly
214451248|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
214451249|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
214451250|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
214451251|NCT05134636|OTHER|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
214451252|NCT01701843|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
214451253|NCT01701843|DRUG|Placebo|Twice daily topical treatment for 14 days
214525845|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
214525846|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
214525847|NCT02845557|OTHER|OGTT and IVGTT tests|
215134944|NCT06360302|DIAGNOSTIC_TEST|Exercise test|"Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes."
215134945|NCT06360302|DIAGNOSTIC_TEST|Blood sample|"A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements"
215134946|NCT06360302|DIAGNOSTIC_TEST|Impedancemetry|measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
215134947|NCT06571253|BEHAVIORAL|Digital Exercise Intervention|Participants in this intervention arm used the Fiziu Digital Physiotherapy Platform. This digital platform provided a structured 6-week corrective exercise program through visual and auditory-guided videos. The intervention included interactive features such as reminders and progress tracking to enhance adherence and engagement.
215134948|NCT06571253|BEHAVIORAL|Paper-Based Exercise Intervention|Participants in this intervention arm followed a traditional paper-based exercise program. This included printed exercise instructions and illustrations for a 6-week period. The program was designed to mimic standard physical therapy exercises without digital support.
215134949|NCT06350032|DRUG|preservative-free parenteral treprostinil|Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
215134950|NCT05081908|PROCEDURE|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
215134951|NCT02570178|OTHER|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
215134952|NCT01571102|BEHAVIORAL|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
215134953|NCT01571102|BEHAVIORAL|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
215134954|NCT00020800|BIOLOGICAL|rituximab|
214451254|NCT05155007|DRUG|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
214451255|NCT05155007|DRUG|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
214451256|NCT04488133|DRUG|Nusinersen|Administered as specified in the treatment arm.
214451257|NCT04977024|BIOLOGICAL|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
214451258|NCT04977024|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
215134955|NCT00020800|DRUG|fludarabine phosphate|
215134956|NCT06009939|OTHER|Occlusion of the circulation in the arm and foot|A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
214451259|NCT04977024|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
215134957|NCT01950182|DRUG|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
214451260|NCT05443737|BEHAVIORAL|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
215134958|NCT01950182|DRUG|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
215134959|NCT05671146|DEVICE|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
215134960|NCT05671146|OTHER|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
215134961|NCT05671146|OTHER|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
214451261|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
214451262|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
214451263|NCT06082921|BEHAVIORAL|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
214451264|NCT06082921|BEHAVIORAL|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
214451265|NCT01293383|DRUG|LEO 90105|Ointment
214451266|NCT06582966|DRUG|Doxycyclin|Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
214451267|NCT05983185|BEHAVIORAL|Prism adaptation therapy|The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
214451268|NCT04528004|DRUG|Nicotinamide riboside|Nicotinamide riboside 250mg capsules
214451269|NCT04528004|OTHER|Placebo|Matching placebo 250mg capsules
214451270|NCT06156280|DRUG|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
215134962|NCT03868423|DRUG|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
214451271|NCT06156280|DRUG|Placebo injection|Placebo comparator
214451272|NCT04757194|DIAGNOSTIC_TEST|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
214451273|NCT02685020|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
214451274|NCT02685020|BIOLOGICAL|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
214451275|NCT02685020|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
214451276|NCT05425992|OTHER|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
214451277|NCT04646460|BEHAVIORAL|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
214451278|NCT04646460|BEHAVIORAL|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
214525848|NCT03771573|OTHER|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
214525849|NCT03771573|OTHER|monitoring|the patients will be under monitoring to investigate the evolution of the disease
214525850|NCT03987672|DIETARY_SUPPLEMENT|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
214708597|NCT05844865|OTHER|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
214708598|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
214708599|NCT06025396|DRUG|Cohort 1 - TMP-301|50 mg BID Fasted
214708600|NCT06025396|DRUG|Placebo|Multiple ascending dose comparator
215134963|NCT03868423|OTHER|Laboratory Biomarker Analysis|Correlative studies
215134964|NCT03868423|OTHER|Quality-of-Life Assessment|Ancillary studies
215134965|NCT03868423|OTHER|Questionnaire Administration|Ancillary studies
215134966|NCT02135861|PROCEDURE|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
215134967|NCT02135861|OTHER|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
214708601|NCT06025396|DRUG|Cohort 2 - TMP-301|50 mg QD Fasted
215134968|NCT05680714|OTHER|Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention|
215134969|NCT04636125|DRUG|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
215134970|NCT03780452|DEVICE|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
215134971|NCT03609073|DEVICE|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
215134972|NCT06225128|OTHER|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, Day of post-cycle 1 and post-cycle 6 evaluation.
215134973|NCT06225128|OTHER|Bone marrow specimens|"Additional volume of 2mL (EDTA)~* at screening for correlative studies,at Day 7 for smears and for correlative studies.~* Post-cycle 1 and post-cycle 6 evaluations for correlative studies.~Optionnal :~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
215134974|NCT04935346|OTHER|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
215134975|NCT03820843|OTHER|Art therapy and standard orthophonic rehabilitation|In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
215134976|NCT00854750|DRUG|ACTHAR|SQ weekly injections
215134977|NCT00854750|DRUG|ACTHAR|SQ weekly injections
215134978|NCT00854750|DRUG|ACTHAR|SQ weekly injections
215134979|NCT00854750|DRUG|ACTHAR|SQ weekly injection
215134980|NCT05321901|OTHER|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
215134981|NCT05321901|OTHER|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
215134982|NCT03130738|DRUG|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
215134983|NCT03130738|DRUG|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
215134984|NCT03130738|DRUG|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
215134985|NCT02704325|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
215134986|NCT02704325|OTHER|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
215134987|NCT03516123|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
215134988|NCT03063528|BEHAVIORAL|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
215134989|NCT03063528|BEHAVIORAL|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
215134990|NCT06205836|DRUG|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
215134991|NCT06205836|DRUG|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
215134992|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 1
214708602|NCT06025396|DRUG|Cohort 3 - TMP-301|50 mg QD Fed
214708603|NCT06025396|DRUG|Cohort 4 - TMP-301|25 mg QD Fed
215134993|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 2
215134994|NCT06310876|DRUG|Placebo|• single oral dose
215134995|NCT06310876|DRUG|Moxifloxacin 400mg|• single oral dose
215134996|NCT06433791|DRUG|Ascorbate-Meglumine|Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
215134997|NCT03098641|PROCEDURE|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
215134998|NCT02775188|DEVICE|interACTION|
215134999|NCT02775188|OTHER|Standard of Care Physical Therapy|
215135000|NCT00809263|DRUG|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
215135001|NCT02490683|DIETARY_SUPPLEMENT|Luna Rich X|
214525851|NCT04869046|DRUG|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
214525852|NCT04203368|DRUG|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
215135002|NCT02490683|DIETARY_SUPPLEMENT|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
215135003|NCT02490683|DIETARY_SUPPLEMENT|Reliv Now|
215135004|NCT03502005|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
215135005|NCT03115944|DEVICE|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
215135006|NCT05272007|PROCEDURE|EUS-biliary drainage|EUS-GBD with LAMS
215135007|NCT04771156|DRUG|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
215135008|NCT04771156|DRUG|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
215135009|NCT06230575|PROCEDURE|erector spinae block|Erector spinae plane block
215135010|NCT06230575|PROCEDURE|retrolaminar block|Retrolaminar block
215135011|NCT06230575|PROCEDURE|serratus anterior block|Serratus anterior plane block
215135012|NCT06230575|PROCEDURE|pectoral nerve block|Pectoral nerve block
215135013|NCT04768504|DRUG|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
215135014|NCT03546309|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214525853|NCT04203368|DRUG|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
214525854|NCT00557154|DEVICE|ultrasound|ultrasound used to identify target vein
214525855|NCT00557154|DEVICE|standard technique for venipuncture|routine equipment
215135015|NCT03546309|OTHER|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists
215135016|NCT05219825|BEHAVIORAL|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
215135017|NCT01440959|DRUG|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
215135018|NCT03814811|DIAGNOSTIC_TEST|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
215135019|NCT03796728|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
215135020|NCT00000928|BEHAVIORAL|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
215135021|NCT02157818|DRUG|midazolam|
215135022|NCT02157818|DRUG|Dexmedetomidine|
215135023|NCT00333775|DRUG|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
215135024|NCT00333775|DRUG|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
215135025|NCT00333775|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
215135026|NCT05214534|OTHER|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
215135027|NCT04156841|DIAGNOSTIC_TEST|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
215135028|NCT04156841|PROCEDURE|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
215135029|NCT00178295|RADIATION|Radiation Therapy|standard of care for the cancer being treated
215135030|NCT03284463|DRUG|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
215135031|NCT03284463|DRUG|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
215135032|NCT03926208|PROCEDURE|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
215135033|NCT03926208|PROCEDURE|Clorhexadine scrub|Clorhexadine scrub (standard of care).
215135034|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
214451279|NCT04646460|BEHAVIORAL|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
214451280|NCT04646460|BEHAVIORAL|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
214451281|NCT06582160|OTHER|Risk-Based Pre-conception Screening|A long form questionnaire screening questionnaire administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
215135035|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 of a 21-day cycle.
215135036|NCT02968134|DRUG|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
215135037|NCT04623346|PROCEDURE|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
215135038|NCT03162926|COMBINATION_PRODUCT|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
215135039|NCT03197298|DRUG|Clopidogrel|
215135040|NCT03197298|DRUG|Ticagrelor|
214451282|NCT06582160|OTHER|Patient-centered Pre-conception Screening|A short form, 2 question screening administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
214451283|NCT05938166|DEVICE|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
214451284|NCT05938166|OTHER|video-based oral hygiene education course|50-minute video-based oral hygiene education course
214451285|NCT06790030|BEHAVIORAL|CBT-T|cognitive behavioral therapy-ten :
214451286|NCT06789718|DIETARY_SUPPLEMENT|GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose)|75 participants will be randomized into the study product group.
214451287|NCT06789718|OTHER|Placebo|75 participants will be randomized into the placebo group.
214451288|NCT06789718|DIAGNOSTIC_TEST|Optional Sub-Study: Neurotransmitter Urine Test|20 participants who opt-in to the sub-study will provide urine tests during baseline, day 2, day 4, day 7, day 14, day 28, and day 42 while simultaneously participating in the main-study.
214451289|NCT06238531|DRUG|Gusacitinib|An orally active dual SYK/JAK kinase inhibitor
214525856|NCT00157209|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
214525857|NCT00157209|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
214525858|NCT00157209|OTHER|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
215135041|NCT01402089|DRUG|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
214451290|NCT06311253|OTHER|Emoform Glic Toothpaste|Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
214451291|NCT06311253|OTHER|Emoform Glic Mouthwash|Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
214451292|NCT04665310|DRUG|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
214451293|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
214525859|NCT06647108|DIETARY_SUPPLEMENT|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium
214525860|NCT06647108|OTHER|Placebo|Placebo
214525861|NCT00725127|DRUG|aspirin|100 mg/day upon awakening for five years
214451294|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
214451295|NCT06800352|OTHER|Control|The degree of diaper dermatitis of the babies will be evaluated before and after the procedure (72 hours after the first procedure) by using the 'Uncomplicated Diaper Dermatitis Severity Rating Scale in Babies (UNDDCS)'. Mothers will be asked to diaper their babies with cotton wool soaked with clear water.
214451296|NCT06385938|DIAGNOSTIC_TEST|Ultrasound with quantitative vibro-acoustic assessment|Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
214525862|NCT00725127|DRUG|aspirin|100 mg/day at bedtime for five years
214525863|NCT02618200|DEVICE|3D prostate ultrasound|
215135042|NCT01402089|DRUG|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
215135043|NCT01402089|DRUG|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
215135044|NCT01402089|DRUG|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
215135045|NCT01383928|DRUG|Ixazomib|Ixazomib capsules
215135046|NCT01383928|DRUG|Lenalidomide|Lenalidomide capsules
215135047|NCT01383928|DRUG|Dexamethasone|Dexamethasone Tablets
215135048|NCT00367822|DRUG|Lisuride|
215135049|NCT00367822|DRUG|Ropinirole|
215135050|NCT00367822|DRUG|Placebo|
215135051|NCT06562205|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
214451297|NCT06777251|OTHER|"analysis of predictive factors of IF in patients with Crohn's disease through the characterization of multiomics parameters"|"The study includes an initial evaluation in which faecal samples will be collected, a blood sample will be taken and an ileocolonoscopy with biopsies will be performed (additional biopsy in conjunction with a biopsy from clinical practice for study-specific analyses).~Patients will then be reevaluated nine months after the initial evaluation. In particular, fecal, blood and additional biopsy samples will be collected in conjunction with clinical practice biopsy and all treatment modifications will be recorded."
215135052|NCT06562205|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
215135053|NCT04742491|DRUG|Immediate Intervention Arm Truvada in the US|Truvada in the United States
215135054|NCT04742491|DRUG|Deferred Intervention Arm Truvada in the US|Truvada in the United States
215135055|NCT04742491|DRUG|Immediate Intervention Arm Truvada in Brazil|Truvada in Brazil
215135056|NCT04742491|DRUG|Deferred Intervention Arm Truvada in Brazil|Truvada in Brazil
215135057|NCT04742491|DRUG|Immediate Intervention Arm Descovy in the US|Descovy in the United States
214451298|NCT06221059|DRUG|HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo|Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
214451299|NCT04336436|BEHAVIORAL|Mindfulness training|Mindfulness training
214451300|NCT04336436|BEHAVIORAL|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
214451301|NCT02421185|DRUG|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
214451302|NCT02682342|OTHER|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
214451303|NCT05697198|DIAGNOSTIC_TEST|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
214451304|NCT06351839|BEHAVIORAL|Sleep-Well despite persistent pain|The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).
214451305|NCT06351839|BEHAVIORAL|TAU (treatment-as-usual)|The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
214525864|NCT04536779|OTHER|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
214525865|NCT02521025|OTHER|Intermittent feeding pattern|Intermittent feeding
215135058|NCT04742491|DRUG|Deferred Intervention Arm Descovy in the US|Descovy in the United States
215135059|NCT05924984|DEVICE|perforator locator|During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
215135060|NCT00212108|DRUG|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
215135061|NCT01254136|DRUG|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
214451306|NCT02797275|DRUG|Albuterol|Beta agonist respiratory inhaler
214451307|NCT02797275|DRUG|Placebo|respiratory inhaler with no medication
214451308|NCT04094688|DRUG|Bevacizumab|Given IV
214451309|NCT04094688|DRUG|Oxaliplatin|Given IV
214451310|NCT04094688|DRUG|Leucovorin Calcium|Given IV
214451311|NCT04094688|DRUG|Fluorouracil|Given IV
214525866|NCT02521025|OTHER|Continuous feeding pattern|Continuous feeding
214525867|NCT03751280|DEVICE|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
215135062|NCT01254136|DRUG|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
215135063|NCT01254136|DRUG|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
215135064|NCT00259597|PROCEDURE|breast ductal lavage|breast ductal lavage and nipple aspiration done once
215135065|NCT05298514|OTHER|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
215135066|NCT06218316|DRUG|botulinum toxin A|Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
215135067|NCT06218316|DEVICE|Transcranial Magnetic Stimulation|Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
215135068|NCT06218316|OTHER|Rehabilitation Training Protocol|Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
215135069|NCT01490151|DEVICE|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
215135070|NCT05841186|OTHER|Timing of pegfilgrastim administration|Timing of pegfilgrastim administration
215135071|NCT03359538|DRUG|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
215135072|NCT03359538|DRUG|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
215135073|NCT02925286|OTHER|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
215135074|NCT06151405|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
215135075|NCT06151405|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
215135076|NCT06151405|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
215135077|NCT01863784|DRUG|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
215135078|NCT04293575|DEVICE|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
215135079|NCT04438486|BEHAVIORAL|Group A|specific dietary advice for Hyperuricemia
215135080|NCT04438486|DIETARY_SUPPLEMENT|Group B|Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
215135081|NCT00279175|BIOLOGICAL|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
215135082|NCT00279175|BIOLOGICAL|Placebo medium supplemented with autologous serum|
214451312|NCT04094688|DRUG|Irinotecan Hydrochloride|Given IV
214451313|NCT04094688|DRUG|Irinotecan|Given IV
214451314|NCT04094688|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214451315|NCT04094688|OTHER|Quality-of-Life Assessment|Ancillary studies
214451316|NCT04094688|OTHER|Questionnaire Administration|Ancillary studies
214525868|NCT03751280|DEVICE|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
214708604|NCT06392724|GENETIC|GEN6050X intravenous injection|GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.
214451317|NCT02651428|DRUG|Neutrolin|Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
214451318|NCT02651428|DRUG|Heparin|Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
214451319|NCT05670626|PROCEDURE|Refractive Surgery|Phakic implantable contact lens ( ICL)
214451320|NCT02380885|BEHAVIORAL|SCIT|psychosocial group intervention
214451321|NCT02380885|BEHAVIORAL|TAFT|psychosocial group intervention
214708605|NCT05220410|DRUG|Psilocybin|Open-Label
214708606|NCT06362005|DRUG|Triamcinolone Acetonide 0.1% Oint|RCT
215135083|NCT04328714|DRUG|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
215135084|NCT01350947|DRUG|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
215135085|NCT02866786|DRUG|Metformin|
215135086|NCT02866786|DRUG|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
215135087|NCT00900653|DRUG|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
215135088|NCT01630148|DRUG|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
215135089|NCT03288532|DRUG|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
214451322|NCT06064955|BEHAVIORAL|Peer Support|Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
214451323|NCT06443892|PROCEDURE|Pericapsular Nerve Block (PENG)|Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
214451324|NCT06443892|PROCEDURE|Suprainguinal Fascia Iliaca Compartment Block (SFICB)|Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
214451325|NCT04774068|DRUG|Parsaclisib|Given PO
214451326|NCT04774068|DRUG|Romidepsin|Given IV
214525869|NCT05812547|DEVICE|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
215135090|NCT03288532|DRUG|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
215135091|NCT05890833|DIAGNOSTIC_TEST|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
215135092|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
215135093|NCT03853473|PROCEDURE|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
215135094|NCT04268641|OTHER|Arm 1|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
214451327|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
215135095|NCT04268641|OTHER|Arm 2|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion"
214525870|NCT05812547|OTHER|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
214525871|NCT00946010|BIOLOGICAL|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
214525872|NCT04161872|DRUG|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
214451328|NCT04551521|DRUG|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
214451329|NCT04551521|DRUG|Cobimetinib|60 mg once daily
214451330|NCT04551521|DRUG|Atezolizumab|840 mg every 2 weeks
214451331|NCT04551521|DRUG|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
214451332|NCT04551521|DRUG|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
214451333|NCT04551521|DRUG|Alectinib|600 mg twice daily
214451334|NCT04551521|DRUG|Ipatasertib|400 mg once daily
214451335|NCT04551521|DRUG|Atezolizumab|1200 mg every 3 weeks
215135096|NCT04268641|OTHER|Arm 3|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair"
214451336|NCT04551521|DRUG|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
214451337|NCT04551521|DRUG|Atezolizumab|1,200 mg every 3 weeks
214451338|NCT04551521|DRUG|Inavolisib|9 mg once daily
214451339|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
215135097|NCT04268641|OTHER|Arm 4|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
215135098|NCT04268641|OTHER|Arm 5|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion"
215135099|NCT04268641|OTHER|Arm 6|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair"
215135100|NCT04910048|OTHER|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
215135101|NCT04910048|OTHER|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
215135102|NCT04741581|DIETARY_SUPPLEMENT|ThickenUp® Gel Express|Thickening gel
215135103|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
215135104|NCT05027321|BEHAVIORAL|Conversational Hypnosis|Conversational Hypnosis during examination
215135105|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
215135106|NCT05940103|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
215135107|NCT04519008|DEVICE|Mobile app|Medical device for improving emotion dysregulation
215135108|NCT04519008|COMBINATION_PRODUCT|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
215135114|NCT06469294|PROCEDURE|Control (C) - Saline Gel|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.
214451340|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
214525873|NCT04161872|DRUG|Placebo|Placebo
215135115|NCT06469294|PROCEDURE|Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue|After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
215135116|NCT04039087|DRUG|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
215135117|NCT04039087|DRUG|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
215135118|NCT03039309|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
215135119|NCT06526494|DRUG|Metformin|Oral ingestion for 12 weeks
215135120|NCT06526494|OTHER|Placebo|Oral placebo for 12 weeks
214451341|NCT05790889|BIOLOGICAL|Rabies vaccine|Vaccine
214451342|NCT05790889|BIOLOGICAL|RH5.1 10μg adjuvated with 50μg Matrix-M|Vaccine
214451343|NCT05790889|BIOLOGICAL|RH5.2 5μg adjuvated with 50μg Matrix-M|Vaccine
214451344|NCT05890768|DRUG|Lumateperone|FDA approved antipsychotic drug
214451345|NCT05890768|DRUG|Risperidone|FDA approved antipsychotic drug
214451346|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
214451347|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
214451348|NCT06162585|BIOLOGICAL|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
214451349|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
214451350|NCT04485039|DRUG|Tecovirimat|oral antiviral
214451351|NCT04485039|DRUG|sevelamer carbonate oral tablet|phosphate binder
214451352|NCT04485039|DRUG|sucroferric oxyhydroxide chewable tablet|phosphate binder
214451353|NCT04485039|DRUG|calcium acetate oral tablet|phosphate binder
214451354|NCT04485039|DRUG|Lanthanum Carbonate Chewable Tablet|phosphate binder
214525874|NCT06090318|DRUG|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
214525875|NCT06090318|DRUG|Atezolizumab|1680mg administered every 4 weeks
215135121|NCT04572217|DRUG|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
215135122|NCT04572217|DRUG|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
215135123|NCT04786743|OTHER|endoscopic intervention|performing endoscopy
214451355|NCT05880381|DEVICE|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
215135124|NCT06961552|OTHER|reflexology masaj group|The women in the reflexology group will receive a reflexology massage with proven regional applications, pressure sliding and circular pressure three times with baby oil for two cycles by the researcher, starting at the end of menstruation (5-7th days of the cycle), for a total of 30 minutes in a single session for each foot, starting at 15 minutes per foot. A total of 8 reflexology massage sessions will be performed, one session per week (Monday) for 8 weeks.
214694839|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
214451356|NCT05880381|OTHER|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
215135125|NCT01349543|BIOLOGICAL|RSV A Memphis 37|Intranasal administration
215135126|NCT03939624|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
215135127|NCT03939624|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
215135128|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
214451357|NCT06251037|BEHAVIORAL|Youth Aware of Mental Health in Galicia|"The program follows a manualized protocol, comprising five interactive one-hour class sessions with adaptations to the Galician school population.~The Inaugural Session consists of an interactive slide presentation, an introduction of materials, the delivery of the manual, and the poster's display. The Second Session involves group discussions on real-life dilemmas. The Third and Fourth Sessions focus on crisis situations, depression, suicidal ideation, and help-seeking behaviors through role-playing games. The Closing Session includes a collective summary of topics and addresses dynamic aspects emerging during the group experience."
214451358|NCT06276127|DRUG|Oral Bisoprolol|Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
214451359|NCT06276127|DRUG|Intravenous Diltiazem|Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
214451360|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
214451361|NCT02732860|OTHER|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
214451362|NCT04785196|DRUG|APG-115|Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
214451363|NCT04785196|DRUG|Toripalimab|Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
214708607|NCT06362005|DRUG|Tacrollimus Topical|RCT
214708608|NCT06362005|DRUG|Selenium|RCT
214451369|NCT04005716|DRUG|Tislelizumab|200 mg administered intravenously on Day 1 of each 21-day cycle
214451370|NCT04005716|DRUG|Cisplatin|75 mg/m² was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of two hours. Treatment with cisplatin was discontinued starting in Cycle 5 and beyond.
214451371|NCT04005716|DRUG|Carboplatin|An area under the curve (AUC) of 5 mg/mL/min was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of 15 to 60 minutes. Treatment with carboplatin was discontinued starting in Cycle 5 and beyond.
214451372|NCT04005716|DRUG|Etoposide|100 mg/m² was administered intravenously from Day 1 to Day 3 of each 21-day cycle, infused over a duration of 60 minutes. Treatment with etoposide was discontinued starting in Cycle 5 and beyond.
214525876|NCT00685659|OTHER|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
214525877|NCT00685659|OTHER|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
214525878|NCT00685659|OTHER|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
214525879|NCT02943109|OTHER|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
214525880|NCT02943109|OTHER|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
215135129|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
215135130|NCT05031819|OTHER|Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.|"* TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH"
215135131|NCT06444659|BEHAVIORAL|Adaptive Physical Activity Classes|The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.
215135132|NCT04829292|BEHAVIORAL|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
215135133|NCT00929214|DRUG|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
215135134|NCT00929214|PROCEDURE|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
215135135|NCT05800860|DRUG|GH001|GH001 administered via inhalation
215135136|NCT05800860|DRUG|Placebo|Placebo administered via inhalation
215135137|NCT03796559|DEVICE|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
215135138|NCT04799964|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
215135139|NCT04799964|DEVICE|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
215135140|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
215135141|NCT05258240|OTHER|Virtual Reality|Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
215135142|NCT05258240|OTHER|Conventional Physical Therapy|Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
215135143|NCT05057312|OTHER|Enhancing Accessibility to Health Care|Receive enhanced access to vaccination
215135144|NCT05057312|OTHER|Informational Intervention|Receive standard CDC information
215135145|NCT05057312|OTHER|Informational Intervention|Receive video narratives
215135146|NCT05057312|OTHER|Informational Intervention|Receive written narratives
215135147|NCT05057312|OTHER|Interview|Ancillary studies
215135148|NCT05057312|OTHER|Questionnaire Administration|Ancillary studies
215135149|NCT01856270|DRUG|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
215135150|NCT03655340|DRUG|Alprolix|Extended half-life factor IX product
215135151|NCT03873883|DRUG|EOS100850|Oral administration
215135152|NCT03873883|DRUG|Pembrolizumab|IV Infusion
215135153|NCT03873883|DRUG|Chemotherapy|Standard of Care IV Infusion
215135154|NCT06105502|BEHAVIORAL|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
215135155|NCT06047210|OTHER|Blood Draws Data Collection|
215135156|NCT05625737|DRUG|Fruquintinib|Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
215135157|NCT05625737|DRUG|Sintilimab|Sintilimab will be administrated as 200mg once every 3 weeks.
215135158|NCT06535880|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm
215135159|NCT06577181|DRUG|hCG + estradiol|Human chorionic gonadotropins
214708609|NCT06362005|DRUG|Selenium & Triamcinolone Acetonide 0.1% Oint|RCT
215135160|NCT06577181|OTHER|Observation arm|estradiol only wuithout giving hcg
215135161|NCT04539496|DRUG|XZP-3287|"* 20-560 mg QD, oral~* 240-480 mg BID, oral"
215135162|NCT04539496|DRUG|XZP-3287;Letrozole;Anastrozole;Fulvestrant|XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
215135163|NCT04539496|DRUG|XZP-3287|480 mg BID, oral
215135164|NCT05502562|DRUG|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
215135165|NCT03680053|DRUG|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
215135166|NCT03680053|DRUG|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
215135167|NCT05444855|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
215135168|NCT03358277|DRUG|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
215135169|NCT02699658|DRUG|Levofloxacin|
215135170|NCT00773448|DEVICE|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
215135171|NCT00773448|OTHER|Limited Malignancy Screening|"1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year."
215135172|NCT05618522|PROCEDURE|vacuum-dehydrated amnion membrane (omnigen)|applying the lens loaded with Omnigen on the cornea
215135173|NCT05618522|DEVICE|the lens loaded with Omnigen|the lens loaded with Omnigen
215135174|NCT00802581|PROCEDURE|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
215135175|NCT00802581|PROCEDURE|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
215135176|NCT02506894|DRUG|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
215135177|NCT02506894|OTHER|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
215135178|NCT05379179|DRUG|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
214451373|NCT04005716|DRUG|Placebo|200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
214451374|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
214451375|NCT05786443|DRUG|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
214451376|NCT05786443|DRUG|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
215135179|NCT05379179|DRUG|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
215135180|NCT02268890|DRUG|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
215135181|NCT04842747|DRUG|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
214451377|NCT06103604|DIAGNOSTIC_TEST|latest generation tympanic thermometer|The patient whose core temperature is monitored during hospitalisation has his temperature at tympanic level taken once during the stay. The research nurse will record the core temperature from the monitor on the CRF and, within the next 5 minutes, take the peripheral temperature with the tympanic thermometer three times in a row, recording all three values on the CRF. Subsequently a second operator will always take the temperature 3 times within 5 minutes of the gold standard measurement. Only the first tympanic measurement will then be used to assess accuracy against the gold standard.
214451378|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
214451379|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
214708610|NCT06362005|DRUG|Selenium& Tacrollimus topical|RCT
215135182|NCT05003401|DEVICE|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
215135183|NCT00175526|BEHAVIORAL|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
215135184|NCT00333125|DRUG|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
215135185|NCT00333125|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
215135186|NCT00333125|OTHER|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
215135187|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
215135188|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
215135189|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
215135190|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
215135191|NCT00474422|BEHAVIORAL|Proactive assignment to attend a breastfeeding clinic|
215135192|NCT02133495|PROCEDURE|Non Cadaveric Human Acellular Dermal Tissue|
215135193|NCT02996201|OTHER|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
214451380|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
214451381|NCT06252506|DRUG|N,N-dimethyltryptamine (DMT) + harmine|DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
214451382|NCT06252506|DRUG|Placebo|Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
214451383|NCT06233825|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Essential Amino Acids|Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
214451384|NCT06233825|DIETARY_SUPPLEMENT|Safflower Oil and Non-Essential Amino Acids|Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.
214451385|NCT06456853|OTHER|Pain assesment|We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
214451386|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
214525881|NCT02943109|OTHER|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
214525882|NCT02943109|OTHER|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
215135194|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
215135195|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
215135196|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
215135197|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
215135198|NCT00868634|DRUG|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
215135199|NCT01828177|DRUG|PDI-320|
215135200|NCT01828177|DRUG|PDI-320 Monad #1|
215135201|NCT01828177|DRUG|PDI-320 Monad #2|
215135202|NCT01828177|DRUG|Vehicle|
215135203|NCT01901445|BEHAVIORAL|Educational action with focal group|
215135204|NCT02721940|PROCEDURE|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
215135205|NCT02721940|BIOLOGICAL|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
215135206|NCT02721940|BIOLOGICAL|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
214525883|NCT03599934|OTHER|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
214525884|NCT03599934|OTHER|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
215135207|NCT02721940|DRUG|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
215135208|NCT02721940|DRUG|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
215135209|NCT01451606|DRUG|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
215135210|NCT01451606|DRUG|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
215135211|NCT05049590|BIOLOGICAL|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
215135212|NCT01590264|DEVICE|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
215135213|NCT02830737|PROCEDURE|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
214451387|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
214451388|NCT03535272|DRUG|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
215135214|NCT02830737|PROCEDURE|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
215135215|NCT04496817|OTHER|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
215135216|NCT04496817|OTHER|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
215135217|NCT02014324|PROCEDURE|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)"
215135218|NCT04420377|DIETARY_SUPPLEMENT|Carnipure|Supplement contains L-carnitine tartrate.
215135219|NCT04420377|OTHER|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
214451389|NCT03535272|DRUG|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
214451390|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
214451391|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
214451392|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
214451393|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
214451394|NCT04302493|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
214451395|NCT04302493|BEHAVIORAL|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
214451396|NCT05552105|OTHER|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
215135220|NCT03071120|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
215135221|NCT05271981|OTHER|Retrospective data collection|Data collection from the medical file of the patients
215135222|NCT05271981|OTHER|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
215135223|NCT01186263|DRUG|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
215135224|NCT01186263|DRUG|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
215135225|NCT00564681|BIOLOGICAL|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
215135226|NCT00564681|BIOLOGICAL|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
215135227|NCT00564681|DRUG|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
214451397|NCT06486311|PROCEDURE|satellite implant|Satellite implant is a additional holding component as a stabilizer to provide a polygonal support to distribute forces and moments on single-standing implants give the implant sufficient resistance to withstand masticatory forces or at least keep it in a stable position during an unloaded healing period to achieve stabilization and subsequent osseointegration of implants.
215135228|NCT01648465|DRUG|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
215135229|NCT05945420|DRUG|Desmopressin Acetate|This arm will receive tamsulosin and desmopressin acetate daily a
215135230|NCT05945420|DRUG|Placebo|This arm will receive tamsulosin and placebo
215135231|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
215135232|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
215135233|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
215135234|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
215135235|NCT05249140|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
215135236|NCT00080665|DRUG|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
215135237|NCT00080665|DRUG|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
215135238|NCT04750317|DRUG|Tofacitinib|Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
215135239|NCT03784872|PROCEDURE|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
215135240|NCT01384981|PROCEDURE|pulmonary rehabilitation|
215135241|NCT04011540|BEHAVIORAL|Digital data|Receiving digital data prior to a scheduled mental health session
215135242|NCT02676414|BEHAVIORAL|Interactive hypertension education program of the DHL©|
215135243|NCT01256268|DRUG|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
215135244|NCT01256268|DRUG|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
215135245|NCT01256268|DRUG|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
215135246|NCT06026384|OTHER|text in non-narrative form|Participants will be asked to read a text and give feedback afterwards
215135247|NCT06026384|OTHER|text in narrative form|Participants will be asked to read a text and give feedback afterwards
215135248|NCT06026384|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and give feedback afterwards
215135249|NCT06026384|OTHER|animated video in narrative form|Participants will be asked to watch a video and give feedback afterwards
215135250|NCT04730440|OTHER|AD-TAR|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
215135251|NCT04730440|OTHER|AD-Cognitive Stimulation|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
215135252|NCT04960527|DIETARY_SUPPLEMENT|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate \[CherryActive, UK\] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
215135253|NCT04960527|OTHER|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
214451398|NCT04993859|DIAGNOSTIC_TEST|Non-invasive Urodynamic Test (niUDS)|A noninvasive urodynamics is a simple test used to evaluate urinary flow.
214451399|NCT04993859|DIAGNOSTIC_TEST|Urinary proteomic screen|Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
215135254|NCT01848015|OTHER|detection of CTCs|
215135255|NCT06472674|OTHER|No intervention|No intervention
215135256|NCT02066363|DIETARY_SUPPLEMENT|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
215135257|NCT02066363|DIETARY_SUPPLEMENT|Parenteral nutrition|Supportive parenteral nutrition.
214451400|NCT04993859|OTHER|Dysfunctional Voiding Symptom Score Survey (DVSS)|The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
215135258|NCT02249338|DRUG|BIIL 284 BS|
215135259|NCT02249338|DRUG|Placebo|
215135260|NCT02356458|DRUG|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
215135261|NCT02356458|DRUG|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
214451401|NCT06781697|DRUG|Ketamine|Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
214451402|NCT06781697|DEVICE|Oculus VR headset|Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
215135262|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting without the use of collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Suturing of the wound in the donor site."
215135263|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting with collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Adaptation of sterile collagen matrix to the donor site~4. Suturing of the wound in the donor site"
214525885|NCT03548272|PROCEDURE|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
215135264|NCT06131255|DRUG|Citalopram|Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
215135265|NCT01026844|DRUG|erlotinib|Taken orally once a day
215135266|NCT01026844|DRUG|hydroxychloroquine|Taken orally once a day
215135267|NCT01260649|DRUG|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
215135268|NCT01260649|OTHER|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
215135269|NCT01260649|PROCEDURE|ECT|ECT will be administered as per standard of care
215135270|NCT01260649|DRUG|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
215135271|NCT01260649|DRUG|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
215135272|NCT02138890|DEVICE|APS|Intra-articular Injection
215135273|NCT02138890|DEVICE|Saline|Intra-articular injection
215135274|NCT02245477|DEVICE|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
215135275|NCT02245477|OTHER|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
215135276|NCT04564417|BIOLOGICAL|W0180|Participants will receive W0180 in a 21-day cycle.
215135277|NCT04564417|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
215135278|NCT04932395|DRUG|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
214451403|NCT03926624|DRUG|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
214451404|NCT03926624|DRUG|Cytarabine|cytosine arabinoside (ara-C)
214451405|NCT03926624|DRUG|Azacitidine|Azacitidine
214451406|NCT03926624|DRUG|Decitabine|Decitabine
214451407|NCT03926624|DRUG|Mitoxantrone|Mitoxantrone
214451408|NCT03926624|DRUG|Etoposide|Etoposide
214451409|NCT03926624|DRUG|Fludarabine|Fludarabine
214451410|NCT03926624|DRUG|Idarubicin|Idarubicin
215135279|NCT04932395|DRUG|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
215135280|NCT06165809|DRUG|TQB3015 tablets|TQB3015 is a protein inhibitor
214451411|NCT03926624|DRUG|Venetoclax|Venetoclax
214451412|NCT03926624|DRUG|Cladribine|Cladribine
214525886|NCT01953406|DRUG|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
214525887|NCT01953406|DRUG|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
214451413|NCT04945629|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
214451414|NCT04945629|DRUG|Blood clot and simple suture|Filling the alveolus with blood clot
214451415|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
214451416|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
214451417|NCT06781775|DRUG|Metformin + Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stay on metformin and add insulin.
214451418|NCT06781775|DRUG|Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stop on metformin and add insulin.
214525888|NCT02956876|DRUG|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
214525889|NCT02956876|OTHER|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
214525890|NCT02956876|OTHER|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
214525891|NCT06270849|OTHER|Questionnaire|The questionnaire to assess severity of LUTS in women.
214525892|NCT01421797|DRUG|Dexamethasone|1 mg PO
214525893|NCT01421797|DRUG|Cortrosyn|single IV bolus of 0.25 mg will be administered
214694840|NCT06531083|BEHAVIORAL|Early physical therapy intervention|Physical therapy including manual therapy, home exercises for the neck and jaw, and use of a jaw stretching device.
214708611|NCT06074068|BEHAVIORAL|Fathers for Change|18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
215135281|NCT01598766|DEVICE|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
215135282|NCT02211560|OTHER|Phosphatidylserine|
215135283|NCT02211560|OTHER|Placebo|
215135284|NCT01446159|DRUG|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
215135285|NCT01446159|DRUG|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
215135286|NCT03546023|OTHER|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
215135287|NCT03766789|DEVICE|Cell phone application|cell phone to organize medications
215135288|NCT04444817|DRUG|Tacrolimus|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
215135289|NCT02327546|DRUG|AKB-6548|
214451419|NCT05350722|RADIATION|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
215135290|NCT02327546|DRUG|Ferrous Sulfate|
214451420|NCT06140875|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
214451421|NCT05943626|BEHAVIORAL|Circadian Intervention|The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
214451422|NCT03892616|DRUG|BI 1358894 (B)|Tablet formulation 2 (TF2a), fed
214451423|NCT03892616|DRUG|BI 1358894 (C)|Tablet formulation 2 (TF2a), fasted
214451424|NCT03892616|DRUG|BI 1358894 (D)|Tablet formulation 2 (TF2b), fed
214451425|NCT03892616|DRUG|BI 1358894 (E)|Tablet formulation 2 (TF2b), fasted
214451426|NCT03892616|DRUG|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
214451427|NCT06475664|OTHER|Personalized legal care services|Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
214451428|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
214451429|NCT03785106|DRUG|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
214451430|NCT03785106|DRUG|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
214451431|NCT04211025|OTHER|Modest|The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
214451432|NCT04211025|OTHER|Intensive|The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
214451433|NCT00378105|DRUG|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
214451434|NCT00378105|DRUG|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
214451435|NCT00378105|DRUG|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
214451436|NCT05874037|DRUG|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
214451437|NCT06295835|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingersticks.
214451438|NCT06255925|BEHAVIORAL|KF-STRIDE® Into Work!|Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
214451439|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
214451440|NCT06128174|DEVICE|Farawave PFA catheter|The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.
214525894|NCT06154733|PROCEDURE|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
215135291|NCT05830552|OTHER|Receving feedback|Receving regular feedback from a health provider
215135292|NCT05830552|OTHER|No regular feedback|No regular feedback from a health provider
215135293|NCT06005467|PROCEDURE|Open reduction and internal fixation of mandibular angle fracture using V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
214451441|NCT05192200|DRUG|Anti-Beta Interferon (PF-06823859)|IV infusion
214451442|NCT06341413|DEVICE|SmartSleep device|Device worn during sleep
215135294|NCT03668873|BEHAVIORAL|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
215135295|NCT03668873|BEHAVIORAL|Sleep Parent Education|SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
215135296|NCT05088564|PROCEDURE|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
215135297|NCT05088564|PROCEDURE|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
215135298|NCT02475538|DEVICE|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
215135299|NCT02475538|DEVICE|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
215135300|NCT03446625|DRUG|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
214451444|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
214451445|NCT06389097|RADIATION|Radium-223|"Radium-223 will be given as per standard of care or other clinical trial. It is typically administered intravenously via slow injection once every 4 weeks with a dosage of 55 kBq/kg per cycle. Patients typically receive up to six cycles unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. These will be performed at 2-4 hr, 24 hr, and 48 hr after any cycle of Radium-223. Protocol preference is for imaging with 2 cycles, ideally cycle 1 and cycle 6, but imaging with any one or two cycle(s) is acceptable.~The imaging time at each time point is approximately 30 minutes per field of view with two fields of view (1 hr total) typically collected sequentially (i.e., without repositioning the patient on the imaging table)."
214525895|NCT06154733|PROCEDURE|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
215135301|NCT03446625|DRUG|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
215135302|NCT03793244|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
214525896|NCT06154733|PROCEDURE|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
214525897|NCT05521555|PROCEDURE|Total knee arthroplasty|First intention total knee arthroplasty
215135303|NCT02343835|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
215135304|NCT06084611|DEVICE|Provox Life|Compliant use of Provox Life HMEs
215135305|NCT01010828|PROCEDURE|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
215135306|NCT01010828|PROCEDURE|Incision technique|Mini Mid-Vastus Approach
215135307|NCT02642601|DRUG|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
215135308|NCT02183675|DRUG|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
215135309|NCT02183675|DRUG|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
215135310|NCT02183675|DRUG|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
214525898|NCT01818245|DRUG|LY2605541|
214525899|NCT01257698|DRUG|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
214525900|NCT06340334|BIOLOGICAL|Tegoprazan-amoxicillin dual therapy|A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days. The eradication rate, adverse reactions, and compliance of the two groups were compared.
215135311|NCT01874002|DEVICE|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
215135312|NCT01521117|DRUG|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
215135313|NCT01521117|DRUG|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
215135314|NCT04282161|DEVICE|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
215135315|NCT00549146|DRUG|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
215135316|NCT00549146|DRUG|fluticasone propionate DISKUS 500mcg|
215135317|NCT01394237|OTHER|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
215135318|NCT03088696|OTHER|stimulation|activation of the acupuncture point
215135319|NCT03088696|OTHER|no stimulation|no activation of the acupuncture point
215135320|NCT01926223|OTHER|Home visiting|
215135321|NCT02558725|DRUG|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
214451446|NCT06389097|RADIATION|177Lu-DOTATATE|"177Lu-DOTATATE to be given as Standard of Care (SOC) or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes with peptide co-infusion prior and during the infusion.~Patients will receive 4 cycles of 177Lu-DOTATATE administered approximately every 8 weeks. Treatment cycle is defined as 8 consecutive weeks (D1-D56) following a dose of 177Lu-DOTATATE. Patients receive up to four infusions of 7.4 GBq (200 mCi) every 8 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is \~ 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
215135322|NCT06082934|DRUG|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
215135323|NCT02480972|PROCEDURE|magnetic resonance imaging|"multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   \------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
214525901|NCT01109602|OTHER|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
214525902|NCT04238299|DIAGNOSTIC_TEST|Multiparametric renal MRI|Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
214525903|NCT00748358|DRUG|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
214525904|NCT01516502|OTHER|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
215135324|NCT03404817|DRUG|Original formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
215135325|NCT03404817|DRUG|New formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
215135326|NCT03874546|OTHER|Questionnaire|"* Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
215135327|NCT00033332|DRUG|dexamethasone|
215135328|NCT00033332|DRUG|pamidronate disodium|
215135329|NCT00033332|DRUG|thalidomide|
215135330|NCT00033332|DRUG|zoledronic acid|
215135331|NCT04716764|OTHER|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
215135332|NCT02228681|DRUG|Everolimus|10mg daily by mouth
215135333|NCT02228681|DRUG|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
215135334|NCT02228681|DRUG|Letrozole|2.5mg once a day by mouth
215135335|NCT02228681|DRUG|Medroxyprogesterone Acetate|200 mg daily by mouth
215135336|NCT03305614|PROCEDURE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
215135337|NCT03305614|PROCEDURE|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
215135338|NCT01942928|OTHER|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
215135339|NCT01942928|OTHER|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
215135340|NCT00001986|DRUG|1-Octanol|
215135341|NCT04894968|DIAGNOSTIC_TEST|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~1. Symptoms of heart failure (e.g. dyspnea on extertion)~2. Preserved ejection fraction (Left ventricular ejection fraction ≥50%~3. NT-proBNP ≥125 pg/mL~4. Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~   * Left atrial volume index \>34 mL/m²~  * Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~  * E/e' ≥13~  * Septal e' \<9 cm/s"
215135342|NCT00334880|DRUG|NRP104|
215135343|NCT03523819|DRUG|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
215135344|NCT03523819|DRUG|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
215135345|NCT01794429|DRUG|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
215135346|NCT01794429|DRUG|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
215135347|NCT04997486|BEHAVIORAL|Time restricted eating|Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
214451447|NCT06389097|RADIATION|177Lu-PSMA-617|"177Lu-PSMA-617 will be given as per SOC or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes.~Up to 6 cycles of 177Lu- PSMA-617 will be administered approximately every 6 weeks. Treatment cycle is defined as 6 consecutive weeks (D1-D42) following a dose of 177Lu- PSMA-617. Patients will receive up to six infusions of 7.4 GBq (200 mCi) every 6 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is approximately 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
214451448|NCT03907397|BIOLOGICAL|Peanut Protein|up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
214451449|NCT03907397|OTHER|Continued peanut avoidance|Standard of care avoidance of peanut
214451450|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
214451451|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
214451452|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
214451453|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
214451454|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
214451455|NCT06836960|DRUG|Probiotic Therapy With Gegen Qinlian Tang|This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily) for 8 weeks. The combination therapy is designed specifically for the prevention and treatment of radiation enteritis, differentiating it from probiotics or herbal therapies used alone.
214708612|NCT06074068|BEHAVIORAL|Duluth BIP|18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
215135348|NCT05942365|DRUG|ZSP1273|Drug Warfarin oral Drug midazolam oral
215135349|NCT01336933|DRUG|prednisone|Given PO
215135350|NCT01336933|DRUG|cyclophosphamide|Given IV
215135351|NCT01336933|DRUG|etoposide|Given PO or IV
215135352|NCT01336933|DRUG|Vincristine|Given IV
215135353|NCT01336933|DRUG|pralatrexate|Given IV
215135354|NCT01336933|OTHER|laboratory biomarker analysis|Correlative studies
215135355|NCT01336933|GENETIC|comparative genomic hybridization|Correlative studies
215135356|NCT01336933|GENETIC|gene expression analysis|Correlative studies
215135357|NCT01336933|GENETIC|nucleic acid sequencing|Correlative studies
215135358|NCT01336933|GENETIC|mutation analysis|Correlative studies
215135359|NCT01336933|OTHER|immunohistochemistry staining method|Correlative studies
215135360|NCT01336933|GENETIC|microarray analysis|Correlative studies
215135361|NCT01336933|GENETIC|RNA analysis|Correlative studies
215135362|NCT04875013|DEVICE|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
215135363|NCT02960386|OTHER|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
215135364|NCT05774535|OTHER|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~* informed consent;~* personal data and medical records;~* registration of medical therapy and post-procedural pharmacological protocol~* surgical check;~* supra-aortic trunks EchocolorDoppler;~* pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~* surgical checks;~* registration of drug therapy;~* recording of all adverse events that occurred during hospitalization~* supra-aortic trunks EchocolorDoppler and cIMT measurement;~* blood sampling."
214451456|NCT04061798|DRUG|ACT guided heparinization|"If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
214451457|NCT04061798|DRUG|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
214451458|NCT06106893|BIOLOGICAL|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
214451459|NCT06834776|DIAGNOSTIC_TEST|TOF (Train-of-Four) monitoring for depth of neuromuscular blockade.|General anesthesia with propofol and fentanyl induction followed by rocuronium for neuromuscular blockade; maintenance with desflurane and remifentanil.
214451460|NCT04973163|DRUG|BI 1823911|BI 1823911
214451461|NCT04973163|DRUG|BI 1701963|BI 1701963
214451462|NCT04973163|DRUG|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
214451463|NCT05878860|BIOLOGICAL|ATSN-201|AAV.SPR-hGRK1-hRS1syn
214451464|NCT04493034|BEHAVIORAL|Art Therapy|"The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health."
214525905|NCT00024102|DRUG|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
214525906|NCT00024102|DRUG|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
214525907|NCT02511808|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
214525908|NCT02511808|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
214525909|NCT02511808|BEHAVIORAL|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
214525910|NCT02894359|DEVICE|cone beam imagery of cervical spine|
214525911|NCT03630458|OTHER|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
215135365|NCT01796717|DRUG|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
215135366|NCT01796717|DRUG|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
215135367|NCT04879056|DIAGNOSTIC_TEST|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
215135368|NCT04643275|DEVICE|BTL-899|Treatment with study device.
215135369|NCT02666872|BEHAVIORAL|Motivational interviewing|
215135370|NCT02306330|DEVICE|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
215135371|NCT02306330|OTHER|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
215135372|NCT02028806|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
215135373|NCT00153296|DRUG|Carbamazepine|
214451465|NCT04493034|BEHAVIORAL|Music Therapy|"Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study."
214525912|NCT03630458|OTHER|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
215135374|NCT00347789|PROCEDURE|Glaucoma surgery- Bleb revision|
215135375|NCT04728958|BEHAVIORAL|Gratitude|A positive psychology intervention using expressions of gratitude
215135376|NCT06009562|PROCEDURE|Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
215135377|NCT06251557|OTHER|Lumbopelvic Massage|10 minutes abdominal massage and 10 minutes lower back massage will be applied in each session. It will take 20 minutes in total.
215135378|NCT06251557|OTHER|Exercise Training|Exercise training will last approximately 10 minutes in each session. In the exercise training, lumbopelvic stabilization exercises (bridge, cat-and-cow and squatting exercises) will be performed for 10 repetitions, lumbopelvic flexibility exercises (child position, happy baby position, adductor muscle stretching, psoas muscle stretching) will be performed for 20 seconds and 5 repetitions, and diaphragmatic breathing exercises will be performed for 5 repetitions in supine, side lying and sitting positions.
215135379|NCT06251557|DEVICE|Pelvic Floor Electromyography (EMG) Biofeedback Therapy|Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
214525913|NCT03630458|OTHER|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
215135380|NCT06251557|BEHAVIORAL|Standard Urotherapy|The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
215135381|NCT05054075|BIOLOGICAL|Marine liquid and fluids|Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
215135382|NCT05054075|BIOLOGICAL|Impregnation|SARS / COVID-19 fluid/liquid - impregnation
215135383|NCT05054075|BIOLOGICAL|Incubation|SARS / COVID-19 fluid-bivalve-incubation
215135384|NCT05054075|BIOLOGICAL|Manipulation|Bivalve Manipulation - Stress inducing
215135385|NCT05054075|BIOLOGICAL|Refrigeration|Refrigerated fluid to check for maintained response
215135386|NCT03220971|OTHER|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
215135387|NCT04576988|BIOLOGICAL|Sotatercept|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
215135388|NCT04576988|DRUG|Placebo|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
215135389|NCT04576988|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
214451466|NCT05555355|DEVICE|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
214525914|NCT03630458|OTHER|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
214708613|NCT06382064|DEVICE|Biweekly replacement contact lenses|Biweekly replacement reusable contact lenses.
215135390|NCT03983733|OTHER|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
215135391|NCT02352480|DEVICE|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
215135392|NCT00617734|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
214451467|NCT05555355|PROCEDURE|Spine surgery|Patients will receive spine surgery
215135393|NCT00617734|BIOLOGICAL|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
215135394|NCT01844765|DRUG|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
215135395|NCT05638256|DRUG|68Ga-NY104|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
214451468|NCT05503485|BEHAVIORAL|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
214451469|NCT05503485|BEHAVIORAL|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
214451470|NCT05497206|DEVICE|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
214451471|NCT06208202|BEHAVIORAL|Behavioral Intervention|Receive and use flavored e-cigarettes (EC) as directed
214451472|NCT06208202|OTHER|Biospecimen Collection|Undergo biosample sample collection
214451473|NCT06208202|OTHER|Survey Administration|Complete surveys
214451474|NCT06512259|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
214451475|NCT06432543|DEVICE|polyethylene|No intervention as this is an observational study
214451476|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
214451477|NCT06835270|OTHER|Yoga Exercises|Yoga group practiced Iyengar yoga asanas, pranayama, and mental focusing components in a group exercise format for 45 minutes.The yoga group was advised to practice yoga exercises at home following their yoga sessions.
214451478|NCT06835270|DEVICE|Standard physiotherapy approaches|Standard physiotherapy approaches group ( standard physiotherapy approaches (therapeutic ultrasound, hotpack) and TENS (5x5 cm electrodes, applied to the thoracic 12 and sacral 1 regions). Four electrodes were applied for 20 minutes with a pulse width of 50-100 µs and a frequency of 60-120 Hz. This group was additionally recommended to perform home exercises
214451479|NCT06835270|OTHER|Kinesiology taping|In the kinesiology taping technique, tape was applied in an I-shape parallel to the m. quadratus lumborum muscle. Interventions were conducted three times a week for four weeks, totaling 12 sessions.This group was additionally recommended to perform home exercises
214451480|NCT06835270|BEHAVIORAL|Awareness training for low back pain|The educational training was based on the WHO's guidelines for back pain. This group was additionally recommended to perform home exercises.
214451481|NCT04765943|DEVICE|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
214451482|NCT05817838|BEHAVIORAL|Financial Incentives|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store
214451483|NCT05817838|BEHAVIORAL|Financial Incentives and Multilevel Multicomponent|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing
214451484|NCT05817838|OTHER|School Engagement|For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
214451485|NCT03562377|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
214451486|NCT03562377|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
214451487|NCT03562377|BIOLOGICAL|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
214451488|NCT03562377|BIOLOGICAL|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
214451489|NCT06837337|OTHER|Music intervention|Music intervention
215135396|NCT02973971|OTHER|volumeric MRI|
215135397|NCT01004952|BEHAVIORAL|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
215135398|NCT04897711|BEHAVIORAL|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
215135399|NCT05208944|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
215135400|NCT05208944|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
215135401|NCT04029233|DEVICE|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
215135402|NCT03678207|OTHER|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
215135403|NCT02367508|BEHAVIORAL|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
215135404|NCT04767659|DEVICE|MAMMOT2|Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
215135405|NCT06097221|BEHAVIORAL|CRT-Advance|Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
215135406|NCT06097221|BEHAVIORAL|Treatment as usual|Treatment as usual in the outpatient psychiatric unit.
215135407|NCT06052761|DEVICE|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
215135408|NCT06176742|OTHER|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
215135409|NCT06176742|OTHER|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
214525915|NCT03630458|OTHER|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
214525916|NCT00974402|BEHAVIORAL|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
215135410|NCT06584890|OTHER|decision|decision-making process regarding patient discharge from the Intensive Care Unit (ICU)
215135411|NCT00556075|DRUG|Proellex 25 mg|1 capsule daily for 4 months
215135412|NCT00556075|DRUG|Placebo|1 capsule daily for 4 months
215135413|NCT00556075|DRUG|Proellex 50 mg|2 capsules daily for 4 months
214451490|NCT05499637|DRUG|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET/CT
214451491|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 1|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
214451492|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 2|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
214451493|NCT06557499|DEVICE|Natural Rubber Latex (NRL) male condom- Control condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
214451494|NCT04431999|DRUG|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
214451495|NCT04431999|DRUG|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
214451496|NCT06834542|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
214451497|NCT06828913|OTHER|Oral Health information on online platforms|oral health
214451498|NCT05254457|BIOLOGICAL|EN3835|Treatment or retreatment with EN3835
214708614|NCT06382064|DEVICE|One week replacement contact lenses|One week replacement reusable contact lenses.
215135414|NCT04863391|DIAGNOSTIC_TEST|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
215135415|NCT01276262|DRUG|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
215135416|NCT01276262|DRUG|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
215135417|NCT01276262|DRUG|Placebo|Oral tablets BID, repeated doses for 21 days
215135418|NCT00869466|BEHAVIORAL|behavioral dietary intervention|
215135419|NCT00869466|BEHAVIORAL|exercise intervention|
215135420|NCT00869466|OTHER|counseling intervention|
215135421|NCT00869466|OTHER|educational intervention|
215135422|NCT00869466|OTHER|laboratory biomarker analysis|
215135423|NCT00869466|OTHER|questionnaire administration|
215135424|NCT00869466|PROCEDURE|quality-of-life assessment|
215135425|NCT00869466|PROCEDURE|support group therapy|
215135426|NCT02485691|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
215135427|NCT02485691|DRUG|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
215135428|NCT02485691|DRUG|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
215135429|NCT02485691|DRUG|prednisone|Pharmaceutical form: tablet Route of administration: oral
215135430|NCT00225901|DRUG|Recombinant human hepatocyte growth factor|
215135431|NCT00604565|DRUG|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
215135432|NCT00604565|OTHER|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
215135433|NCT02451059|BEHAVIORAL|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
215135434|NCT02451059|BEHAVIORAL|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
215135435|NCT02451059|BEHAVIORAL|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
215135436|NCT04292535|DRUG|Placebo into the intranasal mucosa|6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
215135437|NCT04292535|DRUG|20 IU NovoLog Insulin aspart into the intranasal mucosa|5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135438|NCT04292535|DRUG|40 IU NovoLog Insulin aspart into the intranasal mucosa|4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135439|NCT04292535|DRUG|60 IU NovoLog Insulin aspart into the intranasal mucosa|3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135440|NCT04292535|DRUG|80 IU NovoLog Insulin aspart into the intranasal mucosa|2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135441|NCT04292535|DRUG|100 IU NovoLog Insulin aspart into the intranasal mucosa|1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135442|NCT04292535|DRUG|120 IU NovoLog Insulin aspart into the intranasal mucosa|6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
215135443|NCT05708092|BEHAVIORAL|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
215135444|NCT01739998|DIETARY_SUPPLEMENT|functional oil|
215135445|NCT01739998|DIETARY_SUPPLEMENT|Placebo|
215135446|NCT00121017|DRUG|Kaletra (lopinavir/ritonavir)|
215135447|NCT00121017|DRUG|Sustiva (efavirenz)|
214451499|NCT06251063|BEHAVIORAL|Web-based psychoeducational resource|"The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement"
214451500|NCT02199054|OTHER|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
214451501|NCT02199054|OTHER|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
214451502|NCT02199054|OTHER|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
215135448|NCT00121017|DRUG|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
215135449|NCT03515577|PROCEDURE|Computed Tomography|Undergo PET/CT
214451503|NCT04457154|DEVICE|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
214451504|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
214451505|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
214451506|NCT06269146|DRUG|Pramipexole Pill|The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
214451507|NCT06269146|DRUG|Placebo Pill|Placebo will match the study drug in mode of administration, color, size, and taste.
214451508|NCT05694156|OTHER|Music-based cognitive training|8-week music-based cognitive training
214451509|NCT05210322|PROCEDURE|Percutaneous cholangiopancreatoscopy|Per standard treatment protocol for percutaneous cholangiopancreatoscopy, access will be gained into the biliary system using the biliary tube or into the gallbladder using the cholecystostomy tube. After access has been secured, through a peel-away sheath a Spy Glass Discover Digital Catheter will be introduced. Next, either, the stones will then be removed from the biliary system or gallbladder using a combination of baskets, and lithotripsy equipment as required, or in case of biliary strictures, a clamshell biopsy will be taken from the stricture site as identified on endoscopic visualization and cross-sectional imaging. Further intervention maybe performed for the stricture based on operator preference. After the complete stone removal/ stricture management the cholecystostomy/ biliary tube will be removed after the patient passes a clinical capping trial.
214451510|NCT01804634|DRUG|Cyclophosphamide|preparative regimen
214451511|NCT01804634|DRUG|Fludarabine|
214451512|NCT01804634|RADIATION|low dose total body irradiation|
214451513|NCT01804634|DRUG|Melphalan|
214451514|NCT01804634|DRUG|Tacrolimus|
214451515|NCT03001414|BIOLOGICAL|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
215135450|NCT03515577|DRUG|Fluciclovine F18|Given fluciclovine F18
215135451|NCT03515577|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
215135452|NCT03515577|OTHER|Laboratory Biomarker Analysis|Correlative studies
215135453|NCT03515577|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215135454|NCT01992588|DRUG|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
215135455|NCT01992588|DRUG|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
215135456|NCT03836625|OTHER|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
215135457|NCT01897025|DEVICE|real-tDCS with MI-BCI|As in Arm Description
214451516|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
214451517|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
214451518|NCT05400369|DRUG|Sitafloxacin|Oral administration, 50 mg tablets
214451519|NCT05400369|DRUG|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
215135458|NCT00980187|DRUG|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
215135459|NCT00980187|DRUG|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
215135460|NCT00210574|DRUG|topiramate|
215135461|NCT04762511|BIOLOGICAL|Lower dose formulation of HSV vaccine (GSK4108771A)|2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
214451520|NCT05917158|DRUG|RC48-ADC and JS001|Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
214451521|NCT06307470|BEHAVIORAL|EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)|"The intervention will be led by a registered nurse who holds certifications in sexuality counseling and sex education. The therapeutic, online environment will serve as a confidential, private space without judgement to encourage discussion to model safe sexuality communication for breast cancer survivors. The curriculum will include: i) psychoeducation: sexual body, mind-body connection, and sexual relationships; ii) physical-body education: physical response, safety, and navigating physical changes in survivorship; iii) solution-focused tools: tailored vaginal rehydration, lubrication, education; and iv) communication: internal, partnered, and patient-provider communication skills.~The solution-focused tools will include vaginal rehydration and dilation products with vaginal lubrication. Tools will be distributed via mail by Session 2."
214451522|NCT05443048|DEVICE|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
215135462|NCT04762511|BIOLOGICAL|Low dose formulation of HSV vaccine (GSK4108771A)|2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
214451523|NCT05425433|OTHER|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
214451524|NCT05660018|DEVICE|active rTMS first, then sham rTMS|Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
214451525|NCT05660018|DEVICE|sham rTMS first, then active rTMS|Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
214451526|NCT05157490|BEHAVIORAL|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
214451527|NCT06652360|DEVICE|Chemical Debridement|The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.
214451528|NCT06652360|DEVICE|Curettage debridement|The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
214451529|NCT04816461|DRUG|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
214451530|NCT04816461|DRUG|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
214451531|NCT04816461|DIAGNOSTIC_TEST|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
214451532|NCT04562766|DRUG|Rilzabrutinib|400mg Caplet
214451533|NCT04562766|DRUG|Placebo|400mg Caplet
214451534|NCT03272373|DEVICE|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
214451535|NCT03272373|DEVICE|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
214451536|NCT04663087|DEVICE|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
214451537|NCT04663087|OTHER|Standard of Care|As currently provided by EMS services
214451538|NCT05728697|DEVICE|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
214451539|NCT03818711|BEHAVIORAL|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
214451540|NCT03818711|BEHAVIORAL|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
214451541|NCT03951194|BIOLOGICAL|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
214451542|NCT03951194|OTHER|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
214451543|NCT05172934|DRUG|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
214451544|NCT04339166|DIAGNOSTIC_TEST|Non-invasive chromosome screening（NICS）|NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
215135463|NCT04762511|BIOLOGICAL|Medium dose formulation of HSV vaccine (GSK4108771A)|2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
215135464|NCT04762511|BIOLOGICAL|High dose formulation of HSV vaccine (GSK4108771A)|2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
215135465|NCT04762511|DRUG|Placebo (saline)|2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
215135466|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D|
215135467|NCT01121796|OTHER|Water or milk|
214451545|NCT06848582|BIOLOGICAL|umbilical cord blood NK cells|All subjects will receive Ex vivo Expanded and activated umbilical cord blood NK cells infusion.
214451546|NCT06220643|OTHER|resistance exercise|Progressive resistance exercise for 12 weeks
214451547|NCT06220643|DRUG|triamcinolone acetonide plus lidocaine|40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
214451548|NCT05605678|OTHER|No Intervention|This is a non-interventional study.
214451549|NCT06848517|OTHER|BSATP Group|"Participants and the therapist will communicate once weekly synchronously (e.g. through video calls with a 30 minute duration), regarding the proper execution of the PFM exercises, providing motivation etc. Additionally, participants will be advised to watch the educational videos (10 mins duration) asynchronously twice a week. In total, participants will follow a BSATP three times a week (for 12 weeks). The PFM exercise program will include endurance training (slow velocity contractions), speed training (quick contractions) and Knack maneuver training (pre-contraction before the increment of the intra-abdominal pressure).The PFM exercise program will be based on three assessments conducted by the therapist throughout the study (baseline, 6 weeks and 12 weeks). As a result, the PFM exercise program will be individualized to meet their needs and progressively increases in difficulty, with the exercise position being modified every two weeks (e.g. supine, side, prone ect)"
214451550|NCT06848517|OTHER|FtFS Group|Participants will attend one weekly face-to-face session with their therapist, to discuss the progress of their treatment and ensure its seamless continuation (intra-vaginal assessment, adjustments, motivation etc.). Each session will last approximately 30 minutes. Participants will also be advised to perform the PFM program twice a week on their own e.g. at home. In total, participants will follow a PFM program three times a week (for 12 weeks), once with their therapist and twice independently. The participants in the FtFS group will follow the same PFM exercise treatment program as the BSATP group, which will be an individualized program where the position will change every two weeks and include endurance training, speed training and 'Knack maneuver' training.
214451551|NCT06848517|OTHER|Control Group (CG)|The participants will be advised to follow a PFM exercise treatment program at home, based on an educational home leaflet (with instructions and images about PFM exercises) that they received during their first assessment session (baseline). The participants of this group will follow a PFM exercise therapy program (through the leaflet) which will last 12 weeks and they will be advised to attend it three times a week. No face-to-face meetings or supervision will occur by the therapist during the treatment period. Similarly to the other two intervention groups, the provided PFM exercise treatment program will be individualized, will include endurance training, speed training, and 'Knack maneuver' training, and the participants will be encouraged to change their exercise position on their own every two weeks.
214451552|NCT06444087|OTHER|secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
214451553|NCT04572152|BIOLOGICAL|AK119|Subjects will receive AK119 by intravenous administration.
215135468|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D enriched milk|
215135469|NCT03167892|DEVICE|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
215135470|NCT02111421|DRUG|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
215135471|NCT02111421|DRUG|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
215135472|NCT05408377|OTHER|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
215135473|NCT05408377|OTHER|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
215135474|NCT06378775|PROCEDURE|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
215135475|NCT06378775|PROCEDURE|Robotically-assisted minimally-invasive direct coronary artery bypass|Robotically-assisted minimally-invasive direct coronary artery bypass
215135476|NCT06378775|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
215135477|NCT00949182|DRUG|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
215135478|NCT00949182|OTHER|laboratory biomarker analysis|
215135479|NCT03661320|BIOLOGICAL|Nivolumab|Specified dose on specified days
215135480|NCT03661320|DRUG|Gemcitabine|Specified dose on specified days
215135481|NCT03661320|DRUG|Cisplatin|Specified dose on specified days
215135482|NCT00310765|DRUG|Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
215135483|NCT00310765|DRUG|Placebo first followed by open label pregabalin|Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
215135484|NCT04247217|RADIATION|HDR salvage brachytherapy|In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.
215135485|NCT00328939|DRUG|ARIXTRA infusion|
215135486|NCT00328939|DRUG|Enoxaparine infusion|
215135487|NCT06132269|DIETARY_SUPPLEMENT|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
215135488|NCT06132269|DIETARY_SUPPLEMENT|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
215135489|NCT00000669|DRUG|Didanosine|
215135490|NCT02869711|OTHER|Health care quality management|
214451554|NCT04572152|BIOLOGICAL|AK104|On the same day subjects will receive AK104 by intravenous administration.
214451555|NCT05655065|PROCEDURE|increase of mean arterial pressure at 65-70 mmHg|Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)
214451556|NCT05655065|PROCEDURE|increase of mean arterial pressure at 80-85 mmHg|Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
214451557|NCT06850155|PROCEDURE|Sling release|The gluteal sling was released and left unrepaired at the end of the procedure
214451558|NCT06850155|PROCEDURE|Sling release and repair|The gluteal sling was released and then repaired at the end of the procedure
214451559|NCT06849024|DEVICE|Transcutaneous electrical neurostimulation|Transcutaneous electrical nerve stimulation or placebo during 30 minutes three times per week for 60 days.
214451560|NCT00891709|DRUG|LEO 29102|First-in-man. Healthy volunteers
214451561|NCT02670447|PROCEDURE|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
215135491|NCT05569434|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
215135492|NCT05666323|BEHAVIORAL|Single Text Messaging (TM1)|Receives single text message
215135493|NCT05666323|BEHAVIORAL|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
215135494|NCT05666323|BEHAVIORAL|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
215135495|NCT00402857|BEHAVIORAL|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
215135496|NCT01420861|DRUG|GTx-758|two GTx 758 tablets per day
215135497|NCT00271674|DEVICE|Q-switched YAG laser|
215135498|NCT03269526|DRUG|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
215135499|NCT05254626|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
215135500|NCT05254626|DRUG|Pioglitazone 30 mg|Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
215135501|NCT00711698|PROCEDURE|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
215135502|NCT00711698|DRUG|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
215135503|NCT02168868|DIAGNOSTIC_TEST|Blood draw|A blood sample (5 mL) will be collected.
215135504|NCT02168868|DIAGNOSTIC_TEST|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
215135505|NCT02168868|DIAGNOSTIC_TEST|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
215135506|NCT05139472|DRUG|Empagliflozin 10 MG|Daily Empagliflozin
215135507|NCT05420935|DIAGNOSTIC_TEST|IgG group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml"
215135508|NCT05420935|DIAGNOSTIC_TEST|IgE group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling"
215135509|NCT05420935|DIAGNOSTIC_TEST|IgG group + IgE group|"* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling"
215135510|NCT05242029|DRUG|Placebo|Participants will receive placebo in a clinical setting.
215135511|NCT05242029|DRUG|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
215135512|NCT05549817|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
215135513|NCT05549817|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
215135514|NCT03240887|BEHAVIORAL|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
215135515|NCT01247324|DRUG|Interferon beta-1a|
215135516|NCT01247324|DRUG|Ocrelizumab-matching placebo|
214525917|NCT00570804|BEHAVIORAL|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
214525918|NCT00570804|BEHAVIORAL|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
215135517|NCT01247324|DRUG|Ocrelizumab|
215135518|NCT01247324|DRUG|Interferon beta-1a-matching placebo|
215135519|NCT01253291|DRUG|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
215135520|NCT03826719|BIOLOGICAL|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
215135521|NCT03826719|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains(trivalent)
215135522|NCT01739166|OTHER|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
215135523|NCT06098469|DEVICE|Neurofeedback sessions|10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
215135524|NCT05255575|DRUG|Ertapenem|Patients will receive ertapenem therapy.
215135525|NCT01344915|PROCEDURE|Locked knee brace|
215135526|NCT01344915|PROCEDURE|Locked knee brace|
214451562|NCT06848985|BEHAVIORAL|Aerobic combined with Resistance exercise|Participants are required to perform aerobic and resistance exercises. Aerobic exercises included the use of treadmills and elliptical machines, with intensity maintained at 60%-70% of the maximum heart rate (calculated as 220 minus age), for a total of 40 minutes per session (5 minutes of warm-up, 30 minutes of main exercise, and 5 minutes of cool-down). Heart rate monitors were used to ensure the intensity was maintained; resistance exercises involved gym equipment and bodyweight exercises, including the use of a pec deck machine, lat pull-downs, chest presses, bicep curls, tricep extensions, leg curls, and leg presses. The intensity of resistance exercises was set at about 65%-70% of one repetition maximum (1RM), with each session consisting of three sets of 6-8 repetitions and lasting for 30 minutes.
214451563|NCT05868525|DRUG|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
214451564|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
214451565|NCT05918783|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
214451566|NCT06263595|DEVICE|gastric antral sonography|Participant will undergo gastric antrum ultrasound and be scanned in the supine position followed by the right lateral decubitus position. Qualitative and quantitative assessments will be completed.
215135527|NCT05672290|OTHER|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
215135528|NCT05672290|OTHER|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
215135529|NCT05772741|OTHER|Biological sample collection|Collection of biological samples
215135530|NCT03373578|DEVICE|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
215135531|NCT03799796|BEHAVIORAL|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
215135532|NCT04783350|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
215135533|NCT00004100|DRUG|cisplatin|
215135534|NCT00004100|DRUG|gemcitabine hydrochloride|
215135535|NCT00004100|DRUG|vinorelbine tartrate|
215135536|NCT03816033|PROCEDURE|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
215135537|NCT03816033|PROCEDURE|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
215135538|NCT05968820|BEHAVIORAL|Sleep Health Enhancement Intervention|The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
215135539|NCT06569212|DRUG|Metoprolol|"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
215135540|NCT06569212|DRUG|Placebo|"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
215135541|NCT04563377|BIOLOGICAL|ChAdOx1.HTI and MVA.HTI|ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu
214525919|NCT00092209|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium|
214525920|NCT00092209|DRUG|Comparator: placebo, losartan, hydrochlorothiazide|
214525921|NCT05451056|DRUG|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
215135542|NCT02433626|DRUG|COTI2|COTI-2 is a third generation thiosemicarbazone.
215135543|NCT02433626|DRUG|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
214525922|NCT03672071|OTHER|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
214525923|NCT04773054|DIAGNOSTIC_TEST|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
215135544|NCT06592092|BIOLOGICAL|QH104 Cell injection|Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.
215135545|NCT06603649|OTHER|ECPR for out-of-hospital cardiac arrest|Patient with out-of-hospital cardiac arrest enrolled in the ECPR protocol
215135546|NCT06600477|DRUG|olanzapine|7.5 mg
214451567|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
214451568|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
214451569|NCT05987371|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
214451570|NCT05987371|DRUG|TQC3721 matching placebo for inhalation|Placebo without active substance.
214451571|NCT05987371|DRUG|Salbutamol sulfate inhalation aerosol|Salbutamol is short-acting β2 receptor agonists.
214451572|NCT03936218|DRUG|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
214451573|NCT03936218|DRUG|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
214451574|NCT04877041|BEHAVIORAL|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
214451575|NCT06243211|PROCEDURE|DMED|Decompression of spinal cord with stabilization - posterior approach.
214451576|NCT06243211|PROCEDURE|ANGI|Implantation of nerve tissue following decompression ans stabilization.
214451577|NCT05827861|BEHAVIORAL|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
214525924|NCT04773054|DIAGNOSTIC_TEST|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
214525925|NCT04773054|OTHER|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
214525926|NCT04773054|OTHER|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
214525927|NCT04773054|OTHER|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
214525928|NCT04833842|OTHER|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
214708615|NCT04368559|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
214708616|NCT04368559|DRUG|Posaconazole|Oral antifungal therapy
214708617|NCT04368559|DRUG|Fluconazole|Oral antifungal therapy
215135547|NCT03082690|DRUG|DuoGel|1% IQP-0528 in gel formulation
215135548|NCT06933927|OTHER|(Group A: Bioflx crowns)|Minimal preparation will be required due to their flexural adaptability:1. Choose an appropriately sized Bioflex (Nusmile) crown of similar size to the mesiodistal width.2. The tooth will be prepared using a flame stone for occlusal reduction by 1-1.5 mm, including the central groove .3Proximal preparation will be around 0.5 mm, by using a fine, long, tapered diamond stone to cut interproximal slices mesially and distally.4. The crown will be placed with a snug fit and cemented using glass ionomer
215135549|NCT06933927|OTHER|(Group B) : Preformed Zirconia crown|1\. Size Determination can be achieved by holding a crown up to the existing tooth or, if available, using digital x-ray measurements to match the patient's interproximal width to the corresponding crown size.2. OcclusalPerform an occlusal reduction of about 1.5-2 mm, ensuring adequate space for the crown material. 3. Axial ReductionReduce the buccal and lingual surfaces uniformly, ensuring the removal of any prominent buccal bulges to allow for a passive crown fit. 4. Interproximal ReductionClearance: Ensure sufficient interproximal space by removing enough tooth structure to allow the crown to seat without interference.5. Subgingival PreparationMargin Placement: Extend the preparation subgingivally by approximately 2 mm to achieve optimal crown retention and aesthetics. This involves removing the chamfer margin at the tissue level and ensuring a smooth transition from the root to the coronal tooth structure
215135550|NCT06932198|DRUG|Selexipag Film Coated Tablets|1 tablet
215135551|NCT06932198|DRUG|Uptravi® Film Coated Tablets|1 tablet
214525929|NCT04833842|OTHER|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
215135552|NCT06938048|OTHER|short stretch bendage (Lohmann e Raucher)|extensibility between 10% to 100% of the lenght
215135553|NCT06938048|OTHER|high stretch bandage (Coban)|extensibility above 100% of the lenght
215135554|NCT00278343|DRUG|cediranib maleate|30mg given PO, daily
214451578|NCT05827861|BEHAVIORAL|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
214451579|NCT05827861|BEHAVIORAL|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
214451580|NCT03930342|BEHAVIORAL|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
214451581|NCT06967974|OTHER|Tai Chi + Sleep Hygiene Education|Conduct simplified training on the 24 style Tai Chi; Sleep hygiene education includes adjusting sleep time, maintaining regular lifestyle habits, optimizing bedroom environment, reducing nighttime stimulation, avoiding thinking when going to bed, adjusting alarm clock positions, and reducing daytime napping.
214451582|NCT06967974|OTHER|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
214451583|NCT06365320|OTHER|Single basketball training|Single basketball training session with fixed intensity and duration
214451584|NCT03209713|BEHAVIORAL|HPV Vaccine Education|A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
214451585|NCT03209713|BEHAVIORAL|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
214451586|NCT00152087|DEVICE|Brachytherapy|
214451587|NCT05000489|OTHER|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
214451588|NCT04788459|BIOLOGICAL|COVID-eVax|Plasmid DNA Vaccine for COVID-19
214451589|NCT04788459|DEVICE|Cliniporator® and EPSGun|IGEA Electroporation Device
214451590|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
214451591|NCT05824078|PROCEDURE|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
214451592|NCT05824078|PROCEDURE|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
214451593|NCT05523388|OTHER|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
214451594|NCT03859869|DRUG|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
215135555|NCT00278343|OTHER|laboratory biomarker analysis|Correlative studies
215135556|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
215135557|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
215135558|NCT01021020|DRUG|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
215135559|NCT02764385|OTHER|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
215135560|NCT02764385|OTHER|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
215135561|NCT03598036|DRUG|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
215135562|NCT04665401|BEHAVIORAL|Tailored MERIT|see arm description
215135563|NCT04665401|BEHAVIORAL|Standard MERIT|see arm description
215135564|NCT05632159|DRUG|Mg sulphate|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
215135565|NCT05632159|DRUG|conventional anaesthesia|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
215135566|NCT01556022|DEVICE|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
215135567|NCT01556022|DEVICE|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
215135568|NCT02541097|BEHAVIORAL|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
215135569|NCT00593216|DEVICE|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
214451595|NCT03859869|DRUG|Placebo|Placebo is administered orally as capsules with a meal or snack
215135570|NCT04494841|DEVICE|Duotherm VibraCool Back Device|Low back plate belt with mechanicothermal and pressure intervention options.
215135571|NCT01703195|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
215135572|NCT01703195|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
215135573|NCT05260736|PROCEDURE|Infraclavicular brachial plexus block|Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
215135574|NCT03938233|BEHAVIORAL|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
215135575|NCT04312178|OTHER|cash incentive|cash incentive (20€ gift card)
215135576|NCT04312178|OTHER|no intervention|no intervention
215135577|NCT04312178|OTHER|return vaginal self-swab kit in person|hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
215135578|NCT04607668|DRUG|Trilaciclib|Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
215135579|NCT04607668|DRUG|Placebo|Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
215135580|NCT01497041|DRUG|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
215135581|NCT01497041|DRUG|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
214451596|NCT05857020|DEVICE|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
214451597|NCT00558506|DRUG|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
214451598|NCT06565429|BEHAVIORAL|5-Step Method Intervention|The 5-Step Method (5SM) intervention is delivered through a self-help handbook: There are writing prompts for the affected family member (AFM) in each step. The steps end with a summary, a space to reflect and a statement that the step is complete but can be reviewed as needed. The steps are: 1.Explore how the relative's drug and/or alcohol misuse is affecting the family member, causing stress and strain. 2.Determine the information the AFM needs to understand the situation using evidence-based websites in the handbook. 3.Reflect on coping styles, and which ones might be useful. 4.Determine who is a source of positive social support, and who could be one that the AFM has not used yet. 5.Review steps 1-4 and determine if the AFM is feeling less stress and strain, or if more help is needed and use websites to look for additional help. The activities should take about 1 hour per week.
214451599|NCT05374278|DRUG|[18F]RP-115 PET/MRI or PET/CT and MRI|An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
214451600|NCT04750707|DRUG|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
214451601|NCT06853548|OTHER|Assessment|Respiratory function, respiratory muscle strength, and core stability parameters will be assessed in children with hyperkyphosis.
214525930|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
214708618|NCT04368559|DRUG|Trimethoprim-sulfamethoxazole (TMP/SMX)|Oral antibacterial therapy
215135582|NCT04888117|PROCEDURE|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
215135583|NCT04888117|PROCEDURE|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
215135584|NCT06742931|OTHER|Discontinuation of antiplatelet agent group|In this group, antiplatelet monotherapy will be discontinued at the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, all antiplatelet agents will be discontinued after randomization.
215135585|NCT06742931|OTHER|Continuation of antiplatelet agent group|In this group, lifelong antiplatelet monotherapy will be continued after the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, DAPT will be changed to single antiplatelet therapy (aspirin or clopidogrel). The choice between aspirin or clopidogrel will be determined by the physician's discretion.
215135586|NCT05306925|DIETARY_SUPPLEMENT|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
215135587|NCT01488045|DRUG|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
215135588|NCT01488045|DRUG|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
215135589|NCT01488045|DRUG|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
215135590|NCT05043363|DEVICE|LumenEye X1 digital rectoscope|The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
215135591|NCT01481922|DEVICE|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
215135592|NCT01481922|DEVICE|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
215135593|NCT00989911|DRUG|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
215135594|NCT03813355|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
215135595|NCT01380353|DRUG|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
215135596|NCT01472640|DRUG|liraglutide|1.8 mg sc QOD
215135597|NCT01472640|DRUG|placebo|1 U sc QOD
215135598|NCT01285141|BIOLOGICAL|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
215135599|NCT00060528|DRUG|Recombinant Fowlpox-GM-CSF|
215135600|NCT00060528|DRUG|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
215135601|NCT00060528|DRUG|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
215135602|NCT00060528|DRUG|Recombinant Human GM-CSF|
215135603|NCT00739921|PROCEDURE|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
215135604|NCT02096445|DEVICE|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
214451602|NCT06654661|DEVICE|3D-Printed Mechanical Balancer|The 3D printed mechanical balancer is a surgeon-controlled handheld intraoperative tool used that provides a quantifiable measurement of force differences on the medial and lateral sides to guide achievement of a balanced knee. It will be used at one timepoint during scheduled TKA surgery while the patient is under anesthesia. Readings will be taken at 0, 45, and 90 degrees of flexion.
214451603|NCT06979778|DEVICE|See Yourself Differently (syd) mobile app|"The 'syd' mobile app is designed as an AI-powered Life Quality Mentor with the primary aim of enhancing users' quality of life. The app focuses on positive habit development, personalised feedback, and continuous support. It offers personalised guidance across various domains, including Physical health, Emotional health, Brain power, Self-awareness, Purpose, Career, Financial health, Social life and Environment. It utilizes an advanced AI platform and offers features like personalised recommendations, supportive interaction with an AI mentor, habit tracking tools, and integration with wearable technology."
214451604|NCT06602804|DEVICE|Trima Accel Auto RBC Collection|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.
214451605|NCT05752916|DRUG|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
215135605|NCT02096445|OTHER|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
215135606|NCT01874236|DRUG|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
215135607|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
215135608|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
215135609|NCT01592734|DRUG|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
215135610|NCT01592734|DEVICE|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
215135611|NCT05842616|OTHER|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
215135612|NCT05842616|OTHER|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
215135613|NCT00002298|DRUG|Ribavirin|
215135614|NCT02913339|OTHER|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
215135615|NCT00736541|DRUG|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
215135616|NCT04091620|PROCEDURE|Transanal Total Mesorectal Excision|As above
215135617|NCT04091620|PROCEDURE|Robotic Total Mesorectal Excision|As above
214525931|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
214525932|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
215135618|NCT02515916|OTHER|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
215135619|NCT03962036|DEVICE|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
215135620|NCT05494840|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
215135621|NCT03539406|BIOLOGICAL|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
215135622|NCT03539406|DRUG|Chemotherapy|Cyclofosfamide/fludarabine treatment
215135623|NCT04673318|BEHAVIORAL|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
215135624|NCT04673318|BEHAVIORAL|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
215135625|NCT02230410|DEVICE|CryoBalloon Focal Ablation|
215135626|NCT03939143|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
215135627|NCT03939143|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
215135628|NCT04141748|DEVICE|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
215135629|NCT04141748|PROCEDURE|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
215135630|NCT00573222|DRUG|Symbicort|
215135631|NCT06556706|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|"UA is produced by the gut microbiome following the digestion of dietary precursors (polyphenols such as ellagitannins and punicalagins) present in fruits and nuts such as pomegranate, nuts and berries.~In mouse models of aging and muscle dystrophy, UA was shown to induce mitophagy and mitochondrial function in the skeletal muscle. This was associated with improved muscle strength and endurance (Nat. Med, 2016; Sci Tran Med, 2021). In humans, UA was shown to be safe and bioavailable in multiple clinical studies (Nat. Met, 2019; Cell Rep Med, 2022; JAMA Network Open, 2022)."
215135632|NCT06556706|DIETARY_SUPPLEMENT|Placebo|Placebo containing excipients other than Urolithin A (Mitopure)
215135633|NCT02212015|DRUG|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
215135634|NCT01048593|DRUG|IBI-10090|Single intraocular injection
215135635|NCT03670823|DEVICE|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
215135636|NCT02991222|DRUG|SPARC001 type I|Treatment type I
215135637|NCT02991222|DRUG|SPARC001 type II|Treatment type II
215135638|NCT02991222|DRUG|Reference001 type I|Hydrocodone-Acetaminophen
215135639|NCT02991222|DRUG|Reference001 type II|Hydrocodone-Acetaminophen
215135640|NCT06036225|BEHAVIORAL|Prehabilitation|Remote prehabilitation multi-component.
215135641|NCT04701814|OTHER|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
215135642|NCT03992560|DEVICE|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
214708619|NCT04368559|DRUG|Intravenous Placebo|Normal saline
215135643|NCT04732312|OTHER|Home help|Setting up of a formal home help
215135644|NCT04589741|DRUG|Toripalimab Combined With CAV/IE chemotherapy|"CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
215135645|NCT04589741|DRUG|CAV/IE alternate chemotherapy|"CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
215135646|NCT01312857|DRUG|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
215135647|NCT01312857|DRUG|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
214451606|NCT05752916|DRUG|Antiplatelet Agents|Aspirin (150-300mg) is offered to patients allocated in the control arm, unless contraindicated. According to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023, 150-300mg aspirin alone is recommended for acute stroke treatment in patients who are otherwise eligible for intravenous thrombolysis or EVT as soon as possible (Class 1 of recommendation, Level A of evidence). The aspirin dose can be changed to 50-300 mg/day after the acute phase. Clopidogrel is indicated as an alternative in case of aspirin intolerance (Class 2 of recommendation, Level C of evidence)
214451607|NCT06986473|OTHER|Questionnaire that measure the level of awareness of dermatologists|This study will be an observational cross-sectional analytical study that will recruit 165 dermatologists of both genders according to sample size calculation from different outpatient clinics in Cairo teaching hospitals. The aim of the study will be to develope a questionnaire to evaluate the awareness of Egyptian dermatologist towards the role of physical therapy in patients with various skin diseases
214451608|NCT06986668|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
214451609|NCT06986668|OTHER|paraffin bath|It is an effective treatment for the treatment of patients' hands, arms and feet by applying the brushing method to different body parts, relieving pain and improving function, thus providing freedom of life.
214451610|NCT06986668|OTHER|home exersize|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
214525933|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
214525934|NCT01673100|BEHAVIORAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
214525935|NCT02843698|DRUG|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
214451611|NCT06986395|DEVICE|Blood Flow Restriction Training (BFRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
214451612|NCT06986395|OTHER|Conventional Resistance Training (CRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
214451613|NCT06987149|DEVICE|CAD/CAM Zirconia Membrane|A prefabricated, non-resorbable zirconia membrane fabricated using CAD/CAM technology for guided bone regeneration in horizontal ridge deficiencies during simultaneous dental implant placement.
214451614|NCT06987149|PROCEDURE|Contour Augmentation|Traditional guided bone regeneration using particulate bone graft and a resorbable collagen membrane, placed concurrently with the dental implant to augment horizontal ridge deficiencies.
214451615|NCT06984913|OTHER|Ultrasound-guided sphenopalatine ganglion block|Patients will receive an ultrasound-guided sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
214451616|NCT06984913|OTHER|Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
214525936|NCT02843698|DRUG|Normal saline|Normal saline
214525937|NCT06381219|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE
214525938|NCT06381219|OTHER|Implementation of hen's egg in decreasingly heated forms|Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
214708620|NCT04368559|DRUG|Oral Placebo|Microcrystalline cellulose
214525939|NCT01531478|OTHER|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
214525940|NCT04647409|OTHER|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
215135648|NCT02388269|DEVICE|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
215135649|NCT03724136|PROCEDURE|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
215135650|NCT03724136|PROCEDURE|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
215135651|NCT03724136|PROCEDURE|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
214451617|NCT06984913|OTHER|Low dose Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (2 ml bupivacaine 0.25%) (low dose).
214451618|NCT06987630|DEVICE|monitor integrated pulmonary index（IPI） and take appropriate measures|When the IPI is ≤ 6, the patient's jaw is immediately lifted, the oxygen flow rate increases to 6L·min-1, and if the SpO2 continues to decrease by \<90%, the anesthesia mask is pressurized and ventilated.
214451619|NCT06987838|DRUG|Pharmacological treatment|All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3 menstrual cycles.
214451620|NCT06987838|OTHER|Virtual reality|The experimental group will receive virtual reality during the first 2 days of menstruation, for 3 menstrual cycles.
214451621|NCT06988358|DIAGNOSTIC_TEST|Group of children identified by the algorithm as having asthma|150 medical files of children identified by the algorithm as having asthma will be randomly selected for expert appraisal.
214451622|NCT06988358|DIAGNOSTIC_TEST|Group of children not identified by the algorithm as having asthma|150 medical files of children not identified by the algorithm as having asthma will be randomly selected for expert appraisal.
214451623|NCT06986915|OTHER|Aerobic exercise at moderate intensity level|"The intervention involved supervised aerobic activity sessions. Every session contained:~Warm-up (5-10 minutes): To get the body ready, do some light stretching and low-intensity exercises.~The primary aerobic activity (30-45 minutes) should consist of moderately intense exercises that aim to reach 60-75% of the participant's maximal heart rate.~Cool-down (5-10 minutes): Stretching and a gradual decrease in activity to aid in recuperation.~This intervention's objective was to evaluate how moderately intense aerobic exercise affected the anthropometric (body weight, BMI), biochemical (blood sugar, cholesterol), and psychological well-being indicators in obese adult women."
214451624|NCT06987747|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossei (FDI) muscle of the left motor cortex will be targeted using neuronavigation software. A series of 90 triplet pulses will be delivered at 100 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right FDI muscle. The delivery of rTMS requires \~ 15 minutes in total.
214451625|NCT06987305|DRUG|Intravenous rhTNK-tPA|Patients will received intravenous rhTNK-tPA
214451626|NCT06987305|DRUG|Intravenous placebo|Patients will received intravenous placebo
214451627|NCT06987305|PROCEDURE|Endovascular thrombectomy|Patients will received endovascular thrombectomy
214451628|NCT03748342|DEVICE|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
214451629|NCT05152368|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
214451630|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
214451631|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
214525941|NCT04707287|OTHER|No Intervention|No intervention used. This is observational study
214525942|NCT03023878|DRUG|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
215135652|NCT00603317|DRUG|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
215135653|NCT00603317|DRUG|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
215135654|NCT03448406|DRUG|Empagliflozin|Film-coated tablet
215135655|NCT03448406|DRUG|Placebo|Film-coated tablet
215135656|NCT05741424|DIAGNOSTIC_TEST|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
215135657|NCT05741424|DIAGNOSTIC_TEST|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
215135658|NCT02328924|OTHER|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
215135659|NCT00685412|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
215135660|NCT04298320|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
215135661|NCT04298320|DRUG|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
215135662|NCT03405792|DRUG|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
215135663|NCT03405792|DEVICE|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
215135664|NCT03405792|DRUG|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
215135665|NCT04670588|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
215135666|NCT06070883|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
215135667|NCT06208969|BEHAVIORAL|intensive nutrition counseling|individualized regular nutrition education
215135668|NCT05405062|DEVICE|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
215135669|NCT05338684|DEVICE|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
215135670|NCT05720182|DEVICE|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg."
215135671|NCT05720182|PROCEDURE|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
215135672|NCT05720182|OTHER|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
215135673|NCT05134584|DRUG|Linaclotide|290μg once daily, 4 weeks
215135674|NCT05134584|DRUG|Lactulose|20mL once daily, 4 weeks
215135675|NCT05134584|DRUG|Omeprazol|20mg twice daily for the first 10 days
215135676|NCT05134584|DRUG|Itopride|50mg three times daily for the first 10 days
215135677|NCT00770263|DRUG|Erlotinib|
215135678|NCT00770263|DRUG|Temsirolimus|
215135679|NCT04282486|OTHER|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
215135680|NCT01735422|DRUG|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
215135681|NCT01735422|DRUG|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
215135682|NCT01735422|DRUG|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
215135683|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135684|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135685|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135686|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135687|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135688|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135689|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135690|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
215135691|NCT00941746|BIOLOGICAL|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
214525943|NCT03023878|DRUG|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
214525944|NCT03023878|DRUG|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
214525945|NCT01198899|OTHER|blood sampling|Blood sampling will be used.
215135692|NCT06069193|BEHAVIORAL|Touch Intervention|"The participants will be examined, with various areas in the neck and upper back being palpated. Subsequently, the exercises to be performed at home will be demonstrated by the experimenter. The experimenter will ensure correct execution by touching specific areas in the neck and upper back of the participants. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
215135693|NCT06069193|BEHAVIORAL|Control|"The participants will be examined, and they will be asked to describe as accurately as possible the regions where they experience pain. Subsequently, the experimenter will demonstrate the exercises to be performed at home. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
215135694|NCT03905018|DRUG|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
215135695|NCT04232722|DRUG|Arsenicals|As4 S4
215135696|NCT05910684|DIAGNOSTIC_TEST|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
215135697|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
215135698|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
215135699|NCT03614182|DEVICE|physical training concurrent with cognitive training|The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
215135700|NCT03614182|DEVICE|physical training followed by cognitive training|The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
215135701|NCT03614182|DEVICE|physical training without cognitive training|The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
215135702|NCT03882021|PROCEDURE|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
215135703|NCT02485873|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
215135704|NCT02485873|DRUG|Vitamin K antagonists|As prescribed by treating physicians
215135705|NCT05018000|BEHAVIORAL|Financial navigation|The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.
215135706|NCT05018000|BEHAVIORAL|Enhanced usual care|The financial resource sheet lists and describes existing internal and community resources available to KP members
215135707|NCT05255679|DEVICE|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
215135708|NCT05255679|DEVICE|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
215135709|NCT04151212|DRUG|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
214694841|NCT05324826|DEVICE|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
214694842|NCT03794141|BEHAVIORAL|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
214694843|NCT03794141|BEHAVIORAL|life style advise|all test persons were given information on healthy diet and life style
215135710|NCT03763032|BEHAVIORAL|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
215135711|NCT06204965|BEHAVIORAL|Time-restricted eating|Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
215135712|NCT02726997|DRUG|Carboplatin|Given IV
215135713|NCT02726997|BIOLOGICAL|Durvalumab|Given IV
215135714|NCT02726997|OTHER|Laboratory Biomarker Analysis|Correlative studies
215135715|NCT02726997|DRUG|Paclitaxel|Given IV
215135716|NCT02726997|OTHER|Pharmacological Study|Correlative studies
215135717|NCT02726997|OTHER|Quality-of-Life Assessment|Ancillary studies
215135718|NCT03383601|OTHER|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
215135719|NCT03383601|OTHER|Smoking combustible cigarettes|Current smoking of combustible cigarettes
215135720|NCT05830500|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
215135721|NCT03186209|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
215135722|NCT03186209|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
215135723|NCT01099696|DIETARY_SUPPLEMENT|B. infantis 35624|B. infantis 35624 in white capsules
214451632|NCT06303960|DEVICE|Bilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
215135724|NCT01099696|DIETARY_SUPPLEMENT|placebo|white placebo capsules
215135725|NCT00939549|DRUG|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
215135726|NCT04100083|DRUG|Spironolactone 50 MG|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
215135727|NCT04100083|DRUG|Spironolactone 100mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
214451633|NCT06303960|DEVICE|Unilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
214451634|NCT06303960|DEVICE|Vagus Nerve Stimulation|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
214451635|NCT06866509|DRUG|Litorvazet Tablet 10/10mg|Ezetimibe 10 mg + Atorvastatin 10 mg
214451636|NCT06866509|DRUG|Litorvazet Tablet10/20mg|Ezetimibe 10 mg + Atorvastatin 20 mg
214451637|NCT06866509|DRUG|Litorvazet Tablet 10/40mg|Ezetimibe 10 mg + Atorvastatin 40 mg
214451638|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
214451639|NCT03615690|OTHER|Regular Diet|Regular Diet
214451640|NCT06629766|DEVICE|Microfluidic sperm separation device|An aliquot of 850ul will be used for the Zymot sperm selection device. The sperm processing via Zymot will be per manufacturer's guidelines
214708621|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
215135728|NCT04100083|DRUG|Spironolactone 200 mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
215135729|NCT05873049|DEVICE|MolecuLight|MolecuLight is a handheld fluorescence imaging device that is utilized to help real-time visualize clinically undetectable fluorescent bacteria in wounds. It emits a 405 nm wavelength of safe violet light, which interacts with the wound tissue and bacteria causing certain bacteria to emit red or cyan fluorescence. The fluorescence signals were then captured by MolecuLight and those with bacteria at levels of ≥ 10\^4 colony forming units per gram (CFU/g) will be detected and displayed on the screen.
215135730|NCT04244448|DRUG|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
215135731|NCT04244448|DRUG|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
215135732|NCT04244448|DRUG|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
215135733|NCT03011268|OTHER|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
215135734|NCT03011268|OTHER|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
215135735|NCT04162288|OTHER|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
215135736|NCT04162288|OTHER|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
214451641|NCT06629766|OTHER|Density grade centrifugation|5ul of the ejaculated sample will be assessed for DGC via Makler assessment. If the sample for DGC is adequate per lab standard operating procedures, then routine DGC sperm preparation and embryologist sperm selection for the ICSI procedure will occur.
214451642|NCT06835595|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|Paired stimulation protocols of TMS to collect SAI, SICI, ICF measures
214451643|NCT05650645|DRUG|incobotulinum toxin A|The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
214451644|NCT05650645|DRUG|Placebo-Saline|Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
214451645|NCT06927193|PROCEDURE|Regional anaesthesia|Regional anaesthesia
214525946|NCT04478799|DEVICE|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
214708622|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
214451646|NCT06784778|DIAGNOSTIC_TEST|PBMC Kinase Activity Profile|Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments
214451647|NCT06840379|DRUG|Sertraline (Oral Antidepressant)|"* 25 mg/day sertraline, titrated up to 100 mg/day based on clinical response and tolerability.~* Administered orally once daily for 12 weeks.~* Used to assess its effects on C-reactive protein (CRP) levels and depressive symptoms in hemodialysis patients."
214451648|NCT06840379|DRUG|Placebo|"* Identical placebo tablet administered orally once daily for 12 weeks, following the same dosing schedule as the sertraline group.~* Used to compare the effects of sertraline vs. placebo on CRP levels and depression severity in hemodialysis patients."
215135737|NCT05665634|DEVICE|Concurrent transcranial magnetic stimulation and electroencephalogram|Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
215135738|NCT02443467|OTHER|No intervention|
215135739|NCT00217984|OTHER|Usual Care|Referral to smoking cessation clinic
215135740|NCT00217984|BEHAVIORAL|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
215135741|NCT05298579|OTHER|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
215135742|NCT03314103|BIOLOGICAL|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
215135743|NCT03314103|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
215135744|NCT06560385|DIETARY_SUPPLEMENT|BLHK03|BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds
215135745|NCT06560385|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 5mcg of Vitamin B7
215135746|NCT03770546|BIOLOGICAL|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
215135747|NCT03770546|DRUG|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
215135748|NCT05941546|DIAGNOSTIC_TEST|anti-TBEV serology|we will measure by ELISA in microplates the anti-TBEV IgG as well as the anti-TBEV IgM on the sera + in TBEV IgG. We will then send a patient questionnaire with an information note to document the context of this TBEV seropositivity and to eliminate false-positivities (vaccination). Finally, we will perform PCR on CSF if serum positive and CSF available
215135749|NCT05042674|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 2 additional blood draws
215135750|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams|after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws
215135751|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams, daily for 1 week|a blood draw will be administered after a week of consuming 25mg ergothioneine daily
215135752|NCT01124110|BEHAVIORAL|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
215135753|NCT01124110|OTHER|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
214451649|NCT04858139|DRUG|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
214451650|NCT04858139|DRUG|Placebo|Intravenous injection (20 min)
214451651|NCT06073743|OTHER|Conventional Physiotherapy|The conventional physiotherapy program will be applied 2 days a week, 60 minutes a day for 10 weeks and consist of weight bearing on the upper and lower extremities, strengthening, functional stretching exercises, walking training and balance exercises.
214451652|NCT06073743|OTHER|Video Game Based Exercise Training|In the Video Game Based Exercise Training program, in addition to the same conventional physiotherapy application for 30 minutes a day, 2 days a week for 10 weeks, 30 minutes of Microsoft Xbox Kinect video games such as reflex ridge and rallyball are used.
215135754|NCT05039749|DEVICE|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
215135755|NCT04435925|DRUG|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
215135756|NCT04435925|DRUG|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
215135757|NCT02972775|OTHER|no interventions. observational study|
215135758|NCT05397730|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
215135759|NCT04831645|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
215135760|NCT04831645|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
214451653|NCT06630000|BEHAVIORAL|FACT|Two 90-minute FACT sessions led by a trained interventionist.
214708623|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
214708624|NCT02373371|DRUG|Metvix®|
215135761|NCT00028067|DRUG|Atazanavir|
215135762|NCT00028067|DRUG|Nelfinavir mesylate|
214451654|NCT06630000|BEHAVIORAL|Control|Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
214708625|NCT02373371|PROCEDURE|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
215135763|NCT01862146|PROCEDURE|smoke expose|
215135764|NCT00688896|DRUG|JTT-705 600 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
215135765|NCT00688896|DRUG|JTT-705 300 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
215135766|NCT00688896|DRUG|Placebo and pravastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
215135767|NCT00517946|DRUG|pseudoephedrine hydrochloride|
215135768|NCT00517946|DRUG|cetirizine hydrochloride|
215135769|NCT06217042|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|"Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks."
215135770|NCT06217042|DRUG|gemcitabine; capecitabine|Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
215135771|NCT06236906|DEVICE|Device supported behavioural treatment|The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
215135772|NCT04637568|DIAGNOSTIC_TEST|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
215135773|NCT01260493|OTHER|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
215135774|NCT04175223|DIETARY_SUPPLEMENT|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
215135775|NCT04094597|DRUG|Lactoferrin|lactoferrin is given orally in comparsion to placebp
215135776|NCT04094597|DRUG|Placebos|placebp is given in 2 ml saline
215135777|NCT02424396|DRUG|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
215135778|NCT02424396|DRUG|Placebo|
215135779|NCT02989493|DRUG|Doxazosin|Doxazosin
215135780|NCT02989493|OTHER|Placebo|Placebo
215135781|NCT03017963|DRUG|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
215135782|NCT02559622|DRUG|Secukinumab|300 mg secukinumab
215135783|NCT02559622|OTHER|Placebo|Placebo followed by 300 mg secukinumab
215135784|NCT02559622|OTHER|Placebo|Placebo followed by 150 mg secukinumab
215135785|NCT02559622|DRUG|Secukinumab|150 mg secukinumab
215135786|NCT02082496|DRUG|Liraglutide|S.c. liraglutide 3.0mg once daily
215135787|NCT01950416|DRUG|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
215135788|NCT01950416|DRUG|Clopidogrel 600mg loading dose and 150mg maintenance dose|
214708626|NCT02373371|PROCEDURE|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
215135789|NCT04836052|DRUG|Omega 3 fatty acid|omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
215135790|NCT02163538|DEVICE|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
215135791|NCT02163538|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
215135792|NCT02424773|DEVICE|High Flow Nasal Canula (HFNC)|
215135793|NCT02424773|DEVICE|Venturi mask|
215135794|NCT02424773|DRUG|Oxygen|
215135795|NCT05329246|DEVICE|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
215135796|NCT04643808|DEVICE|transcutaneous auricular vagus nerve stimulation|Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
215135797|NCT05945784|OTHER|Use of Rare Beauty makeup products|Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
215135798|NCT06352580|OTHER|Survey|26 survey questions were administered face to face to parents, which they could answer in a short time.
215135799|NCT04906928|DEVICE|MRI|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~* 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
215135800|NCT05400291|DIAGNOSTIC_TEST|Chondroitin Sulfate Staining|Staining of histopathological slides
215135801|NCT02662673|DEVICE|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
215135802|NCT01412996|PROCEDURE|surgery|single ACCESS laparoscopic cholecystectomy
215135803|NCT01412996|OTHER|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
215135804|NCT02395458|DRUG|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
215135805|NCT02395458|DRUG|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
215135806|NCT03037996|OTHER|patients' response|patients' satisfaction to anesthesia services
215135807|NCT01365923|DRUG|remifentanil|remifentanil effect site-TCI 2-4ng/ml
215135808|NCT01365923|DRUG|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
215135809|NCT05951400|DRUG|Dydrogesterone Tablets|used for pituitary suppression in ICSI cycle
215135810|NCT05951400|DRUG|Cetrorelix|GnRH antagonist for pituitary suppression
215135811|NCT01740167|BEHAVIORAL|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
215135812|NCT02521506|DEVICE|Verio Pattern Alert® activated|
215135813|NCT02521506|DEVICE|Verio Pattern Alert® deactivated|
215135814|NCT02641925|PROCEDURE|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
215135815|NCT02641925|PROCEDURE|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
215135816|NCT05072639|BEHAVIORAL|Guided Meditation|23 minute audio recording
215135817|NCT05883501|BEHAVIORAL|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
215135818|NCT05892224|PROCEDURE|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
215135819|NCT00623948|DEVICE|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
215135820|NCT00382486|PROCEDURE|Reduce the risk of allograft rejection|
215135821|NCT05975827|DEVICE|Sterile Wound Care Liquid Dressing|Sterile wound care liquid dressing is used in the wound treatment
215135822|NCT04562922|DIETARY_SUPPLEMENT|Lifemel|
215135823|NCT05403606|DEVICE|GASPARD®|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
215135824|NCT01126749|DRUG|Gemcitabine|Gemcitabine
215135825|NCT01126749|DRUG|E7389|E7389
215135826|NCT01126749|DRUG|Cisplatin|Cisplatin
214525947|NCT04478799|DEVICE|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
215135827|NCT03224208|DRUG|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
215135828|NCT03224208|DRUG|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
215135829|NCT02404961|OTHER|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
215135830|NCT02135250|DRUG|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
215135831|NCT02135250|OTHER|placebo|the placebo is not drug.
215135832|NCT06062563|DRUG|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
215135833|NCT03753802|OTHER|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
215135834|NCT03753802|OTHER|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
215135835|NCT04927546|BEHAVIORAL|Exercise|Thirty minutes of aerobic exercise in a treadmill.
215135836|NCT01318577|DEVICE|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
215135837|NCT01318577|DEVICE|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
215135838|NCT05732467|DEVICE|visual function training software|Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.
215135839|NCT05732467|OTHER|occlusion therapy|Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.
215135840|NCT05732467|OTHER|corrective glasses|corrective glasses
215135841|NCT00627393|DRUG|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
215135842|NCT00627393|BIOLOGICAL|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
215135843|NCT00627393|DRUG|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
215135844|NCT00627393|DEVICE|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
215135845|NCT05512897|PROCEDURE|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
215135846|NCT01056822|DRUG|1|Continue with same dose of MMF as patient was taking before randomisation
215135847|NCT01056822|DRUG|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
215135848|NCT04324034|DEVICE|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
215135849|NCT04324034|PROCEDURE|laparoscopy|The surgery by conventional laparoscopy is used
215135850|NCT01857219|BEHAVIORAL|Tai chi|
215135851|NCT01423500|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
215135852|NCT01423500|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
215135853|NCT01423500|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
214525948|NCT04083690|DEVICE|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
215135854|NCT01423500|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
215135855|NCT01423500|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
215135856|NCT01423500|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
215135857|NCT01423500|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
215135858|NCT05498649|DEVICE|DT1fA|DT1fA contact lenses
215135859|NCT04524949|DRUG|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
215135860|NCT04524949|DRUG|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
215135861|NCT04524949|DRUG|Placebo|Solvent: alum hydroxide
215135862|NCT06340295|OTHER||
215135863|NCT04169035|DEVICE|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
215135864|NCT04169035|PROCEDURE|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
215135865|NCT02234882|DRUG|Rosuvastatin|
215135866|NCT02234882|DRUG|BMS-663068|
215135867|NCT00568022|DRUG|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
215135868|NCT00568022|DRUG|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
215135869|NCT02265458|BEHAVIORAL|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
214525949|NCT02332421|DEVICE|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
215135870|NCT00459459|PROCEDURE|Fine needle aspiration of the thyroid|
215135871|NCT00904449|DRUG|Oxymorphone ER|10mg, 20mg, and 40mg PO
215135872|NCT04003701|BEHAVIORAL|Usual care|Control group: minimal distraction
215135873|NCT04003701|BEHAVIORAL|Robot-assisted puncture procedure|Experimental group: distraction with robot
214525950|NCT00721708|DIETARY_SUPPLEMENT|pure carnosine|one time dose of pure carnosine (450 mg)
214525951|NCT00721708|OTHER|Beef|one time dose, 150 g of beef
214525952|NCT00721708|OTHER|Chicken|One time dose, 150g of chicken breast
215135874|NCT01751529|PROCEDURE|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
215135875|NCT01751529|DRUG|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
215135876|NCT02743208|DEVICE|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
215135877|NCT02743208|DEVICE|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
215135878|NCT05684536|DEVICE|liagsure device|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
215135879|NCT04609956|OTHER|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
215135880|NCT04609956|OTHER|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
215135881|NCT02680249|DRUG|CTP-656|
215135882|NCT05684822|OTHER|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
215135883|NCT05487612|DEVICE|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
215135884|NCT05487612|DEVICE|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
214525953|NCT00721708|OTHER|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
215135885|NCT04611386|DRUG|computerized tomography|Anti Factor Xa level
215135886|NCT03025282|DRUG|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
215135887|NCT03025282|DRUG|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
215135888|NCT03025282|DRUG|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
215135889|NCT03025282|DRUG|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
215135890|NCT03025282|DRUG|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
215135891|NCT03025282|DRUG|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
215135892|NCT00181272|DRUG|azithromycin|
215135893|NCT00006394|DRUG|growth hormone|
215135894|NCT05916183|BEHAVIORAL|Fluid loss and consumption|Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
215135895|NCT03525236|OTHER|Tasting of flavours|"* Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
215135896|NCT05023642|OTHER|resistance training|"Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
215135897|NCT02318316|OTHER|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
215135898|NCT03711513|BEHAVIORAL|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
215135899|NCT05862220|DIAGNOSTIC_TEST|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
214451655|NCT05395767|PROCEDURE|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
214451656|NCT06932367|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
214525954|NCT05115136|DRUG|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
215135900|NCT00295555|DRUG|Effects of doxazosin on morning surge in diabetic patients|
215135901|NCT06038409|DRUG|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
215135902|NCT02761330|DRUG|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
215135903|NCT02761330|PROCEDURE|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
215135904|NCT05280340|DRUG|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
215135905|NCT03923166|DRUG|Pyrotinib|400mg qd
215135906|NCT03923166|DRUG|capecitabine|capecitabine 500mg tid
215135907|NCT00897481|GENETIC|gene expression analysis|
215135908|NCT00897481|GENETIC|mutation analysis|
215135909|NCT00897481|OTHER|diagnostic laboratory biomarker analysis|
215135910|NCT00897481|OTHER|immunohistochemistry staining method|
215135911|NCT00897481|PROCEDURE|sentinel lymph node biopsy|
215135912|NCT04609943|DRUG|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
215135913|NCT02559284|OTHER|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
215135914|NCT02578147|BEHAVIORAL|Mighty Girls|
214525955|NCT05115136|DRUG|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
214525956|NCT04187963|OTHER|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
214525957|NCT04031547|DEVICE|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
214525958|NCT05452005|DRUG|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
214525959|NCT05118308|PROCEDURE|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
215135915|NCT02578147|BEHAVIORAL|Game Girls|
215135916|NCT01456884|BEHAVIORAL|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
215135917|NCT01456884|BEHAVIORAL|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
215135918|NCT03216525|DRUG|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
214525960|NCT05118308|PROCEDURE|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
215135919|NCT03216525|DRUG|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
215135920|NCT03020251|OTHER|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
215135921|NCT03020251|OTHER|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
215135922|NCT03638453|OTHER|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
215135923|NCT03638453|OTHER|Usual Care|Standard care per hospital guidelines.
215135924|NCT06223893|DEVICE|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
215135925|NCT03041740|DRUG|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
215135926|NCT04291781|BIOLOGICAL|RC18 160mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
215135927|NCT04291781|BIOLOGICAL|RC18 240mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
215135928|NCT04291781|BIOLOGICAL|placebo|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
215135929|NCT06443762|DRUG|[68Ga] MDM2/MDMX Peptide|"Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability."
215135930|NCT06384079|PROCEDURE|Antegrade and retrograde pyelogram|Participation in the study will guarantee that participants will receive this procedure.
215135931|NCT05656859|BEHAVIORAL|Single group|Survey
215135932|NCT06348927|DRUG|sunvozertinib in combination with Anlotinib|"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."
215135933|NCT03043313|DRUG|Trastuzumab|Given intravenously (into the vein; IV)
215135934|NCT03043313|DRUG|Tucatinib|Given orally
215135935|NCT05296473|DEVICE|ADHD Therapy|investigational game-play therapy
214451657|NCT06932367|COMBINATION_PRODUCT|Methylprednisolone (Corticosteroid)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
214451658|NCT06932289|DIETARY_SUPPLEMENT|Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF)|Participants will be randomized to either Mediterranean diet (MED), high-fat/low carb diet (HF/LC), or low-fat diet (LF).
214451659|NCT06932289|DEVICE|The integrated sweat sensor and vascular sensor (wearable)|The integrated sweat sensor and vascular sensor will be worn of each diet period.
214451660|NCT06932289|DEVICE|continuous glucose monitor (CGM)|A continuous glucose monitor (CGM) will be placed on the patients during each diet period.
214451661|NCT06932549|BEHAVIORAL|Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.|The TA is tailored to each congregation using the results of the implementation capacity survey completed by the congregation's team and materials from the EB Program selected by the congregation. The TA teams of two research staff are being trained and coached by Dr. Abe Wandersman, lead developer of Getting To Outcomes-TA (GTO-TA). TA sessions are audio-recorded and will be evaluated for fidelity to GTO-TA, and use of specific ERIC strategies.
214451662|NCT06931808|DRUG|Sintilimab plus Chemotherapy|All patients received standard long-term radiation therapy (LCRT) (50.0Gy/25f) and concurrent chemotherapy with capecitabine (825 mg/m2, bid, po) (Phase 1); Xelox scheme (Oxaliplatin 130 mg/m2, ivgtt ，d1； Capecitabine 1000 mg/m2, bid，d1-14) (Phase 2); . During the radiotherapy and chemotherapy period, they also received two cycles of immunotherapy with Sintilimab (200mg, ivgtt, d1, q3w).
214451663|NCT06931808|DRUG|Intestinal microbiota capsules|During Phase 1, intestinal microbiota transplantation treatment, oral intestinal microbiota capsules are used for transplantation treatment, with a dose of 30 capsules/day (about 1U sediment microbiota, containing about 1 × 1013 bacteria). Transplantation is carried out continuously for 3 days starting from each week, for a total of 3 courses of treatment.
214451664|NCT06931808|RADIATION|Standard Long Course Radiotherapy|50.0Gy/25f
214451665|NCT06931808|PROCEDURE|Total mesorectal excision|6-8 weeks after the end of the first phase and combined with 5 cycles of Xelox regimen adjuvant chemotherapy.
215135936|NCT05296473|DEVICE|Control Therapy|control game-play therapy
215135937|NCT06584188|DRUG|anti-inflammatory ketorolac tromethamine|"* Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}."
215135938|NCT06583668|OTHER|Therapeutic Story|Listening and watching the therapeutic story in digital media
215135939|NCT03294694|DRUG|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
215135940|NCT03294694|DRUG|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
215135941|NCT03294694|DRUG|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
215135942|NCT00980954|DRUG|carboplatin|Intravenously
215135943|NCT00980954|DRUG|cisplatin|Intravenously
215135944|NCT00980954|DRUG|paclitaxel|Intravenously
215135945|NCT00980954|RADIATION|intensity-modulated radiation therapy|Daily fractions
215135946|NCT00980954|RADIATION|standard external beam radiation therapy|Daily fractions
215135947|NCT00980954|RADIATION|Optional brachytherapy boost|Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.
215135948|NCT02657889|DRUG|niraparib|
215135949|NCT02657889|BIOLOGICAL|pembrolizumab|
215135950|NCT06110013|DEVICE|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
215135951|NCT02923973|OTHER|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
215135952|NCT04214340|OTHER|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
214451666|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~4. The parameter setting of the equipment: the frequency is set to 2Hz, the pulse width is set to 500μs, continuous wave is used, and the current intensity is the maximum tolerance of the subject's small pain threshold for 30min."
214525961|NCT06552897|PROCEDURE|Intervention 1: Adductor Canal Block (ACB)|"For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization."
215135953|NCT02602886|BEHAVIORAL|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
215135954|NCT04340635|OTHER||Without intervention
215135955|NCT04281290|PROCEDURE|Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|"Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)"
215135956|NCT05627973|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
214525962|NCT06552897|PROCEDURE|Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)|"Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption."
214525963|NCT00586807|OTHER|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
214525964|NCT04679597|DRUG|Capecitabine|comparison of two treatments
215135957|NCT00670423|DRUG|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
215135958|NCT00670423|DRUG|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
215135959|NCT00670423|DRUG|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
215135960|NCT02819921|DRUG|Desvenlafaxine succinate 100mg|Pristiq 100mg
215135961|NCT02819921|DRUG|Desvenlafaxine succinate 50mg|Pristiq 50mg
215135962|NCT02819921|DRUG|Placebo|Placebo
215135963|NCT04907682|DRUG|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
215135964|NCT04907682|DRUG|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
215135965|NCT03541122|DIAGNOSTIC_TEST|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
214525965|NCT06648707|OTHER|Dual-task training|Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.
214525966|NCT00649142|PROCEDURE|Open sutured mesh repair|Open sutured mesh repair
215135966|NCT01427582|DRUG|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
215135967|NCT06157515|DEVICE|Breath-actuated vibrating mesh nebulizer|The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
214525967|NCT00649142|PROCEDURE|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
214525968|NCT01247922|DRUG|Erlotinib|continuous oral Erlotinib 85 mg/m\^2 per day
215135968|NCT06157515|DEVICE|Continuous vibrating mesh nebulizer|When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
215135969|NCT02883569|PROCEDURE|open or endoscopic discectomy|FDA approved surgical procedures
215135970|NCT02883569|PROCEDURE|epidural block|epidural block
215135971|NCT02883569|OTHER|exercise|educated exercise
214451667|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~(4)30 minutes of ineffective microcurrent stimulation."
214451668|NCT06932510|PROCEDURE|Manual Traction|Manual cervical traction will be administered by a trained physical therapist.
214451669|NCT06932510|DEVICE|Cervical Traction Collar|Cervical traction will be administered via Cervical Traction Collar.
214451670|NCT06931223|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of functional dyspepsia.
214451671|NCT06931223|DRUG|Lansoprazole|Placebo and Lansoprazole for functional dyspepsia.
214451672|NCT06931756|DEVICE|Neural Stimulator|Adjust the neural stimulator, with a stimulation duration of 0.1 ms, a stimulation frequency of 1Hz, and a stimulation current of 1.0mA. Under ultrasound guidance, the needle tip is used to touch the radial nerve, ulnar nerve, median nerve, and musculocutaneous nerve respectively, until a clear motor response is observed in the corresponding muscles. Thereafter, the minimum stimulation threshold current is verified by reducing the current until the distal motor response disappears. If no motor response is elicited, the current intensity is appropriately increased to achieve a motor response of the extensor tendon of the radial nerve, and the flexor tendon motor responses of the ulnar nerve, median nerve, and musculocutaneous nerve.
214451673|NCT06932159|DRUG|Empagliflozin + Linagliptin film-coated tablets|1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets
214451674|NCT06932159|DRUG|Glyxambi film-coated tablets|1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets
214525969|NCT02445781|DEVICE|Glucose clamp|Different levels of hypoglycemia
214525970|NCT04281875|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
214525971|NCT04789889|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
214525972|NCT04789889|RADIATION|postoperative radiotherapy|postoperative radiotherapy
214525973|NCT02570815|DRUG|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
214525974|NCT04506359|OTHER|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
214525975|NCT01876823|DRUG|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
215135972|NCT02883569|DRUG|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
215135973|NCT02883569|PROCEDURE|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
215135974|NCT02883569|PROCEDURE|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
215135975|NCT02883569|DRUG|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
215135976|NCT02883569|PROCEDURE|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
215135977|NCT03210558|DRUG|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
215135978|NCT03210558|DRUG|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
215135979|NCT02468817|PROCEDURE|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
215135980|NCT02468817|PROCEDURE|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
215135981|NCT06417840|DIETARY_SUPPLEMENT|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (\>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.
215135982|NCT06417840|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control
215135983|NCT04215224|DIAGNOSTIC_TEST|Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
215135984|NCT00374140|DRUG|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
215135985|NCT01271777|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
215135986|NCT01271777|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
215135987|NCT02547181|BEHAVIORAL|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
215135988|NCT02547181|BEHAVIORAL|Splint|fibreglass splint
215135989|NCT06353594|DEVICE|Primary PCI|Coronary percutaneous revascularization
215135990|NCT04820595|DIAGNOSTIC_TEST|RASS|Richmond Agitation-Sedation Scale
215135991|NCT04820595|DIAGNOSTIC_TEST|CAM-ICU|Confusion Assessment Method for the ICU
215135992|NCT01576341|DRUG|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
215135993|NCT02068924|OTHER|Slow freezing versus vitrification|
215135994|NCT02121223|DEVICE|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (\>=16atm) for at least 15 seconds.
215135995|NCT02121223|DEVICE|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
215135996|NCT03371836|DRUG|Clobazam|Clobazam is used as an adjunct medicine for all participants.
214451675|NCT06931548|PROCEDURE|Implant-based breast reconstruction using polytetrafluoroethylene mesh|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with polytetrafluoroethylene (PTFE) mesh. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
214451676|NCT06931548|PROCEDURE|Implant-based breast reconstruction using Allogeneic dura mater graft|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with an allogeneic dura mater graft. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
214525976|NCT01876823|DRUG|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
214525977|NCT00006578|DRUG|Ritonavir|
214525978|NCT00006578|DRUG|Abacavir sulfate|
214525979|NCT00006578|DRUG|Amprenavir|
214525980|NCT00006578|DRUG|Lamivudine|
214525981|NCT00006578|DRUG|Filgrastim|
214708627|NCT05455190|BEHAVIORAL|Fit Together|Fit Together intervention follows a clinic and community partnership model for childhood obesity treatment. Children with obesity will receive standard of care obesity treatment from their usual provider and will also receive a referral to an activity program run out of the local community center. Each session delivers a combination of high-intensity individual exercises, sports and games, and unstructured playtime to help children reach the US Physical Activity guidelines of 60min moderate-to-vigorous physical activity daily. There will also be a nutrition activity session offered regularly.
215135997|NCT02847962|OTHER|Corn Soy Blend Plus (CSB+)|
215135998|NCT02847962|OTHER|Corn Soy Blend 14 (CSB14)|
215135999|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 1|
215136000|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 2|
215136001|NCT02847962|OTHER|Red Sorghum Cowpea Blend|
215136002|NCT02847962|OTHER|White Sorghum Soy Blend|
215136003|NCT05196763|BEHAVIORAL|the Supplemental Nutrition Assistance Program-Education|The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
215136004|NCT06073626|BEHAVIORAL|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
214451677|NCT06931470|BEHAVIORAL|In-person supervised exercise sessions|Gold-standard, facility-based sessions (3 sessions/week) with an onsite trainer guidance with an exercise Intensity of 40-80% heart rate reserve (HRR) or Rate of Perceived Exertion (RPE) 12-16.
214451678|NCT06931470|BEHAVIORAL|Virtual classes (live-streamed sessions)|Live-streamed exercise classes (3 sessions/week) with a trainer providing real-time feedback.
214451679|NCT06931470|BEHAVIORAL|Self-directed aerobic exercise|Participants exercise independently and follow a weekly progression plan (3-5 sessions/week (depending on the specific progression)).
214708628|NCT05455190|BEHAVIORAL|Educational materials|Participants will receive a child-friendly cooking magazine mailed quarterly and a local Parks and Recreation program guide.
215136005|NCT06073626|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
215136006|NCT05977413|OTHER|CAC Notification|Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
215136007|NCT05977413|OTHER|Clinician Guideline Reminder|The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
215136008|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
215136009|NCT06179199|DEVICE|SOOMA™ tDCS™|The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
215136010|NCT05295212|DRUG|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
214525982|NCT06545045|BEHAVIORAL|Metacognitive Strategy Training (MCST)|The MCST group will follow procedures for the Cognitive Orientation to daily Occupational Performance intervention. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, the therapist introduces the approach to the subject and teach a global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition. The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
214525983|NCT06545045|BEHAVIORAL|Inactive Control Group|Weekly contact will be made via telephone call to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce cognitive symptoms. The content of each of these meetings will be tracked in intervention notes.
214525984|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
214525985|NCT00577096|BEHAVIORAL|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
214525986|NCT00577096|BIOLOGICAL|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
214525987|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
215136011|NCT06347731|DEVICE|Proton Radiation Therapy|All enrolled participants will be treated with Proton radiation therapy using the medical device Varian ProBeam360° Proton Therapy System. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up which is 3 months after treatment completion and long-term follow-up which is 5 years after treatment completion.
215136012|NCT06211179|DRUG|Treatment A: Mavacamten intact oral capsule|Specified dose on specified days
215136013|NCT06211179|DRUG|Treatment B: Mavacamten open capsule in suspension|Specified dose on specified days
215136014|NCT06211179|DRUG|Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)|Specified dose on specified days
215136015|NCT03454295|BEHAVIORAL|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
215136016|NCT03454295|BEHAVIORAL|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
215136017|NCT03454295|BEHAVIORAL|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
214451680|NCT06931470|DEVICE|Myzone mobile application|Training using the Myzone platform, with participants wearing the Myzone heart rate monitor and using the Myzone app to receive real-time feedback and guidance during exercise sessions (3 days per week). Myzone integrates with its proprietary wearable devices to monitor heart rate and other activity metrics, providing real-time data to users via the app.
214451681|NCT06931470|DEVICE|Map My Fitness mobile application|Participants will wear a Bluetooth-compatible heart rate monitor (e.g., apple watch/fitbit) that syncs with MapMyFitness. MapMyFitness automatically records workout sessions (duration, distance, heart rate, calories burned, and elevation gain where applicable).
214451682|NCT06931470|DEVICE|Centralized telemetry|Centralized telemetry monitors heart rates and provides immediate feedback for trainers to adjust exercise intensity.
214451683|NCT06931470|DEVICE|Myzone heart rate monitor|Wearable device (chest strap or armband) that monitors heart rate.
214451684|NCT06932445|DIAGNOSTIC_TEST|Shear Wave Elastography|Shear wave elastography will be used to measure liver and spleen stiffness in all participants. The procedure will be performed using standard ultrasound-based elastography protocols by a pediatric radiologist.
215136018|NCT03226002|DEVICE|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
215136019|NCT03218384|DRUG|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
214451685|NCT06931847|OTHER|SUNRISE program|"The program will use several solutions, each focusing on different aspects of health promotion:~* SmartCoach, a mobile phone-based life-skills training program, focuses on self-management, social skills, and substance use resistance.~* Social robots and conversational assistants aim to engage students through interactive sessions on health topics like diet and physical activity.~* Educational and serious games enhance knowledge and resistance to unhealthy food marketing, providing an engaging way to learn about advertising tactics and healthy eating.~* The influencer campaign tackles nutritional misinformation by using content created by influencers to educate adolescents on detecting and critically evaluating misleading health information.~* Health and advertisement educational module aims to educate students on recognizing deceptive advertising and making informed choices about their health."
215136020|NCT03218384|DRUG|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
215136021|NCT03218384|DEVICE|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
215136022|NCT06024070|OTHER|Rigid Tape|"The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips"
215136023|NCT05881018|DIETARY_SUPPLEMENT|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
215136024|NCT05881018|DIETARY_SUPPLEMENT|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
215136025|NCT05881018|BEHAVIORAL|Physical activity|Participants will include physical activity units
215136026|NCT03247257|PROCEDURE|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
215136027|NCT03247257|PROCEDURE|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
215136028|NCT03760991|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
214451686|NCT06932497|OTHER|Standard of care|Standard of care according to national and international guideline or recommendations
214451687|NCT06932211|OTHER|Toothpaste containing proteins and enzymes|Toothpaste containing proteins, enzymes and 1450 ppm fluoride as sodium fluoride
214525988|NCT00577096|DRUG|Thalidomide|Fifty percent of the participants received 400 mg daily
214525989|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
214525990|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
215136029|NCT05153577|OTHER|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
214525991|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
214525992|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
214525993|NCT00577096|DRUG|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
214525994|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
214525995|NCT00577096|DRUG|Thalidomide|Fifty percent of participants received 400 mg daily
215136030|NCT05153577|OTHER|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
215136031|NCT02211794|OTHER|data collection|
215136032|NCT00265694|DRUG|vinorelbine, gemcitabine and carboplatin|
215136033|NCT06239584|PROCEDURE|Biopsies performed via bronchoscopy|An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
215136034|NCT03674528|OTHER|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
215136035|NCT03674528|DIAGNOSTIC_TEST|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
215136036|NCT02356822|OTHER|Patient registry|Oncology data registry
214451688|NCT06932211|OTHER|Control fluoride toothpaste|Toothpaste containing sodium fluoride at 1450 ppm F
215136037|NCT04190459|PROCEDURE|LSG|Bariatric surgery
215136038|NCT04190459|PROCEDURE|LRYGB|Bariatric surgery
214451689|NCT06932328|DRUG|Qinqiao Yanshu Granules|High - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Extremely low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Rescue medication: Paracetamol tablets. During the trial, if the subject's body temperature exceeds 38.5°C (including 38.5°C), rescue medication can be added. Use it according to the instructions and doctor's advice and record it truthfully.
214525996|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
215136039|NCT05659108|BEHAVIORAL|CPR|HIGH QUALITY CPR
214525997|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
215136040|NCT03925623|OTHER|Novel approaches for the design of child resistant closures|"Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system."
215136041|NCT04146181|DRUG|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
215136042|NCT02203734|PROCEDURE|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
215136043|NCT02203734|PROCEDURE|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
215136044|NCT05759507|PROCEDURE|abdominal surgery|
214451690|NCT06932913|OTHER|plyometric exercise|"Plyometric exercise procedures:~Patients in group (B) will receive Plyometric exercise :~Traditional physical therapy program for 20 to 30 minutes and 30 to 45 minutes of training program consisted of 6 lower extremity plyometric exercises for eight weeks .~Wall jumps : Knees slightly bent, arms raised overhead, bounce up and down off toes . Tuck jumps : From standing position, jump and bring both knees up to chest as high as possible Squat jumps : Standing jump raising both arms overhead, land in squatting position touching both hands to the floor Single leg jump distance : One-legged hop for distance .~Scissors jump : Start in stride position, jump and alternate position in midair .~Bounding in place : Jump from 1 leg to the other straight up and down."
214451691|NCT06932913|OTHER|Plyometric exercise procedures:|"The traditional physical therapy program will be in the form of (active knee range of motion exercise and stretching and strengthen exercise of hamstring) three times a week for eight successive weeks of treatment in 20 to 30 minutes to complete:-~Active range of motion exercises for knee joint:~This type of exercise was performed in the following manner:~Knee flexion :~From prone lying position. The child will asked to Slowly bend his knee by pulling heel to buttocks as far as he can . he should feel a gentle stretch in his thigh muscles and knee. Return to starting position.~Knee extension :~From sitting position at the edge of the plinth the child will asked to move his feet up word toward the ceiling as far as he can then return . he should feel gentle stretch on the hamstring muscle .~Hip and knee bend:"
214451692|NCT06931275|OTHER|EMR-based BPA model|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based BPA implementation at six centers.
214451693|NCT06931275|BEHAVIORAL|Placebo (EMR-based without BPA model)|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based system without BPA at the implementation at six centers.
214451694|NCT06931366|PROCEDURE|Open reduction and internal fixation|plates and screws
214451695|NCT06931782|OTHER|AI|GPT-4o fine-tuned with the Lungdiag database
214451696|NCT06931730|OTHER|Nutritional Intervention|Participants will receive comprehensive dietary education from the nutritionists of the research team, aimed at improving their baseline diet by incorporating nutritional recommendations based on the Mediterranean diet and the Italian dietary guidelines for healthy eating.
214451697|NCT06931730|OTHER|Physical Activity training|Participants will engage in a structured exercise program designed to improve motor competence and confidence. Tailored to each individual's baseline physical abilities and cardiorespiratory capacity, the program will focus on enhancing aerobic fitness, flexibility, and coordination.
214451698|NCT06931730|OTHER|Cognitive training|Participants will undergo an online cognitive training program, with a particular focus on memory enhancement.
214451699|NCT06931730|OTHER|Social Training|A peer interaction program within an ecological setting, meant as a natural context of daily life, will be offered to participants. The program aims to improve active listening skills, comprehension of various communication styles (passive, assertive, aggressive), and the efficient recognition and management of emotions.
214525998|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
214525999|NCT02290197|PROCEDURE|Surgery|Surgical reconstruction of all injured ligaments.
214526000|NCT02290197|DEVICE|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
214451700|NCT06931665|PROCEDURE|Animal Assisted Occupational Therapy|AAT is an ergotherapy including an animal. AAT is a specific type of Animal Assisted Intervention (AAI) with a therapeutic aim.
215136045|NCT03380650|DEVICE|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
214451701|NCT06932393|BIOLOGICAL|exosomes|Each subject will receive 3 injections with an interval of one month.
214451702|NCT06932393|OTHER|saline|Each subject will receive 3 injections with an interval of one month.
214451703|NCT06931561|PROCEDURE|Whole Body MRI|Whole body MRI
214526001|NCT02290197|DEVICE|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
215136046|NCT03380650|DEVICE|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
215136047|NCT03264586|DRUG|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~\- EMLA cream was applied, 1 hour before the expected time of birth."
215136048|NCT03264586|DRUG|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic"
215136049|NCT03264586|PROCEDURE|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
215136050|NCT05918601|OTHER|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
215136051|NCT05918601|OTHER|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
215136052|NCT05918601|OTHER|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
215136053|NCT05918601|OTHER|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
215136054|NCT05918601|OTHER|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
215136055|NCT05918601|OTHER|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
215136056|NCT05236517|DRUG|Semaglutide D Dose 1|Tablet given orally
215136057|NCT05236517|DRUG|Semaglutide D Dose 2|Tablet given orally
215136058|NCT05236517|DRUG|Semaglutide D Dose 3|Tablet given orally
215136059|NCT05236517|DRUG|Semaglutide C Dose 4|Tablet given orally
215136060|NCT05236517|DRUG|Semaglutide C Dose 5 (50 mg)|Tablet given orally
215136061|NCT05236517|DRUG|Placebo (Semaglutide C)|Tablet given orally
215136062|NCT05236517|DRUG|Placebo ( Semaglutide D)|Tablet given orally
214526002|NCT05359705|DEVICE|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
215136063|NCT01769313|DEVICE|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
214451704|NCT06931561|PROCEDURE|Whole Body Ultrasound|Whole Body Ultrasound
214451705|NCT06931561|DEVICE|MCD Assay|Cancer detection blood test
214451706|NCT06931561|OTHER|Occupational Exposure Questionnaire|Questionnaire
214451707|NCT06931171|RADIATION|Patient-Applied Pelvic Lead Shielding|The intervention involves the application of a triple-layer lead apron to the patient's lower abdominal and pelvic region during transradial coronary procedures. The apron measures 75 cm × 45 cm and is composed of three layers of 0.25 mm Pb-equivalent material. This protective shield is placed on the patient in addition to standard operator radiation protection measures. The primary goal of this intervention is to reduce scatter radiation exposure to the operator, thereby improving occupational safety in the catheterization laboratory. This approach leverages existing radiation protection materials in a novel configuration.
214451708|NCT06782945|DIETARY_SUPPLEMENT|BIOHM FX Probiotic Blend|BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.
214451709|NCT06386770|DRUG|Dexmedetomidine Injection [Precedex]|Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
214451710|NCT06386770|DRUG|Bupivacaine Hydrochloride|.Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
214451711|NCT06386770|DRUG|Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
214451712|NCT06932718|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
214526003|NCT05359705|DEVICE|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
214526004|NCT05359705|DEVICE|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
215136064|NCT01769313|DEVICE|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
215136065|NCT02488577|PROCEDURE|Transanal minimally invasive total mesorectal excision|
215136066|NCT02488577|PROCEDURE|transanal minimally invasive locoregional resection|
215136067|NCT00517296|PROCEDURE|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
215136068|NCT00517296|DRUG|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
215136069|NCT00517296|PROCEDURE|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
215136070|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
215136071|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
215136072|NCT04366349|OTHER|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
215136073|NCT05460104|DEVICE|Experimental|Virtual reality sessions with a psychologist (30 minutes per session) once a week for 10 weeks. Work of the psychologist on a virtual environment created for the protocol in partnership with the company.
215136074|NCT05460104|OTHER|Control|Standard care is medical follow-up, no specific psychological care.
215136075|NCT02981147|DRUG|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
215136076|NCT00466544|DEVICE|Plasmaknife|
215136077|NCT00466544|DEVICE|Monopolar|
215136078|NCT03636555|DRUG|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
215136079|NCT03636555|DRUG|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
215136080|NCT00647517|DRUG|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
214451713|NCT06932718|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions for 3 months consist of 2 parts. The first part includes regular messages via instant messages (IM). These messages will serve as probes for real-time chat-based support in which more details explanations and motivation to encourage quitting due to financial reasons. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using health economic principles on behavioral change to motivate smokers to quit. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
215136081|NCT01235897|DRUG|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
215136082|NCT01235897|DRUG|Paclitaxel|80 mg/m2 weekly - paclitaxel
215136083|NCT01235897|DRUG|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
215136084|NCT03021200|DEVICE|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
215136085|NCT03083925|DEVICE|TIPS|Transjugular Intrahepatic Portosystemic Shunt
215136086|NCT02257398|DRUG|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
215136087|NCT02257398|DRUG|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
215136088|NCT02257398|DRUG|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
215136089|NCT02257398|DRUG|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
215136090|NCT04771494|OTHER|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP \> 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
214451714|NCT06932718|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
214451715|NCT06932718|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (10 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
214451716|NCT06932718|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
214451717|NCT06932718|OTHER|Small incentive|Positive incentive was reported to be effective in reducing smoking. Participants in the intervention group will receive HK$ 100 at 3-month follow-up. HK$ 500 will be provided to successful quitters confirmed by biochemical validation at 6 months. A total of HK$ 600 maximum will be rewarded to the participants. The amount of the incentive is comparable to other community events on smoking cessation in Hong Kong. Of note, all smokers who reported quitting, completed and passed the biochemical validation of quitting had been offered HK$ 500 in the past rounds and will also be adopted in this round.
214451718|NCT06931990|DRUG|LT-002-158 tablets|The subjects will orally administered LT-002-158 tablets once a day.
214451719|NCT06931314|PROCEDURE|Aromatherapy massage|Aromatherapy massage refers to a massage to be performed on the neck area with lavender oil.
214451720|NCT06931314|PROCEDURE|Muscle Energy Technique|Muscle Energy Technique is a form of manual therapy that uses active muscle contraction and relaxation to improve musculoskeletal mechanics and relieve pain.
214451721|NCT06932354|DEVICE|CGM|masked continuous glucose monitoring
215136091|NCT00829738|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
215136092|NCT06121102|PROCEDURE|Supervoltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
215136093|NCT06121102|PROCEDURE|Standard voltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
215136094|NCT00467688|DEVICE|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
215136095|NCT02717234|OTHER|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
215136096|NCT02977663|OTHER|Magnetic Resonance Imaging (MRI)|"* Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit"
215136097|NCT05421624|DEVICE|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
215136098|NCT05421624|BEHAVIORAL|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
215136099|NCT03413891|DRUG|Tranexamic Acid|Mouthwash
215136100|NCT03413891|OTHER|Placebo|Mouthwash
215136101|NCT04555486|DRUG|DCR-PHXC|Intervention, drug, DCR-PHXC
215136102|NCT04555486|DRUG|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
215136103|NCT05428969|DRUG|Bexmarilimab|Intravenous
215136104|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
215136105|NCT05428969|DRUG|Venetoclax|Oral
215136106|NCT05857995|BEHAVIORAL|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program|KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
215136107|NCT05857995|BEHAVIORAL|Enhanced Usual Care|EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
215136108|NCT05760365|OTHER|3D printed educational model|3D printed cardiac catheterization model
215136109|NCT05760365|OTHER|Slide-based presention|Slide-based presention
215136110|NCT05358366|BEHAVIORAL|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
215136111|NCT01264796|BEHAVIORAL|culturally tailored diabetes education|lifestyle modification group education
215136112|NCT04272294|DEVICE|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
214451722|NCT06932705|DRUG|PA-111|PA-111 1Tab., Per Oral
214451723|NCT06932705|DRUG|PA-111A|PA-111A 1Capsule., Per Oral
214451724|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
214451725|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
214451726|NCT06932887|BEHAVIORAL|Text Messaging|Weekly SMS messages sent to potential participants to inform them of the opportunity to participate in PA counseling for their arthritis. instructions also provided on how to request a referral.
214451727|NCT06932887|BEHAVIORAL|Motivational Messaging|The use of short motivational messages along with text messages inviting persons to participate in PA counseling. The messages are intended to enhance the motivation to participate in PA counseling.
214451728|NCT06932887|BEHAVIORAL|Physical Activity Counseling and Self-Directed Walk with Ease|All persons consenting to PA counseling receive 6 weekly sessions provided in-person or remote with 2-way video or audio commu¬nication. All participants receive education to address negative psy-chological appraisals of OA, reassur¬ance that PA is safe and beneficial, and a PA program primarily focused on walk¬ing, although additional activities may be included. Additional components include exercises tai¬lored to the partici¬pant's needs and coping strategies such as mindful breathing to help manage stress.
214451729|NCT06932887|BEHAVIORAL|Enhanced Walk with Ease|Along with the portal registration participants in the Enhanced WWE group are also offered the opportunity to participate in virtual group WWE classes offered on a rolling basis in either English or Spanish.
214451730|NCT06404073|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
214451731|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
215136113|NCT06573996|DEVICE|Active TENS Device|"Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device"
215136114|NCT06573996|DEVICE|Intervention 2: Placebo/Sham Device|"The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device"
215136115|NCT06204341|RADIATION|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
215136116|NCT03497637|DIAGNOSTIC_TEST|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
215136117|NCT03497637|DIAGNOSTIC_TEST|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
215136118|NCT05168839|DRUG|FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).|"In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded."
215136119|NCT04483206|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
215136120|NCT04483206|DRUG|Melphalan|Given IV
215136121|NCT04483206|OTHER|Questionnaire Administration|Ancillary studies
215136122|NCT03044509|DIAGNOSTIC_TEST|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
215136123|NCT03044509|DIAGNOSTIC_TEST|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
215136124|NCT00001711|PROCEDURE|MRI|scan of healthy volunteers.
215136125|NCT03755206|OTHER|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
215136126|NCT03844347|BEHAVIORAL|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
215136127|NCT04905134|DEVICE|Nasopharyngoscope|Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
215136128|NCT06455228|DEVICE|insert catheter|A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
215136129|NCT05404828|OTHER|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
215136130|NCT05404828|OTHER|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
215136131|NCT05404828|OTHER|Blood and urine sample|Na, K, Creat, Osm, Urea
215136132|NCT06132451|OTHER|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
215136133|NCT05224271|OTHER|Electronic Health Record Review|Medical records are collected
215136134|NCT05224271|OTHER|Medical Device Usage and Evaluation|Fitbit information is collected
215136135|NCT05224271|OTHER|Survey Administration|Complete surveys
214451732|NCT06631677|DRUG|Dupilumab|Administered per protocol
214451733|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
214451734|NCT06477185|DRUG|Doxycycline|Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
214451735|NCT06477185|DRUG|Placebo|This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
214451736|NCT06211062|DRUG|Floradapt Intensive GI|one capsule daily for the eight week intervention
214451737|NCT06211062|OTHER|Placebo|one capsule daily for the eight week intervention
214451738|NCT04167761|DRUG|Ertugliflozin|Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
214451739|NCT05817591|OTHER|Questionnaires|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
215136136|NCT06253832|PROCEDURE|conservative surgery for placenta accreta spectrum|The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
215136137|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
215136138|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
215136139|NCT06399666|OTHER|Blood sampling|Blood sampling
215136140|NCT03642873|DRUG|Humibid®|Humibid® 1200 mg (single extended release) tablet
215136141|NCT03642873|DRUG|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
215136142|NCT03642873|DRUG|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
215136143|NCT05556265|DRUG|Deucravacitinib|Specified dose on specified days
215136144|NCT05556265|OTHER|Placebo|Placebo was administered.
215136145|NCT05690269|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases. SpO2 will be recorded during that time and up to 10 minutes.
215136146|NCT00712751|BEHAVIORAL|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
215136147|NCT00712751|BEHAVIORAL|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
215136148|NCT06298084|DRUG|Patritumab deruxtecan|5.6 mg/kg every 21 days
215136149|NCT06298084|DRUG|Olaparib|100 mg b.i.d PO days 8-14 every 21 days
215136150|NCT05219695|PROCEDURE|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
215136151|NCT04359810|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
215136152|NCT04359810|BIOLOGICAL|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
214451740|NCT06298396|DEVICE|Program using default MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
214451741|NCT06298396|DEVICE|Program using low-power 1 (LP1) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
214451742|NCT06298396|DEVICE|Program using low-power 2 (LP2) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
214451743|NCT06298396|DEVICE|Program using low-power 3 (LP3) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
214451744|NCT06180837|BEHAVIORAL|Sleep Extension Intervention|Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
214451745|NCT04870112|DRUG|Durvalumab|Anti-PD-L1 antibody
214451746|NCT04870112|DRUG|Cisplatin|Chemotherapy
214526005|NCT05359705|DEVICE|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
214526006|NCT06646198|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
214451747|NCT04870112|DRUG|Carboplatin|Chemotherapy
214451748|NCT04870112|DRUG|Etoposide|Chemotherapy
214526007|NCT06646198|DRUG|Donafenib|Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
214526008|NCT01537263|DEVICE|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
214526009|NCT04031534|DRUG|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
214526010|NCT01849185|OTHER|Food supplement|
214526011|NCT03909334|DRUG|Osimertinib|Osimertinib 80 mg orally on Day 1
214526012|NCT03909334|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
214526013|NCT02518659|DIETARY_SUPPLEMENT|Inulin|This is the Intervention
214526014|NCT03759405|BIOLOGICAL|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
214526015|NCT06360445|DRUG|Olaparib Tablet test formulation 100mg|A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.
214526016|NCT06360445|DRUG|Olaparib Tablet reference formulation 100mg|Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
214526017|NCT06360445|DRUG|Olaparib Tablet test formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
215136153|NCT03221556|BEHAVIORAL|Engagement-Focused Care Coordination (EFCC)|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
215136154|NCT03221556|BEHAVIORAL|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
215136155|NCT04414111|DIAGNOSTIC_TEST|Highly suppressive Treg measurement|Circulating highly suppressive Treg measurement
215136156|NCT03573882|DRUG|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
214451749|NCT05078411|BEHAVIORAL|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
214451750|NCT05078411|BEHAVIORAL|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
214451751|NCT03606642|DRUG|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
214451752|NCT03606642|DEVICE|The Synergy® stent|IVUS guided stent
214451753|NCT06500975|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
214526018|NCT06360445|DRUG|Olaparib Tablet reference formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
214526019|NCT05778799|OTHER|Balance test|10 second left- or right-leg stance with eyes open, and single 10 second left- or right-leg stance with eyes closed
214526020|NCT05185739|DRUG|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
214526021|NCT05185739|DRUG|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks
214526022|NCT05185739|DRUG|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
214526023|NCT05616312|BEHAVIORAL|Educational Teach Back|Patients will receive teach-back education while they fill out questionnaires.
214526024|NCT06584773|DRUG|Everolimus|mTORi added as the fourth maintenance immunosuppressive drug in recipients
214526025|NCT06584773|DRUG|standard maintenance immunosuppression|standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
214526026|NCT06584669|DIETARY_SUPPLEMENT|Krill oil|The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
214526027|NCT06584669|OTHER|Placebo|The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
214526028|NCT06584565|OTHER|microbiome; metabolomics; proteomics|post-stroke change of microbiome; metabolomics; proteomics
214708629|NCT05726305|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
214708630|NCT05726305|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
215136157|NCT04191538|PROCEDURE|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
215136158|NCT04191538|PROCEDURE|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
215136159|NCT04191538|PROCEDURE|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
214526029|NCT03771378|DRUG|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
215136160|NCT04230187|DRUG|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
215136161|NCT04230187|DRUG|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
215136162|NCT04531085|PROCEDURE|Operative treatment|Surgery
215136163|NCT04531085|PROCEDURE|Long arm cast|cast immobilization
215136164|NCT04760782|DRUG|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
215136165|NCT04760782|DEVICE|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
215136166|NCT04166006|BIOLOGICAL|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
215136167|NCT04166006|DRUG|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
215136168|NCT01919528|PROCEDURE|ultrasound|catheterization of the axillary vein under ultrasound guidance
215136169|NCT03808974|OTHER|Educational video|Short educational video describing the mid-urethral sling procedure
215136170|NCT03808974|OTHER|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
214451754|NCT05021640|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
214451755|NCT05021640|DRUG|Placebo for DCR-AUD|0.9% saline for injection
214451756|NCT04737772|BEHAVIORAL|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
214526030|NCT03771378|DRUG|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
214526031|NCT05888402|DRUG|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
214526032|NCT05888402|RADIATION|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
214526033|NCT03672383|DEVICE|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
214526034|NCT05028647|DEVICE|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
215136171|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
215136172|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
215136173|NCT02234843|DRUG|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
215136174|NCT02432443|BEHAVIORAL|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
214451757|NCT04737772|BEHAVIORAL|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
214451758|NCT04911751|DRUG|KBL697|1 capsule BID of KBL697 or Placebo
214451759|NCT04911751|DRUG|KBL697|5 capsules BID of KBL697 or Placebo
214451760|NCT03763253|COMBINATION_PRODUCT|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
214451761|NCT03763253|PROCEDURE|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
214451762|NCT03763253|PROCEDURE|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
214451763|NCT06504732|DRUG|IAH0968|Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
214526035|NCT05028647|DEVICE|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
215136175|NCT02432443|OTHER|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
215136176|NCT03111823|BEHAVIORAL|Exercise Intervention|Undergo aerobic exercise sessions
215136177|NCT03111823|OTHER|Quality-of-Life Assessment|Ancillary studies
215136178|NCT03111823|OTHER|Questionnaire Administration|Ancillary studies
215136179|NCT02254603|DEVICE|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
215136180|NCT02254603|BEHAVIORAL|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
215136181|NCT06206447|PROCEDURE|Tunnel-cuffed Catheter|Tunnel-cuffed Catheter in right internal jugular vein
215136182|NCT06206447|PROCEDURE|Non-ccuffed Catheter|Non-ccuffed Catheter in right internal jugular vein
215136183|NCT03550027|DEVICE|PleurX|Positioning of drainage PleurX
215136184|NCT03550027|DEVICE|Pleurocath|Positioning of drainage Pleurocath
215136185|NCT06209658|DIAGNOSTIC_TEST|breastfeeding education of Teach Back|breastfeeding education simple explanation is given and the woman is asked to explain and practice.
215136186|NCT06209658|OTHER|breastfeeding education simple explanation|breastfeeding education simple explanation
215136187|NCT00037167|DEVICE|Exercise poles|
215136188|NCT03905096|DRUG|BI 425809|Film coated tablet
215136189|NCT03905096|DRUG|Donepezil|Film coated tablet
215136190|NCT02016781|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
215136191|NCT02016781|PROCEDURE|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
215136192|NCT05198921|DEVICE|repetitive Transcranial Magnetic Stimulation|"To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~\------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds"
215136193|NCT05198921|DEVICE|sham repetitive Transcranial Magnetic Stimulation|Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
215136194|NCT06044675|DRUG|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
215136195|NCT06044675|BEHAVIORAL|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
215136196|NCT05518812|DRUG|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
215136197|NCT04156373|BEHAVIORAL|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
215136198|NCT05017415|DEVICE|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
215136199|NCT05017415|DEVICE|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
214526036|NCT04290156|OTHER|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
214526037|NCT04593641|BIOLOGICAL|CT-P59|administered
214526038|NCT03074383|BEHAVIORAL|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
215136200|NCT03267550|DEVICE|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
215136201|NCT02437916|DRUG|AMG 228|AMG 228 will be administered intravenously
215136202|NCT00879021|DRUG|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
215136203|NCT00879021|DRUG|matching placebo|150 mg by mouth ,twice a day for 49 weeks
214451764|NCT05140148|DRUG|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
214451765|NCT05140148|DRUG|Placebo|placebo pills
214451766|NCT05041257|DRUG|Mirvetuximab soravtansine|Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
214451767|NCT05539352|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
214451768|NCT02206295|DRUG|selexipag|
214451769|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
214451770|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
214451771|NCT05660746|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
214451772|NCT05660746|DRUG|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
214526039|NCT03074383|BEHAVIORAL|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
214526040|NCT03143634|BEHAVIORAL|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
214526041|NCT03143634|BEHAVIORAL|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
215136204|NCT01832636|DIETARY_SUPPLEMENT|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
215136205|NCT01673529|DRUG|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
215136206|NCT01673529|DRUG|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
215136207|NCT02336282|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level \< 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
214526042|NCT04321915|OTHER|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
214526043|NCT04321915|OTHER|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
214526044|NCT06390124|DRUG|Platelet Derived Growth Factor (PDGF)|Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
214526045|NCT05958784|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
215136208|NCT02336282|DEVICE|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
215136209|NCT02336282|OTHER|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
214451773|NCT03781128|DRUG|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
214451774|NCT03781128|DRUG|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
214526046|NCT04235894|DRUG|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
214526047|NCT06310330|DIAGNOSTIC_TEST|Comprehensive echocardiographic follow-up|Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
214526048|NCT06310330|DIAGNOSTIC_TEST|Simplified echocardiographic follow-up|Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
214526049|NCT03123224|BEHAVIORAL|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
214708631|NCT06474364|DRUG|Long-acting Cabotegravir injection|Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.
215136210|NCT02336282|OTHER|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
215136211|NCT05506631|PROCEDURE|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
215136212|NCT05506631|PROCEDURE|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
215136213|NCT04834505|OTHER|Diagnostic imaging modalities for validation sample|Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.
215136214|NCT04834505|OTHER|EUS for derivation sample|Endoscopic ultrasound was performed.
215136215|NCT06058442|DRUG|NORTASE®|10-15 capsules of NORTASE® per day - over 6 months
215136216|NCT06058442|DRUG|Placebo|10-15 capsules of placebo per day - over 6 months
215136217|NCT02216708|OTHER|Rapid dehydration|
215136218|NCT02216708|OTHER|Slow rehydration|
215136219|NCT06236971|BEHAVIORAL|MRI scanning first at supine position and then turn into lateral position|Magnetic resonance imaging was used to scan the upper airway of sedated subjects, first at supine position and then turn into lateral position.
215136220|NCT03724942|DRUG|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
215136221|NCT02668497|DRUG|Botulinum Toxin Type A|
215136222|NCT06602518|PROCEDURE|Orthodontic Treatment|All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
215136223|NCT06598098|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
215136224|NCT06589284|PROCEDURE|Silk 0-0 suture covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
214708632|NCT06474364|OTHER|SEARCH-YOUTH|It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
214708633|NCT05446298|DRUG|ONC-392|ONC-392 will be given by IV infusion, q3w.
215136225|NCT06589284|PROCEDURE|2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
215136226|NCT06601348|OTHER|Nutrition education, physical activity intervention, and health promoting school model trials|A nutrition education and physical activity intervention, combining a pilot health promoting school model that includes health education and recreational enhancement with the curriculum of a government-designated healthy school, was designed to reduce childhood overweight and obesity. The programme was implemented over 6 months. This program has been widely conducted in several countries, but there are still many differences from previous studies, especially in terms of strengthening qualitative studies in the first stage, then in the intervention stage using a Cluster Randomised Controlled Trial design. Another advantage of this study is the combination of intervention and health promoting school. In Indonesia, there are few intervention studies in reducing overweight and obesity in children, some only focus on descriptive studies such as nutritional knowledge, physical activity measures using questionnaires to determine the relationship or measure BMI.
215136227|NCT01574586|DEVICE|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
215136228|NCT04689516|DEVICE|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
215136229|NCT03710746|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
215136230|NCT03710746|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
215136231|NCT06593964|DEVICE|Thermosensitive Nanogel Embolic Agent|Thermosensitive Nanogel Embolic Agent
215136232|NCT06596590|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
215136233|NCT06599814|PROCEDURE|vital pulp therapy|vital pulp therapy using two bioactive materials TheraCal and RetroMTA as direct pulp caping materials conventionally and test using Diode laser before application of these materials
215136234|NCT06595056|BEHAVIORAL|Multi-technology MVPA intervention|Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
215136235|NCT06586385|BEHAVIORAL|disaster education|The ADDIE Instructional Design Model will be used due to its suitability for adult education. General Disaster Awareness Training will be prepared according to the ADDIE instructional design model, which consists of five stages: analysis, design, development, implementation and evaluation. The trainings to be given will be given 1 week after the pre-test, 1 training per week, for a total of 3 trainings.
215136236|NCT06603415|PROCEDURE|Total thyroidectomy|Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
214451775|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
215136237|NCT06604377|OTHER|Observe|Ruijin
214451776|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
215136238|NCT06989320|DIETARY_SUPPLEMENT|Low-oxalate diet and glycolate dosing|Low-oxalate diet 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
215136239|NCT06989320|DIETARY_SUPPLEMENT|Oral glycolate dosing|Oral 13C-glycolate dosing (0.5 mg/kg)
215136240|NCT06989320|DIETARY_SUPPLEMENT|Oral 13C- ascorbic acid dosing|Oral 13C- ascorbic acid dosing (0.75 mg/kg)
215136241|NCT06989905|BEHAVIORAL|Up-conditioning of the wrist extensor motor evoked potential|At the beginning of each session, EMG recording and nerve stimulating electrodes are placed over the arm. In all sessions, MEPs will be measured while the sitting subject provides a pre-set level of background muscle EMG with joint angles fixed. In 225 control trials of each baseline sessions and the first 20 trials of conditioning sessions the subject will receive no feedback as to MEP size (i.e., control MEPs). In 225 conditioning trials of each conditioning session, the subject will be encouraged to increase the target muscle MEP, and will receive immediate feedback as to whether MEP size was above a criterion (i.e., whether the trial was a success).
215136242|NCT06991569|PROCEDURE|Non-surgical perforation repair|Root perforation repair using MTA or other perforation repair material
215136243|NCT06595173|BEHAVIORAL|Therapeutic Intervention|"group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated."
215136244|NCT06998472|OTHER|Tuina|According to traditional Chinese medicine (TCM), children's physiological characteristics include immature and delicate internal organs, as well as underdeveloped qi and physical form. Pathologically, their organ systems are described as light and responsive, meaning they react quickly to both internal and external stimuli. Therefore, pediatric tuina must prioritize gentleness in technique. The applied pressure should not exceed 0.3 kilograms, and the depth of skin indentation should not go beyond 0.3 centimeters.
215136245|NCT06998472|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
215136246|NCT06999135|DRUG|Silodosin|Silodosin is an oral medication primarily used to treat benign prostatic hyperplasia (BPH) by relaxing the muscles in the prostate and bladder neck to improve urine flow. It belongs to a class of drugs called alpha-1 adrenergic antagonists, which block receptors responsible for muscle contraction in these areas. This action helps relieve symptoms such as difficulty urinating, urgency, and weak urine stream. Silodosin is taken once daily with food and is known for its high selectivity for alpha-1A receptors, contributing to its effectiveness and safety profile
215136247|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells administered via Ommaya reservoir；2.0\*10\^7 cell/dose
215136248|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；Low-dose group; 2.5\*10\^6 cell/dose
215136249|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；High-dose group; 1.0\*10\^7 cell/dose
215136250|NCT06999525|DEVICE|Therapeutic virtual reality headset (CRVT)|Contribution of the use of a Therapeutic Virtual Reality Headset in the management of anxiety and discomfort in digestive endoscopy
214451777|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
214451778|NCT04696952|DRUG|TS-142|TS-142
214451779|NCT04696952|DRUG|Zopiclone|Zopiclone
214451780|NCT04696952|DRUG|Placebo|Placebo
214451781|NCT04090736|DRUG|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
214451782|NCT04090736|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
214451783|NCT04974541|OTHER|Heart Health Yoga|Yoga-based digital intervention
214451784|NCT04974541|OTHER|Psychosocial education|Standard psychosocial education component
214451785|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
214451786|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
214451787|NCT04805333|DRUG|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
214451788|NCT04805333|DRUG|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
214451789|NCT04805333|DRUG|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
214451790|NCT04805333|DRUG|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
214451791|NCT04805333|DRUG|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
214451792|NCT05101928|DRUG|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
215136251|NCT06998017|OTHER|Low Volume High Intensity Interval Training|Participants will conduct aerobic exercise on a total body recumbent stepper to get their heart rates to levels consistent with high intensity exercise.
215136252|NCT06998797|OTHER|Data collection|Data collection from medical records
215136253|NCT06998888|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to cancer.
214451793|NCT05101928|DRUG|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
214526050|NCT03123224|BEHAVIORAL|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
214708634|NCT05446298|DRUG|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
214451794|NCT05145283|DRUG|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
215136254|NCT06999785|BIOLOGICAL|Blood test|a blood test before and after the first oxygen therapy session, as well as after the last session
215136255|NCT06999941|DRUG|Deucravacitinib 6mg po qd|oral administration
215136256|NCT06998719|DRUG|Durvalumab|Neoadjuvant durvalumab (MEDI 4736)and platinum-based chemotherapy, followed by either surgery and adjuvant durvalumab or CRT and consolidation durvalumab, in borderline resectable stage III NSCLC
215136257|NCT04875975|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
215136258|NCT04875975|DRUG|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
215136259|NCT06997952|DRUG|Febuxostat 40 mg|Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.
215136260|NCT06434337|DIAGNOSTIC_TEST|"Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)"|Given by Diagnostic Test
215136261|NCT06998641|PROCEDURE|Chitosan-covered-gauze application|Effectiveness of chitosan-covered-gauze in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
215136262|NCT06998641|PROCEDURE|Suturation|Effectiveness of suturation in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
215136263|NCT06999421|DEVICE|Robot with interactive animations, gesture recognition, and touch/voice-based input|A humanoid educational robot that provides GDM-related content using animated videos, emotional facial expressions, gesture movements, and voice/touch-based interaction. Designed to increase engagement, reduce anxiety, and improve health literacy among pregnant women.
215136264|NCT06999421|DEVICE|Standard tablet (video playback only).|A standard touchscreen tablet used to deliver pre-recorded educational videos on GDM. This intervention provides passive viewing without any robot interaction or feedback.
215136265|NCT06999083|DRUG|HB0043|HB0043 Drug Product
215136266|NCT06999083|DRUG|Placebo|Placebo
215136267|NCT06999733|BIOLOGICAL|KB801|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-based vector delivering functional, full-length human nerve growth factor (NGF)
214451795|NCT05145283|DRUG|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
214708635|NCT01539811|PROCEDURE|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
215136268|NCT06999733|DRUG|Placebo|Vehicle
215136269|NCT06617312|DRUG|Cytisinicline|Targets α4β2 nicotinic acetylcholine receptors
215136270|NCT06617312|DRUG|Placebo Oral Capsule|Matched to active drug, cytisinicline
215136271|NCT06589739|DEVICE|Virtual Reality Headset|A virtual reality headset will be placed on patients\&#39; head before and during chest drain insertion
215136272|NCT06594172|DRUG|Memantine Oral Tablet|"Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily."
215136273|NCT06594172|DRUG|Pioglitazone 15mg|"Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily."
215136274|NCT06594172|RADIATION|Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)|Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).
215136275|NCT04752618|BEHAVIORAL|P-STAIR|PCIT+ STAIR
215136276|NCT04752618|BEHAVIORAL|Supportive Counseling|Non-trauma focused psychotherapy
215136277|NCT00694629|DRUG|rifampin|tablet, 10 mg/kg, daily, 8 weeks
215136278|NCT00694629|DRUG|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
215136279|NCT00694629|DRUG|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
215136280|NCT00694629|DRUG|rifapentine|20 mg/kg, daily, 8 weeks
215136281|NCT06547619|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
215136282|NCT06599489|PROCEDURE|surgery ..operation|sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
215136283|NCT01360697|OTHER|JADE|"1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information."
215136284|NCT01360697|OTHER|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
214526051|NCT01260259|PROCEDURE|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
215136285|NCT06284005|DEVICE|WRL ATP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
215136286|NCT00380055|BEHAVIORAL|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
215136287|NCT00380055|BEHAVIORAL|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
215136288|NCT06704282|BEHAVIORAL|VR Mindfulness Meditation Program|A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
215136289|NCT06702644|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
215136290|NCT06702644|DEVICE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
215136291|NCT06704555|RADIATION|radiation therapy|received radiation (dose:18～24Gy)
215136292|NCT06704555|DRUG|Tiselizumab|200 mg iv day 1
215136293|NCT06704555|DRUG|Rituximab|375 mg/m2 intravenous \[IV\] day 2
214451796|NCT06023693|BEHAVIORAL|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
214451797|NCT06023693|BEHAVIORAL|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
214451798|NCT06531681|DEVICE|MR-Linac|Radiation therapy with the MR-Linac
214451799|NCT05980936|OTHER|Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
214451800|NCT03887741|BIOLOGICAL|Plasmapheresis|Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma
214451801|NCT03887741|BIOLOGICAL|Plasma infusion|Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
214451802|NCT05991310|OTHER|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
214451803|NCT05991310|OTHER|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
214451804|NCT05309447|OTHER|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
214526052|NCT01260259|PROCEDURE|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
215136294|NCT06704555|DRUG|Cyclophosphamide|750 mg/m2 IV day 3
215136295|NCT06704555|DRUG|Doxorubicin|50 mg/m2 IV day 3
215136296|NCT06704555|DRUG|Vincristine|1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
215136297|NCT06704555|DRUG|Prednisone|100 mg oral days 3-7
215136298|NCT06704308|BEHAVIORAL|Web Application|A web application for vaccine-hesitant parents and their teens with brief, 90-second narrative videos and tailored, motivational content
215136299|NCT06704308|BEHAVIORAL|Provider Elaborated Prompts|A component for providers that suggests elaborated prompts to be used with parents that align with the content of the web application, are tailored to parent concerns, and are motivational in nature
214451805|NCT05033392|DRUG|Toripalimab Injection|A domestic PD-1 antibody
214451806|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
215136300|NCT06706180|OTHER|Exercise for Mood video|As per arm of the same name
215136301|NCT06706180|OTHER|Exercise for Fitness video|As per arm of the same name
215136302|NCT06704438|DIAGNOSTIC_TEST|D-Lactate|D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
215136303|NCT04104854|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
215136304|NCT06705556|PROCEDURE|Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking|"The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day"
215136305|NCT06705556|PROCEDURE|incentive spirometer, percussion, 3-minute of walking|"The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day"
214526053|NCT04887597|DRUG|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
214526054|NCT05060406|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
214526055|NCT01341106|DRUG|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
215136306|NCT06705049|RADIATION|MRI|On MRI, some lesions present as linear enhancement, while others exhibit nodular enhancement
215136307|NCT06705244|PROCEDURE|Trans-nasal sphenopalatine nerve block|"The patient was placed supine with shoulders slightly elevated to flex the neck and extend the head.~Then anterior nares were inspected for polyps, tumors, or significant septal deviation.~Long cotton-tipped applicators saturated with lidocaine 2% were inserted into each naris, until properly seated in the posterior nasopharynx.~These were left in place for 10 minutes to lubricate and anesthetize the mucous membrane, making the procedure more comfortable.~Then a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg were injected through the applicators in the sphenopalatine area in each nostril.~Then the patient was positioned sitting and pain assessments were recorded."
215136308|NCT06705244|PROCEDURE|Greater and lesser occipital nerve block|"The back of the head was sterilized with an antiseptic solution and the landmarks at the base of the skull were identified while the patient in the prone position.~The landmarks were located on the medial third of a line drawn from occipital protuberance to mastoid process. At this level, the greater and lesser occipital nerves lie along the superior nuchal line medial to the occipital artery, halfway between the occipital protuberance and mastoid process.~Under Ultrasound guidance, the skin was infiltrated with 1-2 mL of lidocaine 2%, using a 25-gauge needle. Then the block was performed in this area with a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg to block greater and lesser occipital nerves. Then the procedure was repeated on the other side.~After the procedure, the presence of bilateral occipital numbness was confirmed after 30 minutes. The patient was then positioned sitting and pain scoring was assessed."
215136309|NCT06706531|PROCEDURE|Standard treatment|All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
214451807|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
214451808|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
214451809|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
214451810|NCT04862780|DRUG|BLU-945|Oral administration
214451811|NCT04862780|DRUG|osimertinib|Osimertinib tablets for oral administration
214451812|NCT06029647|OTHER|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
214451813|NCT06029647|OTHER|vanilla wafers|vanilla wafers
214451814|NCT03439488|DRUG|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
214451815|NCT03439488|DRUG|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
214451816|NCT06482034|DRUG|N-acetyl cysteine|N-acetyl cysteine sachets
214451817|NCT06482034|DRUG|Zinc sulfate|zinc sulfate capsules
214451818|NCT06482034|DRUG|saline mouth wash|saline mouth wash
214451819|NCT06425523|BEHAVIORAL|Home Gardening Intervention (HGI)|The Home Gardening Intervention (HGI) provides refugee participants with agricultural inputs and training (field prep., sowing, water management, pest control, weeding, etc.) through a participatory field school approach with a curriculum derived from best practices in agro-ecology. The program includes active monitoring during a 12-month period. The training involves nutrition education on cooking methods and the importance of dietary diversity using garden produce as well as guidance on surplus management and market support. The overall goal of the intervention is to enable climate-resilient farming for improved food security and dietary diversity that is sustainable long-term.
214451820|NCT06425523|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus (SH+) is a 5-session group intervention developed by the WHO and based on Acceptance and Commitment Therapy, delivered by trained local facilitators. It provides tools to manage stress and adversity through pre-recorded audio lessons and a self-help book. Sessions include individual exercises and group discussions.~SH+ aims to decrease psychological distress. It has shown effectiveness among refugees in Uganda and elsewhere."
214526056|NCT03473652|OTHER|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
214526057|NCT00794573|DRUG|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
214526058|NCT00794573|OTHER|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
214526059|NCT06454578|DRUG|Adebrelimab + Apatinib|"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"
214526060|NCT05888272|BEHAVIORAL|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
214526061|NCT02109718|DRUG|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
214708636|NCT01539811|DRUG|Short course antibiotics|Short course (\<2 weeks) of antibiotics will be prescribed
215136310|NCT06706531|PROCEDURE|Sham Dry needling|The sham dry needling group will also receive 6 sessions of sham dry needling on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes.Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm.The plantar and medial surface of the foot and ankle will be cleaned with alcohol. The sham dry needling will be performed for 5 minutes.
215136311|NCT06706531|PROCEDURE|Dry needling|The dry needling group will receive 6 sessions of dry needling using a standardized trigger point protocol on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes. Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm. The calf, plantar and medial surface of the foot and ankle will be cleaned with alcohol. Following insertion, needles will be manipulated bi-directionally to elicit a sensation of aching, tingling, deep pressure, heaviness or warmth. The needles will then left in situ for 5 minutes.
215136312|NCT06706037|OTHER|Exercise|A 6 week reformer pilates exercise program
215136313|NCT06706388|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
215136314|NCT05262075|OTHER|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
215136315|NCT04045535|OTHER|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
215136316|NCT04045535|OTHER|Usual care|Usual clinical care based on current clinical practice guidelines.
215136317|NCT06705985|DEVICE|Implantation of lateral meniscus prosthesis|Implantation of a lateral meniscus prosthesis after meniscectomy.
215136318|NCT06704425|OTHER|For observational studies, participants are not assigned an intervention as part of the study.|For observational studies, participants are not assigned an intervention as part of the study.
215136319|NCT03253393|DEVICE|Smart Touch Technology packaging|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
215136320|NCT03253393|DEVICE|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
215136321|NCT03253393|DEVICE|EDTA|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
215136322|NCT06736457|PROCEDURE|AdvanCore bone grafting|AdvanCore medical device is implanted making sure that is in direct contact with all surfaces of the defect area.
215136323|NCT02914158|DRUG|Goserelin|
215136324|NCT02914158|DRUG|Tamoxifen|
215136325|NCT02914158|DRUG|Aromatase Inhibitors|
215136326|NCT02914158|DRUG|Leuprolide|
215136327|NCT02017197|DRUG|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
215136328|NCT02017197|DRUG|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
215136329|NCT02017197|DRUG|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
215136330|NCT01673607|PROCEDURE|Biopsie liver|
215136331|NCT04684888|PROCEDURE|Visumax Femto-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
215136332|NCT04684888|PROCEDURE|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
215136333|NCT03795571|DRUG|Rituximab|Rituximab 375mg/m2，d0
215136334|NCT03795571|DRUG|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
215136335|NCT03795571|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2，d1
215136336|NCT03795571|DRUG|Dexamethasone|Dexamethasone 40mg/d，d1\~d4
215136337|NCT03795571|DRUG|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle
215136338|NCT02755428|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
215136339|NCT00558142|DRUG|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
215136340|NCT00558142|DRUG|Visipaque 320|100mls IV dose as single dose
215136341|NCT00558142|DRUG|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
214526062|NCT02109718|DRUG|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
214526063|NCT02985086|DRUG|Cefoxitin|
214526064|NCT02985086|DRUG|oxytocin/misoprostol|
214526065|NCT00490113|DRUG|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
214526066|NCT02637466|DRUG|Vortioxetine|
215136342|NCT04515771|BEHAVIORAL|PARTNER-MH|The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
215136343|NCT00000385|DRUG|Lithium|Lithium 600 mg to 2700 mg per day
215136344|NCT00000385|DRUG|Placebo|Matching placebo
215136345|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
215136346|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
215136347|NCT00879736|OTHER|placebo|
215136348|NCT04625504|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
215136349|NCT00948246|DEVICE|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
215136350|NCT01820299|DRUG|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
214526067|NCT01142154|DRUG|Prodarsan|Prodarsan TID, oral solution, 6-8 days
214526068|NCT05967793|OTHER|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
214526069|NCT05872906|DEVICE|Acupuncture|A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
214526070|NCT00848640|DRUG|Sorafenib|400 mg twice daily
214526071|NCT05662878|OTHER|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
214526072|NCT01595724|DRUG|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
215136351|NCT01820299|DRUG|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
215136352|NCT00796939|DEVICE|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
215136353|NCT00796939|DEVICE|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
215136354|NCT00646165|DRUG|Forodesine|
215136355|NCT01213888|DRUG|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
215136356|NCT01213888|DRUG|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
215136357|NCT03572517|PROCEDURE|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
215136358|NCT03572517|PROCEDURE|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
215136359|NCT00257413|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
215136360|NCT02821234|OTHER|MRI|
215136361|NCT02759614|DRUG|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
215136362|NCT02759614|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
215136363|NCT05834634|DEVICE|Ultrasound|The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
215136364|NCT03005444|DRUG|Rivaroxaban|10mg/day, for 2 years
215136365|NCT00202280|DRUG|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
215136366|NCT00135031|DRUG|Bifidobacterium infantis 35624|
215136367|NCT00551317|DRUG|Darapladib (SB480848)|
215136368|NCT01870349|PROCEDURE|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
215136369|NCT04484077|BIOLOGICAL|hCT-MSC|2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
215136370|NCT03429335|BEHAVIORAL|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
214526073|NCT03928821|BIOLOGICAL|PGT121|20 mg/kg administered intravenously
214526074|NCT03928821|BIOLOGICAL|PGDM1400|20 mg/kg administered intravenously
215136371|NCT03429335|BEHAVIORAL|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
214526075|NCT03928821|BIOLOGICAL|10-1074|20 mg/kg administered intravenously
214526076|NCT03928821|BIOLOGICAL|VRC07-523LS|20 mg/kg administered intravenously
215136372|NCT03429335|BEHAVIORAL|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
215136373|NCT05924243|DRUG|RO7486967|For up to approximately 28 days
215136374|NCT05924243|DRUG|Placebo|For up to approximately 28 days
215136375|NCT04896866|BEHAVIORAL|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
215136376|NCT04346745|BEHAVIORAL|Peer Mentoring Program|The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
215136377|NCT05625113|DEVICE|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
215136378|NCT06600347|DIETARY_SUPPLEMENT|DASH diet|The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
214526077|NCT06585475|BEHAVIORAL|Structured training according to premenstrual syndrome symptom map|A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
214526078|NCT05774418|BIOLOGICAL|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
214526079|NCT01083537|DRUG|Cisplatin|"1\) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
214694844|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
214708637|NCT01539811|DRUG|Long course antibiotics|Long course (\>2 weeks) of antibiotics will be prescribed
214708638|NCT00219518|PROCEDURE|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
215136379|NCT06600347|OTHER|Progressive muscle relaxation|The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
215136380|NCT06600347|DRUG|Anti hypertensive drugs|All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
215136381|NCT04199351|DRUG|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
215136382|NCT04199351|DRUG|Placebo|AMG 171 placebo
215136383|NCT03376438|OTHER|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
215136384|NCT04511481|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
215136385|NCT05657340|DIAGNOSTIC_TEST|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
215136386|NCT00492245|PROCEDURE|PTK with mitomycin in Adenoviral Opacities|
215136387|NCT03365102|DEVICE|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
215136388|NCT03365102|DEVICE|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
215136389|NCT03365102|DEVICE|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
215136390|NCT01801163|DRUG|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
215136391|NCT01801163|RADIATION|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
215136392|NCT00474487|BIOLOGICAL|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
215136393|NCT00474487|BIOLOGICAL|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
215136394|NCT00474487|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
215136395|NCT00474487|BIOLOGICAL|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
215136396|NCT00331201|DRUG|SAFEstart|
215136397|NCT05093855|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
215136398|NCT04323696|PROCEDURE|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
214451821|NCT06425523|BEHAVIORAL|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
214451822|NCT05722964|DRUG|SHR-1906|Intravenous injection
214451823|NCT05722964|DRUG|SHR-1906|Intravenous injection
214526080|NCT01083537|DRUG|Paclitaxel|"2\) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
214526081|NCT05156216|OTHER|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
214526082|NCT04985071|PROCEDURE|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
215136399|NCT02228707|DRUG|BIIB061|Participants receive BIIB061
215136400|NCT02228707|OTHER|Placebo|Matched placebo
215136401|NCT04970745|OTHER|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
214451824|NCT05722964|DRUG|Placebo|Placebo，Intravenous injection
214451825|NCT03973320|OTHER|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
214451826|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
215136402|NCT04970745|OTHER|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
215136403|NCT00297544|DRUG|Viagra|
215136404|NCT03524846|DRUG|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
215136405|NCT03524846|DRUG|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
215136406|NCT03524846|DRUG|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
215136407|NCT01831024|DEVICE|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
214451827|NCT06375005|DRUG|Telitacicept|Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
214451828|NCT06375005|DRUG|Mycophenolate Mofetil|All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
214451829|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
214451830|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
214451831|NCT06806696|OTHER|COVID-19 infection|COVID-19 diagnosis in the health database
214526083|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
215136408|NCT05024539|OTHER|nonintervention|
215136409|NCT02786849|OTHER|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
215136410|NCT02786849|OTHER|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
215136411|NCT03630289|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
215136412|NCT04230629|DEVICE|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
215136413|NCT04230629|DEVICE|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
215136414|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
215136415|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
215136416|NCT00293098|DRUG|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
214451832|NCT06237257|BIOLOGICAL|SHR-1316|SHR-1316（Adebrelimab Injection）
214451833|NCT06237257|DRUG|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
214451834|NCT06237257|RADIATION|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
214451835|NCT06237257|DRUG|Paclitaxel Injection|Paclitaxel Injection.
214526084|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
214526085|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
214526086|NCT00117650|OTHER|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
214694845|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
214694846|NCT02348411|DEVICE|ExAblate|
215136417|NCT04009408|DEVICE|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
214451836|NCT03376321|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
214451837|NCT03376321|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
214451838|NCT03376321|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
214451839|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
214451840|NCT02496780|DRUG|levemir insulin|basal insulin once a day
214451841|NCT02496780|DRUG|placebo|once or 3x daily
214451842|NCT05837221|DIAGNOSTIC_TEST|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
214526087|NCT02990299|BEHAVIORAL|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
214526088|NCT02784535|DRUG|Atomoxetine|norepinephrine transporter inhibitor
214526089|NCT02784535|DRUG|Placebo|placebo
215136418|NCT03519035|OTHER|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
215136419|NCT02443688|DRUG|CTX-4430|
215136420|NCT02443688|DRUG|Placebo|
215136421|NCT03182374|DEVICE|nSTRIDE APS|Intra-articular injection
215136422|NCT03182374|DEVICE|Synvisc-One|Intra-articular injection
215136423|NCT04790617|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
215136424|NCT02572102|DIETARY_SUPPLEMENT|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
215136425|NCT02572102|DIETARY_SUPPLEMENT|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
215136426|NCT02572102|OTHER|Placebo|Lime juice, water and cherry flavoring
215136427|NCT05771987|PROCEDURE|pace maker implant guided by acute hemodynamic testing|To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
215136428|NCT01334177|DRUG|TLR8 agonist VTX-2337|Given SC
215136429|NCT01334177|BIOLOGICAL|cetuximab|Given IV
215136430|NCT01334177|OTHER|laboratory biomarker analysis|Correlative studies
215136431|NCT01334177|OTHER|pharmacogenomic studies|Correlative studies
215136432|NCT06178419|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
215136433|NCT06178419|DEVICE|sham-RIC|Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
215136434|NCT03626454|DRUG|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
215136435|NCT03626454|DRUG|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
215136436|NCT03626454|DRUG|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
215136437|NCT03626454|DRUG|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
215136438|NCT01128374|PROCEDURE|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
215136439|NCT01691534|DRUG|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
215136440|NCT01691534|DRUG|PA-824 (PA)|PA-824 200mg Days 1-14
215136441|NCT01691534|DRUG|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
215136442|NCT01691534|DRUG|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
214451843|NCT05837221|DIAGNOSTIC_TEST|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
214451844|NCT06067425|DRUG|SAR442501|Solution for injection; Subcutaneous injection
214451845|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-High（Combined Vaccine）|
214451846|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-Low（Combined Vaccine）|
214451847|NCT02992925|BIOLOGICAL|Hib vaccine|
215136443|NCT01691534|DRUG|Rifafour|Rifafour e-275 mg dosed by weight
215136444|NCT01708200|OTHER|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
214451848|NCT02992925|BIOLOGICAL|DPT-IPV|
214451849|NCT04729907|DRUG|Nusinersen|Administered as specified in the treatment arm
214451850|NCT06486948|DEVICE|CT-156|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
214451851|NCT05774314|BEHAVIORAL|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
214451852|NCT04716140|PROCEDURE|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
214451853|NCT01804816|PROCEDURE|Acupuncture|Standardized acupuncture administration for 10 sessions.
214451854|NCT01804816|OTHER|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
214526090|NCT01796834|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
214526091|NCT06116266|OTHER|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
214526092|NCT06116266|OTHER|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
214451855|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer FDG PET/CT Exam|"The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
214451856|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Cu64-DOTATATE PET/CT Exam|"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
214526093|NCT06116266|OTHER|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
215136445|NCT04506229|GENETIC|Whole exome sequencing|MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
215136446|NCT03248908|DIAGNOSTIC_TEST|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
215136447|NCT03248908|OTHER|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
215136448|NCT03198715|DRUG|DS1040b|DS-1040b in solution for intravenous infusion
215136449|NCT03198715|DRUG|Placebo|Saline solution for intravenous infusion
214451857|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Ga68-DOTATATE PET/CT Exam|"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
214451858|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer PSMA PET/CT Exam|"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
215136450|NCT02303496|BIOLOGICAL|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
215136451|NCT02303496|BIOLOGICAL|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
215136452|NCT05829226|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
215136453|NCT05829226|DRUG|Venetoclax|Bcl-2 inhibitor
215136454|NCT05829226|DRUG|Azacitidine|Hypomethylating agent
215136455|NCT05829226|DRUG|Decitabine|Hypomethylating agent
215136456|NCT04699617|DEVICE|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
215136457|NCT04105036|OTHER|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
215136458|NCT00520182|BEHAVIORAL|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids \[MUFA\]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
215136459|NCT00520182|BEHAVIORAL|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
215136460|NCT00520182|BEHAVIORAL|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
215136461|NCT05419583|DIAGNOSTIC_TEST|Coronary computed tomography angiography|CT scan of the heart arteries
215136462|NCT05419583|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
215136463|NCT05419583|DIAGNOSTIC_TEST|Transthoracic echocardiography|Ultrasound scan of the heart
215136464|NCT05419583|DIAGNOSTIC_TEST|Cardiac MRI scan|An MRI scan to assess the heart structure and function
215136465|NCT05419583|DRUG|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
215136466|NCT05419583|DRUG|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
215136467|NCT05419583|DRUG|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
215136468|NCT05419583|DRUG|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
215136469|NCT00733668|DRUG|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
215136470|NCT00616759|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy as usual
215136471|NCT00616759|PROCEDURE|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
215136472|NCT00616759|DRUG|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
215136473|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
215136474|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
215136475|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
215136476|NCT04154072|DRUG|NLY01|exenatide and polyethylene glycol (PEG)
215136477|NCT04154072|DRUG|Vehicle|Saline (Sodium Chloride)
215136478|NCT04306276|DRUG|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
215136479|NCT05650606|OTHER|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
215136480|NCT05650606|OTHER|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
215136481|NCT01283841|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
214451859|NCT05894681|OTHER|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
214451860|NCT05989958|COMBINATION_PRODUCT|HepaCure|HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.
214451861|NCT05989958|DEVICE|DPMAS and LPE|Using DPMAS and LPE for extracorporeal dialysis treatment.
214451862|NCT03400059|DEVICE|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
214451863|NCT03400059|DEVICE|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
214451864|NCT04168385|DRUG|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"
214451865|NCT05659797|DEVICE|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
214451866|NCT05659797|DRUG|18F-FES|Radiolabelled fluoroestradiol for PET imaging
214451867|NCT04421378|DRUG|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
214526094|NCT06116266|OTHER|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
215136482|NCT00169416|DRUG|valaciclovir HCl granules|
215136483|NCT05479877|DRUG|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
215136484|NCT05479877|DRUG|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
215136485|NCT02007096|DRUG|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight \>100kg: 60ml total
215136486|NCT02007096|DRUG|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight \>100kg: 60ml
215136487|NCT04234477|DRUG|Beta-blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
214451868|NCT04421378|DRUG|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
214451869|NCT04421378|DRUG|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
214451870|NCT04421378|RADIATION|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
214451871|NCT04421378|DRUG|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
214451872|NCT04421378|DEVICE|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
215136488|NCT04234477|DRUG|Calcium channel blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
215136489|NCT04234477|DRUG|Physician preference strategy|"This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil."
215136490|NCT02437344|DRUG|CI-581aa|92 minute infusion of CI-581aa
215136491|NCT02437344|DRUG|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
215136492|NCT04501523|DRUG|Tislelizumab|200mg, q3w, for 1 year
215136493|NCT04501523|DRUG|capecitabine|600-750 mg/m2 PO Bid，continuous, for 1 year
215136494|NCT02682524|DRUG|Pelubiprofen CR 45mg tab.|
215136495|NCT02682524|DRUG|Aceclofenac 100mg tab.|
215136496|NCT05003505|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
215136497|NCT06796361|DRUG|Ketanserin 40mg plus Psilocybin 40mg|40mg Ketanserin oral will be administered followed by 40mg Psilocybin.
215136498|NCT06796361|DRUG|40mg Psilocybin|Placebo oral followed by 40mg Psilocybin one hour later.
215136499|NCT06796361|DRUG|20mg Psilocybin|Placebo oral followed by 20mg Psilocybin one hour later.
215136500|NCT06796361|DRUG|10mg Psilocybin|Placebo oral followed by 10mg Psilocybin oral one hour later.
215136501|NCT06796361|DRUG|5mg Psilocybin|Placebo oral followed by 5mg Psilocybin one hour later
215136502|NCT06796361|OTHER|Placebo|Oral Placebo followed by oral Placebo one hour later
215136503|NCT06825260|DRUG|Senna|Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days
215136504|NCT06825260|DRUG|Polyethylene glycol 3350|Polyethylene Glycol 3350, oral, 17g, daily for 7 days
215136505|NCT03988309|DIAGNOSTIC_TEST|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
215136506|NCT02818972|DEVICE|RelayPro|Endovascular treatment with investigational device.
215136507|NCT04841447|OTHER|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
215136508|NCT01274793|DRUG|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
215136509|NCT01274793|DEVICE|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
215136510|NCT01274793|DEVICE|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
215136511|NCT00017212|DRUG|exatecan mesylate|
214451873|NCT04421378|DRUG|Carmustine|Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
215136512|NCT06387264|DEVICE|Medical Adhesive|Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.
215136513|NCT06387264|DEVICE|ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter|ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
215136514|NCT04552652|BEHAVIORAL|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
215136515|NCT04552652|BEHAVIORAL|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
215136516|NCT06581016|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
215136517|NCT06581016|DEVICE|Ambu aScope Gastro Large|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
214451874|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional impression technique|surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit
214451875|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional digital technique|surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
214451876|NCT06271187|DEVICE|Dynamic-orthosis|Engaging in motion training at home with the use of dynamic orthoses.
214451877|NCT06271187|OTHER|Traditional stroke occupational therapy training|Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.
214451878|NCT05683509|PROCEDURE|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
214451879|NCT05683509|PROCEDURE|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
214451880|NCT05579639|OTHER|Xylitol|Xylitol wipes
214451881|NCT05579639|OTHER|Placebo|Placebo wipes
215136518|NCT06581016|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
215136519|NCT06581016|DEVICE|Therapeutic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
215136520|NCT03015766|OTHER|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
215136521|NCT03015766|OTHER|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
215136522|NCT05559177|BIOLOGICAL|Chimeric exosomal tumor vaccines|Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
215136523|NCT02626585|PROCEDURE|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
215136524|NCT04675970|OTHER|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
215136525|NCT02197884|DRUG|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
215136526|NCT02197884|DRUG|Itraconazole 200 mg|Itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.
215136527|NCT02197884|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
214451882|NCT04150718|BEHAVIORAL|slow-wave disruption|A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
215136528|NCT03715114|DRUG|GV-971|Oral GV-971
215136529|NCT03715114|DRUG|Placebo|Oral Placebo
215136530|NCT01277016|DRUG|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
215136531|NCT03402217|BEHAVIORAL|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
215136532|NCT06419465|BEHAVIORAL|Peer-Led Health Protection and Promotion Training Program|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with peers, encouraging physical activity using the Google Fit mobile application. In order to provide social interaction, walking with peer leaders, health protection and development issues, receiving questions and opinions and giving guidance by individual phone calls regarding E-Nabiz and Google Fit mobile applications, holding peer group meetings and any of the Health Protection and Development Training Program targets. It consists of interventions such as giving a success badge for the relevant behavior if it reaches someone. Individual phone calls are also included in the intervention program.
215136533|NCT06419465|BEHAVIORAL|Health Protection and Promotion Training Program under the Leadership of a Public Health Nurse|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with nurses, encouraging physical activity using the Google Fit mobile application. To achieve any of the Health Protection and Development Training Program targets by walking with the nurse, taking individual phone calls regarding health protection and promotion issues, E-Nabiz and Google Fit mobile applications, receiving questions and opinions and giving guidance, holding group meetings in order to provide social interaction and social interaction. It consists of interventions such as giving a success badge for the relevant behavior. Individual phone calls are also included in the intervention program.
214451883|NCT04641026|OTHER|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
214451884|NCT04641026|OTHER|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
215136534|NCT01426100|DRUG|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
215136535|NCT01426100|DRUG|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
214451885|NCT04641026|OTHER|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
214451886|NCT04641026|OTHER|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
214451887|NCT04659343|OTHER|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
215136536|NCT01426100|DRUG|Telmisartan 80mg|Telmisartan 80mg monotherapy
214451888|NCT04545541|DRUG|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
214451889|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
215136537|NCT02640586|DEVICE|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
215136538|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
215136539|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
215136540|NCT04614363|DRUG|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
215136541|NCT02558894|DRUG|MEDI4736 monotherapy|MEDI4736 via IV infusion.
215136542|NCT02558894|DRUG|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
215136543|NCT05173558|BEHAVIORAL|Uninterrupted motionless standing|Participants remained 20 minutes of uninterrupted motionless standing
215136544|NCT05173558|BEHAVIORAL|Uninterrupted motionless sitting|Participants remained 20 minutes of uninterrupted motionless sitting
214451890|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
214451891|NCT03020303|DRUG|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
214451892|NCT03020303|DRUG|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
214451893|NCT04937868|OTHER|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
214451894|NCT05632614|DEVICE|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
214451895|NCT05632614|DEVICE|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
214451896|NCT04049279|PROCEDURE|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
214451897|NCT04049279|PROCEDURE|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
214451898|NCT04049279|PROCEDURE|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
214451899|NCT05443165|BEHAVIORAL|The effectiveness of the online decision support system developed for symptom self-management|"The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area."
215136545|NCT05173558|BEHAVIORAL|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
215136546|NCT00653510|DRUG|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
215136547|NCT00944853|DIETARY_SUPPLEMENT|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
215136548|NCT00944853|DIETARY_SUPPLEMENT|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
215136549|NCT00944853|DIETARY_SUPPLEMENT|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
215136550|NCT05632042|BEHAVIORAL|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
215136551|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
215136552|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
215136553|NCT02689427|PROCEDURE|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
215136554|NCT02689427|DRUG|Enzalutamide|Given PO
215136555|NCT02689427|OTHER|Laboratory Biomarker Analysis|Correlative studies
215136556|NCT02689427|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
215136557|NCT02689427|DRUG|Paclitaxel|Given IV
215136558|NCT02689427|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
215136559|NCT05506384|BEHAVIORAL|Relaps Preventions Therapy|The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
215136560|NCT05506384|BEHAVIORAL|Treatment as usual|This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
215136561|NCT00004217|BIOLOGICAL|filgrastim|5 μg/kg/day IV or SC
215136562|NCT00004217|BIOLOGICAL|sargramostim|5 μg/kg/day IV or SC starting d 15
215136563|NCT00004217|DRUG|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
215136564|NCT00004217|DRUG|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
215136565|NCT00004217|DRUG|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
215136566|NCT04271878|OTHER|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
215136567|NCT03889496|RADIATION|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
215136568|NCT05943691|DRUG|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
215136569|NCT05943691|DRUG|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
215136570|NCT05293769|OTHER|questionnaire|questionnaire will be filled in by all participants
214451900|NCT05443165|BEHAVIORAL|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
214451901|NCT06518967|DIAGNOSTIC_TEST|analytical performance study|analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
214451902|NCT03567096|DEVICE|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
214451903|NCT03567096|DEVICE|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
214451904|NCT05595486|OTHER|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
214451905|NCT05898516|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
215136571|NCT00598338|DRUG|Prucalopride|4 mg o.d.
214451906|NCT05831670|DRUG|KSP-0243|Oral administration
214451907|NCT05831670|DRUG|Placebo|Oral administration
214451908|NCT05042479|OTHER|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~* Application of a patch or anaesthetic cream 1 hour before the treatment~* Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~* Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~* Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~* The presence of the parents"
214451909|NCT05042479|OTHER|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
214526095|NCT06116266|OTHER|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
214526096|NCT04047680|DRUG|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
214526097|NCT04047680|DRUG|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
214526098|NCT04047680|DRUG|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
214526099|NCT04047680|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
214526100|NCT04047680|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
214526101|NCT04047680|DRUG|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
215136572|NCT00598338|OTHER|Placebo|o.d.
215136573|NCT00512889|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
215136574|NCT00512889|GENETIC|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
215136575|NCT00512889|DRUG|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
215136576|NCT00512889|RADIATION|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
215136577|NCT03581279|DEVICE|T2Lyme Panel testing|The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
215136578|NCT05164003|DRUG|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
215136579|NCT05164003|DRUG|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
215136580|NCT06101212|OTHER|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
214451910|NCT05042479|OTHER|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
215136581|NCT02829424|DRUG|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
215136582|NCT02829424|DRUG|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
215136583|NCT02967991|DEVICE|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
215136584|NCT00270881|PROCEDURE|Cord blood transplantation|unrelated cord blood transplantation
214451911|NCT06454539|OTHER|Functional Inspiratory Muscle Training|Functional IMT is an inspiratory muscle training that ensures core stabilization and maintains postural control. Rhythmic co-contractions of the core muscle areas (diaphragm, transversus abdominis, multifidus, pelvic floor) ensure the stability of the trunk and provide it with the feature of being the support point of movement. In the first stage, the person is given core stabilization training. Secondly, core stabilization is maintained and continued with strong trunk activation exercises. Postural exercises reinforce the other function of the breathing muscles, which is actually 'core' stabilization.
214451912|NCT06454539|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is one of the methods used to increase respiratory muscle strength. Different tools and methods (threshold resistive loading, normocapnic hyperpnea, and threshold pressure loading) have been developed for IMI. The most used method in the literature is the threshold pressure loading method. This method requires subjects to generate a negative pressure sufficient to overcome the load of the device and thus initiate inspiration. ICE is most commonly performed in a sitting position, with upper extremities supported and upper chest/shoulders relaxed. By placing the person in this position, the aim is for the respiratory muscles to focus only on the work of breathing.
214451913|NCT05640089|OTHER|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
214451914|NCT04223024|DRUG|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
214451915|NCT04223024|DRUG|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
214451916|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
214451917|NCT06529185|DEVICE|The BREATHER|The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
214451918|NCT06529185|DRUG|pharmacological treatment|patient will receive the usually pharmacological treatment.
215136585|NCT00270881|RADIATION|TBI|Total body irradiation (TBI) 12Gy
215136586|NCT00270881|DRUG|cyclophosphamide|cyclophosphamide 120mg/kg
215136587|NCT00270881|DRUG|cytarabine|cytarabine 3g/m2x4
215136588|NCT02251262|DEVICE|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
215136589|NCT03732573|BEHAVIORAL|Text messages|Text messages conveying 3 specific behaviour change techniques
215136590|NCT03889184|OTHER|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
215136591|NCT02682953|DRUG|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
215136592|NCT02682953|PROCEDURE|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
215136593|NCT02682953|DRUG|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
215136594|NCT00971659|DRUG|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
215136595|NCT00971659|DRUG|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
215136596|NCT00971659|DRUG|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
215136597|NCT00601224|BEHAVIORAL|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
215136598|NCT00601224|BEHAVIORAL|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
215136599|NCT03866122|DEVICE|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
215136600|NCT02065830|DEVICE|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
215136601|NCT06242132|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
215136602|NCT06242132|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
215136603|NCT02661321|OTHER|No intervention was used in this study, this was an observational study|
215136604|NCT02476617|DRUG|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
215136605|NCT02476617|DRUG|dasabuvir|dasabuvir tablets
215136606|NCT02476617|DRUG|ribavirin|ribavirin tablets
215136607|NCT03636074|PROCEDURE|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
215136608|NCT02241616|DRUG|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
215136609|NCT05933317|DIAGNOSTIC_TEST|Functional lung MRI|Functional lung MRI
215136610|NCT03987269|BEHAVIORAL|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
215136611|NCT03987269|BEHAVIORAL|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
215136612|NCT00635206|DEVICE|BiPap auto with Fi Flex|"* MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3"
215136613|NCT00635206|DEVICE|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)
215136614|NCT05661643|DRUG|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
214451919|NCT04719156|DRUG|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
214451920|NCT04719156|DEVICE|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
214451921|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
214526102|NCT01626677|BIOLOGICAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
215136615|NCT02505607|OTHER|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
215136616|NCT03916133|DIAGNOSTIC_TEST|Intervention group|6s PBV mapping will be conducted
215136617|NCT03486912|DRUG|BMS-986036|Specified dose on specified days.
215136618|NCT03486912|OTHER|Placebo|Specified dose on specified days.
215136619|NCT04020549|BEHAVIORAL|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
215136620|NCT04020549|BEHAVIORAL|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
215136621|NCT06351228|OTHER|Conization plus nodal evaluation|Conization plus nodal evaluation
214451922|NCT05875961|BIOLOGICAL|Intermediate dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
214451923|NCT05875961|BIOLOGICAL|High dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
214526103|NCT01626677|PROCEDURE|Microfracture|Active control
214526104|NCT03928171|OTHER|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
214451924|NCT05875961|BIOLOGICAL|High dose A/H2N3c non-adjuvanted|Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
214451925|NCT05875961|BIOLOGICAL|Lowest dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
215136622|NCT01495949|DRUG|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
215136623|NCT01495949|DRUG|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
215136624|NCT04665453|DIAGNOSTIC_TEST|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
215136625|NCT04665453|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
215136626|NCT04665453|DRUG|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
215136627|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
215136628|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
215136629|NCT02491684|DRUG|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
215136630|NCT02491684|DRUG|Placebo|Placebo solution for once daily inhalation for 14 days
215136631|NCT02199184|DRUG|Cyclophosphamide|Given IV
215136632|NCT02199184|DRUG|Doxorubicin Hydrochloride|Given IV
215136633|NCT02199184|DRUG|Etoposide|Given IV
215136634|NCT02199184|BIOLOGICAL|Ofatumumab|Given IV
215136635|NCT02199184|DRUG|Prednisone|Given PO
215136636|NCT02199184|BIOLOGICAL|Rituximab|Given IV
215136637|NCT02199184|DRUG|Vincristine Sulfate|Given IV
215136638|NCT00005975|DRUG|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
215136639|NCT00005975|DRUG|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
215136640|NCT00005975|DRUG|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
215136641|NCT00005975|DRUG|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
215136642|NCT00368407|DEVICE|308-nm excimer laser|
215136643|NCT04137068|BEHAVIORAL|Reduced Activity|Participants reduce their activity level to \<5,000 steps/day and \<50 % of baseline steps.
215136644|NCT01419964|DRUG|Group 01|ACH24
215136645|NCT01419964|DRUG|Group 02|Placebo
215136646|NCT03983707|DEVICE|Purastat®|Use of Purastat®
214451926|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
214451927|NCT01476371|BEHAVIORAL|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
214451928|NCT05264532|OTHER|Informational Intervention|Receive information-graphic video
214451929|NCT05264532|OTHER|Informational Intervention|Receive family letter
214451930|NCT05264532|OTHER|Survey Administration|Ancillary studies
215136647|NCT05906953|DRUG|HG004|Low dose Medium dose High dose
215136648|NCT06337799|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
215136649|NCT05585788|DEVICE|Addinex Device (ADX-27)|"The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians."
215136650|NCT05932329|BEHAVIORAL|Dietary Advice|Dietary Advice provided
214451931|NCT05664425|DEVICE|Ultrasonic debridement|Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)
214451932|NCT04869683|OTHER|description of MDS pzatient cohort|description of MDS patient cohort
214451933|NCT04341779|COMBINATION_PRODUCT|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
215136651|NCT04197700|OTHER|Target MAP Management|Target MAP Management
215136652|NCT01263769|DRUG|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
215136653|NCT06504992|DRUG|Vancomycin 1000 MG|Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
215136654|NCT06088823|OTHER|Heart surgery|Adult cardiac surgery
215136655|NCT05235009|DIAGNOSTIC_TEST|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
215136656|NCT06497959|DRUG|SonoVue|Placental contrast ultrasound using SonoVue by maternal intravenous injection
215136657|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
215136658|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
215136659|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
215136660|NCT03255603|OTHER|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
215136661|NCT06144307|PROCEDURE|plane block|injection of local anesthetic to the myofascial plane
214451934|NCT05719220|BEHAVIORAL|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
214451935|NCT06115954|OTHER|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
214451936|NCT04847635|DEVICE|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
214451937|NCT04847635|DEVICE|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
214451938|NCT05671562|DIETARY_SUPPLEMENT|Lycopene|Capsule containing lycopene 7mg x 2 daily for 12 weeks
215136662|NCT05847192|DIAGNOSTIC_TEST|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.
215136663|NCT01500733|DRUG|PCI 32765|420 mg daily
215136664|NCT06521723|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
215136665|NCT06521723|DEVICE|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
215136666|NCT05632653|PROCEDURE|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
215136667|NCT02242942|DRUG|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
215136668|NCT02242942|DRUG|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
215136669|NCT02242942|DRUG|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
215136670|NCT01806220|PROCEDURE|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
215136671|NCT01806220|PROCEDURE|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
215136672|NCT03259230|OTHER|Blood Draws|
215136673|NCT03259230|OTHER|Data Collection|
215136674|NCT04332822|DRUG|R-pola-mini-CHP|"* Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
215136675|NCT04332822|DRUG|R-mini-CHOP|"* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
215136676|NCT03541083|DRUG|Blinatumomab|prephase and consolidation (I and II)
215136677|NCT04578769|PROCEDURE|conventional myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
214451939|NCT05671562|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive substance 7mg x 2 daily for 12 weeks
215136678|NCT04578769|PROCEDURE|short myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
215136679|NCT04578769|PROCEDURE|full-thickness myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
215136680|NCT04578769|PROCEDURE|tailored myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
215136681|NCT05772390|RADIATION|Partial breast re-irradiation|partial breast re-irradiation
215136682|NCT05914623|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
215136683|NCT05914623|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
215136684|NCT01095549|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
215136685|NCT01095549|DEVICE|Placebo device|A device without far infrared therapy
215136686|NCT02099851|DEVICE|Carotid body ablation (Cibiem)|
215136687|NCT00561652|BEHAVIORAL|Education & Exercise|Education \& Exercise
215136688|NCT00561652|PROCEDURE|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education \& Exercise)
215136689|NCT04964635|DEVICE|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
215136690|NCT04045860|PROCEDURE|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
215136691|NCT04045860|OTHER|Observation|Standard of care is currently observation
215136692|NCT01063049|DRUG|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
215136693|NCT01063049|DRUG|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
214451940|NCT05855941|DIAGNOSTIC_TEST|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
214451941|NCT02592330|PROCEDURE|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
214451942|NCT02592330|BIOLOGICAL|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
214451943|NCT02592330|PROCEDURE|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
214451944|NCT03948048|DEVICE|ECMO|ECMO is used to intervene septic shock and refractory septic shock
214526105|NCT04310800|PROCEDURE|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
214526106|NCT00719277|DEVICE|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
214451945|NCT05850247|DRUG|[18F]DPA-714 PET/MRI|"To assess the association between plasma ficolin-2 levels and plaque and brain inflammation assessed by \[18F\]DPA-714 PET/MRI in patients managed for transient ischaemic attack or ischaemic stroke related to carotid stenosis.~PET/MRI of the brain and carotid plaque with \[18F\]DPA-714 and gadolinium infusion will be performed at day 5."
215136694|NCT01063049|DRUG|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
215136695|NCT01063049|DRUG|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
215136696|NCT03998540|DIAGNOSTIC_TEST|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
215136697|NCT03998540|OTHER|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
215136698|NCT03998540|OTHER|Mass Spectometry|samples previously used for western blotting will be subjected to mass spectrometry analysis
215136699|NCT03998540|OTHER|RNA seq|analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
215136700|NCT00774371|BEHAVIORAL|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
215136701|NCT05694390|OTHER|Use of sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
215136702|NCT03730909|DRUG|Sodium Lactate|IV infusion
215136703|NCT03730909|DRUG|Sodium chloride|IV infusion
215136704|NCT03249636|DIAGNOSTIC_TEST|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
214451946|NCT03090152|PROCEDURE|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
214451947|NCT03090152|PROCEDURE|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
214451948|NCT03090152|DRUG|Bupivacaine|EPCA: Bupivacaine 0.06%.
214451949|NCT03090152|DRUG|Placebo|EPCA: Saline.
215136705|NCT03019406|DRUG|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
215136706|NCT03019406|DRUG|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
215136707|NCT05544526|BIOLOGICAL|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
215136708|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
215136709|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
215136710|NCT00988494|DRUG|Placebo ophthalmic solution|Topical ocular application
215136711|NCT02608190|BEHAVIORAL|Working memory training|See protocol
215136712|NCT03710187|DRUG|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
215136713|NCT06525298|DRUG|EIS-12656|EIS-12656 tablets given daily
215136714|NCT06525298|DRUG|Olaparib|as per USPI/SmPC
215136715|NCT06525298|DRUG|Trastuzumab deruxtecan|as per USPI/SmPC
215136716|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
215136717|NCT00231816|BIOLOGICAL|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
215136718|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
215136719|NCT00468169|DRUG|Cetuximab|250mg/m2(day 1, weekly x 10);
215136720|NCT00468169|DRUG|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
215136721|NCT00468169|DRUG|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
215136722|NCT00468169|RADIATION|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
215136723|NCT00468169|DRUG|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
215136724|NCT00468169|RADIATION|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
215136725|NCT03735303|DIETARY_SUPPLEMENT|VD3 group|VD3 50000 IU/ week for 8 weeks
215136726|NCT03735303|DIETARY_SUPPLEMENT|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
215136727|NCT03735303|DIETARY_SUPPLEMENT|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
215136728|NCT03735303|OTHER|control group|no intervention was given
215136729|NCT02011906|DIETARY_SUPPLEMENT|omega 3|
215136730|NCT02011906|DIETARY_SUPPLEMENT|vitamin E|
215136731|NCT02011906|DIETARY_SUPPLEMENT|placebo of omega 3|
215136732|NCT02011906|DIETARY_SUPPLEMENT|placebo of vitamin E|
215136733|NCT05588336|DRUG|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
215136734|NCT05207774|DRUG|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
215136735|NCT05207774|DRUG|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
215136736|NCT00384345|DEVICE|Bright Light Therapy|
215136737|NCT00384345|BEHAVIORAL|Exercise|
215136738|NCT04372017|DRUG|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
214526107|NCT06288347|DEVICE|GGON mobile app.|The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
214526108|NCT02916745|DRUG|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
214526109|NCT02916745|DEVICE|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
214526110|NCT02848898|DEVICE|Equistasi|
214526111|NCT02848898|OTHER|Placebo|
214526112|NCT05899868|DEVICE|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
214526113|NCT06577376|DRUG|DP303c|DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
214526114|NCT06577376|DRUG|Simmitinib tablets|A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
214526115|NCT06577376|DRUG|Irinotecan liposomes|A chemotherapy
214526116|NCT06577376|DRUG|Paclitaxel or docetaxel or irinotecan|Paclitaxel or docetaxel or irinotecan is used as a control.
214526117|NCT03749538|OTHER|Transcranial direct current stimulation session.|Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
214526118|NCT06182800|DRUG|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
214526119|NCT00985621|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
214526120|NCT00985621|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
214526121|NCT00985621|DRUG|oxycodone|oxycodone CR, 10-40 mg q12h
214526122|NCT00985621|OTHER|placebo|placebo
214526123|NCT00065234|PROCEDURE|Acupuncture|
215136739|NCT04372017|DIETARY_SUPPLEMENT|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
215136740|NCT02890797|RADIATION|radiology|The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
215136741|NCT05559450|DRUG|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
214526124|NCT00433498|DRUG|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
214526125|NCT00433498|DRUG|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
214526126|NCT00433498|DRUG|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
214526127|NCT00433498|DRUG|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
214526128|NCT05550584|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
215136742|NCT05559450|OTHER|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
215136743|NCT05864729|DIAGNOSTIC_TEST|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
215136744|NCT06432153|OTHER|observation|Participants who receive routine clinical care, without additional intervention from the study
214526129|NCT05550584|DEVICE|LMA|Mechanical ventilation performed by a laringeal mask
214526130|NCT01911819|PROCEDURE|Sinus augmentation|
214526131|NCT01911819|DRUG|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
214526132|NCT01911819|DRUG|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
214526133|NCT01911819|DRUG|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
214526134|NCT04008004|DRUG|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
214526135|NCT04008004|DRUG|Placebo|Placebo to match EDP-514
214526136|NCT03903185|DRUG|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
214526137|NCT05619991|OTHER|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
214526138|NCT05619991|OTHER|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
214526139|NCT03849300|OTHER|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
214526140|NCT03849300|OTHER|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
214526141|NCT03849300|OTHER|Land-based walking exercise group|12 week land-based walking exercise program
214526142|NCT06383507|DRUG|CHT101|After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
214526143|NCT05830422|OTHER|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
214526144|NCT02506322|BEHAVIORAL|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management"
214526145|NCT02506322|BEHAVIORAL|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
214526146|NCT04178876|PROCEDURE|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
214526147|NCT04178876|PROCEDURE|stripping technique|Endometrioma laparoscopic cystectomy
215136745|NCT03497936|BEHAVIORAL|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
215136746|NCT02991183|BEHAVIORAL|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
215136747|NCT02666781|OTHER|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
215136748|NCT01283139|BIOLOGICAL|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
215136749|NCT01283139|BIOLOGICAL|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
215136750|NCT01283139|BIOLOGICAL|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
215136751|NCT01283139|OTHER|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
215136752|NCT04517123|OTHER|Prone Positioning|Prone Positioning
215136753|NCT04357743|OTHER|Chin supported Arm ergometry with pursed lip breathing|"The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week"
215136754|NCT04357743|OTHER|Arm ergometry with pursed lip breathing|"The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week."
215136755|NCT03631485|OTHER|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
214526148|NCT02240836|OTHER|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
214526149|NCT00807053|DRUG|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
214526150|NCT00807053|DRUG|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
214526151|NCT00807053|DRUG|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
215136756|NCT00407121|DRUG|Bevacizumab|
215136757|NCT00407121|PROCEDURE|Intravitreal Injection of Bevacizumab|
215136758|NCT00688116|DRUG|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
215136759|NCT05211947|DRUG|BI 425809|BI 425809
215136760|NCT00007202|DRUG|Atazanavir|
215136761|NCT00007202|DRUG|Stavudine|
215136762|NCT00007202|DRUG|Didanosine|
215136763|NCT06079008|OTHER|calcified cardiac valve|patients have cardiac cardiac valve before surgery
215136764|NCT01623102|DRUG|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
215136765|NCT01623102|DRUG|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
214526152|NCT00807053|DRUG|Placebo|Placebo
214526153|NCT03479502|DRUG|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
214526154|NCT03479502|DRUG|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
214526155|NCT02297945|DRUG|metyrapone|Single arm study
214526156|NCT02400398|OTHER|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
215136766|NCT01463501|OTHER|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
215136767|NCT01463501|OTHER|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
215136768|NCT00976274|DIETARY_SUPPLEMENT|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
215136769|NCT00976274|DIETARY_SUPPLEMENT|starch|5 capsules three times everyday for 12 weeks
215136770|NCT01075243|DRUG|Paracetamol 1000 mg|Paracetamol 1000mg
215136771|NCT01075243|DRUG|Paracetamol 650 mg|Paracetamol 650 mg
215136772|NCT01075243|DRUG|Placebo|Placebo
215136773|NCT01855529|DRUG|Ropivacaine in one arm and placebo (NaCl) in the other arm|
215136774|NCT02329444|PROCEDURE|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
215136775|NCT02329444|PROCEDURE|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
215136776|NCT05587270|OTHER|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
215136777|NCT05587270|RADIATION|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
215136778|NCT03361800|DRUG|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
215136779|NCT04805502|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
215136780|NCT04917172|DIAGNOSTIC_TEST|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell \[WBC\] count and C-Reactive Protein \[CRP\]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
215136781|NCT06375161|BIOLOGICAL|anti-CD19-CAR-T cells|"Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc."
215136782|NCT00437112|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
215136783|NCT00437112|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
215136784|NCT01762410|DRUG|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
215136785|NCT04398771|DRUG|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
215136786|NCT03593902|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
214451950|NCT05238792|BIOLOGICAL|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
214451951|NCT05606289|BEHAVIORAL|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
214451952|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
214451953|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
214451954|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
214451955|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
214451956|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
214526157|NCT00120952|DEVICE|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
214526158|NCT00966706|DRUG|capecitabine|Given systemically
214526159|NCT00966706|DRUG|cisplatin|Given systemically
214526160|NCT00966706|DRUG|docetaxel|Given systemically
214526161|NCT00966706|DRUG|epirubicin hydrochloride|Given systemically
215136787|NCT03593902|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
214526162|NCT00966706|DRUG|gemcitabine hydrochloride|Given systemically
215136788|NCT03593902|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
215136789|NCT03593902|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
215136790|NCT03593902|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
214451957|NCT04278404|DRUG|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
214451958|NCT06300307|DRUG|ATX-01|Solution for infusion
214451959|NCT06300307|DRUG|Placebo|Solution for infusion
214451960|NCT06310213|DEVICE|Non-Invasive Pressure Monitor|Modified smart soft contact lens and cap with reader coil
214451961|NCT06579001|DRUG|Nasal spray dexmedetomidine|Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment
214451962|NCT03135106|DRUG|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
214451963|NCT03135106|DRUG|Fluconazole|A 400-mg fluconazole orally (4\*100 mg capsules) will be administered from Day 1 to Day 11.
214451964|NCT03135106|DRUG|Itraconazole|A 200-mg itraconazole orally (2\*100 mg capsules) will be administered from Day 1 to Day 11.
214451965|NCT06678672|BEHAVIORAL|Contingency Management (CM)|The participants will receive and be trained to use a CO monitor and iCO app to upload videos to verify smoking abstinence at a minimum of once per day, 5 times per week, over 5 weeks. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through remote CO monitoring. They will receive clinician feedback at the time of each CO reading, following the established VA CM protocol developed in the earlier phase of the project. Each CO reading during the weeks 2-5 will also be accompanied with a brief (5-minute) telephone or video feedback CM counseling session from the study clinician.
214451966|NCT06678672|BEHAVIORAL|Treatment as Usual (TAU)|Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (SFVAHCS), i.e., referral to Tobacco Cessation Clinic and the VA Telequit Quitline. The SFVAHCS Tobacco Cessation Clinic is a consult service that calls patients proactively 3 times to offer 1:1 behavioral counseling for smoking cessation. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for up to 5 sessions per NCI Quitline guidelines. The smoker initiates the first call, and subsequent calls will be proactively made by Quitline staff.
214451967|NCT03737045|OTHER|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
214451968|NCT06581068|DEVICE|AURA assisted ART treatment|The AURA device consists of five subsystems, which will operate in logical sequence to deliver comprehensive automation of the laboratory element of an ART cycle. The AURA treatment begins after ovarian stimulation, on the day of egg collection. A sperm sample is provided on the same day of egg collection. Sperm samples will be prepared by the C:SPERM subsystem. Follicular fluid obtained at egg collection will be processed by the C:EGG subsystem. 3 out of every 4 cumulus-oocyte complexes (COCs) recovered will be denuded by the C:EGG subsystem. These denuded eggs will be fertilized by the C:ICSI subsystem, incubated in the C:CULTURE subsystem and all resulting suitable embryos will be vitrified by the C:VIT subsystem. Thawed embryos may be used in conventional frozen embryo transfers.
214451969|NCT03958955|DRUG|Delgocitinib cream|Cream for topical application.
214451970|NCT03958955|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214451971|NCT03226418|DRUG|Cytarabine|Given IV
214451972|NCT03226418|DRUG|Decitabine|Given IV
214451973|NCT03226418|DRUG|Idarubicin|Given IV
214451974|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
214451975|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214451976|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
214526163|NCT03529006|PROCEDURE|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
214526164|NCT03529006|PROCEDURE|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
214526165|NCT06212180|DEVICE|mask|patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation
215136791|NCT03593902|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
215136792|NCT03593902|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
215136793|NCT03593902|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
215136794|NCT03593902|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
215136795|NCT04382950|COMBINATION_PRODUCT|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
215136796|NCT05301660|DRUG|Nicotine transdermal patch|14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
215136797|NCT06266481|DRUG|Topical dexamethasone|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
215136798|NCT06266481|DRUG|10% lidocaine was sprayed over the tube for the second group|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
215136799|NCT05328102|BIOLOGICAL|Plamotamab|Biological
215136800|NCT05328102|BIOLOGICAL|Tafasitamab|Biological
214451977|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
214451978|NCT03226418|DRUG|Azacitidine|Given by infusion
214451979|NCT03226418|DRUG|Venetoclax|oral tablet
214451980|NCT03226418|DRUG|glasdegib|oral tablet
214451981|NCT05932069|BEHAVIORAL|SPIN|Stationary cycling
214451982|NCT05932069|BEHAVIORAL|Non-aerobic, stretching/balance intervention Control|Balance and stretching exercise
214526166|NCT05357599|DIAGNOSTIC_TEST|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
214526167|NCT06061588|DEVICE|Virtual Reality|The use of virtual reality as an adjunct to routine treatment.
214526168|NCT00874393|DRUG|Dopamine|Dopamine
214526169|NCT00874393|DRUG|Hydrocortisone|Hydrocortisone
215136801|NCT05328102|DRUG|Lenalidomide|Drug
215136802|NCT00784563|BEHAVIORAL|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
214451983|NCT05006365|DEVICE|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
214451984|NCT05829902|OTHER|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
214451985|NCT05829902|OTHER|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
214526170|NCT00874393|DRUG|Infusion Placebo|Dextrose (D5W)
214526171|NCT00874393|DRUG|Syringe Placebo|Normal saline
215136803|NCT00784563|BEHAVIORAL|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
215136804|NCT04134416|DRUG|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
215136805|NCT04134416|BEHAVIORAL|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
215136806|NCT04134416|DEVICE|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
215136807|NCT04965701|DRUG|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
215136808|NCT03812731|DRUG|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
215136809|NCT03812731|DRUG|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
215136810|NCT04100486|OTHER|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
215136811|NCT04100486|OTHER|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
214526172|NCT06367244|BEHAVIORAL|Transplant Wellness Program - Kidney and Liver|The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
215136812|NCT04100486|OTHER|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
215136813|NCT04100486|OTHER|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
215136814|NCT04100486|OTHER|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
215136815|NCT04100486|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
214451986|NCT06201728|OTHER|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
214451987|NCT05678998|DRUG|WTX-330|Investigation Product
214451988|NCT04638829|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
214451989|NCT04768322|DEVICE|HeartMate 3 TM Left Ventricular Assist System|The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
214451990|NCT04768322|OTHER|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
214451991|NCT05330975|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214451992|NCT05330975|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214451993|NCT05330975|BIOLOGICAL|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
214451994|NCT05330975|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214451995|NCT01368146|DEVICE|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
214451996|NCT01368146|DEVICE|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
214451997|NCT01368146|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
214526173|NCT00163748|DRUG|gemcitabine, vinorelbine|
215136816|NCT04117555|DIAGNOSTIC_TEST|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
215136817|NCT03559114|DRUG|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
215136818|NCT03559114|DRUG|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
215136819|NCT01614249|DIETARY_SUPPLEMENT|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
215136820|NCT01614249|DIETARY_SUPPLEMENT|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
215136821|NCT02954536|DRUG|pembrolizumab|
215136822|NCT02954536|DRUG|trastuzumab|
215136823|NCT02954536|DRUG|capecitabine|
215136824|NCT02954536|DRUG|cisplatin|
215136825|NCT02954536|DRUG|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
214526174|NCT05602961|DRUG|GLB-COV2-043|COVID-19 vaccine, administered as a booster
214526175|NCT05602961|DRUG|BNT162b2/COMIRNATY®|active control
215136826|NCT02954536|DRUG|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
215136827|NCT04004234|DRUG|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
215136828|NCT04004234|DRUG|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
215136829|NCT04004234|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
215136830|NCT04004234|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
215136831|NCT01239199|OTHER|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
215136832|NCT01164514|BIOLOGICAL|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
215136833|NCT01164514|BIOLOGICAL|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
215136834|NCT01164514|DRUG|Placebo|Normal saline.
215136835|NCT02946580|DRUG|MOVANTIK™ (naloxegol)|
215136836|NCT02946580|DRUG|Sugar Pill|
215136837|NCT06207331|DRUG|Dexmedetomidine 0.5 μg/kg|Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
214451998|NCT05415410|DRUG|Apraglutide|Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
214451999|NCT06408558|OTHER|Hypobaric|The effects of ambient pressure changes on glucose metabolism will be studied
214452000|NCT06408558|OTHER|Ground level|The effects of ambient pressure changes on glucose metabolism will be studied
215136838|NCT06207331|DRUG|Dexmedetomidine 1 μg/kg|Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
215136839|NCT06207331|DRUG|Saline|Participants inhale atomized 2 ml 0.9% saline.
215136840|NCT06301490|OTHER|Myofascial Release|Myofascial release is a popular hands-on method manual therapy technique that uses carefully guided low load, long duration mechanical pressures to modify the myofascial complex (directly or indirectly), with the goal of restoring appropriate length, decreasing discomfort, and improving range of motion, muscle recovery, and physical performance in healthy persons.
215136841|NCT06100588|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
215136842|NCT06100588|OTHER|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
214452001|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
214452002|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
214452003|NCT04297280|DRUG|Sintilimab|a PD-1 immune check inhibitor
214452004|NCT04297280|COMBINATION_PRODUCT|TACE|TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
214452005|NCT05596162|OTHER|Blood Flow Restriction Therapy|Exercise with Blood Flow Restriction
214452006|NCT05596162|OTHER|Standard Physical Therapy|Exercise without Blood Flow Restriction
214526176|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
215136843|NCT01241864|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
215136844|NCT01241864|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
215136845|NCT00788216|OTHER|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
215136846|NCT04906564|OTHER|Identification of genetic variants|Identification of genetic variants
214526177|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526178|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526179|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526180|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526181|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526182|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
214526183|NCT01428622|DRUG|Olodaterol|aqueous solution
214526184|NCT01428622|DRUG|Olodaterol|aqueous solution
214526185|NCT01428622|DRUG|Olodaterol|aqueous solution
214526186|NCT01428622|DRUG|Olodaterol|aqueous solution
214526187|NCT01428622|DRUG|Olodaterol|aqueous solution
214526188|NCT01428622|DRUG|Olodaterol|aqueous solution
214526189|NCT01428622|DRUG|Olodaterol|aqueous solution
214526190|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
214526191|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
214526192|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
214526193|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
214526194|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
215136847|NCT03896438|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
215136848|NCT00256594|DEVICE|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
214526195|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
214526196|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
215136849|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
215136850|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
215136851|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
215136852|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
215136853|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
215136854|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
215136855|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
215136856|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
215136857|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
215136858|NCT03075787|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
215136859|NCT04106297|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
215136860|NCT04106297|DRUG|Placebo oral solution|Placebo for oral administration
215136861|NCT04106297|DRUG|GLPG3970 capsule|GLPG3970 for oral administration
215136862|NCT05529498|BEHAVIORAL|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
214526197|NCT01428622|DRUG|BI54903|ethanolic solution
214526198|NCT01428622|DRUG|BI54903|ethanolic solution
214526199|NCT01428622|DRUG|BI54903|ethanolic solution
214526200|NCT01428622|DRUG|BI54903|ethanolic solution
214526201|NCT01428622|DRUG|BI54903|ethanolic solution
214526202|NCT01428622|DRUG|BI54903|ethanolic solution
214526203|NCT01428622|DRUG|BI54903|ethanolic solution
214526204|NCT04528368|BIOLOGICAL|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
214526205|NCT01786915|DRUG|Bendavia 10mg|
214526206|NCT01786915|DRUG|Bendavia 50mg|
214526207|NCT01786915|DRUG|Placebo|
214526208|NCT00040729|GENETIC|mutation analysis|
214526209|NCT06450275|DRUG|Dolutegravir 50 MG Film Coated Tablet|1 tablet of Dolutegravir 50mg film-coated tablets
214526210|NCT06450275|DRUG|Tivicay 50mg, film-coated tablets|1 tablet of Dolutegravir 50mg film-coated tablets
214526211|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
214526212|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
214526213|NCT00464737|OTHER|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
214526214|NCT00579475|DRUG|Mifegyne|tablets, 50 mg every other day
215136863|NCT05529498|BEHAVIORAL|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
214452007|NCT06148519|DIAGNOSTIC_TEST|2WIN-S portable refractor|All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
214452008|NCT06364189|BEHAVIORAL|Music|Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
214452009|NCT06364189|BEHAVIORAL|Exercise|"The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
214452010|NCT06316843|DRUG|Valacyclovir celecoxib dose 1|1500 mg valacyclovir 200 mg celecoxib taken two times a day
214452011|NCT06316843|DRUG|Valacyclovir celecoxib dose 2|750 mg valacyclovir 200 celecoxib mg taken two times a day
214452012|NCT06316843|DRUG|Placebo|Placebo capsules colored matched to investigational product taken two times a day
214452013|NCT06044987|PROCEDURE|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
214452014|NCT06044987|PROCEDURE|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
214452015|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214452016|NCT06554587|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)|Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
214452017|NCT06237348|DEVICE|Simeox|Daily airway clearance therapy at home during 2 months
215136864|NCT00132392|DRUG|ALGRX 4975|
215136865|NCT04567069|BIOLOGICAL|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
214452018|NCT06237348|COMBINATION_PRODUCT|Control|Daily airway clearance therapy at home during 2 months
214526215|NCT00579475|DRUG|placebo|
214526216|NCT03094520|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
214526217|NCT03094520|DEVICE|sham-tDCS|sham stimulation
214452019|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
214452020|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
214452021|NCT05445960|PROCEDURE|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
214452022|NCT05631262|DRUG|SKB264|Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
214452023|NCT05631262|DRUG|Docetaxel|Part II Control group will receive docetaxel monotherapy.
214452024|NCT02927769|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
214452025|NCT02927769|BIOLOGICAL|brentuximab vedotin|Specified Dose on Specified Days
214452026|NCT02927769|BIOLOGICAL|bendamustine|Specified Dose on Specified Days
214526218|NCT02033668|DRUG|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
214526219|NCT02033668|DRUG|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
214526220|NCT02033668|DRUG|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
214526221|NCT02814279|PROCEDURE|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
214526222|NCT02814279|PROCEDURE|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
215136866|NCT04567069|BIOLOGICAL|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
215136867|NCT04567069|DRUG|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
215136868|NCT01280006|OTHER|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
215136869|NCT01280006|DRUG|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
215136870|NCT01280006|DRUG|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
215136871|NCT01280006|DRUG|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
215136872|NCT04764162|DIETARY_SUPPLEMENT|Choline|1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)
215136873|NCT04764162|DIETARY_SUPPLEMENT|Placebo|Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules
215136874|NCT01242423|DEVICE|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
215136875|NCT02078206|OTHER|Neurocognitive stimulation|
215136876|NCT03660462|DIETARY_SUPPLEMENT|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
215136877|NCT03660462|DIETARY_SUPPLEMENT|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
215136878|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
215136879|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
215136880|NCT00791934|DEVICE|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
215136881|NCT00096902|PROCEDURE|Tilt table test|
215136882|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
214452027|NCT06304831|BEHAVIORAL|Quality ratings of health care providers for children|Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
214452028|NCT02807636|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
214452029|NCT02807636|DRUG|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
214452030|NCT02807636|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
214452031|NCT02807636|OTHER|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
214526223|NCT02814279|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
214526224|NCT02814279|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
214526225|NCT05347524|OTHER|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
214526226|NCT06190145|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
214526227|NCT00676663|DRUG|entinostat|Entinostat 5 mg tablet orally once per week
214526228|NCT00676663|DRUG|exemestane|Exemestane 25 mg tablet orally once daily
214526229|NCT00676663|DRUG|Placebo|Placebo-matching entinostat tablet orally once per week
214526230|NCT06185699|DIAGNOSTIC_TEST|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
215136883|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
215136884|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
215136885|NCT03545555|DIETARY_SUPPLEMENT|Placebo|Effect of placebo on lipid status
215136886|NCT05023733|DEVICE|CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®|Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1
215136887|NCT05685628|OTHER|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates."
215136888|NCT05685628|OTHER|Charcoal dressing|Use of a secondary non-occlusive activated charcoal dressing (brand of your choice)
215136889|NCT02599571|OTHER|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
215136890|NCT02599571|OTHER|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
215136891|NCT04733638|DEVICE|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
215136892|NCT06270147|DRUG|Bupivacaine-epinephrine|A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
215136893|NCT02018562|DEVICE|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
215136894|NCT06679686|OTHER|Role Playing|The group will analyse the instant cases given by the researchers using the role-play method.
215136895|NCT06679686|OTHER|Digital Storytelling|The group will analyse the ethical analysis of the cases containing ethical problems written by themselves by using digital storytelling
215136896|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
215136897|NCT05153837|OTHER|oral water|500 ml oral water
215136898|NCT06155526|OTHER|Activity|patients taking an active rest after swimming sets
215136899|NCT04444076|DEVICE|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
214452032|NCT02807636|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
214452033|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
214452034|NCT03747341|DRUG|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
214452035|NCT03747341|DRUG|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
214452036|NCT03747341|DRUG|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
215136900|NCT05194124|DRUG|Setmelanotide 2 mg|Administered as SC injection
215136901|NCT05194124|DRUG|Setmelanotide 2.5 mg|Administered as SC injection
214452037|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
214452038|NCT03747341|DRUG|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
215136902|NCT05194124|DRUG|Setmelanotide 3 mg|Administered as SC injection
215136903|NCT05194124|DRUG|Setmelanotide 20 mg|Administered as SC injection
215136904|NCT05194124|DRUG|Setmelanotide 25 mg|Administered as SC injection
215136905|NCT05194124|DRUG|Setmelanotide 30 mg|Administered as SC injection
215136906|NCT06676735|DEVICE|Inflatable warming system|Inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient\&#39;s temperature is normal, it can be adjusted back to 38 ℃.
215136907|NCT06676735|DIAGNOSTIC_TEST|Prediction of intraoperative hypothermia risk|According to the Intelligent Care For The Elderly (ICE, an optimized model based on the existing prediction model of our research group after dynamic incremental training), patients are divided into intraoperative hypothermia lowrisk group and intraoperative hypothermia high risk group.
215136908|NCT06676735|OTHER|The difference between axillary temperatature and core temperature in elderly patients|Previous studies have shown that the difference and standard deviation between esophageal temperature and axillary temperature are core 0.05 ℃ and 0.26 ℃, respectively. In light of 10% dropout rate, a integer sample size of 400 achieves 95% power to detect a mean of paired differences of 0.05 with an estimated standard deviation of paired differences of 0.26 and with a significance level (alpha) of 0.05 using a two-sided paired t-test. So 400 patients in the Model optimization group need to undergo core temperature (esophageal temperature or nasopharyngeal temperature).
215136909|NCT06676735|OTHER|Measurement of tympanic membrane temperature|As a intraoperative core temperature reference (measure every 15 minutes) for patients without esophageal temperature or nasopharyngeal temperature monitoring.
215136910|NCT05524493|DIAGNOSTIC_TEST|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
215136911|NCT05524493|DIAGNOSTIC_TEST|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
215136912|NCT05524493|DIAGNOSTIC_TEST|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
215136913|NCT05524493|DIAGNOSTIC_TEST|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
215136914|NCT05524493|DIAGNOSTIC_TEST|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
215136915|NCT05891431|DEVICE|Untire mobile app|"The Untire app is an mHealth intervention (digitally delivered using a smartphone app).~Untire offers a comprehensive program to help you understand cancer fatigue and gives a physical activity program, stress reduction exercises and tips to manage your energy level."
215136916|NCT00010036|DRUG|carboplatin|
215136917|NCT00010036|DRUG|irinotecan hydrochloride|
214452039|NCT03747341|DRUG|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
214452040|NCT04088630|DRUG|Fingolimod|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
214452041|NCT04088630|DRUG|Placebo|A single oral placebo pill within 24 hours of symptom onset
214452042|NCT04088630|DRUG|Open-label Fingolimod|A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
214452043|NCT05991414|DEVICE|Home blood pressure monitor|Participants provided home blood pressure monitor and instructions on use from pharmacist. They will measure home BP every 4-weeks for 7 days as per Hypertension Canada 7-day home BP protocol.
214452044|NCT05991414|PROCEDURE|Enhanced community pharmacist care|Pharmacist to follow up with participants every month to review home BP readings. Then the pharmacist will send home BP readings and recommendations for changes to antihypertensive medication regimen to participants prescribing clinician. Pharmacist will then advise participants to follow up with their prescribing clinician.
214526231|NCT00587899|PROCEDURE|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
214526232|NCT03214471|BEHAVIORAL|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
214452045|NCT05991414|PROCEDURE|Usual pharmacist care|Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
214526233|NCT05434533|DRUG|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
214526234|NCT06296888|PROCEDURE|Radiofrequency balloon catheter ablation|Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
214526235|NCT00023465|PROCEDURE|FDG-PET|
214526236|NCT00023465|PROCEDURE|spirometry|
214526237|NCT00023465|PROCEDURE|bronchoscopy with BAL|
214526238|NCT00354809|DRUG|GW679769|
214526239|NCT04475016|DRUG|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
214526240|NCT04475016|DRUG|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
214526241|NCT04475016|DRUG|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
214526242|NCT04475016|DRUG|Nimotuzumab|400 mg IV on Day 1
214526243|NCT04475016|DRUG|Triprilimab|240 mg IV on Day 1
214526244|NCT04117334|OTHER|Bracing|
215136918|NCT00010036|RADIATION|radiation therapy|
215136919|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
215136920|NCT04921436|PROCEDURE|cardiac surgery|prophylactic use of antibiotic-inhibitors
215136921|NCT04706208|BEHAVIORAL|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
215136922|NCT04706208|OTHER|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
215136923|NCT04706208|BEHAVIORAL|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
215136924|NCT04706208|BEHAVIORAL|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
215136925|NCT04706208|OTHER|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
215136926|NCT05159440|DRUG|TORL-2-307-MAB|monoclonal antibody
215136927|NCT05121272|BEHAVIORAL|cognitive task|cognitive task
215136928|NCT06559696|RADIATION|internal mammary nodal irradiation|chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
215136929|NCT06559696|RADIATION|No internal mammary node irradiation|chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
215136930|NCT06444568|OTHER|Dietary Intervention|The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
215136931|NCT03264859|DIAGNOSTIC_TEST|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
215136932|NCT05730023|DEVICE|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
215136933|NCT05730023|BEHAVIORAL|individualized language training|individualized language training
215136934|NCT05730023|DEVICE|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
215136935|NCT05090696|DEVICE|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
215136936|NCT06268704|DRUG|Dexamethasone|This is a non-particulate steroid commonly used to treat SI joint pain.
215136937|NCT06268704|DRUG|Methylprednisolone|This is a particulate steroid commonly used to treat SI joint pain.
215136938|NCT06268704|DRUG|2% Lidocaine HCl Injection|Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
215136939|NCT04723992|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
215136940|NCT01407510|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
215136941|NCT03538418|OTHER|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
215136942|NCT04827264|DIAGNOSTIC_TEST|Safe Return to Play Following ACL Reconstruction Checklist|"All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports"
215136943|NCT04076540|DRUG|AZD4041|Administration by Oral syringe
215136944|NCT04076540|DRUG|Placebo|Administration by Oral syringe
215136945|NCT03525379|DRUG|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
215136946|NCT03525379|DRUG|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
215136947|NCT02955056|DRUG|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
215136948|NCT05933746|BEHAVIORAL|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
215136949|NCT05933746|BEHAVIORAL|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
215136950|NCT00453895|DRUG|Sunitinib|50mg Sunitinib
215136951|NCT03321357|DIAGNOSTIC_TEST|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
215136952|NCT04467749|OTHER|Suspension Wheel|Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
215136953|NCT04144153|COMBINATION_PRODUCT|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
215136954|NCT04144153|COMBINATION_PRODUCT|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
215136955|NCT00425035|DRUG|Panitumumab (ABX-EGF)|
215136956|NCT03322956|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
215136957|NCT02787564|BEHAVIORAL|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
215136958|NCT00841841|DRUG|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
215136959|NCT00609102|DRUG|Placebo|one capsule BID
215136960|NCT00609102|DRUG|n-aceylcysteine|450 mgm BID
215136961|NCT00002649|BIOLOGICAL|aldesleukin|Given IV
215136962|NCT00002649|BIOLOGICAL|filgrastim|Given SC or IV
215136963|NCT00002649|DRUG|cyclophosphamide|Given IV
215136964|NCT00002649|DRUG|etoposide|Given IV
215136965|NCT00002649|RADIATION|radiation therapy|Undergo radiation therapy
215136966|NCT00002649|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
215136967|NCT00002649|PROCEDURE|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
215136968|NCT06705725|DRUG|CBG002 CAR-T Cell Suspension|"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."
215136969|NCT01748747|DRUG|Montanide ISA 51 VG|Given SC
215136970|NCT01748747|BIOLOGICAL|MART-1 antigen|Given SC
215136971|NCT01748747|OTHER|laboratory biomarker analysis|Correlative studies
215136972|NCT01748747|BIOLOGICAL|Gag:267-274 peptide vaccine|Given SC
215136973|NCT01748747|DRUG|resiquimod|Applied topically
215136974|NCT05910073|DEVICE|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
215136975|NCT04921241|OTHER|In Utero Exposure to SARS-CoV-2|Born to mother with SARS-CoV-2 infection during pregnancy
215136976|NCT04094285|DRUG|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
215136977|NCT04094285|DRUG|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
215136978|NCT05758116|DRUG|Tislelizumab|Tislelizumab: 200mg d1,q21d\*17
214452046|NCT04271709|BEHAVIORAL|Enhanced Intervention Using Patient Navigators|Enhanced support by patient navigators assisted with follow-up eye exam appointment scheduling and arranging transportation over a 1-year period.
214452047|NCT04271709|OTHER|Usual Care|Usual Care subjects who failed the screening and needed vision correction were given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects did not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
214526245|NCT05842278|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214526246|NCT05842278|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214526247|NCT05842278|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
215136979|NCT03851523|OTHER|No intervention|No intervention
214452048|NCT05980000|DRUG|Ramucirumab|Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
214452049|NCT05980000|DRUG|Pembrolizumab|Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
214526248|NCT05842278|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
215136980|NCT05927818|DIAGNOSTIC_TEST|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
215136981|NCT06255275|OTHER|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
215136982|NCT02331056|OTHER|fluid loading|"Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
215136983|NCT02331056|PROCEDURE|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
215136984|NCT02331056|PROCEDURE|thoracotomy|the patient group for scheduled open pulmonary lobectomy
215136985|NCT03474588|BEHAVIORAL|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
215136986|NCT03474588|BEHAVIORAL|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
215136987|NCT01493206|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
215136988|NCT05497830|OTHER|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
214694847|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
214694848|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
215136989|NCT02818907|OTHER|Additional biological samples|blood and tumor tissue samples
215136990|NCT05523674|OTHER|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
215136991|NCT05523674|OTHER|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
215136992|NCT03902418|DRUG|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
215136993|NCT06338774|BEHAVIORAL|Cognitive training|Computerized cognitive training completed on any computer or tablet with internet
215136994|NCT06338774|BEHAVIORAL|Exercise|Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
215136995|NCT02784080|OTHER|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)"
215136996|NCT03448926|OTHER|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
215136997|NCT03448926|DEVICE|7-gene biosignature|Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
215136998|NCT03804528|BEHAVIORAL|Aerobic Exercise|"Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines)."
215136999|NCT06487988|DEVICE|direct conventional laryngoscopy|direct conventional laryngoscopy will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.
215137000|NCT06487988|DEVICE|fiberoptic guided intubation|fiberoptic guided intubation will be performed.
215137001|NCT05203510|DRUG|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
215137002|NCT05203510|DRUG|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
215137003|NCT04398433|DRUG|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
215137004|NCT04398433|DEVICE|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
214452050|NCT05629156|OTHER|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
214452051|NCT03315754|DRUG|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
214452052|NCT05738330|BEHAVIORAL|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
214694849|NCT03506698|OTHER|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
215137005|NCT05110456|BEHAVIORAL|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~1. encourage the use of online material;~2. identify strategies for overcoming obstacles;~3. help apply content to real-life settings; and~4. underscore the participants' success in using effective coping strategies"
215137006|NCT06091111|DEVICE|THD, THN|New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
215137007|NCT03392064|BIOLOGICAL|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
215137008|NCT04223115|BEHAVIORAL|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
215137009|NCT04223115|OTHER|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
215137010|NCT05672550|DRUG|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
215137011|NCT05672550|DRUG|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
215137012|NCT05795166|OTHER|No treatment given|No treatment given
215137013|NCT03433651|DRUG|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
215137014|NCT03433651|DRUG|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
215137015|NCT01607957|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
215137016|NCT01607957|DRUG|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
215137017|NCT04570930|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
215137018|NCT04570930|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
214526249|NCT05842278|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214526250|NCT03814278|BEHAVIORAL|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
215137019|NCT04536909|OTHER|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
214526251|NCT03814278|BEHAVIORAL|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
214526252|NCT03721900|DRUG|SHX-001 Active low dose|ketamine transdermal patch
214526253|NCT03721900|DRUG|Placebo|transdermal patch
215137020|NCT04536909|PROCEDURE|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
214526254|NCT03721900|DRUG|SHX-001 Active High dose|ketamine transdermal patch
214526255|NCT01249976|OTHER|blood culture|blood culture
214526256|NCT02544841|BEHAVIORAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
214526257|NCT02544841|BEHAVIORAL|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
215137021|NCT02598284|OTHER|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
215137022|NCT02598284|OTHER|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
214526258|NCT02135588|DRUG|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
214526259|NCT04357587|DRUG|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
214526260|NCT04357587|RADIATION|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
214526261|NCT04357587|DRUG|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
214526262|NCT00580047|DRUG|Zoledronic Acid|4mg IV Annually
214694850|NCT05125536|OTHER|Music therapy|rutin
215137023|NCT00584948|DRUG|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
214526263|NCT00580047|COMBINATION_PRODUCT|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
214526264|NCT00580047|DRUG|Alendronate|70mg weekly
215137024|NCT00584948|DRUG|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
215137025|NCT02719821|BEHAVIORAL|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
215137026|NCT02515747|PROCEDURE|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
214526265|NCT02674555|DRUG|radio-labeled naquotinib|Oral administration
214526266|NCT02674555|DRUG|naquotinib|Oral administration
215137027|NCT02515747|PROCEDURE|coronary artery bypass grafting|elective surgical myocardial revascularisation
215137028|NCT04761263|OTHER|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
214526267|NCT00662883|DRUG|PMI-150 (intranasal ketamine HCl); mometasone furoate|"* 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15"
215137029|NCT04761263|OTHER|Selected Physical therapy program|"* Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Facilitation of protective reaction from standing position by pushing the child in different directions.~* Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~* Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~* Jumping in place and jumping a board."
215137030|NCT01662167|DRUG|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
215137031|NCT01662167|DRUG|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
215137032|NCT02560259|OTHER|Physiotherapy|Physiotherapy
215137033|NCT02560259|OTHER|Conservative treatment|Conservative treatment
215137034|NCT05025787|DRUG|CNTX-6970|CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
215137035|NCT05025787|DRUG|Placebo|BID
215137036|NCT00498940|DEVICE|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
215137037|NCT00498940|DEVICE|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
215137038|NCT02814006|OTHER|health educational video|visualization of health educational video
215137039|NCT00005800|BIOLOGICAL|Filgrastim|
214526268|NCT05959382|DEVICE|Dental Loupe|Magnification aid
214526269|NCT05959382|DEVICE|Dental Operation Microscope|Magnification aid
214526270|NCT06212934|OTHER|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
214526271|NCT06212934|DRUG|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
215137040|NCT00005800|DRUG|Docetaxel|
215137041|NCT00005800|DRUG|Doxorubicin|
215137042|NCT00005800|PROCEDURE|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
215137043|NCT06186050|DIETARY_SUPPLEMENT|Beetroot drink|Drink containing 10g of beetroot powder in 250 mL cold tap water
214526272|NCT01707498|PROCEDURE|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
215137044|NCT06186050|DIETARY_SUPPLEMENT|Placebo|Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
215137045|NCT06186050|DIETARY_SUPPLEMENT|Control|Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
215137046|NCT05935553|DRUG|Baclofen 30 mg|"* baclofen 10 mg capsule (for the 30 mg-baclofen 30 mg arm)~* Dosage: 3 capsules of baclofen 10 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
215137047|NCT05935553|DRUG|Baclofen 60 mg|"* baclofen 20 mg capsule (for the 60 mg baclofen arm)~* Dosage: 3 capsules of baclofen 20 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
215137048|NCT05935553|DRUG|Placebo|"* placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
215137049|NCT05379803|DRUG|Furmonertinib|furmonertinib 160 mg orally QD
215137050|NCT05701423|DRUG|Natalizumab|Administered as specified in the treatment arm.
215137051|NCT06295185|OTHER|application MARO|It is a mental healthcare application aim to improve mental health.
215137052|NCT06295185|OTHER|Sham application|It is a sham application in order to control spill over bias.
215137053|NCT05279196|OTHER|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
214452053|NCT05738330|BEHAVIORAL|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
214452054|NCT05520047|BEHAVIORAL|COVID19-severe Patient|Behavioral and social test assessment
214452055|NCT05520047|BEHAVIORAL|family of COVID19-severe Patient|Behavioral and social test assessment
214452056|NCT06490796|BEHAVIORAL|Expanded diaphragm exercise|Individuals will be instructed in 360-degree expansive diaphragm exercises using the Ohmbelt device (Nilus Medical LLC, OHMBELT, Redwood City, CA, USA). Two Ohmbelt devices will be used in this study. The placement of the devices will be as described in the literature (14,23,24): The patient will be in a seated position with hips and knees flexed at 90 degrees, both feet supported on the ground, and sitting upright on a chair without back support. In this position, the Ohmbelt devices will be secured to the patient's body. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes
214452057|NCT06490796|BEHAVIORAL|Standard diaphragm exercise|Individuals in this group will be instructed in standard diaphragm exercises. They will be asked to lie on their backs with their heads and knees supported by pillows, and to close their eyes to focus before starting. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes.
215137059|NCT05460754|BEHAVIORAL|Conventional-fed beef|Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.
215137060|NCT05460754|BEHAVIORAL|Organic grass-fed beef|Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
215137061|NCT04262388|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
215137062|NCT04262388|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
215137063|NCT05299307|DIAGNOSTIC_TEST|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
215137064|NCT05313984|DEVICE|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
215137065|NCT03406884|BIOLOGICAL|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
215137066|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
215137067|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
215137068|NCT06037590|COMBINATION_PRODUCT|Levodopa Cyclops®|Orally inhaled dry powder levodopa from the Cyclops® dry powder inhaler
215137069|NCT06037590|COMBINATION_PRODUCT|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
215137070|NCT06202482|OTHER|Connect Active Program|Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
215137071|NCT01708408|GENETIC|Biomarker studies|
215137072|NCT06297083|DRUG|Peanut Oral Powder [PEANUT POWDER]|Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
215137073|NCT06297083|DIETARY_SUPPLEMENT|Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)|Probiotic or placebo-probiotic given daily for 18 months
215137074|NCT03589859|DIAGNOSTIC_TEST|VOR Test|Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
215137075|NCT03589859|OTHER|Computer Game|Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
215137076|NCT03589859|OTHER|Nausea Scale|Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
215137077|NCT05538741|DRUG|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
215137078|NCT05538741|DRUG|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
215137079|NCT06466746|OTHER|Raising the Pulse faba bean-enriched bread|100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
215137080|NCT06466746|OTHER|Conventional White Bread|100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
215137081|NCT04161950|OTHER|Assessment of the safety and validity of echoendoscope|"1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment"
215137082|NCT02331134|DRUG|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
214452058|NCT05708612|PROCEDURE|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
214452059|NCT06297148|OTHER|Self-management|"Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast."
214452060|NCT06297148|OTHER|Usual care|Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
214452061|NCT05964855|DEVICE|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
214452062|NCT05964855|DEVICE|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
214452063|NCT05964855|DEVICE|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
214452064|NCT05964855|DEVICE|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
214452065|NCT05964855|DEVICE|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
214452066|NCT00137540|DEVICE|RF ablation|
215137083|NCT01568177|BEHAVIORAL|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
215137084|NCT01568177|OTHER|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
215137085|NCT01568177|OTHER|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
215137086|NCT01568177|OTHER|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
215137087|NCT01568177|PROCEDURE|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
215137088|NCT04266873|DEVICE|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
214526273|NCT01707498|PROCEDURE|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
214526274|NCT05007600|OTHER|Online Interactive Courses|In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
214526275|NCT00266162|DRUG|Bosentan administration|
214526276|NCT02338310|DRUG|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
214526277|NCT03238599|BEHAVIORAL|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
214526278|NCT05432258|DEVICE|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
215137089|NCT02157532|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
215137090|NCT02157532|DRUG|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
215137091|NCT02641548|DEVICE|Sock of silicone|
215137092|NCT02641548|OTHER|Heel cream|
215137093|NCT04966013|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
215137094|NCT04966013|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
215137095|NCT06342128|OTHER|No intervention|No intervention
215137096|NCT03562273|RADIATION|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
215137097|NCT04315948|DRUG|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
215137098|NCT04315948|DRUG|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
215137099|NCT04315948|DRUG|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
215137100|NCT04315948|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
215137101|NCT04315948|OTHER|Standard of care|Standard of care
215137102|NCT04315948|DRUG|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
214452067|NCT00137540|DRUG|anti-arrhythmic drug therapy|
214452068|NCT05725395|BEHAVIORAL|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
214452069|NCT05725395|BEHAVIORAL|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
214452070|NCT05131321|PROCEDURE|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
214452071|NCT05131321|PROCEDURE|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
214452072|NCT05131321|PROCEDURE|Intramedullary Fibular Nailing (IMFN)|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
214452073|NCT04088370|OTHER|Blood Draw|Blood Draw Only
214452074|NCT05962151|DRUG|NAL ER|Oral tablets
214452075|NCT05962151|DRUG|Placebo|Oral tablets
214452076|NCT06236308|BIOLOGICAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
214526279|NCT05432258|DEVICE|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
214526280|NCT02363933|DRUG|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
214526281|NCT00365183|DRUG|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
214526282|NCT00797186|OTHER|Intensive risk factor management|Aggressive medical and lifestyle therapy.
214526283|NCT05189288|DRUG|D418 Tab.|1T
214526284|NCT05189288|DRUG|CKD-388 Tab.|1T
214526285|NCT04454671|OTHER|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
214526286|NCT04454671|OTHER|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
214526287|NCT00234299|DRUG|Aspirin|325mg, one tablet orally, six months
214526288|NCT00234299|DRUG|Placebo|325mg, one tablet orally every day, 6 months
214526289|NCT01126177|DRUG|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
214526290|NCT01126177|DRUG|Placebo|Placebo (excipients of the SNG001 solution only)
214526291|NCT00403299|PROCEDURE|MDCT of the coronary arteries.|
214526292|NCT05126199|OTHER|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
214526293|NCT05126199|OTHER|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
214526294|NCT02985255|DRUG|Docetaxel|Neoadjuvant Arm
214526295|NCT02985255|DRUG|Cisplatin|Neoadjuvant Arm
214526296|NCT02985255|DRUG|5FU|Neoadjuvant Arm
215137103|NCT04315948|OTHER|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
215137104|NCT02601612|BIOLOGICAL|D46cpΔM2-2 vaccine|Delivered as nose drops
215137105|NCT02601612|BIOLOGICAL|Placebo|Delivered as nose drops
215137106|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content, and Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms, in addition they also receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
215137107|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content|Participants receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
215137108|NCT06229444|BEHAVIORAL|Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms.
215137109|NCT06229444|BEHAVIORAL|No Intervention|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive IILI-related health educational content
215137110|NCT05010707|DRUG|Transdermal patch|Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
215137111|NCT05010707|DIAGNOSTIC_TEST|Pro-thrombotic markers|Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
214526297|NCT02985255|RADIATION|Radiotherapy|Neoadjuvant Arm
214526298|NCT02985255|PROCEDURE|Glossectomy|Neoadjuvant Arm
214526299|NCT05951556|DEVICE|Use of BCI|Clients will utilize BCI with training to communicate wants and needs
214526300|NCT02375607|DEVICE|Algometer|Algometer performed patients
214526301|NCT03045289|BEHAVIORAL|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
214526302|NCT01114334|BEHAVIORAL|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
214526303|NCT01114334|BEHAVIORAL|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
214694851|NCT03847155|DRUG|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
214694852|NCT03847155|OTHER|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
215137112|NCT05010707|DIAGNOSTIC_TEST|Metabolic markers|Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
215137113|NCT05010707|DIAGNOSTIC_TEST|Hormone Profile|Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
215137114|NCT05010707|DRUG|Daily Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
215137115|NCT05010707|DRUG|BID Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
215137116|NCT05010707|DRUG|Spironolactone|All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
215137117|NCT02420847|DRUG|Doxorubicin Hydrochloride|Given IV
215137118|NCT02420847|DRUG|Gemcitabine Hydrochloride|Given IV
215137119|NCT02420847|DRUG|Ixazomib Citrate|Given PO
215137120|NCT04049032|BEHAVIORAL|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
215137121|NCT04049032|BEHAVIORAL|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
215137122|NCT06143852|BEHAVIORAL|Mindfulness|12 minute daily guided meditation
215137123|NCT06143852|BEHAVIORAL|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
215137124|NCT06195748|OTHER|Kinesiotaping|According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
215137125|NCT06195748|OTHER|Placebo kinesiotaping|The same tape will be used for the interventional application with 0 tension.
215137126|NCT03518086|DRUG|Mirikizumab|Administered IV
214526304|NCT01358643|OTHER|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
215137127|NCT03518086|DRUG|Placebo|Administered IV
215137128|NCT06066788|OTHER|CHAMPS|Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
215137129|NCT05967260|DEVICE|DailyDose Smart Snack app|A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
215137130|NCT05967260|DEVICE|Dexcom G6 CGM|A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
215137131|NCT04086927|DEVICE|Unna Boot|The unna boot is a zinc coated compression dressing
215137132|NCT03482726|BEHAVIORAL|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
214526305|NCT04747717|PROCEDURE|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
214526306|NCT03487302|OTHER|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
215137133|NCT03064802|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
214694853|NCT03516019|OTHER|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
214694854|NCT03516019|OTHER|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
215137134|NCT00832663|DRUG|NSAID|Effect of NSAID ingestion on muscle regeneration
215137135|NCT00832663|DRUG|placebo|receive placebo
215137136|NCT00626106|DRUG|AMG 479|AMG 479 administered with exemestane or fulvestrant
215137137|NCT00626106|DRUG|Placebo|Placebo administered with either exemestane or fulvestrant
215137138|NCT06275451|OTHER|Semi-structured interview|Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
215137139|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
215137140|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
214452077|NCT06236308|BIOLOGICAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
214452078|NCT06236308|BIOLOGICAL|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
214452079|NCT05600348|DIETARY_SUPPLEMENT|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
214452080|NCT06075758|OTHER|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
214452081|NCT06257810|DIAGNOSTIC_TEST|VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG|"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."
214452082|NCT06257810|OTHER|Standard of care practices|"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."
214452083|NCT02116335|DRUG|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
214452084|NCT02116335|DRUG|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
214452085|NCT06473233|DEVICE|TEG6S|Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician
214452086|NCT04536090|DRUG|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
214526307|NCT03487302|OTHER|Neuropsychological test battery|"1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
214526308|NCT02905877|OTHER|Behavioural study|reaching studies and other behavioural studies.
214452087|NCT05935917|DRUG|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
214452088|NCT06165601|PROCEDURE|Follow-up at D14|A blood test and urinary test will be performed at D14.
214452089|NCT06165601|PROCEDURE|Follow-up at M1|A blood test and urinary test will be performed at M1.
214452090|NCT06326827|DEVICE|In'Oss™ (MBCP® Putty)|Use of In'Oss™ (MBCP® Putty) in surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia.
214526309|NCT00998114|BEHAVIORAL|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
214526310|NCT04368533|DRUG|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
214694855|NCT03516019|OTHER|am notices|notifications sent at 7 am.
214452091|NCT05644483|DRUG|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
214452092|NCT05644483|DRUG|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
214452093|NCT04010344|BEHAVIORAL|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools."
214452094|NCT04010344|OTHER|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
214452095|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
214452096|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
214452097|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
214452098|NCT04428944|PROCEDURE|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
214452099|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
214452100|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
214452101|NCT04024813|DRUG|Seladelpar|Capsule(s) administered orally once daily
214452102|NCT04024813|DRUG|Placebo to match Seladelpar|Capsule(s) administered orally once daily
214452103|NCT05993845|OTHER|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video \& audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data \& other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- \& postoperative Standard axial hip x-rays pre- \& postoperative Western Ontario \& McMaster Universities Osteoarthritis Index \& Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
214452104|NCT06190093|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
214526311|NCT04368533|DRUG|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
214526312|NCT04830163|COMBINATION_PRODUCT|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
215137141|NCT06599177|OTHER|Informational leaflet|"An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services."
215137142|NCT06595472|DIETARY_SUPPLEMENT|Palm Oil Enriched with Plant Sterols|The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.
215137143|NCT06595472|DIETARY_SUPPLEMENT|Palm oil|The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
215137144|NCT03735875|DRUG|Quizartinib|Given PO
215137145|NCT03735875|DRUG|Venetoclax|Given PO
215137146|NCT06612320|BEHAVIORAL|Questionnaire about acceptance|Questionnaire about acceptance
215137147|NCT06612320|BEHAVIORAL|Questionnaire about refusal|Questionnaire about refusal
215137148|NCT06592404|DEVICE|Robot Tessa|"Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale."
214526313|NCT05542836|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
214526314|NCT05542836|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
214452105|NCT06190093|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
214452106|NCT06258291|DEVICE|Hemosystem REBOOT|The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
214452107|NCT05747222|OTHER|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
214452108|NCT05747222|OTHER|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
214452109|NCT05008783|DRUG|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
214452110|NCT05008783|DRUG|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
214526315|NCT06291298|BEHAVIORAL|COGMUSE-AUT|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
214526316|NCT03256760|BIOLOGICAL|Endotoxin|Endotoxin
214526317|NCT03256760|BIOLOGICAL|Placebo|Placebo
215137149|NCT06585878|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.
215137150|NCT06990529|DRUG|Leniolisib|All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).
215137151|NCT06998368|DRUG|Nimodipine Capsules|Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
215137152|NCT06998368|RADIATION|5G RF-EMF|Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency \[TDD\] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.
215137153|NCT02422706|DRUG|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
215137154|NCT02422706|DRUG|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
215137155|NCT02422706|DRUG|Omeprazole|Omeprazole 20 twice daily
215137156|NCT02422706|DRUG|Clarithromycin|KLacid twice daily
215137157|NCT02422706|DRUG|Levofloxacin|Tavanic. Tavacin
215137158|NCT02422706|DRUG|Doxicycline|Vibramycin 100 mg twice daily
215137159|NCT06998979|BEHAVIORAL|Music therapy|"The music was generated using a beta version of the RIFFUSION program, which is still in its development phase and being refined based on user input. This software operates using neural networks similar to Generative Adversarial Networks (GANs), known as diffusion models. These models begin with random noise and gradually transform it into a musical composition through a process that involves two phases: a diffusion phase-where an existing musical sample is disordered by adding random noise-and a reverse phase, in which the noise is removed to reconstruct a new and distinct musical piece.~The prompt entered into the program was: Relaxing slow music for people with great stress and extreme anxiety and panic caused by dental surgery with effects of wind and waterfall. A total of 20 songs were generated and merged to achieve a combined duration of 49.20 minutes."
215137160|NCT06589310|DEVICE|Exact Sciences Multicancer Early Detection (MCED) Test|Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.
215137161|NCT06999434|DRUG|[ 18F]3F4AP|PET Scan #3
215137162|NCT06999434|DRUG|[18F]MK6240|PET Scan #2
215137163|NCT06999434|DRUG|[11C]PIB|PET Scan #1
215137164|NCT06999512|PROCEDURE|Comprehensive Geriatric Assessment|"CGA:~* Preoperative geriatric consultation~* Perioperative tailored intervention if needed~* Postoperative geriatric follow-up~* M3 geriatric consultation"
215137165|NCT04243499|BIOLOGICAL|IV ICT01|humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
215137166|NCT06999252|DRUG|Rimegepant|Take 75 mg every other day
215137167|NCT06999252|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
214526318|NCT04758559|OTHER|myfood24|An app to support monitoring of food and nutrient intake using robust validated methodology.
214526319|NCT04758559|OTHER|usual care|Patients will receive standard advice as provided by the clinical team, this may or may not include nutrition.
214526320|NCT05065580|PROCEDURE|Osteopathic Manipulative Treatment|Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
215137168|NCT06999356|DEVICE|CGM Device|Fruits and Vegetables and some groups will get CGM devices along with Fruits and Vegetables
215137169|NCT06998238|BEHAVIORAL|Mediterranean-based, carbohydrate restricted, calorie reduced diet|Dietary intervention - calorie reduced (300-500 kcal/day below estimated energy needs), carbohydrate restricted (\<100 grams of available carbohydrates per day), Mediterranean-based (high fat diet with an emphasis on the addition of healthy fats - nuts, avocados, olive oil, increasing whole grains, increasing fruit and vegetables, replacing red meats with fish and poultry, reducing dairy, and reducing added sugars) diet.
214694856|NCT03516019|OTHER|pm notices|notifications sent at 7 pm.
214694857|NCT03516019|OTHER|weekday notices|notifications sent on Wednesday
214694858|NCT03516019|OTHER|weekend notices|notifications sent on Saturday
214694859|NCT00658372|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
215137170|NCT03234699|DRUG|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
215137171|NCT03234699|DRUG|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
215137172|NCT03234699|DRUG|Warfarin Pill|5 mg (Days 7 and 105)
215137173|NCT03234699|DRUG|Omeprazole Pill|20 mg (Days 7 and 105)
215137174|NCT03234699|DRUG|Bupropion Pill|150 mg (Days 1 and 99)
215137175|NCT06236893|OTHER|VH-01 vaginal suppository tablet|Participants will be instructed to take VH-01 Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
215137176|NCT06236893|OTHER|Placebo vaginal suppository tablet|Participants will be instructed to take the placebo on Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
215137177|NCT06589752|DRUG|TARPEYO 4 MG Delayed Release Oral Capsule|TARPEYO dispensing claim for any dose is exposure
215137178|NCT06589752|DRUG|RAS inhibitor|RASi dispensing claim for any dose is reference
215137179|NCT06592716|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free HPV-DNA.
215137180|NCT06869252|BIOLOGICAL|Autologous Adipose Cells Therapy|Participants will receive Autologous Adipose Cells therapy treatment, and the safety and efficacy of the treatment will be monitored by the primary investigator up to 25 weeks.
215137181|NCT06595225|BEHAVIORAL|Nutrition education sessions|Participants received nutrition education each month, covering topics ranging from general nutrition knowledge, nutrition knowledge related to their diagnosis of living with HIV infection whether during the acute or chronic phase. In addition, specific information was shared about other comorbidities the participant could be living with, finally information was shared on ways to improve mental health and enhance physical activity levels.
215137182|NCT06871683|DEVICE|ClotTriever® Thrombectomy System|ClotTriever® Thrombectomy System use for treatment of patients with deep vein thrombosis with acute severe symptoms.
215137183|NCT05856422|DEVICE|Respiratory rate measure based on PPG|"Testing was conducted under normal office environment conditions. Each subject was connected to the reference EtCO2 monitor (GE Datex-Ohmeda) and the Device Under Test, the Gabi SmartCare Gabi Band. A waveform collected from an EtCO2 measurement was used to determine performance of respiratory rate metrics. Each subject was given a nasal cannula that allowed for measurement of the EtCO2 respiratory rate.~The reference respiratory rate was measured simultaneously with the Device Under Test. Data was marked for stable quiet periods that were useable for analysis."
215137184|NCT06702319|OTHER|Exercise|Home exercises and home exercises with internal focus exercises or external focus exercises
215137185|NCT06704789|DEVICE|Measurement of brain activity (fNIRS, EEG)|Brain activity assessments are conducted as a single session lasting approximately 60 minutes
215137186|NCT06706011|OTHER|Virtual Patient|Interactive Educational Activity
215137187|NCT06705777|DRUG|Combinations|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
215137188|NCT06704529|BEHAVIORAL|pitching motion|participants pitch fastball to the strike zone
215137189|NCT06706375|PROCEDURE|Using ultrasound for penile nerve block|30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi
214452111|NCT06088355|BEHAVIORAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
214526321|NCT06646900|BEHAVIORAL|Culturally adapted CBT (CaCBT) based guided self-help manual|The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
215137190|NCT06706375|PROCEDURE|Dorsal Penile Block Anesthesia using landmarks|Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
215137191|NCT06704360|DEVICE|immersive VR pathfinding training|Pathfinding training with immersive VR.
215137192|NCT06704360|OTHER|Occupational therapy|Only receive conventional cognitive training group
214694860|NCT00658372|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
215137193|NCT06705920|DRUG|topical oxygen gel|In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab
215137194|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
215137195|NCT03307109|OTHER|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
215137196|NCT03593499|DRUG|omaveloxolone|
215137197|NCT06706349|BEHAVIORAL|APA managed by qualified instructor|Each session will be led by a qualified APA professional and will include a mix of aerobic, anaerobic, and 'mind-body' activities like yoga, tailored to participant preferences. Intensity will range from moderate to vigorous, with activities such as walking, cycling, and club-based exercises for at least 20 minutes per session. Participants will be progressively involved in session planning to support continued practice post-study. Heart rate monitoring will be used during exercises like the 6-minute walk test and chair rise test, while a daily activity calendar will help ensure adherence, documenting session dates, durations, subjective intensity, and activity type.
215137198|NCT06706349|BEHAVIORAL|Autonomous APA|A leaflet highlighting the importance of non-sedentary behavior according to WHO recommendations will be provided to them. They will have the opportunity to engage in physical activity autonomously according to their preference.
215137199|NCT06171724|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
215137200|NCT04880278|DRUG|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
215137201|NCT04880278|DRUG|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
215137202|NCT00707083|DRUG|dexamethasone|Given oral
215137203|NCT00707083|DRUG|mercaptopurine|Given orally
215137204|NCT00707083|DRUG|methotrexate|Given orally
215137205|NCT00707083|DRUG|vincristine sulfate|Given IV
215137206|NCT06956794|BEHAVIORAL|VirtualDONA Multimodal Program|A group-based behavioral intervention using immersive virtual reality without headsets. The 8-week program includes 16 sessions combining mindfulness, cognitive training, and physical exercises, designed to improve cognitive health and emotional well-being in older women living alone and at risk of poverty.
215137207|NCT02706977|DRUG|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
214452112|NCT06088355|BEHAVIORAL|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
214452113|NCT06088355|BEHAVIORAL|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
214526322|NCT06646900|BEHAVIORAL|Standard CBT Manual|The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
214526323|NCT02737670|DRUG|Sulodexide|25 mg morning and evening for 40 days
214526324|NCT02737670|DRUG|Placebo|1 tablet morning and evening for 40 days
214526325|NCT03057197|PROCEDURE|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
215137208|NCT02706977|DRUG|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
215137209|NCT02706977|DEVICE|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
215137210|NCT02706977|OTHER|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
215137211|NCT02706977|OTHER|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
214694861|NCT00658372|DRUG|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
214694862|NCT00658372|DRUG|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
214694863|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
215137212|NCT05991635|BEHAVIORAL|Gatekeeper training (e-learning)|"The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care"
214526326|NCT03740932|DIAGNOSTIC_TEST|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
214526327|NCT01615614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
215137213|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
215137214|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
215137215|NCT00003403|DRUG|GPX-100|
215137216|NCT00190918|DRUG|Pemetrexed|
215137217|NCT00874510|BEHAVIORAL|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
215137218|NCT03879733|BEHAVIORAL|Thrive by Three|"The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no"
215137219|NCT03879733|BEHAVIORAL|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
215137220|NCT04675593|BEHAVIORAL|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
215137221|NCT04675593|BEHAVIORAL|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
215137222|NCT04060498|BEHAVIORAL|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
215137223|NCT04060498|BEHAVIORAL|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
215137224|NCT06954077|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
215137225|NCT04970134|OTHER|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
214452114|NCT05515614|DIETARY_SUPPLEMENT|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
214452115|NCT05515614|DIETARY_SUPPLEMENT|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
214452116|NCT04166331|DRUG|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
214452117|NCT04166331|DRUG|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
214452118|NCT05034952|DRUG|VX-548|Tablets for oral administration.
214452119|NCT05034952|DRUG|HB/APAP|Capsules for oral administration.
214452120|NCT05034952|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
214526328|NCT01615614|DRUG|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
215137226|NCT04970134|OTHER|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
215137227|NCT04970134|OTHER|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
215137228|NCT04879589|DRUG|Abiraterone Acetate|ATRS-2002
214452121|NCT05034952|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
215137229|NCT04293406|OTHER|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
215137230|NCT05833763|DRUG|Glofitamab|Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
215137231|NCT05833763|DRUG|Pirtobrutinib|Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
215137232|NCT05833763|DRUG|Obinutuzumab|Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
215137233|NCT05833763|DRUG|Tocilizumab|Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
215137234|NCT02065037|DEVICE|room temperature air insufflation|control arm
215137235|NCT02065037|DEVICE|warmed carbon dioxide insufflation|comparator arm
215137236|NCT03475095|OTHER|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
215137237|NCT00262340|OTHER|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
214452122|NCT04238949|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
215137238|NCT04333563|DEVICE|CPAP|Continuous positive airway pressure
215137239|NCT04333563|DEVICE|NIV NAVA|Non-invasive neurally adjusted ventilatory assist
215137240|NCT05740072|OTHER|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
214452123|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
214452124|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
214452125|NCT06364163|DIETARY_SUPPLEMENT|Herring oil concentrate|Capsules containing herring oil concentrate, taken daily for 8 weeks.
214452126|NCT06364163|DIETARY_SUPPLEMENT|Control|Capsules containing control oil, taken daily for 8 weeks.
214452127|NCT04770233|PROCEDURE|Early ACL reconstruction|ACL reconstruction followed by rehabilitation
214452128|NCT04770233|PROCEDURE|Active rehabilitation|Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
215137241|NCT05740072|OTHER|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
215137242|NCT05809557|OTHER|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
215137243|NCT05809557|OTHER|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
215137244|NCT01444612|DRUG|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
215137245|NCT01444612|DRUG|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
215137246|NCT01444612|DRUG|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
214452129|NCT02111798|DRUG|Placebo|Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
214452130|NCT02111798|DRUG|Bupropion XL|Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
214452131|NCT02111798|BEHAVIORAL|Abstinence Initiation|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
214694864|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
215137247|NCT01444612|DRUG|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
215137248|NCT01630369|DRUG|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215137249|NCT03007966|PROCEDURE|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
215137250|NCT03007966|PROCEDURE|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
215137251|NCT03007966|DRUG|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
215137252|NCT03007966|DRUG|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
215137253|NCT03007966|DRUG|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
215137254|NCT02963246|BEHAVIORAL|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
215137255|NCT02655120|PROCEDURE|Drilling|
215137256|NCT02655120|BIOLOGICAL|Bone Marrow +BMP7|
215137257|NCT03063177|PROCEDURE|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
215137258|NCT02902458|OTHER|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
215137259|NCT01181063|DRUG|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
215137260|NCT04062786|OTHER|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
215137261|NCT04057950|OTHER|cosmetic product|Disulfure de sélénium versus placebo formula
215137262|NCT02260687|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
214452132|NCT02111798|BEHAVIORAL|Relapse Prevention|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
214452133|NCT06133829|BEHAVIORAL|upREACH Home Visitation Program|upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
214452134|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
214452135|NCT05450562|BIOLOGICAL|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
214452136|NCT05450562|BIOLOGICAL|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
214452137|NCT06194435|OTHER|Remote Monitoring of Participant Progress and Well-being via Video Calls|Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.
214452138|NCT06194435|OTHER|Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being|Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
214452139|NCT05493787|BEHAVIORAL|Reminder|Patient portal, SMS, email, and/or another modality
214452140|NCT01705119|OTHER|Standing|
214526329|NCT00546884|BEHAVIORAL|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
214526330|NCT00546884|BEHAVIORAL|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
214526331|NCT02367248|DRUG|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
215137263|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
215137264|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
215137265|NCT00751582|DIETARY_SUPPLEMENT|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
215137266|NCT00751582|BEHAVIORAL|Nutrition education|Nutrition education for children for three months
215137267|NCT00751582|OTHER|Control Group|No Nutrition Education
214526332|NCT02367248|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
214526333|NCT02367248|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
215137268|NCT03773224|PROCEDURE|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
215137269|NCT02336152|DEVICE|Anaesthesia, Teles Pro, Body suit|
215137270|NCT01428258|OTHER|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
215137271|NCT01428258|OTHER|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
215137272|NCT00000670|DRUG|Probenecid|
215137273|NCT00000670|DRUG|Zidovudine|
215137274|NCT04763395|OTHER|No intervention|No intervention
214452141|NCT06331403|BEHAVIORAL|Mind-Body Group Intervention|Weekly virtual group meetings with the study interventionist(s) and up to 9 other female cancer survivors over an approximately 6 week period. The group program includes topics related to coping with physical health changes, managing social factors relevant to sexual well-being, and managing thoughts and feelings related to sexual well-being changes.
214452142|NCT04783935|DRUG|Mavenclad®|No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
214452143|NCT04445168|BEHAVIORAL|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
214452144|NCT01600222|DRUG|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
214452145|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"* Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
214452146|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
214452147|NCT04107857|BEHAVIORAL|Data Driven Feedback reports|-Feedback reports will be based on data
214452148|NCT04407338|DEVICE|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
214526334|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
214526335|NCT01346722|OTHER|Diet- CR|conventional rice-based diet
214526336|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
214526337|NCT01346722|OTHER|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
214526338|NCT06107205|DRUG|TTYP01|1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
214526339|NCT06107205|DRUG|Radicava|1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
215137275|NCT02231112|RADIATION|Whole breast RT on prone position|
215137276|NCT00002534|BIOLOGICAL|anti-thymocyte globulin|
215137277|NCT00002534|DRUG|cyclophosphamide|
214526340|NCT06107205|DRUG|Radicava ORS|1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
214526341|NCT02848586|OTHER|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
215137278|NCT00002534|DRUG|cytarabine|
215137279|NCT00002534|DRUG|methylprednisolone|
215137280|NCT00002534|DRUG|thiotepa|
215137281|NCT00002534|PROCEDURE|allogeneic bone marrow transplantation|
215137282|NCT00002534|PROCEDURE|in vitro-treated bone marrow transplantation|
215137283|NCT00002534|RADIATION|low-LET electron therapy|
215137284|NCT00002534|RADIATION|low-LET photon therapy|
215137285|NCT00003127|DRUG|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
215137286|NCT00003127|DRUG|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
215137287|NCT00003127|DRUG|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
215137288|NCT04866784|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
215137289|NCT06051201|OTHER|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
215137290|NCT04188743|BIOLOGICAL|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
215137291|NCT04188743|BIOLOGICAL|Autologous FMT|Transplantation of autologous fecal microbiota
215137292|NCT02132962|DIETARY_SUPPLEMENT|Amino acid infusion|
215137293|NCT02132962|OTHER|Bloodsamples, Biopsies.|
215137294|NCT01485029|PROCEDURE|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
215137295|NCT00248625|DRUG|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
214526342|NCT02848586|BEHAVIORAL|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
214526343|NCT02848586|OTHER|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
214526344|NCT02495402|BEHAVIORAL|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
214526345|NCT05665348|DRUG|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
214526346|NCT05665348|DRUG|Atezolizumab Injection|One of the standard treatment's product for HCC management
214526347|NCT05665348|DRUG|Bevacizumab|One of the standard treatment's product for HCC management
214526348|NCT04382053|DRUG|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
214526349|NCT04382053|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
214526350|NCT00924833|DRUG|placebo|placebo tablet BID
214526351|NCT00924833|DRUG|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
214526352|NCT00924833|DRUG|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
215137296|NCT00248625|DRUG|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
215137297|NCT02214797|DEVICE|Etafilcon A, Lotrafilcon B , Senofilcon A|
214526353|NCT05143580|BEHAVIORAL|Cognitive therapy|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
214526354|NCT05143580|BEHAVIORAL|Routine care|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
214526355|NCT01153997|DRUG|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
214452149|NCT04407338|DEVICE|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
214452150|NCT06546462|OTHER|Osteopathic Manipulative Treatment (OMT)|The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.
214452151|NCT06546462|OTHER|Sham Light touch arm|Sham arm will receive a light touch sham treatment.
215137298|NCT05240820|PROCEDURE|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
215137299|NCT03432676|DRUG|Epacadostat|Given PO
215137300|NCT03432676|BIOLOGICAL|Pembrolizumab|Given IV
215137301|NCT03276507|DIAGNOSTIC_TEST|Pulmonary function studies|
215137302|NCT03276507|DIAGNOSTIC_TEST|Echocardiogram|
215137303|NCT03276507|DIAGNOSTIC_TEST|Electrocardiogram|
215137304|NCT03276507|DIAGNOSTIC_TEST|Chest radiography|
215137305|NCT03276507|DIAGNOSTIC_TEST|Blood test|
215137306|NCT03276507|BEHAVIORAL|Quality of life questionnaire|
214452152|NCT05891119|DIETARY_SUPPLEMENT|Caffeine|Oral liquid
214452153|NCT05891119|DRUG|Metoprolol|Oral tablet
214452154|NCT05891119|DRUG|Midazolam|Oral liquid
214452155|NCT05891119|DRUG|Warfarin|Oral tablet
214452156|NCT05891119|DIETARY_SUPPLEMENT|Vitamin K|Oral tablet
214452157|NCT05891119|DRUG|Omeprazole|Oral capsule
214452158|NCT05891119|DRUG|Rocatinlimab|Subcutaneous injection
215137307|NCT00904605|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
215137308|NCT00904605|DRUG|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
215137309|NCT00730717|DRUG|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
215137310|NCT00730717|DRUG|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
215137311|NCT06429917|OTHER|Subgingival instrumentation|All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
215137312|NCT05856721|DIAGNOSTIC_TEST|stool analysis|"Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients."
214452159|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (MDCK cells)|Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).
214452160|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (Chicken embryo)|Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).
214452161|NCT06342349|OTHER|Phosphate buffer solution|Phosphate buffer solution without vaccine antigen(0.5ml/dose).
214452162|NCT05712746|DRUG|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
214452163|NCT06635915|DIAGNOSTIC_TEST|Postoperative ultrasound|Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.
214452164|NCT06071065|BEHAVIORAL|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
214452165|NCT05226858|DIAGNOSTIC_TEST|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
215137313|NCT05902689|PROCEDURE|alveolar ridge preservation with bio-oss collagen|Alveolar ridge preservation with bio-oss collagen is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting bio-oss collagen in the socket and covering the biological barrier membrane.
215137314|NCT05902689|PROCEDURE|alveolar ridge preservation with sticky bone|Alveolar ridge preservation with sticky bone is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting sticky bone in the socket and covering the biological barrier membrane.
215137315|NCT02365025|OTHER|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
215137316|NCT01451112|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
215137317|NCT04162418|DEVICE|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
215137318|NCT05330559|OTHER|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
215137319|NCT01852877|BEHAVIORAL|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
214526356|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
214526357|NCT01153997|DRUG|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
214526358|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
214526359|NCT02397902|DIETARY_SUPPLEMENT|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
214452166|NCT06678087|OTHER|motherhood preparation meditation training prepared with the thetahealing meditation method|"With Birth and Motherhood Preparation Meditation, all physiological and psychological reasons causing fear of birth will be addressed. How to do the meditation will be taught by the practitioner in the course.~The root belief analysis study for each topic is carried out with the questions of who, what, when, where, why and how. Then, the reprogramming work that allows the change of that belief, feeling, emotion will be done with methods specific to the technique.~The topics to be worked on during meditation each week are listed below. Each week, pregnant women will be given a 15-minute meditation homework per day until the next week regarding the topic worked on.~All meditations begin with relaxation and breathing exercises. In each meditation, the emotion and root-belief analysis related to the relevant topic will be done by the practitioner.~With this application, it is aimed to accelerate the change in the mind with positive language and regular repetition."
214452167|NCT06678087|OTHER|pregnancy school,|"In the pregnancy school, an informational support training is provided to pregnant women and their families to ensure that the pre-pregnancy, pregnancy and birth process is passed in a healthy and conscious manner.~The training content includes:~Reproductive organs and development, Nutrition during pregnancy and puerperium, Common problems during pregnancy, Physiological changes, Non-formological methods, Breathing techniques during birth, Anesthetic methods, Birth methods and techniques, Postpartum and baby care, Newborn Care / Problems, Home-Bag-Hospital preparation, Breast milk - Its importance - Breastfeeding, Family planning topics are given five days a week for 2 hours."
214452168|NCT02437318|DRUG|Fulvestrant|500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
214452169|NCT02437318|DRUG|Alpelisib|300 mg of alpelisib tablets for oral use administered once daily
214452170|NCT02437318|DRUG|Placebo|300 mg of placebo tablets for oral use administered once daily
214452171|NCT05795257|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
214452172|NCT06321354|DRUG|The diprospan plus ropivacaine group|The local infiltration solution containing 0.5ml diprospan and 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214452173|NCT06321354|DRUG|The ropivacaine group|The local infiltration solution containing 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214452174|NCT04859725|DEVICE|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
214452175|NCT06364657|DIAGNOSTIC_TEST|Eye Exam|"* Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface"
214526360|NCT02397902|DIETARY_SUPPLEMENT|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
214526361|NCT04121949|DEVICE|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
215137320|NCT01094236|BEHAVIORAL|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
215137321|NCT04228523|OTHER|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~* A first round table is organized to know the needs and issues related to drug management of patients.~* The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~* The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~* The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
215137322|NCT04228523|OTHER|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
215137323|NCT05077202|DEVICE|ultra sound|chest ultrasound
215137324|NCT04103138|DEVICE|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
215137325|NCT04103138|DEVICE|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
215137326|NCT02360254|DRUG|Insulin degludec|Once daily injection of insulin degludec
215137327|NCT04231578|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
214452176|NCT05275842|BEHAVIORAL|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
214452177|NCT05275842|BEHAVIORAL|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
214452178|NCT03361826|DEVICE|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
214452179|NCT03361826|BEHAVIORAL|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
214452180|NCT04769206|DRUG|Galantamine|4mg daily titrating up to 8mg twice a day
214452181|NCT04769206|DRUG|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
214452182|NCT04769206|DEVICE|TENS 7000|The FDA-approved TENS 7000 device will be used for Trans-auricular vagus nerve stimulation (TaVNS) during a period of enhanced vascular oxidative stress. This device will be supplemented with ear clip electrodes. The site of the stimulation for such electrodes are the tragus or concha. The device will have built in safety controls to minimize additional risks to the subjects (as per FDA guidance on stimulators). We will use typical stimulation conditions (30 Hz, 300 µs) and amplitude dependent on perception threshold.
214452183|NCT04586959|DEVICE|Surgery with UM|The experimental group will have MIS with the placement of a uterine manipulator
214452184|NCT04586959|DEVICE|Surgery without UM|The control group will have MIS without the placement of a uterine manipulator
215137328|NCT01148368|DRUG|fimasartan|single administration of fimasartan 120mg
215137329|NCT02629718|DRUG|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
215137330|NCT02629718|PROCEDURE|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
215137331|NCT00894816|DIETARY_SUPPLEMENT|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
215137332|NCT00894816|DIETARY_SUPPLEMENT|Placebo|Infant cereals without any addition
215137333|NCT03085095|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
215137334|NCT03085095|DRUG|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
214526362|NCT03945409|DEVICE|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
214694865|NCT03966105|DIAGNOSTIC_TEST|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
215137335|NCT06380491|DRUG|Melatonin 3 MG Oral Tablet|Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
215137336|NCT00813241|DRUG|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
215137337|NCT00813241|DRUG|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
215137338|NCT00813241|DRUG|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
215137339|NCT00813241|DRUG|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
215137340|NCT05649215|OTHER|No intervention will be applied.|This is a questionnaire study.
215137341|NCT00408317|DRUG|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
215137342|NCT00408317|DRUG|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
215137343|NCT02545985|DEVICE|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
215137344|NCT01110902|DRUG|Agomelatine (AGO178C)|
215137345|NCT01110902|DRUG|Placebo|
215137346|NCT02628288|DEVICE|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
215137347|NCT01605708|DRUG|REGN846|Dose 1
215137348|NCT04254380|BIOLOGICAL|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
214452185|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
214452186|NCT06422403|DRUG|Extended Dosing Interval - A|Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
214452187|NCT06422403|DRUG|Extended Dosing Interval - B|Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
214452188|NCT06422403|DRUG|Extended Dosing Interval - C|Pembrolizumab 200mg 6 weekly (up to 2 years)
214452189|NCT06422403|DRUG|Standard of Care - A|Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
214452190|NCT06422403|DRUG|Standard of Care - B|Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
214452191|NCT06422403|DRUG|Standard of Care - C|Pembrolizumab 200mg 3 weekly (up to 2 years)
215137349|NCT04254380|BIOLOGICAL|Humalog|Route of administration: subcutaneous injection
214452192|NCT04632784|DEVICE|Artiflex Presbyopic (Artiplus) implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL (Artiplus)
215137350|NCT05517252|OTHER|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
215137351|NCT05517252|OTHER|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
215137352|NCT05716958|RADIATION|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
215137353|NCT03090360|DIETARY_SUPPLEMENT|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
215137354|NCT03090360|DIETARY_SUPPLEMENT|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
215137355|NCT05635019|BEHAVIORAL|BWL+VOUCHER|This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.
215137356|NCT05635019|BEHAVIORAL|BWL+HOME|This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.
215137357|NCT05635019|BEHAVIORAL|Behavioral weight loss counseling (BWL)|The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
215137358|NCT03207971|PROCEDURE|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
215137359|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Single Dose|Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
215137360|NCT04277897|DRUG|Placebo|Placebo to match Hepenofovir Fumarate Tablets
215137361|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Dose4|Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
215137362|NCT05250284|BEHAVIORAL|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
215137363|NCT05250284|BEHAVIORAL|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
215137364|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
215137365|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
215137366|NCT00286468|DRUG|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
215137367|NCT06182137|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.
215137368|NCT03454763|DRUG|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
215137369|NCT03454763|DRUG|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
215137370|NCT05132907|BIOLOGICAL|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
215137371|NCT03494660|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
215137372|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
215137373|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
214526363|NCT03042572|DRUG|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
215137374|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
215137375|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
215137376|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
215137377|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
215137378|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
215137379|NCT05499065|PROCEDURE|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
215137380|NCT05499065|DRUG|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
215137381|NCT06548126|BEHAVIORAL|Online Parenting Program|Online Parenting Program comprised of 12 online modules. Caregivers do one module per week for 12-15 weeks; each unit takes about 20 minutes to do. The Caregiver also practices the tools they learn for Parenting their Children between sessions.
215137382|NCT06548126|OTHER|No online parenting program|List of Parenting resources.
215137383|NCT05703945|OTHER|Progressive training program|The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.
215137384|NCT05703945|OTHER|Control group|The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
215137385|NCT05820035|DEVICE|Pulsed Field Ablation Device and CF-Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the pulsed field ablation device and CF-sensing pulsed field ablation catheter in the management of their paroxysmal supraventricular tachycardia
215137386|NCT06580444|DRUG|Brexanolone|The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
215137387|NCT05265429|GENETIC|Data and Specimen Collection|"* Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
215137388|NCT05156047|DRUG|Open-label pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
215137389|NCT05156047|DRUG|Double-blind placebo|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
215137390|NCT05156047|DRUG|Double-blind pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
215137391|NCT06129240|COMBINATION_PRODUCT|LIQ861|trepostinil inhalation powder
215137392|NCT06102954|OTHER|Falls prevention intervention including exercise and educational components|This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
215137393|NCT03790332|DRUG|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
215137394|NCT06330805|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215137395|NCT06330805|OTHER|Contrast Agent|Given IV
215137396|NCT06330805|DRUG|Leuprolide|Given injection
215137397|NCT06330805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215137398|NCT06330805|OTHER|Physical Performance Testing|Undergo functional fitness tests
215137399|NCT06330805|DRUG|Relugolix|Given PO
215137400|NCT05732311|DEVICE|intermittend theta burst stimulation|intermittend theta burst stimulation
214452193|NCT04596189|DRUG|Dupilumab 300 MG in 2 ML Prefilled Syringe|"The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
214526364|NCT03042572|OTHER|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
214526365|NCT06197100|OTHER|Supportive care training|The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.
214526366|NCT06197100|OTHER|control grups|Mothers in this group will be given an educational brochure containing information about colic.
214526367|NCT01898026|DIETARY_SUPPLEMENT|Bread|Samples of white bread, with or without the addition of PGX fibre blend
214526368|NCT01898026|DIETARY_SUPPLEMENT|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
214526369|NCT01898026|DIETARY_SUPPLEMENT|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
214526370|NCT01898026|DIETARY_SUPPLEMENT|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
215137401|NCT02271919|DRUG|Nicotine Lozenge|Given PO
215137402|NCT02271919|DRUG|Nicotine Patch|Given via patch
215137403|NCT02271919|OTHER|Placebo|Given PO or via patch
215137404|NCT02271919|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
215137405|NCT02271919|DRUG|Varenicline|Given PO
215137406|NCT06177080|OTHER|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
214526371|NCT03247985|DEVICE|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
215137407|NCT04816825|DEVICE|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
215137408|NCT04816825|OTHER|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
215137409|NCT06309628|DIAGNOSTIC_TEST|Breathe sample|Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
215137410|NCT06563700|OTHER|spectacle lens|one of ZEISS BD spectacle lens designs 1 to 5
215137411|NCT06563700|OTHER|single vision lens|single vision lens
215137412|NCT02923726|DEVICE|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
215137413|NCT02923726|DEVICE|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
215137414|NCT05011942|DEVICE|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
214526372|NCT03247985|DEVICE|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
214526373|NCT01776749|DEVICE|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
214526374|NCT03750175|OTHER|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
214526375|NCT00417989|DEVICE|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
214526376|NCT05464199|OTHER|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
215137415|NCT04474080|BEHAVIORAL|Virtual Peer Support Platform|The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
215137416|NCT04474080|BEHAVIORAL|Control Period|The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
215137417|NCT03158844|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
215137418|NCT04839406|BEHAVIORAL|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
215137419|NCT04144569|DRUG|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
215137420|NCT05794620|OTHER|Stool sample|Stool sample
215137421|NCT05817656|DRUG|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
215137422|NCT05659953|DRUG|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
215137423|NCT05659953|DRUG|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
215137424|NCT03446235|BEHAVIORAL|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
215137425|NCT03446235|BEHAVIORAL|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
215137426|NCT03324607|DRUG|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
214452194|NCT04596189|OTHER|Placebo|"The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
214452195|NCT04596189|DRUG|Mometasone Furoate nasal spray|On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert \& SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
214452196|NCT06189066|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
214452197|NCT05020574|DRUG|Cephalexin|Given orally (PO)
214526377|NCT01879735|DRUG|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
215137427|NCT03324607|DRUG|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
215137428|NCT04366414|OTHER|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
215137429|NCT04366414|OTHER|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
215137430|NCT00074711|DRUG|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
215137431|NCT00074711|DRUG|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
215137432|NCT02340793|DIETARY_SUPPLEMENT|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
215137433|NCT03466658|DEVICE|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
215137434|NCT05365217|DRUG|Nonacog beta pegol|Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
215137435|NCT06066177|DIAGNOSTIC_TEST|Triglyceride glucose index TyG|Triglyceride glucose index is an indicator of insulin resistance
215137436|NCT00890734|DRUG|CYT003-QbG10|subcutaneous injection
215137437|NCT00890734|DRUG|Placebo|subcutaneous injection
215137438|NCT03696160|DRUG|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
215137439|NCT03696160|DRUG|Symtuza|Protease inhibitor used to treat HIV-1 infection
215137440|NCT06252181|OTHER|electromagnetic pulsed therapy|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
215137441|NCT06252181|OTHER|elliptical exercise|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
215137442|NCT05766397|DRUG|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
215137443|NCT05746611|BIOLOGICAL|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
214452198|NCT05667701|DRUG|Soy isoflavone|Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
214452199|NCT05667701|DRUG|matching placebo|A matching placebo also administered twice daily.
214452200|NCT06294613|DEVICE|vitreoretinal surgery|Patients undergoing vitreoretinal surgery
214452201|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
214452202|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
214452203|NCT06316791|BIOLOGICAL|single dose of CNCT19|Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
215137444|NCT05746611|BIOLOGICAL|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
214452204|NCT04245501|OTHER|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
214452205|NCT04245501|OTHER|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
215137445|NCT01809938|OTHER|Black tea|300ml of tea without milk
215137446|NCT01809938|OTHER|Tea with milk|250ml of black tea with 50ml of full fat milk
215137447|NCT02210572|DIETARY_SUPPLEMENT|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
215137448|NCT02210572|DIETARY_SUPPLEMENT|Low- FODMAPs diet|
215137449|NCT01007903|BEHAVIORAL|Tai Chi exercise|12-week tai chi exercise class
215137450|NCT05608603|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
215137451|NCT05608603|DIAGNOSTIC_TEST|Cardiorespiratory stress test|Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.
215137452|NCT05608603|DIAGNOSTIC_TEST|Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer|The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
215137453|NCT06150612|BEHAVIORAL|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
215137454|NCT01657383|PROCEDURE|HPB Surgery|Hepatopancreatico Biliary Surgery
215137455|NCT03446872|DRUG|ONIVYDE|irinotecan liposome injection
215137456|NCT03446872|DRUG|5-fluorouracil|a nucleoside metabolic inhibitor
215137457|NCT03446872|DRUG|Leucovorin|an active metabolite of folic acid
215137458|NCT02648308|BEHAVIORAL|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
215137459|NCT01612338|BEHAVIORAL|Targeted|Targeted letter and booklet
215137460|NCT01612338|BEHAVIORAL|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
215137461|NCT02359318|PROCEDURE|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
215137462|NCT02359318|PROCEDURE|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
215137463|NCT03481478|DIAGNOSTIC_TEST|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
215137464|NCT00186576|PROCEDURE|nonmyeloablative allogeneic hematopoietic cell transplant|
215137465|NCT00683436|DRUG|Adipiplon|bilayer tablets 6 mg
215137466|NCT00683436|DRUG|Placebo|Placebo
215137467|NCT00683436|DRUG|Ambien CR|Ambien CR 12.5 mg
215137468|NCT00683436|DRUG|Adipiplon|bilayer tablets 9 mg
215137469|NCT01225874|DRUG|SC-PEG E. coli L-asparaginase|Given IM
215137470|NCT01225874|DRUG|cytarabine|Given IT
215137471|NCT01225874|DRUG|daunorubicin hydrochloride|Given IV
215137472|NCT01225874|DRUG|dexamethasone|Given orally
215137473|NCT01225874|DRUG|methotrexate|Given IT
215137474|NCT01225874|DRUG|pegaspargase|Given IM
214452206|NCT03940456|OTHER|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
214452207|NCT06447675|OTHER|Hyperthermic Baths|The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
214452208|NCT04141020|PROCEDURE|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
214452209|NCT04141020|PROCEDURE|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
214452210|NCT04141020|DRUG|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
214452211|NCT06513897|OTHER|Acupressure|Acupressure will be applied to the foreheads of the babies in this group starting two minutes before the heel prick. Acupressure application will be finished when heel prick blood collection is finished.
214452212|NCT06513897|OTHER|Father's Lap|Infants in this group will be placed on the father's lap two minutes before heel prick blood collection. They will remain on the father's lap during the heel prick procedure.
214452213|NCT04178434|BEHAVIORAL|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
214526378|NCT01879735|DRUG|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
214526379|NCT02465606|DRUG|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
215137475|NCT01225874|DRUG|prednisone|Given orally
215137476|NCT01225874|DRUG|vincristine sulfate|Given IV
215137477|NCT05301959|DEVICE|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
215137478|NCT05301959|DEVICE|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
215137479|NCT05301959|OTHER|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
215137480|NCT03779256|PROCEDURE|2D transvaginal ultrasound|"Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively."
215137481|NCT00129402|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
215137482|NCT00129402|DRUG|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
215137483|NCT00476125|BEHAVIORAL|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
214526380|NCT02465606|DRUG|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
215137484|NCT00476125|BEHAVIORAL|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
214526381|NCT00672100|DRUG|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
215137485|NCT00476125|BEHAVIORAL|16 Hour Fast|Subjects will fast for 16 hours.
215137486|NCT03291535|OTHER|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
214452214|NCT02715284|BIOLOGICAL|Dostarlimab|Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
214452215|NCT05758415|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
214452216|NCT05758415|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
214452217|NCT05784012|DRUG|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
214452218|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
214452219|NCT05784012|DRUG|cisplatin plus radiotherapy|In the concurrent phase
214452220|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
214452221|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
214452222|NCT06417476|RADIATION|Short-course radiotherapy|The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
214452223|NCT06417476|DRUG|Irinotecan|150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
214452224|NCT06417476|DRUG|Oxaliplatin|85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
214452225|NCT06417476|DRUG|Calcium Formate|400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
214452226|NCT06417476|DRUG|Fluorouracil|2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
214452227|NCT06417476|RADIATION|Long-course chemoradiation|The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
214452228|NCT06417476|DRUG|Capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
214452229|NCT06296914|DEVICE|POTSapp|"Participants will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months. T"
214452230|NCT06296914|DEVICE|Waitlist Control|"Participants will receive educational information about online support for POTS via email. Starting at month 4, participants will receive equipment will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months."
214452231|NCT00961571|DRUG|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
214452232|NCT06087432|OTHER|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
214452233|NCT06087432|OTHER|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
215137487|NCT03291535|OTHER|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
215137488|NCT03297047|DEVICE|combi cast|upper arm or forearm combi cast
215137489|NCT05471765|DEVICE|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
214694866|NCT04144452|OTHER|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
215137490|NCT05471765|DEVICE|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
215137491|NCT03212911|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
215137492|NCT02946086|BEHAVIORAL|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
215137493|NCT02946086|BEHAVIORAL|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
215137494|NCT02278510|DRUG|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
215137495|NCT02278510|DRUG|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
215137496|NCT02278510|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
215137497|NCT06352723|DRUG|Cenobamate|"Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7"
215137498|NCT01004068|OTHER|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
215137499|NCT01004068|DRUG|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
215137500|NCT01004068|BEHAVIORAL|Structured exercise program plus hypocaloric diet|SET plus diet
215137501|NCT04645355|DRUG|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
215137502|NCT02731586|DRUG|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
215137503|NCT03802006|DIAGNOSTIC_TEST|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
214452234|NCT06266663|OTHER|Survey|A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.
214452235|NCT06446401|DRUG|ADT + NHT + Docetaxel|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives the triple therapy, i.e. ADT, NHT and Docetaxel.
214452236|NCT06446401|DRUG|ADT + NHT|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.
214452237|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
214452238|NCT03779867|OTHER|Resting|Seated resting
214452239|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
214452240|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
214452241|NCT03070184|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
214452242|NCT03070184|DIETARY_SUPPLEMENT|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
215137504|NCT04475978|DEVICE|IVUS-guide DCB PTCA|IVUS-guide DCB PTCA
215137505|NCT04475978|DEVICE|Angio-guide DCB PTCA|Angio-guide DCB PTCA
215137506|NCT01527149|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
215137507|NCT01527149|DRUG|Cyclophosphamide|Given IV
215137508|NCT01527149|DRUG|Cytarabine|Given IV
215137509|NCT01527149|DRUG|Dexamethasone|Given IV or PO
215137510|NCT01527149|DRUG|Doxorubicin Hydrochloride|Given IV
215137511|NCT01527149|OTHER|Laboratory Biomarker Analysis|Correlative studies
215137512|NCT01527149|DRUG|Methotrexate|Given IV
215137513|NCT01527149|BIOLOGICAL|Ofatumumab|Given IV
215137514|NCT01527149|DRUG|Vincristine Sulfate|Given IV
215137515|NCT03464734|DRUG|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
215137516|NCT00269061|DRUG|pioglitazone|
215137517|NCT01449162|DRUG|Masitinib|6 mg/kg/day
215137518|NCT01449162|DRUG|Placebo|
215137519|NCT04784325|DIAGNOSTIC_TEST|Blood draw through TAP II|Two self-administered blood draws through TAP II device
215137520|NCT04784325|DIAGNOSTIC_TEST|Blood draw through ADx cardT|One self-administered ADx card blood draw
215137521|NCT04784325|DIAGNOSTIC_TEST|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
215137522|NCT00579215|BEHAVIORAL|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
215137523|NCT00579215|BEHAVIORAL|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
215137524|NCT05222334|PROCEDURE|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
214452243|NCT03070184|OTHER|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
214452244|NCT03070184|DRUG|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
214452245|NCT06822348|OTHER|Osteopathic treatment|Osteopathic manipulation
214452246|NCT06822348|BEHAVIORAL|Quality of life assessment|EORTC FA-12 questionnaire
214452247|NCT06822348|BEHAVIORAL|Anxiety assessment|STAI-Y-A and STAI-Y-B questionnaire assessment
214452248|NCT06822348|OTHER|Heart rate variability assessment|rMSSD (root mean square of successive R-R intervals), SDNN (standard deviation of all NN intervals), HF (high frequencies), LF (low frequencies), LF/HF ratio, Heart rate deceleration capacity, Heart rate acceleration capacity, Heart rate (bpm).
214452249|NCT06336304|DIAGNOSTIC_TEST|Urodynamic procedure|Urodynamic procedure
214452250|NCT05327101|OTHER|Patient Preference Survey|Patient preference survey on implantable cardiac pacemaker systems
214452251|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
214452252|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
214452253|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
214452254|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
214452255|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
214452256|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
214452257|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
215137525|NCT05222334|PROCEDURE|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
215137526|NCT05222334|DRUG|Bupivacaine|bupivacaine
215137527|NCT02610296|DRUG|QPI-1002|IV injection
215137528|NCT02610296|OTHER|Placebo|isotonic saline
215137529|NCT06066034|DIAGNOSTIC_TEST|HOMA-IR，ESHRE/ASRM|Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003
215137530|NCT03998410|DEVICE|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
215137531|NCT03149679|DRUG|Cyclophosphamide|Chemotherapy
215137532|NCT02472821|BEHAVIORAL|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
215137533|NCT02472821|BEHAVIORAL|Internet-based educational booster|Visit to an educational Web site focused on hearing health
215137534|NCT01146769|OTHER|Pelvic floor exercise|Pelvic floor strengthening exercise
215137535|NCT01680341|DRUG|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
215137536|NCT01680341|DRUG|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
215137537|NCT05613569|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
215137538|NCT04351542|DIETARY_SUPPLEMENT|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
215137539|NCT04351542|OTHER|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
215137540|NCT03596034|OTHER|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
215137541|NCT00005942|DRUG|liposomal daunorubicin citrate|Given IV
215137542|NCT00005942|DRUG|semaxanib|Given IV
215137543|NCT00005942|OTHER|laboratory biomarker analysis|Correlative studies
215137544|NCT06567145|BEHAVIORAL|Narrative Enhancement Cognitive Therapy (NECT)|The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
214452258|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
214452259|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
214452260|NCT05641610|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
214452261|NCT03532360|OTHER|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
214452262|NCT06489522|BEHAVIORAL|THRIVE|THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
214452263|NCT06201676|DRUG|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
214452264|NCT06201676|OTHER|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
214452265|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
214452266|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
214452267|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
214452268|NCT04638309|DRUG|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
214452269|NCT05337748|DEVICE|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
215137545|NCT00481832|DRUG|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
215137546|NCT00481832|DRUG|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
214526382|NCT00672100|DRUG|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
214526383|NCT00672100|DRUG|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
214526384|NCT04892004|BEHAVIORAL|Symptom recognition|The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
214526385|NCT05833399|DRUG|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
214526386|NCT01436045|DRUG|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
215137547|NCT00481832|DRUG|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
215137548|NCT00481832|DRUG|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
215137549|NCT00481832|DRUG|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
215137550|NCT00481832|DRUG|Cyclosporine|5mg/kgbid,variable, po or IV
215137551|NCT00481832|DRUG|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
215137552|NCT00481832|DRUG|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
215137553|NCT00481832|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
215137554|NCT00481832|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
215137555|NCT00481832|PROCEDURE|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
215137556|NCT00481832|DRUG|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
215137557|NCT00481832|DRUG|Solu-Medrol|1 mg/kg, Day-11 to Day-7
214452270|NCT05337748|DEVICE|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
214452271|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
214452272|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
214452273|NCT03441165|PROCEDURE|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
214452274|NCT04570475|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
214452275|NCT04570475|DIETARY_SUPPLEMENT|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
214452276|NCT04570475|DIETARY_SUPPLEMENT|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
214452277|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
214452278|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
214452279|NCT04173637|BIOLOGICAL|AK101|an anti-IL-12/23p40 monoclonal antibody
214452280|NCT04173637|BIOLOGICAL|Placebo|matching placebo
214452281|NCT06280976|DRUG|Statin|high intensity statin (eg atorvastatin 80 mg daily)
214452282|NCT06280976|DRUG|Aspirin tablet|aspirin 81 mg po qd
214452283|NCT06280976|DRUG|Nexlizet|bempedoic acid-ezetimibe 180-10 mg po qd
214452284|NCT06280976|DRUG|LEQVIO|inclisiran SQ as per product insert
214452285|NCT06280976|DRUG|Vascepa|icosapent ethyl 2g PO BID
214526387|NCT01436045|DRUG|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
215137558|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
215137559|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
214452286|NCT06280976|DRUG|Jardiance|empagliflozin 10 mg PO QD
214452287|NCT06280976|DRUG|Colchicine|Colchicine 0.5 MG po qd
214452288|NCT05243017|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
214452289|NCT05097430|BEHAVIORAL|Alcohol-focused brief intervention|The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
214526388|NCT04910061|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
214526389|NCT05480202|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
214526390|NCT05480202|OTHER|Designed chest physical therapy program|Percussion, vibration and postural drainage
214526391|NCT01265914|BIOLOGICAL|FP-01.1|Ascending doses of FP-01.1 will be administered
214526392|NCT01265914|BIOLOGICAL|placebo|
214526393|NCT04532008|BEHAVIORAL|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
214526394|NCT02580981|OTHER|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
214526395|NCT02061189|OTHER|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
214526396|NCT04342910|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
214526397|NCT04342910|DRUG|Apatinib Mesylate|250 mg qd
214526398|NCT04342910|DRUG|Paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
214526399|NCT04342910|DRUG|Irinotecan|180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
214526400|NCT00294879|PROCEDURE|pressure support ventilation at 0, 5, and 10% IRT|
214526401|NCT06996327|OTHER|Evaluation of dietary consumption of UPFs|Evaluation of dietary consumption of ultraprocessed foods
214526402|NCT07001228|BEHAVIORAL|SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~For SD rehabilitation, shoulder external rotation, push up plus, and shoulder rolls were performed. In the experimental group, rehabilitation for scapular dyskinesis will begin at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
215137560|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
215137561|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
215137562|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
215137563|NCT02992288|DRUG|Placebo|Orally once daily for 20 weeks
215137564|NCT06205277|PROCEDURE|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
215137565|NCT03416985|DEVICE|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
215137566|NCT03416985|DEVICE|BURST Sonic Oral Care|Electric sonic toothbrush
214694867|NCT04144452|OTHER|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
214694868|NCT00003662|BIOLOGICAL|anti-thymocyte globulin|
215137567|NCT03416985|DEVICE|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
215137568|NCT05839964|DIETARY_SUPPLEMENT|CBN and CBD|CBN and CBD in Gummy Format
215137569|NCT05173194|OTHER|Exercise|Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
215137570|NCT02006472|DRUG|Pridopidine|22.5 mg and 45 mg capsules
215137571|NCT02006472|OTHER|Placebo|Capsules matching drug
215137572|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
214694869|NCT00003662|DRUG|busulfan|
214694870|NCT00003662|DRUG|cyclophosphamide|
214694871|NCT00003662|DRUG|cyclosporine|
214694872|NCT00003662|DRUG|melphalan|
214694873|NCT00003662|DRUG|methylprednisolone|
214694874|NCT00003662|PROCEDURE|umbilical cord blood transplantation|
214694875|NCT00003662|RADIATION|radiation therapy|
215137573|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
215137574|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
215137575|NCT00499486|DRUG|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
215137576|NCT02043756|DRUG|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
215137577|NCT02043756|DRUG|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
215137578|NCT05128669|PROCEDURE|CPIP|CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.
215137579|NCT05128669|PROCEDURE|ECS|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
215137580|NCT01803009|BEHAVIORAL|Patient views NCI CRC RAT|
215137581|NCT01803009|BEHAVIORAL|View presentation regarding current chance of having an advanced adenoma|
215137582|NCT00169286|PROCEDURE|Telephone care management|
215137583|NCT00169286|PROCEDURE|peer-led chronic disease self-management workshop|
215137584|NCT00169286|PROCEDURE|professionally-led cognitive behavioral psychotherapy group|
214452290|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
214694876|NCT06603662|DRUG|Prednisone|Subjects assigned to the Intervention A group will receive oral prednisone 50 mg once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours for 5 days.
215137585|NCT06389422|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
215137586|NCT06389422|DRUG|Pembrolizumab|One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
215137587|NCT00656513|DRUG|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
215137588|NCT00656513|PROCEDURE|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
215137589|NCT00002894|DRUG|carboplatin|
215137590|NCT00002894|DRUG|cisplatin|
215137591|NCT00002894|DRUG|paclitaxel|
215137592|NCT03651310|OTHER|Music Listening Group|Waiting in preoperative area with music listening.
215137593|NCT02856568|DRUG|Cisplatin|Given IV
215137594|NCT02856568|DRUG|Gemcitabine Hydrochloride|Given IV
215137595|NCT02856568|OTHER|Laboratory Biomarker Analysis|Correlative studies
215137596|NCT02856568|OTHER|Pharmacological Study|Correlative studies
214452291|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
214452292|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
214452293|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
214452294|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
214452295|NCT04148911|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
214452296|NCT04148911|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
214452297|NCT05676944|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
214452298|NCT04848337|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
214452299|NCT04848337|DRUG|Lenvatinib|Lenvatinib 20 mg orally daily.
214694877|NCT06603662|DRUG|Dexamethasone|Subjects assigned to the Intervention B group will receive a single oral dose of dexamethasone 10 mg, plus standard ibuprofen 600 mg every 8 hours for 5 days.
214694878|NCT06603662|DRUG|Placebo|Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
215137597|NCT02856568|DRUG|Ricolinostat|Given PO
215137598|NCT01969136|DRUG|Drug: EVP-6124|
215137599|NCT01969136|DRUG|Placebo|
215137600|NCT00441909|DRUG|UC-781|0.1% UC-781 Vaginal Gel
215137601|NCT00441909|DRUG|UC-781 placebo|Vaginal Gel Placebo
215137602|NCT00418678|DRUG|Cesamet|2 mg BID on Days 2-5.
215137603|NCT00801957|DRUG|tacrolimus ointment 0.03%|topical application
215137604|NCT00801957|DRUG|hydrocortisone acetate ointment 1%|topical application
215137605|NCT00801957|DRUG|hydrocortisone butyrate ointment 0.1%|topical application
215137606|NCT00801957|BIOLOGICAL|Meningitec|im injection
215137607|NCT00801957|BIOLOGICAL|AC VAX|im injection
215137608|NCT04429711|DRUG|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
215137609|NCT04257357|BEHAVIORAL|8-weeks supervised exercise program|Please refer to group description
215137610|NCT04257357|BEHAVIORAL|Active control|Please refer to group description
215137611|NCT05524025|DIAGNOSTIC_TEST|Salivary TTMV-HPV DNA Test|Mouthwash rinse
215137612|NCT05524025|DIAGNOSTIC_TEST|Blood TTMV-HPV DNA Test|Blood test
215137613|NCT04182516|DRUG|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
215137614|NCT00087152|DRUG|Capecitabine|1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
215137615|NCT00087152|DRUG|Imatinib mesylate|400 mg by mouth daily
215137616|NCT06052579|PROCEDURE|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
215137617|NCT01708356|BEHAVIORAL|Cycling on a residential route|
215137618|NCT03913455|DRUG|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
215137619|NCT03913455|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 5
215137620|NCT00754962|DRUG|protriptyline|10 mg tablet
215137621|NCT03518853|RADIATION|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
215137622|NCT05831033|BIOLOGICAL|BEN101|"Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."
215137623|NCT05467007|DIAGNOSTIC_TEST|BioFire® Respiratory Panel 2.1-EZ|BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
215137624|NCT04488679|OTHER|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
215137625|NCT05876689|DEVICE|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
215137626|NCT05818254|BEHAVIORAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
215137627|NCT05818254|BEHAVIORAL|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
215137628|NCT06644573|PROCEDURE|PROSOMNIA Sleep Therapy™ (PSTx)|PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
215137629|NCT06644573|PROCEDURE|Anesthesia-Induced Sleep Therapy|"1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy."
214452300|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
214452301|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
214452302|NCT05918133|DRUG|PM8002|IV infusion
214452303|NCT05918133|DRUG|nab-paclitaxel|IV infusion
214452304|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
214452305|NCT05358262|OTHER|Standard of Care|The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
214452306|NCT05309655|DRUG|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
214452307|NCT05309655|DIAGNOSTIC_TEST|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
214452308|NCT05309655|DIAGNOSTIC_TEST|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
214694879|NCT06378073|DIAGNOSTIC_TEST|Incentive Spirometer|"Specificity and sensitivity: Incentive spirometry is a specific type of spirometry that aims to encourage people to breathe deeply intentionally but does not provide a measurement or inform management of chronic lung diseases. Less than 5 repetitions per day (sensitivity 93%, specificity 77%) and less than 2 balls per repetition (sensitivity 93%, specificity 77%) were predictive of postoperative pulmonary complications. (1) Validity and reliability: Incentive spirometry can be used as a simple mean to follow lung function, especially VC, in the postoperative period in spontaneously breathing patients. Incentive spirometry is noninvasive and can be performed repeatedly at the bedside in the intensive care setting. (2)~Interpretation:~There are only three numeric values that are required to interpret spirometry:~* Forced Vital Capacity (FVC)~* Forced Expiratory Volume (FEV1)~* FEV1/FVC ratio."
215137630|NCT06644573|DRUG|Diprivan (propofol), Astra-Zeneca|Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA\_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
214526403|NCT07001228|BEHAVIORAL|No SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~In the sham group, rehabilitation for scapular dyskinesis will not begun at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
214526404|NCT04907877|DIETARY_SUPPLEMENT|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
214526405|NCT04907877|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
214694880|NCT06378073|DIAGNOSTIC_TEST|Numeric Pain Rating Scale|"Sensitivity: The area under the receiver operator characteristic curve for the NRS as a test for pain that interferes with functioning was 0.76, indicating fair accuracy. A pain screening NRS score of 1 was 69% sensitive for pain that interferes with functioning. (4) he diagnostic value of different NRS cut-off values for administering analgesics is determined by an ROC curve. Sensitivity of NRS \> 3 for 'unbearable' pain in older patients was 72% with a specificity of 97·2%. With a cut-off point NRS \> 4, sensitivity increased to 83%, while specificity was 96·7%. (5) Validity and reliability: The numerical rating scale is a reliable and valid tool for pain assessment in patients with musculoskeletal impairments. (3)~Measurement (circle): Categorical /Numerical /Both:~Numerical:~The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable)"
214694881|NCT05121077|OTHER|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
215137631|NCT06644573|DEVICE|Continuous EEG Monitoring|Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
215137632|NCT05984121|DRUG|Local ozon injections|"Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively."
215137633|NCT05984121|DRUG|Local dextroz prolotherapy injections|Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
215137634|NCT05984121|OTHER|Exercise Group|Patients will receive a conventional therapy program consisting of exercises
214452309|NCT05309655|OTHER|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
214452310|NCT05309655|BEHAVIORAL|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
214452311|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
214452312|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
214452313|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
214452314|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
214526406|NCT03370861|BIOLOGICAL|Immunotherapy|Medications that increase the activity of the immune system.
214526407|NCT07009067|BEHAVIORAL|Exercise-based Cardiac Rehabilitation|Participated will receive 36 individualized Exercise-based Cardiac Rehabilitation after enrollment in our Cardiac Rehabilitation Center.
214526410|NCT07008365|DRUG|Furosemide 20 Milligrams|Decongestive therapy with e.v. furosemide +/- hydrochlorothiazide will be adjusted by intraabdominal pressure and/or point of care ultrasound
214526411|NCT07009366|PROCEDURE|Sudden weaning of NCPAP|"NCPAP was taken off entirely when the neonate met the stability criteria and remained on oxygen or room air via a headbox or incubator with an aim to stay off NCPAP."
214526412|NCT07009366|PROCEDURE|Gradual weaning with increasing the time off NCPAP|The regimen adopted for this method was 1 hour off twice a day on the 1st day, then 2 hours off twice a day on the 2nd day, hence increasing the time off to 6 hours twice a day (or 12 hours per day), i.e., using a smaller period off. At this point, NCPAP was taken off completely.
215137635|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
215137636|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
215137637|NCT03659266|OTHER|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
215137638|NCT03659266|OTHER|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
215137639|NCT01436149|DRUG|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
215137640|NCT01436149|DRUG|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
215137641|NCT04717037|BIOLOGICAL|Olive Oil Massage|olive oil massage application.
214452315|NCT04321031|DRUG|Placebo|Tablet
214452316|NCT04321031|DRUG|PF-06865571|Tablet
214452317|NCT04321031|DRUG|PF-05221304|Tablet
214452318|NCT06188286|OTHER|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
214452319|NCT06188286|OTHER|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
214452320|NCT06223880|DRUG|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
214452321|NCT06223880|DRUG|Bupropion|Up to 26 weeks in double-blind period
214452322|NCT03941132|DRUG|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
214452323|NCT03941132|DRUG|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
214452324|NCT05509153|DRUG|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
214452325|NCT05509153|DRUG|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
214452326|NCT05390762|OTHER|Common phase|A common face to face day hospital combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.
214452327|NCT05390762|OTHER|Telecare rehabilitation|A Second phase of 5 weeks of telecare rehabilitation of the reconditioning type of 15 sessions.
214452328|NCT05390762|OTHER|Care in Face to Face|A Second phase of 5 weeks of care in face to face day hospital of the reconditioning type of 15 sessions.
214452329|NCT05584124|DEVICE|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
214452330|NCT05584124|DEVICE|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
214452331|NCT06798220|OTHER|Traditional Breakfast|In this intervention, participants are offered a traditional breakfast (consisting of unprocessed or minimally processed foods), and postprandial appetite regulation is evaluated. Traditional breakfast includes chicken egg (boiled), white cheese (full-fat), white bread, black and green olives, tomatoes, cucumbers, and freshly squeezed orange juice.
214452332|NCT06798220|OTHER|UPF Breakfast|In this intervention, participants are offered an ultra-processed breakfast, and postprandial appetite regulation is evaluated. Ultra-processed breakfast includes pan-fried beef sausage (without oil), packaged sandwich bread, tomato-based ketchup, and packaged orange juice.
214452333|NCT00709033|BIOLOGICAL|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
214452334|NCT06792942|OTHER|nature view curtain group|During the fine needle biopsy, the patient will look at the nature view curtain on the ceiling.
214452335|NCT04704037|OTHER|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
214452336|NCT04704037|OTHER|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
214452337|NCT05536440|DRUG|PF-07261271|IV or SC
214452338|NCT05536440|DRUG|Placebo|IV or SC
214452339|NCT06283173|DEVICE|ColActive Plus Collagen Matrix Dressing|"Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article."
214526413|NCT07009366|PROCEDURE|Pressure weaning of NCPAP|In this method the pressure was reduced in steps of 1 cm of H2O every 12 to 24 hours until 5 cm of H2O, and then if the child tolerated it well, NCPAP was removed, and the child was shifted to oxygen via incubator or room air according to the situation.
214526414|NCT07008443|DRUG|Bupivacaine + saline|25 ml of 0.5% bupivacaine combined with 5 ml of normal saline, administered via ultrasound-guided supraclavicular brachial plexus block as a control intervention
215137642|NCT01874639|DEVICE|standard bipolar coagulation|
215137643|NCT01874639|DEVICE|Aquamantys® probe for liver hemostasis|
215137644|NCT05960097|BIOLOGICAL|CV0701 Bivalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137645|NCT05960097|BIOLOGICAL|CV0701 Bivalent Medium dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137646|NCT05960097|BIOLOGICAL|CV0701 Bivalent Low dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137647|NCT05960097|BIOLOGICAL|CV0601 Monovalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137648|NCT05960097|BIOLOGICAL|Control vaccine|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137649|NCT05960097|BIOLOGICAL|CV0801 Monovalent|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
215137650|NCT05473988|OTHER|Admission to General Ward|Admission to General Ward
215137651|NCT05473988|OTHER|Admission to Intensive Care Unit|Admission to Intensive Care Unit
215137652|NCT05473988|OTHER|30 Day Mortality|30 Day Mortality
215137653|NCT05261386|DRUG|CBT-008|Treat MGD
215137654|NCT03893071|DRUG|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
215137655|NCT05811936|BEHAVIORAL|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
215137656|NCT00002754|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
215137657|NCT03151044|DRUG|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
215137658|NCT03151044|DRUG|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
215137659|NCT06347198|DRUG|Fruquintinib|Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
215137660|NCT06347198|DRUG|Sintilimab|Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
215137661|NCT06347198|DRUG|Inulin|Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
215137662|NCT05062655|OTHER|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
215137663|NCT01643668|DRUG|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
215137664|NCT01643668|DRUG|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
214452340|NCT06028113|BEHAVIORAL|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
214452341|NCT04747431|DRUG|PBFT02|PBFT02
214452342|NCT04647786|DEVICE|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
214452343|NCT05919680|DRUG|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
214452344|NCT05919680|DRUG|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
214452345|NCT05919680|OTHER|Matched Placebo|Matched placebo for administration in Part A or Part B
214452346|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
214452347|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
214452348|NCT06123299|DEVICE|pHyph|vaginal tablet
214452349|NCT04519970|BEHAVIORAL|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
214526415|NCT07008443|DRUG|Bupivacaine + nalbuphine|25 ml of 0.5% bupivacaine combined with nalbuphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
215137665|NCT01643668|PROCEDURE|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
215137666|NCT03304561|OTHER|Traditional rehabilitation|traditional ACL rehabilitation program
215137667|NCT03304561|OTHER|Cross-over training|Cross-over training addition to the traditional rehabilidation
215137668|NCT04281407|DIETARY_SUPPLEMENT|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
215137669|NCT00322881|DRUG|Paclitaxel|
215137670|NCT00322881|DRUG|Carboplatin|
215137671|NCT00623272|OTHER|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
215137672|NCT04836468|DIAGNOSTIC_TEST|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
215137673|NCT03113851|RADIATION|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
215137674|NCT03113851|DRUG|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
215137675|NCT00352508|BEHAVIORAL|Dietary advice|
215137676|NCT02779439|BIOLOGICAL|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
215137677|NCT02495428|PROCEDURE|Kinesio Tape Method|
215137678|NCT03549923|DEVICE|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
215137679|NCT03549923|DEVICE|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
215137680|NCT03549923|DRUG|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
215137681|NCT03549923|DRUG|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
215137682|NCT01025908|BEHAVIORAL|Psychotherapy|Cognitive Behavioral Therapy
215137683|NCT01025908|BEHAVIORAL|Supportative psychotherapy|Supportative psychotherapy
215137684|NCT01422096|DRUG|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if \> 37.5 kg im once
215137685|NCT04079439|BEHAVIORAL|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
215137686|NCT02799836|DEVICE|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
215137687|NCT03797651|DRUG|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
215137688|NCT03797651|DRUG|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
215137689|NCT01258777|DRUG|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
215137690|NCT01258777|DRUG|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
215137691|NCT06281587|PROCEDURE|penetrating keratoplasty|replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
215137692|NCT04595071|DEVICE|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
215137693|NCT06512584|DRUG|PJ009|subcutaneous injections, 0.05 mg/kg once daily
215137694|NCT06512584|DRUG|PJ009 Placebo|subcutaneous injections, once daily
215137695|NCT03527849|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
215137696|NCT03527849|BEHAVIORAL|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
215137697|NCT04527952|BEHAVIORAL|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
215137698|NCT03904394|OTHER|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
215137699|NCT06333314|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
214452350|NCT04882449|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
214452351|NCT06431295|DEVICE|FaceScan|"Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing."
214452352|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
214526416|NCT07008443|DRUG|Bupivacaine + morphine|25 ml of 0.5% bupivacaine combined with morphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
215137700|NCT06333314|DRUG|Chemotherapy|"* mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin."
215137701|NCT04982653|OTHER|Quality-of-Life Assessment|Ancillary studies
215137702|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
215137703|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
215137704|NCT00573508|DRUG|Placebo|Oral Administration
215137705|NCT00573508|DRUG|Solifenacin Succinate|Oral Administration
215137706|NCT00010816|DRUG|Herbal remedies|
215137707|NCT04559568|DRUG|LY3522348|Administered orally.
215137708|NCT04559568|DRUG|Placebo|Administered orally.
215137709|NCT04559568|DRUG|Midazolam|Administered orally to some participants.
215137710|NCT03701958|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
215137711|NCT02122016|DEVICE|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
215137712|NCT02122016|OTHER|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
215137713|NCT02285855|DRUG|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
215137714|NCT02285855|OTHER|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
215137715|NCT02285855|RADIATION|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
215137716|NCT03253796|BIOLOGICAL|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
214452353|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
215137717|NCT03253796|BIOLOGICAL|Placebo|Injections of matching placebo for golimumab.
214452354|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
214452355|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
214452356|NCT05123014|OTHER|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
214452357|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
214452358|NCT05607108|DRUG|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
215137718|NCT01581801|PROCEDURE|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
215137719|NCT01581801|PROCEDURE|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
215137720|NCT04662385|DRUG|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
215137721|NCT04662385|DRUG|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
215137722|NCT00181896|DRUG|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
215137723|NCT00528112|DRUG|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
215137724|NCT00528112|DRUG|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
215137725|NCT03403803|DEVICE|Optune|"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."
215137726|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
215137727|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
215137728|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
215137729|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
215137730|NCT04443244|OTHER|Normal Saline|Placebo Comparator: Normal Saline
215137731|NCT04504500|BEHAVIORAL|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
215137732|NCT04504500|BEHAVIORAL|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
214452359|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
214452360|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
214452361|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
214452362|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
214452363|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
214452364|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
214452365|NCT04597372|DRUG|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
214452366|NCT04597372|DRUG|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
214452367|NCT05537766|BIOLOGICAL|Brexucabtagene Autoleucel|Administered intravenously
214452368|NCT05537766|DRUG|Cyclophosphamide|Administered intravenously
214452369|NCT05537766|DRUG|Fludarabine|Administered intravenously
214452370|NCT06015542|DRUG|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
214452371|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|1,330 mg curcumin
214452372|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|350 mg Epigallocatechin gallate (EGCG)
214452373|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
214452375|NCT05780502|BEHAVIORAL|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
214452376|NCT06124521|BEHAVIORAL|ComBaT Glaucoma|ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
214452377|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
214452378|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
214452379|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
214452380|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
214452381|NCT04064086|OTHER|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
214452382|NCT04064086|OTHER|Provision of the freely available resources for Kidney Disease Education|freely available resources
214452383|NCT05146440|DRUG|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
214452384|NCT05309629|DRUG|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
214694882|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
214452385|NCT05309629|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
214694883|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
214526417|NCT07009106|OTHER|Educational video on postpartum care|Participants watched a short educational video on postpartum care during a regularly scheduled prenatal visit.
214526418|NCT07007715|OTHER|Flow of 40L/min|Setting flow rate at 40L/min
214526419|NCT07007715|OTHER|Peak tidal inspiratory flow (PTIF) guided|Setting HFNC flow at 5 L/min above the peak tidal inspiratory flow (PTIF), up to a maximum of 60 L/min.
214526420|NCT07007715|OTHER|PaO2/FiO2 ratio guided|Setting HFNC flow according to P/F ratio prior to extubation. Flow will be set at 60, 50 40 L/min if P/F ratio \<250 mmHg, 250-300 mmHg and \>300 mmHg, respectively.
214526421|NCT07007715|OTHER|Flow of 60L/min|Setting flow rate at 60L/min
215137733|NCT04504500|BEHAVIORAL|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
215137734|NCT04504500|BEHAVIORAL|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
215137735|NCT04504500|BEHAVIORAL|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
215137736|NCT04504500|BEHAVIORAL|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
215137737|NCT04504500|BEHAVIORAL|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
214452386|NCT05309629|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
214452387|NCT03885713|BIOLOGICAL|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
214452388|NCT06298136|BEHAVIORAL|mindfulness-based intervention|Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided
214452389|NCT06298136|BEHAVIORAL|child behavior management|worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
214452390|NCT03890263|BEHAVIORAL|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
214452391|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
214452392|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
214452393|NCT05005442|BIOLOGICAL|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
214452394|NCT01261312|DRUG|Guadecitabine|Subcutaneous injection
214452395|NCT05253612|DIAGNOSTIC_TEST|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
214452396|NCT05253612|DIAGNOSTIC_TEST|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
214452397|NCT06380582|OTHER|Temperature and Airflow combination|23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
214526422|NCT07009678|DIAGNOSTIC_TEST|intravenous access in greater saphenous vein compared to upper extremity site.|Ultrasound access of greater saphenous vein with placement of midline 4French catheter and use of sphygmomanometer to regulate valsalva maneuver, imaging with and without valsalva and injection of agitated saline.
214526423|NCT07007897|DEVICE|Optical Biometry|Biometric measurements of the eye used for surgical planning will be obtained.
214526424|NCT07007897|PROCEDURE|Cataract Surgery|A video recording of the surgical procedure will be obtained.
214526425|NCT03571100|DRUG|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
214526426|NCT03571100|DRUG|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
214526427|NCT07007741|OTHER|Software Group|"Download the Fatty Liver Data Analysis and Management Software, register and update your profile, connect to a scale, and associate with a researcher and dietitian. Upload meal charts and weight and body fat data every day, adjust recipes according to the patient's exercise and diet every week, and customise one-on-one Q\&A according to the patient's uploaded photos every day. After enrolment, w12 and w24 were required to follow-up to complete relevant examinations and scales and collect data."
215137738|NCT04504500|BEHAVIORAL|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
215137739|NCT04504500|OTHER|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
215137740|NCT04504500|OTHER|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
215137741|NCT04504500|OTHER|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
215137742|NCT04504500|OTHER|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
215137743|NCT04504500|OTHER|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
215137744|NCT04504500|OTHER|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
215137745|NCT04504500|OTHER|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
215137746|NCT00556569|OTHER|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
215137747|NCT02403557|BEHAVIORAL|Waitlist|Weekly check up.
215137748|NCT02403557|BEHAVIORAL|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
215137749|NCT02718898|DRUG|Ixekizumab|Administered SC
215137750|NCT02718898|DRUG|Placebo|Administered SC
215137751|NCT02659163|BEHAVIORAL|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
215137752|NCT02659163|BEHAVIORAL|mHealth scale|A wireless scale used by participants to measure and record daily weight.
215137753|NCT02659163|BEHAVIORAL|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
215137754|NCT02659163|BEHAVIORAL|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
215137755|NCT02659163|BEHAVIORAL|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
215137756|NCT02659163|BEHAVIORAL|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
215137757|NCT01161940|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
215137758|NCT01161940|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
215137759|NCT03252769|OTHER|Self-sampling|
215137760|NCT00589225|GENETIC|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
215137761|NCT01861808|OTHER|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
215137762|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous
215137763|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous.
215137764|NCT03784443|DRUG|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
215137765|NCT03784443|DRUG|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
214526428|NCT07008313|BEHAVIORAL|The enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) refers to a series of optimal management measures which are proved to be effective by evidence-based medical evidence in order to reduce patients' psychological and physiological traumatic stress reaction
214526429|NCT07008313|BEHAVIORAL|Traditional treatment methods.|Traditional treatment methods.
215137766|NCT03784443|PROCEDURE|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
215137767|NCT01243164|OTHER|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
215137768|NCT01384175|PROCEDURE|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
215137769|NCT01384175|PROCEDURE|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
215137770|NCT01384175|PROCEDURE|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
215137771|NCT02462694|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
214526430|NCT06285383|OTHER|Music listening|Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
214526431|NCT06285383|OTHER|classic physical therapy|classic physical therapy
215137772|NCT02462694|BEHAVIORAL|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
215137773|NCT03458338|DIAGNOSTIC_TEST|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
215137774|NCT00611936|DRUG|Placebo|Placebo
215137775|NCT00611936|DRUG|Atomoxetine|20mg maximum of d-amphetamine
215137776|NCT00894803|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
215137777|NCT00894803|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
215137778|NCT04484961|DEVICE|Blood flow restriction (BFR)|The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
214526432|NCT06134986|OTHER|Time restricted eating|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
214526433|NCT06134986|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
215137779|NCT04044950|BIOLOGICAL|E7 TCR|The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
214526434|NCT06309368|DRUG|Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|An elliptical transverse incision will be made extending 1-2 cm lateral and medial to the mucocutaneous junction. The mobilization, anastomosis and fascial closure will be performed as in the pursestring closure group. The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan. After one minute the wound will be suctioned dry. The subcutaneous fat will be mobilized and approximated with interrupted 2-0 Vicryl. The skin will be approximated with deep dermal 3-0 Vicryl and a running subcuticular 4-0 Monocryl suture and Dermabond will be applied.
214526435|NCT06309368|PROCEDURE|Pursestring Closure|A circular incision will be made at the mucocutaneous junction of the ileostomy. After complete mobilization of the ileal limbs off the fascia and a stapled side to side functional end to end anastomosis, the fascia including the external and posterior rectus sheath will be closed with two running #0 PDS (Polydioxanone) suture. The wound will then be irrigated with saline and partially closed in the subcuticular plane with a 2-0 Monocryl suture in a pursestring fashion and packed in the middle with plain packing.
214526436|NCT00497198|DRUG|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
214526437|NCT00497198|DRUG|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
214694884|NCT05020938|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
214694885|NCT03135028|DRUG|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
215137780|NCT04871906|OTHER|stretching exercises|Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
215137781|NCT01667900|DRUG|Dulaglutide|
215137782|NCT01667900|DRUG|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
215137783|NCT00253812|PROCEDURE|flexible sigmoidoscopy|
214452398|NCT04119687|BIOLOGICAL|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
215137784|NCT03173885|DIAGNOSTIC_TEST|Preimplantation Genetic Screening|"* laser assisted hatching~* trophectoderm biopsy~* next generation sequencing"
215137785|NCT04228471|PROCEDURE|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
215137786|NCT04228471|PROCEDURE|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
215137787|NCT04031599|DEVICE|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
215137788|NCT04031599|DEVICE|Insulin pump|Tandem Diabetes Care
215137789|NCT04031599|DEVICE|Continuous glucose monitoring system|Dexcom G6
215137790|NCT04031599|DRUG|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
215137791|NCT04031599|OTHER|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
215137792|NCT04031599|OTHER|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
215137793|NCT04031599|OTHER|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
215137794|NCT04031599|OTHER|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
215137795|NCT04031599|OTHER|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
215137796|NCT04031599|OTHER|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
215137797|NCT05414526|OTHER|InterCARE package|"The InterCARE package includes:~1. Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~2. Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~3. Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
215137798|NCT01378364|DRUG|AbGn-168H|single very low dose of AbGn-168H i.v.
214452399|NCT05193786|PROCEDURE|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
214452400|NCT05650723|DRUG|Zanubrutinib Pill|320 mg once per day by mouth
215137799|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H i.v.
215137800|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
215137801|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
215137802|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
215137803|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
215137804|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H i.v.
215137805|NCT01378364|DRUG|AbGn-168H|single high dose of AbGn-168H i.v.
215137806|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H s.c.
215137807|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
215137808|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
215137809|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H s.c.
215137810|NCT00370058|PROCEDURE|ECT treatment|
215137811|NCT01740830|DEVICE|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
215137812|NCT05057611|OTHER|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
214452401|NCT05650723|DRUG|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
214452402|NCT05650723|DRUG|Obinutuzumab Injection|1000 mg IV given every 28 days
215137813|NCT05057611|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
215137814|NCT02438176|PROCEDURE|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
215137815|NCT02438176|PROCEDURE|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
215137816|NCT00654667|DRUG|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
215137817|NCT00654667|DRUG|Resveratrol|
215137818|NCT01964508|OTHER|Fine needle aspiration|
215137819|NCT02236026|DRUG|Supratherapuetic dose of Nestorone|
215137820|NCT02236026|DRUG|Placebo|
215137821|NCT02236026|DRUG|Moxifloxacin|
215137822|NCT01468558|DRUG|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
215137823|NCT01468558|DRUG|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
215137824|NCT01468558|DRUG|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
215137825|NCT01205217|DRUG|Lapatinib|Lapatinib 1000 mg orally once daily continuously
215137826|NCT01205217|DRUG|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
215137827|NCT01205217|DRUG|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
215137828|NCT01205217|DRUG|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
215137829|NCT01205217|DRUG|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
215137830|NCT00791349|DRUG|Immediate release (IR) Paliperidone|
215137831|NCT01761916|DRUG|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
215137832|NCT01761916|DRUG|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
215137833|NCT03449017|BEHAVIORAL|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
215137834|NCT04160052|DRUG|Azacitidine|Given SC or IV
215137835|NCT04160052|DRUG|Venetoclax|Given PO
215137836|NCT01259063|DRUG|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
215137837|NCT02164253|DRUG|Deferiprone|30 mg/kg per day, oral use
215137838|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
215137839|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
215137840|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 3)|Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
215137841|NCT00298012|DRUG|Methotrexate|
215137842|NCT00347022|DRUG|Xenetix|300 mg of iodine/ml
215137843|NCT00347022|DRUG|Visipaque|270 mg of iodine/ml
215137844|NCT05616286|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
215137845|NCT04943952|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Participants will receive JZP458 via intramuscular injection.
215137846|NCT00004563|DRUG|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
215137847|NCT00004563|DRUG|Placebo|Matching gelcaps 25 mgs
215137848|NCT00541372|DEVICE|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
215137849|NCT03337308|COMBINATION_PRODUCT|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
215137850|NCT03337308|DRUG|Bempedoic Acid|bempedoic acid 180 mg tablet
215137851|NCT03337308|DRUG|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
215137852|NCT03337308|DRUG|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
215137853|NCT06005688|DRUG|Vepdegestrant|Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.
215137854|NCT06005688|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
215137855|NCT04308122|DEVICE|Cervical Orthosis (CO)|Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
215137856|NCT04308122|DEVICE|No Orthosis|The NO group will have no specific precautions applied to their neck range of motion.
215137857|NCT01569191|OTHER|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
214526438|NCT06879522|BEHAVIORAL|Maximizing Energy Intervention|A licensed occupational therapist will deliver the intervention. The Maximizing Energy program combines problem-solving therapy (PST) and energy conservation education. Participants will participate in 6 virtual once/week sessions for 30 minutes. The introductory session, they will track their fatigue and identify three key fatigue-related problems. In session 2, they will prioritize one problem and practice problem-solving steps. They then implement an action plan and review progress in the next session. If the solution is ineffective, the therapist helps modify it or create a new one. If successful, the participant moves to the next problem. A MAX workbook supports learning, covering intervention details, fatigue education, energy conservation strategies, and problem-solving worksheets. The goal is to help participants apply these strategies to improve daily life and return to work.
214526439|NCT06879522|BEHAVIORAL|Health Education|To control for the effects of interactions with an interventionist, participants in the attention control group will receive the Health Education intervention. The interventionists will review a workbook covering fatigue, energy conservation, healthy eating, exercise, and relaxation. Like the MAX intervention, Health Education will be delivered virtually in weekly 30-minute one-on-one sessions for six weeks. The interventionist provides education on breast cancer-related fatigue, diet, safe physical activities, and energy conservation strategies tailored to individual needs. A workbook will support learning.
214526440|NCT06716970|DRUG|QR12000 75mg|QR12000 75mg QD
214526441|NCT06716970|DRUG|QR12000 75mg placebo|Matching placebo of QR12000 75mg QD
214526442|NCT06716970|DRUG|QR12000 150mg|QR12000 150mg QD
214526443|NCT06716970|DRUG|QR12000 150mg placebo|Matching placebo of QR12000 150mg QD
214526444|NCT06716970|DRUG|Sacubitril/valsartan 200mg|Sacubitril/valsartan 200mg QD
214526445|NCT06716970|DRUG|Sacubitril/valsartan 200mg placebo|Matching placebo of Sacubitril/valsartan 200mg QD
214526446|NCT06719934|DRUG|Dienogest 2 mg orally|2 mg Dienogest orally
214526447|NCT06719934|PROCEDURE|UAE|under local anasthesia uterine artery embolizationwill be done
214526448|NCT06720558|OTHER|Placebo probiotic|Three-week consumption of placebo probiotic capsules passed off as being actual probiotics
214526449|NCT06720558|OTHER|Open-Label Placebo probiotic|Participants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.
214526450|NCT06720558|OTHER|Control-no treatment|For the first three weeks, the Control group will not be exposed to any intervention.
215137858|NCT01569191|DEVICE|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
215137859|NCT01569191|DRUG|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
214526451|NCT06719687|DEVICE|Self-driving robotic-assisted bronchoscope|All procedures will be performed under general anesthesia with endotracheal intubation and mechanical ventilation. The self-driving robotic-assisted bronchoscope will automatically advance through airway to the target lesion according to the preoperative planning path under the guidance of electromagnetic navigation. After that, the bronchoscopist will use radial endobronchial ultrasound (rEBUS) to confirm the lesion localization. The choice of biopsy tools (eg. forceps, needles, brush, etc.) will be left to the discretion of the bronchoscopist.
214526452|NCT06720428|DEVICE|dry eye acupoint therapy instrument|The dry eye acupuncture point treatment device treat dry eye through stimulating acupuncture points by low pulse current.
214526453|NCT06720428|DRUG|Artificial tear|0.3% Ali eye drops
214526454|NCT04639960|DRUG|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
214526455|NCT04639960|DRUG|Placebo|Twelve weeks of placebo treatment.
214526456|NCT02480283|PROCEDURE|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
214526457|NCT02480283|RADIATION|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
214526458|NCT02480283|PROCEDURE|Venipuncture|To collect blood cells and serum for analyses.
214526459|NCT02480283|PROCEDURE|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
214526460|NCT02286245|OTHER|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
215137860|NCT00003149|BIOLOGICAL|recombinant interleukin-12|
215137861|NCT00691613|DRUG|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
215137862|NCT00691613|DRUG|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
215137863|NCT04225195|DRUG|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
215137864|NCT00762164|DRUG|Vytorin|Vytorin 10/80 split into 4
215137865|NCT00762164|DRUG|Simvastatin|Simvastatin 20 milligrams
215137866|NCT04692064|OTHER|There is no intervention|There is no intervention
215137867|NCT03138369|DEVICE|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
215137868|NCT03138369|DEVICE|Sham vestibular stimulation|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
215137869|NCT01269203|DRUG|Curcumin|1000 mg per day
215137870|NCT01269203|OTHER|Placebo|Administered daily same as Curcumin.
215137871|NCT05707728|DEVICE|intraoperative ultrasound|intraoperative cranial ultrasound
215137872|NCT06246292|PROCEDURE|Ultrasound-guided ESPB|The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
215137873|NCT06246292|PROCEDURE|Anatomical landmark-guided ESPB|The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
215137874|NCT02405689|DRUG|Remifentanil|
215137875|NCT02405689|DRUG|Dexmedetomidine|
215137876|NCT02405689|DRUG|Sevoflurane|
215137877|NCT06118021|DRUG|HS-20094|Administered SC
215137878|NCT06118021|DRUG|Placebo|Administered SC
215137879|NCT04094558|DEVICE|Ingestible capsule|Participants will swallow capsules and collect in stool concurrent with stool samples
215137880|NCT04094558|PROCEDURE|Sedated EGD|Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.
215137881|NCT04094558|DIAGNOSTIC_TEST|Lactulose Breath Test|Hydrogen and methane breath test with lactulose substrate
215137882|NCT00273221|PROCEDURE|Glaucoma Implant Surgery|
215137883|NCT00273221|PROCEDURE|trabeculectomy|
215137884|NCT00273221|PROCEDURE|phacoemulsification|
215137885|NCT00412334|DRUG|Copegus|1200-1600mg/day po
215137886|NCT00412334|DRUG|Copegus|1000-1200mg/day po
215137887|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
214452409|NCT05077735|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215137888|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
215137889|NCT03371667|DRUG|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
215137890|NCT03371667|DRUG|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
215137891|NCT03566602|DEVICE|Dura Sealant Patch|Adjunctive bioresorbable patch
215137892|NCT04298047|OTHER|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
215137893|NCT03094416|DRUG|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
214452410|NCT05077735|OTHER|Questionnaire Administration|Ancillary studies
215137894|NCT03094416|DRUG|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
215137895|NCT03094416|DRUG|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
215137896|NCT03690193|BEHAVIORAL|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
214452411|NCT05077735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214452412|NCT05077735|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
214452413|NCT04164316|DEVICE|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
214526461|NCT02286245|OTHER|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
214526462|NCT06914349|PROCEDURE|Antecolic gastrojejunostomy|Gastrojejunostomy in front of the transverse colon
214526463|NCT06914349|PROCEDURE|Retrocolic gastrojejunostomy|Gastrojejunostomy through the transverse mesocolon
214526466|NCT00586430|DRUG|lorazepam|single 2 mg dose of lorazepam
214526467|NCT00586430|DRUG|placebo|single dose of placebo
214452414|NCT06436560|OTHER|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
214452415|NCT06581627|DRUG|Etavopivat|2 tablets of Etavopivat will be administered in fasted state via oral route
214452416|NCT04682106|DRUG|LY3493269|Administered orally.
214452417|NCT04682106|DRUG|Placebo|Administered orally.
214452418|NCT04682106|DRUG|Salcaprozate Sodium|Administered orally.
214452419|NCT06417892|DRUG|PD-1inhibitor|PD-1 antibody was selected according to first-line drug use
214452420|NCT06417892|DRUG|Fruquintinib|a small molecular anti-tumor angiogensis drug
214452421|NCT06417892|DRUG|albumin paclitaxel|a kind of cytotoxic chemotherapy drug
214452422|NCT05349487|DEVICE|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
214452423|NCT05349487|OTHER|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
214452424|NCT05349487|DEVICE|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
214452425|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
214526468|NCT01801813|OTHER|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
214526469|NCT04641234|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
214526470|NCT06951555|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction~Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency~1. Psychoeducational module and motivational interviewing.~2. Environmental planning~3. Beginning of training in emotional self-regulation techniques.~4. Cognitive errors and cognitive discussion.~5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources.~6. Self-esteem, stigma and life goals~7. Backpack of coping resources, mindfulness and slow breathing training for anxiety~8. Stress coping techniques~9. Lifestyle~10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues.~12\. Relapse prevention"
214526471|NCT03138629|DRUG|VAL-083|VAL-083 will be administered intravenously
214526472|NCT03723057|DRUG|AG-221|Oral AG-221 administered as directed by treating physician.
214526473|NCT00153374|BEHAVIORAL|Women's health|
214526474|NCT03327025|BEHAVIORAL|Health education counseling|Health education counseling
214526475|NCT03542721|DRUG|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
214526476|NCT03542721|DRUG|Placebo of DA-5515|Placebo (three times a day)
214526477|NCT02799745|DRUG|Enzalutamide|Oral
214526478|NCT02799745|OTHER|Active Surveillance|
214526479|NCT04826744|OTHER|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
214452426|NCT05428488|DRUG|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
214452427|NCT05428488|DRUG|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
215137897|NCT05682430|BEHAVIORAL|Heart rate based HIIT|Week1,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week2,90% HRmax long duration HIIT + 90% long duration HRmax HIIT. Week3,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week4,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week5,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week6,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week7,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week8,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week9,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week10,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week11,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week12,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT.
215137898|NCT05682430|BEHAVIORAL|VIFT speed-based HIIT with mechanical work|Week1,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week2,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week3,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week4,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week5,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week6,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week7,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week8,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week9,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week10,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week11,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT. Week12,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT.
215137899|NCT01542047|DRUG|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
215137900|NCT01542047|DRUG|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
214452428|NCT05428488|DRUG|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
214452429|NCT03781141|PROCEDURE|Wound closure|Comparison of two wound closures
214452430|NCT04959487|OTHER|Food support|1\. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
214452431|NCT04959487|OTHER|Nutritional Counseling and education|2\. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
214452432|NCT05165108|DEVICE|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
214452433|NCT05452304|BIOLOGICAL|AZD7798|Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
214452434|NCT05452304|BIOLOGICAL|Placebo|Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
214452435|NCT06582446|DRUG|Androgen Deprivation Therapy (ADT) - Goserelin|"The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.~* ADT will be applied for 24 months in total~* ADT must be given concurrently and adjuvant"
214452436|NCT06582446|RADIATION|High-Dose-Rate Interstitial Brachytherapy (HDR BRT)|HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)
214452437|NCT06582446|RADIATION|radiotherapy|EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction
214452438|NCT06407284|OTHER|Produce Prescription Group|Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
214526480|NCT06452043|OTHER|PARC program|Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
214526481|NCT05982847|DIAGNOSTIC_TEST|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
215137901|NCT02677441|PROCEDURE|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
215137902|NCT02677441|PROCEDURE|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
214694886|NCT03135028|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
215137903|NCT03922100|DRUG|NMS-03592088|Route of administration: Oral
215137904|NCT06229626|OTHER|intensive reeducation|"* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks"
215137905|NCT05623124|OTHER|No intervention|No intervention
215137906|NCT03135600|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
215137907|NCT04246684|DRUG|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
215137908|NCT04246684|DRUG|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
215137909|NCT04246684|DRUG|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
215137910|NCT04246684|DRUG|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
215137911|NCT04246684|DRUG|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
214526482|NCT06082856|DRUG|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
215137912|NCT04246684|DRUG|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
215137913|NCT04246684|RADIATION|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
215137914|NCT04246684|DRUG|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
215137915|NCT04246684|DRUG|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
215137916|NCT04246684|RADIATION|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
215137917|NCT04246684|DRUG|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
215137918|NCT04246684|DRUG|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
214452439|NCT06407284|OTHER|Control Group|Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
214452440|NCT05951166|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
214452441|NCT02531126|DRUG|RPC1063|
214452442|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
214526483|NCT06082856|DRUG|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
214526484|NCT01517490|OTHER|Insulin pump|Insulin pump therapy
214526485|NCT01517490|OTHER|Multiple daily insulin injections|Multiple daily insulin injections
214526486|NCT01517490|PROCEDURE|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
214526487|NCT01517490|OTHER|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
215137919|NCT05050331|PROCEDURE|Muscle Energy Technique|MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening
215137920|NCT05050331|PROCEDURE|Trigger Point Release|Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.
214526488|NCT04125771|DIAGNOSTIC_TEST|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
214526489|NCT04125771|DIAGNOSTIC_TEST|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
214526490|NCT04591964|COMBINATION_PRODUCT|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
215137921|NCT05050331|PROCEDURE|Self-Stretching of Calf and Plantar Fascia|Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily
215137922|NCT04756427|DRUG|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
215137923|NCT04664491|BEHAVIORAL|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
215137924|NCT04664491|OTHER|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
215137925|NCT04528641|BIOLOGICAL|GRAd-COV2|Single intramuscular administration.
215137926|NCT01431612|DRUG|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
215137927|NCT01431612|DRUG|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
215137928|NCT01431612|DRUG|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
215137929|NCT04357535|DRUG|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
214526491|NCT06096818|BEHAVIORAL|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
214694887|NCT03135028|DRUG|Cytarabine|"100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle"
214694888|NCT04747808|DRUG|LL-BMT1|Drug-printed contact lens in both eyes
215137930|NCT03926286|DRUG|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
215137931|NCT05919342|DIAGNOSTIC_TEST|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
215137932|NCT01779765|DIETARY_SUPPLEMENT|PHGG|
215137933|NCT01779765|DIETARY_SUPPLEMENT|Maltodextrin|
214452443|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
215137934|NCT02878499|OTHER|polysomnography|
215137935|NCT03341299|BIOLOGICAL|LY900014|Administered SC
214452444|NCT02240472|PROCEDURE|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
215137936|NCT03341299|BIOLOGICAL|Insulin Lispro|Administered SC
215137937|NCT00299767|PROCEDURE|sequential cord blood transplantation|Infused on Day 0
215137938|NCT01891253|DEVICE|non-invasive determination of cardiac output|
214452445|NCT03436745|DRUG|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr pharmacokinetic (PK) evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
214452446|NCT03436745|DIAGNOSTIC_TEST|ECG|Screening and baseline.
214452447|NCT05154487|DRUG|Alpelisib Pill|Kinase inhibitor
214452448|NCT05154487|DRUG|Fulvestrant injection|estrogen receptor agonist
215137939|NCT06407414|OTHER|control|classical physiotherapy methods
215137940|NCT06407414|OTHER|Exercise|In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
215137941|NCT04467736|DEVICE|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
215137942|NCT05059652|DEVICE|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
215137943|NCT05757128|BEHAVIORAL|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
215137944|NCT05397145|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
215137945|NCT03685760|OTHER|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
215137946|NCT03685760|OTHER|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
215137947|NCT04710901|BEHAVIORAL|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
215137948|NCT04710901|BEHAVIORAL|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
215137949|NCT04710901|BEHAVIORAL|uTECH|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention."
215137950|NCT05411562|DIAGNOSTIC_TEST|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
215137951|NCT06546163|BEHAVIORAL|Baseline survey|Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
215137952|NCT06546163|BEHAVIORAL|Heart rate variability biofeedback|Participants randomized to the intervention arm will receive a standardized HRV sensor and accompanying smartphone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be asked to practice their HRVB skills at home for 10 minutes for two weeks.
215137953|NCT06546163|BEHAVIORAL|Educational materials|Participants randomized to the waitlist control arm will receive educational materials on eating disorders and stress management and will be sent home with these materials after completing the baseline survey. They will be encouraged to read the materials over the next two weeks before coming in for T2 survey.
214452449|NCT03661840|BEHAVIORAL|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
214452450|NCT03661840|OTHER|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
214452451|NCT06209203|DRUG|lowe-dose ZKY001 eye drops|eye drops
214452452|NCT06209203|DRUG|Medium-dose ZKY001 eye drops|eye drops
214452453|NCT06209203|DRUG|placebo|eye drops
214452454|NCT01969539|DRUG|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
214452455|NCT01969539|DRUG|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
214452456|NCT06777459|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Nitrate-rich beetroot juice, \~750 mg NO3- /d
214452457|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
214452458|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
214452459|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
214452460|NCT05092841|DRUG|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
214526492|NCT06096818|BEHAVIORAL|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
214526493|NCT04266613|DIAGNOSTIC_TEST|TruGraf® Testing|5 mL collection PAXgene blood sample
214526494|NCT02217241|OTHER|Handoff Workshop|
214526495|NCT00962221|PROCEDURE|laboratory analysis|laboratory analysis
214526496|NCT01905371|DRUG|Dextroamphetamine|
214526497|NCT01905371|OTHER|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
215137954|NCT06322160|OTHER|Interview|Interview with individual participant will take place via online videoconferencing MS Teams
215137955|NCT05891379|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
215137956|NCT05891379|DRUG|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
214452461|NCT05092841|DRUG|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
215137957|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
215137958|NCT01001975|DRUG|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
215137959|NCT01001975|DRUG|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
215137960|NCT01001975|DRUG|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
215137961|NCT06026033|DRUG|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
215137962|NCT04973124|DRUG|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
215137963|NCT04973124|DRUG|Placebo|These participants will not receive intraoperative dexmedetomidine.
215137964|NCT06396884|DEVICE|Oscillometric intermittent non-invasive blood pressure|The hemodynamic management followed liberal fluid therapy, as determined by the attending anesthetist's discretion
215137965|NCT06396884|DEVICE|ClearSight|The hemodynamic management will be conducted in accordance to a goal-directed fluid therapy (GDFT) utilizing the Clearsight system monitoring.
215137966|NCT00670215|DRUG|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
215137967|NCT00670215|DRUG|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
215137968|NCT00945009|BIOLOGICAL|Dactinomycin|Given IV
215137969|NCT00945009|DRUG|Doxorubicin Hydrochloride|Given IV
214526498|NCT01905371|DRUG|Placebo|
214526499|NCT02868619|OTHER|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
214526500|NCT02868619|OTHER|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
214526501|NCT02868619|OTHER|R-CMAS scale|Evaluate the anxiety
214526502|NCT04059913|DRUG|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
214526503|NCT03632902|DEVICE|supraglottic device|airway management will be collected
214526504|NCT00814632|DRUG|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
214526505|NCT05657275|DIAGNOSTIC_TEST|CRP dosage|multimodal algorithm
214526506|NCT05657275|DIAGNOSTIC_TEST|multiplex PCR|multimodal algorithm
215137970|NCT00945009|RADIATION|Radiation Therapy|Undergo radiation therapy
215137971|NCT00945009|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
215137972|NCT00945009|DRUG|Vincristine Sulfate|Given IV
215137973|NCT06523569|OTHER|Digital Blood Pressure Monitoring System|As a part of the bundled digital health intervention, the participant will receive instructions on how to follow a link in their electronic patient portal that will allow direct input of home blood pressure readings for clinical review.
215137974|NCT06523569|OTHER|Mobile health application|As a part of the bundled digital health intervention, the participant will be given a lifestyle change mobile health application.
215137975|NCT05387278|DRUG|EV-Pure™ and WJ-Pure™|The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
215137976|NCT05387278|DRUG|Placebo|Cryopreservation media plus standard care
215137977|NCT06220032|DRUG|Dexrazoxane|Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.
215137978|NCT06220032|DRUG|Rituximab|Day 1 Cycle 1-6: 375 mg/m2 (iv)
215137979|NCT06220032|DRUG|Cyclophosphamide|Day 1 Cycle 1-6: 750 mg/m2 (iv)
215137980|NCT06220032|DRUG|Doxorubicin|Day 1 Cycle 1-6: 50 mg/m2 (iv)
215137981|NCT06220032|DRUG|Vincristine|Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)
214526507|NCT05657275|DIAGNOSTIC_TEST|chest scan without injection|multimodal algorithm
214526508|NCT04991623|DEVICE|Kinesiology taping|We used kinesiology taping in abdominal muscles
215137982|NCT06220032|DRUG|Prednisolone|Day 1-5 Cycle 1-6: 100 mg (oral)
215137983|NCT06220032|DRUG|Lenalidomide|Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.
215137984|NCT06220032|DRUG|Pegfilgrastim|6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
215137985|NCT06147986|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
215137986|NCT06147986|OTHER|Control group|Standard-of-care for STEMI
215137987|NCT06060925|DIAGNOSTIC_TEST|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
215137988|NCT06060925|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
215137989|NCT06060925|DIAGNOSTIC_TEST|Electromyography|High density electromyography
215137990|NCT06060925|DIAGNOSTIC_TEST|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
215137991|NCT03583853|DEVICE|real time PCR|real time PCR will be used for determination of expression of autophagy genes
215137992|NCT01766453|BEHAVIORAL|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
215137993|NCT01766453|BEHAVIORAL|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
215137994|NCT04607005|DRUG|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
214526509|NCT04991623|OTHER|Conventional physiotherapy|We used conventional physiotherapy to comparate
214526510|NCT04882033|DRUG|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
214526511|NCT03809650|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
214526512|NCT05530382|OTHER|self-guided learning|video-based self-directed learning for medical device training
214694889|NCT04006743|BEHAVIORAL|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
214694890|NCT04006743|BEHAVIORAL|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
214694891|NCT04006743|BEHAVIORAL|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
215137995|NCT04607005|DRUG|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
215137996|NCT04607005|DRUG|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
215137997|NCT02142699|DRUG|Heme arginate|
215137998|NCT06585111|OTHER|Intervention|"In the first motivational interview, the HAPA Model Prenatal Motivation Interview Questionnaire, the first part of the Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, and the Breastfeeding Intention Scale for Pregnant Women Expecting Twins were applied. A brochure on breastfeeding twin babies prepared by the researcher was distributed to women. In the second interview, the HAPA Model Postpartum Motivation Interview Scale, the second part of which was the Personal Information Form, Breastfeeding Follow-up Form, Breastfeeding Motivation Scale and Postpartum Breastfeeding Self-Efficacy Scale were applied. In the third meeting, the Breastfeeding Follow-up Form was applied. Breastfeeding Motivation Scale, Postpartum Breastfeeding Self-Efficacy Scale and Breastfeeding Follow-up Form were applied in the fourth and fifth interviews, and Breastfeeding Follow-up Form was applied in the sixth interview."
215137999|NCT04482660|PROCEDURE|Positron emission tomography with 18F-RO6958948|tau PET ()
215138000|NCT05653973|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
215138001|NCT05653973|DRUG|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
215138002|NCT05305443|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
215138003|NCT05305443|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
215138004|NCT05305443|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
214526513|NCT01319864|DRUG|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
214526514|NCT02493881|DEVICE|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
214526515|NCT00082511|DRUG|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
215138005|NCT05305443|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
214526516|NCT00420563|DRUG|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
214526517|NCT00420563|DRUG|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
215138006|NCT05961722|OTHER|preoperative IV 0.9% saline 400 ml|Group 1 will be infused with IV 0.9% saline 400 mL.
214526518|NCT02004132|DRUG|Axiron|Solution administered topically using pump and applicator
214694892|NCT04006743|BEHAVIORAL|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
214694893|NCT04006743|BEHAVIORAL|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
215138007|NCT05961722|OTHER|preoperative dextrose 5% 400 ml|Group 2 will be infused with dextrose 5% Dekstroz 400 ml.
215138008|NCT05961722|OTHER|preoperative and intraoperative dextrose 5% 400 ml|Group 3 will be infused with dextrose preoperative 200 ml and intraoperative 200 ml 5% dextrose infusion.
215138009|NCT05655299|DRUG|VTX958 Dose A|Dose A
215138010|NCT05655299|DRUG|VTX958 Dose B|Dose B
215138011|NCT05655299|DRUG|VTX958 Dose C|Dose C
214526519|NCT02073721|OTHER|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
214526520|NCT02073721|OTHER|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
214526521|NCT00635570|DRUG|Ortho Tri-cyclen Lo|Low dose oral contraceptive
214526522|NCT00635570|DEVICE|NuvaRing|Contraceptive vaginal ring
214526523|NCT01363336|DRUG|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
214526524|NCT00664261|BEHAVIORAL|smoking cessation intervention|
215138012|NCT05655299|DRUG|VTX958 Dose D|Dose D
215138013|NCT05655299|DRUG|Placebo|Placebo
215138014|NCT03919773|DRUG|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
215138015|NCT03919773|DRUG|Albumin|This will be the matching placebo used in the study.
215138016|NCT04386317|DRUG|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
215138017|NCT02977403|BEHAVIORAL|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
215138018|NCT02977403|BEHAVIORAL|Sham Comparator: AB Control|"Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location"
215138019|NCT04659044|DRUG|Polatuzumab Vedotin|Given IV
215138020|NCT04659044|BIOLOGICAL|Rituximab|Given IV
215138021|NCT04659044|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
215138022|NCT04659044|DRUG|Venetoclax|Given PO
215138023|NCT04038619|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
215138024|NCT04038619|DRUG|Loperamide|Given PO
215138025|NCT05343182|OTHER|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
214526525|NCT00664261|OTHER|cancer prevention|
215138026|NCT05343182|OTHER|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
215138027|NCT04671901|DRUG|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
215138028|NCT02203903|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
215138029|NCT06041737|OTHER|consultation|nephrology consultation during 2020
215138030|NCT03564275|RADIATION|Proton Boost|13-15 treatments with proton therapy given as a boost to standard of care photon therapy
215138031|NCT05468099|OTHER|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
215138032|NCT05468099|DEVICE|High volume evacuator|High volume evacuator held by assistant to capture dental spray
215138033|NCT05468099|DEVICE|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
215138034|NCT05468099|DEVICE|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
214452462|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
214452463|NCT04931641|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
214452464|NCT04931641|OTHER|Maltodextrin|Maltodextrin (placebo)
214452465|NCT04931641|DIETARY_SUPPLEMENT|Ferrous fumarate|50 mg iron as ferrous fumarate
214452466|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
214452467|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
214452468|NCT05045196|BEHAVIORAL|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
214452469|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
214452470|NCT06063616|OTHER|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
214526526|NCT00664261|OTHER|counseling intervention|
214526527|NCT00664261|OTHER|educational intervention|
214526528|NCT00664261|OTHER|laboratory biomarker analysis|
214526529|NCT00664261|OTHER|questionnaire administration|
214526530|NCT00664261|OTHER|survey administration|
214526531|NCT00664261|PROCEDURE|study of high risk factors|
214452471|NCT06063616|OTHER|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
214452472|NCT03406871|DRUG|Regorafenib|One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.
214526532|NCT05566353|OTHER|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
214526533|NCT03494621|BEHAVIORAL|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
214526534|NCT00003502|DRUG|antineoplaston A10|
214526535|NCT00003502|DRUG|antineoplaston AS2-1|
214526536|NCT00003502|PROCEDURE|alternative product therapy|
214526537|NCT00003502|PROCEDURE|biological therapy|
214526538|NCT00003502|PROCEDURE|biologically based therapies|
214526539|NCT00003502|PROCEDURE|cancer prevention intervention|
214526540|NCT00003502|PROCEDURE|complementary and alternative therapy|
214526541|NCT00003502|PROCEDURE|differentiation therapy|
214526542|NCT05298293|DEVICE|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
214452473|NCT03406871|DRUG|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
214526543|NCT04231747|BIOLOGICAL|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
214694894|NCT02065869|BIOLOGICAL|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
214694895|NCT02065869|DRUG|Rimiducid|0.4mg/kg administered IV to treat GVHD
215138035|NCT04906122|OTHER|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling.|The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group. The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
215138036|NCT05510583|OTHER|Control group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
214694896|NCT01791868|DRUG|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
214694897|NCT01791868|DRUG|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
215138037|NCT05510583|OTHER|Treated group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
215138038|NCT05417438|BEHAVIORAL|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
215138039|NCT03426670|DEVICE|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
215138040|NCT02257593|OTHER|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
215138041|NCT02845297|DRUG|pembrolizumab|Intravenous pembrolizumab
214452474|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy for Couples|"Interpersonal Psychotherapy for Couples (IPT-C) consists of 8 weekly conjoint sessions. The clinical goals are to promote resolution of the role dispute via renegotiation of role relations between the marriage partners and improve common mental disorders in the woman. Like Interpersonal Psychotherapy, IPT-C has an initiation phase (Session 1-2), middle phase (Sessions 3-6), and termination phase (Sessions 7-8)."
214452475|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy (Individual)|Interpersonal Psychotherapy (IPT) is an evidence-based treatment to reduce depression and other common mental disorders. It focuses on helping patients resolve interpersonal problems of disagreements, loneliness, life changes, and grief, and/or change their orientation to the problem.
214526544|NCT00675038|PROCEDURE|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
214452476|NCT06541431|OTHER|Abdominal Drainage Fluid Collection|Abdominal drainage fluid will be collected daily from the subjects until they are discharged from the hospital, or their abdominal/pelvic drain is removed, as determined by the treating surgeon.
214526545|NCT06127940|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
214526546|NCT06127940|DRUG|Temporary Stopping|Temporary stop of sotorasib during SBRT
214526547|NCT02652390|DRUG|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
214526548|NCT02652390|DRUG|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
214526549|NCT02652390|OTHER|Saline|2 mL saline + 1 mL lidocaine
215138042|NCT02845297|DRUG|Azacitadine|Intravenous or subcutaneous
215138043|NCT06594536|DIETARY_SUPPLEMENT|Sulforaphane|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
215138044|NCT06594536|OTHER|Placebo|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
215138045|NCT06586996|OTHER|no intervention|no intervention
215138046|NCT06593301|OTHER|Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training|Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)
215138047|NCT05307874|DRUG|ICT01|anti-BTN3A mAb IV Q3W
215138048|NCT05307874|DRUG|Proleukin Injectable Product|1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
215138049|NCT05307874|DRUG|Pembrolizumab injection|200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W
215138050|NCT05762757|OTHER|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
215138051|NCT04053036|DRUG|MDMA|Participants will be given 1.5mg/kg of MDMA
215138052|NCT04053036|DRUG|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
215138053|NCT06589921|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
215138054|NCT06589921|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
215138055|NCT06600295|OTHER|tests/questionnaires|EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
214452477|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
215138056|NCT06600295|BIOLOGICAL|biological samples|blood, saliva, tongue mucus
215138057|NCT06600295|OTHER|evaluation|strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
215138058|NCT06586073|OTHER|cosmetic products|All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream.
215138059|NCT06588335|DRUG|BTLA inhibitor (JS004)|BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
215138060|NCT06588335|DRUG|Toripalimab|Toripalimab:240mg,intravenous infusion, d1, Q3W;
215138061|NCT06588335|DRUG|Paclitaxel, Cisplatin|Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
215138062|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow|All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.
214452478|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
214452479|NCT06125704|BEHAVIORAL|Moderate intensity walking or stepping|30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
214452480|NCT03850366|DRUG|Bortezomib|GVHD prophylaxis
214526550|NCT04387903|PROCEDURE|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
214526551|NCT01586533|DRUG|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
214526552|NCT01586533|DRUG|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
214526553|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
214526554|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
215138063|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol|For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
215138064|NCT06598826|DEVICE|Graston technique (IASTM)|Group A includes 26 patients post ND who received Graston technique (IASTM) , in additional to traditional treatment (ROM exercise, strengthening exercise, and stretching exercise) for 1 month
215138065|NCT06598826|OTHER|Kinesio taping|Group B includes 26 patients who received Kinesiotaping, in addition to traditional treatment (ROM exercise, strengthening exercise, and stretching exercises) for 1 month
215138066|NCT06589375|DIAGNOSTIC_TEST|Sniffin'Sticks|The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.
215138067|NCT06589947|OTHER|Intensified BP control|Treatment goal in the intensified group will be lowering BP ≤60th pct.
215138068|NCT06589947|OTHER|Standard Treatment|Standard treatment is to achieve BP levels \&lt;90th pct.
215138069|NCT06597045|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels)."
215138070|NCT06592690|OTHER|Atrial pacing support|Use a pacing mode with atrial pacing including a rate-resposive sensor.
215138071|NCT06592690|OTHER|Atrial tracking pacing mode|A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
215138072|NCT06603467|PROCEDURE|non-guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested without guide
215138073|NCT06603467|PROCEDURE|guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested with digital guide
215138074|NCT06592469|PROCEDURE|Ureteroscopy|URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter
215138075|NCT06600334|DIAGNOSTIC_TEST|dexa scan|Bone density scans
215138076|NCT06601088|DEVICE|Neuromuscular Electrical Stimulation|Patients will be instructed to apply the wearable NMES-therapy continuously, both day and night at least 10h/daily.
215138077|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Superficial skin biopsy Skin swab
215138078|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
215138079|NCT06589856|DIETARY_SUPPLEMENT|Placebo|Placebo (300 mL salt water, NaCl) = CTR
215138080|NCT06589856|DIETARY_SUPPLEMENT|LAC5|5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
215138081|NCT06589856|DIETARY_SUPPLEMENT|LAC10|10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
215138082|NCT06589856|DIETARY_SUPPLEMENT|LAC20|20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
215138083|NCT06612944|DRUG|Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation|"1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1"
215138084|NCT06003283|DRUG|Rituximab|IV rituximab
215138085|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with obstetric care providers
215138086|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with study RN.
215138087|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine and beetroot juice|Combined effect of beetroot juice and caffeine intake on muscular strength, power and endurance performance
215138088|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine|single effect of caffeine intake on muscular strength, power and endurance performance
215138089|NCT06596395|DIETARY_SUPPLEMENT|Acute beetroot juice|single effect of beetroot juice intake on muscular strength, power and endurance performance
215138090|NCT06596395|DIETARY_SUPPLEMENT|Placebo|single effect of placebo on muscular strength, power and endurance performance
215138091|NCT02360579|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
215138092|NCT06998212|BEHAVIORAL|Offer to record encounter|Patient will be given the option to record their clinical encounter on their personal smartphone
215138093|NCT06600464|DIAGNOSTIC_TEST|Ultrasound|The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound.
214452481|NCT05274347|OTHER|Muti-faceted virtual, remote intervention|Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
215138094|NCT06600464|OTHER|Assessment of Muscle Strength in Both Hands|Muscle strength in both hands was evaluated using grip strength measured with a dynamometer (Jamar Hydraulic Hand Dynamometer, Nottinghamshire, UK)
215138095|NCT06600464|OTHER|Assessment of Pain Threshold|Pressure pain threshold (PPT) for painful and non-painful finger joints was assessed using a hand-held algometer
215138096|NCT06997991|PROCEDURE|adipose micro-grafts injection|Patients were positioned supine, and local anesthesia was administered. A small incision was made to introduce a blunt cannula attached to a Luer-lock 60-cc syringe. Klein sterile solution, containing saline and lidocaine, was injected into the subcutaneous fat layer of either the abdominal or thigh region. Subsequently, approximately 30 mL of adipose tissue was extracted. The collected lipoaspirate was processed under sterile conditions in a closed system using Rigenera® technology (HBW, Turin, Italy). Before injecting, the skin was sterilely dressed, and the injection of 2-3 mL of aMAT was performed into TMC joint with a superolateral approach, under fluoroscopic X-ray guidance and using a disposable 20G needle and a 3 mL Luer-Lock Syringe.
215138097|NCT06589492|DIAGNOSTIC_TEST|Measurement of MMP-9 and SIRT-1 levels in blood serum|Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
215138098|NCT06999057|DEVICE|Joint Effusion via 60 mL Sterile Saline|Injection of sterile saline into the knee joint to simulate joint swelling and induce quadriceps inhibition.
214452482|NCT04702529|DEVICE|Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)|Administration of 3 Rapid Acoustic Pulse (RAP) treatments
214452483|NCT04588298|DRUG|AZD9833|AZD9833 tablets will be administered orally.
214452484|NCT04157231|OTHER|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
214452485|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
214452486|NCT05652322|DRUG|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
214452487|NCT05652322|DRUG|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
214452488|NCT05652322|DRUG|Furosemide Injection|change from intravenous to oral furosemide
214452489|NCT06327646|DRUG|Multiple Micronutrient Supplement Blister|MMS in a blister pack along with related job aids, counselling during ANC, etc.
214452490|NCT06327646|DRUG|Multiple Micronutrient Supplement Bottle|MMS in bottles along with related job aids, counselling during ANC, etc.
214452491|NCT06327646|DRUG|Iron Folic Acid Blister|Standard of Care - IFA in a blister pack along with related job aids, counselling during ANC, etc.
214452492|NCT05669430|BIOLOGICAL|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
214526555|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
215138099|NCT06999057|DRUG|Intra-articular Lidocaine|Injection of 7 mL lidocaine into the knee joint to simulate deafferentation by temporarily blocking sensory input.
215138100|NCT06999057|OTHER|Sham injection|Simulated knee injection using a stage needle without skin penetration, used to blind participants and serve as control.
215138101|NCT06998823|COMBINATION_PRODUCT|Probiotics|Participants will intake 90days Probiotics
214452493|NCT05669430|BIOLOGICAL|GV20-0251|GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
214452494|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
214452495|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
214452496|NCT03781700|DRUG|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
214526556|NCT01583738|DRUG|V0251|single dose
214526557|NCT01583738|DRUG|placebo|single dose
214526558|NCT00347737|DRUG|teriparatide|Teriparatide
214526559|NCT00729053|DRUG|IMO-2055|immunostimulatory oligonucleotide
214526560|NCT02712307|DRUG|Phenoxymethylpenicillin|
215138102|NCT06998849|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is defined as the ratio of pulsatile light absorption to continuous light absorption, denoted as AC/DC. Initially used as a quality signal indicator in pulse oximetry, PI has increasingly been recognized for its potential in non-invasive hemodynamic monitoring. Since PI changes with peripheral blood flow, it may reflect peripheral temperature gradients and, consequently, thermoregulatory responses like peripheral vasoconstriction. Studies have reported that the core-to-peripheral temperature difference correlates with peripheral PI. The findings suggest that both peripheral and core temperatures contribute to the threshold for shivering and that PI reflects the vasoconstriction induced by thermoregulatory responses that precede shivering
215138103|NCT06601530|PROCEDURE|Transversus Thoracic Muscle Plane Block|Transversus thoracic muscle plane block is a single-shot nerve block technique that provides analgesia for the anterior chest wall Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
215138104|NCT06601530|DRUG|Tramadol|Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
215138105|NCT06998459|OTHER|Bian-Stone therapy|Once a week, each session lasting 30 minutes, for a duration of six months.
215138106|NCT06998459|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
215138107|NCT06999837|RADIATION|[68Ga]Ga-PSMA-11|Dynamic whole-body \[68Ga\]Ga-PSMA acquisition to HCC patients
215138108|NCT06084026|OTHER|ActivPal|Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
215138109|NCT04093297|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
215138110|NCT05342961|PROCEDURE|spinous balloon dilatation catheter (Plastic-Blade)|To treat Coronary artery disease
215138111|NCT05342961|PROCEDURE|spinous balloon dilatation catheter(lacrosse NSE)|To treat Coronary artery disease
214452497|NCT03781700|DRUG|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
214452498|NCT05683756|BEHAVIORAL|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
214452499|NCT05683756|BEHAVIORAL|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
214452500|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
214452501|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
214452502|NCT03869996|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
214452503|NCT03869996|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
214452504|NCT06524687|DRUG|Imvotamab|Administered intravenously
214452505|NCT05593510|BEHAVIORAL|No prep ready-to-eat meals|"Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference."
214452506|NCT05593510|BEHAVIORAL|Ingredient bundles (e.g. meal kits)|Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
214526561|NCT03583411|OTHER|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
214526562|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
214526563|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
214526564|NCT02303002|BIOLOGICAL|Botulinum Toxin Type A|Intramuscular injection (IM)
214526565|NCT02303002|BIOLOGICAL|Active Comparator botulinum toxin|IM injection
214526566|NCT02303002|BIOLOGICAL|Placebo Comparator|IM injection
214526567|NCT02760472|DRUG|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
214526568|NCT02760472|DRUG|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
215138112|NCT06276322|OTHER|Low back pain group|The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
215138113|NCT06276322|OTHER|Healthy group|Low back pain kinematics compare them with asymptomatic kontrols
215138114|NCT05943834|OTHER|Series of cognitive tasks during a semi-automated call|"Tasks:~* Verbal learning recall (immediate) or Story Recall task (immediate)~* Narrative Storytelling /free speech~* Verbal fluency task~* Verbal learning recall (delayed) or Story Recall task (delayed)"
215138115|NCT05860946|DEVICE|Remote ischemic conditioning|The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
215138116|NCT02081781|PROCEDURE|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
215138117|NCT02609919|DRUG|Gadoteric Acid|MRI Contrast Agent
215138118|NCT02874872|BEHAVIORAL|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
215138119|NCT00727467|DEVICE|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
215138120|NCT01212835|PROCEDURE|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
215138121|NCT01212835|PROCEDURE|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
215138122|NCT00509054|PROCEDURE|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
215138123|NCT03593746|OTHER|Physical training|Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
215138124|NCT03593746|OTHER|Light-Emitting Diode (LED) therapy|Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
215138125|NCT02886819|OTHER|vibration|Whole body vibration
215138126|NCT03059134|DRUG|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
215138127|NCT00018148|DRUG|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
215138128|NCT00018148|DRUG|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
215138129|NCT03863795|OTHER|Survey Administration|Respond to SurveyGizmo survey online
215138130|NCT04948216|OTHER|No intervention|No intervention
214526569|NCT05114369|PROCEDURE|Curative surgery|
214526570|NCT00092313|DRUG|MK0966, rofecoxib|
214526571|NCT00092313|DRUG|Comparator: oxycodone and acetaminophen|
214526572|NCT02985034|PROCEDURE|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
214526573|NCT03749148|DRUG|Dupilumab|anti-IL4-Receptor alpha
214526574|NCT03749148|DRUG|Placebo|Placebo
214526575|NCT03158935|DRUG|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
214526576|NCT03158935|DRUG|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
214526577|NCT03158935|PROCEDURE|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
214526578|NCT03158935|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
214526579|NCT03158935|BIOLOGICAL|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
214526580|NCT03590717|BEHAVIORAL|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
215138131|NCT00641433|DEVICE|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
215138132|NCT00641433|DRUG|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
215138133|NCT02994108|BEHAVIORAL|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
215138134|NCT02994108|BEHAVIORAL|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
215138135|NCT01156662|DEVICE|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
215138136|NCT01156662|DEVICE|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
215138137|NCT00781768|DRUG|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
215138138|NCT00781768|DRUG|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
215138139|NCT01395797|DRUG|PIO|0, 15, and 45 mg per day.
215138140|NCT01395797|DRUG|Placebo|Placebo
214452507|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
214452508|NCT06353321|DIAGNOSTIC_TEST|PET-CT imaging subsystem of the RefleXion X1 System Device|Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners
214452509|NCT06078514|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
214452510|NCT05153759|OTHER|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
214452511|NCT04830397|DRUG|QLS-101|Ophthalmic solution 1x daily
214452512|NCT04830397|DRUG|Timolol Maleate|Ophthalmic solution 1x daily
214452513|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
214452514|NCT03170453|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
214452515|NCT03170453|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
214452516|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
214452517|NCT02673424|PROCEDURE|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
214452518|NCT02673424|PROCEDURE|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)"
214452519|NCT04899011|OTHER|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
214452520|NCT05051098|OTHER|No intervention|No intervention
214452521|NCT06260514|DRUG|APR-1051|WEE1 Inhibitor
214526581|NCT03590717|OTHER|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
214526582|NCT03590717|OTHER|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
214526583|NCT03330171|BIOLOGICAL|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
214526584|NCT03330171|BIOLOGICAL|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
214526585|NCT03330171|BIOLOGICAL|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
214526586|NCT01585818|OTHER|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
214452522|NCT03398876|DRUG|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
214452523|NCT03398876|DRUG|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
214452524|NCT03398876|OTHER|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
214452525|NCT06155669|DEVICE|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
214452526|NCT06035679|DRUG|Pyrotinib and Trastuzumab|Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
214452527|NCT05557409|DRUG|AXS-05|AXS-05 tablets, taken twice daily
214452528|NCT05557409|DRUG|Placebo|Placebo tablets, taken twice daily
215138141|NCT04567628|OTHER|No Intervention|As this was an observational study, no intervention was administered.
214452529|NCT01747863|OTHER|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
214452530|NCT04531059|DRUG|Esomeprazole|Proton pump inhibitor
214526587|NCT01585818|OTHER|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
214526588|NCT02514577|DRUG|IDP-122 Lotion|Topical lotion
214526589|NCT02514577|DRUG|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
215138142|NCT00150436|DRUG|Pregabalin|
215138143|NCT02025686|DRUG|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
215138144|NCT02025686|OTHER|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
215138145|NCT05882591|PROCEDURE|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
215138146|NCT00079417|DRUG|Carboplatin|Given IV
215138147|NCT00079417|PROCEDURE|Cryosurgery|
215138148|NCT00079417|PROCEDURE|Infrared Laser Therapy|
214452531|NCT04531059|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214452532|NCT04531059|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
214526590|NCT03053115|DRUG|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
215138149|NCT00079417|RADIATION|Iodine I-125|Undergo radioactive therapy
215138150|NCT00079417|RADIATION|Radiation Therapy|Undergo radioactive therapy
215138151|NCT00079417|RADIATION|Ruthenium Ru-106|Undergo radioactive therapy
215138152|NCT00079417|DRUG|Vincristine Sulfate|Given IV
215138153|NCT00896896|OTHER|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
215138154|NCT00896896|OTHER|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
214526591|NCT03053115|DRUG|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
214526592|NCT03053115|DRUG|Placebos|Controls will take placebo two hours after dinner
214526593|NCT01730547|BIOLOGICAL|Autologous mesenchymal stem cells|
214526594|NCT02907450|DEVICE|TwiCare®.|
214526595|NCT00003162|PROCEDURE|pain therapy|
214526596|NCT00003162|RADIATION|radiation therapy|
215138155|NCT00000827|DRUG|Anti-HIV Immune Serum Globulin (Human)|
215138156|NCT04004741|PROCEDURE|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
215138157|NCT04004741|PROCEDURE|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
215138158|NCT02027155|DRUG|AR09 solution|moderate levels of sedation
215138159|NCT02027155|DRUG|placebo|Sterile Saline, USP
215138160|NCT02458313|DRUG|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
215138161|NCT02458313|OTHER|Placebo|Placebo capsules b.i.d. for 12 weeks
215138162|NCT00170586|DEVICE|Underglove coating (skin barrier)|
215138163|NCT05684237|PROCEDURE|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
214452533|NCT04531059|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
214452534|NCT06231810|BEHAVIORAL|Tactile stimulation|Tactile stimuli of differing magnitudes will be applied
214452535|NCT05480995|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
214452536|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
214452537|NCT06074666|BEHAVIORAL|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
214452538|NCT06074666|BEHAVIORAL|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
215138164|NCT05527977|BEHAVIORAL|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H\&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
214452539|NCT01181375|OTHER|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
214452540|NCT02120456|DRUG|LEO 43204|
214452541|NCT02120456|DRUG|Placebo|
214452542|NCT06788223|DEVICE|Parathyroidectomy|Parathyroidectomy under general anesthesia
214452543|NCT05302934|DEVICE|Pheno4U|Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
214452544|NCT06515665|BEHAVIORAL|therapeutic foot orthosis|They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
214452545|NCT00606996|BEHAVIORAL|Group interpersonal psychotherapy (IPT-G)|
214452546|NCT00606996|BEHAVIORAL|Psychoeducation on co-occurring disorders (PSYCHOED)|
214452547|NCT03651076|DEVICE|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
214452548|NCT06150040|DRUG|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
214452549|NCT06150040|DRUG|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
214452550|NCT06150040|DRUG|Venetoclax|Orally, 70 mg, every day on Days 1-28
214452551|NCT05754437|DEVICE|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
214452552|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
214452553|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
214452554|NCT05527392|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
214452555|NCT05697146|OTHER|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
214694898|NCT01583322|DRUG|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
214452556|NCT05520190|BEHAVIORAL|Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)|"The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment."
214452557|NCT05991284|DRUG|Sacubitril-valsartan|sacubitril-valsartan (target dose 97/103 mg twice daily)
214452558|NCT05991284|DRUG|Standard of care|including SGLT-2 inhibitor and MRA
214452559|NCT06219135|OTHER|no intervention - Contamination group|there is no intervention for this group of patients
214452560|NCT06219135|BIOLOGICAL|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
214452561|NCT06219135|OTHER|no intervention - Emergency group|there is no intervention for this group of patients
214452562|NCT06397040|DEVICE|provider monitoring and feedback to remote data|provider monitoring of remote data and feedback to changes in remote data
214452563|NCT06397040|DEVICE|participant monitoring of remote data|participant monitoring of remote data, based upon post-operative instructions
214452564|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
214452565|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
214452566|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
215138165|NCT02558959|DRUG|Irinotecan|
214452567|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
214452568|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
215138166|NCT02558959|DRUG|Capecitabine|
215138167|NCT04017052|DRUG|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
215138168|NCT02081677|DEVICE|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
215138169|NCT02081677|DEVICE|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
215138170|NCT02081677|DEVICE|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
215138171|NCT02081677|DEVICE|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
215138172|NCT04174417|PROCEDURE|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
215138173|NCT04174417|PROCEDURE|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
215138174|NCT00904969|DEVICE|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
214452569|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
214452570|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
214452571|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
214452572|NCT03476187|DEVICE|µCor|Monitor with µCor
214452573|NCT05827926|BIOLOGICAL|Influenza Vaccine 1|quadrivalent seasonal influenza vaccine
214452574|NCT05827926|BIOLOGICAL|mRNA-1083.1|Sterile liquid for injection
214452575|NCT05827926|BIOLOGICAL|mRNA-1083.2|Sterile liquid for injection
214452576|NCT05827926|BIOLOGICAL|mRNA-1083.3|Sterile liquid for injection
214452577|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 1|Sterile liquid for injection
214452578|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 1|Sterile liquid for injection
214452579|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 1|Sterile liquid for injection
214452580|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 2|Sterile liquid for injection
214452581|NCT05827926|BIOLOGICAL|Influenza Vaccine 2|quadrivalent seasonal influenza vaccine
214526597|NCT03756025|PROCEDURE|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
214526598|NCT06171503|BEHAVIORAL|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
214526599|NCT02552810|DEVICE|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
214526600|NCT02552810|DEVICE|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
214526601|NCT05692271|DRUG|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
214526602|NCT05692271|DRUG|Placebo|Matching placebo
215138175|NCT00904969|DEVICE|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
215138176|NCT04267354|OTHER|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
214452582|NCT05827926|BIOLOGICAL|mRNA-1083|Sterile liquid for injection
214452583|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 2|Sterile liquid for injection
214526603|NCT04816708|BEHAVIORAL|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
214526604|NCT02533349|DRUG|Motilitone|30mg, 1 tablet, 3 times a day
215138177|NCT02947321|PROCEDURE|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
215138178|NCT02947321|PROCEDURE|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
215138179|NCT03502928|OTHER|Motor Control|Neck Motor Control
215138180|NCT03502928|OTHER|Manual Therapy|Massage + Joint Mobilizations
215138181|NCT03502928|OTHER|Dry Needling|Dry Needling in Neck Muscles
215138182|NCT05602246|PROCEDURE|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
214452584|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 2|Sterile liquid for injection
214452585|NCT04959201|DRUG|NMDAE plus AO|Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
214452586|NCT04959201|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator.
214452587|NCT05686499|OTHER|Didactic Lectures and demonstrations|"1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
214452588|NCT05836168|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair|multispecies probiotic
214452589|NCT05836168|DIETARY_SUPPLEMENT|Placebo|Placebo
214526605|NCT02533349|DRUG|Pantoprazole|40mg, 1 tablet, 1time a day
214526606|NCT02533349|DRUG|Placebo|30mg, 1 tablet, 3 times a day
214526607|NCT00229086|DEVICE|Gatekeeper Reflux Repari System (Device)|
215138183|NCT05602246|PROCEDURE|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
215138184|NCT01843829|DRUG|Oxaliplatin|
214452590|NCT05116709|DRUG|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
214452591|NCT06816667|DRUG|BMND08|Participants will receive a sublingual dose of 5-MeO-DMT once a week for four consecutive weeks. The intervention will be administered in the form of a sublingual tablet. The substance 5-MeO-DMT, a potent tryptamine, is known for its psychoactive properties but will be administered at a dose that does not induce a full psychedelic experience.
214452592|NCT06816667|PROCEDURE|Brain electrical activity monitor|EEG is a technique used to monitor brain electrical activity by recording brain waves through electrodes placed on the scalp. This procedure allows the assessment of brain waves such as delta, theta, alpha, and beta, specifically to evaluate the changes in brain activity following sublingual administration of 5-MeO-DMT.
214452593|NCT06816667|DIAGNOSTIC_TEST|Pharmacokinetic Study of Sublingually Administered Psychoactive Substance|For pharmacokinetic analysis, approximately 6 mL of EDTA blood will be collected to assess the pharmacokinetics of a sublingual dose of 5-MeO-DMT. Samples will be obtained at baseline (pre-dose, 0 minutes) and at the following time points post-dose: 5, 10, 20, 30, 40, 50, 60, and 120 minutes.
214526608|NCT05033899|OTHER|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
214526609|NCT04680793|OTHER|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
215138185|NCT01843829|DRUG|Capecitabine|
215138186|NCT01843829|DRUG|Carboplatin|
215138187|NCT01843829|DRUG|Paclitaxel|
215138188|NCT01843829|RADIATION|Radiotherapy|
215138189|NCT01843829|PROCEDURE|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
215138190|NCT01097668|BIOLOGICAL|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
215138191|NCT04396756|DRUG|PLN-74809|PLN-74809
215138192|NCT04396756|DRUG|Placebo|Placebo
215138193|NCT02405078|DRUG|Chemotherapy|Given standard salvage chemotherapy
215138194|NCT02405078|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT scan
215138195|NCT02405078|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
215138196|NCT02405078|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT scan
215138197|NCT04363008|DIAGNOSTIC_TEST|serum inflammatory biomarkers|Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)
215138198|NCT00189722|DRUG|Tacrolimus|
215138199|NCT03712696|DEVICE|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
215138200|NCT05684835|PROCEDURE|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
215138201|NCT00199381|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
214452594|NCT06816667|DIAGNOSTIC_TEST|Biochemical determinations|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
214452595|NCT06816667|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
214452596|NCT06816667|DIAGNOSTIC_TEST|vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment
214452597|NCT06816667|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will undergo the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) for attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to assess any cognitive changes in response to the different doses of 5-MeO-DMT (6 mg, 9 mg, 12 mg) or placebo, helping to determine how the intervention may influence cognitive processing, memory, and attention.
214526610|NCT05373225|DEVICE|Acetic acid shockwave phonophoresis therapy|This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
214526611|NCT05373225|DEVICE|Shock wave Therapy|This group composed of subjects and represented the control group who will receive shock wave therapy
214526612|NCT05373225|OTHER|conventional physical therapy program|"Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise"
214526613|NCT04200404|DRUG|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
215138202|NCT02137746|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
215138203|NCT03140241|PROCEDURE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
215138204|NCT03828825|OTHER|Patent Foramen Ovale closure|"The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care."
215138205|NCT00485979|DRUG|larotaxel (XRP9881)|intravenous administration
215138206|NCT00485979|DRUG|docetaxel|intravenous administration
214526614|NCT04200404|DRUG|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
214526615|NCT04467398|PROCEDURE|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
214526616|NCT04922645|DRUG|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
214694899|NCT01583322|DRUG|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
214694900|NCT04757935|BEHAVIORAL|Yoga|Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
215138207|NCT00485979|DRUG|trastuzumab|intravenous administration
215138208|NCT03074136|DEVICE|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
215138209|NCT03074136|DEVICE|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
215138210|NCT03074136|DRUG|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
215138211|NCT02473848|DRUG|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
215138212|NCT05864859|OTHER|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
215138213|NCT00603408|DRUG|Cisplatin|
215138214|NCT00603408|RADIATION|Radiation Therapy|
215138215|NCT00603408|PROCEDURE|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
215138216|NCT00381901|BIOLOGICAL|trastuzumab|
215138217|NCT00381901|GENETIC|polymorphism analysis|
215138218|NCT00381901|PROCEDURE|adjuvant therapy|
214452598|NCT06816667|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
214452599|NCT04044859|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
214452600|NCT06838286|DRUG|SGLT2 inhibitor|SGLT2 inhibitor class of drugs
214452601|NCT06838286|DRUG|Thiazolidinedione|Thiazolidinedione class of drugs
214452602|NCT06838286|DRUG|DPP-4 inhibitor|DPP4 inhibitor class of drugs
214452603|NCT04123847|OTHER|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
214452604|NCT04123847|DEVICE|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
214452605|NCT06827964|DIETARY_SUPPLEMENT|Soy-based Nutrition Package|Dry, vacuum-sealed sachets containing yellow powder, odorless, to be consumed with warm water. Each 12g sachet provides: 209 kJ energy, 3.1g protein, 1.7g fat, 4.6g carbohydrates, 3mg sodium, 200mg calcium, 7.5mg iron, 3mg zinc, 250μg RE vitamin A, 5μg vitamin D, 0.5mg vitamin B1, 0.5mg vitamin B2, 0.5μg vitamin B12, and 75μg folate. Intervention duration: 6 months, with 2 sachets per day. Produced by Tiantianai (Jiangsu) Biotechnology Co., Ltd., a certified supplier for maternal and child nutrition projects in China.The company has a Class D production workshop that meets the latest GMP standards for pharmaceuticals. The product has passed certifications for Food Safety Management System (ISO 22000) and Quality Management System (ISO 9001).
214526617|NCT04922645|DRUG|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
214526618|NCT04794894|BEHAVIORAL|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
214526619|NCT02388932|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214694901|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
214526620|NCT02388932|DEVICE|Positron Emission Tomography|Undergo PET/CT
214526621|NCT02388932|DEVICE|Computed Tomography|Undergo PET/CT
214526622|NCT02388932|OTHER|Quality-of-Life Assessment|Ancillary studies
214526623|NCT04174222|OTHER|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
214694902|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
214526624|NCT04174222|OTHER|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
214526625|NCT04031196|PROCEDURE|QLB|QLB type 2 approach
214526626|NCT04031196|PROCEDURE|TAP block|classic TAP block approach
214526627|NCT00199160|DRUG|BAY 43-9006|
214526628|NCT05842915|BEHAVIORAL|Questionnaire|Baseline and 3 month questionnaire
214526629|NCT02490059|OTHER|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
214526630|NCT01486277|DRUG|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
214694903|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
214694904|NCT03712163|DRUG|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
215138219|NCT00436696|OTHER|Laboratory Biomarker Analysis|Correlative studies
215138220|NCT01786005|DEVICE|Transcranial magnetic stimulation|
215138221|NCT05949736|DEVICE|The Online intervention platform|Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.
215138222|NCT03520829|DEVICE|Intuitive Plan|dosimetric planning software
215138223|NCT00385671|DRUG|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
215138224|NCT00385671|DRUG|pregabalin|Pregabalin (PGB) orally (PO)
215138225|NCT00385671|DRUG|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
215138226|NCT06403397|OTHER|Experimental group: CEASE Care Package and Remember Me Tool|"Before the intervention, the intervention group will first undergo the 'Nurse Identification Form' and the 'Alarm Fatigue Scale'. The current root cause analysis of monitor alarms in the clinical setting will be conducted through the 'CEASE Care Package' and the 'Current Situation Analysis Form'. Each patient monitor in the intensive care unit will be observed and recorded by two observers for a period of 24 hours.The Monitor Alarm Control Tool - Remember Me will be attached beneath each monitor to facilitate easier monitoring by nurses. Nurses are expected to use the tool for a period of 15 days. After intervention; Two observers will conduct a re-evaluation using the CEASE Care Package and the Current Status Analysis Form. Monitor alarms will be continuously assessed and recorded for 24 hours. Following the completion of this stage, the Alarm Fatigue Scale will be reapplied to the intervention group."
215138227|NCT01940952|DRUG|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
215138228|NCT01940952|DRUG|Placebo + Donepezil 5mg or 10mg|
215138229|NCT01940952|DRUG|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
215138230|NCT00698763|DRUG|Levosimendan|from 0.125 mg to 2 mg in escalating doses
215138231|NCT00698763|DRUG|Placebo|Placebo capsules are identical in appearance to active capsules
214452606|NCT06827964|DIETARY_SUPPLEMENT|Probiotics|Dry, vacuum-sealed sachets containing white powder, odorless. Each 2g sachet contains 500\*10\^9 CFU of Lactobacillus plantarum LLY-606 and Pediococcus pentosaceus JQI-7. Intervention duration: 6 months, with 1 sachet per day. Produced by Jiangsu Wecare Biotechnology Co., Ltd., compliant with international standards (cGMP, FSSC 22000, HACCP, ISO 22000, ISO 9001).
214452607|NCT06838195|BIOLOGICAL|S. Flexneri-S. Sonnei bivalent conjugate vaccine|Subjects receive two doses of the vaccine on the day of randomisation (day 0) and day 30.
214452608|NCT06838195|BIOLOGICAL|Placebo|Subjects receive two doses of the placebo on the day of randomisation (day 0) and day 30.
214452609|NCT06158503|DEVICE|AID|Initiation of an automated insulin delivery system
214452610|NCT06097520|OTHER|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
214452611|NCT05791968|PROCEDURE|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
214526631|NCT06041178|DRUG|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
214526632|NCT06041178|DRUG|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
214526633|NCT06041178|OTHER|Placebo|saline
214526634|NCT06442293|DIETARY_SUPPLEMENT|Treatment 1|A dietary supplement containing beet root extract, arginine and citrulline
214526635|NCT06442293|DIETARY_SUPPLEMENT|Treatment 2|A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
214694905|NCT03712163|DRUG|Placebo Oral Capsule|Placebo
214694906|NCT03437772|BEHAVIORAL|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
214694907|NCT02021058|OTHER|Experimental Formula|Experimental formula
214694908|NCT02021058|OTHER|Standard control formula|Standard Infant formula
215138232|NCT04944992|DRUG|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
215138233|NCT04944992|DRUG|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
215138234|NCT05781542|BIOLOGICAL|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
215138235|NCT05781542|BIOLOGICAL|IL-12 DNA|0.1 mg or 0.4 mg
214526636|NCT06442293|DIETARY_SUPPLEMENT|Placebo|a placebo supplement that is similar in appearance to treatment 1
215138236|NCT05781542|BIOLOGICAL|Trimer 4571|100 mcg
214452612|NCT06132035|DRUG|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
214452613|NCT06132035|DRUG|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
214452614|NCT06132035|DRUG|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
214452615|NCT06836843|OTHER|Since this is an observational study rather than an interventional study, the exposure type refers to all potential factors influencing pregnancy both before and during pregnancy|"Since this is an observational study rather than an interventional study or clinical trial, the exposure type refers to all potential factors influencing pregnancy both before conception and during pregnancy. These exposures include:~Lifestyle habits: Such as obesity, smoking and alcohol use before and during pregnancy.~Sociodemographic factors: Such as age, residence, medical insurance. Medications: Any prescription, over-the-counter, or herbal medications used before or during pregnancy.~Past medical history: Pre-existing medical conditions or illnesses, such as hypertension, diabetes, or autoimmune diseases, that could affect pregnancy.~Past surgical history: Previous surgeries, especially those related to the reproductive system or any that may impact pregnancy outcomes.~Previous pregnancies: Information about past pregnancies, including the number of full-term and preterm births, complications, and outcomes.~Abortions: Any history of miscarriages"
214452616|NCT06190275|BIOLOGICAL|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors
214452617|NCT06832475|DEVICE|clear aligners and elastics|"For the Fixed Appliance group, the straight wire treatment included an aligning and leveling phase, achieved by using Nickel-Titanium arches (0.016/0.019 × 0.025 arc sequence) and a phase with heavier stainless steel rectangular arches (0.019 × 0.025); during this last treatment phase patients were instructed to use Class II elastics for at least 16 h/day.~Pre- (T0) and post-treatment (T1) lateral cephalogram were collected from all selected patients. Treatment time was an average of 18 months (T1-T0=18 months)."
214526637|NCT05054283|DIAGNOSTIC_TEST|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
214526638|NCT04902196|OTHER|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
214526639|NCT04902196|OTHER|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
214526640|NCT03558750|BIOLOGICAL|Nivolumab|Given by IV
214526641|NCT03558750|BIOLOGICAL|Rituximab|Given by IV
214526642|NCT03558750|DRUG|Lenalidomide|Given by mouth
214526643|NCT01103271|OTHER|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
214526644|NCT03568708|DRUG|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
214526645|NCT00292305|PROCEDURE|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
215138237|NCT05781542|BIOLOGICAL|3M-052-AF|5 mcg
214526646|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 10 mg
214526647|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 5 mg
214526648|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg
214526649|NCT00126555|DRUG|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
214526650|NCT00126555|RADIATION|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
214526651|NCT00126555|PROCEDURE|Conventional surgery|Undergo surgery
214526652|NCT00126555|OTHER|laboratory biomarker analysis|Correlative studies
215138238|NCT05781542|DRUG|Alum|500 mcg
215138239|NCT01295814|DRUG|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
215138240|NCT01295814|OTHER|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
215138241|NCT05148468|DEVICE|Active spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
214526653|NCT04514289|DRUG|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
214526654|NCT03973645|OTHER|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
214526655|NCT05309356|OTHER|ACCEPT Decision Intervention|The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
215138242|NCT05148468|DEVICE|Sham spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
214526656|NCT05309356|OTHER|Comparator|The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
214526657|NCT02133066|PROCEDURE|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
215138243|NCT02495506|OTHER|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
215138244|NCT02495506|OTHER|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
215138245|NCT01031212|DRUG|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
215138246|NCT01031212|DRUG|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
215138247|NCT01031212|DRUG|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
215138248|NCT01031212|DRUG|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
215138249|NCT02435953|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
215138250|NCT02435953|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
215138251|NCT06245343|DEVICE|Functional inspiratory muscle training group|"Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients."
215138252|NCT06245343|DEVICE|Control group|The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
214694909|NCT01053546|BEHAVIORAL|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
214694910|NCT01053546|OTHER|questionnaire administration|Ancillary study
214526658|NCT02133066|DEVICE|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
215138253|NCT04733469|BEHAVIORAL|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~* A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~* Take-home and online copies of the video for repeat viewing~* A video summary~* A question prompt list patients can use to ask clinicians more questions about palliative care~* Contact information and brochures for local palliative care programs"
215138254|NCT04733469|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~* Usual care~* A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
215138255|NCT02353208|OTHER|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
215138256|NCT02353208|OTHER|Placebo|Participants will not be asked to chew bacon bits
214452618|NCT06832475|DEVICE|class 2 elastics|"Class II malocclusion is the most common malocclusion, and it is one of the main reasons for people to undergo orthodontic treatment. This alteration is characterized by an improper relationship between the maxillary and mandibular arches because of skeletal or dental discrepancies or a combination of both . The treatment protocols may considerably vary depending on professional skills, malocclusion severity and patient compliance . Among all the well-known techniques, it is important to mention the Class II elastics , used to camouflage mild skeletal Class II or to treat mild to moderate Class II occlusal relationship.~During the correction of Class II malocclusions by means of inter-arch elastics, special attention should be paid to the position of the lower incisors."
214452619|NCT06833645|OTHER|molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)|The new imaging agents Aβ and TauPET/CT are molecular imaging, which have the advantage of earlier and more visual, and can study the mechanism of pathological changes and PET manifestations of Alzheimer's disease before symptoms appear from the molecular level.
214452620|NCT04062630|DEVICE|iFuse 3-D in Bedrock Configuration|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
214452621|NCT04062630|PROCEDURE|Multilevel Lumbar Fusion surgery|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
214526659|NCT02133066|PROCEDURE|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
214526660|NCT06299696|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration
214526661|NCT05087797|DRUG|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
215138257|NCT04785313|BIOLOGICAL|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
215138258|NCT04785313|OTHER|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
214526662|NCT04798508|OTHER|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
214526663|NCT00462202|DRUG|sulodexide|
214526664|NCT06538727|OTHER|Osteopathic Manipulation Treatment - Scapular Release|First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
214526665|NCT03383029|BEHAVIORAL|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
214526666|NCT01553578|OTHER|questionnaire administration|Ancillary studies
214526667|NCT01553578|PROCEDURE|therapeutic touch|Receive healing touch therapy
214526668|NCT01553578|BEHAVIORAL|management of therapy complications|Receive healing touch therapy
214526669|NCT01553578|BEHAVIORAL|management of therapy complications|Receive guided imagery audiotapes
214526670|NCT01553578|PROCEDURE|standard follow-up care|Receive standard care
215138259|NCT01376258|DRUG|5ARI|dutasteride or finasteride
214452622|NCT02986516|OTHER|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
214452623|NCT02986516|RADIATION|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
214526671|NCT01204593|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
214526672|NCT01204593|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
214694911|NCT01053546|PROCEDURE|quality-of-life assessment|Ancillary study
215138260|NCT03568214|OTHER|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
214452624|NCT06831682|DEVICE|Kinesiotaping (KT)|Kinesiotaping will be applied using muscle, lymphatic, and ligament taping techniques to promote healing, reduce swelling, and improve muscle function following total knee replacement surgery.
215138261|NCT03763084|DRUG|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
215138262|NCT03763084|DRUG|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
215138263|NCT03414983|BIOLOGICAL|Nivolumab|Specified dose on specified days
215138264|NCT03414983|DRUG|Oxaliplatin|Specified dose on specified days
215138265|NCT03414983|DRUG|Leucovorin|Specified dose on specified days
214452625|NCT06831682|OTHER|Standard Rehabilitation|Patients will receive standard postoperative rehabilitation, including physiotherapy, gait training, and medical exercises, without the application of Kinesiotaping.
214452626|NCT06836167|BEHAVIORAL|exercise promotion|a) Up to 10 weekly 1-hour group sessions of multicomponent exercise guided by a physiotherapist, incorporating resistance, endurance, balance, and flexibility. Supported by materials adapted for low literacy or cognitive impairment, it empowers participants to maintain physical activity. Vivifrail may be used to prevent frailty and falls.
214452627|NCT06836167|DRUG|review medication|d) Comprehensive medication review for optimization and deprescribing. Results show significant improvements in physical performance and intrinsic capacity at three and six months, sustained through empowerment and community resource connections.
214452628|NCT06836167|BEHAVIORAL|promoting healthy aging|b) Non-pharmacological interventions, including nutritional guidance for a Mediterranean diet, dysphagia and cognitive impairment screening, and sleep hygiene counselling.
214452629|NCT06836167|OTHER|against social isolation|Support against social isolation by activating community resources.
214452630|NCT05978986|DIAGNOSTIC_TEST|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
215138266|NCT03414983|DRUG|Fluorouracil|Specified dose on specified days
215138267|NCT03414983|DRUG|Bevacizumab|Specified dose on specified days
215138268|NCT00087841|BEHAVIORAL|Self-hypnotic relaxation|
215138269|NCT01183806|DRUG|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
215138270|NCT01183806|OTHER|Exercise training program|Exercise training program
214452631|NCT05385718|OTHER|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
215138271|NCT06025773|DRUG|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
215138272|NCT06025773|DRUG|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
215138273|NCT00181168|DRUG|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
215138274|NCT01775501|DRUG|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
215138275|NCT01775501|DRUG|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214452632|NCT06838546|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
215138276|NCT01775501|DRUG|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
215138277|NCT01775501|DRUG|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
215138278|NCT06350331|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
215138279|NCT06382038|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
214452633|NCT06830551|DRUG|administration cord blood based eye drops, standardized to the deliver BDNF.|administration cord blood based eye drops customized to deliver epitelio tropic factors, incluiding EGF in EGFR blocked cells
214452634|NCT04855747|DRUG|REL-1017|REL-1017 tablet
214452635|NCT04855747|DRUG|Placebo|Placebo tablet
214452636|NCT06541899|DEVICE|Polarys Cryolipolysis|The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.
214452637|NCT02738788|OTHER|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
214452638|NCT05855421|DEVICE|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
214452639|NCT04190589|DEVICE|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
214452640|NCT03637400|DRUG|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
214452641|NCT03637400|DRUG|DOXY|DOXY will be administered over a period of 7 days.
214452642|NCT05964452|DRUG|Methimazole Tablets|Testing dosing algorithm for efficacy.
214452643|NCT05628415|PROCEDURE|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
214452644|NCT05628415|PROCEDURE|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
214452645|NCT05284552|DRUG|Tinzaparin Injectable Solution|Subcutaneous injection
214452646|NCT02754882|DRUG|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
214452647|NCT02754882|DRUG|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
214526673|NCT02843542|DEVICE|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
214526674|NCT02843542|DEVICE|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
214526675|NCT03661749|OTHER|clean catch|clean catch technique applied to collect urine for PR/CR ratio
214526676|NCT01842399|DIETARY_SUPPLEMENT|Resveratrol|Nutriceutical
215138280|NCT06462937|BEHAVIORAL|Exercise with supervision|Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.
214526677|NCT01842399|DRUG|Placebo|2x/day orally
214526678|NCT01145859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
214526679|NCT05240482|PROCEDURE|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
214526680|NCT03266003|OTHER|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
214526681|NCT03266003|OTHER|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
214526682|NCT03327051|DRUG|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
214526683|NCT03327051|DIETARY_SUPPLEMENT|VSL #3|Probiotics
215138281|NCT06462937|BEHAVIORAL|Exercise without supervision|Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.
215138282|NCT04841122|DEVICE|Camera observation|Supplemental camera observation directly linked to the nurse's phone
214526684|NCT03327051|DRUG|Placebo|Placebo to match omeprazole
214526685|NCT02790047|DEVICE|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
214452648|NCT02754882|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
214526686|NCT02790047|OTHER|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
214526687|NCT02790047|OTHER|Health education|"Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD"
214694912|NCT02532634|DRUG|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
215138283|NCT02325102|OTHER|No intervention|As this is an observational study, no intervention was conducted.
215138284|NCT06472518|DEVICE|pharmaco mechanical thrombolysis|arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
215138285|NCT05115331|RADIATION|Experimental Radiation Dose|16 Gy in 2 fractions
215138286|NCT05115331|RADIATION|Conventional Radiation Dose|8 Gy in a single fraction
215138287|NCT04143035|OTHER|No Intervention|No Intervention
215138288|NCT00830882|DRUG|levosalbutamol|2 puffs four times a day for 2 weeks
215138289|NCT00830882|DRUG|racemic salbutamol|2 puffs four times a day for 2 weeks
215138290|NCT00830882|DRUG|placebo|2 puffs four times a day for 2 weeks
214452649|NCT02754882|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
215138291|NCT02170376|DRUG|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
215138292|NCT02170376|DRUG|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
215138293|NCT02170376|DRUG|Placebo|PLC, placebo
215138294|NCT02170376|DRUG|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
215138295|NCT05479695|DEVICE|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
215138296|NCT05479695|DEVICE|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
215138297|NCT04086901|RADIATION|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
214526688|NCT02790047|OTHER|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing"
214526689|NCT02790047|DRUG|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
214526690|NCT02271737|BEHAVIORAL|Training HC/VHSG, Health Education, and Supportive Supervision|1\. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
214694913|NCT02532634|DRUG|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
215138298|NCT05026593|DRUG|Carboplatin|Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
215138299|NCT05026593|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
215138300|NCT05026593|DRUG|Etoposide|Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
215138301|NCT05026593|DRUG|Sintilimab|Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
214452650|NCT04555512|OTHER|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
214452651|NCT04555512|OTHER|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
214452652|NCT04060355|BEHAVIORAL|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
214452653|NCT04060355|BEHAVIORAL|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
214452654|NCT04648033|DRUG|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
214452655|NCT04648033|DRUG|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
215138302|NCT05026593|DRUG|IBI110|IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
215138303|NCT03975985|OTHER|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~\- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
215138304|NCT03975985|OTHER|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
215138305|NCT03818646|DIAGNOSTIC_TEST|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
214526691|NCT02608697|DRUG|CAT-2054|
214526692|NCT02608697|DRUG|Placebo|
214526693|NCT02608697|DRUG|Atorvastatin|
214526694|NCT02156999|DEVICE|Ibandronic acid, vitamin D|
215138306|NCT02166346|DRUG|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
214452656|NCT04648033|RADIATION|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
214452657|NCT06007092|BIOLOGICAL|HPVDC injection level dose 1|patient receive 3 injections of vaccine at the same level dose
214452658|NCT06007092|BIOLOGICAL|placebo injection level dose 1|patient receive 3 injections of vaccine at the same level dose
214452659|NCT06007092|BIOLOGICAL|HPVDC injection level dose 2|patient receive 3 injections of vaccine at the same level dose
214452660|NCT06007092|BIOLOGICAL|placebo injection level dose 2|patient receive 3 injections of vaccine at the same level dose
214452661|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
214526695|NCT02980198|BIOLOGICAL|IFN-Kinoid|IM administration
214526696|NCT02980198|OTHER|Placebo|IM administration
214526697|NCT02980198|OTHER|ISA 51|adjuvant
214526698|NCT01723332|BEHAVIORAL|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
214526699|NCT01723332|BEHAVIORAL|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
214526700|NCT02669888|DRUG|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
214526701|NCT02669888|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
214526702|NCT03134976|DRUG|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
215138307|NCT02166346|DRUG|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
214526703|NCT04949789|OTHER|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
214526704|NCT04949789|OTHER|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
214526705|NCT04949789|OTHER|IP I|2 Capsules to be taken 30 minutes before breakfast.
214526706|NCT04949789|OTHER|IP II|2 Capsules to be taken 30 minutes before breakfast.
214526707|NCT04949789|OTHER|IP III|2 Capsules to be taken 30 minutes before breakfast.
214526708|NCT04912102|DEVICE|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
214526709|NCT04402021|BEHAVIORAL|Outdoor Walking|Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
214526710|NCT04402021|OTHER|Quiet Rest|The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
214526711|NCT01846637|PROCEDURE|laparoscopic sleeve gastrectomy|
214694914|NCT02830841|DEVICE|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
214694915|NCT02830841|DEVICE|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
215138308|NCT03780244|DEVICE|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
215138309|NCT03780244|DEVICE|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
215138310|NCT01432041|BEHAVIORAL|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
215138311|NCT05996016|OTHER||
215138312|NCT04424095|DIAGNOSTIC_TEST|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
215138313|NCT04424095|DIAGNOSTIC_TEST|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
215138314|NCT05739721|BEHAVIORAL|Attractiveness|Visual attractiveness scale 0-7
215138315|NCT05739721|BEHAVIORAL|Self-Esteem|Self Esteem scale
215138316|NCT05739721|BEHAVIORAL|Trustworthiness|Trustworthiness scale 0-7
215138317|NCT00311675|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
215138318|NCT02323789|DRUG|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
215138319|NCT04422184|DRUG|Sensodyne Repair and Protect|Dentifricie with NOVAMIN technology
215138320|NCT04422184|DRUG|Dentalclean Daily Regenerator|Dentifricie with Refix technology
215138321|NCT04422184|DRUG|Dentalclean Daily Regenerator with potassium citrate|Dentifricie with Refix technology+ potassium citrate
215138322|NCT01695226|DRUG|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
215138323|NCT01695226|DRUG|Placebo|pre-operative placebo twice daily for two to three weeks
215138324|NCT06001047|PROCEDURE|Group A|Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
214452662|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
214452663|NCT03270956|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
214452664|NCT04203576|DEVICE|FIRE1 System|FIRE1 System
214452665|NCT04829500|BEHAVIORAL|Montessori Approaches to Person-Centered Care (MAP-VA)|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities. Staff are also introduced to concrete strategies that improve dignity, control, and independence. MAP-VA is based on the work of Maria Montessori who demonstrated that a structured, supportive environment and meaningful, active roles in the classroom enabled children to fulfill their greatest potential physically, mentally, and emotionally. Montessori principles have been applied to dementia care for more than 20 years to promote functional independence, meaningful engagement, and dignity.
214452666|NCT06171269|RADIATION|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
214452667|NCT06171269|RADIATION|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
214452668|NCT06171269|OTHER|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
214452669|NCT04956861|BEHAVIORAL|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
214526712|NCT03440788|DRUG|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
214694916|NCT00269191|DRUG|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
214694917|NCT00269191|DRUG|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
215138325|NCT06001047|DRUG|Group B|"The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol."
215138326|NCT00628667|DRUG|Esomeprazole|40mg orally twice daily
215138327|NCT00628667|DRUG|Placebo|
215138328|NCT03629535|DEVICE|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
215138329|NCT03629535|DEVICE|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
215138330|NCT04927195|DRUG|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
215138331|NCT04927195|DRUG|Placebo|Placebo oral capsule
215138332|NCT05417646|OTHER|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
215138333|NCT05417646|DRUG|Placebo|Placebo comparator to empagliflozin
215138334|NCT05417646|DRUG|Empagliflozin|Single-dose, 25 mg, two hours before clamp
215138335|NCT00998686|DRUG|dutogliptin|400 mg
215138336|NCT00998686|DRUG|sitagliptin|100 mg
215138337|NCT00901836|RADIATION|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
215138338|NCT00901836|PROCEDURE|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
215138339|NCT03902444|DEVICE|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
215138340|NCT05600634|PROCEDURE|Skin allotransplantation|Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
215138341|NCT04645758|COMBINATION_PRODUCT|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
215138342|NCT04424134|DRUG|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
215138343|NCT04424134|DRUG|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
215138344|NCT02364700|DEVICE|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)"
215138345|NCT01010880|DRUG|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
215138346|NCT03123692|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
215138347|NCT03123692|DRUG|Placebo|14 days treatment with placebo
215138348|NCT00394017|BEHAVIORAL|Reminder letters|3 mailed reminder letters
215138349|NCT01323114|PROCEDURE|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
215138350|NCT01323114|OTHER|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
215138351|NCT03673800|OTHER|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
215138352|NCT03673800|OTHER|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
215138353|NCT05348538|OTHER|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~1. Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~2. Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~3. Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
215138354|NCT02289586|PROCEDURE|invasive ventilation|
215138355|NCT02289586|PROCEDURE|interventional bronchoscopy|
215138356|NCT02289586|DEVICE|noninvasive ventilation|
214452670|NCT05761756|BEHAVIORAL|Sleep Deprivation|24 hours sleep deprivation
214452671|NCT05761756|DRUG|Caffeine|Oral administration of caffeine
214452672|NCT05761756|DRUG|Methylphenidate|Oral administration of methylphenidate
214452673|NCT05761756|DRUG|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
214452674|NCT04418479|DRUG|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
214452675|NCT04418479|DRUG|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
214452676|NCT03034811|DEVICE|Persona Partial Knee system|Fixed bearing partial knee
214452677|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root|This substance is extracted from the root of the plant.
214452678|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root and leaf|This substance is extracted from both the root and leaves of the plant.
214452679|NCT06793891|OTHER|placebo|The inert placebo does not contain any of the plant matter.
215138357|NCT02289586|DRUG|sedation(dezocine and midazolam)|
215138358|NCT02289586|DRUG|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
215138359|NCT02273934|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
215138360|NCT02273934|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
214526713|NCT03229356|OTHER|Best Practices Advisory (BPA)|"1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
214526714|NCT03229356|OTHER|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
214526715|NCT00853203|BEHAVIORAL|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
214526716|NCT00853203|BEHAVIORAL|Questionnaires|Written survey taking about 1 hour.
214526717|NCT00853203|OTHER|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
214526718|NCT00853203|BEHAVIORAL|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
214526719|NCT00853203|BEHAVIORAL|Written Materials|Written educational materials plus community resource information.
214526720|NCT02194777|DRUG|BIBN 4096 BS - in single rising doses|
215138361|NCT02558088|DRUG|Salmeterol|
215138362|NCT04301960|OTHER|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
215138363|NCT04301960|OTHER|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
215138364|NCT00804908|DRUG|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
215138365|NCT00804908|DRUG|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
214526721|NCT02194777|DRUG|Placebo|
214526722|NCT04520685|DRUG|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
214526723|NCT04520685|DRUG|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
214526724|NCT04440514|PROCEDURE|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
215138366|NCT00804908|OTHER|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
215138367|NCT05277415|BIOLOGICAL|Ghrelin|Ghrelin infusion
215138368|NCT05277415|BIOLOGICAL|Placebo|Placebo
215138369|NCT00222612|OTHER|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
214452680|NCT04330430|DRUG|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
214452681|NCT06427980|DRUG|Chinese Herbal formula HuoXue LiShui|The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
214526725|NCT01498523|OTHER|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
215138370|NCT00222612|DRUG|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
215138371|NCT00222612|DRUG|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
215138372|NCT01280903|BEHAVIORAL|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
215138373|NCT01280903|BEHAVIORAL|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
215138374|NCT03453164|RADIATION|Radiotherapy|Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.
214452682|NCT06427980|DRUG|Chinese Herbal formula Placebo|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
214452683|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
214452684|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
214452685|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
214452686|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
214526726|NCT01498523|OTHER|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
214526727|NCT01498523|OTHER|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
214526728|NCT01498523|OTHER|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
214526729|NCT02650726|DIETARY_SUPPLEMENT|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
214526730|NCT02650726|OTHER|Placebo|placebo 320mg daily for 24 weeks
214526731|NCT01250847|DRUG|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
214526732|NCT02107729|PROCEDURE|Large needle gauge lidocaine injection|21 G
214526733|NCT02107729|PROCEDURE|Normal needle gauge lidocaine injection|23 G
214526734|NCT02107729|PROCEDURE|Small needle gauge lidocaine injection|27 G
214526735|NCT04595097|DEVICE|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
214526736|NCT02915354|DRUG|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
214526737|NCT03704571|DRUG|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
214526738|NCT01939405|BEHAVIORAL|built environment use counseling|
215138375|NCT03453164|DRUG|Nivolumab|Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
214526739|NCT02449993|DEVICE|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
214526740|NCT00647283|PROCEDURE|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
214526741|NCT00614536|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
214526742|NCT01960985|OTHER|Physicaltherapy|
214526743|NCT02835937|OTHER|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
214526744|NCT02617433|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
214526745|NCT01862185|OTHER|semi-quantitative procalcitonin|
214526746|NCT05269147|PROCEDURE|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
215138376|NCT05683353|OTHER|None intervention|None intervention.
215138377|NCT05134038|DIAGNOSTIC_TEST|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
215138378|NCT04183660|DEVICE|MOBYBOX System|extracorporeal cardiopulmonary support
214526747|NCT01089387|BIOLOGICAL|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
214526748|NCT03187041|OTHER|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
214526749|NCT04904237|DRUG|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
215138379|NCT06520501|DIETARY_SUPPLEMENT|Herbal Medicine Sambiloto|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
214526750|NCT00694564|DRUG|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
214526751|NCT02742792|OTHER|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
215138380|NCT06520501|BEHAVIORAL|Brisk Walking|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
215138381|NCT06520501|COMBINATION_PRODUCT|Brisk Walking and Herbal Medicine Sambiloto|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute. Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days
215138382|NCT04003467|DRUG|EBP05|tablets
215138383|NCT04003467|DRUG|Placebo of EBP05|tablets
215138384|NCT01125592|DEVICE|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
215138385|NCT04718077|OTHER|Intraosseus|IO dexamethasone injection Dexamethasone 4 mg
214452687|NCT06641232|PROCEDURE|Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.|"The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block."
214452688|NCT05215314|BEHAVIORAL|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
214452689|NCT04974008|DRUG|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
214452690|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
214452691|NCT03181763|DRUG|Placebo|Participants will receive inactive placebo on their second visit.
214452692|NCT03181763|DRUG|Midomafetamine|Participants will receive 100 mg midomafetamine HCl on their second visit
214452693|NCT03181763|BEHAVIORAL|Acoustic startle|Startle assessment
214452694|NCT06161688|DRUG|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
214452695|NCT06161688|OTHER|Placebo|Matching placebo for Ensitrelvir
214452696|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
214452697|NCT00569049|PROCEDURE|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
214452698|NCT04294225|DRUG|Anastrozole|Given PO
214452699|NCT04294225|DRUG|Letrozole|Given PO
214452700|NCT04791709|BEHAVIORAL|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
214452701|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
214452702|NCT06582199|OTHER|Blood sample|Plasma, DNA, RNA and PBMC Sampling
214526752|NCT02742792|OTHER|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
214526753|NCT01647152|DRUG|Ustekinumab|
214526754|NCT04392479|DRUG|Aflibercept-FOLFIRI|Aflibercept-FOLFIRI
214526755|NCT04392479|DRUG|Aflibercept-mFOLFIRI3|Aflibercept-mFOLFIRI3
214526756|NCT03703349|DRUG|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
214526757|NCT03703349|DRUG|Placebo Oral Tablet|Placebo for Magnesium
215138386|NCT04718077|OTHER|Submucoal|SM dexamethasone injection Dexamethasone 4 mg
215138387|NCT02561884|DRUG|Olostar Tab.|
215138388|NCT02561884|DRUG|Co-administration of Olmetec and Crestor|
215138389|NCT04849247|DRUG|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
215138390|NCT06491277|OTHER|Flossband|The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.
214526758|NCT01284634|DRUG|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
215138391|NCT06491277|OTHER|Controlled Group|Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
214526759|NCT01284634|DRUG|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
214526760|NCT01284634|DRUG|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
214526761|NCT01284634|DRUG|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
214526762|NCT06408922|OTHER|prp injection|intraarticular prp
214694918|NCT00252486|DRUG|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
215138392|NCT02242604|OTHER|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)"
215138393|NCT03694886|DRUG|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
215138394|NCT03694886|OTHER|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
215138395|NCT03694886|DRUG|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
215138396|NCT03694886|OTHER|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
215138397|NCT03925090|DRUG|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
215138398|NCT03925090|DRUG|Cisplatin+placebo|chemotherapy
214526763|NCT04873297|DRUG|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
214694919|NCT00530322|PROCEDURE|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
214694920|NCT05960344|PROCEDURE|Spirometry|Supervised v unsupervised spirometry
214694921|NCT04755296|DEVICE|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
215138399|NCT02770014|DRUG|Erlotinib|
215138400|NCT05100550|DIETARY_SUPPLEMENT|Zinc|Zinc is given as written in the arm description, two hours after lunch
215138401|NCT05100550|OTHER|Control|This group will not receive zinc
215138402|NCT05642403|DRUG|XW001|Inhaled XW001
215138403|NCT05642403|DRUG|Placebo|Matched inhaled placebo
215138404|NCT00688987|DRUG|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
215138405|NCT00688987|DIETARY_SUPPLEMENT|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
215138406|NCT05665231|OTHER|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
215138407|NCT05665231|OTHER|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
215138408|NCT05665231|OTHER|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
215138409|NCT05665231|OTHER|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
214526764|NCT04873297|DRUG|Placebo|Placebo 10 ml of plain water Via NG
214526765|NCT01271153|DRUG|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
214526766|NCT01271153|DRUG|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
214526767|NCT03294421|PROCEDURE|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
214526768|NCT03294421|PROCEDURE|standard closed tympanomastoidectomy|"1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0"
214526769|NCT04531371|DRUG|Dexmedetomidine injection|post surgical agitation prophylaxis
214526770|NCT02357719|DEVICE|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
215138410|NCT05665231|OTHER|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
215138411|NCT05665231|OTHER|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
215138412|NCT05665231|OTHER|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
215138413|NCT05665231|OTHER|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
215138414|NCT05665231|OTHER|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~1. interdental distance~2. bucco-palatal distance (BPD)~3. presence of papilla~r. global volume."
215138415|NCT05665231|OTHER|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
214526771|NCT01059526|DRUG|ecallantide|30 mg SC
214526772|NCT00220597|BEHAVIORAL|Trauma-focused group therapy|
214526773|NCT02720081|DRUG|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
214526774|NCT02720081|DRUG|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
214526775|NCT02720081|DRUG|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
214526776|NCT02720081|DRUG|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
214526777|NCT01732588|DRUG|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
214526778|NCT01732588|DRUG|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
214526779|NCT01732588|DRUG|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
214526780|NCT01620398|BEHAVIORAL|BALANCE|
214526781|NCT01620398|BEHAVIORAL|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
214526782|NCT05790187|OTHER|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
214526783|NCT00743223|OTHER|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
214526784|NCT06006832|DRUG|Steroid Drug|Maintaining low-dose oral steroids
215138416|NCT05665231|OTHER|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~1. interdental distance;~2. bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
215138417|NCT05665231|OTHER|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
215138418|NCT02172274|DRUG|[14C]-BI 10773 - oral solution|
215138419|NCT05765916|BEHAVIORAL|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
215138420|NCT04461717|DEVICE|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
215138421|NCT03822117|DRUG|Pemigatinib|Pemigatinib administered orally once daily (QD).
215138422|NCT02178345|PROCEDURE|diffusion weighted (DW) MRI|
215138423|NCT02178345|PROCEDURE|dynamic contrast agent (DCE) MRI|
215138424|NCT02279914|DRUG|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D\&E procedure
215138425|NCT02279914|DRUG|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D\&E procedure
215138426|NCT04317287|DIETARY_SUPPLEMENT|Cardio formulation|Tomato-based formulation with dietary supplement softgels
215138427|NCT04317287|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
214452703|NCT06582199|BEHAVIORAL|Neuropsychological battery tests|"* Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)"
214452704|NCT05932134|DIETARY_SUPPLEMENT|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
214526785|NCT06006832|OTHER|Withdraw all immunosuppresants|Withdraw all immunosuppresants
214526786|NCT01451697|BEHAVIORAL|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
215138428|NCT04144608|DRUG|Toripalimab|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
215138429|NCT00445042|DRUG|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
215138430|NCT01074502|DRUG|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
215138431|NCT01327625|DRUG|azithromycin + N-acetylcystein + inhaled corticosteroid|"* Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months"
215138432|NCT00001188|PROCEDURE|radiation therapy following surgery|
215138433|NCT03459079|DRUG|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
215138434|NCT03459079|OTHER|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
215138435|NCT03117010|DRUG|Steroids|High dose dexamethasone 20 mg PO or IV
215138436|NCT03117010|DRUG|Etoposide|Etoposide 150mg/BSA
214452705|NCT05932134|BEHAVIORAL|UC + HP + core muscle rehabilitation|Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks
214452706|NCT05932134|DEVICE|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
215138437|NCT03874338|DRUG|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
215138438|NCT06356454|OTHER|Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease|"Creating the questionnaire: The self-administered questionnaire was designed based on literature review. The questions of the questionnaire were based on the 3 main components of the World Health Organisation's Knowledge, Attitude and Practice framework. The questions were evaluated by experts in the field such as cardiologists working in paediatric cardiology. The questionnaire, which was finalised with the questions updated according to expert opinions, has 5 sections:~* Section 1: Socio-demographic questions~* Section 2: Questions on the level of knowledge about CR~* Section 3: Questions on attitudes about CR~* Section 4: Questions on Practices about CR"
215138439|NCT02040324|DEVICE|Laryngeal mask with gastric access|
215138440|NCT02040324|DEVICE|Endotracheal tube|
215138441|NCT05329948|OTHER|Haptonomy application|Feeling the fetus by touching the mother's womb with meditation
215138442|NCT00615303|DRUG|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
215138443|NCT00615303|DRUG|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
215138444|NCT04016935|OTHER|Observational|Observational
215138445|NCT04336774|DEVICE|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
215138446|NCT06514625|DEVICE|splint|ready night splints
215138447|NCT03182049|PROCEDURE|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
215138448|NCT03182049|PROCEDURE|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
215138449|NCT00887536|DRUG|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
215138450|NCT00887536|DRUG|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
215138451|NCT00887536|DRUG|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
215138452|NCT00887536|DRUG|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
215138453|NCT00887536|DRUG|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]
215138454|NCT02516761|OTHER|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
215138455|NCT02516761|OTHER|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
214452707|NCT05927090|PROCEDURE|Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair|Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
214452708|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
214452709|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)|Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
215138456|NCT02516761|OTHER|Control group|With this group no intervention is done, but they are assessed like the other groups.
215138457|NCT06127030|BEHAVIORAL|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
215138458|NCT06127030|BEHAVIORAL|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
214452710|NCT05927090|PROCEDURE|Extensive Root and Ascending Aorta Replacement with Total Arch Replacement|This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
214452711|NCT05927090|PROCEDURE|Thoracic Endovascular Aortic Repair|TEVAR patients have a higher incidence of complications and reintervention than open repair patients. TEVAR complications may include endoleak, retrograde type A aortic dissection, stent-graft migration, fracture or collapse, and increased size.
214452712|NCT05927090|PROCEDURE|Open Thoracic Aortic Descendig Repair|Surveillance imaging can detect complications of open repair, such as graft infection and anastomotic pseudoaneurysm. After open repair or TEVAR, patients may develop progressive aneurysmal dilatation of adjacent or remote aortic segments.
214452713|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
214452714|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
214452715|NCT02790502|DEVICE|Food Photography Application©|Group testing RFPM as method of recording plate waste
214452716|NCT05142982|RADIATION|Radiotherapy|A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
214526787|NCT01451697|BEHAVIORAL|Control (Placebo)|The control condition will involve relaxation training.
215138459|NCT05085938|PROCEDURE|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
215138460|NCT04764071|PROCEDURE|percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.
215138461|NCT04764071|PROCEDURE|ultra-mini percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
214452717|NCT06581497|DRUG|ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
214452718|NCT06581497|PROCEDURE|ICIs+MWA|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
214452719|NCT05324501|DRUG|MTX110|Soluble panobinostat
214452720|NCT05324501|DEVICE|Programmable pump and catheter system|To allow Convection-Enhanced Delivery (CED)
214452721|NCT06225479|BEHAVIORAL|Exercise|"An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session)."
214452722|NCT06225479|OTHER|Calls and Newsletter|"A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications."
214452723|NCT05816473|OTHER|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
214452724|NCT06581146|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
214452725|NCT06788457|DEVICE|Exhaled Breath Condensate|Measurement of hydrogen peroxide in exhaled breath
214452726|NCT06510868|RADIATION|Peptide receptor radionuclide therapy (PRRT)|Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
215138462|NCT06956612|DIETARY_SUPPLEMENT|Control (Placebo comparator)|The control group will consume a placebo supplement, entirely free of nitrate, in the form of juice (70 ml) for four weeks while maintaining their habitual diet.
215138463|NCT06956612|DIETARY_SUPPLEMENT|Juice (Active comparator)|The juice group will consume a beetroot supplement enriched with \~400 mg of nitrate in juice form (70 ml) for four weeks while maintaining their habitual diet.
215138464|NCT06956612|DIETARY_SUPPLEMENT|Crystals (Experimental)|The crystals group will consume a beetroot supplement enriched with \~400 mg of nitrate in crystals form (20g) for four weeks while maintaining their habitual diet.
215138465|NCT04334967|DRUG|Hydroxychloroquine|Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.
215138466|NCT04334967|DIETARY_SUPPLEMENT|Vitamin C|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
215138467|NCT03553693|OTHER|RAPID-VL study intervention|"* Viral load (VL) ordering flowsheet with periodic health facility performance feedback~* Rapid near-point-of-care VL testing and telephone delivery of results~* Structured VL counseling package"
215138468|NCT05108259|DRUG|PBP1502|40 mg/0.4 mL single SC injection via PFS
215138469|NCT05108259|DRUG|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
215138470|NCT05108259|DRUG|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
215138471|NCT00956319|DRUG|Zolpidem MR|oral
214452727|NCT06510868|DIAGNOSTIC_TEST|Blood collection|Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
214452728|NCT02153580|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
214452729|NCT02153580|DRUG|Bendamustine Hydrochloride|Given IV
214452730|NCT02153580|DRUG|Cyclophosphamide|Given IV
214452731|NCT02153580|DRUG|Etoposide|Given IV
214452732|NCT02153580|DRUG|Fludarabine Phosphate|Given IV
214452733|NCT05950594|RADIATION|Radiotherapy|Standard of care pre-operative radiotherapy
214452734|NCT05950594|OTHER|Surgery|Standard of care definitive surgery
215138472|NCT00956319|DRUG|Estazolam|oral
215138473|NCT03170596|DRUG|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
215138474|NCT03170596|DEVICE|Microneedling|Microneedling is a method of percutaneous collagen induction
215138475|NCT02784886|BIOLOGICAL|Women at high risk of MAP|Blood sample
214452735|NCT05781243|DRUG|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
214452736|NCT05781243|DRUG|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
214452737|NCT04442763|DEVICE|Densah Burs|osseodensification method
214452738|NCT04442763|DEVICE|Standard drills|conventional drilling
215138476|NCT03906019|PROCEDURE|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
215138477|NCT03906019|DIAGNOSTIC_TEST|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
215138478|NCT03906019|DIAGNOSTIC_TEST|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
215138479|NCT00976183|DRUG|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
215138480|NCT00976183|DRUG|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
215138481|NCT05728437|PROCEDURE|Resistance exercise|The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
214452739|NCT02560233|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
214452740|NCT02560233|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
214452741|NCT03869736|DRUG|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
214452742|NCT03869736|DRUG|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
214452743|NCT06210971|DRUG|liposomal irinotecan|Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2
214452744|NCT06210971|DRUG|Capecitabine|Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
214526788|NCT00356564|BIOLOGICAL|hepatitis B vaccine|
214526789|NCT04875598|PROCEDURE|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
214526790|NCT03690921|DRUG|Cisplatin|Given IV
214526791|NCT03690921|DRUG|Fluorouracil|Given IV
214526792|NCT03690921|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
214526793|NCT03690921|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214694922|NCT04755296|OTHER|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
215138482|NCT01417806|DRUG|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
214452745|NCT06210971|RADIATION|Radiation threapy|50.4Gy/28 fractions
214452746|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
214452747|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
214452748|NCT03947216|DRUG|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
214452749|NCT03947216|DRUG|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
214452750|NCT03947216|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
214452751|NCT03947216|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
214452752|NCT03947216|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
214452753|NCT03947216|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
214694923|NCT04755296|OTHER|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
214694924|NCT01668563|PROCEDURE|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
215138483|NCT03376880|OTHER|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
215138484|NCT00834977|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
214452754|NCT03947216|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
214452755|NCT03947216|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
214452756|NCT03947216|PROCEDURE|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
214452757|NCT03947216|PROCEDURE|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
214452758|NCT03669822|OTHER|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
214452759|NCT05145569|DRUG|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
214526794|NCT03690921|OTHER|Questionnaire Administration|Ancillary studies
214526795|NCT02183350|DRUG|BI 1356 BS - single rising dose|
214526796|NCT02183350|DRUG|Placebo|
214526797|NCT04935918|DEVICE|ACT|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
214526798|NCT02737202|DRUG|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
214526799|NCT00761410|DEVICE|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
214526800|NCT01193062|DRUG|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
215138485|NCT00834977|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
215138486|NCT06392165|OTHER|self-adhesive device|Test device which is self-adhesive
215138487|NCT03119987|DIAGNOSTIC_TEST|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
215138488|NCT05533606|DRUG|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
215138489|NCT00726063|DEVICE|Nanotite dental implant|Nanotite root form titanium dental implant
215138490|NCT00726063|DEVICE|Osseotite dental implant|Osseotite Root form titanium dental implant
215138491|NCT03585881|DEVICE|3DPrinted Windowed Bracket- Positioning tray|3 D printed tray with windows for accurate positioning of brackets
215138492|NCT01529892|DRUG|A single oral 5 mg of duterium labeled methamphetamine|
215138493|NCT03041519|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
215138494|NCT03041519|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
215138495|NCT06293599|OTHER|scapular stabilization exercises|the patients will receive scapular stabilization exercises in the form of scapular orientation exercises,Forward/Backward Bear Crawls,Lateral Bear Crawls and assisted stretch for pectoralis minor
215138496|NCT06293599|OTHER|virtual reality exercises|"The exercises described were done in a consistent manner, emphasizing low intensity, and using lightweight dumbbells (range, 3 to 30 pounds). The weight of the dumbbell was individually selected by the subject for each exercise.~1. elevation of the arm in the sagittal plane (shoulder flexion~2. elevation of the arm in the scapular plane with humeral external rotation (shoulder scaption~3. elevation of the arm in the coronal plane (shoulder abduction)~4. rowing~5. horizontal shoulder abduction~6. horizontal abduction with humeral external rotation~7. push-up with hands apart~8. push-up with a plus-normal push-up adding maximum shoulder and scapular protraction with elbows fully extended~9. dumbbell bench press~10. dumbbell military press~11. shoulder shrug~12. deceleration exercise-simulating the pitching followthrough~13. shoulder extension prone~14. shoulder internal rotation~15. shoulder external rotation~16. press-up"
214452760|NCT05145569|DRUG|HCW9218|HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
214452761|NCT01580488|DRUG|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
214452762|NCT01580488|DRUG|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
215138497|NCT06293599|OTHER|regular routine exercises|the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,
215138498|NCT03351452|DEVICE|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
215138499|NCT03351452|DEVICE|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
215138500|NCT03351452|DEVICE|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
215138501|NCT03740451|OTHER|Active mobilization of soft tissues|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
215138502|NCT03740451|OTHER|Passive mobilization|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
215138503|NCT03633032|DIAGNOSTIC_TEST|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
215138504|NCT00006461|DRUG|cisplatin|Given IV
215138505|NCT00006461|DRUG|cyclophosphamide|Given IV
215138506|NCT00006461|DRUG|vincristine sulfate|Given IV
215138507|NCT00006461|DRUG|etoposide|Given PO
215138508|NCT00006461|PROCEDURE|therapeutic conventional surgery|Undergo surgery
215138509|NCT00006461|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
215138510|NCT00006086|DRUG|BMS-188797|
215138511|NCT00006086|DRUG|carboplatin|
215138512|NCT02851277|DRUG|ASP0892 Intradermal|Intradermal injection
215138513|NCT02851277|DRUG|ASP0892 Intramuscular|Intramuscular injection
215138514|NCT02851277|DRUG|Placebo Intradermal|Intradermal injection
215138515|NCT02851277|DRUG|Placebo Intramuscular|Intramuscular injection
215138516|NCT05030337|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
215138517|NCT04595656|OTHER|verbal autopsy interview|The study involves filling of verbal autopsies for deaths in SEACTN villages. This is an observational study being conducted as a substudy of rural febrile project of SEACTN program.
215138518|NCT05539625|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
215138519|NCT05539625|OTHER|Placebo|Placebo
215138520|NCT05284773|OTHER|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
215138521|NCT05284773|OTHER|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
215138522|NCT05719311|DRUG|adrulipase|Enteric microgranule formulation of adrulipase.
215138523|NCT05176314|DRUG|Rosuvastatin|Administered Orally.
215138524|NCT05176314|DRUG|Pirtobrutinib|Administered Orally.
215138525|NCT06264843|DEVICE|MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes|Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
215138526|NCT06389019|OTHER|Deep learning system for prognostication prediction in bladder cancer|develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
215138527|NCT04922944|DRUG|COVID-19 vaccine|Two-dose COVID-19 vaccine
215138528|NCT06956469|OTHER|Identification of types of anti-HLA-specific memory LBs|Using blood sample, it will be perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. It will be further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.
215138529|NCT05330481|OTHER|Moderate-intensity (relative) exercise with glucose ingestion|120 minutes of cycling at 95% of lactate threshold ingesting 90 g/h of glucose
215138530|NCT05330481|OTHER|Moderate-intensity (absolute) exercise with glucose ingestion|120 minutes of cycling at a power matched to participant in the \<70 kg body mass group, ingesting 90 g/h of glucose
215138531|NCT01231984|DEVICE|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
214452763|NCT01580488|DRUG|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
214452764|NCT01580488|DRUG|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
214452765|NCT01580488|DRUG|Daivonex® ointment|once daily application, 3 weeks
214452766|NCT01580488|DRUG|Daivonex® ointment vehicle|once daily application, 3 weeks
214452767|NCT03738228|DRUG|Atezolizumab|Given IV
214452768|NCT03738228|RADIATION|Brachytherapy|Undergo standard of care image guided brachytherapy
214452769|NCT03738228|DRUG|Cisplatin|Given IV
214452770|NCT03738228|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214452771|NCT06133517|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
214452772|NCT06133517|DRUG|Zimberelimab|ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
214452773|NCT06133517|DRUG|Domvanalimab|DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
215138532|NCT01231984|DEVICE|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
215138533|NCT01231984|DEVICE|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
215138534|NCT04445753|OTHER|Tai Chi exercise|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
215138535|NCT04445753|BEHAVIORAL|Education (control group)|Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
214452774|NCT04269213|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214452775|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
214452776|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
214452777|NCT05751382|DEVICE|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
214452778|NCT05751382|DEVICE|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
214452779|NCT06002789|DRUG|MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
214452780|NCT06002789|DRUG|All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy|For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
214452781|NCT04672889|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 1 months
214452782|NCT04672889|DIETARY_SUPPLEMENT|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
214452783|NCT05470517|DRUG|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
214452784|NCT05470517|PROCEDURE|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
214452785|NCT06776224|OTHER|Measurement of retinal vascular density and visual cognition|During the same visit, we will perform OCT-angiography (10 minutes) and evaluate visual cognition with an eye-tracker (20 minutes)
214452786|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
214452787|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
214452788|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
214452789|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
214452790|NCT06776796|BEHAVIORAL|Online Personalized Normative Feedback Intervention Targeting Alcohol Misuse|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse. It is tailored by the identities chosen by participants including gender, race/ethnicity, and sexual orientation. The intervention is a modified version of an existing evidence-based program, the Brief Alcohol Screening and Intervention for College Students (BASICS) (Dimeff, et. al, 1999).
214452791|NCT06776796|BEHAVIORAL|Mental Health and Substance Use Resources|Participants were directed to a website where information regarding mental health and substance use may be found.
214452792|NCT02285816|BIOLOGICAL|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
214452793|NCT02285816|BIOLOGICAL|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
214452794|NCT01107340|DEVICE|AMIStem Hip System|
214452795|NCT06784544|OTHER|Operational Stressors|Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
214526801|NCT01193062|DRUG|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
214526802|NCT05871190|OTHER|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
215138536|NCT05515484|OTHER|prone position with airbags|prone position with airbags
215138537|NCT05515484|OTHER|prone position without airbags|prone position without airbags
215138538|NCT05021354|DEVICE|Dry needling|dry needling, stretching and eccentric exercise
215138539|NCT05021354|DEVICE|Topical gel|aplication of topical gel to the epicondyle
215138540|NCT05021354|DRUG|NSAIDs|oral intake of NSAIDs
214452796|NCT06782672|OTHER|Cardiovascular measurements|"Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.~These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.~Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.~cardiovascular values will be measured continuously:~* Each participant rested while watching a documentary for 8 minutes.~* During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.~The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort."
214452797|NCT06782672|OTHER|Experimental memory task|"First, a quiet period with the viewing of a documentary film (8min).~Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.~At the end of each difficulty level, self-report measures assessed by the following questions will be collected:~* How much effort did you exert during the task?;~* How difficult did you find the task?~* How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 (no effort at all, very easy, not at all motivated, respectively) to 7 (a lot of effort, very difficult, very motivated, respectively)."
214452798|NCT06782672|OTHER|Questionnaire and semi-structured psychological interview|"psychopathological measures collected using questionnaires:~* Beck Depression Inventory (BDI-II): mood~* State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety~* Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue~* General Self-Efficacy Scale (GSES): defeatist beliefs~* Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group"
214452799|NCT05959811|OTHER|yoga|60 minutes yoga practice ,twice a week for 8 weeks
214452800|NCT05456113|BIOLOGICAL|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
214452801|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
214526803|NCT05871190|PROCEDURE|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
214526804|NCT01315197|OTHER|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
214526805|NCT03964038|DRUG|gilteritinib|oral
214526806|NCT03964038|DRUG|gilteritinib mini tablet|oral
214526807|NCT05585671|DRUG|Belimumab|Lupus patients without previous involvement of kidney are enrolled, and receive 2-year of 10mg/kg belimumab intravenously on the background of standard of care (SOC). During follow-up, we observe whether these patients will develop new-onset lupus nephritis.
214526808|NCT02164136|PROCEDURE|L-PANP-TME|
214526809|NCT02164136|PROCEDURE|O-PANP-TME|
214526810|NCT02754310|OTHER|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
214526811|NCT02754310|OTHER|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
214526812|NCT00634426|PROCEDURE|Surgical excision of the metastatic process|Surgical excision of the metastatic process
214526813|NCT00634426|RADIATION|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
214526814|NCT02274051|DIETARY_SUPPLEMENT|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
214526815|NCT05012397|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
214526816|NCT04974086|OTHER|Sexually transmitted infection (STI) testing clinical decision support (CDS) tool|The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
214526817|NCT00645320|DRUG|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
214526818|NCT00003588|BIOLOGICAL|Ad5CMV-p53 gene|
214526819|NCT00003588|PROCEDURE|laparoscopic surgery|
215138541|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
215138542|NCT06845761|BEHAVIORAL|Self-Guided Cognitive Behavioral Therapy|Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) is a set of seven modules that consist of different skills trainings that can be accessed by devices with an internet connection. The version of CBT4CBT that will be provided is the alcohol-based CBT4CBT.
214526820|NCT05362253|PROCEDURE|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
214526821|NCT05362253|PROCEDURE|Conventional Autologous Conjunctival Transplantation|"1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
214526822|NCT04676672|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
215138543|NCT02070575|OTHER|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
215138544|NCT01968447|OTHER|hypocapnia|Hyperventilation to the level of hypocapnia
215138545|NCT01968447|OTHER|normocapnia|Normal ventilation to the level of nromocapnia
215138546|NCT04050358|DIETARY_SUPPLEMENT|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
215138547|NCT04050358|DIETARY_SUPPLEMENT|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
215138548|NCT00434317|DRUG|Zoledronic acid|
215138549|NCT02179697|OTHER|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
215138550|NCT02179697|PROCEDURE|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
215138551|NCT02946138|RADIATION|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
215138552|NCT02766023|BIOLOGICAL|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
215138553|NCT02766023|DRUG|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
215138554|NCT02766023|OTHER|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
215138555|NCT00408057|OTHER|no intervention|no intervenion
215138556|NCT05902962|DRUG|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
215138557|NCT04018755|BIOLOGICAL|anakinra|anakinra single-use prefilled glass syringes
215138558|NCT06085625|BEHAVIORAL|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
215138559|NCT06085625|BEHAVIORAL|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
215138560|NCT06271993|DEVICE|ColActivePlus Collagen Matrix Dressing|The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
215138561|NCT05946057|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
214526823|NCT01493388|DRUG|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
214526824|NCT05005572|OTHER|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
215138562|NCT05918523|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
215138563|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock and pectointercostal block|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib and pectointercostal plane block (0,25% bupivacaine 15 ml) will perform at 4-5.th intercostal space. Both 2 blocks will perform bilaterally
215138564|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib to the all patients
214452802|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
214452803|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
214452804|NCT06357234|DRUG|Aprepitant|Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
214452805|NCT06357234|DRUG|Placebo|Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
214452806|NCT05534893|DIETARY_SUPPLEMENT|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
214452807|NCT05534893|DIETARY_SUPPLEMENT|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
214452808|NCT06542796|PROCEDURE|Immunotherapy combined with targeted therapy|Immunotherapy combined with targeted therapy
214452809|NCT06542796|OTHER|Standard treatment plan|Standard treatment plan
214452810|NCT03338790|BIOLOGICAL|nivolumab|Specified dose on specified days
214452811|NCT03338790|DRUG|docetaxel|Specified dose on specified days
214452812|NCT03338790|DRUG|enzalutamide|Specified dose on specified days
214452813|NCT03338790|DRUG|rucaparib|Specified dose on specified days
214452814|NCT03338790|DRUG|prednisone|Specified dose on specified days
214452815|NCT06188936|DEVICE|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
214452816|NCT06188936|OTHER|Survey|Surveys will be completed on a hard copy or electronically.
214452817|NCT01912651|DRUG|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
214526825|NCT03939871|DRUG|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
215138565|NCT05989009|OTHER|Breastfeeding|Mothers will breastfeed their newborns
215138566|NCT05788510|OTHER|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
214452818|NCT06782867|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
214452819|NCT04424745|OTHER|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
214452820|NCT06781580|OTHER|Esports Ergonomic Protocol|"The Esports Ergonomic Protocol is a six-week intervention designed to reduce the risk of repetitive strain injuries and enhance gaming performance for esports athletes. It includes an educational session on ergonomics, focusing on proper posture, body mechanics, and workstation setup. The protocol also incorporates warm-up and cool-down exercises to prevent strain and improve flexibility, as well as a postural rehabilitation program targeting the upper extremities and core muscles.~Participants will attend four in-person sessions at specified intervals for ergonomic risk assessments (using REBA) and gaming performance evaluations (using Kovaaks). The intervention also features online resources, including exercise tutorials and ergonomic tips, to support adherence and long-term implementation. Feedback will be collected through post-intervention surveys and an optional focus group to refine the protocol for future use in the esports community."
214452821|NCT06191731|OTHER|biological samples collection|Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
214452822|NCT06213038|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
214452823|NCT05698459|BIOLOGICAL|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
214452824|NCT04126681|DRUG|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
214452825|NCT04126681|DRUG|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
214526826|NCT04097314|DRUG|Zibotentan|10mg OD Zibotentan
214526827|NCT04097314|DRUG|Placebo oral tablet|Placebo
214526828|NCT03334747|DRUG|KAE609|Exploration of different doses of KAE609 to establish safety profile.
214526829|NCT03334747|DRUG|Coartem|Control Arm
215138567|NCT05891704|PROCEDURE|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
215138568|NCT05891704|PROCEDURE|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
215138569|NCT01827137|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
214452826|NCT04126681|DRUG|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
214452827|NCT04126681|DRUG|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
214452828|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
214452829|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
214452830|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
214452831|NCT03303586|OTHER|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
214452832|NCT03303586|OTHER|Control|Participants will not wearing compression stockings for two weeks.
214452833|NCT06048757|DEVICE|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
214526830|NCT02567227|OTHER|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
214526831|NCT02567227|OTHER|Active Control|Computer, multimedia and group based health education programs.
214526832|NCT01961804|DRUG|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
214526833|NCT03570996|PROCEDURE|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
214526834|NCT03570996|PROCEDURE|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
214526835|NCT03570996|PROCEDURE|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
214526836|NCT04362111|DRUG|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
215138570|NCT01827137|BIOLOGICAL|GM-CSF|subcutaneous injection
214526837|NCT04362111|DRUG|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
215138571|NCT01827137|OTHER|Montanide|adjuvant
215138572|NCT01827137|DRUG|lenalidomide|optional post-ASCT therapy
215138573|NCT01827137|DRUG|bortezomib|optional post-ASCT therapy
215138574|NCT05967585|DEVICE|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
215138575|NCT04092504|OTHER|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for elderly patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
214452834|NCT03921502|PROCEDURE|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
214452835|NCT04106583|DEVICE|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
214452836|NCT05498896|DRUG|Atezolizumab|IV infusion
214452837|NCT05498896|DRUG|Ipatasertib|Oral
214452838|NCT05498896|DRUG|Paclitaxel|IV infusion
214452839|NCT05498896|DRUG|Doxorubicin|IV infusion
214452840|NCT05498896|DRUG|Cyclophosphamide|IV infusion
214452841|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
214452842|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
214452843|NCT05067517|DRUG|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
214452844|NCT05067517|DRUG|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
214452845|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
214452846|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
214452847|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
214452848|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
214694925|NCT01668563|PROCEDURE|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
214452851|NCT02329652|DEVICE|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
214452852|NCT01242917|DRUG|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
214452853|NCT01242917|DRUG|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
214452854|NCT01242917|DRUG|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
214452855|NCT04537988|OTHER|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
214452856|NCT03673111|DRUG|Y14|Gut hormone analogue
214452857|NCT03673111|DRUG|Placebo|0.9% saline
214452858|NCT03846505|DRUG|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
214452859|NCT03846505|OTHER|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
214452860|NCT03091725|PROCEDURE|Roux-en-Y gastric bypass surgery|Roux-en-Y gastric bypass surgery will be performed with post-weight loss testing performed after \~16-18% weight loss is achieved.
214452861|NCT03091725|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose \~16-18% of their body weight.
214452862|NCT05238766|BEHAVIORAL|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
214452863|NCT02381535|DRUG|Cisplatin|Given IV
214452864|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214452865|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
214452866|NCT02381535|DRUG|Onalespib|Given IV
214452867|NCT02381535|OTHER|Pharmacological Study|Correlative studies
215138576|NCT03095495|DEVICE|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
215138577|NCT03095495|DEVICE|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
215138578|NCT06407726|OTHER|virtual reality training group|Participants will receive 40-minute sessions five days per week for six weeks of Virtual Reality intervention and conventional therapy.
215138579|NCT06407726|OTHER|vestibular exercise group|Participants will receive 40-minute sessions five days per week for six weeks of Vestibular Exercises and conventional therapy.
215138580|NCT05274815|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
215138581|NCT01565200|DRUG|T-DM1|3.6 mg/kg iv every 3 weeks
215138582|NCT01565200|PROCEDURE|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
215138583|NCT05552664|GENETIC|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
215138584|NCT03557294|DRUG|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
215138585|NCT03557294|DRUG|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
215138586|NCT03557294|DRUG|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
215138587|NCT04026113|DRUG|Linaclotide|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
215138588|NCT04026113|DRUG|Placebo|Matching placebo
215138589|NCT06513858|BEHAVIORAL|Communal Drumming|Communal drumming
215138590|NCT06513858|BEHAVIORAL|Communal drumming recordings|Recordings of drumming taken from the music made during a previous component of the study
215138591|NCT04861103|DRUG|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
214452868|NCT06036199|DEVICE|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
215138592|NCT05562882|DRUG|Daratumumab Injection|intravenous daratumumab administration
215138593|NCT02887820|DEVICE|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
215138594|NCT03535584|BEHAVIORAL|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
215138595|NCT04077801|DIAGNOSTIC_TEST|diagnostic test|diagnostic test
215138596|NCT04077801|DIAGNOSTIC_TEST|Postpartum pain|test
215138597|NCT04077801|OTHER|Visual analogue scale|test TMJ /pelvic angle/lumber angle
215138598|NCT05398757|BEHAVIORAL|Mini mental state exame (MMSE)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
214452869|NCT05601154|DRUG|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
215138599|NCT05398757|BEHAVIORAL|Digit Symbol Substitution Test (DSST)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
215138600|NCT05398757|DIAGNOSTIC_TEST|Numeric rating Scale (NRS)|4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
215138601|NCT05398757|DIAGNOSTIC_TEST|Postoperative inflammation|All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
215138602|NCT05398757|DRUG|Midazolam|For sedation during surgery, patients in midazolam group will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg after spinal anesthesia.
214452870|NCT05601154|DRUG|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
214452871|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
215138603|NCT05398757|DRUG|Propofol|For sedation during surgery, patients in propofol group will receive i.v. propofol in dose 25-27 mcg/kg/min.
215138604|NCT05398757|DRUG|Dexmedetomidin|For sedation during surgery, patients in dexmedetomidin gropu will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
215138605|NCT04613362|BEHAVIORAL|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
215138606|NCT04613362|BEHAVIORAL|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
215138607|NCT04494672|PROCEDURE|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
215138608|NCT04494672|PROCEDURE|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
215138609|NCT06221280|PROCEDURE|Nerve block|"Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia."
215138610|NCT05427344|OTHER|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
215138611|NCT05427344|OTHER|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
215138612|NCT05427344|OTHER|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
215138613|NCT02218372|DRUG|Fidaxomicin oral suspension|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
215138614|NCT02218372|DRUG|Fidaxomicin tablets|Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
215138615|NCT02218372|DRUG|Vancomycin oral liquid|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
215138616|NCT02218372|DRUG|Vancomycin capsules|Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
215138617|NCT05417542|OTHER|EEG|EEG recording during prematurity or around term
215138618|NCT05417542|OTHER|NIRS|NIRS recording during prematurity or around term
215138619|NCT05662410|DRUG|Three monthly injections of intravitreal aflibercept|Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
215138620|NCT06638931|DRUG|Nivolumab|"The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death."
214452872|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
214694926|NCT04436224|DRUG|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
215138621|NCT05339555|OTHER|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
214452873|NCT04487249|OTHER|Vision Therapy|20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.
214694927|NCT04436224|DRUG|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
214694928|NCT04436224|DRUG|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
215138622|NCT06513910|BEHAVIORAL|Music|Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
215138623|NCT05136560|DRUG|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
215138624|NCT05484102|DIETARY_SUPPLEMENT|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
215138625|NCT05484102|DIETARY_SUPPLEMENT|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
215138626|NCT05629988|DEVICE|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
215138627|NCT05380466|OTHER|Quantum Touch|Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
214452874|NCT05922345|DRUG|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
214452875|NCT05922345|DRUG|TQB2450 placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
215138628|NCT06415175|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
215138629|NCT04146051|DRUG|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
215138630|NCT02753283|DRUG|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
215138631|NCT02753283|DRUG|Placebo|Semi-annual saline injection
215138632|NCT02753283|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
215138633|NCT04386291|BEHAVIORAL|Anxiety Reduction Training|Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
215138634|NCT04386291|BEHAVIORAL|Kundalini Yoga and Anxiety Reduction Training|Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
215138635|NCT04386291|BEHAVIORAL|Meditation and Anxiety Reduction Training|Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
214452876|NCT03188146|DRUG|Ursodeoxycholic Acid|Standard care of PBC patients
214452877|NCT03989947|DRUG|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
214452878|NCT06090162|DIAGNOSTIC_TEST|ctDNA detection|ctDNA detection on CSF and blood
214694929|NCT03184909|DRUG|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
214694930|NCT03184909|DRUG|Placebo|Placebo capsules of look alike inert substance for control
214694931|NCT04436822|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
215138636|NCT06206824|DRUG|Leucettinib-21|See arm's description.
215138637|NCT01300754|PROCEDURE|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
215138638|NCT01300754|PROCEDURE|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
215138639|NCT01300754|OTHER|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
215138640|NCT04331587|DEVICE|BF-P190 4 mm thin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
215138641|NCT04331587|DEVICE|BF-MP190F 3 mm ultrathin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
215138642|NCT04331587|DEVICE|Radial ultrasound probe (UM S20-17S)|-Olympus
215138643|NCT04331587|DEVICE|PeriView FLEX 21G Single Use Aspiration Needle|"* NA-403D-2021~* Gyrus ACMI, Inc."
215138644|NCT02674035|PROCEDURE|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
215138645|NCT05172128|DIETARY_SUPPLEMENT|lyophilized blueberry supplement|lyophilized blueberry supplement bid
215138646|NCT01958996|DRUG|idarubicin|
215138647|NCT00671658|DRUG|Rituximab|375 mg/m2 by vein
215138648|NCT00671658|DRUG|Cyclophosphamide (CTX)|300 mg/m2 by vein
215138649|NCT00671658|DRUG|Doxorubicin|50 mg/m2 by vein
215138650|NCT00671658|DRUG|Vincristine|2 mg by vein
215138651|NCT00671658|DRUG|Dexamethasone|40 mg by vein or by mouth (P.O.)
215138652|NCT00671658|DRUG|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
214452879|NCT05766072|OTHER|EMOTION Kids coping with anxiety and depression (Mestrende barn in Norwegian)|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
214452880|NCT05481216|OTHER|COVID-19|Diagnosed with COVID-19 infection
215138653|NCT00671658|DRUG|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
215138654|NCT00671658|DRUG|G-CSF|10 ug/kg subcutaneous injection
215138655|NCT00671658|DRUG|Mesna|600 mg/m2 a day by vein
215138656|NCT00671658|DRUG|Pegylated asparaginase|2000 International units/m2 by vein
215138657|NCT00671658|DRUG|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
215138658|NCT00671658|DRUG|Solumedrol|40 mg by vein for Courses 2,4,6,8
215138659|NCT03864783|DIETARY_SUPPLEMENT|Curcumin (Meriva®)|"Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)"
215138660|NCT03864783|DRUG|Placebo Oral Tablet|"Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®."
215138661|NCT06420804|DEVICE|ZIIP Acne Treatment Device|Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
215138662|NCT01921205|DRUG|Lacosamide|"Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
215138663|NCT01921205|OTHER|Placebo|"Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
215138664|NCT02049775|PROCEDURE|NBI|
215138665|NCT05799287|BIOLOGICAL|Telitacicept|Subcutaneous injection
215138666|NCT05799287|DRUG|Placebo|Placebo to Telitacicept
215138667|NCT01578447|DRUG|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
215138668|NCT01578447|DRUG|Intramuscular DMPA|Intramuscular DMPA
215138669|NCT02678949|DRUG|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
215138670|NCT02678949|DRUG|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
215138671|NCT02678949|DRUG|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
215138672|NCT01082861|BIOLOGICAL|Cervarix|Cervarix, HPV vaccin
215138673|NCT01082861|BIOLOGICAL|Engerix-B|Engerix-B, HBV vaccin
215138674|NCT00758017|OTHER|Acupuncture 1|Application of individualised acupuncture
215138675|NCT00758017|OTHER|Acupuncture 2|Application of standardised acupuncture
215138676|NCT01721135|DRUG|GSK2190915 100mg|Film coated oral tablet
215138677|NCT01721135|DRUG|GSK2190915 200mg|Film coated oral tablet
215138678|NCT01721135|DRUG|moxifloxacin 400mg|Film coated oral tablet
214452881|NCT05481216|OTHER|HIV-1 infection|Diagnosed with HIV-1 infection
214526838|NCT02831439|BEHAVIORAL|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
214694932|NCT03463616|RADIATION|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
214694933|NCT03463616|RADIATION|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
214694934|NCT02347241|OTHER|Educational intervention|Educational Debriefings and High frequency training and team reflection
214694935|NCT03442335|DIAGNOSTIC_TEST|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
215138679|NCT01721135|DRUG|moxifloxacin placebo|Film coated oral tablet
215138680|NCT01721135|DRUG|GSK2190915 placebo|Film coated oral tablet
215138681|NCT05625308|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
215138682|NCT00023777|BIOLOGICAL|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
214452882|NCT03942445|PROCEDURE|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
214694936|NCT03442335|DIAGNOSTIC_TEST|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
215138683|NCT00023777|BIOLOGICAL|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
215138684|NCT00023777|DRUG|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
215138685|NCT00023777|DRUG|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
215138686|NCT00761423|BIOLOGICAL|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
215138687|NCT00761423|BIOLOGICAL|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
215138688|NCT00456846|DRUG|ABI-007|100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
214452883|NCT06249841|DEVICE|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
215138689|NCT03398317|OTHER|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
215138690|NCT03398317|OTHER|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
214452884|NCT06779968|DEVICE|Femoral Nerve Block|In the femoral nerve block (FNB) group, the femoral nerve was blocked distal to the inguinal ligament and lateral to the femoral artery. Under sterile conditions and ultrasound guidance using a short-axis out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the femoral nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
214452885|NCT06779968|DEVICE|Combined Sciatic and Femoral Nerve Block|In the combined sciatic and femoral nerve block (CS-FNB) group, the femoral nerve block was performed as described above. The sciatic nerve block was performed at either the gluteal region or popliteal fossa. Under sterile conditions and ultrasound guidance using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the sciatic nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
214452886|NCT06779968|DEVICE|Lumbar plexus block|In the lumbar plexus block (LPB) group, the lumbar plexus was blocked paraspinally within the psoas muscle. Under sterile conditions, ultrasound guidance, or with the assistance of a nerve stimulator, using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced within the psoas muscle adjacent to the lumbar plexus. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
214452887|NCT06779968|PROCEDURE|Epidural Analgesia|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine was administered followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hr. For pediatric patients, an initial bolus of 0.2% ropivacaine at 0.5-1 mg/kg was administered, not exceeding a maximum total dose of 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
214452888|NCT06779968|DRUG|Intravenous patient-controlled analgesia|For intravenous patient-controlled analgesia (PCA), fentanyl was administered at a dose of 2 mcg/kg, diluted in 100 mL of normal saline. The basal infusion rate was set at 2 mL/hr, with a PCA dose of 2 mL and a lockout interval of 15 minutes.
214452889|NCT06779968|DEVICE|General Aneasthesia|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
214452890|NCT05494866|DRUG|Cobicistat Oral Tablet|Cobicistat Oral Tablet
214452891|NCT05494866|DRUG|Gemcitabin|Gemcitabin
214452892|NCT05494866|DRUG|Nab paclitaxel|nab-Paclitaxel
214694937|NCT00296959|DRUG|topiramate (drug)|
214694938|NCT00501566|DRUG|satavaptan (SR121463B)|
215138691|NCT01241721|DEVICE|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
215138692|NCT01586546|BEHAVIORAL|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
215138693|NCT01586546|OTHER|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
215138694|NCT01586546|OTHER|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
215138695|NCT01586546|BEHAVIORAL|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
215138696|NCT00811122|RADIATION|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
214452893|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
214452894|NCT04993885|DRUG|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
214452895|NCT06780852|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
214452896|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
214452897|NCT02386553|DRUG|Nusinersen|Solution for intrathecal injection
214452898|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
214452899|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
214452900|NCT06130397|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~\- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1."
214452901|NCT06130397|OTHER|Ground truthing|Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
214452902|NCT01744782|DRUG|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
215138697|NCT00811122|RADIATION|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
215138698|NCT00915252|DRUG|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
215138699|NCT00915252|DRUG|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
215138700|NCT01519908|DEVICE|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
215138701|NCT05944302|BEHAVIORAL|EMDR group|Eye Movement Desensitization and Reprocessing
215138702|NCT01185236|DRUG|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
215138703|NCT01185236|DRUG|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
215138704|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate|
215138705|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate - double dose|
214452903|NCT03085108|OTHER|No Intervention|No Intervention
214452904|NCT06201078|RADIATION|Stereotactic Body Radiotherapy|"Salvage SBRT will be performed in three subgroups of patients with local recurrence:~Group A - after conventionally fractionated/moderately hypofractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT~Target volumes:~GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\*~\*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm.~Dose constrains:~The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed:~* Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%)~* Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%)~Dose-volume constrains:~Rectum:~• D30% \<15Gy~Bladder:~• D30% \< 15 Gy"
214452905|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
214452906|NCT04649359|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
214452907|NCT04832295|OTHER|photo-supported conversations|"Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs."
214452908|NCT04832295|OTHER|Care as usual|Medication, psychological treatment
214452909|NCT06545838|OTHER|Analysis of plasma renin concentration|The concentration of plasma renin in patients will be assessed using the immunochemiluminescent method
214452910|NCT06491732|DEVICE|Electrical Impedance Myography|EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
214452911|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
214452912|NCT05027958|DRUG|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
214452913|NCT05200481|DRUG|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
214452914|NCT05200481|DRUG|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
215138706|NCT02147639|DIETARY_SUPPLEMENT|Placebo|
215138707|NCT02147639|PROCEDURE|Increased exercise intensity|
215138708|NCT02496286|DRUG|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
215138709|NCT00771277|BEHAVIORAL|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
215138710|NCT04308421|DEVICE|Red light|Low irradiation 650 nm +/- 5 nm red light
215138711|NCT05118945|DEVICE|Insulin pump Tandem: t:slim X2|"Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered."
215138712|NCT03868514|DEVICE|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
215138713|NCT02904681|OTHER|No intervention. Observational and descriptive study|
215138714|NCT03125395|DRUG|LUM/IVA|Participants received LUM/IVA every q12h.
215138715|NCT03696836|DEVICE|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
215138716|NCT03733717|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
215138717|NCT05230134|PROCEDURE|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
215138718|NCT01668784|BIOLOGICAL|Nivolumab|
215138719|NCT01668784|DRUG|Everolimus|
215138720|NCT04049786|PROCEDURE|Digestive biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
215138721|NCT04049786|DRUG|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
215138722|NCT04049786|PROCEDURE|Serial blood sampling for PK analysis|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
215138723|NCT04049786|DRUG|Metoprolol 100 mg for CYP2D6 phenotyping|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
215138724|NCT04049786|DRUG|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
215138725|NCT04049786|DRUG|Midazolam 2 mg for CYP3A4 phenotyping|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
214452915|NCT05200481|DRUG|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
214452916|NCT05838274|OTHER|Alcohol vs. Placebo beverage conditions|Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.
214452917|NCT04128670|DEVICE|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
214452918|NCT00211289|BEHAVIORAL|Education by community pharmacist|
214452919|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
214694939|NCT05464446|DEVICE|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
214694940|NCT00011765|DRUG|Fluoxetine|
215138726|NCT04049786|OTHER|Genotyping|Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
215138727|NCT00311766|DRUG|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
215138728|NCT00311766|DRUG|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
215138729|NCT05231226|PROCEDURE|Immediately CR|Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD
215138730|NCT05231226|PROCEDURE|Staged (within 45 days) CR|Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
215138731|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
215138732|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
215138733|NCT01648712|DEVICE|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
215138734|NCT01648712|DEVICE|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
215138735|NCT04939766|DEVICE|Activation of a closed loop device in an insulin pump device with GCM|After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
215138736|NCT06372626|BIOLOGICAL|ZG005|"ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage."
215138737|NCT06372626|DRUG|Etoposide|IV infusion
215138738|NCT06372626|DRUG|Cisplatin|IV infusion
215138739|NCT06372626|DRUG|Placebo|0.9% Sodium Chloride Injection
215138740|NCT00768417|BEHAVIORAL|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
215138741|NCT00768417|BEHAVIORAL|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
215138742|NCT00768417|BEHAVIORAL|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
215138743|NCT02015273|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
215138744|NCT06009965|DRUG|CsA+ATG+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
215138745|NCT06009965|DRUG|CsA+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
215138746|NCT01413035|BIOLOGICAL|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
215138747|NCT06156020|PROCEDURE|Endoscopic endonasal surgery|Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
215138748|NCT01780311|DRUG|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
215138749|NCT01780311|PROCEDURE|Catheter Ablation|
215138750|NCT03659188|PROCEDURE|Cortico-alveolar perforations|Mechanical drills will be used on a handpiece
215138751|NCT03659188|PROCEDURE|Traditional Corticotomy|Piezo-surgery will be employed following flaps' elevation.
215138752|NCT02560038|DRUG|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
215138753|NCT02560038|DRUG|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
215138754|NCT02560038|DRUG|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
215138755|NCT00006016|DRUG|thalidomide|Given orally
214452920|NCT05845398|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
214452921|NCT05845398|DRUG|Placebo|0.9% saline for injection.
214526839|NCT02831439|BEHAVIORAL|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
215138756|NCT00006016|DRUG|doxorubicin hydrochloride|Given transarterially (chemoembolization)
215138757|NCT00006016|OTHER|laboratory biomarker analysis|Correlative studies
215138758|NCT03542812|DRUG|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
215138759|NCT04853758|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
215138760|NCT04853758|DRUG|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
215138761|NCT05552846|RADIATION|thoracic radiotherapy|Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
215138762|NCT00579033|OTHER|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
215138763|NCT00579033|OTHER|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
215138764|NCT05068258|PROCEDURE|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
215138765|NCT05672381|PROCEDURE|Lower extremity and/or upper extremity surgery|Lower extremity and/or upper extremity surgery
215138766|NCT01400308|DRUG|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
215138767|NCT01400308|DEVICE|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
215138768|NCT04696432|BIOLOGICAL|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
215138769|NCT01516905|DRUG|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
215138770|NCT06032871|PROCEDURE|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
215138771|NCT06032871|PROCEDURE|Chest physiotherapy|Participants received chest physiotherapy twice a day
215138772|NCT06210646|DRUG|Citicoline 2000|The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
215138773|NCT06210646|DRUG|citocoline 1000|The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
215138774|NCT05101902|OTHER|Pre-Screening|No intervention given
215138775|NCT06552871|BEHAVIORAL|Forming Love around Autistic People to Prevent Suicide|Four-part virtual educational intervention
215138776|NCT04523714|BEHAVIORAL|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
214452922|NCT03443323|BEHAVIORAL|Organizational Skills Training - Tier 2 (OST-T2)|OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
214452923|NCT05858593|BEHAVIORAL|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
214452924|NCT05858593|BEHAVIORAL|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
214452925|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
214452926|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
215138777|NCT04523714|BEHAVIORAL|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
215138778|NCT06334432|DRUG|NUV-1511|Novel small molecule
215138779|NCT03280719|DEVICE|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
215138780|NCT03280719|RADIATION|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
215138781|NCT03280719|DEVICE|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
215138782|NCT03280719|RADIATION|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
215138783|NCT06007872|DEVICE|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
215138784|NCT02783690|RADIATION|Hypofractionation|40 Gy (RBE) in 15 daily fractions
215138785|NCT02800668|DEVICE|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
215138786|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
215138787|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
215138788|NCT04515615|DRUG|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
215138789|NCT04515615|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
215138790|NCT04515615|DRUG|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
215138791|NCT02167490|PROCEDURE|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
215138792|NCT04069689|DRUG|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
215138793|NCT04069689|DRUG|Placebos|Placebo to match EPX-100
215138794|NCT03747549|OTHER|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
215138795|NCT03747549|OTHER|Home Exercise Alone|The prescribed home exercise program alone.
215138796|NCT04156087|DRUG|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
215138797|NCT04156087|DRUG|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
215138798|NCT04156087|DRUG|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
215138799|NCT04156087|PROCEDURE|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
215138800|NCT05178173|OTHER|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
214452927|NCT05062031|DEVICE|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
214452928|NCT05062031|DRUG|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
214452929|NCT05062031|DEVICE|Monofocal lenses|Daily wear for 24 months
214452930|NCT06465563|DRUG|SHR-8068|SHR-8068
215138801|NCT05178173|OTHER|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
215138802|NCT05178173|OTHER|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
215138803|NCT00471055|DRUG|"0.0125% Capsaicin gel CAPSIKA gel"|
215138804|NCT00471055|DRUG|Placebo|Placebo
215138805|NCT05037240|DIETARY_SUPPLEMENT|Quercetin|Quercetin (500 mg), 2 times a day for 3 months
215138806|NCT05037240|COMBINATION_PRODUCT|Placebo|500 mg, 2 times a day for 3 months
214452931|NCT06465563|DRUG|Adebrelimab|Adebrelimab
214452932|NCT06465563|DRUG|Cisplatin|Cisplatin
214452933|NCT06465563|DRUG|Gemcitabine|Gemcitabine
214452934|NCT06568588|DRUG|S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745|250 mg three times a day for 4 months
214452935|NCT04857671|DRUG|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
214452936|NCT04857671|DRUG|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
214526840|NCT02831439|BEHAVIORAL|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
214452937|NCT05559515|BEHAVIORAL|NDPP-Flex|NDPP + patient-centered goal setting
214452938|NCT05559515|BEHAVIORAL|NDPP|Usual care NDPP only
215138807|NCT04732520|DEVICE|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
215138808|NCT00236223|DRUG|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
215138809|NCT00236223|DRUG|Placebo|Matching placebo
214452939|NCT06007391|DRUG|Nicotinamide|nicotinamide 3g per day
214452940|NCT06221735|DIAGNOSTIC_TEST|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
214452941|NCT06221735|DIAGNOSTIC_TEST|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
214452942|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
214452943|NCT04610892|BIOLOGICAL|Placebo|Buffer
214452944|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
214452945|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214526841|NCT02604147|DEVICE|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
215138810|NCT00519441|OTHER|pH study|All patients will have 48 hour pH study
214452946|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
214452947|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
214452948|NCT06285474|DEVICE|Low Intensity Focused Ultrasound Pulsation (LIFUP)|All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
215138811|NCT01723384|DRUG|Intermittent Oral Naltrexone|
215138812|NCT01723384|DRUG|Placebo|
215138813|NCT05306899|DRUG|Ketamine|Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
215138814|NCT05306899|OTHER|0.9% Saline|Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
215138815|NCT02320084|DRUG|Nitisinone|Nitisinone according to prescription
215138816|NCT05907785|BEHAVIORAL|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
215138817|NCT00517387|DRUG|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
215138818|NCT05138653|DRUG|CVL-354|Oral solution/suspension
215138819|NCT05138653|DRUG|Placebo|Placebo matched to CVL-354
215138820|NCT05138653|DRUG|CVL-354|Capsule
215138821|NCT06202365|DEVICE|Whole body Vibration|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
215138822|NCT06202365|OTHER|Sham Whole body vibration|They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
215138823|NCT05880134|PROCEDURE|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
215138824|NCT05880134|PROCEDURE|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
215138825|NCT05220618|BEHAVIORAL|Autobiographical Memory Specificity and Savoring Training: PESCAR|An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
215138826|NCT02624596|DRUG|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
215138827|NCT02624596|DRUG|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
215138828|NCT03491059|DRUG|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
215138829|NCT03491059|RADIATION|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
215138830|NCT06598839|DRUG|Thymosin Alpha1|subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
215138831|NCT06595654|OTHER|repetitive Transcranial Magnetic Stimulation|"* Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized."
215138832|NCT06603194|DIETARY_SUPPLEMENT|Bovine or Marine Collagen|Bovine or Marine Collagen
215138833|NCT06596239|DEVICE|lower-clear-plate-based intermaxillary traction (LCP-IMT)|The patient is instructed to apply elastics between the upper molar bands and the hooks on the lower clear plates.
215138834|NCT06596239|DEVICE|Removable mandibular retractor (RMR)|An appliance is worn on the upper jaw, which affects the lower jaw by using an inferiorly extended labial bow.
215138835|NCT06729658|DRUG|Madopar|Experimental group participants will receive Madopar 125mg for 6 days.
215138836|NCT06729658|DRUG|Placebo|Control group participants will receive placebo for 6 days.
215138837|NCT03066869|DRUG|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
215138838|NCT04272242|DRUG|Dolutegravir (DTG)|Administered orally
215138839|NCT04272242|DRUG|Isoniazid (INH)|Administered orally
215138840|NCT04272242|DRUG|Rifapentine (RPT)|Administered orally
214452949|NCT06292624|DEVICE|Intermittent vacuum therapy (Weyergans High Care® Medial, Germany)|The participants' lower limb will be placed in the vacuum chamber and sealed with a cuff. The maximum negative pressure applied in the experimental group would be -40mmHg (negative pressure/ambient pressure phase: 9s / 7s). The parameters are selected based on the manufacturer's recommendations.
215138841|NCT04272242|DRUG|Antiretroviral Therapy (ART)|Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
215138842|NCT04272242|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
215138843|NCT02702492|DRUG|KPT-9274|
214452950|NCT06292624|BEHAVIORAL|Cycling exercise|The participant will perform 20 minutes of cycling exercise. Aiming at reaching a moderate exercise intensity (50% - 70%) of maximal heart rate on a gym bike.
214452951|NCT05536336|DEVICE|Condom|Contraception
214452952|NCT05987657|DIAGNOSTIC_TEST|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
215138844|NCT02702492|DRUG|Niacin ER|
215138845|NCT02702492|DRUG|Nivolumab|
215138846|NCT01824836|DRUG|anastrozole|Given PO
215138847|NCT03378869|PROCEDURE|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
215138848|NCT06596720|OTHER|Aerobic Exercise|After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
215138849|NCT06592573|OTHER|CBT_ONLINE|10-12 sessions of cognitive behavioural therapy conducted online
215138850|NCT06592573|OTHER|CBT_IN PERSON|10-12 sessions of cognitive behavioural therapy conducted in-person.
215138851|NCT06603909|OTHER|group 1: Use AI to assist nutrition management|group1：AI-assisted nutrition management. group 2：Traditional nutrition management（through the hospital dietitian）.group 3:control.
215138852|NCT06603909|OTHER|group 2：Traditional nutrition management（through the hospital dietitian）|group 2：Traditional nutrition management（through the hospital dietitian）
215138853|NCT06587711|PROCEDURE|acupuncture treatment|Patients in experimental group received acupuncture at specific acupoint on the face, patients in control group received sham acupuncture at non-acupoint on the face.
215138854|NCT06596109|BEHAVIORAL|honey intake and lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
215138855|NCT06596109|BEHAVIORAL|lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
215138856|NCT06589193|OTHER|HOCl|10ml,twice a day
215138857|NCT06589193|OTHER|CHX|10ml,twice a day
215138858|NCT06842615|DIAGNOSTIC_TEST|Pantum detect test|epitope detection in monocyte (EDIM)
214452953|NCT06021795|DEVICE|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
214452954|NCT04059770|DRUG|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
215138859|NCT06593145|BIOLOGICAL|FCTX-CL19-1 (Tarcidomgen Kimleucel)|"It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight"
215138860|NCT06609174|DIAGNOSTIC_TEST|KardiaRx ECG Screening and AI interpretation of ECG|The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
215138861|NCT06989593|BEHAVIORAL|Narrative Medicine Journaling Intervention|Participants will complete the GAD-7 anxiety assessment at baseline. They will then receive a physical journal containing 5 structured, therapeutic writing prompts designed to help process emotions related to their child's diagnosis. Prompts focus on processing experiences with diagnosis, addressing uncertainty, coping with stigma, and developing resilience. Parents will be instructed to complete the 5 journal entries, spending 15-20 minutes on each writing session at least once per week. Following completion of the journaling intervention, participants will complete a follow-up GAD-7 assessment and take part in a 30-45 minute qualitative interview to further assess perceived changes in anxiety, stress, and coping strategies, and to gather feedback on potential group-based writing programs.
215138862|NCT06991335|DEVICE|Deep Brain Stimulation|Medtronic Percept PC with SenSight Directional Leads will be implanted to control the shape and size of stimulation
215138863|NCT06993285|OTHER|Protologic and LAnguage adaptation rehabilitation|Each patient will receive a maximum of 34 weeks of Protologic and LAnguage adaptation rehabilitation by a speech therapist at a rate of one or two speech therapy sessions per week, for a total of 30 sessions maximum. All sessions are filmed and at posteriori analysed with the help of ELAN© software
215138864|NCT06585995|DRUG|vitamin D (cholecalciferol) supplementation|"This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses"
215138865|NCT06593171|BEHAVIORAL|Mentoring program|This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.
214526842|NCT02604147|DEVICE|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
214526843|NCT06210737|BIOLOGICAL|PCV13|3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
214526844|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13, and a booster dose
214526845|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13
214526846|NCT06210737|BIOLOGICAL|PCV13|single dose of PCV13
214526847|NCT03742232|DRUG|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
214526848|NCT03742232|DRUG|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
214526849|NCT01211717|DIETARY_SUPPLEMENT|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
214526850|NCT01211717|OTHER|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
215138866|NCT06593171|BEHAVIORAL|Control (placebo) group|This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
215138867|NCT03905707|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
215138868|NCT03907735|OTHER|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
215138869|NCT05730933|BEHAVIORAL|Intervention|Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
215138870|NCT06999668|DEVICE|Virtual reality cognitive function training|"Participants will receive VR-based cognitive training over 4-5 days prior to surgery, with three daily 30-minute sessions (8:00-10:00 AM, 12:00-2:00 PM, and 5:00-7:00 PM), ensuring a total preoperative training duration ≥6 hours.~The intervention utilizes an immersive VR environment that simulates real-world scenarios and tasks. Training modules target multiple cognitive domains, including memory, executive function, calculation, and abstract reasoning, designed as engaging, game-like activities with a gradual learning curve.~Each participant's regimen is personalized based on baseline cognitive assessments or physician prescriptions, adhering to the 6-hour rule for standardized efficacy evaluation. The system incorporates adaptive difficulty adjustment, dynamically modifying task complexity in response to real-time performance."
215138871|NCT06999668|DEVICE|Virtual scene intervention|The control group will receive non-interactive VR exposure using identical equipment and session duration as the training group (3×30-minute daily sessions for 4-5 days, totaling ≥6 hours), with all interactive functions disabled to eliminate potential media-related biases (e.g., 2D/3D cognitive load differences from tablet-based interventions) and ensure between-group differences stem solely from interactive training while maintaining blinding integrity through equivalent hardware deployment.
215138872|NCT06999746|OTHER|Control|Sleep hygiene education
215138873|NCT06999746|DEVICE|Oropharyngeal Exercise|Device-monitoring oropharyngeal exercise, 1-5 days a week for three months
215138874|NCT06999746|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure, 1-5 days a week for three months
215138875|NCT06999746|DEVICE|Continuous positive airway pressure and oropharyngeal exercise|Continuous positive airway pressure and device-monitoring oropharyngeal exercise, 1-5 days a week for three months
215138876|NCT06998186|BEHAVIORAL|Discharge Education And Telephone Counseling|"Providing training on discharge education to parents of cardiac surgery patients.~Providing telephone counseling for 6 months"
215138877|NCT06589557|OTHER|Virtual Reality (VR) and Standard Rehabilitation|"VR Rehabilitation:~The VR therapy includes exercises designed to improve the range of motion, coordination, and spatial awareness of the cervical spine. Each patient will complete 15 training sessions over three weeks (5 sessions per week, 2 hours per session), with an additional 30 minutes of daily VR exercises.~Standard Rehabilitation Program:~Manual Therapy: Mobilization and manipulation techniques are applied to enhance the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises focus on improving body position awareness, movement, and balance.~Strengthening and Stretching Exercises: Individually tailored exercises are provided to strengthen and stretch the neck muscles."
215138878|NCT06589557|OTHER|Standard Rehabilitation|"Patients in this group will participate solely in the standard rehabilitation program.~Standard Rehabilitation Program:~Number of Sessions: Each patient will complete 15 training sessions, held 5 times per week for 3 weeks, with each session lasting 2 hours.~Program Components:~Manual Therapy: Mobilization and manipulation techniques will be applied to improve the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises aim to enhance body position awareness, movement control, and balance.~Strengthening and Stretching Exercises: Customized exercises will be provided to strengthen and stretch the neck muscles, tailored to individual needs."
215138879|NCT06998693|DRUG|5-ASA (5-Aminosalicylate)|Specialist doctors decide the administration method of 5-ASA based on the patient's condition (all groups), mainly including topical therapy, or oral therapy (2-4 gram/day).
215138880|NCT06998693|PROCEDURE|Colon Endoscopy Procedure|Participants in all groups will receive a standard Colon Endoscopy Procedure at 48-week.
215138881|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 4-week|Participants in will receive a standard Blood Routine Test at 4-week.
215138882|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 8-week|Participants in will receive a standard Blood Routine Test at 8-week.
215138883|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 12-week|Participants in will receive a standard Blood Routine Test at 12-week.
215138884|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 4-week|Participants in will receive a standard Stool Routine Test at 4-week.
215138885|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 8-week|Participants in will receive a standard Stool Routine Test at 8-week.
215138886|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 12-week|Participants in will receive a standard Stool Routine Test at 12-week.
215138887|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 4-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 4-week.
215138888|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 8-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 8-week.
215138889|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 12-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 12-week.
215138890|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 4-week|Participants in will receive a standard C-reactive Protein Test at 4-week.
215138891|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 8-week|Participants in will receive a standard C-reactive Protein Test at 8-week.
215138892|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 12-week|Participants in will receive a standard C-reactive Protein Test at 12-week.
215138893|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 4-week|Participants in will receive a standard Liver Function Test at 4-week.
215138894|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 8-week|Participants in will receive a standard Liver Function Test at 8-week.
215138895|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 12-week|Participants in will receive a standard Liver Function Test at 12-week.
215138896|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 4-week|Participants in will receive a standard Kidney Function Test at 4-week.
215138897|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 8-week|Participants in will receive a standard Kidney Function Test at 8-week.
215138898|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 12-week|Participants in will receive a standard Kidney Function Test at 12-week.
215138899|NCT06998810|DEVICE|cerebellar rTMS|Non-invasive magnetic stimulation targeting the cerebellum using a figure of eight coil
215138900|NCT06999902|DRUG|20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks|Once daily oral
215138901|NCT06999902|DRUG|Placebo|Once daily oral
215138902|NCT07000019|BEHAVIORAL|CARAT: combined aphasia and robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy combined with a standardized picture-word verification therapy task with the goal of improving language and arm movements.
215138903|NCT07000019|BEHAVIORAL|Robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy with the goal of improving arm movements.
215138904|NCT06998771|DRUG|JSKN003|JSKN003 is administered by intravenous infusion.
215138905|NCT06998771|DRUG|KN026|KN026 is administered by intravenous infusion.
215138906|NCT06998771|DRUG|Capecitabine|Capecitabine is for oral administration.
215138907|NCT06998771|DRUG|Enlonstobart|Enlonstobart is administered by intravenous infusion.
215138908|NCT06998771|DRUG|Oxaliplatin|Oxaliplatin is administered by intravenous infusion.
215138909|NCT06998771|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion.
215138910|NCT06998771|DRUG|Pembolizumab|Pembolizumab is administered by intravenous infusion.
215138911|NCT07000032|OTHER|No Intervention: Observational Cohort|This is an observational cohort
215138912|NCT06998342|RADIATION|Short course radiation|The radiation arm in this study involves Short Course Radiation Therapy (SCRT), which consists of 5 fractions delivered twice a week (either Monday/Thursday or Tuesday/Friday).
214452955|NCT04059770|DRUG|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
214452956|NCT04059770|DRUG|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
214452957|NCT06438367|DRUG|[14C]TGRX-326|Healthy subjects will be given TGRX-326 60 mg orally on day 1.
214452958|NCT04297683|DRUG|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
214452959|NCT04297683|DRUG|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
214452960|NCT04896476|DEVICE|EchoMark / EchoSure|"The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.~The follow-up EchoSure scans will be conducted by the designated EchoSure user without the investigator and without the sonographer/RVT conducting the Duplex exam in the room, either during the routine work-up prior to the surgeon seeing the patient or after. The EchoSure results for flow, and vessel depth and diameter are shown as numerical values on the screen of the EchoSure device."
214452961|NCT06071806|OTHER|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
214452962|NCT03426748|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
214452963|NCT03426748|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
214452964|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
214452965|NCT06837831|OTHER|Control group|Give routine nursing measures. Symptom management: Participants were informed that the damage to the anal canal mucosa caused by radiotherapy was mainly manifested as anal pain, and diarrhea could aggravate the symptoms of anal pain. Therefore, the patient should be instructed to monitor the symptoms of diarrhea and anal pain and give timely feedback; Dietary guidance: eat high-protein, high-vitamin, low-slag, low-fiber food, do not eat spicy and irritating food; Medication guidance: Follow the doctor's advice to take the drug orally on time and according to the amount, cooperate with the retention enema, etc., observe the effect of medication; Psychological guidance: strengthen nurse-patient communication, give psychological counseling, and rationally vent anxiety and other emotions. Perianal skin care: Wear loose cotton underwear to keep the perianal area clean and dry.
214526851|NCT00301015|DEVICE|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
214526852|NCT00935649|DEVICE|PinPointe FootLaser|Medical laser
214526853|NCT03291899|COMBINATION_PRODUCT|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
214526854|NCT02498418|DRUG|Rifaximin|Tablets, generic formulation of the brand product.
215138913|NCT06998342|OTHER|Active Surveillance|The Active Surveillance arm (Group M) aims to monitor participants with moderate-risk cutaneous squamous cell carcinoma (cSCC) after surgical resection, without immediate intervention unless disease progression occurs. Participants will undergo regular clinical evaluations, physical exams, and skin checks to detect new lesions or signs of recurrence. Imaging, including ultrasound and CT/MRI scans, will be performed every 6 months for up to 3 years to monitor for metastasis or progression. Blood samples will be collected for future biomarker analysis to identify indicators of disease recurrence. Participants will also complete quality of life assessments using the EORTC QLQ-C30 and Skin Cancer Index (SCI) to evaluate the impact of surveillance on their daily lives. If disease progression is detected, radiation therapy may be initiated. The study will track overall survival without initiating radiation, as well as disease progression and quality of life outcomes, to determine if active s
215138914|NCT06999395|BEHAVIORAL|Virtual online pelvic health program|The program offers a multimodal approach to self-guided treatment for PVD. Its multimodal approach is exemplified by pain education focusing on pelvic health and neuroplasticity to provide the foundation for strategies strengthening the mind-body connection to the pelvis; mindful breathing and relaxation exercises to reduce nervous system overactivation and enhance mood; and gradual progression of exercises encouraging awareness, stretching, and strengthening to promote relaxation of the pelvic floor muscles and reduction of accessory muscle tension resulting from protective guarding. The program uses 3 separate yet interconnected modules: Learn (20 modules of pain science education and skills), Rewire (11 modules featuring mindfulness and relaxation), and Move (45 pelvic and other exercises).
215138915|NCT01243190|DRUG|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
215138916|NCT06998745|BEHAVIORAL|Medication Therapy Management (MTM) model|MTM model comprising five core elements: Medication Therapy Review (MTR), Personal Medication Record (PMR), Medication-Related Action Plan (MAP), interventions \& referrals, and documentation \& follow-up
215138917|NCT06263010|DRUG|Allopregnanolone|Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
215138918|NCT05465174|DRUG|Tovorafenib|Given orally
215138919|NCT06998394|DRUG|AK104 - Chemotherapy|AK104 (10mg/kg, q3w) + cisplatin weekly or every 3 weeks + radiotherapy (pelvic external beam radiotherapy + brachytherapy) until disease progression, intolerable toxicity, or the investigator judgment that the participant can no longer benefit, participant withdrawal of consent, or completion of 2 years of AK104 treatment.
215138920|NCT02711891|DRUG|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
214526855|NCT02498418|DRUG|Xifaxan®|Tablets, brand product.
214526856|NCT02498418|DRUG|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
214526857|NCT00002347|DRUG|Saquinavir|
214526858|NCT00002347|DRUG|Nevirapine|
215138921|NCT02711891|DRUG|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
215138922|NCT06599645|OTHER|CST+BFR+Tai Chi+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~3. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~4. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
215138923|NCT06599645|OTHER|CST+BFR+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
215138924|NCT06599645|OTHER|Tai Chi +BFR+Education|"1. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
215138925|NCT06599645|OTHER|CST+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
215138926|NCT04883281|RADIATION|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
214452966|NCT06837831|COMBINATION_PRODUCT|Experimental group|After the patient emptied urine and feces before going to bed (21:00), the patient was assisted to take the kneeling lateral position, and the anal canal was cleaned with 0.9%Nacl soaked cotton swab, and was fully left to dry. After 30min, the anal pain was relieved. The operator fully exposed the patient's anus and part of the anal canal mucosal lesions with his left thumb and index finger, and applied a 6cm\*6cm adhesive foam dressing on the injured mucosa with his right hand. With the help of a cotton swab, the patient was instructed to take a deep breath, send the foam dressing to 3cm of the anal canal, reveal 2cm, slowly release the left hand, withdraw the cotton swab at the same time the anus automatically retracted, which played a role in securing the dressing, and ask the patient to lie flat and rest, and take it out the next morning (06:00).
214452967|NCT06834165|DRUG|Neffy|Epinephrine nasal spray
214452968|NCT06834165|DRUG|Adrenaline|Epinephrine injection
214452969|NCT06836765|OTHER|the expression negative in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
214452970|NCT06836765|OTHER|the expression positive in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
214452971|NCT06837389|BIOLOGICAL|JY306 universal NK cell injection|"3+3 dose escalation trial"
214452972|NCT06829030|DRUG|5% dextrose prolotherapy|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection
214452973|NCT06829030|DRUG|Diclofenac 75mg/ml|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection (approximately 75 patients).
214452974|NCT04317677|OTHER|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
214526859|NCT00002347|DRUG|Zidovudine|
214526860|NCT00002347|DRUG|Zalcitabine|
214452975|NCT04848870|OTHER|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
214526861|NCT00762502|DEVICE|senofilcon A toric contact lens|soft contact lens
214526862|NCT00762502|DEVICE|balafilcon A toric contact lens|soft contact lens
214526863|NCT05582135|DRUG|2 mg morphine sulfate|The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
214526864|NCT05582135|DRUG|0.25mg/kg esketamine|The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
215138927|NCT04883281|DRUG|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
215138928|NCT06998303|OTHER|Bipolar DBS stimulation|All participants will receive bipolar DBS through stimulation contacts 3 (most dorsal GP contact) and contact 2 (adjacent to contact 3) as specified by the device manufacturer. Bipolar stimulation through contacts 3 and 2 may be different from the settings used by the participant for optimal clinical improvement, as determined by their DBS care provider
215138929|NCT03300128|BEHAVIORAL|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
215138930|NCT03300128|OTHER|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
214452976|NCT06837272|DIAGNOSTIC_TEST|Multi-omics features extraction|Based on multi-omics features extracted from clinical data, gut microbiome, metabolomics, and multi-modal MRI, the diagnostic model of SCD due to preclinical AD will be established.
214452977|NCT03135548|DRUG|Spesolimab (low dose)|12 weeks treatment
214452978|NCT03135548|DRUG|Placebo|12 weeks treatment
214452979|NCT03135548|DRUG|Spesolimab (high dose)|12 weeks treatment
214452980|NCT03467386|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
214452981|NCT03467386|DRUG|Cyclophosphamide|Given IV
214452982|NCT03467386|BIOLOGICAL|Filgrastim|Administer according to City of Hope standard operating procedures
214452983|NCT03467386|OTHER|Laboratory Biomarker Analysis|Correlative studies
214452984|NCT03467386|OTHER|Quality-of-Life Assessment|Ancillary studies
214452985|NCT03467386|OTHER|Questionnaire Administration|Ancillary studies
214452986|NCT03467386|DRUG|Tacrolimus|Given CIV
214452987|NCT03467386|RADIATION|Total Marrow Irradiation|Undergo TMLI
214452988|NCT04461236|DIETARY_SUPPLEMENT|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
214526865|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 2 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
214526866|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 1 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
214452989|NCT04461236|DIETARY_SUPPLEMENT|Placebo|Placebo
214452990|NCT06831786|BIOLOGICAL|Bivalent mRNA SARS-CoV-2 vaccine|Administering a booster dose of the bivalent mRNA vaccine BNT162b2
214452991|NCT06831786|BIOLOGICAL|Quardrivalent influenza vaccine|Administering a VaxigripTetra™
214452992|NCT04190953|OTHER|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
214452993|NCT04190953|OTHER|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
214452994|NCT06836310|BEHAVIORAL|Real Performance Task-Oriented Movement|Participants performed a task-oriented movement in a real environment by throwing balls into a physical pool for 10 minutes. The movement was designed to engage upper extremity function.
215138931|NCT05020977|OTHER|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
215138932|NCT05878418|DEVICE|Thoracolumbosacral Spinal Orthosis (TLSO)|In the TE, PR, PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
215138933|NCT05878418|OTHER|Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)|The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
215138934|NCT04802707|COMBINATION_PRODUCT|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over trid or bid for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 1825. Doses was chosen according to the safety and efficacy doses used in the literature.
214452995|NCT06836310|BEHAVIORAL|Virtual Reality Task-Oriented Movement|Participants performed a task-oriented movement in a virtual environment using the Oculus Quest 2 VR system for 10 minutes. The task involved throwing virtual balls into a virtual pool with real-time feedback.
214452996|NCT03924986|DRUG|Tislelizumab|200 mg intravenously (IV) once every 3 weeks (Q3W)
214452997|NCT03924986|DRUG|Placebo|Placebo to match tislelizumab (administered intravenously Q3W)
214452998|NCT03924986|DRUG|Gemcitabine|1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
214452999|NCT03924986|DRUG|Cisplatin|80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
214453000|NCT06835010|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex, 100 µg/ml; Rewine Pharmaceutical; Varachha, Seurat, Gujarat) was administered before induction of anesthesia in the form of a 1 µg/kg; loading dose. The loading dose was diluted with 10 ml of normal saline and injected slowly for 10 minutes. IO infusion was prepared to provide 0.2-0.7 µg/kg/h, initially the lowest possible dose was infused and was increased gradually to control IO stress reflexes but with MAP, and HR monitoring to guard against IO hypotension and bradycardia. PO infusion was prepared to provide DXM in a dose of 0.15 µg/kg/h for 24-h. Placebo 0.9% saline solution was provided to patients of the SEVO group at a similar rate and duration.
215138935|NCT06879431|BEHAVIORAL|cognitive-behavioral intervention|After enrollment in the experimental group, the guardians were asked to fill out a sleep diary every day before surgery to self-report the children's sleep, and to wear a somatic movement recorder to monitor sleep (non-dominant arm) (wGT3x-BT accelerometer, ActiGraph) during the preoperative hospitalization period, except during surgery, and then to wear it to record the sleep-related parameters until 7 days after surgery or before discharge from the hospital.Preoperative daily cognitive-behavioral interventions (developmental trials were guided with WeChat applets), including cognitive change, sleep hygiene, sleep restriction, stimulus control, and relaxation training
214453001|NCT06835010|DRUG|Sevoflurane inhalant product|Anesthesia was induced by fentanyl 1 μg/kg/min, propofol 1.5-2 mg/kg and rocuronium 0.5 mg/kg, then tracheal intubation was aided by gentle tracheal pressure and an endotracheal tube of appropriate size was inserted with the aid of fiberoptic laryngoscopy and patients were mechanically ventilated to keep ETCO2 in the range of 30-35 mmHg. Anesthesia was maintained for patients of both groups by sevoflurane 2% in oxygen 100% and rocuronium (0.15 mg/ kg) according to the requirements.
214453002|NCT06829810|OTHER|Modelisation of intraocular pressure profile|Modelisation of IOP profile of all surgical techniques and additional procedures during the follow-up
214453003|NCT01687608|BIOLOGICAL|AskBio009|Single dose IV injection
214453004|NCT04922502|BEHAVIORAL|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
214453005|NCT04922502|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
214453006|NCT05267808|PROCEDURE|Drug-induced sleep endoscopy|Endoscopy during drug-induced sleep
214453007|NCT06835543|PROCEDURE|Amnion membrane.|the amnion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material
214453008|NCT06835543|PROCEDURE|Chorion membrane|chorion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 4-0 resorbable suture material.
214453009|NCT06829043|OTHER|clinical practice drug treatment|The study is observational, non-interventional and involves the review of the investigation18F-FDGPET/TC (performed according to the EANM guidelines) by two experts from the Nuclear Medicine Department.
214453010|NCT06838481|OTHER|Concentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Concentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
214453011|NCT06838481|OTHER|Eccentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Eccentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
214453012|NCT06838481|OTHER|Active Control|Walking
214453013|NCT06838234|OTHER|Arabic version QOL questionnaire|Arabic version QOL questionnaire The Wound-QoL is a wound-specific questionnaire containing 17 items from which one can derive three subscales and . The items 1-5, 6-10, and 11-16 belong to the subscale body, psyche, and everyday life, respectively
214453014|NCT04103346|OTHER|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
214453015|NCT04103346|OTHER|sham|air purifier running with air filter removed
214453016|NCT06835335|BEHAVIORAL|opioid prescription|"The intervention consisted of a randomized questionnaire presenting a clinical case of a patient suffering from severe abdominal pain. The control case was As an emergency physician in an adult emergency department, you are presented with the following patient: The patient is a 39-year-old non-smoking male/female with a history of Meniere's disease and an allergy to Bactrim. He/she presents with abdominal pain that began abruptly 2 hours ago and has persisted despite taking NEFOPAM 45 minutes ago. This is his first episode. His/her vital signs are blood pressure 140/66, heart rate 91, pulse ox 97%, temperature 36.8°C. He/she rates his/her pain as 8/10 without any analgesic position. On clinical examination he/she presents with localized epigastric tenderness. The rest of the abdomen is soft, painless and depressed. There are hydro-aeriform noises. No diarrhea or vomiting. The rest of the clinical examination showed no abnormalities.. In the intervention case, patient had history of S"
214453017|NCT06838624|DEVICE|Redcord|"Perticipants will perform exercises in different plank positions using RedCord® while applying local vibration in:~* Supine plank position~* Prone plank position~* Lateral prone plank position"
214453018|NCT06838624|OTHER|Control (Standard treatment)|"Participants will perform exercises in different plank positions:~Supine plank position Prone plank position Lateral prone plank position"
215138936|NCT06704230|DEVICE|video googles|Patients undergoing surgery use video googles and a headphone to distract from surgery
214526867|NCT03042559|DEVICE|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
215138937|NCT06705127|DRUG|TORIPALIMAB INJECTION(JS001 )|"Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles."
215138938|NCT06705127|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
215138939|NCT06705738|DIETARY_SUPPLEMENT|SUPOL|Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
215138940|NCT06705738|OTHER|Dietary Pattern: MeDi|Adherance to Mediterranean dietary pattern to be followed for 12 months.
215138941|NCT06705296|DEVICE|Open Label Deep Brain Stimulation|Patients will receive open label deep brain stimulation
214453019|NCT05514899|DRUG|THC|THC capsule
214453020|NCT05514899|DRUG|CBD|oral solution
214453021|NCT05225922|BEHAVIORAL|Communication Partner Training|This intervention aims to improve the language, communication, participation and overall quality of life of the Person with Aphasia.
215138942|NCT06705296|DEVICE|Double blinded Deep Brain Stimulation|Patients will receive double blinded deep brain stimulation
215138943|NCT06705296|BEHAVIORAL|Prolonged exposure therapy|Patients will receive prolonged exposure therapy
215138944|NCT06705296|DEVICE|Closed loop Deep brain stimulation|Patients will receive closed loop deep brain stimulation
215138945|NCT06705309|BEHAVIORAL|Web-Based Education|The Effect of a Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer on Women's Prevention Methods
214453022|NCT05225922|OTHER|Usual Speech and language Therapy|This group will receive usual speech and language therapy session.
214453023|NCT06837298|OTHER|Placebo control capsules|2.4 grams (g) daily
215138946|NCT06706713|DRUG|BEBT-109 Capsule|Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
215138947|NCT06879678|BEHAVIORAL|Web-Based Exercise Program|Web-Based Exercise Program + standard protocol
215138948|NCT02677493|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
215138949|NCT02677493|BIOLOGICAL|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
215138950|NCT02677493|BIOLOGICAL|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
214453024|NCT06837298|OTHER|PeptiStrong® supplement capsules with same appearance as placebo capsules|2.4 g daily
214453025|NCT06837298|OTHER|PeptiStrong® supplement capsules following muscle damaging exercise on Day 14|2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
214453026|NCT05331885|BIOLOGICAL|Suvratoxumab|Monoclonal antibody
214453027|NCT05331885|DRUG|Placebo|Placebo contains only excipients
214453028|NCT03505203|BEHAVIORAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
215138951|NCT04051996|DRUG|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
215138952|NCT04051996|DRUG|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
215138953|NCT06723106|DRUG|RAY121|Injection
215138954|NCT06704958|OTHER|AMPERE EMA app|AMPERE EMA smartphone app using MyCap
214453029|NCT03505203|BEHAVIORAL|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
214453030|NCT06830330|BEHAVIORAL|Virtual reality|Patients in the experimental group were shown videos of natural landscapes with VR glasses in their beds. This application was used to distract patients who were experiencing negative emotions just before surgery. The video session begins with the introduction of the virtual reality glasses. A motionless virtual area is determined at the point where the patient's stretcher is located. The glasses are placed on the patient's head and both hands of the patient are trained to use the remote control. Video content is selected and started according to the patient's preference. Video sessions last approximately 10 minutes.
214453031|NCT06830265|DEVICE|Novel needle biopsy catheter (test)|Tissue is collected from the prostate by introducing a needle into the prostate and cutting out a sample
214453032|NCT06769763|OTHER|My Journey with MS application|This is an Arabic application for MS patients that provides them with information about self-care like nutrition, exercise, mental health, and self-management, in addition to other features like symptom tracking and medication reminders.
215138955|NCT06705322|DRUG|Cnidium Monnieri Detoxification Formula|"Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment."
215138956|NCT06704711|DIETARY_SUPPLEMENT|Caffeine 300 MG|They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.
215138957|NCT06704711|COMBINATION_PRODUCT|Exercise|The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
215138958|NCT06704711|OTHER|Placebo|They will rinse 20 mL of distilled water in their mouth for 20 seconds.
215138959|NCT06705608|DRUG|Fingolimod|patients who received fingolimod for treating RRMS
215138960|NCT06705608|DRUG|Natalizumab|patients who received natalizumab for treating RRMS (active comparator)
215138961|NCT06705608|DRUG|Dimethyl fumarate (DMF)|patients who received dimethyl fumarate for treating RRMS (active comparator)
215138962|NCT06705608|DRUG|Alemtuzumab|patients who received alemtuzumab for treating RRMS (active comparator)
215138963|NCT06705608|DRUG|Teriflunomide|patients who received teriflunomide for treating RRMS (active comparator)
215138964|NCT05148364|BEHAVIORAL|interview|"A spiritual consultant and a psychologist will interview the participants about their experiences of chronic low back pain, how they interpret their pain experience and how they cope with the persistent pain. Each participant will be interviewed individually.~Questions related to the following three aspects will be asked:~1. Attributes: describe the changes in your personality, mood, and general happiness you have observed after you starting having chronic low back pain.~2. Pain resilience: How would you describe this persisting pain experience? How do you arrange your daily activity? What do you do to deal with this persistent pain?~3. Spirituality: As a person with chronic low back pain, how do you interpret this pain experience? Do you seek connections with higher powers (such as powers from religion) when you are desperate because of pain? Since the pain is chronic and persistent, it might not go away, how would you define your life?"
215138965|NCT06705231|BEHAVIORAL|The Aarhus-intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
215138966|NCT04073173|PROCEDURE|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
215138967|NCT04073173|PROCEDURE|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
215138968|NCT04073173|DRUG|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
215138969|NCT02209714|DRUG|BIIF 1149 BS|
215138970|NCT02209714|DRUG|Placebo|
215138971|NCT01105481|DRUG|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
215138972|NCT01105481|DRUG|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
215138973|NCT03506152|DIAGNOSTIC_TEST|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
215138974|NCT00751296|DRUG|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
214453033|NCT04639934|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
214453034|NCT05854329|BEHAVIORAL|Virtual Reality Exposure|Virtual Reality device using the immersive dental game.
214453035|NCT06837350|OTHER|Music intervention|Listening to Turkish Music
214453036|NCT01141179|DRUG|LEO 27847|2 mL (0.1 mg) dose of oral solution
214453037|NCT06786988|DIAGNOSTIC_TEST|MRI|brain MRI scan: (1) one day before the procedure, (2) 24-36 hours after the procedure and (3) up to 1 year after the procedure
214453038|NCT06786689|DRUG|Azathioprine (AZA)|weekly single dose of tab azathioprine 300mg
214453039|NCT06786689|DRUG|Betamethasone|oral Betamethsone 5mg for 2 consecutive days weekly
214453040|NCT05250895|OTHER|18F-Fluoromisonidazole|Given IV
214453041|NCT05250895|PROCEDURE|Biopsy|Undergo biopsy
214453042|NCT05250895|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
214453043|NCT05250895|PROCEDURE|Positron Emission Tomography|Undergo PET
214708901|NCT06198075|DEVICE|Experimental Group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
215138975|NCT00007254|DRUG|Pain relief for pressure ulcers|
215138976|NCT01972217|DRUG|Olaparib|Olaparib bid
215138977|NCT01972217|DRUG|Placebo|Placebo bid
215138978|NCT01972217|DRUG|Abiraterone|Abiraterone 1000 mg
215138979|NCT01972217|DRUG|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
215138980|NCT00117351|DRUG|VELCADE|
215138981|NCT02824653|BIOLOGICAL|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
215138982|NCT04693819|DIAGNOSTIC_TEST|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
215138983|NCT03762811|DEVICE|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
215138984|NCT03831152|DRUG|ADV7103|Single group assignment
215138985|NCT00441077|BEHAVIORAL|Education|
215138986|NCT04291547|DEVICE|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
215138987|NCT03878563|DEVICE|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
215138988|NCT00578539|DRUG|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
215138989|NCT00578539|DRUG|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
215138990|NCT00578539|DRUG|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
215138991|NCT00578539|RADIATION|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
215138992|NCT00578539|BIOLOGICAL|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
215138993|NCT00578539|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
215138994|NCT05327348|DRUG|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
215138995|NCT05327348|DRUG|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
215138996|NCT01829620|BEHAVIORAL|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
215138997|NCT01829620|BEHAVIORAL|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, \& 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
215138998|NCT04938154|DEVICE|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
215138999|NCT04938154|DEVICE|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
215139000|NCT04106557|DRUG|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
215139001|NCT04106557|DRUG|Placebo|Matching placebo capsules to OV101 capsules.
215139002|NCT02388308|DEVICE|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
215139003|NCT03925285|DRUG|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
215139004|NCT03175367|DRUG|Evinacumab|SC or IV administration
215139005|NCT03175367|DRUG|Matching placebo|SC or IV administration
215139006|NCT03175367|OTHER|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
215139007|NCT00433420|BIOLOGICAL|pegfilgrastim|
215139008|NCT00433420|DRUG|cyclophosphamide|
215139009|NCT00433420|DRUG|epirubicin hydrochloride|
215139010|NCT00433420|DRUG|fluorouracil|
215139011|NCT00433420|DRUG|paclitaxel|
215139012|NCT00433420|PROCEDURE|adjuvant therapy|
215139013|NCT03428984|DRUG|EXPAREL|EXAPREL 266 mg in 20 mL
215139014|NCT03659396|OTHER|individualized Tai Chi|individualized Tai Chi training exercise
215139015|NCT03659396|OTHER|Entire Tai Chi|the classical Yang style Tai Chi program
215139016|NCT03659396|OTHER|home-based program|Home-based exercise
215139017|NCT02254135|DRUG|BEA 2180 BR - rising dose|
215139018|NCT02254135|DRUG|Placebo|
214453044|NCT06342011|BEHAVIORAL|Anti-inflammatory diet group|"Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later."
214453045|NCT03667196|PROCEDURE|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
214453046|NCT06342947|DRUG|ALG-055009|Softgel Capsule
214453047|NCT06342947|DRUG|Placebo|Softgel Capsule
214453048|NCT06838533|PROCEDURE|computer guided advancement genioplasty|PEEK vs Titanium patient specific plates
214526868|NCT03042559|DEVICE|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
214526869|NCT06057259|DEVICE|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
215139019|NCT04909996|DEVICE|Sentinox--Group A|"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
215139020|NCT04909996|DEVICE|Sentinox--Group B|"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
215139021|NCT06036745|DRUG|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
215139022|NCT06292260|DEVICE|mHealth app|The eSkinHealth app is a tablet application that can be used as a portable patient chart for dermatological conditions in areas with poor internet connectivity, and for teledermatology when in need.
215139023|NCT06473857|BEHAVIORAL|Mental health literacy intervention|Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games
215139024|NCT06473857|BEHAVIORAL|Non mental health intervention|Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
215139025|NCT01853670|RADIATION|concurrent chemo + IGRT|
215139026|NCT01853670|RADIATION|neoadjuvant chemo + IGRT|
215139027|NCT02151058|DRUG|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
215139028|NCT02151058|DRUG|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
215139029|NCT02151058|OTHER|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
215139030|NCT02722083|DRUG|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
215139031|NCT02722083|DRUG|Placebo|placebo tablet, single dose, orally
215139032|NCT00809185|DRUG|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
214453049|NCT06833554|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|Dietary supplementation with Omega-3 Fatty Acids to study the effect on the immune system of breast milk
214453050|NCT06833554|DIETARY_SUPPLEMENT|Placebo|Inert dietary supplement, without activity in the activation of the immune system of breast milk
214526870|NCT01550822|OTHER|HEALS|
214526871|NCT03902145|OTHER|Egg|One egg per day for 6 months
214526872|NCT00392314|OTHER|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
214453051|NCT06836206|DIETARY_SUPPLEMENT|Gum Arabic|Gum Arabic (Acacia seyal and Acacia senegal) 30g powdered GA in 100ml water, consumed daily.
214453052|NCT06836206|OTHER|Water|100ml water, consumed daily
214453053|NCT05650970|OTHER|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
214453054|NCT05650970|OTHER|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
214453055|NCT06058299|DRUG|TBAJ-876|tablet
215139033|NCT00809185|OTHER|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
215139034|NCT00809185|PROCEDURE|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
215139035|NCT02181777|BEHAVIORAL|GRASP|GRoup trAining for Social skills in Psychosis
215139036|NCT02181777|BEHAVIORAL|Standard care|Treatment as usual
215139037|NCT06210997|BEHAVIORAL|Questionaires|The questionnaire was done online by the participants from second to fifth-year medical students.
215139038|NCT05625126|OTHER|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
215139039|NCT06029946|DIAGNOSTIC_TEST|elastography, ultrasound|First local anesthesia with lidocaine 2%, then 3 smears will be obtained for each nodule using a 20-22 gauge needle, multiple passes within the lesion will be made to obtain sufficient cells, the aspirate will be spread over a glass, fixed with ethanol 95% and submitted to the pathology department to be reported.
215139040|NCT04427267|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
215139041|NCT04550429|DEVICE|MyoSure Hysteroscopic Morcellator Device|This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
215139042|NCT03593369|DEVICE|KLOX BioPhotonic System (single treatment)+SOC|"KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
215139043|NCT03593369|DEVICE|KLOX BioPhotonic System (consecutive treatments)+SOC|"In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
215139044|NCT03593369|OTHER|Standard of Care (SOC)|Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
215139045|NCT05249556|DRUG|Ganaxolone|Ganaxolone
215139046|NCT05249556|DRUG|Placebo|Placebo (for ganaxolone)
215139047|NCT01792895|PROCEDURE|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
215139048|NCT01792895|PROCEDURE|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
215139049|NCT01792895|PROCEDURE|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
215139050|NCT00674817|DRUG|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
214453056|NCT06058299|DRUG|Pretomanid|200 mg
214453057|NCT06058299|DRUG|Linezolid|600 mg
214453058|NCT06058299|DRUG|Bedaquiline|200 mg for 8 weeks followed by 100 mg for 18 weeks
214453059|NCT06058299|DRUG|HRZE|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
214453060|NCT06058299|DRUG|HR|Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
214453061|NCT06554444|PROCEDURE|Dental Implant Surgery|Dental implants will be placed in edentulous areas.
214453062|NCT03445988|BEHAVIORAL|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
214453063|NCT03445988|BEHAVIORAL|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
214453064|NCT03445988|OTHER|Taper Only|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
214526873|NCT04091919|DIAGNOSTIC_TEST|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
214526874|NCT03623399|PROCEDURE|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
215139051|NCT00674817|DRUG|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
215139052|NCT03776968|DRUG|HC1119|oral
214453065|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using connective tissue graft|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. A connective tissue graft (CTG) will be harvested from the palatal mucosa using the De-epithelialized free gingival graft technique and tailored to the site dimensions. The graft will be carefully positioned under the elevated flap to augment the soft tissue. The palatal wound will be sutured with double-cross sutures.
214453066|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using xenogenic collagen matrix|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. The xenogenic collagen matrix, initially measuring 15 × 20 mm, is first moistened in saline for 10 minutes and slightly compressed to adapt its thickness to the defect. After a superficial incision to release any muscle tension, the XCM is accurately positioned and secured to the buccal mucosa using single sutures.
214453067|NCT06799715|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water
214453068|NCT06799715|DIETARY_SUPPLEMENT|Glucose|33.5g glucose dissolved in 300mL tap water
214453069|NCT06799715|DIETARY_SUPPLEMENT|Fructose|33.5g fructose dissolved in 300mL tap water
214453070|NCT06799715|DIETARY_SUPPLEMENT|Water|300mL water
214453071|NCT06478459|BIOLOGICAL|CAR-NK|Endoscopic ultrasound-guided intratumoral CAR-NK injection once at day 0, combined with intravenous CAR-NK infusion twice at day 4 and 5
214453072|NCT03988608|DRUG|Eltrombopag|Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.
214453073|NCT05424549|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
214453074|NCT05424549|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
214453075|NCT05445479|DRUG|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
214453076|NCT04475536|DEVICE|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
214453077|NCT04034576|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
214453078|NCT04162626|OTHER|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
214453079|NCT04162626|OTHER|Treatment as usual|Follow up at the Child health center according to national regulations
214453080|NCT05441579|BEHAVIORAL|Behavioral Economics (BE) recruitment strategies|Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.
214453081|NCT05441579|OTHER|Biofeedback-based virtual reality (VR-BF)|Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
214453082|NCT05441579|OTHER|Manage My Pain|Commercially available and free app to track, analyze and monitor pain.
214453083|NCT06064500|DRUG|Tarlatamab|Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
214453084|NCT04440254|DIAGNOSTIC_TEST|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
215139053|NCT06177132|BEHAVIORAL|VIS-REHAB protocol|The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasises gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
215139054|NCT06394050|DIAGNOSTIC_TEST|Diagnostic Test|there is no intervention
215139055|NCT00131768|DEVICE|Synvisc (hylan G-F 20)|
215139056|NCT04882735|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
215139057|NCT06296953|DEVICE|PERIsign examination|Patients will be examined with the new device, PERIsign
215139058|NCT05705024|BIOLOGICAL|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
215139059|NCT05705024|OTHER|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
215139060|NCT06187896|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
215139061|NCT06187896|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
215139062|NCT05620628|DRUG|Durvalumab|Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
215139063|NCT05620628|DRUG|Savolitinib|Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
215139064|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
215139065|NCT04733768|DIAGNOSTIC_TEST|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
215139066|NCT05007405|OTHER|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
214453085|NCT02689284|BIOLOGICAL|Margetuximab 10 mg/kg|Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
214453086|NCT02689284|BIOLOGICAL|Margetuximab 15 mg|Margetuximab treatment is administered IV once every 21-day cycle
214453087|NCT02689284|BIOLOGICAL|Pembrolizumab|Pembrolizumab treatment is administered IV once every 21-day cycle
214453088|NCT01742143|BEHAVIORAL|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
214453089|NCT01742143|BEHAVIORAL|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
214453090|NCT04072406|OTHER|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
215139067|NCT06445530|BEHAVIORAL|MFeast ENHANCED|Intervention group will initially receive prepared MTF (low carbohydrate, low-fat meals, which have been shown to improve glycemia in people with prediabetes) delivered by MFeast (10 meals weekly); Tailored Medical Nutrition Therapy (MNT) delivered by dieticians from MFeast via monthly phone calls and focused on only: ↓sugar-sweetened beverages and ↑fruit and vegetable consumption; Lactation snack bundles to boost milk supply + structural support for breastfeeding/pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (via study team-crafted virtual grocery store) for 16 more weeks.
215139068|NCT06445530|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive prepared MTF delivered by MFeast and as needed MNT from 1 to 24 weeks postpartum."
215139069|NCT04413500|BEHAVIORAL|Reminder|A reminder to take the anti-hypertension medication with adjustable frequency.
214453091|NCT04072406|OTHER|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
214453092|NCT05592418|DRUG|Rintatolimod|100 to 400 mg twice weekly
214453093|NCT05592418|OTHER|Placebo / Normal Saline|40 to 160 mL twice weekly
214453094|NCT06010329|DRUG|Sutetinib Maleate Capsule|Oral administration
214453095|NCT03662698|BEHAVIORAL|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
214526875|NCT01485991|DRUG|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
215139070|NCT04413500|BEHAVIORAL|Educational message|An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.
215139071|NCT04413500|BEHAVIORAL|Motivational messages|The motivational short messages to increase the motivational levels.
215139072|NCT04413500|BEHAVIORAL|showing trends|Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
214453096|NCT03662698|OTHER|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
214453097|NCT03424941|DEVICE|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
214453098|NCT03424941|DEVICE|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
214526876|NCT01485991|DRUG|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
214526877|NCT02212483|OTHER|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
215139073|NCT01779830|DRUG|LY2624803 - Capsules|Administered orally as capsules.
215139074|NCT01779830|DRUG|Zolpidem - Tablets|Administered orally as tablets.
215139075|NCT01779830|DRUG|Placebo - Capsules|Administered orally as capsules.
215139076|NCT01779830|DRUG|Placebo - Tablets|Administered orally as tablets.
215139077|NCT03910634|DRUG|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
215139078|NCT03910634|RADIATION|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
215139079|NCT03910634|DRUG|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
214453099|NCT06493045|DRUG|IRL757|IRL757 capsule
214453100|NCT06493045|DRUG|Placebo|Placebo capsule
214453101|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
214453102|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
215139080|NCT04956796|BEHAVIORAL|Airway Video Library Training|A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
215139081|NCT04956796|BEHAVIORAL|Conventional Airway Training|The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
215139082|NCT00754663|BEHAVIORAL|exercise training|walking training at least 3 times a week
215139083|NCT00497614|DRUG|adalimumab|
215139084|NCT00400465|PROCEDURE|Normal dressing|Normal dressing
215139085|NCT00400465|PROCEDURE|Pressure dressing|Pressure dressing
215139086|NCT03379818|BEHAVIORAL|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
215139087|NCT03379818|BEHAVIORAL|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
215139088|NCT03572504|OTHER|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
215139089|NCT03199976|DRUG|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
215139090|NCT03199976|DRUG|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
215139091|NCT03199976|DRUG|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
215139092|NCT03249207|DRUG|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
215139093|NCT03249207|DRUG|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
215139094|NCT04389281|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
215139095|NCT03082521|BEHAVIORAL|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
215139096|NCT05761782|BEHAVIORAL|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
215139097|NCT03826303|OTHER|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
215139098|NCT03826303|OTHER|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
215139099|NCT03826303|OTHER|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
215139100|NCT03826303|OTHER|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
215139101|NCT03505502|DRUG|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
215139102|NCT01532596|BEHAVIORAL|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
215139103|NCT04017663|OTHER|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
214453103|NCT04939142|COMBINATION_PRODUCT|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
214453104|NCT04939142|COMBINATION_PRODUCT|Vd (Bortezomib+dexamethasone)|Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
214453105|NCT03857061|DEVICE|smartphone, smartwatch, WearCOPDv2 application|"WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~1. Data collection service~2. Participant user interface"
214453106|NCT05569252|DRUG|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
215139104|NCT03463057|DRUG|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
215139105|NCT05104138|DRUG|Eplerenone|The patients underwent eplerenone treatment for 6 months
215139106|NCT05104138|DEVICE|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
215139107|NCT01875653|BIOLOGICAL|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
215139108|NCT01875653|BIOLOGICAL|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
215139109|NCT01780506|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
215139110|NCT01780506|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
215139111|NCT01780506|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
215139112|NCT01780506|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
215139113|NCT02322632|DRUG|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
215139114|NCT02527811|DRUG|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
215139115|NCT06368635|DIAGNOSTIC_TEST|Coronary angiography|target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8； or severe stenosis（\>80%）after successful PCI(percutaneous coronary intervention) and FFR ≥0.8
215139116|NCT05936073|DIAGNOSTIC_TEST|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
215139117|NCT03324087|DIAGNOSTIC_TEST|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
215139118|NCT06078254|DEVICE|ULTRASOUND|Ultrasound and CT chest for all patients
215139119|NCT03550599|OTHER|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
215139120|NCT02684825|DEVICE|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
215139121|NCT02788552|DRUG|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
215139122|NCT04577521|DEVICE|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
215139123|NCT03967977|DRUG|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
215139124|NCT03967977|DRUG|Placebo|Tislelizumab placebo to match
215139125|NCT03967977|DRUG|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
215139126|NCT03967977|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
215139127|NCT03967977|DRUG|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
215139128|NCT00005766|DRUG|Creatinine|
215139129|NCT03288675|DEVICE|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
215139130|NCT03288675|BEHAVIORAL|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
214453107|NCT05569252|OTHER|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
214453108|NCT06057922|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.
214453109|NCT05731661|OTHER|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
214453110|NCT05731661|OTHER|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
214453111|NCT05731661|OTHER|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
215139131|NCT03288675|DRUG|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
215139132|NCT02418572|DRUG|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
215139133|NCT02418572|DRUG|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
215139134|NCT00209911|PROCEDURE|cardioversion|
215139135|NCT04942574|OTHER|Total sleep deprivation|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
215139136|NCT04942574|OTHER|Normal sleep|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
215139137|NCT05236270|BEHAVIORAL|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
215139138|NCT05236270|BEHAVIORAL|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
215139139|NCT05236270|BEHAVIORAL|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
215139140|NCT06342258|DRUG|Ultradent Ultra Seal XT Plus|Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
215139141|NCT02241824|DEVICE|In-elastic lumbar brace|
215139142|NCT02241824|DEVICE|Elastic abdominal binder|
215139143|NCT00131222|PROCEDURE|Food supplement: fortified spread|
215139144|NCT00131222|PROCEDURE|Food supplement: maize and soy flour|
215139145|NCT00406250|DRUG|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
214453112|NCT03665597|BIOLOGICAL|Pembrolizumab Dose C|165 mg/mL administered to a final dose of 285 mg via subcutaneous injection
214453113|NCT03665597|BIOLOGICAL|Pembrolizumab Dose A|130 mg/mL administered to a final dose of 285 mg via subcutaneous injection
214453114|NCT03665597|BIOLOGICAL|Pembrolizumab Dose B|200 mg administered via intravenous infusion
214453115|NCT03665597|BIOLOGICAL|Pembrolizumab Dose D|400 mg administered via intravenous infusion
214453116|NCT06493071|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
214453117|NCT06493071|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
214526878|NCT02212483|OTHER|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
214526879|NCT02212483|OTHER|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
214526880|NCT04715711|OTHER|Forearm coolng|forearm immersion will be performed for active cooling assessment
214526881|NCT04715711|OTHER|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
214526882|NCT04715711|OTHER|mist-fan|a mist-fan will be placed in front of the participant for active cooling
214526883|NCT04715711|OTHER|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
215139146|NCT00406250|DRUG|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
215139147|NCT01611714|OTHER|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
215139148|NCT01611714|OTHER|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
215139149|NCT01023763|OTHER|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
215139150|NCT03725397|BEHAVIORAL|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
214708902|NCT04243252|BEHAVIORAL|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
214453118|NCT05953883|PROCEDURE|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
214453119|NCT05260684|DRUG|Encorafenib|450 mg QD
214453120|NCT05260684|DRUG|Binimetinib|45 mg BID
214453121|NCT05260684|DRUG|Vemurafenib|960 mg BID for 28 days/cycle
214453122|NCT05260684|DRUG|Cobimetinib|60 mg QD for 21 days/cycle
214453123|NCT05260684|DRUG|Dabrafenib|150 mg BID
214453124|NCT05260684|DRUG|Trametinib|2 mg QD
214453125|NCT06411639|DRUG|ianalumab|ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
214453126|NCT05770219|DRUG|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
214453127|NCT04739956|OTHER|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
214526884|NCT01365351|OTHER|Growth hormone|Drug given by prescription
214526885|NCT01475370|DRUG|OCV-501|"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
214526886|NCT03895892|BEHAVIORAL|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
214526887|NCT03895892|BEHAVIORAL|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
215139151|NCT03725397|BEHAVIORAL|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
214453128|NCT04739956|OTHER|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
214453129|NCT03167281|COMBINATION_PRODUCT|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
214453130|NCT05430035|DRUG|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
214453131|NCT02386722|DEVICE|Electronic Monitoring with audio reminders and additional support|"Automated reminder:~-Daily audio-reminder, generated by a smartphone.~Support calls (only patients with Smartinhaler):~* When the use of rescue medication doubles.~* When inhaled medication was not inhaled as prescribed for more than two consecutive days.~Feedback on adherence (only patients with POEMS):~-At every clinical visit (after 2, 4 and 6 months)."
214526888|NCT03895892|DIETARY_SUPPLEMENT|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
214526889|NCT03895892|DIETARY_SUPPLEMENT|Ketone|Dietary supplement containing only ketone salts
214526890|NCT03895892|DIETARY_SUPPLEMENT|Water Placebo|Dietary supplement containing only water
214526891|NCT02429752|OTHER|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
215139152|NCT06142058|DIAGNOSTIC_TEST|RecistTM criteria|RecistTM criteria and RECIST criteria were used to evaluate the efficacy of targeted therapy for NSCLC with positive driving gene.
215139153|NCT02922244|OTHER|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
215139154|NCT02922244|OTHER|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
215139155|NCT02922244|OTHER|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
215139156|NCT02922244|OTHER|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
215139157|NCT05176288|DRUG|Axitinib|Taken Orally
215139158|NCT05176288|DRUG|Palbociclib|Taken Orally
215139159|NCT05176288|DRUG|Avelumab|Intravenous infusion
215139160|NCT05876442|DEVICE|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
215139161|NCT05876442|DEVICE|High Intensity Laser Therapy|High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
215139162|NCT05876442|OTHER|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
215139163|NCT00530478|DRUG|Donepezil|
215139164|NCT04030143|DRUG|Aripiprazole|Administered as an intramuscular (IM) depot injection.
215139165|NCT04030143|DRUG|Aripiprazole|Administered as an IM depot injection.
215139166|NCT00101179|DRUG|Azacitidine|Given SC
215139167|NCT00101179|DRUG|Entinostat|Given orally
215139168|NCT01499940|DRUG|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
215139169|NCT05543603|DRUG|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
215139170|NCT05543603|DRUG|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
215139171|NCT05543603|DRUG|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
215139172|NCT05543603|DRUG|Distilled water|15 ml distilled water, one minute rinse
215139173|NCT00412984|DRUG|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
215139174|NCT00412984|DRUG|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
215139175|NCT00004688|DRUG|carmustine|
215139176|NCT00004688|DRUG|mercaptopurine|
215139177|NCT00004688|DRUG|streptozocin|
215139178|NCT02949336|RADIATION|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
214708903|NCT04243252|OTHER|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
215139179|NCT04218526|DEVICE|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
215139180|NCT00037843|DRUG|I-131 Iodocholesterol|
215139181|NCT06409533|OTHER|Rate control|Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
214708904|NCT00114270|DRUG|letrozole|
214708905|NCT00114270|DRUG|zoledronic acid|
214708906|NCT00003219|DRUG|perillyl alcohol|
214708907|NCT04799353|DRUG|Budigalimab|Subcutaneous (SC)
215139182|NCT04166643|BEHAVIORAL|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
215139183|NCT04166643|BEHAVIORAL|Education only control|Education at the start of the project
215139184|NCT04430452|BIOLOGICAL|Durvalumab|Given IV
215139185|NCT04430452|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
215139186|NCT04430452|BIOLOGICAL|Tremelimumab|Given IV
215139187|NCT02854345|DEVICE|Tomoscintigraphic parathyroid imaging on a CZT camera|
215139188|NCT04218240|DRUG|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
215139189|NCT04218240|DRUG|Placebo oral tablet|oral Placebo
215139190|NCT04218240|DRUG|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
215139191|NCT06027580|DEVICE|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
215139192|NCT06027580|OTHER|Standard Care Therapy option|Standard of care Therapy without the use of trunk orthosis
215139193|NCT06070454|DIAGNOSTIC_TEST|Vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
215139194|NCT04735575|BIOLOGICAL|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
215139195|NCT03160118|DRUG|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
215139196|NCT06582901|BEHAVIORAL|Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)|Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
215139197|NCT06582901|BEHAVIORAL|Enhanced - Treatment as Usual|The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
215139198|NCT04502030|BIOLOGICAL|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
215139199|NCT04502030|OTHER|Placebo|Placebo
215139200|NCT04664517|PROCEDURE|Flexible intramedullary nail (FIN)|Both bone FIN
215139201|NCT04664517|PROCEDURE|Reduction auder general anesthesia and long arm cast|Reduction and cast
215139202|NCT04005378|OTHER|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
215139203|NCT04005378|OTHER|Usual Care|Usual Care provided by CSC center
215139204|NCT04914364|OTHER|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
215139205|NCT06962592|BEHAVIORAL|MM+|Participants in both study arms will receive clinic-based HIV counseling, including urine tenofovir testing and biofeedback counseling on recent PrEP or ART use. Activities unique to women enrolled in the intervention arm include: Brief motivational interviewing sessions with a mentor mother focusing on 1) EtG testing and biofeedback on recent alcohol use, 2) counseling and mentorship on ways to reduce alcohol use.
215139206|NCT06962592|BEHAVIORAL|Enhanced HIV attention control (eSOC)|Participants in the enhanced HIV attention control arm (comparison group) will attend a similar number of study visits within the same time frame as intervention participants (5-6 sessions during 6-month timeframe including both pregnancy and postpartum). Control arm sessions will consist of one-on-one educational counseling on HIV risk, partner HIV testing modalities, as well as conducting PrEP/ART urine assay testing followed by real-time in-clinic adherence counseling delivered privately (different from study nurses delivering PrEP/ART biofeedback in MM+ intervention arm to avoid contamination), all coinciding with routine ANC visits.
215139207|NCT04097678|OTHER|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
215139208|NCT03694678|BEHAVIORAL|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
215139209|NCT05874843|DIAGNOSTIC_TEST|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
215139210|NCT02435212|DRUG|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
215139211|NCT02435212|DRUG|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
215139212|NCT02647099|DRUG|Acetylsalicylic acid|
215139213|NCT02647099|DRUG|Placebo|
215139214|NCT05131308|OTHER|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
214453132|NCT06849102|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
214453133|NCT06849102|OTHER|conventional physiotherapy interventions|Patients in this group will receive conventional physiotherapy interventions, including treadmill training, balance training, strengthening and stretching lower limb muscles, for 45 minutes per session, 3 times weekly, for 4 weeks.
214453134|NCT06311760|DRUG|AZD0292|AZD0292 will be administered as single dose via IV infusion.
214453135|NCT06311760|DRUG|Placebo|Placebo will be administered as IV infusion.
214453136|NCT03519581|DEVICE|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
214453137|NCT03519581|DEVICE|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
214453138|NCT06389942|DRUG|9MW3011|Single dose intravenously on day 1
214453139|NCT06389942|DRUG|9MW3011 placebo|Single dose intravenously on day 1
214708908|NCT04799353|DRUG|Placebo|Subcutaneous (SC)
215139215|NCT05773937|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
215139216|NCT05964842|BEHAVIORAL|SMS|Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
214453140|NCT06558071|DRUG|Galatonol 300 mg/Striatin 30 mg|1 film-coated caplet of Herba Asimor, twice daily
214453141|NCT06558071|DRUG|Placebo|1 film-coated caplet of placebo Herba Asimor, twice daily
214453142|NCT05504239|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
214453143|NCT05504239|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
214453144|NCT06843733|OTHER|Mixed reality exergame|The participants will play the Balloon Popping game using Hololens2 (Mixed reality glasses) for one hour. The objective of this game will be to pop all the virtual balloons, focusing on training different executive functions such as inhibitory control and cognitive flexibility. When a participant raises a finger in the air, a virtual needle will appear. After that, the participant will move their finger towards a balloon. Successful contact with a balloon will be indicated by the sound of a pop and the visual effect of confetti.
214453145|NCT06843733|OTHER|Education|The participants will seat on a chair and watch video clip about MCI and dementia for one hour.
214708909|NCT04799353|DRUG|Budigalimab|Intravenous (IV)
214708910|NCT04799353|DRUG|Placebo|Intravenous (IV)
214708911|NCT00001777|DRUG|Sertraline|
214453146|NCT02716012|DRUG|MTL-CEBPA|Intravenous administration
214453147|NCT02716012|DRUG|Sorafenib 200mg|Sorafenib tablets
214453148|NCT06848283|DIAGNOSTIC_TEST|Carotid ultrasonography|All examinations will be performed by a technician specialized in neurosonology, using the same technical protocol. For this purpose, a portable ultrasound device with a linear probe (L3-9 MHz) will be used. A quick screening will be conducted to check for the presence of atherosclerosis.
214453149|NCT06848998|BEHAVIORAL|aerobic exercise|"40 minutes of aerobic exercise, twice per week for six weeks.~Sessions comprised of the following: 10-minute warm-up, 40-minute conditioning period as a circuit, and 10-minute cool-down.~Aerobic exercises (for example, recumbent cycling, stepping, arm crank) commenced at an intensity of 40-50% heart rate reserve (HRR) and increased incrementally by 10% as tolerated, up to a maximum of 70-80%. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
214526892|NCT04864236|DEVICE|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
214526893|NCT03726125|DRUG|LY3374849 - SC|Administered SC
214526894|NCT03726125|DRUG|Insulin Degludec - SC|Administered SC
214526895|NCT03726125|DRUG|LY3374849 - IV|Administered IV
214453150|NCT06848998|BEHAVIORAL|Resistance exercise|"4 x resistance exercises (3 sets of 6 repetitions), twice per week for six weeks.~Strengthening exercises (for example, resistance band work) were prescribed at an intensity that corresponded to 11-12 and incrementally increased to a maximum of 14-15, as tolerated, on the Borg Ratings of Perceived Exertion (RPE) 6-20 Scale. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
214453151|NCT06846840|DIETARY_SUPPLEMENT|Ketone ester|0.29 g per kilogram body mass per hour of ketone monoester (R)-3-hydroxybutyrate (R)-3-hydroxybutyl
214453152|NCT06846840|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides and bitter tastant (Bitrex)
214453153|NCT06848166|DEVICE|liquid embolic agent SQUID 12, liquid embolic agent SQUID 18|Total endovascular embolization of the frontal and parietal branches (less often the occipital branch) of the middle meningeal artery (MMA) with its complete devascularization. In the case of unilateral pain localization, ipsilateral MMA embolization will be performed; in the case of bilateral pain localization, total embolization of both MMA branches will be performed.
214453154|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
214453155|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
215139217|NCT05964842|BEHAVIORAL|Phone call|Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
215139218|NCT05964842|BEHAVIORAL|Mobile money incentive|Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
215139219|NCT05179785|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
214453156|NCT04171661|BIOLOGICAL|SASS|SASS applied on chronic skin wounds as skin graft
214453157|NCT06012929|DRUG|ONC201|ONC201 is an oral medication given once per week
214453158|NCT06845670|OTHER|Wurn technique|Wurn technique is a massage technique and PF relaxation exercises are to relax tighten pelvic floor muscles.
214453159|NCT06850064|PROCEDURE|Pulse Field Ablation (PFA)|The pulse field ablation group will undergo pulse field ablation of the mitral valve commissure.
214526896|NCT03726125|DRUG|Insulin Degludec - IV|Administered IV
214526897|NCT01388088|DRUG|Spironolactone|25 mg twice a day
214526898|NCT01388088|DRUG|Amiloride|5 mg twice a day
214526899|NCT01388088|DRUG|Placebo|twice a day
214526900|NCT05476978|DIAGNOSTIC_TEST|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
215139220|NCT05179785|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
215139221|NCT05153746|DEVICE|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
214453160|NCT06850064|PROCEDURE|Radiofrequency ablation|In the radiofrequency ablation group, patients will undergo radiofrequency ablation targeted at the mitral valve commissure.
214453161|NCT06850779|OTHER|Extracorporeal shock wave therapy (ESWT)|Radial ESWT (Vibrolith OrthoⓇ) was applied to the wrist as 1000 pulses with a frequency of 5 Hz and a power of 1.5 bar. The treatment was applied once a week for a total of 3 sessions.
214453162|NCT06850779|OTHER|Kinesio taping (KT)|KT was prepared as 2 pieces of 2.5 cm I band and 1 piece of 5 cm I band. It was applied with a maximum of 50% tension (without tension on the ends) while the wrist was in 30 degrees of extension, forearm supination and elbow extension. The treatment was applied once a week for a total of 3 sessions.
214453163|NCT06850779|OTHER|Exercise|Median nerve gliding exercises were given to the 4th group during the follow-up period. The same exercises were given to the other groups.
214453164|NCT03396926|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
215139222|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
215139223|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
214453165|NCT03396926|DRUG|Capecitabine|Given orally (PO)
214453166|NCT03396926|PROCEDURE|Specimen collection|For use in correlative studies
214453167|NCT03396926|BIOLOGICAL|Pembrolizumab|Given IV
214453168|NCT06850285|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
214453169|NCT06850454|DRUG|olanzapine|olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
214453170|NCT06850454|DRUG|Placebo|placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
214453171|NCT06849128|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
214453172|NCT06849128|OTHER|Conventional cognitive training|A conventional cognitive training protocol involves structured, repetitive exercises designed to enhance specific cognitive functions, such as memory, attention, executive function, and processing speed. These training programs are delivered through paper-and-pencil tasks, computer-based exercises, and therapist-guided activities. Tasks used include working memory exercises (e.g., digit span recall), attention training (e.g., Stroop test, visual scanning), problem-solving activities (e.g., Tower of Hanoi), and language exercises (e.g., verbal fluency tasks), for 45 minutes per session, 3 times weekly, for 4 weeks.
214453173|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
214453174|NCT04861064|DRUG|Sirolimus|Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
214453175|NCT06242288|DRUG|ISOtretinoin 20 MG|Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
214453176|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
214453177|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
214453178|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
214453179|NCT03737253|DRUG|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
214453180|NCT03737253|DRUG|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
214453181|NCT05491356|DRUG|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
214453182|NCT05491356|DRUG|Placebo|0.9% saline solution, intra-catheter administration, sterile
215139224|NCT04692233|BEHAVIORAL|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
215139225|NCT04692233|BEHAVIORAL|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
215139226|NCT06379659|DRUG|Growh hormone|In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
215139227|NCT06379659|OTHER|Placebo|Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
215139228|NCT05699642|BEHAVIORAL|Tai chi + wearable|The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.
215139229|NCT06218277|DIAGNOSTIC_TEST|ASTAR|Rapid AST with ASTAR
215139230|NCT04526340|DIAGNOSTIC_TEST|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
215139231|NCT04526340|DIAGNOSTIC_TEST|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
215139232|NCT04526340|DIETARY_SUPPLEMENT|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
215139233|NCT04526340|DIAGNOSTIC_TEST|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
215139234|NCT02933008|OTHER|aNMT Biofeedback|"aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention."
215139235|NCT02933008|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
215139236|NCT02933008|OTHER|Neuromuscular Training|Participants will complete a 12-session, pre-season training program, over 6 weeks.
215139237|NCT06011759|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\]."
215139238|NCT06011759|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
215139239|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
215139240|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
215139241|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
215139242|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
215139243|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
215139244|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
215139245|NCT03292926|DRUG|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
214453183|NCT04424407|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
214453184|NCT02919956|OTHER|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
214453185|NCT02919956|OTHER|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
214453186|NCT05435092|RADIATION|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
214453187|NCT03110315|DRUG|Suvorexant|See detailed information in associated Arm Description.
214453188|NCT03110315|DRUG|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
214453189|NCT01781468|DRUG|armodafinil 150 mg|given orally
214453190|NCT01781468|OTHER|Placebo|given orally
214453191|NCT01781468|DRUG|armodafinil 250 mg|given orally
214453192|NCT03365609|DRUG|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
214453193|NCT03365609|DRUG|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
214453194|NCT03365609|DRUG|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
214526901|NCT05056298|OTHER|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
214694941|NCT02329522|DEVICE|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
215139246|NCT03292926|DEVICE|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
214453195|NCT03365609|DRUG|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
214453196|NCT02088645|DRUG|177Lu-PP-F11N|
214453197|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme1|15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol
214453198|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme 2|30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
214453199|NCT06203743|PROCEDURE|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
214453200|NCT06203743|PROCEDURE|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
214453201|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
214453202|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
214453203|NCT04978519|PROCEDURE|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
214526902|NCT05056298|OTHER|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
214694942|NCT02329522|DEVICE|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
215139247|NCT03292926|DRUG|Dexamethasone|Dexamethasone will be used to prolong block duration
215139248|NCT06510439|BEHAVIORAL|Need to Be Needed Intervention|Interventionist-supported volunteering intervention that targets opportunities creating social connections that matter through focus on kindness and gratitude throughout the intervention.
215139249|NCT06510439|OTHER|Active Control Group|Weekly non-directive listening support
215139250|NCT03350529|DEVICE|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
215139251|NCT02453737|RADIATION|Brachytherapy APBI|
215139252|NCT02453737|RADIATION|3D-CRT (photon) APBI|
214526903|NCT05056298|OTHER|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
214526904|NCT05056298|OTHER|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
214526905|NCT01675050|DRUG|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
215139253|NCT02453737|RADIATION|Proton APBI|
215139254|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
214453204|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
214453205|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
214453206|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
214453207|NCT05593575|DRUG|SPH3127+valsartan matching placebo|4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
214453208|NCT05593575|DRUG|SPH3127 matching placebo+valsartan|4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
214453209|NCT04986917|DEVICE|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
214453210|NCT04986917|DIAGNOSTIC_TEST|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
214453211|NCT04986917|DIAGNOSTIC_TEST|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
214453212|NCT04986917|DIAGNOSTIC_TEST|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
214453213|NCT04986917|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
214453214|NCT04986917|DIAGNOSTIC_TEST|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
214453215|NCT04986917|OTHER|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
214453216|NCT04986917|OTHER|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
214453217|NCT04986917|DIAGNOSTIC_TEST|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity."
214453218|NCT04906382|PROCEDURE|Biopsy|Undergo biopsy
214453219|NCT04906382|DRUG|Carboplatin|Given IV
214453220|NCT04906382|DRUG|Paclitaxel|Given IV
214453221|NCT04906382|BIOLOGICAL|Tislelizumab|Given IV
214453222|NCT04373135|BEHAVIORAL|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
214453223|NCT05891613|DRUG|Bupivacaine Hydrochloride|20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
214453224|NCT05891613|DRUG|Liposomal Bupivacaine|20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
214526906|NCT01675050|DRUG|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
214526907|NCT02919397|DEVICE|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
215139255|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
215139256|NCT04954339|DRUG|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
215139257|NCT04913272|DRUG|US-APR2020|US-APR2020 capsules 45 billion CFUs of the LBT.
215139258|NCT04913272|DRUG|Placebo|Placebo
215139259|NCT04852302|BEHAVIORAL|Cancer and Living Meaningfully (CALM) Therapy|The Cancer and Living Meaningfully (CALM) intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
215139260|NCT06577896|DEVICE|Onyx family|Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
215139261|NCT03267277|DRUG|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
215139262|NCT06537193|DIAGNOSTIC_TEST|AMRI|The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
215139263|NCT06537193|DIAGNOSTIC_TEST|CT|CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage was from the basal lung to the iliac crest or pelvis.
215139264|NCT04119986|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.
214453225|NCT06130683|OTHER|Single-cell sequencing|Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
214453226|NCT01083758|DRUG|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
214453227|NCT05416554|BEHAVIORAL|Neuropsychological testing|Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
214453228|NCT05294016|DEVICE|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
214453229|NCT02386371|PROCEDURE|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
214453230|NCT02386371|RADIATION|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
214453231|NCT03825965|DRUG|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
214453232|NCT03825965|DRUG|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
214453233|NCT06465498|PROCEDURE|LUS decongestive strategy|LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
214453234|NCT06465498|PROCEDURE|PE decongestive strategy|PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
214453235|NCT06188754|BEHAVIORAL|Time restricted eating|Limiting food intake to 10 hours per day
214453236|NCT06188754|BEHAVIORAL|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
214453237|NCT04727554|DRUG|AMG 994|Administered as an intravenous (IV) infusion.
214453238|NCT04727554|DRUG|AMG 404|Administered as an intravenous (IV) infusion.
214453239|NCT03590821|DRUG|Aspirin 81 mg|timed administration of aspirin in the evening
214453240|NCT03590821|DRUG|Celecoxib 200mg capsule|daily administration of celecoxib
214453241|NCT05966519|DEVICE|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
214453242|NCT02216838|DRUG|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
214453243|NCT02216838|OTHER|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
214453244|NCT05681520|BEHAVIORAL|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
214453245|NCT06407830|OTHER|motor relearning programme|Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.
214453246|NCT06407830|OTHER|electrical muscle stimulations with motor relearning programme|"Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.~Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions for 8 weeks task specific training based on the motor relearning programme and 10 minutes of the EMS of each muscle during the session."
214453247|NCT05763823|DRUG|Letermovir|Daily 240 mg or 480 mg oral tablets or IV dose
214453248|NCT04754945|DRUG|Bortezomib|Given SC
214453249|NCT04754945|DRUG|Cyclophosphamide|Given IV or PO
214453250|NCT04754945|DRUG|Dexamethasone|Given IV or PO
214453251|NCT04754945|BIOLOGICAL|Isatuximab|Given IV
214453252|NCT04529993|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
214453253|NCT05392192|DRUG|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
214526908|NCT02919397|BEHAVIORAL|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
214526909|NCT02919397|BEHAVIORAL|Motivational messaging|Messages sent via smartphone application
214526910|NCT00629551|DRUG|saredutant (SR48968)|oral administration,capsules
215139265|NCT04119986|DEVICE|drug eluted stent|with regular techniques
215139266|NCT03237624|DEVICE|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
214453254|NCT05392192|DRUG|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
214453255|NCT06367829|PROCEDURE|Lubinus SPII hip stem 130mm|Shorter length of the SPII hip stem
214453256|NCT06367829|PROCEDURE|Lubinus SPII hip stem 150mm|Longer length of the SPII hip stem
214453257|NCT03675815|DRUG|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
214453258|NCT03675815|DRUG|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
215139267|NCT03237624|DEVICE|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
214453259|NCT03675815|DRUG|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
214453260|NCT03675815|DRUG|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
214526911|NCT00629551|DRUG|paroxetine|oral administration, capsules
215139268|NCT03237624|BEHAVIORAL|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
215139269|NCT06088992|GENETIC|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
215139270|NCT05164289|OTHER|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
215139271|NCT05164289|OTHER|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
215139272|NCT04769479|DRUG|acoramidis|acoramidis
215139273|NCT05246592|PROCEDURE|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
215139274|NCT05246592|PROCEDURE|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
215139275|NCT06772376|DIAGNOSTIC_TEST|SERS sensor based on CHA reaction|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
215139276|NCT01766609|DRUG|Triamcinolone Acetonide|
215139277|NCT04849364|DRUG|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
215139278|NCT04849364|DRUG|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
215139279|NCT04849364|DRUG|Pembrolizumab|Per standard of care.
215139280|NCT04849364|DRUG|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
215139281|NCT06578364|DEVICE|Educational Program about Preconception Care|The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
215139282|NCT06577363|DRUG|Maribavir|Maribavir tablets
215139283|NCT05454033|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
215139284|NCT05454033|OTHER|Control|No-treatment control
215139285|NCT04304495|OTHER|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
215139286|NCT05379088|BEHAVIORAL|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
215139287|NCT05214001|DRUG|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
215139288|NCT05214001|DRUG|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
215139289|NCT03521570|RADIATION|IMRT|Undergo intensity-modulated radiation therapy
215139290|NCT03521570|BIOLOGICAL|Nivolumab|Given IV
214453261|NCT03675815|DRUG|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
214453262|NCT03675815|DRUG|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
214453263|NCT03675815|DRUG|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
214453264|NCT06262126|OTHER|Virtual Reality|Virtual Reality therapy
214453265|NCT05229146|BEHAVIORAL|Episodic Future Thinking|Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
214526912|NCT00629551|DRUG|placebo|oral administration, capsules
214526913|NCT03665753|DRUG|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
214694943|NCT05300867|OTHER|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
214694944|NCT05300867|OTHER|Physiotherapy|Physiotherapy 3-week-long
215139291|NCT06301230|DEVICE|Portable Laparoscopic Trainer (PLET)|"The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation."
215139292|NCT06406751|DEVICE|MI Paste|Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
215139293|NCT04076696|DEVICE|Scatter corrected s-DCT|All patients will have a breath held s-DCT scan in an anterior-posterior direction
215139294|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
215139295|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
215139296|NCT03496844|DIAGNOSTIC_TEST|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
215139297|NCT04531176|OTHER|Weight Management Program (WMP)|Weight Management Program (WMP)
215139298|NCT04531176|OTHER|Traditional care|Traditional care
215139299|NCT04531176|DRUG|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
215139300|NCT04531176|DRUG|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
215139301|NCT04531176|DRUG|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
215139302|NCT04531176|DRUG|Orlistat|Medication for chronic weight management (Rx)
215139303|NCT06564571|DEVICE|Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
215139304|NCT03962465|DRUG|Inotuzumab ozogamicin|By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
215139305|NCT03962465|DRUG|Prednisone Pill|Taken daily days 1-28 by mouth
215139306|NCT03962465|DRUG|Daunorubicin|By IV, given on days 1, 8, 15, and 22
215139307|NCT03962465|DRUG|Vincristine|By IV, given on days 1, 8, 15, and 22
215139308|NCT03962465|DRUG|Cytarabine|Intrathecal, administered on day 1 only
215139309|NCT03962465|DRUG|Methotrexate|Intrathecal, administered on days 8 and 29
215139310|NCT03962465|DRUG|Pegaspargase|By IV, given on day 4
215139311|NCT06010654|DEVICE|Software as a Medical device|The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
215139312|NCT04181359|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
215139313|NCT04181359|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
215139314|NCT02663492|DEVICE|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
215139315|NCT02663492|DRUG|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
214453266|NCT05628129|OTHER|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
214453267|NCT03297151|DIETARY_SUPPLEMENT|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
215139316|NCT01250808|DRUG|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
214453268|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
214694945|NCT05616767|OTHER|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
215139317|NCT00003122|PROCEDURE|surgical procedure|
215139318|NCT02943174|BEHAVIORAL|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
215139319|NCT02943174|OTHER|Treatment as Usual (TAU)|Standard personalized treatment of cancer
215139320|NCT02916212|OTHER|Optimized alarm profiles|
215139321|NCT03193840|PROCEDURE|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
215139322|NCT02227914|DRUG|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
215139323|NCT02227914|DRUG|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
215139324|NCT02516696|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
215139325|NCT02516696|DRUG|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
215139326|NCT02516696|DRUG|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
215139327|NCT03526133|DIAGNOSTIC_TEST|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
215139328|NCT05544162|DIETARY_SUPPLEMENT|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
215139329|NCT03210948|DEVICE|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
215139330|NCT03210948|DEVICE|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
214526914|NCT05478681|DEVICE|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
214453269|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
214453270|NCT06104800|OTHER|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
214453271|NCT06104800|OTHER|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
214453272|NCT05371652|DRUG|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
214526915|NCT00631098|PROCEDURE|venous cannulation|External jugular and cubital vein cannulation
214526916|NCT03275441|DIAGNOSTIC_TEST|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
214526917|NCT01076322|DRUG|Meptin® Swinghaler|"Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)"
214526918|NCT01076322|DRUG|Ventolin® MDI|"Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)"
215139331|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
215139332|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
215139333|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
215139334|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
215139335|NCT03118310|BEHAVIORAL|5:2 diet|Dietary intervention according to 5:2 diet during three months.
215139336|NCT03118310|BEHAVIORAL|LCHF|Dietary intervention according to LCHF diet during three months.
215139337|NCT03118310|BEHAVIORAL|Placebo diet|Placebo diet: normal dietary advice
215139338|NCT02958995|OTHER|No Intervention|
215139339|NCT02473081|BEHAVIORAL|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
215139340|NCT02473081|OTHER|Usual care|Usual care was given by their family physicians.
215139341|NCT00355108|DRUG|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
215139342|NCT01338441|DRUG|Erythromycin|4mg/Kg, IV during 20 min once
215139343|NCT01338441|DRUG|Placebo|4mg/Kg, IV during 20 min once
214526919|NCT05621213|OTHER|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
214526920|NCT05881161|BEHAVIORAL|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
215139344|NCT01488604|DEVICE|Polymeric Nasal Spray|Experimental nasal spray
215139345|NCT01488604|DEVICE|Sham Nasal Spray|Sham nasal spray
215139346|NCT04090918|DIAGNOSTIC_TEST|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
215139347|NCT05620667|DIETARY_SUPPLEMENT|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
215139348|NCT05620667|DIETARY_SUPPLEMENT|placebo|Drink 25mL for once, and once a day.
215139349|NCT05620667|BEHAVIORAL|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
215139350|NCT04160117|DRUG|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
215139351|NCT04160117|DRUG|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
215139352|NCT04006288|DRUG|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
215139353|NCT04006288|DRUG|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
215139354|NCT04006288|DRUG|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
215139355|NCT04006288|DRUG|aspirin|all patients will remain on aspirin
215139356|NCT04006288|DRUG|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
215139357|NCT03743272|DEVICE|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
215139358|NCT01650506|DRUG|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
215139359|NCT01650506|DRUG|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
215139360|NCT05246046|DRUG|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
215139361|NCT05320952|DEVICE|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
215139362|NCT04990024|OTHER|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
215139363|NCT04990024|OTHER|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to \<130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
215139364|NCT04837443|BEHAVIORAL|Rubber hand illusion|Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
215139365|NCT04325672|BIOLOGICAL|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.
215139367|NCT00329043|DRUG|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
215139368|NCT00329043|DRUG|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
215139369|NCT00329043|PROCEDURE|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
215139370|NCT01766440|DRUG|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
215139371|NCT03563339|BEHAVIORAL|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
215139372|NCT05062785|DRUG|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
215139373|NCT05996575|OTHER|fNIRS measurement|Kernel Flow2 measurements.
215139374|NCT01345240|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
215139375|NCT01345240|BIOLOGICAL|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
214453273|NCT06455553|OTHER|Blood sample|A blood sample will be taken from all patients included in the study. This blood sampling is an added act of the study. It will be performed as soon as possible after inclusion in the study. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.
214453274|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
214453275|NCT06367218|DRUG|opioid based strategy|Induction and maintenance of anesthesia with opioids
214453276|NCT06367218|DRUG|opioid-free strategy|Esketamine was used for induction and maintenance of anesthesia
214453277|NCT06367218|PROCEDURE|Laryngeal mask airway; Preserved spontaneous breathing|The patient used a laryngeal mask to maintain spontaneous breathing
214453278|NCT06367218|PROCEDURE|Double lumen tracheal tube; Mechanical ventilation|The patient was mechanically ventilated using a double-lumen tracheal catheter
214453279|NCT03778112|RADIATION|SBRT to whole prostate|Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate
214526921|NCT05881161|BEHAVIORAL|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
214694946|NCT03587558|DRUG|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
215139376|NCT01345240|BIOLOGICAL|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
215139377|NCT01345240|BIOLOGICAL|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
215139378|NCT01345240|BIOLOGICAL|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
214453280|NCT03778112|RADIATION|IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions|Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
214453281|NCT04226599|DEVICE|Dissolve AVF|Subjects in the test group will be treated with peripheral scoring drug balloon.
214453282|NCT04226599|DEVICE|Armada 35|Subjects in the test group will be treated with plain balloon catheter.
214453283|NCT00906906|DEVICE|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
214453284|NCT03699319|DRUG|CPI 613|"Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months"
214453285|NCT03699319|DRUG|Oxaliplatin|"Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
214453286|NCT03699319|DRUG|Irinotecan|"Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
214453287|NCT03699319|DRUG|5-flurouracil|"Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
214453288|NCT03699319|DRUG|Folinic acid|"Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
214453289|NCT06288919|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
214453290|NCT06288919|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
214453291|NCT06278961|OTHER|Observational|Observation of movement patterns through video recordings and neurodevelopmental battery of assessments.
214453292|NCT06553547|DRUG|Tenapanor|Tenapanor 5 mg/mL solution
214453293|NCT06553547|DRUG|Placebo|Matching Placebo solution
214453294|NCT05986136|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
214453295|NCT05986136|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
214453296|NCT04223141|PROCEDURE|SIA|As indicated by arm description
214453297|NCT02182245|DRUG|BIBF 1120|
214453298|NCT02182245|DRUG|Paclitaxel|
214453299|NCT02182245|DRUG|Carboplatin|
214453300|NCT06205095|DRUG|Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII|Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
214453301|NCT06205095|OTHER|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
214453302|NCT04195568|DEVICE|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
214453303|NCT03555448|DRUG|Once daily immunosuppression regimen|Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
214453304|NCT03555448|DRUG|Twice daily immunosuppression regimen|This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
214453305|NCT05509595|DRUG|Burosumab|Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
214453306|NCT05545956|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
214453307|NCT05545956|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
214453308|NCT06115070|DRUG|Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
214526922|NCT03130127|DRUG|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
214526923|NCT02721420|DRUG|dihydroartemisinin-piperaquine|
214526924|NCT02721420|OTHER|message(SMS) reminder|
214526925|NCT02721420|OTHER|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
214526926|NCT02721420|OTHER|short message(SMS) reminder|
214526927|NCT03604653|DEVICE|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
214526928|NCT03604653|DRUG|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
214526929|NCT03604653|DRUG|CDDP 50|50mg/m2@T0
214526930|NCT03604653|DRUG|CDDP 75|75mg/m2@T0
214526931|NCT03604653|DRUG|Doxorubicin|15mg/m2@T0
215139379|NCT01345240|BIOLOGICAL|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
215139380|NCT01345240|BIOLOGICAL|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
215139381|NCT01345240|BIOLOGICAL|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
215139382|NCT04298697|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
215139383|NCT03594513|PROCEDURE|MCAF|Periodontal surgical technique to treat gingival recessions.
215139384|NCT03594513|PROCEDURE|PR|Restorative procedure to treat tooth structure loss.
215139385|NCT03594513|PROCEDURE|CTG|Autogenous graft harvested from palate placed in the surgical site.
215139386|NCT03594513|PROCEDURE|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
215139387|NCT03594513|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
215139388|NCT03594513|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
215139389|NCT00449696|DEVICE|Gel-200|Single intra-articular injection
214526932|NCT06125639|BEHAVIORAL|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
214526933|NCT00124137|DEVICE|Aquadex system|
214526934|NCT00124137|DRUG|IV diuretic|
214526935|NCT04474691|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
215139390|NCT00449696|DEVICE|Placebo|Single intra-articular injection
215139391|NCT00641771|DRUG|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
215139392|NCT00641771|DRUG|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
215139393|NCT01392144|PROCEDURE|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
215139394|NCT01392144|BEHAVIORAL|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
215139395|NCT02673372|DRUG|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
215139396|NCT02673372|DRUG|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
215139397|NCT02474316|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
214526936|NCT04474691|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
215139398|NCT02474316|DRUG|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
215139399|NCT00647764|DRUG|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
215139400|NCT00593346|RADIATION|brachytherapy|brachytherapy (radioactive implants)
215139401|NCT01282034|PROCEDURE|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
215139402|NCT01282034|DEVICE|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
215139403|NCT05188859|DRUG|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
215139404|NCT03481400|DRUG|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
215139405|NCT03481400|OTHER|Placebo|Isotonic saline
215139406|NCT04663763|DRUG|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
215139407|NCT04663763|DRUG|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
215139408|NCT04663763|DRUG|Oxaliplatin|Usage: 130mg/m2 d1 q3w
215139409|NCT01064388|DRUG|AZD9742|IV infusion, 15 days
215139410|NCT01064388|DRUG|Placebo|IV infusion, 15 days
215139411|NCT01263080|DRUG|mirtazapine|mirtazapine 30mg QD
215139412|NCT01263080|DRUG|folic acid placebo|folic acid placebo 1 tablet QD
215139413|NCT01263080|DRUG|mirtazapine placebo|mirtazapine placebo 1 tablet QD
215139414|NCT01263080|DRUG|folic acid|folic acid 0.4mg QD
215139415|NCT04916990|BEHAVIORAL|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
215139416|NCT04032964|DRUG|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
215139417|NCT04032964|DRUG|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
215139418|NCT06514950|BEHAVIORAL|Ujjayi Yogic Breathing|Participants will undergo 6 weeks of resistive yogic breathing (Ujjayi) upon exhalation (first three weeks) and upon inhalation and exhalation (second three weeks).
215139419|NCT04777799|DEVICE|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
215139420|NCT01854411|OTHER|analgesic measure|ibuprofen and ketoprofen measured into breast milk
215139421|NCT04412863|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
215139422|NCT04412863|DRUG|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
215139423|NCT06453746|OTHER|Home-based cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
215139424|NCT06453746|OTHER|Supervised cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
215139425|NCT06500390|DIAGNOSTIC_TEST|Examination of temporomandibular joint and masticator muscles|The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.
215139426|NCT04827407|DEVICE|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
214453309|NCT05353140|DEVICE|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
214453310|NCT05353140|DRUG|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
214453311|NCT05353140|DRUG|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
214453312|NCT06156943|PROCEDURE|individualized goal-directed fluid therapy by Starling device|For patients in optimized group, fluids will be managed by Starling device during the lung resection surgery.
214453313|NCT06156943|PROCEDURE|group managed by standard of care|Patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols
214453314|NCT05426005|DRUG|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
214453315|NCT04360928|DEVICE|Graymont X ERIS Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
215139427|NCT06400758|OTHER|questionary|"A questionnaire, based on the main sexual health topics frequently discussed, was given to students by the school management prior to an intervention.~The preventive intervention consisted of comprehensive prevention on the emotional and sexual lives of adolescents. It was carried out by health professionals and was based on questions from the students, who were able to leave their questions anonymously in a box in the school infirmary for several months.~These questions were collected and used to identify several themes for discussion:~emotional life, with notions of affection, love, friendship and the notion of normality, as well as consent and sexual violence physical and sexual aspects, with reminders of the menstrual cycle, contraception, sexually transmitted infections, pregnancy and abortion.~The same questionnaire was given to students after the intervention, to check whether the prevention intervention had improved their general knowledge."
215139428|NCT05928936|DRUG|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
215139429|NCT05928936|BEHAVIORAL|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
215139430|NCT05928936|DRUG|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
215139431|NCT06008795|DRUG|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
215139432|NCT06008795|PROCEDURE|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
215139433|NCT06092450|OTHER|develop and validate a deep learning radiomics model based on preoperative enhanced CT image|develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
215139434|NCT01171859|DRUG|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
215139435|NCT05655351|BIOLOGICAL|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
215139436|NCT00464698|DRUG|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
215139437|NCT01903460|DRUG|LUM001|
215139438|NCT01903460|DRUG|Placebo|
215139439|NCT05269914|OTHER|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
215139440|NCT02928679|DRUG|Liraglutide 3 mg (Saxenda)|
215139441|NCT02928679|DRUG|Liraglutide 3 mg placebo|
215139442|NCT06002412|OTHER|Image quality control|The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
215139443|NCT06448143|DRUG|Indigotindisulfonate sodium 0.8% injection|Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
215139444|NCT05085353|PROCEDURE|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
215139445|NCT03330925|DEVICE|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
215139446|NCT02994563|DEVICE|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
215139447|NCT05322707|DRUG|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
215139448|NCT05322707|DRUG|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
215139449|NCT05322707|DRUG|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
215139450|NCT03728465|BIOLOGICAL|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
214453316|NCT04360928|DEVICE|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
214453317|NCT04401020|DRUG|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
214526937|NCT00913562|DRUG|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
215139451|NCT03728465|BIOLOGICAL|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
215139452|NCT02425410|OTHER|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
215139453|NCT02425410|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
215139454|NCT00240123|DRUG|Benadryl versus Placebo|
215139455|NCT01007201|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
215139456|NCT04202848|DIAGNOSTIC_TEST|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
215139457|NCT04412759|OTHER|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
215139458|NCT05020951|OTHER|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
215139459|NCT02524327|OTHER|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
215139460|NCT02524327|OTHER|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
215139461|NCT02246530|PROCEDURE|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
215139462|NCT02246530|DRUG|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
215139463|NCT00629980|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
215139464|NCT00829569|DIETARY_SUPPLEMENT|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
215139465|NCT05776940|DRUG|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
215139466|NCT05776940|DRUG|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
215139467|NCT03945383|DEVICE|Treatment with IPL device|Treatment with IPL device
215139468|NCT02916186|BIOLOGICAL|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
215139469|NCT02916186|PROCEDURE|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
215139470|NCT03863886|PROCEDURE|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
215139471|NCT03293108|DRUG|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
215139472|NCT03293108|DIETARY_SUPPLEMENT|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
215139473|NCT03293108|DIETARY_SUPPLEMENT|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
214453318|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
214453319|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
214453320|NCT06418984|DEVICE|auxiliary|the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
214453321|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
214453322|NCT04959123|OTHER|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
214526938|NCT00913562|DRUG|Placebo|one tablet a day for 12 weeks
215139474|NCT03810677|DEVICE|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
214526939|NCT01309399|DRUG|Teriparatide|six weeks of teriparatide
214526940|NCT01309399|OTHER|placebo|placebo
214694947|NCT03587558|DRUG|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
214453323|NCT06418425|BEHAVIORAL|counselling on home-based exercise program and dietary protein intake|Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
215139475|NCT01817153|DRUG|hydrocortison hemisuccinate|
215139476|NCT01817153|DRUG|placebo followed by hydrocortisone hemisuccinate|
215139477|NCT06054126|OTHER|Echocardiography|Cardiac function was evaluated by echocardiography at one year follow-up.
215139478|NCT06474455|DRUG|SHR-9839 ；SHR-A2009|SHR-9839 combined with SHR-A2009
214453324|NCT05640752|DIAGNOSTIC_TEST|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
214453325|NCT05640752|DIAGNOSTIC_TEST|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
214453326|NCT05134233|DEVICE|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
214453327|NCT00367666|DEVICE|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
214453328|NCT03386240|DRUG|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
214453329|NCT03386240|OTHER|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
214694948|NCT03375112|PROCEDURE|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
215139479|NCT06474455|DRUG|SHR-9839 ； SHR-A1921|SHR-9839 combined with SHR-A1921
215139480|NCT06474455|DRUG|SHR-9839 ； pemetrexed ；carboplatin|SHR-9839 combined with pemetrexed + carboplatin
215139481|NCT06474455|DRUG|SHR-9839 ； Almonertinib|SHR-9839 combined with Almonertinib
215139482|NCT05430178|OTHER|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
215139483|NCT05430178|OTHER|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
215139484|NCT05430178|OTHER|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
215139485|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
215139486|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
215139487|NCT00888173|DRUG|Brivanib Alaninate|Given PO
215139488|NCT00888173|OTHER|Laboratory Biomarker Analysis|Correlative studies
215139489|NCT01730599|OTHER|neurological exam|motor and cognitive functions
215139490|NCT01396304|DEVICE|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
215139491|NCT01396304|DEVICE|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
215139492|NCT04246788|OTHER|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
215139493|NCT04246788|OTHER|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
215139494|NCT06140589|DRUG|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
215139495|NCT06256406|OTHER|in the field of rehabilitation and neonatal care: the combination of Kangaroo care method and music therapy|Kangaroo care is a practice involving skin-to-skin contact between the infant and a caregiver,. Music therapy is a therapeutic approach that utilizes the expressive and emotional qualities of music to address physical, emotional, cognitive needs of individuals.
215139496|NCT06417424|DEVICE|gastrointestinal external stimulation|We used the device Gastrointestinal multifunctional therapeutic instrument. The positive pole was placed 1 to 2cm above the umbilicus, and the negative pole was placed 4 to 10 cm to the right of the midpoint between the xiphoid process and the umbilicus.
215139497|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
215139498|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
215139499|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
215139500|NCT01488890|BIOLOGICAL|Yellow Fever|0.5 mL, Subcutaneous
215139501|NCT05712460|DRUG|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
215139502|NCT05712460|DRUG|Placebo|Placebo for sisunatovir
215139503|NCT05376150|DRUG|XEN1101 10 mg|XEN1101 oral capsule
215139504|NCT05376150|DRUG|XEN1101 20 mg|XEN1101 oral capsule
215139505|NCT05376150|DRUG|Placebo|Placebo capsule
215139506|NCT05077215|DRUG|EG-007|A Repurposed Drug
215139507|NCT05077215|DRUG|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
215139508|NCT05077215|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
215139509|NCT02233686|DRUG|XEN-D0501|
215139510|NCT02233686|DRUG|Placebo|
215139511|NCT06185725|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve Block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
215139512|NCT06185725|OTHER|Transversus Abdominal Plane Block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
215139513|NCT06265233|OTHER|Group Improv sessions|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
215139514|NCT06265233|BEHAVIORAL|Group Exposure and Response Prevention (ERP) Therapy|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
215139515|NCT05264857|BEHAVIORAL|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
215139516|NCT01213680|DRUG|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
215139517|NCT01213680|DRUG|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
215139518|NCT05900167|BEHAVIORAL|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
215139519|NCT02784756|DEVICE|Quantiferon-CMV assay|
215139520|NCT02735863|DRUG|ABX464|50 mg or 150mg once daily for 28 days
215139521|NCT02735863|DRUG|Placebo|ABX464 matching placebo
215139522|NCT02375854|OTHER|Observation|
215139523|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
215139524|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
215139525|NCT04421677|DRUG|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
215139526|NCT02333435|DIETARY_SUPPLEMENT|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
215139527|NCT02333435|DIETARY_SUPPLEMENT|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
215139528|NCT05446649|OTHER|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
215139529|NCT05446649|OTHER|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
215139530|NCT05446649|OTHER|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
215139531|NCT05611151|DIAGNOSTIC_TEST|Computer Aided Detection (CADe)|Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
215139532|NCT02780648|RADIATION|Stereotactic Body Radiation|
214453330|NCT06424977|DEVICE|Biomarker Targeted Stimulation (BTS)|Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
214453331|NCT01573442|DRUG|testosterone|10.4 mg
214453332|NCT01573442|OTHER|placebo|
214453333|NCT03649659|DRUG|Silver Diamine Fluoride|SDF will be applied twice during the study
214453334|NCT03649659|DRUG|Placebo|This is being compared to the SDF and will also be applied twice
214453335|NCT05359276|DRUG|Olipudase alfa|GZ402665
214453336|NCT02104310|DRUG|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
214453337|NCT04764656|DRUG|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214453338|NCT02302300|DEVICE|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
214453339|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
214453340|NCT04763265|BIOLOGICAL|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
214453341|NCT04763265|BIOLOGICAL|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
214453342|NCT04510974|OTHER|Spinal Cord Injury|Spinal Cord Injury
214453343|NCT04959318|OTHER|Professional nutrition counseling|Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.
214453344|NCT04959318|OTHER|No professional nutrition counseling|Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
214453345|NCT00397358|DRUG|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
214453346|NCT04418466|COMBINATION_PRODUCT|Risperidone|Risperidone Implant
214453347|NCT06516341|PROCEDURE|CD patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
214453348|NCT06516341|PROCEDURE|UC patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
214453349|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
214453350|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
214453351|NCT04785820|DRUG|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
214453352|NCT04785820|DRUG|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
214453353|NCT04785820|DRUG|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
214453354|NCT03047837|DRUG|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
215139533|NCT05495815|DRUG|6 months of SAT|6 months of oral suppressive antibiotic therapy
215139534|NCT05495815|DRUG|12 months of SAT|12 months of oral suppressive antibiotic therapy
215139535|NCT05495815|DRUG|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
215139536|NCT04699864|DIAGNOSTIC_TEST|Screening of DR and DME with artificial intelligence using NeoRetina|Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
215139537|NCT04699864|DIAGNOSTIC_TEST|Routine ophthalmological evaluation of DR and DME|Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
215139538|NCT04699864|DIAGNOSTIC_TEST|Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos|Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
215139539|NCT05560425|BEHAVIORAL|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
215139540|NCT05560425|BEHAVIORAL|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
214453355|NCT03047837|DRUG|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
214453356|NCT03047837|OTHER|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
214453357|NCT06499090|DRUG|Mirtazapine 30 MG|patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
214453358|NCT06499090|DRUG|Placebo|patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
214453359|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
214453360|NCT06383676|OTHER|Functional reaction balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
214526941|NCT02794558|DEVICE|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
214453361|NCT06383676|OTHER|Functional balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
214453362|NCT06092879|OTHER|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
214453363|NCT04958811|DRUG|Tiragolumab|600mg IV administered every 3 weeks.
214453364|NCT04958811|DRUG|Atezolizumab|1200mg IV administered every 3 weeks.
214453365|NCT04958811|DRUG|Bevacizumab|15mg/kg IV administered every 3 weeks.
214453366|NCT05477979|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
214453367|NCT05925569|OTHER|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
215139541|NCT02649166|DEVICE|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
215139542|NCT02649166|DEVICE|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
215139543|NCT05499910|BEHAVIORAL|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
215139544|NCT04945746|PROCEDURE|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
215139545|NCT06222905|OTHER|non interventional|non interventional
214453368|NCT04903470|DRUG|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
214453369|NCT04903470|DRUG|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
214453370|NCT05869591|DRUG|Apixaban 5 MG [Eliquis]|Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
214453371|NCT05869591|DRUG|Edoxaban 60 MG [Lixiana]|Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
214453372|NCT03841318|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
214453373|NCT03841318|BIOLOGICAL|biopsy of the labial salivary gland|Part of the biopsy of the labial salivary gland
214453374|NCT04055207|OTHER|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
214453375|NCT03730454|DEVICE|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
214453376|NCT03730454|OTHER|No Transanastomotic Tube|No transanastomotic tube used during repair
214453377|NCT04680741|BEHAVIORAL|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
214453378|NCT05520710|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
214453379|NCT05520710|OTHER|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
214453380|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
214453381|NCT06318338|OTHER|Virtual Reality Program|Study participants will be provided a HTC or Pico VR head-mounted device (HTC Flow, HTC Focus or Pico Neo Pro) which will be fitted for comfort. Patients will remain seated for the entirety of the VR program. The program generally takes about ten minutes to complete but may last up to 11 minutes. The program displays a relaxing environmental setting with narration based in mindfulness meditation principles. Subjects will be prompted to practice breathing exercises designed to relax and reduce anxiety.
214453382|NCT05794412|OTHER|No intervention|No intervention
214453383|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
214453384|NCT01963793|DRUG|Placebo|gel without active component
214453385|NCT05457738|OTHER|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
214453386|NCT05457738|OTHER|No E-REVA® app|No use smartphone
214453387|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
214453388|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
214453389|NCT04356612|OTHER|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
214453390|NCT06402721|DRUG|BAY3283142|Single oral dose.
214453391|NCT06595615|DEVICE|cardiovascular implantable electronic devices|Standard of care patients indicated for the devices
214453392|NCT05151237|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
214526942|NCT02625922|DRUG|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
214526943|NCT02625922|DRUG|Placebo|Matching placebo i.v infusion
214526944|NCT01209936|DEVICE|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
215139546|NCT06399900|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
215139547|NCT06399900|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
215139548|NCT06399900|BEHAVIORAL|Home-based walking exercise|This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
215139549|NCT05206708|BEHAVIORAL|Personalized psychotherapy|Strategy including personalized psychotherapy
215139550|NCT05206708|BEHAVIORAL|Standard of care|Strategy based standard intregrative psychodynamic therapy
215139551|NCT06320054|BEHAVIORAL|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
215139552|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
215139553|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
214453393|NCT01552473|BEHAVIORAL|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
215139554|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
215139555|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
214453394|NCT01552473|BEHAVIORAL|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
214453395|NCT06800027|OTHER|SALSA group intervention: Going to lunch at the restaurant in a group and attending healthy eating workshops.|"The intervention group will dine at a selected and trained restaurant twice a week for 4 months (from March to June 2024). A facilitator will accompany the participants to the restaurant and supervise them. Once a month, a healthy habits and meal supplementation workshop will be held at the senior citizens' centre. Participants will not be required to pay for the meals at the restaurant or for participation in the workshops. The control group will receive standard care at their Primary Care Centre.~In order for the restaurant to provide appropriate services tailored to the users' needs, training will be conducted by professionals from the Alicia Foundation on how to manage the nutrition of elderly individuals and other participants in the study according to their dietary needs."
214453396|NCT05725941|DEVICE|TogRite stretch Strapping|it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
214526945|NCT03363542|DIETARY_SUPPLEMENT|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
214526946|NCT02218671|DRUG|WE 941 OD tablets|
214526947|NCT01437384|DRUG|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
214526948|NCT01591655|DRUG|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
214526949|NCT01591655|DRUG|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
214526950|NCT01258296|DRUG|Fentanyl|25 mcg/hr transdermal patch
214453397|NCT05725941|OTHER|Traditional upper limb functional exercise training|The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
214453398|NCT02664805|DRUG|LEO 124249 ointment|Ointment
215139556|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
215139557|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
214453399|NCT02664805|DRUG|LEO 124249 ointment vehicle|Ointment vehicle
214453400|NCT03409133|DEVICE|Stimulating nerve electrodes and intramuscular recording electrodes|See Arm Description
214526951|NCT01258296|DRUG|Inactive patch|placebo patch (no drug)
214526952|NCT03331848|DRUG|Placebo oral capsule|BID
214526953|NCT03331848|DRUG|PXT002331 - 20mg|Oral
214526954|NCT04389944|OTHER|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
214526955|NCT00161902|DRUG|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
215139558|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
215139559|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
215139560|NCT04985604|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
215139561|NCT04985604|DRUG|Pimasertib|Pimasertib capsule for oral use.
215139562|NCT02637245|OTHER|No intervention|No intervention
215139563|NCT04503070|BEHAVIORAL|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort"
215139564|NCT05135767|BEHAVIORAL|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
215139565|NCT04943744|DEVICE|Entero-tracker|Esophageal STRING test (Entero-tracker)
215139566|NCT04943744|BIOLOGICAL|omalizumab|Used in the parent study
215139567|NCT04943744|BIOLOGICAL|dupliumab|Used in the parent study
215139568|NCT03475004|DRUG|Pembrolizumab|An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
215139569|NCT03475004|DRUG|Bevacizumab|The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
215139570|NCT03475004|DRUG|Binimetinib|Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
215139571|NCT02376634|BEHAVIORAL|Hypnosis|Patients will be taught self-hypnosis.
215139572|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
215139573|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
215139574|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
215139575|NCT02260934|DRUG|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
215139576|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
215139577|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
214453401|NCT04971343|DIAGNOSTIC_TEST|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
214453402|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
214526956|NCT02260583|DEVICE|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
214526957|NCT06276751|PROCEDURE|End-tidal CO2 monitor|Throughout the study, measurements were taken at 2 and 4 hours after tube thoracostomy was applied to every patient undergoing the procedure.
214526958|NCT01940692|DRUG|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
215139578|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
215139579|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
215139580|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
215139581|NCT02260934|DRUG|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
215139582|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
215139583|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
215139584|NCT02260934|BIOLOGICAL|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
215139585|NCT04936607|PROCEDURE|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
215139586|NCT04936607|PROCEDURE|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
215139587|NCT01931540|BEHAVIORAL|Exercise Training|Three times a week, for four months.
215139588|NCT05829070|BEHAVIORAL|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
215139589|NCT05829070|BEHAVIORAL|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
214453403|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
214453404|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
214453405|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
214453406|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
214453407|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
214453408|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
214453409|NCT05839951|DRUG|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
214453410|NCT05839951|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
214453411|NCT05839951|DRUG|Bevacizumab|VEGFR inhibitor
214453412|NCT04836195|DRUG|PCLX-001 - 20mg|20mg daily oral pills
214453413|NCT04836195|DRUG|PCLX-001 - 40mg|40mg daily oral pills
214453414|NCT04836195|DRUG|PCLX-001 - 70mg|70mg daily oral pills
214453415|NCT04836195|DRUG|PCLX-001 - 100mg|100mg daily oral pills
214453416|NCT04836195|DRUG|PCLX-001 - 140mg|140mg daily oral pills
214453417|NCT04836195|DRUG|PCLX-001 - 210mg|210mg daily oral pills
214453418|NCT04836195|DRUG|PCLX-001 - 280mg|280mg daily oral pills
214453419|NCT05609760|OTHER|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
214453420|NCT05609760|OTHER|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
214526959|NCT01940692|DRUG|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
214526960|NCT05183997|DIAGNOSTIC_TEST|complete blood count|laboratory test
214526961|NCT05183997|DIAGNOSTIC_TEST|prothrombin time|laboratory test
214453421|NCT06852833|BEHAVIORAL|One-day Mind Programme for women with breast cancer|This programme is theoretically founded on contextual behavioural therapies ( ACT and compassion-based interventions) and tailored for women with breast cancer. Its format comprises 1 session with the duration of 7 hours, that will be delivered by 2 psychologists through a secure video calling platform, in two subsequent days.
215139590|NCT04614896|DIAGNOSTIC_TEST|Transoral ultrasound of tongue tumors|A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
215139591|NCT00232063|DRUG|ciclosporin|
215139592|NCT03605667|DRUG|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
215139593|NCT03605667|DRUG|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
215139594|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
215139595|NCT04854343|DIAGNOSTIC_TEST|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
215139596|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
215139597|NCT01702207|DRUG|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
215139598|NCT01702207|DRUG|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
215139599|NCT02010892|PROCEDURE|Stent Grafting (ESR)|
215139600|NCT02010892|PROCEDURE|Open Surgery (OSR)|
215139601|NCT01862289|OTHER|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
215139602|NCT02337413|DRUG|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
215139603|NCT02337413|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
214453422|NCT06283550|DRUG|Abrocitinib 200 mg|Abrocitinib will be available in 100 mg strength tablet
214453423|NCT06283550|DRUG|Abrocitinib 100 mg|Abrocitinib will be available in 100 mg strength tablet
214453424|NCT06283550|DRUG|Placebo|Placebo tablet
214453425|NCT04049643|DEVICE|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
214526962|NCT05183997|DIAGNOSTIC_TEST|prothrombin concentration|laboratory test
214453426|NCT04049643|DEVICE|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
215139604|NCT02337413|BEHAVIORAL|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
214453427|NCT04049643|DEVICE|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
214453428|NCT03814291|DRUG|IBI302|0.05mg/eye;Intraocular injection
215139605|NCT06125834|DRUG|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
214453429|NCT03814291|DRUG|IBI302|0.15mg/eye;Intraocular injection
214453430|NCT03814291|DRUG|IBI302|0.5mg/eye;Intraocular injection
214453431|NCT03814291|DRUG|IBI302|1mg/eye;Intraocular injection
214453432|NCT03814291|DRUG|IBI302|2mg/eye;Intraocular injection
214453433|NCT03814291|DRUG|IBI302|4mg/eye;Intraocular injection
214526963|NCT05183997|DRUG|Verapamil|drug will be add to prolong the effect of regional block
214526964|NCT03100136|DRUG|[11C]PF-06809247|PET Tracer
214526965|NCT02419040|PROCEDURE|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
215139606|NCT04686461|DRUG|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
215139607|NCT01847521|DIETARY_SUPPLEMENT|Luteolin, Quercetin and Rutin combined in a capsule|
215139608|NCT01917058|DRUG|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
215139609|NCT01917058|DRUG|placebo|
215139610|NCT00173472|DRUG|Chemotherapy|
215139611|NCT05165667|OTHER|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
215139612|NCT04880980|DRUG|Terbinafine Pill|Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
215139613|NCT04880980|DRUG|Itraconazole capsule|Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
215139614|NCT05899257|BEHAVIORAL|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
215139615|NCT06365359|OTHER|Blood sample for analysis of plasma of organochlorine pesticides concentration|A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
214526966|NCT02419040|PROCEDURE|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
215139616|NCT06365359|OTHER|Blood sample for cell collection|"A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells)."
215139617|NCT02475590|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
215139618|NCT02475590|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
214453434|NCT06434272|OTHER|Early exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 1-12 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Seated leg extension, standing knee flexion, and seated heel-rise performed at home as an adjunct to usual care treatment.~Each exercise is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~Pause in between sets is 30 seconds. Pause in between exercises are 120 seconds.~In weeks 13-24, patients in this arm follow usual care treatment."
214526967|NCT02419040|PROCEDURE|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
214526968|NCT01261455|PROCEDURE|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
214526969|NCT04136249|DIETARY_SUPPLEMENT|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
215139619|NCT00537134|DEVICE|Embolization, coiling|Endovascular embolization with platinum coils
215139620|NCT03377582|OTHER|Exercise|Both interventions uses exercises
215139621|NCT03597347|DRUG|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
215139622|NCT03597347|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
215139623|NCT05418179|DIETARY_SUPPLEMENT|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
215139624|NCT05418179|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (1 capsule/day)
215139625|NCT04144686|OTHER|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
215139626|NCT02867436|OTHER|Gluten-free diet|
215139627|NCT02401165|OTHER|Blood test|blood test
215139628|NCT02920632|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
215139629|NCT02920632|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
215139630|NCT04414748|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
215139631|NCT04414748|DRUG|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
215139632|NCT02532517|DEVICE|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
215139633|NCT03935984|DRUG|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
215139634|NCT04523194|OTHER|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
215139635|NCT04746391|DEVICE|Dialyzer type|Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers
215139636|NCT04746391|OTHER|Dialysis duration|Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
215139637|NCT03312231|DRUG|AS03|Oil-in-water emulsion based adjuvant system.
215139638|NCT03312231|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
215139639|NCT03312231|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
215139640|NCT03214601|DEVICE|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
215139641|NCT00886002|DRUG|Fentanyl; Buprenorphine; Naloxone|
215139642|NCT02450370|BEHAVIORAL|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
215139643|NCT02450370|BEHAVIORAL|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
215139644|NCT00671736|DRUG|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
215139645|NCT00671736|DRUG|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
215139646|NCT05642728|OTHER|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
215139647|NCT03670680|DEVICE|Use of the Lina LibrataTM|Use of the Lina LibrataTM
215139648|NCT04552951|DRUG|Cholecalciferol|Single doe of 100.000 IU
215139649|NCT05831228|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
215139650|NCT05831228|DIETARY_SUPPLEMENT|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
214453435|NCT06434272|OTHER|Late exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 13-24 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Leg press in machine, heel-rise in machine, knee flexion in machine performed at training facilities as an adjunct to usual care treatment. If facilities are unavailable, three home-based exercises will be provided.~Each exercise, regardless of study arm, is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~In weeks 1-12, patients in this arm follow usual care treatment."
214453436|NCT06031038|OTHER|TECCU Software|patient monitoring by software application
214453437|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
214453438|NCT05089734|DRUG|Docetaxel|Administered intravenously
214453439|NCT03021031|OTHER|Observational|Observational study
214453440|NCT04387422|OTHER|Experimental hyperglycemia|Experimental hyperglycemia with MRI
214453441|NCT06134375|DRUG|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
214453442|NCT06134375|DRUG|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
214453443|NCT06134375|DRUG|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
214453444|NCT05062460|OTHER|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
214453445|NCT05062460|OTHER|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
214526970|NCT01769729|BEHAVIORAL|PEPP|
214526971|NCT01769729|BEHAVIORAL|Care management|
214526972|NCT05240729|PROCEDURE|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
215139651|NCT05720897|OTHER|Auditory Alone|Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
215139652|NCT05720897|DEVICE|Relaxation Virtual Reality|Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
215139653|NCT00400179|DRUG|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
215139654|NCT00400179|DRUG|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
215139655|NCT06541938|DIETARY_SUPPLEMENT|low FODMAP diet|You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
214526973|NCT01642771|DRUG|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
214526974|NCT01642771|DRUG|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
214694949|NCT03375112|DRUG|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
215139656|NCT06541938|DIETARY_SUPPLEMENT|Lactose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk"
215139657|NCT06541938|DIETARY_SUPPLEMENT|Fructose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples"
215139658|NCT06541938|DIETARY_SUPPLEMENT|Sorbitol Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune"
214453446|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
214453447|NCT05821205|BEHAVIORAL|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
214453448|NCT05821205|BEHAVIORAL|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
214453449|NCT05821205|BEHAVIORAL|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
214453450|NCT05821205|BEHAVIORAL|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
214526975|NCT05880459|DRUG|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
214526976|NCT04382183|BEHAVIORAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
214526977|NCT04382183|BEHAVIORAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
214526978|NCT03686917|OTHER|CHAT-P|Survey
214526979|NCT05174871|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
214526980|NCT05174871|BEHAVIORAL|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
214526981|NCT00739024|DRUG|Ramelteon|8 mg tablet, oral, once daily
214453451|NCT06043713|DRUG|Bendamustine|Receive IV
214453452|NCT06043713|PROCEDURE|Biopsy|Undergo tissue biopsy
214453453|NCT06043713|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214453454|NCT06043713|PROCEDURE|Computed Tomography|Undergo CT
214453455|NCT06043713|DRUG|Cyclophosphamide|Receive IV
214453456|NCT06043713|PROCEDURE|Echocardiography|Undergo ECHO
214453457|NCT06043713|DRUG|Fludarabine|Receive IV
214453458|NCT06043713|PROCEDURE|Leukapheresis|Undergo leukapheresis
214453459|NCT06043713|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214453460|NCT06043713|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214453461|NCT06043713|PROCEDURE|Positron Emission Tomography|Undergo PET
214453462|NCT06043713|BIOLOGICAL|T-cell Receptor-engineered T-cells|Receive FHA11KRASG12V-TCR IV
214453463|NCT05904548|DEVICE|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
214453464|NCT05494697|DRUG|Rintatolimod|Rintatolimod (poly I : poly C12U)
215139659|NCT06541938|DIETARY_SUPPLEMENT|Inulin Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic"
214526982|NCT00739024|DRUG|Placebo|Placebo tablet, oral, once daily
214526983|NCT01261793|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
214453465|NCT06854614|OTHER|Comprehensive weight loss|Shared Medical Appointments
214526984|NCT01261793|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
214526985|NCT01261793|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
214526986|NCT00685347|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
215139660|NCT06541938|DEVICE|AIRE-2 Portable breath analyzer|The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
214453466|NCT06854614|OTHER|Enhanced lifestyle changes|Subjects will also be referred to an exercise physiologist for a personalized physical activity program. Physical Activity and Exercise will be discussed during SMAs as well and individually as needed for exercise progression The participants exercise prescription will be individualized based on an initial assessment. Exercise duration and progression will be recommended at the discretion of staff and exercise physiologist. The exercise program will be structured but flexible, which means patients can substitute group exercises with individual exercise if necessary, following the FITT-VP format (frequency, intensity, time, type, volume and progression). Patients can reduce exercise frequency if the duration is prolonged, or intensity is increased. Investigators will encourage patients to use Cleveland Clinic gyms across the enterprise.
214453467|NCT06854614|DRUG|Phentermine-Topiramate|Medication for chronic weight management (Rx)
214453468|NCT06854614|DRUG|Naltrexone-Bupropion Combination|Medication for chronic weight management (Rx)
214453469|NCT06854614|DRUG|Orlistat|Medication for chronic weight management (Rx)
214453470|NCT06987409|PROCEDURE|Continuous erector spinae plane block|The attending surgeon or fellow will place the erector spinae plane catheters in the operating room. Following decompression +/- fusion of the lumbar spine, catheters will be placed under direct vision. The tips of the catheters will be placed superficial to the transverse processes, instrumentation, and bone graft of the lumbar spine, as applicable to the procedure. These will be deep to the erector spinae muscles, which will be closed on top of the catheters.
214453471|NCT06692699|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
214453472|NCT06692699|DEVICE|A.R.R.E.S.T. spectacle film|A.R.R.E.S.T. spectacle film
214453473|NCT06921330|OTHER|white cover|A white cover will be covered over the incubator during phototherapy.
214453474|NCT06921330|OTHER|masaj|-Baby massage will be applied during phototherapy.
214453475|NCT05543798|DEVICE|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
214453476|NCT06845969|OTHER|Education: dry needling theory|Education relating to the theory of dry needling by physiotherapists
214453477|NCT06845969|OTHER|Education: Cadaver anatomy review|Educational instruction regarding the safe implementation of dry needling by physiotherapists using cadaver material.
214453478|NCT05521672|DRUG|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
214526987|NCT00685347|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
214526988|NCT01518517|DRUG|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
214526989|NCT01518517|DRUG|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
214526990|NCT04694859|DEVICE|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
214526991|NCT00832650|DRUG|fesoterodine fumarate|8 mg OD for 14 days
214526992|NCT00832650|DRUG|placebo|OD for 14 days
214526993|NCT00832650|DRUG|solifenacin|10 mg OD for 14 days
214526994|NCT06367426|DRUG|DDN-A-0101 (SAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
214526995|NCT06367426|DRUG|DDN-A-0101 (MAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
214526996|NCT06367426|DRUG|Placebo (SAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
214694950|NCT03375112|DRUG|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
214453479|NCT06925659|DRUG|QLM2011|QLM2011l by intravenous infusion.
214453480|NCT06925659|DRUG|Taxotere®|Taxotere® by intravenous infusion
215139661|NCT04780061|DRUG|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
215139662|NCT04780061|DIETARY_SUPPLEMENT|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
215139663|NCT04780061|DIETARY_SUPPLEMENT|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
215139664|NCT04780061|OTHER|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
215139665|NCT04780061|OTHER|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
214453481|NCT06932042|OTHER|PLADO|Low protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of \<4 g/day and \<3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance
214453482|NCT06932042|OTHER|Standard-of-care diet|Current standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences.
214453483|NCT06927544|PROCEDURE|Pars plana vitrectomy|All operations are performed in a similar fashion using the vitrectomy system with 23-gauge and 25-gauge vitrectomy probes. Surgical approach and technique include the use of tissue-staining dyes, choice of endotamponade, and postoperative face-down positioning regimen.
214453484|NCT06932003|DRUG|LT-002-158 Tablets|The subjects will orally administered LT-002-158 tablets once a day.
214453485|NCT06807853|OTHER|Smartwatch|Smartwatch AppleWatch SE to track Mobility
214453486|NCT06932172|DEVICE|Artificial inteligence based decision support to detect skin cancer|When assessing skin lesions in patients seeking primary care, the primary care physician may use the device to be evaluated in the study (Dermalyser) as a complementary diagnostic doecision support to differentiate skin cancers from benign skin lesions. However, the decision on clinical management of the lesion remains with the physician.
214453487|NCT06933030|DEVICE|titanium mesh with bone graft with delayed implant placement.|titanium mesh with bone graft with delayed implant placement.
214453488|NCT06933030|DEVICE|zirconium mesh with bone graft with delayed implant placement.|zirconium mesh with bone graft with delayed implant placement.
214453489|NCT06931678|PROCEDURE|aPDT|This intervention involves the application of antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer, followed by activation with a light source at an appropriate wavelength. The protocol is applied after conventional root canal preparation and irrigation. The aPDT protocol is standardized and performed in both medically healthy patients and patients with Type 2 Diabetes Mellitus (T2DM), allowing comparison of microbiological and clinical outcomes between the two groups. This intervention aims to enhance root canal disinfection, particularly in anatomically complex areas that are difficult to reach with traditional methods.
214453490|NCT06931288|DEVICE|Blood pressure monitor|In the trial group, atrial fibrillation screening will be integrated into blood pressure measurements using the BP77A1T electronic blood pressure monitor (Omron Healthcare, Kyoto, Japan).
214453491|NCT06931288|DEVICE|Single-lead ECG|In the control group, a single-lead ECG will be recorded for 30s with a handheld ECG for atrial fibrillation detection. Each ECG rhythm strip will be reviewed and analyzed by a cardiologist from the research team.
214453492|NCT05302596|DRUG|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
214453493|NCT06085872|BEHAVIORAL|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
214453494|NCT06085872|BEHAVIORAL|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested."
214694951|NCT04015947|DEVICE|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
214694952|NCT04310163|OTHER|Natural history|Parent interview and video capture
214453495|NCT06085872|BEHAVIORAL|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
214453496|NCT06847893|OTHER|rebozo technique|In accordance with the 'Rebozo Chart' developed by the researcher, the pregnant women in the experimental group were massaged with 4 different rebozo techniques (rebozo technique in hand-knee position, rebozo technique in knee-chest position, umbilical support with rebozo, rebozo technique applied with Pilates ball) in the active phase of labor. After the application, the duration, frequency and cervical dilatation of the pregnant woman were recorded in the chart.
214453497|NCT04520451|DRUG|rilzabrutinib|oral tablet
214453498|NCT04520451|DRUG|Glucocorticoids|oral tablet or capsule
214453499|NCT06196866|OTHER|Conventional Therapy|The control group will develop only conventional treatment for the whole trial (weeks 1-24), consisting of carrying out daily routine activities and/or 1 session/week of physiotherapy (which includes manual therapy, active exercises of repetition of functional movements, walking, stairs and stretching) with a time of 45 minutes/session.
215139666|NCT03090230|DEVICE|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
215139667|NCT02753270|PROCEDURE|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
214453500|NCT06196866|DEVICE|Nintendo Ring Fit Adventure + Conventional Therapy|"In the exergaming group 1, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Jogging: Begginia or Transient Temple.~Minigames: Squat Goals, Squattery Wheel, Gluting Gallery, Thigh Rider, Bank Balance or Dreadmill.~Lower Limbs Training: Knee Lift or Hip Lift.~Yoga: Tree Pose or Chair Pose."
214453501|NCT06196866|DEVICE|Nintendo Wii Fit + Conventional Therapy|"In the exergaming group 2, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Aerobics: Basic Run or Hula Hoop.~Strength Training: Rowing Squat, Single-Leg Extension, Sideways Leg Lift or Single-Leg Twist.~Balance Games: Ski Jump, Balance Bubble, Table Tilt or Penguin Slide.~Yoga: Chair or Standing Knee."
214453502|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
214453503|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
214453504|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
214453505|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
214453506|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
214453507|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
214453508|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
215139668|NCT02753270|PROCEDURE|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
215139669|NCT01526447|PROCEDURE|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
215139670|NCT01526447|PROCEDURE|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
215139671|NCT00635414|DRUG|Esomeprazole|40mg oral
215139672|NCT00635414|DRUG|Esomeprazole|15 minute intravenous infusion
215139673|NCT04236427|DRUG|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
215139674|NCT04236427|DRUG|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
215139675|NCT00114569|DRUG|lorazepam|
215139676|NCT03880097|PROCEDURE|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
215139677|NCT05910996|PROCEDURE|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
215139678|NCT00509977|PROCEDURE|Light Treatment|Light treatment applied to half of the face at each study visit
215139679|NCT00509977|PROCEDURE|Laser Treatment|Laser treatment applied to half of the face at each study visit
215139680|NCT06822062|OTHER|Meal A|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57, native chitin content = 1g)
215139681|NCT06822062|OTHER|Meal B|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + 2g of extrinsically added chitin
215139682|NCT06822062|OTHER|Meal C|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
215139683|NCT06822062|OTHER|Meal D|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58)
215139684|NCT06822062|OTHER|Meal E|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 1g of extrinsically added chitin
215139685|NCT06822062|OTHER|Meal F|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 3g of extrinsically added chitin
215139686|NCT06822062|OTHER|Meal G|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 54) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
215139687|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
215139688|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
214453509|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
214453510|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
214453511|NCT05523401|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
214453512|NCT05523401|DRUG|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
214453513|NCT05523401|OTHER|Placebo|Placebo (Mannitol)
214453514|NCT02443857|DEVICE|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
214453515|NCT02443857|DEVICE|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
214453516|NCT02443857|DEVICE|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
214453517|NCT02443857|DEVICE|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
214453518|NCT02443857|DEVICE|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
214453519|NCT02443857|DEVICE|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
214453520|NCT04353661|DRUG|Azithromycin|Azithromycin will be administered orally.
214453521|NCT04353661|OTHER|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
214453522|NCT05813275|DRUG|AD109|Oral administration at bedtime
214453523|NCT05813275|DRUG|Placebo|Oral administration at bedtime
214453524|NCT00667251|BIOLOGICAL|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
214453525|NCT00667251|DRUG|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
214453526|NCT00667251|DRUG|lapatinib ditosylate|1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
214453527|NCT00667251|DRUG|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
214453528|NCT06352567|OTHER|European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire|"It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively"
215139689|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
215139690|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
215139691|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
215139692|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
215139693|NCT05670093|DEVICE|Neural Pressure Support (mode of mechanical ventilation)|Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
215139694|NCT04495218|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
215139695|NCT05794321|DRUG|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
215139696|NCT04825574|DRUG|Avapritinib|avapritinib tablet
215139697|NCT04507412|DRUG|dexamethasone|perioperatively 9 mg i.v subministration
215139698|NCT05391503|BEHAVIORAL|Light therapy|Morning bright light for 60 minutes after awakening
214453529|NCT04927637|PROCEDURE|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
215139699|NCT05391503|BEHAVIORAL|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
215139700|NCT05598333|DRUG|AB-1002|Intracoronary Infusion of AB-1002 or placebo
215139701|NCT06650709|DRUG|Olaparib|Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
215139702|NCT06650709|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
215139703|NCT06650709|DRUG|Durvalumab|Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
215139704|NCT06653972|DRUG|Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.|Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
215139705|NCT06654362|BEHAVIORAL|nutritional interventions include education and modifying company's restaurant menu|"* Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake."
214453530|NCT04101903|DIAGNOSTIC_TEST|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
214453531|NCT06087601|DRUG|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
214453532|NCT06087601|DRUG|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
214453533|NCT05834608|BEHAVIORAL|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
214453534|NCT06204913|OTHER|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
215139706|NCT06654973|OTHER|GMP-produced SARS-CoV-2 Delta strain|The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.
215139707|NCT06653985|DRUG|Hyaluronic and corticosteroid injection|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.
214453537|NCT04088851|DRUG|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
214453538|NCT04088851|DRUG|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
214453539|NCT05893498|DEVICE|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
214453540|NCT05893498|DEVICE|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
214453541|NCT06541951|OTHER|Services as usual|During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures
214453542|NCT06541951|OTHER|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
214453543|NCT01140880|DRUG|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
214453544|NCT05335967|BEHAVIORAL|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
215139708|NCT06653985|OTHER|Physical Therapy|Patients will receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
215139709|NCT04199221|BEHAVIORAL|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
214453545|NCT05335967|OTHER|Information package|The patients in this group will receive an information package on a healthy diet.
214453546|NCT03949387|OTHER|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
214453547|NCT03949387|OTHER|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
214453548|NCT06312813|DRUG|Imipramine|4% imipramine
214453549|NCT06312813|DRUG|Amitriptyline|4% amitriptyline
214453550|NCT06312813|DRUG|Vehicle|0.1ml propylene glycol
214453551|NCT04990232|DRUG|Anakinra or rhIFNγ|In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.
214453552|NCT04990232|DRUG|Placebo|20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
214453553|NCT01212029|BEHAVIORAL|Behavioral measures|Behavioral tasks/ questionnaires
214453554|NCT01212029|DEVICE|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
214453555|NCT01212029|OTHER|Physiological measures|A set of tasks.
215139710|NCT04199221|BEHAVIORAL|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
215139711|NCT06810960|OTHER|No Intervention|This is a non-interventional study.
215139712|NCT06594913|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
215139713|NCT06599242|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy is an exercise approach belonging to physiotherapists
215139714|NCT06599242|OTHER|American football team training|American football team training
215139715|NCT06594250|DIAGNOSTIC_TEST|Nasal swab|Nasal swab to detect nasal carriage of S. aureus
215139716|NCT06594250|BIOLOGICAL|Venous sampling|Peripheral venous sampling to collect peripheral blood mononuclear cells.
215139717|NCT06594250|BIOLOGICAL|Antibiotic treatment|Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus
215139718|NCT06594250|DEVICE|Nasal swab|A new nasal swab will be taken using the same technique, to see whether or not the carriage persists
215139719|NCT06594250|BIOLOGICAL|Intracellular reservoir test|In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.
215139720|NCT06601608|DRUG|Herbal therapy|rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
215139721|NCT06601608|DRUG|Placebo Drug|a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
214453556|NCT06357546|PROCEDURE|Spontaneous urination during the hour before caesarean section.|Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.
214453557|NCT06357546|PROCEDURE|Systematic bladder catherization during caesarean section.|After implementation of loco-regional analgesia by spinal anesthesia, the patient will be positioned, with a perineal toilet and installation of a bladder catheter type Foley ch. 16.
214453558|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
214453559|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
214453560|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
214453561|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
215139722|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|"Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.~Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore \&amp;amp; Associates) to create a final 6-mm shunt."
215139723|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|After successful puncture, in the 8-mm shunt group, a balloon with a diameter of 6 mm was used to expand the shunt, and then an 8-mm covered stent was implanted (Viatorr; WL Gore \&amp; Associates, Inc.).
215139724|NCT06600958|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
215139725|NCT06596551|BEHAVIORAL|Pre-Post ARCH Intervention|Stroke dyads, consisting of a survivor and primary family caregiver, will engage in a 4 weekly, 1.5 hour experiential dyadic sessions, totalling 6 hours of participation. In Week 1, dyads acknowledge the losses occurring after the stroke to normalize feelings of grief and sadness and find comfort within the familial space. In Week 2, dyads interpret their post-stroke losses within the framework of their existing knowledge for managing adversities (strengths, resources, and values) and identify changes that are most meaningful to them. In Week 3, dyads set specific, measurable, and achievable goals to actualize the meaningful changes identified in Week 2. Finally in Week 4, dyads bring together their individually derived strengths from the previous sessions to culminate into strengthened dyadic bonds. The exercise will also encourage participants to expand beyond the dyadic space to seek support from their communities, social networks and care services that are available to them.
215139726|NCT06590103|BEHAVIORAL|Physically Active Lessons|Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the Physical Education teacher) are in charge of designing and delivering the physically active classes.
215139727|NCT06655571|PROCEDURE|Ultrasound guided caudal Block|caudal block using Ultrasound
215139728|NCT06655571|PROCEDURE|Conventionel|Caudal Block based on anatomical landmarks
214453562|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
214453563|NCT04126200|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214453564|NCT04126200|DRUG|GSK3174998|GSK3174998 will be administered.
214453565|NCT04126200|DRUG|Feladilimab|feladilimab will be administered.
214453566|NCT04126200|DRUG|Nirogacestat|Nirogacestat will be administered.
214453567|NCT04126200|DRUG|Dostarlimab|Dostarlimab will be administered.
214453568|NCT04126200|DRUG|Isatuximab|Isatuximab will be administered.
214453569|NCT04126200|DRUG|Lenalidomide|Lenalidomide will be administered.
214453570|NCT04126200|DRUG|Dexamethasone|Dexamethasone will be administered.
214453571|NCT04126200|DRUG|Pomalidomide|Pomalidomide will be administered.
214453572|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
214453573|NCT04308174|DRUG|Durvalumab + Gem/Cis|Neoadjuvant Durvalumab + Gemcitabine/Cisplatin
214453574|NCT04308174|DRUG|Gem/Cis|Neoadjuvant Gemcitabine/Cisplatin
214453575|NCT03196011|OTHER|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
214453576|NCT03196011|OTHER|TKR with alternative alignment method|TKR implanted using alternative alignment methods
214453577|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
214453578|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
214453579|NCT03131648|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
214453580|NCT03131648|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
214453581|NCT06546982|DIAGNOSTIC_TEST|Surface-enhanced Raman Spectroscopy|The Raman spectra of patient samples will be measured in the presence of gold nanoparticles, which will enhance the spectroscopic characteristics of serum components via near-field enhancements.
214453582|NCT05322785|OTHER|Breath collection|Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
214453583|NCT06415370|BEHAVIORAL|Home Delivered Healthy Meals|In-person delivery of HDHM at least one time weekly for 12 weeks.
214453584|NCT06415370|BEHAVIORAL|"In-person friendly visits"|"Friendly visits last approximately 5-10 minutes and include brief wellness check questions such as, How are you doing today? Did you try \[HDHM recipe\] yesterday- how did it taste? Any suggestions for future flavors? What are some of the things you plan to do in the next few days? Is there anything else you want to share with me?"
214453585|NCT06415370|BEHAVIORAL|Student Companion calls|Student Companions call participants at least one time weekly to provide telephone reassurance- i.e., checking on the participant's well-being. These calls may also include referrals to appropriate resources such as NCCARE 360 (statewide network that connects individuals with complex health and social needs, to community resources and service)
214453586|NCT05203341|DRUG|Placebo|Matching placebo tablets
214453587|NCT05203341|DRUG|NBI-1065845|NBI-1065845 tablets
214453588|NCT04833309|PROCEDURE|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
214453589|NCT04833309|PROCEDURE|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
214453590|NCT06146907|OTHER|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
214453591|NCT06146907|OTHER|exergaming|Nintendo switch games that involve physical activity by participants to complete
214453592|NCT04954664|BIOLOGICAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
214453593|NCT04954664|BIOLOGICAL|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
214453594|NCT05076370|DRUG|CBD Day 1|CBD 400mg
214453595|NCT05076370|DRUG|CBD Day 2|CBD 800mg
214453596|NCT05076370|DRUG|CBD Day 3|CBD 1200mg
214453597|NCT04312308|OTHER|Sample collection|"1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3\. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
214453598|NCT05418699|DEVICE|closed-loop insulin pump|Follow up of patients with real-time closed-loop insulin delivery systems
214526997|NCT06367426|DRUG|Placebo (MAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
214526998|NCT02395224|OTHER|cancer treatment and follow-up according to current regional and national guidelines|
215139729|NCT06312826|PROCEDURE|Abdominal US|The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.
214526999|NCT05043428|BEHAVIORAL|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
215139730|NCT06312826|PROCEDURE|AMRI|The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
214527000|NCT06385418|DRUG|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
214527001|NCT05555121|DRUG|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
214527002|NCT01881100|OTHER|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
214527003|NCT01881100|OTHER|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
214527004|NCT00002099|DRUG|Lentinan|
214527005|NCT00002099|DRUG|Didanosine|
214527006|NCT04419961|BEHAVIORAL|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
214527007|NCT00639236|OTHER|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
214527008|NCT00214071|BIOLOGICAL|Influenza vaccine|
214527009|NCT05300698|DEVICE|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
215139731|NCT06594822|DIETARY_SUPPLEMENT|probiotic plus standard treatment|Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily
215139732|NCT06594822|DRUG|standard treatment|diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
214527010|NCT01998334|OTHER|CVVH 6h|CVVH 6h for first three days
214453599|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
214527011|NCT01998334|OTHER|CVVH 10h|CVVH 10h for first three days
214527012|NCT01998334|OTHER|CVVHDF 6h|CVVHDF 6h for first three days
214527013|NCT05283642|DIETARY_SUPPLEMENT|DCI|Oral supplementation with D-chiro-inositol once daily
214527014|NCT04681209|BEHAVIORAL|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
214527015|NCT04681209|BEHAVIORAL|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
215139733|NCT06595849|BEHAVIORAL|4-week feeling tone intervention program|Participants will take part in a 4-week mindfulness of feeling tone intervention program taught by a registered mindfulness teacher, who is also a registered clinical psychologist. The intervention program includes 4 sessions, with each session lasting for about 2 hours. The program is taught in Cantonese, in a group setting, live online (via Zoom). Participants will practice meditation practices during the session, explore themes of the week, review and explore their meditation experiences. They will also practice meditation practices daily for at least 30 minutes at home, with meditation audio recordings provided by the teacher.
215139734|NCT06591052|OTHER|Passive stretching|The physiotherapist positioned each muscle in its maximum lengthened state and held it there for 30 seconds. This process was repeated three times, with a 30-second rest interval between each stretch of the different muscle groups.
215139735|NCT06591052|OTHER|PNF stretching|The physiotherapist initially positioned each muscle in its most extended state, similar to the positions used in passive stretching. In this extended position, the participants performed an isometric contraction against maximal resistance in the antagonist direction for 5-8 seconds. Following the isometric contraction, participants were instructed to actively relax, and after a 5-second waiting period to ensure complete relaxation, the movement range was passively increased. The new end point of the extended range of motion was held for 30 seconds. This stretching protocol was repeated three times for each muscle group, with a 30-second rest period between each stretch.
215139736|NCT06597903|DRUG|NRL994|"In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid."
214453600|NCT05333185|BEHAVIORAL|DİABOT (mobile application robot )|"DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet."
214453601|NCT04258709|BEHAVIORAL|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
214453602|NCT04258709|BEHAVIORAL|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
214453603|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
214453604|NCT05963425|OTHER|Physical activity|This physical activity program will be based only on the work of basic physical training, in which specifically and mainly the strength and resistance will be worked, but also flexibility
214453605|NCT05963425|OTHER|usual clinical practice|usual clinical practice
214453606|NCT05972512|OTHER|Placebo|Mode of usage: Two times a day Route of administration: Oral
214453607|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
214453608|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
214453609|NCT06664151|BIOLOGICAL|Fluzone Trivalent|Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
214453610|NCT05447689|BEHAVIORAL|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
214453611|NCT05633953|DRUG|Osilodrostat|oral administration
214453612|NCT05061004|DEVICE|Cephea Mitral Valve System|Transcatheter mitral valve replacement
214453613|NCT03047928|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
214453614|NCT03047928|BIOLOGICAL|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
214453615|NCT04487847|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
214453616|NCT05448170|DRUG|Linerixibat|open label investigational product
214527016|NCT04433247|BEHAVIORAL|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
214527017|NCT00246389|DRUG|cyclobenzaprine hydrochloride|
215139737|NCT06592950|OTHER|No treatment given|Online survey
214453617|NCT03839342|DRUG|Binimetinib|MEK inhibitor, 45mg oral tablet
214453618|NCT03839342|DRUG|Encorafenib|BRAF inhibitor, 450mg oral capsule
214527018|NCT02885376|DEVICE|Dentoxol|Mouthrinse
214527019|NCT02885376|DEVICE|Placebo|Mouthrinse
214527020|NCT01884376|DEVICE|Neuromaix|
214527021|NCT03288480|DRUG|PT-112|This is a single arm study
214527022|NCT05620199|PROCEDURE|Upfront resection|Resection of the primary tumor
214453619|NCT04990284|DRUG|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
214453620|NCT04990284|DRUG|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
214453621|NCT06042387|GENETIC|Blood or saliva sample collection|Blood or saliva sample \& clinical data collection
214527023|NCT00524693|DRUG|Montelukast|4mg sachets
214527024|NCT00524693|DRUG|Placebo granules|
214527025|NCT00001623|PROCEDURE|Allogeneic Bone Marrow Transplant|
215139738|NCT06592950|OTHER|No treatment given|Interviews
215139739|NCT06590831|DRUG|Lactoferrin|to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
215139740|NCT06594666|DEVICE|VR/AR visual training group|Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
215139741|NCT06997978|OTHER|Tele-rehabilitation|Patients at the Telerehabilitation group are contacted via laptops that have cameras, microphones, and a reliable internet connection. The therapist's laptop camera is positioned so the patient may watch the therapist while the therapist demonstrates the exercises. After the therapist performs the exercise on himself, the patient must see the therapist via a laptop camera and then perform the same activity again.
215139742|NCT06997978|OTHER|Hand rehabilitation program|"1. Free exercises:~   1\. Wrist flexion and extension 2. Wrist side movement 3. Thumb flexion and extension 4-Finger opposition 5. Palm up and down~2. Ball exercises:~   1. Ball grip~  2. Finger flexion~  3. Thumb extend~  4. The pinch exercise~  5. Opposition 6- Side squeeze~   7\. Extend out~3. Household exercises~   1. Roll movement~  2. Wrist curl~  3. Extending the wrist~4. Pen exercises~   1. Pinch and release~  2. Pen spine~5. Exercises with coins~   1. Coin drop~  2. Coin stacking"
215139743|NCT06999408|DEVICE|Scalp tattoo|A micropigmentation scalp tattoo will be applied at baseline to mark consistent photographic sites.
215139744|NCT06999408|DEVICE|Canfield HairMetrix®|Canfield HairMetrix® imaging will be utilized to capture global and trichoscopic hair measurements.
215139745|NCT06999408|DEVICE|TargetCool|Boosting will be used to apply exosomes
215139746|NCT06999408|DEVICE|Microneedle-facilitated lidocaine application|Microneedling will be performed to a depth of 0.5 mm.
215139747|NCT06998836|BEHAVIORAL|Dementia prevention education|Dementia prevention education:A structured dementia prevention education program developed based on qualitative focus group findings. The program includes multiple interactive sessions covering dementia knowledge, health beliefs, risk reduction strategies, and motivation for preventive actions.
215139748|NCT06998836|OTHER|General Health Education Leaflet|Participants received printed general health education leaflets not specifically related to dementia. The content included general wellness and health maintenance advice.
215139749|NCT06587698|DRUG|Sitagliptin|100 mg QD for 3 month
215139750|NCT06587698|DRUG|BeiDouGen|60 mg BID for 3 month
215139751|NCT06587698|DRUG|Sitagliptin+BeiDouGen|100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
215139752|NCT06998290|OTHER|Blue-Line home telemonitoring program|"* A dedicated telemonitoring team with nurses and pediatric cardiologist~* A dedicated therapeutic patient education programme~* A home telemonitoring medical device with a dedicated platform"
215139753|NCT06602661|PROCEDURE|Fissureless Lobectomy with Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler equipped with the ENDOPATH™ stapler line reinforcement. The ENDOPATH™ device uses bioabsorbable buttress material made from Polyglactin and Polydioxanone, designed to enhance the durability and effectiveness of the staple line.~The reinforcement tool is a novel preloaded device with a click and go mechanism, making it easy to load and use during surgery.~The primary objective is to reduce the average duration of hospital length of stay (LOS) directly caused by prolonged air leak (PAL). Secondary objectives include improving intraoperative characteristics (such as duration and amount of blood loss) and postoperative outcomes (such as incidence and duration of PALs, number of chest tube days, and incidence of hospital."
215139754|NCT06602661|PROCEDURE|Fissureless Lobectomy with Non-Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler without any additional reinforcement. This means the staple lines are created using the standard stapler without the use of bioabsorbable buttress materials.~The ECHELON™ 3000 stapler is used to divide the lung parenchyma, pulmonary artery branches, veins, and bronchus without any reinforcement, relying solely on the standard stapling mechanism."
215139755|NCT06872996|DIAGNOSTIC_TEST|Prick-test|"Several foods may be tested for the same participant depending on the number of food allergies the patient has. PT are performed using the prick-to-prick method with lancets, in a single session per patient, using fresh and preserved native foods. Simultaneously, a positive control and a negative control are performed. The PT are performed and read by nursing or medical staff trained in the technique.~Participants' clinical follow-up is performed continuously for 30 minutes from the performance of the prick-tests and under the responsibility of the allergologist doctor, whose presence is mandatory during the performance of these tests.~For meat, fruit, vegetable, leguminous plant, milk, seafood and fish tests will be performed with fresh products and with products preserved for 3 months as well as with products preserved for 6 months \[-15 days; +15 days\].~For dry foods (nuts and peanuts), tests will be performed with products harvested over 3 separate and consecutive seasons."
214453622|NCT04812366|DRUG|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
214453623|NCT04812366|DRUG|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
214453624|NCT04812366|DRUG|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
214453625|NCT04812366|DRUG|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
214453626|NCT04812366|DRUG|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
214453627|NCT04812366|DRUG|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
214527026|NCT05291962|OTHER|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
215139756|NCT06700824|DEVICE|OTR4132|OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
215139757|NCT06700824|DEVICE|Placebo|saline solution
215139758|NCT03277482|DRUG|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
215139759|NCT03277482|DRUG|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
215139760|NCT03277482|RADIATION|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
215139761|NCT06706466|OTHER|observational study|Non-interventional
215139762|NCT06739746|OTHER|No intervention measures|No intervention measures
215139763|NCT06756880|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards
215139764|NCT06578039|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|allogeneic umbilical cord-derived mesenchymal stem cell
215139765|NCT03215056|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
215139766|NCT03215056|DRUG|Normal saline|Placebo
214527027|NCT06584617|DEVICE|Berovenal®|Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
214527028|NCT06584617|DEVICE|NU-GEL Hydrogel with Alginate|Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
214527029|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
214527030|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
214527031|NCT04260776|BEHAVIORAL|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
214527032|NCT04260776|BEHAVIORAL|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
214527033|NCT02646644|OTHER|Metastasized intestinal NET|This is an observational study
214527034|NCT05066178|BEHAVIORAL|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
214453628|NCT06096701|DEVICE|Blood pressure cuff|The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
214453629|NCT05543369|DRUG|Elafibranor|Oral Tablet
214527035|NCT06184295|DEVICE|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
214527036|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
214527037|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
214527038|NCT01229527|DRUG|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
215139767|NCT01254617|BIOLOGICAL|Cetuximab|Given IV
215139768|NCT01254617|OTHER|Laboratory Biomarker Analysis|Correlative studies
215139769|NCT01254617|DRUG|Lenalidomide|Given PO
215139770|NCT00269217|DRUG|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
215139771|NCT00269217|DRUG|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
215139772|NCT00269217|DRUG|Comparator: simvastatin|Duration of Treatment 12 Weeks
215139773|NCT00638677|DIETARY_SUPPLEMENT|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
215139774|NCT00638677|DIETARY_SUPPLEMENT|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
215139775|NCT00638677|DIETARY_SUPPLEMENT|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
215139776|NCT04602663|DEVICE|Esophageal Variceal Band ligation|Band ligation of OV
215139777|NCT02928887|OTHER|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
215139778|NCT00303069|BIOLOGICAL|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
215139779|NCT00303069|BIOLOGICAL|Comparator: Placebo|Single dose of saline placebo intramuscularly
214527039|NCT04655222|DRUG|Interferon Beta Therapy|Administered as specified in the treatment arm.
214527040|NCT04453306|DRUG|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
214527041|NCT04453306|DRUG|Placebo|innocuous substance is coated in tablets in an independent laboratory
215139780|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)
215139781|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
215139782|NCT06472232|DRUG|Chloroprocaine|Selection of low concentration of chloroprocaine as local anesthetic for labor analgesia
215139783|NCT04664686|PROCEDURE|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
215139784|NCT04664686|PROCEDURE|AV node ablation|AV node ablation
215139785|NCT01632696|DRUG|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
215139786|NCT02647619|DRUG|Xiapex|Injection of collagenase of primary dupytren cord
215139787|NCT02647619|PROCEDURE|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
215139788|NCT05984017|OTHER|No treatment is included in this study|No drug intervention or tissue sampling will be included in this study.
215139789|NCT01924338|DEVICE|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
215139790|NCT01924338|DEVICE|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
215139791|NCT01924338|PROCEDURE|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
215139792|NCT05557084|PROCEDURE|laparoscopic vertical clip gastroplasty (LVCG) with Bariclip.|The investigator performed laparoscopic vertical clip gastroplasty, This procedure consists of a nonadjustable clip that is vertically placed around the stomach, parallel to the lesser curvature, mimicking the effect of sleeve gastrectomy. The clip restricts oral intake, the anatomy of the stomach is not permanently changed, the small bowel remains untouched, the digestive pathway is not diverted, no stapling or resection are required and the magnitude of restriction is supposed to remain constant during the years. The vertical clip is thus placed without risks of staple line leak, malabsorption side effects, changes in anatomy, and is potentially reversible \[9\]. creating a 4-cm window to enter the lesser sac while lifting the stomach to create sufficient space to be able to suture. Plication of the antrum for 3-5 cm is performed. Fluid testing for patency is performed with methylene blue or normal saline and the procedure is terminate.
215139793|NCT00574197|DRUG|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
215139794|NCT01883258|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
215139795|NCT01883258|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
215139796|NCT03010449|DEVICE|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
215139797|NCT05165134|OTHER|Kinesiotape|Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
215139798|NCT03077971|BEHAVIORAL|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
215139799|NCT03077971|BEHAVIORAL|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
215139800|NCT02403128|DRUG|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
215139801|NCT03574584|DRUG|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
215139802|NCT03574584|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
215139803|NCT03574584|DRUG|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
215139804|NCT02799446|DRUG|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
215139805|NCT02799446|DRUG|Placebo|Matching Placebo intravenous (IV)
215139806|NCT04318873|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
214453630|NCT05933265|DRUG|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
214453631|NCT05933265|DRUG|Spironolactone|A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.
214453632|NCT05933265|DRUG|Olaparib|A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.
214453633|NCT02729311|BEHAVIORAL|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
214453634|NCT02729311|BEHAVIORAL|Waitlist control|After engaging in usual activities for 12 weeks, the Waitlist control group participates in the Paired PLIÉ program.
214453635|NCT02677025|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
214453636|NCT02677025|BEHAVIORAL|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
215139807|NCT05535296|BEHAVIORAL|Risk profile|Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
215139808|NCT03247647|BEHAVIORAL|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
215139809|NCT03247647|BEHAVIORAL|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
215139810|NCT02670317|DRUG|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
215139811|NCT02670317|DRUG|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
215139812|NCT02670317|DRUG|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
215139813|NCT01622166|BEHAVIORAL|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
215139814|NCT06225453|OTHER|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
215139815|NCT06225453|OTHER|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
215139816|NCT06327269|DRUG|Lenvatinib 10 mg|Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
214453637|NCT05324124|DRUG|Selpercatinib|Administered orally.
214453638|NCT05018494|OTHER|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
214453639|NCT05018494|OTHER|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
214453640|NCT02026843|DRUG|Chorioretinal diseases|chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
214453641|NCT03842592|DIAGNOSTIC_TEST|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
214527042|NCT00355732|PROCEDURE|Weaning from mechanical ventilation|
215139817|NCT06070064|OTHER|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
215139818|NCT03258385|DIETARY_SUPPLEMENT|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
215139819|NCT03258385|DIETARY_SUPPLEMENT|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
215139820|NCT03234322|OTHER|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
215139821|NCT05360004|DRUG|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
215139822|NCT02958917|DRUG|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
215139823|NCT02958917|OTHER|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
215139824|NCT04672278|DIETARY_SUPPLEMENT|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
215139825|NCT02656771|DEVICE|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
215139826|NCT03018652|DRUG|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
215139827|NCT03018652|DRUG|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
215139828|NCT02318706|DRUG|DS-5565|
214453642|NCT04034251|DRUG|Paclitaxel|Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m\^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m\^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
214453643|NCT04034251|DRUG|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
214453644|NCT04034251|DEVICE|BardPort Titanium Implanted Port with Peritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
214453645|NCT01105286|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
214453646|NCT04843722|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
214527043|NCT02822040|OTHER|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
214527044|NCT03588195|OTHER|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
214453647|NCT05585580|DRUG|Serplulimab|300mg d1 q3w
214453648|NCT05585580|DRUG|Lenvatinib|8mg po qd
214453649|NCT05585580|DRUG|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
214527045|NCT03588195|DEVICE|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
214527046|NCT04749771|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
214527047|NCT04749771|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
214527048|NCT02335242|DRUG|Sildenafil 20 mg tablets|
214527049|NCT02335242|OTHER|Placebo tablets (resembling Revatio)|
214527050|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after phage treatment.
214527051|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after standard infection treatment.
215139829|NCT02318706|DRUG|placebo|
215139830|NCT04176471|OTHER|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
215139831|NCT04176471|OTHER|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
215139832|NCT03598686|DIAGNOSTIC_TEST|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
215139833|NCT02556385|DEVICE|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
215139834|NCT02556385|DEVICE|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
215139835|NCT06289790|PROCEDURE|Erector Spinae Plane (ESP) block|Erector Spinae Plane (ESP) block with bupivacaine and for pain management in VATS procedure
215139836|NCT06289790|DRUG|Lignocaine|Lignocaine bolus and infusion for pain management in VATS procedure
215139837|NCT06289790|DRUG|Bupivacaine|Bupivicaine with adrenaline will be used to perform the ESP block
214453650|NCT03643861|RADIATION|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
214453651|NCT04414280|DEVICE|Medtronic MiniMed 670G|The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
214453652|NCT04414280|DEVICE|Medtronic MiniMed 780G|The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.
214453653|NCT04414280|DEVICE|Tandem Control-IQ|The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
214453654|NCT05142059|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
214453655|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
215139838|NCT02018718|DEVICE|Magnetic Resonance Imaging (MRI)|
214453656|NCT06519279|DEVICE|Opals|Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
214453657|NCT06519279|DEVICE|Axivity|"At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering."
215139839|NCT04859738|DRUG|Lidocaine Spray|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
215139840|NCT04859738|DRUG|Benzokain Sprey|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
215139841|NCT04859738|OTHER|Alcohol|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
214453658|NCT06636539|DEVICE|CEM Exam in Investigational Device|All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
214453659|NCT05935059|DRUG|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
214453660|NCT05935059|DRUG|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
214453661|NCT04419389|DRUG|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
214453662|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
214453663|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
214453664|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT|APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
214453665|NCT04639206|BEHAVIORAL|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
214453666|NCT05273749|DRUG|TNX-102 SL Tablet, 5.6 mg|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
214453667|NCT05273749|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
214453668|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
214453669|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
214527052|NCT04916340|BEHAVIORAL|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
214453670|NCT03706170|BEHAVIORAL|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
214453671|NCT03706170|BEHAVIORAL|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
214527053|NCT04916340|BEHAVIORAL|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
214527054|NCT06448390|BEHAVIORAL|Physical training|The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
214527055|NCT01637337|PROCEDURE|laparoscopic pyelolithotomy|laparoscopy
215139842|NCT03921957|RADIATION|stereotactic radiotherapy|first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
215139843|NCT01921595|OTHER|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
215139844|NCT01921595|OTHER|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
215139845|NCT02151864|DRUG|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
215139846|NCT04301375|DRUG|Pertuzumab and trastuzumab FDC subcutaneous|Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
215139847|NCT04301375|DRUG|Paclitaxel|80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
214453672|NCT05285826|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
214453673|NCT05285826|OTHER|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
214453674|NCT03410615|RADIATION|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
214453675|NCT03410615|DRUG|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
214453676|NCT03410615|DRUG|Durvalumab|Given in concurrent and adjuvant phase
214453677|NCT03410615|DRUG|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
214453678|NCT05974267|DRUG|M5717 60 mg|Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
214453679|NCT05974267|DRUG|Pyronaridine|Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
214453680|NCT05974267|DRUG|Atovaquone-Proguanil|Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
214453681|NCT05974267|DRUG|M5717 200 mg|Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
214453682|NCT05974267|DRUG|M5717 660mg|Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
215139848|NCT04301375|DRUG|TDM1|3,6 mg/kg, 14 adjuvant cycles if not complete response
215139849|NCT04301375|DRUG|Endocrine therapy|Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
215139850|NCT04301375|PROCEDURE|Omission surgery|Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
215139851|NCT01456039|DRUG|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
215139852|NCT05096403|DRUG|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
215139853|NCT04936945|PROCEDURE|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
215139854|NCT00451360|DRUG|diacerein|
215139855|NCT02869152|OTHER|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
215139856|NCT02869152|OTHER|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
215139857|NCT02869152|OTHER|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
215139858|NCT02869152|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
215139859|NCT02869152|PROCEDURE|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
215139860|NCT02869152|PROCEDURE|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
215139861|NCT03584477|DEVICE|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
215139862|NCT03584477|OTHER|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
215139863|NCT00497094|DEVICE|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
215139864|NCT00648609|OTHER|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
215139865|NCT00648609|OTHER|Standard of care|Usual care for COPD patients
215139866|NCT02700061|PROCEDURE|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
215139867|NCT02700061|PROCEDURE|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
215139868|NCT00473239|DRUG|cholecalciferol.|100,000 IU of Vitamin D
215139869|NCT04398927|DRUG|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
215139870|NCT04398927|DRUG|Sintilimab|Sintilimab
215139871|NCT04949997|OTHER|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
215139872|NCT04618536|OTHER|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
215139873|NCT04618536|OTHER|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
215139874|NCT04799834|OTHER|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
214453683|NCT05629143|PROCEDURE|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
214453684|NCT05629143|PROCEDURE|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
214453685|NCT05629143|DRUG|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
214453686|NCT04585477|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
214453687|NCT04585477|DRUG|Durvalumab|Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
214453688|NCT04585477|DRUG|Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy|Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
214453689|NCT06286514|OTHER|No intervention|This is an observational study
214453690|NCT03800550|DRUG|Bedaquiline|Bedaquiline tablet will be administered, orally.
214453691|NCT03800550|DRUG|Clarithromycin|Clarithromycin tablet will be administered, orally.
214453692|NCT05876858|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
214453693|NCT05876858|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
214453694|NCT04643379|DRUG|Olaparib|Supplied by Merck \& Co.
214453695|NCT04643379|DRUG|Pembrolizumab|Supplied by Merck \& Co.
214453696|NCT04643379|DRUG|Carboplatin|Commercially available
214453697|NCT04643379|PROCEDURE|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
214527056|NCT01637337|PROCEDURE|percutaneous nephrolithotomy|percutaneous nephrolithotomy
215139875|NCT03819439|OTHER|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
214453698|NCT06426576|OTHER|Standard one-off instruction using a scale|"The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback."
214453699|NCT06426576|DEVICE|Plantar pressure insoles|The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
214453700|NCT05290974|OTHER|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
214453701|NCT05290974|OTHER|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
214453702|NCT04969419|OTHER|Exposure of skin cancer of interest|Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.
215139876|NCT01798043|OTHER|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
215139877|NCT01798043|OTHER|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
215139878|NCT01678235|DRUG|Insulin glulisine|
215139879|NCT01678235|DRUG|Insulin aspart|
215139880|NCT04273737|DRUG|Amantadine Hydrochloride|6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
215139881|NCT00335777|DRUG|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
215139882|NCT00335777|DRUG|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
215139883|NCT00045760|DRUG|Drotrecogin alfa (activated)|
215139884|NCT00967746|DRUG|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
215139885|NCT00967746|DRUG|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
215139886|NCT00967746|DRUG|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
215139887|NCT00967746|DEVICE|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
214453703|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
214453704|NCT03270111|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
214453705|NCT03270111|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
214453706|NCT03270111|BEHAVIORAL|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
214453707|NCT03270111|BEHAVIORAL|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
214453708|NCT05547984|DEVICE|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
214527057|NCT06059963|DEVICE|Signal-C™|Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
214527058|NCT02214017|DEVICE|A videotelephone, TandBerg E20,|
214527059|NCT02214017|BEHAVIORAL|Behavioral motivation|Optimization of medical care in diabetes
214527060|NCT00296309|DRUG|Tacrolimus|Immunosuppression
214453709|NCT05547984|DEVICE|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
214527061|NCT06385288|OTHER|Blood and tissue collection for immunological studies, advanced imaging.|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
214527062|NCT06385288|OTHER|neoadjuvant Therapy|neoadjuvant Therapy
215139888|NCT00562224|DRUG|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
215139889|NCT01029275|DRUG|Pre-treatment with octreotide|Pre-treatment with octreotide
215139890|NCT03682419|PROCEDURE|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
215139891|NCT03682419|PROCEDURE|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
215139892|NCT02798627|DRUG|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
215139893|NCT02798627|DRUG|placebo|Placebo pills identical in appearance to the NS2359 will be provided
215139894|NCT00385359|PROCEDURE|aerosol drug deposition strategies|
215139895|NCT00385359|DRUG|Albuterol|
215139896|NCT05036863|BEHAVIORAL|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
214453710|NCT05247489|DRUG|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
214453711|NCT05247489|DEVICE|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
214527063|NCT00257556|DRUG|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
214527064|NCT00257556|DRUG|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
214527065|NCT05351697|DRUG|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
214527066|NCT06026462|DIAGNOSTIC_TEST|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
214527067|NCT03760809|DRUG|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
214527068|NCT03760809|DRUG|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
215139897|NCT05336162|OTHER|Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)|A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
215139898|NCT04395976|OTHER|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
215139899|NCT00992108|DRUG|lidocaine|1cc 1%
215139900|NCT00992108|DRUG|chemodenervation|botulinum toxin
215139901|NCT03821402|BIOLOGICAL|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
215139902|NCT03821402|BIOLOGICAL|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
215139903|NCT03821402|BIOLOGICAL|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
215139904|NCT03821402|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
215139905|NCT04448535|DIETARY_SUPPLEMENT|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
215139906|NCT00533208|DRUG|MK0524|
215139907|NCT00390143|BIOLOGICAL|Meningococcal vaccine 134612|One intramuscular dose during the primary study
215139908|NCT00390143|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose during the primary study
215139909|NCT00535639|DRUG|Betula Verrucosa allergen extract|
214453712|NCT03771898|DRUG|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
214453713|NCT03467360|DRUG|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
214453714|NCT03467360|DRUG|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
214527069|NCT05324748|DRUG|Methylprednisolone|Injection with prednisolon
214527070|NCT05324748|DRUG|Saline solution|0,9%
215139910|NCT03755258|DRUG|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
215139911|NCT03755258|DRUG|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
215139912|NCT03755258|DRUG|GCK 300 mg|GCK 300 mg, oral, 12 weeks
214453715|NCT05515367|DRUG|Desidustat|Oral tablet
214453716|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
215139913|NCT03755258|DRUG|Placebo 300mg|Placebo 300mg, oral, 12 weeks
215139914|NCT02271204|DRUG|Ibandronic acid|As prescribed by physician
215139915|NCT02083900|DEVICE|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
215139916|NCT02083900|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
215139917|NCT04639245|DRUG|Atezolizumab|Given IV
215139918|NCT04639245|DRUG|Cyclophosphamide|Given IV
215139919|NCT04639245|DRUG|Fludarabine|Given IV
215139920|NCT04639245|BIOLOGICAL|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
215139921|NCT04639245|BIOLOGICAL|PD1 Inhibitor|Given IV
215139922|NCT04985279|DEVICE|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
215139923|NCT04985279|DEVICE|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
215139924|NCT01702311|DRUG|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
215139925|NCT00690508|PROCEDURE|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
215139926|NCT01167075|DIETARY_SUPPLEMENT|Fresubin Original|
215139927|NCT01167075|DIETARY_SUPPLEMENT|Intestamin plus Fresubin Original|
215139928|NCT03271658|BEHAVIORAL|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
215139929|NCT03271658|BEHAVIORAL|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
215139930|NCT05133388|GENETIC|ARMS PCR|ARMS PCR using primer pairs that only amplify individual alleles
215139931|NCT06210568|OTHER|no intervention|no intervention
215139932|NCT03079622|PROCEDURE|Electric Vacuum Aspiration|
214453717|NCT06015945|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study."
214453718|NCT05257135|BIOLOGICAL|Biological collection|\- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
214453719|NCT05708833|DEVICE|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
214527071|NCT00383994|DRUG|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
214527072|NCT00383994|DRUG|Rituximab|375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
214527073|NCT00383994|BIOLOGICAL|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
214527074|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
215139933|NCT03079622|PROCEDURE|Manual Vacuum Aspiration|
215139934|NCT02404935|DRUG|Cetuximab|
215139935|NCT02404935|DRUG|FOLFIRI and cetuximab|
215139936|NCT03527459|BEHAVIORAL|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
215139937|NCT03527459|BEHAVIORAL|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
215139938|NCT04642027|RADIATION|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
214453720|NCT05708833|DEVICE|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
214453721|NCT05026541|BEHAVIORAL|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
214453722|NCT05026541|BEHAVIORAL|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
214453723|NCT04541706|DRUG|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
214453724|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
214453725|NCT05704621|DRUG|chemotherapy|six cycles of platinum-based chemotherapy +/- bevacizumab
214453726|NCT03364530|DRUG|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
214694953|NCT06419868|BEHAVIORAL|"Universal preventive intervention for depression and anxiety for university students"|"This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning."
215139939|NCT04642027|RADIATION|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
215139940|NCT01314313|DEVICE|TAVR Implantation with SAPIEN XT|Operable Group with SAPIEN XT
215139941|NCT01314313|DEVICE|SAVR Implantation|Control Group
215139942|NCT03902431|BEHAVIORAL|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
215139943|NCT00495313|DRUG|doxycycline|COL-101, QD plus metronidazole
215139944|NCT00495313|DRUG|doxycycline|40 mg with metronidazole QD
215139945|NCT05371626|PROCEDURE|Suture-less surgical procedure|Suture-less technique will be used in treatment for cicatricial upper eyelid entropion
215139946|NCT01178047|DRUG|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
215139947|NCT02723708|OTHER|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
215139948|NCT03916770|DEVICE|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
215139949|NCT03916770|DEVICE|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
215139950|NCT04035460|DEVICE|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
215139951|NCT04035460|DEVICE|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
215139952|NCT06185816|DEVICE|Active Treatment|The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
215139953|NCT06185816|DEVICE|Non-active Treatment|The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
215139954|NCT06314802|OTHER|no intervention|No intervention
214527075|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
215139955|NCT04665167|BEHAVIORAL|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
215139956|NCT04665167|BEHAVIORAL|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
215139957|NCT01209689|DRUG|Tocilizumab|
215139958|NCT01209689|DRUG|Placebo|
215139959|NCT04812392|DEVICE|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
215139960|NCT01411046|DIAGNOSTIC_TEST|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
214527076|NCT02716272|DRUG|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
214527077|NCT02716272|DRUG|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
215139961|NCT05642364|BEHAVIORAL|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
214527078|NCT03826056|BEHAVIORAL|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
215139962|NCT05642364|OTHER|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
215139963|NCT02668562|PROCEDURE|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
215139964|NCT02668562|PROCEDURE|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
215139965|NCT02271269|BEHAVIORAL|Value Pricing Subsidies|"* Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
215139966|NCT03337477|DRUG|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
215139967|NCT03337477|DRUG|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
215139968|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
215139969|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
214453727|NCT03364530|PROCEDURE|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
215139970|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
215139971|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
215139972|NCT06262815|PROCEDURE|Nasogastric tube placement|Conventional nasogastric tube placement done for decompression of small bowel obstruction
215139973|NCT06262815|DIAGNOSTIC_TEST|Clinical Frailty Scale|The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.
215139974|NCT00767988|DIETARY_SUPPLEMENT|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
215139975|NCT00767988|OTHER|Placebo|Capsule once daily at approximately the same time each day for 6 months.
214453728|NCT06796439|OTHER|Static stretching|"Participants will be divided into two groups with sample size of 52 participants in each group.~Group 1: Participants will perform static Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of static stretching exercises. After the general warm-up, participants would engage in a sequence of randomized static stretches including Lower back stretch, Quads stretch, Hams Stretch, Calf Stretch and Upper limb Stretches (biceps, Triceps, Arm across chest, Arm pull and head tilt, Side stretch, backward arm stretch, Pect. stretch and Towel Stretch). All stretches were done as 3 sets of 30 seconds for 20 minutes for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.~Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants wou"
214453729|NCT06796439|OTHER|Dynamic Stretching|Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants would engage in a sequence of randomized static stretches including Jumping Jacks, Lunges, Trunk Circles, arm swings and butt Kicks. All stretches were done as 3 sets of 30 seconds for 20mins for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.
214453730|NCT06476002|OTHER|Questionnaire|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
214453731|NCT06495008|OTHER|no intervention, only questionnaires, saliva collection and taste/smell tests|no intervention, only questionnaires, saliva collection and taste/smell tests
214453732|NCT05534620|DRUG|Treosulfan|IV infusion
214453733|NCT05534620|DRUG|Fludarabine|IV infusion
215139976|NCT03181932|DRUG|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
215139977|NCT03181932|DRUG|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
214453734|NCT02987530|DRUG|Dolutegravir|Oral use, 50mg/day
214453735|NCT02987530|DRUG|Darunavir-cobicistat|Oral use, 800-150mg/day
214453736|NCT02987530|DRUG|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
214453737|NCT06564701|DEVICE|Phonak Roger TouchScreen Microphone|Transmitter microphone system operating on the 2.4 GHz band, which allows for low-delay and reliable long-range broadcast to a compatible Roger receiver, designed to be used in educational settings. It features six microphones and adaptive technology in which speech signals are increased when background noise increases to ensure that the speech signal is always above the noise level.
214453738|NCT06564701|DEVICE|Phonak Partner Mic|Wireless microphone that uses Phonak proprietary AirStream technology to connect to Phonak hearing aids. It uses a fixed directional microphone, and is paired to the hearing aids such that the hearing aid microphones are attenuated at a fixed level when the microphone is in use.
215139978|NCT03181932|DRUG|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
215139979|NCT02576483|BEHAVIORAL|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
214453739|NCT04726501|OTHER|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
214453740|NCT00781690|DEVICE|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
214453741|NCT06317220|BIOLOGICAL|Vedolizumab|Administered over 30 minute infusion at MGH main campus
214453742|NCT05152927|DEVICE|Parathyroid Eye (PTeye)|Intraoperative Tool
214453743|NCT04712851|BIOLOGICAL|Pembrolizumab|Given IV
214453744|NCT05664841|BEHAVIORAL|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
214453745|NCT06637891|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
214453746|NCT05563246|DRUG|LY3473329|Administered orally
214453747|NCT05563246|DRUG|Placebo|Administered orally
214453748|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
214453749|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
214453750|NCT05471414|BEHAVIORAL|Whole-food, Plant-Based Diet|Pre-packaged, freshly made plant-based meals (provided by either Plantable or CookUnity) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals with staff assistance available.
214453751|NCT05471414|BEHAVIORAL|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
214453752|NCT05651399|DRUG|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
214453753|NCT05651399|DRUG|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
214527079|NCT03826056|BEHAVIORAL|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
214453754|NCT02167867|DEVICE|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
214453755|NCT02167867|DEVICE|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
214453756|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
214453757|NCT05537727|DEVICE|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
214527080|NCT05274490|PROCEDURE|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
214527081|NCT01681394|DIETARY_SUPPLEMENT|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
214527082|NCT01681394|DIETARY_SUPPLEMENT|Chocolate cream|
214527083|NCT03031353|DRUG|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
215139980|NCT04698863|DEVICE|Oxygen reserve index|eveluating oxygen reserve in blood
214527084|NCT03031353|DRUG|Placebos|placebos tablet will be given before elective Cesarean sections
214527085|NCT04974021|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
214527086|NCT05698888|DRUG|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
215139981|NCT01590719|DRUG|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
215139982|NCT01590719|DRUG|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
215139983|NCT01590719|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
214453758|NCT05537727|DEVICE|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
214453759|NCT05537727|DEVICE|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
214453760|NCT06639256|DRUG|Test Product HY07121|HY07121 should be administered intravenously at recommended dose.
214527087|NCT00386802|DRUG|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
215139984|NCT01590719|DRUG|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
215139985|NCT01590719|DRUG|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
215139986|NCT01590719|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
215139987|NCT04631419|OTHER|Flapless laser corticotomy|The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
215139988|NCT04631419|OTHER|Canine retraction|canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
215139989|NCT00237302|DRUG|topiramate|
215139990|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.
215139991|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
215139992|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
215139993|NCT00941213|DEVICE|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
215139994|NCT00941213|DEVICE|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
215139995|NCT00707889|DRUG|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
215139996|NCT00707889|DRUG|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
215139997|NCT00707889|DRUG|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
215139998|NCT00707889|DRUG|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
215139999|NCT00707889|DRUG|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
215140000|NCT00707889|DRUG|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
214453761|NCT01416831|OTHER|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
214527088|NCT02418819|DRUG|PF-06412562 3mg BID|PF-06412562
214527089|NCT02418819|DRUG|PF-06412562 9mg BID|PF-06412562
214527090|NCT02418819|DRUG|PF-06412562 45mg BID|PF-06412562
214527091|NCT02418819|OTHER|Placebo|Placebo
214527092|NCT05776745|BEHAVIORAL|Speech|Patients read specific words and sentences
214527093|NCT05776745|DEVICE|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
214527094|NCT01299324|DEVICE|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
214527095|NCT04743999|OTHER|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
214527096|NCT03191526|DRUG|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
214527097|NCT03191526|DRUG|Placebo (saline)|Intravenous injection every 12 weeks.
214527098|NCT02523417|PROCEDURE|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
214527099|NCT01597999|RADIATION|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
214527100|NCT01400945|DRUG|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
214527101|NCT01721759|DRUG|Nivolumab|
214527102|NCT00003731|DRUG|temozolomide|
215140001|NCT06175806|DRUG|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
215140002|NCT06175806|DRUG|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
215140003|NCT03011918|OTHER|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
215140004|NCT03011918|OTHER|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
215140005|NCT03011918|OTHER|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
215140006|NCT03011918|OTHER|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
215140007|NCT02220920|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
215140008|NCT02220920|DRUG|Placebo|The patients will receive Placebo orally for 16 weeks
215140009|NCT02220920|DRUG|Insulin|
215140010|NCT01703143|PROCEDURE|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
215140011|NCT03410277|OTHER|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
215140012|NCT00853307|DRUG|Alisertib|Alisertib capsules
215140013|NCT04894266|DRUG|Apabetalone|Apabetalone 100mg BID
215140014|NCT04894266|OTHER|Standard of care|Standard of Care
214694954|NCT03695991|PROCEDURE|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
214694955|NCT02081339|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|
214694956|NCT02072317|DRUG|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
214694957|NCT02072317|DRUG|taxol|taxol 135 mg/m2, every three weeks for a cycle
214694958|NCT04301882|DRUG|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
215140015|NCT01939613|DRUG|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
215140016|NCT00896077|DRUG|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
215140017|NCT01080079|DRUG|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
215140018|NCT01080079|OTHER|Purified Water|Purified Water
215140019|NCT00473564|PROCEDURE|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
215140020|NCT00959855|OTHER|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
215140021|NCT00733018|BEHAVIORAL|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
215140022|NCT04046913|BEHAVIORAL|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
215140023|NCT04490070|BEHAVIORAL|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
215140024|NCT04169217|BEHAVIORAL|Prehabilitation|"A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform."
215140025|NCT03040544|PROCEDURE|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
215140026|NCT03040544|PROCEDURE|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
215140027|NCT05681182|COMBINATION_PRODUCT|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
215140028|NCT01112917|DEVICE|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
215140029|NCT01112917|PROCEDURE|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
215140030|NCT04681443|DRUG|Crystallized phenol application|Crystallized phenol application into the sinus tract
215140031|NCT00667199|DRUG|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
215140032|NCT00003449|DRUG|dexamethasone|
215140033|NCT00003449|DRUG|gemcitabine hydrochloride|
215140034|NCT00003449|DRUG|paclitaxel|
215140035|NCT03264677|COMBINATION_PRODUCT|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
215140036|NCT03264677|COMBINATION_PRODUCT|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
215140037|NCT03264677|COMBINATION_PRODUCT|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
215140038|NCT00643747|BIOLOGICAL|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
215140039|NCT00898417|BIOLOGICAL|bevacizumab|
215140040|NCT00898417|DRUG|carboplatin|
215140041|NCT00898417|DRUG|paclitaxel|
215140042|NCT00898417|GENETIC|proteomic profiling|
215140043|NCT00898417|OTHER|laboratory biomarker analysis|
215140044|NCT00898417|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
215140045|NCT06322628|DRUG|VSA006|every 12 weeks, subcutaneous injections
215140046|NCT06322628|DRUG|Placebo|every 12 weeks, subcutaneous injections
215140047|NCT04754048|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
215140048|NCT02433418|PROCEDURE|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
215140049|NCT02433418|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
215140050|NCT05630924|OTHER|SI! Program-NYC|SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
215140051|NCT02177123|DEVICE|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
215140052|NCT01112826|DRUG|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
215140053|NCT05753943|DRUG|QUALI|Medication 1 pill at night
215140054|NCT05686902|OTHER|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
215140055|NCT05690308|OTHER|Visual perturbation treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.
215140056|NCT05690308|OTHER|Regular treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill
214694959|NCT04301882|DRUG|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
215140057|NCT04723056|DEVICE|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
215140058|NCT04441138|DRUG|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
215140059|NCT05561920|DEVICE|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
215140060|NCT05561920|DEVICE|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
215140061|NCT05561920|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires
215140062|NCT02118584|DRUG|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
215140063|NCT03727217|DIAGNOSTIC_TEST|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
214694960|NCT03169010|OTHER|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
214694961|NCT03169010|GENETIC|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
215140064|NCT03956849|OTHER|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
215140065|NCT01076478|DRUG|Cilostazol|100 mg, 200mg tablet Cilostazol
215140066|NCT02559453|PROCEDURE|Debridement|Removing dead tissue from infected wounds.
215140067|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
215140068|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
215140069|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
215140070|NCT05040464|DRUG|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
215140071|NCT05040464|DRUG|MTX|MTX 25 mg SC once a week
215140072|NCT05040464|BIOLOGICAL|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
215140073|NCT02614300|OTHER|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
215140074|NCT02614300|OTHER|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
215140075|NCT02614300|OTHER|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
215140076|NCT02748083|DEVICE|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
215140077|NCT02748083|DEVICE|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
215140078|NCT03103542|BIOLOGICAL|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
215140079|NCT01719016|PROCEDURE|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min"
215140080|NCT06242652|DRUG|608 Dose A|608 subcutaneous (SC) injection.
215140081|NCT06242652|DRUG|608 Dose B|608 subcutaneous (SC) injection.
215140082|NCT06242652|DRUG|608 Dose C|608 subcutaneous (SC) injection.
215140083|NCT06242652|DRUG|Adalimumab|Adalimumab subcutaneous (SC) injection.
215140084|NCT06242652|DRUG|Placebo|Placebo subcutaneous (SC) injection.
215140085|NCT04721860|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
215140086|NCT04721860|BEHAVIORAL|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
215140087|NCT06471244|OTHER|Finger tapping|The volunteer is tapping with his/her right hand index finger.
215140088|NCT06471244|OTHER|Median nerve stimulation|Electrical pulses are applied at the wrist to the median nerve.
215140089|NCT06471244|OTHER|Speech processing|German sentences are played to the volunteers and the volunteers have to fulfill a semantic task.
215140090|NCT06175767|DRUG|MT101-5|Tablet
215140091|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.
215140092|NCT03406780|DRUG|Placebo|Placebo
215140093|NCT03884829|DRUG|CYC140|CYC140 single agent
215140094|NCT00837434|DRUG|Etanercept|50 mg dose of etanercept by subcutaneous injection
215140095|NCT00837434|DRUG|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
215140096|NCT01122238|DRUG|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
215140097|NCT01122238|DRUG|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
215140098|NCT01122238|BEHAVIORAL|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
215140099|NCT01122238|BEHAVIORAL|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
215140100|NCT01122238|OTHER|No Intervention|No Intervention
215140101|NCT01122238|DRUG|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
215140102|NCT02163239|DEVICE|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
215140103|NCT03041038|DRUG|Secukinumab|Anti IL-17A antibody
215140104|NCT03041038|DRUG|Placebo|
215140105|NCT02574624|PROCEDURE|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
215140106|NCT05908916|DRUG|AtezoBev with combined radiotherapy|Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.
215140107|NCT03350997|BEHAVIORAL|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
215140108|NCT03350997|BEHAVIORAL|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
215140109|NCT04420234|DRUG|narfurine hydrochloride orally disintegrating tablets|Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
215140110|NCT03732417|OTHER|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
215140111|NCT00360230|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
215140112|NCT00360230|BIOLOGICAL|Rabipur|3-dose intramuscular injection.
215140113|NCT01954498|DIETARY_SUPPLEMENT|Walnuts|
215140114|NCT01954498|DIETARY_SUPPLEMENT|OTC multivitamin|
215140115|NCT04734028|DRUG|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
215140116|NCT01825460|OTHER|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
215140117|NCT01825460|OTHER|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
215140118|NCT02675465|DRUG|ATB200|
215140119|NCT02675465|DRUG|AT2221|
215140120|NCT00581308|DEVICE|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
215140121|NCT02042417|DEVICE|INRatio2 and CoaguChek|
215140122|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk without vitamin D|710ml per day for 49 days
215140123|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
215140124|NCT00886379|DIETARY_SUPPLEMENT|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
215140125|NCT00886379|DIETARY_SUPPLEMENT|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
215140126|NCT00886379|DIETARY_SUPPLEMENT|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
215140127|NCT00886379|DIETARY_SUPPLEMENT|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
215140128|NCT05889104|OTHER|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
215140129|NCT05889104|OTHER|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
215140130|NCT00006396|DRUG|Nevirapine|
215140131|NCT00006396|DRUG|Zidovudine|
215140132|NCT05068297|OTHER|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
215140133|NCT05068297|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
215140134|NCT04558125|DRUG|TNKase|Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
215140135|NCT04558125|DRUG|Placebo|Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
215140136|NCT04558125|DRUG|Enoxaparin|All participants must also receive standard of care anticoagulation therapy.
215140137|NCT05311709|DRUG|sotorasib|single group, all patients receive sotorasib
215140138|NCT04815941|OTHER|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
215140139|NCT05074992|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
215140140|NCT03537989|DRUG|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
215140141|NCT02286349|DEVICE|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
215140142|NCT02286349|DEVICE|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
215140143|NCT03922386|DEVICE|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
215140144|NCT03401346|COMBINATION_PRODUCT|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
215140145|NCT03401346|DRUG|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
215140146|NCT03401346|COMBINATION_PRODUCT|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
215140147|NCT03730753|DEVICE|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
215140148|NCT03730753|DEVICE|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
215140149|NCT01722617|OTHER|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
215140150|NCT01614886|DRUG|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
214527103|NCT04733989|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
214527104|NCT01399905|DRUG|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
214527105|NCT00243568|DRUG|Vicriviroc|
214527106|NCT05512988|BIOLOGICAL|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person."
214527107|NCT05512988|BIOLOGICAL|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
214527108|NCT00703365|DRUG|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
215140151|NCT01614886|DRUG|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
215140152|NCT01750151|DIETARY_SUPPLEMENT|Glucose Beverage|
215140153|NCT01750151|BEHAVIORAL|Video Game Playing|
215140154|NCT01750151|DIETARY_SUPPLEMENT|Control Beverage|
215140155|NCT03848325|BEHAVIORAL|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
215140156|NCT00761995|DRUG|Azopt|topical eye drop dosed 1 drop 3 times daily
215140157|NCT00761995|DRUG|Cosopt|topical eye drop dosed 1 drop 2 times daily
215140158|NCT01207414|DRUG|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
215140159|NCT00842114|BIOLOGICAL|R+CVP+IFN|Immunochemotherapy
215140160|NCT01527370|BIOLOGICAL|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
215140161|NCT02191111|BEHAVIORAL|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
215140162|NCT01748292|DRUG|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
214527109|NCT05530434|OTHER|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
214527110|NCT05530434|OTHER|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
214527111|NCT03063983|DRUG|Cyclophosphamide|Continuous oral cyclophosphamide
214527112|NCT03063983|DRUG|Methotrexate|Continuous oral methotrexate
214527113|NCT01668992|BEHAVIORAL|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
214527114|NCT05588661|OTHER|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
214527115|NCT05588661|OTHER|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
214527116|NCT03074968|DRUG|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
214527117|NCT03074968|DRUG|Normal saline|normal saline application
214527118|NCT02074865|BIOLOGICAL|biological samples|
215140163|NCT05163080|BIOLOGICAL|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
215140164|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
215140165|NCT01503203|OTHER|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
215140166|NCT01503203|OTHER|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
214453762|NCT01416831|DRUG|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
214453763|NCT06507956|OTHER|Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis|Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive and/or hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
214453764|NCT06107582|OTHER|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
214453765|NCT04179500|DRUG|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
214453766|NCT04179500|DRUG|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
214453767|NCT04179500|DRUG|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
214453768|NCT04179500|DRUG|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
214527119|NCT04091945|DRUG|LT3001 Drug Product|Active comparator
215140167|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
215140168|NCT01503203|OTHER|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
215140169|NCT01654354|DRUG|NEOVIST 370 INJ.(Iopromide 768.86mg)|
215140170|NCT01654354|DRUG|Ultravist 370 INJ.(Iopromide 768.86mg)|
215140171|NCT04959994|DEVICE|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
215140172|NCT03177317|DRUG|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
215140173|NCT03959514|BIOLOGICAL|NovoRapid|Rapid acting prandial insulin aspart
215140174|NCT03959514|BIOLOGICAL|Fiasp|Fast acting prandial insulin aspart
215140175|NCT03959514|BIOLOGICAL|AT247|Ultra rapid acting prandial insulin aspart
215140176|NCT03324269|DEVICE|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase."
215140177|NCT03924050|DRUG|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
215140178|NCT02891499|PROCEDURE|Low-level laser therapy|"1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
215140179|NCT02891499|PROCEDURE|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
215140180|NCT03530215|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
215140181|NCT02928042|OTHER|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
215140182|NCT03159429|BEHAVIORAL|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
214527120|NCT04091945|DRUG|Placebo|Placebo comparator
214527121|NCT04640376|DRUG|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
215140183|NCT03159429|BEHAVIORAL|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
214527122|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
215140184|NCT00192985|DEVICE|Nitrofuranzone coated bladder catheter|
215140185|NCT02224560|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
215140186|NCT02224560|DRUG|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
215140187|NCT03774732|RADIATION|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
215140188|NCT03774732|DRUG|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
215140189|NCT03774732|DRUG|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
215140190|NCT00200369|DEVICE|MEMS cap|
215140191|NCT04467684|DRUG|CB-0406 100 mg|Single oral dose
215140192|NCT04467684|DRUG|CB-0406 200 mg|Single oral dose
215140193|NCT04467684|DRUG|CB-0406 400 mg|Single oral dose
215140194|NCT04467684|DRUG|CB-0406 800 mg|Single oral dose
215140195|NCT04467684|DRUG|CB-0406 1,000 mg|Single oral dose
215140196|NCT04467684|DRUG|Matched placebo|Color and size matched placebo
214453769|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
214453770|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
214453771|NCT06258005|DIAGNOSTIC_TEST|PocDoc|PocDoc is a digital rapid 5-marker lipid test
214453772|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
214453773|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
214453774|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
214527123|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
214527124|NCT04640376|DRUG|Placebo|Dummy treatment
215140197|NCT04128852|DEVICE|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
215140198|NCT04690660|OTHER|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
215140199|NCT04690660|OTHER|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
215140200|NCT04690660|OTHER|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
215140201|NCT04690660|OTHER|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
214527125|NCT01549171|DRUG|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
214527126|NCT01549171|OTHER|normal saline|Supplement with vehicle only no Iloprost.
214527127|NCT00513292|DRUG|Cyclophosphamide|Given IV
214527128|NCT00513292|DRUG|Epirubicin Hydrochloride|Given IV
214527129|NCT00513292|OTHER|Laboratory Biomarker Analysis|Correlative studies
214527130|NCT00513292|DRUG|Paclitaxel|Given IV
214527131|NCT00513292|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215140202|NCT04690660|OTHER|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
215140203|NCT06553703|OTHER|Acceptance and commitment therapy based group psychoeducation|Acceptance and commitment therapy-based group psychoeducation aimed at increasing nursing students' psychological flexibility and reducing their somatic symptoms.
215140204|NCT02250846|DRUG|EGFR-TKI|egfr-TKI treatment
215140205|NCT03955198|COMBINATION_PRODUCT|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
215140206|NCT01941810|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|Given PO
215140207|NCT01941810|OTHER|questionnaire administration|Ancillary studies
215140208|NCT01941810|PROCEDURE|quality-of-life assessment|Ancillary studies
215140209|NCT01941810|OTHER|laboratory biomarker analysis|Correlative studies
215140210|NCT04138940|BEHAVIORAL|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
215140211|NCT03165617|BIOLOGICAL|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
215140212|NCT03165617|BIOLOGICAL|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
215140213|NCT03255122|BEHAVIORAL|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
215140214|NCT03255122|BEHAVIORAL|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
215140215|NCT05920590|OTHER|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~* Application of the hold - relax technique to increase the range of motion of knee flexion.~* Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~* Application of stabilizing reversals from a sitting and standing position.~* Application of dynamic reversals from a standing position.~* Rhythmic stabilization.~* Combination of isotonics.~* Gait retraining."
214453775|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
214453776|NCT02565069|DEVICE|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
214453777|NCT06822478|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30.
214453778|NCT06822478|DRUG|Meglumine antimoniate.|"Monotherapy with intralesional pentavalent antimonials is one of the treatments of care used for LC in Colombia and will be used as a comparator for safety evaluation.~Pentavalent antimonials: administered intralesionally. At a dose of 0.008 ml X mm of area of each lesion, maximum 15 ml in total, once a week for 5 weeks."
214453779|NCT05515198|OTHER|Patient Education|Patients will be provided educational opportunities.
214453780|NCT05515198|OTHER|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
215140216|NCT05920590|OTHER|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
215140217|NCT05920590|OTHER|Control|Participants in this group will be given an exercise leaflet for home-based exercises and will be instructed to perform these exercises three times a week for the same period as the other two groups (6 weeks). They will also be given recommendations to maintain and increase their physical activity.
215140218|NCT06208124|DRUG|IMM-6-415|Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.
215140219|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
215140220|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
215140221|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
215140222|NCT03435250|DRUG|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
215140223|NCT03435250|DRUG|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
214453781|NCT05515198|OTHER|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
214453782|NCT03420833|DEVICE|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
214453783|NCT05389436|PROCEDURE|Ambulatory care|The surgery is performed in ambulatory setting
214453784|NCT05389436|PROCEDURE|Inpatient care|The surgery is performed during inpatient care
214453785|NCT03659760|OTHER|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
214453786|NCT05376813|PROCEDURE|CT-Scan and MRI|CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
214527132|NCT00513292|BIOLOGICAL|Trastuzumab|Given IV
215140224|NCT03435250|DRUG|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
215140225|NCT06346717|BEHAVIORAL|"Knee Prosthesis-M mobile application service"|"In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks."
215140226|NCT03260946|OTHER|Complementary medicine use|The prevalence of complementary medicine use
215140227|NCT00460161|PROCEDURE|acupuncture|2 treatments/week for 4 weeks
215140228|NCT00460161|OTHER|placebo/sham acupuncture|2 treatments/week for 4 weeks
215140229|NCT00159393|OTHER|registry and database|data collection
215140230|NCT05310240|PROCEDURE|Hip arthroscopy|Arthroscopic surgery of the hip
215140231|NCT02585856|DEVICE|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
215140232|NCT02585856|DEVICE|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
215140233|NCT03635281|PROCEDURE|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
215140234|NCT03635281|PROCEDURE|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
215140235|NCT04730453|PROCEDURE|ENB-guided ablation therapy combined with VATS|After receiving multidisciplinary assessments, Lesion A will receive ENB-guided ablation therapy and Lesion B will receive VATS at the same time.
215140236|NCT01876836|DEVICE|i-gel|i-gel placed after induction
215140237|NCT01876836|DEVICE|C-LMA|placed after induction
214453787|NCT03662607|BEHAVIORAL|Virtual reality experience|"* Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again."
214453788|NCT05318066|DRUG|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
215140238|NCT02940795|OTHER|Coke|Patients were given a 20 ounce bottle of Coke Cola.
214453789|NCT06345170|OTHER|The DIR/Floortime™ Therapy Program|The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
214527133|NCT02278822|OTHER|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
214527134|NCT02278822|OTHER|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
214527135|NCT05406206|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
214527136|NCT05406206|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
214527137|NCT03734172|DIAGNOSTIC_TEST|Sample collection|Specimen collection
214527138|NCT03038152|PROCEDURE|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
214527139|NCT03038152|PROCEDURE|Localization|Undergo axillary lymph node localization
214527140|NCT03038152|DEVICE|Medical Device|Receive Magseed via ultrasound guided injection
214527141|NCT05513222|PROCEDURE|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
214527142|NCT05534451|BEHAVIORAL|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
214527143|NCT05534451|BEHAVIORAL|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
214527144|NCT05534451|BEHAVIORAL|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
215140239|NCT02940795|OTHER|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
215140240|NCT05829694|OTHER|Parental Status|The aim of the study is to assess the impact parenthood has on health outcomes.
215140241|NCT03373123|PROCEDURE|Endoscopy|Endoscopy
215140242|NCT03373123|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
215140243|NCT06413992|DRUG|Fluzoparib|During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
214453790|NCT06345170|OTHER|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
214453791|NCT04371913|RADIATION|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
214453792|NCT05618002|DRUG|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
214453793|NCT04812535|DRUG|Vilobelimab|Vilobelimab Monotherapy
214453794|NCT04812535|DRUG|Vilobelimab + pembrolizumab combination therapy|Vilobelimab + pembrolizumab combination therapy
214453795|NCT04886531|DRUG|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.
214453796|NCT04886531|DRUG|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*
214453797|NCT04886531|DRUG|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
214453798|NCT03336333|DRUG|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
214453799|NCT03336333|DRUG|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
214453800|NCT03336333|DRUG|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
214453801|NCT03336333|DRUG|Venetoclax|400 mg tablets administered orally once daily.
214453802|NCT05754333|DRUG|pudexacianinium chloride|Intravenous
214453803|NCT04863430|DRUG|Apatinib|500mg oral qd
214453804|NCT04863430|DRUG|Oxaliplatin|130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
214453805|NCT04863430|DRUG|S1|According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
214453806|NCT02664870|PROCEDURE|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
214453807|NCT02664870|PROCEDURE|Arthroplasty|Total hip, shoulder, or knee arthroplasty
215140244|NCT06413992|DRUG|Camrelizumab|During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
215140245|NCT06413992|DRUG|paclitaxel (albumin bound)|Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
214527145|NCT05611476|BEHAVIORAL|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
214527146|NCT00401791|BEHAVIORAL|Exercise|"* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
214527147|NCT01630161|BEHAVIORAL|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
214527148|NCT01630161|BEHAVIORAL|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
214527149|NCT06045364|DRUG|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
214527150|NCT06045364|DRUG|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
214527151|NCT00124644|DRUG|cytarabine|
214453808|NCT03940911|OTHER|Measurement of aerobic exercise on cycloergometer|"The incremental effects tests will be performed in a service specialized in the exploration of the exercise (physiology or cardiology according to the centers) in a spacious and air-conditioned room, in the presence of a medical specialist. exercise and close to the resuscitation equipment.~Before the test, weight and height will be collected. Information on the conduct of the test will be given to the patient. A multi-derivation ECG recording will be detected throughout the duration of the test and followed by a physician experienced in the ECG effort.~O2 saturation by oximetry of hens will be recorded continuously. Blood pressure will be recorded at each level. The collection of expired gases in the face mask whose tightness will be verified to measure the fractions inspired and expired in O2 and CO2 (Sensor Medics Vmax229, Yorba Linda, CA, USA) and calculations VO2 max and VCO2.~Maximal power (W max) will be recorded. Patients will be encouraged during the test."
214453809|NCT05078086|OTHER|No intervention|No intervention
214453810|NCT05147519|BEHAVIORAL|Novel interventions to achieve HIV remission|To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
214453811|NCT06430021|BIOLOGICAL|blood sample|8 mL blood sample in EDTA tube
214453812|NCT06424483|BEHAVIORAL|Awareness, Courage, and Love Group Psychotherapy|Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
214453813|NCT02665507|DEVICE|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
214453814|NCT02665507|DEVICE|Sham|Hand held laser that emits no LLLI
214453815|NCT04977310|DEVICE|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
214453816|NCT05318001|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
214453817|NCT05318001|OTHER|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
214527152|NCT00124644|DRUG|daunorubicin hydrochloride|
214527153|NCT00124644|DRUG|etoposide|
214527154|NCT00124644|DRUG|tipifarnib|
214527155|NCT00124644|PROCEDURE|chemotherapy|
214527156|NCT00124644|PROCEDURE|enzyme inhibitor therapy|
215140246|NCT06413992|DRUG|Carboplatin injection|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
215140247|NCT06413992|DRUG|Carboplatin|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
215140248|NCT06413992|RADIATION|External irradiation|Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
215140249|NCT04963010|DIAGNOSTIC_TEST|second forward view|second forward view examination of the proximal colon
215140250|NCT03536208|DRUG|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
215140251|NCT03743168|OTHER|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
215140252|NCT03743168|OTHER|Continuous stretch|2 minutes continuous stretch
214694962|NCT04042610|BEHAVIORAL|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
215140253|NCT05426499|DRUG|Patients requiring cefotaxime treatment|Dosage according to SmPC
215140254|NCT05426499|DRUG|Patients requiring meropenem treatment|Dosage according to SmPC
215140255|NCT05426499|DRUG|Patients requiring fluconazole treatment|Dosage according to SmPC
215140256|NCT05426499|DRUG|Patients requiring isavuconazole treatment|Dosage according to SmPC
215140257|NCT05426499|DRUG|Patients requiring anidulafungin treatment|Dosage according to SmPC
215140258|NCT01062958|OTHER|Neevo® (a medical food)|
215140259|NCT01062958|OTHER|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
215140260|NCT06329830|DRUG|177Lu-PSMA-617|7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
215140261|NCT06329830|DRUG|Niraparib abiraterone acetate|Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
215140262|NCT06329830|DRUG|Prednisone|5 mg orally twice per day
215140263|NCT06253442|PROCEDURE|Patients will receive Supra scapular nerve block and Axillary nerve block.|"Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique."
215140264|NCT06253442|PROCEDURE|Patients will receive Interscalene block.|Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
215140265|NCT03932344|DRUG|Anakinra|Anakinra according to prescription
215140266|NCT03788213|RADIATION|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
215140267|NCT03788213|RADIATION|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
214694963|NCT05941949|DIETARY_SUPPLEMENT|Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E|2 softgels per day
214694964|NCT05941949|DIETARY_SUPPLEMENT|Placebo|2 softgels per day
214453818|NCT05318001|OTHER|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
214453819|NCT05318001|OTHER|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
214453820|NCT03992274|OTHER|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
214453821|NCT05336136|DEVICE|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
214453822|NCT05336136|DEVICE|Current commercial mask|Current commercial mask used for administration of non-invasive ventilation
214453823|NCT05557877|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214453824|NCT05557877|DRUG|Low-Dose Aspirin|Given PO
214453825|NCT05557877|OTHER|Questionnaire Administration|Ancillary studies
214453826|NCT05557877|PROCEDURE|Biopsy|Undergo breast biopsy
214453827|NCT03574727|PROCEDURE|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
214453828|NCT06317350|DRUG|GNS-212-E1|Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.
214453829|NCT06317350|DRUG|GNS-212-E2|Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.
215140268|NCT06560372|PROCEDURE|Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV|"Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics)."
215140269|NCT06098755|BEHAVIORAL|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
214453830|NCT06317350|DRUG|GNS-212-ER|Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
214453831|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
214453832|NCT06276764|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
214453833|NCT06782399|COMBINATION_PRODUCT|Microdevice|"Device: Microdevices~The microdevice is an investigational miniaturized implantable nanodose drug delivery device. It was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. The microdevice releases nanodoses of several approved drugs into the tumor, and is then excised minimally invasively several days later.~Other: Standard of care therapy~Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy"
214453834|NCT05772169|DRUG|Mifepristone 300 MG [Korlym]|Mifepristone tablets for once daily oral dosing
214453835|NCT05772169|DRUG|Placebo for mifepristone|Placebo tablets for once daily oral dosing
214453836|NCT02051374|PROCEDURE|Decompression alone|
214453837|NCT02051374|PROCEDURE|Decompression followed by fusion with instrumentation|
214453838|NCT03623321|DRUG|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
214453839|NCT05790850|BEHAVIORAL|Pre-operative physical exercise|Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.
214453840|NCT05790850|BEHAVIORAL|Pre-operative mindfulness meditation practice|Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
214453841|NCT04028687|DEVICE|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
214453842|NCT05192798|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
214453843|NCT05192798|DRUG|Apatinib Mesylate|Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
214453844|NCT05192798|DRUG|Bevacizumab|Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
214453845|NCT04511286|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
214453846|NCT03180996|DEVICE|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
214527157|NCT00124644|PROCEDURE|high-dose chemotherapy|
214527158|NCT02319304|DRUG|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
214453847|NCT05692492|DRUG|ZSP1601|50mg BID
214453848|NCT05692492|DRUG|ZSP1601|100mg BID
214527159|NCT02319304|RADIATION|Low dose fractionated radiation therapy (LDFRT)|see arm description
214527160|NCT00966641|DRUG|Naproxen|Single orally administered dose of 500 mg naproxen
214527161|NCT00966641|DRUG|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
214527162|NCT01874470|DEVICE|renal denervation|
214527163|NCT01874470|OTHER|standard medication|
214694965|NCT01574222|BIOLOGICAL|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
214527164|NCT02785900|DRUG|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
214527165|NCT02785900|DRUG|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
214527166|NCT02785900|DRUG|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
214527167|NCT02785900|DRUG|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
214527168|NCT04915456|DRUG|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
214527169|NCT04915456|OTHER|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
215140270|NCT04848298|BEHAVIORAL|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise."
215140271|NCT06075082|DEVICE|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
215140272|NCT06629376|DRUG|Pegylated Recombinant Candida Utilis Uricase for Injection|According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
215140273|NCT02340026|OTHER|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
215140274|NCT02340026|OTHER|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
215140275|NCT03948971|PROCEDURE|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
214453849|NCT05692492|DRUG|Placebo|Placebo
214453850|NCT06109909|DEVICE|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
215140276|NCT05557916|OTHER|Standard rehab|Standard rehab protocol including knee orthosis following meniscal repair
215140277|NCT05557916|OTHER|accelerated rehab group|accelerated rehab group, no orthosis
215140278|NCT06312150|OTHER|Analysis of peripheral blood (control group)|Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.
215140279|NCT06312150|OTHER|Analysis of biological sample (Substudy-solid neoplasms)|peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy
214453851|NCT06029114|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
214453852|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
214453853|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
214453854|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
214453855|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
214453856|NCT06510764|OTHER|intradermal needles|Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosen for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.
214453857|NCT06510764|DRUG|Ziyinxiehuo Granules of traditional Chinese Medicine|Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
214453858|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
214453859|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
214453860|NCT05627479|DRUG|GIK solution|Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
214453861|NCT05627479|DRUG|Isotonic Normal Saline Solution|Placebo injection - administered intravenously.
214453862|NCT05847595|OTHER|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
214453863|NCT05847595|OTHER|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
214527170|NCT04685759|OTHER|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
214527171|NCT04685759|OTHER|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
214527172|NCT05206916|PROCEDURE|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
215140280|NCT06312150|OTHER|Analysis of biological sample (substudy-leukaemia patients)|sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
215140281|NCT05911984|DRUG|9MW3811 Injection|Intravenous injection
215140282|NCT05582434|DRUG|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
215140283|NCT05582434|DRUG|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
215140284|NCT05582434|DRUG|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
215140285|NCT05974722|DEVICE|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
215140286|NCT05974722|OTHER|Pledgeted sutures|Patient will receive pledgeted sutures
215140287|NCT01058980|PROCEDURE|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
215140288|NCT01058980|PROCEDURE|No additional ablation|Presence of dormant PV conduction, no additional ablation.
214527173|NCT02077556|DRUG|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
214453864|NCT05847595|OTHER|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
214453865|NCT04495959|DRUG|68Ga-HTK03149|PET/MRI scan with radiotracer 68Ga-HTK03149
214453866|NCT06508294|BEHAVIORAL|8 week artificial intelligence based posture exercises|8 week artificial intelligence based posture exercises
214453867|NCT05894694|DRUG|first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
214453868|NCT05894694|DRUG|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
214453869|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
214453870|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
214453871|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
214453872|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
214453873|NCT03001830|BIOLOGICAL|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
214453874|NCT05657054|OTHER|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
214453875|NCT05657054|OTHER|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
214453876|NCT01785719|BEHAVIORAL|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
214527174|NCT02077556|DRUG|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)
214527175|NCT02077556|DRUG|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
215140289|NCT01058980|PROCEDURE|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
215140290|NCT01058980|PROCEDURE|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
215140291|NCT05398653|DRUG|MIL62|An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.
215140292|NCT05398653|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
215140293|NCT03432598|DRUG|Tislelizumab|Administered 200 mg intravenously (IV) as specified in the treatment arm
215140294|NCT03432598|DRUG|Paclitaxel|Administered 175 mg/m² IV as specified in the treatment arm
215140295|NCT03432598|DRUG|Gemcitabine|Administered 1250 mg/m² IV as specified in the treatment arm
215140296|NCT03432598|DRUG|Etoposide|Administered 100 mg/m2 IV as specified in the treatment arm
215140297|NCT03432598|DRUG|Pemetrexed|Administered 500 mg/m² IV as specified in the treatment arm
215140298|NCT03432598|DRUG|Cisplatin|Administered 75 mg/m²/day IV as specified in the treatment arm
215140299|NCT03432598|DRUG|Carboplatin|Administered AUC 5 as specified in the treatment arm
215140300|NCT03844997|DRUG|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
215140301|NCT03844997|DRUG|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
215140302|NCT05614531|GENETIC|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
214453877|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
214453878|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
215140303|NCT04854174|DRUG|ZN-d5|Oral agent; 25 mg formulation
215140304|NCT00135226|DRUG|Aspirin|
215140305|NCT00135226|DRUG|Omega-3 Ethyl Esters|
215140306|NCT00135226|DRUG|Placebo Aspirin|
215140307|NCT00135226|DRUG|Placebo Omega-3 Ethyl Esters|
215140308|NCT05569044|OTHER|Control Group|No intervention
215140309|NCT05569044|OTHER|Oral Rehydration Solution|Participants will be administered ORS during one of the study visits
215140310|NCT05569044|OTHER|Water|Participants will be administered water during one of the study visits
215140311|NCT02647125|DRUG|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
215140312|NCT02647125|RADIATION|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
215140313|NCT06540079|DEVICE|Solia CSP S lead|The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.
215140314|NCT02679313|DEVICE|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
215140315|NCT04552301|BEHAVIORAL|Cognitive Processing Therapy|Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
215140316|NCT04552301|BEHAVIORAL|Psychotherapy|The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
215140317|NCT04552301|BEHAVIORAL|Targeted Asthma Education|The manualized 10-session program of asthma self-management
215140318|NCT04552301|BEHAVIORAL|General Asthma Education|A 10-session program of similar time
215140319|NCT05722860|DRUG|L-Citrulline, capsule|5g/daily dose for the duration of 1 week intervention
215140320|NCT01184898|DRUG|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
215140321|NCT01184898|DRUG|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
215140322|NCT01184898|DRUG|Etoposide|100 mg/m2/day IV
215140323|NCT01184898|DRUG|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
215140324|NCT05375617|OTHER|Observational|No intervention
215140325|NCT06383871|DRUG|HRS-7058 capsule/ HRS-7058 tablet|HRS-7058 capsule/ HRS-7058 tablet
215140326|NCT06075901|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
215140327|NCT06075901|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
215140328|NCT06075901|OTHER|Training Protocol|The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
215140329|NCT05323474|OTHER|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
215140330|NCT05323474|OTHER|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
215140331|NCT06379529|OTHER|NuvoAir clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
215140332|NCT05734768|BEHAVIORAL|State-Trait Anxiety Inventory - Y ou STAI-Y|Questionnaire
215140333|NCT06094322|OTHER|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
215140334|NCT05960890|BEHAVIORAL|Remote monitoring assisted by community physicians|"Patients upload data such as wristband data, blood pressure, weight through their mobile phones, while physicians can check the data on the platform. Upon detecting alerts, community physicians review participant-related medical information, conduct structured symptom assessments via StarNet Home platform/phone within 2 hours, and initiate protocol-guided interventions (e.g., diuretic adjustment for fluid overload)."
215140335|NCT06194864|DRUG|Itraconazole|itraconazole 200 mg QD Days 6 to 16
215140336|NCT06194864|DRUG|rifampicin|rifampicin 600 mg QD Days 6 to 20
215140337|NCT06194864|DRUG|Ecopipam|89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
215140338|NCT04007692|PROCEDURE|Esophageal stent placement|Exposure of interest is standard of care esophageal stent placement
215140339|NCT03745508|OTHER|Instant Coffee|Instant coffee prepared at different caffeine concentrations
215140340|NCT03365414|BIOLOGICAL|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
215140341|NCT03365414|DRUG|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
215140342|NCT05520203|OTHER|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
215140343|NCT00074165|DRUG|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
215140344|NCT00074165|DRUG|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
215140345|NCT00074165|DRUG|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
215140346|NCT00074165|DRUG|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
215140347|NCT00074165|DRUG|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
215140348|NCT00074165|DRUG|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
215140349|NCT00074165|DRUG|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
215140350|NCT00074165|DRUG|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
215140351|NCT00074165|DRUG|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
215140352|NCT05855798|DRUG|Bupivacain|Bupivacaine is a local anesthetic agent commonly used in ESP block.
215140353|NCT05855798|DRUG|Magnesium sulfate|Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
215140354|NCT05855798|DRUG|Ketamine Hydrochloride|Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
215140355|NCT04080661|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
215140356|NCT04080661|OTHER|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
215140357|NCT03136744|BEHAVIORAL|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
215140358|NCT00660725|DRUG|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
214453879|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
215140359|NCT00660725|DRUG|Gemcitabine|30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.
215140360|NCT00660725|DRUG|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
214453880|NCT03151616|OTHER|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
214453881|NCT05432245|DEVICE|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
214527176|NCT02077556|DRUG|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
214527177|NCT02077556|DRUG|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
214527178|NCT01808144|DRUG|lesinurad|Tablets, 400 mg once daily (QD)
214527179|NCT01808144|DRUG|lesinurad|Tablets, 200 mg QD
214527180|NCT01808144|DRUG|febuxostat|Tabletsm 80 mg QD
214527181|NCT00409500|DRUG|AQW051|
214527182|NCT05493605|PROCEDURE|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
214527183|NCT06133569|BEHAVIORAL|ReDirection|Self help program based on principles for cognitive behavioral therapy
215140361|NCT06072794|DRUG|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
215140362|NCT04797585|OTHER|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
215140363|NCT04797585|OTHER|Vaginal hysterectomy|Vaginal hysterectomy
215140364|NCT06416566|DRUG|Subcutaneous Enoxaparin|Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
215140365|NCT02738801|DRUG|GLPG1690 600 mg QD|GLPG1690 capsules, administered at a dose of 600 mg, orally QD
215140366|NCT02738801|DRUG|Placebo QD|Matching placebo capsules, administered orally QD
215140367|NCT03279081|DRUG|Cx601|Cx601 eASCs intralesional injection.
215140368|NCT03279081|OTHER|Placebo|Cx601 placebo-matching eASCs intralesional injection.
215140369|NCT04771455|BEHAVIORAL|Behavioral weight loss|Participants will receive behavioral weight loss intervention
215140370|NCT04771455|BEHAVIORAL|Intervention component: Decrease overvaluation of weight and shape|Participants will receive an intervention component to decrease overvaluation of weight and shape
214453882|NCT05735600|BEHAVIORAL|AyuDa Virtual: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
215140371|NCT04771455|BEHAVIORAL|Intervention component: Decrease unhealthy weight control practices|Participants will receive an intervention component to decrease unhealthy weight control practices
215140372|NCT04771455|BEHAVIORAL|Intervention component: Decrease negative affect|Participants will receive an intervention component to decrease negative affect
215140373|NCT02575534|DRUG|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
215140374|NCT04895839|BEHAVIORAL|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
215140375|NCT01210313|OTHER|Physical exercise|Defined exercise program
215140376|NCT03664297|DRUG|SHR1459|SHR1459 will be administered continually till disease progression or unacceptable toxicity.
215140377|NCT00000211|DRUG|Buprenorphine|
215140378|NCT03501082|OTHER|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
215140379|NCT03501082|OTHER|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
215140380|NCT03501082|OTHER|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
214453883|NCT05735600|BEHAVIORAL|AyuDa Written: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
214527184|NCT04425070|COMBINATION_PRODUCT|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
214527185|NCT04425070|COMBINATION_PRODUCT|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
214527186|NCT04425070|COMBINATION_PRODUCT|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
215140381|NCT03501082|OTHER|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
215140382|NCT00500123|PROCEDURE|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
215140383|NCT04877626|DRUG|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
215140384|NCT01796145|OTHER|Fibroscan|
215140385|NCT01710345|DRUG|Sufentanil NanoTab 20 mcg|
215140386|NCT01710345|DRUG|Sufentanil NanoTab 30 mcg|
215140387|NCT01710345|DRUG|Placebo NanoTab|
215140388|NCT04475081|BIOLOGICAL|MMR vaccine|Merck MMR-II vaccine
215140389|NCT04554784|OTHER|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
214453884|NCT06568471|DRUG|Lerodalcibep|PCSK9 inhibitor
215140390|NCT04554784|PROCEDURE|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
214453885|NCT06568471|DRUG|matching placebo|placebo
214453886|NCT05952453|DRUG|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
214453887|NCT05952453|DRUG|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
215140391|NCT05491265|BEHAVIORAL|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
214453888|NCT05391893|DRUG|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
214453889|NCT05391893|DRUG|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
214453890|NCT05636293|DRUG|Ritlecitinib|200mg Ritlecitinib
214453891|NCT05636293|DRUG|Placebo|Placebo
214453892|NCT05636293|OTHER|Gluten|10g of gluten
214453893|NCT06541691|DRUG|Enteric-coated aspirin|Enteric-coated aspirin tablet 81 mg, once daily
214453894|NCT06541691|DRUG|Plain aspirin|Plain aspirin tablet 81 mg, once daily
214453895|NCT06541691|OTHER|Hybrid strategy|"A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days"
214453896|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the DMPFC or left DLPFC
214453897|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the left DLPFC
215140392|NCT06360380|DEVICE|AquaPass System|a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
214453898|NCT06305598|PROCEDURE|Biopsy|Undergo biopsy
214453899|NCT06305598|PROCEDURE|Bone Scan|Undergo bone scan
214453900|NCT06305598|PROCEDURE|Computed Tomography|Undergo CT scan
214453901|NCT06305598|DRUG|Leuprolide Acetate|Given SC
214453902|NCT06305598|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214453903|NCT06305598|OTHER|Survey Administration|Ancillary studies
214453904|NCT06305598|DRUG|Testosterone Cypionate|Given IM
214453905|NCT06273917|OTHER|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
214453906|NCT05090722|DEVICE|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
214453907|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214453908|NCT04750473|DRUG|Fluciclovine F18|Given IV
214453909|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
214453910|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214527187|NCT05663541|DIAGNOSTIC_TEST|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
214453911|NCT06568302|DRUG|SerpinPC|Administered as SC injection.
214453912|NCT05891496|DRUG|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
214453913|NCT05891496|DRUG|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
214453914|NCT06569121|BEHAVIORAL|Group Lifestyle Balance for People Post Stroke (GLB-CVA)|12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
214453915|NCT06392360|DIETARY_SUPPLEMENT|Betaine|White betaine powder
214453916|NCT06392360|DIETARY_SUPPLEMENT|Placebo|White placebo powder
214453917|NCT00900575|DEVICE|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
214453918|NCT00900575|DEVICE|Portable Optical Spectrometer|This device is a portable optical spectrometer
214527188|NCT06088082|DRUG|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
214527189|NCT06647121|BEHAVIORAL|ACT Psychoeducational Workshop|The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
214527190|NCT06647121|BEHAVIORAL|ACTaide Mobile App|The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
214527191|NCT06647121|BEHAVIORAL|Reminders-only mobile app|This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
214527192|NCT02744105|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
214527193|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 1 Creatine HCl|Creatine hcl
214527194|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 2 Creatine HCl|Creatine hcl
214527195|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 3 Creatine Ethyl ester|Creatine ethyl ester
215140393|NCT00057200|PROCEDURE|Telephone, videophone care|
215140394|NCT02236286|BEHAVIORAL|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
215140395|NCT05711810|DRUG|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
215140396|NCT05711810|DIAGNOSTIC_TEST|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
214453919|NCT00900575|DEVICE|Transvaginal colposcope|
214453920|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
215140397|NCT05711810|BEHAVIORAL|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
214453921|NCT04594486|OTHER|Medical treatment of acute appendicitis|All cases will be treated medically and will be followed for recurrences
214453922|NCT03511963|DRUG|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
214453923|NCT03511963|DRUG|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
214453924|NCT06472713|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection once every 3 weeks for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
214453925|NCT06472713|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
214453926|NCT05188027|OTHER|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
214453927|NCT05188027|OTHER|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
214453928|NCT05188027|OTHER|No exercise|Participants will rest in a supine position for 30 minutes.
214453929|NCT02482376|RADIATION|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
214453930|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
214453931|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
214453932|NCT04294290|BIOLOGICAL|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
214527196|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 4 Placebo|Placebo
214527197|NCT06601504|DRUG|HMPL-760 planned dose 1|HMPL-760 planned dose 1 daily (QD) orally
214527198|NCT06601504|DRUG|R-GemOx|R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
215140398|NCT05711810|DRUG|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
215140399|NCT05711810|DRUG|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
214527199|NCT06601504|DRUG|HMPL-760 placebo planned dose 1|HMPL-760 placebo planned dose 1 daily (QD) orally
215140400|NCT05711810|DRUG|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
214453933|NCT06277778|OTHER|Taekwondo training with music therapy|Taekwondo training with music therapy
214453934|NCT06277778|OTHER|Taekwondo training alone|Taekwondo training without music therapy
214453935|NCT05187182|DRUG|CA-4948|Provided by Curis, Inc.
214453936|NCT05187182|BIOLOGICAL|Nivolumab|240 mg IV on Day 1 of each cycle
214453937|NCT05187182|BIOLOGICAL|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
214453938|NCT05187182|DRUG|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
214453939|NCT05187182|DRUG|mFOLFOX7|Standard of care
214453940|NCT05337943|BEHAVIORAL|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
214453941|NCT05337943|DEVICE|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
214453942|NCT04747496|DRUG|Edoxaban|This is a non-interventional, observational study.
214453943|NCT06470763|DRUG|ANV600|ANV600 administered by intravenous (IV) infusion
214453944|NCT06470763|DRUG|ANV600 + pembrolizumab (KEYTRUDA®)|ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
214453945|NCT04799912|PROCEDURE|Elective labor induction|Elective labor induction at 39 weeks of gestation
214453946|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
214527200|NCT06601504|DRUG|HMPL-760 planned dose 2|HMPL-760 planned dose 2 daily (QD) orally
214527201|NCT06601504|DRUG|HMPL-760 placebo planned dose 2|HMPL-760 placebo planned dose 2 daily (QD) orally
214527202|NCT03476551|DRUG|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
214527203|NCT02697552|DRUG|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
214527204|NCT00383500|DEVICE|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
214527205|NCT00383500|DEVICE|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
214527206|NCT06519981|DRUG|HRS-9231or matching placebo|HRS-9231 injection or matching placebo will be administered through IV injection.
215140401|NCT05711810|DIETARY_SUPPLEMENT|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
215140402|NCT05711810|DIETARY_SUPPLEMENT|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
215140403|NCT05711810|DIETARY_SUPPLEMENT|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
215140404|NCT05711810|DRUG|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
215140405|NCT05711810|DRUG|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
215140406|NCT01502293|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
215140407|NCT01502293|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
215140408|NCT01808755|DIETARY_SUPPLEMENT|D Mannose|1 gr. every 8 hours
215140409|NCT01808755|DRUG|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
215140410|NCT05075265|DRUG|Methadone|Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
215140411|NCT01707342|DRUG|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
215140412|NCT04638088|OTHER|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
215140413|NCT02543684|OTHER|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
215140414|NCT02543684|OTHER|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
215140415|NCT02543684|OTHER|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
215140416|NCT02543684|OTHER|oral glucose load|glucose load providing 50g of carbohydrates
215140417|NCT03166917|PROCEDURE|3D printing implant|3D printing implants in bone defect
215140418|NCT03166917|PROCEDURE|autogenous bone grafting|3D printing implants in bone defect
215140419|NCT00812994|DRUG|Escitalopram|SSRI antidepressant
215140420|NCT00812994|DRUG|Placebo|
215140421|NCT04263623|DRUG|Dexmecamylamine HCl|Investigational drug
215140422|NCT04263623|OTHER|Placebo|Oral tablet containing no active drug.
215140423|NCT05722925|DRUG|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
215140424|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
215140425|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
215140426|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
215140427|NCT04768738|DIAGNOSTIC_TEST|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
215140428|NCT01783613|DIETARY_SUPPLEMENT|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
215140429|NCT01783613|DIETARY_SUPPLEMENT|Placebo: 50 mg/kg/day during 12 months|
215140430|NCT00352768|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
215140431|NCT00352768|DRUG|Placebo|Placebo
215140432|NCT01932593|PROCEDURE|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
215140433|NCT02105740|BEHAVIORAL|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
215140434|NCT02105740|BEHAVIORAL|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
215140435|NCT01054014|DRUG|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
215140436|NCT01054014|DRUG|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
215140437|NCT01054014|DRUG|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
215140438|NCT03889223|PROCEDURE|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
215140439|NCT02554292|DEVICE|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
215140440|NCT05041413|BEHAVIORAL|Moms Quit|Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
214453947|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
214453948|NCT06837662|BEHAVIORAL|"MOUD Plus Intervention (treatment as usual + coordinated counseling and referral to community based peer)"|"In addition to treatment as usual (clinic visits for primary care and MOUD), patients will meet with clinic based addictions counselor who provides 1) rapport building ; 2) brief counseling interventions (e.g. motivational interviewing, change talk/solutions based therapy, harm reduction counseling); 3) referral to community resources. Patients will also be referred to community based peer recovery services who are credentialed and trained to meet the person where they are in the community and provide advocacy and support for client directed goals."
214453949|NCT06837662|BEHAVIORAL|Treatment As Usual (primary care with low threshold MOUD prescribing)|Treatment as usual arm consists of primary care clinical appointments with prescribers who treat medical issues and are trained to diagnosis and treat OUD using low threshold prescribing approaches.
214453950|NCT06836635|PROCEDURE|ESPB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
214453951|NCT06836635|PROCEDURE|TPVB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
214453952|NCT06574217|BEHAVIORAL|Stepping Stones (StSt)|StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.
214453953|NCT06574217|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
214453954|NCT06836596|DEVICE|Peripheral sensory electrical stimulation via Elettronica Pagani Roland series model: ET 20 S/N: 1907 (Made in Italy)|Sensory electrical stimulation, Transcutaneous electrical nerve stimulation (TENS) involves delivering electrical current through electrodes placed on the skin to manage pain. It can be applied at different frequencies, ranging from low (50 Hz). The intensity can be adjusted from sensory to motor levels. Sensory intensity is when the patient experiences a strong yet comfortable sensation without triggering muscle contraction
214453955|NCT06836596|DEVICE|Alternating electromyogram (EMG) neuromuscular electrical stimulation via MyoTrac Infiniti device (T9800, Thought Technology Ltd. Montreal, Quebec, Canada)|the device detects the EMG threshold value (peak muscle torque) of the target muscle and activates stimulation to enhance the patient's voluntary activation of the targeted muscle groups. It is used to assess peak muscle torque and deliver alternating and EMG-triggered stimulation. Surface electrodes are employed to detect electromyography in the affected muscle and administer electrical stimulation to the targeted muscle during treatment. The device stimulates the targeted muscles, after which the patient attempts to replicate the same movement until reaching the preset EMG feedback level
214453956|NCT06834841|DRUG|Dexmedetomidine|the preservative-free dexmedetomidine 100 μg/ml will be loaded into a 100-unit insulin syringe (1 μg/unit) and 5 units will be added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
214453957|NCT06834841|DRUG|Fentanyl|Fentanyl (Fentanyl Hameln® 0.1mg/2ml) 25 mcg will be given intrathecally added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
214453958|NCT05523713|BIOLOGICAL|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
214453959|NCT06836713|PROCEDURE|Surgical Risk Stratification|Database implementation to formulate a regional risk score
214453960|NCT06365918|DRUG|VG2025|Given by Intraperitoneal
214453961|NCT06056518|OTHER|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
214453962|NCT04406857|DRUG|Capecitabine|Given PO
214453963|NCT04406857|RADIATION|Radiation Therapy|Undergo radiation therapy
214453964|NCT04406857|DRUG|Ropidoxuridine|Given PO
214453965|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
214453966|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
214527207|NCT07000097|DEVICE|PTA planning supported by 3D-printed model|Custom-made 3D-printed model as an additional tool to computed tomography angiography for planning Percutaneous Transluminal Angioplasty in aorto-iliac-femoral-popliteal artery disease
214527208|NCT07000097|DEVICE|PTA (Standard of Care)|Preoperative planning performed based on computed tomography angiography
215140441|NCT05041413|BEHAVIORAL|Text4Baby|Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
214527209|NCT06324188|OTHER|Early atrial fibrillation ablation|Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
214527210|NCT06324188|OTHER|Usual Care|Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
215140442|NCT00253149|DRUG|risperidone|
215140443|NCT03268772|DRUG|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
215140444|NCT01091064|OTHER|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
215140445|NCT04735263|DRUG|Atorvastatin 80mg|Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
215140446|NCT03186300|DEVICE|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
215140447|NCT04065269|DRUG|Ceralasertib|ATR inhibitor
215140448|NCT04065269|DRUG|Olaparib|PARP inhibitor
215140449|NCT04065269|DRUG|Durvalumab|Anti-PD-L1 immunotherapy
215140450|NCT06294626|OTHER|Group 1|21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
215140451|NCT05962528|DEVICE|Soft lens|Patients were randomly fitted with five different designs of soft lenses
214453967|NCT06831006|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
214453968|NCT03699709|BEHAVIORAL|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
214453969|NCT06837675|DEVICE|high tone power therapy|High tone Power therapy (HiToP191-H) device is a new electrotherapy technology. Its primary impact on the body is to provide energy to the body to activate cells and rebuild it. It can cause an oscillation or vibration that promotes metabolism, nand erve regeneration and relieves pain by dispersing pain and inflammation mediators, nutrients, and waste products
214453970|NCT06837675|OTHER|selected physical therapy program|selected physical therapy protocol for 45 minutes 3 times per week for 3 months in form of pelvic floor exercises and core stability exercise
214453971|NCT06752915|BEHAVIORAL|acupressure application|Acupressure massage will be applied to LI4, HT7, LU1 and ST 36 acupuncture points for 2 minutes.
214453972|NCT06836778|DRUG|Carvedilol Tablets|Non-selective beta blocker (Carvedilol 3.125 mg BD for 3 days followed by 6.25 mg BD , maximum dose would be 12.5 mg BD , same shall be switch to maximum tolerable dose if Systolic BP\< 90 , H,R\<55)
214453973|NCT06836778|PROCEDURE|Endoscopic Variceal Ligation|EVL every 3 weeks till eradication of varices followed by every 3 months.
214453974|NCT04344899|OTHER|Observational|Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
214453975|NCT02945020|DRUG|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
215140452|NCT04440475|PROCEDURE|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
215140453|NCT00736021|DRUG|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
215140454|NCT05215431|PROCEDURE|periodontal examination&amp;#39;s, determination of salivary antioxidants and cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid, Non-surgical therapy of periodontitis|Periodontal parameters has been recorded on six sites of each tooth using a manual periodontal probe. Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits. Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits . The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
215140455|NCT05215431|DIAGNOSTIC_TEST|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA)|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits.
215140456|NCT05215431|DIAGNOSTIC_TEST|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits .
215140457|NCT05215431|PROCEDURE|Periodontal treatment|The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
214453976|NCT02945020|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
214453977|NCT02945020|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
214527211|NCT07000435|DEVICE|3D printed custom-made mouth guards|Participants in the first group will receive 3D printed custom-made mouth guards
214527212|NCT07000435|DEVICE|Traditional custom-made mouth guards|Participants in the active comparator arm will receive traditional custom-made mouth guards as an intervention
214527213|NCT06672055|BIOLOGICAL|VXA-CoV2-3.1|Tablets for oral use.
214527214|NCT06672055|BIOLOGICAL|COMIRNATY®|Intramuscular (IM) injection.
214527215|NCT06672055|BIOLOGICAL|VXA-CoV2-3.3|Tablets for oral use.
215140458|NCT03038061|OTHER|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
215140459|NCT00522093|DRUG|TJ-100|TJ-100 2.5g three times per day for 6 weeks
215140460|NCT04008472|OTHER|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
215140461|NCT00140452|DRUG|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
215140462|NCT04124809|DEVICE|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
215140463|NCT05810740|DRUG|Binimetinib 15 MG|Binimetinib 15 mg tablet
215140464|NCT05810740|DRUG|Binimetinib 45 MG|Binimetinib 45 mg tablet
215140465|NCT02233777|DRUG|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
215140466|NCT02233777|DRUG|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
215140467|NCT03613441|BEHAVIORAL|Mindful Awareness Practices (MAPs)|Please refer to arm description
215140468|NCT00048425|DRUG|Levosimendan|
215140469|NCT01539824|BIOLOGICAL|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
214453978|NCT06835998|OTHER|stress ball|"the stress ball intervention was initiated. Before starting, the researcher provided instructions and demonstrations on how to use the stress ball, allowing then the patients to practice. The stress ball intervention was administered during the second hour of the hemodialysis session when patients were most comfortable. Patients were instructed to squeeze the stress ball once, counting internally as 1-2-3 with each squeeze. The stress ball intervention was administered three times weekly during hemodialysis sessions for 15 minutes each session, totaling 12 sessions for a period of four weeks. Throughout the intervention, patients were observed by the same researcher."
214453979|NCT06827405|DIETARY_SUPPLEMENT|Lactase enzyme|Patients were given 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, 5-30 minutes before feeding
214453980|NCT06827405|DIETARY_SUPPLEMENT|Lactose-free formula feed|Patients were advised lactose-free formula milk/diet.
214453981|NCT04675567|BEHAVIORAL|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
214453982|NCT06325371|DEVICE|Visceral aneurysm stenting|Flow diverter stenting
214453983|NCT06248398|PROCEDURE|Surgery with RobOtol®|Patient having cochlear implantation surgery with RobOtol®.
214453984|NCT06248398|PROCEDURE|Conventional manual surgery|Patient having conventional manual cochlear implantation surgery
214453985|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
214453986|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
215140470|NCT01539824|RADIATION|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
214453987|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
214453988|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
214453989|NCT06387108|OTHER|training course|Two-hour online training course for educational professionals at schools on depression and mental health in children and adolescents (including symptoms, causes, comorbidity, prevention) and practical tips for everyday school life to reduce stress.
214453990|NCT06377189|OTHER|Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings|"The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective."
215140471|NCT06532578|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
215140472|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q4W|Subcutaneous injection of CPX101 or placebo
215140473|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
215140474|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q4W|Subcutaneous injection of CPX101 or placebo
215140475|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q2W|Subcutaneous injection of CPX101 or placebo
215140476|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q2W|CPX101 or placebo 360mg Q2W
215140477|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q4W|CPX101 or placebo 360mg Q4W
215140478|NCT05679388|DRUG|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
214453991|NCT06377189|OTHER|Control Arm - Treatment As Usual (TAU)|PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
214527216|NCT02648282|DRUG|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
215140479|NCT05679388|DRUG|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
215140480|NCT05679388|DRUG|Itraconazole|A drug used to treat fungal infections.
215140481|NCT05452486|DIAGNOSTIC_TEST|English APD assessment|Materials presented in English
215140482|NCT05452486|DIAGNOSTIC_TEST|Spanish APD assessment|Materials presented in Spanish
214453992|NCT06838377|DEVICE|standard Champy mini plate|the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments. Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone then mobilize the broken segment , Arch bar was made to achieve proper occlusion put the Champy 2.0 plate on the ventral surface of the external oblique of the mandible and remove it for further bending using plate pliers for further accommodation of the plate then fix it in place using mono cortical screws.
214453993|NCT06838377|DEVICE|computer guided screw holes locating guide and Patient Specific Champy plate|"the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments.~Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone to accommodate the screw holes locating guide and the custom-made Champy plate.~, Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made Champy plate and fix it with screw for passive reduction of the segments. Then suture the mucosa."
214453994|NCT06835634|PROCEDURE|Self reported questionnaires|PROMs and psychological tests submission in patients affected by neurosurgical diseases
214453995|NCT06231108|OTHER|Kinesio Taping|"Three different taping applications will be applied, namely ankle correction, quadriceps facilitation, and gluteus maximus facilitation.~1. Taping: Functional correction technique will be used to facilitate dorsal flexion movement.~2. Taping: Quadriceps Femoris (QF) Facilitation Technique - In taping to activate the QF muscle and regulate muscle tone, the patient will be placed in a supine position with hips and knees in neutral.~3. Taping: Gluteus Maximus (GM) Facilitation Technique - For taping to facilitate the GM muscle, a double-band application will be performed."
214453996|NCT04562649|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
214527217|NCT02648282|DRUG|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
214527218|NCT02648282|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
214527219|NCT02648282|RADIATION|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
214527220|NCT06283693|OTHER|mindfulness-based stress reduction|Müdahale grubundaki kadınlara depresyon, anksiyete ve stres düzeylerini azaltmak için farkındalık temelli bir stres azaltma programı uygulanacaktır. Program, haftada bir seans olmak üzere haftada iki kez toplam 4 hafta boyunca 8 seanstan oluşacaktır. Müdahale grubu haftada 2 seans alacaktır. Her seans 80 dakika sürecektir. Çalışmadaki seanslar, katılımcıların iş yoğunluğu, hayattaki sorumlulukları ve 4 hafta boyunca düzenli olarak katılamama ihtimalleri göz önünde bulundurularak zoom programı üzerinden gerçekleştirilecektir. 4 hafta/8 oturumluk MBSR programı tamamlandıktan sonra müdahale grubundaki kadınlara veri toplama formları tekrar uygulanacak ve son test ölçümleri yapılacaktır. Son test ölçümlerinden sonra müdahale grubundaki kadınların takip ölçümleri ölçümlerden 8 hafta sonra yapılacaktır.
214694966|NCT00695591|OTHER|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
215140483|NCT04632680|DEVICE|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
215140484|NCT00535314|DRUG|RTA 402 Dose1|
215140485|NCT00535314|DRUG|RTA 402 Dose2|
215140486|NCT06235775|DRUG|GV1001 Placebo|0.9% normal saline
214453997|NCT04562649|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
215140487|NCT06235775|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
215140488|NCT04211753|BEHAVIORAL|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
215140489|NCT04211753|DEVICE|Mobile app|Medical device for crisis intervention
215140490|NCT02402816|DEVICE|MultiPoint Pacing ON|MultiPoint Pacing ON
215140491|NCT02402816|DEVICE|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
215140492|NCT00446979|DRUG|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
215140493|NCT00446979|DRUG|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
215140494|NCT01402752|BIOLOGICAL|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
215140495|NCT03059849|DRUG|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
215140496|NCT02569385|OTHER|Spontaneous breathing trial|
214453998|NCT06036004|DRUG|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
214453999|NCT06036004|OTHER|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
214454000|NCT06833125|DRUG|Garlic powder standardized to allicin|The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial effect) for 6 days just after ICU admission
214454001|NCT00582231|OTHER|Questionnaires.|Questionnaires.
214454002|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
214454003|NCT04942535|BEHAVIORAL|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
214527221|NCT07009470|DRUG|Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar)|First, perform a single session of TACE. Followed by three cycles of neoadjuvant therapy with Finotonlimab combined with bevacizumab. Proceed with curative resection. Finally, initiate postoperative adjuvant targeted-immunotherapy . Finotonlimab: intravenously every three weeks ,200mg. bevacizumab：intravenously every three weeks , with a dosage based on body weight: 15 mg (≤60 kg) .
214527222|NCT07009470|PROCEDURE|TACE|Initial Perform a single session of TACE procedure.TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
214527223|NCT07009587|PROCEDURE|Endoscopy|endoscopic procedure
214527224|NCT07008326|BEHAVIORAL|High Intensity Circuit Training|HICT: 3x/week high intensity circuit training for 12 weeks
214527225|NCT07008326|BEHAVIORAL|Moderate Intensity Continuous Training|3x/week moderate intensity continuous training for 12 weeks
214527226|NCT07008612|DIAGNOSTIC_TEST|Patients with a genetic syndrome linked to the MYT1L gene|"* Neuropsychological assessment by the neuropsychologist (lasting 1h30)~* Speech and language assessment (including language and prosody) by the speech therapist, lasting 1h30"
214527227|NCT07008612|DIAGNOSTIC_TEST|Patients with a neurodevelopmental disorder of genetic origin but not linked to MYT1L|Evaluation de la prosodie par l'orthophoniste (45 minutes)
214527228|NCT07008157|OTHER|1. IFC|IFC therapy was applied while the patient lay in a supine position with the knees slightly apart. Each treatment session involved four electrodes enclosed in lint cloth covers. Two electrodes were positioned bilaterally on the lower abdomen, just below the anterior superior iliac spines (ASIS), while the remaining two were placed on the inner surfaces of both thighs. To maintain hygienic standards, the cloth covers were replaced for each participant at every session. The intervention was administered three times weekly over an eight-week period. A frequency range of 0-10 Hz was used, and the current intensity was carefully adjusted based on each patient's comfort and tolerance. Each IFC session lasted 15 minutes, with the aim of modulating pelvic region activity to support improved bladder function. This protocol was implemented three times per week over an eight-week period
214527229|NCT07008157|OTHER|2. Timed voiding.|The approach involved instructing participants to follow a fixed, scheduled voiding routine, typically every 3 hours, irrespective of the sensation to urinate. Additionally, patients were advised to adjust their toileting posture by sitting and leaning forward at an angle of approximately 45 degrees, allowing adequate time for complete bladder emptying. The technique also included practicing double voiding, where the individual would stand up and sit down again after the initial void to help ensure maximum bladder evacuation
214694967|NCT03943758|DIETARY_SUPPLEMENT|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
215140497|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
215140498|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
215140499|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
215140500|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
215140501|NCT05065060|OTHER|Observation|Observation
215140502|NCT04727970|DRUG|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
215140503|NCT01838395|DRUG|Ara-C|IV (intravenous administration)
215140504|NCT01838395|DRUG|BL-8040|SC (subcutaneous injection)
215140505|NCT04088149|DRUG|GXNPC1|Autologous ADSCs
214527230|NCT07008157|OTHER|motor imagery training|Prior to initiating MIT, participants watched a 10-minute instructional video in a quiet treatment space, illustrating proper PFM contractions through both visual and auditory cues. The therapist provided a detailed explanation, using a simple analogy of the bladder as a balloon filled with urine, connected by a tube (the urethra) to the outside, and controlled by the PFM. It was explained that contracting these muscles tightens the balloon, holding back urine, whereas weak or relaxed muscles may lead to leakage. Patients were then guided to mentally visualize contracting and holding these muscles until they reached a suitable time and place (the toilet), without physically performing the action. Following this explanation, patients were asked to sit comfortably with their eyes closed and spend 10 minutes visualizing the movement and control of their PFM while remaining physically relaxed. Throughout the session, the therapist used open-ended prompts to help maintain the patient's focu
214527231|NCT07008157|OTHER|pelvic floor muscles training|Before beginning each treatment session, participants were instructed to empty their bladders to promote comfort and relaxation during the exercises. All patients were taught a structured PFMT routine, to be performed daily in multiple positions such as lying, sitting, and standing. The program consisted of contracting the PFM for 10 seconds, followed by a 10-second relaxation period, with this sequence repeated 15 times in each session. To gradually enhance the endurance of the slow-twitch muscle fibers, both contraction and relaxation times were increased by one second each week. In addition, to activate and strengthen the fast-twitch muscle fibers, patients were directed to perform 20 quick, repetitive contractions and relaxations of the levator ani muscles - simulating the act of stopping urine flow, followed by a 10-second rest. This rapid contraction sequence was repeated for 2 to 4 sets in each session. This protocol was implemented three times per week over an eight-week period
214527232|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
214527233|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
214527234|NCT07006961|OTHER|Generative AI-based food chaining device|Our group has developed the only generative-AI tool that produces allergy-safe food-chaining recommendations, but it has not yet been clinically tested. This proposal builds on that proof of concept to evaluate its effectiveness in a broader pediatric ARFID population.
214527235|NCT07009327|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
214527236|NCT03586284|DRUG|Valganciclovir Hydrochloride|21 to 28 days of oral valganciclovir treatment
214527237|NCT03586284|DRUG|Ganciclovir Sodium|21 to 28 days of topical ganciclovir solution treatment
214527238|NCT03586284|DRUG|Placebo Oral Tablet|21 to 28 days of placebo pill treatment
214527239|NCT03586284|DRUG|Topical placebo|21 to 28 days of topical placebo treatment
214527240|NCT07009496|BEHAVIORAL|Tibialis Anterior Fatigue Protocol|Participants lie in a supine position with the ankle fixed at 100° dorsiflexion using a custom apparatus. They perform repeated isometric dorsiflexion contractions for 30 seconds followed by 15 seconds of rest. The protocol continues until a perceived exertion of ≥7 is reported on the Modified Borg Scale. Evaluations include joint position sense, balance, muscle elasticity, pain threshold, and performance metrics recorded at four time points: pre-, post-, 24h, and 48h.
214694968|NCT03943758|DIETARY_SUPPLEMENT|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
215140506|NCT05917899|BEHAVIORAL|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
215140507|NCT00723736|DRUG|Desloratadine|2.5 ml (1.25 mg) once daily
215140508|NCT03694353|DRUG|Pegvaliase|40-60mg/day
215140509|NCT05400967|DRUG|68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
215140510|NCT05415761|BEHAVIORAL|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
215140511|NCT05415761|BEHAVIORAL|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
215140512|NCT05415761|BEHAVIORAL|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
215140513|NCT00651742|DRUG|S-1|All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
214527241|NCT07009496|BEHAVIORAL|Gastrocnemius Fatigue Protocol|Participants lie in a prone position with their foot placed against a wall. They perform repeated isometric plantarflexion contractions for 30 seconds with 15 seconds of rest between repetitions. The exercise is continued until a Modified Borg score of ≥7 is reached. Measurements of neuromuscular and biomechanical parameters are conducted at the same four time points: before, immediately after, 24 hours, and 48 hours post-exercise.
214527242|NCT07009561|BEHAVIORAL|Motor Execution Typing Task|Participants will perform a 3-minute typing task using custom-designed text that emphasizes index finger use. This task is designed to actively engage the motor cortex and will be administered in a controlled environment using standard posture and equipment. The task aims to elicit changes in cortical excitability, which will be measured pre- and post-intervention using TMS.
214527243|NCT07009561|BEHAVIORAL|Action Observation of Typing Task|Participants will observe a 3-minute first-person video of an individual typing the standardized text. The video is designed to activate mirror neuron systems through visual engagement with a familiar motor task. It will be shown once in a controlled setting, and post-assessment of cortical excitability will follow immediately after.
214527244|NCT04142385|OTHER|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
214527245|NCT04142385|OTHER|Laboratory Biomarker Analysis|Correlative studies
215140514|NCT05106647|BEHAVIORAL|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
215140515|NCT06115642|DRUG|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215140516|NCT03762590|OTHER|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
215140517|NCT03762590|OTHER|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
215140518|NCT06006299|DEVICE|transauricular Vagus Nerve Stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.
215140519|NCT05913882|DEVICE|Respiratory Muscle Strength Training (LVR+EMST)|Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
215140520|NCT05720286|DEVICE|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
215140521|NCT00693407|PROCEDURE|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.
214527246|NCT04142385|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
214527247|NCT04142385|PROCEDURE|Physical Examination|Undergo targeted physical exam
215140522|NCT01088568|PROCEDURE|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
215140523|NCT01088568|PROCEDURE|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
215140524|NCT01570413|PROCEDURE|No Pelvic Exam|Will not receive pelvic examination.
215140525|NCT01570413|PROCEDURE|Pelvic Examination|Pelvic examination will be performed.
215140526|NCT05824650|OTHER|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
214527248|NCT04142385|PROCEDURE|Proctoscopy with Biopsy|Undergo HRA
214527249|NCT04142385|OTHER|Questionnaire Administration|Ancillary studies
214527250|NCT06095492|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
214527251|NCT06095492|DRUG|Linagliptin|linagliptin 5 mg once a day
214527252|NCT07008716|RADIATION|Radiation Therapy|Twice-daily (45 Gy/30 fractions) or once-daily (45 Gy/15 fractions) thoracic radiotherapy after 2-4 cycles of chemotherapy
214527253|NCT07008716|DRUG|Etoposide + carboplatin; Etoposide + cisplatin|Carboplatin IV (AUC=5) on day 1 combined with etoposide IV (100mg/m2) on days 1-3, or cisplatin IV (25mg/m2) on days 1-3 combined with etoposide IV (100mg/m2) on days 1-3. Treatment is repeated every 21 days for 4-6 cycles.
214527254|NCT07008716|RADIATION|Creating CTV for primary tumor|A margin of 0.8 cm beyond the gross target volume of primary tumor.
214527255|NCT07008716|RADIATION|prophylactic cranial irradiation (PCI)|Beginning 4-6 weeks after chemoradiotherapy completion, patients in both arms who achieve a complete or partial response without brain metastasis receive PCI at 25 Gy/10 fractions or 26 Gy/13 fractions, delivered once daily (5 days per week).
215140527|NCT06081296|PROCEDURE|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
215140528|NCT06081296|PROCEDURE|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
215140529|NCT06081296|PROCEDURE|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
214454004|NCT04942535|BEHAVIORAL|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
214454005|NCT04942535|BEHAVIORAL|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
214454006|NCT05432635|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
214454007|NCT05432635|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
214454008|NCT05432635|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214454009|NCT05432635|PROCEDURE|Myeloablative Conditioning|Given standard conditioning regimen
214454010|NCT06188026|DRUG|NNC0194-0499|Once a week for 5 weeks as an injection in dose of 30 mg. The injection will be given under the skin
214454011|NCT06188026|DRUG|ethinylestradiol/levonorgestrel|Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
214454012|NCT06832527|OTHER|Rehabilitation treatment|ROM, strength, stretch and proprioception exercises
214454013|NCT06832527|OTHER|Virtual Reality games|Virtual Reality games using META QUEST PRO glasses
214454014|NCT05540639|BEHAVIORAL|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
214454015|NCT01480206|OTHER|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
214454016|NCT05244889|BEHAVIORAL|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
214454017|NCT05244889|BEHAVIORAL|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
214694969|NCT06554392|DIAGNOSTIC_TEST|Blood sample|Blood sample from each subject to detect Glutathione Peroxidase 4.
214527256|NCT06167330|OTHER|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
214527257|NCT06167330|OTHER|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
215140530|NCT06081296|PROCEDURE|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
214527258|NCT06009861|DRUG|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
214454020|NCT06835244|OTHER|68Ga-PSMA-11|All patients with non prostatic neoplasm expressing PSMA undergo 68\[Ga\]Ga-PSMA-11-PET/CT
214454021|NCT05977114|BEHAVIORAL|family conflict intervention group|The family conflict preventive intervention includes the introduction to the occurrence of family conflicts, communication skills training, and role play to practice the skills.
214454022|NCT05977114|BEHAVIORAL|handicraft-making group|The group involves handicraft-making.
215140531|NCT01535040|DRUG|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
215140532|NCT01535040|DRUG|placebo|Placebo by mouth through completion of 12 weeks.
215140533|NCT03479814|RADIATION|IMRT-SIB plus sequential IG-RT boost|
215140534|NCT02734875|OTHER|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
215140535|NCT05430854|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
215140536|NCT04314284|BEHAVIORAL|I Can PIC|-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
215140537|NCT04314284|OTHER|Historical control survey|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
215140538|NCT04314284|OTHER|Post-intervention survey (I Can PIC participants)|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
214454023|NCT06831708|BEHAVIORAL|Psychoanalytic Psychotherapy|This intervention involves short-term psychoanalytic therapy based on a standardized framework. Although not rigidly manualized, the treatment protocol includes core psychoanalytic concepts (such as transference, resistance, and the exploration of unconscious conflicts). Sessions will be conducted weekly (50 minutes each) for a total of 12 sessions. This intervention is delivered by two study authors who have undergone dedicated training and calibration to ensure consistent application of the framework.
214454024|NCT06831708|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention consists of a structured and manualized CBT program specifically tailored for individuals with Generalized Anxiety Disorder (GAD). The intervention includes defined session objectives, cognitive restructuring techniques, behavioral experiments, and homework assignments. Participants will receive 12 weekly sessions (50 minutes each), delivered by two study authors who are trained in CBT.
214454025|NCT05822557|OTHER|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
214454026|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
214454027|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
214454028|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
214454029|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
214454030|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
214454031|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
214454032|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
214454033|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
214454034|NCT05891236|OTHER|Control|No drug or placebo will be administered.
214454035|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
214454036|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
214454037|NCT05562791|DRUG|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
214454038|NCT05562791|DIAGNOSTIC_TEST|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
214454039|NCT06458894|BEHAVIORAL|Prerehabilitation|Home prerehabilitation was performed on the basis of routine preoperative preparation
214454040|NCT06836362|OTHER|Acupuncture treatment|"Children will receive 8 acupuncture sessions during 10 weeks (1 session per week during 6 weeks, followed by 1 session every other week during 4 weeks).~At each acupuncture session, the acupuncturist records the patient's bowel habits, gastrointestinal symptoms and the use of escape medication during the period between sessions. After 3, 6 and 8 acupuncture treatments respectively, patients will visit the research team after they receive acupuncture to evaluate adverse events.~After completion of these 10 weeks, an acupuncture-free follow-up period of 4 weeks commences. The follow-up period will be used to investigate if and how long effects of the intervention will persist. During the intervention period and the follow-up period, escape medication (bisacodyl or enemas) is allowed under the same conditions as during the run-in period."
214454041|NCT05570994|DRUG|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
214454042|NCT05570994|DRUG|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
214527259|NCT06009861|DRUG|Albumin-Bound Paclitaxel|Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
214527260|NCT06009861|DRUG|Cisplatin|Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
214527261|NCT06686888|DIETARY_SUPPLEMENT|SCFA|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
214527262|NCT06686888|DIETARY_SUPPLEMENT|microcristalline cellulose|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
214527263|NCT04387201|DRUG|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
214527264|NCT04387201|DRUG|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
214454043|NCT03861897|OTHER|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
214527265|NCT06698276|OTHER|Alveolar Ridge Reconstruction|It will be used a combination of two biomaterials for alveolar ridge preservation
215140539|NCT04314284|OTHER|Follow-Up survey (I Can PIC participants)|-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
215140540|NCT06114238|DRUG|Itepekimab AI|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
215140541|NCT06114238|DRUG|Itepekimab PFS|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
215140542|NCT05650749|BIOLOGICAL|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
215140543|NCT04638231|OTHER|Supportive messages|Daily supportive messages via SMS or email
215140544|NCT05375461|DRUG|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
215140545|NCT05375461|DRUG|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
214454044|NCT03861897|OTHER|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
214454045|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
214454046|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
214527266|NCT04341584|DRUG|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
214527267|NCT04320602|BIOLOGICAL|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
214527268|NCT04320602|BIOLOGICAL|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
214454047|NCT05430360|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
214454048|NCT06347874|DRUG|Cryoablation|an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
214454049|NCT06347874|DRUG|ESP Catheter|an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
214694970|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
215140546|NCT05375461|DRUG|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
215140547|NCT06204757|OTHER|questionary|questionary relating to birth trauma are completed by midwives and patients
215140548|NCT05083741|DEVICE|Chitogel|post-operative dressing within standard of care
215140549|NCT05083741|DEVICE|Nexfoam|post-operative dressing within standard of care
214454050|NCT06010446|OTHER|No intervention, just retrospective analysis of data.|
215140550|NCT06061991|BEHAVIORAL|Mobile instant messaging-based lifestyle intervention|Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.
215140551|NCT06061991|BEHAVIORAL|Text messaging reminders|Follow-up reminders via text messaging as attention control.
215140552|NCT06061991|BEHAVIORAL|Brief advice on GDM prevention|Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy
215140553|NCT06061991|BEHAVIORAL|Usual care|Usual care provided by the prenatal clinic.
215140554|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 750 mg|750 mg administered orally
215140555|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 1500 mg|1500 mg administered orally
215140556|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 3000 mg|3000 mg administered orally
215140557|NCT06033222|DRUG|Placebo|Contains no active ingredient.
215140558|NCT06584695|DRUG|Transversus abdominis plane block|Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
215140559|NCT06584695|DRUG|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
215140560|NCT06584695|DRUG|Control group|"Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane."
214454051|NCT06826391|DEVICE|Calcium hydroxylapatite|This intervention consists of calcium hydroxylapatite injections into the attached gingiva of a patient who has gingival recession to stabilize, grow and reverse gingival recession. These injections will also reduce tooth hypersensitivty in the affected teeth.
214454052|NCT06065020|BEHAVIORAL|VIDACTIVA sessions|"Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)"
214454053|NCT06065020|BEHAVIORAL|Standard Care|Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
214454054|NCT05463874|BEHAVIORAL|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
214454055|NCT06198374|DIETARY_SUPPLEMENT|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
214454056|NCT06198374|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
214454057|NCT06838182|DIAGNOSTIC_TEST|Salivary biomarkers tests|saliva samples are collected from participants
215140561|NCT06065670|DRUG|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
215140562|NCT06065670|DRUG|Placebo|Matched sugar tablet
215140563|NCT01652235|DEVICE|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
215140564|NCT04718415|DRUG|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
215140565|NCT04718415|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
215140566|NCT06006208|DEVICE|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
215140567|NCT03548532|DEVICE|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
215140568|NCT04327154|DEVICE|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
214454058|NCT05569382|DRUG|Verapamil|"1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
214454059|NCT05569382|DRUG|Bisoprolol|"1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
214454060|NCT05569382|DRUG|Placebo|"1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
215140569|NCT05317403|DRUG|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
215140570|NCT05317403|DRUG|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
215140571|NCT05317403|DRUG|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
215140572|NCT05317403|DRUG|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~1. \- 1.99 years old: 30 mg~2. \- 2.99 years old: 50 mg~   * 3 years old: 70 mg"
214454061|NCT05893082|DEVICE|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
214454062|NCT03792282|BEHAVIORAL|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
214454063|NCT03792282|BEHAVIORAL|Usual care|Participants receive a general lifestyle counseling.
214454064|NCT05368103|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
214454065|NCT03025698|DRUG|Eltrombopag|Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
214454066|NCT03025698|DRUG|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
214454067|NCT03025698|DRUG|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
214454068|NCT04238676|DRUG|PP353|active administered by intradiscal injection
214454069|NCT04238676|OTHER|Placebo|Sham injection
214454070|NCT04864691|BIOLOGICAL|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
215140573|NCT05317403|DRUG|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
214454071|NCT05823740|OTHER|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
214454072|NCT05823740|OTHER|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
214454073|NCT05823740|OTHER|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
214454074|NCT05823740|OTHER|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
214694971|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
214454075|NCT05823740|OTHER|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
214454076|NCT05823740|OTHER|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
214454077|NCT05823740|OTHER|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
215140574|NCT05317403|DRUG|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
215140575|NCT06212856|OTHER|Plyometric training|"The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws"
215140576|NCT06212856|OTHER|Conventional|"The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running"
215140577|NCT05142787|DEVICE|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
214527269|NCT06702774|DIAGNOSTIC_TEST|Active case finding|Villagers will be informed through public announcements and social workers. Before the campaign, social workers and village doctors will recruit participants and obtain consent through door-to-door visits. A mobile van equipped with an AI-assisted digital radiography (DR) machine and a refrigerator will visit villages on agreed dates. Participants will complete a TB symptom questionnaire and undergo DR screening. Those with TB symptoms or abnormal DR results will provide on-site sputum samples and collect additional morning and night samples. Trained staff will ensure proper collection and offer nebulizer support if needed. Samples will be transported daily to hospitals for testing using smear, culture, and GeneXpert. Participants with negative bacteriological results but abnormal findings will be referred for further clinical assessment.
214527270|NCT06695988|BEHAVIORAL|Time Restricted Eating|The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
214527271|NCT06719895|BEHAVIORAL|web based education|experimental
214527272|NCT06716281|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL
215140578|NCT04060303|PROCEDURE|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
215140579|NCT06069128|DEVICE|Neurotrigger Basic. eye blinking stimulator|NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
215140580|NCT06547684|DEVICE|fESWT|"Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle."
214454078|NCT05823740|OTHER|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
214454081|NCT06838260|OTHER|24°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 24°C for the T1 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
214454082|NCT06838260|OTHER|37°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 37°C for the T2 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
214454083|NCT05753189|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
214454084|NCT05753189|DRUG|Placebo|Placebo: Proprietary Vehicle Solution
214454085|NCT05753189|DRUG|Aceclidine Ophthalmic Solution|Aceclidine
214454086|NCT04876742|OTHER|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
214454087|NCT04876742|OTHER|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
214454088|NCT02616445|DRUG|UE2343|"* UE2343~* 10mg, 20, 35mg~* twice daily for 9 days"
214454089|NCT02616445|DRUG|Placebo|"* 10mg, 20, 35mg~* twice daily for 9 days"
214454090|NCT02616445|DRUG|Placebo|"* Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
214527273|NCT06716281|BIOLOGICAL|Placebo|Sodium Chloride Injection
214527274|NCT06719999|DIETARY_SUPPLEMENT|B4HT Mediterranean Lunch box|lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)
214527275|NCT06720883|PROCEDURE|Major hepatectomy|All patients will undergo robotic major hepatectomy with S1 resection, hilar lymphadenectomy and biliary reconstruction
214694972|NCT00369668|BEHAVIORAL|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
214694973|NCT03440216|DRUG|blood sampling|"* temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
215140581|NCT06332495|OTHER|Questioning the patient during hygiene care|The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
214454091|NCT02616445|DRUG|UE2343|"* Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
214454092|NCT02616445|DRUG|UE2343|"* UE2343~* twice daily for 3 days~* single dose on day 4"
214454093|NCT05814874|DIETARY_SUPPLEMENT|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
214454094|NCT05814874|DIETARY_SUPPLEMENT|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
214454095|NCT05814874|OTHER|Placebo|Placebo pill
214454096|NCT06830226|DIETARY_SUPPLEMENT|Test group|In this group the Miris Human Milk analyzer will be used, consisting of a real-time mid-infrared technology that directly measures the concentration of protein, fat and carbohydrate, and calculates the energy content based on direct measurements.
214454097|NCT06830226|DIETARY_SUPPLEMENT|Reference group|In this group the Kjeldahl method will be used to assess total nitrogen concentration, the Röse-Gottlib method to assess fat concentration, and energy and carbohydrate concentration will be calculated by differences. Kjeldahl and the Röse-Gottlib are considered reference methods
214454098|NCT06836986|DRUG|Norepinephrine Bolus|"Prophylactic norepinephrine bolus of 8 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of norepinephrine 4 micrograms will be administered in case of hypotension."
214454099|NCT06836986|DRUG|Phenylephrine bolus|"Prophylactic phenylephrine bolus of 100 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of phenylephrine 50 micrograms will be administered in case of hypotension."
214454100|NCT05056194|DRUG|Valiloxybate|XW10172 MR Granules for Oral Suspension
214454101|NCT05056194|OTHER|Placebo|Placebo Granules for Oral Suspension
214454102|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
214454103|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
214454104|NCT06164314|DRUG|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
214454105|NCT06838338|DRUG|JAB-21822|Tablet, oral, 800 mg/QD, until PD or intolerable toxicity
214694974|NCT03440216|DRUG|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
214694975|NCT03440216|DRUG|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
215140582|NCT04046497|OTHER|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
215140583|NCT04046497|OTHER|Usual Care|Usual Care provided by CSC clinic
214454106|NCT06838338|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by clinical practice
214454107|NCT06838338|DRUG|Bevacizumab|According to the assessment by investigator
214454108|NCT06787495|PROCEDURE|Arterial repair|Arterial repair starting from simple repair or vein graft or synthetic graft
214454109|NCT06485401|DRUG|ADC189|45 mg per tablet, oral administration, single dose.
214454110|NCT04650087|DRUG|Apixaban 2.5 MG|Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
214454111|NCT04650087|DRUG|Placebo|Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
214454112|NCT05243342|DRUG|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
214454113|NCT05243342|DRUG|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
214454114|NCT05763537|BEHAVIORAL|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
214454115|NCT05763537|BEHAVIORAL|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
214454117|NCT06475378|DEVICE|Moonbird|Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
214454118|NCT06475378|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
215140584|NCT02023086|PROCEDURE|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
215140585|NCT02023086|PROCEDURE|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
215140586|NCT02023086|PROCEDURE|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
215140587|NCT02023086|PROCEDURE|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
215140588|NCT02023086|DRUG|Tropicamide|Used to dilate patient's pupil during testing
215140589|NCT02023086|DEVICE|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
215140590|NCT03657628|OTHER|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
214454119|NCT06833515|OTHER|one flare+wave one gold glider+wave one gold|In this clinical study, the teeth will first undergo coronal shaping with the One Flare file. Then, the glide path and final shaping will be performed in reciprocal mode with reciprocal files.
214454120|NCT06833515|OTHER|wave one gold glider+wave one gold|In this group, only the glide path and final shaping will be performed using reciprocal files, without coronal shaping.
214454121|NCT06833515|OTHER|wave one gold|In this group, shaping will be performed using only a reciprocating file, without coronal shaping and glide path preparation.
214454122|NCT06833515|OTHER|15K-type stainless-steel hand file|The operator prepared the glide path using a #15K-type stainless-steel hand file with push-pull motion. On sensing resistance, the file was withdrawn, recapitulation was performed with a #10K-type stainless-steel file, and debris was removed by irrigating the canals with 5% NaOCl. The operator repeated this procedure until the #15K-file reached the complete working length
214454123|NCT06838598|OTHER|OCT-BIO-KTA cohort|Dynamic full-field optical coherence tomography (D-FF-OCT) analysis of arterial catheter sections before microbiological analysis of catheter biofilm
214454124|NCT06835205|BEHAVIORAL|Tous Épanouis à l'École (TEAL Program)|The TEAL Program is a structured, five-session behavioral intervention targeting psychosocial skill development in children. Delivered by healthcare students in elementary school classrooms, the program includes interactive activities designed to improve communication, empathy, social proximity, and prosocial behaviors. The intervention aims to reduce bullying behaviors (victims and aggressors) and enhance classroom climate. Each session is guided by a detailed manual and includes active participation from students and their teachers.
214454125|NCT06835205|BEHAVIORAL|Standard Health Education Sessions|This intervention consists of five sessions on general health topics unrelated to bullying, such as nutrition, sleep hygiene, and physical activity. The sessions are facilitated by healthcare students as part of their Service Sanitaire training. These sessions provide a comparable structure and duration to the TEAL program but do not address bullying prevention.
214454126|NCT06830707|DEVICE|experimental group|The treatment comprised 5 robot-assisted gait training sessions over a 2-week period, followed by 10 lower limb Constraint Induced Movement Therapy(CIMT) sessions with a torque assisted exoskeleton.
214454127|NCT05975450|DRUG|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~\- Abatacept 125 mg subcutaneous weekly"
214694976|NCT02597023|DRUG|MitoQ|Mitoquinone pill, 20 mg/day
214694977|NCT02597023|DRUG|Placebo|Placebo pill with inert excipient, 1 time/day
214694978|NCT02963714|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
214694979|NCT02963714|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
215140591|NCT03007732|DRUG|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
215140592|NCT03007732|DRUG|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
215140593|NCT03007732|DRUG|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
215140594|NCT03007732|DRUG|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
215140595|NCT03007732|DRUG|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
215140596|NCT03007732|RADIATION|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
215140597|NCT05005429|DRUG|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
215140598|NCT04764799|PROCEDURE|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
215140599|NCT05929274|DEVICE|tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.
215140600|NCT05929274|DEVICE|sham tDCS|For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
215140601|NCT06060899|PROCEDURE|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
215140602|NCT06060899|PROCEDURE|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
214694980|NCT03264508|BEHAVIORAL|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
214694981|NCT03264508|BEHAVIORAL|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
214694982|NCT05048823|OTHER|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
214454131|NCT03039023|DIETARY_SUPPLEMENT|Choline Bitartrate|500mg choline bitartrate tablets
214454132|NCT03039023|OTHER|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
214454133|NCT03039023|OTHER|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
214454134|NCT03039023|DIETARY_SUPPLEMENT|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
214454135|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
214454136|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
214454137|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
214454138|NCT04926766|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
214454139|NCT04890041|DRUG|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
214454140|NCT06057649|OTHER|Effleurage Abdominal Massage|perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
214454141|NCT06333392|PROCEDURE|Total underwater colonoscopy|one grooup will be randomized to receive a total underwater colonoscopy
214454142|NCT06333392|PROCEDURE|Conventional colonoscopy|one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
214454143|NCT06850012|BEHAVIORAL|Meleis' Transition Theory-Based Educational Program|This intervention is a 7-week online educational program based on Meleis' Transition Theory, aimed at helping immigrant nurses understand and cope with migration challenges, improve social integration, manage stress, and enhance professional self-efficacy. The program will be divided into three groups (12-12-11 participants), and it will include interactive sessions, group discussions, and practical activities such as breathing exercises to promote active participation and engagement.
214694983|NCT05048823|OTHER|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
214694984|NCT00894413|DRUG|Tadalafil|20 mg once daily for 10 - 14 days
214694985|NCT00894413|OTHER|Placebo Pill|Placebo
214694986|NCT03112213|DRUG|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
214694987|NCT03112213|DRUG|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
214527276|NCT06721364|BEHAVIORAL|Suicide prevention treatment|"Intervention I:RAAHI RAAHI is a suicide literacy module that is specially designed to provide individuals with essential knowledge and skills by equipping them with tools to navigate the complexities of mental health and suicide prevention. This module aims to empower people to recognize signs of suicidal ideation, engage in empathetic communication through open discussion, combat stigma, and connect individuals in crisis with appropriate support and resources. The duration of the module will be of three hours.~Intervention II: safeTALK The \&#34;safeTalk\&#34; program is a psychoeducational initiative designed for suicide prevention among adolescents, consisting of a 4-hour workshop that incorporates presentations, videos, discussions, and questions.The workshop is designed according to the standard practices of safeTALK, to assist participants in (a) identifying warning signs of suicide; (b) Avoiding frequent impulses to overlook, dismiss, or avoid discussions about suicide."
215140603|NCT06359015|DRUG|Metformin|"Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance."
214454144|NCT05858671|OTHER|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
214454145|NCT05858671|OTHER|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
214454146|NCT02515110|RADIATION|External Beam Radiation Therapy|Undergo hypofractionated RNI
214454147|NCT02515110|OTHER|Questionnaire Administration|Ancillary studies
214454148|NCT02515110|OTHER|Laboratory Biomarker Analysis|Correlative studies
214454149|NCT06531928|OTHER|chest tube withdrawal|The Effect of Chest Tube Withdrawal on Patients' Anxiety Levels in Thoracic Surgery Cases Performed with Video-Assisted Thoracoscopic Surgery
214454150|NCT06324123|OTHER|Peacetil|Nutraceutical supplement Peacetil for a period of 2 months
214454151|NCT06848257|OTHER|Exercise|postural exercises
214454152|NCT06848933|OTHER|Test meal|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
214454153|NCT06848933|DEVICE|Each participant will consume the test meal when on Medtronic Minimed 780G and will consume test meal on Medtronic Minimed 780G on manual mode|After the intervention, blood glucose values will be documented from continued glucose measurement system for postprandial 5 hours,and compared in manual mode and auto mode
214454154|NCT06848933|DEVICE|Advanced hybrid closed loop system mode|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
214454155|NCT04163523|DRUG|Zanubrutinib|
214454156|NCT06850493|DIETARY_SUPPLEMENT|VLCKD (ketogenic diet)|diets prior to bariatric surgery
214454157|NCT06850493|DIETARY_SUPPLEMENT|VLCD (Very-low-calorie-diet)|diets prior to bariatric surgery
214454158|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
214454159|NCT06843850|DEVICE|regenerative endodontics|The effect of different irrigation solutions on lesion healing in regenerative endodontics will be compared.
214454160|NCT05341167|DEVICE|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
214454161|NCT05341167|DRUG|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
214454162|NCT06844435|OTHER|continuous renal replacement therapy|continuous renal replacement therapy during OLT in surgery room
214527277|NCT06721442|DRUG|Dapagliflozin (DAPA)|Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
215140604|NCT06359015|DRUG|Esomeprazole|40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
215140605|NCT06651541|DRUG|BZ371A|Formulation with the active ingredient
215140606|NCT06651541|DRUG|Placebo|Formulation without the active ingredient
215140607|NCT03096743|DIAGNOSTIC_TEST|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
215140608|NCT03096743|DIAGNOSTIC_TEST|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
215140609|NCT03096743|PROCEDURE|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
215140610|NCT03096743|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
215140611|NCT03096743|DIAGNOSTIC_TEST|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
215140612|NCT06494267|BEHAVIORAL|Experimental (Video-Assisted Self-Assessment on Nasogastric Tube Insertion)|Students in the experimental group will be videotaped while practicing and students will make self-evaluations.
215140613|NCT02700607|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
215140614|NCT02700607|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
215140615|NCT00558584|DEVICE|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
215140616|NCT00558584|DEVICE|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
215140617|NCT05640830|DRUG|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
215140618|NCT04458402|RADIATION|Hypofractionated WPRT|Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
215140619|NCT01244841|PROCEDURE|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
215140620|NCT01343394|BIOLOGICAL|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
215140621|NCT05536635|BEHAVIORAL|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
215140622|NCT02693366|OTHER|Bone marrow stem cell|Endovascular infusion of bone marrow derived cells in both renal arteries.
215140623|NCT00846976|DRUG|Bicalutamide|200mg daily
215140624|NCT01141517|BEHAVIORAL|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
215140625|NCT05609292|DEVICE|observational|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
215140626|NCT00570830|DEVICE|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
215140627|NCT02608684|DRUG|Pembrolizumab|Pembrolizumab IV solution
215140628|NCT02608684|DRUG|Gemcitabine|Gemcitabine IV solution
214454163|NCT06845449|PROCEDURE|tenting screw combined with particulate autogenous|In Tenting screw cases, the screws will be placed in suitable positions and depths, blocks will be crushed into particulates which will then be mixed with equal amount of bovine particles. the mixture will be applied to the recipient site all around the tenting screws a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures.
214454164|NCT06845449|PROCEDURE|autogenous ring block grafts combined with xenogenic bone|In the non screw group, the blocks will be adapted to fit the recipient sites and secured to the alveolar bone using titanium bone fixation screws. Following the placement of the blocks, bovine particles will be applied over the graft and into any remaining gaps between the block and the recipient site, a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures
214694988|NCT02390336|OTHER|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
215140629|NCT02608684|DRUG|Cisplatin|Cisplatin IV solution
215140630|NCT04029636|OTHER|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
215140631|NCT02984813|DRUG|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
215140632|NCT02984813|DRUG|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
215140633|NCT02984813|DRUG|Placebo|No active ingredients
215140634|NCT06311487|BEHAVIORAL|Fasted-AM|Participants will engage in aerobic exercise within 4 hours of waking up, following a \>10h overnight fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~08:00, \~13:00, and \~19:00. Plasma metabolite samples will be drawn immediately pre- and post- exercise.
215140635|NCT06311487|BEHAVIORAL|Fed-AM|Participants will engage in exercise within 4 hours of waking up, approximately 1h after consuming breakfast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
215140636|NCT06311487|BEHAVIORAL|Fasted-PM|Participants will engage in exercise between 8-12 hours after waking up, following a \~10h fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00 and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
215140637|NCT06311487|BEHAVIORAL|Fed-PM|Participants will engage in exercise between 8-12 hours after waking up, approximately 1h after consuming dinner across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
215140638|NCT03819192|DIAGNOSTIC_TEST|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
215140639|NCT03819192|DIAGNOSTIC_TEST|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
215140640|NCT03819192|DIAGNOSTIC_TEST|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
215140641|NCT01203202|DRUG|Clomipramine|15mg and 30mg on demand
215140642|NCT00136396|DRUG|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
215140643|NCT03544684|BEHAVIORAL|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
215140644|NCT06120374|RADIATION|Radiotherapy|"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
215140645|NCT06120374|DRUG|Chemotherapy|For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
215140646|NCT06120374|DRUG|Immunotherapy|For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
215140647|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
215140648|NCT00689858|DRUG|Cilostazol, Ginkgo biloba and placebo|dosing time
215140649|NCT05233306|DEVICE|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
215140650|NCT04464486|OTHER|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
215140651|NCT00312429|PROCEDURE|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
215140652|NCT04833582|DRUG|ZN-c3|ZN-c3 is an investigational drug.
215140653|NCT04833582|DRUG|Gemcitabine|Gemcitabine is an approved drug
215140654|NCT00072709|DRUG|TCH346|
214454165|NCT06844942|DIAGNOSTIC_TEST|vessel Fractional Flow Reserve|Optical coherence tomography and vessel fractional flow reserve evaluation of coronary arteries with intermediate to severe stenosis.
214454166|NCT06846151|DEVICE|retinal functional imaging|this is a proof of concept study
214454167|NCT06841315|DRUG|varegacestat|experimental intervention
214454168|NCT06848374|DRUG|40 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
214454169|NCT06848374|DRUG|80 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
214454170|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
214454171|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
214454172|NCT06848569|DRUG|Sintilimab in combination with AVD chemotherapy|Sintilimab in combination with AVD chemotherapy treating classical Hodgkin lymphoma
214454173|NCT05048667|DEVICE|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
215140655|NCT04495244|DIAGNOSTIC_TEST|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
214454174|NCT05048667|DRUG|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
214454175|NCT05048667|OTHER|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
214454176|NCT05048667|OTHER|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
214454177|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
214454178|NCT06849817|OTHER|Diet - higher protein|Beef consumption 7 times per week (1 serving per day; 25 grams protein per serving (\~100 grams beef) as part of a higher protein diet (1.6 g protein/kg body weight)
215140656|NCT01487798|DRUG|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
215140657|NCT01487798|DRUG|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
215140658|NCT05270720|BIOLOGICAL|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
215140659|NCT01108016|BEHAVIORAL|Videoconferencing support group|
215140660|NCT00948376|GENETIC|IFT80 screening|Natural History
215140661|NCT02746653|DEVICE|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
215140662|NCT02252003|OTHER|Pain scales testing|
215140663|NCT00670254|DRUG|Placebo|Application is identical to experimental arm
215140664|NCT00670254|DRUG|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
215140665|NCT05176405|BEHAVIORAL|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
215140666|NCT05176405|BEHAVIORAL|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
215140667|NCT05251168|PROCEDURE|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
215140668|NCT05251168|PROCEDURE|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
215140669|NCT02168244|OTHER|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
214454179|NCT06849817|BEHAVIORAL|Physical activity and resistance training|150 minutes of physical activity including strength training 3 times per week
214454180|NCT04048278|DRUG|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
214454181|NCT04048278|DRUG|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
214454182|NCT04266951|BEHAVIORAL|Singstrong:|Group singing and breathing control training
214454183|NCT05009004|BEHAVIORAL|text messages to support medication adherence|text messages to support medication adherence
214454184|NCT05256706|DIAGNOSTIC_TEST|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
214454185|NCT05256706|OTHER|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
214527278|NCT06721429|OTHER|dual task exercise group|Dual task exercise group Patients in the dual-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training. In addition, cognitive exercise training will be incorporated into each session, performed concurrently with the conventional physiotherapy. The cognitive exercises provided in this study are structured to target areas such as memory, verbal fluency, executive functions, calculation, and attentioN Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
214527279|NCT06721429|OTHER|single task group|Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
215140670|NCT02168244|OTHER|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
215140671|NCT04011046|DEVICE|Stent|
215140672|NCT00157677|PROCEDURE|D-dimer testing|Uniform D-dimer use
215140673|NCT00157677|PROCEDURE|D-dimer testing|Selective D-Dimer use
215140674|NCT01470521|BIOLOGICAL|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
215140675|NCT01470521|BIOLOGICAL|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
215140676|NCT04295720|DEVICE|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
215140677|NCT04818853|OTHER|Observation to monitor patients for these infections|We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
215140678|NCT02456415|DEVICE|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
215140679|NCT06102005|DRUG|Lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215140680|NCT06102005|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215140681|NCT05642052|DIETARY_SUPPLEMENT|low carb diet|low carb meals will be 50% less carbs than the regular meals
215140682|NCT05642052|DIETARY_SUPPLEMENT|Regular diet|Regular diet
215140683|NCT05552937|DRUG|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
215140684|NCT00752349|PROCEDURE|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
215140685|NCT01407432|DRUG|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
215140686|NCT01407432|DRUG|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
215140687|NCT05458115|PROCEDURE|Liver resection|Patient underwent hepatic R0 resection within a week
215140688|NCT02461641|OTHER|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
215140689|NCT02461641|OTHER|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
215140690|NCT02461641|OTHER|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
215140691|NCT04400201|DRUG|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
215140692|NCT04400201|DRUG|Propofol|Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
215140693|NCT00000197|DRUG|Propranolol|
215140694|NCT04214938|OTHER|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
215140695|NCT00512915|DEVICE|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
215140696|NCT06009211|OTHER|QueaseEase|Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
215140697|NCT03614650|BIOLOGICAL|engineered immune cells|Engineered immune effector cells (EIE)
214454186|NCT06248476|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation is non-invasive stimulation technique which modifies cortical excitability through forming magnetic field
214454187|NCT06309745|PROCEDURE|retroperitoneal lymph node dissection|retroperitoneal lymph node dissection
214527280|NCT06887426|DRUG|Cladribine|To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
214527281|NCT06898788|DRUG|Visbiome|"Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus.~Participants will be instructed to consume the powder mixed in water."
214527282|NCT06898788|DRUG|Placebo|Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).
214527283|NCT04957251|PROCEDURE|anterior approach to the hip|anterior hip hemiarthroplasty
215140698|NCT00755183|DRUG|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
215140699|NCT00755183|DRUG|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
215140700|NCT01547078|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
215140701|NCT01547078|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
215140702|NCT03016728|BEHAVIORAL|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
215140703|NCT00148317|DRUG|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
215140704|NCT00148317|DRUG|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
215140705|NCT00148317|DRUG|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
214454188|NCT06309745|DRUG|Carboplatin AUC10|Carboplatin AUC10
214454189|NCT06445270|BEHAVIORAL|GDM Prevention Program|Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
214454190|NCT04036448|DRUG|REVLIMID®|REVLIMID®
214527284|NCT04957251|PROCEDURE|posterior approach to the hip|posterior hip hemiarthroplasty
214527285|NCT05223647|PROCEDURE|Thoracic radiotherapy|30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
214527286|NCT05223647|DRUG|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
214527287|NCT06313268|DRUG|Bevacizumab Biosimilar MB02|5 mg/kg to 15 mg/kg in combination with chemotherapy.
215140706|NCT00148317|DRUG|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
215140707|NCT00148317|DRUG|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
215140708|NCT00755664|DIETARY_SUPPLEMENT|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
215140709|NCT02767414|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
214527288|NCT06900998|DRUG|Nimodipine|Nimodipine will be administered orally beginning on the evening prior to the study lab session. 90mg doses will be administered at 6:00pm, 12:00am, 6:00am, and 12:00pm.
214527289|NCT06905561|DRUG|Diclofenac Sodium Gel|Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.
214527290|NCT06905561|OTHER|Placebo gel|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
214527291|NCT05344352|DIETARY_SUPPLEMENT|Multistrain Probiotic|8-week daily administration
214527292|NCT05344352|OTHER|Placebo|8-week daily administration
214527293|NCT06620809|DRUG|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）
215140710|NCT02767414|DEVICE|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
215140711|NCT02767414|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
215140712|NCT06118632|OTHER|Observational|Observational
215140713|NCT06271577|DEVICE|AliveCor 12-lead ECG|The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
215140714|NCT04254458|DIAGNOSTIC_TEST|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
215140715|NCT04652752|DEVICE|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
215140716|NCT04349397|BEHAVIORAL|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
214454191|NCT06389656|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.
214454192|NCT06389656|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
214454193|NCT06487364|OTHER|Rehabilitation|A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
214454194|NCT04631094|OTHER|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
214454195|NCT04631094|OTHER|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
214454196|NCT04631094|OTHER|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
214454197|NCT04631094|OTHER|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
214454198|NCT05956028|PROCEDURE|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
214454199|NCT05956028|PROCEDURE|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
214454200|NCT06039865|BEHAVIORAL|Immediate Intervention|Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
214454201|NCT06039865|BEHAVIORAL|Waitlist control|Participants only receive usual care from the sleep center.
214454202|NCT04410042|DRUG|Tranexamic Acid|Given IV
214527294|NCT06620809|DRUG|A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles placebo(5×10\^9 particles）
214527295|NCT05963854|OTHER|Survey Curbside|Observational. Waste will be collected on specific days for 2 consecutive weeks and surveys will be completed to coincide with the waste collections.
214527296|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
214527297|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
214694989|NCT02390336|OTHER|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
214694990|NCT04719338|DIAGNOSTIC_TEST|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
215140717|NCT04377893|DEVICE|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
215140718|NCT00124943|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
214454203|NCT04410042|OTHER|0.9% sodium chloride|Given IV
214454204|NCT03898986|BIOLOGICAL|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
214454205|NCT03898986|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
214454206|NCT03374319|PROCEDURE|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
214454207|NCT03850678|DEVICE|Hearing Aid|Hearing Aid
214454208|NCT05860751|PROCEDURE|Dry Needling with electrical stimulation|Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
214454209|NCT05971888|BEHAVIORAL|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
214454210|NCT03720795|BEHAVIORAL|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
214454211|NCT06849453|BEHAVIORAL|Exercise snacks group|Exercise snacks on the stairs for 8 weeks.
214454212|NCT06849453|BEHAVIORAL|Sprint interval training group|Sprint interval training on the stairs for 8 weeks.
214454213|NCT06838611|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair of the tricuspid valve for the treatment of severe tricuspid valve regurgitation.
214454214|NCT04022616|OTHER|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
214454215|NCT05493891|OTHER|Visual analogue scale (VAS)|VAS is a reliable and valid method for assessing the intensity of low back pain (LBP)
214454216|NCT05493891|DEVICE|Pressure Biofeedback Unit (PBU)|PBU is a valid and reliable instrument for measuring the maximal voluntary isometric contraction of both lumbar multifidus and transversus abdominis muscles (core muscle strength)
214454217|NCT06022003|DRUG|AzaCITIDine Oral Tablet|AML study treatment
214454218|NCT06022003|DRUG|Xospata|R/R FLT3-mutated AML standard treatment
214527298|NCT06926153|OTHER|TABAPSY|"The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.~The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur"
214527299|NCT06926153|OTHER|Usual Care|Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)
215140719|NCT00905944|OTHER|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
214527300|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
215140720|NCT01896167|OTHER|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
215140721|NCT01896167|OTHER|Placebo|Inhalation of atmospheric air
215140722|NCT04238923|DRUG|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
215140723|NCT00346580|DRUG|Nelfinavir|
215140724|NCT02187419|OTHER|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
215140725|NCT05430399|DRUG|utidelone|Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
215140726|NCT05430399|DRUG|docetaxel|Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
215140727|NCT00508794|BEHAVIORAL|Yoga Group|3 sessions of yoga each week for 6 weeks.
215140728|NCT00508794|BEHAVIORAL|Stretching Control Group|3 sessions of stretching each week for 6 weeks
215140729|NCT00508794|BEHAVIORAL|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
215140730|NCT00508794|OTHER|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
214454219|NCT01492751|BEHAVIORAL|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
214454220|NCT01492751|PROCEDURE|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
214454221|NCT01492751|RADIATION|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
214527301|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
214527302|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
214527303|NCT04800978|BIOLOGICAL|BAVC-C+Durvalumab|"* Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion"
214527304|NCT06923007|DEVICE|Vagus Nerve Stimulation|After randomization, VNS is performed for 6 months. The stimulation parameters will be 30 Hz and 250 μs, the maximum tolerable current is selected according to the patients' adverse reactions (dizziness, palpitations, abnormal sensations, local pain, etc.), and the recommended treatment intensity is 0.8 mA.
214527305|NCT06923007|DEVICE|Sham Vagus Nerve Stimulation|After randomization, sham vagus nerve stimulation VNS treatment is performed for 6 months. The stimulation parameters will be 30 Hz, 250 μs, and the treatment intensity will be 0 mA.
215140731|NCT01213563|DRUG|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
215140732|NCT01213563|DRUG|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
215140733|NCT05784896|DIAGNOSTIC_TEST|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of \>96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
215140734|NCT04743843|DEVICE|Omnyx Dynamyx Software|Digital pathology image management and viewing software.
215140735|NCT06004999|OTHER|Whole body vibration|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program on the vibration platform will be applied to the 1st group.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
215140736|NCT06004999|OTHER|The exercise program on flat ground without a vibration platform|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program will be applied to the group.~The exercise program will be applied to the 2nd group (controls) on flat ground without a vibration platform.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
215140737|NCT04971161|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
215140738|NCT04971161|DRUG|Placebo|One topical application with a syringe
215140739|NCT04730700|PROCEDURE|Radiofrequency Ablation with MEE|RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
215140740|NCT04730700|BEHAVIORAL|Conventional Medical Management|Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
214454222|NCT01492751|RADIATION|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
214454223|NCT04415424|BIOLOGICAL|4CMenB vaccine|A four-component meningococcal B vaccine
214454224|NCT04415424|OTHER|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
214454225|NCT06545175|DRUG|Intracochlear application of VSF1.01|During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
214454226|NCT03891667|DRUG|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
214454227|NCT03595293|DEVICE|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
214454228|NCT03595293|DEVICE|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
214454229|NCT03302494|DEVICE|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
214454230|NCT03302494|DEVICE|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
214454231|NCT03799991|BEHAVIORAL|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
214454232|NCT03799991|BEHAVIORAL|Active control|Strength and flexibility exercises that do not involve head movements.
214454233|NCT00179868|BEHAVIORAL|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~1. Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~2. Acute GVHD \> grade II defined according to the Seattle criteria~3. VOD- defined according to the modified Seattle criteria"
214454234|NCT05937321|BEHAVIORAL|Share plus intervention|"Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR"
214454235|NCT05937321|BEHAVIORAL|Control group|Diabetes self-management education materials
214694991|NCT03054077|OTHER|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
214527306|NCT02475499|DRUG|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527307|NCT02475499|DRUG|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527308|NCT02475499|DRUG|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527309|NCT02475499|DRUG|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527310|NCT02475499|DRUG|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
215140741|NCT06329817|PROCEDURE|Incidence of regurgitation in two different position.|Preventing aspiration pneumonia in general anaesthesia in two different position supine v/s semi - Fowler
215140742|NCT06366217|DEVICE|MydCombi Device|ophthalmic spray
215140743|NCT06366217|DRUG|MydCombi Drug|Tropicamide 1% and phenylephrine HCl 2.5%
215140744|NCT04196777|BEHAVIORAL|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
215140745|NCT06132659|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
215140746|NCT06132659|OTHER|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
215140747|NCT06224205|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
215140748|NCT02939287|DRUG|o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1|Add aprepitant to anti-emetic regimen
215140749|NCT02939287|DRUG|Olanzapine10 mg orally daily on Days -1,0,+1 and +2|add olanzapine to anti-emetic regimen
215140750|NCT02939287|DRUG|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
214527311|NCT02475499|DRUG|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527312|NCT02475499|DRUG|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
214527313|NCT05969119|DRUG|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
214527314|NCT05969119|DRUG|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
214527315|NCT04853238|OTHER|Prospective observational cohort study|Prospective observational cohort study. No study treatment was administered in this study.
214527316|NCT04688554|DIAGNOSTIC_TEST|fMRI and DTI|Neurologic imaging correlates
214527317|NCT04688554|BEHAVIORAL|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
214527318|NCT04688554|BEHAVIORAL|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
214527319|NCT04688554|BEHAVIORAL|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
214527320|NCT05652387|BEHAVIORAL|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
214527321|NCT06212622|DRUG|Alfentanil|Subcutaneous injection
215140751|NCT02903771|DRUG|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
215140752|NCT02903771|DRUG|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
215140753|NCT06268236|OTHER|Electroacupuncture|Electro-acupuncture at Shuigou and Yintang.
215140754|NCT06268236|OTHER|Sham electroacupuncture|Sham-EA at sham-Shuigou and sham-Yintang.
215140755|NCT05292794|DEVICE|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
215140756|NCT04033926|DRUG|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
215140757|NCT04033926|DRUG|Placebo|Subcutaneous injection for 16 weeks
215140758|NCT04231773|DRUG|Nitric Oxide|40 parts per million dosage
215140759|NCT04231773|DRUG|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
215140760|NCT03299556|OTHER|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
215140761|NCT00287105|DRUG|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
215140762|NCT05994612|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
215140763|NCT05994612|BEHAVIORAL|Services as Usual|Participants will receive services that they would normally receive in the community.
215140764|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
215140765|NCT00758732|DRUG|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
215140766|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
215140767|NCT00758732|DRUG|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
215140768|NCT02309346|DRUG|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
215140769|NCT04172181|PROCEDURE|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
214454236|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
215140770|NCT03520998|DRUG|GRF6019|GRF6019 for IV infusion
215140771|NCT01473888|DRUG|T89(Dantonic)|capsule, 225mg B.I.D.
214454237|NCT04513626|DRUG|DORAVIRINE 100 MG [Pifeltro]|Immediate switch
214454238|NCT04774003|DRUG|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
214454239|NCT04774003|DRUG|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
214454240|NCT04774003|DRUG|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
214454241|NCT05603234|BEHAVIORAL|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
214454242|NCT06071312|BIOLOGICAL|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
214454243|NCT06071312|BIOLOGICAL|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
214454244|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
214454245|NCT00534469|BIOLOGICAL|aldesleukin|
215140772|NCT05207488|DIETARY_SUPPLEMENT|Fructooligosaccharides (FOS)|FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
215140773|NCT05207488|BEHAVIORAL|Exercise|During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
215140774|NCT05207488|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
215140775|NCT04961775|DRUG|Perflubutane Microspheres for Injection|16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.
214454246|NCT00534469|BIOLOGICAL|filgrastim|
214454247|NCT00534469|DRUG|busulfan|
214454248|NCT00534469|DRUG|cytarabine|
214454249|NCT00534469|DRUG|etoposide|
214454250|NCT00534469|DRUG|idarubicin|
214454251|NCT00534469|PROCEDURE|autologous hematopoietic stem cell transplantation|
214454252|NCT00534469|PROCEDURE|bone marrow transplantation|
214454253|NCT00534469|PROCEDURE|peripheral blood stem cell transplantation|
214454254|NCT00534469|RADIATION|total-body irradiation|
214454255|NCT04622943|BEHAVIORAL|firearms safety|interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety
214454256|NCT04622943|BEHAVIORAL|nutrition|interactive and engaging website with videos and educational games to teach children about nutrition and wellbeing
214454257|NCT05873504|DEVICE|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
214454258|NCT05873504|DEVICE|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
214454259|NCT05717907|DEVICE|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
214454260|NCT05977270|DEVICE|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
214454261|NCT06469398|DEVICE|Cutera Laser System|Subjects will receive up to 6 laser treatments
214454262|NCT05858008|BEHAVIORAL|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
215140776|NCT06319014|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
214454263|NCT06212440|DIAGNOSTIC_TEST|Radioactive Isotope (RI) Mapping|Administered via peritumoral or subareolar injection for sentinel lymph node detection.
214454264|NCT06212440|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG-F) Mapping|Administered via peritumoral or subareolar injection, detected using near-infrared fluorescence imaging.
214454265|NCT06212440|DIAGNOSTIC_TEST|Vital Dye Mapping|Administered via peritumoral or subareolar injection for intraoperative visualization of lymphatic drainage pathways.
214454266|NCT03952351|RADIATION|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
214454267|NCT05076708|OTHER|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
214454268|NCT03159702|DRUG|Evomela|140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
214454269|NCT03159702|DRUG|Fludarabine|40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
214454270|NCT03159702|RADIATION|Total Body Irradiation|200 cGy on Day: -1
214527322|NCT06212622|DRUG|Oxycodone|Oral solution
214694992|NCT01811849|DRUG|Insulin LISPRO|
214694993|NCT01811849|DRUG|Insulin LISPRO|
214694994|NCT01811849|DRUG|Insulin LISPRO|
214694995|NCT04091282|OTHER|No intervention|No intervention
214454271|NCT05110443|OTHER|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
215140777|NCT01988155|OTHER|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
215140778|NCT01988155|OTHER|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
215140779|NCT06132672|BEHAVIORAL|Navigators (peer navigator) training|The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
215140780|NCT06132672|BEHAVIORAL|delayed-intervention|Those in the delayed-intervention group will be trained in year 5
215140781|NCT06071247|OTHER|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
215140782|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose A - single-dose intravenous infusion
215140783|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose B - single-dose subcutaneous injection
214454272|NCT04751929|DRUG|Abemaciclib|Taken orally 2x daily
214454273|NCT04751929|DRUG|Atezolizumab|Intravenously Day 1 of 21 day cycle
214454274|NCT04115540|DEVICE|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
214454275|NCT06214949|DEVICE|Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over 3-4 weeks. Specifically, the active or sham treatments will be conducted \~5 times a week during the treatment phase of the study. The treatment protocol parameters (stimulus location, frequency, duration, and intensity) will be derived from the PrTMS software algorithm which incorporates clinical inputs from neurocognitive surveys and quantitative EEG analysis. The mechanical parameters will adhere to the recommended PrTMS parameters for pain treatment: figure of 8 coil that produces biphasic stimulatory pulses to the central zone cortex, frontal zone cortex, Broca's area, and frontal pre-cortex areas at a stimulation depth of 2 cm. Treatment parameters will be unique to each participant but will remain within known ranges. The frequency will be between 8 and 13 Hz, at an amplitude of 20-30% (approximately 30-40% of RMT), and about 3200-7200 pulses per session. Since parameters are specific to each participant, treatment settings will vary.
214454276|NCT06214949|DEVICE|Sham Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over the course of 3-4 weeks. More specifically, the active or sham treatments will be conducted roughly 5 times a week during the course of the treatment phase of the study. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
214454277|NCT01383512|DEVICE|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
214527323|NCT04137978|DRUG|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
214527324|NCT04137978|DRUG|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
214527325|NCT06271083|BEHAVIORAL|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
215140784|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose C - single-dose subcutaneous injection
215140785|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose D - single-dose subcutaneous injection
215140786|NCT00416910|BIOLOGICAL|Filgrastim|
215140787|NCT00416910|DRUG|Fludarabine|
215140788|NCT00416910|DRUG|Cyclophosphamide|
215140789|NCT00416910|DRUG|Mitoxantrone|
215140790|NCT05738642|DRUG|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
215140791|NCT00910650|BIOLOGICAL|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
215140792|NCT00910650|DRUG|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
215140793|NCT03367793|DEVICE|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
215140794|NCT03367793|DEVICE|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
215140795|NCT03367793|DEVICE|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
215140796|NCT03071588|DEVICE|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
215140797|NCT03071588|DEVICE|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
215140798|NCT02435992|DRUG|RPC1063|
215140799|NCT02435992|DRUG|Placebo|
215140800|NCT05216549|OTHER|Water-based exercise|8 weeks x 2 times per week for 45 min
215140801|NCT05216549|OTHER|Land-based exercise|8 weeks x 2 times per week for 45 min
215140802|NCT00260533|DRUG|atomoxetine|Flexible dose, up to 50 mg per day
215140803|NCT00260533|DRUG|placebo|placebo (matching to atomoxetine)
215140804|NCT00566319|BEHAVIORAL|PREPARE with pedometer|Structured educational programme with pedometer use
215140805|NCT00566319|BEHAVIORAL|PREPARE|Structured educational programme
215140806|NCT05512884|BEHAVIORAL|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
215140807|NCT04106492|DRUG|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
215140808|NCT01459211|DRUG|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
215140809|NCT01761877|DRUG|Sulindac|
215140810|NCT05087706|DRUG|Pyrotinib|Pyrotinib 400mg qd po
215140811|NCT05087706|DRUG|Bicalutamide|Bicalutamide was administered orally at a daily dose of 50 mg
215140812|NCT05087706|DRUG|Leuprorelin|Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
215140813|NCT04514185|DEVICE|Passive industrial exoskeleton for the upper limb|The goal is to compare the human response to the simulated industrial tasks
215140814|NCT04514185|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
215140815|NCT03542877|DRUG|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
215140816|NCT01424384|DRUG|Citalopram|Neurophysiological testing.
215140817|NCT01424384|DRUG|GSK424887|Neurophysiological testing
214454278|NCT01383512|OTHER|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
215140818|NCT01424384|DRUG|Plactebo To Match|Neurophysiological testing
215140819|NCT04965818|DRUG|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
214454279|NCT05441969|OTHER|No intervention/expousure|No interventions/expousure since this is an observational study.
214454280|NCT05574946|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
214454281|NCT05774548|OTHER|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
214527326|NCT06271083|BEHAVIORAL|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
214527327|NCT02096809|PROCEDURE|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
214527328|NCT02096809|DEVICE|Cochlear Baha BI300/BA400 Implant System|
214527329|NCT02956122|BIOLOGICAL|GLASSIA|GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
214527330|NCT02956122|DRUG|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
214527331|NCT02956122|BIOLOGICAL|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
214527332|NCT04744805|OTHER|face mask or not|long term face mask wear
215140820|NCT01310777|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
215140821|NCT01310777|DRUG|Brinzolamide 1% ophthalmic suspension|
215140822|NCT01310777|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
215140823|NCT02195102|DEVICE|Transcatheter aortic valve Replacement|
215140824|NCT03857854|DRUG|Pirfenidone|treatment group
214454282|NCT05774548|OTHER|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
214454283|NCT05429125|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
214454284|NCT05429125|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
214454285|NCT03846167|DRUG|Imaging Drug FluorThanatrace (FTT)|\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
214454286|NCT03641092|BEHAVIORAL|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
214454287|NCT03641092|BEHAVIORAL|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
214454288|NCT04336644|DEVICE|BodyGuardian Mini Plus|The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
214527333|NCT00300963|DRUG|Talnetant|
214694996|NCT00218036|DRUG|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
215140825|NCT03857854|DRUG|Placebos|placebo group
215140826|NCT03466814|OTHER|Non-Interventional|Non-Interventional
215140827|NCT01795677|DRUG|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
215140828|NCT04337645|PROCEDURE|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
215140829|NCT05962060|OTHER|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
215140830|NCT05962060|OTHER|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
215140831|NCT06430970|DEVICE|endoscopy|upper and lower endoscopy
215140832|NCT00994513|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|1200 mg/day
215140833|NCT00994513|DIETARY_SUPPLEMENT|Placebo|1200 mg/day
215140834|NCT00043316|DRUG|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
215140835|NCT02203396|DRUG|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
214527334|NCT01974453|RADIATION|Radiation dose|Radiation dose adsorbed by operators
214527335|NCT04082481|DRUG|TAK-988|TAK-988 tablets.
214527336|NCT04082481|DRUG|TAK-988 Placebo|TAK-988 placebo-matching tablets.
215140836|NCT03697252|DRUG|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
215140837|NCT03697252|DRUG|Placebo Capsules|Placebo Capsules
215140838|NCT01713920|DRUG|SEVIKAR|
215140839|NCT03817216|DEVICE|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
214454289|NCT05490290|OTHER|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
214454290|NCT05590312|OTHER|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
214454291|NCT03269136|DRUG|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
214454292|NCT03269136|DRUG|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
214454293|NCT03269136|DRUG|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
214454294|NCT03269136|DRUG|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
214454295|NCT06439901|OTHER|Screening|A first step to identify and recruit people eligible for screening,
214454296|NCT06439901|OTHER|Inclusion|A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
214454297|NCT06439901|OTHER|Chest CTscan and follow-up|A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
214454298|NCT06193525|DRUG|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
214454301|NCT04456517|DRUG|Ranolazine|500 mg tablet
214454302|NCT04456517|DRUG|Placebo|Ranolazine-matched placebo tablet
214454303|NCT03543202|DRUG|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
214454304|NCT03543202|DRUG|local infiltration anesthesia|will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
214454305|NCT03543202|DRUG|Intravenous patient controlled analgesia|will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
214454306|NCT05999084|DRUG|Anti-amyloid Monoclonal Antibodies (mAbs)|Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
214454307|NCT05999084|COMBINATION_PRODUCT|Standard of Care|The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
214454308|NCT04376242|BEHAVIORAL|use of virtual reality|The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
214454309|NCT04376242|BEHAVIORAL|use of standard technology|the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
214454310|NCT03485469|BEHAVIORAL|Hypnosis|"There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
214454311|NCT03485469|BEHAVIORAL|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
214454312|NCT04055090|GENETIC|Long-Term Follow-Up of Patients who Received Engensis (VM202)|No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
214454313|NCT04055090|DRUG|Long-Term Follow-Up of Patients who Received Placebo|No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
215140840|NCT02878031|DRUG|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
215140841|NCT00488371|BIOLOGICAL|Pneumococcal Conjugated Vaccine (Prevnar®)|
215140842|NCT03835195|OTHER|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
215140843|NCT03835195|OTHER|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
215140844|NCT01697917|OTHER|Total Gastrectomy or Proximal Gastrectomy|
215140845|NCT02124837|BEHAVIORAL|Park walk during lunch break|
215140846|NCT02124837|BEHAVIORAL|Relaxation during lunch break|
215140847|NCT06296069|OTHER|exergame-based cognitive-motor training on an unstable surface|"The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side."
215140848|NCT06296069|OTHER|exergame-based cognitive-motor training on an stable surface|"The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces."
215140849|NCT02281916|DRUG|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
215140850|NCT02383576|OTHER|No Intervention|No intervention administered in this study.
215140851|NCT06035159|BEHAVIORAL|online psychotherapy|6 modules
215140852|NCT04081493|OTHER|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
215140853|NCT04150614|DRUG|Granisetron Transdermal Patch|Antiemetic
215140854|NCT04150614|DRUG|Intravenous Dexamethasone|Antiemetic
215140855|NCT04150614|DRUG|Ondansetron|ondansetron
215140856|NCT06329440|DIAGNOSTIC_TEST|Ultrasonographic measurement of diaphragm thickness|Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
215140857|NCT03042689|DRUG|Regorafenib|Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
215140858|NCT06486987|OTHER|Constraint induced movement therapy delivered by televideo|In-home Constraint induced movement therapy delivered by a therapist participating by televideo
215140859|NCT04711850|DRUG|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
214694997|NCT00218036|DRUG|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
215140860|NCT05683028|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
215140861|NCT05683028|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
214694998|NCT00218036|DRUG|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
214694999|NCT00218036|DRUG|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
214695000|NCT00218036|DRUG|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
215140862|NCT06527469|OTHER|PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP|Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
215140863|NCT01379898|DRUG|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
215140864|NCT01379898|DRUG|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
214454314|NCT03673709|BEHAVIORAL|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
214454315|NCT03085147|DRUG|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
214454316|NCT05521776|PROCEDURE|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
214454317|NCT03888170|OTHER|No intervention|No intervention
214454318|NCT04286490|OTHER|Prone position|Abdomen suspension in prone position
214454319|NCT04721912|DRUG|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
214454320|NCT02643498|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
214454321|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
214454322|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
214454323|NCT06013345|DRUG|Remimazolam|analgosedation without secured airway
214454324|NCT06013345|DRUG|Propofol|analgosedation with secured airway
214454325|NCT06013345|DRUG|Propofol|TIVA with secured airway
214454326|NCT05282173|BEHAVIORAL|Siyakhana CHW Training|Please see arm description.
214527337|NCT03238456|BEHAVIORAL|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
214527338|NCT03157492|BEHAVIORAL|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
214527339|NCT03157492|BEHAVIORAL|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
214527340|NCT00138918|BIOLOGICAL|OGX-011|See Detailed Description, Treatment Plan
215140865|NCT02685969|PROCEDURE|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
215140866|NCT02439723|DRUG|Regorafenib|
215140867|NCT04686474|DRUG|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
215140868|NCT00927108|OTHER|Progenitor Stem Cell Culture|
215140869|NCT00774046|DRUG|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
215140870|NCT00774046|DRUG|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
215140871|NCT00774046|DRUG|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
215140872|NCT00274586|DRUG|Aggrenox® modified release capsules|
215140873|NCT00274586|DRUG|Aggrenox® modified release capsules matching placebo|
215140874|NCT03773640|DEVICE|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
215140875|NCT03773640|DRUG|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
214454327|NCT05184335|DRUG|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
214454328|NCT05184335|OTHER|Placebo|RP5063 matching Placebo
214454329|NCT02653755|DEVICE|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
214454330|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
214454331|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
214454332|NCT06657703|DRUG|HC022|Administered as specified in the treatment arm
214527341|NCT02854839|BIOLOGICAL|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
214454333|NCT06657703|DRUG|Placebo|Administered as specified in the treatment arm
215140876|NCT03715556|DRUG|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
215140877|NCT03715556|DRUG|0.9% physiological solution|Administration of 0.9% physiological solution.
214454334|NCT06312696|OTHER|SMT|"SMT will be provided by a licensed chiropractor with at least 5 years' experience.~Treatment will last 15 to 20 minutes each and include a brief history and examination of the cervical spine. SMT will consist of low velocity, variable amplitude spinal mobilization to the cervical spine - Maitland grades 3 or 4. Spinal segments will be determined by the chiropractor using manual palpation and the patients' response to care. Drop-table or instrument-assisted SMT will not be allowed."
214454335|NCT06312696|OTHER|Light Massage|Light Massage will be provided as a pseudo-sham intervention to control for time, attention, and touch by a licensed chiropractor with at least 5 years' experience to control for touch and is intended to be delivered gentler and shorter than recommended for therapeutic massage.
214527342|NCT02364505|BEHAVIORAL|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
214527343|NCT02364505|BEHAVIORAL|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
214527344|NCT02176356|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
214527345|NCT02176356|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
214527346|NCT02176356|DEVICE|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
214527347|NCT02176356|DEVICE|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
214527348|NCT02176356|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
215140878|NCT00079469|BEHAVIORAL|smoking cessation intervention|
215140879|NCT00079469|DRUG|bupropion hydrochloride|
215140880|NCT05672758|BEHAVIORAL|Sprint training|One-year cycle including specific sprint-oriented athletic training
215140881|NCT05672758|BEHAVIORAL|Endurance training|One-year cycle including specific endurance-oriented athletic training
215140882|NCT05672758|BEHAVIORAL|Recreational Training|One year of nonspecific recreational training
215140883|NCT04069234|DRUG|Ticagrelor|ticagrelor 60 mg BID for 30 days
215140884|NCT04069234|DRUG|Clopidogrel|clopidogrel 75mg OD for 30 Days
215140885|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
215140886|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
215140887|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
215140888|NCT05354596|PROCEDURE|STRICT LUNG|Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
215140889|NCT05354596|PROCEDURE|STAR LUNG|Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
215140890|NCT02731469|BIOLOGICAL|BCD-131|
215140891|NCT02731469|BIOLOGICAL|Mircera®|
215140892|NCT02731469|BIOLOGICAL|Aranesp®|
215140893|NCT02364375|DEVICE|Menai mask (full face)|Prototype mask system (full face variant) with novel vent and humidification system
215140894|NCT02364375|DEVICE|Menai Standard mask (full face)|Prototype mask system (full face variant) with conventional vent and humidification system
215140895|NCT02364375|DEVICE|Menai mask (nasal)|Prototype mask system (nasal variant) with novel vent and humidification system
215140896|NCT02364375|DEVICE|Menai Standard mask (nasal)|Prototype mask system (nasal variant) with conventional vent and humidification system
215140897|NCT02364375|DEVICE|Menai mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
215140898|NCT02364375|DEVICE|Menai Standard mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
215140899|NCT01353898|DRUG|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
215140900|NCT01353898|DRUG|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
215140901|NCT01670344|PROCEDURE|Treatment with investigational method (virtual implant positioning system)|
215140902|NCT01670344|PROCEDURE|Treatment with surgical standard of care|
214454336|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
214454337|NCT05093829|BIOLOGICAL|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
214695001|NCT03596359|BEHAVIORAL|Education with Teach-Back method|
214695002|NCT03596359|OTHER|Received routine treatment|
214695003|NCT03027804|PROCEDURE|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
215140903|NCT05459363|OTHER|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
215140904|NCT05096195|DRUG|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
215140905|NCT05096195|OTHER|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
215140906|NCT05096195|DIAGNOSTIC_TEST|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
215140907|NCT05310955|OTHER|daily rehabilitation interventions|including Naikan therapy, Morita therapy, group art therapy, group painting therapy
215140908|NCT05310955|OTHER|shen-based Qigong exercise|a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
215140909|NCT03558737|OTHER|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
215140910|NCT03558737|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
215140911|NCT00284947|DRUG|basiliximab|40 mg once every 28 days intravenously for 24 weeks
215140912|NCT00284947|DRUG|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
215140913|NCT00284947|DRUG|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
215140914|NCT05584514|OTHER|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
215140915|NCT05584514|OTHER|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
215140916|NCT00740038|BEHAVIORAL|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, \& provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
215140917|NCT00740038|BEHAVIORAL|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
214454338|NCT05093829|BIOLOGICAL|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
214454339|NCT05212610|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
214527349|NCT03148483|OTHER|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
215140918|NCT00740038|BEHAVIORAL|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
215140919|NCT00740038|BEHAVIORAL|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
215140920|NCT03153592|PROCEDURE|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
215140921|NCT03153592|PROCEDURE|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
215140922|NCT05798494|BEHAVIORAL|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
215140923|NCT00103584|BIOLOGICAL|LC16m8 Smallpox Vaccine|
215140924|NCT01729780|DEVICE|EEG-NF|
215140925|NCT00022191|DRUG|cisplatin|
215140926|NCT00022191|DRUG|gemcitabine hydrochloride|
215140927|NCT00022191|DRUG|paclitaxel|
215140928|NCT02964689|DRUG|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
215140929|NCT02964689|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
215140930|NCT02964689|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
215140931|NCT00810563|DRUG|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
215140932|NCT00810563|DRUG|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
215140933|NCT00006445|PROCEDURE|Ultrasound|
215140934|NCT00006445|PROCEDURE|Serum screen|
215140935|NCT03779009|OTHER|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
214527350|NCT03148483|OTHER|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
215140936|NCT05324462|DRUG|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
215140937|NCT00210496|DRUG|topiramate; almotriptan malate|
215140938|NCT03183869|DRUG|Fecal microbiota|fecal microbial transplantation
215140939|NCT05471466|PROCEDURE|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
215140940|NCT03041181|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
215140941|NCT03041181|DRUG|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
215140942|NCT03041181|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
215140943|NCT03041181|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
215140944|NCT06173687|DEVICE|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
215140945|NCT06359951|BEHAVIORAL|Project YES|Digital SSI
215140946|NCT03536572|BEHAVIORAL|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
215140947|NCT03879512|DRUG|depletion of regulatory T cells|oral metronomic cyclophosphamide
215140948|NCT03879512|PROCEDURE|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
215140949|NCT03879512|BIOLOGICAL|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
215140950|NCT03879512|BIOLOGICAL|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
215140951|NCT06100653|DRUG|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
215140952|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
215140953|NCT04500366|BEHAVIORAL|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
215140954|NCT04500366|BEHAVIORAL|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
215140955|NCT04500366|COMBINATION_PRODUCT|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
215140956|NCT04500366|BEHAVIORAL|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
215140957|NCT00286728|BEHAVIORAL|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
215140958|NCT00000794|DRUG|Sulfadiazine|
214454340|NCT06923735|OTHER|Utilization of the Finnish Nutrition Navigator and the Finnish Nutrition Path|Participant fills in the food intake questionnaire of the Finnish Nutrition Navigator and receives an automated feedback on the diet before the visit to the occupational healthcare. At the visit, the information about the quality of diet can be utilized with the occupational healthcare professional. The client can utilize the self-care path (the Finnish Nutrition Path) for possible dietary changes independently or with the professional.
214454341|NCT06932419|OTHER|Ozone exposure|Participants' forearms were exposed to 200 ppb ozone for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
214454342|NCT06932419|OTHER|Clean air exposure|Participants' forearms were exposed to clean air for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
215140959|NCT00000794|DRUG|Clarithromycin|
214454343|NCT06931821|DEVICE|Isochronal Late Activation Mapping (ILAM)|an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters)
214454344|NCT06931821|DEVICE|High Density Voltage Mapping|high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV).
214454345|NCT06932068|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.
214454346|NCT06932068|DRUG|Oxallplation|130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.
214454347|NCT06932068|DRUG|Capectitabine Tablets|1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.
214454348|NCT06931249|BEHAVIORAL|The observational study|This study is being conducted to create a Turkish version of the English version of the PAED scale, which did not exist before, and to determine its cultural suitability.
214454349|NCT06933004|DEVICE|Posterior Spinal Fixation System|Using spine implants SmartMIS Spinal Fixation System or ASA Spinal Fixation System.
215140960|NCT00000794|DRUG|Atovaquone|
215140961|NCT00000794|DRUG|Pyrimethamine|
215140962|NCT00000794|DRUG|Leucovorin calcium|
215140963|NCT02712346|DRUG|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
215140964|NCT02712346|DRUG|Placebo|One inactive pill daily for twelve weeks
215140965|NCT03396796|PROCEDURE|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
215140966|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
215140967|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
215140968|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
215140969|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
215140970|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
215140971|NCT03662867|BEHAVIORAL|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
215140972|NCT03662867|OTHER|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
215140973|NCT00657319|DRUG|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
215140974|NCT00548665|DEVICE|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
215140975|NCT00548665|BEHAVIORAL|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
214454350|NCT05194514|DEVICE|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
214454351|NCT05194514|OTHER|Cold Storage|FDA-approved method for organ procurement
215140976|NCT04757506|DRUG|Naltrexone|opioid receptor antagonist
214454352|NCT03310957|DRUG|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
214454353|NCT03310957|DRUG|Pembrolizumab|IV infusion every 3 weeks
214454354|NCT04793958|DRUG|MRTX849|28 Day Cycle
214454355|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
214454356|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
214454357|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
214454358|NCT02727699|DRUG|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
214454359|NCT02727699|DRUG|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
215140977|NCT04757506|DRUG|Placebo|
215140978|NCT02362815|OTHER|Apple juice|Intervention consists in allowing drinks during labour
215140979|NCT03866746|DRUG|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
214527351|NCT03148483|DIETARY_SUPPLEMENT|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
214527352|NCT03148483|DIETARY_SUPPLEMENT|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
214527353|NCT00174356|DRUG|CI 1033|
214527354|NCT00174356|DRUG|PACLITAXEL|
214527355|NCT00174356|DRUG|CARBOPLATIN|
214527356|NCT02591706|DEVICE|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
215140980|NCT03866746|OTHER|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
215140981|NCT06253988|DRUG|Probiotic Formula|intra-pocket formula (local delivery drug)
215140982|NCT06253988|DRUG|placebo formula|intra-pocket formula (local delivery drug)
215140983|NCT04545749|BIOLOGICAL|UB-612|UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
215140984|NCT04649112|GENETIC|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
215140985|NCT05958901|OTHER|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
215140986|NCT01292135|DRUG|PCI-32765|420 mg daily
214527357|NCT02674048|OTHER|Metvix|
214527358|NCT03659890|DIETARY_SUPPLEMENT|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
215140987|NCT04696484|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.
215140988|NCT00011596|PROCEDURE|Gait Training|
215140989|NCT01017185|DRUG|HF10|
215140990|NCT03050801|DEVICE|rTMS|Altering the connectivity of trans-synaptic pathways
215140991|NCT00102466|DRUG|vildagliptin|
215140992|NCT00102466|DRUG|Gliclazide|
215140993|NCT00102466|DRUG|Metformin|
214454360|NCT06488222|DRUG|Docetaxel|Subjects will receive 40 mg docetaxel intravesically.
214454361|NCT06488222|DRUG|Gemcitabine|Subjects will receive 1 mg gemcitabine intravesically.
215140994|NCT03817164|DEVICE|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
214454362|NCT02365623|DRUG|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
214527359|NCT03659890|DIETARY_SUPPLEMENT|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
215140995|NCT03817164|DEVICE|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
215140996|NCT02249364|PROCEDURE|Control|Routine practice
215140997|NCT02249364|PROCEDURE|Hypnosis|Hypnosis session before induction of anesthesia
215140998|NCT02249364|DRUG|propofol|Closed-loop administration of propofol for anesthesia induction
215140999|NCT00822614|DRUG|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
214527360|NCT03659890|DIETARY_SUPPLEMENT|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
214695004|NCT05233696|DRUG|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
215141000|NCT00822614|DRUG|Opioid|Current optimized BTP treatment
215141001|NCT00358475|DRUG|GW685698|
215141002|NCT03520881|OTHER|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
215141003|NCT05656417|BEHAVIORAL|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
215141004|NCT01814111|PROCEDURE|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
215141005|NCT03987360|OTHER|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
215141006|NCT02803788|DRUG|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
215141007|NCT03340389|PROCEDURE|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
215141008|NCT01131975|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
215141009|NCT03600909|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
215141010|NCT03600909|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
215141011|NCT03600909|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
215141012|NCT03600909|DRUG|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
215141013|NCT03600909|DEVICE|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
215141014|NCT03600909|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
215141015|NCT03667274|PROCEDURE|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
215141016|NCT04973449|BIOLOGICAL|AZD1222|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
215141017|NCT04973449|BIOLOGICAL|AZD2816|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
215141018|NCT05763043|DRUG|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
215141019|NCT00521079|DEVICE|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
215141020|NCT00521079|DEVICE|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
215141021|NCT03002961|DRUG|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
215141022|NCT03002961|DRUG|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
215141023|NCT02651675|GENETIC|AAV directed hLDLR gene therapy|AAV directed hLDLR gene therapy is a novel adeno-associated viral (AAV8) vector with human low-density lipoprotein receptor (hLDLR) gene
215141024|NCT03674411|DRUG|Fludarabine (FLU)|25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)
214454363|NCT02365623|DRUG|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
214454364|NCT03509116|OTHER|Observations, documents|Consultation observations, documentary analysis
215141025|NCT03674411|DRUG|Cyclophosphamide (CY)|60 mg/kg IV over 2 hours
215141026|NCT03674411|DRUG|Total Body Irradiation (TBI)|165 cGy twice daily
215141027|NCT03674411|DRUG|Tacrolimus (Tac)|Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
215141028|NCT03674411|DRUG|Mycophenolate Mofetil (MMF)|MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
215141029|NCT03674411|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5 ug/kg/d until the absolute neutrophil count (ANC) is \>2500/uL for 2 consecutive days
215141030|NCT03674411|DRUG|Busulfan (BU)|BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
215141031|NCT03674411|DRUG|Melphalan|50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min
215141032|NCT03674411|DRUG|MGTA 456 Infusion|The target cell dose is \>10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
214454365|NCT03509116|OTHER|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
214695005|NCT05233696|DRUG|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
215141033|NCT01748734|PROCEDURE|quality-of-life assessment|Ancillary studies
215141034|NCT01748734|OTHER|questionnaire administration|Ancillary studies
215141035|NCT01748734|OTHER|counseling intervention|Undergo cognitive behavioral therapy
215141036|NCT01748734|BEHAVIORAL|behavioral intervention|Undergo cognitive behavioral therapy
215141037|NCT03586765|OTHER|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
215141038|NCT01506596|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
215141039|NCT03816696|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
215141040|NCT03816696|DRUG|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
215141041|NCT01066013|OTHER|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
214454366|NCT05552534|OTHER|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
214454367|NCT02995434|DEVICE|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe\_Lucem\_\_Seize\_The\_Light\_VR/"
214454368|NCT02995434|OTHER|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
214454369|NCT05840250|OTHER|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
214695006|NCT05233696|RADIATION|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
215141042|NCT04685863|OTHER|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
215141043|NCT01314183|OTHER|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
215141044|NCT01314183|OTHER|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
215141045|NCT02012140|DRUG|ticagrelor|
215141046|NCT02858622|DRUG|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
215141047|NCT02858622|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
215141048|NCT02858622|DRUG|perfalgan|intravenous paracetamol
215141049|NCT02858622|DRUG|fentanyl|
215141050|NCT06281132|DRUG|CKD-341, D956|A single dose of 1 tablet under fasting condition
215141051|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
215141052|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
215141053|NCT01564160|DIETARY_SUPPLEMENT|Fish Oil|Source of omega-3 fatty acids.
215141054|NCT01564160|DIETARY_SUPPLEMENT|PCSO-524|Extract of Greenshell Mussel
214454370|NCT05426928|OTHER|Additional temperature monitoring/recording|All patients in this study will receive the same standard of care treatment for their HIPEC procedure. The only difference will be the use of additional temperature probes to collect more robust data regarding intraabdominal temperature, and the prospective collection of actual boundary conditions of the system.
215141055|NCT05721456|BIOLOGICAL|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
214454371|NCT03779204|BEHAVIORAL|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
214454372|NCT03779204|BEHAVIORAL|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
214695007|NCT05233696|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
214695008|NCT03352414|DRUG|Alvimopan|alvimopan pill
214695009|NCT03352414|DRUG|Placebo|placebo pill
214695010|NCT02642887|PROCEDURE|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
214695011|NCT00846079|DEVICE|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
214695012|NCT05391984|OTHER|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
214695013|NCT05391984|OTHER|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
215141056|NCT06513845|BEHAVIORAL|Communal drumming recordings|Segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle. Segments will be categorized as highly synchronized
215141057|NCT03606902|PROCEDURE|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
215141058|NCT03606902|DRUG|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
215141059|NCT03606902|DRUG|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
215141060|NCT03606902|PROCEDURE|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
215141061|NCT06266429|DIAGNOSTIC_TEST|Blood collection|Collecting blood pre-op and post-op for metabolite levels.
215141062|NCT00247663|DRUG|Letrozole|
215141063|NCT05865990|DRUG|Patritumab deruxtecan|HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
215141064|NCT03310138|DEVICE|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
215141065|NCT03310138|DEVICE|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
215141066|NCT06442319|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction
215141067|NCT06198933|DEVICE|Pulsed-field ablation|Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
215141068|NCT05625061|BEHAVIORAL|Core Behavioral Weight Loss (BWL) Intervention|"All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals."
215141069|NCT05625061|BEHAVIORAL|Behavior Change Technique 1 Message (Action Planning)|Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).
214454373|NCT04327557|BEHAVIORAL|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
214454374|NCT04327557|BEHAVIORAL|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
214454375|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
214454376|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
214454377|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle.
214695014|NCT03699787|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
215141070|NCT05625061|BEHAVIORAL|Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)|Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
215141071|NCT05625061|BEHAVIORAL|Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)|Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).
214454378|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
214454379|NCT06418555|BEHAVIORAL|A home rehabilitation program centered on exercise|Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
214454380|NCT05509192|DRUG|MTPI|Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
214454381|NCT05509192|DRUG|Classic Induction|Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
214454382|NCT05014984|BEHAVIORAL|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1). In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
215141072|NCT05625061|BEHAVIORAL|Behavior Change Technique 4 Message (Social Support)|Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).
215141073|NCT05625061|BEHAVIORAL|Behavior Change Technique 5 Message (Social Comparison)|Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).
214454383|NCT05014984|BEHAVIORAL|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
215141074|NCT05625061|BEHAVIORAL|Behavior Change Technique 6 Message (Social Reward)|Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
214695015|NCT02473133|RADIATION|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
215141075|NCT05625061|BEHAVIORAL|Behavior Change Technique 7 Message (Focus on Past Success)|Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
214454384|NCT05014984|BEHAVIORAL|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study. Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
215141076|NCT03645122|OTHER|Paired corticospinal-motoneuronal stimulation (PCMS)|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
215141077|NCT03645122|OTHER|Sham stimulation|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
215141078|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
215141079|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
215141080|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
215141081|NCT05133297|DRUG|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
215141082|NCT04606134|DEVICE|Hybrid fractional laser|two treatments given one month apart
215141083|NCT04606134|OTHER|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
215141084|NCT04606134|OTHER|Cetaphil face cream|applied twice daily
215141085|NCT00142155|DRUG|Rituximab|
215141086|NCT00142155|DRUG|monoclonal antibodies|
215141087|NCT01752335|OTHER|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
215141088|NCT06016803|DEVICE|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
215141089|NCT05198869|DEVICE|Spectral scan|Consenting participants will have a SpotLight-19 scan
215141090|NCT03698071|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
214454385|NCT05014984|BEHAVIORAL|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies. To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
214454386|NCT00740948|DRUG|Rituximab (mabthera) Injection|2 \* 1g of Rituximab at the 1st day and at the 14th day.
214454387|NCT00740948|DRUG|Placebo: NaCl 0.9% or Glucose 5%|2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
214454388|NCT06385925|DRUG|TSN1611|TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
214454389|NCT04814446|BIOLOGICAL|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
214454390|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A standard dose will be administered on day 0 of the study.
214454391|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
214695016|NCT02473133|RADIATION|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
214695017|NCT01868178|DEVICE|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
214695018|NCT00093093|DRUG|Viramidine|
214695019|NCT00093093|DRUG|Ribavirin|
215141091|NCT03698071|BIOLOGICAL|urine sample|6 ml
215141092|NCT02658526|BEHAVIORAL|anesthesia - surgery|
215141093|NCT03373240|BEHAVIORAL|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
215141094|NCT03373240|BEHAVIORAL|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
215141095|NCT03633370|OTHER|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
215141096|NCT00370734|DRUG|Botulinum toxin A injection|
215141097|NCT05428501|OTHER|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
215141098|NCT01249352|DRUG|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
215141099|NCT01249352|DRUG|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
215141100|NCT01249352|DRUG|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
215141101|NCT01249352|RADIATION|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
215141102|NCT06706362|DRUG|Bactrim or Macrobid|Participants will be assigned to Bactrim or Macrobid depending on participants' allergies
215141103|NCT06706362|DRUG|Placebo|Participants will be assigned to identical appearing placebo
215141104|NCT03043417|BEHAVIORAL|CHC's given the intervention|CHC's NOT given the intervention
215141105|NCT05579678|BEHAVIORAL|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
215141106|NCT06419920|OTHER|Flat terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on a level treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
215141107|NCT06419920|OTHER|Uneven terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
215141108|NCT05818085|DRUG|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
215141109|NCT05818085|DRUG|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
215141110|NCT05818085|OTHER|Placebo|ABP-671 matching placebo
215141111|NCT05120180|PROCEDURE|axillary lymph node dissection with vein branches reservation|Spare the vein branches when ALND being performed
215141112|NCT05120180|PROCEDURE|axillary lymph node dissection without vein branches reservation|Don't spare the vein branches when ALND being performed
215141113|NCT04235608|DRUG|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
215141114|NCT04235608|DRUG|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
215141115|NCT03327948|DEVICE|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
215141116|NCT05542069|DEVICE|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
215141117|NCT05276596|DRUG|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
215141118|NCT05276596|DRUG|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
215141119|NCT06116045|DRUG|BZ371A 7.5 mg (1.5 ml)|7.5 mg gel
215141120|NCT06116045|DRUG|BZ371A 5.0 mg (1.0 ml)|5.0 mg gel
215141121|NCT06116045|DRUG|BZ371A 2.5 mg (0.5 ml)|2.5 mg gel
215141122|NCT06116045|DRUG|Placebo (1.5 ml)|BZ371A-matched placebo
215141123|NCT06116045|DRUG|Placebo (1.0 ml)|BZ371A-matched placebo
215141124|NCT06116045|DRUG|Placebo (0.5 ml)|BZ371A-matched placebo
214454392|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
214454393|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
214454394|NCT02182219|DRUG|BIBF 1120|
214454395|NCT05359939|DIAGNOSTIC_TEST|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
214454396|NCT06490900|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.
214454397|NCT06490900|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
214454398|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
214454399|NCT03818659|OTHER|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
214695020|NCT00093093|DRUG|pegylated interferon alfa-2a|
215141125|NCT06561919|PROCEDURE|bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper|Best medical treatment according to widely accepted expert consensus Paper
215141126|NCT06561919|DRUG|best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper|Best medical treatment according to widely accepted consensus Paper
215141127|NCT06555406|BEHAVIORAL|Time-restricted eating for 8 weeks|limiting food intake to 10 hours per day
215141128|NCT03459755|BEHAVIORAL|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
215141129|NCT05684419|OTHER|Fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers|Evaluation of the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.
215141130|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
214527361|NCT00996814|BEHAVIORAL|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
214695021|NCT04970771|BEHAVIORAL|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
214695022|NCT03213626|DRUG|Cabozantinib 40 MG|To be taken orally once daily
215141131|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
214454400|NCT03818659|OTHER|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
214454401|NCT03363711|OTHER|AYA STEPS|a mobile health application
214454402|NCT00200200|DRUG|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
215141132|NCT00002009|DRUG|Sargramostim|
215141133|NCT03380312|PROCEDURE|rTARUP technique|robot-assisted rTARUP technique
215141134|NCT03951103|OTHER|rFVIIIFc|Drug according to prescription
215141135|NCT00133484|BIOLOGICAL|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
215141136|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Bacillus anthrax|
215141137|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Escherichia coli|
215141138|NCT02067078|DRUG|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
215141139|NCT02067078|DRUG|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
215141140|NCT02067078|DRUG|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
215141141|NCT04106414|DRUG|Nivolumab|Nivolumab 480 mg every 4 weeks.
215141142|NCT04106414|DRUG|BMS- 986205|BMS-986205 100 mg every 4 weeks.
215141143|NCT04052854|DRUG|Zanubrutinib|Zanubrutinib will be orally administered in participants with treatment naive or R/R WM
215141144|NCT05226442|DRUG|Argatroban|Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
215141145|NCT05226442|DRUG|Unfractionated heparin|Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
215141146|NCT04309396|DEVICE|Hydrogen content recording|Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.
214527362|NCT05808062|PROCEDURE|Root canal obturation|Root canal dryness
214527363|NCT00332488|DRUG|Technosphere Insulin|Inhalation, 15U/30U, prandial
214695023|NCT03213626|DRUG|Erlotinib 100Mg Tab|To be taken orally once daily
214695024|NCT00142519|DRUG|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
215141147|NCT06313736|BEHAVIORAL|Action Brings Change Project (15-minute adult version)|The ABC Project is a self-guided online single-session intervention based on principles of behavioral activation. In a slightly different form intended for adolescents, it has demonstrated efficacy in several studies. Its adult version has also shown some efficacy.
215141148|NCT06313736|BEHAVIORAL|Action Brings Change Project (10-minute adult version)|This is a 10-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
215141149|NCT06313736|BEHAVIORAL|Action Brings Change Project (6-minute adult version)|This is a 6-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
214695025|NCT00142519|DRUG|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
215141150|NCT06313736|BEHAVIORAL|Action Brings Change Project (2-minute adult version)|This is a 2-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
215141151|NCT06540742|DIAGNOSTIC_TEST|Artificial intelligence identifies liver hydatids|Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology
215141152|NCT04042441|DRUG|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
215141153|NCT06172959|BEHAVIORAL|Vocal Intonation Therapy (VIT)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Vocal Intonation Therapy is a music therapy technique consisting of breathing and vocal exercises to target respiratory function and vocal quality.
215141154|NCT06172959|BEHAVIORAL|Therapeutic Singing (TS)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Therapeutic Singing is a music therapy technique used to work on the rehabilitation of vocal and respiratory function.
215141155|NCT04930445|DRUG|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
215141156|NCT04050553|DRUG|Tirzepatide|Administered SC
215141157|NCT04050553|DRUG|Placebo|Administered SC
215141158|NCT00938704|DRUG|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
215141159|NCT00938704|DRUG|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
215141160|NCT05672784|PROCEDURE|GNB plus standard analgesia|When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
215141161|NCT05672784|PROCEDURE|GNB plus IPACK block plus standard analgesia|IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
215141162|NCT05672784|DRUG|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
215141163|NCT06584968|OTHER|training with visual feedback|Training with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams.
215141164|NCT06584968|OTHER|classical learning|Study of the test with practical applications on the researcher who plays the role of the patient
215141165|NCT06313515|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin
215141166|NCT06313515|BEHAVIORAL|Arm-crank bike exercise|Exercise using an arm-bike to target cardiovascular functioning.
215141167|NCT06313515|OTHER|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin.
215141168|NCT06585397|OTHER|Grup 1|Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
214454403|NCT00200200|DRUG|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
214454404|NCT03772743|OTHER|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
214454405|NCT03772743|OTHER|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
214454406|NCT05625217|DIAGNOSTIC_TEST|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
214454407|NCT03378102|BIOLOGICAL|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
214527364|NCT00332488|DRUG|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
215141169|NCT05507138|DEVICE|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
214454408|NCT06405490|DRUG|Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab|Use the above medications on a regular basis
214454409|NCT04363515|BEHAVIORAL|Social support network counseling intervention|Pilot social support counseling intervention for kidney transplant candidates along with their social support networks
214454410|NCT06139211|BIOLOGICAL|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
214527365|NCT00332488|DRUG|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
215141170|NCT05507138|BEHAVIORAL|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
215141171|NCT05743335|BIOLOGICAL|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
215141172|NCT05743335|OTHER|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
215141173|NCT03581487|BIOLOGICAL|Durvalumab|Given IV
215141174|NCT03581487|DRUG|Selumetinib|Given PO
215141175|NCT03581487|BIOLOGICAL|Tremelimumab|Given IV
215141176|NCT06477055|DRUG|Osimertinib|Osimertinib, 80mg, po, qd.
215141177|NCT05380427|DRUG|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
215141178|NCT06621264|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\&#39;s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.
215141179|NCT06621264|OTHER|Control (Standard treatment)|Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices
215141180|NCT04249245|OTHER|Nasal Swab|All
215141181|NCT06652243|BIOLOGICAL|SN301A|"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."
215141182|NCT05878665|DIAGNOSTIC_TEST|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
215141183|NCT06978335|OTHER|Acupoint Stimulation|This intervention involves acupoint stimulation and auricular acupressure. Stimulation of selected body acupoints is administered by trained personnel following a standardized protocol. The intervention is provided once daily for three consecutive days, beginning post-surgery. For auricular acupressure, additional auricular points are chosen based on the involved abdominal organ and its corresponding viscera-meridian locations on the auricle. Vaccaria seeds are applied to the selected points with adhesive patches, and patients are instructed to apply pressure to the points regularly throughout the day.
215141184|NCT06978335|OTHER|Sham Acupoint Stimulation|Participants in this group will receive a sham acupoint stimulation procedure. Acupoint stimulation will be using identical procedures to the experimental group, without applying pressure. No stimulation or manipulation was performed. The frequency and timing of the sham intervention matched that of the experimental group.
215141185|NCT04713644|DRUG|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
215141186|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - EARLY|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
215141187|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - DELAYED|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
215141188|NCT05498883|OTHER|Score completion|completion of the SRI score
215141189|NCT06555120|BIOLOGICAL|blood sample|A 5-ml blood sample in a dry tube (or 500-µl cone) is taken and sent to the biochemistry laboratory for lipid analysis.
214695026|NCT02731703|DEVICE|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
214454411|NCT06139211|BIOLOGICAL|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
214454412|NCT06139211|BIOLOGICAL|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
214454413|NCT06139211|DRUG|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
214527366|NCT00066378|DRUG|anastrozole|
214527367|NCT00066378|DRUG|gefitinib|
214695027|NCT04422665|OTHER|Resistance exercise|Single-legged resistance exercise
215141190|NCT06584604|OTHER|There is no intervention|There is no intervention
215141191|NCT04855552|BEHAVIORAL|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
215141192|NCT04855552|BEHAVIORAL|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
215141193|NCT04855552|BEHAVIORAL|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram"
215141194|NCT03472885|DRUG|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
215141195|NCT03472885|DRUG|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
215141196|NCT04380740|DRUG|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
215141197|NCT04380740|DRUG|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
215141198|NCT03390686|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
215141199|NCT03390686|DRUG|HD204|15 mg/kg IV every 3 weeks on Day 1
215141200|NCT03390686|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
215141201|NCT03390686|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
215141202|NCT05653492|DRUG|Sulforaphane|Dosing study one to four 30 mg/d tablets depending on weight
215141203|NCT06466200|DIAGNOSTIC_TEST|Schiff Test|Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.
215141204|NCT06466200|OTHER|GOHAI questionnaire|Oral health-related quality of life assessment by questionnaire
215141205|NCT06466200|OTHER|OHIP questionnaire|Oral health-related quality of life assessment by questionnaire
215141206|NCT06466200|OTHER|DHEQ fr questionnaire|dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
215141207|NCT05978193|RADIATION|LDRT+CFRT|"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"
215141208|NCT05978193|DRUG|Immunotherapy|PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
214454414|NCT06139211|DRUG|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
214454415|NCT06139211|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
214527368|NCT00371462|BEHAVIORAL|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
215141209|NCT05978193|DRUG|Chemotherapy|Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
215141210|NCT06812442|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes)· Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes). RT sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
214454416|NCT06139211|BIOLOGICAL|Bevacizumab|Bevacizumab of 5mg/kg will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or7.5mg/kg on day 1 every 21 day cycle, based on different combined chemotherapy.
214454417|NCT06139211|DRUG|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
214454418|NCT06139211|DRUG|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
214454419|NCT06139211|DRUG|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
214454420|NCT06139211|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
214527369|NCT00371462|BEHAVIORAL|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
214695028|NCT06088316|DRUG|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
215141211|NCT06970236|OTHER|Exercise|Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
215141212|NCT06654479|OTHER|In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.|The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
215141213|NCT06654921|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
215141214|NCT06654921|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
215141215|NCT06654921|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
215141216|NCT06654869|BEHAVIORAL|lauhgter yoga|include laughter yoga effects on cancer patients' symptom management
215141217|NCT06655103|OTHER|Educational movie|There are three groups in this research. The 1st group will be shown an educational movie about intrathecal chemotherapy treatment before intrathecal chemotherapy treatment, the 2nd group will be shown a cartoon movie before intrathecal chemotherapy treatment, and the 3rd group will not receive any intervention before intrathecal chemotherapy treatment. In all groups, measurements will be made in parallel; fear and pain scales as well as electrodermal activity, pulse, respiration and O2 saturation values 30 minutes before IT chemotherapy treatment, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
214454421|NCT06163547|RADIATION|MMA embolization|Middle meningeal artery embolization
214454422|NCT05091593|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
214454423|NCT05091593|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
214454424|NCT04318548|COMBINATION_PRODUCT|Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)|1 dose of rMenB+OMV administered intramuscularly at day 1 and 61 to participants in MenB+MenACWY group and MenB group and as 1 dose at day 91 to participants in MenACWY group.
214454425|NCT04318548|BIOLOGICAL|Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)|1 dose of MenACWY administered intramuscularly at day 1 to participants in MenB+MenACWY group and MenACWY group, 1 dose at day 91 to participants for MenB group.
214454426|NCT04318548|COMBINATION_PRODUCT|Placebo|1 dose of Placebo administered intramuscularly at 1 to participants in MenB group and MenACWY group and as 1 dose at day 91 to participants in MenB+MenACWY group.
214454427|NCT05021419|OTHER|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
214454428|NCT05021419|OTHER|Standard Protocol|Current standard optimization protocol as per NICE and ESC
214454429|NCT05316740|OTHER|No intervention|Repeated clinical evaluation and sample collection
214454430|NCT05879757|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
214454431|NCT06280989|OTHER|kinesio taping|"Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,."
215141218|NCT06653998|OTHER|Early mobilization and rehabilitation|"In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity."
215141219|NCT06654492|PROCEDURE|The dimension of the window for lateral window maxillary sinus elevation surgery|The window size for a single implant site should not exceed 25 square millimeters, while the window size for consecutive multiple implant sites should not exceed 40 square millimeters.
215141220|NCT06655116|BEHAVIORAL|Diabetic Foot Education|"Patients in the intervention group will be interviewed and their diabetic foot knowledge will be evaluated. During the interview, the individual's knowledge about the definition of diabetic foot, risk factors, symptoms, treatment, complications, care and prevention will be evaluated.~In order to systematically plan, implement and evaluate the training to be used in the intervention, it is aimed to implement androgogical training based on the 'Interpersonal Relations Theory'. In this context, the stages in the theory will be followed as follows."
215141221|NCT04835311|PROCEDURE|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
215141222|NCT01651728|DRUG|Simvastatin|Tablet 20 mg once daily for 30 days
215141223|NCT01651728|DRUG|Placebo|daily for 30 days
215141224|NCT04647370|PROCEDURE|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
215141225|NCT04647370|PROCEDURE|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
215141226|NCT00704015|BEHAVIORAL|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
214454432|NCT06280989|OTHER|myofascial release technique|"myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus."
214454433|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
214454434|NCT04913220|DRUG|THOR-707|Solution for infusion: intravenous infusion
214454435|NCT04913220|DRUG|Cemiplimab|Solution for infusion: intravenous infusion
214454436|NCT05350527|OTHER|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
214527370|NCT05592769|DEVICE|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
214527371|NCT02983877|BEHAVIORAL|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
214527372|NCT02955706|DRUG|Acetyl-L-Carnitine|TID
214527373|NCT02955706|DRUG|Placebo of Acetyl-L-Carnitine|TID
214527374|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
214527375|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
214454437|NCT05253664|BEHAVIORAL|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
215141227|NCT03183453|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
215141228|NCT00982293|DEVICE|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
215141229|NCT00982293|DEVICE|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
215141230|NCT01343953|PROCEDURE|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
215141231|NCT02201953|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
215141232|NCT02201953|DRUG|SOF|400 mg tablet administered orally once daily
215141233|NCT02201953|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215141234|NCT04546711|OTHER|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
215141235|NCT06589869|DEVICE|EM Chair|Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
215141236|NCT06589869|OTHER|Standard of care|Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
215141237|NCT06592196|OTHER|stain|This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
215141238|NCT06603116|OTHER|treatment of class two cavities|restorations in class 2 cavities
214454438|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
214454439|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
214454440|NCT04927065|BIOLOGICAL|mRNA-1273.211|Sterile liquid for injection
214454441|NCT04927065|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214695029|NCT06088316|DRUG|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
214695030|NCT00163150|DRUG|Atorvastatin|
214454442|NCT04927065|BIOLOGICAL|mRNA-1273.617.2|Sterile liquid for injection
215141239|NCT06398197|BEHAVIORAL|Nourish Intervention then No Intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.
215141240|NCT06398197|BEHAVIORAL|No Intervention then Nourish Intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
215141241|NCT06598904|OTHER|Aroma diffuser with single-note lavender essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.
215141242|NCT06598904|OTHER|Aroma diffuser with single-note orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
215141243|NCT06598904|OTHER|Aroma diffuser with deionized water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
214454443|NCT04927065|BIOLOGICAL|mRNA-1273.213|Sterile liquid for injection
214454444|NCT04927065|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
214454445|NCT04927065|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214454446|NCT04927065|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
214454447|NCT04927065|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
214454448|NCT04927065|BIOLOGICAL|mRNA-1273.231|Sterile liquid for injection
214454449|NCT04137913|BEHAVIORAL|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
214454450|NCT04854317|PROCEDURE|Endoscopic gastroplasty|Endoscopic Gastroplasty
214454451|NCT06502132|OTHER|Patient Education Group|Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
214454452|NCT06502132|OTHER|Therapeutic Touch Group|Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
214454453|NCT04690738|DIAGNOSTIC_TEST|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
214454454|NCT05701059|PROCEDURE|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
214454455|NCT05701059|DEVICE|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
214527376|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
214527377|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
214527378|NCT03721978|BIOLOGICAL|VGX-3100|1 milliliter (mL) VGX-3100 injected IM.
214454456|NCT05701059|DEVICE|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
214527379|NCT03721978|BIOLOGICAL|Matched Placebo|1 mL of matched Placebo injected IM.
214527380|NCT03721978|DEVICE|CELLECTRA™-5PSP|CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
214527381|NCT01782729|DRUG|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
214527382|NCT05244226|DRUG|Fentanyl/Hydromorphone|Per routine care
214527383|NCT05244226|DRUG|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
214527384|NCT03767972|DEVICE|Energy-based device|Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
214527385|NCT02048683|DRUG|Short term sedation with sevoflurane in ICU|
214527386|NCT03453424|PROCEDURE|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
214527387|NCT03453424|PROCEDURE|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
215141244|NCT06602713|OTHER|Questionnaires|Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
215141245|NCT06602713|OTHER|Exercices|isokinetic evaluation
214454457|NCT03378570|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
214454458|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
214454459|NCT03210688|DRUG|Prednisolone|Tablet prednisolone
214454460|NCT03210688|DRUG|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
214454461|NCT04180930|DIAGNOSTIC_TEST|CAPS-5|Clinician Administered PTSD Scale for DMS-5
214454462|NCT04180930|DIAGNOSTIC_TEST|PSSI-5|PTSD Symptom Scale Interview for DSM-5
214454463|NCT04180930|DIAGNOSTIC_TEST|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
214454464|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
214454465|NCT06565715|DRUG|Remimazolam|Remimazolam is used for sedation during anesthetic induction and maintenance.
214454466|NCT06565715|DRUG|Propofol|propofol is used for sedation during anesthetic induction and maintenance.
214454467|NCT06567587|DRUG|Dexmedetomidine|Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
214454468|NCT06567587|DEVICE|BIPAP|Put exaggerated COPD patients on non invasive ventillation
214454469|NCT06567561|BEHAVIORAL|Whole Foods Plant-Based Diet|Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
214454470|NCT06567561|BEHAVIORAL|Usual Firehouse Diet|Usual firehouse meals.
214527388|NCT00605995|DRUG|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
214695031|NCT04363489|DEVICE|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
214695032|NCT04363489|DIAGNOSTIC_TEST|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
214695033|NCT04363489|DIAGNOSTIC_TEST|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
214527389|NCT02459236|DRUG|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
214527390|NCT02459236|DRUG|Placebo|
214695034|NCT05323968|DIAGNOSTIC_TEST|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
215141246|NCT06595641|DEVICE|Transfer Energy Capacitive Resistive Therapy|It's a physical treatment modality commonly used to treat musculoskeletal pain. It normally uses a longwave radiofrequency of \~0.5 MHz. The system consists of a neutral plate and two different electrodes that can transfer energy in two modalities: capacitive and resistive
215141247|NCT06595641|OTHER|strength training program|"Each session includes five exercises, each performed for three sets of 10 repetitions:~Shoulder Retraction - Strengthens muscles between shoulder blades. Shoulder Scaption - Improves stability and range of motion. Shoulder External Rotation from Side Lying - Targets rotator cuff muscles. Shoulder Protraction - Enhances shoulder blade function. Shoulder Extension - Strengthens posterior shoulder muscles"
215141248|NCT06594718|PROCEDURE|Endoscopic diverticulotomy with Z-POEM|Endoscopic diverticulotomy with Z-POEM
214527391|NCT02841345|OTHER|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
214527392|NCT01165359|DRUG|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
214527393|NCT01165359|DRUG|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days."
214695035|NCT05323968|DIAGNOSTIC_TEST|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
215141249|NCT06594718|PROCEDURE|Endoscopic diverticulotomy using a non-tunnelization technique|Endoscopic diverticulotomy with diverticuloscope, Knife Septotomy, or Clutch Cutter
215141250|NCT06590818|PROCEDURE|High tibial osteotomy (HTO|To investigate the effect of body mass index (BMI) on the early efficacy of high tibial osteotomy (HTO) in the treatment of varus knee osteoarthritis
215141251|NCT06597136|OTHER|Diaphragmatic kinesiology taping|The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.
215141252|NCT06597136|OTHER|Accessory respiratory muscle kinesiology taping|Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.
215141253|NCT06597136|OTHER|Sham kinesiology taping|Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.
215141254|NCT06591013|PROCEDURE|Fecal microbiota transplantation|Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
215141255|NCT06595979|DRUG|Polymyxin B|Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
214695036|NCT01249872|DRUG|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
215141256|NCT06595043|DEVICE|the tip opening angle to the left|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.
214695037|NCT01249872|DRUG|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
214695038|NCT01249872|DRUG|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
214695039|NCT01249872|DRUG|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
214695040|NCT01249872|DRUG|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
214695041|NCT01249872|DRUG|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
215141257|NCT06595043|DEVICE|the tip opening angle to the right|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
215141258|NCT06602843|PROCEDURE|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
215141259|NCT06596512|DRUG|PARTICS using a single ICS add on|Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
215141260|NCT06596512|DRUG|MART|Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
215141261|NCT06592729|BEHAVIORAL|education|intervention group was taken to scenario-based simulat
215141262|NCT06604273|DIAGNOSTIC_TEST|Fibroblast Activation Protein Inhibitor|PET CT imaging using the fibroblast activation protein inhibitor tracer
215141263|NCT06595927|DIAGNOSTIC_TEST|Cervical extensor endurance test|Monitoring the clinical parameters of head and neck immobility during the cervical extensor endurance test to correlate them with muscular activity by MRI and other cervical clinical tests
215141264|NCT06591260|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
215141265|NCT06592560|DEVICE|ELISA|Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
214454471|NCT06566430|BEHAVIORAL|PrEP My Way intervention|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
214454472|NCT06566430|BEHAVIORAL|PrEP My Way intervention without STI testing|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
214454473|NCT06566430|BEHAVIORAL|Enhanced standard of care|These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
214454474|NCT04241068|DRUG|Aducanumab|Administered as specified in the treatment arm.
214454475|NCT02955784|DEVICE|Sinasprite Mobile App|Mobile App
214454476|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
214454477|NCT06566196|PROCEDURE|Cardiac Cath|Patient will undergo standard of care Cardiac Cath and in addition invasive CPET (Cardiopulmonary exercise testing) will be performed during the procedure.
214454478|NCT06040827|DEVICE|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
214454479|NCT03317158|DRUG|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
214454480|NCT03317158|RADIATION|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
215141266|NCT06594276|OTHER|Local instillation of antibiotics|Systemic antibiotics are usually used with needle aspiration of breast abscess. However local instillation of antibiotics will be an in intervention in this study.
215141267|NCT06593873|OTHER|Use of typodont head model in addition to theoretical periodontal education|Use of typodont phantom head model in addition to theoretical periodontal education
215141268|NCT06593873|OTHER|Theoretical periodontal education|Theoretical periodontal training only
215141269|NCT06596174|PROCEDURE|Transcutaneous spinal cord stimulation (tSCS)|The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).
215141270|NCT06596174|PROCEDURE|Short-term Machine-Assisted Ankle Movement Training with tSCS|The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time
215141271|NCT06596174|PROCEDURE|Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS|"The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS).~Each session will last for 30 minutes, conducted three times per week, over a period of four weeks."
215141272|NCT06598566|OTHER|Nottingham Hip Fracture Score (NHFS) score|Nottingham Hip Fracture Score (NHFS) score in patients above 60 years undergoing hip fracture surgery.
215141273|NCT06598566|OTHER|Acute Physiology and Chronic Health Evaluation (APACHE)-II score|Acute Physiology and Chronic Health Evaluation (APACHE)-II score in patients above 60 years undergoing hip fracture surgery
215141274|NCT06590766|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
215141275|NCT06603974|PROCEDURE|surgery|After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.
215141276|NCT06603974|DRUG|Benmelstobart|1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
215141277|NCT06603974|DRUG|tegafur|it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
215141278|NCT06603974|DRUG|oxaliplatin|130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
215141279|NCT06603974|DRUG|albumin paclitaxel|260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
215141280|NCT06596122|DRUG|Vitamin D (Cholecalciferol )|In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.
215141281|NCT06595186|DRUG|JK-1201I|JK-1201I will be administered.
215141282|NCT06595186|DRUG|Temozolomide (TMZ)|Temozolomide will be administered.
215141283|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at camp with the guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at camp will follow the same principles as the usual HABIT-ILE. The therapy will take place in a rehabilitation center, and caregivers will provide therapy during the sessions, coached by trained supervisors on site~* The intervention day will then take place, lasting for 5 hours with the constant presence of supervisors. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
215141284|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at home with the online guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at home will follow the same principles as the usual HABIT-ILE. The therapy will take place at children's home, caregivers will provide therapy during the sessions, coached by trained supervisors online~* The intervention day will then take place, lasting for 5 hours with the supervisors through online setting. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
215141285|NCT06588816|DEVICE|optical coherence tomography|"Optical coherence tomography (OCT) is a non-invasive imaging test . It uses light waves to take cross-section pictures of the retina .~With OCT, the ophthalmologist can see each of the retina's distinctive layers, and so we can use it to study the changes in pseudoexfoliation syndrome."
215141286|NCT06596824|BEHAVIORAL|Training intervention|Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
215141287|NCT06594341|PROCEDURE|Visit frequency|"Fortnightly visit frequency for moderate phase~Nutritional supplement: 1 daily sachet of RUTF as soon as a child admitted with MUAC\<115mm or edema reaches a MUAC=\>115mm or absence of edema."
215141288|NCT06594341|DIETARY_SUPPLEMENT|Suppression of the transition period|Transitioning children admitted with MUAC\<115mm or edema to receiving 1 daily sachet of RUTF as soon as they reach a MUAC=\>115mm and absence of edema
215141289|NCT06594341|PROCEDURE|Simplified treatment|Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=\>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=\>125mm for 2 consecutive weeks.
215141290|NCT06589817|DRUG|Hydrochloride Carliprazine capsules|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
215141291|NCT06589817|DRUG|Aripiprazole tablets|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
215141292|NCT06590636|PROCEDURE|Expressive touching|"Woman's anxiety level was measured with the State-Trait Anxiety Inventory scale Following these measurements, expressive touching that lasted 15-20 minutes was performed in the following manner.~The hands of the expressive touching performer warmed to body temperature (should not be cold).~The woman's hand close to the performer was placed between the hands of the expressive touching performer.~The woman's palm was gently grasped with the palms of the expressive touching performer.~The hand below was fixed and the upper part of the woman's hand was gently rubbed with the hand above.~Before and after massaging, the woman's arms and shoulders were touched at intervals.~During the procedure, the woman was called by her name, and verbal communication with the woman was continued by holding her hands firmly and sincerely as if a handshaking done.~Before the woman's discharge from the center, her anxiety level was measured with the State-Trait Anxiety Inventory scale"
215141293|NCT06604013|PROCEDURE|non-surgical full-mouth periodontal therapy without using adjunct disinfectants|Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
215141294|NCT06604013|DIAGNOSTIC_TEST|GCF level of adiponectin and resistin|Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
215141295|NCT06593613|BEHAVIORAL|RUBI-A|"The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills."
215141296|NCT06593613|BEHAVIORAL|R-ISLEA|R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
215141297|NCT06601036|DRUG|Sevoflurane|Patients will undergo fiberoptic intubation under sevoflurane sedation.
215141298|NCT06601036|DRUG|2% Xylocaine (2 ml )|Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
215141299|NCT06592898|BEHAVIORAL|straight leg raise|The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
214454481|NCT03317158|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
214454482|NCT03317158|DRUG|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
215141300|NCT06592898|BEHAVIORAL|wall squat|The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.
215141301|NCT06592898|BEHAVIORAL|direct squat|The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle. The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
214454483|NCT03317158|DRUG|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
214454484|NCT03317158|BIOLOGICAL|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
214454485|NCT03317158|DRUG|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
214454486|NCT03317158|OTHER|To be determined|Other regimens to be determined
214454487|NCT04126018|DIAGNOSTIC_TEST|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
214454488|NCT04126018|DIAGNOSTIC_TEST|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
215141302|NCT06592898|BEHAVIORAL|wall squat assisted by elastic bands|Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
214527394|NCT03038945|OTHER|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
215141303|NCT06601777|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
215141304|NCT06601777|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
215141305|NCT06590779|OTHER|Aminexil® active+ lotion|Aminexil® active+ lotion
215141306|NCT06590779|OTHER|Finasteride 1mg|Finasteride 1 mg
215141307|NCT06599112|OTHER|Densah Burs|Series of drilling burs inserted in the osteotomy with special design that have a large negative rake angle flute, a cutting chisel edge and a tapered shank, so as they enter deeper into the osteotomy and they have a progressively increasing diameter that controls the expansion process. These burs are used with a standard surgical engine and can densify bone by rotating in the noncutting direction (counterclockwise at 800-1,200 rotations per minute) or drill bone by rotating in the cutting direction (clockwise at 800-1,200 rotations per minute) with an in and out movement together with copious saline irrigation and increasing bone plasticity and ability to expand under rate dependent stress.
215141308|NCT06599112|OTHER|Osteotomes|The osteotomes kit are a series of tools that first designed by Summers in 1994. The concept was to maintain the existing bone by compressing trabecular bone laterally and apically with minimal trauma to improve the bone density. The condensed bone in this way will have to put in act a double repairing mechanism, from one side represented by the normal processes of osteointegration and on the other side from the processes of the reparation post fracture like that depends on BMU (bone modelling units) which create new spaces for the new vessels and afterwards filling all the gaps between the bone and the implant.
215141309|NCT06599112|OTHER|Conventional drilling|The implant drilling kit provided by the manufacturer will be used for the implant placement, using the pilot drill followed by consequent drills according to the size of the osteotomy needed.
215141310|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
215141311|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
215141312|NCT06586060|OTHER|lung ultrasound guided fluid balance strategy|"Lung ultrasound (LUS) guided fluid management based on B-Line score assessment using LUS within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first~In patients with BLS = 0-14, a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with BLS ≥ 15, a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15. To reach daily targeted FB, furosemide-induced diuresis and RRT will be used In case of shocked patients with BLS \&amp;amp;lt; 15: they will receive fluid boluses and packed RBCs to achieve a Hb of 10 and a MAP of \&amp;amp;gt;65 mmHg.~In case of shocked patients with BLS ≥ 15: they will start norepinephrine infusion to reach a MAP of \&amp;amp;gt;65 mmHg."
215141313|NCT06586060|OTHER|usual care guided fluid balance strategy|fluid balance management will be guided to maintain an adequate intravascular volume while minimising weight gain within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values To reach daily targeted fluid balance, furosemide-induced diuresis and RRT will be used
215141314|NCT06592430|OTHER|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
215141315|NCT06592430|OTHER|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
215141316|NCT06603506|OTHER|tumour and blood samples|Tumour and blood samples
215141317|NCT00837382|BEHAVIORAL|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
214527395|NCT03038945|OTHER|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
214527396|NCT01801423|DRUG|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
214454489|NCT03907904|DEVICE|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
214454490|NCT04492007|BEHAVIORAL|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
215141318|NCT00837382|BEHAVIORAL|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
215141319|NCT00505271|GENETIC|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
215141320|NCT06590701|OTHER|Early dart throwing motion-mobilization|We compare two different mobilisations in the rehabilitation of patients following scapholunate ligament reconstruction
215141321|NCT03493997|COMBINATION_PRODUCT|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
215141322|NCT03493997|RADIATION|Radiotherapy only|Radiotherapy only
215141323|NCT06591104|DIAGNOSTIC_TEST|24 hour urinary protein|proteinuria and renal function impairment will be detected in patients of four groups
215141324|NCT06604676|PROCEDURE|guided soft tissue grafting|guided soft tissue grafting techniquea special digital guide was fabricated for one intervention non-guided soft tissue grafting technique receive the traditional technique without guide
215141325|NCT06604676|PROCEDURE|non-guided soft tissue grafting technique|the graft was taken with traditional technique without guide
215141326|NCT06592417|DRUG|JSKN016 injection|JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
215141327|NCT06585800|OTHER|sample collection|blood and/or tissue collection
215141328|NCT06604247|BEHAVIORAL|Cognitive Behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
215141329|NCT06654635|DRUG|Rhomboid intercostal plane block|The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
215141330|NCT06654635|OTHER|Erector spinae plane block|The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. Erector spinae plane block will be performed at the level of T9 bilaterally.
215141331|NCT06654635|OTHER|Control group|No block will be performed, and patient will receive general anesthesia (GA) only.
214454491|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
214454492|NCT05598203|BEHAVIORAL|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
214454493|NCT06537323|DRUG|Femoral nerve block with0.25% bupivacaine guided by ultrasound.|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
214527397|NCT05163106|DRUG|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
214527398|NCT05163106|DRUG|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
214527399|NCT06214598|DIETARY_SUPPLEMENT|Supplement|Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
214527400|NCT06214598|DIETARY_SUPPLEMENT|AI diet|diet rich in whole grains, healthy oils and polyphenols,
214527401|NCT06214598|DIETARY_SUPPLEMENT|Placebo|Placebo caps with standard diet
214527402|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
214527403|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
215141332|NCT06988410|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
214454494|NCT06537323|DRUG|PENG block with0.25% bupivacaine guided by ultrasound.|PENG block with0.25% bupivacaine guided by ultrasound.
215141333|NCT06993168|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
215141334|NCT06596902|BEHAVIORAL|Physical Activity|The 12-month intervention will progressively increase in intensity and complexity to teach parents/children more complex sports skills and behavioral techniques, to prepare them to become future team leaders for nutrition education and sports sessions. In addition, the family Olympics events will take place after every 3-month to reinforce progression, social support; progressive improvements: Phase 1: Beginner (months 0-3) will focus on introductory concepts and basic sports skills and will focus on establishing consistent behavioral patterns and social support. Phase 2: Intermediate (months 4-6) will begin to introduce slightly more complex nutrition behavioral concepts and increase difficulty of sport skills, and reinforce behavioral patterns from phase 1. Phase 4: Advanced (months 10-12) will teach parents and children advanced sports skills ; nutrition knowledge so that they may become team leaders to help implement future activity sessions and nutrition education sessions.
215141335|NCT06591208|DEVICE|pulsed dye laser|PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm
215141336|NCT06591208|DEVICE|Carboxytherapy|"carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic popcorn appearance."
215141337|NCT06588114|OTHER|Antistress Ball|Hemodialysis patients will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention
215141338|NCT06588114|OTHER|The Valsalva maneuver|The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm.
215141339|NCT06588114|OTHER|Skin cooling|Hemodialysis patients will be provided with lowering of skin temperature with a skin cooling device by the researcher for 10 minutes before arteriovenous fistula intervention is made to hemodialysis patients
214454495|NCT06537323|DRUG|Preoperative IV fentanyl 100microgram|Preoperative IV fentanyl 100microgram
214454496|NCT06137937|BEHAVIORAL|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
214454497|NCT04347161|DEVICE|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
214454498|NCT04347161|OTHER|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
214454499|NCT05401630|OTHER|Study Procedures|"All participants will answer a series of questionnaires that address several factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours before testing. Participants will also undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use.~A 3-day food recall diary, cognitive assessments via the NIH Toolbox, and a Sleep diary during home monitoring will be collected."
214454500|NCT04451044|DEVICE|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
214454501|NCT04451044|PROCEDURE|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
214527404|NCT03822195|PROCEDURE|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
215141340|NCT06604052|PROCEDURE|Reduced-Port Fusion Surgery|(1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon\&#39;s trocar placement plan and the stoma therapist\&#39;s positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.
215141341|NCT06604052|PROCEDURE|Traditional surgery|(1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.
215141342|NCT06991244|BEHAVIORAL|EMDR 2.0 Group Protocol|A short-term trauma-focused group protocol adapted from EMDR 2.0, delivered in three sessions over one week, targeting PTSD, depression, and anxiety symptoms among earthquake survivors. The first session lasted 90 minutes, followed by two 60-minute sessions. The intervention was administered face-to-face in a container city in Malatya, Türkiye. All sessions were conducted by a certified EMDR therapist who had completed advanced EMDR 2.0 training.
214527405|NCT00733226|DRUG|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
214527406|NCT00733226|DRUG|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
214527407|NCT02397343|DRUG|Hyperbaric oxygen|
214527408|NCT03964181|OTHER|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
214527409|NCT04596605|OTHER|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
214527410|NCT04596605|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules daily for 12 weeks
214527411|NCT02845310|PROCEDURE|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
214454502|NCT04058743|DEVICE|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
214454503|NCT04058743|DEVICE|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
214454504|NCT04169373|DRUG|Upadacitinib|Upadacitinib tablet administered orally
214454505|NCT04169373|DRUG|Placebo|Placebo for upadacitinib tablet administered orally
214527412|NCT02845310|PROCEDURE|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
214527413|NCT01911923|PROCEDURE|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
214527414|NCT01911923|PROCEDURE|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
215141343|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
214527415|NCT05705336|DRUG|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
214527416|NCT05705336|DRUG|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
214527417|NCT03014817|PROCEDURE|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
214454506|NCT03974217|DRUG|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
214454507|NCT03974217|DRUG|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
214454508|NCT05057429|DEVICE|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
214454509|NCT05057429|OTHER|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
214527418|NCT03014817|PROCEDURE|Electrocautery|Dissection with electrocautery
214527419|NCT03722485|DEVICE|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
214527420|NCT03722485|BIOLOGICAL|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
215141344|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
215141345|NCT06996418|OTHER|Intergenerational mealtime (intervention + follow-up)|Intergenerational lunchtime at an intentional intergenerational dining room 4 days a week for 8 weeks. Once this period is over, this group will move on to a follow-up phase that will last for another 8 weeks, during which they will eat 5 days a week in different dining rooms with their generational peers, as they had been doing up to the time of the intervention. Finally, they will undergo a last follow-up period of about 2 weeks.
215141346|NCT06996418|OTHER|Intergenerational mealtime (wait + intervention)|Waiting period consisting of 8 weeks (while Intervention Group #1 is using the intergenerational dining room). During this period toddlers and older people will eat lunch 5 days a week with their generational peers in separate dining rooms as they have been doing before the intervention. They will then move to eating together lunch 4 days a week for 8 weeks in the intergenerational dining room. Once this period is over they will enter a final follow-up phase for about 2 weeks during which they will go back to eat in generationally separate dining rooms.
215141347|NCT06999538|OTHER|Radiologist interpretation|two interpretations (with and without Liflow, oncology imaging tool).
215141348|NCT06999759|DEVICE|cute serum box|After the children in the intervention group were made to draw pictures, they were glued to the designed cute serum box and chemotherapy drug serum was hidden and they were provided to receive their treatment.
215141349|NCT06999759|OTHER|coloring book and coloring pencils|Children in the intervention group were provided with a coloring book and coloring pencils to make a picture to hang on the picture box.
215141350|NCT03928132|BEHAVIORAL|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
215141351|NCT06997965|DRUG|Mirikizumab|Mirikizumab is an IL-23 antagonist.
215141352|NCT06998758|DRUG|Megestrol Acetate|Oral megestrol acetate at 625 mg/day is given from the beginning to the end of neoadjuvant chemotherapy.
215141353|NCT06999681|OTHER|No Interventions|this is an observational cohort study. There was no intervention.
215141354|NCT06999681|OTHER|No interventions|No interventions in this study. This study is an observational study.
215141355|NCT06089668|OTHER|Observational Study|None, this is a non-interventional trial
215141356|NCT05010629|DRUG|9-ING-41|Intravenous infusion
215141357|NCT05010629|DRUG|Carboplatin|Intravenous infusion
215141358|NCT06871267|BEHAVIORAL|General Healthy Diet|Participants will follow the quarter-quarter-half plate diet as per the Malaysian Healthy Plate guideline.
215141359|NCT06871267|BEHAVIORAL|Crohn's Disease Exclusion Diet (CDED)|Participants will follow the Crohn's Disease Exclusion Diet (CDED), which consists of three phases with specific dietary restrictions.
215141360|NCT06382597|OTHER|Nordic hamstring exercise|Nordic Hamstring Exercise involves a controlled descent of the upright torso from a vertical kneeling position forward towards the ground (parallel to the ground) and returning to the starting position. The ankle joints are stabilized by the other person's grip during a series of exercises.
215141361|NCT04998331|OTHER|No Intervention|This is a non-interventional study.
215141362|NCT04887116|BEHAVIORAL|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person.
215141363|NCT06700135|OTHER|sensorimotor stimulation program sessions|The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
215141364|NCT06704737|DEVICE|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia
215141365|NCT06704737|DEVICE|Patching|Conventional patching therapy.
215141366|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Psychological Distancing|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
214454510|NCT06064721|OTHER|Buerger-Allen Exercise|Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
214454511|NCT05150197|DEVICE|VisuALL|Virtual Reality Visual Field Device
214454512|NCT05150197|DEVICE|Humphrey Visual Field|Standard of care Visual Field test
214454513|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous KR|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
214454514|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous PS|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous PS femoral component"
214454515|NCT05624944|DRUG|TS-142 5 mg|Single-dose of 5 mg of TS-142
214454516|NCT04793841|OTHER|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
214454517|NCT05661552|DRUG|Evolocumab 140 MG/ML|Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe
214454518|NCT05661552|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg will be assigned to all participants
214454519|NCT05661552|DRUG|Ezetimibe 10mg|Ezetimibe 10mg will be assigned to all participants
214454520|NCT06470971|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody|Receive anti-PD-L1 monoclonal antibody therapy
214454521|NCT06470971|BIOLOGICAL|Anti-PD1 Monoclonal Antibody|Receive anti-PD1 monoclonal antibody therapy
214454522|NCT06470971|PROCEDURE|Biopsy|Undergo biopsy
214454523|NCT06470971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214454524|NCT06470971|PROCEDURE|Bone Scan|Undergo bone scan
214454525|NCT06470971|PROCEDURE|Computed Tomography|Undergo CT
214454526|NCT06470971|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214454527|NCT06470971|OTHER|Quality-of-Life Assessment|Ancillary studies
214454528|NCT06470971|BIOLOGICAL|Siltuximab|Given IV
214454529|NCT04143711|DRUG|DF1001|Immunotherapy agent targeting NK cells.
214454530|NCT04143711|DRUG|Nivolumab|Anti-PD-1 immunotherapy agent
214454531|NCT04143711|DRUG|Nab paclitaxel|A chemotherapy treatment combining paclitaxel with albumin
214454532|NCT04143711|DRUG|Sacituzumab Govitecan-hziy|A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
214454533|NCT05220709|DIAGNOSTIC_TEST|bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)|The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is \< 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
214454534|NCT03481881|DRUG|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
214454535|NCT04911452|DEVICE|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
214454536|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
214454537|NCT01497405|BEHAVIORAL|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
214454538|NCT01497405|BIOLOGICAL|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
214454539|NCT05939453|OTHER|Sham Light|Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
214454540|NCT05939453|OTHER|Bright Light Therapy|Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
214454541|NCT06491563|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
214454542|NCT06491563|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
214454543|NCT06491563|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
214454544|NCT05454137|BEHAVIORAL|Shared medical appointment|Shared medical appointment
214454545|NCT04635098|DRUG|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
214454546|NCT04635098|DRUG|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
215141367|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Reinterpretation|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
215141368|NCT05926297|PROCEDURE|Application NaOCl gel + HA gel|First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel
215141369|NCT05926297|PROCEDURE|Non-surgical mechanical debridement|Only mechanical debridement with curettes ans scaler tips
215141370|NCT06705283|PROCEDURE|yoga and home exercise|"The intervention period for the study was determined as 6 weeks. It has been decided that yoga practice will be done 3 times a week for 45 minutes.~Poses to be practiced in the yoga group:~1. Tadasana (mountain pose)~2. Utkatasana (chair pose)~3. Trikonasana (triangle pose)~4. Malasana (squat pose):~5. Viparita Karani Variation (legs up the wall pose)~6. Salamba Set Bandhasana (supported bridge pose)~7. Supta Baddha Konasana (reclining bound angle pose)~8. Savasana (dead pose)"
215141371|NCT06705283|PROCEDURE|whole body vibration training and home exercise|A total of 40-45 minutes of training was planned for WBVT, including warm-up (10 minutes), active phase (25-30 minutes) and cooling phase (5 minutes).
215141372|NCT06705283|PROCEDURE|home exercise group|Pelvic floor muscle training will be done in the home exercise group. This training will be done in the form of slow and fast contractions of the pelvic floor muscles in supine, chin up, sitting, squat and standing positions.
214454547|NCT04898777|PROCEDURE|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
214454548|NCT01333969|PROCEDURE|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
214454549|NCT04986605|DEVICE|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
214454550|NCT04986605|DRUG|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
214454551|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
214454552|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
214454553|NCT06538961|OTHER|Blood samples: Main Study group|the collection of blood samples at specified time points.
214454554|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
214454555|NCT06538961|OTHER|Urine Sample- Main Study group|-Post-transplant monthly urine sample collection for 6 months in 10-18% of subjects
214454556|NCT06538961|OTHER|Urine sample- Sub-study group|\- Post-transplant monthly urine sample collection for 6 months in all subjects
214454557|NCT06538961|OTHER|Blood sample: Sub-study group|Monthly blood sample collection for 6 months
214454558|NCT05294588|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
214454559|NCT05294588|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
214454560|NCT05294588|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
214454561|NCT05294588|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
215141373|NCT04668690|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
214454562|NCT05294588|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
214454563|NCT05294588|BIOLOGICAL|Influenza Vaccine|All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
214454564|NCT05294588|BIOLOGICAL|Tetanus-diptheria Vaccine|All participants will receive the Td vaccine, 0.5 mL intramuscularly.
214454565|NCT05982015|DEVICE|Remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
214527421|NCT03477409|OTHER|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
214527422|NCT00349622|DRUG|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
214527423|NCT00349622|OTHER|placebo|an inactive substance
214527424|NCT04713176|DRUG|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
214527425|NCT04713176|DRUG|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
215141374|NCT04668690|DRUG|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
215141375|NCT06730126|DRUG|Soquelitinib|Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.
215141376|NCT06845644|OTHER|Quantitative neuromuscular MRI|Quantitative neuromuscular MRI is used to quantify a number of biomarkers associated with these pathophysiological processes
215141377|NCT06845644|OTHER|Neuromuscular ultrasound|Neuromuscular ultrasound is used to quantified nerve diameter variation
215141378|NCT06847217|OTHER|Mouth moisturization|This intervention will include mouth cleaning with water and gauze to remove plaque and debris. Water-based hydrating gels (bioXtra Dry Mouth Oral Gel, Lifestream Pharma N.V., Seneffe, Belgium) will be then applied to all oral structures, including the lips, tongue, palate, and cheeks, using gloved fingers or a small toothbrush. In the presence of dried secretions, the gels will be massaged into these areas and left to act for a few minutes to facilitate removal and reduce patient discomfort.
215141379|NCT06847217|OTHER|Mechanical oral hygiene care|Patients with natural teeth will be treated using a soft toothbrush and a sodium lauryl sulfate-free fluoride toothpaste (meridol® toothpaste, Colgate-Palmolive Company, Belgium). The teeth will be brushed using the modified BASS technique. Subsequently, the tongue will be cleaned with either a scraper. For participants wearing dentures, the dentures will be cleaned using a denture brush and soap.
214454566|NCT05982015|DEVICE|Sham remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
214454567|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy with a radiologist's guidance with map|All patients will undergo prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after mapping extracted by a single genitourinary radiologist in the Department of Radiology of our hospital.
214454568|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy without a radiologist's guidance with map|All patients will undergo cognitive prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after reported by a single genitourinary radiologist in the Department of Radiology of our hospital.
214527426|NCT06478108|DEVICE|IRSW-MIM|IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
214527427|NCT06292559|DEVICE|Bilateral STN deep brain stimulation|patients with Meige syndrome underwent bilateral subthalamic stimulation
214527428|NCT06292559|DEVICE|Bilateral GPi deep brain stimulation|patients with Meige syndrome underwent bilateral pallidal stimulation
215141380|NCT06847217|OTHER|Combined care|Patients will receive a comprehensive oral hygiene intervention incorporating mouth cleaning, mechanical oral hygiene, and moisturization. The procedure will begin with oral cleaning using water and gauze, followed by mechanical oral hygiene, and conclude with the application of the hydrating gel.
215141381|NCT06848439|DRUG|benmelstobart-Anlotinib-Chemo|"Neoadjuvant Treatment Regimen :~Benmelstobart: 1200mg, Day 1, IV (21 days per cycle); Anlotinib: 10mg, Days 1-14, orally (21 days per cycle); Cisplatin: 60mg/m², Day 1, IV (21 days per cycle); Albumin-bound Paclitaxel: 260mg/m², IV infusion, Day 1 (21 days per cycle). Total of 3 cycles.~Surgery is performed within 2 weeks after completing neoadjuvant therapy. Postoperative adjuvant treatment is selected based on pathological grading:~Group A (pCR): Postoperative RT alone: 40Gy/5 weeks. Group B (MPR): Postoperative RT alone: 50Gy/5 weeks. Group C (partial pathological response/no pathological response) : low and intermediate-risk patients: RT: 60Gy/6w; High-risk patients: CCRT: 60-66Gy/6-6.6w + cisplatin: 60mg/m2 Q3W, 2-3 cycles.~All patients also received adjuvant Benmelstobart 3-4 weeks after surgery, as well as maintenance Benmelstobart for a total duration of 1 year."
215141382|NCT04498598|DEVICE|A/Z Supraglottic airway|Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
215141383|NCT06239493|DIAGNOSTIC_TEST|IVUS Guided|Those already undergoing an IVUS guided percutaneous vascular intervention
214454569|NCT05179655|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
214527429|NCT04662736|OTHER|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
214527430|NCT01902381|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214527431|NCT06170502|DEVICE|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
215141384|NCT06812819|DIAGNOSTIC_TEST|Cryostimulation is a form of cooling the body using low temperatures without causing tissue damage. The stimulus effect is achieved at temperatures below - 110⁰C, in a short time of 1-3 minutes. The p|PBC protocol involved the participant being in a JUKA cryosauna (model 0104-1), for 3 minutes at - 140 ° C± - 20 ° C with the lid at shoulder height and the head over the chamber. The cryosauna was cooled with liquid nitrogen, and the temperature was monitored by a computer. Participants entered the cabin wearing clogs, wool socks, shorts, gloves, caps, and disposable PP non-woven masks to protect against inhalation of nitrogen fumes. The temperature inside the cryosauna was recorded at 30-second intervals using a sensor placed on the bottom of the cabin. The temperature of the room where the cryosauna was located was 21.0 ± 0.9° C, and the humidity of the air during the treatment was 35 ± 2, 0 % monitored with a QUIGG type LE 2014.14 moisture absorber.
215141385|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
214454570|NCT05179655|OTHER|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
214454571|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
214454572|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
214454573|NCT06206811|DRUG|OD-07656|innate immune modulator
214454574|NCT06298487|OTHER|Patient questionnaires|Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
214454575|NCT04729686|DRUG|Pericapsular Nerve Block|Per Standard Institutional Practice
215141386|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
214454576|NCT04729686|DRUG|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
214454577|NCT05923385|DIAGNOSTIC_TEST|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
214454578|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
214454579|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
214454580|NCT05081583|DRUG|Midazolam Hcl 1Mg/Ml Inj|0.5 mL of an intravenous solution (1 mg/mL) will be administered.
214454581|NCT05081583|DIETARY_SUPPLEMENT|Goldenseal (Hydrastis canadensis)|Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.
214454582|NCT05463887|BEHAVIORAL|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
214454583|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
215141387|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
215141388|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
214454584|NCT06515132|PROCEDURE|SCS Stimulation|Participants will accept the SCS stimulus for six months
214527432|NCT05138432|BEHAVIORAL|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
214527433|NCT00755716|DRUG|Placebo (sugar pill)|patients receive
214527434|NCT00755716|DRUG|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
214527435|NCT00755716|DRUG|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
215141389|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
215141390|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
215141391|NCT02153632|DRUG|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
215141392|NCT02153632|DRUG|Placebo|subjects are given an identical placebo tablet
215141393|NCT05888038|DEVICE|virtual reality|virtual reality
214454585|NCT06515132|PROCEDURE|Sham Stimulation|Sham stimulation will be performed in the first three months after surgery, and SCS stimulation will be started in the fourth month after surgery
214454586|NCT05257850|DEVICE|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
214454587|NCT05257850|DEVICE|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
214454588|NCT01413100|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214454589|NCT01413100|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
214527436|NCT02394509|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
214527437|NCT02762500|DRUG|LYC-30937-EC|
215141394|NCT01615939|DRUG|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
215141395|NCT01615939|DRUG|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
214454590|NCT01413100|DRUG|Cyclophosphamide|Given IV
214454591|NCT01413100|BIOLOGICAL|Filgrastim|Given SC
214454592|NCT01413100|OTHER|Laboratory Biomarker Analysis|Correlative studies
214454593|NCT01413100|DRUG|Mycophenolate Mofetil|Given PO
214454594|NCT01413100|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
214454595|NCT01413100|DRUG|Plerixafor|Given SC
214454596|NCT01413100|OTHER|Quality-of-Life Assessment|Ancillary studies
214454597|NCT01413100|OTHER|Questionnaire Administration|Ancillary studies
214527438|NCT02762500|DRUG|Placebo|
214527439|NCT02229396|DRUG|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
214527440|NCT02229396|DRUG|Exentide|2 mg
214527441|NCT02229396|DRUG|Dapagliflozin|10 mg once daily Dapagliflozin
215141396|NCT04671017|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
215141397|NCT02892344|DRUG|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
215141398|NCT02892344|DRUG|MF 200 μg|MF 200 μg o.d. via Twisthaler®
215141399|NCT04062539|DEVICE|Sentinel and Spider|Dual filter and single filter
215141400|NCT02611297|PROCEDURE|Cryoprobe|
214454598|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
214454599|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
214454600|NCT06537232|DIETARY_SUPPLEMENT|Greens-based Supplement|Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
214454601|NCT06437977|RADIATION|SBRT|SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
214527442|NCT06479551|OTHER|high intensity-low volume resistance training|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
214527443|NCT06479551|OTHER|Moderate intensity-high volume resistance training|13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
215141401|NCT05661617|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|"Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests."
215141402|NCT04459884|PROCEDURE|mechanical ventilation|mechanical ventilation \> 48h
215141403|NCT02998463|DEVICE|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
215141404|NCT05678881|DRUG|High dose RLS103|8 mg CBD inhaled powder
215141405|NCT05678881|DRUG|placebo inhaled powder|placebo inhaled powder
215141406|NCT05678881|DRUG|Low dose RLS103|4 mg CBD inhaled powder (open label)
214454602|NCT06437977|DRUG|Toripalimab|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
214454603|NCT05369403|DRUG|Lebrikizumab|Administered SC
214454604|NCT04207814|BIOLOGICAL|biological sample|biological samples will be taken from the subjects included
214527444|NCT02267564|PROCEDURE|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
214527445|NCT02267564|PROCEDURE|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
214527446|NCT01565239|DEVICE|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
214527447|NCT02599077|DRUG|Dienogest|patients assigned to this treatment receive 2 milligrams per day
214527448|NCT02599077|DRUG|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
215141407|NCT02705742|BIOLOGICAL|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
215141408|NCT03290066|DEVICE|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
215141409|NCT03290066|OTHER|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
215141410|NCT04524780|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
215141411|NCT01520506|DEVICE|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
215141412|NCT00425269|BEHAVIORAL|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
215141413|NCT03997344|BEHAVIORAL|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
215141414|NCT03997344|BEHAVIORAL|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
215141415|NCT03549936|OTHER|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
215141416|NCT00758667|DRUG|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
215141417|NCT01546610|OTHER|insoles intervention|EVA insole with arch support and bar retrocapital
215141418|NCT01546610|OTHER|placebo insole|EVA insole flat
215141419|NCT03886896|DRUG|Lidocaine|Lidocaine infusion during surgery
215141420|NCT01980563|PROCEDURE|ultrasound|
215141421|NCT01980563|PROCEDURE|combined monitoring|
214454605|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
214454606|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
214454607|NCT05402930|DIAGNOSTIC_TEST|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
214454608|NCT05949658|DRUG|Sirolimus|5mg, 10mg, or 15mg once weekly sirolimus
214454609|NCT05949658|DRUG|Everolimus|5mg, 10mg, or 15mg once weekly everolimus
214454610|NCT04750525|DEVICE|BreEStim|120 BreEStim stimuli will applied for about 10-30 minutes.
214454611|NCT04750525|DEVICE|EStim|120 EStim stimuli will applied for about 10-30 minutes.
214454612|NCT05612971|BEHAVIORAL|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
214454613|NCT05612971|BEHAVIORAL|iAmHealthy|The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
214454614|NCT06273241|OTHER|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
214454615|NCT04855526|DRUG|High THC/No CBD Marihuana|high THC (65 mg THC) and no CBD (0 mg CBD)
215141422|NCT04953858|OTHER|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
215141423|NCT02762916|OTHER|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
215141424|NCT03521284|OTHER|Parental educational program|Behavior: psychotherapy, life hygiene advice
215141425|NCT03521284|OTHER|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
215141426|NCT06097715|DIAGNOSTIC_TEST|upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy to asses present of esophageal varices and will be done to all patient group
215141427|NCT06097715|DIAGNOSTIC_TEST|1- Complete blood count 2- Coagulation profile|cmplete blood count to detect thrombocytopenia, liver function test to detect if they are elevated,and any impaired coagulation profile
215141428|NCT03531112|BEHAVIORAL|Appetite Awareness Treatment + Lifestyle Modification|The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
215141429|NCT03544749|DEVICE|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
215141430|NCT03544749|DEVICE|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
215141431|NCT01423175|DRUG|Clofarabine, ara-C|
215141432|NCT01423175|DRUG|FLAMSA|
215141433|NCT01084655|DRUG|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
215141434|NCT01084655|DRUG|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
215141435|NCT01084655|DRUG|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
215141436|NCT01999881|BEHAVIORAL|exercise intervention|Receive aerobic and exercise intervention
215141437|NCT01999881|PROCEDURE|standard follow-up care|Receive usual care
215141438|NCT01999881|PROCEDURE|quality-of-life assessment|Ancillary studies
215141439|NCT01999881|OTHER|laboratory biomarker analysis|Correlative studies
215141440|NCT03554525|DIETARY_SUPPLEMENT|Fat-binder damm|3 sticks every day during 12 months
215141441|NCT03554525|DIETARY_SUPPLEMENT|Placebo|3 sticks every day during 12 months
215141442|NCT02931877|DRUG|sevoflurane|
215141443|NCT02931877|DRUG|propofol|
215141444|NCT05894915|PROCEDURE|open surgery|Open surgery is a traditional surgery method.
215141445|NCT05894915|PROCEDURE|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
215141446|NCT03072407|BIOLOGICAL|PB-119 injection|
215141447|NCT03072407|BIOLOGICAL|PB-119 injection placebo|
215141448|NCT06109896|OTHER|Self Report Questionaires|Collection and analysis of information from patient self-report assessments and integration with clinical information from assessments performed routinely during cancer treatment.
215141449|NCT05379374|COMBINATION_PRODUCT|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
215141450|NCT03980054|DRUG|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
215141451|NCT03980054|DRUG|Placebo|placebo 400mg, orally once daily for one year
215141452|NCT05019326|DRUG|Andrographis Paniculata|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
215141453|NCT05019326|DRUG|Boesenbergia|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
215141454|NCT05019326|OTHER|Standard supportive treatment|as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
215141455|NCT03638193|BIOLOGICAL|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
215141456|NCT02804113|DEVICE|Supera Peripheral Stent System|
215141457|NCT04179136|DIETARY_SUPPLEMENT|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
215141458|NCT04179136|DIETARY_SUPPLEMENT|Placebo treatment matching intervention|Placebo treatment matching intervention
215141459|NCT06016049|OTHER|EMLA® adjuvant|cutaneous forearm deafferentation
215141460|NCT06016049|BEHAVIORAL|Sensory training|Sensibility training of the median nerve
215141461|NCT02397161|OTHER|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
215141462|NCT02397161|OTHER|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
215141463|NCT02397161|OTHER|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
215141464|NCT02084992|OTHER|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
215141465|NCT02084992|OTHER|Telephonic disease management|
215141466|NCT04255238|DRUG|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
215141467|NCT04255238|DRUG|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
215141468|NCT03045796|DEVICE|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
215141469|NCT05910437|OTHER|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
215141470|NCT03847597|PROCEDURE|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
215141471|NCT00248404|DRUG|NB1011|
215141472|NCT02415322|OTHER|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
215141473|NCT01507259|OTHER|cocoa|70% versus 34%
215141474|NCT00625170|DRUG|olanzapine|olanzapine 10 mg/day for 8 days
215141475|NCT00625170|DRUG|Haloperidol|haloperidol 3 mg/day for 8 days
215141476|NCT03098875|DRUG|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
215141477|NCT03098875|DRUG|Propofol|General anesthesia using propofol as a hypnotic agent
215141478|NCT03098875|DRUG|Remifentanil|General anesthesia using remifentanil as an analgesic.
215141479|NCT04937218|BEHAVIORAL|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
215141480|NCT04428853|BEHAVIORAL|iyengar yoga|different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
215141481|NCT00535496|DRUG|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
215141482|NCT01841099|DRUG|Mesalamine|Mesalamine granules
215141483|NCT01841099|DRUG|Placebo granules|Provided by Ferring Pharma
215141484|NCT05056389|DRUG|Oxaliplatin|Administration of oxaliplatin intraperitoneally
215141485|NCT00239330|DRUG|Rosuvastatin|
215141486|NCT00239330|DRUG|Atorvastatin|
215141487|NCT01074814|DRUG|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
214454616|NCT04855526|DRUG|High THC/High CBD Marihuana|high THC (65 mg THC) and high CBD (50 mg CBD)
215141488|NCT03841461|OTHER|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
215141489|NCT03841461|OTHER|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; \>5 refers to poor sleep quality.
215141490|NCT03841461|OTHER|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
214454617|NCT04855526|DRUG|No THC/No CBD Marihuana|no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
214454618|NCT03507608|DRUG|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
214454619|NCT03507608|OTHER|Placebo|placebo prior to brachytherapy and prostatic biopsy
214454620|NCT00579202|DEVICE|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
214454621|NCT05176951|DRUG|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
214454622|NCT05176951|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
214454623|NCT06836973|DRUG|Blinatumomab|Blinatumomab is used at its starting dose of 9 µg per day and administered as continuous infusion for 5 days (total dose of 38.5 µg). After a 1-week pause, the patients receive a second 5-day infusion with blinatumomab of total 38.5 µg of the drug.
214454624|NCT06836427|BIOLOGICAL|CMTS0929|CMTS0929 is defined as suspension from washed microbiota.
214454625|NCT06455631|PROCEDURE|Facilitated Tucking, Oral Breast Milk , Kangaroo Care|Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
214454626|NCT05887609|DRUG|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
214568445|NCT06534957|OTHER|Online mindfulness-based stress reduction|The online MBSR intervention sessions will be available in a website created specifically for this purpose, where each pre-recorded session will be uploaded so that each patient can begin the intervention at the same time as their chemotherapy regimen. Each session will last approximately 1 hour, for a total of 6 sessions. The topics that will be covered in these sessions include: mindfulness overview, stress and suffering, emotional regulation, meditation, management of stressful situations, self-compassion and acceptance. Participants will watch 1 session per week following the order that will be indicated on the website; patients will be encouraged to watch the sessions during their chemotherapy infusions. During these sessions, patients will be instructed in mindfulness practice and will perform targeted exercises to promote complete consciousness, including mindful body awareness (body scan), gentle yoga exercises, and meditation.
214454627|NCT05887609|DRUG|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
214454628|NCT03836911|OTHER|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
214454629|NCT03836911|OTHER|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
214454630|NCT05683548|DRUG|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
214454631|NCT05683548|DRUG|Tenofovir Disoproxil Fumarate|
214454632|NCT05683548|DRUG|Pegylated interferon alpha2a|
214454633|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
214454634|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
214454635|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
214454636|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
215141491|NCT03841461|OTHER|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
215141492|NCT01114243|DEVICE|Ultrasound imaging|
215141493|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
215141494|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
215141495|NCT00364104|DRUG|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
215141496|NCT00364104|DRUG|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
215141497|NCT00961077|DRUG|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
215141498|NCT02671708|DRUG|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
215141499|NCT02671708|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
215141500|NCT02671708|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
215141501|NCT03013803|DIETARY_SUPPLEMENT|Nutricomp Drink Plus Fibre|
215141502|NCT01391078|DEVICE|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
215141503|NCT01391078|DEVICE|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
215141504|NCT02667795|OTHER|Monitored walking based exercise|Monitored walking based exercise
215141505|NCT00586378|DEVICE|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
215141506|NCT00000817|DRUG|Amitriptyline hydrochloride|75 mg oral tablet taken daily
215141507|NCT00000817|DRUG|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
215141508|NCT00000817|PROCEDURE|Point acupuncture|Standardized or alternate acupuncture procedure
215141509|NCT05024032|DRUG|Tirzepatide|Administered SC
215141510|NCT05024032|DRUG|Placebo|Administered SC
215141511|NCT02231086|PROCEDURE|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
215141512|NCT02231086|DRUG|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
215141513|NCT02231086|PROCEDURE|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
215141514|NCT01222052|DRUG|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
215141515|NCT05727124|DEVICE|Poul Gjessing|maxillary canine retraction
215141516|NCT05727124|DEVICE|T loops|T loops
214454637|NCT06837025|OTHER|Fascial manipulation|Fascial manipulation once a week
214454638|NCT06656286|DEVICE|Intra-Uterine suturing by X-TACK device and hysteroscope|"After general anesthesia and entering the abdomen with the laparoscope, Truclear hysteroscope with X-tack attached will be inserted to the uterine cavity. Insertion of normal saline to the cavity and applying 4 points suturing to the uterus. The procedure will be monitored by external laparoscopic camera located in the abdominal cavity. After the hysterectomy the uterus will be opened and the suture will be examine.~A preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure."
214454639|NCT06243588|OTHER|clinical records review|review the medical records, radiological imaging, and histological data of these patients
214454640|NCT06828055|DRUG|Placebo|Matching Placebo to VK2735
214454641|NCT06828055|DRUG|VK2735|Active Treatment
214454642|NCT06209606|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
214454643|NCT06209606|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
214454644|NCT06209606|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
214454645|NCT06562634|PROCEDURE|erector spinea plane block|an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivicaine 0.25%, and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
214454646|NCT06562634|DRUG|Morphine Sulfate|intravenous morphine will be given in a dose of 0.1-0.2mg/kg to maintain intraoperative analgesia.
215141517|NCT04909047|DEVICE|parassacral transcutaneous electrostimulation|Use of parassacral transcutaneous electrostimulation
215141518|NCT02865447|DEVICE|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
215141519|NCT05592717|DRUG|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
215141520|NCT03529032|DRUG|Methadone|methadone for control postoperative pain
215141521|NCT05939882|DRUG|low concentration atropine (0.01%)|low concentration atropine (0.01%)
215141522|NCT05939882|DRUG|low concentration atropine (0.02%)|low concentration atropine (0.02%)
215141523|NCT05939882|DRUG|low concentration atropine (0.04%)|low concentration atropine (0.04%)
215141524|NCT05939882|DRUG|Placebo|Placebo eye drop
215141525|NCT03591406|DRUG|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
215141526|NCT03591406|DRUG|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
215141527|NCT02644421|DRUG|VVZ-149|
214454647|NCT06836817|OTHER|1-Laryngyscopic examination 2-Acoustic analysis|"1. History taking.~2. voice sample by recording (in sustained vowel \|a\| )~3. Auditory Perceptual Assessment (APA): (Kotby et al., 1986)~4. Laryngyscopic examination:~   Patients will taken to a room with a tower on which the 8.5 mm 70 rigid laryngoscope (KARL STORZ - endoscope) (Tele pack X LED).~5. Acoustic analysis: The voice sample will be subjected to computerized acoustic analysis using Multidimensional voice program software(MDVP)."
214454648|NCT06160999|BEHAVIORAL|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
214454649|NCT06160999|BEHAVIORAL|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
214454650|NCT06837519|DRUG|Lidocaine|Patients will receive lidocaine 0.3 mg/kg over 10 min loading, 0.3 mg/kg/h infusion after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of dexmedetomidine.
214454651|NCT06837519|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of lidocaine.
214454652|NCT06837519|DRUG|Lidocaine and Dexmedetomidine|Patients will receive lidocaine (0.3 mg/kg in 10 min loading, 0.3 mg/kg/h infusion) and dexmedetomidine infusions (0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h) till 10 min before the end of the operation.
214454653|NCT02736500|DRUG|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
214454654|NCT02736500|DRUG|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
215141528|NCT02644421|DRUG|Lidocaine|
215141529|NCT02644421|DRUG|Placebo|
215141530|NCT03599674|BEHAVIORAL|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
215141531|NCT01083771|DIETARY_SUPPLEMENT|Olive Oil|Minimum of 3 tablespoon of olive oil per day
215141532|NCT02066181|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215141533|NCT02066181|OTHER|Placebo Administration|Given PO
215141534|NCT02066181|OTHER|Quality-of-Life Assessment|Optional ancillary studies
215141535|NCT02066181|DRUG|Sorafenib Tosylate|Given PO
215141536|NCT04495595|OTHER|No intervention|There is no intervention due to the observational, cross-sectional design of the study
215141537|NCT00000982|DRUG|Zidovudine|
215141538|NCT00000982|DRUG|Didanosine|
215141539|NCT02695108|OTHER|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
215141540|NCT02695108|OTHER|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
215141541|NCT02334904|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
215141542|NCT02334904|DRUG|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
215141543|NCT01449968|OTHER|home visit|home visit of UMG
215141544|NCT01449968|OTHER|telephone management|telephone management of the situation reported by the patient's GP
215141545|NCT04446884|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
215141546|NCT04446884|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
215141547|NCT00379964|DRUG|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC\>500/mm3), and for up to 72 hours later.
215141548|NCT02393378|DRUG|Namilumab|Namilumab injection
215141549|NCT02393378|DRUG|Adalimumab|Adalimumab SC injection
215141550|NCT02393378|DRUG|Methotrexate|Methotrexate tablet
215141551|NCT02393378|DRUG|Folic Acid|Folic Acid Tablet
215141552|NCT00939393|DEVICE|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
215141553|NCT00939393|DEVICE|Balloon Sinuplasty|Balloon dilatation of sinuses
215141554|NCT05669911|DEVICE|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
215141555|NCT02851615|BEHAVIORAL|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
215141556|NCT03461614|OTHER|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
214454655|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
214454656|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
214454657|NCT06467227|OTHER|exercise modality|exercise using legs and arms
214454658|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
214454659|NCT02649790|DRUG|KPT-8602|Participants will receive KPT-8602 oral tablets.
215141557|NCT03461614|OTHER|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
215141558|NCT04871126|OTHER|inflammatory indexes and CHA2DS2-VASc score|inflammatory indexes and CHA2DS2-VASc score
215141559|NCT00471939|DRUG|I-020502|1 mcg/mL TG-PDGF.AB
215141560|NCT00438009|DRUG|Coxsackievirus A21|Two doses of drug, separated by 48 hours
215141561|NCT06299046|PROCEDURE|robot-assisted radical prostatectomy|surgical removal of the entire prostate and the seminal vesicles, followed by the vescico-urethral anastomosis to restore the continuity of the lower urinary tract performed using Da Vinci Si and Xi Surgical System (Intuitive Surgical, Sunnyvale, California, USA)
215141562|NCT00354978|DRUG|5-Fluorouracil|"400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection."
215141563|NCT00354978|DRUG|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
215141564|NCT00354978|DRUG|Leucovorin|400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
215141565|NCT00354978|DRUG|Irinotecan|180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
215141566|NCT04214158|OTHER|Assessment|Assessment
214454660|NCT02649790|DRUG|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
214454661|NCT02649790|DRUG|Dexamethasone|Participants will receive dexamethasone oral tablets.
214454662|NCT05072340|BEHAVIORAL|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
214454663|NCT05729399|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
214454664|NCT03337971|DIETARY_SUPPLEMENT|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
214527449|NCT04919330|BEHAVIORAL|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
214527450|NCT04919330|BEHAVIORAL|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
214527451|NCT00960284|DRUG|capecitabine|Given orally
214527452|NCT00960284|DRUG|cisplatin|Given IV
214527453|NCT00960284|DRUG|epirubicin hydrochloride|Given IV
214527454|NCT00960284|DRUG|fluorouracil|Given IV
214527455|NCT00960284|DRUG|gemcitabine hydrochloride|Given IV
214527456|NCT04768751|DIAGNOSTIC_TEST|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
214527457|NCT03279536|COMBINATION_PRODUCT|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
214527458|NCT03279536|COMBINATION_PRODUCT|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
214527459|NCT00045097|DRUG|ixabepilone|
214695042|NCT03570281|DRUG|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
215141567|NCT05764785|BEHAVIORAL|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
215141568|NCT01843621|BIOLOGICAL|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
215141569|NCT02389296|OTHER|Questionnaire|Questionnaires will be distributed to nursing staff
215141570|NCT00714727|PROCEDURE|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
215141571|NCT02670811|DIETARY_SUPPLEMENT|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
214527460|NCT05082662|DRUG|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|One Diclofenac tablet was administered orally.
214527461|NCT05082662|DRUG|Cataflam® 50 coated tablet|One Diclofenac tablet was administered orally.
214527462|NCT02185365|RADIATION|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
214527463|NCT01514630|DRUG|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
214527464|NCT01170871|DRUG|Ixabepilone|
214527465|NCT01170871|DRUG|Pemetrexed|
214527466|NCT03942861|DRUG|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
214527467|NCT03974451|DEVICE|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
214527468|NCT03974451|DEVICE|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
215141572|NCT02670811|DIETARY_SUPPLEMENT|Acidified milk|150 mL daily of artificially acidified milk
215141573|NCT03937570|DEVICE|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
215141574|NCT03606369|DRUG|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
214527469|NCT04330261|OTHER|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
214527470|NCT00889733|DRUG|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
214527471|NCT00912054|DRUG|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
214527472|NCT00912054|DRUG|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
214695043|NCT03570281|DRUG|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
214695044|NCT00003117|DRUG|carboplatin|
214695045|NCT00003117|DRUG|paclitaxel|
214695046|NCT04335266|DRUG|SHR2554|SHR2554
214454665|NCT03337971|DIETARY_SUPPLEMENT|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
214454666|NCT06838156|DRUG|Bupivacain|Suprainguinal Fascia Iliaca Compartment block was performed with a linear probe placed over the inguinal ligament using a portable ultrasound device. After visualization of the femoral nerve, 30 ml of 0.25% bupivacaine was injected into the fascia iliaca overlying the iliopsoas muscle using an appropriate needle.
215141575|NCT03606369|DRUG|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
215141576|NCT03742323|DRUG|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
215141577|NCT02946723|PROCEDURE|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
215141578|NCT02946723|PROCEDURE|X-ray|Lead implantation surgery for SNM using X-ray technique
215141579|NCT00224575|OTHER|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
215141580|NCT00224575|OTHER|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
215141581|NCT00371150|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
215141582|NCT02426021|DRUG|MLN1202|Subcutaneous administration of MLN1202
215141583|NCT02426021|DRUG|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
215141584|NCT03714672|DRUG|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
215141585|NCT03714672|DRUG|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
214454667|NCT06838156|DRUG|Bupivacain|Quadratus Lumborum Type 3 block was performed using a portable ultrasound device with a linear probe placed between the costal margin and the iliac crest on the lateral abdominal wall. 30 ml of 0.25% bupivacaine was injected between the quadratus lumborum and psoas muscles using an appropriate needle.
214454668|NCT02907099|DRUG|CXCR4 Antagonist BL-8040|Given SC
214454669|NCT02907099|BIOLOGICAL|Pembrolizumab|Given IV
214454670|NCT02907099|OTHER|Pharmacological Study|Correlative studies
214454671|NCT06832956|PROCEDURE|robotic bronchoscopy system|cryobiopsy with the help of RBS
215141586|NCT03714672|DRUG|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
215141587|NCT03714672|DRUG|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
215141588|NCT00732030|DEVICE|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
215141589|NCT03176706|OTHER|no intervention|this is a completely observational study, NO INTERVENTION
215141590|NCT05189717|DRUG|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
214527473|NCT01137552|DRUG|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
214527474|NCT02149576|PROCEDURE|Low Dose Computed Tomography Imaging|
214527475|NCT02149576|PROCEDURE|Chest Radiograph Imaging|
214527476|NCT02842125|DRUG|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
214527477|NCT02842125|DRUG|Xeloda|Oral metronomic chemotherapeutic agent
214527478|NCT02842125|DRUG|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
214527479|NCT02842125|DRUG|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
214527480|NCT02810483|DRUG|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
215141591|NCT02345070|DRUG|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215141592|NCT02345070|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215141593|NCT04383600|PROCEDURE|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
214527481|NCT02810483|DRUG|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
214527482|NCT04717362|DRUG|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
214527483|NCT01381614|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
214527484|NCT03711825|DRUG|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
215141594|NCT02887677|DRUG|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
214527485|NCT03711825|PROCEDURE|Imaging Assessment (MRI)|Imaging assessments \[MRI\] will be performed on specified days according to protocol
214527486|NCT03711825|PROCEDURE|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
215141595|NCT02887677|DRUG|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
215141596|NCT01136161|BIOLOGICAL|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
215141597|NCT01136161|BIOLOGICAL|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
215141598|NCT01136161|BIOLOGICAL|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
215141599|NCT01136161|BIOLOGICAL|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
215141600|NCT03081117|DRUG|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
214527487|NCT05213559|OTHER|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
214527488|NCT05213559|OTHER|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
214527489|NCT04881396|BIOLOGICAL|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
214527490|NCT03275402|BIOLOGICAL|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
214527491|NCT01247870|DRUG|Metformin|Metformin 1 g twice daily for 28-35 days
214527492|NCT01247870|DRUG|Placebo|Placebo
214527493|NCT06036797|DRUG|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
215141601|NCT03081117|DRUG|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
215141602|NCT05800080|DRUG|Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
215141603|NCT01742026|PROCEDURE|Aspergillus PCR technique|Aspergillus DNA PCR technique
215141604|NCT01742026|PROCEDURE|Aspergillus AGA technique|Aspergillus AGA technique
215141605|NCT00125177|BEHAVIORAL|Knack therapy|
215141606|NCT01245530|DRUG|Aricept|Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks
215141607|NCT01245530|DRUG|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
215141608|NCT04179669|DRUG|IBI306|Administered by subcutaneous injection
214454672|NCT06837207|DEVICE|transcranial magnetic stimulation|Individualized transcranial magnetic stimulation of targets based on the association between the orbitofrontal cortex and the functional activity of the habenula .
214454673|NCT00346788|PROCEDURE|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
214454674|NCT06828978|PROCEDURE|Full Pulpotomy|After control of bleeding in teeth allocated to the intervention group, the gel is to be placed into the pulp chamber to a level 3 mm below the cementoenamel junction (CEJ) over the root pulp stumps.
214454675|NCT05597878|DRUG|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
215141609|NCT04179669|DRUG|placebo|Administered by subcutaneous injection
214454676|NCT05597878|DRUG|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
214527494|NCT06036797|DRUG|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
214527495|NCT06036797|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
214527496|NCT00199992|PROCEDURE|application of autologous platelet gel|
214527497|NCT01282749|BEHAVIORAL|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
214527498|NCT01282749|BEHAVIORAL|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
215141610|NCT03408093|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
215141611|NCT01747395|OTHER|Exercise training|The heart failure patients are subjected to differents protocols of physical training
215141612|NCT01949818|DRUG|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
215141613|NCT01949818|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
214527499|NCT01256372|DRUG|AP214|AP214
214527500|NCT01256372|DRUG|Placebo|Placebo; intravenous infusion
214527501|NCT05135156|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
214527502|NCT05135156|BEHAVIORAL|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
214527503|NCT04148716|PROCEDURE|additional biopsies|additional biopsies during a fibroscopy planned in the care
214527504|NCT03344913|BEHAVIORAL|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
215141614|NCT03474419|PROCEDURE|laser surgery|laser surgery
215141615|NCT01303016|DIETARY_SUPPLEMENT|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
215141616|NCT01398709|OTHER|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
215141617|NCT01398709|OTHER|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
215141618|NCT00275912|DRUG|Oxcarbazepine|
215141619|NCT05511233|DIETARY_SUPPLEMENT|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
214454677|NCT05597878|DRUG|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
214454678|NCT05597878|DRUG|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
214454679|NCT05597878|DRUG|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
214454680|NCT06087471|DIETARY_SUPPLEMENT|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
214454681|NCT06087471|DIETARY_SUPPLEMENT|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
215141620|NCT01533207|OTHER|Clinical Observation|Patients followed clinically
215141621|NCT01533207|DRUG|Docetaxel|Given IV
215141622|NCT01533207|DRUG|Doxorubicin Hydrochloride|Given IV
215141623|NCT01533207|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
215141624|NCT01533207|DRUG|Gemcitabine Hydrochloride|Given IV
215141625|NCT01533207|BIOLOGICAL|Pegfilgrastim|Given SC
215141626|NCT04057326|DRUG|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
215141627|NCT04057326|DRUG|Placebo|2 tablets/time, 3 times daily,Oral Administration.
215141628|NCT04489836|DIETARY_SUPPLEMENT|Glutalytic®|Glutalytic® capsule
215141629|NCT04489836|DIETARY_SUPPLEMENT|DE111®|DE111® capsule
215141630|NCT04489836|OTHER|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
215141631|NCT01100619|DRUG|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
215141632|NCT01100619|DRUG|XL184|dosed with capsules daily
215141633|NCT05887388|BEHAVIORAL|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
215141634|NCT02451722|DEVICE|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
215141635|NCT00321620|DRUG|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
215141636|NCT00321620|BIOLOGICAL|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
215141637|NCT01287962|DRUG|apatinib|750 mg，po，QD； 28 days every cycle
215141638|NCT01287962|DRUG|placebo|po，QD； 28 days every cycle
215141639|NCT02490098|OTHER|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
215141640|NCT02490098|OTHER|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
215141641|NCT02490098|OTHER|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
215141642|NCT02490098|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
215141643|NCT02490098|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
215141644|NCT02490098|DEVICE|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
215141645|NCT02490098|DEVICE|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
215141646|NCT01238926|DIETARY_SUPPLEMENT|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
215141647|NCT01238926|OTHER|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
215141648|NCT01238926|OTHER|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
215141649|NCT00828776|BIOLOGICAL|Heparin sodic - Cristália|5000UI/mL
215141650|NCT00828776|BIOLOGICAL|heparin - Liquemine (Roche)|5000UI/mL
214454682|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
214454683|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
214454684|NCT06819293|BIOLOGICAL|IB-T101 injection|IB-T101 injection to treat advanced clear renal cell carcinoma
214454685|NCT00390793|DRUG|Cyclophosphamide|Given IV
214454686|NCT00390793|DRUG|Cytarabine|Given IV or IT
214454687|NCT00390793|DRUG|Dasatinib|Given PO
214454688|NCT00390793|DRUG|Dexamethasone|Given IV or PO
214454689|NCT00390793|DRUG|Doxorubicin|Given IV
214454690|NCT00390793|DRUG|Methotrexate|Given IV or IT
214454691|NCT00390793|DRUG|Prednisone|Given PO
214454692|NCT00390793|DRUG|Vincristine|Given IV
214454693|NCT06126809|DEVICE|Steep-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
214454694|NCT06126809|DEVICE|Flat-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
214454695|NCT06126809|DEVICE|Sham-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
214454696|NCT06837597|DRUG|Jianzhong Qushi Formula|Jianzhong Qushi Formula (A Chinese traditional formula, approved by Chinese Patent, No. ZL202210097886.0)
214454697|NCT06837597|DRUG|Placebo|A simulated Chinese medicine placebo, with similar appearance and smell to Jianzhong Qushi Formula.
214454698|NCT06832397|PROCEDURE|Diagnostic laparoscopy|Diagnostic laparoscopy with peritoneal biopsies
214454699|NCT06836505|BIOLOGICAL|CART therapy|GD2/B7H3 CAR T-cell therapy
214454700|NCT06837753|OTHER|Exercise|It consist of traditional exercises.
214454701|NCT06833099|DIAGNOSTIC_TEST|VAS Point and Imaging Examination|"This intervention uses a machine learning model to predict the risk of recurrent lumbar disc herniation (rLDH) in patients who have had percutaneous endoscopic interlaminar discectomy (PEID) at the L5-S1 level. The model combines clinical data (e.g., BMI, disease duration, diabetes) and imaging metrics (e.g., posterior disc height index, spinal canal stenosis) to create a personalized risk score, unlike traditional methods that rely on clinical judgment or imaging alone.~Key Features:~Data-Driven Approach: Developed using data from 309 patients for real-world relevance.~Advanced Variable Selection: Identifies eight key predictors using LASSO regression.~Multiple Machine Learning Techniques: Uses algorithms like support vector machine, random forest, and extreme gradient boosting.~Optimized for Clinical Decision-Making: Assists surgeons in personalizing treatment plans to reduce recurrence risk."
214454702|NCT05706077|DEVICE|active tDCS|The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.
214454703|NCT05706077|DEVICE|sham tDCS|The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.
214454704|NCT05706077|OTHER|real Physical Therapy|Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.
214454705|NCT05706077|OTHER|placebo Physical Therapy|The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
214527505|NCT01724047|BEHAVIORAL|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
214568451|NCT04883242|DRUG|Carfilzomib|Given IV
214568452|NCT04883242|DRUG|Dexamethasone|Given PO or IV
215141651|NCT03829228|DIETARY_SUPPLEMENT|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
215141652|NCT02962414|DRUG|everolimus|everolimus, 2mg dispersible tablets
215141653|NCT02515370|OTHER|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
215141654|NCT00807508|DIETARY_SUPPLEMENT|placebo|wheat meal capsules with each main meal
215141655|NCT00807508|DIETARY_SUPPLEMENT|leucine|daily leucine capsules with each main meal
215141656|NCT05259189|DRUG|NBL-012 Injection|a single subcutaneous injection
215141657|NCT05259189|DRUG|Placebo|a single subcutaneous injection
215141658|NCT06371092|DRUG|UltraEZ|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
215141659|NCT06371092|DRUG|Placebo|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
215141660|NCT06834295|DRUG|Vapendavir|Single oral dose of \[14C\]vapendavir
215141661|NCT06228170|BEHAVIORAL|Rehabilitation therapy|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
215141662|NCT06228170|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215141663|NCT01123798|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
215141664|NCT00150085|DRUG|cyclosporine micro-emulsion|
215141665|NCT05742542|OTHER|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
215141666|NCT02844569|DEVICE|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
215141667|NCT02844569|DEVICE|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
214454706|NCT06822751|DRUG|Fosfomycun-trometamol|Study of the efficacy and safety of Fosfomycin trometamol as a 14-day treatment using a 3 g sachet every 2 days for 14 days for the treatment of male urinary tract infections in primary care: open-label, non-randomised, multicentre, inter-regional trial.
214454707|NCT06513416|PROCEDURE|Elective upper abdominal surgery|The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
214454708|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
214527506|NCT01724047|BEHAVIORAL|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
214527507|NCT03284489|OTHER|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
214527508|NCT00059735|DRUG|E7070|
214527509|NCT01372826|DRUG|NKTR118 Group1|Oral dose, 25 mg
214527510|NCT01372826|DRUG|NKTR118 Group 2|Oral dose, 25 mg
214527511|NCT01372826|DRUG|NKTR118 Group3|Oral dose, 25 mg
214527512|NCT01372826|DRUG|NKTR118|Oral dose, 25 mg
214527513|NCT05814679|OTHER|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
214527514|NCT05814679|OTHER|Attention match|kidney function instruction
215141668|NCT02844569|DEVICE|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
215141669|NCT03304626|DRUG|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
215141670|NCT03304626|DRUG|Standard of Care Prednisone|Prednisone taper (Standard of Care)
215141671|NCT01887327|PROCEDURE|Phototherapy|Phototherapy starts within 30 minutes before or after injection
214454709|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
214454710|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
214454711|NCT04850274|BEHAVIORAL|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
214454712|NCT04850274|BEHAVIORAL|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
214454713|NCT06835192|OTHER|Experimental group|Initially, the first author presented a 25-minute lecture with a PowerPoint presentation to the nurses of the EG. Following this, each nurse received an IAD directive wheel chart. In the subsequent 25 minutes, the first author presented three clinical cases examples and relevant information, encouraging the nurses to utilize the IAD directive wheel chart in groups. To conclude the session, a 5-minute quiz was conducted, featuring five actual clinical photographs. After the course, the nurses were instructed to take the IAD directive wheel chart back to their clinics for review and use in health education and teaching.
214527515|NCT00543634|DRUG|Premarin/MPA|0.625 mg/2.5 mg X4
214527516|NCT00543634|DRUG|Premarin/MPA|0.625 mg/5 mg X 2
214527517|NCT00543634|DRUG|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
214527518|NCT02445183|OTHER|None, N/A|
214568453|NCT04883242|BIOLOGICAL|Isatuximab|Given IV
214568454|NCT04883242|DRUG|Pomalidomide|Given PO
214568455|NCT04883242|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214527519|NCT00926952|DRUG|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
214527520|NCT00926952|DEVICE|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
214527521|NCT05600998|DRUG|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
214527522|NCT03824353|BEHAVIORAL|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
214527523|NCT03824353|BEHAVIORAL|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
214527524|NCT03669900|PROCEDURE|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
214527525|NCT02574897|OTHER|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
215141672|NCT01887327|DRUG|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
215141673|NCT01887327|DRUG|Placebo|Matching placebo administered by IM injection
215141674|NCT01816035|OTHER|Laboratory Biomarker Analysis|Correlative studies
215141675|NCT01816035|OTHER|Pharmacological Study|Correlative studies
215141676|NCT01816035|BIOLOGICAL|Trastuzumab Emtansine|Given IV
215141677|NCT03027609|DRUG|AR-105|monoclonal antibody
214454714|NCT06835192|OTHER|Control Group|The first author conducted a 25-minute knowledge lecture for the nurses in the CG on the same topics covered in the EG. This lecture included an explanation of IAD, its causes, the latest global classification of IAD, as well as methods for skin prevention and IAD care. Following the lecture, the same three clinical examples presented in the EG were discussed for an additional 20 minutes, during which the nurses were divided into groups for case discussions. Finally, a 5-minute quiz competition was held, featuring the same five actual clinical photographs used in the EG.
214454715|NCT03349996|DEVICE|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
214454716|NCT06829394|OTHER|Program Assignment|The intervention group will include People living with HIV who were assigned to the Arms Around You Program in the lottery.
214454717|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
214454718|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
214454719|NCT02791204|DEVICE|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
214454720|NCT02791204|DEVICE|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
214454721|NCT05079256|DEVICE|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
214454722|NCT05491382|PROCEDURE|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
214454723|NCT05491382|PROCEDURE|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
214454724|NCT05491382|PROCEDURE|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
214527526|NCT02574897|OTHER|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
214527527|NCT04405856|DEVICE|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
214527528|NCT04433949|OTHER|Best Practice|Receive standard of care
214527529|NCT04433949|RADIATION|Low Dose Radiation Therapy|Undergo LDRT
214527530|NCT03857516|DEVICE|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
214527531|NCT00647998|DRUG|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
214527532|NCT00647998|OTHER|Standard care|
215141678|NCT03027609|DRUG|Placebo|matching placebo (+ SOC antibiotics)
215141679|NCT00027534|BIOLOGICAL|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
215141680|NCT01434615|DEVICE|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
215141681|NCT01434615|OTHER|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
215141682|NCT00499070|GENETIC|polymerase chain reaction|
215141683|NCT00499070|OTHER|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
215141684|NCT00499070|OTHER|immunologic technique|
215141685|NCT00499070|PROCEDURE|biopsy|
215141686|NCT01462370|DRUG|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
215141687|NCT01462370|DRUG|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
215141688|NCT01462370|DRUG|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
215141689|NCT01462370|DRUG|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
215141690|NCT01462370|DRUG|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
215141691|NCT03036202|DRUG|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
214527533|NCT02727647|DRUG|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
214527534|NCT02727647|DRUG|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
214527535|NCT00308841|DRUG|Lidocaine (drug)|
214527536|NCT01259440|BEHAVIORAL|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
214527537|NCT01259440|BEHAVIORAL|Usual Care|Consists of one week telephone call and one month clinic visit
214568456|NCT04883242|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214568457|NCT04883242|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal x-ray
215141692|NCT02809482|OTHER|Eucaloric feeding|3 days of a diet designed to maintain energy balance
215141693|NCT02809482|OTHER|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
215141694|NCT01501565|PROCEDURE|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
215141695|NCT02224807|BEHAVIORAL|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
215141696|NCT02224807|BEHAVIORAL|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
215141697|NCT03341702|OTHER|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
215141698|NCT05828147|DRUG|Rituximab|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
215141699|NCT02341183|DEVICE|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
215141700|NCT02341183|DEVICE|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
215141701|NCT01834989|DRUG|Insulin-like growth factor I|
215141702|NCT01834989|DRUG|Placebo|
215141703|NCT06525012|OTHER|Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin|During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
215141704|NCT06450899|DRUG|Prochlorperazine Maleate|Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.
215141705|NCT06450899|DRUG|Placebo|The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
215141706|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 1|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
215141707|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 2|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
215141708|NCT05106894|BEHAVIORAL|smartphone application to promote nurturing care|see arm description
215141709|NCT05106894|BEHAVIORAL|printed caregiving materials|see arm description
215141710|NCT05021185|OTHER|Interactive Mobile Doctor (iMD)|Video educational tool
215141711|NCT05941481|COMBINATION_PRODUCT|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)|"1. Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid\*14d + oxaliplatin 130mg/m2, d1, q21d);~2. Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f."
215141712|NCT05697770|DRUG|Sodium bicarbonate|Sodium bicarbonate 8.4% will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
214454725|NCT06829589|OTHER|Removal of economic incentives linked to 7 quality-of-care indicators|"The 7 intervened indicators will be the following:~* Blood pressure (BP) control in type-2 diabetes mellitus.~* BP control in ischemic cardiopathy/cerebrovascular accident.~* Hypertension: BP control in chronic renal insufficiency.~* Hypertension: BP control.~* Diagnostic adequacy of hypertension.~* Correct treatment of atrial fibrillation.~* Inhaler verification.~Professionals randomized to an arm with this intervention will no longer receive an economic reward for reaching a specific goal in the results of these 7 indicators.~The study guarantees no financial loss since the amount of money linked to these incentives will be automatically given to professionals under the concept of participating in the study."
214568458|NCT04883242|PROCEDURE|Computed Tomography|Undergo CT
214568459|NCT04883242|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
215141713|NCT05697770|DRUG|5% Dextrose|5% dextrose will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
215141714|NCT05236816|OTHER|Fatigue (physical exercise)|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
215141715|NCT06166732|BEHAVIORAL|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
214568460|NCT04883242|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214527538|NCT05388864|BEHAVIORAL|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
214527539|NCT02924181|DEVICE|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
214527540|NCT06423859|DRUG|Articaine|supraclavicular brachial plexus block with articaine 2%
214527541|NCT06423859|DRUG|Dexmedetomidine|supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
215141716|NCT06166732|BEHAVIORAL|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
215141717|NCT04385277|PROCEDURE|Biospecimen Collection|Correlative studies
215141718|NCT04385277|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
215141719|NCT04385277|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
215141720|NCT04385277|PROCEDURE|Computed Tomography|Undergo CT
214454726|NCT06829589|OTHER|Removal of information provision linked to 7 quality-of-care indicators|"The 7 indicators will be the same as the previous intervention.~Professionals randomized to an arm with this intervention will no longer see the following in the online platform:~* Numeric result of the indicator.~* Color coding to represent indicator result in relation to the yearly goal.~* 12-month evolution graph.~Next to the 7 indicator names, only the link to a list of patients that are not fulfilling the indicator criteria will be presented (identifying the patients missing a treatment, a control or any other intervention), since this is considered a tool to support clinical practice beyond informing on the result of an indicator."
214454727|NCT06836557|DRUG|Tradipitant|BID
214454728|NCT03675282|DRUG|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
214454729|NCT03675282|DRUG|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
214454730|NCT04186520|BIOLOGICAL|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
214454731|NCT04186520|BIOLOGICAL|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
214454732|NCT04186520|BIOLOGICAL|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
214454733|NCT06838494|BEHAVIORAL|IVR-CST (Immersive Virtual Reality Cognitive Stimulation Therapy)|IVR-CST involves 14 sessions of cognitive stimulation therapy conducted twice a week in a virtual reality environment. Each session lasts approximately 45 minutes and utilizes head-mounted displays (HMDs) to immerse participants in engaging, themed activities. The therapy aims to enhance cognitive function and social interaction through interactive and stimulating virtual experiences tailored for individuals with mild cognitive impairment (MCI).
214527542|NCT03968536|BEHAVIORAL|fall prevention|Training in physiotherapy sessions and ergonomic home development
214527543|NCT02966600|OTHER|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
214527544|NCT02966600|OTHER|Physical Activity|The control group followed its usual weekly physical activity routine
214527545|NCT06149052|OTHER|SMART TRAINING|Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
215141721|NCT04385277|BIOLOGICAL|Dinutuximab|Given IV
215141722|NCT04385277|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
215141723|NCT04385277|RADIATION|Iobenguane I-123|Undergo 123I-MIBG
215141724|NCT04385277|DRUG|Irinotecan|Given IV
215141725|NCT04385277|DRUG|Isotretinoin|Given PO
215141726|NCT04385277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215141727|NCT04385277|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215141728|NCT04385277|BIOLOGICAL|Sargramostim|Given SC or IV
215141729|NCT04385277|DRUG|Temozolomide|Given PO or via enteral tube
215141730|NCT01596010|DRUG|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
215141731|NCT03692624|BEHAVIORAL|Biofeedback|Heart Rate Variability Biofeedback
215141732|NCT00335088|DRUG|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
215141733|NCT03566511|DRUG|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
215141734|NCT03566511|DRUG|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
215141735|NCT04538989|DRUG|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
215141736|NCT04538989|DRUG|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
215141737|NCT04538989|DRUG|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
215141738|NCT04538989|DRUG|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
215141739|NCT02988466|BIOLOGICAL|Haplo HCT <55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
215141740|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"
215141741|NCT02988466|DRUG|GVHD Prophylaxis|"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"
215141742|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 and < 65 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"
215141743|NCT02988466|BIOLOGICAL|Haplo HCT ≥65 and ≤75 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"
215141744|NCT04691648|DRUG|Gilteritinib Exposure|Oral
215141745|NCT05371717|OTHER|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
215141746|NCT05371717|OTHER|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
215141747|NCT00981656|DRUG|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
215141748|NCT00981656|DRUG|5-fluorouracil|Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
215141749|NCT00981656|DRUG|Mitomycin|IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
215141750|NCT00981656|RADIATION|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
215141751|NCT00687596|DRUG|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
215141752|NCT00687596|DRUG|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
214454734|NCT06838494|BEHAVIORAL|Intervention Name: Conventional CST (Cognitive Stimulation Therapy)|Conventional CST consists of 14 sessions of cognitive stimulation therapy conducted twice a week, each lasting about 45 minutes. In this arm, participants engage in group activities using physical materials, such as photos, pictures, and real objects, rather than virtual reality. The therapy focuses on providing cognitive stimulation through discussions and activities designed to improve cognitive function and social engagement among individuals with mild cognitive impairment (MCI).
214527546|NCT06149052|OTHER|FIRE training|Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
215141753|NCT05450835|PROCEDURE|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
215141754|NCT05450835|PROCEDURE|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
215141755|NCT02195765|DRUG|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
215141756|NCT02195765|PROCEDURE|Open flap debridement|Open flap debridement
215141757|NCT00683527|DRUG|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
215141758|NCT01537666|DRUG|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
215141759|NCT01537666|DRUG|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
215141760|NCT01917617|DRUG|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
215141761|NCT01917617|DRUG|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
215141762|NCT02258737|BEHAVIORAL|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
215141763|NCT02258737|BEHAVIORAL|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
215141764|NCT03331315|DRUG|Celecoxib|
215141765|NCT03331315|DRUG|Ketorolac|
215141766|NCT02121158|DEVICE|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
214454735|NCT06835257|PROCEDURE|Acute normovolemic hemodilutions|Crystalloid infusion throughout the autologous blood collection (3 ml of crystalloid infusion for every 1 ml of blood)
214454736|NCT06835257|DRUG|Vasopressor infusion|Vasopressor infusion throughout the autologous blood collection (according to mean arterial pressure)
214527547|NCT05803902|DRUG|Experimental drug 9MW1911|Experimental drug administered with IV infusion
215141767|NCT02121158|OTHER|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
215141768|NCT05879185|BIOLOGICAL|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
215141769|NCT06522646|DEVICE|SPCM|During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis
215141770|NCT06522646|DEVICE|Usual Prothesis|During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
215141771|NCT03171649|DEVICE|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
215141772|NCT03171649|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
215141773|NCT02396576|BEHAVIORAL|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
215141774|NCT00403520|DRUG|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
215141775|NCT00403520|DRUG|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
215141776|NCT01099722|DRUG|Flutiform|inhaler 2 puffs bd daily
215141777|NCT01099722|DRUG|Symbicort Turbohaler|2 puffs bd daily
215141778|NCT00425776|DEVICE|acupuncture|
215141779|NCT00425776|DEVICE|Sham acupuncture|
215141780|NCT00643864|BEHAVIORAL|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
215141781|NCT04665947|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
215141783|NCT02461758|BIOLOGICAL|Standard dose Influenza vaccine (SDIV)|
215141784|NCT02461758|BIOLOGICAL|High dose influenza vaccine (HDIV)|
215141785|NCT05206994|BEHAVIORAL|Close to Home|Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
215141786|NCT04111380|DRUG|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
215141787|NCT04031105|DEVICE|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
215141788|NCT03316924|PROCEDURE|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
215141789|NCT06371612|OTHER|Standard Care|Parental Presence
215141790|NCT06371612|OTHER|Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use
215141791|NCT06371612|BEHAVIORAL|Ball Squeezing + Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
215141792|NCT01341834|DRUG|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
215141793|NCT06513871|BEHAVIORAL|Social perception tasks|social perception tasks
215141794|NCT05199337|DRUG|ZN-d5|ZN-d5 will be administered orally
215141795|NCT04819126|OTHER|Nintendo Wii Virtual Reality Application|The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
215141796|NCT06261320|DRUG|Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate|4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
215141797|NCT05542641|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|real versus sham rTMS
214527548|NCT05803902|DRUG|Placebo|Placebo administered with IV infusion
214527549|NCT00981929|DRUG|Tramadol|50 mg single oral dose
214527550|NCT00981929|DRUG|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
215141798|NCT04689139|DIAGNOSTIC_TEST|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
215141799|NCT02380573|DRUG|Methylene Blue|
215141800|NCT02380573|DRUG|FD&C Blue # 2|
215141801|NCT02380573|DRUG|Phenazopyridine hydrochloride|
215141802|NCT04531410|DIETARY_SUPPLEMENT|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
215141803|NCT04531410|DIETARY_SUPPLEMENT|oleic acid supplementation|Oils given at morning meal with extra enzymes
215141804|NCT05179135|OTHER|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
215141805|NCT05521607|DEVICE|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
215141806|NCT06300697|OTHER|Data and biospecimen collection|Enrolled participants will have health-related information and blood specimens collected.
215141807|NCT06300697|OTHER|Skin biopsies|Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
215141808|NCT06300697|OTHER|Oral Food Challenge (OFC) procedures|Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
215141809|NCT00596414|PROCEDURE|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
215141810|NCT00596414|DRUG|placebo|
215141811|NCT00596414|DRUG|midazolam|
215141812|NCT00596414|DRUG|midazolam + pethidine|
215141813|NCT02798666|OTHER|High intensity exercise training|Exercise training using sprint interval exercise
215141814|NCT02798666|OTHER|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
215141815|NCT04421053|BEHAVIORAL|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
215141816|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
214527551|NCT00981929|DRUG|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
214527552|NCT00212719|DRUG|ONO-5920|
215141817|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
215141818|NCT02325934|DRUG|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
215141819|NCT02325934|DRUG|Stribild, crushed|Crushed Stribild tablet
214527553|NCT02846597|PROCEDURE|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
214527554|NCT03058237|DRUG|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
214527555|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
215141820|NCT05356897|BIOLOGICAL|Trastuzumab|Given IV
215141821|NCT05356897|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
215141822|NCT05356897|DRUG|Tucatinib|Given PO
215141823|NCT02226367|DRUG|prazosin hydrochloride|study drug arm prazosin
215141824|NCT02226367|DRUG|placebo|study drug arm placebo
215141825|NCT05829551|DRUG|RAY1216 dose 1|RAY1216 dose 1 or Placebo
215141826|NCT05829551|DRUG|RAY1216 dose 2|RAY1216 dose 2 or Placebo
215141827|NCT05829551|DRUG|RAY1216 dose 3|RAY1216 dose 3 or Placebo
215141828|NCT05829551|DRUG|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 \&ritonavir or Placebo
215141829|NCT05829551|DRUG|RAY1216 dose 5|RAY1216 dose 5 or Placebo
215141830|NCT05829551|DRUG|RAY1216 dose 6|RAY1216 dose 6 or Placebo
215141831|NCT05829551|DRUG|RAY1216 dose 7|RAY1216 dose 7 or Placebo
215141832|NCT05829551|DRUG|RAY1216 dose 8|RAY1216 dose 8 or Placebo
215141833|NCT05829551|DRUG|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
215141834|NCT05829551|DRUG|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
214527556|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
215141835|NCT04405791|PROCEDURE|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
215141836|NCT05573633|PROCEDURE|ECG|the POAF will be diagnosed using a 12-lead ECG and according to the usual monitoring protocols for patients in the cardiac surgery department of Amiens University Hospital.
215141837|NCT05573633|PROCEDURE|scanwatch|POAF will be diagnosed with a Withings SM (ScanWatch). FAPO diagnosed by the SW will have to be confirmed by a 12-lead ECG.
215141838|NCT04240210|DRUG|Symtuza|The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
215141839|NCT03773978|DRUG|Baricitinib|Administered orally.
215141840|NCT03773978|DRUG|Placebo|Administered orally.
215141841|NCT05678608|PROCEDURE|surgical excision|posterior midline approach and total excision for spinal cord tumors
215141842|NCT02577172|BEHAVIORAL|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
215141843|NCT02577172|BEHAVIORAL|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
215141844|NCT03366610|OTHER|Non-interventional|Non-interventional
215141845|NCT01237756|DEVICE|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
215141846|NCT05455021|COMBINATION_PRODUCT|Vessel Restoration System (VRS)|"The VRS includes the following components:~* VRS 10-8-10 Dimer Coated Balloon Catheter~* VRS Light Fiber~* VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
215141847|NCT06507254|DIETARY_SUPPLEMENT|Polyphenol Supplement|Dietary supplement taken twice daily for 12 months.
215141848|NCT06507254|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary supplement taken twice daily for 12 months.
215141849|NCT01033019|DRUG|LDE225 0.75%|0.75% cream
214527557|NCT03058237|DRUG|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
214527558|NCT04563247|DIAGNOSTIC_TEST|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
215141850|NCT01033019|DRUG|Vehicle|matching placebo cream to 0.75% LDE225 cream
215141851|NCT04659863|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
215141852|NCT04659863|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
215141853|NCT02683512|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
215141854|NCT03162146|OTHER|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
215141855|NCT02528994|DIETARY_SUPPLEMENT|L-serine|Participants will take dietary serine supplementation daily
214527559|NCT03378778|PROCEDURE|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
214527560|NCT05004805|DRUG|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
214527561|NCT05004805|DRUG|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
214527562|NCT02402465|DRUG|Placebo|Patients will be treated by placebo
214527563|NCT02402465|DRUG|Fluticasone propionate|Patients will receive fluticasone nasal spray
214527564|NCT02402465|DRUG|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
214527565|NCT02402465|PROCEDURE|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
214527566|NCT01763034|PROCEDURE|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
214527567|NCT01296178|DRUG|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
214527568|NCT01296178|DRUG|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
214527569|NCT06031870|DEVICE|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
214527570|NCT06031870|BEHAVIORAL|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
214527571|NCT06031870|PROCEDURE|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
214527572|NCT05537519|BIOLOGICAL|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
214527573|NCT03807700|DRUG|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
214527574|NCT00288379|DRUG|formoterol|
214527575|NCT00288379|DRUG|budesonide/formoterol|
214527576|NCT05021965|PROCEDURE|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
214527577|NCT03211897|DRUG|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
214527578|NCT03211897|DRUG|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
214527579|NCT03211897|DRUG|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
215141856|NCT06130761|PROCEDURE|Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block|"For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane."
214527580|NCT03211897|DRUG|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
214527581|NCT04189341|DRUG|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214527582|NCT04189341|DRUG|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214527583|NCT00785850|DRUG|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
214527584|NCT02766010|DEVICE|TensorTip|Non Invasive screening of various physiological and hematological parameters.
214527585|NCT03630523|BIOLOGICAL|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
214527586|NCT04632797|DEVICE|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
214527587|NCT01820221|PROCEDURE|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
214527588|NCT03209050|DEVICE|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
214695047|NCT02848690|BEHAVIORAL|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
215141857|NCT06130761|PROCEDURE|trans muscular quadratus lumborum block|With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
215141858|NCT02700321|DEVICE|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
215141859|NCT02700321|PROCEDURE|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
214454737|NCT05859191|BIOLOGICAL|Blood sample|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
214454738|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
214454739|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
214454740|NCT05817708|DRUG|CX-4945|"Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib"
214454741|NCT05818696|BEHAVIORAL|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
214454742|NCT05818696|BEHAVIORAL|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
214454743|NCT03605550|DRUG|PTC596|Oral tablets
214454744|NCT03605550|RADIATION|Radiotherapy|Cycle1
214454745|NCT06261450|DRUG|CBD Oral Solution (eCBD system Target)|Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
214454746|NCT06261450|DRUG|Placebo|Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
214527589|NCT03738254|OTHER|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
214527590|NCT03738254|OTHER|Paper Survey|Paper version of daily survey
214527591|NCT03738254|OTHER|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
214527592|NCT04323332|DRUG|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
215141860|NCT00174408|DRUG|Genotropin|
215141861|NCT05370196|DEVICE|Test Product|Synthetic Male Condom
215141862|NCT05370196|DEVICE|Control Product|Latex Male Condom
215141863|NCT02302599|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Infusion treatment
215141864|NCT02302599|BIOLOGICAL|Controlled suspension liquid|Infusion treatment
215141865|NCT04772001|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
215141866|NCT04772001|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
215141867|NCT04772001|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
215141868|NCT05954637|DEVICE|Optical coherence tomography|Heidelberg Engineering Spectralis
215141869|NCT06184217|OTHER|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
215141870|NCT06184217|OTHER|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
214454747|NCT03955510|OTHER|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
214454748|NCT03955510|OTHER|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
215141871|NCT04636268|BIOLOGICAL|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
215141872|NCT00121498|DRUG|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
215141873|NCT06072053|PROCEDURE|Burr Hole Craniostomy and Postoperative Exhaustive Drainage Strategy|According to the preoperative CT results, drilling and drainage was performed at the thickest level of the hematoma; during the operation, the hematoma cavity was adequately flushed with saline and a drainage tube was left in the hematoma cavity; after the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
215141874|NCT06072053|PROCEDURE|YL-1 puncture needle and Postoperative Exhaustive Drainage Strategy|Based on preoperative CT, the thickest level of the hematoma was selected and localized. During the operation, an electric drilling needle was used to rapidly break through the skull and dura to enter the cavity of the subdural hematoma, and the puncture needle was fixed to the skull to drain the subdural hematoma. After the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
215141875|NCT03760094|DEVICE|Colour Doppler|evaluation of lymph nodes by Doppler
215141876|NCT01933737|DEVICE|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
215141877|NCT01933737|DEVICE|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
215141878|NCT01629264|DEVICE|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
215141879|NCT01629264|DEVICE|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
215141880|NCT01629264|OTHER|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
215141881|NCT05471323|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
215141882|NCT00306501|PROCEDURE|Swallowing Training|Swallowing Training with press of button
215141883|NCT01236209|OTHER|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
215141884|NCT01236209|OTHER|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
215141885|NCT05577247|OTHER|functional magnetic resonance imaging|Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
215141886|NCT04964180|DRUG|Indomethacin suppository|two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
215141887|NCT04964180|DRUG|Lidocaine 2% Injectable Solution|200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
215141888|NCT00888134|DRUG|Selumetinib|Given PO
215141889|NCT02008799|PROCEDURE|Bone marrow stem cell injection|Injection should be in testis and testicular artery
214454749|NCT03955510|PROCEDURE|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
214527593|NCT02470611|DRUG|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel
214527594|NCT02470611|OTHER|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
215141890|NCT02507232|DEVICE|NovoTTF-200A|12 cycles
215141891|NCT02507232|DRUG|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
215141892|NCT03094325|DEVICE|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
215141893|NCT03094325|DEVICE|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
215141894|NCT03094325|DEVICE|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
215141895|NCT03094325|DEVICE|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
215141896|NCT04562870|DRUG|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
215141897|NCT04562870|OTHER|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
215141898|NCT02826070|DRUG|Telbivudine|Telbivudine, 600mg, oral, daily
215141899|NCT02826070|DRUG|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
215141900|NCT02826070|OTHER|off-treatment follow-up|
215141901|NCT06494644|DRUG|AZD6793|Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
215141902|NCT06494644|DRUG|Itraconazole|Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
215141903|NCT06494644|DRUG|AZD6793+ Itraconazole|Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
215141904|NCT00863278|PROCEDURE|pulsed dye laser treatment|On one side of the face according to Arm placement.
215141905|NCT00863278|DRUG|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
215141906|NCT05633602|DRUG|Chemotherapy|Receive standard of care chemotherapy
215141907|NCT05633602|BIOLOGICAL|Pembrolizumab|Given IV
215141908|NCT05633602|BIOLOGICAL|Ramucirumab|Given IV
215141909|NCT03224819|DRUG|Emerfetamab|Administered by intravenous (IV) infusion.
215141910|NCT05764265|DRUG|LTP001|LTP001 will be administered orally once daily in the morning
215141911|NCT00278577|BIOLOGICAL|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
215141912|NCT03104868|BEHAVIORAL|TAKE IT Strategy|"The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
215141913|NCT02174965|DEVICE|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
214454750|NCT03955510|PROCEDURE|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
214454751|NCT03955510|OTHER|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
214454752|NCT06826157|DIAGNOSTIC_TEST|Electroencephalogram|EEGs will be acquired to explore progressive alteration of EEG patterns throughout the neuropathology progression.
214454753|NCT06826157|DIAGNOSTIC_TEST|3 Tesla MRI|MRI evaluations will be performed to investigate structural alterations and resting state functional MRI (RS-fMRI) connectivity in participants. Longitudinal measures of cortical/subcortical atrophy and RS-fMRI connectivity will be assessed and their relationship with EEG parameters will be explored.
214454754|NCT06826157|GENETIC|Apolipoprotein E genetic test|At baseline, a sample of blood will be collected to perform genetic analysis (APOE alleles) for all participants
214527595|NCT00251290|PROCEDURE|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
215141914|NCT02174965|DEVICE|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
215141915|NCT01849510|RADIATION|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT
215141916|NCT01849510|RADIATION|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
215141917|NCT00003574|PROCEDURE|surgical procedure|
215141918|NCT00003574|RADIATION|brachytherapy|
215141919|NCT00003574|RADIATION|intraoperative radiation therapy|
215141920|NCT00003574|RADIATION|iodine I 125|
215141921|NCT04789603|OTHER|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
215141922|NCT04789603|OTHER|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
215141923|NCT04789603|OTHER|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
215141924|NCT04299373|DRUG|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
215141925|NCT04299373|DRUG|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
214454755|NCT06788080|DRUG|BioRBC|Autologous biotin-labeled RBCs will be transfused to study participants
214454756|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
214527596|NCT00570557|OTHER|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
214527597|NCT01414556|OTHER|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
214527598|NCT01414556|OTHER|saline|
214527599|NCT02005029|DRUG|Erythromycin|
214527600|NCT02005029|DRUG|placebo|
214527601|NCT00360750|DRUG|carboplatin|
215141926|NCT00566436|PROCEDURE|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
215141927|NCT00566436|PROCEDURE|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
215141928|NCT02769923|DEVICE|Westpharma ID adapter|device used for administering intradermal injection
215141929|NCT02769923|DEVICE|Star ID syringe|device used for administering intradermal injection
215141930|NCT02769923|DEVICE|BCG NS|syringe used for administering intradermal injection
215141931|NCT00005780|DRUG|EPOCH-R|EPOCH-R for 6 cycles
215141932|NCT00005780|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
214527602|NCT00360750|DRUG|cytarabine|
214527603|NCT00360750|DRUG|etoposide|
214527604|NCT00360750|DRUG|vincristine sulfate|
214527605|NCT00360750|OTHER|clinical observation|
214527606|NCT00360750|PROCEDURE|adjuvant therapy|
214527607|NCT00360750|RADIATION|radiation therapy|
214527608|NCT02316847|DRUG|diazepam nasal spray|
215141933|NCT00005780|BIOLOGICAL|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
215141934|NCT03572946|PROCEDURE|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
215141935|NCT03572946|PROCEDURE|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
215141936|NCT05495789|OTHER|Virtual Reality|A relaxing video will be watched with virtual reality glasses.
215141937|NCT05495789|OTHER|Music|Relaxing music will be played by wearing headphones.
215141938|NCT00619034|DRUG|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
215141939|NCT00619034|DRUG|Diclofenac|dicolfenac eyedrops twice daily i one eye
215141940|NCT00619034|DRUG|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
215141941|NCT06315712|OTHER|inspiratory exercise|The training consisted of 6 sets of 30 breaths per day, divided into 2 sessions per day. A one-minute rest interval between each set. Training was prescribed 5 days a week for 8 weeks
215141942|NCT06315712|OTHER|Pulmonary rehabilitation|Four resistive exercises, aerobic exercise, and deep breathing exercises, five sessions per week for 8 weeks
215141943|NCT02873858|OTHER|smell and taste tests|
215141944|NCT05657002|OTHER|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
215141945|NCT05657002|OTHER|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
215141946|NCT05657002|OTHER|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
215141947|NCT05657002|OTHER|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
215141948|NCT01128933|PROCEDURE|Renal artery stenting|
215141949|NCT06410274|DEVICE|Transcranial Doppler ultrasonography (TCD)|TCD will be used to measure cerebral blood velocity (CBv) in the middle and posterior cerebral arteries (MCA and PCA). Following confirmation of a suitable TCD window, participants will undergo a ten-minute rest period in the supine or semi-supine position. Continuous measurements of CBv, blood pressure (BP), heart rate, and end-tidal carbon dioxide will be recorded. Baseline BP will be measured using an automated BP device prior to each recording to allow calibration of the files offline for analysis. This will occur at the first visit and at follow-up, 4-7 days post-onset of intracerebral haemorrhage.
215141950|NCT06190171|BEHAVIORAL|Active respiratory muscle strength training|Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
215141951|NCT06190171|BEHAVIORAL|Sham respiratory muscle strength training|Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
215141952|NCT05382845|DIAGNOSTIC_TEST|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
214454757|NCT06834555|DIAGNOSTIC_TEST|Mobile phone thermal imaging|"The patient was supine, and the lower limb was naturally relaxed on a 20cm high stent to drain blood from the vein. The leg temperature was lowered with a cold towel at 2-6 ° C for five minutes. A tourniquet was applied to the upper 1/3 of the thigh and the level of the fibula of the lower leg with enough pressure to block the great saphenous vein and the small saphenous vein. The patient is then asked to stand. The smart phone and the supporting thermal imaging system were used to conduct continuous real-time imaging and take photos of the front, bilateral and rear of the thigh and lower leg. The hot spot of rapid rewarming of the lower limb was marked with a marker."
214527609|NCT03191214|DEVICE|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
214527610|NCT03743129|DRUG|Anlotinib|Anlotinib 12mg p.o, qd
215141953|NCT05122975|DRUG|S48168 (ARM210)|Ryanodine Receptor modulator
215141954|NCT05122975|DRUG|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
215141955|NCT04789655|DRUG|CC-96191|CC-96191
215141956|NCT04408989|DRUG|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
215141957|NCT04408989|DRUG|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
215141958|NCT04408989|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
215141959|NCT05540132|DIETARY_SUPPLEMENT|maltodextrin|Pre-exercise carbohydrate, fast-acting
215141960|NCT05540132|DIETARY_SUPPLEMENT|super starch|Pre-exercise carbohydrate, slow-acting
215141961|NCT05082857|BEHAVIORAL|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
215141962|NCT05082857|BEHAVIORAL|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
214454758|NCT06838143|BIOLOGICAL|Ilaris|Prospective observational study. There is no treatment allocation.
215141963|NCT04855916|DEVICE|ABLE Exoskeleton|Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
215141964|NCT04855916|DEVICE|KAFO Orthosis|Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
215141965|NCT04324827|DEVICE|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
215141966|NCT04324827|OTHER|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
215141967|NCT03807986|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
215141968|NCT03807986|PROCEDURE|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
215141969|NCT03807986|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
215141970|NCT02202122|OTHER|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
214454759|NCT04660955|OTHER|No Intervention - Observational study with MRI|90 minute MRI of the knees
214527611|NCT06120114|PROCEDURE|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
214527612|NCT01011127|DRUG|pravastatin, rosuvastatin|
215141971|NCT01943643|PROCEDURE|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
215141972|NCT04672239|BEHAVIORAL|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
215141973|NCT04672239|BEHAVIORAL|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
215141974|NCT04672239|BEHAVIORAL|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
215141975|NCT00937313|OTHER|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
215141976|NCT04266067|OTHER|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
214454760|NCT01639859|OTHER|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
214454761|NCT04354675|GENETIC|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
214454762|NCT04354675|GENETIC|Genetics counselor|Traditional in-person genetic counseling
214454763|NCT04354675|OTHER|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
214527613|NCT02751801|OTHER|no intervention|
214527614|NCT03375840|BEHAVIORAL|Text-only PWL|Control condition
214454764|NCT04354675|OTHER|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
214527615|NCT03375840|BEHAVIORAL|Low-emot PWL|Pictorial warning
214527616|NCT03375840|BEHAVIORAL|High-emot PWL|Pictorial warning
214527617|NCT03375840|BEHAVIORAL|Immediate posttest|
215141977|NCT04266067|OTHER|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
215141978|NCT00000336|DRUG|Selegiline|
214527618|NCT03375840|BEHAVIORAL|delay posttest|
214527619|NCT04811118|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
214454765|NCT04354675|DEVICE|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
214527620|NCT04811118|DRUG|Taxotere|Taxotere
214527621|NCT02555488|DEVICE|diode laser|MB and diode
214527622|NCT02555488|DEVICE|diode laser|diode laser
214527623|NCT02555488|DRUG|Methylene blue|Methylene blue and diode laser was used
214527624|NCT05450640|OTHER|satisfaction survey|1 eQuestionnaire per patient completed during study
214454766|NCT06837012|DRUG|Duloxetine - low dose|Only patients who underwent single bilateral Total knee arthroplasty and WITHOUT central sensitisation were evaluated
214527625|NCT00001666|DEVICE|Cadwell High-Speed Magnetoelectric Stimulator|
214527626|NCT00001666|DEVICE|Magpro High-Speed Magnetoelectric Stimulator|
214527627|NCT03207698|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
215141979|NCT04543708|PROCEDURE|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
215141980|NCT04543708|PROCEDURE|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
215141981|NCT06139510|OTHER|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
215141982|NCT00006020|DRUG|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
215141983|NCT02961894|DEVICE|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
215141984|NCT03871777|OTHER|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
215141985|NCT03871777|OTHER|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
214454767|NCT06837012|DRUG|Placebo|starch capsules identical in appearance and weight to the duloxetine capsules
214454768|NCT06413641|OTHER|Follow up at general practice|As described before
214454769|NCT06413641|OTHER|Consultation|As described before
214454770|NCT06413641|OTHER|Visualization of CTA images|As described before
214454771|NCT06786429|BIOLOGICAL|Gardasil 9 vaccine|Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
214527628|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
214527629|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
214527630|NCT02716857|DRUG|Oxycodone extended-release|
214527631|NCT02716857|DRUG|Placebo of oxycodone extended-release|
214527632|NCT04180306|OTHER|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
214527633|NCT03694119|DRUG|Phenelzine|Phenelzine
214527634|NCT03694119|DRUG|Tyramine|Tyramine
214527635|NCT03694119|DRUG|Phenelzine placebo|Phenelzine placebo
214527636|NCT03694119|DRUG|ozanimod placebo|ozanimod placebo
214527637|NCT03694119|DRUG|ozanimod|ozanimod
214527638|NCT04335370|OTHER|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion"
214527639|NCT06215625|OTHER|Robot-assisted therapy|The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
214527640|NCT06215625|OTHER|Task-oriented training|The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.
214527641|NCT05127590|DRUG|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
214527642|NCT02599090|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
214527643|NCT02599090|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
215141986|NCT04730102|PROCEDURE|Rectal washout|Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
215141987|NCT02345447|DRUG|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
215141988|NCT02345447|DRUG|Placebo|Aqueous ethanol solution non-distinguishable from verum
215141989|NCT04634422|PROCEDURE|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
215141990|NCT00417326|DRUG|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
215141991|NCT00417326|DRUG|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
215141992|NCT06326814|DRUG|Humanized anti-Factor Bb monoclonal antibody|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
215141993|NCT06326814|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
215141994|NCT04827069|DRUG|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
215141995|NCT04599244|OTHER|emergency pulpotomy|removal of coronal pulp
215141996|NCT04551547|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml
215141997|NCT04551547|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml
215141998|NCT04551547|OTHER|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
215141999|NCT03010215|OTHER|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
215142000|NCT05552287|DRUG|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
215142001|NCT05572255|DRUG|Cenobamate|200 mg Cenobamate Tablet
215142002|NCT00872820|BEHAVIORAL|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
215142003|NCT00872820|BEHAVIORAL|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
215142004|NCT06064279|DRUG|Poly ICLC|Tol like receptor 3 agonist
215142005|NCT06064279|DRUG|IVIG|pooled IVIG
215142006|NCT04876521|DRUG|Amisulpride|low dose of Amisulpride at 100-300 mg/day
215142007|NCT04876521|DRUG|Olanzapine-Fluoxetine Combination|Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
215142008|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
215142009|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
214454772|NCT06786429|BIOLOGICAL|Hepatitis B Virus Vaccine(HBV)|Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
214527644|NCT02599090|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
214527645|NCT00683397|OTHER|Blood sampling|Screening of thrombophilia
214527646|NCT02242799|DRUG|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
214454773|NCT06786429|BEHAVIORAL|Cognitive Behavioral Therapy|Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
214454774|NCT04919109|BIOLOGICAL|CodaVax-RSV|live attenuated vaccine against RSV
214454775|NCT04919109|BIOLOGICAL|Normal Saline|Placebo comparator
214454776|NCT06787807|PROCEDURE|bariatric surgery|sleeve gastrectomy
214454777|NCT06783205|OTHER|Restriction of the Dominant Hand Due to Splint Use|This study aimed to assess whether the non-dominant hand function changes in patients using splints or casts on their dominant hand during the tissue healing period.
214454778|NCT06830213|OTHER|Questionnaire study|Questionnaire application
214454779|NCT06248190|OTHER|ENHANCE intervention (health systems)|The intervention tools include a consolidated clinical decision support tool, health education posters, waiting room talks, medication list for treatment literacy and a patient health diary. Training session are delivered at all intervention sites and include 1 facility team session to introduce the ENHANCE study to the whole team; 3 clinical sessions for nurses and doctors; 2 sessions for community health workers and health promoters; Maintenance sessions to keep the ENHANCE intervention going for at least 12 months
214454780|NCT06782646|DRUG|Berberine|Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
214454781|NCT06782646|DRUG|Placebo|Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
214454782|NCT05773378|DEVICE|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 10-week period.
214527647|NCT02242799|DRUG|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
214527648|NCT02242799|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
214527649|NCT04717713|DRUG|steroid injection|steroid injection at surgical location
214527650|NCT04717713|DRUG|placebo|saline injection at surgical location
214527651|NCT02205723|BEHAVIORAL|Asthma teaching in ER|Asthma teaching
215142010|NCT04137952|BEHAVIORAL|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
215142011|NCT05408429|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
214454783|NCT05773378|DEVICE|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period.
214454784|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
214454785|NCT06832254|OTHER|Cryotherapy|The root canals were irrigated with 2 °C saline solution in final irrigation in cryotherapy group.
214454786|NCT06832254|DRUG|Dexamethasone|Each root canal was irrigated with 1 mL dexamethasone solution in final irrigation in dexamethasone group.
214527652|NCT02205723|BEHAVIORAL|Smartphone Asthma Control|Smartphone Asthma Control
214527653|NCT03739697|OTHER|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
214527654|NCT01370018|BIOLOGICAL|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
214527655|NCT03497780|PROCEDURE|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
214568465|NCT01525654|BEHAVIORAL|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
214568466|NCT06588855|DRUG|Afimkibart|Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.
215142012|NCT05408429|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
214454787|NCT03056040|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
214454788|NCT03056040|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
215142013|NCT06057766|OTHER|Physical activity tele coaching program|"The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented."
215142014|NCT06061926|DRUG|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
215142015|NCT06061926|DRUG|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
215142016|NCT03108131|DRUG|Atezolizumab|Given IV
215142017|NCT03108131|DRUG|Cobimetinib|Given PO
215142018|NCT04020809|DRUG|Atezolizumab|Anti-PD-L1 monoclonal antibody
215142019|NCT06458465|DIETARY_SUPPLEMENT|Curcumin|\- Curcumin capsules 500 mg twice daily for 6 months
215142020|NCT06458465|DRUG|Pentoxifylline 400 MG|\- Pentoxifylline 400 mg twice daily for 6 months.
215142021|NCT06498349|PROCEDURE|bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment|according to widely accepted expert consensus paper
215142022|NCT06498349|DRUG|best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations|according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
215142023|NCT05569408|DRUG|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
215142024|NCT06117618|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
215142025|NCT06117618|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
215142026|NCT03671330|DRUG|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
215142027|NCT03671330|DRUG|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
215142028|NCT03671330|DRUG|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
215142029|NCT03671330|DRUG|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
215142030|NCT03671330|DRUG|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
215142031|NCT02825498|DEVICE|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
215142032|NCT00877500|OTHER|Best Practice|Receive standard of care
215142033|NCT00877500|DRUG|Ixabepilone|Given IV
214454789|NCT04718675|DRUG|KB-0742|Oral capsules
214527656|NCT04056741|COMBINATION_PRODUCT|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
215142034|NCT04610346|BEHAVIORAL|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
215142035|NCT05995210|PROCEDURE|Kinesio taping|A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.
215142036|NCT05995210|PROCEDURE|Orthosis|They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.
215142037|NCT05995210|PROCEDURE|Control|An exercise program focused on the knee and hip muscles was given two days a week.
215142038|NCT05376917|DEVICE|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
215142039|NCT05376917|DEVICE|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
215142040|NCT05376917|DEVICE|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
215142041|NCT05376917|DEVICE|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
215142042|NCT04377100|BEHAVIORAL|Computer task questionnaires|MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
215142043|NCT04033796|DIETARY_SUPPLEMENT|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);
214527657|NCT03386214|DRUG|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
214527658|NCT03386214|DRUG|Ruxolitinib|-Standard of care outside of protocol
215142044|NCT04033796|DIETARY_SUPPLEMENT|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);
215142045|NCT04033796|DIETARY_SUPPLEMENT|Placebo|A placebo (administered orally every two months) supplementation control group.
215142046|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
215142047|NCT01074970|DRUG|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
215142048|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
215142049|NCT00161759|DRUG|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
215142050|NCT05177965|OTHER|Exposure to shift work|Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
215142051|NCT05609565|DRUG|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
215142052|NCT05609565|DRUG|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
215142053|NCT04249999|BEHAVIORAL|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
215142054|NCT06585098|OTHER|game based learning|"The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher."
215142055|NCT06305650|DIETARY_SUPPLEMENT|Probiotic|Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.
215142056|NCT06584903|OTHER|Temperature Ramp Protocol|Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
215142057|NCT04205227|DRUG|ENB003|ENB003 is selective Endothelin B Receptor Antagonist
215142058|NCT04205227|DRUG|Pembrolizumab|anti-PD1
215142059|NCT03205709|OTHER|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
215142060|NCT03205709|OTHER|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
215142061|NCT06177483|DIETARY_SUPPLEMENT|95% curcumin extract powder|95% curcumin extract powder
214527659|NCT03386214|PROCEDURE|Peripheral blood draw|"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"
214527660|NCT03386214|PROCEDURE|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
214568467|NCT06588855|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
215142062|NCT06177483|DIETARY_SUPPLEMENT|curQ+ curcumin formulation|curQ+ curcumin formulation
215142063|NCT05819138|DRUG|Semaglutide Pen Injector|Semaglutide injection
215142064|NCT05819138|DRUG|Placebo|Semaglutide placebo injection
215142065|NCT04760613|DRUG|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
215142066|NCT04760613|DRUG|Placebo|identical capsules containing placebo (taken daily by mouth)
215142067|NCT04971642|DEVICE|Intraoral ultrasound|Intraoral ultrasound scanning of the periodontium complex
215142068|NCT03030586|OTHER|volumetric MRI|
215142069|NCT05754645|OTHER|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
215142070|NCT06551610|OTHER|Triage Tool|Tool that uses patient characteristics to triage patients for an earlier procedure date vs the standard of care 12 week wait for procedure.
215142071|NCT06465147|BIOLOGICAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
215142072|NCT04499326|OTHER|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
215142073|NCT05148156|DEVICE|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
215142074|NCT05819658|DRUG|GV1001 Placebo|0.9% normal saline
215142075|NCT05819658|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
215142076|NCT05819658|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
215142077|NCT02444338|DEVICE|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
215142078|NCT02444338|OTHER|standard of care|
215142079|NCT05205031|DEVICE|Intraosseous access|Needle placed in the bone marrow.
215142080|NCT05205031|DEVICE|Intravenous|Needle placed in a vein.
215142081|NCT04838171|OTHER|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
215142082|NCT05048134|DRUG|HRS2300|HRS2300 monotherapy
215142083|NCT05048134|DRUG|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
215142084|NCT05048134|DRUG|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
214454790|NCT06838299|DEVICE|aerobic exercise + inspiratory muscle training|inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set. The resistance was adjusted every week to be 60% of the new maximum inspiratory pressure and if it remained the same, the subject continued to train at the level of the previous week Aerobic exercise: by bicycle ergomete 5-minute warm-up before exercise and a 5-minute cool-down following exercise at intensity (40-65%HR max) were carried out each time. In addition, the exercise was performed in the first half of the dialysis session over a 3 months period for 3 sessions a week
214454791|NCT06838299|DEVICE|resistance exercise + inspiratory muscle training|"Resistance exercise:~Dynamic closed- and open-chain resistance exercises performed by the patients quadriceps and hamstrings muscles . Patients started at 50% of their initial one-repetition maximum (1-RM) with 5 repetitions for each exercise and later progressed to three sets of 8 repetitions at 70% of their 1-RM according to the patient Borg scale of exertion; training loads were increased when patients could comfortably complete three sets with good form.~inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set."
214454792|NCT06838299|OTHER|control group|there is no exercise , patients do assessment pre and post 3 months and follow up
214454793|NCT06829342|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
214454794|NCT03677999|DIAGNOSTIC_TEST|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
214454795|NCT04317716|BEHAVIORAL|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
214454796|NCT04317716|OTHER|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
214454797|NCT06833242|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
214454798|NCT04977947|BEHAVIORAL|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
214454799|NCT05207085|DRUG|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
214454800|NCT05207085|OTHER|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
214454801|NCT05258422|RADIATION|stereotactic body radiotherapy, 20 Gy in 1 fraction|A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
215142085|NCT05048134|DRUG|HRS2300、trametinib|HRS2300 combined with trametinib
215142086|NCT05048134|DRUG|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
215142087|NCT03255408|DRUG|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
215142088|NCT03255408|DRUG|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
215142089|NCT03255408|DRUG|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
215142090|NCT03255408|DRUG|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
215142091|NCT06500338|PROCEDURE|free-fall|"The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, hypergravity), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas."
215142092|NCT05565742|DRUG|LY3819469|Administered SC
215142093|NCT05565742|DRUG|Placebo|Administered SC
215142094|NCT06284343|DRUG|Anticoagulant|Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
215142095|NCT02855125|DRUG|TAS-114|TAS-114 was a modulator of 5-fluorouracil (5-FU).
215142096|NCT02855125|DRUG|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
215142097|NCT03996824|OTHER|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
215142098|NCT06652893|DRUG|Sinovial|"A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea"
215142099|NCT04467905|DRUG|Etripamil|The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
215142100|NCT04467905|DRUG|Placebo|The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
215142101|NCT06291441|OTHER|No intervention|No intervention (observational study)
215142102|NCT06654817|DRUG|Ofatumumab subcutaneous injection|To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
214454802|NCT06837285|DEVICE|mandibular advancement device|Results of clinical trials on MADs are regularly published in the international literature but are generally very strongly controlled studies, still far away from being applied in routine daily clinical practice. The current retrospective study evaluates real-world data to determine the extent to which MAD improves both symptoms in patients with OSA. It is estimated that about 3% of newly diagnosed OSA patients are treated with MAD. In the light of new future treatment conventions, health government departments are increasingly demanding real-world data to stimulate knowledge of the relative effectiveness and value of treatments in the management of patients in routine clinical settings.
214454803|NCT04029688|DRUG|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
214454804|NCT04029688|DRUG|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
214454805|NCT04029688|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
214454806|NCT04029688|DRUG|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m\^2 as an IV infusion.
214454807|NCT04029688|DRUG|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m\^2 as an IV infusion.
214454808|NCT04029688|DRUG|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m\^2 as an IV infusion.
214454809|NCT04029688|DRUG|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
214454810|NCT06833307|DRUG|SHR-1314|SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3
214454811|NCT06830811|RADIATION|EOSedge imaging|Full body or full spine image
214454812|NCT06564493|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214454813|NCT06564493|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214454814|NCT06564493|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
214454815|NCT06837571|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
214454816|NCT06837571|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
214454817|NCT06837571|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
214454818|NCT06836271|DRUG|Isopropyl Alcohol|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 70% Isopropyl alcohol every time it came into contact with the rectal mucosa.
214454819|NCT06836271|DRUG|Povidine-iodine|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with povidine-iodine every time it came into contact with the rectal mucosa.
215142103|NCT06594003|PROCEDURE|Radiofrequency|There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves . Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support
215142104|NCT06591143|PROCEDURE|ART|Caries excavation with hand instruments only and restoration with glass ionomer filling
215142105|NCT06591143|PROCEDURE|Hall technique|Stainless steel crown placement without tooth preparation
215142106|NCT06589427|OTHER|Invasive ventilation.|Patients were subjected to invasive ventilation.
215142107|NCT06591273|BIOLOGICAL|Infliximab-dyyb Biosimilar (Remsima)|Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
215142108|NCT06586099|DRUG|Aza, tislelizumab|combination chemotherapy for the refractory/relapsed AML
215142109|NCT05902260|DIETARY_SUPPLEMENT|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
215142110|NCT05902260|DRUG|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
215142111|NCT06443814|BEHAVIORAL|Health Education|This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
215142112|NCT06443814|BEHAVIORAL|Transcendental Meditation|TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
215142113|NCT06586294|DRUG|Drug: AK129 Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
215142114|NCT06586294|DRUG|Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
215142115|NCT06596928|DIETARY_SUPPLEMENT|Essential Elements T-Hero Platinum|Participants will take two capsules daily for 90 days
215142116|NCT06596928|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take two placebo capsules daily for 90 days.
215142117|NCT06588790|OTHER|Home-based rapid testing|Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.
215142118|NCT06588790|OTHER|Community health worker rapid testing|Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.
215142119|NCT06599372|OTHER|The rTMS method|The patient receives treatment under naturalistic conditions in routine practice.
215142120|NCT06599372|OTHER|The cTBS method|The patient receives the treatment under naturalistic conditions in routine practice.
215142121|NCT06604572|PROCEDURE|Transabdominal preperitoneal approach|The enrolled patients underwent either open tension-free hernia repair or Transabdominal preperitoneal approach
215142122|NCT06597552|OTHER|Training Group|"Inspiratory muscle training (IMT) was performed using the Threshold IMT device using the threshold loading method. The IMT was administered to the patients in the training group at 30% of the MIP value, 5 days a week, twice a day, for 15 minutes for 8 weeks. The patients in the training group were called for a check-up once a week and the MIP value was re-evaluated. The training workload for that week was determined by taking 30% of the new measured MIP value.~During the training, the patients were asked to sit with their upper body (shoulders and upper chest) in a relaxed position, and after the nose was closed with the clip, the mouthpiece of the device was tightly closed with the lips. While in this position, the patient was asked to inhale and exhale 5 times into the device, then remove the device from their mouth and listen for 5 breaths, and continue this cycle for 15 minutes."
215142123|NCT06597552|OTHER|Control Group|The training intensity of the control group was given at the lowest load (9 cm H2O) for 8 weeks, five days a week, twice a day for 15 minutes. To eliminate the effect of learning, the MIP measure of the control group was measured once a week, but the intensity of the training was not increased during the 8 weeks.
215142124|NCT06606600|OTHER|Intensive Kebbi robot interventions|The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
214454820|NCT06836271|COMBINATION_PRODUCT|formaldehit|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 10% formaldehit every time it came into contact with the rectal mucosa.
214454821|NCT06836271|PROCEDURE|Standard BP control|No disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy.
215142125|NCT06591520|DRUG|AK112, Gemcitabine, Cisplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
215142126|NCT06591520|DRUG|Durvalumab, Gemcitabine, Cisplatin|Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
215142127|NCT06592235|OTHER|No intervention|No intervention
215142128|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies.
215142129|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies with Prefabricated Landmarks|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies with prefabricated landmarks in place.
215142130|NCT06592066|DEVICE|Splinted Open Top Tay Conventional Impression Technique|Splinted open-top tray conventional impression technique will be preformed by using medium body silicone impression material.
215142131|NCT06596863|DIAGNOSTIC_TEST|The association of serum uromodulin with DN|Meta analysis of association of serum uromodulin with DKD
215142132|NCT06596863|DIAGNOSTIC_TEST|The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN|DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
215142133|NCT06589622|PROCEDURE|Atraumatic Restorative Treatment|Caries excavation with hand instruments only and restoration with Glass ionomer filling
215142134|NCT06589622|PROCEDURE|Hall technique|Crown placement without tooth preparation
215142135|NCT06604611|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
215142136|NCT06590714|DRUG|Experimental(Acelex cap m2mg)|"Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN)."
215142137|NCT06590714|DRUG|Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)|NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
215142138|NCT06601244|OTHER|Pharmacokinetic|Biliary and blood concentration of the DALBAVANCINE
215142139|NCT06601491|BEHAVIORAL|Lifestyle Intervention|Participants in the intervention group receive structured, pesonalised lifestyle, dietary and physical activity consultations. They undergo various assessments such as aortic stiffness measurement, blood pressure measurement, and complete several questionnaires (e.g., whole exome sequencing, IPAQ, handgrip strength, socio-demographic, clinical history, quality of life, smoking, alcohol consumption, sleep patterns, stress assessment).
215142140|NCT06588062|OTHER|Picture Exchange Communication System (PECS)|Picture exchange communication System (PECS) is a widely useful tool for developing skills in ASD children. Visual supports rather work better for their intellectual level as these children usually respond less to verbal and written instructions. PECS is considered as an augmentative communication system commonly used with non-verbal ASD children. It is helpful for an individual with ASD to quickly acquire a functional means of communication. This is highly beneficial for the child to communicate with his parents and caregivers, as well as with their peers. Moreover, the pictorial approach of PECS is a source of facilitating element in attaining student's concentration. The reason for wide acceptance of this tool in clinical and social settings for children with ASD is its' ease of use, ability to teach two-way communication and inexpensiveness. PECS has demonstrated successful use in teaching various skills in ASD affected children lacking speech.
214454822|NCT05875142|BEHAVIORAL|Behavioral: Digital Tutorial Overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.
214454823|NCT05875142|BEHAVIORAL|Behavioral: Training Materials|10 weeks post-tutorial access to additional digital training materials.
214454824|NCT05875142|BEHAVIORAL|Behavioral: Feedback and Coaching|10 weeks post-tutorial access to additional digital training materials and systematic feedback and coaching.
214454825|NCT05664945|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
214454826|NCT05664945|BEHAVIORAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
215142141|NCT06602557|DRUG|Amikacin|Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
215142142|NCT06602557|DRUG|Standard of care|Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
215142143|NCT06600932|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
215142144|NCT06600932|PROCEDURE|control group|The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
215142145|NCT06604260|DIAGNOSTIC_TEST|68Ga-FAPi-46|68Ga FAPi PET-CT scan
215142146|NCT06596070|OTHER|No intervention was carried out|This study is an observational study and no intervention was performed on the patients.
215142147|NCT05624632|OTHER|Remote cognitive testing|Remote cognitive testing
215142148|NCT06992011|PROCEDURE|SMILE|Small Incision Lenticule Extraction
215142149|NCT06992011|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
215142150|NCT06991361|BIOLOGICAL|EVE-Treg|Ex Vivo-Expanded (EVE) Regulatory T cells.
215142151|NCT06705361|DEVICE|Transparent Radial Artery Band (Screw-Type)|The researcher will randomly assign patients undergoing radial arterial line removal after open heart surgery into four groups: ice-bag pressure, transparent radial band compression device (screw type), transparent radial band compression device (air type), and control group. The researcher will assign specific card colors to each group: white for the control group, yellow for the ice-bag pressure group, pink for the Transparent Radial Band Compression Device - Screw Type group, and green for the Transparent Radial Band Compression Device - Air Type group. The researcher will place all these cards in a container, allowing the participant to select their preferred color, and then apply the intervention separately to each group.
215142152|NCT06884592|PROCEDURE|Difficult Intubation|Determination of difficult intubation, according to the Cormack-Lehane scale, intubation will be considered easy for grade I or II and difficult for grade III or IV. If intubation could not be performed with the Macintosh laryngoscope in three attempts, the next step would be to perform intubation with the videolaryngoscope and the third step would be to place the laryngeal mask airway (LMA). The correct position of the tube in the trachea will be confirmed after intubation, preferably by visual confirmation of the tube passing through the glottic opening, auscultation of the chest with a stethoscope and a normal capnograph. If the LMA attempt fails, the patient will be allowed to awaken, with the final step being ventilation using a face mask and consideration of reversing the muscle relaxant effect with sugammadex (4-5 mg/kg). If intubation fails on the first attempt, an intubation stylet will be used if necessary. The intubation method used, total number of attempts for successful i
215142153|NCT06704880|OTHER|rehabilitation|children in the CIMT group will RECIEVE lower limb CIMT for the non-hemiplegic limb using whole leg orthosis. Children in cross-education group will receive strengthening training for the non-hemiplegic lower limb
215142154|NCT06706648|BEHAVIORAL|Nursing-Led Psychological Capital Interventions|The participating nurses received session about Nursing-Led Psychological Capital Interventions
215142155|NCT06704984|BEHAVIORAL|Intervention Name: WeChat Intervention Based on the IMB Model|A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
215142156|NCT06706635|DEVICE|Application of App|Full Access to Mobile App
215142157|NCT06656988|DRUG|CO2|CO2 will be used as contrast medium sparing strategy during peripheral angiography
215142158|NCT06656988|DRUG|Iodinated Contrast Media (ICM)|Iodinated contrast medium will be used as in routine care during peripheral angiography
215142159|NCT02077010|DRUG|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
215142160|NCT06904586|OTHER|Thyromental distance|Distance between the chin and thyroid cartilage with a tape measure when the patient is in a neutral position
215142161|NCT06904586|OTHER|Neck circumference|Measurement of neck circumference with a tape measure when the patient is in a neutral position
215142162|NCT06904586|OTHER|Mouth opening distance|Distance between the upper and lower teeth at the point where the mouth opening is maximum when the patient is in a neutral position.
215142163|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in neutral position|Distance from mentum to hyoid bone with neck in neutral position by ultrasonography
215142164|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in extension|Ultrasound measurement of distance from mentum to hyoid bone with neck in extension
215142165|NCT06904586|OTHER|Distance between skin and trachea|Ultrasound measurement of distance between skin and trachea
215142166|NCT06904586|OTHER|Distance between skin and epiglottis|Distance between skin and epiglottis measured by ultrasonography
215142167|NCT06904586|OTHER|Distance between skin and anterior commissure of vocal cord:|Distance between skin and anterior commissure of vocal cord measured by ultrasonography
215142168|NCT06904586|OTHER|Distance between skin and hyoid bone|Distance between skin and hyoid bone measured by ultrasonography
215142169|NCT06904586|OTHER|Maximum Tongue Thickness|Measurement of Maximal Tongue Thickness by Ultrasonography
214695048|NCT02848690|OTHER|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
215142170|NCT03894124|DRUG|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
215142171|NCT03904849|DRUG|Cannabidiol|Cannabidiol oral solution
215142172|NCT03904849|DRUG|Placebo|Placebo oral solution
215142173|NCT06932991|BEHAVIORAL|Cognitive Remediation|cognitive remediation
215142174|NCT03651752|DRUG|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
215142175|NCT06844383|DRUG|Talazoparib with enzalutamide|Talazoparib (0.5 mg PO QD) and enzalutamide (160 mg PO QD) will be administered in continuous 28-day cycles.
215142176|NCT06844383|DRUG|Talazoparib|Talazoparib (1 mg PO QD) will be administered in continuous 28-day cycles.
215142177|NCT04433065|DEVICE|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
215142178|NCT06955546|DRUG|Toothpaste Product|"Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/"
215142179|NCT06955546|DRUG|Mouthwash Product|"Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/"
215142180|NCT06955546|DIETARY_SUPPLEMENT|Probiotic|Patients received a daily tablet of Curasept Prevent Probiotics. Link at: https://curaseptspa.it/prodotti/curasept-prevent-probiotico-integratore-alimentare/
215142181|NCT06955546|OTHER|Placebo|Patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.
215142182|NCT05118022|OTHER|Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system|Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
215142183|NCT03493152|DRUG|Everolimus|mTOR inhibitor
215142184|NCT05527015|DEVICE|Bifocal Spectacles|Bifocals with a +3.00 Diopter flat top 35
215142185|NCT05527015|DEVICE|Single Vision Lenses|Single vision lens as prescribed by provider
215142186|NCT03493165|DRUG|Everolimus|mTOR inhibitor
215142187|NCT05790720|DRUG|Propofol|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
215142188|NCT02037971|PROCEDURE|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
215142189|NCT02037971|OTHER|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
215142190|NCT02911168|PROCEDURE|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
214454827|NCT05664945|BEHAVIORAL|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
214454828|NCT05784662|BEHAVIORAL|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
214454829|NCT05912387|DRUG|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
214454830|NCT02925871|BEHAVIORAL|Co-designed person-centred care transitions|The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
214527661|NCT02125656|OTHER|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
214527662|NCT03448289|BEHAVIORAL|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
214527663|NCT03809806|PROCEDURE|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
214527664|NCT03809806|DIAGNOSTIC_TEST|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
215142191|NCT02911168|PROCEDURE|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
215142192|NCT04371159|DEVICE|Velieve U.S.|The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
215142193|NCT01777386|PROCEDURE|preexpanded perforator flap surgery|
215142194|NCT02189317|DRUG|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
215142195|NCT00680108|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
215142196|NCT05514977|PROCEDURE|Erector spine plane block|Thoracic ESPB
215142197|NCT02419001|DRUG|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
215142198|NCT02419001|DRUG|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
215142199|NCT02419001|DRUG|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
215142200|NCT02419001|DRUG|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
215142201|NCT06139120|DIAGNOSTIC_TEST|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
215142202|NCT00744497|DRUG|Placebo|
215142203|NCT00744497|DRUG|Dasatinib|
214527665|NCT03809806|DIAGNOSTIC_TEST|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
214527666|NCT03809806|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
214527667|NCT03809806|DIAGNOSTIC_TEST|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
214527668|NCT03809806|DIAGNOSTIC_TEST|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
214527669|NCT01525641|DRUG|Mirapex LA|Pramipexole Hydrochloride Hydrate
215142204|NCT00744497|DRUG|Docetaxel|
215142205|NCT00744497|DRUG|Prednisone|
215142206|NCT03925012|BEHAVIORAL|Intervention|
215142207|NCT03303963|DIAGNOSTIC_TEST|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
215142208|NCT03303963|DIAGNOSTIC_TEST|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis"
215142209|NCT05784038|DIAGNOSTIC_TEST|Viral genomic|Evaluation of mpox viral genomic
215142210|NCT05784038|DIAGNOSTIC_TEST|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
215142211|NCT03298035|DEVICE|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
214527670|NCT03772041|DRUG|OPC-61815|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
215142212|NCT03298035|DEVICE|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
215142213|NCT05247671|GENETIC|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
215142214|NCT05247671|GENETIC|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
215142215|NCT03819114|DRUG|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
215142216|NCT04983446|DRUG|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
215142217|NCT04983446|OTHER|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
215142218|NCT05194644|OTHER|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
215142219|NCT05194644|OTHER|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
215142220|NCT02379728|DEVICE|PrenaBelt|"The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine."
215142221|NCT02379728|DEVICE|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
215142222|NCT02379728|DEVICE|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
215142223|NCT02135432|DRUG|Ivacaftor|
215142224|NCT02135432|DRUG|Placebo|
215142225|NCT00242502|DRUG|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
215142226|NCT00242502|DRUG|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
215142227|NCT05101122|DRUG|Dosing 1: Atomoxetine|Oral administration at bedtime
214527671|NCT03772041|DRUG|Tolvaptan Tab 15 MG|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
214527672|NCT00219869|DRUG|Galantamine|
215142228|NCT05101122|DRUG|AD313|Escalating dose of AD313; Oral administration at bedtime
215142229|NCT03710499|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
215142230|NCT03131219|BIOLOGICAL|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
215142231|NCT03819530|DIETARY_SUPPLEMENT|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
215142232|NCT04155762|OTHER|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
215142233|NCT04155762|OTHER|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
214527673|NCT05470881|DRUG|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
215142234|NCT01528332|DEVICE|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
215142235|NCT01528332|DEVICE|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
215142236|NCT05313295|OTHER|Home-based physiotherapy|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
215142237|NCT05313295|OTHER|Usual Physiotherapy|Usual care provided for the management of neurological disorders in children
215142238|NCT02194335|DRUG|BIBN 4096 BS - in single rising doses|
215142239|NCT02194335|DRUG|Placebo|
215142240|NCT04945733|DRUG|Amivantamab|Amivantamab will be administered intravenously.
215142241|NCT04470154|DRUG|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
215142242|NCT04470154|DRUG|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
215142243|NCT04470154|DRUG|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
215142244|NCT04470154|DRUG|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
215142245|NCT04470154|DRUG|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
215142246|NCT04470154|DRUG|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
215142247|NCT05208060|BIOLOGICAL|MV130|Treatment administered sublingually
215142248|NCT05208060|OTHER|Placebo|Treatment administered sublingually
215142249|NCT00207077|DRUG|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
215142250|NCT05626621|DRUG|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
215142251|NCT05626621|DRUG|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
215142252|NCT05626621|DRUG|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
215142253|NCT02897323|OTHER|description|
214454831|NCT02925871|BEHAVIORAL|Current care transitions|Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
214454832|NCT06642389|OTHER|Sonoanatomical Structure Identification|ChatGPT-4 will analyze the ultrasound images to identify key anatomical landmarks such as nerves, muscles, blood vessels, and fascial planes that are critical for successful regional anesthesia. These structures will be labeled and compared to the expert anesthesiologist's assessment to determine accuracy.
214454833|NCT06642389|OTHER|Block Type Prediction|Based on the ultrasound images and the position of the probe, ChatGPT-4 will predict the type of regional anesthesia block being performed (e.g., supraclavicular block, femoral nerve block). These predictions will be compared to the actual block performed to evaluate the AI's accuracy.
214454834|NCT06642389|OTHER|Block Success Assessment|After analyzing the ultrasound images from the block application, ChatGPT-4 will assess whether the block was successfully administered. This assessment will be based on the correct placement of the needle, the spread of the anesthetic, and proximity to target structures. The AI's evaluation of block success will be compared to the expert anesthesiologist's judgment.
214527674|NCT05287698|OTHER|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
215142254|NCT01841411|DRUG|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
215142255|NCT01841411|DRUG|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
215142256|NCT01841411|DRUG|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
215142257|NCT00286247|GENETIC|INGN 201|
215142258|NCT02052258|DRUG|Oxytocin|
215142259|NCT00078585|BIOLOGICAL|PROSTVAC®-VF/TRICOM™|
215142260|NCT00897832|OTHER|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
215142261|NCT02796599|DEVICE|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
215142262|NCT04758572|OTHER|Manual Therapy|Mobilization, massage and stretching
215142263|NCT04758572|OTHER|Massage muscle chain|Massage very soft following the directions of the muscle chains, massage and stretching
215142264|NCT05097079|DRUG|MYOBLOC Low Dose|Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
215142265|NCT05097079|DRUG|MYOBLOC High Dose|Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
215142266|NCT05097079|DRUG|Placebo|Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
215142267|NCT05953389|DRUG|Pitolisant|histamine H3 receptor antagonist/inverse agonist
215142268|NCT05953389|DRUG|Placebo|Matching placebo of pitolisant tablets
215142269|NCT06107608|PROCEDURE|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
215142270|NCT05369845|OTHER|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
215142271|NCT03499483|DRUG|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
215142272|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
215142273|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone
215142274|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
214454835|NCT06168721|OTHER|Expert survey|The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
215142275|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
215142276|NCT05581680|OTHER|dental impressions|dental impressions
215142277|NCT05581680|OTHER|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
215142278|NCT05581680|OTHER|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
215142279|NCT05581680|OTHER|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
214454836|NCT06283082|DIAGNOSTIC_TEST|Lithiasis assessment|Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.
214527675|NCT02795819|DRUG|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
214527676|NCT02795819|DRUG|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
214527677|NCT04584216|OTHER|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
215142280|NCT05917197|OTHER|survey based information|Only survey based information collected
214527678|NCT04584216|OTHER|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
215142281|NCT04361396|OTHER|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
215142282|NCT05670951|DRUG|ELGN-2112|Human insulin \[rDNA\]
215142283|NCT05670951|DRUG|Placebo|Placebo
215142284|NCT03708614|OTHER|Controlled energy diet with elevated protein intake|Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
215142285|NCT02584686|DRUG|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
215142286|NCT02584686|DRUG|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
214454837|NCT04274764|BEHAVIORAL|Personalized eHealth Education & Motivational Interviewing|This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web-based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
214454838|NCT05601752|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
215142287|NCT04986072|DRUG|Sodium Nitroprusside|Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
215142288|NCT04986072|DRUG|5% Dextrose solution|Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
215142289|NCT02352025|DRUG|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
215142290|NCT03480581|BEHAVIORAL|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
215142291|NCT03480581|BEHAVIORAL|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
215142292|NCT01709721|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
215142293|NCT01709721|DEVICE|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
215142294|NCT05549960|DEVICE|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
215142295|NCT06139276|PROCEDURE|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
215142296|NCT06139276|OTHER|Standard treatment|Standard treatment
215142297|NCT02234167|BEHAVIORAL|Risk behaviour and infectious diseases|through counselling, testing vaccination
215142298|NCT05493917|BIOLOGICAL|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
215142299|NCT00213044|DRUG|Carraguard (PC-515)|
215142300|NCT00763035|DRUG|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
214454839|NCT05601752|COMBINATION_PRODUCT|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
214454840|NCT00051532|DRUG|Seocalcitol|
214454841|NCT02810704|DRUG|Enteric Coated Aspirin|
214454842|NCT02810704|DRUG|Warfarin|
214454843|NCT02810704|DRUG|Rivaroxaban|
214454844|NCT03276832|DRUG|Imiquimod|Applied cutaneously
214454845|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
215142301|NCT00763035|DRUG|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
215142302|NCT01781936|DRUG|Fluocinolone Acetonide|
215142303|NCT05564468|OTHER|Best Practice|Receive standard of care
215142304|NCT05564468|OTHER|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
215142305|NCT05564468|OTHER|Questionnaire Administration|Ancillary studies
215142306|NCT03817359|COMBINATION_PRODUCT|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
214454846|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
214454847|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214454848|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214454849|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214527679|NCT01081119|BEHAVIORAL|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
214527680|NCT04213820|DEVICE|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
214454850|NCT03362736|DRUG|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to \[\<=\] 55 kilogram \[kg\] will receive 260 milligram \[mg\] ustekinumab; \> 55 kg to \<= 85 kg will receive 390 mg ustekinumab; and \> 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
214454851|NCT06523413|BEHAVIORAL|Game activity|A game determined by the researcher will be played with the patients in the patient room.
214454852|NCT06523413|DEVICE|Stres Ball|Patients will use the stress ball for 15 minutes.
214454853|NCT06044584|OTHER|No intervention|Observational study with no intervention - Monitoring
214454854|NCT01851694|DRUG|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
214454855|NCT01851694|DRUG|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
214454856|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
214454857|NCT02677298|DRUG|Placebo|Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area
215142307|NCT01539421|BEHAVIORAL|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
215142308|NCT01371396|OTHER|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
215142309|NCT01371396|OTHER|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
215142310|NCT04627402|DRUG|Conbercept and TA|Intravitreous injection of Conbercept and TA
215142311|NCT04627402|DRUG|Conbercept|Intravitreous injection of Conbercept
215142312|NCT02587676|OTHER|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
215142313|NCT03576586|BEHAVIORAL|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
215142314|NCT03576586|BEHAVIORAL|Attention placebo control|Brief cognitive task plus usual care in the maternity department
215142315|NCT03515486|OTHER|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
215142316|NCT02131259|DRUG|Afatinib dimaleate|20mg - 50mg
215142317|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
215142318|NCT05387200|DRUG|Masibone S|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
215142319|NCT05387200|DRUG|Fosamax|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
215142320|NCT01479296|BIOLOGICAL|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
215142321|NCT01479296|BIOLOGICAL|rAd5 env A|Given intramuscularly
215142322|NCT01479296|BIOLOGICAL|rAd5 env B|Given intramuscularly
214454858|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
215142323|NCT01479296|BIOLOGICAL|rAd5 env C|Given intramuscularly
215142324|NCT01479296|BIOLOGICAL|rAd5 gag-pol|Given intramuscularly
214454859|NCT03611621|DRUG|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
215142325|NCT01479296|BIOLOGICAL|Placebo Vaccine|Given intramuscularly
215142326|NCT03496311|DIAGNOSTIC_TEST|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
215142327|NCT05394155|DIETARY_SUPPLEMENT|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
215142328|NCT03219723|DRUG|Vonoprazan|Vonoprazan tablets
215142329|NCT03219723|DRUG|Amoxicillin hydrate|Amoxicillin hydrate (potency)
215142330|NCT03219723|DRUG|Clarithromycin|Clarithromycin (potency)
215142331|NCT03219723|DRUG|Metronidazole|Metronidazole
215142332|NCT05955716|DEVICE|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
215142333|NCT06020820|OTHER|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
215142334|NCT06020820|OTHER|control group group B|"1. Relax shoulders and neck sufficiently~2. look down~3. turn face to the right~4. turn face to the left~5. incline head to the right~6. incline head to the left~7. turn shoulders round and round~8. slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
215142335|NCT03137381|DRUG|CTP-543|Administered as tablets.
214454860|NCT03210272|DRUG|Placebo|Tablet
214454861|NCT03210272|DRUG|BI 1358894|Tablet
214454862|NCT03210272|DRUG|BI 1358894 (Test)|Fasting state
214454863|NCT03210272|DRUG|BI 1358894 (Reference)|Fed state
214454864|NCT05397223|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214454865|NCT05397223|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
215142336|NCT03137381|DRUG|CTP-543 matching placebo|Administered as tablets.
215142337|NCT05122338|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
215142338|NCT05122338|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214454866|NCT05397223|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214454867|NCT05397223|BIOLOGICAL|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
214454868|NCT05397223|BIOLOGICAL|mRNA-1647|Sterile lyophilized product
214454869|NCT03499821|DEVICE|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
214527681|NCT04213820|BEHAVIORAL|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
214454870|NCT06478719|DRUG|Placebo|Placebo oral capsule
214454871|NCT06478719|DRUG|FB-1603|FB-1603 (165 mg/cap) oral capsule
214527682|NCT04213820|BEHAVIORAL|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
214527683|NCT00823446|DEVICE|Revera Wound Care|Revalesio Part Number MDW0060
214454872|NCT05737628|DRUG|BYON4228 + Rituximab|"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
214454873|NCT05789602|DRUG|BPI-460372|Subjects will receive BPI-460372 until disease progression
214527684|NCT00823446|DEVICE|Normal Saline|Sodium Chloride for Irrigation
214454874|NCT03369106|OTHER|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
214454875|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
214454876|NCT04693598|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
214527685|NCT01742650|PROCEDURE|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
214527686|NCT01742650|PROCEDURE|TightRope|TightRope transfixation of syndesmosis
214527687|NCT03255915|DRUG|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
214527688|NCT03255915|OTHER|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
214527689|NCT03643705|OTHER|Multi-component intervention|4 components as described
214527690|NCT03643705|OTHER|General prevention education|General education as described
215142339|NCT05122338|DRUG|Compound lidocaine|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
215142340|NCT05122338|DRUG|Esketamine|Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
215142341|NCT00430014|DRUG|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
215142342|NCT01684917|BEHAVIORAL|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
215142343|NCT02143804|BIOLOGICAL|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
215142344|NCT03146923|OTHER|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives"
214454877|NCT06074900|OTHER|prospective cohort study|"This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient.~Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment."
214454878|NCT04339452|DEVICE|Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.5 with SmartAssist, followed by Impella-supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
214454879|NCT05214092|BEHAVIORAL|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
214454880|NCT05936684|BEHAVIORAL|Breathing with prolonged exhalation (ProlEx) during risky decision-making|20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
214527691|NCT06054633|DIETARY_SUPPLEMENT|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
214527692|NCT06054633|DIETARY_SUPPLEMENT|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
214527693|NCT02552706|DIETARY_SUPPLEMENT|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
214527694|NCT02552706|DIETARY_SUPPLEMENT|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
214527695|NCT03279172|PROCEDURE|direct laryngoscope|procedure entubatıon
214527696|NCT03279172|PROCEDURE|videolaryngoscope|
214527697|NCT01016275|DEVICE|Misago (stent placement)|Misago iliac stent
214527698|NCT01123044|BIOLOGICAL|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
214527699|NCT01123044|PROCEDURE|Medical Therapy|Under usual care treatment
214527700|NCT04306445|DEVICE|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
214527701|NCT04306445|DIETARY_SUPPLEMENT|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
214454881|NCT05936684|BEHAVIORAL|Normal breathing (Eupnea/Control) during risky decision-making|20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
214454882|NCT04021719|OTHER|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
214454883|NCT04021719|OTHER|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
215142345|NCT03146923|OTHER|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio"
215142346|NCT04690686|DEVICE|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
215142347|NCT04690686|DEVICE|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
215142348|NCT04690686|DEVICE|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
215142349|NCT03566290|DRUG|GTx-024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
214454884|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
214454885|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 old +/- 6 months to 18 years old +/- 6 months
214454886|NCT05776836|DEVICE|Dermal filler|Subjects will be consecutively included to receive FASY F in nasolabial folds and cheeks and FASY P in periorbital areas.
214454887|NCT03920111|BIOLOGICAL|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
214454888|NCT06848920|DRUG|Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment|Sinibolimab combined with Lenvatinib in neoadjuvant treatment
214568476|NCT04577456|DEVICE|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
214568479|NCT04124029|DEVICE|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
215142350|NCT01328886|DRUG|Omalizumab|omalizumab lyophilized 150 mg injection
214454889|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be navigated via Meta Quest II headset devices and will be used as an intervention.
214454890|NCT06850376|BEHAVIORAL|COVID Feel Good VR Self-Help Protocol|The intervention consists of a 7-day self-help protocol based on daily exposure to 'The Secret Garden' 360° VR video (10 minutes per day) available at www.covidfeelgood.com, combined with different daily cognitive and social exercises. Participants use a smartphone with VR headset compatible with the Cardboard format. Each day's exercise addresses different psychological aspects: fighting rumination, awakening self-esteem, autobiographical memory, sense of community, goals and dreams, empathy, and planning for change. Exercises are designed to be performed individually and then discussed with a partner.
214454891|NCT06850376|OTHER|Waiting Period|Participants in the control group initially undergo a 7-day waiting period before receiving the VR self-help protocol. During this period, they complete the same baseline assessments as the experimental group but do not receive any specific intervention.
214454892|NCT06848972|OTHER|Structured musculoskeletal exercise programme|The module emphasizes specific exercises, strength training with and without weight, flexibility exercises and balancing exercises.
214454893|NCT06211088|DRUG|famotidine plus10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine
214454894|NCT06211088|OTHER|10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo
214454895|NCT05205850|DRUG|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
214454896|NCT06850233|OTHER|No intervention|No intervention
214454897|NCT06848309|PROCEDURE|Bronchoscopy|Some participants in all 5 groups may undergo an optional bronchoscopy procedure with bronchoalveolar lavage and endobronchial biopsy collection if they choose.
214454898|NCT06849609|BIOLOGICAL|VGN-R13|An adeno-associated viral vector 9 gene therapy product.
214454899|NCT06850597|DRUG|dimethyl fumarate|480 mg per day
214454900|NCT04024917|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~\- The program cardiac coherence will be performed during 90 days after the surgery"
214454901|NCT04024917|OTHER|Standard care|Standard care
214454902|NCT06846125|OTHER|GROUP A: Combined Mindfulness and Strength Training|"Week Exercises Reps x Sets 1-2 Mindfulness Training: Breathing exercises, body scans, and meditation. Strength Training: Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Mindfulness Training: Guided visualization and mindfulness integration during exercises.~Strength Training: Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Mindfulness Training: Focus on movement awareness and posture during high-intensity drills.~Strength Training: Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Mindfulness Training: Integration during advanced functional movements. Strength Training: Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4"
215142351|NCT05929963|OTHER|HCV infection status|Divided into 3 groups based on HCVAb and HCVRNA status
215142352|NCT06009133|PROCEDURE|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
214454903|NCT06846125|OTHER|GROUP B: Strength Training Only|Week Exercises Reps x Sets 1-2 Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4
214454904|NCT05118269|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
214454905|NCT05118269|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
214454906|NCT06841952|DRUG|ATRA+Venetoclax+Azacitidine|Participants will receive a standard dose of azacitidine (75mg/m²/day)，venetoclax (target dose, 400 mg)，ATRA 45mg/m²/day
214454907|NCT06841952|DRUG|Chemotherapy drug|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).
214454908|NCT06841393|OTHER|Biometrological measurements|"Measurements will be taken from the face:~* For acne group: inflammatory lesional area and non-lesional area~* For control group: non-lesional area"
214454909|NCT06841393|OTHER|Biological sampling|"Samples will be taken from the face:~* For acne group: inflammatory lesional area, non-lesional area and retentional area~* For control group: non-lesional area"
214454910|NCT06841393|OTHER|Clinical assessments|Only for acne group: acne scores will be evaluated on the face by the investigator
214454911|NCT06841393|OTHER|Questionnaire|Only for acne group: consumers' perception
214568480|NCT04124029|PROCEDURE|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
214454912|NCT06843161|DEVICE|The jog or ground go no go task for retraining automatic bias|Recruited participants will be performing the JOGGNG Task on the Kinarm Endpoint Laboratory. This task requires participants to control a robotic handle to manipulate a virtual avatar that looks as if it is jogging across a field. During the jogging, a frisbee will appear and quickly move towards the avatar, eventually tilting clockwise or counterclockwise. Participants are required to either reach quickly to grab the frisbee from the air during clockwise tilts or to not move during counterclockwise tilts. This tilt/movement associated is reversed to control for a potential bias in tilt angle and movement. An image of physical activity or sedentary behaviour will appear inside of the frisbee but participants are not told that it is associated with any of the tilts. Each trial consists of one frisbee and participants will complete a total of 3 blocks of 360 trials each which will take approximately 30 minutes to complete.
214454913|NCT05591196|DEVICE|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
214454914|NCT05591196|OTHER|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
214454915|NCT04342962|DRUG|tagraxofusp|Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
214454916|NCT06850129|BEHAVIORAL|DIGITAL INTERVENTION|All patients received specific information about DM, treatments and po-tential complications. Then, patients were randomized to the digital interven-tion group or usual care. Those patients randomized to the intervention group were educated in the use of different social networks with access to infor-mation related to healthy lifestyle habits, dietary support, optimization of physi-cal activity, insulin titration, therapeutic targets, self-care, based on validated material from scientific societies and endorsed in diabetes education. Patients also had the valuable resource of a Digital Diabetes Coach: an online expert specializing in therapeutic education. This virtual guide provided patients with the flexibility to interact in both unidirectional and bidirectional ways, using methods such as chat boxes, audio messages, videos, and more. Through this digital medium, patients could seek guidance and have their questions re-solved.
214454917|NCT06848322|BEHAVIORAL|resistance exercise|Participants will perform resistance exercise for 8 weeks
214454918|NCT06848322|BEHAVIORAL|aerobic exercise|Participants will perform aerobic exercise for 8 weeks
214454919|NCT06848322|OTHER|Control (placebo)|Participants will maintain their usual lifestyle for 8 weeks.
214454920|NCT06849180|COMBINATION_PRODUCT|Interventional therapies combined with or without systemic drugs|The study will include adult patients with histologically/cytologically confirmed unresectable CHC. Collect patient genomics, proteomics, immune microenvironment, pathology reports, medical images and clinical electronic medical records, etc., to form high-quality and deeply labeled data sets to support the subsequent development and application of AI large models. Based on multi-source heterogeneous data of CHC patients, a large model for comprehensive diagnosis and treatment was constructed. Firstly, multi-modal data of different stages of disease were integrated by using cross-modal multi-course fusion technology to achieve efficient fusion of complex data. Secondly, by fine-tuning the large model, tasks such as CHC classification, prognosis inference and treatment plan recommendation are accurately completed, and potential information in the diagnosis and treatment process is mined.
215142353|NCT06009133|PROCEDURE|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
214527702|NCT04306445|PROCEDURE|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
214527703|NCT03417375|PROCEDURE|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
214527704|NCT04051645|DEVICE|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
214527705|NCT00856453|BEHAVIORAL|Home yoga practice|training for and tracking of patient's practice of yoga at home
214527706|NCT00856453|BEHAVIORAL|yoga classes|organized out of home classes for yoga
214527707|NCT05557253|DRUG|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
214527708|NCT05557253|DRUG|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
214527709|NCT03994900|DIAGNOSTIC_TEST|Blood sampling for HbNO assessment|Blood sampling
215142354|NCT00459316|BIOLOGICAL|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
214454921|NCT04691960|OTHER|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
215142355|NCT01106612|PROCEDURE|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
214454922|NCT04691960|DRUG|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
214454923|NCT06850181|BEHAVIORAL|game experience and learning motivation|game experience and learning motivation
214454924|NCT06848270|OTHER|Early palliative care integration|Early follow up by the palliative care team, from diagnosis
214454925|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
214454926|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
214454927|NCT04764448|OTHER|Placebo|Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
214454928|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
214454929|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
214454930|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
214454931|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
214454932|NCT05542238|BEHAVIORAL|One bout of moderate-intensity sub-maximal aerobic exercise|The intervention is a 20-min acute exercise using arm ergometer
214454933|NCT06639204|DEVICE|Electrical stimulation|A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
214454934|NCT06639204|PROCEDURE|Orthodontic treatment without acceleration|No additional appliances will be used. Only the traditional fixed appliances (braces).
214454935|NCT03382977|BIOLOGICAL|VBI-1901|The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
214454936|NCT03382977|DRUG|Carmustine|Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
214454937|NCT03382977|DRUG|Lomustine|Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
214454938|NCT06093841|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
214527710|NCT02231814|DIETARY_SUPPLEMENT|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
214527711|NCT02231814|OTHER|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
215142356|NCT01106612|PROCEDURE|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
215142357|NCT03837223|DRUG|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
214454939|NCT06093841|DRUG|Fludarabine|Administered according to package insert
214454940|NCT06093841|DRUG|Cyclophosphamide|Administered according to package insert
215142358|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
214454941|NCT05820997|DRUG|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
214454942|NCT06276894|DEVICE|Motek C-Mill™ treadmill|We will enroll 10 to 15 participants to participate in a VR treadmill training session while wearing an fNIRS cap.
214454943|NCT06276894|OTHER|training session with and without VR wearing the fNIRS cap|training session with and without VR wearing the fNIRS cap
214454944|NCT05552547|DEVICE|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
214454945|NCT05552547|DEVICE|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
214454946|NCT01997840|DRUG|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
214454947|NCT04014673|BEHAVIORAL|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
214527712|NCT02513810|DEVICE|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
214454948|NCT05304936|DRUG|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
214454949|NCT06405971|DRUG|Metformin|Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
214454950|NCT06262139|DRUG|MT218 injection|a targeted magnetic resonance imaging contrast agent
214454951|NCT05355363|DIAGNOSTIC_TEST|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
214454952|NCT06813807|DRUG|0.5% TM|From D1 to D10, each subject will receive one drop of 0.5% timolol maleate ophthalmic gel forming solution each in the left and right eyes once daily at the same time every day under fasted condition.
214454953|NCT04711551|COMBINATION_PRODUCT|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices
214454954|NCT04509102|DRUG|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
214454955|NCT04509102|DRUG|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
214454956|NCT05321056|DEVICE|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
214454957|NCT05872477|DRUG|Ruxolitinib Topical|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
214454958|NCT05872477|DRUG|Placebo|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
214454959|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
214454960|NCT04487145|DRUG|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
214454961|NCT04961567|DRUG|Litifilimab|Administered as specified in the treatment arm.
214454962|NCT04961567|DRUG|Placebo|Administered as specified in the treatment arm.
214454963|NCT03250975|DRUG|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
214454964|NCT03250975|OTHER|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
214454965|NCT06442059|OTHER|Kinesiophobia Level Due to Dyspnea|Kinesiophobia Level Due to Dyspnea
214527713|NCT02513810|DEVICE|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
214527714|NCT03005483|DRUG|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
214527715|NCT03005483|OTHER|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
214527716|NCT04759599|PROCEDURE|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
214527717|NCT05422040|OTHER|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
214527718|NCT05422040|OTHER|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
214527719|NCT04185142|COMBINATION_PRODUCT|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
214454966|NCT01494662|DRUG|HKI-272|240 mg orally, once daily
214454967|NCT01494662|PROCEDURE|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
214454968|NCT01494662|DRUG|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
214454969|NCT01494662|DRUG|HKI-272|160 mg orally, once daily
214454970|NCT01494662|DRUG|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
214454971|NCT03656549|DRUG|Pemetrexed + oral folinic acid rescue|3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
214527720|NCT00100945|DRUG|gefitinib|
214527721|NCT04748445|DIAGNOSTIC_TEST|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
214527722|NCT01679457|BEHAVIORAL|ACT-Focused ERP|
214527723|NCT01679457|BEHAVIORAL|TAU-ERP|
214527724|NCT05331716|PROCEDURE|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
214568489|NCT04928287|BIOLOGICAL|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
214568490|NCT04928287|OTHER|Placebo|Placebo will be administered intravenously to study participants who qualify.
214527725|NCT05063292|PROCEDURE|Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation|Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
214527726|NCT05307120|DEVICE|Diameter integrated in secondary diabetes care|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
214527727|NCT04879875|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
214527728|NCT04879875|DEVICE|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
215142359|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
215142360|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
215142361|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
214527729|NCT00786721|DEVICE|Diffuse Optical Spectroscopy|muscle properties scanning
214527730|NCT01861795|OTHER|Preterm Neonates|Preterm Neonates
214527731|NCT04596241|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
214527732|NCT06477887|BIOLOGICAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin"
214527733|NCT06477887|BIOLOGICAL|Autogenous Partially Demineralized Dentine Matrix|"The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft."
215142362|NCT04323969|BEHAVIORAL|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
215142363|NCT04323969|BEHAVIORAL|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
215142364|NCT02116036|DRUG|Rivaroxaban|
215142365|NCT01682434|PROCEDURE|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
214454972|NCT03729804|DRUG|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
214454973|NCT03729804|DRUG|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
214454974|NCT03729804|DRUG|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
214454975|NCT03729804|DRUG|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
214454976|NCT06543940|DRUG|Vancomycin|vancomycin dose is 7.5 to 10 mg/kg
214454977|NCT05311384|BEHAVIORAL|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
214454978|NCT03767855|DRUG|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
214454979|NCT03767855|DRUG|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
214454980|NCT03767855|DRUG|CK-3773274 - Tablets|CK-3773274 formulated as tablets
214454981|NCT06155279|DRUG|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
214454982|NCT04322643|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
214454983|NCT04322643|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
214454984|NCT04322643|DRUG|Durvalumab|Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
214454985|NCT04322643|DRUG|Nivolumab|Nivolumab 480mg IV over 30 minutes every 4 weeks
214454986|NCT04322643|DRUG|Avelumab|Avelumab 800 mg IV over 60 minutes every 2 weeks
214454987|NCT04353804|OTHER|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
214454988|NCT04353804|OTHER|Active Control computer games|Active Control computer games
214454989|NCT05995535|DRUG|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
214527734|NCT02896439|DEVICE|Neurophysiological MONITORING|"The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention"
214454990|NCT05995535|DRUG|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
214454991|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
214527735|NCT02581371|DRUG|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
214527736|NCT02581371|OTHER|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
214527737|NCT00850798|DRUG|Intensive glycemic control|Intensive glycemic control
214527738|NCT00850798|DRUG|Conservative glycemic control|OADs and insulin
214527739|NCT01225705|DRUG|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
214527740|NCT01225705|DRUG|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
214527741|NCT01994538|OTHER|Longer therapy duration|14 days of antimicrobial treatment
215142366|NCT01239953|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
215142367|NCT01239953|DEVICE|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
215142368|NCT01980017|BEHAVIORAL|Ottawa Model for Smoking Cessation|
215142369|NCT03044106|DEVICE|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
215142370|NCT03733015|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
215142371|NCT06486194|DEVICE|Targeted breast milk fortification using preemie device|Mother's breast milk will have additional macronutrient added to it based on analysis with the Preemie device, to ensure it meets current European recommendations for nutrient intakes for preterm infants
215142372|NCT06486194|DIETARY_SUPPLEMENT|Standard Breast milk fortification|Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants
214454992|NCT04561232|BEHAVIORAL|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
214454993|NCT06304324|DRUG|0.9% Sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
214454994|NCT06304324|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
214454995|NCT06304324|DRUG|0.05ug/kg Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
214454996|NCT06798480|OTHER|Self-administered survey|An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.
214454997|NCT05353829|DRUG|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
214454998|NCT05302921|PROCEDURE|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
214454999|NCT05302921|DRUG|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
214527742|NCT01994538|OTHER|Shorter therapy duration|7 days of antimicrobial treatment
214527743|NCT01855997|DRUG|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
214527744|NCT04854616|BEHAVIORAL|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
214527745|NCT02896218|OTHER|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
214527746|NCT03612453|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
214527747|NCT03612453|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
214527748|NCT03571347|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
214527749|NCT03571347|OTHER|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
215142373|NCT05778604|BEHAVIORAL|Physio-feedback|"The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9."
215142374|NCT05778604|BEHAVIORAL|Cognitive reframing|Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
214695049|NCT04020484|BEHAVIORAL|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
214695050|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
214695051|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
214695052|NCT03302793|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
214695053|NCT03302793|DEVICE|tDCS|tDCS will be applied for 20 minutes.
214695054|NCT03302793|DEVICE|tDCS sham|
214695055|NCT00870831|OTHER|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
214695056|NCT01272297|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
214695057|NCT04574297|BEHAVIORAL|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
215142375|NCT05778604|BEHAVIORAL|Peer-led exercises|The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
214455000|NCT05302921|DRUG|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
214455001|NCT04704999|DRUG|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
214455002|NCT04704999|DRUG|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
214455003|NCT04704999|DRUG|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
214455004|NCT05329493|DEVICE|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
214455005|NCT06346262|BEHAVIORAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
214455006|NCT06346262|DRUG|Valtoco Nasal Product|Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
214455007|NCT03584295|DEVICE|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
214455008|NCT03584295|OTHER|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
214455009|NCT06209801|BEHAVIORAL|Mirror therapy|60 seconds of intervention
214455010|NCT06209801|DEVICE|Neuromuscular electrical stimulation|60 seconds of intervention
214455011|NCT06209801|BEHAVIORAL|Motor imagery|60 seconds of intervention
214455012|NCT06007651|DRUG|LY3885125|Administered SC
214455013|NCT06007651|DRUG|Placebo|Administered SC
214455014|NCT03513614|PROCEDURE|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
214455015|NCT03513614|RADIATION|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
214455016|NCT03513614|RADIATION|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
214695058|NCT04574297|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
214695059|NCT01079962|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
214695060|NCT01079962|DRUG|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
214695061|NCT01331239|DRUG|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
214695062|NCT01887249|DRUG|Clarithromycin|
214695063|NCT01887249|DRUG|metronidazole|
214695064|NCT01887249|DRUG|esomeprazole|
214455017|NCT06167343|PROCEDURE|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
214455018|NCT06227832|DRUG|KP-001|KP-001
214455019|NCT06227832|DRUG|Metformin|oral dose of 850 mg Metformin
214455020|NCT06227832|DRUG|Midazolam|oral dose of 2 mg Midazolam
214455021|NCT06227832|DRUG|Clarithromycin|oral doses of 1000 mg Clarithromycin
214455022|NCT05386758|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
214455023|NCT01524965|PROCEDURE|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
214455024|NCT01524965|PROCEDURE|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
214455025|NCT01524965|DEVICE|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
214455026|NCT05638620|DRUG|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
214455027|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
214455028|NCT02698462|OTHER|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
214455029|NCT02515955|DRUG|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
214455030|NCT02515955|DRUG|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
214455031|NCT02515955|DRUG|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
214455032|NCT02515955|DRUG|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
214527750|NCT01536535|DRUG|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
214527751|NCT01536535|DRUG|IV Corticosteroid|Treatment with IV Corticosteroid
214527752|NCT01536535|DRUG|Oral Corticosteroids|Treatment with oral corticosteroids
214527753|NCT01536535|OTHER|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
214527754|NCT01536535|PROCEDURE|Colectomy|Colectomy
214527755|NCT03315988|OTHER|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
214527756|NCT04545983|OTHER|Motion Analysis|Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
214527757|NCT02788617|DEVICE|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
214527758|NCT03334773|BEHAVIORAL|Nutrition education|
214695065|NCT00850018|PROCEDURE|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
214695066|NCT00850018|BEHAVIORAL|Usual care|Participants will receive usual care for the treatment of SCD.
214695067|NCT00207766|DRUG|infliximab or placebo|
214695068|NCT02390115|OTHER|Elastic tape application in shoulder|
214695069|NCT05818527|DEVICE|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
214695070|NCT00946530|DEVICE|Bright light|Participants uses bright light
214695071|NCT00946530|DEVICE|Control|Participants uses dim light
214695072|NCT01192750|OTHER|immunohistochemistry staining method|
214695073|NCT01192750|OTHER|laboratory biomarker analysis|
214527759|NCT03703141|DIETARY_SUPPLEMENT|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
214527760|NCT06350370|PROCEDURE|Natural orifice specimen extraction|We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
214527761|NCT05738070|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
214527762|NCT05452837|PROCEDURE|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
214695074|NCT01192750|OTHER|medical chart review|
214455033|NCT02515955|DRUG|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
214455034|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Fixation|Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.
214455035|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Removal|Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
214455036|NCT04145466|BEHAVIORAL|High-fat diet|"The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
214455037|NCT04145466|BEHAVIORAL|High-carbohydrate diet|"The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
214455038|NCT03563144|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
214455039|NCT03563144|DRUG|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
214455040|NCT03563144|DRUG|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
214455041|NCT03563144|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214455042|NCT03563144|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214527763|NCT05452837|PROCEDURE|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
214527764|NCT03866434|DRUG|SPD422|Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
214695075|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 0 and 4
214695076|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
214695077|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 12
214455043|NCT03563144|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
214455044|NCT03563144|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214455045|NCT03563144|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
214455046|NCT03563144|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
214527765|NCT03866434|DRUG|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
214695078|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
214455047|NCT03563144|BIOLOGICAL|GI-6207|CEA yeast vaccine
214455048|NCT03563144|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214455049|NCT03563144|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
214455050|NCT03563144|DRUG|Avelumab|Avelumab
214455051|NCT03563144|DRUG|Bevacizumab|Bevacizumab
214455052|NCT03563144|DRUG|Capecitabine|Capecitabine
214455053|NCT03563144|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214455054|NCT03563144|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214455055|NCT03563144|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214455056|NCT03563144|DRUG|Oxaliplatin|Oxaliplatin
214527766|NCT00519714|DIETARY_SUPPLEMENT|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
214527767|NCT00519714|DIETARY_SUPPLEMENT|Placebo|Placebo
214527768|NCT01705951|OTHER|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
214527769|NCT01705951|BIOLOGICAL|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
214695079|NCT05212155|BEHAVIORAL|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
214695080|NCT03524833|DRUG|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
214695081|NCT03524833|DRUG|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
214695082|NCT00121511|DRUG|Efudex (5-fluorouracil)|
215142376|NCT05778604|BEHAVIORAL|CDC older adults fall prevention|Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
215142377|NCT06061796|PROCEDURE|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~* ratio P/F \> 150 mm Hg~* FiO2 \< 60%~* PEEP ≤ 10 cm d'H2O"
215142378|NCT05895188|DEVICE|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
215142379|NCT02057250|DRUG|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
215142380|NCT02057250|DEVICE|Auto-Injector Device (AID)|
215142381|NCT02057250|DEVICE|Pre-filled Syringe (PFS)|
215142382|NCT02057250|DRUG|Methotrexate|Dispensed according to local practice.
215142383|NCT02057250|DRUG|Sulfasalazine|Dispensed according to local practice.
215142384|NCT02057250|DRUG|Leflunomide|Dispensed according to local practice.
215142385|NCT02057250|DRUG|Hydroxychloroquine|Dispensed according to local practice.
214455057|NCT05403736|OTHER|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
214455058|NCT04522375|DRUG|FP-045|activator of aldehyde dehydrogenase
215142386|NCT00497484|DRUG|recombinant human somatotropin|
215142387|NCT04843007|DRUG|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
215142388|NCT05993858|DRUG|3cycles (Toripalimab + cetuximab)|"Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9."
215142389|NCT05993858|PROCEDURE|Surgery|After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
215142390|NCT05993858|RADIATION|Radiotherapy or chemoradiotherapy|Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
215142391|NCT03104127|DEVICE|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
215142392|NCT03104127|OTHER|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
215142393|NCT00349518|DRUG|Dasatinib|
215142394|NCT03772886|DEVICE|Peanut Ball|A peanut shaped exercise ball.
214455059|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
214455060|NCT02502435|OTHER|Observation|Observational study
214455061|NCT05896267|DEVICE|Masimo INVSENSOR00061|Masimo INVSENSOR00061 will be used to measure noninvasive SpO2 (Oxygen Saturation )
214455062|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
214455063|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
214455064|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
214455065|NCT05710107|OTHER|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
214455066|NCT05710107|OTHER|QL Block|Subjects randomized to this group will receive a QL Block
214455067|NCT03395132|DRUG|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
214455068|NCT03395132|DRUG|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
214527770|NCT04139239|DIAGNOSTIC_TEST|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
215142395|NCT01008020|DIETARY_SUPPLEMENT|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
215142396|NCT02372955|DRUG|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
215142397|NCT02372955|DRUG|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
215142398|NCT00649038|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
215142399|NCT00649038|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
215142400|NCT03997188|DEVICE|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
214527771|NCT00167323|BEHAVIORAL|Adherence therapy|
214527772|NCT00387907|DRUG|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
214527773|NCT00387907|DRUG|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
214527774|NCT00729885|DEVICE|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
215142401|NCT02032017|PROCEDURE|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
215142402|NCT02032017|PROCEDURE|Percutaneous assisted approach|
214527775|NCT00729885|DEVICE|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
215142403|NCT02032017|PROCEDURE|Anterolateral approach|
215142404|NCT02032017|OTHER|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
215142405|NCT01434212|DRUG|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
215142406|NCT03854175|DRUG|sildenafil citrate|25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
214455069|NCT03395132|DRUG|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
214455070|NCT03395132|DRUG|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
214455071|NCT03790787|DRUG|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
214455072|NCT03790787|DRUG|Dorzagliatin|Glucokinase activator currently under development
215142407|NCT03854175|DRUG|Estradiol Valerate 2 MG|2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
215142408|NCT02578069|DEVICE|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
214455073|NCT04869670|PROCEDURE|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
214455074|NCT04869670|PROCEDURE|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
214527776|NCT04134455|PROCEDURE|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
214527777|NCT04134455|PROCEDURE|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
214527778|NCT02003664|DRUG|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
214527779|NCT02003664|DRUG|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
214527780|NCT05216952|DRUG|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
214527781|NCT05216952|DRUG|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
214527782|NCT02806596|DRUG|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
214527783|NCT00376207|BEHAVIORAL|Physical exercise|
214527784|NCT00385697|BIOLOGICAL|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
214527785|NCT00385697|DRUG|Placebo|Daily IV dosing for 14 days, repeated at Week 26
215142409|NCT02578069|DEVICE|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
215142410|NCT04859907|DEVICE|Clamp-like system|Craniotomy closure
215142411|NCT04859907|DEVICE|Plates and screws|Craniotomy closure
215142412|NCT01921309|DEVICE|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
214455075|NCT05517850|BEHAVIORAL|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
214455076|NCT05517850|BEHAVIORAL|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
214455077|NCT04644185|DRUG|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
214455078|NCT04644185|OTHER|Placebo|all SCTA01 excipients without active component+best supportive care
214455079|NCT05218447|DEVICE|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
214455080|NCT05218447|OTHER|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
214455081|NCT04680663|DIAGNOSTIC_TEST|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
214527786|NCT04117906|BEHAVIORAL|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
214527787|NCT02403284|DRUG|Liraglutide|Subcutaneous injection by patient
215142413|NCT01921309|DEVICE|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
215142414|NCT00600262|DRUG|intravitreal bevacizumab|
215142415|NCT01271946|DEVICE|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
215142416|NCT04592302|DIAGNOSTIC_TEST|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
215142417|NCT05073874|OTHER|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
215142418|NCT02948127|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
215142419|NCT02948127|BIOLOGICAL|Placebo|Administered as nose drops
215142420|NCT00423579|DRUG|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
215142421|NCT00423579|DRUG|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
215142422|NCT05647317|OTHER|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
215142423|NCT02392637|DRUG|Cisplatin|Given IV
215142424|NCT02392637|DRUG|Gemcitabine Hydrochloride|Given IV
215142425|NCT02392637|OTHER|Laboratory Biomarker Analysis|Correlative studies
215142426|NCT02392637|DRUG|Nab-paclitaxel|Given IV
215142427|NCT03763838|OTHER|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
215142428|NCT03763838|OTHER|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
215142429|NCT03763838|OTHER|Standard of Care|Fatigue management provided by participants' health care providers.
215142430|NCT02850653|BIOLOGICAL|PCR : 16S ribosomal DNA and real-time targeted PCR|
215142431|NCT02850653|BIOLOGICAL|Sampling of aqueous humour|
215142432|NCT01875796|BEHAVIORAL|Cognitive-Behavioral Therapy|
215142433|NCT01875796|BEHAVIORAL|Motivation Enhancement Therapy|
215142434|NCT01875796|BEHAVIORAL|Integrated Cannabis and Anxiety Reduction Treatment|
215142435|NCT01875796|BEHAVIORAL|False Safety Behavior Elimination Therapy|
214695083|NCT00883480|DRUG|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
215142436|NCT03367663|DRUG|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
215142437|NCT03367663|DRUG|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
215142438|NCT01048619|DRUG|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
215142439|NCT02835378|OTHER|No intervention|
215142440|NCT05281302|DEVICE|Neck muscle vibration|Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
215142441|NCT05281302|DEVICE|Neck muscle vibration + sham-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device."
215142442|NCT05281302|DEVICE|Neck muscle vibration + anodal-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy."
215142443|NCT03013231|BEHAVIORAL|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
214455082|NCT04680663|DIAGNOSTIC_TEST|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
214455083|NCT03352258|RADIATION|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
214455084|NCT06550141|DRUG|Emapalumab|An interferon gamma (IFNγ) blocking antibody
214455085|NCT06550141|DRUG|Cyclophosphamide|Alkylating agent
214455086|NCT06550141|DRUG|Fludarabine Phosphate|Purine antagonist antimetabolite
214455087|NCT06550141|DRUG|Axicabtagene Ciloleucel|Autologous treatment
214455088|NCT04717492|OTHER|Observational|Observational
214455089|NCT06550284|OTHER|Physical Therapy|The intervention will be physical therapy standard care.
214455090|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
214455091|NCT04423185|DRUG|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
214455092|NCT04423185|DRUG|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
214455093|NCT04423185|DRUG|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
214455094|NCT04423185|DRUG|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
214527788|NCT02403284|DRUG|Sugar Pill|Subcutaneous injection daily
214695084|NCT00883480|DRUG|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
214695085|NCT00883480|DRUG|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
214695086|NCT00883480|DRUG|Erlotinib|Erlotinib 150 mg/day x 21 days
215142444|NCT00427453|BIOLOGICAL|MVA85A|
215142445|NCT02192489|DRUG|CC-220 0.3 mg Daily|
215142446|NCT02192489|DRUG|CC-220 0.6mg Daily|
215142447|NCT02192489|DRUG|Placebo|
215142448|NCT01412502|OTHER|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
215142449|NCT02660151|DEVICE|Hyper-CL™ lens|
215142450|NCT02660151|DEVICE|Regular soft contact lens|
215142451|NCT02660151|DRUG|Salt solution|
215142452|NCT03279744|DRUG|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
214455095|NCT04423185|DRUG|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
214455096|NCT04423185|DRUG|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
214455097|NCT04423185|DRUG|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
214455098|NCT04423185|DRUG|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
214455099|NCT04423185|DRUG|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
214455100|NCT04423185|DRUG|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
214455101|NCT04423185|DRUG|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
214455102|NCT03657771|OTHER|DED|DED: Diet eliminating dairy
214455103|NCT03657771|OTHER|FREE|FREE: Diet eliminating dairy and food additives
214455104|NCT05044000|DEVICE|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
214455105|NCT05441501|DRUG|JNJ-80038114|JNJ-80038114 will be administered.
214455106|NCT04016818|DRUG|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
214455107|NCT04016818|DEVICE|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
214455108|NCT04367883|DRUG|Antihistamine|No intervention is performed. We propose an observational study.
214455109|NCT04367883|DRUG|Amantadine|No intervention is performed. We propose an observational study
214455110|NCT04367883|DRUG|ACEI|No intervention is performed. We propose an observational study.
214455111|NCT04367883|DRUG|ARB|No intervention is performed. We propose an observational study.
214455112|NCT04367883|OTHER|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
214455113|NCT05701306|DRUG|APG-115|Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
214455114|NCT05701306|DRUG|APG-2575|Orally once a day (QD) for 21 days, 21 days as a cycle.
214455115|NCT01477957|PROCEDURE|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
214455116|NCT05071807|DRUG|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
214455117|NCT05071807|OTHER|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
214455118|NCT05706480|DIAGNOSTIC_TEST|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
214455119|NCT05706480|DIAGNOSTIC_TEST|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
214455120|NCT05706480|DIAGNOSTIC_TEST|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
214455121|NCT05485090|OTHER|Questionnaire : Adapted Safety Assessment Scale|Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
214455122|NCT05435495|PROCEDURE|Single-photon emission computed tomography|Imaging procedure
214455123|NCT05435495|PROCEDURE|Blood Draw|Blood draw for future research tests (45-60 mL).
214455124|NCT05435495|PROCEDURE|Tumor Biopsy|Guided biopsy of lesion
214455125|NCT05259072|DIAGNOSTIC_TEST|99m-technetium pyrophosphate scintigraphy|Imaging test
214455126|NCT05456165|DRUG|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
214455127|NCT05456165|DRUG|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
215142453|NCT05536401|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
215142454|NCT05536401|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
215142455|NCT06387693|DIAGNOSTIC_TEST|Holter monitoring, intracoronary ECG|Holter monitoring device to track ECG abnormalities during spontaneous chest pain in the outpatient setting. Intracoronary ECG to evaluate perprocedural ECG responses
215142456|NCT05266989|OTHER|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
215142457|NCT02992795|DEVICE|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
215142458|NCT02161016|DEVICE|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
215142459|NCT04976400|PROCEDURE|semi-individualized total knee replacement treatment with a gender-specific design|Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.
215142460|NCT04976400|PROCEDURE|Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)|Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
215142461|NCT05182593|OTHER|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
215142462|NCT05182593|OTHER|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
215142463|NCT05955248|DIETARY_SUPPLEMENT|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
215142464|NCT05955248|OTHER|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
214695087|NCT04705558|OTHER|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
215142465|NCT05955248|DIETARY_SUPPLEMENT|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
215142466|NCT05900596|DIAGNOSTIC_TEST|Fetal blood sampling|Fetal scalp blood sampling and analysis
215142467|NCT00240513|DRUG|Minocycline|100 mg capsules OD for 3 months
215142468|NCT00240513|DRUG|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
215142469|NCT00003475|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215142470|NCT00597220|DIETARY_SUPPLEMENT|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
215142471|NCT00597220|DRUG|Placebo|Placebo
215142472|NCT00167843|DRUG|sulfadoxine-pyrimethamine|
215142473|NCT04591613|OTHER|Questionnaire|Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
214455128|NCT05456165|DRUG|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
214695088|NCT04705558|OTHER|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
215142474|NCT04591613|OTHER|Biocollection|Total serum, plasma samples will be collected
215142475|NCT04591613|OTHER|Follow-up visit|All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
215142476|NCT01961037|OTHER|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
215142477|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
215142478|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
215142479|NCT01107054|DRUG|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
215142480|NCT01107054|DRUG|placebo|A single oral dose of non-matched placebo on Day 4.
215142481|NCT03288103|DRUG|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
215142482|NCT00003153|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215142483|NCT01574729|DRUG|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
215142484|NCT01574729|PROCEDURE|Surgery|Surgery plus post-surgery chemotherapy
215142485|NCT05324852|DRUG|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
215142486|NCT05324852|DRUG|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
215142487|NCT03354195|PROCEDURE|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
214455129|NCT05456165|DRUG|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
215142488|NCT01671696|OTHER|Cardiac MRI|Cardiac MRI
215142489|NCT02386397|DRUG|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
215142490|NCT02386397|DRUG|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
215142491|NCT02481674|DRUG|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
215142492|NCT02481674|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
215142493|NCT06002880|DEVICE|Optibond Universal|OBU™ will be used used for the cementation of indirect restorations (ceramic restorations, composite, zirconia and metal crowns) and pretreatment for indirect restoration, according to manufacturer's Instruction For Use in self-etch and total-etch modes.
215142494|NCT03297450|DEVICE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
215142495|NCT03297450|BEHAVIORAL|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
215142496|NCT03297450|DEVICE|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
215142497|NCT06522620|PROCEDURE|Posterior Femoral Cutaneous Nerve Combined With Proximal Sciatic and Saphenous Nerve Block|All nerve blocks were performed under ultrasound guidance，single supragluteal approach sciatic nerve block using a nerve stimulator, 20 ml of drug was injected around the sciatic nerve, the extent of drug diffusion was observed, the needle tip was turned into the deep surface of the gluteus maximus muscle below the deep gluteal artery and 5 ml of drug was injected, followed by a retractile canal saphenous nerve block injected with 15 ml of drug, and the difference in sensation of the posterior thighs of the bilateral thighs was measured after 15 min to ensure posterior femoral cutaneous nerve were blocked
215142498|NCT06522620|PROCEDURE|Simple Sciatic and Saphenous Nerve Blocks|All nerve blocks were performed under ultrasound guidance，single subgluteal approach sciatic nerve block using a nerve stimulator, with 25 ml of drug injected around the sciatic nerve, followed by a retractile canal saphenous nerve block with 15 ml of drug injection
215142499|NCT04909450|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
215142500|NCT04909450|BIOLOGICAL|Vehicle Control|Matching vehicle control without the drug substance
215142501|NCT03675126|DRUG|SRP-5051|SRP-5051 administered as an IV infusion.
215142502|NCT03772249|DRUG|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
215142503|NCT03772249|DRUG|Placebo for DCR-HBVS|Sterile 9% saline for injection.
215142504|NCT03691376|BIOLOGICAL|Aldesleukin|Given SC
214695089|NCT03081286|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
215142505|NCT03691376|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
215142506|NCT03691376|OTHER|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
215142507|NCT03691376|DRUG|Melphalan|Given IV
215142508|NCT06560489|DRUG|Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
215142509|NCT05609591|DIETARY_SUPPLEMENT|Liquid diet group|Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.
215142510|NCT05609591|DIETARY_SUPPLEMENT|Enteral nutrition group|100% short peptide enteral nutrition are given to children for bowel preparation
215142511|NCT05609591|DIETARY_SUPPLEMENT|Low residual diet group|Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
215142512|NCT06511258|BEHAVIORAL|Prehabilitation|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
214695090|NCT03081286|PROCEDURE|Fat graft|The harvested lipoaspirate is injected at the site of pain.
214695091|NCT03081286|PROCEDURE|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
215142513|NCT00001959|DRUG|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
214455130|NCT05456165|DRUG|Adjuvant chemotherapy|Administered according to standard of care.
214455131|NCT04918823|DRUG|Restasis|Subject will use one drop of Restasis in the lens before insertion
214455132|NCT04072380|DRUG|SUVN-G3031|SUVN-G3031 Tablets
214695092|NCT03175003|OTHER|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
214695093|NCT02126111|BIOLOGICAL|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
214527789|NCT00815347|DRUG|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
214527790|NCT00815347|DRUG|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
214455133|NCT04072380|DRUG|Placebo|Placebo Tablets
214455134|NCT03144765|PROCEDURE|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
214455135|NCT06259448|OTHER|urine self-sampling|urine self-sampling
214455136|NCT05551637|DIETARY_SUPPLEMENT|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
214455137|NCT01659411|OTHER|Observational|Yearly clinical visits
214455138|NCT05009264|PROCEDURE|OMT|OMT will be performed on identified areas of trapezius trigger points
214455139|NCT02878915|DEVICE|Ultrasound guided femoral puncture|
214455140|NCT03114553|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
214455141|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
214455142|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
214527791|NCT01031186|DRUG|GSK356278|GSK356278
214527792|NCT01031186|DRUG|PLACEBO|PLACEBO
214695094|NCT02126111|BIOLOGICAL|DEPIGOID Placebo|Placebo for subcutaneous administration
215142514|NCT06153589|OTHER|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
215142515|NCT02698215|DRUG|Varenicline|Varenicline 1 mg twice daily
215142516|NCT02698215|DRUG|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
215142517|NCT04971746|DRUG|Pirfenidone|On Days 1 and 13, participants will receive an oral dose of pirfenidone.
215142518|NCT04971746|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 daily.
215142519|NCT04971746|DRUG|Nintedanib|On Days 1 and 13, participants will receive an oral dose of nintedanib.
214455143|NCT06266260|DEVICE|EUS PPG measurement|Direct EUS PPG measurement
214455144|NCT06191861|BEHAVIORAL|Most hoped for future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for future self for 20 minutes.
214455145|NCT06191861|BEHAVIORAL|Most feared future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most feared future self for 20 minutes.
214455146|NCT06191861|BEHAVIORAL|Control (trip to zoo)|Participants in this condition think and write about a future trip to the zoo
214527793|NCT01909947|OTHER|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
214527794|NCT05559164|DRUG|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
215142520|NCT04393935|BEHAVIORAL|Pharmacy Delivered PrEP Intervention|Pharmacy client participants who are eligible and agree to the HIV test will be provided with a pre-packaged kit of a self-administered test for HIV and directed back to the private area of the pharmacy to perform their screening. Pharmacy client participants who test HIV negative will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Pharmacy client participants will be contacted after 3 months to determine whether they continued PrEP use.
214455147|NCT06191861|BEHAVIORAL|Balanced future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for and feared future self for 20 minutes.
214455148|NCT06800807|OTHER|Observation of several factors involved in eating and nutrition disorders|Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.
214455149|NCT05582746|BEHAVIORAL|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
215142521|NCT04757766|DRUG|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
214455150|NCT06598930|OTHER|Routine follow-up|As recommended: a vascular doctor exclusively, face-to-face consultations.
214455151|NCT06598930|OTHER|Intensive follow-up|a vascular physician and an IPA, with alternating face-to-face and remote consultations.
214455152|NCT03530306|DEVICE|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
214455153|NCT03530306|DEVICE|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
214455154|NCT03530306|DEVICE|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
214455155|NCT03530306|DEVICE|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
214455156|NCT05252962|DIETARY_SUPPLEMENT|Collagen Peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
215142522|NCT05176899|DEVICE|Use of Eko CORE electronic stethoscope|Recording of heart sounds using electronic stethoscope
215142523|NCT04651192|OTHER|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
214455157|NCT05655078|RADIATION|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
214455158|NCT04872790|DRUG|Dasatinib|Given PO
214455159|NCT04872790|DRUG|Methotrexate|Given IT
214455160|NCT04872790|DRUG|Prednisone|Given PO
214455161|NCT04872790|BIOLOGICAL|Rituximab|Given IV
214455162|NCT04872790|DRUG|Venetoclax|Given PO
214455163|NCT04872790|BIOLOGICAL|Blinatumomab|Given IV
215142524|NCT06016504|BEHAVIORAL|Health Education|Participate in an adaptive virtual consultation
215142525|NCT06016504|BEHAVIORAL|Health Education|Participate in a non-adaptive virtual consultation
215142526|NCT06016504|OTHER|Informational Intervention|Given information-only
215142527|NCT06016504|OTHER|Survey Administration|Ancillary studies
214455164|NCT04872790|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214455165|NCT04872790|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214455166|NCT04872790|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214455167|NCT06018454|OTHER|Handout on PGT-A|Educational handout on PGT-A
214455168|NCT06018454|OTHER|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
214455169|NCT06241651|DEVICE|Conduction system pacing|Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
214455170|NCT06241651|DEVICE|Biventricular pacing|Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
214455171|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
214455172|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
214455173|NCT05231837|BEHAVIORAL|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
214455174|NCT05231837|BEHAVIORAL|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
214455175|NCT06519968|DRUG|AZD4604|AZD4604 will be administered as Dry Powder Inhalation (DPI).
214455176|NCT06519968|DRUG|Placebo|Placebo will be administered as DPI.
214455177|NCT06304298|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride
214455178|NCT06304298|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine
214455179|NCT04855227|PROCEDURE|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
214455180|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
214455181|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
214455182|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
214455183|NCT05945212|DEVICE|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
214455184|NCT05945212|DEVICE|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
214455185|NCT05945212|OTHER|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
214455186|NCT05945212|OTHER|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
214455187|NCT05945212|OTHER|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
214455188|NCT05945212|OTHER|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
214455189|NCT05945212|OTHER|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
214455190|NCT05945212|OTHER|Barthel index|The Barthel index measure autonomy in daily life.
214455191|NCT05945212|OTHER|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
214455192|NCT05945212|OTHER|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
214455193|NCT05945212|OTHER|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
214455194|NCT05945212|OTHER|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
214455195|NCT05945212|OTHER|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
214455196|NCT05982938|DRUG|Danicopan|Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
214527795|NCT02538471|RADIATION|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
214527796|NCT02538471|DRUG|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
214527797|NCT01243398|PROCEDURE|quality-of-life assessment|
214527798|NCT00988897|DRUG|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
214527799|NCT00988897|DRUG|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
214527800|NCT00988897|DRUG|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
214527801|NCT00988897|DRUG|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
214527802|NCT06321900|DIAGNOSTIC_TEST|Personalized risk model|WE will test the hypothesis that interpretable artificial intelligence models including clinical, bio-humoral, genetic, electrocardiography, echocardiography, cardiac magnetic resonance, and nuclear imaging data will predict the risk of SCD in patients with left ventricular dysfunction more accurately than NYHA class and LVEF, and this will translate in a more cost-effective use of ICDs compared to current clinical practice.
214527803|NCT01314638|OTHER|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
214527804|NCT02216149|DRUG|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
215142528|NCT04680585|OTHER|Enhanced Usual Care|A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
215142529|NCT04680585|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
215142530|NCT02374242|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
215142531|NCT02374242|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
215142532|NCT03286036|OTHER|biomarkers|This is an observational study, there is no intervention
215142533|NCT03450161|DRUG|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
215142534|NCT05965258|DIAGNOSTIC_TEST|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
215142535|NCT01479842|DRUG|BTK inhibitor PCI-32765|Given PO
214527805|NCT02216149|DRUG|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
214527806|NCT02216149|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
215142536|NCT01479842|BIOLOGICAL|rituximab|Given IV
215142537|NCT01479842|DRUG|bendamustine hydrochloride|Given IV
215142538|NCT01479842|OTHER|pharmacogenomic studies|Correlative studies
215142539|NCT01479842|OTHER|pharmacological study|Correlative studies
215142540|NCT01479842|OTHER|laboratory biomarker analysis|Correlative studies
215142541|NCT03244878|BEHAVIORAL|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
215142542|NCT04189952|DRUG|Acalabrutinib|Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
215142543|NCT04189952|DRUG|Rituximab|Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
215142544|NCT04189952|DRUG|Ifosfamide|Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
215142545|NCT04189952|DRUG|Carboplatin|Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
215142546|NCT04189952|DRUG|Etoposide|Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
215142547|NCT03986970|DRUG|Tenofovir|Pre-exposure prophylaxis
214527807|NCT01439997|DRUG|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
214527808|NCT00084747|DRUG|bortezomib|
214527809|NCT02157129|DEVICE|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
214527810|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
214527811|NCT00877188|OTHER|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
214527812|NCT04313790|DRUG|Heparin Infusion|500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
214527813|NCT04313790|OTHER|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
214527814|NCT00386997|DRUG|liposomal amphotericin B (AmBisome®)|
214527815|NCT01136798|DRUG|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
215142548|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
215142549|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
215142550|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
215142551|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
215142552|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
215142553|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
215142554|NCT06537700|DRUG|OnabotulinumtoxinA OBT-A|Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
215142555|NCT04762095|OTHER|mindfulness stress reduction program|mindfulness stress reduction program
215142556|NCT02884869|DEVICE|Intubating Laryngeal Mask|Direct laryngoscopy
214455197|NCT05451940|DRUG|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
214455198|NCT05451940|DRUG|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
214455199|NCT01396655|DRUG|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
214455200|NCT06282016|OTHER|Case-control study (no intervention)|Observation of risk factors in cases and controls
214455201|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
214455202|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
214455203|NCT06779435|DRUG|Low intensity treatment options|"Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks"
214455204|NCT06779435|DRUG|Conventional immunochemotherapy regimen|"Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks"
214455205|NCT05351554|DRUG|Namilumab|Specified dose on specified days
214455206|NCT06926335|PROCEDURE|Breast consevative surgery|plastic surgery principles within the context of sound oncological resection. Volume-reducing or volume- replacing methods are utilised to optimise postoperative appearances whilst prioritizing negative margin resection, supported by prompt adjuvant therapy
214455207|NCT06786247|BEHAVIORAL|ActivaTeen|"The ActivaTeen app is built on HIPAA-compliant instance of a popular messaging software. Participants in the treatment group can access the app at any time via desktop or mobile, where they can find features designed to enhance their receipt of BA therapy.~These features include: weekly BA skills and homework completion support, in-app messaging with their BA therapist, mood and activity tracking and data visualizations, chatbot check-ins on progress and guided problem-solving around barriers, and moderated peer support using the ActivaTeen app. The app will have a moderator, who is part of the study team, to manage peer-to-peer interactions within ActivaTeen."
214455208|NCT06786247|BEHAVIORAL|Behavioral Activation|Behavioral activation therapy involves individual weekly sessions with a trained therapist for 12 weeks. The sessions are completed either in-person or via telehealth. The treatment focuses on behavioral manifestations of depression such as isolating, and how these behaviors are interconnected with low mood and depressive emotions. BA helps patients find ways to engage in behaviors that are meaningful to them based on their values, priorities, and goals, with the aim of creating positive loops between doing meaningful activities and improved mood. The therapist provides structure and problem-solving for activating these behaviors and keeping track of changes over time.
214455209|NCT03774082|DRUG|INC424|"Ruxolitinib was taken orally based on age groups as follows:~Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid"
214455210|NCT06797765|DEVICE|OCTA|Optical Coherence Tomography Angiography
214527816|NCT01136798|DRUG|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
215142557|NCT06666413|DRUG|Avalglucosidase alfa|Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion
215142558|NCT04603846|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
215142559|NCT04603846|DRUG|albumin bound paclitaxel|Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
215142560|NCT02706756|OTHER|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
215142561|NCT02706756|OTHER|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
214455211|NCT06790329|PROCEDURE|Endoscopic sleeve gastroplasty with fundal mucosal ablation|Mucosal ablation around the gastric fundus is initially performed using a hybrid argon plasma coagulation (H-APC) probe, following a submucosal saline injection, until ablation coagulum is visible. Subsequently, endoscopic sleeve gastroplasty (ESG) is performed using a full-thickness endoscopic suturing device (Overstitch, Apollo). This is done in a standard manner, employing 6-8 permanent full-thickness sutures along the greater curvature of the stomach in a running plication, starting from the angular incisura and extending proximally while sparing the fundus. Hemostasis is carefully checked and confirmed before the procedure is completed.
214527817|NCT00919009|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
214527818|NCT02382406|DRUG|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
214527819|NCT02382406|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
214455212|NCT06832163|DEVICE|Nitric Oxide Generation and Delivery System|"The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.~iNO devices with intelligent closed-loop offline function are required to meet the import and discharge standards. The initial concentration of NO withdrawal is 20ppm. In accordance with the withdrawal criteria outlined in the Chinese Guidelines, it is essential to conduct a comprehensive efficacy evaluation prior to initiating withdrawal. Furthermore, the process of inhaled nitric oxide (iNO) evacuation should commence only if specific conditions are satisfied."
214527820|NCT02382406|DRUG|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
214527821|NCT02382406|DRUG|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
214527822|NCT01032746|OTHER|educational intervention|
214527823|NCT01032746|OTHER|internet-based intervention|
214527824|NCT01032746|PROCEDURE|evaluation of cancer risk factors|
214527825|NCT01032746|PROCEDURE|fecal occult blood test|
214455213|NCT06831396|BEHAVIORAL|Dose comparison (same intervention)|The intervention under investigation is a motor-phonetic approach to articulation therapy, enhanced with ultrasound visual biofeedback (UVBF). The treatment group will receive the intervention immediately, while the waitlist control group will receive treatment after the initial group completes the study. This design allows for comparative outcome assessments between both groups, ensuring that all participants ultimately receive treatment.
214455214|NCT06837116|BIOLOGICAL|Vaccine|Subcutaneous route vs Intradermal route
214455215|NCT04889755|BEHAVIORAL|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
214455216|NCT06845475|OTHER|Designed physical therapy program|Both groups will receive a designed physical therapy program, in the form of myofascial trigger points pressure release, stretching of the upper trapezius muscle, strengthening exercises, and infrared radiation for 4 weeks.
214527826|NCT01032746|PROCEDURE|screening colonoscopy|
214527827|NCT03383809|DIETARY_SUPPLEMENT|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
214527828|NCT03383809|DIETARY_SUPPLEMENT|Strawberry Juice|Source of Polyphenols
214527829|NCT03383809|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
214527830|NCT01625949|PROCEDURE|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
214527831|NCT01625949|PROCEDURE|coronary dilatation and stenting|coronary dilatation and stenting
214695095|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
214527832|NCT01093183|DRUG|lenalidomide|Given PO
214527833|NCT01093183|DRUG|cyclophosphamide|Given PO
214527834|NCT01093183|OTHER|laboratory biomarker analysis|Correlative studies
214527835|NCT01093183|OTHER|questionnaire administration|Ancillary studies
214527836|NCT01093183|OTHER|quality-of-life assessment|Ancillary studies
214527837|NCT01936298|DEVICE|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
214527838|NCT01936298|DEVICE|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
214527839|NCT03841006|DEVICE|MRI|dynamic MRI pelvis
214527840|NCT01436383|OTHER|Hypoxic exposure|Hypoxic exposure
214527841|NCT02360865|OTHER|Exercise|
215142562|NCT02706756|OTHER|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
214455217|NCT06845475|OTHER|Extracorporeal shock wave therapy (ESWT)|Adolescents of the experimental group will receive Extracorporeal shock wave therapy with the following parameters; low-level energy radial extracorporeal shock wave by (STORZ MEDICAL Master Pulse MP200), each subject received 3 sessions per week for 4 weeks with 700 impulse/session 400 impulse was applied to tight band and 300 impulses will be applied surrounding the tight band, with frequency \[10HZ\], resulting in positive energy flux density \[EFD\] 0.056mJ/mm.
214455218|NCT06836583|OTHER|trans-nasal pterygopalatine Fossa block|Patients will be placed in 15-degree reverse Trendelenburg position, between the middle and inferior turbinates. This passage will be sterilized by an cotton-tipped applicator soaked with iodine solution. A 20-gauge/5-inch spinal needle will be used after bending 2-3 mm of its tip along the port side with a sterile needle holder to form a 45 angle. The needle will be lubricated with 5% lidocaine jelly, inserted into the nasal meatus and advanced with the bevel pointer facing laterally. Under endoscopic control (0\_ optics, 4 mm diameter), the needle will be inserted between middle and inferior turbinate. A total of 4 ml 0.25% bupivacaine will be injected after negative aspiration just behind and over middle turbinate tail, where the pterygopalatine fossa is deeply located.
214455219|NCT06836583|OTHER|US-guided infrazygomatic percutaneous pterygopalatine Fossa block|"US- guided percutaneous PPFB:~Patients will be placed in the lateral head position; the patient's mouth is slightly opened. Following standard sterile preparations, US linear probe covered with sterile sheath is positioned horizontally on the side of the face just below the zygomatic bone superior to the mandibular notch and anterior to the mandibular condyle to visualize the coronoid process, the lateral pterygoid muscle, the lateral pterygoid plate, and the maxillary bone, and the maxillary artery. Needle will be inserted in-plane parallel to the transducer probe and advanced from medial to lateral toward the pterygopalatine fossa. Following negative aspiration, the injectate is deposited deep to the lateral pterygoid muscle and plate. A total of 4 ml 0.25% bupivacaine will be injected."
214455220|NCT06462014|DRUG|Relugolix|relugolix
214527842|NCT01445990|DEVICE|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
214527843|NCT01128777|BEHAVIORAL|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
214527844|NCT01128777|BEHAVIORAL|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
214527845|NCT06345924|BEHAVIORAL|MERAKI_PC|"The three music therapy sessions focus on helping the patient to adjust to their situation. The aim is to provide emotional support and encourage communication between family members through music. In addition, the therapy will help the patient to appreciate their remaining abilities and encourage their involvement in the rehabilitation process. The second session focuses on living in the present through re-identification. The session aims to improve the symptoms associated with the illness by focusing on the present situation and encouraging expression.~The main aim of the final session, 'The Journey of Life - Leaving a Mark', is to recapitulate and provide support.~Songs are used during the session, taking into account musical preferences."
214527846|NCT04543942|DRUG|Alcohol|Alcohol will be administered by IV infusion (60mg%).
214527847|NCT04543942|DRUG|Saline|Saline is administered as the placebo
214527848|NCT03840278|DEVICE|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
214527849|NCT03840278|DEVICE|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
214527850|NCT03840278|DRUG|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
214527851|NCT05707689|BEHAVIORAL|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
214527852|NCT03805698|DEVICE|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
214527853|NCT03805698|OTHER|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
214527854|NCT00926978|RADIATION|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
215142563|NCT02706756|OTHER|Supervised neglect|Monitoring of group without formal intervention.
215142564|NCT06569901|BEHAVIORAL|Hope Intervention|"Group meetings after hospital discharge reflecting on themes that may have an impact on hope.~The Hope Intervention consists of four group meetings and two individual conversations during a four week period."
214455221|NCT06932029|BEHAVIORAL|SMBP with clinical pharmacist support|Self-measured blood pressure with clinical pharmacist support
214455222|NCT06931496|OTHER|PROSTia test|questionnaire with 50 questions
214455223|NCT06931236|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) can noninvasively modulate cortical activity by delivering a sequence of magnetic pulses.
215142565|NCT06244628|DRUG|Iguratimod|Oral administration of Iguratimod, 25mg twice daily
215142566|NCT01245309|PROCEDURE|scratching|endometrial scratching before COH in IVF
215142567|NCT01245309|PROCEDURE|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
215142568|NCT05219851|RADIATION|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
215142569|NCT03737929|PROCEDURE|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
215142570|NCT03737929|PROCEDURE|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
215142571|NCT01082770|DEVICE|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
215142572|NCT01082770|DEVICE|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
215142573|NCT06054490|BEHAVIORAL|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
215142574|NCT06054490|OTHER|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
215142575|NCT04091555|DIETARY_SUPPLEMENT|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
215142576|NCT01052493|DRUG|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
215142577|NCT01052493|DRUG|Placebo|0.9% saline
215142578|NCT02524925|PROCEDURE|fast track protocol|Evaluation of postoperative stress
214455224|NCT06931236|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham tDCS was delivered using the same protocol and current intensity, but it is carried out as the coil is turned away from the skull at 90°.
214455225|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
214455226|NCT06184373|DEVICE|Continuous glucose monitor|CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
214455227|NCT06184373|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
214455228|NCT06184373|DIAGNOSTIC_TEST|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
214455229|NCT04588896|DEVICE|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
214455230|NCT04588896|BEHAVIORAL|Lifestyle modification programme|Lifestyle modification programme
214455231|NCT06310967|DRUG|IG3018|Oral administration
214455232|NCT06310967|OTHER|Placebo matching IG3018|Oral administration
214455233|NCT05744869|BEHAVIORAL|SBAT Implementation|Implementation of the SBAT Program
214455234|NCT05744869|BEHAVIORAL|Usual Care|Usual Care for children with asthma
214455235|NCT04516772|DEVICE|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
214455236|NCT06281119|BIOLOGICAL|Cervavac as three dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
214455237|NCT06281119|BIOLOGICAL|Cervavac as two dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
214455238|NCT06281119|BIOLOGICAL|Gardasil as three dose regimen|Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
214455239|NCT05387551|DEVICE|CGM|Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
214455240|NCT05521308|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
214455241|NCT05521308|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
214455242|NCT05521308|DEVICE|Hearing Aid - Variation #2|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
214455243|NCT05521308|DEVICE|Hearing Aid - Variation #3|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
214455244|NCT05521308|DEVICE|Hearing Aid - Variation #4|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
214455245|NCT05514847|DRUG|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
214455246|NCT05514847|DRUG|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
214455247|NCT05260255|DRUG|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
215142579|NCT01498068|DRUG|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
215142580|NCT01498068|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
215142581|NCT01498068|DRUG|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
215142582|NCT04423666|BEHAVIORAL|Walking using a wireless pedometer|See arm/group
215142583|NCT03931941|DRUG|RBX2660|RBX2660 is a microbiota suspension administered as an enema
214527855|NCT05651334|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
214527856|NCT05651334|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
214455248|NCT05260255|DRUG|Placebo|add on placebo ( 2 cap ) for 12 weeks
214527857|NCT06119386|DEVICE|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
214527858|NCT02097056|DRUG|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
214527859|NCT06645587|DEVICE|Active HD-tDCS over pre-SMA|Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over Fz. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
214568503|NCT06422143|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
214568504|NCT06422143|BIOLOGICAL|sac-TMT|IV infusion
215142584|NCT04046367|BEHAVIORAL|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
215142585|NCT04046367|BEHAVIORAL|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
215142586|NCT00915746|DRUG|JNJ-31001074; ketoconazole|
215142587|NCT06035016|DRUG|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
215142588|NCT06035016|DRUG|treatment of physician's choice|Treatment of physician's choice
215142589|NCT02894346|OTHER|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
215142590|NCT03982121|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
215142591|NCT03982121|DRUG|Nivolumab|Nivolumab 240 mg
215142592|NCT03982121|DRUG|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
215142593|NCT03982121|DRUG|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
215142594|NCT05623878|DRUG|68Ga-labeled NY108|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
215142595|NCT00802308|DRUG|Morphine sulphate|Extended release tablet combined with alcohol or water
215142596|NCT05516446|DEVICE|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
214455249|NCT05800366|DRUG|Glofitamab|human IgG1-bispecific antibody, via IV infusion
215142597|NCT05516446|DEVICE|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
215142598|NCT00125255|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
215142599|NCT00125255|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
215142600|NCT00743834|DRUG|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
215142601|NCT00743834|BEHAVIORAL|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
214455250|NCT05800366|DRUG|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
214455251|NCT05800366|DRUG|Rituximab|Per standard care, via IV infusion
214455252|NCT05800366|DRUG|Doxorubicin Hydrochloride|Per standard care, via IV infusion
214455253|NCT05800366|DRUG|Cyclophosphamide|Per standard care, via IV infusion
214455254|NCT05800366|DRUG|Prednisone|Per standard care, orally
214455255|NCT03792256|DRUG|Palbociclib|Given PO (or via NG- tube)
214455256|NCT03792256|DRUG|Cytarabine|Given intrathecally (IT)
214455257|NCT03792256|DRUG|Methotrexate|Given intrathecally (IT)
214455258|NCT03792256|DRUG|Hydrocortisone|Given IT
214455259|NCT03792256|DRUG|Doxorubicin|Given intravenously (IV)
214455260|NCT03792256|DRUG|Prednisolone|Either prednisone or prednisolone is given PO
214455261|NCT03792256|DRUG|Vincristine|Given IV
214455262|NCT03792256|DRUG|Pegaspargase|Given IV
214455263|NCT03792256|DRUG|Hydrocortisone|Given intrathecally (IT)
214455264|NCT03792256|DRUG|Prednisone|Either prednisone or prednisolone is given PO
214455265|NCT04781543|DRUG|HZN-825 BID|300 mg oral tablets BID
214455266|NCT04781543|DRUG|Placebo|Placebo BID
214455267|NCT04781543|DRUG|HZN-825 QD|300 mg oral tablets QD
214527860|NCT06645587|DEVICE|Active HD-tDCS over left DLPFC|Active cathodal HD-tDCS over left DLPFC cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over F3. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
214527861|NCT06645587|DEVICE|Sham HD-tDCS|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex for 10 days (3 sessions per week). The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. Each Sham session will last 20 minutes.
214527862|NCT06647290|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
215142602|NCT02252666|DEVICE|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
215142603|NCT02811068|OTHER|venepuncture|single venepuncture
215142604|NCT01499836|OTHER|PVB|paravertebral block
215142605|NCT05698550|DRUG|Erzhi Tiangui Granule|The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
215142606|NCT05698550|DRUG|Erzhi Tiangui Placebo|The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
215142607|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
214568505|NCT06422143|DRUG|Carboplatin|Participants receive AUC 6 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
214455268|NCT05931289|BEHAVIORAL|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
214568506|NCT06422143|DRUG|Paclitaxel|Participants receive 200 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
214568507|NCT06422143|DRUG|Nab-paclitaxel|Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
214455269|NCT05931289|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
214455270|NCT04760678|OTHER|Observational study|No intervention (observational study in human participants)
214455271|NCT06836882|PROCEDURE|Selective caries removal|Selective caries removal followed by cavity disinfection with NaOCl \& CHX in each test group \& no cavity disinfection in control group.
214455272|NCT06836882|PROCEDURE|Selective caries removal with NaOCl|elective caries removal followed by cavity disinfection with NaOCl
214455273|NCT06836882|PROCEDURE|Selective caries removal with CHX|elective caries removal followed by cavity disinfection with CHX
214455274|NCT01458782|PROCEDURE|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
214527863|NCT06645639|OTHER|Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)|"The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment)."
214527864|NCT06645561|PROCEDURE|X-ray|defined radiographic semiological criteria to determine an analytical methodology to facilitate the dating of long bone fractures of infants under one year of age
214527865|NCT05961488|OTHER|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
214527866|NCT01323309|BEHAVIORAL|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
214527867|NCT01323309|BEHAVIORAL|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
214527868|NCT01323309|BEHAVIORAL|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
214527869|NCT02819271|DRUG|CXL-1427 Ascending Dose|
214527870|NCT02819271|OTHER|Placebo|
214527871|NCT02819271|DRUG|CXL-1427 Descending Dose|
214527872|NCT02200029|DRUG|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
214527873|NCT02200029|DRUG|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
214527874|NCT00472056|DRUG|Carmustine|300 mg/m\^2 IV for 1 Day
215142608|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
215142609|NCT05804591|DRUG|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
215142610|NCT05804591|DRUG|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
215142611|NCT00742612|DRUG|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
215142612|NCT00742612|DRUG|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
214527875|NCT00472056|DRUG|Etoposide|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
214695096|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
214695097|NCT02017678|BIOLOGICAL|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
214455275|NCT05920980|DRUG|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
214455276|NCT05920980|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
214455277|NCT03208062|OTHER|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
214455278|NCT06295965|OTHER|Non-Interventional Study|Non-interventional study
214527876|NCT00472056|DRUG|Cytarabine|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
214527877|NCT00472056|DRUG|Melphalan|140 mg/m\^2 IV x 1 Day
214527878|NCT00472056|DRUG|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
215142613|NCT02277938|DRUG|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
215142614|NCT01318915|DRUG|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
215142615|NCT01318915|DRUG|Rituximab|375 mg/m\^2 IV infusion on day -6 before transplant and on day 1 after transplant.
215142616|NCT01318915|DRUG|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
215142617|NCT01318915|DRUG|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
215142618|NCT01318915|DRUG|MMF|1 g twice daily on days 0 through 12
215142619|NCT02183662|DRUG|BI 224436|
215142620|NCT02183662|DRUG|Placebo to BI 224436|
214455279|NCT03148678|BEHAVIORAL|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
214455280|NCT03148678|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
214455281|NCT03148678|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
214455282|NCT03148678|BEHAVIORAL|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
214455283|NCT06838520|OTHER|Bone health assessment|Assessments of physical function, DXA scan
214455284|NCT01748448|DRUG|Vitamin D|"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"
214455285|NCT01748448|DRUG|Placebo: Oil|
214455286|NCT06836544|BEHAVIORAL|ALL YOU NEED IS LOVE syllabus|"1. Week 1: Introduction to the Kidneys~2. Week 2: Chronic Kidney Disease, Medication Management~3. Week 3: Making Healthy Choices~4. Week 4: Learning about Self-Care~5. Week 5: Becoming Independent~6. Week 6: Review and Self-assessment"
214455287|NCT06836726|DRUG|Evofosfamide|This study is evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.
215142621|NCT00453206|PROCEDURE|allogeneic bone marrow transplantation|
215142622|NCT00453206|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
215142623|NCT00453206|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
215142624|NCT00453206|PROCEDURE|peripheral blood stem cell transplantation|
215142625|NCT00133783|BEHAVIORAL|intermedin|
215142626|NCT03429699|BEHAVIORAL|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
215142627|NCT03429699|BEHAVIORAL|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
214527879|NCT05486871|PROCEDURE|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
214695098|NCT05729217|OTHER|SBQ-LC survey|Symptom burden questionnaires of Long COVID
214695099|NCT06687174|DRUG|MY008211A tablets|MY008211A BID
214455288|NCT06040957|BIOLOGICAL|Bone marrow aspirate concentrate injection|single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
214455289|NCT06040957|BIOLOGICAL|intra-articular injection of Minimally manipulated adipose tissue|single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
214455290|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
214455291|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
214455292|NCT03561805|DEVICE|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
214455293|NCT05803811|DIETARY_SUPPLEMENT|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
214455294|NCT06838104|DRUG|Melatonin|Participants in this group will receive 6 mg of melatonin orally, administered as two 3 mg tablets 30 minutes before bedtime daily for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
214527880|NCT05282316|DIETARY_SUPPLEMENT|EVOO polyphenols enriched|Addition of 40 ml daily of healthy polyphenols enriched EVOO to mediterranean diet for 6 months
214527881|NCT05282316|DIETARY_SUPPLEMENT|EVOO standard|Addition of 40 ml daily of standard EVOO to mediterranean diet for 6 months
214527882|NCT06090487|DIAGNOSTIC_TEST|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
214527883|NCT05000593|OTHER|normal saline|Intra-articular injection of normal saline
214527884|NCT05000593|OTHER|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
214527885|NCT04825210|BEHAVIORAL|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
214695100|NCT06687174|DRUG|MY008211A tablets matched placebo|Matching placebo to MY008211A taken twice a day.
214455295|NCT06838104|DRUG|Placebo|Participants in this group will receive placebo tablets identical in shape, size, smell, taste, and color to melatonin tablets, administered in the same manner (two tablets 30 minutes before bedtime) for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
214455296|NCT06438172|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
214695101|NCT06692595|DIAGNOSTIC_TEST|digital PCR|digital PCR quantification of subgingival plaque samples
214695102|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
214455297|NCT06438172|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
214695103|NCT06693375|DEVICE|Rectal Magnetomotoric ultrasound (MMUS)|MMUS examination of lymphnodes in rectum
214695104|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
214695105|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
214695106|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
214695107|NCT06052735|OTHER|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
214695108|NCT00444223|PROCEDURE|fluorine F 18 FEQA + positron emission tomography|
215142628|NCT01338740|DRUG|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
214455298|NCT06438172|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
214455299|NCT06438172|DRUG|HPP2002-1|Placebo drug. Take it once daily for 8 weeks orally.
214455300|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
214455301|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
214455302|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
214455303|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
214455304|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
214455305|NCT06823778|DEVICE|Radiofrequency ablation|In this group of patients, epicardial radiofrequency left atrial posterior wall isolation will be performed with AtriCure Isolator Synergy OLL2 bipolar radiofrequency clamp without opening the left atrium.
214455306|NCT06364514|OTHER|Clinical Stability Assessment|Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
214455307|NCT06832111|OTHER|Kinesio Taping 1|A specific Kinesio taping technique applied to the ankle to evaluate its effects on joint position sense and balance.
214455308|NCT06832111|OTHER|Kinesio Taping 2|A different Kinesio taping technique applied to the ankle to assess its impact on proprioception and postural stability.
214455309|NCT06832111|OTHER|Sham Kinesio Taping|A placebo taping application that mimics the real Kinesio tape placement but lacks therapeutic tension or functional support, serving as a control condition to evaluate the true effects of the experimental interventions.
215142629|NCT01298089|DEVICE|Carriazo Pendular microkeratome|
215142630|NCT00013533|PROCEDURE|Stem cell transplantation|\>3 x 106/kg CD34+ stem cells by IV infusion
215142631|NCT03026595|OTHER|no intervention|no intervention
215142632|NCT00107341|DRUG|bortezomib|
215142633|NCT00107341|DRUG|carboplatin|
215142634|NCT00107341|DRUG|paclitaxel|
215142635|NCT06809764|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.
214527886|NCT04825210|BEHAVIORAL|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
215142636|NCT06655311|BIOLOGICAL|Enlicitide Chloride|Oral administration
214455310|NCT06837428|OTHER|Peer comparison-based Risk Communication (PRICOM)|Based on the Health Belief Model, a risk communication intervention, Peer comparison-based Risk Communication (PRICOM), was developed for primary care physicians to counsel patients with T2DM on their glycaemic control and the complications that could arise, and to recommend ways to improve glycaemic control and prevent complications (or further complications). This will be supported by information from an AI (Artificial Intelligence) based diabetes tool. PRICOM aims to promote health actions in patients with T2DM by increasing their risk perceptions of diabetes complications.
214455311|NCT03452111|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
214455312|NCT05041023|OTHER|Relative section|"Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death."
214455313|NCT05041023|OTHER|Caregiver section|"Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist."
214455314|NCT06837545|OTHER|No Intervention (Observational Study)|"This study is an observational analysis of preoperative serum uric acid levels and their association with postoperative outcomes. No intervention was administered."
214455315|NCT05501483|DRUG|Pioglitazone 45 mg|Starts with 45 mg
214455316|NCT05501483|DRUG|Empagliflozin 25 MG|Starts with 25 mg
214455317|NCT05501483|DRUG|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
214455318|NCT06833177|OTHER|Beautilink SA cement|"According to the manufacturer's instructions (BeautiLink SA - Shofu USA)~* To enhance the adhesion, adhesive bonding agent BeautiBond Xtreme, Shofu will be applied on the tooth and cured according to the manufacturer's instructions.~* Press the plunger of the auto-mix syringe of Beautilink SA to dispence the cement on the adhesive surface of the restoration.~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 1-2 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 5 minutes after light-curing to allow for chemical curing."
214455319|NCT06833177|OTHER|RelyX resin cement|"According to the manufacturer's instructions (Espe).~* To enhance the adhesion, adhesive bonding agent 3M™ Scotchbond™ Universal Plus Adhesive will be applied on the tooth and cured according to the manufacturer's instructions.~* Application of 3M™RelyX™ Universal Resin Cement into the cavity~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 2-3 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 6 minutes after light-curing to allow for chemical curing."
214455320|NCT06054477|DRUG|ALE.C04|Q3W
214455321|NCT06054477|DRUG|Pembrolizumab|200mg Q3W
214455322|NCT06837883|PROCEDURE|Percutaneous nephrolithotomy through and through guiedwire|In the study group, a modification in percutaneous nephrolithotomy was carried out to have through-and-through guidewire.
214455323|NCT06837883|PROCEDURE|Standard percutaneous nephrolithotomy|Standard percutaneous nephrolithotomy without using through and through guide wire
214455324|NCT04666571|DEVICE|TOKA|The device is a digitally planned (using individual CT scan measured anatomic data) personalised opening wedge high tibial osteotomy (HTO) procedure using a custom 3D printed surgical guide and plate.
214455325|NCT04666571|DEVICE|Tomofix or ActivMotion|The comparators, Tomofix and ActivMotion, are the most widely used devices for HTO procedures in the UK. Surgical procedures using the Tomofix and ActiveMotion are similar to TOKA, however, they are not patient specific and do not use custom-made plates.
214527887|NCT05789199|DRUG|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
214527888|NCT03588676|OTHER|Melatonin|5mg Melatonin
214527889|NCT03588676|OTHER|Placebo|5mg Placebo capsule
214527890|NCT05457296|DRUG|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
214527891|NCT03771209|DIAGNOSTIC_TEST|ultrasound examination|ultrasound assessment
214527892|NCT05862779|DIETARY_SUPPLEMENT|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
214527893|NCT05862779|DIETARY_SUPPLEMENT|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
214527894|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
215142637|NCT06655311|OTHER|Placebo|Oral administration
215142638|NCT06654583|BEHAVIORAL|Interactive Play Mat|Use of developed interactive play mat that utilizes haptic feedback vibrations to assist children with delayed milestones in achieving Gross Motor Skills. The play mat aims to provide a therapeutic and engaging experience by incorporating visuals, sounds, and lights to encourage movement that might otherwise be challenging for these children.
215142639|NCT06654583|BEHAVIORAL|Conventional Physical Therapy|Stretching and Strengthening exercises
215142640|NCT02873871|DEVICE|Standardized compressive dressing|Standardized compressive dressing
215142641|NCT02873871|DEVICE|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
215142642|NCT01664975|DRUG|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
215142643|NCT01664975|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
215142644|NCT00020488|DRUG|FOLFIRI regimen|
215142645|NCT00020488|DRUG|fluorouracil|
215142646|NCT00020488|DRUG|irinotecan hydrochloride|
215142647|NCT00020488|DRUG|leucovorin calcium|
214455326|NCT03601728|BEHAVIORAL|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
214455327|NCT06833021|OTHER|Transcriptomic Analysis|FFPE tissue blocks from patients diagnosed with CAC, including low- and high-grade dysplasia and adenocarcinoma, obtained from pathological archives will be used. RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results.
214455328|NCT06833021|OTHER|Transcriptomic Analysis|RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results. FFPE tissue blocks from CRC, diverticulitis, IC and CD without cancer patients will be utilized as controls.
214455329|NCT05065658|DRUG|Posaconazole|Intravenous posaconazole prophylaxis
214455330|NCT00583349|DRUG|Abraxane|"Abraxane is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Intravesically administered, dose escalation, 6 weekly instillations"
214455331|NCT06822036|PROCEDURE|Arm A - Application of 5g of ARISTA™ AH|Perioperative application of 5g of ARISTA™ AH to the prostate bed and neurovascular bundles during and at the end of the surgery to control bleeding and oozing in accordance with labelled directions; no other hemostyptic agent in aforementioned area
214455332|NCT00706420|PROCEDURE|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
214455333|NCT00706420|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
214455334|NCT05488847|DRUG|Celecoxib|preoperative pain medication given to all patients
214455335|NCT05488847|DRUG|Pregabalin|preoperative and discharge pain medication given to all patients
214455336|NCT05488847|DRUG|Tramadol|preoperative pain medication given to all patients
214455337|NCT05488847|DRUG|Dexamethasone|Intraoperative and discharge pain medication given to all patients
214455338|NCT05488847|DRUG|Acetaminophen|Intraoperative and discharge pain medication given to all patients
214455339|NCT05488847|DRUG|Ropivicaine|Intraoperative pain medication given to all patients
214455340|NCT05488847|DRUG|Epinephrine|Intraoperative pain medication given to all patients
214455341|NCT05488847|DRUG|Ketorolac|Intraoperative pain medication given to all patients
214455342|NCT05488847|DRUG|Tizanidine|Discharge pain medication given to all patients
214455343|NCT05488847|DRUG|Magnesium|Discharge pain medication given to all patients
214455344|NCT05488847|DRUG|Ibuprofen|Discharge pain medication given to all patients
214455345|NCT05488847|DRUG|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
214455346|NCT04755140|BEHAVIORAL|Questionnaires|The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.
214455347|NCT04755140|BEHAVIORAL|Interviews|Cognition and memory interviews will take place with the patient.
214455348|NCT04755140|DIAGNOSTIC_TEST|Blood Test|Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.
215142648|NCT06603168|OTHER|Autonomic Recalibration Treatment|An initial history to r/o pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance throughout the myofascial system. The pattern of sympathetic dominance (pattern of trigger point) is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. The absence of a trigger point indicates that the treatment is complete.
215142649|NCT06598046|DRUG|Utidelone and capecitabine|Utidelone: intravenous capecitabine: oral
215142650|NCT06590922|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
215142651|NCT06590922|DEVICE|The conventional endoscopic biting group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
215142652|NCT06601413|OTHER|M-TAPA Block|M-TAPA block will administer ultrasound guided (Sonosite, Inc., Bothell, WA, USA) bilaterally by same anesthesiologist (E.E.) who had more than 10 years experience of regional anesthesia, before weaking from general anesthesia after the surgical procedure. A high-frequency (6-13 MHz) linear probe (HFL38) will be used to identify the transversus abdominis, internal oblique, and external oblique muscles on the costochondral angle in the sagittal plane at the 10th costal margin. In the midclavicular line, between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue, at the level of the 10th rib, 20 mL of 0.25 percent bupivacaine will be injected (arcus costarum). The same procedure will be followed on the other side.
215142653|NCT06601413|OTHER|Trocar site local anesthetic infiltration|At the end of surgery, infiltration analgesia will be applied to all trocar entry sites (4 port entries) by the surgeon with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
215142654|NCT06593223|DEVICE|Assess Non-invasive filling pressure(NIFP) in heart failure patients|Assess Non-invasive filling pressure(NIFP) in outpatients with stable heart failure and inpatients with acute heart failure in ward
215142655|NCT06596850|BEHAVIORAL|Wheelchair Skills Training Program|Participants will receive 5, 45-minute weekly WC skills training sessions that will take place in the community, in and around the participants home. Each session will be customized to the participant's' goals and based on the learner's impairments (i.e., weakness, spasticity, movement disorders \[e.g. ataxia, tremor\], contractures, cognition). The WSTP sessions will begin with a 5-minute review of goals/progress, followed by a 10-minute warm-up (wheeling activities, random practice of previously leaned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment.
215142656|NCT06597643|OTHER|Eccentric Training|"Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return"
215142657|NCT06597643|OTHER|Deep Friction Massage|The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
214455349|NCT04755140|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
214455350|NCT06568029|OTHER|Questionnaire|In the study, the validity and responsiveness of EQ-5D-3L will be assessed. The EQ-5D-3L measures HRQoL and consists of two parts. The first part contains five questions about mobility, daily activities, self-care, pain/discomfort, and anxiety/depression (EuroQoL 1990, Brooks 1996). Each question can be answered with no problem (1), some/moderate problem (2) unable to perform certain activities/having extreme problems (3). The answers can be summarized in an index value based on an existing preference-based value set. In this study, the EQ-5D-3L value set by Dolan (Dolan 1997) will be used for the main analyses and a Swedish experience-based value set in a sensitivity analysis (Burström, Sun et al. 2014). For the EQ-5D-3L index, 1 represents full health and 0 represents a value equal to being dead. EQ VAS measures the persons health today on a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health) (EuroQoL 1990, Brooks 1996).
214455351|NCT06497660|DRUG|Deoxyadrenaline|Deoxyadrenaline is a vasoactive drug
214455352|NCT06497660|DRUG|normal saline|Deoxyadrenaline is a vasoactive drug
214527895|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
215142658|NCT06603272|DEVICE|The da Vinci robotic system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) was used for all robotic gastrectomy|"Surgical intervention was initiated after obtaining informed consent from all patients, which included the additional costs of robotic surgery, a comprehensive explanation of surgical risks, and potential alternative treatments, thus facilitating informed surgical approach choices (i.e., LG or RG) within the participating institutions. Adherence to the Japanese Gastric Cancer Treatment Guidelines was maintained for determining the extent of gastrectomy and lymphadenectomy."
215142659|NCT06590272|DEVICE|TECNIS PCB00 intraocular lens|In this study, we select TECNIS PCB00 IOL for inserting in the eyes during the cataract surgery
215142660|NCT06590272|DEVICE|HumanOptics Diff-Aay intraocular lens|In this study, we select HumanOptics Diff-Aay IOL for inserting in the eyes during the cataract surgery
215142661|NCT06590272|DEVICE|TECNIS Symfony ZXR00 intraocular len|In this study, we select TECNIS Symfony ZXR00 IOL for inserting in the eyes during the cataract surgery
215142662|NCT06590272|DEVICE|ZEISS AT LISA tri 839MP intraocular len|In this study, we select ZEISS AT LISA tri 839MP IOL for inserting in the eyes during the cataract surgery
214455353|NCT06089980|BEHAVIORAL|Effects from acute kratom exposure|Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.
214455354|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
214455355|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
214455356|NCT01570998|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
214455357|NCT01570998|OTHER|Laboratory Biomarker Analysis|Correlative studies
214455358|NCT06636721|BEHAVIORAL|LuCA Behavioral Intervention|The intervention will integrate aspects of Cognitive Behavioral Therapy (identifying and challenging automatic thoughts, engaging in behavioral activation) and Acceptance and Commitment Therapy (integrating one's values, distancing skills). The intervention will include skills such as problem-solving, communicating with close others and the medical team, and breathing techniques to improve shortness of breath related to lung cancer.
214455359|NCT01926496|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
214455360|NCT01926496|DRUG|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
214455361|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
214455362|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
214455363|NCT03427580|BEHAVIORAL|MERIT|Metacognitive Reflection and Insight Therapy
214455364|NCT06165978|BEHAVIORAL|Self-monitoring|pedometer/activity band provided to each participant
214455365|NCT06165978|BEHAVIORAL|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
214455366|NCT06165978|BEHAVIORAL|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
214455367|NCT06165978|BEHAVIORAL|Feedback|Daily or weekly feedback for patients (emotional/social support)
214455368|NCT06165978|BEHAVIORAL|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
214455369|NCT06165978|BEHAVIORAL|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
214455370|NCT06165978|BEHAVIORAL|Report|Daily or weekly reporting for therapists (messages)
214455371|NCT06165978|BEHAVIORAL|Social support|Support meetings (in-person), parallel to educational sessions
214455372|NCT06165978|BEHAVIORAL|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
214455373|NCT06165978|BEHAVIORAL|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
214455374|NCT04741542|DRUG|SP-420|This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
214455375|NCT05847517|DRUG|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
214527896|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
214527897|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
214527898|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
215142663|NCT06594029|BEHAVIORAL|Community Navigator Intervention|see previous section
215142664|NCT06594029|OTHER|Control Group|Participants receive information on how to increase their community participation
215142665|NCT06591442|DIAGNOSTIC_TEST|This is an observational study|This study divides the elderly population into two groups: the Elderly group and the Advanced age group. By observing the enhanced recovery after spinal fusion surgery in these two distinct age groups of elderly patients, risk factors affecting postoperative enhanced recovery will be identified. Detection index: Blood routine examination, blood biochemistry, coagulation function, imaging examination (X-ray, CT 3D reconstruction), Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) pain score. The number of participants for all adverse events, serious adverse events, implant-related adverse events and drug-related serious adverse events, and the adverse events were summarized accordingly. The severity of adverse events will be rated according to NCI-CTCAE version 4.0.
214455376|NCT05847517|DRUG|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
214455377|NCT06406881|OTHER|physical therapy|"Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
214455378|NCT06406881|OTHER|myofascial release therapy|"Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
214455379|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)
214455380|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
214455381|NCT06299748|BIOLOGICAL|Efgartigimod|Efgartigimod IV or SC
214455382|NCT05273320|DRUG|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
214455383|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
214455384|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
214455385|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
214455386|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
214455387|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
214455388|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
214455389|NCT03020212|DRUG|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
214455390|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
215142666|NCT06600451|OTHER|observational study, no intervention is required|"Retrospective chart review, investigators provides data after reviewing patient\&#39;s existing medical record; no interaction with patients is required.~Patients were treated as per standard of care"
214455391|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
214455392|NCT04066660|DIETARY_SUPPLEMENT|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
214455393|NCT04066660|DIETARY_SUPPLEMENT|Placebo|4.4 g placebo powder, oral, BID
214455394|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
214455395|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
214455396|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
214455397|NCT03232138|DRUG|Placebo|Inactive ingredients
214455398|NCT05477407|DRUG|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
214455399|NCT06540326|DRUG|irinotecan liposome (II)|irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
214527899|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
214455400|NCT06540326|DRUG|fluorouracil|fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
214455401|NCT06540326|DRUG|cetuximab|cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
214455402|NCT06540326|DRUG|bevacizumab|bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
214455403|NCT02914535|DRUG|Filgotinib|Tablet(s) administered orally once daily
214455404|NCT02914535|DRUG|Placebo|Tablet(s) administered orally once daily
214455405|NCT03418818|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
214455406|NCT03418818|DRUG|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
214455407|NCT05529459|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
214455408|NCT04852328|DRUG|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
214455409|NCT03729518|RADIATION|Radiation Therapy (IMRT or IMPT)|"* Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
214455410|NCT04700527|DRUG|Short Chain Fatty Acid|Participants will take the supplement as prescribed to determine if it can help with GI toxicity
214455411|NCT04700527|DRUG|Tapioca Flour|Participants taking this will be used as a control group compared to those receiving the SCFA supplement
214527900|NCT02133131|DRUG|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
214527901|NCT02133131|DRUG|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
214527902|NCT06130904|BEHAVIORAL|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
214527903|NCT02144194|DRUG|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
214527904|NCT02144194|DRUG|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
214527905|NCT03209336|RADIATION|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
214527906|NCT06461949|DRUG|Dupilumab|Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
214527907|NCT02512107|DIETARY_SUPPLEMENT|Juice Plus+|Dried fruit and vegetable juice capsule.
215142667|NCT06591676|BEHAVIORAL|Dysfunctional Attitude Scale (DAS)|Dysfunctional Attitude Scale (DAS) is a self-report scale designed to measure the presence and intensity of dysfunctional attitudes. It is widely used to assess impaired cognitive patterns associated with depression and other mental health conditions. Initially developed in English, its usefulness can be extended by translating and culturally adapting it into Urdu language.
215142668|NCT06600568|OTHER|Translation analysis|Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
214527908|NCT02512107|OTHER|Placebo|Placebo capsule
214527909|NCT01544153|BEHAVIORAL|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
214527910|NCT01544153|BEHAVIORAL|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
215142669|NCT06591663|BEHAVIORAL|Cognitive Therapy Rating Scale (CTRS)|"CBT is the Cognitive Therapy Rating Scale (CTRS), an important assessment tool designed to assess the quality and effectiveness of cognitive therapy sessions.~Mental health professionals, such as therapists and psychologists, commonly use the CTRS to evaluate various aspects of a therapy session. This includes the extent to which the therapist adheres to CBT principles, their skill in applying cognitive and behavioral techniques, their ability to develop a therapeutic relationship with the client, and the overall quality of the session. The scale may also include specific criteria or items that another trained therapist or researcher observes based on their observations during the therapy session (Pingol, 2023)."
215142670|NCT06601205|DRUG|Flutamide|1 tablet daily until the day before surgery
215142671|NCT06601205|DRUG|Finasteride|1 tablet daily until the day before surgery
215142672|NCT06601205|OTHER|Placebo|1 tablet daily until the day before surgery
215142673|NCT06601855|PROCEDURE|Cholecystectomy|Cholecystectomy, whether open or laparoscopic
215142674|NCT06598267|PROCEDURE|SASI|single anastomosis sleeve ileal bypass
215142675|NCT06598267|PROCEDURE|RYGB|Roux-en-Y gastric bypass
214527911|NCT01544153|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
214527912|NCT06386575|OTHER|control group; Patients who received physiological saline|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
214527913|NCT06386575|OTHER|suprainguinal fascia block; Patients receiving local anesthetic|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
214527914|NCT02070289|DRUG|PF-06372865|Tablets, 2.5 mg BID, 14 days
215142676|NCT06596746|OTHER|Observation|In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
214455412|NCT06215313|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|In the EMDR condition, the Dutch version of the treatment protocol based on Shapiro's original work (2001) is followed. In the first session, the rationale of EMDR is explained. The patient describes the memory, and identifies the most aversive still image, the associated negative cognition, desired positive cognition, feelings, somatic sensations, and perceived tension, as measured by Subjective Unit of Distress (SUDs). Desensitization then begins by asking patients to focus on the still image while following the movement of a light bar or the therapist's fingers with their eyes (i.e., eye tracking task). Then, in the installation phase, the patient focuses on the positive cognition during the eye tracking task. When the validity of the positive cognition is 6 to 7 on a 7-point Likert scale, a body scan is performed to ensure that no unresolved traumatic material remains. Each session ends with a reflection and debriefing.
214527915|NCT02070289|DRUG|Placebo|Tablets, BID, 14 days
214695109|NCT02197039|DRUG|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
215142677|NCT06601920|BEHAVIORAL|Forest healing activities|The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.
215142678|NCT06594874|DRUG|HS-10370|HS-10370 administered orally every day
215142679|NCT06594874|DRUG|Adebrelimab|Administered intravenously every 21 days; dose by label.
214527916|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
214527917|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
214527918|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
214527919|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
214527920|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
214527921|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
214527922|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
214527923|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
214527924|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
215142680|NCT06594874|DRUG|Cisplatin|Administered intravenously every 21 days; dose by label.
215142681|NCT06594874|DRUG|Carboplatin|Administered intravenously every 21 days; dose by label.
215142682|NCT06594874|DRUG|Pemetrexed|Administered intravenously every 21 days; dose by label.
215142683|NCT06586476|BEHAVIORAL|Nightly Timed Awakening|Patients in this arm will be awakened 1-hr after going to bed by their caregiver(s) to use the restroom and then returned to sleep. This awakening will occur every night.
215142684|NCT06591689|OTHER|Evaluation of Cases with Quadriparetic Cerebral Palsy|20 quadriparetic cerebral palsy cases were evaluated with the Communication Function Classification System (CFCS), Pediatric Functional Independence Scale (WeeFIM) and Gross Motor Function Measure-88 (GMFM-88).
214527925|NCT02127892|BIOLOGICAL|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
214527926|NCT02127892|BIOLOGICAL|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
214527927|NCT02127892|BIOLOGICAL|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
214527928|NCT02127892|DEVICE|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
215142685|NCT06593925|DEVICE|Production of polyoxymethylene telescopic denture|Remaining teeth will be prepared by conventional grinding technique, followed by impression, casting and scanning with extra oral scanner. Inner telescopic crowns will be made of cobalt-chromium alloy by milling technique and outer crowns together with denture framework will be made of polyoxymethylene by the method of single phase injection moulding. Denture delivery is done by inserting both inner and outer crown at the same time, during which the inner crown is cemented to the abutment tooth and the contact surfaces of the outer and inner crown are isolated so that the outer crown and denture framework can be removed.
215142686|NCT06593925|DEVICE|Production of conventional complex partial denture with clasps|A conventional complex partial denture is a removable partial denture with clasps combined with metal-ceramic surveyed crowns with milled surfaces for removable dentures. The metal-ceramic surveyed crowns are shaped in such a way that they build a morphological and functional whole with complementary elements of the removable partial denture's framework. In the control group, as well as in the experimental group, the remaining teeth are prepared using a conventional grinding technique, then an impression is taken for dedicated metal-ceramic crowns, casting, and milling of crowns, ceramic sintering, impression through the metal-ceramic surveyed crowns and fabrication of a removable partial denture's framework with clasps using the casting method. Dedicated fixed restorations will be made of Co-Cr alloy inside the crown and ceramic layer on the surface, and the framework and clasps of the removable partial denture will be made of Co-Cr-Mo alloy.
215142687|NCT06586463|OTHER|kinitic control training|"kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation."
214527929|NCT03743597|DEVICE|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
214527930|NCT03743597|DEVICE|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
214527931|NCT02249429|DRUG|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
214527932|NCT02600988|DRUG|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
215142688|NCT06594952|OTHER|Questionnaire and Physical Exam|"Diagnosis of Anxiety using the state-trait anxiety inventory scale (STAI). Depression using Edinburgh Postnatal Depression Scale (EPDS)~* Coping using the Brief Coping Scale~* Socioeconomic using the Socioeconomic Scale of Egypt~* Personality using the short-form Eysenck Personality Questionnaire-Revised (EPQ-R)~* Behaviour using Impact of Erect Scale (IES-22)"
215142689|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
214455413|NCT06215313|BEHAVIORAL|Imagery Rescripting|The IR condition, following Arntz and Weertman's (1999) protocol, addresses traumatic or aversive memories by creating alternative scenarios. In the first session, the method is explained. The patient describes their memory in the present tense, from the first-person perspective, and describes associated feelings, thoughts, and emotional needs. The therapist then seeks permission to 'enter' the scene, guiding the patient to visualise an alternative, emotionally satisfying course of events. This may involve the therapist or patient intervening in the situation, ensuring the patient's emotional needs are met. The patient then relives the memory from the point of view of their younger self, with the adult-self intervening in the scene. The process continues until all emotional needs are fulfilled. Generally, one trauma memory is rescripted per session. The initial IR session involves therapist-led rescripting, with subsequent sessions encouraging patient-led rescripting whenever possible.
214455414|NCT02424929|PROCEDURE|Sedation|Propofol anesthesia administered during entire surgery.
214455415|NCT02424929|PROCEDURE|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
214455416|NCT05340049|PROCEDURE|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
214455417|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (PCST, PMRT, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the cranial blocks and primitive reflexs therapies were expressed as block or normal and active or inactive, depending on what finds the physiotherapist in his evaluation"
214455418|NCT01440257|DRUG|Placebo|Placebo capsules once daily
214455419|NCT01440257|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
214527933|NCT02600988|DRUG|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
214527934|NCT00884793|DRUG|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
214527935|NCT00884793|DRUG|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
214527936|NCT00884793|DRUG|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
214527937|NCT03169530|OTHER|Alcohol|\~15 gm daily of beer, wine, or spirits for \~6 years
215142690|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
215142691|NCT04152018|DRUG|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
215142692|NCT04152018|DRUG|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
215142693|NCT06590753|DEVICE|osseodensification bur|osseodensification bur
215142694|NCT06592651|BEHAVIORAL|Play Therapy Workshop|"4 session group intervention foucused on psycho-educational knowledge regarding tools for effective emotional coping with stressful events in the context of the Iron Swords war, focusing on building mental resilience in the parent-child dyad through play therapy. Each group consists of 5 parent-child dyads with children aged 3-6 years, who have been evacuated from war zones in the northern and southern regions of the country."
215142695|NCT03396809|DEVICE|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
215142696|NCT06825520|BEHAVIORAL|Habit Reversal Training|Participants learn to identify when their tics occur and then learn a competing response to engage in instead of the 3 identified tics and then practice competing responses learned in session during the practice sessions throughout the week.
215142697|NCT05488444|BEHAVIORAL|Navigator Phone Calls|"The patient navigator will call you every week as described above in Study Groups. These phone calls will continue until you begin receiving chemotherapy."
215142698|NCT05488444|BEHAVIORAL|Exit Interview|Participants will be asked to complete an exit interview either in person or by phone
214455420|NCT00881920|BIOLOGICAL|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa"
214455421|NCT04142788|DRUG|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
214455422|NCT06188793|DEVICE|Virtual reality-directed BGBT|Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
214455423|NCT04386070|DRUG|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
214455424|NCT04566991|DRUG|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
214455425|NCT04566991|DRUG|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
214527938|NCT06270004|OTHER|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
215142699|NCT06982807|PROCEDURE|Group 4.0-VISULYZE|The 4.0-VISULYZE group had their infusion rates precisely calibrated using 4.0-VISULYZE
215142700|NCT06982807|PROCEDURE|traditional group|The traditional group had their infusion rates based on past experience.
214527939|NCT01032200|DRUG|Armodafinil|Given orally
214527940|NCT01032200|OTHER|placebo|Given orally
214527941|NCT03145519|DEVICE|Vasofix Certo Catheter|Placement of IV-catheter
214527942|NCT03145519|DEVICE|OptiVein Catheter|Placement of IV-catheter
214527943|NCT00067808|DRUG|Decitabine|10 mg/m\^2 by vein over 1 hour daily for 10 days
214527944|NCT00067808|DRUG|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
214527945|NCT00067808|DRUG|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
214527946|NCT02338206|DRUG|Growth hormone|
214527947|NCT03188549|OTHER|AniosGel 85 NPC|Hand hygiene formula
214527948|NCT03188549|OTHER|Softa-Man (Braun)|Hand hygiene formula
214527949|NCT03188549|OTHER|Septol|alcohol-based hand rub
214527950|NCT05414656|DEVICE|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
215142701|NCT06991309|BEHAVIORAL|MBSR|MBSR will be conducted as group sessions, with each session lasts for 2.5 hours, once a week for 8 weeks with another 45 minutes of home practice on daily basis. The MBSR sessions will be based on therapy format developed by Kabat-Zinn. All the sessions focus on mindfulness practices, sharing of experiences with others, and didactic teaching on stress. Mindfulness practices which will be discussed include body scan exercise, and mindful breathing meditation techniques, three-minute breathing exercises, five-minute seeing or hearing exercises, bodily mindfulness in movement and mindful stretching, yoga and sitting meditation. The therapists will review feedbacks for each session, acknowledge the thoughts, feelings, and senses, examine how participants practice mindfulness, and give assignments to encourage participants to continually practice mindfulness at home. Each participant will receive a CD detailing on meditation practices and a workbook on the mindfulness practices.
215142702|NCT05607446|DRUG|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
214455426|NCT03372902|DEVICE|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
214455427|NCT03372902|DEVICE|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
214455428|NCT03372902|OTHER|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
214455429|NCT03372902|PROCEDURE|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
214455430|NCT03372902|BEHAVIORAL|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
214455431|NCT04968119|OTHER|Exercise Intervention|Participate in telehealth exercise sessions
214455432|NCT04968119|OTHER|Quality-of-Life Assessment|Ancillary studies
214455433|NCT04968119|OTHER|Questionnaire Administration|Ancillary studies
214455434|NCT06850649|OTHER|endocrowns|IPS Empress CAD Vita Enamic VarseoSmile Crown Plus
214527951|NCT00665106|DRUG|"NOVA63035 Corticosteroid"|Single injection in the study eye
214527952|NCT06077695|OTHER|therapeutic education|The themes covered concern head trauma in the chronic phase.
215142703|NCT05607446|DRUG|Placebo tablets|The intervention drug is placebo.
215142704|NCT05607446|DRUG|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
215142705|NCT05607446|DRUG|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
215142706|NCT06611501|DRUG|Metformin Hydrochloride|Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.
215142707|NCT06611501|DRUG|Placebo|1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
215142708|NCT06586944|BEHAVIORAL|Nursing Practices Based On Roy Adaptation Model Integrated With Virtual Reality|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group (Table...). In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals.Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions.
215142709|NCT06586944|BEHAVIORAL|Roy Adaptation Model|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals
215142710|NCT06991920|DRUG|Blinatumomab|CD19-positive, Ph+ patients with favorable financial status may receive VP + TKI + blinatumomab therapy；CD19-positive, Ph- patients with favorable financial status may receive VCP + blinatumomab therapy.
214527953|NCT06077695|OTHER|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
215142711|NCT06991920|DRUG|Venetoclax|CD19-positive, Ph+ patients with poor financial status may receive VP + TKI + VEN therapy；CD19-negative or CD19-positive, Ph- patients ineligible for blinatumomab may receive VPCLP + VEN therapy.
215142712|NCT06992765|DIETARY_SUPPLEMENT|Intervention|2 bottles of light green tea daily containing totally 684 mg of catechin
215142713|NCT06992765|DIETARY_SUPPLEMENT|Placebo|2 bottles of light green tea daily containing totally 108 mg of catechin
215142714|NCT06992648|DRUG|Trifluridine/Tipiracil + Regorafenib|Trifluridine/tipiracil will be administered orally BID at a starting dose of 30 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Regorafenib will be administered orally QD at a dose-escalation strategy (80 mg/day, followed by weekly increase of 40 mg to 120 mg/day), if no significant drug-related adverse events occurred and 120 mg/day for 21 days of a 28-day cycle.
215142715|NCT06992648|DRUG|Trifluridine/tipiracil + bevacizumab|Trifluridine/tipiracil will be administered orally BID at a starting dose of 35 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered IV every 2 weeks (day 1 and day 15).
215142716|NCT06992349|DEVICE|bioptron light therapy|"BIOPTRON® Hyperlight is a proprietary, optimized blend of visible and infrared light properties that Bio-stimulate cells and speeding up the healing process of a wide range of medical diseases.~Bioptron© light therapy has been utilized as a non-invasive treatment for wound healing, skin ulcers, and various musculoskeletal conditions(Abd Elhamid et al., 2020)."
215142717|NCT06993428|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
215142718|NCT06993428|DRUG|Alli® 60 mg|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
215142719|NCT06993428|DIETARY_SUPPLEMENT|Vi-Siblin® S|Vi-Siblin® S will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
215142720|NCT06993428|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
215142721|NCT06991517|OTHER|The ABC Bicuspid Sizing Algorithm|The ABC Bicuspid Sizing Algorithm is a valve sizing algorithm. It guides operators' evaluations of CT scans, helping inform (1) treatment allocation between TAVR and surgical aortic valve replacement, and (2) valve choice for patients undergoing TAVR. In select cases, the algorithm will suggest gated CT evaluation or artificial intelligence-based simulation models be used to further evaluate the risk of the planned valve size and deployment volume. The operators will consider the findings of the ABC Bicuspid Sizing Algorithm as well as other clinical factors when making their final treatment decisions.
215142722|NCT06993337|DIETARY_SUPPLEMENT|35% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
215142723|NCT06993337|DIETARY_SUPPLEMENT|50% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
215142724|NCT06993337|DRUG|0.1% Topical Triamcinolone Acetonide in Orabase|Triamcinolone acetonide in orabase, a corticosteroid-based standard treatment for Recurrent Aphthous Stomatitis (RAS), is used for its strong anti-inflammatory and immunosuppressive effects. In this study, it serves as the conventional treatment against the novel therapy
215142725|NCT06992050|DEVICE|Submariner suit|Participants wearing full-body Submarine Escape Immersion Equipment (SEIE) suits
214455435|NCT06848608|PROCEDURE|traditional physiotherapy group|"* Resistance training: It is planned to give strengthening exercises for the upper and lower extremities (quadriceps, hamstrings, gluteus medius, gastrosoleus, deltoids, triceps and biceps brachii) with the resistive exercise band. The fatigue severity perceived by the patients during the exercises is aimed to be 4-6 according to the Modified Borg scale~* Pursed-lip breathing training (10 repetitions)~* Chest breathing exercise (10 repetitions)~* Diaphragmatic breathing exercise (10 repetitions)~* Thoracic expansion exercises (10 repetitions - apical expansion, unilateral basal expansion, bilateral basal expansion, posterior basal expansion)~Additionally In terms of aerobic training, free walking will be provided 3 days a week. (Based on distance determined by 6 DYT)"
214455436|NCT06848608|PROCEDURE|yoga program|"Pranayamic techniques:~Nadi Shodhana: 2 sets of nadi shodhana pranayama consisting of 8 breathing cycles will be applied.~Ujjai: Two sets of ujjayi technique consisting of 10 breathing cycles with an inhalation:exhalation ratio of 1:2 in each session will be applied with a 1-minute rest period between sets.~Bhramari: Two sets of bhramari pranayama consisting of 10 breathing cycles will be applied with a low respiratory rate with a 1-minute rest period between sets.~Sukha Pranayama : It will be applied 5:5 inhalation:exhalation ratio for 5 minutes.~Kapalabhati: 15 quick breaths in 10 seconds followed by a 20-second break (30 breaths per minute in total) will be practiced for 3 minutes~Asanas:~Sukhasana Bharadvajasana Marjaryasana- Bitilasana Bhujaganasana Kapotasana Hasta uttanasana Virabhadrasana I~In addition, free walking will be given 3 days a week in terms of aerobic training. (Based on distance determined by 6 DYT)"
214695110|NCT02197039|PROCEDURE|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
215142726|NCT06992895|DEVICE|The visual presentation utilizes a three-dimensional holographic fan device.|This study is among the first to examine the effect of holographic fan technology on pain, anxiety, and fear in children during burn dressing. In comparison with other distraction methods, holographic fans represent a novel technological intervention designed to mitigate pain and anxiety by engaging children's attention through the use of visual illusions. Furthermore, extant studies on the effectiveness of this technology during prolonged and distressing procedures, such as burn dressing, have been found to lack sufficient data.
215142727|NCT06991946|GENETIC|Liquid Biopsy|Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
215142728|NCT06991946|GENETIC|Archival Tumor DNA|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
215142729|NCT06993493|GENETIC|CD19 CART|"The dose escalation is carried out according to the principle of 3+3 escalation, with a total of 3 dose groups set up.~Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases (i.e. ≥ 2/6 cases in this dose group), it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is MTD."
214527954|NCT06077695|OTHER|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
214527955|NCT05566626|DEVICE|Hyperspectral retinal image|Hyperspectral image of both eyes
214527956|NCT05566626|DRUG|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
214527957|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
214527958|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
214527959|NCT00714688|DRUG|Placebo|2xplacebo once daily for 13 weeks
214527960|NCT04542109|BEHAVIORAL|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
214527961|NCT04542109|BEHAVIORAL|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
214527962|NCT02391571|DRUG|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
214527963|NCT02391571|DRUG|Oxycodone|Oxycodone to be taken with stable dose of Methadone
214527964|NCT02391571|DRUG|Placebo|2 day placebo run in prior to test and active drug phase of study
214527965|NCT03314116|OTHER|Guidance on auditory protection|by video or medic
215142730|NCT06993246|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|The intervention involves the use of contrast-enhanced mammography (CEM) to supplement standard mammography for breast cancer screening. This method utilizes iodinated contrast medium to enhance the visualization of breast lesions by assessing tumor neovascularization. CEM will be offered to women with dense breast tissue who are currently awaiting supplemental ultrasound screening. It is designed to be performed in conjunction with regular mammography, offering a more efficient and cost-effective alternative to MRI, with comparable sensitivity in detecting breast cancer. Participants will undergo the CEM procedure in a single visit, allowing for reduced wait times and improved detection rates compared to traditional methods. The procedure is well-tolerated, with minimal side effects, and provides a quicker and more accessible option for supplemental breast cancer screening.
214527966|NCT02931994|OTHER|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
214527967|NCT00500539|DRUG|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
214527968|NCT02076802|BEHAVIORAL|physical exercises|
214527969|NCT04493307|DIAGNOSTIC_TEST|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
214527970|NCT04114279|PROCEDURE|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
214527971|NCT00370188|DRUG|Topiramate|
214527972|NCT03071341|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
214527973|NCT02316171|BIOLOGICAL|CVA21|CAVATAK is a purified preparation of CVA21
214527974|NCT02316171|DRUG|Mitomycin C|Chemotherapy
214527975|NCT03537534|DRUG|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
214527976|NCT03537534|DRUG|Placebos|Applying surgilube following endourologic procedure
214527977|NCT05149716|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
214527978|NCT05149716|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
214527979|NCT01524887|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
214527980|NCT01524887|BIOLOGICAL|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
215142731|NCT06602882|BEHAVIORAL|chatbot-delivered screening and brief intervention|"1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking."
215142732|NCT06603038|DIETARY_SUPPLEMENT|Gainful Daily Performance Greens|Daily supplementation for 28 days
215142733|NCT06587581|OTHER|Control Group|Participants from the intervention group will receive the usual care over the 6-month intervention period
215142734|NCT06587581|OTHER|Intervention Group|Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
215142735|NCT06596343|DRUG|Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy|"1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors."
215142736|NCT06594601|PROCEDURE|lung recruitment potential assessed by 3D EIT|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential."
215142737|NCT06594601|PROCEDURE|PEEP titration by 3D eit|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The PEEP titriatino by 3D EIT fwas as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. RM: PEEP was switched to a 21cmH2O for 2min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) ≥90%.~3. PEEP was stepwise decrease from 21 to 0 cmH2O PEEP in steps of 3cm H2O every 2min.~4. 3D EIT was used to monitor regional ventilation distribution during PEEP titration."
215142738|NCT06594380|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination
215142739|NCT06594380|DEVICE|Endoscopic bite group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
215142740|NCT06603233|DIAGNOSTIC_TEST|The Difference Between The AI Model and Dentists Group|The clinical feasibility of the best performing model, statistical hypothesis tests are performed that compares the predictions of the AI model with the assessments from three dentists.
215142741|NCT06603233|DIAGNOSTIC_TEST|Deep Learning Models|DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer were trained on 354 images and tested on 79 images.
215142742|NCT06593821|DEVICE|Occlusal splint|The occlusal splint was fabricated from a 2 mm hard splinting resin material on the plaster model obtained by taking impressions of the patients\&amp;#39; upper jaw.
215142743|NCT06593821|BEHAVIORAL|preventive advice|Control group given protective advice such as supporting the jaw when yawning, not chewing gum, not opening the mouth for too long and not opening it too wide, and chewing on both sides when eating.
214455437|NCT06849323|OTHER|Sujok therapy|The researchers will first detect the pain points in the hands by palpating them with a metal probe, then apply a clockwise massage to the painful point with the same metal probe, and finally complete the intervention by fixing the natural seed. The fixed seed should remain in the area where it is fixed for at least 4-8 hours, it should not come into contact with water or any liquid during this period, and the seed used should be used only once. There should be no wounds/cuts/scratches in the area where the massage and seed are applied, and the tissue integrity should be complete. According to the International Sujok Association (ISA), seeds similar to organs will be used in seed therapy, as well as neutral seeds (fenugreek, buckwheat and mung bean). Buckwheat seed, which is a powerful acupressure, will be applied. The effectiveness of the su jok treatment will be evaluated using the Bournemouth Neck Pain Question on the 11th day after all interventions and as a follow-up after 4 weeks
214455438|NCT06849921|DRUG|Cellular Therapy|"This intervention involves the infusion of autologous or allogeneic CAR-T cells into patients with relapsed/refractory hematologic malignancies. CAR-T cells are modified to target specific antigens on the surface of cancerous cells. After the infusion, patients will be monitored for response and safety.~Administration: Intravenous infusion. Dosage: The maximum tolerated dose (MTD) will be determined as part of the study, with dose escalation used to identify the optimal and safest dose of CAR-T cells for treatment."
214527981|NCT06585644|DRUG|Furmonertinib in combination with Anrotinib and chemotherapy|The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
215142744|NCT06593821|DRUG|Botulinum toxin|A total of 50 U of botulinum toxin, 25 U in each muscle, was injected
215142745|NCT06586684|DRUG|Inclisiran|Patients with carotid plaques undergoing treatment with inclisiran
214455439|NCT06848751|PROCEDURE|Non-intubated thoracoscopic surgery|Non-intubated thoracoscopic lung surgery for patients with impaired pulmonary function
214455440|NCT06843616|PROCEDURE|Endoscopic surgery|Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma
214455441|NCT05954143|DRUG|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
214455442|NCT05954143|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
214455443|NCT06846788|OTHER|Physical exercise|A traditional sensory relearning rehab session will be performed after our intervention consisting of 30 minutes of physical exercise.
214455444|NCT06841861|GENETIC|Stem cell|Primary cell cultures of tissue cells will be established. Cell cultures will undergo genetic reprogramming to induce the long-term propagation of living cells.
214455445|NCT06841861|GENETIC|Genetic Screening|Serum samples are processed through RNA sequencing to reveal known and novel infertility-related biomarkers and genes.
214455446|NCT06841861|GENETIC|Genetic Reprogramming|Genes or gene products will be reinserted into cells to observe how the cells can be changed, or reprogrammed, into embryonic-like cells or into sperm precursor cells.
214455447|NCT06841861|GENETIC|Cell Maturation|Genetically unmodified and modified cells are placed in a laboratory-based testicular environment to promote spermatogenesis into maturity.
214527982|NCT00547300|DRUG|Metoprolol ER|Metoprolol ER once daily, oral administration
214527983|NCT00547300|DRUG|Nebivolol|Nebivolol once daily, oral administration
214527984|NCT01596699|DRUG|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
214527985|NCT01596699|DRUG|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
214527986|NCT01596699|DRUG|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
214527987|NCT01596699|DRUG|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
214527988|NCT00002371|DRUG|Indinavir sulfate|
215142746|NCT06604390|DIETARY_SUPPLEMENT|catechin extracts (health food)|"Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;"
215142747|NCT06604390|OTHER|plasebo|Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.
215142748|NCT06587087|DEVICE|Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.|The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
215142749|NCT06586502|OTHER|Model of Care|The intervention described in the RECOVER study involves developing, implementing, and evaluating a comprehensive Model of Care for childhood cancer survivors. This model, known as the RECOVER Model of Care, integrates digital health solutions and is co-designed with input from childhood cancer survivors, caregivers, and clinical experts. The intervention aims to address the long-term and late effects of cancer treatment by providing continuous, risk-based, interdisciplinary care. It includes steps such as identifying patients nearing the end of treatment, conducting health assessments, creating personalized care plans, and coordinating follow-up care through digital platforms. The study will assess the feasibility, acceptability, and effectiveness of this model in improving the quality of life and care experience for survivors and their families.
215142750|NCT06589544|DEVICE|Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)|"The CEREBRUM-VELA virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
214527989|NCT00002371|DRUG|Lamivudine|
214527990|NCT00002371|DRUG|Stavudine|
214527991|NCT00002371|DRUG|Zidovudine|
214527992|NCT05081778|BEHAVIORAL|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
214527993|NCT03373188|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
214527994|NCT03373188|BIOLOGICAL|Ipilimumab|Given IV
214527995|NCT03373188|BIOLOGICAL|Nivolumab|Given IV
214527996|NCT03373188|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
214527997|NCT04380688|DRUG|Acalabrutinib|Acalabrutinib administered orally
214527998|NCT06602206|OTHER|Conventional Treatment|Hot pack,TENS, ultrasound and exercises
214527999|NCT06602206|OTHER|shoulder mobilization|In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
214528000|NCT06602206|OTHER|neck mobilization|Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.
214528001|NCT06574724|OTHER|Visiting a green space|Participants are asked to visit a green space for a defined time period
214528002|NCT06647147|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
214528003|NCT06647147|OTHER|Diaphragmatic breathing exercises|From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
214528004|NCT02779127|OTHER|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
215142751|NCT06589544|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)|"Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
215142752|NCT06589544|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
215142753|NCT06586554|OTHER|Static stretching|The SS group received static stretching, which was applied with gentle and firm pressure while pulling opposite the hamstring muscle contraction.
214528005|NCT02779127|OTHER|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
214528006|NCT02779127|OTHER|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
214528007|NCT02779127|OTHER|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
214528008|NCT02779127|OTHER|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
214528009|NCT02249156|BEHAVIORAL|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
214528010|NCT03616314|DEVICE|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
215142754|NCT06586554|OTHER|Myofascial release|Myofascial release is applied with cross-handed stretches over hamstring muscle
215142755|NCT06600503|BEHAVIORAL|RehabLung mobile application|Participants in the intervention group will receive in-person pulmonary rehabilitation during their surgical admission and access to a mobile pulmonary rehabilitation application for self-training. This program begins one month before surgery and continues for seven weeks after surgery. The application is designed to encourage participants to engage in pulmonary rehabilitation exercises from preoperative preparation through postoperative care. It offers guided chest breathing exercises, using visual and movement instructions created and remotely prescribed by a physical therapist. Participants will receive daily breathing exercise prescriptions throughout the study period.
215142756|NCT06600503|BEHAVIORAL|Lung cancer postoperative standard care|Participants in the usual care group will receive in-person pulmonary rehabilitation during surgical admission, pre-operative healthcare, and guidance on breathing exercises to practice before surgery. They will also receive post-operative breathing exercise prescriptions to follow at home.
215142757|NCT06600503|OTHER|Healthcare interactive Web Platform|The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.
215142758|NCT06592976|DIETARY_SUPPLEMENT|Multi-strain Oral Probiotic (CDS22-formula)|All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
214455448|NCT06841211|PROCEDURE|Targeted and perilesional biopsy (TPLBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. For each predefined mpMRI suspicious lesion, two-core TBs are obtained within the ROI, followed by ring-distributed four cores within a 10-15 mm radius around the ROI. The location of these cores depends on the shape and location of the suspicious lesion.
214528011|NCT03616314|DEVICE|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
214528012|NCT03616314|OTHER|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
214528013|NCT06597435|OTHER|Nicotine pouch|Participants will self-administer an experimenter-provided nicotine pouch
214528014|NCT06242184|PROCEDURE|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
214528015|NCT06242184|PROCEDURE|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
214528016|NCT06261840|DRUG|Metronidazole 500 mg|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
214528017|NCT06261840|DRUG|Secnidazole 2000 MG|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
214528018|NCT06329544|DIETARY_SUPPLEMENT|Fructose|12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
214528019|NCT06329544|DIETARY_SUPPLEMENT|glucose|12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
214528020|NCT03993054|BEHAVIORAL|Culturally-tailored cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 10 weeks. This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
214528021|NCT03805685|PROCEDURE|Non-Cardiac Surgery|Non-cardiac surgery
214708639|NCT04752449|BEHAVIORAL|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
215142759|NCT06590142|PROCEDURE|Observational study of tissue specimens|No intervention will be made
215142760|NCT06587542|OTHER|Injection of protein purified derivative|Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion
215142761|NCT06593509|DEVICE|Maquet,Servo I.|Model number: 06487800, Serial Number: 19761, SKU#: Inv-00344191, Made in Sweden
214528022|NCT06606769|OTHER|Exercise|supervised exercise training; twice a week for 12 months
214528023|NCT07002320|DRUG|SX-682|SX-682 is supplied as 100mg film coated tablets.
214528024|NCT07002320|DRUG|Apalutamide|Apalutamide is supplied as 60mg film coated tablets.
215142762|NCT06593509|DEVICE|Vapotherm|INC ,100 domain drive Exeter, NH 03833, Made in U.S.A
215142763|NCT06593509|DEVICE|venturi mask|Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK.,REF. 1107085, LOT,31757961
215142764|NCT06596707|PROCEDURE|Zirconomer|zirconia modified glass ionomer
215142765|NCT06596707|PROCEDURE|Nanohybrid composite|conventional composite
214528025|NCT07000422|OTHER|Selected gait training program|All children in both groups will receive selected gait training (treadmill) sessions for five times per week over 6 successive months.
215142766|NCT05393791|OTHER|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
214455449|NCT06841211|PROCEDURE|Combined targeted and systematic biopsy (CTSBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. Two-core TBs from the lesion were performed within each predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
214455450|NCT06563245|DRUG|Brentuximab Vedotin for Injection|1.8mg/kg/dose (MAX 180 mg)
214455451|NCT06563245|RADIATION|response-adapted radiation|For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
214455452|NCT06563245|DRUG|Doxorubicin|25mg/m2/dose,
214455453|NCT06563245|DRUG|Etoposide|125 mg/m2/dose
214455454|NCT06563245|DRUG|Prednisone|20 mg/m2, BID, orally
214455455|NCT06563245|DRUG|Cyclophosphamide|600 mg/m2/dose
214455456|NCT06563245|DRUG|Dacarbazine|250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
214455457|NCT06563245|DRUG|Tislelizumab Injection|3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
214455458|NCT06563245|DRUG|Bedamustine|180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
214455459|NCT05516147|BEHAVIORAL|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
214455461|NCT03992339|DRUG|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
214455462|NCT03868592|PROCEDURE|Gastric sleeve/bariatric surgery|weight loss
214455463|NCT03895567|DRUG|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
214455464|NCT03895567|DRUG|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"
214455465|NCT03895567|DRUG|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"
214455466|NCT06848777|BEHAVIORAL|Intervention group:|After a 50-meter walk while listening to the sounds of nature, the patient will walk 50 meters again to his/her room and then to his/her bed, where he/she will be seated. Then, the researcher nurse will remove the headphones from the patient's ears and ensure that the patient rests in a comfortable position.
214455467|NCT03338933|BEHAVIORAL|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
214455468|NCT05694286|PROCEDURE|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
214455469|NCT01728857|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214455470|NCT04907136|OTHER|Preferred ENDS|Preferred ENDS without HWL on device
214528026|NCT07000422|OTHER|Eye movement exercise|All children in the experimental group will receive eye training exercises for five times per week over 6 successive months. The exercises include tasks to improve visual focus and tracking. Children search for a specific card among 20 while covering one eye, repeated 10 times. They follow a pencil moving vertically, horizontally, in circles, and in a figure 8, maintaining a 1m distance. Exercises include shifting gaze between two pencils, recognizing letters on a shaking card, and tracking a pencil from 5cm to 50cm. Tasks are done with each eye covered separately. Another task involves walking while focusing on a fixed target 1m away at eye level for 5 minutes.
215142767|NCT05393791|DRUG|Abiraterone acetate|Use of abiraterone or enzalutamide
215142768|NCT05393791|DRUG|Enzalutamide|Use of abiraterone or enzalutamide
215142769|NCT06590805|PROCEDURE|Electrotherapy using Chattanooga stimulation unit|Electroacupoint stimulation using the Chattanooga intellect transport 2-channel electrotherapy stimulation unit 2783. It uses the influences energy flows by needling the acupuncture points which lie along the body meridians to achieve a harmonious balance between physical, emotional, and spiritual states. The same effect can be achieved without the use of needles. These needleless stimulations are noninvasive and nontraumatic and are useful for individuals who are scared of needles. They are also associated with decreased risk of infection or bruise.
214455471|NCT04907136|OTHER|Preferred ENDS with HWL|Preferred ENDS with a HWL on device
214455472|NCT06174272|BEHAVIORAL|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
214455473|NCT03853746|DRUG|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
214455474|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
214455475|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
215142770|NCT06590805|DIETARY_SUPPLEMENT|Balanced Diet using domperidone drug, iron, and folic acid supplementation.|"Postnatal care diet in form of balanced diet using domperidone drug, iron, and folic acid supplementation. Additionally, drinking sufficient clean water and routine postnatal care.~It was performed by asking the participant to take ten mg domperidone three times a day after meals. Iron and folic acid supplementation were also continue for three months after birth."
215142771|NCT06590415|PROCEDURE|Subcutaneous adipose tissue biopsy|Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
215142772|NCT06590415|OTHER|Blood sampling|One 4 mL tube of blood will be collected
215142773|NCT05523089|DRUG|Saline placebo|Sterile normal saline for injection
215142774|NCT05523089|COMBINATION_PRODUCT|CD388|CD388 liquid for injection
214455476|NCT05027503|OTHER|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
214455477|NCT05027503|OTHER|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
214455478|NCT05737953|DIAGNOSTIC_TEST|cfDNA methylation sequencing and proteome analysis|Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples
214455479|NCT02777879|PROCEDURE|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
214455480|NCT05873244|DRUG|Zabadinostat (CXD101) and Geptanolimab|"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
214455481|NCT05873244|DRUG|Lenvatinib and Sorafenib|"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
214455482|NCT06158529|DEVICE|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
214455483|NCT06158529|DEVICE|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
214455484|NCT03426579|DEVICE|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
214455485|NCT04947020|DRUG|Metformin|Metformin use before operation due to previously diagnosed diabetes.
214455486|NCT04497220|BEHAVIORAL|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
214528027|NCT05667727|DRUG|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
214528028|NCT05667727|DRUG|Salbutamol|Patient will receive salbutamol as 4th nebulization.
214528029|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
214528030|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
215142775|NCT06861998|BEHAVIORAL|Message-based bedtime routine|The intervention group implemented sleep hygiene education and the Message-based bedtime routine, including nutritional activities-hygiene-communication-message.
215142776|NCT06861998|BEHAVIORAL|sleep hygiene education|Sleep hygiene education includes sleep environment, sleeping location, regular sleep schedule, bedtime routines, sleeping methods, and sleeping posture.
215142777|NCT06991491|COMBINATION_PRODUCT|GnP in combination with Ivonescimab and SBRT|Gemcitabine 1000mg/m2, ivgtt,vdays 1 and 8, nab-Paclitaxel 125mg/m2, ivgtt, days 1 and 8 in combination with Ivonescimab 20mg/kg d1, every 21 days. Cycle 2 will be synchronized with primary or metastatic SBRT.
215142778|NCT05919875|BEHAVIORAL|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~1. Awareness and automatic pilot~2. Living in our heads~3. Being present in the body~4. Recognizing aversion~5. Allowing / Letting be~6. How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
215142779|NCT05919875|BEHAVIORAL|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
214528031|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
214708640|NCT04669782|DIETARY_SUPPLEMENT|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
215142780|NCT06993103|DIETARY_SUPPLEMENT|Standard care Cow's milk based formula|Standard hospital care would be given as as per local unit policy at the site.
215142781|NCT06993103|DIETARY_SUPPLEMENT|Dietary Supplement: PDHM Pasteurised Donor Human Milk|PDHM will be given to infants randomised to the intervention group
215142782|NCT06369909|PROCEDURE|EUS-FNA|For patients with pancreatic masses, EUS-FNA is performed to confirm pathological diagnosis, and pancreatic biopsy samples and duodenal mucosal biopsy samples are collected.
215142783|NCT06991426|DIETARY_SUPPLEMENT|CreaSafe® creatine|Will receive CreaSafe® creatine (0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
215142784|NCT06991426|COMBINATION_PRODUCT|Placebo 0.03 g/kg/day|will receive a placebo (microcrystalline cellulose; 0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
215142785|NCT06672120|BEHAVIORAL|Exercise training|Combined, home-based, supervised, video- assisted, endurance and resistance training
215142786|NCT06672406|DIETARY_SUPPLEMENT|Lactobacillus reuterii|Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding \> 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics
214455487|NCT04497220|BEHAVIORAL|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
214455488|NCT06561854|DRUG|Dexamethasone|"ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)"
214455489|NCT03981705|RADIATION|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
214455490|NCT00999804|DRUG|Lapatinib|1000 mg of Lapatinib by mouth daily
214455491|NCT00999804|DRUG|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
214455492|NCT00999804|DRUG|Trastuzumab|6 mg/kg intravenously, every 3 weeks
214695111|NCT06693401|OTHER|Intervention group: PD rehabilitation complemented with Occupational Therapy programme|"In intervention group both Physiotherapy and Occupational Therapy programmes were implemented.~Occupational Therapy programme consisted in trainning the amplitude of the movements involved in the realization of each letter of the alphabet separately and through fine motor exercises. Specifically the tasks consisted of performing:~1. 2 types of handwriting exercises, namely for tracing the upper and lower-case letters of the alphabet guided by dotted lines and writing a sentence with and without spatial boundaries, in Portuguese language (to be performed for about 45 minutes, three times a week) and;~2. 4 groups of fine motor tasks exercises, namely for hand manipulation (2 exercises), finger isolation (3 exercises), finger flexion and extension (2 exercises) and coordination (1 exercise). All exercises were performed 10 times, in triplicate, for each hand on a regular basis of 2-3 times per week."
214695112|NCT06693401|OTHER|Control Group: conventional physiotherapy programme|In this group only the conventional physiotherapy programme was implemented. This programme has the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support. In this regard, participants were guided and supervised in each physiotherapy session by a Parkinson's disease healthcare specialist.
214695113|NCT06692582|OTHER|Electrolysed saline rinse|EOS ph = 7, 200 ppm free available Chlorine
214695114|NCT00406640|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
214455493|NCT06191250|DRUG|Durvalumab|one dose of durvalumab (750 mg IV)
214455494|NCT06191250|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
214695115|NCT00406640|DRUG|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
214695116|NCT06777654|OTHER|Robotic therapy (RT)|The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.
214708641|NCT04669782|DRUG|Teriparatide|Teriparatide will be administered as standard of care
215142787|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
215142788|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
215142789|NCT06992128|DRUG|Romiplostim N01 combined with dexamethasone|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection within 4 days of dexamethasone treatment once a week for up to 6 months.
214455495|NCT06379360|DRUG|Hypomethylating agent, Azacitidine or Decitabine|All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
215142790|NCT06992128|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
215142791|NCT06992414|DIETARY_SUPPLEMENT|Creatine monohydrate|8 g/day creatine monohydrate powder
215142792|NCT06991439|DEVICE|A self-monitoring mobile application for stress management at work|STAPP@Work is a digital self-monitoring intervention designed for the workplace to manage work-related stress. The app prompts users multiple times per day to self-monitor their stress by answering short questions about their current activity, mood, and stress signals. It provides real-time feedback, visual summaries of stress patterns over time, and practical tips for stress management.
214455496|NCT03751709|DRUG|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
215142793|NCT06991660|BEHAVIORAL|sleep hygiene education|This study will be conducted to examine the effects of sleep hygiene training, which is given to women in menopause to eliminate sleep problems and menopause symptoms that they often experience, on sleep and menopause symptoms experienced by women.
214455497|NCT03751709|OTHER|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
214455498|NCT05023369|DRUG|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
214455499|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
214455500|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
214455501|NCT05602779|DEVICE|tVNS Program|Participants will use the Neuvana Xen device 30 minutes a day for 30 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
214455502|NCT05602779|OTHER|Phone App Program|Participants will have access to a specially designed phone app (MindTiles) in order to play a game designed for this study. Participants in the active intervention will be able to connect with a fellow participant who is matched as their peer for social support and they will complete a daily puzzle together and respond to a conversational prompt to encourage communication.
214455503|NCT05602779|COMBINATION_PRODUCT|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
214455504|NCT05602779|OTHER|Sham tNVS and Control App|Participants will have access to our program's phone app so the can complete the daily puzzle on their own. They will also engage in a sham tVNS session for 30min per day for 30 days during which no stimulation is provided.
214455505|NCT04383119|DRUG|Trabectedin|Trabectedin in monotherapy
214455506|NCT04383119|DRUG|Gemcitabine|Gemcitabine, control arm
214708642|NCT06422377|DRUG|Soticlestat|Soticlestat tablets or mini-tablets
214708643|NCT06030362|DIETARY_SUPPLEMENT|Probiotic|Dietary Supplement taken once daily for 3 months (90 days).
215142794|NCT06992687|DRUG|HB0052 Injection|An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
214455507|NCT04383119|DRUG|No Intervention: Observational Cohort|Treatment according clinical practice
214455508|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
214455509|NCT05523154|PROCEDURE|Biospecimen Collection|Undergo collection of bile samples
214455510|NCT05523154|OTHER|Laboratory Procedure|Undergo routine laboratory testing
214455511|NCT05523154|DEVICE|Nanopore Sequencing|Undergo nanopore sequencing
214528032|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
214528033|NCT07007624|OTHER|Basketball training (Sport and diet)|The intervention program will last for 3 years, and each year will be divided into two periods: a preseason, beginning in early September and lasting for the first 6 weeks, followed immediately by a 32-week season (until the end of the school year). The preseason will include 5 training sessions per week, each lasting 2 hours (Monday to Friday). The following season will include 3 training sessions per week, each lasting 2 hours (after school), and one match on the weekend. Each session will be divided into 2 periods separated by a 10-minute break: the first period will focus on individual skills with moderate to high-intensity exercises (60-85% of heart rate), and the second period will focus on gameplay (tactics and strategy). The trainers had a high level of professional training, ensuring the quality of the sessions. Dietary recommendations based on the Mediterranean diet will be given to the subjects.
214528034|NCT07009041|OTHER|Strength training program|Strength training was implemented for eight weeks, including full-body, core, and leg exercises.
214528035|NCT07009041|OTHER|Stretching exercises program|Stretching exercises were performed after strength training for the entire eight-week period. The training was administered exclusively to participants in the experimental group, following a consistent schedule and sequence. The program was conducted three days a week for eight weeks, separate from regular football training.
214528036|NCT07009041|OTHER|Plyometric exercises program|Plyometric exercises were included only one day per week, and a minimum one-day rest period was maintained between training sessions.Since this program was originally 6 weeks long, it was implemented in the first 6 weeks of the study's implementation process.
214528037|NCT07009041|DIAGNOSTIC_TEST|Demographic tests|Demographic tests were applied to determine the height, weight and BMI values for the identification of the participants.
214528038|NCT07009041|DIAGNOSTIC_TEST|Jump tests|Jump tests (CMJ, CMJ Free, SJ, DJ, Horizontal Jump). Three different measurements were taken at three different times.(Before starting, end of week 4 and after completion of week 8).
215142795|NCT06992830|PROCEDURE|cardioneuroablation|Participants diagnosed with medication-refractory variant angina or those unable or unwilling to take medications regularly will undergo a catheter-based cardioneuroablation (CNA) procedure. CNA targets epicardial cardiac ganglionated plexi (GP), which are clusters of autonomic ganglia involved in parasympathetic modulation of cardiac function. The procedure is designed to reduce parasympathetic overactivity contributing to coronary artery spasms. Ablation will be performed using a radiofrequency catheter to eliminate GP areas identified by anatomical landmarks and electrophysiological mapping. No control or sham procedure is included in this single-arm study.
215142796|NCT06414369|OTHER|Diathermy|A DT equipment (CET 400 VA - RET 130 Watts - Winback, France), with a frequency of 500 kHz and intensity at 40% will be used. It will be applied utilizing a flat capacitive head 4 cm in diameter. It will be applied using longitudinal and transverse movements and a conductive cream for DT. DT will be used over the TP of the right and left trochanteric prominence. The settings will be calibrated so that patients fell no more than mild warmth during the treatment.
215142797|NCT06414369|OTHER|Simulated Diathermy|This same intervention that has been given to the experimental group, will be simulated as placebo in the control group; the DT will not be activated during administration.
214455512|NCT06831201|DEVICE|Flow trigger sensitivity group|1\. Pressure support ventilation will be titrated at a level sufficient to achieve a respiratory rate of 20-30 breath/min and tidal volume 4-6 ml/kg. Pressure support will be reduced by 2 cm H2O every hour to reach pressure support 8 cm H2O. Two exercise sessions will be performed, at 9 AM and 5 PM. Training will be based on decreasing the trigger sensitivity gradually in order to increase muscle endurance. The trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training (In the first session), inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reach 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing trigger sensitivity by 10% of the initial MIP. Patients who could not tolerate IMT with 20% of MIP for 5 min were trained with 10% of MIP. Training consists of 5 to 6 sets of repetitions through the trainer.
214455513|NCT06831201|PROCEDURE|Active proprioceptive facilitation technique ( active PNF) technique|"1. patients in this group treated with the rhythmic initiation technique derived from the PNF concept. The RIT will be applied in four manual positions of the therapist's hands: The upper and lower chest wall, the sternum and below the rib cage, so that the patient can learn the correct breathing pattern. Verbal commands will be also used by the PT to reinforce the manual stimulation with each pattern/exercise being performed 10 times.~2. patients treated with the initial stretch technique ,This technique facilitates the initiation of inhalation. The IST was applied to help the patient to initiate the inhalation phase, increase the force developed by the inspiratory muscle, and to enhance the active range of motion of the chest wall and the diaphragm. At the final stage of exhalation, when inspiratory muscles will be elongated optimally, the stretch reflex will be initiated by applying a quick tap to elicit a strong and active inspiratory muscle contraction"
214455514|NCT06831201|PROCEDURE|Passive proprioceptive facilitation technique ( passive PNF) technique|"Perioral pressure is provided by applying pressure with the therapist's finger on the top lip between the nose and lip. The pressure is maintained for the length of time that the therapist wishes the patient to breathe in the activated pattern.~Intercostal stretch is provided by applying pressure to the upper border of a rib in order to stretch the intercostal muscle in a downward(not inward) direction. The stretch position is then maintained while the patient continues to breathe in his/her usual manner.~vertebral pressure high - manual pressure applied to thoracic vertebrae in the region T2 - T5.~vertebral pressure low - manual pressure applied to thoracic vertebrae in the region T9 - T10.~Co-contraction of the Abdomen Provided by the therapist by pressing adequate pressure on the lower ribs and pelvis on the same side, so that pressure is applied at right angles to the patient.~Moderate Manual Pressure of the open hand(s) is maintained over the area in which expansion is desired"
214455515|NCT04582825|OTHER|N/A - Observational Study|N/A - Observational Study
214455516|NCT06373562|OTHER|hypoxia|The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
214455517|NCT05849064|BEHAVIORAL|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
214455518|NCT05849064|BEHAVIORAL|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
214455519|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
214455520|NCT06422390|BIOLOGICAL|Platelet - Rich Plasma|Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
214708644|NCT06030362|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement taken once daily for 3 months (90days).
215142798|NCT02681523|DRUG|Eribulin|
215142799|NCT04574284|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
215142800|NCT04574284|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
215142801|NCT06999200|DRUG|neural therapy|This prospective study will be conducted with mothers who underwent general anesthesia for labor or elective cesarean delivery and local anesthesia for postoperative pain management during a one-year period following ethical approval.
215142802|NCT03914443|BIOLOGICAL|Nivolumab|240 mg or 360 mg
215142803|NCT03914443|DRUG|5-FU|750 or 800 mg\^2
215142804|NCT03914443|DRUG|CDDP|70 or 80 mg/m\^2
215142805|NCT03914443|DRUG|DTX|70 mg/m\^2
215142806|NCT06600555|PROCEDURE|metabolic surgery with SLEEVE technique|metabolic surgery with SLEEVE technique
215142807|NCT06600555|PROCEDURE|metabolic surgery with BY-PASS technique|metabolic surgery with BY-PASS technique
215142808|NCT06591559|DEVICE|Permobil Explorer Mini|The Explorer Mini (Permobil AB, Sweden) is a commercially available, FDA approved powered mobility device intended for young children between 12-36 months of age with mobility limitations (weight limit: 35 lbs; height limit: 39.4 inches). It is lightweight (52 lbs. including battery) and fits in most automobiles (length: 25 inches; width: 19 inches; adjustable height: 29-37 inches). The Explorer Mini runs on a 12-volt battery with a driving range of 3.5 miles and a maximum speed of 1.5 mph, is controlled via a joystick with a 360-degree turning radius, has proportional speed control with 5 speed options, and can be used in a seated or standing position.
215142809|NCT06591559|DEVICE|Portable Mobility Aid for Children (PUMA)|The Portable Mobility Aid for Children (PUMA; Enliten LLC) is a portable canopy system that utilizes an overhead support rail structure and a counterweight. The rail structure consists of two rigid parallel beams that mount to the canopy structure and one perpendicular mobile beam that allows for freedom of movement in one direction. Freedom of movement in the opposite direction is achieved by a system of pulleys along the movable beam that connects the harness to a counterweight. The counterweight provides a passive vertical force, counteracting gravity. The PUMA provides 2-dimensional mobility support over 81 ft2 (9 ft x 9 ft). The overhead bar is connected at 4 points to a child-worn harness. Children are free to move through many postures including sitting, crawling, standing, and walking.
215142810|NCT06600061|OTHER|Erector Spinae Plane Block|Patients will receive erector spinae plane block after induction of anesthesia.
215142811|NCT06588361|OTHER|Training Based on Kolcoba Comfort Theory|Training Based on Kolcoba Comfort Theory
215142812|NCT06603129|DIAGNOSTIC_TEST|prognostic nutritional index|Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.
215142813|NCT06999603|DRUG|SNG001|SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing 0.65 mL of drug product solution containing 12 MIU/mL of IFNβ 1a.
215142814|NCT06999603|DRUG|Placebo|The placebo nebuliser solution is presented in glass syringes containing 0.65 mL of solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).
215142815|NCT06600594|OTHER|Beginners dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
215142816|NCT06600594|OTHER|Experience dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
215142817|NCT06998108|DRUG|BEBT-209 capsules|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
215142818|NCT06998108|DRUG|BEBT-209 Placebo capluses|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
215142819|NCT06998108|DRUG|Fulvestrant Injection|500 mg intramuscular injection, with a 28-day treatment cycle. Administration on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle.
215142820|NCT06999499|OTHER|Scanner of the whole body using the VECTRA 3D|Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma
215142821|NCT07000071|DEVICE|NCPAP|Apply nasal continuous positive airway pressure in intubated patients with respiratory distress at time of weaning
215142822|NCT07000071|DEVICE|NIPPV|Apply nasal intermittent positive pressure ventilation in intubated patients with respiratory distress at time of weaning
215142823|NCT07000071|DEVICE|NHFOV|Apply nasal high frequency ventilation in intubated patients with respiratory distress at time of weaning
215142824|NCT06604585|BEHAVIORAL|Parenthood - a journey together. Digital tool to increase security in parenthood, a way to promote public health..|"The project involved the development of an internet-based parental support program to be delivered via the national Support and Treatment (Sob) platform and used in primary care to enhance traditional parental support within child healthcare, as needed. The innovation has been developed in collaboration with the Innovation Fund in Västra Götaland. The aim is to increase the experience of parental competence and a sense of security in parenting by reflecting on attitudes and approaches in interaction with the child through an interactive, digital parental support program. The four themes in the parental support program, Parenthood a journey together, are named: Being a good enough parent, understanding one's child, interacting with one's child, and meeting daily challenges as a parent regarding food, sleep, play, screen time, and physical activity. The four modules will include explanatory and psychoeducational texts, written exercises, videos, and homework."
214455521|NCT04101474|DRUG|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
214455522|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
214708645|NCT03086681|DRUG|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
215142825|NCT06601972|PROCEDURE|Beautifil II LS (Low-Shrinkage)|The most remarkable feature of this light-cured universal composite for anterior and posterior restorations is its unique shrinkage of 0.85 percent by volume
215142826|NCT06601972|PROCEDURE|Nanohybrid resin composite|Nanohybrid resin composites are the most popular, because they improve the distribution of fillers in the matrix by combining nanoparticles with submicron particles to achieve better mechanical, chemical, and optical properties
215142827|NCT06998732|DRUG|remimazolam sedation|remimazolam sedation
215142828|NCT06604403|OTHER|Massage|After the hemodialysis, the patients will receive a 15-20 minute hand and foot massage. This application will be applied to the patients in two weekly dialysis sessions for a total of 8 sessions for four weeks. Before starting the massage applications, the patient's hands and feet will be washed and dried thoroughly. The patients will be given a semi-sitting or lying position that they can feel comfortable in. Before starting the hand and foot massage, the researcher will gently rub and warm their hands and wrists. The massages will start with a hand massage. A foot massage will be performed after the hand massage. 3-5 drops of baby oil applied at room temperature will be used to reduce friction during the massage. Effleurage, petrissage and friction styles of the massage will be applied.
214455523|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
214455524|NCT04130854|DRUG|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
214455525|NCT04130854|DRUG|mFOLFOX and Radiation Therapy 5Gy x 5 days|"1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
214455526|NCT05415124|DEVICE|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
214455527|NCT05415124|PROCEDURE|Endoscopy|Endoscopy is performed as scheduled.
214455528|NCT06069778|DRUG|BNT321 Dose Level 1|Intravenous infusion
214455529|NCT06069778|DRUG|BNT321 Dose Level 2|Intravenous infusion
214455530|NCT06069778|DRUG|mFOLFIRINOX|Intravenous infusion
214455531|NCT06069778|DRUG|BNT321 RP2D|Intravenous infusion
214455532|NCT06155266|DIAGNOSTIC_TEST|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
214455533|NCT06139042|DIAGNOSTIC_TEST|Blood drawing|The participants had their blood drawn.
214455534|NCT06797960|DEVICE|Ultra sound guided Injection of PRF intra articularly|Intra articular injection of PRF
214455535|NCT06797960|DRUG|Intra articular injection of HA|Intra articular injection of HA
214455536|NCT01901770|OTHER|educational intervention|Receive HPV vaccination educational materials
214455537|NCT01901770|OTHER|educational intervention|Receive influenza vaccination educational materials
214455538|NCT06288191|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
214455539|NCT05079789|DRUG|Amiloride|Treatment with amiloride, start dose 5 mg
214455540|NCT05079789|DRUG|Furosemide|Treatment with furosemide, start dose 40 mg
214455541|NCT02801812|DEVICE|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
214455542|NCT05984069|OTHER|observational prospective data collection|Collection of data from medical records.
214455543|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
214455544|NCT04733950|OTHER|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
214455545|NCT04733950|OTHER|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
214455546|NCT05606705|DIETARY_SUPPLEMENT|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
214455547|NCT05980806|DRUG|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
215142829|NCT06998654|BEHAVIORAL|Muli-app|The Muli-app is designed after a traffic-light model, indicating different levels of severity of emotional distress and need for help. Green parts represent self-management measures that can be taken to try to regulate themselves (coping plan, write notes for their next appointment , and exercises to reduce emotional distress.) Yellow parts represent contact-based measures when the patient needs someone to talk to outside office hours, to de-escalate emotional distress and to avoid further crisis. This function connects study participants with mental health professionals at the local psychiatric hospital outside office hours (chat, phone or videocall). When the patient activates this function, the staff at the local hospital have 30 minutes to reply. The red part also activates contact with the local psychiatric hospital, but with a need of acute response, activating acute measures stated in the coping plan, such as access to an open bed in the municipality.
215142830|NCT06998511|OTHER|interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention|The observation group received interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention based on the COM-B model on the basis of routine care.
215142831|NCT06998511|OTHER|routine nursing intervention|The control group received routine nursing intervention, including basic drug treatment, diet and exercise guidance, psychological counseling, etc.
215142832|NCT06587620|DRUG|Tranexamic acid|Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
215142833|NCT06587620|DRUG|Dexmedetomidine|Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
215142834|NCT06587620|OTHER|Saline (NaCl 0,9 %) (placebo)|IV infusion of 50 ml saline over 10 min before induction of anesthesia. IV saline infusion immediately after induction till 15 min before the end of surgery.
215142835|NCT06602609|OTHER|Remote Patient Monitoring Strategy|Continuous remote monitoring with the SmartCardia device includes continuous heart rate and cardiac conduction rhythm tracking through a 7-lead ECG enhanced by machine learning. This system can detect cardiac rhythm disturbances, measure breathing and heart rate, and provide live-alert notifications. Daily 12-lead ECG will be collected from each patient for 7 days after discharge; patients are instructed to perform a daily 12-lead ECG on the SHL device, along with recording blood pressure and oxygen saturation levels. Each ECG is interpreted by the trial team, and a cardiologist\&#39;s interpretation is confirmed, and patients will undergo remote consultations with a cardiologist or research nurse each day if needed. During the initial 30 days of patient recruitment, if the individual exhibits potential cardiac symptoms, they can activate a remote consultation by performing an extra 12-lead ECG and recording blood pressure and oxygen saturation levels.
215142836|NCT06602609|OTHER|Standard Medical Therapy|No intervention is required. Patients in this arm will fill out a self-reported anxiety report (SHAI form) and provide recent admission information
215142837|NCT06593795|PROCEDURE|ultrasound|"before ECV procedure, an ultrasound will be performed to evaluate~* fetal biometry (BPD, HC, AC, FL, EFW);~* Occiput position (right, left);~* Back position (anterior, posterior, right, left);~* Breech variant (footling, frank, complete);~* Fetal leg posture (extended, flexed)~* Placental localization;~* Amniotic Fluid Index (AFI);~* Fore-bag of amniotic fluid;~* Eventual presence of nuchal cords;~* Fetal head ballottement (yes, no);~* Occiput-spine angle These parameters will be compared to find predictive factors for successful ECV"
215142838|NCT06992856|PROCEDURE|Conventional colonoscope passage|Use conventional colonoscope passage through the sigmoid colon
215142839|NCT06992856|PROCEDURE|left colon water exchange colonoscope passage|Use left colon water exchange colonoscope passage through the sigmoid colon
215142840|NCT06992856|PROCEDURE|cap-assisted left colon water exchange colonoscope passage|Use cap-assisted left colon water exchange colonoscope passage through sigmoid colon
215142841|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|Sham tPCS current will be delivered through Channel 1, while active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via surface electrodes. The placement of electrodes will be exactly the same as the active tPCS montage.
215142842|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|This group will receive active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via 6\*9cm Silica gel electrodes on top of the tPCS that is delivered through Channel 1. The placement of the electrodes will be on the part of the spinal segment innervating the lower limbs (L1-L5), the adductor muscles and the gastrocnemius muscles.
214455548|NCT05980806|DRUG|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
214455549|NCT05980806|DRUG|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
214455550|NCT05980806|DRUG|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
214455551|NCT05980806|DRUG|Momelotinib|Participants will receive momelotinib 200 mg once daily.
214455552|NCT05226598|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
214455553|NCT05226598|DRUG|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
214455554|NCT05226598|DRUG|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
214455555|NCT05226598|DRUG|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
214455556|NCT05226598|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
214455557|NCT05226598|DRUG|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
214455558|NCT05226598|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
214528039|NCT07009041|DIAGNOSTIC_TEST|Knee Valgus tests|It was conducted to determine the right and left knee valgus values of the participants.Three different measurements were taken at three different times. (Before starting, end of week 4 and after completion of week 8).
215142843|NCT06998160|OTHER|glycine subgingival sandblasting group and erythritol subgingival sandblasting group|Given glycine subgingival sandblasting group glycine subgingival sandblasting group. Swiss EMS ultrasonic therapy instrument and EMS glycine sandblasting were used. Before the operation, both parties should wear safety glasses and place the mouth opener after the patient gargled. The location of sandblasting was selected to be 1-2 mm below the gingiva. During the operation, the time of sandblasting in the planting area should be controlled within 10 minutes, and then the time of sandblasting at other sites with the same amount of water and power should be controlled within 5s. After sandblasting, the patient's mouth was continuously rinsed with normal saline for 20s. After the operation, the patient was informed of the precautions after the operation, and the patient was instructed to master the correct oral maintenance method, pay attention to maintaining the cleanliness around the implant, and adhere to regular periodontal maintenance.
215142844|NCT06998160|OTHER|control group|The control group was given ultrasonic subgingival curettage. With Swiss EMS ultrasonic therapy instrument, both the operator and the patient should wear safety goggles before operation. After the operator guides the patient to gargle, the mouth opener should be placed to perform ultrasonic subgingival curetting. The debridement time of the implant area should be controlled within 6 minutes, and the debridement time of other sites should be 5 s.
215142845|NCT06998173|DRUG|DAT-1604 tablet|DAT-1604, a potent and selective oral small molecule inhibitor of DNA Polymerase θ (Pol θ).
215142846|NCT06998901|OTHER|FIFA 11+ Kids training program|Participants in this arm will receive the FIFA 11+ Kids training program in addition to their regular basketball practice. The program consists of structured neuromuscular warm-up exercises designed to improve balance, coordination, strength, and overall movement control. It will be implemented over a period of 7 weeks, with sessions conducted four times per week, each lasting approximately 15-20 minutes. The exercises are age-appropriate and follow a progressive format to enhance athletic performance and reduce injury risk in youth athletes.
215142847|NCT06999889|DIAGNOSTIC_TEST|Recording of Periodontal Parameters.|Periodontal Parameters recording in terms of various indices,measurements and radiographs.
215142848|NCT06998589|OTHER|DPL|The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments..The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.
215142849|NCT06998004|BIOLOGICAL|AVX70120 low dose level|Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
215142850|NCT06998004|BIOLOGICAL|AVX70120 middle dose level|Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
215142851|NCT06998004|BIOLOGICAL|AVX70120 high dose level|High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
215142852|NCT06998004|BIOLOGICAL|AVX70481 low dose level|Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
215142853|NCT06998004|BIOLOGICAL|AVX70481 middle dose level|Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
215142854|NCT06998004|BIOLOGICAL|AVX70481 high dose level|High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
215142855|NCT06998004|OTHER|Placebo|Placebo
215142856|NCT06998940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215142857|NCT06998940|PROCEDURE|Computed Tomography|Undergo CT scan
215142858|NCT06998940|DRUG|Fluorouracil|Given IV
215142859|NCT06998940|DRUG|Gemcitabine|Given IV
215142860|NCT06998940|DRUG|Irinotecan|Given IV
214455559|NCT05845918|BEHAVIORAL|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
214455560|NCT05571878|DRUG|Humalog|All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
214455561|NCT05571878|DRUG|Saline nasal spray|All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
214455562|NCT04166773|DRUG|Tirzepatide|Administered SC
214455563|NCT04166773|DRUG|Placebo|Administered SC
214455564|NCT05038332|RADIATION|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
214455565|NCT05038332|RADIATION|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
214455566|NCT06511752|BEHAVIORAL|Psychosocial educational, support group and implementation of strategies|Psychosocial educational, support group and implementation of strategies
214455567|NCT01544803|BEHAVIORAL|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
214528040|NCT02160548|DRUG|Standard care|Standard management for OP poisoning
214455568|NCT01544803|BEHAVIORAL|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
214455569|NCT04175847|DRUG|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
214528041|NCT02160548|DRUG|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
214528042|NCT02160548|DRUG|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
215142861|NCT06998940|DRUG|Irinotecan Sucrosofate|Given IV
215142862|NCT06998940|DRUG|Leucovorin|Given IV
215142863|NCT06998940|DRUG|Nab-paclitaxel|Given IV
215142864|NCT06998940|BIOLOGICAL|Panitumumab|Given IV
215142865|NCT06998940|OTHER|Questionnaire Administration|Ancillary studies
215142866|NCT06999369|OTHER|MedChef App|Once patients have been randomized to the MedChefs arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use.
215142867|NCT06999369|OTHER|MedChefs and Instacart food voucher|Once patients have been randomized to the MedChefs arm and voucher arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use and use of Instacart food vouchers. Patients will also be given a $100 voucher to buy food recommended by the app. Vouchers will be provided once a month for the 6 months of the study
215142868|NCT06999070|DRUG|Dexamethasone 0.1mg/kg|On incidence of Shivering after spinal anaethesia
215142869|NCT06999070|DRUG|Dexamethasone 0.3mg/kg|On incidence of Shivering after spinal anaethesia
215142870|NCT06998316|OTHER|Screening questionnaire|Every patient will answer the 2 screening questionnaires given to them, once at baseline and a second time after 1 month.
215142871|NCT06999967|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|All study subjects will undergo monitoring via a portable electroencephalogram (pEEG), the CGX EEG system (a Research-grade 2-Channel EEG device) to measure the brainwaves of patients admitted to Stanford Medical Center. Investigators will then use the Lucidify software to allow for the interpretation of obtained brainwaves for the detection of delirium .
215142872|NCT06999343|DRUG|Metformin 850Mg Tab|Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.
215142873|NCT06999343|OTHER|Placebo|Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.
215142874|NCT06999551|DRUG|switch NPH to glargin|Switch of patients with type 2 diabetes mellitus from NPH insulin to insulin glargine
215142875|NCT06998121|OTHER|Intrarectal ıce application|Patients included in the study group will receive intrarectal ice application by researchers (E.K.D. and M.B.) in addition to the outpatient clinic's routine treatment and care practices. For each patient, a new glove (size 8) will be filled with water and frozen to obtain the cold application material. Immediately before the procedure, the lubricated ice will be inserted into the patient's rectum and held in place for 5 minutes (Caliskan and Mutlu, 2015).
215142876|NCT05491811|DRUG|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
215142877|NCT05491811|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
215142878|NCT05270759|DIAGNOSTIC_TEST|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
215142879|NCT05270759|DIAGNOSTIC_TEST|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
215142880|NCT04167657|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab."
215142881|NCT06999031|BIOLOGICAL|BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell|Chimeric Antigen Receptor Autologous T-cell
215142882|NCT06541574|DRUG|Methotrexate Injection|Methotrexate injection
215142883|NCT06541574|DRUG|Methotrexate Infusion|Methotrexate Infusion
214455570|NCT06282887|OTHER|Music therapy|The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
214455571|NCT02524717|DRUG|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
214455572|NCT05759013|DEVICE|Breath synchronized abdominal FES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
215142884|NCT06541574|DRUG|Sham Injection|Sham Injection
215142885|NCT06597864|BEHAVIORAL|Seven-step phenomenological psychotherapy for self-disorders|Phenomenological exploration of anomalous self-experiences, meaning attributions and behavioral consequences. Psychoeducation. Dialogical approach focusing on self-narratives, searching for new meaning and understanding of self-disorders
215142886|NCT06600230|OTHER|Education and exercise|Training including information on pelvic floor and dysmenorrhea and exercise practices were given both theoretically and practically by physiotherapists.
214455573|NCT05759013|DEVICE|Sham breath synchronized abdominal FES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
214455574|NCT06483503|DEVICE|EFOV Colonoscope|Routine colonoscopy using the EFOV lens in the colonoscope.
214455575|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
214455576|NCT04423029|DRUG|DF6002|Specified dose on specified days
214455577|NCT04423029|DRUG|Nivolumab|Specified dose on specified days
214528043|NCT07004465|DIETARY_SUPPLEMENT|cyanocobalamin|Group A will be given vitamin B12 tablets (1000 mcg) once daily.
214528044|NCT07004465|DEVICE|triamcinolone acetonide|Group B will be given Kenalog gel (triamcinolone acetonide 40 mg/ml). The other ingredients are benzyl alcohol, polysorbate 80, carmellose sodium, sodium chloride and water, by covering the area twice daily
214528045|NCT07008274|PROCEDURE|surgery|laparoscopic sleeve gastrectomy
214528046|NCT07008430|OTHER|No Intervention: Observational Cohort|There will be no intervention. Only archival data will be analyzed
214708646|NCT03086681|DRUG|DDP|DDP: 40mg /m2，per week, for 5 cycles
215142887|NCT06600230|OTHER|Self-method like resting or heat|Classical self-methods such as rest and heat application were applied.
215142888|NCT06593535|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 4 days (7 capsules per day)
215142889|NCT06593535|OTHER|Astaxanthin (AST trial)|The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
215142890|NCT06867380|DEVICE|Investigational sound coding strategy|SPARC (Stimulation Place and Rate Coding) sound coding strategies
215142891|NCT06867380|DEVICE|Cochlear default sound coding strategy|ACE (Advanced Combination Encoder) sound coding strategy
215142892|NCT04276870|BIOLOGICAL|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
215142893|NCT06601582|DEVICE|Use of a operative blood salvage system|The surgical team will use a operative blood salvage system
215142894|NCT06595537|DEVICE|Hand held ultrasound|Determination of gastric feeding tube position with the use of Lumify handheld ultrasound
215142895|NCT06603714|OTHER|Instrument assisted soft tissue mobilization|We will perform instrument assisted soft tissue mobilization on calf muscles. The intervention will last 9 min. For the first minute of treatment light pressure will be applied for tissue preparation. Afterwards, four different strokes will be applied by maintaining the tool at a 30° of inclination for one minute. This will be repeated for a second set, with a tool inclination of 45°.
214455578|NCT05602571|OTHER|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
214455579|NCT05602571|PROCEDURE|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
214455580|NCT05602571|PROCEDURE|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
214528047|NCT07008131|DEVICE|Double J stent|Extravesical ureteroneocystostomy with double J-catheter placement
214528048|NCT07008131|PROCEDURE|No Double J stent|Extravesical ureteroneocystostomy with no Double J stent colocation
214528049|NCT07009262|OTHER|Inapplicable|Inapplicable
214528050|NCT06701149|DRUG|Rademikibart injection|300 mg administered subcutaneously on the first day
214528051|NCT06701149|DRUG|CBP-201 injection|300 mg administered subcutaneously on the first day
214528052|NCT06721923|DIETARY_SUPPLEMENT|Dietary protein|Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
214528053|NCT06721273|DIETARY_SUPPLEMENT|Iodine|In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
214528054|NCT06721273|DIETARY_SUPPLEMENT|Placebo|Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
214528055|NCT06720766|DIAGNOSTIC_TEST|FibbroScan and biopsy|In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.
214528056|NCT06720792|OTHER|EscapeCovid|Online Escape Game with 4 players and a game guide. The players, in a group, must solve enigmas to win.
214528057|NCT06721286|DRUG|Teripalimab|240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
214528058|NCT06721286|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
214528059|NCT06721286|PROCEDURE|Surgery|Radical resection
214528060|NCT06720753|BEHAVIORAL|Opposite to emotion action|Participants will be taught the opposite action skill from Dialectical Behavior Therapy
214528061|NCT06720753|BEHAVIORAL|GIVE|Participants will be taught the GIVE skill from Dialectical Behavior Therapy
215142896|NCT04272086|DRUG|Bupivacaine|0.25%
215142897|NCT04272086|DRUG|Bupivacaine liposome|10mL
215142898|NCT04272086|DRUG|normal saline|10ml
215142899|NCT06690359|COMBINATION_PRODUCT|IM19 chimeric antigen receptor T cell injection|"IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose"
215142900|NCT06617897|BIOLOGICAL|CSL511 Fibrinogen concentrate (human)|CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
215142901|NCT06617897|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate will be administered via IV infusion.
215142902|NCT05229887|PROCEDURE|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
215142903|NCT05229887|PROCEDURE|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
215142904|NCT06586697|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
215142905|NCT06596057|BIOLOGICAL|CAR-T/CAR-NK cells|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion
215142906|NCT05030597|DRUG|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
215142907|NCT05030597|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
215142908|NCT05030597|DIAGNOSTIC_TEST|Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.|"This observational study evaluates the application of paired FDG and FAPI PET/CT in oral cancer.~1. Baseline phase: All participants undergo baseline FDG and FAPI PET/CT scans.~2. Post-neoadjuvant phase: For patients with resectable locally advanced disease receiving neoadjuvant therapy (as per clinician decision), a second FAPI PET/CT scan is performed after 2 cycles of treatment to assess treatment response.~3. Purpose: To explore the utility of FAPI PET in (a) initial staging, (b) treatment response evaluation, and (c) prognostic value in oral cancer."
215142909|NCT04935372|OTHER|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
215142910|NCT06599775|DRUG|Adebrelimab injection|Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
215142911|NCT06599775|DRUG|Albumin-Bound Paclitaxel|Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
215142912|NCT06599775|DRUG|Carboplatin injection|Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
215142913|NCT01899040|DEVICE|neuromodulation for episodic migraine headache|
215142914|NCT03712358|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO.
215142915|NCT06695130|BIOLOGICAL|RIV (recombinant influenza vaccine)|Influenza, inactivated, split virus or surface antigen
215142916|NCT06695130|BIOLOGICAL|rC19 (dose 1)|Protein subunit
214528062|NCT06720194|DEVICE|Virtual therapy|Virtual therapy has been applied for four weeks, three times a week. We administered a total of twelve sessions with a duration of 30 minutes each. Prior to virtual therapy experimental group have received kinesitherapy for 15 minutes to improve and prevent muscle spasticity and joint contractures. Therapists recorded the order of the session and they have providen the same external aid to all patients. Two days a week the experimental group have received the conventional treatment for 45 minutes (kinesitherapy, strengthening exercises muscle, trunk control, transfers, standing and walking). In addition to physiotherapy treatment, participants have done occupational therapy 5 days a week (training to perform ADLs, tracking techniques and search, manipulation, reach and grasping of different utensils, etc.), for 30 minutes each session.
214695117|NCT06777654|OTHER|Mirror therapy (MT)|The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.
215142917|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 1)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
215142918|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 2)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
215142919|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 3)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
215142920|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 4)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
215142921|NCT06695130|OTHER|Placebo (0.9% NaCl)|Normal saline
215142922|NCT06630598|BEHAVIORAL|Online Family Violence Education Resource|"The VEGA Family Violence Education Resources (© 2020 VEGA Project, McMaster University) is an on-line suite of educational resources that target professionals who are likely to encounter survivors of family violence in professional and clinical settings. The resources provide information about family violence, appropriate clinical responses, legal obligations, and more. The resources are broken down into several training modules and include three interactive learning scenarios. The training modules include:~Know About Family Violence in Canada Creating Safety Recognizing and Responding Safely to Child Maltreatment Recognizing and Responding Safely to Intimate Partner Violence Voices of those with Lived Experiences of Family Violence"
214455581|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
214455582|NCT04063267|OTHER|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
214455583|NCT04063267|OTHER|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
214455584|NCT03695276|BEHAVIORAL|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
214455585|NCT03695276|BEHAVIORAL|Usual care|The standard of care, which usually means management within primary care.
214455586|NCT06475222|OTHER|Study 1: Facial serum with alpha albutin|Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
214455587|NCT06475222|OTHER|Study 1: Facial serum with Tubtim Chumpae rice extract|Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
214455588|NCT06475222|OTHER|Study 2: Facial mask with Hom Pathum rice extract|Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
214455589|NCT06475222|OTHER|Study 3: Control jelly|Consumption with control jelly as active comparator at 3.5 g/kg body weight.
214455590|NCT06475222|OTHER|Study 3: Jelly with Tubtim Chumpae rice|Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
214455591|NCT06475222|OTHER|Study 3: Jelly with Hom Pathum rice|Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
214455592|NCT05182242|OTHER|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
214455593|NCT05182242|BIOLOGICAL|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
214455594|NCT05182242|OTHER|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
214455595|NCT05182242|OTHER|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
214455596|NCT05182242|OTHER|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
214455597|NCT06382727|OTHER|EN will be continued up to extubation (EN will not be withheld prior to extubation)|As per the arm/group descriptions.
214455598|NCT04474353|DEVICE|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
214455599|NCT04474353|DRUG|Gadolinium|Gadolinium contrast medium
214455600|NCT04474353|DRUG|Temozolomide|Chemotherapy agent
214455601|NCT04474353|RADIATION|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
214455602|NCT05345327|DRUG|Dapagliflozin|SGLT2 inhibitor
214455603|NCT05345327|DRUG|Metformin|Metformin
214455604|NCT06127225|DRUG|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
214455605|NCT06127225|DRUG|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
214455606|NCT03964727|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214455607|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
214528063|NCT06720194|OTHER|Usual treatment|Patients assigned to the control group have received the conventional treatment five days a week. They have done physiotherapy session and occupational therapy for 45 and 30 minutes a day each one.
215142923|NCT06448117|BEHAVIORAL|Mind Nutrition|"The 6-month nutrition intervention includes two individual and three group dietary counseling sessions. During the first individual meeting, a research dietitian will assess the participants' diet quality and eating habits, and each participant will set personal goals in cooperation with the research dietitian. At the second individual meeting, the attainment of the goals will be evaluated, and potential challenges and solutions discussed. Each group session has its theme and content in the following chronological order:~1. Introduction to the theme and importance of a regular meal frequency~2. Principals of health-promoting diet, mindful eating~3. Successful eating regulation skills, psychology of the long-term lifestyle changes.~Additionally, participants receive home assignments and a workbook containing informational material and exercises."
215142924|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
215142925|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
215142926|NCT05884645|PROCEDURE|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
215142927|NCT03600233|DRUG|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
215142928|NCT06701864|DIAGNOSTIC_TEST|Palpation|Identification of the cricothyroid membrane using PALPATION, a procedure used to prepare for front of neck airway access
215142929|NCT06701864|DIAGNOSTIC_TEST|Ultrasound|"Identification of the cricothyroid membrane, using ULTRASONOGRAPHY with either the String of pearls or TACA aproach as chosen by the participant , a procedure used to prepare for front of neck airway access"
215142930|NCT06632639|OTHER|Corrective exercise protocol|The program requires 60 minutes consisting of a ten-minute warm-up, a forty-minute Thera-band exercise, and a ten-minute cool-down. Thera-band exercises are to improve the external rotators, and the extensors and for strengthening the quadriceps and the gluteus. A set consists of 15 reps, each of the exercise methods consisted of three sets.
215142931|NCT06632639|OTHER|Lateral wedged insoles with subtalar strapping|A silicon rubber 10 mm lateral wedge has a 10 mm lateral elevation and a 75 mm width, which has an approximately 7.6 inclination. This silicon rubber material is usually used for cosmetic remodeling and has a natural form-fit to the skin. The 75 mm width silicon rubber is scaphoid shaped and it is suitable for attachment to a barefoot of all of the subjects. The rational for using this inclination is that 7.6 is approximately the median between 5 and 10. Patients will be instructed to use the wedge in an appropriate shoe (not high heels or narrow-toed shoes), 1 h a day during the first week. The duration of use gradually will be increased to the minimum of 8 h a day.
215142932|NCT05801120|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
214455608|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
214455609|NCT04259632|BEHAVIORAL|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
214455610|NCT04259632|BEHAVIORAL|Caloric Restriction (CR)|15% daily caloric deficient
214455611|NCT05305235|DEVICE|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
214455612|NCT05305235|DEVICE|Relaxation Control|Guides users through relaxation techniques.
214455613|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
214455614|NCT05868213|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
214455615|NCT06451809|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
214455616|NCT05697393|DEVICE|Shaker Pressure Band|
214455617|NCT05885360|DRUG|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
214528064|NCT06721832|PROCEDURE|Erector spina plane block (ESP)|"The block will be performed in prone position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) T1 transverse process will be approached with an 18 G Tuohy's needle in caudal-to-cranial direction. A total of 30 ml of 0.25% bupivacaine with 150 μg of clonidine and 8 mg dexamethasone was administered deep to erector spinae muscle (ESM) bilaterally."
214528065|NCT06720233|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
214695118|NCT06777654|OTHER|Dose-matched control intervention|Participants in the control group will receive therapist-mediated rehabilitation per session.
214695119|NCT06753383|OTHER|To the Virtual Reality Based Exercise|After posterior fusion surgery, a rehabilitation program will be applied to individuals with AIS using Kinect Sports Ultimate for 30 minutes per day for a total of 6 weeks, 2 days a week.
214455618|NCT04257097|DEVICE|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
215142933|NCT06700304|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
215142934|NCT06700304|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
215142935|NCT06700668|DEVICE|MIT Powered Knee|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
215142936|NCT06700473|OTHER|reiki|Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with a seventh VAS measurement and administration of the EC-4. The EC-4 will also be reassessed by the researchers online at six weeks postpartum
215142937|NCT06702072|DEVICE|Endobronchial valve treatment|Endobronchial valve treatment
215142938|NCT06879626|OTHER|Pecan|2 oz of whole raw pecans
215142939|NCT06879626|OTHER|Pretzel|3.5 oz of pretzel snacks daily
215142940|NCT06705569|DRUG|Tafamidis 61 mg free acid tablet (Test)|Tafamidis 61 mg free acid tablet (Test)
215142941|NCT06705569|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
215142942|NCT06706115|OTHER|Intranasal human breast milk|"The information in the Physiologic Parameter Follow-up Form will be recorded by the investigator just 5 minutes before the intervention. The researcher will drip 0.2 ml of breast milk at room temperature (approximately 22 °C) into the nose of the infant lying in the supine position, 0.1 ml in the right nose-0.1 ml in the left nose. 5 minutes after the intervention (T1), 15 minutes after the intervention (T2) and 30 minutes after the intervention (T3), the data in the Physiologic Parameter Follow-up Form will be recorded by the researcher. After intranasal breast milk administration, the baby will be fed by the neonatal nurse as in routine practice. The implementation of the intervention in the study will last for three days and this process will be repeated three times every day (09.00, 12.00 and 15.00)."
215142943|NCT06706297|OTHER|pranayama breathing exercise|Normal breathing, focusing on breathing, Alternative Nose Breathing, Cooling Breath, Bee Buzzing Sound, A breathing exercise of 20 minutes in total, consisting of 5 stages: normal breathing and focusing on breathing.
215142944|NCT06704893|DRUG|ASA injection 40 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
215142945|NCT06704893|DRUG|ASA injection 20 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
215142946|NCT06704893|DRUG|HA injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
215142947|NCT06704893|DRUG|Normal saline injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
215142948|NCT06706583|BEHAVIORAL|Telematic educational interviews + standard training|"Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview.~In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA)."
215142949|NCT06706583|BEHAVIORAL|Standard training|Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).
215142950|NCT06706193|PROCEDURE|Total hip arthroplasty using CPE|
215142951|NCT06706193|PROCEDURE|Total hip arthroplasty using HXLPE|
214455619|NCT04257097|DEVICE|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
214455620|NCT04256954|BEHAVIORAL|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
214455621|NCT04956432|DRUG|SHR4640|SHR4640 Dose 1 ,tablets, QD
214455622|NCT04956432|DRUG|Allopurinol|Allopurinol 300mg, tablets, QD
214455623|NCT05632575|BEHAVIORAL|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
214455624|NCT05901519|DRUG|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
215142952|NCT06880341|OTHER|Standard of Care|Standard of care treatment of Transient Neurologic Events (TNEs) as needed
215142953|NCT06706050|BIOLOGICAL|Microbiome Therapeutic LP-51|Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis
215142954|NCT06706050|OTHER|placebo cream (M23004-03)|placebo cream (M23004-03) was applied on the participants
214528066|NCT06721858|OTHER|Emotion Focused Therapy application|Participants in the intervention group will first be given face-to-face individual interviews to establish the therapeutic environment and relationship (Individual interviews are designed as orientation, diagnosis and planning stages, 30-minute interviews). Then, three intervention stages (40-minute, group therapy) will be applied and the last session will be both intervention (post-test application) and termination stage (completion of emotion-focused therapy application). After the individual interviews, individuals will be included in 3 intervention sessions as group training. It is planned that each group will have at least 4 and at most 6 people. If the specified number cannot be reached, the study will continue until the specified number is reached.
214528067|NCT06721858|OTHER|scale form|Emotion-focused therapy contributes to the treatment compliance and functionality of psychiatric patients.
214528068|NCT06721377|PROCEDURE|Novaloc attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region \& will be loaded by Novaloc attachment.
215142955|NCT06705335|OTHER|Blood sample|On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
215142956|NCT06704490|OTHER|Cesarean section|Observational study without intervention
215142957|NCT06705803|PROCEDURE|Prostate Ablation|Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
215142958|NCT06704828|DRUG|SHR-4602|SHR-4602
215142959|NCT06704854|DIAGNOSTIC_TEST|Screening Platform|assessment of low-frequency fatigue using myocene
215142960|NCT06705036|OTHER|surgery|Samples were obtained from patients by surgical excision and matched into groups
215142961|NCT06704659|RADIATION|Breast conserving surgey and radiotherapy|The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
215142962|NCT06704659|PROCEDURE|Mastectomy|The patients will undergo mastectomy
215142963|NCT06704750|BEHAVIORAL|6-minute walk test|patients were instructed to walk back and forth in a marked 30-meter-long straight corridor as fast as they could tolerate
215142964|NCT06705179|BEHAVIORAL|Behavioral task performance|Measures of performance on behavioral tasks
215142965|NCT06917742|DRUG|CPTX2309|Single Escalating Dose of CPTX2309. CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
215142966|NCT06917742|DRUG|CPTX2309|Multiple Escalating Dose of CPTX2309.CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
215142967|NCT06736340|DRUG|Rupatadine|10mg tablets
214455625|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
214695120|NCT06753383|OTHER|Routine physiotherapy and rehabilitation program|14 patients with posterior fusion AIS routinely in the postoperative clinic for 6 weeks. the physiotherapy program used will be applied.
215142968|NCT03204188|DRUG|Ibrutinib|Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
215142969|NCT03204188|DRUG|Fludarabine|Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.
215142970|NCT03204188|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
215142971|NCT06924697|DRUG|Application of GLP-1RAs drugs|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs
215142972|NCT06924697|DRUG|DPP-4i group|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.
215142973|NCT06944106|DRUG|AK112|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with gemcitabine and nab-paclitaxel
215142974|NCT02103387|BEHAVIORAL|Cognitive Behavioral Training|Cognitive Behavioral Training \[CBT\] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
215142975|NCT02103387|BEHAVIORAL|Relaxation Training|Relaxation Training \[RT\] (muscle relaxation, deep breathing, guided imagery, meditation)
214455626|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
214455627|NCT06178354|OTHER|Survey Administration|Ancillary studies
214455628|NCT05342480|OTHER|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
214695121|NCT06898892|DIAGNOSTIC_TEST|Fetal MRI|all participant will undergo MRI fetal weight estimation
214695122|NCT06754982|OTHER|Myofascial release|Nine myofascial release techniques will be applied to each group: Transverse hamstring play; Transverse hamstring and adductor magnus play: posterior to anterior pressure; Transverse gastrocnemius-soleus play; Tibia bone clearing: posterior tibia; Tibia bone clearing: prone grip with half chisel; Lateral fascial distraction of the tibia; Lateral elongation of the peroneal tissue; Cross-friction of the gastrocnemius-soleus musculotendinous junction; Manipulation of the plantar fascia.
214708647|NCT04796025|DRUG|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
215142976|NCT02103387|BEHAVIORAL|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
215142977|NCT00821548|PROCEDURE|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
215142978|NCT03939689|DRUG|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
215142979|NCT03939689|DRUG|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
214708648|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
215142980|NCT05777499|BEHAVIORAL|Music Therapy|Music Therapy will comprise individual and group sessions 20-45 minutes. Participants usually have 1-2 individual sessions, and 1 group session/week. Group sessions include 2-6 participants. On average, participants receive an average 1 hour 30 minutes Music Therapy/week, timetabled when they would not otherwise be undergoing any therapy sessions. The Music Therapist will use the Nordoff Robbins approach and work flexibly as a musician. Techniques include (but are not limited to) empathic listening, musically matching, turn taking and sequencing, call and response. Sessions may also involve songwriting, singing familiar songs, listening to, sharing and discussing music, developing specific musical skills of interest to the participant, structured musical games and activities, joint working with other members of the therapy team in sessions focused on functional development and communication skills.
215142981|NCT05777499|BEHAVIORAL|Control Therapy|Control Therapy sessions will be carried out by a member of the clinical team, matched in duration and number to Music Therapy sessions as closely as possible. Participants will usually have 1-2 individual sessions and 1 group session/week. Group sessions include 2-6 participants. The Control Therapy intervention will continue throughout participant's rehabilitation program until participants have completed a total of 15 hours intervention, which will usually take 10 weeks to complete. The content of sessions is designed to reflect 'usual care' however control therapy sessions will not include access to specific specialist equipment such as MOTOmed, therabike or neuro-muscular electrical stimulation, to ensure the control group does not get additional specialist intervention beyond usual care. Content of control therapy sessions will therefore be restricted to the following five domains: gaming, education, mindfulness, current affairs discussions, and passive and dynamic stretching.
215142982|NCT04089995|OTHER|data collection|No intervention
214455629|NCT05765214|BEHAVIORAL|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
214455630|NCT05623007|DIETARY_SUPPLEMENT|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
214455631|NCT05623007|BEHAVIORAL|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
214455632|NCT05623007|DIETARY_SUPPLEMENT|Placebo probiotics|Maltodextrin
214455633|NCT06499740|BEHAVIORAL|Adapted SAFETY-A for PC|This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
214455634|NCT06499740|BEHAVIORAL|Treatment as Usual|Treatment as usual delivered in participating clinics.
214455635|NCT02378805|DRUG|ACE-inhibitor|observational study
214455636|NCT02378805|DRUG|Angiotensin-receptor blocker (ARB)|observational study
214455637|NCT02378805|DRUG|HMG-Coenzyme inhibitor (statin)|observational study
214455638|NCT02378805|DRUG|Spironolactone or Finerenone|observational study
214455639|NCT02378805|DRUG|Paricalcitol|observational study!
214455640|NCT02378805|DRUG|SGLT2 inhibitor|observational study
214455641|NCT06488313|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
214455642|NCT05856591|BEHAVIORAL|Food Resources & Kitchen Skills (FoRKS)|Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
214455643|NCT05856591|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
214455644|NCT04322370|PROCEDURE|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
214455645|NCT04322370|DEVICE|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
214455646|NCT03195699|DRUG|TTI-101|Oral capsule
214455647|NCT03195699|DRUG|TTI-101|Oral tablet
214455648|NCT02984852|DRUG|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
214455649|NCT02984852|DRUG|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
214455650|NCT02984852|DRUG|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
214455651|NCT02984852|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
214455652|NCT06206343|OTHER|TENS application, Tele-rehabilitation treatment program|Exercise training
214528069|NCT06721377|PROCEDURE|Equator attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region\& will be loaded by Equator attachment.
214528070|NCT06723587|OTHER|Instep weights use|"Players will perform their scheduled training sessions while wearing a 150-gram instep weight. The use of instep weights in the intervention group will be introduced progressively and gradually, increasing both the frequency of sessions and the duration of their use.~During weeks 1-2, instep weights will be used in one training session per week. During weeks 3-5, will be used in two training sessions per week.~And during weeks 6-8, will be used in three training sessions per week.~The duration of instep weight usage within each session will increase by 5% weekly, starting at 40% in Week 1 and reaching 75% by Week 8."
215142983|NCT05809375|OTHER|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
215142984|NCT06165289|OTHER|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
215142985|NCT01323101|DRUG|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
215142986|NCT01323101|OTHER|No doxycycline|
215142987|NCT02922322|OTHER|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
215142988|NCT01466712|DRUG|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
215142989|NCT01466712|DRUG|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
215142990|NCT00393731|DRUG|Misoprostol|
215142991|NCT00393731|DRUG|oxytocin|
215142992|NCT04402034|BEHAVIORAL|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
215142993|NCT00188344|PROCEDURE|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
215142994|NCT00188344|PROCEDURE|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
215142995|NCT03515668|DRUG|Ritalin 20 mg Tablet|Single dose for all participants
215142996|NCT03515668|DRUG|Placebo Oral Tablet|Placebo with same appearance/taste
215142997|NCT04216056|BEHAVIORAL|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
214528071|NCT06717113|DRUG|18F-FDG|Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
214708649|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
214708650|NCT05157711|DRUG|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
214708651|NCT05157711|DRUG|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
214528072|NCT06717113|DRUG|68Ga-BC1|The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
214528073|NCT06711458|BEHAVIORAL|AI-Generated Discharge Instructions|Patient-friendly hospital discharge instructions generated by GPT-4, an advanced natural language processing model.
214528074|NCT06711458|BEHAVIORAL|Standard of Care Discharge Instructions|Standard hospital discharge instructions.
214528075|NCT06719557|DRUG|MK-1084|Oral Tablet
214528076|NCT06719557|DRUG|Itraconazole|Oral solution
214528077|NCT06719557|DRUG|Phenytoin|Oral capsule (extended)
214528078|NCT06721182|DEVICE|REBOA|endovascular balloon occlusion of the aorta
214528079|NCT06721104|OTHER|Dual Task|"The dual-task abilities of individuals will be assessed by adding motor and cognitive tasks to the 10-Meter Walk Test. The tasks given to participants are as follows:~Single Motor Task (comfortable walking): The individual is asked to walk at a normal pace, and the time is recorded.~Motor-Motor Dual Task: The individual carries a half-filled water bottle in each hand while walking, and the time is recorded.~Motor-Cognitive Dual Task (mental): The individual counts backward from 10 in increments of one while walking, and the time is recorded.~Motor-Cognitive Dual Task (memory): The individual is asked to recall three previously mentioned words while walking, and the time is recorded."
214528080|NCT06721104|OTHER|Functional Balance|"Functional balance will be assessed using the Timed Up and Go (TUG) test. The TUG test measures the time it takes for an individual to stand up from a chair upon the ready, go signal, walk a distance of 3 meters, turn around, walk back to the chair, and sit down again. The TUG test is a reliable and sensitive measure of balance and functional mobility in children.~At the beginning of the test, participants will be seated on an armless chair with their hips and knees flexed at approximately 90 degrees and their feet flat on the ground. The children will be instructed to stand up from the chair, walk as quickly as possible, touch a target on the wall, walk back, and sit down again."
214528081|NCT06721104|OTHER|Social Adaptation Assessment|Adaptive behavior will be evaluated using the Vineland Adaptive Behavior Scales. This is a parent interview designed to assess functionality in daily life. Specifically, adaptive behavior is evaluated in four domains: Communication, Daily Living Skills, Socialization, and Motor Skills. The Vineland scales are known for their reliability and up-to-date validity. They have been reported to be sensitive to the challenges faced by children with Autism Spectrum Disorder (ASD).
214528082|NCT06721104|OTHER|Cervical Posture Assessment:|"Cervical posture will be evaluated using the Android-based PostureScreen Mobile application (version 8.5, developed by Posture Co. Inc., USA). This application assesses the static posture of individuals. After determining reference points, the application draws reference lines and records postural deviations. At least two photos of each participant will be taken for the assessment. Participants should not wear clothing items that cover the neck (e.g., scarves, shawls).~While the primary focus of the application is to assess postural deviations, it also includes a dental evaluation feature. The validity and reliability of the application have been established in previous studies. In addition to using the application, the posture of individuals will also be evaluated through observational analysis, and the findings will be documented."
214708652|NCT05157711|DRUG|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
215142998|NCT05497999|OTHER|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
215142999|NCT05497999|OTHER|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
215143000|NCT00663182|DRUG|Entecavir|Entecavir 0.5 mg/d
215143001|NCT04350762|DIETARY_SUPPLEMENT|Protein shake + Fish Oil|2 shakes of protein as well as 1 fish oil daily.
215143002|NCT02268357|DRUG|Propranolol|Oral propranolol capsules
215143003|NCT00999778|BEHAVIORAL|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
215143004|NCT00999778|BEHAVIORAL|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
214708653|NCT04104061|OTHER|iron profile|blood test
214708654|NCT02843178|BEHAVIORAL|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
215143005|NCT04743778|BEHAVIORAL|Virtual Diabetes Self-Management Education and Support|Diabetes self-management education and support delivered through Zoom for health.
215143006|NCT01896219|DEVICE|Navigation station (IMACTIS-CT®)|
215143007|NCT01896219|DEVICE|CT|Reference method for gestures (carried out under CT) guidance
215143008|NCT04841083|DEVICE|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
215143009|NCT04988581|OTHER|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
215143010|NCT00588497|PROCEDURE|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
215143011|NCT00588497|RADIATION|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
215143012|NCT00588497|PROCEDURE|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
215143013|NCT00588497|RADIATION|Hysterosalpingogram|Performed 3 months after micro-inserts placement
215143014|NCT04875143|DIETARY_SUPPLEMENT|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
215143015|NCT00231738|DRUG|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
215143016|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
215143017|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
215143018|NCT06079814|OTHER|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
215143019|NCT03162263|DEVICE|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
215143020|NCT04299607|DIAGNOSTIC_TEST|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
215143021|NCT05205122|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
215143022|NCT05743491|OTHER|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
215143023|NCT05743491|BEHAVIORAL|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
215143024|NCT01926457|OTHER|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
215143025|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
215143026|NCT03980080|DRUG|Placebo|Vehicle study drug
215143027|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
214708655|NCT01002898|DRUG|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
214708656|NCT03271060|PROCEDURE|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
214708657|NCT03271060|PROCEDURE|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
214708658|NCT01985971|RADIATION|PET/CT Imaging|
214455653|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
214455654|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
215143030|NCT01515553|DRUG|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
215143031|NCT01597804|PROCEDURE|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
215143032|NCT01820338|BEHAVIORAL|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
215143033|NCT01820338|BEHAVIORAL|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
215143034|NCT01820338|OTHER|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains \& carbohydrates. Topics will also include use of vitamin \& mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
214455655|NCT05546749|DEVICE|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
214455656|NCT05546749|DEVICE|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
214455657|NCT05621811|DRUG|Naronapride|Naronapride is a 5HT-4 agonist
214455658|NCT05621811|DRUG|Placebo|Placebo
214455659|NCT05145127|DRUG|PF-06741086|"For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria."
214455660|NCT05326776|DRUG|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
214455661|NCT06442631|BEHAVIORAL|MyStroke|MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
214455662|NCT06038487|PROCEDURE|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
214455663|NCT06038487|PROCEDURE|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
214528083|NCT06721104|OTHER|Temporomandibular Joint (TMJ) Assessment|"The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population."
214528084|NCT06721676|DEVICE|transcatheter aortic valve replacement in severe aortic stenosis|transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis
214708659|NCT05912036|BEHAVIORAL|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
214708660|NCT00539318|PROCEDURE|Blood drawing|Once when enroll in study
214708661|NCT00554255|DRUG|SB751689|
214708662|NCT00289861|DRUG|Risperidone|
215143035|NCT04818788|DRUG|Biological Drug|we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
215143036|NCT02928965|DRUG|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
215143037|NCT02928965|DRUG|Placebo|Matching placebo with appearance of over - encapsulated minocycline
215143038|NCT01198795|DRUG|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
215143039|NCT03928184|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
215143040|NCT03928184|DRUG|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
215143041|NCT06284889|BEHAVIORAL|Behavioural activation|"Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log;~Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
215143042|NCT06284889|OTHER|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
215143043|NCT04830332|DIAGNOSTIC_TEST|abdominal fluid CA-125 levels test|One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
215143044|NCT01197118|RADIATION|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
215143045|NCT01197118|DRUG|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
215143046|NCT01116986|BEHAVIORAL|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
214455664|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 1)|Single dose of AZD3152 300 mg IM on Visit 2 Day 1
214455665|NCT05932641|BIOLOGICAL|Placebo (Cohort 1)|Single dose of Placebo IM on Visit 2 Day 1
214455666|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 2)|Single dose of AZD3152 600 mg IM on Visit 2 Day 1
214455667|NCT05932641|BIOLOGICAL|Placebo (Cohort 2)|Single dose of Placebo IM on Visit 2 Day 1
214708663|NCT00289861|DRUG|placebo|
215143047|NCT01116986|BEHAVIORAL|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
215143048|NCT01116986|BEHAVIORAL|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
215143049|NCT01116986|BEHAVIORAL|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
215143050|NCT01116986|BEHAVIORAL|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
215143051|NCT01116986|DRUG|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
215143052|NCT01116986|DRUG|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
215143053|NCT01116986|DRUG|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
214455668|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 3)|Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
214455669|NCT05932641|BIOLOGICAL|Placebo (Cohort 3)|Single dose of Placebo IM on Visit 2 Day 1
214455670|NCT03834753|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
214455671|NCT03834753|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
214708664|NCT05041153|DRUG|Lenvatinib|Given by PO
214708665|NCT05041153|BIOLOGICAL|Pembrolizumab|Given by IV
214455672|NCT06096038|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
214455673|NCT06096038|DRUG|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
214455674|NCT06096038|BIOLOGICAL|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
214455675|NCT03432936|DEVICE|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
214455676|NCT04952909|DEVICE|ShortCut™|Splitting bioprosthetic aortic valve leaflets
214455677|NCT03927638|BEHAVIORAL|sit/stand|Subjects will be asked to both sit and stand during a single trial.
214455678|NCT05467943|DRUG|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
214455679|NCT05149872|OTHER|Muscle relaxation|Rocuronium will be used to induce partial paralysis
214455680|NCT05149872|OTHER|Reversal|Sugamamdex will be used to reverse muscle relaxation
214455681|NCT05634954|DRUG|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
214455682|NCT05634954|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
214455683|NCT05634954|DIAGNOSTIC_TEST|Static - PET/CT Scan|Group 2: Static whole-body scans
214455684|NCT06528743|RADIATION|RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.|Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
214708666|NCT06580184|BEHAVIORAL|LEARN 2 Platform|The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.
214455685|NCT06439147|PROCEDURE|U shaped capsular incision during capsulorrhaphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
214455686|NCT06439147|PROCEDURE|T-shaped capsular incision diuring capsulorraphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
214708667|NCT04112732|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
214708668|NCT04112732|OTHER|Placebo|Placebo
214528085|NCT06719739|DEVICE|Intraocular lens implantation|Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.
215143054|NCT01116986|DRUG|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
214455687|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
214455688|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
214455689|NCT04557163|DRUG|TS-142|TS-142 will be given as 1 mg per capsule administered orally with water.
214455690|NCT04557163|DRUG|Itraconazole|Itraconazole will given as 50 mg per capsule administered orally with water.
215143055|NCT01116986|DRUG|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
214455691|NCT06353841|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
214455692|NCT06295757|OTHER|Cigarettes|Participants will smoke their own usual brand cigarettes. Cigarette butts will be collected.
214455693|NCT02754765|DRUG|Bedaquiline|
215143056|NCT00936715|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
214455694|NCT02754765|DRUG|Delamanid|
214455695|NCT02754765|DRUG|Clofazimine|
214455696|NCT02754765|DRUG|Levofloxacin|
214455697|NCT02754765|DRUG|Moxifloxacin|
214455698|NCT02754765|DRUG|Linezolid|
214455699|NCT02754765|DRUG|Pyrazinamide|
214455700|NCT02754765|DRUG|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
214695123|NCT06758128|GENETIC|Evaluation of HS1,2 polymorphisms|"Echocardiograms will be performed by experienced operators of the echocardiography service.~Inflammatory profile. A single additional blood sample (3 cc) will be collected. Plasma will be isolated from whole blood to determine pro-inflammatory cytokines.~Immunoprofile: Circulating lymphocytes will be separated according to Ficoll gradient (into the two different components of immunity (B and T lymphocytes) with different inflammatory phenotypes.~Evaluation of HS1,2 polymorphisms and estrogen levels: DNA purifications and amplifications will be performed from an aliquot of the single whole blood sample. Genomic DNA will be isolated using the QIAamp DNA Mini and Blood Mini kit (QIAGEN Hilden, Germany) according to the manufacturer's protocol. 9 single nucleotide polymorphisms (SNPs) in four specific polymorphic regions of the 3'-1 Regulatory Region (3'RR-1) of the human immunoglobulin (IgH) heavy chain locus will be sequenced."
214455701|NCT04302727|BEHAVIORAL|Med-South Weight Loss Intervention|Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.
214455702|NCT04302727|BEHAVIORAL|WW|If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
214455703|NCT06391125|DRUG|normal Saline|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
214455704|NCT06391125|DRUG|Lidocaine|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
214528086|NCT06720025|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
214528087|NCT06720025|DRUG|rHuEPO injection|Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
214708669|NCT06067893|DRUG|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
214708670|NCT06067893|DRUG|Normal Saline|Patient receives normal saline for 48 hours post-operatively
214528088|NCT05357066|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
214695124|NCT06898190|BEHAVIORAL|Learning Early Infant Feeding Cues (LEIFc)|Coaching sessions using SS-OO-PP-RR are conducted at infant age of 2 and 3 months. This occurs during an infant feeding session between mother and infant with the interventionists offering coaching specific to responsive feeding during the session. At the conclusion of the visit, the interventionists and mother develop specific strategies to practices prior to the next visit. At the following visit, a discussion of reflection and review occurs prior to the infant feeding session to identify what is going well and what still needs work.
214455705|NCT04962672|DRUG|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
214455706|NCT04962672|DRUG|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
214455707|NCT06129825|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
214455708|NCT05167968|OTHER|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~* Self-questioning of medication adherence: Girerd questionnaire~* Assessment of the Medication Possession Ratio~* Social and demographic data~* Comorbidities~* PH characteristics"
214455709|NCT03575897|DIAGNOSTIC_TEST|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
214455710|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
214455711|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
214455712|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
214455713|NCT03525964|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
214455714|NCT03525964|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
214455715|NCT03525964|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
214455716|NCT04859283|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
214455717|NCT04859283|DRUG|Placebo|Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
214455718|NCT05751694|PROCEDURE|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
214455719|NCT05751694|PROCEDURE|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
214455720|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
214695125|NCT06899100|BEHAVIORAL|Primary Services|Participants receive 26 hours of Next Level Fatherhood curriculum, 2 hours of child maltreatment workshops, 2 hours of anger management workshops, and 2 hours of optional legitimation workshops. Participants also receive ongoing case management and support services.
214455721|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
214455722|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
214455723|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
214455724|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
214455725|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
214455726|NCT03981952|OTHER|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
214455727|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
214455728|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
215143057|NCT05048277|BEHAVIORAL|Single Session Consultation|"Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources."
215143058|NCT01216553|OTHER|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
215143059|NCT01840241|DRUG|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
215143060|NCT01840241|DRUG|normal saline|
215143061|NCT05341141|DEVICE|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
215143062|NCT05341141|DRUG|ddEC-ddT|Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
214455729|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
214455730|NCT06442657|OTHER|Hydrocellular dressing|Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.
214455731|NCT06442657|OTHER|Hydrocolloids dressing|Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
214455732|NCT06014411|OTHER|Time to bathing (delayed)|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
214455733|NCT06014411|OTHER|Time to bathing (early)|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
214455734|NCT05618054|BEHAVIORAL|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
214455735|NCT05984511|PROCEDURE|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
214455736|NCT05984511|PROCEDURE|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
215143063|NCT04862546|DEVICE|Laser Acupoint|Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject
215143064|NCT04862546|DEVICE|Tap water iontophoresis|"Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes."
215143065|NCT03247946|BEHAVIORAL|upright head position|Bottle feeding of infants with their head in upward and not supine head position
215143066|NCT02492763|DRUG|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
214695126|NCT06897956|OTHER|Oral health educational program|Oral health educational program about oral hygiene, prevention of dental caries and techniques of tooth brushing
215143067|NCT02492763|DRUG|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
215143068|NCT02492763|DRUG|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
215143069|NCT02492763|DRUG|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
215143070|NCT04286945|PROCEDURE|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
215143071|NCT05027555|OTHER|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
215143072|NCT05027555|OTHER|Conventional training|Conventional training included strengthening, balance training and gait training
215143073|NCT00003553|OTHER|HLA Matched Peripheral BLood Stem Cells|Cell Product
215143074|NCT03868657|DRUG|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
215143075|NCT03868657|DRUG|Placebo|Placebo
215143076|NCT06271746|DEVICE|FibroNova (Active mode)|FibroNova neurostimulator of conditional pain modulation (CPM)
215143077|NCT06271746|DEVICE|FibroNova (Sham mode)|FibroNova neurostimulator with an electrical output not intended for neurostimulation
215143078|NCT03193502|DRUG|rivaroxaban|rivaroxaban
215143079|NCT04962308|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
215143080|NCT04962308|BIOLOGICAL|The SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
215143081|NCT05969834|DRUG|uHCG|Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
215143082|NCT05969834|DRUG|rHCG|Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
215143083|NCT05969834|DRUG|uHCG and GnRHa|Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
215143084|NCT03813927|DIETARY_SUPPLEMENT|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
215143085|NCT03813927|DIETARY_SUPPLEMENT|Placebo|Placebo with tablet 20 μg Vitamin each day.
215143086|NCT05972980|OTHER|COVID-19|The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
215143087|NCT01337960|BEHAVIORAL|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
215143088|NCT01337960|BEHAVIORAL|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
215143089|NCT01337960|BEHAVIORAL|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
215143090|NCT00489593|DRUG|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
215143091|NCT01772316|DRUG|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
215143092|NCT01418625|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
215143093|NCT03532867|OTHER|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
214455737|NCT05984511|DRUG|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
214455738|NCT04909931|DRUG|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
214455739|NCT04909931|DRUG|Placebo|Second arm : add on placebo for 12 weeks
214455740|NCT04191460|DRUG|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
214455741|NCT05886816|DRUG|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
214455742|NCT05886816|OTHER|Placebo|Placebo pills
214695127|NCT06898541|DEVICE|Coronary sinus reducer|Implantation of a Coronary Sinus Reducer device
214695128|NCT06898541|OTHER|Sham CSR procedure|Patients will undergo a complete sham CSR implantation procedure without actual deployment of the CSR.
214455743|NCT04795843|OTHER|Exercise and patient education|Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
214455744|NCT04795843|OTHER|Usual Care|Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
215143094|NCT03532867|OTHER|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
215143095|NCT03532867|OTHER|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
215143096|NCT00193661|DRUG|Testosterone Gel (1%)|
215143097|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
215143098|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
215143099|NCT01038843|DRUG|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
215143100|NCT01747876|DRUG|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
215143101|NCT02919839|OTHER|non-Interventional|
215143102|NCT06324513|DIETARY_SUPPLEMENT|Mediterranean Crohn's Disease Exclusion Diet (Med-CDED)|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
215143103|NCT06324513|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease.
215143104|NCT02960581|BIOLOGICAL|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
215143105|NCT02960581|BIOLOGICAL|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
215143106|NCT02960581|BIOLOGICAL|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
214455745|NCT06315374|OTHER|Use soft mist inhaler|Only use soft mist inhaler
214455746|NCT06315374|DEVICE|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
214455747|NCT04205110|DIAGNOSTIC_TEST|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
214455748|NCT06107738|DRUG|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
214708671|NCT05817955|DRUG|Azacitidine (AZA) with Ruxolitinib|"1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
215143107|NCT02960581|BIOLOGICAL|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
215143108|NCT02960581|BIOLOGICAL|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
215143109|NCT03002337|BEHAVIORAL|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
215143110|NCT03002337|BEHAVIORAL|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
215143111|NCT02190695|DRUG|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
215143112|NCT02190695|DRUG|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
215143113|NCT02190695|DRUG|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
215143114|NCT01341353|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
215143115|NCT01341353|DRUG|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
215143116|NCT06428292|DEVICE|Virtual reality device branded ''Meta Quest 2''|Combining different exercise equipment with a virtual reality device and using them in a virtual environment can be used to decide which one is more effective.
214455749|NCT06107738|DRUG|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
214455750|NCT03150810|DRUG|Pamiparib|Administered by mouth as a capsule twice daily
214455751|NCT03150810|DRUG|Temozolomide|TMZ at various doses administered by mouth as a capsule once daily.
214455752|NCT03206671|DRUG|Rituximab window|Rituximab window (375 mg/m²)
215143117|NCT02092610|DEVICE|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
215143118|NCT02092610|DEVICE|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
214455753|NCT03206671|DRUG|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
214455754|NCT03206671|DRUG|Cyclophosphamide|see detailed protocol description
214455755|NCT03206671|DRUG|Cytarabine|see detailed protocol description
214455756|NCT03206671|DRUG|Dexamethasone|see detailed protocol description
214455757|NCT03206671|DRUG|Doxorubicin hydrochloride|see detailed protocol description
214455758|NCT03206671|DRUG|Vindesine Sulfate|see detailed protocol description
215143119|NCT02987426|BEHAVIORAL|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
214455759|NCT03206671|DRUG|Etoposide|see detailed protocol description
214455760|NCT03206671|DRUG|Ifosfamide|see detailed protocol description
214455761|NCT03206671|DRUG|Methotrexate|see detailed protocol description
214455762|NCT03206671|DRUG|Prednisolone|see detailed protocol description
214455763|NCT03206671|DRUG|Vincristine|see detailed protocol description
214455764|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
214455765|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
214455766|NCT05735977|DIAGNOSTIC_TEST|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
214455767|NCT03884855|OTHER|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
214455768|NCT03884855|OTHER|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
215143120|NCT00685191|DRUG|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
215143121|NCT01790724|BEHAVIORAL|Walking exercise|
215143122|NCT00228267|DRUG|Propofol|
215143123|NCT03742557|DRUG|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
214455769|NCT05381844|OTHER|Blood sampling|30 ml blood sampling for virological research
214455770|NCT04898595|PROCEDURE|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
214455771|NCT03972930|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
214455772|NCT05116787|DRUG|Placebo|Administered orally twice daily
214708672|NCT05363709|DRUG|Balstilimab|Given by Vein (IV)
215143124|NCT04379856|DRUG|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
215143125|NCT03488953|PROCEDURE|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
215143126|NCT00648063|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
214455773|NCT05116787|DRUG|BCX9930 monotherapy|Administered orally twice daily
214455774|NCT03841305|PROCEDURE|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
214455775|NCT05217420|BEHAVIORAL|Moving Well|Experimental arm
214455776|NCT05217420|BEHAVIORAL|Staying Well|Active comparator arm
214455777|NCT05159830|DRUG|Cannabidiol oral oil|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
214455778|NCT05159830|DRUG|Placebo oral oil|Placebo of similar cannabidiol galenic form
214455779|NCT04516564|DRUG|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
214455780|NCT04516564|DRUG|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
214455781|NCT03983018|DRUG|Rituximab|Infusion
214455782|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
214455783|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
214455784|NCT04325789|DEVICE|nanofiber scaffold|Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
214695129|NCT06899256|OTHER|Horticultural Activity Program|Prior to the commencement of the horticultural intervention program, the nursing home was visited to assess its physical environment and to inform staff about the program's objectives. Participants were recruited, and baseline data was collected. The program was structured around weekly activities and visits, with a three-day interval between each session. Activities included plant identification, gardening tasks, and nature-based art projects. The program was designed to foster social interaction, cognitive stimulation, and physical activity, while promoting a sense of accomplishment and well-being among participants. Throughout the program, regular assessments were conducted to monitor participants' progress and satisfaction.
214695130|NCT06899178|DRUG|Atomoxetine|Initial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose)
214695131|NCT06899178|DRUG|Placebo|Matching placebo oral capsule
214695132|NCT06769646|OTHER|No tretament given|No treatment given
214455785|NCT04712773|DEVICE|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
214455786|NCT04712773|DEVICE|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
214455787|NCT05090540|DEVICE|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
214695133|NCT03754608|DIAGNOSTIC_TEST|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
214455788|NCT05090540|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
214455789|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
214455790|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
214695134|NCT03437538|DEVICE|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
214695135|NCT03437538|DEVICE|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
214695136|NCT07070674|DRUG|AC-003|AC-003 capsules will be administered orally.
214695137|NCT06896240|DIETARY_SUPPLEMENT|Assigned Interventions|"The Green Smoothie Guide from the American College of Lifestyle Medicine contains guidelines for a 6-step smoothie to include whole and high fiber foods."
214695138|NCT07083440|DRUG|Remimazolam|Intravenous bolus administered over 1 minute (prepared as a 1 mg/mL solution). Doses: 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg according to group allocation.
214695139|NCT07083440|DRUG|Propofol|Intravenous (10 mg/mL emulsion), initial titrated dose ranging from 0.5 to 2 mg/kg, administered slowly until MOAA/S ≤ 2. Supplemental 0.5 mg/kg boluses as needed.
215143127|NCT00648063|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
215143128|NCT02170571|DRUG|Dabigatran etexilate|
215143129|NCT03891407|DIAGNOSTIC_TEST|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
215143130|NCT00331097|DRUG|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
215143131|NCT00331097|DRUG|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
214455791|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
214455792|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
214455793|NCT04650256|OTHER|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
214455794|NCT06757270|OTHER|Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis|Second arm : aleovera 3 times daily after brushing teeth
214455795|NCT01519154|DRUG|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
214455796|NCT01519154|DRUG|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
214455797|NCT06355778|OTHER|Magnetic Resonance Imaging (MRI)|Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
214455798|NCT06355778|BEHAVIORAL|Computer Tasks|Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
214455799|NCT06796387|BEHAVIORAL|Enhanced Implementation of SBAT|"For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~* Telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT school-based DOT of preventive asthma medications~* Follow-up telemedicine asthma control assessments~* Centralized case management support~* Care coordination"
214455800|NCT06796387|BEHAVIORAL|Usual Care|During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
214455801|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
214455802|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
214455803|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
214455804|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
214455805|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
214455806|NCT05679154|BEHAVIORAL|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
214455807|NCT05679154|BEHAVIORAL|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
214455808|NCT02742493|OTHER|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
214455809|NCT02742493|OTHER|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
214455810|NCT02742493|OTHER|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
214455811|NCT04512547|DRUG|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
214455812|NCT04783571|OTHER|Placebo|Auditory stimulation will not be delivered during the nap
214455813|NCT04783571|OTHER|Auditory Stimulation|Auditory stimulation will be delivered during the nap
214455814|NCT05487248|OTHER|Blood Sample Collection|"For subjects receiving treatments with a 2- or 4-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 2 weeks after treatment start (day 15)~Plasma :~* Before the treatment start (day 1)~* 4 weeks after treatment start (day 29)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1~For subjects receiving treatments with a 3-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 3 weeks after treatment start (day 22)~Plasma :~* Before treatment start (day 1)~* 6 weeks after treatment start (day 43)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1"
215143132|NCT00331097|DRUG|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
215143133|NCT00331097|DRUG|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
215143134|NCT00914316|DRUG|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
215143135|NCT00914316|DRUG|Placebo|twice daily
215143136|NCT00740649|DRUG|HSD-016|
215143137|NCT00740649|DRUG|placebo|
215143138|NCT05295095|PROCEDURE|positive pressure during extubation procedure|positive pressure during extubation procedure
215143139|NCT03656159|BEHAVIORAL|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
215143140|NCT03656159|BEHAVIORAL|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
214455815|NCT04740567|BEHAVIORAL|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
214455816|NCT04740567|BEHAVIORAL|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
214455817|NCT05936281|DRUG|Genakumab for injection|150 mg/1ml/ vial
214455818|NCT05936281|DRUG|Colchicine|0.5 mg/table
214455819|NCT05851378|DRUG|Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)|Given intravenously at time of imaging
214455820|NCT05851378|PROCEDURE|Magnetic Resonance Image (MRI)|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
214455821|NCT04605809|DEVICE|combined motor and cognitive training|The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.
214455822|NCT04605809|DEVICE|motor training alone|The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
214455823|NCT04605809|DEVICE|cognitive training alone|The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
214455824|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
214455825|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
214455826|NCT03339817|DIAGNOSTIC_TEST|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
214455827|NCT06642428|DRUG|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
214455828|NCT06642428|DRUG|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
214455829|NCT06637787|OTHER|Pads|A specially desigend pad is used to collect information about leakage and body movement at night.
214455830|NCT06556394|DRUG|RAG-17|RAG-17 is a therapeutic small interfering RNA (siRNA).
214455831|NCT06556394|DRUG|Placebo|Placebo will be administered via intrathecal injection
214455832|NCT06637592|OTHER|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
214455833|NCT06637592|OTHER|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
214455834|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
214528089|NCT05357066|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
214528090|NCT03441659|PROCEDURE|ACL reconstruction|Surgical ACL reconstruction
214695140|NCT07083440|DRUG|Sufentanil|Intravenous dose of 0.1 µg/kg administered approximately 30 minutes before the start of the procedure.
214455835|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
214455836|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
214455837|NCT03557697|BEHAVIORAL|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
214455838|NCT03557697|BEHAVIORAL|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
214455839|NCT04121858|OTHER|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
214455840|NCT04121858|OTHER|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
214455841|NCT05363631|DRUG|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
214455842|NCT05363631|DRUG|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
214455843|NCT05363631|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy
214455844|NCT03611491|DEVICE|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
214455845|NCT05796583|DEVICE|Active Pulsed Shortwave Treatment|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
214455846|NCT05796583|DEVICE|Sham Treatment|Application of 8 days of a nonfunctional sham device
214455847|NCT03373071|BIOLOGICAL|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
214455848|NCT06050109|DRUG|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
214455849|NCT06050109|DIAGNOSTIC_TEST|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
214455850|NCT06299137|PROCEDURE|Serratus Anterior Plane Block|Patients who undergo randomization to the intervention arm will undergo the Serratus Anterior Plane Block.
214455851|NCT06299137|DRUG|Ropivacaine injection|For the Serratus Anterior Plane Block, Ropivacaine will be used as the anesthetic.
214455852|NCT05026320|DRUG|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
214528091|NCT06720402|BEHAVIORAL|Sun protection knowledge|To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.
214528092|NCT06720337|DRUG|bupivacaine 0.5%|patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique
214455853|NCT05026320|DRUG|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
214455854|NCT05026320|DRUG|Placebo gel|bid for 5 days (final application on morning of Day 6)
214455855|NCT04930822|OTHER|Table Top Visual Intervention|Table top visual interventions and exercises.
214455856|NCT04930822|DEVICE|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
214455857|NCT05666960|DRUG|R-3750|Probiotic
214455858|NCT06082063|DRUG|Aspirin tablet|Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
214528093|NCT06720337|DRUG|Dexmedetomidine|patients will receive plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side
214528094|NCT06720337|DRUG|MgSO4|patients will receive plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
214528095|NCT02475707|BIOLOGICAL|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
214695141|NCT07082842|DRUG|HEC585|HEC585 tablet, taken once daily
214695142|NCT07082842|DRUG|Placebo|HEC585 Simulation Board, taken once daily
215143141|NCT02802540|DRUG|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
214455859|NCT06082063|DRUG|Semaglutide|GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
214455860|NCT06082063|DRUG|Sotagliflozin|SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
214455861|NCT06082063|DRUG|Finerenone|Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
214455862|NCT05595239|DEVICE|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
214695143|NCT07082842|DRUG|Pirfenidone|Pirfenidone, taken three times a day
215143142|NCT02802540|DRUG|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
215143143|NCT03843840|DEVICE|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
215143144|NCT04642092|BEHAVIORAL|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
215143145|NCT04642092|BEHAVIORAL|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
215143146|NCT04135417|BIOLOGICAL|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
215143147|NCT03806361|PROCEDURE|Fat grafts supplemented with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
215143148|NCT03806361|PROCEDURE|Structural fat grafting|Fat grafts without supplementation of ADRC
215143149|NCT04513223|DRUG|SHR-A1811|There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
215143150|NCT05131737|PROCEDURE|High altitude exposure|Exposure to 2500m of altitude
215143151|NCT05131737|PROCEDURE|Low altitude exposure|Exposure to 490 m
215143152|NCT03163303|BEHAVIORAL|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
215143153|NCT03163303|BEHAVIORAL|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
215143154|NCT03163303|DRUG|nicotine patch|14-day supply of nicotine patch
215143155|NCT00600080|DEVICE|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
215143156|NCT00600080|DEVICE|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
215143157|NCT06201780|DIAGNOSTIC_TEST|serum levels of Janus Kinase 1and 2|assessment of serum levels of Janus Kinase 1and 2 by ELISA
215143158|NCT05621434|DRUG|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
214455863|NCT05595239|DEVICE|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
214455864|NCT05595239|DEVICE|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
214455865|NCT05478499|DRUG|Deucravacitinib|Specified dose on specified days
214455866|NCT05478499|OTHER|Placebo|Specified dose on specified days
214695144|NCT07083635|DRUG|Transdermal Ethinyl Estradiol/Norelgestromin Patch|Transdermal contraceptive patch containing ethinyl estradiol 600 micrograms and norelgestromin 6 milligrams per patch, manufactured by GEDEON RICHTER PLC and imported by Abbott.
214695145|NCT07083635|DRUG|Placebo Patch|Identical-appearing transdermal patches without active hormonal ingredients , manufactured and imported by Convatec.
214695146|NCT07083245|BEHAVIORAL|Psychosocial care|Psychosocial support to chemotherapy patients during their treatment sessions through conversations, board games, movies, and gift baskets
215143159|NCT05570825|PROCEDURE|Biopsy|Undergo biopsy
215143160|NCT05570825|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215143161|NCT05570825|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
215143162|NCT05570825|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
215143163|NCT05570825|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215143164|NCT05570825|BIOLOGICAL|Pembrolizumab|Given IV
215143165|NCT05570825|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215143166|NCT01157403|BIOLOGICAL|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
215143167|NCT00991016|DRUG|PF-04805712|ascending single and multiple doses starting at 30 mg
215143168|NCT04163952|BIOLOGICAL|Panitumumab|Given IV
215143169|NCT04163952|BIOLOGICAL|Talimogene Laherparepvec|Given IM
215143170|NCT06172062|OTHER|laparoscopic pancreaticoduodenectomy|we recorded the surgical videos of laparoscopic pancreaticoduodenectomy, and labeled the information in the video to build and test the algorithms.
215143171|NCT00705952|OTHER|Lifestyle intervention|Diet, exercise and behavioural change intervention.
215143172|NCT00960882|DRUG|DMMET-01|1050.6 mg daily for 30 days
215143173|NCT01497288|DRUG|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
214528096|NCT06474546|OTHER|Diet intervention|"A diet based on the principles of the Mediterranean Diet (MedDiet): consists of an abundance of plant foods - unrefined cereals, fruit, vegetables, and extra-virgin olive oil - a moderate consumption of poultry, dairy products, eggs, and low consumption of sweets and red meats.~All subjects will be instructed to follow the MedDiet for 8 weeks by the study team. Families will be given the option to continue for 12 weeks if they wish to do so."
214528097|NCT06897982|BEHAVIORAL|One-arm feasibility pilot of a nutrition intervention to recruit, engage, and retain DPP participants in the safety-net setting in Los Angeles|This clinical trial incorporates a behavioral intervention as the primary outcome of Aim 3 is to assess the feasibility and acceptability of adding an educational intervention using nutritional demonstrations aligned with the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes. The purpose of this study is to assess if having a nutritional demonstration as part of the DPP would be accepted by clinic DPP patients and hear their perspectives about if this would help them in achieving DPP goals of achieving at least 5% weight loss and implementing sustainable lifestyle changes with healthy eating to reduce their risk of prediabetes. The intervention is designed to encourage healthier eating habits and encourage clinic DPP patients to incorporate this into their daily lives. This study will also determine if it is feasible to incorporate nutritional demonstrations to enhance the existing DPP curriculum
214528098|NCT04731428|BEHAVIORAL|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
214528099|NCT04269811|DRUG|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
214528100|NCT06868303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
214695147|NCT07083453|OTHER|Comparator 1|$10 rebate offered with an online caries and periodontal risk assessment
214455867|NCT02962895|BIOLOGICAL|VAY736|VAY736
214455868|NCT02962895|OTHER|Placebo|Placebo control
214455869|NCT04252781|OTHER|Exhaustive exploration|"* clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index"
214455870|NCT06801067|BIOLOGICAL|SER-155|SER-155 (Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated) is an experimental designed ecology of 16 unique, human-commensal bacterial strains encapsulated for oral administration and will be provided by Seres as an investigational drug
214455871|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
214455872|NCT06800495|BEHAVIORAL|THALEA (Thalassemia Education and Awareness) Kit|"By using the opinions obtained by the experts, THALEA's content will then be designed using the Theory of Planned Behaviour (TPB) by Ajzen and Fishbein.~Development of THALEA:~• Language: Malay and English.~• Contents of the THALEA kit: i. PowerPoint or Canva presentations with discussion prompts (softcopy form) ii. Links/joining codes to free educational game platforms such as Kahoot or Quizziz iii. Videos - convey messages on thalassemia awareness and screening importance.~iv. Illustrated guides/brochures - to provide step-by-step tutorials on how to get thalassemia screening in both the public and private healthcare.~• Developer would be the main researcher with aid from: i. Illustrator ii. Video graphic designer iii. Influencers~• Delivery of THALEA to students by: i. Medical personnel"
214695148|NCT07083453|OTHER|Comparator 2|20 rebate offered without risk assessment
214695149|NCT07083453|OTHER|Comparator 3|$30 rebate offered without risk assessment
214695150|NCT07083453|OTHER|Comparator 4|$50 rebate offered without risk assessment
214695151|NCT07083453|OTHER|Control|$10 rebate offered with no risk assessment
214695152|NCT07083648|RADIATION|Magnetic resonance Imaging-guided online adaptive radiotherapy|On each day of treatment, a new MRI scan in the treatment position will be acquired using the dedicated MR simulator, co-registered with the original one. The original target and organ at risk (OAR) contours will be propagated to the new image set using rigid and deformable image registration. The contours will be adapted to changes detected with MRI of the day. The original SBRT treatment plan will be adapted to the changed and hence adapted anatomy of targets and OARs by plan optimization. Dose calculation will be performed on the newly generated synthetic CT (preferred) or, if there is a contra-indication for synthetic CT, on the original image.
214695153|NCT07084441|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
214695154|NCT07084441|OTHER|Supportive Care|\*Please see description for supportive care arm.
214695155|NCT07083908|DEVICE|THD® Anopress (Sensyprobe) first|Anorectal manometry with THD® Anopress (Sensyprobe) first then with High Resolution Anorectal Manometry (Laborie)
215143174|NCT05836506|DRUG|ABBV-903 Tablet Form 1|Oral Tablets
214455873|NCT06800495|BEHAVIORAL|Basic thalassemia and family health education|They are basic family health education in which it is the usual family health education given by the MOH, usually delivered by a medical officer, to fourth form students at government schools prior to the thalassemia screening programme. It will consist of a delivery of a PowerPoint presentation and videos, that will be obtained from government public health clinics in Klang Valley.
214455874|NCT06800690|DIAGNOSTIC_TEST|Urinary Estrogen Level|Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.
214455875|NCT06570655|DRUG|Huperzine A injection|intramuscular
214455876|NCT06570655|DRUG|Huperzine A injection|intravenous bolus
214455877|NCT06801119|DRUG|HN2301 injection|Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
214455878|NCT06800924|OTHER|Postural and mobility analysis|Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)
214455879|NCT05003739|PROCEDURE|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
214455880|NCT06429436|BEHAVIORAL|VENDY|At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
214455881|NCT05581745|PROCEDURE|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
214455882|NCT05965609|BEHAVIORAL|CBTI|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
214455883|NCT05965609|BEHAVIORAL|MRTI|Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
214455884|NCT05894577|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
214455885|NCT05894577|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
214455886|NCT05481320|BEHAVIORAL|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
214455887|NCT05481320|BEHAVIORAL|Enhanced Control|A single phone session providing education about dementia.
214455888|NCT06323408|DIAGNOSTIC_TEST|Tissue, blood, cerebrospinal-spinal fluid|Processing, analysis
214455889|NCT05093478|DRUG|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
214455890|NCT05093478|DRUG|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
214455891|NCT06800937|OTHER|Determination of sphingolipidomic profile|The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.
214455892|NCT05971563|DIETARY_SUPPLEMENT|Casein|Natural protein
214455893|NCT05971563|DIETARY_SUPPLEMENT|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
214455894|NCT05971563|DIETARY_SUPPLEMENT|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
214528101|NCT06868303|BEHAVIORAL|New Life Psychiatric Rehabilitation Association electronic clinic for psychological service|The eClinic treatment spans eight to fourteen week and is designed for individuals with moderate to severe mental health issues. The service is provided in a hybrid format, incorporating an in-person initial screening using the Patient Health Questionnaire-9 and General Anxiety Disorder-7, followed by online self-learning resources and sessions with a therapist. Pre- and post-treatment assessments as well as follow-ups will be used to keep track of service users' progress.
214455895|NCT06789237|OTHER|weighted blanket|Participants will be covered with a weighted blanket for 30 minutes
214695156|NCT07083908|DEVICE|High Resolution Anorectal Manometry first|Anorectal manometry with High Resolution Anorectal Manometry (Laborie) first followed by THD® Anopress (Sensyprobe)
214695157|NCT07084155|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
215143175|NCT05836506|DRUG|ABBV-903 Tablet Form 2|Oral Tablets
214455896|NCT06789237|OTHER|non-weighted blanket|Participants will be covered with a sham non-weighted blanket for 30 minute
214455897|NCT06546384|DRUG|Semaglutide|"Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d."
214455898|NCT06546384|BEHAVIORAL|Weight reduction recommendations (nutritional and exercise)|Participants will receive nutritional and exercise recommendations and 2 telephone consultations
214455899|NCT06801730|DRUG|Irinotecan liposome combined with bevacizumab|Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
214455900|NCT05100251|DRUG|WBC100 QOD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 7 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QOD. The second dose group is 1mg QOD. The third dose group is 1.5 mg QOD. The fourth dose group is 2.0 mg QOD. The fifth dose group is 2.5 mg QOD. The sixth dose group is 3.0 mg QOD. The seven dose group is 3.5 mg QOD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
214455901|NCT05100251|DRUG|WBC100 QD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
214455902|NCT05100251|DRUG|WBC100 BID|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
214455903|NCT04509674|DRUG|Empagliflozin|Empagliflozin
214455904|NCT04509674|DRUG|Placebo|Placebo
214455905|NCT04636229|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
214455906|NCT04636229|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
214455907|NCT06800612|DRUG|Oncologic drugs administered for treatment of breast cancer|Data on oncologic drugs administered for treatment of breast cancer will be recorded
214455908|NCT06800612|DRUG|Oncologic drug administered for treatment of gynecologic cancer|Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
214455909|NCT05480384|DRUG|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
214455910|NCT05480384|DRUG|Trastuzumab deruxtecan|Given in combination with Nivolumab.
214455911|NCT04943497|OTHER|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
214455912|NCT04943497|OTHER|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
214455913|NCT04943497|OTHER|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
214455914|NCT04943497|OTHER|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
214455915|NCT06801990|PROCEDURE|S1 transforaminal epidural steroid(dexamethasone) injection|"The designed study will examine the effect of oblique entry angles on contrast distribution patterns and treatment outcomes. Therefore, it aims to compare the smallest and largest angles that can be achieved under co-axial imaging at the S1 foramen. For this purpose, patients will be divided into two groups through randomization using a computer program. In the first group, after angling cranially and visualizing the foramen, the needle entry point will be determined. In the second group, after achieving optimal imaging by cranially angling the C-arm fluoroscope, an additional ipsilateral oblique angle will be applied to the fluoroscope.~In this context, Plastaras et al. reported that an angle of 5° ± 5° is the most suitable range for the S1 foramen. Additionally, another study examining dorsal and ventral S1 foramen via tomography images found that the average angle providing the widest view of the dorsal foramen was 26.6° ± 3°. In the current study, no oblique angle will be applied"
214455916|NCT02972801|PROCEDURE|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
214455917|NCT06800911|OTHER|Questionnaires|Metacognition Questionnaire Penn State Worry Questionnaire Ruminative Response Scale Anger Rumination scale Difficulties in Emotion Regulation Scale Emotional Eating subscale of the Dutch Eating Behavior Questionnaire
214455918|NCT06800677|PROCEDURE|Hysterectomy|Elective hysterectomy
214455919|NCT06800898|OTHER|Blood samples and Questionnaires|"Blood samples for methylation of the promoter of the OX-A and OX-B genes and questionnaires:~Eating Disorder Examination Q Eating Disorder Inventory 3 Major Depression Inventory Symptom Checklist-revised ESS - Epworth Sleepiness Scale Pittsburgh Sleep Quality Index Horne \& Ostberg questionnaire"
214455920|NCT05620771|DRUG|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
214455921|NCT05620771|DRUG|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
214455922|NCT02474862|BEHAVIORAL|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
215143176|NCT02146066|BIOLOGICAL|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
214528102|NCT06868303|BEHAVIORAL|Integrated Community Centres for Mental Wellness|Integrated Community Centres for Mental Wellness (ICCMWs) are the main community-based mental health services in Hong Kong. However, their reach among young people is limited, as their broad target age range primarily focuses on middle-aged individuals. ICCMW offers comprehensive, district-based community support and social rehabilitation services, from early prevention to risk management, for people in mental recovery, those with suspected mental health issues, their families and carers, and residents within the service area, all accessible through a single-entry point.
214528103|NCT06868303|OTHER|General Practitioner|Services provided by genersl practitioner
214528104|NCT06868303|BEHAVIORAL|Hub Casework|Services provided during hub casework sessions
214528105|NCT04956094|DIAGNOSTIC_TEST|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
215143177|NCT06192654|PROCEDURE|Small intestinal submucosa (SIS) graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
215143178|NCT06192654|PROCEDURE|Autologous oral bucal mucosa graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
215143179|NCT04782583|OTHER|Questionnaire|questionnaire for the patients and the volontaire
215143180|NCT00312156|DRUG|insulin detemir|
214455923|NCT02474862|BEHAVIORAL|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
214455924|NCT05565534|BEHAVIORAL|Nurse-practitioner led intervention|"* Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
214455925|NCT03367533|DRUG|Ketamine|Intravenous ketamine
214455926|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
214455927|NCT03367533|DRUG|Placebo|Oral placebo
214455928|NCT05699928|DIAGNOSTIC_TEST|General pediatrician autism diagnostic assessment|General pediatricians will assess children for possible autism spectrum disorder diagnosis as they usually would (i.e. no specific tests will be required).
214455929|NCT05699928|DIAGNOSTIC_TEST|Multidisciplinary team diagnostic assessment|The multidisciplinary team will assess children for possible autism spectrum disorder diagnosis. The team consists of a developmental pediatrician, a psychologist, and a psychometrist. Administered tests include the Autism Diagnostic Interview - Revised (ADI-R; a developmental history will be substituted for children with a developmental age of \<18 months), the Autism Diagnostic Observation Schedule (ADOS), and the Mullen Scales of Early Learning. When needed and available, the team will call a preschool or school teacher to gather more information about the child.
214455930|NCT05699928|DIAGNOSTIC_TEST|Autism Assessment for Preschoolers with Language Element Sequence|The AAPLES was developed at the Glenrose/Holland Bloorview and is designed for children who have flexible phrase speech. The assessment will be conducted virtually over Zoom Health by a trained clinician. This tool involves coaching the caregiver to interact with the child in specific ways to allow a trained professional to observe for features of ASD while watching remotely. It should take about 30-45 minutes. The individual who conducts the assessment will be blinded to the results of the other assessments. This virtual assessment will occur after the other assessments have been completed so as to not delay the child receiving a potential diagnosis.
214455931|NCT04461405|BEHAVIORAL|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
214455932|NCT06801470|DRUG|CD-001|CD-001 administered as an intravenous (IV) infusion.
214528106|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
214528107|NCT04990973|BEHAVIORAL|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
214528108|NCT04990973|BEHAVIORAL|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
214695158|NCT07082010|DEVICE|MBPS App|A MBPS web application designed and built on a customizable case management platform (CommCare) to support non-specialist providers will be used by study participants for approximately 3 months.
214695159|NCT07083869|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
215143181|NCT00312156|DRUG|insulin NPH|
215143182|NCT00312156|DRUG|insulin aspart|
215143183|NCT04286984|OTHER|unified protocol of Patient Blood Management measure|upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level \< 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb\<12g/dL and/or ferritin \<300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb \< 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb \< 7 g/dL for the rest of patients in absence of active bleeding.
215143184|NCT04053777|DEVICE|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
215143185|NCT01392105|DRUG|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
215143186|NCT01392105|DRUG|Control group|No additional treatment of mesenchymal stem cells
215143187|NCT03095859|OTHER|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
215143188|NCT06130488|BEHAVIORAL|KMC|KMC implementation as per protocol
215143189|NCT01081652|DRUG|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
214455933|NCT02893267|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
214455934|NCT02893267|OTHER|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
215143190|NCT01081652|DRUG|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
214455935|NCT02893267|OTHER|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
214455936|NCT02893267|DEVICE|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
214455937|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
214455938|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
214455939|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
214455940|NCT06224790|DRUG|Pirfenidone|Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
214455941|NCT06224790|OTHER|Placebo|2 Capsules 3 times a day for 3 months
214455942|NCT05183204|DRUG|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
214455943|NCT05183204|DRUG|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
214455944|NCT05183204|OTHER|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
214455945|NCT04842253|DEVICE|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
214455946|NCT03377361|BIOLOGICAL|Nivolumab|Specified dose on specified days
214455947|NCT03377361|DRUG|Trametinib|Specified dose on specified days
214455948|NCT03377361|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214455949|NCT03377361|DRUG|Regorafenib|Specified dose on specified days
214455950|NCT01701817|OTHER|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
214455951|NCT05184894|BEHAVIORAL|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
214455952|NCT06177457|DRUG|PF-07293893|PF-07293893 will be administered as tablets every day (QD) over 14 days
215143191|NCT05114954|DEVICE|CardioPulsesTM pulsed field ablation system|Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
214455953|NCT06177457|DRUG|Placebo|Placebo will be administered as tablets; QD over 14 days
214455954|NCT06177457|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
214455955|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
214455956|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
214455957|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
215143192|NCT02206633|DEVICE|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
215143193|NCT00524836|DRUG|levocetirizine dihydrochloride|
215143194|NCT02047032|PROCEDURE|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
215143195|NCT02047032|DRUG|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
214455958|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
214455959|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
214455960|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
214455961|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
214455962|NCT06070194|BEHAVIORAL|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
214455963|NCT06551090|OTHER|CAMERA (Context-Aware Multimodal Ecological Research and Assessment)|The CAMERA platform is a multimodal, hardware-software framework for measuring brain-behavior interactions in an unstructured environment and predict ecological states. CAMERA will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy. CAMERA consists of: Wristband sensors of autonomic physiologic signals, emphasizing heart rate metrics and electrodermal activity; Smartphone usage, emphasizing natural language processing of text input for linguistic features; Subject-tracking audiovisual array, emphasizing subject vocal activity; Intracranial neural recordings, emphasizing hippocampal theta power and high-frequency activity (\~70-200 Hz).
214455964|NCT05119296|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
214455965|NCT02751762|OTHER|Observation Only|No Intervention
214455966|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
214455967|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
214695160|NCT07083869|BEHAVIORAL|Sleep Well|Sleep Well is a website that is mobile enabled that provides psychoeducation about healthy sleep habits that is based on NIH Health Guide to Health Sleep and VA's Whole Health Change Your Habits to Sleep Better.
215143196|NCT02047032|PROCEDURE|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
215143197|NCT05660577|DEVICE|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
215143198|NCT02261701|OTHER|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
214455968|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
214455969|NCT03476460|DRUG|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
214455970|NCT03476460|DRUG|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
214455971|NCT06302946|OTHER|neuromuscular stimulation and mindfulness breathing|Receive neuromuscular stimulation and mindfulness breathing; the experimental group participants will receive neuromuscular electrical stimulation with Mindful breathing.
214455972|NCT06302946|OTHER|neuromuscular electrical stimulation|participants in the control group perceived neuromuscular electrical stimulation
214455973|NCT02766231|DEVICE|Physica CR|Cruciate retaining total knee replacement
214455974|NCT02766231|DEVICE|Physica PS|Posterior Stabilized total knee replacement
214455975|NCT06626672|BEHAVIORAL|Digital Health Intervention|Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
214455976|NCT05059041|DEVICE|Dilated Refraction|The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.
214455977|NCT05059041|DEVICE|Non-Dilated Refraction|The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
214455978|NCT05656794|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
214455979|NCT02222155|DRUG|CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
214455980|NCT02222155|DRUG|CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids|
214455981|NCT02222155|OTHER|Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
214455982|NCT06249191|PROCEDURE|Biopsy|Undergo tumor biopsy
214455983|NCT06249191|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214455984|NCT06249191|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214455985|NCT06249191|PROCEDURE|Computed Tomography|Undergo CT scan
215143199|NCT02261701|OTHER|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
215143200|NCT05198596|BIOLOGICAL|MVC-COV1901|Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
215143201|NCT05198596|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
215143202|NCT00225485|DRUG|Effexor XR|
215143203|NCT06212362|BEHAVIORAL|Step-by-step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
214455986|NCT06249191|DRUG|Cyclophosphamide|Given IV
214455987|NCT06249191|DRUG|Doxorubicin|Given IV
214455988|NCT06249191|PROCEDURE|Echocardiography|Undergo echocardiography
214455989|NCT06249191|DRUG|Etoposide|Given IV
214455990|NCT06249191|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214455991|NCT06249191|BIOLOGICAL|Mosunetuzumab|Given IV
214455992|NCT06249191|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214455993|NCT06249191|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214455994|NCT06249191|DRUG|Prednisone|Given PO
214455995|NCT06249191|DRUG|Vincristine|Given IV
214455996|NCT06389032|BEHAVIORAL|Peer Mentor Support and Caregiver Education|12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
214455997|NCT06389032|BEHAVIORAL|Caregiver Education|12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
214455998|NCT06225245|DEVICE|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
214455999|NCT05193149|BEHAVIORAL|Inspiratory muscle training|Training of respiratory muscles
214456000|NCT05193149|BEHAVIORAL|Exercise training|Supervised aerobic exercise intervention
214456001|NCT04123366|DRUG|Olaparib|Oral tablet
214456002|NCT04123366|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214456003|NCT03984097|DRUG|TAK-079|TAK-079 subcutaneously.
214456004|NCT03984097|DRUG|Lenalidomide|Lenalidomide orally.
214456005|NCT03984097|DRUG|Dexamethasone|Dexamethasone orally.
214456006|NCT03984097|DRUG|Bortezomib|Bortezomib subcutaneously.
214708673|NCT05411328|DEVICE|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
214456007|NCT03984097|DRUG|Pomalidomide|Pomalidomide orally.
214456008|NCT06190340|DRUG|TNP-2092 capsules|Administration orally.
214456009|NCT06190340|DRUG|Placebo|Administration orally.
214456010|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
214456011|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
214456012|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
214456013|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
214456014|NCT06327945|DEVICE|Lung uDCD Protocol|The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
215143204|NCT06212362|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (90-120 minutes)"
214456015|NCT06609889|GENETIC|ION283|Anti-sense Oligonucleotide therapy that includes intrathecal (IT) injections by lumbar puncture (LP) with dose level of 15 mg.
214456016|NCT05583448|DEVICE|ExploR Radial Head|Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
214456017|NCT00144261|DRUG|nevirapine|
214456018|NCT05328635|DRUG|Candesartan|Multdisciplinary approach
214456019|NCT01606215|DRUG|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
214456020|NCT01606215|DRUG|Placebo|Placebo
214456021|NCT05976672|OTHER|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
214456022|NCT05207202|DEVICE|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
214456023|NCT04592549|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
214456024|NCT04592549|OTHER|Placebo|Placebo
214456025|NCT05184192|DRUG|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
214456026|NCT05184192|DRUG|Placebo|lactose monohydrate NF
214456027|NCT03797716|DEVICE|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
214456028|NCT05545761|OTHER|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
214456029|NCT04610710|PROCEDURE|Operation|Operation for deep infiltrating endometriosis
214456030|NCT04610710|PROCEDURE|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
214456031|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
214456032|NCT03042988|OTHER|Heating pad|Heat stress applied on the trunk for up to 8 hours
214456033|NCT03042988|OTHER|Sham control|heating pad turned off applied on the trunk for up to 8 hours
214456034|NCT06543732|OTHER|Return to work program|The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
214456035|NCT04054596|BEHAVIORAL|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
215143205|NCT05189808|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation (non-experimental)
215143206|NCT06802003|DEVICE|Biometric wearable and handheld devices|In this study, participants will be equipped with biometric wearable devices, i.e. ring and wristband, as well as with a handheld oscillometer, to measure their physiological parameters and lung mechanical changes (lung function).
215143207|NCT06523959|DRUG|Apixaban 2.5 MG|To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
214456036|NCT05565092|DRUG|ALXN1820|ALXN1820 will be administered subcutaneously.
214456037|NCT04823585|DRUG|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
214456038|NCT04823585|DRUG|Placebo|Solution. Subcutaneous.
214456039|NCT06793098|DIAGNOSTIC_TEST|Measurement of kisspeptin concentration|Measurement of kisspeptin concentration in fasting venous blood serum
214456040|NCT06793098|DIAGNOSTIC_TEST|Measurement of ghrelin concentration|Measurement of ghrelin concentration in fasting venous blood serum
214456041|NCT06793098|DIAGNOSTIC_TEST|Measurement of zonulin concentration|Measurement of zonulin concentration in fasting venous blood serum
214456042|NCT06126198|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
214456043|NCT03257215|DRUG|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
214456044|NCT03257215|DRUG|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
214456045|NCT03257215|DRUG|Stoss placebo|A single 1.5 mL dose administered on Day 1
214456046|NCT03257215|DRUG|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
214456047|NCT04644289|DRUG|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
215143208|NCT04941716|DRUG|Acalabrutinib|Given PO
215143209|NCT04941716|DRUG|Venetoclax|Given PO
215143210|NCT04941716|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214695161|NCT07084623|DRUG|Pre-procedure lignocaine spray (PPL)|Administration of 2 mL of 4% lignocaine spray in the oropharynx before the fiberoptic bronchoscopy procedure, followed by additional 2% lignocaine spray according to body weight (3 mg/kg)
215143211|NCT04941716|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
215143212|NCT04941716|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
215143213|NCT04941716|PROCEDURE|Computed Tomography|Undergo CT
215143214|NCT04941716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215143215|NCT05753449|DEVICE|Baseline (or standard of care) DBS programming|Baseline (or standard of care) DBS programming.
215143216|NCT05753449|DEVICE|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
215143217|NCT04587518|BEHAVIORAL|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
215143218|NCT05924633|DIETARY_SUPPLEMENT|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
214456048|NCT04644289|DRUG|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
214456049|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214456050|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
214456051|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
214456052|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
214456053|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
214456054|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
214456055|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
214456056|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 4.1 Usage|Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.
214456057|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
214456058|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 5.1 Usage|Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.
214456059|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 7|Participants will use their Placebo Control Form 7 as directed for a period of 6 weeks.
214456060|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.1 as directed for a period of 6 weeks.
214695162|NCT07084623|DRUG|Lignocaine Spray (Spray-as-you-go)|Administration of 2% lignocaine spray via oral scope insertion during the fiberoptic bronchoscopy procedure, according to body weight (3 mg/kg), with standard procedural sedation with midazolam and initial 2 mL of 4% lignocaine spray in the oropharynx for gag reflex suppression
214695163|NCT07082049|PROCEDURE|Prostate surgery|Including but not limited to open radical prostatectomy, laparoscopic radical prostatectomy (LapRP) and robot-assisted radical prostatectomy (RARP).
215143219|NCT05924633|DIETARY_SUPPLEMENT|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
215143220|NCT02479399|DRUG|ipragliflozin|Tablets
214456061|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.2|Participants will use their Placebo Control 7.2 as directed for a period of 6 weeks.
214456062|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.2.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
214456063|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.3.0|Participants will use their Placebo Control 7.3 as directed for a period of 6 weeks.
214456064|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.3.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.3.1 as directed for a period of 6 weeks.
214456065|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.4.0|Participants will use their Placebo Control 7.4 as directed for a period of 6 weeks.
214456066|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.4.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.4.1 as directed for a period of 6 weeks.
214456067|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
215143221|NCT06254638|BEHAVIORAL|Multicomponent school-based intervention.|"Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the research team) are in charge of the physically active classes.~Active break: the intervention consists of 2 active pauses per day. The development of each pause is carried out through a specific digital platform in which students follow the instructions of an avatar, who is in charge of guiding the realization of the active break. Each active break takes a total of 4 minutes, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed.~Active break: The intervention consists of a daily active break, every school day of the week. The design and supervision of each active break will be carried out by the support technician and the teaching staff based on the students' tastes."
214456068|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
215143222|NCT06584318|OTHER|Intermittent hypoxia intervention|The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
215143223|NCT05856734|DEVICE|Weight and body composition change|1- Anthropometric Measurements: Body Weight (BW), Body Mass Index (BMI), Sitting Height Ratio (SHR), Waist to Hip Ratio (WHR), Finger Ratio (FR), Body Fat (BF%), and Weight-for-age growth charts. (Single measure)
215143224|NCT05856734|BEHAVIORAL|Change in dietary intake|"1. 24-hour recalls using Intake24 (online survey) over 3-day.~2. Self reported questionnaire. (Single measure)"
215143225|NCT05856734|DEVICE|Change in physical activity|"1. ActiGraph GT9X Link accelerometer over 7-day.~2. Self reported questionnaire. (Single measure)"
215143226|NCT05856734|BEHAVIORAL|Change in stress|1- Self reported questionnaire. (Single measure)
215143227|NCT05856734|BEHAVIORAL|Change in socio-demographic characteristics|1- Self reported questionnaire. (Single measure)
215143228|NCT05856734|DEVICE|Change in sleep|ActiGraph GT9X Link accelerometer over 7-day. (Single measure)
215143229|NCT04804384|DEVICE|Prehension neuroprosthesis|"The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive."
215143230|NCT03363841|DRUG|SCY-078|Oral SCY-078
215143231|NCT02020265|DEVICE|EEG neurofeedback|
214456069|NCT06822777|BEHAVIORAL|RISE for Nurse Preceptors Program|Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
214456070|NCT06821334|BIOLOGICAL|MK-6194|Subcutaneous Administration
214456071|NCT06821334|BIOLOGICAL|Placebo|Subcutaneous administration
214456072|NCT05349500|BEHAVIORAL|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
214456073|NCT05349500|BEHAVIORAL|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
214528109|NCT04822246|PROCEDURE|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
214456074|NCT03703492|DRUG|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
214695164|NCT07082049|BEHAVIORAL|LLM-assisted communication|Preoperatively, patients will communicate with the LLM, which will provide direct answers to their various questions, including but not limited to diagnosis, treatment options, operative risks, and complication management. To ensure the accuracy of LLM-generated responses in real-world clinical settings, all answers will undergo verification by the researchers before being provided to patients.
214708674|NCT00665678|DRUG|paroxetine|treatment for three months with paroxetine
214708675|NCT00665678|DRUG|placebo|treatment for three months with placebo
214708676|NCT02420795|DRUG|Akt/ERK Inhibitor ONC201|Given PO
215143232|NCT05358665|OTHER|mask use|long term mask use
215143233|NCT00563056|DRUG|Flutiform|
215143234|NCT00563056|DRUG|Flixotide plus Foradil|
214456075|NCT03703492|DRUG|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
215143235|NCT04560400|DIAGNOSTIC_TEST|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
215143236|NCT04560400|DIAGNOSTIC_TEST|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
215143237|NCT03343912|DRUG|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
215143238|NCT03343912|DRUG|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
214456076|NCT06807567|OTHER|Receipt of healthcare for long-term conditions|The patient participants are people who are already receiving healthcare for CKD and/or hypertension, diabetes, HIV, heart failure and/or stroke at one of the named study sites, for at least 6 months prior to recruitment into this qualitative study. The caregiver participants are caregivers for patients meeting these criteria.
214456077|NCT06807567|OTHER|Provision of healthcare|The healthcare worker participants are all providing care to patients with long-tem conditions, at one of the names study sites
214456078|NCT06807567|OTHER|Policy making|The policy makers recruited to this study will be individuals involved in policy making for long-term conditions in Malawi
214456079|NCT06292975|OTHER|Supervised Vigorous intensity aerobic interval exercise|7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
214456080|NCT06014593|DEVICE|expirogram|Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
214456081|NCT06300528|DRUG|Pemigatinib|Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
214456082|NCT02348749|RADIATION|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
214456083|NCT02348749|DEVICE|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
214456084|NCT02348749|OTHER|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
214456085|NCT06210633|OTHER|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
214456086|NCT06210633|OTHER|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
214456087|NCT05732428|DRUG|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
214456088|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
214456089|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars.
214456090|NCT06484569|OTHER|Control|The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.
214456091|NCT06484569|OTHER|exercise and cranio sacral therapy|Posture exercises Stretching exercises Strengthening Exercises In addition, deep tissue massage will be applied to increase blood circulation and cranio-sacral therapy will be applied to increase cerebrospinal fluid circulation.
214456092|NCT04550468|OTHER|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
215143239|NCT03343912|DRUG|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
215143240|NCT01744977|BEHAVIORAL|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
214456093|NCT04550468|OTHER|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
214456094|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
214456095|NCT06807658|BEHAVIORAL|Experimental: Cardiac tele-rehabilitation|Patients will connect to their health care provider via a tele-call
214456096|NCT06807658|BEHAVIORAL|Other: Control, in person cardiac rehabilitation|Patients will attend an ambulatory cardiac rehabilitation unit
214456097|NCT03640312|DRUG|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
214456098|NCT03640312|DRUG|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
214456099|NCT06168253|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
214456100|NCT06168253|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
214456101|NCT06069843|DRUG|IV Ketamine|0.5 mg/kg IV Ketamine
214708677|NCT02420795|OTHER|Laboratory Biomarker Analysis|Correlative studies
214708678|NCT02420795|OTHER|Pharmacological Study|Correlative studies
214456102|NCT05988515|BEHAVIORAL|Speech-Language Pathologist-led Speech Motor Chaining|Sessions begin with Pre-practice to elicit the /r/ sound. During Structured Practice, the same utterance is practiced several times in a row (with systematic increases in difficulty based on performance). Our web-based software manipulates the principles of motor learning, including feedback prompts for the clinician, the complexity of the utterance, and the variability in the practice trial; the software will analyze the clinician's rating to increase the difficulty of practice when the child is more accurate. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order. A trained speech-language pathologist is involved in all practice trials to provide feedback throughout the session.
215143241|NCT00821795|DRUG|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
215143242|NCT00821795|DRUG|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
215143243|NCT05577507|DRUG|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
215143244|NCT05577507|DRUG|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcimate 500 mg three times daily within meals
215143245|NCT01253278|DRUG|LY2393910|as capsules, administered orally once daily for two weeks
215143246|NCT01253278|DRUG|Placebo|as capsules, administered orally once daily for two weeks
214456103|NCT05988515|BEHAVIORAL|Artificial Intelligence-led Speech Motor Chaining (CHAINING-AI)|Sessions include Structured Practice and Randomized Practice using our web-based software with an Artificial Intelligence clinician to address the /r/ sound. Within a practice session, participants speak into a microphone, and the audio file is sent to a server to be analyzed by a classifier, which returns a binary accurate/inaccurate rating of productions in a fashion similar to SLP judgment. Our web-based software manipulates the principles of motor learning, including feedback prompts, the complexity of the utterance, and the variability in the practice trial. The software will analyze the child's accuracy as determined by the classifier to increase the difficulty of practice when the child is more accurate.
214456104|NCT06772480|DRUG|Thalidomide|Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
214456105|NCT06772480|PROCEDURE|Argon Plasma Coagulation|Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
214528110|NCT04822246|PROCEDURE|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
214528111|NCT04822246|PROCEDURE|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
214528112|NCT00801749|BEHAVIORAL|sleep|
214528113|NCT04267393|DRUG|BMS-986263|Specified dose on specified days
214528114|NCT04267393|OTHER|Placebo|Specified dose on specified days
214528115|NCT00701597|DRUG|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
214708679|NCT01874119|DRUG|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
215143247|NCT03713736|DIAGNOSTIC_TEST|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
215143248|NCT03713736|DIAGNOSTIC_TEST|Pregnancy test|Urinary pregnancy test
215143249|NCT03713736|BEHAVIORAL|Sexual activity questionnary|Sexual activity questionnary
215143250|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
215143251|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
214456106|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
214708680|NCT01646567|DRUG|SHP-141C|Topical Cream
214528116|NCT04994418|DIETARY_SUPPLEMENT|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
214528117|NCT04994418|DIETARY_SUPPLEMENT|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
214528118|NCT04994418|DIETARY_SUPPLEMENT|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
214528119|NCT06941311|BEHAVIORAL|Cognitive Behavioral Therapy for Suicide Prevention (CBT-SP)|Clinicians will provide this specialized evidence-based mental health care. The study focuses on the acute phase of CBT-SP, which is 12 sessions. CBT-SP's goals are to reduce suicide risk factors, enhance coping, and prevent future suicidal behavior. Identifying the emotional, cognitive, behavioral, or familial processes that precede a suicide crisis is a major focus, which yields an individualized treatment plan. Each session lasts one hour and can be completed either in person or via a secure telehealth platform. Most youths will attend sessions on a weekly basis and therapists typically like to be in contact with parents as well.
215143252|NCT00738933|DIETARY_SUPPLEMENT|placebo|Margarine product without plant stanol or sterol esters
215143253|NCT03421483|DIETARY_SUPPLEMENT|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
215143254|NCT03421483|DIETARY_SUPPLEMENT|Adult Multivitamin|Participants will receive an adult multivitamin supplement
214456108|NCT06240325|BEHAVIORAL|SPP|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
214528120|NCT06941311|BEHAVIORAL|Youth-Nominated Support Team|Youth will nominate up to 4 trusted adults. Following parental approval, Support Persons will attend an orientation session with their assigned intervention specialist, learn about the youth's difficulties, treatment plan, and receive ideas for supporting the youth. Support Persons will be asked to have contact with the youth each week for up to three months to offer emotional support, encourage participation in treatment, and support the youth's healthy behaviors. Support Persons will have weekly check-ins with their intervention specialist every week for the 3 months of the study. During these calls, Support Persons have an opportunity to discuss any questions or concerns they may have about the youth and how best to support them.
214528121|NCT01935193|DRUG|lysine acetylsalicylate|
214528122|NCT00421122|DRUG|budesonide/formoterol (Symbicort)|inhalation therapy
214528123|NCT00421122|DRUG|budesonide (Pulmicort)|inhalation
214528124|NCT00421122|DRUG|terbutaline sulfate (Bricasol)|inhalation therapy
214528125|NCT01516606|DRUG|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
214528126|NCT03273283|BEHAVIORAL|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
214528127|NCT00710814|DRUG|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
215143255|NCT04734691|PROCEDURE|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
215143256|NCT02600234|DEVICE|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
215143257|NCT02600234|OTHER|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
215143258|NCT02624076|OTHER|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
214456109|NCT06240325|BEHAVIORAL|Sleep Psychoeducation|Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
214528128|NCT00710814|OTHER|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
215143259|NCT02624076|OTHER|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
215143260|NCT06483295|OTHER|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
215143261|NCT04052880|DRUG|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
214456110|NCT06109753|PROCEDURE|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
214456111|NCT06109753|PROCEDURE|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
214528129|NCT06023888|OTHER|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
214528130|NCT06023888|OTHER|Mapping strategy|PVI+ non-PV trigger
214528131|NCT05648448|DRUG|Oseltamivir|Oral oseltamivir 75mg BD for 5/7
214528132|NCT05648448|DRUG|Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
215143262|NCT04052880|DRUG|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
214528133|NCT05648448|DRUG|Zanamivir|Inhaled zanamivir 10mg BD for 5/7
214528134|NCT05648448|DRUG|Baloxavir|"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
215143263|NCT04052880|DRUG|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
215143264|NCT04052880|DRUG|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
215143265|NCT04052880|DRUG|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
215143266|NCT00420446|BEHAVIORAL|Adjusted diet|
215143267|NCT01046708|DRUG|micronized progesterone|600mg in 3 separate doses per day
215143268|NCT03687060|BEHAVIORAL|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
215143269|NCT03687060|BEHAVIORAL|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
215143270|NCT03687060|BEHAVIORAL|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
215143271|NCT02986295|DEVICE|BioMimeTM Stent, Ultimaster® Stent|
215143272|NCT03770988|DRUG|Treatment with Poziotinib|Treatment with Poziotinib
215143273|NCT06432218|OTHER|video education|A re-watchable video provided before pessary fitting which mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy.
215143274|NCT06432218|OTHER|conventional education|Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.
214456112|NCT06143306|DRUG|bupivacaine.|an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
214456113|NCT06143306|DRUG|Saline|an ultrasound guided pectoserratus block with 25 mL of saline
214456114|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
214456115|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
214456116|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
214528135|NCT05648448|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5/7
214528136|NCT05648448|DRUG|Peramivir|Intravenous peramivir 600mg once only
214528137|NCT05648448|DRUG|Laninamivir|Inhaled laninamivir 40mg once only
214528138|NCT05648448|DRUG|Oseltamivir and Baloxavir|"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
214528139|NCT05648448|DRUG|Oseltamivir and Favipiravir|"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"
214528140|NCT05648448|DRUG|Favipiravir and Baloxavir|"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
214528141|NCT05823519|DEVICE|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
214528142|NCT02548754|DEVICE|Parasym device|
214708681|NCT01646567|DRUG|Placebo to SHP-141C|Placebo Topical Cream
214708682|NCT01646567|DRUG|Betamethasone Valerate|Topical cream, 0.02%
214708683|NCT01646567|DRUG|Calcipotriol|Topical cream, 0.005%
214456117|NCT06205368|BEHAVIORAL|Combine mobile app|"* HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~* Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~* Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~* Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~* Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
214528143|NCT03394183|OTHER|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
214528144|NCT03159325|BEHAVIORAL|Healing Circles|See description in the arm description.
215143275|NCT06119282|OTHER|inhaler|Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
215143276|NCT06119282|OTHER|Control Group|Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
215143277|NCT06119282|OTHER|massage|Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
215143278|NCT02878343|BEHAVIORAL|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
214528145|NCT02565888|DRUG|Daclatasvir|
215143279|NCT02878343|BEHAVIORAL|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
215143280|NCT06225414|OTHER|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
215143281|NCT06225414|BEHAVIORAL|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
214528146|NCT02565888|DRUG|Atazanavir|
214528147|NCT02565888|DRUG|Ritonavir|
214528148|NCT02565888|DRUG|Cobicistat|
214456118|NCT06205368|BEHAVIORAL|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
215143282|NCT06225414|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
215143283|NCT06225414|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
214456119|NCT06205368|BEHAVIORAL|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
214456120|NCT06543953|DEVICE|HearCare MED-EL App|The main task of the HearCare MED-EL App is to perform technical checks on both implants and audio processors and create backups of audio processor configurations so that these configurations can be written on to an empty audio processor of the same type.
214456121|NCT05485376|DEVICE|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
214456122|NCT05158101|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
214456123|NCT04703166|DEVICE|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
214456124|NCT05202990|DRUG|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
214456125|NCT05202990|DRUG|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
214456126|NCT05123118|BEHAVIORAL|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
214456127|NCT05123118|BEHAVIORAL|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
214456128|NCT06450782|OTHER|Post-isometric Relaxation Technique|"Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier."
214456129|NCT06450782|OTHER|Myofascial Release Technique|"Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times."
214456130|NCT06450782|OTHER|Control|Participants will rest for thirty minutes.
214456131|NCT03486067|DRUG|CC-93269|Specified dose on specified days
214456132|NCT06918925|DRUG|JUV-161, Placebo|Single-Ascending, Placebo-Controlled
214456133|NCT06884761|BEHAVIORAL|Maximal Rest|Participants in this group are instructed to follow maximal rest protocols. They are advised to avoid strenuous activities, including prolonged standing, lifting heavy objects, or engaging in physically demanding tasks. This group represents the traditional bed rest approach to managing pregnancies with a short cervix.
214456134|NCT05081037|DEVICE|Wearable Care Group|"Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels."
214456135|NCT06377631|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214708684|NCT00786097|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
214456136|NCT06377631|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214528149|NCT04792255|PROCEDURE|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
214708685|NCT02438046|PROCEDURE|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
214456137|NCT06930183|DRUG|Awake thoracic epidural anesthesia|Patients will preoperatively receive awake thoracic epidural anesthesia.
214456138|NCT06930183|DRUG|General anesthesia|Patients will receive general anesthesia.
214456139|NCT06728696|PROCEDURE|Immediate implant with with dual zone technique using concentrated growth factor graft.|In the test group, pouch technique + CGFG will be used. The CGFG will be packed in the split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket. A convenient blood sample will be withdrawn from a peripheral venous blood from the patient using a specialized vacutaine. A standard, disposable, 10-ml non- anticoagulant tube and a matching centrifuge device was used. To prepare the CGFG, the centrifuge is accelerated for 30 seconds, then centrifuged at 2700 rpm for 2 minutes, 2400 rpm for 4 minutes, 2700 rpm for 4 minutes, and 3000 rpm for 3 minutes before being decelerated for 36 seconds to stop.
214456140|NCT06728696|PROCEDURE|Immediate implant with dual zone technique using connective tissue graft.|Patients assigned to the control group will receive pouch technique + CTG. Following implant placement, a split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket will be performed using 15c mini blade to allow for the placement of a CTG. The pouch preparation will be extended apical beyond the muco-gingival junction and to the neighboring teeth mesiodistally. The CTG will be harvested from the palate with a thickness of 1.5 mm using single-incision technique, which was done approximately 2-3 mm apical to the gingival margin of the maxillary teeth and parallel to the palatal long axis. A resorbable suture will be used to first pierce the labial mucosa along with the periosteum at an apical part, which then exits from the sulcus. Afterward, the CTG will be tucked in the pouch, labial to the suture, and held at a coronal area by using the needle to pierce it from its inner surface toward the labial soft tissue. The knot will then be se
214456141|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
214456142|NCT06911892|OTHER|Group Serratus Anterior Plane Block|Patients will receive a serratus anterior plane block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
214456143|NCT06911892|OTHER|Group Parasternal Block|Patients will receive a parasternal block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
214456144|NCT06911892|OTHER|Group Interpectoral+Pectoserratus Plane Block|"Patients will receive an interpectoral + pectoserratus plane block preoperatively under ultrasound guidance.~Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis."
214456145|NCT06913088|PROCEDURE|ultrasonication-mediated microbubbles dressing|The microbubble suspension is diluted with normal saline to a concentration of 2x10\^7 bubbles/mL, applied to a gauze cloth, and covered on the joint skin surface. The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan), and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
214456146|NCT06913088|PROCEDURE|ultrasonication using pure gel|The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan) with pure gel, and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
214456147|NCT06825273|OTHER|space maintainer|3-D printed partial denture space maintainer will designed for each child patient who has premature loss of primary teeth after doing intraoral scanning
214456148|NCT06825273|OTHER|space maintainer|a conventional impression will be done for a child patient with premature loss of his primary teeth, then a plaster model will gained. A conventional acrylic partial denture will be designed and delivered to the patient.
214456149|NCT06916819|DIAGNOSTIC_TEST|Home-Based Food Challenge|Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels.
214528150|NCT04792255|PROCEDURE|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
214528151|NCT04792255|DIAGNOSTIC_TEST|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
214528152|NCT00003212|DRUG|doxorubicin hydrochloride|
215143284|NCT06225414|BEHAVIORAL|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
215143285|NCT06225414|BEHAVIORAL|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
215143286|NCT01202097|DRUG|Salmeterol/Fluticasone|
215143287|NCT01202097|DRUG|Seretide|
215143288|NCT05955482|OTHER|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
215143289|NCT00611104|DIETARY_SUPPLEMENT|standardized freeze-dried table grape powder|
215143290|NCT00611104|OTHER|laboratory biomarker analysis|
215143291|NCT00611104|OTHER|pharmacological study|
215143292|NCT05481463|DRUG|Surufatinib|surufatinib,250mg, qd, po, 28 days for a cycle
215143293|NCT05481463|DRUG|TAS-102|TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
215143294|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
214456150|NCT06916819|DIAGNOSTIC_TEST|In-Clinic Food Challenge|Standard of care - Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels.
214456151|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
214456152|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
214456153|NCT06132867|DRUG|Brigatinib|Brigatinib oral solution
214456154|NCT06132867|DRUG|Brigatinib|Brigatinib tablet
214456155|NCT06931834|DRUG|Probucol|Probucol 250 mg tablets orally up to a daily dose of 1,000 mg
214456156|NCT05071729|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
214456157|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
214456158|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
214456159|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
214456160|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
214456161|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
214456162|NCT05361317|DEVICE|Nexis® PECA Bunion device|Hallux valgus correction with percutaneous chevron and Akin osteotomy.
214528153|NCT00003212|DRUG|ifosfamide|
214528154|NCT04532983|PROCEDURE|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
215143295|NCT06238544|DRUG|HRS-5965 Capsules|HRS-5965 capsules.
215143296|NCT03787511|OTHER|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
215143297|NCT03787511|OTHER|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
214456163|NCT05556174|OTHER|periodic lung recruitment maneuvers|lung recruitment maneuvers repeated every 30 minutes
214456164|NCT06089707|DRUG|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
215143298|NCT03787511|OTHER|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
215143299|NCT04971499|DRUG|Dapansutrile|500 mg tablet
215143300|NCT04971499|DRUG|Pembrolizumab|Single-use vial containing 100 mg/4 mL of pembrolizumab
214456165|NCT04480918|DEVICE|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
214456166|NCT04480918|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
214456167|NCT04480918|DRUG|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
214456168|NCT04480918|DRUG|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
214456169|NCT04480918|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
214456170|NCT06581770|OTHER|Survey using a questionnaire.|It is a validity and reliability study that can evaluate digital health readiness.
214456171|NCT06581770|OTHER|Survey using a questionnaire.|This is a reliability and validity study.
214456172|NCT06212752|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
214456173|NCT06212752|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
214456174|NCT06212752|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
214456175|NCT06212752|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
214456176|NCT06212752|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
214456177|NCT06212752|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
214456178|NCT06212752|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
214456179|NCT06212752|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
214456180|NCT06212752|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
214456181|NCT01105234|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
214456182|NCT02710734|DRUG|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
214456183|NCT02710734|DRUG|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
214456184|NCT02710734|DRUG|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
214456185|NCT02710734|DRUG|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
214456186|NCT02710734|RADIATION|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
214456187|NCT02710734|PROCEDURE|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
214456188|NCT02710734|DRUG|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
214456189|NCT02710734|DRUG|Mitomycin C|Intravenous on day 1 with radiation treatment
214456190|NCT00009633|OTHER|No Intervention|No Intervention
214528155|NCT04532983|PROCEDURE|mesh placement without fixation|mesh placement in preperitoneal space without fixation
214456191|NCT05171075|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
214456192|NCT05171075|DRUG|Dalteparin|Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
214456193|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
214528156|NCT05277818|PROCEDURE|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
215143301|NCT01510483|BEHAVIORAL|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
214456194|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
214456195|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
214456196|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
214456198|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
214456199|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
214528157|NCT02093897|BIOLOGICAL|rVIII-SingleChain|
214528158|NCT00088452|DRUG|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
214528159|NCT00088452|DRUG|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
214528160|NCT00088452|DRUG|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
214528161|NCT03429595|DRUG|ATx201|ATx201 GEL
214528162|NCT03429595|OTHER|ATx201 GEL Vehicle|Vehicle
214456200|NCT03463824|BEHAVIORAL|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
214456201|NCT03463824|BEHAVIORAL|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
215143302|NCT01510483|BEHAVIORAL|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
214456202|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
214456203|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
214456204|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
214456205|NCT03169790|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214456206|NCT03169790|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
214456207|NCT03169790|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214456208|NCT03169790|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214456209|NCT03169790|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214456210|NCT03169790|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214528163|NCT03377725|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
214528164|NCT03377725|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
214528165|NCT02264418|DRUG|ODM 203|ODM 203
214528166|NCT02264418|DRUG|ODM 203|ODM 203
215143303|NCT05101070|DRUG|S-531011|Administered by intravenous infusion
215143304|NCT05101070|DRUG|Pembrolizumab|Administered by intravenous infusion
214456211|NCT03169790|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214456212|NCT03169790|DRUG|Lovaza|Omega-3-acid ethyl esters
214456213|NCT03169790|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214456214|NCT03169790|DRUG|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
214456215|NCT03169790|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
214456216|NCT03169790|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
214456217|NCT03169790|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
214456218|NCT03169790|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
214456219|NCT04177823|DRUG|Belantamab mafodotin|Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
214456220|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
214456221|NCT04229992|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
214456222|NCT04229992|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
214456223|NCT06404931|PROCEDURE|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
214456224|NCT06404931|PROCEDURE|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
214456225|NCT06404931|PROCEDURE|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
214528167|NCT02629419|DRUG|Amphotericin B|Oral lipid nanocrystal formulation of amphotericin B
214528168|NCT02596399|DRUG|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
214528169|NCT02596399|DRUG|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
214528170|NCT02081196|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214528171|NCT02936492|DRUG|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
214528172|NCT02936492|DRUG|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
214528173|NCT02936492|DRUG|BAY1003803 0.01% ointment|Topical administration for 22 h per day
214528174|NCT02936492|DRUG|BAY1003803 0.1% ointment|Topical administration for 22 h per day
214528175|NCT02936492|DRUG|Lipophilic cream vehicle|Topical administration for 22 h per day
214528176|NCT02936492|DRUG|Ointment vehicle|Topical administration for 22 h per day
214528177|NCT02936492|DRUG|Clobetasol propionate|Topical administration for 22 h per day
214528178|NCT02055053|DRUG|0.5% Bupivicaine|Local anesthetic
214528179|NCT00399997|BEHAVIORAL|Exercise on Prescription|
214528180|NCT03098797|DRUG|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
214528181|NCT03098797|DRUG|Placebo|daily subcutaneous injection for 12 weeks
215143305|NCT04090203|DRUG|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
214456226|NCT03351504|OTHER|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
214456227|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
214456228|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
214456229|NCT04873401|BEHAVIORAL|Chain-referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing. The peer recruiters are paid for each suvcessful and eligible recruit who enrolls to be tested. Those individuals are then themselves trained to recruit peers from their social networks to receive COVID-19 testing. This is repeated over a period of 4-6 months."
214456230|NCT04873401|BEHAVIORAL|Credible Messenger|In the credible messenger intervention, peers noted to be popular and socially influential individuals with lived experience will be trained to engage within community settings and areas to encourage community members to receive COVID-19 testing at the community partnering agencies. Peers will recruit community members over a period of 4-6 months.
214456231|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
214456232|NCT03457142|DRUG|Dexamethasone|Given PO
214456233|NCT03457142|DRUG|Ixazomib Citrate|Given PO
214456234|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
214456235|NCT05384119|DRUG|TTI-101|Oral tablet
214456236|NCT05384119|DRUG|Palbociclib|Oral capsule
214456237|NCT05384119|DRUG|Aromatase inhibitor (AI)|Oral tablet
214456238|NCT05384119|DRUG|fulvestrant|Oral tablet
214456239|NCT05384119|DRUG|ribociclib|Oral tablet
214456240|NCT05963711|OTHER|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
214456241|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
214456242|NCT06031402|PROCEDURE|Endoscopy|Endoscopy
214528182|NCT03018847|DEVICE|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
214528183|NCT01176136|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
214528184|NCT04814615|DRUG|89Zr-daratumumab PET/CT|CD38-targeting imaging
214695165|NCT07082049|BEHAVIORAL|Routine preoperative communication|Preoperatively, patients will attend a consultation with the attending surgeon and surgical team. This physician-led communication will comprehensively discuss, current disease status, treatment options, operative risks, potential complication. The surgical team will subsequently address patient inquiries, followed by executing the informed consent form.
214456243|NCT06183892|DRUG|Tacrolimus Sustained-release Capsules|"Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)"
214456244|NCT06002932|PROCEDURE|Procedure: planed 2-stent strategy|Procedure: planed 2-stent strategy
214456245|NCT06002932|PROCEDURE|Procedure: provisional 1-stent plus DEB strategy|Procedure: provisional 1-stent plus DEB strategy
214456246|NCT04448002|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
214456247|NCT04448002|BEHAVIORAL|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
214456248|NCT03770273|BIOLOGICAL|sarilumab|Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.
214456249|NCT03770273|OTHER|Placebo|Placebo
214456250|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
214456251|NCT00418886|DRUG|Vandetanib|oral once daily tablet
214456252|NCT00418886|DRUG|Pemetrexed|intravenous infusion
214456253|NCT02446132|DRUG|AVP-786|
214456254|NCT05556473|DRUG|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
214528185|NCT02895698|DEVICE|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
214528186|NCT02895698|OTHER|Stretching exercises|"* The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds."
214456255|NCT03946111|DRUG|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
214456256|NCT03946111|OTHER|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
214456257|NCT05685927|DRUG|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
214456258|NCT05685927|PROCEDURE|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
214528187|NCT03683914|DRUG|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
214456259|NCT04784247|DRUG|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
214456260|NCT04784247|DRUG|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
214528188|NCT03683914|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
214528189|NCT04734847|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
214456261|NCT06524843|OTHER|Analysis|Analysis and review of imaging and clinical data
214456262|NCT02753777|OTHER|Questionnaires|
214528190|NCT04734847|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
214528191|NCT05813535|DRUG|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
214695166|NCT07083856|BEHAVIORAL|Reiki|Reiki
214695167|NCT07083856|BEHAVIORAL|Self-Acupressure|Self-Acupressure
214708686|NCT02818413|OTHER|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
214708687|NCT03780413|BEHAVIORAL|PR-ESSENCE treatment|
214708688|NCT03780413|BEHAVIORAL|Control (TAU)|
214708689|NCT01158066|PROCEDURE|CT Cardiac|the patient will undergo cardiac CT
214456263|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
214456264|NCT04060654|DRUG|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
214456265|NCT06207006|BEHAVIORAL|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
214456266|NCT06207006|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
215143306|NCT06488820|DEVICE|Catheter ablation using pulsed-field ablation (PFA) system|PFA will be used to isolate the pulmonary veins and additional left atrial structure as needed
215143307|NCT04984616|DRUG|40 mg Atorvastatin/day for 120 days P.O.|Oral administration of Atorvastatin 40 mg/daily for 120 days
215143308|NCT04984616|DRUG|Atorvastatin 80|Oral administration of Atorvastatin 80 mg/daily for 120 days
215143309|NCT04984616|DRUG|Placebo|Oral administration of Placebo daily for 120 days
215143310|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
214456267|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
214456268|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
214456269|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
214456270|NCT03906695|DRUG|ASTX727|oral decitabine 20mg + cedazuridine
214456271|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
214456272|NCT03572985|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
214456273|NCT03572985|OTHER|Car-following test|Driving with simulator program for DCV measurement
214695168|NCT07084207|DEVICE|Symani® Surgical System|"Robotic-assisted surgery consists of participants who undergo nerve coaptation with the Symani Surgical System, according to the Instruction for Use (IFU). In order for the surgery to be considered a robotic assisted surgery, the participants must be randomized to the RAS group which will include:~* Participants where all nerve coaptations were performed entirely with Symani.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using Symani but a switch to manual suturing occurred during the procedure"
215143311|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
214708690|NCT04863313|DIETARY_SUPPLEMENT|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
215143312|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
215143313|NCT02595125|DEVICE|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
215143314|NCT00002022|DRUG|Epoetin alfa|
214456274|NCT03572985|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
214456275|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
214456276|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
214456277|NCT04887129|DIAGNOSTIC_TEST|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
214456278|NCT04887129|OTHER|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
214456279|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
214456280|NCT05823363|DRUG|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
214456281|NCT05823363|DRUG|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
214456282|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
214708691|NCT04863313|DIETARY_SUPPLEMENT|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
214456283|NCT03332940|DRUG|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
214456284|NCT03332940|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214456285|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).
214456286|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
214456287|NCT06084572|OTHER|Questionnaires|FSSG \& BEDQ
214456288|NCT05439759|BEHAVIORAL|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
214456289|NCT05439759|BEHAVIORAL|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
214456290|NCT05439759|BEHAVIORAL|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
214456291|NCT05439759|BEHAVIORAL|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
214456292|NCT06158399|DRUG|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
214456293|NCT06567821|DEVICE|RELIEVA SPINPLUS® NAV Balloon Sinusplasty System|The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
214456294|NCT06074419|DEVICE|Occulus quest 2 virtual reality glasses|Patients will be shown nature videos via the specified virtual reality connection.
214456295|NCT06656013|BEHAVIORAL|Motivational Interview|After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
214456296|NCT03310905|PROCEDURE|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
214456297|NCT03310905|PROCEDURE|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
214456298|NCT03725878|PROCEDURE|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
215143315|NCT03181022|BEHAVIORAL|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
215143316|NCT05513534|OTHER|Yoga|A standard yoga program will be provided using Hatha poses.
215143317|NCT05513534|OTHER|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
214528192|NCT05964556|OTHER|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
214528193|NCT05964556|OTHER|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
214695169|NCT07084207|PROCEDURE|Manual Surgery|"Manual surgery consists of participants who undergo nerve coaptation through manual techniques by a surgeon using handheld instruments without robotic assistance. In order for the surgery to be considered a manual surgery, the participants must be randomized to the MS group which will include:~* Participants where all nerve coaptations were performed entirely manually.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using manual suturing but a switch to Symani occurred during the procedure."
214695170|NCT05676528|OTHER|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
214528194|NCT01868516|DRUG|dexmecamylamine|
214528195|NCT01868516|DRUG|Placebo|
214695171|NCT07083193|DRUG|AC-101|AC-101 tablets will be administered orally.
215143318|NCT03891134|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
214456299|NCT03725878|PROCEDURE|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration \>400 ng/ml before pregnancy is recommended.
214456300|NCT03725878|PROCEDURE|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
214456301|NCT06410391|RADIATION|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
214456302|NCT02203552|DRUG|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
214456303|NCT02203552|OTHER|placebo|Placebo given by mouth for 9 weeks
214528196|NCT04568356|DIAGNOSTIC_TEST|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
214528197|NCT02821078|OTHER|4D flow imaging sequence|4D flow imaging sequence
215143319|NCT00620451|DRUG|larazotide acetate|gelatin capsule
215143320|NCT00620451|DRUG|placebo|gelatin capsule
215143321|NCT02212639|DRUG|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
215143322|NCT01753232|DEVICE|DALI-adsorber|Recording of treatment data. No extra interventional treatment
215143323|NCT01753232|DEVICE|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
215143324|NCT02614001|DEVICE|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
215143325|NCT02614001|OTHER|post-stroke rehabilitation program|
215143326|NCT04805034|OTHER|Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level|Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
215143327|NCT02604394|PROCEDURE|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
215143328|NCT02604394|PROCEDURE|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
215143329|NCT03418714|DRUG|Salvinorin A|Salvinorin A, blinded doses
215143330|NCT03711968|OTHER|Rehabilitative treatment protocol|A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
214456304|NCT02203552|OTHER|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
214456305|NCT02203552|OTHER|Questionnaire administration|The CES-D and STAI will be administrated weekly.
214456306|NCT04606069|DRUG|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
214456307|NCT04606069|OTHER|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
214456308|NCT05659264|DRUG|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
214456309|NCT05659264|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
215143331|NCT05468996|DRUG|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
215143332|NCT05586438|DRUG|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
215143333|NCT05751187|BIOLOGICAL|Pembrolizumab|Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
214456310|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
214456311|NCT02852694|DRUG|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
214456312|NCT02852694|DRUG|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
214456313|NCT02852694|DRUG|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
214456314|NCT04195451|OTHER|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
214456315|NCT04195451|OTHER|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
214528198|NCT01216059|PROCEDURE|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
214528199|NCT05037721|OTHER|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
214528200|NCT05037721|OTHER|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
214456316|NCT06487741|OTHER|Home-based stretching exercises|The intervention comprises six weeks of daily static stretching exercises (six minutes a day) in accordance with the recommendation of the American College of Sports Medicine. The intervention is self-administered and consists of two bouts of 30-second bilateral static stretches of the knee flexors, hip abductors, and shoulder elevators.
214528201|NCT03982875|DEVICE|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
215143334|NCT05751187|BIOLOGICAL|Bevacizumab|Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
215143335|NCT05751187|DRUG|Pemetrexed|Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
215143336|NCT05751187|DRUG|Cisplatin|Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
215143337|NCT05751187|DRUG|Carboplatin|Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
215143338|NCT05751187|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
215143339|NCT05751187|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
215143340|NCT05751187|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
215143341|NCT03513159|BEHAVIORAL|Pathfinder support|A pathfinder will support the patient with structured activities.
215143342|NCT04725578|BEHAVIORAL|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
214456317|NCT04278157|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
214456318|NCT04278157|BEHAVIORAL|Treatment as Usual|Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
214456319|NCT06829082|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Antiretroviral therapy (ART) has advanced with the introduction of integrase strand transfer inhibitors (INSTIs), such as the fixed-dose combination of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC), known as Biktarvy®. This regimen is preferred for its high genetic barrier to resistance, minimal drug interactions, and once-daily, single-tablet formulation, which enhances adherence and long-term treatment outcomes. While clinical trials have demonstrated its efficacy, real-world data specific to Colombia are lacking.
214456320|NCT06783153|DRUG|Rifaximin 550 MG|Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
214708692|NCT04904380|OTHER|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
214708693|NCT00702260|DRUG|Ramipril|10 mg capsule
214708694|NCT06441747|DRUG|Durvalumab|Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
214528205|NCT02846935|DRUG|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
214528206|NCT02846935|DRUG|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
214528207|NCT03354897|DRUG|Torasemide 5Mg Tablet|16 weeks treatment
214528208|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
215143343|NCT00424710|DRUG|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
215143344|NCT00005966|BIOLOGICAL|recombinant interferon alfa|
215143345|NCT00005966|DRUG|thalidomide|
215143346|NCT03879772|DRUG|Mometasone furoate nasal spray|intranasal administration
215143347|NCT03879772|DRUG|Beclomethasone dipropionate nasal spray|intranasal administration
214456321|NCT06783153|DRUG|Standard Care Chemoradiation|Patients will receive standard chemotherapy and/or radiation
214456322|NCT02921230|DEVICE|Peripheral stenting|stent implantation during the index procedure
214456323|NCT06778785|BEHAVIORAL|Digital Intervention|game-based digital intervention app
214456324|NCT06778785|BEHAVIORAL|Health Education|traditional health education app
215143348|NCT03879772|DRUG|Placebo nasal spray|intranasal administration
215143349|NCT03879772|DRUG|Chlorpheniramine maleate syrup|oral administration
215143350|NCT06236269|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
215143351|NCT01670084|DRUG|nilotinib|Given PO
215143352|NCT01670084|BIOLOGICAL|rituximab|Given IV
215143353|NCT01670084|DRUG|cyclophosphamide|Given IV
215143354|NCT01670084|DRUG|doxorubicin hydrochloride|Given IV
215143355|NCT01670084|DRUG|vincristine sulfate|Given IV
215143356|NCT01670084|DRUG|methotrexate|Given IV or IT
215143357|NCT01670084|DRUG|cytarabine|Given IV or IT
214456325|NCT06778785|OTHER|Personalization Algorithm|a proprietary algorithm that adaptively adjust the treatment module and parameters to personalize the treatment regime
214456326|NCT05547347|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214456327|NCT05547347|PROCEDURE|Mammogram|Undergo a mammogram
214456328|NCT05547347|PROCEDURE|Ultrasound|Undergo a breast ultrasound
214456329|NCT05547347|PROCEDURE|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
214456330|NCT05547347|DEVICE|Twinkle marker|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
214456331|NCT04691297|OTHER|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
214456332|NCT04691297|OTHER|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
214456333|NCT03436290|BEHAVIORAL|Palliative Care Intervention|These patients will receive the palliative care intervention.
214456334|NCT06232902|DRUG|QL1101|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
214456335|NCT06232902|DRUG|Avastin®|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
214456336|NCT06348160|BEHAVIORAL|iHERO Toolkit Resource|iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
214456337|NCT06529250|DRUG|HAD|"Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
214456338|NCT06529250|DRUG|Daunorubicin+Cytarabine|"Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
214456339|NCT05276973|PROCEDURE|Biopsy|Undergo biopsy
214456340|NCT05276973|DRUG|Carboplatin|Given IV
214456341|NCT05276973|DRUG|Ipatasertib|Given PO
214456342|NCT05276973|DRUG|Paclitaxel|Given IV
214456343|NCT05773820|DRUG|WJB001|"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
214456344|NCT05953155|OTHER|Control|Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
214456345|NCT05953155|OTHER|Yoga|Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
214456346|NCT03064217|DEVICE|Making impression at surgery|Making impression at surgery
214456347|NCT01088542|BEHAVIORAL|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
214456348|NCT03784014|DRUG|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456349|NCT03784014|DRUG|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456350|NCT03784014|DRUG|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
215143358|NCT01670084|DRUG|prednisone|Given PO
215143359|NCT01670084|DRUG|mesna|Given IV
215143360|NCT01670084|DRUG|dexamethasone|Given IV or PO
215143361|NCT01670084|DRUG|leucovorin calcium|Given IV
215143362|NCT01577992|DRUG|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
215143363|NCT01577992|PROCEDURE|determination of objective and subjective pain threshold|Test without levodopa intake
215143364|NCT00157131|BIOLOGICAL|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
215143365|NCT00157131|OTHER|Staples|Administration by mechanical/multiple point fixation.
215143366|NCT03856788|DRUG|Saline|40 mL sterile normal saline
214456351|NCT03784014|DRUG|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456352|NCT03784014|DRUG|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456353|NCT03784014|COMBINATION_PRODUCT|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
214456354|NCT03784014|COMBINATION_PRODUCT|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456355|NCT03784014|DRUG|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
214456356|NCT03784014|DRUG|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
214456357|NCT03784014|DRUG|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
214456358|NCT03784014|OTHER|Next Generation sequencing exome|Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
214456359|NCT03900793|DRUG|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily, dose level 2 dosing will not exceed 100 mg daily, and dose level 3 dosing will not exceed 150 mg total daily (75 mg twice daily). Doses should be taken at approximately the same time daily and patients should fast for at least 4 hours prior to dosing
214456360|NCT03900793|DRUG|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2. Sunitinib is given as capsules or liquid formulation. Doses should be taken at approximately the same time daily.
214456361|NCT01084876|DRUG|CT-P6|Administered every 3 weeks
214456362|NCT01084876|DRUG|Herceptin|Administered every 3 weeks
214456363|NCT01084876|DRUG|Paclitaxel|Administered every 3 weeks
214456364|NCT04927741|OTHER|Sweet Marjoram Essential Oil|"Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
214456365|NCT04927741|OTHER|Grapeseed Oil|"Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
214528209|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
214528210|NCT04301700|BEHAVIORAL|mindfullness and relaxation|three arms: mindfullness and relaxation
215143367|NCT03856788|DRUG|Bupivacaine|40 mL 0.25% bupivacaine
214528211|NCT06363513|DRUG|Aescin in Horse Chestnut|Can aescin reduce bleeding in early hemorrhoid
214528212|NCT06363513|DRUG|Flavonoid|Can combine aescin and MPFF reduce bleeding in early hemorrhoid
214528213|NCT02514226|PROCEDURE|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
214528214|NCT02514226|PROCEDURE|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
214708695|NCT06441747|DRUG|Olaparib|Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
215143368|NCT02972437|OTHER|sample taking|throat culture and oral cavity sample
215143369|NCT01642576|BEHAVIORAL|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
215143370|NCT01403532|DRUG|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
215143371|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
215143372|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
215143373|NCT03818321|DRUG|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
215143374|NCT03818321|DRUG|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
215143375|NCT05973032|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
215143376|NCT00106704|DRUG|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
215143377|NCT00106704|DRUG|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
214456366|NCT01085253|OTHER|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
214456367|NCT04053283|BIOLOGICAL|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
214456368|NCT05398484|DRUG|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
214456369|NCT05398484|DRUG|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
214456370|NCT05398484|BEHAVIORAL|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
214456371|NCT06073119|DRUG|SAR441566|Tablet
214456372|NCT06073119|DRUG|Placebo|Tablet
214456373|NCT05360680|DRUG|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
214456374|NCT06199869|OTHER|Evaluation of risk factors by direct interview with subjects who have atherosclerotic cardiovascular patients|Individuals identified with a diagnosis of ASCVD will fill a one page form of the associated risk factors they have
214456375|NCT05530070|OTHER|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
214456376|NCT05530070|OTHER|Standard of care|Patients will receive standard of care and baseline dietary education.
214456377|NCT05530070|DIAGNOSTIC_TEST|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
214456378|NCT05615558|OTHER|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
214528215|NCT02514226|PROCEDURE|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
215143378|NCT00106704|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
215143379|NCT03415685|DEVICE|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
215143380|NCT05185869|DRUG|SHR6390|SHR6390, Oral Administration
215143381|NCT05185869|DRUG|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
214456379|NCT04971395|DRUG|Placebo|Single dose of 2 or 4 mg/kg
214456380|NCT04971395|DRUG|XTMAB-16 2 mg/kg|Single dose of 2 mg/kg
214456381|NCT04971395|DRUG|XTMAB-16 4mg/kg|Single dose of 4 mg/kg
214456382|NCT06581575|BIOLOGICAL|JCXH-105|IM injection
214456383|NCT06581575|BIOLOGICAL|Shingrix|IM injection
214456384|NCT06581237|OTHER|Eat2Win App|Voluntary use of the app will occur throughout the sport season.
214456385|NCT02924818|OTHER|Clinical assessment|
214528216|NCT02514226|OTHER|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
214528217|NCT01509937|DEVICE|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
214528218|NCT01509937|DEVICE|Device|participants in control arm will not receive BCM measurement.
215143382|NCT05185869|DRUG|Gemcitabine|Gemcitabine, Intravenous Injection
215143383|NCT03216226|DRUG|dasiglucagon|Glucagon Analog
215143384|NCT03216226|DRUG|GlucaGen|Native Glucagon
214456386|NCT02924818|BEHAVIORAL|questionnaires|
214456387|NCT02924818|OTHER|pulmonary function test|
214456388|NCT02924818|BIOLOGICAL|blood test|
214456389|NCT02924818|BIOLOGICAL|microbiology|
214456390|NCT02924818|BIOLOGICAL|histology|
214456391|NCT02924818|OTHER|imaging|
214456392|NCT05363852|DIAGNOSTIC_TEST|Standard set of visual word and picture stimuli|Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
214528219|NCT03966534|OTHER|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
214528220|NCT02615548|OTHER|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
214528221|NCT02615548|OTHER|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
214528222|NCT02077153|BEHAVIORAL|Reminiscence therapy|
214528223|NCT02077153|BEHAVIORAL|Active participation in group setting|
214528224|NCT00640185|DRUG|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
214528225|NCT00640185|DRUG|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
214528226|NCT02358083|BEHAVIORAL|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
214528227|NCT02580968|DEVICE|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
214528228|NCT02580968|DRUG|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
214528229|NCT05182970|DRUG|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
214528230|NCT04005456|DIETARY_SUPPLEMENT|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
214528231|NCT04005456|BEHAVIORAL|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
214528232|NCT04005456|OTHER|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
214528233|NCT01101464|DRUG|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
214528234|NCT01101464|DRUG|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
214528235|NCT06065709|BEHAVIORAL|Mindfulness breath awareness meditation|Mindfulness breath awareness meditation
214528236|NCT04279756|OTHER|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
214528237|NCT00306956|BEHAVIORAL|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
214528238|NCT04103086|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
214528239|NCT04103086|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
214456393|NCT06300320|DRUG|TQ05105 tablets|Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
214456394|NCT04904601|DIETARY_SUPPLEMENT|Kale supplement|Kale (blanched freeze-dried Kale) group1
214456395|NCT04904601|DIETARY_SUPPLEMENT|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
214456396|NCT03444064|BIOLOGICAL|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
214456397|NCT05455281|DEVICE|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
214528240|NCT00381888|DRUG|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
214456398|NCT06522516|BEHAVIORAL|Evidence-based caregiving training|This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.
214528241|NCT04162236|DIAGNOSTIC_TEST|Ecocardiographyc ultrasound|"* Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
214528242|NCT01319825|DRUG|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
214528243|NCT01083407|DRUG|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
214528244|NCT01083407|OTHER|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
214695172|NCT07083219|BEHAVIORAL|Aerobic High Intensity Interval Training|"HIIT Protocol (Individualization of Exercise Program): Peak power will be calculated with Graded Exercise Test (GXT), with 90% of peak power used as the target range for the intervention.~Total Training Time: 35 minutes.~Warm-Up Phase:~1. Duration: 10 minutes~2. Intensity: 40-50% of peak power~HIIT Work and Rest Cycles:~Each session includes 20 minutes of intervals with the following pattern:~Work: 1 minute at 90% of peak power Rest: 3 minutes at 40% of peak power Repeat for five cycles. 5 minute cool down at 40% of peak power~Monitoring:~VO₂ and heart rate will be continuously measured.~Lactate levels will be measured at the following points:~1. Before the warm-up~2. After completing the warm-up (1st-minute intervention)~3. During the second minute of each rest period"
215143385|NCT02969746|DRUG|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
214456399|NCT06522516|BEHAVIORAL|family resilience intervention|The intervention will be developed based on the Maccubbin Family Resilience Theory, and Delphi methods. The content will contain 8 topics and be incorporated into caregiving training manual.
215143386|NCT05119881|BEHAVIORAL|mirror therapy|a mirror box will be placed in front of the participants with the mirror reflection side toward the non-paretic limb. The paretic arm will be placed behind the mirror, and the mirror box will block the vision of the paretic limb. Through this method, the patients can only view the movement of the non-paretic limb and its mirror reflection from the mirror. The participants will be instructed to move or perform functional tasks with their non-paretic limb and look at the mirror reflection of the non-paretic limb and mentally imagine that it is the paretic arm moving. At the same time, the participants will be encouraged to move the paretic arm along with the mirror reflection of the non-paretic arm. Activities practice during MT will include gross motor movements, fine motor movements, and functional tasks.
215143387|NCT05119881|DEVICE|tDCS|The tDCS will be delivered by a DC-stimulator (Soterix Medical Inc, New York, USA) through 2 saline-soaked surface sponge electrodes (anodal electrode size: 25 cm2; cathode electrode size: 25 cm2). The anodal electrode will be placed over the ipsilesional M1 while the cathodal electrode will be placed over the contralesional M1. The stimulation intensity will be ramped up to 2mA in 15 seconds, and maintained at 2mA throughout the 20-minute stimulation for the MT+tDCS group.
215143388|NCT05119881|BEHAVIORAL|sham mirror therapy|For the sham MT (s-MT) condition, the same mirror box will be used except that the mirror side will be made blurred to view; thus, the participants will not be able to view the mirror reflection of the paretic limb. The participants will perform the same activities as the real MT condition.
215143389|NCT05119881|DEVICE|sham tDCS|For the sham tDCS group, the electrodes will be placed on the brain regions as the real tDCS group. The intensity will first be ramped up to 2mA within 15 seconds and then the stimulator will be turned off gradually within the next 30 seconds.
215143390|NCT06324162|DEVICE|bracket removal pliers, LODI|Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
215143391|NCT01161277|DRUG|Aripiprazole|Dose: 5-10 mg depending on subject weight
215143392|NCT01161277|DRUG|Haloperidol|Dose: 1-2 mg depending on subject weight
215143393|NCT01161277|DRUG|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
215143394|NCT00497081|DRUG|mirtazapine|mirtazapine 30 mg daily for 3 months
215143395|NCT00497081|DRUG|placebo|placebo 30 mg daily for 3 months
215143396|NCT00871975|DEVICE|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
215143397|NCT05515809|DRUG|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
215143398|NCT05515809|DRUG|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
215143399|NCT06555107|OTHER|questionnaire|Patients included in the study will be asked to complete a questionnaire 48 to 72 hours after surgery to assess their perception of pain and preoperative anxiety
214456400|NCT06522516|BEHAVIORAL|usual service|This means the usual service provided by the local community health center from nurses during bi-weekly home visit.
214456401|NCT06256003|DEVICE|UC-A|Mobile app digital therapy
214456402|NCT06256003|DEVICE|UC-N|Mobile app digital therapy
214456403|NCT06270173|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
214456404|NCT02924272|DRUG|Ixazomib|Ixazomib Capsules
214528245|NCT05463926|BEHAVIORAL|PDA mobile application|"Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot."
214528246|NCT02189369|OTHER|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
214528247|NCT02189369|OTHER|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
214528248|NCT05851456|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214528249|NCT03535077|OTHER|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
214528250|NCT03308747|DIETARY_SUPPLEMENT|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
214528251|NCT00985283|BEHAVIORAL|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
214528252|NCT00985283|BEHAVIORAL|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
214528253|NCT01231464|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
214528254|NCT01231464|DRUG|placebo|placebo
215143400|NCT06555107|OTHER|phone call|Patients will then be interviewed by phone 3 months after their emergency surgery. During the interview, they will be questioned via a standardised questionnaire on the existence of CPSP
214456405|NCT06392373|DIETARY_SUPPLEMENT|CHO+PRO|0.9 g CHO/kg/hr + 0.3 g PRO/kg/hr
214456406|NCT06392373|DIETARY_SUPPLEMENT|CHO|1.2 g CHO/kg/hr
214456407|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
214456408|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
214456409|NCT04069624|OTHER|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
214456410|NCT04975399|DRUG|CC-92328|CC-92328
214528255|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
214528256|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
214528257|NCT01580111|BIOLOGICAL|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
215143401|NCT05249582|OTHER|Virtual Reality|Virtual reality wireless headset
215143402|NCT05249582|OTHER|Television Condition|Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
215143403|NCT03302325|PROCEDURE|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
215143404|NCT04181658|OTHER|Real tDCS and Physical Therapy|The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
215143405|NCT04181658|OTHER|Sham stimulation and Physical Therapy|The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
215143406|NCT06474338|DIAGNOSTIC_TEST|detection by artificial intelligence|The bladder lesion(s) are detected by artificial intelligence algorithm.
215143407|NCT06474338|DIAGNOSTIC_TEST|detection by urologists|The bladder lesion(s) are detected by urologists.
215143408|NCT02192580|DRUG|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
214528258|NCT01848262|PROCEDURE|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
214528259|NCT01848262|PROCEDURE|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
214528260|NCT03055923|DEVICE|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
214528261|NCT01410084|DIETARY_SUPPLEMENT|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
214528262|NCT01410084|DIETARY_SUPPLEMENT|Vitamin E|400 IU vitamin E once monthly for 5 months
214528263|NCT00993798|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
214528264|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
214528265|NCT00993798|DRUG|Bupivacaine HCl Treatment 1c|20.0 ml
214528266|NCT00993798|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
214528267|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
214528268|NCT00993798|DRUG|Bupivacaine HCl Treatment 2c|20.0 ml
214528269|NCT03787238|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
214528270|NCT01397188|DEVICE|PiCCO|transpulmonary thermodilution technique
215143409|NCT06183762|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
214528271|NCT01397188|OTHER|sham, no intervention|no intervention
214528272|NCT02108197|DEVICE|Continuous positive airway pressure (S9, ResMed)|
214528273|NCT04280679|DEVICE|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
214528274|NCT00531063|DRUG|Everolimus (RAD001)|
214528275|NCT01249677|DRUG|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
214528276|NCT05964751|DIAGNOSTIC_TEST|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
214528277|NCT05964751|DIAGNOSTIC_TEST|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
214528278|NCT01357109|DRUG|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
214528279|NCT01357109|DRUG|Placebo|Matched placebo bid
214528280|NCT03045055|DEVICE|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
214528281|NCT03045055|PROCEDURE|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
215143410|NCT00283296|DEVICE|Endeavor|Collapsible, forward folding manual wheelchair
214528282|NCT03045055|DEVICE|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
214528283|NCT00383630|BIOLOGICAL|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
214528284|NCT00383630|BIOLOGICAL|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
214528285|NCT00383630|DEVICE|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
215143411|NCT03278275|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
215143412|NCT03278275|DEVICE|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
215143413|NCT02512705|DEVICE|Pinel Restraints|
215143414|NCT02512705|BEHAVIORAL|Seclusion Room|
215143415|NCT03238378|RADIATION|Brachytherapy|Brachytherapy d 1-5(6)
214528286|NCT02612805|OTHER|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
214528287|NCT02612805|OTHER|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
214528288|NCT02612805|OTHER|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
214528289|NCT01589523|DRUG|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
214528290|NCT00709540|BIOLOGICAL|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
214528291|NCT02245464|DRUG|Telmisartan|
214528292|NCT04039555|DEVICE|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
214528293|NCT04039555|DEVICE|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
214528294|NCT04039555|DEVICE|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
214528295|NCT06289023|RADIATION|HA-WBRT-SIB|A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
214528296|NCT06151847|PROCEDURE|Biospecimen Collection|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2
214528297|NCT06151847|DRUG|Cyclophosphamide|Given IV
214528298|NCT06151847|PROCEDURE|Echocardiography|Undergo echocardiography
214528299|NCT06151847|DRUG|Fludarabine|Given IV
214528300|NCT06151847|BIOLOGICAL|Interleukin-2|Given IV
214528301|NCT06151847|BIOLOGICAL|Lifileucel|Given IV
214528302|NCT06151847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214528303|NCT06151847|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214528304|NCT06151847|PROCEDURE|Tumor Resection|Undergo tumor resection
214528305|NCT05591170|DRUG|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
214528306|NCT01916642|DRUG|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
215143416|NCT03238378|OTHER|Hyperthermia|Hyperthermia d 2 + 5
215143417|NCT04409925|DRUG|rhDNase I|Inhaled nebulisations
215143418|NCT06473740|DRUG|Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)|"The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection."
215143419|NCT04084236|DEVICE|electrical stimulation|electrical stimulation
215143420|NCT04084236|DEVICE|Sham|no stimulation
215143421|NCT06515197|OTHER|Motivational Music|Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
215143422|NCT06515197|OTHER|Self-Selected Music|Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
215143423|NCT02668653|DRUG|Chemotherapy|
215143424|NCT02668653|DRUG|Quizartinib|
215143425|NCT02668653|DRUG|Placebo|
215143426|NCT05318586|PROCEDURE|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
215143427|NCT05318586|PROCEDURE|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
214708696|NCT01187134|BEHAVIORAL|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
215143428|NCT02167698|DEVICE|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
215143429|NCT02167698|OTHER|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
214456411|NCT06213194|OTHER|MindZone|The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
214456412|NCT06508697|DIAGNOSTIC_TEST|invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital
214456413|NCT05506319|OTHER|Norepinephrine|The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).
214456414|NCT05506319|OTHER|Vasopressin|The patients will be randomized for the initial suspension of vasopressin (vasopressin group).
214456415|NCT02100813|DRUG|LEO 43204|
214456416|NCT02100813|DRUG|Placebo|
214456417|NCT04028674|DEVICE|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
214456418|NCT06507462|PROCEDURE|prostate biopsy|All patients were required to underwent transperineal prostate biopsy and have corresponding pathological diagnosis results.
214456419|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
214456420|NCT06210958|OTHER|Intertransverse process block|The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
214528307|NCT01916642|DRUG|Lidocaine 1.5mg/kg|same as other
215143430|NCT02167698|DRUG|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
214456421|NCT06112002|OTHER|Educational Intervention|Attend an educational session
214456422|NCT06112002|BEHAVIORAL|Health Education|Receive educational materials
214456423|NCT06112002|OTHER|Survey Administration|Ancillary studies
214456424|NCT04496947|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being."
214528308|NCT01916642|DRUG|Lidocaine 2mg/kg|same as other
214528309|NCT01916642|DRUG|Lidocaine 2.5mg/kg|same as other
214528310|NCT00449436|DRUG|TRIZIVIR|TRIZIVIR
215143431|NCT02167698|OTHER|Restrictive fluid therapy|Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
215143432|NCT02167698|DRUG|sedo-analgesia titration|
215143433|NCT02167698|OTHER|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
215143434|NCT02167698|OTHER|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
215143435|NCT02167698|OTHER|Biomarker Assay|Biomarker Assay for patients in both arms
215143436|NCT03942796|DRUG|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
214528311|NCT00449436|DRUG|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
214528312|NCT00449436|DRUG|Boosted Protease Inhibitor|Boosted Protease Inhibitor
214528313|NCT03545178|BEHAVIORAL|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
214456425|NCT05703490|DIAGNOSTIC_TEST|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
214456426|NCT04701047|DEVICE|vaginal pessary|insertion and follow up of a vaginal pessary
215143437|NCT03942796|PROCEDURE|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
215143438|NCT05153616|DIAGNOSTIC_TEST|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
215143439|NCT05698485|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
215143440|NCT05698485|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
214456427|NCT04701047|PROCEDURE|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
214456428|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
214528314|NCT03545178|DIAGNOSTIC_TEST|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
214695173|NCT07082881|OTHER|Colostrum|The treatment group will undergo the following treatment protocol within the initial 48-72 h: Investigators will select storage bags with the closest lactation time to the current time while wearing sterile gloves for the entire procedure. Next, using two 1-mL sterile syringes, investigators will draw 0.1 mL of colostrum from each bag and tightly cap the needle hubs to ensure hygiene and safety. Each syringe will be labeled with the hospitalization number, the infant's name, and the date of the mother's colostrum expression. The bags will be then left to sit at room temperature for 5 min to reach an appropriate temperature for oropharyngeal administration of the colostrum. Subsequently, the tip and cap of the first syringe will be removed, and the colostrum will be slowly injected along the right oral mucosa of the participants, lasting at least 20 s. After injection, a sterile cotton swab will be used to gently wipe the right buccal mucosa for at least 10 s.
215143441|NCT05698485|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
215143442|NCT05655741|OTHER|Questionnaire|"Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round."
215143443|NCT04137640|DRUG|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
215143444|NCT04137640|DRUG|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
215143445|NCT00979940|DRUG|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
215143446|NCT05362656|DEVICE|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
215143447|NCT00974792|BIOLOGICAL|pegfilgrastim|
215143448|NCT00974792|BIOLOGICAL|rituximab|
215143449|NCT00974792|DRUG|cyclophosphamide|
215143450|NCT00974792|DRUG|cytarabine|
215143451|NCT00974792|DRUG|doxorubicin hydrochloride|
214456429|NCT03729999|DEVICE|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
214456430|NCT06071871|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant)."
214456431|NCT06071871|DRUG|Polatuzumab vedotin|Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
214456432|NCT06071871|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
214528315|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
214528316|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
214528317|NCT03844178|DRUG|installation of Tetracaine 1%|installation of Tetracaine 1%
215143452|NCT00974792|DRUG|etoposide phosphate|
215143453|NCT00974792|DRUG|ifosfamide|
215143454|NCT00974792|DRUG|leucovorin calcium|
215143455|NCT00974792|DRUG|methotrexate|
215143456|NCT00974792|DRUG|vincristine sulfate|
214456433|NCT02285140|DRUG|Cefazolin|administration as outlined
215143457|NCT04780646|BEHAVIORAL|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
215143458|NCT04780646|BEHAVIORAL|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
215143459|NCT03193255|DEVICE|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
215143460|NCT04893369|OTHER|The Low Back Pain and Disability Drivers Management model|"PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability."
215143461|NCT04893369|OTHER|Low back pain clinical practice guidelines|For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
215143462|NCT02046967|PROCEDURE|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
215143463|NCT02046967|PROCEDURE|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
215143464|NCT00732056|DRUG|GRN163L|25% dose escalation infused over 2 hours weekly
215143465|NCT02158442|PROCEDURE|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
215143466|NCT02158442|DRUG|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
215143467|NCT02405741|DEVICE|Hyperbaric chamber treatment|
215143468|NCT00634777|OTHER|pet scan|pet scan
215143469|NCT01751698|BEHAVIORAL|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
214456434|NCT02285140|DRUG|Vancomycin|administration as outlined
214456435|NCT02503709|DRUG|CDK Inhibitor AT7519|Given IV
214456436|NCT02503709|OTHER|Laboratory Biomarker Analysis|Correlative studies
214456437|NCT02503709|DRUG|Onalespib|Given IV
214456438|NCT02503709|OTHER|Pharmacological Study|Correlative studies
214528318|NCT03844178|PROCEDURE|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
214456439|NCT03455582|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
214456440|NCT03455582|OTHER|Ecological evaluation|Virtual reality task and Actual reality
214528319|NCT06478576|DEVICE|multibranched stent graft system|To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)
214528320|NCT04513275|DRUG|non-medicine intervention|rating by MCCB only one time
214456441|NCT03455582|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
214456442|NCT03455582|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
214456443|NCT03455582|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
215143470|NCT01751698|BEHAVIORAL|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
214528321|NCT00961896|DRUG|Vehicle|Placebo cream
214528322|NCT00961896|DRUG|LDE225 0.25%|
214528323|NCT00961896|DRUG|LDE225 0.75%|
214528324|NCT05283356|DRUG|Ticagrelor 60mg|Ticagrelor 60mg BID after TAVI
214528325|NCT00272454|DRUG|Cilostazol|
215143471|NCT06338098|BEHAVIORAL|8-week wellness and relaxation meditation program|Heartfulness Meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
214456444|NCT05642715|BEHAVIORAL|EX+|All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
214456445|NCT05642715|DRUG|Varenicline|All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
214456446|NCT05642715|BEHAVIORAL|HR|Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
214456447|NCT05642715|BEHAVIORAL|TAU|Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
214456448|NCT05287568|DRUG|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
214456449|NCT05287568|DRUG|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
214456450|NCT05723601|DRUG|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
214456451|NCT05723601|DRUG|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
214456452|NCT05936099|BEHAVIORAL|E-cigarette & Tobacco Use Treatment Intervention|The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
214528326|NCT00272454|DRUG|Aspirin|
215143472|NCT05894109|DIETARY_SUPPLEMENT|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
214528327|NCT04692376|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
214528328|NCT04692376|DRUG|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
214528329|NCT04692376|DRUG|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
214528330|NCT00020969|DRUG|arsenic trioxide|
214528331|NCT02529371|DEVICE|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
214528332|NCT05684666|OTHER|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
214528333|NCT05684666|OTHER|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
214528334|NCT00298337|DRUG|Mixture of probiotic bacteria and prebiotic oligosaccharide|
214528335|NCT01304771|BIOLOGICAL|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
214695174|NCT07082881|OTHER|Normal Saline|For the control group, normal saline will be used instead of colostrum. The rest of the procedure will be the same as that for the treatment group.
215143473|NCT05894109|OTHER|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
215143474|NCT02123901|OTHER|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
215143475|NCT02123901|OTHER|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
215143476|NCT02123901|OTHER|No exercise|Sedentary life style.
215143477|NCT02552043|OTHER|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
215143478|NCT04907058|DEVICE|novel device with a comfortable mask|Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
215143479|NCT06103435|PROCEDURE|Extent od surgical resection|
215143480|NCT01099176|DRUG|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
215143481|NCT03264326|OTHER|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
215143482|NCT03264326|OTHER|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
215143483|NCT03264326|OTHER|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
215143484|NCT02514135|OTHER|No intervention|
215143485|NCT04744246|OTHER|load carriage|35 pound load carried on the back
215143486|NCT02659254|DEVICE|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
214695175|NCT07084259|DRUG|PCSK9 inhibitor|Single dose of subcutaneous administration of PCSK9 inhibitors (evolocumab) after PCI in patients with coronary artery disease and elevated post-PCI lipid core burden (maxLCBI4mm ≥ 200).
214695176|NCT07084259|DRUG|Standard Lipid-Lowering Therapy|Lipid-lowering therapy with high-intensity or maximally tolerated statins with or without ezetimibe, as per current clinical guidelines, excluding the use of PCSK9 inhibitors.
215143487|NCT04365725|DRUG|Remdesivir|Compassionate provision
215143488|NCT04885907|BIOLOGICAL|mRNA-1273 vaccine|COVID vaccine 3rd dose
215143489|NCT04885907|OTHER|Normal Saline Placebo|Normal Saline Placebo
215143490|NCT00622050|BEHAVIORAL|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
215143491|NCT00622050|BEHAVIORAL|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
215143492|NCT01294553|DRUG|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
215143493|NCT01475760|OTHER|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
215143494|NCT01475760|OTHER|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
215143495|NCT03800381|OTHER|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
215143496|NCT06189521|OTHER|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
215143497|NCT06189521|OTHER|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
215143498|NCT06189521|OTHER|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
215143499|NCT04142931|COMBINATION_PRODUCT|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
215143500|NCT00648440|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
215143501|NCT00648440|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
215143502|NCT01646580|DRUG|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
215143503|NCT05799820|DRUG|QL1706|5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
215143504|NCT05799820|DRUG|Bevacizumab|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
215143505|NCT05799820|DRUG|Oxaliplatin injection|130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
215143506|NCT05799820|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
215143507|NCT06038604|BEHAVIORAL|Psychosocial Support Intervention|Participants will receive six weekly 60-minute sessions conducted by videoconference.
215143508|NCT01437657|DRUG|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
215143509|NCT01437657|DRUG|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
214528336|NCT02503982|DRUG|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
214528337|NCT00815022|DRUG|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
214528338|NCT00522470|DRUG|rosiglitazone|
214528339|NCT00046683|DRUG|alemtuzumab|
214528340|NCT00004097|DRUG|fluorouracil|
214528341|NCT00004097|DRUG|gemcitabine hydrochloride|
214528342|NCT00004097|DRUG|paclitaxel|
214528343|NCT00004097|RADIATION|radiation therapy|
214528344|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
214528345|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
214528346|NCT03209245|BIOLOGICAL|Purethal Mites|perennial allergren specific immunotherapy during 24 months
214528347|NCT03209245|OTHER|placebo injection|perrenial injection wich were administered in same protocol as Purethal
214528348|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
214528349|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
214528350|NCT01623206|DRUG|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
214528351|NCT06442163|DEVICE|AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.|"After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours."
214528352|NCT01919346|DRUG|Eculizumab|
214528353|NCT01919346|DRUG|Normal Saline|
214528354|NCT01015378|PROCEDURE|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
214528355|NCT01997437|DEVICE|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
214528356|NCT00175656|PROCEDURE|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
214528357|NCT05338112|DIAGNOSTIC_TEST|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
214528358|NCT02490605|PROCEDURE|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
214528359|NCT02490605|PROCEDURE|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
214528360|NCT04397614|OTHER|mHealth Assessments|Daily symptom tracker
214528361|NCT06544421|OTHER|Assigned Interventions|Assigned Interventions
214528362|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
215143510|NCT01437657|DRUG|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
215143511|NCT05716802|BEHAVIORAL|dance/movement therapy|dance/movement therapy plus treat as usual
214528363|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
214528364|NCT00555997|DRUG|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
214528365|NCT02507687|DRUG|Bimatoprost SR|Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
214528366|NCT02507687|DRUG|Sham Bimatoprost SR|Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
214528367|NCT02507687|PROCEDURE|Selective Laser Trabeculoplasty|"SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method."
214528368|NCT02507687|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
214528369|NCT01540578|OTHER|laboratory biomarker analysis|Correlative studies
214528370|NCT06260241|PROCEDURE|Traction Dressing|Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.
215143512|NCT05716802|BEHAVIORAL|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
215143513|NCT01151189|BIOLOGICAL|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
215143514|NCT01151189|BIOLOGICAL|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
215143515|NCT03729739|DIAGNOSTIC_TEST|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
215143516|NCT03729739|DIAGNOSTIC_TEST|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
215143517|NCT05713656|OTHER|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
215143518|NCT03771924|DIETARY_SUPPLEMENT|inorganic phosphate|Sodium phosphate
215143519|NCT03771924|DIETARY_SUPPLEMENT|placebo|Sodium chlorid
215143520|NCT00926237|DEVICE|Sham rTMS - Sham repetitive transcranial magnetic stimulation|Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
215143521|NCT00926237|DEVICE|Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
215143522|NCT00926237|DEVICE|Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
215143523|NCT05220072|DRUG|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
215143524|NCT00153244|DRUG|Lamotrigine|
215143525|NCT03800992|OTHER|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
215143526|NCT05525325|PROCEDURE|General Anesthesia|Patients randomized to the GA arm are intubated after anesthetic induction. For this purpose, they are pre-oxygenated with an oxygen mask and non-invasive monitoring is established. After sufficient pre-oxygenation has been applied, analgesic and sedative medication are administered. If the patient is sufficiently long nil by mouth they are manually ventilated before a muscle relaxant is administered. A rapid-sequence induction is performed with administration of an opioid, sedative and muscle relaxant in rapid succession and without intermediate manual ventilation in non-nil by mouth patients. To secure the airway, an endotracheal tube is inserted into the trachea with the aid of a laryngoscope. After insertion of the endotracheal tube, its endotracheal position is confirmed with auscultation and capnography. GA maintenance therapy with opioids, sedatives and catecholamines, if needed, will then be started.
215143527|NCT04796155|DIAGNOSTIC_TEST|Intrapartum ultrasound|Intrapartum ultrasound will be performed by suprapubic and transperineal approach for 30 seconds.
215143528|NCT06333912|PROCEDURE|dental implant placement with ridge splitting.|ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement
215143529|NCT03558711|DIAGNOSTIC_TEST|18F-PSMA|18F-PET imaging
215143530|NCT03108807|DIAGNOSTIC_TEST|D-dimer test|D-dimer test
215143531|NCT02054689|RADIATION|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
215143532|NCT04243564|DEVICE|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
215143533|NCT00632229|DRUG|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
215143534|NCT00632229|DRUG|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
215143535|NCT00026260|DRUG|semaxanib|
214456456|NCT05406817|DRUG|Revumenib|Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
214456457|NCT04359108|DEVICE|Navigation system mode: Argus Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Argus mode~* Haptics: none~* Audio: none Since this mode only provides the standard Argus vision, it is equivalent to using the base Argus II system without the navigational aid."
214456458|NCT04359108|DEVICE|Navigation system mode: Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: none~* Audio: none"
215143536|NCT01617824|DRUG|Linagliptin|Linagliptin 5 mg tablets for 4 days
215143537|NCT01617824|DRUG|Placebo|Placebo tablets for 4 days
215143538|NCT06288997|DEVICE|Active transcranial alternating current stimulation|Hi-tACS with a current level of 15mA with a patented frequency of 77.5Hz.
214695177|NCT07083804|DIAGNOSTIC_TEST|Gastric biopsies|"After obtaining informed consent, patients receive routine endoscopic procedures with an additional biopsy taken for research purposes.~Invasive screening method used in routine care."
214695178|NCT07083804|DIAGNOSTIC_TEST|Stool sampling|"Stool samples are taken and sent within 10 days of the endoscopy. Self-collected stool samples are analyzed using antigen testing and molecular techniques to detect H. pylori and associated resistance mutations.~Experimental diagnosis."
214528371|NCT06260241|OTHER|Without Traction Dressing|Without Traction Dressing
215143539|NCT06288997|DEVICE|Sham transcranial alternating current stimulation|The device for the sham group has the same appearance and technical settings as the one used in the active group, designed to produce similar sensations on the scalp, but without effective penetration of the electric field into the brain.
215143540|NCT00602602|BIOLOGICAL|bevacizumab|
215143541|NCT00602602|DRUG|fluorouracil|
215143542|NCT00602602|DRUG|gemcitabine hydrochloride|
215143543|NCT00602602|DRUG|oxaliplatin|
215143544|NCT00602602|OTHER|immunohistochemistry staining method|
215143545|NCT00602602|OTHER|laboratory biomarker analysis|
215143546|NCT00602602|PROCEDURE|conventional surgery|
215143547|NCT00602602|PROCEDURE|endoscopic biopsy|
214456459|NCT04359108|DEVICE|Navigation system mode: Depth Vision with Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: yes~* Audio: yes"
215143548|NCT00602602|PROCEDURE|laparoscopy|
215143549|NCT00602602|RADIATION|radiation therapy|
215143550|NCT05373459|BIOLOGICAL|Third COVID-19 booster|Third COVID-19 booster
215143551|NCT05386329|BEHAVIORAL|Mindset: Therapist-guided smartphone-delivered CBT|All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
215143552|NCT03658681|OTHER|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
215143553|NCT03658681|OTHER|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
215143554|NCT00577889|DRUG|gemcitabine hydrochloride|750 mg/m2 Given IV
215143555|NCT00577889|DRUG|tanespimycin|154 mg/m2 Given IV
215143556|NCT03146585|DEVICE|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
215143557|NCT03937934|BEHAVIORAL|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
215143558|NCT05607758|BEHAVIORAL|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
215143559|NCT02261935|OTHER|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
214456460|NCT04359108|DEVICE|Navigation system mode: Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: none~* Haptics: yes~* Audio: yes Since this mode does not provide any visual feedback, it is equivalent to using navigational aid completely blind without a visual prosthesis."
214456461|NCT04359108|DEVICE|Navigation system mode: High Field-of-View Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: High Field-of-View Depth mode (at twice the Argus II resolution and field-of-view along each dimension)~* Haptics: none~* Audio: none"
214528372|NCT04934241|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
214528373|NCT03698630|DRUG|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
215143560|NCT02261935|OTHER|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
215143561|NCT01850121|DRUG|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
214528374|NCT03698630|DRUG|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone."
214528375|NCT02475018|DIETARY_SUPPLEMENT|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
214528376|NCT02475018|DIETARY_SUPPLEMENT|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
214528377|NCT02510222|DIETARY_SUPPLEMENT|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
214528378|NCT02510222|OTHER|Placebo|
214528379|NCT05000411|DRUG|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
214528380|NCT05000411|DRUG|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
215143562|NCT05063799|OTHER|pulmonary rehabilitation|pulmonary rehabilitation programs
215143563|NCT06146920|OTHER|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
214456462|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: Low"
214456463|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: High"
214456464|NCT04359108|DEVICE|Distance test vision mode: High Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: Low"
214456465|NCT04359108|DEVICE|Distance test vision mode: High Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: High"
214528381|NCT05285956|BEHAVIORAL|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
214528382|NCT02675998|DRUG|Tenapanor|
215143564|NCT06436131|BEHAVIORAL|In-phase Bilateral Exercise|"The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks."
214456466|NCT05340270|DRUG|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
214528383|NCT02675998|DRUG|Placebo|
214528384|NCT00900406|GENETIC|gene expression analysis|blood collection
214528385|NCT00900406|GENETIC|microarray analysis|Blood collection
214528386|NCT00900406|GENETIC|polymorphism analysis|Blood collection
214528387|NCT00900406|GENETIC|proteomic profiling|Blood collection
214528388|NCT00900406|OTHER|flow cytometry|Blood collection
214528389|NCT00900406|OTHER|immunologic technique|Blood collection
214528390|NCT00900406|OTHER|laboratory biomarker analysis|Blood collection
214528391|NCT00900406|PROCEDURE|biopsy|Blood collection
214528392|NCT02197143|DRUG|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
214528393|NCT02197143|DRUG|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
214528394|NCT02197143|DRUG|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
214528395|NCT02916706|DRUG|Teneligliptin 20mg|
214528396|NCT02916706|DRUG|Placebo|
214528397|NCT05688098|DRUG|Irbesartan/Amlodipine High FDC|Irbesartan/Amlodipine High FDC
214695179|NCT07082296|BEHAVIORAL|iCBT-Academia|iCBT-Academia is a brief, self-guided, internet-based cognitive behavioral therapy (iCBT) program specifically tailored to address the real-life challenges faced by the university and research community. It consists of four modules, each designed to be completed over a week.
214695180|NCT07082101|OTHER|temporal interference|In this intervertion, patients with SEEG operation will take temporal interference (TI) stimulation and the deep brain EEG will be monitorated through the entire experiment.
214528398|NCT05688098|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine High
214528399|NCT05688098|DRUG|Amlodipine High|Co-administration of Irbesartan and Amlodipine High
214528400|NCT02867111|DEVICE|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
214528401|NCT02867111|OTHER|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
214528402|NCT02867111|PROCEDURE|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
215143565|NCT06436131|BEHAVIORAL|Conservative exercises|The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.
215143566|NCT03745534|OTHER|eABR|eABR
215143567|NCT01547611|OTHER|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
215143568|NCT01547611|OTHER|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
215143569|NCT05654974|OTHER|measurements and questionnaire|paper-based survey administration; erect penis length and girth measurements
215143570|NCT00110448|DRUG|Aspirin|Aspirin 81 mg or 100 mg per day
215143571|NCT00110448|DRUG|No aspirin|No aspirin use
215143572|NCT02667119|BEHAVIORAL|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
215143573|NCT02667119|BEHAVIORAL|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
215143574|NCT05835817|OTHER|Magnetoencephalography|40 minutes of Magnetoencephalography with Optical Pump Magnetometer
215143575|NCT05345600|OTHER|MILTA probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
215143576|NCT05345600|OTHER|placebo probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
215143577|NCT04011176|PROCEDURE|Standard treatment + placebo|Placebo microcurrent
215143578|NCT04011176|PROCEDURE|Standard treatment + Microcurrent Therapy|Actual microcurrent
215143579|NCT03783078|DRUG|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
215143580|NCT06122831|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
215143581|NCT06122831|DRUG|TQB3617 Capsules|TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
215143582|NCT00534612|PROCEDURE|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
214456467|NCT05340270|DRUG|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
214456468|NCT04087707|DRUG|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
214456469|NCT04087707|DRUG|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
214456470|NCT04087707|DRUG|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
214456471|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
214456472|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
214456473|NCT06393088|DEVICE|IR REHAB|Participants undergo therapy sessions with active, dual frequency, low level laser therapy device
214456474|NCT06393088|DEVICE|Sham|Participants undergo therapy sessions with disabled device producing no laser energy
214456475|NCT06266689|BEHAVIORAL|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
214456476|NCT02515773|DRUG|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
214456477|NCT02515773|BEHAVIORAL|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
214456478|NCT05391971|DRUG|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
215143583|NCT06237725|OTHER|Nutrition of Continuous|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
215143584|NCT06237725|OTHER|Nutrition of Bolus|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
215143585|NCT05035537|PROCEDURE|PGDT|The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
215143586|NCT02758210|DEVICE|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
215143587|NCT02758210|DEVICE|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
215143588|NCT01404819|DRUG|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
215143589|NCT01404819|DRUG|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
215143590|NCT05992883|DRUG|Ketorolac|Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
215143591|NCT05992883|DRUG|Triamcinolone|Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
215143592|NCT03571438|COMBINATION_PRODUCT|CK2 and ATM inhibitors serine/ threonin Kinase combination|Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
214456479|NCT05391971|DRUG|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
214456480|NCT06302010|BEHAVIORAL|Stress Ball Intervention|The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
214456481|NCT03836248|OTHER|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
214456482|NCT03836248|OTHER|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
214695181|NCT07083557|OTHER|Endothelial cell collection|Participants may opt to have testing performed including blood sampling, urine sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS, having adipose (fat) or muscle biopsies, or non-invasive endothelial function testing to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
214456483|NCT03836248|OTHER|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
215143593|NCT03571438|DRUG|Sunitinib|Treatment of cell culture with Sunitinib
215143594|NCT03571438|DRUG|Pazopanib|Treatment of cell culture with Pazopanib
215143595|NCT03571438|DRUG|Temsirolimus|Treatment of cell culture with Temsirolimus
215143596|NCT02338674|DRUG|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
215143597|NCT02338674|DRUG|Tenofovir|tenofovir administered at least 48 weeks
215143598|NCT05083234|OTHER|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
215143599|NCT05083234|OTHER|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
214528403|NCT04981353|PROCEDURE|bilateral erector spinae plane block at T11|A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
214528404|NCT00575367|DRUG|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
214528405|NCT00575367|DRUG|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
214528406|NCT02534753|DRUG|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
214528407|NCT01194271|DRUG|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
214528408|NCT01194271|DRUG|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
214528409|NCT01194271|PROCEDURE|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
214528410|NCT02881021|OTHER|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
214528411|NCT02881021|DEVICE|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
214528412|NCT02475876|DRUG|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg."
214528413|NCT02475876|DRUG|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose = 4 mg/kg."
215143600|NCT05083234|OTHER|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
215143601|NCT00594412|PROCEDURE|Diagnostic Radiology: 1H-MRS of the liver|
215143602|NCT01511406|BEHAVIORAL|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
215143603|NCT02059278|DRUG|T-2345|T-2345 Ophthalmic Solution
215143604|NCT02059278|DRUG|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
215143605|NCT03200249|RADIATION|Preoperative chemo-radiation with IG-IMRT dose escalation|
215143606|NCT02689635|OTHER|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
215143607|NCT02689635|OTHER|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
215143608|NCT04834661|OTHER|surgery inside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
215143609|NCT04834661|OTHER|surgery outside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
215143610|NCT06345274|BEHAVIORAL|Measurement Based Care Training and Monthly Consultation|Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
214528414|NCT04164498|OTHER|music|exposure to music to investigate its effects on reducing noise adverse effects
214528415|NCT01750086|DRUG|Teriparatide 40-mcg subcutaneous injection|
214528416|NCT01750086|DRUG|Denosumab Injection|One-time Denosumab injection
214528417|NCT01750086|DRUG|Alendronate Oral Tablet|weekly alendronate for 8 weeks
214528418|NCT00381797|BIOLOGICAL|Bevacizumab|Given IV
214528419|NCT00381797|RADIATION|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
214528420|NCT00381797|DRUG|Irinotecan Hydrochloride|Given IV
214528421|NCT00003133|BIOLOGICAL|filgrastim|
214528422|NCT00003133|DRUG|cisplatin|
214528423|NCT00003133|DRUG|doxorubicin hydrochloride|
214528424|NCT00003133|DRUG|gemcitabine hydrochloride|
214528425|NCT00003133|DRUG|paclitaxel|
215143611|NCT02953002|DEVICE|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
215143612|NCT05795036|DEVICE|mHealth 1|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks.
215143613|NCT05795036|DEVICE|mHealth 2|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks. In addition, they will receive daily motivational text message.
215143614|NCT02180100|DRUG|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
215143615|NCT02180100|DRUG|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
215143616|NCT00737672|DEVICE|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
215143617|NCT00737672|PROCEDURE|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
215143618|NCT00446004|DRUG|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
215143619|NCT00446004|DRUG|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
214456484|NCT05280652|BEHAVIORAL|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
215143620|NCT02694185|OTHER|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
215143621|NCT05614817|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection
215143622|NCT05614817|DRUG|Placebo|subcutaneous(SC) injection
215143623|NCT03564808|DRUG|MSC|Adipose tissue enriched with mesenchymal stem cells
215143624|NCT05522439|DRUG|SHR-1703|SHR-1703 will be administered by SC injection.
215143625|NCT05522439|DRUG|SHR-1703 Placebo|Matching Placebo will be administered by the SC route.
215143626|NCT05369351|DRUG|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
215143627|NCT05369351|OTHER|Standard treatment|Standard treatment
215143628|NCT03628768|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
215143629|NCT02250222|DRUG|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)
215143630|NCT02250222|DRUG|Placebo (Captisol ®)|betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
214456485|NCT05280652|BEHAVIORAL|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
214456486|NCT06223035|OTHER|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
215143631|NCT06008314|OTHER|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
215143632|NCT00614302|DRUG|TPV|
215143633|NCT05187689|BEHAVIORAL|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
215143634|NCT05187689|BEHAVIORAL|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
215143635|NCT03843814|PROCEDURE|APT MRI|
215143636|NCT01551186|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
215143637|NCT04612504|BIOLOGICAL|SynOV1.1|SynOV1.1 will be administered intratumorally.
215143638|NCT01625299|DIETARY_SUPPLEMENT|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
215143639|NCT01625299|DIETARY_SUPPLEMENT|Placebo|Rice flour 1.0 g/kg/day
215143640|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
215143641|NCT04029883|BEHAVIORAL|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
215143642|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
215143643|NCT03391362|RADIATION|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
215143644|NCT05897203|DRUG|TAZCOV|Herbal Syrup
215143645|NCT05897203|DRUG|Vidicine|Herbal Syrup
215143646|NCT06964217|DRUG|Monotherapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two ore more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be monotherapy."
215143647|NCT06964217|DRUG|Combination therapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two or more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be combination therapy."
215143648|NCT04080505|DRUG|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
215143649|NCT03175679|BIOLOGICAL|iNKT cells|The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.
215143650|NCT03175679|DRUG|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
215143651|NCT03175679|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
214456487|NCT06196801|DRUG|Triple-combination therapy|phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
215143652|NCT05372757|PROCEDURE|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
215143653|NCT04139733|PROCEDURE|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
215143654|NCT04139733|PROCEDURE|Supine positon|Conventional supine position ventilation, no prone position.
214456488|NCT04176965|DEVICE|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
214456489|NCT04176965|DEVICE|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
214456490|NCT04851145|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
214456491|NCT03903146|BEHAVIORAL|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
214456492|NCT03808987|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
214528426|NCT03015597|BEHAVIORAL|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
214528427|NCT06383429|OTHER|forward head posture by using mobile application. And patients will fill out headache disability index.|forward head posture by using mobile application. And patients will fill out headache disability index.
214528428|NCT02151630|DRUG|Pyruvic acid|
214528429|NCT02151630|DRUG|Salicylic Acid|
214695182|NCT07082218|BEHAVIORAL|Sleep Intervention|The investigators will randomly assign participants (adolescents with concussion) to a personalized sleep schedule and sleep health recommendation, based on a meeting with an administrator after enrollment and randomization. They will undergo testing prior to the intervention, after the intervention (2 weeks after the initial visit, intervention length=2 weeks), and 6 weeks after intervention completion.
215143655|NCT05820581|BEHAVIORAL|Mentalisation|Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
215143656|NCT03587961|DRUG|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
215143657|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 10μg|mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
215143658|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 30μg|mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
215143659|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 100μg|mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
215143660|NCT05972993|DRUG|Placebo|Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
215143661|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 3μg|mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
214528430|NCT01984749|DRUG|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8."
214528431|NCT04252300|DRUG|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
214528432|NCT04252300|DRUG|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
214528433|NCT02288364|DRUG|1% Lidocaine|
214528434|NCT02288364|DRUG|1% Lidocaine plus sodium bicarbonate|
214528435|NCT01828359|DRUG|Amosartan® tab|comparison of different combination of anti-hypertension drug
215143662|NCT05146882|DRUG|Belcesiran|Belcesiran will be administered subcutaneously (SC) in the treatment arm.
215143663|NCT04792645|DRUG|Placebo|Pill that contains no medicine
215143664|NCT04792645|DRUG|Memantine|Cognition-enhancing medication
215143665|NCT05308537|BEHAVIORAL|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
215143666|NCT03866577|BIOLOGICAL|Biological: M254|M254 administered as intravenous infusion
215143667|NCT03866577|DRUG|Placebo|Placebo administered as intravenous infusion
215143668|NCT03866577|BIOLOGICAL|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
215143669|NCT06704321|DIETARY_SUPPLEMENT|TOTUM-448|16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day)
215143670|NCT06704321|DIETARY_SUPPLEMENT|Placebo|16 weeks of placebo supplementation (8 capsules per day)
215143671|NCT04825678|DRUG|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
215143672|NCT02512822|PROCEDURE|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
215143673|NCT03818256|DRUG|Miricorilant|Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
215143674|NCT03818256|DRUG|Placebo|Placebo tablets for once-daily oral dosing
214456493|NCT03808987|BEHAVIORAL|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
214456494|NCT03861975|OTHER|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
214456495|NCT05394818|DRUG|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
214456496|NCT01874769|OTHER|Blood collection|"* 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
214528436|NCT01828359|DRUG|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
214528437|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
214528438|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 48 weeks
214528439|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
214528440|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 24 weeks
214528441|NCT03555708|OTHER|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
214528442|NCT00043186|DRUG|Placebo|Placebo subcutaneous injection
214528443|NCT00043186|DRUG|Denosumab|Denosumab for subcutaneous injection
214528444|NCT00043186|DRUG|Alendronate|Alendronate 70 mg tablets
215143675|NCT04336553|BEHAVIORAL|Social prescribing in Sweden (SPiS)|Social prescribing in sweden (SPiS)
215143676|NCT03827096|DRUG|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
215143677|NCT05494190|DRUG|Docetaxel|60 mg/m2 i.v. day 1
215143678|NCT05494190|DRUG|Cisplatin|60 mg/m2 i.v. day 1-3
215143679|NCT05494190|DRUG|Capecitabine|750 mg/m2 po bid day 1-14
215143680|NCT05494190|RADIATION|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
215143681|NCT05494190|PROCEDURE|Surgery|Neck dissection and primary tumor resection
215143682|NCT06080334|DEVICE|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
215143683|NCT06080334|DEVICE|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
215143684|NCT05826314|OTHER|Boxing training|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
215143685|NCT05826314|OTHER|Exercise|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
214528445|NCT02763163|BEHAVIORAL|Sun exposure routine|
214528446|NCT04077385|BEHAVIORAL|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.
214528447|NCT04077385|BEHAVIORAL|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
214528448|NCT00958711|DEVICE|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
214528449|NCT00958711|OTHER|Saline and Gauze|gauze moistened with sterile saline
214528450|NCT03181919|DRUG|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
214528451|NCT05668000|OTHER|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
214528452|NCT05668000|OTHER|Mobile application|The mobile application provide only self-management interventions.
214528453|NCT00949793|DEVICE|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
215143686|NCT04895891|DEVICE|EOS hand imaging|For each patient, EOS images are compared with CT images
214456497|NCT01874769|OTHER|Skin biopsies|"* A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
214456498|NCT04427709|DRUG|Oxytocin|Intramuscular injection of Oxytocin (Pitocin®)
214456499|NCT04427709|DRUG|Placebo|Intramuscular placebo injection
214456500|NCT05614024|OTHER|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
214456501|NCT05614024|OTHER|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
214456502|NCT02919683|DRUG|Nivolumab|
214456503|NCT02919683|DRUG|Ipilimumab|
214456504|NCT02919683|PROCEDURE|Standard of Care Surgery|
214456505|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
214456506|NCT05854251|DRUG|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
214528454|NCT02246634|OTHER|Diffusion Weighted MRI scan|Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
214528455|NCT01929577|DRUG|ASP015K|oral tablet
214695183|NCT07083518|DEVICE|Anodal transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes.
214695184|NCT07083518|DEVICE|Sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
215143687|NCT04097938|DRUG|GLPG3667 oral suspension|GLPG3667 oral suspension
215143688|NCT04097938|DRUG|Placebos|Placebo oral suspension
215143689|NCT04097938|DRUG|GLPG3667 capsules|GLPG3667 capsules
215143690|NCT05109364|DRUG|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
215143691|NCT04347798|OTHER|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
215143692|NCT02086175|DRUG|Imprime PGG|
214695185|NCT05145244|OTHER|NO intervention|No intervention
214695186|NCT05497778|DRUG|Gemcitabine|Given by IV (vein)
214695187|NCT05497778|DRUG|Nab paclitaxel|Given by IV (vein)
214695188|NCT05497778|DRUG|IM156|Given by PO
215143693|NCT02086175|DRUG|Rituximab|
215143694|NCT00734149|DRUG|Bortezomib|
215143695|NCT00734149|DRUG|Melphalan|
215143696|NCT00734149|DRUG|Prednisone|
215143697|NCT06521125|DIAGNOSTIC_TEST|High resolution Computed Tomography (HRCT) scans of the Chest|A chest high-resolution computed tomography (HRCT) scan will be performed
215143698|NCT06521125|DIAGNOSTIC_TEST|Pulmonary Function Testing (PFTs)|Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
215143699|NCT06521125|DIAGNOSTIC_TEST|Digital lung sounds auscultation|Lung sounds will be recorded using a manual approach with a digital stethoscope
215143700|NCT06521125|DIAGNOSTIC_TEST|Laboratory Assessments|Clinical laboratory tests will be collected from each participant
215143701|NCT06521125|GENETIC|DNA sequencing|A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
215143702|NCT03353688|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
215143703|NCT01710982|DRUG|TZP-101|
215143704|NCT01710982|OTHER|Placebo|
214456507|NCT05854251|DRUG|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
214456508|NCT05911633|DEVICE|BioPearl™|TACE
214456509|NCT06052345|DEVICE|Garmin smartwatch|"* Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)"
214456510|NCT06052345|OTHER|REBECCA Mobile application|"* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
214456511|NCT06052345|OTHER|REBECCA PC plug-in|"* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
214456512|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
214456513|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
214456514|NCT05690581|DRUG|CM369|Specified dose on specified days.
214456515|NCT05413018|DRUG|CC-486|Specified dose on specified days
214456516|NCT05413018|OTHER|Placebo|Specified dose on specified days
214456517|NCT05619900|OTHER|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
214456518|NCT04187651|OTHER|platelet rich plasma|platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
214456519|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
214456520|NCT06771180|DRUG|Dara-CyBorD|Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
214456521|NCT03652688|BEHAVIORAL|Nightlife Safety Plans (NSP)|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
214456522|NCT03652688|BEHAVIORAL|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
214456523|NCT05722652|BEHAVIORAL|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
214456524|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
214456525|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
214456526|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
214456527|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
214456528|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
214456529|NCT04266080|OTHER|Fitbit Inspire HR|assessing step counts
214456530|NCT04266080|OTHER|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
214456531|NCT06223854|DIETARY_SUPPLEMENT|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
215143705|NCT06578468|DEVICE|End-tidal oxygen monitor|"The only additional equipment required for this study is the Philips™ IntelliVue G7m Gas Analyser Module 866173. This provides a non-dispersive infrared measurement of respiratory gases and a paramagnetic measurement of oxygen. At Lincoln Medical Center, the gas analyser used will be a Philips G5 gas analyser connected to a Philips Intellivue MP 70. At the University of New Mexico Medical Center, the Masimo root monitor is used.~The gas analysers produce display waves for O2 and CO2, together with numerics for end-tidal values for O2 and CO2 and to our knowledge, there are no differences in values between the various devices used. The gas sampling occurs through a side-stream sampling tube at a rate of 200ml/min ±20 ml/min, which is either obtained from a nasal cannula in the spontaneously breathing patient or a sidestream line if connected to a BVM."
215143706|NCT05739019|OTHER|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
214456532|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
214456533|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
214456534|NCT02050802|DRUG|Moxifloxacin 400 mg|
214456535|NCT02050802|DRUG|Macitentan 10 mg|
214456536|NCT02050802|DRUG|Macitentan 30 mg|
214456537|NCT02050802|OTHER|Placebo|
214456538|NCT05030155|DRUG|Mepolizumab|300 mg/month subcutaneous
214456539|NCT05030155|DRUG|cyclophosphamide/azathioprine|Patients with FFS≥1 will receive cyclophosphamide then azathioprine
214456540|NCT05030155|DRUG|Placebo|Patients with FFS=0 will receive placebo
214456541|NCT06343896|OTHER|monitorization reliability|evaluation of the use of the integral pulmonary index in the child patient group
214456542|NCT06158412|DRUG|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."
214456543|NCT02587897|OTHER|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
214456544|NCT02587897|OTHER|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
214456545|NCT03468218|DRUG|Cabozantinib|Given PO
214456546|NCT03468218|BIOLOGICAL|Pembrolizumab|Given IV
214456547|NCT05991986|OTHER|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100\~500 ml of midstream urine, 20\~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
214456548|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
214456549|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
215143707|NCT04844827|GENETIC|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
215143708|NCT03043794|RADIATION|Stereotactic Body Radiation Therapy SBRT|Stereotactic Body Radiation Therapy to the breast to 21 Gy
214695189|NCT05032053|DRUG|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
214695190|NCT06104228|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490
215143709|NCT06306599|DIAGNOSTIC_TEST|S-Detect for Thyroid|"Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS."
215143710|NCT04486768|OTHER|Survey Instrument|This registry contains several surveys that will be released for patient/caregiver completion at enrollment and at time points following enrollment. These surveys can be completed on any computer that is connected to the internet.
215143711|NCT06462794|DRUG|CX-801|Investigational drug
215143712|NCT06462794|DRUG|pembrolizumab|Standard of Care Therapy
215143713|NCT03600324|BEHAVIORAL|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
215143714|NCT05331638|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
215143715|NCT05331638|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
215143716|NCT05897658|DRUG|Levetiracetam|Tablets
215143717|NCT05897658|OTHER|Placebo|Tablets
215143718|NCT06986811|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
215143719|NCT06986811|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
214456550|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
214456551|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
214456552|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
215143720|NCT06857695|DRUG|AZD5004 film-coated tablet|oral, fasted
215143721|NCT06857695|DRUG|[14C]AZD5004 Solution for Infusion|intravenous, fasted
214456553|NCT01814501|BIOLOGICAL|panitumumab|Each vial of panitumumab will contain 20 mL of a sterile protein solution containing a 20-mg/mL solution of panitumumab. The vial will contain approximately 400mg of panitumumab and is for single dose use only.
214456554|NCT01814501|DRUG|irinotecan hydrochloride|Diluted with 5% dextrose (D5W) to a total volume of 500 mL and infused intravenously over 90 minutes. Nothing else should be added to the bag. Patients will be given a dose of 180 mg/M2 by intravenous infusion.
214456555|NCT01814501|DRUG|fluorouracil|Administered intravenously. A bolus of 400 mg/m2 to be followed by a continuous infusion over 46 hrs at a dose of 2400mg/m2.
214456556|NCT01814501|DRUG|leucovorin calcium|Leucovorin will be administered at a dose of 200 mg/m2 over 120 minutes prior to the 5-FU bolus. Leucovorin may be run simultaneously with irinotecan infusion via y-site connection.
215143722|NCT06857695|DRUG|[14C]AZD5004 Oral Solution|oral, fasted
215143723|NCT06587126|DEVICE|Curie Artificial Intelligence (AI) cough monitor|All patients are given nighttime cough monitors for home use for 3-4 months
215143724|NCT06595836|DEVICE|Silicone Lubricated Synthetic polyisoprine condom|Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity
215143725|NCT06595836|DEVICE|Silicone Lubricated Natural Rubber Latex Condom|Natural rubber latex condoms are made from natural rubber
215143726|NCT06599307|DRUG|Rituximab|Rituximab 1gm vial diluted on 500 ml normal saline 0.9%
215143727|NCT06599307|OTHER|Saline (NaCl 0,9 %) (placebo)|500 ml of normal saline 0.9%
215143728|NCT06600113|OTHER|Education and teaching of coping strategies|the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
215143729|NCT06599346|OTHER|Standard Care|Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.
215143730|NCT06599346|BIOLOGICAL|MSC Supernatant + Standard Care|"Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"
215143731|NCT06602700|BEHAVIORAL|HIIT|high-intensity interval training
214528456|NCT03032640|OTHER|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
214528457|NCT03032640|OTHER|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
214528458|NCT03032640|OTHER|Stool sampling|Subjects will provide a stool sample.
215143732|NCT06602700|BEHAVIORAL|MICT|moderate-intensity continuous training
215143733|NCT06592170|DRUG|Linperlisib combination with obinutuzumab|"Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle."
215143734|NCT06407921|DEVICE|Whole Body Vibration|On vibration plate pate child will do kneeling, and one leg standing, standing horizontally or vertically. Along routine physical therapy such as stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, elbow and wrist flexors, pronators, and ulnar deviators, each stretch will be given for 30 seconds with 3 repetitions.Strength training to hip flexor, knee extensor, and ankle dorsiflexors for 15 minutes 3 times a week for 8 weeks. Session will be of 30 minutes
214456557|NCT03075254|DEVICE|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
214456558|NCT03075254|DEVICE|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
214528459|NCT03032640|OTHER|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
214528460|NCT03032640|OTHER|Placebo|Subjects in group 2 will be provided with placebo.
214528461|NCT03032640|OTHER|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
214528462|NCT02836041|BEHAVIORAL|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
214528463|NCT02836041|DEVICE|actigraph|This device reliably measures sleep by monitoring the child's motion.
214528464|NCT00121446|DRUG|tenecteplase|
214528465|NCT00121446|DRUG|enoxaparin|
214528466|NCT00121446|DRUG|clopidogrel|
214456559|NCT03075254|DEVICE|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
214528467|NCT00121446|PROCEDURE|percutaneous coronary intervention|
214528468|NCT01013688|PROCEDURE|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
215143735|NCT06407921|DEVICE|BOSU ball|Exercises such as (1) standing on a BOSU ball while throwing and catching a ball (2) 1-legged standing (affected leg) on the BOSU ball while throwing and catching a ball with therapist support; and (3) small jumps on the BOSU ball. Three sets of 6 repetitions for each exercise will be perform every 2 weeks up to a maximum of 10 repetitions if the participants were still able to perform the training easily. Total dose of balance training in 1 session will be 15 minutes
215143736|NCT06596200|DEVICE|Spinal Cord Stimulation Implant|Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord
215143737|NCT05950035|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
215143738|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
215143739|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
215143740|NCT05950035|BEHAVIORAL|Waitlist|Waitlist for delayed intervention.
215143741|NCT06704581|DRUG|5 mg BGM0504 injection|5mg BGM0504 injection administered subcutaneously (SC) once a week.
215143742|NCT06704581|DRUG|10 mg BGM0504 injection administered subcutaneously (SC) once a week|10mg BGM0504 injection administered subcutaneously (SC) once a week.
215143743|NCT06704581|DRUG|15 mg BGM0504 injection|15mg BGM0504 injection administered subcutaneously (SC) once a week.
215143744|NCT06704581|DRUG|BGM0504 placebo|BGM0504 placebo administered SC once a week.
215143745|NCT06604455|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
215143746|NCT06604455|OTHER|acupressure/relaxation|The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
215143747|NCT06748209|DEVICE|Left prefrontal Transcranial Magnetic Stimulation (TMS)|FDA cleared TMS
215143748|NCT06748209|DEVICE|FDA cleared TMS for treating depression|This is FDA approved TMS
214456560|NCT05404958|OTHER|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
214456561|NCT06180135|OTHER|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
214456562|NCT06180135|OTHER|FENNEL TEA DRINK|FENNEL TEA DRINK
214456563|NCT06274307|PROCEDURE|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
214456564|NCT04641897|PROCEDURE|Respiratory rate modification|"During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate)."
215143749|NCT06754670|DRUG|Sodium Glycerophosphate 216 MG/ML|Low phosphorus patients receive intravenous phosphate supplementation according to the clinical phosphate supplementation protocol at our center: patients with blood phosphorus \< 0.4mmol/L receive 40mmol of glycerol phosphate sodium intravenously via infusion or injection over 4-6 hours; patients with blood phosphorus 0.4-0.8mmol/L receive 30mmol of glycerol phosphate sodium intravenously via infusion or injection; Normal phosphorus patients do not require any special treatment.
215143750|NCT06778109|OTHER|hypnosis|T0) basal evaluation of physiological data T1) evaluation of physiological data after recollecting a negative memory for 3 minutes T2) evaluation of physiological data after that a brief session of hypnosis (performed with positive memories) T3) evaluation of physiological data recolling, for the second time, the negative memory.
215143751|NCT06874478|DIAGNOSTIC_TEST|Ultrasound|The main pulmonary artery will be seen between the pulmonary valve and the bifurcation of the right and left branches. The pulsed Doppler sample gate will be adjusted to 3 mm, and the angle of insonation will be kept at or around 15°. Doppler gain and scale will be tailored for optimizing the velocity waveform display, clearly showing the peak systolic velocity (PSV) and early diastolic notch. The MPA Doppler waveform will show a sharp systolic peak blood flow with a needle-like appearance. After the optimum fetal main pulmonary artery waveform, Doppler velocity will be manually traced three times, and the average will be taken.
215143752|NCT06775587|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|"1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~3. The following is the general sequence of events during the 3 months evaluation period:~4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring."
215143753|NCT06839105|DRUG|Taxol|135\~175 mg/m2, Q3W
215143754|NCT06839105|DRUG|Cisplatin or Carboplatin|Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
214456565|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
214456566|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
214456567|NCT03829410|DRUG|Onvansertib|Onvansertib orally.
214456568|NCT03829410|BIOLOGICAL|Bevacizumab|Bevacizumab intravenously.
214456569|NCT03829410|DRUG|FOLFIRI|FOLFIRI intravenously.
214456570|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
214456571|NCT04537312|OTHER|Survey Administration|ancillary correlative
214456572|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
214456573|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
214456574|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
214456575|NCT03668977|DIETARY_SUPPLEMENT|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
214456576|NCT04290221|OTHER|Ultrasound-guided percutaneous electrolysis in the lumbar nerve root|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 6 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
214456577|NCT04290221|OTHER|Electrical Dry Needling in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
214456578|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
215143755|NCT06839105|DRUG|Pemetrexed|500 mg/m2, Q3W
215143756|NCT06839105|DRUG|Oxaliplatin|130 mg/m2, Q3W
215143757|NCT06839105|DRUG|Capecitabine|1000 mg/m2, BID, day1-14, oral, q3w
215143758|NCT06839105|DRUG|Bevacizumab|7.5 mg/kg, Q3W
215143759|NCT06839105|DRUG|Renvastinib|8mg or 20mg, QD
215143760|NCT06839105|DRUG|AWT020|q3w or q2w, i.v.
215143761|NCT05844501|DRUG|Ondansetron 8mg|Ondansetron 8 mg orally twice daily for 28 days
215143762|NCT05844501|DRUG|Placebo|Matched placebo orally twice daily for 28 days
215143763|NCT06780891|BEHAVIORAL|Telephysical therapy|The experimental group is undergoing a tele-assisted therapeutic exercise program (T-TPT/T-FIS), which involves physical exercises aimed at improving cardiovascular fitness, muscle strength, and balance, among others. Participants will complete exercises under virtual supervision and submit progress reports.
215143764|NCT06780891|BEHAVIORAL|Educational session|The educational session will focus on raising awareness about stroke risk factors, such as hypertension, diabetes, and smoking, while promoting healthy lifestyle changes. The goal is to empower them with the knowledge to reduce stroke risk and improve overall well-being.
214528469|NCT04859218|PROCEDURE|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
215143765|NCT06772363|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
215143766|NCT05958251|OTHER|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
215143767|NCT05958251|OTHER|Standard Care (in control arm)|Standard care
215143768|NCT00595088|BIOLOGICAL|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
215143769|NCT00735436|DRUG|Gliadel/Avastin/CPT-11|
215143770|NCT06903637|OTHER|Hierarchical Cluster Analysis|The complexity of clinical follow-up stems from the wide range of variables involved, such as physical performance, mobility, pain, psychological well-being, and prosthetic functionality. Therefore, developing methods to identify the most relevant and interrelated clinical variables is critical for enhancing patient management. To address this need, Hierarchical Cluster Analysis (HCA) offers a powerful multivariate statistical approach for detecting relationships among clinical variables.
215143771|NCT06878547|DEVICE|Ultrasound|Non-invasive breast imaging using VisR ultrasound
215143772|NCT04323124|DRUG|PF-07059013|Participants will recieve PF-07059013
214456579|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
214456580|NCT03033576|BIOLOGICAL|Ipilimumab|Given IV
214456581|NCT03033576|BIOLOGICAL|Nivolumab|Given IV
214456582|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
214456583|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
214456584|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
214456585|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
214456586|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
214456587|NCT05179837|DEVICE|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
214456588|NCT06237062|OTHER|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
214528470|NCT00942513|OTHER|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
214528471|NCT00942513|OTHER|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
214528472|NCT00942513|OTHER|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
214528473|NCT00942513|OTHER|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
214695191|NCT04042571|DEVICE|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
214528474|NCT00942513|OTHER|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
214528475|NCT00942513|OTHER|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
214528476|NCT00942513|OTHER|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
214528477|NCT06201715|DRUG|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
214695192|NCT05408312|BIOLOGICAL|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
214695193|NCT05408312|BIOLOGICAL|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
215143773|NCT04323124|DRUG|Placebo|Participants will recieve placebo
215143774|NCT06497270|PROCEDURE|Theca and Granulosa Cell Isolation|These patients will receive standard procedure during the risk reducing surgery but their ovaries will be used to extract theca and granulosa cells which will be used for the 3D bioprinted device's realisation.
215143775|NCT06056596|DRUG|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
215143776|NCT06056596|DRUG|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
215143777|NCT04074044|BEHAVIORAL|BHmApp|Use of BHmApp for bladder education and training in pregnancy
215143778|NCT00489307|DRUG|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
215143779|NCT00489307|DRUG|Placebo|Placebo PO twice daily x 14 days
215143780|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
215143781|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
215143782|NCT04586205|DEVICE|active TMS|Participants receive active repetitive transcranial magnetic stimulation (rTMS) while performing the International Affective Picture System (IASP). Stimulation is delivered at 120% of resting motor threshold (RMT), in triplet 50 Hz bursts, repeated at 5 Hz (2s on, 8s off), totaling 600 pulses per session.
215143783|NCT04586205|DEVICE|sham TMS|Participants receive sham rTMS while performing the IASP task. Stimulation is mimicked without actual neural activation using the same schedule and coil placement as the active condition.
214456589|NCT04119544|OTHER|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
214456590|NCT04119544|DEVICE|Intensive Visual Simulation|"* First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
214456591|NCT05364879|BEHAVIORAL|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
214456592|NCT06453083|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 6-days.
214456593|NCT06453083|DRUG|Medrol|Medrol tablets will be dispensed to the participants for 6-days.
214456594|NCT02008045|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
214456595|NCT02008045|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
214456596|NCT05674539|DRUG|Fludarabine and Busulfan|Fludarabine with total dose of 150 mg/m\^2 in combination with Busulfan with total dose of 6.4 mg/kg
214456597|NCT05674539|DRUG|Fludarabine and Melphalan|Fludarabine with total dose of 150 mg/m\^2 in combination with Melphalan with total dose of 140 mg/m\^2
214456598|NCT06636708|COMBINATION_PRODUCT|Nanodropper and Proparacaine HCl 0.5%|The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
214456599|NCT06636708|COMBINATION_PRODUCT|Standard Eye Drop Bottle with Proparacaine HCl 0.5%|This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
214456600|NCT06637904|DIAGNOSTIC_TEST|TriVerity Test|Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
214456601|NCT03719443|BIOLOGICAL|VIS649|Single IV dose of study product on Day 1 of study
214456602|NCT03719443|BIOLOGICAL|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
214456603|NCT06638229|DEVICE|The StimaWELL 120MTRS system|A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
214528478|NCT06632925|PROCEDURE|Catheter ablation|"The catheter ablation strategy is the same as the current treatment approach in patients with AF, according to the consensus of catheter ablation of AF. All procedures will be performed under local sedation or general anesthesia depending on the operator, and each patient will undergo an electrophysiological study and substrate mapping in the fasting state with adequate pre-ablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. All antiarrhythmic drugs except amiodarone will be discontinued for at least 5 half-lives before the procedure.~Step I: Substrate mapping before ablation, Step II: Pulmonary vein isolation (PVI), Step III: Post-ablation mapping in SR immediately after ablation, Step IV: Inducibility after ablation, Step V: Remmaping 30 minutes after ablation"
214528479|NCT04100239|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
214528480|NCT02759887|PROCEDURE|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
214528481|NCT02759887|OTHER|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
214528482|NCT02759887|OTHER|caregiver questionnaire|
214528483|NCT02759887|PROCEDURE|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
214528484|NCT02759887|PROCEDURE|MRI|Magnetic resonance imaging of the head and brain.
214528485|NCT02759887|PROCEDURE|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
214528486|NCT02759887|PROCEDURE|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
215143784|NCT04586205|BEHAVIORAL|IASP Task|Participants complete the IASP (emotional image viewing) task during each TMS session (active and sham). The task includes both high- and low-load trials, designed to activate the dorsolateral prefrontal cortex (DLPFC). Task order and load levels are consistent across both stimulation sessions.
215143785|NCT04586205|BEHAVIORAL|SST Task|In a separate MRI session prior to TMS sessions, participants complete the SST which includes both high-load and low-load trials. This cognitive task is used to examine baseline DLPFC activation and to contrast cognitive vs. emotional activation profiles.
214456604|NCT06315959|PROCEDURE|Bilateral ultrasound guided erector spinae plane block|"Bilateral ultrasound-guided ESP(total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS).~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
214456605|NCT06315959|DRUG|morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
214456606|NCT06315959|OTHER|Control group|"Patients in this group will not be performed plane blocks. Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS) .~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
214456607|NCT06315959|DRUG|morphine PCA|V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
214456608|NCT05051124|BEHAVIORAL|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
214456609|NCT05051124|BEHAVIORAL|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
214456610|NCT06365125|BEHAVIORAL|eCHECKUP TO GO|Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
214456611|NCT06365125|BEHAVIORAL|Text messaging boosters|Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
214456612|NCT05647369|DIETARY_SUPPLEMENT|Mastic mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
214456613|NCT05647369|DIETARY_SUPPLEMENT|Placebo mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
214456614|NCT05586516|DRUG|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
214695194|NCT05408312|BIOLOGICAL|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
215143786|NCT04586205|OTHER|MRI|Participants undergo MRI sessions to measure DLPFC cortical reactivity and connectivity.
215143787|NCT06831110|PROCEDURE|Aquagenic Wrinkling|Participants will be asked to remove all jewelry from the hand(s) and wrist(s) that will be undergoing the aquagenic wrinkling procedures. Photographs will be taken of the palmar surface of the hand(s). The participant will submerge the hand(s) undergoing testing in a water bath for one minute. After one minute, they will remove their hand(s), dry them gently with a towel, and photographs will be taken of the palmar surface of the hand(s). The participant will re-submerge their hand(s) in the appropriate conditions for another minute and the process will be repeated 20 times for 20 total minutes submerged in the water.
215143788|NCT06653387|DEVICE|CGuard Prime 80cm stent system|This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
215143789|NCT04965623|DEVICE|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
214528487|NCT02759887|PROCEDURE|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
214528488|NCT03065205|DEVICE|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
214528489|NCT02182583|DRUG|Ba253MDI|
215143790|NCT06134518|OTHER|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
214456615|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
214456616|NCT06643052|OTHER|No intervention|No intervention
214456617|NCT05080842|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
214456618|NCT05845476|OTHER|Patient SOGI Self-Report|"EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record."
214456619|NCT05845476|OTHER|SOGI Resource for Clinical Care Education (SORCE)|SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
214456620|NCT05845476|OTHER|Cancer Center Care Environment|At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
214456621|NCT06638866|DIAGNOSTIC_TEST|PDAC|Participants with algorithm-identified PDAC will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
214528490|NCT02182583|DRUG|Ba253BINEB|
214528491|NCT06413277|DEVICE|Saluda Evoke Smart SCS System|Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation
214528492|NCT00157690|DRUG|Alendronate|70 mg 1x weekly for 12 months
214528493|NCT00157690|DRUG|Placebo|70 mg 1 x weekly for 12 months
214528494|NCT02999932|OTHER|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
214528495|NCT00887185|OTHER|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
214528496|NCT05382910|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
214528497|NCT05382910|DRUG|Placebo|Placebo
215143791|NCT06134518|OTHER|the initial orientation from the PHCs|the initial orientation from the PHCs
215143792|NCT05452863|DEVICE|O2matic administered oxygen|Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
215143793|NCT05452863|DEVICE|Manual oxygen supply and adjustments|Oxygen supply is adjusted from manual measurements of the oxygen saturation
215143794|NCT06940869|OTHER|NURTURE Registry|To improve pregnancy and birth outcomes for women with rheumatic diseases and to understand risk factors associated with poor pregnancy outcomes.
215143795|NCT04684836|OTHER|Exposure to telemedicine, after the onset of the pandemic|The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
215143796|NCT06943534|DRUG|5mg/kg omalizumab injection|5mg/kg of omalizumab
215143797|NCT06943534|DRUG|15mg/kg omalizumab injection|15mg/kg of omalizumab
215143798|NCT04856358|DRUG|GLPG3121|GLPG3121 modified-release tablet
215143799|NCT04856358|DRUG|Placebo|Matching placebo
215143800|NCT05687851|DRUG|Cadonilimab（AK104）|q3w iv
215143801|NCT05687851|RADIATION|EBRT|45-50.4Gy
215143802|NCT05687851|RADIATION|BT|≥80Gy
215143803|NCT02633124|DEVICE|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
215143804|NCT02633124|DEVICE|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
215143805|NCT00204178|BEHAVIORAL|Oxidative stress in kidney transplant recipients|
215143806|NCT04103619|DEVICE|AccuTite|Subjects will undergo treatment with AccuTite
215143807|NCT04103619|DEVICE|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
215143808|NCT04374669|PROCEDURE|Neuroplasty with Racz catheter|The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
214456622|NCT06638866|DIAGNOSTIC_TEST|Pancreatic precursor lesions|Participants with algorithm-identified pancreatic precursor lesions will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
214528498|NCT02977780|DRUG|Temozolomide|Temzolomide capsules
215143809|NCT06319690|OTHER|Lion's Breath Technique|"Patients receive training in Lion's Breath Technique, emphasizing deep diaphragmatic breathing and controlled exhalation.~Daily supervised Lion's Breath Technique sessions for 20 minutes for 1 week"
215143810|NCT06319690|OTHER|Chest Percussion Therapy|"Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week."
215143811|NCT03401801|PROCEDURE|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
215143812|NCT04041635|PROCEDURE|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
215143813|NCT04041635|PROCEDURE|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
215143814|NCT06215170|DEVICE|SafeMedWaste|SafeMedWaste opioid disposal kit
215143815|NCT03384615|BEHAVIORAL|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
215143816|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143817|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143818|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
215143819|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143820|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
215143821|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143822|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143823|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
215143824|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143825|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143826|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143827|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
215143828|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
214456623|NCT06638853|BEHAVIORAL|Distress Tolerance Skills Training|"These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions."
215143829|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143830|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143831|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
215143832|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
215143833|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
215143834|NCT03745612|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
215143835|NCT03745612|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
214456624|NCT06637254|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
214456625|NCT06637254|DRUG|Placebo|the placebo comparator of study
214456626|NCT06641284|DRUG|Spironolactone|All patients will receive Spironolactone as a part of their GDMT for Heart Failure
214528499|NCT02977780|DRUG|Neratinib|Neratinib tablets
214456627|NCT05056129|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
214456628|NCT05056129|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
214456629|NCT06556940|BIOLOGICAL|LMN-401|Orally delivered tablets and capsules
214456630|NCT06128200|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
214456631|NCT06128200|DEVICE|Sham NEUROMARK System|Sham ablation procedure using the NEUROMARK System
214456632|NCT05068648|OTHER|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
214456633|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
214528500|NCT02977780|DRUG|QBS10072S|QBS10072S administered intravenously
214528501|NCT01341444|DEVICE|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
214528502|NCT01341444|OTHER|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
214528503|NCT05311774|DRUG|Duloxetine 30 mg|tablet
214528504|NCT05311774|DRUG|Tramadol|tablet
214528505|NCT05311774|DRUG|Placebo|tablet
214528506|NCT06268431|OTHER|Oxytocin rest|60-minute oxytocin rest
214528507|NCT05329649|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
214528508|NCT05082233|DRUG|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
214528509|NCT00038298|DRUG|Placebo|Placebo given 3 times weekly
215143836|NCT00320450|DRUG|SB-681323|
214528510|NCT00038298|DRUG|AMG 719|50 mg 3 times weekly
214528511|NCT00038298|DRUG|AGM 719|200 mg 3 times weekly
214528512|NCT00038298|DRUG|AMG 719|400 mg 3 times weekly
214528513|NCT00038298|DRUG|placebo to AMG 719|Placebo dose given 3 times weekly
214456634|NCT06641635|COMBINATION_PRODUCT|Moderated hypofractionated online adaptive radiotherapy|"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
214456635|NCT06641635|COMBINATION_PRODUCT|Conventional radiotherapy|"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
214456636|NCT04924660|DRUG|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
214456637|NCT04924660|DRUG|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
214456638|NCT04924660|DRUG|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
214456639|NCT04924660|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
214456640|NCT04769765|OTHER|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
214456641|NCT05275855|DRUG|EDI048|Oral Liquid
214456642|NCT05275855|OTHER|Placebo|Oral Liquid
214456643|NCT05712564|OTHER|Questionnaire|Questionnaire for fatigue assessment
214456644|NCT03707691|BEHAVIORAL|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
214456645|NCT03707691|BEHAVIORAL|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
214456646|NCT03707691|BEHAVIORAL|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
214528514|NCT04143737|BEHAVIORAL|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
214528515|NCT02312609|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
214528516|NCT02763150|BEHAVIORAL|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
214528517|NCT02763150|OTHER|Health Promotion|The health promotion group will receive education on healthy eating and activity
214528518|NCT02609035|BEHAVIORAL|Telephonic prompt|
215143837|NCT00587522|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
215143838|NCT01586364|DRUG|Ospemifene 60Mg Oral Tablet|
215143839|NCT04475367|OTHER|App hypercross group|hypertensive patients using HyperCrossApp
215143840|NCT04475367|OTHER|without App hypercross group|Interdisciplinary health care
215143841|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
215143842|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
215143843|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
215143844|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
214456647|NCT05957536|BIOLOGICAL|D3L-001|Intravenous administration
214456648|NCT04422912|BIOLOGICAL|DSG3-CAART or CABA-201|"Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201."
215143845|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
215143846|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
215143847|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
215143848|NCT02121535|DRUG|T80/A5 mg FDC tablet|
215143849|NCT02121535|DRUG|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
215143850|NCT02121535|DRUG|H12.5 mg tablet|
215143851|NCT02121535|DRUG|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
215143852|NCT02121535|DRUG|H12.5 mf tablet|A HCTZ 12.5 mg tablet
215143853|NCT02121535|DRUG|T80/A5/H12.5 mg FDC tablet|
215143854|NCT06440434|BEHAVIORAL|Time of night shift|Early vs. late night split night shift
215143855|NCT01780740|DRUG|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
215143856|NCT01780740|DRUG|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
215143857|NCT01968200|DRUG|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
214456649|NCT05694767|DRUG|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
214456650|NCT06008951|OTHER|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
214456651|NCT06008951|OTHER|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
214456652|NCT06643195|OTHER|ImmediateAllogeneic Hematopoietic Stem Cell Transplantation|patients proceeded to allogeneic HSCT as soon as possible. Patients were allowed to receive low-dose chemotherapy that is not intended for the purpose of achieving a second remission.
214456653|NCT06643195|OTHER|Retreatment|Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
214456654|NCT06082739|OTHER|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
214456655|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
214456656|NCT06643494|DIETARY_SUPPLEMENT|N-111|A combination of Acetogenins
214456657|NCT06643494|OTHER|Placebo|Placebo
214456658|NCT04234685|DEVICE|High Intensity Physio Light Therapy (HIPL Therapy™)|HIPL Therapy™ is an advanced phototherapy method that utilizes an emission wavelength spectrum that has been optimized for treatment of musculoskeletal disorders (MSD) such as OA.
214456659|NCT04234685|BEHAVIORAL|Education|Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
214456660|NCT04234685|BEHAVIORAL|Aerobic Exercise|Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
214528519|NCT05278065|OTHER|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
214528520|NCT01701271|OTHER|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
215143858|NCT03266510|OTHER|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
215143859|NCT03266510|OTHER|Sham training|Subjects will perform sham training for 6 weeks.
215143860|NCT05447780|PROCEDURE|regional anesthesia|regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
215143861|NCT00091949|DRUG|pioglitazone|a thiazolidinedione drug
215143862|NCT00091949|DRUG|placebo|an inactive substance
215143863|NCT05969158|DRUG|Hetrombopag|"After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT \< 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5)."
215143864|NCT06176079|DRUG|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
215143865|NCT06176079|DRUG|Hyperpolarized 13C-Urea|Given intravenously (IV)
215143866|NCT06176079|PROCEDURE|Magnetic Resonance Imaging|Imaging procedure
215143867|NCT06176079|PROCEDURE|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
215143868|NCT02769117|PROCEDURE|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
215143869|NCT02769117|PROCEDURE|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
215143870|NCT04427813|BEHAVIORAL|questionaire to husband and wife|a form of questions will be asked to every partner
214528521|NCT00550771|DRUG|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
214528522|NCT00550771|DRUG|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
214528523|NCT04598945|OTHER|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
214528524|NCT00730847|BIOLOGICAL|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
214528525|NCT00333502|DRUG|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
215143871|NCT01669837|DEVICE|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
215143872|NCT03390946|DRUG|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
215143873|NCT03390946|DRUG|Good responder group adjuvant chemotherapy|"Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
214456661|NCT04234685|BEHAVIORAL|Resistance Exercise|Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
214456662|NCT04234685|DEVICE|Placebo Physio Light Therapy (HIPL Therapy™)|Phototherapy delivered at an intensity of 5 mW/cm2, a dosage at which there is no therapeutic benefit expected, but the light will still be visible to the participant.
214456663|NCT06449742|DIAGNOSTIC_TEST|AI software and automatic 3D reconstruction|Radiological medical evaluation with automatic 3D reconstruction of the thoracic and lumbar spine and through application of the AI software NanoxAIHealthVCF, NANO-X IMAGING LTD on abdomen-chest CT studies.
214456664|NCT06643156|DRUG|GP681 10mg/20mg/40mg|0.5/1/2×20mg power for oral suspension taken orally
214456665|NCT05596630|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
214456666|NCT05190471|DRUG|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
214456667|NCT05190471|DRUG|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
214456668|NCT03642665|DRUG|Natural cycle|no medication
214456669|NCT03642665|DRUG|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
214528526|NCT02733835|DRUG|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
214528527|NCT04767802|DRUG|PTG-300|Hepcidin mimetic
214528528|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily.
214695195|NCT05408312|BIOLOGICAL|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
215143874|NCT01256788|DEVICE|Euflexxa|4 injections of 2ml of Euflexxa
215143875|NCT01256788|OTHER|Saline|4 injections of 3 ml of sterile saline
215143876|NCT04093102|DIAGNOSTIC_TEST|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
215143877|NCT01954446|DEVICE|3M|Conventional measuring of BP
215143878|NCT01954446|DEVICE|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
215143879|NCT01954446|DEVICE|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
214456670|NCT03642665|DRUG|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
214528529|NCT04655183|DRUG|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
214528530|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
214528531|NCT04655183|DRUG|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
214695196|NCT04825119|DRUG|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
215143880|NCT04911140|RADIATION|Photobiomodulation twice a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
215143881|NCT04911140|RADIATION|Photobiomodulation three times a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
215143882|NCT04911140|OTHER|Simulated Photobiomodulation|Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
215143883|NCT03399019|DRUG|Dexmedetomidine|initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
215143884|NCT03399019|DRUG|Propofol|continuous infusion (0.75-3mg/kg/hr)
215143885|NCT03399019|DRUG|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
215143886|NCT03347721|DRUG|lidocaine gel|2% lidocaine jelly, injected into the urethra
215143887|NCT03347721|DRUG|Lubricant Gel|Lubricating gel
215143888|NCT04289064|DEVICE|Taking a fundus image|The participant only needs to take a fundus image as usual.
215143889|NCT05908825|DRUG|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
215143890|NCT05908825|DRUG|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
215143891|NCT02044640|PROCEDURE|Appendectomy|
215143892|NCT02083354|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
214456671|NCT05410509|PROCEDURE|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
214456672|NCT05165407|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
214456673|NCT05165407|DRUG|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
215143893|NCT02083354|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
215143894|NCT03469453|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
215143895|NCT01955421|DRUG|Erlotinib 100mg qd|
214456674|NCT05165407|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
214456675|NCT06557577|OTHER|No intervention group.|There is no intervention group.
214456676|NCT05818332|OTHER|Observational study|No intervention, observational only
214695197|NCT01985373|DRUG|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
214695198|NCT00228150|DRUG|SR57667B|
215143896|NCT01955421|DRUG|Gefitinib 250mg qd|
215143897|NCT00844961|BEHAVIORAL|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
214695199|NCT01303380|DRUG|Canakinumab|
215143898|NCT03475836|DIETARY_SUPPLEMENT|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
215143899|NCT03475836|DIETARY_SUPPLEMENT|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
215143900|NCT03312634|DRUG|Palovarotene|Palovarotene was taken orally once daily at approximately the same time each day following a meal.
215143901|NCT00000285|DRUG|Phenytoin|
215143902|NCT01660724|PROCEDURE|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
215143903|NCT01660724|PROCEDURE|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
215143904|NCT00309491|DRUG|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
215143905|NCT00309491|DRUG|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
215143906|NCT00139152|DRUG|Placebo|Saline, Sub-Cuteanous (SQ)
215143907|NCT00139152|DRUG|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
215143908|NCT05957835|DIETARY_SUPPLEMENT|BR-HIGH|4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
215143909|NCT05957835|DIETARY_SUPPLEMENT|BR-MOD|2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
215143910|NCT05957835|DIETARY_SUPPLEMENT|BR-LOW|1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
215143911|NCT05957835|DIETARY_SUPPLEMENT|PL|4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
215143912|NCT02757235|PROCEDURE|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
214708697|NCT00300612|BIOLOGICAL|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
215143913|NCT02757235|PROCEDURE|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
215143914|NCT00671294|DRUG|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
215143915|NCT00906204|BIOLOGICAL|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
215143916|NCT00906204|BIOLOGICAL|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
215143917|NCT02853617|BIOLOGICAL|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
215143918|NCT02853617|BIOLOGICAL|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
215143919|NCT02853617|BIOLOGICAL|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
215143920|NCT02853617|BIOLOGICAL|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
215143921|NCT04328077|DRUG|TERN-101|Investigational drug
215143922|NCT04328077|OTHER|Placebo|Matching placebo
215143923|NCT01680042|DRUG|Phenytoin paste|
215143924|NCT01680042|DRUG|Placebo|
215143925|NCT02699424|RADIATION|External radiation therapy|
215143926|NCT02983201|OTHER|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
215143927|NCT02983201|OTHER|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
214456677|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
214456678|NCT06576765|DRUG|AZD0780|Dose 1
214456679|NCT06576622|OTHER|biological sampling|"As part of the health check-up oral, Will be taken:~* Salivary samples by sputum.~* Samples of subgingival plaque in the periodontal sulcus~* A collection of the history and disease risk factors will then be carried out.~* periodontal problems by a routine care interview, the clinical examination and radiological examination."
214456680|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
214456681|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
214456682|NCT05052723|DRUG|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
214456683|NCT05052723|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
214456684|NCT05402202|OTHER|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
214456685|NCT05402202|OTHER|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
214456686|NCT05195151|DIETARY_SUPPLEMENT|Taking capsule containing probiotics or placebo|The probiotics capsule containing two strains of probiotics.
214456687|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
214456688|NCT04572399|DEVICE|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
215143928|NCT06769334|OTHER|PLAY Program|The PLAY Program is a web-based program created for caregivers of childhood cancer survivors. The program consists of seven modules with the following topics: 1) Introduction to the program 2) Self-Care 3) Relationships 4) Getting Ready for School 5) Talking, Reading, and Counting together 6) Social and Emotional Development 7) Review Module. The program is meant to be completed over approximately three months, and caregivers in the program will meet with a coach on a weekly or bi-weekly basis to discuss what they learned in the modules and how to practice it in their daily lives.
215143929|NCT05764447|BEHAVIORAL|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
215143930|NCT05764447|BEHAVIORAL|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
215143931|NCT05291520|BIOLOGICAL|VH3810109|VH3810109 was administered.
215143932|NCT05291520|BIOLOGICAL|rHuPH20|rHuPH20 was administered.
215143933|NCT01347112|DRUG|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
215143934|NCT01347112|DRUG|placebo|sugar pill twice daily for 12 weeks
215143935|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
215143936|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
215143937|NCT05202886|DIAGNOSTIC_TEST|Liver from deceased donors|Liver donors photographed
215143938|NCT04190641|DEVICE|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
215143939|NCT01679314|DEVICE|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
215143940|NCT02342808|BEHAVIORAL|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
215143941|NCT02342808|BEHAVIORAL|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
215143942|NCT03208010|BEHAVIORAL|Diabetes Prevention Intervention|"* Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
215143943|NCT03208010|OTHER|Enhanced Usual Care|"* Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials"
215143944|NCT02751723|OTHER|validated questionnaires|
215143945|NCT01615120|DRUG|GTx-758 125 mg|One 125 mg tablet once a day
215143946|NCT01615120|DRUG|GTx-758 250 mg|two 125 mg tablets once daily
215143947|NCT00696072|DRUG|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
215143948|NCT00696072|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
215143949|NCT01597596|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
215143950|NCT01597596|BIOLOGICAL|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
214456689|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
214456690|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
214456691|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
214708698|NCT03654079|OTHER|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
215143951|NCT05990010|DIAGNOSTIC_TEST|Berlin Questionnaire|The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
215143952|NCT06274736|DEVICE|Motiva Sizer|No intervention will be made,
214456692|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
214456693|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
214456694|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
214456695|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214456696|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214456697|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214456698|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
215143953|NCT06517420|OTHER|kefir consumption|Support and information was received from the Food Technology Department of a university's Experimental Medicine Application and Research Center. It was decided to choose the kefir to be used, which is produced from pasteurized cow's milk, lactase enzyme, probiotic culture (B. Lactis) and kefir culture, will meet the B12 need, contribute to increasing vitality and energy, and has the most suitable content in the market. Kefir, supplied by the researcher, was given to the patients at the end of each session in the amount that the patients should consume for a week, following the cold chain rule. While consuming kefir, it was recommended to gargle it in the mouth, hold it for a while, and then swallow. Patients were contacted for a week after the session to ensure that they applied kefir correctly.
215143954|NCT01744106|DRUG|pseudoephedrine hydrochloride 30 mg tablets|
215143955|NCT01744106|DRUG|Placebo tablets|
215143956|NCT01601236|DRUG|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].
215143957|NCT01601236|DRUG|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
215143958|NCT03821727|PROCEDURE|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
215143959|NCT02124369|DRUG|Abraxane|125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
215143960|NCT02124369|DRUG|Gemcitabine|1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
215143961|NCT00218868|PROCEDURE|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
214456699|NCT06576882|DRUG|Vonoprazan|Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
214456700|NCT06576882|DRUG|Amoxicillin|Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
214456701|NCT06576882|DRUG|Clarithromycin|Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
214456702|NCT05270733|DRUG|Ustekinumab|Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
214456703|NCT06576596|OTHER|apnoeic Oxygenation|One approach to preventing adverse respiratory events due to hypoxaemia during paediatric anaesthesia is the use of apnoeic oxygenation. The principle is to deliver oxygen to the airways of anaesthetised patients via a conventional nasal cannula. As less carbon dioxide is produced than oxygen is consumed during apnoea, the supply of oxygen to the upper airways leads to an 'inward diffusion' of oxygen, which may prolongs the time until desaturation and hypoxaemia occur.
214456704|NCT04711278|DEVICE|Mask-wearing hypnosis|"Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient."
214456705|NCT04711278|OTHER|Without hypnosis|No hypnosis during surgery of Hallux valgus.
214456706|NCT06576817|OTHER|High intensity circuit exercise class - Lower and upper extremity|Exercises performed at high intensity effort in the circuit (8 total) will focus on both the lower extremity (4) and upper extremity (4)
215143962|NCT04950647|DRUG|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
215143963|NCT04950647|DRUG|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
214456707|NCT06576817|OTHER|High intensity circuit exercise class - Lower extremity alone|All exercises performed at high intensity effort in the circuit (8 total) will focus on the lower extremity alone
214456708|NCT05932485|PROCEDURE|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
214456709|NCT06033001|DRUG|[Lu-177]-PNT2002|\[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
214456710|NCT05773326|DRUG|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
214456711|NCT06263101|OTHER|Biochemical testing of abdominal drainage fluid|Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).
214456712|NCT06263101|OTHER|Cytological examination of abdominal drainage fluid|Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)
214456713|NCT06263101|OTHER|Peripheral blood cytology tests|Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
214456714|NCT06528964|DIAGNOSTIC_TEST|Immunohistochemistry and immunofluorescence|Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
214528532|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
214528533|NCT04655183|DRUG|Niraparib|Niraparib will be administered as single agent at the approved dose.
214528534|NCT03460847|DRUG|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
215143964|NCT04950647|DRUG|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
215143965|NCT01340846|DRUG|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
214528535|NCT04514796|DRUG|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
214528536|NCT03022578|PROCEDURE|Laser Interstitial Thermal Therapy|Undergo LITT
214528537|NCT03022578|DRUG|Lomustine|Given PO
214528538|NCT02536885|PROCEDURE|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
214528539|NCT02536885|PROCEDURE|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
214528540|NCT00429078|GENETIC|2nd Generation Designer T Cells|
214528541|NCT01855178|DEVICE|Emfit Movement Monitor|Factory settings
214456715|NCT05662631|DEVICE|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
214456716|NCT05048706|DEVICE|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
214456717|NCT05048706|DEVICE|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
214456718|NCT03153527|DRUG|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
214456719|NCT03153527|OTHER|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
214456720|NCT05743673|DEVICE|Shape II|cardiopulmonary exercise testing apparatus
214456721|NCT05279690|DRUG|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
214456722|NCT03189641|DEVICE|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
214456723|NCT04458883|PROCEDURE|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
214456724|NCT04458883|PROCEDURE|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
214456725|NCT04458883|PROCEDURE|Electrocardiogram|Electrocardiogram
214456726|NCT04458883|PROCEDURE|Echocardiogram|Echocardiogram
214456727|NCT04749615|DRUG|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
214456728|NCT04749615|DRUG|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
214456731|NCT06220071|OTHER|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
214456732|NCT05686590|BEHAVIORAL|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
214456733|NCT06491758|DEVICE|ML1101 Stimulus Isolator|Electrical stimulation electrodes will be placed on the ear with the intensity of the current being increased by 10 percent every 60 seconds, the subject will grade the intensity of the current on a scale of 0-10. Increasing of the current will occur until the subject reports a comfortable level. Once the target level has been achieved the stimulation will be delivered for 2 minutes.
214528542|NCT02625129|OTHER|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
214528543|NCT06235385|OTHER|Intervention not provided|This study is purely observational
214528544|NCT00823004|DRUG|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
214528545|NCT00823004|DRUG|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
214528546|NCT00823004|DRUG|GnRH agonist (buserelin)|50 µg SC twice daily
214528547|NCT00823004|DRUG|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
214528548|NCT00823004|DRUG|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
214528549|NCT04656860|DIETARY_SUPPLEMENT|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
214528550|NCT02160678|DRUG|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
214528551|NCT02160678|DRUG|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
214528552|NCT02160678|DRUG|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
214528553|NCT05428241|BEHAVIORAL|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
214528554|NCT04517877|BEHAVIORAL|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
214528555|NCT04517877|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
214695200|NCT02827994|OTHER|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
215143966|NCT01340846|DRUG|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
215143967|NCT01340846|DRUG|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
215143968|NCT01340846|DRUG|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
215143969|NCT01340846|DRUG|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
215143970|NCT03714958|DRUG|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215143971|NCT03714958|DRUG|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215143972|NCT02937116|DRUG|IBI308|
215143973|NCT02937116|DRUG|IBI308\Cisplatinum\Pemetrexed|
215143974|NCT02937116|DRUG|IBI308\cisplatin\gemcitabine|
215143975|NCT02937116|DRUG|IBI308\oxaliplatin\capecitabine|
214528556|NCT02605278|OTHER|Clinical program for pain and depression|Already described
214528557|NCT02605278|OTHER|Control|Care as usual
214528558|NCT00397137|PROCEDURE|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
214528559|NCT00397137|PROCEDURE|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
214528560|NCT05142072|DRUG|Vitamin D3|intranasal film
214528561|NCT00003698|DRUG|fosbretabulin disodium|
214528562|NCT04703868|DRUG|Rabeprazole Sodium 10mg|Part A: 1 tablet administered before the breakfast during 7 days
214528563|NCT04703868|DRUG|Rabeprazole Sodium 20mg|Part B: 1 tablet administered before the breakfast during 7 days
214528564|NCT03245762|DRUG|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
214528565|NCT03245762|DRUG|Placebo|4 IU/day of placebo administered via nasal spray device each morning
214695201|NCT01992666|GENETIC|Blood sampling|Immunologic and genetic analysis from a single blood sample.
215143976|NCT02937116|DRUG|IBI308\etoposide\cisplatin|
215143977|NCT02937116|DRUG|IBI308\irinotecan\5-FU|
215143978|NCT05403346|DEVICE|CoviDx™ Covid-19 Antigen Self-Test|All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing
215143979|NCT06523361|DEVICE|H'ability|H'ability is introduced depending the randomization result, during the baseline (before session 4, 5, 6 or 7 with occupational therapist
215143980|NCT04122716|DRUG|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
215143981|NCT04122716|BEHAVIORAL|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
215143982|NCT04968002|DRUG|pablizumab combined with apatinib and neoadjuvant chemotherapy|The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
215143983|NCT02398435|BIOLOGICAL|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
215143984|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
214456734|NCT06491758|PROCEDURE|Vagal Maneuver|"Subjects will undergo the following procedures to stimulate the vagus nerve.~* Cough: 6 to 8 forceful coughs~* Cold stimulus: a washcloth soaked in ice water will be placed on the face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor will be inserted for 10 seconds into the mouth touching the back of the mouth.~* Valsalva maneuver: subjects will will be asked to bear down as if they were having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a machine that measures how hard they are blowing.~* Eating: Subjects will be asked to drink water ( 8oz or 1 cup) or/ and Ensure Original ( 8 oz or 1 cup) that has 220 calories after fasting overnight to see that effect on vagal activity during eating."
215143985|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
215143986|NCT00966134|OTHER|exposure to high altitude|
215143987|NCT05682716|COMBINATION_PRODUCT|Controlled low central venous pressure (CLCVP) technology|Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.
215143988|NCT05682716|DRUG|Nitroglycerin|nitroglycerin (0.2-1 ug/kg \* min)
214456735|NCT03810287|DRUG|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
214456736|NCT06445556|BEHAVIORAL|NatureUplift|a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.
214456737|NCT06445556|BEHAVIORAL|NatureUplift+Active|NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
214456738|NCT05499897|PROCEDURE|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
214456739|NCT05499897|PROCEDURE|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
214456740|NCT03769415|DEVICE|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
214456741|NCT04676022|DEVICE|WaveWriter|To receive Spinal Cord Stimulation programming
214456742|NCT04676022|OTHER|Conventional Medical Managament|To receive conventional medical management
214528566|NCT03666208|DEVICE|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
214528567|NCT05056701|OTHER|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
214528568|NCT03498586|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
215143989|NCT04056390|PROCEDURE|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
215143990|NCT05128916|BIOLOGICAL|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
215143991|NCT05128916|DRUG|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
214456743|NCT03736720|DRUG|Fluorouracil|Given IV
214528569|NCT03498586|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
214528570|NCT03474042|DRUG|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
214528571|NCT03474042|DRUG|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
214528572|NCT02384083|DRUG|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
214695202|NCT02376595|DRUG|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
214695203|NCT03056495|DRUG|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
214456744|NCT03736720|DRUG|Leucovorin|Given IV
214456745|NCT03736720|DRUG|Liposomal Irinotecan|Given IV
214456746|NCT03736720|PROCEDURE|Quality-of-Life Assessment|Correlative studies
214456747|NCT05620342|BIOLOGICAL|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
214528573|NCT03168009|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
214528574|NCT02773407|DRUG|Azithromycin|
214528575|NCT02773407|DRUG|Co-trimoxazole|
214528576|NCT04604951|DEVICE|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
215143992|NCT06398756|OTHER|conventional rehabilitation|17 patients with cerebral palsy meeting the criteria will undergo conventional rehabilitation
215143993|NCT06398756|OTHER|aquatic therapy|17 patients with cerebral palsy meeting the criteria will undergo convertional rehabilitation and aquatic therapy
214456748|NCT06513936|PROCEDURE|The skin care Bundle|S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown
214456749|NCT06513936|PROCEDURE|Routine care|Routine care delivered in the unit
214456750|NCT04188470|BEHAVIORAL|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
214456751|NCT06425198|DRUG|BMS-986278|Specified dose on specified days
214456752|NCT02914951|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
214456753|NCT02914951|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
214695204|NCT06552858|DRUG|Fluzoparib|150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
215143994|NCT03517878|BEHAVIORAL|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
215143995|NCT01895413|PROCEDURE|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
215143996|NCT03008434|OTHER|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
215143997|NCT04195763|DRUG|asfotase alfa|This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
214456754|NCT02235909|DRUG|Azilsartan Medoxomil Low-dose|Azilsartan medoxomil low-dose (AZM-L) 10 mg
214456755|NCT02235909|DRUG|Losartan|
214456756|NCT02235909|DRUG|Placebo for Azilsartan Medoxomil|
214456757|NCT02235909|DRUG|Placebo for Losartan|
214456758|NCT02235909|DRUG|Azilsartan Medoxomil Medium-dose (20 mg)|Azilsartan medoxomil medium-dose (AZM-M) 20 mg
214456759|NCT02235909|DRUG|Azilsartan Medoxomil High-dose (40 mg)|Azilsartan medoxomil high-dose (AZM-L) 40 mg
214456760|NCT02235623|PROCEDURE|Single-stage Fowler-Stephens orchidopexy (FSO)|
214456761|NCT02235623|PROCEDURE|Two-stage Fowler-Stephens orchidopexy (FSO)|
214456762|NCT06435299|DRUG|Cannabis oil|Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
214456763|NCT06435299|DRUG|Placebo|Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
214456764|NCT05538533|RADIATION|46 Gy Radiation Therapy|Dose per fraction of 4.6.
214456765|NCT05538533|RADIATION|40 Gy Radiation Therapy|Dose per fraction 5.7.
214456766|NCT05538533|RADIATION|35 Gy Radiation Therapy|Dose per fraction 7.0.
214456767|NCT05065970|DRUG|Felzartamab|anti-CD38+ monoclonal antibody
214456768|NCT05065970|OTHER|Placebo|Placebo comparator
214528577|NCT04406142|DEVICE|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
214528578|NCT02203045|OTHER|Total Knee Arthroplasty|
214528579|NCT01502605|DRUG|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
214528580|NCT02657759|DIETARY_SUPPLEMENT|CARDICHOL|
214528581|NCT02657759|DIETARY_SUPPLEMENT|PLACEBO|
214528582|NCT01304251|OTHER|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
214528583|NCT01304251|OTHER|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
215143998|NCT02351622|DRUG|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
214456769|NCT05591144|DRUG|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
214456770|NCT05591144|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
214456771|NCT03547869|DEVICE|Active tDCS|Active tDCS will be adminestered
214456772|NCT03547869|DEVICE|Sham tDCS|Sham tDCS will be administered
214456773|NCT05757596|DRUG|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
214456774|NCT05757596|DRUG|Placebo|0.9% Saline, volume matched
214456775|NCT06178198|PROCEDURE|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
214456776|NCT04266210|DEVICE|Fuji Bulk|Restorative system
214456777|NCT04266210|DEVICE|G-ænial Posterior|Restorative system
214456778|NCT05559671|BIOLOGICAL|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
214456779|NCT05559671|BIOLOGICAL|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
214456780|NCT03194217|DRUG|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
214456781|NCT03194217|DRUG|Placebo|Placebo
214456782|NCT04585035|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
214456783|NCT04585035|DRUG|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
214456784|NCT06666517|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Routine surgery after neoadjuvant chemotherapy for breast cancer according to current guidelines.
214456785|NCT06666517|OTHER|Immunohistochemistry Analysis|Determination of breast cancer subtypes through immunohistochemical analysis, and selection of Luminal B, HER2-positive, and triple-negative groups.
214456786|NCT06666517|PROCEDURE|Second Biopsy|Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
214456787|NCT06484309|BEHAVIORAL|Reflexology Group|"* In the 3rd stage of labor, local anesthesia (5 ml lidocaine 2%) will be applied and episiotomy repair will begin.~* Reflexology application will be started at the same time,~* Reflexology application will continue for at least 20-30 minutes during the episiotomy repair until the episiotomy repair is completed,~* Pain will be evaluated with VAS to determine the pain level four times in total: just before suturing, during perineal suturing (internal), during skin suturing and immediately after suturing is completed,~* Approximately 15-20 minutes after the end of the episiotomy repair, a face-to-face interview will be held and the McGill Pain Questionnaire will be filled out."
214528584|NCT02413099|DRUG|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
214528585|NCT02136342|DRUG|chlorogenic acid|
214528586|NCT06074445|OTHER|No intervention|No intervention
214528587|NCT00206505|DRUG|Taxotere|
214528588|NCT03681353|BEHAVIORAL|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
214528589|NCT01520077|DRUG|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
214528590|NCT00873561|DRUG|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
215143999|NCT02351622|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
215144000|NCT02351622|DRUG|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
215144001|NCT02856672|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
215144002|NCT02856672|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
215144003|NCT04626908|DRUG|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
215144004|NCT02208310|DRUG|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
215144005|NCT02208310|DRUG|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
215144006|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
215144007|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
215144008|NCT00313014|DRUG|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
214456788|NCT03784248|OTHER|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
214456789|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
214456790|NCT06045936|DRUG|Placebo|Saline injection
214456791|NCT06801431|DEVICE|Transcutaneous spinal cord stimulation|Individuals will receive a 10-day course of daily, 30-minute sessions of transcutaneous spinal cord stimulation to the thoracolumbar spine cord using the Chattanooga Mobile 2 Stim Device. These sessions will be conducted in the morning before bowel care and therapy. Cathode pads will be placed between the T10 and T11 spinous processes and the T12 and L1 spinous processes. Anode pads will be placed over the iliac crests. Stimulation will consist of 1 millisecond duration, biphasic pulses, at 30 Hertz frequency. The intensity of the current, will be adjusted to be suprasensory and sub-motor, and no more than 140 milli-amperes.
214456792|NCT06801691|OTHER|Experimental: Intervention group|Educational materials: Iodine Feedback Tool, lecture on the topic of iodine and health, booklet, exercises, group assignments and a webpage This is a pre/post intervention with no control group.
214456793|NCT06801613|OTHER|Intervention Group|Group/Cohort Description: Participants with Upper Cross Syndrome (UCS) who undergo the prescribed exercise or treatment protocol.
214456794|NCT06800742|OTHER|Collection of anthropometric and biochemical parameters|Collection of anthropometric parameters biochemical parameters basal metabolic rate body composition questionnaires
214456795|NCT05784584|PROCEDURE|Blood samples collection|The study population will take blood samples for virological and immunological measurements.
214456796|NCT05876598|DRUG|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
214456797|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
214456798|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
214456799|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
214456800|NCT06297434|DRUG|Placebo|Orally, once daily before meals
214456801|NCT06560112|DRUG|AK104|ivgtt
214456802|NCT06560112|DRUG|AK112|ivgtt
214456803|NCT06560112|DRUG|Chemotherapy|ivgtt
214456804|NCT06801028|BIOLOGICAL|injection Sekucinumab|All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.
214456805|NCT05597345|DRUG|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
214456806|NCT04336228|DRUG|Escitalopram|20mg daily for 3-4 weeks.
214456807|NCT04336228|DRUG|Placebo oral tablet|20mg placebo tablet daily for 3-4 weeks.
214456808|NCT03197662|DRUG|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
214456809|NCT03197662|DRUG|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
214456810|NCT04757519|BEHAVIORAL|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
214456811|NCT04757519|BEHAVIORAL|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
214456812|NCT05505916|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
214528591|NCT05384236|OTHER|kinesiology taping|To apply kinesiology taping in plantar fascia
214528592|NCT05384236|OTHER|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
214528593|NCT03618212|DIAGNOSTIC_TEST|MRI|Skeletal MRI and pelvic and spinal MRI
214528594|NCT01997749|DIETARY_SUPPLEMENT|Ketocal 4:1 (Nutricia)|
214528595|NCT01997749|DIETARY_SUPPLEMENT|Control diet: Regular diet offered at the hospitals|
214528596|NCT01997749|DIETARY_SUPPLEMENT|Ketogenic meals|
214695205|NCT06552858|DRUG|Dalpiciclib|150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
214456813|NCT05505916|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg
214456814|NCT05640765|OTHER|Best Practice|Receive standard of care services
214528597|NCT00476918|DRUG|Intravitreal injection (triamcinolone acetonide)|
215144009|NCT03986086|DRUG|MPH966|RP2D tablet
215144010|NCT03986086|DRUG|Placebo|MPH966 placebo table
215144011|NCT00301314|PROCEDURE|Autologous stem cell transplant|
215144012|NCT01054885|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
215144013|NCT01054885|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
215144014|NCT01054885|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
215144015|NCT01054885|DRUG|Placebo|Placebo
214695206|NCT02004587|DRUG|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
214695207|NCT01670656|DRUG|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
214456815|NCT05640765|OTHER|Educational Intervention|Receive additional educational and supportive material
214456816|NCT05640765|OTHER|Health Promotion and Education|Participate in BeWell360-CG Care Model sessions
214695208|NCT01670656|DRUG|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
214456817|NCT05640765|OTHER|Questionnaire Administration|Ancillary studies
214456818|NCT06129344|OTHER|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
214456819|NCT06129344|OTHER|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
214695209|NCT01670656|DRUG|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
214456821|NCT06033898|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1000 steps. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
214456822|NCT06033898|BEHAVIORAL|24 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 24 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
214456823|NCT06033898|BEHAVIORAL|36 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 36 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
214456824|NCT06514677|PROCEDURE|Ultrasonic Carbon Tip|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
214456825|NCT06514677|PROCEDURE|Titanium Curette|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
214456826|NCT05299931|DRUG|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
214695210|NCT01670656|DRUG|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
214695211|NCT00789958|DRUG|capecitabine|"Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
214695212|NCT00789958|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
214695213|NCT00789958|RADIATION|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
214456827|NCT06398886|BEHAVIORAL|Ericksonian Hypnosis|The Ericksonian hypnosis intervention was designed to create a nurturing and therapeutic setting, specifically tailored to the unique challenges of prolonged grief faced by university students. This approach focused on accessing the subconscious, using symbolic and imaginative techniques to facilitate change. The goal was to alleviate the emotional pain associated with prolonged grief and to empower students to adapt more effectively to their loss. This intervention highlighted the transformative potential of Ericksonian methods in addressing deep-seated emotional issues through gentle and indirect therapeutic modalities.
214456828|NCT06398886|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention aimed to provide a supportive and healing environment, addressing the specific challenges of prolonged grief within a university student population. The focus was on developing concrete skills to manage the cognitive and behavioral aspects of grief. This approach sought to mitigate the pain of prolonged grief and empower students to adapt more healthily to their loss, emphasizing practical strategies for change and coping. Participants were encouraged to actively engage in exercises that challenged their thought patterns and promoted behavioral adjustments tailored to their individual needs.
214456829|NCT05891353|OTHER|Cold Water Immersion|Cold Water Immersion task of hand
214456830|NCT05891353|OTHER|Pain Inducing Stretch|Moderately painful stretch of the neck
214456831|NCT05891353|OTHER|Pain Free Stretch|Pain free stretch of the neck
214695214|NCT00789958|RADIATION|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
214695215|NCT01782794|OTHER|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
214695216|NCT01146249|OTHER|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
214708699|NCT03776162|PROCEDURE|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
215144016|NCT00644800|DRUG|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
215144017|NCT05461534|BEHAVIORAL|mindfulness yoga|Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
214456832|NCT05315999|DRUG|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
214456833|NCT05315999|DRUG|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
214456834|NCT04818060|OTHER|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
214456835|NCT04818060|DIAGNOSTIC_TEST|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
214456836|NCT04818060|DIAGNOSTIC_TEST|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
214456837|NCT06208215|DRUG|RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
214456838|NCT06208215|DRUG|RZ358 (10 mg/kg) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
214456839|NCT06208215|DRUG|RZ358 (5-10 mg/kg) + SOC|Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
214456840|NCT05077618|OTHER|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
214456841|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
214456842|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
214456843|NCT06481475|BIOLOGICAL|YY003|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
214456844|NCT06481475|BIOLOGICAL|Vehicle Control|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
214456845|NCT02496754|DRUG|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
214456846|NCT02496754|DRUG|GnRH-anta|In control group, patients use GnRH-antagonist. Patients' serum or follicle fluid will be collected if needed.
214456847|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
214456848|NCT05381597|DRUG|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
214456849|NCT05381597|DRUG|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
214456850|NCT04702581|DRUG|PCV chemotherapy|"1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given."
214456851|NCT04702581|DRUG|Radiotherapy and PCV chemotherapy|"Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally"
214456852|NCT01463423|RADIATION|iSABR, 25 Gray in 1 fraction for small peripheral tumors|Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
214456853|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium peripheral tumors|Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
214456854|NCT01463423|RADIATION|iSABR, 54 Gray in 3 fractions for large peripheral tumors|Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
215144018|NCT03881852|DRUG|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
215144019|NCT03881852|DRUG|Placebo|Dosed orally, twice daily for up to 3 weeks
215144020|NCT02297594|DRUG|AK0529|AK0529 capsule for oral administration
215144021|NCT02297594|DRUG|Placebo|Sugar placebo capsule for oral administration
215144022|NCT01421719|DRUG|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
214528598|NCT04915079|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
214528599|NCT00002432|DRUG|Foscarnet sodium|
214528600|NCT04564859|DEVICE|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
214528601|NCT05117385|DIETARY_SUPPLEMENT|Botanical extract|1 capsule per day
215144023|NCT03877328|OTHER|BiotechCoachForAll|A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
214456855|NCT01463423|RADIATION|iSABR, 40 Gray in 4 fractions for small central tumors|Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
214456856|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium central tumors|Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.
214456857|NCT01463423|RADIATION|iSABR, 60 Gray in 8 fractions for large central tumors|Radiotherapy procedure for participants with large central tumors \> 30 cc.
214456858|NCT05792280|DEVICE|AI system|Patients will undergo EUS examination with the assistance of AI system.
214456859|NCT05730231|OTHER|Effects of calorie restriction and time-restricted eating on human health|Calorie restriction plan will be prepared for each participant. After nutritional data collection at baseline, all participant will attend educational sessions about healthy diet and beneficial effects of time-restricted eating. To estimate total energy needs, individuals' RMR will be measured from indirect calorimeter and multiplied by the appropriate factor of physical activity (from 1.3 to 1.6), and then a reduction of 200-500 kcal will be made. Macronutrient composition of the diet will be approximately 45-55% of carbohydrate, 30-35% of fat, and 15-20% of protein. 30% of daily energy intake will be consumed by breakfast, 40% by lunch and 30% by dinner. During posting participants will be allowed to consume only water and herbal infusions without added sugars or sweeteners. Dietary intake of participants will be followed during the study using a 24-h recall. Dietary data will be analysed using the Open Platform for Clinical Nutrition accessible through the website http://opkp.si/.
214456860|NCT04920812|GENETIC|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
214456861|NCT06107634|PROCEDURE|Gastropexy|"In the intervention group, a three-point gastropexy is added to the repair. First, the right fundus flap is adapted posteriorly to the crural portion of the diaphragm with a 2-3 cm long running non-absorbable suture (posterior gastropexy). Second, the left fundus flap is adapted to the diaphragm anterolateral to the hiatus with a 2-3 cm long running non-absorbable suture (left anterolateral gastropexy). Finally, the minor curvature of the anterior stomach wall is adapted during reduced intraabdominal pressure to the anterior abdominal wall with a 2-3 cm long running non-absorbable suture (anterior gastropexy)."
214456862|NCT06107634|PROCEDURE|Paraesophageal hernia repair|Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
214456863|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
214456864|NCT05858515|DRUG|Placebo|Placebo
214456865|NCT06021197|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of CIAS
214456866|NCT06021197|DRUG|Placebo Cap|Use of placebo as a comparator
214456867|NCT05033314|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
214456868|NCT05033314|DRUG|Placebo|matching placebo daily
214456869|NCT04541147|DRUG|Dexamethasone|dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
214528602|NCT03142828|DRUG|Chlorhexidine|Healing abutment with Clorhexidine
214528603|NCT03142828|OTHER|Placebo|Healing abutment without any antiseptic
214528604|NCT05515913|OTHER|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
214528605|NCT05515913|BEHAVIORAL|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
214528606|NCT05515913|OTHER|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
214528607|NCT05515913|OTHER|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
214456870|NCT04541147|DRUG|Analgesics|"standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)"
214456871|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
214456872|NCT01030328|DRUG|Placebo|2 sugar pills by mouth once a day.
214456873|NCT01030328|DRUG|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
214456874|NCT05998226|OTHER|Virtual Antimicrobial stewardship Team (VAT)|The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
214456875|NCT06330116|DEVICE|IQoro|Please refer to arm/group description for information
214456876|NCT06330116|DEVICE|eXciteosa|Please refer to arm/group description for information
214456877|NCT06330116|BEHAVIORAL|Grouptraining|Please refer to arm/group description for information
214456878|NCT04619069|RADIATION|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
214456879|NCT04619069|DRUG|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
214456880|NCT05538325|DEVICE|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion of the lumbar spine
214456881|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
214456882|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
214456883|NCT04495894|DRUG|Preoperative Ketorolac|30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
214456884|NCT06799637|DRUG|XNW28012|Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
214456885|NCT05661669|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
214456886|NCT05661669|DRUG|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
214456887|NCT05682937|DEVICE|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5.
214456888|NCT06279221|DRUG|LITFULO|as provided in real world practice
214456889|NCT05865561|OTHER|VOC sampling|"* Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~* Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
214456890|NCT05650775|DRUG|Concerta|3-week trial of oral methylphenidate extended release
214456891|NCT05650775|DRUG|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
214456892|NCT06058949|BEHAVIORAL|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
214456893|NCT06058949|BEHAVIORAL|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
214456894|NCT06204094|RADIATION|node-sparing short-course radiotherapy|5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
214456895|NCT06204094|DRUG|Sintilimab|200mg intravenous infusion d1 of each cycle\*8cycles
214456896|NCT06204094|DRUG|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
214456897|NCT06204094|DRUG|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle\*8cycles
214456898|NCT06204094|PROCEDURE|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
214456899|NCT06204094|PROCEDURE|watch and wait|WW for cCR patients
214456900|NCT04535271|DRUG|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
214456901|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
214456902|NCT06242405|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Umbilical cord mesenchymal stem cells injected through peripheral veins
214456903|NCT03937128|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
214456904|NCT03937128|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
214456905|NCT05579899|DRUG|EVO101|Topical Cream
214456906|NCT03364647|OTHER|Arm A - blood flow restriction training|Group receive standard of care plus blood flow restriction training
214456907|NCT03364647|OTHER|Arm B - standard of care|Group will receive standard of care plus a sham version of blood flow restriction training
214456908|NCT06506084|DRUG|Ropeginterferon alfa-2b|"Data will be collected at each visit during the observational study (total duration: 24 months). In accordance with routine clinical practice in this patient population, visits are expected to take place every 6 months.~Patients who discontinue ropeginterferon alfa-2b treatment at any time will no longer be followed up."
214528608|NCT05515913|OTHER|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
214456909|NCT05750680|DRUG|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
215144024|NCT00684008|DRUG|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
215144025|NCT00684008|DRUG|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
215144026|NCT02433808|DRUG|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
215144027|NCT02433808|OTHER|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
215144028|NCT05360797|OTHER|Outpatient|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
215144029|NCT05360797|OTHER|Medical home care|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
214456910|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
214456911|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
214456912|NCT06537622|OTHER|Implementation group|Implementation strategies to increase uptake of the clinical practice guidelines for earlier diagnosis of cerebral palsy
214456913|NCT06537622|OTHER|Standard of care|No active implementation strategies
214456914|NCT04064164|BEHAVIORAL|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
214456915|NCT05604391|PROCEDURE|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
214456916|NCT05604391|PROCEDURE|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
214456917|NCT06332430|DRUG|CAN2109|CAN2109 IT injection (once every 3 weeks)
214456918|NCT04172038|BEHAVIORAL|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
214456919|NCT04172038|BEHAVIORAL|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
214456920|NCT04172038|BEHAVIORAL|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences"
214456921|NCT06176664|DEVICE|Low flow oxygen|Standard nasal cannula oxygen up to 2 liters/minute
214456922|NCT06176664|DEVICE|High-flow nasal cannula oxygen|High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
214456923|NCT03224858|OTHER|SUMMIT intervention|See description in experimental arm.
214456924|NCT03224858|OTHER|Enhanced usual care|See description in active comparator arm.
214528609|NCT05515913|OTHER|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
214528610|NCT04662606|BEHAVIORAL|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
215144030|NCT05360797|OTHER|Hospitalization|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI\_1) in each center.
215144031|NCT03782506|BEHAVIORAL|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
214528611|NCT00613223|DRUG|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
214528612|NCT00560807|PROCEDURE|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
214528613|NCT06640998|DEVICE|Matrix Pro|Study subjects received up to three (3) study treatments with the Matrix Pro applicator
214528614|NCT01189617|DEVICE|Formula PD-F-7619|Off-White to Beige Lotion
214456925|NCT05373862|DEVICE|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
214456926|NCT02951845|DRUG|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
214456927|NCT02951845|DRUG|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
214456928|NCT02951845|DRUG|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
214456929|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
214456930|NCT06160908|DEVICE|sham NirsCure|Non near-infrared light irradiation；only the equipment appearance is consistent with the test device；Once a day, once for 30 minutes, 6 times a week
214456931|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
214456932|NCT06455059|DRUG|Vosoritide|Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
214456933|NCT06455059|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
214456934|NCT04724447|DRUG|Valganciclovir|2 x 450mg VGCV tablets
214456935|NCT04724447|DRUG|Placebo|Placebo equivalent of 900mg/day VGCV
214456936|NCT06179407|DRUG|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
214456937|NCT06179407|DRUG|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
214456938|NCT05736133|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
214456939|NCT05736133|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
214528615|NCT03581344|DIAGNOSTIC_TEST|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
214528616|NCT02660047|DRUG|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
214708700|NCT03776162|DEVICE|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
215144032|NCT03782506|BEHAVIORAL|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
215144033|NCT01875406|OTHER|diagnostic exercises|
215144034|NCT04228380|OTHER|No intervention|No intervention
214528617|NCT02660047|DRUG|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
214528618|NCT00021021|BIOLOGICAL|anti-FLT-1 ribozyme|
215144035|NCT05650359|DEVICE|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
215144036|NCT05650359|OTHER|No intervention|No intervention
215144037|NCT03692299|DRUG|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
215144038|NCT03692299|DRUG|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
215144039|NCT01942837|DRUG|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
215144040|NCT03056092|DRUG|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
215144041|NCT02267551|OTHER|Mimic dv-Trainer|
215144042|NCT02267551|OTHER|daVinci Skills Simulator|
214456940|NCT05179187|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
214456941|NCT06072768|DRUG|15-day taper prednisone|The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
214456942|NCT06072768|DRUG|150-day taper prednisone|The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
214456943|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
214456944|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
214456945|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214456946|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
214456947|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
214456948|NCT06371300|DEVICE|Red LLLT|Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
214456949|NCT06371300|DEVICE|Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
214456950|NCT06371300|DEVICE|Sham Red LLLT|Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
214456951|NCT06371300|DEVICE|Sham Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
214456952|NCT04897256|BEHAVIORAL|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
214456953|NCT06254313|OTHER|Additional tubes and LBA|4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
215144043|NCT02628912|OTHER|blood draw|
215144044|NCT02628912|BEHAVIORAL|study questionnaire|
215144045|NCT02628912|OTHER|cardiopulmonary exercise testing (CPET)|
215144046|NCT02628912|OTHER|DXA (dual-energy x-ray absorptiometry) scan|
215144047|NCT01635166|DEVICE|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
214456954|NCT01000961|DRUG|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
214528619|NCT05389254|DEVICE|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
214528620|NCT05389254|DEVICE|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
215144048|NCT00055757|DRUG|tipifarnib|Given orally
215144049|NCT00055757|DRUG|cisplatin|Given IV
214528621|NCT01295775|DRUG|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
214528622|NCT02640807|DRUG|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
214528623|NCT02640807|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
215144050|NCT00055757|DRUG|gemcitabine hydrochloride|Given IV
215144051|NCT00055757|OTHER|laboratory biomarker analysis|Correlative studies
215144052|NCT05956015|OTHER|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
215144053|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
215144054|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
215144055|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
215144056|NCT02501291|DRUG|Thalidomide|
215144057|NCT00912535|DRUG|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
215144058|NCT00912535|DRUG|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
215144059|NCT01152957|BEHAVIORAL|CARIÑO Project|Care Attention Resources Information Nutrition \& Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
215144060|NCT01152957|BEHAVIORAL|Enhanced Usual Care|Usual care plus 4 health education brochures
215144061|NCT01725516|PROCEDURE|Myofascial release technique|
215144062|NCT01424215|DRUG|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
215144063|NCT04125589|BEHAVIORAL|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
215144064|NCT04125589|BEHAVIORAL|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
214456955|NCT01000961|DRUG|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
214456956|NCT06092671|OTHER|Family-centred perioperative care for anaesthesia|The patient in intervention group and parent will receive the Family-centred perioperative care for anaesthesia, including video education, anaesthesia mask practice, electronic pamphlet, distraction strategies and parental presence. The patient will not receive sedatives before surgery. During the anesthesia induction period, it is recommended that the parent be instructed by the anesthesiologist to complete the induction of inhalation of the anesthesia mask, and the patient will be accompanied by the parent during the awakening period.
214456957|NCT05156983|DRUG|TAK-330|Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
215144065|NCT03642587|OTHER|There is no intervention in this study.|There is no intervention in this study.
215144066|NCT02396121|DIETARY_SUPPLEMENT|Oral nutritional supplement : Renutryl® Booster|
215144067|NCT02993107|BIOLOGICAL|AR101|AR101 powder provided in capsules \& sachets
214456958|NCT05156983|DRUG|SOC 4F-PCC|Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
214528624|NCT04493983|PROCEDURE|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
214528625|NCT04493983|PROCEDURE|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
214528626|NCT02452125|DIETARY_SUPPLEMENT|Nicotine gum|Nicotine chewing gum
214528627|NCT05065892|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
214528628|NCT03113214|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
215144068|NCT03549767|DEVICE|Springfusor|Springfusor for administration of magnesium sulphate
215144069|NCT03549767|PROCEDURE|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
215144070|NCT05002712|OTHER|Heavy resistance training|Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
215144071|NCT05002712|OTHER|Contrast strength training|Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
215144072|NCT05002712|OTHER|Elastic resistance training|During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
215144073|NCT00972062|OTHER|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
215144074|NCT00972062|OTHER|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
215144075|NCT03874988|BEHAVIORAL|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
215144076|NCT03874988|BEHAVIORAL|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
215144077|NCT03874988|BEHAVIORAL|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
215144078|NCT03874988|BEHAVIORAL|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
215144079|NCT06025214|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
215144080|NCT06025214|DRUG|ADVAIR DISKUS® 500/50|2 inhalations in one study period
214456959|NCT04263051|DRUG|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
214456960|NCT04263051|DRUG|standard chemotherapy|Second line chemotherapy at the choice of the investigator
214528629|NCT03113214|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
214528630|NCT03113214|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
214528631|NCT03113214|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
215144081|NCT02183649|DRUG|pentoxyverine citrate|
215144082|NCT02183649|DRUG|Placebo|
215144083|NCT04146948|OTHER|no intervention|no intervention in this study
215144084|NCT03729700|OTHER|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
215144085|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
215144086|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
215144087|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
215144088|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
215144089|NCT03469414|OTHER|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
214456961|NCT05629286|DEVICE|McConnell taping|non-stretch rigid McConnell tape will be applied
214456962|NCT05629286|DEVICE|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
214456963|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
214456964|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
214456965|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
214456966|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
214456967|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
214456968|NCT03686345|DRUG|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
214456969|NCT04775719|OTHER|Patient-Specific Prediction of Functional Outcome|Information sheet that describes whether a patient is more likely to improve on or maintain their current preoperative function.
215144090|NCT03469414|OTHER|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
215144091|NCT03469414|OTHER|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
214528632|NCT03113214|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
215144092|NCT03469414|OTHER|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
215144093|NCT03469414|OTHER|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
215144094|NCT03469414|OTHER|PART-O|The PART-O is a community participation measure.
215144095|NCT03469414|OTHER|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
215144096|NCT04611646|BEHAVIORAL|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
215144097|NCT04611646|BEHAVIORAL|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
215144098|NCT05930223|DRUG|VAL-1221|VAL-1221 20mg/kg intravenous (IV) infusion every other week
215144099|NCT04226742|BEHAVIORAL|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
215144100|NCT04226742|BEHAVIORAL|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
215144101|NCT00528034|PROCEDURE|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
214456970|NCT04775719|OTHER|Standard Pre-Operative Total Knee Arthroplasty Information|Standard of care information that is routinely provided at patient preadmission appointments.
214456971|NCT06262932|DRUG|Amiodarone|Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
214456972|NCT04881032|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
214528633|NCT03113214|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
214528634|NCT02358499|DRUG|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
214528635|NCT04113928|DIETARY_SUPPLEMENT|Broccoli & mustard seed soup|200ml acute feed
214528636|NCT04113928|DIETARY_SUPPLEMENT|Broccoli soup|200ml acute feed
215144102|NCT03631992|BEHAVIORAL|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
215144103|NCT03631992|BEHAVIORAL|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
215144104|NCT03979287|OTHER|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
214456973|NCT04881032|RADIATION|radiotherapy|60 Gy in 6 weeks
214456974|NCT04881032|DRUG|Temozolomide|"Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
214456975|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
214456976|NCT05421416|DRUG|Placebo|Placebo sugar pill
214695217|NCT05267912|PROCEDURE|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
214695218|NCT02288624|DIETARY_SUPPLEMENT|Processed orange juice|3 different formulation of edible orange drinks
215144105|NCT03979287|OTHER|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
215144106|NCT01047358|DRUG|Aromasin|25 mg table QD
215144107|NCT01047358|DRUG|Aromasin|25 mg table QD
214456977|NCT05828810|PROCEDURE|Chlorhexidne Gluconate-Alcohol Skin Preparation|"Participants will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using a wet chlorhexidine surgical scrub brush followed by immediate drying using towels. The definitive preparation will then be carried out using tinted chlorhexidine gluconate-alcohol sponges applied with forceps. The drying time and the minimum number of sponge packs used will comply with the product 'Instructions for Use'. The drapes can be applied as per the surgeon's usual approach and they will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
214456978|NCT05828810|PROCEDURE|Poviodine-iodine Skin Preparation|"Participants will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using iodine detergent soaked gauze pads followed by immediate drying using towels. The definitive preparation will then be carried out using povidone-iodine soaked gauze pads applied with forceps. The drapes can be applied as per the surgical team's usual approach and they otherwise will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
214456979|NCT06798870|DEVICE|removable appliances|removable appliances; clear aligner and removable inclined plane, for correcting anterior crossbite vin mixed dentition patient
214456980|NCT03993171|DRUG|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
214456981|NCT06543537|BEHAVIORAL|Collaborative Agenda-Setting Intervention|A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
214456982|NCT05871905|DRUG|TY-9591|C14 TY-9591
214456983|NCT06480448|OTHER|Traditional physical herapy|core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.
214456984|NCT06480448|OTHER|Treadmill training|Treadmill training for 20 minutes three time a week.
214456985|NCT05538754|DEVICE|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
214456986|NCT06147726|OTHER|Upper extremity position matching exercises in virtual reality|In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
214456987|NCT06147726|OTHER|Conventional physiotherapy|proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
214456988|NCT04322357|DRUG|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
214456989|NCT04322357|BEHAVIORAL|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
214456990|NCT04322357|DRUG|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
214456991|NCT03555578|DRUG|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
214456992|NCT06224530|DRUG|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
214695219|NCT01648452|BIOLOGICAL|NT-501 CNTF-releasing implant|20 ng/day released into the eye
214695220|NCT01000727|DRUG|Darapladib 160 mg|Lp-PLA2 inhibitor
214695221|NCT01000727|DRUG|Placebo|Placebo administered
214695222|NCT01000727|OTHER|Standard Therapy|Guideline mandated therapy for individual's condition
215144108|NCT04683614|DRUG|Norepinephrine|5 mic/kg/hr norepinephrine
215144109|NCT04683614|BIOLOGICAL|Fresh frozen plasma|early administration of fresh frozen plasma
215144110|NCT04761224|DEVICE|Fluido® Irrigation Fluid Heater System|"Patients in the Heated group will benefit from intraoperative warming by means of NaCl bags instilled using the Fluido® Irrigation warming cassette and with the use of specific instillation tubing (SEBAC laboratory, Set URO Fluido® Irrigation): this device allows continuous and precise heating of the solution with an instillation temperature of 38-39°C."
215144111|NCT00997776|OTHER|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
215144112|NCT00997776|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
215144113|NCT02556840|OTHER|insulin therapy|
214456993|NCT06224530|DRUG|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
214456994|NCT05901246|DIETARY_SUPPLEMENT|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
214456995|NCT05901246|OTHER|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
214456996|NCT05480124|DEVICE|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
214456997|NCT05480124|DEVICE|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
214456998|NCT05558813|DIAGNOSTIC_TEST|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
214456999|NCT05558813|BIOLOGICAL|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
214457000|NCT06806605|OTHER|3d analisys|To analyze the orthodontic-surgical set-up carried out as part of the normal care pathway of patients operated since January 2015 and who completed treatment on May 30, 2020 in the Orthodontic First patient.
214457001|NCT04860726|OTHER|Joint mobilization|Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
214457002|NCT04860726|OTHER|Myofascial Release|"Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes"
214457003|NCT04860726|OTHER|Joint mobilization & Myofascial Release|"Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min"
214457004|NCT06528145|OTHER|Evalation|Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
214457005|NCT02405858|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
214457006|NCT02405858|DRUG|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
214457007|NCT03576248|DEVICE|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
214457008|NCT03576248|DEVICE|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
214457009|NCT03576248|DEVICE|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
214457010|NCT03576248|DEVICE|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
214457011|NCT06137963|OTHER|Transform10 Diabetes Prevention Program|"The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation."
215144114|NCT05790369|BEHAVIORAL|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
215144115|NCT05790369|BEHAVIORAL|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
215144116|NCT00122083|DEVICE|Health education information|
215144117|NCT02979496|DIETARY_SUPPLEMENT|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
215144118|NCT02979496|DIETARY_SUPPLEMENT|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
215144119|NCT02979496|DIETARY_SUPPLEMENT|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
215144120|NCT02979496|DIETARY_SUPPLEMENT|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
214457012|NCT05000684|DRUG|JS004 in combination with toripalimab|Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks
214457013|NCT06807294|BEHAVIORAL|Tai Chi Program|12-week virtual Tai Chi program with experienced Tai Chi instructor. Sessions will be conducted via the HIPPA-compliant teleconference platform, Zoom.
214457014|NCT06758752|DIETARY_SUPPLEMENT|ZAX.1400.EC.02|ZAX.1400.EC.02, applied twice daily for 3 weeks after enrolment
214457015|NCT06758752|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
214457016|NCT06169254|DEVICE|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
214457017|NCT06781970|DRUG|Oral Vitamin C|Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
214457018|NCT06781970|DRUG|Placebo|Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
214457019|NCT04832282|DEVICE|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
214457020|NCT04832282|OTHER|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
214457021|NCT05794022|OTHER|MRI|1 MRI at 1 month with gadolinium injection
214457022|NCT05794022|BIOLOGICAL|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
214457023|NCT05794022|BEHAVIORAL|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
214457024|NCT05544864|DEVICE|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
214457025|NCT05544864|DEVICE|Drug coated ballloon (DCB)|DCB angioplasty with any commercially available drug-coated balloon
214457026|NCT05003258|DEVICE|Intravitreal injection of Dexamethasone implant|Intravitreal injection of Dexamethasone implant
214457027|NCT03885518|OTHER|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
214457028|NCT04709783|OTHER|3-Step Workout for Life|Participants will receive the modified 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and/or lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life exercise, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
214457029|NCT05225584|DRUG|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
214457030|NCT04542161|DRUG|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
214457031|NCT04542161|DRUG|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
214457032|NCT04542161|DRUG|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
214457033|NCT06357013|PROCEDURE|Bilateral Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.
214457034|NCT06357013|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
214457035|NCT06408688|DRUG|Immune checkpoint inhibitors plus Iscador® Qu.|Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
214457036|NCT06408688|DRUG|Immune Checkpoint Inhibitors|Standard cancer treatment.
214457037|NCT06267014|BEHAVIORAL|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
214695223|NCT00000417|PROCEDURE|Counseling intervention|
214695224|NCT00000417|DEVICE|Informational film|
215144121|NCT01759446|DRUG|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
215144122|NCT01759446|DRUG|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
215144123|NCT01759446|DRUG|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
215144124|NCT01759446|DRUG|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
215144125|NCT01759446|DRUG|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
215144126|NCT04530084|DEVICE|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
215144127|NCT00195104|DRUG|Arsenic Trioxide (Tricenox)|
215144128|NCT00195104|DRUG|Cytarabine|
215144129|NCT02338596|PROCEDURE|Total hip replacement|"1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
215144130|NCT04112719|OTHER|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
215144131|NCT04112719|OTHER|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
215144132|NCT04112719|OTHER|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
215144133|NCT00400166|BEHAVIORAL|Recovery Mentor|Provided Recovery Mentor services
215144134|NCT01751620|BEHAVIORAL|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
215144135|NCT01751620|BEHAVIORAL|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
215144136|NCT02755246|DIETARY_SUPPLEMENT|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
215144137|NCT02755246|DIETARY_SUPPLEMENT|Placebo supplementation|3 months of placebo intake (3 capsules/day)
215144138|NCT05825352|DEVICE|Carmellose eye drops|Ocular drops based upon carmellose
215144139|NCT04204525|DIAGNOSTIC_TEST|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
215144140|NCT02991872|PROCEDURE|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
215144141|NCT05757544|DRUG|IV Ganaxolone|IV Ganaxolone will be administered.
214457038|NCT05359848|OTHER|Diet|Using dietary interventions as an adjuvant tool may represent an effective step toward advancing the treatment options of cancer. Dietary modifications can impact the growth and proliferation of tumors via multiple mechanisms
214457039|NCT05030233|BEHAVIORAL|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
214457040|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
214457041|NCT05639478|OTHER|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
214457042|NCT06128863|DRUG|Pembrolizumab, Eftilagimod alpha|Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
214457043|NCT03365882|BIOLOGICAL|Cetuximab|Given IV
214457044|NCT03365882|DRUG|Irinotecan Hydrochloride|Given IV
214457045|NCT03365882|OTHER|Laboratory Biomarker Analysis|Correlative studies
214457046|NCT03365882|BIOLOGICAL|Pertuzumab|Given IV
214457047|NCT03365882|BIOLOGICAL|Trastuzumab|Given IV
214457048|NCT03365882|DEVICE|HER-2 testing|Central testing of HER-2 for eligibility
214457049|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
215144142|NCT05757544|DRUG|IV Placebo|IV Placebo will be administered
215144143|NCT03400839|DIAGNOSTIC_TEST|Daily physical activity levels|Objectively measured physical activity using activity monitors.
214457050|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
214457051|NCT06786455|DRUG|SHR-1905 Injection|SHR-1905 Injection,medium dose, administered by subcutaneous injection;
215144144|NCT03400839|DIAGNOSTIC_TEST|6-minute walk test|Assessment of functional exercise capacity.
215144145|NCT03400839|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Assessment of maximal exercise capacity.
215144146|NCT03400839|DIAGNOSTIC_TEST|Muscle Function|Assessment of muscle force, muscle endurance and muscle fatigability
215144147|NCT03400839|DIAGNOSTIC_TEST|Lung Function|Assessment of whole-body plethysmography and spirometry.
215144148|NCT03400839|DIAGNOSTIC_TEST|Body composition|Assessment of bioelectrical impedance.
215144149|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SGRQ-I|"Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)"
215144150|NCT03400839|DIAGNOSTIC_TEST|Symptoms - UCSD/SOBQ|"Assessment of symptoms by the UCSD Short of breath questionnaire"
215144151|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SF36|"Assessment of Health-related quality of life by the SF-36 questionnaire"
215144152|NCT03400839|DIAGNOSTIC_TEST|Anxiety and depression|"Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale"
215144153|NCT03400839|DIAGNOSTIC_TEST|Symptoms - mMRC|"Assessment of symptoms by the modified Medical Research Council (mMRC) scale"
215144154|NCT03400839|DIAGNOSTIC_TEST|Sleep quality|"Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)"
215144155|NCT03400839|DIAGNOSTIC_TEST|Sleepiness|"Assessment of sleepiness by the Epworth Sleepiness Scale"
215144156|NCT03400839|DIAGNOSTIC_TEST|Inflammatory markers and oxidative stress|"blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP."
215144157|NCT03400839|DIAGNOSTIC_TEST|Functional performance tests|Timed-up-and-go at usual pace (TUGu) and at a fast pace (TUGf), four-metre gait speed test (4MGS), sit-to-stand test using three protocols: 30 seconds (30sec-STS), one minute (1min-STS) and five-repetition (5rep-STS) and Short Physical Performance Balance (SPPB).
214457052|NCT05772845|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
214457053|NCT05772845|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
214457054|NCT06848946|COMBINATION_PRODUCT|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
214457055|NCT06848946|PROCEDURE|Sham procedure in conjunction with cataract surgery|Sham procedure in conjunction with cataract surgery
214695225|NCT04812418|DIETARY_SUPPLEMENT|Noctesia|3 tablets every day at bedtime with a large glass of water
214695226|NCT04812418|DIETARY_SUPPLEMENT|Placebo|3 tablets every day at bedtime with a large glass of water
214695227|NCT04482699|BIOLOGICAL|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
215144158|NCT06519708|DRUG|Erector Spinae Plane Block|Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
215144159|NCT06519708|DRUG|External Oblique Intercostal Plane Block|Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
215144160|NCT03108326|BIOLOGICAL|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
215144161|NCT01357525|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
215144162|NCT05357001|OTHER|Connective tissue manipulation|to remove muscle spasticity
215144163|NCT05357001|OTHER|stretching exercises|to remove muscle spasticity
215144164|NCT04646044|DRUG|Bempegaldesleukin|Administered as an intravenous infusion
215144165|NCT04646044|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
215144166|NCT04646044|OTHER|Placebo|Administered as an intravenous infusion
215144167|NCT04375280|OTHER|"Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness."|"Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)"
214457056|NCT05044793|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
214457057|NCT03270020|DRUG|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
214457058|NCT05688111|DRUG|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
214457059|NCT05688111|OTHER|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
214457060|NCT06847243|DIAGNOSTIC_TEST|Nutrigenetic diet according the genetic test|Subjects within the nutrigenetic intervention group will be provided with a dietary plan according to nutrient intake characteristics by alghoritm genetic afinity.
214457061|NCT06847243|OTHER|Control intervention group|Subjects within the control intervention group will be provided with a dietary plan according to general nutrient recommendation by the AHA (American Hearth association) and national cholesterol education program
214695228|NCT04482699|OTHER|Placebo|RAPA-501-Allo cell placebo
214528637|NCT05092477|BEHAVIORAL|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response"
214528638|NCT05092477|BEHAVIORAL|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
214528639|NCT05439525|OTHER|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
215144168|NCT04554680|DRUG|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day \& oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- \& post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
215144169|NCT05808829|OTHER|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
215144170|NCT04374942|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
215144171|NCT04374942|DRUG|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
215144172|NCT01391546|BIOLOGICAL|ZOSTAVAX|1 dose 0.65 mL
214457062|NCT06844266|PROCEDURE|Administration of the ACT + PA-R questionnaires|"The ACT + PA-R questionnaires will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
214457063|NCT06844266|PROCEDURE|ACT questionnaire|"The ACT questionnaire will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
214457064|NCT06816992|DRUG|ORIC-114 Dose 1 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
214457065|NCT06816992|DRUG|ORIC-114 Dose 2 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
214457066|NCT06816992|DRUG|ORIC-114 Dose 3 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
214457067|NCT06322407|PROCEDURE|Stellate Ganglion Block (SGB)|All SGB procedures will be performed by the same experienced physicians. Patients will be positioned in a supine position with the neck slightly hyperextended and receive a SGB procedure using the B-ultrasound visualization technique (Aurora A5 Ultrasound, Risco Tech Co., Ltd.). 1% lidocaine 5mL (Shanxi Jinxin Shuanghe Pharm Co., Ltd.) will be injected below the prevertebral fascia on the surface of longus colli muscle
214457068|NCT06322407|DRUG|standardized drug treatment|Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
214457069|NCT06202118|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
214457070|NCT06152003|BEHAVIORAL|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
214457071|NCT06562946|DRUG|Pimicotinib|Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
214528640|NCT05439525|OTHER|conventional therapy|"1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness"
214528641|NCT03630783|BEHAVIORAL|Combined Cognitive Bias Modification|
214528642|NCT00982540|DRUG|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
214528643|NCT01928407|DRUG|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
214528644|NCT01928407|DRUG|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
214528645|NCT02456298|BEHAVIORAL|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
214528646|NCT02456298|BEHAVIORAL|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
215144173|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITH ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS
215144174|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITHOUT ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS WITH ELEVATOR SYSTEM
215144175|NCT03187392|DRUG|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
215144176|NCT03187392|DRUG|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
215144177|NCT03666754|PROCEDURE|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
215144178|NCT03666754|PROCEDURE|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
215144179|NCT03580811|DEVICE|Dental Implant &ADMG|A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
215144180|NCT03580811|DEVICE|Dental implant & ADMG & BDX|Dental Implant will be placed with ADMG that covers the BDX
215144181|NCT03431207|OTHER|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
215144182|NCT04295447|OTHER|Standard of care|"1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
215144183|NCT04295447|DRUG|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
214457072|NCT05177848|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214457073|NCT05177848|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457074|NCT05177848|OTHER|Nicotine vaping products at 2x market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457075|NCT05177848|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457076|NCT05177848|OTHER|Heated tobacco products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457077|NCT05177848|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457078|NCT05177848|OTHER|Nicotine pouch products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457079|NCT06561971|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214457080|NCT06848738|PROCEDURE|FNB|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the 3rd generation FNB needle
214457081|NCT06848738|PROCEDURE|FNA|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the standard FNA needle
214457082|NCT06849908|DRUG|Baricitinib|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.
214457083|NCT06849908|DRUG|Adalimumab|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.
214457084|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
214457085|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
214457086|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
214457087|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
214528647|NCT05135923|DIETARY_SUPPLEMENT|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
214528648|NCT00726388|DRUG|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
214528649|NCT02072798|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
214528650|NCT05415644|DRUG|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
214528651|NCT05415644|DRUG|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
214528652|NCT01924637|DRUG|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
214528653|NCT01924637|DRUG|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
214528654|NCT04105062|DRUG|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
214528655|NCT04105062|DEVICE|Cancer Vision Goggles|-Non-significant risk device
214528656|NCT04070729|OTHER|Placebo gel|Localized subgingival application
214528657|NCT04070729|DRUG|Hyaluronic acid gel|Localized subgingival application
214528658|NCT04070729|BIOLOGICAL|Platelet rich fibrin|Localized subgingival application
215144184|NCT04981483|PROCEDURE|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
214528659|NCT01628289|OTHER|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
215144185|NCT04266704|BEHAVIORAL|Sharing Intervention|intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
215144186|NCT03961672|DRUG|Duvelisib|Given PO
215144187|NCT01099605|DEVICE|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
215144188|NCT01099605|DEVICE|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
215144189|NCT06793917|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
215144190|NCT06793917|DRUG|Oxaliplatin injection|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
215144191|NCT06793917|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
215144192|NCT06793917|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
215144193|NCT06793917|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 135mg/m2
215144194|NCT04822337|DRUG|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
214528660|NCT01628289|OTHER|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
214528661|NCT01257412|DRUG|Dapagliflozin|5mg Oral dose od
214528662|NCT01257412|DRUG|Dapagliflozin|10 mg Oral dose od
215144195|NCT02156076|DRUG|BMS-919373|
214528663|NCT01257412|DRUG|placebo|5/10 mg Oral dose od
214528664|NCT02682004|OTHER|leptin, serotonin and adiponectin level|
214528665|NCT02682004|OTHER|leptin,serotonin, adiponectin level|
214528666|NCT03207620|DIAGNOSTIC_TEST|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
214528667|NCT03207620|DIAGNOSTIC_TEST|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
214528668|NCT00111839|DRUG|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
215144196|NCT02156076|DRUG|Placebo (Matching with BMS-919373)|
215144197|NCT01101867|DRUG|Aspart fixed dose|fixed dose
215144198|NCT01101867|DRUG|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
214528669|NCT00111839|DRUG|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
214528670|NCT04323111|PROCEDURE|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
215144199|NCT01213472|BIOLOGICAL|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
215144200|NCT02327832|PROCEDURE|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
215144201|NCT02327832|DRUG|bone marrow-derived mesenchymal stem cells|
215144202|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
215144203|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
215144204|NCT02910882|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
215144205|NCT02910882|DRUG|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
215144206|NCT02910882|RADIATION|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
215144207|NCT01100801|DRUG|TS-1 with cisplatin|
215144208|NCT01100801|DRUG|TS-1 with oxaliplatin|
215144209|NCT02620748|DRUG|Tranexamic Acid|
214457088|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
214457089|NCT06849375|PROCEDURE|phakic IOL implantation|specular microscopy examination to assess endothelial cells before and after phakic IOL implantation
214457090|NCT06850675|OTHER|Clinical performance|Supraglottic airway devices were evaluated for ease of insertion, time of insertion, success rate at first attempt, number of attempts, ease of gastric tube insertion, oropharyngeal leak pressure, and intraoperative and postoperative complications
214457091|NCT06848764|DRUG|Lidocaine|Patients will receive lidocaine (1.5 mg/kg loading then 1mg/kg/h infusion) just after induction of anesthesia induction and continued until the end of the operation.
214457092|NCT06848764|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg/kg/h just after induction of anesthesia induction and continued until the end of the operation.
214457093|NCT06846307|DRUG|Mannitol|mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
214457094|NCT06843707|OTHER|Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.|This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.
214457095|NCT06848556|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
214528671|NCT01502787|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
215144210|NCT02620748|OTHER|Saline Solution|
215144211|NCT00004169|DRUG|carboplatin|
215144212|NCT00004169|DRUG|cyclophosphamide|
215144213|NCT00004169|DRUG|etoposide|
215144214|NCT00004169|PROCEDURE|peripheral blood stem cell transplantation|
215144215|NCT00004169|RADIATION|radiation therapy|
214457096|NCT06848556|PROCEDURE|Transarterial Embolization|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
214457097|NCT06848556|PROCEDURE|TACE|Patients received standard Transarterial Chemoembolization (TACE) with intra-arterial injection of a mixture of epirubicin and iodized oil at a personalized dose, followed by embolization completed by injecting a suspension of gelatin sponge and contrast agent.
214528672|NCT01502787|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
214528673|NCT01502787|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
215144216|NCT02790892|BEHAVIORAL|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
215144217|NCT05378750|OTHER|Diuretic algorithm|Implementing diuretic algorithm
215144218|NCT02299843|PROCEDURE|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
215144219|NCT02299843|PROCEDURE|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
215144220|NCT03678519|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
215144221|NCT02342236|DEVICE|cemented or cementless type of hip prothesis|
214528674|NCT01502787|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
215144222|NCT02309242|BEHAVIORAL|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
215144223|NCT00635297|PROCEDURE|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
215144224|NCT04909281|DIAGNOSTIC_TEST|Self-sampling HPV|In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
214457098|NCT06849856|DEVICE|non-surgical peri-implantitis therapy with airflow device|Airflow device with erythritol powder will be used in the treatment of non-surgical peri-implantitis
214457099|NCT06849856|PROCEDURE|non-surgical peri-implantitis therapy with titanium curette|Titanium curette will be used for non-surgical treatment of peri-implantitis
214457100|NCT05041647|DRUG|25:1 CBD/THC|"* 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC"
214457101|NCT05041647|DRUG|5:1 CBD/THC|"* 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC"
214457102|NCT05041647|OTHER|Placebo|"* 1 dose (1 mL) of PLACEBO~* No active ingredients"
214457103|NCT04612309|DRUG|Immunotherapy|patient treated with at least 1 immunotherapy administration
214457104|NCT04469842|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
214457105|NCT04469842|DRUG|Tacrolimus|Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
214457106|NCT04469842|DRUG|Mycophenolate Mofetil Hydrochloride|Standard immunosuppression of the anti-proliferative class.
214457107|NCT04469842|DRUG|Prednisone|Standard immunosuppression (corticosteroid class).
214457108|NCT04469842|DRUG|Azathioprine|Standard immunosuppression of the anti-proliferative class.
214457109|NCT04843683|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
214528675|NCT01502787|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
214457110|NCT06295796|DRUG|MK-8527|Oral Capsule
215144225|NCT04737616|DEVICE|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
215144226|NCT04737616|DEVICE|OCT|Optical coherence tomography endoscope
215144227|NCT05408741|OTHER|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
215144228|NCT05408741|OTHER|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
215144229|NCT04980404|DRUG|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
214457111|NCT04771195|BEHAVIORAL|Examination of students' naturally occurring social ties|In this observational study, features of students' social lives, such as the number of quality of relationships they form, and their subjective loneliness, will be used to predict their mental health and well being at later time points.
214457112|NCT05141487|DEVICE|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
214457113|NCT05141487|DEVICE|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
214457114|NCT03899103|DRUG|Rituximab|First course Course Rituximab at Randomization.
214457115|NCT03899103|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
214457116|NCT05050591|DEVICE|Patient-Specific Silicone Airway Stent|The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
214457117|NCT06492031|DRUG|Icodextrin Peritoneal Dialysis Solution|The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
214457118|NCT06492031|DRUG|Glucose Peritoneal Dialysis Solution|The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
215144230|NCT06055270|PROCEDURE|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
214528676|NCT01502787|PROCEDURE|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
214528677|NCT01502787|DRUG|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
215144231|NCT06055270|OTHER|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
215144232|NCT01843413|RADIATION|stereotactic radiosurgery|Undergo SRS
215144233|NCT01843413|PROCEDURE|quality-of-life assessment|Ancillary studies
215144234|NCT01843413|PROCEDURE|cognitive assessment|Ancillary studies
215144235|NCT02647996|PROCEDURE|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
215144236|NCT03244332|OTHER|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
215144237|NCT03244332|OTHER|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
215144238|NCT04225897|DRUG|RV521|RV521 is an RSV F protein inhibitor administered orally
215144239|NCT04225897|DRUG|Placebo|vehicle administered orally
215144240|NCT06024824|RADIATION|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
214457119|NCT05777889|OTHER|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
214457120|NCT05834257|PROCEDURE|Normal Saline for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).
214457121|NCT05834257|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
214528678|NCT03152500|DEVICE|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
215144241|NCT05773664|DRUG|Azeliragon|Given PO
215144242|NCT05773664|PROCEDURE|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
215144243|NCT05773664|PROCEDURE|Computed Tomography|Undergo CT scan
215144244|NCT05773664|DRUG|Dexamethasone|Given PO or IV
215144245|NCT05773664|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
215144246|NCT04119115|DEVICE|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
215144247|NCT04119115|OTHER|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
215144248|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
215144249|NCT05705934|OTHER|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
215144250|NCT04897997|PROCEDURE|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
215144251|NCT02085460|DRUG|Placebo|
215144252|NCT02085460|DRUG|2% Rebamipide liquid|
215144253|NCT02085460|DRUG|4% Rebamipide liquid|
215144254|NCT06088121|DEVICE|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
215144255|NCT06088121|DEVICE|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
215144256|NCT06088121|DEVICE|ATNC BN-V1|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
214528679|NCT03152500|DEVICE|Acrysof SN60WF IOL|IOL in the bag
214528680|NCT00377312|DRUG|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
214528681|NCT00626158|DRUG|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
214528682|NCT00626158|DRUG|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
214528683|NCT02775214|DEVICE|Video Laryngoscopy|
214528684|NCT05971186|DRUG|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
214528685|NCT05971186|OTHER|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
214528686|NCT05971186|OTHER|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
215144257|NCT06088121|DEVICE|ATNC BN-V2|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
215144258|NCT01285323|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
215144259|NCT01285323|DRUG|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
215144260|NCT02995746|DRUG|Dexamethasone|"* On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~* Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~* Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~* Anticipated duration of the study: 6 months"
215144261|NCT02476253|DRUG|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
215144262|NCT01293734|OTHER|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
215144263|NCT01293734|OTHER|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
215144264|NCT01293734|OTHER|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
215144265|NCT01293734|DRUG|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
215144266|NCT00237406|PROCEDURE|interactive voice response|
214457122|NCT05834257|PROCEDURE|Ringer's Lacatate for fluid resusciation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
214457123|NCT04637620|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of MDD
214457124|NCT04637620|DRUG|Sertraline|Use of SSRI as an active comparator
214457125|NCT04637620|DRUG|Placebo Cap|Use of placebo as a comparator
214457126|NCT06338826|DRUG|TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI|"The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir"
214457127|NCT06338826|DRUG|Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)|dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
214528687|NCT05234645|OTHER|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
214528688|NCT06227442|DIAGNOSTIC_TEST|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
214528689|NCT01532102|DRUG|AP611074|
214528690|NCT01532102|DRUG|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
214528691|NCT00192166|BIOLOGICAL|CAIV-T|
215144267|NCT06184022|COMBINATION_PRODUCT|Augmented reality serious game design for promoting children's science education cognition:|"The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing.~The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter, and the children's behavioral characteristics were recorded. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test. Before and after the intervention, each participant's performance on the game was recorded."
215144268|NCT02703597|BEHAVIORAL|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
214457128|NCT04648878|OTHER|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
214528692|NCT03398434|DRUG|MAA868|3 MAA868 doses, single administration, subcutaneous,
214528693|NCT03398434|DRUG|Apixaban|Apixaban 5 mg b.i.d
215144269|NCT02703597|BEHAVIORAL|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
215144270|NCT02703597|BEHAVIORAL|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
215144271|NCT04970485|BEHAVIORAL|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
215144272|NCT02741063|BEHAVIORAL|screen low autistic subjects|screen subjects with low ASQ score
215144273|NCT02741063|BEHAVIORAL|screen high autistic subjects|screen subjects with high ASQ score
215144274|NCT02741063|DRUG|oxytocin|intranasal administration of oxytocin (24 IU)
215144275|NCT02741063|DRUG|placebo|intranasal administration of placebo (24 IU)
215144276|NCT03548948|OTHER|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
215144277|NCT03548948|OTHER|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
215144278|NCT03548948|OTHER|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
215144279|NCT01716377|DRUG|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
215144280|NCT01351181|BEHAVIORAL|Leaflet|Advice Leaflet
215144281|NCT01351181|BEHAVIORAL|Exercise Advice|Leaflet
215144282|NCT01351181|BEHAVIORAL|Normal Care|Normal Care
215144283|NCT02606643|PROCEDURE|Slight traction|Slight traction will be applied to the balloon catheter
215144284|NCT02606643|PROCEDURE|Foley Catheter to no traction|Foley Catheter to no traction
214457129|NCT04648878|OTHER|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
214457130|NCT04648878|OTHER|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
214457131|NCT05740904|OTHER|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
214457132|NCT05740904|OTHER|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
214457133|NCT03609593|DRUG|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
214457134|NCT03609593|DRUG|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
214457135|NCT03609593|DRUG|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
214457136|NCT02020720|PROCEDURE|Biopsy|Undergo image-guided biopsy
214457137|NCT02020720|PROCEDURE|Computed Tomography|Undergo 18F-DOPA-PET/CT
214457138|NCT02020720|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
215144285|NCT01253837|DRUG|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
215144286|NCT05994196|BEHAVIORAL|Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)|Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
215144287|NCT03989258|DIAGNOSTIC_TEST|Mammography outside official screening|Radiologic study
214457139|NCT02020720|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
214457140|NCT02020720|OTHER|Laboratory Biomarker Analysis|Correlative studies
214457141|NCT02020720|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
214457142|NCT02020720|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
214457143|NCT02020720|PROCEDURE|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
214457144|NCT06254846|OTHER|Urine sample, 1st stream|Use of the Colli-Pee® device for collecting the first urine stream
214457145|NCT06254846|OTHER|Cervico-vaginal swab|"Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged)."
215144288|NCT04663282|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
215144289|NCT04663282|DRUG|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
215144290|NCT01522222|PROCEDURE|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
215144291|NCT05386420|DRUG|Hymecromone tablets|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
215144292|NCT05386420|OTHER|Placebo|Conventional treatment combined with Placebo.
215144293|NCT03869047|DRUG|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
215144294|NCT03869047|DRUG|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
215144295|NCT01068847|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
215144296|NCT02376998|DEVICE|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
215144297|NCT00523510|PROCEDURE|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
215144298|NCT04467203|DRUG|Fadanafil|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
215144299|NCT05410184|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
215144300|NCT05410184|OTHER|mural curtain group|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
215144301|NCT02796170|DRUG|Dapagliflozin|5mg pill taken once daily
215144302|NCT02796170|DRUG|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
215144303|NCT03823521|DRUG|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
215144304|NCT00180336|DEVICE|CRT-D|
215144305|NCT03216512|OTHER|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
215144306|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
215144307|NCT02029716|DRUG|Lotion vehicle/placebo|
215144308|NCT01011894|DRUG|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
215144309|NCT06266247|DIAGNOSTIC_TEST|Take blood samples|Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
215144310|NCT04782869|DEVICE|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
215144311|NCT04240496|OTHER|Determination of plasma concentration of clozapine/ Genotyping|Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
215144312|NCT03690687|PROCEDURE|Primary anastomosis|
215144313|NCT03690687|PROCEDURE|Delayed anastomosis|
214457146|NCT05700474|BEHAVIORAL|Comprehensive outpatient behavioral health care|Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
215144314|NCT03690687|PROCEDURE|Enterostomy|
215144315|NCT04313244|BIOLOGICAL|9vHPV Vaccine|9vHPV intramuscular injection
214528694|NCT00762723|DEVICE|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
214457147|NCT06063499|BEHAVIORAL|Healthy Minds Program for Addictions|The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has \>100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
215144316|NCT04313244|BIOLOGICAL|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
215144317|NCT01839955|DRUG|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
215144318|NCT01839955|DRUG|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
215144319|NCT01839955|OTHER|laboratory biomarker analysis|Correlative studies
214457148|NCT06127784|OTHER|Motivational interviewing counselling session|Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
214457149|NCT04147832|OTHER|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
214457150|NCT03771417|BEHAVIORAL|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
214528695|NCT00382408|BIOLOGICAL|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
214528696|NCT00382408|OTHER|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
214528697|NCT02751645|PROCEDURE|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
214528698|NCT03358303|DEVICE|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
214528699|NCT01150019|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
214528700|NCT05867550|DRUG|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
214528701|NCT05867550|DRUG|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
214528702|NCT05867550|DRUG|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
214528703|NCT05867550|DRUG|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
214528704|NCT02299856|OTHER|Cardiac magnetic resonance scan|
214528705|NCT02145897|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
214528706|NCT02145897|BIOLOGICAL|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
214528707|NCT02145897|OTHER|Control|
215144320|NCT01839955|OTHER|pharmacological study|Correlative studies
215144321|NCT01839955|DRUG|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
215144322|NCT00089752|DEVICE|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
215144323|NCT00089752|DEVICE|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
214457151|NCT06552507|PROCEDURE|Duroplasty|The investigators open the dura from midline and repaired with fish mouth for dura augmentation
214457152|NCT05482711|OTHER|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
214457153|NCT00885716|BEHAVIORAL|patient training in shared decision making|
214457154|NCT00885716|BEHAVIORAL|cognitive training|
214457155|NCT03903120|BEHAVIORAL|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
215144324|NCT03946475|OTHER|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
214457156|NCT04378439|BEHAVIORAL|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
214457157|NCT04378439|BEHAVIORAL|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
214457158|NCT05827809|BEHAVIORAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
214457159|NCT05483283|OTHER|Empowerment and Navigation|Empowerment and Navigation
214457160|NCT05483283|OTHER|SOC|SOC
214457161|NCT05087693|DRUG|Salbutamol|Inhaling 200ug of salbutamol
214457162|NCT05087693|DRUG|Placebo medication|Inhaling placebo medication
214457163|NCT05087693|OTHER|Ozone|Breathing 170ppb ozone
214457164|NCT05087693|OTHER|Filtered Air|Breathing filtered air
214457165|NCT05087693|OTHER|Exercise|Cycling at 60% of VO2max on a cycle ergometer
214528708|NCT03198936|DIETARY_SUPPLEMENT|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
214528709|NCT03198936|DIETARY_SUPPLEMENT|Placebo|2 capsules to be taken twice a day with meals with glassful of water
214528710|NCT06478225|DRUG|BGT007H Cell Injection|"Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28)."
214528711|NCT01145417|DRUG|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
214695229|NCT03544268|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
214708701|NCT04920136|PROCEDURE|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
215144325|NCT01686919|DIETARY_SUPPLEMENT|milk-free|milk-free diet during 8 preoperative weeks
215144326|NCT06003972|DRUG|Copaxone|Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
215144327|NCT06003972|DRUG|guideline directed medical therapy (GDMT)|GDMT for heart failure according to the AHA guidelines.
214528712|NCT01921777|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
215144328|NCT03149562|DRUG|plasma transfusions|These critical ill neonates with plasma transfusions
215144329|NCT03149562|DRUG|non-plasma transfusions|These critical ill neonates without plasma transfusions
214528713|NCT01921777|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
214528714|NCT02435381|DRUG|Carisbamate|600mg Orally on days 2-4
214528715|NCT02435381|DRUG|Placebo|Placebo treatment only
214528716|NCT02779283|DRUG|Cyclophosphamide|Given IV
214528717|NCT02779283|DRUG|Cytarabine|Given IV
214528718|NCT02779283|DRUG|Dasatinib|Given PO
215144330|NCT01472289|OTHER|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
215144331|NCT06169969|DEVICE|magnetic therapy|Kegel exercises
215144332|NCT03052270|DRUG|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
215144333|NCT00907335|DRUG|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
215144334|NCT00907335|DRUG|Vehicle control|Color-matched facial gel vehicle control used once daily
215144335|NCT02933749|DEVICE|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
215144336|NCT02933749|DEVICE|BIS|Bispectral index
215144337|NCT04475796|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed after ERCP
215144338|NCT00784914|DRUG|temsirolimus|Receive temsirolimus IV
215144339|NCT00784914|OTHER|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
215144340|NCT00784914|OTHER|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
214457166|NCT04779918|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
215144341|NCT04444726|DEVICE|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
214457167|NCT05781347|PROCEDURE|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is an endoscopic treatment performed under general anesthesia. It utilizes radiofrequency (RF) energy delivered to the lower esophageal sphincter (LES) and the gastric cardia to enhance the antireflux barrier.
214457168|NCT05781347|DEVICE|Stretta|Stretta is a FDA approved device for the management of GERD.
214457169|NCT05504057|DRUG|Antihistamine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
214457170|NCT05504057|DRUG|Amantadine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
214457171|NCT06271291|OTHER|Non-Interventional Study|Non-interventional study
214457172|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
214457173|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
215144342|NCT04444726|DEVICE|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
215144343|NCT04444726|DRUG|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
215144344|NCT01387477|DRUG|Lactate|Infusion of 66 mmol of lactate
215144345|NCT01387477|DRUG|Glucose|Infusion of 33 mmol of glucose
215144346|NCT05367596|BEHAVIORAL|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
214457174|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
214457175|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
214528719|NCT02779283|DRUG|Dexamethasone|Given PO
214528720|NCT02779283|DRUG|Doxorubicin Hydrochloride|Given IV
214528721|NCT02779283|DRUG|Idarubicin|Given IV
214528722|NCT02779283|DRUG|Idelalisib|Given PO
214528723|NCT02779283|DEVICE|In Vitro Kinase Inhibitor Assay|Correlative studies
215144347|NCT05367596|BEHAVIORAL|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
215144348|NCT05367596|BEHAVIORAL|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
215144349|NCT05367596|BEHAVIORAL|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
214528724|NCT02779283|DRUG|Leucovorin Calcium|Given IV
214528725|NCT02779283|DRUG|Methotrexate|Given IV
214528726|NCT02779283|DRUG|Methylprednisolone Sodium Succinate|Given IV
215144350|NCT05367596|BEHAVIORAL|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
215144351|NCT05367596|BEHAVIORAL|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
215144352|NCT05367596|BEHAVIORAL|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
215144353|NCT01109472|OTHER|patient magazine|patient magazine individually tailored to patient's prior feedback
215144354|NCT00183040|DRUG|Topical testosterone|
215144355|NCT00183040|DRUG|Recombinant human growth hormone|
215144356|NCT03144154|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
215144357|NCT00646880|DRUG|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
215144358|NCT00646880|DRUG|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
215144359|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
214457176|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
214457177|NCT02737878|BEHAVIORAL|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
214457178|NCT02737878|BEHAVIORAL|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
214528727|NCT02779283|DRUG|Ponatinib Hydrochloride|Given PO
214528728|NCT02779283|BIOLOGICAL|Rituximab|Given IV
214528729|NCT02779283|DRUG|Ruxolitinib Phosphate|Given PO
214528730|NCT02779283|DRUG|Sorafenib Tosylate|Given PO
214528731|NCT02779283|DRUG|Sunitinib Malate|Given PO
214528732|NCT02779283|DRUG|Vincristine Sulfate|Given IV
214528733|NCT03227978|COMBINATION_PRODUCT|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
214528734|NCT01191697|DRUG|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
214528735|NCT01191697|DRUG|trastuzumab|Given intravenously on day 1 of each treatment cycle
214528736|NCT01191697|DRUG|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
214528737|NCT01191697|DRUG|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
214528738|NCT03939793|BEHAVIORAL|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
214528739|NCT03939793|BEHAVIORAL|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
214528740|NCT03939793|OTHER|Usual Care|Usual Care
214528741|NCT06154798|BEHAVIORAL|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
215144360|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
215144361|NCT03873116|DRUG|Placebo oral capsule|Matching placebo capsules administered orally once daily
215144362|NCT00912808|DRUG|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
215144363|NCT00912808|DRUG|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
215144364|NCT00419406|PROCEDURE|UVA1 phototherapy|
215144365|NCT00419406|PROCEDURE|NB-UVB phototherapy|
214457179|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
214457180|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
214457181|NCT05746494|DEVICE|tDCS|active anodal tDCS and sham tDCS
214457182|NCT06027554|DRUG|Mitoquinone Mesylate|MitoQ given 20 mg per day for 12 weeks.
214457183|NCT06027554|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule taken every day for 12 weeks.
214457184|NCT03762291|BIOLOGICAL|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
214457185|NCT06072105|OTHER|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
214457186|NCT06072105|OTHER|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
214457187|NCT06800326|DIAGNOSTIC_TEST|Ultrasound|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
214457188|NCT06800326|DIAGNOSTIC_TEST|MRE Scan|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
214457189|NCT06800573|OTHER|Conventional physical therapy|including strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior, (2 sets of 10 repetitions per day) and stretching exercises for pectoralis muscles (20seconds hold, 5 repetition.
214457190|NCT06800573|OTHER|lying posture with progression|"Exercise 1, the lying posture with leg extension progression, was aimed to stretch the anterior muscle chain (diaphragm, pectoralis minor, scalene, sternocleidomastoid, intercostalis, iliopsoas, arm, forearm, and hand flexors)(Bonetti et al., 2010).~Exercise 2, the lying posture with flexion of the thighs, was intended to stretch the posterior chain (upper trapezius, levator scapulae, suboccipital, erector spinae, gluteus maximus, ischiotibial, triceps surae, and foot intrinsic muscles)."
214457191|NCT06800573|OTHER|smartphone app exercises|about 50 min a day, 4 days a week for an 8-week period also, performed exercises which were reminded by a smartphone app at predetermined times.
214528742|NCT04232488|PROCEDURE|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
214528743|NCT04232488|PROCEDURE|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
214528744|NCT01066897|DRUG|Pramipexole|Patients will received increasing dose of pramipexole
214528745|NCT02939859|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
214528746|NCT02939859|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
214528747|NCT02939859|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
215144366|NCT04029285|OTHER|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
214528748|NCT00635011|BEHAVIORAL|psychotherapy|Cognitive Behavioral therapy
214528749|NCT04113902|BEHAVIORAL|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
214528750|NCT06434545|BEHAVIORAL|Palliative Reasoning methodology|Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
214457192|NCT06801132|BEHAVIORAL|Online self-delivered death anxiety intervention|"The online self-guided death anxiety intervention developed in this study is based on the Death Education and CBT framework. It took approximately two hours to complete the full intervention. The main content includes:~1. Emotional reactions and behavioral manifestations about death, fear management theories, and Chinese cultural attitudes toward death;~2. Imagine what you would like to say to yourself at the end of your life, and learn about various attitudes towards death through numerous examples;~3. Expressive writing, with moderate emotional exposure to stimulate reflection, accompanied by breathing exercises and positive thinking about death, to improve tolerance and control of death anxiety, and finally to correct biased perceptions by examining bad beliefs about death;~4. Prioritize the importance of things and make a practical action plan to enrich your life."
214457193|NCT06801132|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked not to use our death anxiety intervention or seek additional help related to death anxiety during the 1-week intervention period. After the one-month follow-up of the experimental group, the WL group will receive the same intervention for death anxiety. WL participants will also be given contact information to use in case of increasing distress.
215144367|NCT06515600|DEVICE|Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.|"All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min."
215144368|NCT04252534|COMBINATION_PRODUCT|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
215144369|NCT04252534|BIOLOGICAL|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
215144370|NCT00288132|BEHAVIORAL|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
215144371|NCT00288132|BEHAVIORAL|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
215144372|NCT01096875|DRUG|Atorvastatin|40mg/day once daily for two weeks prior to surgery
214457194|NCT06457945|BEHAVIORAL|ASRT|The task involves the presentation of a visual stimulus in one of four horizontal locations on the screen, and participants are instructed to indicate the location of the target stimulus by pressing the corresponding key on the keyboard. In case of correct response, the target stimulus disappears, and after a 120 ms interstimulus interval, the next stimulus appears. In case of an incorrect response, the target stimulus remains in place until the first correct response. The stimuli follow a probabilistic eight-element sequence, with pattern and random elements alternating with each other. Each participant will be assigned to one of 24 possible sequences throughout the task. The ASRT task will be composed of 25 blocks, with each block containing ten repetitions of the eight-element sequence. After each block, participants will have to take a short break and answer the thought probes before continuing. All patients will perform the task one time.
214457195|NCT06457945|BEHAVIORAL|Questionnaires|"All patients will have to fill questionnaire at the beginning of the study~* Spontaneous and Deliberate Mind Wandering Scales (SDMWS)~* Epworth Sleepiness Scale~* Narcolepsy Severity Index~* Idiopathic Hypersomnia Severity Scale~* Hospital Anxiety and Depression scale~* Horne \& Ostberg questionnaire~* Attention Deficit Hyperactivity Disorder (ADHD) auto-evaluation~* Pittsburgh Sleep Quality Index~* Insomnia Severity Index~* Psychotic-like experiences scale"
214457196|NCT06457945|DEVICE|Electrophysiological recordings|A subset of patients in each arm will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT
214457197|NCT06453551|DRUG|TRN501 - Dose 1|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214528751|NCT03861429|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
214528752|NCT02338778|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
215144373|NCT01096875|DRUG|Placebo|1tb/day once daily for two weeks prior to surgery
215144374|NCT03189004|BEHAVIORAL|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring"
215144375|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT)|2x8 weeks of high-intensity interval training (HIIT)
215144376|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT) + intermittent fasting|2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
215144377|NCT06403969|BEHAVIORAL|Applied Behavior Analysis|Applied Behavior Analysis focusing on nocturnal awakenings. It starts with identification of target behaviors and goals. A functional analysis is conducted to analyze the underlying function of a behavior in connection to the problem. A treatment plan is formulated, including strategies to achieve the goals, and methods to evaluate. Families receive education sleep hygiene. Adaptations focus on antecedents and consequences, with an emphasis on positive reinforcement of favorable behaviors. Various components of Cognitive Behavioral Therapy may be applicable. These include changes in sleep environment, stimulus control, bedtime routines with visual support and prompting. Sleep restriction and bedtime fading are included. Modified extinction techniques with parental presence can be applied, gradually phasing out parental immediate presence. The intervention continues until goals are achieved or for a maximum of 8 sessions (each lasting up to 60 minutes) spread over 8 weeks.
215144378|NCT00624182|BIOLOGICAL|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
215144379|NCT00624182|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
215144380|NCT03941288|DRUG|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
215144381|NCT03941288|OTHER|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
215144382|NCT00399906|DRUG|BMS-582949|Tablets, Oral, Once daily, 12 weeks
215144383|NCT00399906|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks
215144384|NCT00393159|DEVICE|Ear Popper|
215144385|NCT00456222|BEHAVIORAL|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
215144386|NCT01310452|DRUG|insulin detemir|insulin detemir once daily with metformin
215144387|NCT01310452|DRUG|neutral protamine insulin|neutral protamine insulin once daily with metformin
215144388|NCT05005234|DRUG|GFH925|Administered as an oral tablet formulation
215144389|NCT06474247|DEVICE|Postbiotic|Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
215144390|NCT06474247|DEVICE|Placebo|Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
215144391|NCT05542420|OTHER|No treatment given|The study will be based on data already recorded in the medical record
215144392|NCT03239392|DRUG|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
214457198|NCT06453551|DRUG|TRN501 - Dose 2|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457199|NCT06453551|DRUG|TRN501 - Dose 3|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
215144393|NCT02323217|RADIATION|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
215144394|NCT02323217|DRUG|Idazoxan|Idazoxan block of \[11C\]BU99008
215144395|NCT02323217|DRUG|Isocarboxazid|Isocarboxazid block of \[11C\]BU99008
215144396|NCT04278599|DRUG|Oral Zinc supplementation|In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
215144397|NCT04278599|DRUG|Oral placebo supplementation|In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
215144398|NCT04864093|DIAGNOSTIC_TEST|muscular ultrasound|respiratroy and muscular ultrasound
214528753|NCT02338778|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
214528754|NCT01447251|BEHAVIORAL|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
215144399|NCT01925456|DRUG|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
215144400|NCT05676619|DEVICE|3D foot scanner|Reliability of 3D foot scanner during repeated scans
215144401|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix with collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane"
214457200|NCT06453551|DRUG|TRN501 - Dose 4|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457201|NCT06453551|DRUG|TRN501 - Dose 5|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457202|NCT06453551|DRUG|TRN501 - Dose 6|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457203|NCT06453551|DRUG|TRN501 - Dose 7|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457204|NCT06453551|DRUG|TRN501 - Dose 8|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
214457205|NCT03318406|DEVICE|Bronchoscopic Thermal Vapor Ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
214457206|NCT01214616|DRUG|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
214457207|NCT01214616|DRUG|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
214457208|NCT01214616|DRUG|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
214457209|NCT03721952|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
214457210|NCT05292365|BEHAVIORAL|RE-PACT Intervention|"* Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching"
214457211|NCT05780372|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
214457212|NCT05780372|DRUG|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
214457213|NCT06784076|DRUG|Anifrolumab|Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
214457214|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
214528755|NCT00529555|DRUG|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
214528756|NCT00529555|PROCEDURE|Scaling and root planing|scaling and root planing
215144402|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix (MPM) without collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM."
215144403|NCT03994081|DEVICE|tACS|XCSITE100
215144404|NCT03994081|DEVICE|Sham tACS|XCSITE100
215144405|NCT06521749|DEVICE|USB as a stylet|USB used as a bougie
215144406|NCT06521749|DEVICE|USB as a bougie|USB used as a bougie
215144407|NCT04426734|DEVICE|Dextenza Dexamethasone Implant|The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.
215144408|NCT04426734|DRUG|Topical Prednisolone Acetate 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
215144409|NCT04544813|DRUG|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
215144410|NCT04544813|DRUG|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
215144411|NCT00054886|DRUG|SU-011,248|
215144412|NCT04865159|DRUG|Tipifarnib|Cardiac Safety of Tipifarnib
214457215|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
214457216|NCT05817357|DEVICE|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
214457217|NCT04633122|DRUG|Ripretinib|Oral kinase inhibitor
214457218|NCT04633122|DRUG|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
214457219|NCT05385367|OTHER|Regional anesthetic|Patient having just the nerve block for surgery
214457220|NCT05385367|OTHER|General anesthetic|Patient having just general anesthetic ie. 'go completely under' for surgery
214457221|NCT05385367|OTHER|Combined general anesthetic and regional anesthetic|Patient having a combination of a nerve block and general anesthetic for surgery
214528757|NCT04985747|OTHER|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
214528758|NCT04985747|OTHER|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
214457222|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
214528759|NCT04985747|OTHER|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
214528760|NCT01372735|RADIATION|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
214528761|NCT01372735|RADIATION|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
214528762|NCT04385628|BEHAVIORAL|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
215144413|NCT04500912|DEVICE|Supraflex Cruz 60 Micron|percutaneous coronary intervention
215144414|NCT04500912|DEVICE|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
215144415|NCT05194254|OTHER|MRI-ET|coupled fMRI and Eye Tracking tools
215144416|NCT06226129|DRUG|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
215144417|NCT02346123|GENETIC|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
215144418|NCT02620774|DRUG|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
215144419|NCT02620774|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
215144420|NCT00474812|DRUG|dasatinib|
215144421|NCT00474812|PROCEDURE|laboratory biomarker analysis|Correlative study
215144422|NCT00474812|PROCEDURE|physiologic testing|Correlative study
215144423|NCT00685230|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
215144424|NCT00685230|OTHER|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
215144425|NCT02997215|DRUG|Lidocaine|lidocaine infusion during surgery
215144426|NCT02997215|DRUG|Saline Placebo|saline infusion at same rate as intervention group during surgery
215144427|NCT00700479|DRUG|aldosterone|4 hour infusion
215144428|NCT00700479|DIETARY_SUPPLEMENT|low or high sodium diet|
215144429|NCT00700479|DRUG|placebo|placebo
215144430|NCT04426422|DRUG|Metformin Hydrochloride|treated with metformin 1500-2000mg daily
215144431|NCT03911167|PROCEDURE|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
215144432|NCT03096808|RADIATION|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
214457223|NCT04630899|OTHER|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
214457224|NCT04630899|OTHER|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
214457225|NCT06541145|DRUG|Mupirocin|Participants will place a pea-sized amount (or approximately 1cm ribbon) of 2% mupirocin ointment (Duke formulary) on a cotton swab and gently massage it into the anterior nares twice daily for 5 days.
214457226|NCT06541145|DRUG|Chlorhexidine baths|Participants will be instructed to use pre-packaged chlorhexidine cloths. Each cloth will be used to wipe designated body areas (i.e., arms, legs, chest and neck, back and perineum) once a day for 5 days. These are inexpensive cloths that are easy to use and have been shown to be effective at eradicating Staph aureus carriage. Ideally, participants will be instructed not to rinse off immediately after using the cloths. Baths should be performed on the same 5 days as they apply the intranasal mupirocin.
214528763|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
214528764|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
214528765|NCT05348642|DIETARY_SUPPLEMENT|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
214528766|NCT05348642|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
214528767|NCT00424723|DRUG|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
214528768|NCT06108752|OTHER|Scapular stabilization exercises|The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
214528769|NCT06108752|OTHER|Thoracic extension exercises|Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
215144433|NCT03785015|OTHER|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
215144434|NCT03785015|OTHER|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
215144435|NCT00061438|DRUG|meropenem|
215144436|NCT05007054|PROCEDURE|PCI or CABG|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
214528770|NCT05789927|PROCEDURE|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
214528771|NCT03086070|DRUG|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
214528772|NCT03086070|DRUG|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
214528773|NCT02635711|BEHAVIORAL|Adapted Taekwondo training|Adapted Taekwondo training for beginners
214528774|NCT02635711|BEHAVIORAL|Control|Daily jogging
214528775|NCT05946447|DEVICE|Ultrasound|The gastric antrum will be scanned using ultrasound.
215144437|NCT06452563|DIETARY_SUPPLEMENT|ketoanalogue supplementation|This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021
215144438|NCT06452563|OTHER|intradialytic exercise|low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
215144439|NCT01723982|DRUG|Barusiban (FE 200440)|
215144440|NCT01723982|DRUG|Placebo Comparator|
215144441|NCT01623570|DRUG|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
215144442|NCT01623570|DRUG|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
215144443|NCT03542487|BEHAVIORAL|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
215144444|NCT03542487|BEHAVIORAL|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
215144445|NCT03542487|BEHAVIORAL|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
215144446|NCT03542487|BEHAVIORAL|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
214457227|NCT05991882|BEHAVIORAL|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
214457228|NCT05991882|BEHAVIORAL|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
214457229|NCT05991882|BEHAVIORAL|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
214457230|NCT05991882|BEHAVIORAL|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
214457231|NCT05991882|BEHAVIORAL|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
214457232|NCT05991882|BEHAVIORAL|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
214457233|NCT05991882|BEHAVIORAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
214457234|NCT05991882|BEHAVIORAL|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
214528776|NCT00393198|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
214528777|NCT00393198|DRUG|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
214528778|NCT00393198|DRUG|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
214528779|NCT00412828|DRUG|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
214528780|NCT01661244|DRUG|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
214528781|NCT01661244|DRUG|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
215144447|NCT03529669|DEVICE|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
215144448|NCT04407754|DIETARY_SUPPLEMENT|Inositol supplement|Inositol supplements given to inositol arm
215144449|NCT04407754|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement given to placebo arm
215144450|NCT06318468|OTHER|Nursing health assessment teaching and discussion using humanoid diagrams|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
215144451|NCT06318468|OTHER|Nursing health assessment teaching and discussion using case study|The comparison group will receive the nursing health assessment teaching for 50 minutes and discussion using case study for 40 minutes to learn comprehensive nursing assessment.
215144452|NCT03632863|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
215144453|NCT03632863|BEHAVIORAL|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
215144454|NCT00296621|DRUG|L-Glutamine|L-Glutamine
215144455|NCT00296621|DRUG|placebo|placebo
215144456|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
215144457|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
214457235|NCT06798116|PROCEDURE|Experimental: open flap debridement and demineralized freeze-dried bone allograft and mixed with liquid (PRF|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement and DFDBA and mixed with liquid (PRF)"
214457236|NCT06798116|PROCEDURE|defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects."
214528782|NCT01661244|DRUG|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
214528783|NCT01661244|DRUG|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
214528784|NCT06330857|PROCEDURE|Laparoscopic vaginorectopexy|Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
214528785|NCT02503306|DRUG|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
214528786|NCT02503306|DRUG|placebo|Pharmaceutical form:tablets Route of administration: oral
215144458|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
215144459|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
215144460|NCT05659589|OTHER|blood sample|Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.
215144461|NCT05459181|DIAGNOSTIC_TEST|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
215144462|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
215144463|NCT03955146|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
214457237|NCT06798116|PROCEDURE|defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane"
215144464|NCT03955146|DRUG|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
215144465|NCT04798183|DIAGNOSTIC_TEST|3-dimensional scan|Facial 3-dimensional scan according to posture
215144466|NCT06250205|DRUG|Obicetrapib|oral administration
215144467|NCT06250205|DRUG|Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)|oral administration
215144468|NCT06250205|DRUG|Drospirenone / Ethinyl Estradiol (COC)|oral administration
215144469|NCT03783572|OTHER|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
215144470|NCT03783572|OTHER|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
215144471|NCT04363320|BEHAVIORAL|NIATx Coaching|NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.
215144472|NCT04363320|BEHAVIORAL|ECHO|The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.
215144473|NCT06338787|OTHER|FeSC|Iron/yeast complex
215144474|NCT06052852|DRUG|BDC-3042|Dectin-2 agonist antibody
215144475|NCT06052852|DRUG|Cemiplimab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
215144476|NCT06277687|DIAGNOSTIC_TEST|Virtual Augmented Reality Combined With Finder|After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
215144477|NCT02002598|DRUG|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2"
215144478|NCT02002598|DRUG|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2"
215144479|NCT02002598|DRUG|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
215144480|NCT05525416|DRUG|Sodium Nitroprusside|A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
215144481|NCT05525416|DRUG|Phenylephrine Hydrochloride|A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
215144482|NCT05525416|DRUG|Phenylephrine Hydrochloride|Investigators will give three incremental doses via brachial artery catheter to observe α1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
215144483|NCT05525416|DRUG|Norepinephrine|Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
215144484|NCT05525416|OTHER|Isometric Handgrip and Post-Exercise Circulatory Occlusion|Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
215144485|NCT05525416|OTHER|Rhythmic Handgrip|Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
215144486|NCT05525416|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
214528787|NCT05372913|DEVICE|Woebot for Adolescents (W-GenZD) Mobile Application|"Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
214528788|NCT05372913|BEHAVIORAL|CBT-Lite Teletherapy Group|The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
214457238|NCT06798116|PROCEDURE|open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane.|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane."
214457239|NCT05364515|DRUG|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
214457240|NCT05364515|DRUG|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
214457241|NCT05601596|DIAGNOSTIC_TEST|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
214457242|NCT04848740|DEVICE|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
214457243|NCT06631391|BIOLOGICAL|umbilical cord blood NK cells|This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells) and other therapy.
214457244|NCT04979130|DRUG|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
214457245|NCT04979130|DRUG|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
215144487|NCT05525416|DRUG|Propranolol Hydrochloride|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
215144488|NCT05525416|DRUG|Phentolamine Mesylate|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
215144489|NCT05632211|BIOLOGICAL|AVT05|Pre filled syringes filled with AVT05
215144490|NCT05632211|BIOLOGICAL|Simponi|Pre filled syringes filled with Simponi
215144491|NCT06685302|OTHER|US-guided PNM|The patient will be positioned in supine with approximately 20 degrees of knee flexion, supported by a cushion. The treatment area is sterilized in advance with 2% chlorhexidine, and new needles and ultrasound probe covers are used for each intervention. The femoral nerve is targeted under ultrasound guidance, just distal to the inguinal ligament, with an electrode patch placed on the patellar tendon to complete the circuit. A current of 2 Hz, 250 μs pulse width, and variable intensity is applied to reach the patient's comfortable contraction threshold without inducing pain, for a duration of 25 minutes, following the protocol established by MVClinic Institute. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
214457246|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
214457247|NCT05738148|DRUG|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
214457248|NCT05738148|DRUG|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC."
214457249|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
214457250|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
214457251|NCT04185298|BEHAVIORAL|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
214457252|NCT04185298|BEHAVIORAL|Activity monitoring|Participants will have activity monitored (via Fitbit)
214457253|NCT03847636|DEVICE|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
214457254|NCT01798498|DEVICE|Princess® VOLUME|
214457255|NCT03896789|OTHER|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
214457256|NCT06360237|DRUG|Olezarsen|Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
214457257|NCT05367414|OTHER|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
214457258|NCT05367414|OTHER|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
214457259|NCT05389202|OTHER|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
214457260|NCT06283238|DRUG|Immune checkpoint inhibitor (ICI) or chemotherapy alone|Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone
214457261|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
214457262|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
214457263|NCT06068686|DRUG|Vildagliptin 50 MG|vildagliptin plus their metformin.
214457264|NCT06068686|DRUG|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
214457265|NCT04471038|BIOLOGICAL|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
214457266|NCT04471038|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
214457267|NCT05145309|DRUG|KMgCit|Supplement that provide K, Mg, and citrate
214457268|NCT05145309|DRUG|Placebo|Power with identical appearance to KMgCit
214457269|NCT06639503|DRUG|Bupivacain|5mL 0.25% bupivacain
214457270|NCT04722848|DRUG|Ponatinib + Blinatumomab|"Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation"
214457271|NCT04722848|DRUG|Chemotherapy + Imatinib|patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
214457272|NCT03787693|BEHAVIORAL|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
214457273|NCT04485104|DRUG|GWP42003-P|Oral Solution
214457274|NCT06129682|OTHER|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
214457275|NCT05871385|DEVICE|rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
214457276|NCT05871385|DEVICE|placebo rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
214457277|NCT05869760|OTHER|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
214457278|NCT05869760|OTHER|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
214457279|NCT06545214|PROCEDURE|Video-EEG monitoring|Video-EEG monitoring
215144492|NCT06685302|OTHER|US-guided PE|The patient will be positioned in supine with approximately 20º of knee flexion, supported by a cushion. Prior to the EP procedure, the treatment area will be sterilized with 2% chlorhexidine, and new needles and ultrasound probe covers will be used for each session. Three EP interventions will be performed under ultrasound guidance following the protocol developed by MVClinic Institute (2) for treating tendinopathies, using a longitudinal, long-axis view of the patellar tendon. A galvanic current of 3 mA will be applied for 3 seconds, with slight three-dimensional adjustments in needle placement after each impact to administer a total of 3 impacts on the target tissue. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
215144493|NCT06685302|OTHER|EE|Three sets of 15 repetitions of single-leg squats on a 25º inclined plane, performed twice daily, following Young's protocol for patellar tendinopathies. The speed of execution may be increased as long as, if there is pain during the exercise, it does not exceed a 2-3 on the VAS scale.
215144494|NCT02628873|DEVICE|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
215144495|NCT04860323|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
215144496|NCT05338294|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
215144497|NCT05076006|DRUG|PF-06700841|Active study drug
215144498|NCT05076006|DRUG|Placebo|placebo comparator
215144499|NCT00541658|DRUG|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
215144500|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
215144501|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
215144502|NCT06274645|DEVICE|The OptiCross High Definition (60 MHz) and OptiCross (40MHz) Intravascular Ultrasound (IVUS) catheter from Boston Scientific|The IVUS-guided PCI procedure includes the use of IVUS before PCI (highly recommended) and after PCI (mandatory)
215144503|NCT00495196|PROCEDURE|Experimental lung function test|Administration of several CO2 gas mixtures
215144504|NCT04501042|PROCEDURE|Bariatric surgery|Bariatric surgery
215144505|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)"
215144506|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)"
215144507|NCT04440033|OTHER|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
215144508|NCT04440033|OTHER|Speech assessments|"* Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)"
215144509|NCT04440033|OTHER|Audiology assessments|"* Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
215144510|NCT03772392|PROCEDURE|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
215144511|NCT02570607|BIOLOGICAL|BNP dosage|
215144512|NCT06253351|DEVICE|Hybrid closed loop (HCL)|"* Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6"
214457280|NCT06545214|PROCEDURE|Respiratory monitoring and polysomnography|heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)
214528789|NCT04741815|DEVICE|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
215144513|NCT04353141|DIAGNOSTIC_TEST|standardized Lung Ultrasound (LUS) examination|14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
215144514|NCT04123470|GENETIC|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
215144515|NCT04123470|BIOLOGICAL|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
215144516|NCT03865979|DEVICE|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
215144517|NCT05070923|BEHAVIORAL|HealthyLifetime|HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
215144518|NCT02195518|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
215144519|NCT05530252|DRUG|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
215144520|NCT05530252|DRUG|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
215144521|NCT05530252|OTHER|SRP|only scaling and root planning was performed on the patient
215144522|NCT05196152|BEHAVIORAL|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
215144523|NCT05196152|BEHAVIORAL|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
215144524|NCT00305513|PROCEDURE|The phasic alerting treatment|
215144525|NCT05949333|DRUG|Eflapegrastim|long-acting granulocyte-colony stimulating factor
215144526|NCT00873483|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
215144527|NCT04370873|DRUG|Frespaciguat|Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
215144528|NCT04370873|DRUG|Placebo|Placebo administered as dry powder inhalation according to randomization
215144529|NCT05271240|DRUG|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
215144530|NCT05271240|DRUG|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
215144531|NCT04073875|DIAGNOSTIC_TEST|18F-GP1|18F-GP1 PET-CT scan
215144532|NCT02344108|DEVICE|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
215144533|NCT06592339|DRUG|MK-0616|oral administration
215144534|NCT06587152|PROCEDURE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
215144535|NCT06593899|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiotherapy Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume
215144536|NCT06593899|DRUG|3 cycles of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)
215144537|NCT06591117|DEVICE|Vizio Aqueous Microshunt|Ocular microshunt placement for the treatment of Glaucoma
215144538|NCT06598748|OTHER|Mechanical Interface Mobilisation Technique|In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
215144539|NCT06598748|OTHER|Exercise Therapy|"Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26)."
215144540|NCT06604312|OTHER|Sacroiliac Joint Manipulation|Sacroiliac manipulation was performed using manual treatment method by lying patients on their sides. First, the patient was positioned firmly on the edge of the examination table, while the restricted sacroiliac joint remains on the upper side. Then, the physician's hand was positioned on the patient's hip, and the flexion was made on the lumbar spine with the movement from the hip to the upper thigh, and the impulse given by the HVLA technique was applied in the anteroinferior direction to the iliac crest and trochanter major.
215144541|NCT06593444|PROCEDURE|Thalamic Ventral Intermediate-DBS|Participants will undergo Thalamic Ventral Intermediate-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
215144542|NCT06655584|DEVICE|Virtual reality headset Bliss DTX|The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
215144543|NCT00911170|DRUG|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
215144544|NCT00911170|DRUG|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
215144545|NCT00911170|BIOLOGICAL|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
215144546|NCT00911170|DRUG|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
215144547|NCT06987110|OTHER|Transverse thoracic plane block|Patients will receive a transverse thoracic plane block.
215144548|NCT06987110|OTHER|Midpoint transverse process plane to pleura block|Patients will receive a midpoint transverse process plane to pleura block.
215144549|NCT06987110|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
215144550|NCT05189314|PROCEDURE|Thyroidectomy|Surgical Resection of thyroid nodules
215144551|NCT05189314|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
215144552|NCT06665789|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
215144553|NCT02594124|DRUG|nusinersen|Administered by intrathecal (IT) injection
215144554|NCT04662255|DRUG|Pirtobrutinib|Oral
215144555|NCT04662255|DRUG|Ibrutinib|Oral
214457281|NCT06545214|PROCEDURE|1 Hypercapnic challenge while participant is awake|The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
214528790|NCT04741815|DEVICE|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
214528791|NCT02986659|DRUG|Metformin|
215144556|NCT04662255|DRUG|Acalabrutinib|Oral
215144557|NCT04662255|DRUG|Zanubrutinib|Oral
215144558|NCT06594302|OTHER|Functional performance tests and scales measuring biopsychosocial characteristics|Functional performance tests and scales applications
215144559|NCT06598176|DEVICE|Colli-Pee 20mL device with UCM|Women will collect a first-void urine (the initial part of the urine stream) sample at home the day before a hospital appointment using the 20mL Colli-Pee device prefilled with urine conservation medium (UCM, Novosanis, Belgium).
215144560|NCT06598176|DEVICE|Evalyn Brush|Women will collect a vaginal self-sample using the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before a hospital appointment.
215144561|NCT06587594|BEHAVIORAL|Solution Focused Brief Therapy|A behavioral health intervention designed to help autistic adults to make a positive change in their life using strength-based approach.
215144562|NCT06591962|OTHER|Questionnaire application for diabetes mellitus|Scales will be applied to individuals diagnosed with diabetes mellitus
215144563|NCT06591962|OTHER|Questionnaire application for without diabetes mellitus|Scales will be applied to individuals diagnosed without diabetes mellitus
215144564|NCT06602531|BIOLOGICAL|ARCT-2304|Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.
215144565|NCT06602531|BIOLOGICAL|Control vaccine younger adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
215144566|NCT06602531|BIOLOGICAL|Control vaccine older adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
215144567|NCT06602531|OTHER|Placebo Vaccine|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
214528792|NCT02986659|DRUG|Placebo|
215144568|NCT06592365|DIETARY_SUPPLEMENT|GTE|oral administration of GTE tablets once daily for 12 weeks
215144569|NCT06592365|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo tablets once daily for 12 weeks
215144570|NCT06586866|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
215144571|NCT06603935|OTHER|QHSLab Digital Tools (AME and ARIS)|Participants will use the QHSLab digital platform, which includes two tools: the Allergy Management Evaluation (AME) and the Allergic Rhinitis Intervention Steps (ARIS). The AME provides a comprehensive digital assessment for identifying and monitoring allergic rhinitis symptoms. The ARIS offers personalized feedback based on patient-reported outcomes and continuously adjusts treatment recommendations through an algorithm. These tools support better symptom management, adherence to medication, and overall improvement in quality of life.
215144572|NCT06590948|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system
215144573|NCT06601725|DIAGNOSTIC_TEST|Clusterin level|Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
215144574|NCT06602622|DRUG|Integrase inhibitor|Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
215144575|NCT06602622|DRUG|Doravirine + tenofovir DF + lamivudine|Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
215144576|NCT06587022|RADIATION|Target volume delineation|Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
215144577|NCT06599970|OTHER|No intervention|This is an observational study. No experimental interventions included. The mobility of people will be studied.
215144578|NCT06596837|DEVICE|virtual reality|"The investigators manipulated the following two variables within the experimental design:~Immersion in the virtual environment. This was a nominal variable with two levels: a low-immersive environment (Other group) and a highly immersive environment (Experimental group) using the Cold River application.~Order of virtual reality (VR) deployment during the first session. This was also a nominal variable with two levels: VR during the first part of the dressing change (removing the dressing) and VR during the second part of the dressing change (cleaning the wound and applying a new dressing). In each subsequent session, the order of VR deployment was swapped for each participant.~The values of both variables were assigned to participants according to their numbers (e.g., 1. highly immersive, VR first; 2. low immersive, VR first; 3. highly immersive, VR last; 4. low immersive, VR last, etc.)."
215144579|NCT06592105|PROCEDURE|Endovascular aortic aneurysm repair (EVAR)|Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
215144580|NCT06587178|DIETARY_SUPPLEMENT|peptison liquid|CD patients requiring bowel resection and preoperative EEN were randomized to receive peptison liquid for 6 weeks.
215144581|NCT06587178|DIETARY_SUPPLEMENT|Enteral nutritional suspension|CD patients requiring bowel resection and preoperative EEN were randomized to receive enteral nutritional suspension for 6 weeks.
215144582|NCT06588998|DEVICE|Xengenic Cortical membranes|soft tissue surgery around dental implant dehiscence
215144583|NCT06588998|PROCEDURE|connective tissue graft|soft tissue surgery around dental implant dehiscence
215144584|NCT06590597|BEHAVIORAL|EDUCATIONAL INTERVENTION FOR MALARIA PREVENTION|The intervention consisted of 4 modules administered in the same number of face-to-face sessions in which educational strategies such as classes, guided discussions, workshops and a booklet designed for the study were used.
215144585|NCT06603350|OTHER|No intenvention|No intenvention
215144586|NCT06596564|BEHAVIORAL|choice architecture|Display the sugar content of the drink on the platform.
215144587|NCT06596564|BEHAVIORAL|choice architecture|Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.
215144588|NCT06596564|BEHAVIORAL|choice architecture|The platform shows the information that the majority of their peers have chosen mineral water.
215144589|NCT06597851|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
215144590|NCT06597851|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic Clamp test|Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
215144591|NCT06612060|PROCEDURE|Cardiac surgery with the use of extracorporeal circulation|All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.
215144592|NCT06992180|BEHAVIORAL|Generative Artificial Intelligence Intervention|The intervention is delivered via a generative artificial intelligence platform called Emohaa. Participants will register and gain access to the platform prior to the start of the trial. Emohaa's responses are based on Hill's helping skills theory in psychology and are designed to simulate the basic communication strategies of a human counselor. The system demonstrates strong capabilities in active listening, emotional mirroring, and empathy, supporting users in understanding their own thoughts and feelings, learning to cope with emotional challenges, and achieving a more optimistic and positive mental and emotional state.
215144593|NCT06992180|BEHAVIORAL|Individual Psychological Counseling|Participants in the traditional counseling group will receive individual psychological counseling sessions conducted by certified psychotherapists.
214457282|NCT06545214|PROCEDURE|2 Hypercapnic challenges while participant is sleeping|"In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance."
214457283|NCT06545214|PROCEDURE|Auditory stimulus|Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.
214457284|NCT06545214|OTHER|Questionnaires|Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS
214457285|NCT04022850|BEHAVIORAL|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
214528793|NCT02883140|OTHER|Three-dimensional sialography CBCT and MRI sialography|"1. MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~2. 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
215144594|NCT06992700|DEVICE|Dynamic perturbation-based intervention|The patient will be asked to perform simple motor tasks while wearing the glove at home under remote supervision of the staff involved in the study. In this way, in order to complete the task, the patient will be forced to overcome the elastic force and perform the movement with greater control. What is innovative compared to the common application of this device is its purpose: specifically, the orthosis will be used by applying resistance to the distal phalanx of the fingers of the hand characterised by a stenic deficit. Contrary to the usual application, which involves the use of this device to facilitate deficient movements, it is hypothesised that the application of resistance will induce the central nervous system (CNS) to create alternative strategies offering them the variety and difficulty necessary to stimulate adaptation without subjecting them to stress resulting from sudden and excessive levels of challenge.
214457286|NCT04022850|BEHAVIORAL|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
214457287|NCT04022850|BEHAVIORAL|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
214457288|NCT05222451|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
214457289|NCT05222451|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
214528794|NCT03586752|OTHER|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
214528795|NCT03586752|OTHER|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
215144595|NCT06992700|OTHER|Exercises without dynamic perturbations|Patients in this group will perform the exercises at home with the paretic upper limb wearing the orthosis (to stabilise the wrist and eliminate this possible confounding variable), but without the springs that determine resistance (i.e., eliminating the elastic resistance that is the subject of this study);
215144596|NCT06992115|BEHAVIORAL|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet|A dietary pattern which promotes the intake of olive oil, fish, leafy greens \& other vegetables, fruits, whole grains, and legumes, and discourages processed foods, red meat, and sugar.
215144597|NCT06992115|BEHAVIORAL|Small Group|Education and social support on topics related to multiple sclerosis such as disease-modifying therapies and MRI in MS.
215144598|NCT06992661|DRUG|ICF004 inhaled powder|"ICF004 is an investigational inhaled powder formulation containing epigallocatechin gallate (EGCG), the most biologically active polyphenol component derived from green tea extract. Developed for targeted pulmonary delivery, ICF004 utilizes a proprietary RS01 dry powder inhaler device to achieve localized therapeutic effects in lung tissue while minimizing systemic exposure.~The formulation consists of micronized EGCG (≥90% purity) in precisely dosed capsules (1mg or 4mg per unit). Preclinical studies demonstrate that inhaled administration achieves 10-20× higher lung concentrations compared to oral dosing, with correspondingly lower plasma levels - potentially reducing the hepatotoxicity risk associated with high oral EGCG doses (European Food Safety Authority recommends \<800mg/day orally)."
215144599|NCT06992661|DRUG|Oral Teavigo® capsules|Teavigo® is a standardized, high-purity epigallocatechin gallate (EGCG) supplement developed by DSM Nutritional Products. The oral capsules contain ≥94% pure EGCG extracted from green tea (Camellia sinensis), making them one of the most concentrated commercially available EGCG formulations.
215144600|NCT06992973|RADIATION|Treatment based on stereotactic radiosurgery|"Treatment based on stereotactic radiosurgery fractionated within 48-72, followed by surgery for symptomatic brain lesions, amenable to surgical treatment, associated or not with a maximum of 3 additional smaller metastatic brain lesions. The dose will be 27 Gy in three fractions (9 Gy per fraction) on alternate days.~If other lesions are present, up to a maximum of 3 lesions and a total volume of 35 cc, these will be treated with radical stereotactic radiosurgery according to guidelines."
215144601|NCT06991582|BIOLOGICAL|Injectable composite resin restoration|Injectable composite Beautifil flow Plus X (Shofu INC., Koyoto, Japan)
215144602|NCT06991582|BIOLOGICAL|packable composite|Packable Composite Beautifil II (Shofu INC., Koyoto, Japan)
215144603|NCT06992206|OTHER|Metabolik taş analizi ile retrospektif gözlem|This study did not involve an active intervention. It retrospectively analyzed medical records of 506 patients who underwent compositional analysis of kidney stones to identify metabolic abnormalities. The aim was to evaluate stone composition in relation to metabolic parameters such as serum and 24-hour urine values, without modifying patient treatment.
214457290|NCT05222451|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
214457291|NCT00179829|PROCEDURE|WT 1 Testing|
214528796|NCT00447629|DRUG|PPM-204|
214528797|NCT02931240|DEVICE|Revivent TC|Treatment of LV scar
214528798|NCT02895854|RADIATION|Hypofractionated RT 5 x 7,25 Gy|
214457292|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
214457293|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
214457294|NCT06479486|DIAGNOSTIC_TEST|Assigned Interventions|warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
214457295|NCT04057638|PROCEDURE|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
214457296|NCT04152655|DRUG|Idebenone|30mg tablets three times a day
214457297|NCT04152655|DRUG|Placebo oral tablet|placebo tablets three times a day
214457298|NCT01987895|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
215144604|NCT06991881|OTHER|Biobank sampling for new biomarkers|Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies.
215144605|NCT06992336|DRUG|Anlotinib ,|Anlotinib 8mg qd PO，357days
215144606|NCT06992336|DRUG|Benmelstobart|Benmelstobart 200mg i.v. Q3W
215144607|NCT06992336|DRUG|Capecitabine|Capecitabine 1000 or 1250 mg/m2 BID day1-14
215144608|NCT06992219|OTHER|Non surgical periodontal treatment evaluated through probing pocket depth reduction|Patients were treated with Minimally invasive non surgical treatment (MINST) or quadrant-subgingival instrumentation (Q-SI). The efficacy of treatment in both groups was evaluated through Probin Pocket Depth reduction in millimetres measurement before and after treatment.
215144609|NCT06992388|OTHER|Manual Therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
215144610|NCT06992388|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
215144611|NCT06992388|OTHER|Tape elastic|The following intervention will be performed: application with an elastic band
215144612|NCT06992453|OTHER|Fecal microbiota transplantation (FMT)|Patients will receive a first donor FMT by colonoscopy, after a pre-conditioning with vancomycin and neomycin + bacitracin for 3 days, because data from our group show that pre-FMT antibiotics are associated with higher rates of microbial engraftment. Then they will receive two cycles, respectively after 3 and 7 days after colonoscopy - FMT, of frozen donor FMT capsules (15 capsules b.i.d. per 3 days). Patients will always receive feces from the same donor.
214457299|NCT01987895|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
214457300|NCT01987895|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
215144613|NCT06991933|BEHAVIORAL|Plastination Model Group|"Model Specifications:~S10 silicone plastination models of brainstem structures (1:1 scale) with:~• Sectioned at 2mm intervals to reveal internal architecture"
215144614|NCT06991933|BEHAVIORAL|Traditional Methods Group|"1. Netter's Atlas of Human Anatomy (9th ed.)~2. Standardized PowerPoint lectures"
215144615|NCT06587867|BIOLOGICAL|efgartigimod|active drug efgartigimod to be administer
215144616|NCT06600841|DRUG|Immunotherapy（Adebrelimab）|Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
215144617|NCT06600841|DRUG|immunotherapy（Adebrelimab）|anti-PD-L1
214457301|NCT01987895|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
214457302|NCT06107010|DEVICE|Use of the Atalante exoskeleton|Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
214457303|NCT04696185|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 mg (daily oral dose)
214528799|NCT02895854|RADIATION|LDR-brachytherapy with I125 seeds|
214528800|NCT01955720|DRUG|BI 655075|
215144618|NCT06999473|DEVICE|Virtual reality training|This training is built for the HMD Pico 4 Enterprise, which has six degrees of freedom, a 4k RGB display, a 101-degree field of view, and built-in eye-tracking hardware and software. The virtual environment is a 3-dimensional immersive environment in which the participant will be placed in three different virtual scenes: a picnic table, a kitchen, and a playground. This allows for the placement of stimuli in three different regions: near peripersonal (reaching) space, far peripersonal space, and extrapersonal (far) space. The goal of the game is to search for items that appear in front of the view, as accurately and quickly as possible.
215144619|NCT06999473|BEHAVIORAL|physiotherapy and occupational therapy|The conventional treatment consists of a problem-solving approach mainly based on the neurodevelopmental treatment approach. For VSN, the conventional treatment mainly consists of a mix of prism adaptation, visual scanning, and compensatory strategies based on the individual needs of the patient.
214457304|NCT04325035|DRUG|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
214457305|NCT04325035|DRUG|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
214457306|NCT06807788|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
214457307|NCT06060782|DRUG|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
214528801|NCT01955720|DRUG|BI 655075|
214457308|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
214457309|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
214457310|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
214457311|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
214457312|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
214457313|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
214528802|NCT01955720|DRUG|Placebo|
214528803|NCT01955720|DRUG|BI 655075|
214528804|NCT01955720|DRUG|Placebo|
214528805|NCT01955720|DRUG|Placebo|
214528806|NCT01955720|DRUG|Placebo|
214457314|NCT05956756|BEHAVIORAL|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
214528807|NCT01955720|DRUG|BI 655075|
214457315|NCT04682691|DRUG|Erythromycin (400mg)|oral Erythromycin (400mg)
214457316|NCT04682691|DRUG|metoclopramide (10mg)|oral metoclopramide (10mg)
214457317|NCT04682691|DIETARY_SUPPLEMENT|naturally flavored water|naturally flavored water
214457318|NCT05364671|DRUG|Raphamin|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
214457319|NCT05364671|DRUG|Placebo|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
214457320|NCT05317611|DRUG|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
214528808|NCT05281419|OTHER|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
214528809|NCT05281419|OTHER|No intralesional triamcinolone injection|No intralesional triamcinolone injection
214528810|NCT00162058|DRUG|Peflutren Lipid Microsphere Injectable Suspension|
214528811|NCT01386411|GENETIC|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
214528812|NCT00191984|DRUG|pemetrexed|400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
214528813|NCT00191984|DRUG|irinotecan|180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
214528814|NCT05112172|OTHER|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
214528815|NCT02137239|DRUG|Thymoglobulin|
214528816|NCT02137239|DRUG|Belatacept|
214528817|NCT02137239|DRUG|mycophenolate mofetil(MMF)|
214528818|NCT02137239|DRUG|Corticosteroids|
214528819|NCT02137239|DRUG|Everolimus(EVL)|
214528820|NCT02137239|DRUG|Tacrolimus(TAC)|
214528821|NCT06254079|PROCEDURE|video based education|The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
214528822|NCT03595826|DRUG|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
215144620|NCT06999473|DEVICE|Assessment|During assessments with SpatialSense, participants will sit in a wheelchair or on a straight-back chair. The trunk will be restricted to the chair. Finally, the data will be exported from SpatialSense and analyzed by investigators to define different search strategies while performing scanning tasks.
214457321|NCT05317611|DRUG|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
214528823|NCT00019136|BIOLOGICAL|MOv-gamma chimeric receptor gene|
214528824|NCT00019136|BIOLOGICAL|aldesleukin|
214528825|NCT00019136|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214528826|NCT05682040|DIAGNOSTIC_TEST|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
214528827|NCT02042625|PROCEDURE|Nasopharyngeal|
214528828|NCT02970721|DRUG|Antipsychotic|Antipsychotic monotherapy
214528829|NCT02970721|DRUG|Antidepressant|Antidepressant monotherapy
214528830|NCT02970721|DRUG|Antipsychotic and Antidepressant|Polytherapy
214528831|NCT00437619|DRUG|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
214528832|NCT02961777|OTHER|implementation of care pathway|implementation of a care pathway
214457322|NCT05317611|DRUG|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
214457323|NCT06413810|OTHER|Calmarell|Food ingredient
214457324|NCT06413810|OTHER|Placebo|Blinded placebo
215144621|NCT06999148|PROCEDURE|Sonodynamictherapy|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day1to day 5, followed by a 23-day rest period. Each cycle lasts 28 days. If well-tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
215144622|NCT06999148|DRUG|Radiotherapy plus temozolomide|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
215144623|NCT06597708|BEHAVIORAL|keto diet|They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively.
215144624|NCT06597708|BEHAVIORAL|intermittent fasting with calorie restriction|The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period.
214457325|NCT02359890|DEVICE|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
215144625|NCT06998862|DRUG|colchicine treatment in chronic kidney disease patients|colchicine treatment 0.5 mg/day
215144626|NCT06998862|DRUG|placebo treatment|placebo treatment 1 pill/day
215144627|NCT06999291|BEHAVIORAL|Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)|The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.
215144628|NCT06999096|DIAGNOSTIC_TEST|Long-read whole genome sequencing|Pseudonymized blood samples will undergo high-molecular-weight DNA extraction, followed by long-read whole-genome sequencing (lrWGS) using Oxford Nanopore technology. Index cases will be sequenced at high depth (\>30X), while relatives will be multiplexed (\>15X). Sequencing data will be analyzed through a dedicated bioinformatics pipeline to detect SNVs, indels, structural variants, and repeat expansions. Results will be interpreted by expert teams and discussed in monthly clinical-genetic meetings. Variants of interest will be validated by appropriate molecular techniques, and family segregation will be assessed when relevant.
215144629|NCT06998706|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
215144630|NCT06997913|COMBINATION_PRODUCT|Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）|The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.
214457326|NCT01762462|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214457327|NCT04755517|OTHER|Frequent information of cytological/ HPV DNA screening results|"All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end."
214457328|NCT06772870|DRUG|DT-216P2|DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
214457329|NCT06772870|DRUG|Saline|Normal saline solution will be used as placebo control.
214528833|NCT00139659|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
214457330|NCT05090033|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214457331|NCT02356653|DEVICE|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
214457332|NCT04750200|PROCEDURE|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
215144631|NCT06586307|OTHER|quantitative analysis of DNA methylation at single-base resolution (QASM)|qPCR-based quantitative analysis for single-base methylation (QASM) The methylation percentage of each candidate CpG site was determined in multiple cohorts using a MethyLight-based QASM assay that has been developed and validated in our previous work. In short, the bisulfite-converted DNA was amplified, in which we exploited the locus-specific PCR primers flanking a pair of methylated and unmethylated probes labeled with the fluorescent dyes 6-carboxyfluorescein (6-FAM) and 2-chloro-7phenyl-1,4-dichloro-6-carboxyfluorescein (VIC), respectively. The methylation percentage was calculated by methylation/(methylation+unmethylation)×100%. QASM was performed using the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (Thermo).
214457333|NCT05256017|DRUG|Acoziborole|Single dose administration of acoziborole (3 tablets of 320 mg) on Day 1
214457334|NCT05256017|DRUG|Placebo|Single dose administration of placebo (3 tablets of 320 mg) on Day 1
214457335|NCT06770530|DRUG|Fluconazole|400 mg inravenous Fluconazole, single dose 200 ml
214457336|NCT06770530|DRUG|Isotonic saline solution|Intravenous saline solution, single dose 200 ml
214457337|NCT05782582|DIAGNOSTIC_TEST|Package investigation|Investigations performed on a single visit, according to arm description
214457338|NCT05782582|DEVICE|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
214457339|NCT05782582|DIAGNOSTIC_TEST|Standard investigation|Sequential investigations according to arm description
214457340|NCT05757778|PROCEDURE|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
214457341|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
214457342|NCT06766487|BEHAVIORAL|Tongue resistance exercises|"The TRE program consisted of the following exercises:~Exercise 1: Tongue Protrusion and Retraction Against Resistance, Exercise 2: Anterior Tongue Protrusion and Retraction Against Resistance, Exercise 3: Middle Tongue Protrusion and Retraction Against Resistance, Exercise 4: Middle Tongue Elevation with Pharyngeal Sound Production, Exercise 5: Tongue Elevation and Posterior Sweeping, and Exercise 6: Saliva Swallowing with Lip Closure."
214457343|NCT06766487|BEHAVIORAL|cheek bulging exercises|Cheek bulging exercises involved a series of movements: Lip Closure: Participants began by closing their lips. Unilateral Cheek Bulging: They then bulged their right cheek, followed by relaxation and return to the initial position. This was repeated on the left side. Bilateral Cheek Bulging: Finally, participants bulged both cheeks simultaneously.
214457344|NCT04018859|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
214457345|NCT04018859|DRUG|Saline|intradermal injections to the eyebrows
214457346|NCT05368402|DRUG|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) were administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules were swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
214457347|NCT05368402|OTHER|Placebo|Placebo was administered with the same ladarixin schedule.
214457348|NCT05780437|BIOLOGICAL|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
214528834|NCT00139659|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
214528835|NCT06209905|PROCEDURE|Alveolar ridge augmentation|Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
214528836|NCT01341418|PROCEDURE|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
214528837|NCT01341418|PROCEDURE|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
214528838|NCT04728659|DRUG|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
214528839|NCT04728659|DRUG|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
214457349|NCT05780437|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
214457350|NCT05780437|BIOLOGICAL|Remdesivir|Antiviral agent
214457351|NCT03947190|BIOLOGICAL|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
214457352|NCT03947190|BIOLOGICAL|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
214457353|NCT03947190|BIOLOGICAL|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
214457354|NCT04015167|DEVICE|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
214457355|NCT06584812|DRUG|Tiprogrel|Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
215144632|NCT06999915|PROCEDURE|Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the test group, bone augmentation will be performed by adding biomaterial 3 mm beyond the Individual Phenotypical Dimension (IPD) to achieve over-contour augmentation. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth.
215144633|NCT06999915|PROCEDURE|Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the control group, bone augmentation will be performed by adding biomaterial up to the IPD line in order to achieve a contour augmentation with bone grafting remaining within the boundaries defined by the IPD. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth
215144634|NCT06587048|PROCEDURE|periapical surgery|In piezo group, the periapical surgery will be performed using piezoelectric device.
215144635|NCT06587048|PROCEDURE|periapical surgery|In conventional bur group, the periapical surgery will be performed using rotary burs.
215144636|NCT06591169|BEHAVIORAL|diet restriction and exercise|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes
215144637|NCT06591169|BEHAVIORAL|diet restriction|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily) and program of low diet intake
215144638|NCT05370495|DRUG|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
215144639|NCT05370495|DRUG|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
215144640|NCT05370495|DRUG|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
215144641|NCT05370495|DRUG|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
215144642|NCT02514083|DRUG|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
214457356|NCT06584812|DRUG|Tiprogrel|Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
214457357|NCT06584812|DRUG|Clopidogrel|Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.
214528840|NCT03048058|DRUG|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
214528841|NCT03048058|DRUG|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
214528842|NCT00924209|DRUG|Gemcitabine|1250 mg/m\^2 dose for two doses on days 1 and 8
214528843|NCT00924209|DRUG|Cisplatin|80 mg/m\^2 on day 1
214528844|NCT00924209|DRUG|Bevacizumab|7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
214528845|NCT00924209|PROCEDURE|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
214528846|NCT00924209|DRUG|Etoposide|100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
214528847|NCT01654835|OTHER|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
214457358|NCT06584812|DRUG|Ticagrelor|Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.
214457359|NCT04265950|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214457360|NCT03092635|DRUG|OPC|OPC is a derivative of grape seed extract
214457361|NCT05192863|OTHER|No Intervention|This is a non-interventional study.
214457362|NCT05564221|DRUG|YH35324|Subcutaneous injection of YH35324
214528848|NCT01654835|OTHER|standard of care|A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
214528849|NCT00333554|DIETARY_SUPPLEMENT|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
214528850|NCT00333554|DIETARY_SUPPLEMENT|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
214528851|NCT00966056|DRUG|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
214528852|NCT00966056|DEVICE|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
214528853|NCT03856645|DRUG|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
215144643|NCT02514083|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
215144644|NCT06156514|DRUG|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
215144645|NCT06156514|DRUG|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
215144646|NCT06591494|DRUG|Classic quadruple therapy|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
215144647|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of bismuth|Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID
215144648|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of clarithromycin|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
215144649|NCT06601426|PROCEDURE|CSP|cold snare polypectomy
215144650|NCT06599164|OTHER|Anthrogenic Muscle Inhibition (AMI) Assessment Protocol|This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.
215144651|NCT06585956|BEHAVIORAL|Comminication via Telemedicine|Comminication via Telemedicine With Patients
215144652|NCT06585956|BEHAVIORAL|Information|Informing the patient and their relatives
215144653|NCT06601985|PROCEDURE|J-pouch anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
215144654|NCT06601985|PROCEDURE|direct anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
215144655|NCT06771076|OTHER|Cream with CBD and natural ingredients|Topical application of the cream with CBD and natural ingredients on the injured areas, twice per day (after waking up, and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
215144656|NCT06771076|OTHER|Cream without CBD and natural ingredients|Topical application of the cream without CBD and natural ingredients on the injured areas, twice per day (after waking up and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
215144657|NCT06896708|DRUG|Intensive lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation. If the target LDL-C level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
215144658|NCT06896708|DRUG|Standard lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin, and the type and dosage of drugs can be adjusted according to the situation. If the target L-DLC level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
215144659|NCT03913507|DEVICE|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
215144660|NCT00265993|DRUG|enoxaparin|"* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
215144661|NCT04165577|DEVICE|rTMS|1-Hz rTMS targeting frontal pole
215144662|NCT04165577|DEVICE|sham rTMS|sham rTMS targeting frontal pole
215144663|NCT04240535|DRUG|OnabotulinumtoxinA 50 UNT [Botox Cosmetic]|Injections to the Depressor Anguli Oris
214528854|NCT04232475|OTHER|1 minute of stair climbing and descending|1 minute of stair climbing and descending
215144664|NCT00890123|DIETARY_SUPPLEMENT|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
215144665|NCT04259814|BEHAVIORAL|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
215144666|NCT04259814|BEHAVIORAL|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
215144667|NCT02750917|DRUG|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
215144668|NCT02750917|DRUG|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
214528855|NCT04232475|OTHER|3 minute of stair climbing and descending|3 minute of stair climbing and descending
214528856|NCT04232475|OTHER|10 minute of stair climbing and descending|10 minute of stair climbing and descending
214528857|NCT04488809|OTHER|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
214528858|NCT06194786|BEHAVIORAL|Group D|Usual care
214528859|NCT01110551|DRUG|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
214528860|NCT01110551|DRUG|Placebo (ID)|Phosphate buffered saline administered intradermally.
215144669|NCT04942821|PROCEDURE|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
215144670|NCT04942821|PROCEDURE|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
214457363|NCT05564221|DRUG|Placebo|Subcutaneous injection of None of active ingredient
214457364|NCT05564221|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
214457365|NCT04493645|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
214457366|NCT04493645|BEHAVIORAL|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
214457367|NCT03198702|DRUG|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
214457368|NCT03198702|OTHER|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
214457369|NCT03536754|OTHER|Placebo|Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
214457370|NCT03536754|DRUG|CCX140-B|One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
214457371|NCT03536754|DRUG|CCX140-B|Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
214457372|NCT03536754|DRUG|CCX140-B|Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
214457373|NCT03452579|DRUG|Nivolumab|240mg
214457374|NCT03452579|DRUG|Standard Dose Bevacizumab|10mg/kg
214528861|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
214457375|NCT03452579|DRUG|Low Dose Bevacizumab|3mg/kg
214457376|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
214457377|NCT05300464|DEVICE|Clinical investigation medical device class IIa marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
214457378|NCT03167177|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214457379|NCT03167177|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
214457380|NCT03167177|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214457381|NCT03167177|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214457382|NCT03167177|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214457383|NCT03167177|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214457384|NCT03167177|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214457385|NCT03167177|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214457386|NCT03167177|BIOLOGICAL|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
214457387|NCT03167177|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
214457388|NCT03167177|RADIATION|Stereotactic Body Radiation Therapy|radiation
214457389|NCT03167177|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214457390|NCT03167177|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
215144671|NCT04581213|PROCEDURE|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
215144672|NCT01963416|DIETARY_SUPPLEMENT|macro- and micro-nutrient matched control (240 ml)|
215144673|NCT01963416|DIETARY_SUPPLEMENT|Orange juice|
215144674|NCT01963416|DIETARY_SUPPLEMENT|whole orange fruit|
215144675|NCT01963416|DIETARY_SUPPLEMENT|Processed whole orange|
215144676|NCT04687982|BIOLOGICAL|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
215144677|NCT06339372|DIETARY_SUPPLEMENT|Standard feeding|Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20\_35% from fats and 10-35% from protein)
215144678|NCT06339372|DIETARY_SUPPLEMENT|Omega 3 and dipeptiven|Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
214457391|NCT03167177|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214457392|NCT03167177|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
214457393|NCT03167177|BIOLOGICAL|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
214457394|NCT03167177|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
214457395|NCT03167177|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
214457396|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
214457397|NCT03382652|DEVICE|Metal-on-Metal Articulation|\<Metal-on-Metal Articulation\>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component\>:Continuum Acetabular Shell, \<Femoral Component\>: Zimmer® M/L Taper Hip Stem
215144679|NCT06465628|BEHAVIORAL|Self-administered acupressure|The participants should perform self-administered acupressure 12 weeks after training
215144680|NCT06465628|OTHER|Oral health education|The participants should perform general oral care by themselves after the oral health education relating to xerostomia
215144681|NCT05668052|OTHER|questionnaire|This survey was conducted in Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 2022 to December 2023. The research objects were patients with COVID-19.
215144682|NCT02415413|DRUG|carfilzomib|
215144683|NCT02415413|DRUG|Lenalidomide|
215144684|NCT02415413|DRUG|Dexamethasone|
215144685|NCT02415413|DRUG|Melphalan|
215144686|NCT02230995|DRUG|metformin|single dose of metformin given as tablets
215144687|NCT02230995|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
215144688|NCT02230995|DRUG|empagliflozin|single dose of empagliflozin given as tablet
215144689|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
215144690|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
215144691|NCT06137417|DEVICE|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
215144692|NCT05663606|COMBINATION_PRODUCT|Happy Bob|Application, which gives stars when subject reachs Time In Range
215144693|NCT05663606|DEVICE|CGM|Dexcom CGM
214457398|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
214457399|NCT06109194|OTHER|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
214457400|NCT02658565|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
215144694|NCT00740311|DEVICE|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
214457401|NCT06451549|DEVICE|Syndi recommender system for mental health apps|Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
214457402|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
214457403|NCT04919057|DEVICE|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
215144695|NCT05650385|DRUG|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
215144696|NCT01699438|DRUG|Mesalazine|2400 mg q.d. for 8 weeks
215144697|NCT01699438|DRUG|Placebo|3 tablets q.d. for 8 weeks
215144698|NCT00104286|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
215144699|NCT04349332|DEVICE|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate \<30breaths/min and PaO2 \>75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
215144700|NCT04053660|PROCEDURE|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
215144701|NCT04643210|BEHAVIORAL|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
215144702|NCT04643210|OTHER|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
215144703|NCT05483777|PROCEDURE|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
215144704|NCT05322681|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
215144705|NCT03510546|DRUG|Pyridostigmine|Study dose as per protocol.
215144706|NCT03510546|DRUG|Placebo oral capsule|Study dose as per protocol.
215144707|NCT02141295|DRUG|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
215144708|NCT02141295|DRUG|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
215144709|NCT02141295|DRUG|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
215144710|NCT02141295|DRUG|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
215144711|NCT02141295|DRUG|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
215144712|NCT00551811|DRUG|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
214457404|NCT04858321|PROCEDURE|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
214457405|NCT06780371|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels.~Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
214457406|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
214528862|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
214528863|NCT01309555|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
214528864|NCT02359552|DRUG|Rasagiline|
214528865|NCT02359552|DRUG|Placebo|
214528866|NCT02391116|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
215144713|NCT00551811|DRUG|Placebo|Placebo tablets will be intended to be administered orally.
215144714|NCT03902977|PROCEDURE|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
214457407|NCT06482528|OTHER|Motor Imagery|"After the measurement devices are connected to the individuals, they will be seated in a comfortable chair.~After the calibration of the devices, individuals will undergo a 2-minute relaxation session. During the relaxation session, individuals will be asked to focus on their breathing and relax as much as possible.~Then, heart rate variability, electrodermal activities and respiratory frequencies of the individuals will be measured in a sitting position for 5 minutes. In case of rest, after taking the variables, individuals will be kept to rest for 10 minutes.~After 10 minutes, the devices will be placed on the individuals again and a 2-minute relaxation session will be held.~Then, individuals will be asked to imagine running through kinesthetic imagery for 5 minutes.~Feedback will be given to individuals throughout the entire session. These feedbacks will be given verbally with an audio recording prepared by the physiotherapist."
214457408|NCT05925855|OTHER|US with fastum|apply fastum on trigger point with US
214457409|NCT05925855|OTHER|US with reparil|apply reparil on trigger point with US
214457410|NCT05925855|OTHER|US with plain gel|apply gel on trigger point with US
214457411|NCT06419712|DRUG|vitamin D (cholecalciferol) supplementation|This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
214457412|NCT03866109|DRUG|Temferon|Genetically modified HSPCs
214457413|NCT06141187|PROCEDURE|Vertebroplasty|PVP
214457414|NCT06141187|PROCEDURE|Sham Vertebroplasty|Sham PVP
214457415|NCT06360757|DIAGNOSTIC_TEST|NeuMoDx SARS-CoV-2 Assay|The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
214457416|NCT04810650|OTHER|Mobility Dynamic Treatment Intervention|"1\) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
214457417|NCT04810650|OTHER|Health Living Intervention for Heavy Alcohol Users|1\) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
214457418|NCT04810650|OTHER|Hypertension Linkage|1\) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
214457419|NCT04810650|OTHER|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
214528867|NCT06537219|OTHER|Assessment|Assessment of pain severity,pain thresold of the fascia, pain sensitivity
214528868|NCT05615896|DEVICE|Imaging Session|Various scans will be captured on both devices
214528869|NCT06454071|OTHER|Blood test|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
214528870|NCT02572999|PROCEDURE|Not applicable (observational design)|
214528871|NCT05492123|DRUG|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
214528872|NCT05492123|DRUG|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
214528873|NCT05492123|RADIATION|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
214528874|NCT00399659|DRUG|Tegaserod|
214528875|NCT05261347|PROCEDURE|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
214528876|NCT05261347|PROCEDURE|sham|a lateral glide
214528877|NCT02520414|DEVICE|Symphion® Bipolar Hysteroscopic Tissue Resection System|
215144715|NCT03902977|PROCEDURE|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
215144716|NCT01710501|DRUG|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
215144717|NCT01710501|BIOLOGICAL|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
214528878|NCT03451526|PROCEDURE|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
214528879|NCT02580214|DIETARY_SUPPLEMENT|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
214528880|NCT06073444|DEVICE|Picterus JP|Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
215144718|NCT01710501|DRUG|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
215144719|NCT01710501|DRUG|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
215144720|NCT06185543|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
215144721|NCT06185543|DRUG|Placebo|Placebo matches active drug in size, color and taste
215144722|NCT02536976|DRUG|mirabegron|
215144723|NCT02536976|DRUG|Placebo|
214457420|NCT04810650|OTHER|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
214457421|NCT04810650|OTHER|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
214528881|NCT02282917|DRUG|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
214528882|NCT01747629|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
214528883|NCT01747629|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
214528884|NCT00794911|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
214528885|NCT00794911|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
214528886|NCT03830515|DEVICE|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
214528887|NCT06398171|OTHER|Exercise|Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
214528888|NCT05834361|DRUG|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
214528889|NCT05834361|DRUG|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
214528890|NCT05469763|OTHER|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week."
214528891|NCT04691336|BEHAVIORAL|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
214528892|NCT05192226|BEHAVIORAL|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
214528893|NCT05440578|DRUG|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
214528894|NCT03081351|PROCEDURE|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
214528895|NCT03081351|PROCEDURE|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
214457422|NCT04810650|OTHER|Standard of Care|Local country standard of care protocols
214528896|NCT06293014|DRUG|TAS-102+bevacizumab|TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
214528897|NCT06293014|DRUG|Standard chemotherapy+bevacizumab|Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
214528898|NCT06263296|BEHAVIORAL|Self Management Education|Smartphone assisted self management education incorporated with the concept of motivational interviewing
214528899|NCT00400257|BEHAVIORAL|Early detection of heart failure|Early detection of heart failure
214528900|NCT01395914|DRUG|Anamorelin HCl|
214528901|NCT01395914|DRUG|Placebo|
214528902|NCT02605772|DRUG|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
214528903|NCT02605772|DRUG|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
214528904|NCT02605772|DRUG|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
214528905|NCT00700518|DRUG|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
214457423|NCT04810650|OTHER|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
214457424|NCT05868902|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
214457425|NCT03763604|DRUG|Abemaciclib|Administered orally.
214457426|NCT03682250|DEVICE|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
214457427|NCT03682250|DEVICE|Holter monitor|A Holter monitor will be used to measure heart's activity
214457428|NCT05794243|DRUG|LY3493269|Administered orally.
214457429|NCT05794243|DRUG|Sodium Caprate (C10)|Administered orally.
214457430|NCT05794243|DRUG|Salcaprozate Sodium (SNAC)|Administered orally.
214457431|NCT05935527|DRUG|POLAT-001|Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
214457432|NCT05935527|DRUG|Placebo|Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
214457433|NCT03099499|DRUG|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
214457434|NCT06688448|DEVICE|Dafodil prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
214457435|NCT06688448|DEVICE|Aortic Valve Replacement - Inspires Resilia prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
214528906|NCT00700518|DRUG|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
214457436|NCT03942419|DRUG|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered with a microdose dispenser
214457437|NCT03942419|DRUG|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered with a microdose dispenser
214457438|NCT03942419|DRUG|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered with a microdose dispenser
214457439|NCT05733975|OTHER|Decision Making Guide|The tool includes a brief introduction to the tool and decision-making, a values clarification exercise, and a question prompt list.
214457440|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
214457441|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 100mcg
214457442|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
214457443|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 500mcg
214528907|NCT00700518|DRUG|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
214528908|NCT00700518|DRUG|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
214528909|NCT00700518|DRUG|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
214528910|NCT02802579|RADIATION|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
214457444|NCT05999565|OTHER|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
214528911|NCT02802579|RADIATION|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
214528912|NCT02802579|RADIATION|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
214528913|NCT06196073|OTHER|Osteopathic manual therapy|Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
214528914|NCT06196073|DIETARY_SUPPLEMENT|conservative treatment|Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
214528915|NCT02316145|BEHAVIORAL|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
215144724|NCT03053817|OTHER|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
215144725|NCT00071890|DRUG|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
215144726|NCT00071890|DRUG|HAART|HAART from week 0 to week 24
215144727|NCT00071890|DRUG|Treatment interruption|HAART is interrupted from week 24 in both arms
215144728|NCT01671319|DRUG|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
215144729|NCT01709084|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
215144730|NCT01709084|DRUG|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
215144731|NCT01709084|DRUG|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
215144732|NCT01709084|DRUG|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
215144733|NCT01955252|DRUG|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
215144734|NCT02144610|BIOLOGICAL|HGF Plasmid (AMG0001)|IM
215144735|NCT02144610|BIOLOGICAL|Matching Placebo|IM
215144736|NCT02644499|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
215144737|NCT02644499|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
215144738|NCT02644499|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
215144739|NCT02644499|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
215144740|NCT02644499|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
215144741|NCT03290885|COMBINATION_PRODUCT|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
215144742|NCT03290885|DEVICE|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
215144743|NCT04280250|OTHER|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
215144744|NCT04280250|OTHER|Control condition|Psychoeducational self-help sheet
215144745|NCT01288885|DRUG|ASP1941|Oral
215144746|NCT01288885|DRUG|Placebo|Oral
215144747|NCT00545454|DRUG|SSR150106|
214457445|NCT05999565|OTHER|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
214528916|NCT04414397|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC injectable gel
215144748|NCT00545454|DRUG|Placebos|
215144749|NCT04669626|OTHER|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with Octenilin® on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with Octenilin®~* Application of new dressing (according to the wound healing phases, medical prescription)"
215144750|NCT04669626|OTHER|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
215144751|NCT01453218|DRUG|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
215144752|NCT01639378|PROCEDURE|Renal Denervation|Symplicity Catheter System
215144753|NCT05558202|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
215144754|NCT03056508|BEHAVIORAL|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
214457446|NCT05328687|DIAGNOSTIC_TEST|Shear wave elastography|or measuring the muscle stiffness, we use a linear 9 MHz ultrasound probe (9L) and the Logic E9 scanner, both from GE Healthcare (Chalfont St Giles, UK). All measurements are performed with the probe parallel to the muscle fibers. We will measure the stiffness of the trapezius muscle in the middle botulinum toxin A injection side (G1) according to the PREEMPT protocol. All data are saved as images by the observer and subsequently analyzed by a blinded observer.
214457447|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (face-to-face care)|A Program structured in 28 visits (in group and individual) and 21 contacts (through phone calls or video calls) to guide the improvement of diet quality, self-care, and regular practice of physical activity
214457448|NCT06426277|BEHAVIORAL|Diet|Hypocaloric diet prescription
214457449|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (remote care)|A Program structured in 49 contacts delivered through telehealth (through phone calls or video calls between professional and participant) to guide the improvement of diet quality, self-care, and regular practice of physical activity
214457450|NCT05057247|DRUG|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
214457451|NCT05057247|DRUG|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
214457455|NCT05729945|BEHAVIORAL|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
214457456|NCT06803160|PROCEDURE|Laparoscopic Extravesical Fistula Excision of Uterovesical Fistula|• In extravesical approach, the posterior bladder wall and the anterior uterine wall around the fistula will be dissected. Scar tissue around the orifice of the fistula will be removed and trimmed. After suturing uterine and bladder wall, intervening omentum will be placed in-between.
214457457|NCT06803160|PROCEDURE|Laparoscopic Combined Fistula Excision of Uterovesical Fistula|• In the combined approach, bladder will be opened bivalved till the site of the fistula. Scar tissue around the orifice of the fistula will be removed and trimmed. Careful dissection around the bladder and uterus will be done to suture both walls and place an intervening omentum in-between.
214457458|NCT06473961|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
214528917|NCT04414397|OTHER|No-treatment control|Participants received no treatment for 3 months during the Control Period.
214528918|NCT02031445|DRUG|MRX-6|
214528919|NCT02031445|OTHER|Placebo|
214457459|NCT01093547|PROCEDURE|Blood samples|Samples taken monthly
214457460|NCT01093547|PROCEDURE|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
214528920|NCT05439720|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
214528921|NCT05439720|DIETARY_SUPPLEMENT|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
214528922|NCT05439720|BEHAVIORAL|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
214528923|NCT02502487|PROCEDURE|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
214528924|NCT02502487|DRUG|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
214528925|NCT02502487|DRUG|Tetracaine|1% Tetracaine gel instilled into urethra
214528926|NCT06430151|DEVICE|CUE1|Sternal worn focused vibrotactile stimulation and cueing device
214528927|NCT01150500|DEVICE|MDT-4107 Zotarolimus-Eluting Coronary Stent|
215144755|NCT03056508|BEHAVIORAL|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
215144756|NCT03714152|DRUG|ABI-H2158|5 mg or 25 mg tablets
214457461|NCT06697717|OTHER|Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., \>0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen."
215144757|NCT03714152|DRUG|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
215144758|NCT02169427|DRUG|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
215144759|NCT05360121|OTHER|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
215144760|NCT05360121|OTHER|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
215144761|NCT05360121|OTHER|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
215144762|NCT05360121|OTHER|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
214457462|NCT06697717|OTHER|EIT-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes."
214528928|NCT01920178|DEVICE|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
215144763|NCT05360121|OTHER|Back strengthening exercises|"1. Supine Abdominal Draw In~2. Supine Butt Lift with Arms at Side~3. Abdominal Draw In with Heel Slide~4. Abdominal Draw In with Knee to Chest~5. Abdominal Draw In with feet on the ball~6. Abdominal Draw In with feet on the ball- add movement"
215144764|NCT05360121|OTHER|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
215144765|NCT06342505|PROCEDURE|Venipunctures|Extra venipunctures
215144766|NCT01112839|BEHAVIORAL|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
215144767|NCT01112839|BEHAVIORAL|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
215144768|NCT00214201|DRUG|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
215144769|NCT00274729|BEHAVIORAL|Mono Unsaturated Fatty Acids in Obesity|
215144770|NCT05022732|DIETARY_SUPPLEMENT|Polyglucosamine L112|750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients
215144771|NCT05022732|COMBINATION_PRODUCT|Placebo|excipients and gum arabic
215144772|NCT03038828|BIOLOGICAL|Leukocyte Interleukin, Injection|Immunotherapy
215144773|NCT04667130|BEHAVIORAL|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
214457463|NCT02369770|DEVICE|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
214457464|NCT06803394|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
214457465|NCT06803394|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
214457466|NCT02774421|DRUG|Trastuzumab after SubQ GM-CSF|Administration of trastuzumab following subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Trastuzumab is a monoclonal antibody targeting HER2-positive cancers, commonly used in breast and gastric cancer treatment.
214457467|NCT02774421|DRUG|Trastuzumab in combination with SubQ GM-CSF|Combine trastuzumab, a monoclonal antibody targeting HER2-positive cancers, with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF functions as an immune system modulator, promoting the activation and proliferation of dendritic cells, macrophages, and granulocytes.
214457468|NCT05221671|OTHER|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
214457469|NCT06760403|DRUG|Hypochlorous acid|Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
214457470|NCT06804044|BEHAVIORAL|Intermittent Fasting|A 16:8 intermittent fasting with a daytime eating window model was applied.
214457471|NCT06804044|BEHAVIORAL|Standart Diet Therapy|Meal plan with 3 main meals and 3 snacks was applied.
214528929|NCT03962270|DEVICE|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
215144774|NCT00006206|DRUG|naltrexone (Revia)|
215144775|NCT00006206|DRUG|acamprosate (Campral)|
215144776|NCT03944317|DRUG|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
215144777|NCT03944317|DRUG|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
215144778|NCT02442388|PROCEDURE|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
215144779|NCT02442388|PROCEDURE|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
215144780|NCT02442388|PROCEDURE|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
215144781|NCT04220541|BEHAVIORAL|Motor learning based exercise|Symptomatic exercise
214457472|NCT05024734|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
214457473|NCT05024734|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
214457474|NCT05024734|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
214528930|NCT04931199|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
215144782|NCT02256280|DRUG|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
215144783|NCT02256280|DRUG|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
215144784|NCT03674905|PROCEDURE|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
215144785|NCT03674905|PROCEDURE|Peripheral nerve block|Pre-operative peripheral nerve block.
215144786|NCT01764880|DRUG|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
215144787|NCT05252780|BEHAVIORAL|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
215144788|NCT02805829|DRUG|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
215144789|NCT01399372|BIOLOGICAL|Rituximab|One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
214457475|NCT05024734|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
214457476|NCT06803381|OTHER|Salivary test|"In order to determine the quantity and quality of patients saliva before food tasting a saliva test will be performed using a Saliva-Check BUFFER kit. A small quantity of saliva will be collected and discarded immediately after the test result obtained.~The test will be done only once for each patient."
214457477|NCT06803381|OTHER|Food tasting|Patients will be invited to taste four different food samples, 2 sweet and 2 salty samples, and to evaluate them using a visual analog scale (0 : I don't like at all to 100 : I like a lot). The intervention will be done once for each patient during one of their standard of care treatment visit.
214457478|NCT06803381|OTHER|Questionnaires|Patients will be invited to answer to some questionnaires : socio-demographics, appreciation of food samples, self-assessment of oral symptoms and sensory perceptions, QLQ-C30 quality of life and food quality of life questionnaire. They will answer to all questionnaires only once during participation to the study.
214457479|NCT06803381|OTHER|sensory capacity evaluation|"For the sensory capacity the test 6-n-propylthiouracil (PROP) taste strip will be used. One tasting strip will be placed on the tongue and patients will be asked to assess the intensity of bitterness.~The test will be done only once for each patient."
214457480|NCT06502327|OTHER|Instructions A|"Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
214457481|NCT06502327|OTHER|Instructions B|"Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
214457482|NCT04487054|OTHER|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
214457483|NCT05965440|DRUG|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
214457484|NCT05538247|DRUG|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
214457485|NCT05538247|DIETARY_SUPPLEMENT|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
214457486|NCT05538247|DRUG|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
214457487|NCT04474613|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
214528931|NCT04931199|BEHAVIORAL|CBT+App|Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
214528932|NCT04341415|PROCEDURE|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
214528933|NCT04341415|PROCEDURE|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
214457488|NCT03964571|DIAGNOSTIC_TEST|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
214457489|NCT04987723|OTHER|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
215144790|NCT01399372|DRUG|Cytarabine|One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
215144791|NCT01399372|DRUG|Methotrexate|One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
214457490|NCT04987723|OTHER|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
214457491|NCT04987723|OTHER|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
214457492|NCT04987723|OTHER|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
214457493|NCT06461832|PROCEDURE|Group 1|In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.
214457494|NCT06461832|PROCEDURE|Group 2|In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
214457495|NCT06132503|DRUG|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
214528934|NCT02798276|PROCEDURE|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
215144792|NCT01399372|DRUG|Procarbazine|One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
215144793|NCT01399372|DRUG|Vincristine|One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
215144794|NCT01399372|RADIATION|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
215144795|NCT06355700|PROCEDURE|Liver biopsy|The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
215144796|NCT05641480|DEVICE|Transcutaneous electrical acupoint stimulation&Music therapy|"Procedure: electro-acupuncture;Points: Shenting（DU24）, Benshen（BG13）, Tou Wei （ST8）.The specially-made pad is stick on pierced acupoints, until local sour and heavy feeling coming. The electric stimulator is applied to bilateral BG13 and ST8, with dilatational wave,10/50 Hz and electric current 1-5mA(milliampere).Every session lasts for 30 min per day. The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each participants in all.~Selecting the participants' music of memory and music of favourite(Music is purchased and downloaded from music stores), forming a personalized music playlist, and the decibel level is suitable for participants.~The treatment is designed based on recent literature research in 10 years, former result and expert consensus.~Other Names:~* JS-502-A Intelligent and portable electroacupuncture~* apparatus(Han's low frequency neuromodulator, made in China)"
215144797|NCT05641480|DRUG|Donepezil hydrochloride tablets or carpalatine bitartrate tablets|"① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months."
215144798|NCT04669444|DEVICE|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
215144799|NCT02027441|OTHER|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
215144800|NCT05098431|OTHER|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
215144801|NCT00938067|BEHAVIORAL|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
215144802|NCT05243511|DEVICE|Digital ACT|Participants in this arm receive Digital ACT as well as standard of care.
214457496|NCT02848040|OTHER|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
214457497|NCT06803199|DRUG|FSH and LH|In the study group, participants receive FSH and LH in IVF cycle
214457498|NCT06803199|DRUG|FSH|In the control group, participants receive FSH alone in IVF cycle
214457499|NCT06800443|OTHER|Silica-based fluoride toothpaste containing clay, charcoal, blue covarine and green covarine|Silica-based toothpaste containing charcoal, clay, blue covarine, green covarine and fluoride as sodium fluoride
214457500|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing lower level of blue covarine and fluoride as sodium monofluorophosphate
214457501|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing higher level blue covarine and fluoride as sodium monofluorophosphate
214457502|NCT06800443|OTHER|Control silica-based fluoride toothpaste|Control silica-based toothpaste containing fluoride as sodium fluoride
214528935|NCT02798276|OTHER|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
215144803|NCT05243511|OTHER|Digital Symptom Tracker|Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
214457503|NCT04345250|OTHER|Energy restriction|A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
214457504|NCT01597388|DRUG|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
214457505|NCT01597388|DRUG|Fulvestrant|IM monthly after loading dose
214457506|NCT04903899|COMBINATION_PRODUCT|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
214457507|NCT06798987|OTHER|Meteorological conditions and air pollution|Climate change e.g. global surface temperature rise; extreme weather events e.g. heat waves, floods
214457508|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
214457509|NCT05407129|BEHAVIORAL|Family safety reporting intervention|Family safety reporting intervention for patients/families
214457510|NCT05377242|DIETARY_SUPPLEMENT|Curcumin|"Curcumin (chemical C21H20O6) is derived from turmeric (Curcuma longa) root extract, standardized to contain 95% curcuminoids. The greatest obstacle with curcumin is its poor natural bioavailability. To help circumvent that issue, a piperazine is included as black pepper 5.3mg (Piper nigrum) fruit extract standardized to 95% piperine. The botanical we are using is provided by Pure Encapsulations. Curcumin being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive curcumin. Participants will receive placebo, low-dose (500 mg/day), medium-dose (1000 mg/day), and/or high dose (2000 mg/day) curcumin in a randomized order."
214457511|NCT05377242|DIETARY_SUPPLEMENT|Resveratrol|"Resveratrol (chemical C14H12O3) is provided as 99% Pure Trans-Resveratrol (MegaResveratrol) from polygonum cuspidatum root). Resveratrol being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive resveratrol. Participants will receive placebo, low-dose (250 mg/day), medium-dose (500mg/day), and/or high dose (1000mg/day) resveratrol in a randomized order."
214457512|NCT05377242|DIETARY_SUPPLEMENT|Stinging Nettle|"Stinging nettle is derived from nettle (Urtica spp) leaf. The botanical we are using is provided by Pure Encapsulations. Stinging Nettle being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive stinging nettle. Participants will receive placebo, low-dose (435mg/day), medium-dose (870mg/day), and/or high dose (2610mg/day) stinging nettle in a randomized order."
214457513|NCT05352074|PROCEDURE|Total colectomy with ileorectal anastomosis|Following complete colonic mobilization without preservation of the ileocolic vascular pedicle, the surgical specimen was extracted by extending the right lower quadrant trocar incision to approximately 4-5 cm. A resection of ileum, 2-3 cm proximal to the ileocecal junction, will be conducted by stapler. The anvil of a 29-mm circular stapler was inserted into the proximal ileal lumen and repositioned intra-abdominally. Ileorectal anastomosis was performed by transanal insertion of the circular stapler, aiming to achieve a tension-free, contamination-minimized reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in layers.
214528936|NCT02391545|DRUG|Duvelisib|PI3K Inhibitor
214457514|NCT05352074|PROCEDURE|Subtotal colectomy with cecal-rectal anastomosis|Following complete colonic mobilization with preservation of the ileocolic vascular pedicle and its branches, the surgical specimen was extracted by extending the right lower quadrant trocar incision to 4-5 cm. After insertion of the anvil from a 29-mm circular stapler through the ascending colon resection margin, a resection about 3 cm distal to the ileocecal junction will be conducted. The cecum was then positioned in the pelvis without rotational torsion, and an antiperistaltic cecorectal anastomosis was created between cecal fundus (after appendectomy) and the rectal stump. The anastomosis was performed via transanal insertion of the circular stapler to ensure tension-free, contamination-controlled reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in a layered fashion.
214457515|NCT06801574|OTHER|Erector Spinae Plane Block|After the surgical team places the final suture, while the patient is in the prone position, an ultrasound-guided ESP (Erector Spinae Plane) block will be administered bilaterally using a block needle. A total of 40 mL of 0.25% bupivacaine will be injected.
214528937|NCT02391545|DRUG|Rituximab|monoclonal antibody
214528938|NCT02391545|DRUG|Obinutuzumab|monoclonal antibody
214528939|NCT04366648|DRUG|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
214528940|NCT05961228|OTHER|exercise|"Three different posture with and without correction according to the Schroth method"
214528941|NCT04265742|RADIATION|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
214528942|NCT04265742|RADIATION|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
215144804|NCT01432730|DRUG|Gefapixant|Oral tablets, BID
215144805|NCT01432730|DRUG|Placebo|Oral tablets, BID
215144806|NCT04976101|DEVICE|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
215144807|NCT04976101|DEVICE|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
215144808|NCT05402488|BEHAVIORAL|Auditory stimulation|Auditory stimulation during sleep
215144809|NCT02505919|DEVICE|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
215144810|NCT02505919|PROCEDURE|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
215144811|NCT03924167|BEHAVIORAL|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
215144812|NCT00500435|PROCEDURE|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
215144813|NCT05467969|BEHAVIORAL|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
215144814|NCT01712399|BIOLOGICAL|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
215144815|NCT05913765|DEVICE|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
215144816|NCT02896803|DRUG|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
215144817|NCT01696110|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
215144818|NCT01696110|DRUG|heparin|heparin monotherapy
215144819|NCT01696110|DRUG|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
215144820|NCT02484118|PROCEDURE|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
215144821|NCT03404700|BEHAVIORAL|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
215144822|NCT03404700|BEHAVIORAL|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
214457516|NCT06801574|OTHER|infiltration|Before the surgical team closes the incision, local infiltration with 40 mL of 0.25% bupivacaine will be performed at the surgical site.
214457517|NCT06801327|DEVICE|Simeox|The Investigators chose to evaluate this device for respiratory physiotherapy in our patients because it is the only one that offers innovative technology, as, unlike other commercially available devices, it does not require the patient to perform forced breathing. Instead, the patient can exhale calmly at tidal volume. This is expected to reduce the patient's effort and improve compliance with treatment. Furthermore, the vibratory signal with small, rapid, and sequential depressions within the airways could be more effective in mobilizing mucus from the airways, preventing collapse.
214457518|NCT03891576|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
214457519|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
214457520|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
214457521|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
214457522|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
214457523|NCT05455086|PROCEDURE|Computed Tomography|Undergo PET/CT
214457524|NCT05455086|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214457525|NCT05455086|OTHER|Questionnaire Administration|Ancillary studies
214457526|NCT06802120|OTHER|osteopathy real|treatment with real osteopathy 2 times a week for 8 weeks
214528943|NCT04265742|DIAGNOSTIC_TEST|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
214528944|NCT04265742|OTHER|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
214528945|NCT04265742|OTHER|clinical tests|physical performance tests and grip strenght measurement
214528946|NCT00000521|BEHAVIORAL|diet, sodium-restricted|
214528947|NCT00000521|BEHAVIORAL|diet, potassium-supplemented|
214528948|NCT00795977|BIOLOGICAL|dendritic cells, OK-432|Single Group Assignment
214457527|NCT06802120|OTHER|sham osteopathy|treatment with sham osteopathy 2 times a week for 8 weeks
214457528|NCT05764863|RADIATION|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
214528949|NCT06138834|DRUG|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
215144823|NCT03404700|BEHAVIORAL|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
215144824|NCT03404700|BEHAVIORAL|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
215144825|NCT06172309|DRUG|NTQ1062|tablet(s) PO
215144826|NCT02201394|DRUG|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
215144827|NCT02201394|DRUG|Aspirin loading dose|Single loading dose of Aspirin 325 mg
215144828|NCT02201394|DRUG|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
215144829|NCT02201394|DRUG|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
215144830|NCT03918837|OTHER|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
215144831|NCT03918837|OTHER|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
215144832|NCT02648919|DRUG|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
214457529|NCT05390918|BEHAVIORAL|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
214457530|NCT05390918|OTHER|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
214457531|NCT06802341|OTHER|Normal protein diet|Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids
214457532|NCT06802341|OTHER|Animal protein diet|Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
214457533|NCT06802341|OTHER|Plant based diet|Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
214457534|NCT06803095|BEHAVIORAL|free walking with dog and diet restriction|the total participants of tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet.. this diet will be applied for 12 weeks.. during this period the study, this group will receive free walking (30 min) with dog three timmes weekly.
214457535|NCT06803095|BEHAVIORAL|diet restriction|the total participants with tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet only .. this diet will be applied for 12 weeks..
214528950|NCT06138834|DRUG|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
214528951|NCT06138834|DRUG|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
214528952|NCT06138834|DRUG|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
214528953|NCT06138834|DRUG|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
215144833|NCT01660048|PROCEDURE|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
215144834|NCT01660048|PROCEDURE|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
215144835|NCT05692375|OTHER|"Invitation to play the game Save the shame!"|The experimental group was asked to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform . The control group neither used nor had access to the game. Afterwards both groups performed the ALS knowledge assessment test. It is a test with 20 multiple choice questions each scored as right (0.5 points) or wrong (0 points).
215144836|NCT03252431|DRUG|F-627|single dose pre-filled syringe
215144837|NCT03252431|DRUG|Neulasta|single dose pre-filled syringe
215144838|NCT04289974|DRUG|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
215144839|NCT02650076|DRUG|SK-1405|
215144840|NCT01831388|OTHER|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~\- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
215144841|NCT01831388|BEHAVIORAL|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
214457536|NCT06802510|PROCEDURE|Microwave Ablation|The MWA group followed a similar resection procedure as the control group. The area of ablation was evaluated strictly by radiologists and surgeons according to the following criteria: 1) Areas of tumor response, progression, or suspicious invasion (intermediate-high signal and edema range in T2) were assessed. Wide margins of at least 2-3 cm or more were obtained over the normal tissue around the tumor. Ablation margins were covered using a microwave ablation array with antennas (Microwave Ablation System BD-GT, Baird Medical LLC), aimed at completely inactivating the tumor in situ. Ablation needles were strategically arranged to form a matrix covering the target zone. The ablation time and power were determined based on the extent of the lesion, ensuring the temperature of the ablation area remained between 70-80°C. A 50 ml syringe was used to continuously drip and spray ice-cold saline to keep surrounding tissue temperatures below 40-43°C.
214457537|NCT06803459|OTHER|Baduanjin|36 times.
214457538|NCT06803459|OTHER|PNF|36 times.
214457539|NCT05227664|DRUG|AK117|Intravenous (IV) infusion
214457540|NCT05227664|DRUG|AK112|Intravenous (IV) infusion
214457541|NCT05227664|DRUG|Nab paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
214457542|NCT05227664|DRUG|paclitaxel|Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
214457543|NCT06803875|BIOLOGICAL|Autologous hALK.CAR T cells|Autologous chimeric antigen receptor T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor
214457544|NCT06802796|DIAGNOSTIC_TEST|Plasma NGAL test|Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.
214457545|NCT06451848|DRUG|Genakumab Injection (T, Solution for injection)|A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
214457546|NCT06451848|DRUG|Genakumab for Injection (R, Powder for solution for injection)|A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
214457547|NCT06802250|BEHAVIORAL|RINEW intervention|The intervention included behavioral recommendations and guidance on the topics of Nutrition, WASH, Lead exposure prevention, Mental Health, and child stimulation. The intervention also included the provision of nutritional supplements based on age and nutritional status, low-cost picture books and toys, and soapy water bottles.
214457548|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
214457549|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
214457550|NCT02761057|PROCEDURE|Biospecimen Collection|Undergo collection of plasma and serum samples
214457551|NCT02761057|PROCEDURE|Bone Scan|Undergo bone scan
214457552|NCT02761057|DRUG|Cabozantinib S-malate|Given PO
214457553|NCT02761057|PROCEDURE|Computed Tomography|Undergo CT
214457554|NCT02761057|DRUG|Crizotinib|Given PO
214457555|NCT02761057|DRUG|Savolitinib|Given PO
214457556|NCT02761057|DRUG|Sunitinib Malate|Given PO
214457557|NCT06082804|OTHER|APN and medical management|Patients are followed by the advanced practice nurse and the hematologist.
214457558|NCT06082804|OTHER|Medical management|Patients are followed by the hematologist only (standard of care).
214457559|NCT06082804|BEHAVIORAL|Quality of life assessment|EORTC-QLQ-C30 questionnaire
214457560|NCT06082804|BEHAVIORAL|Treatment compliance assessment|GIRERD questionnaire
214457561|NCT06227182|DIAGNOSTIC_TEST|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
214457562|NCT06227182|DIAGNOSTIC_TEST|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
215144842|NCT02781714|BEHAVIORAL|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered"
214457563|NCT05261282|BEHAVIORAL|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
214457564|NCT05828680|OTHER|Observation|No intervention
214457565|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
214457566|NCT04788511|DRUG|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
214457567|NCT04788511|DRUG|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
214457568|NCT06345157|DRUG|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
214457569|NCT06441422|OTHER|Blood flow restriction training|Participants randomized to blood flow restriction training will complete low load resistance training exercises while the limb is occluded at 80% arterial occlusion pressure.
214457570|NCT06441422|OTHER|No blood flow restriction training|Participants randomized to no blood flow restriction training will complete low load resistance without occlusion.
214457571|NCT05918263|BEHAVIORAL|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
214457572|NCT03737734|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214457573|NCT05828459|DRUG|OT-A201|OT-A201 IV infusion qw or q2w
214457574|NCT05828459|DRUG|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
214457575|NCT05828459|DRUG|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
214457576|NCT05828459|DRUG|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
214457577|NCT05828459|DRUG|TBD Compound|Combination regimen for hematological malignancy
214457578|NCT04250116|DRUG|NOAC monotherapy|Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
214457579|NCT04250116|DRUG|Dual antithrombotic therapy with NOAC and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
214528954|NCT05850858|DIAGNOSTIC_TEST|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
214457580|NCT06645483|OTHER|ChatGPT-assisted instruction|"ChatGPT will interactively support students by answering questions, initiating discussions, and providing customized learning materials in line with the course objectives. It will be supervised by the instructor to ensure guidance and prevent misinformation.~Duration: ChatGPT-assisted learning for the first two weeks, followed by traditional teaching for the next two weeks."
214457581|NCT06645483|OTHER|Traditional lecture-based instruction|"Students will learn through a traditional teaching format, where the instructor delivers the course content through lectures and presentations.~Duration: Traditional teaching for the first two weeks, followed by ChatGPT-assisted learning for the next two weeks."
214528955|NCT04964609|DEVICE|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
215144843|NCT02817646|OTHER|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
215144844|NCT02817646|DIETARY_SUPPLEMENT|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
215144845|NCT01308177|DRUG|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
214457582|NCT05185947|DRUG|Paclitaxel|Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.
214457583|NCT05185947|DRUG|Nilotinib|Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
214457584|NCT06153810|DEVICE|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
214457585|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
214457586|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone|20ml 0.2% Ropivacaine + 4mg Dexamethasone
214457587|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
214457588|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
214457589|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
214457590|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
214457591|NCT06510062|DRUG|2.5% Diclofenac Patches|Topical pain relief gel worn via SAM patch.
214457592|NCT05682157|OTHER|Paula Method of muscle exercises|12 weekly sessions of Paula Method of exercise
214457593|NCT05926934|DEVICE|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
214457594|NCT05926934|DEVICE|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
214457595|NCT05926934|DEVICE|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
214457596|NCT04499053|DRUG|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
214457597|NCT04499053|DRUG|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
214457598|NCT03637660|DRUG|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
214528956|NCT05172557|BEHAVIORAL|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
215144846|NCT03039218|DEVICE|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
215144847|NCT03039218|DEVICE|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
215144848|NCT02038933|DRUG|Nivolumab|
215144849|NCT05979246|DEVICE|Lance CLEAR dental implant|The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
215144850|NCT02170623|DRUG|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
215144851|NCT02170623|DRUG|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
215144852|NCT02170623|DRUG|Pantoprazole|40 mg pantoprazole
215144853|NCT02170623|DRUG|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
215144854|NCT04154904|OTHER|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
215144855|NCT01392339|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
215144856|NCT05747235|RADIATION|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
215144857|NCT00053651|BEHAVIORAL|Survival Skills for Moms with New Babies|
215144858|NCT05333198|OTHER|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
214528957|NCT05172557|BEHAVIORAL|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
214457599|NCT03618199|DEVICE|Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing|"Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testing stimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified."
214457600|NCT05733910|RADIATION|simultaneous integrated boost of carbon ions radiation therapy|"CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB).~The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion)."
214528958|NCT01193023|OTHER|Pressure Support|Ventilation under pressure support
214528959|NCT01193023|DEVICE|NAVA|Ventilation under NAVA
214528960|NCT03868735|DEVICE|CleanSweep Closed Suction System|Device with balloon sweeping technology
215144859|NCT05333198|OTHER|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
215144860|NCT00267059|DRUG|Lenalidomide|10 mg/day, orally once a day for 28 days
215144861|NCT02085161|DRUG|placebo to tiotropium + olodaterol|comparator
215144862|NCT02085161|DRUG|tiotropium+olodaterol|tiotropium 5 mcg once daily
215144863|NCT02085161|DRUG|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
215144864|NCT02085161|DRUG|tiotropium|tiotropium 5 mcg once daily fixed dose combination
214457601|NCT05304481|BIOLOGICAL|ATL administration|Subjects have ATL administration using intravenous infusion
214457602|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
214528961|NCT03549299|BIOLOGICAL|LSC2|Topical application of IMP on target eye
214528962|NCT06493669|DIAGNOSTIC_TEST|Cognitive assessment|MoCA
215144865|NCT01376934|PROCEDURE|procedure hysteroscopy|office hysteroscopy with gas or saline solution
215144866|NCT04515316|DEVICE|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
214528963|NCT01557699|BIOLOGICAL|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
214528964|NCT01557699|BIOLOGICAL|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
214528965|NCT01557699|BIOLOGICAL|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
214528966|NCT03635437|DRUG|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
214528967|NCT03635437|DRUG|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
215144867|NCT04515316|DEVICE|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
215144868|NCT06083740|DEVICE|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
215144869|NCT04591353|DRUG|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
215144870|NCT04591353|DRUG|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
215144871|NCT04856800|DIETARY_SUPPLEMENT|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
215144872|NCT04856800|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
214457603|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
214457604|NCT04929951|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
214528968|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
214528969|NCT01002547|DRUG|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
214528970|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
214528971|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
214528972|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
215144873|NCT01647217|DRUG|Terpinen-4-ol|Lid scrub once or twice per day for one month.
215144874|NCT01647217|OTHER|Placebo|Lid scrub once or twice per day for one month
215144875|NCT04282603|COMBINATION_PRODUCT|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
215144876|NCT01523093|DRUG|Ondansetron|Orally Disintegrating Tablets 8mg
214457605|NCT04929951|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
214457606|NCT05846867|DRUG|AK119|AK119 IV every 2 weeks.intravenous infusion
214457607|NCT05846867|DRUG|AK112|AK112 IV every 2 weeks.intravenous infusion
214457608|NCT05846867|DRUG|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
214457609|NCT05846867|DRUG|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
214457610|NCT05846867|DRUG|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
214457611|NCT05846867|DRUG|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
214457612|NCT04652700|DRUG|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
215144877|NCT06223984|DRUG|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
215144878|NCT04363970|OTHER|removal of the urinary catheter|in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
215144879|NCT01936870|DRUG|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
214457613|NCT04652700|DRUG|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
214457614|NCT04652700|DRUG|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
214457615|NCT04652700|DRUG|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
214457616|NCT04652700|DRUG|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
214457617|NCT04652700|DRUG|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
214457618|NCT04507568|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
214457619|NCT05955066|DRUG|Baricitinib 4 MG|1 capsule (4mg) daily for 24 weeks
214457620|NCT05955066|DRUG|Placebo|1 capsule daily
214457621|NCT06105060|DRUG|Rosuvastatin 20mg|to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
214457622|NCT06408597|PROCEDURE|Nitroglycerin Infusion|"Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU."
214528973|NCT01002547|DRUG|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
214528974|NCT01039259|DEVICE|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
214528975|NCT00672763|DRUG|Colecalciferol D3 (Vigantol Oil)|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
214528976|NCT00672763|DRUG|Medium chain triglycerides|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)"
214528977|NCT04528537|OTHER|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
214457623|NCT06408597|PROCEDURE|Mannitol Infusion|"Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes."
214457624|NCT06408597|PROCEDURE|Fluid Regimen|"Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status."
214528978|NCT03146754|OTHER|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
214528979|NCT02476708|DIETARY_SUPPLEMENT|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
214528980|NCT02476708|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule
214528981|NCT00985634|DEVICE|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
214528982|NCT00985634|DEVICE|Control|Vessel loops
214528983|NCT04258215|DEVICE|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
214528984|NCT04145323|DIAGNOSTIC_TEST|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
214528985|NCT04410315|OTHER|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
214528986|NCT04410315|OTHER|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
214528987|NCT02515656|DRUG|POLYGYNAX®|
214457625|NCT06570447|DRUG|Glofitamab|For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.
214457626|NCT06570447|DRUG|Chidamide|Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.
214457627|NCT06067139|OTHER|SHUTi|"Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like."
214457628|NCT06067139|OTHER|Patient Education|The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
214457629|NCT01898754|OTHER|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
214457630|NCT06579599|OTHER|an integrated working group nursing|(1) Establishment of an integrated team in the operating room; (2) Development of a nursing plan; (3) Nursing safety training and reflection in the operating room; (4) Designate a person to manage instruments and equipment in the operating room and establish protocols (5) Nurses should also participate in the development of the patient's individualized surgical plan communicate with the surgeon about the preparation of items needed for surgery to ensure seamless coordination. Assist anesthesiologists and surgeons and oversee the implementation of aseptic procedures.
214457631|NCT06161337|DIETARY_SUPPLEMENT|Meals|"Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition."
214457632|NCT02921581|RADIATION|FDG-PET guided dose painting|
214457633|NCT06037369|BEHAVIORAL|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
214528988|NCT02515656|DRUG|GYNODAKTARIN®|
214528989|NCT02515656|DRUG|Placebo|
214528990|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
214528991|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
214528992|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
214528993|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
214528994|NCT00434577|BIOLOGICAL|Placebo|Single intramuscular injection
214528995|NCT04826926|PROCEDURE|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
214528996|NCT01967719|OTHER|mTHS 2.2|Single use of mTHS 2.2
214528997|NCT01967719|OTHER|mCC|Single use of subject's own mCC
214528998|NCT01967719|OTHER|NNS|Single administration of 1 mg of nicotine
214528999|NCT00761397|BEHAVIORAL|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
215144880|NCT03651479|OTHER|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
215144881|NCT03651479|OTHER|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
215144882|NCT02658396|DRUG|GO-203-2C|
215144883|NCT02658396|DRUG|Bortezomib|
215144884|NCT00543413|DRUG|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
215144885|NCT00543413|DRUG|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
215144886|NCT00543413|DRUG|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
215144887|NCT00355966|DRUG|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
215144888|NCT00355966|DRUG|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
214457634|NCT04209465|DRUG|BDTX-189|Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.
214457635|NCT04759794|DIAGNOSTIC_TEST|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
214457636|NCT06381700|OTHER|MySmile app|"The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders"
214457637|NCT06381700|OTHER|Control|"This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained."
214457638|NCT03041805|PROCEDURE|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
214457639|NCT03041805|PROCEDURE|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
214457640|NCT03041805|PROCEDURE|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
214457641|NCT03041805|PROCEDURE|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
214457642|NCT03041805|PROCEDURE|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
214457643|NCT03041805|PROCEDURE|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
214457644|NCT03041805|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
214457645|NCT03041805|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
214457646|NCT05492318|DRUG|Givinostat 10 mg/mL|10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.
214457647|NCT05492318|DRUG|Midazolam 1mg/ml IV|Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
214457648|NCT05492318|DRUG|Midazolam 2.5 mg oromucosal solution|"Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration.~Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose.~Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
214529000|NCT00761397|BEHAVIORAL|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
214529001|NCT00761397|OTHER|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
215144889|NCT01635504|BIOLOGICAL|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
215144890|NCT00240396|DRUG|Narcotics alone|
215144891|NCT00240396|DRUG|Narcotics and NSAIDS|
215144892|NCT04539132|BEHAVIORAL|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
215144893|NCT02399163|DRUG|Fluoride free toothpaste|Brushing with fluoride free toothpaste
215144894|NCT02399163|DRUG|Fluoride toothpaste|Brushing with fluoride containing toothpaste
215144895|NCT02399163|DRUG|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
215144896|NCT03910244|DRUG|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
214457649|NCT05492318|DRUG|Dabigatran etexilate 75 mg oral hard capsules|"Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration.~Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
214529002|NCT00761397|OTHER|Questionnaire|Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
214529003|NCT02329223|BIOLOGICAL|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
215144897|NCT03910244|DRUG|Placebo oral capsule|Matching placebo will be given.
215144898|NCT03734692|DRUG|Rintatolimod|200 mg by IP administration over 1-2 hours
215144899|NCT03734692|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
215144900|NCT03734692|DRUG|Cisplatin|50mg/m\^2 solution
215144901|NCT00217399|DRUG|sorafenib tosylate|Given orally
215144902|NCT00217399|DRUG|anastrozole|Given orally
215144903|NCT00720915|OTHER|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
215144904|NCT00720915|OTHER|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
214529004|NCT02329223|OTHER|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
214529005|NCT05982080|DRUG|FP002 Injection|Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
214529006|NCT06050083|BEHAVIORAL|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
215144905|NCT03371069|OTHER|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
215144906|NCT02631408|DRUG|Vancomycin|Locally, intrawound applied vancomycin powder
215144907|NCT00803569|BIOLOGICAL|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
215144908|NCT00803569|BIOLOGICAL|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
215144909|NCT05856617|DRUG|Remimazolam besylate|Remimazolam besylate anesthesia induction
215144910|NCT05338619|DRUG|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
215144911|NCT03891108|DRUG|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
215144912|NCT03891108|DRUG|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
215144913|NCT03891108|DRUG|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
215144914|NCT03891108|DRUG|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
215144915|NCT02986360|BEHAVIORAL|Vidscrip educational video|Vidscrip educational video provide to women
215144916|NCT03497624|OTHER|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
215144917|NCT01745939|OTHER|Lumbar Manipulation|Manual therapy intervention
215144918|NCT01745939|OTHER|Sham manipulation|Manual therapy intervention
215144919|NCT04111991|BEHAVIORAL|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
215144920|NCT04111991|BEHAVIORAL|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
215144921|NCT04686669|DRUG|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
215144922|NCT04686669|DRUG|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
215144923|NCT00257985|DRUG|GTN|
215144924|NCT03345784|DRUG|Adavosertib|Given PO
214529007|NCT04196829|DRUG|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
214529008|NCT04196829|DRUG|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
214529009|NCT04314570|PROCEDURE|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
215144925|NCT03345784|DRUG|Cisplatin|Given IV
215144926|NCT03345784|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
215144927|NCT01655732|PROCEDURE|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
215144928|NCT06048120|DRUG|BAY2701250 IV|Single does, intravenous infusion
215144929|NCT06048120|DRUG|Placebo IV|Matching placebo for BAY2701250 IV
214457650|NCT01892137|DRUG|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
214457651|NCT05008835|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
214457652|NCT05008835|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
214457653|NCT05008835|DRUG|Placebo|Placebo
214457654|NCT04171999|OTHER|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
214457655|NCT03411083|PROCEDURE|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
214457656|NCT05668780|BEHAVIORAL|NIATx Coaching|"The intervention will consist of:~1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD~2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD~3. training for primary care providers"
214457657|NCT03993509|DEVICE|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
214457658|NCT03973853|BEHAVIORAL|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
214457659|NCT03973853|BEHAVIORAL|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
214457660|NCT06269978|PROCEDURE|Biopsy|Undergo biopsy
214457661|NCT06269978|PROCEDURE|Biospecimen Collection|Undergo collection of blood and IP fluid samples
214457662|NCT06269978|PROCEDURE|Computed Tomography|Undergo CT
214457663|NCT06269978|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
214457664|NCT06269978|DRUG|Fluorouracil|Given via IP infusion
214457665|NCT06269978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214457666|NCT06269978|DRUG|Oxaliplatin|Given via IP infusion
214457667|NCT06269978|PROCEDURE|Surgical Procedure|Undergo placement of indwelling IP port
214457668|NCT04079686|DRUG|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
214457669|NCT04079686|OTHER|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
214457670|NCT04505904|DRUG|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
214457671|NCT04505904|DRUG|Placebo|Placebo spray with no active ingredient.
214457672|NCT03629990|BEHAVIORAL|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
214457673|NCT03629990|BEHAVIORAL|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
214457674|NCT03629990|BEHAVIORAL|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
214529010|NCT04314570|PROCEDURE|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
214529011|NCT04759118|BEHAVIORAL|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
214529012|NCT04854278|OTHER|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
214529013|NCT04526314|OTHER|observational|observational
214529014|NCT03767400|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
214529015|NCT03767400|OTHER|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
214529016|NCT02924350|OTHER|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
214529017|NCT02924350|OTHER|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
214529018|NCT00097708|DRUG|experimental anti-anxiety drug|
214529019|NCT04739488|DEVICE|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
214529020|NCT04739488|BEHAVIORAL|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
214529021|NCT06144788|DRUG|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
215144930|NCT06048120|DRUG|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
215144931|NCT06048120|DRUG|Placebo SC|Matching placebo for BAY2701250 SC
215144932|NCT04560699|OTHER|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
215144933|NCT04560699|OTHER|medical care|medical care three times during the study period; baseline, week 13 and week 26
215144934|NCT03013270|OTHER|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
215144935|NCT03013270|OTHER|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
215144936|NCT03013270|OTHER|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
215144937|NCT03013270|OTHER|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
214529022|NCT01195740|BEHAVIORAL|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
214529023|NCT01195740|BEHAVIORAL|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
214529024|NCT03614221|DRUG|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
214529025|NCT03614221|DRUG|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
214529026|NCT03856398|DEVICE|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
214529027|NCT04605822|DEVICE|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
214529028|NCT04605822|DEVICE|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
214529029|NCT04605822|DEVICE|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
214529030|NCT04605822|OTHER|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
214529031|NCT03380598|BEHAVIORAL|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
214529032|NCT03380598|BEHAVIORAL|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
214529033|NCT00854971|BIOLOGICAL|TKCell|Biological/Vaccine: TKCell
214529034|NCT00506922|DRUG|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2"
214529035|NCT00506922|DRUG|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
214529036|NCT00506922|DRUG|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
214529037|NCT06319547|PROCEDURE|Thoracocentasis|patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
215144938|NCT04798196|BEHAVIORAL|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
214529038|NCT05584813|OTHER|Hypobaric Hypoxia|The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
214529039|NCT01502306|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
214529040|NCT01502306|DRUG|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
214529041|NCT01502306|BEHAVIORAL|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
214529042|NCT06250088|BIOLOGICAL|Emdogain (EMD) - test|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
214529043|NCT06250088|PROCEDURE|Sham group|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
214529044|NCT00262249|DRUG|somatropin|
214529045|NCT03378947|OTHER|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
214529046|NCT02137499|DEVICE|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
214529047|NCT00022607|BIOLOGICAL|bevacizumab|
214529048|NCT00022607|DRUG|thalidomide|
214529049|NCT00848393|DRUG|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
214695230|NCT03544268|DRUG|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
214695231|NCT05866653|DRUG|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
214695232|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for control|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
214695233|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for patients|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
215144939|NCT04798196|BEHAVIORAL|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
215144940|NCT04798196|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual (TAU)
215144941|NCT01743222|GENETIC|eASC|"* First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
214529050|NCT00848393|DRUG|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
214695234|NCT00084812|DRUG|cisplatin|
215144942|NCT01743222|DRUG|Placebo|"* First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
215144943|NCT00911456|PROCEDURE|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
215144944|NCT00911456|PROCEDURE|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
215144945|NCT00911456|PROCEDURE|3 DUS|3 DUS
214695235|NCT00084812|DRUG|safingol|
214695236|NCT01690689|DEVICE|Implant surgery|surgery
214695237|NCT01818388|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
214695238|NCT04908241|OTHER|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
214695239|NCT04908241|OTHER|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
214695240|NCT01193816|DRUG|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
215144946|NCT03836313|DEVICE|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
214529051|NCT00848393|DRUG|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
214529052|NCT01430117|BIOLOGICAL|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
214529053|NCT05965960|DEVICE|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
214529054|NCT05965960|DEVICE|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
214529055|NCT01628406|PROCEDURE|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
214529056|NCT05137405|PROCEDURE|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
214529057|NCT00695370|DRUG|Pegfilgrastim (drug)|
214529058|NCT00243217|DRUG|SPM 936|
214529059|NCT02480244|BEHAVIORAL|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
214529060|NCT02480244|OTHER|Control|Control arm receives no health-related behavioral intervention
214695241|NCT01193816|DRUG|Placebo|Placebo
214529061|NCT03334799|DEVICE|sacroiliac belt|standing and walking with the belt on and with the belt off
214529062|NCT06190184|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214695242|NCT00931580|DIETARY_SUPPLEMENT|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
214695243|NCT00375817|PROCEDURE|Myoblasts injection with MyoCath catheter|
214695244|NCT00297362|DRUG|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
214695245|NCT01206010|DRUG|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
215144947|NCT01834911|DRUG|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
215144948|NCT04496713|OTHER|Internet-connected computer tablet|An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
215144949|NCT00000715|DRUG|Pentamidine isethionate|
215144950|NCT00000715|DRUG|Sulfamethoxazole-Trimethoprim|
215144951|NCT02512783|DRUG|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
215144952|NCT02512783|DRUG|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
215144953|NCT02512783|DRUG|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
215144954|NCT03543644|OTHER|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
215144955|NCT03543644|OTHER|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
215144956|NCT03543644|OTHER|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
215144957|NCT01874899|DEVICE|RestoreSensor Neurostimulation|
214457675|NCT03937050|BEHAVIORAL|Intervention|"Three film-based components:~1. Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~2. Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~3. Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices."
214457676|NCT04605679|PROCEDURE|Kidney Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
214457677|NCT05724264|DIAGNOSTIC_TEST|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
214457678|NCT06332326|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.
214457679|NCT06332326|BEHAVIORAL|vestibular rehabilitation|vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
214457680|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
214457681|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
214457682|NCT04277442|DRUG|Decitabine|Given IV
214457683|NCT04277442|BIOLOGICAL|Nivolumab|Given IV
214457684|NCT04277442|DRUG|Venetoclax|Given PO
214457685|NCT05757310|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214457686|NCT05757310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214457687|NCT05757310|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
214457688|NCT05757310|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214457689|NCT05757310|DRUG|Cyclophosphamide|Given PO and IV
214457690|NCT05757310|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
214457691|NCT05757310|DRUG|Pentostatin|Given IV
214457692|NCT05757310|OTHER|Questionnaire Administration|Ancillary studies
214695246|NCT01206010|DRUG|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
214457693|NCT04118660|OTHER|Tissue Banking|Blood, tissue, and fluid collection
214457694|NCT06465225|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of developing pressure injury, without pressure injury, up during the day and lying between 15 and 20 hours per day will ly a on a R'GO Soins overlay mattress
214457695|NCT03544281|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as an infusion.
214457696|NCT03544281|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
214457697|NCT03544281|DRUG|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
214457698|NCT03544281|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
214457699|NCT05903807|DRUG|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
214457700|NCT05235750|BEHAVIORAL|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
214529063|NCT06190184|OTHER|Control arm|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
214529064|NCT04830761|BEHAVIORAL|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
214529065|NCT04830761|BEHAVIORAL|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
214529066|NCT04830761|BEHAVIORAL|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
214529067|NCT01111136|BEHAVIORAL|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
214529068|NCT04038320|DRUG|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
214529069|NCT02406040|OTHER|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
214529070|NCT00069628|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
214529071|NCT00069628|DEVICE|Continuous Glucose Monitoring System (CGMS)|
214529072|NCT00331851|DRUG|liraglutide|
215144958|NCT06226493|DEVICE|Transcutaneous vagus nerve stimulation|The Parasym Plus device (https://parasym.io) is a transcutaneous auricular vagus nerve stimulator that has been deemed non-significant risk (NSR) by the FDA. Transcutaneous auricular vagus nerve stimulator is a non-significant risk device, as it involves electrical stimulation of the external ear using an ear clip, with no invasive components. The stimulation parameters will be limited to the confines of existing published data. tVNS is safe and well tolerated at doses tested in research studies. The Parasym device is considered low risk when used in accordance with the instructions for use. Participants will be properly trained to use the device, and those with contraindications will be excluded for extra precaution. A low incidence of skin irritation has been reported. No serious adverse events have been reported.
215144959|NCT02559141|DRUG|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
215144960|NCT01153932|DRUG|GSK2402968|Subcutaneous injection
215144961|NCT01153932|DRUG|matched placebo|Subcutaneous injection
215144962|NCT03426891|DRUG|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
214457701|NCT05930353|OTHER|COHORT|this evaluation includes a brief interview with perma profiler scale
214457702|NCT04946734|DEVICE|PFO closure device|Device PFO closure.
214457703|NCT04946734|DRUG|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
214457704|NCT04946734|DRUG|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
214529073|NCT00331851|DRUG|insulin glargine|
214529074|NCT00331851|DRUG|metformin|
214529075|NCT00331851|DRUG|glimepiride|
214529076|NCT02303847|DRUG|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
214529077|NCT00002216|DRUG|Lamivudine/Zidovudine|
214529078|NCT00002216|DRUG|Abacavir sulfate|
214529079|NCT00002216|DRUG|Amprenavir|
214529080|NCT00002216|DRUG|Nelfinavir mesylate|
214529081|NCT03135821|DIAGNOSTIC_TEST|TCM|
214457705|NCT03958474|DRUG|Oxycodone|Participants receive oxycodone or placebo.
214457706|NCT03958474|DRUG|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
215144963|NCT03426891|DRUG|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
214457707|NCT04906447|BEHAVIORAL|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
214457708|NCT04906447|OTHER|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
214457709|NCT04876118|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
214457710|NCT05922176|OTHER|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
214457711|NCT05922176|OTHER|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
215144964|NCT03426891|DRUG|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
215144965|NCT03426891|RADIATION|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
215144966|NCT03611829|BEHAVIORAL|ACT Intervention|
215144967|NCT03611829|BEHAVIORAL|Standard Care|
215144968|NCT01190462|BIOLOGICAL|cetuximab|
215144969|NCT01190462|DRUG|simvastatin|
215144970|NCT01190462|OTHER|laboratory biomarker analysis|
215144971|NCT00728689|DRUG|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
215144972|NCT00728689|DRUG|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
215144973|NCT01525069|DRUG|Floxuridine|
215144974|NCT01525069|DRUG|Dexamethasone|
215144975|NCT01525069|DRUG|Gemcitabine|
215144976|NCT01525069|DRUG|Oxaliplatin|
215144977|NCT04210531|DIETARY_SUPPLEMENT|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
215144978|NCT04210531|DIETARY_SUPPLEMENT|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
215144979|NCT06243536|DRUG|Semaglutide|Semaglutide will be administered through 12 weeks.
215144980|NCT06243536|DRUG|standard of care|Patients not assigned to receive semaglutide will receive standard of care.
215144981|NCT00782990|PROCEDURE|Surgical treatment: TVT|
214457712|NCT04809311|DRUG|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
215144982|NCT00782990|PROCEDURE|Surgical treatment: colposuspension|
215144983|NCT00272584|DRUG|Risperidone|
215144984|NCT04712682|OTHER|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
215144985|NCT01850667|RADIATION|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
215144986|NCT05447052|DEVICE|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
215144987|NCT05447052|DEVICE|Innova Stent|Innova Stent implantation
215144988|NCT00929695|DRUG|prednisone|immunosuppressive drug
215144989|NCT00929695|DRUG|methylprednisolone|immunosuppressive drug
214695247|NCT01206010|DRUG|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
214695248|NCT04895163|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
215144990|NCT00929695|OTHER|questionnaire administration|Ancillary studies
215144991|NCT03184688|PROCEDURE|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
215144992|NCT03184688|DRUG|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
215144993|NCT04570007|PROCEDURE|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
215144994|NCT00002485|PROCEDURE|psychosocial assessment and care|
214457713|NCT04809311|DRUG|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
214457714|NCT04809311|DRUG|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
214457715|NCT06333808|DRUG|Bictegravir|Tablets administered orally without regard to food
214457716|NCT06333808|DRUG|Lenacapavir|Tablets administered orally without regard to food
214457717|NCT06333808|DRUG|B/F/TAF|Tablets administered orally without regard to food
214457718|NCT06333808|DRUG|Placebo to match B/F/TAF|Tablets administered orally without regard to food
214457719|NCT06333808|DRUG|Placebo to match BIC/LEN|Tablets administered orally without regard to food
214457720|NCT02986698|BIOLOGICAL|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
214457721|NCT01703806|PROCEDURE|Early Surgery|MItral valve surgery
214457722|NCT01703806|PROCEDURE|Watchful Observation|Watchful observation
214457723|NCT06227221|DRUG|Sorafenib|Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
214457724|NCT06227221|DRUG|Placebo|Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
214457725|NCT06105684|DRUG|Capecitabine Pill|Will be given once per day by mouth
214457726|NCT05437055|DEVICE|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
214457727|NCT05970367|OTHER|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
214457728|NCT06354010|GENETIC|Genotyping|Genotyping to determine if patients present mutations to the gene GJB2.
214457729|NCT06354010|OTHER|Audiological assessments|Audiological assessments
214457730|NCT06456671|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214457731|NCT06456671|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457732|NCT06456671|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457733|NCT06456671|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
214457734|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
214457735|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
214457736|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
214457737|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
214457738|NCT04113642|OTHER|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
214457739|NCT01693263|OTHER|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
214457740|NCT03092518|PROCEDURE|Surgery|Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
214457741|NCT03092518|DRUG|Cisplatin|Cisplatin (90 mg/m\^2) will be administered via circuit to the peritoneal cavity
214695249|NCT05958095|DEVICE|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
214457742|NCT03092518|DRUG|Mitomycin C|Mitomycin C 10 mg/m\^2 will be administered via circuit to the peritoneal cavity
214457743|NCT03092518|DRUG|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
214457744|NCT03092518|PROCEDURE|Tumor Biopsy|At screening, baseline (if not done at screening) and operation (as clinically indicated).
214457745|NCT03092518|DIAGNOSTIC_TEST|CT C/A/P|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
214457746|NCT03092518|DIAGNOSTIC_TEST|PET-CT|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
214457747|NCT03092518|DIAGNOSTIC_TEST|MRI|If computed tomography (CT) contraindicated.
214457748|NCT03092518|DIAGNOSTIC_TEST|EKG|At screening and baseline (if not done at screening).
214457749|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
214457750|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
214457751|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
214457752|NCT02301910|DRUG|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
214457753|NCT02301910|DRUG|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml"
214457754|NCT04517149|BIOLOGICAL|4D-125 IVT Injection|4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
214457755|NCT04517149|OTHER|Observational|Natural History
214457756|NCT02845882|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
215144995|NCT01213628|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
215144996|NCT02870595|DEVICE|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
214695250|NCT05958095|DEVICE|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
215144997|NCT02870595|DEVICE|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
215144998|NCT03788512|OTHER|observational only- no intervention|observational only- no intervention
215144999|NCT00425802|BIOLOGICAL|anti-thymocyte globulin|
215145000|NCT00425802|BIOLOGICAL|filgrastim|
215145001|NCT00425802|BIOLOGICAL|graft-versus-tumor induction therapy|
215145002|NCT00425802|BIOLOGICAL|rituximab|
215145003|NCT00425802|DRUG|cyclophosphamide|
215145004|NCT00425802|DRUG|cyclosporine|
215145005|NCT00425802|DRUG|fludarabine phosphate|
214457757|NCT02845882|DRUG|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
214457758|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
214695251|NCT04876703|DEVICE|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
215145006|NCT00425802|DRUG|mycophenolate mofetil|
215145007|NCT00425802|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
215145008|NCT00425802|RADIATION|total-body irradiation|
214457759|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
214457760|NCT02845882|DRUG|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
214457761|NCT02845882|DRUG|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
214457762|NCT02845882|DRUG|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
214457763|NCT06000059|BEHAVIORAL|Radio Drama|An hour long radio drama adapted from from a previous community-led theater intervention
214457764|NCT03160612|BEHAVIORAL|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
214457765|NCT04594278|BEHAVIORAL|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
214457766|NCT04747613|DRUG|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
214457767|NCT02547987|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
214457768|NCT02547987|DRUG|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
214457769|NCT04282148|DEVICE|ABT NG DES 48 EECSS|Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
214457770|NCT06144086|DRUG|Foscenvivint|Administered by intravenous (IV) infusion over 3-4 hours
214457771|NCT06559332|DIAGNOSTIC_TEST|Risk-based CAD management|Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.
214457772|NCT06559332|DIAGNOSTIC_TEST|Invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
214457773|NCT06547866|DRUG|zanubrutinib + BGB-11417|"The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose"
214457774|NCT05589194|BEHAVIORAL|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
214457775|NCT04925986|DRUG|Sitravatinib|Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
214457776|NCT04925986|DRUG|Pembrolizumab|All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
214457777|NCT04861571|DIETARY_SUPPLEMENT|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
214457778|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
214695252|NCT04876703|OTHER|Standard motor training|Standard motor training is the conventional rehabilitation treatment
214457779|NCT03203603|OTHER|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
214457780|NCT06181760|DRUG|Fenretinide|Ascending single doses of oral fenretinide
214457781|NCT06181760|DRUG|Placebo|Single oral dose of matching placebo capsules
214457782|NCT06647160|DEVICE|Blue star MAX-5 spectacle lens|The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
214457783|NCT06647160|DEVICE|Single-vision spectacle lens|The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
214695253|NCT02932189|DEVICE|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
214695254|NCT02119884|DRUG|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
214695255|NCT02119884|DRUG|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
214457784|NCT06647225|DEVICE|Artificial intelligence augmented ultrasound|"The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan)."
214457785|NCT06077513|PROCEDURE|CAD-CAM designed and preprinted Ti-Mesh frame|CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.
214457786|NCT06077513|PROCEDURE|Conventional chairside fabrication of Ti-Mesh frame|A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
214457787|NCT05965765|DIAGNOSTIC_TEST|Total knee arthroplasty|who got total knee arthroplasty because of osteoarthritis
214457788|NCT05965765|DIAGNOSTIC_TEST|osteoarthritis without surgery|who has osteoarthritis and didn't get any surgery
214457789|NCT05965765|DIAGNOSTIC_TEST|control group|healthy people
214457790|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
214457791|NCT06450522|OTHER|Usual care|Usual care
214457792|NCT04770532|DRUG|Insulin degludec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
214457793|NCT04770532|DRUG|Insulin Icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
214457794|NCT06340282|DEVICE|Virtual reality|Immersive virtual reality
214457795|NCT06340282|BEHAVIORAL|multicomponent exercise|individualized exercise
214457796|NCT04938492|BEHAVIORAL|Cognitive Behavioral Therapy for loneliness (CBT-L)|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
214457797|NCT04938492|BEHAVIORAL|Physical Health Education Training (PHET)|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
214457798|NCT04982237|BIOLOGICAL|AK104|IV infusion
214457799|NCT04982237|DRUG|paclitaxel|IV infusion
214457800|NCT04982237|DRUG|carboplatin|iv infusion
214457801|NCT04982237|DRUG|cisplatin|iv infusion
214457802|NCT04982237|DRUG|bevacizumab|iv infusion
214457803|NCT04982237|DRUG|Placebo|iv infusion
214457804|NCT04529044|PROCEDURE|Biopsy|Undergo biopsy
214457805|NCT04529044|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214457806|NCT04529044|PROCEDURE|Computed Tomography|Undergo PET/CT
214457807|NCT04529044|RADIATION|Gallium Ga 68-DOTATATE|Receive 68Ga
214457808|NCT04529044|DRUG|Lutetium Lu 177 Dotatate|Given IV
214457809|NCT04529044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214457810|NCT04841148|DRUG|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
214457811|NCT04841148|DRUG|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
214457812|NCT04841148|DRUG|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
214457813|NCT05866562|DRUG|Dupilumab|Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;
214457814|NCT05866562|DRUG|Placebo|Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
214457815|NCT05897710|OTHER|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
214457816|NCT05897710|OTHER|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
214457817|NCT04899141|DEVICE|Percutaneous Coronary Intervention|stenting with the ihtDEStiny® sirolimus eluting stent
214457818|NCT05265546|DRUG|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
214695256|NCT03001154|BEHAVIORAL|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
215145009|NCT04902976|OTHER|CPC+ZN|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the solution for 30 s
215145010|NCT04902976|OTHER|CPC|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the proposed solution for 30 s;
215145011|NCT04902976|OTHER|Negative Control|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of distilled water for 30 s.
215145012|NCT01526863|DIETARY_SUPPLEMENT|HA egg|Daily dose of HA egg or placebo for 6 months
214457819|NCT05739279|DIAGNOSTIC_TEST|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
214457820|NCT05739279|DIAGNOSTIC_TEST|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
214457821|NCT05739279|DIAGNOSTIC_TEST|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
214457822|NCT05739279|DIAGNOSTIC_TEST|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
214457823|NCT05436600|OTHER|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
214457824|NCT05555199|RADIATION|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
214457825|NCT05555199|DRUG|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
214457826|NCT06296498|PROCEDURE|Leukocyte Platelet-rich fibrin|Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis
214457827|NCT06296498|OTHER|Standard of care OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
214457828|NCT04025554|DRUG|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
214457829|NCT06351306|DRUG|Thioguanine (Tabloid ®)|60-80mg/m\^2 oral tablet
214457830|NCT06351306|DRUG|DecitabineCedazuridine (Inqovi ®)|35 mg decitabine and 100 mg cedazuridine oral tablet
214457831|NCT06459726|OTHER|shi style mobilization|Step 1 soothing tendon stepTherapist will aerate patient's neck 3 to 6 times.Step 2 moblization step Therapist will apply low velocity small amplitude oscillatory movement without thrust. Head will be in 45 degrees of flexion or extension. Repeat this for 3 to 6 times. Then distraction force is applied to the cervical. Step 3 dredging collateral step Therapist holds thenar and hypothenar muscles of patient's hand on affected side and gently shook the upper limb ebb and flow with small shaking and high frequency. Repeat the procedure 3 times 6 sesions over 2 weeks for 20minutes
214457832|NCT06459726|OTHER|SNAGS|Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced. the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patientsNumber of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10second
214457833|NCT05992220|RADIATION|Atezolizumab plus bevacizumab, combined EBRT to vascular invasion|"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
214457834|NCT05992220|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab q3w
215145013|NCT00002337|DRUG|Vesnarinone|
215145014|NCT00887809|DRUG|gemcitabine|
215145015|NCT00887809|DRUG|docetaxel|
215145016|NCT00887809|DRUG|bevacizumab|
215145017|NCT05393440|BIOLOGICAL|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
214457835|NCT05948267|DRUG|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
214457836|NCT05948267|DRUG|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
215145018|NCT01615484|PROCEDURE|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
215145019|NCT01615484|DEVICE|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
215145020|NCT05722392|PROCEDURE|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
215145021|NCT05627830|PROCEDURE|Prolotherapy|Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
215145022|NCT04356898|OTHER|No intervention|No intervention
215145023|NCT06161246|DEVICE|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
215145024|NCT03469557|DRUG|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
214457837|NCT01052467|DRUG|Xamiol® Gel|Once daily application for about 4 weeks
214457838|NCT06178887|DIAGNOSTIC_TEST|imaging|cardiac angioMR
214457839|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
214457840|NCT05545150|PROCEDURE|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
214457841|NCT05545150|DEVICE|Lumpectomy|Per standard of care (SOC)
214695257|NCT03001154|BEHAVIORAL|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
214695258|NCT03001154|OTHER|Waiting-list|Weekly assessments of public speaking
214695259|NCT02231450|DRUG|Lu AE58054 encapsulated film-coated tablets|
214695260|NCT00483275|DRUG|Alfacalcidol|
214457842|NCT06298318|OTHER|Vodka|BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.
214457843|NCT06298318|OTHER|water|equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
214457844|NCT03854214|DEVICE|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 revolutions per minute (RPM). Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
214695261|NCT00483275|BEHAVIORAL|Balance, gait and strength training|
214695262|NCT00483275|BEHAVIORAL|Patient education|
214695263|NCT03916172|BEHAVIORAL|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
214695264|NCT01248910|BEHAVIORAL|Alpine Skiing|
215145025|NCT03469557|DRUG|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
215145026|NCT03469557|DRUG|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
215145027|NCT03469557|DRUG|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
215145028|NCT03469557|DRUG|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
215145029|NCT06442943|BEHAVIORAL|Multi-domain Cognitive Intervention|"* Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly."
215145030|NCT05465317|DRUG|Empagliflozin|Empagliflozin
215145031|NCT05465317|DRUG|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
214457845|NCT03854214|DEVICE|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
214457846|NCT04354480|BIOLOGICAL|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
214457847|NCT04354480|OTHER|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
214457848|NCT04263467|OTHER|Exercise intervention|The exercise intervention will consist a intermediate to high aerobic exercise training program.
214457849|NCT04263467|OTHER|Standard oncological treatments|Standard oncological treatments
214457850|NCT04255615|OTHER|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
214457851|NCT06407713|OTHER|Intrinsic foot muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with intrinsic foot muscle training
214529082|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
214529083|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
214529084|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
214529085|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
215145032|NCT03115866|BEHAVIORAL|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
215145033|NCT05100121|DEVICE|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
215145034|NCT05100121|OTHER|Supportive Care|During the health dialogues with the nurse, the patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patients health record.
214457852|NCT06407713|OTHER|Hip abductor muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with hip abductor muscle training
214457853|NCT06492239|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
214457854|NCT06492239|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
214457855|NCT04857164|DRUG|Pembrolizumab combined with Chemotherapy|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
215145035|NCT01690143|DRUG|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
215145036|NCT01690143|DRUG|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
215145037|NCT04349267|BIOLOGICAL|BMS-986315|Specified dose on specified days
215145038|NCT04349267|BIOLOGICAL|nivolumab|Specified dose on specified days
215145039|NCT04349267|BIOLOGICAL|cetuximab|Specified dose on specified days
215145040|NCT05806580|DRUG|Relma-cel|Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
215145041|NCT04245150|OTHER|Stool sample|Stool sample
215145042|NCT04245150|OTHER|Skin Swab Sample|Skin Swab Sample
215145043|NCT00648102|BIOLOGICAL|CDX-1307|
215145044|NCT04337970|DRUG|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
215145045|NCT04337970|DRUG|Axitinib|5 mg PO BID
215145046|NCT05589662|OTHER|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
215145047|NCT04752215|DRUG|BI 765049|BI 765049
214457856|NCT05056727|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~\- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water."
214457857|NCT05056727|DRUG|Placebo|"Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~\- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water."
214457858|NCT05056727|DRUG|Lisinopril|Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
214457859|NCT05056727|DRUG|Valsartan|Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
214457860|NCT05056727|DRUG|Irbesartan|"Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved."
214457861|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
214457862|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
214457863|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
214457864|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
215145048|NCT04752215|DRUG|ezabenlimab|ezabenlimab
215145049|NCT03777982|DRUG|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
215145050|NCT03777982|DRUG|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
215145051|NCT03777982|DRUG|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
215145052|NCT03777982|DRUG|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
215145053|NCT06388512|DEVICE|prototype prone positioning device|The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
215145054|NCT00870740|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
215145055|NCT00870740|DRUG|Placebo|Placebo SC injection
215145056|NCT00148395|DRUG|Gemcitabine|
215145057|NCT00148395|DRUG|Navelbine|
215145058|NCT00148395|DRUG|Carboplatin|
215145059|NCT00148395|DRUG|Cisplatin|
215145060|NCT00148395|DRUG|Mitomycin|
215145061|NCT00148395|DRUG|Ifosfamide|
215145062|NCT05647408|DRUG|Dexamethasone|The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
215145063|NCT00034177|DRUG|S-8184 Paclitaxel Injectable Emulsion|
215145064|NCT00034177|DRUG|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
215145065|NCT05919186|DRUG|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
214529086|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
214529087|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
215145066|NCT05919186|DEVICE|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
215145067|NCT05919186|DEVICE|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
215145068|NCT00678782|DRUG|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
215145069|NCT00678782|DRUG|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
215145070|NCT03841396|DRUG|Sodium chloride|All participants received a single dose of sodium chloride as placebo
215145071|NCT06180343|OTHER|Mandala|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
214457865|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
214457866|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
214457867|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
214529088|NCT00478439|DIETARY_SUPPLEMENT|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
215145072|NCT00817843|DRUG|Simvastatin|6 weeks of treatment with simvastatin 80 mg
215145073|NCT00817843|DRUG|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
215145074|NCT03755934|DRUG|MEDI7352|Participants will receive IV infusion of MEDI7352 as stated in arm description.
214457868|NCT04420676|DIETARY_SUPPLEMENT|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
214529089|NCT00478439|DIETARY_SUPPLEMENT|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
214695265|NCT04143620|PROCEDURE|Procedure|Triple procedure
214695266|NCT00377611|BIOLOGICAL|Fluarix™|
214695267|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
215145075|NCT03755934|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
215145076|NCT03557749|DIAGNOSTIC_TEST|Blood Sample|60 ml heparinized blood 10 ml serum
215145077|NCT03557749|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount
215145078|NCT03557749|DIAGNOSTIC_TEST|Urine Sample|10 ml
215145079|NCT03557749|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) fluid|10 ml
215145080|NCT03557749|DIAGNOSTIC_TEST|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
215145081|NCT03557749|DIAGNOSTIC_TEST|Skin biopsy|2-4 mm punch
215145082|NCT03557749|DIAGNOSTIC_TEST|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
215145083|NCT03557749|DIAGNOSTIC_TEST|Apheresis Product|Up to 10 ml of apheresis product
215145084|NCT03557749|DIAGNOSTIC_TEST|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
215145085|NCT02628990|OTHER|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
215145086|NCT02628990|OTHER|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
215145087|NCT02628990|OTHER|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
215145088|NCT02628990|OTHER|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
215145089|NCT02628990|OTHER|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
215145090|NCT02681029|PROCEDURE|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
215145091|NCT02681029|PROCEDURE|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
215145092|NCT03160261|DRUG|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
215145093|NCT04263155|BEHAVIORAL|The Body Project|The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
215145094|NCT00307801|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
214457869|NCT04420676|DIETARY_SUPPLEMENT|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
215145095|NCT00307801|DRUG|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
215145096|NCT01720108|DRUG|rivaroxaban and ASA|
215145097|NCT03431259|OTHER|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
215145098|NCT01069003|DRUG|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
214457870|NCT05846620|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
214457871|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
214457872|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
214457873|NCT05972655|RADIATION|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
214457874|NCT05972655|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
214457875|NCT05972655|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
214457876|NCT05972655|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214457877|NCT03428763|DEVICE|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~* Joint score by the patient~* Patient global disease activity measured on a 0-100 mm visual analogue scale.~* CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
214457878|NCT03428763|OTHER|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
214457879|NCT02534272|OTHER|Stool sampling and sequencing of gut microbiota.|
214457880|NCT03194685|DRUG|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
214457881|NCT00742482|DRUG|HL 10|Freeze dried HL 10
215145099|NCT01069003|DRUG|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
215145100|NCT01069003|DEVICE|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
215145101|NCT00785759|DRUG|AH110690 (18F) Injection|All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
215145102|NCT04886635|OTHER|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
215145103|NCT03476486|PROCEDURE|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
215145104|NCT00551642|DRUG|Nitric oxide|Nitric Oxide vapour (gas) for inhalation (400 ppm)
215145105|NCT00551642|DRUG|Placebo|Placebo gas for inhalation
215145106|NCT06059482|OTHER|Assessment|Evaluations will be made once.
215145107|NCT04125927|DRUG|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
215145108|NCT02222623|DRUG|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
215145109|NCT02222623|DRUG|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
215145110|NCT05058339|OTHER|Survey Administration|Complete survey
215145111|NCT02596867|DRUG|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
215145112|NCT03631602|DRUG|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
214457882|NCT06424223|PROCEDURE|Horizontal Ridge augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
214457883|NCT06042803|OTHER|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
214457884|NCT06042803|OTHER|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
214457885|NCT06042803|OTHER|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
214457886|NCT05732805|BIOLOGICAL|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
214457887|NCT05732805|BIOLOGICAL|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
214457888|NCT05732805|BIOLOGICAL|Placebo|Placebo
214457889|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
214457890|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
214457891|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
214457892|NCT05804136|DEVICE|Duramesh|Laparotomy closure with Duramesh
214457893|NCT05804136|DEVICE|Polydioxanone suture|Laparotomy closure with standard PDS
214457894|NCT05981833|DEVICE|Repair with DAA (dermal allograft augmentation)|Patients undergo rotator cuff repair with dermal allograft augmentation.
214457895|NCT06173206|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
214457896|NCT06173206|DRUG|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
214457897|NCT06173206|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
214457898|NCT02377999|DRUG|Picato|
214457899|NCT04338061|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.
214457900|NCT04338061|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
214457901|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
214457902|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
214529090|NCT05319002|BEHAVIORAL|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
214529091|NCT01090232|OTHER|blood samples|
214529092|NCT01090232|OTHER|blood samples|
215145113|NCT04822116|OTHER|goal directed intraoperative haemodynamic optimization|all interventions that were pre-specified to be administered as part of the protocol
214529093|NCT06162637|DEVICE|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
214529094|NCT06162637|DEVICE|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
214529095|NCT03753750|DEVICE|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
214529096|NCT01347281|PROCEDURE|Injection of [18F]HX4|"Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position"
214529097|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
214529098|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
214529099|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
214529100|NCT02178397|DRUG|ERLOTINIB WITH CHEMOTHERAPY|
214529101|NCT02178397|DRUG|CHEMOTHERAPY ONLY|
215145114|NCT00361296|BIOLOGICAL|K562/GM-CSF cell vaccine|
214529102|NCT05225285|BIOLOGICAL|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
214529103|NCT05225285|BIOLOGICAL|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
214529104|NCT02312622|DRUG|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
214529105|NCT05475496|OTHER|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
215145115|NCT05516381|DEVICE|Optetrak Logic CR Knee System|The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
215145116|NCT01481753|PROCEDURE|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
215145117|NCT01481753|PROCEDURE|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
215145118|NCT02269969|DRUG|Tobramycin|
215145119|NCT01884467|DRUG|Gentamicin|Comparison of Gentamicin versus placebo
215145120|NCT01884467|DRUG|Placebo|
215145121|NCT01808586|PROCEDURE|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
215145122|NCT01808586|PROCEDURE|Dexamethasone|4mg/mL
215145123|NCT01808586|PROCEDURE|Intramuscular Lidocaine|2%
215145124|NCT01808586|BEHAVIORAL|Home Exercise|Standardized home exercise program
215145125|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
214529106|NCT00936754|DIETARY_SUPPLEMENT|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
214529107|NCT00936754|DIETARY_SUPPLEMENT|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
214529108|NCT02361177|DRUG|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
214529109|NCT04589390|DRUG|Selexipag|treatment with selexipag
214695268|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
214457903|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
214457904|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
214457905|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
214457906|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
214457907|NCT03286699|BEHAVIORAL|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
214457908|NCT03286699|BEHAVIORAL|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
214457909|NCT06275945|DEVICE|Voro Urologic Scaffold|radical prostatectomy
214457910|NCT04946253|BEHAVIORAL|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
214457911|NCT04946253|BEHAVIORAL|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
214457912|NCT04946253|BEHAVIORAL|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
214529110|NCT04835233|DRUG|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
214529111|NCT05161143|DRUG|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
214529112|NCT00871143|BEHAVIORAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
214529113|NCT00871143|BEHAVIORAL|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
214529114|NCT03535480|DRUG|G-CSF|G-CSF subcutaneously during five days
214695269|NCT04095806|OTHER|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
215145126|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
214457913|NCT02361827|PROCEDURE|Embryo transfer|For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
214457914|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
214457915|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
214457916|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
214457917|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
214457918|NCT03631784|DRUG|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
214457919|NCT03631784|DRUG|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
214457920|NCT03631784|DRUG|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
214457921|NCT03631784|DRUG|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
214457922|NCT03631784|DRUG|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
214457923|NCT03631784|RADIATION|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
214529115|NCT03535480|COMBINATION_PRODUCT|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
214529116|NCT05362513|DRUG|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
214529117|NCT05362513|DRUG|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
214529118|NCT03686241|PROCEDURE|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
214529119|NCT03686241|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
214529120|NCT01717547|BEHAVIORAL|Yoga-based treatment|
215145127|NCT03521128|PROCEDURE|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
215145128|NCT03521128|PROCEDURE|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
215145129|NCT02032732|OTHER|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
214457924|NCT03631784|DRUG|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
214457925|NCT03631784|DRUG|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
214457926|NCT05494411|DRUG|Mitomycin for pyelocalyceal solution|
214457927|NCT06423482|OTHER|PEEK bar|The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
214457928|NCT06423482|OTHER|Titanium bar|The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
214457929|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
214457930|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
214457931|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
214529121|NCT04165525|DEVICE|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
214529122|NCT05353621|BEHAVIORAL|VAS reported Stress|VAS reported Stress measurement during simulation
214529123|NCT00352053|DRUG|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
214529124|NCT00352053|DRUG|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
214529125|NCT02591797|PROCEDURE|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system."
215145130|NCT00198822|DIETARY_SUPPLEMENT|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
215145131|NCT00131079|BEHAVIORAL|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
215145132|NCT00131079|BEHAVIORAL|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
215145133|NCT01186289|DRUG|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
215145134|NCT03141138|BIOLOGICAL|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
215145135|NCT03141138|BIOLOGICAL|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
215145136|NCT03011099|DEVICE|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
215145137|NCT03011099|OTHER|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
214457932|NCT05895149|OTHER|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
214457933|NCT05895149|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
214457934|NCT04589026|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
214457935|NCT04589026|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
214457936|NCT04484012|DRUG|Acalabrutinib|Given PO
214457937|NCT04484012|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
214529126|NCT00520403|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
214529127|NCT00520403|DRUG|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
214529128|NCT00520403|DRUG|Vinblastine|0.1mg/kg iv every 3 weeks
214529129|NCT05871918|DRUG|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
214529130|NCT04239950|DRUG|Placebo|Placebo
214529131|NCT04239950|DRUG|Ethyl Icosapentate|Ethyl Icosapentate
214529132|NCT04751461|OTHER|Product A|P0213420, a 1.8% nicotine ENDS product
214529133|NCT04751461|OTHER|Product B|P0213520, a 1.8% nicotine ENDS product
214529134|NCT04751461|OTHER|Product C|P0211220, a 1.8% nicotine ENDS product
214529135|NCT04751461|OTHER|Product D|P0211820, a 1.8% nicotine ENDS product
214529136|NCT04751461|OTHER|Product E|P0213417, a 2.4% nicotine ENDS product
214529137|NCT02125097|DEVICE|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
214695270|NCT04343313|DEVICE|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
214695271|NCT05611840|PROCEDURE|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
214695272|NCT05611840|PROCEDURE|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
214529138|NCT02435797|DRUG|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
215145138|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
215145139|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
215145140|NCT03537755|OTHER|Observation|Examine thoughts and behaviors
215145141|NCT00963859|PROCEDURE|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
215145142|NCT02575963|DRUG|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
215145143|NCT02575963|BIOLOGICAL|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
215145144|NCT02575963|DRUG|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
215145145|NCT02575963|DRUG|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
215145146|NCT05773729|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
215145147|NCT04232358|DRUG|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
215145148|NCT04232358|DRUG|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
215145149|NCT00129246|DRUG|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
215145150|NCT00129246|DRUG|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
215145151|NCT03675347|OTHER|angioplasty|angioplasty
215145152|NCT01427764|DEVICE|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
215145153|NCT01651156|DRUG|Tolvaptan|oral taken
215145154|NCT01651156|DRUG|Placebo|
215145155|NCT04692259|DIAGNOSTIC_TEST|MRI|Liver MRI before liver resection
215145156|NCT03902353|OTHER|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
215145157|NCT02072668|DRUG|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
214695273|NCT00905723|DRUG|estradiol|1 mg daily for 6 months
214695274|NCT00905723|DRUG|isoflavone|150 mg isoflavone daily for 6 months
214457938|NCT00597805|BEHAVIORAL|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
214457939|NCT02876588|OTHER|Unrestricted|Users may open up to 4 patient records at a time.
214457940|NCT02876588|OTHER|Restricted|Users are restricted to open 1 patient record at a time.
214457941|NCT01956084|DRUG|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
214457942|NCT01956084|DRUG|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
214457943|NCT04722575|DRUG|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
214457944|NCT04722575|DRUG|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
214457945|NCT04722575|DRUG|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
215145158|NCT02072668|DRUG|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
215145159|NCT01539161|DEVICE|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
215145160|NCT01539161|PROCEDURE|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
215145161|NCT04885452|OTHER|biobank|"* Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
215145162|NCT04362241|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
215145163|NCT05618977|BEHAVIORAL|Dramatization simulation|Ethical attitudes of nursing students will be evaluated with dramatization simulation application.
215145164|NCT05618977|BEHAVIORAL|In-class case studies|In-class case studies will be conducted with the control group students.
215145165|NCT02294708|BEHAVIORAL|postoperative postures|two postoperative postures: supine and temporal-lateral
215145166|NCT06199843|DRUG|Rifaximin|Rifaximin 550 mg BD
215145167|NCT06199843|DRUG|Norfloxacin|Norfloxacin 400 mg OD
215145168|NCT02574117|PROCEDURE|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
214457946|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
214457947|NCT06110975|OTHER|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
214695275|NCT00905723|DRUG|Placebo|sugar pill daily for six months
215145169|NCT05666869|DRUG|Esketamine perfusion|Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
215145170|NCT02786017|BIOLOGICAL|Conventional therapy|Patients will receive the conventional therapy.
215145171|NCT02786017|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
215145172|NCT01088867|OTHER|Acupuncture|Electroacupuncture
215145173|NCT01621269|DRUG|Fingolimod|
215145174|NCT01957995|DRUG|nanosomal docetaxel lipid suspension|Given IV
215145175|NCT01957995|OTHER|pharmacological study|Correlative studies
215145176|NCT03377608|DRUG|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
215145177|NCT03377608|DRUG|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
215145178|NCT01796808|PROCEDURE|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
215145179|NCT01796808|OTHER|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. \<200ml). Only a few cc's of fat are needed for injection into the foot."
214457948|NCT06822803|BEHAVIORAL|Gardening Nutrition Education Program|This intervention was a 6-week Social Cognitive Theory based, urban gardening, cooking and nutrition education program designed to change health behavior mediators, fruit and vegetable intake, stress, and life satisfaction in food insecure college students.
214457949|NCT06017544|PROCEDURE|PCI|The T2DM affected by AMI will be referred for receiving PCI.
214457950|NCT03506867|BEHAVIORAL|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
214457951|NCT03506867|BEHAVIORAL|Standard Care|Usual care will receive information on locally available services.
214457952|NCT02733328|PROCEDURE|CPB Surgery|
214457953|NCT06054776|DRUG|Acalabrutinib|Given PO
214457954|NCT06054776|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214457955|NCT06054776|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsies
214457956|NCT06054776|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214457957|NCT06054776|PROCEDURE|Echocardiography|Undergo ECHO
214457958|NCT06054776|BIOLOGICAL|Glofitamab|Given IV
214457959|NCT06054776|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214457960|NCT06054776|BIOLOGICAL|Obinutuzumab|Given IV
214457961|NCT06054776|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214457962|NCT04616469|PROCEDURE|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
214457963|NCT04616469|PROCEDURE|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
214457964|NCT06253130|DRUG|IMP1734|PARP1 selective inhibitor
214457965|NCT06183216|BIOLOGICAL|Sinovac PCV13|0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
214457966|NCT06183216|BIOLOGICAL|PREVNAR 13|0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
214457967|NCT04624906|DRUG|Acalabrutinib|100 mg oral capsules twice daily for 1 year
214457968|NCT04624906|DRUG|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
214457969|NCT04624906|DRUG|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
214457970|NCT05147701|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214457971|NCT04921917|OTHER|neoadjuvant exercise therapy|brief exercise regimen completed immediately prior to neoadjuvant radiation therapy. Rubber bands will be used for the exercise training of patients with lower extremity tumors while an electronic hand-held dynamometer will be used for the exercise training for patients with upper extremity tumors.
214457972|NCT03301506|DRUG|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
214457973|NCT03301506|DRUG|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
215145180|NCT06380621|PROCEDURE|Totally Extra Peritoneal repair (TEP) repair|TEP repair
214457974|NCT06597305|BEHAVIORAL|Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)|Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.
214457975|NCT05144529|DRUG|Nivolumab|Nivolumab IV 240 mg
214457976|NCT05144529|DRUG|Ipilimumab|Ipilimumab IV 1 mg/kg
214457977|NCT05144529|DRUG|Evolocumab|Evolocumab 14 mg subcutaneous injection
214457978|NCT04598230|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
214457979|NCT04598230|DRUG|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
214457980|NCT06791265|DEVICE|Guided Eminectomy|The patients will be subjected to computer-guided osteotomy utilizing a virtually preplanned cutting guide
214457981|NCT06791265|PROCEDURE|Free hand Eminectomy|The patients will be subjected to a free-hand Eminectomy utilizing the routine surgical technique
214457982|NCT02251548|DRUG|Ibrutinib|Oral BTK inhibitor
214457983|NCT02251548|DRUG|Fludarabine|IV purine analogue chemotherapy agent
214457984|NCT02251548|DRUG|Cyclophosphamide|IV alkylator chemotherapy agent
214457985|NCT02251548|DRUG|Rituximab|IV anti-CD20 monoclonal antibody
214457986|NCT06830018|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
214457987|NCT06830018|COMBINATION_PRODUCT|Standard Treatment|Standard Treatment，First-line treatment (chemotherapy + immunotherapy/targeted therapy)
214457988|NCT04437615|PROCEDURE|Colonoscopy|Standard of care colonoscopy, with added use of CDSD as an adjunctive tool
215145181|NCT05893784|OTHER|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
215145182|NCT04479995|BEHAVIORAL|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
214457989|NCT04437615|DEVICE|Clinical Decision Support Device|The investigational device consists of software residing on a dedicated computer enabling display of predicted diminutive polyp histology during colonoscopy.
214457990|NCT06915363|DEVICE|BioPoly|partial resurfacing knee replacement
214457991|NCT06915363|PROCEDURE|surgical standard of care (SSOC)|either microfracture or debridement
214457992|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
214457993|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
214457994|NCT06917768|PROCEDURE|Adenotonsillectomy|Children undergoing adenoidectomy and intracapsular tonsillectomy using Coblation™, by the same surgeon at HDF.
214457995|NCT06917768|DRUG|Prednisolone|The second Group includes children whose parents have refused surgery despite informed understanding of the therapeutic algorithm of OSA. They received medical treatment consisting of a 1-month treatment with intranasal corticosteroids, coupled with a 5-day course of oral corticosteroids (prednisolone) at a safe dose of 1mg/kg.
214457996|NCT00587314|OTHER|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
214457997|NCT06931184|OTHER|self-sampling|increase screening coverage by self-sampling
215145183|NCT04479995|BEHAVIORAL|Usual Care|Standard medical visits with additional paper or electronic booklet.
215145184|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁷ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: single intradermal dose of 10⁷ PFU/0.2 ml of vaccinia virus."
215145185|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁶ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: two intradermal doses of 10⁶ PFU/0.2 ml of vaccinia virus (given 28 days apart)."
215145186|NCT05846243|BIOLOGICAL|Live Smallpox Vaccine|"Live smallpox vaccine (Smallpox vaccine) (manufactured by the Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of Russia).~Batch No. Т30 (expiry date: March, 2021). Dosage: Single 1x10⁶ PFU dose administered by multiple-pricking technique on the 30th/60th day after full series of vaccination with VAC∆6."
215145187|NCT05846243|OTHER|Placebo (Sodium chloride bufus, 0.9%)|"Sodium chloride bufus, a 0.9% solvent for the preparation of a dosage form for injections (manufactured by JSC Pharmaceutical manufacturing company Obnovlenie, Russia).~Batch: 391219 (expiry date: January, 2025)."
215145188|NCT05227196|DRUG|Semaglutide D Dose 1|Tablet given orally
215145189|NCT05227196|DRUG|Semaglutide D Dose 2|Tablet given orally
215145190|NCT05227196|DRUG|Semaglutide D Dose 3|Tablet given orally
215145191|NCT05227196|DRUG|Semaglutide Dose 4|Tablet given orally
215145192|NCT05227196|DRUG|Semaglutide Dose 5|Tablet given orally
215145193|NCT05227196|DRUG|Semaglutide Dose 6|Tablet given orally
215145194|NCT01051895|OTHER|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
215145195|NCT01051895|OTHER|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
215145196|NCT03025971|DEVICE|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
215145197|NCT05558969|DRUG|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
215145198|NCT05558969|DRUG|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
215145199|NCT06242574|OTHER|Survey|Each group will have to complete a questionnaire online, taking about 30 minutes.
214457998|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with low-dose adjuvant|Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
214457999|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with high-dose adjuvant|Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
214458000|NCT06932523|BIOLOGICAL|Low-dose adjuvant|Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
214458001|NCT06932523|BIOLOGICAL|High-dose adjuvant|Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
214458002|NCT06932523|BIOLOGICAL|Shingrix (GSK)|Positive control, Intramuscular injection, 0, 2 months schedule
215145200|NCT06133179|PROCEDURE|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
215145201|NCT06119308|OTHER|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing (led by pharmacist/clinician/psychologist) over a 10-week Trial.
215145202|NCT05595707|OTHER|Expert-Guided Early Tracheostomy|Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
215145203|NCT01367106|PROCEDURE|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
215145204|NCT06585657|DEVICE|brain visual perception training group|Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
215145205|NCT06275685|DEVICE|SeizureWise algorithm|An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
215145206|NCT06275685|DEVICE|Multi-day Visualizations|Multi-day visualizations of sensor derived data
214458003|NCT06932523|BIOLOGICAL|Normal Saline|Placebo control, Intramuscular injection, 0, 2 months schedule
214458004|NCT06835777|COMBINATION_PRODUCT|Positive Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance enhancing neurostimulant,. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance enhancing qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
214458005|NCT06835777|COMBINATION_PRODUCT|Negative Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance inhibiting neuro-depressant. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance inhibiting qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
214458006|NCT06835777|OTHER|Control|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about EEG research and set ups and give general information about isometric strength testing. They will be shown neutral adjectives unrelated to performance instead of implicit adjectives related to performance (experimental groups). EEG set up and strength testing remains the same as the experimental groups.
214458007|NCT05634109|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
214458008|NCT04581590|OTHER|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
214458009|NCT02035787|DRUG|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
214458010|NCT02978456|DEVICE|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).
214458011|NCT02978456|DEVICE|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
214458012|NCT06414213|BEHAVIORAL|Motor Imagery (MI)|Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
214458013|NCT06414213|DEVICE|Active tDCS|"The participants received a 20-minute active session of tDCS at a 2-milliamp current."
214458014|NCT06414213|DEVICE|Sham tDCS|"The participants received a 20-minute session of sham tDCS."
214458015|NCT06849947|DRUG|Ribociclib with fulvestrant|"▪ Ribociclib group~\- Ribociclib (600 mg orally once daily on days 1 to 21 in a 28 day cycle) + Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day 15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
214458016|NCT06849947|DRUG|Physician's choice treatments group|"▪Fulvestrant or exemestane group~1. Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or periomenopausal women) OR,~2. Exemestane (25 mg orally once daily on day 1 to 28 in a 28 day cycle) + Everolimus (10 mg orally once daily on day 1 to 28 in a 28 day cycle) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
214458017|NCT06178900|DIAGNOSTIC_TEST|Assisted by the AI-Gatekeeper software group|The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
214458018|NCT05623202|BEHAVIORAL|Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults|The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
214458019|NCT05691270|BEHAVIORAL|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
214458020|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
214458021|NCT03985839|DEVICE|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
214458022|NCT03985839|DEVICE|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
214458023|NCT03985839|DEVICE|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
214458024|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
214458025|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
214458026|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
214458027|NCT05549713|PROCEDURE|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
215145207|NCT04310462|OTHER|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
214458028|NCT05452408|DRUG|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
215145208|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (neoadjuvant)|Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
215145209|NCT05724329|PROCEDURE|surgery|Standard of care
215145210|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (adjuvant)|Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
215145211|NCT06601114|DRUG|Paracetamol Group|Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
215145212|NCT06601114|DRUG|Ibuprofen group|Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
215145213|NCT05387122|DEVICE|mandibular advancement device (MAD)|mandibular advancement device (MAD) is a removable oral appliance. It is an alternative therapy for patients of Obstructive Sleep Apnea who are non compliant to Continuous positive airway pressure(CPAP) which is the most accepted therapy for Obstructive Sleep Apnea.
215145214|NCT05997225|OTHER|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
215145215|NCT05997225|OTHER|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
215145216|NCT05893485|BEHAVIORAL|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
215145217|NCT03013998|BIOLOGICAL|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
215145218|NCT03013998|BIOLOGICAL|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
215145219|NCT03013998|OTHER|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
214458029|NCT01396278|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
215145220|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
214529139|NCT02435797|DRUG|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
214529140|NCT01828398|DEVICE|real-tDCS + UE robot-assisted therapy|
215145221|NCT03013998|DRUG|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
215145222|NCT03013998|DRUG|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
215145223|NCT03013998|DRUG|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
215145224|NCT03013998|DRUG|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
215145225|NCT03013998|DRUG|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
215145226|NCT03013998|DRUG|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
215145227|NCT03013998|DRUG|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
215145228|NCT03013998|DRUG|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
215145229|NCT03013998|DRUG|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
215145230|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
215145231|NCT03013998|DRUG|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance \>30 mL/min and \<50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
215145232|NCT03013998|DRUG|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
214458030|NCT01396278|DRUG|Fluticasone propionate|Fluticasone propionate HFA MDI
214458031|NCT01396278|DRUG|BI 54903|BI 54903 via Respimat inhaler
215145233|NCT03013998|DRUG|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
215145234|NCT03013998|DRUG|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
215145235|NCT03013998|DRUG|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
214458032|NCT04786106|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
214458033|NCT04786106|PROCEDURE|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
214458034|NCT04786106|PROCEDURE|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
214458035|NCT04786106|DEVICE|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
214458036|NCT02143726|DRUG|sorafenib|Given PO
214458037|NCT02143726|DRUG|everolimus|Given PO
214529141|NCT01828398|DEVICE|sham-tDCS + UE robot-assisted therapy|
214529142|NCT05635955|DRUG|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
214529143|NCT05635955|DRUG|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
215145236|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
215145237|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
215145238|NCT03013998|DRUG|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression \[if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored\]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
215145239|NCT03013998|DRUG|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
215145240|NCT03013998|DRUG|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
214458038|NCT04175119|DEVICE|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
214458039|NCT02322060|PROCEDURE|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
214458040|NCT02322060|PROCEDURE|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
214458041|NCT02322060|PROCEDURE|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
214458042|NCT02322060|PROCEDURE|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
214529144|NCT05635955|DRUG|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
214529145|NCT00153556|BIOLOGICAL|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
214529146|NCT02671578|DRUG|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
214529147|NCT02969005|RADIATION|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
214695276|NCT00236119|DRUG|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
214458043|NCT05256394|BEHAVIORAL|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
214529148|NCT03849521|DIAGNOSTIC_TEST|MRI|Enhanced carotid calcification presented by UTE MR.
214529149|NCT01490359|BEHAVIORAL|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
214529150|NCT01490359|BEHAVIORAL|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
214529151|NCT04977297|BEHAVIORAL|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
214529152|NCT04977297|BEHAVIORAL|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
214529153|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
214529154|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions during fast
215145241|NCT03013998|DRUG|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
215145242|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
215145243|NCT03013998|DRUG|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
215145244|NCT03013998|DRUG|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
215145245|NCT03013998|DRUG|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
214458044|NCT04774965|DEVICE|Slumber Curve sleep aid|Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
214458045|NCT06239402|OTHER|Observation|Observation of mortality, haemorrhagic and ischemic events in the studied population
214458046|NCT06166654|DRUG|Acetazolamide|1\. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
214458047|NCT06166654|DRUG|Metolazone 2.5 MG|2\. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
214458048|NCT06166654|OTHER|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
214458049|NCT04515576|DRUG|LY3493269|Administered SC
214458050|NCT04515576|DRUG|Dulaglutide|Administered SC
214458051|NCT04515576|DRUG|Placebo|Administered SC
215145246|NCT03013998|DRUG|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
215145247|NCT03013998|DRUG|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
215145248|NCT03013998|DRUG|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 or days 1 through 14 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
215145249|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
215145250|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
215145251|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
215145252|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
215145253|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
215145254|NCT03013998|DRUG|ZE46-0134 (BAML-16-001-S21)|10 mg or 50 mg oral on Days 1-28 of each 28-day cycle for up to 24 cycles. On the first day of Cycle 1, a loading dose of 30 mg to 150 mg will be administered, after which the daily maintenance dose of 10 mg to 100 mg will be administered on days 2-28 of Cycle 1. Maintenance dose continues in subsequence cycles, for up to 24 cycles total.
215145255|NCT04327700|DEVICE|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
215145256|NCT04327700|DRUG|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
214458052|NCT05116527|DRUG|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
214458053|NCT05116527|DRUG|Placebo|Placebo THC - marijuana flower with no THC content
214458054|NCT05670067|PROCEDURE|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
214458055|NCT05670067|PROCEDURE|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
214458056|NCT05028634|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
214458057|NCT05028634|BIOLOGICAL|Pneumococcal polysaccharide vaccine|PPSV23
214458058|NCT05028634|BIOLOGICAL|Seasonal influenza vaccine|Seasonal influenza vaccine
214458059|NCT04871191|DRUG|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
214458060|NCT04871191|DRUG|Tocilizumab|Subcutaneous injection of 162 mg per week
214458061|NCT04871191|DRUG|Tofacitinib|\- Tofacitinib, administered orally at a dose of 5 mg twice a day. Tofacitinib will start at week 0. Treatment will be continued until week 52
214458062|NCT04728347|BIOLOGICAL|ARCT-021|ARCT-021 single dose
214458063|NCT06388109|OTHER|Positive Peers mobile app|Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
214458064|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
214458065|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
214529155|NCT05816577|DIETARY_SUPPLEMENT|EcN Colibactin knockout|E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin
214458066|NCT05547750|DRUG|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
214458067|NCT05547750|DRUG|Placebo|Similar-looking placebo tablets
214458068|NCT05480761|BIOLOGICAL|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
215145257|NCT05321134|DEVICE|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety \& quality event rate for SP platform transabdominal and transanal colorectal operations."
215145258|NCT04482647|OTHER|Media Intervention|View instructional video
215145259|NCT04482647|PROCEDURE|Meditation Therapy|Perform meditation
215145260|NCT04482647|OTHER|Quality-of-Life Assessment|Ancillary studies
215145261|NCT04482647|OTHER|Questionnaire Administration|Ancillary studies
215145262|NCT04482647|PROCEDURE|Yoga|Perform breathing techniques
215145263|NCT04401813|DRUG|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
215145264|NCT03008291|PROCEDURE|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
215145265|NCT03008291|PROCEDURE|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
215145266|NCT03008291|PROCEDURE|Dual Chamber Pacemaker Implantation|
215145267|NCT01416220|DRUG|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
215145268|NCT01416220|DRUG|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
215145269|NCT03670966|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given via infusion
215145270|NCT03670966|DRUG|Cyclophosphamide|Given IV
215145271|NCT03670966|RADIATION|Total-Body Irradiation|Undergo TBI
215145272|NCT03670966|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
215145273|NCT03670966|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
215145274|NCT03670966|DRUG|Mycophenolate Mofetil|Given IV or PO
215145275|NCT03670966|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given IV or SC
215145276|NCT03670966|DRUG|Fludarabine Phosphate|Given IV
215145277|NCT03670966|DRUG|Tacrolimus|Given IV or PO
215145278|NCT03670966|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
215145279|NCT03670966|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215145280|NCT05271643|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
215145281|NCT04223479|DRUG|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
215145282|NCT04223479|DRUG|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
215145283|NCT04930367|BEHAVIORAL|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
215145284|NCT04930367|BEHAVIORAL|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
215145285|NCT04930367|BEHAVIORAL|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
214458069|NCT01605565|PROCEDURE|A nasal brushing|A nasal brushing in every nostril
215145286|NCT04930367|BEHAVIORAL|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
215145287|NCT04930367|OTHER|Pill Container|A discreet pill container to support ART adherence.
215145288|NCT04930367|OTHER|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
215145289|NCT04930367|OTHER|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
215145290|NCT04930367|OTHER|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
214458070|NCT03249181|DRUG|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
214458071|NCT03249181|DRUG|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
214458072|NCT03368963|DRUG|Nanoliposomal Irinotecan|Given IV
214458073|NCT03368963|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214458074|NCT06409169|OTHER|DBS TaT|Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
214458075|NCT06409169|OTHER|Usual Care|Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
214458076|NCT06549803|DEVICE|skin bond|"In the skin bond group, fascia closure is performed for incision sites of 10 mm or more, and skin bond is sufficiently applied after subcuticular suture.~For incision sites less than 10 mm, subcuticular closure is performed without closing the fascia, and then skin bond is applied."
214458077|NCT06549803|DEVICE|skin stapler|"In the skin stapler group, fascia closure is performed on incision sites larger than 10 mm, and the skin is closed at 2-3 mm intervals using a stapler.~For incision sites less than 10 mm, skin closure is performed using a skin stapler without closing the fascia."
214458078|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
214458079|NCT02487056|BEHAVIORAL|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of HF patients|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of patients were recorded.
214458080|NCT05231993|PROCEDURE|Conization|A cone biopsy to remove abnormal tissue.
214458081|NCT05231993|PROCEDURE|Colposcopy|"1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
214529156|NCT05816577|DIETARY_SUPPLEMENT|E Coli Nissle|E Coli wildtype strain
214529157|NCT00405912|DRUG|Placebo|Placebo (inactive drug) given 3 times per day
215145291|NCT04930367|OTHER|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
215145292|NCT04930367|BEHAVIORAL|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
214458082|NCT06538675|OTHER|Psychotherapy|Patients are assigned to a therapist and will receive psychotherapy
214458083|NCT06537063|OTHER|G4 DNAm test|Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
214458084|NCT06546293|OTHER|core stabilization exercises|The program consists of lumbo-pelvic/core strength and stability exercises. The program will be implemented individually under the supervision of a physiotherapist twice a week for 12 weeks.
214529158|NCT00405912|DRUG|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
214529159|NCT00405912|DRUG|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
214529160|NCT03408223|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
215145293|NCT04930367|BEHAVIORAL|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
215145294|NCT04930367|BEHAVIORAL|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
215145295|NCT04930367|BEHAVIORAL|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
215145296|NCT04930367|BEHAVIORAL|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
214695277|NCT00236119|DRUG|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
215145297|NCT02449122|PROCEDURE|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
215145298|NCT03751241|DEVICE|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
214458085|NCT06546293|OTHER|daily physical activity program|The program consists of a daily physical activity program established and monitored for participation through weekly exercise tracking chart. The program will be implemented through weekly physiotherapist's control of the exercise tracking chart for 12 weeks.
214458086|NCT03933735|DRUG|TNB-383B|Intravenous (IV) Injection
214458087|NCT03002207|DEVICE|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
214458088|NCT03002207|PROCEDURE|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
214458089|NCT05182827|OTHER|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
214458090|NCT06438705|DIAGNOSTIC_TEST|SPECT-CT imaging|The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
214458091|NCT03991481|BIOLOGICAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
214458092|NCT03991481|BIOLOGICAL|Liquid-stored platelets|Liquid-stored platelets as per standard practice
214458093|NCT05308004|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
214458094|NCT06507345|OTHER|Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]|In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.
214458095|NCT06507345|OTHER|Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]|Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
214458096|NCT06108596|DRUG|Sintilimab with Interleukin-2+CAPOX|Sintilimab with Interleukin-2+CAPOX
214458097|NCT03762915|DRUG|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
214458098|NCT06557434|DEVICE|MIRIA|The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
214458099|NCT05534802|DRUG|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
214458100|NCT05534802|OTHER|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
214458101|NCT04645550|DRUG|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
214458102|NCT04645550|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
214458103|NCT04645550|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
214529161|NCT03408223|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
215145307|NCT04163341|BEHAVIORAL|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
215145308|NCT05773755|DEVICE|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
215145309|NCT05030129|DRUG|5-Hydroxytryptophan|5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
215145310|NCT05030129|DRUG|Ergoloid Mesylates|Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
215145311|NCT05030129|DRUG|Matching placebo for Ergoloid mesylates|Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
215145312|NCT05030129|DRUG|Matching placebo for 5-Hydroxytryptophan|Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
215145313|NCT06649578|PROCEDURE|Metabolic-bariatric surgery|Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
215145314|NCT03161249|BEHAVIORAL|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
214458104|NCT04645550|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
214458105|NCT04645550|DRUG|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
214458106|NCT02672917|DRUG|MVT-5873|intravenous infusion (IV)
214458107|NCT02672917|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|IV
215145315|NCT03161249|OTHER|Control group|Group that does not receive any treatment added to its usual treatment
215145316|NCT06020521|OTHER|Three spectrometry differents technics|"Collection of expired air as follows:~* For online mass spectrometry techniques (PTR-MS and SICRIT)~* For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~* By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~* By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
214458108|NCT02672917|DRUG|gemcitabine + nab-paclitaxel|IV
214458109|NCT04979104|PROCEDURE|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
214458110|NCT01160211|DRUG|Lapatinib|1000 mg by mouth once a day
214458111|NCT01160211|DRUG|Trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks)
214458112|NCT01160211|DRUG|Aromatase Inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
214458113|NCT01160211|DRUG|Lapatinib|1500 mg by mouth once daily
214458114|NCT04719273|DRUG|Extended-release Onapristone|Given PO
214458115|NCT04719273|DRUG|Anastrozole|Given PO
214458116|NCT04719273|OTHER|Quality-of-Life Assessment|Ancillary studies
214458117|NCT04719273|OTHER|Questionnaire Administration|Ancillary studies
214458118|NCT04719273|DIAGNOSTIC_TEST|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
214458119|NCT04719273|DIAGNOSTIC_TEST|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
214458120|NCT06521671|DEVICE|Dynaloc implant|Internal fixation with Dynaloc implant
214458121|NCT06521671|DEVICE|Cannulated cancellous screws|Internal fixation with two or three cannulated cancellous screws
214458122|NCT06150326|DEVICE|medical honey Activon® 25g Tube|no blinding procedures will be set up for the adminisration of the treatement
214458123|NCT06150326|DEVICE|standard of care|no blinding procedures will be set up for the adminisration of the treatement
214458124|NCT05866211|OTHER|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
214458125|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
214458126|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
215145317|NCT06653907|DRUG|Levothyroxine Sodium (LT4) Tablets|"Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
215145318|NCT06653907|DRUG|Placebo|"Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
214458127|NCT04173559|BEHAVIORAL|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
214529162|NCT06086405|DEVICE|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
214695278|NCT00236119|DRUG|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
214458128|NCT02206984|DRUG|Tamoxifen|
214458129|NCT02206984|DRUG|Anastrozole|
214458130|NCT02206984|DRUG|Fulvestrant|
214458131|NCT05519878|OTHER|Best Practice|Undergo routine treatment and usual follow up care
214458132|NCT05519878|DEVICE|Bright White Light Therapy|Undergo bright white therapy
214458133|NCT05519878|BEHAVIORAL|Occupational Therapy|Undergo occupational therapy
214458134|NCT05519878|OTHER|Questionnaire Administration|Complete questionnaires
214458135|NCT06345898|DRUG|JWK002|Subretinal administration of gene therapy vector JWK002 to one eye.
214458136|NCT03292861|DRUG|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
214458137|NCT03292861|DRUG|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
214458138|NCT03292861|DRUG|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
214458139|NCT03292861|DRUG|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
214458140|NCT03292861|DRUG|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
214458141|NCT06532994|OTHER|Early rehabilitation intervention|"Based on the indications for early rehabilitation intervention outlined in the Chinese Expert Consensus on Neurological Critical Care Rehabilitation, early rehabilitation interventions are categorized into three stages according to the patient's consciousness level (GCS score), degree of cooperation (S5Q score), and sedation status (RASS score)"
214529163|NCT04921748|PROCEDURE|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
214529164|NCT03730662|DRUG|Tirzepatide|Administered SC.
214529165|NCT03730662|DRUG|Insulin Glargine|Administered SC
214529166|NCT01797562|DIAGNOSTIC_TEST|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
215145319|NCT04240002|DRUG|gilteritinib|Administered orally.
215145320|NCT04240002|DRUG|fludarabine|Administered by intravenous (IV) infusion
215145321|NCT04240002|DRUG|cytarabine|Administered by intravenous (IV) infusion
215145322|NCT04240002|DRUG|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
215145323|NCT01967849|DIAGNOSTIC_TEST|Oral Glucose tolerance test|
215145324|NCT06655168|DEVICE|Video Laryngoscopy|orotracheal intubation by C-Mac ( Video laryngoscopy)
215145325|NCT06655168|DEVICE|Direct Laryngoscopy|Orotracheal intubation using Direct Laryngoscopy
215145326|NCT06654011|DRUG|IN10018|100 mg, orally, once daily
215145327|NCT06654011|DRUG|Nab-paclitaxel|260 mg/m², IV infusion, Q3W
215145328|NCT06654011|DRUG|Cadonilimab|10 mg/kg, IV infusion, Q3W
215145329|NCT06655129|DEVICE|intense pulsed light|intense pulsed light (IPL) using the Medical Device Anthelia
215145330|NCT06654518|DIAGNOSTIC_TEST|Preoperative CBCT for Bone Density and Ridge Width Measurement|Participants in this arm underwent preoperative Cone Beam Computed Tomography (CBCT) scanning to evaluate bone density and alveolar ridge width. The CBCT scans provide high-resolution, 3D images, which was used to guide the planning and placement of dental implants. The primary goal of the intervention was to assess how well the measurements obtained from CBCT could predict the primary stability of the implants postoperatively.
215145331|NCT06596421|OTHER|abdominal massage|abdominal massage
215145332|NCT06589141|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin (500 to 2000 mg orally)
215145333|NCT06589141|DRUG|GlyBURIDE 2.5 MG Oral Tablet|Glyburide (2.5 mg to 20 mg orally)
215145334|NCT06588179|DRUG|SHR-1501+SHR-2005|SHR-1501, instillation；SHR-2005, instillation
215145335|NCT06594484|OTHER|Ml Based Algorithm 1|The values in the ML algorithm were selected according to logistic regression analysis and the values used in the other six scores tested. The success rate of the constructed networks correct predictions was considered as the success rate of the algorithm. The usefulness of the test was determined through AUROC analysis. Two algorithms were tested in our study. In the first algorithm (ML1), the dependent variable was erythrocyte suspension (ES) consumption, and the independent variables included patients; demographic data, laboratory data, and operational data
215145336|NCT06594484|OTHER|Ml Based Algroithm 2|is an Ml algorithm created by combining commonly used bleeding scores
215145337|NCT06594484|OTHER|Bleeding Scores|ACTION CRUSCADE TRACK WILL-BLEED PAPWORTH TRUST ACTAPORT skores used to predict ES need
215145338|NCT06589076|DIAGNOSTIC_TEST|Clinical and Radiographic assessment + Questionnaires|"* Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression."
215145339|NCT06597227|PROCEDURE|Proximal radical gastrectomy|Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\&#39;s habit.
215145340|NCT06597227|PROCEDURE|Total radical gastrectomy|total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended
215145341|NCT06595017|DRUG|Magnesium sulphate|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
215145342|NCT06595017|DRUG|Lidocaine (drug)|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
215145343|NCT06595017|DRUG|Saline|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
215145344|NCT06589349|BEHAVIORAL|Kangaroo Care|Physiological parameters will be measured in the Day (10:00) - Night (22:00) cycle for 3 days, just before being taken into kangaroo care in the experimental group, and when the kangaroo care is terminated, the baby will be measured in the mother's arms. Then, the mother and baby will be placed in kangaroo care for a minimum of 70 minutes
215145345|NCT06595485|BEHAVIORAL|online mindfulness based intervention|We anticipate the online MBI to be 10-20 minutes once daily, at least 5 days per week, for 8 weeks. Online MBI will be available free of charge on iOS and Android platforms. Participants will be instructed to download the app and use for practices. The online MBI group will be introduced to practice including mindful breathing (simple attention to the flow of the breath, inhalations, and exhalations), body scan (attention and awareness of different body parts) and practice of non-judgement of thoughts and emotions and guided meditation (sitting meditation). In addition, we anticipate participants in MBI group will have a group discussion via skype, 30 minute a week for 8 weeks. Moreover, we anticipate participants in MBI group to record how they practice in each day (attendance) as home assignment using online MBI application. For the details of mindfulness practice, we will develop based on data from interview and focus group
215145346|NCT06599853|OTHER|Fever Education|Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
215145347|NCT06591702|OTHER|Questionnaire study|Questionnaire application
215145348|NCT06594081|BEHAVIORAL|Intervention podcasts|Students in the experimental group will listen to podcasts.
215145349|NCT06591910|DRUG|Chemoimmunotherapy|Induction Serplulimab combined with chemotherapy
215145350|NCT06591910|PROCEDURE|Surgery|After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
215145351|NCT06591910|RADIATION|Radiation|After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.
215145352|NCT06603740|DEVICE|Arthrex Nanoscope|Arthrex's all-in-one disposable, 2 mm, chip-on-tip camera system now allows surgeons to miniaturize their treatment solutions
215145353|NCT06603740|DEVICE|Conventional Arthroscopy without Arthrex Nanoscope|partial meniscectomy using conventional arthroscopy
215145354|NCT06594692|DRUG|Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab|"Radiotherapy Protocol:~Short-course radiotherapy using three-dimensional conformal or intensity-modulated radiation therapy techniques. The radiation field will be limited to the tumor bed of the primary colon lesion, excluding surrounding draining lymph nodes and enlarged lymph nodes. The dose is fractionated as 5Gy per fraction, for a total of 25Gy over 5 fractions. Titanium clips will be placed on the proximal and distal ends of the colonic lesion via colonoscopy to guide radiation therapy positioning.~Chemotherapy Protocol (CAPOX Regimen):~1. Oxaliplatin: 130 mg/m², administered intravenously (ivgtt), on day 1 (d1).~2. Capecitabine: 1000 mg/m², orally (po), twice daily (bid), from day 1 to day 14 (d1-14).~Immunotherapy Protocol:~During preoperative treatment, Sintilimab (immune checkpoint inhibitor) will be administered concurrently with each chemotherapy cycle."
215145355|NCT06594692|DRUG|CAPOX Chemotherapy|Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
214458142|NCT03051997|BEHAVIORAL|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
214458143|NCT03051997|BEHAVIORAL|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
214458144|NCT04700878|BEHAVIORAL|Internet-based compassion course for stress managemant|A five week long, structured self-help program with weekly reports to, and feedback from a compassion-focused (CFT) therapist over the Internet. Includes traditional CFT-methods for stress-related problems.
214458145|NCT04700878|BEHAVIORAL|General Internet-based cognitive behavioural course for stress management|A five week long, structured self-help program with weekly reports to, and feedback from a cognitive-behavioral (CBT) therapist over the Internet. Includes traditional CBT-methods for stress-related problems.
214529167|NCT05173233|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
214529168|NCT03372577|BEHAVIORAL|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
214529169|NCT03372577|OTHER|Treatment as usual|Routine discharge counseling
214529170|NCT06188312|OTHER|Health education program|"A pretest questionnaire will be filled out, asking the participants about their knowledge, attitudes, and practices toward chemical hazards and the use of personal protective equipment (PPE) then analysis of the obtained pre-test data will be done.~we will apply a health education program. Development phase: developing the message of the health education program and preparing the materials (slide presentation, brochures, and an educational video).Implementation phase: A group health education session through face-to-face, one hour long, interactive lecture combined with slide presentation will be carried out by the researcher. Evaluation phase: A post-test will be done, after 6 months of the first session, to assess the changes of their knowledge and attitude after the intervention."
214529171|NCT03892928|DRUG|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
214529172|NCT01309243|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
214529173|NCT01309243|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
214529174|NCT05329233|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
214695279|NCT00236119|DRUG|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
214695280|NCT06463548|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
214695281|NCT06463548|DRUG|Capecitabine|Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
214458146|NCT04416815|OTHER|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
214695282|NCT06463548|DRUG|Lenvatinib|Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
214695283|NCT00498238|DRUG|Levothyroxine|
214695284|NCT04831515|DEVICE|Lens A|daily disposable soft contact lens - test lens
214695285|NCT04831515|DEVICE|Lens B|daily disposable soft contact lens - control lens
214458147|NCT04816851|PROCEDURE|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
214458148|NCT05724875|DEVICE|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
214458149|NCT05724875|DEVICE|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
214458150|NCT05899036|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
214458151|NCT03168854|BIOLOGICAL|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
214458152|NCT03168854|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
214458153|NCT06554158|RADIATION|Radiation Therapy|De-escalation of Adjuvant Radiotherapy
214458154|NCT05147649|DIAGNOSTIC_TEST|functional magnetic resonance imaging|functional magnetic resonance imaging
215145356|NCT06591039|PROCEDURE|The study did not involve intervention in the patient's treatment regimen|This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.
215145357|NCT06602986|DIAGNOSTIC_TEST|TACE|"study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima"
215145358|NCT06600035|DEVICE|Gastric ultrasound|A curved array, low-frequency (2-5 MHz) transducer providing a scan depth up to 30 cm will be used. Patients will be scanned in the supine position followed by right lateral decubitus (RLD) position. The sonographic appearance of the gastric antrum will be classified as Grade 0,1 or 2, signifying empty antrum, fluid detected in RLD position only and antral fluid in both supine and RLD positions, respectively, based on the appearance in both the positions. Cross-sectional area (CSA) will be calculated by using two perpendicular diameters-anteroposterior (AP) and craniocaudal (CC) and the formula for area of an ellipse:CSA = (AP × CC × π)/4
215145359|NCT06601816|PROCEDURE|maxillary sinus lift with reamer|Lateral window created with specially designed burs for lateral sinus lift
215145360|NCT06601816|PROCEDURE|maxillary sinus lift with piezzo|lateral window was created using piezo surgery and surgical guide
215145361|NCT06601816|PROCEDURE|maxillary sinus lift with conventional burr|the lateral window was created with conventional rotary instrument burs
215145362|NCT06586424|DIAGNOSTIC_TEST|Anion gap|Patient was taken blood examination before PPCI
215145363|NCT06594224|DRUG|Ibuprofen|Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
215145364|NCT06594224|DRUG|Nalbuphine|Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
214458155|NCT06443125|OTHER|Natural psychotherapy|Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
214458156|NCT04526782|DRUG|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
214529175|NCT03930238|BEHAVIORAL|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
214529176|NCT03930238|BEHAVIORAL|Fitbit Only|Fitbit Only
214529177|NCT02721433|DRUG|Pamidronate|Bone-targeted agent as standard of care
214529178|NCT02721433|DRUG|Denosumab|Bone-targeted agent as standard of care
214529179|NCT02721433|DRUG|Zoledronate|Bone-targeted agent as standard of care
214529180|NCT01458080|DRUG|eltrombopag|eltrombopag
214529181|NCT00632931|DRUG|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
214529182|NCT00632931|DRUG|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
214529183|NCT04332679|DEVICE|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
214529184|NCT04332679|DEVICE|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
214529185|NCT03009019|DRUG|DFN-15 Active|
214529186|NCT03009019|OTHER|DFN-15 Placebo|
214458157|NCT04526782|DRUG|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
214458158|NCT05409183|DRUG|CRD-740|Tablets administered orally.
214458159|NCT05409183|DRUG|Placebo|Tablets administered orally.
214529187|NCT04705402|DRUG|Mannitol|"Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes."
214529188|NCT04705402|DRUG|Saline|Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
214529189|NCT04095598|DIAGNOSTIC_TEST|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
214529190|NCT01965145|DRUG|Gevokizumab|Sterile solution administered subcutaneously
214529191|NCT01965145|DRUG|Placebo|Sterile solution administered subcutaneously
214529192|NCT01441583|DEVICE|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
214529193|NCT01441583|DEVICE|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
215145365|NCT06595316|OTHER|Exercise intervention group|"Exercise will consist of two supervised sessions per week. Starting with vital signs monitoring (blood pressure, temperature, blood oxygen levels, heart rate).~The aerobic component consists of a 5-minute warm-up, followed by 3 bouts of 4-minute cycling at an intensity of 60-65% HRR, with 2-minute active recovery periods in between and a 5-minute cool down. The goal is to increase up to an intensity of around 80%-85% HRR by weeks 16 to 18. Intensity will be monitored with The Borg Rating Scale of Perceived Exertion (RPE). The resistance component will consist of upper body and lower body exercises (door frame rows, wall push-ups, glute bridges, triceps lifts and squat to calf rise) starting on week one with a set of 12 repetitions of each exercise, with 2-minute recovery in between exercises aiming to increase the number of sets and reducing the number of repetitions."
215145366|NCT06603142|DRUG|Febuxostat 20MG Tablets|Febuxostat 20MG Tablets
215145367|NCT06603142|DRUG|Febuxostat 20MG Placebo|Febuxostat 20MG Placebo
215145368|NCT06603142|DRUG|AR882 25MG|AR882 25 MG Capsules
215145369|NCT06603142|DRUG|AR882 12.5MG|AR882 12.5 MG Capsules
215145370|NCT06603142|DRUG|AR882 25MG Placebo|AR882 25MG Placebo
215145371|NCT06603142|DRUG|AR882 12.5MG Placebo|AR882 12.5MG Placebo
215145372|NCT06603142|DRUG|Febuxostat 40MG Tablets|Febuxostat 40MG Tablets
215145373|NCT06603142|DRUG|Febuxostat 40MG Placebo|Febuxostat 40MG Placebo
215145374|NCT06590506|DEVICE|Wearable|Continuous monitoring thought data recorded with wearable (Vivosmart Garmin bracelet)
215145375|NCT06595732|BEHAVIORAL|Pelvic floor and abdominal training|Participants in this group will undergo 12 weeks of in-person training, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. Exercises will target both the pelvic floor muscles and the abdominal muscles. The exercises will be divided into three phases, with progressively increasing difficulty each month. The progression will be achieved by increasing the load, the number of repetitions, and the complexity of the exercises.
215145376|NCT06595732|BEHAVIORAL|Abdominal Hypopressive Technique Exercises|Participants in this group will perform Hypopressive Abdominal Gymnastics exercises as proposed by Marcel Caufriez (1997). The training will last 12 weeks and be conducted in person, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by changing body positions, increasing the number of repetitions, and extending the duration of inspiratory apnea.
215145377|NCT06595732|OTHER|Pelvic floor muscle training|Participants in this group will undergo 12 weeks of in-person training, supervised by a specialist physical therapist, in groups of up to four women. Specific exercises targeting the pelvic floor muscles will be performed, with voluntary and maximal contractions, without involving other muscle groups. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by increasing the load (transitioning from gravitational to antigravitational positions), increasing the number of repetitions, and combining sustained and rapid contractions to enhance the difficulty of execution.
215145378|NCT06586333|DRUG|stress ulcer prophylaxis|In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines
215145379|NCT06591351|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
215145380|NCT06591351|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
215145381|NCT06599151|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
215145382|NCT06594887|DEVICE|SpaceOAR Vue|Peri-rectal hydrogel spacer consists of a layer of polyethylene-glycol gel (SpaceOAR vue) in order to outdistance the prostate from anterior rectal wall
215145383|NCT06594887|DEVICE|BioProtect Balloon Implant System|The balloon spacer is a biodegradable balloon made of poly (L-Lactide-co-caprolactone) which is a co-polymer of Poly Lactide acid and epsilon Caprolactone (BioProtect Balloon Implant System, BioProtect Ltd) inflated with saline, providing around 18 mm space height , and can be deflated and repositioned if needed, both laterally and along the distal /proximal planes, for optimal uniformity of spacing.
215145384|NCT06588933|OTHER|completion of a questionnaire|completion of a questionnaire by participant
215145385|NCT06595433|OTHER|Experimental|In the PAPE 90% protocol, participants performed a general warm-up (e.g., jogging on a treadmill) for 5 minutes and a weightlifting-specific warm-up for 5 minutes, followed by 2 minutes of rest. After resting, they were asked to perform ten repetitions of dip squats with body weight and rested for 1 minute.Then, unlike the unloaded protocol, they performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes. After resting, they performed a snatch to exhaustion with 75% of their maximum snatch weight. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions between sets was recorded.
214529194|NCT04517968|OTHER|immediate implant with customized healing abutment|"* All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant."
214529195|NCT00849745|PROCEDURE|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
214529196|NCT03014908|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
214529197|NCT00735228|DEVICE|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
214529198|NCT05291585|DEVICE|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
214529199|NCT05291585|DEVICE|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
214529200|NCT06375018|OTHER|Placebo Technique|In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.
214529201|NCT06375018|OTHER|Diaphragm Stretching|The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
214529202|NCT03341312|BIOLOGICAL|LY900014|Administered SC
214529203|NCT03341312|BIOLOGICAL|Insulin Lispro|Administered SC
214529204|NCT02640326|OTHER|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
214529205|NCT02640326|OTHER|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
214529206|NCT04712500|DRUG|AND017|AND017 oral capsule
214529207|NCT05692414|DIETARY_SUPPLEMENT|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
214529208|NCT06448845|PROCEDURE|Arm intravenous regional anesthesia|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
215145386|NCT06595433|OTHER|Experimental|In the PAPE 50% protocol, 5 minutes of general warm-up (jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up were followed by 2 minutes of rest as in the other protocols. After resting, they were asked to perform ten repetitions of body-weighted dip squats and rested for 1 minute. Then, unlike the unloaded and PAPE 90% protocols, they performed eight repetitions of bottom squats with 50% of their maximal bottom squats for one repetition and rested for 4 minutes. After resting, they performed snatches with 75% of their maximum snatch weight until exhaustion. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions was recorded for statistical analysis.
215145387|NCT06595433|OTHER|unloaded protocol|In the unloaded protocol, subjects performed a 5-minute general warm-up (e.g., jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up followed by 2 minutes of rest. After resting, they performed ten repetitions of bottom squats with their body weight and then rested for 1 minute. After rest, they performed the snatch movement with 75% of their maximum snatch weight until exhaustion. Then, they rested for 2 minutes and again performed the snatch with 75% of their maximum snatch weight until exhaustion. The maximum number of snatch repetitions performed by the weightlifters was recorded for statistical analysis.
214529209|NCT06448845|PROCEDURE|Forearm IVRA block|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
215145388|NCT05006352|DRUG|DNL343|Oral repeating dose
214529210|NCT00839306|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
214529211|NCT00839306|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
215145389|NCT05006352|DRUG|Placebo|Oral repeating dose
215145390|NCT05813574|OTHER|Observational patient reported outcomes|Of COVID-19 patients
215145391|NCT06979440|OTHER|No intervention|No intervention
215145392|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
214458160|NCT02274662|BIOLOGICAL|Cultured Thymus Tissue|"Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection."
214458161|NCT02274662|PROCEDURE|Blood Draw|
214458162|NCT02274662|DRUG|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
214458163|NCT02692105|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
214458164|NCT02692105|RADIATION|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
214458165|NCT05931484|DRUG|Gemfibrozil|Oral Solution
214458166|NCT05931484|DRUG|Placebo|Daily dose of Placebo
214458167|NCT03709758|DRUG|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
214458168|NCT03709758|DRUG|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
214458169|NCT03709758|DRUG|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
214458170|NCT03469362|PROCEDURE|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
214458171|NCT03469362|PROCEDURE|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
214529212|NCT03780699|PROCEDURE|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
214529213|NCT01812707|DRUG|Alirocumab|Two SC injections in the abdomen only
214529214|NCT01812707|DRUG|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
214529215|NCT01812707|DRUG|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
214529216|NCT05060237|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
214529217|NCT00965302|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
214529218|NCT00965302|BEHAVIORAL|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
214529219|NCT00001848|DRUG|Raloxifene|
214529220|NCT01819428|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
214529221|NCT06363877|DRUG|Povidone-Iodine|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline."
214529222|NCT06363877|DRUG|Normal Saline|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline."
214458172|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
214458173|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
214458174|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
214458175|NCT03472807|OTHER|Collection of blood sample or saliva|at Inclusion
214458176|NCT03472807|OTHER|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
214458177|NCT03472807|OTHER|Collection of blood sample if tumor sample is not available|at Inclusion
214458178|NCT05255224|OTHER|Not applicable as observational study|Not applicable as observational study
214458179|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
214458180|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
214529223|NCT02007421|PROCEDURE|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
214529224|NCT02007421|PROCEDURE|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
214529225|NCT00218075|DRUG|Levodopa|
214529226|NCT00218075|DRUG|Carbidopa|
214529227|NCT00218075|BEHAVIORAL|Clinical Management|
214529228|NCT00218075|BEHAVIORAL|Relapse Prevention Therapy|
214529229|NCT00218075|BEHAVIORAL|Contingency Management|
214529230|NCT03221634|BIOLOGICAL|Pembrolizumab|IV infusion
214529231|NCT03221634|BIOLOGICAL|Daratumumab|IV infusion
214529232|NCT01697592|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
214529233|NCT01697592|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
214529234|NCT05733000|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214529235|NCT05733000|PROCEDURE|Computed Tomography|Undergo CT
214529236|NCT05733000|DRUG|Devimistat|Receive IV
215145393|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
215145394|NCT06985732|OTHER|Virtual Reality|Use of virtual reality to elicit positive emotions and improve the well-being of elderly patients hospitalized in SMR
215145395|NCT02484391|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
215145396|NCT02484391|DRUG|Cytarabine|Given IV
215145397|NCT02484391|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplant
214529237|NCT05733000|DRUG|Fluorouracil|Receive IV
214708702|NCT04920136|PROCEDURE|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
214708703|NCT06356155|DRUG|Enfortumab vedotin|1.25 mg/kg IV
215145398|NCT02484391|DRUG|Mitoxantrone Hydrochloride|Given IV
214529238|NCT05733000|DRUG|Gemcitabine Hydrochloride|Receive IV
214529239|NCT05733000|DRUG|Hydroxychloroquine|Receive PO
214529240|NCT05733000|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214529241|NCT05315076|OTHER|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
214529242|NCT05315076|OTHER|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
214529243|NCT02396758|DEVICE|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
215145399|NCT06602323|COMBINATION_PRODUCT|TMLI/Flu/Mel|Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
215145400|NCT06587503|BIOLOGICAL|BioNTech - Pfizer COVID-19 vaccine|Vaccine for protection from COVID-19
215145401|NCT06587503|BIOLOGICAL|1mL saline solution|Placebo
215145402|NCT06587503|BIOLOGICAL|rVSV∆G-ZEBOV-GP|Vaccine for protection from Zaire Ebola virus
215145403|NCT06597890|BEHAVIORAL|educational content (sleep hygiene)|app-based sleep hygiene-related educational content
215145404|NCT06597890|BEHAVIORAL|sleep hygiene strategies|app-based self-selection of sleep hygiene strategies
215145405|NCT06597890|BEHAVIORAL|reminders|daily reminders sent via push notifications
215145406|NCT06597890|BEHAVIORAL|review of behavioural goal|app-based review of behavioural goal
215145407|NCT06597890|BEHAVIORAL|educational content (sleep guidelines)|app-based educational content on recommended sleep guidelines
215145408|NCT06597890|BEHAVIORAL|comparison of current behaviour to ideal behaviour|use of smartwatch/smartphone data to assess current behaviour and compare it to ideal behaviour
215145409|NCT06597890|BEHAVIORAL|goal setting|prompt participant to set a goal in relation to targeted behaviour
214529244|NCT02396758|BIOLOGICAL|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
214529245|NCT02312362|PROCEDURE|Combined sclerotomy ab interno and phaco|
214529246|NCT02312362|PROCEDURE|Phacoemulsification with IOL implantation|
214529247|NCT01132222|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
214529248|NCT00764010|DIETARY_SUPPLEMENT|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
214529249|NCT00764010|DIETARY_SUPPLEMENT|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
214529250|NCT00764010|DIETARY_SUPPLEMENT|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
214529251|NCT00111163|DRUG|sulfadoxine-pyrimethamine with artesunate|
215145410|NCT06597890|BEHAVIORAL|educational content (Vigorous Intermittent Lifestyle Physical Activity (VILPA))|app-based educational content on VILPA
214458181|NCT05415501|BEHAVIORAL|Sentence training|Participants will be trained to read, make, and recall sentences during each session.
214458182|NCT04049331|DRUG|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
214458183|NCT04049331|OTHER|placebo|first two doses four weeks apart; following three more doses every ten weeks.
214529252|NCT00111163|DRUG|amodiaquine with artesunate|
214529253|NCT00111163|DRUG|chlorproguanil-dapsone|
214529254|NCT00829647|DRUG|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
214529255|NCT06106789|DRUG|Tobramycin inhalation solution|"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."
214529256|NCT00485914|BEHAVIORAL|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
214529257|NCT00485914|BEHAVIORAL|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
214529258|NCT01095601|DRUG|Avanafil|"* Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
214529259|NCT05376735|BEHAVIORAL|Purrble intervention|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
214568511|NCT03949855|DRUG|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
214708704|NCT06356155|DRUG|Pembrolizumab|200 mg IV
215145411|NCT06597890|BEHAVIORAL|screentime breaks|repeated daily reminders to break up screentime
214458184|NCT06798727|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
214458185|NCT06798727|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
214458186|NCT06798727|DRUG|High Hyal Plus|A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
214458187|NCT06051695|BIOLOGICAL|A2B694|Autologous logic-gated Tmod CAR T cells
214458188|NCT06051695|DIAGNOSTIC_TEST|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
214458189|NCT06800365|DEVICE|Sensor|The FreeStyle Libre Pro sensor is a device whereby a sensor is inserted into subcutaneous tissue (upper arm) and measures the interstitial blood glucose which is then available for later download. It comes pre-calibrated meaning that no fingerstick glucose monitoring is required to improve accuracy of the sensor.
214458190|NCT00131703|DRUG|Amodiaquine|
214458191|NCT00131703|DRUG|Sulphadoxine-pyrimethamine|
214458192|NCT00131703|DRUG|Chloroquine|
214458193|NCT06801392|PROCEDURE|pulsed-field ablation|PVI + PW ablation
214458194|NCT02838381|OTHER|Additional biological samples|blood and tissue samples
214695286|NCT02698618|PROCEDURE|Diagnostic|"Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
215145412|NCT06593990|DEVICE|echocardography|"Patients will be subjected to transthoracic echocardiography including, the following parameters will be measured:~* Left ventricular (LV) dimensions: end diastolic and systolic dimensions and LV ejection fraction (EF).~* Trans- mitral Doppler flow velocities including early (E) and late(A) diastolic velocities, E/A ratio.~* LA anteroposterior diameter measure from 2D parasternal long axis view targeted M-mode.~* LA superior-inferior and medio-lateral diameters measure from the apical 4 chamber view.~* LA volume included:~* Maximal LA volume measure at the end of systole~* Minimal LA volume will be measured at end diastole just at the closure of the mitral valve.~* Pre contractile LA volume ( LAV pre-A\] measured at P-wave onset on ECG just before atrial contraction."
215145413|NCT06593990|DEVICE|musculoskeletal ultrasonography|Ultrasound detected synovitis t
215145414|NCT06593990|DIAGNOSTIC_TEST|lipid profile test|The lipid profile typically includes measurement of total cholesterol, HDL-cholesterol (often called good cholesterol), LDL-cholesterol (often called bad cholesterol), and triglycerides.
215145415|NCT06593990|DIAGNOSTIC_TEST|C reactive protein|A c-reactive protein test measures the level of c-reactive protein (CRP) in a sample of your blood. CRP is a protein that your liver makes. Normally, you have low levels of c-reactive protein in your blood. Your liver releases more CRP into your bloodstream if you have inflammation in your body. High levels of CRP may mean you have a serious health condition that causes inflammation.
214458195|NCT04806451|DRUG|Crinecerfont|CRF type 1 receptor antagonist
214458196|NCT04806451|DRUG|Placebo|Non-active dosage form
214458197|NCT05356195|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
214458198|NCT06699433|BEHAVIORAL|Virtual standardized patients (VSPs)|Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
214458199|NCT06699433|BEHAVIORAL|Case teaching manuals|Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
214458200|NCT06699433|BEHAVIORAL|Case teaching videos|Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
214458201|NCT04893278|OTHER|Virtual reality|Use of Virtual reality goggles during procedure
214458202|NCT06801301|DEVICE|whole body vibration|Standing in different static positions or exercising on a vibrating platform.The mechanical stimuli of vibration transmitted to the body and stimulate muscle spindles which activate the alpha motor neurons and initiates muscle contractions comparable to the ''tonic vibration reflex. The effect of WBV on the neuromuscular properties of skeletal muscles and spinal mechanisms is demonstrated by a decreased electromechanical delay.
214458203|NCT06801301|OTHER|Resistance Exercise|Resistance training as a mode of exercise to promote several health benefits, including improvements in the muscle mass and strength of healthy adults.Resistance training, where muscles are required to contract against an opposing load, has been shown to be a beneficial form of rehabilitation in clinical populations prone to muscle wasting, providing stimuli to increase protein synthesis and muscle mass.
214458204|NCT06517680|OTHER|tight control management|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
214458205|NCT06517680|OTHER|standard follow-up|Patients are monitored according to standard practice
214458206|NCT03530774|DIETARY_SUPPLEMENT|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
214458207|NCT03530774|DIETARY_SUPPLEMENT|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
214458208|NCT04705623|BEHAVIORAL|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
214458209|NCT05796739|DIAGNOSTIC_TEST|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
214458210|NCT05796739|DIAGNOSTIC_TEST|Medical treatment without further testing|Optimal medical treatment for primary prevention.
214529260|NCT05376735|BEHAVIORAL|Single Session Intervention|"The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
214529261|NCT00265096|BIOLOGICAL|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
214529262|NCT00265096|BIOLOGICAL|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
214529263|NCT00265096|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
214529264|NCT05611658|OTHER|MR, PET CT|diagnostic method
214529265|NCT00774306|DRUG|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
214529266|NCT00774306|DRUG|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
214529267|NCT00774306|DRUG|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
214529268|NCT05325658|OTHER|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
214529269|NCT02269033|BEHAVIORAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
214529270|NCT02269033|BEHAVIORAL|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
214529271|NCT01862679|OTHER|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
214529272|NCT01862679|PROCEDURE|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
214529273|NCT05478200|BEHAVIORAL|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
214529274|NCT05478200|OTHER|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
214529275|NCT03126188|DRUG|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
214695287|NCT02698618|DRUG|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
214708705|NCT03421574|DEVICE|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
215145416|NCT06593990|DIAGNOSTIC_TEST|Complete blood count CBC|"A complete blood count, or CBC, is a blood test that measures many different parts and features of your blood, including:~Red blood cells, which carry oxygen from your lungs to the rest of your body. White blood cells, which fight infections and other diseases. There are five major types of white blood cells. A CBC test measures the total number of white cells in your blood. A different test called a CBC with differential measures the number of each type of these white blood cells.~Platelets, which stop bleeding by helping your blood to clot. Hemoglobin, a protein in red blood cells that carries oxygen from your lungs to the rest of your body.~Hematocrit, a measurement of how much of your blood is made up of red blood cells.~Mean corpuscular volume (MCV), a measure of the average size of your red blood cells."
215145417|NCT06593990|DIAGNOSTIC_TEST|Erythrocyte sedimentation rate (ESR).|An erythrocyte sedimentation rate (ESR) is a blood test that that can show if you have inflammation in your body. Inflammation is your immune system\&#39;s response to injury, infection, and many types of conditions, including immune system disorders, certain cancers, and blood disorders.
214529276|NCT03126188|DRUG|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
215145418|NCT06593990|DEVICE|x ray of the hand|The X-ray may show a hand with advanced rheumatoid arthritis. \&#34;Bone erosion\&#34; means cartilage and bone are worn away. \&#34;Bone displacement\&#34; means that a bone has moved out of its normal position. This X-ray shows how bone erosion and bone displacement can change the shape of the hand.
215145419|NCT06591390|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
215145420|NCT06591390|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
215145421|NCT06591650|DRUG|gemcitabine hydrochloride|800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
215145422|NCT06591650|DRUG|Cisplatin|25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.
215145423|NCT06591650|DRUG|Nab-paclitaxel|100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
215145424|NCT06591650|DRUG|Durvalumab|1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.
215145425|NCT06588764|PROCEDURE|modified deep lateral and/or medial wall decompression|Modified deep lateral orbital wall decompression is based on traditional outer wall decompression with combined abrasion of the deep outer orbital wall (including the greater pterygoid wing) to achieve adequate enlargement of the orbital cavity.
215145426|NCT06589843|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
215145427|NCT06586801|OTHER|Patient-reported outcome|"Patient-reported outcome data will be collected using the following instruments:EORTC QLQ-C30, EORTC QLQ-LC13, selected items from the PRO-CTCAE, EORTC-IL46.~The first collection of the information in questionnaires (EORTC QLQ-C30, EORTC QLQ-LC13, PRO-CTCAE \[select items\]), which defined as baseline- PROs, will be completed at Cycle 1, Day 1±7days prior to administration of study drug; then the rest times of collection will be completed at every two treatment cycle prior to administration of study drug (i.e., on Cycle 3, Day 1±7days; Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days) . EORTC-IL46 will be completed at Cycle 3, Day 1±7days (baseline) prior to administration of study drug; then at every other study treatment cycle prior to administration of study drug (i.e., on Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days)"
215145428|NCT06599450|DEVICE|Root form dental implant|Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
215145429|NCT06588881|DEVICE|nebulized application of the haemostatic surgical sealant after gastrointestinal endoscopic resection|ENDONEB, a nebulizing catheter containing the synthetic haemostatic-sealant Glubran®, is inserted in the operative channel of the endoscope until it is pushed out of the endoscope tip approximately 2 cm. The haemostatic-sealant is nebulized over the surface of the post resection mucosal defect by activating the propellant (medical-inert-gas) container. An amount of about 0.3 mL of Glubran® 2 (or more - depending on dimension of the lesion) is applied on mucosal or sub-mucosal defect in order to create a proper haemostaticsealant film.
215145430|NCT06598501|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|an open arm study of 10 gambling disorder subjects will be conducted to determine the efficacy and feasibility of a multimodalistic therapy of rTMS and Cognitive Behavioral Therapy (CBT) for gambling disorder in Indonesia.
214458211|NCT06701968|OTHER|Healthy Nordic Diet|Participants will be adviced a healthy Nordic diet and will also receive certain Nordic foods high in wholegrains and polyunsaturated fat from vegetable sources
215145431|NCT06595394|OTHER|Exercise|Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.
214458212|NCT06701968|BEHAVIORAL|Usual Care|Usual care lifestyle advice and national and general recommendations on diet
214458213|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
214458214|NCT02936752|DRUG|Entinostat|Given PO
214458215|NCT02936752|BIOLOGICAL|Pembrolizumab|Given IV
214458216|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
214458217|NCT06801769|DIAGNOSTIC_TEST|C-peptide|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT).
214529277|NCT03126188|DRUG|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
214529278|NCT01039597|DRUG|ORE1001|Oral capsules containing 300 mg of the active, study drug
214529279|NCT01039597|DRUG|Placebo|placebo capsules
214529280|NCT04927559|OTHER|Survey Administration|Complete survey
214529281|NCT02261545|DIETARY_SUPPLEMENT|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
214529282|NCT02261545|DIETARY_SUPPLEMENT|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
214529283|NCT01024829|RADIATION|Radiotherapy|Radiotherapy
214529284|NCT00558220|PROCEDURE|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
215145432|NCT06595394|OTHER|Home program|The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
215145433|NCT06590246|BIOLOGICAL|Armored and GPC3-targeted autologous CAR T-cell|Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.
215145434|NCT06596967|DEVICE|Heat therapy|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will be set to warm the water to 42°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
215145435|NCT06596967|DEVICE|Sham|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will warm the water to 33°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
215145436|NCT06586567|OTHER|Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas|"2\. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori"
215145437|NCT06590909|COMBINATION_PRODUCT|Fractional CO2 laser assisted PDT|Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
215145438|NCT06585813|PROCEDURE|dental implant|we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery
215145439|NCT06585813|PROCEDURE|Fibrogide membrane|we were comparing the efficacy of Fibrogide with the Connective tissue graft
215145440|NCT06585813|PROCEDURE|connective tissue graft|the control group was the connective tissue graft group and the test group was the Fibrogide group
215145441|NCT06585813|PROCEDURE|second stage|second stage to determine the thickness gained after the graft and to place a healing abutment
215145442|NCT06602505|PROCEDURE|Group A: Field Block Group|Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
215145443|NCT06594471|OTHER|Questionnaire on late-term physical effects|Patients will be asked to indicate any potential late-term physical effects following cancer treatment: neurocognitive, auditory, ocular, oral/dental, dermatologic, cardiovascular, pulmonary, gastro-intestinal, urinary tract, genital, endocrine/metabolic, musculoskeletal, neurological, immune disorders and occurrence of any subsequent malignant neoplasms.
214458218|NCT04197765|DEVICE|accelerated Thetaburst stimulation|"We will administer 20-30 treatment sessions over the course of the study. The study technician will place the coil over the Fp2 electrode of a 10-20 International EEG system hair net, to approximate stimulation of the R-OFC). For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays. We estimate all study-related treatments will be complete in 5-6 weekdays."
214458219|NCT04197765|DEVICE|Sham Comparator|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
214458220|NCT04605549|DRUG|CIN-107 2 mg dosing|One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
214529285|NCT00558220|PROCEDURE|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
214529286|NCT00558220|PROCEDURE|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
215145444|NCT06594471|OTHER|Questionnaire on sexual and reproductive health outcomes|Patients will be asked to complete the following questionnaires: Body Appreciation Scale-2 (BAS-2), Body Image Scale (BIS), EORTC QLQ-SH22, Body Image Scale in Gynecological Cancer (SABIS-G). Patients who underwent a fertility-sparing procedure will be asked to fill out the Reproductive Concerns after Cancer (RCAC) and Decision Regret Scale (DRS), whereas those who experienced iatrogenic menopause will complete the MENQOL questionnaire to assess menopause-related quality of life.
215145445|NCT06594471|OTHER|Questionnaire on psychological outcomes|Patients will be asked to complete the following questionaires: EORTC QLQ-C30, Clinical outcomes in Routine Evaluation (CORE-OM), Ten Item Personality Inventory (TIPI), Hospital Anxiety and Depression Scale (HADS), General Self-Efficacy (GSE) Scale, Mini-Mental Adjustment to Cancer (Mini-MAC), Cancer Worry Scale (CWS), Multidimensional Scale of Perceived Social Support (MSPSS), the Patient Health Engagement scale and the Supportive Care Needs Survey-Short Form (SCNS-SF34).
215145446|NCT06594471|OTHER|Questionnaire on social outcomes|Patients will be asked to complete the following questionaires: Medical Consumption Questionnaire (iMCQ), Productivity Cost Questionnaire (iPCQ) and the Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire.
215145447|NCT06595511|DEVICE|Sensory Entrainment-Integrated Cognitive Game Kit|Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.
215145448|NCT06590571|DEVICE|TRAcelet™|The group using TRAcelet™ after transradial angiography/intervention receives 2 hours and 15 minutes of compression from the device, followed by 3 stepwise releases every 15 minutes. There are two sizes of TRAcelet™ available, large and medium. Assuming that a Korean adult's wrist size is smaller than that of the Western population, we used a medium-sized TRAcelet™.
214458221|NCT04605549|DRUG|CIN-107 4 mg dosing|Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
214458222|NCT04605549|DRUG|CIN-107 8 mg dosing|Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
214458223|NCT06801938|PROCEDURE|Perioperative Cystoscopy and Methylene Blue Test|The ability of perioperative methylene blue and cystoscopy versus postoperative cystoscopy to detect complications will be compared in patients.
214458224|NCT06801795|DEVICE|AviClear|"Participants will receive as many as 4 treatments, each treatment lasts approximately 10 minutes, with intervals of up to 5 weeks apart. The treatments will be conducted in person. Participants will be followed at approximately week 5 post-treatment completion (via phone) at 12 weeks and 24 weeks post treatment completion onsite.~This is a 1726 nanometer laser treatment"
214458225|NCT03659734|BEHAVIORAL|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
214458226|NCT03659734|BEHAVIORAL|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
214458227|NCT06800950|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
214458228|NCT06800950|BIOLOGICAL|QIV Control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
214458229|NCT04489771|DRUG|Belzutifan|Oral administration
214458230|NCT06801652|OTHER|Sperm morphology indexes|We analyzed all sperm morphology indexes in all groups.
214458231|NCT06147622|DRUG|Prazosin + cyproheptadine|Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.
214458232|NCT06147622|DRUG|KT110|Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.
214458233|NCT04776330|BIOLOGICAL|BCMA targeted prime CAR-T cells|BCMA targeted prime CAR-T cell therapy
214529287|NCT00558220|PROCEDURE|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
214529288|NCT00558220|PROCEDURE|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
214529289|NCT00558220|RADIATION|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
214568512|NCT03949855|DRUG|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
214708706|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
214708707|NCT05387577|DRUG|Transdermal patch|Estradiol patch therapy for 8 weeks
214458234|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
214458235|NCT05899452|BEHAVIORAL|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
215145449|NCT06590571|OTHER|Gauze pad|Patients received radial artery compression by a gauze pad fastened with 3M™ Durapore™ surgical tape. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
215145450|NCT06589609|BIOLOGICAL|FluBHPVE6E7|Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.
215145451|NCT06592885|PROCEDURE|Atraumatic Restorative Treatment in treatment of carious primary molars|ART, which took place in Tanzania during the mid-1980s, is a conservative approach involving the removal of carious lesions using hand instruments, followed by the application of a glass ionomer restoration. This technique aims to be minimally invasive, promoting the preservation of tooth structure. The ART technique, employed in situations where ideal clinical conditions are challenging to achieve, has demonstrated effectiveness as a reliable method for managing cases where conventional treatment methods face resistance from children . However, concerns exist regarding the longevity of ART restorations and the impact of operator skill on outcomes.
215145452|NCT06592885|PROCEDURE|Hall Technique in treatment of carious primary molars|"The Hall technique, proposed by Norna Hall in the 1980s, involves the placement of preformed metal crowns on primary molars without any tooth preparation or local anesthesia.~Advocates of the Hall technique emphasize its simplicity, reduced need for traditional drilling, and high reported success rates in clinical studies.~However, concerns have been raised regarding long-term aesthetics and potential psychological impacts due to the visibility of metal crowns."
215145453|NCT06596083|DIETARY_SUPPLEMENT|Placebo supplement|oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water
215145454|NCT06596083|DIETARY_SUPPLEMENT|Ketone ester supplement|Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
215145455|NCT06590311|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability evaluation through different domains
214458236|NCT05899452|BEHAVIORAL|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
214458237|NCT06565819|DIAGNOSTIC_TEST|The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)|DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
214458238|NCT03241459|DEVICE|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
214458239|NCT03241459|DEVICE|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
214458240|NCT06796296|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide involves administering Loperamide orally, with a daily dosage of 2mg. This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate sysmptoms associated with LARS
214458241|NCT06795633|OTHER|Holistic Care Program for High-Risk Pregnancies|High-risk pregnant women admitted to the perinatology clinic participated in the Holistic Care Program for High-Risk Pregnancies in addition to the midwifery care provided in the clinic.
214458242|NCT03476746|DRUG|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
214458243|NCT03476746|DRUG|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
214458244|NCT06801873|OTHER|Endotoxin (E. coli O:113, Reference Endotoxin)|Intravenous administration of 1 ng/kg (total body weight) endotoxin (Lot no. 94332B1; List Biological Laboratories, Campbell, USA). This is a non-investigational product. Endotoxin is used as challenge agent to achieve a controlled inflammatory state.
214458245|NCT05978180|DEVICE|Medical Device : HO-1|The injection will be performed at Day 1.
214458246|NCT05978180|DEVICE|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
214458247|NCT05978180|DEVICE|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
214458248|NCT03793972|OTHER|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
214458249|NCT03793972|OTHER|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
214529290|NCT03897049|BEHAVIORAL|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
215145456|NCT06593002|BEHAVIORAL|Therapeutic play|The children in the experimental group were given a therapeutic toy designed for them by the student nurse half an hour before the treatment, the toy and game were introduced, and they were allowed to play with this toy for half an hour, accompanied by the student nurse.
215145457|NCT06602284|COMBINATION_PRODUCT|Dermapen 4™|Dermapen 4™ conjunction with MG-CLR
215145458|NCT06586450|DEVICE|Low level laser therapy|The participants will receive Low Level Laser on lumbo-pelvic region for 20 min/sessions,3 sessions / week for 12 weeks, with the following parameters: Wavelength: 808 nm, continuous mode, Output power: 160 mw, Penetration depth: 4 cm, Power density:0.16 J/cm2.
214458250|NCT05558501|OTHER|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
214458251|NCT05558501|OTHER|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
215145459|NCT06586450|DEVICE|Interferential current|All participants will receive interferential current on lumbopelvic region ( quadripolar technique) for 25 min/session, 3 sessions/week for 12 weeks, with the following parameters: carrier frequency of 4 KHZ and sweep frequency 95 HZ, intensity based on patient's tolerance without muscle contraction.
215145460|NCT06586450|OTHER|Core stability exercise|The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.
215145461|NCT06601881|OTHER|Experimental|"Thoracic mobilization exercises will include:~1. Thoracic Spine Extension exersice~2. Thoracic rotation exersice~3. Cat-Camel Exercise~4. Lateral Flexion of the Thoracic Spine~5. Muscules Psoas Stretching~6. Diaphragm Release Technique~Diaphragmatic Breathing Training will include:~1. Diaphragmatic Breathing~2. Crocodile Breathing Technique~3. Breathing with an exercise band~4. Pursed lip breathing"
215145462|NCT06601881|OTHER|Control (placebo) group|"Placebo Thoracic mobilization exercises will include:~1. Placebo Thoracic Spine Extension exersice~2. Placebo Thoracic rotation exersice~3. Placebo Cat-Camel Exercise~4. Placebo Lateral Flexion of the Thoracic Spine~5. Placebo Muscules Psoas Stretching~6. Placebo Diaphragm Release Technique~Placebo Diaphragmatic Breathing Training will include:~1. Placebo Diaphragmatic Breathing~2. Placebo Crocodile Breathing Technique~3. Placebo Breathing with an exercise band~4. Placebo Pursed lip breathing"
215145463|NCT06604182|OTHER|Community-based Simplified HCV Testing and Treatment Algorithm|The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
215145464|NCT06588517|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
215145465|NCT06588517|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
215145466|NCT06600529|DEVICE|Photo-Biomodulation|Application at acupuncture points for 20 seconds each week. using 810nm Laser probe
215145467|NCT06600529|BIOLOGICAL|Autologous PRP|IV injection of Autologous Plasma Rich Platelets (PRP) on Days 0, 15, 30, and 45.
214458252|NCT02979522|DRUG|Brentuximab vedotin|Brentuximab vedotin infusion
214458253|NCT02979522|DRUG|Doxorubicin|Doxorubicin infusion
214458254|NCT02979522|DRUG|Vinblastine|Vinblastine infusion
214458255|NCT02979522|DRUG|Dacarbazine|Dacarbazine infusion
214458256|NCT06453616|BEHAVIORAL|Hello bundle|"Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)"
214458257|NCT04289870|DEVICE|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
214458258|NCT03197571|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214458259|NCT03197571|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
214458260|NCT03197571|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214458261|NCT03197571|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214458262|NCT03197571|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214458263|NCT03197571|DRUG|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214458264|NCT03197571|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
214458265|NCT03197571|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214458266|NCT03197571|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214458267|NCT03197571|DRUG|Lovaza|Omega-3-acid ethyl esters
215145468|NCT06600529|BIOLOGICAL|Exosome Therapy|IV injection of Umbilical Cord-Derived Exosomes at laser acupuncture points Umbilical Cord-Derived Exosomes
215145469|NCT06600529|OTHER|Standard Care (in control arm)|Routine conventional including Applied Behavioral Analysis (ABA) for Autism Spectrum Disorder (ASD)
214458268|NCT03197571|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
214458269|NCT03197571|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
214458270|NCT03197571|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
214708708|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
215145470|NCT06588127|BEHAVIORAL|nudge|Nudge interventions are developed based on the scoping review and qualitative research by the research team, which involves commitment (behavioral contracts), norms (case and experience sharing), significance and framing effects (posters, health behavior identification posts), reminders, and incentives (arteriosclerosis detection). The content encompasses diet, physical activity, medication management, self-monitoring, and control of smoking and alcohol. From the viewpoint of bounded rationality in behavioral economics, and drawing on prior research that has pinpointed decision-making biases in patients' self-management behaviors, nudging strategies have been developed to assist individuals in overcoming these biases or to utilize the patterns of these biases to steer them toward making choices that are in line with their health.
215145471|NCT06402773|DEVICE|The Signati Separo™ Vessel Sealing System|Vessel Sealing System
215145472|NCT06993025|DRUG|Ivonescimab+chemotherapy|"Dosing Schedule:~1. Ivonescimab: 20 mg/kg, Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~2. Irinotecan Liposome: 70 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~3. Calcium Folinate (LV): 400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~4. 5-FU: 2400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W)."
215145473|NCT06993259|DEVICE|Virtual Reality|Children in the virtual reality (VR) group watched a 360° Ice Age video via headset starting three minutes before and continuing throughout the allergy test. The video, selected by pediatric experts, was age-appropriate, visually rich, and emotionally neutral. VR provided immersive distraction to reduce pain, fear, and anxiety. After the test, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction through structured forms.
215145474|NCT06993259|DEVICE|Serious game|Children in the serious game group played Subway Surfers on a tablet starting three minutes before and continuing throughout the skin prick test. The game was chosen by pediatric experts for its age-appropriateness and ability to sustain attention without overstimulation. As a fast-paced, interactive tool, it served as an effective distraction to reduce pain, fear, and anxiety. After the procedure, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction using structured feedback forms.
215145475|NCT06993311|DEVICE|Xen Gel Stent implantation|Consecutive patients who underwent either stand-alone Xen stent insertion with MMC(mitomycin C) or combined phacoemulsification between 2018 and 2022
215145476|NCT06866431|PROCEDURE|Piezoclean|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group.Test group sites will receive 90 seconds of ultrasonic cavitation treatment with 0.9% sodium chloride via a specific insert (Piezoclean, Esacrom, Imola, Italy) driven by a piezoelectric device with the following modalities: i) piezo settings: SURGERY 1 U 040 V 080 P 100; ii) no pressure should be applied to prevent the steel insert from coming into contact with the bone; iii) do not create a complete seal to avoid heating the liquid, which could cause potential discomfort or harm to the patient.~An X suture will be then applied using non-resorbable synthetic monofilament."
215145477|NCT06866431|PROCEDURE|Control|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group. In control group, a simple 0.9% sodium chloride irrigation (control group) will be performed.~An X suture will be then applied using non-resorbable synthetic monofilament."
215145478|NCT06589206|OTHER|modified design of twin block|Vacuum formed twin block appliance with sagittal blocks
215145479|NCT06599801|PROCEDURE|Thoracodorsal artery perforator flap reconstruction surgery|Oral squamous cell carcinoma patients underwent reconstruction with thoracodorsal artery perforator (TDAP) flaps following tumor resection.
215145480|NCT06599801|PROCEDURE|Forearm flaps reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
215145481|NCT06599801|PROCEDURE|Anterolateral thigh flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection
214458271|NCT03197571|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
214458272|NCT03197571|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214458273|NCT03197571|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
214458274|NCT03197571|BIOLOGICAL|GI-4000|RAS yeast vaccine
214458275|NCT03197571|BIOLOGICAL|GI-6207|CEA yeast vaccine
214458276|NCT03197571|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214458277|NCT03197571|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
214529291|NCT03897049|BEHAVIORAL|General Health App|The control group will download a mobile app that addresses COVID and provides COVID resources.
214529292|NCT00666835|DRUG|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
214529293|NCT00666835|DRUG|ERYPO®, Janssen-Cilag|Solution for i.v. injection
214458278|NCT06245369|BEHAVIORAL|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes"
214458279|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
214529294|NCT01126879|DIETARY_SUPPLEMENT|genistein|Given orally
214529295|NCT01126879|OTHER|placebo|Given orally
214529296|NCT01126879|PROCEDURE|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
214529297|NCT03978299|DIAGNOSTIC_TEST|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
215145482|NCT06599801|PROCEDURE|Fibula flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with fibula flaps after tumor resection
215145483|NCT06599801|PROCEDURE|Forearm flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
215145484|NCT05484635|PROCEDURE|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
215145485|NCT05484635|PROCEDURE|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
215145486|NCT06633588|DRUG|Polyhexanide|Participants will apply Prontoderm® Nasal Gel and perform whole-body wash with Prontoderm® Foam daily for 5 days before surgery.
215145487|NCT06633588|DRUG|Mupirocin and Chlorhexidine|Participants will apply Bactroban® Nasal ointment and perform whole-body wash with Lifo-Scrub® daily for 5 days before surgery.
215145488|NCT06706401|DRUG|Vesanoid|Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
215145489|NCT06706401|RADIATION|Standard radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
215145490|NCT06706401|RADIATION|Tailored radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 weeks (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
215145491|NCT06706401|DRUG|Cisplatin|"Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks)."
215145492|NCT06706401|DRUG|Cetuximab|"Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2."
215145493|NCT06714682|PROCEDURE|Modified Pectoral Plane block group|The patient will lay supine with the ipsilateral arm abducted and externally rotated and the elbow flexed at 90 degrees. The probe will be placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe will be pushed 1-2 cm caudally and medially. In a caudal tilt, within a biconvex space, the artery will be recognised. After that, the block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25 bupivacaine.
215145494|NCT06714682|PROCEDURE|Erector spinae plane block group.|The block will be performed with the patient in a sitting position , The high-frequency linear probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes identified, the block needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle, 20 mL of 0.25% bupivacaine will be administered for block performance.
215145495|NCT06705400|BEHAVIORAL|Multi-behavioural|The Bloom Study is implemented in an existing and highly accepted health service delivered by community health nurses. Beyond focusing on food, meals, motor skills and movement, the intervention also target sleep and family sense of security. The intervention commence in pregnancy and continues until the child is 2½ years old.
215145496|NCT06705699|PROCEDURE|Urethral mobilisation|Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
215145497|NCT06705699|PROCEDURE|Mathieu|Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
214458280|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
214458281|NCT06226662|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
214458282|NCT06226662|DRUG|Placebo|Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
214458283|NCT06801249|DRUG|Metarapone|Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
214458284|NCT06801249|DRUG|Standardized antihypertensive therapy|Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.
214458285|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns with retention grooves|Zirconia-based primary anterior crowns with retention grooves
214529298|NCT04903912|DIAGNOSTIC_TEST|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
214529299|NCT04903912|DIAGNOSTIC_TEST|Laboratory tests|Metabolic profile and platelet reactivity
214529300|NCT04903912|DRUG|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
214529301|NCT04903912|PROCEDURE|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
215145498|NCT06705751|DIAGNOSTIC_TEST|Autonomic response in AAOCA|"Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited.~Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch.~The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions."
215145499|NCT06706024|OTHER|breathing exercise|Patients Under Hemodialysis
215145500|NCT06706128|OTHER|reflex rolling technique|received reflex rolling technique for 20 min, 5 days a week, for 2 weeks.
215145501|NCT06706128|OTHER|lung squeezing technique|lung squeezing technique for 20 min, 5 days a week, for 2 weeks
215145502|NCT06705114|PROCEDURE|complete denture|Each patient received a newly constructed conventional complete denture with optimal denture extension and lingualized balanced occlusal concept
215145503|NCT06705114|PROCEDURE|implant overdenture|Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.After 3-4 months, the dental implants were exposed and ball abutments were screwed into the implants. The housing of the ball attachments were incorporated into the fitting surface of the mandibular denture using a direct pick-up technique (Fig. 1B). The mandibular overdenture was then inserted into the patient's mouth and occlusal adjustment was done using articulating paper to remove any occlusal interferences. Follow-up visits were scheduled.
215145504|NCT06743256|DEVICE|Surgical System|Levita Magnetic Surgical System
214458286|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns without retention grooves|Zirconia-based primary anterior crowns without retention grooves
214458287|NCT06801353|BIOLOGICAL|Stapokibart|Stapokibart subcutaneously every two weeks
214458288|NCT06801353|DRUG|Mometasone Furoate Nasal Spray (MFNS)|mometasone furoate nasal spray 200 μg once daily
214458289|NCT05092126|BEHAVIORAL|Exercise|Calculate oxygen consumption
214458290|NCT06266806|BEHAVIORAL|Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources|Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
214458291|NCT03496402|OTHER|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
214458292|NCT04855786|PROCEDURE|Thoracic duct drainage|drain placement into the thoracic duct
214458293|NCT05918328|DRUG|Albumin paclitaxel+trastuzumab+pyrrolitinib|albumin paclitaxel （260mg/㎡ every 3 weeks or 125mg/㎡ weekly）+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg, once every 3 weeks)+pyrrolitinib (320mg, QD), 3 weeks as one cycle.
214458294|NCT05918328|DRUG|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
214458295|NCT05831345|DRUG|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
214458296|NCT05831345|DRUG|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
214458297|NCT06523595|DRUG|VX-993|Suspension for Oral Administration.
214458298|NCT06523595|DRUG|Metformin|Tablets for Oral Administration.
214529302|NCT05295992|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
214529303|NCT04778683|PROCEDURE|Virtual Reality|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
214529304|NCT03254992|DEVICE|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
214529305|NCT03254992|DEVICE|ASD - Tangible task|Experimental group using Keyboard with more real activity.
214529306|NCT03254992|DEVICE|TD - Abstract task|Control group using Kinect with more virtual activity.
215145505|NCT06775002|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period. 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
215145506|NCT06764407|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery and intraoperative period.
215145507|NCT06764407|OTHER|No Music|Patients will not listen to music.
215145508|NCT06772740|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization within 7 days after randomization
215145509|NCT06786676|DRUG|AS-S603|Oral administration of AS-S603 tablet
214708709|NCT01705548|RADIATION|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
214529307|NCT03254992|DEVICE|TD - Tangible task|Control group using Keyboard with more real activity.
214529308|NCT00692445|DRUG|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
214529309|NCT00692445|DRUG|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
215145510|NCT06786676|DRUG|Placebo|Oral administration of Placebo tablet
215145511|NCT06810609|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Surgical removal of the tumor in patients with resectable or borderline resectable NSCLC
215145512|NCT06810609|RADIATION|Chemoradiotherapy|Chemoradiotherapy
215145513|NCT06810609|DRUG|Immunotherapy|Immunotherapy (Durvalumab).
215145514|NCT06822257|DRUG|Alcohol beverage|moderate dose of alcohol
215145515|NCT06822257|OTHER|Non-alcohol beverage|No alcohol given
215145516|NCT03294707|DRUG|AG10 oral tablet|Active single ascending dose
215145517|NCT03294707|DRUG|Placebo Oral Tablet|Placebo single dose
215145518|NCT06906770|OTHER|Eye movement desensitization and reprocessing phobia treatment in virtual reality|Short form and frequent eye movement desensitization and reprocessing (EMDR) in virtual reality for specific phobia treatment.
215145519|NCT00905164|DRUG|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
215145520|NCT00905164|DRUG|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
215145521|NCT06911372|DRUG|Intradermal Microdialysis|A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site). After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow with sodium nitroprusside.
215145522|NCT06911372|OTHER|Brain Blood Flow Tests|Participants will complete CO2 breathing procedures to evaluate brain blood vessel health.
215145523|NCT06911372|OTHER|Local Heating|A dime-sized heater will be placed on the skin to evaluate cutaneous microvascular function
215145524|NCT06351124|BIOLOGICAL|Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's|Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.
215145525|NCT06519942|DIAGNOSTIC_TEST|Blood sampling|Fasting blood samples will be obtained.
215145526|NCT06519942|DIAGNOSTIC_TEST|Electromyoneurography (EMNG)|Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
214458300|NCT06189209|DRUG|Tenalisib|Tenalisib will be administered 800mg/ 400mg BID, orally
214458301|NCT05916664|BEHAVIORAL|Kinto Care Coaching|Describe the basics of the intervention
214458302|NCT05885464|BIOLOGICAL|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
214458303|NCT04118192|PROCEDURE|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
214529310|NCT01233492|DRUG|boron phenylalanine|
214529311|NCT01233492|DRUG|mannitol|
214529312|NCT01233492|OTHER|biologic sample preservation procedure|
214529313|NCT01233492|RADIATION|radiation therapy treatment planning/simulation|
214529314|NCT02024399|OTHER|Exercise|Strength training, aerobic exercise and core strengthening, running
214708710|NCT03865511|DRUG|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
215145527|NCT06519942|PROCEDURE|Muscle biopsy|Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
215145528|NCT06519942|RADIATION|Quantitative peripheral computed tomography (qPCT)|A qPCT scan of the calf will be performed.
215145529|NCT06519942|DEVICE|Mechanography|Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
215145530|NCT06519942|DIAGNOSTIC_TEST|Electrocardiography (ECG)|A 15-minute resting ECG will be performed.
215145531|NCT06519942|OTHER|Questionnaires|Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
215145532|NCT06519942|OTHER|Anthropometry|Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.
215145533|NCT05174221|DRUG|Mezagitamab|TAK-079 subcutaneous injection.
215145534|NCT06827717|DRUG|irinotecan liposome (II) + temozolomide + fluzoparib|"Drug Irinotecan Hydrochloride Liposome Injection（II）56.5mg/m2, IV infusion administered on day 1 of every 28-day cycle until disease progression, unacceptable toxicity or death. Other names: HR070803.~Drug Fluzoparib 50mg PO bid, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle. Other names: SHR-3162.~Drug Temozolomide 30mg/m2 PO qd, administered on day 1 to day 5 of every 28-day cycle until disease progression, unacceptable toxicity or death."
215145535|NCT06412159|OTHER|Selective laser melting framework was fabricated using completely digital workflow|completely digital work flow Conventional technique versus complete digital technique
215145536|NCT06921551|DEVICE|ABLE Exoskeleton|Participants will undergo 60-min gait training sessions with the exoskeleton once a week for up to12 months
214458304|NCT03059030|DEVICE|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
214458305|NCT06799221|BIOLOGICAL|Out-of-specification obecabtagene autoleucel|Out-of-specification (OOS) obecabtagene autoleucel (obe-cel) given as a split-dose infusion based on tumor burden assessment at lymphodepletion according to the United States prescribing information.
214458306|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
214458307|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
214458308|NCT05374525|DRUG|APRETUDE|Available as intramuscular injection.
214458309|NCT05374525|DRUG|Cabotegravir OLI|Available as marketed orally administered tablets.
214458310|NCT06243913|PROCEDURE|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
214458311|NCT05642923|DRUG|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
214458312|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
214458313|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
214458314|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214458315|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
214458316|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
214458317|NCT05936658|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
214458318|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
214529315|NCT02336113|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
214529316|NCT02718053|OTHER|L-stiff|spasticity measurement with Lokomat
214529317|NCT02718053|OTHER|Ashworth|spasticity measurement with Ashworth scale
214458319|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
215145537|NCT06915142|DRUG|HRS-7058 + SHR-1316|HRS-7058 + SHR-1316
215145538|NCT06915142|DRUG|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
215145539|NCT06915142|DRUG|HRS-7058 + Cetuximab|HRS-7058 + Cetuximab
215145540|NCT06915142|DRUG|HRS-7058 + SHR-1826|HRS-7058 + SHR-1826
215145541|NCT06915142|DRUG|HRS-7058 + SHR-1826 + SHR-1316|HRS-7058 + SHR-1826 + SHR-1316
214529318|NCT02801916|OTHER|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
215145542|NCT06331819|DIAGNOSTIC_TEST|In-lab polysomnography|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
215145543|NCT06331819|DEVICE|Continuous positive airway pressure|A machine that uses air pressure to keep breathing airways open while patients sleep.
214458320|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
215145544|NCT06331819|DIAGNOSTIC_TEST|Home sleep study device|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
215145545|NCT06917287|DIETARY_SUPPLEMENT|Native CT-II® (undenatured type II collagen)|"Strength: 40 mg in 3 capsules~Dose Regimen:~3 yellow capsules containing MCC after breakfast with water 3 blue capsules containing 40 mg Native CT-II® \& MCC after dinner with water Route of administration: Oral"
215145546|NCT06917287|DIETARY_SUPPLEMENT|Glucosamine HCL + Chondroitin Sulphate (G+C) [Comparator]|2700 mg (1500 mg G + 1200 mg C) 3 yellow capsules containing G+C orally after breakfast with water \& 3 blue capsules containing G+C after dinner with water
215145547|NCT06917287|DIETARY_SUPPLEMENT|Placebo [Microcrystalline Cellulose (MCC)|2700 mg excipient 3 yellow capsules containing MCC orally after breakfast with water 3 blue capsules containing MCC after dinner with water.
215145548|NCT06936566|DRUG|Ruxolitinib|Ruxolitinib twice daily for 56 days followed by a short taper Given orally
214458321|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
214458322|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
214458323|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
214458324|NCT05470088|OTHER|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
214458325|NCT05227248|DIETARY_SUPPLEMENT|Dark chocolate|Patients were administered 20 grams of dark chocolate
214458326|NCT05227248|DIETARY_SUPPLEMENT|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
214529319|NCT02801916|OTHER|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
214529320|NCT02801916|OTHER|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
214529321|NCT02801916|OTHER|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
214529322|NCT03319719|DEVICE|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
214529323|NCT03319719|DEVICE|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
215145549|NCT06936566|DRUG|Methylprednisolone|Starting dose 2 mg/kg/d for at least three days, then taper Given IV or orally
214458327|NCT02949362|DRUG|Teduglutide|0.05mg/kg
214458328|NCT02949362|OTHER|SOC|Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
214458329|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
215145550|NCT02633059|DRUG|Dexamethasone|Given PO
215145551|NCT02633059|DRUG|Idasanutlin|Given PO
215145552|NCT02633059|DRUG|Ixazomib Citrate|Given PO
215145553|NCT02633059|OTHER|Laboratory Biomarker Analysis|Correlative studies
215145554|NCT02633059|OTHER|Pharmacological Study|Correlative studies
215145555|NCT06507774|DEVICE|3D Reconstruction Technology|Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.
215145556|NCT06507774|DEVICE|No 3D reconstruction is used|This group did not use 3D reconstruction for surgical navigation
215145557|NCT06939166|DRUG|UCAR T-cell|Universal allogeneic anti-CD19/BCMA CAR T-cells
215145558|NCT06939855|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg iv q3w
215145559|NCT06819852|OTHER|Acute hospital care at home|Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.
215145560|NCT06819852|OTHER|Standard medical treatment|Standard acute and emergency care delivered in a brick-and-mortar hospital setting.
215145561|NCT06952140|DIETARY_SUPPLEMENT|Ketone ester|Ketone ester: 3-hydroxybutyrate as enteral bolus (500 mg/kg)
215145562|NCT06952140|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isovolumic and isocaloric placebo) as enteral bolus
214529324|NCT03715413|OTHER|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
214529325|NCT03715413|DRUG|Tamoxifen|received Tamoxifen 10 mg daily
214529326|NCT02764788|OTHER|Specific auriculotherapy|Specific auriculotherapy with needles
214529327|NCT02764788|OTHER|non-specific auriculotherapy|non-specific auriculotherapy with needles
214529328|NCT02764788|OTHER|seed auriculotherapy|non-specific auriculotherapy with seeds
214529329|NCT06204614|DEVICE|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
214529330|NCT06204614|DRUG|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
214529331|NCT06204614|DRUG|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
214529332|NCT06204614|DRUG|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
214529333|NCT06204614|DRUG|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
214529334|NCT06204614|DRUG|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
214529335|NCT06204614|DRUG|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
214529336|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
214529337|NCT06204614|DRUG|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
214529338|NCT06204614|DRUG|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
214529339|NCT06204614|DRUG|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
214529340|NCT06204614|DRUG|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
214529341|NCT06204614|DRUG|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
214529342|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
214529343|NCT06204614|DRUG|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
214529344|NCT06204614|DRUG|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
215145563|NCT04730804|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
215145564|NCT04730804|DRUG|Placebo|Placebo will be administered as SC infusion(s).
215145565|NCT05825560|DRUG|OFA multimodal analgesia|Multimodal opioid free analgesia
215145566|NCT05825560|DRUG|Standard multimodal analgesia|Standard remifentanil analgesia
215145567|NCT04004364|OTHER|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
215145568|NCT03405194|DRUG|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
215145569|NCT03405194|DRUG|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
214529345|NCT06204614|DRUG|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
214529346|NCT06204614|DRUG|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
214529347|NCT06204614|DRUG|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
214529348|NCT06204614|DRUG|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
214529349|NCT06204614|DRUG|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
214529350|NCT06457347|PROCEDURE|Ultra early (<24 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
214529351|NCT06457347|PROCEDURE|Early (24-72 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
214529352|NCT03682237|DEVICE|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
214529353|NCT03682237|DEVICE|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
214529354|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
214529355|NCT02537236|BEHAVIORAL|TLC nutritional intervention|nutritional orientation.
214529356|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
214529357|NCT01212952|DRUG|pomalidomide|Given orally
214529358|NCT01212952|DRUG|bortezomib|Given IV
214529359|NCT01212952|DRUG|dexamethasone|Given orally
214529360|NCT01212952|OTHER|laboratory biomarker analysis|Optional correlative studies
214529361|NCT01212952|OTHER|gene expression analysis|Optional correlative studies
214529362|NCT05973357|PROCEDURE|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
215145570|NCT05366738|DRUG|Vonoprazan|Orally via tablet
215145571|NCT05366738|DRUG|Vonoprazan|Orally via sprinkle pellets
215145572|NCT01931293|DIETARY_SUPPLEMENT|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
215145573|NCT01684761|BIOLOGICAL|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
215145574|NCT01684761|BIOLOGICAL|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
215145575|NCT02876549|DRUG|Chloroquine|10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
215145576|NCT02876549|DRUG|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
215145577|NCT02876549|DRUG|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
214458330|NCT03986697|DRUG|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
214458331|NCT06165146|DRUG|Repaglinide|Administered orally.
214458332|NCT06165146|DRUG|Pirtobrutinib|Administered orally.
214458333|NCT03390322|DEVICE|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
214458334|NCT03199469|GENETIC|Resamirigene bilparvovec|Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
214458335|NCT05879055|DRUG|PM8002|IV infusion
214458336|NCT05879055|DRUG|FOLFIRI|IV infusion
214458337|NCT05332366|DRUG|Delgocitinib cream|Cream for topical application
214458338|NCT05332366|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214458339|NCT05754073|DRUG|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
214458340|NCT05754073|DRUG|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
214458341|NCT05754073|DRUG|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
214458342|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
214458343|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
214458344|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
214458345|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
214458346|NCT05453773|OTHER|Questionnaire Administration|Ancillary studies
214458347|NCT05453773|BEHAVIORAL|Tobacco Smoking|Smoke waterpipe tobacco
214458348|NCT01186224|DRUG|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
214458349|NCT06242821|OTHER|Standard of Care (SOC)|Patients will continue with their current standard of care treatment.
214529363|NCT05973357|PROCEDURE|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
214458350|NCT06242821|OTHER|Yoga|Patients will be randomized to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
214529364|NCT03134937|DEVICE|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
214529365|NCT01538901|OTHER|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
215145578|NCT01610934|DRUG|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
215145579|NCT01610934|DRUG|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
215145580|NCT06514560|DRUG|Miltefosine|Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
215145581|NCT06472843|BEHAVIORAL|Exercise Intervention|The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).
215145582|NCT03217604|DRUG|Placebo|Treatment with placebo
215145583|NCT03217604|DRUG|PF-06852231|Treatment with PF-06852231
215145584|NCT00553878|DRUG|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
215145585|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
215145586|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
215145587|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
214458351|NCT03195777|DEVICE|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
214458352|NCT05594693|OTHER|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
214458353|NCT05594693|OTHER|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
214458354|NCT03017755|OTHER|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
214458355|NCT04184375|BEHAVIORAL|cognitive stimulation|"Patients participate in one session per week according to the following schedule:~* 2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~* 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~* 2 voluntary attention sessions: improve daily attention.~* 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~* 2 sessions of structuring through language: impact on social life.~* 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips."
214529366|NCT01538901|DRUG|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
214529367|NCT01405521|BIOLOGICAL|Vaccine placebo (excipients only)|single oral dose,
214529368|NCT01405521|BIOLOGICAL|Ty21a|3 oral doses, alternate days
214529369|NCT01405521|BIOLOGICAL|M10ZH09 vaccine|single oral dose
214529370|NCT00234221|BEHAVIORAL|Strengths Based Case Management|
214529371|NCT00234221|BEHAVIORAL|Motivational Enhancement Therapy|
214529372|NCT00234221|BEHAVIORAL|Brief Informational Feedback|
214529373|NCT04208815|OTHER|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
214529374|NCT04208815|OTHER|Milk Fat|Effects of the addition of 20 g milk fat.
214529375|NCT03193216|DRUG|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
214529376|NCT06158971|DEVICE|Flexible Bronchoscopic Microwave Ablation|The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
214529377|NCT02373605|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
214529378|NCT02373605|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
215145588|NCT04164875|DIAGNOSTIC_TEST|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
215145589|NCT00941096|DRUG|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
215145590|NCT00330434|OTHER|Trial Withdrawn 1|Trial Withdrawn 1
215145591|NCT00330434|OTHER|Trial Withdrawn 2|Trial Withdrawn 2
215145592|NCT04248426|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
215145593|NCT04248426|DRUG|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
214529379|NCT02924532|BIOLOGICAL|immediate post operative bioassay of Parathyroid Hormone|
214529380|NCT02641106|OTHER|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
214529381|NCT02641106|OTHER|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
214529382|NCT04978012|DRUG|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
215145594|NCT00848601|DRUG|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
215145595|NCT01935778|DRUG|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
215145596|NCT01935778|DRUG|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
215145597|NCT06248749|DRUG|IV iron|Intravenous Iron supplement
215145598|NCT05959148|OTHER|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
215145599|NCT05959148|OTHER|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
215145600|NCT04433676|OTHER|no intervention|
215145601|NCT03024099|OTHER|Hippotherapy once a week|Hippotherapy once a week
215145602|NCT03024099|OTHER|Hippotherapy twice a week|Hippotherapy twice a week
215145603|NCT02694692|PROCEDURE|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
214458356|NCT02023866|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
214458357|NCT04840355|DRUG|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
214458358|NCT02648542|OTHER|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
214458359|NCT02648542|DEVICE|transcranial direct current stimulation|Low-current electrical brain stimulation
214458360|NCT02648542|OTHER|Combined CAS and tDCS|Combined auditory and electrical stimulation
214458361|NCT02648542|OTHER|Sham stimulation|Sham stimulation
214458362|NCT05534971|PROCEDURE|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
214458363|NCT04713774|DEVICE|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
214458364|NCT02485938|DRUG|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
214458365|NCT06397456|BEHAVIORAL|In-Person Patient Education|In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
214458366|NCT06397456|BEHAVIORAL|Commitment to Change|Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
214458367|NCT06397456|BEHAVIORAL|Blood pressure monitoring|Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
214458368|NCT06397456|BEHAVIORAL|Written Patient Education|Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
214458369|NCT06397456|BEHAVIORAL|Text-based reinforcement for CKD self-management|Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
214529383|NCT05217290|BEHAVIORAL|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
214529384|NCT03718819|OTHER|exercise|Pilates and aquaplyometric exercises will be done combinedly.
214529385|NCT03228277|DRUG|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
214529386|NCT00735462|DRUG|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
215145604|NCT02694692|BEHAVIORAL|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
215145605|NCT00660634|PROCEDURE|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
215145606|NCT00161772|BIOLOGICAL|Tick-borne Encephalitis Vaccine|
214529387|NCT00735462|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
215145607|NCT05145101|BIOLOGICAL|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
214529388|NCT00735462|DRUG|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
215145608|NCT05659186|DRUG|Tislelizumab|200mg IV Q3W
215145609|NCT05659186|DRUG|Anlotinib|12mg PO QD
215145610|NCT05659186|RADIATION|Radiotherapy|Multimodal Radiotherapy
215145611|NCT04585126|DRUG|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
215145612|NCT01150188|DIETARY_SUPPLEMENT|Amino acids|11 g amino acids two times per day for eight weeks
215145613|NCT01150188|DIETARY_SUPPLEMENT|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
215145614|NCT00169897|BEHAVIORAL|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
215145615|NCT04082819|DEVICE|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
214529389|NCT00607256|DRUG|[S,S]-reboxetine|S\_S reboxetine dosed daily.
214529390|NCT02236598|DRUG|K+ supplement|
214529391|NCT02236598|DRUG|Placebo|
214529392|NCT06123364|DRUG|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
215145616|NCT04082819|DEVICE|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
215145617|NCT03599739|BIOLOGICAL|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
215145618|NCT00897299|GENETIC|microarray analysis|
215145619|NCT00897299|GENETIC|protein expression analysis|
215145620|NCT00897299|OTHER|immunohistochemistry staining method|
215145621|NCT00897299|OTHER|laboratory biomarker analysis|
215145622|NCT04065672|DRUG|Low-dose IL-2|After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
215145623|NCT04065672|DRUG|Placebo|After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
215145624|NCT04989335|DRUG|Bisantrene|Combined escalated dose chemotherapy
215145625|NCT04989335|DRUG|Fludarabine|Combined escalated dose chemotherapy
215145626|NCT04989335|DRUG|Clofarabine|Combined escalated dose chemotherapy
215145627|NCT00781703|OTHER|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
215145628|NCT01955330|PROCEDURE|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
215145629|NCT05777356|DIAGNOSTIC_TEST|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
215145630|NCT05674305|DRUG|Radiotherapy|IMRT for primary and regional field
214529393|NCT06123364|DEVICE|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
214529394|NCT06123364|DEVICE|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
215145631|NCT05674305|DRUG|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
214529395|NCT05923398|BEHAVIORAL|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
214529396|NCT01484314|DRUG|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
214529397|NCT01264887|DRUG|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
214529398|NCT00443677|DRUG|COPPEBVCAD vs BEACOPP vs ABVD|
214529399|NCT02959177|DRUG|Galcanezumab|Administered SC
214529400|NCT02959177|DRUG|Placebo|Administered SC
214529401|NCT05482256|DIAGNOSTIC_TEST|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
214529402|NCT05482256|OTHER|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
214529403|NCT05482256|DIAGNOSTIC_TEST|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
214529404|NCT00668512|BIOLOGICAL|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
214529405|NCT04613622|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
214529406|NCT01974934|DRUG|Desvenlafaxine Succinate|
214529407|NCT01947153|DRUG|Metformin|Free combination
214529408|NCT01947153|DRUG|Linagliptin|Fixed dose combination
215145632|NCT01124006|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
215145633|NCT01124006|OTHER|Water for injection|Sterile water for injection
215145634|NCT04405453|PROCEDURE|trapezius muscle injection|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
215145635|NCT04405453|PROCEDURE|erector spina plane block|1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
215145636|NCT00565084|DRUG|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
215145637|NCT00565084|DRUG|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
214529409|NCT01947153|DRUG|Metformin|Combination
214529410|NCT01947153|DRUG|Linagliptin|Free combination
214529411|NCT03553849|DIETARY_SUPPLEMENT|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
214529412|NCT04367363|BEHAVIORAL|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
215145638|NCT04812717|DEVICE|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
214529413|NCT01856010|OTHER|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
215145639|NCT03124342|OTHER|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals"
215145640|NCT05511584|PROCEDURE|VO2 estimation|"1. st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) \* minute volume (Volmin)~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
215145641|NCT05511584|PROCEDURE|SEVOup estimation|"1. st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) \* Volmin~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
214458370|NCT06397456|BEHAVIORAL|Community-based education session, reinforcement for self-management|"Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection"
215145642|NCT01060332|OTHER|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
215145643|NCT02575638|DRUG|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
215145644|NCT01815346|PROCEDURE|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
215145645|NCT01815346|BEHAVIORAL|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
215145646|NCT01815346|OTHER|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
214458371|NCT06397456|BEHAVIORAL|Text-based reinforcement for general health self-management|Patient educator will use text messages to send general health management messages
214458372|NCT06170034|BEHAVIORAL|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
214458373|NCT06170034|OTHER|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
214458374|NCT05571865|DIETARY_SUPPLEMENT|Probiotic|Oral administration of a probiotic
214458375|NCT06041867|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
214458376|NCT06041867|DIETARY_SUPPLEMENT|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
214458377|NCT06041867|DIETARY_SUPPLEMENT|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
214458378|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
214458379|NCT04380558|OTHER|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
214458380|NCT05260957|DRUG|Mosunetuzumab|"Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77."
214529414|NCT01856010|OTHER|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
215145647|NCT06249802|DRUG|Nebivolol|12-month intake of medication
215145648|NCT06249802|DRUG|Placebo|12-month intake of matching placebo
214529415|NCT05560945|DRUG|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
214529416|NCT05560945|DRUG|1.5% Arginine Dentifrice|Toothpaste
214529417|NCT05560945|DRUG|8.0% Arginine Dentifrice|Toothpaste
214529418|NCT04915157|DEVICE|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
214529419|NCT01061775|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
214458381|NCT05260957|DRUG|Polatuzumab|"Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77."
214458382|NCT05260957|BIOLOGICAL|CAR-T Cell Therapy|Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
214458383|NCT03307343|BEHAVIORAL|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
214458384|NCT05564273|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
214458385|NCT05564273|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
214458386|NCT06205420|DRUG|Injectable composite resin restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
214529420|NCT05812209|PROCEDURE|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
214529421|NCT00293332|BIOLOGICAL|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
214529422|NCT00293332|DRUG|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
214529423|NCT00293332|DRUG|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
214529424|NCT00293332|PROCEDURE|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
214529425|NCT04448821|DRUG|Metformin|Single administration of metformin
214529426|NCT04448821|DRUG|Metformin + Nilotinib|Coadministration of metformin and nilotinib
214529427|NCT04349124|DRUG|Nifedipine Extended-Release Tablets|Antihypertensive
214529428|NCT00360971|BIOLOGICAL|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
214529429|NCT00360971|DRUG|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
214529430|NCT00360971|OTHER|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
214529431|NCT00360971|PROCEDURE|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
214529432|NCT00360971|RADIATION|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
214529433|NCT06379906|OTHER|Assessment|Baseline assessment
214529434|NCT01854372|DRUG|R-HCVAD and R-MC|
214529435|NCT04350983|BEHAVIORAL|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
214529436|NCT01313299|BIOLOGICAL|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
214529437|NCT01313299|BIOLOGICAL|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
214529438|NCT01313299|DRUG|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
214529439|NCT02773121|BEHAVIORAL|Physical Activity|Trainer-guided at-home behavioral intervention
214529440|NCT01137123|DRUG|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
215145649|NCT04836650|DIAGNOSTIC_TEST|Postural stability assessment with a force platform.|The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.
215145650|NCT04836650|DIAGNOSTIC_TEST|Muscular assessment with a electromyograph|The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
215145651|NCT04441892|DEVICE|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
215145652|NCT03841604|DRUG|Safinamide Methanesulfonate|50 mg, 100 mg
215145653|NCT03841604|OTHER|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
215145654|NCT01635439|DRUG|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
214458387|NCT06205420|DRUG|Injectable giomer restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
214458388|NCT05088876|DRUG|Placebo|Blinded withdrawal of regular co-medication with paracetamol
214458389|NCT05088876|DRUG|Paracetamol|Paracetamol in the dose already used
214458390|NCT05831566|DRUG|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
214458391|NCT06636006|BEHAVIORAL|Aerobic Exercise|50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
214458392|NCT06636006|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
214458393|NCT06261437|OTHER|CCAR|The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.
214458394|NCT06261437|OTHER|FSR|The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
214458395|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
214458396|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
214458397|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
214458398|NCT06254807|DRUG|CT-0525|Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
214458399|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
214458400|NCT04683744|OTHER|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
214529441|NCT01137123|PROCEDURE|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
214529442|NCT01137123|PROCEDURE|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
214529443|NCT01137123|PROCEDURE|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
214529444|NCT01907022|DEVICE|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
215145655|NCT01635439|DRUG|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
214458401|NCT04683744|OTHER|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
214458402|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
214458403|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
214458404|NCT04472598|DRUG|Navitoclax|Tablet; Oral
214458405|NCT04472598|DRUG|Ruxolitinib|Tablet; Oral
214458406|NCT04472598|DRUG|Placebo for Navitoclax|Tablet; Oral
214458407|NCT05182398|OTHER|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
214458408|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
214458409|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
214458410|NCT02432404|DRUG|NuvaRing|
214458411|NCT05464160|DEVICE|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
214458412|NCT05464160|OTHER|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
214458413|NCT05987735|BEHAVIORAL|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
214458414|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
214458415|NCT03315806|OTHER|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
214458416|NCT03315806|OTHER|Placebo|140 mL of beetroot juice isent of nitrate
214458417|NCT05761366|DRUG|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
214458418|NCT05136417|DEVICE|intra-procedural intracardiac echocardiography (ICE) probe|placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
214458419|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
214458420|NCT04859530|DIAGNOSTIC_TEST|AVC test|The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
214458421|NCT06800222|OTHER|modern agents rehab|rehabilitation interventions containing modern physical agents together with classical interventions
214458422|NCT06800222|OTHER|classical rehab|classical rehabilitation interventions
214458423|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
214458424|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
214529445|NCT03944902|DRUG|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
214529446|NCT03944902|DRUG|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
214529447|NCT02176317|BIOLOGICAL|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
214529448|NCT01461343|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
215145656|NCT00370968|DRUG|Zinc sulphate|
215145657|NCT04723277|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf)|Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
215145658|NCT04723277|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
214458425|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
214458426|NCT06213298|DRUG|Kava|75 mg kavalactones
214458427|NCT06213298|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
214458428|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
214458429|NCT06475521|OTHER|Infant Formula|Test group
214458430|NCT06415942|OTHER|Maternal Outcome Monitoring and Support system|The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
214458431|NCT06797986|BIOLOGICAL|BVAC-E6E7 (low level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
214458432|NCT06797986|BIOLOGICAL|BVAC-E6E7 (high level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
214458433|NCT06797986|BIOLOGICAL|BVAC-E6E7 (RP2D)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
214458434|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
214458435|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
214458436|NCT05206422|DEVICE|Doraya Catheter|The Doraya Catheter is a temporary intravenous flow regulator, positioned in the inferior vena cava below the level of the renal veins
214529449|NCT05021757|DEVICE|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
215145659|NCT00984217|RADIATION|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
215145660|NCT00984217|DRUG|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
215145661|NCT01238068|DEVICE|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
214458437|NCT04227769|DRUG|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
214458438|NCT05842265|OTHER|Self acupressure|patients will do self acupressure
214458439|NCT03737643|DRUG|Bevacizumab|Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
214458440|NCT03737643|DRUG|Durvalumab|Durvalumab by intravenous infusion
214458441|NCT03737643|DRUG|Olaparib|Olaparib tablets
214458442|NCT03737643|DRUG|Placebo olaparib|Placebo tablets to match olaparib
214458443|NCT03737643|DRUG|Durvalumab placebo|Matching placebo for intravenous infusion
214458444|NCT03737643|DRUG|Carboplatin+Paclitaxel|Standard of care chemotherapy
214529450|NCT04764877|OTHER|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
214529451|NCT04255173|DIAGNOSTIC_TEST|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
214529452|NCT04255173|DIAGNOSTIC_TEST|waist circumference|waist circumference is measured as cm
214529453|NCT04255173|DIAGNOSTIC_TEST|hip circumference|hip circumference is measured as cm
214529454|NCT04255173|DIAGNOSTIC_TEST|height|height is measured as cm
214458445|NCT05495490|PROCEDURE|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
214458446|NCT05495490|PROCEDURE|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
214458447|NCT03447470|DRUG|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
214458448|NCT03447470|DRUG|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
214458449|NCT05689684|DIETARY_SUPPLEMENT|AG+XOS+AXOS|4-month parallel randomized controlled study
214458450|NCT05689684|DIETARY_SUPPLEMENT|Placebo Maltodextrin|4-month parallel randomized controlled study
214458451|NCT06494943|DRUG|Sintilimab|PD-1 inhibitor
214458452|NCT06494943|DRUG|IBI110|LAG-3 inhibitor
214458453|NCT06494943|DRUG|Paclitaxel|Chemotherapy
214458454|NCT06494943|DRUG|Cis Platinum|Chemotherapy
214458455|NCT06494943|PROCEDURE|Surgery|Definitive surgery
214458456|NCT06494943|RADIATION|Adjuvant radiation|Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
214458457|NCT04464707|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
214458458|NCT04464707|DRUG|Placebo|Matching placebo
214458459|NCT04613947|BEHAVIORAL|Informed consent|The style of informing patients about the procedure they will undergo
214458460|NCT04613947|PROCEDURE|Third molar surgery|Surgical extraction of the third molar tooth
214458461|NCT05462353|DRUG|2mg of ASC41|ASC41 tablet administered orally once daily.
214458462|NCT05462353|DRUG|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
214458463|NCT05462353|DRUG|Placebo|Placebo tablets administered orally once daily.
214458465|NCT01521039|PROCEDURE|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
214458466|NCT05851573|BEHAVIORAL|Psychosocial intervention|an SLP-administered 5-week treatment focused on psychological well-being
214458467|NCT05950841|DRUG|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
214458468|NCT05950841|DRUG|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
214458469|NCT05950841|DRUG|Carob flour|Twice daily dose of 1 capsule (carob flour)
214458470|NCT05255965|DIAGNOSTIC_TEST|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
214458471|NCT04284865|OTHER|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
214458472|NCT05569122|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
214458473|NCT05569122|DEVICE|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
214458474|NCT05569122|DEVICE|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
214458475|NCT05569122|DEVICE|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
214529455|NCT04255173|DIAGNOSTIC_TEST|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
215145662|NCT04670302|PROCEDURE|Tendon repair procedure|"Tendon repair procedure:~1. Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~2. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~3. Then, double suturing of the supraspinatus tendon is performed."
215145663|NCT04670302|PROCEDURE|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
215145664|NCT02642185|PROCEDURE|Microwave ablation|CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
215145665|NCT02642185|PROCEDURE|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
215145666|NCT02317900|BIOLOGICAL|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
214458476|NCT05569122|DRUG|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
214458477|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214458478|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 1.1|Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
214458479|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
214458480|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 2.1|Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
214458481|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
214458482|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 3.1|Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.
214458483|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
214529456|NCT04255173|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
214529457|NCT04255173|DIAGNOSTIC_TEST|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
214529458|NCT04255173|DIAGNOSTIC_TEST|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
214529459|NCT04255173|DIAGNOSTIC_TEST|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
215145667|NCT02317900|BIOLOGICAL|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
215145668|NCT02317900|BIOLOGICAL|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
215145669|NCT03877510|DRUG|IPX203|IPX203 extended release capsules
214529460|NCT00596258|DRUG|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
214529461|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
215145670|NCT04824924|DRUG|The combination of HHT, venetoclax, AZA, G-CSF|HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
214458484|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.1|Participants will use their Radicle Relaxation Active Study Product 4.1 as directed for a period of 6 weeks.
214458485|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.2|Participants will use their Radicle Relaxation Active Study Product 4.2 as directed for a period of 6 weeks.
214458486|NCT06771401|DIAGNOSTIC_TEST|cervical mucus sampling|Monitoring of menstrual cycle will be conducted in the follicular, ovulatory and luteal phases during which cervical mucus, serum and urine samples will be collected and pelvic ultrasound scans performed (3-5 ultrasound scans/samples within the cycle).
214458487|NCT06414018|DRUG|Alfentanil|alfentanil 10ug/kg is used for anesthesia induction
214458488|NCT06433245|PROCEDURE|effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
215145671|NCT01417377|DRUG|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
215145672|NCT02113982|DRUG|Tagraxofusp|
215145673|NCT04281862|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
215145674|NCT04281862|DRUG|Topical Prednisolone|Standard of care topical drop treatment
215145675|NCT05411315|OTHER|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
215145676|NCT05411315|OTHER|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
215145677|NCT00218777|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|
215145678|NCT01774721|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
215145679|NCT01774721|DRUG|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
215145680|NCT03054246|OTHER|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
215145681|NCT00988806|DRUG|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
215145682|NCT00988806|DRUG|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
215145683|NCT02524782|BIOLOGICAL|MEDI-4166|MEDI-4166 administered subcutaneously
215145684|NCT02524782|BIOLOGICAL|Placebo|Placebo administered subcutaneously
215145685|NCT03762057|DIAGNOSTIC_TEST|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
215145686|NCT03106311|DIAGNOSTIC_TEST|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
215145687|NCT02289261|DRUG|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
215145688|NCT02289261|DRUG|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
215145689|NCT01595542|BEHAVIORAL|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~1. Cover letter~2. Vaccine promotional flyer~3. Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~4. Improved consent form~5. Note advertising a lottery for free movie tickets for returning the consent form~6. Self-addressed stamped envelope"
215145690|NCT03035357|DRUG|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
215145691|NCT03199586|DRUG|NP-G2-044|capsule
215145692|NCT03076151|DRUG|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
215145693|NCT03594110|DRUG|Empagliflozin|Taken daily with or without food
215145694|NCT03594110|DRUG|Matching placebo|Taken daily with or without food
214458489|NCT06798376|DRUG|≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
214458490|NCT06798376|DRUG|≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
214458491|NCT06798376|PROCEDURE|Gastrectomy|Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed
214458492|NCT04856982|DRUG|Tofersen|Administered as specified in the treatment arm
215145695|NCT05280067|COMBINATION_PRODUCT|ZetaMet™ (ZetaFuse™ Bone Graft)|ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
215145696|NCT06642220|DEVICE|Y-90 Selective Internal Radiation Therapy (SIRT)|Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
215145697|NCT03851991|DRUG|Arbidol|oral
215145698|NCT03851991|DRUG|Placebos|controle
215145699|NCT06161389|DEVICE|Partially inflated mask|Manikin ventilation with a partially inflated mask
215145700|NCT06161389|DEVICE|Fully inflated mask|Manikin ventilation with a fully inflated mask
215145701|NCT05955911|BEHAVIORAL|Exercise|20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.
215145702|NCT05955911|BEHAVIORAL|Coloring|20 minutes of coloring in adult coloring book
215145703|NCT04780477|DIETARY_SUPPLEMENT|High Fiber Diet Featuring Legumes (HLD)|The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (\~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. \~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
215145704|NCT04780477|DIETARY_SUPPLEMENT|Healthy American Diet|The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
215145705|NCT02191735|DEVICE|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
215145706|NCT02191735|DEVICE|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
215145707|NCT00180778|DRUG|Low dose steroids|
215145708|NCT00871416|DEVICE|NovoFine® needle 6 mm|
215145709|NCT00871416|DEVICE|NovoFine® needle 12 mm|
215145710|NCT02351817|DEVICE|Test A|Ostomy appliance
215145711|NCT02351817|DEVICE|Test B|Ostomy appliance
214458493|NCT04856982|DRUG|Placebo|Administered as specified in the treatment arm
214458494|NCT03523975|DRUG|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
214458495|NCT03523975|DRUG|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
214458496|NCT03523975|DRUG|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
214458497|NCT04221945|BIOLOGICAL|Pembrolizumab|IV infusion
214529462|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
214529463|NCT05664230|OTHER|osteopathy|five osteopathy sessions
214529464|NCT04893785|DRUG|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
214529465|NCT04089332|OTHER|Oral Glucose Tolerance Test (OGTT)|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
215145712|NCT02351817|DEVICE|Baseline|Ostomy appliance
215145713|NCT01194856|DRUG|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
214529466|NCT04089332|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
214529467|NCT04089332|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
215145714|NCT01194856|DRUG|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
215145715|NCT02488915|DEVICE|EmboTrap® Revascularization Device|
215145716|NCT06277427|DRUG|PRG-1801 （CAR-T against BCMA）|Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
215145717|NCT03622489|DRUG|Acetaminophen|mentioned above
214458498|NCT04221945|DRUG|Placebo for pembrolizumab|IV infusion
214458499|NCT04221945|DRUG|Cisplatin|IV infusion
214458500|NCT04221945|RADIATION|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
214458501|NCT04221945|RADIATION|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
214458502|NCT06461845|OTHER|Whole Body Vibration group|This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
214458503|NCT06461845|OTHER|conventional therapy|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
214458504|NCT02994160|OTHER|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
214458505|NCT00300859|BEHAVIORAL|brief motivational intervention|
214458506|NCT06158139|BIOLOGICAL|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
214529468|NCT04089332|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
215145718|NCT03622489|DRUG|Ibuprofen 400 mg|mentioned above
215145719|NCT03622489|DRUG|Dipyrone|mentioned above
215145720|NCT03622489|DRUG|Tramadol|mentioned above
215145721|NCT03622489|DRUG|Morphine|mentioned above
215145722|NCT03622489|DRUG|Tramal|mentioned above
215145723|NCT05535725|DRUG|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
215145724|NCT03846336|OTHER|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
214458507|NCT01667952|GENETIC|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
214458508|NCT01667952|GENETIC|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
214458509|NCT01667952|OTHER|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
214458510|NCT04624633|DRUG|Acalabrutinib|Oral, twice a day, predetermined dosage
214458511|NCT04624633|DRUG|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
214458512|NCT04624633|DRUG|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
214458513|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
214458514|NCT04316871|DRUG|1.5 mg of Morphine Sulfate|1.5 mg of Morphine Sulphate will be given epidurally.
214458515|NCT04316871|DRUG|Normal saline|Normal saline will be given epidurally.
214458516|NCT04316871|DRUG|3 mg of Morphine Sulfate|3 mg of Morphine Sulphate will be given epidurally.
214458517|NCT04316871|DRUG|4.5 mg of Morphine Sulfate|4.5 mg of Morphine Sulphate will be given epidurally.
214529469|NCT06485830|PROCEDURE|Neural mobilization of the lower limb|"Static neural mobilization techniques will be performed for the lower limb. Static procedures will consist of two sets of 10 repetitions, with one minute rest between sets. Next, dynamic neural mobilization techniques will be performed, with each exercise lasting 5 minutes per set, with one minute rest between them. Therefore, dynamic procedures will consist of 10 minutes per mobilization technique (with one minute rest between exercises).~At the end of all dynamic mobilization exercises, static mobilizations of the sciatic nerve will be performed again in the same order and with the same duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
214529470|NCT06485830|PROCEDURE|Conventional physical therapy|"The intervention will include a first part in which active mobilizations, active-assisted mobilizations, and active stretches will be performed, followed by activities aimed at improving physical training, mobility training, and strength training oriented towards specific tasks. After this second part, the first part will be repeated in the same order and duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
214529471|NCT05984147|DRUG|AUR108|3 Days dosing, and 4 days no dose in a week
214529472|NCT00050167|DRUG|Paclitaxel|80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
214529473|NCT00050167|DRUG|Docetaxel|75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
214529474|NCT00050167|DRUG|Capecitabine|1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
214529475|NCT01026883|OTHER|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
214529476|NCT03418701|BEHAVIORAL|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
214529477|NCT04754594|BIOLOGICAL|BNT162b2|Intramuscular Injection
214529478|NCT04754594|OTHER|Placebo|Intramuscular Injection
214695288|NCT02698618|PROCEDURE|PCI|"1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
215145725|NCT03846336|OTHER|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
215145726|NCT06278714|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
215145727|NCT06026917|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|D1\~D6, 40mg/ tablet, 1 tablet per time, once a day, D7\~D10, 80mg/ tablet, 1 tablet per time, once a day, D11\~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11\~D42, 80mg/ tablet, one tablet each time, once a day.
215145728|NCT00495352|DRUG|Hihg-doseNRT, Low-dose NRT, bupropion|
215145729|NCT03779295|DEVICE|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
215145730|NCT03779295|DRUG|Clindamycin|The entire face (both halves) will receive clindamycin.
214458518|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
214458519|NCT05366075|OTHER|Intervention 1 (simple exercise program)|Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
214458520|NCT05366075|OTHER|Intervention 2 (comprehensive exercise program)|Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
214458521|NCT05087992|DRUG|BI 905711|BI 905711
214458522|NCT05087992|DRUG|FOLFIRI|FOLFIRI
214458523|NCT05087992|DRUG|Bevacizumab|Bevacizumab
214458524|NCT05148507|DEVICE|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2003.
214458525|NCT04867122|BEHAVIORAL|Problem-Solving Therapy|Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.
214458526|NCT04867122|OTHER|Attention-matched Control|"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."
214458527|NCT04867122|OTHER|In-depth interviews|The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.
214458528|NCT04091750|DRUG|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
214458529|NCT04091750|DRUG|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
214458530|NCT04091750|DRUG|Cabozantinib|Induction and Maintenance: 40mg PO daily
214529479|NCT03386357|COMBINATION_PRODUCT|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
214529480|NCT03386357|DRUG|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
214529481|NCT05250492|PROCEDURE|Prosthetic hip surgery|"Total hip prosthesis performed by an anterior approach with intra-articular infiltration of an anesthetic product intraoperatively.~OR~\- Total hip prosthesis performed by an anterior approach with infiltration of the same anesthetic product by ultrasound-guided PENG block intraoperatively."
214529482|NCT06049433|BEHAVIORAL|Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
214529483|NCT06049433|BEHAVIORAL|On-Demand + Discussion board (DB)|Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
214529484|NCT06049433|BEHAVIORAL|Arm 2|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
214529485|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
214529486|NCT06049433|BEHAVIORAL|Arm 3|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
214529487|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
214529488|NCT04998032|BIOLOGICAL|supaglutide injection+metformin|supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
214529489|NCT04998032|OTHER|placebo+metformin|placebo subcutaneous injection combined with metformin treatment
214529490|NCT06051721|DRUG|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
214529491|NCT06051721|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
214529492|NCT05908149|DEVICE|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
214529493|NCT05820815|DEVICE|in-bed self-exercises based on EMG-sensor feedback intervention|It presents the exercise method and amount of exercise for self-exercise and performs self-exercise while receiving feedback from muscle activity during self-exercise.
214529494|NCT01923870|DRUG|Androxal 25 mg|
214529495|NCT03467789|DRUG|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
214529496|NCT03467789|RADIATION|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
214529497|NCT03467789|DRUG|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
214458531|NCT05006859|OTHER|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
214529498|NCT06217497|OTHER|Foot massage|Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
215145731|NCT06041607|BEHAVIORAL|Shared meditation|"Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
214458532|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
214529499|NCT05789667|DRUG|Lenvatinib|Patients will be treated by lenvatinib as recommended by good clinical practice
214529500|NCT04376255|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
214529501|NCT04896502|BEHAVIORAL|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
214529502|NCT04896502|OTHER|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
214529503|NCT06015620|PROCEDURE|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
214529504|NCT05433129|PROCEDURE|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
215145732|NCT06041607|BEHAVIORAL|Meditation with patients oly|"Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
214458533|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
214458534|NCT05758922|DRUG|AZ-3102 (Dose 1)|"Pharmaceutical form: capsule~Route of administration: oral"
214529505|NCT05433129|PROCEDURE|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
214529506|NCT05433129|PROCEDURE|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
214568513|NCT03949855|DRUG|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
214568514|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.
214568515|NCT04501120|DRUG|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
214568516|NCT04501120|DRUG|standard-dose HHT|2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
214568517|NCT04501120|DRUG|Azacitidine|75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
215145733|NCT04946409|OTHER|no intervention|no intervention
215145734|NCT04402372|DEVICE|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
214458535|NCT05758922|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
214458536|NCT05758922|DRUG|AZ-3102 (Dose 2)|"Pharmaceutical form: capsule~Route of administration: oral"
214458537|NCT06545682|DRUG|Alpelisib + Pembrolizumab|Given by mouth (PO) Given by vein (IV)
214458538|NCT06773273|PROCEDURE|CapsuLaser-Assisted Capsulorhexis and Flanged Prolene Suture|CapsuLaser-Assisted Capsulorhexis and Flanged 6-0 Prolene Suture for Cionni Ring Scleral Fixation
214458539|NCT06114940|DRUG|Toripalimab|"Preoperative: Toripalimab 240mg, IV on day 1 in a 3-week cycle. Preoperative Toripalimab contains 4-5 cycles.~Postoperative: Toripalimab 240mg, IV on day 1 of a 3-week cycle. Postoperative Toripalimab following surgery within 4 weeks for patients mentioned above in cohort 1, 2 and 3."
214458540|NCT06114940|DRUG|Lenvatinib|"Preoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Preoperative Lenvatinib contains 4-5 cycles.~Postoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Postoperative Lenvatinib following surgery within 4 weeks for patients in cohort 3.~Adjustment of dose: For patients with intolerable adverse reactions (CTCAE v5.0 grade 3 or grater), the dose could be reduced to 12mg for those who were suitable to continue taking the drug after systematic evaluation by the investigator. Patients who are assessed as intolerable and not suitable for continued medication will discontinue and undergo nephrectomy within 4 weeks."
214529507|NCT05433129|PROCEDURE|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
214529508|NCT05955365|DRUG|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
214529509|NCT05955365|DRUG|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
214529510|NCT05955365|DRUG|DOAC|The choice of DOAC is left at investigator's discretion.
214529511|NCT05383651|DEVICE|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
214529512|NCT05383651|DEVICE|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
214458541|NCT04900818|DRUG|TJ033721 (givastomig)|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
214458542|NCT04900818|DRUG|TJ033721 (givastomig) , nivolumab, chemotherapy|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
214458543|NCT06806462|GENETIC|Biomolecular profile of bone metastases|Describe the biomolecular profile of bone metastases
214458544|NCT05700123|PROCEDURE|In-Office Hysteroscopy|In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
214458545|NCT01842542|DEVICE|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
214458546|NCT01192464|DRUG|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
214458547|NCT03016533|DRUG|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 50 mg tablets.
214458548|NCT03016533|DRUG|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
214458549|NCT03016533|DRUG|ABC/DTG/3TC immediate release tablets|ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
214458550|NCT03016533|DRUG|ABC/DTG/3TC film-coated dispersible tablets|ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
214458551|NCT06774209|DIAGNOSTIC_TEST|three kinds of examinations|Following the enrollment of patients, both Gallium-68 labeled Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography (68Ga-FAPI-04 PET/CT) and Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) scans are carried out. Additionally, within a one-week interval before and after the aforementioned examinations, Fluorine-18 labeled Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is performed on the same cohort of patients.
214529513|NCT05820256|DIETARY_SUPPLEMENT|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
214529514|NCT05820256|DIETARY_SUPPLEMENT|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
214529515|NCT05657613|DRUG|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
214529516|NCT05657613|DRUG|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
214568518|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.
214568519|NCT04501120|DRUG|olverembatinib|orally, with meals, QOD, every 28 days as a cycle.
215145735|NCT04252144|PROCEDURE|Dietary assessment|Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
215145736|NCT03423784|DEVICE|HA BPX V3.3|medical device containing HA
215145737|NCT03423784|OTHER|Dentinox-Gel N|Anaesthetic gel
215145738|NCT01465555|BEHAVIORAL|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
215145739|NCT03216772|DEVICE|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
215145740|NCT01075529|DRUG|fluoxetine|fluoxetine 20 mg/d
215145741|NCT00694941|DRUG|ONO-2506PO|1200mg QD / 5 years
214529517|NCT05657613|DRUG|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
214695289|NCT04263948|DEVICE|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
214695290|NCT06220630|OTHER|Breast cancer|Male patients who were microscopically diagnosed as primary breast cancer.
214695291|NCT06153082|DIAGNOSTIC_TEST|ROTEM|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
214695292|NCT06153082|DIAGNOSTIC_TEST|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
214695293|NCT03059719|BIOLOGICAL|Exenatide injection(Byetta)|
215145742|NCT03583892|DRUG|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
215145743|NCT01486719|PROCEDURE|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
215145744|NCT00338845|BEHAVIORAL|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
214458552|NCT06381284|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
214458553|NCT06381284|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
214458554|NCT06381284|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
214458555|NCT04457687|DRUG|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
214458556|NCT04473222|BEHAVIORAL|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
214458557|NCT04473222|BEHAVIORAL|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
214458558|NCT06271278|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
214458559|NCT04636528|DEVICE|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
214529518|NCT02720783|DRUG|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
214695294|NCT03059719|BIOLOGICAL|PB-119 injection|
214529519|NCT02720783|DRUG|Placebo plus Econazole nitrate 150 mg vaginal pessary|
214529520|NCT02720783|DRUG|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
214529521|NCT02720783|DRUG|Placebo vaginal pessary|
214568523|NCT04035499|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
215145745|NCT00338845|BEHAVIORAL|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
215145746|NCT02726568|DRUG|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
215145747|NCT02726568|RADIATION|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
214458560|NCT04636528|DEVICE|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, physical therapists will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
215145748|NCT04316845|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
215145749|NCT00000393|DRUG|Peptide T|
215145750|NCT01471288|DRUG|Carum Cravi|40mg/kg of body weight
214458561|NCT03713268|DEVICE|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
214458562|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
214458563|NCT05165524|DEVICE|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
214458564|NCT05165524|DRUG|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
214458565|NCT06807814|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT))|A well-defined and structured rehabilitation program that restricts the use of the unaffected limb to promote the functional recovery of the affected limb in chronic stroke patients(Franck et al., 2019). Sit-to-stand transitions, Indoor overground walking (forward, backward, and sideways), Weight-bearing movements in different directions: Stepping over obstacles and climbing stairs, Ideally, specific tasks to involve the paretic limb according to the activity of stroke survivors. This task was repeated ten times as part of the therapy sessions. Dynamic strengthening exercises like squats and lunges are integrated, progressively increasing intensity as patients gain confidence and strength. Balance and core stability exercises, including single-leg stances and seated weight shifts on therapy balls, address postural control and stability.(Cabanas-Valdés \& Boix-Sala, 2021)
214529522|NCT05204472|DEVICE|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -\> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
215145751|NCT01471288|DRUG|Placebo|Placebo
215145752|NCT00852449|OTHER|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
215145753|NCT05106400|DRUG|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
215145754|NCT05106400|DRUG|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
215145755|NCT05106400|DRUG|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
215145756|NCT05106400|DRUG|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
215145757|NCT00417417|DRUG|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
215145758|NCT00417417|DRUG|Placebo|Normal saline subcutaneously at each treatment visit.
215145759|NCT00684021|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
215145760|NCT00684021|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
214458566|NCT06807814|BEHAVIORAL|Mirror Therapy|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. The MT protocol included 10 minutes of warm-up, 1 hour of mirror box training, and 50 minutes of functional task practice. The warm-up activities included stretching and passive range of motion exercises. During the mirror box training, a mirror box that reflected the image of the unaffected arm was placed in the participant's midsagittal plane. Participants were required to symmetrically move both hands as simultaneously as possible while watching the reflection of the unaffected arm in the mirror as if it were the affected one. To ensure that the participants focused on the reflection, the unaffected arm was placed in the mirror box, and vision of the affected arm was occluded by a vertical board placed beside the mirror box. The activities consisted of transitive (eg, gross motor tasks, such as reaching
214458567|NCT04002518|DEVICE|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
214458568|NCT05740813|DRUG|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
214458569|NCT05740813|DRUG|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
214458570|NCT05740813|DRUG|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
214458571|NCT02103361|DRUG|Ustekinumab|
214458572|NCT02103361|DRUG|Guselkumab|
214458573|NCT04680403|OTHER|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
214458574|NCT05966961|DEVICE|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
214458575|NCT05966961|DEVICE|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
214458576|NCT06087536|DRUG|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
215145761|NCT00004854|DRUG|Carvedilol|
215145762|NCT01815970|BEHAVIORAL|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
215145763|NCT00927953|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
215145764|NCT00927953|BIOLOGICAL|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
215145765|NCT05670886|PROCEDURE|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
215145766|NCT02633150|OTHER|Supplementation with red grapes polyphenol|
215145767|NCT06025864|OTHER|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
215145768|NCT01477398|DEVICE|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
215145769|NCT05907863|OTHER|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
215145770|NCT05353270|BEHAVIORAL|Yoga|Yoga sessions will be completed 5 times per week for 4 weeks.
215145771|NCT05353270|BEHAVIORAL|Waitlist control|Waitlisted participants will maintain their normal exercise and diet for 4 weeks. After follow up testing at week 4, participants will be rerandomized to the yoga condition.
215145772|NCT02976038|DRUG|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
215145773|NCT00264186|DRUG|LPS 2 ng/kg intravenous (IV) bolus|
215145774|NCT00264186|DRUG|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
215145775|NCT00264186|DRUG|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
215145776|NCT00264186|DRUG|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
214458577|NCT06087536|DRUG|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
214458578|NCT06410950|DIAGNOSTIC_TEST|MyotonPRO Assessment of Muscle Biomechanical Properties|"Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements."
214458579|NCT05119491|DEVICE|uitrasonography and spirometry|chest uitrasonography and spirometry
215145777|NCT00264186|DRUG|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
214458580|NCT03696225|BEHAVIORAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
214458581|NCT03696225|BEHAVIORAL|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
214458582|NCT06806501|BEHAVIORAL|Unilateral Resistance Exercise|Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.
214458583|NCT06577090|BIOLOGICAL|Nimacimab injection|Nimacimab injection 200 mg
214458584|NCT06577090|BIOLOGICAL|Nimacimab placebo injection|matching nimacimab placebo injection
214458585|NCT06577090|COMBINATION_PRODUCT|semaglutide injection|semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
214529523|NCT05204472|DEVICE|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -\> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
214529524|NCT06288451|DRUG|Oral calcitriol with cinacalcet rescue|Participants will receive in-center oral calcitriol at a fixed dose of 0.5 mcg three times weekly at their dialysis treatment sessions regardless of their parathyroid hormone (PTH) concentrations over the 12-month trial period. Only if their serum PTH exceeds 800 pg/mL over 2 consecutive measurements will they be started on cinacalcet at 30 mg/d in order to protect against severe unremitting hyperparathyroidism.
214529525|NCT06288451|DRUG|IV activated vitamin D|Participants will continue to receive intravenously-administered activated vitamin D per the Northwest Kidney Center treatment protocol, dose-titrated to monthly to quarterly parathyroid hormone concentrations.
214529526|NCT03340766|DRUG|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
214529527|NCT03340766|DRUG|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
214529528|NCT03443752|OTHER|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
214529529|NCT03443752|OTHER|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
214529530|NCT04473118|OTHER|Survey|An online-based questionnaire sent to participants via email
214529531|NCT02867371|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
214529532|NCT04542642|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
214529533|NCT04542642|DEVICE|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
215145778|NCT04254003|DEVICE|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
215145779|NCT04254003|DEVICE|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
214458586|NCT05759156|DRUG|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
214458587|NCT04201457|DRUG|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
214458588|NCT04201457|DRUG|Trametinib|Tablet; Powder for Oral Solution
214458589|NCT04201457|DRUG|Hydroxychloroquine|Tablet
214458590|NCT06321809|BEHAVIORAL|intensive lifestyle|INTENSIVE LIFESTYLE INTERVENTIONS
214458591|NCT06529796|DRUG|IXP|Tablet for oral administration.
214458592|NCT04863222|DEVICE|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
214458593|NCT04863222|BIOLOGICAL|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
215145780|NCT06267755|OTHER|Extracorporeal Shockwave therapy|the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
215145781|NCT06267755|OTHER|Traditional physical therapy|the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
215145782|NCT03632889|BEHAVIORAL|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
214458594|NCT03123848|DRUG|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
214458595|NCT01369355|DRUG|Placebo SC|Placebo will be administered subcutaneously.
214458596|NCT01369355|DRUG|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
214458597|NCT01369355|DRUG|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
214458598|NCT01369355|DRUG|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
214458599|NCT01369355|DRUG|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
214458600|NCT05827718|BEHAVIORAL|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
214458601|NCT05827718|BEHAVIORAL|Source of Contact|Behavioral Intervention studied here is source of contact (personal clinic vs. research team)
214458602|NCT05827718|BEHAVIORAL|Framing Method (Appeal to Altruism or Social Proof|"Behavioral Intervention studied here is the framing methods appeal to altruism and social proof"
214458603|NCT05827718|BEHAVIORAL|Incentive Structure|Behavioral Interventions studied here are guaranteed vs. lottery incentives
214458604|NCT02436096|DRUG|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
214458605|NCT02436096|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
214458606|NCT06296459|OTHER|3D R100 scanner|A cone beam computed tomography used for planning of implant surgery
214458607|NCT06296459|OTHER|Conventional Radiograph|Imaging used as standard of care to plan for implant surgery
214458608|NCT03131154|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
214458609|NCT03131154|DRUG|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
214458610|NCT06185101|BEHAVIORAL|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
214458611|NCT05339451|DIAGNOSTIC_TEST|Blood biomarkers|Blood biomarkers in plasma and serum.
214458612|NCT06550219|DEVICE|Nasal humidified heated high flow cannula (NHHHC)|Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.
214458613|NCT06550219|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV)|Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.
214458614|NCT06550219|DEVICE|Nasal continuous positive airway pressure NCPAP|Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
214458615|NCT06550219|DEVICE|lung ultrasound|Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
214458616|NCT06424236|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks, at escalating doses; at target, dosing was every 2 weeks
214458617|NCT05211635|DIETARY_SUPPLEMENT|Vitamin D|One capsule daily for 84 days
214458618|NCT05211635|OTHER|Placebo|One capsule daily for 84 days
214458619|NCT06311565|BEHAVIORAL|Education|Individuals in this group will be trained on acquiring healthy lifestyle behaviors to protect against colorectal cancer. Training will be individual, face-to-face and in the form of question and answer. At the end of the training, training brochures prepared by the researchers after taking expert opinions will be distributed to the participants. The training will take approximately 25-30 minutes. The training will take place in the training hall at the family health center.
214458620|NCT04734626|DIAGNOSTIC_TEST|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
214458621|NCT03183570|DRUG|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
214529534|NCT06394193|BEHAVIORAL|Community-based participatory research intervention|Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
214529535|NCT05609682|DRUG|Gabapentin|Scheduled gabapentin given for two weeks after surgery
214529536|NCT05609682|DRUG|Placebo|Placebo given for two weeks after surgery
214529537|NCT02987088|DRUG|Sodium Nitrite|
214529538|NCT05057078|BEHAVIORAL|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
214529539|NCT03514745|DEVICE|GlideScope|Endobronchial intubation is performed using the GlideScope.
214529540|NCT03514745|DEVICE|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
214529541|NCT05343819|DRUG|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
214529542|NCT05343819|DRUG|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
214529543|NCT06415747|OTHER|Observational pain and motor function assessments, and also comorbidities assessments with x-ray.|There was no intervention in our study, only observational and quantitative clinical evaluations.
214458622|NCT06143293|DEVICE|Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters|Duty cycle: At Visit 1, while the frequencies are being changed over Period 1, 2, and 3, duty cycle will be held constant at the participant's randomly assigned first duty cycle setting. At Visit 2, duty cycle will be held constant at the participant's randomly assigned second duty cycle setting. At Visit 2 the participant will receive whichever duty cycle they were not randomly assigned at Visit 1. Therefore, by completing the combination of three frequencies at two duty cycles, each participant will have received all six possible VNS parameter combinations over the two study visits. Chronic period: The VNS setting for the Chronic Period in between Visit 1 and Visit 2 will be the same settings as tested during Visit 1 Period 3. Since Visit 1 Period 3 settings were already randomly assigned to each participant, another randomization for the chronic period is not needed.
214458623|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
214458624|NCT01824394|DEVICE|nMARQ Navigation Catheters|
214458625|NCT01824394|DEVICE|NaviStar ThermoCool Catheters|
214458626|NCT04014088|DEVICE|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
214458627|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
214458628|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
214458629|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
214458630|NCT04920175|OTHER|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
214458631|NCT06807398|GENETIC|Data will be used to develop a novel predictive model assessing the risk of LNI.|The epigenetic signature will be tested on DNA extracted from PCa tissue obtained at prostate biopsy. For each patient, 2 positive cores will be analysed. The 2 cores will be selected as follows: (i) one core from the index lesion; the core with the highest Gleason Score will be selected. In case of two or more cores with the same Gleason Score, the one with the highest percentage of cancer involvement will be selected; (ii) one core with the highest Gleason score outside the index lesion. In case of two or more cores with the same Gleason score, the one with the highest percentage of cancer involvement will be selected. The epigenetic signature will be tested on DNA extracted from prostate cancer tissue obtained from the two positive cores. In particular, the epigenetic score will be calculated on the prostatic tissue using the epigenetic signatures previously identified \[8\].In patients diagnosed with PCa who will be treated with RP, ePLND will be performed when the predicted LNI risk
214458632|NCT05081999|OTHER|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
214458633|NCT05081999|OTHER|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
214458634|NCT02876510|DRUG|Fludarabine|Fludarabine infusion
214458635|NCT02876510|DRUG|Cyclophosphamide|Cyclophosphamide infusion
214458636|NCT02876510|BIOLOGICAL|IMA101 product|i.v. infusion of IMA101 product(s).
214458637|NCT02876510|BIOLOGICAL|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
215145783|NCT03228550|DIETARY_SUPPLEMENT|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
215145784|NCT03228550|BEHAVIORAL|Aerobic exercise|Static exercise cycle
214458638|NCT02876510|DIAGNOSTIC_TEST|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
214458639|NCT02876510|DRUG|Atezolizumab|Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
214458640|NCT05298358|BIOLOGICAL|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines."
214458641|NCT05204719|PROCEDURE|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
214458642|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
214458643|NCT03511846|DRUG|Oral capsaicin|Subjects will drink a solution with capsaicin
214458644|NCT03511846|DRUG|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
214458645|NCT03511846|DRUG|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
214529544|NCT00131690|DRUG|Nescafé Gold Blend (exposed)|
214529545|NCT00131690|DRUG|Nescafé Decaffeinated (controls)|
214529546|NCT03922295|PROCEDURE|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
214529547|NCT00581009|OTHER|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
215145785|NCT03228550|DIETARY_SUPPLEMENT|Placebo multinutrient|Placebo multinutrient supplement
215145786|NCT06151457|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
215145787|NCT06151457|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
215145788|NCT03755310|DRUG|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
215145789|NCT03755310|DRUG|Placebo|Equivalent dosage, route of administration and dose regimen
215145790|NCT01919502|DEVICE|Semi-quantitative urine pregnancy test|
214458646|NCT03511846|OTHER|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
214458647|NCT03511846|OTHER|Medical Air|Subjects will be exposed to medical air
214458648|NCT03511846|DRUG|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
214458649|NCT03511846|DRUG|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
214458650|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
214458651|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
214458652|NCT06059339|OTHER|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
214458653|NCT05562297|DRUG|sintilimab|Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
214458654|NCT05562297|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
214458655|NCT05562297|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
214529548|NCT00581009|DRUG|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
214529549|NCT00581009|RADIATION|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
214529550|NCT03772119|PROCEDURE|Surgical resection|Surgical resection of hemivertebra
214695295|NCT01819311|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
215145791|NCT01046396|DRUG|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
215145792|NCT01046396|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
215145793|NCT02638194|OTHER|Active smoking of Tobacco Hookah for 2 hours|
215145794|NCT02638194|OTHER|Exposure to tobacco hookah second hand smoke|
215145795|NCT02638194|OTHER|Visit a win bar|Participants will visit a wine bar for food and/or drinks
215145796|NCT01208207|DRUG|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
215145797|NCT01208207|DRUG|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
215145798|NCT01208207|DRUG|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
215145799|NCT01208207|DRUG|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
215145800|NCT01208207|DRUG|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
215145801|NCT01208207|DRUG|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
215145802|NCT01208207|DRUG|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
215145803|NCT01208207|DRUG|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
214529551|NCT05044078|OTHER|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
214529552|NCT05044078|OTHER|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
214529553|NCT02849509|DRUG|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
214529554|NCT02849509|DRUG|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
214529555|NCT02735278|OTHER|different test paradigms|
214458656|NCT06306612|DRUG|Systemic Chemohormonal Therapy|Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
214458657|NCT06306612|DRUG|Systemic Hormonal Therapy|Under continuous ADT, oral darolutamide 600mg twice per day
214458658|NCT06306612|PROCEDURE|Cytoreductive Prostatectomy|Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
214458659|NCT06306612|PROCEDURE|Postoperative Adjuvant Radiotherapy|Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
214458660|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
214458661|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
214458662|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
214458663|NCT04837248|OTHER|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
214458664|NCT04837248|OTHER|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
214458665|NCT06141720|BEHAVIORAL|pain education|Pain education
214458666|NCT06141720|BEHAVIORAL|mindfulness of pain introduction and intervention|Brief mindfulness of pain introduction and intervention
214458667|NCT05948306|OTHER|Critical Patient-Centered Skin Care Protocol|"A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added."
214458668|NCT05465616|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
214458669|NCT05257967|DIAGNOSTIC_TEST|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
214458670|NCT05956067|DEVICE|Green Light stimulation|A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.
214458671|NCT05956067|DEVICE|Equal Energy White stimulation|A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.
214458672|NCT05956067|DEVICE|S-cone modulating white light|A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
214458673|NCT05841212|OTHER|DBT for ADHD|See information included in arm/group description.
214458674|NCT04513639|DRUG|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
214458675|NCT04513639|DRUG|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
214458676|NCT02381353|DRUG|Bupivacaine|Intraoperative orbital injection of local pain medication
214458677|NCT06074536|PROCEDURE|patient-centered approach training|face to face training of general practitioner of interventional arm
214458678|NCT05603143|DRUG|Obeldesivir|Tablets administered orally without regard to food.
214458679|NCT05603143|DRUG|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
214529556|NCT03823261|BEHAVIORAL|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
215145804|NCT01208207|DRUG|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
215145805|NCT01208207|DRUG|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
214458680|NCT05783102|BEHAVIORAL|Knowledge and Interpersonal Skills to Develop Exemplary Relationships|During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
214458681|NCT05647304|DEVICE|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
214458682|NCT05647304|DEVICE|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
214458683|NCT04148560|OTHER|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
214458684|NCT03414970|RADIATION|Radiation Therapy|Undergo RT
214458685|NCT03414970|OTHER|Questionnaire Administration|Ancillary studies
214458686|NCT03414970|OTHER|Quality-of-Life Assessment|Ancillary studies
214458687|NCT03414970|OTHER|Laboratory Biomarker Analysis|Correlative studies
214458688|NCT03414970|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
214458689|NCT04605770|DRUG|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
214458690|NCT05795842|DEVICE|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
214458691|NCT05795842|OTHER|Samsung Galaxy Watch 6|"The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development."
214458692|NCT05795842|DEVICE|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
214458693|NCT05302089|OTHER|Pain management and shoulder bandage|All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
214529557|NCT00149071|DEVICE|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
214529558|NCT00149071|DEVICE|TMS|Transcraniel Magnetic Stimulation active and sham
214529559|NCT00149071|DEVICE|rTMS|active Transcranial Magnetic Stimulation
214529560|NCT00149071|DEVICE|rTMS|daily for three weeks
214529561|NCT04389983|DIETARY_SUPPLEMENT|Medium Chain Triglyceride oil|Bulletproof Braine Octane MCT oil
214529562|NCT00207298|PROCEDURE|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
215145806|NCT01208207|DRUG|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
215145807|NCT01208207|DRUG|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
215145808|NCT04396418|BEHAVIORAL|Education|Randomization between two groups at site level. One cluster with education and one without.
215145809|NCT00402948|DRUG|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
215145810|NCT00402948|DRUG|ASM8|inhalation 0.25mg daily for 14 days
215145811|NCT02808117|DIETARY_SUPPLEMENT|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
215145812|NCT03086811|BEHAVIORAL|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips."
214458694|NCT05302089|OTHER|One-time physiotherapy instruction|Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
214458695|NCT05302089|OTHER|Usual rehabilitation care|At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
214458696|NCT05452889|DIAGNOSTIC_TEST|18F-FGLN PET Imaging|PET/CT Imaging: The study visit will take around 3-4 hours, the duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Participants will be retained in the PET facility following the PET scan to promote urination to increase elimination of the radiotracer.
214458697|NCT05452889|DRUG|(18F)FPGLU|\[F-18\]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
214458698|NCT05048056|DRUG|Placebo|Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
214458699|NCT05048056|DRUG|AK120|AK120 Regimen 1- subcutaneous injection every 2 weeks.
214458700|NCT05048056|DRUG|AK120|AK120 Regimen 2- subcutaneous injection every 2 weeks
214458701|NCT05476913|DEVICE|geko™ device|Neuromuscular electrical stimulation of the peroneal nerve
214458702|NCT06645574|OTHER|The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.|"Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires"
214458703|NCT06068985|DRUG|PHESGO|Subcutaneous formulation with pertuzumab and trastuzumab.
214458704|NCT06238609|DEVICE|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
214458705|NCT06238609|DEVICE|Control Group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
214458706|NCT01363388|DRUG|Placebo|BID for 84 days
214458707|NCT01363388|DRUG|CCX168|BID for 84 days
214458708|NCT05444751|DRUG|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
214458709|NCT05444751|DRUG|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
214458710|NCT06083948|DRUG|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
214458711|NCT06083948|DRUG|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
214458712|NCT05964998|DEVICE|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
215145813|NCT02631239|DRUG|Methotrexate|1g/m2/d IV \*1d
215145814|NCT02631239|DRUG|Etoposide|200mg/d PO \*3d
215145815|NCT02631239|DRUG|Dexamethasone|40mg/d PO \*3d
215145816|NCT02631239|DRUG|Pegaspargase|2500IU/m2/d IM \*1d
215145817|NCT02631239|RADIATION|Radiotherapy|50-56Gy
214458713|NCT05964998|DEVICE|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
214458714|NCT05646589|BEHAVIORAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
214458715|NCT05646589|BEHAVIORAL|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
214458716|NCT06041568|DRUG|Imvotamab|Administered intravenously
214529563|NCT02256488|BIOLOGICAL|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
215145818|NCT05871216|DIAGNOSTIC_TEST|Clinical tests and balance evaluation using the Delos Proprioceptive System|Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
215145819|NCT04041414|OTHER|Proud & Empowered!|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
215145820|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
215145821|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
215145822|NCT03483402|PROCEDURE|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
215145823|NCT01537705|DRUG|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
215145824|NCT06066320|BEHAVIORAL|MMST|Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones
214458717|NCT06313892|BEHAVIORAL|Home based Exercise|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
214458718|NCT02683447|OTHER|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
214458719|NCT03448107|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
214458720|NCT03448107|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
214458721|NCT03448107|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
214458722|NCT04883463|DEVICE|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
214458723|NCT04851340|OTHER|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
214458724|NCT04851340|OTHER|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
214458725|NCT06005987|BEHAVIORAL|OneTouch Reveal application|Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
214458726|NCT03115476|DRUG|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
214458727|NCT03115476|DRUG|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
214458728|NCT03115476|OTHER|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
214458729|NCT06279780|DIETARY_SUPPLEMENT|very low-calorie diet|Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
214458730|NCT05559931|DRUG|N,N-Dimethyltryptamine|IV infusion over 6 hours
214458731|NCT05559931|DRUG|Placebo|Placebo infusion over 6 hours
214458732|NCT02489903|DRUG|RRx-001|
214458733|NCT02489903|DRUG|Cisplatin|
214529564|NCT02256488|BIOLOGICAL|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
214529565|NCT02256488|BIOLOGICAL|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
214529566|NCT02256488|BIOLOGICAL|TIVf|Single IM administration dose of 0.5 mL of TIVf
214529567|NCT00449488|DRUG|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
214529568|NCT02108483|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
214529569|NCT02108483|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
215145825|NCT06066320|BEHAVIORAL|TSST|Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
215145826|NCT01694914|PROCEDURE|corneal graft|
215145827|NCT04004988|DRUG|Tirzepatide|Administered SC
215145828|NCT04004988|DEVICE|Prefilled syringe (PFS)|PFS used to administer tirzepatide
215145829|NCT04004988|DEVICE|Auto-injector (AI)|AI used to administer tirzepatide
214529570|NCT03847389|DRUG|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
214529571|NCT02864147|DRUG|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
214529572|NCT02864147|DRUG|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
214529573|NCT05739799|PROCEDURE|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
214529574|NCT05739799|PROCEDURE|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
214529575|NCT02019238|OTHER|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
214529576|NCT01351883|DIETARY_SUPPLEMENT|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
214529577|NCT06546566|OTHER|Video Game-Based Breathing Exercises|The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
214529578|NCT06546566|OTHER|Conventional Breathing Exercises|The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
214529579|NCT00975130|BIOLOGICAL|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
214529580|NCT00975130|BIOLOGICAL|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
214529581|NCT00240097|DRUG|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
214695296|NCT01819311|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
214695297|NCT01679093|DRUG|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
214695298|NCT01679093|DRUG|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
215145830|NCT00930046|DEVICE|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
214458734|NCT02489903|DRUG|Etoposide|
214458735|NCT02489903|DRUG|Carboplatin|
214458736|NCT02489903|DRUG|Irinotecan|
214458737|NCT02489903|DRUG|Vinorelbine|
214458738|NCT02489903|DRUG|Doxil|
214458739|NCT02489903|DRUG|Gemcitabine|
214458740|NCT02489903|DRUG|Taxane|
214458741|NCT02489903|DRUG|Paclitaxel|
214458742|NCT02489903|DRUG|Nab-Paclitaxel|
214458743|NCT02489903|DRUG|Pemetrexed|
214458744|NCT04980248|BIOLOGICAL|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
214458745|NCT05855083|DRUG|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
214458746|NCT04828681|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
214695299|NCT01679093|DRUG|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
214695300|NCT03441893|DIAGNOSTIC_TEST|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
214695301|NCT03441893|DRUG|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
215145831|NCT00930046|DEVICE|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
215145832|NCT04346381|DRUG|Camrelizumab|Intravenous (IV) camrelizumab on Day 1 of each cycle
215145833|NCT04346381|DRUG|Famitinib|famitinib po qd
215145834|NCT01598532|DEVICE|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
215145835|NCT02982746|OTHER|gPCC (Gothenburg Person Centred Care)|
215145836|NCT04682366|DRUG|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
215145837|NCT04682366|DRUG|Placebo|Oral drug: 10 days of identical-appearing placebo
215145838|NCT04600596|BEHAVIORAL|Recording of food intake.|The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
215145839|NCT02130843|DEVICE|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
215145840|NCT00813202|DRUG|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
215145841|NCT04051424|DEVICE|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
215145842|NCT04051424|DEVICE|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
215145843|NCT04051424|DEVICE|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
214695302|NCT03441893|DRUG|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
214458747|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
214458748|NCT04542317|BEHAVIORAL|REACH VN|4-6 sessions delivered over the course of 2-3 months.
214458749|NCT04542317|BEHAVIORAL|Enhanced control|A single session providing education about dementia
214458750|NCT05760274|DIAGNOSTIC_TEST|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
214458751|NCT02933736|DRUG|Ribociclib|
214458752|NCT05831241|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
214458753|NCT05831241|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
214458754|NCT05353348|DRUG|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
214458755|NCT05353348|PROCEDURE|conventional treatment|Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team
214458756|NCT05739643|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
214458757|NCT02859961|DRUG|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
214458758|NCT02859961|DRUG|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
214458759|NCT02859961|DRUG|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
214458760|NCT06318143|BEHAVIORAL|TASSH|Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
214529582|NCT00240097|DRUG|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
214529583|NCT03204318|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
214529584|NCT03204318|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
214458761|NCT04700163|BIOLOGICAL|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
214458762|NCT05590962|OTHER|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
214458763|NCT03976362|BIOLOGICAL|Pembrolizumab|IV infusion
214458764|NCT03976362|DRUG|Carboplatin|IV infusion
214458765|NCT03976362|DRUG|Paclitaxel|IV infusion
214695303|NCT03441893|DRUG|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
215145844|NCT00702221|BIOLOGICAL|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
215145845|NCT00702221|BIOLOGICAL|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
214458766|NCT03976362|DRUG|Nab-paclitaxel|IV infusion
214458767|NCT03976362|DRUG|Olaparib|Tablets
214529585|NCT03204318|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
214529586|NCT03204318|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
215145846|NCT02989597|DRUG|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
215145847|NCT02989597|OTHER|Standard pain regimen|Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
215145848|NCT02989597|PROCEDURE|Spinal Fusion Surgery|Clinically-indicated spinal fusion surgery
215145849|NCT02989597|DRUG|Dexamethasone|Post operative swelling and pain control
214529587|NCT03792789|DEVICE|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
214529588|NCT03792789|DEVICE|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
214529589|NCT01018576|OTHER|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
214529590|NCT02599987|DEVICE|POWERbreathe® Classic Light|Inspiratory Muscle Training
214529591|NCT05603299|OTHER|Educational Materials on the Dawn test|Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
214529592|NCT02383927|DRUG|Tipifarnib|FTase inhibitor
214529593|NCT02973945|DEVICE|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
214529594|NCT02973945|DEVICE|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
214529595|NCT05590845|OTHER|Survey|"Patients, 65 and above, scheduled for elective total hip replacement surgery, will be invited to participate in a survey (consisting of 15 questions) testing their knowledge regarding PND.~After completion of the survey, patients will receive a standard preoperative brochure on anaesthesia-related topics and delirium.~T-MOCA scores will be collected (22 = perfect score; \<18 = cutoff for cognitive impairment) (through a pre-operative telephone call).~Six weeks post-operatively patients will once again be called for T-moca scores.~Initially a feasibility study for 1/3 of sample size will be done."
214529596|NCT02815618|DEVICE|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
214529597|NCT02948205|PROCEDURE|3D group|infertility patient get TU-LESS by 3D Laparoscopy
214529598|NCT02948205|PROCEDURE|normal group|infertility patient get normal laparoscopic surgery
214529599|NCT03093597|OTHER|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
214529600|NCT03093597|OTHER|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
214529601|NCT03093597|OTHER|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
214529602|NCT03093597|OTHER|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
214695304|NCT03441893|DRUG|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
215145850|NCT02989597|DRUG|Ketamine|Perioperative anesthesia medication
215145851|NCT02989597|DRUG|Remifentanil|Perioperative pain medication
214529603|NCT00734851|DRUG|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
214695305|NCT03102359|DRUG|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
214695306|NCT03102359|DEVICE|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
214695307|NCT03837353|DRUG|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
215145852|NCT02989597|DRUG|Sufentanil|Perioperative pain medication
215145853|NCT01230983|DRUG|asparaginase|Given IV
215145854|NCT01230983|DRUG|cytarabine|Given IV
215145855|NCT01230983|DRUG|dexrazoxane hydrochloride|Given IV
215145856|NCT01230983|DRUG|doxorubicin hydrochloride|Given IV
215145857|NCT01230983|DRUG|leucovorin calcium|Given IV
215145858|NCT01230983|DRUG|mercaptopurine|Given orally
215145859|NCT01230983|DRUG|methotrexate|Given IV
215145860|NCT01230983|DRUG|prednisone|Given orally
215145861|NCT01230983|DRUG|therapeutic hydrocortisone|Given IT
215145862|NCT01230983|DRUG|vincristine sulfate|Given IV
215145863|NCT01230983|RADIATION|radiation therapy|Radiation to cranium
215145864|NCT05035381|DRUG|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
215145865|NCT00025181|BIOLOGICAL|MART-1 antigen|
215145866|NCT00025181|BIOLOGICAL|gp100 antigen|
214529604|NCT00734851|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
214529605|NCT00734851|RADIATION|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
214529606|NCT00260702|DRUG|Omalizumab (Xolair)|
214529607|NCT02259569|OTHER|Pressure-controlled ventilation|
214529608|NCT02259569|OTHER|Volume-controlled ventilation|
214529609|NCT06531811|DRUG|AZD8630 (test formulation) via test inhaler|Participants will receive AZD8630 via test inhaler.
214529610|NCT06531811|DRUG|AZD8630 (reference formulation) via Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
214529611|NCT06531811|DEVICE|Test inhaler|Participants will receive AZD8630 via test inhaler.
215145867|NCT00025181|BIOLOGICAL|incomplete Freund's adjuvant|
215145868|NCT00025181|BIOLOGICAL|ipilimumab|
215145869|NCT00025181|BIOLOGICAL|tyrosinase peptide|
215145870|NCT00025181|PROCEDURE|adjuvant therapy|
215145871|NCT02406508|DEVICE|Melphalan/HDS|
215145872|NCT02406508|DRUG|Sorafenib|
215145873|NCT00823017|OTHER|Patient-preferred music|Music of patients' preference
215145874|NCT00823017|OTHER|Relaxation Music|Relaxation music compiled from results of first three stages of study
215145875|NCT00823017|OTHER|Standard Care Environment|Control, no interventions
215145876|NCT04318353|OTHER|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
215145877|NCT03160443|BEHAVIORAL|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
215145878|NCT05827172|PROCEDURE|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
215145879|NCT05827172|OTHER|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
215145880|NCT02399176|BEHAVIORAL|Yoga|Subjects assume 10 physical postures for 30 seconds each
214529612|NCT06531811|DEVICE|Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
214529613|NCT06646211|DRUG|Zanubrutinib , Thiotepa|"First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
214529614|NCT06646211|DRUG|Methotrexate , Thiotepa and Zanubrutinib|"Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
215145881|NCT00637975|DRUG|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
215145882|NCT00637975|DRUG|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
215145883|NCT01034332|PROCEDURE|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
215145884|NCT03704896|OTHER|Lung function measurement|Spirometry-derived lung function measurements
215145885|NCT03591211|BEHAVIORAL|Qigong Training|Eight-Section Brocades; participants were trained individually.
215145886|NCT03591211|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
215145887|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
215145888|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
215145889|NCT02282618|DEVICE|Cardiac Sympathetic Blockade|
215145890|NCT02955667|PROCEDURE|invivo microscopy group|patients receive invivo micro-colposcopy examination
215145891|NCT02955667|PROCEDURE|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
215145892|NCT03031015|DEVICE|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
215145893|NCT03031015|DEVICE|Plating|Fractures were reduced and then fixed with Plate.
215145894|NCT01028820|DRUG|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
215145895|NCT04129996|DRUG|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
215145896|NCT04778137|DRUG|Omalizumab|Biological: CMAB007 Biological: Xolair
215145897|NCT02729532|DEVICE|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
215145898|NCT06369727|DRUG|MOB015B|Topcal formulation
215145899|NCT06369727|DRUG|MOB015B vehicle|Topcal formulation
215145900|NCT06369727|DRUG|Negative irritant solution of 0.9% saline|Negative control
214458768|NCT03976362|DRUG|Placebo|Placebo to olaparib, tablets
214458769|NCT05575440|PROCEDURE|Computed Tomography|Undergo a PET/CT scan
214458770|NCT05575440|RADIATION|Fluorine F 18 Tetrafluoroborate|Given IV
214458771|NCT05575440|PROCEDURE|Positron Emission Tomography|Undergo a PET/CT scan
214458772|NCT05575440|OTHER|Survey Administration|Ancillary studies
214458773|NCT04852783|DEVICE|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
214458774|NCT00613106|DRUG|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
214458775|NCT00613106|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
214458776|NCT04118673|BEHAVIORAL|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
214458777|NCT05949645|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
214458778|NCT05574387|DRUG|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
214458779|NCT03142568|DRUG|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
214458780|NCT03142568|OTHER|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
214458781|NCT03906331|DRUG|Selpercatinib|Open-label expanded access
214458782|NCT03593018|DRUG|Oral azacitidine|Azacitidine tablets
214458783|NCT03593018|DRUG|Romidepsin|Romidepsin injection
214458784|NCT03593018|DRUG|Bendamustine|Bendamustine injection
214458785|NCT03593018|DRUG|Gemcitabine|Gemcitabine injection
214458786|NCT05610644|OTHER|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
214458787|NCT04672863|BEHAVIORAL|Dietary Intervention|Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
214458788|NCT06164002|OTHER|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
214458789|NCT04164069|BIOLOGICAL|Bevacizumab|Given IV
214458790|NCT04164069|DRUG|Dasatinib|Given PO
214458791|NCT04164069|DRUG|Fluorouracil|Given IV
214458792|NCT04164069|DRUG|Leucovorin|Given IV
214458793|NCT04164069|DRUG|Leucovorin Calcium|Given IV
214458794|NCT04164069|DRUG|Oxaliplatin|Given IV
214458795|NCT04164069|OTHER|Quality-of-Life Assessment|Ancillary studies
214458796|NCT06004479|OTHER|Carotenoid Intake|Carotenoid intake assess by 24 hour dietary recalls
214458797|NCT06004479|OTHER|Serum carotenoid concentration|Serum total carotenoid concentration
214458798|NCT05241392|BIOLOGICAL|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
214458799|NCT02396134|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Given SC
214529615|NCT06646211|DRUG|ASCT±Zanubrutinib|"Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)"
214529616|NCT05126537|OTHER|no intervention|prospective and observational study with no intervention
215145901|NCT01387997|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
215145902|NCT05708053|DRUG|Metformin|Metformin 500 mg twice
215145903|NCT06141525|DEVICE|Remote ischemic conditioning|An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).
215145904|NCT05248152|COMBINATION_PRODUCT|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
215145905|NCT05248152|DRUG|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
215145906|NCT05248152|DRUG|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
215145907|NCT04442828|DIAGNOSTIC_TEST|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
215145908|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
215145909|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
215145910|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
215145911|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
214458800|NCT02396134|OTHER|Placebo|Given SC
214458801|NCT02396134|OTHER|Laboratory Biomarker Analysis|Correlative studies
214458802|NCT04923945|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest. Or patient will receive Savolitinib \[Savolitinib 300 mg, po, twice per day (BID) continuously in patients with baseline weight ≥50 kg, and Savolitinib 200 mg, po, BID in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
214458803|NCT03596788|DIETARY_SUPPLEMENT|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
214458804|NCT03596788|DIETARY_SUPPLEMENT|Placebo Beverage|The placebo beverage will contain aspartame.
214458805|NCT01424150|OTHER|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
214458806|NCT01424150|OTHER|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
214458807|NCT04768257|BEHAVIORAL|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
214458808|NCT05658874|DRUG|Multimodal Bundle Drugs|multimodal pain therapy
214458809|NCT05658874|PROCEDURE|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
214458810|NCT05658874|BEHAVIORAL|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
214529617|NCT04320472|OTHER|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
214529618|NCT03427177|BEHAVIORAL|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
214529619|NCT03639194|DRUG|ABBV-011|Intravenous
214458811|NCT05658874|OTHER|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
214458812|NCT05658874|OTHER|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
214458813|NCT05658874|DRUG|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
214458814|NCT05658874|DRUG|Vaginal estrogen|Topical vaginal estradiol application
214458815|NCT05658874|DRUG|Methenamine|UTI prevention/bladder therapeutic
214458816|NCT05658874|DRUG|Amitriptyline/Gabapentin|Part of multimodal pain therapy
214458817|NCT05126433|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
214458818|NCT06417944|DIAGNOSTIC_TEST|Scoliosis study form|Scoliosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in detail.
214458819|NCT06417944|DIAGNOSTIC_TEST|Scoliosis X-ray (orthorontgenogram)|Patients whose Adam's forward bending test and clinical evaluation results are compatible with scoliosis, scoliosis graphy are requested. (Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 5 degrees in those with BMI (Body Mass Index) above 85%. If it is below 85% and above 7 degrees, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis film will be requested.).Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
214458820|NCT06417944|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. We will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
214458821|NCT06417944|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter- cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
214529620|NCT03639194|DRUG|Budigalimab|Intravenous
214529621|NCT05472883|PROCEDURE|blood samples|\- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
214529622|NCT05472883|PROCEDURE|collection of body tissues|removal of intra-abdominal fat and muscle tissue
214529623|NCT05472883|PROCEDURE|routine care procedure|"* Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens."
214529624|NCT03562117|DRUG|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
214529625|NCT02817685|OTHER|3 months|
214529626|NCT02817685|OTHER|6 months|
214529627|NCT02817685|OTHER|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
214529628|NCT05248425|OTHER|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
214529629|NCT05807542|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
214529630|NCT05807542|DRUG|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
214529631|NCT05807542|DRUG|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
214529632|NCT06149533|DRUG|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
214529633|NCT02804347|DEVICE|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
214529634|NCT02804347|DEVICE|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
214529635|NCT02804347|OTHER|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
214529636|NCT06135779|BEHAVIORAL|A Lust for Life|A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
214529637|NCT06135779|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life School programme.
214529638|NCT00829517|OTHER|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
214529639|NCT00829517|OTHER|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
214529640|NCT01294358|DRUG|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
214529641|NCT00104364|DRUG|MK0731|
214529642|NCT01446822|DEVICE|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
214529643|NCT01446822|DEVICE|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
214529644|NCT03356145|DRUG|12 mL paracervical block|Injection of 12 mL of lidocaine
214529645|NCT03356145|DRUG|20 mL paracervical block|Injection of 20 mL of lidocaine
215145912|NCT06209307|BEHAVIORAL|Pelvic floor physical therapy|"Pelvic floor physical therapy (i.e., Kegel exercises):~* Finding the right muscles: To identify pelvic floor muscles, the patient should stop urination in midstream or tighten the muscles that keep from passing gas. These maneuvers use pelvic floor muscles. Once the pelvic floor muscles are identified, the patient can do the exercises in any position, although doing them lying down at first might be the easiest approach.~* Perfecting the technique: Tighten pelvic floor muscles, hold the contraction for three seconds, and then relax for three seconds. Try it a few times in a row. When muscles get stronger, try doing Kegel exercises while sitting, standing, or walking.~* Maintaining focus: For best results, focus on tightening only pelvic floor muscles. Be careful not to flex the muscles in the abdomen, thighs, or buttocks. Avoid breath-holding. Instead, breathe freely during the exercises.~* Repeat 3 times a day. Aim for three sets of 10 repetitions a day."
215145913|NCT03449290|OTHER|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
215145914|NCT03449290|OTHER|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
215145915|NCT05556044|DRUG|Empagliflozin 10 MG|This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
214529646|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
214529647|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
214529648|NCT01511744|BIOLOGICAL|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
214529649|NCT06046976|PROCEDURE|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
214529650|NCT06046976|PROCEDURE|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
214529651|NCT04885478|OTHER|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring"
214695308|NCT03837353|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
214695309|NCT05837052|PROCEDURE|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
214695310|NCT03170583|DEVICE|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
214695311|NCT03623334|RADIATION|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
215145916|NCT02661334|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
215145917|NCT02661334|DIETARY_SUPPLEMENT|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
215145918|NCT01523366|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
215145919|NCT01523366|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
215145920|NCT03488017|DEVICE|Ocular Coil|Non-invasive ocular device
215145921|NCT02945488|OTHER|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
215145922|NCT02945488|OTHER|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
214458822|NCT06417944|PROCEDURE|Three-dimensional Exercise (BSPTS Schroth Exercise)|"It only provides outpatient treatment, but it has different practices, intensive or regular, depending on local and external patients. For local patients, it is applied once a week, accompanied by a therapist, and the treatment duration is determined according to the patient's condition. In patients coming from outside; It can be continued as 2 hours a day for 10 days, then as additional treatment for 1-2 weeks for 3-6 months depending on the patient's condition. I In regular treatment; 30 sessions of 90 minutes group treatment, the first 8 sessions are carried out under the supervision of a therapist for a shorter period of time.~We will give 10 sessions of BSPTS Schroth exercises, either outpatient or inpatient. After 10 sessions of the Schroth exercise program, the home program will continue two months after outpatient/inpatient schroth exercise(Home program: 5 days/week, 45-60 minutes for all patients)."
214458823|NCT06417944|PROCEDURE|Home Exercise|In the home exercise program; daily living activities, neutral pelvis exercises, coronal balance exercises, rotational angular breathing exercises and axial elongation exercises were taught by the physiotherapist in one session. A total of 10-week home exercise program was planned, with exercises to be performed twice a week for the first two weeks, once every 15 days for 1 month (twice in one month), and then once a month.
214458824|NCT04775381|DRUG|Vitamin D|Patients will receive a cholecalciferol supplementation added to a fruit juice.
215145923|NCT02945488|OTHER|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
215145924|NCT01885130|OTHER|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
215145925|NCT00589394|BIOLOGICAL|pneumococcal vaccination (Pneumovax)|pneumovax was given
215145926|NCT05166200|OTHER|Experimental Formula|Diabetes-specific study formula
214458825|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
214458826|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
214458827|NCT05226806|OTHER|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
214695312|NCT01030458|DRUG|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
214695313|NCT01030458|DRUG|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
215145927|NCT05166200|OTHER|Test Meal|Instant oatmeal
215145928|NCT02910531|DIETARY_SUPPLEMENT|Alpha lipoic acid|Already mentioned in arm/group descriptions.
215145929|NCT02910531|DRUG|Placebo|Already mentioned in arm/group descriptions.
215145930|NCT06295484|OTHER|Alternating traditional CPAP, NIPPV, and high CPAP|The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
215145931|NCT06521307|DIETARY_SUPPLEMENT|Nicotinamide riboside|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
214529652|NCT02420938|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
214529653|NCT02420938|DRUG|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
214529654|NCT02963922|DRUG|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
214529655|NCT02963922|DRUG|Placebo|Injected subcutaneously (s.c., under the skin) once daily
214529656|NCT06585436|PROCEDURE|partial caries removal|removal of all cavity caries except last layer related to the pulp
214529657|NCT00702234|BIOLOGICAL|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
214529658|NCT00702234|BIOLOGICAL|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
214529659|NCT00702234|BIOLOGICAL|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
214529660|NCT00702234|BIOLOGICAL|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
215145932|NCT06521307|OTHER|Placebo|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
215145933|NCT00254696|DRUG|Extended-Spectrum-Lactamases (ESBLs)|
215145934|NCT04298242|DEVICE|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
215145935|NCT04367818|PROCEDURE|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
215145936|NCT04367818|PROCEDURE|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
215145937|NCT04543279|DRUG|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
215145938|NCT04543279|DRUG|Ruxolitinib|Ruxolitinib is commercially available.
215145939|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
215145940|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
214529661|NCT00702234|DRUG|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
214529662|NCT03554200|DRUG|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
214529663|NCT03554200|DRUG|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
214529664|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
214529665|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
214529666|NCT00659971|DRUG|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
214529667|NCT02684942|DRUG|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
215145941|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
215145942|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
215145943|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
215145944|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
215145945|NCT01067053|DRUG|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
215145946|NCT00023660|DRUG|celecoxib|
215145947|NCT00023660|DRUG|cisplatin|
215145948|NCT00023660|DRUG|fluorouracil|
215145949|NCT00023660|RADIATION|brachytherapy|
215145950|NCT00023660|RADIATION|radiation therapy|
215145951|NCT05669274|OTHER|Milk containing A1 and A2 beta-casein|Milk dose for 2 weeks
215145952|NCT05669274|OTHER|Milk containing only A2 beta-casein|Milk dose for 2 weeks
215145953|NCT01592357|BEHAVIORAL|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
215145954|NCT01592357|BEHAVIORAL|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
215145955|NCT03430284|BEHAVIORAL|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
215145956|NCT03430284|DRUG|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
215145957|NCT03430284|OTHER|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
215145958|NCT03430284|OTHER|General treatment|General treatment is carried out based on the device from the general practitioners at present.
215145959|NCT04565132|DEVICE|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
215145960|NCT06222892|DRUG|Camlipixant|Camlipixant will be administered.
215145961|NCT03631251|DRUG|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
215145962|NCT02886455|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
214458828|NCT05226806|OTHER|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
214458829|NCT06330233|OTHER|Moxibustion|The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control. The drug treatment group received mecobalamin tablets and epalrestat orally for four weeks along with their daily treatment. Moxibustion 15-minute group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11), and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment. The moxibustion 30-minute group except for the operating time will use the same intervention as above.
214458830|NCT06517264|DRUG|Antibiotic|antibiotic treatment, analgesics and hygienic-dietetic measures
214458831|NCT06517264|OTHER|Non antibiotic|Analgesics and hygienic-dietetic measures
214458832|NCT04158804|DIAGNOSTIC_TEST|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
214458833|NCT02423603|DRUG|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
214458834|NCT02423603|DRUG|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
214458835|NCT02423603|DRUG|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
214458836|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
214458837|NCT06020677|OTHER|L-WebTIPS|This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
214458838|NCT06139458|BEHAVIORAL|Cryotherapy|Participants will receive cryotherapy on both hands and feet
214458839|NCT06139458|BEHAVIORAL|Compression|Participants will receive compression on both hands and feet
214458840|NCT02774746|OTHER|35-week delivery|Induction at 35 weeks gestational age
214458841|NCT02774746|OTHER|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
214458842|NCT05084508|BIOLOGICAL|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously.
214458843|NCT05084508|BIOLOGICAL|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.
215145963|NCT02886455|OTHER|New adhesive strip|This a newly developed adhesive strip.
215145964|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
215145965|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
215145966|NCT01352715|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
214458844|NCT05084508|BIOLOGICAL|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously.
214458845|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 1|1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.
215145967|NCT01352715|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
215145968|NCT01352715|DRUG|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
215145969|NCT01352715|DRUG|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
215145970|NCT01352715|DRUG|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
215145971|NCT01352715|DRUG|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
214529668|NCT02684942|DRUG|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
215145972|NCT01352715|DRUG|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
215145973|NCT01352715|DRUG|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
215145974|NCT03131323|PROCEDURE|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~* Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~* The camera: fitted with Three-CCD (Charged Couple Device) sensors.~* A high resolution monitor.~* A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required \[8\].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
214529669|NCT03198416|DEVICE|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
214529670|NCT04374019|DRUG|Ivermectin|"Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)"
215145975|NCT03500718|DEVICE|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
215145976|NCT02098785|DRUG|Caffeine citrate|Oral solution
214529671|NCT04374019|DRUG|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
215145977|NCT06019702|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
215145978|NCT03990961|DRUG|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
215145979|NCT04596267|DRUG|Pitolisant|8.9mg Pitolisant for 5 days
214458846|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 2|1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.
214458847|NCT05084508|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.
214529672|NCT04374019|DIETARY_SUPPLEMENT|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
214529673|NCT04374019|DRUG|Artesunate|Days 1-14:
214529674|NCT03071900|DIAGNOSTIC_TEST|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
215145980|NCT04596267|DRUG|Placebo|Inert ingredients
215145981|NCT02511548|OTHER|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
214458848|NCT05084508|BIOLOGICAL|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly.
214458849|NCT05084508|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.
214458850|NCT05296525|DRUG|GDA-201|NAM-expanded allogeneic NK cells
215145982|NCT02416336|DEVICE|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
215145983|NCT00071058|DRUG|XR9576 (Tariquidar)|
215145984|NCT02096302|DIETARY_SUPPLEMENT|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
215145985|NCT02096302|DIETARY_SUPPLEMENT|Standard formula|Standard formula without probiotics
215145986|NCT05781906|DRUG|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
215145987|NCT05781906|DRUG|150 µCi [14C]HMPL-523|D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
215145988|NCT01523106|DRUG|L-carnitine|dietary supplement
215145989|NCT01523106|OTHER|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
214458851|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
214458852|NCT05606887|OTHER|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~1. Completion of brief text-message based surveys 2-3 times per week~2. Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~3. Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
214529675|NCT06195878|DEVICE|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
214708711|NCT03865511|GENETIC|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
215145990|NCT02000440|DRUG|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
215145991|NCT06458881|COMBINATION_PRODUCT|Mixture of Simethicone and Tyndallized Bacillus Coagulans|. Enrolled infants were treated for 28 days with a mixture of Tyndallized B. Coagulans and Simethicone: 20 drops, four times a day. At enrolment, clinical and dietary history, obstetrical data and anthropometry were recorded. The subjects were classified as having IC based on their parents' responses to the validated questionnaires regarding IC according to Rome IV criteria.
215145992|NCT00981448|DIETARY_SUPPLEMENT|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
215145993|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
215145994|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
215145995|NCT01134185|DRUG|prucalopride|single dose of 2 mg prucalopride
215145996|NCT01649778|DRUG|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
215145997|NCT04109547|DRUG|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
215145998|NCT04109547|DRUG|Placebo|Tablets to be taken once-daily for 26 weeks
215145999|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
214458853|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
214458854|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
214458855|NCT02213731|OTHER|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
214458856|NCT04536857|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
214458857|NCT06815835|BIOLOGICAL|Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd|Live attenuated vaccine
214458858|NCT06815835|BIOLOGICAL|Yellow fever Vaccine (WHO prequalified)|Live attenuated vaccine
214458859|NCT06072807|DIAGNOSTIC_TEST|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
214458860|NCT06074055|OTHER|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
214458861|NCT02918890|OTHER|Constraint-induced Movement Therapy|
214458862|NCT02918890|OTHER|Hand-arm Bimanual Intensive Therapy|
214458863|NCT04898413|BEHAVIORAL|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
214458864|NCT04898413|BEHAVIORAL|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
214458865|NCT05758688|RADIATION|Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
214458866|NCT03138863|DEVICE|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio-opaque inclusion
214458867|NCT03138863|DEVICE|Catheter System|100 cm tapered micro-catheter
214458868|NCT05479578|DRUG|Cyclophosphamide|Given PO
214458869|NCT05479578|DRUG|Dexamethasone|Given PO
214529676|NCT00655668|DRUG|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
215146000|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
215146001|NCT06318741|OTHER|aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.|aerobic exercise on the treadmill
215146002|NCT06318741|OTHER|Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.|Walking at an intensity of 12-13 RPE
215146003|NCT01656408|DRUG|MK-8150|
215146004|NCT01656408|DRUG|Placebo for MK-8150|
215146005|NCT06246773|BEHAVIORAL|Positive Parenting Program|During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.
215146006|NCT06246773|BEHAVIORAL|Usual Care|Participants will receive services available to them at the shelter or housing facility
215146007|NCT04438265|DRUG|levobupivacaine|local anesthetic
215146008|NCT04438265|DEVICE|ultrasound device|scream
215146009|NCT05975684|DRUG|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
214458871|NCT06207227|DEVICE|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
214458872|NCT04065841|DRUG|Tropifexor|100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
214458873|NCT04065841|DRUG|Licogliflozin|30mg tablet of licoglifozin taken orally every day
214458874|NCT04065841|OTHER|Placebo|licogliflozin placebo + tropifexor placebo
214458875|NCT03651414|OTHER|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
214458876|NCT05601687|PROCEDURE|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
214458877|NCT05601687|PROCEDURE|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
214458878|NCT04222972|DRUG|Pralsetinib|Administered orally
214458879|NCT04222972|DRUG|Carboplatin|Administered IV
214458880|NCT04222972|DRUG|Cisplatin|Administered IV
214458881|NCT04222972|DRUG|Pemetrexed|Administered IV
214458882|NCT04222972|DRUG|Pembrolizumab|Administered IV
214458883|NCT04222972|DRUG|Gemcitabine|Administered IV
214458884|NCT04222972|DRUG|Paclitaxel|Administered IV
214458885|NCT04222972|DRUG|Nab-Paclitaxel|Administered IV
215146010|NCT05975684|DRUG|Placebo|Placebo three times a day for 4 weeks
214458886|NCT01420237|DEVICE|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
214458887|NCT06065176|BIOLOGICAL|Novavax COVID-19 vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Novavax vaccine.
214458888|NCT06065176|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Pfizer vaccine.
214529677|NCT04783272|DIAGNOSTIC_TEST|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
214529678|NCT04053517|OTHER|Medical Chart Review|Medical chart is reviewed
214529679|NCT04053517|OTHER|Quality-of-Life Assessment|Ancillary studies
214529680|NCT04053517|OTHER|Questionnaire Administration|Ancillary studies
214458889|NCT06539104|PROCEDURE|arteficial inteligence evaluation of oocyte and embryo development|apply AI to find out the complex oocyte quality, embryo development, embryo ploidy and pregnancy success probability from the sequence of the data starting from the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse record of early embryo development.
214458890|NCT06243016|BEHAVIORAL|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
214458891|NCT06243016|BEHAVIORAL|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
214458892|NCT06500598|DRUG|Evinacumab|
214458893|NCT04322279|DIAGNOSTIC_TEST|Serology|SARS-CoV-2 serology
214458894|NCT04322279|GENETIC|Sequencing|Whole exome sequencing
214458895|NCT02923570|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
214458896|NCT02923570|RADIATION|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
214458897|NCT03373695|DEVICE|Dissolve™|Dissolve™ are to be used in the trial
214458898|NCT03373695|DEVICE|SeQuent®Please|SeQuent®Please are to be used in the trial
214458899|NCT06837324|DEVICE|home-based Neofect Smart Glove|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart Glove, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeks.
214458900|NCT06837324|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
214458901|NCT05771545|OTHER|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
214458902|NCT06793839|DEVICE|Transcranial Enhanced Ultrasonography localizing microscopy|3 bilateral transcranial enhanced (with Sonovue) ultrasonography per patient to visualize cranial arteries of the anterior circulation of the brain
214529681|NCT03231579|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
214529682|NCT04763863|OTHER|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
214529683|NCT04763863|OTHER|Clinical usability evaluation of the Body Assessment Tool|"The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool."
214529684|NCT00690950|DRUG|Dutasteride|0.5mg capsule, taken once daily for 12 months
214529685|NCT03771534|DRUG|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
214529686|NCT04477954|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
215146011|NCT03913533|DEVICE|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
214458903|NCT06845306|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.
214458904|NCT06845306|OTHER|Conventional Bowel Anastomosis group|conventional perfusion assessment
214458905|NCT06801808|DIETARY_SUPPLEMENT|Myosave|Nutritional supplementation with Myosave
214458906|NCT06477406|DRUG|Cannabidiol|Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
214458907|NCT06477406|DRUG|Placebo|An active placebo containing supplemental terpenes matched to the high-CBD product.
214458908|NCT06954662|DRUG|Amino acid supplement|a targeted amino acid supplement designed to provide dietary nutrients that are commonly deficient in people with PD while minimizing interference with L-Dopa medication
214458909|NCT06954662|DIETARY_SUPPLEMENT|Whey Protein Supplement|Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. We will use a 20 gram dose.
214458910|NCT06954662|DIETARY_SUPPLEMENT|Isonitrogenous Placebo Supplement|The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the whey protein and the targeted amino acid supplement (16.2 grams).
214458911|NCT06228846|DRUG|YY001|Oral
214458912|NCT06016712|DEVICE|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
214458913|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
214458914|NCT05147844|DRUG|Toripalimab|"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
214458915|NCT06010004|DRUG|Orforglipron|Administered orally
215146012|NCT03913533|DEVICE|Heart rate assessment using Tap-based smartphone application|At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
215146013|NCT03995368|OTHER|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
215146014|NCT03675997|OTHER|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
215146015|NCT04351581|OTHER|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
215146016|NCT04351581|OTHER|Continuation of ACEi/ARB|Continuation of ACEi/ARB
215146017|NCT03167749|DIAGNOSTIC_TEST|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
214458916|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
214458917|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
214458918|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
214458919|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
214458920|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
214458921|NCT04266275|DRUG|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
214458922|NCT04266275|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
214529687|NCT06292832|PROCEDURE|Ultrasound-guided pain block|Ultrasound-guided pain block after cesarean section
214529688|NCT06292832|DEVICE|Ultrasound Machine|Ultrasound machine used to guide the nerve block.
214529689|NCT02832830|RADIATION|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
214529690|NCT02832830|RADIATION|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
214529691|NCT01707914|DIETARY_SUPPLEMENT|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
214529692|NCT01707914|DIETARY_SUPPLEMENT|placebo|
214529693|NCT00004171|DRUG|busulfan|
214529694|NCT00004171|DRUG|cyclophosphamide|
214529695|NCT00004171|PROCEDURE|peripheral blood stem cell transplantation|
214529696|NCT03873038|DRUG|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
214529697|NCT03873038|DRUG|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
214529698|NCT02458274|OTHER|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
214529699|NCT01074034|DEVICE|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
214529700|NCT02301104|DRUG|TAS-102|
215146018|NCT03592186|BEHAVIORAL|Parenting Wisely+|Parenting Wisely+ experimental intervention
215146019|NCT03592186|BEHAVIORAL|Treatment as Usual|Treatment as Usual
214529701|NCT03311997|PROCEDURE|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
214568535|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
214568536|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
215146020|NCT04392622|DRUG|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
215146021|NCT04392622|RADIATION|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
215146022|NCT04392622|DRUG|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
215146023|NCT04392622|OTHER|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
214458923|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
214458924|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
214458925|NCT05837533|OTHER|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
214458926|NCT05925582|OTHER|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
214458927|NCT05925582|OTHER|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
214458928|NCT06086821|DIAGNOSTIC_TEST|Periodontal Re-Evaluation|Recording of the periodontal charting
214458929|NCT06849193|DRUG|Systemic chemotherapy combined with immunotherapy|The electronic medical record system was used to collect patients' basic information and treatment plan information, including treatment plan, administration cycle, administration date, administration dose, frequency, number of cycles, efficacy, adverse reactions, etc.
214458930|NCT06843954|DRUG|Bevacizumab|bevacizumab (7.5mg/kg every 21 days) for minimum of 3 cycles
214458931|NCT06505863|PROCEDURE|Transanal total mesorectal excision|Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
214458932|NCT06505863|PROCEDURE|Abdominal total mesorectal excision|Patients who underwent laparoscopic, robotic, or open total mesorectal excision with anastomosis for primary rectal cancer UICC stage I to III
214458933|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
214458934|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
214458935|NCT06413537|DRUG|SPG601|synthetic small molecule
214458936|NCT06413537|DRUG|Placebo|Placebo
214458937|NCT06486636|PROCEDURE|Left Posterior Pericardiotomy|The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass. A soft channel drain will be put into place at an angle directed toward the posterior pericardium. The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm. The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
214458938|NCT06846918|BEHAVIORAL|High-Intensity Interval Training|"The high-intensity interval training (HIIT) protocol will run for 12 weeks, with two weekly sessions, totaling 24 sessions. Each 20-minute session will follow a group-based circuit format with functional exercises (e.g., jogging, jumping jacks, step-ups). High-intensity phases will be performed at maximum effort, while moderate-intensity phases will be maintained at a Borg scale rating of 4-6.~Training will amount to 40 minutes per week. The intensity ratio will progress over time:~* Weeks 1-4: 15 sec high / 60 sec moderate (1:4)~* Weeks 5-8: 15 sec high / 45 sec moderate (1:3)~* Weeks 9-12: 15 sec high / 30 sec moderate (1:2)~* Weeks 13-16: 15 sec high / 15 sec moderate (1:1)~This progressive structure ensures gradual adaptation while maximizing effectiveness."
214458939|NCT06846918|BEHAVIORAL|Exercise Snacks Protocol|The exercise snack protocol will last for 12 weeks, with sessions held twice a week, totaling 24 sessions. The exercise snacks will amount to 40 minutes per week, divided across the five weekdays. Participants will be required to perform 4 minutes of functional exercises (e.g., jogging in place, jumping jacks in place, modified burpees in place, etc.) in both the morning (AM) and evening (PM), completing a total of 8 minutes per day. The exercises must be performed at high intensity, with a score of \>8 on a modified Borg scale.
214458940|NCT04617496|BEHAVIORAL|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
214458941|NCT04617496|BEHAVIORAL|Health education|Provision of general information about a variety of topics
214458942|NCT06177990|OTHER|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
215146024|NCT04487366|OTHER|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
215146025|NCT02079896|DRUG|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
215146026|NCT02079896|DRUG|Placebo|
215146027|NCT01809600|OTHER|No intervention (observational study)|
215146028|NCT00563875|DRUG|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
214458943|NCT06177990|OTHER|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
214458944|NCT06151015|OTHER|Nitrate-rich beetroot juice plus calorie-restricted diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).
214458945|NCT06151015|OTHER|Nitrate-rich beetroot juice plus weight-maintenance diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
215146029|NCT00502476|PROCEDURE|Bathing with Chlorhexidine Impregnated Washcloths|
215146030|NCT02968758|DEVICE|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
215146031|NCT03104907|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
215146032|NCT04934540|PROCEDURE|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
215146033|NCT03460795|BIOLOGICAL|MSC and Tregs|conventional plus MSC and Tregs or placebo treatment
215146034|NCT00195364|DRUG|Etanercept|
215146035|NCT04466943|DEVICE|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
215146036|NCT04046120|OTHER|Heel-free bandage|The bandage is made by leaving the heel uncovered.
214458946|NCT05787379|BEHAVIORAL|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
214458947|NCT05787379|BEHAVIORAL|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
214458948|NCT05286970|DRUG|AK115|Abdominal subcutaneous injection
214529702|NCT04222088|DRUG|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
214529703|NCT04222088|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
214529704|NCT04222088|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
215146037|NCT01409707|BEHAVIORAL|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
214458949|NCT05286970|DRUG|Placebo|Abdominal subcutaneous injection
214458950|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
214458951|NCT01461655|DRUG|marketed topical NSAID|once daily application, 4 weeks
214458952|NCT01461655|DRUG|vehicle gel|once daily application, 4 weeks
214458953|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
214529705|NCT00595764|BEHAVIORAL|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
214529706|NCT00595764|BEHAVIORAL|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
215146038|NCT01409707|BEHAVIORAL|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
215146039|NCT01409707|BEHAVIORAL|Healthy lifestyles sessions|
215146040|NCT02792686|DRUG|ABX464|Single Administration
215146041|NCT06286345|BEHAVIORAL|GLI-LEEF|"GLI-LEEF is an 18-week program, during which various lifestyle topics are discussed, such as nutrition, exercise, sleep, relationships and intimacy, and specific education about depression and its influence on lifestyle. GLI-LEEF is aimed at improving the activity level, quality of life and (cardiovascular) health of patients and thus increasing the general functioning and well-being of patients and at the same time reducing psychological complaints.~GLI-LEEF consists of 14 group meetings and 4 individual meetings, the group meetings last 90 minutes, the individual meetings 30 minutes. Patients are asked to wear a FitBit and to complete short homework assignments. Each group contains 8-10 patients. Patients are asked to find a buddy who can support them during the program."
214458954|NCT06215560|OTHER|PDMP Check CDS|Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
214458955|NCT06470191|DRUG|B007|B007： Subcutaneous injection was administered on days 1 and 15
215146042|NCT05686603|DEVICE|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
214458956|NCT06470191|DRUG|Cyclosporin Capsules|Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
214458957|NCT05607381|BEHAVIORAL|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
214458958|NCT05607381|OTHER|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
214458959|NCT04791371|BEHAVIORAL|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
214458960|NCT04435054|DIAGNOSTIC_TEST|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~\- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
214458961|NCT05653427|DRUG|Amivantamab|Amivantamab will be administered intravenously.
214458962|NCT05006963|OTHER|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
214458963|NCT06329141|DRUG|Vutiglabridin|Once-daily oral administration
214458964|NCT06329141|DRUG|Placebo|Once-daily oral administration
214458965|NCT02637505|PROCEDURE|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
214458966|NCT02637505|PROCEDURE|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
214458967|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
214458968|NCT06445985|OTHER|Hydrotherapy|Physiotherapy led pool session
214458969|NCT05818423|BEHAVIORAL|Brain Health Academy|The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
214458970|NCT05818423|BEHAVIORAL|Brain Health Together|The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
214458971|NCT05818423|BEHAVIORAL|Maintain Brain Health Together|The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
214458972|NCT06470568|BEHAVIORAL|Progressive Resistance exercise training|"The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions)."
214458973|NCT06188949|DIETARY_SUPPLEMENT|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
214458974|NCT06188949|DIETARY_SUPPLEMENT|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
214458975|NCT06188949|DIETARY_SUPPLEMENT|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
214458976|NCT05191901|OTHER|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
214458977|NCT05789524|DRUG|SerpinPC|Administered as SC injection.
214529707|NCT02467673|DRUG|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
214529708|NCT02467673|DRUG|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
214529709|NCT01071317|DRUG|Naproxen|Naproxen 500mg PO bid prn headache
214529710|NCT01071317|DRUG|Sumatriptan|100mg po q day prn headache
214458978|NCT03461354|OTHER|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
214458979|NCT03461354|OTHER|Sodium Bicarbonate|Sodium bicarbonate oral rinse
214458980|NCT05426265|DEVICE|MEL-T01|A 12 week intervention with MEL-T01.
214458981|NCT05426265|DEVICE|MEL-S01|A 12 week intervention with MEL-S01.
214529711|NCT01071317|BEHAVIORAL|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
214529712|NCT01071317|BEHAVIORAL|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
214529713|NCT01071317|OTHER|Typical care|Care to be determined by attending physician
214529714|NCT05749562|DEVICE|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
214458982|NCT05238285|BEHAVIORAL|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
214458983|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
214458984|NCT03820687|OTHER|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
214458985|NCT03820687|OTHER|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
214458986|NCT03820687|OTHER|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
214458987|NCT03820687|OTHER|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
214458988|NCT03584945|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
214458989|NCT03584945|OTHER|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
214458990|NCT06257576|DRUG|Tamsulosin|"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."
214458991|NCT06257576|OTHER|Control Group|A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
214458992|NCT01972347|DRUG|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
214458993|NCT01972347|DRUG|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
214529715|NCT02270125|PROCEDURE|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
214529716|NCT01865695|DRUG|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
214529717|NCT01865695|OTHER|Placebo|
214529718|NCT01159756|DRUG|Travacom|Travacom ophthalmic solution (1 drop per day)
215146043|NCT05686603|DEVICE|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
215146044|NCT00628420|DRUG|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
215146045|NCT00628420|DRUG|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
215146046|NCT00628420|DRUG|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
214458994|NCT05290766|PROCEDURE|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
214458995|NCT05290766|PROCEDURE|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
214458996|NCT05290766|DEVICE|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
214458997|NCT06442592|OTHER|Blood sampling|An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.
215146047|NCT01658436|DRUG|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
215146048|NCT03077334|DEVICE|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
215146049|NCT01217229|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
214458998|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (CA)|The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.
214458999|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (Nantes)|The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.
214459000|NCT06442592|OTHER|Assessment of the parental stress|Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.
214459001|NCT05675969|OTHER|Blood sample|Collection of 2 additional tubes of 4.5mL of citrate blood
214459002|NCT05122325|DEVICE|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
214459003|NCT05122325|DEVICE|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
214459004|NCT05122325|DEVICE|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
214459005|NCT06005454|DIETARY_SUPPLEMENT|Fish oil (Omega)|We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
214459006|NCT04671446|DIAGNOSTIC_TEST|Autoantibody ELISA|Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
214459007|NCT04671446|DIAGNOSTIC_TEST|Granulocyte Immunofluorescence|The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
214459008|NCT05166343|DRUG|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
214459009|NCT04256941|DRUG|Abemaciclib|Given PO
214459010|NCT04256941|DRUG|Anastrozole|Given PO
214459011|NCT04256941|DRUG|Fulvestrant|Given IM
214459012|NCT04256941|DRUG|Letrozole|Given PO
214459013|NCT04256941|DRUG|Palbociclib|Given PO
214459014|NCT04256941|DRUG|Ribociclib|Given PO
214459015|NCT04119791|OTHER|wild rice|30 grams of wild rice in the form salad, snack bar and soup
214529719|NCT04301518|OTHER|Multimodal intervention strategy|"* Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
214459016|NCT06257303|OTHER|Frontal Plane Projection Angle|Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.
214459017|NCT02933970|OTHER|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
214459018|NCT05914363|OTHER|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
214459019|NCT05914363|BEHAVIORAL|Behaviour change intervention|Support for behaviour change through 'floor clubs' and the provision of printed guides
214459020|NCT05914363|DRUG|Routine deworming|Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
214459021|NCT05914363|PROCEDURE|treatment for tungiasis|Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
214529720|NCT01748851|DRUG|XELOX|capecitabine 1000mg/m2 bid po D1-D14
214529721|NCT01748851|DRUG|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
215146050|NCT00044616|DRUG|Fluoxetine|
215146051|NCT00044616|DRUG|Lithium|
215146052|NCT03798951|OTHER|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
215146053|NCT04291469|DRUG|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
215146054|NCT04291469|DIETARY_SUPPLEMENT|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
215146055|NCT04291469|DIETARY_SUPPLEMENT|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
215146056|NCT05154786|OTHER|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
214459022|NCT03300648|OTHER|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
214459023|NCT03300648|DRUG|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
214459024|NCT02674295|DRUG|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
214459025|NCT02674295|DRUG|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
214459026|NCT05447741|DIAGNOSTIC_TEST|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
214459027|NCT06202651|DEVICE|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
214459028|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
214459029|NCT05969080|BEHAVIORAL|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
214459030|NCT05969080|OTHER|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
214459031|NCT05688956|DIETARY_SUPPLEMENT|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
214459032|NCT05688956|OTHER|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
214459033|NCT05688956|OTHER|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
214459034|NCT06295328|DRUG|Terbinafine|terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
214459035|NCT06295328|DRUG|Placebo|Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
214459036|NCT06295328|DRUG|Tenofovir|Tenofovir 245mg standard of care
214459037|NCT02722525|PROCEDURE|Magnetic Resonance Imaging|Undergo treadmill stress CMR
214529722|NCT03974308|OTHER|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
214529723|NCT03974308|OTHER|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
214529724|NCT03974308|OTHER|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
214529725|NCT05385991|BIOLOGICAL|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
215146057|NCT05154786|OTHER|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
214459038|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete treadmill exercise
214459039|NCT02722525|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
214529726|NCT06055400|DEVICE|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
214459040|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete resistive lower extremity exercise
214459041|NCT02722525|PROCEDURE|Spectroscopy|Undergo skeletal muscle PMRS
214459042|NCT02722525|OTHER|Laboratory Biomarker Analysis|Correlative studies
214459043|NCT02908477|RADIATION|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
214459044|NCT02908477|DRUG|Docetaxel|15 mg/m2. Experimental arm only.
214459045|NCT02908477|DRUG|Cisplatin|40 mg/m2. Standard arm only.
214459046|NCT03160794|DIAGNOSTIC_TEST|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
214459047|NCT03160794|RADIATION|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
214459048|NCT02140554|GENETIC|lovo-cel|lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
215146058|NCT03987503|DRUG|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
215146059|NCT03987503|DRUG|Standard of care|Standard of HCV care provided by medical care provider
214459049|NCT05590403|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
214459050|NCT05590403|DRUG|Placebo|One dose administered intramuscularly at Day 1.
214459051|NCT06315855|BEHAVIORAL|Telehealth Intervention (THI)|The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
214459052|NCT05659537|DRUG|Dulaglutide|Administered SC
214459053|NCT05720546|OTHER|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
214459054|NCT05720546|OTHER|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
214459055|NCT05720546|OTHER|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
214459056|NCT04503551|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
214459057|NCT04503551|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
214459058|NCT05187351|PROCEDURE|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-100% de novo SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
214459059|NCT02664337|OTHER|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
214459060|NCT02664337|OTHER|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
214459061|NCT05826184|BEHAVIORAL|Time restircted eating|8 hour time restricted eating alone
214459062|NCT05826184|BEHAVIORAL|Time restricted eating + prebiotic|8 hour TRE with a prebiotic supplement
214459063|NCT02289209|RADIATION|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
214459064|NCT02289209|DRUG|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
214459065|NCT05636514|DRUG|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
214459066|NCT05636514|DRUG|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
214459067|NCT04968210|DRUG|Hyperpolarized 13C-pyruvate|Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
214459068|NCT03298542|DRUG|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
214459069|NCT03298542|DRUG|Placebo|Matching placebo to golimumab.
214459070|NCT05858944|DRUG|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
214459071|NCT05858944|DRUG|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
214459072|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
214459073|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
214459074|NCT04998682|PROCEDURE|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
214459075|NCT06484686|BIOLOGICAL|Live Attenuated Varicella Vaccine|lyophilized powder, subcutaneous injection
214529727|NCT03474978|DEVICE|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
215146060|NCT03987503|DEVICE|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
215146061|NCT05479019|BEHAVIORAL|Visual stimuli|Stimuli will be shown to participants and they will be asked to perform a visual task.
214459076|NCT05087667|DEVICE|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
214459077|NCT05087667|DEVICE|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
214459078|NCT05239299|OTHER|No intervention, observational study|Focus Group
214459079|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
214459080|NCT02853851|OTHER|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
214459081|NCT05516836|OTHER|Multicomponent exercise program|"Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
214459082|NCT05516836|OTHER|Tele-health primary care rehabilitation program|A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
214459083|NCT06453902|DRUG|TGRX-678|All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
214459084|NCT04784832|DEVICE|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
214459085|NCT04784832|DEVICE|Peripheral Nerve Stimulation|Electric stimulation of the nerves
214459086|NCT04784832|DEVICE|Transcranial direct current stimulation|Electric stimulation of the cortex
214459087|NCT04784832|DEVICE|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
214459088|NCT04784832|DEVICE|Wrist|Short-term immobilization of the arm
214459089|NCT04784832|DEVICE|Robotic arm|External perturbation of force field induced by robotic arm
214459090|NCT04784832|DEVICE|Cervicomedullar stimulation|Electric stimulation of the muscle
214459091|NCT04784832|OTHER|Physical training|Training to perform the task by actually doing the task
214459092|NCT04784832|OTHER|Mental training|Training to perform the task by imaging doing the task
214459093|NCT04966247|OTHER|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
214459094|NCT05369533|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
214459095|NCT05369533|DRUG|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
214459096|NCT05369533|DRUG|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
214459097|NCT04799704|DIAGNOSTIC_TEST|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
214459098|NCT06476275|BIOLOGICAL|Influenza A/Texas/71/2017 (H3N2)|Virus will be administered intranasally
214459099|NCT06476275|BIOLOGICAL|Sham placebo|Placebo will be administered intranasally
214459100|NCT06221800|DIAGNOSTIC_TEST|Microbiome|Stool and saliva samples will be collected
214459101|NCT03715738|OTHER|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
214459102|NCT06142630|OTHER|Alteration of patients' position after erector spinae plane block|After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
214459103|NCT05424237|BEHAVIORAL|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
214459104|NCT04526704|DRUG|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
214708912|NCT01853098|BEHAVIORAL|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
214459105|NCT05290792|BIOLOGICAL|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
214459106|NCT05931614|BEHAVIORAL|Free fluid intake|Patients are recommended a free fluid intake
214459107|NCT04409600|BEHAVIORAL|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
214459108|NCT04409600|BEHAVIORAL|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
214529728|NCT03735368|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
214529729|NCT03735368|DRUG|Placebo oral capsule|placebo oral capsules
214529730|NCT03735368|DRUG|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
214529731|NCT03735368|DRUG|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
214529732|NCT01555879|DRUG|Abatacept|As prescribed by a doctor for patient medical care.
214529733|NCT00471549|DRUG|Statin (simvastatin)|
214529734|NCT00585910|DRUG|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
214529735|NCT00814554|BEHAVIORAL|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
214529736|NCT00814554|BEHAVIORAL|Screening strategy|2\. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
214529737|NCT00814554|OTHER|Environmental strategy|3\. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
214529738|NCT04567745|DIAGNOSTIC_TEST|Retinal fundus photography|Fundus photographs
214529739|NCT00209053|PROCEDURE|Coronary Artery Bypass|
214529740|NCT01657552|DRUG|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
215146062|NCT02664896|OTHER|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
214459109|NCT04409600|DRUG|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
214459110|NCT04409600|DRUG|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
214459111|NCT00881621|DRUG|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
214459112|NCT05921747|OTHER|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
214459113|NCT05921747|DEVICE|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
214459114|NCT03158714|BEHAVIORAL|Couples Connecting Mindfully|
214459115|NCT03158714|BEHAVIORAL|ELEVATE|
214459116|NCT02118272|DEVICE|Physica KR|
214459117|NCT04574024|DRUG|NBT-NM108|MS Patients received NBT-NM108 at 60 g/day.
214529741|NCT01657552|DRUG|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
214529742|NCT01657552|DRUG|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
214529743|NCT01332318|DRUG|XP13512|XP13512 once daily for 16 days
214529744|NCT01332318|DRUG|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
214529745|NCT01332318|DRUG|Placebo|XP13512 placebo once daily for 16 days
214529746|NCT02040532|DRUG|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
214529747|NCT02468882|DIETARY_SUPPLEMENT|Watercress|100g of watercress daily during radiation therapy
214529748|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
214529749|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
214529750|NCT03138356|DRUG|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
215146063|NCT02664896|OTHER|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
215146064|NCT01706133|OTHER|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
214459118|NCT03936322|DEVICE|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
214459119|NCT05474404|DIAGNOSTIC_TEST|Cervical smear test|collection of cervical cells using spatula
214459120|NCT06439004|OTHER|Quantitative Sensory Testing|Performing QST on the dominant hand, right forearm, right flank and lower back.
214459121|NCT05760885|BEHAVIORAL|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
214459122|NCT05760885|BEHAVIORAL|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
214459123|NCT06799611|DRUG|CM336 Injection|subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
214459124|NCT06042569|DRUG|Cyclophosphamide|Given IV
214459125|NCT06042569|DRUG|Docetaxel|Given IV
214459126|NCT06042569|OTHER|Medical Chart Review|Ancillary studies
214459127|NCT06042569|OTHER|Questionnaire Administration|Ancillary studies
214459128|NCT06293079|OTHER|Exercise Program|Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
214529751|NCT03138356|DRUG|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
214529752|NCT03138356|DRUG|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
214529753|NCT03138356|DRUG|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
214529754|NCT03138356|DRUG|500 mg Glucophage XR®|Used in treatments C, F and I.
214529755|NCT04741984|BIOLOGICAL|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
214529756|NCT03973437|DEVICE|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
214529757|NCT03973437|DEVICE|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
214529758|NCT03956147|OTHER|Munich Shoulder Questionnaire|Validation and Reability study
214529759|NCT06372756|DIAGNOSTIC_TEST|Deep learning image reconstruction|Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
215146065|NCT04913077|OTHER|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
215146066|NCT00464633|DRUG|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
215146067|NCT01955135|DRUG|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
214459129|NCT04447911|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
214459130|NCT04447911|DRUG|Placebo|Placebo per os once daily for 30 days
214459131|NCT05275231|BEHAVIORAL|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
214459132|NCT05994157|DRUG|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
214459133|NCT05856786|DIAGNOSTIC_TEST|Optical coherence tomography|Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
214459134|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
214459135|NCT01504815|DRUG|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
214459136|NCT01504815|RADIATION|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
214459137|NCT01504815|RADIATION|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
214459138|NCT06771570|BIOLOGICAL|Silver Nanoparticles Irrigation|to evaluate the postoperative pain, antimicrobial efficiency, and periapical tissue healing following the use of silver nano particles solution as a final irrigation, using either conventional needle irrigation or XP-Endo Finisher activation, in necrotic mandibular molar teeth.
214459139|NCT05434078|DEVICE|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
214459140|NCT05846594|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
214459141|NCT05846594|DIAGNOSTIC_TEST|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
214459142|NCT05206630|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
214459143|NCT06161818|DRUG|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
214459144|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit|Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
214459145|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit + Food Care|Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
214459146|NCT06192316|BEHAVIORAL|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
214459147|NCT05417100|DRUG|Methadone|methadone 0.2 mg/kg IV.
214529760|NCT02287571|DEVICE|Derotation splint|This group is the actual intervention group.
214529761|NCT02287571|DEVICE|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
214529762|NCT05985109|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
214459148|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
214459149|NCT05167409|DRUG|Evorpacept (ALX148)|IV QW
214459150|NCT05167409|DRUG|Cetuximab|IV QW
214459151|NCT05167409|DRUG|Pembrolizumab|IV Q3W
214459152|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
215146068|NCT01955135|DRUG|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
214459153|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
214459154|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
214459155|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
214529763|NCT05985109|DRUG|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
214529764|NCT03229525|BEHAVIORAL|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
214529765|NCT03229525|BEHAVIORAL|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
214529766|NCT01350388|DRUG|Febuxostat|80 mg/day of febuxostat for 24 weeks
214529767|NCT01350388|DRUG|Placebo|1 placebo tablet per day for 24 weeks
214529768|NCT00789399|DRUG|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
214529769|NCT00789399|OTHER|Placebo|subcutaneous equivolume isotonic saline
214529770|NCT00928876|DRUG|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
214529771|NCT00928876|DRUG|Placebo|placebo s/c daily for four weeks
214529772|NCT02767596|DRUG|Lixisenatide|
214529773|NCT02767596|DRUG|Basal insulins|patients are on basal insulin treatment
214529774|NCT01266499|DRUG|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
215146069|NCT01955135|DRUG|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
215146070|NCT00655902|DIETARY_SUPPLEMENT|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
215146071|NCT00655902|DIETARY_SUPPLEMENT|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
215146072|NCT01915784|DEVICE|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
215146073|NCT01915784|DEVICE|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
215146074|NCT04418648|DRUG|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
215146075|NCT00168584|DRUG|Vitamin A|
215146076|NCT03678493|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Oral Capsule
214459156|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
214459157|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
214459158|NCT03748524|DRUG|Influenza Vaccine|Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
214459159|NCT04265625|DEVICE|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
214459160|NCT05114616|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
214459161|NCT05114616|DEVICE|Ellcie Healthy Glasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
214459162|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
214459163|NCT06244810|DEVICE|Lingual retainer from Fiber|lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
214459164|NCT06244810|DEVICE|Lingual retainer from metal|lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
214459165|NCT06244810|DEVICE|Traditional retianer from braided|lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
214459166|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
214459167|NCT03158129|DRUG|Carboplatin|Given IV
214529775|NCT01266499|DRUG|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
214529776|NCT01266499|DRUG|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
214529777|NCT01266499|DRUG|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
214529778|NCT02820298|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
214529779|NCT00860522|DRUG|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
214529780|NCT00860522|DRUG|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
214529781|NCT03274206|BIOLOGICAL|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
214529782|NCT03274206|DRUG|Placebo|BLS-ILB-E710c-placebo
214529783|NCT01894256|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
215146077|NCT03678493|OTHER|Placebo|Oral Capsule
215146078|NCT01001026|BIOLOGICAL|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
215146079|NCT01001026|BIOLOGICAL|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
215146080|NCT02551939|PROCEDURE|Autologous Fat Grafting|Autologous Fat Grafting
214459168|NCT03158129|DRUG|Cisplatin|Given IV
214529784|NCT05079958|BEHAVIORAL|cognitive-behavioral education|four-week cognitive-behavioral education course
214529785|NCT05079958|BEHAVIORAL|12-week brisk walking|12-week brisk walking
214529786|NCT02599376|DEVICE|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
214529787|NCT04486742|BEHAVIORAL|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
214529788|NCT03441152|DEVICE|tDCS|Transcranial direct current stimulation
214529789|NCT01039116|BEHAVIORAL|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
214529790|NCT01039116|BEHAVIORAL|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
214529791|NCT03662854|BIOLOGICAL|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
215146081|NCT02643914|DRUG|Nicotine|
215146082|NCT02643914|DEVICE|MR Compatible Nicotine Delivery Device|
215146083|NCT02784548|OTHER|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
215146084|NCT01093157|DRUG|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
215146085|NCT00656448|DRUG|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
215146086|NCT05269459|DRUG|Cannabidiol Administered as Nantheia ATL5|Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
215146087|NCT05269459|DRUG|Placebo|Participants will take 4 matching gel capsules twice daily containing no active drug.
215146088|NCT04027517|DRUG|JTZ-951|"Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
215146089|NCT04027517|DRUG|Darbepoetin Alfa|"Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
215146090|NCT01929317|DRUG|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
215146091|NCT01929317|DRUG|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
215146092|NCT01929317|DRUG|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
215146093|NCT00335595|DRUG|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
215146094|NCT00335595|DRUG|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
214529792|NCT03662854|OTHER|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
214529793|NCT05887479|DRUG|Botulinum toxin type A|Toxin of Clostridium Botulinum
214529794|NCT05887479|DRUG|%0,9 NaCl|%0,9 NaCl
214529795|NCT03261934|OTHER|No intervention|No intervention
214529796|NCT04291716|DEVICE|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
214529797|NCT02516371|OTHER|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
214529798|NCT01780584|DRUG|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
214529799|NCT01780584|DRUG|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
215146095|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
215146096|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
214529800|NCT01780584|DRUG|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
214529801|NCT04793555|OTHER|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
214529802|NCT02750371|OTHER|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
214529803|NCT03298347|DRUG|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
214529804|NCT03298347|DRUG|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
215146097|NCT02382536|DEVICE|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
215146098|NCT02382536|DEVICE|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
215146099|NCT05799885|OTHER|Neuro-vestibular-ocular group|Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training
215146100|NCT05799885|OTHER|Myofascial Release group|Manual myofascial release will be applied by the physiotherapist.(30 football players)
214529805|NCT01579461|DRUG|mirabegron|oral
214529806|NCT05194631|OTHER|Quadriceps microbiopsy using a Tru-Cut biopsy needle|During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
214529807|NCT03433378|DRUG|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
214529808|NCT03433378|DRUG|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
214529809|NCT03433378|DRUG|Vehicle of the test product|Vehicle of the test product
214529810|NCT01022671|DRUG|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
214708913|NCT00418210|RADIATION|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
214708914|NCT02685657|DRUG|Drug: Selumetinib|
215146101|NCT01297829|DRUG|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
215146102|NCT01297829|OTHER|IV Placebo|IV normal saline
214529811|NCT05723029|OTHER|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
214529812|NCT05723029|OTHER|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
214529813|NCT04248049|OTHER|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
215146103|NCT04071717|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
214459169|NCT03158129|DRUG|Docetaxel|Given IV
214459170|NCT03158129|BIOLOGICAL|Ipilimumab|Given IV
214459171|NCT03158129|BIOLOGICAL|Nivolumab|Given IV
214459172|NCT03158129|DRUG|Pemetrexed|Given IV
214529814|NCT02515526|DRUG|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
214529815|NCT02515526|DRUG|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
214529816|NCT05347602|DIETARY_SUPPLEMENT|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
214529817|NCT05347602|DIETARY_SUPPLEMENT|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
214529818|NCT03747159|DRUG|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
214529819|NCT00233207|DRUG|IC14|
214529820|NCT01618578|PROCEDURE|rubber hand illusion|"There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
214529821|NCT00223561|DRUG|methylphenidate|
214529822|NCT01772147|DRUG|Umeclidinium bromide 62.5mcg|Inhalation powder
215146104|NCT04071717|BEHAVIORAL|Sham NIRS neurofeedback|Sham NIRS neurofeedback
214459173|NCT06640101|OTHER|sham IMT|with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted on a stable surface
214459174|NCT06640101|OTHER|IMT-stable group (sitting on a stable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on a stable surface
214529823|NCT01772147|DRUG|Umeclidinium bromide 125mcg|Inhalation powder
214529824|NCT01772147|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
214529825|NCT03415347|PROCEDURE|Abscess de-roofing and curettage|Abscess de-roofing and curettage
214529826|NCT03415347|PROCEDURE|Abscess wide local excision|Abscess wide local excision
215146105|NCT04322526|DRUG|Naltrexone 50 Mg Oral Tablet|Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
215146106|NCT04322526|DRUG|Placebo oral tablet|Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
214459175|NCT06640101|OTHER|IMT-unstable group (sitting on an unstable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on an unstable surface
214459176|NCT06640101|OTHER|Conventional treatment|Participants in all groups will receive a standardised conventional rehabilitation protocol. It includes limb range of motion, muscle tone reduction, strengthening and endurance of limb muscles, transfer skills, task-directed movements, general gait training, and activities of daily living training.
214459177|NCT06638567|OTHER|Basal bolus insulin regimen|Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
214459178|NCT05435677|DRUG|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
214459179|NCT05435677|DRUG|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
214459180|NCT05435677|DRUG|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
214459181|NCT03267303|DRUG|TS-091 5mg|Orally taken once daily for 3 weeks
214459182|NCT03267303|DRUG|TS-091 10mg|Orally taken once daily for 3 weeks
214459183|NCT03267303|DRUG|Placebo|Orally taken once daily for 3 weeks
214459184|NCT05862454|DRUG|Magnesium|Magnesium injection therapy
214529827|NCT03386305|DRUG|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
214529828|NCT03386305|DRUG|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
214529829|NCT02275845|DRUG|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
214529830|NCT02275845|OTHER|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
214708915|NCT02685657|DRUG|Doxorubicin|
215146107|NCT01981408|DRUG|[^14C]-LY2801653|Administered orally
215146108|NCT04586439|DRUG|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
214529831|NCT03130816|BIOLOGICAL|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
215146109|NCT06166615|DRUG|Ramosetron|Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
215146110|NCT06166615|DRUG|Psyllium|Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
215146111|NCT03616028|DEVICE|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
215146112|NCT04845282|DIETARY_SUPPLEMENT|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
215146113|NCT04845282|DIETARY_SUPPLEMENT|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
215146114|NCT00100971|DRUG|autologous tumor cell vaccine|
215146115|NCT00100971|DRUG|therapeutic autologous dendritic cells|
215146116|NCT00100971|PROCEDURE|tumor cell-derivative vaccine therapy|
215146117|NCT00503763|DRUG|Simvastatin|
215146118|NCT05714410|DIETARY_SUPPLEMENT|PHGG|PHGG
215146119|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
214459185|NCT06257641|OTHER|High-intensity Mediterranean diet intervention|Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
214459186|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
214459187|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
214459188|NCT06642792|DRUG|AK129|Subjects receive AK129 intravenously.
214459189|NCT06642792|DRUG|AK117|Subjects receive AK117 intravenously.
214459190|NCT03321656|DRUG|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
214459191|NCT03321656|DRUG|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
214459192|NCT06308497|OTHER|Probiotic Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
214459193|NCT06308497|OTHER|Standard Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
214459194|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
214459195|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
214529832|NCT00564564|DRUG|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
214459196|NCT06488365|DEVICE|Cytophone|"The Cytophone clinical prototype incorporates two pulse lasers, optical system for delivery of laser light to the skin, ultrasound transducer array and detection electronics for acquisition of acoustic waves from CTCs.~Parameters of lasers:~C-Wedge 1064 (Bright Solutions, Cura Carpignano (PV), Italy): Wavelength,1064 nm; pulse width, 0.6 ns; pulse rate: 1 kHz; pulse energy, 240 μJ.~C-Wedge 18901 (Bright Solutions, Cura Carpignano (PV), Italy):~Wavelength, 770 nm; pulse width 3 ns; pulse rate, 1 kHz; pulse energy, 240 μJ. Detection of acoustic waves from CTCs is performing by a focused ultrasound transducer array placed in an acoustic contact with the skin of the subject with ultrasound gel. The signals from the transducers are amplified with a 16 channel amplifier, then digitized by a 12-bit, 500 MSPS high speed board digitizer (ATS9350, AlazarTech, Canada). This information is then transferred to a data recording system using a secure computer."
214529833|NCT00564564|DRUG|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
214529834|NCT04877132|DRUG|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
214529835|NCT03025997|DIETARY_SUPPLEMENT|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
215146120|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
215146121|NCT01457508|BIOLOGICAL|Hib (Hiberix™)|Three doses administered intramuscularly
215146122|NCT03990792|BEHAVIORAL|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
215146123|NCT03990792|OTHER|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
214459197|NCT06022302|DRUG|Diet + laxative|The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.
214459198|NCT06022302|OTHER|Diet only|This is only a control and participants will not receive Movicol.
214459199|NCT06019949|DEVICE|Transcutaneous spinal cord stimulator|Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
214459200|NCT06019949|DEVICE|Respiratory Training|Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
214459201|NCT03667599|OTHER|home care|This is the interventional arm where patients receive the transplant care in their homes.
214459202|NCT02566668|OTHER|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
214459203|NCT02869074|GENETIC|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
214459204|NCT06181006|DRUG|Pirtobrutinib|Administered orally.
214459205|NCT05682885|PROCEDURE|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
214459206|NCT06642675|DEVICE|Intermittent theta burst stimulation(iTBS)|By using the TMS Navigation System, the iTBS will be targeted at the left Supramarginal Gyrus.iTBS will be performed using Magstim Rapid² stimulator, parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, intensity of 90% resting motor threshold(RMT), total duration of 10 minutes.
214459207|NCT06642675|DEVICE|Sham stimulation|Patients in sham group would receive the same intervention procedure as the active ITBS group, but the coil will be replaced with sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
214459208|NCT06640049|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214459209|NCT06640959|PROCEDURE|Procedure - blood, urine and stool sample collection|Samples will be collected (blood, urine, stool and optional rectal swab) at baseline (prior to the start of radiotherapy), weekly during radiotherapy for 4 weeks, 6-8 weeks and 12 weeks from start of radiotherapy, and at 6-month and 12-month follow-up appointments
214459210|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
214459211|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
214459212|NCT06264141|DRUG|Nitric Oxide Releasing Solution|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
214459213|NCT06264141|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
214529836|NCT03025997|DIETARY_SUPPLEMENT|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
214529837|NCT04382768|DRUG|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
214529838|NCT00000133|PROCEDURE|Trans-scleral Cryotherapy|
214529839|NCT03838419|RADIATION|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
214529840|NCT03838419|RADIATION|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
214529841|NCT00787813|DRUG|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
214529842|NCT00787813|DRUG|Placebo|
214529843|NCT01630395|PROCEDURE|protective ventilation|low tidal volume and PEEP
214529844|NCT01630395|PROCEDURE|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
214529845|NCT04306913|DRUG|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
214529846|NCT04306913|DRUG|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
214708916|NCT02685657|DRUG|Cyclophosphamide|
215146124|NCT01523756|DEVICE|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
214459214|NCT05629858|OTHER|6-h Time restricted eating (TRE)|Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
214459215|NCT05629858|OTHER|Calorie restriction (CR)|25% energy restriction every day
214459216|NCT05629858|OTHER|Control|Usual diet, eating over \>10 h per day
214459217|NCT02427698|PROCEDURE|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
214459218|NCT02427698|PROCEDURE|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
214459220|NCT06644066|PROCEDURE|Partial pressure of Oxygen Control method|During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
214459221|NCT05384496|DRUG|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
214459222|NCT05384496|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
214459223|NCT05384496|DRUG|axitinib|5mg twice daily
214459224|NCT06644378|DRUG|[14C]-LY3866288|Administered orally.
214459225|NCT06644378|DRUG|LY3866288|Administered orally.
214459226|NCT06644378|DRUG|[14C]-LY3866288|Administered IV.
214529847|NCT03795935|OTHER|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
214529848|NCT01628341|DRUG|insulin|Patients will be asked to complete 2 self-assessment questionnaires
214459227|NCT05586997|DEVICE|Bonded-Hyrax|The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
214459228|NCT05586997|COMBINATION_PRODUCT|Bonded Rapid Maxillary Expansion and low-Level Laser therapy|Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
214459229|NCT05494723|DRUG|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
214459230|NCT06645145|BEHAVIORAL|Orthographic facilitation|Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.
214459231|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
214529849|NCT03561025|DIAGNOSTIC_TEST|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
214459232|NCT06643754|DRUG|SHR-3276|"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."
214459233|NCT06157749|OTHER|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
214459234|NCT03850756|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
214459235|NCT03850756|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
214459236|NCT03850756|DIAGNOSTIC_TEST|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
214459237|NCT03866525|BIOLOGICAL|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
214459238|NCT06578182|DRUG|Colchicine|Colchicine 0.5mg tablets once a day for 3 to 4.5 years
214459239|NCT06578182|DRUG|Placebo|Placebo tablets once a day for 3 to 4.5 years
214459240|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
214459241|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
214459242|NCT00554788|DRUG|Carboplatin|Given IV
214459243|NCT00554788|DRUG|Cisplatin|Given IV
214459244|NCT00554788|DRUG|Cyclophosphamide|Given IV
214459245|NCT00554788|DRUG|Etoposide|Given IV
214459246|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
214459247|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
214459248|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
214459249|NCT00554788|DRUG|Thiotepa|Given IV
214529850|NCT03561025|DIAGNOSTIC_TEST|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
214529851|NCT05087953|DIAGNOSTIC_TEST|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
215146125|NCT01523756|DEVICE|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
215146126|NCT00993967|DRUG|idebenone|Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients \> 45 kg
215146127|NCT00533455|DRUG|Gabapentin|
215146128|NCT01658319|DRUG|fludarabine phosphate|Given IV
215146129|NCT01658319|DRUG|methoxyamine|Given IV
215146130|NCT01658319|OTHER|laboratory biomarker analysis|Correlative studies
215146131|NCT01658319|OTHER|pharmacological study|Correlative studies
215146132|NCT01658319|GENETIC|western blotting|Correlative studies
215146133|NCT01658319|OTHER|mass spectrometry|Correlative studies
215146134|NCT01658319|GENETIC|DNA analysis|Correlative studies
215146135|NCT02231359|DRUG|Berodual® Respimat® solution for inhalation|
215146136|NCT06584006|DRUG|Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections|Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
215146137|NCT06584006|DRUG|Recombinant Human Interleukin-2 Injections|Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
215146138|NCT01483261|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
215146139|NCT03131024|DIETARY_SUPPLEMENT|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
215146140|NCT03131024|OTHER|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
215146141|NCT02760498|DRUG|cemiplimab|
215146142|NCT03469947|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
215146143|NCT01784224|PROCEDURE|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
215146144|NCT04500587|DRUG|ZN-d5|Oral agent; 25 mg or 100 mg formulation
214459250|NCT00554788|DRUG|Vincristine Sulfate|Given IV
214459251|NCT02702102|DRUG|11C-PBR28|Up to 20 millicuries
214459252|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
214459253|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
214459254|NCT03905005|PROCEDURE|Mandibular reconstruction with free tissue transfer.|Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
214459255|NCT05347693|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."
214459256|NCT05347693|DRUG|Local standard of care|Local SoC in the country to be used as per local label
214459257|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
214459258|NCT03272698|DRUG|Ketamine|IV Ketamine 0.50 mg/kg
214459259|NCT03272698|PROCEDURE|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
214459260|NCT05244486|DEVICE|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
214459261|NCT05244486|DEVICE|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
214459262|NCT04895631|DRUG|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
214459263|NCT04895631|PROCEDURE|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
214459264|NCT04532047|DRUG|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
214529852|NCT05087953|DIAGNOSTIC_TEST|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
214529853|NCT00435981|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
214529854|NCT00888407|BEHAVIORAL|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
214529855|NCT00888407|BEHAVIORAL|Nutrition - Small group educational session|Small group session with diet \& nutrition focused, topic related resources provided.
214529856|NCT06076798|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
214529857|NCT05235841|OTHER|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
214529858|NCT05664399|OTHER|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
214708917|NCT02685657|DRUG|Docetaxel|
215146145|NCT05035238|BIOLOGICAL|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
215146146|NCT00896402|DRUG|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
215146147|NCT00896402|DRUG|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
215146148|NCT06411262|OTHER|Parkiboks|A non-contact boxing sessions for individuals with Parkinson disease, made-up of 3 sections: a warm-up, a boxing section, a cool-down. Each section is split into a range of exercises. The session is led by a boxing coach with training and expertise in Parkinson disease.
215146149|NCT02410226|PROCEDURE|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
215146150|NCT02410226|RADIATION|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
215146151|NCT02410226|RADIATION|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
214459265|NCT05557812|DRUG|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
214459266|NCT05557812|DRUG|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
214459267|NCT05119023|BEHAVIORAL|SRT Observational Learning|All participants completed a computer-based serial response time (SRT) task intended to measure observational (implicit) learning ability. The SRT Observational learning task is a classic paradigm, which has been integral to the understanding of implicit learning (see Schwarb \& Schumacher, 2012). The current task is a replication of classic SRT tasks first described by Nissen and Bullemer (1987), adapted for eye-tracking by Kinder et al. (2008). In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
214459268|NCT05119023|BEHAVIORAL|AGL Observational Learning|All participants completed a computer-based observational artificial grammar learning (AGL) task. The AGL Observational learning task is another classic test of implicit learning involving learning of ordered items through exposure (Schuchard \& Thompson, 2017). Artificial grammars contain hierarchal dependencies, similar to the rules that govern word-order and syntax in natural language. In this task, participants look at sequences of geometric shapes on a computer screen. Participants judged if two sequences matched or did not match. After training, participants are shown sequences and must judge if sequences adhere to the pattern or not.
214459269|NCT05119023|BEHAVIORAL|AGL Rule-based Learning|All participants completed a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability of an artificial grammar expressed in nonlinguistic form (sequences of shapes). In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
214459270|NCT05119023|BEHAVIORAL|Standardized cognitive-linguistic assessment|Participants completed standardized cognitive-linguistic assessments that evaluate their ability to produce and understand language and evaluate cognitive skills of attention, executive function and working memory important for learning. Tests involve paper and pencil, looking at pictures, listening to words, indicating responses on a keyboard and talking.
214459271|NCT05119023|OTHER|Brain imaging|Enrolled participants who were safe to scan via magnetic resonance imaging (MRI) completed a structural MRI scan between one-month and five months from behavioral testing of learning.
214459272|NCT05944289|BEHAVIORAL|Acceptance and Commitment Therapy|a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy
214459273|NCT05944289|BEHAVIORAL|Caregiver Support Group|Caregiver support group to run parallel to the ACT intervention group.
214459274|NCT04818255|BEHAVIORAL|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
214459275|NCT06156163|OTHER|Perturbation training|The exercise program will be applied 2 days/week for 8 weeks, with the addition of progressive perturbation conditions.
214459276|NCT06156163|OTHER|Exercise|The exercise program will be applied 2 days/week for 8 weeks.
214459277|NCT06785961|PROCEDURE|Regeneration of traumatic tooth|Revascularization is a new treatment method for immature necrotic , pulp revascularization allows also the stimulation of the apical development and the root maturation of immature teeth ( growth and thickening of dentinal walls ).
214459278|NCT05850546|DRUG|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
214459279|NCT05850546|DRUG|Corticosteroid|guideline-recommended corticosteroid therapy
214459280|NCT02284919|DRUG|[18F]ISO-1|\[18F\]ISO-1 PET/CT scan
214459281|NCT03153410|DRUG|Cyclophosphamide|"200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
214459282|NCT03153410|DRUG|GVAX Pancreas Vaccine (GVAX)|"5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
214459283|NCT03153410|DRUG|Pembrolizumab|"200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
215146152|NCT02529072|DRUG|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
215146153|NCT02529072|BIOLOGICAL|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
215146154|NCT01113255|PROCEDURE|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
215146155|NCT03719079|DEVICE|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
215146156|NCT00935584|BEHAVIORAL|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
214459284|NCT03153410|DRUG|IMC-CS4|"75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
214459285|NCT04976660|DRUG|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
215146157|NCT00687193|DRUG|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
215146158|NCT00687193|DRUG|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
215146159|NCT00687193|DRUG|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
215146160|NCT00687193|DRUG|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
215146161|NCT00687193|DRUG|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
215146162|NCT00687193|DRUG|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
215146163|NCT05225090|OTHER|Smartphone App|"Medisafe is a Med\_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
214459286|NCT04817735|PROCEDURE|TAVI|TAVI sizing with dedicated algorithm
214459287|NCT05915988|DEVICE|UNEEG EpiSight solution|Implantation subcutis under local anesthetics
214459288|NCT03408340|PROCEDURE|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
214459289|NCT03408340|DRUG|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
214459290|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
215146164|NCT06010160|BEHAVIORAL|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
215146165|NCT03534804|DRUG|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
215146166|NCT03534804|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
215146167|NCT06313112|OTHER|Observational study|Observational study
215146168|NCT05830396|DRUG|Ambroxol Hydrochloride|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
215146169|NCT05830396|DRUG|Placebo|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
215146170|NCT04986904|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
215146171|NCT05835284|DEVICE|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
215146172|NCT02718404|PROCEDURE|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
215146173|NCT02718404|DRUG|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
214459291|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
214459292|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
214459293|NCT05463432|DRUG|HR19024|Intravenous infusion
214459294|NCT04728932|DRUG|Levosimendan|A continuous infusion of Levosimendan over 24h
214459295|NCT04728932|DRUG|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
214459296|NCT06328647|DEVICE|POC Quantra QPlus System|The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
214529859|NCT03626311|DIETARY_SUPPLEMENT|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
214708918|NCT04673669|DIAGNOSTIC_TEST|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
215146174|NCT02718404|PROCEDURE|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
215146175|NCT04214821|DRUG|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
215146176|NCT04214821|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
215146177|NCT00453141|DRUG|dosing of Betamethasone|
214459297|NCT06328647|OTHER|Routine care|Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
214459298|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
214459299|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
214459300|NCT06801509|BIOLOGICAL|Placebo control: Saline|The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;
214529860|NCT03626311|OTHER|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
214529861|NCT03626025|OTHER|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
214529862|NCT04588519|DEVICE|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
214529863|NCT00305097|DIETARY_SUPPLEMENT|Decaffeinated coffee|5 cups per day for 8 weeks
214529864|NCT00305097|DIETARY_SUPPLEMENT|Caffeinated coffee|5 cups per day for 8 weeks
214529865|NCT00305097|DIETARY_SUPPLEMENT|No coffee|
215146178|NCT06038110|DIAGNOSTIC_TEST|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
215146179|NCT00174187|DRUG|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
215146180|NCT02000206|DRUG|Propofol|
214459301|NCT06801509|BIOLOGICAL|Shingrix®|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart
214459302|NCT06801509|BIOLOGICAL|Ganwei®|Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60；
214529866|NCT03927677|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
214529867|NCT06058117|OTHER|No intervention|no intervention, this is an observational study
214459303|NCT03884946|OTHER|Getting Off App|"A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included."
214459304|NCT06801106|DEVICE|Acapella|is an airway clearance device that combines the resistive features of a positive expiratory pressure device with oscillations, which diminishes the mucus adhesiveness and decrease the collapsibility of airways
214529868|NCT06157619|PROCEDURE|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
214529869|NCT04755023|DRUG|Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide|Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
214529870|NCT01921114|DEVICE|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
214695314|NCT05641038|OTHER|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
215146181|NCT02000206|DRUG|Ketamine|
214459305|NCT06801106|DEVICE|Lung flute|is a new oscillatory positive expiratory pressure (OPEP) device that produces a low frequency acoustic wave with vigorous exhalation that increases mucociliary clearance
215146182|NCT02000206|DRUG|Alfentanil|
214459306|NCT06795841|RADIATION|Photobiomodulation|It was applied for upper respiratory tract over tonsils, trachea, and main bronchi (bilaterally parasternal at the level of angle of Lewis)
214459307|NCT06795841|PROCEDURE|Myofascial release therapy|technique was applied from supine position, with both hands cupping both diaphragmatic domes
214459308|NCT06795841|DEVICE|traditional chest physiotherapy|included traditional chest physiotherapy (postural drainage, percussion and shaking), stretching exercise
214459309|NCT06797622|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtecan (T-DXd)
214529871|NCT01921114|DEVICE|Bard® Dual-Lumen PowerPICC SOLO2®|
214529872|NCT00189683|PROCEDURE|Monitoring|
214529873|NCT00189683|PROCEDURE|Xeloda|
214529874|NCT00796614|DRUG|tamsulosin hydrochloride|Oral
214529875|NCT00796614|DRUG|Placebo|Oral
214529876|NCT00509821|DRUG|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
214529877|NCT00509821|DRUG|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
214529878|NCT02967809|DEVICE|echography|cardiac and pulmonary echography
214529879|NCT06171282|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214529880|NCT04675905|OTHER|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
215146183|NCT06553937|DRUG|Macitentan and Tadalafil|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
215146184|NCT06553937|DRUG|PrOpsynvi® Film-Coated Tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
215146185|NCT04126135|DRUG|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
215146186|NCT04126135|DRUG|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
214529881|NCT04899401|DIETARY_SUPPLEMENT|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
214529882|NCT04899401|OTHER|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (\>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
214529883|NCT01816685|DEVICE|CPAP|
214529884|NCT01722864|DRUG|COV155|COV155 tablets
214529885|NCT01520844|BIOLOGICAL|blood sampling|blood sampling
214529886|NCT01865500|DRUG|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
214695315|NCT05641038|OTHER|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
214695316|NCT03179280|DRUG|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
214695317|NCT01978158|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
214459310|NCT04824235|OTHER|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
215146187|NCT06012916|DRUG|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
214459311|NCT04824235|OTHER|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
214459312|NCT05303090|DRUG|H101|H101 intratumorally injection starts at day 0.
214459313|NCT05303090|DRUG|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214695318|NCT01332019|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
214459314|NCT05303090|DRUG|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214459315|NCT06800391|COMBINATION_PRODUCT|Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day|Capecitabine (1250 mg/m2 /day) and Cyclophosphamide (50 mg/day) continuous daily dosing. Cycles are to be repeated every 28 days for a total of 6 cycles.
214459316|NCT02645149|DRUG|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
214459317|NCT02645149|DRUG|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
214459318|NCT02645149|DRUG|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
214459319|NCT02645149|DRUG|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
214459320|NCT02645149|DRUG|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
214529887|NCT01865500|DRUG|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
215146188|NCT03435211|DEVICE|INVSENSOR00006|Noninvasive pulse oximeter sensor
215146189|NCT00759941|DRUG|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
214529888|NCT01865500|DRUG|Metil prednisolone|
214529889|NCT00319813|BEHAVIORAL|Education|
214529890|NCT05654298|DRUG|Sumatriptan|Sumatriptan 100 mg
214529891|NCT05654298|DRUG|Ubrogepant|Ubrogepant 100 mg
215146190|NCT00759941|DRUG|Placebo eye drops|One drop three times a day in both eyes for 3 months
215146191|NCT00759941|DRUG|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
215146192|NCT04537624|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214529892|NCT03200236|BEHAVIORAL|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
215146193|NCT06104462|DEVICE|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10\*3\*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 \* (Dsitex - Dm1). Therefore, 2.8 \* 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
215146194|NCT04760808|DIAGNOSTIC_TEST|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
214529893|NCT03200236|BEHAVIORAL|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
215146195|NCT04760808|RADIATION|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
215146196|NCT04760808|DIAGNOSTIC_TEST|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
215146197|NCT04760808|RADIATION|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
215146198|NCT04322890|DRUG|Osimertinib|Osimertinib 80mg, po, qd;
215146199|NCT04322890|DRUG|Alectinib 150 MG|Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
215146200|NCT04322890|DRUG|Crizotinib 250 MG|Crizotinib 250 MG po bid.
215146201|NCT04322890|DRUG|Savolitinib, Crizotinib.|Savolitinib, 300mg po qd.
215146202|NCT04322890|DRUG|Chemotherapy|500mg, ivgtt, every 21day.
215146203|NCT06339099|OTHER|Conventional physical therapy program|This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
215146204|NCT06339099|OTHER|Loaded gait training|An extra weight was added around the distal legs during gait training in the intervention group. This weight began at 0.5 kg and was gradually increased every two weeks to a maximum of 2 kg
215146205|NCT05398172|DEVICE|MorpheusV Applicator|Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
215146206|NCT04017546|DRUG|CYC065|intravenous infusion
214459321|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
214459322|NCT06242028|DRUG|Group P|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
214459323|NCT06242028|DRUG|Group S|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
214459324|NCT06554093|DEVICE|Medical Device - PKS|The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
214459325|NCT05393882|RADIATION|Computed tomography coronary angiogram|"Preparation~* Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~* Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~* 18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~* Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~* Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~* Scanning coverage: From the thoracic inlet to diaphragm"
214459326|NCT06801366|DIAGNOSTIC_TEST|Parent-recorded smartphone video clips|Parents will record smartphone video clips of their child asleep, which will be scored by pediatric sleep physicians for presence of moderate-severe OSA. Children will then undergo clinically indicated polysomnography (PSG). Video clips will be evaluated for diagnostic accuracy, with PSG as the gold standard.
214529894|NCT03449134|DRUG|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
214529895|NCT03449134|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
215146207|NCT04017546|DRUG|Venetoclax|oral capsule
215146208|NCT06135805|DRUG|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
215146209|NCT06135805|DRUG|Placebo|Application of placebo oral gel on oral lesions
215146210|NCT04882202|DRUG|Acetaminophen|Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
215146211|NCT04882202|OTHER|Placebo|Normal saline 100 ml (equal amount of acetaminophen) IV every 6 hours
215146212|NCT04006587|DEVICE|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
215146213|NCT04806685|BEHAVIORAL|Sleep education|Medical nutrition therapy plus behavior-based sleep education intervention
215146214|NCT04806685|BEHAVIORAL|Diet only|No sleep education
214695319|NCT04791267|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
214695320|NCT06100484|DIAGNOSTIC_TEST|Echocardiography|Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
214695321|NCT00980785|DRUG|Ramipril|Ramipril 5 mg/day
214695322|NCT00980785|DRUG|Placebo|Matching Placebo
214695323|NCT04043715|DEVICE|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
214695324|NCT04043715|DEVICE|Epidural spinal stimulation|Physical therapy to improve standing and walking
214695325|NCT02791087|OTHER|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
214695326|NCT02791087|OTHER|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
214695327|NCT05436886|DRUG|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
215146215|NCT01016249|DRUG|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
215146216|NCT01016249|DRUG|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
215146217|NCT01016249|DRUG|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
215146218|NCT03873077|PROCEDURE|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
214695328|NCT05436886|DRUG|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
215146219|NCT03863080|DRUG|RVT-1401|Subcutaneous administration of RVT-1401
215146220|NCT03863080|DRUG|Placebo|Subcutaneous administration of Placebo
215146221|NCT02220543|OTHER|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
214695329|NCT05684601|DEVICE|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
215146222|NCT02220543|OTHER|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
215146223|NCT04951024|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
215146224|NCT04951024|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
214695330|NCT04868370|OTHER|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
214695331|NCT00089453|DRUG|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
215146225|NCT04684277|DRUG|antidepressant treatment|depression recieve antidepressant treatment
215146226|NCT04684277|OTHER|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
215146227|NCT01342211|BIOLOGICAL|Placebo|Intravenous placebo monthly during treatment phase.
215146228|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
215146229|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
215146230|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
215146231|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
215146232|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
214459327|NCT05805865|DRUG|Toothpaste Tablet|Colgate Anywhere Toothpaste Tablets
214459328|NCT05805865|DRUG|Conventional Toothpaste|Colgate Cavity Protection
214459329|NCT06801457|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
214459330|NCT06801457|OTHER|Control|Best medical care
214459331|NCT04742205|DRUG|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
214459332|NCT06801925|PROCEDURE|GPT-4o and RAG Voice Chatbot for PHQ-9 Screening|"This study involves the use of a voice-based chatbot powered by GPT-4o and Retrieval-Augmented Generation (RAG) to conduct depression screening using the Patient Health Questionnaire-9 (PHQ-9).~The chatbot aims to evaluate the feasibility and acceptability of using AI-powered conversational tools for mental health screening.~Participants interact with the chatbot in a single session, answering PHQ-9 questions and receiving responses generated using GPT-4o and RAG technologies."
215146233|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
215146234|NCT01342211|DRUG|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
214459333|NCT02719314|DRUG|Glucocorticoid treatment|Glucocorticoid treatment
214459334|NCT06224725|OTHER|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
214459335|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
214459336|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
214459337|NCT03274310|BEHAVIORAL|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
214459338|NCT06196099|DEVICE|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
214459339|NCT06196099|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
214459340|NCT06196099|BEHAVIORAL|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
214459341|NCT05664477|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
214459342|NCT05664477|DRUG|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
214459343|NCT00817219|DRUG|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
214459344|NCT06800703|BEHAVIORAL|follow up interviews for 12 months to determine opioid use|Follow-up
214459345|NCT06801184|BIOLOGICAL|Plasma Sample|A peripheral venous blood sample will be collected on the day of the inclusion consultation and during the follow-up consultation at V2. These samples will be collected in a single2 tubes (4 mL and 5 mL)l tube and will be taken simultaneously with routine blood samples, which require 2 tubes (10 3 mL and 4 mLl).
214459346|NCT06801184|BIOLOGICAL|Stool Sample|Approximately 1 gram of stool will be collected by the patient at home within 72 hours following the inclusion consultation and the follow-up consultation at V2, using the kits provided along with the instructions. The stools will be immediately collected into two tubes: one tube with nucleic acid preservative and one tube conservative to ensure for future metabolomic analyses. The patient will then send the sample using the pre-paid envelope included in the kit to the HCL microbiota biobank (CRB GHN) for aliquoting and storage at -80°C.
214459347|NCT06802042|OTHER|Intervention with probiotic bacteria|The intervention group (n=20) received free intervention with probiotic bacteria (Lactobacillus reuteri DSM 8 +) for 4 weeks (1 bag bid)
214459348|NCT06802042|DRUG|Lactulose oral solution treatment|The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)
214459349|NCT06801951|OTHER|acute resistance exercise with oral nutrition supplementation|acute bout of resistance exercise on an isokinetic exercise machine of each limb (i.e., right and left arm and right and left leg) allowing control of velocity and force. Immediately upon completion, 1 serving of liquid nutrition supplement will be consumed. An additional serving of the liquid nutrition supplement will be sent home for consumption in the evening.
214459350|NCT06801951|OTHER|stable tracer infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
214459351|NCT06800378|DRUG|Zolpidem 10 mg|Zolpidem tartrate 10 mg tablet (taken before bedtime)
215146235|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
215146236|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
215146237|NCT05802212|DRUG|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
215146238|NCT05724277|BEHAVIORAL|Mindfulness Meditation|A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.
215146239|NCT05724277|BEHAVIORAL|Virtual Reality|A 10-minute virtual reality experience will be provided by using virtual reality glasses.
215146240|NCT06543745|BEHAVIORAL|Low-Resistance Training|"The following 6 exercises will be performed in 3 sets of 15-15-15 repetitions, 3 times per week for 12 weeks:~Elbow Flexion, Elbow Extension, Lateral Hip Extensions, Hip Extensions, Knee Extensions, Wall push-ups"
215146241|NCT01877070|BEHAVIORAL|assessments|
215146242|NCT06214689|OTHER|biomarkers analysis|IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
215146243|NCT05063058|DRUG|Molecular guided therapy|Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
215146244|NCT06967194|DRUG|Metoprolol (MET)|Administration of metoprolol 25 mg twice daily
215146245|NCT06967194|DRUG|Plcacebo|Administration of matching placebo
215146246|NCT06972121|BEHAVIORAL|Mindset Intervention|The mindset intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. The content introduces meta-mindsets (beliefs about how mindsets shape experiences and outcomes) and reframes non-severe physical symptoms (e.g., muscle soreness, fatigue) as signs of physiological adaptation. Modules cover: (1) what mindsets are and how they affect performance; (2) how to interpret normal training symptoms as positive signals; (3) how to maintain adaptive mindsets during peak training; and (4) race-day mindset preparation. Each module includes brief text, visuals, and reflection questions and takes approximately five minutes to complete.
215146247|NCT06972121|BEHAVIORAL|Marathon Performance Training|The marathon performance training intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. Content is based on publicly available half-marathon training guidance and excludes any mindset-related material. Modules cover: (1) setting race goals and structuring training plans; (2) training tips and best practices (e.g., pacing, injury prevention); (3) navigating peak training periods (e.g., distance increases, rest and recovery); and (4) practical race-day preparation strategies (e.g., pacing, fueling, warm-up routines). Each module includes concise text, visuals, and actionable tips designed to take approximately five minutes to complete.
215146248|NCT06972277|BEHAVIORAL|Commercial weight management program|Participants will receive evidence-based behavioral / lifestyle support from a commercial weight management program.
215146249|NCT05890664|DRUG|Colchicine|"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."
214459352|NCT06800378|OTHER|Placebo|Starch 10 mg tablet (taken before bedtime)
214459353|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
214459354|NCT05721560|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
214459355|NCT06778811|DRUG|Intraoperative infusion of dexmedetomidine|Intraoperative infusion of 0.3ug/kg/h dexmedetomidine
214459356|NCT06778811|DRUG|Intraoperative infusion of esketamine|Intraoperative infusion of 0.3mg/kg/h esketamine
214459357|NCT06778811|DRUG|Saline control|Intraoperative infusion of equal volumes of saline
214459358|NCT05879211|BEHAVIORAL|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
214459359|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
214459360|NCT02359825|DRUG|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
214459361|NCT03676764|DRUG|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
214459362|NCT03676764|DRUG|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
214459363|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
214459364|NCT05393193|DIAGNOSTIC_TEST|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
214459365|NCT05393193|DRUG|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
214459366|NCT06524310|DEVICE|Stimulation with low frequency rTMS at 1 Hz|Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
215146250|NCT05890664|DRUG|Placebo|Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
215146251|NCT01582269|DRUG|LY2157299 monohydrate|Orally administered as tablets
215146252|NCT01582269|DRUG|Lomustine|Orally administered as capsules
214459367|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
214459368|NCT05910164|DEVICE|PELGRAZ prefilled syringe or PELGRAZ prefilled pen|PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
214459369|NCT04947449|DEVICE|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
214459370|NCT04090086|DRUG|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
214459371|NCT04090086|DRUG|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
214459372|NCT06109181|GENETIC|LX2020|LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
214459373|NCT06559124|OTHER|Traditional Physiotherapy + Sham Kinesiotape|"As exercise training, joint range of motion, flexion and abduction external cycle will be practiced with the gymnasts.~Circumference measurements will be taken for shoulder bone swelling and for atrophy.~Shoulder joint mobilizations will be applied (posterior cutting for flexion limitation, downward shifting and scapular mobilizations for abduction limitation).~Flexion and abduction will be stretched externally. Friction massage will be applied. Strengthening exercises for flexion, abduction and external rotation in the lower and upper segments of the shoulder with dumbbells and theraband, shoulder wheel and finger ladder will be practiced.~Codman exercises and staff exercises will be practiced."
214459374|NCT06559124|OTHER|Kinesiotape with Facilitation Method + Traditional Physiotherapy|Kinesio tape will be applied with 0 tension at the starting point when the arm is in a relaxed position and will be slightly heated. Since the deltoid muscle is a three-headed muscle, it will be applied with 0 tension in the flexed position at the elbow, for the front part, the arm with the elbow in full extension, and for the middle part of the deltoid, the I tape will be applied along the muscle without applying tension.
214459375|NCT06559124|OTHER|Kinesiotape with Inhibition Method + Traditional Physiotherapy|The Y-shaped kinesio tape will be placed on the deltoid muscle with inhibition and mechanical correction technique, and the Y-shaped kinesio tape will be placed on the supraspinatus muscle with inhibition technique, 3 cm below the humerus tuberculum deltoidea without tension. The Y tape will be applied along the outer edge of the anterior deltoid of the forearm with 15-25% light tension, and the posterior arm will be applied along the outer edge of the posterior deltoid with 15-25% light tension up to the lateral acromion. The last 3-5 cm of the tails will be applied to their permanent locations without tension. The shoulder will be held in maximum transverse extension and external rotation for the forearm of the Y support, and in 45 degrees transverse flexion and horizontal adduction for the posterior arm of the Y support. In addition, ultrasound, electrotherapy and cold application will be applied to the participants depending on their tolerance.
214459376|NCT04426968|DRUG|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
214459377|NCT04426968|DRUG|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
214459378|NCT04426968|DRUG|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
214459379|NCT04426968|DRUG|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
214459380|NCT04426968|DRUG|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
214459381|NCT04426968|DRUG|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
214459382|NCT04426968|DRUG|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
214459383|NCT05976139|DEVICE|subthreshold treatment with micropulsed laser|"The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~* Power: 5% Duty Cycle~* Power 250 mw~* Pulse duration 200 ms~* Spot size 100 micron~* Pattern spacing 0.0 confluente, griglie 7x7"
214459384|NCT06427005|DRUG|Fruquintinib|Fruquintinib 5 mg daily for 14 days followed by a 7-day break
214459385|NCT06427005|DRUG|S-1|S-1 80-120 mg daily for 14 days, followed by a 7-day break
214459386|NCT06427005|DRUG|raltitrexed|raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
214459387|NCT05564611|DRUG|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
214459388|NCT05513716|OTHER|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
215146253|NCT01582269|DRUG|Placebo|Orally administered as tablets
214459389|NCT03208868|DIETARY_SUPPLEMENT|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
214459390|NCT03208868|DIETARY_SUPPLEMENT|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
215146254|NCT00289042|DRUG|Enoxaparin|
214459391|NCT05456360|DEVICE|ViSi Mobile device|Participants will wear the device on your wrist like a watch, and it will continuously (non-stop) monitor your pulse, blood pressure, temperature, breathing rate, heart rate, and pulse rate
214459392|NCT05456360|DRUG|Sleep enhancement intervention|Participants will receive a medication administration will be limited to before bedtime.
214459393|NCT00875277|DRUG|LEO 29102 cream|
214459394|NCT00875277|DRUG|LEO 29102 Cream Vehicle|
214459395|NCT00875277|DRUG|Betamethasone Dipropionate Cream|
214459396|NCT00875277|DRUG|LEO 29102 Plus Calcipotriol Cream|
215146255|NCT06175884|OTHER|Video about pain neuroscience education with enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will show evidence-based communication skills to effectively convey information to patients.
215146256|NCT06175884|OTHER|Video about pain neuroscience education without enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will not show evidence-based communication skills to effectively convey information to patients.
215146257|NCT03626103|BEHAVIORAL|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
214459397|NCT00875277|DRUG|LEO 29102 Plus Betamethasone Dipropionate|
214529896|NCT02604706|DEVICE|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
214459398|NCT00875277|DRUG|Daivobet® Ointment|
214529897|NCT02604706|DEVICE|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
214529898|NCT02604706|BEHAVIORAL|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
214529899|NCT04120662|PROCEDURE|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
214529900|NCT04120662|DEVICE|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
214529901|NCT01330992|OTHER|Ocular light or darkness exposure|Ocular light or darkness exposure
214529902|NCT01504009|OTHER|Muscle training|12 weeks of strength training 2-3 times/week
214695332|NCT00089453|DRUG|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
214695333|NCT00089453|DRUG|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.
215146258|NCT03626103|BEHAVIORAL|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
215146259|NCT04021654|PROCEDURE|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
215146260|NCT05481723|DRUG|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
215146261|NCT05481723|PROCEDURE|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
215146262|NCT06482125|DRUG|Dexmedetomidine|Intervention group will receive Total Intravenous Dexmedetomidine as their anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour continued as the sole anesthetic maintenance agent, thereafter.
215146263|NCT06482125|DRUG|Sevoflurane|Inhalation Sevoflurane will be administered as an anesthetic maintenance agent. Sevoflurane at 2 - 3 Vol% will be administered throughout the operative procedure.
215146264|NCT05353777|DEVICE|Levita Robotic Platform|Levita Robotic Platform
215146265|NCT05667181|DEVICE|Surform|Da Vinci linear cutting stapler
215146266|NCT05979311|DRUG|Dolutegravir|Dolutegravir will be administered once daily.
215146267|NCT05979311|DRUG|Lamivudine|Lamivudine will be administered once daily.
215146268|NCT05979311|DRUG|Bictegravir|Bictegravir will be administered once daily.
215146269|NCT05979311|DRUG|Emtricitabine|Emtricitabine will be administered once daily.
214459399|NCT01293526|DEVICE|Control|Patients who respond will have leads will be placed using standard procedures.
214459400|NCT01293526|DEVICE|Experimental|Patients who respond will have their leads placed based on study measurements.
214459401|NCT01293526|DEVICE|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
215146270|NCT05979311|DRUG|Tenofovir alafenamide|Tenofovir alafenamide will be administered once daily.
214459402|NCT05660798|BEHAVIORAL|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
214529903|NCT03924128|DEVICE|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
214529904|NCT06277518|PROCEDURE|Surgery for malignant tumors of the digestive system|Related treatment or palliative surgery under general anesthesia for digestive system malignancies
214695334|NCT00089453|DRUG|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
214695335|NCT00089453|DRUG|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
214695336|NCT00089453|PROCEDURE|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
214695337|NCT00089453|DRUG|Interleukin|2 at 3x10x6 IU on days +1 to 13.
215146271|NCT04809987|OTHER|Virtual Gait|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.
215146272|NCT04809987|OTHER|Physical Exercise|Specific gait exercise was conducted.
215146273|NCT04809987|OTHER|Documental projection|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
215146274|NCT06178055|DRUG|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
215146275|NCT06178055|DRUG|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
215146276|NCT06178055|DRUG|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
214459403|NCT03463785|OTHER|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
214459404|NCT05332756|OTHER|Conservative management|Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
214459405|NCT04719390|BEHAVIORAL|Text Message|"Maternal-Focused Message: When randomized to receive a maternal-focused message, participants will receive a message that is focused on the transition to motherhood and the joys and challenges of caring for a newborn.~Drinking-Focused Message:~When randomized to receive a drinking-focused message, participants will receive a message that is focused on reducing alcohol use.~All messages of both types are designed to map onto behavior change techniques that are empirically supported for alcohol use."
214459406|NCT04292223|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
214459407|NCT04840797|DEVICE|HeartStart HS1|Automated External Defibrillator
214695338|NCT00089453|PROCEDURE|Infusion #1|Infusion of donor NK Cells #1 on day 0
215146277|NCT06970093|PROCEDURE|One Anastomosis Gastric Bypass|Participants will undergo One Anastomosis Gastric Bypass (OAGB), a laparoscopic bariatric procedure that creates a long narrow gastric pouch and anastomoses it to a loop of jejunum approximately 150-200 cm from the ligament of Treitz. This bypasses the compressed duodenum to relieve symptoms of SMAS while promoting weight gain or nutritional restoration in undernourished patients.
215146278|NCT06970093|PROCEDURE|Duodenojejunostomy|Participants will undergo Duodenojejunostomy (DJ), a standard surgical procedure to bypass the compressed segment of the duodenum. It involves creating an anastomosis between the duodenum and the jejunum distal to the point of compression, allowing normal food passage and relieving symptoms of Superior Mesenteric Artery Syndrome.
215146279|NCT02828826|OTHER|telephone coaching|
214459408|NCT05231187|DIAGNOSTIC_TEST|T2Resistance Panel|"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)"
214459409|NCT00391365|PROCEDURE|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
214459410|NCT06635720|DRUG|Prednisone|This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.
214459411|NCT03513562|DRUG|Ibrutinib|Given PO
214459412|NCT03513562|OTHER|Laboratory Biomarker Analysis|Correlative studies
215146280|NCT02582775|DRUG|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
215146281|NCT02582775|DRUG|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
215146282|NCT02582775|DRUG|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
215146283|NCT02582775|RADIATION|Total Body Irradiation|See arm description for dosing.
215146284|NCT02582775|PROCEDURE|Bone marrow infusion|Bone marrow infusion on Day 0
215146285|NCT02582775|DRUG|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.
215146286|NCT02582775|DRUG|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
215146287|NCT02582775|BIOLOGICAL|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
214459413|NCT03513562|DRUG|Venetoclax|Given PO
215146288|NCT02582775|DRUG|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
215146289|NCT01885299|RADIATION|SRS/SBRT|Intervention varies by condition being treated.
215146290|NCT04720183|DRUG|Sulfasalazine|On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
215146291|NCT04720183|DRUG|GLPG3970|On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
214529905|NCT02406274|OTHER|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
215146292|NCT06573879|BEHAVIORAL|Eccentric Exercise|It was investigated whether volleyball athlete participants would develop muscle architecture, muscle strength and performance parameters differently from the control group by performing eccentric exercises in addition to their exercise routines.
215146293|NCT05964218|BEHAVIORAL|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
215146294|NCT02352896|DRUG|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
214529906|NCT04700475|DEVICE|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
214529907|NCT04700475|DRUG|citric acid solution|citric acid solution applied as a mouth rinse
214529908|NCT00242164|DRUG|Dialysate Magnesium (Concentration)|
214529909|NCT05172518|DRUG|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
214529910|NCT05172518|DRUG|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
214529911|NCT05172518|DRUG|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
214529912|NCT05172518|DRUG|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
214529913|NCT01997489|DRUG|Enzyme replacement|Observational study of current treatment and with no comparative groups
214529914|NCT03418181|PROCEDURE|Standard Haemodialysis|Thrice weekly dialysis.
214529915|NCT03418181|PROCEDURE|Incremental dialysis|Individualised dialysis dose according to native kidney function.
214695339|NCT00089453|PROCEDURE|Leukapheresis #2|on day +2
215146295|NCT06510153|OTHER|Environmental Music Therapy|The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution during approximately 20 minutes.
215146296|NCT06510153|OTHER|Pre-recorded music|The protocol for pre-recorded music is the same as for EMT.
214459414|NCT04955470|DRUG|Ketamine Injectable Solution|A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
214529916|NCT04635085|BEHAVIORAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
214529917|NCT06176053|OTHER|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
215146297|NCT06510153|OTHER|Standard care only|Standard care in the emergency room waiting room as provided by each hospital without being exposed to EMT or pre-recorded music.
215146298|NCT05104606|OTHER|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~* The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~* The second TEE will be performed at H24 to performed new measurements."
214529918|NCT00957996|DRUG|Peramivir|300 mg twice daily
214529919|NCT00957996|DRUG|Peramivir|600 mg once daily
214529920|NCT04695821|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
214529921|NCT02542410|DRUG|Cabergoline|
214529922|NCT02542410|DRUG|Norethindrone acetate|
214529923|NCT00256685|DRUG|DVS-233 SR|
214529924|NCT00000897|DRUG|Zidovudine|
214529925|NCT06395922|DEVICE|Blockbuster LMA|The LMA was inserted using the recommended technique, with the patient's head in the sniffing position. The appropriate size was selected based on body weight (size 3 for 30-50 kg, size 4 for 50-70 kg)
215146299|NCT05104606|OTHER|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
215146302|NCT01588522|DRUG|Compound 31543 Calcitriol 5 μg/mL|5 μg/mL Topical Solution
215146303|NCT01588522|DRUG|Compound 31543 Calcitriol 10 μg/mL|10 μg/mL Topical Solution
215146304|NCT01588522|DRUG|Compound 31543 Calcitriol 20 μg/mL|20 μg/mL Topical Solution
215146305|NCT01588522|DRUG|Compound 31543 Calcitriol 40 μg/mL|40 μg/mL Topical Solution
215146306|NCT01588522|DRUG|Compound 31543 Calcitriol 60 ug/mL|60 ug/mL Topical Solution
214459415|NCT04955470|DRUG|Midazolam Injectable Solution|A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
214459416|NCT04955470|DRUG|Normal Saline 0.9% Injectable Solution|A 0.9% normal saline solution will be infused over a 40 minute period.
215146307|NCT01588522|DRUG|Compound 31543 Calcitriol 80 μg/mL|80 μg/mL Topical Solution
214459417|NCT06502717|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214529926|NCT06395922|DEVICE|Baska Mask|The BM was inserted by opening the mouth, avoiding the tongue, and negotiating the palatopharyngeal curve using the hand-tab.
214529927|NCT06229249|OTHER|Carpal ligament self-myofascial stretching|Carpal ligament self-myofascial stretching is a technique that involves applying pressure and stretching to the carpal ligaments and surrounding myofascial tissues of the wrist and hand. The objective is to release tension, improve flexibility, and alleviate discomfort or pain in the wrist and hand area.
214529928|NCT06229249|OTHER|Conventional physical therapy|In this technique, ultrasound therapy, nerve gliding exercise, tendon gliding exercise, and wrist splinting were performed.
214529929|NCT00547053|DRUG|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
214529930|NCT02072278|DRUG|Vortioxetine 10 mg|
214529931|NCT02072278|DRUG|Vortioxetine 20 mg|
214529932|NCT02072278|DRUG|Escitalopram 15 mg|
214529933|NCT02072278|DRUG|Placebo|
214529934|NCT02071680|OTHER|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
214529935|NCT05611853|DRUG|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
214459418|NCT04815720|DRUG|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
215146308|NCT05500794|OTHER|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~* Guided meditation practices;~* Mindfulness stretching and yoga;~* Reflection and group discussion periods aimed at promoting mindfulness in daily life;~* Practice instructions and opportunity to ask questions;~* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
215146309|NCT04077099|DRUG|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
215146310|NCT05060211|OTHER|Vancouver symptom score for dysfunctional elimination syndroms|Validated questionnaire concerning bladder and bowel symptoms
215146311|NCT05060211|OTHER|Magnetic resonance imaging|Known MRI results of the patient file
215146312|NCT04050735|OTHER|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
215146313|NCT04050735|OTHER|Placebo|Placebo beverage
215146314|NCT04574271|BEHAVIORAL|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
215146315|NCT04574271|BEHAVIORAL|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
214459419|NCT05540860|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
214459420|NCT05540860|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
214459421|NCT05540860|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
214459422|NCT05540860|DRUG|Sevasemten Dose 4|Sevasemten is administered orally once per day
214459423|NCT05540860|DRUG|Sevasemten Dose 5|Sevasemten is administered orally once per day
214459424|NCT05540860|DRUG|Placebo|Placebo is administered orally once per day
214459425|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
214459426|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
214459427|NCT06789705|DRUG|MDMA|MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
214459428|NCT06789705|OTHER|Placebo|Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
214459429|NCT06086418|DRUG|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
214459430|NCT06086418|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
214459431|NCT06086418|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
214459432|NCT04021498|DRUG|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
214459433|NCT04021498|OTHER|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
214459434|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
214459435|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
214459436|NCT06100900|DRUG|BCX10013|Multiple dose levels may be tested in this study.
214459437|NCT05467345|DEVICE|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
214459438|NCT04101851|PROCEDURE|omission of SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
214459439|NCT04963270|DRUG|Satralizumab|Satralizumab will be administered as a subcutaneous injection
214459440|NCT04963270|OTHER|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
214459441|NCT04026555|OTHER|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
214459442|NCT04026555|OTHER|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
214459443|NCT06289647|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
214459444|NCT02786277|OTHER|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
214459445|NCT04150900|DRUG|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
214459446|NCT04150900|DRUG|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214529936|NCT02304562|BIOLOGICAL|UCB Mesenchymal Stem Cells treatment|reduce skin injury
215146316|NCT03361761|OTHER|Health education program|formalized/official Health education program
215146317|NCT03361761|OTHER|Health education program|non formalized/official Health education program
215146318|NCT06477120|BEHAVIORAL|Time Restricted Eating|The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
215146319|NCT06342037|DRUG|Tiragolumab|600mg every 3 weeks (Q3W)
214459447|NCT06799468|PROCEDURE|liver transplantation|Liver transplantation or hepatic transplantation is the replacement of a diseased liver with the healthy liver from another person (allograft). Liver transplantation is a treatment option for end-stage liver disease and acute liver failure, although availability of donor organs is a major limitation. Liver transplantation is highly regulated, and only performed at designated transplant medical centers by highly trained transplant physicians. Favorable outcomes require careful screening for eligible recipients, as well as a well-calibrated live or deceased donor match.
214459448|NCT06040320|DRUG|Polatuzumab vedotin|Given at 1.8 mg/kg
214459449|NCT06040320|DRUG|Rituximab|Given at 375 mg/m\^2
214459450|NCT06040320|DRUG|CHP|Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
214529937|NCT04632212|BEHAVIORAL|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
214529938|NCT04632212|BEHAVIORAL|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~* Video: subjects will watch a video briefly explaining the food labels on the store.~* My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
214529939|NCT04632212|BEHAVIORAL|Ordering|To order food items by Nutri-Score (high to low).
214529940|NCT04632212|BEHAVIORAL|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
214529941|NCT00468507|DIETARY_SUPPLEMENT|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
214529942|NCT01391676|PROCEDURE|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
214529943|NCT01805206|OTHER|Assessment of urinary iFABP|
214529944|NCT01805206|OTHER|Administration of enteral feedings|
215146320|NCT06342037|DRUG|Atezolizumab|1200mg every 3 weeks (Q3W)
215146321|NCT06342037|DRUG|Ipilimumab|1 mg/kg, maximum of 4 cycles
215146322|NCT04504253|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate loose powder
215146323|NCT04504253|DRUG|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
215146324|NCT03667378|BEHAVIORAL|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
214459451|NCT05910749|DEVICE|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
214459452|NCT06547268|DEVICE|Wireless sensor and platform|Skin-mounted sensor that pairs with tablet platform
214459453|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
214529945|NCT01538225|DRUG|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
214529946|NCT01538225|DRUG|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
214529947|NCT02123277|DEVICE|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
214529948|NCT05336981|RADIATION|Low-Level Light Therapy|The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
214529949|NCT01050361|PROCEDURE|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
214529950|NCT01957592|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
214695340|NCT00089453|PROCEDURE|Infusion #2|on day +2
214695341|NCT00089453|PROCEDURE|Auto Graft|on day +14
215146325|NCT03667378|BEHAVIORAL|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
215146326|NCT03667378|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
215146327|NCT03667378|BEHAVIORAL|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
215146328|NCT03667378|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
215146329|NCT03667378|BEHAVIORAL|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
215146330|NCT03667378|BEHAVIORAL|visits with a supportive care clinician|Monthly visits with a supportive care clinician
215146331|NCT05546879|DRUG|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
215146332|NCT05546879|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
215146333|NCT05546879|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
215146334|NCT03205423|DRUG|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
215146335|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
215146336|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
215146337|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
215146338|NCT04364867|DRUG|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
215146339|NCT04364867|DRUG|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
215146340|NCT03757546|OTHER|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
214459454|NCT05302193|OTHER|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
214459455|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
214459456|NCT05376579|OTHER|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
214459457|NCT01724580|DRUG|Baricitinib|Administered orally
214459458|NCT06381713|BEHAVIORAL|High intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks."
214459459|NCT06381713|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks."
214459460|NCT04927364|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
214459461|NCT03547323|DEVICE|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
214459462|NCT03547323|DEVICE|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
214459463|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
214459464|NCT04583293|OTHER|No intervention|This study does not involve any intervention or new treatment.
214529951|NCT06545110|DRUG|Baricitinib Oral Tablet|Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
214529952|NCT04917263|DIAGNOSTIC_TEST|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
214529953|NCT04596098|OTHER|Blood sampling|During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
214529954|NCT02622256|BEHAVIORAL|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
214529955|NCT04143906|DRUG|Vinorelbine|injection
214529956|NCT04143906|DRUG|Gemcitabine|injection
214529957|NCT04143906|DRUG|Carboplatin|injection
214529958|NCT01324739|DRUG|human BNP-32|3pmol/kg/min infusion
214529959|NCT06255912|DRUG|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
214459465|NCT05478564|OTHER|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
214459466|NCT06486584|BEHAVIORAL|Contingency Management|Contingency management payment for no disruptive behaviors each week.
214459467|NCT05219123|OTHER|ERCP with no PD cannulation|ERCP with no PD cannulation
214459468|NCT05219123|OTHER|ERCP with single PD cannulation|ERCP with single PD cannulation
214459469|NCT04215978|DRUG|BGB-A445|Administered as specified in the treatment arm
214459470|NCT04215978|DRUG|tislelizumab|Administered as specified in the treatment arm
214459471|NCT03483610|BEHAVIORAL|Provider Referral|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
214459472|NCT03483610|BEHAVIORAL|Text Messaging|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
214459473|NCT00858312|OTHER|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
214459474|NCT00858312|OTHER|Low Dairy|less than 1 serving of dairy foods per day.
214459475|NCT04899310|BIOLOGICAL|mRNA-3705|A sterile liquid for injection
214459476|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
214459477|NCT00621894|DRUG|Placebo|Placebo
214459478|NCT06353191|OTHER|Non-Interventional Study|Non-interventional study
214459479|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
214459480|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
214459481|NCT04118088|BIOLOGICAL|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
214459482|NCT04169906|DRUG|Placebo|Participants will receive placebo once daily for 7 consective days
214459483|NCT04169906|DRUG|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
214459484|NCT04169906|DRUG|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
214529960|NCT06255912|DRUG|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
214529961|NCT03511573|PROCEDURE|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
214529962|NCT00275301|DRUG|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
214529963|NCT02097849|DRUG|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
214459485|NCT04169906|DRUG|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
214459486|NCT03539822|DRUG|Cabozantinib|by mouth
214529964|NCT02097849|BIOLOGICAL|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
214529965|NCT02097849|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
214529966|NCT02097849|BIOLOGICAL|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
214529967|NCT02097849|DRUG|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
214529968|NCT05906901|OTHER|Cranial listening technique|5 minutes
214529969|NCT05906901|OTHER|Suboccipital muscles inhibition technique|6 minutes
214529970|NCT00361036|DEVICE|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
214529971|NCT00361036|DEVICE|Uterine fibroid embolization Embosphere®|Embosphere - control arm
215146341|NCT01349608|BEHAVIORAL|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
215146342|NCT02386475|OTHER|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
214459487|NCT03539822|DRUG|Durvalumab|infusion
214459488|NCT03539822|DRUG|Tremelimumab|infusion
214459489|NCT04807192|RADIATION|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
214459490|NCT04807192|DRUG|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
214459491|NCT06468280|PROCEDURE|Local treatment (Surgical)|Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
214459492|NCT06468280|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
214459493|NCT06468280|DRUG|XELOX Chemotherapy Regimen|"Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle."
214459494|NCT06468280|PROCEDURE|Local Treatment (Non-surgical)|"Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team."
214459495|NCT03589339|DRUG|NBTXR3|Single intra Tumoral injection
214459496|NCT03589339|RADIATION|SABR|Radiotherapy given as a definite number of fractions at the dose defined for each radiation field
214459497|NCT03589339|DRUG|Nivolumab|Anti-PD-1 monotherapy
214459498|NCT03589339|DRUG|Pembrolizumab|Anti-PD-1 monotherapy
214459499|NCT06242119|DIAGNOSTIC_TEST|J-PET scan|Diagnostic Test: Positron-Emission Tomography Imaging Examination of radiation distribution in the patient body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA, \[18F\]choline or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
214459500|NCT05921357|OTHER|Questionnaire|Questionnaire and examine
214459501|NCT02657486|DRUG|BGJ398|
214459502|NCT05342064|OTHER|patient-centered TB preventive therapy|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
214459503|NCT05342064|OTHER|TB preventive therapy adherence support|As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
214459504|NCT04888312|BIOLOGICAL|CD40 agonist mitazalimab in combination with chemotherapy|Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.
214459505|NCT02584244|DRUG|LUM015|
214459506|NCT02584244|DEVICE|LUM 2.6 Imaging Device|
214459507|NCT06770231|OTHER|Single drill system|New system for drilling
214529972|NCT01814436|DEVICE|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
214529973|NCT02874105|OTHER|Group C: physiotherapy protocol with Conventional physiotherapy.|
214459508|NCT04106466|DEVICE|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
214459509|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
214459510|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
214459511|NCT03844074|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
214459512|NCT03844074|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
214459513|NCT05388916|OTHER|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
214459514|NCT03033446|RADIATION|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
214459515|NCT03033446|DRUG|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
214529974|NCT02874105|OTHER|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
214529975|NCT02561078|DRUG|Human regular U-500 insulin (CSII)|Administered SC
214529976|NCT02561078|DRUG|Human regular U-500 insulin (MDI)|Administered SC
214529977|NCT04240600|DIETARY_SUPPLEMENT|Experimental group|2 cans or bottles (200ml)per day, orally
214529978|NCT04240600|DIETARY_SUPPLEMENT|Control group|2 cans or bottles (200ml)per day, orally
214459516|NCT06797557|DIAGNOSTIC_TEST|2D Ultrasound|"* Crow- rump length (CRL) measurement using 2D ultrasound. Proper measurement of the CRL was done according to obtaining a true, unflexed, longitudinal section of the embryo or fetus, with the end-points of the crown (the top of the head) and rump (the end of the trunk) clearly defined, and then placing the calipers correctly on these defined end-points.~* Yolk sac diameter (largest outer to outer measure).~* Mean gestational sac diameter (arithmetic mean of 3 diameters).~* Embryonic heart rate. the heart rate was determined from M-mode tracings using electronic calipers .The sweep speed was set at 4 s and the calculation of the heart rate was made by measuring the time interval of two cardiac cycles, using clearly identified points in the M-mode tracing"
214459517|NCT06797557|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound rotational VOCAL method was used. YSV measurement (axial, sagittal and coronal). The sagittal plane was chosen as the reference plane and 'scanned' to obtain the longest axis of the yolk sac. Then a magnification of image was used and the yolk sac moved to the center of the plane. The VOCAL switch was then activated using a 30° rotation angle and the manual setting. Calipers were positioned on the superior and inferior extremities of the structure and after obtaining six sequential planes, the equipment automatically displayed the yolk sac as a 3D image with its volume in cm3
214459518|NCT02919306|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
214459519|NCT02919306|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
214459520|NCT02919306|DRUG|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
214529979|NCT03376698|DRUG|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
214529980|NCT03376698|DRUG|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
214529981|NCT03376698|DRUG|Placebo|oral administration of Placebo once daily for 12 weeks
214529982|NCT01983462|DRUG|Clonidine|
214529983|NCT01983462|DRUG|Hydrochlorothiazide|
214529984|NCT01983462|DRUG|Placebo|
214529985|NCT05005286|OTHER|Past history of vaginal Infections|With or without vaginal infection during pregnancy
214529986|NCT00684203|DRUG|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
214529987|NCT00684203|DRUG|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
214529988|NCT00684203|DRUG|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
214529989|NCT00684203|DRUG|Clopidogrel|100 mg two or three times daily for 60 days.
214529990|NCT05203809|DEVICE|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
214529991|NCT00719212|BIOLOGICAL|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
214529992|NCT06426147|DIETARY_SUPPLEMENT|L-citrulline|1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
214529993|NCT06426147|DIETARY_SUPPLEMENT|Placebo|1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
214529994|NCT00508274|DRUG|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
214529995|NCT00508274|DRUG|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
214529996|NCT03296566|BEHAVIORAL|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
214529997|NCT00369603|DRUG|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
214529998|NCT00369603|DRUG|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
214529999|NCT02396446|OTHER|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
214530000|NCT02344017|DRUG|ODM-204|co-administered with prednisone, orally daily
214530001|NCT02344017|DRUG|Prednisone|ODM-204 is co-administered with oral prednisone
214530002|NCT04276636|DRUG|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
214530003|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
214530004|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
214530005|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
214530006|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
214530007|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
214530008|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
214530009|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
214695342|NCT00871377|DRUG|Placebo|corn oil (n-6 fatty acids)
214459521|NCT06774937|DIAGNOSTIC_TEST|All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his|"Thorough clinical examination:~1\. General examination including general look, vital signs and anthropometric measurements.~2\. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
214459522|NCT06774937|DIAGNOSTIC_TEST|EMG ,rNST,Ach R antibodies & thyroid function|"C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
214459523|NCT03560609|DEVICE|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
214459524|NCT03560609|DEVICE|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
214459525|NCT03560609|DEVICE|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
214459526|NCT03560609|DEVICE|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
214459527|NCT03560609|DEVICE|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
214459528|NCT04293055|BEHAVIORAL|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
214459529|NCT04293055|BEHAVIORAL|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
214459530|NCT02839161|BIOLOGICAL|Na-GST-1/Alhydrogel|
214459531|NCT02839161|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
214459532|NCT02839161|BIOLOGICAL|Hepatitis B Vaccine|
214530010|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
214530011|NCT00821119|DEVICE|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
214530012|NCT06240377|DEVICE|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
214530013|NCT06240377|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
214530014|NCT00349245|DRUG|Remifentanil|
214530015|NCT00349245|DRUG|Dexmedetomidine|
214530016|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
214530017|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
214530018|NCT00555646|DRUG|Control|No treatment control.
214459533|NCT06519487|BEHAVIORAL|Cyberball|"Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars."
214459534|NCT06561477|OTHER|Intensive care cirrhosis outcome (ICCO) score|ICCO score will be calculated for the participants to use it as a predictor for mortality and ICU outcome The ICCO score is 0.3707 + (0.0773 x bilirubin (mg/dl)) - (0.00849 x cholesterol (mg/dl)) -(0.0155 x creatinine clearance (ml/min)) + (0.1351 x lactate (mmol/l))
214459535|NCT06192329|BEHAVIORAL|Hot water therapy|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
214459536|NCT06192329|BEHAVIORAL|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
214459537|NCT06293950|BIOLOGICAL|WJMSC|\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
214459538|NCT06186401|BIOLOGICAL|E-SYNC T Cells|Given IV
214459539|NCT06186401|DRUG|Cyclophosphamide (non-investigational)|Given IV
214459540|NCT06186401|DRUG|Fludarabine (non-investigational)|Given IV
214459541|NCT06186401|PROCEDURE|Leukapheresis|Undergo leukapheresis
214459542|NCT06186401|PROCEDURE|Surgical resection|Undergo surgical resection of tumor tissue
214459543|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
214459544|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
214459545|NCT04195698|DRUG|Upadacitinib|Upadacitinib will be administered oral as tablet
214459546|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
214459547|NCT06806358|DEVICE|IUD insertion|"* Perform a bimanual examination~* Insert a warm, moistened speculum.~* Cleanse the cervix with an antiseptic solution.~* Open the sterile insertion instruments without touching~* Remove the tenaculum by its handle and grasp the anterior or posterior lip of the cervix.~* Apply gentle traction with the tenaculum to straighten the canal.~* Remove the sound by its handle and gently insert it to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed~* Open the IUD pack without touching its contents.~* Put on sterile gloves.~* Load the IUD and insert it into the uterine cavity according to the manufacturer instructions.~* Gently remove the tenaculum.~* Trim the strings of the IUD to 3-4 cm in length~* Remove the speculum and assess the woman."
214459548|NCT05507684|OTHER|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
214459549|NCT06269484|DRUG|Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
214459550|NCT06269484|DRUG|Zibotentan + placebo (placebo matching dapagliflozin tablet)|"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"
214459551|NCT06269484|DRUG|Zibotentan + dapagliflozin|"zibotentan capsule~dapagliflozin 10 mg tablet"
214459552|NCT05553860|OTHER|Speech positioning technique|Speech positioning technique
214459553|NCT01959425|OTHER|Off OAT Group (Test)|Discontinuation of OAT Therapy
214459554|NCT01959425|OTHER|On OAT Group (Control)|Continuation of OAT Therapy
214530019|NCT03577756|OTHER|Neurodevelopmental assessments|Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
214530020|NCT02645773|DEVICE|non-ablative laser|non-abaltive laser pre, immediate and post wounding
214459555|NCT04625283|DRUG|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
214459556|NCT04625283|DRUG|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
214459557|NCT04625270|DRUG|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
214459558|NCT04625270|DRUG|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
215146343|NCT02386475|DRUG|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
215146344|NCT02386475|DRUG|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
215146345|NCT05786651|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
215146346|NCT05097586|DEVICE|active tDCS|2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
215146347|NCT05097586|OTHER|workbook|Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
214459559|NCT06821958|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
214459560|NCT03881098|PROCEDURE|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
215146348|NCT05097586|DEVICE|sham tDCS|Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
215146349|NCT05937165|OTHER|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
215146350|NCT05083923|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
215146351|NCT04390763|BIOLOGICAL|NIS793|anti-TGFb antibody. NIS793 2100 mg every 2 weeks by intravenous (i.v.) infusion.
215146352|NCT04390763|BIOLOGICAL|Spartalizumab|anti-PD-1 antibody. spartalizumab 400 mg every 4 weeks by i.v. infusion.
215146353|NCT04390763|DRUG|gemcitabine|SOC chemotherapy. Gemcitabine (1000 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
215146354|NCT04390763|DRUG|nab-paclitaxel|SOC chemotherapy. Nab-paclitaxel (125 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
215146355|NCT06651944|DEVICE|Invisalign® System with mandibular advancement featuring occlusal blocks|Class II correction using the Invisalign® System with mandibular advancement featuring occlusal blocks
215146356|NCT06653075|PROCEDURE|mandibular advancement with acrylic splint Herbst Appliance|Mandibular advancement with acrylic splint Herbst Appliance
214459561|NCT03881098|PROCEDURE|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
214459562|NCT03881098|PROCEDURE|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
214459563|NCT03715478|DRUG|GSK2857916 with Pomalidomide and Dexamethasone|Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
215146357|NCT04115761|BIOLOGICAL|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
215146358|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
215146359|NCT05874791|BEHAVIORAL|Goal Management training|metacognitive group intervention
214530021|NCT03935932|DEVICE|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
214530022|NCT06477237|BIOLOGICAL|HB0017 Q4W|HB0017 at W0,1,2,4,8+HB0017Q4W
214530023|NCT06477237|BIOLOGICAL|HB0017 Q8W|HB0017 at W0,1,2,4,8+HB0017Q8W
214530024|NCT06477237|BIOLOGICAL|placebo|placebo at W0,1,2,4,8+HB0017Q4W
214530025|NCT05204316|OTHER|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
214530026|NCT00616486|DEVICE|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
215146360|NCT06038864|DIAGNOSTIC_TEST|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
214459564|NCT05781893|OTHER|Digital intervention (DiLCoS)|The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.
214459565|NCT05781893|OTHER|Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
214459566|NCT05181540|BIOLOGICAL|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
214459567|NCT05181540|OTHER|Placebo|Placebo
214459568|NCT05968937|DRUG|20 mg baclofen vaginal suppository daily per vagina|20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
214459569|NCT05968937|DRUG|Placebo|Vaginal suppository composed of Supposibase F daily per vagina
215146361|NCT05786924|DRUG|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
215146362|NCT06655376|DRUG|Aspirin|81-100 mg, oral
215146363|NCT06655376|DRUG|Warfarin|Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
215146364|NCT06503874|OTHER|Attention Training|The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).
215146365|NCT06503874|OTHER|Music Group|This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.
215146366|NCT05743400|DRUG|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
215146367|NCT05743400|BIOLOGICAL|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~* 1 after each end of perfusion ;~* 1 though concentration before each perfusion ;~* 3 blood samples in 3 different days during the first week;~* 1 weekly for 2 weeks post HSCT."
215146368|NCT06978491|OTHER|Group C|Spinal anesthesia.
215146369|NCT06978491|OTHER|Group T|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied bilaterally between the transversus abdominis and internal oblique muscle.
215146370|NCT06978491|OTHER|Group W|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied to the wound site.
214530027|NCT00616486|DEVICE|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
215146371|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
214530028|NCT02206464|BIOLOGICAL|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
214530029|NCT02206464|BIOLOGICAL|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
215146372|NCT06597110|BEHAVIORAL|listened to ASMR|ASMR refers to a physiological sensation triggered by specific auditory stimuli.ASMR, characterized by low-frequency human voice and ambient sounds, has garnered significant attention across social media platforms, short and long-form video platforms, and podcasts, owing to its unique pleasurable and stimulating effects. listen to ASMR for 10mins.
215146373|NCT06587438|DEVICE|Sinocare iCan I3 CGM|Real-time Continuous glucose monitoring
215146374|NCT06587438|DEVICE|Sinocare jinzhi+Blood glucose meter|Self-monitoring of blood glucose
215146375|NCT06598735|DRUG|HRS-4508|HRS-4508
215146376|NCT06597825|DRUG|root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)|After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
215146377|NCT05464680|OTHER|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
215146378|NCT04139057|DRUG|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
215146379|NCT06603610|OTHER|Intensive geriatric service worker model of care|"Participants in the intervention group will receive care from an intensive geriatric service worker (IGSW), who will help the participant:~(i) Coordinate community resources and actively support participants' instrumental activities of daily living (IADLs) (e.g., linking participants with Meals-on-Wheels, taking participants to appointments) (ii) Advocate for support from home care for completing activities of daily living (ADLs) (iii) Implement patients' prioritized treatment recommendations made by healthcare professionals (e.g., supporting patients to purchase and install home safety equipment because this aligns with their values and preferences)."
215146380|NCT06603610|OTHER|Information brochure and telephone follow-up support|Participants will be e-mailed or mailed a booklet containing information about locally available resources including (1) meal preparation, (2) grocery delivery, (3) housekeeping, (4) pharmacies that deliver medications, (5) home care, and (6) Wheel-Trans. Participants will receive a scripted phone call from the study research coordinator one and three months after study enrolment to see if they have questions about the booklet material.
215146381|NCT06587009|PROCEDURE|Shock wave therapy|Received shock wave therapy 7 times a week and functional exercise therapy intervention
215146382|NCT06587009|PROCEDURE|Conventional conservative treatment|Conventional conservative treatment and functional exercise were given
215146383|NCT06591507|DIETARY_SUPPLEMENT|BCAA Nutritional Intervention|Patients will receive BCAA nutritional supplements. The supplement is taken orally twice daily, with each sachet containing 10g of powder, of which 6g is BCAA, and the remainder consists of preservatives and fruit flavorings to enhance palatability. The morning dose is taken with breakfast, and the second dose is taken as a late evening snack after dinner. For critically ill patients, enteral nutrition is provided instead. During each follow-up visit, patients are required to retain and submit all empty and unused sachets to accurately assess compliance. Dietitians will adjust the type and amount of food for each patient according to the guidelines of the European Society for Parenteral and Enteral Nutrition to ensure a total caloric intake of 35-40 kcal/kg and a protein intake of 1.2-1.5 g/kg (including BCAA supplements).
214459570|NCT05974254|DEVICE|Acupuncture|Electroacupuncture
215146384|NCT06591507|BEHAVIORAL|Muscle Rehabilitation Training|Phase 1: Resistance Training (During Hospital Stay, First Month) Phase 2: Resistance Training (Home-Based, From Hospital Discharge Until 3 Months Post-Surgery) Phase 3: Physical Activity Training (Post-Surgery, After 3 Months)
214459571|NCT06648811|DEVICE|Pain management after surgery|Kinesio tapes will be applied to the patients in the study group after gynecological laparoscopic operations. The routine pain management will also be provided in these patients in addition to the kinesio tapes. Only postoperative pain management will be provided to the patients in the control group. The patients will be consisted of only the patients who will be operated laparoscopically for gynecological diseases.
214459572|NCT05465928|DEVICE|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
214459573|NCT05465928|DEVICE|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
214530030|NCT01648985|OTHER|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
214530031|NCT02223507|DRUG|BIIR 561 CL|
214530032|NCT02223507|DRUG|Placebo|
214530033|NCT00787683|DEVICE|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
214530034|NCT01807936|PROCEDURE|Lymphadenectomy|
214530035|NCT00024570|DRUG|IL13-PE38QQR|
214530036|NCT00024570|PROCEDURE|targeted fusion protein therapy|
214530037|NCT00024570|PROCEDURE|surgery|
214530038|NCT04420741|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
215146385|NCT06591507|DIETARY_SUPPLEMENT|Standard Nutritional Therapy|Standard Nutritional Therapy
215146386|NCT06589011|OTHER|Pressure Support Ventilation|The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min
215146387|NCT06589011|OTHER|spontaneously assisted breathing|The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
215146388|NCT06595550|DIETARY_SUPPLEMENT|Whey protein|Powder milk
215146389|NCT06595550|DIETARY_SUPPLEMENT|no Whey protein|Powder milk
215146390|NCT06600724|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215146391|NCT06600724|OTHER|EPIEFFECT|Participants will receive weekly applications of EPIEFFECT and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
215146392|NCT06600724|OTHER|EPIXPRESS|Participants will receive weekly applications of EPIXPRESS and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
214459574|NCT04500613|PROCEDURE|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
214459575|NCT04500613|OTHER|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
214459576|NCT06802627|OTHER|Education session|"The information that will be delivery is going to be focused on:~* Lifestyle changes regarding nutrition and daily physical activity.~* Abstinence of the additive behaviors smoking, alcohol, and drug consumption.~* Personal hygiene care and hospital routines.~* Importance of postoperative physiotherapy. A booklet summarizing the information provided at the education session will be delivered for all participants."
214459577|NCT06802627|OTHER|Inspiratory muscle training group|"Education Session (described in the control group) Inspiratory muscle training (IMT) After the education session, patients will start the IMT program that will last two weeks.~The IMT will be 5 days/ week, lasting 20 minutes, using the PowerBreath KH2 device. In the first week, the intensity of the PowerBreath KH2 will be set at 50% of the maximal inspiratory pressure (with 12 breaths per minute), and it will be increasing by 10% in the second week (with 15 breaths per minute). Patients will be continuously monitored by an oximeter and modified Borg scale"
215146393|NCT06594653|OTHER|pre treatment assesment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
215146394|NCT06594653|OTHER|post treatment assessment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
215146395|NCT00899132|GENETIC|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
215146396|NCT00899132|GENETIC|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
214459578|NCT06802627|OTHER|Expiratory muscle training group|"Education Session (described in the control group) Expiratory muscle training (EMT)~After the education session, patients will start the EMT that will last two weeks, 5 days a week. The sessions will last 20 minutes and will be structured as follows:~4 minutes of total body stretching exercises 8 minutes of abdominal resistance exercises:~1. First week: 2 exercises, 4 sets of 8 repetitions~2. Second week: 2 exercises, 4 sets of 10 repetitions 8 minutes of specific EMT using the Philips Respironics Threshold PEP device (Load: 20 cmH2O; 10 expirations for minute) Patients will be continuously monitored by an oximeter and modified Borg scale."
214459579|NCT06802627|OTHER|Global exercise training group|"The GET-G will be submitted to an education session (equal to the CG) plus 2-weeks of physical exercise, 3 sessions per week, 45-60 minutes.~The structure is:~Warm-up: 5 minutes of whole-body stretching exercises~Main workout:~-Aerobic: Week 1: 20 min of treadmill walking at 70% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate. Week 2: 20 min of treadmill walking at 80% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate.~-Resistance Week 1: 8 exercises, 2 sets of 8-10 repetitions, using body weight and elastic bands. Week 2: 8 exercises, 2 sets of 10-12 repetitions, using body weight and elastic bands Coll-down: 5 min of whole-body stretching exercises, holding the point of feeling lightness discomfort for 15 seconds.~Patients will be continuously monitored by an oximeter and modified Borg scale."
214459580|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
214459581|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
214459582|NCT03032107|DRUG|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
214530039|NCT04420741|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
214530040|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
214530041|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
214695343|NCT00871377|DRUG|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
215146397|NCT00899132|OTHER|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
215146398|NCT06987136|OTHER|Transversus thoracic muscle plane block|Patients will receive a transversus thoracic muscle plane block.
215146399|NCT06987136|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
215146400|NCT06987136|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block.
215146401|NCT06597578|DEVICE|Extraction tools|The effect of different extraction tools on outcome parameters will be evaluated
215146402|NCT06595745|GENETIC|Wolbachia induced incompatible mating|The intervention will be performed by weekly release of male Aedes aegypti carrying Wolbachia (wAlbB strain) to mate with wild females, resulting in the death of their eggs for birth control. Before release, these males will be irradiated with X-rays to minimize the chance of any residual fertile female releases. The intervention will lead to Ae. aegypti population suppression or even elimination and preventing dengue transmission in release sites.
215146403|NCT06595745|COMBINATION_PRODUCT|Standard traditional chemical mosquito control|Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population
215146404|NCT06601153|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to characterize coronary atherosclerosis
215146405|NCT02446574|DRUG|Paclitaxel|starting dose 20mg/m2 qw
215146406|NCT02446574|DRUG|Cisplatin|dose 25mg/m2 qw
215146407|NCT02446574|RADIATION|Radiation|60Gy/2Gy/30f
215146408|NCT02331212|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215146409|NCT02331212|OTHER|Laboratory Biomarker Analysis|Correlative studies
215146410|NCT01209416|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
215146411|NCT01209416|DRUG|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
215146412|NCT01209416|OTHER|Placebo|placebo tablets or saline infusion
215146413|NCT03666663|DRUG|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
215146414|NCT03666663|DRUG|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
215146415|NCT03666663|DRUG|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
215146416|NCT03666663|DRUG|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
215146417|NCT01484119|DRUG|ACT-129968|daily tablets
215146418|NCT01484119|DRUG|Placebo|matching placebo tablets and capsules
215146419|NCT01484119|DRUG|Cetirizine|daily capsules
215146420|NCT05647148|BEHAVIORAL|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
214459583|NCT03032107|DRUG|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
214459584|NCT02728284|PROCEDURE|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
214459585|NCT02728284|PROCEDURE|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
214459586|NCT05396586|BEHAVIORAL|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
214459587|NCT05396586|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
214459588|NCT05396586|BEHAVIORAL|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
214459589|NCT02907554|DRUG|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
214459590|NCT02907554|DRUG|Placebo|control group receives a placebo
214459591|NCT03940690|DRUG|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
214459592|NCT03940690|DEVICE|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
214459593|NCT05758376|BEHAVIORAL|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
214459594|NCT06499896|BIOLOGICAL|MTP-101-C|MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
214459595|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
214459596|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
214459597|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
214459598|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
214530042|NCT01065207|BIOLOGICAL|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
214530043|NCT00946634|DRUG|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
214530044|NCT00946634|DRUG|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
214530045|NCT00946634|DRUG|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
214530046|NCT02674009|DRUG|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
214530047|NCT00062686|DRUG|GW572016|
214530048|NCT03328845|DRUG|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
214459599|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
214459600|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
214459601|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
214459602|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
214459603|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
214530049|NCT03328845|DRUG|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
214530050|NCT03328845|DRUG|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
214530051|NCT03328845|DRUG|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
214530052|NCT03328845|DRUG|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
214530053|NCT02080390|PROCEDURE|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
214530054|NCT05846438|OTHER|Showering 48 hours after surgery|The main intervention is allowing patients to shower 48 hours after surgery
214530055|NCT03879083|OTHER|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
214530056|NCT03879083|OTHER|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
215146421|NCT00420771|DRUG|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
215146422|NCT00420771|DRUG|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
215146423|NCT02823067|OTHER|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
215146424|NCT04271397|OTHER|Multiple blood samples|Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
215146425|NCT04271397|OTHER|Single blood sample|Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
215146426|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 1g|Ginseng extract 1g, parallel design
215146427|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 3g|Ginseng extract 3g, parallel design
215146428|NCT02763280|DIETARY_SUPPLEMENT|Placebo|placebo, parallel design
215146429|NCT02696967|DRUG|CLR325|CLR325 Concentrate for solution for infusion
215146430|NCT02696967|OTHER|Placebo|Normal saline
214530057|NCT04482270|DRUG|fezolinetant|Oral
214530058|NCT02982070|BEHAVIORAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
214530059|NCT05698511|DRUG|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
214530060|NCT00255515|DRUG|Quetiapine fumarate|oral
214530061|NCT00255515|DRUG|conventional treatment for schizophrenia|various standard therapies
214530062|NCT05999513|DRUG|casdatifan|Administered as specified in the treatment arm
214530063|NCT00692523|OTHER|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
214530064|NCT00692523|OTHER|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
214530065|NCT00076063|BIOLOGICAL|ALVAC-HIV (vCP1452)|experimental vaccine
214530066|NCT00076063|BIOLOGICAL|LIPO-5|experimental vaccine
214530067|NCT01631825|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
214530068|NCT02982096|DEVICE|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
214530069|NCT02982096|OTHER|Standard of Care|Acellular burn wound management
214530070|NCT06143488|PROCEDURE|Endovascular therapy|"Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
214530071|NCT06143488|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
214530072|NCT02499835|BIOLOGICAL|Pembrolizumab|Given IV
215146431|NCT04289935|PROCEDURE|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
215146432|NCT06598085|DEVICE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
215146433|NCT04411498|DIAGNOSTIC_TEST|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
215146434|NCT04165317|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
215146435|NCT04165317|DRUG|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
214459604|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
214459605|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
214459606|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
214459607|NCT06036849|PROCEDURE|Spinal manipulation|The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
214459608|NCT06036849|PROCEDURE|Spinal mobilization|The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
214459609|NCT04844073|DRUG|TAK-186|TAK-186 IV infusion.
214459610|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
214459611|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
214459612|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
214459613|NCT05823116|DRUG|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
214459614|NCT05823116|DRUG|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
214459615|NCT04844463|DRUG|JNJ-68179280|JNJ-68179280 will be administered as an oral capsule.
214459616|NCT04844463|OTHER|Placebo|Matching placebo will be administered as an oral capsule.
214459617|NCT05696132|DRUG|Betadine|Nasal decolonization with betadine gel
215146436|NCT02242526|DEVICE|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
215146437|NCT02242526|DEVICE|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
215146438|NCT01803607|DRUG|odanacatib|odanacatib 50 mg oral tablet
215146439|NCT01803607|OTHER|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
215146440|NCT03077412|DRUG|Filgotinib|Tablet(s) administered orally once daily
215146441|NCT03077412|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
215146442|NCT00112996|DRUG|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
215146443|NCT00112996|OTHER|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
215146444|NCT04469907|DRUG|AZD9977|Participants will receive a single oral dose of AZD9977 under fasted conditions.
214459618|NCT04561947|PROCEDURE|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
214459619|NCT04561947|PROCEDURE|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
214459620|NCT04561947|OTHER|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
214530073|NCT02499835|BIOLOGICAL|pTVG-HP Plasmid DNA Vaccine|Given ID
214695344|NCT00871377|DRUG|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
214695345|NCT00165061|PROCEDURE|Esophagectomy|
215146445|NCT03586492|DIAGNOSTIC_TEST|CZT SPECT acquisition|CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
215146446|NCT03478098|OTHER|Low GI mealtest|Meal with low glycaemic index (GI) is consumed over 20 min
215146447|NCT03478098|OTHER|Low GI mealtest and subsequent exercise|Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
215146448|NCT03478098|OTHER|High GI mealtest|Meal with high glycaemic index (GI) is consumed over 20 min
215146449|NCT03478098|OTHER|High GI mealtest and subsequent exercise|Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
214459621|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
214459623|NCT04923984|PROCEDURE|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
214459624|NCT06519877|DIETARY_SUPPLEMENT|Soluble corn fiber|Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
214459625|NCT06419075|DRUG|Tranexamic acid|The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
214459626|NCT06419075|DRUG|Vasopressin|The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
214459627|NCT06419075|OTHER|NaCl 0.9%|The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
214459628|NCT03070106|DIETARY_SUPPLEMENT|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
214459629|NCT05622006|BEHAVIORAL|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
214459630|NCT04187833|DRUG|Nivolumab|480mg intravenously every 4 weeks (28 days)
214459631|NCT04187833|DRUG|Talazoparib|1mg orally daily
214459632|NCT05030675|DRUG|Fostamatinib|Given PO
214459633|NCT04448301|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
214459634|NCT04605081|DRUG|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
214459635|NCT04605081|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
214459636|NCT02962557|DEVICE|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
214459637|NCT02674100|OTHER|Registry|
214459638|NCT03097549|DEVICE|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
215146450|NCT06233136|DEVICE|Leg pedalling exercise|Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
215146451|NCT06233136|OTHER|The designed physical therapy program|"It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises"
215146452|NCT04114318|OTHER|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
215146453|NCT02532881|OTHER|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
215146454|NCT02532881|OTHER|Treatment as usual|Treatment as usual
215146455|NCT03824769|BEHAVIORAL|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
215146456|NCT03824769|BEHAVIORAL|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
215146457|NCT04266145|DRUG|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
215146458|NCT04266145|DRUG|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
215146459|NCT05410210|OTHER|Pharmaceutical care|The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
215146460|NCT05087004|BEHAVIORAL|Teen Council|Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
215146461|NCT04688008|DRUG|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
215146462|NCT02266888|BIOLOGICAL|Rituximab (Rituxan®)|2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
215146463|NCT02266888|BIOLOGICAL|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
215146464|NCT02131506|DRUG|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
215146465|NCT02351856|DRUG|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
214459639|NCT03097549|DEVICE|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
214459640|NCT02547233|DRUG|LEO 43204 gel|
214459641|NCT02547233|DRUG|Vehicle gel|
214459642|NCT06530355|OTHER|The same evaluation methods were used for both groups. No intervention was applied to individuals in two groups..|No intervention was applied to individuals in this group.
214459643|NCT04008355|DRUG|AZP2006 oral solution|Once daily intake in the morning
214459644|NCT04008355|DRUG|Placebo oral solution|Once daily intake in the morning
214459645|NCT02638116|DRUG|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
214459646|NCT02638116|DRUG|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
214530074|NCT04481334|OTHER|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
214530075|NCT03362684|DRUG|Cetuximab|Cetuximab every 2 weeks
214459647|NCT05620433|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
214459648|NCT05620433|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
214530076|NCT03362684|DRUG|FOLFOX|FOLFOX-4 every 2 weeks
214530077|NCT03226353|DEVICE|somofilcon A|contact lens
214530078|NCT03226353|DEVICE|omafilcon A|contact lens
214530079|NCT01797822|DRUG|Dexamethasone|
214530080|NCT01797822|DRUG|Artificial tear|
214530081|NCT01367613|DRUG|SC Methylnaltrexone|
214530082|NCT02429232|DRUG|Pioglitazone|Pioglitazone 30mg/tablet once daily
214530083|NCT02429232|DRUG|Linagliptin|Linagliptin 5mg/tablet once daily
214695346|NCT00165061|PROCEDURE|Chemoradiation|
214459649|NCT02146378|DRUG|Vyndaqel|20mg/day
214459650|NCT03603600|DEVICE|enVista MX60E|enVista MX60E monofocal IOL
214459651|NCT03603600|DEVICE|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
214459652|NCT05373823|OTHER|MySmartSkin enhancement|Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
214459653|NCT05373823|OTHER|Educational webpage on Skin Self-Examination|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
214459654|NCT05373823|OTHER|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
214459655|NCT03490201|DEVICE|Market Approved RF Ablation System|Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
214459656|NCT03490201|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment using an ablation system that is not FDA approved.
214459657|NCT06488508|BEHAVIORAL|MoveEarly|"The intervention has two levels: the kindergarten level and the child level.~1. Staff will receive approximately 60 hours of professional development, including 6 full-day physical seminars, 2 full-day kindergarten visits, 6 written tasks with follow-up webinars and an online resource. The focus will be how to promote movement, play and exploration among children aged 1-6 years.~2. Staff is supposed to promote children's movement, play and exploration through 7 pedagogical principles: 1. Value, understand and promote movement, 2. Value, understand and promote play, 3. Value, understand and promote exploration, 4. Create rich physical environments, 5. Create opportunities for meaningful participation, 6. Create good balance between challenge and support, and 7. Create good dialogue through action and words."
214459658|NCT05028972|OTHER|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
214459659|NCT05028972|OTHER|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
214459660|NCT01497184|PROCEDURE|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
214459661|NCT01497184|GENETIC|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
214459662|NCT05967364|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
214459663|NCT05967364|BEHAVIORAL|Stress Management|Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
214459664|NCT05170009|DRUG|Baloxavir Marboxil|Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
214459665|NCT05170009|DRUG|Placebo|Placebo at baseline, day 4, and day 7.
214459666|NCT05170009|DRUG|Oseltamivir|Oseltamivir 75 mg twice daily for 10 days.
214459667|NCT00243464|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
214459668|NCT05457465|DRUG|Cannabidiol|Custom formulation of a hemp-derived, high-CBD product that contains no THC.
214459669|NCT05285683|DRUG|Methylphenidate|0.5 mg/kg
214459670|NCT05285683|DRUG|carbidopa-levodopa|25 mg/100 mg
214459671|NCT05285683|DRUG|Placebo|oral pill
214459672|NCT04304625|DRUG|Tranexamic Acid / Sodium chloride|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
214459673|NCT01836497|DEVICE|SD01 ICD lead|
214459674|NCT03807310|DIETARY_SUPPLEMENT|Targeted nutrient supplementation (Long-drink)|Once daily for at least 12 months
214459675|NCT03807310|DIETARY_SUPPLEMENT|Placebo supplement|Once daily for at least 12 months
214459676|NCT03807310|BEHAVIORAL|Counselling|Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
214459677|NCT04023110|DRUG|Carvedilol|Individually dosed carvedilol
214530084|NCT05221216|OTHER|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
214530085|NCT03138616|DRUG|vitamin D|take 1600 units of vitamin D daily for nine months
214530086|NCT03139383|OTHER|dextrose solution|The patients received 5%D/N/2 during surgery
214530087|NCT03139383|OTHER|saline solution|The patients received NSS during surgery
214530088|NCT02821689|DRUG|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
214530089|NCT04244708|DRUG|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
214530090|NCT04244708|OTHER|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
214530091|NCT00220116|DRUG|Capecitabine, Oxaliplatin|
214530092|NCT03459521|BIOLOGICAL|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
214530093|NCT04086719|DRUG|BMS-986165|Oral administration of tablet BMS- 986165
214530094|NCT04086719|DRUG|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
214530095|NCT02814097|DRUG|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
214530096|NCT02814097|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
214459678|NCT06156592|PROCEDURE|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
214459679|NCT04838288|DRUG|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
214459680|NCT03524612|DRUG|eltrombopag|12.5, 25, 50 and 75 mg tablets for oral use once daily
214459681|NCT04612699|DRUG|Jaktinib|Administered orally
214459682|NCT04612699|DRUG|Placebo|Administered orally
214459683|NCT05919290|OTHER|MRI|Non-invasive imaging technique that is used to take pictures of organs within the body.
214459684|NCT04470453|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
214459685|NCT04470453|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
214459686|NCT06047353|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
214459687|NCT06047353|DEVICE|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
214459688|NCT04404088|DRUG|Acalabrutinib|Given PO
214459689|NCT04404088|DRUG|Lenalidomide|Given PO
214459690|NCT04404088|BIOLOGICAL|Rituximab|Given IV
214459691|NCT06628557|OTHER|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients
214459692|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
214459693|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
214459694|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
214459695|NCT06381258|PROCEDURE|Ultrasound|Fetal echocardiography using ultrasound device
214530097|NCT04077775|DIAGNOSTIC_TEST|assesment|assesment
214530098|NCT00498433|DRUG|Aliskiren|300 mg tablet once daily
214530099|NCT00498433|DRUG|Amlodipine|5 mg capsule once daily
214530100|NCT00498433|DRUG|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
214530101|NCT00498433|DRUG|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
214530102|NCT04491006|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
214459696|NCT05933135|DRUG|Factor XIII Injection|Patients could have had an Factor XIII Injection in clinical routine
214530103|NCT04491006|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
214530104|NCT00295048|BEHAVIORAL|Computer Assisted Cognitive Remediation (CACR)|
215146466|NCT01550224|DRUG|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
214530105|NCT04318587|DIAGNOSTIC_TEST|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
214530106|NCT00215631|DRUG|tadalafil|
214530107|NCT01639014|DRUG|F2695|75 mg OD in 2 capsules
214459697|NCT05457647|DEVICE|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure is performed using the C4V CHROMO4VIS™ medical device equipped with theranostic software module in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop is done for 15 minutes for the epi-off CXL treatment and 20 minutes for the epi-on CXL treatment. Estimates of riboflavin concentration into the cornea are monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the pre-set dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A light irradiation of the cornea with 5.4 J/cm2 total energy dose (10 mW/cm2 for 9 min.) and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score are performed by the C4V CHROMO4VIS™ system during UV-A light irradiation.
214530108|NCT01639014|DRUG|placebo|2 capsules
214530109|NCT04297839|DRUG|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
214530110|NCT04297839|DRUG|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
215146467|NCT01550224|DRUG|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
215146468|NCT04512157|BEHAVIORAL|Promoting Alternative Thinking Strategies (PATHS), Preschool Edition|PATHS® is a universal teacher implemented, and school-based intervention that aims to give preschool children a strategically timed boost in social emotional competence. Specifically, PATHS® encourages the use of interactive techniques to bolster children's ability to self-regulate, increase their adeptness at social cognitive problem solving, as well as to gain insight into their emotions and emotions of others.
215146469|NCT04269668|DEVICE|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
215146470|NCT04269668|DEVICE|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
214530111|NCT00744796|PROCEDURE|DSAEK|Endothelial Keratoplasty
214530112|NCT00744796|DIAGNOSTIC_TEST|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
214530113|NCT00744796|DIAGNOSTIC_TEST|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
214530114|NCT02536547|DEVICE|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
215146471|NCT02202200|DRUG|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
215146472|NCT04664452|OTHER|Questionnaire|Participants will be asked to fill the questionnaire
215146473|NCT01281124|DRUG|Azacitidine|Given subcutaneously
215146474|NCT01281124|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
215146475|NCT01281124|OTHER|Pharmacological Study|Correlative studies
215146476|NCT03038100|DRUG|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
215146477|NCT03038100|DRUG|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
215146478|NCT03038100|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
215146479|NCT03038100|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
215146480|NCT03038100|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
214530115|NCT03696732|OTHER|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
214530116|NCT03696732|OTHER|VAS questionnaire|verbal numerical scale (VNS) anxiety score
215146481|NCT01697670|DRUG|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
215146482|NCT00013221|BEHAVIORAL|Exercise|
215146483|NCT03484208|OTHER|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
215146484|NCT00404144|DEVICE|Drug Eluting Balloon|PCI of small vessels single arm study
215146485|NCT05760040|OTHER|vırtual reality|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
215146486|NCT05760040|OTHER|Control Group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
215146487|NCT02651207|OTHER|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
214530117|NCT03192202|DRUG|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
214530118|NCT00994396|DIETARY_SUPPLEMENT|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
214530119|NCT00994396|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
214530120|NCT02581189|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
214530121|NCT02581189|DRUG|Dasabuvir|Tablet
214530122|NCT02581189|DRUG|Ribavirin|Tablet
214530123|NCT01641289|DRUG|Paracetamol|\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
214530124|NCT01641289|DRUG|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
214530125|NCT02117856|PROCEDURE|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
214530126|NCT02117856|PROCEDURE|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
214530127|NCT02117856|PROCEDURE|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
214530128|NCT02117856|DEVICE|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
214530129|NCT02117856|DEVICE|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
214530130|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
214530131|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
214530132|NCT03744741|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
214530133|NCT01444547|DRUG|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
214530134|NCT02543697|RADIATION|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
214530135|NCT00004740|DRUG|isoniazid|
214530136|NCT00425906|DRUG|nicotine|
214530137|NCT00425906|OTHER|Placebo|
214530138|NCT00425906|PROCEDURE|Quality of life|
214530139|NCT03470103|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
215146488|NCT06331936|BEHAVIORAL|Emotion regulation|Each participant will attend four intervention sessions. They will also be invited to a booster Session, where they will be invited for interviews to share what they have gained from the sessions. The contents of the intervention and the booster session are as follows: (1) understand emotions, (2) attention and positivity, (3) emotional regulation, (4) connectedness and intimacy, and (5) review and sharing.
215146489|NCT03109964|DEVICE|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
215146490|NCT03109964|DEVICE|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
215146491|NCT01744262|DRUG|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
215146492|NCT01744262|DRUG|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
215146493|NCT02739906|DRUG|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
215146494|NCT02739906|DRUG|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
215146495|NCT02739906|DRUG|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
214530140|NCT04092621|DRUG|Amiodarone in Parenteral Dosage Form|Amiodarone IV
214530141|NCT04092621|DRUG|Amiodarone Pill|Amiodarone tablet
214530142|NCT04092621|PROCEDURE|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
214530143|NCT04092621|DRUG|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
215146496|NCT04899596|OTHER|No intervention|No intervention
215146497|NCT01113086|DEVICE|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
215146498|NCT00918255|BIOLOGICAL|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
214530144|NCT04024371|BEHAVIORAL|Self-rating Questionnaires|"* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)"
214530145|NCT04024371|BEHAVIORAL|Measures of Reward processing/reinforcement learning|"* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
214530146|NCT04024371|BEHAVIORAL|Additional Schizophrenia-specific Questionnaires and Interviews|"* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
214530147|NCT03342170|GENETIC|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
214530148|NCT04498871|DRUG|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
214530149|NCT01514864|DRUG|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
214530150|NCT05913583|DRUG|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
214530151|NCT03402321|DRUG|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
214530152|NCT03402321|DRUG|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
214530153|NCT04361916|OTHER|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
214530154|NCT03845335|DEVICE|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
215146499|NCT00918255|DRUG|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
215146500|NCT04381754|DEVICE|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
215146501|NCT01683357|PROCEDURE|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
215146502|NCT00478543|DRUG|Furosemide|
215146503|NCT02392624|DRUG|Omalizumab|Omalizumab 300 mg administered SC Q4W.
215146504|NCT02392624|DRUG|Placebo|Placebo matched to omalizumab administered SC Q4W.
215146505|NCT04199806|OTHER|Questionnaire review|Review data from questionnaires received about MMS experience.
215146506|NCT00706238|BIOLOGICAL|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
215146507|NCT05995106|OTHER|Heart4U|Mobile app.
215146508|NCT04557891|DEVICE|Active LIFUP Treatment|8 LIFUP Treatments
215146509|NCT04557891|DEVICE|Sham LIFUP Treatment|8 sham LIFUP treatments
215146510|NCT02518438|DRUG|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
214530155|NCT00271466|DRUG|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
214530156|NCT02399683|BIOLOGICAL|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
215146511|NCT03898739|OTHER|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
215146512|NCT03833505|OTHER|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
215146513|NCT05976412|RADIATION|Regional lymph node radiotherapy|Regional lymph node radiotherapy
214459698|NCT02679352|DEVICE|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
214459699|NCT05266495|OTHER|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
214459700|NCT05066412|OTHER|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
214459701|NCT02124239|DRUG|Ingenol mebutate|
214459702|NCT06283498|DEVICE|Device Morpheus8V|Assigned to be treated using the modified Morpheus8V
214459703|NCT06129019|BEHAVIORAL|Reiki|Reiki application will be done
214459704|NCT06122142|DEVICE|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
214459705|NCT06122142|DEVICE|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
214459706|NCT06122142|DEVICE|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
214459707|NCT02535338|DRUG|Erlotinib Hydrochloride|Given PO
214459708|NCT02535338|OTHER|Laboratory Biomarker Analysis|Correlative studies
214459709|NCT02535338|DRUG|Onalespib Lactate|Given IV
214459710|NCT02535338|OTHER|Pharmacological Study|Correlative studies
214459711|NCT04454788|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
214459712|NCT04454788|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
214459713|NCT04137289|DRUG|BI 905711|BI 905711
214459714|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
214459715|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
214459716|NCT04696042|DRUG|Lanreotide autogel|Lanreotide autogel 90-120 mcg, every 4 weeks
214459717|NCT06306586|BEHAVIORAL|Digital Treatment for Adolescents With Eating Disorders|"The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media."
214459718|NCT05329090|DRUG|Rituximab Injection|anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
214459719|NCT05329090|DRUG|placebo|placebo experimental treatment
214459720|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
214459721|NCT04793737|RADIATION|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
214459722|NCT06199453|DRUG|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
214459723|NCT03815825|DRUG|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
214459724|NCT03815825|DRUG|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
214459725|NCT03991130|DRUG|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
214530157|NCT02253147|DEVICE|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
214530158|NCT02223871|DRUG|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
214530159|NCT02223871|OTHER|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
215146514|NCT05976412|RADIATION|chest/whole breast irradiation|chest/whole breast irradiation
215146515|NCT05072600|DRUG|Pembrolizumab|pembrolizumab 200 mg Q3W
215146516|NCT04969302|DIAGNOSTIC_TEST|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
215146517|NCT01698333|DRUG|122-0551|Applied twice daily for 2 weeks
214530160|NCT02223871|DRUG|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
214530161|NCT02223871|DRUG|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
214530162|NCT00004016|BIOLOGICAL|recombinant interferon gamma|
214530163|NCT00478322|DRUG|Placebo|Matching placebo of 100 mg BID
214530164|NCT00478322|DRUG|INCB013739|INCB013739 100 mg BID
214530165|NCT03487341|OTHER|Cord drainage|Cord drainage
214530166|NCT03487341|OTHER|Cord clamping|Cord clamping
214530167|NCT04836338|DEVICE|orotracheal intubation|orotracheal intubation
214530168|NCT01615107|DEVICE|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
214530169|NCT01615107|DRUG|PITOCIN|: Oxytocin infusion alone (Standard Protocol
214530170|NCT01615107|OTHER|double balloonand oxytocin|balloonand oxytocin
214530171|NCT01615107|OTHER|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
214530172|NCT01615107|PROCEDURE|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
214530173|NCT03965247|DRUG|Lithium|
214530174|NCT03965247|OTHER|Placebo - Rayotabs|
214568544|NCT05315739|DEVICE|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
214568545|NCT05315739|DEVICE|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
214568546|NCT02003222|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
214568547|NCT02003222|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214568548|NCT02003222|BIOLOGICAL|Blinatumomab|Given IV
214568549|NCT02003222|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214568550|NCT02003222|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214568551|NCT02003222|DRUG|Cyclophosphamide|Given IV
214568552|NCT02003222|DRUG|Cytarabine|Given IT, IV, or SC
214568553|NCT02003222|DRUG|Daunorubicin|Given IV
214568554|NCT02003222|DRUG|Daunorubicin Hydrochloride|Given IV
214568555|NCT02003222|DRUG|Dexamethasone|Given PO
214568556|NCT02003222|DRUG|Etoposide|Given IV
214568557|NCT02003222|DRUG|Leucovorin Calcium|Given IV or PO
214568558|NCT02003222|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214568559|NCT02003222|DRUG|Mercaptopurine|Given PO
214568560|NCT02003222|DRUG|Methotrexate|Given PO, IT or IV
214568561|NCT02003222|DRUG|Pegaspargase|Given IM or IV
214568562|NCT02003222|DRUG|Prednisone|Given PO
214568563|NCT02003222|BIOLOGICAL|Rituximab|Given IV
214568564|NCT02003222|DRUG|Vincristine|Given IV
214568565|NCT02003222|DRUG|Vincristine Sulfate|Given IV
214568566|NCT02003222|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214459726|NCT04492722|DRUG|AZD5718|Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
214459727|NCT04492722|DRUG|Dapagliflozin 10 mg|Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
214459728|NCT04492722|DRUG|Placebo|Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
214459729|NCT06324318|BEHAVIORAL|Parenting in 2 Worlds (P2W)|P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
214459730|NCT06324318|BEHAVIORAL|Healthy Families in 2 Worlds (HF2W)|HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
214459731|NCT05415904|OTHER|HANTA-NE|Observational cohort study
214695347|NCT03698188|PROCEDURE|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
214695348|NCT03698188|PROCEDURE|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
214695349|NCT04428658|BEHAVIORAL|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
215146518|NCT00874094|BIOLOGICAL|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
215146519|NCT00309374|DRUG|LPS 2ng/kg intravenous bolus|
215146520|NCT00309374|DRUG|Simvastatin 80mg; administered daily p.o. over 5 days|
215146521|NCT00309374|DRUG|Rosuvastatin 40mg; administered daily p.o. over 5 days|
215146522|NCT04291898|DEVICE|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
215146523|NCT04291898|DEVICE|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
215146524|NCT04291898|DEVICE|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
215146525|NCT05779540|DEVICE|Safeback SBX|The intervention consists in the test of the active device.
215146526|NCT05779540|DEVICE|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
215146527|NCT04168918|BEHAVIORAL|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
215146528|NCT04244292|OTHER|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
215146529|NCT00555698|DEVICE|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
215146530|NCT01263847|DIETARY_SUPPLEMENT|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
215146531|NCT01849991|BIOLOGICAL|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
214459732|NCT05329220|BIOLOGICAL|ABNCoV2|ABNCoV2 100μg single dose
214459733|NCT05329220|BIOLOGICAL|Comirnaty|Comirnaty
214459734|NCT03848689|OTHER|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
214459735|NCT03848689|OTHER|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
214459736|NCT06251180|DRUG|Rocbrutinib|orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
214459737|NCT06251180|BIOLOGICAL|Rituximab|375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
214459738|NCT06251180|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
214459739|NCT06251180|DRUG|doxorubicin|50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
214459740|NCT06251180|DRUG|Vincristin|1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
214459741|NCT06251180|DRUG|Prednisone|100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
214459742|NCT05687084|DEVICE|Uterine manipulator use|The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
214695350|NCT04428658|BEHAVIORAL|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
214530175|NCT03256370|PROCEDURE|milk collection|"* Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
214530176|NCT01873573|PROCEDURE|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
214530177|NCT01873573|OTHER|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
214530178|NCT01873573|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
214530179|NCT03348969|DRUG|Mitomycin c|Neoadjuvant Mitomycin C
214530180|NCT00470171|DRUG|Ursodesoxycholic acid|
214530181|NCT05065164|DRUG|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
214530182|NCT00131183|DRUG|Nebido|
214530183|NCT00371618|PROCEDURE|Fluoroscopy|
214530184|NCT04066400|OTHER|Nutritional Intervention|Dietary Counselling
214530185|NCT02054598|BEHAVIORAL|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
214530186|NCT00978497|DRUG|placebo|oral BID
215146532|NCT01849991|BIOLOGICAL|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
214530187|NCT00978497|DRUG|ANA598|oral 200mg BID
214530188|NCT00978497|DRUG|ANA598|oral 400mg BID
215146533|NCT02341677|PROCEDURE|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
214530189|NCT00978497|DRUG|Peginterferon|180 μg dose via subcutaneous injection weekly
214530190|NCT00978497|DRUG|Ribavirin|oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
214530191|NCT05915832|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
214530192|NCT05915832|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214530193|NCT02254681|DRUG|Gemcitabine|
214530194|NCT02254681|DRUG|Cisplatin|
214530195|NCT02254681|RADIATION|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
214530196|NCT01181583|BEHAVIORAL|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
214695351|NCT04428658|BEHAVIORAL|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
215146534|NCT01193244|DRUG|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
215146535|NCT01193244|DRUG|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
215146536|NCT01193244|DRUG|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
215146537|NCT04731545|DEVICE|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
215146538|NCT01129856|DRUG|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
215146539|NCT01129856|DRUG|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
215146540|NCT02909400|DRUG|KH176|
215146541|NCT02909400|DRUG|placebo|
215146542|NCT02678026|DEVICE|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
215146543|NCT00689507|BIOLOGICAL|LY2127399|monoclonal antibody
214530197|NCT01181583|BEHAVIORAL|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
214530198|NCT01181583|BEHAVIORAL|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
214530199|NCT02611375|OTHER|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
214530200|NCT02611375|OTHER|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
214530201|NCT02611375|OTHER|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
214530202|NCT04316221|DIETARY_SUPPLEMENT|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
214530203|NCT04316221|OTHER|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
214530204|NCT00207233|BEHAVIORAL|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
214530205|NCT00207233|BEHAVIORAL|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
214530206|NCT00207233|PROCEDURE|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
214530207|NCT00465907|DRUG|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
214530208|NCT02604485|DRUG|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
214530209|NCT02604485|DRUG|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
214530210|NCT02604485|DRUG|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
214530211|NCT02604485|DRUG|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
214530212|NCT05845840|DRUG|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
214530213|NCT05845840|DRUG|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
214530214|NCT00797511|BIOLOGICAL|TdcP-IPV vaccine|0.5 mL, Intramuscular
215146544|NCT02263027|BIOLOGICAL|Vaccine|Licensed trivalent inactivated influenza vaccine
215146545|NCT05324059|DRUG|Pregabalin 75mg/ Tramadol 50 mg|Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
215146546|NCT05324059|DRUG|Pregabalin 75mg|Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
215146547|NCT04605172|OTHER|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
215146548|NCT00384670|BIOLOGICAL|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
215146549|NCT00384670|BIOLOGICAL|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
215146550|NCT05442788|BIOLOGICAL|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
215146551|NCT05442788|BIOLOGICAL|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
215146552|NCT05442788|BIOLOGICAL|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
214530215|NCT01700114|DEVICE|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
214530216|NCT02880332|OTHER|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
214459743|NCT06312436|PROCEDURE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
214459744|NCT02601313|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
214459745|NCT02601313|DRUG|Cyclophosphamide|Administered intravenously
214459746|NCT02601313|DRUG|Fludarabine|Administered intravenously
214459747|NCT02601313|DRUG|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
214459748|NCT04410341|DRUG|Vildagliptin 50 MG|Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.
214459749|NCT04410341|DRUG|Escitalopram 20 mg|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
214459750|NCT04989686|OTHER|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
214459751|NCT06405607|DRUG|Psilocybin|30 mg single dose
214459752|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
214459753|NCT04511845|DRUG|SPYK04|SPYK04 capsule
214459754|NCT06130501|DEVICE|Sparrow Ascent tAN|The Sparrow Ascent device from Spark Biomedical (Dallas, TX), applies stimulation frequencies of 15 Hz at the cymba concha (vagal innervation) and 100 Hz anterior to the tragus (trigeminal innervation). Both tAN and active sham conditions have square biphasic waveforms with identical pulse widths of 250 µs separated by a 125 µs interval between pulses. Stimulation is applied using a duty cycle of 5-minutes ON and 10 seconds OFF. The stimulation intensities (mA) will be programmed for each individual based on the highest amplitude for each channel that is both comfortable and perceptible. Patients using the device may alter the intensity of stimulation at these sites using the Patient Controller to achieve the desired effect.
214459755|NCT06130501|DEVICE|Sparrow Ascent Active Sham|The Sparrow Ascent Active Sham is a modified version of the Sparrow Ascent tAN System that has been designed to provide sub-therapeutic stimulation to the trigeminal nerve only and no stimulation to the vagus nerve. The trigeminal nerve will receive 1 Hz stimulation at the temporomandibular region at an amplitude that is comfortable and perceptual. The pulse duration will be set to a value that does not exceed 250 μs in a square biphasic waveform. The patient controller device for the active sham will give the appearance that stimulation is being applied at both vagal and trigeminal electrode sites.
214459756|NCT03766009|OTHER|Usual Care|Usual Care
214459757|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
214459758|NCT04552223|DRUG|Nivolumab|Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
214459759|NCT04552223|DRUG|Relatlimab|Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
214459760|NCT00169806|OTHER|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
214459761|NCT04790396|DEVICE|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
214459762|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
214459763|NCT03869866|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
214459764|NCT02013583|OTHER|No intervention|This is an observational registry. No interventions are required or provided.
214459765|NCT04682587|DRUG|Axitinib|Inlyta, axitinib
214459766|NCT04682587|DRUG|Avelumab|Avelumab, Bavencio
214459767|NCT04682587|DRUG|Pembrolizumab|Pembrolizumab, Keytruda
214459768|NCT06171828|DEVICE|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
214459769|NCT06116682|BIOLOGICAL|Amivantamab|Given amivantamab-SC
214459770|NCT06116682|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214459771|NCT06116682|PROCEDURE|Computed Tomography|Undergo CT scan
214459772|NCT06116682|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214459773|NCT00506519|DRUG|Antithrombin alfa (INN name)|
214459774|NCT00506519|DRUG|Control (Standard treatment)|
214459775|NCT04913012|COMBINATION_PRODUCT|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
214459776|NCT04913012|COMBINATION_PRODUCT|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
214459777|NCT04913012|COMBINATION_PRODUCT|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
214459778|NCT04913012|COMBINATION_PRODUCT|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
214459779|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
214459780|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
214459781|NCT01186367|BEHAVIORAL|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
214459782|NCT01186367|BEHAVIORAL|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
214459783|NCT01186367|BEHAVIORAL|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
214459784|NCT01186367|OTHER|Cardiopulmonary exercise test (CPET)|
214459785|NCT01186367|OTHER|Blood draws|Complete blood count
214459786|NCT06114108|OTHER|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
214459787|NCT06114108|OTHER|Surgery|Surgery
214459788|NCT06114108|RADIATION|Radiotherapy|Radiotherapy
214459789|NCT06403111|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment (lung adenocarcinoma) / albumin-bound paclitaxel + platinum-based treatment (lung squamous cell carcinoma) for 4-6 cycles. If there is no progression of the disease after 4-6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. Patients will receive tislelizumab maintenance treatment (lung squamous cell carcinoma), or tislelizumab + pemetrexed maintenance treatment (lung adenocarcinoma).
214459790|NCT06075368|DEVICE|GENOSS Sirolimus Eluting Coronary Stent System|The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.
214459791|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
214459792|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
214459793|NCT02975882|OTHER|Pharmacological Study|Correlative studies
214459794|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
214459795|NCT02975882|DRUG|Temozolomide|Given PO
214459796|NCT05419479|DRUG|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
214459797|NCT05419479|DRUG|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
214695352|NCT06240494|PROCEDURE|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
214530217|NCT02880332|OTHER|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
214530218|NCT02880332|OTHER|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
214530219|NCT00979329|OTHER|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
214530220|NCT02762539|DRUG|omega-3 enriched SMOF lipid emusion|
214530221|NCT03471897|DIAGNOSTIC_TEST|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
214530222|NCT00843115|OTHER|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
214695353|NCT04781569|OTHER|data collection|Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
214695354|NCT04781569|DIAGNOSTIC_TEST|blood draw|2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
214695355|NCT04781569|DIAGNOSTIC_TEST|nose swabs|2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
214695356|NCT04781569|DIAGNOSTIC_TEST|Intraoperative tissue samples|Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
214695357|NCT01590394|DEVICE|Large plastic biliary stent|Stent placement for bile duct obstruction.
214695358|NCT05828732|OTHER|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
215146553|NCT05791604|DIETARY_SUPPLEMENT|probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG|Take probiotics, 2g each time, twice a day, for 12 weeks
215146554|NCT05791604|DIETARY_SUPPLEMENT|Prebiotics with galactomannan and oligofructose|Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
215146555|NCT01173367|OTHER|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
215146556|NCT01173367|OTHER|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
215146557|NCT03839160|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
215146558|NCT03839160|DRUG|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
214695359|NCT01724112|DRUG|LY2940094|Administered orally
214695360|NCT01724112|DRUG|Placebo|Administered orally
214695361|NCT00658710|BEHAVIORAL|physical therapy sessions|two physical therapy sessions per week for two months
214695362|NCT04050813|BEHAVIORAL|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
214695363|NCT06365892|DRUG|open-label placebo|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
215146559|NCT00549835|PROCEDURE|Real Acupuncture|
215146560|NCT00549835|PROCEDURE|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
215146561|NCT03763877|DRUG|PXL770|Oral capsule
214459798|NCT05419479|DRUG|APX005M|Via IV on two days per cycle, dosage per protocol
214459799|NCT05419479|DRUG|FOLFIRI|every two weeks through an infusion at a dose determined by physician
214459800|NCT05264480|PROCEDURE|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
214459801|NCT05264480|PROCEDURE|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
214459802|NCT04563507|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
214459803|NCT04563507|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
214459804|NCT04563507|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
214459805|NCT06378138|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
214459806|NCT06378138|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
214459807|NCT06275724|OTHER|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
214459808|NCT05844436|DRUG|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
214459809|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily|(2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
214459810|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily|(2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
214459811|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
214459812|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
214459813|NCT02737436|DRUG|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
214459814|NCT02737436|DRUG|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
214459815|NCT02737436|PROCEDURE|Functional MRI scanning|All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
214459816|NCT06331182|DRUG|Ketamine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
214459817|NCT06331182|DRUG|Dexmedetomidine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
214459818|NCT06331182|DRUG|Bupivacaine|29 ml bupivacaine 0.25%
214459819|NCT05289414|DEVICE|Radiofrequency on mid cervical medial branches|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on mid cervical medial branches
214459820|NCT05289414|DEVICE|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on Greater occipital nerve
214459821|NCT05607732|DIAGNOSTIC_TEST|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
214459822|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
214459823|NCT06425068|DEVICE|Exposure of the patient to a novel air mattress.|"see information provided in the Arms section (experimental)"
214459824|NCT06425068|DEVICE|Exposure of the patient to a conventional foam mattress.|"see information provided in the Arms section (active comparator)"
214459825|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
214459826|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
214695364|NCT06365892|OTHER|Treatment as usual|Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
214695365|NCT05257577|PROCEDURE|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
215146562|NCT03763877|DRUG|Placebo Oral Capsule|Oral capsule
215146563|NCT03040336|BEHAVIORAL|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
215146564|NCT01982097|DRUG|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
215146565|NCT01686542|PROCEDURE|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
215146566|NCT01686542|PROCEDURE|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
215146567|NCT01601548|BEHAVIORAL|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
215146568|NCT01262196|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
215146569|NCT01262196|DRUG|Saline|Normal saline (0.9%) solution
215146570|NCT01735006|BIOLOGICAL|HPV Vaccine|3 doses at month 0,1 and 6
214459827|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
214459828|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
214459829|NCT06016920|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
214459830|NCT06016920|DRUG|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
214459831|NCT06800131|DEVICE|Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)|A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).
214459832|NCT06800131|BIOLOGICAL|Active comparator vaccine via intramuscular injection|10 subjects administered with active comparator vaccine via intramuscular injection.
214459833|NCT06795282|DRUG|MTA|MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.
214459834|NCT04674462|BIOLOGICAL|CpG-adjuvanted HBV Vaccine|Subjects receiving CpG-adjuvanted HBV vaccine will require two doses at 0 and 1 month after initiation. The second dose will be considered the same as the one month time point following the first dose.
214459835|NCT04674462|BIOLOGICAL|Traditional HBV Vaccine|Subjects receiving traditional HBV vaccine series will require three doses at 0, 1, and 6 months after initiation. The second dose will be considered the same as the one month time point following the first dose.
214695366|NCT00930605|DRUG|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
214695367|NCT00930605|DRUG|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
214459838|NCT05605587|DRUG|Leflunomide 20 mg|once daily for 6 months
214459839|NCT03984201|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
214459840|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
214459841|NCT02694809|DRUG|Conjugated Estrogens/Bazedoxifene|Given PO
214459842|NCT02694809|OTHER|Laboratory Biomarker Analysis|Correlative studies
214459843|NCT02694809|OTHER|Pharmacological Study|Correlative studies
214459844|NCT02694809|OTHER|Placebo|Given PO
214459845|NCT02694809|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214459846|NCT02694809|OTHER|Questionnaire Administration|Ancillary studies
214459847|NCT03085316|DEVICE|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
214459848|NCT06641895|GENETIC|BBM-D101|BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
214459849|NCT04205968|DRUG|Fluorouracil|Given IV bolus or IV
214459850|NCT04205968|DRUG|Irinotecan|Given IV
214459851|NCT04205968|DRUG|Irinotecan Hydrochloride|Given IV
214459852|NCT04205968|DRUG|Leucovorin|Given IV
214695368|NCT00810056|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
214695369|NCT00810056|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
215146571|NCT01735006|BIOLOGICAL|HEV vaccine|3 doses at month 0,1 and 6
215146572|NCT02026531|OTHER|3-Helium gas|3-Helium gas for MRI contrast
215146573|NCT03537404|DRUG|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
215146574|NCT03537404|DRUG|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
215146575|NCT03537404|DRUG|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
215146576|NCT03537404|DRUG|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
214695370|NCT03737604|DRUG|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
215146577|NCT03906448|COMBINATION_PRODUCT|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
214695371|NCT03737604|DRUG|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
214695372|NCT01536977|OTHER|quality-of-life assessment|Ancillary studies
215146578|NCT01765283|BIOLOGICAL|HepaStem|
214459853|NCT04205968|DRUG|Leucovorin Calcium|Given IV
214459854|NCT04205968|DRUG|Paclitaxel|Given IV
214459855|NCT04205968|BIOLOGICAL|Ramucirumab|Given IV
214459856|NCT06639724|COMBINATION_PRODUCT|Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)|Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
214459857|NCT06642649|PROCEDURE|General Anesthesia (control group)|Only General Anestesia
214459858|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and no fentanyl)|General anesthesia + spinal anesthesia with local anesthetic and morfine
214459859|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and 20 mcg fentanyl)|General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
214459860|NCT06220019|DRUG|TCM|We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
214459861|NCT02105766|DRUG|Alemtuzumab|Immunosuppressant
214459862|NCT02105766|DRUG|Sirolimus|Immunosuppressant
214459863|NCT02105766|DRUG|Cyclophosphamide|Immunosuppressant
214459864|NCT02105766|DRUG|Pentostatin|Immunosuppressant
214459865|NCT02105766|PROCEDURE|Radiotherapy|Immunosuppressant and myelosuppressant
214459866|NCT02105766|DRUG|Filgrastim|mobilize peripheral blood stem cells for apheresis collection
214459867|NCT06257485|DIAGNOSTIC_TEST|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
214459868|NCT06568367|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
214459869|NCT06568367|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
214459870|NCT06568367|DRUG|Placebo|Placebo tablets, taken once daily
214459871|NCT03701399|DRUG|troriluzole|Administered orally
214459872|NCT03701399|DRUG|Placebo|Administered orally
214459873|NCT06644157|DEVICE|Laser Néo Élite|One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
214459874|NCT06643676|PROCEDURE|Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data|Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment
214459875|NCT06643676|PROCEDURE|Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis|A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
214459876|NCT06216483|OTHER|PDM Alert|passive digital marker (PDM) for postoperative delirium risk
214695373|NCT01536977|OTHER|questionnaire administration|Ancillary studies
214695374|NCT01536977|BEHAVIORAL|management of therapy complications|Undergo BBT-I
214695375|NCT01536977|BEHAVIORAL|cognitive assessment|Ancillary studies
214695376|NCT01536977|BEHAVIORAL|educational intervention|Undergo BBT-I
214695377|NCT03474406|OTHER|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
214695378|NCT06444243|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.
215146579|NCT05028543|PROCEDURE|Conventional TLH|"Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached."
214459877|NCT05511909|DRUG|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
214459878|NCT05511909|DRUG|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
214459879|NCT05511909|DRUG|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
214459880|NCT06393998|DEVICE|Breathing with CO2 during daytime and night at high altitude|Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.
214459881|NCT06393998|DEVICE|Sleep and doing exercise test under inhalation of air|Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
214459882|NCT05829265|BEHAVIORAL|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
214459883|NCT05852184|OTHER|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
214459884|NCT06800417|DEVICE|Percutaneous fixation by internal cemented screw (InnoFix®)|Percutaneous fixation by internal cemented screw
214459885|NCT06801483|OTHER|Strengthening|All subjects will recieve an ankle muscle strenghening training program twice a week for six weeks.
214459886|NCT05191472|BIOLOGICAL|Pembrolizumab|Given IV
214459887|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
214459888|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
214459889|NCT02132936|DRUG|LEO 90100 aerosol foam|
214459890|NCT02132936|DRUG|Aerosol foam vehicle|
214459891|NCT02132936|DRUG|Calcipotriol BDP gel|
214459892|NCT02132936|DRUG|Gel vehicle|
214459893|NCT05538338|OTHER|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
214459894|NCT05538338|OTHER|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
214459895|NCT02561585|DRUG|LEO 124249|
214459896|NCT02561585|OTHER|Vehicle|
214459897|NCT03622749|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
214459898|NCT06009458|DEVICE|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
214530223|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
214459899|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
215146580|NCT05028543|PROCEDURE|Clipping of utrine artery at its origin before bginning of TLH|"the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method."
215146581|NCT01175577|DIETARY_SUPPLEMENT|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
215146582|NCT01175577|DIETARY_SUPPLEMENT|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
215146583|NCT01175577|OTHER|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
214459900|NCT03134196|DRUG|Masked Placebo|Oral Placebo
214459901|NCT03134196|DRUG|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
214459902|NCT06531421|OTHER|Equity Report Cards|At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
214459903|NCT06416111|DEVICE|NIRS|Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
214459904|NCT06416111|OTHER|Pinprick Test|"With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling"
214459905|NCT06416111|OTHER|Modified Bromage Scale|"Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers."
214459906|NCT06416111|DRUG|Bupivacaine|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
214459907|NCT06416111|DRUG|Prilocaine|Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
214459908|NCT02648997|DRUG|Nivolumab - 240 mg|240 mg every 2 weeks
214459909|NCT02648997|DRUG|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
214459910|NCT02648997|DRUG|Nivolumab - 480 mg|480 mg once every 4 weeks
214459911|NCT02648997|DRUG|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
214459912|NCT02648997|RADIATION|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
215146584|NCT01175577|OTHER|Placebo|Safflower oil-filled capsules, one twice daily with meals
215146585|NCT06212336|DRUG|Favipiravir|Interventional Medicinal Product (IMP)
215146586|NCT06212336|DRUG|Ribavirin|Control arm
215146587|NCT06212336|DRUG|Dexamethasone|Interventional Medicinal Product (IMP)
215146588|NCT00001209|DRUG|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
215146589|NCT04226755|DIETARY_SUPPLEMENT|Sodium chloride|1 gram tid (with every meal)
215146590|NCT00068692|RADIATION|Radiotherapy|Undergo external beam radiation therapy
215146591|NCT00068692|DRUG|Fluorouracil|Given IV
214459913|NCT06206291|DRUG|Placebo|Matching placebo twice daily for first 4 weeks
215146592|NCT00068692|DRUG|Leucovorin Calcium|Given IV
215146593|NCT00068692|DRUG|Oxaliplatin|Given IV
215146594|NCT00068692|DRUG|Irinotecan|Given IV
215146595|NCT01222689|DRUG|erlotinib hydrochloride|Given PO
215146596|NCT01222689|DRUG|selumetinib|Given PO
215146597|NCT01222689|OTHER|laboratory biomarker analysis|Correlative studies
215146598|NCT03110523|DRUG|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
215146599|NCT04889638|OTHER|Cessation Intervention|"1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging"
215146600|NCT01096355|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
215146601|NCT01096355|OTHER|diagnostic laboratory biomarker analysis|
214459914|NCT06206291|DRUG|Cannabidiol (CBD) 200mg|First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
215146602|NCT01096355|OTHER|pharmacogenomic studies|
215146603|NCT01096355|OTHER|pharmacological study|
215146604|NCT03278457|DIAGNOSTIC_TEST|Positron Emission Tomography|Positron Emission Tomography
215146605|NCT04672668|DIAGNOSTIC_TEST|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
215146606|NCT04590521|BIOLOGICAL|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
215146607|NCT03854266|DRUG|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
215146608|NCT03854266|DRUG|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
215146609|NCT03854266|DEVICE|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
215146610|NCT04790916|DRUG|RO7049665|RO7049665, subcutaneous injection, Q2W.
215146611|NCT04790916|OTHER|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
215146612|NCT05345899|DIAGNOSTIC_TEST|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
214459915|NCT06206291|DRUG|Cannabidiol (CBD) 400mg|Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
214459916|NCT05857384|DRUG|IHL42X|IHL-42X consists of acetazolamide and dronabinol.
214459917|NCT05857384|DRUG|Acetazolamide 250 MG|A solid tablet containing 250 mg acetazolamide
214459918|NCT05857384|DRUG|Dronabinol 2.5 MG|A soft gelatin capsules containing 2.5mg dronabinol
214459919|NCT00819546|DRUG|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
214459920|NCT00819546|DRUG|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
214459921|NCT03696784|BIOLOGICAL|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
214459922|NCT03696784|DRUG|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
214459923|NCT03696784|DRUG|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
214459924|NCT03696784|DRUG|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
214459925|NCT03696784|DRUG|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
214459926|NCT03800108|PROCEDURE|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
214459927|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
214459928|NCT03443388|DEVICE|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
214459929|NCT06343649|OTHER|Visual|Delivery of images to conduct several exercises of Explicit Motor Imagery
214459930|NCT06343649|OTHER|Auditory|Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
215146613|NCT05345899|OTHER|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
214459931|NCT05888870|DRUG|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
215146614|NCT05147363|DEVICE|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
215146615|NCT00248040|DRUG|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
214459932|NCT05888870|DRUG|SCT800|SCT800 50IU/kg TIW alone
214459933|NCT06516705|BEHAVIORAL|Hypoglycemia education|Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
214459934|NCT05400252|BEHAVIORAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
214459935|NCT05400252|BEHAVIORAL|Health and Wellness|Health \& Wellness is an educational wellness intervention
214459936|NCT04507178|DRUG|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
214459937|NCT03651349|DRUG|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
214459938|NCT03651349|DRUG|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
214459939|NCT06519305|OTHER|Survey completion|Participants will be asked to fill out the survey via email.
215146616|NCT00248040|DRUG|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
215146617|NCT00248040|OTHER|placebo infusion|placebo was volume/schedule matched saline
215146618|NCT03530072|DIAGNOSTIC_TEST|Karius Test|Next Generation Sequencing
215146619|NCT06416124|DIAGNOSTIC_TEST|Anthropometric assessment|A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
215146620|NCT00541541|PROCEDURE|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
215146621|NCT00842335|DRUG|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
215146622|NCT05441748|OTHER|Walnuts|The intervention treatment will contain walnuts.
215146623|NCT05441748|OTHER|Walnut Oil|The intervention treatment will contain walnut oil.
215146624|NCT05441748|OTHER|Control|The control treatment will contain corn oil.
214459941|NCT06544707|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
214459942|NCT03003572|OTHER|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
214459943|NCT03992755|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
214530224|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
214459944|NCT06615518|PROCEDURE|transforaminal endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
215146625|NCT03221153|PROCEDURE|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
214530225|NCT02621047|DRUG|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
215146626|NCT05448196|OTHER|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
215146627|NCT00512213|DIETARY_SUPPLEMENT|Immunonutrition for 5 days preoperative|Impact vs Meritene
215146628|NCT00512213|DIETARY_SUPPLEMENT|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
215146629|NCT03570710|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
214459945|NCT06615518|PROCEDURE|Interlaminar endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
214459946|NCT06615518|PROCEDURE|Microdiscectomy|"Microdiscectomy is a conventional surgical technique for treating lumbar disc herniation, involving a small open incision. In this procedure, the surgeon makes an incision typically between 2-3 cm in length, then uses an operating microscope to gain magnified visualization of the herniated disc. The surgeon removes part of the lamina (laminotomy) to access the disc and nerves. Special instruments are used to remove the herniated portion of the disc that is compressing the spinal nerves, relieving symptoms such as pain, numbness, and weakness.~What distinguishes this intervention:~* Larger incision (2-3 cm) compared to FELD, but still smaller than traditional open discectomy, allowing better visualization.~* Microscopic magnification allows precise removal of disc material while minimizing trauma to surrounding neural structures.~* Direct access to the affected area via the removal of part of the lamina (laminotomy), offering a well-established and highly effective approach to reli"
214459947|NCT05715463|OTHER|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
214530226|NCT04262778|DIAGNOSTIC_TEST|electrochemical skin conductance measurement|electrochemical skin conductance measurement
214530227|NCT06312995|DEVICE|T3DDY01|Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
214530228|NCT06312995|DEVICE|PLASTER|Standard treatment plaster for fractures.
214530229|NCT04621422|BIOLOGICAL|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
214530230|NCT05765890|OTHER|No treatment given|No treatment given
214530231|NCT00153023|DRUG|Telmisartan|
214530232|NCT00153023|DRUG|Valsartan|
214530233|NCT01448382|DEVICE|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
214530234|NCT03140449|DRUG|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
214530235|NCT03140449|DRUG|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
214530236|NCT03140449|DRUG|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
214530237|NCT06294483|DIAGNOSTIC_TEST|CBC|Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
214530238|NCT06294483|DIAGNOSTIC_TEST|Antinuclear Antibody tests (ANA)|To be tool in diagnosis of SLE
214530239|NCT06294483|DIAGNOSTIC_TEST|Rest of ANA profile|As tool of diagnosis of SLE
214530240|NCT06294483|DIAGNOSTIC_TEST|C3 and C4 complement level.|As method of detection of acute acivity of SLE
214530241|NCT06294483|DIAGNOSTIC_TEST|Anti phospholipid marker|To detect antiphospholipid syndrome if there is sign of thrombosis
214530242|NCT06294483|DIAGNOSTIC_TEST|Serum creatinine and Alb/create ratio|To detct complication of disease on kidney
214530243|NCT06294483|OTHER|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.|Is criteria of diagnosis of SLE
214530244|NCT06294483|OTHER|SLEDAI scores|Is score to detect the activity of disease
214695379|NCT06444243|DRUG|Niacin|"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control."
214695380|NCT00922194|DRUG|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
214695381|NCT04423900|DIAGNOSTIC_TEST|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
214695382|NCT06270355|PROCEDURE|Risk based screening|Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
214459948|NCT05715463|OTHER|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
214459949|NCT05715463|OTHER|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
214459950|NCT06300372|PROCEDURE|M-TAPA plane block|As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
214459951|NCT06300372|PROCEDURE|Postoperative pain management|For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
214459952|NCT00753545|DRUG|AZD2281|Tablets Oral BID
214459953|NCT00753545|DRUG|matching placebo|matching placebo bid
214459954|NCT02531607|OTHER|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
214459955|NCT06410287|OTHER|ArtSpective|ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
214459956|NCT04244214|OTHER|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
214459957|NCT06791252|BEHAVIORAL|genital hygiene education|"The pregnant women in the experimental group were given genital hygiene training individually and in their own homes by the researcher. During the training, the privacy of the client was observed and the researcher and the pregnant women were left alone in the room where the training would be given. Care was taken to ensure that the environment was quiet and calm while the training was given. It was preferred that the pregnant women be in the most comfortable position during the training.~The training was completed by explaining each topic in the training booklet in an average of 20-25 minutes.~Genital hygiene training content:~Session 1 (Day 1): After the introduction phase, information was given about the method to be followed in the study to the pregnant women who agreed to participate in the study. Then, the Minimum Informed Consent Form was given to these women, and the pregnant women who approved the form after reading it were included in the study. Pre-test data were collecte"
214695383|NCT02867449|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
214695384|NCT02867449|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
214530245|NCT03512587|PROCEDURE|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
214530246|NCT03512587|PROCEDURE|Placebo|Headphones will be place in patients without playing quantum sonotherapy
214530247|NCT04785742|DRUG|Almonertinib|Almonertinib
214530248|NCT01951261|PROCEDURE|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
215146630|NCT03570710|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
215146631|NCT03570710|DRUG|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
215146632|NCT01715324|DRUG|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
215146633|NCT02532803|OTHER|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
215146634|NCT04764422|BIOLOGICAL|Normal Saline|0.9% normal saline for injection
215146635|NCT04764422|BIOLOGICAL|NDV-HXP-S vaccine|Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
215146636|NCT05132023|DRUG|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
214459958|NCT06799442|PROCEDURE|Erector Spinae Plane Block|Patients will be placed in lateral position with the surgical site upward. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. An echogenic needle needle will be inserted using an in-plane approach and craniocaudally direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.
214459959|NCT06799442|DRUG|Dexmedetomidine|50 mic dexmedetomidine which is diluted to 2ml.
214530249|NCT03175835|DRUG|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
214530250|NCT03175835|DRUG|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
214530251|NCT03175835|DRUG|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
214530252|NCT02025361|DRUG|intrarectal lidocaine gel|intrarectal local anesthetic application
214530253|NCT02025361|DRUG|periprostatic nerve blockade|periprostatic local anesthetic application
214530254|NCT03887871|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
215146637|NCT05132023|DRUG|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
214459960|NCT06799442|DRUG|fentanyl|100 mic fentanylwhich is also diluted to 2 ml.
214459961|NCT06190691|DRUG|Pirtobrutinib|Administered orally
214459962|NCT06799299|OTHER|No Intervention|No intervention
214459963|NCT06793137|DRUG|Metronidazole|This intervention involves administering the oral antibiotic metronidazole during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma who are undergoing total neoadjuvant treatment. Metronidazole is considered a safe medication, with a very low risk of adverse effects. It is commonly used to treat infections caused by anaerobic bacteria that are part of the intestinal microbiota. Additionally, it is well established that certain genera of anaerobic bacteria are linked to a poorer response to treatment.
214459964|NCT06382155|DRUG|Vosoritide Injection|Experimental Drug Lyophilized powder for reconstitution
214459965|NCT06382155|DRUG|Human Growth Hormone|Commercial product containing somatotropin
214459966|NCT06382155|DRUG|Placebo|Lyophilized powder for reconstitution
214530255|NCT03887871|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
214530256|NCT03974997|DIAGNOSTIC_TEST|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
214530257|NCT00495612|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
214530258|NCT00495612|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
214530259|NCT02766764|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
214530260|NCT02766764|DRUG|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
215146638|NCT04724993|OTHER|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
215146639|NCT04724993|OTHER|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
215146640|NCT02153320|PROCEDURE|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
215146641|NCT03481595|DEVICE|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
215146642|NCT00220896|DRUG|Donepezil|
215146643|NCT00135824|DRUG|Povidone K25 eye drops (povidone)|
215146644|NCT01682889|DIETARY_SUPPLEMENT|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
215146645|NCT01682889|DIETARY_SUPPLEMENT|Placebo|NaCl 0.9% intravenously for 24h
215146646|NCT02944149|PROCEDURE|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
215146647|NCT03252379|PROCEDURE|hepaticojejunostomy|"* Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
215146648|NCT03252379|PROCEDURE|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
214459967|NCT05473767|BEHAVIORAL|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
214459968|NCT05473767|BEHAVIORAL|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
214459969|NCT04290546|DRUG|Interleukin-15 Superagonist (N-803)|"\-- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight."
214459970|NCT04290546|BIOLOGICAL|CIML NK cell Infusion|(Dose 0 or -1) infused on Day 0
214459971|NCT04290546|DRUG|Ipilimumab|single dose of lead-in ipilimumab via iv per protocol determined dose
214459972|NCT04290546|DRUG|Cetuximab|Starting day +15, every 14 days for 8 total doses via IV per protocol
214459973|NCT05822414|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
214530261|NCT02766764|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
214530262|NCT02766764|DRUG|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
214530263|NCT05662215|DRUG|CK-3828136|CK-3828136
215146649|NCT03252379|PROCEDURE|modified hepaticojejunostomy with gastric access loop|"* In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
215146650|NCT02368587|BIOLOGICAL|WJMSCs Vs. placebo|WJMSCs Vs. placebo
215146651|NCT02368587|BIOLOGICAL|Placebo|WJMSCs Vs. placebo
215146652|NCT00832299|DRUG|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
215146653|NCT00832299|PROCEDURE|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
215146654|NCT00149266|PROCEDURE|Surgery: abdominal and transhiatal approach|
215146655|NCT00149266|PROCEDURE|Surgery: left thoraco-abdominal approach|
214530264|NCT05662215|DRUG|Placebo for CK-3828136|Placebo for CK-3828136
214530265|NCT06091969|DIETARY_SUPPLEMENT|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
214530266|NCT06091969|DIETARY_SUPPLEMENT|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
214530267|NCT02189122|DRUG|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
214530268|NCT02189122|DRUG|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
214530269|NCT02189122|DRUG|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
215146656|NCT02732574|DEVICE|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
214459974|NCT05746455|BEHAVIORAL|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
214459975|NCT05144763|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
214459976|NCT06475846|DRUG|HRS5580|HRS5580; low dose
214459977|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
214459978|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
214459979|NCT06475846|DRUG|Ondansetron|Ondansetron
214459980|NCT06475846|DRUG|blank preparation|blank preparation.
214459981|NCT04869449|DRUG|Ketoconazole|400 mg (two 200 mg tablets) orally
214459982|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
214459983|NCT05130762|DEVICE|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
214459984|NCT05575505|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
214459985|NCT05640115|DEVICE|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
214459986|NCT05640115|DEVICE|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
214459987|NCT05743868|BEHAVIORAL|Standardized Dinner|De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
214459988|NCT05743868|BEHAVIORAL|Premeal exercise|DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
214459989|NCT05979974|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
214459990|NCT05979974|OTHER|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
214459991|NCT05979974|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
214459992|NCT00454467|PROCEDURE|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
214459993|NCT00454467|PROCEDURE|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
214459994|NCT00454467|PROCEDURE|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
214459995|NCT00454467|PROCEDURE|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
214459996|NCT00454467|PROCEDURE|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
214459997|NCT00454467|PROCEDURE|Cost Data|Cost Data will be collected via hospital billing databases.
214459998|NCT00454467|PROCEDURE|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
214459999|NCT06799182|PROCEDURE|periodontal treatment|Based on the results of the dental examination and the diagnosis of the periodontal tissue condition according to the new classification of periodontal disease, we performed appropriate non-surgical treatment of periodontal disease, provided oral hygiene instruction, and took a biofilm sample from the deep periodontal pocket. We then collected a sample of the altered mucosa during bowel surgery for colorectal cancer and conducted a microbiological investigation using quantitative culture to compare the presence of Fusobacterium nucleatum and Porphyromonas gingivalis in the pariodontal pocket and altered intestinal mucosa.
214460000|NCT04585594|BEHAVIORAL|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
214530270|NCT02189122|DRUG|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
214530271|NCT02189122|DRUG|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
214530272|NCT02189122|DRUG|Placebo|Subjects will take matching placebo for five days.
215146657|NCT02732574|DEVICE|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
214530273|NCT04026074|DRUG|Fentanyl|Weight adapted drug application
214530274|NCT04026074|DRUG|Remifentanil|Weight adapted drug application
214530275|NCT04026074|DRUG|Clonidine|Weight adapted drug application
215146658|NCT00165477|DRUG|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
215146659|NCT00165477|RADIATION|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
215146660|NCT02930824|GENETIC|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
215146661|NCT03256461|BEHAVIORAL|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
215146662|NCT03256461|BEHAVIORAL|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
215146663|NCT03256461|BEHAVIORAL|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
214460001|NCT04585594|BEHAVIORAL|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
214460002|NCT02807129|BIOLOGICAL|blood withdrawn|
214460003|NCT02807129|BIOLOGICAL|urine collection|
214460004|NCT06259227|OTHER|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
214460005|NCT06635538|DRUG|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
214460006|NCT06635538|DRUG|Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
214460007|NCT06635538|DIAGNOSTIC_TEST|Monitoring cycle|Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
214530276|NCT04026074|DRUG|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
214530277|NCT04026074|DRUG|Placebo iv|i.v. administration of 0,9% NaCl
215146664|NCT03758053|OTHER|No intervention|No intervention
215146665|NCT00112619|DRUG|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
215146666|NCT01534702|DRUG|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
215146667|NCT05459896|BEHAVIORAL|Physical Activity Training|Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
215146668|NCT05459896|OTHER|Mindfulness-based Intervention|Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
215146669|NCT05459896|OTHER|Energy Conservation Techniques|Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
215146670|NCT03586154|COMBINATION_PRODUCT|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
215146671|NCT03586154|DRUG|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
215146672|NCT06051149|PROCEDURE|caudal adhesolysis using RACZ Catheter|caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy
215146673|NCT06051149|PROCEDURE|caudal adhesiolysis using NAVI Catheter|caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
215146674|NCT02324192|OTHER|Ultrasonography|imaging findings
214460008|NCT06798831|BIOLOGICAL|Pertussis containing vaccine|Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),
214460009|NCT03477968|DIAGNOSTIC_TEST|DDimer test|Measuring the level of DDimer in blood sample
214460010|NCT06636344|OTHER|Pseudoxanthoma Elasticum|Answer to the PSQ-18, patient care confidence score (likert scale) and SF-12 questionaries at each visit, for an estimated duration of 15 minutes.
214460011|NCT04961619|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
214460012|NCT04961619|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
214460013|NCT04704648|PROCEDURE|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
214460014|NCT06635226|DRUG|ID110521156|ID110521156 capsules taken orally once daily
214460015|NCT06635226|DRUG|Placebo of 110521156|ID110521156 placebo capsules taken orally once daily
214460016|NCT05882292|DRUG|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
214460017|NCT06334965|OTHER|Simultaneous 18F-Choline PET-MRI|before first TARE administration (after work-up procedure) and one month after TARE administration
214460018|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
214460019|NCT05697302|BEHAVIORAL|Education|Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
214460020|NCT05697302|BEHAVIORAL|Follow-up|Among the data collection forms, LATCH-Breastfeeding Diagnostic Scale and IMDAT-The Baby's Breastmilk Scoring System will be applied at each interview, and the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale will be applied at the first interview, at the end of the 1st month and at the end of the 2nd month. Mother interviews will be held in their homes or at the Family Health Center (whichever they prefer). At each meeting, an appointment schedule will be made for the next meeting and this information will be shared with the mothers in writing.
214530278|NCT04026074|DRUG|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
214530279|NCT03600090|BIOLOGICAL|EOC202|EOC202 will be SC injection.
214530280|NCT03600090|DRUG|Paclitaxel|Paclitaxol will be IV injection
214530281|NCT04542551|PROCEDURE|Dilation 60-Fr non stricture|Dilation of patients with subjective dysphagia and normal endoscopy
215146675|NCT06384014|DEVICE|retrograde and orthograde root canal filling|Apical resection application after root canal filling
215146676|NCT04558034|OTHER|cryotherapy|cryotherapy will be delivered
215146677|NCT04900116|DRUG|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
215146678|NCT04900116|DRUG|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
215146679|NCT04900116|DRUG|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
215146680|NCT04900116|DRUG|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
215146681|NCT02459483|BEHAVIORAL|Nurse phone call|
215146682|NCT00183482|BEHAVIORAL|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
215146683|NCT00183482|BEHAVIORAL|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
215146684|NCT03834181|DEVICE|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate"
215146685|NCT02431962|PROCEDURE|Computed Tomography|Low dose chest CT screening annually x 3
215146686|NCT02431962|BEHAVIORAL|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
215146687|NCT02431962|BEHAVIORAL|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
215146688|NCT05136924|DRUG|OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo|OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo
215146689|NCT05136924|OTHER|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
215146690|NCT04986267|OTHER|ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
215146691|NCT05756959|DEVICE|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
215146692|NCT05756959|DEVICE|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
215146693|NCT05756959|DEVICE|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
215146694|NCT02540629|PROCEDURE|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
215146695|NCT06374628|PROCEDURE|breast reconstruction|breast reconstruction in two-stages using tissue expander entirely wrapped by acellular dermal matrix
215146696|NCT03283501|PROCEDURE|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
215146697|NCT02298582|DRUG|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
215146698|NCT00628108|DRUG|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
215146699|NCT00628108|OTHER|Placebo|Placebo oral liquid once a day for two weeks
214460021|NCT05697302|BEHAVIORAL|Referral to Lactation and Relactation Polyclinic|Due to the nature of the research, mothers in the control group will not be given any training, and they will be referred to the Lactation and Relaxation Polyclinic in Erzincan Mengücek Gazi Training and Research Hospital.
214460022|NCT05335850|BEHAVIORAL|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
214460023|NCT05335850|BEHAVIORAL|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
214530282|NCT04542551|PROCEDURE|Sham|Sham dilator for patients with subjective dysphagia and normal endoscopy
214530283|NCT04542551|PROCEDURE|Non severe stricture - dilation with 60-Fr|Dilation of non severe stricture with 60-Fr dilator
214530284|NCT04542551|PROCEDURE|Non severe stricture - dilation with 46-Fr|Dilation of non severe stricture with 46-Fr dilator
214460024|NCT05335850|BEHAVIORAL|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
214460025|NCT05335850|OTHER|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
214530285|NCT04542551|PROCEDURE|Severe stricture - dilation with 51-Fr|Dilation of a severe stricture with 51-Fr dilator
214530286|NCT04542551|PROCEDURE|Severe stricture - dilation with 42-Fr|Dilation of a severe stricture with 42-Fr dilator
214530287|NCT02671071|BEHAVIORAL|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
214530288|NCT03093233|OTHER|no intervention|only descriptive data analysis
215146700|NCT00668278|DEVICE|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
214460026|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
214460027|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 1 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
215146701|NCT00668278|DEVICE|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
215146702|NCT00668278|OTHER|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
215146703|NCT01737437|DRUG|group C|0.9% normal saline was applied to trachea and laryngoscope blade
215146704|NCT01737437|DRUG|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
215146705|NCT01737437|DRUG|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
215146706|NCT01737437|DRUG|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
215146707|NCT02292589|DEVICE|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
215146708|NCT02292589|DEVICE|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
215146709|NCT02292589|DEVICE|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
215146710|NCT01886066|BIOLOGICAL|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
215146711|NCT04617626|DRUG|Azithromycin|Single dose of azithromycin suspension
215146712|NCT03848832|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
215146713|NCT03848832|DRUG|Placebo|Matching placebo oral solution
215146714|NCT04840823|DRUG|Enoxacin|Oral 200mg tablet
215146715|NCT04840823|DRUG|Placebo|Oral tablet
215146716|NCT00232427|PROCEDURE|Hemodynamic monitoring system PiCCO|
215146717|NCT03074838|PROCEDURE|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
215146718|NCT03074838|PROCEDURE|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
215146719|NCT00693771|DRUG|Insulin Glargine|Once daily and up-titrate accordingly
214460028|NCT06451159|DRUG|Chemotherapy: cyclophosphamide (CYC)|Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
214460029|NCT06451159|DRUG|Chemotherapy: fludarabine (FLU)|Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
214530289|NCT03876678|OTHER|Lactobacillus salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
215146720|NCT03413488|OTHER|kinesio taping|Apply exercise and kinesio taping for intervention
215146721|NCT03413488|OTHER|exercise|Apply only exercise intervention
215146722|NCT02538224|DRUG|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
215146723|NCT02538224|DRUG|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
215146724|NCT04202107|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
215146725|NCT04202107|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
215146726|NCT00193271|DRUG|Docetaxel|
215146727|NCT00193271|DRUG|Estramustine|
215146728|NCT05060029|DRUG|Lactobacillus Species|Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
214530290|NCT03876678|OTHER|Bifidobacterium animalis subspecies lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
214530291|NCT03876678|OTHER|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
214530292|NCT03071874|DRUG|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
214530293|NCT01972373|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
214530294|NCT01972373|DEVICE|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
214530295|NCT00818519|DRUG|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
214530296|NCT00818519|DRUG|Placebo|Inert tablet
215146729|NCT05060029|OTHER|Placebo|Coconut Oil Fatty Acids
215146730|NCT05731063|PROCEDURE|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
215146731|NCT03859310|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
215146732|NCT04106752|DIETARY_SUPPLEMENT|Caffeine|Provide caffeine supplements with or without meal before exercise
214460030|NCT03524183|BEHAVIORAL|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
214460031|NCT06634797|BIOLOGICAL|mRNA-1273.712|Intramuscular (IM) injection.
214460032|NCT06634797|BIOLOGICAL|Placebo|Sodium chloride for IM injection.
214460033|NCT03016754|DEVICE|Wearable Cardioverter Defibrillator|LifeVest is the brand of Wearable Cardioverter Defibrillator used in this study.
214460034|NCT03570632|DRUG|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
214460035|NCT03671629|OTHER|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
214460036|NCT03839940|DRUG|Dexamethasone|Given as mouthwash
214460037|NCT03839940|OTHER|Placebo|Given as mouthwash
214460038|NCT03839940|OTHER|Questionnaire|Ancillary studies
214460039|NCT03839940|OTHER|Quality-of-Life Assessment|Ancillary studies
214460040|NCT03839940|DRUG|Everolimus|Standard of care
214460041|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
214460042|NCT06086886|OTHER|Placebo|Specified dose on specified days
214460043|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
215146733|NCT04199988|DIAGNOSTIC_TEST|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
215146734|NCT06030024|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
215146735|NCT03960996|PROCEDURE|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
215146736|NCT00588835|DRUG|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
215146737|NCT00588835|DRUG|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
215146738|NCT05971082|OTHER|Follow-up|Follow-up study of progression/remission of liver disease
214460044|NCT02103725|DRUG|Vehicle cream|
214460045|NCT04340596|BIOLOGICAL|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
214460046|NCT04340596|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
214460047|NCT04340596|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
214460048|NCT04599192|OTHER|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
214460049|NCT03180216|BIOLOGICAL|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
214460050|NCT06799624|OTHER|Observation only|Only observation following standard of care (histological diagnosis, molecular classification, progestine therapy)
214460051|NCT03241745|DRUG|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
214460052|NCT06634654|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty is performed using conventional surgical techniques.
214460053|NCT06634654|DIAGNOSTIC_TEST|Multifaceted diagnostic assessments|Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.
214460054|NCT06634654|BEHAVIORAL|Follow-ups|Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.
214460055|NCT06634654|GENETIC|Genetic screening|Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
214460056|NCT06417255|OTHER|kinesiotape application|The strips used for kinesiological taping can be applied by giving different shapes. These shapes are I, Y, X, ring (donut), rake and net
214460057|NCT06417255|OTHER|foam roller application|"In the foam roller group, Actifoam brand non-serrated foam rollers with a size of 15x90 cm were used."
214460058|NCT03367299|DRUG|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
214460059|NCT03023410|PROCEDURE|VERASENSE|Sensor-Assisted Revision TKA
215146739|NCT05046561|DRUG|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
214460060|NCT03956407|DEVICE|Suprathreshold repetitive peripheral sensory stimulation|Suprathreshold repetitive peripheral sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For suprathreshold stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
214460061|NCT03956407|DEVICE|Subthreshold repetitive sensory stimulation|Subthreshold repetitive sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For subthreshold stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
214460062|NCT06469138|DRUG|Bemcentinib|Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
214460063|NCT04647240|BIOLOGICAL|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
214460064|NCT05141695|DEVICE|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
214460065|NCT05141695|DEVICE|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
214460066|NCT02693223|OTHER|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
214460067|NCT05084235|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
214460068|NCT05084235|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling
214460069|NCT06324721|OTHER|Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)|"Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis~Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography"
214460070|NCT06324721|OTHER|Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)|Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)
214460071|NCT06324721|OTHER|Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer|Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer
214460072|NCT06542484|DRUG|Gefapixant Citrate|An additional treatment of gefapixiant will be performed for 12 weeks.
214460073|NCT03437057|OTHER|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
214530297|NCT05888142|BEHAVIORAL|in clinic pain VR reduction exercises|"During the in clinic training phase, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality. But this group will not take a VR system home until after completing the in clinic training phase."
215146740|NCT05046561|DRUG|Placebo|Placebo oral capsule
215146741|NCT04237597|DRUG|K-877|K-877 tablets
214460074|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
214460075|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
214530298|NCT05888142|BEHAVIORAL|In clinic VRpain reduction exercises + VR homeworks|"During the training phase, participants will use commercially available VR during in clinic physical therapy exercises, and during the training phase, they will also receive a VR system they take home and will begin VR homeworks during the traininng phase, to help reduce their pain and improve functionality."
215146742|NCT04237597|DRUG|CSG452|CSG452 tablets
215146743|NCT01154257|PROCEDURE|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
215146744|NCT01154257|PROCEDURE|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
215146745|NCT03071926|DRUG|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
215146746|NCT02024919|DRUG|intracoronary administration of diltiazem|
215146747|NCT02024919|DRUG|intracoronary injection of 5 mL saline|
214530299|NCT01754545|DRUG|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
214530300|NCT01754545|DRUG|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
214530301|NCT00282009|BEHAVIORAL|Basic Internet|Basic Internet control intervention
214530302|NCT00282009|BEHAVIORAL|Enhanced Internet|enhanced Internet cessation intervention
214530303|NCT00282009|BEHAVIORAL|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
214530304|NCT01995149|BEHAVIORAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
214530305|NCT00593983|BEHAVIORAL|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
214530306|NCT00593983|BEHAVIORAL|Time-matched health education|Health education and standard of care treatment
214530307|NCT02942628|OTHER|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
214530308|NCT05473221|BIOLOGICAL|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
214530309|NCT02502851|DEVICE|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
214530310|NCT02502851|DEVICE|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
214530311|NCT03899844|OTHER|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
214530312|NCT02961816|DRUG|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
214530313|NCT02961816|DRUG|Panobinostat|20 mg by mouth daily from Day -9 to -2.
214530314|NCT02961816|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
214530315|NCT02961816|DRUG|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
214530316|NCT02961816|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
214530317|NCT02961816|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
215146748|NCT04099199|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
214530318|NCT02961816|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
214530319|NCT02961816|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
214530320|NCT02961816|DRUG|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
214530321|NCT02961816|OTHER|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
214530322|NCT02961816|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
214530323|NCT02961816|BIOLOGICAL|Stem Cell Infusion|Stem cells administered by vein on Day 0.
214530324|NCT02961816|DRUG|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
214530325|NCT06585345|BIOLOGICAL|CD7 CAR-T cell|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
214530326|NCT06584981|PROCEDURE|pectoral nerve block (PECS II), parasternal and serratus plane blocks|These block applications are performed under sterile conditions under the guidance of ultrasonography
215146749|NCT05684393|OTHER|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
215146750|NCT06519474|DEVICE|Theraband chest compression|Chest compression applicated via a Red Theraband over the upper or lower chest region
215146751|NCT02198404|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
215146752|NCT00736762|OTHER|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
215146753|NCT03200288|DEVICE|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
215146754|NCT03200288|DEVICE|Placebo|2 ml intra-articular single injection
215146755|NCT03308071|BEHAVIORAL|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
214530327|NCT06584981|OTHER|analgesic|Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
214530328|NCT04306549|OTHER|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
214530329|NCT05768321|DRUG|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
214530330|NCT03724695|OTHER|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
214695385|NCT01993862|OTHER|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
215146756|NCT03501849|DEVICE|Polypectomy using a cold snare|Polypectomy by cold-snare technique
214460076|NCT04799899|BEHAVIORAL|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
214530331|NCT05584397|PROCEDURE|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
214530332|NCT05584397|PROCEDURE|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
214460077|NCT04799899|BEHAVIORAL|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
214460078|NCT04718805|DRUG|Darunavir|Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
214530333|NCT05584397|PROCEDURE|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
214530334|NCT05584397|PROCEDURE|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
214695386|NCT02134327|DRUG|Combination of Dexmedetomidine with Midazolam|
214695387|NCT01321840|PROCEDURE|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
214695388|NCT00288860|BEHAVIORAL|Telephone monitoring|Three months of biweekly telephone monitoring and support
214460079|NCT04718805|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
214460080|NCT04718805|DRUG|Darunavir/Cobicistat FDC|Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
214460081|NCT05051761|DRUG|Jaktinib|Administered orally.
214460082|NCT05051761|DRUG|placebo|Administered orally.
214460083|NCT00470704|DRUG|Lapatinib|
214695389|NCT00288860|OTHER|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
214695390|NCT05014048|DIETARY_SUPPLEMENT|Vitamin D3|20 mikrog vitamin D3 daily
214695391|NCT05014048|DIETARY_SUPPLEMENT|Placebo|Placebo
214460084|NCT00470704|DRUG|Herceptin|
214460085|NCT03838549|PROCEDURE|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
214460086|NCT06631508|OTHER|Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge|Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
214460087|NCT04153032|DRUG|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
214460088|NCT04153032|DRUG|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
214460089|NCT04634513|BIOLOGICAL|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
214460090|NCT04634513|OTHER|Placebo|Sodium bicarbonate buffer
214530335|NCT05584397|PROCEDURE|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
214530336|NCT00523926|DRUG|TMC207|
214530337|NCT03899285|DRUG|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
214530338|NCT00908245|PROCEDURE|Control|Surgery without preconditioning surgery
214530339|NCT00908245|PROCEDURE|Preconditioning ischemia|Surgery with a preconditioning ischemia
215146757|NCT03788252|DRUG|Renamezin|7 capsules once, three times a day, for 48 weeks
215146758|NCT01377103|DRUG|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
215146759|NCT01377103|DRUG|Placebo|
214530340|NCT06132906|PROCEDURE|Orthognathic surgery (lefort1)|"1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure"
214530341|NCT04106336|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
214530342|NCT01239056|PROCEDURE|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
214530343|NCT03467997|BEHAVIORAL|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
214530344|NCT03467997|OTHER|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
214530345|NCT04198272|BEHAVIORAL|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
214530346|NCT04835493|OTHER|Intervention|In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
214530347|NCT04940780|OTHER|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
214530348|NCT04940780|OTHER|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
214530349|NCT03740919|DRUG|LY900014|Administered SC
214530350|NCT03740919|DRUG|Insulin Lispro|Administered SC
214530351|NCT03740919|DRUG|Insulin Glargine|Administered SC
214530352|NCT03740919|DRUG|Insulin Degludec|Administered SC
214530353|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate high dose|
214530354|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate low dose|
214530355|NCT03063346|DIETARY_SUPPLEMENT|Placebo|
214530356|NCT03670199|OTHER|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
214530357|NCT03670199|OTHER|Physiotherapist intervention|Respiratory capacity Functional capacity
214530358|NCT03670199|OTHER|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
214530359|NCT03670199|OTHER|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
214568577|NCT02928497|DEVICE|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
214568578|NCT02928497|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
214568579|NCT04705116|BIOLOGICAL|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
215146760|NCT06282978|DRUG|Elranatamab (PF-06863135)|The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
215146761|NCT06383533|DRUG|Disitamab Vedotin Plus Cadonilimab|Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
215146762|NCT02192411|DRUG|Lidocaine|1/4 dose lidocaine
214460091|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
214460092|NCT06629168|DIAGNOSTIC_TEST|lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.
214460093|NCT06629168|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
214460094|NCT06629168|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
214530360|NCT04035863|DEVICE|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
214530361|NCT01963858|PROCEDURE|Functional relaxation|Functional relaxation during colonoscopy
214530362|NCT01963858|PROCEDURE|No relaxation|No relaxation during colonoscopy
214530363|NCT06564246|DRUG|Vonoprazan 20 mg versus Pantoprazole 40 mg|Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
214530364|NCT00043368|DRUG|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
214530365|NCT05532319|COMBINATION_PRODUCT|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
215146763|NCT02200406|DRUG|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
214460095|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #1|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
214460096|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #2|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
214568581|NCT04101630|BEHAVIORAL|Activity Monitoring|Monitoring with FitBit
215146764|NCT03318302|OTHER|Survey|Survey of the adult population in Israel
215146765|NCT03386383|BEHAVIORAL|Intervention|Individual session, physical activity tracker, online intervention
215146766|NCT03766737|DEVICE|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
215146767|NCT03071042|DRUG|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
215146768|NCT03071042|DRUG|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
215146769|NCT02939443|RADIATION|supine- and prone-position Computed Tomography|
215146770|NCT05928962|DRUG|Recombinant Human Adenovirus Type 5 Injection|"1. Recombinant Human Type 5 Adenovirus Injection:~   This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~2. PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
215146771|NCT02528552|DEVICE|LH80 PRO|
215146772|NCT02528552|DEVICE|Sham Device|
215146773|NCT03329638|DRUG|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
215146774|NCT03329638|DRUG|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
215146775|NCT03329638|DRUG|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
214460097|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #3|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
215146776|NCT03329638|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
215146777|NCT02001259|DRUG|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
215146778|NCT02001259|DRUG|epidural lidocaine|add into catheter at 48 hr after surgery
215146779|NCT05530564|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
215146780|NCT05530564|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
215146781|NCT00565292|DRUG|MK0859|
215146782|NCT00467116|BIOLOGICAL|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
215146783|NCT00467116|DRUG|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes"
215146784|NCT00467116|RADIATION|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions \> 3 days."
215146785|NCT04075032|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
215146786|NCT04075032|OTHER|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
215146787|NCT04808661|PROCEDURE|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
215146788|NCT04808661|DRUG|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
215146789|NCT00751608|DRUG|APL180|
215146790|NCT00751608|DRUG|APL180|
215146791|NCT00751608|DRUG|Placebo|
215146792|NCT05684211|DRUG|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
215146793|NCT05684211|DRUG|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
215146794|NCT05684211|DRUG|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
215146795|NCT05684211|DRUG|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
215146796|NCT00804921|DRUG|bevacizumab|
215146797|NCT00804921|PROCEDURE|anterior chamber paracentesis|
215146798|NCT00804921|DRUG|acetazolamide|
215146799|NCT00804921|DRUG|brimonidine|
215146800|NCT02404025|DRUG|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
215146801|NCT02404025|DRUG|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
215146802|NCT02404025|DRUG|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
215146803|NCT05078840|OTHER|Evaluation of first line treatment in patients with stage I and II LBCL|Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
215146804|NCT01326949|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
215146805|NCT01326949|PROCEDURE|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
214460098|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #4|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
214460099|NCT06629168|DIAGNOSTIC_TEST|Telemetric prechamber reading|Non-invasive reading of telemetric prechamber made during each follow-up control.
214460100|NCT06629168|OTHER|Valve setting change|Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
215146806|NCT02061371|OTHER|virtual therapy|
215146807|NCT02061371|OTHER|conventional physiotherapy|
215146808|NCT01574092|DRUG|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
215146809|NCT02199210|OTHER|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
215146810|NCT02871908|DRUG|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8
215146811|NCT02871908|DRUG|Placebo|Placebo
214460101|NCT04118608|OTHER|No intervention|No intervention
214460102|NCT04019873|DRUG|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
214460103|NCT04019873|DRUG|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
214530366|NCT03850847|OTHER|Step 1: Semi-structured Interviews|"1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
215146812|NCT04392180|OTHER|Qualitative Interview|There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
215146814|NCT03681314|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
215146815|NCT05004441|DRUG|Fruquintinib Combined With mFOLFOX6/FOLFIRI|Fruquintinib (3mg) will be given p.o. daily
215146816|NCT01715740|DRUG|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
215146817|NCT01715740|DRUG|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
215146818|NCT02869880|OTHER|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
215146819|NCT02869880|OTHER|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
215146820|NCT01524796|OTHER|No intervention. Non-interventional study|No intervention. Non-interventional study
215146821|NCT00193544|DRUG|Arsenic Trioxide|
215146822|NCT00193544|DRUG|Thalidomide|
215146823|NCT02248519|PROCEDURE|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
215146824|NCT02248519|PROCEDURE|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
215146825|NCT00080535|BIOLOGICAL|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
215146826|NCT02929394|DRUG|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
214460104|NCT04019873|DRUG|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
214460105|NCT02305277|DRUG|BIA 9-1067 (clinical micronized, CM)|
214460106|NCT02305277|DRUG|BIA 9-1067 (to-be-marketed, TBM)|
214530367|NCT03850847|OTHER|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
214530368|NCT00755924|DIETARY_SUPPLEMENT|Vinegar|Apple cider vinegar 2 TBlsp/day
214530369|NCT00755924|OTHER|Placebo|Water placebo colored with balsamic vinegar
214530370|NCT01338051|BIOLOGICAL|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
214530371|NCT02612363|DRUG|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose"
214530372|NCT05106023|DRUG|SHR-1701|SHR-1701 combined with temozolomide
214530373|NCT05106023|DRUG|Temozolomide|SHR-1701 combined with temozolomide
214530374|NCT01740999|PROCEDURE|silicone arthroplasty|silicone arthroplasty
214530375|NCT01740999|PROCEDURE|arthrodesis|arthrodesis
214530376|NCT03392779|DRUG|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
214530377|NCT03392779|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
215146827|NCT01484587|DRUG|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
215146828|NCT01484587|DRUG|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
215146829|NCT01374438|DRUG|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
215146830|NCT01374438|DRUG|Placebo|Placebo capsules given once daily for 90 days
215146831|NCT03938259|DRUG|Fentanyl|identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
215146834|NCT00025688|DRUG|carboplatin|
215146835|NCT00025688|DRUG|paclitaxel|
215146836|NCT02891577|PROCEDURE|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
215146837|NCT01002339|DRUG|Tacrolimus with rapid steroid withdrawal|"* Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
215146838|NCT01002339|DRUG|Tacrolimus with steroids minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
214460107|NCT06798688|DEVICE|A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations|"This Study aims to pilot software algorithms based on respiratory features and hemodynamics for predicting exacerbations on a total of 20 participants with COPD. The end-points of this Study includes the following:~1. To validate respiratory-based biomarkers in models to predict exacerbations - benchmarking to be done versus physician assess exacerbations, emergency department visits, hospitalizations and any other visit.~2. To validate level of compliance, drop-out rate and if additional measures are required to get participants to follow-on"
214460108|NCT06629597|DRUG|YL201|YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
214460109|NCT06629597|DRUG|Docetaxel|Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
214460110|NCT06629597|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
214460111|NCT06629597|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
214460112|NCT06151834|PROCEDURE|KeriFuse implant implantation|The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
214460113|NCT04309188|DEVICE|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
214460114|NCT04309188|OTHER|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
214460115|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
214460116|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
214460117|NCT06628258|OTHER|Moiz Cleansing Lotion|"Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
214460118|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
214460119|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
214460120|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
214460121|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
214460122|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
214460123|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
214460124|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
214460125|NCT05449132|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
214460126|NCT05449132|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
214460127|NCT04048993|OTHER|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
214460128|NCT05720949|DRUG|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
214460129|NCT03830762|DRUG|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
214460130|NCT03830762|DRUG|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
214460131|NCT03344250|DRUG|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
214460132|NCT03344250|DRUG|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
214530378|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
214530379|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
214530380|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
214530381|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
214530382|NCT03392779|DRUG|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
214530383|NCT03392779|DRUG|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
214530384|NCT03392779|DRUG|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
214530385|NCT03392779|DRUG|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
214530386|NCT03392779|DRUG|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
214530387|NCT03392779|DRUG|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
214695392|NCT03831802|DEVICE|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
214695393|NCT03831802|DEVICE|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
214695394|NCT04966195|RADIATION|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
214695395|NCT05161351|DRUG|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
214695396|NCT05161351|DRUG|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
215146839|NCT01002339|DRUG|CsA with steroid minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d"
215146840|NCT04881994|DRUG|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
215146841|NCT01452698|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
214530388|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
214530389|NCT03392779|DRUG|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
214530390|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
214530391|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
214530392|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
214530393|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
214530394|NCT02330861|DEVICE|combowire and IVUS|
214530395|NCT01464671|DRUG|Bivalirudin|Anticoagulation during percutaneous coronary intervention
214530396|NCT01464671|DRUG|Heparin|Anticoagulation during percutaneous coronary intervention
214530397|NCT04222335|OTHER|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
214695397|NCT04329611|DRUG|Hydroxychloroquine|COVID19
215146842|NCT01452698|DRUG|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
215146843|NCT01452698|DRUG|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
215146844|NCT01452698|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
214530398|NCT03640754|BIOLOGICAL|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
214530399|NCT03640754|OTHER|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
214530400|NCT05729477|DEVICE|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
214530401|NCT05729477|DEVICE|Phaco Subject Cohort|Phaco Subject Cohort
214530402|NCT02108496|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
214530403|NCT02108496|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
214530404|NCT02108496|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
214530405|NCT02108496|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
214530406|NCT00861354|DEVICE|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
214530407|NCT02691884|PROCEDURE|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
214530408|NCT05075135|DEVICE|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
214530409|NCT05075135|DEVICE|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
215146845|NCT01907854|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
215146846|NCT01907854|DRUG|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
215146847|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
215146848|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
214530410|NCT05329402|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
214530411|NCT05329402|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
214530412|NCT03249272|DRUG|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
214530413|NCT03249272|DRUG|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
214530414|NCT05858606|DIAGNOSTIC_TEST|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"1. pre-inclusion consultation~2. inclusion consultation~   * personal history~  * height, weight, cranial perimeters, and spans of both parents~  * clinical examination of the child~  * photographs of the child~  * additional X-rays"
214568582|NCT04889105|BEHAVIORAL|Smart MOVE!|"Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring"
214568583|NCT04889105|BEHAVIORAL|General walking advice|Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
215146849|NCT04959877|BEHAVIORAL|health education|data collect / Telemedicine
215146850|NCT02004041|DRUG|VLY-686|
215146851|NCT02004041|DRUG|Placebo|
215146852|NCT04659876|DIAGNOSTIC_TEST|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
215146853|NCT00002696|DRUG|CAF regimen|
215146854|NCT00002696|DRUG|CMF regimen|
215146855|NCT00002696|DRUG|cyclophosphamide|
215146856|NCT00002696|DRUG|doxorubicin hydrochloride|
215146857|NCT00002696|DRUG|fluorouracil|
215146858|NCT00002696|DRUG|methotrexate|
215146859|NCT00002696|PROCEDURE|adjuvant therapy|
215146860|NCT00002696|PROCEDURE|conventional surgery|
215146861|NCT00002696|PROCEDURE|neoadjuvant therapy|
214460133|NCT04701645|COMBINATION_PRODUCT|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
214460134|NCT05210608|BEHAVIORAL|Working Memory Training + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
214460135|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
214460136|NCT01120223|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
214460137|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Three-Dimensional Printer|Band and loop space maintainer produced with three-dimensional printer using micro laser sinterisation method
214460138|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Conventional Technique|Band and loop space maintainer produced with conventional methods
215146862|NCT00002696|RADIATION|radiation therapy|
215146863|NCT03378986|PROCEDURE|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
214460139|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in EFT
214460140|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in ERT
214460141|NCT05012176|OTHER|Quality-of-Life Assessment|Ancillary studies
214460142|NCT05012176|OTHER|Questionnaire Administration|Ancillary studies
214460143|NCT06245187|OTHER|GWTG Atrial Fibrillation program|Evidence based recommended therapies and counseling prior to hospital discharge.
214460144|NCT05375643|BEHAVIORAL|SURGE|Video with or without person to person guidance to support decision making around genetic testing
214460145|NCT02912897|BIOLOGICAL|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
214460146|NCT05653661|PROCEDURE|Biopsy|Undergo tissue biopsies
214460147|NCT05653661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214460148|NCT05653661|PROCEDURE|Computed Tomography|Undergo CT scans
214460149|NCT05653661|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
215146864|NCT03378986|PROCEDURE|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
215146865|NCT05950074|BEHAVIORAL|"It´s Up To You program"|The main goal of this program is to prevent substance use and engagement in addictive behaviors through enabling teenagers to make informed and responsible decisions. It seeks to support students in the anticipation of realistic choice situations and problems typically affecting this age group. It is based on social influences, considering the peer group influences (peer pressure) and the affective and cognitive factors that intervene at the time of decision-making and problem-resolution. This program is intended to be delivered by trained teachers in six sessions through six different modules.
215146866|NCT04012957|DRUG|Desidustat Oral Tablet|Desidustat tablet
215146867|NCT04012957|DRUG|Darbepoetin Alfa|Darbepoetin injection
215146868|NCT02215252|DRUG|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
215146869|NCT02215252|DRUG|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
215146870|NCT02215252|DRUG|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
215146871|NCT02215252|DRUG|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
215146872|NCT06217510|DEVICE|Test Brace|Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
215146873|NCT00661050|PROCEDURE|Alternative Medicine|
215146874|NCT00661050|PROCEDURE|Tai Chi instruction and class participation or walking exercise and sitting meditation|
215146875|NCT01185210|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
215146876|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
215146877|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
215146878|NCT03774576|DRUG|RO7017773|Single doses of RO7017773
215146879|NCT03774576|DRUG|Itraconazole|Multiple doses of Itraconazole
215146880|NCT02906748|PROCEDURE|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
214695398|NCT02711709|OTHER|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~1. muscle weakness~2. fatigue~3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
215146881|NCT02906748|PROCEDURE|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
215146882|NCT05969652|OTHER|Heavy slow resistance training|"Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets\*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3\*15 2-3.week 3\*12 4th-5th week 3\*10 6th week 3\*8"
215146883|NCT05969652|OTHER|Eccentric exercise training|"Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week."
215146884|NCT03228823|PROCEDURE|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
215146885|NCT03228823|DRUG|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
215146886|NCT05361707|DRUG|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
215146887|NCT06530147|OTHER|Transversalis Fascia Plane Block|One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
214460150|NCT05653661|DRUG|Nab-paclitaxel/Danburstotug Complex AP160|Given IV
214460151|NCT00832325|BEHAVIORAL|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
214460152|NCT00832325|BEHAVIORAL|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
214460153|NCT00832325|BEHAVIORAL|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
214460154|NCT04045184|OTHER|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
214460155|NCT06493422|BEHAVIORAL|Reaching Movements|participants will perform a perceptual decision making task while moving their hand.
214460156|NCT06771167|BEHAVIORAL|Building Community Resilience Program (BCR)|To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).
214460157|NCT04380545|DRUG|Fluorouracil|Given IV
214460158|NCT04380545|BIOLOGICAL|Nivolumab|Given IV
214460159|NCT04380545|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Given SC
214460160|NCT05552014|BEHAVIORAL|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
214460161|NCT05552014|BEHAVIORAL|Mental Health Education|Mental Health Education Seminar
214460162|NCT05307133|OTHER|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
214460163|NCT06068543|DRUG|Epigallocatechin-3-Gallate (EGCG)|800mg Epigallocatechin-3-Gallate (EGCG)
214460164|NCT06068543|DRUG|Microcrystalline cellulose (MCC)|800mg microcrystalline cellulose (MCC)
214460165|NCT06068543|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C)|250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
214460166|NCT06577584|OTHER|Follow-up in the Diabetes Care Trajectory|Being followed-up in the Diabetes Care Trajectory in Belgium
214460167|NCT06577584|OTHER|Follow-up in the Diabetes Convention|Being followed-up in the Diabetes Convention in Belgium
214460168|NCT04478890|DIAGNOSTIC_TEST|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
214460169|NCT06313866|DIETARY_SUPPLEMENT|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
214460170|NCT06313866|OTHER|Electronuchal acupuncture group treatment|Electronuchal acupuncture
215146888|NCT06530147|OTHER|Transversus Abdominis Plane Block|One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
214530415|NCT05858606|PROCEDURE|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~* either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~* or to the authentified idiopathic short stature group"
215146889|NCT03761992|DIETARY_SUPPLEMENT|Gingko Baloba|Tablets
215146890|NCT03761992|OTHER|Placebo|Tablets
215146891|NCT03150953|DEVICE|MRI-safe bore covering|
215146892|NCT03223896|DRUG|Naloxone hydrochloride 20mg/ml|Nasal spray
215146893|NCT03146416|DRUG|Evinacumab|SC or IV administration of Evinacumab
215146894|NCT03146416|DRUG|Placebo|Matching placebo
215146895|NCT03294252|DRUG|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
215146896|NCT03294252|DRUG|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
215146897|NCT03294252|DRUG|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
215146898|NCT02877407|PROCEDURE|patient who undergo laparoscopic/robotic-assisted hysteropexy|
215146899|NCT02877407|PROCEDURE|patient who undergo vaginal hysterectomy|
215146900|NCT01473901|DRUG|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
214460171|NCT06313866|OTHER|Smell therapy group treatment|nasal suction intervention with volatile oil of Acorus calamus
214460172|NCT06313866|OTHER|Electronuchal acupuncture combined with smell and inhalation therapy group treatment|On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.
214460173|NCT06313866|OTHER|Sham stimulation|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
214460174|NCT04908722|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
214460175|NCT06807385|OTHER|Reaction Training|"* The exercise list consists of 15 different exercises that aim to both shorten reaction time and improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks (tasks related to the color of the light to be touched, giving the command to read lights that are lit in different directions) and a second cognitive task.~* Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes.~  * Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points) according to the Borg scale."
214460176|NCT06807385|OTHER|Conventional Exercises|"The exercises used in reaction training will be applied as in conventional training without reaction training system. The difficulty of the exercise will be increased by changing the support surface and ground properties, taking the difficulty perceived by the individual as the criterion, as in reaction training.~The exercise list consists of 15 different exercises that aim to improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks and a second cognitive task. Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes. Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points for Borg Scale)."
214568584|NCT04889105|BEHAVIORAL|Performance evaluation|"Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2\) N-of-1 trials to refine the intervention"
215146901|NCT01473901|DRUG|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
215146902|NCT02757508|DIETARY_SUPPLEMENT|protein powder supplement|
215146903|NCT02757508|DIETARY_SUPPLEMENT|Vitamins/minerals|
215146904|NCT01716234|DRUG|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
215146905|NCT01716234|DRUG|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
214460177|NCT02319759|DRUG|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
214695399|NCT02711709|OTHER|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
215146906|NCT01716234|DRUG|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
214460178|NCT02319759|DRUG|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
214460179|NCT02319759|DRUG|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
215146907|NCT01716234|DRUG|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
215146908|NCT04466319|OTHER|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
215146909|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
215146910|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
215146911|NCT00702299|DRUG|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
215146912|NCT00702299|DRUG|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
214460180|NCT04931810|BEHAVIORAL|All Nations Breath of Life|Same.
214460181|NCT02187848|DRUG|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
214460182|NCT05206929|OTHER|Self Managed Care|Self Managed Care
214695400|NCT02711709|OTHER|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
214695401|NCT02711709|OTHER|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
214695402|NCT03969797|DEVICE|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
214695403|NCT06457984|DIETARY_SUPPLEMENT|Selenium nutritional supplementation|Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
214695404|NCT06203730|BEHAVIORAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
214460183|NCT04501536|BEHAVIORAL|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
214460184|NCT04213872|BEHAVIORAL|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
214460185|NCT05292625|BIOLOGICAL|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
214460186|NCT05292625|BIOLOGICAL|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
214460187|NCT05292625|OTHER|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
215146913|NCT00702299|DRUG|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
215146914|NCT00702299|OTHER|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
215146915|NCT03901872|DEVICE|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
215146916|NCT05105204|DEVICE|ArteVu|The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
215146917|NCT02643212|DRUG|Rivaroxaban|
215146918|NCT02643212|DRUG|Placebo|
215146919|NCT06387121|DRUG|Vincristine|Anti-tumor alkaloids
215146920|NCT06387121|DRUG|Cyclophosphamide|Alkylating agent
215146921|NCT06387121|DRUG|Dexamethasone|Glucocorticoids
215146922|NCT06387121|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
215146923|NCT06387121|DRUG|Inotuzumab ozogamicin|A humanized monoclonal antibody-drug conjugate targeting CD22
215146924|NCT06387121|DRUG|Blinatumomab|Bi-specific anti-CD19/CD3 antibodies
215146925|NCT06387121|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
215146926|NCT06387121|DRUG|Methotrexate|Antifolate antineoplastic drug
215146927|NCT06387121|DRUG|Cytarabine|Pyrimidine antimetabolites
215146928|NCT06387121|DRUG|Prednisone|Glucocorticoids
215146929|NCT00515619|DRUG|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
214530416|NCT05858606|GENETIC|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
214530417|NCT03426332|OTHER|No intervention|No intervention
214530418|NCT00322764|DRUG|Uridine|
214530419|NCT04314102|OTHER|No intervention will be made.|No intervention will be made. Only checks will be made
214530420|NCT00825513|DEVICE|Akreos Toric IOL|Lens implant following cataract surgery
214530421|NCT00825513|DEVICE|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
214530422|NCT02458794|PROCEDURE|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
214530423|NCT02458794|DEVICE|LMA SupremeTM|
214530424|NCT02458794|DEVICE|Ambu-Aura GainTM|
215146930|NCT03815929|DRUG|Estradiol 100 Micrograms Patch|Standard
215146931|NCT03815929|DRUG|Estradiol Patch|Individualized
215146932|NCT00891943|OTHER|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
215146933|NCT04616989|BEHAVIORAL|Psycho-education|Provide psycho-education to members of the community
215146934|NCT04616989|BEHAVIORAL|Comparator|Distribution of COVID-19 leaflets to members of the community
215146935|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
215146936|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
215146937|NCT01590355|RADIATION|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
215146938|NCT01590355|PROCEDURE|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
214530425|NCT03916159|PROCEDURE|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
214530426|NCT03916159|PROCEDURE|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
214530427|NCT03638700|DEVICE|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
214530428|NCT03638700|DEVICE|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
214530429|NCT03638700|DEVICE|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
214530430|NCT03638700|DEVICE|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
214530431|NCT01924468|DRUG|Oral methylphenidate and Oral haloperidol|
214530432|NCT03157414|DRUG|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
214530433|NCT03157414|OTHER|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
214530434|NCT00975078|PROCEDURE|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
214530435|NCT00975078|DRUG|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
214530436|NCT03734614|DRUG|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
214530437|NCT05939050|DEVICE|Powered toothbrush|Oral-B Powered toothbrush
214530438|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
214530439|NCT01679613|DRUG|Nintedanib|low dose oral administration
214695405|NCT03072719|DRUG|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
215146939|NCT03452969|OTHER|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
214530440|NCT01679613|DRUG|Ketoconazole|oral administration
214530441|NCT01679613|DRUG|Nintedanib|low dose oral administration
214530442|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
214530443|NCT01679613|DRUG|Ketoconazole|oral administration
214530444|NCT04783519|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
214530445|NCT04783519|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
214530446|NCT03087461|BEHAVIORAL|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
214530447|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
214695406|NCT03072719|DRUG|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
214695407|NCT03791437|DEVICE|Digital chest drainage system|patients who received Digital chest drainage system
215146940|NCT00771758|DRUG|oxycodone IR|maximum daily dose 450 mg
215146941|NCT00771758|DRUG|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
215146942|NCT00771758|DRUG|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
215146943|NCT03067077|PROCEDURE|SMILE|SMILE surgery
215146944|NCT03067077|PROCEDURE|LASIK|LASIK surgery
215146945|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
215146946|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
215146947|NCT03458819|DIAGNOSTIC_TEST|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
215146948|NCT02612272|DRUG|Ketorolac|intra-articular ketorolac
215146949|NCT02612272|DRUG|Betamethasone|intra-articular betamethasone
215146950|NCT00684918|DRUG|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
215146951|NCT04504825|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
215146952|NCT04504825|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
215146953|NCT04504825|DRUG|cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen|According to institutional standard of care.
215146954|NCT01781546|PROCEDURE|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).
215146955|NCT01781546|PROCEDURE|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).
215146956|NCT00529438|DRUG|Bardoxolone methyl|
215146957|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
215146958|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
215146959|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
215146960|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
215146961|NCT05500144|OTHER|Not applicable- no intervention administered|Not applicable- no intervention administered
214460188|NCT06806826|DRUG|Omalizumab|The patients in the study group were started on omalizumab and intranasal fluticasone propionate. Omalizumab was administered subcutaneously to these patients at a dose of 300 mg once a month. . Twenty-five patients in the control group were started on intranasal fluticasone propionate spray and a tablet containing 5 mg desloratadine+10 mg montelukast sodium at the same dose and in the same manner as the patients in the study group. The patients were asked to use 100 mg of suspension equivalent to 50 micrograms of fluticasone propionate as two sprays into each nostril once daily and to use the tablet once daily. Patients in both groups were asked to fill out the visual analog scale and their total Ig E levels were checked. Patients who were called for a check-up after eight to ten weeks were evaluated again with the visual analog scale.
214460189|NCT04016142|DRUG|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
214460190|NCT02162563|DRUG|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
214460191|NCT02162563|DRUG|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
214460192|NCT02162563|DRUG|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
214460193|NCT03339713|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.
214460194|NCT03339713|BIOLOGICAL|Fluarix|Fluarix will be administered as intramuscular injection.
214530448|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
214530449|NCT04090788|DIETARY_SUPPLEMENT|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
214530450|NCT04090788|DIETARY_SUPPLEMENT|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
214695408|NCT03791437|DEVICE|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
214695409|NCT00209599|DRUG|fospropofol disodium|
214530451|NCT03453177|DRUG|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
214695410|NCT00337376|DRUG|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
214695411|NCT00337376|DRUG|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
214695412|NCT01901731|PROCEDURE|transjugular coil embolisation of pelvic veins|
214695413|NCT01901731|PROCEDURE|endovenous treatment of leg varicose veins|
214695414|NCT02600325|DRUG|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
214695415|NCT03201146|DRUG|Apatinib|Doses to be determined following the completion of Phase I of the study.
214695416|NCT03201146|DRUG|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
214695417|NCT03201146|DRUG|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
214695418|NCT03201146|DRUG|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
214695419|NCT03201146|DRUG|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
214695420|NCT00264602|DRUG|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
214695421|NCT01027208|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
214695422|NCT01863407|DRUG|DAM|composed of dexamethasone, allantoin and metronidazole
214695423|NCT01863407|DRUG|Normal Saline|Normal Saline 250ml
215146962|NCT03747562|DRUG|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
215146963|NCT03747562|OTHER|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
214695424|NCT00882999|DRUG|LY2127399|Administered via Injection
214695425|NCT00882999|DRUG|Placebo|Administered via Injection
214695426|NCT02689232|BIOLOGICAL|Fresh Frozen Plasma|
215146964|NCT01394016|DRUG|Abemaciclib|Administered orally.
215146965|NCT01394016|DRUG|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks in Part G only.
214695427|NCT02689232|BIOLOGICAL|Platelets Concentrate|
214695428|NCT02689232|BIOLOGICAL|Cryo Precitipitate|
214695429|NCT03271385|DIAGNOSTIC_TEST|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
214695430|NCT06312449|OTHER|The side-lying position with the peanut ball during the second stage of labor.|"The usage of the peanut ball is divided into two stages:~Stage one: The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The peanut ball is placed between the legs, allowing for leg separation. The parturient can choose to lie on either the left or right side according to preference.~Stage two: When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides. The peanut ball is then positioned between the legs with the knees bent together, for pushing"
214695431|NCT06312449|OTHER|During the second stage, the patient is placed in a lateral position|The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The parturient can choose to lie on either the left or right side according to preference.When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides, for pushing
214695432|NCT06139679|PROCEDURE|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
214695433|NCT02132234|DRUG|Etanercept|biological treatment according to rheumatologic indication
214695434|NCT02132234|DRUG|Adalimumab|biological treatment according to rheumatologic indication
214695435|NCT02132234|DRUG|Certolizumab|biological treatment according to rheumatologic indication
214530452|NCT03453177|PROCEDURE|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
215146966|NCT05821127|BEHAVIORAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
215146967|NCT05821127|BEHAVIORAL|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
215146968|NCT05877924|DRUG|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
215146969|NCT05313971|OTHER|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
215146970|NCT00344201|DEVICE|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
215146971|NCT05142501|OTHER|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
215146972|NCT01238367|DRUG|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
215146973|NCT04334824|DRUG|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
215146974|NCT04334824|DRUG|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
215146975|NCT03736863|DRUG|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
215146976|NCT03736863|DRUG|Apatinib+ SHR-1316（Adebrelimab）|Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
215146977|NCT03736863|DRUG|SHR-1316（Adebrelimab）+SHR-A2009|SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
215146978|NCT05089825|OTHER|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
215146979|NCT05089825|OTHER|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
215146980|NCT04220307|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration
215146981|NCT04248634|PROCEDURE|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~\- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
215146982|NCT02368834|BEHAVIORAL|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
215146983|NCT01851642|PROCEDURE|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
215146984|NCT01851642|PROCEDURE|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
214530453|NCT03453177|PROCEDURE|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
214530454|NCT05490368|DEVICE|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
214530455|NCT00727259|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
214530456|NCT00727259|DRUG|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
214530457|NCT03594786|DEVICE|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
214695436|NCT02132234|DRUG|Infliximab|biological treatment according to rheumatologic indication
214530458|NCT01021683|DRUG|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
214530459|NCT06269393|DRUG|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
214530460|NCT06269393|DRUG|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
214530461|NCT00355771|DRUG|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
214530462|NCT00355771|DRUG|Placebo|1 tablet OD in the morning for 8 weeks
214530463|NCT01339156|DRUG|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
214530464|NCT01339156|DRUG|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
214530465|NCT02579941|PROCEDURE|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
214530466|NCT02579941|PROCEDURE|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
214530467|NCT00471562|BIOLOGICAL|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
214530468|NCT02926495|DEVICE|eCoin System|Median nerve neurostimulator.
214530469|NCT05160402|DRUG|IGM-6268|Active comparator
214530470|NCT05160402|DRUG|Placebo|Placebo comparator
214530471|NCT06540248|DEVICE|Ialuadapter|minimally invasive syringe device for bladder catherization
214530472|NCT03785418|BEHAVIORAL|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
214530473|NCT00645099|DRUG|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
214530474|NCT00645099|DRUG|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
214530475|NCT02921438|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
214530476|NCT03149432|PROCEDURE|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
214530477|NCT03149432|DRUG|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
214530478|NCT03149432|PROCEDURE|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
214530479|NCT03149432|OTHER|Local care|local care for directed healing of the stump.
214530480|NCT03920761|DEVICE|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
214530481|NCT03920761|DEVICE|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
214530482|NCT06477562|OTHER|Endoscopy|surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
214530483|NCT01914302|DEVICE|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530484|NCT01914302|DEVICE|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530485|NCT01914302|DEVICE|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530486|NCT01914302|DEVICE|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
215146985|NCT01851642|PROCEDURE|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
215146986|NCT01851642|DRUG|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
215146987|NCT06117605|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
215146988|NCT06117605|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
214460195|NCT03339713|BIOLOGICAL|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
214460196|NCT05917171|BEHAVIORAL|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
214460197|NCT06425211|BEHAVIORAL|Therapeutic exercises|Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.
214460198|NCT06425211|DEVICE|Perineal electromyographic biofeedback|Free muscle work and gross motor coordination:
214460199|NCT06425211|DEVICE|Electrical stimulation|Muscular proprioceptive work: 50 Hz 300 µs
214530487|NCT01914302|DEVICE|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530488|NCT01914302|DEVICE|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530489|NCT01914302|DEVICE|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530490|NCT01914302|DEVICE|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
214530491|NCT06040138|DIAGNOSTIC_TEST|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
214530492|NCT05234008|OTHER|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from \>3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
215146989|NCT01899521|PROCEDURE|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
214460200|NCT06213857|DIETARY_SUPPLEMENT|Silymarin|Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
214460201|NCT06213857|DRUG|Mesalamine|A 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.
214460202|NCT06213857|DRUG|Azathioprine|An immunosuppressive medication that is used for the treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis). It works by decreasing the activity of the body's immune system so it will not attack itself.
214460203|NCT01902173|PROCEDURE|Biopsy|Undergo a biopsy
214460204|NCT01902173|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214460205|NCT01902173|PROCEDURE|Computed Tomography|Undergo a CT scan
214460206|NCT01902173|DRUG|Dabrafenib Mesylate|Given PO
214460207|NCT01902173|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214460208|NCT01902173|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214460209|NCT01902173|DRUG|Uprosertib|Given PO
214460210|NCT02649842|DEVICE|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
214460211|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
215146990|NCT01899521|DIETARY_SUPPLEMENT|Zinc sulfate 220 mg once daily|
215146991|NCT01899521|DIETARY_SUPPLEMENT|S-adenosylmethionine 400 mg twice daily|
215146992|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
215146993|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
215146994|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
215146995|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
215146996|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
215146997|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
215146998|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
215146999|NCT04506411|DIETARY_SUPPLEMENT|Turmipure GOLD®|TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
215147000|NCT04506411|DIETARY_SUPPLEMENT|Turmeric rhizome PE 95% curcuminoids|STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
215147001|NCT04506411|DIETARY_SUPPLEMENT|Placebo|Placebo: Maltodextrin - 4 capsules once daily- as prescribed
214460212|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
214460213|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
214460214|NCT06162728|DRUG|Briquilimab|Subcutaneous Administration
214460215|NCT06162728|OTHER|Placebo|Placebo Comparator
214460216|NCT06216808|DEVICE|HyperQure Renal Denervation System|"The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA."
214460217|NCT04619745|OTHER|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
214460218|NCT06770179|OTHER|recruitment maneuver|in the group 2, in addition to the fixed PEEP of 5 cm H₂O, a recruitment maneuver is planned at the end of the surgery. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, before extubation.
214460219|NCT06770179|OTHER|positional recruitment maneuver|In the third group, in addition to the fixed PEEP, a recruitment maneuver will be performed at the end of the surgery before extubation. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, with 3 breaths in the right lateral decubitus position and 3 breaths in the left lateral decubitus position
214460220|NCT02835222|DRUG|Cytarabine|Given IV
214530493|NCT06475092|OTHER|Tanita device|bioelectric impedance analysis
214530494|NCT03037814|DEVICE|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
214530495|NCT03037814|DEVICE|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
214530496|NCT03037814|DEVICE|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
214530497|NCT03037814|DEVICE|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
214530498|NCT06472960|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
214530499|NCT06472960|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
214530500|NCT06472960|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
214530501|NCT02095938|DRUG|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
214530502|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
214530503|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
214530504|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
214695437|NCT04685070|DRUG|HS-10296 (Almonertinib)|Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
214460221|NCT02835222|DRUG|Daunorubicin Hydrochloride|Given IV
214460222|NCT02835222|DRUG|Selinexor|Given PO
214460223|NCT06495216|DEVICE|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
214460224|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
214460225|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
214530505|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
214530506|NCT00729508|BIOLOGICAL|Cat-PAD|Placebo
214695438|NCT02456870|OTHER|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
214460226|NCT05540665|DRUG|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
214460227|NCT04207723|OTHER|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
214460228|NCT04207723|DRUG|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
214460229|NCT06422936|DRUG|BO-112|Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
214460230|NCT06384183|DEVICE|Kerecis Fish Skin Graft|Patients already treated with a Kerecis device
214460231|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
214460232|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
214460233|NCT06807762|DRUG|Cannabis oil|"Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages:~Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg.~Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days."
214460234|NCT02619838|DEVICE|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
214460235|NCT04821440|DEVICE|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
214460236|NCT04821440|DEVICE|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
214460237|NCT05397912|DIAGNOSTIC_TEST|Uterine Elastography|Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
214460238|NCT05505292|DRUG|Lifitegrast 5% Ophthalmic Solution|Dosed twice a day for 8 weeks
214460239|NCT05505292|OTHER|Lifitegrast Ophthalmic Solution Vehicle|Dosed twice a day for 8 weeks
214460240|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
214460241|NCT06771466|PROCEDURE|Bilateral Ultrasound-Guided Erector Spinae Plane Block (group E)|The curvilinear ultrasound transducer should be placed in a cephalocaudal orientation over the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level. The transverse process will be more superficial and wider, while the rib will be deeper and thinner. Upon verification of the transverse process, the trapezius muscle, rhomboid major muscle (if performing at T5 level or higher), and erector spinae muscle should be identified superficial to the transverse process. The Tuohy needle should be inserted superior to the ultrasound probe using an in-plane approach in the cephalad to caudal direction.
214460242|NCT06771466|PROCEDURE|Bilateral Ultrasound-guided Quadratus Lumborum, Lateral approach (group Q)|With the patient positioned in the lateral position, scanning is usually started at the mid-axillary line between the iliac crest and subcostal margin, moving the probe posteriorly until tapering of the three abdominal muscle layers and appearance of fascia transversalis and QL muscle are observed. The fascia transversalis usually appears as a hyperechoic layer, which forms a safe landmark to separate the muscle layers from the peri-nephric fat and the abdominal contents
214460243|NCT06252285|BIOLOGICAL|RSVt Vaccine|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
214460244|NCT06252285|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
214460245|NCT05140200|BIOLOGICAL|GSK3511294|GSK3511294 will be administered.
214460246|NCT06616454|BEHAVIORAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
214460247|NCT06125132|PROCEDURE|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
214460248|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
214530507|NCT01685307|DIETARY_SUPPLEMENT|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
214530508|NCT01601639|DEVICE|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
214530509|NCT01601639|DEVICE|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
214530510|NCT01121497|DRUG|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
214695439|NCT00741143|OTHER|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
214530511|NCT04804228|OTHER|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
214530512|NCT04804228|OTHER|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
214530513|NCT05510102|DEVICE|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
214460249|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
214460250|NCT04066244|DRUG|BLZ945|Investigational drug capsules taken orally or via enteral infusion
214460251|NCT06771557|OTHER|656 Online Platform|The 656 Platform provides valuable information regarding three common ailments among the elderly, namely stroke, dementia, and fall-related fractures. Serving as an online platform, the 656 Platform incorporates a Chatbot feature that facilitates connections between local caregivers, social workers, and community members to various services. Serving as an online platform, the 656 Platform incorporates an AI Chatbot and a Live Chat feature that facilitates connections between local caregivers, social workers, and community members to various services. Apart from this, the 656 Platform offers several features that enhance its functionality and user experience, including problem-based elderly resource database, interim care solutions, exchange forum, data analytics and research, and professional knowledge and resources.
214460252|NCT01073566|DEVICE|Finesse|Finesse Insulin Delivery Patch
214460253|NCT01073566|DEVICE|Pen/Syringe (Usual injection device)|Pen/Syringe
214460254|NCT06765993|DRUG|Isosorbide oral solution|30 mL, TID
214460255|NCT06765993|DRUG|Placebo|30 mL, TID
214460256|NCT05188092|OTHER|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
214460257|NCT02936102|DRUG|FAZ053|Anti-PD-L1 Antibody
214460258|NCT02936102|DRUG|PDR001|Anti-PD-1 Antibody
214460259|NCT05057845|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
214460260|NCT05057845|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214460261|NCT05057845|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
214460262|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
214460263|NCT05082181|BEHAVIORAL|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
214530514|NCT05510102|DEVICE|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
214530515|NCT01863888|DRUG|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
214530516|NCT01863888|DRUG|cholestyramine|Pharmaceutical form:powder Route of administration: oral
214460264|NCT05082181|BEHAVIORAL|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
214460265|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
215147002|NCT06663670|OTHER|Intraneural Facilitation Therapy|"* The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure."
215147003|NCT06663670|OTHER|Nerve Flossing Technique|"Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload."
215147004|NCT04531618|BEHAVIORAL|Emotional Exchange (EE)|These sessions, conducted by a trained study staff member through Zoom, will involve storytelling and discussing emotional experiences with the baby, with prompts like sharing about the pregnancy or reactions to the baby's smiles.
215147005|NCT04531618|OTHER|Newborn Care (NC)|Newborn Care (NC) is a teaching curriculum designed to provide mothers with developmentally appropriate information about newborn care. The curriculum is adapted from previously studied literature that increased maternal knowledge about both medical and developmental concerns.
215147006|NCT06588166|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
214460266|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
214460267|NCT05073666|OTHER|NO INTERVENTION|NO INTERVENTION
214460268|NCT04218708|OTHER|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
214460269|NCT04218708|BEHAVIORAL|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
214460270|NCT04218708|BEHAVIORAL|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
214460271|NCT04218708|BEHAVIORAL|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
214460272|NCT04218708|OTHER|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver \>300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
214460273|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923 cell suspension
214460274|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
214460275|NCT03168971|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
214460276|NCT01579409|OTHER|PNNS guidelines|Application of PNNS guidelines
214460277|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
215147007|NCT06587880|DRUG|Chlorhexidine Gluconate|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction, the patient is instructed to pour 10 ml of the mouthwash into a measuring cup, rinse for 1 minute at an alternative time to teeth brushing. Do not eat or drink for 30 min after use.
215147008|NCT06587880|DRUG|Bone Bioactive Liquid|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
214695440|NCT01104584|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
215147009|NCT06587880|DRUG|Hyaluronic Acid mouthwash|Prescribed for 7 days period 3-4 times a day starting 24 hours post-extraction, the patient is instructed to pour 20 ml of the mouthwash into a measuring cup and rinse for 1 minute, at an alternative time to teeth brushing. Do not eat or drink for 30 mins after use.
215147010|NCT06587880|DRUG|Warm Saline Mouth Rinse|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
214460278|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
214530517|NCT01863888|DRUG|charcoal|Pharmaceutical form:granule Route of administration: oral
214460279|NCT06807671|OTHER|Experimental Group|Patients in the intervention group received HBM based training for a period of 6 months. During the training, one-on-one interviews were provided with each patient. Patients were shown a power point presentation, a brochure, and 3 training videos. Any questions patients had were answered one-on-one.
214460280|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
214460281|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
214460282|NCT04326673|OTHER|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
214460283|NCT04326673|OTHER|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
214460284|NCT03903562|BIOLOGICAL|V503|0.5 mL 9vHPV VLP Vaccine
214530518|NCT03206489|DEVICE|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
214530519|NCT03206489|DEVICE|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
214530520|NCT02089984|BEHAVIORAL|Internet Based CBT Training|
214530521|NCT01971424|DIETARY_SUPPLEMENT|Mg oxide|
214530522|NCT01971424|OTHER|healthy diet|
214530523|NCT00415025|PROCEDURE|adjuvant therapy|
214530524|NCT00415025|PROCEDURE|management of therapy complications|
214530525|NCT00415025|PROCEDURE|quality-of-life assessment|
214530526|NCT00415025|RADIATION|intensity-modulated radiation therapy|
214530527|NCT01201915|DRUG|Vismodegib|Vismodegib was supplied in gelatin capsules.
214530528|NCT04753281|OTHER|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
214530529|NCT05734885|OTHER|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
214530530|NCT04354623|OTHER|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
214530531|NCT06653569|DRUG|Baloxavir Marboxil|"The antiviral baloxavir marboxil administered in one unique dose.~1 capsule (40 mg) if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg"
214530532|NCT06653569|DRUG|Placebo|Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.
214530533|NCT05024266|DRUG|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
214530534|NCT02154516|DEVICE|ODH Hip System|
214530535|NCT02173756|DRUG|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
214530536|NCT02173756|DRUG|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
214530537|NCT03406507|BIOLOGICAL|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
214530538|NCT00911014|OTHER|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
214530539|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
214530540|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
214530541|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
214530542|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
214530543|NCT01515202|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
214530544|NCT01282918|DEVICE|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
214460285|NCT03309306|OTHER|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
214460286|NCT03309306|BEHAVIORAL|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns"
214460287|NCT03916042|DRUG|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
214460288|NCT03916042|DRUG|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
214460289|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
214460290|NCT05916456|DIAGNOSTIC_TEST|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
214460291|NCT05916456|DIAGNOSTIC_TEST|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
214460292|NCT05916456|DIAGNOSTIC_TEST|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
214460293|NCT05062187|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
214460294|NCT05039151|BIOLOGICAL|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
214460295|NCT05039151|BIOLOGICAL|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
214460296|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
214460297|NCT05685615|DRUG|BV100 plus Polymyxin B|Rifabutin for Infusion plus Polymyxin B for Injection
214460298|NCT05685615|DRUG|BAT|The best avaialble antibiotic therapy to treat CRAB
214460299|NCT05604508|OTHER|Many posters with prices|No poster number or price restrictions
214460300|NCT05604508|OTHER|Many posters, no prices|No poster number restrictions, but price restrictions
214460301|NCT05604508|OTHER|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
214460302|NCT05702138|OTHER|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
214460303|NCT03420547|BEHAVIORAL|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
214530545|NCT01282918|DEVICE|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
214530546|NCT01540019|DRUG|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
214460304|NCT05533359|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
214530547|NCT05248217|BEHAVIORAL|healthcare workers|healthcare
214530548|NCT00663923|PROCEDURE|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
214530549|NCT05799040|DEVICE|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
214530550|NCT05799040|DEVICE|Chartis detection system|The participants would evaluated by the Chartis detection system.
215147011|NCT06590662|DRUG|Solriamfetol|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period."
215147012|NCT06590662|DRUG|Placebo|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period."
214460305|NCT05533359|BEHAVIORAL|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
215147013|NCT06589882|OTHER|Effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques|Evaluate the effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques practiced in French expert centers over the next 10 years with the rate of technical success (procedure completed) and clinical success (cure) of the digestive pathology presented by the patient who indicated endoscopy without recourse to a new intervention (endoscopic or surgical) within 30 days of the procedure.
215147014|NCT06591065|BEHAVIORAL|Yoga Flow|The study participants were subjected to an intervention comprising hatha yoga sessions conducted twicw weekly over an twelve weeks period, with each session lasting 60 minutes.
214460306|NCT05533359|BEHAVIORAL|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
214460307|NCT06485609|PROCEDURE|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
214460308|NCT05972005|OTHER|The Intervention (Stronger at Home Intervention)|The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.
214530551|NCT05020886|BEHAVIORAL|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
214530552|NCT02084589|OTHER|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
214530553|NCT02084589|OTHER|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
214530554|NCT00522678|DRUG|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
214530555|NCT00522678|DRUG|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
214530556|NCT05308342|PROCEDURE|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
214530557|NCT05308342|DRUG|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
214530558|NCT01588379|BEHAVIORAL|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
214530559|NCT01588379|BEHAVIORAL|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
215147015|NCT06591065|OTHER|Controlled|The control group did not receive any yoga training
215147016|NCT06594731|OTHER|Hip belt squat training|Hip belt squat training performed twice per week for 6 weeks
214460309|NCT05972005|OTHER|Usual care (Control)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
214460310|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
214460311|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
214460312|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
214460313|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
214460314|NCT06802432|DRUG|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)
214460315|NCT06802237|OTHER|Other|Assess and Evaluate hair growth and scalp health
214460316|NCT05856552|BEHAVIORAL|CBT|Cognitive behavioral therapy delivered by community resource persons via home visits.
214460317|NCT05856552|BEHAVIORAL|Group Activities|Weekly hour-long group activities delivered by community resource persons in community spaces.
214460318|NCT06802302|BEHAVIORAL|Planet Nutrition Program|"The intervention in this study will be the same for both intervention groups, both based on the previously designed and tested Planet Nutrition Program (PNP). The program components include: nutrition education lessons (one 1-hour session per week), physical activity classes (two 1-hour sessions per week), and nutrition information for parents. The intervention will be implemented from February to June 2025."
214460319|NCT06451250|OTHER|Adult Day Service use for family member with dementia|Self-collection of salivary biomarkers 4 times daily for 5 days, two of those days the family member with dementia has to use adult day services
214530560|NCT01588379|OTHER|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
214530561|NCT02832453|BEHAVIORAL|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
214530562|NCT02832453|BEHAVIORAL|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
214530563|NCT02832453|BEHAVIORAL|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
214530564|NCT03313544|DRUG|Nivolumab|NIVOLUMAB
214530565|NCT03313544|DEVICE|MRI|Cardiac MRI 6 MONTHS
214530566|NCT03313544|BIOLOGICAL|BLOOD SAMPLES|biological (BNP and troponin)
214530567|NCT03313544|DEVICE|trans-thoracic echocardiography|1, 3 and 6 months
214530568|NCT02039596|OTHER|Diet|
214530569|NCT01991678|DRUG|145 mg/m2 NKTR 102|
214530570|NCT01991678|DRUG|120 mg/m2 NKTR 102|
214530571|NCT01991678|DRUG|50 mg/m2 NKTR 102|
214530572|NCT02156089|OTHER|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
214530573|NCT00000647|DRUG|CD4-IgG|
214530574|NCT00000647|DRUG|Zidovudine|
214530575|NCT00000647|DRUG|Interferon alfa-n1|
214530576|NCT00000647|PROCEDURE|Peripheral lymphocyte infusion|
214530577|NCT00000647|PROCEDURE|Bone marrow transplant|
214695441|NCT00904540|DRUG|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
214695442|NCT03247660|OTHER|PFM training|See information included in arm/group descriptions.
215147017|NCT06594978|DEVICE|dual-site anodal tDCS over the M1|M1: motor cortex
215147018|NCT06594978|DEVICE|dual-site anodal tDCS over the DLPFC|DLPFC: dorsolateral prefrontal cortex
215147019|NCT06594978|DEVICE|sham tDCS|sham stimulation
215147020|NCT06599437|PROCEDURE|laparoscopic cholecystectomy|Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.
215147021|NCT06599437|PROCEDURE|Late laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
214460320|NCT06803264|OTHER|Activity Oriented therapy (N.A.P.)|"The following six exercises were used, each of which was performed 10 times. Their progression was introduced by changing positions, individually adjusted to the patient's capabilities.~1. Eccentric infrahyoid muscle work during breathing activity and phonation of the lsound.~2. Reciprocal innervation of suboccipital muscles in gaze activity.~3. Stimulation of the diaphragm in the activity of breathing and phonation.~4. Repeated eccentric activity of the sternocleidomastoid (SCM) muscles during body transfer activity.~5. Repeated eccentric activity of scalene muscles in blanket pulling activity.~6. Eccentric work of suboccipital muscles in the activity of biting a snack."
214460321|NCT06803264|OTHER|Traditional therapy|"Traditional therapy included:~1. Isometric work of the neck muscles.~2. Self-assisted active exercises for the shoulder girdle muscles.~3. Active exercises in relief for the muscles of the shoulder girdle performed in the sitting position in the transverse plane.~4. TENS current treatment performed in the cervical spine and shoulder girdle in the forward lying position.~5. The local cryotherapy treatment with carbon dioxide."
215147022|NCT06604507|DEVICE|non-pharmacological app|Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
215147023|NCT06591754|BEHAVIORAL|ISTDP|Both the individual therapy and the group therapy is based on ISTDP (Intensive Short-Term Dynamic Psychotherapy), an affect-focused psychodynamic therapy method. The therapy focus on the relationship between feelings, anxiety and dysfunctional emotion regulation (i.e. defenses). The purpose is to increase the capacity of anxiety regulation in the patient and to help the patient identify the dysfunctional patterns developed to avoid internal stress and then gradually approach previously warded of feelings. The individual therapy consists of 25 weekly sessions. The group treatment consists of 18 weekly sessions and is structured in three phases. Phase one: Psychoeducation about anxiety and exercises in anxiety regulation. Phase two: patients takes turn to observe their own anxiety and defenses together with a therapist. Phase three: Every session two patients will work with a chosen problem and identify defenses, anxiety and feelings together with a therapist in front of the group.
214460322|NCT05006872|DEVICE|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
214460323|NCT04590664|DRUG|Verteporfin|Given IV
214460324|NCT03424018|DRUG|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
214460325|NCT06802718|DRUG|Interferon|Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.
214460326|NCT06803550|OTHER|Enhanced recovery after surgery protocol|"ERAS pathway was developed based on the available guidelines and protocols it includes 14 items:~1. Preoperative patient education using an information sheet which includes instructions on postoperative wound care, pain management, and preventing and managing constipation.~2. Single preoperative enema 2 hours prior to surgery.~3. Solid or semisolid food stopped 6 hours before surgery.~4. Clear liquids may be continued up to 2 hours before surgery.~5. Preoperative carbohydrate loading in non-diabetic patients for up to 2 hours prior to surgery in the form of a single 330 ml high-carbohydrate clear drink (apple juice).~6. Saddle anesthesia.~7. Single dose of intravenous 500 mg metronidazole at the time of the anaesthesi induction.~8. Restriction of intraoperative intravenous fluids to less than 500 ml.~9. Balanced chloride-restricted crystalloid solutions should be used for maintenance infusions and fluid boluses.~10. A bundle measures to reduce surgical site infection which includes"
214460327|NCT06803550|OTHER|Routine pathway|This is the routine preoperative preparation at our institute
214460328|NCT01972919|RADIATION|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
214460329|NCT01972919|DRUG|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
214460330|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
214460331|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
214460332|NCT06532591|DRUG|cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin|PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
214460333|NCT04149704|BEHAVIORAL|ACP video decision aid|10 minute video decision aid describing the goals-of-care options
214460334|NCT04149704|OTHER|Usual Care-|Verbal description of the three types of care
214460335|NCT05071963|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
214530578|NCT04404699|DIAGNOSTIC_TEST|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
214695443|NCT03247660|OTHER|HE|See information included in arm/group descriptions.
215147024|NCT06595355|DRUG|bevacizumab with oral curcumin|According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
215147025|NCT06595355|DRUG|bevacizumab with oral placebo|Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
215147026|NCT06596408|OTHER|optical coherence tomography angiography|OCTA will be used to evaluate the macular vascular density and to exclude patients with pathological myopic maculopathy
215147027|NCT06598995|PROCEDURE|Coronary artery bypass grafting or unroofing|Patients had an MB with \&gt;75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \&lt; 5mm (whether deal with these MB with a depth \&lt;5mm depends on the surgeon and the period time of patients received a surgery).
215147028|NCT06587646|DIAGNOSTIC_TEST|Virtual Examination under Anaeastehtic - 3D reconstruction imaging|3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.
214460336|NCT05815030|OTHER|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
214460337|NCT00528268|DRUG|Sodium phenylbutyrate|Sodium phenylbutyrate is dispensed as a powder, 450-600 mg/kg/day, divided into four doses. For cohort 1, treatment and monitoring continues for 18 months. For cohort 2, treatment and monitoring continues for 24 months.
214460338|NCT06470672|DRUG|SHR-A1921|Anti-TROP-2 ADC
214460339|NCT06470672|DRUG|Adebrelimab|PD-L1 inhibitor
214460340|NCT06077903|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
214460341|NCT06274970|OTHER|Enhanced recovery protocols|Aforementioned in the detailed description
214530579|NCT02827799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
214530580|NCT02827799|BEHAVIORAL|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
214460342|NCT06274970|OTHER|Conventional Protocols|Conventional protocols for non-ERASP group Eg: No preoperative vitamin D and calcium supplementation etc.
214460343|NCT06192940|BEHAVIORAL|Counseling home caregivers|Advice on the proper use of insulin therapy will be given, if necessary, to caregivers. Patients are reviewed at 1 month of this first visit with a collection of the same data
214530581|NCT02965599|DRUG|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
214530582|NCT02965599|DRUG|Placebo|Placebo is a white, opaque, gelatin capsule.
214530583|NCT00090558|DRUG|nitroglycerin|
214530584|NCT05762978|DEVICE|In-Check Dial|Patient will have their NIF measured with In-Check Dial
214695444|NCT03247660|BEHAVIORAL|Educational strategy|See information included in arm/group descriptions.
214530585|NCT05762978|DEVICE|Inhaler Device|Children will use inhaler per standard of care.
214530586|NCT06052683|RADIATION|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
214695445|NCT01833767|DRUG|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
215147029|NCT06587646|DIAGNOSTIC_TEST|Standard Care - Written MRI report|A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
215147030|NCT06601829|OTHER|abdominal ultrasound|abdominal ulterasound showing multiple cysts in the kidnets and hepatic fibrosis
214460345|NCT05845086|BEHAVIORAL|Preoperative patient education|In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
214460346|NCT04402216|BEHAVIORAL|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
214460347|NCT04402216|BEHAVIORAL|MRI preparation video|A descriptive video about what to expect when undergoing MRI
214460348|NCT04402216|BEHAVIORAL|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
214460349|NCT05609786|BEHAVIORAL|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
214460350|NCT02268253|DRUG|Tagraxofusp Injection|Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
215147031|NCT06592157|OTHER|NewEpi Plus Liquid Wound Dressing|"1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions."
215147032|NCT06592157|OTHER|standard wound care|The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
215147033|NCT06599060|OTHER|Trinity Amputation and Prosthesis Experience Scale|Participants were administered a questionnaire.
215147034|NCT06588036|DRUG|Prebiotic|. The primary outcome measure will be the mean time from the initiation of treatment to the resolution of diarrhea symptoms. This objective seeks to provide evidence-based insights into the optimal management strategies for childhood diarrhea and inform clinical practice guidelines.
215147035|NCT06588036|OTHER|Duration|every participant is alloted a group based on RCT.
215147036|NCT06588036|DRUG|Smecta|Group 4 will be given smecta scahet
215147037|NCT06602115|OTHER|Observational study, no interventions involved|Observational study, no interventions involved
215147038|NCT06591585|RADIATION|Fracture Healing|"A-Clinical evaluation~1. Patients will be recruited for evaluation of documented short / long term complications:~   * subcutaneous haematoma~  * pin tract infection~  * surgical site infection~  * limb length discrepancy~  * arthritis of the hip and spine~  * SI joint pain or fusion~  * scoliosis~2. Visually assisted gait analysis B- Radiographic evaluation~1-Radiographic evaluation of pelvic integrity by plain X-ray ( Antero-posterior . inlet . outlet views) 2- Long film for limb length discrepancy 3- plain x ray whole spine Anterior -posterior \&amp; lateral for scoliosis"
215147039|NCT06599385|OTHER|Platelet transfusion if platelet count ≤ 10 G/L|Platelet transfusion as soon as platelet count falls ≤ 10 G/L
215147040|NCT06599385|OTHER|Platelet transfusion when platelet count ≤ 20 G/L|Platelet transfusion will be initiated immediately after randomisation
215147041|NCT06587815|OTHER|musical starry sky projector|Children in intervention group received musical starry sky projector during their sleep time
215147042|NCT06601283|DRUG|Vitmain C plus herbal medicine|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
215147043|NCT06587971|PROCEDURE|Standard periodontal treatment protocol|Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.
215147044|NCT06587971|BEHAVIORAL|Oral hygiene education|Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
215147045|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
215147046|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice placebo|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
215147047|NCT03397966|DRUG|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
215147048|NCT03397966|DRUG|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
215147049|NCT05823480|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
215147050|NCT05823480|DRUG|Azacitidine|Given IV
215147051|NCT05823480|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215147052|NCT05823480|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
215147053|NCT05823480|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
215147054|NCT05823480|PROCEDURE|Echocardiography|Undergo ECHO
215147055|NCT05823480|BIOLOGICAL|Magrolimab|Given IV
215147056|NCT05823480|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215147057|NCT05823480|OTHER|Questionnaire Administration|Ancillary studies
215147058|NCT04071990|BEHAVIORAL|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
215147059|NCT04071990|BEHAVIORAL|CBGT|CBGT for OCD patients, without involvement of family members
215147060|NCT04983680|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
215147061|NCT05163158|OTHER|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
215147062|NCT04215731|DRUG|Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
215147063|NCT04215731|PROCEDURE|Restaging|Restaging by pelvic magnetic resonance imaging (MRI)
215147064|NCT04215731|RADIATION|Concomitant Chemoradiotherapy|Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
215147065|NCT04215731|PROCEDURE|Surgery|Radical surgery (TME or more extended surgery)
215147066|NCT04215731|RADIATION|Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)|Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
215147067|NCT04215731|DRUG|Induction chemotherpay with FOLFOX|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
215147068|NCT06590844|DRUG|Injectable coenzyme I|On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
215147069|NCT06991829|PROCEDURE|HLA-matched pancreatic endocrine organoids transplantation|Islet cells are isolated from resected pancreatic tissue obtained from patients undergoing surgery, followed by ex vivo expansion and culture. Subsequent procedures include HLA typing, functional assessment of organoid-like structures, and biobanking. After matching for HLA, the cells are administered into patients with type 3c diabetes mellitus (T3cDM) via ultrasound-guided percutaneous transhepatic portal vein catheterization. A 52-week follow-up is conducted to evaluate the safety of the cell therapy and its clinical efficacy in glycemic control.
215147070|NCT06992557|PROCEDURE|Biological drilling osteotomy protocol|"* Osteotomy site preparation through sequential biologic drilling in healed bony site with a pilot drill at 800 rpm with irrigation initiates the drilling process, which is then followed by drills of different sizes and shapes at low speeds at 150rpm without irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
215147071|NCT06992557|PROCEDURE|Conventional drilling osteotomy protocol|"* Preparation for osteotomy site with conventional sequential drilling in healed bony site at 1200 rpm with irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
215147072|NCT06992635|BEHAVIORAL|using non-processing screens|ask subjects to use non-processing screens
215147073|NCT06992635|BEHAVIORAL|using AR screens|ask subjects to use AR screens
215147074|NCT06992635|BEHAVIORAL|using AR+CP screens|ask subjects to use AR+CP screens
214460351|NCT05632107|DEVICE|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
214460352|NCT05857761|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.
214460353|NCT05857761|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Five sessions of sham rTMS therapy will be distributed over 2 weeks
214460354|NCT03674424|DRUG|Avelumab|Chemotherapy with or without avelumab followed by surgery
214460355|NCT03674424|PROCEDURE|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
214460356|NCT03674424|COMBINATION_PRODUCT|CG|Chemotherapy 4 cycles of 3 weeks
214460357|NCT03674424|COMBINATION_PRODUCT|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
214460358|NCT03674424|COMBINATION_PRODUCT|PG|Chemotherapy 2 cycles of 4 weeks
214460359|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
214460360|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
214695446|NCT03428412|DRUG|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
215147075|NCT06992739|DRUG|Trilaciclib and Sacituzumab Tirumotecan|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to sacituzumab tirumotecan.~Sacituzumab Tirumotecan: 5 mg/kg on days 1 \& 15 of a 28 day cycle via intravenous (IV) infusion until progressive disease or discontinuation."
215147076|NCT06993441|BEHAVIORAL|Experimantal group|Participants in the experimental group listened to MusICure music via speakers for 30 minutes during each radiotherapy session. The intervention was administered concurrently with radiotherapy and aimed to reduce anxiety and emotional distress.
215147077|NCT06993441|BEHAVIORAL|control group|No intervention
215147078|NCT06991764|DEVICE|Non-Invasive Brain Stimulation (tDCS / tPCS / sham-tPCS)|This is a novel non-invasive brain stimulation technique that we hope to be investigating, and this technique will be compared with an active control (tDCS) and a control (sham-tPCS).
215147079|NCT06992570|DIAGNOSTIC_TEST|Quantification of mild trauma brain injury risk|Measure the incidence and severity of mTBI among soldiers engaged in high-risk training activities. (e.g. parachute jumps, high-caliber firearms shooting, artillery fire, explosions). Concentration of brain injury biomarkers (GFAP, UCH-L1) in blood samples collected within 24 hours post-exposure
215147080|NCT06992570|OTHER|Biomechanical Analysis of Head Impact Forces|Evaluate the mechanical forces experienced by soldiers during high-risk activities using wearable accelerometers and high-speed video analysis. Peak head acceleration (g-force) and pressure wave analysis during training activities.
215147081|NCT06991959|OTHER|Educaton|Family Planning and Sexually Transmitted Diseases Training: The training program used a training module developed by UNFPA based on health belief theory, theory of reason-based behavior, social learning theory and transtheoretical model.
215147082|NCT06991543|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
215147083|NCT06991543|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)"
215147084|NCT00526812|DRUG|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
215147085|NCT00526812|DRUG|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
214460361|NCT06580899|DEVICE|Intra-articular catheter|Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period
214460362|NCT06580899|OTHER|Routine Standard of Care Treatment|No changes to what would occur outside of the study.
214460363|NCT06127550|DEVICE|active taVNS|low level stimulation to the auricular branch of the vagus nerve
214460364|NCT06127550|DEVICE|sham taVNS|device placed with no current administered
214460365|NCT05731791|RADIATION|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
214460366|NCT05776563|BEHAVIORAL|Nutrition visits|Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee
214460367|NCT05776563|OTHER|Intensification of diabetes regimen|Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
214460368|NCT05776563|OTHER|Continuous glucose monitor (CGM)|Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
214460369|NCT03001713|BEHAVIORAL|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
215147086|NCT06993051|BEHAVIORAL|Social-HEROES Health-Promotion Program|"Six-month, cluster-level, stakeholder-co-created health-promotion programme delivered in preschool settings. The programme is developed through participatory innovation labs and includes:~* Educator training sessions (monthly)~* Classroom activities on healthy eating, active play and socio-emotional skills (weekly)~* Family workshops and take-home materials promoting 24-hour movement behaviour (diet, physical activity, reduced sedentary time, adequate sleep) (every 4-6 weeks)~* Community engagement events (beginning and end of intervention). Implementation period: 6 months; dosage approx. 20-24 contact hours per child."
215147087|NCT06992193|DEVICE|Digital Anesthesia|Computer-controlled intraosseous anesthesia system (Dental Hi Tec, France) used to deliver 1.3 mL of 4% articaine with 1:200,000 epinephrine in two stages: gingival and intraosseous injection. The system provides consistent flow and reduced pain perception in children.
215147088|NCT06992193|DRUG|Infiltration Anesthesia|1 mL of 2% lidocaine with epinephrine was delivered via buccal infiltration using a conventional aspirating syringe and 27-gauge short needle. Topical benzocaine gel was applied for 30 seconds prior to injection.
215147089|NCT06992193|DRUG|Mandibular Block|1 mL of lidocaine was administered using the inferior alveolar nerve block technique via a conventional dental syringe and 27-gauge long needle. Negative aspiration was confirmed prior to slow deposition.
215147090|NCT06991777|DEVICE|Precision sedation in intensive care using neurophysiologic and respiratory targets.|Sedation titration using EEG and ventilator parameters
215147091|NCT06991374|PROCEDURE|combined burst mode|the combined burst mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
214460370|NCT05723588|DEVICE|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
214460371|NCT05723588|DEVICE|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
214460372|NCT05723588|BEHAVIORAL|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
214460373|NCT05723588|DRUG|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
214460374|NCT03997162|OTHER|Best Practice|Complete standard of care enhanced recovery after surgery protocol
214460375|NCT03997162|OTHER|Quality-of-Life Assessment|Ancillary studies
214460376|NCT03997162|OTHER|Questionnaire Administration|Ancillary studies
214460377|NCT01803477|DRUG|once daily for two consecutive days (Picato)|
214460378|NCT05613153|DIETARY_SUPPLEMENT|Peppermint Oil|Participants weighing more than 40 kg will receive 2 peppermint oil capsules 3 times a day. Smaller children who weigh between 30 kg and 40 kg will receive 1 capsule of peppermint oil 3 times a day. All subjects will receive 8 weeks of treatment.
214460379|NCT04752826|DRUG|BI-1808|BI-1808 administered as a flat-dose IV infusion once every 3 weeks
214460380|NCT04752826|DRUG|Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection|Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.
214460381|NCT03870633|OTHER|Medical Chart Review|Undergo medical chart abstraction
214460382|NCT03870633|OTHER|Interview|Complete telephone interview
214460383|NCT03870633|OTHER|Questionnaire|Ancillary studies
214460384|NCT03870633|OTHER|Quality-of-Life Assessment|Ancillary studies
214460385|NCT04251585|DRUG|Regular Novolin R|Intranasal insulin
214460386|NCT04251585|DRUG|Placebo|Intranasal placebo (0.9% saline)
214460387|NCT05068232|RADIATION|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
214460388|NCT05068232|DRUG|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
214460389|NCT05068232|DRUG|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
214460390|NCT05068232|DRUG|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
214460391|NCT05554211|DRUG|Tranexamic acid|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
214460392|NCT05554211|DRUG|Normal saline|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
214460393|NCT04463576|OTHER|Discharge Prescription|All hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions of the Bordeaux and Rennes University Hospital and Georges Pompidou European Hospital will be recorded between June 1, 2018 and June 1, 2019.
214460394|NCT05373719|OTHER|No intervention; observational|No intervention; observational
214530587|NCT06052683|RADIATION|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
214530588|NCT04999683|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory diet for 14 days
214530589|NCT05401669|PROCEDURE|Trans-radial access|Cerebral angiography performed by trans-radial access
215147092|NCT06991374|PROCEDURE|torsional mode|the toesional mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
215147093|NCT06993012|BEHAVIORAL|Mobile Health Stress Self Management System|FWD has been developed using proprietary machine-learning algorithms to detect physiological markers of stress/PTSD hyperarousal in veterans using a wearable smart watch sensor. Additionally, FWD includes a suite of self-management and monitoring tools through the smartphone app designed through several rounds of human factors design
215147094|NCT06993012|BEHAVIORAL|Intensive Cycling Activity|The Project Hero Ride 2 Recovery is a unique event hosted by Project Hero where veterans participate in a week long cycling challenge where they cycle across the continental US about 50-70 miles per day for a total of over 350 miles within a group of peers.
215147095|NCT06991465|RADIATION|Radiation Therapy|High Dose Hypofractionated Radiotherapy 35 Gy over 5 fractions.
215147096|NCT06991465|DRUG|FOLFOX regimen|Radiosensitizing chemotherapy
215147097|NCT06991465|DRUG|Capecitabine|Radiosensitizing chemotherapy
215147098|NCT06070766|DRUG|Ketamine|The use of ketamine in chronic conditions.
215147099|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption|Volunteers were asked to consume lupins in brine for 4 weeks.
215147100|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption and dietary suggestion|Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
214460398|NCT03600883|DRUG|sotorasib|Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
214460399|NCT03600883|DRUG|Anti PD-1/L1|Administered as an intravenous (IV) infusion
214460400|NCT03600883|DRUG|Midazolam|Administered as an oral hydrochloride (HCI) syrup
214460401|NCT04868903|DIETARY_SUPPLEMENT|Vitamin D3|Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
214460402|NCT06618989|OTHER|Blood sampling and follow-up call|An additional 1.5 mL of blood will be collected at the time of the child care in the pediatric emergency department. In addition, a telephone call for patient follow-up (unless still hospitalized) will be done.
214530590|NCT05401669|PROCEDURE|Trans-femoral access|Cerebral angiography performed by trans-femoral access
214530591|NCT01398345|BEHAVIORAL|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
214530592|NCT01693159|DEVICE|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
214530593|NCT01693159|OTHER|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
214530594|NCT00230971|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
215147101|NCT06591546|DEVICE|Telescoping nail|"The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc."
215147102|NCT06588543|DEVICE|Endovascular treatment|Endovascular treatment
214530595|NCT00230971|DRUG|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
214530596|NCT01919255|DRUG|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
214530597|NCT01919255|DRUG|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
215147103|NCT06604338|DIAGNOSTIC_TEST|Exome test|An exome will be performed on the participants of RPL group.
214530598|NCT02840812|DRUG|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
214530599|NCT02710578|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
214530600|NCT02710578|DRUG|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
214530601|NCT03216915|DRUG|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
215147104|NCT06604338|DIAGNOSTIC_TEST|Microbiota analysis|A cervical microbiota analysis will be performed in the RPL and control groups.
215147105|NCT06597162|BEHAVIORAL|education of patient safety|"For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group."
215147106|NCT06594809|OTHER|PNF|Upper extremity PNF exercise is an exercise method that dynamically stabilizes the scapula and affect scapular muscles activity (Witt et al., 2011). Upper extremity PNF patterns consisted of four diagonal patterns (D1 flexion, D2 flexion, D1 extension, and D2 extension) and six key components manual contact, body position, verbal cues pattern of movement, timing of movement and resistance. Patient will be at sitting position with involved side up, head, spine, and scapula in neutral
215147107|NCT06594809|OTHER|Traditional neck pain treatment|Cervical muscles stretch + Craniocervical retraction ex + Manual therapy
215147108|NCT06594809|OTHER|Traditional neck pain treatment + Blackburn scapular stabilization exercises|The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises). Blackburn exercises are one of the ways to treat scapular dyskinesia. Perform 2 sets of 20 repetitions of each exercise each session (3 sessions per week) for four weeks (panse et al .,2018). The exercise load will be 60% of the one-repetition maximum (1-RM) during the first week due to their first exposure to the exercises. The evaluation of one-repetition maximum (1-RM) will be every week for all exercises. From the second evaluation, more weight will be added (compare to the previous evaluation) to maintain the overload.
215147109|NCT06597461|OTHER|Myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
215147110|NCT06597461|OTHER|Placebo myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.
215147111|NCT06603428|DEVICE|internal fixation by plate or screws|\- Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
215147112|NCT06599944|DIAGNOSTIC_TEST|Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale|Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.
215147113|NCT06592326|DRUG|9MW2821|9MW2821, 1.25mg/kg, intravenous (IV) infusion
215147114|NCT06592326|DRUG|Toripalimab|Toripalimab, 240mg, intravenous (IV) infusion
215147115|NCT06592326|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, intravenous (IV) infusion
215147116|NCT06592326|DRUG|Cisplatin/Carboplatin|Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
215147117|NCT06586203|DEVICE|Polygenic Risk Score|The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
215147118|NCT06586749|OTHER|Group B: nurse-led education|Group B: nurse-led education No educational video, will be shown to this group of patients
214460403|NCT06332378|OTHER|Experimental group 1 :Ball training|Ball training Training in sitting position (the participants sat on the ball and did the exercises): holding balance position on the ball, active movements (flexion, extension, abduction, adduction) of one upper extremity, active movement of two upper extremities, trunk movements (bending forward and rotation), raising heel, raising toes, raising heel and toes simultaneously, resistance against perturbation, and weight shifting on ball and 2-Training in standing position: moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand, throwing the ball against the wall with foot
214530602|NCT03166397|DRUG|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
214530603|NCT03166397|DRUG|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
214530604|NCT03166397|BIOLOGICAL|TIL|TIL administration
215147119|NCT06586749|OTHER|Group C: nurse-led education and implementation of teleinterventions|Group C: nurse-led education and implementation of teleinterventions An educational video, made for the purposes of the study only, will be shown to them. This is the difference between the two groups
215147120|NCT06595901|OTHER|Actigraph|Participants will wear an Actigraph hip-worn accelerometer on their non-dominant hip during all waking hours, and on the wrist while sleeping
215147121|NCT06595901|OTHER|Questionnaires|"* Patient Health Questionnaire Anxiety and Depression Scale30 (PHQ-ADS), a validated composite of anxiety and depressive symptoms.~* Self-reported cognition will be assessed by the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog)."
214530605|NCT03166397|DRUG|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
214530606|NCT03166397|DRUG|Nivolumab|Nivolumab 480 mg fixed dose
214530607|NCT03166397|DRUG|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
214530608|NCT03166397|DRUG|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
214530609|NCT05350514|DRUG|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
214530610|NCT02045745|BIOLOGICAL|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
214530611|NCT00005088|DRUG|cisplatin|
214530612|NCT00005088|RADIATION|radiation therapy|
214530613|NCT05243498|OTHER|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
214530614|NCT05243498|OTHER|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
214530615|NCT03941587|DRUG|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
214530616|NCT03941587|DRUG|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
214530617|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
215147122|NCT06595901|OTHER|BrainBaseline application|Objective measures of cognitive function will include those from the BrainBaseline application, a validated research tool developed by Digital Artefacts to remotely measure domains of cognition
215147123|NCT06595901|OTHER|Semi-structured interviews|Semi-structured individual interviews will be conducted with up to 15 healthcare stakeholders and 15-30 patients with breast cancer at any time during the study period, as determined by participant preference.
214530618|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
214530619|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
214530620|NCT04614194|DRUG|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
214530621|NCT04614194|DRUG|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
214530622|NCT06646861|OTHER|Exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included.
214530623|NCT03254524|OTHER|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
214530624|NCT00689195|DIETARY_SUPPLEMENT|Curcumin powder|oral capsules containing the investigational agent
214530625|NCT00689195|DIETARY_SUPPLEMENT|Ashwagandha extract|4.5% extract of ashwagandha
214530626|NCT05186493|PROCEDURE|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
214530627|NCT06602128|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
215147124|NCT06600516|BEHAVIORAL|CBTi: Stimulus Control Core|Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
215147125|NCT06600516|BEHAVIORAL|CBTi: Sleep Restriction Core|Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
215147126|NCT06600516|BEHAVIORAL|CBTi: Sleep Compression Core|Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
215147127|NCT06586242|DRUG|Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin|200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
215147128|NCT06591988|BEHAVIORAL|Lifestyle factors|introduction of environmental risk mitigation policies, from data and evidence from case studies (several European cities) with different levels of exposure to environmental, health, geographic, and socioeconomic factors.
215147129|NCT06589037|OTHER|shock wave treatment control group|The control group, consisting of 24 people, will receive shock wave treatment on the sole of the foot to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
215147130|NCT06589037|OTHER|shock wave treatment experimental group|The experimental group, consisting of 24 people, will receive shockwave treatment on the back of the leg to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
215147131|NCT06599515|PROCEDURE|robotic surgical platform|robot-assisted laparoscopic inguinal hernia repair (rTAR)
214530628|NCT01818453|BEHAVIORAL|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
214530629|NCT01879085|DRUG|Docetaxel|75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
214530630|NCT01879085|DRUG|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
214695447|NCT03428412|DRUG|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
214460404|NCT06332378|OTHER|Experimental group 2 :Frenkel Exercises|"Frenkel Exercises Supine position~1. Flex and extend one leg, heel sliding down a straight line on table.~2. Abduct and adduct leg with knee and hip extended, leg sliding on table. Sitting position~1\. Place foot on therapist's hand, which will change position. 2. Raise leg and put foot on traced footprint on the wall. 3. Rise and sit with knees together. Standing position~1. Place foot forward and backward on a straight line.~2. Walk along a winding strip.~3. Walk between two parallel lines"
214460405|NCT06332378|OTHER|Control Group|By using random allocation, the participants will divided into three groups: an intervention group (N=30) that receive ball training exercise, another intervention group (N=30) that receive Frenkel training exercise and a control group (N=30
214695448|NCT03918603|OTHER|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
214460406|NCT04103879|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
215147132|NCT06993194|DRUG|Haloperidol|Haloperidol will be administered intravenously at a dose of 2.5 milligrams every eight hours over ten minutes. Treatment will begin 48 hours after admission to the intensive care unit and will continue for up to seven days or until delirium and agitation resolve. The need for additional sedation will be addressed with intravenous midazolam and fentanyl as required. The patient's clinical status will be monitored using standardized assessments including the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
214530631|NCT01879085|DRUG|Vorinostat|given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
214530632|NCT01879085|DRUG|Pegfilgrastim|administered on day 9 subcutaneously at 6 mg
214530633|NCT01554345|DRUG|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
214530634|NCT01709071|DRUG|IPV|
214530635|NCT01709071|DRUG|Low dose Sabin-IPV|
214530636|NCT01709071|DRUG|Low dose adjuvanted Sabin-IPV|
214530637|NCT01709071|DRUG|Middle dose Sabin-IPV|
214530638|NCT01709071|DRUG|Middle dose adjuvanted Sabin-IPV|
214530639|NCT01709071|DRUG|High dose Sabin-IPV|
215147133|NCT06993194|DRUG|Dexmedetomidine|Dexmedetomidine will be administered by continuous intravenous infusion at a dose of 0.5 micrograms per kilogram. Treatment will begin 48 hours after admission to the intensive care unit and will be repeated every other day for up to seven days or until delirium and agitation resolve. Rescue sedation may be provided with intravenous midazolam and fentanyl as clinically indicated. Delirium and agitation will be assessed regularly using validated tools such as the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
214530640|NCT01709071|DRUG|High dose adjuvanted Sabin-IPV|
214530641|NCT03285633|BEHAVIORAL|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
214530642|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
214530643|NCT04248881|BEHAVIORAL|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
214530644|NCT06517706|COMBINATION_PRODUCT|Combination of tDCS (device) with cognitive training (behavioral)|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
215147134|NCT06145321|DEVICE|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
215147135|NCT06145321|DRUG|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
215147136|NCT06992492|PROCEDURE|vojta therapy +conventional chest physical therapy|infants will receive reflex rolling technique along with conventional chest physical therapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. This maneuver includes a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface. A digit pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. Each treatment consists in delivering four stimuli, two to the left half of the chest (stimulations I and II) and two to the right half of the chest (stimulations III and IV). Each stimulus will be consisted of slight pressure, progressively oriented in dorsal, medial and cranial direct
214530645|NCT06517706|BEHAVIORAL|Categorization Program|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
214530646|NCT03891433|DRUG|Meropenem|Carbapenems group intervention.
214530647|NCT03891433|DRUG|Ertapenem 1000 MG|Carbapenems group intervention.
214530648|NCT03891433|DRUG|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
214530649|NCT06607315|OTHER|physical properties of soft tissue|Using the Myoton Pro device, the physical properties such as elasticity and viscosity of the Achilles tendon, patellar tendon, gastrocnemius, quadriceps, and hamstring muscles will be measured.
214530650|NCT06607315|OTHER|Analysis of Running Form|High-speed camera systems will be used to analyze biomechanical parameters in detail, such as angular movements of the lower extremity joints (tibia, ankle, knee, hip), step length, and ground contact time during running. These analyses will allow us to objectively characterize different running forms.
214530651|NCT06377059|DEVICE|WARD|Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
214530652|NCT03741309|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
214530653|NCT03741309|OTHER|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
214530654|NCT03741309|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
214530655|NCT06673433|DIAGNOSTIC_TEST|obesity|Patients diagnosed with obesity (BMI ≥ 28kg/m2)
214460407|NCT05780723|DRUG|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
215147137|NCT06992492|PROCEDURE|lung squeezing technique +conventional chest physical therapy|"infants will receive lung squeezing technique along with conventional chest physiotherapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. Lung squeeze technique consists of 3- cumulative chest compressions lasting for 5 seconds, followed by a gentle low release phase, with the chest wall completely released; the second compressions are performed successively for5 minutes on one hemithorax, then 5 minutes on the other hemi thorax. The infant will be in supine position, and without body tilt, for a total of 10 minutes. Use both hands to perform the squeeze on one hemithorax at one time. Place One hand on the posterolateral aspect of the hemi thorax and the other hand covered the anterior chest extending from the lower ribs to above the clavicle of the infant."
214460408|NCT05780723|DRUG|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
214460409|NCT03758989|DRUG|Rituximab Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
214530656|NCT06673433|DIAGNOSTIC_TEST|health|the health control group include paticipants with nomal BMI
214530657|NCT02676739|DRUG|Adderall XR|
214530658|NCT03019809|BIOLOGICAL|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
214530659|NCT03019809|BIOLOGICAL|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
214530660|NCT07007884|DEVICE|Active Transauricular Vagus Nerve Stimulation|Active taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left ear cymba choncae with a stimulator. Active taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform. In the sham group, stimulation was applied to the lobulus auriculae of the left ear (which is not innervated by the vagus nerve) using the same current intensity and duration as the active group.
214530661|NCT07007884|DEVICE|Sham Transauricular Vagus Nerve Stimulation|Sham taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left lobulus auriculae of the left ear (which is not innervated by the vagus nerve) with a stimulator. Sham taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform.
214530662|NCT07008794|DRUG|Atorvastatin 40 mg|Rosuvastatin 20 mg
214530663|NCT07008924|OTHER|No intervention is provided. We monitor natural recovery to full sleep.|Return to normal sleep observation.
214530664|NCT06721624|OTHER|Naturopathic medicine|Whole system naturopathic medicine
214530665|NCT06030440|RADIATION|Eliminating RT to the elective neck|Reduction of radiation volume by eliminating radiotherapy to the elective neck
214460410|NCT03758989|DRUG|Cyclophosphamide|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
214460411|NCT03758989|DRUG|Doxorubicin|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
214460412|NCT03758989|DRUG|Vincristine|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
214460413|NCT03758989|DRUG|Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
214460414|NCT06044025|DRUG|Metformin|Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
215147138|NCT06992492|PROCEDURE|conventional chest physical therapy|Conventional Chest Physical Therapy will be given for both the groups A and B and for group C in isolation manner with medical treatment with special emphasis on whether Surfactant therapy is given or not.it includes postural drainage, vibration, and percussion. Postural drainage will be applied to infants by elevating head of the infant at 30 degrees to prevent gastro esophageal reflex and aspiration. In neonates and infants 'tenting' (using the first three or four fingers of one hand with slight elevation of the middle finger). Chest percussion will be given with motion from the wrist. Vibration of the chest will be done manually by placing the fingers on the chest wall over the segment being drained and the wrist and the elbow remained immobile, isometrically contracting the muscles of the forearm and hand to cause a vibratory motion. The procedure will be performed for 5min. Chest percussion position lying down on the right side and on the left, with 5 min duration on each side
215147139|NCT06992921|OTHER|Dietary intervention|Iterventional dietary study using standardised meals with different fat content and carbohydrate quantity and quality or mixed meal tolerance test to predict for an individuals metabolic response.
214460415|NCT06044025|DRUG|Turmeric|Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
214460416|NCT05362487|DEVICE|Spiriva® Respimat®|Spiriva® Respimat®
214460417|NCT05362487|DEVICE|Spiriva® HandiHaler®|Spiriva® HandiHaler®
214460418|NCT05362487|DRUG|Tiotropium bromide|Tiotropium bromide
214460419|NCT06505499|OTHER|Gait Profile Score|Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009).
214460420|NCT06505499|OTHER|Gait Visual Score|Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009)
214460421|NCT04274127|DIAGNOSTIC_TEST|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
214460422|NCT06350279|DRUG|HSK39297|50-600mg
214460423|NCT01743807|DRUG|GNKG168|"GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168."
214460424|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
214460425|NCT01935869|DRUG|LEO 90100|
214460426|NCT01935869|DRUG|Vehicle|
214460427|NCT01935869|DRUG|Petrolatum ointment|
214460428|NCT06215521|DRUG|Pirtobrutinib|Administered orally
214460429|NCT06215521|DRUG|Placebo|Administered orally
214460430|NCT06215521|DRUG|Moxifloxacin|Administered orally
214460431|NCT04096040|DEVICE|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
214530666|NCT06030440|RADIATION|RT standard of care|postoperative radiotherapy of the head and neck region according to current standard including elective nodal irradiation
214530667|NCT06719830|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of the septal accessory pathway
214530668|NCT06721130|DIAGNOSTIC_TEST|FDG radiotracer|Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome
214530669|NCT06720740|DEVICE|RELIEF Ureteral Stent|The study intervention is placement of the RELIEF Ureteral Stent
214530670|NCT06720740|DEVICE|Standard of Care Ureteral Stent|The control product is the Ascerta stent by Boston Scientific.
214530671|NCT05505110|PROCEDURE|Vaginal Seeding|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
214530672|NCT05505110|PROCEDURE|Sterile Swab|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.
214530673|NCT06777589|DEVICE|Monitoring of anesthesia depth|During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
214530674|NCT06890923|DRUG|Foralumab TZLS-401 100 µg|Patients meeting the requirements of the dose escalation rules will receive nasal foralumab 100 µg three (3) days a week (Monday-Wednesday-Friday) for two weeks, followed by a one-week rest, comprising 3-week cycles.
215147140|NCT06991647|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine at a dose of 2 mcg/kg body weight, diluted in 1 mL of 0.9% NaCl, administered using a 1 mL syringe connected to a Teleflex MAD Nasal device while in the supine position. The soft tip of the device will be gently placed into each nostril without applying pressure. The solution will be sprayed slowly to create a fine mist. The total dose will be divided equally, with 0.5 mL delivered into each nostril, administered approximately 30 minutes before intubation during induction.
215147141|NCT06991647|DRUG|0.9% NaCl solution|Participants will receive 1 ml of 0.9% NaCl solution administered intranasally using a 1 ml syringe connected to a Teleflex MAD nasal device while in the supine position. The soft tip of the Teleflex MAD nasal device is gently placed into each nostril without applying pressure. The solution is slowly sprayed to create a fine mist for patient comfort. The dose is divided equally, delivering 0.5 ml into each nostril, approximately 30 minutes before intubation during induction.
215147142|NCT06992232|DRUG|Intense androgen deprivation therapy|Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.
214460432|NCT03333590|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
214460433|NCT04973254|OTHER|CAB-RPV LA|Monthly administration of injectable HIV medication
214460434|NCT04973254|OTHER|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
214460435|NCT06113068|DEVICE|Fistura® procedure|The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
214460436|NCT06355622|DIAGNOSTIC_TEST|Characterization of pain|Standardized scales and questionnaires to detect and characterize pain, blood sample for pain biomarkers, neurophysiological tests
214460437|NCT04165330|DRUG|AL3818|"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."
214460438|NCT04165330|DRUG|Nivolumab Injection|Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
214460439|NCT05504317|DRUG|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
214460440|NCT05504317|DRUG|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
214460441|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor restricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
214460442|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor unrestricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
214460443|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor restricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
214460444|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
214460445|NCT01814813|BIOLOGICAL|HSPPC-96|intradermal infusion
214460446|NCT01814813|DRUG|bevacizumab|intravenous
214460447|NCT06360796|DRUG|[(14)C]ADC189|Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
214460448|NCT05920824|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound scan of the heart
214460449|NCT06093477|DIETARY_SUPPLEMENT|Fast-Dissolve Melatonin Pill|Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.
214460450|NCT06093477|OTHER|Fast-Dissolve Placebo Pill|Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
214460451|NCT03892265|OTHER|Observational Study|No intervention is included in this observational study.
214460452|NCT04390308|PROCEDURE|Ovarian puncture|Egg collection
214460453|NCT04390308|OTHER|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
214460454|NCT04390308|DIAGNOSTIC_TEST|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
214460455|NCT04835129|DRUG|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
214460456|NCT04835129|DRUG|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
214460457|NCT04835129|DRUG|Pomalidomide|4 mg PO days 1-21 of each cycle.
214460458|NCT04835129|DRUG|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
214460459|NCT04835129|DRUG|Dexamethasone|40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
214460460|NCT03821779|BEHAVIORAL|In vivo social exposure|Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.
214460461|NCT03821779|BEHAVIORAL|Social exposure in a virtual reality setting|Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.
214460462|NCT03821779|OTHER|EEG recording|EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control
215147143|NCT06992232|RADIATION|Radiation Therapy|Those allocated radiotherapy received 70Gy/2.8Gy/25f schedule for primary tumor and 70Gy/2.6-2.8Gy/25f or 37.5Gy/7.5Gy/5f for metastatic lymph nodes and bone lesions based on the size and location. Radiation should be finished within 2 years' systemic therapy.
215147144|NCT06992232|PROCEDURE|radical prostatectomy|Those allocated surgery received robot-assisted laparoscopic radical prostaectomy plus extended pelvic lymph node dissection for local treatment. Surgery should be finished within 2 years' systemic therapy.
214460463|NCT03821779|DIAGNOSTIC_TEST|Psychometric evaluation|"Subjects will be evaluated prior to inclusion using the following assessment tools~* Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire~* Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses)~* Liebowitz Social Anxiety Scale (LSAS)~* Montgomery Asberg Depression Rating Scale (MADRS)~* Brief Anxiety Scale of Tyrer (BAS)~* State-Trait Anxiety Inventory (STAI A-B)~* Global Assessment of Functioning (GAF)"
214460464|NCT03821779|DIAGNOSTIC_TEST|Visual Analogue Scale of anxiety|"Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)"
214460465|NCT03109210|BEHAVIORAL|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
214460466|NCT03109210|BEHAVIORAL|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
214460467|NCT03344094|DRUG|ocrelizumab|FDA-approved MS drugs
214460468|NCT03808818|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
214460469|NCT03808818|DRUG|Nicotine Replacement|Given NRT patch or lozenge (or both)
214460470|NCT03808818|OTHER|Quality-of-Life Assessment|Ancillary studies
214460471|NCT03808818|OTHER|Survey Administration|Ancillary studies
214460472|NCT03808818|OTHER|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
214460473|NCT05292118|DEVICE|Navitian|Patients in whom treatment with (Navitian) has been attempted
214460474|NCT06016959|OTHER|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition \& also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
214460475|NCT06016959|OTHER|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton \& Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
214460476|NCT05134922|DRUG|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
214460477|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
214460478|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
214460479|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
215147145|NCT06991790|DRUG|Sacituzumab Govitecan (SG)+Toripalimab|"Sacituzumab govitecan (Trodelvy): 10mg/kg, administered by intravenous infusion on day 1 and day 8.~Toripalimab: 240mg, administered by intravenous infusion on day 1."
215147146|NCT06992323|DIETARY_SUPPLEMENT|EPA + HT|Volunteers will consume during 12 weeks 2 g/d of EPA and 15 mg/d of HT, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
215147147|NCT06992323|DIETARY_SUPPLEMENT|EPA|Volunteers will consume during 12 weeks 2 g/d of EPA corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
215147148|NCT06992323|DIETARY_SUPPLEMENT|Sunflower Oil|Volunteers will consume during 12 weeks 2 g/d of Sunflower Oil, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
214460480|NCT04442022|DRUG|Placebo matching for Selinexor (combination therapy)|Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
214460481|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
214460482|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
214460483|NCT04442022|DRUG|Gemcitabine (combination therapy)|Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
214460484|NCT04442022|DRUG|Dexamethasone (combination therapy)|Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
214460485|NCT04442022|DRUG|Cisplatin (combination therapy)|Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
214460486|NCT04442022|DRUG|Selinexor (continuous therapy)|Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
214460487|NCT04442022|DRUG|Placebo matching for Selinexor (continuous therapy)|Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
214460488|NCT05838313|BEHAVIORAL|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
214460489|NCT04704986|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
214460490|NCT04704986|DRUG|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
214460491|NCT05415722|DRUG|TERN-501|Investigational drug
214460492|NCT05415722|DRUG|TERN-101|Investigational drug
214460493|NCT05415722|OTHER|Placebo|Matching placebo
214460494|NCT06155838|OTHER|"Early Adolescent Skills for Emotions (EASE)"|"Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care"
214460495|NCT05028738|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
214460496|NCT02650505|DRUG|LEO 43204|
214460497|NCT02650505|DRUG|LEO 43204 Vehicle|
214460498|NCT06646523|OTHER|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
214460499|NCT06646523|OTHER|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
214460500|NCT04968808|PROCEDURE|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
214530675|NCT05368922|DEVICE|Virtual reality rehabilitation|"The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks."
214530676|NCT06919640|DRUG|Psilocybin|10mg oral psilocybin
214530677|NCT06192537|BEHAVIORAL|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
215147149|NCT06602895|OTHER|Intensive short-term functional strength training|All players underwent a rigorous 2-week intensive short-term functional strength training program, with training sessions held for 5 days a week. One group engaged in intensive short-term functional strength training exercises, while the other group focused on balance training. The training regimen was then reversed for the two groups. Each daily training session lasted approximately 2 hours, with 1 hour of either intensive short-term functional strength training or balance training. Every intensive short-term functional strength training session spanned roughly 60 minutes, starting with a 10-minute warm-up followed by dynamic mobility exercises targeting key joints. During the 40-minute core segment of our intensive short-term functional strength training sessions, participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability.
214695449|NCT06187116|OTHER|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
215147150|NCT06602895|OTHER|Balance Training|Participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability ball exercises. This was followed by 15 minutes of multi-joint strength exercises, where athletes performed compound movements like squats, deadlifts, push-ups or bench presses, and pull-ups or lat pull-downs, each for t sets of 8-10 repetitions. The session concluded with 15 minutes of agility and coordination drills, incorporating high-intensity activities such as lateral sprints and rope pulling, specifically designed to improve quickness and neuromuscular coordination, thereby enhancing overall athletic performance. The session concluded with a 10-minute cooldown involving flexibility exercises for the limbs and trunk. Exercise intensity was regulated to correspond with a 6-7 on the repetitions in the reserve-based Rating of Perceived Exertion (RPE) scale, where a s indicates that the exerciser feels they could perform approximately.
214695450|NCT06187116|OTHER|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
214695451|NCT04829019|RADIATION|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
215147151|NCT06586775|PROCEDURE|Pulpotomy|complete pulpotomy
215147152|NCT06603376|DRUG|FOLFIRI + Vemurafenib + Cetuximab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
215147153|NCT06603376|DRUG|FOLFIRI ± Bevacizumab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
215147154|NCT06601231|DIAGNOSTIC_TEST|GAAD score|In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).
215147155|NCT04949490|BIOLOGICAL|BNT162b2s01|intramuscular (IM) injection
215147156|NCT04949490|BIOLOGICAL|BNT162b2|IM injection
215147157|NCT06590194|DRUG|PH009-1 tablet|PH009-1 will be administered in fasting state
215147158|NCT06604000|BEHAVIORAL|GMT Usual|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks."
215147159|NCT06604000|BEHAVIORAL|GMT Cuing|"The participants will receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP; as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends."
214460501|NCT04968808|PROCEDURE|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
214460502|NCT04361331|DRUG|Lenvatinib combined with gemox|Arm2: Lenvatinib + gemox
214460503|NCT04361331|DRUG|Toripalimab combined with lenvatinib|Toripalimab combined with lenvatinib
214460504|NCT04629716|OTHER|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
214460505|NCT04251117|BIOLOGICAL|GNOS-PV02|GNOS-PV02 delivered by intradermal injection and electroporation
214460506|NCT04251117|BIOLOGICAL|INO-9012|INO-9012 delivered by intradermal injection and electroporation
214460507|NCT04251117|DRUG|Pembrolizumab|Pembrolizumab administered as an intravenous (IV) infusion
214460508|NCT04251117|DEVICE|CELLECTRA®2000 EP Device|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
214460509|NCT04266418|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
214460510|NCT04266418|DIETARY_SUPPLEMENT|Banana flower stamens extract|consume 1 sachet per day for 2 months
214695452|NCT04829019|DRUG|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
214695453|NCT06395428|DRUG|Haloperidol|Intramuscular injection of drug
214695454|NCT06395428|DRUG|Ketorolac Tromethamine|Intramuscular injection of drug
214460511|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
214460512|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
214460513|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
214460514|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
214460515|NCT04061967|OTHER|Sending of screening summon.|"2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent."
214460516|NCT05477420|OTHER|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
214460517|NCT04948749|DEVICE|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
214460518|NCT04948749|DRUG|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
214460519|NCT04948749|BEHAVIORAL|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
214460520|NCT04948749|DRUG|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
214460521|NCT02903290|OTHER|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait
214460522|NCT02903290|OTHER|walking track GAITRite,manual dynamometer, and treadmill|walking track GAITRite,manual dynamometer, and treadmill
214460523|NCT05467657|DEVICE|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
214460524|NCT03031470|DRUG|Reparixin|"Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours).~Reparixin was provided as 33 mg/ml concentrated solution to be diluted for i.v. infusion, packaged into 250 mL clear glass vials. To give a final concentration of 11 mg/mL, the content of a vial (250 ml) was diluted with 500 ml of 0.9% sterile saline to a total volume of 750 ml. The dosing solution was placed in a 1000 ml sterile empty Infusion Bag. Dosing solutions were to be used within 72 h from preparation, unless more restrictive rules.~Reparixin infusion started approximately 60-90 minutes before the anticipated time of OLT. Infusion interruption was allowed for no more than 60 min.~All patients received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.~Patients and allograft survival were monitored up to 1 year after OLT."
214460525|NCT03031470|OTHER|Control|The patients who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.
214460526|NCT03461276|BIOLOGICAL|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.
214460527|NCT03461276|BIOLOGICAL|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.
214695455|NCT01374776|DRUG|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
214695456|NCT05514652|DRUG|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
214695457|NCT02887833|OTHER|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
214530678|NCT04027491|BEHAVIORAL|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
214530679|NCT02748902|DRUG|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
214530680|NCT00174798|DRUG|SSR240600C|once daily
214530681|NCT00174798|DRUG|Placebo|oral
214530682|NCT00174798|DRUG|Tolterodine|once daily
214530683|NCT00286975|BEHAVIORAL|Leadership development program educational intervention|
214530684|NCT06436495|OTHER|Hair Wash Shampoo|A standard marketed hair wash shampoo is to be used for the hair wash intervention post baseline evaluations of the scalp.
214530685|NCT00283777|DRUG|Chromium Picolinate|
214530686|NCT03948464|DRUG|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
214530687|NCT03948464|DRUG|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
214530688|NCT02007811|BIOLOGICAL|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
214530689|NCT02970357|OTHER|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline"
214530690|NCT02970357|BEHAVIORAL|WHO-5|5 item questionnaire of the World Health Organization about quality of life
214530691|NCT01268124|DRUG|HTC-867|
214530692|NCT05426447|OTHER|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
214530693|NCT05426447|OTHER|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
214530694|NCT02383238|DRUG|Dapagliflozin|10 mg, oral for 6 weeks
214530695|NCT02383238|DRUG|Placebo|oral for 6 weeks
214530696|NCT04523298|PROCEDURE|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
214530697|NCT04523298|OTHER|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
214530698|NCT03385798|PROCEDURE|Endowrist|Anastomosis made by Endowrist
214695458|NCT03408652|DRUG|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
215147160|NCT06604000|BEHAVIORAL|GMT Boost|"After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
215147161|NCT06599424|OTHER|Observational|Observational
215147162|NCT06595407|DIAGNOSTIC_TEST|Blood analysis for loss-of-Y chromosome|Analysis for the percentage of circulating leukocytes with loss-of-y chromosome
215147163|NCT06171009|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
215147164|NCT06171009|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
214530699|NCT03385798|PROCEDURE|Endo-GIA|Anastomosis made by Endo-GIA
214530700|NCT01960348|DRUG|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
214530701|NCT01960348|DRUG|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
214530702|NCT01019499|OTHER|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
214530703|NCT01019499|OTHER|control products|two portions daily
214530704|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
214530705|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
214695459|NCT03860545|DIAGNOSTIC_TEST|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
215147165|NCT02086578|DEVICE|Breast MRI|
215147166|NCT02086578|BEHAVIORAL|Breast-Q© questionnaire|
215147167|NCT02086578|RADIATION|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
215147168|NCT05074979|OTHER|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
215147169|NCT05074979|OTHER|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
215147170|NCT05074979|OTHER|informed program|will informed after COVID 19
214460528|NCT01414400|OTHER|Blood draw for culture|Blood will be drawn and sent for culture.
214460529|NCT05770284|OTHER|12 weeks exercise|12 weeks exercise
214460530|NCT05770284|OTHER|Standard Medical Treatment|Standard Medical Treatment
214460531|NCT05841797|BEHAVIORAL|In-Person Program Management Plus (PM+)|PM+ sessions conducted in-person by mentor mothers
214460532|NCT05841797|BEHAVIORAL|Mobile Program Management Plus (mHealth PM+)|PM+ sessions conducted via phone
214460533|NCT06304610|BEHAVIORAL|Questionnaire|Questionnaire to probe socio-demographic data and information regarding sexual and reproductive health.
214460534|NCT06304610|PROCEDURE|HPV self-sample|Collection of HPV self-sample. The study nurse will explain step by step how the participant should take the test. The participant will also be given written instructions and the study nurse will always be around if the participant has any questions. The participant will be asked to take the self-sample in a private room with toilet. After collection the sample is handed back to the study nurse, who will then take the samples to the laboratory for analysis.
214460535|NCT06304610|PROCEDURE|Endocervical sample|Endocervical sample taken by the gynaecologist. This procedure can be somewhat uncomfortable but not painful. The participant may always ask questions if she has any doubts or questions. The gynaecologist will perform the standard colposcopy examination after collection (for which the woman sits in the colposcopy waiting room)
214460536|NCT03954522|OTHER|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
214460537|NCT06528704|DEVICE|Ventilation feedback device|Device showing delivered ventilation frequency and volume.
214460538|NCT03333616|DRUG|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
214460539|NCT03333616|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
214460540|NCT04960735|OTHER|VOICE intervention|"The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Best practice sharing: Identifying what lessons could be learned from the best-performing sites, according to the results of the VOICE community benchmarking and following qualitative techniques."
214460541|NCT02310646|DRUG|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
214460542|NCT02310646|DRUG|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
214460543|NCT03865498|BEHAVIORAL|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
214460544|NCT03865498|BEHAVIORAL|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
214460545|NCT02619994|DRUG|Linezolid|
214460546|NCT02619994|DRUG|Delamanid|
214460547|NCT02619994|DRUG|Levofloxacin|
214460548|NCT02619994|DRUG|Pyrazinamide|
214460549|NCT02619994|DRUG|Locally-used WHO-approved MDR-TB regimen in Korea|
214460550|NCT04028947|PROCEDURE|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
214460551|NCT05947357|OTHER|Nutrition Assistance Program|Patients will receive in the intervention group a $40.00 per month voucher for 6 months for use in the produce section of a local grocery store.
214530706|NCT04527783|OTHER|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
214530707|NCT04527783|OTHER|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
215147171|NCT05285371|DIAGNOSTIC_TEST|Urinalysis (UA)|Urinalysis will be performed twice daily starting on Postoperative Day 0.
215147172|NCT05285371|DIAGNOSTIC_TEST|Complete Metabolic Panel (CMP)|A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
214530708|NCT04930003|BIOLOGICAL|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
214530709|NCT04930003|OTHER|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
214530710|NCT01580995|DRUG|Valacyclovir|Valacyclovir 500 mg po bid
214530711|NCT01580995|DRUG|Placebo|Placebo tablet twice daily
214530712|NCT04274062|PROCEDURE|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
214530713|NCT04210804|DIETARY_SUPPLEMENT|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
214530714|NCT02684955|DEVICE|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
214460552|NCT05256576|OTHER|Implementation of an innovative multi-modal peri-operative care pathway|The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
214460553|NCT01565109|DRUG|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
214460554|NCT01565109|RADIATION|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
214460555|NCT05183854|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
214460556|NCT05183854|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
214460557|NCT05183854|OTHER|Questionnaire Administration|Ancillary studies
214460558|NCT05938478|DRUG|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
214460559|NCT06168383|DRUG|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
214460560|NCT06168383|DRUG|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
214460561|NCT06168383|DRUG|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
214460562|NCT06543381|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214460563|NCT06543381|DRUG|Olutasidenib|Given PO
214460564|NCT05703074|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
214460565|NCT05703074|BEHAVIORAL|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
214460566|NCT05703074|BEHAVIORAL|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
214460567|NCT05703074|DIETARY_SUPPLEMENT|Placebo|4 capsules (empty) 2 times daily for 84 days.
214530715|NCT02684955|DEVICE|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
214530716|NCT04996537|OTHER|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
214460568|NCT04767282|OTHER|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
214460569|NCT06068530|DRUG|DHA/piperaquine and a SLD-PQ|Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
214460570|NCT06068530|BIOLOGICAL|Study vaccine R21/Matrix-M™|The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
214460571|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
214460572|NCT01048281|PROCEDURE|Blood draw|
214460573|NCT01048281|PROCEDURE|Tissue tumor biopsy|
214460574|NCT05869383|DRUG|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
214460575|NCT05869383|DRUG|Placebo|Placebo 2x5 grams
214530717|NCT02222883|GENETIC|Testing of BRCA status regarding germline and somatic mutation|
214530718|NCT03105778|DIAGNOSTIC_TEST|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
214530719|NCT00130910|DRUG|Albendazole|Albendazole 400mg x 3 first dose observed
215147173|NCT05285371|DIAGNOSTIC_TEST|Glucose Stick Test (d-Stick)|A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
215147174|NCT05285371|OTHER|Medical Chart Review|A medical chart review will be performed for all subjects enrolled.
214530720|NCT00130910|DRUG|Placebo|Albendazole Placebo 400mg x 3 first dose observed
214530721|NCT04219878|BEHAVIORAL|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
214460576|NCT04552756|DIAGNOSTIC_TEST|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
214530722|NCT04219878|OTHER|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
214530723|NCT02424019|DRUG|ILUVIEN 0.19 MG|
214530724|NCT01179906|BEHAVIORAL|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
214530725|NCT01179906|BEHAVIORAL|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
214530726|NCT03758794|OTHER|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
214530727|NCT03758794|OTHER|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
214530728|NCT04845087|OTHER|Ozonized water|Irrigation of dental implants with ozonized water
214530729|NCT04845087|OTHER|Placebo|Irrigation of dental implants with water
214530730|NCT02157688|OTHER|no intervention : case control study|
214530731|NCT03967119|DEVICE|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
214530732|NCT05109117|DRUG|CAP Unscented|Sunscreen lip balm.
214530733|NCT00115986|BIOLOGICAL|Influenza A/H5N1 Vaccine|
215147175|NCT05712330|OTHER|non invasive ventilation samples|machine samples for bacterial culture will be performed
215147176|NCT05712330|OTHER|patient samples|Patient samples for sputum culture
215147177|NCT05712330|OTHER|parent questionnaire|parent questionnaire
215147178|NCT03430297|BIOLOGICAL|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
215147179|NCT03430297|DRUG|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = \[body surface area (BSA) x (1000mg/m2)\].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184\* (cm0.725) \* (kg0.425)"
215147180|NCT02017405|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
215147181|NCT02017405|OTHER|Matching Placebo|
215147182|NCT05383937|OTHER|Speech Therapy INTENS-DYS|During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
215147183|NCT06107036|DRUG|BI 1015550|BI 1015550
215147184|NCT06107036|DRUG|Moxifloxacin|Moxifloxacin
215147185|NCT06107036|DRUG|Placebo|Placebo-matching BI 101550
215147186|NCT06590012|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
215147187|NCT06590012|DRUG|Tertinat|Participants will take Tertinat capsules in addition to standard treatment for a year.
215147188|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
215147189|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
215147190|NCT00811590|DRUG|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
215147191|NCT02864394|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
215147192|NCT02864394|DRUG|Docetaxel|Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
215147193|NCT06882902|BEHAVIORAL|habit formation training|Participants need to perform habit formation exercises for 4 consecutive days. During the exercises, participants will see a picture stimulus and need to learn the corresponding key press. Each day, participants will spend 30 minutes on the training.
215147194|NCT06667687|DRUG|ABBV-291|Intravenous Infusion
215147195|NCT06004739|DRUG|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
215147196|NCT06004739|OTHER|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
215147197|NCT06757530|DIAGNOSTIC_TEST|AI|Using artificial intelligence models to distinguish between patients with lymph node metastasis and those without lymph node metastasis.
215147198|NCT06778434|DRUG|Imipramine|10% imipramine
215147199|NCT06778434|OTHER|Control Vehicle|polyethylene glycol: dimethyl sulfoxide Solution
215147200|NCT04057664|BEHAVIORAL|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
214530734|NCT02874248|DRUG|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
214530735|NCT02874248|DRUG|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
215147201|NCT06867328|PROCEDURE|Platelet-Rich Plasma (PRP) Dressing|"* PRP will be prepared by centrifugation of 20 mL venous blood with an anticoagulant.~* The extracted PRP will be applied twice weekly to the wound.~* A sterile gauze will be placed over the wound after PRP application.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
215147202|NCT06867328|PROCEDURE|Normal Saline Dressing|"Wound will be cleansed with normal saline and covered with sterile gauze.~* Dressing changes will be done twice weekly following wound debridement.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
215147203|NCT06818747|PROCEDURE|Best corrected monocular visual acuity|Assessed with the Monoyer scale and expressed in logMAR at 24 months after corneal transplantation
215147204|NCT06775015|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Serum Raman spectroscopy intelligent diagnostic system Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
215147205|NCT06947408|DRUG|Placebo|Healthy participants and patients with asthma will receive matched placebo.
215147206|NCT06947408|DRUG|IBI3002|Healthy participants and patients with asthma will receive IBI3002 at the corresponding dose and dosing interval.
215147207|NCT05004129|DRUG|Tideglusib|Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.
215147208|NCT03330470|BEHAVIORAL|exercise|participants will be subjected to 4 months supervised exercise intervention
215147209|NCT03330470|DIETARY_SUPPLEMENT|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
215147210|NCT03330470|BEHAVIORAL|stretching|participants will be subjected to 4 months supervised stretching program
215147211|NCT03330470|DIETARY_SUPPLEMENT|supplementation with placebo|participants will be instructed to take placebo 2 times daily
215147212|NCT04402567|OTHER|No Intervention|Not Apply
215147213|NCT04874246|DRUG|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
215147214|NCT00777153|DRUG|Cediranib|30 mg/day, oral, until progression
215147215|NCT00777153|DRUG|Cediranib|20 mg/day, oral, until progression
215147216|NCT00777153|DRUG|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
215147217|NCT00777153|DRUG|Placebo Cediranib|Oral, until progression
215147218|NCT04060927|DEVICE|SGRT|Surface Guided Radiation Therapy
215147219|NCT00809718|DRUG|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
215147220|NCT05089786|DEVICE|Exablate Neuro Type 1.0 System with Echo Focusing|MR-Guided Focused Ultrasound
215147221|NCT01516541|OTHER|Background care|Guidelines-based medical care
215147222|NCT01516541|DRUG|Placebo|Matching dalcetrapib placebo orally daily
215147223|NCT01516541|DRUG|dalcetrapib|600 mg orally daily
214460577|NCT04473430|DEVICE|Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance.~Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).~Diagnostic Test: Real-time CGM will be used to collect outcomes variables"
214460578|NCT04473430|DEVICE|POC Glucose Testing|"POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.~Diagnostic Test: Professional CGM will be used to collect outcomes variables (including during the POC BG testing)."
214530736|NCT02874248|DRUG|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
214530737|NCT02874248|DRUG|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
214530738|NCT02874248|DRUG|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
214530739|NCT02210611|PROCEDURE|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
214530740|NCT02210611|PROCEDURE|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
214530741|NCT00937456|PROCEDURE|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
214530742|NCT03551197|DRUG|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
214530743|NCT02666170|DRUG|Alpha-lipoic acid|
215147224|NCT00554216|DRUG|VI-0521|3.75 mg phentermine/23 mg topiramate
214530744|NCT01359878|DRUG|Fibrinogen Concentrate|2 gram intra venous
214530745|NCT01359878|DRUG|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
214530746|NCT01002911|DRUG|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
214530747|NCT01002911|DRUG|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
214530748|NCT00497692|DRUG|Lactoserum|
215147225|NCT00554216|DRUG|VI-0521|15 mg phentermine/92 mg topiramate
215147226|NCT00554216|DRUG|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
215147227|NCT01933568|RADIATION|SABR|combined CFRT and SABR with concurrent cisplatin
215147228|NCT01933568|DRUG|Cisplatin|combined CFRT and SABR with concurrent cisplatin
215147229|NCT03572660|BIOLOGICAL|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
215147230|NCT02559999|OTHER|Painful tonic stimuli|
215147231|NCT02559999|OTHER|non-painful stimuli|
215147232|NCT04430816|PROCEDURE|double mesh modification of chevrel's technique|repair of midline incisional hernia by double mesh modification of chevrel's technique
215147233|NCT04430816|PROCEDURE|on lay mesh hernioplasty|repair of midline incisional hernia by online mesh hernioplasty
215147234|NCT01570946|BEHAVIORAL|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
215147235|NCT02472470|DEVICE|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
215147236|NCT04775940|PROCEDURE|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
215147237|NCT04775940|PROCEDURE|Occlusive collagen membrane|Occlusive collagen membrane
215147238|NCT04674423|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
215147239|NCT00110747|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
215147240|NCT00110747|DRUG|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
215147241|NCT02079246|DRUG|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
215147242|NCT06298799|GENETIC|DNA Sequencing and Analysis|DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
214460579|NCT05703932|OTHER|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
214460580|NCT03761446|BEHAVIORAL|Bed rest|The participant will remain in bed rest for 10 complete days.
214460581|NCT05760144|DRUG|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
214460582|NCT05760144|DRUG|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
214460583|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
214460584|NCT03270501|DRUG|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
214460585|NCT05521269|DRUG|ANX1502|ANX1502 is a prodrug of ANX1439.
214460586|NCT05521269|DRUG|Placebo|Placebo comparator.
214460587|NCT06513832|BEHAVIORAL|The asthma navigator|The asthma navigator is a Registered Respiratory Therapist and Certified Asthma Educator who will review the care plan at discharge and provide asthma education; assist with follow-up clinic appointment scheduling, medication access, and transportation; and daily as-needed telephone support.
214460588|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
214460589|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
214460590|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
214460591|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
214460592|NCT05643846|PROCEDURE|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
214530749|NCT01624597|BEHAVIORAL|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
214460593|NCT05988255|DEVICE|Static progressive stretching|A stretching technique applies a mechanical progressive stretch
214460594|NCT05988255|OTHER|Cyclic manual stretching|A stretching technique applies an intermittent manual stretch
214460595|NCT04141956|OTHER|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
214460596|NCT04316013|DRUG|Sevoflurane|Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
214460597|NCT04316013|DRUG|Propofol|Intravenous anaesthetic used for induction and maintenance of anaesthesia
214460598|NCT04316013|DRUG|Lidocaine IV|1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
214460599|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
214460600|NCT04476160|DIETARY_SUPPLEMENT|Cinnamon|children recipe 3 grams by day of cinnamon
214460601|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
214460602|NCT06549608|DRUG|Mavacamten|As per product label
214460603|NCT04441034|DRUG|Anti-convulsant medications|Anti-convulsants are very commonly used to treat patients with chronic pain.
214460604|NCT04441034|DRUG|Anti-depressant medications|Anti-depressants are very commonly used to treat patients with chronic pain.
214460605|NCT06376734|DEVICE|Transcranial magnetic stimulation|Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
214460606|NCT04623944|BIOLOGICAL|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
215147243|NCT06298799|GENETIC|differential expression analysis with RNA-sequencing (RNA seq) experiments|Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
215147244|NCT06305832|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
215147245|NCT06305832|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
215147246|NCT06305832|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
215147247|NCT03903237|OTHER|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
215147248|NCT03458104|OTHER|Cone Beam Computed Tomography|Cone Beam CT of the larynx
215147249|NCT03458104|DIAGNOSTIC_TEST|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
215147250|NCT03458104|DIAGNOSTIC_TEST|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
215147251|NCT04822506|PROCEDURE|Routine perioperative management and PEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Preoperation:RN 6 + RN 4 +ST30 + ST 36+ Hegu (bilateral),De qi, electroacupuncture, continuous wave, 5Hz, 30min before surgery at 19:00 PM Inoperatively: LI 4+ PC 6 + ST36 + GB 34 (bilateral) ,Deqi, electroacupuncture with density wave, 2/100Hz, 30 minutes before operation to the end of the operation Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
215147252|NCT04822506|PROCEDURE|Routine perioperative management and postEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
215147253|NCT04490096|DRUG|[11C]-PBR28|"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."
215147254|NCT04730219|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
215147255|NCT04730219|DRUG|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
215147256|NCT02645669|PROCEDURE|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
215147257|NCT02645669|PROCEDURE|Control site|Only Scaling and Root planing was done.
214460607|NCT04580446|RADIATION|Hypofractionated intensity modulated radiotherapy|Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
214460608|NCT04430179|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
214530750|NCT01624597|BEHAVIORAL|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
214460609|NCT04430179|OTHER|Placebo|No active drug
214460610|NCT05558904|DRUG|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
214460611|NCT05558904|PROCEDURE|Computed Tomography|Undergo PET/CT
214460612|NCT05558904|OTHER|Laboratory Biomarker Analysis|Correlative studies
214460613|NCT05558904|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214460614|NCT06180954|DRUG|[14C]-LOXO-305|Administered orally
214460615|NCT06180954|DRUG|LOXO-305|Administered orally
214460616|NCT06180954|DRUG|[14C]-LOXO-305|Administered IV
214460617|NCT05714683|DRUG|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
214460618|NCT05854550|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
214530751|NCT00397020|DRUG|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
214530752|NCT00397020|DRUG|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
214530753|NCT04326153|DRUG|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
214530754|NCT02406495|DEVICE|filcon IV 1|contact lens
214530755|NCT02406495|DEVICE|ocufilcon D|contact lens
215147258|NCT05194735|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"
215147259|NCT05194735|BIOLOGICAL|Aldesleukin (IL-2)|To support growth and activation of TCR-T cell drug product
215147260|NCT06061302|OTHER|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
215147261|NCT06061302|OTHER|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
215147262|NCT06229275|DEVICE|Pap smear collection using the Personal Pap Smear (PPS) Device|Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.
214460619|NCT03327805|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
214460620|NCT03327805|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
214460621|NCT04036682|DRUG|CLN-081|CLN-081 tablets
214460622|NCT02561936|DRUG|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
214460623|NCT02561936|DRUG|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10\*2.5 mg tablets.
214460624|NCT02561936|DRUG|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10\*2.5 mg tablets.
214460625|NCT02561936|DRUG|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
214460626|NCT02561936|DIETARY_SUPPLEMENT|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter \[mL\]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) \[189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins\]).
214530756|NCT05546424|BEHAVIORAL|EMRESERVA|training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
214530757|NCT04421313|DRUG|Dietary Fiber Supplementation|12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
214530758|NCT05110014|OTHER|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
214530759|NCT00703105|BIOLOGICAL|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
214530760|NCT00582959|OTHER|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
214530761|NCT02271685|OTHER|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
214530762|NCT02271685|OTHER|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
214530763|NCT02271685|OTHER|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
215147263|NCT06229275|DEVICE|Active Comparator: Pap smear collection using the Rovers Cervex-Brush|Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.
215147264|NCT00479427|DRUG|GW842166|100 mg once daily
215147265|NCT00479427|DRUG|Placebo|once daily
214460627|NCT05775471|PROCEDURE|Biopsy|Undergo tissue biopsy
214460628|NCT05775471|PROCEDURE|Biospecimen Collection|Undergo blood and urine collection
214460629|NCT05775471|DRUG|Enfortumab Vedotin|Given IV
214460630|NCT05775471|PROCEDURE|MR Urography|Undergo MRU
214460631|NCT05775471|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy
214460632|NCT05775471|BIOLOGICAL|Pembrolizumab|Given IV
214530764|NCT02271685|OTHER|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
214530765|NCT05273177|OTHER|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
214530766|NCT03371485|BIOLOGICAL|AST-VAC2|Allogeneic dendritic cell vaccine.
215147266|NCT05991297|OTHER|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~\- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
215147267|NCT05991297|OTHER|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
215147268|NCT04704596|DEVICE|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
214530767|NCT02204319|DEVICE|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
214530768|NCT02723305|OTHER|No intervention|
214530769|NCT02228135|DRUG|Dexamethasone|
214530770|NCT00383747|DRUG|transdermal nicotine patch|14mg transdermal nicotine application
214530771|NCT00383747|DRUG|Transdermal Nicotine Patch|14mg transdermal nicotine application
214530772|NCT05500898|DRUG|DWP16001|Tablets, Oral, multiple doses of DWP16001
214530773|NCT05500898|DRUG|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
214530774|NCT05500898|DRUG|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
214530775|NCT03121729|PROCEDURE|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
214695460|NCT00941954|BEHAVIORAL|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
214695461|NCT00941954|BEHAVIORAL|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
214460633|NCT06273293|DIAGNOSTIC_TEST|Fractional Flow Reserve|"Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center."
214460634|NCT04835506|DRUG|Infliximab|infliximab
214460635|NCT05503927|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
214460636|NCT05206500|DRUG|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC \>0 and \<10,000
214460637|NCT05206500|DEVICE|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
214460638|NCT06600022|DRUG|SCTB41|SCTB41 of different doses,IV,every 3 weeks
214460639|NCT06798064|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stem cells|
214460640|NCT05013957|DIAGNOSTIC_TEST|Methylation analysis|Methylation analysis
214460641|NCT06001749|DRUG|Psilocybin|A tryptamine derivative, capsule, taken orally.
214460642|NCT06783452|OTHER|Exercise|"Clinical Pilates Session:~Each clinical Pilates movement will have three difficulty levels: beginner, intermediate, and advanced. The progression criteria for increasing difficulty will be determined by the prevention of compensatory movements, the ability to activate target muscles, achieving more controlled movements during exercise, and maintaining a more stable posture. This program will include standard hip-focused as well as full-body clinical Pilates movements."
214460643|NCT06783452|OTHER|Exercise|"Conventional Therapeutic Exercise Program:~The Conventional Therapeutic Physiotherapy Exercise Program will consist of strengthening exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors. Additionally, stretching exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors, will be included. Stretching exercises will be performed at a pain-free point where tension is felt, holding for 10-30 seconds to achieve a total duration of 60 seconds per muscle group. These exercises will represent standard hip-targeted exercises.~During the exercises, patients will be asked to rate their perceived exertion using the BORG scale (0-10). When the difficulty level reaches 5-6 points, progression will first be achieved by increasing the number of sets, followed by the use of resistance bands."
214460644|NCT04523493|COMBINATION_PRODUCT|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
214460645|NCT04523493|COMBINATION_PRODUCT|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
214530776|NCT04675762|DRUG|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
214530777|NCT04675762|OTHER|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
214530778|NCT02046798|DRUG|ASP3652|oral
214530779|NCT05068271|BEHAVIORAL|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
214695462|NCT04017442|DRUG|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
215147269|NCT04704596|DEVICE|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
215147270|NCT02751190|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
215147271|NCT02751190|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
214460646|NCT06956300|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
214460647|NCT06956300|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
214460648|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
214460649|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
214460650|NCT06101745|DRUG|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0 or 2.5 mg depending on trial phase.
214460651|NCT06101745|DRUG|Placebo Comparator|In Phase 3A only, \~50 subjects will be randomly allocated to receive sugar placebo
214460652|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
214460653|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
214460654|NCT05909137|RADIATION|IMRT+adjuvant immunotherapy|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.
214460655|NCT04421066|PROCEDURE|Gingival and bone sample collection|Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
214530780|NCT05068271|BEHAVIORAL|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
214530781|NCT01746277|DRUG|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
214530782|NCT01746277|DRUG|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
214530783|NCT04636957|DRUG|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
214530784|NCT04636957|DRUG|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
214530785|NCT05428592|BIOLOGICAL|LVRNA009|50μg /0.5 mL/Vial/person
214530786|NCT05428592|BIOLOGICAL|CoronaVac®|0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
214530787|NCT02099136|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
214695463|NCT04017442|DRUG|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
215147272|NCT02751190|PROCEDURE|Open anterior mesh repair|
214460656|NCT04421066|PROCEDURE|Healthy individuals|Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
214460657|NCT03812679|DEVICE|AMIA APD Solution Generation System|The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
214460658|NCT03079999|DRUG|Aspirin|Twice daily aspirin
214460659|NCT03079999|DRUG|Placebo|Twice daily placebo
214460660|NCT05257070|DIAGNOSTIC_TEST|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
214460661|NCT04508543|OTHER|Non-verbal communication score|1\. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
214460662|NCT03060421|DEVICE|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
214530788|NCT02099136|OTHER|Placebo|Given PO
214530789|NCT02099136|DRUG|Celecoxib|Given PO
215147273|NCT02751190|PROCEDURE|Open Anterior Non Mesh|
215147274|NCT02751190|PROCEDURE|Combined anterior and posterior repair|
215147275|NCT02751190|PROCEDURE|Open preperitoneal mesh repair|
215147276|NCT00463567|DRUG|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
215147277|NCT00463567|DRUG|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
215147278|NCT00463567|DRUG|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
215147279|NCT00463567|DRUG|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
214530790|NCT02099136|PROCEDURE|Biopsy|Undergo skin biopsy
215147280|NCT00463567|DRUG|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
215147281|NCT02721472|PROCEDURE|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
215147282|NCT02721472|PROCEDURE|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
215147283|NCT03296319|DEVICE|Echocardiography|Echocardiography guided fluid administration
215147284|NCT03063320|OTHER|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
215147285|NCT00186589|DRUG|90Y Ibritumomab tiuxetan|
215147286|NCT01429740|DRUG|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
215147287|NCT01429740|DRUG|Placebo|Placebo oral solution or capsules
215147288|NCT00395668|DEVICE|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
214460663|NCT05486078|DEVICE|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
214460664|NCT04838418|PROCEDURE|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
214460665|NCT05988684|DRUG|Metformin|Patients randomized to metformin group will be instructed to take 500 mg metformin daily for 1 week before titrating up to twice a day
214460666|NCT03610750|OTHER|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
214460667|NCT06460948|DRUG|Norethindrone Acetate-Ethinyl Estradiol|Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
214460668|NCT04864080|BEHAVIORAL|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
214460669|NCT04864080|BEHAVIORAL|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
214530791|NCT02099136|OTHER|Imaging Biomarker Analysis|Correlative studies
214530792|NCT00866983|DRUG|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
214530793|NCT03783858|DEVICE|P200TE|OCT images
214695464|NCT04973033|DRUG|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
215147289|NCT02432755|BEHAVIORAL|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
215147290|NCT02432755|BEHAVIORAL|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
215147291|NCT02432755|BEHAVIORAL|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
215147292|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
215147293|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
215147294|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
215147295|NCT04785534|OTHER|Survey Administration|Complete survey
215147296|NCT05605002|DRUG|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
214695465|NCT06102252|DRUG|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
214695466|NCT06102252|DRUG|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
215147297|NCT05605002|PROCEDURE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
215147298|NCT05605002|PROCEDURE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
215147299|NCT00460083|DRUG|Elidel(R) (pimecrolimus 1%)|
215147300|NCT00460083|DEVICE|EpiCeram(R) -ceramide based barrier repair cream|
214460670|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
214460671|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
214460672|NCT06574425|OTHER|long-term, high blood flow hemoadsorption therapy|Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
214460673|NCT04061382|PROCEDURE|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
214460674|NCT04061382|PROCEDURE|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
214460675|NCT06460454|DEVICE|PET scan of 18F-FDG|VEREOS PET scanner. Philips VEREOS digital PET-CT scanners are installed in the nuclear medicine department.
214460676|NCT06643793|DRUG|Irinotecan liposome (ll) + 5-FU/LV + bevacizumab|"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."
214460677|NCT06547099|DIAGNOSTIC_TEST|Clinical tau PET|Tau PET (flortaucipir)
214460678|NCT06547099|DIAGNOSTIC_TEST|Clinical amyloid test|Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
214460679|NCT06547099|OTHER|Research blood collection|Research blood assays for amyloid, tau, and neurodegeneration
214460680|NCT06547099|OTHER|Cognitive assessments|Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
214460681|NCT02985957|BIOLOGICAL|Nivolumab|Specified dose on specified days
214460682|NCT02985957|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214460683|NCT02985957|DRUG|Cabazitaxel|Specified dose on specified days
214460684|NCT02985957|DRUG|Prednisone|Specified dose on specified days
214460685|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
214460686|NCT04148352|DRUG|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
214460687|NCT04148352|OTHER|Placebo|Placebo injected every 2 weeks for 18 weeks
214460688|NCT04583514|BEHAVIORAL|Control|Weight-stable Control group
214460689|NCT04583514|BEHAVIORAL|Overfeeding|30% Overfeeding group
214460690|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
214460691|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
214460692|NCT04887558|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
214460693|NCT03266302|DEVICE|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
214460694|NCT06062082|PROCEDURE|adrenalectomy|laparoscopic exeresis of the adrenal gland
214460695|NCT04447651|OTHER|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
214460696|NCT04711447|DEVICE|kinesio-tape|Twenty-two individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
214460697|NCT05626153|OTHER|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
214460698|NCT05626153|OTHER|Improved anesthesia care|"* Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery."
214460699|NCT06794333|PROCEDURE|Transperineal laser Ablation|Treatments are performed with the combined EchoLaser EVO system (Elesta SpA - Calenzano, FI). The EchoLaser EVO consists of the Echolaser X4, a multi-source laser system with a wavelength of 1064 nm, and the Echolaser Smart Interface (ESI). The procedure are performed with the patient in the lithotomy position. Local anesthesia of the perineal region and periprostatic block with lidocaine is administered under ultrasound guidance. A catheter is placed during the irradiation to allow continuous irrigation of the urethra with saline solution, protecting the urethra from temperature rise. The Echolaser Smart Interface, defines: the number and positioning of fibers, the optimal dose, and the need for multiple pullbacks. 2 to 4 21G needles are inserted simultaneously (1 or 2 per lobe) in the peri-urethral area via transperineal ultrasound guidance. A 300-micron optical fiber will be placed in each needle. Each treatment delivers a maximum energy of 1800 J per fiber with a power of 3-5 W.
214460700|NCT06794333|PROCEDURE|Rezum Vapor Therapy|The treatment involves the insertion of a radiofrequency needle into the prostate tissue and the emission of water vapor. Treatment under local anesthesia/sedation. Treatment planning using the REZUM device, with the number of injections proportional to the recommended therapeutic scheme based on prostate volume (1 injection every centimeter starting 1 cm below the bladder neck and 1 cm in front of the verumontanum). Water vapor emission for 9-second intervals with a maximum of 9 applications per patient. Three-way bladder catheter to decrease local temperature. The bladder catheter will be removed 15 days after patient discharge. Regarding the REZUM, it is a system that uses sterile single-use handpieces available within the company, where a special optics is inserted for direct visualization. The handpiece features a device that allows the manual insertion of a needle into the prostate, from which water vapor is emitted for the described treatment.
214460701|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
214460702|NCT05263037|DEVICE|EaseVRx|VR software with interactive content
214460703|NCT05263037|DEVICE|Sham VR|VR with neutral non-interactive content
214460704|NCT06168461|DRUG|Aspirin|162mg aspirin capsule
214460705|NCT06168461|DRUG|Placebo|placebo capsule
214460706|NCT04902352|PROCEDURE|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
214460707|NCT04902352|PROCEDURE|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
214460708|NCT02813135|DRUG|Ribociclib|
214460709|NCT02813135|DRUG|Topotecan|
214460710|NCT02813135|DRUG|Temozolomide|
214460711|NCT02813135|DRUG|Everolimus|
214460712|NCT02813135|DRUG|Adavosertib|
214460713|NCT02813135|DRUG|Carboplatin|
214460714|NCT02813135|DRUG|Olaparib|
214460715|NCT02813135|DRUG|Irinotecan|
214460716|NCT02813135|DRUG|Vistusertib|
214460717|NCT02813135|DRUG|Nivolumab|
214460718|NCT02813135|DRUG|Cyclophosphamide|
214460719|NCT02813135|DRUG|Selumetinib|
214460720|NCT02813135|DRUG|Enasidenib|
214530794|NCT02672397|BEHAVIORAL|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
214460721|NCT02813135|DRUG|Lirilumab|
214460722|NCT02813135|DRUG|Fadraciclib|
214460723|NCT02813135|DRUG|Cytarabine|
214460724|NCT02813135|DRUG|Dexamethasone|
214460725|NCT02813135|DRUG|Ceralasertib|
214460726|NCT02813135|DRUG|Futibatinib|
214460727|NCT02813135|DRUG|Capmatinib|
214460728|NCT02813135|DRUG|Avelumab|
214460729|NCT02813135|DRUG|Peposertib|
214460730|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
214460731|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
214460732|NCT02918253|RADIATION|targeted focal HDR brachytherapy|
214460733|NCT02918253|RADIATION|Whole-gland HDR Brachytherapy|Control/Standard of Care
214530795|NCT00700453|BEHAVIORAL|Control group with no video game play|Subjects will abstain from all video game play during study participation.
214460734|NCT05438823|OTHER|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
214530796|NCT00700453|BEHAVIORAL|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
214530797|NCT00700453|BEHAVIORAL|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
214460735|NCT06245421|DEVICE|DM934|1 drop in each eye, 4 to 6 times per day
214460736|NCT06245421|DEVICE|Théalose|1 drop in each eye, 4 to 6 times per day
214530798|NCT00700453|BEHAVIORAL|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
214530799|NCT05784077|DIAGNOSTIC_TEST|Polysomnography|Study of the sleep pattern
214530800|NCT05784077|BEHAVIORAL|Lifestyle counselling|Weight loss counselling
214530801|NCT05306522|OTHER|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
214530802|NCT06452927|PROCEDURE|Endoscopic enucleation of the prostate|"Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3"
214530803|NCT00249730|DRUG|Sildenafil|
214530804|NCT01263990|DEVICE|NexFin|noninvasive finger cuff system
214530805|NCT04970381|DRUG|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
214530806|NCT04009720|DEVICE|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] \<1.0 cm2 or AVA index \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
214530807|NCT04876768|PROCEDURE|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
214530808|NCT01327027|DRUG|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
214530809|NCT01327027|DRUG|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
214530810|NCT03389451|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
215147301|NCT02633306|DEVICE|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
215147302|NCT05957380|DRUG|DA-2803|All participants are administered one tablet per day for 48 weeks
214460737|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
214460738|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
214460739|NCT04802967|DRUG|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
215147303|NCT05957380|DRUG|DA-2803-R|All participants are administered one tablet per day for 48 weeks
215147304|NCT05957380|DRUG|Placebo of DA-2803|All participants are administered one tablet per day for 48 weeks
215147305|NCT05957380|DRUG|Placebo of DA-2803-R|All participants are administered one tablet per day for 48 weeks
215147306|NCT04040348|BIOLOGICAL|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
215147307|NCT06408649|DEVICE|Lehfilcon A spherical contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)
215147308|NCT06408649|DEVICE|Lehfilcon A toric contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
215147309|NCT06401239|OTHER|Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
215147310|NCT06401239|OTHER|Self-efficacy|Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.
215147311|NCT06401239|OTHER|Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
215147312|NCT03605485|DEVICE|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
215147313|NCT04369573|COMBINATION_PRODUCT|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
214460740|NCT04802967|DRUG|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
214460741|NCT04802967|DRUG|Gabapentin|300 mg
214460742|NCT04802967|OTHER|Placebo|2 capsules to maintain the blind
214460743|NCT06257706|BIOLOGICAL|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
214460744|NCT05957432|DRUG|Black Seed Oil Cap/Tab|possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
214460745|NCT05957432|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|H pylori vonoprazan based treatment
214460746|NCT06057909|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Test that looks at the structure of the brain.
214460747|NCT06057909|DIAGNOSTIC_TEST|Electroencephalography|Non-invasive technique to measure brain waves
214530811|NCT06236828|DEVICE|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
214530812|NCT06024135|DEVICE|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
214530813|NCT05246384|DRUG|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
214530814|NCT04097691|DRUG|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
215147314|NCT04369573|OTHER|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
215147315|NCT05912257|BEHAVIORAL|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
215147316|NCT05912257|BEHAVIORAL|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
215147317|NCT04190862|DRUG|E-CEL UVEC|Injection of E-CEL UVEC
215147318|NCT05531292|DEVICE|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
215147319|NCT05531292|DEVICE|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
214460748|NCT06057909|DIAGNOSTIC_TEST|Electromyography|Technique to evaluate muscle activity
214460749|NCT02708810|DEVICE|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
214530815|NCT03630692|DRUG|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
214530816|NCT01860807|DRUG|Ibudilast|
214460750|NCT02708810|RADIATION|80 Gy Radiation|
214530817|NCT01860807|DRUG|Placebo|
214530818|NCT02921139|RADIATION|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
214530819|NCT02921139|PROCEDURE|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
214530820|NCT02726035|DRUG|Naltrexone|oral naltrexone 50 mg daily
214530821|NCT02726035|OTHER|Placebo|oral placebo (appearing identical to naltrexone) once daily
214530822|NCT01586429|OTHER|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
214530823|NCT03146897|DIETARY_SUPPLEMENT|Supplementary Food|Supplementary food for treating MAM
215147320|NCT00956007|BIOLOGICAL|cetuximab|intravenously
215147321|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
215147322|NCT05972317|OTHER|Low FODMAP dietary regimen|"intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2."
215147323|NCT00492492|PROCEDURE|trans-styloid and intrafocal pinning on the one side|
215147324|NCT00492492|PROCEDURE|volar fixed-angle plating on the other side|
215147325|NCT01143376|BEHAVIORAL|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
215147326|NCT01143376|BEHAVIORAL|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
215147327|NCT01143376|BEHAVIORAL|Moderate intensity exercise|
215147328|NCT05592106|DIAGNOSTIC_TEST|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
215147329|NCT01746901|DRUG|Placebo|Placebo solution + Placebo ALO-02 (intact)
215147330|NCT01746901|DRUG|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
215147331|NCT01746901|DRUG|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
214530824|NCT02171130|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
214530825|NCT00129506|DRUG|methotrexate + misoprostol|
214530826|NCT00129506|DRUG|misoprostol|
214530827|NCT04531813|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
214530828|NCT04531813|DRUG|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
214695467|NCT00207259|BEHAVIORAL|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
215147332|NCT01746901|DRUG|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
215147333|NCT01746901|DRUG|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
215147334|NCT01746901|DRUG|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
215147335|NCT00742495|DRUG|Forodesine|PK study
214530829|NCT04531813|OTHER|Negative Control|A blank patch was applied to the Negative Control test site.
214530830|NCT02805985|DEVICE|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
214530831|NCT02853305|BIOLOGICAL|Pembrolizumab|IV infusion
214530832|NCT02853305|DRUG|Cisplatin|IV infusion
214530833|NCT02853305|DRUG|Carboplatin|IV infusion
214530834|NCT02853305|DRUG|Gemcitabine|IV infusion
214530835|NCT00858507|BEHAVIORAL|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
214530836|NCT00858507|BEHAVIORAL|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
214530837|NCT00781417|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
214530838|NCT00781417|OTHER|Placebo|Matching Placebo
214530839|NCT00349388|DRUG|Asacol|Asacol is given once a day versus twice or three times a day
214530840|NCT02981537|DEVICE|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
214530841|NCT02981537|DEVICE|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
215147336|NCT06219408|BEHAVIORAL|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
214530842|NCT04701528|DRUG|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
214530843|NCT04701528|DRUG|Tacrolimus|Comparator
214530844|NCT03836742|PROCEDURE|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
214530845|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
215147337|NCT05750849|PROCEDURE|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
215147338|NCT04513483|DEVICE|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
215147339|NCT04513483|DEVICE|Placebo|Observation. Treat AF as cardiologist's discretion.
215147340|NCT02683577|DRUG|telotristat etiprate|
215147341|NCT06033248|DIAGNOSTIC_TEST|urine sample|urine sample will be collected
215147342|NCT04857476|DIAGNOSTIC_TEST|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
215147343|NCT02968004|DRUG|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
215147344|NCT02968004|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
214530846|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
214530847|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
214530848|NCT00644956|DRUG|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
215147345|NCT05121064|BEHAVIORAL|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
214530849|NCT00644956|DRUG|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
214530850|NCT05022290|PROCEDURE|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
214530851|NCT02510053|DRUG|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
215147346|NCT05121064|BEHAVIORAL|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
215147347|NCT05121064|BEHAVIORAL|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
215147348|NCT05029362|BEHAVIORAL|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
215147349|NCT04022213|DRUG|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
215147350|NCT04022213|RADIATION|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
215147351|NCT05571605|BEHAVIORAL|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
215147352|NCT05571605|BEHAVIORAL|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
215147353|NCT06221306|PROCEDURE|Dental implant: NDI|Placement of narrow diameter implants (NDI) (3.3) in the dentoalveolar ridge
215147354|NCT06221306|PROCEDURE|Dental implant: SDI|Placement of standard diameter implants (SDI) (4.1) in the dentoalveolar ridge with simaltenous bone augmentation
214530852|NCT00280020|BEHAVIORAL|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
214530853|NCT00280020|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
214530854|NCT00280020|BEHAVIORAL|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
214530855|NCT02353455|PROCEDURE|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
214530856|NCT03883698|DRUG|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
215147355|NCT00419952|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
215147356|NCT00419952|DRUG|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
215147357|NCT06400693|OTHER|Endotracheal Intubation|Preparation of all necessary equipment for endotracheal intubation
214530857|NCT03883698|DRUG|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
214530858|NCT01340300|BEHAVIORAL|Exercise training|Two supervised exercise sessions per week
214695468|NCT03470649|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
214695469|NCT04755712|DRUG|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
214695470|NCT04755712|DRUG|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
214695471|NCT04755712|DRUG|Morphine|Morphine via pump (patient controlled analgesia)
214530859|NCT01340300|DRUG|Metformin|Oral metformin QD for two weeks, then BID
214530860|NCT01340300|OTHER|Educational information|educational information
214530861|NCT05503693|DRUG|AP303 50 μg|AP303 tablet
214530862|NCT05503693|DRUG|AP303 150 μg|AP303 tablet
214530863|NCT05503693|DRUG|AP303 300 μg|AP303 tablet
214530864|NCT05503693|DRUG|AP303 600 μg|AP303 tablet
214530865|NCT05503693|DRUG|Placebo 50 μg|Placebo tablet
214530866|NCT05503693|DRUG|Placebo 150 μg|Placebo tablet
214530867|NCT05503693|DRUG|Placebo 300 μg|Placebo tablet
214530868|NCT05503693|DRUG|Placebo 600 μg|Placebo tablet
214695472|NCT02912728|BEHAVIORAL|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
214530869|NCT04757714|PROCEDURE|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
214530870|NCT04757714|PROCEDURE|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
214530871|NCT04757714|OTHER|Questionnaires|"* a physical activity questionnaire (PHAS instrument)~* a COPD quality of life questionnaire (St George Hospital)"
214530872|NCT04757714|OTHER|A search for sarcopenia by studying the strength of the grip (dynamometer)|A search for sarcopenia by studying the strength of the grip (dynamometer)
214530873|NCT02036255|DRUG|Taurolidine Urokinase|
214530874|NCT02036255|DRUG|Taurolidine Heparin|
214530875|NCT03544229|DRUG|TAK-906 Maleate|TAK-906 maleate capsules.
214530876|NCT03544229|DRUG|Placebo|TAK-906 maleate placebo-matching capsules.
214530877|NCT04778787|DRUG|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
214530878|NCT03600649|DRUG|Seclidemstat|Twice daily administration of seclidemstat
214695473|NCT02912728|DEVICE|Standard CGM|use of CGM alone to assess CGM adherence
214695474|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
214695475|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
214695476|NCT00723411|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
214530879|NCT03600649|DRUG|Cyclophosphamide|250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
214530880|NCT03600649|DRUG|Topotecan|0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
214530881|NCT06504212|OTHER||
214530882|NCT04772313|BIOLOGICAL|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
214530883|NCT04772313|DRUG|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
214530884|NCT02005068|DRUG|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
214530885|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
214530886|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
214530887|NCT02143310|DEVICE|EVP|
214530888|NCT01836198|DRUG|LY2409021|
214530889|NCT01836198|DRUG|Gemfibrozil|
214530890|NCT01836198|DRUG|Ketoconazole|
214530891|NCT01836198|DRUG|Clarithromycin|
214695477|NCT01085058|DRUG|lenograstim|
214695478|NCT02082145|DEVICE|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
214695479|NCT04182698|DRUG|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
214695480|NCT06175962|BEHAVIORAL|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
214695481|NCT01153191|PROCEDURE|Normal saline pressurized irrigation|same
214695482|NCT01153191|DRUG|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
214695483|NCT00970957|DRUG|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
214530892|NCT03187353|DRUG|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
214530893|NCT03187353|DRUG|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
214530894|NCT05183243|DRUG|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
214530895|NCT02215954|DRUG|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
215147358|NCT06400693|OTHER|Supraglottic Airway|Preparation of all necessary equipment for laryngeal mask
215147359|NCT06480201|DRUG|Ketamine|Ketamine infusion amount is dictated by BMI, sex, and age.
215147360|NCT06480201|OTHER|Saline|Saline infusion amount is dictated by BMI, sex, and age.
215147361|NCT04851964|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
214460751|NCT05177146|DRUG|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
215147362|NCT04851964|OTHER|Placebo|Placebo subcutaneous injection
215147363|NCT06184776|OTHER|Lumbar Stiffness Disability Index|The development and evaluation of the Turkish version of the Lumbar Stiffness Disability Index (LSDI) are planned. After ensuring the eligibility of adult participants included in the study, language validity will be established for the Turkish version of LSDI, and internal consistency will be assessed using Cronbach's alpha coefficient. Additionally, the test-retest reliability of the index will be evaluated by reapplying it to participants with a one-week interval. For external structure validity, LSDI scores will be correlated with Oswestry Disability Index, Functional Reach Test, and goniometric measurements. The study will include demographic data and measurements to examine the eligibility of individuals with specific medical conditions for the intervention.
215147364|NCT03126591|DRUG|Olaratumab|Administered IV
215147365|NCT03126591|DRUG|Pembrolizumab (KEYTRUDA®)|Administered IV
215147366|NCT06353893|DEVICE|Anika Integrity Implant System|The implant is a porous, flexible construct knitted using HYAFF® fibers and designed to support cell infiltration and regenerative healing. HYAFF is Anika's proven and proprietary esterified HA technology that resorbs over time as tissue remodels. Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a truly unique and differentiated solution for shoulder surgeons to treat rotator cuff tears.
215147367|NCT05766813|DRUG|Lenrispodun|Lenrispodun 30 mg tablets administered orally, once daily.
215147368|NCT05766813|DRUG|Placebo|Matching tablets administered orally, once daily.
214460752|NCT05315492|BEHAVIORAL|Community Care Consortium (CCC)|The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
214460753|NCT05985018|OTHER|Traditional Diet|Provided as an educational leaflet
214460754|NCT05985018|OTHER|Mediterranean Diet|Provided as an educational leaflet
214460755|NCT03853395|DIAGNOSTIC_TEST|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
214460756|NCT04114877|BEHAVIORAL|Attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.
214460757|NCT04114877|BEHAVIORAL|Visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
214530896|NCT02215954|DRUG|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
214530897|NCT01656486|RADIATION|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
214530898|NCT06541340|PROCEDURE|Modified strategy|Modified preoperative biliary drainage strategy with prealbumin as the main indicator
214530899|NCT06541340|PROCEDURE|Traditional strategy|Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
214530900|NCT00203723|DRUG|Risperidone|
214530901|NCT01593865|PROCEDURE|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
214530902|NCT01593865|PROCEDURE|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
214530903|NCT05710198|DRUG|Citicoline eye drops 2%|Eye drops containing Citicoline 2%
214530904|NCT05710198|DRUG|Placebo|Eye drops containing placebo matching product
214530905|NCT05247476|DRUG|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
214530906|NCT05247476|DRUG|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
214460758|NCT05896228|DRUG|Iberdomide|"Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy"
214460759|NCT05896228|DRUG|Carfilzomib|"Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15."
214460760|NCT05896228|DRUG|Daratumumab|"Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1."
214460761|NCT05896228|DRUG|Dexamethasone|"Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15."
214460762|NCT05896228|DRUG|Acetaminophen|"Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1."
214460763|NCT05896228|DRUG|Diphenhydramine|"Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1."
214460764|NCT05896228|DRUG|Montelukast|"Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D)."
214460765|NCT06799676|DRUG|a combination treatment of Linperlisib and the VRD regimen|Subjects will be administered Linperlisib orally at doses of 40 mg, 60 mg, or 80 mg once daily for 4 consecutive weeks, combined with the VRD regimen at standard doses. Subsequently, during the expansion phase, at least four cycles of Linperlisib at the recommended Phase II dose (RP2D) will be combined with the VRD regimen for induction therapy.
214460766|NCT06386094|DIAGNOSTIC_TEST|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
214460767|NCT06298227|OTHER|Postoperative analgesia management with Paracerol® and IV PCA with Talinat®|In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
214460768|NCT06298227|OTHER|Erector spinae plane block|The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
214460769|NCT06298227|OTHER|Quadratus lumborum plane block|QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
214530907|NCT00510263|DRUG|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
214530908|NCT00510263|DRUG|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
214530909|NCT00510263|DRUG|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
214530910|NCT00510263|DRUG|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
214530911|NCT04060732|DEVICE|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
214530912|NCT02683213|DRUG|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
214530913|NCT02683213|DRUG|Placebo|Matching placebo.
214530914|NCT02460562|DEVICE|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
215147369|NCT05081180|DRUG|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
215147370|NCT05081180|DRUG|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
215147371|NCT04449250|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
215147372|NCT01269021|DRUG|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d
215147373|NCT01269021|DRUG|Prednisone in full dose|0.8-1mg/kg/d
215147374|NCT05327296|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
215147375|NCT05327296|DRUG|Propofol|Intravenous infusion of propofol
215147376|NCT03898544|DEVICE|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
214460770|NCT05637320|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
214460771|NCT06772220|DIETARY_SUPPLEMENT|Folic Acid 1 MG|Folic Acid 1mg per day
214460772|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B6 25 MG|Vitamin B6, 25mg per day
214460773|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, 1,000 ug per day
214460774|NCT05344469|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
214460775|NCT05344469|OTHER|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
214460776|NCT05344469|OTHER|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
214460777|NCT03804944|RADIATION|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
214460778|NCT03804944|DRUG|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
214460779|NCT03804944|BIOLOGICAL|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
214460780|NCT03945292|DRUG|Fazisiran Injection|solution for subcutaneous (sc) injection
214460781|NCT03945292|OTHER|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
214460782|NCT06429319|DEVICE|"Hydrous biopolymer with silver ions Argiform (HBISA) endoprosthesis of synovial fluid NOLTREX™"|If clinically indicated patients received a repeat course of NOLTREX™ (one or two weekly intra-articular injections of 4.0 NOLTREX™ at the investigator's discretion depending on the stage of OA and clinical response to treatment).
214460783|NCT04295798|DEVICE|Conventional tDCS|The anode will be placed over F3 and the cathode over the contralateral supraorbital margin. At the beginning of stimulation, the current will be increased from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
214460784|NCT04295798|DEVICE|Optimized tDCS|This intervention will utilize eight gel electrodes with placement and current parameters optimized to the cohort, with the goal of generating an average nE over the left dlPFC of the same size as the one delivered by a conventional montage using sponges. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
214460785|NCT04295798|DEVICE|Conventional Sham|Conventional sham will be used to maximize blinding of conventional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration described above will be used; however, current will be automatically ramped down 60 seconds after ramp-up.
214530915|NCT02460562|DEVICE|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
214530916|NCT01816100|OTHER|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
215147377|NCT03898544|DEVICE|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
215147378|NCT05651061|BIOLOGICAL|SS109|27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
214530917|NCT01816100|BEHAVIORAL|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
214530918|NCT03441919|RADIATION|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
214530919|NCT03441919|DIAGNOSTIC_TEST|Blood drawn|Blood drawn
214530920|NCT00888394|PROCEDURE|chiropody|basic procedure of chiropody in podiatry
214530921|NCT00888394|PROCEDURE|basic orthesis|individual basic orthesis of foot
214530922|NCT00888394|PROCEDURE|advantage orthesis|advantage orthesis of foot with special material and design
214530923|NCT00888394|PROCEDURE|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
214530924|NCT04451031|BEHAVIORAL|LiFT Program|
214530925|NCT04494243|DRUG|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
214530926|NCT04494243|DRUG|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
214530927|NCT02728947|DRUG|ROTIGOTINE|1 week at each dose
214530928|NCT01933659|DRUG|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
214530929|NCT03303521|DRUG|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
214530930|NCT03303521|DRUG|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
214530931|NCT01654289|OTHER|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
214530932|NCT01654289|OTHER|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
214695484|NCT00970957|DRUG|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
215147379|NCT04277338|DRUG|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
215147380|NCT04030910|OTHER|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
215147381|NCT02158546|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
214460786|NCT04295798|DEVICE|Optimized Sham|An active sham will be used in which very low-level currents (0.5 mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. We have shown that this active sham effectively blinds participants and operators to stimulation condition and does not affect functional outcomes.
214460787|NCT01857245|OTHER|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
214530933|NCT04653571|OTHER|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
214530934|NCT06233045|DRUG|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
214530935|NCT06233045|DRUG|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
214530936|NCT02642159|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
214530937|NCT02642159|DRUG|Statins|Statins at stable dose without other LMT as clinically indicated.
214530938|NCT02642159|DRUG|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
214530939|NCT02642159|DRUG|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
214530940|NCT02642159|DRUG|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
214530941|NCT02642159|DRUG|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
214530942|NCT02642159|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
215147382|NCT02158546|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
215147383|NCT03863106|OTHER|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
214530943|NCT04194541|DEVICE|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
214530944|NCT04194541|DEVICE|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
214530945|NCT04194541|DEVICE|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
214530946|NCT04431739|DEVICE|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
214530947|NCT03472859|DEVICE|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
214695485|NCT00144755|DRUG|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
215147384|NCT02446522|PROCEDURE|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
214460788|NCT06772831|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Patients meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique.
214460789|NCT06772831|BEHAVIORAL|Downregulate condition|Patients either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
214460790|NCT06004973|DEVICE|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
214460791|NCT02750826|OTHER|Health Education Program|
214460792|NCT02750826|OTHER|Weight Loss Intervention|
214460793|NCT04434664|DRUG|Amlodipine Besylate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
214460794|NCT04434664|DRUG|Metoprolol Succinate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
214460795|NCT05536531|DEVICE|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
214460796|NCT04374175|BIOLOGICAL|Blood sample|Blood sample will be performed
214460797|NCT04611022|BEHAVIORAL|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
214460798|NCT04063501|OTHER|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
214460799|NCT04063501|OTHER|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
214460800|NCT04872413|PROCEDURE|Biospecimen Collection|Undergo blood, saliva or tissue sample collection
214460801|NCT04872413|OTHER|Follow-Up|Undergo follow-up
214460802|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
214460803|NCT05281809|DRUG|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
214460804|NCT06293339|BIOLOGICAL|CHMI with 3D7 malaria|Controlled human malaria infection with 3D7 malaria through mosquito bites
214460805|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
214460806|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
214460807|NCT05601440|OTHER|Observation|Monitoring arm
214530948|NCT03472859|DEVICE|KTP|This is the traditional green laser (KTP)
214530949|NCT00269126|DRUG|fluticasone propionate/salmeterol combination DISKUS|
214530950|NCT00269126|DRUG|salmeterol xinafoate|
214695486|NCT02326207|DEVICE|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
214460808|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
214460809|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
214460810|NCT05601440|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
215147385|NCT02446522|PROCEDURE|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
214460811|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
214460812|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
214460813|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
214460814|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
214460815|NCT05968586|OTHER|Body positioning|Body positioning of infants prone vs supine.
214460816|NCT05378035|DIAGNOSTIC_TEST|Blood Tests|Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
214460817|NCT05792176|BEHAVIORAL|Music Training Intervention|The Music Training Intervention (MTI) entails 12-weeks of online instruction to learn to play the ukulele. Participants will be taught the basic information on how to handle and hold the ukulele, musical chords, and popular songs. They will be instructed to play at least 30-minutes a day, five days a week.
214460818|NCT05792176|BEHAVIORAL|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
214460819|NCT06800235|OTHER|Computer-Assisted Simulation|Nursing students in the experimental group were informed about computer-based simulation. They were also informed about the aspiration skill form and general competency scale.
214460820|NCT06800235|OTHER|Control grup|Nursing students in the control group were informed about the standard procedure/traditional method. They were also informed about the aspiration skill form and general competency scale.
214460821|NCT04321395|DRUG|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
214460822|NCT03509012|DRUG|Durvalumab|IV (intravenous)
214460823|NCT03509012|DRUG|Tremelimumab|IV
214460824|NCT03509012|DRUG|Cisplatin (dose level 4)|IV
214460825|NCT03509012|DRUG|Cisplatin (dose level 3)|IV
214460826|NCT03509012|DRUG|Carboplatin (dose level 1)|IV
214460827|NCT03509012|DRUG|Carboplatin (dose level 2)|IV
214530951|NCT03373500|OTHER|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
214530952|NCT05615662|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
214460828|NCT03509012|DRUG|Etoposide (dose level 1)|IV
214460829|NCT03509012|DRUG|Etoposide (dose level 2)|IV
214460830|NCT03509012|DRUG|Paclitaxel|IV
214460831|NCT03509012|DRUG|Pemetrexed|IV
214695487|NCT03598569|OTHER|dyspnea|dyspnea assessment
214695488|NCT06555211|PROCEDURE|MRI|MRI will be performed
215147386|NCT00244569|DRUG|13C-Methacetin|
215147387|NCT00244569|DEVICE|Breath ID Machine|
215147388|NCT00998361|PROCEDURE|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
215147389|NCT05370638|OTHER|Rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
215147390|NCT01082068|DRUG|XL147 (SAR245408)|given orally once daily as tablets
215147391|NCT01082068|DRUG|XL765 (SAR245409)|given orally twice daily as capsules
215147392|NCT01082068|DRUG|letrozole (Femara)|given orally once daily as tablets
214460832|NCT03509012|RADIATION|External beam radiation (dose level 1)|radiation therapy
214460833|NCT03509012|RADIATION|External beam radiation (dose level 2)|radiation therapy
214460834|NCT03509012|RADIATION|External beam radiation (hyperfractionated)|radiation therapy
214460835|NCT03509012|DRUG|Cisplatin (dose level 1)|IV
214460836|NCT03509012|DRUG|Cisplatin (dose level 2)|IV
214460837|NCT03509012|RADIATION|External beam radiation (standard)|radiation therapy
214460838|NCT06798246|DRUG|Chemotherapy|Gemicitabin and cisplatin
214460839|NCT06798246|DRUG|Immunotherapy|PD-1/PD-L1
214695489|NCT06555211|PROCEDURE|PET/CT|PET/CT will be performed
214695490|NCT02586233|DRUG|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
214695491|NCT02586233|DRUG|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
214695492|NCT04191291|BEHAVIORAL|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
214530953|NCT05615662|BEHAVIORAL|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
214530954|NCT02628613|DRUG|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
214530955|NCT02628613|DRUG|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
215147393|NCT02621450|BIOLOGICAL|standart dialysis|dialysate sodium consentration 140 mEq
215147394|NCT02621450|BIOLOGICAL|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
214695493|NCT06248905|OTHER|Rehabilitation program based on the strengthening of gluteal muscles|Physiotherapy program (8 weeks)
214460840|NCT06798246|DRUG|ADC|ADC drug like RC48
214530956|NCT00237900|DRUG|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
214530957|NCT00030745|DRUG|cisplatin|
214695494|NCT06248905|OTHER|Extracorporeal shock wave therapy|Focused shock wave therapy (3 weeks)
215147395|NCT06198296|GENETIC|21.15.GPC3-CAR T cells|"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2"
214460841|NCT06798246|DRUG|Chemotherapy combined with immunotherapy|Chemotherapy combined with immunotherapy
214460842|NCT03524118|DRUG|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
214460843|NCT03524118|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
214530958|NCT00030745|DRUG|gemcitabine hydrochloride|
214530959|NCT00030745|PROCEDURE|conventional surgery|
214530960|NCT03746483|DRUG|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
214530961|NCT03746483|DRUG|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
214530962|NCT02745184|BIOLOGICAL|Lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
214530963|NCT05712850|PROCEDURE|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
214530964|NCT05645744|BIOLOGICAL|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
214530965|NCT05645744|BIOLOGICAL|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
214530966|NCT00187135|DRUG|Fentanyl|"1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
214530967|NCT00187135|DRUG|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
214530968|NCT00187135|DRUG|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
214695495|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
214695496|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
214695497|NCT04089813|DRUG|Metformin|Patients use metformin to control blood sugar
214695498|NCT04447703|OTHER|Interview|Attend Interview
214695499|NCT04447703|OTHER|Internet Based Intervention|Use web-based genetic education tool online
214695500|NCT04447703|OTHER|Survey Administration|Ancillary Studies
215147396|NCT01469169|DRUG|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
215147397|NCT00951340|OTHER|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
215147398|NCT00951340|BEHAVIORAL|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
215147399|NCT00951340|BEHAVIORAL|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
215147400|NCT02586740|PROCEDURE|Pulmonary artery rehabilitation|
214460844|NCT06772818|DRUG|Nemtabrutinib|Oral Tablet
214460845|NCT06581003|DRUG|Oxygen 99.7 %|The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
214460846|NCT06581003|DRUG|Oxygen 21 %|The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
214530969|NCT00187135|DRUG|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
214695501|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
214695502|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
214695503|NCT04447703|OTHER|Survey Administration|Ancillary Studies
214695504|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
214695505|NCT04447703|OTHER|Internet-Based Intervention|Use web-based genetic education tool online
214695506|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
214695507|NCT04447703|OTHER|Survey Administration|Ancillary Studies
215147401|NCT05679752|OTHER|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
215147402|NCT05679752|OTHER|Massage therapy|frictional massage to stimulate the weak muscle groups
214460847|NCT04872738|OTHER|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
214460848|NCT06325332|OTHER|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
214460849|NCT06095817|BEHAVIORAL|Internet Delivered Brief Intervention (IDBI)|The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
214460850|NCT05578300|DIAGNOSTIC_TEST|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
214460851|NCT05578300|DIAGNOSTIC_TEST|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
214460852|NCT06646432|PROCEDURE|Tunnel with connective tissue graft and injectable platelet rich fibrin|Tunnel with connective tissue graft and injectable platelet rich fibrin
214460853|NCT06646432|PROCEDURE|Tunnel with connective tissue graft only|Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
214460854|NCT03122847|DRUG|Methylprednisolone|Intravenous methylprednisolone
214460855|NCT03792763|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
214460856|NCT03792763|DRUG|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
214460857|NCT04971889|BEHAVIORAL|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
214460858|NCT04971889|BEHAVIORAL|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
214460859|NCT05789134|OTHER|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
214460860|NCT03624608|DEVICE|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
214460861|NCT06063083|BEHAVIORAL|"Tell Me More (Dime Mas)"|Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
214460862|NCT06063083|BEHAVIORAL|"Peer Ambassador Stories [Listen Miami (Oye Miami)]"|Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
214460863|NCT06063083|BEHAVIORAL|Standard Community Outreach|Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
214460864|NCT03916510|BIOLOGICAL|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
214460865|NCT03916510|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
214460866|NCT03916510|RADIATION|Radiotherapy|50 Gy/25#
215147403|NCT00235274|DRUG|Subcutaneous Secretin|
215147404|NCT02266511|DRUG|Flomax®, Norman II facility|
215147405|NCT02266511|DRUG|Flomax®, Nishine facility|
214460867|NCT04219280|DRUG|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
214460868|NCT04219280|DRUG|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
214460869|NCT04472091|DEVICE|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
214460870|NCT06487182|OTHER|reiki|reiki
214460871|NCT06487182|OTHER|placebo reiki|placebo reiki
214460872|NCT02716116|DRUG|TAK-788|TAK-788 capsules.
214460873|NCT06236620|DIETARY_SUPPLEMENT|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
214530970|NCT06023745|GENETIC|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
214530971|NCT00607737|DRUG|insulin detemir|3 cutaneous injections
214530972|NCT00607737|DRUG|saline|3 cutaneous injections
215147406|NCT03317015|DRUG|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
215147407|NCT03317015|DRUG|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
215147408|NCT03490695|OTHER|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
214460874|NCT04650269|DRUG|Biktarvy 50Mg-200Mg-25Mg Tablet|Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
214460875|NCT04650269|OTHER|HIV care|HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
214530973|NCT01389609|DRUG|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
214530974|NCT01389609|DRUG|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
214530975|NCT01389609|DRUG|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
214530976|NCT02683356|OTHER|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
214530977|NCT02683356|OTHER|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
214530978|NCT03480945|DIAGNOSTIC_TEST|serotonin|Endothelium-dependent dilatation
214530979|NCT02949622|BEHAVIORAL|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
215147409|NCT03490695|OTHER|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
215147410|NCT02900378|DRUG|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
214530980|NCT02949622|OTHER|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
214530981|NCT01610622|DEVICE|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
214530982|NCT04796389|OTHER|Music|Preferred music of the participant administered using headphones.
214530983|NCT01779427|BEHAVIORAL|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
214530984|NCT03841227|DEVICE|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
214530985|NCT03841227|DEVICE|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
214530986|NCT02840071|OTHER|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
214530987|NCT00640523|DRUG|forodesine HCl|2 x 100mg capsules daily
214530988|NCT00011778|DRUG|bortezomib|
214460876|NCT05935761|DRUG|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
214460877|NCT05935761|DRUG|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
214460878|NCT05935761|DRUG|Placebo|Same as active comparator arms, except placebo dispensed
214460879|NCT05398679|DRUG|Cefaclor|cefaclor intravenous 2 gr/day
214530989|NCT00011778|RADIATION|radiation therapy|
214530990|NCT02650934|PROCEDURE|Percutanous coronary intervention|
214530991|NCT04715919|DIAGNOSTIC_TEST|Chest Computed Tomography|Evaluation of Lung Structure
214530992|NCT04715919|DIAGNOSTIC_TEST|Pulmonary Function Tests|Respiratory Capacity
214530993|NCT04715919|OTHER|Six Minutes Walk Test|Exercise Capacity
214530994|NCT04715919|OTHER|Quality of Life|Physical disability assessment tool
214695508|NCT05910541|BEHAVIORAL|Mindful breathing|30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
214460880|NCT05398679|DRUG|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
214460881|NCT05398679|DRUG|Ciprofloxacin Injection|1200 mg/day maximum dose IV
214695509|NCT05910541|OTHER|Standard care (control)|Standard care such as pain control, oxygen supplement.
214695510|NCT00082758|BIOLOGICAL|hu14.18-Interleukin-2 fusion protein|Given IV
214530995|NCT00043407|DRUG|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
214530996|NCT06338254|OTHER|percussion massage therapy|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks. Percussion massage was applied to both extremities at separate times for 5 minutes each with the Hypervolt device. (Fig. 2) Four muscles in total were focused on; These muscles are medial gastrocnemius, lateral gastrocnemius, peronus longus, and tibialis anterior. Percussion massage was applied in the longitudinal direction of the muscle, from distal to proximal and back to distal, going from posterior to anterior muscle groups. Percussion massage started on the medial side and ended on the lateral side for each muscle. Equal pressure and duration were applied to each muscle.
214530997|NCT05979402|OTHER|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
214530998|NCT05979402|OTHER|Control group|No intervention
214530999|NCT02730676|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
214531000|NCT02730676|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
214531001|NCT00309621|DRUG|alitretinoin|
214531002|NCT01138189|PROCEDURE|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
214531003|NCT01138189|PROCEDURE|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
214531004|NCT05436145|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
214531005|NCT05533645|OTHER|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
214531006|NCT01924806|DEVICE|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
214695511|NCT02598518|BEHAVIORAL|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
214695512|NCT02598518|BEHAVIORAL|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
215147411|NCT02900378|DRUG|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
215147412|NCT02900378|DRUG|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
215147413|NCT02900378|DRUG|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
215147414|NCT06961097|OTHER|Virtual Reality Group|control group
215147415|NCT01887457|DRUG|VFEND|voriconazole will be administered in iv form
215147416|NCT01807624|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
215147417|NCT05201300|DRUG|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
214460882|NCT05398679|DRUG|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
214460883|NCT05398679|DRUG|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
214460884|NCT05398679|DRUG|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
214460885|NCT05398679|DRUG|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
214460886|NCT05398679|DRUG|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
214460887|NCT05398679|DRUG|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
214460888|NCT05398679|DRUG|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
214460889|NCT05398679|DRUG|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
214460890|NCT05398679|DRUG|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
214460891|NCT05398679|DRUG|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
214460892|NCT05398679|DRUG|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
214460893|NCT05398679|DRUG|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
214460894|NCT05398679|DRUG|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
214460895|NCT05398679|DRUG|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
214460896|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
214460897|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
214460898|NCT05398679|DRUG|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
214460899|NCT05398679|DRUG|Tedizolid Injection|200 mg (maximum x day)
214460900|NCT05398679|DRUG|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
214460901|NCT05398679|DRUG|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
214460902|NCT05398679|DRUG|Cefaclor Capsules|2 gr/day
214460903|NCT01881048|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Given PO
215147418|NCT05201300|DRUG|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
214460904|NCT01881048|DRUG|Celecoxib|Given PO
214460905|NCT04987320|DRUG|Olpasiran|Subcutaneous injection
215147419|NCT05201300|DRUG|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
214531007|NCT01924806|DEVICE|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
214531008|NCT03284593|DRUG|intensive chemotherapy|
214531009|NCT03284593|DRUG|Azacitidine|
214531010|NCT01954771|BEHAVIORAL|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
214531011|NCT01954771|OTHER|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
214531012|NCT02278133|DRUG|WNT974|
214531013|NCT02278133|DRUG|LGX818|
214531014|NCT02278133|BIOLOGICAL|Cetuximab|
214531015|NCT05532683|BEHAVIORAL|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller \& Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
214531016|NCT00088075|DRUG|Risperidone|
215147420|NCT02868632|DRUG|MEDI4736|anti-PD-L1 human monoclonal antibody
215147421|NCT02868632|DRUG|Tremelimumab|anti-CTLA4 human monoclonal antibody
214531017|NCT00184496|DRUG|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
214531018|NCT03343288|DEVICE|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
214531019|NCT00229190|PROCEDURE|Nasal lavage|
214531020|NCT00229190|PROCEDURE|Allergy skin testing|
214695513|NCT05570045|DIETARY_SUPPLEMENT|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
214695514|NCT00238303|DRUG|vorinostat|Given orally
215147422|NCT02868632|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
215147423|NCT03693924|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
215147424|NCT00686413|DRUG|AZD3480|single dose, oral
215147425|NCT00686413|RADIATION|2-[18F]-F-A85380|Single dose, IV
214531021|NCT00229190|PROCEDURE|Peak nasal inspiratory flow|
214531022|NCT00229190|PROCEDURE|Acoustic rhinometry|
214531023|NCT00229190|PROCEDURE|Nasal examination|
214531024|NCT00229190|PROCEDURE|Quality of Life Questionnaire|
214531025|NCT00229190|PROCEDURE|Physical examination|
214531026|NCT02886234|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
214531027|NCT02886234|BEHAVIORAL|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
215147426|NCT02531802|BIOLOGICAL|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~* Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~* E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~* E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~* E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~* E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
215147427|NCT02531802|BIOLOGICAL|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
215147428|NCT02531802|OTHER|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
215147429|NCT04653077|OTHER|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
215147430|NCT05021406|DRUG|Carvedilol 12.5 MG|Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
215147431|NCT01773044|DRUG|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
214460906|NCT01437709|BIOLOGICAL|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
214460907|NCT01437709|OTHER|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
214460908|NCT06542588|COMBINATION_PRODUCT|HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)|Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
214460909|NCT06408181|DRUG|Aspirin 162 mg|Aspirin is a nonsteroidal anti-inflammatory drug.
214460910|NCT06408181|DRUG|Aspirin 81mg|Aspirin is a nonsteroidal anti-inflammatory drug.
214460911|NCT05858424|OTHER|Multidisciplinary day hospitalization|"This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment."
214460912|NCT04200547|OTHER|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
214460913|NCT04200547|OTHER|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI \> 220 together with an increase of 70 points) and biological relapse (CRP \> 10mg/mL and fecal calprotectin \> 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
214460914|NCT03227146|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
214460915|NCT03227146|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
214460916|NCT06551246|DRUG|Solifenacin|According to randomization.
214460917|NCT06551246|DRUG|Mirabegron|According to randomization.
214695515|NCT00238303|PROCEDURE|conventional surgery|Patients undergo surgery to remove tumor
214695516|NCT02090192|PROCEDURE|WBV training|
214695517|NCT02090192|PROCEDURE|PRT training|
215147432|NCT01773044|DRUG|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
215147433|NCT01773044|DRUG|Placebo (for alcalinized lidocaine)|
215147434|NCT00594841|PROCEDURE|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws"
215147435|NCT00594841|OTHER|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
215147436|NCT03769519|BEHAVIORAL|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
215147437|NCT04014517|OTHER|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
215147438|NCT04014517|DIETARY_SUPPLEMENT|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
215147439|NCT03854097|DEVICE|Active Intermittent Negative Pressure (INP)|Application of -40mmHg negative pressure on the lower limb
214460918|NCT06181344|BEHAVIORAL|FCR screening and referral program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
215147440|NCT03854097|DEVICE|Placebo Intermittent Negative Pressure (INP)|Application of -10mmHg negative pressure on the lower limb
215147441|NCT02153749|BEHAVIORAL|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
215147442|NCT02153749|BEHAVIORAL|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
214460919|NCT05634967|OTHER|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
214460920|NCT00579072|BEHAVIORAL|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
214531028|NCT05106816|OTHER|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
214695518|NCT04876989|PROCEDURE|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
215147443|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
215147444|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO|Slow-release CHO, alginate encapsulated
215147445|NCT06165393|DIETARY_SUPPLEMENT|CHO|Carbohydrate-only, control
214531029|NCT05106816|OTHER|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
214460921|NCT00579072|BEHAVIORAL|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
214460922|NCT00579072|DEVICE|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
214531030|NCT05171361|PROCEDURE|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
214531031|NCT03635775|DEVICE|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
214531032|NCT03635775|DEVICE|Sham tDCS|Sham-setting--no electrical current delivered.
214531033|NCT02937051|OTHER|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
214531034|NCT05937971|OTHER|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
214531035|NCT05937971|OTHER|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
214531036|NCT05542225|PROCEDURE|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
214460923|NCT06046742|BIOLOGICAL|M1-c6v1|Intravenous drip administration
214460924|NCT06073665|DRUG|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
214460925|NCT00085735|DRUG|Cisplatin|Given IV
214460926|NCT00085735|RADIATION|Craniospinal Irradiation|Undergo craniospinal Irradiation
214460927|NCT00085735|DRUG|Cyclophosphamide|Given IV
215147446|NCT02795702|DEVICE|tDCS|Transcranial direct current stimulation
215147447|NCT02795702|BEHAVIORAL|training|Cognitive training
215147448|NCT00767364|BIOLOGICAL|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
215147449|NCT05201313|DRUG|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
215147450|NCT05201313|DRUG|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
215147451|NCT03429270|DEVICE|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
214460928|NCT00085735|RADIATION|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
214460929|NCT00085735|OTHER|Laboratory Biomarker Analysis|Correlative studies
214460930|NCT00085735|DRUG|Lomustine|Given orally
214460931|NCT00085735|OTHER|Quality-of-Life Assessment|Ancillary studies
214460932|NCT00085735|RADIATION|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
215147452|NCT04109261|DRUG|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
215147453|NCT01035125|BEHAVIORAL|Self-management program|Participants will receive a one week inpatient self-management program
215147454|NCT04035148|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
214460933|NCT00085735|DRUG|Vincristine Sulfate|Given IV
214460934|NCT05582668|PROCEDURE|Bariatric surgery|Bariatric surgery
214460935|NCT01824875|DRUG|temozolomide|Given PO
214460936|NCT01824875|DRUG|capecitabine|Given PO
214460937|NCT04436835|BEHAVIORAL|Psychotherapy|Undergo ART
214460938|NCT04436835|OTHER|Questionnaire Administration|Ancillary studies
214531037|NCT05542225|PROCEDURE|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
214531038|NCT05542225|PROCEDURE|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
214531039|NCT00003359|DRUG|batabulin sodium|
214531040|NCT06223100|DRUG|Eravacycline|There is no other intervention.
214531041|NCT01007721|DRUG|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
214531042|NCT01007721|DRUG|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
214531043|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
214531044|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
214531045|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
214531046|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
214531047|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
214531048|NCT01007721|DRUG|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
214531049|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
214531050|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
214531051|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
214531052|NCT01007721|DRUG|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
214531053|NCT01007721|DRUG|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
214531054|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
214531055|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
214531056|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
214531057|NCT01007721|DRUG|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
214531058|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
214531059|NCT01007721|DRUG|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
214531060|NCT01007721|DRUG|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
214531061|NCT00825214|DEVICE|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
214531062|NCT00825214|DEVICE|Inactivated zapperclick device|placebo
215147455|NCT01249261|DRUG|Risedronate|5 mg/day
215147456|NCT01249261|DRUG|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
215147457|NCT04098718|DRUG|Benralizumab|100mg sub cut once only
215147458|NCT04098718|DRUG|Prednisolone|30mg tablet daily for 5 days
214460939|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
214460940|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
214531063|NCT04783883|DEVICE|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
214531064|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"
214531065|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"
214531066|NCT00262769|DRUG|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
214531067|NCT00262769|DRUG|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
214531068|NCT01242033|DIETARY_SUPPLEMENT|red raspberries|single serving of one, two or four cups red raspberries
214531069|NCT01242033|DIETARY_SUPPLEMENT|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
214531070|NCT04787900|DEVICE|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
214531071|NCT04787900|DEVICE|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
214531072|NCT01802476|DRUG|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
214531073|NCT01802476|DRUG|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
214460941|NCT06021782|OTHER|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
214531074|NCT01990378|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
214531075|NCT05562583|BEHAVIORAL|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
214531076|NCT04034914|OTHER|Questionnaire administration|Ancillary studies
214531077|NCT05463835|DIETARY_SUPPLEMENT|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
214531078|NCT05463835|DIETARY_SUPPLEMENT|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
214531079|NCT05463835|DIETARY_SUPPLEMENT|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
214531080|NCT04331015|DIAGNOSTIC_TEST|Pure tone audiometry|pure tone audiometry
214531081|NCT00487513|PROCEDURE|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
214531082|NCT02811393|OTHER|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
214531083|NCT03229096|DRUG|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
214531084|NCT04098497|BEHAVIORAL|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
214531085|NCT01325818|DRUG|pravastatin, rosuvastatin|"1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
214531086|NCT04960436|PROCEDURE|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
215147459|NCT06462456|DEVICE|Verofilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
215147460|NCT06462456|DEVICE|Verofilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
214460942|NCT06555562|DEVICE|Ultrasound Stimulation|Ultrasound therapy will be administered to the appropriate target.
214460943|NCT06555562|DEVICE|Non-active ultrasound stimulation|Non-active ultrasound therapy will be administered to the appropriate target
214460944|NCT06358274|OTHER|Thru-hiking|planning to embark on the Colorado Trail
214531087|NCT04960436|PROCEDURE|Meniscectomy|patients received surgery of Meniscectomy
214531088|NCT04364750|DIETARY_SUPPLEMENT|L-Histidine|1 capsule (0.6g) twice daily
214531089|NCT04364750|DIETARY_SUPPLEMENT|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
214531090|NCT04364750|DIETARY_SUPPLEMENT|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
214531091|NCT04364750|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
214531092|NCT04364750|OTHER|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
214531093|NCT03178318|PROCEDURE|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
214531094|NCT01823640|OTHER|placebo|
215147461|NCT00002013|DRUG|Zidovudine|
215147462|NCT00002013|DRUG|AS-101|
215147463|NCT04347876|DIAGNOSTIC_TEST|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
215147464|NCT02964143|DEVICE|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
214531095|NCT01823640|OTHER|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
214531096|NCT03807453|OTHER|Microbiota|The scalp microbiota
214531097|NCT00162552|DRUG|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
214531098|NCT00162552|DRUG|PLACEBO|Patients with severe cirrhosis treated with a placebo
214531099|NCT00095017|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
214531100|NCT00236483|DRUG|tramadol hydrochloride + acetaminophen|
214531101|NCT06406868|OTHER|American Cancer Society|"After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down"
214531102|NCT03653377|OTHER|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
214531103|NCT00556764|DRUG|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
215147465|NCT02964143|DEVICE|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
215147466|NCT02964143|DEVICE|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
215147467|NCT01686399|BEHAVIORAL|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
215147468|NCT02819804|DRUG|Dasatinib|Given PO
215147469|NCT02819804|OTHER|Laboratory Biomarker Analysis|Correlative studies
215147470|NCT02819804|BIOLOGICAL|Nivolumab|Given IV
214531104|NCT00556764|DRUG|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
214531105|NCT02739490|PROCEDURE|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
215147471|NCT02819804|OTHER|Pharmacological Study|Correlative studies
215147472|NCT03060096|OTHER|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
214531106|NCT06425094|DIETARY_SUPPLEMENT|Microalgae Extract Capsules|Tetrasol extract
214531107|NCT06425094|DIETARY_SUPPLEMENT|Placebo|maltodextrin \& vegetable magnesium stearate
214531108|NCT03128541|DIAGNOSTIC_TEST|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
214531109|NCT01644825|DRUG|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
214531110|NCT01644825|DRUG|pazopanib|orally, 800 mg orally daily
214531111|NCT01018797|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
214531112|NCT01537406|RADIATION|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
214531113|NCT02216578|DRUG|cabozantinib|Oral
214531114|NCT04957407|OTHER|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
214531115|NCT00297778|DRUG|Pramipexole|Dopamine agonist
214531116|NCT00297778|OTHER|Placebo|
214531117|NCT00212797|DRUG|Org 34517|low dose Org 34517
214531118|NCT00212797|DRUG|Org 34517|high dose Org 34517
214531119|NCT00212797|DRUG|Placebo|placebo
214531120|NCT04531878|DRUG|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
214531121|NCT01381458|DRUG|FSC|fluticasone propionate / salmeterol xinofoate combination
215147473|NCT03060096|OTHER|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
214531122|NCT01381458|DRUG|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
214531123|NCT00679549|DEVICE|CPAP Therapy|CPAP therapy is provided as an inpatient.
214531124|NCT04300322|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
214531125|NCT04300322|DRUG|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
214531126|NCT04700566|BIOLOGICAL|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
214531127|NCT01865578|DEVICE|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
214531128|NCT01865578|DEVICE|Sham Stimulation|no electrical stimulation
214531129|NCT06183905|DIAGNOSTIC_TEST|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
215147474|NCT03060096|OTHER|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
215147475|NCT03487237|BIOLOGICAL|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
215147476|NCT00482053|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
215147477|NCT00482053|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
215147478|NCT00482053|PROCEDURE|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
215147479|NCT00482053|DRUG|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
215147480|NCT00482053|DRUG|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
215147481|NCT00482053|DRUG|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
215147482|NCT00482053|DRUG|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
215147483|NCT00482053|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
214531130|NCT06183905|PROCEDURE|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
214531131|NCT03280108|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
214531132|NCT03280108|DEVICE|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
214531133|NCT02957162|DRUG|Atorvastatin|
215147484|NCT00482053|DRUG|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
215147485|NCT00482053|DRUG|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
215147486|NCT00482053|DRUG|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
215147487|NCT00482053|DRUG|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
215147488|NCT00482053|DRUG|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
215147489|NCT00482053|DRUG|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
215147490|NCT00482053|DRUG|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
215147491|NCT03004937|OTHER|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
215147492|NCT01441076|DRUG|Anakinra|Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
215147493|NCT03114683|DRUG|PD1|IBI308 200mg/3 weeks
215147494|NCT02947789|PROCEDURE|Emergency surgery|Patients undergoing emergency surgery
214460945|NCT02014649|DRUG|20 mg laninamivir octanoate|
214460946|NCT02014649|DRUG|Placebo|
214460947|NCT02014649|DRUG|40 mg laninamivir octanoate|
214460948|NCT06807229|DEVICE|Transcutaneous electrical nerve stimulation|We will apply high frequency TENS for low back pain relief as it showed effectiveness more than low frequency TENS in pain relief (21). The recommendation is to apply the TENS at the highest tolerable intensity (22). While adjusting the current amplitude in a continuous manner so that its presence will be noticeable throughout the treatment. We applied a TENS device (ENRAF NONIUS Model, four electrodes) with a frequency of 0- 100/HZ and 90-100 pulse /seconds was applied for 20 minutes, to increase circulation and to have pain relief at the first day of menstrual complaints without taking any analgesics. Patients lied in prone position with a thin pillow placed under their abdomen. Two electrodes were placed to the proximal margin of low back area, and two others were placed to the proximal of gluteal region laterally. The intensity of stimulation was increased up to the tolerated level without causing any contraction
214460949|NCT06807229|OTHER|stretching exercises|"The first stretching exercise: The subjects will be asked to stand and bend trunk forward from the hip joint so that the shoulders and back were positioned on a straight line and the upper body was placed parallel to the floor for 5 seconds repetition; 10 times.~The second stretching exercise: The subjects will be requested to stand then raise 1 heel off the floor, then repeat the exercise with the other heel alternatively. The exercise will be performed 20 times.~The third stretching exercise: The subjects will be asked to spread their feet shoulder width, place trunk and hands in forward stretching.~The fourth stretching exercise: The subjects will be asked to spread her feet wider than shoulder width. Then the subject was asked to bend and touch left ankle with her right hand while putting her left hand in a stretched position above her head so that the head was in the middle and her head was turned and looked for her left hand, this exercise was repeated for the opposite foot with"
214460950|NCT01973179|RADIATION|Radiation therapy|Radiation therapy with protons
214460951|NCT02857777|DRUG|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
214460952|NCT06181929|DIAGNOSTIC_TEST|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
214460953|NCT04255784|DEVICE|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
214460954|NCT04255784|DEVICE|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
214460955|NCT06506721|DEVICE|Double ballon device, Cook|"Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
214531134|NCT02957162|OTHER|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
214531135|NCT01717170|DRUG|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
214531136|NCT04585568|OTHER|Biosensors|Measures of blood flow and preassures
214531137|NCT02511340|DRUG|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
214531138|NCT02996097|DEVICE|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
214531139|NCT02996097|DRUG|Intralesional Triamcinolone Acetonide|
214531140|NCT05050435|PROCEDURE|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
214531141|NCT02201771|DRUG|Aspirin|
214531142|NCT02201771|DRUG|Ticagrelor|
214531143|NCT01300078|DRUG|MF101|MF101 10 g/day MF101 15 g/day
214531144|NCT02716753|BIOLOGICAL|seminal plasma|
214531145|NCT02716753|BIOLOGICAL|Physiological NaCL solution|
214531146|NCT00218998|BEHAVIORAL|exercise training|
214531147|NCT05458830|BEHAVIORAL|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
214531148|NCT05458830|BEHAVIORAL|Plain advisory text|Care as usual
214531149|NCT01999543|DIETARY_SUPPLEMENT|plant-based dietary supplement|
214531150|NCT01999543|OTHER|Placebo|
214531151|NCT04719819|PROCEDURE|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
214531152|NCT01820637|DEVICE|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
215147495|NCT00346697|DRUG|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
215147496|NCT00346697|DRUG|Placebo|Corn-oil placebo
215147497|NCT05133141|DEVICE|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
215147498|NCT02633904|PROCEDURE|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
215147499|NCT02633904|PROCEDURE|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
215147500|NCT02895893|BEHAVIORAL|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
215147501|NCT04670978|DRUG|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
215147502|NCT04186143|OTHER|Closed Cinetic Chain Exercises|Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
215147503|NCT04186143|OTHER|Open Kinetic Chain Exercises|Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
215147504|NCT04186143|OTHER|Control Group|Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
214460956|NCT06506721|DEVICE|Hygroscopic cervix dilators, Dilapan-S|"A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
215147505|NCT01940796|DRUG|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
214531153|NCT02852278|OTHER|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
214531154|NCT00264498|DRUG|Gefitinib|oral tablet
214531155|NCT00264498|DRUG|Gemcitabine|intravenous injection
214531156|NCT00264498|DRUG|Carboplatin|intravenous injection
214531157|NCT00583115|DRUG|Gleevec|260 mg/M2/day, given once daily by mouth
214531158|NCT03412513|DRUG|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
214531159|NCT03412513|DRUG|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
214531160|NCT05534464|OTHER|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
214531161|NCT05534464|OTHER|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
214531162|NCT05534464|OTHER|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
214695519|NCT04876989|PROCEDURE|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
214531163|NCT01378598|OTHER|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
215147506|NCT02062840|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
215147507|NCT02062840|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
215147508|NCT02062840|DEVICE|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
215147509|NCT02062840|OTHER|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
215147510|NCT03619720|OTHER|Records|Respiratory records, Vocal records Video records Questionnaires
215147511|NCT01680471|DRUG|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
215147512|NCT01680471|DRUG|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
214460957|NCT05840263|BEHAVIORAL|Qualitative interview|Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
214460958|NCT05840263|BEHAVIORAL|Cognitive Interviews|The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
214460959|NCT05739149|DIAGNOSTIC_TEST|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
214460960|NCT05739149|PROCEDURE|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
214531164|NCT05363605|DRUG|[225Ac]-FPI-1966|\[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
214531165|NCT05363605|DRUG|[111In]-FPI-1967|\[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
214531166|NCT05363605|BIOLOGICAL|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
214531167|NCT01767662|PROCEDURE|manipulation|home programme
214460961|NCT02342249|DRUG|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
214460962|NCT02342249|DRUG|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
214460963|NCT02342249|DRUG|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
214460964|NCT02342249|DRUG|Placebo|Subjects will receive matching placebo of Oseltamivir
214460965|NCT05916170|BEHAVIORAL|Health Warnings|Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
214460966|NCT05916170|BEHAVIORAL|No Warnings|No warnings posted in the hookah café
214460967|NCT05756985|PROCEDURE|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
214460968|NCT00433329|DRUG|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
214531168|NCT01767662|PROCEDURE|No intervention|observation
214531169|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg Ferrous sulfate
214531170|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg ferrous sulfate
214531171|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|6 mg ferrous sulfate
215147513|NCT01680471|DRUG|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
215147514|NCT04454918|DRUG|TAK-906 Oral Capsule|TAK-906 capsule.
215147515|NCT04454918|DRUG|[14C]-TAK-906 Intravenous Infusion|\[14C\]-TAK-906 intravenous infusion.
215147516|NCT04454918|DRUG|[14C]-TAK-906 Oral Solution|\[14C\]-TAK-906 oral solution.
215147517|NCT04497259|OTHER|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
214460969|NCT00433329|DRUG|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
214460970|NCT03484078|DEVICE|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
214531172|NCT01712295|DRUG|17% Salicylate with ethyl pyruvate|
214531173|NCT01712295|DRUG|Salicylates|
214531174|NCT04072666|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach \& Gysin-Maillart, 2017).
215147518|NCT04497259|OTHER|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
215147519|NCT04497259|OTHER|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
214531175|NCT04072666|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
215147520|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
215147521|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
215147522|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
215147523|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
215147524|NCT03271086|BEHAVIORAL|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
214460971|NCT03484078|DEVICE|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
214460972|NCT06806566|OTHER|Carvacrol|"1-absorbable gelatine sponge soaked in carvacrol oil placed in the palatal donor site.~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a carvacrol loaded absorbable gelatin sponge (test group)"
214695520|NCT02623595|RADIATION|Stereotactic body radiotherapy|A type of radiation therapy
214695521|NCT02623595|DRUG|rhGM-CSF|Immune modulating agents
214695522|NCT02351843|DEVICE|MECTA Spectrum 5000Q|
214695523|NCT03287752|DEVICE|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
215147525|NCT03271086|BEHAVIORAL|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
215147526|NCT03271086|BEHAVIORAL|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
214460973|NCT06806566|OTHER|Gelatin Sponge Sheet|"Absorbable gelatin sponge placed in the palatal donor site~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a absorbable gelatin sponge(control group)."
214460974|NCT01098812|DEVICE|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
214460975|NCT01098812|DEVICE|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
214460976|NCT06616857|BEHAVIORAL|NUDGE|Individuals in this condition will receive intervention content to promote physical activity.
214460977|NCT06616857|OTHER|Education|Individuals will receive educational materials about how to increase physical activity
214460978|NCT05180526|DRUG|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
214460979|NCT01129102|DRUG|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
214460980|NCT01129102|DRUG|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
214460981|NCT01129102|DRUG|Placebo|Placebo for NPC-01
214460982|NCT05962606|DRUG|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
214460983|NCT05962606|DRUG|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
214460984|NCT05360459|RADIATION|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
214460985|NCT06450210|DRUG|psilocybin trihydrate|Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
214460986|NCT06450210|DRUG|Placebo|Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
214460987|NCT06294769|OTHER|essencial oil of lavandula angustifolia|The intervention will consist of the application of aromatherapy with 2% lavender essential oil cutaneously and inhalation via by a nurse, associated with usual care, in the immediate postoperative period
215147527|NCT04868786|DRUG|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
215147528|NCT01055197|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
215147529|NCT01055197|RADIATION|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
215147530|NCT04948372|DRUG|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
215147531|NCT04948372|DRUG|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
215147532|NCT03739203|DRUG|Cariprazine|Cariprazine supplied in capsules
215147533|NCT03739203|DRUG|Placebo|Placebo supplied in capsules
215147534|NCT03739203|DRUG|Antidepressant Therapy (ADT)|ADT as prescribed by the physician per standard of care in clinical practice.
215147535|NCT04425109|BEHAVIORAL|meal test response|soy fermented versus non fermented meal test
215147536|NCT05647798|OTHER|Blood sugar check every 2 hours|Blood sugar check every 2 hours
215147537|NCT05647798|OTHER|Blood sugar check every 4 hours|Blood sugar check every 4 hours
215147538|NCT05056233|OTHER|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
214460988|NCT06294769|OTHER|grape seed vegetable oil|The placebo group will only receive the application of grape seed vegetable oil associated with usual care in the immediate postoperative period.
215147539|NCT03405246|BEHAVIORAL|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
215147540|NCT03405246|BEHAVIORAL|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
215147541|NCT03131570|DRUG|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
215147542|NCT03131570|DRUG|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
215147543|NCT02633098|DRUG|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
215147544|NCT02633098|DRUG|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
215147545|NCT03193957|DRUG|Etanercept|Etanercept PFS and Autoinjector
214460989|NCT05501379|OTHER|No intervention - observational study only|No intervention - observational study only
214695524|NCT03287752|DEVICE|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
214708919|NCT00617318|DIETARY_SUPPLEMENT|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
215147546|NCT03193957|DEVICE|Autoinjector|Autoinjector
215147547|NCT02724891|OTHER|paper form|questionnaires in paper form
215147548|NCT02724891|OTHER|web/smartphone form|questionnaires in web/smartphone
215147549|NCT01782378|DEVICE|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
214460990|NCT06437314|BEHAVIORAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
214460991|NCT04663724|BEHAVIORAL|Computer-Based Treatment|A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
214460992|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
214460993|NCT01715285|DRUG|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
214460994|NCT01715285|DRUG|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
214460995|NCT01715285|OTHER|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
214460996|NCT01715285|DRUG|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
214460997|NCT01715285|DRUG|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
214460998|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
214460999|NCT05180435|BEHAVIORAL|Family Meals|A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.
214461000|NCT05180435|BEHAVIORAL|Standard|A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
214461001|NCT06553989|OTHER|osteopatic visceral mobilization|a combination of breathing and visceral mobilizations
214461002|NCT05333016|BEHAVIORAL|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
214461003|NCT05987410|OTHER|Nordic Walking (NW)|The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
214461004|NCT05987410|OTHER|Standard Rehabilitation (SR)|The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
214461005|NCT05987410|OTHER|Cardiological Counselling (CC)|The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
214461006|NCT04780971|DIAGNOSTIC_TEST|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) and subsequent OCT of the CTO vessel will be performed. OCT may also be performed during a staged procedure when clinically indicated.
214461007|NCT06675435|DEVICE|Nitric oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
214461008|NCT03897374|DIAGNOSTIC_TEST|Genetic Testing|Buccal swab
214461009|NCT04087759|DRUG|Bedaquiline (Test formulation)|Participants will receive bedaquiline orally.
214461010|NCT04087759|DRUG|Bedaquiline (Reference formulation)|Participants will receive bedaquiline orally.
214461011|NCT03647124|DRUG|Lenalidomide|Specified dose on specified days
214461012|NCT02598388|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
214461013|NCT02598388|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units).
214531176|NCT04072666|BEHAVIORAL|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
215147550|NCT01782378|DEVICE|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
214461014|NCT02598388|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
214461015|NCT05896137|DRUG|CS0159|Oral QD
214461016|NCT01867554|GENETIC|gene analysis|gene analysis
215147551|NCT04043299|DRUG|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
214461017|NCT05020249|DRUG|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
214461018|NCT05020249|OTHER|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
214531177|NCT04205136|DRUG|Spironolactone|If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is \>5.0 but less than 5.5 or creatinine \>4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
214531178|NCT04205136|DRUG|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
214531179|NCT01800539|BEHAVIORAL|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
215147552|NCT04043299|DRUG|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
214461019|NCT06635889|DRUG|Bupivacaine|The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
214531180|NCT04692883|PROCEDURE|Percutaneous suturing|
214531181|NCT05153785|DRUG|Lidocaine|Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
214531182|NCT05153785|DRUG|Normal saline|Placebo
214531183|NCT02419209|OTHER|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
214461020|NCT06635889|OTHER|Normal saline|Placebo of 50 ml of Normal Saline
214461021|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
214461022|NCT06770296|DRUG|Pyrotinib low dose group|Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
214461023|NCT06770296|DRUG|Pyrotinib normal dose group|Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
214461024|NCT05998785|DEVICE|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
214531184|NCT02046447|DRUG|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
214531185|NCT02046447|OTHER|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
214531186|NCT02046447|OTHER|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
215147553|NCT05579613|DEVICE|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
215147554|NCT02288741|DRUG|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
214461025|NCT03628924|DRUG|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
214461026|NCT03628924|DRUG|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
214461027|NCT03628924|DRUG|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
214461028|NCT03628924|DRUG|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
214461029|NCT05420324|DRUG|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
214461030|NCT05420324|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
214461031|NCT05420324|DRUG|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
214531187|NCT02046447|OTHER|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
215147555|NCT02288741|DRUG|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
215147556|NCT02288741|DRUG|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
214461032|NCT06770218|OTHER|pelvic girdle stability training and therapeutic tapping|pelvic girdle stability training performed along with therapeutic taping in experimental group tapping involves applying strips one and two over the paraspinal region from l4 to t1 in a caudo cephalic directions. strips 3 and 4 along the lower portion of trapezius with a medially directed force from the acromion process to T12 obliquely. total session time 45 minutes to 60 minutes
214461033|NCT06770218|OTHER|pelvic girdle stability training only|participates engaged in pelvic girdle stability training focusing on exercises therapeutics taping was not be administrated during these stability exercises. excercise include pelvic brigde, one leg bridge, calm exercise for gluteus medius, leg lift 4 point kneelig arm lift
215147557|NCT02288741|PROCEDURE|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
215147558|NCT02288741|DRUG|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
215147559|NCT02288741|PROCEDURE|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
215147560|NCT04569565|DEVICE|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
214531188|NCT04230668|BEHAVIORAL|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
214531189|NCT04230668|BEHAVIORAL|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
214531190|NCT04561167|OTHER|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
214531191|NCT04561167|OTHER|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
214531192|NCT03008304|DRUG|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
215147561|NCT04668755|DEVICE|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
215147562|NCT04668755|DEVICE|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
214461034|NCT06266403|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
214461035|NCT06266403|BEHAVIORAL|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the \_\_\_ this time. Participations will be instructed to overenunciate the critical words."
214531193|NCT06550297|BEHAVIORAL|Medically Tailored Meals and Nutritional Counseling|God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
214531194|NCT06550297|BEHAVIORAL|Cardiovascular Health Promotion Educational Program|Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
214531195|NCT05204771|OTHER|Ultrasound exam|Ultrasound exam
214531196|NCT05204771|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
214531197|NCT05204771|OTHER|Pediatric Follow up|Pediatric Follow up
214695525|NCT06215456|DEVICE|Virtual reality therapy|VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.
214695526|NCT05329779|DRUG|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
214695527|NCT05329779|DRUG|placebo|The placebo is a 0.45% sodium chloride infusion.
214695528|NCT01833741|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
214695529|NCT00208494|DEVICE|Total Hip Replacement|Total hip replacement
215147563|NCT01935206|DRUG|Naloxone (2 mg/kg)|
215147564|NCT01935206|DRUG|Placebo|
215147565|NCT05338346|DRUG|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
215147566|NCT00830440|DEVICE|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
215147567|NCT00830440|BEHAVIORAL|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
214461036|NCT06266403|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
215147568|NCT00130572|DRUG|Pimecrolimus|
215147569|NCT02398890|OTHER|routine care|routine care
215147570|NCT01342861|DIETARY_SUPPLEMENT|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
215147571|NCT04077216|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
215147572|NCT05513404|DIETARY_SUPPLEMENT|Honeyberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
215147573|NCT05513404|DIETARY_SUPPLEMENT|Cherry|To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
215147574|NCT05513404|DIETARY_SUPPLEMENT|Raspberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
214461037|NCT06266403|BEHAVIORAL|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
214461038|NCT03710902|DIAGNOSTIC_TEST|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
214461039|NCT03710902|OTHER|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
214461040|NCT02872259|DRUG|BGB324+pembrolizumab|Combination
214461041|NCT02872259|DRUG|BGB324+dabrafenib and trametinib|Combination
214461042|NCT02872259|DRUG|pembrolizumab|Monotherapy
214461043|NCT02872259|DRUG|dabrafenib and trametinib|Combination
214461044|NCT05058560|DRUG|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
214461045|NCT05435014|DRUG|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
214461046|NCT05435014|DRUG|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
214461047|NCT04855032|BEHAVIORAL|Reactive Perturbations|A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.
214531198|NCT01746628|PROCEDURE|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
214531199|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
214531200|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
214531201|NCT05029271|DEVICE|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
214531202|NCT04351100|DRUG|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
214531203|NCT03111849|OTHER|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
215147575|NCT01514799|PROCEDURE|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
214531204|NCT00669292|BIOLOGICAL|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
214531205|NCT01425541|DRUG|estrace|0.5-1 mg once a day PO for 7 days
215147576|NCT04266717|BEHAVIORAL|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
215147577|NCT04266717|BEHAVIORAL|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
215147578|NCT00391586|DRUG|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
215147579|NCT00391586|DRUG|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
215147580|NCT04769934|DEVICE|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
214461048|NCT04855032|BEHAVIORAL|Proactive Perturbations|A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
214461049|NCT04893434|DRUG|Gadobutrol|Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
214461050|NCT04893434|DIAGNOSTIC_TEST|MRI|All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations. For SA1, subjects will undergo a single research DCE-MRI exam. Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
214461051|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
214531206|NCT01425541|DRUG|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
214531207|NCT02088723|BEHAVIORAL|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
214531208|NCT03868098|DRUG|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
214531209|NCT03868098|DRUG|Placebo ointment|Placebo ointment (vehicle)
214531210|NCT05253547|BEHAVIORAL|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
214531211|NCT05253547|BEHAVIORAL|Healthy dietary guidelines|Personalised healthy dietary recommendations
214531212|NCT04533334|PROCEDURE|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
214531213|NCT02569944|PROCEDURE|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
214531214|NCT02569944|PROCEDURE|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
214531215|NCT05846048|OTHER|semi-structures questionaire|semi -structured questionnaire prepared by the researcher collect sociodemographic data , awareness ,attitudes about marital rape and health consequences
214531216|NCT04847908|OTHER|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
214531217|NCT02429037|DRUG|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
214531218|NCT02429037|RADIATION|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
214531219|NCT02429037|DRUG|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
214531220|NCT00000922|DRUG|Indinavir sulfate|
214461052|NCT03959696|BEHAVIORAL|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
214461053|NCT03959696|BEHAVIORAL|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
214461054|NCT03474679|DRUG|Ibrutinib|Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
214461055|NCT06191653|BEHAVIORAL|Mindfulness and Self-Compassion for Caregivers working in Youth Detention Centres|The adapted form of the MSC is a 12-session structured program, delivered on a weekly basis in group. It intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind and courageous way. Each session lasts about 2 hours. Each session has the following structure: Grounding exercise; sharing individual insights about the weekly practice; Reviewing the previous session and link for the session theme; coffee break; soft landing exercise; Formal/Informal practice(s); Session summary and challenges to be applied during the week; Session evaluation and take-off. Each participant receives a manual with the contents shared in each session as well as some space for individual reflections. On the day after each session, a summary email is sent to the participants, resuming the contents and with records of the (in)formal practices delivered. All the sessions will be delivered in a space on each YDC.
214461056|NCT04684966|DEVICE|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
214461057|NCT04684966|DEVICE|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
214461058|NCT03298386|OTHER|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
214461059|NCT03057964|DEVICE|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
214461060|NCT03057964|DEVICE|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
214531221|NCT00000922|DRUG|Abacavir sulfate|
214531222|NCT00000922|DRUG|Nelfinavir mesylate|
214531223|NCT00000922|DRUG|Efavirenz|
214531224|NCT00000922|DRUG|Nevirapine|
214531225|NCT00000922|DRUG|Lamivudine|
214531226|NCT00000922|DRUG|Stavudine|
214531227|NCT00000922|DRUG|Didanosine|
214531228|NCT02169245|OTHER|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
214531229|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
214531230|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
214531231|NCT02109107|DEVICE|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
214531232|NCT01643902|DRUG|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
214531233|NCT04184856|DIAGNOSTIC_TEST|fMRI|(Imaging while) performing reward related tasks.
214531234|NCT02811042|DEVICE|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
214531235|NCT02811042|DEVICE|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
214531236|NCT04714788|DEVICE|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
214531237|NCT04714788|OTHER|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
214531238|NCT05561296|PROCEDURE|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
214695530|NCT00208494|DEVICE|Total hip replacement|Total hip replacement
215147581|NCT00904982|BEHAVIORAL|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
215147582|NCT00904982|DEVICE|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
215147583|NCT04820569|PROCEDURE|Resection and chemotherapy|
215147584|NCT03125486|DRUG|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
214461061|NCT05337306|OTHER|GogyUp Reader|Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
214461062|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
214461063|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
214461064|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
214461065|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
214461066|NCT06064136|PROCEDURE|Psoas tenotomy under ultrasound|Tenotomy of the ilio-psoas tendon under ultrasound is performed using an ultrasound machine, a 3 mm Acufex hook blade and a specific kit usually used for guided vertebroplasty and which allows the introduction of the Acufex hook blade atraumatically (foam end). The patient, under general anesthesia, is placed in supine position with the hip extending from 15 to 20°.
214461067|NCT05917067|DIAGNOSTIC_TEST|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
214461068|NCT06293261|DRUG|Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg|Experimental only, not included active and placebo comparator
214461069|NCT04991324|DRUG|Vitamin D3|24,000 IU cholecalciferol
214461070|NCT06314399|DIAGNOSTIC_TEST|Bile culture and phenotypic antibiogram resistance test|Extraction of 3-5ml of bile from surgical specimen (gallbladder) to be taken for bacterial culture testing and phenotypical antibiogram resistance if positive
214461071|NCT05756777|DRUG|Gilteritinib|Dose level (-1) 80mg, (1) 120mg, (2) 120mg
214461072|NCT05756777|DRUG|Ivosidenib|Dose level (-1) 250mg, (1) 250mg, (2) 500mg
214461073|NCT05756777|DRUG|Enasidenib|Dose level (-1) 50mg, (1) 50mg, (2) 100mg
215147585|NCT06473181|OTHER|Core stability exercises|Exercises applied to trunk , pelvis and abdomen to improve ability to stand , walk and balance.
214461074|NCT06542939|BEHAVIORAL|Integrated CHW Intervention|Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
214461075|NCT06542939|BEHAVIORAL|CHW Session 1 Only|Participants will attend only the first group-based health education session on hypertension and diabetes management.
215147586|NCT04906811|DEVICE|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
214461076|NCT06007274|OTHER|No intervention|No intervention
214461077|NCT06489106|DEVICE|Activity based upper extremity training with and without stimulation|Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
214461078|NCT04687631|DRUG|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
214461079|NCT04687631|DRUG|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
214461080|NCT06800105|OTHER|High fat smoothie|Participants will consume a standardized 490 kcal high-fat smoothie, consisting of 57% fat, 23% carbohydrate, and 20% protein.
214461081|NCT06432647|DRUG|ATH-1105|ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
214461082|NCT06432647|DRUG|Placebo|Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
214461083|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
214531239|NCT00741351|DRUG|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
214531240|NCT00741351|DRUG|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
214531241|NCT00741351|DRUG|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
215147587|NCT04906811|DEVICE|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
214461084|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
214461085|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
214461086|NCT03291028|BIOLOGICAL|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
214461087|NCT06802783|OTHER|Photo consent|The first group was shown photographs of the devices alongside the written consent form, while the second group received only the written consent. The study compared the pain, depression and anxiety scores between the two groups.
214461088|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
214461089|NCT06803277|PROCEDURE|endodontic retreatment|Root canal retreatment is recommended when endodontic disease persists or develops after root canal treatment. Root canal retreatment is believed to be the elimination of the main causes of treatment failure.
214461090|NCT06800118|DEVICE|Music intervention|Music will be played for patients undergoing coronary angiography, and vasospasm and pain levels will be evaluated.
214461091|NCT06800157|DRUG|Drug: LW402|Oral tablets administered BID
214461092|NCT06800157|DRUG|Other: placebo|Placebo to match LW402 administered BID
214461093|NCT06800196|DRUG|KNT-0916|• KNT-0916 is an oral inhibitor of FGFR2.
214461094|NCT04309474|DRUG|Elezanumab|Intravenous (IV) infusion
214461095|NCT04309474|DRUG|Placebo|Intravenous (IV) infusion
214461096|NCT06798519|DRUG|HNC364 Injectable Suspension|Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.
214461097|NCT06798519|DRUG|Rasagiline Tablets|Subjects in rasagiline tablets cohort will receive 1 mg of rasagiline tablets orally once daily for 20 days, followed by 2 mg once daily for 5 days. Subjects will remain domiciled at the clinic stay until Day 26 and have a follow-up visit on Day 29 due to PK and PD blood sample collections
214461098|NCT06800729|DRUG|TIX100, an orally available inhibitor of thioredoxin-interacting protein|TIX100, an orally available inhibitor of thioredoxin-interacting protein
214461099|NCT06800729|DRUG|Placebo|placebo
214461100|NCT06611592|DRUG|Pramipexole 0.088mg/tid|Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).
214461101|NCT06611592|DRUG|Pramipexole 0.18 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt)."
214461102|NCT06611592|DRUG|Pramipexole 0.35 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt)."
214461103|NCT06800469|DIAGNOSTIC_TEST|Microbiota analysis|Upon acquisition of informed consent, fecal, digiunal mucosa, biliary and pancreatic fluid samples will be collected for microbiota analysis
214695531|NCT04365816|OTHER|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
214695532|NCT05853523|COMBINATION_PRODUCT|Gas ozone|The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
215147588|NCT04355169|DRUG|Naldemedine|Oral tablet
215147589|NCT04355169|DRUG|Placebo|Oral tablet
215147590|NCT05798767|BEHAVIORAL|Neuropsychological tests|"Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium."
215147591|NCT02420821|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
215147592|NCT02420821|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
215147593|NCT02420821|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
215147594|NCT04488614|PROCEDURE|Breast Concervative or Meastectomy|National treatment guidelines in Norway
215147595|NCT04824339|BEHAVIORAL|Immediate Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
214461104|NCT06801782|BEHAVIORAL|Experimental Cognitive training in Immersive Virtual Reality and Telemedicine approach|The cognitive training involved a 4-week immersive virtual reality program to improve planning, cognitive flexibility, and information updating in patients with mild cognitive impairment related to Parkinson's disease. Over 12 sessions of 30 minutes each, participants trained in a virtual supermarket to strengthen attentional and executive skills. The planning task required creating and following a route to collect items while following rules, with increasing complexity. The cognitive flexibility task involved alternating between selecting items from different categories, with difficulty rising due to more categories and distractors. The updating task, set at a virtual checkout, challenged participants to memorize and recall items on a conveyor belt, with difficulty increasing based on sequence length and item count. Progression to higher levels required three successful trials, with feedback provided to support performance improvement
214461105|NCT06801782|BEHAVIORAL|Active Comparator #1|The active placebo used the same virtual environment, Oculus Go system, and telemedicine setup as the training group, but engaged in tasks with low cognitive demands, mimicking everyday activities. The placebo-planning task involved following a fixed shopping list order in a modified version of the Zoo Map Test. The placebo-shifting task required selecting items from shelves without alternating between categories, while the placebo-updating task involved recalling only the last item from a conveyor belt sequence. The sessions mirrored the training group's structure, with 12 sessions over 4 weeks (3 per week, 30 minutes each), maintaining the same frequency, duration, and levels than Training.
214461106|NCT06803992|DRUG|Dinoprostone vaginal insert|Described in the arm descriptions
214461107|NCT06803992|COMBINATION_PRODUCT|Dinoprostone gel and Foley catheter balloon|Described in the arm descriptions
214461108|NCT01753414|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Daily fractions
214461109|NCT01753414|PROCEDURE|Surgery|Radical resection
214531242|NCT04260984|PROCEDURE|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
214531243|NCT04260984|PROCEDURE|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
214531244|NCT02526771|PROCEDURE|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
214531245|NCT02526771|PROCEDURE|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
215147596|NCT04824339|BEHAVIORAL|Delayed Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
215147597|NCT00686712|DRUG|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
215147598|NCT00686712|DRUG|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
215147599|NCT00686712|DRUG|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
215147600|NCT05251480|PROCEDURE|Standard of Care|debridement, wound dressings, offloading
215147601|NCT05251480|OTHER|DermGEN™|Decellularized human dermal matrix created from donated human skin
215147602|NCT03842527|DEVICE|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
214461110|NCT06802458|OTHER|Motivational interviewing|A total of 9 sessions were conducted, including 1 preparation session, 6 motivational interviews, 1 initial follow-up interview one week after the intervention, and 2 follow-up interviews 4 weeks after the initial follow-up. Considering the interactive training method, the motivational interviewing sessions were conducted in the training room of the Health Center in groups of 10 at three different days (Monday, Thursday, Friday) once a week, through face-to-face sessions each lasting 50-60 minutes. During the interviews, the women were provided with counseling to activate their own sources of motivation, develop healthy lifestyle behaviors and improve their quality of life specific to menopause
214531246|NCT04159051|DEVICE|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
214531247|NCT03126214|DRUG|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
214531248|NCT01001130|DRUG|fluticasone furoate group|patients who are administered fluticasone furoate at least once
215147603|NCT02506088|BEHAVIORAL|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
215147604|NCT02875236|DRUG|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
215147605|NCT02875236|DRUG|Ringer-acetat|Crystalloid used as standard of care.
215147606|NCT03533049|OTHER|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
215147607|NCT03058146|BEHAVIORAL|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
214461111|NCT06803329|BEHAVIORAL|Qnnections|A novel group-based suicide prevention intervention that augments standard VA mental health services for LGBTQ+ Veterans with current suicidal thoughts or recent suicidal behavior. Informed by the empirically-supported theoretical framework of the interpersonal theory of suicide and prior work tailoring interventions for minority stress, Qnnections is a structured 10-week group that uses a cognitive behavioral framework to target perceived burdensomeness and thwarted belongingness. Veterans will also receive safety planning and referrals.
214461112|NCT06803329|BEHAVIORAL|Enhanced Usual Care|The active control condition includes: 1) VA Safety Planning Intervention and 2) referrals to VA and non-VA services relevant to the individual. The safety plan will be conducted by Dr. Chang, a licensed psychologist. Therefore, EUC only differs from the Qnnections condition as it does not have the 10-session Qnnections intervention. EUC is intended to include elements of VA suicide prevention standard practice. The control condition is considered enhanced as all participants will receive these elements, whereas Veterans are not guaranteed to receive all of these services if not enrolled in this study.
214461113|NCT03913702|DRUG|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
214461114|NCT03913702|DRUG|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
214461115|NCT06803212|OTHER|Conventional Physiotherapy Program|The patients' conventional physiotherapy program included stretching, strengthening, balance, and coordination exercises according to their individual needs
214531249|NCT03090893|DRUG|ATryn continuous infusion|replenish serum thrombin levels
214531250|NCT03052478|DRUG|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
214531251|NCT02745314|OTHER|Frailty measurement|Frailty measurement under Fried at el criteria
214531252|NCT02745314|OTHER|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
214531253|NCT03164525|DIAGNOSTIC_TEST|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
214531254|NCT03525483|DIAGNOSTIC_TEST|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
215147608|NCT03058146|BEHAVIORAL|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
214708920|NCT00617318|DIETARY_SUPPLEMENT|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
215147609|NCT00859196|DRUG|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
215147610|NCT00859196|DRUG|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
215147611|NCT03410706|DRUG|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
215147612|NCT02293694|DRUG|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
215147613|NCT05680402|OTHER|Soft Tissue mobilization|mobilization of soft tissues of body
215147614|NCT05680402|OTHER|Piriformis Syndrome (Piriformis muscle stretching)|Stretching of Piriformis muscle
215147615|NCT03563014|DRUG|Radium-223 (Xofigo, Bay88-8223)|Follow the physician's prescription in routine clinical practice.
214461116|NCT06803212|OTHER|Dual-Task Interference|This intervention consisted of counting backward, reading words backward, and remembering word exercises.
214461117|NCT06803108|BEHAVIORAL|pyramidal activity program|the participating subjects of this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In this group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. this form form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned, the this group will follow low clorie diet
214461118|NCT06803108|BEHAVIORAL|aerobic activity program|the participating subjects of the this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in this group with moderate intensity. the form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned , this group will follow low clorie diet
214461119|NCT06435039|DRUG|APL-1202|APL-1202 IR tablets.
214461120|NCT06435039|DRUG|APL-1501|APL-1501 ER capsules.
214461121|NCT05209997|OTHER|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
214531255|NCT01630837|OTHER|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
214531256|NCT04289714|DEVICE|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
214531257|NCT04868318|OTHER|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
214531258|NCT04868318|OTHER|Standard-high protein enteral formula|Peptamen® (16% protein)
215147616|NCT03429114|OTHER|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
215147617|NCT00469599|DRUG|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
215147618|NCT00469599|DRUG|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
215147619|NCT05613140|DRUG|sacubitril/valsartan|Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
215147620|NCT00999102|DRUG|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
215147621|NCT00999102|DRUG|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
215147622|NCT03524508|DRUG|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
215147623|NCT03524508|DRUG|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
215147624|NCT05663658|OTHER|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
215147625|NCT05663658|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
215147626|NCT05142813|DIAGNOSTIC_TEST|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
215147627|NCT00225316|PROCEDURE|Acupuncture|See Detailed Description.
215147628|NCT00746382|DRUG|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
215147629|NCT00746382|DRUG|Placebo cream|Placebo cream
215147630|NCT03056222|DEVICE|Ablation catheter|Ablation of paroxysmal atrial fibrillation
214461122|NCT04925505|PROCEDURE|Interscalene brachial plexus blocks with ultrasound guidance under general anesthesia|Ultrasound-guidance, interscalene brachial plexus blocks, in-plane technique, perineural injection, 0.5% ropivacaine 12.5ml and 0.2% lidocaine 12.5ml
215147631|NCT04436952|DEVICE|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
215147632|NCT04436952|DEVICE|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
215147633|NCT04436952|BEHAVIORAL|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
215147634|NCT02871986|DRUG|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
215147635|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 1)|0.5ml/vial
215147636|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 2)|0.5ml/vial
215147637|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 3)|0.5ml/vial
215147638|NCT01352793|BIOLOGICAL|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
215147639|NCT01352793|BIOLOGICAL|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
215147640|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
215147641|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
215147642|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
215147643|NCT02982980|PROCEDURE|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
215147644|NCT02982980|PROCEDURE|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
215147645|NCT03000608|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
215147646|NCT03000608|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
215147647|NCT03203096|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate / Magnesium oxide
215147648|NCT03203096|DIETARY_SUPPLEMENT|Placebo|
215147649|NCT03075514|OTHER|MKD|Modified ketogenic diet
215147650|NCT03075514|OTHER|MCT|Medium chain triglyceride ketogenic diet
215147651|NCT02743052|DRUG|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
214461123|NCT05649306|OTHER|Additional Education|Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
214461124|NCT05649306|OTHER|Questionnaires|Female Sexual Function Index, Demoralization Scale-II
214461125|NCT05649306|OTHER|Attendance Diary|Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
214461126|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
214461127|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
214708921|NCT04884672|DEVICE|SMILE|Small incision lenticule extraction, a refractive surgery procedure for the corrcetion of myopia with or without astigmatism
214461128|NCT05018481|DRUG|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
214461129|NCT05018481|DRUG|Placebo|A placebo will be given in capsule form to study participants
214461130|NCT04971681|DEVICE|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
214461131|NCT04971681|DEVICE|Sham|The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
214461132|NCT06020716|DRUG|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
215147652|NCT00100269|DRUG|Menevit anti-oxidant|
215147653|NCT02751853|DEVICE|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
215147654|NCT01838096|DEVICE|THA using 4th generation CoC|
215147655|NCT02480387|DRUG|Ledipasvir/Sofosbuvir FDC|
215147656|NCT02839200|DRUG|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
215147657|NCT02839200|DRUG|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
215147658|NCT02839200|DRUG|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
215147659|NCT02839200|DRUG|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
215147660|NCT02839200|DRUG|Placebo 1|Placebo capsules matching ACT-541468 capsules
215147661|NCT02839200|DRUG|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
215147662|NCT03791814|DRUG|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
215147663|NCT02876432|DEVICE|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
214461133|NCT06020716|DRUG|Placebo|Three times daily
214461134|NCT04191655|DEVICE|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
214461135|NCT04191655|DEVICE|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
214461136|NCT00686335|DRUG|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
214461137|NCT00686335|DRUG|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
214461138|NCT04767906|DRUG|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
214461139|NCT06446661|OTHER|High Intensity|Daily texts
214461140|NCT06446661|OTHER|No Text Messagings|Standard Care
214461141|NCT06446661|OTHER|Low Intensity Text Messaging|Weekly Texts
214461142|NCT06403020|PROCEDURE|Block|qadratus lumboroum (QL) block
214461143|NCT03375892|OTHER|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
214461144|NCT03375892|OTHER|Free breathing during radiation|The patient will be instructed to breathe freely.
214461145|NCT04169386|DRUG|AK102|AK102 single dose administered subcutaneously
214461146|NCT04169386|DRUG|Placebo|Placebo single dose administered subcutaneously
214461147|NCT05714306|BIOLOGICAL|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
214461148|NCT05714306|BIOLOGICAL|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
214461149|NCT05714306|BIOLOGICAL|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
214461150|NCT05714306|DRUG|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
214461151|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
214461152|NCT04332926|OTHER|Tobacco product administration and assessment, own brand cigarettes|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
214461153|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
214461154|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
214461155|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
215147664|NCT02876432|DRUG|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
215147665|NCT02876432|OTHER|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
215147666|NCT02633514|DRUG|Cisplatin|25mg/m2,iv gtt,d1-3
215147667|NCT02633514|DRUG|Etoposide|75mg/m2,iv gtt,d1-3
215147668|NCT02633514|RADIATION|radiotherapy|60Gy/30Fx
215147669|NCT00411684|DRUG|CDB-2914|
215147670|NCT04575389|DIAGNOSTIC_TEST|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
215147671|NCT01198496|DRUG|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|\<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
215147672|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
215147673|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
215147674|NCT02629900|BEHAVIORAL|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
215147675|NCT00646048|DEVICE|TriVascular Stent-Graft System|TriVascular Stent-Graft System
215147676|NCT00086632|DRUG|oregovomab|
215147677|NCT04404491|DRUG|Procedural death 1|200mg,d1,15,29,43,57,I.V
215147678|NCT04404491|DRUG|Capecitabine|Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
215147679|NCT04404491|RADIATION|Radiotherapy|radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
215147680|NCT04404491|DRUG|Placebo|placebo: 200mg,d1,15,29,43,57,I.V
215147681|NCT00965861|OTHER|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
215147682|NCT06112353|DRUG|Neostigmine Injectable Solution|Examine GI-2 recovery
215147683|NCT06112353|DRUG|Sugammadex injection|Examine GI-2 recovery
215147684|NCT01094119|DEVICE|heated blanket|heated blanket
215147685|NCT01094119|DEVICE|heated pad|patients will be warmed with a heated pad during surgery.
215147686|NCT06379204|BEHAVIORAL|the maximum physiological value standardized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and HRR heart rate reserve method, gradually increasing.
215147687|NCT06379204|BEHAVIORAL|the ventilatory threshold individualized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and three zone threshold model, gradually increasing.
214461156|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
214461157|NCT03017911|PROCEDURE|Piccline|
214461158|NCT05832996|DRUG|Refresh Plus Preservative-free Lubricant Eye Drops|Refresh Plus Preservative-free Lubricant Eye Drops at either 4 or 25 degree Celsius
214461159|NCT05641103|OTHER|Patient with splenomegaly or splenectomy|No interventional study
214531259|NCT05846308|BEHAVIORAL|Structured synchronous physical training|"The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~1. Warm-up (10 minutes)~2. Social Game (10 minutes)~3. Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~4. Cool-down (10 minutes)"
214708922|NCT05099536|DRUG|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
215147688|NCT03865901|DIAGNOSTIC_TEST|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
215147689|NCT01873872|DIETARY_SUPPLEMENT|Theralac probiotic|
215147690|NCT01873872|DIETARY_SUPPLEMENT|Culturelle probiotic|
215147691|NCT01873872|OTHER|placebo|
215147692|NCT03401619|COMBINATION_PRODUCT|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
215147693|NCT03351725|DEVICE|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
215147694|NCT05581342|DIAGNOSTIC_TEST|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
215147695|NCT00684931|OTHER|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
215147696|NCT02779101|DRUG|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
215147697|NCT03533504|OTHER|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
215147698|NCT00516360|DEVICE|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
215147699|NCT02642016|BIOLOGICAL|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
215147700|NCT00201110|BEHAVIORAL|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
215147701|NCT00201110|BEHAVIORAL|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
215147702|NCT01553890|OTHER|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
215147703|NCT03561480|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
215147704|NCT03561480|DRUG|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
215147705|NCT03214848|BEHAVIORAL|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
215147706|NCT05733832|OTHER|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
215147707|NCT05509140|OTHER|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
215147708|NCT03352609|DEVICE|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
215147709|NCT03352609|DEVICE|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
215147710|NCT00689039|DRUG|AZD1305|ER tablet, administered as single and repeated doses.
215147711|NCT00689039|DRUG|Placebo|Tablet, administered as single and repeated doses.
215147712|NCT01544205|OTHER|fMRI-based neurofeedback|5 sessions lasting one hour each
214531260|NCT05846308|BEHAVIORAL|Structured non-synchronous physical training|The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
214531261|NCT02251197|DRUG|BIII 890 CL|
214531262|NCT02251197|DRUG|Placebo|
214531263|NCT02371161|DRUG|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
214531264|NCT05666063|DIAGNOSTIC_TEST|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
214531265|NCT04653207|OTHER|Glucose Solution 1|50g glucose dissolve in 300ml of water
214531266|NCT04653207|OTHER|Glucose Solution 2|50g glucose dissolve in 300ml of water
214531267|NCT04653207|OTHER|Glucose Solution 3|50g glucose dissolve in 300ml of water
214531268|NCT04653207|OTHER|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
214531269|NCT04653207|OTHER|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
214531270|NCT04653207|OTHER|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
214531271|NCT04653207|OTHER|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
214531272|NCT04653207|OTHER|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
214531273|NCT04653207|OTHER|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
214531274|NCT04390893|DEVICE|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
214531275|NCT04390893|DIAGNOSTIC_TEST|air leakage test|Anesthesiologist would use air leakage test to position the LMA
214531276|NCT04800133|BIOLOGICAL|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
214531277|NCT04800133|BIOLOGICAL|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
214531278|NCT04800133|BIOLOGICAL|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
215147713|NCT06373965|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
215147714|NCT05611788|BEHAVIORAL|Structure Learning Training|Participants will undergo 12 sessions of structure learning training lasting about 1 hour each along with 2 testing sessions interspersed within the 12 training sessions. Each session will be conducted in a remote-guided manner with an approximate 1-day gap in between sessions. The entire training will last around two weeks
215147715|NCT05189821|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
215147716|NCT02205736|OTHER|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
215147717|NCT03326713|BEHAVIORAL|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 30-45 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
215147718|NCT03326713|BEHAVIORAL|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
215147719|NCT03326713|OTHER|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
215147720|NCT06188637|DRUG|Ozanimod Oral Capsule|open label ozanimod
215147721|NCT03623165|DEVICE|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
215147722|NCT00305188|DRUG|Xaliproden (SR57746A)|oral administration
215147723|NCT00305188|DRUG|Placebo|oral administration
215147724|NCT00305188|DRUG|Oxaliplatin|IV administration
215147725|NCT00305188|DRUG|5-Fluorouracil|IV administration
215147726|NCT00305188|DRUG|Leucovorin|IV administration
215147727|NCT01071304|DRUG|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
215147728|NCT01071304|DRUG|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
215147729|NCT04514861|DEVICE|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
215147730|NCT01624350|DEVICE|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
214461160|NCT03495973|DRUG|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
214461161|NCT06030141|OTHER|sesame oil application|sesame oil application
214461162|NCT06030141|OTHER|nigella sativa oil application|nigella sativa oil application
214461163|NCT02615730|DRUG|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
214461164|NCT02615730|DRUG|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
214531279|NCT06280118|OTHER|Fatigue|Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
214531280|NCT02694198|OTHER|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
214531281|NCT00607789|DRUG|Duloxetine|30 mg/day - 120 mg/day
214531282|NCT00607789|DRUG|Placebo|identical to study drug
215147731|NCT01135550|DRUG|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
214531283|NCT03439397|DEVICE|Ballon Technique|Ballon Technique
215147732|NCT01135550|DRUG|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
215147733|NCT00434746|DRUG|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
214531284|NCT03439397|DEVICE|SOAI|SOAI
214531285|NCT01406808|BEHAVIORAL|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
214461165|NCT06156371|OTHER|lymphatic drainage massage|"Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated."
214461166|NCT06156371|OTHER|classic massage|The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.
214461167|NCT04691817|DRUG|Atezolizumab|1200mg infusion
214461168|NCT04691817|DRUG|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
214531286|NCT04832815|BEHAVIORAL|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
214531287|NCT04832815|BEHAVIORAL|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
214531288|NCT02863913|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
214531289|NCT02863913|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
214531290|NCT02863913|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
214531291|NCT01174485|PROCEDURE|exercise|combined resistance and aerobic training
214531292|NCT00160979|PROCEDURE|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
214531293|NCT04786431|OTHER|Blood collection for lipid profiling by LC-MS|Blood withdrawal
214708923|NCT03783442|DRUG|Cisplatin|Cisplatin 60-80 mg/m² administered by intravenous infusion every 3 weeks. Cisplatin was used as the platinum agent in China, Taiwan, and Japan.
214708924|NCT03783442|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m² administered by intravenous infusion every 3 weeks.
215147734|NCT02794909|DEVICE|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
215147735|NCT03656289|DRUG|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
215147736|NCT05991271|DEVICE|Venus-Vitae Transcatheter Heart Valve System|The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
215147737|NCT06110026|OTHER|Brunkow Exercise Program|The brunkow exercise program will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
214461169|NCT06500130|DEVICE|Body Surface Gastric Mapping|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
214531294|NCT00524810|DRUG|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
214708925|NCT03783442|DRUG|Fluorouracil (5-FU)|Fluorouracil 750-800 mg/m² administered by intravenous infusion on Days 1-5 of each treatment cycle.
215147738|NCT06110026|OTHER|Lumbar Stabilization Exercises|The lumbar stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
215147739|NCT05674656|DRUG|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
215147740|NCT03957577|OTHER|Prospective observational cohort study|Prospective observational cohort study
214461170|NCT03409614|DRUG|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
214461171|NCT03409614|DRUG|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
214461172|NCT03409614|OTHER|Chemotherapy|Platinum-based doublet chemotherapy Part 1
214461173|NCT03409614|DRUG|Placebo|Matching placebo Part 2
214461174|NCT02291302|OTHER|integrated pest management|integrated pest management and environmental strategy
214461175|NCT02291302|OTHER|air purifier|air purifiers
214461176|NCT02291302|OTHER|No intervention (control)|no integrated pest management and sham air purifier
214461177|NCT02598219|DRUG|Pre-operative SN mapping with radionucleide|"1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
214461178|NCT02598219|DRUG|Intra-operative SN mapping with patent V blue dye|"1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~3. SN are detected by direct visualization of blue colored lymphatics and node"
214531295|NCT00524810|DRUG|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
214531296|NCT04512898|DRUG|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
214531297|NCT02947581|DRUG|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
215147741|NCT00636298|DRUG|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
215147742|NCT04773535|DEVICE|3D Motion analysis|Motion analysis using DyCare® Lynx system with inertial based sensors as well as an optoelectronic motion analysis system based on infrared cameras (11x Vicon infrared high speed cameras)
215147743|NCT05899426|OTHER|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 2 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
214531298|NCT02947581|DRUG|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
214531299|NCT01130714|BEHAVIORAL|Exercise|Resistance training with resistance bands.
214708926|NCT03783442|DRUG|Capecitabine|Capecitabine 1000 mg/m² administered orally twice daily on Days 1-14 of each treatment cycle
214708927|NCT03783442|DRUG|Paclitaxel|Paclitaxel 175 mg/m² administered by intravenous infusion every 3 weeks.
214708928|NCT03783442|BIOLOGICAL|Tislelizumab|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks.
214531300|NCT02650206|DRUG|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
214531301|NCT02650206|OTHER|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
215147744|NCT05899426|OTHER|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
215147745|NCT03777306|OTHER|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
215147746|NCT03777306|OTHER|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
214461179|NCT02598219|DRUG|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
214461180|NCT02598219|PROCEDURE|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"* Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~* Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~* Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
214461181|NCT02598219|PROCEDURE|Current initial staging protocols|Current French initial staging protocols
214531302|NCT02174159|DRUG|Ulonivirine|MK-8507 administered as a single oral dose
214531303|NCT00400959|PROCEDURE|cd133+cell intracoronary administration|
214531304|NCT02456675|DRUG|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
214461182|NCT06030700|OTHER|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
214531305|NCT02456675|DRUG|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
214531306|NCT02456675|DRUG|itacitinib|The dose of itacitinib will be given orally once daily (QD).
214531307|NCT05643443|OTHER|Gradual increase of force|steady force
214531308|NCT04402203|DRUG|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
214531309|NCT04402203|DRUG|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
214531310|NCT01645358|DEVICE|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
214531311|NCT01645358|DEVICE|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
214461183|NCT05925985|OTHER|NA-Observational Registry|NA Observational Registry
214461184|NCT06118905|DRUG|Denosumab 60 MG/ML|Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
214461185|NCT06118905|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Infusion|Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
214461186|NCT05027841|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
214461187|NCT04350463|DRUG|CC-90011|CC-90011
214461188|NCT04350463|DRUG|Nivolumab|Nivolumab
214531312|NCT00364221|DRUG|Rosiglitazone|
214531313|NCT02496143|DRUG|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
214531314|NCT02496143|DRUG|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
214531315|NCT03269513|BEHAVIORAL|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
214708929|NCT03783442|DRUG|Placebo|Placebo to match tislelizumab administered by intravenous infusion every 3 weeks.
215147747|NCT02898181|DEVICE|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
215147748|NCT03645824|DRUG|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
215147749|NCT03793946|OTHER|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
215147750|NCT06463808|DRUG|Recombinant Human Brain Natriuretic Peptide|we divide our subjects into two groups;one is required to take recombinant human brain natriuretic peptide,the other is not required to take recombinant human brain natriuretic peptide
215147751|NCT00361348|DRUG|Palifermin|
215147752|NCT00361348|DRUG|Heparin|
215147753|NCT05228951|DRUG|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
214531316|NCT02494453|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
214531317|NCT02494453|PROCEDURE|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
214531318|NCT02950688|BIOLOGICAL|Seasonal LAIV|10\^7.0 fluorescent focus units (FFU); administered by intranasal spray
215147754|NCT02012413|DEVICE|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
215147755|NCT02012413|DEVICE|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
215147756|NCT03453268|OTHER|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
214461189|NCT06487650|BEHAVIORAL|sleep intervention|At the beginning of the intervention, participants will have an orientation and overview of the program. Then, participants will follow the curriculum of modules, and professional feedback to complete the intervention.
214461190|NCT06487650|BEHAVIORAL|Control group|Participants in control group will follow standardized usual care and a perinatal health booklet
214531319|NCT02950688|BIOLOGICAL|Placebo|Administered by intranasal spray
214531320|NCT02950688|BIOLOGICAL|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10\^6 TCID50; administered intranasally
214531321|NCT02262390|PROCEDURE|Partner Notification Reminders|"For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
214531322|NCT03271918|DRUG|Cabergoline|
215147757|NCT03453268|OTHER|Control|usual treatment
215147758|NCT04978675|DRUG|Fluorine F 18 rhPSMA-7.3|Given IV
214461191|NCT04111536|DRUG|liothyronine|Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
214461192|NCT04111536|OTHER|Placebo|Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
214461193|NCT03689842|PROCEDURE|Uterine transplantation|Uterine transplantation from living donor
214461194|NCT05275439|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
214461195|NCT05275439|DRUG|Azacitidine (AZA)|Chemotherapy drug approved for use in MDS and AML.
215147759|NCT04978675|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
215147760|NCT04978675|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
215147761|NCT03529695|BEHAVIORAL|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
214461196|NCT05275439|DRUG|Venetoclax|Drug approved for use in AML.
214461197|NCT04234022|DRUG|Zn-DDC|Zn-DDC added to myeloma samples for culturing
214461198|NCT04234022|DRUG|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
215147762|NCT03529695|BEHAVIORAL|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
215147763|NCT06582381|OTHER|Meal set A|morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
215147764|NCT06582381|OTHER|Meal set B|morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
215147765|NCT06582381|OTHER|Meal set C|morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
215147766|NCT06582381|OTHER|Meal set D|morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
215147767|NCT05394324|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
215147768|NCT06078124|BEHAVIORAL|Sibling Support for Adolescent Girls in Emergencies|"The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls."
215147769|NCT01198977|BEHAVIORAL|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
215147770|NCT01198977|OTHER|Education counseling|Mailed informational video of exercise programs
215147771|NCT02713893|DRUG|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
215147772|NCT02713893|DRUG|Placebo plus Econazole nitrate 1% intravaginal cream|
215147773|NCT02713893|DRUG|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
215147774|NCT02713893|DRUG|Placebo intravaginal cream|
215147775|NCT02864290|DRUG|ASP1235|intravenous (IV) infusion
215147776|NCT06125041|DRUG|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
215147777|NCT02917096|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
214461199|NCT04234022|DRUG|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
214461200|NCT06430437|DRUG|SHR-A1811|Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
214461201|NCT06430437|DRUG|Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin|"Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)"
215147778|NCT02917096|DRUG|Fludarabine|Given IV
215147779|NCT02917096|DRUG|Fludarabine Phosphate|Given IV
215147780|NCT02917096|OTHER|Laboratory Biomarker Analysis|Correlative studies
215147781|NCT02917096|DRUG|Melphalan|Given IV
215147782|NCT02917096|OTHER|Pharmacological Study|Correlative studies
214461202|NCT05289063|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
214461203|NCT05289063|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
214461204|NCT05289063|OTHER|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
214461205|NCT05339425|OTHER|No additional intervention will be administered.|No additional intervention will be administered.
214461206|NCT06098833|DRUG|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
214461207|NCT06098833|DRUG|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
214461208|NCT06284213|OTHER|No interventions|This is an observational study with no interventions.
215147783|NCT02917096|DRUG|Ruxolitinib|Given PO
215147784|NCT02917096|DRUG|Ruxolitinib Phosphate|Given PO
215147785|NCT02917096|DRUG|Sirolimus|Given PO
215147786|NCT02917096|DRUG|Tacrolimus|Given IV and PO
215147787|NCT04040205|DRUG|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily.
215147788|NCT01285557|DRUG|S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
215147789|NCT01285557|DRUG|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
215147790|NCT06432296|DRUG|M701|Intra-peritoneal infusion of M701 in experimental group (M701 group\_
214531323|NCT02245750|DEVICE|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
215147791|NCT06432296|PROCEDURE|paracentesis|Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
215147792|NCT06333860|DRUG|Risankizumab|Solution for Subcutaneous (SC) injection
215147793|NCT06333860|DRUG|Deucravacitinib|Oral tablet
215147794|NCT06345690|OTHER|VIA Disc NP|VIA Disc NP - Allograft tissue injection
215147795|NCT05927623|BEHAVIORAL|Multifaceted Virtual Fracture Prevention Program|"* Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Wibbi app (wibbi.com) and monthly virtual exercise consultations.~* Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~* Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
214461209|NCT06315920|DRUG|Parecoxib|Single dose of 40mg of IV Parecoxib.
214461210|NCT06315920|DRUG|Morphine|Single dose of 5 mg of IV Morphine.
214461211|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
214461212|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
214461213|NCT05022316|OTHER|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
214461214|NCT05369975|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
214461215|NCT05369975|OTHER|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
214461216|NCT03810196|DEVICE|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
214461217|NCT05710744|BEHAVIORAL|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
214461218|NCT04364256|DEVICE|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
214461219|NCT05119842|DEVICE|APrevent® VOIS-Implant|To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
214461220|NCT06580067|BEHAVIORAL|Pray Until Something Happens (PUSH)|Self-monitoring of outcomes + alerts/reminders + use of PUSH
214461221|NCT06580067|BEHAVIORAL|Self-monitoring|Self-monitoring of outcomes + alerts/reminder
214461222|NCT04518280|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
214461223|NCT04518280|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
214461224|NCT04518280|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214461225|NCT04518280|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
214461226|NCT03340519|DEVICE|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
214531324|NCT00181532|DRUG|Celecoxib|
214531325|NCT03772600|DEVICE|Dexcom G6 CGM|Use of Dexcom G6
214531326|NCT03327077|OTHER|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
215147796|NCT05927623|BEHAVIORAL|Attention Control|"* Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~* Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~* Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
215147797|NCT06371768|BEHAVIORAL|AYA Educational Information|AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions. Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.
214531327|NCT04520581|OTHER|"group O"|"Endotracheal tube was made O shape by assistants."
215147798|NCT06371768|BEHAVIORAL|AYA STEPS|The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care. Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques. Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
215147799|NCT01781728|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
215147800|NCT05444530|BIOLOGICAL|VAC85135|Participants will receive VAC85135 as IM injection.
215147801|NCT05444530|DRUG|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
215147802|NCT00794716|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
215147803|NCT05615922|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
215147804|NCT05615922|BEHAVIORAL|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
215147805|NCT05378672|DRUG|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.
215147806|NCT04410367|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
215147807|NCT02835287|OTHER|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
215147808|NCT03227913|OTHER|Two samples of saliva|"1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
215147809|NCT03227913|OTHER|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
214461227|NCT05986422|DRUG|Methylprednisolone|The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
214461228|NCT05932992|OTHER|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
214461229|NCT01453127|DRUG|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
214461230|NCT01453127|DEVICE|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
214461231|NCT04547920|DEVICE|Wearable Bladder Modulation System|Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation Device
214461232|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
214461233|NCT05535933|DRUG|HMPL-523(300mg PO QD)|HMPL-523(300mg PO QD)
214461234|NCT05535933|DRUG|Placebo|Placebo(300mg PO QD)
214461235|NCT06166381|DRUG|Parenteral Antibacterial Agents|Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
214461236|NCT06166381|DRUG|Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft|in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
214461237|NCT04390009|DIAGNOSTIC_TEST|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
214461238|NCT04390009|DRUG|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
214461239|NCT04881630|BEHAVIORAL|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
215147810|NCT03227913|OTHER|Study of the food bolus|"* Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying"
215147811|NCT01047488|DRUG|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
215147812|NCT01047488|DRUG|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
215147813|NCT01047488|DRUG|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
215147814|NCT01047488|DRUG|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
215147815|NCT01655459|PROCEDURE|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
215147816|NCT02315742|BEHAVIORAL|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
215147817|NCT02374528|PROCEDURE|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
215147818|NCT02374528|PROCEDURE|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
215147819|NCT05569083|GENETIC|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
215147820|NCT05569083|DIAGNOSTIC_TEST|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
215147821|NCT05569083|DIAGNOSTIC_TEST|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
214461240|NCT04881630|OTHER|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
214461241|NCT05672069|PROCEDURE|Osteosynthesis|Foot pathologies
214461242|NCT05177692|DEVICE|Vguard|VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
214531328|NCT00984399|DRUG|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
214461243|NCT06503692|DEVICE|DKutting PTA Scoring Balloon Dilatation Catheter|The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.
214461244|NCT06503692|DEVICE|Peripheral Balloon Catheter|The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.
214461245|NCT05915286|DRUG|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
214461246|NCT05915286|DRUG|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
214461247|NCT03674567|DRUG|FLX475|tablet
214461248|NCT03674567|DRUG|pembrolizumab (KEYTRUDA®)|IV infusion
214531329|NCT02369588|OTHER|Food portion size|
214531330|NCT05615480|OTHER|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
214531331|NCT01919398|DRUG|LY2940680|Administered orally
215147822|NCT05569083|DIAGNOSTIC_TEST|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
215147823|NCT05569083|DIAGNOSTIC_TEST|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
215147824|NCT05569083|DIAGNOSTIC_TEST|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
215147825|NCT05569083|DIAGNOSTIC_TEST|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
215147826|NCT04305691|DRUG|Ixazomib Citrate|Given PO
215147827|NCT04305691|OTHER|Quality-of-Life Assessment|Ancillary studies
215147828|NCT04305691|OTHER|Questionnaire Administration|Ancillary studies
215147829|NCT05589857|DEVICE|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
215147830|NCT05589857|DEVICE|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
215147831|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
214461249|NCT05655091|DRUG|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
214461250|NCT05655091|DRUG|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
214461251|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
214461252|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 200 mg|Participants in this Arm will take 200 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
214461253|NCT06575751|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
214461254|NCT03958838|BEHAVIORAL|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
214461255|NCT05318222|DIAGNOSTIC_TEST|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
214461256|NCT05793866|BEHAVIORAL|BUTEYKO RESPIRATORY TECHNIQUE|Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
214531332|NCT01359722|DRUG|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
214531333|NCT01359722|DRUG|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
215147832|NCT05686772|DRUG|Antipsychotic use|Use of first/second generation antipsychotics, use of third-generation antipsychotics, use of aripiprazole specifically
215147833|NCT05686772|OTHER|Psychiatric comorbidities|Substance use disorders, cluster B personality disorders, anxiety disorder, major depressive disorder, attention-deficit/hyperactivity disorder, tobacco smoking
215147834|NCT05686772|OTHER|Sociodemographics/socioeconomic status|Age, gender identity, ethnicity, highest educational attainment, employment, at school, homelessness, in a relationship
215147835|NCT05686772|OTHER|Gambling history|Non-problematic gambling at the time of admission and/or previous 12 months
215147836|NCT05686772|OTHER|Clinical variables|Main psychiatric diagnosis, history of psychiatric hospitalizations, severity of illness (CGI-S), functioning (SOFAS), concomitant psychotropic medications use
215147837|NCT05030753|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
215147838|NCT05030753|BEHAVIORAL|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
215147839|NCT05631587|BEHAVIORAL|WExercise|A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
215147840|NCT05631587|BEHAVIORAL|Control|A control group receiving an information sheet for self-directed exercise.
215147841|NCT01763697|BEHAVIORAL|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
215147842|NCT01763697|BEHAVIORAL|Recorded meal|
215147843|NCT06564519|DEVICE|Posture Biofeedback Device|Participants will wear a commercially available posture training device for a two-week tracking period and a two-week training period while performing laparoscopic procedures.
215147844|NCT06969066|BEHAVIORAL|Cognitive Remediation Therapy plus Sleep Hygiene Education (CRT+SHE)|Participants will receive Cognitive Remediation Therapy (CRT) combined with Sleep Hygiene Education (SHE). CRT includes structured training sessions targeting attention, memory, visuospatial skills, calculation ability, logical reasoning, and language abilities. Sessions will be conducted daily for 50 minutes over 6 weeks. Sleep Hygiene Education will cover standard recommendations to improve sleep behaviors.
215147845|NCT06969066|BEHAVIORAL|Sleep Hygiene Education Only (SHE)|Participants will receive Sleep Hygiene Education (SHE) only, including guidance on adjusting sleep schedules, maintaining healthy sleep environments, minimizing stimulant intake, and managing sleep-related behaviors, without any CRT intervention.
215147846|NCT06973486|BEHAVIORAL|psychometric scales|Perceived Stress Scale (PSS) Pain Tolerance Scale (PRS) Surgical Anxiety Scale
215147847|NCT06517160|OTHER|MedBook Portal|"Intervention Group (With MedBook Portal \&amp; MedBook Portal Notice)~1. MedBook Portal Notice in front of the patient home-based medical card~2. Discharge prescriptions are uploaded into MedBook Portal and can be retrieved by doctors \&amp; pharmacists.~MedBook portal (https://aplikasi.jknsarawak.moh.gov.my/medbook) is a webpage that enable sharing of patient medication records among healthcare facilities under Ministry of Health. Sarawak State Health Department owned and managed this portal. All the information is kept under their server. Doctors in the Health Clinics and Study Pharmacists will be given access to this portal whereby each of the healthcare providers shall log in using their Identification Number and the password created by them. Doctor shall log in to MedBook Portal to check on discharge medication list when reviewing the patient at health clinic. MedBook Portal can be accessed both using a smartphone or a computer."
215147848|NCT03003325|DRUG|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
215147849|NCT03003325|PROCEDURE|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
215147850|NCT03003325|DRUG|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
215147851|NCT06332521|OTHER|Acoustic signal analysis method|Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.
214461257|NCT04884724|OTHER|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
214461258|NCT05285878|DRUG|Fingolimod|0.5 mg daily
214461259|NCT05285878|DRUG|Placebo|0.5 mg daily
214461260|NCT04995341|DEVICE|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
214461261|NCT04995341|DEVICE|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
214531334|NCT00887380|DRUG|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
215147852|NCT05818189|DEVICE|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
215147853|NCT05818189|DEVICE|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
215147854|NCT05368753|OTHER|Blood sample|Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA
215147855|NCT05368753|DRUG|Lidocain|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
215147856|NCT05368753|DRUG|ropivacaine|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
215147857|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
215147858|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
215147859|NCT03173248|DRUG|AG-120|Tablets administered orally
215147860|NCT03173248|DRUG|Placebo|Tablets administered orally
215147861|NCT03173248|DRUG|Azacitidine|Administered SC or IV
215147862|NCT05174416|DRUG|Mavacamten|Mavacamten Capsules
215147863|NCT05174416|DRUG|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
215147864|NCT01648751|DRUG|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
215147865|NCT01648751|DRUG|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
215147866|NCT05777187|OTHER|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
215147867|NCT06210724|DIAGNOSTIC_TEST|Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome|Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
215147868|NCT02833233|PROCEDURE|Cryoablation|
215147869|NCT02833233|DRUG|Ipilimumab|
214695533|NCT05853523|COMBINATION_PRODUCT|Diode laser and desensitized gel|"The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel."
215147870|NCT02833233|DRUG|Nivolumab|
215147871|NCT06575959|DRUG|Enlicitide|Oral tablet
215147872|NCT03111121|DRUG|Sugammadex|receive reversal with sugammadex 4mg/kg
214531335|NCT00887380|RADIATION|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
214695534|NCT00121069|DRUG|Escitalopram|
215147873|NCT03111121|DRUG|neostigmine|receive reversal with neostigmine 0.04 mg/kg
215147874|NCT03111121|DRUG|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
215147875|NCT06250049|OTHER|Diabetic foot care protocol|Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
215147876|NCT06250049|OTHER|Group education sessions for patients and/or caregivers|Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
215147877|NCT02991768|DRUG|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
215147878|NCT02991768|DRUG|Placebos|Placebo is matched to the study drug.
215147879|NCT05759026|OTHER|Accompaing cares|"After signing the consent form, the patient will be randomised. The ones randomised in VR groups will choose their preferred environment (e.g. landscapes, animals...).~The participant will be managed during 1 care (one care in control condition (no material used), care with the VR headset, one care with the VR set and the prefered environnent of the patient) for an average of 30 minutes (including the completion of the scales and questionnaires)."
215147880|NCT03604783|DRUG|TP-1287|TP-1287 by oral administration
215147881|NCT05202119|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.
214531336|NCT00887380|DRUG|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
214531337|NCT01975636|DRUG|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
215147882|NCT05202119|DEVICE|Sham Transcranial direct current stimulation|To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.
214461262|NCT05215353|OTHER|Music Therapy|Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.
214461263|NCT05215353|OTHER|Cognitive Behavioral Therapy|Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.
214461264|NCT05215353|OTHER|assessments|Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
214461265|NCT05095701|BIOLOGICAL|Investigational Live Attenuated Varicella Vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
214461266|NCT05095701|BIOLOGICAL|Placebo (Freeze Dired Dilution)|The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
214461267|NCT01451502|BIOLOGICAL|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
214461268|NCT05847166|RADIATION|[99mTc]Tc-PSMA-T4|\[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
214461269|NCT05296356|DRUG|OSU6162|OSU6162
214461270|NCT04830137|DRUG|NX-2127|Oral NX-2127
214461271|NCT06462625|OTHER|High tibial osteotomy|Correction of lower limb malalignement with tibial bone wedge insertion/removal
214461272|NCT04855695|DRUG|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
214461273|NCT04855695|DRUG|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
214461274|NCT04855695|DRUG|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
214461275|NCT05652179|DRUG|Stellate ganglion block|After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.
214461276|NCT05797753|DRUG|SAR443820|Tablet by oral administration
214461277|NCT05797753|DRUG|SAR443820|Capsule by oral administration
214461278|NCT05797753|DRUG|Erythromycin ethyl succinate|Tablet by oral administration
214461279|NCT05797753|DRUG|Itraconazole|Capsule by oral administration
214461280|NCT04562194|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
214531338|NCT03997708|OTHER|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
214531339|NCT03997708|OTHER|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
214531340|NCT02860299|DRUG|citrate 4%|
214531341|NCT02860299|DRUG|unfractionated heparin|
214461281|NCT04162938|OTHER|Patient-Centered Electronic App|The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
214531342|NCT02860299|BIOLOGICAL|blood sample|
214531343|NCT05110651|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
214531344|NCT05438446|PROCEDURE|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
215147883|NCT06096922|OTHER|No intervention|No intervention
215147884|NCT05686356|DRUG|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
215147885|NCT05686356|DRUG|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
215147886|NCT05686356|DRUG|Pretomanid|Pretomanid will be given at its approved dose
215147887|NCT05686356|DRUG|Bedaquiline|Bedaquiline will be given at its approved dose
215147888|NCT05686356|COMBINATION_PRODUCT|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
215147889|NCT03467750|DRUG|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
215147890|NCT03467750|DRUG|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
215147891|NCT02023463|DRUG|Enzalutamide|Given PO
215147892|NCT02023463|DRUG|Goserelin acetate|Given SC
215147893|NCT02023463|DRUG|Leuprolide acetate|Given IM or SC
215147894|NCT02023463|RADIATION|Radiation therapy|Undergo image-guided radiation therapy
215147895|NCT05673876|DRUG|GDC-8264|GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
215147896|NCT06141226|DRUG|TQB2450 +Anlotinib+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug."
214461282|NCT05833542|BEHAVIORAL|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
214461283|NCT05833542|BEHAVIORAL|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
214461284|NCT06258564|BIOLOGICAL|vaccination against human papillomavirus infection (HPV vaccination)|Women with or without HPV vaccination before or after excision
214531345|NCT01785771|DRUG|ITCA 650 (exenatide in DUROS)|
214531346|NCT00457171|DRUG|GI-270384|
214531347|NCT03106337|DEVICE|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
214531348|NCT02592928|OTHER|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
214531349|NCT04923230|BEHAVIORAL|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
215147897|NCT06141226|DRUG|TQB2450 +Androtinib Placebo+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug."
214461285|NCT02175342|DRUG|Tiotropium 0.625 mcg/puff|
214461286|NCT02175342|DRUG|Tiotropium 1.25 mcg/puff|
214461287|NCT02175342|DRUG|Tiotropium 2.5 mcg/puff|
214461288|NCT02175342|DRUG|Tiotropium 5 mcg/puff|
214461289|NCT02175342|DRUG|Placebo solution|
214461290|NCT02175342|DRUG|Tiotropium-18 lactose powder|
214461291|NCT02175342|DRUG|Placebo lactose powder|
214461292|NCT02175342|DRUG|Tiotropium 10 mcg/puff|
214461293|NCT02175342|DEVICE|Respimat|
214531350|NCT05026242|BEHAVIORAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
214531351|NCT05026242|BEHAVIORAL|Control|Participants will be provided with isocaloric snacks
214531352|NCT05268822|OTHER|Home exercise|Movement control exercise with or without specific breathing techniques
214531353|NCT04056117|BIOLOGICAL|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
215147898|NCT04979546|OTHER|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
215147899|NCT04979546|OTHER|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
215147900|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
215147901|NCT04467437|OTHER|Gait Training|Training that targets rehabilitation of walking function
215147902|NCT04467437|DEVICE|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
215147903|NCT03052829|BEHAVIORAL|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
215147904|NCT03052829|BEHAVIORAL|Usual care|Subjects will undergo their usual care without intervention
215147905|NCT05424406|BEHAVIORAL|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
215147906|NCT05424406|BEHAVIORAL|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
215147907|NCT05424406|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
215147908|NCT05424406|BEHAVIORAL|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
215147909|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
215147910|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
215147911|NCT03818854|BIOLOGICAL|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
215147912|NCT03818854|BIOLOGICAL|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
215147913|NCT05562999|DRUG|Rocuronium Bromide|Moderate NMB (TOF 1-2)
215147914|NCT05562999|DRUG|Rocuronium Bromide|Deep NMB (PTC 1-2)
215147915|NCT06646185|OTHER|Menstrual Pads|Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
215147916|NCT06646185|OTHER|Menstrual Cups|Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
215147917|NCT06646185|OTHER|Tampons|Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
215147918|NCT04500158|DRUG|Lidocaine|2% Lidocaine with 1:100,000 epi
215147919|NCT04572815|DRUG|Placebo Administration|Given IV and SC
215147920|NCT04572815|OTHER|Quality-of-Life Assessment|Ancillary studies
215147921|NCT04572815|OTHER|Questionnaire Administration|Ancillary studies
214531354|NCT04056117|BIOLOGICAL|MenACWY|Control vaccine administrated to adults and infants
214531355|NCT04056117|BIOLOGICAL|Rabies|Control vaccine administrated to children
215147922|NCT04572815|BIOLOGICAL|Ustekinumab|Given IV and SC
215147923|NCT06193096|DIETARY_SUPPLEMENT|Experimental product|Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.
214461294|NCT02175342|DEVICE|Handihaler|
214461295|NCT06331858|DEVICE|hip device-assisted concentric abductor strengthening (HDACAS)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
214461296|NCT06331858|DEVICE|knee device-assisted concentric flexor-extensor strengthening (KDACFES)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
214461297|NCT05183464|BIOLOGICAL|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
215147924|NCT06193096|DIETARY_SUPPLEMENT|Control product|"Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks"
215147925|NCT04701762|DEVICE|GlideScope videolaryngoscope (Verathon, Bothell, Washington 98011)|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, Washington 98011) is an FDA-cleared commercially available portable videolaryngoscope.
215147926|NCT04701762|DEVICE|Direct laryngoscopy|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
215147927|NCT02749422|DIAGNOSTIC_TEST|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
215147928|NCT02110069|DRUG|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
215147929|NCT02110069|DRUG|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
215147930|NCT04327804|DIAGNOSTIC_TEST|Odd/Even birth year intervention groups|The nostril used and order of testing will be different in each arm.
215147931|NCT06108414|DRUG|low-dose rivaroxaban|Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
215147932|NCT06108414|DRUG|Standard-dose rivaroxaban|Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
215147933|NCT06651684|BEHAVIORAL|CanCEASE with Health Navigator|"CanCEASE is a digital intervention to identify parents who smoke, assess their motivation and willingness to quit, as well as to provide direct linkage to evidence-based smoking interventions, including effective behavioural and pharmacological resources that can be used alone or in combination.~Participants will have the choice to receive CanCEASE at three timepoints (0, 6 and 12 months). CanCEASE will be combined with an offer of support sessions with a Health Navigator.~Health Navigators will be research personnel hired specifically for this study and trained formally in health navigation, tobacco cessation counseling and strategies to address unmet social needs. The investigators will leverage knowledge and experience of two ongoing RCTs of HNs in pediatrics to inform training strategies."
215147934|NCT04080648|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
215147935|NCT04080648|OTHER|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
215147936|NCT06586840|OTHER|rescue analgesia|. If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia
215147937|NCT06586840|PROCEDURE|Adductor Canal Block|For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.
215147938|NCT06586840|PROCEDURE|Adding an IPACK Block to the Adductor Canal Block|For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
215147939|NCT06589063|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with implantation of new-generation balloon-expandable or self-expandable bioprostheses
214461298|NCT05183464|BEHAVIORAL|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
214461299|NCT05183464|BEHAVIORAL|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
214461300|NCT05183464|BEHAVIORAL|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
214461301|NCT05183464|BEHAVIORAL|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
214461302|NCT06019559|DRUG|K-757 120 mg BID and K-833 100 mg BID|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally."
214461303|NCT06019559|DRUG|K-757 120 mg BID and matching placebo to K-833|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally."
215147940|NCT05509998|BEHAVIORAL|Screening Method (SM)|All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
215147941|NCT05509998|BEHAVIORAL|Screening and Communication Method (SCM)|Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
215147942|NCT06601803|DRUG|sterile saline solution|The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
215147943|NCT06601803|DRUG|Surgiphor|The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant
215147944|NCT06601803|PROCEDURE|Sample Collection|During the surgical procedure, 4 swabs of the surgical wound will be taken at various times throughout the procedure
215147945|NCT06593561|OTHER|Breast Edema Questionnare|The Breast Edema Questionnaire, developed to evaluate breast edema in women undergoing breast cancer surgery, will be applied.
215147946|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
215147947|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
215147948|NCT06591624|OTHER|Prolonged Mechanical Ventilation|The neurosurgical patients who could extubated within 24 h after surgery
215147949|NCT06591624|OTHER|remain intubation after surgery|could not extubated after surgery and prolong mechanical ventilation for 48 hours
215147950|NCT06601400|COMBINATION_PRODUCT|Erythropoietin (EPO) with xenograft|After atraumatic extraction of the non-restorable tooth, Implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft and erythropoietin.
215147951|NCT06601400|OTHER|Xenograft alone|After atraumatic extraction of the non-restorable tooth, implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft alone.
214461304|NCT06019559|DRUG|Matching placebo to K-757 and matching placebo to K-833|Both administered orally.
214461305|NCT04417530|DRUG|AU-011|AU-011 Via Suprachoroidal Administration
214461306|NCT04417530|DEVICE|Suprachoroidal Microinjector|Suprachoroidal Injection Device
214461307|NCT04417530|DEVICE|PDT Laser|Laser Administration
214461308|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
214461309|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
214461310|NCT05949788|OTHER|No intervention|Retrospect study, no direct intervention
214461311|NCT04094844|OTHER|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
214461312|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets
214461313|NCT04094844|OTHER|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
214461314|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system with Positive Activities|Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
214461315|NCT05670730|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
214461316|NCT05670730|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion.
214461317|NCT06565078|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|CUVITRU 20% Solution
214461318|NCT06166433|BEHAVIORAL|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
215147952|NCT06591195|DEVICE|Distraction by use of kaleidoscope|"À kaleidoscope is an optical device consisting of mirrors that reflect images of bits of coloured glass in a symmetrical geometric design through a viewer.~A kaleidoscope was selected as the non-electronic method of distraction, because of its wide availability due to low costs, its evolving and colourful visual stimuli, the fact that is blocks out any visualisations from the environment when used properly, and because it requires active participation (i.e., greater attention) from the subject."
214461319|NCT05213390|OTHER|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
214461320|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
214461321|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
214461322|NCT06458959|BEHAVIORAL|PEM+|The Young Children's Participation in Environment Measure (YC-PEM), an evidence-based and promising electronic patient-reported outcome (e-PRO) when combined with the Participation and Environment Measure Plus (PEM+) care planning application that yields a summary report and is paired with a program-specific decision-support tool, may support family engaged Early Intervention (EI) service plan development. Intervention group caregivers will complete the YC-PEM e-PRO and PEM+ intervention before their child's annual review of progress. The online summary report will be combined with a program-specific decision-support tool to guide EI service plan development.
214461323|NCT04551040|DRUG|Terazosin|Terazosin 1 mg oral capsule
214461324|NCT01824537|BIOLOGICAL|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
214461325|NCT01824537|BIOLOGICAL|Hepatitis A vaccine|Provided by Sanofi Pasteur.
214461326|NCT05533697|BIOLOGICAL|mRNA-4359|Intramuscular Injection
214461327|NCT05533697|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214461328|NCT03476655|DRUG|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
214461329|NCT04629469|DIAGNOSTIC_TEST|Hyperfine MRI|• Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
214461330|NCT04179448|PROCEDURE|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
214461331|NCT04179448|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
214461332|NCT03374085|DRUG|CC-92480|CC-92480
214461333|NCT03374085|DRUG|Dexamethasone|Dexamethasone
214461334|NCT06066346|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression
214461335|NCT05866640|DEVICE|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
214461336|NCT06623253|OTHER|not aplicable|no intervention
214461337|NCT04711733|OTHER|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
214461338|NCT04711733|OTHER|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~* Pediatric Quality of Life Inventory Cancer module~* Screen for Child Anxiety Related Emotional Disorders Revised~* Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~* 36-Item Short Form Health Survey~* Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
214461339|NCT04711733|OTHER|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~\- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
214531356|NCT04056117|BIOLOGICAL|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
215147953|NCT06653959|DEVICE|active Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.
214531357|NCT04056117|BIOLOGICAL|Placebo|Control administrated to adults
214531358|NCT05042362|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
214531359|NCT05042362|DRUG|Placebo|Matching placebo orally once daily
214695535|NCT03435172|DEVICE|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
215147954|NCT06653959|DEVICE|sham Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.
215147955|NCT03583814|BEHAVIORAL|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
215147956|NCT03583814|BEHAVIORAL|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
215147957|NCT06818851|DRUG|Henggliflozin|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.
215147958|NCT06818851|OTHER|Placebo|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.
215147959|NCT06986551|OTHER|5% NaF fluoride varnish|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It will be dried with air and isolated using cotton rolls.~Package will be unpacked, and the application guide will be used to display the contents and mix to avoid the separation of sodium fluoride components. After isolation, a thin layer of the varnish will coat . The participants will be asked to keep their mouths closed to allow the varnish to set in the presence of saliva. Rinsing or suction was not allowed immediately after the application of the varnish.~The participants will be asked to avoid consumption of rough and viscid food or hot drinks for two hours after application of the varnish. For the rest of that day, participants will be asked to eat soft food and stop tooth brushing (Ezzeldin et al., 2024)."
215147960|NCT06986551|OTHER|PRG Barrier coat|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It was then dried with air and isolated using cotton rolls.~\| P a g e 13 According to the manufacturer's instructions, the application of PRG barrier coat varnish a drop of the active will be mixed with the base using the attached brush. After isolation with cotton rolls, the brush will be used to smear the WSLs with the mix. I will be undisturbed for at least three seconds, then cured for 10 seconds using the visible-light curing unit (Ezzeldin etal.,2024).~And there will be no post operative instruction to patient after application (light cured resin material)."
215147961|NCT06655519|BIOLOGICAL|CAR-T（RD140 injection）|"This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once."
214461340|NCT06177977|DEVICE|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
214461341|NCT02725463|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
214461342|NCT06486103|OTHER|MetSheFlora - Vaginal Health|Take one slow-release capsule twice a day, after meal.
214461343|NCT05810129|OTHER|concentric-eccentric strength training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
214695536|NCT03105206|PROCEDURE|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
214695537|NCT00005050|DRUG|ethynyluracil|
214695538|NCT00005050|DRUG|fluorouracil|
214695539|NCT00005050|DRUG|oxaliplatin|
214695540|NCT05929417|OTHER|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
215147962|NCT06654908|PROCEDURE|resisted exercise using sand bags,resistance machines and elastic bands|Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
215147963|NCT02538510|OTHER|Laboratory Biomarker Analysis|Correlative studies
215147964|NCT02538510|BIOLOGICAL|Pembrolizumab|Given IV
215147965|NCT02538510|DRUG|Vorinostat|Given PO or via PEG
215147966|NCT06604702|PROCEDURE|Autologous Fat Injection for Rectocele|In this procedure, autologous fat is harvested from the patient\&#39;s lower abdomen using a multiport cannula. The fat is then processed via centrifugation to separate the viable fat cells, which are emulsified into nanofat. This nanofat is injected into the submucosal layer of the rectocele through the posterior vaginal wall, using an anoscope for guidance. The procedure is intended to reinforce the rectovaginal fascia, alleviate rectocele symptoms such as obstructive defecation and vaginal bulge, and reduce prolapse recurrence.
215147967|NCT06596330|BEHAVIORAL|Validation of language model prompts in increasing short-term physical activity|"Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change."
215147968|NCT06596330|BEHAVIORAL|Assessment of long-term changes to physical activity and glycemic control|"Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app)."
215147969|NCT06991452|DIAGNOSTIC_TEST|Liquid biopsy|Serum protein profile, serum metabolic mass spectrometry, plasma cfDNA/cfRNA genomic and epigenomic assays, and serum tumor markers were performed. Patients were followed up for 3 years at a 3-month interval. Collect surgically removed colorectal cancer samples to construct PDX models if necessary.
215147970|NCT03579251|BEHAVIORAL|Black Men's Care|12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
215147971|NCT06592287|DRUG|Adebrelimab + Apatinib + Lrinotecan liposome|"Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
215147972|NCT06598020|BEHAVIORAL|Supportive Care|Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)
215147973|NCT06593080|OTHER|The comprehensive TDA based approach|"The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively.~Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB."
215147974|NCT06586814|OTHER|Suture|Wound Closure
215147975|NCT06586814|OTHER|Staple|Wound Closure
215147976|NCT06615206|GENETIC|HG204|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
215147977|NCT06992869|BEHAVIORAL|Group-based psychological therapy|Group-based psychological therapy for (1) adjusting to diagnosis; (2) Parkinson's anxiety and/or depression; and (3) Parkinson's-related cognitive decline
215147978|NCT06991907|PROCEDURE|125I seed implantation|125I seed implantation
214461344|NCT05810129|OTHER|eccentric strength training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
214461345|NCT05810129|OTHER|standard physical therapy|Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
215147979|NCT06991907|DRUG|PD-1 Inhibitors|PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks. According to the manufacturer's guidelines, the dose is reduced or discontinued based on the severity of adverse effects.
214461346|NCT03858634|DRUG|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
214461347|NCT03858634|DRUG|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
214461348|NCT04676763|DRUG|Substance P|Participants will receive Substance P
214461349|NCT04676763|DRUG|Normal Saline|Participants will receive normal saline as Negative control
214461350|NCT04676763|DRUG|Histamine|Participants will receive histamine as Positive control
215147980|NCT06993272|BEHAVIORAL|MIndful Jazz|Mindful Jazz Group: Participants in this group will watch an introduction to jazz appreciation and mindfulness training video, including the use of jazz for pain tolerance prior to the 4-week intervention. Participants in the Mindful Jazz Group will be informed that listening to music they are not comfortable with (i.e., jazz) can enhance long-term pain tolerance.
215147981|NCT06993272|BEHAVIORAL|Reggae Stereotypes|Reggae Stereotype Group: Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks.
215147982|NCT06993272|BEHAVIORAL|Traditional Mindfulness|Participants will listen to a traditional mindfulness practice over the 4 weeks
215147983|NCT06993272|BEHAVIORAL|Pain psychoeducation|Participants listen to an audio recording of the pain psychoeducation video they watch during training over the 4 weeks. Video: https://www.youtube.com/watch?v=azwEQXh5enA
215147984|NCT06991478|DRUG|SK-NK injection|In this stage, two dose groups are preset, namely 20×108 cells and 30×108 cells. Subjects who meet the inclusion criteria will receive intravenous infusion of SK-NK injection once a week for six consecutive times. After completing six consecutive infusions of SK-NK injection, the researchers evaluated that the patient benefited and could continue to receive six consecutive infusions of SK-NK injection. After completing twelve infusions, the decision on whether to continue the treatment subsequently could be made based on the patient's condition
215147985|NCT06991478|DRUG|SK-NK injection|Based on the dose selected from the results of the first stage, the clinical efficacy, safety, tolerability and pharmacokinetic characteristics of RP2D were further verified. The types of cancer and the number of cases enrolled in stage II are to be determined
215147986|NCT06992271|BEHAVIORAL|Fast Eccentric|Resistance training done quickly
215147987|NCT06992271|BEHAVIORAL|Slow Eccentric|Resistance training done slowly
215147988|NCT06991634|DRUG|Azvudine tablets|"Phase I: oral administration of 5 mg of Azvudine tablets on an empty stomach, single dose, 5 tablets per dose.~Phase II: oral administration of 5 mg of Azvudine tablets once a day on an empty stomach, 5 tablets once a day, for 7 consecutive days."
215147989|NCT03375788|DRUG|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
215147990|NCT03375788|DRUG|Identical Placebo|Placebo injection daily
215147991|NCT06993454|OTHER|Magnetic Resonance Liver Assessment|Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
215147992|NCT06993454|OTHER|Bike Exercise VO2max|Maximal fitness measured by cycle ergometer.
214461351|NCT06458868|OTHER|salt water or tap water before UVA|Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
215147993|NCT06993454|OTHER|DEXA|Measure body composition (fat and lean body mass).
214461352|NCT04213547|BEHAVIORAL|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
214461353|NCT05571189|BEHAVIORAL|Daily Activity Text|Participants will receive a text each day with instructions about the daily activity they should complete for that day.
214461354|NCT05571189|BEHAVIORAL|Control Text|"Participants will receive a text each day with no instructions about daily activity. It will have messages like have a nice day."
214461355|NCT03937609|DRUG|Infliximab|infliximab iv 5mg/kg
214461356|NCT05731609|OTHER|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
214461357|NCT04818268|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
214461358|NCT04818268|OTHER|cTBS|continuous theta-burst stimulation
214461359|NCT05109494|RADIATION|Conventional Fractionated|50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive \> 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
214461360|NCT05109494|RADIATION|Hypofractionated|27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive \> 97% of the prescribed dose
214461361|NCT04974099|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
214461362|NCT04974099|DRUG|Precision dosing with a dashboard|The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
214461363|NCT04927299|DRUG|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
214461364|NCT04927299|DRUG|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
214461365|NCT06487078|DRUG|Lorlatinib|ALK-positive NSCL treatment
214461366|NCT03832998|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
215147994|NCT06536673|BEHAVIORAL|Intervention to reduce infectious complications of peritoneal dialysis|"* Before catheter placement: The nurse and doctor provide the patient and/or caregiver with a PD simulation.~* Initial training: from the placement of the catheter to the beginning of the technique at home, approximately 4 weeks, 6 and 7 sessions, duration 1-2 hours per session. Individualized learning taking into account learning abilities and education. It includes the explanation of the PD and the display of informational pictograms/capsules.~* Step-by-step teaching: peritoneal exchange, peritoneal orifice care, administration of intraperitoneal medication, recording of constants, detection of complications and risk behaviors.~* Nutritional education and water intake.~* Administration of the Objective Structured Assessment (OSA) checklist.~* Retraining: between the 1st and 3rd month of the start, after an episode of peritonitis and/or hospitalization, risk behaviors, functional/cognitive impairment, passivity/demotivation behaviors, and regularly once the year."
214695541|NCT06361264|COMBINATION_PRODUCT|Karanahan|During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
214695542|NCT04136080|OTHER|vasopressors|control the mean arterial pressure with vasopressors
215147995|NCT06536673|BEHAVIORAL|Data collection from the patient's clinical history|Data collection from the patient's clinical history because this new standardized educational intervention was not used.
215147996|NCT06538896|DRUG|Tislelizumab + Nab-Paclitaxel|Tislelizumab, 200mg, intravenous, every 3 weeks
215147997|NCT06538896|OTHER|Rankl inhibitor|RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
215147998|NCT06991998|PROCEDURE|Autogenous bone graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous bone graft harvested from a secondary intraoral donor site (mandibular ramus or maxillary tuberosity) with a bone scraper. The bone graft is placed into the debrided intraosseous defect, and enamel matrix derivative (EMD) is applied to the root surface. Surgical access is performed using a single flap approach (SFA), and primary closure is achieved with microsurgical sutures.
215147999|NCT06991998|PROCEDURE|Autogenous tooth-derived graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous tooth-derived particulate graft processed from an extracted tooth using a standardized protocol (Bonmaker® device and chemical decontamination), combined with enamel matrix derivative (EMD) applied to the root surface. The surgical site is accessed using a single flap approach (SFA), and graft material is placed into the non-self-contained intraosseous defect after debridement. Primary closure is achieved with microsurgical sutures.
215148000|NCT06992817|BEHAVIORAL|Hydration-Coach Encouragement|Athletes were encouraged by their coaches to consume fluids during the training session.
215148001|NCT06992817|BEHAVIORAL|Short Hydration Informative Session|Athletes were given a brief educational session related to importance of hydration before the exercise session.
215148002|NCT06991400|OTHER|Trans-Amniotic Suture Placement|Trans-Amniotic Suture placement
215148003|NCT06992245|DIAGNOSTIC_TEST|DW-MRI|Predict changes in ovarian diffusion using DW-MRI scan
215148004|NCT06991621|OTHER|Puzzle game|Scenario-based puzzle game sessions (group format)
215148005|NCT06991621|OTHER|Manual Education|Standardized death education manual distribution
215148006|NCT06211361|OTHER|Cardiac rehabilitation|Physical exercise intervention within a cardiac rehabilitation program, lasting 2 months, 3 days per week. The intervention consists of a first part of warm up the large muscle groups, accompanied by breathing exercises, followed by a part of strength and muscular resistance training exercises (upper and lower limbs and abdominal muscles), another part of aerobic exercise part (continuous and interval), using a treadmill or cycle ergometer, and finally a part of stretching exercises and a cool-down phase.
214695543|NCT00039442|DRUG|Capecitabine|Given orally
214461367|NCT03832998|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
214461368|NCT03832998|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
214461369|NCT03832998|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
214461370|NCT06324604|DRUG|Placebo|Placebo
214461371|NCT06324604|DRUG|MTX-101|MTX-101 (bispecific CD8 Treg modulator)
214461372|NCT06407791|DEVICE|LymphaVibe|The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
214461373|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
214461374|NCT02000050|DRUG|FOLFOX4|FOLFOX4
214461375|NCT02000050|RADIATION|Tomotherapy|Tomotherapy
214461376|NCT02000050|PROCEDURE|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
214531360|NCT04230993|OTHER|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
214531361|NCT01683643|BEHAVIORAL|SBIRT|Screening, brief intervention, and referral to treatment.
215148007|NCT06061003|OTHER|Clinical Anatomical Education with Fractured Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
215148008|NCT06061003|OTHER|Clinical Anatomical Education with Standard Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
215148009|NCT06527950|OTHER|no intervention|observational study , no intervention
215148010|NCT06766201|DRUG|Metformin|Metformin mixed with propylene glycol
215148011|NCT04493008|BEHAVIORAL|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
215148012|NCT05609487|OTHER|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
215148013|NCT05609487|DEVICE|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
215148014|NCT06852313|PROCEDURE|Laparoscopic ovarian cyst surgery|Laparoscopic ovarian cyst surgery is any surgery with the goal of removal or drainage of an ovarian cyst. The exact surgical technique will be predefined by randomization.
215148015|NCT05327946|DRUG|BI 770371|BI 770371
215148016|NCT05327946|DRUG|ezabenlimab|ezabenlimab
215148017|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
215148018|NCT06466590|DIAGNOSTIC_TEST|Use of Measurement Instrument|Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions. The results from both sessions will be compared to assess the instrument's consistency and accuracy
215148019|NCT06929299|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the STSA-1301 on the dates specified in the protocol
215148020|NCT06929299|DRUG|Placebo|Subjects will receive the placebo on the dates specified in the protocol
215148021|NCT01704209|DRUG|Fibroblast Treatment|
215148022|NCT01704209|PROCEDURE|Vehicle|
215148023|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
215148024|NCT04988477|BEHAVIORAL|Study 3: Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 9 months.
215148025|NCT04988477|BEHAVIORAL|Study 2: Pilot trial|Providers trained in brief provider intervention and 1 outreach call over 3 months.
215148026|NCT04900324|DEVICE|MRI guidance|Injections of botulinum toxin performed using MRI guidance
214531362|NCT01683643|BEHAVIORAL|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
214531363|NCT05014906|DRUG|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
214531364|NCT05014906|DRUG|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
214531365|NCT04817930|DEVICE|Polyetheretherketone patient specific implant|a customized peek patient specific implant is place to augment the chin
214531366|NCT04817930|DEVICE|Computer guided advancement genioplasty|advancement genioplasty using patient specific cutting and positioning surgical stents
214531367|NCT05150002|DEVICE|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
214531368|NCT00261625|DRUG|alendronate|
214531369|NCT05401149|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
214531370|NCT02103426|DRUG|ASP0113|intramuscular injection
214531371|NCT02103426|DRUG|Placebo|intramuscular injection
214695544|NCT00039442|OTHER|Laboratory Biomarker Analysis|Correlative studies
215148027|NCT04900324|DEVICE|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
215148028|NCT05092100|BEHAVIORAL|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
214531372|NCT05889221|OTHER|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
214531373|NCT04593771|DRUG|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
214531374|NCT05572697|BEHAVIORAL|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
214531375|NCT05572697|BEHAVIORAL|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
214531376|NCT02264353|DRUG|Donepezil|Donepezil 10mg before sleep
214531377|NCT02264353|DRUG|placebo|One piece of placebo before sleep
214531378|NCT04461938|OTHER|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
214531379|NCT04475497|OTHER|Blood management|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
214531380|NCT04475497|OTHER|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
214531381|NCT02574234|OTHER|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
214531382|NCT02574234|OTHER|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
214531383|NCT02574234|OTHER|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
214531384|NCT02574234|OTHER|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
214531385|NCT02574234|OTHER|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
214531386|NCT02769390|DRUG|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
214531387|NCT02769390|DRUG|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
214531388|NCT02769390|DRUG|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
214531389|NCT00139971|DRUG|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
214531390|NCT00139971|DRUG|UFT 250mg/m2, daily for 1 year|
214531391|NCT05733793|OTHER|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
214531392|NCT04242342|RADIATION|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
214531393|NCT00337922|DRUG|Lamivudine / Abacavir Sulfate|
214531394|NCT03809871|BIOLOGICAL|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
215148029|NCT05092100|OTHER|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
214531395|NCT02865135|DRUG|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
214531396|NCT02865135|DRUG|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
214531397|NCT03601949|DEVICE|SInergy Cooled Radiofrequency|ablation of low back pain
214531398|NCT03601949|OTHER|Medical Management|physical therapy, medications, lifestyle changes
214695545|NCT02561299|DEVICE|Peripheral Orbital Atherectomy System|Orbital Atherectomy
215148030|NCT05092100|BEHAVIORAL|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
215148031|NCT06526533|OTHER|Liberal RBC Transfusion|Liberal transfusion trigger group (patient receives RBC transfusion if Hb \<90g/L).
215148032|NCT06526533|OTHER|Restrictive RBC Transfusion|Restrictive transfusion trigger group (patient receives RBC transfusion if Hb \<70g/L).
215148033|NCT03365089|PROCEDURE|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
215148034|NCT00208871|PROCEDURE|Stereoscopic Digital Mammography|screening digital 3D mammogram
215148035|NCT01999257|OTHER|Online pre-test genetic education tool|See Arm Descriptions above.
215148036|NCT05973617|DIAGNOSTIC_TEST|Measurement of corneal biomechanical properties|Measurement of corneal biomechanics
215148037|NCT01271296|DIETARY_SUPPLEMENT|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
215148038|NCT01271296|DIETARY_SUPPLEMENT|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
215148039|NCT04333719|OTHER|Type of sedations|Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
215148040|NCT02534740|DRUG|tafamidis|relative bioavailability
215148041|NCT02534740|DRUG|tafamidis|fasted
215148042|NCT02534740|DRUG|tafamidis|fed
215148043|NCT00750503|BEHAVIORAL|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
215148044|NCT01694498|DRUG|A: Desmopressin 25 µg|
214531399|NCT04337502|DIAGNOSTIC_TEST|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
214531400|NCT00025545|DRUG|cyclophosphamide|
214531401|NCT00025545|DRUG|methotrexate|
214531402|NCT00025545|PROCEDURE|peripheral blood stem cell transplantation|
214531403|NCT00025545|RADIATION|radiation therapy|
215148045|NCT01694498|DRUG|B. Desmopressin 50 µg|
214531404|NCT06264661|BEHAVIORAL|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
215148046|NCT01694498|DRUG|Placebo|
215148047|NCT04610281|DEVICE|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
215148048|NCT04884464|DEVICE|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
215148049|NCT04884464|DRUG|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
215148050|NCT06611553|PROCEDURE|Biospecimen Collection|Undergo collection of cervical sample by clinician
215148051|NCT06611553|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
215148052|NCT06611553|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
215148053|NCT06611553|OTHER|Electronic Health Record Review|Ancillary studies
215148054|NCT06611553|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
215148055|NCT06611553|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
215148056|NCT06611553|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
215148057|NCT06611553|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal sample and cervical sample
215148058|NCT06611553|OTHER|Questionnaire Administration|Ancillary studies
215148059|NCT06611553|OTHER|Survey Administration|Ancillary studies
215148060|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
214531405|NCT02269683|PROCEDURE|Robot-assisted distal pancreatectomy|
214531406|NCT02269683|PROCEDURE|Laparoscopic distal pancreatectomy|
214531407|NCT04935762|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
214531408|NCT02026505|DRUG|Bortezomib|
215148061|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
214531409|NCT00404599|DRUG|atrorvastatin 10mg|Atorvastatin 10 mg once a day
214531410|NCT00404599|DRUG|simvastatin 40mg|simvastatin 40mg once a day
214695546|NCT02561299|DEVICE|014 Drug Coated Balloon|Drug Coated Balloon
214695547|NCT03508141|DRUG|Fibrinogen Concentrate|Experimental
214695548|NCT03508141|DRUG|Cryoprecipitate|Comparator
215148062|NCT00029484|BEHAVIORAL|Tai chi chih|
215148063|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
215148064|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
215148065|NCT00940953|DRUG|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
215148066|NCT04412512|PROCEDURE|VATS approach|video-assisted thoracic surgery approach
215148067|NCT04412512|PROCEDURE|Thoracotomy approach|
215148068|NCT02789293|DEVICE|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
215148069|NCT05076162|DIAGNOSTIC_TEST|PAED|Delirium positive or negative
215148070|NCT05581550|RADIATION|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
215148071|NCT05581550|RADIATION|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
215148072|NCT05117931|DRUG|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (\<80kg) or 1400mg (\>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh \<80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
215148073|NCT06328335|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214531411|NCT06116942|DEVICE|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
215148074|NCT06328335|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
214531412|NCT06116942|DEVICE|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
214531413|NCT00456183|BIOLOGICAL|MVA 85A|
214531414|NCT06171919|OTHER|Organizational Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
214531415|NCT06171919|OTHER|HIV Continuum Care|Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
214531416|NCT04407533|OTHER|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
215148075|NCT00604487|DEVICE|ARD (Atad Ripener Device)|Atad double balloon ripener device
215148076|NCT00604487|DEVICE|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
215148077|NCT00604487|DEVICE|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
215148078|NCT00712439|DRUG|Gabapentin Extended Release tablets|
215148079|NCT00712439|DRUG|Placebo|
215148080|NCT02812342|DRUG|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
215148081|NCT05612620|DIAGNOSTIC_TEST|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
215148082|NCT05178004|OTHER|Faecal and Urine sample collection|This is an observational study.
215148083|NCT06118398|DRUG|Intravenous methylprednisolone (IVMP) and Efgartigimod|IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
215148084|NCT06118398|DRUG|IVMP|IVMP 800-1000mg/day for 3-5 days.
215148085|NCT00793897|DRUG|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
214531417|NCT01547182|BEHAVIORAL|Caloric restriction|Caloric restriction
214531418|NCT01547182|BEHAVIORAL|Aerobic Training|Walking
214531419|NCT01547182|BEHAVIORAL|Resistance Training|Lifting weights
214531420|NCT03927742|BEHAVIORAL|Shade + app with messaging|Shade wearable device and application with UV messaging activated
215148086|NCT00793897|DRUG|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
215148087|NCT00793897|DRUG|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
215148088|NCT02859571|DRUG|Oxytocin|
215148089|NCT03754621|DIAGNOSTIC_TEST|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
215148090|NCT05813600|DRUG|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
215148091|NCT04415203|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)|Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
215148092|NCT04415203|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)|Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
215148093|NCT06456502|DEVICE|Non-invasive neuromodulation|The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
215148094|NCT06456502|OTHER|Placebo|The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
215148095|NCT02955173|PROCEDURE|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
215148096|NCT02549872|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
215148097|NCT02132988|BIOLOGICAL|OPT-822/OPT-821|
215148098|NCT03208647|OTHER|AA or not|to study their risk factors
215148099|NCT06442878|OTHER|Belly Dance Program|All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
215148100|NCT01707732|DRUG|Enoxaparin|Administration of Enoxaparin
215148101|NCT03317184|PROCEDURE|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
215148102|NCT03317184|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
215148103|NCT02911584|PROCEDURE|Laparoscopic procedure|
215148104|NCT05368246|DEVICE|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
215148105|NCT01560663|DRUG|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
214531421|NCT03927742|BEHAVIORAL|Shape + app without messaging|Shade wearable device and application without UV messaging activated
214531422|NCT04238130|DIAGNOSTIC_TEST|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
214531423|NCT04027673|BEHAVIORAL|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
214531424|NCT05999344|OTHER|commercially available cannabis administered prior to commercially available alcohol|Self administration of cannabis prior to researcher administered alcohol
214531425|NCT05999344|OTHER|commercially available alcohol administered prior to commercially available cannabis|Researcher administered alcohol prior to self-administration of cannabis
214531426|NCT01196741|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
214531427|NCT01196741|DRUG|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
214531428|NCT01196741|DRUG|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
214531429|NCT01138137|DRUG|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
214531430|NCT01138137|DRUG|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
214531431|NCT01138137|DRUG|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
215148106|NCT01458392|BIOLOGICAL|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
214531432|NCT01702155|DRUG|DFP-10917|
214531433|NCT04021147|BEHAVIORAL|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
214531434|NCT04021147|BEHAVIORAL|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
214531435|NCT04021147|BEHAVIORAL|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
215148107|NCT01685502|DRUG|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
215148108|NCT06200662|OTHER|Analgesic strategies during the S visit:|Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.
215148109|NCT06200662|OTHER|Analgesic strategies at visit M|Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
215148110|NCT03762993|BEHAVIORAL|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
215148111|NCT05812872|DRUG|Toothgraft|Particulate dentin
215148112|NCT05812872|DRUG|Allograft|Mineralized corticocancellous allograft
215148113|NCT05812872|DRUG|Alloplast|Beta tri-calcuim phosphate
214531436|NCT04021147|BEHAVIORAL|Exercise|Orofacial exercises
215148114|NCT04685044|DEVICE|IH 1Tx32Rx Head Array|BrainPET insert
214531437|NCT06128434|OTHER|zinc carbonate nano-hydroxyapatite toothpaste|Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.
214531438|NCT06128434|OTHER|8% arginine toothpaste|Participants will brush their teeth with 8% arginine toothpaste twice daily.
214531439|NCT06128434|OTHER|Fluoride toothpaste|Participants will brush their teeth with Fluoride toothpaste twice daily.
214531440|NCT02368366|BEHAVIORAL|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
214531441|NCT02368366|BEHAVIORAL|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
214531442|NCT02368366|BEHAVIORAL|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
214531443|NCT02273180|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
214531444|NCT02273180|DRUG|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
214531445|NCT02273180|DRUG|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
214531446|NCT06069596|COMBINATION_PRODUCT|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
214531447|NCT06410625|DIAGNOSTIC_TEST|FLT PET imaging|Evaluation of response to chemotherapy with FLT PET imaging
215148115|NCT04899986|OTHER|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
215148116|NCT04899986|OTHER|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
215148117|NCT03840018|OTHER|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
214531448|NCT00509925|DRUG|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
214531449|NCT00509925|DRUG|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
214531450|NCT00509925|DRUG|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
214531451|NCT04299724|BIOLOGICAL|Pathogen-specific aAPC|The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
214531452|NCT02801747|BEHAVIORAL|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
214531453|NCT02297529|DRUG|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
214695549|NCT04185883|DRUG|Sotorasib|Sotorasib administered orally as a tablet.
214695550|NCT04185883|DRUG|Trametinib|Trametinib administered orally as a tablet.
214695551|NCT04185883|DRUG|RMC-4630|RMC-4630 administered orally as a capsule.
214695552|NCT04185883|DRUG|Afatinib|afatinib administered orally as a tablet.
215148118|NCT04262154|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks
215148119|NCT04262154|DRUG|Abiraterone|Abiraterone 1000 mg daily
215148120|NCT04262154|DRUG|Prednisone|Prednisone 5 mg daily
215148121|NCT04262154|DRUG|GnRH analog|Any GnRH analog that is commercially available, injectable, and long acting analog of the native LHRH peptide and is administered to subjects via intramuscular injection. For this study, any GnRH analog can be used and thee manufacturer's instructions for dose and frequency should be followed.
215148122|NCT04262154|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Intensity-modulated, image-guided, ultra-hypofractionated external beam radiotherapy (7.25-7.5 Gy x 5 to prostate and seminal vesicles QOD) will begin around 12 weeks (at Cycle 5 Day 1 (+/-5 days)
215148123|NCT04262154|DRUG|Enzalutamide|160 mg once daily
215148124|NCT04262154|OTHER|Follow up|Subjects who discontinue study treatment for reasons other than progression will be followed every 6 months (+/- 4 weeks) until a documented progression event (i.e., PSA, radiographic, or clinical progression). After a documented progressionevent (whether on treatment or during follow up), subjects will continue to be followed every 6 months (+/- 4 weeks) for overall survival via chart review and/or telephone call.
214695553|NCT04185883|DRUG|Pembrolizumab|pembrolizumab administered as an intravenous (IV) infusion.
214695554|NCT04185883|DRUG|Panitumumab|Panitumumab administered as an IV infusion.
214695555|NCT04185883|DRUG|Carboplatin, pemetrexed, docetaxel, paclitaxel|Carboplatin, pemetrexed, docetaxel administered as an IV infusion.
214695556|NCT04185883|DRUG|Atezolizumab|Atezolizumab administered as an IV injection.
214531454|NCT05056675|PROCEDURE|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
214695557|NCT04185883|DRUG|Palbociclib|Palbociclib administered orally as a tablet.
215148125|NCT06035913|DRUG|Dihydroergot mesylate|take medicine
215148126|NCT00307710|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
215148127|NCT04698369|DEVICE|Vibration Massage Therapy|WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
215148128|NCT03800147|DRUG|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
215148129|NCT03800147|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
215148130|NCT03800147|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
215148131|NCT03800147|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
215148132|NCT00753506|DIETARY_SUPPLEMENT|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
215148133|NCT00753506|DIETARY_SUPPLEMENT|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
214695558|NCT04185883|DRUG|MVASI® (bevacizumab-awwb)|MVASI® (bevacizumab-awwb) administered as an IV infusion.
214695559|NCT04185883|DRUG|TNO155|TNO155 administered orally as a capsule.
214695560|NCT04185883|DRUG|IV Chemotherapy (Regimen 1)|Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
214695561|NCT04185883|DRUG|IV Chemotherapy (Regimen 2)|IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
214695562|NCT04185883|DRUG|BI 1701963|BI 1701963 administered orally
214695563|NCT04185883|DRUG|AMG 404|AMG 404 administered as an IV infusion.
214695564|NCT04185883|DRUG|Everolimus|Everolimus administered orally.
214695565|NCT06319339|DRUG|Vumerity|diroximal fumarate 462 mg (2 capsules)
214695566|NCT06319339|OTHER|Placebo|Microcrystalline cellulose 462 mg (2 capsules)
215148134|NCT05264922|DRUG|Tisseel Injectable Product|Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
215148135|NCT05264922|BIOLOGICAL|Stromal Vascular Fraction Cells|Stromal Vascular Fraction cells are autologously harvested, processed and reinjected into the affected shoulder.
215148136|NCT02510521|DEVICE|acute muscle exercise by NMES|
215148137|NCT02510521|DEVICE|daily workout sequence with NMES in one week|
215148138|NCT02510521|OTHER|rest situation|
215148139|NCT00001614|DRUG|Chicken type II collagen|
215148140|NCT03153943|DEVICE|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
215148141|NCT03153943|OTHER|Workbook support|Printed material support
215148142|NCT02178150|DIETARY_SUPPLEMENT|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
215148143|NCT02178150|DIETARY_SUPPLEMENT|Placebo|
215148144|NCT00722943|OTHER|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
215148145|NCT00722943|OTHER|no intervention|The infant will not be touched by the therapist.
215148146|NCT04766840|DRUG|CAR-T cells|Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
215148147|NCT03900091|DIAGNOSTIC_TEST|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
215148148|NCT03900091|DIAGNOSTIC_TEST|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
215148149|NCT03900091|DIAGNOSTIC_TEST|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
215148150|NCT03900091|OTHER|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
215148151|NCT01791712|PROCEDURE|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
215148152|NCT01791712|PROCEDURE|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
215148153|NCT01232023|DRUG|Indobufen|Single Oral Dose of
215148154|NCT05166772|DRUG|Donafenib|200 mg BID，oral administration will start before the first HAIC treatment.
215148155|NCT05166772|DRUG|Sintilimab|200 mg，Q3W，Intravenous infusion will performe before HAIC treatment.
215148156|NCT05166772|OTHER|HAIC|Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
215148157|NCT01394003|DRUG|LY2584702|administered orally
215148158|NCT03891381|DEVICE|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
215148159|NCT04570137|DIETARY_SUPPLEMENT|Dietary fiber supplementation|"1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory"
215148160|NCT04380285|DEVICE|Custom heel pads and modified soft molded orthotics|
214531455|NCT05056675|PROCEDURE|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
214531456|NCT05657132|DRUG|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
214531457|NCT05657132|DRUG|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
214531458|NCT02709798|DRUG|Shenfu Injection|
214531459|NCT02709798|DRUG|5% Glucose Injection|
214531460|NCT03171389|DRUG|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
214531461|NCT06650137|DIAGNOSTIC_TEST|diaphragmatic ultrasound|"The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured."
214531462|NCT06658704|BEHAVIORAL|Supervised exercise in a group setting|Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.
214531463|NCT06658704|BEHAVIORAL|Usual care (Physical activity on Prescription)|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.
214531464|NCT02046057|PROCEDURE|PNB of SLN|Percutaneous biopsy of sentinel node
214531465|NCT06608459|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
214531466|NCT06608498|BEHAVIORAL|SPARK Coping|SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.
214531467|NCT06593275|PROCEDURE|Protection of the palatal donor area with flowable resin|Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days
214531468|NCT06593275|PROCEDURE|Protection of the palatal donor area with a self-adhesive dressing|Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
214531469|NCT03582917|DRUG|Alphacalcidol|Alphacalcidol 0,5mg tablet
214531470|NCT01379989|DRUG|Carboplatin|Carboplatin AUC 5
214531471|NCT01379989|DRUG|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
214531472|NCT01379989|DRUG|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
214531473|NCT02207322|OTHER|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
214531474|NCT03302559|OTHER|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
214531475|NCT03302559|OTHER|Facial cleanser|Facial cleanser in the morning and in the evening.
214531476|NCT03302559|OTHER|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
214531477|NCT03302559|OTHER|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
214531478|NCT03302559|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
214531479|NCT07007767|DRUG|sintilimab|"Sintilimab (anti-PD-1 monoclonal antibody) Specification: 100 mg/10 mL (10 mg/mL concentrated solution)~Administration:~Dose: 200 mg (fixed dose) Route: Intravenous (IV) infusion over 30-60 minutes Schedule: Day 1 of each 21-day cycle (Q3W)"
215148161|NCT04380285|DEVICE|Custom hard orthotic|
215148162|NCT04500899|DRUG|Mydfrin|A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. BP will be monitored after each bolus of phenylephrine. Subsequent Mydfrin injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
215148163|NCT03227120|OTHER|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
215148164|NCT04147663|OTHER|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
215148165|NCT00637455|DRUG|fexofenadine HCl|
215148166|NCT03557034|DEVICE|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
215148167|NCT05391672|PROCEDURE|we will do ACL augmentation surgery to the patients who have partial ACL tear|we will do ACL augmentation surgery to the patients who have ACL partial tear using hamstring graft and fixation of the graft to the femoral part by adjustable loop and tibial part with Bio or peak screws +\\- staples.
215148168|NCT00692835|PROCEDURE|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
215148169|NCT00692835|PROCEDURE|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
214461377|NCT03691857|PROCEDURE|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
214461378|NCT05424276|DRUG|IkT-148009|Oral administration gelatin capsule
214461379|NCT05424276|DRUG|Placebo|Oral administration gelatin capsule
214461380|NCT06184568|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
214461381|NCT06184568|DRUG|Semaglutide|Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
214461382|NCT05086380|BEHAVIORAL|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
214461383|NCT05086380|DEVICE|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
214461384|NCT05086380|BEHAVIORAL|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
214461385|NCT05086380|DEVICE|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
214461386|NCT05086380|DEVICE|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
214461387|NCT05086380|DEVICE|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
214531480|NCT07007767|DRUG|Bevacizumab Biosimilar|"Bevacizumab biosimilar (anti-VEGF monoclonal antibody) Specification: 100 mg/4 mL (25 mg/mL concentrated solution)~Administration:~Dose: 7.5 mg/kg (body weight-adjusted) Route: IV infusion Schedule: Day 1 of each 21-day cycle (Q3W)"
214531481|NCT07007767|DRUG|Decitabine|"Decitabine (hypomethylating agent) Specification: 10 mg lyophilized powder per vial~Administration:~Dose: 10 mg/m²/day (body surface area-adjusted) Route: IV infusion over 1 hour Schedule: Days 1-5 of each 21-day cycle (Q3W)"
214531482|NCT07009444|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
214531483|NCT07009444|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
214531484|NCT06728774|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD)|8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.
214695567|NCT05811676|DRUG|Tranexamic acid|Intravenous administration of 10 mL (1 g of tranexamic acid), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
215148170|NCT04259996|PROCEDURE|PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT|The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
215148171|NCT01295164|DEVICE|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
215148172|NCT01295164|DEVICE|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
215148173|NCT02494323|DEVICE|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
215148174|NCT01962740|DEVICE|Drug-eluting stent implantation|
215148175|NCT06431152|BIOLOGICAL|UC-MSC sEV|Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
215148176|NCT04324411|DRUG|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
215148177|NCT04509219|DRUG|Methylprednisolone Injection|methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
215148178|NCT01088698|RADIATION|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
215148179|NCT06483113|DEVICE|Delefilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
215148180|NCT06483113|DEVICE|Delefilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
215148181|NCT06483113|DEVICE|Delefilcon A multifocal soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with presbyopia
214461388|NCT05086380|BEHAVIORAL|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
214461389|NCT06362668|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
214461390|NCT06362668|DRUG|Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
214461391|NCT04615104|PROCEDURE|Operative|surgical treatment
214461392|NCT04615104|PROCEDURE|Nonoperative|nonsurgical treatment
214461393|NCT06448247|DRUG|SPY001-001|Experimental
214461394|NCT06448247|OTHER|Placebo|Placebo
214461395|NCT02667873|DRUG|SL-801|SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
214461396|NCT02724449|DEVICE|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
214461397|NCT04052061|BIOLOGICAL|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
214461398|NCT06141850|BEHAVIORAL|COVID-19 Test Reporting|Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.
214461399|NCT06141850|BEHAVIORAL|Personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.
214461400|NCT06141850|BEHAVIORAL|Non-personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
214461401|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
214531485|NCT06728774|BEHAVIORAL|Goal-focused Supportive Contact|8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.
214531486|NCT06724562|OTHER|Anti-IL1 Therapy|Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients
214531487|NCT06720506|DRUG|fentanyl|Fentanyl will be given intrathecal with dose 10-20ug
214531488|NCT06720506|DRUG|Nalbuphine|Nalbuphine will given IV as shot in Dose 1mg /kg
214531489|NCT06719843|BEHAVIORAL|ACT-based intervention|"Participants in the intervention group will receive the face-to-face ACT-based intervention weekly for 4 weeks (each session lasting approximately 90 minutes), with each group consisting of 6-8 older adults. The intervention consists of 4 sessions:~Session 1 (acceptance and cognitive fusion) Session 2 (contact with the present moment and self-as-context) Session 3 (values) Session 3 (committed action)"
214531490|NCT00767286|DRUG|flutamide|
214531491|NCT00767286|DRUG|goserelin acetate|
214531492|NCT00767286|RADIATION|low-LET cobalt-60 gamma ray therapy|
214531493|NCT00767286|RADIATION|low-LET photon therapy|
214531494|NCT01939210|OTHER|Educational Intervention|Participate in breathing training sessions
214531495|NCT01939210|OTHER|Meditation Therapy|Participate in breathing training sessions
214531496|NCT01939210|OTHER|Questionnaire Administration|Ancillary studies
215148182|NCT06584474|DRUG|Azithromycin neubilization|"nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro"
215148183|NCT06584474|DEVICE|Lung ultrasound|Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
215148184|NCT02122328|PROCEDURE|Sequential laser photocoagulation of communicating vessels.|
215148185|NCT02122328|PROCEDURE|Selective laser photocoagulation of communicating vessels|
215148186|NCT00608374|DRUG|chlorambucil|
215148187|NCT00608374|DRUG|fludarabine phosphate|
215148188|NCT00608374|PROCEDURE|quality-of-life assessment|
215148189|NCT02324348|PROCEDURE|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
214695568|NCT05811676|OTHER|0.9% sodium chloride|Intravenous administration of 10 mL placebo(0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
214461402|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
214461403|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
215148190|NCT02324348|PROCEDURE|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
215148191|NCT03440164|OTHER|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
214461404|NCT06539936|DEVICE|Glide|Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
214461405|NCT06539936|DEVICE|Direct Control|Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
214461406|NCT05825547|PROCEDURE|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
214461407|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
214461408|NCT05817786|DEVICE|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
214461409|NCT05817786|OTHER|sham stimulation|treated by sham stimulation
214461410|NCT06725602|DEVICE|"TQ - Proximal Application (high and tight)"|"Tourniquet application: proximal (high and tight) on arms and thighs."
214461411|NCT06725602|DEVICE|TQ - Controlled application (2-3 inches)|TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.
214461412|NCT06515990|DRUG|DM005|An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
214461413|NCT04543357|OTHER|Blood Draw|Blood Samples for NAb and ADA to AAV9
214461414|NCT06352359|DRUG|ONC-841|ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
214461415|NCT06112275|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
215148192|NCT02815501|BIOLOGICAL|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
215148193|NCT01281800|PROCEDURE|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
214461416|NCT06190613|BEHAVIORAL|Combination Peer navigation and mHealth intervention|Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
214461417|NCT06566534|BEHAVIORAL|Reminder|Flu shot messages via SMS
214461418|NCT04482140|DEVICE|Genta-Foil resorb®|Use of Genta-Foil resorb® to prevent adhesions in patients undergoing hand surgery
214461419|NCT05337189|DIAGNOSTIC_TEST|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
214461420|NCT05337189|PROCEDURE|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
214461421|NCT04623671|BIOLOGICAL|CAP-1002|Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)
214461422|NCT04623671|BIOLOGICAL|Placebo|Matching placebo solution
214461423|NCT04950075|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
214531497|NCT02482532|BIOLOGICAL|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
215148194|NCT04341870|DRUG|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
215148195|NCT04341870|DRUG|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
215148196|NCT04341870|DRUG|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
215148197|NCT03371043|OTHER|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
214461424|NCT04950075|DRUG|Placebo|Placebo
214461425|NCT03800693|DRUG|Fluorouracil|Given IV
214461426|NCT03800693|DRUG|Leucovorin|Given IV
214461427|NCT03800693|DRUG|Oxaliplatin|Given IV
214461428|NCT04621279|PROCEDURE|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
214461429|NCT04621279|PROCEDURE|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
215148198|NCT05125588|DRUG|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
215148199|NCT05125588|DRUG|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
215148200|NCT06438653|OTHER|No-intervenyion|No-intervenyion
215148201|NCT02879409|DRUG|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
215148202|NCT02879409|DRUG|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
215148203|NCT02879409|DRUG|Sitagliptin|Oral: 100 mg once daily
215148204|NCT02879409|DRUG|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
215148205|NCT02879409|DRUG|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
215148206|NCT02879409|DRUG|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
215148207|NCT02879409|DRUG|human insulin|insulin dosage and administration according to physician
215148208|NCT00790842|DRUG|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
215148209|NCT00790842|DRUG|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
214531498|NCT04419805|DEVICE|Single Palatal TAD|A single mini-screw inserted in the mid-palate
215148210|NCT00790842|DRUG|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
215148211|NCT03809104|OTHER|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
215148212|NCT06499064|PROCEDURE|mHealth|"Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference."
214531499|NCT04419805|DEVICE|Two buccal TADs|Two buccal TADs inserted in the upper jaw
215148213|NCT06266091|DRUG|M701|Intra-peritoneal infusion of M701 combined with system therapy
215148214|NCT06266091|DRUG|paracentesis|paracentesis combined with system therapy
215148215|NCT05462522|DRUG|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
215148216|NCT05462522|DRUG|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
215148217|NCT06205628|DRUG|ADX-850|siRNA duplex oligonucleotide
215148218|NCT06205628|DRUG|Placebo|Saline
215148219|NCT04197921|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
215148220|NCT05531201|PROCEDURE|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
215148221|NCT02115048|DRUG|Letrozole|
215148222|NCT02115048|DRUG|Afatinib|
215148223|NCT05406674|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
215148224|NCT05406674|DRUG|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
215148225|NCT06132945|DRUG|Cabozantinib|Cabozantinib (40 mg PO daily)
215148226|NCT06132945|DEVICE|Nivolumab|Nivolumab (480 mg IV Day 1)
215148227|NCT06132945|RADIATION|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
215148228|NCT02451982|DRUG|Cyclophosphamide|200 mg/m2 IV
215148229|NCT02451982|BIOLOGICAL|GVAX pancreatic cancer|5x10\^8 cells intradermal injection
214461430|NCT06108336|PROCEDURE|TMS during sequence-demanding task|TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
214461431|NCT06108336|PROCEDURE|No TMS during sequence-demanding task|TMS is not administered during the execution of sequence-demanding task.
214461432|NCT06108336|PROCEDURE|TMS during non-sequence-demanding task|TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
214461433|NCT06108336|PROCEDURE|No TMS during non-sequence-demanding task|TMS is not administered during the execution of non-sequence-demanding task
214461434|NCT06167317|DRUG|GS-0201|Pill administered orally
214461435|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
214461436|NCT04742452|PROCEDURE|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
214461437|NCT04742452|PROCEDURE|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
214461438|NCT05151926|PROCEDURE|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
214461439|NCT05151926|PROCEDURE|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
215148230|NCT02451982|DRUG|Nivolumab|480 mg IV
215148231|NCT02451982|DRUG|Urelumab|8 mg IV
214461440|NCT05151926|PROCEDURE|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
214461441|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
214461442|NCT06778577|OTHER|intra-articular corticosteroid injection (IACI) group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
214461443|NCT06778577|PROCEDURE|suprascapular nerve radiofrequency group (SCNRFT)|"SCNRFT is a new choice for treatment of frozen shoulder. The suprascapular nerve is the nerve that is most commonly affected in the condition of a frozen shoulder and it is for this reason that the suprascapular nerve is directly targeted by pulsed radiofrequency treatment. As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to tag the nerve accurately without injury to the nerves or vessels."
214461444|NCT06210477|DRUG|medical treatment for lower urinary tract symptoms|The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
214531500|NCT02990923|DEVICE|High-Flow Needleless Valve|
214531501|NCT02990923|DEVICE|DualCap Disinfection Devices|
215148232|NCT02451982|DRUG|BMS-986253|2400 mg IV
215148233|NCT04417517|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
215148234|NCT04417517|DRUG|azacitidine|Hypomethylating agent (HMA)
215148235|NCT02740023|DEVICE|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
215148236|NCT02740023|DEVICE|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
215148237|NCT03754777|PROCEDURE|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
215148238|NCT00664625|DRUG|BMS-791325|Capsules, Oral, Once Daily, Single Dose
215148239|NCT00664625|DRUG|Placebo|Capsules, Oral, Once Daily, Single Dose
215148240|NCT00093041|DRUG|Zalutumumab|Weekly infusion
215148241|NCT03397069|PROCEDURE|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
214461445|NCT05237648|OTHER|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
214461446|NCT05237648|OTHER|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
214461447|NCT04663737|DRUG|Silmitasertib|Capsules
214461448|NCT04663737|DRUG|SOC|Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
214461449|NCT04855799|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
214461450|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
214531502|NCT05937815|PROCEDURE|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
214531503|NCT00598871|DRUG|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
214461451|NCT06018233|OTHER|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
214531504|NCT00598871|OTHER|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
214531505|NCT00348868|BEHAVIORAL|enhanced behavioral motivation counseling|
214531506|NCT00348868|BEHAVIORAL|Motivational counseling|
214531507|NCT00348868|BEHAVIORAL|Standard counseling|
214531508|NCT00152399|DRUG|Somatostatin UCB (drug)|
214531509|NCT00513058|DRUG|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
214531510|NCT00513058|DRUG|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
214531511|NCT04961242|DEVICE|Together for Wellness digital mental health website|The intervention is a digital mental health resources website that includes multiple, free resources for broad public use. Different categories of resources include information on COVID-19 from CDC, multi-language versions of the UCLA Mindfulness App and other meditation programs, resources for families and social connection, including addressing discrimination or equity, and resource links.
214531512|NCT03884062|DRUG|DAAs|lab, U/S, Fibroscan \& CT if needed
214531513|NCT06133686|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
214531514|NCT06133686|DRUG|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
214531515|NCT01106365|DEVICE|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
214531516|NCT05780216|DRUG|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
215148242|NCT03397069|PROCEDURE|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
215148243|NCT03397069|PROCEDURE|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
214461452|NCT05652699|OTHER|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
214461453|NCT05652699|OTHER|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
214461454|NCT05657691|DRUG|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
215148244|NCT05108012|BIOLOGICAL|NK cell therapy|Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
215148245|NCT03408392|DRUG|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
215148246|NCT03408392|DRUG|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
215148247|NCT04668456|DRUG|Dexmedetomidine|the drug administered either subtenon ot iv
215148248|NCT04668456|DRUG|lidocaine 2%|subtenon injection
215148249|NCT04668456|DRUG|bupivacine 0.5%|subtenon injection
215148250|NCT04668456|DRUG|Normal saline|either subtenon or iv
215148251|NCT06300112|BEHAVIORAL|YOGA|Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
215148252|NCT03303976|BIOLOGICAL|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
215148253|NCT03303976|BIOLOGICAL|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
215148254|NCT00885170|DRUG|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
215148255|NCT00885170|DRUG|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
215148256|NCT00885170|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
215148257|NCT00885170|DIETARY_SUPPLEMENT|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
215148258|NCT06204640|DRUG|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
215148259|NCT00783068|DRUG|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
215148260|NCT00783068|DRUG|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
215148261|NCT00783068|DRUG|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
215148262|NCT00561925|DRUG|nevirapine IR|200 mg BID
215148263|NCT00561925|DRUG|nevirapine XR|400 mg QD
215148264|NCT03207295|DRUG|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
215148265|NCT03207295|DRUG|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
214695569|NCT01358877|DRUG|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
215148266|NCT04941209|DEVICE|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
215148267|NCT04941209|DIAGNOSTIC_TEST|(PPA >95%) FDA EUA RT-PCR|Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
215148268|NCT04941209|RADIATION|HR-CT-scan|High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
215148269|NCT01910363|DRUG|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
215148270|NCT01910363|DRUG|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
215148271|NCT01544010|BEHAVIORAL|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
215148272|NCT01544010|BEHAVIORAL|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
215148273|NCT01544010|BEHAVIORAL|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
215148274|NCT01544010|BEHAVIORAL|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
215148275|NCT01544010|BEHAVIORAL|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
215148276|NCT01928212|DEVICE|Optical coherence tomography|
215148277|NCT00724698|DRUG|Desloratadine|Desloratadine 5 mg once daily
215148278|NCT03006003|DRUG|Raloxifene|Raloxifene tratment more than 4 weeks
215148279|NCT03006003|DRUG|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
215148280|NCT03637738|RADIATION|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
215148281|NCT03637738|RADIATION|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
215148282|NCT05021978|DRUG|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
215148283|NCT05021978|DRUG|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
215148284|NCT05021978|DRUG|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
215148285|NCT04984746|DIETARY_SUPPLEMENT|No Intervention: (control group)|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
215148286|NCT04984746|DIETARY_SUPPLEMENT|Experimental: intervention group|"Molybdenum Iodine group~Lettuces with Iodine and Molybdenum biofortification was assigned to each participant belonging to the intervention group which ate 100gr of each type of lattuce every day for 10 days"
215148287|NCT01658033|DRUG|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
215148288|NCT04932486|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
215148289|NCT06371781|DIAGNOSTIC_TEST|Serum Netrin-4, Resistin and Sfrp-5 level measurement|Measurements of the levels of these molecules in the serum samples of the study group will be done with the ELISA kit.
215148290|NCT03367988|DRUG|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
215148291|NCT03367988|DRUG|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
215148292|NCT03193099|OTHER|Brain imaging|Volume, DWS and DTI
215148293|NCT03193099|OTHER|Neurological assessments|UHDRS
215148294|NCT03193099|BEHAVIORAL|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
215148295|NCT03193099|BEHAVIORAL|Behavioural assessments|Computerized game
215148296|NCT03672708|DIAGNOSTIC_TEST|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
215148297|NCT04458870|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
215148298|NCT04276896|BIOLOGICAL|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
215148299|NCT03122509|DRUG|durvalumab|1500 mg durvalumab via IV infusion
215148300|NCT03122509|DRUG|tremelimumab|75 mg tremelimumab via IV infusion
215148301|NCT03122509|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
215148302|NCT03122509|PROCEDURE|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
215148303|NCT03855488|BEHAVIORAL|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
214695570|NCT01358877|DRUG|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
214695571|NCT01358877|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
214695572|NCT01358877|DRUG|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
214695573|NCT01358877|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
214695574|NCT01358877|DRUG|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
214695575|NCT01358877|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
214695576|NCT01358877|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
215148304|NCT03855488|BEHAVIORAL|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
215148305|NCT03855488|BEHAVIORAL|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
215148306|NCT02177032|BIOLOGICAL|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
214461455|NCT05657691|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
214461456|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
214461457|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
214461458|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
214461459|NCT05095935|OTHER|N/A observational registry|N/A observational registry
214461460|NCT04215146|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
214461461|NCT04215146|BIOLOGICAL|Pelareorep|Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
214461462|NCT04215146|DRUG|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
214461463|NCT06585241|BIOLOGICAL|mRNA-1273 Variant-containing Formulation|Sterile liquid for injection
214461464|NCT01943409|DRUG|Intralipid|soybean oil-based lipid emulsion
214461465|NCT01943409|DRUG|ClinOleic|olive oil-based lipid emulsion
214461466|NCT03281798|DEVICE|Fetoscopes|Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.
214695577|NCT01358877|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
214695578|NCT01358877|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
214695579|NCT04769635|DEVICE|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
214461467|NCT03281798|PROCEDURE|Fetal Cystoscopy|A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.
214461468|NCT03480594|DRUG|MRI Tracer|Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
214461469|NCT06201156|DEVICE|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
214461470|NCT04983043|DRUG|Low dose QiShen YiQi Dripping Pills 3 bags|Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
214461471|NCT04983043|DRUG|High dose QiShen YiQi Dripping Pills 3 bags|High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
214461472|NCT04983043|DRUG|QiShen YiQi Dripping Pills placebo 3 bags|QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
214461473|NCT06397846|OTHER|Biological sample|blood sample will be collected at baseline
214461474|NCT04115163|DRUG|Gemcitabine|Given IV
214461475|NCT04115163|DRUG|Nab-paclitaxel|Given IV
214461476|NCT03848065|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
214461477|NCT03848065|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
214461478|NCT03848065|BIOLOGICAL|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
214531517|NCT05780216|DRUG|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
215148307|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
215148308|NCT02177032|BIOLOGICAL|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
215148309|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
215148310|NCT04719078|DIAGNOSTIC_TEST|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
215148311|NCT02321020|PROCEDURE|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
215148312|NCT02321020|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
215148313|NCT03862326|BEHAVIORAL|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
215148314|NCT00378157|BEHAVIORAL|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
215148315|NCT00665652|DRUG|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
215148316|NCT04074889|DIETARY_SUPPLEMENT|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
215148317|NCT04074889|OTHER|Placebo|Placebo sachet with no microbial cell preparation
215148318|NCT06316050|PROCEDURE|humeral retroversion|REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
215148319|NCT04592887|RADIATION|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
215148320|NCT00672321|GENETIC|gene expression analysis|
215148321|NCT00672321|GENETIC|mutation analysis|
215148322|NCT00672321|GENETIC|polymorphism analysis|
215148323|NCT00672321|OTHER|laboratory biomarker analysis|
214461479|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
215148324|NCT00672321|OTHER|questionnaire administration|
215148325|NCT03498898|OTHER|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
215148326|NCT01749215|DRUG|Topiramate|Experimental study drug
215148327|NCT01749215|DRUG|placebo|Placebo comparator
215148328|NCT01749215|BEHAVIORAL|Medical Management|Brief alcohol counseling
215148329|NCT02346162|BEHAVIORAL|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.
214461480|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
214461481|NCT02659735|DRUG|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
214461482|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
214461483|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
215148330|NCT02346162|OTHER|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
215148331|NCT00203099|DRUG|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
215148332|NCT02556177|PROCEDURE|MRI|MRI scanning
215148333|NCT03739268|DRUG|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
215148334|NCT03739268|DRUG|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
215148335|NCT04852926|OTHER|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~* T0 (at inclusion) : before disease + since diagnosis~* C4 (chemotherapy course n°4)~* C6 (chemotherapy course n°6)~* M3 (3 months after chemotherapy)~* M6 (6 months after chemotherapy)~* A1 (1 year after chemotherapy)~* A2 (2 years after chemotherapy)"
215148336|NCT03262844|BEHAVIORAL|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
215148337|NCT03262844|PROCEDURE|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
215148338|NCT04994288|BIOLOGICAL|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
215148339|NCT04994288|OTHER|placebo injection|placebo injection 0.5ml
215148340|NCT01526577|DRUG|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
215148341|NCT01526577|DRUG|placebo|LC23-1306 placebo
215148342|NCT01526577|DRUG|Ticagrelor|Ticagrelor 90mg
215148343|NCT03008057|DIETARY_SUPPLEMENT|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
215148344|NCT03008057|DIETARY_SUPPLEMENT|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
215148345|NCT00458263|DRUG|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
215148346|NCT03743181|OTHER|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
215148347|NCT00577304|DRUG|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
215148348|NCT00577304|DRUG|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
215148349|NCT00976924|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
215148350|NCT00002080|DRUG|Rifabutin|
215148351|NCT03657082|DEVICE|PEP-10|Bottle PEP with a water level of 10 cmH2O
215148352|NCT03657082|DEVICE|PEP-1|Bottle PEP with a water level of 1 cmH2O
215148353|NCT01672580|BEHAVIORAL|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
215148354|NCT01672580|BEHAVIORAL|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
215148355|NCT01672580|BEHAVIORAL|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
215148356|NCT01672580|BEHAVIORAL|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
215148357|NCT03481686|DEVICE|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
215148358|NCT04200599|OTHER|duration of initiation of oxytocin|mode of delivery
215148359|NCT01308437|BIOLOGICAL|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
215148360|NCT01308437|BIOLOGICAL|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
215148361|NCT03236636|DRUG|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
215148362|NCT03236636|DRUG|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
215148363|NCT05196295|DRUG|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
215148364|NCT00624598|BEHAVIORAL|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
215148365|NCT06082362|OTHER|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
215148366|NCT03745014|DIAGNOSTIC_TEST|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
215148367|NCT03745014|DIAGNOSTIC_TEST|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
215148368|NCT00334048|DRUG|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
215148369|NCT02415608|DRUG|Ibrutinib|Given orally in 28-day cycles
215148370|NCT02871934|GENETIC|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
215148371|NCT04788329|BEHAVIORAL|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
215148372|NCT04788329|BEHAVIORAL|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
215148373|NCT06110130|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
215148374|NCT06110130|DRUG|Placebo|Take Placebo 10 mg orally daily for 4 months
215148375|NCT04800809|OTHER|This study does not entail offering any intervention; all data collected will be based on standard of care.|This study does not entail offering any intervention; all data collected will be based on standard of care.
215148376|NCT00734539|DRUG|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
215148377|NCT00734539|DRUG|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
215148378|NCT04000633|DRUG|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
215148379|NCT04000633|DRUG|Normal saline|Normal saline
215148380|NCT02207777|PROCEDURE|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
215148381|NCT02207777|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
215148382|NCT00649207|DRUG|ABT-888|Oral Capsules
215148383|NCT00649207|RADIATION|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
215148384|NCT01187355|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
215148385|NCT01187355|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
215148386|NCT01187355|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
215148387|NCT02504151|DRUG|Cannabidiol|
215148388|NCT02504151|DRUG|Placebo|
215148389|NCT02342028|BIOLOGICAL|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
215148390|NCT05855707|BIOLOGICAL|WJ-MSC infusion|cellular therapy
215148391|NCT01942694|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
215148392|NCT01942694|OTHER|Placebo|Administered as one soft-gel pill daily by mouth
215148393|NCT00389610|BIOLOGICAL|GVAX pancreas vaccine|Given intradermally
215148394|NCT00840112|DIETARY_SUPPLEMENT|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
215148395|NCT03943654|OTHER|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
215148396|NCT00538902|BIOLOGICAL|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
215148397|NCT00538902|BIOLOGICAL|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
215148398|NCT00538902|BIOLOGICAL|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
215148399|NCT04530214|OTHER|Blood collection|Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
215148400|NCT04530214|OTHER|Saliva collection|Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
215148401|NCT04530214|OTHER|Electrocardiography (ECG)|Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability
215148402|NCT04530214|BEHAVIORAL|Questionnaires|Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)
215148403|NCT01948596|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
215148404|NCT00472576|DRUG|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
215148405|NCT00472576|DRUG|Placebo|Daily double-blind administration of placebo
215148406|NCT04690049|OTHER|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
215148407|NCT04690049|OTHER|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
215148408|NCT01957007|DRUG|Docetaxel|Docetaxel will be administered IV.
215148409|NCT01957007|DRUG|vantictumab|Vantictumab will be administered intravenously
215148410|NCT04324437|OTHER|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
215148411|NCT04170608|DEVICE|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
215148412|NCT04840693|BIOLOGICAL|Biological samples|blood, urine, saliva
215148413|NCT04840693|OTHER|Complications|bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
215148414|NCT01826019|OTHER|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
215148415|NCT01826019|OTHER|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
215148416|NCT02080715|DRUG|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
215148417|NCT02080715|DRUG|Placebo|
215148418|NCT00993577|OTHER|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
215148419|NCT00993577|DEVICE|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
215148420|NCT00993577|DEVICE|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
215148421|NCT01916954|DRUG|3-day artemether-lumefantrine|
215148422|NCT01916954|DRUG|5-day artemether-lumefantrine|
215148423|NCT00985764|PROCEDURE|cesarean delivery|
215148424|NCT02557139|DRUG|Belumosudil Tablet|
215148425|NCT02557139|DRUG|Belumosudil Capsule|
215148426|NCT04495023|PROCEDURE|Left elective colectomy|Open or laparoscopic left elective colectomy with colo-rectal anastomosis
215148427|NCT02622126|DRUG|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
215148428|NCT02622126|DRUG|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
215148429|NCT02622126|DRUG|Morphine|Sub arachnoid 200 meg morphine
215148430|NCT02622126|DRUG|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
215148431|NCT02622126|DRUG|Ephedrine|If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
215148432|NCT02622126|DRUG|Atropine|Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
215148433|NCT00860093|OTHER|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
215148434|NCT00860093|DRUG|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
215148435|NCT01454102|BIOLOGICAL|Nivolumab|
215148436|NCT01454102|DRUG|Gemcitabine|
215148437|NCT01454102|DRUG|Cisplatin|
215148438|NCT01454102|DRUG|Pemetrexed|
215148439|NCT01454102|DRUG|Paclitaxel|
215148440|NCT01454102|DRUG|Carboplatin|
215148441|NCT01454102|DRUG|Bevacizumab|
215148442|NCT01454102|DRUG|Erlotinib|
214461484|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
214461485|NCT05721209|DEVICE|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
214695580|NCT05296850|OTHER|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
215148443|NCT01454102|BIOLOGICAL|Ipilimumab|
215148444|NCT03356041|OTHER|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
215148445|NCT01378871|DRUG|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
215148446|NCT04355143|DRUG|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
215148447|NCT04355143|OTHER|Current care per UCLA treating physicians|Current care
215148448|NCT04892381|DIAGNOSTIC_TEST|Skin Biopsy|"* Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP"
215148449|NCT02148874|BIOLOGICAL|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
215148450|NCT01287702|DIETARY_SUPPLEMENT|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
215148451|NCT01287702|DIETARY_SUPPLEMENT|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
215148452|NCT01287702|DIETARY_SUPPLEMENT|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
215148453|NCT04647188|OTHER|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
215148454|NCT03559374|OTHER|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
215148455|NCT02592798|DRUG|Abatacept|Abatacept IV administered on Day 1, 15, 29 and then every 28 days
215148456|NCT02592798|OTHER|Normal Saline|Normal Saline administer on Day 1, 15, 29 and then every 28 days
215148457|NCT02592798|OTHER|D5W|Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
215148458|NCT03083834|DIAGNOSTIC_TEST|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
215148459|NCT03470389|PROCEDURE|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
215148460|NCT03455595|PROCEDURE|Endoscopic exams|Coloscopy
215148461|NCT05715099|DRUG|Saffron|Dietary Supplement: saffron supplement for IBD
215148462|NCT05715099|DRUG|Placebo|Dietary Supplement: placebo for IBD
215148463|NCT03699514|DEVICE|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
215148464|NCT02622282|OTHER|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
215148465|NCT02622282|OTHER|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
215148466|NCT02622282|OTHER|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
215148467|NCT00705016|DRUG|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
215148468|NCT00705016|DRUG|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
215148469|NCT00705016|DRUG|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
215148470|NCT00705016|DRUG|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
214461486|NCT05721209|DEVICE|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
215148471|NCT00705016|DRUG|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
215148472|NCT02233517|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
215148473|NCT02233517|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
215148474|NCT06029829|DRUG|Sintilimab|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
214461487|NCT05721209|DEVICE|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
214461488|NCT05721209|DEVICE|Hunova|Used to conduct fall-risk assessment.
214531518|NCT02759237|DEVICE|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system"
215148475|NCT04381364|DRUG|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
215148476|NCT00588107|OTHER|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
215148477|NCT00588107|BEHAVIORAL|print materials|tailored print materials designed to aid in smoking reduction and cessation
215148478|NCT04042948|DRUG|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
215148479|NCT06131736|OTHER|Tabata Training|This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
215148480|NCT06131736|OTHER|Cluster Training|The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
215148481|NCT02307825|DRUG|Azithromycin|The drug will be taken three times a week for four months.
215148482|NCT02307825|DRUG|Placebo|The placebo will be taken three times a week for four months.
215148483|NCT00765206|DRUG|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
215148484|NCT00765206|DRUG|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
215148485|NCT01588730|DEVICE|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
214461489|NCT03908099|BEHAVIORAL|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
214461490|NCT03908099|OTHER|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
214461491|NCT00670358|BIOLOGICAL|pegfilgrastim|
214461492|NCT00670358|BIOLOGICAL|rituximab|
214461493|NCT00670358|DRUG|cyclophosphamide|
214461494|NCT00670358|DRUG|doxorubicin hydrochloride|
214461495|NCT00670358|DRUG|lenalidomide|
214461496|NCT00670358|DRUG|prednisone|
214461497|NCT00670358|DRUG|vincristine sulfate|
214461498|NCT00670358|GENETIC|polymorphism analysis|
215148486|NCT01588730|PROCEDURE|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
215148487|NCT01967940|DRUG|TAF|25 mg tablet administered orally once daily with food
215148488|NCT01967940|DRUG|Placebo|Tablets to match TAF administered orally once daily with food
215148489|NCT01967940|DRUG|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
214461499|NCT00670358|OTHER|laboratory biomarker analysis|
214461500|NCT03847480|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
214461501|NCT05029635|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
214461502|NCT05029635|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
214461503|NCT06625892|BEHAVIORAL|the multidimensional interventions|The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
214461504|NCT00185744|RADIATION|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
214461505|NCT00185744|PROCEDURE|Lumpectomy|
214461506|NCT00185744|RADIATION|Whole Breast Radiotherapy|six and a half week treatment
214461507|NCT00185744|RADIATION|Intracavitary Brachytherapy|5 day treatment
214461508|NCT00185744|RADIATION|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
215148490|NCT01967940|DRUG|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
215148491|NCT01967940|DRUG|ATV|300 mg tablet administered orally once daily.
215148492|NCT02416206|DRUG|BeEAM|BeEAM
215148493|NCT04706455|DEVICE|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
215148494|NCT04706455|DEVICE|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
215148495|NCT00942604|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
215148496|NCT00942604|DRUG|Vehicle gel|two day treatment
215148497|NCT02725918|DRUG|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
215148498|NCT02725918|DRUG|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
215148499|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
214461509|NCT00185744|RADIATION|Stereotactic APBI|4 day treatment
215148500|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
214461510|NCT03496168|DRUG|mavacamten|mavacamten capsules
214461511|NCT02379793|DRUG|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
214461512|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
214461513|NCT06494891|DRUG|Intravenous Alcohol|Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an alcohol challenge. During the challenge, participants will be administered alcohol designed to reach target BrACs of 20, 40, and 60 mg%, each over 15 min. After reaching the last target BrAC (0.06 g/dl) participants will complete a self-administration (SA) paradigm. Participants will be invited to work (button press) for alcohol according to a log-linear progressive ratio schedule.
214461514|NCT06251609|DRUG|Naloxone 2 MG|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
215148501|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
215148502|NCT00232661|DRUG|ARIMIDEX (anastrazole)|
215148503|NCT00232661|DRUG|NOLVADEX (tamoxifen)|
215148504|NCT04046809|OTHER|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
215148505|NCT04046809|OTHER|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
215148506|NCT00224822|DRUG|Aripiprazole|
215148507|NCT00212641|DRUG|ONO-5129|
215148508|NCT03651570|DEVICE|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
215148509|NCT03651570|BEHAVIORAL|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
215148510|NCT00005080|DRUG|nelarabine|Given IV
214461515|NCT06251609|DRUG|Saline 2ml|Placebo
214461516|NCT06308861|DRUG|Single administration Amg dose Group|Orally, Amg tablet single administration
214461517|NCT06308861|DRUG|Single administration Bmg dose Group|Orally, Bmg tablet single administration
214461518|NCT06308861|DRUG|Single administration Cmg dose Group|Orally, Cmg tablet single administration
215148511|NCT02846025|DIETARY_SUPPLEMENT|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
215148512|NCT02846025|DIETARY_SUPPLEMENT|Folate and placebo|rich diet aministracao folate and placebo
215148513|NCT02846025|DIETARY_SUPPLEMENT|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
215148514|NCT01143246|DRUG|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
215148515|NCT01143246|DRUG|Placebo|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
215148516|NCT01666028|DEVICE|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
215148517|NCT01666028|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
215148518|NCT01663103|DRUG|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
214461519|NCT06308861|DRUG|Single administration Dmg dose Group|Orally, Dmg tablet single administration
214461520|NCT06308861|DRUG|Single administration Emg dose Group|Orally, Emg tablet single administration
214461521|NCT06308861|DRUG|Single administration Amg dose Group-Placebo|Orally, Placebo Amg tablet, single administration
214461522|NCT06308861|DRUG|Single administration Bmg dose Group-Placebo|Orally, Placebo Bmg tablet, single administration
214461523|NCT06308861|DRUG|Single administration Cmg dose Group-Placebo|Orally, Placebo Cmg tablet, single administration
214461524|NCT06308861|DRUG|Single administration Dmg dose Group-Placebo|Orally, Placebo Dmg tablet, single administration
215148519|NCT01663103|DRUG|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
215148520|NCT05510349|OTHER|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
215148521|NCT00613561|DRUG|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
215148522|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region."
215148523|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region."
215148524|NCT05318352|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
215148525|NCT00363480|DRUG|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
214461525|NCT06308861|DRUG|Single administration Emg dose Group-Placebo|Orally, Placebo Emg tablet, single administration
214461526|NCT06308861|DRUG|Multiple administration Amg dose group|Orally, Amg 1 tablet, once a day for 3 days, multiple administration
214461527|NCT06308861|DRUG|Multiple administration Bmg dose group|Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
214461528|NCT06308861|DRUG|Multiple administration Cmg dose group|Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
214461529|NCT06308861|DRUG|Multiple administration Dmg dose group|Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
214461530|NCT06308861|DRUG|Multiple administration Emg dose group|Orally, Emg 1 tablet, once a day for 3 days, multiple administration
214461531|NCT06308861|DRUG|Multiple administration Amg dose group - Placebo|Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
214461532|NCT06308861|DRUG|Multiple administration Bmg dose group - Placebo|Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
214461533|NCT06308861|DRUG|Multiple administration Cmg dose group - Placebo|Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
214461534|NCT06308861|DRUG|Multiple administration Dmg dose group - Placebo|Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
214461535|NCT06308861|DRUG|Multiple administration Emg dose group - Placebo|Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
214461536|NCT04137367|BEHAVIORAL|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
214461537|NCT04137367|BEHAVIORAL|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
214461538|NCT03907878|BIOLOGICAL|Ligelizumab|Liquid in vial
214461539|NCT04858230|DEVICE|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
214695581|NCT05296850|OTHER|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
215148526|NCT00363480|DRUG|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
215148527|NCT00363480|DEVICE|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
214461540|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
214461541|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
215148528|NCT06437041|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days.
215148529|NCT06437041|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
215148530|NCT03517397|BEHAVIORAL|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
215148531|NCT03365349|OTHER|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
215148532|NCT03365349|OTHER|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
215148533|NCT03659045|OTHER|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
214461542|NCT05144009|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
214461543|NCT05144009|DRUG|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
214461544|NCT04499924|DRUG|tucatinib|300 mg given twice daily orally
214461545|NCT04499924|DRUG|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
214461546|NCT04499924|DRUG|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
214461547|NCT04499924|DRUG|paclitaxel|60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
214461548|NCT04499924|OTHER|tucatinib placebo|Given twice daily orally
214461549|NCT04499924|OTHER|trastuzumab placebo|IV on Days 1 and 15 of each cycle
214461550|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
215148534|NCT04636684|DIAGNOSTIC_TEST|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
215148535|NCT04008745|OTHER|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
215148536|NCT05098834|DEVICE|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
214461551|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
215148537|NCT05083169|DRUG|Daratumumab|Daratumumab will be administered SC injection.
215148538|NCT05083169|DRUG|Pomalidomide|Pomalidomide will be administered orally.
215148539|NCT05083169|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
215148540|NCT05083169|DRUG|Bortezomib|Bortezomib will be administered SC injection.
215148541|NCT05083169|DRUG|Teclistamab|Teclistamab will be administered SC injection.
214461552|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
214461553|NCT04469296|DIETARY_SUPPLEMENT|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
214461554|NCT04469296|DIETARY_SUPPLEMENT|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
214461555|NCT04772937|PROCEDURE|LLETZ|LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
214461556|NCT04772937|PROCEDURE|LEEP|LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
214461557|NCT03966313|DEVICE|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~* After anesthetic induction~* Before starting the device~* 2h, 6h and 48h after starting the device"
214461558|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
214461559|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
214461560|NCT04358874|OTHER|Medication reconciliation|Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
214461561|NCT04358874|OTHER|Blood Pressure Management|Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (\>160/100)
215148542|NCT05094206|BIOLOGICAL|0.75x10^6 cells/kg CAR20.19.22 cells|"Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
215148543|NCT05094206|BIOLOGICAL|1x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
215148544|NCT05094206|BIOLOGICAL|2.5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
215148545|NCT05094206|BIOLOGICAL|5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
215148546|NCT05094206|BIOLOGICAL|Dose expansion: The maximum tolerated dose of CAR20.19.22 cells|Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
215148547|NCT05567783|BIOLOGICAL|VIR-2482 (450 mg)|VIR-2482 450mg given by intramuscular injection
215148548|NCT05567783|BIOLOGICAL|VIR-2482 (1200 mg)|VIR-2482 1200 mg given by intramuscular injection
215148549|NCT05567783|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
215148550|NCT06540261|DRUG|ONO-7913|Specified dose on specified days
214461562|NCT05777460|DEVICE|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
214461563|NCT06105918|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214461564|NCT06105918|PROCEDURE|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
214461565|NCT06105918|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214461566|NCT06105918|OTHER|Flotufolastat F-18|Given IV
214461567|NCT06105918|DRUG|Lutetium Lu 177 PSMA-10.1|Given IV
214461568|NCT06105918|PROCEDURE|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
214461569|NCT06105918|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
214461570|NCT04600466|OTHER|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
214461571|NCT04600466|OTHER|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
214461572|NCT04600466|OTHER|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
214461573|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
214461574|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
214461575|NCT03616496|DRUG|Neuraceq PET/CT imaging|PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
215148551|NCT06540261|DRUG|ONO-4538|Specified dose on specified days
215148552|NCT06540261|DRUG|Fluorouracil|Specified dose on specified days
214461576|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
214461577|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
214461578|NCT06126588|DRUG|Everolimus|Patient will be treat during 7 months of Everolimus
214461579|NCT00769223|OTHER|medical chart review|
214461580|NCT00769223|OTHER|questionnaire administration|
214461581|NCT00769223|PROCEDURE|quality-of-life assessment|
214461582|NCT00769223|RADIATION|brachytherapy|
214461583|NCT00769223|RADIATION|radiation therapy|
214461584|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
214461585|NCT03479671|DRUG|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
214461586|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
214461587|NCT05403827|DRUG|Placebo|Vehicle Solution
214461588|NCT00310830|DRUG|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
214461589|NCT04569435|DRUG|ANX005|IV Infusion
214461590|NCT02732834|BEHAVIORAL|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
214461591|NCT02732834|BEHAVIORAL|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
214461592|NCT02732834|BEHAVIORAL|Audio recordings of clinical consultations|
214461593|NCT02732834|BEHAVIORAL|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
214461594|NCT02732834|BEHAVIORAL|2-hour empathic communication skills training|2-hour empathic communication skills training
214461595|NCT02732834|BEHAVIORAL|Standardized Patient Assessments|pre-training SPA, post-training SPA
215148553|NCT06540261|DRUG|Oxaliplatin|Specified dose on specified days
215148554|NCT06540261|DRUG|Levofolinate|Specified dose on specified days
215148555|NCT06540261|DRUG|Bevacizumab|Specified dose on specified days
215148556|NCT06540261|DRUG|Cetuximab|Specified dose on specified days
215148557|NCT05610059|OTHER|Blood Pressure Technology System M|Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
215148558|NCT05610059|OTHER|Blood Pressure Technology System E|Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
215148559|NCT06577155|DRUG|Levobupivacaine|Regional anesthesia / analgesia
215148560|NCT06577155|DRUG|Levobupivacaine plus nalbuphine|Regional anesthesia / analgesia
214461596|NCT02732834|BEHAVIORAL|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
214461597|NCT02732834|BEHAVIORAL|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
214461598|NCT05681962|DIAGNOSTIC_TEST|Bronchoscopy|Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
214461599|NCT04475679|DEVICE|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth surface
214461600|NCT04475679|DEVICE|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth
214461601|NCT05597085|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
214461602|NCT03379675|DRUG|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
214461603|NCT03379675|DRUG|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
214461604|NCT03379675|DRUG|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
214461605|NCT06086431|DRUG|0.9% sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
214461606|NCT06086431|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
214461607|NCT06086431|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
214461608|NCT05931432|OTHER|Comprehensive Well-Being Intervention|The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
214461609|NCT04418037|DEVICE|Digital Health Feedback System(DHFS)|We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
215148561|NCT05395026|OTHER|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
214461610|NCT06773286|OTHER|Active Stimulation|Participants will receive activity-based training (ABT) while receiving concomitant, active spinal stimulation (scTS) applied at the cervical and thoracic spinal segments over the dorsal skin with optimized and customized stimulation parameters. Round self-adhesive electrodes will be placed over the skin at the midline of spinous processes as cathodes and a pair of rectangular anodes electrodes will be placed over the anterior iliac crests of the pelvis. The stimulation waveform is rectangular pulse with 1-ms duration filled with a carrier frequency of 5kHz. Target simulation will be sub-threshold for UE muscle activation and verified by the absence of visible muscle contraction. The stimulation parameters will be adjusted as needed throughout the intervention course based on the participant's performance and comfort level. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
215148562|NCT05005182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215148563|NCT05005182|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
215148564|NCT05005182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
215148565|NCT05005182|DRUG|Hydroxyurea|Given PO
215148566|NCT05005182|BIOLOGICAL|Luspatercept|Given SC
215148567|NCT05005182|OTHER|Questionnaire Administration|Ancillary studies
215148568|NCT06448676|DRUG|Botulinum toxin type A|Head-to-head comparison of all commercially available botulinum neurotoxin type A products
215148569|NCT06800794|BEHAVIORAL|Behavioral Skill Training|7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.
215148570|NCT06800794|OTHER|Meal Provisioning|3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.
215148571|NCT06201026|OTHER|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
215148572|NCT06201026|OTHER|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
215148573|NCT04352777|DRUG|Abemaciclib|50 - 150mg tablet BID as prescribed per standard of care
215148574|NCT04352777|DRUG|Fulvestrant|500mg as prescribed per standard of care
215148575|NCT04352777|DRUG|Aromatase Inhibitors|Letrozole, anastrozole as prescribed per standard of care
215148576|NCT05863559|BEHAVIORAL|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
215148577|NCT06038136|BEHAVIORAL|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
215148578|NCT04195633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
215148579|NCT04195633|DRUG|Cyclophosphamide|Given IV
215148580|NCT04195633|DRUG|Cyclosporine|Given IV or PO
215148581|NCT04195633|BIOLOGICAL|Filgrastim|Given IV
215148582|NCT04195633|DRUG|Fludarabine|Given IV
215148583|NCT04195633|DRUG|Mycophenolate Mofetil|Given IV or PO
215148584|NCT04195633|DRUG|Mycophenolate Sodium|Given PO
215148585|NCT04195633|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
215148586|NCT04195633|DRUG|Treosulfan|Given IV
215148587|NCT04195633|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214461611|NCT06773286|OTHER|Sham|The sham-control group will go through ABT paired with sham stimulation to control for placebo effects associated with the perception of scTS. Stimulation will be delivered at one cervical location. No stimulation mapping procedure will be performed. During the training session, the stimulation intensity will be briefly ramped up to a level at which the participants report perceiving the stimulation, and then ramped down to 0mA at both the start and the end of session. The stimulator and electrodes will remain attached to the participant while receiving ABT training. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
214531519|NCT05493098|OTHER|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
214531520|NCT05493098|OTHER|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
215148588|NCT04195633|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215148589|NCT04195633|PROCEDURE|Echocardiography|Undergo echocardiography
215148590|NCT04195633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215148591|NCT04195633|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215148592|NCT04195633|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215148593|NCT06676579|DRUG|Avacopan|Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
215148594|NCT06676579|DRUG|Prednisone|0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
215148595|NCT06676579|DRUG|Methylprednisolone (drug)|Methylprednisolone 1g intravenous on day +1
215148596|NCT06676579|DRUG|Prednisolone|Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
215148597|NCT06353971|DRUG|Briquilimab|Subcutaneous Injection
215148598|NCT05411393|OTHER|ADL-enhanced program|The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.
215148599|NCT05411393|OTHER|Usual home health rehabilitation therapy|Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
215148600|NCT03982355|DEVICE|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
215148601|NCT03113487|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
215148602|NCT03113487|BIOLOGICAL|Pembrolizumab|Given IV
215148603|NCT04916587|OTHER|Implementation Strategy of ACEs Screenings|We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.
215148604|NCT04916587|OTHER|Usual Care|"The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services."
215148605|NCT06002269|COMBINATION_PRODUCT|Dietary and Exercise Intervention|Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
215148606|NCT04473911|DRUG|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
215148607|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
214461612|NCT06773286|OTHER|Training only|articipants in ABT group will receive ABT only. ABT will concentrate on activities of gross UE movement, grasping, pinching, gross and fine motor skill. The hand grasp task will focus on grasping objects with different shapes and weights (i.e. weighted container and tennis ball) and placing/removing them from small storage container; the pinch task involves picking up, translating, and releasing small objects with varied sizes (i.e. blocks, dices, marble balls, nuts, etc.). The training therapist selects tasks based on participant's level of impairment and individual goals. The dosage of ABT will be 30 minutes/session, with approximately 15 minutes allocated on each side.
214461613|NCT06788015|DIETARY_SUPPLEMENT|Hydrogen-infused water|Water containing molecular hydrogen
214461614|NCT06788015|DIETARY_SUPPLEMENT|Placebo|Water containing no molecular hydrogen
214461615|NCT06822608|DRUG|dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
214461616|NCT06822608|DRUG|Placebo|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
214461617|NCT06807866|DRUG|Duloxetine|Participants will come in person and receive a one time 60 mg dose by mouth.
214461618|NCT06807866|OTHER|Placebo|Participants will come in person and receive a one time 60 mg placebo pill dose by mouth.
214461619|NCT06441630|DRUG|AD-227A|Per Oral, 1 Tablet, Once a day for 8 weeks
214461620|NCT06441630|DRUG|AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
214461621|NCT06441630|DRUG|AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
214461622|NCT06441630|DRUG|Placebo of AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
214461623|NCT06441630|DRUG|Placebo of AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
214461624|NCT01134653|OTHER|Jump Stretch|distraction with early mobilization
214461625|NCT04502888|DRUG|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
214461626|NCT05964868|DRUG|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
214461627|NCT05964868|DRUG|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
214531521|NCT04257422|OTHER|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
215148608|NCT04473911|RADIATION|TBI|Total body irradiation (TBI) once per cycle.
215148609|NCT04473911|DRUG|Melphalan|Melphalan, infusion, determined dosage, once per cycle
215148610|NCT04473911|DRUG|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
215148611|NCT04473911|DRUG|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
215148612|NCT04473911|DRUG|RGI-2001|IV, predetermined dose, weekly to 6 total doses
215148613|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
215148614|NCT03184168|DRUG|[14C]lorlatinib|Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
214461628|NCT05964868|OTHER|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
214461629|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
214461630|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
214461631|NCT06228924|GENETIC|TN-401|TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
214461632|NCT05472558|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
214461633|NCT05915013|DRUG|Ketamine|Intravenous ketamine
214461634|NCT05915013|DRUG|Perampanel|Oral perampanel (6 mg)
214461635|NCT05915013|DRUG|Placebo|Oral placebo
214531522|NCT06483386|DRUG|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
214695582|NCT06093282|BEHAVIORAL|ARCH|"ARCH is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* A 12-session adaptation of Behavioral Activation Treatment for Depression~* Weekly contacts from an outreach worker~* Optional resources aimed at promoting physical activity and weight management"
214695583|NCT06093282|BEHAVIORAL|Traditional Health Outreach|"The Traditional Health Outreach comparator is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* Support calls from an outreach worker at least once every 3 weeks"
215148615|NCT03944577|DRUG|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
215148616|NCT04345120|DRUG|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
215148617|NCT04345120|DRUG|SY-008 matching placebo|SY-008 matching placebo
215148618|NCT03953352|OTHER|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
215148619|NCT02809001|PROCEDURE|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
215148620|NCT03852056|DRUG|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
215148621|NCT03852056|DRUG|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
215148622|NCT06104826|DRUG|Emicizumab|Emicizumab in Hemophilia A
215148623|NCT00940771|DRUG|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
215148624|NCT04351334|DRUG|Alectinib|Observational treatment based on physician choice
215148625|NCT05361668|DRUG|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
215148626|NCT05361668|DRUG|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
215148627|NCT05007769|DRUG|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
215148628|NCT05007769|DRUG|Atezolizumab|Atezolizumab will be commercially available.
215148629|NCT05007769|DRUG|N-803|Will be supplied free of charge to the participants by ImmunityBio
215148630|NCT00000996|DRUG|Doxorubicin hydrochloride|
215148631|NCT02246790|PROCEDURE|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
215148632|NCT02246790|PROCEDURE|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
215148633|NCT04701827|COMBINATION_PRODUCT|AWARE intervention|Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
215148634|NCT02048670|DEVICE|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
215148635|NCT00722072|DRUG|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
215148636|NCT00722072|DRUG|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
215148637|NCT01798771|PROCEDURE|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
215148638|NCT01798771|PROCEDURE|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
215148639|NCT02787902|BEHAVIORAL|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
215148640|NCT02787902|BEHAVIORAL|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
215148641|NCT03782246|BEHAVIORAL|MBCT|Mindfulness- based Cognitive Therapy
215148642|NCT03782246|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
215148643|NCT03129568|BIOLOGICAL|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
215148644|NCT05127954|DRUG|Ubrogepant|Oral Tablet
214461636|NCT03543852|BEHAVIORAL|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
214461637|NCT03506308|DEVICE|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
215148645|NCT05679869|OTHER|Masking Sound|Prerecorded environmental noise and masking sounds played from headphones
215148646|NCT05679869|OTHER|No masking sound|Prerecorded environmental noise but no masking sounds played from headphones
215148647|NCT05067725|OTHER|CarePath|During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
215148648|NCT04971434|DEVICE|laser stimulation for acupoints|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
215148649|NCT04971434|OTHER|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
215148650|NCT06086717|OTHER|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
214461638|NCT01480440|DEVICE|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
214461639|NCT05402293|DIAGNOSTIC_TEST|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
214461640|NCT04072198|DRUG|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
214461641|NCT04072198|DRUG|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
214461642|NCT04072198|DRUG|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
214461643|NCT04072198|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
214695584|NCT04183179|BEHAVIORAL|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
214695585|NCT03575884|BEHAVIORAL|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
214695586|NCT05935215|DRUG|Iptacopan|Open Label
214695587|NCT06368622|DEVICE|Surpass Evolve Flow Diverter System|Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
214695588|NCT05613049|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
214695589|NCT05585645|BIOLOGICAL|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
214695590|NCT06376916|DRUG|Magnesium Sulfate 2 G|Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
214695591|NCT06376916|DRUG|Magnesium Sulfate 4 G|Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
214461644|NCT04072198|DRUG|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
214461645|NCT04072198|DRUG|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
214695592|NCT06376916|DRUG|Saline|The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
214695593|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
214695594|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
214695595|NCT05872152|DIAGNOSTIC_TEST|FTIR results|Weekly transmission of FTIRS typing of ESBL-E to centers
214695596|NCT06470685|BEHAVIORAL|Qualitative Research Interviews|Research Interviews
214695597|NCT06060223|OTHER|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
214461646|NCT03462030|DRUG|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
214461647|NCT03462030|DRUG|Placebo: Tapioca Powder|Placebo control.
214461648|NCT06070012|DRUG|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
214461649|NCT05832216|DRUG|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
214461650|NCT06128343|OTHER|collection of biological samples|Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
214461651|NCT06316778|BEHAVIORAL|Pelvic floor muscle training|12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
214461652|NCT06218303|BIOLOGICAL|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
214461653|NCT06218303|DRUG|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
214461654|NCT06218303|DRUG|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
214695598|NCT01911845|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
214695599|NCT01911845|DRUG|ABT-333|Tablet
215148651|NCT06086717|OTHER|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
215148652|NCT00949702|DRUG|vemurafenib|960 mg b.i.d. continuous oral dosing
215148653|NCT01654302|DRUG|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
215148654|NCT01654302|DRUG|Inactive patch|placebo patch applied once for 12 hours
215148655|NCT00570986|DRUG|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
215148656|NCT00570986|BIOLOGICAL|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
215148657|NCT00570986|BIOLOGICAL|ABT-874|100mg every 12 weeks.
215148658|NCT00363259|DRUG|Peginterferon alfa-2b|
215148659|NCT00363259|DRUG|Ribavirin|
215148660|NCT05397925|BEHAVIORAL|ADSProgram - Self management for substance dependence program|GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
215148661|NCT05397925|BEHAVIORAL|Treatment as usual - Regular nursing consultation on a medication-based program|Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
215148662|NCT00059462|DRUG|Interleukin-2 SA|HAART and Bay 50-4798
215148663|NCT00059462|DRUG|HAART|HAART alone
214461655|NCT03381196|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
214461656|NCT03381196|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
214461657|NCT03381196|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
214461658|NCT06771596|DRUG|Nimotuzumab Injection|Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
214695600|NCT01911845|DRUG|Ribavirin (RBV)|Tablet
214695601|NCT04005898|DEVICE|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
214695602|NCT06683365|PROCEDURE|Sural Nerve Graft to the Substantia Nigra|Participants assigned to this arm will have the sural nerve biopsied from one of their ankles. This cellular tissue will be deposited bilaterally into the substantia nigra area of their brain by a specialized cannula via bilateral scalp incisions and skull burr holes.
214695603|NCT06683365|PROCEDURE|Sham surgery|Participants assigned to this arm will have the sural nerve from one of their ankles biopsied in the same fashion as the experimental arm. Bilateral incisions will be made on the participants scalp but no burr holes into the skull and no cannula passes into the brain will occur.
215148664|NCT04119414|BEHAVIORAL|Spear and Shield (S&S) Program|The S\&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
215148665|NCT04119414|BEHAVIORAL|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
215148666|NCT01135173|BEHAVIORAL|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
215148667|NCT05915910|DIAGNOSTIC_TEST|Specimen Donation|blood donation
215148668|NCT00434291|DRUG|TG-873870(Nemonoxacin)|
215148669|NCT05862077|DEVICE|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
215148670|NCT05862077|BEHAVIORAL|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
215148671|NCT05862077|BEHAVIORAL|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
215148672|NCT05862077|DEVICE|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
215148673|NCT05323227|DIAGNOSTIC_TEST|Coronary CTA|Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
215148674|NCT02354898|DRUG|BBI503|
215148675|NCT02354898|DRUG|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
215148676|NCT00035243|DRUG|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
214461659|NCT04735653|BEHAVIORAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
214461660|NCT04735653|BEHAVIORAL|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
214461661|NCT03810807|DRUG|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
214461662|NCT03810807|DRUG|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
214461663|NCT06807931|OTHER|Interactive film|An interactive film, co-produced with young people, that aims to provide young people with a virtual experience of making choices and facing consequences in various life scenarios. At key moments the action is paused and the user decides the outcome. The particular film series that was commissioned and included in the trial was 'Jessica's story', which focused on perinatal mental health, as well as many other public health issues relevant to young people, including mental wellbeing, domestic violence, and help-seeking behaviour.
214461664|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
214461665|NCT04638946|BEHAVIORAL|Titration to high intensity exercise (T-HIE)|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate \[220-age\] - resting heart rate)\*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.
214461666|NCT04638946|BEHAVIORAL|Low intensity exercise prescription|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate \[220-age\] - resting heart rate)\*30-39% (lower/upper limit of zone) - resting heart rate.
214461667|NCT06803186|DEVICE|High-power laser therapy|"High power laser therapy (HPLT) with a neodymium-yttrium aluminum garnet laser with a pulsating waveform produced by a ( Hilterapia device , ASA, Arcugnano, Vicenza, Italy). It will be set at the following parameters: Nd:YAG laser with pulsed emission (1064 nm), very high peak powers with average power 6 W, high levels of fluency (760 mJ/cm energy density), short pulse duration (250 μs), low frequency (10-40 Hz), and 5-cm probe diameter for 15 minutes.~The scanning will be performed longitudinally \&transversely from the C3 to C7 posterior neck in the paraspinal region, upper back, inter-scapular area, trapezius, sternocleidomastoid muscles, and posterior \& lateral shoulder areas"
214695604|NCT01994226|DRUG|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
214695605|NCT01994226|DRUG|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
215148677|NCT02134496|PROCEDURE|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
215148678|NCT02431637|BIOLOGICAL|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
215148679|NCT02431637|DRUG|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
215148680|NCT01455701|DRUG|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
215148681|NCT03327662|OTHER|Active CTC Assessment|CTC Counts used to guide treatment switch
215148682|NCT01167504|OTHER|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
215148683|NCT00651690|BIOLOGICAL|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
215148684|NCT00651690|BIOLOGICAL|Placebo|Saline injection on Day 0
214461668|NCT06803186|DEVICE|Placebo (PL) high power laser|laser probe scanning will be applied to the same areas as that applied in the HPLT procedure. PL will be applied while the lights of the device will be on, with no current flowing through the device. Placebo therapy will be applied at the same frequency as HPLT (Three sessions a week for six weeks for a total of 18 sessions; one session will be lasted 15 minutes).
214461669|NCT06803186|OTHER|Conventional physical therapy program|A specific program of 45-min exercise of three sessions a week for six weeks for a total of 18 sessions. Corrective exercises will be performed initially by stretching exercises for(suboccipital, upper trapezeius, scalene, levator scapulae, sternocleidomastoid, pectoralis major/minor muscles) will be given four repetitions with 30 second hold. each with 3 seconds rest between each stretch Then, strengthening exercises will be performed initially in an isometric manner for weak muscles (deep cervical flexors, rhomboidus, and lower trapezeius muscles) will be done initially without weight and afterward by using Theraband and dumbells. All patients will be instructed to achieve three sets of 12 repetitions of the strengthening exercises (isometrics exercises) with 1 to 2 minutes rest in between each set. Contraction will be held for 5 seconds/repetitions. 10-20 repetitions for strengthening exercises and 3 sets of 30 repetitions for endurance exercise
215148685|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
214461670|NCT06807125|PROCEDURE|Resin matrix ceramic block|Milled resin composite block for fabrication of permanent, indirect restorations using a CAD/CAM grinding process. shock absorbing affect due to the dentin- like modulus of elasticity makes BRILLIANT Crios will suited or indirect restoration.
214461671|NCT03371381|BIOLOGICAL|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
214461672|NCT03371381|DRUG|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
214461673|NCT05971147|DIETARY_SUPPLEMENT|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
214461674|NCT06465524|DEVICE|High-intensity laser therapy|High-intensity laser therapy (HILT), also referred to as Class IV laser therapy, involves the administration of collimated and monochromatic electromagnetic radiation within the infrared or red spectrum. It operates at power levels exceeding 500 milliwatts (0.5 W), leveraging both photobiomodulation and thermal effects. This distinguishes HILT from Class III lasers (low-level laser therapy, or LLLT), which lack photothermal effects when operating below 500 mW.
214461675|NCT06589518|DRUG|Tenofovir Alafenamide Citrate|Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
214461676|NCT05561478|DEVICE|Implantation of Synthesis Plus IOL (control device)|Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.
214461677|NCT05561478|DEVICE|Implantation of Synthesis Plus Toric IOL (investigational device)|Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
214461678|NCT06276205|DRUG|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
214461679|NCT06276205|DRUG|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
214461680|NCT02979327|DRUG|Adderall capsule|25 mg orally one time
214461681|NCT02979327|DRUG|Placebo capsule|Looks exactly like the study drug, but it contains no active ingredient. Taken one time.
214461682|NCT04841434|DRUG|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
215148686|NCT04833218|DRUG|Propranolol|Test of catecholamines level in moderate traumatic brain injury
214461683|NCT05465629|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214461684|NCT05465629|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
214461685|NCT06129188|DRUG|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
215148687|NCT05765578|BIOLOGICAL|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
215148688|NCT05765578|BIOLOGICAL|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
215148689|NCT05765578|BIOLOGICAL|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
215148690|NCT05765578|BIOLOGICAL|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
215148691|NCT05765578|BIOLOGICAL|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
215148692|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
215148693|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
215148694|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
215148695|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
215148696|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
215148697|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
215148698|NCT05610345|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
214695606|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
214708712|NCT03865511|GENETIC|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations"
215148699|NCT05610345|PROCEDURE|Placenta Blood Not Drained|Placenta Blood Not Drained
215148700|NCT03964831|DEVICE|P200TxE|The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
214461686|NCT06129188|DRUG|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
214461687|NCT06803719|OTHER|Observations on main concerns and attracting factors when choosing the surgical approach for thyroid disease|Size of incision, cost, operation duration, postoperative recovery, postoperative hospitalization, absence of the anterior incision
214461688|NCT06104384|BEHAVIORAL|Behavioral and supportive therapy|Behavioral and supportive therapy
214461689|NCT05775965|DRUG|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
214461690|NCT05775965|DRUG|acetylsalicylic acid (ASA) 81mg Oral Tablet|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
214461691|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
214461692|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
214461693|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
214461694|NCT05559983|OTHER|Placebo Cohort A|Sterile 0.9% sodium chloride
214461695|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
214461696|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
214461697|NCT05559983|OTHER|Placebo Cohort B|Sterile 0.9% sodium chloride
214461698|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
214461699|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
214461700|NCT05559983|OTHER|Placebo Cohort C|Sterile 0.9% sodium chloride
214461701|NCT02014675|DEVICE|SD01 ICD lead|
214461702|NCT03069924|BEHAVIORAL|Gain-framed messaging|Gain-framed messaging materials
214461703|NCT03069924|COMBINATION_PRODUCT|Unframed messaging materials|Unframed smoking cessation materials
214461704|NCT05030545|DRUG|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
214461705|NCT04098263|BIOLOGICAL|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
214461706|NCT05961982|PROCEDURE|Chemical Ablation|Undergo EUS-guided chemoablation
214461707|NCT05961982|PROCEDURE|Computed Tomography|Undergo CT
215148701|NCT03964831|DEVICE|P200DTx|The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
215148702|NCT06234761|DRUG|Dupilumab|Patient who start to take dupilumab will be followed. This study is only observational
215148703|NCT05826938|DEVICE|Virtual reality technology|Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
215148704|NCT03646097|PROCEDURE|Angio-PCI|PCI only with angiography and without OCT findings
215148705|NCT03646097|PROCEDURE|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
214708713|NCT02849249|BIOLOGICAL|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
214708714|NCT05710965|DEVICE|FRx-001|Wearable digital therapy
215148706|NCT03646097|PROCEDURE|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
215148707|NCT04057417|OTHER|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
215148708|NCT00308490|DRUG|iron sucrose|
215148709|NCT00633113|PROCEDURE|MPPA|\- Medial Parapatellar Arthrotomy
215148710|NCT00633113|PROCEDURE|SV|\- Subvastus Technique
215148711|NCT04516447|DRUG|ZN-c3|Investigational drug
215148712|NCT04516447|DRUG|Carboplatin|Carboplatin is an approved drug
215148713|NCT04516447|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
215148714|NCT04516447|DRUG|Paclitaxel|Paclitaxel is an approved drug
215148715|NCT04516447|DRUG|Gemcitabine|Gemcitabine is an approved drug
214461708|NCT05961982|OTHER|Electronic Health Record Review|Ancillary studies
214461709|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
214461710|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
214461711|NCT05961982|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
214461712|NCT05961982|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/MRCP
214461713|NCT04305548|DRUG|Trabectedin|Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
214461714|NCT06480864|DRUG|Adebrelimab Injection|Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
214461715|NCT06480864|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
214461716|NCT06480864|DRUG|Carboplatin|Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
214461717|NCT06480864|DRUG|Cisplatin|Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
214461718|NCT06480864|DRUG|Etoposide|Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
214461719|NCT01539083|DRUG|Thalidomide|Thalidomide 100 mg tablet, orally.
214461720|NCT01539083|DRUG|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
214461721|NCT01539083|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 orally.
214461722|NCT01539083|DRUG|Dexamethasone|Dexamethasone 20 mg orally.
214461723|NCT01539083|DRUG|Prednisolone|Prednisolone 50 mg orally.
214461724|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
214708715|NCT05710965|DEVICE|FRx-003|Wearable digital therapy
214708716|NCT05710965|DEVICE|FRx-004|Wearable digital therapy
214708717|NCT03678584|OTHER|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
215148716|NCT04516447|BIOLOGICAL|Bevacizumab|Combined with azenosertib
215148717|NCT06046118|DEVICE|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~* 1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~* 2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
215148718|NCT06046118|DEVICE|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
215148719|NCT00397501|BIOLOGICAL|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
215148720|NCT00397501|DRUG|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
215148721|NCT00397501|DRUG|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
215148722|NCT00397501|DRUG|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
215148723|NCT05720312|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
215148724|NCT00630838|DRUG|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
215148725|NCT00630838|DRUG|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
215148726|NCT00222300|BEHAVIORAL|Strength training program|
215148727|NCT05488041|PROCEDURE|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, … AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
215148728|NCT02885701|OTHER|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.
215148729|NCT02885701|OTHER|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
215148730|NCT02885701|OTHER|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
215148731|NCT02689037|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
215148732|NCT02689037|DRUG|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
215148733|NCT00670748|BIOLOGICAL|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
215148734|NCT00670748|DRUG|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
215148735|NCT00670748|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
214461725|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
214461726|NCT06401512|BEHAVIORAL|Guided self-determination (GSD) follow-up approach by primary care nurses.|The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
214461727|NCT06802744|DEVICE|Addition of an artificial air-pocket device during simulated avalanche burial|In contrast to the control group, the subjects in this arm are provided with a functioning device that directs the exhaled air away from the area of the respiratory cavity.
214461728|NCT06802744|DEVICE|Addition of a non-functioning artificial air-pocket device during simulated avalanche burial|In contrast to the intervention arm, the subjects in this arm are provided with a non-functioning artificial air-pocket device which does not redirect the exhaled air away from the breathing-cavity.
214461729|NCT06803706|BEHAVIORAL|6-weeks CBT smoking cessation programme|Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.
215148736|NCT00670748|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
215148737|NCT00670748|BIOLOGICAL|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
215148738|NCT01424072|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
215148739|NCT01424072|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
215148740|NCT04633265|DEVICE|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
215148741|NCT05599893|OTHER|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
215148742|NCT05599893|OTHER|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
214461730|NCT06803706|BEHAVIORAL|Long-term drug therapy within a therapeutic community|The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.
214461731|NCT06803472|DEVICE|pulsed high intensity laser therapy|The high-intensity laser therapy (HILT), which involves laser radiation with high-intensity, is a kind of novel and powerful . The HILT possesses its own photomechanical, photothermal, and the photo-chemical properties.
214461732|NCT06803472|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy is an acoustic wave that mechanically disrupts tissue by cavitation.Shock waves develop microscopic injuries in scar tissue and break down collagen fibers which lead to scar remodelin .The patient is positioned in a comfortable position. The scar site is prepared with contact gel to conduct the shock waves, 30-50 shocks/cm2 , with an energy flux density of 0.25mJ/mm2 and a frequency of 6Hz. Each treatment region is covered with 2500 to 3000 impulses with an average session time of 10-15min .
214461733|NCT05254262|PROCEDURE|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
214461734|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
214461735|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
214461736|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
214461737|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
214461738|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
214461739|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
214461740|NCT06800664|BEHAVIORAL|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
214461741|NCT06800664|BEHAVIORAL|Control Group|Providers in the control group will not receive ISS support
214461742|NCT05139121|DRUG|MR-100A-01|Transdermal contraceptive delivery system
214461743|NCT06800521|BEHAVIORAL|Mixed Reality Breastfeeding Education|"Mixed Reality Breastfeeding Education:~This intervention includes an innovative mixed reality-based educational strategy combined with traditional breastfeeding counseling. Participants use mixed reality goggles to experience immersive breastfeeding scenarios, interact with audio-visual materials tailored for breastfeeding education, and engage with realistic breastfeeding simulations. The session is delivered once during the third trimester of pregnancy and lasts approximately 90 minutes. This intervention is designed to improve maternal confidence, satisfaction, and adherence to exclusive breastfeeding through an engaging and practical learning environment."
214461744|NCT06800521|BEHAVIORAL|Traditional Breastfeeding Counseling|This intervention involves standard prenatal breastfeeding education provided by trained healthcare professionals. Participants receive verbal and visual explanations of breastfeeding techniques, benefits, and solutions to common challenges. Delivered in a single session during the third trimester of pregnancy, the session lasts approximately 60 minutes and represents the current standard of care in breastfeeding education.
214708718|NCT00966069|OTHER|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
215148743|NCT04940585|OTHER|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
215148744|NCT06515912|OTHER|Ketogenic Diet|A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
214461745|NCT06802770|DIAGNOSTIC_TEST|Anxiety, Depression levels|Parents of children with spina bifida will be filled out symptom scores regarding depression and anxiety levels.
214461746|NCT05176509|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
214461747|NCT05176509|DRUG|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
214461748|NCT05176509|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
214461749|NCT06759805|OTHER|eCardiacRehab|Interdisciplinary supervised home-based digital secondary prevention programme (12-week programme) based on the European Society of Cardiology guidelines for cardiac rehabilitation for patients after percutaneous coronary intervention.
214461750|NCT04105777|DEVICE|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
214461751|NCT04105777|DEVICE|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
214461752|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
214461753|NCT06042309|OTHER|SLS|Exposure to SLS on a randomized arm
214461754|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
214461755|NCT06042309|OTHER|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
214461756|NCT06802107|BEHAVIORAL|Backward-treadmill Walking|A backward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
214531523|NCT04338230|OTHER|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
214531524|NCT01699698|OTHER|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
214531525|NCT00485706|PROCEDURE|high calcium dialysate|
215148745|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in first stage|Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
215148746|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in second stage|Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
215148747|NCT04377659|DRUG|Tocilizumab|Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
215148748|NCT06651619|OTHER|Water|Prescribed amount of bottled water the evening prior and 2 hours prior to team practice
215148749|NCT06651619|OTHER|Hydration Education|30-60 minutes
215148750|NCT06653361|PROCEDURE|Green laser|Green Laser
215148751|NCT06978946|PROCEDURE|Deep Cervical Lymphaticovenous Anastomosis(DLVA)|This surgery will enhance the drainage of cerebral lymphatic fluid by surgically establishing a connection between lymphatic vessels and veins in the neck
215148752|NCT04475146|OTHER|video vizualisation|video vizualisation
215148753|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
214531526|NCT03837236|OTHER|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
214531527|NCT02106364|DRUG|Insulin Peglispro|Administered SQ
214531528|NCT02106364|DRUG|Insulin Glargine|Administered SQ
215148754|NCT06655350|OTHER|MRI|Morphological data on the tendon (appearance) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
215148755|NCT06655350|OTHER|Measure|Morphological data on the tendon (diameter) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
215148756|NCT06654154|DIAGNOSTIC_TEST|variation of serum level vitamine B12|"There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture"
215148757|NCT06588569|DEVICE|Multi-mode tumor treatment system|The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.
215148758|NCT06588569|DEVICE|Radiofrequency ablation therapeutic apparatus|The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.
215148759|NCT06586034|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for both English and Spanish languages and is culturally tailored for Hispanic/Latino/Latinx individuals who smoke. Impacto will be developed for both iOS and Android platforms. The mobile app aims to aid smoking cessation by targeting elevated anxiety sensitivity.
214461757|NCT06802107|BEHAVIORAL|Forward-treadmill Walking|A forward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
214461758|NCT06802107|OTHER|Traditional physiotherapy|"Traditional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.~To be done 3 times a week / 8 weeks. 20 min hotpack + 7 min ultrasound + 20 min TENS and knee osteoarthritis exercises (hip knee flexion extension, knee extension while sitting on a chair, quadriceps isometric exercise in the supine position, straight leg raise exercises) are planned to be applied in the clinic with the physiotherapist. The exercises are planned to be started with 5 repetitions in the first week and the intensity of the exercise is planned to be increased with 10 repetitions, 15 repetitions and 20 repetitions depending on the patient's tolerance."
214461759|NCT06045663|PROCEDURE|laminectomy without lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
214461760|NCT06045663|PROCEDURE|laminectomy with lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
214461761|NCT05549349|PROCEDURE|Cholecystectomy|Gallbladder removal
214461762|NCT06803953|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
214461763|NCT06803953|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
214461764|NCT06803953|DIAGNOSTIC_TEST|Nasal Allergen Challenge|nasal allergen challenge with either house dust mite allergens or birch pollen allergens
214461765|NCT02318654|OTHER|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
214461766|NCT02318654|DRUG|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
214461767|NCT05499377|DEVICE|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
214461768|NCT05347667|OTHER|Unilateral Resistance Exercise Leg|One leg will perform unilateral resistance exercise
214461769|NCT05347667|OTHER|Control Leg|One leg will serve as a non-exercise control
214461770|NCT06802133|OTHER|Post Market Study|Prospective case series without a concurrent comparator group.
214531529|NCT00599833|BIOLOGICAL|cetuximab|
214531530|NCT00599833|RADIATION|3-dimensional conformal radiation therapy|
215148760|NCT06594458|PROCEDURE|Observation of newborn with respiratory distress in the delivery room|Newborn manifesting tachypnea or respiratory distress at birth (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians. A clinical evaluation will be carried out every 15 minutes, with the detection of vital parameters. In case of clinical improvement and suspension of oxygen therapy, the newborn will be transferred to the Neonatal Observation Ward to perform multiparameter monitoring of vital signs up to 6 hours of life and then be reunited with the mother. In case of clinical worsening, a bedside thoracic ultrasound will be carried out and depending on the result and the lung ultrasonography score, it will be evaluated whether to continue the observation in the delivery room or to admit the newborn in the Neonatal Care, Neonatal Sub-Intensive Care or Neonatal Intensive care Units
215148761|NCT06600984|DEVICE|whole body vibration|On a vibration platform, the children went into a complete squat. The device was calibrated at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 minutes. After the vibration was turned on, the children were told to stay in the squatting position and to report any discomfort that could occur. The vibration automatically shut off after five minutes. The children then rested for a minute. Next, under the identical conditions as for the squatting position, they were instructed to stand on the vibration platform for five minutes with the therapist\&#39;s assistance. Consequently, WBV was applied for a total of 10 minutes during each session.
215148762|NCT06600984|OTHER|designed physiotherapy program|structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.
215148763|NCT06589336|OTHER|Dietary changes via Instacart vouchers|Instacart will provide consumers with the dignity of choice to shop at preferred retail stores, which is key for our behavioral change strategy. Delivery and service fees will be waived for patients, so 100% of the vouchers will be applied to groceries (all food products excluding alcohol and tobacco). The investigators will use a custom study store front with an integrated website and email option.
215148764|NCT06589336|OTHER|Dietary changes via access to Mid-Ohio Farmacy|Mid-Ohio Farmacy will provide healthy food provisions through a network of food banks with fresh produce and other items.
215148765|NCT06589336|OTHER|Behavior changes via access to Health Impact Ohio Hub|Health Impact Ohio Hub is a regional coordination entity that has connections with community care agencies that employ community health workers to assess social needs and make connections to resources to address social needs. The community health workers will conduct an initial needs assessment, and guide the participant through appropriate care pathways to address social needs.
215148766|NCT06589336|OTHER|Behavioral nutrition counseling|All dietary recommendations will be individualized and informed by existing guidelines to improve diet quality and cardiovascular health through the Mediterranean Diet.
215148767|NCT06589336|OTHER|Cooking classes|Registered dietician nutritionists will also lead cooking demonstrations every 2 weeks, focused on culinary education and building engagement among SUSTAIN participants.
215148768|NCT06589336|OTHER|Dietary changes to Delivery fees|Delivery fees will be supported for SUSTAIN participants.
215148769|NCT06599398|OTHER|Jeroen Pit Huis|The JPH is a unique and innovative Transitional Care Unit (TCU) situated in close proximity of the AUMC. In this TCU, patients and their family reside in separate private home-like apartments. The families can stay while practising in, and adapting to, their new reality until they are ready to transition home. A multidisciplinary team of healthcare experts (nurses, psychosocial care workers, family counsellors, and paediatricians) are gradually guiding parents towards taking on the role of their child's primary caregiver. This process is guided by a newly developed seven phase care path.One condition for staying in the JPH is that one parent is always present. In this form (24/7 parental stay and nursing care directly available under the supervision of pediatricians) the JPH is unique in the Netherlands.
214531531|NCT00197119|BIOLOGICAL|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
214531532|NCT00197119|BIOLOGICAL|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
215148770|NCT06603584|RADIATION|Chest x- Rays|prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
215148771|NCT06589323|PROCEDURE|Coronary artery bypass graft|All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
215148772|NCT06587672|DEVICE|Micra AV implantation|Patients received Micra AV implantation
215148773|NCT06603389|OTHER|Psychiatric Non-Suicidal Self-Injury Risk Assessment Scale|sacles or questionnaires
215148774|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 3 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
215148775|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 5 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
215148776|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 7 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
215148777|NCT06591416|PROCEDURE|minimally invasive surgical technique|minimally invasive surgical technique
214461771|NCT04034706|OTHER|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
214461772|NCT04034706|OTHER|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
214461773|NCT04034706|OTHER|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
214461774|NCT04034706|PROCEDURE|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
214461775|NCT04034706|OTHER|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
214461776|NCT04279236|OTHER|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
214461777|NCT04279236|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
214461778|NCT04279236|OTHER|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
214461779|NCT04439019|OTHER|Lifestyle and dietary modification program|"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown."
214461780|NCT05944016|DRUG|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
214461781|NCT05944016|DRUG|Placebo|Placebo (standard dose p.o. once daily)
214461782|NCT02573493|DRUG|nab-Paclitaxel|
214461783|NCT02573493|DRUG|Cisplatin|
214461784|NCT02573493|BIOLOGICAL|Cetuximab|
214461785|NCT02573493|RADIATION|Intensity-Modulated Radiation Therapy|
214461786|NCT06425133|PROCEDURE|Blood sample|Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection
214461787|NCT06425133|OTHER|Quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
214461788|NCT06425133|PROCEDURE|Biopsy|Fresh tumor biopsy at baseline and week 8
214461789|NCT06425133|DRUG|Regorafenib|"For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
214531533|NCT02151643|DRUG|PT20|Modified ferric oxide adipate tablets
214531534|NCT02151643|DRUG|Placebo|Placebo tablets matched to each PT20 dose arm
214531535|NCT00383903|BIOLOGICAL|HRV vaccine|Two or three oral doses
214531536|NCT03619889|OTHER|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
214531537|NCT03619889|OTHER|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
215148778|NCT06591416|PROCEDURE|minimally invasive surgical technique with granulation tissue preservation|minimally invasive surgical technique with granulation tissue preservation
215148779|NCT06595771|DEVICE|continuous positive airway pressure|continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
215148780|NCT06595771|DEVICE|Polysomnography|"Polysomnography measures Apnea-hypopnea index (Minutes)~Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):~1. Apnea-hypopnea index: 5-14.9 olan; mild OSAS~2. Apnea-hypopnea index: 15-29.9: moderate OSAS~3. Apnea-hypopnea index ≥30: severe OSAS measures duration and percentage of time oxygen saturation dropped below 90% the total minutes of sleep"
215148781|NCT06587828|PROCEDURE|Companion blood samples with procedure|Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.
215148782|NCT06603545|OTHER|Digital education for osteoporosis patients|DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
215148783|NCT06588023|OTHER|Observational study to evaluate professional practices|"It consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.~The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight)."
215148784|NCT06598969|DRUG|Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide|Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
215148785|NCT06599892|OTHER|Intervention mapping|Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
214461790|NCT06425133|COMBINATION_PRODUCT|Regorafenib + metronomic chemotherapy|"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression."
214461791|NCT06494436|DEVICE|All Microvention Class III implantable device CE marked|Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
214461792|NCT06143917|BEHAVIORAL|parent-child sleep intervention|The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
214461793|NCT03629678|OTHER|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
214461794|NCT04530799|OTHER|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
214461795|NCT05743049|OTHER|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
214461796|NCT05707975|OTHER|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
214461797|NCT05937438|DRUG|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
215148786|NCT06591325|OTHER|exercise|The RT program was performed in the morning and in groups, three days per week (Mondays, Wednesdays, and Fridays), in the University fitness facility over 12 weeks. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise session) with substantial RT experience to ensure consistent and safe exercise performance. Throughout the intervention period, the RT program was carried out on machines and free weights (Ipiranga Fitness, Presidente Prudente, SP, Brazil). The training program was carried out in groups. Participants performed four exercises for the trunk and upper limbs (chest press, seated row, triceps pushdown, preacher curl) and four exercises for the lower limbs (horizontal leg press, leg extension, lying leg curl, seated calf raise) in three sets of 10-15 repetitions based on previous guidelines (9,22).
215148787|NCT06591325|OTHER|Control|maintaining the daily routine
215148788|NCT06586632|DEVICE|AID technology|Automated insulin delivery system combined with a CGM
215148789|NCT06586632|DEVICE|CGM|CGM alone
215148790|NCT06595524|BEHAVIORAL|online mindfulness-based intervention|The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
215148791|NCT06588309|BEHAVIORAL|Eye movement desensitization and reprocessing (EMDR)|Integrated addiction and traumafocused treatment.
215148792|NCT06588309|BEHAVIORAL|CRA|CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.
215148793|NCT06600828|OTHER|Data collection|Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
215148794|NCT06588985|BEHAVIORAL|Emotion Coaching Parent Training Workshop|Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.
215148795|NCT06588985|BEHAVIORAL|Waitlist Control|Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
215148796|NCT06595797|DRUG|HRS9531|HRS9531
215148797|NCT06595797|DRUG|HRS9531placebo|HRS9531placebo
215148798|NCT06600893|DEVICE|Low intensity shockwave therapy (LiSWT)|The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment
215148799|NCT06600893|DEVICE|Sham|With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.
214461798|NCT03556839|DRUG|Atezolizumab|Intravenous Infusion
214461799|NCT03556839|DRUG|Bevacizumab|Intravenous Infusion
214461800|NCT03556839|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
214461801|NCT03556839|DRUG|Paclitaxel|Intravenous Infusion
214461802|NCT02951325|OTHER|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
215148800|NCT06592456|BIOLOGICAL|Chickenpox Vaccines|The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
215148801|NCT06604351|DRUG|Sintilimab, Nab-Paclitaxel, and Carboplatin|Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
214461803|NCT06621641|BEHAVIORAL|The new HFNC weaning protocol|Patients will be randomly assigned to two groups: one following the new HFNC weaning protocol and another using the standard care protocol. The new protocol includes stepwise flow reduction based on the patient's clinical stability and uses the Respiratory Assessment Scale (RAS) to monitor weaning progress. The protocol emphasizes a multidisciplinary approach involving pediatricians, nurses, and respiratory therapists, with consistent training and application of weaning criteria
214461804|NCT01251406|DRUG|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
214461805|NCT01251406|DRUG|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
214461806|NCT01251406|DRUG|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
214461807|NCT06324071|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
214531538|NCT01179412|DRUG|2% povidone-iodine|apply 4 times a day for one week
214531539|NCT01179412|DRUG|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
215148802|NCT02581241|DEVICE|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
215148803|NCT06090422|DRUG|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
214531540|NCT02968823|OTHER|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
215148804|NCT06090422|DRUG|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
215148805|NCT05427422|DIAGNOSTIC_TEST|MRI recording|MRI imaging was performed using a 3 Tesla Siemens Prisma system with a 64-channel head/neck coil (Siemens Medical Systems, Erlangen, Germany). The MRI protocols included as follows: (i) Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes: TR/TE/ TI1/TI2 = 5000/2.98/700/2500 ms, voxel size = 1.0 × 1.0 × 1.0 mm3, FOV = 256 × 240 × 176 mm3; (ii)Gradient-echo EPI: TR 720 ms, TE 33.1 ms, flip angle 52 deg, FOV 208x180 mm, Matrix 104x90, Slice thickness 2.0 mm; 72 slices; 2.0 mm isotropic voxels, Multiband factor 8, Echo spacing 0.58 ms, BW 2290 Hz/Px; (iii) DSI : TR/TE = 3300/73 ms, FOV = 220 × 220 × 60 mm3, voxel size = 2 × 2 × 2 mm3, 128 diffusion direction, b-max = 3000 sec/mm2, AT = 7:22 min); (iv) T2-weighted fluid-attenuated inversion recovery: TR/TE = 9000/84 ms, FOV = 270 × 320 × 22 mm2, voxel size = 0.72 × 0.72 × 6.6 mm3.
215148806|NCT05427422|DIAGNOSTIC_TEST|EEG recording|"EEG was performed using a BrainAmp MR 32 amplifier (BrainProducts GmbH, München, Germany). The EEG protocols included as follows: (i) EEG-fMRI fusion: Sampling rate: 5000 Hz, low cut off-high cut off: DC-1000Hz;(2) EEG-fMRI fusion: Sampling rate: 1000 Hz, low cut off-high cut off: DC-1000Hz.~In (i) an ECG channel would be used to collect artifact of pulse and not used in (ii)."
215148807|NCT03123731|BEHAVIORAL|Control Arm|Wearing Physical Activity Monitor
215148808|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity Intervention
215148809|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity and Diet Intervention
215148810|NCT05848752|BEHAVIORAL|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
215148811|NCT06053671|GENETIC|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
215148812|NCT01704716|DRUG|Vincristine|given during Rapid COJEC and modified N7 therapy
214531541|NCT02968823|OTHER|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
214531542|NCT06096376|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
214531543|NCT00791102|DRUG|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
214531544|NCT00791102|DRUG|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
215148813|NCT01704716|DRUG|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
215148814|NCT01704716|DRUG|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
215148815|NCT01704716|DRUG|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
214531545|NCT01878136|DRUG|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
214695607|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
214695608|NCT04209647|OTHER|REHIT Exercise|"-Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
215148816|NCT01704716|DRUG|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
214531546|NCT01742234|PROCEDURE|Organ Donation|People in this study will donate either a lung or kidney
214531547|NCT01187147|DIETARY_SUPPLEMENT|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
215148817|NCT01704716|DRUG|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
215148818|NCT01704716|DRUG|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
215148819|NCT01704716|DRUG|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
215148820|NCT01704716|DRUG|G-CSF|G-CSF is given during Induction Treatment
215148821|NCT01704716|DRUG|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
215148822|NCT01704716|DRUG|Melphalan|Melphalan is given during MAT treatment
215148823|NCT05304195|DIAGNOSTIC_TEST|Glucocerebrosidase|Blood sample (10ml) for GCase activity
215148824|NCT05304195|GENETIC|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
214461808|NCT06324071|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
214461809|NCT05337163|DIAGNOSTIC_TEST|Diagnostic Test: Sputum DNA methylation analysis|Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
214461810|NCT05337163|PROCEDURE|chest CT or pathological examination|Subjects will undergo chest CT or pathological examination.
214461811|NCT01496313|DRUG|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
214461812|NCT01496313|DRUG|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
214461813|NCT05507099|BIOLOGICAL|Bone Marrow Aspirate, Lipoaspirate Concentrate|Autologous Cell Therapy.
214461814|NCT05562752|DIETARY_SUPPLEMENT|Probiotic|multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.
214461815|NCT05562752|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 12 weeks.
214461816|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
214461817|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
214461818|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
214461819|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
214461820|NCT06415773|DRUG|HTD1801|HTD1801 1000 mg BID administered orally BID as four capsules
214461821|NCT06415773|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablet administered orally QD
214461822|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
214461823|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
214531548|NCT01084239|RADIATION|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
214461824|NCT05714761|DEVICE|Dexcom glucose sensor|Use of a Dexcom G6 Pro
214461825|NCT02882425|DRUG|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
214461826|NCT02882425|DRUG|Selexipag for oral use|Tablet containing 200 µg of selexipag
214531549|NCT01872156|OTHER|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
215148825|NCT05304195|DIAGNOSTIC_TEST|Macrophage biomarkers|Blood sample (20ml) for macrophage biomarkers
215148826|NCT06992531|OTHER|Questionnaire and Physical Exam|Standardised participant questionnaires assessing neurological symptoms, including pain (NPSI, DN4, BPI), fatigue (Fatigue Severity Scale), depression and anxiety (PHQ9 and GAD7) and autonomic dysfunction (Malmo PoTS Score and COMPASS-31).
215148827|NCT06992531|DIAGNOSTIC_TEST|Nerve conduction studies|Measures how fast an electrical impulse moves through sensory and motor nerves. The test will be used to identify/rule out large fibre peripheral neuropathy.
215148828|NCT06992531|DIAGNOSTIC_TEST|Microneurography|Electrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction.
215148829|NCT06992531|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Measures psychophysical sensory perception in response to different types of stimuli, such as thermal, mechanical, pressure and vibration. The test will be used to identify/rule out nerve fibre dysfunction, by generating a quantitative sensory profile of different sensory modalities.
215148830|NCT06992531|DIAGNOSTIC_TEST|Skin biopsy|Safe and minimally invasive procedure to quantify intraepidermal nerve fibres density (IENFD). Reduced IENF density is associated with small fibre neuropathy.
214531550|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
215148831|NCT06992531|BIOLOGICAL|Blood Product|A blood sample of a maximum of 120ml will be collected from a superficial upper limb vein. Blood aliquots (50ml tubes) will then be centrifuged to separate serum from the peripheral blood cells.
215148832|NCT06992986|OTHER|Investigating differences in the bladder microbiome|"Urine samples and tissue from radical cystectomy specimens will be analyzed for the assessment of the urinary microbiome.~The 16s rRNA gene will be amplified and the resulting amplicons analyzed by Illumina sequencing. To distinguish contaminants, DNA from the sample will be quantified by qPCR and compared to a known urine sample of E. coli. DNA will be extracted using the Quiagen kit and stored at -20 °C until PCR amplification. Bacterial DNA will be amplified with specific primers covering the V1-V3 hypervariable region of the 16S rRNA gene. Libraries will be prepared using the Illumina 16S microbiome sequencing protocol, and their quality will be verified by Bioanalyzer and quantity by qPCR. Sequencing will be performed in paired-end mode on Illumina sequencers. Alpha, beta diversity and species richness will be measured."
215148833|NCT05056415|OTHER|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
215148834|NCT05056415|OTHER|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
215148835|NCT04922216|BEHAVIORAL|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
215148836|NCT04922216|BEHAVIORAL|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
215148837|NCT04922216|BEHAVIORAL|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
215148838|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
215148839|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
215148840|NCT04922216|BEHAVIORAL|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
215148841|NCT04922216|BEHAVIORAL|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
215148842|NCT04922216|BEHAVIORAL|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
215148843|NCT04922216|BEHAVIORAL|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
215148844|NCT04922216|BEHAVIORAL|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
215148845|NCT04922216|BEHAVIORAL|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
215148846|NCT06603701|DIAGNOSTIC_TEST|Bioimpedancemetry|"2\. Bioimpedancemetry at T1, T2, T3 ; the measurement will be~1. Squeletic mass (total and for each of the 4 limbs)~2. Angle phase (total and for each of the 4 limbs)"
215148847|NCT06603701|OTHER|Dynamometry|Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3
215148848|NCT06596681|GENETIC|GA+clozapine|Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
215148849|NCT06589232|OTHER|Food allergy|Threshold dose to pistachio
215148850|NCT06595199|OTHER|Online peer support|A closed online peer support group
215148851|NCT06590545|DRUG|KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy|A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
214531551|NCT04163835|DRUG|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
214695609|NCT04209647|OTHER|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
214531552|NCT04163835|DRUG|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
214531553|NCT04163835|DRUG|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
214531554|NCT04163835|DRUG|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
214531555|NCT01774461|OTHER|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
214695610|NCT03075176|DEVICE|Wavefront optimized LASIK|Wavefront optimized laser vision correction
215148852|NCT06992375|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
215148853|NCT06992375|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
215148854|NCT06992375|OTHER|Exercise|The following exercise will be performed:push-ups
214461827|NCT06488183|PROCEDURE|preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q|preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
214461828|NCT05412381|PROCEDURE|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
214461829|NCT05412381|PROCEDURE|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
214461830|NCT04847843|BEHAVIORAL|Mindfulness Orientated Recovery Enhancement|The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.
214461831|NCT04847843|BEHAVIORAL|Control Intervention|The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
214461832|NCT06350851|BIOLOGICAL|Biological samples collection (blood drawing + feces)|Blood and feces samples will be collected from each volunteer.
214461833|NCT06533566|PROCEDURE|Erector spinae plane block|patients will be placed in the lateral decubitus position. The ESP block is usually performed at the level of fourth transvers process. The ultrasound probe should be placed in a cephalo-caudal orientation over the midline of the back at the desired level.Under aseptic conditions, the block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T4 transverse process at erector spinae plane. After hydro-dissection with 2-3 mL of isotonic saline solution to confirm the correct needle tip position and after negative aspiration to prevent intra vascular injection or position, (20 ml) of plain bupivacaine 0.25% will be injected deep to the erector spinae muscle.
214461834|NCT06533566|PROCEDURE|local wound infiltration|after the surgeon complete the surgery and insert the surgical drains (pectoral and axillary drains) we will inject 20ml of plain bupivacaine 0.25% in each surgical drain, the drains will be clamped for 20 minutes then declamped.
214461835|NCT05127187|DIAGNOSTIC_TEST|Rapid diagnosis test against HIV and hepatitis C and B|combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
214461836|NCT04922229|PROCEDURE|RCT|This is the standard of care for this diagnosis
214461837|NCT04922229|PROCEDURE|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
214461838|NCT06532734|DEVICE|EsoGuard|device used to collect esophageal cell samples to test for the presence of abnormal cells which may indicate a dx of Barrett's esophagitis.
214461839|NCT05695924|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
215148855|NCT06614881|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
215148856|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
215148857|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
215148858|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
215148859|NCT06614881|DRUG|Normal saline|loading dose of saline was injected 10-min before induction of anesthesia.
214461840|NCT05695924|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
214461841|NCT05378100|DRUG|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
214461842|NCT05378100|DRUG|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
214531556|NCT02889783|OTHER|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
214531557|NCT05501847|RADIATION|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
214531558|NCT02637258|OTHER|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
215148860|NCT06590155|DRUG|Erythropoietin|the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy
215148861|NCT06598215|PROCEDURE|Duckett urethroplasty|hybrid duckett urethroplasty vs modified duckett urethroplasty
215148862|NCT06588959|OTHER|validity and reliability study|Determination of strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. 6PBRT, which is one of the tests serving this purpose, has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma, but when the literature is reviewed, it is seen that 6PBRT has not been studied in patients with scleroderma. This study was planned as a non-interventional safety study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, the test will be performed 2 times with a 1-hour rest break. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The level of dyspnea and fatigue and baseline values of heart rate will be checked before the second trial to ensure patients are stable. All assessments will be performed by the same physiotherapist.
215148863|NCT06586671|DRUG|Nemtabrutinib|Oral administration
215148864|NCT05156385|BIOLOGICAL|Blood sample for the determination of antihypertensives or their metabolites.|15 ml of Blood sample for the determination of antihypertensives or their metabolites
215148865|NCT05156385|BEHAVIORAL|Questionnaire on sexual activity|Questionnaire on sexual activity in women
215148866|NCT05156385|BEHAVIORAL|Scale on hospital anxiety and depression|Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
215148867|NCT05156385|BEHAVIORAL|Morisky Questionaire|anti-hypertensive medication compliance questionnaire
215148868|NCT06993207|DEVICE|Home Lab|The main goal is to comprehensively assess the cognitive and behavioral status of all participants, regardless of their assigned groups. Validated clinical tests (considered the gold standard) will be used, with measurements taken at participants' homes using a biosignal monitoring kit-the focal tool of the project. Whether in the control or specific groups, all participants will undergo an identical battery of tests in both the laboratory and home settings. The study design includes an introductory session for participants to understand the study's purpose and sign informed consent. Following consent, participants will have three sessions within a 3 to 6-week timeframe: one for autonomous technology use instruction and the other two for cognitive and functional evaluations.
215148869|NCT06991985|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum STN and C4 levels were detected
215148870|NCT06259916|OTHER|Alcohol|Participants in this condition will receive the standard alcohol dose
215148871|NCT06259916|OTHER|Cannabis|Participants in this group will self-administer legal-market flower cannabis
214461843|NCT06233578|DEVICE|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
214461844|NCT05943509|BEHAVIORAL|Alternative rehabilitation strategies|Counseling intervention.
214461845|NCT05943509|BEHAVIORAL|Usual Care|Usual care audiology pathway.
215148872|NCT06405932|COMBINATION_PRODUCT|Mental Fitness Training Camp|The Mental Fitness Training camp employs and incorporates core learning content derived from Cognitive Behavioral Therapy and Mindfulness. The program comprises nine thought animations, emotional diary, daily breathing exercises, and pleasure lists.
215148873|NCT03837041|OTHER|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
214461846|NCT03150173|BEHAVIORAL|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
214461847|NCT03150173|BEHAVIORAL|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
214531559|NCT05221437|OTHER|antibiotic prescription|
214531560|NCT00170417|BEHAVIORAL|Cognitive Behaviour Therapy|
214531561|NCT05019313|DEVICE|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
214461848|NCT03150173|DRUG|Buprenorphine|all participants will receive buprenorphine
214461849|NCT05986916|DIAGNOSTIC_TEST|Liverscope® exam|Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
214695611|NCT03075176|DEVICE|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
214461850|NCT05986916|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
214461851|NCT05986916|DIAGNOSTIC_TEST|FibroScan® exam (optional)|Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.
214461852|NCT05986916|OTHER|Blood draw|Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.
214461853|NCT05986916|OTHER|Body measurements|Participants will have their height, weight, waist circumference, and hip circumference measured.
214531562|NCT02396953|DRUG|Lanreotide PRF|
214531563|NCT05762081|PROCEDURE|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
214531564|NCT05762081|PROCEDURE|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
214695612|NCT03075176|DEVICE|Topography-guided LASIK|Topography-guided laser vision correction
215148874|NCT06590363|OTHER|Listening to zen music|We conducted a quasi-randomized controlled clinical trial with two groups: Intervention Group (I), which corresponded to patients and doctors who underwent the period of musical listening in the office; and the Control Group (C), composed of patients and doctors who did not undergo the period of musical listening.
215148875|NCT06585852|DRUG|RGD|Study group main material
215148876|NCT06585852|DRUG|Xenograft|Scaffold material of choice
215148877|NCT06585852|PROCEDURE|Split crest technique|Piezoelectric surgery
214461854|NCT05986916|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
214461855|NCT06384560|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.
214461856|NCT06384560|DRUG|Folfirinox|FOLFIRINOX is a combination of systemic chemotherapy agents. FOLFIRINOX consists of oxaliplatin at a dose of 85 mg/m2, given as a 2-hour intravenous infusion, immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector. This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks. (The FOLFIRINOX given in the trial is the modified scheme, whereby the fluorouracil bolus at a dose of 400 mg/m2 is omitted and the irinotecan dose reduced to 150 mg/m2).
214461857|NCT06384560|RADIATION|SABR|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on five non-consecutive days.
214461858|NCT06453512|DEVICE|Doublebase Once|Emollient
214461859|NCT04410536|DRUG|Symptomatic drugs|indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
214461860|NCT04410536|DRUG|Bridge therapy|prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
214461861|NCT04410536|BEHAVIORAL|Mindfulness program|home based withdrawal program
214461862|NCT05135390|DRUG|HSK21542|three times per week
214461863|NCT05135390|DRUG|Placebo|three times per week
214461864|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
214461865|NCT06645873|DEVICE|Continuous glucose monitoring (CGM) device|All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
214461866|NCT05418010|DRUG|Tysabri Injectable Product|Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
214461867|NCT05418010|DRUG|Placebo|Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
214461868|NCT05366465|OTHER|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
214461869|NCT05295927|DRUG|EPI-7386|EPI-7386 will be administered orally once daily.
214461870|NCT05295927|DRUG|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
214461871|NCT05295927|DRUG|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
214461872|NCT05295927|DRUG|Apalutamide|Apalutamide will be administered orally once daily.
214531565|NCT05748678|DEVICE|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
214531566|NCT03866980|BIOLOGICAL|AK105|IV infusion
214531567|NCT03866980|DRUG|carboplatin|IV infusion
214695613|NCT03075176|DEVICE|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
214531568|NCT03866980|DRUG|pemetrexed|IV infusion
214531569|NCT03866980|DRUG|placebo|IV infusion
214531570|NCT03866980|DRUG|Anlotinib|PO
214531571|NCT03957408|DEVICE|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
214695614|NCT03217773|PROCEDURE|ESD|Refer to arm description
215148878|NCT06590298|DRUG|Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females|The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
215148879|NCT04819542|DEVICE|Bandage|Bandage
215148880|NCT04819542|DEVICE|No bandage|No bandage
214695615|NCT03217773|PROCEDURE|TAMIS|Refer to arm description
214695616|NCT01929655|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
214695617|NCT01955850|BEHAVIORAL|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
215148881|NCT05485896|DRUG|Pembrolizumab plus Lenvatinib|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
215148882|NCT03941236|DRUG|dasiglucagon|Glucagon analog
215148883|NCT04721977|DRUG|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
215148884|NCT04721977|BIOLOGICAL|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
215148885|NCT04721977|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 administered BID via oral tablet
214461873|NCT06646562|DRUG|Cabotegravir LA + Rilpivirine LA|Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
214461874|NCT06581523|BEHAVIORAL|SKY Breath and Meditation|SKY Breath and Meditation is a unique breath-based technique that uses cyclical, rhythmic patterns of breath to bring the mind and body effortlessly into meditation. It has been empirically validated and holds distinct advantages over other forms of meditation.
214461875|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
214461876|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
214461877|NCT06349837|DRUG|Tislelizumab|Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
214461878|NCT06349837|RADIATION|Low Dose Radiotherapy|LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.
215148886|NCT05790551|DEVICE|Addinex|Medication dispensing system for Suboxone
215148887|NCT03278249|OTHER|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
215148888|NCT06770543|OTHER|Inclisiran|There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.
215148889|NCT06587425|DRUG|LM-302+Candonilimab+Capecitabine|LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
215148890|NCT06594328|BEHAVIORAL|mHealth|participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
214461879|NCT06349837|RADIATION|Stereotactic Ablative Radiotherapy|Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
214461880|NCT04182204|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
215148891|NCT06867588|DIAGNOSTIC_TEST|PSMA PET|patients included in the study will perfom a PSMA PET
215148892|NCT06587724|OTHER|Questionnaire study|Questionnaire application
214461881|NCT04182204|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
214461882|NCT04182204|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
214461883|NCT04182204|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
214461884|NCT03906708|OTHER|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
214461885|NCT05477095|BIOLOGICAL|UB-313|A synthetic peptide-based immunotherapy
214461886|NCT05477095|BIOLOGICAL|Placebo|Normal saline
214461887|NCT04518917|BEHAVIORAL|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
214461888|NCT04518917|BEHAVIORAL|Listening to music|Participants listen to their song and match their footfalls to the beat.
214531572|NCT03911362|BEHAVIORAL|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
214531573|NCT03911362|BEHAVIORAL|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
214531574|NCT05598606|DRUG|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
214531575|NCT05598606|DRUG|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
214531576|NCT03987659|PROCEDURE|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
214531577|NCT03987659|PROCEDURE|Conventional Irrigation protocols|Conventional Irrigation protocols
215148893|NCT06598111|OTHER|Amplified Benefits|Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.
215148894|NCT06598111|OTHER|Amplified Consequences|Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.
215148895|NCT06598111|OTHER|Control|Participants write a brief narrative considering a future free of concern about finances.
215148896|NCT06861504|DEVICE|Femscope Calm Collect Device|The Femscope Calm Collect Device uses a patented brush for cervical cell collection.
214461889|NCT03443128|DRUG|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
214461890|NCT05322031|DRUG|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
214461891|NCT03895359|RADIATION|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
214531578|NCT04933838|DEVICE|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
214531579|NCT05579145|OTHER|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
214695618|NCT03520816|OTHER|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
214695619|NCT00501046|DRUG|Placebo|9g /day (3 times a day)
214461892|NCT03895359|DRUG|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
214461893|NCT02191618|DEVICE|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
214695620|NCT00501046|DRUG|AST-120|9g /day (3 times a day)
215148897|NCT05130528|BEHAVIORAL|Sensorimotor Intervention|Infants in the experimental group will receive 2 sensorimotor intervention sessions in the Neonatal Intensive Care Unit (NICU) and 8 sensorimotor intervention sessions in the home or in a clinic (parent choice) at 1, 3, 5, 8, 11, 15, 20, 26 weeks post NICU discharge. The 2 intervention sessions in the NICU will consist of collaborating with parents to recognize their infant's cues to engage in interaction, readiness for sensory exposures, and anticipatory guidance on the transition to home. The 8 intervention sessions in the home will focus on supporting the parents to read their infant's cues to identify the ideal times for interaction and provide 20 minutes of daily intervention addressing four key principles: encourage 1) self-initiated movement, 2) movement variability, 3) visual and manual object interaction, and 4) social interaction. Parents are encouraged not to impose movement on the infant but to encourage movement through environmental enrichment
215148898|NCT02938299|DRUG|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
215148899|NCT02938299|PROCEDURE|Surgery|Surgical resection of melanoma tumor lesions
215148900|NCT06638190|OTHER|100% Orange juice|250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
215148901|NCT06638190|OTHER|50% Orange juice|250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
215148902|NCT06638190|OTHER|0% Orange juice|250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
215148903|NCT06638190|OTHER|Glucose|250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
215148904|NCT06638190|OTHER|100% Orange juice Rep|Repetition of the 100% orange juice intervention
215148905|NCT06638190|OTHER|0% Orange juice Rep|Repetition of the 0% orange juice intervention
215148906|NCT06578650|DEVICE|Synthetic Electrospun Fiber Matrix|Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound
215148907|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
215148908|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
215148909|NCT05987930|DEVICE|bone lid technique|group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
215148910|NCT05987930|DEVICE|standard technique|group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
215148911|NCT00755989|OTHER|None available|
215148912|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
215148913|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
214461894|NCT02316002|DRUG|Pembrolizumab|
214461895|NCT05556655|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
214461896|NCT06180902|DIAGNOSTIC_TEST|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'."
214461897|NCT06180902|DIAGNOSTIC_TEST|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP \> 12 mmHg (16.3 cm H2O) indicates a non-responder."
214461898|NCT06180902|DIAGNOSTIC_TEST|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP \> 12 mmHg (16.3 cm H2O)."
214531580|NCT05579145|OTHER|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
214531581|NCT04715503|RADIATION|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
214531582|NCT04715503|RADIATION|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
214531583|NCT02679079|DRUG|NBI-98854|
214531584|NCT02679079|DRUG|Placebo|
214531585|NCT05283525|DIETARY_SUPPLEMENT|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
214531586|NCT05283525|DIETARY_SUPPLEMENT|Oxygen Saturation|0 - 90 Days of Treatment
214531587|NCT05283525|DIETARY_SUPPLEMENT|Total Blood Chemistry|0 and 90 Days of Treatment
215148914|NCT02786394|BEHAVIORAL|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
215148915|NCT02785549|DRUG|Ibuprofen|600 mg/8hours
215148916|NCT02785549|DRUG|Acetaminophen|1 g/8 hours
215148917|NCT02785549|DRUG|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
215148918|NCT05348343|BIOLOGICAL|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
215148919|NCT05784493|OTHER|Study group|Washing by heated saline group
215148920|NCT06834945|BEHAVIORAL|AYA SPARK|Intervention includes video conferencing based sessions to cover topics related to fertility-related information needs and concerns among female adult survivors of childhood cancer over a 6-8 week period.
215148921|NCT04828343|DRUG|rozanolixizumab|Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
215148922|NCT04828343|OTHER|Placebo|Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
214531588|NCT05283525|DIETARY_SUPPLEMENT|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
214531589|NCT05283525|DIETARY_SUPPLEMENT|Body Weight Monitoring|0 - 90 Days of Treatment
214531590|NCT05283525|DIETARY_SUPPLEMENT|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
215148923|NCT01341613|DIETARY_SUPPLEMENT|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
215148924|NCT01341613|DIETARY_SUPPLEMENT|Placebo capsule|Twice per day (BID), 9 weeks
215148925|NCT00538668|DRUG|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
215148926|NCT05150119|DIAGNOSTIC_TEST|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
215148927|NCT01302990|BIOLOGICAL|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
215148928|NCT06094582|OTHER|questionnaire|Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.
215148929|NCT06522100|DRUG|Intravenous administration of Methylprednisolone|Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
215148930|NCT06522100|DRUG|Oral Prednisone|After intravenous administration of Methylprednisolone patients will take by oral Prednisone 1mg/kg per day once a day (with a maximum dose of 90 mg per day for patients weighing \> 90kg) for 1 month, followed with a progressive decrease of 10 mg Prednisone every 15 days until a dose of 10mg per day during 15 days (= stop).
215148931|NCT06522100|DRUG|Perfusion of placebo|Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
215148932|NCT06522100|DRUG|Oral Prednisone placebo|After the perfusion of placebo, patients will take by oral Prednisone placebo once a day for the same duration as that required if the patient was in the investigational medicinal products group (1 month + progressive decrease).
215148933|NCT04147780|PROCEDURE|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
215148934|NCT02506348|DRUG|Diclofenac|
215148935|NCT02506348|DRUG|Nepafenac|
215148936|NCT06022692|DEVICE|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
214531591|NCT03361618|DIETARY_SUPPLEMENT|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
214531592|NCT00304668|DRUG|dapivirine (TMC120) vaginal gel|
214531593|NCT06285227|BIOLOGICAL|CM313 injection|CM313
214531594|NCT00689520|DRUG|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
214531595|NCT00689520|DRUG|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
215148937|NCT06022692|DRUG|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
215148938|NCT04641208|DEVICE|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
215148939|NCT04598802|DEVICE|covered stent|atherosclerotic aorto-iliac aneurysm
215148940|NCT00775190|DRUG|ortho tricyclen|brand name oral contraceptive
215148941|NCT00775190|DRUG|Trinessa|generic oral contraceptive
215148942|NCT00843596|PROCEDURE|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
215148943|NCT05504785|DEVICE|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
215148944|NCT03710200|OTHER|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
215148945|NCT03710200|OTHER|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
215148946|NCT03710200|OTHER|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
215148947|NCT03710200|OTHER|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
215148948|NCT03710200|OTHER|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
215148949|NCT03710200|OTHER|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
215148950|NCT03710200|OTHER|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
215148951|NCT03710200|OTHER|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
215148952|NCT01965678|OTHER|Osteopathic Manipulative Treatment|
215148953|NCT02194478|BEHAVIORAL|Meditation|30 minute, 8 week meditation
215148954|NCT04791163|DEVICE|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
215148955|NCT02476539|DRUG|Hemay022|
215148956|NCT04188561|DRUG|Intra articular injection Group|"Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average."
215148957|NCT04188561|DEVICE|Radiofrequency Group|Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
215148958|NCT03088735|PROCEDURE|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
215148959|NCT03088735|PROCEDURE|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
215148960|NCT00412919|DRUG|Azacitidine|
215148961|NCT02784691|DEVICE|Feeligreen patch|
215148962|NCT01608945|DRUG|Hydrocortisone sodium succinate|100mg/day
215148963|NCT02455830|BIOLOGICAL|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
215148964|NCT05350397|OTHER|How Important Is Acupress Applyıng In Atrıal Fıbrılatıon Treatment?|The acupressure wristband was correctly attached to the Experimental Group and acupressure was applied. The placebo group was fitted with an inverted and loose acupressure wristband. No intervention was applied to the control group.
215148965|NCT02800629|DIETARY_SUPPLEMENT|Modified Citrus Pectin|MCP versus placebo
215148966|NCT02800629|DIETARY_SUPPLEMENT|Placebo|
215148967|NCT00741182|DRUG|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
215148968|NCT05217316|BEHAVIORAL|Supervised Virtual Toothbrushing|"A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision."
215148969|NCT05306756|DIAGNOSTIC_TEST|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
215148970|NCT05306756|DIAGNOSTIC_TEST|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
215148971|NCT02841514|DEVICE|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
215148972|NCT02841514|OTHER|OTC toothpaste and an unoperated Y10 device|
215148973|NCT00510822|DRUG|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
215148974|NCT00510822|DRUG|Placebo|tablet
215148975|NCT01691222|DEVICE|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
215148976|NCT00959985|DEVICE|Compression Sleeve|Worn for a minimum of 12 hours per day
215148977|NCT00959985|DEVICE|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
215148978|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
215148979|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
215148980|NCT00492635|DRUG|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
215148981|NCT00256672|DEVICE|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
215148982|NCT00004567|DRUG|Mycophenolate Mofetil|
215148983|NCT02482818|DRUG|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
215148984|NCT02482818|DRUG|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
215148985|NCT02606201|OTHER|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
215148986|NCT00904033|DRUG|Calcitriol|Calcitriol tablet taken once per week.
215148987|NCT00904033|BEHAVIORAL|Exercise|Exercise consisting of progressive walking and resistance band training
215148988|NCT00904033|DIETARY_SUPPLEMENT|Multivitamin|
215148989|NCT05611294|DEVICE|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
215148990|NCT05611294|DEVICE|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
215148991|NCT02626312|OTHER|Laboratory Biomarker Analysis|Correlative studies
214461899|NCT06180902|DIAGNOSTIC_TEST|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase \> 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement \> 12 mmHg (16.3 cm H2O)."
214531596|NCT01549249|DEVICE|optical coherence tomography|spectral-domain optical coherence tomography
215148992|NCT02626312|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
215148993|NCT02626312|RADIATION|Radiation Therapy|Undergo radiation therapy
215148994|NCT02626312|OTHER|Survey Administration|Ancillary studies
215148995|NCT03282396|DRUG|Ibrutinib|Given PO
214531597|NCT04312971|DRUG|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
215148996|NCT06322654|PROCEDURE|Robotically Assisted Locomotion|"* Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy"
215148997|NCT06322654|PROCEDURE|Robotically Assisted Verticalization|"* Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy"
215148998|NCT01837121|OTHER|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
215148999|NCT04939714|BEHAVIORAL|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
215149000|NCT04963647|DIAGNOSTIC_TEST|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
215149001|NCT04126941|OTHER|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
215149002|NCT05373407|OTHER|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
215149003|NCT02564003|DRUG|Oxycodone|oxycodone 0,1 mg/kg iv
215149004|NCT05940220|OTHER|Acetazolamide|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm
215149005|NCT05940220|OTHER|placebo|placebo
215149006|NCT05626868|DEVICE|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
215149007|NCT03689621|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|
214531598|NCT04312971|DRUG|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
214461900|NCT06180902|PROCEDURE|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
214461901|NCT06640725|DRUG|Avelumab administration at 10mg/kg|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"
214461902|NCT06640725|DRUG|Cetuximab (Erbitux)|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"
214531599|NCT04312971|OTHER|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
214531600|NCT04312971|OTHER|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
214531601|NCT01437813|DRUG|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
215149008|NCT03531346|OTHER|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
215149009|NCT00936767|DRUG|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
215149010|NCT00936767|DRUG|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
215149011|NCT02528981|DRUG|Probiotic|Lactobacillus GR-1 and RC-14
214531602|NCT05655234|BEHAVIORAL|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
215149012|NCT02528981|DRUG|Placebo|
214461903|NCT03611686|DRUG|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
215149013|NCT01870518|DEVICE|Bilateral GPi DBS|
215149014|NCT01870518|DEVICE|Bilateral STN DBS|
215149015|NCT03202602|OTHER|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
215149016|NCT03202602|OTHER|Standard care|Office visits and monitoring of CPAP treatment at each visit.
215149017|NCT06119932|PROCEDURE|Evacuation for subdural hematoma by one burrhole|Evacuation for subdural hematoma by one burrhole
215149018|NCT05434286|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
215149019|NCT03995602|DIETARY_SUPPLEMENT|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
215149020|NCT03995602|DIETARY_SUPPLEMENT|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
215149021|NCT00090207|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
215149022|NCT00090207|DRUG|Comparator: ondansetron / Duration of Treatment: 4 days|
215149023|NCT05204004|DEVICE|Sunrise|"Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test."
215149024|NCT05204004|DEVICE|Polygraphy|Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
215149025|NCT01600716|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
215149026|NCT01600716|DRUG|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
215149027|NCT00779155|DEVICE|The Resonator|active magnetic field therapy
215149028|NCT00779155|DEVICE|The Resonator control|inactive magnetic field therapy with placebo fields
215149029|NCT02592590|BEHAVIORAL|Group A|"This condition receives three study components:~1. The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~2. The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~3. The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
215149030|NCT02592590|BEHAVIORAL|Group B|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
215149031|NCT02592590|BEHAVIORAL|Group C|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
215149032|NCT02592590|BEHAVIORAL|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
215149033|NCT04510818|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
214461904|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
214531603|NCT05655234|BEHAVIORAL|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
214531604|NCT01395498|OTHER|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
214531605|NCT05199441|DRUG|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
215149034|NCT02698553|DRUG|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
214531606|NCT05199441|DRUG|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
215149035|NCT02698553|DRUG|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
215149036|NCT05505617|OTHER|Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.|"Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)"
215149037|NCT02298010|DRUG|Capecitabine, oxaliplatin|
215149038|NCT05115071|BEHAVIORAL|Childbirth preparation education|"Purpose: The aim of the birth preparation education is to eliminate the fears and concerns of pregnant women about birth and to prepare them for birth during the Covid-19 Pandemic process.~Education hours: The education will be completed in total two weeks and eight hours, consisting of two days and four hours each week.~Method: The education will be given online through the Microsoft Teams application. Each training day will consist of two lessons. Each lesson will last 45 minutes. There will be a 15-minute break between the two lessons. The first lesson will be conducted in the form of a question and answer session with a power-point presentation.In the second lesson, relaxation exercises will be applicated and evaluations will be taken at the end of the lesson.~The group that will receive the education: Healthy pregnant women between 24-34 weeks of gestation will be included in the training. Trainings will continue with closed groups."
215149039|NCT02601248|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
215149040|NCT05447884|OTHER|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
215149041|NCT05447884|OTHER|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
215149042|NCT05447884|OTHER|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
215149043|NCT04613037|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
215149044|NCT01748513|OTHER|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
215149045|NCT03349034|DRUG|Ropivicaine|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
214531607|NCT04150341|DRUG|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
214531608|NCT04150341|DRUG|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
214531609|NCT05097898|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
214531610|NCT05097898|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
215149046|NCT03349034|DRUG|Local Saline Infusion|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
215149047|NCT00658125|PROCEDURE|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
215149048|NCT01177397|DRUG|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
214531611|NCT05097898|PROCEDURE|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
215149049|NCT02565368|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
215149050|NCT02565368|DRUG|CKD-395 0.5/1000mg|single oral administration
215149051|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
215149052|NCT04922632|BEHAVIORAL|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
215149053|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
215149054|NCT04922632|BEHAVIORAL|Treatment As Usual (TAU)|TAU is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
215149055|NCT06129708|OTHER|Aquatic Exercise|The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and
215149056|NCT06129708|OTHER|Aerobic Exercise|The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).
214461905|NCT06538142|PROCEDURE|Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
214461906|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
214461907|NCT04770571|DEVICE|observational study|observational
214461908|NCT04390347|DIETARY_SUPPLEMENT|Yakult|A fermented milk product with live microorganisms.
214461909|NCT04390347|DIETARY_SUPPLEMENT|Placebo|A milk product with no live microorganisms.
214461910|NCT06193174|DRUG|C134 Re-Administration|Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
214461911|NCT06128382|BIOLOGICAL|OVX033|One single administration intramuscularly on Day 1
214461912|NCT06128382|BIOLOGICAL|Saline solution|One single administration intramuscularly on Day 1
214695621|NCT06018610|OTHER|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
214461913|NCT02852330|DEVICE|SA16 research software|Software for measurement of voltage tomography intraoperatively.
214461914|NCT02852330|DEVICE|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
214461915|NCT03507842|DRUG|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
214461916|NCT03507842|DRUG|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
214461917|NCT03507842|DRUG|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
214461918|NCT05674578|BEHAVIORAL|Patient Navigation|Assigned a patient navigator and receive coaching
214461919|NCT05674578|OTHER|Quality-of-Life Assessment|Ancillary studies
214461920|NCT05674578|OTHER|Questionnaire Administration|Ancillary studies
214695622|NCT06018610|OTHER|Control|Conventional rehabilitation will be applied to the control group.
214695623|NCT05700955|DRUG|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
214695624|NCT04638712|OTHER|Microbiopsy sample|before and after chemotherapy
215149057|NCT06299059|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
214461921|NCT05641402|OTHER|Text messages|Text messages based on behaviour change techniques
214461922|NCT03364803|OTHER|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
214461923|NCT03364803|OTHER|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
214461924|NCT03364803|OTHER|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
214461925|NCT03364803|OTHER|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
214461926|NCT03364803|OTHER|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
214461927|NCT03364803|OTHER|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
214461928|NCT03364803|OTHER|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
214461929|NCT03364803|OTHER|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
214461930|NCT03364803|OTHER|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
214461931|NCT03364803|OTHER|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
214461932|NCT03364803|OTHER|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
214461933|NCT04446481|DEVICE|Neurofeedback|Neurofeedback will be tested in both groups of Vets
214461934|NCT06349408|DRUG|IBI3001|"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"
214461935|NCT02706704|DRUG|Adalimumab|
214461936|NCT05606731|BEHAVIORAL|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
214461937|NCT05967247|OTHER|The experimental group used App for MBSR intervention|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
214461938|NCT05967247|OTHER|"the Heart Care Life app"|"Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app."
215149058|NCT06299059|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
215149059|NCT02352389|OTHER|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
215149060|NCT02352389|OTHER|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
214461939|NCT05967247|OTHER|APP|APP
214461940|NCT06455917|DRUG|Combination of TIL Transfer and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses)."
214461941|NCT05659654|DRUG|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
215149061|NCT02352389|OTHER|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
215149062|NCT02352389|OTHER|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
215149063|NCT02352389|OTHER|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
214461942|NCT04467723|DRUG|Atezolizumab|Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
214461943|NCT01802788|DEVICE|St Jude Medical Portico replacement aortic valve|
214461944|NCT01802788|PROCEDURE|Transcatheter Aortic Valve Implant|
214461945|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
214461946|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
214461947|NCT06158386|DRUG|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
214461948|NCT06335043|GENETIC|Pharmacogenetics Testing|Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
214461949|NCT05445167|DRUG|KLH-2109|Oral administration
214461950|NCT05445167|DRUG|Placebo|Oral administration
214461951|NCT04573517|PROCEDURE|Amniotomy|Artificial rupture of amniotic membranes
214461952|NCT04573517|DEVICE|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
214461953|NCT03625349|DRUG|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
214461954|NCT05759754|DRUG|TCM+ Routine Therapy|"The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued."
214461955|NCT05759754|DRUG|Routine Therapy|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
214531612|NCT05097898|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
214531613|NCT05097898|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214461956|NCT06494722|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
214461957|NCT06494722|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
214461958|NCT04625686|BEHAVIORAL|Mental Health Treatment|Treatment of suicidal ideation
214461959|NCT05355766|DRUG|CN128 Tablets|Iron chelator, oral tablets
214461960|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
214461961|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
214461962|NCT05243680|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
214461963|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
214461964|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
215149064|NCT05510596|OTHER|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
215149065|NCT05510596|OTHER|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
215149066|NCT05510596|OTHER|Neuropsychological tests|Neuropsychological tests
215149067|NCT06081816|OTHER|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
215149068|NCT05306535|PROCEDURE|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
215149069|NCT04359316|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
215149070|NCT04359316|DRUG|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
215149071|NCT02425852|DRUG|Azathioprine|Azathioprine alone versus Azathioprine and IFX
215149072|NCT02425852|DRUG|Infliximab|
215149073|NCT02425852|DRUG|Prednisolone|
215149074|NCT02425852|DRUG|Hydrocortisone|
215149075|NCT05985252|PROCEDURE|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
215149076|NCT05985252|PROCEDURE|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
215149077|NCT02734459|DRUG|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
215149078|NCT06188143|COMBINATION_PRODUCT|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
215149079|NCT03261752|DIAGNOSTIC_TEST|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
215149080|NCT02850926|OTHER|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
215149081|NCT00865566|BIOLOGICAL|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
214461965|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
214461966|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
214461967|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
214461968|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
214461969|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
214461970|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
214461971|NCT05214729|DIAGNOSTIC_TEST|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
214461972|NCT05214729|DIAGNOSTIC_TEST|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
215149082|NCT00865566|BIOLOGICAL|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
215149083|NCT00865566|BIOLOGICAL|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
214461973|NCT05997875|BEHAVIORAL|Educational Materials|"Participants are provided with the Getting Ready: Your Vascular Access Journey video and brochure about hemodialysis vascular access. The video is available for viewing via smartphone or computer. Both the brochure and video were created with input from patients with chronic kidney disease."
214695625|NCT04638712|OTHER|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
215149084|NCT00865566|BIOLOGICAL|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
215149085|NCT01898260|DEVICE|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
215149086|NCT01898260|DEVICE|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
215149087|NCT02905227|DRUG|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
214461974|NCT05997875|BEHAVIORAL|Motivational Interviewing|Participants receive coaching with telehealth-based motivational interviewing designed to prepare participants to move forward with vascular access creation. Motivational interviewing will consist of a minimum of 3 and maximum of 8 telehealth sessions with a coach. The coach will use patient-centered communication skills to work though the stages of pre-contemplative, contemplative, preparation, action, and maintenance of an arteriovenous vascular access.
214461975|NCT05997875|BEHAVIORAL|Usual Care|Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
214461976|NCT05997875|OTHER|Patient Lists for Clinicians: System-Level Intervention|Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
214461977|NCT02775500|DRUG|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
214461978|NCT05008042|DRUG|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
214461979|NCT05008042|OTHER|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
214461980|NCT03011333|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
214461981|NCT03011333|DRUG|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
214461982|NCT03011333|DRUG|Saline Placebo|Saline placebo via nerve block.
214461983|NCT04831580|DEVICE|da Vinci|Minimally invasive robotic-assisted radical or simple hysterectomy
214461984|NCT04831580|OTHER|open surgery|open radical or simple hysterectomy
214461985|NCT04089943|PROCEDURE|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
214461986|NCT04089943|OTHER|Control group|Healthy non-PAD participants will be recruited for the study.
214461987|NCT04876053|BEHAVIORAL|Healthy Food Delivery Intervention|Each weekly food box will include \~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
214461988|NCT04024761|BIOLOGICAL|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
214461989|NCT04024761|DRUG|Fludarabine|Fludarabine is a chemotherapy agent
214461990|NCT04024761|DRUG|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
214461991|NCT05827094|OTHER|Mobile app|The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
214461992|NCT05827094|OTHER|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
215149088|NCT03403283|OTHER|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
215149089|NCT03403283|OTHER|Healthy Controls 15 age matched control subjects|
214461993|NCT03735472|DEVICE|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
214461994|NCT04520672|OTHER|Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
214461995|NCT04520672|OTHER|Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
214461996|NCT04117295|DEVICE|Carmat Total Artificial Heart|Heart replacement therapy
214461997|NCT06382402|RADIATION|CCTA scan|• CCTA will be performed per the standard clinical protocol using a Cannon Aquilion ONE scanner with 16 cm z-axis coverage at 0.5 mm resolution, low contrast, and reduced radiation dose requirements.
214461998|NCT03287453|OTHER|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
214461999|NCT03287453|OTHER|Survey Administration|Ancillary studies
215149090|NCT04052633|RADIATION|intraoperative cholangiography|success or failure of cholangiography
215149091|NCT02596932|OTHER|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60mg/dL
215149092|NCT02596932|OTHER|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60 mg/dL
215149093|NCT03098732|DEVICE|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
214695626|NCT05503654|BEHAVIORAL|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
214695627|NCT00139685|DRUG|Depo-Provera Contraceptive Injection - DP150CI|
214695628|NCT04333121|OTHER|weight|we can monitoring the growth of the infants by weight gain degree
214695629|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
215149094|NCT03098732|DEVICE|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
215149095|NCT01565824|OTHER|web-based support|
215149096|NCT00719472|DRUG|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
215149097|NCT00719472|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
215149098|NCT00719472|DRUG|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
215149099|NCT00719472|DRUG|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
215149100|NCT03703427|DRUG|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
215149101|NCT03703427|DRUG|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
214462000|NCT02610361|DRUG|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
214462001|NCT05577702|DRUG|Tislelizumab|Administered as an intravenous infusion
214462002|NCT05577702|DRUG|Ociperlimab|Administered as an intravenous infusion
215149102|NCT02395471|DEVICE|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
214462003|NCT05577702|DRUG|LBL-007|Administered as an intravenous infusion
214462004|NCT05577702|DRUG|Cisplatin|Administered as an intravenous infusion
214462005|NCT05577702|DRUG|Carboplatin|Administered as an intravenous infusion
214462006|NCT05577702|DRUG|Pemetrexed|Administered as an intravenous infusion
214462007|NCT05577702|DRUG|Paclitaxel|Administered as an intravenous infusion
214462008|NCT03051282|DRUG|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
214462009|NCT04082689|BEHAVIORAL|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
214462010|NCT06029062|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
214462011|NCT06029062|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
214462012|NCT06029062|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
214462013|NCT04039347|DRUG|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
214531614|NCT03962764|BEHAVIORAL|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
214531615|NCT00419419|DRUG|Topical AmphiMatrix with nitroglycerin (MQX-503)|
214531616|NCT01932983|DEVICE|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
214531617|NCT05648513|BEHAVIORAL|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
214531618|NCT03713073|DEVICE|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
214531619|NCT03713073|DEVICE|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
214531620|NCT01907113|DRUG|BI 10773|oral administration
214531621|NCT01907113|DRUG|BI 10773|oral administration
214531622|NCT01907113|DRUG|BI 10773|oral administration
214531623|NCT01907113|DRUG|BI 10773|oral administration
214531624|NCT01907113|DRUG|BI 10773|oral administration
214531625|NCT01646528|PROCEDURE|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
214531626|NCT02869815|PROCEDURE|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
214531627|NCT00833898|DEVICE|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
214531628|NCT00833898|BEHAVIORAL|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development \& application of various stress-mgmt techniques such as effective problem-solving, identifying \& challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support \& goal setting.
214531629|NCT06446271|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines."
214531630|NCT00805285|DRUG|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
214531631|NCT00917462|DRUG|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
214462014|NCT04039347|DRUG|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
214462015|NCT04100174|RADIATION|focal brachytherapy boost to SBRT|As above
214462016|NCT05504850|OTHER|Multicultural Health Diet|The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
214462017|NCT05890976|DRUG|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
214462018|NCT05890976|DRUG|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
215149103|NCT04172818|BEHAVIORAL|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
215149104|NCT01244893|DEVICE|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
215149105|NCT01244893|DEVICE|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
215149106|NCT06516380|DEVICE|Combined treatment of Cyberdyne HAL single joint with TecnoBody D-Wall and Walker View 3.0 SCX devices|HAL-SJ sessions were conducted 5 days a week for 3 months and 2 hours a day for a total of 60 sessions. HAL-SJ application was performed in cybernic voluntary control (CVC) mode for 90 minutes. In addition to each HAL-SJ session, balance exercises were performed with TecnoBody D-Wall for 30 minutes net.
215149107|NCT00357552|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
215149108|NCT00357552|DRUG|Lopinavir/Ritonavir|Twice daily
215149109|NCT05338814|OTHER|scapular corrective exercises|40 minutes each, three times a week for six weeks
214531632|NCT00917462|PROCEDURE|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
214531633|NCT01402063|DRUG|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
214708719|NCT00966069|OTHER|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
215149110|NCT05338814|OTHER|conventional neck exercises|40 minutes each, three times a week for six weeks
215149111|NCT00976404|BIOLOGICAL|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
214462019|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
214462020|NCT05885880|OTHER|Blue-button screening|Patients will be screened for clinical trial matches using the Blue-button tool
214462021|NCT06426381|BEHAVIORAL|Therapeutic Touch|Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
214462022|NCT04641221|BEHAVIORAL|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
214462023|NCT02171650|DRUG|BIBW 2992|
214462024|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
214462025|NCT04210102|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
214462026|NCT04210102|DIAGNOSTIC_TEST|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
214462027|NCT05718479|BEHAVIORAL|Trauma Informed Prenatal Intervention (TPI)|TPI is designed to foster behavior change and health coping by enhancing knowledge, beliefs, regulation skills and abilities. In the experimental group, a research staff member will meet with participants and help them to identify a health behavior they want to change, explore the pros and cons of making a change, create a behavior change plan, and learn several mindfulness meditation techniques. The facilitator will check-in with the participants about their behavior change plan in the subsequent sessions regarding progress made, barriers encountered, and changes in the plan and/or goal going forward. Participants will be instructed to implement an at-home mental wellness skills and provided with a tracking log to report the frequency and dose of daily/weekly practice.
215149112|NCT00976404|DRUG|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
215149113|NCT00976404|DRUG|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
214695630|NCT06204068|DEVICE|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
214695631|NCT06204068|DEVICE|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
214695632|NCT02306603|PROCEDURE|Endoscopic Mucosal Resection|
214531634|NCT01402063|DRUG|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
214531635|NCT00002878|DRUG|dexamethasone|
214531636|NCT00002878|DRUG|doxorubicin hydrochloride|
214531637|NCT00002878|DRUG|valspodar|
214695633|NCT02669004|DRUG|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
214695634|NCT02669004|DRUG|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
214695635|NCT04548687|PROCEDURE|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
215149114|NCT05170997|DIETARY_SUPPLEMENT|Cows' milk|Intervention groups will receive a free 12 week supply of cows' milk equating to a pint a day for study participants. Milk is provided by Lakeland dairies.
215149115|NCT05170997|OTHER|British Dietetic Association Iodine Fact Sheet.|All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
215149116|NCT04558294|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
215149117|NCT04558294|DRUG|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
215149118|NCT04558294|DRUG|Ketanserin|A dose of 40 mg Ketanserin will be administered.
214531638|NCT00002878|DRUG|vincristine sulfate|
214531639|NCT03378895|BEHAVIORAL|online questionnaire|Risk assessment identified by online questionnaire
214531640|NCT00825643|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
214531641|NCT02375932|BEHAVIORAL|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
214531642|NCT02375932|BEHAVIORAL|Usual Care Control|Patients continue to receive usual care from their primary care provider
214695636|NCT04548687|PROCEDURE|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
214695637|NCT02426060|DRUG|Imrecoxib|
214695638|NCT02426060|DRUG|Warfarin|
214695639|NCT01435239|DEVICE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
214695640|NCT01435239|DEVICE|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
214695641|NCT06197945|OTHER|Mulligan bent leg raise|Mulligan bent leg raise
214695642|NCT06197945|OTHER|Mulligan bent leg raise with Bowen therapy|Mulligan bent leg raise with Bowen therapy
214695643|NCT04322630|OTHER|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
214695644|NCT00375115|DRUG|Sambucol|
214695645|NCT03625362|DIETARY_SUPPLEMENT|Hydrogen|Hydrogen-rich water
214695646|NCT03625362|DIETARY_SUPPLEMENT|Placebo|Tap water
214695647|NCT01938781|DRUG|entecavir|antiviral therapy
215149119|NCT03428035|OTHER|Package Insert|Modified package insert of Ibuprofen given postprocedural as pain medication
215149120|NCT02086500|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
215149121|NCT02086500|OTHER|Saline control|Saline Control
215149122|NCT00711191|BIOLOGICAL|monoclonal antibody|CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles
215149123|NCT00711191|DRUG|chemotherapy|gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
214531643|NCT01535196|DRUG|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
215149124|NCT00990197|DRUG|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
215149125|NCT03584789|OTHER|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
215149126|NCT03584789|OTHER|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
215149127|NCT05550493|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
215149128|NCT05550493|BEHAVIORAL|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
215149129|NCT05550493|BEHAVIORAL|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
214531644|NCT01057888|OTHER|Autodialer|Autodialer telephone calls
214531645|NCT01057888|OTHER|Letters|Mailed reminder letters
214531646|NCT03794128|PROCEDURE|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
214531647|NCT03794128|PROCEDURE|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
214531648|NCT05139576|DIAGNOSTIC_TEST|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
214531649|NCT01003379|DRUG|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
214531650|NCT01003379|DRUG|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
214531651|NCT02110225|DRUG|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
214531652|NCT02110225|DRUG|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
214531653|NCT02110225|DRUG|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
214531654|NCT02176018|DRUG|Dextromethorphan and quinidine|
214531655|NCT02176018|DRUG|Placebo|
214531656|NCT03022045|DRUG|risankizumab|risankizumab administered by subcutaneous injection
214695648|NCT01938781|DRUG|Peg-IFN|antiviral and antifibrosis therapy
214531657|NCT03436433|DRUG|Lacosamide|LCM 100mg twice a day.
214531658|NCT03436433|DRUG|Levetiracetam|LEV 1000mg twice a day.
214531659|NCT01653171|DRUG|Water (Placebo)|Water 100 mL
214531660|NCT01653171|DRUG|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
214531661|NCT01653171|DRUG|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
214531662|NCT01653171|DRUG|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
214531663|NCT02607345|DIETARY_SUPPLEMENT|Zusto|25gr
214531664|NCT02607345|DIETARY_SUPPLEMENT|Glucomedics®|25gr
214531665|NCT01751451|DRUG|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
214531666|NCT01751451|DRUG|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
214531667|NCT01751451|DRUG|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
214531668|NCT03972137|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
214531669|NCT03972137|BEHAVIORAL|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
214531670|NCT03972137|DRUG|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
214531671|NCT00899379|DRUG|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
214531672|NCT00899379|DRUG|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
214531673|NCT02056600|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
214531674|NCT02056600|DRUG|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
214531675|NCT01906658|DRUG|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
214708720|NCT04327518|DEVICE|TECNIS® Toric II|Toric Intraocular Lens
214708721|NCT03920878|DRUG|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
215149130|NCT05550493|BEHAVIORAL|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
215149131|NCT00598676|DEVICE|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
214462028|NCT05718479|OTHER|Prenatal Education Topics|In the control group, a research staff member will provide participants with four different weekly prenatal education topics, including information on prenatal care, labor and delivery, postpartum care, and newborn care.
214462029|NCT05440708|DRUG|TTI-101|Oral tablet
214462030|NCT05440708|DRUG|Pembrolizumab|Intravenous (IV) infusion
214462031|NCT05440708|DRUG|Atezolizumab|Intravenous (IV) infusion
214462032|NCT05440708|DRUG|Bevacizumab|Intravenous (IV) infusion
214462033|NCT05913388|DRUG|GB1211|Administered orally twice daily at 100mg.
214462034|NCT05913388|DRUG|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
214462035|NCT05913388|DRUG|Placebo|Administered orally twice daily at 100mg.
214462036|NCT04198454|OTHER|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
214462037|NCT04198454|OTHER|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
214462038|NCT04198454|DEVICE|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
214462039|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Sanger technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
214462040|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
214462041|NCT06458400|DRUG|Tegileridine|single dose+PCA dose
214462042|NCT06458400|DRUG|Oliceridine|single dose+PCA dose
214462043|NCT06458400|DRUG|Morphine|single dose+PCA dose
214462044|NCT03026127|BEHAVIORAL|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
214462045|NCT03026127|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
214462046|NCT04433351|DEVICE|Enriched rehabilitation|"The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter."
214462047|NCT04433351|DEVICE|Simple rehabilitation|The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
214462048|NCT04880590|OTHER|Sex intercourse|A heterosexual sexual relationship
214462049|NCT05074303|BIOLOGICAL|Influenza Vaccine|All subjects will receive the influenza vaccine.
214462050|NCT05074303|DIETARY_SUPPLEMENT|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
215149132|NCT00598676|DEVICE|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
215149133|NCT00598676|DEVICE|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
215149134|NCT02035267|DRUG|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214462051|NCT05074303|DIETARY_SUPPLEMENT|Placebo|2 - 250 mg capsules/day of cellulose
215149135|NCT02035267|DRUG|Placebo|Phosphate buffered saline placebo for injection.
215149136|NCT05526482|DEVICE|mobile app|preoperative respiratory exercises and thoracic surgery with a mobile application
215149137|NCT06103786|BEHAVIORAL|Assigned Interventions|"Ice hockey players did 12 weeks of on-ice high-intensity interval training. Their training included:~Repetitive sprint training Sprint interval training Long-pass tracking drills Chase-the-rabbit tracking drills High-intensity interval training in four types improved college ice hockey players' sports performance in 12 weeks."
214531676|NCT03865862|OTHER|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
214708722|NCT03920878|DRUG|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
214708723|NCT03199508|DIAGNOSTIC_TEST|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
215149138|NCT06103786|BEHAVIORAL|Random Interventions|"Ice hockey players did 12 weeks of traditional on-ice training. Their training included:~Varied pacing skating Dribbling and shooting Passing and catching drills 2-on-1 offensive tactics Traditional training in four types improved college ice hockey players' sports performance in 12 weeks.~A 12-week on-ice training program was conducted on college players to observe its effects on their physical fitness, skills, and tactical performance compared to an experimental and control group."
215149139|NCT00517088|DRUG|IPAQ|
214462052|NCT04094298|DRUG|FX006 Injection|One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
214462053|NCT03888950|DIAGNOSTIC_TEST|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
214462054|NCT05799105|DRUG|Omeprazole 40 milligrams|Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
214462055|NCT05269667|DRUG|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
214462056|NCT06285357|DIETARY_SUPPLEMENT|EGCG + folic acid + B12|EGCG + folic acid + B12
214462057|NCT05160272|DRUG|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
214462058|NCT05160272|DRUG|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
214462059|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks."
214462060|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed on the vertex target location."
214462061|NCT06584071|DRUG|PM8002|PM8002 via IV infusion, Q3W
214462062|NCT06584071|DRUG|PM1009|PM8002 via IV infusion, Q3W
214462063|NCT06584071|DRUG|atezolizumab|atezolizumab,1200mg, via IV infusion, Q3W
214462064|NCT06584071|DRUG|bevacizumab|bevacizumab,15mg/kg, via IV infusion, Q3W
214462065|NCT06344143|DIAGNOSTIC_TEST|Various labs and imaging tests|Dexamethasone Suppression Test, Adrenocorticotropic Hormone (ACTH), Salivary Cortisol Levels, Vasopressin Stimulation test, Fasting Glucose, Fasting Insulin, Complete Metabolic Panel (CMP), Gamma-glutamyl transferase (GGT), Sex Hormone Binding Globulin, Cat scan of abdomen/Pelvis, Whole body dual energy x-ray absorptiometry (DXA) scan, Ultrasound Fibroscan Transient Elastography
214462066|NCT06411080|DIAGNOSTIC_TEST|Ultrasound evaluation of fluid tolerance|Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.
214462067|NCT05355753|DRUG|CFT8634|Oral dose of CFT8634
214462068|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
215149140|NCT05053958|OTHER|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
215149141|NCT00614731|BIOLOGICAL|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
214531677|NCT03865862|OTHER|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
215149142|NCT04827680|DEVICE|Venus Viva MD|The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
215149143|NCT01146717|BEHAVIORAL|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
215149144|NCT01146717|BEHAVIORAL|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
215149145|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
215149146|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
215149147|NCT02037308|DIETARY_SUPPLEMENT|Bread|
215149148|NCT01045837|DRUG|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
215149149|NCT01045837|BEHAVIORAL|Gluten free diet|Only gluten free diet will be given in this group
215149150|NCT05457010|BIOLOGICAL|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
215149151|NCT05457010|BIOLOGICAL|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
214531678|NCT02127814|DIETARY_SUPPLEMENT|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
214531679|NCT03220776|DRUG|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
214531680|NCT03220776|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
214531681|NCT03220776|DRUG|Placebo Oral Tablet|5 day trial of matched placebo
214531682|NCT05939089|DIAGNOSTIC_TEST|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
214531683|NCT05723289|DEVICE|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
215149152|NCT04917016|DIAGNOSTIC_TEST|Plasma B-HCG levels|Blood sample
215149153|NCT03678220|DEVICE|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
215149154|NCT04207762|DIAGNOSTIC_TEST|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
215149155|NCT04207762|DIAGNOSTIC_TEST|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
215149156|NCT02345993|DRUG|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~\+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
214531684|NCT05262439|DEVICE|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
214531685|NCT01608958|DRUG|Oxytocin|10 IU oxytocin in 500 ml infusion
214531686|NCT01608958|DRUG|Oxytocin|10 IU oxytocin IM injection
214531687|NCT06537141|PROCEDURE|selective embolization of thyroid arteries (SETA)|selective embolization of thyroid arteries
215149157|NCT04097964|BEHAVIORAL|brief intervention|1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
215149158|NCT04097964|BEHAVIORAL|treatment as usual|standard care conducted by primary care providers during clinic visits
215149159|NCT04446104|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
215149160|NCT04446104|DRUG|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
215149161|NCT04446104|DRUG|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
215149162|NCT04446104|DRUG|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
215149163|NCT04446104|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 500mg daily for 42 days
215149164|NCT05097040|BEHAVIORAL|acceptance and commitment therapy (ACT)|The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
215149165|NCT06067217|DRUG|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
215149166|NCT06067217|DRUG|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
215149167|NCT04493788|OTHER|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
215149168|NCT03378271|DEVICE|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
215149169|NCT03967613|DEVICE|Functional eletrical stimulation|Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
215149170|NCT05053204|OTHER||
214462069|NCT04165694|PROCEDURE|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
214462070|NCT06256432|DRUG|Ambrisentan|Endothelin receptor antagonist
214462071|NCT06256432|DRUG|Terlipressin|Terlipressin
214462072|NCT05939830|PROCEDURE|Stained region Lymph Node Biopsy (SrLNB)|Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
214531688|NCT06244706|COMBINATION_PRODUCT|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
214531689|NCT01659177|DRUG|LY2140023|Administered orally
214531690|NCT03441789|DRUG|Enstilar|Enstilar foam applied to affected areas daily
214531691|NCT03441789|DRUG|Vehicle|vehicle foam applied to affected areas once daily
214531692|NCT03441789|DRUG|Otezla|Otezla 30mg
214695649|NCT02125006|BEHAVIORAL|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
214695650|NCT03047148|OTHER|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
215149171|NCT04989868|PROCEDURE|Trans-Nasal Afferent Loop Decompression|A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (\<3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
215149172|NCT04989868|PROCEDURE|Without Trans-Nasal Afferent Loop Decompression|No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
215149173|NCT00955916|DRUG|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
215149174|NCT00955916|DRUG|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
215149175|NCT04896515|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
214531693|NCT01780545|DRUG|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
214695651|NCT00407264|DRUG|Fluticasone propionate|
214695652|NCT06335368|OTHER|Nutrition and Growth Status|Nutrition and Growth Status
214695653|NCT04087421|DEVICE|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
214462073|NCT05939830|RADIATION|Regional lymph node radiotherapy (RNI) including the axilla|RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
214462074|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
214695654|NCT04087421|DRUG|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
214695655|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
214462075|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
214462076|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
214462077|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
214462078|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
214462079|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
214462080|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
214462081|NCT05376488|OTHER|One meal|One meal given to assess impact on ammonia levels serially
214462082|NCT02392130|DRUG|Clobetasol propionate 0.05% ointment|
214462083|NCT02392130|DRUG|LEO 130852A gel 1%|
214462084|NCT02392130|DRUG|LEO 130852A placebo gel|
214462085|NCT04349371|DRUG|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
214462086|NCT04349371|DRUG|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
214462087|NCT05022329|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|This arm receives Pfizer-BioNTech COVID-19 Vaccine
214462088|NCT05022329|BIOLOGICAL|MODERNA SARS-CoV-2 Vaccine|This arm receives MODERNA SARS-CoV-2 Vaccine
214462089|NCT05332522|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
214462090|NCT05822687|BEHAVIORAL|Education|This is a constant component; all participants will get a psychoeducation digital module.
214462091|NCT05822687|BEHAVIORAL|Reappraisal Coping|This digital module will teach reappraisal coping skills.
214462092|NCT05822687|BEHAVIORAL|Distraction Coping|This digital module will teach distraction coping skills.
214462093|NCT05822687|BEHAVIORAL|Relaxation Coping|This digital module will teach relaxation coping skills.
214462094|NCT06449196|DRUG|Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.
214462095|NCT06449196|DRUG|: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
214462096|NCT05319639|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
214462097|NCT05319639|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
214695656|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
214708724|NCT03199508|DIAGNOSTIC_TEST|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
214708725|NCT06456138|DRUG|Trametinib|Trametinib will be administrated orally every day.
215149176|NCT04834622|BEHAVIORAL|Melodies for Mums|Melodies for Mums (M4M) is an intervention that was developed and tested as part of a collaboration between the Royal College of Music, Imperial College London and University College London from 2015-2017. The programme involved weekly singing classes for mothers and their babies delivered in groups of 8-12 in Children's Centres for 10 weeks. A trained artist delivers 1-hour long singing sessions to mothers with postnatal depression (and their babies) for a period of 10-weeks. The sessions are aimed at the mothers, with songs ranging from sound baths to folk songs and songs created by the mothers themselves. Mothers randomised to the intervention will be prompted via text message, each week before the session, to attend these singing sessions.
214462098|NCT05319639|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
214462099|NCT05319639|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
214462100|NCT05319639|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
214462101|NCT05319639|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
214462102|NCT05745246|BEHAVIORAL|e-health training program|"1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
214462103|NCT05256199|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
214462104|NCT05662423|BEHAVIORAL|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
214462105|NCT05662423|BEHAVIORAL|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
214462106|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
214462107|NCT06158724|OTHER|Personal Protective Equipment|Simplified PPE for use in COVID-19 departments.
214462108|NCT05246280|DRUG|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214462109|NCT05849090|DRUG|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
214462110|NCT05849090|DRUG|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
214462111|NCT06010563|DEVICE|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
214462112|NCT06010563|DEVICE|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
214462113|NCT04546958|DIETARY_SUPPLEMENT|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
214462114|NCT04546958|OTHER|Nutritional counseling|Nutritional counseling by dietitians for 3 months
214462115|NCT06412055|DEVICE|NEURO SWING AFO (Fior& Gentz, Lüneburg, Germany)|stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
214462116|NCT06412055|DEVICE|WalkOn Reaction® (Ottobock, Duderstadt)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
214531694|NCT01780545|DRUG|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
214531695|NCT03097302|PROCEDURE|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
214462117|NCT06412055|DEVICE|Matrix Max2® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
214462118|NCT06412055|DEVICE|Matrix® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)
214462119|NCT01909245|BIOLOGICAL|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
214462120|NCT01909245|DRUG|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
214462121|NCT01909245|DRUG|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
214531696|NCT04127019|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
214531697|NCT04127019|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
215149177|NCT04834622|BEHAVIORAL|Control Community Sessions|Group mother-baby interventions in the community (i.e. baby play, baby reading sessions, baby massage, etc). A list of these activities will be collected from the activities on offer in the community. All the mothers randomised to the control group will be pointed towards these activities, prompted by text messages in line with the prompts received by the mothers in the intervention group. Mothers will be encouraged to attend these non-music based community activities once a week with their babies.
214531698|NCT04127019|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
214531699|NCT04127019|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
214531700|NCT04127019|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
214531701|NCT04872634|BIOLOGICAL|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
215149178|NCT02600039|OTHER|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
215149179|NCT02600039|DEVICE|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
215149180|NCT05842161|BEHAVIORAL|QUIT-AD|An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence
215149181|NCT05842161|OTHER|Enhanced Treatment as Usual|Standard treatment for HIV/TB with one session of psychoeducation.
215149182|NCT00436514|BEHAVIORAL|diet and absorption of ColoPEG|4l of PEG during 2 days
215149183|NCT00436514|PROCEDURE|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
215149184|NCT00436514|PROCEDURE|Standard colonoscopy|1l of PEG the morning just before colonoscopy
215149185|NCT02538393|DRUG|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A
214462122|NCT06318117|OTHER|Rice infant formula|Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
214531702|NCT04872634|DRUG|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
214531703|NCT04872634|BIOLOGICAL|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
214531704|NCT03825614|BEHAVIORAL|training|plates and therapeutic exercises applied on young adults
214462123|NCT05967195|BEHAVIORAL|Financial Incentive and Text-Messages|"Patient-participants will receive modest financial incentive for attending therapy or medication management appointments combined with text messages to encourage attendance at these appointments. Text messages will be informed by principles of behavioral economics. Maximum incentive = $50/month if all appointments attended. Incentives will be pro-rated by percentage of appointments attended. Pro-rating strategies (e.g., uniform amount per appointment, escalating \[aka, 'back-loaded'\], or decreasing \[aka 'frontloaded'\] will be sequentially changed based on acceptability and other intervention-related data gathered from participants during the trial.~Clinician-participants will not receive any intervention, but will receive surveys and interviews to assess their perceptions about the optimization, acceptability, scalability, and other implementation barriers/facilitators for the intervention."
214462124|NCT06058663|PROCEDURE|Angiography|Undergo mapping angiography
214531705|NCT06477757|PROCEDURE|Minimally Invasive Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
214531706|NCT06477757|PROCEDURE|Conventional Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
214531707|NCT05668442|BEHAVIORAL|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
214531708|NCT01906645|OTHER|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
214708726|NCT06456138|DRUG|Anlotinib|Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
215149186|NCT02538393|DRUG|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
215149187|NCT06383728|DRUG|Osimertinib|Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
215149188|NCT05317325|BIOLOGICAL|OCDC vaccine; NeoDC vaccine|OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
215149189|NCT02025413|DEVICE|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
215149190|NCT03134703|DRUG|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
215149191|NCT03134703|DRUG|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
215149192|NCT01684865|DRUG|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
215149193|NCT02896413|DRUG|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
214462125|NCT06058663|PROCEDURE|Biopsy|Undergo biopsy
214462126|NCT06058663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214531709|NCT03317899|PROCEDURE|Hematopoietic Cell Transplantation|Undergo auto HSCT
214531710|NCT03317899|DRUG|Tbo-filgrastim|Given subcutaneously
214531711|NCT03317899|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214531712|NCT01091844|PROCEDURE|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
214531713|NCT00003926|DRUG|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
214531714|NCT00003926|DRUG|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
214531715|NCT00003926|DRUG|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
214531716|NCT00003926|DRUG|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
214531717|NCT00003926|DRUG|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
214531718|NCT00003926|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
214462127|NCT06058663|PROCEDURE|Computed Tomography|Undergo CT
214462128|NCT06058663|BIOLOGICAL|Durvalumab|Given IV
214462129|NCT06058663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214531719|NCT03168425|OTHER|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
214531720|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
214708727|NCT06456138|DRUG|Tislelizumab|Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
215149194|NCT02896413|DRUG|Control group|0.9% saline infusion
215149195|NCT00004669|DRUG|hydrocortisone|
215149196|NCT06140862|OTHER|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
214462130|NCT06058663|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214462131|NCT06058663|BIOLOGICAL|Tremelimumab|Given IV
214462132|NCT06058663|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
214462133|NCT05432427|RADIATION|64Cu-DOTATATE and 18F-FDG|All participants will get a 64Cu-DOTATATE-PET and 18F-FDG-PET/CT.
214462134|NCT05536752|DRUG|QA102/Placebo|Capsules
214462135|NCT05536752|DRUG|QA102|Capsules
214462136|NCT05536752|DRUG|Placebo|Capsules
214531721|NCT02747121|BEHAVIORAL|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
214531722|NCT04233983|PROCEDURE|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
214531723|NCT00003402|DRUG|carmustine|
214531724|NCT00003402|DRUG|cisplatin|
214531725|NCT00003402|DRUG|cyclophosphamide|
214531726|NCT00003402|DRUG|dexamethasone|
214531727|NCT00003402|DRUG|etoposide|
214531728|NCT00003402|DRUG|melphalan|
214531729|NCT00003402|DRUG|paclitaxel|
215149197|NCT03543878|DEVICE|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
215149198|NCT05860972|DEVICE|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
214462137|NCT06193213|PROCEDURE|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference \> 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
214462138|NCT06434480|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given."
214462139|NCT06456762|BEHAVIORAL|iPEACE: Intervention for Parent Education about Care after the ED|Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
214531730|NCT00003402|PROCEDURE|bone marrow ablation with stem cell support|
214531731|NCT00003402|PROCEDURE|peripheral blood stem cell transplantation|
214531732|NCT03089502|OTHER|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
214531733|NCT05743114|DEVICE|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
214531734|NCT02599870|GENETIC|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
214531735|NCT00546702|DRUG|Insuline Glulisine|
214531736|NCT02892006|BEHAVIORAL|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
214531737|NCT05563428|PROCEDURE|Free gingival graft|A free gingival graft will be carried out for recession treatment.
214531738|NCT05563428|PROCEDURE|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
214531739|NCT03029234|DRUG|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
214531740|NCT03029234|DRUG|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
214531741|NCT00042302|PROCEDURE|Chemotherapy|
214531742|NCT00042302|DRUG|tariquidar + paclitaxel/carboplatin|
214531743|NCT00042302|DRUG|placebo + paclitaxel/carboplatin|
214531744|NCT02694588|DRUG|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
215149199|NCT03794336|DRUG|Alogliptin|"Pharmaceutical form: tablet~Route of administration: oral administration"
214531745|NCT02694588|DRUG|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
214531746|NCT01591668|DRUG|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
214531747|NCT01591668|DRUG|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
214531748|NCT01443546|DRUG|HCG|hCG Trigger
215149200|NCT03794336|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
215149201|NCT03794336|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral administration"
215149202|NCT03794336|DRUG|Aspirin|"Pharmaceutical form: tablet~Route of administration: oral administration"
215149203|NCT06096571|DRUG|Aterixen|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
215149204|NCT00836693|DRUG|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
214531749|NCT01443546|DRUG|Lupron Trigger|leuprolide acetate 2 mg SQ
214531750|NCT01443546|DRUG|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
215149205|NCT00836693|DRUG|placebo|tablet administered orally once a day for 12 weeks.
215149206|NCT02741739|DRUG|REGN1033|
215149207|NCT02612779|DRUG|Elotuzumab|
215149208|NCT02612779|DRUG|Pomalidomide|
215149209|NCT02612779|DRUG|Dexamethasone|
215149210|NCT02612779|DRUG|Nivolumab|
215149211|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
215149212|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
215149213|NCT06370806|BEHAVIORAL|Weight loss and lifestyle intervention|Interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
215149214|NCT05127733|BEHAVIORAL|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
215149215|NCT05127733|BEHAVIORAL|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
215149216|NCT05127733|BEHAVIORAL|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
215149217|NCT00897494|GENETIC|protein expression analysis|Venous blood collection
215149218|NCT00897494|OTHER|laboratory biomarker analysis|Venous blood collection
214462140|NCT06456762|BEHAVIORAL|Text Messaging Reminders Only|Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
214462141|NCT04599062|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
214462142|NCT04599062|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
214462143|NCT03374787|DEVICE|Fusion Sound Processor|Sound Processor
214462144|NCT04527315|OTHER|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
214462145|NCT05524922|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
214462146|NCT04895137|DRUG|mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
214462147|NCT04074759|BIOLOGICAL|FPT155|A soluble CD80 fusion protein
214462148|NCT04074759|BIOLOGICAL|pembrolizumab|An anti-PD1 antibody
214462149|NCT04509791|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
214462150|NCT06049329|DRUG|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
214462151|NCT06049329|DRUG|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
214462152|NCT03521830|DRUG|Nivolumab|480mg IV every 4 weeks
215149219|NCT00897494|OTHER|mass spectrometry|Venous blood collection
215149220|NCT00897494|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
215149221|NCT01957306|DIETARY_SUPPLEMENT|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
215149222|NCT06046170|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
214462153|NCT03521830|DRUG|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
214462154|NCT03521830|DRUG|Relatlimab|480 mg IV q4wks
214462155|NCT05831891|DRUG|Fruquintinib combined with Serplulimab|Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
214462156|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
214462157|NCT03197584|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214462158|NCT03197584|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
214462159|NCT03197584|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214462160|NCT03197584|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214462161|NCT03197584|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214462162|NCT03197584|DRUG|Fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
214462163|NCT03197584|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214462164|NCT03197584|DRUG|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214462165|NCT03197584|DRUG|omega-3 acid ethyl esters|omega-3 acid ethyl esters
214462166|NCT03197584|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214462167|NCT03197584|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
214462168|NCT03197584|BIOLOGICAL|ALT-803|Recombinant human super agonist IL-15 complex
214462169|NCT03197584|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2 vaccine
214462170|NCT03197584|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214462171|NCT03197584|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1 vaccine
214462172|NCT03197584|BIOLOGICAL|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
215149223|NCT06046170|OTHER|Treatment as Usual|Participants will receive treatment as usual at a community mental health center, including receiving skills training.
214462173|NCT03197584|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
214462174|NCT03197584|BIOLOGICAL|haNK®|NK-92 \[CD16.158V, ER IL-2\]
214462175|NCT05456789|DEVICE|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
214462176|NCT05456789|OTHER|conventional treatment|conventional treatment of pulmonary embolism
214462177|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
214462178|NCT06528626|DIAGNOSTIC_TEST|rapid HIV and HCV serological tests|In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
214462179|NCT06581952|BEHAVIORAL|Poem writing|"The poem themes will focus on accomplishment moments, joyful moments, and gratitude. Participants will be motivated to write at least one poem in each session. The instructor will lead the participants to improve the poem after the participants complete the first draft. The participants will be encouraged to perform in reading their completed poem, sharing their feelings and expressing the meaning of the poems during the session.~In the second session, participants will be invited to do a poem reading performance using one of their newly written poems."
214462180|NCT05500443|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone-7)|Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
215149224|NCT03708276|OTHER|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
214462181|NCT05506449|DEVICE|Impella CP®|"Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm."
215149225|NCT00074048|DRUG|BL22|Dosing via IV on Days 1,3, and 5.
215149226|NCT02118961|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
215149227|NCT02118961|BIOLOGICAL|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
215149228|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
215149229|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
215149230|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
215149231|NCT00801177|BIOLOGICAL|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
215149232|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
215149233|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
215149234|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
215149235|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
215149236|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
215149237|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 4~600 mg I.V."
214462182|NCT05506449|OTHER|Standard of Care|This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
214462183|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
214462184|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
214531751|NCT03700463|OTHER|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
214531752|NCT02166047|DRUG|Vesatolimod|Vesatolimod tablet administered orally
214531753|NCT02166047|DRUG|Placebo|Placebo to match vesatolimod tablet administered orally
214531754|NCT02812628|PROCEDURE|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
215149238|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
215149239|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
215149240|NCT05414058|DRUG|Apo-Methylphenidate ER|For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
215149241|NCT05573997|DIAGNOSTIC_TEST|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
215149242|NCT01147510|DRUG|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
215149243|NCT01147510|DRUG|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
215149244|NCT03751917|DRUG|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
215149245|NCT01856959|DRUG|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
215149246|NCT01856959|DRUG|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
215149247|NCT01856959|DRUG|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
215149248|NCT00104923|DRUG|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
215149249|NCT04433988|DRUG|Pentoxifylline|Pentoxifylline 400 mg SR tablet
215149250|NCT04433988|DRUG|Placebo|Placebo tablet
215149251|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
214462185|NCT04982757|DEVICE|MagVenture MagPro System with Brainsight neuronavigation device|10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
215149252|NCT04055623|OTHER|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
215149253|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
215149254|NCT01599624|BEHAVIORAL|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
214462186|NCT06417918|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
214462187|NCT03208686|BEHAVIORAL|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
214462188|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
214462189|NCT05302648|DRUG|Human Derived anti-BCMA CAR-T Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
214531755|NCT02812628|PROCEDURE|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
214531756|NCT03146325|DRUG|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
214531757|NCT03146325|DRUG|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
214531758|NCT03638401|PROCEDURE|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
214531759|NCT06407947|DRUG|Chimeric antigen receptor modified T cells Infusion|chimeric antigen receptor T cells
214531760|NCT03389321|DRUG|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
214531761|NCT03389321|DRUG|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
214531762|NCT00700947|DRUG|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
214531763|NCT03287375|DRUG|PIPAC|
214531764|NCT02302625|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
214531765|NCT00676429|DRUG|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
214531766|NCT00676429|DRUG|Placebo|Placebo as oral solution, individually titrated
214531767|NCT00639964|OTHER|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
214462190|NCT04204265|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
214462191|NCT05092386|BIOLOGICAL|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
214462192|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
215149255|NCT01599624|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad \& Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
215149256|NCT00279487|DRUG|Gabapentin|
215149257|NCT00279487|DRUG|Placebos|
215149258|NCT01087463|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
214462193|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
214462194|NCT04325334|BEHAVIORAL|Running volume increase|"Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the 10% rule advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run."
214462195|NCT05523999|OTHER|Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA|Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.
214462196|NCT02165007|DRUG|peripheral blood stem cell graft that are CD34+ selected|The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
214462197|NCT05086497|DIAGNOSTIC_TEST|Whole Brain Spectroscopy Imaging Array Mapping Layout|All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
214462198|NCT04908423|DRUG|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
214462199|NCT06137482|DRUG|REGN13335|Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
214462200|NCT06137482|DRUG|Matching Placebo|Administered IV or SC, sequential ascending single dose
214462201|NCT06007521|OTHER|interview with neurologist|interview with neurologist
214462202|NCT04983368|DRUG|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
214462203|NCT04983368|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
214462204|NCT04983368|DRUG|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
214462205|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
214462206|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
214462207|NCT04324164|DRUG|Third-generation EGFR-TKI|Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
214462208|NCT04324164|DRUG|EGFR-TKI|All EGFR-TKI
214462209|NCT06490276|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
214462210|NCT06490276|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
215149259|NCT00034502|DRUG|ALIMTA|
215149260|NCT00034502|DRUG|irinotecan|
215149261|NCT01807988|BEHAVIORAL|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
214462211|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
214462212|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
214531768|NCT00639964|OTHER|diet questionnaire|questions about nutrition before and during pregnancy
214531769|NCT00639964|OTHER|umbilical cord blood collect|collected at the delivery
215149262|NCT00072839|DRUG|ALX-0600|teduglutide
214531770|NCT00639964|OTHER|placenta collect|collected at the delivery
214531771|NCT01960114|DRUG|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
214531772|NCT01960114|DRUG|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
215149263|NCT00072839|DRUG|placebo|placebo solution injected subcutaneously
215149264|NCT00072839|DRUG|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
214531773|NCT02413554|DRUG|Rivastigmine patch|acetylcholine esterase inhibitor
215149265|NCT00072839|DRUG|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
215149266|NCT00072839|DRUG|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
215149267|NCT00072839|DRUG|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
215149268|NCT04264936|DRUG|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
214462213|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
214462214|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
214462215|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
214462216|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
214462217|NCT04937179|PROCEDURE|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
214462218|NCT04937179|PROCEDURE|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
214462219|NCT05208164|BEHAVIORAL|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
214462220|NCT05038878|DRUG|Elagolix|Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
214462221|NCT05459857|OTHER|Product A|Heated tobacco (HT) device with Intense HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
214462222|NCT05459857|OTHER|Product B|Heated tobacco (HT) device with Regular HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
214462223|NCT05459857|OTHER|Product C|Heated tobacco (HT) device with Menthol HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
214462224|NCT05459857|OTHER|Product D|Subject's own brand combustible cigarette, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
214531774|NCT02636751|BEHAVIORAL|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
214531775|NCT02636751|DEVICE|Walking aid adjustment|Walking aid adjustment
214531776|NCT02636751|BEHAVIORAL|Information about pain control|General information about pain control, such as ice application and medication usage
215149269|NCT01750229|DEVICE|Sham|Frequency Setting - Sham
214462225|NCT06394167|DRUG|VX-993|Solution for IV administration.
214462226|NCT06394167|DRUG|Placebo|Solution for IV administration.
214462227|NCT04985487|OTHER|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
214462228|NCT05589389|OTHER|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
214462229|NCT05589389|OTHER|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
214531777|NCT00572351|OTHER|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
214531778|NCT00572351|OTHER|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
215149270|NCT01750229|DEVICE|1200 Hz|Frequency Setting - 1200 Hz
215149271|NCT01750229|DEVICE|3030 Hz|Frequency Setting - 3030 Hz
215149272|NCT01750229|DEVICE|5882 Hz|Frequency Setting - 5882 Hz
215149273|NCT03439228|DEVICE|Lumbar brace|3 months of lumbar brace wear
215149274|NCT06410092|DRUG|FTL001|IV infusion every 2 weeks
215149275|NCT05842902|BEHAVIORAL|mPRISM|PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
215149276|NCT02941601|DRUG|Necitumumab|Administered IV
215149277|NCT02941601|DRUG|Gemcitabine|Administered IV
215149278|NCT02941601|DRUG|Carboplatin|Administered IV
215149279|NCT03722238|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
215149280|NCT03771664|DRUG|SAGE-217|Administered as capsules.
215149281|NCT03771664|DRUG|Placebo|Administered as capsules.
215149282|NCT03703284|OTHER|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
215149283|NCT03276338|BEHAVIORAL|HOLA|To increase condom use and HIV testing
214531779|NCT03650361|DRUG|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
215149284|NCT00891904|BIOLOGICAL|cetuximab|Given IV
215149285|NCT00891904|RADIATION|stereotactic body radiation therapy|Undergoing Radiotherapy
215149286|NCT04871646|DRUG|CKD-314+SOC|CKD-314 is administered intravenously and standard of care is also performed.
214462230|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
214462231|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
214462232|NCT04432532|OTHER|No intervention|There are no interventions
214462233|NCT01783288|OTHER|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
214462234|NCT01783288|OTHER|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
214462235|NCT01783288|PROCEDURE|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
214462236|NCT01783288|OTHER|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
214462237|NCT06185790|OTHER|LCHF diet|Low-carb high-fat (LCHF) diet
214462238|NCT06454812|DEVICE|Mechanical vibration|The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The same procedure was repeated for DTaP-IPV-Hib vaccine administered to the the right extremity. The baby will be swaddled and placed in the mother's lap.
214462239|NCT06454812|BEHAVIORAL|Helfer skin tap technique (HSTT)|In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4).
214462240|NCT06117579|OTHER|Inspiratory muscle training|"Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device."
214531780|NCT03650361|DRUG|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
214531781|NCT03650361|DRUG|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
214531782|NCT02639078|DRUG|TD-0714|One time dosing in capsule formulation
214531783|NCT02639078|DRUG|Placebo Comparator|One time dosing in capsule formulation
214531784|NCT05514197|DRUG|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
214531785|NCT05514197|DRUG|Control Rx|Intravenous loading 100ml normal saline
214531786|NCT03391583|OTHER|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
214531787|NCT03248713|DRUG|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
214531788|NCT03248713|DRUG|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
214531789|NCT00000398|BEHAVIORAL|Coping skills training|
214531790|NCT00000398|BEHAVIORAL|Physical exercise training|
215149287|NCT04871646|DRUG|CKD-314 Placebo+SOC|CKD-314 placebo is administered intravenously and standard of care is also performed..
215149288|NCT00598910|DRUG|Omacor|n-3 PUFA
215149289|NCT00598910|DRUG|Placebo|Placebo
215149290|NCT05537662|DEVICE|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
215149291|NCT01322620|OTHER|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
215149292|NCT02769585|BEHAVIORAL|Self-hypnosis|Self-hypnosis
215149293|NCT02769585|BEHAVIORAL|CDE training|standard CDE training for an obese diabetic
215149294|NCT01128634|DRUG|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
215149295|NCT01128634|DRUG|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
215149296|NCT02692521|DIETARY_SUPPLEMENT|Human Milk|
215149297|NCT01259414|OTHER|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
215149298|NCT01259414|OTHER|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
215149299|NCT01312103|BEHAVIORAL|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
215149300|NCT01312103|BEHAVIORAL|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
215149301|NCT01054989|BIOLOGICAL|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
215149302|NCT04069702|BEHAVIORAL|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
214462241|NCT04732533|OTHER|tES (transcranial electrical stimulation)|"Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tES. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tES sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 52 weeks.~Phase 4: The participant will receive up to 780, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 156 weeks."
214462242|NCT06296537|PROCEDURE|Dynamic Neuromuscular Stabilization Training (DNS)|Dynamic neuromuscular stabilization training has been developed, which optimizes the movement system based on the scientific principles of developmental kinesiology. DNS training aims to stimulate the natural movement control system in the brain to activate the body's stabilization system. Supine, prone, oblique sitting, tripod, high kneeling, hanging stance-midstance faze, hanging stance- propulsion, bear, squat exercises will be applied.
214462243|NCT06296537|PROCEDURE|Balance Training|Multi-plane single limb challenges, jumping and landing exercises, proprioceptive exercises, and perturbation exercises
214462244|NCT06296537|PROCEDURE|Conventional Training|Education, electrotherapy, soft tissue fascia massage, stretching, range of motion, strengthening and postural control exercises
214531791|NCT00000398|BEHAVIORAL|Coping skills training plus physical exercise training|
214531792|NCT02358213|PROCEDURE|Ultrasound|Ultrasound examinations are done 5 times
214531793|NCT02469077|BEHAVIORAL|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
214531794|NCT02469077|DRUG|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
214531795|NCT02469077|DRUG|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
214531796|NCT02469077|DRUG|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
214531797|NCT05212597|DRUG|Sacubitril-valsartan|50mg\~100mg twice daily
214531798|NCT05212597|DRUG|Amlodipine-losartan|amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
214531799|NCT01373333|DRUG|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
214531800|NCT02223013|DRUG|BIBV 308 SE solution|
215149303|NCT03096288|DRUG|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
215149304|NCT03096288|OTHER|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
215149305|NCT01765933|DIETARY_SUPPLEMENT|DMAA|no placebo
215149306|NCT01644357|OTHER|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
215149307|NCT04944004|OTHER|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
214462245|NCT04159259|OTHER|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
214462246|NCT04159259|OTHER|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
214462247|NCT04159259|OTHER|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
214462248|NCT05806593|BEHAVIORAL|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
214462249|NCT05448443|DRUG|AD981|Oral administration of AD981 in the morning and before sleep for 14 days
214462250|NCT05448443|OTHER|Placebo|Oral administration of placebo in the morning and before sleep for 14 days
214462251|NCT03468868|BEHAVIORAL|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
214462252|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
214462253|NCT06164392|DRUG|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
214462254|NCT06075836|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~\- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
214462255|NCT06075836|OTHER|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
214462256|NCT05443347|BEHAVIORAL|Aerobic exercise|Supervised aerobic exercise
214462257|NCT05443347|BEHAVIORAL|Newsletter|Biweekly newsletter
214462258|NCT05356104|DRUG|Exenatide extended release|2mg once weekly via subcutaneous injection
214462259|NCT05985356|DEVICE|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
214462260|NCT04696965|OTHER|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
214462261|NCT04696965|OTHER|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
214462262|NCT06802679|DRUG|Urokinase|In the higher dose group: 30,000unit (1.5ml) per catheter lumen is instilled per catheter lumen (in both arterial and venous ports respectively). This allows utilization of the entire vial of Urokinase to prevent wastage and to assess if this increase in dose improves catheter patency and survival, thus reducing the need for a TDC exchange in our HD patients. The urokinase lock is dwelled for at least 2 hours, after which aspiration and catheter testing will be done by a trained HD nurse.
214462263|NCT06802679|DRUG|Urokinase|20,000unit (1ml) is instilled per catheter lumen (in both arterial and venous ports respectively); and the remaining 1ml is discarded.
214462264|NCT06246045|DIAGNOSTIC_TEST|Walking test|"PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy."
214462265|NCT05399459|DRUG|Rimegepant 25 MG|Single dose of 25 mg orally disintegrating tablet of rimegepant
214462266|NCT05399459|DRUG|Rimegepant 75 MG|Single dose of 75 mg orally disintegrating tablet of rimegepant
214462267|NCT05399459|DRUG|Placebo|Matching placebo tablet
215149308|NCT04944004|OTHER|Training As Usual (TAU)|Training As Usual (TAU)
215149309|NCT03702153|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
215149310|NCT03597945|PROCEDURE|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
215149311|NCT03597945|PROCEDURE|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
215149312|NCT03597945|PROCEDURE|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
215149314|NCT03721003|DEVICE|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
215149315|NCT00588016|DRUG|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
215149316|NCT02372188|OTHER|water|Control
215149317|NCT02372188|DIETARY_SUPPLEMENT|caffeine|
215149318|NCT02372188|DIETARY_SUPPLEMENT|caffein + homoeriodictyol sodium salt|
215149319|NCT02372188|DIETARY_SUPPLEMENT|homoeriodictyol sodium salt|
215149320|NCT04683484|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
215149321|NCT04683484|BIOLOGICAL|Placebo|0,5 mg Al PO4
215149322|NCT00166777|PROCEDURE|exercise training|
215149323|NCT01394796|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
215149324|NCT01394796|DRUG|Placebo|No active treatment is given.
215149325|NCT06001073|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
215149326|NCT03367520|BEHAVIORAL|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
215149327|NCT04958473|DRUG|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
215149328|NCT04958473|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
215149329|NCT06116669|DIETARY_SUPPLEMENT|Iron supplementation|Iron supplements as 100 mg oral iron as FeSO4 given daily
215149330|NCT06116669|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
214462268|NCT06802640|COMBINATION_PRODUCT|Transcutaneous spinal cord electrical stimulation and Kunming Locomotor Training|Patients will undergo Kunming Locomotor Training along with transcutaneous spinal cord stimulation. . The training is at least 1 hour per day, 5 hours per week, for 6 consecutive months.
214462269|NCT06802705|BEHAVIORAL|Psychosocial Stress on Quality of Life|Psychosocial Stress on Quality of Life in Saudi Arabian Patients with Alopecia Areata
214462270|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
214462271|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
214462272|NCT02231164|DRUG|placebo|oral placebo
214462273|NCT02231164|DRUG|nintedanib|oral experimental therapy
214462274|NCT06041971|DEVICE|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
214462275|NCT03245489|DRUG|Pembrolizumab|200mg intravenous (IV) over 30 minutes
214462276|NCT03245489|DRUG|Clopidogrel|75mg/day oral
214462277|NCT03245489|DRUG|acetylsalicylic acid|81mg/day oral
214462278|NCT05598372|BEHAVIORAL|shotblocker|infant pain during vaccination and mother anxiety
214462279|NCT05598372|BEHAVIORAL|lullaby|infant pain during vaccination and mother anxiety
214462280|NCT06580054|PROCEDURE|Computed Tomography|Undergo CT
214462281|NCT06580054|OTHER|Digital Photography|Undergo photographs of tumor
214531801|NCT02223013|DRUG|BIBV 308 SE capsule L|
214531802|NCT02223013|DRUG|BIBV 308 SE capsule S|
214531803|NCT06400264|PROCEDURE|Biopsy|Undergo biopsy
214531804|NCT06400264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214531805|NCT06400264|PROCEDURE|Computed Tomography|Undergo CT scan
214531806|NCT06400264|PROCEDURE|Echocardiography|Undergo ECHO
214531807|NCT06400264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214531808|NCT06400264|BIOLOGICAL|Nivolumab|Given IV
214531809|NCT06400264|BIOLOGICAL|Relatlimab|Given IV
214531810|NCT04107077|DRUG|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
215149331|NCT06116669|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
215149332|NCT06116669|OTHER|Placebo|matching placebo capsules given daily
215149333|NCT06116669|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
215149334|NCT02835248|OTHER|Fall Detection|All participants will wear a device configured to detect falls.
215149335|NCT03430102|DIAGNOSTIC_TEST|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
215149336|NCT02547818|DRUG|ALZT-OP1a|1\) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
215149337|NCT02547818|DRUG|ALZT-OP1b|Anti-inflammatory
215149338|NCT02547818|OTHER|Placebo ALZT-OP1a|Non-active capsules
215149339|NCT02547818|OTHER|Placebo ALZT-OP1b|Non-active tablets
215149340|NCT01495403|DRUG|Hydroxychloroquine|daily dosing
215149341|NCT02254070|DRUG|BIBT 986 BS|
215149342|NCT02690948|BIOLOGICAL|Pembrolizumab|Given IV
215149343|NCT02690948|DRUG|Vismodegib|Given PO
215149344|NCT02928614|DRUG|Liraglutide 3 mg (Saxenda)|
215149345|NCT02928614|DRUG|Liraglutide 3 mg placebo|
215149346|NCT05324514|PROCEDURE|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
214462282|NCT06580054|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214462283|NCT06580054|BIOLOGICAL|Pembrolizumab|Given IV
214462284|NCT02141919|RADIATION|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
214462285|NCT02172690|PROCEDURE|Laparoscopic Staging|Laparoscopic Staging
214462286|NCT06069661|DEVICE|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
214462287|NCT04895761|BIOLOGICAL|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
214462288|NCT04895761|DRUG|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
214462289|NCT04895761|DRUG|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
214462290|NCT04895761|RADIATION|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
214531811|NCT04107077|DRUG|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
215149347|NCT05324514|DEVICE|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
215149348|NCT05324514|DEVICE|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
215149349|NCT02551887|BEHAVIORAL|Automated Reminder|Automated reminder shown to provider
214462291|NCT04116398|DRUG|Dexamethasone with 2 loading doses followed by PRN regimen.|"* Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~* Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®/Topcon; and/or increase of CSMT \> 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~* Minimal time limit between two IVI : 12 weeks~* Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
214462292|NCT06493227|OTHER|No routine fibrinolysis inhibitors after surgery|Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.
214462293|NCT06493227|OTHER|Routine fibrinolysis inhibitors after surgery|During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
214531812|NCT02991703|DEVICE|pOpmètre®|the pOpmètre® uses saturation sensors,
214531813|NCT02991703|DEVICE|Sphygmocor|the Sphygmocor uses applanation tonometry
214531814|NCT00637832|BIOLOGICAL|rituximab|
214531815|NCT00637832|DRUG|cyclophosphamide|
214531816|NCT00637832|DRUG|doxorubicin hydrochloride|
215149350|NCT02551887|BEHAVIORAL|Automated Reminder Plus Script|Provider sees both reminder and script.
215149351|NCT04551482|DRUG|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
215149352|NCT04551482|DRUG|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
215149353|NCT05819151|DIAGNOSTIC_TEST|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
215149354|NCT01411891|DEVICE|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
215149355|NCT02004093|DRUG|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
215149356|NCT02004093|DRUG|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
215149357|NCT02004093|DRUG|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
215149358|NCT02004093|DRUG|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
215149359|NCT02868593|OTHER|Pharyngeal swab|
215149360|NCT05498714|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
215149361|NCT05498714|DRUG|CSP＋lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
215149362|NCT02783807|DEVICE|Eyenez Retinal Camera v200|
215149363|NCT02783807|DEVICE|Volk Pictor Ret 1|
215149364|NCT01703234|DRUG|Ramipril|ramipril 10 mg/day during 3 months
215149365|NCT02445898|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
215149366|NCT02445898|DRUG|Isotonic Sodium Chloride|Placebo
215149367|NCT04926987|OTHER|brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders
215149368|NCT04639258|DEVICE|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
215149369|NCT00414596|DEVICE|DRX9000™|Device is designed to apply spinal decompressive forces.
215149370|NCT02253862|DRUG|Tadalafil|administered days 1, 8 and 16
214462294|NCT05412433|BEHAVIORAL|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
214462295|NCT05412433|BEHAVIORAL|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
214462296|NCT05412433|BEHAVIORAL|Control|Standard of care
214462297|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
214462298|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
214462299|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
214462300|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
214462301|NCT04099394|BEHAVIORAL|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
214462302|NCT04099394|BEHAVIORAL|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
214462303|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
214462304|NCT06505980|BEHAVIORAL|Brief Behavioral Parenting Program|The brief behavioral parenting program is a 6 session, group-based behavioral parent training program. The components include support-building, parenting strategy education, and actively practicing parenting strategies. It is delivered through telehealth.
214462305|NCT05452902|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
214531817|NCT00637832|DRUG|prednisolone|
215149371|NCT02253862|DRUG|Tipranavir|administered days 8-18
214462306|NCT05452902|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
214462307|NCT05486156|OTHER|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
214462308|NCT01210807|DEVICE|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
214462309|NCT01210807|DEVICE|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
214531818|NCT00637832|DRUG|vincristine sulfate|
214531819|NCT00637832|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214531820|NCT01347177|PROCEDURE|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
214531821|NCT01347177|PROCEDURE|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
214708728|NCT04173039|DIAGNOSTIC_TEST|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
215149372|NCT02253862|DRUG|Ritonavir|administered days 8-18
215149373|NCT04999540|DRUG|Tucidinostat|30 mg, administered orally twice per week (BIW)
215149374|NCT04999540|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
215149375|NCT02824341|DEVICE|fMRI|
215149376|NCT02757209|DEVICE|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
215149377|NCT02757209|DEVICE|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
214531822|NCT00078234|DRUG|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
214531823|NCT03322852|OTHER|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
214531824|NCT06353009|OTHER|NOVA4 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 4 - Ultra-processed foods. They are the ones that use many ingredients including food additives that improve palatability, processed raw materials (hydrogenated fats, modified starches, etc.) and ingredients that are rarely used in home cooking such as soy protein or mechanically separated meat. These foods are mainly of industrial origin and are characterized by a good pleasantness and the fact that they can be stored for a long time."
214531825|NCT06353009|OTHER|NOVA1-3 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 1 - Unprocessed or minimally processed foods (fruit, vegetables, eggs, meat, milk, etc.)~Group 2 - Foods processed in the kitchen with the aim of extending their shelf life. In practice, these are ingredients to be used in the kitchen such as fats, aromatic herbs, etc. to be kept in jars or in the refrigerator to be able to use them later.~Group 3 - Processed foods. These are the foods obtained by combining foods of groups 1 and 2 to obtain the many food products for domestic use (bread, jams, etc.) made up of a few ingredients"
214531826|NCT04719468|OTHER|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
214531827|NCT00991029|DRUG|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
214531828|NCT00991029|DRUG|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
214531829|NCT01318538|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
214531830|NCT01318538|BEHAVIORAL|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
214531831|NCT02935777|DIETARY_SUPPLEMENT|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
214531832|NCT02935777|DIETARY_SUPPLEMENT|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
215149378|NCT02757209|DEVICE|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
215149379|NCT03232697|DIAGNOSTIC_TEST|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
215149380|NCT03232697|DIAGNOSTIC_TEST|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
215149381|NCT00519753|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
215149382|NCT00003523|DRUG|aminocamptothecin colloidal dispersion|
215149383|NCT00494793|PROCEDURE|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
215149384|NCT02135913|DIETARY_SUPPLEMENT|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
215149385|NCT00126243|DRUG|rituximab|
215149386|NCT00126243|DRUG|CHOP|
215149387|NCT04579107|COMBINATION_PRODUCT|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
214531833|NCT06247618|DEVICE|visor|The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
214531834|NCT00053352|PROCEDURE|conventional surgery|
214531835|NCT00053352|DRUG|cisplatin|Given IV
214531836|NCT00053352|DRUG|etoposide|Given IV
214531837|NCT00053352|BIOLOGICAL|bleomycin sulfate|Given IV
214531838|NCT00053352|OTHER|laboratory biomarker analysis|Correlative studies
215149388|NCT01035801|DRUG|IN-105|Prandial Oral Insulin
215149389|NCT01035801|DRUG|Insulin Lispro Injection|Insulin Lispro Injection
215149390|NCT03930082|OTHER|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
215149391|NCT03566134|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
215149392|NCT03566134|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
215149393|NCT03566134|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
215149394|NCT03566134|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
215149395|NCT03566134|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
215149396|NCT04178668|OTHER|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
215149397|NCT04198558|DRUG|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
215149398|NCT04198558|DRUG|Placebo|Placebo
215149399|NCT00017576|DIETARY_SUPPLEMENT|calcitriol|
215149400|NCT00017576|DRUG|carboplatin|
215149401|NCT04320316|DRUG|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
215149402|NCT06960382|DRUG|ALUTARD SQ® Felis domesticus|The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection
215149403|NCT02558296|DRUG|Bexagliflozin|20 mg, tablet
215149404|NCT02558296|DRUG|Placebo|20 mg tablet to match active comparator
214462310|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
214462311|NCT04436276|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
214462312|NCT04436276|BIOLOGICAL|Placebo|Participants will receive Placebo.
214531839|NCT00439647|DRUG|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
214531840|NCT00439647|DRUG|Placebo|Placebo intravenous (i.v.) once a year
214531841|NCT02845375|DRUG|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
214531842|NCT02845375|DRUG|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
214531843|NCT02845375|DRUG|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
215149405|NCT02987686|DRUG|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
215149406|NCT00297258|DRUG|pazopanib|oral tablet
214531844|NCT03679468|OTHER|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
215149407|NCT01502826|DIETARY_SUPPLEMENT|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
215149408|NCT05695378|DRUG|KM-819|Subjects will receive KM-819 400 mg orally daily.
215149409|NCT05695378|DRUG|Placebo|Subjects will receive Placebo orally daily.
215149410|NCT00755053|DRUG|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
214531845|NCT03679468|OTHER|Sham Exercise|Sets of balance and stretching exercises
215149411|NCT00755053|DRUG|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
215149412|NCT03183297|DRUG|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
215149413|NCT03183297|DRUG|Naproxen|Naproxen sodium 220mg
214531846|NCT03679468|OTHER|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
214531847|NCT03679468|OTHER|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
214531848|NCT01265121|DEVICE|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
214531849|NCT01265121|OTHER|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
214531850|NCT04310527|DRUG|Enasidenib|Enasidenib
214531851|NCT02934542|DEVICE|AutoLap system|
214531852|NCT01593436|BEHAVIORAL|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
214531853|NCT06460181|DIETARY_SUPPLEMENT|Astaxanthin|Manufactured by AstaReal Inc
214531854|NCT06460181|DIETARY_SUPPLEMENT|Placebo|Manufactured by AstaReal Inc
214531855|NCT05215418|DRUG|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
214531856|NCT05215418|DRUG|Phentermine|Phentermine 30 mg capsule
214531857|NCT05215418|DRUG|Placebo|Inactive oral capsule
215149414|NCT03183297|DRUG|Fexofenadine|Fexofenadine 60mg
215149415|NCT03183297|DRUG|placebo|placebo comparator
215149416|NCT04588571|PROCEDURE|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
215149417|NCT04588571|PROCEDURE|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
215149418|NCT02217826|DRUG|DG3173|
215149419|NCT02217826|DRUG|Saline|
215149420|NCT02217826|DRUG|Octreotide|
214531858|NCT05730517|DIETARY_SUPPLEMENT|CP5HA|Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
214531859|NCT05730517|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
214531860|NCT05730517|DIETARY_SUPPLEMENT|CP5|Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
214531861|NCT00221702|DRUG|PegIntron|100 mcg SC/week for 36 months
214531862|NCT00221702|DRUG|intron A|3mui TIWW SC for 18 months
214531863|NCT02694796|BEHAVIORAL|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
214531864|NCT03433209|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
214531865|NCT03433209|DEVICE|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
214531866|NCT02315053|OTHER|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
214531867|NCT04651556|DRUG|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
214531868|NCT04651556|DRUG|paracetamol & ketorolac|parenteral analgesics
214531869|NCT03442140|OTHER|Harmonica playing|Patients will play the harmonica for up to 6 months
214531870|NCT04168021|BEHAVIORAL|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
214531871|NCT00392886|DRUG|carboplatin|Given IV
214531872|NCT00392886|DRUG|cisplatin|Given IV
214695657|NCT00661401|BIOLOGICAL|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
214695658|NCT03071549|DRUG|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
214695659|NCT03071549|DRUG|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
215149421|NCT00571493|DRUG|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
214695660|NCT00084916|DRUG|temsirolimus|Given IV
214695661|NCT00084916|OTHER|laboratory biomarker analysis|Correlative studies
214695662|NCT03616665|OTHER|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
215149422|NCT00571493|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
215149423|NCT00485095|BEHAVIORAL|Intake of plant sterols|
214531873|NCT00392886|DRUG|cyclophosphamide|Given IV
214531874|NCT00392886|DRUG|etoposide|Given IV and orally
214531875|NCT00392886|DRUG|methotrexate|Given IV
214531876|NCT00392886|DRUG|temozolomide|Given orally
214531877|NCT00392886|DRUG|thiotepa|Given IV
214531878|NCT00392886|DRUG|vincristine sulfate|Given IV
214695663|NCT04026152|BEHAVIORAL|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
214708729|NCT01293006|DRUG|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
214708730|NCT01293006|DRUG|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
214708731|NCT04712487|DIAGNOSTIC_TEST|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
215149424|NCT03672968|GENETIC|GS010|
215149425|NCT01512238|OTHER|Pharmaceutical care|Information about medicine, sideeffect, adherence
215149426|NCT03405597|DRUG|Commercial Hepatitis B vaccine|Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
215149427|NCT03405597|OTHER|Standard Treatment|HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
214531879|NCT00392886|PROCEDURE|autologous bone marrow transplantation|Given on day 0
215149428|NCT01170169|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
215149429|NCT01170169|DRUG|Prilosec|Prilosec® 40 mg of Merck \& Co.Inc.
215149430|NCT00470886|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
215149431|NCT01385293|DRUG|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
214531880|NCT00392886|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
214531881|NCT00392886|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
214531882|NCT00392886|RADIATION|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
214531883|NCT03781947|DRUG|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
214531884|NCT01792596|OTHER|Pasta with protein|Pasta with Protein
214531885|NCT01792596|OTHER|Pasta with Fiber|Pasta with Fiber
214531886|NCT01792596|OTHER|Pasta|Pasta
215149432|NCT05380180|OTHER|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
214531887|NCT05334706|BIOLOGICAL|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
214531888|NCT01753596|DEVICE|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
214531889|NCT01753596|OTHER|Physiological Sodium Chloride solution (0,9%)|Placebo
214531890|NCT04673877|DRUG|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
214531891|NCT04673877|PROCEDURE|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
215149433|NCT05380180|OTHER|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
215149434|NCT02567578|DRUG|YH12852 0.1 mg|
215149435|NCT02567578|DRUG|YH12852 0.25 mg|
215149436|NCT02567578|DRUG|YH12852 0.5 mg|
215149437|NCT02567578|DRUG|Placebo|
215149438|NCT05851261|DRUG|PA3670|Placebo as control
215149439|NCT04182828|DRUG|Lidocaine|both the drugs will be prepared in same volume, color, consistency and appearance
215149440|NCT04467372|DIETARY_SUPPLEMENT|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
215149441|NCT04467372|DIETARY_SUPPLEMENT|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
215149442|NCT04467372|DIETARY_SUPPLEMENT|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
215149443|NCT04467372|DIETARY_SUPPLEMENT|Capsule placebo|Two placebo capsules daily for 30 days
215149444|NCT03032978|OTHER|Calcium hydroxide|Pulp capping material
215149445|NCT03032978|OTHER|Calcium silicate|Pulp capping material
215149446|NCT02566421|OTHER|Laboratory Biomarker Analysis|Correlative studies
215149447|NCT02566421|OTHER|Quality-of-Life Assessment|Ancillary studies
215149448|NCT02566421|OTHER|Targeted Therapy|Receive treatment based on genomic sequencing
215149449|NCT05903768|OTHER|Mobilization|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)"
215149450|NCT05903768|OTHER|Cyriax capsular stretching|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times."
215149451|NCT02290249|DEVICE|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
215149452|NCT02290249|DEVICE|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
215149453|NCT04772612|DRUG|sitravatinib|sitravatinib
215149454|NCT06836063|DRUG|Ropanicant|Tablet dosage form, twice a day
215149455|NCT06836063|DRUG|Placebo|Matching placebo tablets, twice a day
215149456|NCT03248206|BEHAVIORAL|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
215149457|NCT06516978|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
215149458|NCT06516978|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
215149459|NCT06516978|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214462313|NCT04573387|PROCEDURE|Operation|All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
215149460|NCT06516978|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
215149461|NCT06516978|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
215149462|NCT06516978|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
215149463|NCT06516978|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
215149464|NCT06516978|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
215149465|NCT06516978|DRUG|Chidamide|Chidamide PO will be administered as per the schedule specified in the respective arm.
215149466|NCT06516978|DRUG|Penpulimab|Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
215149467|NCT06516978|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
215149468|NCT02676141|OTHER|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
215149469|NCT02352155|PROCEDURE|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
215149470|NCT02352155|OTHER|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
215149471|NCT04607538|OTHER|No intervention is made|No intervention is made. This i an observational study.
215149472|NCT01036048|DEVICE|drug eluting stent|pts with cabg disease treated with drug eluting stent
215149473|NCT01036048|DEVICE|bare metal stent|pts with cabg disease treated with bare metal stent
215149474|NCT04522284|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of capecitabine and Ibrutinib for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
215149475|NCT04522284|DRUG|Capecitabine|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. , 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 625mg/m2 twice daily for single agent capecitabine). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
215149476|NCT04522284|DRUG|XELOX|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELOX regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range. The doses of other drug in the XELOX regimen (oxaliplatin) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
214531892|NCT04673877|DRUG|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
215149477|NCT04522284|DRUG|XELIRI|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELIRI regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELIRI regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.~The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care."
215149478|NCT04522284|DRUG|Ibrutinib|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 4-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range.~Maximum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 100% of standard starting dose (i.e. 420 mg once daily for 4 weeks, which constitutes the total of 11760 mg per cycle). Minimum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 50% of the standard starting dose (i.e. 280 mg once daily on alternative days with 140 mg once daily, which constitutes the total of 5880 mg per cycle). The dosing range may be altered to suit the specific circumstances of the participant, thus giving the participant-specific safe dosing range."
215149479|NCT05467306|BEHAVIORAL|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
215149480|NCT04067817|DRUG|norepinephrine|patient who was received the treatment of norepinephrine
215149481|NCT04067817|DRUG|Phenylephrine|patient who was received the treatment of phenylephrine
214462314|NCT04573387|PROCEDURE|Fixed-time drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
214462315|NCT04573387|PROCEDURE|Exhaustive drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
214531893|NCT03411928|DEVICE|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
214531894|NCT05442073|OTHER|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
214531895|NCT01177137|DEVICE|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
214531896|NCT01177137|DEVICE|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
214531897|NCT01177137|BEHAVIORAL|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
214531898|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
215149482|NCT02030652|PROCEDURE|Intermittent nasal positive pressure positive ventilation.|
215149483|NCT02030652|PROCEDURE|CPAP|Nasal continuous positive airway pressure
215149484|NCT05902247|RADIATION|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer
215149485|NCT05352503|DEVICE|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
214531899|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
214531900|NCT03044002|DEVICE|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
214531901|NCT03044002|DEVICE|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
214531902|NCT05168709|BIOLOGICAL|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
214531903|NCT04675671|OTHER|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
214531904|NCT01905293|OTHER|Feeding Study|
214531905|NCT05544539|DRUG|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
214531906|NCT05544539|DRUG|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
214531907|NCT02277587|DRUG|Plenadren|Oral Tablets: 20-25-30 mg
214531908|NCT02277587|DRUG|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
214531909|NCT01287416|BEHAVIORAL|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
214531910|NCT01287416|BEHAVIORAL|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
214531911|NCT00010270|BIOLOGICAL|LMB-9 immunotoxin|
214531912|NCT00728832|DRUG|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
214531913|NCT05132530|BEHAVIORAL|yoga|yoga practice will be done two days a week for 10 weeks.
214531914|NCT00857298|BEHAVIORAL|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
214531915|NCT04255654|OTHER|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
214531916|NCT05095714|OTHER|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
214531917|NCT05095714|OTHER|Liver ultrasound|Half-yearly liver ultrasound
214531918|NCT05654805|DIETARY_SUPPLEMENT|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
215149486|NCT05510388|DEVICE|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
215149487|NCT05510388|DEVICE|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
215149488|NCT03005158|OTHER|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
214531919|NCT01708005|DRUG|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
214531920|NCT01708005|DRUG|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
214531921|NCT04271566|BEHAVIORAL|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
214531922|NCT01068223|DRUG|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
214531923|NCT01068223|DRUG|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
214531924|NCT01068223|DRUG|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
214531925|NCT02689752|DRUG|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
214531926|NCT01705314|DIETARY_SUPPLEMENT|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
215149489|NCT03005158|OTHER|Randomization Phase|Standard care or HighSTEACS pathway.
215149490|NCT03005158|OTHER|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
215149491|NCT05867238|OTHER|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
214531927|NCT01705314|DIETARY_SUPPLEMENT|placebo|7mls of placebo drops per week for 8 months.
214531928|NCT05127018|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
214531929|NCT02506881|DRUG|Darbepoetin alfa|
214708732|NCT06339606|OTHER|Biospecimen collection|Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
215149492|NCT05038982|DRUG|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
215149493|NCT02125669|PROCEDURE|Laser treatment|Pulsed dye laser 595nm
215149494|NCT02125669|DEVICE|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
215149495|NCT01774396|DRUG|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
215149496|NCT01774396|DRUG|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
215149497|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
215149498|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
214462316|NCT04573387|PROCEDURE|Postoperative computed tomography|All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
214462317|NCT04052971|DRUG|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
214462318|NCT04052971|DRUG|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
214462319|NCT06426940|OTHER|anesthesia-related critical events|anesthesia-related critical events
214462320|NCT05313620|DRUG|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
214462321|NCT05313620|DRUG|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
214462322|NCT00324805|BIOLOGICAL|Bevacizumab|Given IV
214462323|NCT00324805|DRUG|Cisplatin|Given IV
214462324|NCT00324805|DRUG|Docetaxel|Given IV
214462325|NCT00324805|DRUG|Gemcitabine Hydrochloride|Given IV
214462326|NCT00324805|OTHER|Laboratory Biomarker Analysis|Correlative studies
214708733|NCT01184456|DIETARY_SUPPLEMENT|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
214462327|NCT00324805|DRUG|Pemetrexed Disodium|Given IV
214462328|NCT00324805|OTHER|Questionnaire Administration|Ancillary studies
214462329|NCT00324805|DRUG|Vinorelbine Tartrate|Given IV
214462330|NCT03931174|BEHAVIORAL|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
214708734|NCT01184456|DRUG|Placebo|1 capsule per day for 90 days.
214531930|NCT06279299|PROCEDURE|lateral pelvic lymph node dissection|Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
215149499|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
215149500|NCT01046487|PROCEDURE|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
215149501|NCT00005804|DRUG|cyclophosphamide|
214531931|NCT02774564|DRUG|BIA 3-202|Nebicapone tablets 50 mg, oral administration
215149502|NCT00005804|PROCEDURE|allogeneic bone marrow transplantation|
215149503|NCT00005804|RADIATION|radiation therapy|
215149504|NCT03133793|DRUG|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
215149505|NCT03133793|DRUG|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
215149506|NCT03133793|OTHER|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
215149507|NCT03133793|OTHER|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
215149508|NCT01859624|DRUG|Albuterol|Albuterol 4 mg
215149509|NCT04764708|BEHAVIORAL|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
215149510|NCT04764708|BEHAVIORAL|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
215149511|NCT05803239|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
215149512|NCT05803239|PROCEDURE|EBUS-TBMC via a tunnel|Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
215149513|NCT05506124|DEVICE|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
215149514|NCT05506124|DEVICE|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
215149515|NCT05484752|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
215149516|NCT05484752|BEHAVIORAL|Education|Conventional exercise and life style modification
215149517|NCT02247986|DRUG|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
214462331|NCT03931174|BEHAVIORAL|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
214462332|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
214462333|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
214462334|NCT03322267|DRUG|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
214462335|NCT06177912|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214462336|NCT06177912|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214531932|NCT02774564|DRUG|Placebo|Nebicapone matching placebo tablets
214531933|NCT02774564|DRUG|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
214708735|NCT04297293|DRUG|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
214708736|NCT01189799|BEHAVIORAL|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
214708737|NCT01189799|BEHAVIORAL|Dual Recovery Anonymous/Tx as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
215149518|NCT04476797|DRUG|GC4711 +SBRT|15 minute IV Infusion prior to SBRT
215149519|NCT04476797|DRUG|Placebo +SBRT|15 minute IV infusion prior to SBRT
215149520|NCT03192735|DRUG|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
215149521|NCT00264732|DRUG|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
215149522|NCT00264732|DRUG|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
215149523|NCT00264732|OTHER|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
215149524|NCT03614156|DRUG|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
215149525|NCT03614156|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
215149526|NCT01040910|DRUG|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
215149527|NCT01040910|DRUG|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
215149528|NCT02535806|DRUG|Velcade|4 doses of study drug will be given.
215149529|NCT02535806|DRUG|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
215149530|NCT02535806|DRUG|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
215149531|NCT02535806|DRUG|Dexamethasone|Days 1-5 and 15-19
215149532|NCT02535806|DRUG|Mitoxantrone|Days 1 and 2
215149533|NCT02535806|DRUG|Vincristine|Days 1, 8, 15, 22
215149534|NCT02535806|DRUG|Pegaspargase|Days 3 and 17
215149535|NCT02936596|DRUG|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
214531934|NCT02199249|DEVICE|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
215149536|NCT02936596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid
215149537|NCT00036985|DRUG|cyclophosphamide|
215149538|NCT00036985|DRUG|doxorubicin hydrochloride|
215149539|NCT00036985|PROCEDURE|conventional surgery|
215149540|NCT00036985|PROCEDURE|neoadjuvant therapy|
215149541|NCT00036985|PROCEDURE|thermal ablation therapy|
215149542|NCT05181436|DIAGNOSTIC_TEST|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
215149543|NCT04287517|DEVICE|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
215149544|NCT02074501|OTHER|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
215149545|NCT04771117|BEHAVIORAL|Fear of Covid-19 Scale|"The Fear of Covid-19 Scale (FCV-19S) is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. The FVC-19S consists of seven items, such as It makes me uncomfortable to think about coronavirus-19, I am afraid of losing my life because of coronavirus-19, and When watching news and stories about coronavirus-19 on social media, I become nervous or anxious, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19."
215149546|NCT01021891|DRUG|Technosphere®/Insulin|
214531935|NCT02199249|DEVICE|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
214531936|NCT01044836|BIOLOGICAL|HD203|Injectable form
214531937|NCT00741468|DRUG|Proellex|2, 25 mg Proellex capsules administered daily
214531938|NCT00741468|DRUG|CYP1A2 probe|Caffeine (200 mg)
215149547|NCT03070964|DRUG|plitidepsin|
215149548|NCT05849753|DEVICE|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
215149549|NCT00845767|PROCEDURE|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
215149550|NCT02899468|DEVICE|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
215149551|NCT05808231|DRUG|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
215149552|NCT05808231|DRUG|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
215149553|NCT03420599|PROCEDURE|splenectomy|Traumatic patients who performed total splenectomy
214531939|NCT00741468|DRUG|CYP2C9 probe|Tolbutamide (250 mg)
214531940|NCT00741468|DRUG|CYP2C19 probe|Omeprazole (20 mg)
214531941|NCT00741468|DRUG|CYP2D6 probe|Dextromethorphan (30 mg)
214531942|NCT00741468|DRUG|CYP3A4 probe|Midazolam (2mg)
214531943|NCT01766414|DRUG|C1-esterase inhibitor|intravenously
214531944|NCT01766414|DRUG|Endotoxin|intravenously
214531945|NCT05414006|DRUG|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
214531946|NCT04834063|DIAGNOSTIC_TEST|Serum Zinc a level|Diagnostic test
214531947|NCT04834063|DIAGNOSTIC_TEST|serum selenium level|Diagnostic test
214531948|NCT04834063|DIAGNOSTIC_TEST|Fibroscan measurement|Diagnostic test
214531949|NCT06478056|PROCEDURE|pancreatectomy|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
215149554|NCT06086769|DEVICE|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
215149555|NCT01131832|DIETARY_SUPPLEMENT|Plant sterol|
215149556|NCT01131832|DIETARY_SUPPLEMENT|Placebo|
215149557|NCT05160181|OTHER|Yogatherapy|Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
215149558|NCT04985123|DEVICE|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
215149559|NCT05024019|DRUG|Nimotuzumab|The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
215149560|NCT01352000|BEHAVIORAL|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
215149561|NCT00002786|BIOLOGICAL|aldesleukin|
214531950|NCT01077011|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
214531951|NCT01077011|OTHER|GenTeal Gel|1 drop in each eye, one time
214531952|NCT04509583|DIETARY_SUPPLEMENT|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
214531953|NCT04509583|OTHER|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
214531954|NCT04865510|PROCEDURE|Regional citrate anticoagulation|"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."
214531955|NCT01888627|OTHER|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
214531956|NCT01372683|OTHER|Dietary Intervention|Comparison of oat based breakfast cereals
214531957|NCT03888261|BEHAVIORAL|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
214531958|NCT05904288|DEVICE|Smartwatch Garmin Vivosmart [wearable sensor]|Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
214531959|NCT05904288|DEVICE|Soturi™ [digital mobile app]|Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
214531960|NCT05904288|OTHER|Clinical Assessment|Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
214531961|NCT03121040|DIETARY_SUPPLEMENT|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
214531962|NCT06105996|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
214531963|NCT01270217|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
214531964|NCT05756348|DEVICE|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
214531965|NCT05845099|DEVICE|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
214531966|NCT05845099|DEVICE|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
214531967|NCT00000441|DRUG|lorazepam (Ativan)|
214531968|NCT00000441|DRUG|carbamazepine (Tegretol)|
214531969|NCT02085590|BIOLOGICAL|BCG vaccine|
214531970|NCT02085590|BIOLOGICAL|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
214531971|NCT01363297|DRUG|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
214531972|NCT06473272|OTHER|Cardiovascular and cerebrovascular diseases|Cardiovascular and cerebrovascular diseases
214531973|NCT05783154|BIOLOGICAL|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
214531974|NCT02515097|DRUG|IDP-122 Lotion|Medicated topical lotion
214531975|NCT02515097|DRUG|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
214531976|NCT00743496|BIOLOGICAL|Anti-GD2 antibody|Anti-GD2 antibody
214531977|NCT04188119|DRUG|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
214531978|NCT04188119|DRUG|Aspirin|300mg tablets
214531979|NCT04188119|DRUG|Lansoprazole|30mg
214531980|NCT05721378|PROCEDURE|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
214531981|NCT05721378|PROCEDURE|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
215149562|NCT00002786|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
215149563|NCT03612752|DIETARY_SUPPLEMENT|CMI-168|Dietary supplement
215149564|NCT03612752|OTHER|Placebo|Placebo
215149565|NCT02851472|DRUG|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
215149566|NCT02851472|DRUG|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
214531982|NCT01880944|OTHER|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
214531983|NCT03277586|DRUG|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
214531984|NCT03277586|DRUG|Placebo|Identically formulated and packaged inactive substance
214531985|NCT05043688|DRUG|Camrelizumab|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
214531986|NCT05043688|RADIATION|radiotherapy|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
214531987|NCT01090700|DRUG|TMC435|TMC435 150 mg daily for 7 days
215149567|NCT00041561|DRUG|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
215149568|NCT00041561|DRUG|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
215149569|NCT02708186|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
215149570|NCT02708186|DRUG|Placebo|once daily, oral, matching tablets
215149571|NCT00854399|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
215149572|NCT04125472|DRUG|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
215149573|NCT02629263|DIETARY_SUPPLEMENT|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
215149574|NCT05599867|BEHAVIORAL|quality of life|to assess quality among patients with patients with IBD
215149575|NCT00834093|BIOLOGICAL|Epstein-Barr Virus Specific Immunotherapy|
215149576|NCT02973750|PROCEDURE|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
214462337|NCT05513443|PROCEDURE|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
214462338|NCT05513443|PROCEDURE|Radical prostatectomy|Radical prostatectomy
214462339|NCT05513443|RADIATION|Radiation therapy|Radiation therapy for prostate cancer
214462340|NCT06005168|DRUG|Cefazolin for Injection|2 grams or 3 grams based on standard of care or morphomic-based decision
214462341|NCT06036914|DRUG|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
214462342|NCT06036914|DRUG|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
214531988|NCT01090700|DRUG|Escitalopram|Escitalopram 10 mg daily for 7 days
214531989|NCT01090700|DRUG|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
214531990|NCT00705042|DRUG|Etanercept|
214531991|NCT00579657|OTHER|control diet, supported by dietary supplement twice daily|control diet, see above
214462343|NCT05543733|BEHAVIORAL|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
214462344|NCT05898529|DIAGNOSTIC_TEST|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
214462345|NCT03046251|DRUG|Natalizumab|
214462346|NCT05119387|OTHER|Observation|Observation of genetic characteristics
214531992|NCT00579657|OTHER|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
214531993|NCT00579657|OTHER|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
214531994|NCT00579657|OTHER|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
215149577|NCT02973750|PROCEDURE|Tissue Collection|Tissue collection during debulking surgery.
215149578|NCT02973750|PROCEDURE|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
215149579|NCT02444078|OTHER|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
215149580|NCT02444078|OTHER|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
214462347|NCT03206814|OTHER|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
214462348|NCT03206814|OTHER|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
214462349|NCT05757453|DEVICE|mHealth|Mobile platform
214462350|NCT05251129|DRUG|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
214462351|NCT05251129|DRUG|Pravastatin 40 Mg Oral Tablet|Lower intensity statin
214531995|NCT01489462|BEHAVIORAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
214531996|NCT01489462|BEHAVIORAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
214531997|NCT01489462|BEHAVIORAL|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
214531998|NCT00006099|BIOLOGICAL|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
215149581|NCT06414629|OTHER|Simulation Based Mentorship Program|"In this program, local level mentors were developed to provide regular mentorship on low-dose high-frequency approach in contrast to one-time coaching in a long gap. This program combined the existing package of the continuum of care along with Helping Babies Survive (HBS) \& Helping Mothers Survive (HMS) guidelines, adopting a simulation-based onsite mentoring and coaching approach. The mentors provided monthly mentorship on following seven modules topics to the nurses of the intervention birthing centers:~1. Infection prevention~2. Antenatal care and counseling~3. Essential care of labor and birth~4. Helping babies breathe~5. Bleeding after birth~6. Essential care of labor and birth~7. Postnatal care and counseling~Every monthly session was followed by four weekly practice sessions. The nurses from intervention birthing centers were also called mentees."
215149582|NCT00460616|DRUG|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
215149583|NCT03399188|PROCEDURE|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
215149584|NCT02425943|DEVICE|injectable poly-L-lactic acid Sculptra Aesthetic|
215149585|NCT06492525|DRUG|Ensartinib|225 mg oral dose on day 1 in period 1 and on day 18 in period 2
215149586|NCT06492525|DRUG|Rifampicin|600 mg QD from day 9 to day 22 in period 2
215149587|NCT06492525|DRUG|Itraconazole|200 mg QD from day 9 to day 19 in period 2
215149588|NCT06492525|DRUG|Ensartinib|100 mg oral dose on day 1 in period 1 and on day 12 in period 2
214462352|NCT06742593|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
214462353|NCT03705416|PROCEDURE|Endoscopy|endoscopic suturing of stomach
214531999|NCT06016127|DEVICE|iovera system|"The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The 190 Smart Tip will be used in this study."
214532000|NCT06016127|DEVICE|Radiofrequency ablation|The RFA system consists of a Cosman, G4 Generator. The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman. A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.
214532001|NCT05417555|DEVICE|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
214462354|NCT03705416|PROCEDURE|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
214462355|NCT05564104|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
214462356|NCT06075615|DRUG|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
214462357|NCT06036836|BIOLOGICAL|favezelimab/pembrolizumab|IV infusion
214532002|NCT01624012|DEVICE|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
214532003|NCT01624012|DEVICE|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
214462358|NCT06036836|BIOLOGICAL|pembrolizumab|IV infusion
214462359|NCT06036836|DRUG|lenvatinib|Oral administration of capsule
214462360|NCT03097536|OTHER|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
214462361|NCT03360591|DEVICE|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
215149589|NCT06394141|BEHAVIORAL|Real-time triggers|The first intervention group (n= 30 professional drivers) will receive real-time triggers related to acute stress and sleepiness/fatigue. The real-time feedback involves giving relevant triggers when exceeding some critical stress values or detecting events of \&#39;energy-takers\&#39; based on accurate measurements of mental energy in a fully automated way. The selected triggers will be based on the co-creation workshops with drivers (e.g., auditive, visual) in order to select the most efficient (type or combination of) trigger(s) for the real-time feedback. The warning messages will be tailored to the preferences of the driver (e.g., personalized comfort- and safety-related settings) and aim to generate a warning message/signal meant to alert drivers and prevent they might end up with high stress levels
215149590|NCT06394141|BEHAVIORAL|Personalized tailored feedback|The second intervention group (n= 30 professional drivers) will receive personalized tailored feedback to reduce chronic stress and sleepiness/fatigue. The advice involves personalized (semi-)automatic feedback to drivers about a reduced stress level via the mobile app with automatic reports, as well as post-intervention during the next work break or at the end of the workday, based on the preferences of the driver. The (semi-)automatic feedback is based on the theory of Stages of Change, by which a driver will only receive relevant feedback based on their attitude and willingness during daily life.
215149591|NCT06394141|BEHAVIORAL|Real-time triggers + Personalized tailored feedback|The third intervention group (n= 30 professional drivers) will receive both real-time feedback related to acute stress and sleepiness/fatigue, as well as personalized tailored feedback related to chronic stress and sleepiness/fatigue, similar as in the first and second intervention groups.
215149592|NCT06394141|BEHAVIORAL|App-supported exercise therapy|The fourth intervention group (n= 30 professional drivers) will receive app-supported exercise therapy. The intervention will be based on principles of high-intensity training exercises that focus on the improvement of cardiorespiratory exercise capacity, as well as on the reduction of stress levels during work. Participants will receive instructions via the app to do some short, vigorous exercises adapted to their work environment at regular intervals, e.g., bending-and-stretching exercises with a weight in their hands, walking up and down the stairs of their vehicle for a few minutes, etc.
215149593|NCT06394141|BEHAVIORAL|Conventional intervention|The active control group (n= 20 professional drivers) will get a conventional intervention to reduce stress, e.g., mindfulness.
215149594|NCT00531544|DRUG|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
215149595|NCT02379091|DRUG|Namilumab|Namilumab subcutaneous injection
215149596|NCT02379091|DRUG|Placebo|Namilumab placebo-matching subcutaneous injection
215149597|NCT02379091|DRUG|Methotrexate|Methotrexate tablets
215149598|NCT02379091|DRUG|Folic/folinic acid|Folic/folinic acid tablets
215149599|NCT04834102|DIAGNOSTIC_TEST|Blood Tests|Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity
215149600|NCT03545958|BEHAVIORAL|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
214462362|NCT05746299|BEHAVIORAL|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
214462363|NCT05746299|BEHAVIORAL|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
214462364|NCT05746299|BEHAVIORAL|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
214462365|NCT04392193|RADIATION|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
214462366|NCT04786067|DRUG|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
214462367|NCT05086250|DRUG|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
214462368|NCT05086250|DRUG|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
215149601|NCT03545958|BEHAVIORAL|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
215149602|NCT04335006|DRUG|Carelizumab|Participants receive SHR-1210 intravenously (IV)
214462369|NCT05086250|DRUG|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
215149603|NCT04335006|DRUG|Nab-paclitaxel|administered intravenously every 4-week cycle
215149604|NCT04335006|DRUG|Apatinib|administered orally every 4-week cycle
215149605|NCT04015544|DIETARY_SUPPLEMENT|Watermelon|Pureed whole (100%) watermelon
215149606|NCT01724099|DRUG|Euiiyin-tang|Korean medicinal herbal drug
215149607|NCT01724099|DRUG|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
215149608|NCT04844398|OTHER|Clown visits by RED NOSES Clowndoctors Austria|Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
215149609|NCT03230461|BEHAVIORAL|Compression depth|
215149610|NCT02951377|OTHER|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
215149611|NCT02951377|DRUG|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
215149612|NCT00040989|DRUG|BAY 56-3722|
215149613|NCT00040989|PROCEDURE|enzyme inhibitor therapy|
214462370|NCT05086250|DRUG|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
214462371|NCT06332469|BEHAVIORAL|Internet based education and support program for patients awaiting kidney transplantation|"A guided internet based support an education program consisting of 9 modules running over 9 weeks. First, an introductory module is given that involves goal setting, followed by two educational modules with information regarding kidney disease, treatment and self-care in severe renal failure and while waiting for kidney transplantation, and kidney transplant-specific areas. Supportive content consist of three behavioral components spread over five modules/weeks and are based on cognitive behavioural therapy principles. The last module is a summation focusing on consolidating the knowledge learned during the program.~Each module consists of texts, illustrations, short films, reminders to practice physical activity and weekly homework for which the participants receive feedback from a contact person."
214462372|NCT06314724|BIOLOGICAL|Varicella Vaccine|lyophilized powder,subcutaneous injection
214462373|NCT06314724|BIOLOGICAL|Varivax|lyophilized powder,subcutaneous injection
214532004|NCT06543407|BEHAVIORAL|SWITCH IT|"Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6."
214462374|NCT05440630|DIETARY_SUPPLEMENT|Probiotics|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
214532005|NCT06543407|OTHER|E-cig Provision Only|Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
214532006|NCT03915951|DRUG|encorafenib|self-administered orally
214532007|NCT03915951|DRUG|binimetinib|self-administered orally
215149614|NCT00967070|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
215149615|NCT00967070|DRUG|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
214462375|NCT05440630|DIETARY_SUPPLEMENT|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
214462376|NCT05440630|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
214532008|NCT05631379|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
214532009|NCT05631379|DIAGNOSTIC_TEST|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
214532010|NCT05631379|DIAGNOSTIC_TEST|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
214532011|NCT05631379|DIAGNOSTIC_TEST|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
214532012|NCT05631379|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
214462377|NCT06127914|BEHAVIORAL|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
214532013|NCT05631379|DIAGNOSTIC_TEST|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
214532014|NCT02656745|DEVICE|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
215149616|NCT02936804|DEVICE|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
214532015|NCT01948882|DEVICE|ESS505 (BAY1454033)|
214532016|NCT05813132|DRUG|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
214532017|NCT05813132|DRUG|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
214532018|NCT06241677|DRUG|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
214532019|NCT04760327|COMBINATION_PRODUCT|Electrochemotherapy with bleomycin or cisplatin|Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
214532020|NCT03928678|PROCEDURE|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
214532021|NCT05364645|DRUG|Carboplatin|Given IV
214532022|NCT05364645|DRUG|Pemetrexed|Given IV
214532023|NCT05364645|DRUG|Selpercatinib|Given PO
214532024|NCT02269917|DRUG|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
214532025|NCT02269917|DRUG|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
214532026|NCT02269917|DRUG|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
214532027|NCT06105099|BEHAVIORAL|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
214532028|NCT06105099|BEHAVIORAL|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
215149617|NCT04200846|BEHAVIORAL|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
215149618|NCT01662765|PROCEDURE|Surgery|modified umbilectomy
215149619|NCT01662765|OTHER|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
215149620|NCT00119184|PROCEDURE|External cephalic version|7.5 mg bupivacaine intrathecally
215149621|NCT00119184|DRUG|spinal anesthesia|spinal anesthesia
215149622|NCT02129699|DRUG|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
215149623|NCT02129699|OTHER|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
215149624|NCT05378191|DRUG|COMIRNATY|One dose of COMIRNATY
214462378|NCT05017766|OTHER|analysis of antimicrobial resistance|"In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data."
214462379|NCT03852472|DRUG|Avacopan|Active treatment
214462380|NCT03852472|OTHER|Placebo|Placebo
214462381|NCT03267758|DIETARY_SUPPLEMENT|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
214462382|NCT03267758|DIETARY_SUPPLEMENT|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
214462383|NCT06214312|DIAGNOSTIC_TEST|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
214462384|NCT06104839|DRUG|NXC736|oral administration
214462385|NCT06104839|DRUG|Placebo|oral administration
214462386|NCT04029337|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
214462387|NCT05627167|OTHER|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
214462388|NCT05627167|OTHER|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
214462389|NCT06020235|DRUG|5% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
214462390|NCT06020235|DRUG|10% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
214532029|NCT06105099|BEHAVIORAL|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
214462391|NCT06020235|DRUG|Placebo|Placebo gel is either applied once per day or twice per day to the infected ulcer.
214462392|NCT01919554|BIOLOGICAL|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 10 days
214462393|NCT01919554|BIOLOGICAL|1000 IR house dust mites allergen extract tablet|Two sublingual tablets daily during 10 days
214462394|NCT01919554|BIOLOGICAL|1500 IR house dust mites allergen extract tablet|Three sublingual tablets daily during 10 days
214462395|NCT01919554|BIOLOGICAL|Placebo tablet|One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets
214708738|NCT04600687|OTHER|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
215149625|NCT05422898|BEHAVIORAL|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
215149626|NCT05422898|BEHAVIORAL|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
215149627|NCT01173094|DEVICE|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
214462396|NCT06647810|DRUG|BI 690517 formulation 1|BI 690517 formulation 1
214462397|NCT06647810|DRUG|BI 690517 formulation 2|BI 690517 formulation 2
214462398|NCT06647810|DRUG|Probenecid|Probenecid
214462399|NCT06107231|OTHER|Honey|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)
214462400|NCT06107231|OTHER|Sucrose|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)
214462401|NCT06107231|OTHER|Honey plus almonds|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
214462402|NCT06107231|OTHER|Sucrose plus almonds|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
214462403|NCT06546592|DEVICE|AI assisted contouring|Initial are generated automatically using software powered by artificial intelligence
214462404|NCT06648239|OTHER|Usual Care|In the usual care group, patients will proceed directly to ICA following referral from community cardiology, as is the current standard of care. Research staff will screen participants in this group for significant CAD using the decision support tool; however, the tool's recommendations will not affect their care, as all patients in this group will invariably receive ICA.
215149628|NCT01173094|DEVICE|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
214462405|NCT06648239|OTHER|Centralized triage with risk score-based screening for obstructive CAD|Patients randomized to the intervention will have selected features of their medical history, recorded on their referral form, entered into a decision support tool by research personnel to generate a recommendation of whether they should proceed directly to ICA or whether they should receive CCTA. Patients with recommendations for ICA will proceed directly to ICA. Patients with recommendations for CCTA will be referred to CCTA. Based on the results of the CCTA, recommendations for medical management versus referral for ICA will be made.
215149629|NCT01607255|DRUG|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
215149630|NCT01607255|PROCEDURE|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
214462406|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
214532030|NCT05408156|OTHER|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
214532031|NCT02185586|PROCEDURE|laparoscopic cholecystectomy|
214532032|NCT00303017|DIETARY_SUPPLEMENT|flavocoxid|flavonoid mixture
214532033|NCT00303017|DRUG|Naproxen|non-steroidal anti-inflammatory drug
214532034|NCT01596894|DRUG|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
214532035|NCT01596894|DRUG|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
214532036|NCT05383053|DEVICE|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
214532037|NCT00613132|DRUG|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
214532038|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
214532039|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
214532040|NCT02453802|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
214532041|NCT02453802|DRUG|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
214532042|NCT02453802|DRUG|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
214532043|NCT01914458|PROCEDURE|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
214532044|NCT05621746|DRUG|Esperoct|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
214532045|NCT01334905|DRUG|YM178|oral
214532046|NCT06646705|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214532047|NCT06645613|DEVICE|Transcranial Magnetic Stimulation Device|Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
214532048|NCT04449133|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
214532049|NCT04449133|DRUG|Placebo|Oral administration of two capsules before sleep for 7 days.
215149631|NCT01607255|PROCEDURE|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
214462407|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
214462408|NCT05200260|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
214532050|NCT02709447|BEHAVIORAL|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
214462409|NCT05200260|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
215149632|NCT01607255|PROCEDURE|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
215149633|NCT03208829|OTHER|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
215149634|NCT03208829|OTHER|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
215149635|NCT04382352|BIOLOGICAL|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
215149636|NCT01088724|DRUG|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
215149637|NCT05261646|DRUG|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
215149638|NCT05261646|DRUG|Matching placebo|Matching placebo（Stage 1；Stage 2）
215149639|NCT02530515|BIOLOGICAL|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
215149640|NCT02530515|OTHER|Laboratory Biomarker Analysis|Correlative studies
215149641|NCT03723642|DIAGNOSTIC_TEST|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
215149642|NCT03723642|DIAGNOSTIC_TEST|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
215149643|NCT03723642|DIAGNOSTIC_TEST|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
215149644|NCT03723642|DIAGNOSTIC_TEST|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
215149645|NCT03723642|DIAGNOSTIC_TEST|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
214462410|NCT05200260|DRUG|PARP inhibitor|For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy. In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.
214532051|NCT02709447|BEHAVIORAL|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
215149646|NCT03723642|DIAGNOSTIC_TEST|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
215149647|NCT03723642|DIAGNOSTIC_TEST|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
214462411|NCT05200260|DRUG|Bevacizumab|For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy. In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.
214532052|NCT05966545|PROCEDURE|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
214532053|NCT00291863|DRUG|Simvastatin|
214532054|NCT02893371|DRUG|Lithium Carbonate|Exposure to all dosages and delivery forms.
214532055|NCT02893371|DRUG|Lamotrigine|Exposure to all dosages and delivery forms.
214532056|NCT02893371|DRUG|Valproic Acid|Exposure to all dosages and delivery forms.
214532057|NCT02893371|DRUG|Oxcarbazepine|Exposure to all dosages and delivery forms.
214532058|NCT02893371|DRUG|Carbamazepine|Exposure to all dosages and delivery forms.
215149648|NCT03723642|DIAGNOSTIC_TEST|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
215149649|NCT03723642|DIAGNOSTIC_TEST|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
215149650|NCT03723642|DIAGNOSTIC_TEST|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
214532059|NCT02893371|DRUG|Ziprasidone|Exposure to all dosages and delivery forms.
214532060|NCT02893371|DRUG|Risperidone|Exposure to all dosages and delivery forms.
214532061|NCT02893371|DRUG|Quetiapine|Exposure to all dosages and delivery forms.
214532062|NCT02893371|DRUG|Olanzapine|Exposure to all dosages and delivery forms.
214532063|NCT02893371|DRUG|Aripiprazole|Exposure to all dosages and delivery forms.
215149651|NCT03723642|DIAGNOSTIC_TEST|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
215149652|NCT03723642|DIAGNOSTIC_TEST|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
215149653|NCT06125600|OTHER|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
215149654|NCT06231589|DEVICE|Sperm Selection|Sperm selection using physiological intracytoplasmic sperm injection (PICSI dish) or magnetic-activated cell sorting (MACS) for selecting sperm with high-quality, better morphology and lower DNA fragmentation.
215149655|NCT03307499|OTHER|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
215149656|NCT02283853|DRUG|dimethyl fumarate|administered orally
215149657|NCT02283853|DRUG|Interferon β-1a|administered by intramuscular injection
215149658|NCT06150066|OTHER|Recruiting samples|The GCF, plaque, and saliva samples will recruited from participants.
215149659|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
215149660|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
215149661|NCT05668481|BEHAVIORAL|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
214462412|NCT06283251|BEHAVIORAL|PediRISE Resource Program|A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
214462413|NCT06648824|DRUG|Mitapivat|Oral tablets
214462414|NCT06648824|DRUG|Midazolam|Oral syrup
214462415|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
214462416|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
214462417|NCT06125860|DIETARY_SUPPLEMENT|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
214462418|NCT06648642|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues
214462419|NCT06649552|DIAGNOSTIC_TEST|Psychiatric and psychological diagnostic tests|French validation of the SPI-CY
214462420|NCT04060082|OTHER|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
214462422|NCT06257771|DRUG|Alcohol (Ethanol)|Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
214462423|NCT05022485|DEVICE|ZNN Bactiguard tibia|Tibia fracture fixation
214462424|NCT05977530|BEHAVIORAL|self-rescue training|children will receive training for self-rescue if they are alone in water
214462425|NCT05533216|OTHER|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
214462426|NCT04416984|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
214462427|NCT04416984|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214462428|NCT04416984|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214462429|NCT04416984|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214462430|NCT06457802|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
214462431|NCT06148194|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
214462432|NCT06148194|COMBINATION_PRODUCT|Probiotic 1|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device (Product declaration: No. 210001337/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.
214532064|NCT02893371|DRUG|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
214532065|NCT02893371|DRUG|Haloperidol|Exposure to all dosages and delivery forms.
215149662|NCT04400643|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV is software accessory that automatically adjust ventilation and oxygenation variables to keep the patient within clinician-set target ranges.
215149663|NCT04400643|DEVICE|Non-automated ventilation|In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
215149664|NCT06596993|OTHER|IMU-based balance training|Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training
215149665|NCT06596993|OTHER|general health education or exercise training|general health education or exercise training
215149666|NCT06600009|DRUG|Secukinumab|Patients had received secukinumab per their dosing regimens prior to this observational study.
215149667|NCT06600009|DRUG|Adalimumab|Patients had received adalimumab per their dosing regimens prior to this observational study.
215149668|NCT06589401|DRUG|INP12|Oral paclitaxel
215149669|NCT06597630|OTHER|Tissue specimens were stained by histopathology of hematoxylin-eosin|Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing
215149670|NCT06590259|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.
215149671|NCT06590259|DRUG|Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab|Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
215149672|NCT06591312|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
215149673|NCT06591312|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
215149674|NCT06602154|OTHER|Resin modified glass ionomer|"The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds."
215149675|NCT04791735|PROCEDURE|Laparoscopy|"* Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~* Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~* Use of laparoscopic specific devices:~  * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~ * Use of a laparoscopic camera system with 0° or 30°~ * Use of a dedicated laparoscopic ultrasound probe.~ * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~* Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
215149676|NCT04791735|PROCEDURE|Laparotomy|"* Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~* Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~* Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~* Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
215149677|NCT06592612|RADIATION|SBRT and second-line systemic therapy|Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
214532066|NCT02893371|DRUG|Perphenazine|Exposure to all dosages and delivery forms.
214532067|NCT02893371|DRUG|Clozapine|Exposure to all dosages and delivery forms.
214532068|NCT02893371|DRUG|Asenapine|Exposure to all dosages and delivery forms.
214532069|NCT02893371|DRUG|Lurasidone|Exposure to all dosages and delivery forms.
214532070|NCT02893371|DRUG|Paliperidone|Exposure to all dosages and delivery forms.
214532071|NCT02893371|DRUG|Mirtazapine|Exposure to all dosages and delivery forms.
214532072|NCT02893371|DRUG|Bupropion|Exposure to all dosages and delivery forms.
214532073|NCT02893371|DRUG|Desvenlafaxine|Exposure to all dosages and delivery forms.
214532074|NCT02893371|DRUG|Duloxetine|Exposure to all dosages and delivery forms.
214532075|NCT02893371|DRUG|Venlafaxine|Exposure to all dosages and delivery forms.
215149678|NCT06592612|DRUG|Second-line systemic therapy|Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
214532076|NCT02893371|DRUG|Citalopram|Exposure to all dosages and delivery forms.
214532077|NCT02893371|DRUG|Escitalopram|Exposure to all dosages and delivery forms.
214532078|NCT02893371|DRUG|Fluoxetine|Exposure to all dosages and delivery forms.
214532079|NCT02893371|DRUG|Fluvoxamine|Exposure to all dosages and delivery forms.
214532080|NCT02893371|DRUG|Paroxetine|Exposure to all dosages and delivery forms.
214532081|NCT02893371|DRUG|Sertraline|Exposure to all dosages and delivery forms.
214532082|NCT02893371|DRUG|Vilazodone|Exposure to all dosages and delivery forms.
214532083|NCT02893371|DRUG|Doxepin|Exposure to all dosages and delivery forms.
214532084|NCT01792206|DRUG|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
214532085|NCT01792206|DRUG|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
214532086|NCT01954758|OTHER|personalized Embryo Transfer (pET)|
214532087|NCT01954758|OTHER|Frozen Embryo Transfer (FET)|
214695664|NCT04026152|BEHAVIORAL|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
214695665|NCT03014167|DRUG|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
214695666|NCT04799236|DRUG|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
214695667|NCT04799236|DRUG|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
214695668|NCT04799236|DRUG|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
214695669|NCT02036593|BEHAVIORAL|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
214695670|NCT02167841|BEHAVIORAL|Knee-Chest Position|
214695671|NCT06350227|COMBINATION_PRODUCT|the absorbable hemostat and suture|The hemostasis method of the experimental group is to use both the absorbable hemostat and suture.
214532088|NCT01954758|OTHER|Fresh Embryo Transfer (ET)|
215149679|NCT06600139|BEHAVIORAL|The Collaboration-Screening-Referral (SSH) model|The SSH aims to identify parents in need of mental health support and to strengthen social workers' competence in addressing mental illness. The SSH includes three components: 1) Collaborating - establishing collaboration with local services offering support to adults with mental illness, 2) Screening - using screening instruments for depression (the Patient Health Questionnaire - PHQ-9) and anxiety (GAD-7) to identify symptoms of mental illness among parents, and 3) Referral - Discussing the results of the screening with parents and referring to appropriate services. Techniques from motivational interviewing are included. Social workers receive training and material to administer the screening and refer parents in need of support.
215149680|NCT05156567|DIAGNOSTIC_TEST|Deep Learning System|The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
214532089|NCT02033499|BEHAVIORAL|SMBG|Blood glucose levels are tested once daily.
214695672|NCT06350227|COMBINATION_PRODUCT|electrocoagulation and suture|The active comparator group is to use electrocoagulation and suture simultaneously to stop bleeding.
214532090|NCT02411214|OTHER|survey|questionnaire survey sent by regular mail for 3 groups
214532091|NCT02772445|BEHAVIORAL|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
214532092|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
214532093|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
214532094|NCT01562821|DRUG|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
214532095|NCT04313036|DRUG|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
214532096|NCT01393314|DEVICE|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
214532097|NCT00574171|DRUG|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
214532098|NCT00574171|DRUG|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
214532099|NCT00405002|PROCEDURE|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
214695673|NCT06350227|OTHER|suture|The placebo comparator is to use suture alone for hemostasis.
214695674|NCT04451655|DRUG|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
214695675|NCT04004624|DEVICE|Ablation|Cardiac Ablation
215149681|NCT06590519|OTHER|Date Seed Extract|"Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules."
214695676|NCT03668691|DEVICE|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
215149682|NCT06604715|DRUG|JNJ-87562761|JNJ-87562761 will be administered.
215149683|NCT06591832|OTHER|Exercise|Virtual reality based progressive relaxation exercise
214462433|NCT06148194|COMBINATION_PRODUCT|Probiotic 2|In Vietnam, LiveSpo Navax Kid is manufactured as a Class-A medical device (Product declaration: No. 220002534/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.
214462434|NCT06380114|BEHAVIORAL|Communication|Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.
214462435|NCT06380114|BEHAVIORAL|Standing Orders|Practice personnel (providers and nurses) receive training in the implementation of standing orders for HPV vaccination via an online learning module and meetings with the study team.
214462436|NCT04870177|DRUG|AK112|AK112 infusion biweekly
214462437|NCT01467427|DRUG|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
214462438|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
214462439|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
214462440|NCT03161028|DRUG|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
214462441|NCT03161028|DRUG|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
214462442|NCT03497962|PROCEDURE|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
214462443|NCT03497962|PROCEDURE|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
214462444|NCT03492216|BEHAVIORAL|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
214462445|NCT03492216|BEHAVIORAL|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
214462446|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
214462447|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
214462448|NCT05186753|DRUG|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
214695677|NCT06553183|PROCEDURE|immersive virtual reality|Exercise based on virtual reality video games. Immersive type will be used.
214462450|NCT05810064|OTHER|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
214462451|NCT05680363|DEVICE|HyperSperm|Multi-step sperm preparation
214462452|NCT05680363|DEVICE|Standard Sperm Preparation|Standard sperm preparation
214462453|NCT05966870|OTHER|Unsweetened flavored sparkling water|Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
214462454|NCT05955729|BEHAVIORAL|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
214462455|NCT05955729|BEHAVIORAL|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
214695678|NCT06553183|PROCEDURE|traditional physicaltherapy|pneumatic compression, exercise and skin care
214695679|NCT02991157|DRUG|Nimodipine|
214695680|NCT00436566|BIOLOGICAL|trastuzumab|
214695681|NCT00436566|DRUG|cyclophosphamide|
214695682|NCT00436566|DRUG|doxorubicin hydrochloride|
214695683|NCT00436566|DRUG|lapatinib ditosylate|
214695684|NCT00436566|DRUG|paclitaxel|
214695685|NCT00436566|GENETIC|gene expression analysis|
214695686|NCT00436566|GENETIC|reverse transcriptase-polymerase chain reaction|
214695687|NCT00436566|OTHER|fluorophotometry|
214695688|NCT00436566|OTHER|laboratory biomarker analysis|
214695689|NCT00436566|OTHER|mass spectrometry|
215149684|NCT06591637|BEHAVIORAL|Fertility supportive behavior education based on Watson's Theory of Human Care|In this study, Watson's Theory of Human Caring guided the development of a care framework and nursing intervention for women with infertility. The researchers adapted the theory and focused on six of the ten carative factors : 1) Adopting values of humanity and devotion; 4) Developing supportive care relationships; 6) Using problem-solving methods for informed decisions; 7) Tailoring teaching to individual needs; 8) Creating a comfortable, peaceful environment; 9) Assisting with basic needs. The nursing care program, integrated with IVF treatments (14-18 days), involved four transpersonal interviews lasting 45-90 minutes each. These interviews were recorded in notes, used to individualize future sessions. The approach included active listening, empathy, and support, with participants encouraged to keep diaries for discussion. Communication was maintained in person, by phone, or email.
215149685|NCT06591637|PROCEDURE|Routine nursing care|"Routine nursing care during IVF treatment includes:~Pre-Treatment Counseling: Providing information and addressing patient questions.~Monitoring and Assessment: Regular checks of health, hormone levels, and ovarian function.~Medication Administration: Giving prescribed fertility drugs and other medications.~Assisting with Procedures: Preparing and assisting with egg retrieval and embryo transfer.~Emotional Support: Offering emotional and psychological support. Education: Instructing on medication use, self-care, and recognizing complications.~Follow-Up Care: Scheduling and managing follow-up appointments to monitor progress"
214462456|NCT05955729|DEVICE|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
214462457|NCT05955729|DEVICE|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
214462458|NCT05955729|DEVICE|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
214462459|NCT05955729|DEVICE|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
214462460|NCT05955729|BIOLOGICAL|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
214462461|NCT05955729|OTHER|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
214462462|NCT05955729|OTHER|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
214462463|NCT05955729|OTHER|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
214462464|NCT05955729|OTHER|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
214462465|NCT05955729|OTHER|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
214462466|NCT05955729|OTHER|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
214462467|NCT05955729|DEVICE|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
214462468|NCT06207877|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
214462469|NCT06207877|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
214462470|NCT06207877|DRUG|Placebo|Placebo will be administered subcutaneously.
214462471|NCT06779058|DEVICE|MRE|All imaging studies were performed by using a 1.5T/3.0-T MRI system
214462472|NCT06779058|DEVICE|Liver biopsy|Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.
214462473|NCT06778915|PROCEDURE|surgery|surgery
214462474|NCT07062978|DRUG|QL1206|QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
214462475|NCT07062978|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
214462476|NCT05022173|DEVICE|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
214462477|NCT05022173|DEVICE|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
214462478|NCT06806943|DEVICE|avatar-based interactions|SUD patients were investigated using the Autobiographical Memory Test in two conditions: face-to-face and avatar-based interactions. Patients had to recall 6 neutral cue words and 6 substance-related cue words for each condition.
214462479|NCT06234176|BEHAVIORAL|Personalised psychomotor therapy|"The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.~The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.~Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.~The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.~During each session, the participant will be required to complete the Duke health profile."
214695690|NCT00436566|PROCEDURE|adjuvant therapy|
214695691|NCT00436566|PROCEDURE|quality-of-life assessment|
214532100|NCT05240664|BEHAVIORAL|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
215149686|NCT06591637|DEVICE|"The booklet Fertility-Supporting Health Training"|This booklet was prepared in line with the relevant literature and contained educational content aimed at improving healthy lifestyle behaviours . The training booklet included information on the effects of factors such as obesity, weakness, exposure to environmentally harmful substances, smoking and caffeine use on fertility and the methods of coping with these factors. In addition, information on how to use proper nutrition, develop exercise habits and cope with stress was provided. The booklet was distributed to the women at at the onset of the study.
214532101|NCT05240664|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
214532102|NCT06140485|DIETARY_SUPPLEMENT|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
214532103|NCT06140485|DRUG|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
214532104|NCT03652870|DRUG|Nortriptyline|A medication used to treat conditions such as depression
214532105|NCT03652870|DRUG|Escitalopram|A medication used to treat conditions such as depression
214532106|NCT03652870|DRUG|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
214532107|NCT03716583|DRUG|Melatonin|25 mg
214532108|NCT03716583|DRUG|Dimethyl Sulfoxide|150 mg
214532109|NCT03716583|DRUG|Placebos|1 g
214532110|NCT02991781|OTHER|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
214532111|NCT02991781|DRUG|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
214532112|NCT02991781|OTHER|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
214532113|NCT02991781|OTHER|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
214532114|NCT01121185|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
214532115|NCT01121185|OTHER|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
214532116|NCT05765838|DIAGNOSTIC_TEST|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532117|NCT05765838|DIAGNOSTIC_TEST|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532118|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214695692|NCT05744115|DRUG|Ga-68-PSMA-11|Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
214695693|NCT02222454|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
214695694|NCT06210191|PROCEDURE|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
214695695|NCT03077126|OTHER|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
214695696|NCT03077126|DEVICE|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
214532119|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532120|NCT05765838|DIAGNOSTIC_TEST|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532121|NCT05765838|DIAGNOSTIC_TEST|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214462480|NCT06234176|OTHER|Usual treatment|Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
214695697|NCT03077126|DIAGNOSTIC_TEST|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
214462481|NCT02110212|PROCEDURE|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
214462482|NCT02110212|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
214462483|NCT05388149|DRUG|Neratinib|Neratinib administered as 40mg tablets
214462484|NCT06913855|DRUG|EMLA Cream|EMLA cream is applied once, 3 hours before the tube is removed. EMLA cream will be applied by the researcher in a thin layer to an area of 7-10 cm2, with the chest tube entrance to the skin remaining in the center. It will be covered with a Tegaderm transparent film dressing.
214462485|NCT06913855|PROCEDURE|Cold application|Cold application will be made with an ice cube pack immediately before the chest tube removal procedure. Cold application will be applied to a 7 cm diameter area, with the chest tube entrance to the skin being considered as the center. Skin temperature will be measured with an infrared thermometer and will be ensured to reach 13.0 degrees. Ice pack application is expected to last approximately 9-10 minutes.
214462486|NCT06419985|DRUG|80mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 40mg BID
214462487|NCT06419985|DRUG|160mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 80mg BID
214462488|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
214462489|NCT06634823|DRUG|Triamcinolone Acetonide Injectable Suspension|Triamcinolone injection into deltoid muscle (arm)
214462490|NCT06634823|DRUG|Saline injection|Saline injection into deltoid muscle (arm)
214462491|NCT04016662|DEVICE|Tandem t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
214462492|NCT05268809|OTHER|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
214462493|NCT03021096|OTHER|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
214462494|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
214462495|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
214462496|NCT05082116|DRUG|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
214462497|NCT03478553|OTHER|Blood draw|Blood draw
214462498|NCT03478553|OTHER|Questionnaire|Pulmonary Fibrosis Questionnaire
214462499|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
214462500|NCT05382650|BIOLOGICAL|Human rabies immune globulin 300 IU/mL|All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
214462501|NCT03604302|DEVICE|fMRI Paradigms|T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
214462502|NCT03655886|PROCEDURE|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
214462503|NCT03655886|RADIATION|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
214462504|NCT04821817|DRUG|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
214462505|NCT04821817|DRUG|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
214462506|NCT06074497|DRUG|KGX101- Cohort -1|Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
214462507|NCT06074497|DRUG|KGX101- Cohort 1|Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
214462508|NCT06074497|DRUG|KGX101- Cohort 2|Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
214462509|NCT06074497|DRUG|KGX101- Cohort 3|Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
214462510|NCT06074497|DRUG|KGX101- Cohort 4|Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
214462511|NCT06074497|DRUG|KGX101- Cohort 5|Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
214462512|NCT06074497|DRUG|KGX101 and Envafolimab|Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
214462513|NCT03583866|DRUG|Candesartan|7 days of Candesartan (16mg/day)
214462514|NCT03583866|DRUG|Placebo|7 days of Placebo
214462515|NCT01037881|DRUG|LEO 29102|comparison of different dosages of drug
214462516|NCT01037881|DRUG|Elidel®|comparison
214462517|NCT04477460|DIETARY_SUPPLEMENT|Thickened feeds|Thickened feeds directed by medical team
214462518|NCT04477460|DIETARY_SUPPLEMENT|Non-thickened feeds|Non-thickened feeds directed by medical team
214462519|NCT00764751|DRUG|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
214462520|NCT00764751|DRUG|Dovonex® cream|Twice daily application
214462521|NCT00764751|DRUG|Cream vehicle|Twice daily application
214462522|NCT04563546|OTHER|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
214462523|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
214462524|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
214462525|NCT04844931|PROCEDURE|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
214462526|NCT04844931|PROCEDURE|Standard PCI|Standard PCI
214462527|NCT05554848|DRUG|Dexmedetomidine|dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
214462528|NCT05554848|DRUG|Magnesium sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
214462529|NCT03739853|DRUG|Methotrexate|Used in all three arms of study
214462530|NCT03739853|DRUG|Sulfasalazine|Used in arm 2 of study
214462531|NCT03739853|DRUG|Leflunomide|Used in arm 2 of study
214462532|NCT03739853|DRUG|Adalimumab|Used in arm 3 of the study only
214462533|NCT03977662|COMBINATION_PRODUCT|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
214462534|NCT04817891|DEVICE|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
214462535|NCT03298477|DEVICE|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
214462536|NCT06412315|DRUG|Citalopram|Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
214462537|NCT06412315|DRUG|Placebo|Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
214462538|NCT05309551|DEVICE|IMT- Intervention group|The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
214462539|NCT05309551|DEVICE|IMT- Placebo group|The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
214462540|NCT02809443|BIOLOGICAL|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
214532122|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532123|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532124|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532125|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532126|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532127|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
214532128|NCT03015181|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
214532129|NCT03835403|OTHER|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
214532130|NCT03505918|OTHER|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
214532131|NCT02880124|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
214532132|NCT02880124|BEHAVIORAL|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
214532133|NCT02880124|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
214695698|NCT03077126|PROCEDURE|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
215149687|NCT06591871|OTHER|Self-management educational program for post mastectomy lymphedema women|"The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage)."
215149688|NCT05042414|BEHAVIORAL|High intensity interval training|Four times four minutes treadmill interval training
215149689|NCT05042414|BEHAVIORAL|Moderate intensity training|Moderate intensity treadmill training
214532134|NCT02880124|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
214532135|NCT02880124|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
214532136|NCT02880124|OTHER|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
214532137|NCT02880124|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
214532138|NCT02880124|BEHAVIORAL|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
214532139|NCT04340466|OTHER|No intervention|No intervention
214532140|NCT03905213|DEVICE|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
214532141|NCT03905213|DEVICE|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
214532142|NCT03905213|DEVICE|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
214532143|NCT02611921|DRUG|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
214532144|NCT02611921|DRUG|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
214532145|NCT03711799|BEHAVIORAL|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
214532146|NCT03456635|OTHER|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
214532147|NCT04713813|OTHER|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
214532148|NCT04713813|OTHER|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
214532149|NCT03519477|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
214532150|NCT05404126|OTHER|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
214532151|NCT00005968|DRUG|irofulven|
214532152|NCT00690534|DRUG|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
214532153|NCT00690534|DRUG|L-NMMA|variable rate for 3 hours
214532154|NCT00690534|DRUG|Sodium Nitroprusside|variable rate for 3 hours
214532155|NCT00690534|OTHER|mixed meal|mixed meal
214532156|NCT02851394|DRUG|Levobupivacaine|
215149690|NCT05042414|BEHAVIORAL|Resting|No training
215149691|NCT06992154|DIETARY_SUPPLEMENT|Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule|Probiotic capsule will contain Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, and Bifidobacterium Infantis
215149692|NCT06991595|PROCEDURE|cytoreductive resection of adenomyosis, myomectomy, resection of endometriosis|All women chosen for the study will be divided into the groups (AD, UF, DE, ETRS, CTRL) based on the inclusion/exclusion criteria (Table 2).A meticulous concern will be dedicated to patients´ education on advantages and disadvantages (including the eventual risks) of surgical and conservative management of AD and UF. These patients will be allocated into surgical or conservative arm of the study based on their inclinations: either to fertility saving surgical procedure (FSS) with subsequent IVF, or directly to IVF. This phenomenon of the importance of patients´ preferences in controversial clinical situations is the usual part of the management of infertile patients with AD or UF.
215149693|NCT06991595|PROCEDURE|hysteroscopy|Sampling of endometrium (Hysteroscopy) The samples will be collected using hysteroscopy, scheduled into the secretory phase of endometrial cycle. During hysteroscopy, the uterine cavity will be observed and described in the surgical protocol (capacity, symmetry, presence of intrauterine pathologies, internal ostia of the tubes). The 3.2 mm wide hysteroscope will be used. Its usage usually does not require any anaesthesia. The endometrium will be taken using biopsy forceps (7 French / 2.3 mm) and immediately frozen on dry ice and stored at -80 °C until processing. Two pieces of endometrium per patient will be collected - one for isolation of RNA and bulk RNA-Seq and/or RT-qPCR and the second one for isolation of nuclei and snRNA-Seq or validation using snRT-qPCR. If some unexpected findings would be observed during hysteroscopy (especially some interfering with fertility), they would be hysteroscopically removed and endometrial sampling postponed.
215149694|NCT06112509|OTHER|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
215149695|NCT05543330|DRUG|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
215149696|NCT05543330|PROCEDURE|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
214532157|NCT02851394|DRUG|levobupivacaine|
215149697|NCT05543330|DRUG|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
215149698|NCT06088069|OTHER|Virtual reality|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
215149699|NCT06601049|DIETARY_SUPPLEMENT|ResArgin|Resveratrol-based supplement
214532158|NCT02851394|DRUG|tramadol|
215149700|NCT02775786|OTHER|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
215149701|NCT06679062|DRUG|Suvorexant|Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
215149702|NCT06679062|OTHER|Placebo|Film coated tablet to match the active drug.
215149703|NCT07014982|BEHAVIORAL|Guided Meditation|Participants who complete guided meditation will be asked to meditate for 5 minutes a day, five times a week for two 6-week periods.
215149704|NCT06321263|OTHER|Peripheral Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
215149705|NCT06321263|OTHER|Inspiratory Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
215149706|NCT05908461|BEHAVIORAL|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
215149707|NCT03012503|DRUG|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
215149708|NCT03012503|DRUG|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
215149709|NCT06586047|DIAGNOSTIC_TEST|PET imaging|Imaging with FDG PET/CT and Pyl PET/CT
214462541|NCT02802618|OTHER|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
214462542|NCT05543655|OTHER|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
214462543|NCT00082745|OTHER|Laboratory Biomarker Analysis|Correlative studies
214462544|NCT00082745|OTHER|Questionnaire Administration|Ancillary studies
214532159|NCT05944133|OTHER|No intervention, observational retrospective study|No intervention
214532160|NCT05483192|DIETARY_SUPPLEMENT|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
214532161|NCT02465775|DEVICE|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
215149710|NCT04801420|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
215149711|NCT04801420|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
215149712|NCT04774094|DRUG|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
215149713|NCT07023666|DRUG|Deferoxamine|Deferoxamine is used to reduce excess iron accumulation after monitoring iron levels. Adjustment to therapy will be based on iron burden assessments throughout the study duration.
215149714|NCT07023666|DRUG|Deferasirox|Deferasirox is used for iron chelation therapy based on iron burden assessment throughout the study.
215149715|NCT07023666|DRUG|Deferiprone|Deferiprone is used for iron chelation therapy used throughout the study.
215149716|NCT07023666|DEVICE|Echocardiography|This device uses ultrasound waves to create images of heart to help evaluate the heart's structure and function. This allows the detection of abnormalities of heart due to iron overload through out the study.
215149717|NCT07023666|DEVICE|Electrocardiogram (ECG)|The Electrocardiogram (ECG) device records the electrical activity of the heart. It is crucial for identifying arrhythmias and conduction abnormalities, which can be exacerbated by iron accumulation in the heart.
215149718|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
215149719|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
215149720|NCT06233396|OTHER|Extra 4DCT scan|Extra 4DCT scan after routine simulation
215149721|NCT03723304|PROCEDURE|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
215149722|NCT03723304|PROCEDURE|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
214532162|NCT01811823|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
214532163|NCT02150109|DEVICE|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
214532164|NCT02150109|DEVICE|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
214532165|NCT05076955|DRUG|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
214532166|NCT00523133|DRUG|naltrexone|50 mg naltrexone daily for 3 months
214532167|NCT00523133|DRUG|naltrexone|50 mg of naltrexone daily for 6 months
214532168|NCT00523133|BEHAVIORAL|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
215149723|NCT00462813|DRUG|oral microencapsulated diindolylmethane|
214532169|NCT00523133|BEHAVIORAL|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
214532170|NCT04938739|OTHER|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
214532171|NCT04938739|OTHER|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
215149724|NCT00462813|GENETIC|polymerase chain reaction|
215149725|NCT00462813|OTHER|cervical Papanicolaou test|
215149726|NCT00462813|OTHER|cytology specimen collection procedure|
215149727|NCT00462813|PROCEDURE|colposcopic biopsy|
215149728|NCT03074552|DIETARY_SUPPLEMENT|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
215149729|NCT03074552|OTHER|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
215149730|NCT01357850|DRUG|GSK716155|GSK716155
215149731|NCT01357850|DRUG|Placebo|Placebo
215149732|NCT01202968|PROCEDURE|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
215149733|NCT04632836|OTHER|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
215149734|NCT00815659|DRUG|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
215149735|NCT00936923|DRUG|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
215149736|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
215149737|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
215149738|NCT03847896|DRUG|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
215149739|NCT03847896|DRUG|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
215149740|NCT03847896|OTHER|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
215149741|NCT05224999|DRUG|nivolumab|nivolumab 3mg/kg (every 2 weeks)
215149742|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
214462545|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume \~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
214532172|NCT02789098|OTHER|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
214532173|NCT01885377|OTHER|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
214532174|NCT01885377|OTHER|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
214532175|NCT02860559|BIOLOGICAL|TBX-1400|Hematopoietic stem cells transplantation
214532176|NCT01628783|DRUG|escitalopram 10 mg|orally once daily
214532177|NCT01628783|DRUG|Placebo|once daily
214532178|NCT01442623|OTHER|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
214532179|NCT03314389|DEVICE|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
215149743|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
215149744|NCT01090661|DRUG|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
215149745|NCT01090661|DRUG|placebo|placebo intravenous (IV) single dose
215149746|NCT01090661|DRUG|placebo|placebo subcutaneous (SC) single dose
215149747|NCT05859503|OTHER|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
215149748|NCT05859503|OTHER|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
215149749|NCT00118417|DRUG|Clonazepam|Participants will receive clonazepam.
215149750|NCT00118417|DRUG|Sertraline|Participants will receive sertraline.
215149751|NCT00118417|BEHAVIORAL|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
215149752|NCT01977989|DRUG|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
215149753|NCT01980537|PROCEDURE|Magnetic wire navigation|
215149754|NCT01980537|PROCEDURE|Conventional wire navigation|
215149755|NCT01216826|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
215149756|NCT05838118|DRUG|Fecal Microbiota Transplantation|Biologically active human fecal fluid (donor stool) is provided in fluid form.
214532180|NCT02517476|DIETARY_SUPPLEMENT|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
214532181|NCT06111183|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
214532182|NCT06111183|OTHER|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
214532183|NCT00984347|DRUG|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
214532184|NCT00984347|PROCEDURE|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
214532185|NCT02825849|BIOLOGICAL|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
214695699|NCT01196624|DEVICE|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
214695700|NCT01196624|DEVICE|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
214695701|NCT06254352|DIAGNOSTIC_TEST|scoring system|Clinical Risk Scores in Prediction of Outcome of Acute Upper Gastrointestinal Bleeding in Non Cirrhotic Patients.
215149757|NCT05838118|OTHER|Standard of Care for Chronic Kidney Disease|Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
214462546|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
214695702|NCT06242067|DRUG|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
214462547|NCT02998268|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
215149758|NCT03847051|DIAGNOSTIC_TEST|MRI|Brain MRI without intravenous contrast
215149759|NCT05353153|OTHER|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
215149760|NCT05353153|OTHER|standart care|no intervention no hypnosis
215149761|NCT03891849|DRUG|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
214462548|NCT02998268|DRUG|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
214462549|NCT02998268|DRUG|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
214462550|NCT05950191|OTHER|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
214532186|NCT01396733|DRUG|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
214532187|NCT05455554|DIAGNOSTIC_TEST|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
214532188|NCT05455554|DIAGNOSTIC_TEST|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
214532189|NCT01189136|DEVICE|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
214695703|NCT01870024|DRUG|Clonazepam|clonazepam 0,015 mg/kg
214695704|NCT01870024|DRUG|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
214695705|NCT01870024|DRUG|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
214695706|NCT01870024|DRUG|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
214695707|NCT03959449|BEHAVIORAL|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
214695708|NCT03959449|BEHAVIORAL|Motor imagery|Motor imagery of running
215149762|NCT01777113|OTHER|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
215149763|NCT01777113|OTHER|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
215149764|NCT01777113|OTHER|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
215149765|NCT02978781|DRUG|SAGE-217|SAGE-217 Oral Solution
215149766|NCT02978781|DRUG|SAGE-217|SAGE-217 Capsules
215149767|NCT02978781|DRUG|Placebo|SAGE-217 matching placebo capsules
215149768|NCT03543228|DIAGNOSTIC_TEST|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
215149769|NCT00785785|DRUG|Nilotinib (AMN107)|
215149770|NCT00785785|DRUG|imatinib (STI571)|
215149771|NCT02453321|PROCEDURE|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
215149772|NCT02453321|PROCEDURE|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
215149773|NCT02453321|PROCEDURE|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
215149774|NCT02453321|DRUG|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
215149775|NCT02763501|PROCEDURE|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
215149776|NCT02763501|PROCEDURE|non-closure of mesenteric defects|Mesenteric defects are left open
215149777|NCT03894683|DRUG|Melatonin 10 mg|Melatonin tablets (10 mg)
215149778|NCT03894683|DRUG|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
215149779|NCT04417699|DRUG|TAS 102|Oral medication over Days 1-5
215149780|NCT04417699|DRUG|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
215149781|NCT00025519|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215149782|NCT00025519|DRUG|fludarabine phosphate|
215149783|NCT00025519|DRUG|mycophenolate mofetil|
215149784|NCT00025519|DRUG|tacrolimus|
215149785|NCT00025519|DRUG|thalidomide|
215149786|NCT00025519|PROCEDURE|peripheral blood stem cell transplantation|
215149787|NCT00025519|RADIATION|radiation therapy|
215149788|NCT01887483|DIETARY_SUPPLEMENT|Vetal Laban active|Dairy product with probiotic
215149789|NCT01887483|DIETARY_SUPPLEMENT|Placebo|Dairy product without probiotic
215149790|NCT06047418|PROCEDURE|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
215149791|NCT01796366|DRUG|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
215149792|NCT01796366|DRUG|placebo|S.c placebo administered in combination with insulin 338
215149793|NCT01796366|DRUG|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
215149794|NCT01796366|DRUG|placebo|Oral placebo administered in combination with s.c. insulin glargine
215149795|NCT06373952|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
215149796|NCT04268381|OTHER|Biochemical analysis|aMMP-8 is measured by immunofluorometric assay (IFMA).
215149797|NCT02117661|DIETARY_SUPPLEMENT|L-carnitine capsules|Oral
215149798|NCT02117661|DIETARY_SUPPLEMENT|Cellulose capsules|oral
215149799|NCT02497170|BEHAVIORAL|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
215149800|NCT04863469|BEHAVIORAL|B-POC high load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
215149801|NCT04863469|BEHAVIORAL|B-POC low load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
215149802|NCT00850239|DRUG|dutogliptin|400 mg
215149803|NCT00850239|DRUG|placebo|
215149804|NCT00521404|DRUG|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
215149805|NCT00521404|DRUG|gemcitabine|Gemcitabine - 1000mg/meter sq
215149806|NCT04600661|OTHER|Traditional exercise therapy|Neuromuscular training
215149807|NCT03416543|OTHER|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
215149808|NCT02196948|OTHER|Electrolysis Percutaneous Therapeutic (EPTE)|
215149809|NCT02196948|OTHER|Eccentric exercise|
215149810|NCT00753181|OTHER|Nutritional Formula|nutritional shake daily
215149811|NCT00753181|OTHER|Usual diet|usual dietary habits
215149812|NCT00753181|OTHER|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
215149813|NCT02740101|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
215149814|NCT02740101|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
215149815|NCT00876551|PROCEDURE|Endoscopic vacuum assisted closure|"1. Endoscopic debridement of wound using a regular biopsy forceps.~2. Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~3. Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson \& Johnson, St-Stevens-Woluwe, Belgium).~4. Trimming of the sponge to the specific wound size.~5. Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~6. Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~7. Sponge exchange twice a week until wound grounds are clean and closed"
215149816|NCT01136083|BEHAVIORAL|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
215149817|NCT01136083|OTHER|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
215149818|NCT00967837|PROCEDURE|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
215149819|NCT00842296|DEVICE|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
214532190|NCT01189136|OTHER|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
215149820|NCT00424892|DRUG|Desvenlafaxine Sustained Release|
215149821|NCT04951635|DRUG|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
215149822|NCT04951635|DRUG|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
215149823|NCT06311097|OTHER|Fermented dairy|Participants will consume 300g of yogurt daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
214532191|NCT01064856|BIOLOGICAL|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
214532192|NCT01064856|BIOLOGICAL|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
214532193|NCT02831751|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
215149824|NCT06311097|OTHER|Non-fermented dairy|Participants will consume 300g of milk daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
215149825|NCT02282605|DRUG|XF-73 nasal gel|
214532194|NCT02831751|BIOLOGICAL|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
214532195|NCT02831751|BIOLOGICAL|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
214532196|NCT02831751|BIOLOGICAL|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
215149826|NCT02282605|DRUG|Placebo nasal gel|
215149827|NCT02282605|OTHER|Chlorhexidine gluconate 2% topical cloths|
214532197|NCT03427606|PROCEDURE|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
214695709|NCT03959449|BEHAVIORAL|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
215149828|NCT02791503|PROCEDURE|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
215149829|NCT02791503|PROCEDURE|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
214532198|NCT05272787|OTHER|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
214532199|NCT05272787|OTHER|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
214532200|NCT05272787|OTHER|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
214532201|NCT05272787|OTHER|Sunscreen|Auxiliary product
214532202|NCT05272787|OTHER|Facial wash|Auxiliary product.
214532203|NCT00447239|PROCEDURE|glucontrol (insulin therapy)|
214532204|NCT05318716|DEVICE|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
214532205|NCT05318716|DEVICE|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
214532206|NCT03302871|DRUG|Botulinum toxin type A|
214532207|NCT03302871|DEVICE|transcranial direct current stimulation|
214532208|NCT03302871|OTHER|hybrid training model of CIMT and BIT|
214532209|NCT03302871|OTHER|usual care|
214532210|NCT02223299|DIETARY_SUPPLEMENT|L-tyrosine|6g/d daily for 30 days
214532211|NCT02223299|DIETARY_SUPPLEMENT|L-Tryptophan|2g/d daily for 30 days
214532212|NCT02223299|DRUG|deplin|15mg daily for 30 days
214532213|NCT02223299|OTHER|Placebo A|a sugar-pill that looks like a real medication
214532214|NCT02223299|OTHER|Placebo B|a sugar-pill that looks like a real medication
214532215|NCT04870814|DEVICE|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
215149830|NCT04581694|DIAGNOSTIC_TEST|TAVI without contrast|TAVI without contrast
215149831|NCT03041506|DRUG|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
215149832|NCT03041506|PROCEDURE|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
215149833|NCT03041506|DRUG|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
215149834|NCT03041506|DRUG|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
214532216|NCT04870814|DIAGNOSTIC_TEST|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
214695710|NCT06163456|OTHER|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
214695711|NCT01752582|DEVICE|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
214695712|NCT01752582|DEVICE|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
214532217|NCT04870814|OTHER|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
214532218|NCT03323814|DEVICE|Slow-wave optimization|employing sensory stimulation to enhance slow waves
214532219|NCT06219902|DRUG|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
214532220|NCT06219902|DRUG|Placebo to elinzanetant|Oral administration
214532221|NCT06219902|DRUG|Zopiclone|Oral administration
214532222|NCT06219902|DRUG|Placebo to zopiclone|Oral administration
214532223|NCT05114902|DIAGNOSTIC_TEST|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
214532224|NCT01478256|DRUG|Erythromycin|Topical erythromycin ointment twice a day
214532225|NCT01478256|DRUG|Besifloxocin|Topical Besifloxocin twice a day
214695713|NCT00069420|BEHAVIORAL|Cognitive Motivational Behavior Therapy|
214695714|NCT05066828|OTHER|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
214695715|NCT01643759|DRUG|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
214695716|NCT02697084|OTHER|anal cancer|Anal cancer patients with TEP TDM
214695717|NCT01980706|DRUG|Baclofen|Baclofen is a GABA-B agonist
214695718|NCT01980706|DRUG|Placebo|Pill containing no pharmacologically active substance.
214695719|NCT02403830|DRUG|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
215149835|NCT03396263|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
215149836|NCT03396263|BEHAVIORAL|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
214695720|NCT02403830|OTHER|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
214695721|NCT02403830|DRUG|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
214695722|NCT02403830|DRUG|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
214695723|NCT06295016|OTHER|High-intensity intensive training|"Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume."
214462551|NCT05950191|OTHER|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
214462552|NCT05950191|BEHAVIORAL|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
214462553|NCT06393790|BEHAVIORAL|FMG (Fibromyalgia group)|This intervention will report results of a strength training programme in people with fibromyalgia
214462554|NCT06393790|BEHAVIORAL|HG (Healthy group)|This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
214462555|NCT06407089|OTHER|Spinertial Group|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
214462556|NCT06249945|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
214462557|NCT06249945|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
214462558|NCT05215548|PROCEDURE|therapeutic thoracic surgery|The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
214462559|NCT05215548|DRUG|Afatinib|The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
214462560|NCT04016155|DEVICE|Abbott FreeStyle Libre|Flash CGMS
214462561|NCT04016155|DEVICE|Patient Own SMBG|Market SMBG
214462562|NCT06332859|OTHER|Resilience training|The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
214462563|NCT04794868|DIAGNOSTIC_TEST|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
214462564|NCT04794868|DIAGNOSTIC_TEST|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
214462565|NCT05495269|DRUG|QLS-101 ophthalmic solution, 2.0 %|ophthalmic solution in a single use dropper vial
214462566|NCT05133973|DEVICE|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
214695724|NCT06295016|OTHER|Taper|"Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%."
214695725|NCT01261806|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
214695726|NCT01261806|BEHAVIORAL|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
215149837|NCT03396263|BEHAVIORAL|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
215149838|NCT04823013|OTHER|high power pain threshold ultrasound which the dose was kept constant|Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
215149839|NCT04823013|OTHER|high power pain threshold ultrasound which the dose reduced to one half|Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
215149840|NCT04823013|OTHER|ischemic compression|Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
215149841|NCT00345748|DRUG|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
215149842|NCT00345748|DRUG|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
215149843|NCT02559804|OTHER|survival and late effects|survival and late effects
215149844|NCT01993797|OTHER|Lung US|
215149845|NCT05562219|DRUG|QA108 granules|Take the medication as required for 24 weeks
215149846|NCT05562219|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
215149847|NCT05023668|OTHER|No intervention|No intervention
215149848|NCT00808652|OTHER|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~1. Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~2. NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
215149849|NCT02441296|OTHER|Formula with lactose|
215149850|NCT02441296|OTHER|Formula with maltodextrins|
215149851|NCT01567540|DRUG|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
215149852|NCT05676177|DIAGNOSTIC_TEST|Ultra Low Dose CT|"* Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD\_DECT\_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)\>30), that is 5 or 10 mAs~* Second scan (ULD\_DECT\_2) 80 kVp - fixed current 20 or 40 mA (if BMI\>30), that is 10 or 20 mAs"
215149853|NCT05676177|DIAGNOSTIC_TEST|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
214462567|NCT00179946|PROCEDURE|HLA typing|
214462568|NCT06030219|DRUG|Omadacycline|10-day course
214462569|NCT06030219|DRUG|Vancomycin Pill|10-day course
214462570|NCT06030219|DRUG|Moxifloxacin|10-day course
214462571|NCT05615974|DRUG|LM101|Administered intravenously
214462572|NCT05615974|DRUG|Toripalimab|Administered intravenously
214462573|NCT05615974|DRUG|Rituximab|Administered intravenously
214462574|NCT06269120|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
214462575|NCT04870515|OTHER|Best Practice|Receive standard lifestyle recommendations
214462576|NCT04870515|OTHER|Dietary Intervention|Receive dietary instructions
214462577|NCT04870515|OTHER|Exercise Intervention|Complete aerobic and strength/resistance exercises
214462578|NCT04870515|OTHER|Quality-of-Life Assessment|Ancillary studies
214462579|NCT04870515|OTHER|Questionnaire Administration|Ancillary studies
214462580|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
214462581|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
214462582|NCT04315064|DRUG|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
214462583|NCT05475808|DEVICE|Static wrist splint treatment|Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
215149854|NCT02937324|DEVICE|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
214532226|NCT00860301|OTHER|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
214532227|NCT05709886|DEVICE|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
214532228|NCT04547101|DRUG|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
215149855|NCT02937324|OTHER|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
215149856|NCT02110836|DIETARY_SUPPLEMENT|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
215149857|NCT02110836|DIETARY_SUPPLEMENT|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
215149858|NCT05532306|DRUG|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
215149859|NCT05532306|DRUG|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
215149860|NCT05538715|PROCEDURE|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
214462584|NCT05475808|OTHER|Tendon and nerve gliding exercises|"Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding)."
214462585|NCT05475808|DRUG|Wrist local steroid injection|"Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance."
214462586|NCT05787405|OTHER|Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.
214462587|NCT04690972|PROCEDURE|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
214462588|NCT04690972|PROCEDURE|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
214462589|NCT04690972|DIAGNOSTIC_TEST|Blood sample during diagnostic test|Blood sample as part of the care
214462590|NCT05512793|DIAGNOSTIC_TEST|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
214462591|NCT05512793|DIAGNOSTIC_TEST|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
214462592|NCT03286686|BEHAVIORAL|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
214462593|NCT03286686|BEHAVIORAL|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
214462594|NCT03286686|BEHAVIORAL|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
214462595|NCT05781100|BEHAVIORAL|Technology Use during Feeding Conditions|At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
214462596|NCT05144776|DIAGNOSTIC_TEST|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
214462597|NCT05144776|DIAGNOSTIC_TEST|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
214462598|NCT04458272|DRUG|DS-1001b|250 mg, twice daily, continuous oral administration
214462599|NCT06117046|DRUG|Cardiopeptidin|Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
214462600|NCT06117046|DRUG|50 ml of normal saline intravenous infusion|50 ml of normal saline intravenous infusion
214462601|NCT05098613|DRUG|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
214462602|NCT02637479|DEVICE|GammaKnife®|
214462603|NCT02637479|DEVICE|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
214462604|NCT02637479|DEVICE|MRI|
215149861|NCT05538715|PROCEDURE|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
215149862|NCT04663659|OTHER|no intervention|no intervention
215149863|NCT02538913|BEHAVIORAL|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
214462605|NCT03692065|DRUG|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
214462606|NCT06532877|BEHAVIORAL|Acceptance and Commitment Therapy|Patients and caregivers in the acceptance and commitment therapy arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
215149864|NCT02538913|PROCEDURE|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
215149865|NCT06286761|OTHER|endothelial cell collection|Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
215149866|NCT05169359|BEHAVIORAL|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
214462607|NCT06532877|BEHAVIORAL|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
214462608|NCT06802354|DRUG|Ozone|In Ozone group, ozone will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar, according to the manufacturer's recommendation for wound treatment following tooth extraction.
214462609|NCT06802354|DRUG|Placebo|In the control group, a sham ozone therapy will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar .
214462610|NCT03221517|OTHER|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
214462611|NCT05919810|OTHER|Probiotic|Oral probiotic
214462612|NCT05919810|DIETARY_SUPPLEMENT|Oral herbal powder supplement|oral herbal powder
214462613|NCT04594447|DEVICE|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
214462614|NCT04594447|DEVICE|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
214462615|NCT05523700|OTHER|Mobile Application|Intervention is a mobile application than combines patient data via EMR with PROMIS outcome measures.
214462616|NCT01175356|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
214462617|NCT01175356|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
214462618|NCT01175356|DRUG|Busulfan|Given IV
214462619|NCT01175356|DRUG|Cisplatin|Given IV
214462620|NCT01175356|DRUG|Cyclophosphamide|Given IV
214462621|NCT01175356|DRUG|Doxorubicin Hydrochloride|Given IV
214462622|NCT01175356|DRUG|Etoposide Phosphate|Given IV
214462623|NCT01175356|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
214462624|NCT01175356|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
214462625|NCT01175356|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
214462626|NCT01175356|RADIATION|Iobenguane I-131|Given IV
214462627|NCT01175356|DRUG|Isotretinoin|Given PO
214462628|NCT01175356|OTHER|Laboratory Biomarker Analysis|Correlative studies
214462629|NCT01175356|DRUG|Melphalan|Given IV
214462630|NCT01175356|OTHER|Pharmacological Study|Correlative studies
214462631|NCT01175356|OTHER|Questionnaire Administration|Ancillary studies
214462632|NCT01175356|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214462633|NCT01175356|DRUG|Topotecan Hydrochloride|Given IV
214462634|NCT01175356|DRUG|Vincristine Sulfate|Given IV
214462635|NCT04686175|DRUG|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
214462636|NCT02268461|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
214462637|NCT02268461|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
214462638|NCT05761743|DIAGNOSTIC_TEST|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
214462639|NCT06407063|PROCEDURE|Micro-decompression alone|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
215149867|NCT02713282|DRUG|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
214532229|NCT03465670|DEVICE|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
215149868|NCT02481661|PROCEDURE|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
215149869|NCT04287036|DEVICE|JJVC Investigational Contact Lens|TEST
215149870|NCT04287036|DEVICE|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
214532230|NCT03465670|DEVICE|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
214532231|NCT04675086|DRUG|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
214532232|NCT04675086|DRUG|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
214532233|NCT05254288|OTHER|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
214532234|NCT05254288|OTHER|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
214532235|NCT01204775|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
214532236|NCT01204775|DRUG|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
214532237|NCT01204775|DRUG|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
214532238|NCT01204775|DRUG|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
214532239|NCT01204775|DRUG|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
214532240|NCT05270889|DRUG|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
214532241|NCT00860899|DRUG|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
214532242|NCT02008539|DRUG|MSC_apceth_101|
215149871|NCT05802225|DRUG|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
214532243|NCT02567786|PROCEDURE|Surgery with CPB|
214532244|NCT02567786|OTHER|Fresh Frozen Plasma|
214532245|NCT02567786|OTHER|Plasmalyte|
214532246|NCT01552642|BEHAVIORAL|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
214532247|NCT04090216|DEVICE|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
214532248|NCT01427231|DIETARY_SUPPLEMENT|glucose|The effect of a glucose solution on cognitive performance will be measured.
214532249|NCT01427231|DIETARY_SUPPLEMENT|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
214532250|NCT01427231|DIETARY_SUPPLEMENT|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
214532251|NCT01690286|DRUG|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
214532252|NCT01690286|DRUG|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
214532253|NCT01690286|DRUG|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
214532254|NCT01690286|DRUG|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
214532255|NCT04135469|OTHER|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
214532256|NCT04135469|OTHER|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
215149872|NCT05802225|DRUG|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
215149873|NCT02350296|DRUG|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
215149874|NCT02350296|DRUG|OKi® 80 mg|"OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight)."
215149875|NCT04396639|BIOLOGICAL|Moroctocog-alfa (AF-CC)|Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
215149876|NCT04285970|OTHER|cycle detection|6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
215149877|NCT04285970|OTHER|detection of effort intensity|6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
215149878|NCT00965172|OTHER|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
215149879|NCT00965172|OTHER|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
215149880|NCT01452841|OTHER|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
215149881|NCT01452841|OTHER|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
215149882|NCT02229669|PROCEDURE|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
215149883|NCT02229669|PROCEDURE|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
215149884|NCT01544335|OTHER|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
215149885|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
214532257|NCT03148301|OTHER|Survey|Survey
214532258|NCT03165344|OTHER|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
214532259|NCT03165344|OTHER|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
214532260|NCT03165344|OTHER|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
214532261|NCT01374971|DRUG|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
214532262|NCT01374971|PROCEDURE|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
214532263|NCT05938959|DRUG|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
215149886|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
215149887|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
215149888|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
215149889|NCT05866315|DRUG|Remimazolam|Administer remimazolam
214532264|NCT05938959|DRUG|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
215149890|NCT05866315|DRUG|Desflurane|administer desflurane
215149891|NCT05866315|DRUG|Remifentanil|administer remifentanil
214532265|NCT05466968|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
214532266|NCT05466968|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
214532267|NCT05793827|BEHAVIORAL|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
215149892|NCT01752777|BEHAVIORAL|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
214532268|NCT05793827|BEHAVIORAL|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
214532269|NCT05213117|BEHAVIORAL|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
214532270|NCT06141772|OTHER|Measure of the circulating tumor DNA|Blood assessment to measure the kinetics au circulating tumor DNA
214532271|NCT05465486|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab."
214532272|NCT05465486|DEVICE|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab"
214532273|NCT04266366|OTHER|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
215149893|NCT01752777|BEHAVIORAL|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
215149894|NCT03879005|OTHER|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
215149895|NCT03565094|DRUG|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
215149896|NCT03565094|DRUG|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
215149897|NCT05778825|DRUG|Oral Minoxidil|minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
215149898|NCT05778825|OTHER|Placebo|placebo for 4 months
215149899|NCT06169059|DRUG|JLP-2004|administration of JLP-2004(COX-2 inhibitor)
215149900|NCT06169059|DRUG|JC-013|administration of JC-013(COX-2 inhibitor))
215149901|NCT00253318|DRUG|Docetaxel|40 mg/m\^2 IV over 1 hour on Day 1.
215149902|NCT00253318|DRUG|RAD001|30 mg orally on Days 1 and 8.
215149903|NCT00253318|DRUG|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
215149904|NCT02694484|OTHER|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
214462640|NCT06407063|PROCEDURE|Decompression and instrumented fusion|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
214462641|NCT05914246|DEVICE|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
214462642|NCT05700903|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH)|8 weeks of GnRH agonist
214462643|NCT05700903|DRUG|Androgen receptor (AR) inhibitor|2 weeks of AR Inhibitor
214462644|NCT05700903|DRUG|Placebo|Placebo tablet and injection
214462645|NCT03559569|BIOLOGICAL|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
214462646|NCT05212090|DIAGNOSTIC_TEST|EOS X-Ray|Repeated Anteroposterior (AP) Pelvis x-ray and Lateral Lumbar EOS x-ray
214462647|NCT04565743|BEHAVIORAL|Support on dentification and treatment of patients with high risk of osteoporotic fractures|Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
215149905|NCT05050227|BEHAVIORAL|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
214532274|NCT04266366|OTHER|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
214532275|NCT05300217|OTHER|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
214532276|NCT05300217|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
214532277|NCT05803525|OTHER|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
214532278|NCT02722122|DRUG|AIR DNase™|
214532279|NCT04127383|DEVICE|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
214532280|NCT00247117|DRUG|Metformin|
214532281|NCT00494208|DRUG|Testosterone|Testosterone ester
214532282|NCT02885883|DEVICE|MRI 3T|
214532283|NCT06352034|BEHAVIORAL|Empathy Training|"The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique."
214532284|NCT05173506|OTHER|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
214532285|NCT00275678|PROCEDURE|Blood stem cell versus bone marrow transplant|"1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
214532286|NCT02946788|DRUG|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
214532287|NCT03749616|DRUG|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
215149906|NCT05050227|BEHAVIORAL|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
215149907|NCT06344221|DEVICE|Dextrain Manipulandum and haptic feedback device|Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.
214532288|NCT03749616|DRUG|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
214532289|NCT07000318|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
214532290|NCT07000344|DRUG|Cohort 1 (triple-drug group)|"Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle.~Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred."
215149908|NCT03107871|DRUG|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
214532291|NCT07000344|DRUG|Cohort 2 (dual-drug group)|Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred.
214532292|NCT04457011|DRUG|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
214532293|NCT04457011|DRUG|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
214532294|NCT04457011|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
215149909|NCT03107871|DRUG|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
215149910|NCT06526039|OTHER|a novel short regimen|An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
215149911|NCT04135274|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
214462648|NCT06074172|DRUG|Cannabidiol (246mg press pill)|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
214462649|NCT06074172|DRUG|Placebo (246mg press pill)|Placebo press pills were provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
214462650|NCT01571700|PROCEDURE|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension \>5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
214462651|NCT03020199|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
214462652|NCT03020199|RADIATION|nb-UVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
214462653|NCT05496751|BEHAVIORAL|Low amount, low intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
214462654|NCT05496751|BEHAVIORAL|Low amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
214462655|NCT05496751|BEHAVIORAL|High amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
214462656|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
214462657|NCT05372029|BEHAVIORAL|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
214462658|NCT05372029|BEHAVIORAL|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
214462659|NCT06195319|DRUG|Simufilam|100 mg of \[14C\]-simufilam
214695727|NCT04753814|DIAGNOSTIC_TEST|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
214695728|NCT01288898|DRUG|ASP1941|Oral
214695729|NCT01288898|DRUG|Placebo|Oral
214695730|NCT01515995|DRUG|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
214695731|NCT03972644|PROCEDURE|Aortic valve replacement|Open heart surgery or transcatheter surgery
215149912|NCT05162963|OTHER|fixed implant denture|Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
214462660|NCT05583578|DEVICE|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
214462661|NCT05583578|DEVICE|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
214695732|NCT02481726|RADIATION|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
214695733|NCT03314220|BEHAVIORAL|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
214695734|NCT05249088|OTHER|Protocolised reduction of non-resuscitation fluids|"* Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
214695735|NCT05249088|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol"
214695736|NCT00005986|DRUG|busulfan|
214695737|NCT00005986|DRUG|cyclophosphamide|
214695738|NCT00005986|DRUG|filgrastim|
214695739|NCT00005986|DRUG|recombinant interferon alfa|
214695740|NCT00005986|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214462662|NCT04547309|RADIATION|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
214462663|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
214462664|NCT05216315|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus HDC stimulator (Newronika TM)
214462665|NCT05216315|DEVICE|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.10 sessions
214462666|NCT04005794|BEHAVIORAL|social VR (virtual reality) training|Social skills game that we developed in the R21 phase will be used across 8 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 4-5 weeks.
214462667|NCT04005794|BEHAVIORAL|Cognitive training (control game)|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
214462668|NCT05677113|DRUG|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
214462669|NCT05677113|DRUG|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
215149913|NCT05162963|OTHER|removable implant denture|removable implant denture
215149914|NCT05330286|DRUG|LMI070|oral solution
214532295|NCT06600815|PROCEDURE|preemptive stepwise infiltration anaesthesia(PSIA)|For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
214532296|NCT06600815|PROCEDURE|postoperative local infiltration analgesia(PLIA)|Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
214532297|NCT02074878|DRUG|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
214532298|NCT02074878|DRUG|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
214532299|NCT02074878|DRUG|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
214532300|NCT04435522|DRUG|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
214532301|NCT05942183|DIAGNOSTIC_TEST|ONSD|ultrasound measurement of the optic nerve sheath diameter
214532302|NCT02661581|BEHAVIORAL|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
214532303|NCT01874522|DRUG|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
215149915|NCT05330286|DRUG|LMI070|Oral solution
214462670|NCT05563038|DEVICE|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
214462671|NCT05563038|DRUG|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
214462672|NCT02859727|DRUG|CDZ173|140 mg/day
214462673|NCT04855188|DEVICE|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
214462674|NCT04855188|DEVICE|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
214462675|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
214532304|NCT01874522|DRUG|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
214532305|NCT03713437|DIAGNOSTIC_TEST|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
214532306|NCT03925402|DRUG|Ertapenem|Ertapenem injection
214532307|NCT03925402|DRUG|Carbapenems|Other carbapenems injection
214532308|NCT06611657|DRUG|Antirotinib hydrochloride|Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
214532309|NCT05430074|DEVICE|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
214532310|NCT05430074|DEVICE|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
214532311|NCT06274892|OTHER|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
214532312|NCT03770338|DRUG|Teriparatide|20ug dosage daily injection, 1-month preoperative
215149916|NCT05330286|DRUG|LMI070|Oral solution given in fasted state
215149917|NCT05330286|DRUG|LMI070|Oral solution given in fed state
215149918|NCT03457896|DRUG|Trastuzumab|Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
215149919|NCT03457896|DRUG|Cetuximab|Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
215149920|NCT03457896|DRUG|Neratinib|240 mg taken by mouth daily until disease progression.
214532313|NCT03386799|DEVICE|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
214462676|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
214462677|NCT05180240|DRUG|CardiolRx|Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
214462678|NCT04313972|DRUG|low-dose naltrexone|2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
214462679|NCT04313972|DRUG|Placebo oral tablet|1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
214462680|NCT05557838|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214462681|NCT05557838|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
214462682|NCT03482349|PROCEDURE|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
214462683|NCT06195514|DRUG|TAK-113|Description: TAK-113 5 mg capsules, orally, once daily, in a 3 weeks on/1 week off schedule for each 4-week cycle per treatment guidelines.
214462684|NCT06194773|PROCEDURE|Totalfil|Root canal treatment using TotalFil sealer
214462685|NCT06194773|PROCEDURE|NeoSealer|Root canal treatment using NeoSealer
214462686|NCT06194773|PROCEDURE|AH-Plus sealer|Root canal treatment using AH-Plus sealer
214462687|NCT05642442|DRUG|Placebo|Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
214462688|NCT05642442|DRUG|Suvecaltamide|Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
214462689|NCT04778046|DRUG|Hyperpolarized 129Xe|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
214462690|NCT02547363|DRUG|LEO 43204 gel|
214462691|NCT02547363|DRUG|Vehicle gel|
214462692|NCT04447469|DRUG|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
214462693|NCT04447469|OTHER|Placebo|matching placebo
214462694|NCT06529978|DEVICE|CoreMap EP Mapping System Mapping|Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
214462695|NCT06529978|DEVICE|CoreMap EP Mapping System Map-Guided Ablation|Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
214462696|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
214462697|NCT04701853|OTHER|Usual care|Care according to each center.
214462698|NCT05634993|OTHER|Assessment|Assessment of disability level and trunk control
214462699|NCT06090734|OTHER|My Voice|The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
214462700|NCT05846685|OTHER|Patient Phone Interviews|Collecting perceptions about automated falls-risk screening and referral tool
214462701|NCT05846685|OTHER|Patient In Person Interviews|Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
214462702|NCT06428214|DEVICE|Restylane Shaype|Injection
214462703|NCT06428214|DEVICE|Restylane Defyne|Injection
214462704|NCT06428214|DEVICE|Restylane Lyft lidocaine|Injection
214462705|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
214462706|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
214532314|NCT06715787|BEHAVIORAL|FEAST Perinatal Support Program|The intervention will include the core perinatal support program (PSP) with $15 weekly grocery gift cards for healthful food (fruit, vegetables, whole grains), The PSP will be completed during weekly group sessions over 16 weeks. The core PSP includes the two primary behavior change techniques: group-based nutrition education based on current United States Department of Agriculture (USDA) national guidelines for pregnant individuals and guided group sharing and engagement.
214532315|NCT06719648|DEVICE|Acellular dermal matrix + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
214462707|NCT04849572|BEHAVIORAL|Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
214695741|NCT00005986|PROCEDURE|peripheral blood stem cell transplantation|
214695742|NCT00005986|PROCEDURE|radiation therapy|
214532316|NCT06719648|PROCEDURE|Connective Tissue graft + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
214532317|NCT06720285|PROCEDURE|nerve block with 0.5% ropivacaine|Compared to active comparator arm, the experimental arm received the same procedure except in the analgesia maintenance which was performed by nerve block of the scalp using 0.5% ropivacaine. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
215149921|NCT03457896|DIAGNOSTIC_TEST|Guardant360 Diagnostic Test|Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
214532318|NCT06720285|DRUG|General anesthesia and opioids (fentanyl, propofol, rocuronium)|Compared to experimental arm, the active comparator arm received the same procedure except in the analgesia maintenance which was performed through continuous fentanyl infusion. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
214532319|NCT06721078|BEHAVIORAL|Peer navigation effectiveness|To determine the effectiveness of peer navigation on viral suppression and retention in care among adolescents living with HIV in South Africa.
215149922|NCT05518097|OTHER|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
214532320|NCT06719596|DRUG|Bifidobacterium Bifidum Oral Capsule|enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
214695743|NCT03902743|OTHER|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
214695744|NCT03925818|DRUG|Bismuth Subcitrate Potassium|Pylera capsules
215149923|NCT04931368|DRUG|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
215149924|NCT04931368|DRUG|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
214695745|NCT03925818|DIETARY_SUPPLEMENT|Gastrus|Gastrus 1 tablet
214695746|NCT03379610|DIAGNOSTIC_TEST|Nasopharngeal brush|"1. Baseline nasopharngeal brush before treatment~2. Post-treatment reassessment of residual NPC"
214695747|NCT05682820|DIAGNOSTIC_TEST|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
214695748|NCT03404596|DRUG|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
214695749|NCT03404596|BEHAVIORAL|Counseling|Brief counseling sessions, 10-15 minutes each.
214695750|NCT03404596|BEHAVIORAL|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
215149925|NCT01532986|OTHER|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
215149926|NCT01532986|OTHER|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
215149927|NCT00265603|PROCEDURE|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
214462708|NCT04849572|BEHAVIORAL|Delayed Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
214462709|NCT05201079|BIOLOGICAL|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
214462710|NCT05201079|DRUG|Fidaxomicin|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
214462711|NCT00267137|DEVICE|Pacing Algorithms|
214462712|NCT03569631|DRUG|BPN14770|25 mg BPN14770 capsules
214462713|NCT03569631|DRUG|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
214462714|NCT06592144|DRUG|Testosterone cypionate (200mg/3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
214462715|NCT06592144|OTHER|Sesame oil (3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
214462716|NCT05814653|BEHAVIORAL|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
214462717|NCT05814653|BEHAVIORAL|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
214462718|NCT04662489|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy
214462719|NCT04662489|PROCEDURE|Radial ablation|Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.
214462720|NCT01837576|DRUG|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
214532321|NCT06721325|BEHAVIORAL|THERAPEUTIC EDUCATION IN PHYSIOTHERAPY|Educational program of physiotherapy for women survivors of sexual violence and female genital mutilation.
214532322|NCT06721325|BEHAVIORAL|Psychotherapy and legal advice|Usual psychological and legal advice therapy for this population
214532323|NCT06720480|DIAGNOSTIC_TEST|Homglobin Electrophoresis|To diagnose thalassaemia \&amp;best method to control disease progress
214532324|NCT06719921|PROCEDURE|AF ablation|"The primary ablation strategy for both groups will be pulmonary vein isolation (PVI).~Other additional ablation, including but not limited to linear ablation, complex fractionated atrial electrogram (CFAE) ablation, or superior vena cava (SVC) isolation is not recommended unless necessitated by one of the following:~* Documented atrial flutter (AFL) or atrial tachycardia (AT) observed during the procedure, or~* Arrhythmias originating from the specific region requiring intervention."
214532325|NCT06719921|OTHER|AF ablation in a non-fluoroscopic EP lab|This procedure will take place in a non-fluoroscopic lab.
214532326|NCT06719921|OTHER|AF ablation in a fluoroscopic lab|This procedure will take place in a fluoroscopic lab.
214532327|NCT06720532|DIAGNOSTIC_TEST|characterization of renal function.|Blood and urine sample collection
214532328|NCT06720532|DIAGNOSTIC_TEST|Handgrip strength test|Assess the peak isometric strength of the hand and forearm muscles, as well as their susceptibility to fatigue.
214532329|NCT06720532|DIAGNOSTIC_TEST|Questionaires|The questionnaires evaluate quality of life, psychological distress, fear of progression, frailty, pain, decision regret and treatment expectations.
214532330|NCT06721052|DRUG|meta-Peng block|The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.
214695751|NCT03404596|OTHER|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
214695752|NCT01858155|DRUG|Melatonin|
214695753|NCT00001261|DRUG|Gamma Globulin|
214695754|NCT05591898|BEHAVIORAL|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
214532331|NCT06721052|DRUG|Postoperative analgesia management|We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
214695755|NCT02417909|OTHER|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
214695756|NCT04899791|OTHER|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
214695757|NCT04899791|OTHER|Wheat bread|Wheat bread
214695758|NCT01078701|BIOLOGICAL|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
215149928|NCT03650231|OTHER|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
215149929|NCT02994446|DEVICE|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
215149930|NCT06374563|OTHER|group 1 received topical Bee venom gel|Group 1 received a topical application of Bee Venom gel, 3 times per weeks. The wound dressing changed day after day and was cleaned every time with normal saline.
215149931|NCT06374563|OTHER|Group 2: Phonophoresis of Bee Venom gel|group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per weeks
215149932|NCT05204277|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
215149933|NCT05204277|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
215149934|NCT05204277|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
215149935|NCT05606445|BEHAVIORAL|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
214532332|NCT06721039|DRUG|Bilateral QL block|sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes
215149936|NCT03913520|OTHER|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
214532333|NCT06721039|DRUG|Intraperitoneal and port sites infiltration|with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
214532334|NCT06721650|OTHER|Perturbation-Based Balance Training|Perturbation-based balance training (PBT; or reactive balance training or perturbation training) is balance training that uses repeated, externally applied mechanical perturbations to trigger rapid reactions to regain postural stability in a safe and controlled environment
214532335|NCT06721650|OTHER|the selected physical therapy exercise program|trunk control therapeutic exercise, static and dynamic balance treaining exercises
214532336|NCT06720779|OTHER|TRAK physio knee prosthesis protocol|The exercise protocol designed for knee conditions is carried out through TRAK, the digital rehabilitation tool.
214695759|NCT01078701|BIOLOGICAL|Placebo|SPGN buffer
215149937|NCT03218046|BEHAVIORAL|EMDR|Eye Movement Desensitisation and Reprocessing
215149938|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One Placebo capsule to be taken 30 minutes after sachet in the morning."
215149939|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~\- One Placebo capsule to be taken 30 minutes after whey protein in the morning"
215149940|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning"
215149941|NCT04295278|DIAGNOSTIC_TEST|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
215149942|NCT05060367|DIETARY_SUPPLEMENT|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
214532337|NCT06720779|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
214532338|NCT06721117|OTHER|Grip strength assessment|Jamar hand dynamometer, recommended by the American Hand Therapists Association and accepted as the gold standard in many studies due to its high validity and reliability, will be used to measure hand grip strength. Pinchmeter (Baseline Mechanical Pinch Gauge) will be used to measure fine grip strength. Hand grip and finger grip strength measurements will be made in the recommended standard position of sitting, shoulder adduction and neutral rotation, elbow 90 degrees flexed, forearm in mid-rotation and supported, wrist in neutral. In the test procedure, 3 measurements will be taken for hand grip and finger grip strengths with one-minute intervals between each measurement and the averages will be recorded.
215149943|NCT05060367|DIETARY_SUPPLEMENT|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
215149944|NCT01052337|DRUG|anaesthetics: sevofluorane|0.5%of sevofluorane with air
215149945|NCT00078598|DRUG|Rituximab or Iodine I 131 Tositumomab Therapy|
215149946|NCT06064214|PROCEDURE|u/s guided intermediate cervical plexus block|The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
215149947|NCT04444453|DEVICE|Wearable Pedometer|Pedometer worn on wrist
215149948|NCT02454088|OTHER|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
215149949|NCT02454088|DEVICE|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
215149950|NCT00290316|PROCEDURE|Endoscopy ultrasound|
215149951|NCT00631072|BIOLOGICAL|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
215149952|NCT00631072|DRUG|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
215149953|NCT06359730|OTHER|LARS score questionnaire|LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life
214462721|NCT05859737|BEHAVIORAL|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
214462722|NCT05859737|OTHER|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
214462723|NCT03838536|DIETARY_SUPPLEMENT|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
214462724|NCT03838536|DIETARY_SUPPLEMENT|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
214462725|NCT06436378|BEHAVIORAL|Music intervention in person|The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
214462726|NCT06081452|BEHAVIORAL|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
214462727|NCT05923216|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
214462728|NCT05923216|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
214462729|NCT05808257|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
214462730|NCT05808257|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
214462731|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
214462732|NCT03726398|DRUG|Opsumit 10 Mg Tablet|Oral tablet taken once daily
214462733|NCT03649633|DRUG|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
214462734|NCT03649633|DRUG|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
214462735|NCT04042233|DRUG|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
214462736|NCT04042233|DRUG|Standard IV administration of vancomycin|IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
215149954|NCT05855811|DRUG|Dostarlimab|Dostarlimab should initiated within 6 months after the end of treatment for FPC.
215149955|NCT04916691|PROCEDURE|EPSB for rib fractures|EPSB for rib fractures
215149956|NCT04916691|DRUG|Ropivacaine|Standard of care weight-based optimal Ropivacaine dosing for ESPB
215149957|NCT01584375|OTHER|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~\--------------------------------------------------------------------------------"
215149958|NCT01584375|OTHER|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
215149959|NCT05689996|DRUG|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
215149960|NCT03473054|OTHER|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
215149961|NCT03328091|OTHER|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
215149962|NCT03328091|OTHER|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
215149963|NCT01412684|PROCEDURE|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
214462737|NCT03986931|OTHER|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
214462738|NCT03986931|OTHER|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
214462739|NCT05918380|BEHAVIORAL|PAL2|"Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
214462740|NCT05918380|OTHER|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
214462741|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
214462742|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
214462743|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
214462744|NCT04907851|BIOLOGICAL|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
214462745|NCT04907851|BIOLOGICAL|pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
214462746|NCT04226313|DIAGNOSTIC_TEST|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
214462747|NCT04226313|DIAGNOSTIC_TEST|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
214462748|NCT04752709|DEVICE|ELITONE UUI|External electrical stimulation
214462749|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
215149964|NCT06256796|OTHER|fresh frozen plasma|repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
215149965|NCT04178603|OTHER|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
215149966|NCT02559024|DRUG|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
215149967|NCT04572789|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
215149968|NCT04572789|DIETARY_SUPPLEMENT|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
215149969|NCT05565625|OTHER|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
215149970|NCT05565625|OTHER|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
215149971|NCT05565625|OTHER|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
215149972|NCT05565625|OTHER|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
215149973|NCT05565625|OTHER|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
215149974|NCT05565625|OTHER|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
215149975|NCT04614974|DRUG|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
215149976|NCT04614974|OTHER|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
215149977|NCT00076635|DRUG|Interferon gamma-1b|200 mcg, SQ, 3x per week
215149978|NCT01635153|DIETARY_SUPPLEMENT|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
215149979|NCT01635153|DIETARY_SUPPLEMENT|Micronutrient|Dar-vite Multivitamin
214462750|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
214462751|NCT06076512|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
214532339|NCT06721117|OTHER|Forearm muscle strength assessment|Wrist isometric muscle strength assessment will be performed with a handheld dynamometer (Lafayette Instrument Company, Lafayette, Indiana, USA). Patients will be placed in the supine, prone and sitting positions using the positions required for the fine muscle test method defined by Lovett and will be performed without compensatory movements. Wrist flexor and extensor muscles will be assessed. The values obtained with isometric contraction will be recorded in kg. Muscle strength measurements will be assessed bilaterally, in three repetitions for 5 seconds. The average value of the three repetition results will be recorded.
214462752|NCT06071429|DEVICE|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
214462753|NCT06071429|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
214532340|NCT06721117|OTHER|Pain threshold assessment|"Pain sensitivity to pressure will be assessed with a pain measuring device called an algometer. The Baseline Dolorimeter brand algometer will be used in the assessment. 3 measurements will be taken from the midpoint of the upper trapezius muscle and C7 points between the lateral edge of the acromion and C7. The areas will be marked before the measurement. The algometer will be placed perpendicular to these points. The patients will be asked to report the moment they first felt the pain and 30 seconds of rest will be given between the measurements. The value on the display will be read and the pain threshold will be recorded in pounds (1kg=2.2 pounds)."
214462754|NCT06417021|OTHER|Frontal Ultrasound Machine|Ultrasound machine will be placed in a frontal position
214462755|NCT06417021|OTHER|Lateral Ultrasound Machine|Ultrasound machine will be placed in a lateral position
214462756|NCT06475638|DEVICE|brachial artery doppler|brachial artery doppler evaluation before and after supraclavicular block
214532341|NCT06721117|OTHER|Anxiety level assessment|"The anxiety level will be determined with the Beck Anxiety Inventory. The Beck Anxiety Inventory is a scale developed by Aaron T. Beck (1988). This scale consists of 21 questions. For each item, the patient is asked to report how he/she has felt during the past week.~The items are scored as 0, 1, 2 or 3. The score range is between 0-63. For the total score, \< 21 is considered mild, 22-35 is considered moderate, and \> 36 is considered severe. The Turkish validity study of the Beck anxiety scale was conducted by Ulusoy et al (1996)."
214532342|NCT06719622|DRUG|budesonide|1 mg budesonide ampoule twice daily for patients weighing ≤35 kg or 2 mg twice daily for patients weighing \>35 kg
214532343|NCT06719622|DRUG|omeprazole (proton pump inhibitor)|omeprazole 10 mg twice daily for patients weighing ≤35 kg or 20 mg twice daily for patients weighing \>35 kg
214532344|NCT06720805|DRUG|Pentabiocel|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
214695760|NCT05290142|OTHER|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
215149980|NCT02067481|BEHAVIORAL|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
215149981|NCT00455182|PROCEDURE|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
215149982|NCT00455182|PROCEDURE|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
214462757|NCT06481280|DIETARY_SUPPLEMENT|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
214462758|NCT06481280|DIETARY_SUPPLEMENT|Placebo Formula|Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
214462759|NCT05801380|DRUG|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
214462760|NCT05801380|DRUG|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
215149983|NCT00455182|PROCEDURE|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
215149984|NCT02231931|DRUG|Digoxin|single dose, fasted
215149985|NCT02231931|DRUG|Rosuvastatin|single dose, fasted
215149986|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
215149987|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
215149988|NCT02231931|DRUG|Metformin hydrochloride|single dose, fasted
215149989|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
215149990|NCT02231931|DRUG|Furosemide|single dose, fasted
215149991|NCT01032122|DRUG|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
215149992|NCT06367140|DEVICE|EMG-triggered CIMCT device|The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.
215149993|NCT06367140|DEVICE|general cycling training|The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
215149994|NCT00658359|DRUG|Cyclosporine|Standard of care
215149995|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
215149996|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
215149997|NCT02754440|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
215149998|NCT03212781|DRUG|Iron dextran|total dose infusion
215149999|NCT03212781|DRUG|Ferrous Fumarate|oral tablets
215150000|NCT02560558|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
215150001|NCT01540552|OTHER|medical chart review|
215150002|NCT01540552|PROCEDURE|computed tomography|
215150003|NCT01540552|PROCEDURE|computer-aided detection/diagnosis|
215150004|NCT02245217|DEVICE|PET/CT scan to assess treatment efficacy|
215150005|NCT00176917|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
215150006|NCT00176917|DRUG|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
214462761|NCT05472961|BEHAVIORAL|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
214462762|NCT05711758|PROCEDURE|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
214462763|NCT05562401|DEVICE|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
214462764|NCT05562401|DRUG|Oral Electrolytes|Is be considered a drug that not require medical prescrption and containing water, carbohydrates and electrolytes.
214462765|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
214695761|NCT05290142|OTHER|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
215150007|NCT00533117|DRUG|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
215150008|NCT00533117|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
215150009|NCT00533117|BEHAVIORAL|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
214462766|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
214462767|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
214462768|NCT04081701|DIAGNOSTIC_TEST|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
214462769|NCT03849443|DRUG|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
214462770|NCT03849443|DRUG|Vitamin C 250 MG Oral Tablet|Oral method of placebo
214462771|NCT03849443|DRUG|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
214462772|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
214462773|NCT05810220|DEVICE|Electrode-Neural Interface|Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
214462774|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
214462775|NCT01529983|DEVICE|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
214462776|NCT04996017|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
214462777|NCT04996017|DRUG|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
214462778|NCT06447987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
214462779|NCT06447987|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214462780|NCT06447987|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214462781|NCT06447987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214462782|NCT06447987|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
214462783|NCT06447987|BIOLOGICAL|Cetuximab|Given IV
214462784|NCT06447987|PROCEDURE|Computed Tomography|Undergo CT and PET
214462785|NCT06447987|DRUG|Cyclophosphamide|Given IV
214462786|NCT06447987|PROCEDURE|Echocardiography|Undergo ECHO
214462787|NCT06447987|DRUG|Fludarabine|Given IV
214462788|NCT06447987|PROCEDURE|Leukapheresis|Undergo leukapheresis
214462789|NCT06447987|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214462790|NCT06447987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214462791|NCT06447987|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214695762|NCT01980121|DEVICE|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
214695763|NCT05804409|DIAGNOSTIC_TEST|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
214695764|NCT04209777|DRUG|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
214462792|NCT06539416|PROCEDURE|MitraClip implantation|The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
214462793|NCT06539520|OTHER|Aerobic training program|Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
214462794|NCT06539520|OTHER|Selected physical therapy program for post stroke patients|Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
214462795|NCT03566940|BIOLOGICAL|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
214462796|NCT03566940|BIOLOGICAL|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
214462797|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
214462798|NCT00704262|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
214462799|NCT06449287|OTHER|Diet|The diet intervention will start after all baseline testing is complete
214462800|NCT06449287|BIOLOGICAL|Blood Draw|Blood samples will be collected biweekly.
214462801|NCT06449287|BIOLOGICAL|Ketone/Glucose Monitoring|Hand-held glucometer will be used daily to monitor dietary intervention adherence.
214462802|NCT06449287|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
214462803|NCT06449287|BIOLOGICAL|Urine Analysis|24 hour urine collection will be done biweekly.
214695765|NCT04209777|DRUG|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
214695766|NCT00132821|DRUG|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
215150010|NCT02037399|DRUG|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
215150011|NCT02037399|DRUG|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
215150012|NCT02910479|DEVICE|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
215150013|NCT02910479|DEVICE|Rectal thermometer|
215150014|NCT02910479|DEVICE|Esophageal thermometer|
215150015|NCT02910479|DEVICE|Vital sense capsule thermometer|
215150016|NCT01263197|DRUG|LY2216684|administered orally
215150017|NCT01263197|DRUG|albuterol|administered orally
215150018|NCT01263197|DRUG|propranolol|administered orally
215150019|NCT01263197|DRUG|placebo for LY2216684|administered orally
215150020|NCT01263197|DRUG|placebo for albuterol|administered orally
214532345|NCT06720805|DRUG|Placebo|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
215150021|NCT01263197|DRUG|placebo for propranolol|administered orally
215150022|NCT04926389|OTHER|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
215150023|NCT04926389|OTHER|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
215150024|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
215150025|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
215150026|NCT02837770|DRUG|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
215150027|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
215150028|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
215150029|NCT02837770|DRUG|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
215150030|NCT06170294|DRUG|TCR-MAGE-A4 T-Cells|"* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells"
215150031|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with external ureteral catheter|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.
214462804|NCT06449287|BEHAVIORAL|Neuropsychological Measures - ANAM|The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
214462805|NCT05281562|DRUG|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
214462806|NCT05281562|DRUG|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
214462807|NCT05281562|DRUG|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
214462808|NCT03189498|DRUG|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
214532346|NCT00951171|PROCEDURE|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
214532347|NCT00951171|PROCEDURE|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
214695767|NCT00132821|DRUG|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
214532348|NCT06525753|OTHER|Weaning off Parenteral Nutrition|pediatric intestinal failure patients who have been weaned off parenteral nutrition
214532349|NCT00919061|DRUG|Gemcitabine|Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
214532350|NCT00919061|DRUG|Cisplatin|20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
214695768|NCT00132821|DRUG|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
214695769|NCT00132821|DRUG|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
214695770|NCT03973684|DEVICE|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
214695771|NCT03973684|OTHER|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
214695772|NCT01413984|BEHAVIORAL|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
214695773|NCT02444819|DRUG|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
215150032|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with double J internal ureteral stent|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
215150033|NCT01134055|DRUG|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
215150034|NCT01134055|DRUG|placebo|placebo eye drops
215150035|NCT01134055|BIOLOGICAL|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
215150036|NCT04609176|DRUG|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
215150037|NCT04609176|DRUG|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
215150038|NCT02314819|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
215150039|NCT02314819|DRUG|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
214532351|NCT00919061|DRUG|Sorafenib|400 mg PO once a day continuously.
214532352|NCT05820451|DEVICE|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
214695774|NCT00490763|BEHAVIORAL|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
214695775|NCT01934894|DRUG|cabazitaxel|
214695776|NCT01934894|DRUG|lapatinib|
214532353|NCT05820451|DEVICE|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
214532354|NCT02868788|DIETARY_SUPPLEMENT|dietary fiber|Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
214532355|NCT02868788|OTHER|HFHC meal|910 Calorie HFHC meal
214532356|NCT04769895|DRUG|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
214695777|NCT03416738|BEHAVIORAL|Semantically focused treatment|"Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
214532357|NCT06317259|BEHAVIORAL|Hypoxic breathwork plus music and messaging|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
214532358|NCT06317259|BEHAVIORAL|Hypoxic breathwork only|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
214532359|NCT06317259|BEHAVIORAL|Music and messaging meditation|Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
214532360|NCT03127618|DRUG|Lorlatinib|
214532361|NCT04967677|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
214532362|NCT03658694|PROCEDURE|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
214532363|NCT03658694|PROCEDURE|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
214532364|NCT03658694|PROCEDURE|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
214532365|NCT03658694|PROCEDURE|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
214532366|NCT02270463|DRUG|Tagraxofusp-erzs|Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
214532367|NCT06374186|BEHAVIORAL|Behavioral Intervention with financial rewards and coaching|Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
214532368|NCT06374186|BEHAVIORAL|Control|Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
214532369|NCT03579680|BEHAVIORAL|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
214532370|NCT03579680|BEHAVIORAL|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
214532371|NCT05589584|DRUG|N acetyl cysteine with weight reduction|high dose 2400mg/day
214532372|NCT02896153|OTHER|Questionnaire|
214532373|NCT05294328|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
214532374|NCT05294328|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
214532375|NCT05294328|DRUG|Vehicle Proprietary Ophthalmic Solution|Proprietary Vehicle Ophthalmic Solution
214532376|NCT00442026|DRUG|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
214532377|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
214532378|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
214532379|NCT00647374|OTHER|this is an observational study|
214532380|NCT01319175|OTHER|Hip flexion strength training|
214532381|NCT05926232|DRUG|Repotrectinib|Repotrectinib
214532382|NCT04225234|OTHER|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
214532383|NCT02056873|DEVICE|Continuous DBS|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
214532384|NCT02056873|DEVICE|Responsive Brain Stimulation (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
214532385|NCT05327725|OTHER|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
214532386|NCT04950387|OTHER|Breathing exercises|Based in yoga, common load
214532387|NCT02972242|RADIATION|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
214532388|NCT04572997|DRUG|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
214532389|NCT06309485|DRUG|WGI-0301 at MTD/RP2D dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
214532390|NCT06309485|DRUG|WGI-0301 at MTD/RP2D -1 dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
214532391|NCT06309485|DRUG|Sorafenib 400 mg PO, BID continuously|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
214532392|NCT06309485|DRUG|Sorafenib 400 mg PO, BID|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
214532393|NCT02956278|DRUG|Allopurinol|
214532394|NCT02956278|OTHER|Placebo|lactose placebo pill
214532395|NCT00018759|DRUG|paroxetine|
214532396|NCT00018759|BEHAVIORAL|ongoing psychological screening|
214532397|NCT04633213|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
214532398|NCT04633213|DRUG|Placebo|Ophthalmic Solution
214532399|NCT03084198|PROCEDURE|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
214532400|NCT03084198|PROCEDURE|Standard care for ALF|A standard of care for subjects with acute liver failure.
214532401|NCT02782208|DRUG|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
214532402|NCT02782208|DRUG|Placebo|Placebo is administered 4 times previous to and during the investigation day.
214532403|NCT02782208|DRUG|GH substitution|GH substitution as usually
215150040|NCT04587661|BEHAVIORAL|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
214532404|NCT02782208|OTHER|GH pause|GH substitution pause two days prior to the experimental day
214532405|NCT06479525|OTHER|Big Toe Flexor Strengthening Exercises|16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
214532406|NCT06479525|OTHER|Calf Strengthening Exercises|16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
214532407|NCT01281215|BEHAVIORAL|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
214532408|NCT03067610|RADIATION|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
214532409|NCT03067610|DRUG|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
214532410|NCT02587013|PROCEDURE|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
214532411|NCT02587013|PROCEDURE|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
214532412|NCT01226485|DRUG|Taladegib|Administered IV
214532413|NCT04145609|BEHAVIORAL|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
214532414|NCT01795521|RADIATION|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
214532415|NCT00049335|DRUG|capecitabine|1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
215150041|NCT04587661|BEHAVIORAL|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
215150042|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
215150043|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
215150044|NCT00304551|DRUG|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
215150045|NCT00304551|DRUG|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
215150046|NCT00304551|DRUG|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
215150047|NCT03023397|BIOLOGICAL|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
215150048|NCT03705689|OTHER|validation of Bitts|No intervention, observation of photographs of stool
215150049|NCT04341246|DEVICE|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
215150050|NCT02387502|DEVICE|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
214695778|NCT03416738|BEHAVIORAL|Phonologically focused treatment|"Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
214532416|NCT02125318|DRUG|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
214532417|NCT01765452|DRUG|Closone|75mg/100mg, 8weeks, PO
214532418|NCT01765452|DRUG|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
214532419|NCT04560777|OTHER|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
214532420|NCT05063123|DRUG|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
214532421|NCT00740597|GENETIC|gene expression analysis|
214532422|NCT00740597|GENETIC|polymerase chain reaction|
214532423|NCT00740597|GENETIC|western blotting|
214532424|NCT00740597|PROCEDURE|neoadjuvant therapy|
214532425|NCT00740597|PROCEDURE|therapeutic conventional surgery|
214532426|NCT00740597|RADIATION|intensity-modulated radiation therapy|
214532427|NCT01165164|OTHER|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
215150051|NCT02387502|DEVICE|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
214532428|NCT03436043|DEVICE|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
214532429|NCT03955354|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214532430|NCT03955354|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
214532431|NCT04402983|OTHER|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
215150052|NCT02387502|DEVICE|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
214532432|NCT05101083|DEVICE|New Receiver-in-Canal Device|Successor of previous device generation
214532433|NCT05101083|DEVICE|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
214532434|NCT01181219|PROCEDURE|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
214532435|NCT01181219|PROCEDURE|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
214532436|NCT00841607|PROCEDURE|pancreaticojejunostomy vs pancreaticogastrostomy|
214695779|NCT04345926|DRUG|Propofol|Stepped propofol concentration after 20 min of LOS
214695780|NCT04345926|DEVICE|Electroencephalogram recording|Acquisition of EEG activity
214695781|NCT03102320|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
214695782|NCT03102320|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
214695783|NCT03102320|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
214532437|NCT00413075|DRUG|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
214532438|NCT00399503|PROCEDURE|Spectral T Wave Alternans|
215150053|NCT05805917|DEVICE|Neoviderm Skin Emulsion medical device|Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
215150054|NCT05805917|DRUG|Connettivina 0.2% Cream|Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
215150055|NCT02466893|OTHER|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
215150056|NCT04434443|OTHER|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
215150057|NCT04434443|OTHER|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
215150058|NCT04708561|BEHAVIORAL|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1\) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
215150059|NCT03171961|BEHAVIORAL|online visit group|subjects has online visit with dietitian every 2 weeks+diet
215150060|NCT03171961|BEHAVIORAL|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
215150061|NCT03171961|BEHAVIORAL|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
215150062|NCT03177655|OTHER|Guided Imagery|Guided Imagery meditation
215150063|NCT03177655|OTHER|Journaling|Keeping a journal
215150064|NCT04601961|DRUG|Propofol|"Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1."
215150065|NCT04601961|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
215150066|NCT01146795|DRUG|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
214532439|NCT00399503|PROCEDURE|Modified Moving Average T Wave Alternans|
214532440|NCT00399503|PROCEDURE|Baroreceptor Sensitivity|
214695784|NCT01790971|DRUG|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
214532441|NCT00399503|PROCEDURE|Heart Rate Variability|
214532442|NCT00399503|PROCEDURE|Heart Rate Turbulence|
214532443|NCT00399503|PROCEDURE|Deceleration Capacity|
214532444|NCT00399503|PROCEDURE|Signal Averaged ECG|
214695785|NCT01790971|DRUG|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
214695786|NCT00570752|OTHER|Placebo|
214532445|NCT01304108|OTHER|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
214532446|NCT01304108|OTHER|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
214532447|NCT01304108|OTHER|Usual Care|No addition to the baseline system for care
214532448|NCT01359683|DEVICE|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
214532449|NCT04438122|OTHER|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
214532450|NCT04438122|OTHER|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
214532451|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
215150067|NCT01146795|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
215150068|NCT01146795|DRUG|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
214532452|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
215150069|NCT01538095|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
215150070|NCT01538095|OTHER|Laboratory Biomarker Analysis|Correlative studies
215150071|NCT01538095|OTHER|Pharmacological Study|Correlative studies
214532453|NCT03439098|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
214532454|NCT00932659|DEVICE|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
214532455|NCT03443063|DRUG|Lemborexant|oral tablet
214532456|NCT00552513|PROCEDURE|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
214532457|NCT00552513|PROCEDURE|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
214532458|NCT00990262|RADIATION|Cardiac Computed Tomography|"1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
214695787|NCT00570752|DRUG|BMS-582949|
214695788|NCT00570752|DRUG|Atorvastatin|
214695789|NCT00570752|DRUG|Statin|
214695790|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
214695791|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
215150072|NCT01538095|BIOLOGICAL|Trebananib|Given IV
215150073|NCT00232752|DEVICE|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
215150074|NCT06239818|DEVICE|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
215150075|NCT06239818|OTHER|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
215150076|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
214532459|NCT02827578|DRUG|Tamsulosin|Tamsulosin
214532460|NCT02827578|DRUG|Solifenacin|Solifenacin
214532461|NCT02827578|DRUG|Solifenacin placebo|Solifenacin placebo
214532462|NCT02825277|DEVICE|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
214532463|NCT02239081|DRUG|CTP-730|
215150077|NCT06480591|OTHER|Blood Draw|The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
215150078|NCT00385216|DRUG|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
215150079|NCT00385216|OTHER|Placebo|Placebo nasal spray 0mg x 1 before surgery
215150080|NCT06540417|DEVICE|External trigeminal nerve stimulation|The stimulation parameters were set to 120Hz, 250μs, 30s ON-30s OFF, with the intensity adjusted for patient comfort.
214532464|NCT02239081|DRUG|Placebo for CTP-730|
214695792|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
214695793|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
215150081|NCT06112093|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
215150082|NCT06112093|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
215150083|NCT06411561|BEHAVIORAL|SLEEP + COG|Combination of SLEEP and COG interventions
215150084|NCT06411561|BEHAVIORAL|COG|Daily 30-minute session of computerized cognitive training
214462809|NCT03490240|BEHAVIORAL|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
214532465|NCT00514475|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
214532466|NCT04137302|DRUG|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
214532467|NCT04316520|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet 2:1
214462810|NCT03490240|BEHAVIORAL|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
214462811|NCT03029884|DEVICE|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
214462812|NCT03029884|DEVICE|Sham Stimulation|No Active Stimulation
214462813|NCT03029884|DEVICE|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
214462814|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
214462815|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
214532468|NCT05771597|OTHER|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
214532469|NCT05771597|OTHER|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
214532470|NCT01827098|PROCEDURE|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
215150085|NCT06411561|BEHAVIORAL|SLEEP|Nighttime use of both ear plugs and eye masks
215150086|NCT06411561|BEHAVIORAL|AC|Educational modules on cognitive and sleep health
215150087|NCT01088178|DEVICE|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
215150088|NCT04431817|DEVICE|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
215150089|NCT06475976|DIAGNOSTIC_TEST|Chest computed tomography (CT) with angiography|A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.
215150090|NCT06475976|DIAGNOSTIC_TEST|Bronchoscopy with bronchoalveolar lavage|During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.
214462816|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
214462817|NCT05405426|OTHER|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
214462818|NCT05322044|BEHAVIORAL|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
214462819|NCT06501859|OTHER|Standard of care physical therapy|Standard rehabilitation protocol for 3 months.
214462820|NCT06501859|DEVICE|Shoulder pacemaker with physical therapy|Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
214532471|NCT05418686|BIOLOGICAL|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"* Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination."
214532472|NCT02867241|BEHAVIORAL|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
214532473|NCT02867241|BEHAVIORAL|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
214462821|NCT05477186|BIOLOGICAL|CV0501 (3 μg)|Study vaccine was administered as a single intramuscular injection.
214462822|NCT05477186|BIOLOGICAL|CV0501 (6 μg)|Study vaccine was administered as a single intramuscular injection.
214462823|NCT05477186|BIOLOGICAL|CV0501 (12 μg)|Study vaccine was administered as a single intramuscular injection.
215150091|NCT06475976|DIAGNOSTIC_TEST|Echocardiography|An echo uses sound waves to create computer pictures of the heart.
215150092|NCT06475976|DIAGNOSTIC_TEST|"24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)"|24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
214462824|NCT05477186|BIOLOGICAL|CV0501 (25 μg)|Study vaccine was administered as a single intramuscular injection.
215150093|NCT06464991|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
214462825|NCT05477186|BIOLOGICAL|CV0501 (50 μg)|Study vaccine was administered as a single intramuscular injection.
214462826|NCT05477186|BIOLOGICAL|CV0501 (100 μg)|Study vaccine was administered as a single intramuscular injection.
214462827|NCT05477186|BIOLOGICAL|CV0501 (200 μg)|Study vaccine was administered as a single intramuscular injection.
214462828|NCT04164641|DEVICE|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
215150094|NCT06464991|DRUG|Daratumumab|"dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1"
215150095|NCT06464991|DRUG|Pomalidomide|dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
215150096|NCT06464991|DRUG|Bortezomib|dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
214462829|NCT06449638|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215150097|NCT06464991|DRUG|Dexamethasone|dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
215150098|NCT04307329|BIOLOGICAL|Monalizumab|Monalizumab 750 mg every two weeks
215150099|NCT04307329|BIOLOGICAL|Trastuzumab|Trastuzumab 4 mg/kg every two weeks
215150100|NCT03323346|DRUG|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
215150101|NCT06303388|OTHER|Bruegger,s Exercise|Bruegger's Exercise protocol along with conventional Physiotherapy.
215150102|NCT06303388|OTHER|Egoscue Exercise|Egoscue Exercise along with conventional Physiotherapy.
215150103|NCT02317471|BIOLOGICAL|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
215150104|NCT02317471|DRUG|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
215150105|NCT01721044|DRUG|Placebo|Administered orally
215150106|NCT01721044|DRUG|Baricitinib|Administered orally
215150107|NCT01721044|DRUG|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
215150108|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
215150109|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
215150110|NCT03824249|DIAGNOSTIC_TEST|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
215150111|NCT02144896|OTHER|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
215150112|NCT00997308|DRUG|AZD1446|Solution, oral, for 4 weeks
215150113|NCT00997308|DRUG|Placebo|
215150114|NCT04032093|BIOLOGICAL|RSV vaccine|RSV vaccine
215150115|NCT04032093|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
215150116|NCT01258686|DRUG|Silymarin|700mg thrice daily
215150117|NCT01258686|DRUG|Placebo|Placebo 700mg thrice daily
215150118|NCT03394820|DRUG|Dexamethasone|The intervention is the time when dexamethasone is administered
215150119|NCT04987333|DRUG|Efavaleukin alfa|Administered as a single dose SC injection.
214462830|NCT06449638|OTHER|Revita|Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214462831|NCT06449638|OTHER|Relese|Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214462832|NCT06449638|OTHER|Cogenex|Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214462833|NCT06449638|OTHER|Enverse|Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214462834|NCT05813236|DEVICE|Novosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
214462835|NCT05813236|DEVICE|Monosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
214462836|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with metal/Bio-Tenodesis screws|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by\~10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Metal/Bio-Tenodesis screw(MBS). The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with an MBS in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
214532474|NCT03647202|DRUG|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
214532475|NCT03647202|DRUG|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
214532476|NCT03647202|DRUG|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
214532477|NCT01417702|DEVICE|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
215150120|NCT04957875|DEVICE|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
215150121|NCT04114760|DEVICE|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
215150122|NCT04114760|DEVICE|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
214532478|NCT02720185|DRUG|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
214532479|NCT02720185|PROCEDURE|Conventional Surgery|Undergo surgery
214532480|NCT02720185|OTHER|Laboratory Biomarker Analysis|Correlative studies
214532481|NCT01157351|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
214462837|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with Shark Screws®|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by approx.10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Shark Screw®. The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with the Shark Screw® in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
214462838|NCT04137107|DRUG|Oxaliplatin|Given standard of care oxaliplatin
214462839|NCT04137107|DRUG|Duloxetine Hydrochloride|Given PO
214532482|NCT01157351|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 15 months
214462840|NCT04137107|DRUG|Duloxetine|Given PO
214462841|NCT04137107|OTHER|Quality-of-Life Assessment|Ancillary studies
214462842|NCT04137107|OTHER|Questionnaire Administration|Ancillary studies
214462843|NCT04137107|OTHER|Placebo|Given PO
214462844|NCT05158166|DRUG|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
214462845|NCT06078085|OTHER|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
214462846|NCT05573126|DRUG|Vosilasarm|Vosilasarm is an orally administered investigational selective androgen receptor modulator (SARM)
214462847|NCT05573126|DRUG|Elacestrant|Oral SERD
214462848|NCT05573126|DRUG|Everolimus|mTOR Inhibitor
214462849|NCT02747303|PROCEDURE|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
214462850|NCT06307600|DRUG|RD06-03 cell injection|The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
214532483|NCT01157351|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
214532484|NCT01157351|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
214532485|NCT01157351|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
214532486|NCT01157351|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
215150123|NCT00613873|PROCEDURE|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
214462851|NCT04550182|PROCEDURE|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
214462852|NCT06295744|RADIATION|Radiation Therapy|WBI with SIB delivered over 5 fractions
214462853|NCT04364048|DRUG|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
214532487|NCT01157351|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
214532488|NCT01157351|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
214532489|NCT05188625|OTHER|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
214532490|NCT03140566|DIAGNOSTIC_TEST|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index \>50% in addition to relief of symptoms and signs of congestion before discharge.
214532491|NCT03140566|DIAGNOSTIC_TEST|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
214532492|NCT03418493|DRUG|LY3316531 - IV|Administered IV.
214532493|NCT03418493|DRUG|LY3316531 - SC|Administered SC.
214532494|NCT03418493|DRUG|Placebo - IV|Administered IV.
214532495|NCT06063447|OTHER|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
215150124|NCT04205877|DEVICE|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
215150125|NCT02015260|DRUG|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
215150126|NCT02015260|DRUG|Placebo|Placebo
215150127|NCT01457703|DRUG|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
215150128|NCT01457703|DRUG|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
215150129|NCT01457703|DRUG|Recombinant LH|Used to stimulate ovarian function in women.
215150130|NCT01457703|DRUG|Letrozole|An aromatase inhibitor.
215150131|NCT02271672|DEVICE|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
215150132|NCT02271672|DEVICE|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
215150133|NCT03530982|OTHER|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
215150134|NCT01481844|DRUG|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
215150135|NCT01481844|DRUG|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
215150136|NCT00828594|DRUG|RAD001|
215150137|NCT00828594|DRUG|RAD001, sorafenib|
214462854|NCT04364048|DRUG|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
214462855|NCT04364048|RADIATION|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
214462856|NCT04364048|DRUG|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
214695794|NCT05792670|PROCEDURE|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
214462858|NCT03687814|OTHER|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
214532496|NCT04847310|OTHER|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
215150138|NCT00514839|BEHAVIORAL|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
214462859|NCT03687814|OTHER|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
214462860|NCT06558123|PROCEDURE|block|Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
214462861|NCT05792085|BEHAVIORAL|EHR-based GDMT Optimization|Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
214462862|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
214462863|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
214462864|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
214462865|NCT06189365|DEVICE|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
214695795|NCT02021448|OTHER|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
214695796|NCT04496440|OTHER|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
215150139|NCT03136510|DRUG|Apixaban 5 mg|"Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month"
215150140|NCT00043862|DRUG|topotecan|
215150141|NCT06044779|PROCEDURE|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
215150142|NCT06044779|PROCEDURE|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
215150143|NCT00088088|DRUG|Paclitaxel|
215150144|NCT00088088|DRUG|Carboplatin|
215150145|NCT00088088|DRUG|STA 4783|
215150146|NCT02203968|DRUG|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
214462866|NCT06326099|BEHAVIORAL|Brief Online Binge Eating and Drinking Intervention|The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
214462867|NCT06318455|OTHER|Breathing exercise|For 12 weeks they will do kumbaka breathing exercise for 5 minutes twice a day in the morning and evening
214462868|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
214462869|NCT06185491|OTHER|HGI|Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
214532497|NCT04847310|OTHER|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
214462870|NCT04380831|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214695797|NCT05047159|DEVICE|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
214695798|NCT05047159|DEVICE|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
215150147|NCT02203968|DRUG|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
215150148|NCT06177548|PROCEDURE|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
215150149|NCT04941677|OTHER|no intervention|no intervention in this study
215150150|NCT01771289|DRUG|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
215150151|NCT01771289|RADIATION|Radiation|chemoradiation
215150152|NCT06120400|DRUG|Whole Egg|Whole Large, Grade A Egg
214695799|NCT05047159|DEVICE|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
214695800|NCT05047159|DEVICE|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
214695801|NCT05047159|DRUG|drug therapy|There is no restriction on the choice of therapeutic drugs.
214695802|NCT04273399|OTHER|High-impact exercise intervention|"* Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading"
214695803|NCT04273399|OTHER|Acute response to high-impact exercise|"* First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise"
214695804|NCT01563640|OTHER|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
214695805|NCT01563640|OTHER|washing|normal washing of school uniforms, without permethrin insecticide impregnation
215150153|NCT04275362|DEVICE|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
215150154|NCT04275362|DEVICE|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
215150155|NCT04275362|DEVICE|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
215150156|NCT04275362|DEVICE|Control|No total knee replacement
215150157|NCT03257059|OTHER|Breakfast|Glutinous rice (75 grams of available carbohydrate)
215150158|NCT03257059|OTHER|No Breakfast|No food to be served in the morning
214462871|NCT04380831|DRUG|Cyclophosphamide|Undergo HSCT
214462872|NCT04380831|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
214462873|NCT04380831|PROCEDURE|Total-Body Irradiation|Undergo TBI using IMRT
214462874|NCT03709680|DRUG|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
214462875|NCT03709680|DRUG|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
214462876|NCT03709680|DRUG|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
214462877|NCT03709680|DRUG|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
214462878|NCT03709680|DRUG|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
214462879|NCT06777446|PROCEDURE|Elective Adhesionlysis|See descriptions in study arms
214462880|NCT06777446|DEVICE|Adhesion barrier|At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).
214462881|NCT05802056|BIOLOGICAL|Aldesleukin|Given IP
214462882|NCT05802056|PROCEDURE|Biopsy|Undergo biopsy
214462883|NCT05802056|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214462884|NCT05802056|PROCEDURE|Computed Tomography|Undergo PET/CT
214462885|NCT05802056|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
214695806|NCT00364494|PROCEDURE|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not
215150159|NCT02765516|OTHER|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
215150160|NCT02765516|OTHER|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
215150161|NCT05506033|PROCEDURE|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
215150162|NCT04477096|DRUG|HS-10234|HS-10234
215150163|NCT04477096|DRUG|Emtricitabine|Emtricitabine
215150164|NCT04002232|DEVICE|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
215150165|NCT05279677|DRUG|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
214695807|NCT01842308|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
215150166|NCT02952820|DRUG|lemborexant|
214695808|NCT01842308|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
214695809|NCT01842308|DRUG|Carfilzomib|Given IV
214695810|NCT01842308|OTHER|Laboratory Biomarker Analysis|Correlative studies
215150167|NCT02952820|DRUG|Placebo|
215150168|NCT03310918|OTHER|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
215150169|NCT03310918|OTHER|Standard Leukemia care|Standard care per the hospital guideline
215150170|NCT06237985|PROCEDURE|ProTaper Gold file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.
215150171|NCT06237985|PROCEDURE|OneShape file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.
215150172|NCT06237985|PROCEDURE|TruNatomy file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
215150173|NCT03074240|PROCEDURE|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
214462886|NCT05802056|DRUG|Fluorouracil|Given IV
214462887|NCT05802056|DRUG|Leucovorin Calcium|Given IV
214462888|NCT05802056|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214462889|NCT05802056|BIOLOGICAL|Nivolumab|Given IV
214462890|NCT05802056|DRUG|Oxaliplatin|Given IV
214462891|NCT05802056|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
215150174|NCT03074240|PROCEDURE|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
214462892|NCT05280548|DRUG|Venglustat (GZ402671)|Tablet; Oral
214462893|NCT05280548|DRUG|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
214462894|NCT05280548|DRUG|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
214462895|NCT05280548|DRUG|Migalastat|Hard capsules; Oral
214462896|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
214462897|NCT05742178|BEHAVIORAL|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
214462898|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
214462899|NCT05096364|BIOLOGICAL|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
214462900|NCT05743270|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
214462901|NCT05743270|OTHER|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
214462902|NCT05743270|OTHER|carboplatin and paclitaxel|chemotherapeutic agents
214462903|NCT05743270|BIOLOGICAL|nivolumab|anti-PD1 monoclonal antibody
214462904|NCT01767636|DRUG|Pazopanib Hydrochloride|Given PO
214462905|NCT04881838|DRUG|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
214462906|NCT04881838|DRUG|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
214462907|NCT04881838|DRUG|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
214462908|NCT04881838|DRUG|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
214462909|NCT04881838|DRUG|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
214462910|NCT04881838|DRUG|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
214462911|NCT04881838|DRUG|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
214462912|NCT04881838|DRUG|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
214532498|NCT04847310|OTHER|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
214695811|NCT01842308|DRUG|Melphalan|Given IV
214695812|NCT03237988|DRUG|CPI-444 Capsules|100mg Capsule
214695813|NCT03237988|DRUG|CPI-444 Tablets|100mg Tablets
214695814|NCT03349541|OTHER|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
214695815|NCT01971489|DRUG|Buparlisib|Given PO
214532499|NCT02454049|DIETARY_SUPPLEMENT|beetroot juice|6mmol nitrate
214695816|NCT01971489|DRUG|Cisplatin|Given IV
214695817|NCT01971489|DRUG|Gemcitabine Hydrochloride|Given IV
214695818|NCT01971489|OTHER|Laboratory Biomarker Analysis|Correlative studies
214695819|NCT01971489|OTHER|Pharmacological Study|Correlative studies
214532500|NCT02454049|DIETARY_SUPPLEMENT|sodium nitrate|6mmol sodium nitrate
214532501|NCT02454049|DIETARY_SUPPLEMENT|water|plain water
214532502|NCT02028247|BEHAVIORAL|Personalized Cognitive-behavioral therapy|
214532503|NCT02028247|BEHAVIORAL|Standard Practice Cognitive-behavioral therapy|
214532504|NCT02028247|BEHAVIORAL|Treatment as Usual|
214532505|NCT05446714|DEVICE|CH 4 band|expansion of maxilla and observation improvement of the air way
214532506|NCT05446714|DEVICE|HH 2 bands|expansion of maxilla and observation improvement of the air way
214532507|NCT05446714|DEVICE|MSE 2 bands and 4|expansion of maxilla and observation improvement of the air way
214532508|NCT06412536|OTHER|Blood work|Blood work on some participants to review eligibility for future clinical trials
214532509|NCT03253120|OTHER|Water|Patient/ Healthy volunteer will drink 5dl of Water
214532510|NCT02742532|DRUG|Oxytocin|Intranasal oxytocin 40 IU
214532511|NCT02742532|DRUG|Placebo|Intranasal saline solution
214532512|NCT03499561|DIAGNOSTIC_TEST|urine analysis|Intervention is (urine analysis ): of a mid stream urine sample will be taken
214532513|NCT02392663|OTHER|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
214532514|NCT02392663|OTHER|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
214695820|NCT01971489|OTHER|Questionnaire Administration|Ancillary studies
214695821|NCT03374384|OTHER|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
214695822|NCT00459485|DIETARY_SUPPLEMENT|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
215150175|NCT03074240|PROCEDURE|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
214532515|NCT02392663|OTHER|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
214695823|NCT00459485|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 3 weeks
214695824|NCT00864422|BEHAVIORAL|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
214695825|NCT00864422|BEHAVIORAL|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
214695826|NCT05275621|DEVICE|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
214695827|NCT05275621|PROCEDURE|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
214695828|NCT02565771|OTHER|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
214695829|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
214695830|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
214695831|NCT03038243|OTHER|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
214695832|NCT01226355|DEVICE|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
214695833|NCT02843646|DEVICE|Walk Aide training|
215150176|NCT04139018|DRUG|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
214532516|NCT01335412|BIOLOGICAL|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
215150177|NCT04139018|DRUG|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
215150178|NCT02077452|DRUG|HMS5552|
214532517|NCT01907945|BEHAVIORAL|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
214532518|NCT01907945|BEHAVIORAL|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
214532519|NCT06153030|OTHER|no intervention|No intervention
214532520|NCT04591262|DRUG|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
214532521|NCT04591262|DRUG|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
214532522|NCT04591262|DRUG|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
214532523|NCT00197106|DRUG|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
214532524|NCT00197106|DRUG|fluticasone propionate 2 x 100 mcg|comparator
214532525|NCT01881152|OTHER|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
214532526|NCT01881152|OTHER|Usual care|Information on stroke usually delivered at the community level.
214532527|NCT01709123|DRUG|chromium niacinate|200ug or 500ug supplementation in pill form
214532528|NCT01709123|DRUG|placebo|Placebo pill for chromium niacinate
214532529|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
214532530|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
214532531|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
214532532|NCT02457442|DRUG|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
214532533|NCT02457442|DRUG|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
214532534|NCT02457442|DRUG|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
214532535|NCT02457442|DRUG|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
214532536|NCT02457442|DRUG|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
215150179|NCT02077452|DRUG|Placebo|
215150180|NCT03233581|BEHAVIORAL|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
215150181|NCT03233581|BEHAVIORAL|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
215150182|NCT01730482|DRUG|[14C] AT1001|150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
215150183|NCT02243995|OTHER|Physical training|
215150184|NCT02243995|BEHAVIORAL|Physical training|
215150185|NCT02484885|OTHER|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
215150186|NCT00002476|BIOLOGICAL|bleomycin sulfate|
215150187|NCT00002476|DRUG|fluorouracil|
215150188|NCT00002476|DRUG|leucovorin calcium|
215150189|NCT00002476|DRUG|methotrexate|
214532537|NCT02457442|DRUG|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
214532538|NCT03532269|DEVICE|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
214532539|NCT02179853|DRUG|Anakinra|First two doses IV followed by SQ dosing
214532540|NCT02786290|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
214532541|NCT00629317|OTHER|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
214532542|NCT00629317|DRUG|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
214532543|NCT04838964|DRUG|MRG003|Administrated intravenously
214532544|NCT02927899|OTHER|Survey Administration|Ancillary studies
214532545|NCT02927899|DIETARY_SUPPLEMENT|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
214532546|NCT00562185|DRUG|carboplatin|
214532547|NCT00562185|DRUG|doxorubicin hydrochloride|
214532548|NCT02762292|DEVICE|Measurement of work of breathing using indirect calorimeter|"1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
214532549|NCT04372537|BEHAVIORAL|hypnosis|use of hypnosis.
214532550|NCT04372537|BEHAVIORAL|standard care|standard clinical procedure
214532551|NCT01530477|DEVICE|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
214532552|NCT01530477|DEVICE|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
214532553|NCT01530477|DEVICE|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
214532554|NCT06172998|DRUG|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
214532555|NCT06402578|DIAGNOSTIC_TEST|HbA1c testing|Bloods will be take pre and post 12 week intervention.
214532556|NCT05383105|PROCEDURE|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
214532557|NCT01649557|DRUG|OPC-34712|oral administered once daily
214532558|NCT04016350|BEHAVIORAL|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
214532559|NCT04016350|BEHAVIORAL|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
214532560|NCT02985047|OTHER|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
214532561|NCT04700488|DIAGNOSTIC_TEST|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
214695834|NCT04736706|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
214695835|NCT04736706|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
215150190|NCT00002476|DRUG|vincristine sulfate|
215150191|NCT00002476|RADIATION|low-LET cobalt-60 gamma ray therapy|
215150192|NCT00002476|RADIATION|low-LET photon therapy|
215150193|NCT00002476|RADIATION|radiation therapy|
215150194|NCT03486834|BIOLOGICAL|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
215150195|NCT03486834|DRUG|Placebo|Saline solution administered as a 0.5 mL IM injection
215150196|NCT00255489|DRUG|Gefitinib|
215150197|NCT00255489|PROCEDURE|palliative thoracic radiotherapy|
215150198|NCT02364570|OTHER|Glucose (100g)|Ingestion of glucose (100g)
215150199|NCT02364570|OTHER|Glucose (75g)|Ingestion of glucose (75g)
215150200|NCT02364570|OTHER|Whole Eggs|Ingestion of 1.5 whole eggs
215150201|NCT02364570|OTHER|Egg Whites|Ingestion of 7 egg whites
215150202|NCT02364570|OTHER|Egg Yolks|Ingestion of 2 egg yolks
215150203|NCT00638014|DEVICE|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
215150204|NCT00638014|DEVICE|Conventional wire closure|Conventional wire closure of sternum
215150205|NCT02405832|DIETARY_SUPPLEMENT|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
215150206|NCT02405832|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
215150207|NCT01786577|OTHER|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
215150208|NCT01786577|BEHAVIORAL|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
215150209|NCT04515472|DRUG|Botnia Clamp|This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.
215150210|NCT04515472|OTHER|Withdrawal of Gender Affirming Hormone Therapy (GAHT)|GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.
215150211|NCT00148096|DEVICE|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
215150212|NCT03309735|DRUG|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
215150213|NCT03309735|DRUG|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
215150214|NCT03309735|DRUG|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
215150215|NCT01281904|BEHAVIORAL|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
215150216|NCT01281904|BEHAVIORAL|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
215150217|NCT03638037|DIAGNOSTIC_TEST|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
215150218|NCT01020240|BEHAVIORAL|Avolition|\- avolition for cesarean discomforts
215150219|NCT01020240|BEHAVIORAL|Orientation|"* avolition of cesarean discomfort~* physiotherapy orientation"
215150220|NCT01020240|BEHAVIORAL|Guide|"* avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation"
215150221|NCT00248768|DEVICE|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
214532562|NCT05962515|PROCEDURE|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
214532563|NCT02444351|DRUG|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
215150222|NCT05914337|BEHAVIORAL|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
215150223|NCT05914337|BIOLOGICAL|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
214532564|NCT02444351|OTHER|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
214695836|NCT04736706|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
215150224|NCT02745119|DRUG|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
215150225|NCT05322382|PROCEDURE|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
214695837|NCT04736706|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
214695838|NCT01800006|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
215150226|NCT02721329|DEVICE|APAP|Automatic Continuous Positive Airway Pressure
215150227|NCT02721329|DEVICE|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
215150228|NCT01587924|DRUG|GSK1278863|tablet
215150229|NCT01587924|DRUG|rhEPO|injection
215150230|NCT00404469|PROCEDURE|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
215150231|NCT00404469|PROCEDURE|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
215150232|NCT00404469|PROCEDURE|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
215150233|NCT00432172|DRUG|Epirubicin|
215150234|NCT00432172|DRUG|Cyclophosphamide|
215150235|NCT00432172|DRUG|Docetaxel|
215150236|NCT00432172|DRUG|Exemestane|
215150237|NCT00432172|DRUG|Goserelin|
214532565|NCT01154465|PROCEDURE|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
214532566|NCT01154465|DEVICE|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~\- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
214532567|NCT01565252|DIETARY_SUPPLEMENT|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
215150238|NCT00432172|DRUG|Carboplatin|
214532568|NCT00344539|BIOLOGICAL|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
214532569|NCT00344539|BIOLOGICAL|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
214532570|NCT05367752|OTHER|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
214532571|NCT05367752|OTHER|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
214532572|NCT05367752|OTHER|Conventional TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
214532573|NCT05367752|OTHER|Sham TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
215150239|NCT05876715|DRUG|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
215150240|NCT02791672|BEHAVIORAL|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
215150241|NCT03810105|DRUG|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
215150242|NCT03810105|DRUG|Durvalumab|Durvalumab 1500mg IV monthly
215150243|NCT00585026|DEVICE|D-28 bifocal lenses and frame|
215150244|NCT00585026|DEVICE|Progressive addition computer lenses and frame|
215150245|NCT04843657|BEHAVIORAL|Observation for symptom distress|Observation for symptom distress
215150246|NCT02790190|OTHER|Radiotherapy dose|
215150247|NCT02544581|OTHER|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
215150248|NCT01106248|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
215150249|NCT05397158|PROCEDURE|single administration of low dose polyethylene glycol|"Patients in single administration of low dose polyethylene glycol (PEG) group: Take 30ml lactulose and 2L PEG.~Patients in control group: Take 4L PEG."
215150250|NCT03725891|DRUG|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
215150251|NCT03725891|DRUG|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
215150252|NCT03725891|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
215150253|NCT05172908|DRUG|Dexamethasone|"5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes.~The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
215150254|NCT05172908|DRUG|Saline|"A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
215150255|NCT00357903|BIOLOGICAL|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
214462913|NCT03173703|DEVICE|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
214462914|NCT03173703|PROCEDURE|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
214462915|NCT03173703|DEVICE|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
214462916|NCT05095571|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
214462917|NCT03547336|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
214462918|NCT03547336|DEVICE|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
214462919|NCT06648759|DEVICE|Vagal Nerve Stimulator|The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.
214462920|NCT06648759|DEVICE|Placebo Vagal Nerve Stimulator|The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
214462921|NCT06647888|DRUG|Envlo Tablet|Envlo Tab. 0.3mg
214462922|NCT06647888|DRUG|Envlomet SR Tablet|Envlomet SR Tablet 0.3/ Metformin1,000mg
214462923|NCT04421547|DRUG|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
214462924|NCT04421547|DRUG|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
214462925|NCT03906253|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
214462926|NCT05336214|OTHER|Virtual CGM initiation service|Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.
214462927|NCT05336214|OTHER|Online educational module on CGM|Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.
214462928|NCT05336214|OTHER|Practice facilitation|A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
214462929|NCT05919602|OTHER|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
214462930|NCT02431845|DRUG|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
214462931|NCT05429476|DRUG|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
214462932|NCT04413955|DEVICE|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
214462933|NCT06151392|DRUG|Probiotic Formula|probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
214462934|NCT06151392|DRUG|Zinc|Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
214532574|NCT00301041|OTHER|laboratory biomarker analysis|
214532575|NCT00301041|PROCEDURE|adjuvant therapy|
214532576|NCT00301041|RADIATION|radiation therapy|
214532577|NCT02191527|DEVICE|PIMA® for quantitative analysis of CD4-count|
214532578|NCT02191527|DEVICE|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
214532579|NCT02191527|DEVICE|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
214532580|NCT00318981|DRUG|Concerta|
214532581|NCT02958059|BIOLOGICAL|Pacetin® (cefoxitin)|1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
214532582|NCT02958059|BIOLOGICAL|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
214532583|NCT03068793|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
214532584|NCT02224183|BEHAVIORAL|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
214532585|NCT02224183|BEHAVIORAL|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
214532586|NCT00808145|DRUG|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
214532587|NCT01763645|DRUG|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
214532588|NCT01763645|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
215150256|NCT00606593|DRUG|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150257|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150258|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150259|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150260|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150261|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150262|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150263|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150264|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
214532589|NCT01763645|DRUG|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
214532590|NCT02115178|OTHER|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
214532591|NCT00666198|DRUG|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
214532592|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
214532593|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
214532594|NCT02324309|DRUG|BIOD-531|
214532595|NCT02324309|DRUG|Humalog Mix 75/25|
214532596|NCT02324309|DRUG|Humulin R U-500|
214532597|NCT02324309|DRUG|BIOD-531|
215150265|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
215150266|NCT03714880|DRUG|Mifepristone 200 MG|Ingestion of study medication vs placebo
215150267|NCT03714880|DRUG|Placebo Oral Tablet|Ingestion of study medication vs placebo
215150268|NCT03181529|DRUG|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
214462935|NCT05299658|DRUG|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
214532598|NCT00598286|DRUG|[18F]FMPEP-d2|
214532599|NCT04838145|DRUG|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
214532600|NCT04838145|DRUG|Placebos|Randomized to treatment with placebo
214532601|NCT04562714|DEVICE|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
215150269|NCT05614596|OTHER|CT guided and Flouroscopic guided injection of corticosteroid and local anathesia|Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
215150270|NCT04618107|PROCEDURE|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
215150271|NCT04618107|PROCEDURE|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
215150272|NCT05103046|DRUG|UCT-03-008|Orally available kinase inhibitor
215150273|NCT03207061|DIAGNOSTIC_TEST|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
215150274|NCT05828329|BEHAVIORAL|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
215150275|NCT05828329|BEHAVIORAL|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
214462936|NCT06356168|BEHAVIORAL|Social Virtual Reality|Participants interact using virtual reality during dialysis.
214462937|NCT06356168|BEHAVIORAL|Individual Virtual Reality|Participants use virtual reality alone during dialysis.
214462938|NCT06085183|OTHER|Saline Injection 0.9%|Placebo
214462939|NCT06085183|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
214462940|NCT05121545|RADIATION|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
214462941|NCT04427384|DEVICE|GammaTile|Surgically Targeted Radiation Therapy
214462942|NCT05151653|DRUG|BI 765250|BI 765250
214462943|NCT05151653|DRUG|Placebo|Placebo
214462944|NCT04102150|DRUG|Valemetostat Tosylate|Once a day, 200 mg, oral administration
214462945|NCT01652196|BIOLOGICAL|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
214462946|NCT01652196|DRUG|oxaliplatin|85 mg/m2 IV infused over 2 hours
214462947|NCT01652196|DRUG|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
214462948|NCT01652196|DRUG|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
214462949|NCT01652196|OTHER|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
214462950|NCT01652196|PROCEDURE|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
214462951|NCT01652196|RADIATION|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
214462952|NCT01652196|PROCEDURE|PET (positron emission tomography)|Correlative studies
214462953|NCT06286930|DEVICE|anodal trans cranial direct current stimulation (tDCS)|1 20-minute anodal tDCS stimulation
214462954|NCT06286930|DEVICE|cathodal trans cranial direct current stimulation (tDCS)|1 20-minute cathodal tDCS stimulation
214462955|NCT02419976|OTHER|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
214462956|NCT02419976|DEVICE|Aeonose|
215150276|NCT02064257|BEHAVIORAL|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
215150277|NCT02139007|DRUG|Alendronate|
215150278|NCT04968275|BEHAVIORAL|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
215150279|NCT05275504|DRUG|TT-01488|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
215150280|NCT00003439|BIOLOGICAL|recombinant interleukin-12|
215150281|NCT02612519|DEVICE|Alfapump|Implantation of Alfapump
215150282|NCT02612519|DEVICE|TIPS|Implantation of TIPS
214532602|NCT04562714|OTHER|Diabetes self-management education|"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
214532603|NCT05141071|DRUG|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
214532604|NCT05141071|DRUG|Placebo|50 ml of saline will be administrated enterally
214532605|NCT04686370|OTHER|laser treated implant surface|Better marginal bone stability is expected for this type
214532606|NCT04995406|DIAGNOSTIC_TEST|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
215150283|NCT03586557|DEVICE|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
214532607|NCT03052283|DIAGNOSTIC_TEST|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
214532608|NCT05753241|OTHER|no intervention|It's only observational study. No interventions.
214532609|NCT03116672|DRUG|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
214532610|NCT03116672|DRUG|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
214532611|NCT03116672|DRUG|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
214532612|NCT00922441|DRUG|Fimasartan 60 mg group|Fimasartan 60 mg
215150284|NCT03586557|DRUG|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
215150285|NCT01811966|OTHER|Volume|
214532613|NCT00922441|DRUG|Fimasartan 120 mg group|Fimasartan 120 mg
214532614|NCT00922441|DRUG|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
214532615|NCT03606850|DEVICE|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
214532616|NCT05042713|OTHER|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
215150286|NCT01811966|OTHER|Control|
215150287|NCT05803733|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
215150288|NCT05803733|OTHER|Routine strength training|range of motion exercises and strength training
214532617|NCT02723383|DRUG|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
214532618|NCT02723383|DRUG|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
214532619|NCT04486079|DIETARY_SUPPLEMENT|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
214532620|NCT06090019|BEHAVIORAL|Routine PICU nursing care for children on mechanical ventilator.|Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
214532621|NCT06090019|BEHAVIORAL|Self-instructional module for VAP care bundle prevention|Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
214532622|NCT05255198|PROCEDURE|Anterior versus lateral approach to hip joint|
214532623|NCT00543101|DRUG|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
214532624|NCT00543101|DRUG|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
214532625|NCT00996359|BIOLOGICAL|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
215150289|NCT00530972|DRUG|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)
214532626|NCT00996359|RADIATION|total-body irradiation|100 cGy TBI
214532627|NCT01040403|DRUG|olodaterol (BI 1744) low|olodaterol (BI 1744) low
214532628|NCT01040403|DRUG|low tiotropium bromide|low tiotropium bromide
214532629|NCT01040403|DRUG|olodaterol (BI 1744) high|olodaterol (BI 1744) high
214532630|NCT01040403|DRUG|medium tiotropium bromide|medium tiotropium bromide
214532631|NCT01040403|DRUG|high tiotropium bromide|high tiotropium bromide
214532632|NCT01040403|DRUG|Placebo|Placebo
214532633|NCT01040403|DEVICE|Respimat|Respimat inhaler
214532634|NCT03925662|DRUG|Folfox with avastin|Folfox with avastin only
214532635|NCT03925662|DRUG|Mebendazole|Folfox with avastin with mebendazole
214532636|NCT00828529|DRUG|TMC207|
214695839|NCT01928108|BEHAVIORAL|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
214695840|NCT01928108|BEHAVIORAL|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
215150290|NCT03507569|DRUG|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
215150291|NCT03507569|OTHER|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
215150292|NCT06042855|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215150293|NCT06042855|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
215150294|NCT01050504|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215150295|NCT01050504|OTHER|Laboratory Biomarker Analysis|Correlative studies
215150296|NCT03313037|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
215150297|NCT03313037|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
214532637|NCT04664985|DEVICE|Mucogyne® ovule|hyaluronic acid, vaginal ovule
214532638|NCT02017132|DIETARY_SUPPLEMENT|Pomegranate extract|
214532639|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
214695841|NCT02352792|RADIATION|radiochemotherapy with 70 Gy|
214695842|NCT02352792|RADIATION|radiochemotherapy with 77 Gy|
214695843|NCT02731118|DIETARY_SUPPLEMENT|Salovum|AF-enriched egg yolk
214695844|NCT02731118|DIETARY_SUPPLEMENT|Placebo|egg yolk
214695845|NCT03021291|DEVICE|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
214695846|NCT02864966|DEVICE|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
214532640|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
214532641|NCT03228953|OTHER|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
214532642|NCT05773027|BEHAVIORAL|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
214532643|NCT05773027|BEHAVIORAL|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
214532644|NCT02973477|DRUG|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
214532645|NCT02973477|DRUG|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
214532646|NCT01364441|DRUG|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
214532647|NCT01364441|DRUG|Placebo|Placebo dosed in the same manner as ONO-2952
214532648|NCT01885936|DRUG|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
214532649|NCT01885936|DRUG|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
214532650|NCT02654457|PROCEDURE|Women with Breast Cancer|IVD Study
214532651|NCT03036150|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
214532652|NCT03036150|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
214532653|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
214532654|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
214532655|NCT06111443|DRUG|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
214532656|NCT03500263|DRUG|PTI-808|Active
214532657|NCT03500263|DRUG|Placebo|Placebo
214532658|NCT03500263|DRUG|PTI-801|Active
214532659|NCT03500263|DRUG|PTI-428|Active
214532660|NCT03500263|DRUG|Placebo|Placebo
214532661|NCT04857775|BEHAVIORAL|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
214532662|NCT03109652|DRUG|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
214532663|NCT02554552|DRUG|YY1201 2ml|YY1201 2ml
214532664|NCT02554552|DRUG|Placebo 2ml|phosphate buffered saline 2ml
214695847|NCT03357146|DEVICE|Optical coherence tomography angiography|OCTA scans per built-in device protocol
214532665|NCT02554552|DRUG|YY1201 3ml|YY1201 2ml
214532666|NCT02554552|DRUG|Placebo 3ml|phosphate buffered saline 3ml
214532667|NCT05324813|BEHAVIORAL|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
214532668|NCT06339814|OTHER|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
214532669|NCT06339814|OTHER|Treatment As Usual|Treatment As Usual condition will receive only standard support.
214532670|NCT02619305|OTHER|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
214532671|NCT02455284|DEVICE|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
214532672|NCT03413540|OTHER|Jump|Drop jump from step
215150298|NCT03313037|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
215150299|NCT03313037|OTHER|Saline|Placebo
215150300|NCT04664127|DRUG|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
215150301|NCT04664127|DRUG|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
215150302|NCT05164991|BEHAVIORAL|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
215150303|NCT03806764|DIAGNOSTIC_TEST|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
215150304|NCT06413082|DRUG|Torasemide|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
215150305|NCT06413082|DRUG|Spironolactone|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
215150306|NCT00485784|OTHER|Blood test|Blood test
215150307|NCT00000258|DRUG|Nitrous oxide 10% & placebo|
215150308|NCT00000258|DRUG|Nitrous oxide 20% & placebo|
215150309|NCT00000258|DRUG|Nitrous oxide 30% & placebo|
215150310|NCT00000258|DRUG|Nitrous oxide 40% and placebo|
215150311|NCT06503263|DRUG|Zanubrutinib plus Lenalidomide as Maintenance Therapy|Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
215150312|NCT01783691|DRUG|NKTT120|
215150313|NCT01767090|DRUG|ASP1707|Oral
214532673|NCT03528109|BEHAVIORAL|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
214532674|NCT02690493|PROCEDURE|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
214532675|NCT02690493|OTHER|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
214532676|NCT02690493|OTHER|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
214532677|NCT03646695|PROCEDURE|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
214532678|NCT03646695|PROCEDURE|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
214532679|NCT00317603|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
214532680|NCT03758703|OTHER|Pre-recorded music intervention group|Refer to the arm/group descriptions.
214695848|NCT00677690|OTHER|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
215150314|NCT01767090|DRUG|Placebo|Oral
215150315|NCT01767090|DRUG|Leuprorelin acetate|subcutaneous
215150316|NCT02165098|DRUG|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
215150317|NCT02165098|DRUG|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
215150318|NCT02165098|DRUG|Cariprazine capsule|Cariprazine capsule - fasted
214532681|NCT03758703|OTHER|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
215150319|NCT02165098|DRUG|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
215150320|NCT02165098|DRUG|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
215150321|NCT05056935|DRUG|LB1148|A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
215150322|NCT05056935|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
215150323|NCT00763880|DRUG|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
215150324|NCT00763880|DRUG|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
215150325|NCT00231569|DRUG|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
215150326|NCT00231569|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
214532682|NCT00523549|DRUG|valsartan|160 mg or 320 mg tablets once a day
214532683|NCT00523549|DRUG|amlodipine|5 mg or 10 mg tablets once a day
214532684|NCT02359578|DRUG|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
214532685|NCT02664025|PROCEDURE|vaginal examination simulator|
214532686|NCT02487251|BEHAVIORAL|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
214532687|NCT02487251|BEHAVIORAL|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
214532688|NCT02747719|BEHAVIORAL|Light and exercise|Exposure to light and exercise
214532689|NCT03987490|BEHAVIORAL|Text Message|Vaccine reminder notification sent via text
214532690|NCT03987490|BEHAVIORAL|PostCard|Vaccine reminder notification sent via standard mail
214532691|NCT03987490|BEHAVIORAL|Standard of Care|No additional information given to parents
214532692|NCT03987490|BEHAVIORAL|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
214532693|NCT05183321|PROCEDURE|periodontal therapy|periodontal cleaning
214532694|NCT00427778|DEVICE|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
214532695|NCT03068221|OTHER|anaerobic exercise|assessing anaerobic exercise status
215150327|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
215150328|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
214532696|NCT01408875|DEVICE|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
214532697|NCT04883021|DEVICE|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
214532698|NCT02822209|BEHAVIORAL|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
214532699|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
214532700|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
214532701|NCT02822209|BEHAVIORAL|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
214532702|NCT02494752|PROCEDURE|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
214532703|NCT02494752|PROCEDURE|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
214532704|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
214532705|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
214532706|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
214532707|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
214695849|NCT00677690|OTHER|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
215150329|NCT00231569|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
215150330|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
215150331|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
215150332|NCT03208946|OTHER|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
215150333|NCT03208946|OTHER|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
215150334|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
215150335|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
215150336|NCT00404612|DRUG|Placebo|PO BID
215150337|NCT00404612|DRUG|LX211|0.2 mg/kg, twice a day (BID)
215150338|NCT00404612|DRUG|LX211|0.4 mg/kg, twice a day (BID)
215150339|NCT00404612|DRUG|LX211|0.6 mg/kg, twice a day (BID)
214532708|NCT02621502|DIETARY_SUPPLEMENT|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
214532709|NCT01388478|DRUG|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
214532710|NCT03287778|DIETARY_SUPPLEMENT|Pyridoxine|Max dose of 400 mg QD PO
214532711|NCT03287778|DIETARY_SUPPLEMENT|Placebo|Matching placebos will be administered.
214532712|NCT04112875|DIETARY_SUPPLEMENT|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
214532713|NCT04112875|DIETARY_SUPPLEMENT|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
214532714|NCT04150185|PROCEDURE|Donor hepatectomy|
214532715|NCT01990664|DEVICE|senofilcon A|
214532716|NCT01990664|DEVICE|senofilcon A for Astigmatism|
214532717|NCT01037413|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
214532718|NCT01037413|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
214532719|NCT02188277|DRUG|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
214532720|NCT02188277|DRUG|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
214532721|NCT04623359|DEVICE|High resolution manometry|High resolution manometry
215150340|NCT02562677|DEVICE|Transcutaneous Trigeminal Nerve Stimulation|
215150341|NCT03210194|BEHAVIORAL|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
214532722|NCT01218295|DEVICE|Spirotiger®|training session :10 minutes twice a day X 4 weeks
214695850|NCT00209521|DRUG|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
214695851|NCT00209521|DRUG|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
215150342|NCT03210194|BEHAVIORAL|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
214532723|NCT04959461|BEHAVIORAL|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
214532724|NCT04959461|BEHAVIORAL|Usual Care|6 hours of driver education
214532725|NCT00619983|DRUG|donepezil|Group 1: Will receive donepezil 5mg once a day
214532726|NCT00619983|DRUG|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
214532727|NCT00619983|DRUG|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
214532728|NCT00619983|DRUG|placebo|Group 4: Will receive placebo pills
214532729|NCT00619983|DRUG|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
214532730|NCT02798913|DRUG|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
214532731|NCT02798913|DRUG|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
214695852|NCT06330597|DIAGNOSTIC_TEST|Echocardiography and lung ultrasound|All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
215150343|NCT02061410|DEVICE|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
214532732|NCT05767814|OTHER|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
214532733|NCT02520596|OTHER|Bioavailability of Raspberry polyphenols|
214532734|NCT05296252|BEHAVIORAL|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
214532735|NCT05296252|BEHAVIORAL|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
214532736|NCT04546659|OTHER|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
214532737|NCT04546659|OTHER|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
214532738|NCT00931918|DRUG|Bortezomib|Bortezomib IV
214532739|NCT00931918|DRUG|Rituximab|Rituximab IV
214532740|NCT00931918|DRUG|Cyclophosphamide|Cyclophosphamide IV
214532741|NCT00931918|DRUG|Doxorubicin|Doxorubicin IV solution
214532742|NCT00931918|DRUG|Vincristine|Vincristine IV
214532743|NCT00931918|DRUG|Prednisone|Prednisone tablet
214532744|NCT02127489|DRUG|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
214532745|NCT00003597|BIOLOGICAL|recombinant human thrombopoietin|
214532746|NCT00003597|DRUG|carboplatin|
214532747|NCT00003597|DRUG|etoposide|
214532748|NCT00003597|DRUG|ifosfamide|
214532749|NCT00003597|BIOLOGICAL|G-CSF|
214532750|NCT04304313|DRUG|Sildenafil citrate tablets|0.1g/day for 14 days
215150344|NCT03933007|DRUG|Colchicine,|"the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
214532751|NCT01781013|OTHER|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
214532752|NCT00554944|PROCEDURE|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
214532753|NCT00586118|DRUG|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
214532754|NCT00586118|DRUG|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
214532755|NCT00570921|DRUG|Everolimus|Everolimus tablets, two-5 mg tablets a day
214532756|NCT00570921|DRUG|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
214532757|NCT04683211|OTHER|Evaluation of iodine supplementation|survey of iodine supplementation
214532758|NCT02013895|DEVICE|99mTc-GSA|
214532759|NCT05321771|OTHER|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
214532760|NCT05524415|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
214532761|NCT05573347|PROCEDURE|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
214695853|NCT00551538|DRUG|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
214695854|NCT00551538|DRUG|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
214695855|NCT01106625|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
215150345|NCT03933007|DRUG|midazolam,|Midazolam 1 mg
215150346|NCT03933007|DRUG|fexofenadine|Fexofenadine 120 mg
214532762|NCT05573347|PROCEDURE|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
214532763|NCT02380638|DEVICE|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
215150347|NCT01886053|DRUG|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
215150348|NCT01886053|DRUG|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
214532764|NCT02314585|OTHER|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
214532765|NCT02314585|OTHER|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
214532766|NCT06187597|DRUG|S-1|Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
214532767|NCT06187597|DRUG|Toripalimab|Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
214532768|NCT06187597|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
214532769|NCT03686618|DRUG|Secretin|Drug to stimulate pancreatic secretion
214532770|NCT05001997|DIETARY_SUPPLEMENT|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
214532771|NCT00108498|DRUG|mirtazapine|
214532772|NCT03616236|DRUG|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
214532773|NCT03616236|OTHER|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
214532774|NCT02832284|DEVICE|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
215150349|NCT01886053|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
215150350|NCT02939911|DEVICE|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
214532775|NCT03493568|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
214532776|NCT03493568|DRUG|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
214532777|NCT05896111|PROCEDURE|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
214532778|NCT00280709|DEVICE|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
214532779|NCT04300153|PROCEDURE|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
214532780|NCT04300153|OTHER|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
214532781|NCT04300153|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
214532782|NCT02802150|DIETARY_SUPPLEMENT|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
214532783|NCT02802150|DIETARY_SUPPLEMENT|Soy Bean Oil;placebo(4g/day)|parallel design
214532784|NCT02513979|DRUG|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
214532785|NCT00784277|DRUG|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
214532786|NCT00784277|DRUG|oxycodone IR|10mg for 14 days
214532787|NCT00784277|DRUG|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
214532788|NCT00784277|DRUG|Tapentadol IR (CG5503)|50mg for 14 days
214532789|NCT00784277|DRUG|Tapentadol IR (CG5503)|75mg for 14 days
214532790|NCT00784277|DRUG|placebo|1 capsule for 14 days
214532791|NCT00784277|DRUG|placebo|Tablets and capsules 2 x a day for 28 days
214532792|NCT00598637|DEVICE|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
214532793|NCT00598637|DEVICE|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
215150351|NCT05433207|DRUG|Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)
215150352|NCT00196482|DRUG|changing of fortifier|
215150353|NCT01516021|DIETARY_SUPPLEMENT|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
215150354|NCT01524575|DRUG|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
215150355|NCT00084071|DRUG|Tifacogin|
215150356|NCT02546388|DRUG|Indium-111 Pentreotide|
215150357|NCT02546388|DRUG|Gallium-68 DOTATATE|
214532794|NCT03857737|PROCEDURE|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
214532795|NCT03857737|PROCEDURE|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
214532796|NCT05315817|DEVICE|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
214532797|NCT01585688|DRUG|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
214532798|NCT02222337|BEHAVIORAL|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
214532799|NCT03198351|DRUG|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
214532800|NCT00375583|DRUG|DEC/Albendazole|
214532801|NCT04052932|DRUG|SHR4640 dose1|tablets，dose1，QD
214532802|NCT04052932|DRUG|SHR4640 dose2|tablets，dose2，QD
214532803|NCT04052932|DRUG|Placebo oral tablet|tablets，QD
214532804|NCT04052932|DRUG|Allopurinol 300 MG|tablets，300mg，QD
214532805|NCT03013725|OTHER|No intervention|No intervention
214532806|NCT04785586|BEHAVIORAL|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
214532807|NCT04785586|BEHAVIORAL|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
214532808|NCT04785586|BEHAVIORAL|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
214532809|NCT02702739|DRUG|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
214532810|NCT01202669|OTHER|No intervention planned, observational study only.|No intervention planned, observational study only.
214532811|NCT00789932|BEHAVIORAL|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
214532812|NCT00789932|BEHAVIORAL|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
214532813|NCT05558098|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
214532814|NCT05558098|OTHER|Standard of Care|Current standard of care for management of critically ill patients
214532815|NCT04968015|DRUG|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
214532816|NCT04968015|DRUG|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
214695856|NCT01106625|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
215150358|NCT00699114|DRUG|Placebo|Lactose as powder in gelatine capsules, single dose
215150359|NCT00699114|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
215150360|NCT00699114|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
215150361|NCT00699114|DRUG|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
215150362|NCT00699114|DRUG|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
215150363|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
215150364|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
215150365|NCT04546672|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
215150366|NCT04546672|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
215150367|NCT00252096|DEVICE|Nucleic acid amplification test|
215150368|NCT01982656|OTHER|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
215150369|NCT02490865|DRUG|RNS60|RNS60, 4 ml dose nebulized twice daily
215150370|NCT02490865|DRUG|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
215150371|NCT00437229|DRUG|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
215150372|NCT00437229|DRUG|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
215150373|NCT00437229|DRUG|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
215150374|NCT02529969|DIETARY_SUPPLEMENT|curcumin|
215150375|NCT02529969|DIETARY_SUPPLEMENT|Placebo|
215150376|NCT00507780|DRUG|GnRH antagonist|
215150377|NCT00387504|DRUG|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
215150378|NCT00387504|OTHER|pharmacological study|samples drawn per protocol
215150379|NCT04257929|DRUG|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
214532817|NCT04171921|PROCEDURE|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
214532818|NCT04171921|PROCEDURE|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
214532819|NCT00999141|BIOLOGICAL|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
214532820|NCT02781077|PROCEDURE|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
214532821|NCT01641627|PROCEDURE|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
214532822|NCT05784649|OTHER|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
214695857|NCT01106625|DRUG|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
214695858|NCT01106625|DRUG|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
215150380|NCT04257929|DRUG|Placebo oral tablet|Matching placebo tablets
215150381|NCT03710577|BEHAVIORAL|Yoga|1 session
215150382|NCT03710577|BEHAVIORAL|Quiet Rest|1 session
215150383|NCT02790411|DEVICE|Imaging devices|technological adjustment tests
215150384|NCT02790411|DEVICE|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
215150385|NCT00525161|DRUG|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
215150386|NCT00002999|DRUG|cisplatin|
215150387|NCT00002999|DRUG|fluorouracil|
215150388|NCT00002999|RADIATION|radiation therapy|
215150389|NCT01898559|OTHER|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
215150390|NCT02735811|DEVICE|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
215150391|NCT03250715|OTHER|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
215150392|NCT00516516|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 1g orally, twice daily
215150393|NCT00516516|DIETARY_SUPPLEMENT|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
215150394|NCT02447003|BIOLOGICAL|Pembrolizumab|IV infusion of 200 mg.
215150395|NCT01939418|DRUG|RAD001|Afinitor 5mg qd. po.
215150396|NCT01939418|DRUG|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
215150397|NCT01939418|DRUG|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
215150398|NCT02677883|OTHER|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
215150399|NCT02677883|OTHER|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
215150400|NCT03848728|OTHER|SEARCH Youth combination intervention|"* Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
215150401|NCT06273995|OTHER|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
215150402|NCT05294549|OTHER|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
214532823|NCT05784649|BEHAVIORAL|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
214532824|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
214532825|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
214532826|NCT02113150|DRUG|remifentanil|renal function
214532827|NCT02113150|DRUG|Ketamine|renal function
214532828|NCT01262118|DRUG|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
214532829|NCT02929316|DRUG|Vedolizumab|IV infusion week 0, 2 and 6
214532830|NCT03994341|DIAGNOSTIC_TEST|A FLIR Thermovision a320M thermal IR camera|"1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on."
214532831|NCT04101019|DRUG|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
214532832|NCT04101019|DRUG|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
214532833|NCT00694135|DRUG|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
214532834|NCT00694135|DRUG|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
214532835|NCT00694135|DRUG|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
214532836|NCT00694135|DRUG|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
215150403|NCT04013477|DRUG|DA-5207|DA-5207 Transdermal Delivery System
215150404|NCT04013477|DRUG|Donepezil Hydrochloride|donepezil HCl 10mg QD
215150405|NCT06306807|OTHER|Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications|Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
214462957|NCT04399941|DIAGNOSTIC_TEST|Venography|The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.
214532837|NCT02046941|BEHAVIORAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
214532838|NCT03719118|GENETIC|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
215150406|NCT06306807|OTHER|PNF exercise program|The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
215150407|NCT04161157|BEHAVIORAL|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
215150408|NCT04606602|DRUG|SLN360|SLN360 for subcutaneous (s.c.) injection
215150409|NCT04606602|DRUG|Placebo|Sodium chloride for subcutaneous (s.c.) injection
215150410|NCT03726580|DRUG|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
215150411|NCT02581410|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
214462958|NCT04399941|DIAGNOSTIC_TEST|Intravascular ultrasound (IVUS)|IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.
214462959|NCT04399941|OTHER|Image processing|Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
214462960|NCT03543683|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
214462961|NCT03543683|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
214462962|NCT06124079|OTHER|OPY interactive messaging service|2 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The two versions differ in the motivational techniques interspersed throughout the OPY experience.
214462963|NCT06124079|OTHER|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
214462964|NCT02688140|DRUG|Arsenic trioxide|
214462965|NCT02688140|DRUG|Idarubicin|
214462966|NCT02688140|DRUG|Cytarabine|
214462967|NCT02688140|DRUG|Tretinoin|
214462968|NCT02688140|DRUG|Mitoxantrone|
214462969|NCT02688140|DRUG|Mercaptopurine|
214462970|NCT02688140|DRUG|Methotrexate|
214462971|NCT04594057|BEHAVIORAL|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
214462972|NCT05692960|OTHER|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
214462973|NCT05692960|DEVICE|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
214462974|NCT06375343|DRUG|PRO-240|-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
214462975|NCT06375343|DRUG|Optive®|\- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.
214462976|NCT04048551|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
214462977|NCT04048551|BEHAVIORAL|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
214462978|NCT04992767|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
214532839|NCT03719118|OTHER|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
214532840|NCT06329271|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
214532841|NCT00087477|DRUG|Pivanex|
214532842|NCT03545321|BEHAVIORAL|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
214532843|NCT03595137|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
214532844|NCT03595137|DEVICE|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
214532845|NCT02025985|DRUG|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
214532846|NCT00033189|DRUG|Coenzyme Q10|
214532847|NCT00404508|DRUG|Hydralazine and magnesium valproate|
214532848|NCT02414555|DRUG|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
214532849|NCT02414555|DRUG|fluid bolus|
214532850|NCT02414555|DEVICE|oesophagus doppler (CardioQ)|
214532851|NCT02414555|DRUG|Normal Saline|
214532852|NCT02414555|DEVICE|arterial cannulation|
214532853|NCT02414555|DEVICE|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
214532854|NCT02414555|DRUG|Elo-Mel Isoton (balanced acetat-based infusate)|
214532855|NCT05235776|OTHER|observation|observation
214532856|NCT03336073|DRUG|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
214532857|NCT03336073|DRUG|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16
214532858|NCT03336073|DRUG|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
214532859|NCT03041701|DRUG|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
214532860|NCT03041701|DRUG|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
214532861|NCT03041701|DRUG|Ganitumab|Once every 2 weeks beginning on day 0.
214532862|NCT00585208|DRUG|Ramelteon|Ramelteon 8mg daily
214532863|NCT00585208|DRUG|Placebo|matching placebo for ramelteon 8mg daily
214532864|NCT02865759|BEHAVIORAL|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
214532865|NCT00745121|DEVICE|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
214532866|NCT05625568|DRUG|VYNT-0126|Liquid for oral administration once daily
214532867|NCT05625568|DRUG|Placebo|Liquid for oral administration once daily
214532868|NCT01713998|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214532869|NCT03644706|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
214532870|NCT03644706|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
214532871|NCT04233502|DRUG|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
214532872|NCT04233502|DRUG|Placebo|Placebo melatonin
214532873|NCT04260399|OTHER|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
214532874|NCT04260399|OTHER|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
214532875|NCT04788966|DEVICE|the translation tool BabelDr|Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
214532876|NCT02287740|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
214532877|NCT02287740|BEHAVIORAL|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
214532878|NCT02287740|BEHAVIORAL|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
214532879|NCT02101268|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
215150412|NCT01393392|BEHAVIORAL|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
215150413|NCT01393392|BEHAVIORAL|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
215150414|NCT06268275|PROCEDURE|Scalp block|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
215150415|NCT06268275|DRUG|Esmolol|Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
214462979|NCT04992767|BEHAVIORAL|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
214462980|NCT05699239|DRUG|TS-172 10mg bid|oral administration of TS-172 10 mg bid
215150416|NCT00658385|GENETIC|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
215150417|NCT03752567|OTHER|Follow up|like group descriptions
215150418|NCT05589467|OTHER|DASH-FP|Dash diet with only fried potatoes
215150419|NCT05589467|OTHER|DASH-NFP|Dash diet with only non-fried potatoes
215150420|NCT05589467|OTHER|Control|Dash diet with no potatoes
215150421|NCT02390193|PROCEDURE|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
215150422|NCT03172988|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
215150423|NCT03172988|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
215150424|NCT03172988|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
215150425|NCT03172988|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
215150426|NCT05986695|BEHAVIORAL|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
215150427|NCT05986695|BEHAVIORAL|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
215150428|NCT05069948|OTHER|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
214462981|NCT05699239|DRUG|TS-172 30mg bid|oral administration of TS-172 30 mg bid
214532880|NCT02101268|DRUG|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
214532881|NCT02719925|OTHER|Mg(+)|"* 1,5 L per day during 30 days~* No livestyle counseling"
214532882|NCT02719925|OTHER|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
215150429|NCT03810924|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
214462982|NCT05699239|DRUG|TS-172 60mg bid|oral administration of TS-172 60 mg bid
214462983|NCT05699239|DRUG|TS-172 20mg tid|oral administration of TS-172 20 mg tid
214462984|NCT05699239|DRUG|Placebo|oral administration of placebo
214462985|NCT01953588|DRUG|fulvestrant|Fulvestrant 500 mg IM
214532883|NCT00740870|DEVICE|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
214532884|NCT02785445|DEVICE|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
214532885|NCT02785445|DEVICE|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
214532886|NCT01092988|DEVICE|Exablate 2100|MR guided focused ultrasound
214532887|NCT02831998|DRUG|ZuraPrep|Apply topically.
215150430|NCT03810924|BEHAVIORAL|Ergometer|Riding ergometer
214532888|NCT02831998|DRUG|ChloraPrep|Apply topically.
214532889|NCT02831998|DRUG|ZP Vehicle|Apply topically.
214532890|NCT02222961|DRUG|BIIR 561 CL|
214532891|NCT02222961|DRUG|Placebo|
214532892|NCT01659047|DRUG|GS-1101|150 mg taken twice daily by mouth
215150431|NCT03810924|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
215150432|NCT03810924|BEHAVIORAL|Reading Newspaper|Participants read newspaper
215150433|NCT04854187|DEVICE|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
215150434|NCT06851052|OTHER|sample collection|Samples could include blood, skin biopsy, urine, plucked hair.
214462986|NCT01953588|DRUG|anastrozole|Anastrozole 1 mg oral tablet
214462987|NCT04719832|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
215150435|NCT06851052|OTHER|Seeking consent|
215150436|NCT06851052|OTHER|Sample Collection: Surgical|Excess surgical tissue (diseased tissue or tissue being removed for a clinical reason).
215150437|NCT06848491|BEHAVIORAL|AYA WELL Intervention|Behavioral weight management intervention for adolescent and young adult cancer survivors with digital tools, smartphone web app behavioral program, text messages, and expert-guided closed social networking group for peer support.
215150438|NCT06848491|BEHAVIORAL|Self-Guided|Self-guided intervention with digital tools, periodic informational support, and moderated social networking group for peer support.
214462988|NCT04719832|DRUG|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
214462989|NCT05230043|OTHER|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
214462990|NCT05230043|OTHER|functional MRI|"* Two 8s sequences of spin echo field map with phase encoding AP and PA~* A 12:00min bold sequence for resting-state~* A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~* A 6:38min T1w MPR sequence~* A 7:40min T1w MPR sequence~* A 5:57min T2w SPC sequence~* A 8:24min T2w SPC sequence~* A 8:32min FLAIR T2w sequence~* Two 8:26min Multi-echo GRE sequence~* A 8:29min high resolution multi-echo GRE sequence~* Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~* Two 6:03min diffusion weighted images with phase encoding AP and PA"
214462991|NCT04203303|OTHER|Observational|Observational
214462992|NCT05633303|OTHER|Substrate guided ablation|Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
214462993|NCT04382664|BIOLOGICAL|UV1|UV1 vaccine (300 μg) will be injected intradermally.
214462994|NCT04382664|BIOLOGICAL|Sargramostim|Sargramostim (75 μg) is used as a vaccine adjuvant.
214462995|NCT04382664|BIOLOGICAL|Ipilimumab|Ipilimumab is dosed according to label.
214462996|NCT04382664|BIOLOGICAL|Nivolumab|Nivolumab is dosed according to label.
214462997|NCT04006951|OTHER|Biological collection|"Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)"
215150439|NCT04113447|OTHER|observational|observational
215150440|NCT06407232|DRUG|Letermovir|480 mg taken orally once daily, for 84 days
215150441|NCT01200771|PROCEDURE|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
214532893|NCT04970693|DRUG|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
214532894|NCT02028468|PROCEDURE|hemiarthroplasty|
215150442|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
215150443|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
215150444|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
215150445|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
215150446|NCT06337630|DRUG|PLX038 + Tuvusertib|"Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor."
215150447|NCT05136703|BEHAVIORAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months. Participants receive up to three individually delivered booster sessions through 6 months.
215150448|NCT05136703|BEHAVIORAL|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
215150449|NCT06083506|DEVICE|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
215150450|NCT05934877|BEHAVIORAL|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
214532895|NCT00177385|BEHAVIORAL|Modest sleep deprivation with sleep hygiene education|
214532896|NCT00488228|BEHAVIORAL|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
214462998|NCT03948139|DEVICE|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
214462999|NCT03948139|DEVICE|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
214463000|NCT04763577|OTHER|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
214463001|NCT05971381|DEVICE|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
214463002|NCT04591275|DRUG|CMAB807 Injection|mAb targeting RANKL, human monoclonal antibody targeting RANKL
215150451|NCT05934877|BEHAVIORAL|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
215150452|NCT05934877|BEHAVIORAL|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
215150453|NCT05889546|PROCEDURE|Biospecimen Collection|Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
215150454|NCT05609916|BEHAVIORAL|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
215150455|NCT04258800|DEVICE|Music during colonoscopy|Music during colonoscopy
215150456|NCT02809235|DIETARY_SUPPLEMENT|coconut oil|3 tablespoons per day of supplemental coconut oil
215150457|NCT04260802|DRUG|OC-001|Administered IV.
215150458|NCT04260802|DRUG|Drug: OC-001 in Combination with Avelumab|Administered IV.
215150459|NCT02000115|DEVICE|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
215150460|NCT02000115|DEVICE|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
214463003|NCT04591275|DRUG|Prolia®|mAb targeting RANKL, human monoclonal antibody targeting RANKL
214463004|NCT05586334|BIOLOGICAL|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
215150461|NCT05704764|BEHAVIORAL|Ending Self Stigma for Persons living with HIV and Use Substances|One-on-one intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
215150462|NCT04815824|BEHAVIORAL|Exercise Mode|Stationary cycling or treadmill walking
215150463|NCT05783037|OTHER|New Organic Infant Formula|New organic infant formula fed daily ad libitum
215150464|NCT05783037|OTHER|Commercial Organic Infant Formula|Commercially available organic infant formula fed daily ad libitum
214532897|NCT02892864|OTHER|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
214532898|NCT02892864|OTHER|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
215150465|NCT04353258|BEHAVIORAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
215150466|NCT04353258|BEHAVIORAL|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
215150467|NCT06603792|BEHAVIORAL|EEG-neurofeedback|Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.
215150468|NCT05522153|DRUG|Arista|hemostatic powder
215150469|NCT06597812|PROCEDURE|Sevoflurane|Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).
215150470|NCT06599541|BEHAVIORAL|Hypopressive Exercise|A hypopressive exercise program will be carry out.
215150471|NCT06599541|BEHAVIORAL|Pilates Exercise|A pilates exercise program will be carry out.
215150472|NCT06603922|BEHAVIORAL|Psychological treatment (P-MCT)|Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.
215150473|NCT06603922|BEHAVIORAL|Psychological treatment (MCT)|"Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center."
215150474|NCT05415072|DRUG|DYP688|Single agent DYP688
215150475|NCT06655259|PROCEDURE|TURP|Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor
214463005|NCT05586334|BIOLOGICAL|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
214463006|NCT05586334|OTHER|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
214463007|NCT06777797|DEVICE|PU condoms (Test PU Condom A, Test PU Condom B, Test PU Condom C, Test PU Condom D)|Participants will be provided with PU condoms (2 condoms per variant) to use during masturbation.
214463008|NCT06777797|DEVICE|NRL condoms (Test NRL Condom A, Test NRL Condom B, Test NRL Condom C, Test NRL Condom D)|Participants will be provided with NRL condoms (2 condoms per variant) to use during masturbation.
214463009|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
214463010|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
214532899|NCT05447728|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
214532900|NCT05447728|DIAGNOSTIC_TEST|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
214532901|NCT02109861|DRUG|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
214532902|NCT02109861|DRUG|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
214532903|NCT02109861|DRUG|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
215150476|NCT06655259|DRUG|Standard Medical Therapy|Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
215150477|NCT06666218|BEHAVIORAL|Behavioral Intervention|Complete the HOPE intervention workshop
215150478|NCT06666218|OTHER|Electronic Health Record Review|Ancillary studies
215150479|NCT06666218|OTHER|Interview|Complete an interview
215150480|NCT06666218|OTHER|Survey Administration|Complete a survey
215150481|NCT06666218|OTHER|Survey Administration|Ancillary studies
215150482|NCT06389955|DRUG|TP 3654|TP 3654 is an investigational orally delivered drug
215150483|NCT03493464|DRUG|BR55|A novel targeted ultrasound contrast agent
215150484|NCT06597669|PROCEDURE|Placement of stainless steel crowns on primary molars|Preformed metal crowns have been placed to treat caries in primary molars
215150485|NCT06592131|DRUG|BF844|BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
215150486|NCT06594835|BEHAVIORAL|Better Together|Better Together (BT) is a 90-min, age-appropriate, culturally relevant prevention intervention to prevent substance use among Black youth experiencing household challenges (ages 11-13) by addressing the multilevel influences of substance use.
215150487|NCT06594835|BEHAVIORAL|Youth In the Media (YM)|Delivered in eight in-person, 90-minute sessions concurrently with BT sessions, the YM program was designed to (1) increase participants' awareness of and access to the different types of media and free resources available at the participants local libraries, (2) discuss different types of media that center stories and experiences of Black youth, and (3) expose participants to careers in media.
215150488|NCT06593730|DRUG|NRL001 cream 0.5%w/w|
215150489|NCT06593730|DRUG|NRL001 cream 0.75%w/w|
215150490|NCT06593730|DRUG|NRL001 cream 1.0%w/w|
215150491|NCT06593730|DRUG|NRL001 cream 1.5%w/w|
215150492|NCT06593730|DRUG|NRL001 cream 2.0%w/w|
215150493|NCT06593730|DRUG|NRL001 cream 2.5%w/w|
215150494|NCT06591000|PROCEDURE|tricuspid valve replacement|Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
215150495|NCT06993298|DEVICE|Augmented Reality Ergonomics Training (ARPE)|Participants in this arm will receive an interactive training module using Augmented Reality (AR) delivered via the MAKAR XR app. The module aims to enhance ergonomic knowledge, self-prevention, and self-evaluation related to work-related musculoskeletal disorders (WMSDs)
215150496|NCT06993298|BEHAVIORAL|Conventional Ergonomics Training|Participants in this arm will receive conventional ergonomic training based on the Department of Occupational Safety and Health (DOSH) guidelines for manual material handling (MMH) workers. The training includes lectures, printed materials, and standard instructional content focused on safe lifting techniques, proper posture, risk factor identification, and strategies to prevent work-related musculoskeletal disorders (WMSDs). This training is delivered in a one-time session with follow-up reminders, simulating current standard practices in workplace safety education.
215150497|NCT06857864|DEVICE|Test myopia control lenses (BSL)|Test spectacle lenses will be provided to the subjects throughout the 1 year clinical trial.
214532904|NCT01677949|DRUG|Clofarabine|Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours
214532905|NCT01677949|DRUG|Etoposide|Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
215150498|NCT06592625|DRUG|SHR-A1811|SHR-A1811
215150499|NCT06592625|DRUG|Adebrelimab|Adebrelimab
215150500|NCT06586983|DRUG|Tenofovir Disoproxil Fumarate|300 mg po OD
215150501|NCT06603896|OTHER|Aromatherapy|Aromatherapy and placebo patches will be used
215150502|NCT06603857|DRUG|CE Ferulic|CE Ferulic serum regimen combined with laser treatment
215150503|NCT06603857|DRUG|Sham Comparator|Vehicle serum regimen combined with laser treatment
215150504|NCT06603857|DEVICE|1927nm (Clear and Brilliant Perméa®)|non-ablative fractional diode laser
215150505|NCT04515810|OTHER|Internet-Based Intervention|Use smartphone application
215150506|NCT04515810|OTHER|Best Practice|Engage in standard care
215150507|NCT04515810|OTHER|Questionnaire Administration|Ancillary studies
215150508|NCT06613789|BIOLOGICAL|426c.Mod.Core-C4b|self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
215150509|NCT06613789|BIOLOGICAL|3M-052-AF|3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
215150510|NCT06613789|BIOLOGICAL|Aluminum hydroxide suspension (Alum)|Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
215150511|NCT06613789|BIOLOGICAL|Placebo and Diluent|Tris-NaCl buffer.
214532906|NCT01677949|DRUG|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
214532907|NCT01677949|BIOLOGICAL|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
214532908|NCT06447298|OTHER|Satisfaction questionnaires|Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
214532909|NCT00839332|DRUG|LY2603618|
215150512|NCT06543199|PROCEDURE|local application of hyaluronic acid agent to the wound site|Evaluation of the effect of local use of hyaluronic acid agent on wound healing
215150513|NCT06543199|PROCEDURE|Local application of hypericum perforatum L to the wound site|Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi
215150514|NCT06543199|PROCEDURE|wound healing monitoring|Doctor visit on days 3, 7, 14, 21 and 28
215150515|NCT06602687|DEVICE|PICSI|The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).
214532910|NCT00839332|DRUG|Gemcitabine|
214532911|NCT00433797|DIETARY_SUPPLEMENT|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
215150516|NCT06591130|BEHAVIORAL|Youth culturally adapted manual assisted psychological intervention (Y-CMAP)|YCMAP (Youth culturally adapted manual assisted psychological intervention) is based on CBT principles. It comprises of 8-10 sessions delivered individually over 3 months (weekly for 1 month then fortnightly), lasting for 60 minutes. The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the self-harm attempt using virtual stories of four young people. Therapists and young person choose from a list of techniques those which are most relevant to the young person's problems. Therapy is therefore adapted to fit with the young person's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change. To help determine the most appropriate coping strategy a coping tree is designed. Training in assertiveness and anger management are offered to help the young person to develop resilience to cope with stress.
215150517|NCT06597318|OTHER|Hospitalization|The investigators collect PROMs amongst up to 1000 patients in general internal medicine divisions of all five Swiss university hospitals
215150518|NCT06596278|DEVICE|Memesto|Memesto wearable audio player
215150519|NCT06588270|BEHAVIORAL|Virtual Reality Therapy for the Negative Symptoms of Schizophrenia|VRTNSS is a 12-session therapy using psychological intervention principles. Each therapy session will involve engaging with different VR based tasks where participants can experience different activities.
215150520|NCT06588270|BEHAVIORAL|Sham- VR|Patients will attend to VR sessions without the software created activities for treatment (sham-VR).
215150521|NCT06587477|OTHER|Hormonal profile|Blood for FSH, LH, testosterone
215150522|NCT06587477|OTHER|Semen analysis|Semen analysis
215150523|NCT06587477|OTHER|Questionnaire|The European Male Ageing Study (EMAS) questionnaire
215150524|NCT05934565|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
215150525|NCT05514886|DEVICE|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
215150526|NCT07015398|DRUG|NAL ER|Oral tablets
215150527|NCT07015398|DRUG|Pirfenidone|Oral tablets
215150528|NCT07015398|DRUG|Nintedanib|Oral capsules
215150529|NCT05320445|BEHAVIORAL|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
215150530|NCT03075072|RADIATION|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
214532912|NCT00123019|BEHAVIORAL|Exercise and diet|Advice and measurement only
214532913|NCT00123019|BEHAVIORAL|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
214532914|NCT00123019|BEHAVIORAL|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
215150531|NCT03075072|RADIATION|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
215150532|NCT06474832|OTHER|High-intensity interval training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform HIIT with 5 intervals at 80% heart rate reserve (HRR), each interval lasting 4 minutes, with 3-minute intervals at 40% HRR between each interval.
215150533|NCT06474832|OTHER|Moderate intensity continuous training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform continuous exercise at 59% HRR for 35 minutes.
215150534|NCT06874803|PROCEDURE|Acupuncture and Moxibustion (AM)|Acupuncture and moxibustion group (AM): Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (BL33), and bilateral Weiyang (BL39), combined with moxibustion at Shuifen (CV9) and Zhongliao (BL33).
214532915|NCT00123019|BEHAVIORAL|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
214532916|NCT03722498|DRUG|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214532917|NCT03722498|DRUG|Sorafenib|administration of Sorafenib
214532918|NCT01200485|DRUG|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
215150535|NCT06874803|PROCEDURE|Sham Acupuncture and Moxibustion (Sham-AM)|Sham acupuncture and moxibustion group (sham-AM): Acupuncture at non-acuipoints of bilateral Hegu (LI4) and bilateral Zusanli (ST36), with fake moxibustion at Shuifen (CV9) and bilateral Zhongliao (BL33).
215150536|NCT03868995|PROCEDURE|Sham injection|Dextrose water injection to subcutaneous layer at tender point
215150537|NCT03868995|PROCEDURE|Tendon injection|Dextrose water injection to injured tendon
215150538|NCT06592391|OTHER|educational innovation dynamic school day|Schools will form a community of practice, and will be supported with regular workshop to develop a dynamic school day that matches the local context.
214532919|NCT01200485|DRUG|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
214532920|NCT06080438|DRUG|Botulinum toxin|15 units of botulinum toxin administered one time to the eye via eye drops
214532921|NCT03569475|DRUG|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
214532922|NCT03569475|DRUG|Fluoxetine|Fluoxetine oral capsules
214532923|NCT03569475|DRUG|Placebo|Matching placebo oral capsules
215150539|NCT06592391|OTHER|e-learning on a dynamic school day|Schools will form a community of practice, and will develop a dynamic school day that matches their local context using e-learning materials
215150540|NCT06592391|OTHER|expert schools|Schools that have developed a local dynamic school day without additional support
215150541|NCT05625490|DRUG|Ga-68 Galmydar|Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
215150542|NCT05625490|DRUG|13N-ammonia|Two intravenous injections of PET radiotracer \[13N\]Ammonia.
215150543|NCT05755516|DEVICE|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
215150544|NCT05755516|DEVICE|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
215150545|NCT07025317|OTHER|Perceptual-cognitive|"The intervention is to determine the effectiveness of NeuroTracker for treating cognitive deficits associated with a prior history of concussion. NeuroTracker has a virtual cloud-based platform (NeuroTrackerX), which has been validated for use in research. This online platform allows participants to complete the interventions from home and greatly increases the accessibility of the program. Participants will have two 30-minute training sessions per week over the course of the 6-month intervention. Each session will consist of 3 blocks of 20 trials. For each trial in a block, participants sit upright, approximately 20 away from a standard computer or laptop screen, and wear anaglyph 3D glasses while focusing on the center of a standard 20 computer screen."
215150546|NCT04429256|OTHER|data collection|retrospective analysis of perioperative data collected from patient medical charts and from a telephone enquiry
215150547|NCT07024758|BEHAVIORAL|Parent Coached Exposure Therapy|Parent-based cognitive behavioral therapy with guidance from a therapist
215150548|NCT07024758|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
215150549|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
215150550|NCT06705452|OTHER|Additional 4D Flow MRI or additional 4D Flow sequence|Additional 4D Flow MRI or additional 4D Flow sequence
215150551|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket wire in high level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in low level for the treatment of anterior deep bite .
215150552|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket with wire in low level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in high level for the treatment of anterior deep bite .
214532924|NCT06485648|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Treatment: G(glucocorticoid) + i.v. uc-MSC (1×106 cells/Kg)
214532925|NCT06485648|DRUG|Normal saline|Control: G(glucocorticoid) + i.v. Normal saline
214532926|NCT03638258|DRUG|Roflumilast Cream 0.3%|Applied once daily for 12 weeks
214532927|NCT03638258|DRUG|Roflumilast Cream 0.15%|Applied once daily for 12 weeks
214532928|NCT03638258|DRUG|Vehicle Cream|Applied once daily for 12 weeks
214532929|NCT04238533|OTHER|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
214532930|NCT04238533|OTHER|Conventional training|Conventional training with Myoboy has been the only training available to users.
214532931|NCT02630706|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
214532932|NCT02630706|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
214532933|NCT02630706|DRUG|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
214532934|NCT02630706|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
215150553|NCT02374450|PROCEDURE|Blood collection|For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
215150554|NCT06706999|OTHER|PREVAIL model of care|"Components 1, 2, and 3 are essential components that all participants will receive. Components 4 and 5 are based on the results of either the DAPS tool or the PT consultation call.~1. Screening tool (DAPS) completed at baseline to determine current level of limitation with valued life activities.~2. Recommendation to rheumatology clinician based on screening results to provide exercise resource and/or recommend a PT consult call during routine visit.~3. Exercise resource (PREVAIL website) provided to all participants by their rheumatology clinician at their routine visit.~4. Brief consultation call with a study physical therapist to determine level of priority for PT referral. Only applicable for those with/at risk for limitation with valued life activities.~5. Referral to PT. Only applicable if determined by study physical therapist to meet priority requirements."
215150555|NCT06053775|DEVICE|Transcranial Direct Current Stimulation|tDCS+OCT
215150556|NCT06053775|DEVICE|Transcranial Alternating Current Stimulation|tACS+OCT
215150557|NCT06053775|DEVICE|tES sham|tES sham + OCT
215150558|NCT06053775|DEVICE|Online Cognitive Training|OCT
215150559|NCT03694938|DEVICE|Magnetic resonance imaging|Annually magnetic resonance imaging
215150560|NCT06706687|DIAGNOSTIC_TEST|DISBAND protocol|For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
215150561|NCT07040917|DRUG|CAR-T cell|CAR-T cell
215150562|NCT04167878|DEVICE|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
215150563|NCT04167878|DEVICE|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
215150564|NCT06708520|DRUG|Rupatadine|10 mg tablets
215150565|NCT06720220|DRUG|Dexmedetomidine Hydrochloride|"procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3)."
215150566|NCT06720220|OTHER|Nebulization|nebulization session through a face mask nebulizer attached to an oxygen source. The nebulizer chamber was filled with 10 ml of 2% lidocaine (200 mg). The oxygen flow was adjusted at a rate of 8-10 L/min for 10-15 minutes.
214532935|NCT02630706|DRUG|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
214532936|NCT05122078|DEVICE|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
215150567|NCT06720220|OTHER|Atomization|"Airway topicalization by atomization (through a modification of McKenzie technique). This modification utilizes a 10-Fr suction catheter instead of 20-gauge cannula. This suction catheter was attached to oxygen tubing with a three-way stopcock. The oxygen tubing was attached to an oxygen source, which delivers a flow of 2-4 L/min. A 10-ml syringe filled with 10 ml of lidocaine 2% was attached to top port of the three-way stopcock.~Local anesthetic was injected via the syringe forming a jet- like spray for topicalization of the nasal and oral mucosa"
215150568|NCT06720220|OTHER|Spray-As-You-Go|airway topicalization method using the fiberoptic bronchoscope itself. The fiberoptic bronchoscope, preloaded with a 6.5 or 7 mm endotracheal tube, was passed under direct vision through the nose into the pharynx. Then 10-ml syringe containing 10 ml Lidocaine 2%, was attached to the working channel, and thus the local anesthetic was sprayed towards the mucosa of postnasal space and back of throat, while advancing the fiberscope. At the level of the epiglottis and around the vocal cords 2-4 ml of lidocaine 2% were sprayed toward these structures as the patient takes a deep breath to achieve sufficient anesthesia to the laryngeal inlet. The patient was asked to take another deep breath as the scope was passed through the vocal cords and 2 ml of lidocaine 2% is sprayed to the trachea and the scope was advanced further until the carina was visualized.
215150569|NCT06877377|BIOLOGICAL|hDNAgr Therapy|A novel investigational therapy that uses fragmented therapeutic double-stranded DNA, designed to correct or replace locally damaged genomic regions in hematopoietic stem cells and elongate telomeres. The hDNAgr therapy is administered according to the study protocol schedule (Visits at Day 0, 14, 28, 60, 90, and 180), with blood draws and safety evaluations at each time point to assess hematological parameters, telomere length, and potential impacts on biological aging.
215150570|NCT06877377|OTHER|Placebo|An inactive formulation identical in appearance to the hDNAgr therapy but lacking the active DNA fragments. It is administered under the same schedule and conditions as the experimental intervention to maintain blinding and enable comparison of safety and efficacy outcomes.
215150571|NCT05715931|DRUG|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
214532937|NCT05122078|OTHER|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
214532938|NCT03134547|DRUG|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
214532939|NCT03134547|DRUG|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
214532940|NCT04410549|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|To perform OCT in pulmonary artery of patient with COVID-19
214532941|NCT00216788|DRUG|Esomeprazole (Nexium) 40 mg/day|
214532942|NCT01678898|DRUG|PRX-102|
214532943|NCT00221156|DRUG|Acarbose|
214532944|NCT00915460|DRUG|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
214532945|NCT03489837|DRUG|Levotuss|oral taken
214532946|NCT04934878|BIOLOGICAL|Referral information|first visit to our hospital/transfer from another hospital
214532947|NCT06453304|DRUG|Calcium Hydroxide|Intracanal medication
214532948|NCT06453304|DRUG|Leddermix|Intracanal medication
214532949|NCT06453304|DRUG|Glycirrhizin|Intracanal medication
214532950|NCT00752999|DRUG|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
215150572|NCT05715931|DRUG|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
214532951|NCT00752999|DRUG|Placebo|Placebo tablet, oral, twice-a-day
214532952|NCT01953471|OTHER|Allergic rhinitis|Questionnaire
214532953|NCT00224809|DRUG|Angiotensin-Converting Enzyme Inhibitors|
214532954|NCT00224809|PROCEDURE|Coronary Artery Bypass Graft|
215150573|NCT05715931|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
215150574|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 1 sachet|1 dose day to be absorbed sublingually
214532955|NCT00224809|DRUG|Angiotensin Receptor Blockers|
215150575|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 2 sachet day|1 sachet two times a day to be sublingually absorbed
215150576|NCT06718452|DIETARY_SUPPLEMENT|Placebo|Same administration of PEA-LUT
215150577|NCT06725888|DEVICE|Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:|"Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days"
214532956|NCT00224809|DRUG|Spironolactone|
214532957|NCT00224809|DRUG|Aspirin|
214532958|NCT00224809|DRUG|Clopidogrel|
214532959|NCT00224809|PROCEDURE|Surgical Ventricular Restoration|
214532960|NCT05888558|DEVICE|Body fluid diagnosis|miRNAs derived from exosomes in the serum
214532961|NCT00549042|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
214532962|NCT00549042|DRUG|Placebo|Placebo
214532963|NCT00144716|DEVICE|Insect Repellent plus Insecticide Treated Net|
214532964|NCT04471480|DRUG|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
214532965|NCT04521933|OTHER|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
214532966|NCT00703599|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
214532967|NCT03535493|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
214532968|NCT03535493|BEHAVIORAL|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
214532969|NCT03535493|BEHAVIORAL|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
214532970|NCT02631616|DRUG|Somatostatin|Monthly injections of Somatostatin
214532971|NCT00068835|BEHAVIORAL|Lindamood-Bell training for dyslexia|
214532972|NCT04782596|PROCEDURE|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
215150578|NCT07043972|DRUG|Gemcitabine|IV over 30 minutes given on days 1 and 8 of a 21 day cycle
215150579|NCT07043972|DRUG|Carboplatin|IV over 30 minutes given on day 1 of a 21 day cycle
215150580|NCT03672578|OTHER|loss-frame|loss frame label
215150581|NCT03672578|OTHER|gain-frame|gain frame label
215150582|NCT03672578|OTHER|text-only|text-only label
215150583|NCT03672578|OTHER|icon|label with icon and text
215150584|NCT03672578|OTHER|attribution|label with attribution
215150585|NCT03672578|OTHER|no attribution|label with no attribution
215150586|NCT03672578|OTHER|No label|No label
215150587|NCT01582477|DRUG|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
215150588|NCT01582477|DRUG|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
215150589|NCT04145349|DRUG|Ramucirumab|Administered IV
215150590|NCT04145349|DRUG|Cyclophosphamide|Administered orally
215150591|NCT04145349|DRUG|Vinorelbine|Administered IV
214532973|NCT01527500|DRUG|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
214532974|NCT01527500|DRUG|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
214532975|NCT01527500|DRUG|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
214532976|NCT00003924|BIOLOGICAL|recombinant interferon alfa|
214532977|NCT00672347|DRUG|Clonidine|1 mcg/kg
214532978|NCT00672347|DRUG|Morphine|20 mcg/kg
214532979|NCT00672347|DRUG|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
214532980|NCT00672347|DRUG|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
214532981|NCT03521206|BEHAVIORAL|ACP+ programme|Training program for nursing home staff.
214532982|NCT04355052|DRUG|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
214532983|NCT04355052|DRUG|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
214532984|NCT03039088|OTHER|Follow-up after 12 weeks after TNF alpha blockers initiation|
214532985|NCT03790878|BEHAVIORAL|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
214532986|NCT03790878|BEHAVIORAL|Habituation|An exposure procedure that reduces emotional distress through habituation
214532987|NCT03790878|BEHAVIORAL|Control|No emotion regulation intervention, placebo
214532988|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
214532989|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
214532990|NCT04851171|PROCEDURE|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
214532991|NCT04851171|PROCEDURE|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
214532992|NCT03657537|DRUG|Ketone infusion|β-hydroxybutyrate is infused intravenously.
214532993|NCT03657537|DRUG|Saline infusion|saline is infused intravenously.
214532994|NCT00655083|DRUG|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
214532995|NCT00655083|DRUG|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
214532996|NCT00895089|DRUG|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
214532997|NCT00895089|DRUG|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
214532998|NCT00484172|PROCEDURE|blood draws|
214532999|NCT02541799|PROCEDURE|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
214533000|NCT02541799|PROCEDURE|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
214533001|NCT03078751|DRUG|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
214533002|NCT03078751|DRUG|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
214533003|NCT03078751|DRUG|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
214695859|NCT03822871|DRUG|CTT1403|Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
215150592|NCT05531734|DEVICE|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
215150593|NCT05531734|BEHAVIORAL|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
215150594|NCT00002330|DRUG|Ganciclovir|
215150595|NCT03365271|PROCEDURE|drainage|Applying a drain tube during TKA procedure
215150596|NCT03365271|PROCEDURE|non-drainage|No drain tube will be applied during TKA procedure
215150597|NCT04783493|DEVICE|Non-invasive magnetic stimulation of the spinal cord|Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
215150598|NCT04783493|OTHER|Coil will not be connected to the stimulation device|coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
215150599|NCT02553226|DRUG|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
214533004|NCT05666271|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
214533005|NCT02960334|DEVICE|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
214533006|NCT02093117|PROCEDURE|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
215150600|NCT02553226|DRUG|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
214533007|NCT02093117|PROCEDURE|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
214533008|NCT06117761|OTHER|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
215150601|NCT01035086|DIETARY_SUPPLEMENT|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
215150602|NCT04842812|BIOLOGICAL|TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3|TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
215150603|NCT02061488|OTHER|open-loop night|During the open-loop night the patient is using his insulin pump as usual
215150604|NCT02061488|OTHER|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
214533009|NCT06117761|OTHER|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
215150605|NCT02543957|PROCEDURE|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
215150606|NCT00504647|DEVICE|Biventricular Pacemaker|
215150607|NCT01964820|BEHAVIORAL|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
215150608|NCT00942227|OTHER|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
215150609|NCT00942227|OTHER|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
215150610|NCT04279626|PROCEDURE|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
215150611|NCT02306317|OTHER|Standard procedure|FiO2 manually controlled by nursing
215150612|NCT02306317|OTHER|Experimental procedure|FiO2 manually controlled by parents, after training.
214533010|NCT06117761|OTHER|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
214533011|NCT00198198|DRUG|Aripiprazole|
214533012|NCT04934124|DRUG|ITI-333|ITI-333 oral solution
214533013|NCT04934124|OTHER|Placebo|Matching placebo
215150613|NCT01148979|DRUG|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
215150614|NCT01148979|DRUG|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
215150615|NCT05216809|BEHAVIORAL|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.
215150616|NCT05216809|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
215150617|NCT00132470|DRUG|AX200 (G-CSF)|
215150618|NCT04440527|DEVICE|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
215150619|NCT04440527|OTHER|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
215150620|NCT02132429|DRUG|AMG 333|Oral administration available in varying dose strength.
215150621|NCT02132429|DRUG|Placebo|Placebo containing no active drug
215150622|NCT01376804|DRUG|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
215150623|NCT00093704|DRUG|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
215150624|NCT02446119|DEVICE|EndoFLIP|Measurement of pyloric resistance and compliance
214533014|NCT02900222|PROCEDURE|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
214533015|NCT03212950|DRUG|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
214533016|NCT03212950|DRUG|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
214533017|NCT05067543|DEVICE|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
214533018|NCT04848103|BEHAVIORAL|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
215150625|NCT02005861|PROCEDURE|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
215150626|NCT02942459|OTHER|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
215150627|NCT02942459|OTHER|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
215150628|NCT05982418|DEVICE|3D Printed Models (3D printing facilities at GSTT)|3D patient-specific printed models are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D printing.
215150629|NCT05982418|DEVICE|3D Virtual Models (Innersight Labs)|3D patient-specific virtual models loaded into Innersight Labs platform are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D visualisation.
215150630|NCT04527770|DRUG|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
215150631|NCT04527770|DRUG|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
215150632|NCT04910997|OTHER|Aerobic exercise training|Combination of supervised and home-based aerobic exercise training
215150633|NCT00157989|PROCEDURE|Controlled tidal volume resuscitation|
215150634|NCT00882557|DRUG|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
215150635|NCT00882557|DRUG|daptomycin|6 mg/kg administered after a hemodialysis session
215150636|NCT01295437|DEVICE|Vypro II mesh|partly absorbable mesh
215150637|NCT01295437|DEVICE|Premilene LP|lightweight mesh
215150638|NCT01295437|DEVICE|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
215150639|NCT04816552|BEHAVIORAL|CHoBI7 mHealth program Arm|We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
215150640|NCT04816552|BEHAVIORAL|general message on oral rehydration solution (ORS)|general message on oral rehydration solution (ORS)
215150641|NCT05322473|DRUG|Sonelokimab (M1095)|randomized treatment; parallel-group
215150642|NCT05322473|DRUG|Adalimumab|randomized treatment; parallel-group
215150643|NCT05322473|OTHER|Placebo|randomized treatment; parallel-group
215150644|NCT00575640|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
215150645|NCT01908062|DRUG|Extended Release Naltrexone|
215150646|NCT01908062|OTHER|Treatment As usual|
215150647|NCT01383356|DRUG|Metformin Single Tablet|Metformin medium doseTablet
215150648|NCT01383356|DRUG|Linagliptin/Metformin Combo|Fixed dose combination
215150649|NCT01383356|DRUG|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
215150650|NCT02796183|DRUG|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
215150651|NCT00916331|PROCEDURE|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
215150652|NCT00916331|PROCEDURE|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
215150653|NCT03770767|DRUG|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
215150654|NCT03770767|DRUG|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
215150655|NCT04250909|DEVICE|Passeo-18|POBA
214533019|NCT03410095|DIAGNOSTIC_TEST|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
214533020|NCT04646135|DRUG|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
215150656|NCT04250909|DEVICE|Passeo-18 Lux|DCB
215150657|NCT02461277|OTHER|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
215150658|NCT04235751|BEHAVIORAL|Professional Coaching|6 individualized professional coaching sessions via phone
215150659|NCT02253446|DRUG|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
215150660|NCT02253446|DRUG|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
215150661|NCT05848999|BIOLOGICAL|UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
214533021|NCT01845311|DEVICE|ReZolve2 Scaffold|
214533022|NCT01209286|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
214533023|NCT02723513|OTHER|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
214533024|NCT04903847|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
214533025|NCT04903847|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
214533026|NCT05257252|BEHAVIORAL|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
214533027|NCT02218775|DRUG|LY2456302|Mood and Anxiety Disorders
214533028|NCT05861778|DRUG|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
214533029|NCT04865614|DRUG|Etomidate|Use of etomidate
214533030|NCT04865614|DRUG|Sevoflurane|Use of sevoflurane
214533031|NCT05093023|GENETIC|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
214533032|NCT04136964|OTHER|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
214533033|NCT06337240|OTHER|Pelvic floor on COPD patients|"Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months."
214533034|NCT06337240|OTHER|Pilates exercises on COPD patients|"Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months."
215150662|NCT05295069|BEHAVIORAL|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
215150663|NCT04803396|DRUG|DF2755A|"DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14)."
215150664|NCT04803396|OTHER|Placebo|Single oral dose administration on D1
215150665|NCT04755686|PROCEDURE|Fast-tracking|
214533035|NCT04469452|DEVICE|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
215150666|NCT02079961|DIETARY_SUPPLEMENT|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
215150667|NCT02079961|BEHAVIORAL|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
215150668|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
215150669|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
215150670|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
215150671|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
215150672|NCT00602472|DRUG|linagliptin|active
215150673|NCT00602472|DRUG|placebo|placebo to linagliptin 5 mg
215150674|NCT01416324|DRUG|placebo|Vehicle used to dilute the powder for oral administration.
215150675|NCT01416324|DRUG|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150676|NCT01416324|DRUG|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150677|NCT01416324|DRUG|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150678|NCT01416324|DRUG|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150679|NCT01416324|DRUG|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150680|NCT01416324|DRUG|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150681|NCT01416324|DRUG|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
215150682|NCT03038880|DRUG|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
215150683|NCT03038880|DRUG|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
215150684|NCT03038880|DRUG|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
215150685|NCT01718405|OTHER|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
215150686|NCT01718405|GENETIC|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
215150687|NCT03807921|DRUG|Warfarin|Oral anticoagulation
215150688|NCT03807921|DRUG|Aspirin|Antiplatelet treatment
214533036|NCT02780739|BEHAVIORAL|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
214695860|NCT03822871|DRUG|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
215150689|NCT01823913|DRUG|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
215150690|NCT01823913|DRUG|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
215150691|NCT01817803|DRUG|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
215150692|NCT01817803|DRUG|metolazone/no spironolactone|metolazone (add 2.5mg qod)
215150693|NCT01817803|DRUG|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
215150694|NCT01817803|DRUG|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
215150695|NCT03746158|DIETARY_SUPPLEMENT|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
215150696|NCT00224991|PROCEDURE|Intensive systematic information (osteoporosis school)|
215150697|NCT01359085|DRUG|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
215150698|NCT01359085|PROCEDURE|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
215150699|NCT05337839|PROCEDURE|home exercises|stretching, balance and strengthening exercises
215150700|NCT00031317|DRUG|Paroxetine|
215150701|NCT00031317|DRUG|Clozapine|
215150702|NCT02724748|BEHAVIORAL|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
215150703|NCT02885025|DIETARY_SUPPLEMENT|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
215150704|NCT02885025|DRUG|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
215150705|NCT02885025|DIETARY_SUPPLEMENT|broccoli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
215150706|NCT02885025|DRUG|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
215150707|NCT02013271|DEVICE|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
215150708|NCT03522311|PROCEDURE|Vitrectomy|
214695861|NCT03822871|DRUG|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
215150709|NCT01981018|OTHER|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
215150710|NCT00194532|DRUG|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
214463011|NCT06122701|DIETARY_SUPPLEMENT|Thiamin p.o.|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
214463012|NCT06122701|DIETARY_SUPPLEMENT|Thiamin i.v.|"A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
214463013|NCT05891587|DRUG|Semaglutide|Semaglutide pen injector
214463014|NCT05891587|DRUG|Placebo|Saline solution
214463015|NCT05631223|BEHAVIORAL|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
214463016|NCT04880863|DRUG|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that are linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP is administered at a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg is administered on Day 1.
214463017|NCT04880863|DRUG|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel is administered in combination with the study drug, NAP, on Day 2.
214695862|NCT03489135|DEVICE|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
214695863|NCT01088438|BEHAVIORAL|Contextualization workshop|A four-hour course on contextualization.
215150711|NCT00194532|DRUG|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
215150712|NCT02054104|BIOLOGICAL|H1299 cell lysates|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
214463018|NCT04880863|DRUG|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
214463019|NCT04539587|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
214463020|NCT04528173|DRUG|Ketorolac|Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
214463021|NCT04528173|DRUG|Dexmedetomidine|Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
214463022|NCT04528173|DRUG|Morphine|Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
214463023|NCT04528173|DRUG|Fentanyl|Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
214463024|NCT04822363|DRUG|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
214463025|NCT04822363|DRUG|Clopidogrel|Arms C and E
215150713|NCT02054104|DRUG|Cyclophosphamide|50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
215150714|NCT02054104|DRUG|Celecoxib|400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
215150715|NCT02054104|BIOLOGICAL|Iscomatrix adjuvant|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
215150716|NCT03658590|DRUG|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
215150717|NCT03658590|DRUG|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
215150718|NCT00823615|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
215150719|NCT00823615|DEVICE|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
215150720|NCT03926611|DRUG|LOU064 Arm 1|10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
214463026|NCT05118295|DEVICE|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
214463027|NCT01006239|OTHER|No study intervention|The is no study related intervention.
214463028|NCT04978623|OTHER|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
214533037|NCT02780739|BEHAVIORAL|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
215150721|NCT03926611|DRUG|LOU064 Arm 2|35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
215150722|NCT03926611|DRUG|LOU064 Arm 3|100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
215150723|NCT03926611|DRUG|LOU064 Arm 4|10mg bid of LOU064 orally, twice daily from Day 1 to 85
215150724|NCT03926611|DRUG|LOU064 Arm 5|25 mg bid of LOU064 orally, twice daily from Day 1 to 85
214463029|NCT06206876|PROCEDURE|Biopsy|Undergo biopsy
214463030|NCT06206876|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214463031|NCT06206876|PROCEDURE|Computed Tomography|Undergo CT
214463032|NCT06206876|DRUG|DDX5 Degrader FL118|Given PO
214463033|NCT06206876|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214463034|NCT05572957|DRUG|Guideline-Directed Medical Therapy(GDMT)|"Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~\*Criteria for \<3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest."
215150725|NCT03926611|DRUG|LOU064 Arm 6|100 mg bid of LOU064 orally, twice daily from Day 1 to 85
215150726|NCT03926611|DRUG|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
215150727|NCT05457439|BEHAVIORAL|Sustainable diet promotion through behavioral change intervention|15 weeks digital intervention to promote sustainable diets through workshops, and behavioral change techniques in a mobile application, to decrease environmental impact of diets and improve health.
215150728|NCT03446196|DEVICE|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV \> 12%
215150729|NCT04295824|DIAGNOSTIC_TEST|Skin imaging and Skin biopsy|"Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed."
215150730|NCT05820906|DRUG|Cadonilimab+Regorafenib+GC|Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8
215150731|NCT03110913|OTHER|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
215150732|NCT00569517|BEHAVIORAL|CBT|6-CBT based sesions
215150733|NCT00569517|OTHER|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
215150734|NCT00084136|DRUG|Atazanavir|400 mg taken orally daily
215150735|NCT00084136|DRUG|Didanosine (enteric-coated)|400 mg taken orally daily
215150736|NCT00084136|DRUG|Efavirenz|600 mg taken orally daily
215150737|NCT00084136|DRUG|Emtricitabine|200 mg taken orally daily
215150738|NCT00084136|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
215150739|NCT00084136|DRUG|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
215150740|NCT00336596|PROCEDURE|transcranial ultrasound in patients treated with iv t-PA|
215150741|NCT02230670|DRUG|IDN-6556|25 mg BID
215150742|NCT02230670|DRUG|Placebo|
215150743|NCT02154698|OTHER|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
215150744|NCT02154698|OTHER|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
215150745|NCT01041755|DRUG|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
215150746|NCT01041755|DRUG|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
215150747|NCT03669497|RADIATION|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
215150748|NCT01926262|BEHAVIORAL|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
215150749|NCT00140582|DRUG|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
215150750|NCT00921375|DRUG|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
215150751|NCT00893438|BEHAVIORAL|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
215150752|NCT00893438|OTHER|Usual care|Usual care treatment for adolescents with CFS
215150753|NCT04567992|PROCEDURE|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
214533038|NCT02780739|BEHAVIORAL|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
214533039|NCT02780739|DEVICE|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
214533040|NCT02780739|DEVICE|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
215150754|NCT02987790|OTHER|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak\> 100mg / L), with a limit of seven days, if there is clinical improvement.
215150755|NCT01464437|DRUG|AMG 151|Drug: AMG 151 50 mg BID
215150756|NCT01464437|DRUG|Placebo|Placebo
215150757|NCT01464437|DRUG|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
215150758|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg BID
215150759|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg BID
215150760|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg QD
215150761|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg QD
215150762|NCT01464437|DRUG|AMG 151|Drug: AMG 151 400 mg QD
215150763|NCT00445926|DEVICE|deep TMS H-coil|
215150764|NCT00462995|DRUG|Erlotinib|150mg once a day for 28 days
215150765|NCT00462995|DRUG|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
215150766|NCT05434416|OTHER|mobile app|mobile app self-guided psychological interventions
215150767|NCT00566761|DRUG|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
215150768|NCT05488535|DEVICE|cochlear implant headpiece|investigational cochlear implant headpiece
215150769|NCT06521333|DRUG|Resveratrol-Based gel|The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
215150770|NCT06521333|DRUG|Hyaluronic acid gel 0.2%|The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
215150771|NCT06521333|DEVICE|Stent|The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
215150772|NCT03705338|DEVICE|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
215150773|NCT03705338|DRUG|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
215150774|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given weekly
215150775|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given monthly
215150776|NCT00892099|OTHER|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
215150777|NCT06341478|DRUG|various neoadjuvant therapies|Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
215150778|NCT04129567|OTHER|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
215150779|NCT04129567|OTHER|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
215150780|NCT04129567|OTHER|Humidified air|Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
215150781|NCT04129567|OTHER|Dry air|Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
215150782|NCT02376699|DRUG|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
215150783|NCT02376699|DRUG|Pembrolizumab|Given intravenously; schedule is cohort-specific.
215150784|NCT02376699|DRUG|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
215150785|NCT02376699|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
215150786|NCT02376699|DRUG|Nab-paclitaxel|125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
215150787|NCT00217607|DRUG|paclitaxel|
215150788|NCT03352037|DIAGNOSTIC_TEST|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
215150789|NCT00404222|DRUG|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
215150790|NCT00404222|DRUG|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
215150791|NCT00404222|DRUG|Placebo|q 4 hours x 3
215150792|NCT05576454|DRUG|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
215150793|NCT05576454|DRUG|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
215150794|NCT05576454|DRUG|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
215150795|NCT01672671|DRUG|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
215150796|NCT01657019|DRUG|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
215150797|NCT01167413|DEVICE|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
214533041|NCT02780739|BEHAVIORAL|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
214533042|NCT02108847|DRUG|.2% Ropivacaine|
215150798|NCT01167413|OTHER|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
215150799|NCT01367990|DRUG|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
215150800|NCT00041743|BEHAVIORAL|Group Cognitive Behavioral Therapy|
214533043|NCT02108847|DRUG|Saline|
214533044|NCT02108847|PROCEDURE|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
214533045|NCT00317447|DRUG|Oral Prednisone|
214533046|NCT01536613|DRUG|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
214533047|NCT00985530|DRUG|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
214533048|NCT00985530|DRUG|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
214533049|NCT04751019|DEVICE|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
215150801|NCT00473213|DRUG|Interferon Beta 1|
215150802|NCT05866952|DIAGNOSTIC_TEST|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
215150803|NCT00030732|DRUG|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
215150804|NCT00030732|DRUG|Gemcitabine alone|Gemcitabine alone
215150805|NCT06297811|DRUG|Trilaciclib Injection|Experimental: trilaciclib group Intervention: Drug: Trilaciclib Injection \[Cosela\] 240 mg/m\^2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
215150806|NCT06297811|DRUG|Paclitaxel|Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.
215150807|NCT06297811|DRUG|Carboplatin|area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.
215150808|NCT03339752|DRUG|Rosuvastatin|10 mg tablet
215150809|NCT03339752|DRUG|ACT-541468|25 mg hard capsule
215150810|NCT02518295|OTHER|Positive control|200ml milk containing 18g lactose
215150811|NCT02518295|OTHER|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
215150812|NCT02518295|OTHER|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
215150813|NCT02518295|OTHER|Negative control|200 ml of UHT Lactose free milk
215150814|NCT04144790|DIETARY_SUPPLEMENT|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
215150815|NCT05283811|DEVICE|NEUROPACE RNS SYSTEM|This device is indicated as a therapy in reducing the frequency of seizures in individuals
215150816|NCT05283811|BEHAVIORAL|EMU|Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
215150817|NCT05252533|DRUG|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
214533050|NCT02201147|PROCEDURE|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
214533051|NCT02201147|PROCEDURE|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
214533052|NCT02201147|DEVICE|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
214533053|NCT02201147|DEVICE|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
215150818|NCT03352102|PROCEDURE|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
215150819|NCT00998296|DRUG|BIBW 2992|EGFR inhibitor
215150820|NCT00998296|DRUG|BIBF 1120|VEGF inhibitor
215150821|NCT02346721|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
215150822|NCT00892476|DIETARY_SUPPLEMENT|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
215150823|NCT00892476|OTHER|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
215150824|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
215150825|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
215150826|NCT04749004|BEHAVIORAL|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
215150827|NCT05039983|OTHER|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 30 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
215150828|NCT02052518|BEHAVIORAL|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
214533054|NCT02580019|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
214533055|NCT02814461|DRUG|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
214533056|NCT02814461|RADIATION|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
214533057|NCT00981578|DEVICE|ExAblate 2100|Conformal Bone System
214533058|NCT01169571|DRUG|Dexmedetomidine|
214533059|NCT03030599|DRUG|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
214533060|NCT03030599|OTHER|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
214533061|NCT06584747|DIAGNOSTIC_TEST|PET scan|18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
214533062|NCT02900313|OTHER|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
214533063|NCT05583734|DEVICE|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
214533064|NCT03291873|PROCEDURE|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
214533065|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
214533066|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
214533067|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
214533068|NCT01180790|DRUG|Placebo|Powder in capsule once daily
214533069|NCT01180790|DRUG|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
215150829|NCT02231905|DRUG|BI-Sifrol®|
215150830|NCT00297518|DEVICE|PerioWave|
215150831|NCT00297518|PROCEDURE|Scaling and Root Planing|
215150832|NCT05427188|BEHAVIORAL|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
214533070|NCT01180790|DRUG|Ribavirin|400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
215150833|NCT05427188|BEHAVIORAL|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
215150834|NCT00350415|DRUG|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
215150835|NCT02641782|DRUG|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
215150836|NCT02641782|DRUG|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
215150837|NCT02641782|DRUG|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
215150838|NCT02641782|DRUG|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
215150839|NCT02641782|DRUG|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
215150840|NCT06092593|DEVICE|Upper endoscopy|Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients
215150841|NCT04028219|DIAGNOSTIC_TEST|Online surveys|Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
215150842|NCT05542719|OTHER|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
215150843|NCT04682054|PROCEDURE|ocular surgery|surgery to remove the pathological eye tissue
214533071|NCT04582864|DRUG|Flotetuzumab|Will be provided by MacroGenics Inc.
215150844|NCT03385980|OTHER|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
215150845|NCT05933382|OTHER|Corticosteroid Group|Conventional exercise and corticosteroid injection
215150846|NCT05933382|OTHER|Mulligan Group|Conventional exercise and mulligan mobilization
215150847|NCT04733859|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
215150848|NCT04733859|DIETARY_SUPPLEMENT|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
215150849|NCT00971152|DRUG|menotropins for injection|comparison of different dosages
215150850|NCT00971152|DRUG|urofollitropin for injection|comparison of different dosages
215150851|NCT03348228|DIETARY_SUPPLEMENT|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
215150852|NCT05234697|DRUG|Remifentanil|Remifentanil was used for maintenance of anesthesia.
215150853|NCT00031278|DRUG|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
214533072|NCT04582864|PROCEDURE|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
214533073|NCT04263883|DEVICE|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
214533074|NCT00316589|BIOLOGICAL|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
215150854|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
215150855|NCT00031278|DRUG|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
215150856|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
215150857|NCT00031278|DRUG|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
215150858|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
215150859|NCT00031278|DRUG|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
215150860|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
215150861|NCT02180776|OTHER|Summit 456 TLSO|Thoracolumbarsacral orthosis
215150862|NCT01895556|OTHER|Information|
214533075|NCT05016778|DRUG|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
214533076|NCT01482819|DEVICE|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
214533077|NCT01482819|DEVICE|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
214533078|NCT01482819|DEVICE|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
214533079|NCT01482819|DEVICE|polymacon|contact lenses worn bilaterally for 8-12 hours
215150863|NCT01895556|OTHER|Control|
215150864|NCT00124514|DRUG|Triptorelin pamoate|IM injection given monthly
215150865|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
215150866|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
215150867|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
215150868|NCT00124514|OTHER|placebo|placebo 0.9% normal saline IM injection
215150869|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
215150870|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
215150871|NCT05432440|BEHAVIORAL|The digital asthma education program|The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
215150872|NCT00584636|DRUG|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
215150873|NCT06238258|BEHAVIORAL|SPECTROM Training|Training regarding treatment of behavioral challenges in adults with intellectual disability
214533080|NCT01482819|OTHER|spectacles|habitual spectacles owned by subject, non-specific manufacturer
214533081|NCT02332434|OTHER|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
214533082|NCT03440580|DEVICE|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
214533083|NCT03379909|DRUG|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
215150874|NCT05488665|DEVICE|Crush technique|Treatment for bifurcation with the Crush technique
215150875|NCT05488665|DEVICE|Culotte technique|Treatment for bifurcation with the culotte technique
215150876|NCT04631250|DRUG|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
214463035|NCT05572957|COMBINATION_PRODUCT|left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)|"GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by \>10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique."
214533084|NCT00263783|DRUG|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
214463036|NCT04898673|DEVICE|CP1110|Sound Processor
214463037|NCT04898673|DEVICE|CP1000|Sound Processor
214463038|NCT06319430|OTHER|robots|LEGO robots with adaptation according to child's age and developmental skills.
214463039|NCT06319430|OTHER|conventional|A pack of conventional play tools consists of dolls, teddy bears, miniature wild animals, and small cars. All are available, and the child can choose to play with them.
214463040|NCT06075979|OTHER|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
214463041|NCT06075979|OTHER|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
214463042|NCT03899259|DRUG|Baricitinib|Administered orally
214463043|NCT03899259|DRUG|Placebo|Administered orally
214463044|NCT06291428|DIAGNOSTIC_TEST|Raman spectroscopy|Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
214463045|NCT06269549|OTHER|Non-training Real Dietary Supplement (G1)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen.
214463046|NCT06269549|OTHER|Training Placebo Dietary Supplement (G2)|One capsule of placebo glucosamine three times daily, and one packet containing placebo collagen + physical exercise (60 minutes per session twice a week)
214463047|NCT06269549|OTHER|Training Real Dietary Supplement (G3)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen + physical exercise (60 minutes per session twice a week)
214463048|NCT05146973|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
214463049|NCT05115942|DRUG|Hydronidone capsules|After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.
214463050|NCT05115942|DRUG|The placebo capsules|After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
214463051|NCT03639701|DRUG|Thymidine|Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
214463052|NCT06582355|OTHER|Neurofeedback|The participants will be instructed to use cognitive strategies to upregulate (increase) their brain activity in the selected brain region, with the suggestion that motor imagery may be particularly effective, for example, mental imagery of swimming or playing a musical instrument. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner, and the brain activity of the putamen will be displayed in real-time using a thermometer bar for visualization.
214463053|NCT06582355|OTHER|Kinesthetic imagery|The participants will be instructed to imagine movements during the active blocks. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner. No feedback is provided regarding brain activity.
214463054|NCT03847714|DIETARY_SUPPLEMENT|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
214463055|NCT03847714|DIETARY_SUPPLEMENT|placebo|similar looking and tasting powder
214463056|NCT05700877|OTHER|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
214463057|NCT05700877|OTHER|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
214463058|NCT04797897|DEVICE|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
214463059|NCT04797897|DEVICE|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
214463060|NCT05670587|DEVICE|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
214533085|NCT05905445|DRUG|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
215150877|NCT05811286|PROCEDURE|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
215150878|NCT03501498|DRUG|Loperamide|Alters intestinal transit time.
214533086|NCT03379311|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
214533087|NCT04560192|BEHAVIORAL|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU."
214533088|NCT04560192|OTHER|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
214533089|NCT04950049|DRUG|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
214533090|NCT04950049|OTHER|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
214533091|NCT04950049|OTHER|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
215150879|NCT03501498|DRUG|Senna|Alters intestinal transit time.
215150880|NCT02120898|DRUG|Imiquimod|Cream, generic formulation of the brand product.
215150881|NCT02120898|DRUG|Zyclara®|Cream, brand product.
215150882|NCT02120898|DRUG|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
215150883|NCT00831181|DRUG|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
214533092|NCT04950049|OTHER|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
214533093|NCT04273854|DEVICE|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
215150884|NCT00831181|DRUG|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
215150885|NCT00831181|DRUG|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
215150886|NCT00831181|PROCEDURE|mesorectal excision|mesorectal excision
215150887|NCT06359353|DRUG|Pitavastatin|"Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision."
215150888|NCT03470610|DRUG|Progesterone|6 mg estradiol and vaginal and rectal progesterone
215150889|NCT05945342|DRUG|Escitalopram|The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
215150890|NCT05945342|OTHER|Interpersonal Psychotherapy for Adolescent|Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
215150891|NCT05945342|OTHER|Escitalopram combined with psychotherapy|The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
215150892|NCT05945342|OTHER|Escitalopram combined with rTMS|The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
215150893|NCT05945342|DRUG|Escitalopram combined with sham rTMS|The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
214533094|NCT00273650|DRUG|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
214533095|NCT00273650|OTHER|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
215150894|NCT00780312|OTHER|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
215150895|NCT01749332|OTHER|Perihepatic Phlebotomy|
215150896|NCT02046577|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol administration
214533096|NCT04115956|DRUG|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
214533097|NCT04115956|DRUG|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
214533098|NCT05532618|PROCEDURE|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
214533099|NCT05532618|DRUG|Levobupivacaine|Levobupivacaine
214533100|NCT05532618|DRUG|Placebo|10 ml of sodium chloride 0.9%
214533101|NCT02062671|PROCEDURE|renal denervation|
214533102|NCT01297452|DRUG|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
215150897|NCT02046577|DIETARY_SUPPLEMENT|Placebo|Placebo liquid
215150898|NCT00506363|PROCEDURE|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
215150899|NCT03475147|DEVICE|eyeFusion|Smartphone app based flicker fusion test.
215150900|NCT05336591|OTHER|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
215150901|NCT01929746|BIOLOGICAL|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
215150902|NCT05072236|PROCEDURE|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
215150903|NCT02579304|PROCEDURE|transbronchial lung cryobiopsy|bronchoscopic sampling
214533103|NCT01297452|DRUG|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
214533104|NCT01297452|DRUG|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
214533105|NCT01297452|DRUG|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
214533106|NCT04685018|DEVICE|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
214533107|NCT04601883|DRUG|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
214533108|NCT04601883|DRUG|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
214533109|NCT00562484|BIOLOGICAL|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
214533110|NCT00562484|BIOLOGICAL|Placebo|Placebo
214533111|NCT03427879|DRUG|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
214533112|NCT03427879|DRUG|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
214533113|NCT02811302|DEVICE|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
215150904|NCT00589199|PROCEDURE|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
215150905|NCT01907035|BEHAVIORAL|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
215150906|NCT01907035|OTHER|Usual care|
215150907|NCT05335226|PROCEDURE|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation|Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation. (HLA 6-10/10, TNC≥1-3×10-7/Kg)
215150908|NCT05335226|PROCEDURE|haploidentical hematopoietic stem cell transplantation|Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
215150909|NCT01042106|DRUG|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
215150910|NCT01042106|DRUG|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
215150911|NCT03029871|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
214533114|NCT02413502|BIOLOGICAL|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
214533115|NCT05809726|OTHER|Manual lymph drainage|one session 20 minutes
214533116|NCT05744791|BEHAVIORAL|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
214533117|NCT05306730|DEVICE|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
214533118|NCT06240403|DRUG|Digoxin 0.125 MG|One capsule containing digoxin per day for three months
214533119|NCT04557865|DIAGNOSTIC_TEST|18F-PMPBB3 (APN-1607) PET imaging|"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"
214533120|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
214533121|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
214533122|NCT00702520|DRUG|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
214533123|NCT00702520|BIOLOGICAL|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
214533124|NCT00702520|BIOLOGICAL|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
214533125|NCT05119166|DIETARY_SUPPLEMENT|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
214533126|NCT05119166|BIOLOGICAL|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
215150912|NCT05240027|BEHAVIORAL|Vape use survey|pre \& post test surveys
215150913|NCT04048356|DRUG|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
215150914|NCT05386771|DIETARY_SUPPLEMENT|Whey/collagen protein blend|Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
215150915|NCT05386771|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
215150916|NCT03802292|BIOLOGICAL|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
215150917|NCT03802292|BIOLOGICAL|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
215150918|NCT00196313|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
214533127|NCT05119166|DIETARY_SUPPLEMENT|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
214533128|NCT06646588|DRUG|Fruquintinib|Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
215150919|NCT00196313|DRUG|Placebo tablet|1 tablet daily by mouth
215150920|NCT03760042|DRUG|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
215150921|NCT03760042|DRUG|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
215150922|NCT00043979|DRUG|F-18 Fluorodeoxyglucose|
215150923|NCT00043979|BIOLOGICAL|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
214533129|NCT06646588|DRUG|Tislelizumab|Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
214533130|NCT06646588|RADIATION|Radiotherapy|Radiotherapy synchronised with drugs.
215150924|NCT00043979|DRUG|cyclophosphamide|"Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
215150925|NCT00043979|DRUG|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
214695864|NCT05848830|DIETARY_SUPPLEMENT|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
214695865|NCT05848830|DIETARY_SUPPLEMENT|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
214533133|NCT03196622|DEVICE|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
214533134|NCT03597997|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
214533135|NCT03597997|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
214533136|NCT06290557|DRUG|HY_133|A recombinant chimeric bacteriophage endolysin HY-133
214533137|NCT06290557|DRUG|Placebo|Placebo
214533138|NCT06092684|DRUG|BT-KTM-I|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
214533139|NCT06092684|DRUG|Ketanest®S|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
214533140|NCT05876286|OTHER|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
214533141|NCT03460132|DEVICE|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
214533142|NCT05450822|DRUG|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
214533143|NCT05450822|DRUG|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
214533144|NCT05450822|DRUG|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
214533145|NCT04459949|DEVICE|Sharkskin|Use of Sharkskin ILM forceps
214533146|NCT04459949|DEVICE|Grieshaber|Use of Grieshaber ILM forceps
214533147|NCT04671251|DRUG|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
215150926|NCT00043979|DRUG|doxorubicin hydrochloride|Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
215150927|NCT00043979|DRUG|etoposide|50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
214533148|NCT02481934|PROCEDURE|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
214533149|NCT02481934|DRUG|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
215150928|NCT00043979|DRUG|fludarabine phosphate|"Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
215150929|NCT00043979|DRUG|melphalan|Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
215150930|NCT00043979|DRUG|prednisone|Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
215150931|NCT00043979|DRUG|sirolimus|Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
214533150|NCT02481934|DRUG|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
215150932|NCT00043979|DRUG|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
215150933|NCT00043979|DRUG|vincristine sulfate|Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
215150934|NCT00043979|PROCEDURE|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
215150935|NCT00043979|DRUG|Filgrastim|
214533151|NCT03044834|OTHER|PPB|Global current care
215150936|NCT00043979|PROCEDURE|Peripheral Blood Stem Cell donation|
215150937|NCT06214273|DEVICE|Low level diode laser|diode laser with a wave length range of 800-980 n m and power less than 500 ml
215150938|NCT06214273|DRUG|Chamomile|Chamomile 3% mucoadhesive gel
215150939|NCT06214273|DRUG|Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel|Topical anti-inflammatory, topical analgesic and topical antifungal
215150940|NCT03904914|OTHER|TOCI|TOCI staging evaluated
215150941|NCT06286488|DRUG|Vaxigrip|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
215150942|NCT01119378|OTHER|Dual isotope technique|Dual isotope technique using stable isotopes
215150943|NCT03071107|BEHAVIORAL|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
215150944|NCT04485390|OTHER|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
215150945|NCT01440894|DEVICE|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
215150946|NCT01460693|DRUG|Imatinib|Oral Imatinib 100mg daily
214533152|NCT04907344|DRUG|Camrelizumab|IV infusion
214533153|NCT04907344|DRUG|Nab-Paclitaxel|IV infusion
214533154|NCT04907344|DRUG|Carboplatin|IV infusion
214533155|NCT06310278|DIAGNOSTIC_TEST|Ossicular mobility measurement|Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
214533156|NCT05025553|DIETARY_SUPPLEMENT|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
214533157|NCT03152474|DRUG|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
214533158|NCT03152474|DRUG|Vitamin A 100,000 IU|Dosed Intramuscular once daily
215150947|NCT01460693|DRUG|Dasatinib|Oral Dasatinib 100mg daily
214533159|NCT03152474|OTHER|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
214695866|NCT05848830|BEHAVIORAL|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
214695867|NCT03106194|OTHER|case management|
214695868|NCT00511342|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
215150948|NCT04085289|DRUG|Galcanezumab|Administered SC
215150949|NCT04085289|DRUG|Placebo|Administered SC
215150950|NCT02097264|DRUG|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
215150951|NCT02097264|DRUG|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
215150952|NCT02097264|DRUG|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
215150953|NCT04382040|DRUG|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
215150954|NCT04382040|DRUG|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
215150955|NCT03516188|DRUG|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
215150956|NCT03516188|DRUG|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
215150957|NCT00645996|DIETARY_SUPPLEMENT|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
215150958|NCT00645996|DIETARY_SUPPLEMENT|Cornflor|Cornflour 2 gram daily
215150959|NCT06054074|BEHAVIORAL|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
215150960|NCT06054074|BEHAVIORAL|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
215150961|NCT01219881|DRUG|Desflurane|5.4 to 7.4% desflurane
215150962|NCT01219881|DRUG|Sevoflurane|1.4 to 2.5% Sevoflurane
215150963|NCT00168857|DRUG|telmisartan|
215150964|NCT00168857|DRUG|losartan|
215150965|NCT03848026|OTHER|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
214533160|NCT06012877|BEHAVIORAL|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
214533161|NCT04818047|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
214533162|NCT03735147|BIOLOGICAL|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
214533163|NCT00016237|BIOLOGICAL|tucotuzumab celmoleukin|
214533164|NCT00033462|DRUG|erlotinib hydrochloride|Given orally
215150966|NCT03848026|OTHER|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
215150967|NCT05302726|DRUG|Estrogen|Transdermal and oral estrogen both as substitution therapy
215150968|NCT04648397|OTHER|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
215150969|NCT04648397|OTHER|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
215150970|NCT03798353|COMBINATION_PRODUCT|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
215150971|NCT03798353|PROCEDURE|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
215150972|NCT03751930|OTHER|Samples|Urinary and faecal samples
215150973|NCT05174403|OTHER|Cerebral and spinal cord magnetic resonance imaging|"Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium).~Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331)."
215150974|NCT03994848|BEHAVIORAL|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
215150975|NCT03292796|DRUG|Prostaglandins|
215150976|NCT05761548|DIAGNOSTIC_TEST|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
215150977|NCT04001322|OTHER|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
215150978|NCT04001322|OTHER|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
215150979|NCT04001322|OTHER|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
215150980|NCT04001322|OTHER|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
215150981|NCT04001322|OTHER|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
214533165|NCT00033462|OTHER|laboratory biomarker analysis|Correlative studies
214533166|NCT04577586|OTHER|oral contrast|negative oral contrast utilization in PET/CT studies
214533167|NCT05980975|OTHER|Coffee|4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
214533168|NCT05980975|OTHER|Hot water|hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
214533169|NCT05382871|BIOLOGICAL|BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
214533170|NCT05382871|BIOLOGICAL|WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
214533171|NCT05382871|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
214533172|NCT04946097|OTHER|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
214533173|NCT04946097|OTHER|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
214533174|NCT04946097|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
214533175|NCT00223132|DEVICE|Absorbable sutures|
214533176|NCT00749671|DEVICE|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
214533177|NCT00749671|OTHER|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
214533178|NCT03973047|DRUG|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
214533179|NCT03973047|DRUG|Zofran|8 mg tablet (over-encapsulation in a capsule)
214533180|NCT03973047|DRUG|Placebo|capsule
214533181|NCT00068718|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
214533182|NCT05517577|BEHAVIORAL|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
214533183|NCT00960505|OTHER|Alternate day fasting|
214533184|NCT00960505|OTHER|Calorie restriction|
214533185|NCT00960505|OTHER|Control diet|
214533186|NCT06593288|OTHER|Pressure Support Ventilation|Conduct the Spontaneous breathing trial with pressure support
214533187|NCT06593288|OTHER|continuous positive airway pressure (CPAP)|Conduct the spontaneous breathing trial with CPAP
214533188|NCT06042270|DIETARY_SUPPLEMENT|Betaine|3 grams per day for \~4 weeks
214533189|NCT06042270|DIETARY_SUPPLEMENT|Placebo|3 grams per day for \~4 weeks
214533190|NCT06589453|DEVICE|Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants|This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
214533191|NCT06589453|DEVICE|Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants|Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
214533192|NCT04601090|OTHER|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
214533193|NCT05085808|DRUG|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
214533194|NCT05085808|DRUG|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
215150982|NCT04001322|OTHER|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
215150983|NCT04001322|OTHER|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
215150984|NCT01544257|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
215150985|NCT01544257|PROCEDURE|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
215150986|NCT05199103|DRUG|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
214533195|NCT05085808|DRUG|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
215150987|NCT04029402|OTHER|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
214533196|NCT06721195|DRUG|Remimazolam for Gastrointestinal Endoscopy Sedation|"This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction."
215150988|NCT02145377|BIOLOGICAL|PXVX0200 10E8|Oral dose of PXVX0200 10E8
215150989|NCT02145377|BIOLOGICAL|PXVX0200 10E9|Oral dose of PXVX0200 10E9
215150990|NCT02145377|BIOLOGICAL|Placebo|Oral dose of sodium bicarbonate buffer
215150991|NCT02145377|BIOLOGICAL|Shanchol|Licensed comparator
215150992|NCT01121770|DRUG|fondaparinux sodium injection|1.5mg subcutaneously every day
214533197|NCT06721533|DEVICE|Cerebellar rTMS|Cerebellar rTMS applied to pharyngeal area of right hemisphere
214533198|NCT01029678|DRUG|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
214533199|NCT01029678|DRUG|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
214533200|NCT01029678|RADIATION|Radiotherapy|66Gy, 33 fractions, 6 week
214695869|NCT00511342|DRUG|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
214695870|NCT00403312|BEHAVIORAL|Smoking Cessation Behavioral Program|
214695871|NCT00403312|DRUG|Nicotine Patch|
214695872|NCT00403312|BEHAVIORAL|Physical Activity|
215150993|NCT04721886|PROCEDURE|Ultrasonsgraphy|Undergo ultrasonography
215150994|NCT04721886|DRUG|Perflutren Lipid Microcpheres|Given IV
215150995|NCT04721886|PROCEDURE|Contrast - Enhanced Ultrasound|Undergo CEUS
215150996|NCT00897234|OTHER|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
215150997|NCT00606606|OTHER|Clinical Decision Support|
215150998|NCT00482248|DRUG|Omalizumab|
215150999|NCT01000792|DRUG|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
215151000|NCT01000792|DRUG|Levocetirizine|Levocetirizine
215151001|NCT01531569|OTHER|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
215151002|NCT02919995|DRUG|RPL554|RPL554 suspension administered using a nebuliser
215151003|NCT02919995|DRUG|Placebo|Placebo solution administered using a nebuliser
215151004|NCT01364844|DRUG|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
215151005|NCT01282762|BIOLOGICAL|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
215151006|NCT01282762|BIOLOGICAL|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
215151007|NCT04876469|PROCEDURE|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
215151008|NCT06516016|RADIATION|PET|\[18F\]DPA-714 will be injected intravenously as a 1 minute intravenous bolus injection and dynamic PET acquisition will last 90 min. The aim is the quantification of the neuroimmune reaction during neuroinflammation process.
215151009|NCT06516016|OTHER|MRI 3T|Brain MRI will aim at providing imaging biomarkers which will allow evaluating brain structure, microstructure, iron load, myelin, neurodegeneration of the substantia nigra and locus coeruleus, functional connectivity, brain perfusion and the glymphatic system.
215151010|NCT06516016|OTHER|Oculomotricity assessment|Recording eye movements in a controlled environment (requiring no specific room or area) in binocular vision at a frequency \> 500Hz, while retaining infrared video footage of eye movements for high-quality clinical monitoring.
215151011|NCT06516016|OTHER|Magnetoencephalography assessment|Recording brain magnetic activity using the Elekta Neuromag® TRIUX Magnetoencephalograph ; The participant will be comfortably seated in an adjustable-height chair. The device is enclosed in a shielded room isolated from external electric and magnetic fields to measure the extremely weak magnetic activities produced by the brain.
215151012|NCT06516016|OTHER|Body posture and gait assessment|The acquisition of kinematic gait parameters will be achieved ; markers are positioned on the different segments of members, recognized by a camera system positioned on the walls. Neurophysiologic muscular activity of the lower limbs will also be recorded.
215151013|NCT06516016|OTHER|Voice recording|Participants will be recorded during a single session at every visit upon baseline with a professional quality head mounted microphone.
215151014|NCT06516016|OTHER|Video-polysomnography|Participants will complete standard sleep questionnaires before the visit and perform neurophysiological tests including cognitive tasks before and after the sleep recording.
215151015|NCT06516016|BIOLOGICAL|Blood sampling, skin biopsy, excreta sampling, lumbar puncture|Experimental analyses, genetic and multi-OMIC analyses for biomarker research.
215151016|NCT03196349|DRUG|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
215151017|NCT03196349|DRUG|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
215151018|NCT03196349|DRUG|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
215151019|NCT01963078|DRUG|Oxytocin|
215151020|NCT01963078|DRUG|Placebo|
215151021|NCT05242380|OTHER|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
215151022|NCT02542319|DIETARY_SUPPLEMENT|Mablet 360 mg|
215151023|NCT02542319|DIETARY_SUPPLEMENT|Placebo|
215151024|NCT02369796|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
215151025|NCT03330301|OTHER|D-tect|"1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
215151026|NCT04549129|BEHAVIORAL|Breastfeeding education video|"An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes)."
215151027|NCT04549129|BEHAVIORAL|Breastfeeding website|"The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby)."
215151028|NCT04549129|BEHAVIORAL|Usual breastfeed education|The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
215151029|NCT04306341|BEHAVIORAL|real time fMRI neurofeedback|Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
215151030|NCT06379815|OTHER|Sodium Lactate|See arm/group description.
215151031|NCT06379815|OTHER|Sodium Chloride|See arm/group description.
215151032|NCT02422667|OTHER|Patient Registry|Orthopedic Data Registry
215151033|NCT02202941|OTHER|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
215151034|NCT02202941|OTHER|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
215151035|NCT05346419|DRUG|Risedronate|Participants received risedronate 35 mg once a week for 6 months.
215151036|NCT05346419|DRUG|Vitamin D|Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
215151037|NCT03903588|DEVICE|Optical Coherence Tomography|Imaging of the Retina
215151038|NCT02892448|OTHER|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
215151039|NCT06522490|OTHER|Virtual discrete trial training|VDT was given to Experimental group.
215151040|NCT04239391|DRUG|Triferic|Ferric Pyrophosphate Citrate
215151041|NCT01877395|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
215151042|NCT01877395|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
215151043|NCT05741671|OTHER|Questionnaire|Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
215151044|NCT05419778|DEVICE|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
215151045|NCT05419778|DEVICE|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
215151046|NCT03811704|DEVICE|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
215151047|NCT03811704|DRUG|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
215151048|NCT06225713|DEVICE|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
215151049|NCT06225713|DEVICE|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
215151050|NCT01012440|DEVICE|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
215151051|NCT01012440|DEVICE|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
215151052|NCT00206817|DEVICE|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
214533201|NCT06908486|BEHAVIORAL|Cognitive Bias Modification for Interpretation|"Cognitive Bias Modification involves administering the Ambiguous Scenarios paradigm. This is a series of ambiguous scenarios which could be resolved to be associated with pain. The task consists of 30 unique scenarios and an associated comprehension question (pertaining to the pain-relatedness of the scenario), which are presented in a random order to participants.~Each scenario presents an ambiguous sentence, ending with a word fragment which the participant must complete. The statement remains ambiguous until the completion of the word fragment, which resolves the statement as either pain-related or benign. For example, the statement You are bush walking. Suddenly, you trip over and fall onto your knees. Your knees feel all wet, and you look down to see... can be followed by le\_v\_s \[leaves\] for a benign resolution, or bl\_\_d \[blood\] for a pain-related resolution. In the intervention group, all 30 scenarios will be followed with the benign word fragment."
214533202|NCT06908486|BEHAVIORAL|Placebo|The Ambiguous Scenarios paradigm described previously will be used for the placebo intervention. The same 30 scenarios will be presented to participants, however 50% (15) trials will be followed by the benign word fragment, ad 50% (15) trials will be followed by the pain-related word fragment.
215151053|NCT00594815|DRUG|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
215151054|NCT05568303|BEHAVIORAL|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
215151055|NCT00071630|BEHAVIORAL|Cognitive Behavioral Therapy|
215151056|NCT00560001|BEHAVIORAL|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
215151057|NCT04950621|DRUG|remimazolam|Remimazolam will be administered during induction and maintenance for general anesthesia.
215151058|NCT04950621|DRUG|propofol|Propofol will be administered during induction and maintenance for general anesthesia.
215151059|NCT02784899|DRUG|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
214533203|NCT04130061|BIOLOGICAL|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
214533204|NCT06096506|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
214533205|NCT00938288|DRUG|KW-3357|50IU/mL, IV single dose
214533206|NCT00202332|PROCEDURE|Coronary artery bypass|
214533207|NCT01568112|DRUG|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
214533208|NCT01568112|DRUG|BG00012 placebo|Placebo matching BG00012
214533209|NCT01568112|DRUG|ASA|325 mg microcoated aspirin (ASA)
214533210|NCT01568112|DRUG|ASA placebo|Placebo matching aspirin
214533211|NCT06098443|OTHER|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.
215151060|NCT02784899|DRUG|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
215151061|NCT02903329|OTHER|Detoxification|Two ways of composing the detoxification protocol
215151062|NCT05418205|OTHER|Families with FGP support|Non-randomized controlled trial with four points of measurement ( in 18 months)
215151063|NCT00593190|DRUG|Gas SF6 (Sulfur Hexafluoride)|ONCE
215151064|NCT06523920|DEVICE|University of Wisconsin solution + cold storage|Preservation of the free flap with UW solution and cold storage during ischemia time
215151065|NCT06523920|OTHER|Unperfused free flap under warm ischemia|Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time
215151066|NCT06198582|OTHER|Virtual Reality Exercises|In addition to conventional treatment, patients in the study group underwent a virtual reality-based task-specific exercise program in a computer-based virtual reality station. Two different virtual reality games that fit the definition of task-specific exercise were selected for our study. In order for the patient to complete the task in the game, the patient was asked to extend the upper extremity and hand to touch the virtual object through the reflection on the screen and to first grasp the object in the virtual environment by making active flexion with all fingers and to move it from one place to another on a certain plane without disturbing the grasping posture of the hand. These virtual reality exercises selected in our study were practiced under the supervision of the researcher 3 days a week for 15 minutes each for a total of 4 weeks. These sessions consisted of three sets of 2.5 minutes each for each game, with 15-second breaks between sets.
215151067|NCT03768934|OTHER|1X airtime incentive|An incentive given in the form of airtime.
215151068|NCT03768934|OTHER|2X airtime Incentive|An incentive given in the form of airtime.
215151069|NCT03768934|OTHER|Lottery airtime incentive|An incentive given in the form of airtime.
215151070|NCT02691507|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
215151071|NCT02691507|DRUG|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
215151072|NCT05766046|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with LDCT at one or two years interval
215151073|NCT05766046|OTHER|blood test|blood analysis for microRNA and other biomarkers detection
215151074|NCT01812252|DRUG|Azacitidine (AZC)|Given IV or SC
214533212|NCT06098443|DEVICE|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
214533213|NCT06401096|PROCEDURE|Preoperative respiratory exercises|The Triflo Exerciser
214533214|NCT03390933|DRUG|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
214533215|NCT03371706|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
215151075|NCT01812252|DRUG|Decitabine|Given IV or SC
215151076|NCT01812252|OTHER|Quality-of-Life Assessment|Ancillary studies
215151077|NCT04603599|DIAGNOSTIC_TEST|serum soluble L1CAM (sL1CAM)|blood sample
215151078|NCT04288726|BIOLOGICAL|CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach an MTD. This will be administered as a single infusion of the full dose for each level, which was already shown to be safe in the first 3 patients treated at dose level 3. Since we have not observed any dose limiting toxicities at the current dose level (Dose Level 3 as of June 2022), we propose to include a new higher dose level (8 × 10\^8).There will be a gap of 4 weeks between the first and second patient, and between the second and the third patient, on each dose level.
215151079|NCT05126953|DEVICE|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
215151080|NCT05126953|DEVICE|Commercially Available B+L Ultra Lenses|Commercially Available B+L Ultra Lenses
215151081|NCT06346769|OTHER|Polyethylene Fiber|In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
215151082|NCT06463249|BEHAVIORAL|CORE Helpline|All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
215151083|NCT06463249|BEHAVIORAL|Extended Helpline|Those who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving all CORE resources including1-on-1 coaching through 1 optional participant-initiated call per month for 6 months.
215151084|NCT06463249|BEHAVIORAL|Enhanced Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 1 optional participant-initiated call/month for 6 months. Additionally, the participants will receive 2 individualized coach-scripted feedback emails per month, and the option to receive daily text message reminders.
215151085|NCT06463249|BEHAVIORAL|Intensive Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 2 scheduled coaching calls/month for 6 months. Additionally, the participants will receive 2 individual coach-scripted feedback emails per month, and the option to receive daily text message reminders.
215151086|NCT06124807|DRUG|LY3305677|Administered SC
215151087|NCT06124807|DRUG|Placebo|Administered SC
215151088|NCT06422819|OTHER|Heart rate variability Biofeedback [HRV-BFB]|"Biofeedback (BFB), sometimes referred to as biological feedback technique, is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population."
214533216|NCT03371706|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
214533217|NCT03747614|DRUG|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
214533218|NCT03747614|DEVICE|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
215151089|NCT06422819|OTHER|Pseudo HRV-BFB|The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.
214533219|NCT00560313|BIOLOGICAL|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
214533220|NCT00560313|BIOLOGICAL|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
214533221|NCT01704066|OTHER|Training and education|
214533222|NCT00746785|DRUG|2.5 mg Olanzapine|2.5 mg
214533223|NCT00746785|DRUG|5mg Olanzapine|5 mg
214533224|NCT00746785|DRUG|placebo|placebo
214533225|NCT03140878|DIETARY_SUPPLEMENT|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
214533226|NCT03140878|DIETARY_SUPPLEMENT|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
214533227|NCT06250478|DIAGNOSTIC_TEST|Dynamic ultrasound of the calf muscles|Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
214533228|NCT04243122|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
214533229|NCT04243122|DRUG|Aspirin 81 mg|81mg once per day for 6 months Then treated \& followed up as per standard of care
214533230|NCT06274450|COMBINATION_PRODUCT|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
214533231|NCT06274450|OTHER|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
214533232|NCT02137395|DRUG|Dexamethasone|dexamethasone administration, intravenously
214533233|NCT02137395|DRUG|Placebo|saline administration intravenously
214533234|NCT04860856|DRUG|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
214533235|NCT04860856|DRUG|Normal Saline|20ml of normal saline
214533236|NCT04786483|OTHER|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
214533237|NCT00566839|PROCEDURE|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
214533238|NCT00566839|PROCEDURE|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
214533239|NCT02752217|OTHER|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
215151090|NCT05107336|DRUG|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
214533240|NCT02752217|OTHER|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
214533241|NCT05750342|DIETARY_SUPPLEMENT|Experimental Product Caqui|Supplement extracted from persimmon
214533242|NCT05750342|DIETARY_SUPPLEMENT|Control product placebo|Product with identical characteristics to the experimental product.
214533243|NCT03876002|DRUG|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
214533244|NCT00196378|DRUG|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
215151091|NCT05107336|DRUG|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
215151092|NCT03844399|DEVICE|Ablation|The medical device will passively record image data during the standard care ablation
214533245|NCT00196378|OTHER|Placebo|1 tablet daily
214533246|NCT00002721|DRUG|doxorubicin hydrochloride|
214533247|NCT00002721|DRUG|estramustine phosphate sodium|
214533248|NCT00002721|PROCEDURE|drug resistance inhibition treatment|
214533249|NCT02645539|DEVICE|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
214533250|NCT02450617|BEHAVIORAL|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
214533251|NCT02450617|BEHAVIORAL|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
214533252|NCT02450617|BEHAVIORAL|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
214533253|NCT05849324|DEVICE|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
215151093|NCT03844399|DEVICE|Biopsy|The medical device will passively record image data during the standard care biopsy
215151094|NCT04513509|DRUG|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
215151095|NCT00760032|DRUG|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
215151096|NCT00760032|DRUG|Placebo|Placebo capsules, one capsule per day during four weeks.
215151097|NCT04634253|DRUG|Placebo|Given IV
215151098|NCT04634253|DRUG|LY3462817|Given IV
215151099|NCT03155841|BEHAVIORAL|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
215151100|NCT03155841|BEHAVIORAL|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
215151101|NCT02353975|DRUG|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
215151102|NCT01966016|PROCEDURE|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
214533254|NCT05849324|DEVICE|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
214533255|NCT00120185|DRUG|Interleukin-2|
214533256|NCT02783053|DRUG|Metformin|Metformin vs no metformin
214533257|NCT03015870|BEHAVIORAL|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
214533258|NCT03015870|BEHAVIORAL|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
214533259|NCT00344253|DRUG|Interferon beta|
215151103|NCT02930512|PROCEDURE|DXA scan|
214533260|NCT00344253|DRUG|Methotrexate|
214533261|NCT02282423|BEHAVIORAL|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
214533262|NCT02282423|PROCEDURE|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
214533263|NCT02282423|PROCEDURE|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
214533264|NCT02282423|PROCEDURE|VO2max.|VO2max.
214533265|NCT02282423|BEHAVIORAL|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
215151104|NCT02930512|PROCEDURE|pQCT scan|
215151105|NCT05464342|BEHAVIORAL|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
215151106|NCT05464342|BEHAVIORAL|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
215151107|NCT05464342|BEHAVIORAL|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
215151108|NCT04580979|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
215151109|NCT05156034|DRUG|SRK-001|Participants will receive IV doses of SRK-001.
215151110|NCT05156034|DRUG|Placebo|Participants will receive IV doses of placebo.
215151111|NCT01973764|PROCEDURE|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
215151112|NCT01973764|PROCEDURE|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
215151113|NCT03350594|BEHAVIORAL|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
215151114|NCT03350594|BEHAVIORAL|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
215151115|NCT05816447|BEHAVIORAL|interview|Interview patient's perception
215151116|NCT04311021|OTHER|No intervention|No intervention
215151117|NCT04313062|BEHAVIORAL|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
215151118|NCT05086107|DRUG|BV100|Rifabutin for infusion
214533266|NCT02282423|PROCEDURE|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
214533267|NCT02602353|DRUG|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
214533268|NCT02602353|DRUG|Placebo Patch|One Placebo Patch applied daily for 3 days
214533269|NCT02602353|DRUG|No Treatment|No Treatment for 3 days
214533270|NCT01533558|DRUG|caspofungin|normal dosage for caspofungin, not adapted for the study
214533271|NCT05549336|DRUG|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
214533272|NCT00012636|PROCEDURE|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
214533273|NCT01145820|DIETARY_SUPPLEMENT|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
214533274|NCT00263484|DRUG|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
214533275|NCT00263484|DRUG|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
214533276|NCT00263484|DRUG|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
214533277|NCT04302649|DRUG|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
214533278|NCT04290611|DRUG|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
214533279|NCT01796223|BEHAVIORAL|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
214533280|NCT01796223|BEHAVIORAL|Control|
215151119|NCT04529902|DRUG|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
215151120|NCT04529902|DRUG|Abatacept|Abatacept claim is used as the exposure group.
215151121|NCT05690802|DRUG|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
214533281|NCT04804059|DRUG|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
214533282|NCT04804059|DRUG|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
214533283|NCT00356993|DRUG|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
215151122|NCT05812066|PROCEDURE|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
215151123|NCT04646421|BEHAVIORAL|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
215151124|NCT01569607|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
215151125|NCT01569607|DEVICE|Sham stimulation|Sham stimulation
215151126|NCT02753504|DRUG|CKD-519|
215151127|NCT02753504|DRUG|placebo|
215151128|NCT03790202|DEVICE|VistaCare®|Controlled atmosphere wound healing device
215151129|NCT02056587|DRUG|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
214533284|NCT00356993|BEHAVIORAL|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
214533285|NCT06067022|OTHER|observation|Planned measurements and scales will be applied
214533286|NCT04813432|DIAGNOSTIC_TEST|Computed Tomography of the Abdomen|"Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.~Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.~Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.~Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase."
214533287|NCT04315129|DIAGNOSTIC_TEST|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
215151130|NCT01356277|BEHAVIORAL|Action-focused problem-solving|"* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
215151131|NCT01356277|DEVICE|Electronic pillbox monitoring, dose reminders, and feedback|"* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders"
215151132|NCT00378365|PROCEDURE|Arsenic trioxide|Arsenic trioxide
215151133|NCT00378365|PROCEDURE|ATRA|ATRA
215151134|NCT02186418|GENETIC|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
215151135|NCT02765646|DEVICE|Coronary stent procedure (CSP)|
215151136|NCT00276341|DRUG|EGb 761® (Tanakan®)|
214533288|NCT00461643|DRUG|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
214533289|NCT05827770|DRUG|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
214533290|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
214533291|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
214533292|NCT01605786|OTHER|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
214533293|NCT05076188|DIAGNOSTIC_TEST|Emergency radiography|The intervention is to determine how the radiographer classify emergency radiography.
214533294|NCT01966198|OTHER|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
214533295|NCT05411874|DRUG|Chidamide|5mg po biw for 24 weeks
214533296|NCT05411874|DRUG|HD-DXM|40mg po qd for 4days
214533297|NCT00966979|DEVICE|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
214533298|NCT00092326|DRUG|MK0966, rofecoxib|
214533299|NCT00092326|DRUG|Comparator: oxycodone with acetaminophen, placebo|
214533300|NCT02993536|OTHER|Biospecimen Collection|
214533301|NCT04735783|DIETARY_SUPPLEMENT|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
214533302|NCT04735783|DIETARY_SUPPLEMENT|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
214533303|NCT04735783|DIETARY_SUPPLEMENT|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
214533304|NCT01542554|OTHER|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
214533305|NCT01542554|OTHER|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
214533306|NCT04140266|DRUG|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
214533307|NCT04140266|DRUG|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
214533308|NCT05431998|PROCEDURE|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement
214533309|NCT05431998|PROCEDURE|the use of autogenous bone graft in the jumping gap during immediate implant placement|the use of autogenous bone graft in the jumping gap during immediate implant placement
215151137|NCT06563102|COMBINATION_PRODUCT|Albuterol/Budesonide|Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation
215151138|NCT06563102|COMBINATION_PRODUCT|Albuterol|Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
215151139|NCT01065987|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
215151140|NCT05037929|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
215151141|NCT05037929|DRUG|Placebo|Participants will receive SC placebo Q2W.
215151142|NCT04673643|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
215151143|NCT04673643|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
215151144|NCT05269238|OTHER|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
215151145|NCT05269238|OTHER|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
215151146|NCT05403424|OTHER|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
215151147|NCT05403424|DIAGNOSTIC_TEST|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
215151148|NCT05403424|OTHER|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
215151149|NCT05403424|OTHER|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
215151150|NCT03313778|BIOLOGICAL|mRNA-4157|IM injection
214533310|NCT04924088|BEHAVIORAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
214533311|NCT04924088|BEHAVIORAL|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
214533312|NCT05835076|DIAGNOSTIC_TEST|Stool antigen test|Antigen test in the stool analysis
214533313|NCT01050387|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
214533314|NCT06308731|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Energy drink with 200 mg caffeine
214533315|NCT06308731|OTHER|Placebo|Placebo
215151151|NCT03313778|BIOLOGICAL|Pembrolizumab|Intravenous infusion
215151152|NCT03313778|BIOLOGICAL|SoC Treatment|Intravenous infusion
215151153|NCT06577610|BEHAVIORAL|Feedback from colonoscopy monitoring program|Adenoma detection rate feedback from colonoscopy monitoring programs
215151154|NCT06494826|OTHER|colonoscopy procedure|"Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only ."
215151155|NCT06486064|DIETARY_SUPPLEMENT|heat-treated Limosilactobacillus fermentum|one capsule daily for 8 weeks
215151156|NCT06486064|DIETARY_SUPPLEMENT|Placebo|one capsule daily for 8 weeks
214533316|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
214533317|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
214533318|NCT05645900|BIOLOGICAL|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
214533319|NCT06146790|PROCEDURE|endovascular treatment|For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
214533320|NCT06146790|OTHER|Standard medical management|Standard medical management
214533321|NCT01912183|BEHAVIORAL|Communication through PHR outside clinic|
214533322|NCT01912183|BEHAVIORAL|Monitoring device in PHR|
214533323|NCT01912183|DEVICE|Physical activity and sleep monitor|
214533324|NCT01912183|OTHER|PHR|Access to their PHR
214533325|NCT01859221|RADIATION|Stereotactic radiation|Stereotactic radiation
214533326|NCT02750553|DRUG|SHR0534|
214533327|NCT02750553|DRUG|Placebo|
215151157|NCT05989217|DEVICE|Occlusal Splint|Occlusion Splint
215151158|NCT05989217|RADIATION|Laser Therapy|Laser Therapy
215151159|NCT05989217|RADIATION|Acupuncture Laser Therapy|Acupuncture Laser Therapy
215151160|NCT03529422|DRUG|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
214533328|NCT02168621|PROCEDURE|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
214533329|NCT02168621|PROCEDURE|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
214533330|NCT06102798|DEVICE|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
215151161|NCT03529422|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
215151162|NCT05006573|BIOLOGICAL|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
214533331|NCT06102798|DEVICE|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
214533332|NCT05259397|DRUG|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
214533333|NCT05259397|DRUG|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
214533334|NCT02711813|DRUG|TAB08|biologic
214533335|NCT02711813|OTHER|Placebo|
214533336|NCT01990313|DEVICE|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
214533337|NCT05992636|PROCEDURE|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
214533338|NCT06355128|OTHER|NOT|NOT
214533339|NCT06168422|DEVICE|DES|drug eluting stent
214533340|NCT06168422|DEVICE|DCB|drug-coated balloon
214533341|NCT03426553|BIOLOGICAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
214533342|NCT03426553|BIOLOGICAL|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
214533343|NCT03511378|DRUG|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
214533344|NCT03511378|DRUG|Neulasta®|Administration of Neulasta®
214533345|NCT00837096|DEVICE|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
214533346|NCT00837096|DEVICE|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
214533347|NCT01026116|DRUG|Epirubicin|75 mg/m2 every-3-week for four cycles
214533348|NCT01026116|DRUG|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
214533349|NCT01026116|DRUG|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
215151163|NCT05006573|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
215151164|NCT01967238|BIOLOGICAL|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
215151165|NCT05028556|DRUG|Cohort 1 of Y101D|Y101D, 1mg/kg, Q2W, intravenous infusion
215151166|NCT05028556|DRUG|Cohort 2 of Y101D|Y101D, 3mg/kg, Q2W, intravenous infusion
215151167|NCT05028556|DRUG|Cohort 3 of Y101D|Y101D, 10mg/kg, Q2W, intravenous infusion
215151168|NCT05028556|DRUG|Cohort 4 of Y101D|Y101D, 20mg/kg, Q2W, intravenous infusion
215151169|NCT05028556|DRUG|Cohort 5 of Y101D|Y101D, 30mg/kg, Q2W, intravenous infusion
215151170|NCT05011097|DRUG|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
215151171|NCT05992753|OTHER|Questionnaire application|The research data were collected from 455 mothers admitted to the postpartum and lactation unit of a city hospital in Istanbul between September and November 2022. The mothers to be included in the study sample were determined according to the non-probability sampling method, considering the inclusion criteria of the study. The research data were collected by the researchers face-to-face through a questionnaire that lasted about 10-20 minutes.
215151172|NCT03897777|BEHAVIORAL|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
215151173|NCT06599229|DIAGNOSTIC_TEST|myocardial contrast echo|Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
215151174|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
215151175|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
215151176|NCT06593782|DRUG|Dolasetron|"1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
215151177|NCT06593340|BEHAVIORAL|Messenger 1|The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
215151178|NCT06593340|BEHAVIORAL|Messenger 2|The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
215151179|NCT06593340|BEHAVIORAL|Format 1|The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.
215151180|NCT06593340|BEHAVIORAL|Format 2|The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
215151181|NCT06594965|DRUG|HS-20106|HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
215151182|NCT05318313|OTHER|Telerehabilitation|The TR PT evaluation and follow-up visits will be performed via Zoom software
215151183|NCT06592118|OTHER|Different Pathological Types (FTC vs PTC)|Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients
215151184|NCT06604559|OTHER|Discharge using Apollo application|Discharge using Apollo application
215151185|NCT06604559|OTHER|Regular discharge|Discharge with the regular process
215151186|NCT06603454|RADIATION|Preoperative CT|Preoperative contrast enhanced CT
215151187|NCT06591611|OTHER|PEEK reinforced fixed all-on-four prosthesis|Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK
215151188|NCT05929300|BEHAVIORAL|Yoga|The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.
215151189|NCT05929300|OTHER|Usual Care|"This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
215151190|NCT06601023|BEHAVIORAL|Psychosocial intervention|The PM+MiLE is a low-intensity intervention. The intervention will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The problem management ambit will include understanding adversity, managing stress, managing problems, getting going and keep doing, strengthening social support and staying well and looking forward, including positive behaviour modification.The intervention will also incorporate child development and building positive parenting interactions with children.
215151191|NCT06591923|OTHER|No Interventions|No interventions.
215151192|NCT06595667|PROCEDURE|Pulse pressure variation|Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.
215151193|NCT06595667|PROCEDURE|Central venous pressure|Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
215151194|NCT06603480|BEHAVIORAL|Exercise|Aerobic exercise (moderate intensity) at 50-70% of maximum heart rate for 60 minutes, 3 days a week for 12 weeks
215151195|NCT06603480|OTHER|Metformin|Patients who started Metformin 2\*1
215151196|NCT06600399|DIAGNOSTIC_TEST|glioblastoma|All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval
214533350|NCT03293472|DRUG|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
214533351|NCT03293472|DRUG|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
215151197|NCT06591156|PROCEDURE|Root coverage|"Treatment of gingival recession, Miller\&#39;s Class I or Cairo\&#39;s RT1, which is the most predictable group to receive interventions without any impairment or problem for the patients.~After local anesthesia, a horizontal incision was made, delimitating the coronal part of the flap. This horizontal incision of the envelope flap consists of an oblique submarginal incision in the interdental areas that creates a surgical papilla. The incisions continue with the intrasulcular incision in the recession defects and are extended to form an envelope flap between the central and molar. This design facilitates the planned coronal repositioning of the flap tissue on the exposed root surfaces.~The apical gingival tissue at root exposures is raised to a full thickness to provide the critical part of the flap for root coverage with more thickness. Finally, the most apical portion of the flap is elevated in a split-thickness to facilitate coronal displacement of the flap."
215151198|NCT06591156|PROCEDURE|control group|Coronally advanced flap without any graft or biomaterial
215151199|NCT06597877|RADIATION|CT|Patients with unilateral ear pathology will be randomly assigned to do CT temporal bone, The presence of five variants was determined. These variants were: a high dehiscent jugular bulb, an anteriorly located sigmoid sinus, a deep sinus tympani, an enlarged cochlear aqueduct, and an enlarged internal auditory meatus (IAM). A GE LightSpeed 16, four-slice, helical CT scanner (Fairfield, Connecticut, USA) was used for all patients. The scan parameters were as follows: 1 mm slices, smart Ma (50-250 Ma), 120 kV, 0.8-second rotation time, 0.562:1 pitch factor, and 5.62 mm rotation speed. All scans covered an area from 1 cm inferior to the mastoid tip to 1 cm superior to the petrous temporal bone.
215151200|NCT06593028|BEHAVIORAL|Veggie Vouchers pilot|This intervention aims to increase awareness and use of a Supplemental Nutrition Assistance Program (SNAP) fruit and vegetable incentive program in South Carolina among families with young children experiencing food insecurity. To do so, brief education about this SNAP program is delivered by pediatricians to caregivers during well-child visits. Subsequently, caregivers are given 3 free produce boxes as a free trial of this program to incentivize first time use.
215151201|NCT06591845|DRUG|Ziresovir 125 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
215151202|NCT06591845|DRUG|Ziresovir 500 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
215151203|NCT06591845|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
215151204|NCT06591845|DRUG|Moxifloxacin hydrochloride tablet 400 mg|Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
215151205|NCT06591247|DEVICE|Double Baloon Catheter|A double Baloon Catheter will be inserted for 12 hours to one of the arms of the study
215151206|NCT06591247|PROCEDURE|Membrane Stripping|Stripping will be considered as 3-5 rotations of separating the amniotic sac from the cervix and will be perfomed twice (every 4-6 hours)
215151207|NCT06596161|DRUG|Iron sucrose|Receving iron
215151208|NCT06596161|DRUG|Placebo|Placebo
215151209|NCT04895644|OTHER|No Hard Collar|The patient in the intervention arm will not wear a Hard Collar for 12 weeks post injury
215151210|NCT06299475|OTHER|Online counseling and invitation|"Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website"
215151211|NCT06372691|OTHER|Subparaneural Injection (Grup S), Block|Comparison of two different methods in terms of various features
215151212|NCT06372691|OTHER|Interneural Injection (Grup I), Block|Comparison of two different methods in terms of various features
215151213|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.1.0|Participants will use their placebo control 7.1.0 as directed for a period of 6 weeks.
215151214|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.1 usage|Participants will use their Radicle Health Active Study Product 7.1.1 as directed for a period of 6 weeks.
215151215|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.2 usage|Participants will use their Radicle Health Active Study Product 7.1.2 as directed for a period of 6 weeks.
215151216|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.2.0|Participants will use their placebo control 7.2.0 as directed for a period of 6 weeks.
215151217|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.2.1 usage|Participants will use their Radicle Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
215151218|NCT05104112|OTHER|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
214533352|NCT02861625|BEHAVIORAL|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
215151219|NCT06593808|PROCEDURE|Weaning from the incubator to open coat at a weight greater than or equal to 1400 grams|They will be dressed in a woolen hat and dress, wrapped in a blanket and placed in crib with preheated mattress.Vital signs will be monitored daily.Axillary temperature will be measured every 3 hours for the first 12 hours, if above or equal to 36.5°C it will be measured every 6 hours for the next 36 hours. If normothermia for 48 hours, the preheated mattress will be turned off and temperature monitoring will be continued every 3 hours for 24 hours.If greater than or equal to 36.5°C, thermal control will be continued every 8 hours for 48 hours, at the end of which time, if normothermic, care will be confirmed.If not it will be placed back in the crib with heated mattress.If temperature still below 36.5°C, an additional blanket will be placed and it will be rechecked after 2 hours.If it remains below 36.5°C, the infant will be placed under a radiant lamp and the temperature will be checked after 3 hours.If hypothermia persists, the infant will be transferred back to the incubator.
215151220|NCT06594861|OTHER|No intervention|No intervention.
215151221|NCT06598917|DRUG|S-1|"Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request."
215151222|NCT06600256|BEHAVIORAL|Viz HCM ECG Review|Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&amp;#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.
215151223|NCT06600256|BEHAVIORAL|Baseline Effectiveness Cohort|A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.
215151224|NCT06599905|OTHER|Episodic Migraine (EM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
215151225|NCT06599905|OTHER|Chronic Migraine (CM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
215151226|NCT06991413|DEVICE|PMS App|The PMS App helps to implement multimodal self help measures in the daily lives of PMS patients through various functions such as symptom diary and interactive exercises.
215151227|NCT04370210|BEHAVIORAL|Questionnaires|Child of both groups enrolled, and their parents, must complete online questionnaires
215151228|NCT06588465|DEVICE|On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
215151229|NCT06588465|DEVICE|low dose On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
215151230|NCT06599294|PROCEDURE|Digital scanning|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
214533353|NCT05251857|BEHAVIORAL|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
214533354|NCT03692689|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
214533355|NCT05188547|DEVICE|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
214533356|NCT04732247|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
214533357|NCT04732247|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
214533358|NCT02446379|DRUG|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
214533359|NCT02446379|DEVICE|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
214533360|NCT02446379|DEVICE|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
215151231|NCT06599294|PROCEDURE|Two digital impressions will be recorded, one with a conventional intra-oral scanner and another one with an intra-oral photogrammetry scanner.|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
215151232|NCT04852172|DRUG|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
215151233|NCT04852172|OTHER|D5 1/2NS|Saline
215151234|NCT06614959|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) Therapy|The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
214533361|NCT01124214|PROCEDURE|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
215151235|NCT06073938|DRUG|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
215151236|NCT06991504|BEHAVIORAL|Cervical Stabilization Exercises|The main goal of this training is to increase the strength and endurance of the deep cervical flexor and extensor muscles.
215151237|NCT06991504|BEHAVIORAL|vestibular exercises|Vestibular exercises are a training used in individuals with migraine to ensure balance and coordination.
215151238|NCT06991504|BEHAVIORAL|Classic cervical/ neck exercises|Classic cervical neck exercises including stretching and strengthening
214533362|NCT03433183|DRUG|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
214533363|NCT03433183|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
214463061|NCT05795959|BEHAVIORAL|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
214463062|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
214463063|NCT06394206|OTHER|Specialized Unit|The participant will be visited every three months for one year
214463064|NCT06394206|OTHER|Usual Follow-Up|The participant will be visited as usual, it means they will be visited at Digestive Consultation
214533364|NCT00035802|DRUG|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
214533365|NCT00035802|DRUG|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
214533366|NCT02230293|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
214533367|NCT02230293|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
214533368|NCT00333281|DRUG|tadalafil|
214533369|NCT04249518|BEHAVIORAL|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
214533370|NCT05006417|DRUG|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
214533371|NCT00280683|DRUG|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
214533372|NCT00280683|DRUG|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
214533373|NCT02921152|PROCEDURE|bone marrow aspiration /trephine biopsy|
214533374|NCT01536873|DRUG|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
214533375|NCT03025555|OTHER|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
214463065|NCT01197378|DRUG|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
214463066|NCT05296109|DIAGNOSTIC_TEST|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
214533376|NCT03025555|OTHER|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
214533377|NCT05495919|OTHER|Control|No intervention was perfomed to reduce anxiety in control group
214533378|NCT05495919|OTHER|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
214533379|NCT05495919|OTHER|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
214533380|NCT01243411|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
214695873|NCT03579524|PROCEDURE|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
215151239|NCT06669845|PROCEDURE|Ultrasonography, Pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
214463067|NCT04866888|PROCEDURE|closure of the uterine wall defect|Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
214463068|NCT04866888|DIAGNOSTIC_TEST|ultrasound|"Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded."
214463069|NCT04866888|DIAGNOSTIC_TEST|outpatient hysteroscopy|Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
214463070|NCT06113289|DRUG|ASTX727|Given by PO
214463071|NCT06113289|DRUG|ASTX029-01|Given by PO
214533381|NCT03299127|BEHAVIORAL|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
214533382|NCT04678713|DIETARY_SUPPLEMENT|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
214533383|NCT04678713|OTHER|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
214533384|NCT00038155|PROCEDURE|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
214533385|NCT00082641|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
214463072|NCT04458792|OTHER|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
214463073|NCT04458792|OTHER|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
215151240|NCT06993090|DEVICE|Kinesio Tape|A thin, flexible, and elastic therapeutic tape intended for skin application to provide support for muscles and joints. This tape may help decrease pain, swelling, and inflammation while permitting movement. It is commonly utilized to enhance athletic performance and facilitate injury recovery. The tape functions by elevating the skin, which can enhance blood and lymph circulation, and is believed to engage the nervous system through proprioceptive feedback.
215151241|NCT06993077|OTHER|environment Exposure|No special intervention
215151242|NCT06992479|DEVICE|high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)|"The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.~The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6"
215151243|NCT06992479|DEVICE|NIV routine treatment|Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.
215151244|NCT04757168|DEVICE|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
215151245|NCT06673238|DRUG|ABBV-722|Oral Capsule
215151246|NCT06673238|DRUG|Placebo|Oral Capsule
215151247|NCT05455879|OTHER|Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
215151248|NCT06518057|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
215151249|NCT06518057|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
215151250|NCT06518057|OTHER|Electronic Health Record Review|Ancillary studies
215151251|NCT06518057|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
215151252|NCT06518057|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215151253|NCT06518057|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215151254|NCT06518057|RADIATION|Proton Beam Craniospinal Irradiation|Undergo proton CSI
215151255|NCT06518057|OTHER|Survey Administration|Ancillary studies
215151256|NCT06518057|RADIATION|Volume Modulated Arc Therapy|Undergo photon VMAT CSI
215151257|NCT06518057|PROCEDURE|Hippocampal-Avoidance Craniospinal Irradiation|Undergo HA
215151258|NCT06594211|BIOLOGICAL|ACT-001 CAR-NK cell|Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
215151259|NCT06542835|BEHAVIORAL|Video text message|Video text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.
215151260|NCT06542835|BEHAVIORAL|In-clinic CRC screening promotion|Stool-test orders, colonoscopy referrals.
215151261|NCT06542835|BEHAVIORAL|Mailed FIT|Mailed FIT kits.
215151262|NCT06542835|BEHAVIORAL|Social needs navigation|Patient navigation to address social needs.
215151263|NCT06542835|BEHAVIORAL|Reminders|Centralized text and/or telephone reminders for ordered tests.
215151264|NCT06587373|OTHER|Assessment of the quality of mother-child dyadic relationships|Filling out questionnaires
214463074|NCT06259981|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily
214463075|NCT06259981|DRUG|Placebo|4 placebo capsules orally twice daily
215151265|NCT07022353|PROCEDURE|Bilevel erector spinae plane block|Block will be performed unilaterally with the patient in the sitting position leaning forward. The block will be done using a high frequency linear probe (6-13 MHz). The block area will be adequately sterilized and draped, then the ultrasound probe will be placed 2-3 cm laterally from the midline at the level of the T3 spinous process using a sagittal approach to identify the hyperechoic transverse process shadow deep to the trapezius, rhomboid major, and erector spinae muscles. Then, the needle will be inserted craniocaudally in-plane to reach the transverse process deep to the erector spinae muscle. Correct positioning of the needle will be confirmed through real-time visualization of 2-mL saline hydro dissection. After confirmation of needle position, 15 mL of bupivacaine 0.25% will be injected at each level. The same procedure was repeated for the second level T5 spinous process. block failure defined as the presence of full sensation after 30 minutes, patients will be excluded .
215151266|NCT07022353|DRUG|Placebo Oral Capsule|One hour prior to anesthesia induction, the patients will recieve oral placebo capsule that will have the same color, smell, and size as tizanidine.
214463076|NCT05648591|DRUG|Iloperidone|oral tablet
214463077|NCT06066125|DRUG|AK111|AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
214463078|NCT06066125|DRUG|AK111|AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
214463079|NCT06066125|DRUG|Placebo|Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
214463080|NCT05778695|DIETARY_SUPPLEMENT|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
214463081|NCT06437574|DRUG|Vytorin|Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
214463082|NCT06437574|DRUG|Ezetimibe|Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
215151267|NCT07022353|DRUG|tizanidine oral capsule|One hour prior to anesthesia induction, the tizanidine group will receive a 4 mg tizanidine oral capsule.
215151268|NCT07033052|BEHAVIORAL|Improvisation + Wellness|Theatrical improvisation exercises, the theatrical art of performance and storytelling without a script, will be combined with wellness techniques
215151269|NCT07033052|BEHAVIORAL|Improvisation|Theatrical improvisation exercises (the theatrical art of performance and storytelling without a script) will be completed in this arm. These exercises will be fairly similar to that from the improvisation + wellness but without the wellness techniques.
214463083|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
214463084|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
214463085|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
214463086|NCT04649476|DRUG|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
214463087|NCT04649476|DRUG|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
214533386|NCT02335398|DRUG|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
214533387|NCT06426095|BEHAVIORAL|Group A (instructional video),|Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars.
214695874|NCT03579524|PROCEDURE|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
214533388|NCT06426095|BEHAVIORAL|Group B (live demonstration)|Participants in Group B were provided with live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique
214533389|NCT06426095|BEHAVIORAL|Group C (hybrid)|Group C received a dual approach, combining instructional video guidance with live demonstrations.
214533390|NCT03404050|OTHER|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
214533391|NCT00685425|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
214533392|NCT00685425|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
215151270|NCT07033052|BEHAVIORAL|Social Craft|Participants assigned to the Social Craft group will engage in arts and crafts projects and activities
215151271|NCT06709222|OTHER|robotic rehabilitation|robotic rehabilitation
214463088|NCT04517487|BIOLOGICAL|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
214463089|NCT04517487|BIOLOGICAL|Placebo|Placebo
214463090|NCT06591026|BEHAVIORAL|Standard Helpline (SH)|One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
214463091|NCT06591026|BEHAVIORAL|Motivational Interviewing (MI)|One digital helpline session that includes a structured motivational interviewing brief intervention.
214695875|NCT05273840|DIETARY_SUPPLEMENT|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
214695876|NCT05273840|BEHAVIORAL|lifestyle intervention|Patients will receive lifestyle interventions.
214695877|NCT01793519|DRUG|Etanercept|Subcutaneous
215151272|NCT06709222|OTHER|exercise|dual-task exercises
215151273|NCT06707493|DRUG|Ivosidenib|Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.
215151274|NCT06707493|DRUG|Placebo|Placebo tablets are taken orally.
215151275|NCT06704685|DRUG|Butylphthalide|Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.
214695878|NCT01793519|DRUG|Infliximab|Infusion
214695879|NCT01793519|DRUG|Adalimumab|Subcutaneous
215151276|NCT06704685|DRUG|Butylphthalide placebo|Butylphthalide placebo
215151277|NCT05232682|DIETARY_SUPPLEMENT|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
215151278|NCT06377033|BEHAVIORAL|Behavioral nudge|Comparison of genetic rates among individuals for whom it may make a difference in their care across study arms.
215151279|NCT06428006|BEHAVIORAL|Cognitive behavioral therapy for insomnia|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
214463092|NCT06591026|BEHAVIORAL|Coping Skills Training (CST)|One digital helpline session that includes a structured cognitive coping skills brief intervention.
214533393|NCT00195884|BEHAVIORAL|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
214533394|NCT06123949|DEVICE|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
214533395|NCT00510198|DEVICE|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
214533396|NCT00510198|DEVICE|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
214533397|NCT03018223|DRUG|Fludarabine|Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
214533398|NCT03018223|DRUG|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
214533399|NCT03018223|DRUG|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
214533400|NCT03018223|RADIATION|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
214695880|NCT01793519|DRUG|Placebo|Matching Placebo
214695881|NCT03943979|OTHER|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
214463093|NCT06591026|BEHAVIORAL|Automated Text Messaging (ATM)|Automated text messages are sent daily for 4 weeks.
214463094|NCT06608394|OTHER|no intervention|no intervention
214463095|NCT06225310|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
214463096|NCT06225310|DRUG|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
214463097|NCT06225310|DRUG|Methylprednisolone|Glucocorticoid, steroid
214463098|NCT06823674|OTHER|core endurance test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
215151280|NCT06428006|BEHAVIORAL|Sleep and lifestyle education|"The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises"
215151281|NCT06891001|DEVICE|Unilateral neutral shoe insert|In the treatment group, subjects will undergo the addition of a neutral shoe insert to the involved lower extremity according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
214695882|NCT03943979|DEVICE|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
214695883|NCT01891422|OTHER|Non-interventional.|
215151282|NCT06891001|DEVICE|Bilateral Shoe Insert|For subjects placed in the sham group, subjects will undergo the addition of a neutral shoe insert to both lower extremities according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol with guidelines .
215151283|NCT06891001|OTHER|Physical Therapy|For subjects placed in the control group, subjects will undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
215151284|NCT03002870|OTHER|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
215151285|NCT06743958|OTHER|Exercise intervention|Specific strength and balance training intervention during neoadjuvant chemotherapy, twice per week for 30 min, progression according to individual status
215151286|NCT06845566|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training. The occupational problem is defined. The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model. Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
215151287|NCT06845566|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupational therapy was completed
214533401|NCT03018223|PROCEDURE|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
214533402|NCT03018223|DRUG|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
214533403|NCT03018223|DRUG|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
214695884|NCT05662228|DRUG|Lorazepam|Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
214533404|NCT03018223|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is \> 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
214533405|NCT03823274|DRUG|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
214533406|NCT00000454|DRUG|nicotine replacement patch|
214533407|NCT00000137|PROCEDURE|Histocompatibility Matching|
214695885|NCT05662228|DRUG|Intravenous immunoglobulin (IVIG)|IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
214695886|NCT05662228|DRUG|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
214695887|NCT04982120|DEVICE|Repris Needle|Injection of Botox
215151288|NCT05298956|OTHER|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
215151289|NCT03387085|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
215151290|NCT03387085|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
215151291|NCT03387085|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
215151292|NCT03387085|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
215151293|NCT03387085|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
215151294|NCT03387085|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
215151295|NCT03387085|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
215151296|NCT03387085|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
215151297|NCT03387085|BIOLOGICAL|haNK for Infusion|NK-92 \[CD16.158V, ER IL-2\]
215151298|NCT03387085|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
215151299|NCT03387085|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
215151300|NCT03387085|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
215151301|NCT03387085|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
215151302|NCT03387085|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
215151303|NCT03387085|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
215151304|NCT03387085|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
215151305|NCT03387085|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
215151306|NCT03387085|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
215151307|NCT07059624|PROCEDURE|"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane (MDNTP-SAOP)"|Patients will have their femoral arterial line inserted using the MDNTP-SAOP technique.
214533408|NCT05236140|DEVICE|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
215151308|NCT07059624|PROCEDURE|"Conventional, Short-Axis, Out-Of-Plane (C-SAOP)"|Patients will have their femoral arterial lines inserted using the C-SAOP technique.
215151309|NCT06420999|OTHER|Diaphragmatic ultrasound and data collection|At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
215151310|NCT07069101|OTHER|Erector spinae block|Patients will receive continuous ipsilateral erector spinae plane block.
215151311|NCT07069101|OTHER|Edge of lamina block|Patients will receive continuous ipsilateral edge of laminar block.
215151312|NCT06849037|DRUG|zinacef tretment|prophylactic antibiotic treatment with zinacef
215151313|NCT06849037|OTHER|Placebo|I.V SALINE 100 CC X3/d
215151314|NCT07074496|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with ph+ ALL.
215151315|NCT07074496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
215151316|NCT07074496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
215151317|NCT07074496|DRUG|Olverembatinib|a third-generation TKI
214533409|NCT00255671|OTHER|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
215151318|NCT07074834|DRUG|Metoprolol Succinate Sustained-Release Tablets|Oral administration. Dose was 23.75 mg once daily for the first two weeks, then increased to 47.50 mg once daily.
215151319|NCT07074834|DRUG|Trimetazidine|Oral administration. Dose was one tablet twice daily.
215151320|NCT07074834|DRUG|Routine Drug Therapy|Included oral nitroglycerin tablets (0.5 mg twice daily), aspirin enteric-coated tablets (0.1 g once daily), and rosuvastatin calcium tablets (10 mg three times daily).
215151321|NCT07074210|DEVICE|non invasive ventilation|Non invasive mechanical ventilation pressure support
215151322|NCT07074652|DRUG|Escitalopram|Participants received 2-3 weeks of escitalopram.
215151323|NCT07074652|DRUG|Placebo|Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.
215151324|NCT07074899|OTHER|Multi-component HIV testing and linkage-to-services intervention|"The intervention includes two core components:~1. HIV testing offered at sex-on-premises-venues \[SOPVs\];~2. mHealth-supported linkage to treatment/prevention services (enrollment in a two-way text messaging application adapted from the WelTel platform).~In this trial, the specific format of HIV testing offered will differ according to intervention arm."
215151325|NCT07074171|BEHAVIORAL|Text message-based education intervention|The intervention consisted of enhanced behavioral and educational text messages, up to three messages each week, providing updates on COVID-19 testing and vaccination. The text messages included digitally delivered intervention content such as a video with low-literacy instructions for administering the rapid antigen tests, guidance if they tested positive (e.g., quarantine, notify contacts, wearing a mask), and other relevant strategies and content focused on increasing COVID-19 testing and vaccination.
215151326|NCT07075978|BEHAVIORAL|Remote patient monitoring|The usual interprofessional program activities are delivered via remote patient monitoring kits. The kit includes a tablet for virtual visits with the Mobile Health and Wellness Team and access to educational videos, as well as at-home monitoring devices for blood pressure, blood sugar if diabetic, pulse ox if COPD, and/or weight scale.
215151327|NCT07075978|BEHAVIORAL|Telephone|The usual interprofessional program activities are delivered via telephone visits without any at-home monitoring devices.
215151328|NCT07074847|OTHER|Measure QFR|Collect blood samples from 100 patients with normal coronary angiography or stenosis less than 50%, centrifuge and collect plasma, and then send them for further metabolomics testing to analyze the test results.
215151329|NCT07075328|OTHER|Drug:5-ALA, Device:Photodynamic system|"\[Phase I part\] Patients will receive 5-ALA administered orally once. After administration of 5-ALA, patients will receive Photodynamic system once.~Dosage of 5-ALA: 10 mg/kg (1st cohort), 20 mg/kg (2nd cohort), 40 mg/kg (3rd cohort), 60 mg/kg (4th cohort) \[Phase II part\] Patients will receive 5-ALA and Photodynamic system once a week for 6 months."
215151330|NCT07075575|DRUG|Nicotine Polacrilex Gum (2 mg)|"Participants chew 2 mg nicotine gum according to a tapering 12-week schedule: Weeks 1-6: 1 piece every 1-2 hours; Weeks 7-9: 1 piece every 2-4 hours; Weeks 10-12: 1 piece every 4-8 hours. Max 24 pieces/day. Gum is distributed every 2 weeks during study visits.~Arm(s) Used In:~NRT Gum Only CBGT + NRT Gum"
215151331|NCT07075575|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|"Participants attend six weekly sessions of group-based cognitive behavioral therapy focused on smoking cessation. Sessions include education on cravings, relapse prevention, stress management, and self-efficacy building.~Arm(s) Used In:~CBGT Only CBGT + NRT Gum"
215151332|NCT07074132|BEHAVIORAL|Combined Aerobic and Muscle-Strengthening Training Program|A combined training program including both aerobic and muscle-strengthening physical activities within the same session, conducted over a period of 8 months. Aerobic training is performed at an intensity of 50-70% of heart rate reserve (HRR), and strength training at 60-70% of one-repetition maximum (1-RM). The training is conducted three times per week.
215151333|NCT07075549|OTHER|Maintenance phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema in the maintenance phase of decongestive lymphatic therapy (with compression garments) were included
215151334|NCT07075549|OTHER|Intensive phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema who are treated in the intensive phase of Decongestive Lymphatic Therapy (with multilayer bandages) were included
215151335|NCT07074509|OTHER|Manual therapy|Patients were treated by manual therapy in the form of nerve gliding, soft tissue release, and carpal bone mobilization, three sessions per week for 4weeks.
215151336|NCT07074509|OTHER|Extracorporeal shock wave therapy|Patients were treated by extracorporeal shock wave therapy. 4 sessions, one week apart, 2000 pulses per session, intensity 1.6 mj/mm, and frequency 8Hz.
215151337|NCT07075198|DEVICE|Caesar Foot|The investigators developed a bimodal, passive mechanical prosthetic foot called the Caesar Foot. The Caesar Foot has two modes: one optimized for walking, and one optimized for higher-energy activities like running. It has a switching device that was designed such that when it switches modes, it inherently accounts for the alignment and stiffness differences between walking and running feet (such as the longer length, higher stiffness, and different ground contact points required for running feet). Therefore, it should be largely comparable to a daily use prosthesis / walking foot when in walking mode, and an running specific prosthesis / running blade when in running mode. This foot is attached and aligned to the user's usual prosthetic socket.
215151338|NCT07075744|OTHER|Intraoperative Heart Rate Monitoring|This is a non-interventional observational analysis of intraoperative heart rate metrics, including minimum, maximum, average, and time-weighted average heart rate recorded during non-cardiac surgery. The study also includes duration-based metrics such as time spent below or above specific heart rate thresholds. These variables were retrospectively analyzed for their association with 30-day postoperative mortality. No clinical intervention or treatment was administered as part of this study.
215151339|NCT07075224|DRUG|IMP 08P2002F0|Fixed combination of 0.34 % tropicamide and 2.5 % phenylephrine Hydrochloride (HCl) Eye drop Solution.
215151340|NCT07075224|DRUG|Mydriasert® insert|0.28 mg tropicamide and 5.4 mg phenylephrine hydrochloride
214533410|NCT04735913|DRUG|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
214533411|NCT06478134|DRUG|Trimix tear substitutes|Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
214533412|NCT06478134|DRUG|Hyaluronic acid tear substitute|Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
214533413|NCT02176382|DRUG|denosumab|denosumab subcutaneous injection
214533414|NCT02176382|DRUG|teriparatide|teriparatide daily subcutaneous injection
214533415|NCT02176382|DRUG|Zoledronic acid|zoledronic acid infusion
214533416|NCT02335333|OTHER|No treatment|
214533417|NCT02209610|DEVICE|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
214533418|NCT02209610|DRUG|Intrathecal Fentanyl|Mu-opioid receptor agonist
214533419|NCT04547621|DEVICE|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
214533420|NCT04547621|DEVICE|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
214533421|NCT04547621|DRUG|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
214533422|NCT00414089|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|
214533423|NCT04475237|OTHER|CT-scan evaluation and segmentation|CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
214533424|NCT00899145|OTHER|Laboratory Biomarker Analysis|Correlative studies
215151341|NCT07074106|DRUG|Carboplatin and a Taxane|"All patients will receive Carboplatin and a Taxane for 4 cycles.~* Patients who achieve a complete radiological response will proceed directly to surgery.~* Patients without a complete radiological response will receive Doxorubicin and Cyclophosphamide, with or without Pembrolizumab, for an additional 4 cycles before surgery."
215151342|NCT07073937|OTHER|Retrospective chart review|Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.
215151343|NCT07074639|OTHER|Personalized, home-based motor-cognitive exergame training|"The simultaneous cognitive-motor training in this study will be delivered using the exergame platform Senso Flex by Dividat (Dividat AG, Schindellegi, Switzerland), which is a pressure-sensitive foldable mat that connects to standard televisions (or any big screen). Games will be allocated across three primary domains: cognition (consisting of five sub-domains), balance (consisting of four sub-domains) and endurance. The five sub-domains of cognition are visuospatial orientation (Cognition A), memory (Cognition B), response inhibition (Cognition C), choice reaction time (Cognition D) and task switching (Cognition E). The four sub-domains of balance are mediolateral weight-shifting (Balance A), multidimensional weight-shifting (Balance B), free walking/stepping (Balance C) and mediolateral stepping (Balance D). The training sessions will be personalized in terms of difficulty level."
215151344|NCT07074639|OTHER|Otago Exercise Program|Participants in the CG will receive the evidence-based OEP on fall prevention. The OEP was selected as an active control to mirror usual care in real-world clinical settings and support the pragmatic nature of our study design. The program will be implemented in the form of a booklet, designed to provide a comprehensive guide for improving balance, strength, and overall physical function. Specifically tailored for older adults, the program includes a variety of exercises targeting key areas such as lower limb strength, balance, and flexibility. It features step-by-step instructions, illustrations, and tips to ensure exercises are performed safely and effectively.
215151345|NCT07074561|DRUG|CBZ placebo|Patients received oral administration of one 100 mg placebo tablet three times daily (TID) after meals for four consecutive weeks.
214463099|NCT06823674|OTHER|cervical stabilization test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
214463100|NCT06823674|OTHER|cervical proprioception test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
214463101|NCT06823882|BEHAVIORAL|Floor-Rise Training|Practicing getting up from the floor using the Backward Chaining Method (BCM) for 20 minutes per week for 5 weeks
214533425|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
214533426|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
214533427|NCT02932553|DEVICE|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
214533428|NCT06258954|OTHER|3D reconstruction|3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
214533429|NCT06258954|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and height.
214533430|NCT02020746|DRUG|EscharEx|
214533431|NCT02020746|DRUG|Gel Vehicle|
214533432|NCT01783158|PROCEDURE|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
214533433|NCT04393792|DRUG|Povidone-Iodine|0.23% three times daily (tds) for 3 days
214533434|NCT04393792|DRUG|Normal saline|0.9% three times daily (tds) for 3 days
214533435|NCT00387959|BIOLOGICAL|filgrastim|
214533436|NCT00387959|BIOLOGICAL|rituximab|
214533437|NCT00387959|DRUG|cyclophosphamide|
214463102|NCT06823882|BEHAVIORAL|Video Demonstration|Watching a 20-min video on floor-rise technique and over 5 weeks, with discussions. This video explains how to get up safely from the floor and how to practice.
214533438|NCT00387959|DRUG|cyclosporine|
214533439|NCT00387959|DRUG|fludarabine phosphate|
214533440|NCT00387959|DRUG|mycophenolate mofetil|
214533441|NCT00387959|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214533442|NCT00387959|PROCEDURE|umbilical cord blood transplantation|
214533443|NCT00387959|RADIATION|total-body irradiation|
214533444|NCT03712449|DEVICE|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
214533445|NCT03712449|DRUG|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
214533446|NCT03712449|DRUG|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
214695888|NCT00997321|DRUG|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
214463103|NCT06823986|DEVICE|Retraction of anterior teeth by putting miniscrews and power arm|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolar on miniscrews and power arm
214463104|NCT06823986|DEVICE|Retraction of upper anterior teeth by putting miniscrews and welded hooks in main wire arch|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolars on miniscrews and welded hooks in main wire arch
214463105|NCT06823219|OTHER|endurance training program|Groupe 2: 52 weeks of out-of-hospital physical activity Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity
214463106|NCT04224779|BIOLOGICAL|Biological collection|The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
214463107|NCT06238076|DEVICE|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
214463108|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
214463109|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
214463110|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
214463111|NCT04223505|DIAGNOSTIC_TEST|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
214463112|NCT04223505|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
214463113|NCT05814666|DRUG|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
214463114|NCT05814666|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
214463115|NCT00063063|OTHER|No Intervention|
214533447|NCT03712449|OTHER|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
214533448|NCT05432518|DRUG|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
215151346|NCT07074561|DRUG|CBZ|In the EA + CBZ + placebo group, patients received oral carbamazepine (CBZ) at a dosage of 100 mg per tablet three times daily (TID) after meals for 4 consecutive weeks. In the sham EA + CBZ group, patients were administered oral CBZ at 200 mg per dose TID after meals for the same 4-week duration.
215151347|NCT07074561|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
215151348|NCT07074561|PROCEDURE|Sham electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent +GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent +ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
215151349|NCT07074405|OTHER|Questionnaire and Physical Exam|This is an online questionnaire that the patients fill in
215151350|NCT07075172|OTHER|Instrumented-assisted soft tissue mobilization|Instrumented-assisted soft tissue mobilization of the posterior leg and Achilles tendon region
215151351|NCT07075120|DRUG|Ipilimumab and Nivolumab|Immunotherapy combination (Ipilimumab and Nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response.
215151352|NCT07075120|RADIATION|Stereotactic Body Radiotherapy (SBRT)|High-dose radiation therapy delivered in 3-5 fractions for local control of tumors in combination with immunotherapy. Radiation dosages are based on the RTOG 1112 trial guidelines to minimize normal tissue exposure.
215151353|NCT07075289|DRUG|DLBS1033|Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
215151354|NCT07075289|DRUG|Betahistine Mesylate tablet|Patients would get betahistine mesylate (12 mg, MERTIGO SR tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
215151355|NCT07075601|BIOLOGICAL|Take 1 ml of blood|Take 1 ml of blood
215151356|NCT07075601|BIOLOGICAL|DNA sequencing|DNA sequencing
215151357|NCT07075601|PROCEDURE|Valve collection (healthcare waste)|Valve collection (healthcare waste)
215151358|NCT07075601|OTHER|Collection of serious post-operative complications|Collection of serious post-operative complications
215151359|NCT07074873|OTHER|Descriptive information form|The age, gender, height, weight, body mass index, age at menarche, time of initial diagnosis, how it was detected (medical history), family history (genealogy), dominant hand use, exercise habits (type of sport and duration), and corset use of individuals participating in the study will be recorded.
215151360|NCT07074873|OTHER|Health-Related Quality of Life Assessment|The Paediatric Quality of Life Inventory is a valid and reliable health-related quality of life questionnaire used for children. This inventory, which has been adapted into Turkish, consists of two forms for children and families. Both forms include sections on physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (5 items). Scoring is done on a scale of 0-5 for each question (0 = Never causes a problem, 1 = Rarely causes a problem, 2 = Sometimes causes a problem, 3 = Often causes a problem, and 4 = Always causes a problem). The total score of the inventory ranges from 0 to 100 points (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). A high score indicates better health-related quality of life. Since our study population is aged 10-18, the inventories developed for the 8-12 and 13-18 age groups will be used.
215151361|NCT07074873|DIAGNOSTIC_TEST|Trunk rotation angle|The Adam's Forward Bend Test is used as the primary assessment test in the clinical examination of scoliosis patients. In our study, the scoliometer assessment will be performed on the study group while the subjects are standing with equal weight on both feet. Patients will be asked to bend forward so that their shoulder level is aligned with their hip level (body parallel to the ground), and measurements will be taken with the scoliometer, with the highest degree recorded. The Baseline Scoliometer will be used for evaluations.
214533449|NCT05432518|DRUG|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
214533450|NCT05432518|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
214533451|NCT05432518|DRUG|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
214533452|NCT05432518|DRUG|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
214533453|NCT00226993|DRUG|CPG 7909|
215151362|NCT07074873|DIAGNOSTIC_TEST|Cobb angle measurement|The Cobb angle allows for the evaluation of deformity in the frontal plane in scoliosis. It is obtained by measuring the lateral flexion angle of scoliosis from a standing spinal X-ray taken in the posterior-anterior direction. The angle between the perpendicular lines connecting the parallel line drawn from the upper edge of the uppermost vertebra (upper vertebra) involved in the curvature and the parallel line drawn from the lower edge of the lowest vertebra (lower vertebra) gives the Cobb angle. In our study, the Cobb angle will be recorded from the spinal X-ray.
215151363|NCT07074873|DIAGNOSTIC_TEST|Pelvic floor muscle activation measurement|The physiotherapist will position the child in a supine position with the knees flexed at 140 degrees, the soles of the feet in contact with the bed, and the thighs and feet approximately 30 centimetres apart. Two surface electrodes will be placed at the 3 and 7 o'clock positions on the perineal region, and a 30×30 mm single-use electrode will be placed on the right thigh as a reference electrode. Children will be taught to contract the correct pelvic floor muscles to move in the ventral and cranial directions. The 'Work-Rest Assessment,' lasting a total of 55 seconds, will be applied to each child using the same device. First, children will be asked to relax their pelvic floor muscles. Then, 5 seconds of contraction (work) and 5 seconds of relaxation (rest) will be performed, and a total of 10 cycles of contraction and relaxation of the pelvic floor muscles will be requested. The device provides a report of the data in graphical and numerical form at the end of the measurement.
215151364|NCT07074028|DIAGNOSTIC_TEST|Medical Research Council sum score (MRC-SS) test|Medical Research Council (MRC)-sumscore evaluates global muscle strength. Manual strength of six muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) is evaluated on both sides using MRC scale
215151365|NCT07074028|DIAGNOSTIC_TEST|Handgrip test combined with surface electromyography (sEMG)|Handgrip test combined with surface electromyography (sEMG) of the flexor digitorum superficialis
215151366|NCT07074028|DIAGNOSTIC_TEST|Electrical activity during maximal voluntary contraction of the rectus femoris|Surface EMG amplitude (RMS) during maximal voluntary contraction measured by surface electromyography (sEMG) of the rectus femoris
215151367|NCT07074028|DEVICE|Musculoskeletal Ultrasound|Measurement of the cross-sectional area (CSA) of the rectus femoris by ultrasound
215151368|NCT07074028|DEVICE|Diaphragmatic ultrasound|Diaphragmatic ultrasound is a non-invasive technique that allows for sequential assessment of diaphragm mobility (excursion) and contraction (thickening) in mechanically ventilated patients
215151369|NCT07074028|BIOLOGICAL|blood sampling|Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to: 1) describe the inflammatory profile (plasma measurements of CRP, IL-1, IL-6, TNFα, IL-10, fibrinogen, ferritin, cortisol), 2) assess organ dysfunction and calculate the SOFA score (arterial blood gases, lactate levels, liver function tests, complete blood count, and blood electrolyte panel)
215151370|NCT07074028|DEVICE|Electroneuromyogram|Analysis of peripheral neurogenic and myogenic components involved in intensive care unit-acquired muscle dysfunction through the performance of an electroneuromyogram
215151371|NCT07074028|DIAGNOSTIC_TEST|6-minute walk test|The 6-minute walk test (6MWT) is a simple test that requires a quiet, indoor, flat 30-meter course, ideally in a straight rectangular hallway
215151372|NCT07074028|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test and assesses cognitive functions most broadly (attention, concentration, executive functions, memory, language, visual-constructive abilities, abstraction, calculation, orientation).
214533454|NCT01592396|BIOLOGICAL|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
214533455|NCT04849377|RADIATION|RT 50 Gy|Radiation Therapy (RT) 50 GY
214533456|NCT04849377|RADIATION|RT 54 GY|Radiation Therapy (RT) 54 GY
214533457|NCT04849377|RADIATION|RT 60 GY|Radiation Therapy (RT) 60 GY
214533458|NCT04849377|OTHER|Induction Therapy|Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
214533459|NCT04849377|DRUG|Carboplatin|Carboplatin AUC 9.0
214533460|NCT04849377|DRUG|Cisplatin 200|200 mg/m2
214533461|NCT04849377|DRUG|Cisplatin 240|240mg/m2
214533462|NCT04386993|RADIATION|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
214533463|NCT01984567|DIETARY_SUPPLEMENT|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
214533464|NCT01984567|DIETARY_SUPPLEMENT|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
214533465|NCT01984567|DIETARY_SUPPLEMENT|Control|Daily consumption of 3 placebo capsules
214533466|NCT03859817|OTHER|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
214533467|NCT05376787|DEVICE|Medline NE Grounding Pad|Split Universal Grounding Pads
214533468|NCT06279208|BIOLOGICAL|Blood sample|Recovery of plasma from the bottom of a blood collection tube.
215151373|NCT07074028|BEHAVIORAL|MNA-SF|The MNA-SF (Short Form) is a simplified version that allows us to determine whether the elderly person is well nourished, at risk of malnutrition or malnourished.
215151374|NCT07074262|DRUG|Ketamine|to compare the effect of Ketamine versus Dexmedetomidine on postoperative cognitive dysfunction and delirium in all cardiac patient undergoing low risk non-cardic surgery.
215151375|NCT07075809|DEVICE|The laser acupuncture|The intervention group in this study receives laser acupuncture therapy using a laser Micropad GL2+ device with an infrared wavelength of 880 nm. The laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
215151376|NCT07075809|DEVICE|Sham Laser acupuncture|The Control group in this study receives sham laser acupuncture therapy using a laser Micropad GL2+ device with deactivation mode. The sham laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
215151377|NCT07076043|DRUG|Multiple Product PrEP Program|In the intervention phase, clinics will offer a multi-product PrEP program, which includes daily oral PrEP and other forms of PrEP that are available. To start, the dapivirine vaginal ring will be included among the other forms of PrEP that are available. Others will be added as they become available in Kenya.
215151378|NCT07074743|OTHER|community-based PI care bundle|"The PI care bundle follows the aSSKINg model and is delivered in addition to routine care. Key components include:~Assessment Pre-discharge evaluation Ongoing skin, nutrition, and hydration monitoring Caregiver training for home assessment Equipment and Resources~Customized provision of necessary devices based on needs:~Sliding sheets Repositioning cushions Skin barriers Moisturizers Pressure-relieving overlays Alternating air mattresses Implementation Caregivers demonstrate device usage competency Documentation checklist for monitoring Regular follow-up by community nurses Professional Support Community nurses trained by PI specialists Standardized care protocols Regular effectiveness assessment~All participants receive routine care including:~Pre-discharge nutrition assessment Dietician referral if needed Educational materials Basic wound care referrals Hospital-to-home team support for complex cases The intervention provides structured, comprehensive support beyond standard care."
215151379|NCT07074743|OTHER|Wait-list|"During hospitalisation:~Patient's nutritional status assessed. Referred to a dietician before discharge if needed. Nurse assesses caregiver training needs and arranges training if required.~At discharge:~Patients receive PI educational pamphlets (hardcopy or softcopy). Emphasis on regular repositioning, skin inspection, proper nutrition, and hydration.~Patients with PI wounds:~Referred to home nursing or polyclinics for wound care. Only those with complex PI (stage \>3) receive up to two follow-ups by the H2H care team.~H2H team supports general care transition, not PI-specific follow-up alone. Any signs of PI deterioration will be monitored weekly throughout the waiting period for safety and ethical considerations.~If the index PI advances to a higher stage and reports increased pain after a week, the investigator will refer them to a community wound care nurse and record this as a deterioration and will start PI care bundle"
215151380|NCT07074795|PROCEDURE|Inhalation of Nitrous Oxide (N₂O) during Office Operative Hysteroscopy|Inhaled nitrous oxide
215151381|NCT07074795|PROCEDURE|inhalation of ambient air during office hysteroscopy|inhalation of ambient air
214695889|NCT00997321|DRUG|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
214695890|NCT06522581|DRUG|Citicoline Sodium|one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
214695891|NCT05662254|BEHAVIORAL|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
215151383|NCT07075666|DIAGNOSTIC_TEST|PSA|Prostate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis.
214463116|NCT06821984|PROCEDURE|FGG secured using cyanoacrylate tissue adhesive without sutures.|The intervention involved securing the free gingival graft (FGG) using cyanoacrylate adhesive instead of conventional sutures. After harvesting the graft from the hard palate, hemostasis at the donor site was achieved with gauze compression. The recipient site was prepared with a partial-thickness dissection to ensure a stable graft bed. In the intervention group, cyanoacrylate adhesive was applied along the margins of the graft and underlying periosteal bed, ensuring complete coverage without the use of sutures. The adhesive polymerized within seconds, creating an immediate bond between the graft and recipient site, minimizing micro-movements and reducing the need for additional fixation.
214463117|NCT06823544|DRUG|Alvogyl|this is standard treatment drug
214695892|NCT00932529|DRUG|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
214695893|NCT00932529|DRUG|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
214695894|NCT00932529|DRUG|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
214463118|NCT06823544|DRUG|Eugenol|this not standard drug for the treatment of Alveolar Osteitis but an antiseptic agent
214463119|NCT06823544|DRUG|Nigella Sativa Oil|it not standard medicine for Alveolar Osteitis. it is a herbal medicine
214695895|NCT00932529|DRUG|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
214695896|NCT01806246|BEHAVIORAL|integrative rehabilitation program|
214695897|NCT02217319|DRUG|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
215151384|NCT07075666|DIAGNOSTIC_TEST|DRE|A digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities.
215151385|NCT07075783|DRUG|MgSO4 plus Ropivacaine|1ml 50% MgSO4 added to 0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline for scalp block
215151386|NCT07075783|OTHER|Plain Ropivacaine|0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline and 1 ml of 0.9% NaCl
215151387|NCT07074951|DRUG|Immunosuppressive treatment|"Patients will be able to receive the corticosteroid (CS) monotherapy or CS in combination with other immunosuppressive drugs (e.g. cyclophosphamide, mycophenolic acid) by a decision of treating physician.~CS treatment will start with intravenous or oral induction. In the first case, methylprednisolone will be administered intravenously for 1-3 days at the dosage of 500-1000 mg. Oral prednisolone will be initiated at a dose of 0.5 to 1.0 mg/kg body weight, not exceeded 60 mg/day (week 1) with a rapid decrease by 5 mg each subsequent week until a maintenance dose of 5 mg/day will be reached. Patients will receive maintenance dose for 6 to 12 months."
215151388|NCT07074951|PROCEDURE|Tonsillectomy|Tonsillectomy will be done in accordance with local clinical practice. TE has to be performed no earlier than 12 months before and no later than 12 months after the initiation of IST.
215151389|NCT07075965|DRUG|Amlodipine|Evaluating 2 different doses of amlodipine, after an initial titration phase (2.5 mg daily), amlodipine is increased to the target doses of 5 mg and 10 mg
215151390|NCT07075731|OTHER|No intervention|Observational study
215151391|NCT06902766|DEVICE|Active telemonitoring using real-time data from digital inhalers.|"Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI, one for the controller the other for the reliever treatment.~Active telemonitoring using real-time data from digital inhalers.~Investigators will be alerted by email if a child:~1. fails to take his or her controller treatment for 4 continuous days and/or~2. uses \> 4 doses of reliever treatment over 24 hours~3. uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment)~In these cases, investigators will be asked to schedule a teleconsultation within 2 working days with the family and to adapt treatments as needed. They may ask the family to use the portable spirometer and oximeter if necessary.~No systematic consultation will be planned."
215151392|NCT06902766|OTHER|Standard|Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers
215151393|NCT06497543|DRUG|Intrathecal Pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
215151394|NCT02434406|BEHAVIORAL|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
215151395|NCT07074067|PROCEDURE|Laparoscopic surgery|the laparoscopic (LPC) arm, 21 patients will be assigned to conventional LPC and another 21 to robotic surgery, consecutively.
215151396|NCT07074067|PROCEDURE|surgery via v-NOTES|surgery via v-NOTES
215151397|NCT06907446|DIAGNOSTIC_TEST|Comparison of Biopsy Needle Types for Prostate Biopsy|Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle
215151398|NCT01811992|BIOLOGICAL|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
215151399|NCT03422900|DIETARY_SUPPLEMENT|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
215151400|NCT03422900|DIETARY_SUPPLEMENT|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
214533469|NCT04156178|BIOLOGICAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
214533470|NCT05153499|BIOLOGICAL|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
214533471|NCT05153499|OTHER|Placebo|Placebo
214533472|NCT00793299|BEHAVIORAL|Video Illness Narrative|video
214533473|NCT01369706|DEVICE|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
214533474|NCT04528953|BEHAVIORAL|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
215151401|NCT06016114|DIAGNOSTIC_TEST|HIV Latency Diagnostic Sampling|This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.
215151402|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
215151403|NCT06910670|OTHER|Standard developed materials|Participants will be given the option to receive different types of results from genomic sequencing. The choices available to them will be explained by research staff following a script that describes what each type of result means. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information
215151404|NCT06910670|OTHER|Genetics Advisor Decision Aid|Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.
215151405|NCT07074665|BIOLOGICAL|5µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. The standard paediatric dose is 5µg R21/50µg Matrix-M.
215151406|NCT07074665|BIOLOGICAL|10µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. 10µg R21/50µg Matrix-M is the standard adult dose.
215151407|NCT07075029|DIAGNOSTIC_TEST|NP swabs|Nasopharyngeal (NP) swabs will be collected from all participants for respiratory pathogen detection using point-of-care testing (POCT) and/or centralized laboratory analysis.
215151408|NCT07074431|PROCEDURE|EYE 1 SURGERY BY CATAPULSE TECHNIC|In arm 2: 1st eye operated by high-frequency pulsed vacuum technology / 2nd eye operated by phacoemulsification
215151409|NCT07074431|PROCEDURE|EYE 2 SURGERY BY CATAPULSE TECHNIC|In arm 1: 1st eye operated by phacoemulsification / 2nd eye operated by high-frequency pulsed vacuum technology
215151410|NCT05169060|DRUG|Fish Oil Concentrate, 1000 Mg Oral Capsule|Oral capsules, 2 grams or 4 grams per day.
215151411|NCT05169060|DRUG|Salsalate Oral Tablet|Oral tablets, 1.5 gram or 3.0 gram per day.
215151412|NCT06923618|BIOLOGICAL|Blood samples|Blood samples (5 ml) during surgery
215151413|NCT05585905|DEVICE|Virtual Reality|The VR system will be worn for approximately 5-10 minutes during dental sealant application
215151414|NCT05585905|BEHAVIORAL|Basic Behavior Guidance Techniques|Basic behavior guidance techniques will be used as a distraction technique when the VR system is not used during the dental sealant application
214695898|NCT02217319|DRUG|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
215151415|NCT05228587|DRUG|Indocyanine green|Indocyanine green will be injected in all donor
215151416|NCT05387239|DRUG|VL-PX10 and VL-P22 plus standard care|The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
215151417|NCT05387239|DRUG|Placebo|Saline plus standard care
215151418|NCT06938061|DEVICE|3D Imaging|The Derma Monitor device is a handheld, battery powered camera incorporating polarized LED illumination, a high-resolution CMOS color image sensor and a 3D depth sensor, allowing for the imaging and mapping of a patient's skin.
214533475|NCT02315079|OTHER|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
214533476|NCT02315079|OTHER|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
214533477|NCT04018547|DEVICE|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
214695899|NCT02537314|DRUG|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
215151419|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
215151420|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
215151421|NCT00093626|OTHER|Laboratory Biomarker Analysis|Correlative studies
215151422|NCT00093626|DRUG|Sorafenib Tosylate|Given orally
215151423|NCT01408173|DRUG|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
214695900|NCT02537314|OTHER|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
215151424|NCT06286202|BEHAVIORAL|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.
215151425|NCT06286202|BEHAVIORAL|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
215151426|NCT05490927|BEHAVIORAL|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
215151427|NCT05251558|OTHER|Telerehabilitation|The telerehabilitation platform is used to deliver the home exercise program.
215151428|NCT05251558|OTHER|Conventional Education Program|The patient is given education about the points to be considered for the disease and the exercises to be applied.
215151429|NCT01442103|DEVICE|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
215151430|NCT06109636|OTHER|Pentacam, Corvis ST and Casia2|scleral and ciliary muscle thickness were obtained by Casia2, biomechanical parameters were obtained by Pentacam and Corvis ST
215151431|NCT03713658|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
215151432|NCT03713658|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
215151433|NCT03713658|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
215151434|NCT03713658|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
215151435|NCT03713658|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
214463120|NCT04438304|DRUG|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
214463121|NCT05943639|OTHER|The Cultural Marginality Theory-Based Education|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
214463122|NCT06370000|DRUG|Oral Azacitidine|Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.
215151436|NCT03713658|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
215151437|NCT03713658|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
215151438|NCT03713658|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
215151439|NCT03713658|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
215151440|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
215151441|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
215151442|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.
214463123|NCT04990141|PROCEDURE|Peripheral blood collection in cases group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group
214695901|NCT01545908|OTHER|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
214695902|NCT01545908|OTHER|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
214695903|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 25 mg b.i.d
214695904|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg qhs
214695905|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg b.i.d.
215151443|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
215151444|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
215151445|NCT02264236|BIOLOGICAL|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
215151446|NCT00791505|DRUG|ciprofloxacin|1500 mg a day for 10 days
215151447|NCT00791505|DRUG|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
214463124|NCT04990141|PROCEDURE|Peripheral blood collection in control group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
215151448|NCT02080598|BEHAVIORAL|2 cigarettes in 15 minutes|
215151449|NCT01241136|PROCEDURE|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
214533478|NCT04461184|BEHAVIORAL|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
214463125|NCT06823232|DRUG|[14C]XY0206|On the morning of the day of medication (D1), the subject took \[14C\] XY0206 suspension orally on an empty stomach (containing approximately 37.5 mg/100 µ Ci \[14C\] XY0206).
214463126|NCT06366711|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device for pregnancy care
214533479|NCT01046071|PROCEDURE|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
214533480|NCT01046071|PROCEDURE|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
215151450|NCT01241136|PROCEDURE|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
215151451|NCT02202759|DRUG|MLN0264|MLN0264 IV infusion
215151452|NCT01987453|DRUG|LDV/SOF|Tablet(s) administered orally once daily
215151453|NCT01987453|DRUG|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
215151454|NCT04259099|OTHER|Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)|Administer the questionnaires to 150 participants to classify their status of quality of life.
215151455|NCT00213434|DEVICE|Herbst oral appliance|
215151456|NCT00013416|PROCEDURE|Hearing|
214533481|NCT01552668|DRUG|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
214533482|NCT01552668|DRUG|Placebo|Receive Placebo twice daily
214533483|NCT01292317|OTHER|application of intravenous volume|weight based intravenous application of volume
214533484|NCT01292317|OTHER|oral fluid application|oral fluid application
214533485|NCT02084355|DRUG|oral oxycodone|
215151457|NCT02064582|DRUG|Enzalutamide|160mg by mouth each day
214463127|NCT06366711|DRUG|Pulsenmore device|Remote ultrasound device for pregnancy care
214463128|NCT05787821|DEVICE|Total Knee Arthroplasty|Total knee replacement.
214463129|NCT05713110|DRUG|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
214463130|NCT05713110|DRUG|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
214463131|NCT06555822|DRUG|AZD5004|Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
214463132|NCT06555822|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
214463133|NCT06122662|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
214463134|NCT06122662|OTHER|Placebo|Matching Placebo Comparator
214533486|NCT02084355|DRUG|oral hydromorphone|
214533487|NCT02084355|DRUG|fentanyl patch|
214533488|NCT04073849|DRUG|EPOGEN® (epoetin alfa)|Active drug
214533489|NCT04073849|OTHER|Normal Saline|Placebo
214533490|NCT00996619|PROCEDURE|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
214533491|NCT05740969|DRUG|5Fluorouracil|Cream
214533492|NCT05740969|DRUG|Imiquimod|Cream
214533493|NCT05740969|DRUG|Melatonin|Cream
215151458|NCT02064582|DRUG|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
215151459|NCT02064582|RADIATION|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
215151460|NCT01590888|DRUG|PBT2|250mg capsules administered orally once per day for 26 weeks
215151461|NCT01590888|DRUG|PBT2|100mg capsules administered orally once per day for 26 weeks
215151462|NCT01590888|DRUG|Placebo|Matching capsules administered orally once per day for 26 weeks
215151463|NCT04556799|PROCEDURE|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
215151464|NCT04556799|PROCEDURE|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
215151465|NCT06464822|PROCEDURE|Bariatric Surgery|weight control procedures, including intragastric balloon (IGT) \[5\], laparoscopic adjustable gastric banding (LAGB) \[6\], laparoscopic gastric bypass (LGB) operation and laparoscopic sleeve gastrectomy (LSG)
214695906|NCT00360243|DRUG|placebo|placebo
214695907|NCT02316756|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
215151466|NCT04285619|OTHER|Positive expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects"
215151467|NCT04285619|OTHER|Neutral expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes."
215151468|NCT01646125|DRUG|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
215151469|NCT01646125|DRUG|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
214463135|NCT05482698|DRUG|MC2-25 cream|Topical application
214463136|NCT05482698|DRUG|MC2-25 vehicle|Topical application
214463137|NCT06379685|DRUG|PRO-190|Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
214463138|NCT06379685|DRUG|Systane Ultra®|Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
214463139|NCT05286151|BEHAVIORAL|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
214463140|NCT03589846|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
214463141|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
214463142|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
214463143|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
214463144|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
214463145|NCT02639897|OTHER|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
214463146|NCT06244511|OTHER|Early Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.
214463147|NCT06244511|OTHER|Late Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
214463148|NCT06377371|DIAGNOSTIC_TEST|Brain Imaging with [Cu64]DOTATATE|Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
214463149|NCT06377371|PROCEDURE|Radio-guided Surgery With Neoprobe Utilization|After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
214463150|NCT06330922|OTHER|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
214463151|NCT04214561|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
214463152|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
214463153|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
214463154|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
214463155|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
214463156|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
214463157|NCT06536140|OTHER|Home observations and interview|"If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth."
214695908|NCT02316756|DRUG|Placebo|Placebo which will be given as oral suspension
214695909|NCT05137509|DEVICE|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
214695910|NCT06145685|PROCEDURE|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
214695911|NCT06145685|PROCEDURE|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
214533494|NCT01359514|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
215151470|NCT01646125|DRUG|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
215151471|NCT03780296|DEVICE|Real-time action observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
215151472|NCT00554632|DRUG|Ethinyl estradiol and norgestimate|Oral contraceptive
215151473|NCT00554632|DRUG|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
215151474|NCT02118441|DEVICE|Ultrasound-guided Radial Artery Catheter Insertion|
215151475|NCT02118441|DEVICE|Direct Palpation-guided Radial Artery Catheter insertion|
214533495|NCT01359514|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
214533496|NCT03296007|BEHAVIORAL|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
214533497|NCT01730742|BEHAVIORAL|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
214533498|NCT01730742|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
214533499|NCT01730742|PROCEDURE|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
214695912|NCT04392102|DRUG|ZL-2306(Niraparib）|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
215151476|NCT04695717|BIOLOGICAL|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
215151477|NCT05813041|DEVICE|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
215151478|NCT04499313|DRUG|Dexamethasone|Injectable solution
215151479|NCT04499313|DRUG|Methylprednisolone|Injectable solution
215151480|NCT05647603|OTHER|data collection|Information about contraception
215151481|NCT01771224|DIETARY_SUPPLEMENT|Palmitoleic acid|Palmitoleic acid and 5-ASA
215151482|NCT06252324|OTHER|Prime taper implant + cover screw|tissue level implant placement with the addition of a cover screw
215151483|NCT06252324|OTHER|Prime taper implant + healing screw|bone level implant placement with the addition of a healing screw
215151484|NCT02334540|DIETARY_SUPPLEMENT|purses|food intake
215151485|NCT02334540|DIETARY_SUPPLEMENT|a calorie/protein matched smoothie|
214533500|NCT00414219|BEHAVIORAL|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
214533501|NCT01165502|DRUG|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
214533502|NCT01165502|DRUG|Placebo|Placebo for compound CM3.1-AC100 s.c.
214533503|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
214533504|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
214533505|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
214533506|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
214533507|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
214695913|NCT05344144|OTHER|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
215151486|NCT00373997|PROCEDURE|Esophageal and Laryngeal biopsies|one day procedure
215151487|NCT00373997|PROCEDURE|egd with biopsy|standard of care procedure with biopsy
215151488|NCT05188833|DEVICE|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
215151489|NCT05188833|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
215151490|NCT03063034|OTHER|PD21864AA|A king size menthol cigarette.
215151491|NCT03063034|OTHER|PD21864AB|A king size menthol cigarette.
215151492|NCT00178776|BEHAVIORAL|Transtheoretical Model Group Therapy|
215151493|NCT00178776|BEHAVIORAL|Education & Advice|
215151494|NCT04463459|DRUG|Vitamin C, Vitamin E|Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
215151495|NCT00000991|DRUG|Pentamidine isethionate|
215151496|NCT00000991|DRUG|Sulfamethoxazole-Trimethoprim|
215151497|NCT00000991|DRUG|Dapsone|
215151498|NCT00000991|DRUG|Zidovudine|
215151499|NCT04922567|DRUG|Lenalidomide|25mg po on day 1-10
215151500|NCT04922567|DRUG|Cyclophosphamide|750mg/m² iv on day1
215151501|NCT04922567|DRUG|Doxorubicin|50mg/m² iv on day 1
214695914|NCT05344144|OTHER|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
215151502|NCT04922567|DRUG|Vincristine|1.4mg/m² iv on day 1
215151503|NCT04922567|DRUG|Prednisone|100mg po on day1-5
215151504|NCT05814172|OTHER|no intervention|no intervention
215151505|NCT00322660|DRUG|Adrenaline|
215151506|NCT02232906|DRUG|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
215151507|NCT05462756|DRUG|Insulin Efsitora Alfa|Administered SC
214533508|NCT01649297|DRUG|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
214533509|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
214533510|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
214533511|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
214533512|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
214533513|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
215151508|NCT05462756|DRUG|Insulin Lispro (U100)|Administered SC
215151509|NCT05462756|DRUG|Insulin Glargine (U100)|Administered SC
214533514|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
214533515|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
214533516|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
214533517|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
214533518|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
214533519|NCT01649297|DRUG|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
214533520|NCT01649297|DRUG|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
214533521|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
215151510|NCT02336529|DRUG|Bupivacaine|
215151511|NCT02336529|DRUG|NaCl|
215151512|NCT02042274|DIETARY_SUPPLEMENT|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
215151513|NCT04475887|DRUG|Iron Carboxymaltose|see above
214533522|NCT01649297|DRUG|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
214533523|NCT03230110|DIAGNOSTIC_TEST|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
214533524|NCT04108975|PROCEDURE|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
214533525|NCT04108975|PROCEDURE|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
214533526|NCT01858064|DRUG|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
214533527|NCT00507975|DRUG|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
215151514|NCT04475887|DRUG|Placebo|see above
215151515|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
215151516|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
215151517|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
215151518|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
215151519|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
215151520|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
215151521|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
215151522|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
215151523|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
215151524|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
215151525|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
215151526|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
215151527|NCT01757925|BEHAVIORAL|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
215151528|NCT01757925|OTHER|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
215151529|NCT04090359|DEVICE|Dual Mobility Implant|Patients in this intervention will receive a dual mobility implant
215151530|NCT04090359|DEVICE|Conventional, single-bearing implant|Patients in this intervention will receive a conventional, single-bearing implant
215151531|NCT04678219|OTHER|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
215151532|NCT00145808|DEVICE|Given® Diagnostic System|
215151533|NCT05519475|DRUG|ALN-HSD|Administered by subcutaneous injection (SC)
215151534|NCT05519475|DRUG|Placebo|Administered by SC injection
215151535|NCT01549418|DRUG|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
215151536|NCT01549418|DRUG|Placebo|
214463158|NCT04034862|DRUG|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
215151537|NCT02259335|DEVICE|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
215151538|NCT04040933|DEVICE|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
215151539|NCT04040933|DEVICE|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
215151540|NCT04040933|DEVICE|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
215151541|NCT04040933|DEVICE|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
215151542|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
214463159|NCT04696289|DIAGNOSTIC_TEST|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
214533528|NCT05009147|OTHER|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
214533529|NCT01839383|OTHER|different dialysate calcium concentration|
214695915|NCT02458690|BEHAVIORAL|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
214695916|NCT02458690|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
215151543|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
215151544|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
214463160|NCT06779344|OTHER|MxA and CRP tests|A whole blood sample will be collected on the day of randomization for MxA and CRP testing.
214463161|NCT06779344|OTHER|MxA and CRP feedback|MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.
214463162|NCT06779344|OTHER|Follow up|"Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death."
214463163|NCT06518122|DRUG|HCP1306|Take it once a day per period.
215151545|NCT05687669|DRUG|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
215151546|NCT02897440|PROCEDURE|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
215151547|NCT02897440|PROCEDURE|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
214463164|NCT06518122|DRUG|RLD2302|Take it once a day per period.
215151548|NCT02941718|BEHAVIORAL|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
215151549|NCT02941718|BEHAVIORAL|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
215151550|NCT04754659|DEVICE|Stentgraft|Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
215151551|NCT04422678|DRUG|Imatinib Mesylate|Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
215151552|NCT04422678|DRUG|Standard of Care|Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
215151553|NCT06101589|DIETARY_SUPPLEMENT|25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.|5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
215151554|NCT06101589|DIETARY_SUPPLEMENT|Placebo|Olive oil in 1 ml ethyl oleate with no vitamin D3 content
215151555|NCT05884827|DEVICE|EMG|Measure the electrical activity of the muscle and nerve
215151556|NCT03202771|DEVICE|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
215151557|NCT03202771|OTHER|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
214463165|NCT06518122|DRUG|RLD2102|Take it once a day per period
214463166|NCT05294042|OTHER|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
214463167|NCT06182527|DEVICE|Free Style Libre Pro IQ|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
214463168|NCT00855036|OTHER|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
214463169|NCT03868618|DEVICE|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
214463170|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject's comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
214463171|NCT06070870|BEHAVIORAL|Patient Navigation|"Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening"
214533530|NCT03228654|PROCEDURE|Unipolar Electrocautery sealing of vessels|"1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
215151558|NCT03518255|OTHER|Nature video|After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
215151559|NCT01041963|DRUG|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
215151560|NCT01041963|DRUG|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
215151561|NCT01041963|DRUG|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
215151562|NCT05494164|OTHER|Nigella sativa nasal oil drops|in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
215151563|NCT05494164|DRUG|standard treatment|intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
215151564|NCT02386644|OTHER|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
215151565|NCT02386644|DEVICE|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
215151566|NCT02386644|DEVICE|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
215151567|NCT02386644|OTHER|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
215151568|NCT02386644|OTHER|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
215151569|NCT02653417|DRUG|RAD1901|RAD1901
215151570|NCT02653417|OTHER|Placebo|Placebo
215151571|NCT01705509|DRUG|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
215151572|NCT01527097|DRUG|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
215151573|NCT01527097|DRUG|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
215151574|NCT00804076|BIOLOGICAL|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
214533531|NCT03228654|PROCEDURE|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
214533532|NCT00465478|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
214533533|NCT03976778|OTHER|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
214533534|NCT04509414|DRUG|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
215151575|NCT04769388|DRUG|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
215151576|NCT04769388|DRUG|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
215151577|NCT03168776|DEVICE|BuMA Supreme DES|Implant BuMA Supreme stent only
215151578|NCT03168776|DEVICE|Xience or Promus DES|Implant XIENCE family or Promus family only
214533535|NCT04509414|DRUG|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
214533536|NCT01302301|PROCEDURE|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
214533537|NCT02538718|DRUG|MgSO4|
214533538|NCT02538718|DRUG|YTP(Ritodrine)|
214533539|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
214533540|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
214533541|NCT01176435|DRUG|Placebo|Solution taken orally three times a day.
214533542|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
215151579|NCT03024476|BEHAVIORAL|Behavioral intensification|"Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
214533543|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
214533544|NCT03313583|PROCEDURE|Transfusion of blood products|
214695917|NCT02458690|DRUG|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
215151580|NCT03024476|DRUG|Pharmacological intensification based on olmesartan|"* Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
215151581|NCT03024476|DEVICE|Bluetooth-equipped sphygmomanometer|"* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
215151582|NCT00082225|BIOLOGICAL|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
215151583|NCT00082225|BIOLOGICAL|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
215151584|NCT00958906|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
215151585|NCT03992248|BEHAVIORAL|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
215151586|NCT03992248|BEHAVIORAL|Control|Eating for at least 14hrs per day.
215151587|NCT04342533|PROCEDURE|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
215151588|NCT04342533|PROCEDURE|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
215151589|NCT02301416|DRUG|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
215151590|NCT02301416|OTHER|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
215151591|NCT03310853|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
215151592|NCT03310853|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
215151593|NCT01528969|DIETARY_SUPPLEMENT|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
215151594|NCT01528969|DIETARY_SUPPLEMENT|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
215151595|NCT01293656|OTHER|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
215151596|NCT05965544|DRUG|Bupivacain (preoperative)|After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
215151597|NCT05965544|DRUG|Bupivacaine-fentanyl|The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
215151598|NCT05965544|DRUG|Bupivacain (Postoperative)|After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
215151599|NCT00933452|DRUG|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
215151600|NCT00933452|DRUG|duloxetine|15mg, oral administer
215151601|NCT00933452|DRUG|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
215151602|NCT00072319|BIOLOGICAL|filgrastim|
215151603|NCT00072319|DRUG|cyclophosphamide|
215151604|NCT00072319|DRUG|epirubicin hydrochloride|
215151605|NCT00072319|DRUG|paclitaxel|
215151606|NCT00072319|PROCEDURE|adjuvant therapy|
215151607|NCT00072319|PROCEDURE|neoadjuvant therapy|
215151608|NCT02538978|BIOLOGICAL|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
215151609|NCT02538978|BIOLOGICAL|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
215151610|NCT02685332|RADIATION|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30"
215151611|NCT06144112|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
215151612|NCT06144112|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
215151613|NCT01203969|PROCEDURE|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
215151614|NCT01203969|PROCEDURE|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
215151615|NCT01662102|DRUG|Zevalin|Zevalin administered intravenously.
214463172|NCT05533918|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
214463173|NCT05533918|BEHAVIORAL|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
214463174|NCT06007352|DRUG|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
214463175|NCT06007352|OTHER|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
215151616|NCT01662102|DRUG|Rituximab|Rituximab administered intravenously.
215151617|NCT01062932|DRUG|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
215151618|NCT01062932|DRUG|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
215151619|NCT02196844|BEHAVIORAL|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
215151620|NCT02196844|BEHAVIORAL|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
215151621|NCT02196844|OTHER|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
215151622|NCT06441240|DIAGNOSTIC_TEST|MRI|Breast MRI
215151623|NCT01312740|OTHER|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
215151624|NCT01312740|OTHER|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
215151625|NCT05984576|RADIATION|Reirradiation|Reirradiation recurrent rectal cancer
215151626|NCT02314559|DRUG|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
215151627|NCT02314559|DRUG|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
215151628|NCT06400381|BEHAVIORAL|Mindfulness|There are many mindfulness-based interventions protocol that can be implemented and practice by healthcare organization. In the current study, the intervention protocol the investigators will use is based on Smiths version of mindfulness meditation (Smith, 2005). This version is compromised of several components includes being mindful of breathing, thought, sounds, taste, body scan, and sitting. The initial educational session by power point presentation will be given to the participant to explain the intervention rationale and procedure of mindfulness in daily life. In addition to giving opportunity for the participant to ask questions during the educational session.
215151629|NCT02694016|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
215151630|NCT01666041|DRUG|placebo|
215151631|NCT01666041|DRUG|fenofibrate/omega|
215151632|NCT01666041|DRUG|fenofibrate|
215151633|NCT02424877|PROCEDURE|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
215151634|NCT06317740|OTHER|green management intervention program|The program activities focused on integrating green management concepts into both theory and practice learning
215151635|NCT02386540|BEHAVIORAL|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
215151636|NCT03033095|DRUG|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
215151637|NCT02832115|DRUG|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
215151638|NCT02832115|DRUG|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
215151639|NCT00560170|DRUG|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
215151640|NCT00560170|DRUG|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
215151641|NCT06356896|BEHAVIORAL|diaphragmatic breathing exercise|Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
215151642|NCT05479357|DRUG|Oxytocin|10 iu will be given intravenously.
214463176|NCT06709963|DEVICE|ITBS|"We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold."
214533545|NCT03722797|PROCEDURE|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
215151643|NCT05479357|DRUG|Carbetocin|100 micrograms will be given intravenously.
215151644|NCT02847052|OTHER|Non interventional study|
215151645|NCT04568616|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
215151646|NCT00445913|BIOLOGICAL|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
215151647|NCT00445913|BIOLOGICAL|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
215151648|NCT01443052|OTHER|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
215151649|NCT02700906|DRUG|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
215151650|NCT02700906|DRUG|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
215151651|NCT00275509|DRUG|Thymoglobulin|
215151652|NCT00275509|DRUG|Daclizumab|
215151653|NCT00275509|OTHER|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
215151654|NCT00275509|DRUG|Mycophenolate mofetil|2 gm/day. Standard of care
215151655|NCT00275509|DRUG|Tacrolimus|To achieve serum level of 8-10 ng/ml.
215151656|NCT00275509|DRUG|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
215151657|NCT00275509|DRUG|Prednisone|Taper over three months to 5 mg daily
215151658|NCT00275509|DRUG|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
215151659|NCT00464776|DRUG|Aliskiren|
215151660|NCT00464776|DRUG|Aliskiren|
215151661|NCT00464776|DRUG|Aliskiren|
215151662|NCT00464776|DRUG|Aliskiren|
215151663|NCT01585376|GENETIC|mutation analysis|
215151664|NCT01585376|GENETIC|nucleic acid sequencing|
215151665|NCT01585376|OTHER|laboratory biomarker analysis|
215151666|NCT05237076|DIAGNOSTIC_TEST|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
215151667|NCT04640220|PROCEDURE|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
215151668|NCT03308370|BIOLOGICAL|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
215151669|NCT05469659|DRUG|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
215151670|NCT05469659|DRUG|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
215151671|NCT02874989|DRUG|Dasatinib + Quercetin|
215151672|NCT02874989|DRUG|Placebo|
214533546|NCT01940523|DRUG|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
214533547|NCT01940523|DRUG|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
215151673|NCT03755349|DEVICE|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
215151674|NCT03755349|OTHER|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
215151675|NCT04883372|OTHER|continuous glucose monitoring|a continuous glucose monitoring CGM system through the ETAPES telemedicine program
215151676|NCT01967329|DRUG|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
215151677|NCT01967329|DRUG|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
215151678|NCT01967329|DRUG|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
215151679|NCT04846738|DEVICE|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
215151680|NCT04846738|DEVICE|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
214533548|NCT02676440|OTHER|Treatment|F13/T38
214533549|NCT02676440|OTHER|Comparator|M26
215151681|NCT02640534|DRUG|Enzalutamide|Enzalutamide 160 mg od until disease progression
215151682|NCT02640534|DRUG|Metformin|850 mg bid until disease progression
215151683|NCT06246461|DRUG|capecitabine|The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
215151684|NCT05064137|DRUG|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
214533550|NCT01529541|DRUG|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
215151685|NCT05064137|DRUG|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
215151686|NCT05064137|DRUG|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
215151687|NCT05679258|DRUG|HLX15|A single dose (8 mg/kg) of HLX15 via intravenous infusion.
215151688|NCT05679258|DRUG|US-sourced DARZALEX®|A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
215151689|NCT05679258|DRUG|CN-sourced DARZALEX®|A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
215151690|NCT05679258|DRUG|EU-sourced DARZALEX®|A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
215151691|NCT03920319|DRUG|Bupropion|Bupropion 150 mg sustained release
215151692|NCT03920319|OTHER|Placebo|
215151693|NCT03388164|DRUG|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
215151694|NCT03388164|DRUG|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
215151695|NCT02359097|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
215151696|NCT02359097|DRUG|Ferumoxytol|Given IV
215151697|NCT02359097|DRUG|Gadoteridol|Given IV
215151698|NCT02359097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
215151699|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel for lip augmentation
215151700|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
215151701|NCT03775135|OTHER|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
215151702|NCT03441815|DRUG|XC8|
215151703|NCT03441815|DRUG|Placebo|
215151704|NCT04830319|OTHER|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
215151705|NCT04830319|OTHER|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
215151706|NCT00655200|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215151707|NCT02210039|DEVICE|SECM Probe|Imaging of the esophagus using SECM probe and system.
215151708|NCT04355039|DRUG|Pomalidomide|4 mg Days 1-21
215151709|NCT04355039|DRUG|Dexamethasone|40 mg Days 1, 8, 15 and 22
215151710|NCT04355039|DRUG|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
215151711|NCT04355039|DRUG|INCB053914 65 mg BID|Dose level 1: 65 mg BID
215151712|NCT04355039|DRUG|INCB053914 80 mg BID|Dose level 2: 80 mg BID
215151713|NCT02064101|PROCEDURE|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
215151714|NCT01821118|BIOLOGICAL|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
215151715|NCT01821118|OTHER|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
215151716|NCT00642083|DEVICE|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
215151717|NCT05104177|PROCEDURE|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~* Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~* Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~* Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~* Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~* A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
215151718|NCT01605799|BEHAVIORAL|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
215151719|NCT01605799|BEHAVIORAL|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
215151720|NCT03805282|DRUG|Lidocaine|Continuous infusion, variable dose of lidocaine.
215151721|NCT00345358|BIOLOGICAL|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
215151722|NCT00345358|BIOLOGICAL|Infanrix IPV/Hib|4 intramuscular injections
215151723|NCT01099462|DRUG|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
215151724|NCT02350140|OTHER|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
215151725|NCT02350140|OTHER|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
215151726|NCT03917953|DEVICE|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3)."
215151727|NCT06450483|DEVICE|Auricular vagus nerve stimulation|"Auricular vagal nerve stimulation using TPN dual channel TENS will be used for the study.The device used to stimulate is a conventional TENS. The stimulation is by applying a clip electrode placed on the tragus of the left ear and a second electrode applied on the left upper trapezius of the participant which will then stimulate the vagus nerve.Auricular vagus nerve stimulation session will be applied for 15 minutes. Participant is seated and relaxed.After the first session ended; heart rate will be measured and recorded once again to see the effect of the VNS.~Before the last AVNS session started; heart rate will be measured and recorded. The participants' vagus nerve is then stimulated for 15 minutes."
215151728|NCT03143062|DIAGNOSTIC_TEST|NEWS|NEWS
215151729|NCT00499083|BIOLOGICAL|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
215151730|NCT00499083|DRUG|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
215151731|NCT00499083|DRUG|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
215151732|NCT00499083|DRUG|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
215151733|NCT00499083|DRUG|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
215151734|NCT00499083|DRUG|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
215151735|NCT00499083|GENETIC|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
215151736|NCT00499083|GENETIC|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
214463177|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
215151737|NCT00499083|GENETIC|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
215151738|NCT00499083|OTHER|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
214463178|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
214463179|NCT05585814|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles
214463180|NCT05585814|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 3cycles
214463181|NCT05585814|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 3 cycles
214463182|NCT05585814|DRUG|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
214463183|NCT03717142|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
214463184|NCT05694871|DRUG|Palbociclib|Given PO
214463185|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
214463186|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
214463187|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
214463188|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
214463189|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
214463190|NCT06193577|DIETARY_SUPPLEMENT|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
214463191|NCT06193577|DIETARY_SUPPLEMENT|Placebo|The placebo control does not contain active ingredients.
215151739|NCT00499083|OTHER|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
215151740|NCT00499083|OTHER|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
215151741|NCT00499083|PROCEDURE|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
215151742|NCT00499083|PROCEDURE|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
215151743|NCT00499083|PROCEDURE|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
215151744|NCT00499083|PROCEDURE|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
215151745|NCT00499083|RADIATION|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
215151746|NCT06152393|DIAGNOSTIC_TEST|Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.|"Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118)."
215151747|NCT02731235|OTHER|High-intensity training|high intensity training 5 days a week for 12 weeks
215151748|NCT02731235|DRUG|prophylactic stroke medication|Usual care medication for stroke prophylaxis
215151749|NCT02731235|BEHAVIORAL|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
214463192|NCT06233903|DRUG|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
214463193|NCT05858125|OTHER|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to \>65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
214463194|NCT03024437|DRUG|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
214463195|NCT03024437|DRUG|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
214463196|NCT03024437|DRUG|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
214463197|NCT04697095|OTHER|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
215151750|NCT01902095|DEVICE|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
215151751|NCT01902095|DEVICE|Tooth paste (control)|Active Comparator
215151752|NCT02094924|DRUG|GSK587323|Single dose of FDC tablet formulation to be taken orally.
215151753|NCT02094924|DRUG|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
215151754|NCT03860493|PROCEDURE|Perfusion evaluation with indocyanine green|"1\. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3\. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs."
215151755|NCT04287790|BEHAVIORAL|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
215151756|NCT04287790|DRUG|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
215151757|NCT00704119|DRUG|RhuDex®|"* Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
215151758|NCT00686686|BIOLOGICAL|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
215151759|NCT03463928|BIOLOGICAL|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
215151760|NCT03650283|OTHER|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of \>0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
215151761|NCT04100252|OTHER|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
215151762|NCT02198378|DRUG|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
215151763|NCT02198378|DRUG|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
215151764|NCT01278212|RADIATION|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
215151765|NCT06517589|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|PBT (20 sessions), intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
215151766|NCT06517589|OTHER|Cognitive Behavioral Therapy (CBT)|CBT (20 sessions), intervention planning as usual based on manual.
215151767|NCT00515762|DEVICE|elasto-gel cap|scalp cooling cap
215151768|NCT02102178|OTHER|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
215151769|NCT02102178|OTHER|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
214533551|NCT01529541|DRUG|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
214533552|NCT05433311|OTHER|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
214533553|NCT02994264|RADIATION|adjuvant concurrent chemoradiation|
214533554|NCT02541942|OTHER|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
214533555|NCT04665778|OTHER|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
214533556|NCT02490878|DRUG|bevacizumab|IV
214533557|NCT02490878|DRUG|corticosteroids|IV
214533558|NCT02490878|OTHER|placebo|IV
215151770|NCT02102178|OTHER|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
215151771|NCT02102178|OTHER|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
215151772|NCT01559857|DRUG|Pioglitazone|30mg once daily for 12 weeks
215151773|NCT01559857|DRUG|Sugar Pill|Placebo
215151774|NCT00742261|DRUG|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
215151775|NCT02912689|DEVICE|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
215151776|NCT02912689|DEVICE|Pressure support ventilation|PS during Non-invasive ventilation
214533559|NCT01020942|PROCEDURE|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
214533560|NCT01020942|PROCEDURE|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
214533561|NCT03298633|OTHER|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
214533562|NCT03298633|OTHER|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
214533563|NCT02544113|DRUG|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
214533564|NCT02544113|DRUG|Placebo|Normal transplant immunosuppression
214533565|NCT05425173|OTHER|Conventional treatment|Chest Physical Therapy as required
214533566|NCT05425173|OTHER|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
214533567|NCT03962478|DEVICE|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
214533568|NCT03962478|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
214533569|NCT01750177|BEHAVIORAL|Television Viewing before mealtime|
214533570|NCT01750177|BEHAVIORAL|Video Game Playing|
214533571|NCT01750177|BEHAVIORAL|Computer Use|
214533572|NCT01750177|BEHAVIORAL|Sitting quietly|
214533573|NCT06259513|PROCEDURE|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
214533574|NCT02950714|OTHER|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
214533575|NCT02950714|OTHER|LIN_WAIT|Usual care for three months prior to access to the LIN
214533576|NCT05195450|DRUG|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
214533577|NCT03122483|DIAGNOSTIC_TEST|blood biomarker|
214533578|NCT01661530|DIETARY_SUPPLEMENT|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
214533579|NCT01661530|DIETARY_SUPPLEMENT|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
214533580|NCT00451555|DRUG|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
214533581|NCT00451555|DRUG|placebo|oral, daily
215151777|NCT00210743|DRUG|epoetin alfa|
215151778|NCT04221867|PROCEDURE|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
215151779|NCT04221867|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
215151780|NCT02900040|OTHER|kidney transplantation|
215151781|NCT03254758|BIOLOGICAL|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
215151782|NCT00379691|DRUG|phenylephrine|
215151783|NCT03553355|DEVICE|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
215151784|NCT03553355|DEVICE|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
215151785|NCT02112071|BEHAVIORAL|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
215151786|NCT02222948|DRUG|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
215151787|NCT02222948|DRUG|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
215151788|NCT00215839|DRUG|Peginterferon a-2a plus Ribavirin|
215151789|NCT01760252|DRUG|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
215151790|NCT00131248|DRUG|Metaclopramide|
215151791|NCT00131248|DRUG|Ranitidine|
214463198|NCT06261671|DRUG|antioxidants-enriched culture medium (Gx)|Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
215151792|NCT00131248|DRUG|placebo|
215151793|NCT02296645|DRUG|ZuraPrep|Apply topically.
215151794|NCT02296645|DRUG|ChloraPrep|Apply topically.
215151795|NCT00342108|BEHAVIORAL|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
215151796|NCT04029077|OTHER|NA: intervention is not part of the study|NA: it is not an interventional study
215151797|NCT06252688|BEHAVIORAL|Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.|"All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
215151798|NCT01130480|DEVICE|Accu-Chek Integra Glucometer|
215151799|NCT04189887|BEHAVIORAL|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
215151800|NCT04189887|BEHAVIORAL|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
215151801|NCT04310371|BEHAVIORAL|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
214463199|NCT04455750|DRUG|Enzalutamide|Given PO
214463200|NCT04455750|DRUG|Rucaparib camsylate|Given PO
215151802|NCT02207452|DEVICE|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
215151803|NCT02207452|DRUG|Salbutamol|Salbutamol 5mg nebulised single dose
215151804|NCT02207452|DRUG|Ipratropium|Ipratropium 500mcg nebulised single dose
214463201|NCT04455750|DRUG|Placebo|Given PO
214463202|NCT04455750|DRUG|Leuprolide Acetate|Given IM
214463203|NCT04455750|DRUG|Goserelin Acetate|Given SC
214463204|NCT04455750|DRUG|Degarelix|Given SC
215151805|NCT02207452|DEVICE|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
215151806|NCT00477386|DRUG|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
215151807|NCT01174719|DRUG|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
214463205|NCT04455750|OTHER|Quality-of-Life Assessment|Ancillary studies
214463206|NCT04455750|OTHER|Questionnaire Administration|Ancillary studies
214463207|NCT05681923|OTHER|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
214463208|NCT05681923|OTHER|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
215151808|NCT01174719|DRUG|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
215151809|NCT01174719|DRUG|volume replacement|up 10 50mL/kg/24 hours
215151810|NCT01724632|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
215151811|NCT01254422|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
215151812|NCT01254422|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
215151813|NCT05242120|OTHER|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
215151814|NCT04986514|OTHER|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
215151815|NCT02207088|DRUG|ombitasvir/paritaprevir/ritonavir|tablet
215151816|NCT02207088|DRUG|dasabuvir|tablet
215151817|NCT02207088|DRUG|Ribavirin|tablet
215151818|NCT00450268|PROCEDURE|blood draw, skin shave biopsy|
215151819|NCT01166880|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
215151820|NCT06090136|DRUG|TPN171H|5 mg TPN171H tablets，single dose,oral
215151821|NCT00643162|DRUG|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
215151822|NCT00643162|BEHAVIORAL|Light touch|Light touch twice a week, for 8 weeks
214533582|NCT00451555|DRUG|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
215151823|NCT00643162|BEHAVIORAL|Massage|Massage twice a week, for 8 weeks.
215151824|NCT00724087|OTHER|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
215151825|NCT00724087|OTHER|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
215151826|NCT03551561|DRUG|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
215151827|NCT03551561|DRUG|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
215151828|NCT00046462|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
215151829|NCT00046462|DRUG|Metformin|
215151830|NCT00046462|DRUG|Glyburide|
215151831|NCT00046462|DRUG|Thiazolidinedione|
215151832|NCT00580307|PROCEDURE|Septoplasty|Surgical straightening of nasal septum
215151833|NCT00580307|PROCEDURE|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
215151834|NCT02347137|OTHER|step-reduction|reduce daily physical activity to less than 1500 steps per day
215151835|NCT02347137|OTHER|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
214533583|NCT02847637|DRUG|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
215151836|NCT05267522|OTHER|Egg diet|30% fat \[6% saturated fat\], 20% protein, 40% carbohydrate, 600 mg cholesterol
215151837|NCT05267522|OTHER|Egg-free Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 300 mg cholesterol
215151838|NCT05267522|OTHER|Control Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 600 mg cholesterol
215151839|NCT00483769|DRUG|Glargine|
215151840|NCT05711212|DIETARY_SUPPLEMENT|micellar solubilized Xanthohumol|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
215151841|NCT05711212|DIETARY_SUPPLEMENT|Placebo|single administration of 4 soft gelatine capsules containing only micelles
215151842|NCT00647959|DRUG|Doxycycline Tablets, 150mg|150mg, single dose fasting
215151843|NCT00647959|DRUG|Adoxa Tablets 150 mg|150mg, single dose fasting
215151844|NCT00382759|PROCEDURE|stem cell transplant|
215151845|NCT02324101|DEVICE|Hsp90|Detect plasma Hsp90α concentration
215151846|NCT03798769|OTHER|Supportive Oncology Care at Home|"Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
215151847|NCT02135796|OTHER|Echocardiography|
215151848|NCT04522232|PROCEDURE|conventional Total laparoscopic hysterectomy|"the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached."
214533584|NCT02847637|DRUG|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
214533585|NCT01457833|DEVICE|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
215151849|NCT04522232|PROCEDURE|Total laparoscopic hysterectomy with prior uterine artery ligation at its origin|"the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy"
215151850|NCT02516137|PROCEDURE|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
215151851|NCT02516137|PROCEDURE|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
215151852|NCT02516137|PROCEDURE|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
215151853|NCT02516137|OTHER|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
215151854|NCT02284243|DRUG|Intranasal Dexmedetomidine|
215151855|NCT02284243|DRUG|Intranasal Placebo|
215151856|NCT05882708|DRUG|Ivabradine|After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
215151857|NCT01812863|PROCEDURE|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
215151858|NCT06276829|DIAGNOSTIC_TEST|LDH/albumin ratio|LDH/Albumin ratios of patient and control groups were recorded.
215151859|NCT04539795|DRUG|Alvelestat|oral tablet
215151860|NCT04539795|DRUG|Placebo|oral tablet
214533586|NCT01457833|DEVICE|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
214533587|NCT04017949|DRUG|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
214533588|NCT04929054|DIAGNOSTIC_TEST|imaging|ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules
214533589|NCT04177628|BEHAVIORAL|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
214533590|NCT00026013|DRUG|hypericum perforatum|
215151861|NCT06007950|BEHAVIORAL|Time-restricted eating 10-hr|Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
214533591|NCT03460496|BEHAVIORAL|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
215151862|NCT00454324|DRUG|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
215151863|NCT00454324|DRUG|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
215151864|NCT01875094|OTHER|Self-Management / MTM using Health IT|
215151865|NCT04613648|DIAGNOSTIC_TEST|Imaging|Ultrasonographic imaging of the shoulder
215151866|NCT02699749|DRUG|TAK-931|TAK-931 oral capsules.
215151867|NCT00065078|PROCEDURE|Home dispensing of contraception|
215151868|NCT02874378|DRUG|Dexmedetomidine|
215151869|NCT02874378|DRUG|0.9%NaCl solution|
215151870|NCT06150391|DEVICE|Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks|Visionary exercises are computer gammified activities that run on a computer with internet connection to facilitate home therapy. Patient must wear anaglyph glasses. Visual stimuli consists in dichoptic Gabor Patches presented to the amblyopic eye. Frequency is adjusted to actual patient visual acuity, and contrast to actual patient performance (contrast sensitivity). A band-filtered noise mask at the same frequency than the Gabor patch is presented to the fellow eye in certain ocassions.
215151871|NCT06150391|DEVICE|Patching|PEDIG (Pediatric Eye Disease Investigator Group) recommended amblyopia treatment. Consist on covering a child's better-seeing eye with a patch for 2 hours per day for mild and moderate amblyopia or 6 hours per day for severe amblyopia
215151872|NCT01483521|OTHER|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
215151873|NCT03780140|DRUG|Cefiderocol|Cefiderocol for intravenous infusion
215151874|NCT04724109|DRUG|Equfina|Equfina oral tablets.
215151875|NCT04982263|DIAGNOSTIC_TEST|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
215151876|NCT00734500|DRUG|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
215151877|NCT02721966|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
215151878|NCT02721966|DRUG|Secukinumab and Placebo|Placebo matching AIN457
215151879|NCT06037902|DEVICE|CPAP|patients undergo simulation twice, with and without CPAP
214533592|NCT03460496|BEHAVIORAL|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
215151880|NCT05908019|OTHER|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
215151881|NCT03857867|DEVICE|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
215151882|NCT05740501|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215151883|NCT05740501|OTHER|Electronic Health Record Review|Medical records are reviewed
215151884|NCT05740501|OTHER|Questionnaire Administration|Ancillary studies
215151885|NCT03367637|OTHER|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
215151886|NCT03367637|OTHER|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
215151887|NCT02728167|DEVICE|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
215151888|NCT05702606|OTHER|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
214533593|NCT03460496|BEHAVIORAL|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
215151889|NCT03522896|OTHER|control|balancing sugars and organic acids
215151890|NCT03522896|OTHER|test meal 1|orange juice plus hesperidin low dose
215151891|NCT03522896|OTHER|test meal 2|orange juice plus hesperidin higher dose
215151892|NCT03522896|OTHER|test meal 3|diluted orange juice plus hesperidin low dose
215151893|NCT04784572|OTHER|first injection delay and second injection delay|"During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance."
215151894|NCT04151576|OTHER|aromatherapy massage|aromatherapy massage
215151895|NCT05425472|DRUG|HR070803|HR070803
215151896|NCT03186742|DRUG|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
215151897|NCT00212589|DRUG|Capecitabine|
215151898|NCT00212589|DRUG|Fluorouracil + folinic acid|
215151899|NCT02550834|OTHER|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
215151900|NCT04455256|OTHER|x box binding protein|Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
215151901|NCT06057467|DRUG|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
215151902|NCT02633202|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
215151903|NCT02633202|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
214533594|NCT03460496|BEHAVIORAL|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
215151904|NCT02157883|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
215151905|NCT02157883|DRUG|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
215151906|NCT02157883|DRUG|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
215151907|NCT06023017|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
215151908|NCT06023017|BEHAVIORAL|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
215151909|NCT00888940|DRUG|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
215151910|NCT00888940|DRUG|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
215151911|NCT05704582|OTHER|Avatar Intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
215151912|NCT05704582|OTHER|Addiction supportive intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
214533595|NCT03460496|BEHAVIORAL|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
214533596|NCT03460496|BEHAVIORAL|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
214533597|NCT03460496|BEHAVIORAL|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
214533598|NCT03460496|BEHAVIORAL|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
214533599|NCT03460496|BEHAVIORAL|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
214533600|NCT04232800|DRUG|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
214533601|NCT04232800|OTHER|Placebo|An inert, standard placebo in identical capsules to primary intervention.
214533602|NCT03988478|BEHAVIORAL|Detoxification & psychotherapeutic support|
214533603|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #1|Main Hairfinity formulation
214533604|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #2|Variation to main formulation
214533605|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #3|Variation to main formulation
214533606|NCT03106792|DIETARY_SUPPLEMENT|Placebo|No active ingredients
214533607|NCT03430050|DRUG|Progesterone|Progesterone capsule
214533608|NCT03430050|DRUG|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
214533609|NCT06047613|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
214533610|NCT06047613|OTHER|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
215151913|NCT01915069|DRUG|Cilostazol|
215151914|NCT05158764|DEVICE|Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification|Etiological treatment of venous disease of the lower limbs stage C6 / C6r
215151915|NCT05716282|OTHER|Accuracy of neuromuscular recovery estimation|"Accuracy of the estimation of neuromuscular recovery will be measured as:~* Correct attribution of the patients to the groups slow, intermediate or fast recovery~* Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery"
215151916|NCT05601895|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
214533611|NCT06047613|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
214533612|NCT05592236|OTHER|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
214533613|NCT05592236|OTHER|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
214533614|NCT06320327|OTHER|Cannabidiol cream|Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
214533615|NCT06320327|OTHER|Placebo cream|Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
214533616|NCT02685007|OTHER|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
214533617|NCT02690415|PROCEDURE|Antibiotics Given|Patients who's treating physician prescribed antibiotics
214533618|NCT02690415|PROCEDURE|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
214533619|NCT04126122|DIAGNOSTIC_TEST|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
214533620|NCT00169585|DRUG|Levofloxacin oral tablets|
214533621|NCT01887990|DRUG|Ketamine|single dose IV 0.2 mg/kg ketamine
214533622|NCT01887990|DRUG|placebo|saline infusion
214533623|NCT04570254|DRUG|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
214533624|NCT04570254|DRUG|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
215151917|NCT04948359|OTHER|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
215151918|NCT04948359|OTHER|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
215151919|NCT04948359|OTHER|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
215151920|NCT01070017|OTHER|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
215151921|NCT02817048|DEVICE|chest tube|
215151922|NCT02817048|PROCEDURE|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
215151923|NCT02817048|PROCEDURE|VATS with chest tube placement|
214533625|NCT04570254|DRUG|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
214533626|NCT04570254|DRUG|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
214533627|NCT04570254|DRUG|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
214533628|NCT06454318|DIAGNOSTIC_TEST|Wellue O2 ring|Wellue O2 ring wore when doing the polysomnography
214533629|NCT00005797|DRUG|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
215151924|NCT02763670|OTHER|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
215151925|NCT02763670|OTHER|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
215151926|NCT01694797|DRUG|Metoprolol Succinate|
215151927|NCT01521793|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
215151928|NCT03068585|DRUG|Neovasculgen (Cambiogeneplasmid)|treatment
215151929|NCT04607018|DEVICE|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
215151930|NCT04256083|BIOLOGICAL|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
215151931|NCT03651297|OTHER|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
215151932|NCT03651297|OTHER|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
214533630|NCT00005797|DRUG|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
214533631|NCT00005797|DRUG|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
215151933|NCT05612828|BEHAVIORAL|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
215151934|NCT00713518|DRUG|0.5 mg ranibizumab|
215151935|NCT00713518|DRUG|3 mg PF-04523655|
215151936|NCT00713518|DRUG|1 mg PF-04523655|
215151937|NCT04879251|OTHER|No intervention|No intervention
215151938|NCT00121615|DRUG|etanercept|
215151939|NCT06009848|DRUG|Cadonilimab|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
215151940|NCT00501917|DRUG|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
215151941|NCT02653599|DRUG|TTP273|
215151942|NCT02653599|DRUG|Placebo|
215151943|NCT00176267|RADIATION|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 \& 36 of chemotherapy
215151944|NCT00176267|DRUG|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
215151945|NCT00176267|DRUG|Carboplatin|AUC of 6 on Days 1 \& 22
215151946|NCT04921072|BEHAVIORAL|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
215151947|NCT04921072|BEHAVIORAL|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
215151948|NCT00607373|DRUG|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
215151949|NCT00607373|DRUG|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
215151950|NCT01918306|DRUG|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~\--------------------------------------------------------------------------------"
215151951|NCT01918306|OTHER|laboratory biomarker analysis|correlative studies
215151952|NCT01918306|OTHER|pharmacological study|correlative studies
215151953|NCT01918306|PROCEDURE|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
215151954|NCT01918306|DRUG|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
214695918|NCT02458690|OTHER|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
215151955|NCT00243438|DEVICE|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
215151956|NCT02952404|PROCEDURE|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
215151957|NCT01184157|BEHAVIORAL|Home screening|
215151958|NCT01184157|BEHAVIORAL|Clinic screening|
215151959|NCT06402656|DEVICE|Customized facemask|The customized face mask will be fabricated from a 3D digital image of the patient's face obtained by means of a 3D scanner. Such a scanner consists of 6 digital SLR cameras and software capable of processing a 3-D image of the patient's face exportable as an stl file.
215151960|NCT06402656|DEVICE|Standard facemask|The standard facemask is the commercially available Petit standard facemask
215151961|NCT02170077|DRUG|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
215151962|NCT02170077|DRUG|Placebo|Placebo tablets administered orally
215151963|NCT04197596|BIOLOGICAL|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
215151964|NCT03568227|PROCEDURE|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
215151965|NCT03568227|PROCEDURE|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
215151966|NCT05271877|PROCEDURE|Laparoscopy|Diagnostic/operative laparoscopic procedure
215151967|NCT05932823|OTHER|Laminary airflow|A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
215151968|NCT05107726|BEHAVIORAL|TRE Group|This group will practice time-restricted eating
215151969|NCT03171363|BEHAVIORAL|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
215151970|NCT02070536|OTHER|sRAGE|
215151971|NCT01355952|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
215151972|NCT01986426|DRUG|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
215151973|NCT01986426|DRUG|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
215151974|NCT01986426|DRUG|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
215151975|NCT01986426|DRUG|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
215151976|NCT06218966|DEVICE|intracochlear catheter|intracochlear administration of steroids through the intracochlear catheter INCAT
215151977|NCT06008990|DRUG|Buprenorphine|Pregnant mother must be taking Buprenorphine
215151978|NCT06008990|DIAGNOSTIC_TEST|Maternal Brain MRI|Maternal Brain MRI obtained between 24-32 week gestation
215151979|NCT06008990|OTHER|Blood Samples|During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
215151980|NCT06008990|BEHAVIORAL|Questionnaires|Participants will answer questionnaires about their medical history, pregnancy, and substance use.
215151981|NCT04994847|DRUG|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
215151982|NCT01780974|DRUG|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
215151983|NCT01780974|DRUG|Placebo|placebo capsules
215151984|NCT03276624|PROCEDURE|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
215151985|NCT01580163|DRUG|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
215151986|NCT01580163|DRUG|Methadone|Oral Solution，1mg/ml
215151987|NCT01580163|DRUG|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
215151988|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
215151989|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
215151990|NCT04336917|DRUG|Rhomboid Intercostal and Subserratus Plane Block with local anesthetic|Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
214533632|NCT00005797|RADIATION|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
214533633|NCT00563745|DEVICE|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
214533634|NCT05404698|OTHER|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
214533635|NCT05404698|OTHER|Control|CONT: participants will receive hemodialysis treatment only (usual care)
214695919|NCT01887028|DEVICE|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
214695920|NCT01333839|OTHER|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
215151991|NCT06390748|DRUG|esmolol|The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
215151992|NCT01724346|DRUG|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
215151993|NCT01724346|DRUG|Next-line ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
215151994|NCT06071689|DEVICE|screw retained prosthesis|all-on-4 screw-retained prosthesis.
215151995|NCT05120401|DEVICE|presbyopia glasses|fogging for glasses for far and intermediate
215151996|NCT00598793|DRUG|biphasic insulin aspart|
215151997|NCT00598793|DRUG|insulin glargine|
215151998|NCT00598793|DRUG|metformin|
215151999|NCT00598793|DRUG|pioglitazone|
215152000|NCT00397865|BEHAVIORAL|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
215152001|NCT02694289|DRUG|Metformin|Treatment/continuation of metformin therapy during admission
215152002|NCT02694289|DRUG|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
215152003|NCT00996853|OTHER|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
215152004|NCT00332176|DRUG|Celgosivir|400mg qd + standard of care for 12 weeks
215152005|NCT00332176|DRUG|Celgosivir|600mg qd + standard of care for 12 weeks
215152006|NCT00332176|DRUG|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
215152007|NCT03237455|DIAGNOSTIC_TEST|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
215152008|NCT03237455|DIAGNOSTIC_TEST|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
215152009|NCT03237455|OTHER|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
215152010|NCT03262480|OTHER|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
215152011|NCT05880186|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
214533636|NCT06479226|DRUG|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|mouthrinse
214533637|NCT04228900|DIETARY_SUPPLEMENT|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
214533638|NCT04228900|DRUG|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
214533639|NCT00196118|DEVICE|Günther Tulip Vena Cava Filter|
214533640|NCT01396200|DRUG|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
214533641|NCT01396200|DRUG|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
214533642|NCT05764590|DRUG|AP-306|A blood phosphorus lowering drug with a novel mechanism
214533643|NCT05764590|DRUG|Sevelamer Carbonate|A phosphate binder
214695921|NCT02456181|BEHAVIORAL|JumpMath|
214695922|NCT00643591|OTHER|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
215152012|NCT02863120|DRUG|liposomal bupivacaine|
215152013|NCT02863120|DRUG|bupivacaine HCl|
215152014|NCT02863120|DRUG|Ropivacaine|
215152015|NCT02863120|DRUG|Saline|
215152016|NCT01025518|OTHER|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
215152017|NCT01025518|DIETARY_SUPPLEMENT|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
215152018|NCT01025518|DIETARY_SUPPLEMENT|Placebo|Maltodextrine
215152019|NCT02073058|DEVICE|No treatment|
214695923|NCT04809389|BIOLOGICAL|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
214695924|NCT04809389|BIOLOGICAL|Matching placebo|0.9% NaCl solution
214695925|NCT02559154|DRUG|Bortezomib|
214695926|NCT02559154|DRUG|Dexamethasone|
214695927|NCT02559154|DRUG|Doxorubicin|
215152020|NCT04416841|BEHAVIORAL|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
215152021|NCT04416841|BEHAVIORAL|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
214463209|NCT05681923|OTHER|Neurodevelopmental assessment visit|"High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals."
215152022|NCT04416841|BEHAVIORAL|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
215152023|NCT00131261|DRUG|PXD101|
215152024|NCT00131261|DRUG|Dexamethasone|
214533644|NCT02845713|DRUG|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
214533645|NCT00932555|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
214533646|NCT06208800|OTHER|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
214533647|NCT01834768|DRUG|Eplerenone|
215152025|NCT05975203|PROCEDURE|skin-to-skin contact|Immediately after delivery the infant will receive skin-to-skin contact with the mother.
215152026|NCT01926561|OTHER|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
215152027|NCT06409546|DRUG|Tocopherol and pentoxifilline topical gel|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
215152028|NCT06409546|DRUG|Placebo|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
215152029|NCT00569400|DRUG|human insulin|
215152030|NCT06418802|PROCEDURE|STN-DBS surgery|bilateral subthalamic nucleus deep brain stimulation surgery
215152031|NCT06418802|DEVICE|pulse width|a short pulse width (30s)
215152032|NCT06418802|DEVICE|frequency|frequency parameters of STN-DBS (60,100, and 130HZ)
215152033|NCT02211846|DRUG|Mirabegron|oral
215152034|NCT05689372|DRUG|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
215152035|NCT04494802|BEHAVIORAL|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
214463210|NCT05681923|OTHER|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
214533648|NCT00256347|DRUG|intramuscular injections of morphine|
214533649|NCT04301115|OTHER|attachment|unilateral attachment from rehine 83
214533650|NCT04301115|OTHER|bridge|tooth implant supported bridge
214533651|NCT04301115|OTHER|CONVENTIONAL|conventional metalic partial denture
214533652|NCT05282641|DIETARY_SUPPLEMENT|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
214533653|NCT05282641|DIETARY_SUPPLEMENT|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
214533654|NCT05262465|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
214695928|NCT02559154|DRUG|Cyclophosphamide|
214695929|NCT02559154|DRUG|Mitoxsnteone|
215152036|NCT04494802|BEHAVIORAL|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
215152037|NCT04154774|DRUG|Apalutamide|Apalutamide will be administered orally.
214463211|NCT06066996|DRUG|Transdermal Nicotine Patch|Blinded Nicotine Patch
214533655|NCT05262465|DRUG|Azacitidine|azacytidine 50-75mg/m2
214695930|NCT02559154|DRUG|Thalidomide|
214695931|NCT02042495|DRUG|Metformin|
214463212|NCT06066996|DRUG|Placebo Nicotine Patch|Blinded Patch with No Nicotine
214533656|NCT05262465|DRUG|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
215152038|NCT01298986|PROCEDURE|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
214463213|NCT05969392|DEVICE|Intradiscal Gelified Ethanol (Discogel)|Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
214463214|NCT03536052|DEVICE|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
215152039|NCT01298986|PROCEDURE|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
215152040|NCT01298986|PROCEDURE|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
215152041|NCT01298986|PROCEDURE|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
215152042|NCT02876601|DRUG|Defibrotide|6.25mg/kg bodyweight over 2h infusion
215152043|NCT02876601|DRUG|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
215152044|NCT02876601|DRUG|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
215152045|NCT02876601|DRUG|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
215152046|NCT00256997|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
215152047|NCT00256997|DRUG|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
215152048|NCT00354432|DIETARY_SUPPLEMENT|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
215152049|NCT00354432|DRUG|Venlafaxine|Patients receive oral venlafaxine 75mg.
215152050|NCT00354432|DIETARY_SUPPLEMENT|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
215152051|NCT00354432|DRUG|Placebo Pill|Patients receive oral placebo pill.
214695932|NCT02953392|DEVICE|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
214695933|NCT02953392|DEVICE|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
214463215|NCT06004453|OTHER|Heart Failure medications|There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
214463216|NCT06273436|OTHER|H.E.A.R. for Mamas|H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
214463217|NCT06667726|PROCEDURE|Computed Tomography|Undergo PET/CT
214463218|NCT06667726|DRUG|Fluorodopa F 18|Given IV
214463219|NCT06667726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214463220|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
215152052|NCT02736578|DRUG|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
215152053|NCT02736578|DRUG|Cetuximab|Administered as a 100 mg IV loading dose
215152054|NCT02874521|OTHER|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
214533657|NCT05641714|OTHER|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
215152055|NCT02874521|OTHER|Intra-dialytic cycle training|Cycle training during haemodialysis
215152056|NCT02706106|DEVICE|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
215152057|NCT03976219|OTHER|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
214533658|NCT05641714|OTHER|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
214533659|NCT05641714|OTHER|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
215152058|NCT04722419|OTHER|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
215152059|NCT03636100|DEVICE|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
215152060|NCT02086253|DRUG|BQ-788 and/or BQ-123|
215152061|NCT06555549|DRUG|DEH113|tablets
215152062|NCT06555549|DRUG|Placebo|tablets
215152063|NCT04151303|PROCEDURE|Cervical cerclage|Cervical cerclage and cervical cerclage removal
215152064|NCT01913496|OTHER|ebalance|using the ebalance application for 14 weeks
215152065|NCT01815697|DEVICE|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
215152066|NCT02641028|DRUG|CERC-501|CERC-501
215152067|NCT02641028|DRUG|Placebo|Placebo
214533660|NCT05641714|OTHER|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
214533661|NCT05641714|OTHER|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
214533662|NCT02624505|DRUG|90 mcg Reference Product|Drug: 90 mcg Reference Product
214533663|NCT02624505|DRUG|180 mcg Reference Product|Drug: 180 mcg of Reference Product
214533664|NCT02624505|DRUG|90 mcg Test Product|Drug: 90 mcg of Test Product
214533665|NCT02624505|DRUG|Placebo|Placebo Product
214533666|NCT06146413|DRUG|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
214533667|NCT06146413|DRUG|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
215152068|NCT01039740|DRUG|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
215152069|NCT05858723|DIAGNOSTIC_TEST|ROAT|Repeated Open Application Test
215152070|NCT06666270|DRUG|SYN818|Patients will orally receive SYN818
215152071|NCT04325321|OTHER|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
215152072|NCT02827877|RADIATION|Copper Cu 64-DOTA-Trastuzumab|Given IV
215152073|NCT02827877|OTHER|Laboratory Biomarker Analysis|Correlative studies
215152074|NCT02827877|BIOLOGICAL|Pertuzumab|Given IV
215152075|NCT02827877|PROCEDURE|Positron Emission Tomography|Undergo PET
215152076|NCT02827877|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215152077|NCT02827877|BIOLOGICAL|Trastuzumab|Given IV
215152078|NCT05206773|DRUG|Venglustat (GZ402671)|Pharmaceutical form: Tablet Route of administration: Oral
215152079|NCT05206773|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
215152080|NCT06174363|DRUG|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
214533668|NCT01510002|PROCEDURE|Total thyroidectomy|Extracapsular total thyroidectomy
215152081|NCT06174363|DRUG|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
215152082|NCT06589089|DRUG|autologous hematopoietic stem cell|Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
215152083|NCT02357771|DRUG|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
215152084|NCT02357771|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
215152085|NCT06603688|DRUG|esomeprazole|Esomeprazole 40mg, twice daily for 14 days.
215152086|NCT06603688|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
215152087|NCT06603688|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
215152088|NCT06603688|DRUG|clarithromycin|clarithromycin 500mg, twice daily for 14 days.
215152089|NCT06603688|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
215152090|NCT06603688|DRUG|Minocycline|Minocycline 100 mg, twice daily for 14 days
214533669|NCT01510002|PROCEDURE|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
214533670|NCT02741713|PROCEDURE|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
214533671|NCT02741713|PROCEDURE|Interscalene Block|An interscalene block will be performed on the subjects.
214533672|NCT02741713|PROCEDURE|Sham Block|
214533673|NCT02741713|DRUG|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
214533674|NCT02741713|DRUG|Solution for Injection in Sham Block|Lidocaine 1%
214533675|NCT02741713|DRUG|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
214533676|NCT02081118|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
214533677|NCT02081118|DRUG|Placebo|Placebo for HM11260C
215152091|NCT06588374|PROCEDURE|lateral internal sphincterotomy|Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
215152092|NCT06597357|PROCEDURE|Arthroscopy &amp; saline irrigation alone|the meniscus scaffold is aimed at replacing partial meniscus defect with a synthetic device.
215152093|NCT06654427|BEHAVIORAL|Obstetric Trauma Informed Care Toolkit|The OB-TIC toolkit will include provider and staff training on trauma- informed care and information on trauma-related perinatal concerns; trauma assessment tools; trauma-informed procedure modifications; clinical language guides; patient-facing resources including birth strategies, referral resources, and education; and clinical language. The OB-TIC intervention will utilize the toolkit to integrate trauma-informed care into clinical practice. Implementation strategies will be assessed to determine the most effective method for integrating OB-TIC content into practice.
215152094|NCT06655597|DIETARY_SUPPLEMENT|REDS Powder|Dietary supplement powder
215152095|NCT03812757|DIAGNOSTIC_TEST|Supraclavicular fossa US scanning|As previously stated.
215152096|NCT06313307|COMBINATION_PRODUCT|topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.
215152097|NCT06313307|DEVICE|Thulium 1927-nm Fractional Laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
215152098|NCT04372381|DEVICE|Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro|Treatment of aortic valve stenosis using transcatheter aortic valve replacement
215152099|NCT06508385|OTHER|Breathing exercise|"Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds)."
215152100|NCT06984354|BEHAVIORAL|Pain education and clinical hypnosis delivered via a mobile app|Pain education and clinical hypnosis will be delivered via a mobile app. The 8-week intervention includes daily sessions on pain education and clinical hypnosis for managing back pain (5 minutes of education, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes). The first six weeks will be semi-standardised, with participants following a set program with the option to repeat sessions. The last two weeks will be flexible, allowing participants to choose a specific program or self-paced continuation of the intervention. Adherence will be monitored by tracking the number of days participants complete sessions, as recorded by the mobile app.
215152101|NCT06984354|BEHAVIORAL|Guideline-informed factsheet|A single guideline-informed factsheet for back pain delivered via a webpage. Participants will be informed that the factsheet intends to provide reassurance for their back pain and encourage reflections on treatments and self-management options.
215152102|NCT06589973|OTHER|Study Cohort|Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.
215152103|NCT06992947|OTHER|Healthy food subsidy: $27/household/week|Participants receive 16 weeks of coupons valued at $27/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
215152104|NCT06992947|OTHER|Healthy food subsidy: $54/household/week|Participants receive 16 weeks of coupons valued at $54/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
215152105|NCT06992947|OTHER|Healthy food subsidy: $81/household/week|Participants receive 16 weeks of coupons valued at $81/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
215152106|NCT06992947|OTHER|Nutrition skill-building|Participants are eligible, but not required, to attend optional nutrition skill-building activities (e.g. cooking and gardening classes).
215152107|NCT06601361|DEVICE|Fibroscan|Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.
214533678|NCT04668534|DEVICE|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
214533679|NCT04668534|DEVICE|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
214533680|NCT04668534|DEVICE|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
214533681|NCT01086332|DRUG|Nelfinavir|1250 mg twice daily
214533682|NCT01086332|DRUG|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
214695934|NCT02953392|DEVICE|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
215152108|NCT06591299|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
215152109|NCT06591299|DRUG|Clopidogrel 75mg|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
215152110|NCT06588452|OTHER|RECTIFIER - a generative artificial intelligence screening tool|RECTIFIER is a large-language model based, generative artificial intelligence-enabled inclusion and exclusion criteria assessment tool.
214533683|NCT03882996|DRUG|Ezetimibe|Ezetimibe 10 mg daily in the morning
214533684|NCT03882996|DRUG|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
214533685|NCT02243761|OTHER|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
214533686|NCT02764177|DIETARY_SUPPLEMENT|Protein drink|The protein drink was administered during this trial
214533687|NCT02764177|DIETARY_SUPPLEMENT|Carbohydrate drink|The carbohydrate drink was administered in this trial
214533688|NCT04724005|OTHER|No drug|No drug used
214533689|NCT02735356|DRUG|Itraconazole|Applied topically
214533690|NCT02735356|OTHER|Placebo|Applied topically
214533691|NCT00131898|PROCEDURE|Surgical Resection|
214533692|NCT00131898|PROCEDURE|Intensity Modulated Radiation Therapy (IMRT)|
214533693|NCT06118177|PROCEDURE|connective tissue harvesting|The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of canine and the mesial of first molar in the palate. Connective tissue dimensions were approximately 10 × 5 × 2 mm. Finally, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture
214533694|NCT06118177|DIAGNOSTIC_TEST|ultrasonography|A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the donor site in the palatal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit: Pulsality index (PI) = (Vmax-Vmin)/(Vmean) (Vmax is peak systolic flow velocity, Vmin is diastolic flow velocity and Vmean is mean flow velocity). The mean PI values of each patient were measured.
214533695|NCT06118177|OTHER|autolog platelet rich fibrin application|Leukocyte rich PRF (L-PRF) was obtained with the centrifugation of the two tubes at 2800 rpm for 12 minutes. After centrifugation, L-PRF clots were taken from the tubes using sterile tweezers, separated from the red blood cell base using scissors. Then L-PRF membrane was placed into the donor site.
214533696|NCT01019798|DRUG|sunitinib, docetaxel, cisplatin|"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"
214533697|NCT05887206|OTHER|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
214533698|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
214533699|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
214533700|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
214533701|NCT01093222|DRUG|Erlotinib Hydrochloride|Given PO
214533702|NCT01093222|DRUG|Sorafenib Tosylate|Given PO
214533703|NCT02388399|PROCEDURE|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)
214533704|NCT02388399|PROCEDURE|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
214695935|NCT02953392|DEVICE|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
215152111|NCT06588452|OTHER|Manual clinical trial screening by study staff|The current gold standard - study staff manually review potentially eligible patients through chart review.
215152112|NCT04574960|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle
214533705|NCT03230071|DRUG|TMBCZG|0.1g per pill which contains 14mg TMBCZG
215152113|NCT04574960|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle
214533706|NCT03230071|OTHER|placebo|0.1g per pill which contains 0mg TMBCZG
215152114|NCT04574960|DRUG|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
215152115|NCT06175104|BEHAVIORAL|HeartGPS|"HeartGPS includes three key components:~1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
215152116|NCT04207788|OTHER|HIP-REP|HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.
215152117|NCT04207788|OTHER|Usual care|The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
215152118|NCT07026448|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
215152119|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
215152120|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
215152121|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 3|Participants will use their Energy Active Product 3 as directed for a period of 6 weeks.
215152122|NCT05560607|DRUG|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
215152123|NCT07046221|DRUG|Tislelizumab|200mg，d1，q3w，1years
215152124|NCT07046221|DRUG|Albumin-Bound Paclitaxel|125mg/m2，d1，d8，q3w，2cycles
214533707|NCT05820321|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
214533708|NCT05820321|OTHER|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
214695936|NCT03615469|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
215152125|NCT07046221|DRUG|cis-platinum|75mg/m2，d1，q3w，2cycles
215152126|NCT07046221|PROCEDURE|Surgery|Radical resection of esophageal cancer
215152127|NCT07046221|RADIATION|Radiation|50.5Gy/28f
215152128|NCT07046221|DRUG|Nedaplatin|80-100mg/m2，d1，q3w，2cycles
215152129|NCT07046221|DRUG|Carboplatin|AUC=5，d1，q3w，2cycles
215152130|NCT06736262|DRUG|Briquilimab|No additional details needed
215152131|NCT07045363|BEHAVIORAL|Cognitive Intervention|Participants in the intervention arm will receive a personalized one-page Heart Age report based on data from their government-funded annual health check. The report is delivered by trained physicians using a standardized communication script during a routine follow-up visit. The control group receives usual chronic disease care without structured risk communication.
215152132|NCT06891417|BIOLOGICAL|Chlamydia mRNA Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration:~Intramuscular injection"
215152133|NCT06891417|OTHER|Placebo|"Pharmaceutical Form:~Solution for injection~Route of Administration:~Intramuscular injection"
215152134|NCT06740747|DEVICE|Intermittent theta-burst stimulation|Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
215152135|NCT06740747|DEVICE|Sham intermittent theta-burst stimulation|Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
215152136|NCT06746116|DRUG|Durvalumab + Chemotherapy phase|Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.
215152137|NCT06746116|DRUG|Durvalumab + Olaparib phase|durvalumab (IV) with olaparib (tablets) every four weeks until progression.
215152138|NCT07051746|BEHAVIORAL|Metacognitive Training (MCT), Traditional Chinese version|The intervention is a culturally adapted version of Metacognitive Training (MCT) for psychiatric populations in Taiwan. The program consists of 8 group sessions over 4 weeks. Each session includes psychoeducation, cognitive exercises, and group discussion to help participants recognize and reduce cognitive biases.
215152139|NCT06132373|BEHAVIORAL|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
215152140|NCT07063862|DRUG|Psilocybin|Participants randomized to the psilocybin microdosing intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of psilocybin daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
215152141|NCT07063862|DRUG|Placebo|Participants randomized to the placebo intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of placebo daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
215152142|NCT07057882|BEHAVIORAL|Health Belief Model-based Education|The intervention is a structured educational program based on the Health Belief Model (HBM), developed to improve health perception and reduce risky behaviors among international university students. The program includes six weekly sessions lasting approximately 45 minutes each, delivered face-to-face in small groups. The training content is tailored to address perceived susceptibility, severity, benefits, barriers, and self-efficacy related to health behaviors. Interactive discussions, visual materials, and culturally sensitive examples are used. Participants in the intervention group receive this training in addition to usual care or routine university services..
215152143|NCT06767319|OTHER|No intervention|The difference in diopters of depth of focus range achieving a threshold of 0.20 logMAR between Trial lens vs. Chart testing method per pre-study IOL group.
215152144|NCT07067190|DEVICE|Conventional Bar Attachment|A rigid cast bar attachment fabricated and screwed onto three mandibular implants (placed at the midline and canine areas). The bar connects the implants to provide splinting and retention for a mandibular overdenture without the use of additional retentive components such as OT Caps. The overdenture is adjusted to fit passively over the bar and picked up intraorally.
215152145|NCT07067190|DEVICE|Bar with OT Cap Attachment|A cast bar attachment fitted with two OT Cap attachments, which are designed to improve prosthesis retention and load distribution. This bar system is installed on three mandibular implants (midline and canine regions). The mandibular overdenture is relined to incorporate the female retentive caps that snap onto the OT Caps. This system combines the splinting benefits of the bar with the resilient retention of stud attachments.
215152146|NCT01008540|BIOLOGICAL|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
214533709|NCT00588341|DRUG|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
214533710|NCT04696926|OTHER|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
214533711|NCT03941990|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
214533712|NCT03941990|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
214533713|NCT00543166|DRUG|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
214533714|NCT03435809|PROCEDURE|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
214533715|NCT00347802|DRUG|Bimatoprost 0.03%, Travoprost 0.004%|
214533716|NCT01039558|DRUG|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
214533717|NCT01039558|DRUG|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
214533718|NCT01039558|DRUG|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
214533719|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
214533720|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
214533721|NCT05527509|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
214533722|NCT05527509|BEHAVIORAL|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
214533723|NCT00983424|DRUG|Cyclosporins|dose escalation, administered orally twice a day
214533724|NCT00983424|DRUG|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
215152147|NCT07068152|BEHAVIORAL|Preoperative telenursing|The role of Nursing in Telenursing includes Nursing Consultation, Interconsultation, Consulting, Monitoring, Health Education and Reception of Spontaneous Demand mediated by Information and Communication Technologies. In this research, the researcher will make a telephone call the day before surgery to patients scheduled in the surgical map in order to guide them on immediate preoperative care.
214533725|NCT01670188|DEVICE|Pneumatic SCD - VenaFlow System (DJO Global)|
214533726|NCT03121599|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
214533727|NCT05245084|DRUG|CKD-386(3)|QD, PO
214533728|NCT05245084|DRUG|D013, D326, D337|QD, PO
214533729|NCT00836914|DRUG|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
214533730|NCT00836914|DRUG|Placebo|Placebo capsules administered orally BID for 7 days
214533731|NCT01372202|DRUG|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
214533732|NCT01372202|DRUG|Cisplatin|"Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29."
214533733|NCT01372202|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
215152148|NCT07068347|COMBINATION_PRODUCT|VR + lifestyle modification|"VR + lifestyle modification (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.In lifestyle modification walking at home for 30 min in 3-5 days /week. Dietry habits will be given according to American Institute for cancer Research.~In sleep habits Recommended Sleep Hours 7-9 hours per night,Establish a Consistent Sleep Schedule,Create a Comfortable Sleep Environment,Limit Screen Time Before Bed,Engage in Relaxation Techniques,Limit Caffeine and Alcohol Intake,Manage Nighttime Discomfort,Maintain a Pre-Sleep Routine,Address Emotional Health,Avoid Daytime Naps.Deep breathing exercise for stress management"
215152149|NCT07068347|COMBINATION_PRODUCT|VR only|VR only (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.
215152150|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy + lifestyle modification|Conventional physical therapy + lifestyle modification In Conventional physical therapy(Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated)
215152151|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy only|Conventional physical therapy only((Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated) ,Trunk lateral flexion with arms in 90 degrees abduction in standing position,Theraband (flexion-extension-abduction, adduction and internal-external rotation),Muscles of upper limb strengthening ,Mobilization for passive glenohumeral joint ,Tissue massage for scars.
215152152|NCT07068477|BEHAVIORAL|Values Assessment Tool|The Values Assessment Tool was provided to the participants at baseline and every clinic visit for 3 months
215152153|NCT07064915|BEHAVIORAL|Medical-Financial Partnership Support|"The Medical-Financial Partnership (MFP) intervention will include (at minimum):~1. A relationship with a trained MFP intervention team member~2. Establishment of financial and social goals in the initial meeting, with connection to public anti-poverty programs, employment opportunities, and other income supports, among others, as tailored to participant goals~3. Establishment of an action plan to reach short, medium and long-term goals in core MFP domains~4. Co-designing with the participant to identify and refine goals and action steps longitudinally~5. A standard toolkit for access to financial services and public benefits"
215152154|NCT07068594|DEVICE|Virtual Reality Goggles|A device consisting of glasses placed on the head of patients in the intervention group and earphones attached to the glasses
215152155|NCT07068386|OTHER|Early intervention with telerehabilitation|"All premature infants aged 3 to 5 months included in the study were assessed for motor development using the General Movements Assessment (GMs) and the Alberta Infant Motor Scale (AIMS), based on videos submitted by their parents. Following the video evaluations, parents were contacted via video call. An intervention program was developed in collaboration with the parents, guided by the video-based assessments.~The intervention program focused on the acquisition of age-appropriate motor development and included components such as massage, positioning, trunk control, movement selectivity, and anti-gravity activities. It was delivered to parents through synchronous. Parents were advised to implement the program for 30 minutes per day, 4 days a week, over a 12-week period. After the intervention, the infants were re-evaluated using the AIMS via video call."
215152156|NCT02819011|DEVICE|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
215152157|NCT02819011|OTHER|Control|Subjects will be provided with a pair of New Balance 813 shoes
215152158|NCT07069621|BEHAVIORAL|Triple p level parenting program|An evidence-based program with self-agency strategies enhances trust and confidence in managing children's ADHD behaviors
215152159|NCT07071675|DRUG|Calcium Hydroxide Intracanal medication|Treated using calcium hydroxide based material as an intracanal medicament
215152160|NCT07071675|DRUG|bioceramic based intracanal medication|treated using bio-ceramic based material as an intracanal medicament
215152161|NCT07065253|OTHER|blood ponction|blood ponction
215152162|NCT07065253|OTHER|urines collection|urines collection
215152163|NCT07065253|OTHER|hair collection|hair collection
214533734|NCT01372202|DRUG|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29."
214533735|NCT01372202|RADIATION|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
214533736|NCT01372202|PROCEDURE|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
214533737|NCT05662683|OTHER|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
214533738|NCT05662683|OTHER|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
214533739|NCT05662683|OTHER|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
214533740|NCT05924048|OTHER|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
215152164|NCT07065253|OTHER|saliva collection|saliva collection
215152165|NCT07065253|OTHER|stools collection|stools collection
215152166|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
215152167|NCT07063563|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
215152168|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
215152169|NCT07064928|BEHAVIORAL|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 for the Ghanaian context, and among pregnant and/or postpartum women living with HIV
215152170|NCT07068555|BIOLOGICAL|Immunomodulatory DC vaccines to target prostate cancer|1 to 2 injections, with an interval of one month, of 1\~2x10\^7 DC vaccine administered subcutaneously
214533741|NCT03504371|DEVICE|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
214533742|NCT03504371|DEVICE|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
214533743|NCT00658983|OTHER|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
214533744|NCT00658983|OTHER|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
214533745|NCT06277024|DRUG|Combination of Cardonizumab with Lenvatinib and SOX regimen|"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."
214533746|NCT04433286|OTHER|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
214533747|NCT03936075|BEHAVIORAL|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
214533748|NCT03936075|BEHAVIORAL|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
214533749|NCT03986983|DEVICE|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
215152171|NCT07072611|DRUG|SOF-SKN 0.25%|cream for topical application
215152172|NCT07072611|DRUG|SOF-SKN 0.5%|cream for topical application
215152173|NCT07072611|DRUG|SOF-SKN 1%|cream for topical application
215152174|NCT07072611|DRUG|SOF-SKN 2%|cream for topical application
215152175|NCT07072611|DRUG|Placebo|cream for topical application
215152176|NCT07069192|BEHAVIORAL|Counselling|Received structured caregiver counseling - weekly sessions for 1 month and biweekly for the next 2 months.
215152177|NCT07069647|OTHER|VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration|VeriSee DR is an AI-assisted diagnosis screening tool for diabetic retinopathy, the software received medical device license approval from the TFDA in 2020 (MOHW-MD-No.006966). VeriSee AMD is an AI-assisted diagnosis screening tool for age-related macular degeneration, the software also received medical device license approval from the TFDA in 2022 (MOHW-MD-No.007652).
215152178|NCT07069647|OTHER|Standard fundus photography with physician interpretation|The control group will undergo the fundus photography without AI-functionality, with reports interpreted solely by physicians. Participants must schedule a follow-up visit to receive their results.
215152179|NCT07075263|OTHER|Questionnaire|A self-administered structured questionnaire
215152180|NCT07074002|DRUG|BP1.4979|Selective dopamine D3 partial agonist
215152181|NCT07074002|DRUG|Placebo|Matching placebo of BP1.4979 tablet
215152182|NCT07075796|DEVICE|GLUCUBE system|A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
215152183|NCT07074821|DRUG|Taurolidine citrate 4% and heparin 500|Taurolidine ,citrate 4% and heparin 500 units per ml used as lock solution in tunneled hemodialysis catheter
215152184|NCT07075250|DRUG|Realgar-Indigo Naturalis Formulation Combined with Anlotinib|"RIF: Oral administration after meals, 6 tablets each time, three times daily (tid), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Anlotinib : Oral administration before breakfast, 10 mg each time, once daily (qd), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Subjects will continue the study treatment until meeting the protocol-defined discontinuation criteria. The total treatment duration should not exceed 18 months."
215152185|NCT07074340|DEVICE|occlusal stabilization splint manufactured with a conventional workflow|Heat-cured acrylic resin occlusal stabilization splint
215152186|NCT07074340|DEVICE|occlusal stabilization splint manufactured with Fully-digital workflow|3D printed occlusal stabilization splints
215152187|NCT06895031|DRUG|JYP0015|JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.
214533750|NCT03986983|OTHER|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
214533751|NCT00948103|DRUG|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
214533752|NCT00948103|DRUG|Oxygen|oxygen
215152188|NCT07075562|DRUG|Bevacizumab Arterial Perfusion plus TACE|The intervention consists of a combination treatment. Patients undergo transcatheter hepatic artery chemoembolization (TACE), a procedure involving localized delivery of chemotherapy and embolization of the tumor-feeding arteries. This is combined with a targeted arterial perfusion of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF).
215152189|NCT07075562|PROCEDURE|Conventional Therapy|Patients in the control group received conventional therapy, which typically consists of TACE alone for this patient population. This involves the selective catheterization of hepatic arteries supplying the tumor, followed by the infusion of chemotherapeutic agents and an embolic agent to induce tumor necrosis.
215152190|NCT07074678|DIAGNOSTIC_TEST|Functional MRI (fMRI)|Research MRI, which will include both structural and functional sequences, will either be collected independently, or in conjunction with clinically-indicated sequences. Functional MRI captures the blood oxygen level dependent (BOLD) signal that reflects brain activity. A subset of the PREDICT study fMRI will include sequences with auditory and/or noxious stimulation. Noxious stimulation will be delivered with an MRI-compatible device that delivers intermittent nailbed pressure under computerized control. Additionally, the BOLD signal will be captured at rest to investigate functional neural networks.
215152191|NCT07074587|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises will be taught with an innovative approach based on the principles of finding, feeling, forcing, following and functional training of the pelvic floor muscles. Pelvic floor muscle exercises will be applied as 3 sets in the first 2 weeks, 4 sets in the 3rd and 4th weeks, 5 sets in the 5th and 6th weeks, and finally 6 sets in the 7th and 8th weeks. Individuals will continue their pelvic floor muscle exercises as a home program.
215152192|NCT07074587|BEHAVIORAL|Spinal stabilization exercises focusing on the pelvic floor + Pelvic floor muscle exercises|This program consists of 3 phases: 30 minutes of spinal stabilization exercises focusing on the pelvic floor, 5 minutes of warm-up and 5 minutes of cool-down exercises.The exercises will consist of 3 phases: static, dynamic and functional phases. Individuals will perform static phase exercises for the first 2 weeks, then dynamic phase exercises in the 3rd and 5th weeks and finally functional phase exercise in the 6th and 8th weeks. Individuals will be asked to maintain neutral spine position and abdominal bracing during pelvic floor muscle contraction during all exercises. Individuals will maintain the contraction for 5-10 seconds for 10 repetitions in each position in all phases.
215152193|NCT07074717|PROCEDURE|Buccal Mucosal Graft (BMG) Urethroplasty|Urethroplasty using a buccal mucosal graft harvested from the inner cheek. The graft is dorsally onlaid to reconstruct the strictured urethral segment. The procedure is conducted under spinal or general anesthesia.
215152194|NCT07074717|PROCEDURE|Penile Skin Graft (PSG) Urethroplasty|Urethroplasty using a penile skin graft harvested from the ventral surface of the penis. The graft is applied dorsally after excision of the fibrotic urethral segment. The surgery is performed under spinal or general anesthesia.
215152195|NCT07075211|DEVICE|MARPE (mini-screw assisted rapid palatal expansion)|MARPE (mini-screw assisted rapid palatal expansion) with two min screws in post-pubertal patients
215152196|NCT07074093|COMBINATION_PRODUCT|app+smartband+education|"Intervention:~Behavioral: Health education~Device: AirVisual App~Device: Amazfit Band 5"
215152197|NCT07075107|PROCEDURE|Blood collection|Blood is collected in order to perform transcriptomic sequencing from blood
215152198|NCT07075107|PROCEDURE|skin biopsy|A biopsy of skin is performed in order to perform transcriptomic sequencing on fibroblasts obtained from the biopsy
215152199|NCT07075393|OTHER|full renal workup|full renal workup (biology and echography)
215152200|NCT07074457|DRUG|Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)|"3 cycles of BvC treatment for all enrolled patients.~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;"
215152201|NCT07074457|DRUG|Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)|"Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment).~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;~Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years"
215152202|NCT07074457|DRUG|Maintenance therapy-chidamide|Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years
215152203|NCT07074522|PROCEDURE|Single-layer closure|Patients who underwent single-layer closure of the transverse lower segment during cesarean section.
215152204|NCT07074522|PROCEDURE|Double-layer closure|Patients who underwent double-layer closure of the transverse lower segment during cesarean section.
215152205|NCT07074925|OTHER|Video assisted informed consent|The 2-minute video (available in English or Spanish) will use animation to explain the neonatal LP procedure, benefits, and risks.
215152206|NCT07074925|OTHER|Standard consent|The standard consent group will receive usual procedure description and consent.
215152207|NCT07074860|BEHAVIORAL|Peer to peer video to raise awareness about substance use|A total of 4 short, animated videos will be created using design concepts and language created by the VT RAYS. Each video will be \<2 minutes in length and address a specific topic including e-cigarette, cannabis, alcohol and other substance use. These videos will be curated online and shown to study participants during their scheduled primary care visits. The video will be followed by a short online survey available immediately after viewing to collect feedback on the content.
215152208|NCT07075055|OTHER|Metapaste Calcium Hydroxide|To compare the effect of calcium hydroxide and Bio-C Temp as intra canal medications on postoperative pain via VAS and periapical healing via CBCT
215152209|NCT07075055|OTHER|Bio C-Temp|Bio C-Temp
214533753|NCT03305471|DRUG|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
214533754|NCT03305471|DRUG|Placebo|Placebo matching stock solution in bottle
214533755|NCT03305471|DRUG|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
214533756|NCT03305471|DRUG|DS-2330b Tablet|DS-2330b as tablet formulation
215152210|NCT07073989|DEVICE|Afferent stimulation|Stimulation applied through mechanical vibration or low-intensity electric currents
215152211|NCT07074119|DEVICE|wearable-based adjustment therapy|"* Patients will wear the BWS for 7 days prior to each of the visit : baseline (V1) at week 0, V2 at week 4 (phone call at 1 month), V3 at week 12 (3 months visit) and V4 at week 24 (6 months).~* Data extracted from each session of monitoring with the BWS will be made available to the neurologist (only in the experimental group) prior to V1 (W0), V2 (W4), V3 (W12) and V4 (W24) respectively~* Treatment adjustment will be guided by the current consensus guidelines for treatment adjustment for motor fluctuations in PD using reports from BWS data. Reports will be screened by neurologists before the patient's visit so the groups blinding is correctly observed"
214533757|NCT00000701|DRUG|Zidovudine|
214533758|NCT01580007|DRUG|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
214533759|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
214533760|NCT01580007|DRUG|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
214695937|NCT03615469|DEVICE|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
215152212|NCT07074418|DRUG|Empagliflozin 10 MG then Placebo|Taking Empagliflozin first
215152213|NCT07074418|DRUG|Placebo then Empagliflozin 10 MG|Taking the Empagliflozin in second
215152214|NCT07074613|DEVICE|Traditional Treadmill Walking|Participants walked on a traditional treadmill with standard time, speed, and distance tracking, no AR features.
215152215|NCT07074613|DEVICE|JOHNSON 8.1T treadmill with Passport AR system|Participants walked on an AR-integrated treadmill with immersive virtual environments and real-time feedback.
214533761|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
214533762|NCT02574949|RADIATION|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
214533763|NCT02574949|RADIATION|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
214533764|NCT02574949|RADIATION|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
214533765|NCT04998097|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
214533766|NCT04998097|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
214533767|NCT03510377|OTHER|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
214533768|NCT03510377|OTHER|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
214533769|NCT03510377|OTHER|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
215152216|NCT07075042|DEVICE|Training with PRC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
215152217|NCT07075042|DEVICE|Training with DC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
215152218|NCT07075042|DEVICE|PRC Device use in community and home|After the training sessions, all subjects will use the PRC device in their homes, just in a different order.
215152219|NCT07075042|DEVICE|DC Device use in community and home|After the training sessions, all subjects will use the DC device in their homes, just in a different order
215152220|NCT07075952|BEHAVIORAL|Food-specific inhibitory control training delivered through the FoodTraining App|"Participants will complete one training session per day for the first week and three sessions per week for the following three weeks (4 weeks in total). Each session lasts about 5 minutes and includes 3 blocks of stimuli presentation. In each block, 32 images (8 low-energy-dense foods, 8 high-energy-dense foods, 16 neutral objects) are presented for 1500ms with a 500ms interstimulus interval. One-hundred ms after the image presentation, a red or green circle appears. Participants will have to tap the image when a green circle appears (go trials) and inhibit a response when a red circle appears (no-go trials). Low-energy-dense foods are always paired with go trials, high-energy-dense foods with no-go trials, and neutral objects with either go or no-go trials. After each block, participants receive feedback on mean accuracy and reaction time. Participants can personalise the training by selecting up to three categories of high-energy-dense foods to include."
215152221|NCT07075952|BEHAVIORAL|Waiting list|Participants allocated to the control condition will not have access to the FoodTraining App during the active phase of the study (8 weeks), but will be offered the opportunity to access the app at the end of the 8-week follow-up period. This ensures that all participants, regardless of group allocation, will have the chance to benefit from the intervention once data collection is complete.
215152222|NCT07073911|BEHAVIORAL|Exercise|Les Mills Thrive is a 45-minute class that consists of flexibility, strength, and coordination exercises. This program aims to improve sensorimotor control and strength via functional weight-bearing exercises and floor exercises to isolate targeted hip and core muscles. In each class (whether in person or online), a certified Les Mills Thrive instructor will provide options to either increase or decrease the intensity of each exercise to cater to varying fitness levels and fluctuating symptoms. Each exercise has an assisted (using a chair for balance), body weight, and resisted (weight or exercise tubing) option. Participants will have the option to attend group fitness classes or do the classes asynchronously at home using a link to access a recorded class.
215152223|NCT07075939|OTHER|No Intervention: Observational Cohort|Observational data collection only
215152224|NCT07074548|DIETARY_SUPPLEMENT|Placebo|Placebo oral capsule identical in appearance to hydroxytyrosol supplement, administered once daily for 4 weeks.
215152225|NCT07074548|DIETARY_SUPPLEMENT|Hydroxytyrosol|Hydroxytyrosol is a natural polyphenol with antioxidant and anti-inflammatory properties, derived from olives. In this study, hydroxytyrosol 10 mg will be administered orally once daily for 4 weeks to assess its effects on blood pressure and inflammatory biomarkers in hypertensive pregnant women.
215152226|NCT07074912|OTHER|Prescription for weight-based dosing of antipyretic|The intervention group (n=220) will receive prescription with weight-based dosing for acetaminophen (also prescribed and known as Tylenol) and ibuprofen (also prescribed and known as Motrin).
215152227|NCT07074912|OTHER|Standard discharge instructions|The control group (n=220) will also receive standardized printed discharge instructions but no prescription. The discharge instructions include the appropriate dose of acetaminophen (also known as Tylenol) and ibuprofen (also known as Motrin).
214533770|NCT00865813|PROCEDURE|Punch Biopsy|"1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
215152228|NCT07074626|OTHER|transrectal ultrasound|"A- Complete history was taking (personal, past, medical, surgical and family history) with careful attention to abdominal examination and suspected cause of pelvic pathology B- Through physical examination (general and abdominal examination). C- Investigations.~* Trans-rectal ultrasound will be conducted to all the virgin patients as the standard US examination to detect the pelvic pathology~* Patient anticipation for pain will be documented before the exam according to pain visual analogue scale (VAS)~* Lidocaine gel will be used on the probe during TRU~* The intensity of pain during trans-rectal US based on the pain visual analogue scale (0-10 ) points and the adverse events like extreme pain, inability to complete the examination and inability to detect the pathology will be reported.A Visual Analogue Scale (VAS) is one of the valided pain rating scales used for the first time in 1921 by Hayes and Patterson."
215152229|NCT07075458|BEHAVIORAL|Magic Rope Trick|Children will be distracted using a magic rope trick during local anesthesia administration.
215152230|NCT07075458|BEHAVIORAL|Magic Thumb Sleeves|Children will be distracted using light-up magic thumb sleeves during local anesthesia administration
215152231|NCT07075458|BEHAVIORAL|Tell-Show-Do (TSD)|Children will receive the conventional Tell-Show-Do behavior management technique during local anesthesia administration
215152232|NCT07075003|DEVICE|nociceptive level|remifentanil infusion dose adjustment according to the changes of nociceptive level
215152233|NCT07074808|DEVICE|aiTriage risk score|Risk score generated by AI App aiTriage for chest pain patients
215152234|NCT07076017|BEHAVIORAL|Dry-land strength and conditioning programme|Participants in the experiment group will be asked to complete two supervised gym sessions per week for 10 weeks. Each session will include a variety of plyometric and strength exercises, selected for their relevance to start and turn performance in swimming.
215152235|NCT07076017|BEHAVIORAL|Active control condition|The control group will complete their usual swimming training which comprises of several pool-based session and one land-based session each week.
215152236|NCT07075692|OTHER|Physiotherapy|Physiotherapy program will include patient education, lifestyle recommendations (fluid intake, diet, correct urination/defecation position, weight control, etc.), breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks
215152237|NCT07074600|DEVICE|Electroacupuncture Therapy|Participants in the experimental group will receive daily electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Acupoint selection will target anatomical domains spanning the cranial, upper limb, and lower limb regions.
215152238|NCT07074600|DEVICE|Sham electroacupuncture intervention|Participants in the control group will receive daily sham electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Sham electroacupuncture procedures will target non-acupoint locations outside recognized cranial, upper limb, and lower limb anatomical domains.
215152239|NCT06857240|DRUG|Ruxolitinib Topical Cream|1.5% cream
215152240|NCT06002724|OTHER||
215152241|NCT05153694|PROCEDURE|Cystectomy|Removal of the urinary bladder
214533771|NCT02728375|OTHER|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
214695938|NCT01925859|DRUG|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
215152242|NCT05784844|DRUG|Meropenem|Carbapenem antibiotic
215152243|NCT05784844|DRUG|Micafungin|Echinocandin antifungal
215152244|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
215152245|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
215152246|NCT05141890|DIETARY_SUPPLEMENT|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
215152247|NCT04748354|BEHAVIORAL|Otago Exercise Program|An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
214695939|NCT04041388|OTHER|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
215152248|NCT04748354|OTHER|Usual Care|Clinical care provided by a geriatrician.
215152249|NCT00456859|DRUG|Kremezin|
214533772|NCT02728375|OTHER|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
214533773|NCT04677933|DRUG|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
214533774|NCT04677933|DRUG|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
215152250|NCT05868434|PROCEDURE|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
215152251|NCT01937832|DRUG|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
215152252|NCT01937832|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
215152253|NCT05012384|OTHER|Vergence exercises (Orthoptic exercises)|Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)
215152254|NCT05012384|GENETIC|Placebo|Generic management plan with non-visual elements
215152255|NCT01378585|DRUG|DLBS1033|3 x 490 mg DLBS1033 daily
215152256|NCT01378585|DRUG|Placebo|3 x 1 tablet daily
215152257|NCT00532610|DRUG|GSK189075|
215152258|NCT04953728|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
215152259|NCT00458172|BEHAVIORAL|Assessment of beliefs and attitudes|
215152260|NCT02462135|BEHAVIORAL|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
215152261|NCT02462135|BEHAVIORAL|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
215152262|NCT00056069|OTHER|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
214533775|NCT04677933|DRUG|C: Placebo|10 patients will receive Placebo BIW
214533776|NCT03462498|DRUG|1-months DAPT|1-month DAPT followed by 59-month monotherapy
214533777|NCT03462498|DRUG|12-month DAPT|12-month DAPT followed by 48-month monotherapy
214533778|NCT01311414|DRUG|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
214533779|NCT05742659|OTHER|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
214533780|NCT01558778|PROCEDURE|management of therapy complications|Undergo mechanical stimulation
214533781|NCT01558778|PROCEDURE|musculoskeletal complications management/prevention|Undergo mechanical stimulation
215152263|NCT01136980|DEVICE|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
215152264|NCT01136980|OTHER|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
215152265|NCT02923297|OTHER|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
215152266|NCT02103673|DRUG|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
215152267|NCT02103673|DRUG|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
214533782|NCT03756922|DRUG|FDL169|CFTR corrector
214533783|NCT03756922|DRUG|FDL176|CFTR potentiator
214533784|NCT03557450|DEVICE|PET/CT Scan|PET/CT scanning with sodium fluoride
215152268|NCT04070872|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
215152269|NCT04070872|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
214533785|NCT00941109|DRUG|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
214533786|NCT00941109|DRUG|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
214533787|NCT00941109|DRUG|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
214533788|NCT00941109|DRUG|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
214533789|NCT01744756|DRUG|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
214533790|NCT02535962|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
214695940|NCT01153763|DRUG|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
214695941|NCT05942937|OTHER|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
214695942|NCT06297343|PROCEDURE|Creation of an arteriovenous fistula|Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.
214695943|NCT01707212|BEHAVIORAL|Pain management education|Education about pain management during infant immunization
215152270|NCT01512511|PROCEDURE|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
214695944|NCT01707212|BEHAVIORAL|No pain management education|Control - no education about pain management during infant immunization
214695945|NCT04371172|OTHER|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
214695946|NCT02402218|OTHER|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
214695947|NCT02402218|OTHER|Usual care plus incentives|Participants are given incentives after completing treatment goals.
215152271|NCT02554461|OTHER|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
215152272|NCT01685515|DRUG|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
215152273|NCT01685515|DRUG|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
215152274|NCT05932667|DRUG|Milademetan|The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
214695948|NCT02402218|OTHER|Usual Care|Participants receive standard of care in the clinic from their health care team.
214695949|NCT03572270|DIAGNOSTIC_TEST|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
214533791|NCT02535962|OTHER|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
214533792|NCT06183827|PROCEDURE|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
214533793|NCT00614588|DEVICE|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
214533794|NCT03577925|DIAGNOSTIC_TEST|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
214533795|NCT00564252|DRUG|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
214533796|NCT05092776|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
214533797|NCT05092776|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
214533798|NCT05449847|BIOLOGICAL|Blood Sampling|Blood sampling under a complete aseptic conditions
214533799|NCT01961921|DRUG|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
215152275|NCT05932667|BEHAVIORAL|Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)|Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
215152276|NCT05536596|PROCEDURE|Orthognathic Surgery|Prognathism/Retrognathism correction through surgical procedures
215152277|NCT05536596|DRUG|Melatonin 10 MG Oral Tablet|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
215152278|NCT05536596|DRUG|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
215152279|NCT05536596|DRUG|Centrum|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneuron). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
214533800|NCT01673295|DRUG|RTX infusions|RTX + Standard of Care
214533801|NCT01673295|OTHER|Standard of Care|Standard of Care only
214533802|NCT00075283|DEVICE|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
214533803|NCT02362347|DEVICE|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
214533804|NCT02362347|OTHER|exercise|exercise
214533805|NCT03023852|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
214533806|NCT03023852|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
214533807|NCT03416621|BEHAVIORAL|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
214533808|NCT03416621|BEHAVIORAL|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
214533809|NCT03416621|DRUG|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
214533810|NCT02388113|BEHAVIORAL|accumulated exercise|
214695950|NCT03572270|DIAGNOSTIC_TEST|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
215152280|NCT02105662|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
215152281|NCT02997241|BIOLOGICAL|OncoCare|Personalized monitoring
215152282|NCT02997241|DRUG|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
215152283|NCT01915836|OTHER|web-based video game (Quit IT)|
215152284|NCT01915836|BEHAVIORAL|Questionnaires|
214533811|NCT02388113|BEHAVIORAL|traditional exercise|
214533812|NCT04761341|DRUG|NUTROF TOTAL|1 per day over a course of 3 months
214533813|NCT03618836|OTHER|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
215152285|NCT01915836|BEHAVIORAL|Evaluation Interview|
215152286|NCT02109185|DRUG|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
215152287|NCT02109185|DRUG|Nasonex® Nasal Spray, 50 μg/actuation|
215152288|NCT02109185|DRUG|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
214533814|NCT01281917|DRUG|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
214533815|NCT01281917|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
214533816|NCT00120822|DRUG|Folic acid|
214533817|NCT05866341|DIETARY_SUPPLEMENT|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
214533818|NCT05866341|DIETARY_SUPPLEMENT|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
214533819|NCT00096109|DRUG|tanespimycin|Given IV
214533820|NCT00096109|OTHER|laboratory biomarker analysis|Correlative studies
214533821|NCT04647318|BEHAVIORAL|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
214533822|NCT03598725|DRUG|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
214695951|NCT02496637|BEHAVIORAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
214695952|NCT02496637|BEHAVIORAL|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
214695953|NCT01291329|GENETIC|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
215152289|NCT02109185|DRUG|Placebo Nasal Spray, 50 μL/actuation|
215152290|NCT02331277|DRUG|BI 655064|subcutaneous injection
215152291|NCT02331277|DRUG|Placebo|Placebo
215152292|NCT03240549|DRUG|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
215152293|NCT03978117|DIETARY_SUPPLEMENT|Freeze Dried Watercress Preparation|Freeze dried watercress containing gluconasturtiin, which when added to provided water with flavor powder, will result in a total target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
215152294|NCT03978117|DIETARY_SUPPLEMENT|Placebo Preparation|Maltodextrin added to provided water with flavor powder. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
215152295|NCT03967353|BEHAVIORAL|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
215152296|NCT04375085|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
214533823|NCT03598725|DRUG|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
215152297|NCT02707822|OTHER|Clinical and genetic factors|
215152298|NCT00990704|DRUG|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
215152299|NCT00990704|DRUG|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
215152300|NCT02409277|OTHER|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
214533824|NCT03598725|DRUG|Rituximab|375mg/Square meter for consecutive 4 months
214533825|NCT00646711|DRUG|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
214533826|NCT00646711|DRUG|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
214533827|NCT01187407|DRUG|LY2216684|
214533828|NCT01187407|DRUG|Placebo|
214533829|NCT01187407|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
214533830|NCT06245161|DEVICE|Quicksleeper5|intraosseous anesthesia for dental treatment
214533831|NCT06245161|DEVICE|conventional anesthesia|inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
214533832|NCT04491084|DRUG|FLT3 Ligand (CDX-301)|Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.
214695954|NCT02334332|OTHER|Educational Intervention|Receive educational brochure
214695955|NCT02334332|PROCEDURE|Standard Follow-Up Care|Receive standard post-operative care
214695956|NCT02334332|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
215152301|NCT03204734|DRUG|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
215152302|NCT03204734|DRUG|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
215152303|NCT03307876|OTHER|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
215152304|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
215152305|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
214533833|NCT04491084|BIOLOGICAL|anti-CD40 antibody (CDX-1140)|CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
215152306|NCT00913952|DRUG|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
215152307|NCT03993652|BEHAVIORAL|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
215152308|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - single dose
215152309|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - Single dose
215152310|NCT01872390|OTHER|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
215152311|NCT01872390|OTHER|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
215152312|NCT04675008|DRUG|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
215152313|NCT00560196|OTHER|Observation|
215152314|NCT05446818|DIETARY_SUPPLEMENT|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
215152315|NCT05446818|OTHER|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
215152316|NCT04670367|BEHAVIORAL|Walk 30mins|aerobic exercise
215152317|NCT04670367|BEHAVIORAL|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
215152318|NCT04670367|OTHER|usual care|routine care
215152319|NCT04670367|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
214533834|NCT04491084|RADIATION|SBRT|For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
215152320|NCT00641667|DRUG|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
215152321|NCT01235741|DRUG|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
215152322|NCT01235741|DRUG|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
215152323|NCT01794767|DRUG|0,9% NaCl flush|Normal Saline solution
215152324|NCT01794767|DRUG|Heparin 50U/ml|Heparin solution
215152325|NCT00538018|DRUG|Telithromycin|
215152326|NCT03679507|PROCEDURE|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
214533835|NCT02873325|OTHER|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
215152327|NCT03679507|OTHER|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
215152328|NCT05885399|DRUG|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
215152329|NCT04141904|DRUG|Tofacitinib 5 MG [Xeljanz]|Tofacitinib 5mg capsules twice a day for 7-10 days
215152330|NCT04141904|OTHER|Placebo|Placebo capsules twice a day for 7-10 days
215152331|NCT00451633|DRUG|E2007|
215152332|NCT06168448|OTHER|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
215152333|NCT06168448|OTHER|Video information|Explanatory video applied after physician's formal information
215152334|NCT00809302|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
215152335|NCT01795170|DIETARY_SUPPLEMENT|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
215152336|NCT01795170|DRUG|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
215152337|NCT01106690|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
215152338|NCT01106690|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
215152339|NCT01106690|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
215152340|NCT01106690|DRUG|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
215152341|NCT01106690|DRUG|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
215152342|NCT00506974|DRUG|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
215152343|NCT00489658|DRUG|Eflornithine plus Nifurtimox combination therapy|
215152344|NCT00042315|PROCEDURE|Chemotherapy|
215152345|NCT00042315|DRUG|tariquidar + vinorelbine|
215152346|NCT00042315|DRUG|placebo + vinorelbine|
214533836|NCT04878575|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
214533837|NCT04878575|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
214695957|NCT05005741|DRUG|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
215152347|NCT05847816|OTHER|Experimental group: infrared vascular imaging|"Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin."
215152348|NCT00004114|BIOLOGICAL|filgrastim|
215152349|NCT00004114|DRUG|cyclophosphamide|
215152350|NCT00004114|DRUG|cytarabine|
215152351|NCT00004114|DRUG|fludarabine phosphate|
215152352|NCT00004114|PROCEDURE|peripheral blood stem cell transplantation|
215152353|NCT00218218|DRUG|Transdermal Nicotine Patch|42 mg transdermal nicotine
215152354|NCT00218218|DRUG|21 mg transdermal nicotine|
215152355|NCT00218218|DRUG|placebo patch|
214533838|NCT00504413|DRUG|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
214533839|NCT00504413|DRUG|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
214533840|NCT00504413|DRUG|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
214533841|NCT00003478|PROCEDURE|conventional surgery|
215152356|NCT05615038|PROCEDURE|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
215152357|NCT05615038|PROCEDURE|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
215152358|NCT03292601|DEVICE|NYRC Brace Scoliosis Monitor|Scoliosis Monitor is a system that allows the continuous monitoring of the scoliosis brace use compliance and posture. This product includes a brace wearable that enables the monitoring of the scoliosis brace. The wearable device is able to communicate with a companion mobile application which stores and processes the collected data and is responsible for data synchronization.
215152359|NCT00675272|DRUG|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
215152360|NCT00675272|DRUG|sodium chloride|sodium chloride every 6 hours iv
215152361|NCT02863419|DRUG|semaglutide|Oral semaglutide once-daily.
215152362|NCT02863419|DRUG|liraglutide|Subcutaneous (s.c.) injection once-daily.
215152363|NCT02863419|DRUG|placebo|Placebo once-daily.
215152364|NCT01371357|DRUG|TEST 1|2.4 g/day of guanidinoacetic acid
215152365|NCT01371357|DRUG|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
215152366|NCT01371357|DRUG|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
215152367|NCT01371357|DRUG|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
215152368|NCT02586298|OTHER|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
215152369|NCT02586298|OTHER|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
215152370|NCT05682196|DRUG|Rituximab added to standard of care treatment|Rituximab with standard of care treatment
215152371|NCT05682196|DRUG|standard of care treatment alone|Standard of care treatment alone
215152372|NCT05846854|OTHER|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
215152373|NCT03645720|DEVICE|Plastic cannula|puncture using plastic cannula
215152374|NCT05824780|OTHER|Exercise training|4-week weightlifting strength training
215152375|NCT01924949|DRUG|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
215152376|NCT03805152|DRUG|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
215152377|NCT03805152|DRUG|Dysport (R)|Intramuscular injection
215152378|NCT06096961|BEHAVIORAL|Baby smell|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process.
215152379|NCT05585450|DEVICE|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
215152380|NCT05585450|DEVICE|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
215152381|NCT02217202|DEVICE|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
215152382|NCT03863158|OTHER|No intervention|No intervention / medical records only
215152383|NCT00757302|DEVICE|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
215152384|NCT02722993|DIETARY_SUPPLEMENT|Probiotics|
215152385|NCT02722993|DIETARY_SUPPLEMENT|Placebo|
214695958|NCT05005741|DRUG|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
214533842|NCT00003478|RADIATION|iodine I 131 monoclonal antibody 81C6|
214533843|NCT00003478|RADIATION|radiation therapy|
214695959|NCT00321100|DRUG|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
214533844|NCT03951012|PROCEDURE|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
214533845|NCT05725733|OTHER|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
214695960|NCT00321100|DRUG|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
215152386|NCT04193995|BEHAVIORAL|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
215152387|NCT00831480|DRUG|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
215152388|NCT03332706|OTHER|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
215152389|NCT01662570|BEHAVIORAL|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
215152390|NCT01662570|OTHER|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
215152391|NCT02590224|DRUG|Ferrous bis-glycinate|
215152392|NCT02590224|DRUG|Ferrous glycine sulphate|
215152393|NCT03674853|DRUG|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
215152394|NCT03674853|DRUG|Oryzanol|take oryzanol in active comparator group for 2 months
215152395|NCT03066947|BIOLOGICAL|SV-BR-1-GM|See above
215152396|NCT03066947|DRUG|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
215152397|NCT03066947|BIOLOGICAL|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
214463221|NCT06777888|BEHAVIORAL|Family Healthy Living Program weekly group sessions|Children aged 8-12 and at least one caregiver will meet for 9 weekly virtual group intervention sessions (2 hours per session) with program facilitators and will also have access to a virtual Q and A session and up to 3 virtual cooking classes with a Registered Dietician. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions.
214463222|NCT06777888|BEHAVIORAL|Self-guided Web Portal Resources Only|Children aged 8-12 and at least one caregiver will be offered access to digital educational content and downloadable resources on topics such as physical activity, healthy eating, and positive mental well-being.
214463223|NCT06349642|PROCEDURE|Biospecimen Collection|Undergo optional research blood sample.
214533846|NCT06162065|DRUG|Oxybutynin Pill|pharmacological antimuscarinic treatment
214533847|NCT06162065|DIETARY_SUPPLEMENT|Boldo supplement|treatment supplemented with boldo
214533848|NCT01728688|OTHER|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
214533849|NCT01728688|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
214533850|NCT02879799|OTHER|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
214533851|NCT02949076|BEHAVIORAL|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
214695961|NCT00321100|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
214695962|NCT00321100|DRUG|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
214695963|NCT03029416|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
214695964|NCT01606592|BEHAVIORAL|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
214695965|NCT01606592|BEHAVIORAL|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
214463224|NCT06349642|PROCEDURE|Tissue Collection|Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\&#39;t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.
215152398|NCT01904994|PROCEDURE|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
215152399|NCT01904994|PROCEDURE|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
215152400|NCT01904994|BEHAVIORAL|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
215152401|NCT01904994|BEHAVIORAL|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
215152402|NCT01904994|OTHER|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
215152403|NCT02717923|OTHER|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
215152404|NCT02670096|DRUG|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
215152405|NCT01915589|DRUG|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
215152406|NCT00002127|DRUG|Thalidomide|
215152407|NCT00070967|PROCEDURE|Acupuncture|
214463225|NCT03257462|DRUG|SPR001|SPR001 Capsules
214463226|NCT04625465|BEHAVIORAL|CBT Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
214463227|NCT04625465|BEHAVIORAL|Attention Control Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
215152408|NCT04663009|DEVICE|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
215152409|NCT01059435|DRUG|Romosozumab|Administered subcutaneously or intravenously
214533852|NCT01068106|DEVICE|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
214533853|NCT01068106|DEVICE|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
215152410|NCT01059435|DRUG|Placebo|Administered subcutaneously or intravenously
215152411|NCT03228225|BEHAVIORAL|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
215152412|NCT02660372|DRUG|Imonogas|Simethicone 120 mg in gel capsules
215152413|NCT02660372|DRUG|Espumisan|Simethicone 40 mg in gel capsules
215152414|NCT03677557|DRUG|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
215152415|NCT02988895|RADIATION|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
215152416|NCT04491318|OTHER|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
215152417|NCT02531672|DRUG|11C-choline|
215152418|NCT02531672|DEVICE|PET/CT Scan|
215152419|NCT04550884|DIAGNOSTIC_TEST|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
215152420|NCT05369741|OTHER|TIME™ at Home|"Components of each 1.5-hour session:~1. Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~2. Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~3. Post-class social time (15 min): Structured and unstructured social interactions~4. Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~5. Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
215152421|NCT05445791|DRUG|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
215152422|NCT05445791|OTHER|Placebo|Placebo 500 mg twice daily until disease progression
215152423|NCT03524976|DEVICE|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
215152424|NCT00491634|DRUG|treosulfan|12 g/m2 x 3 days
215152425|NCT00491634|DRUG|Treosulfan|12 g/m2 x 3
215152426|NCT02889952|DEVICE|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
215152427|NCT05103137|OTHER|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
215152428|NCT05133310|DRUG|Simvastatin|Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
215152429|NCT02454517|BEHAVIORAL|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
215152430|NCT02454517|BEHAVIORAL|Exercise Intervention|Undergo DPP lifestyle intervention
215152431|NCT02454517|OTHER|Informational Intervention|Receive oral and written guidelines and meet with dietician
215152432|NCT02454517|OTHER|Laboratory Biomarker Analysis|Correlative studies
215152433|NCT02454517|OTHER|Quality-of-Life Assessment|Ancillary studies
215152434|NCT02454517|OTHER|Questionnaire Administration|Ancillary studies
215152435|NCT00809952|PROCEDURE|recombinant FSH|
215152436|NCT03109496|OTHER|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
215152437|NCT04641182|OTHER|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
215152438|NCT06232824|BEHAVIORAL|Tele-rehabilitation|The whole program is constituted of preoperative education and postoperative rehabilitation (in hospital and out of hospital). All the participants received the same preoperative education through the mobile phone application and oral communication. Participants in the intervention group get the multicomponent supervised tele-rehabilitation, while participants in the control group get the home-based self-rehabilitation. All the postoperative rehabilitation programs are presented and executed through the mobile phone application.
214695966|NCT01606592|OTHER|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
214695967|NCT01201096|RADIATION|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
214695968|NCT01201096|PROCEDURE|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
215152439|NCT04943653|DRUG|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
214695969|NCT04561635|DIETARY_SUPPLEMENT|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
215152440|NCT03319147|DIETARY_SUPPLEMENT|Active|4g of essential amino acids
215152441|NCT03319147|DIETARY_SUPPLEMENT|Placebo|4g of maltdextrin
215152442|NCT03849508|DRUG|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
215152443|NCT03849508|DRUG|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
215152444|NCT00473382|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
215152445|NCT00473382|DRUG|Sham injection|
214463228|NCT05986240|DRUG|Danvatirsen|Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
214463229|NCT05986240|COMBINATION_PRODUCT|Danvatirsen + Venetoclax|"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
215152446|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
215152447|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
215152448|NCT01019083|OTHER|Control|Control will be selected from the Arsenic non contaminated Area
215152449|NCT01019083|DRUG|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
214463230|NCT04501614|DRUG|Ponatinib|Ponatinib tablets.
214463231|NCT04501614|DRUG|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
214463232|NCT04221451|DRUG|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
214463233|NCT04221451|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214463234|NCT05881278|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
214463235|NCT04708145|DRUG|Aflibercept Injection|Intravitreal 2mg aflibercept injection
214463236|NCT06283589|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
214463237|NCT05566639|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214463238|NCT05566639|BIOLOGICAL|Fluarix Quadrivalent|Sterile suspension for injection.
214463239|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
214463240|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
214463241|NCT04818645|DEVICE|ASSERT Insertable Cardiac Monitor|Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
214463242|NCT04818645|OTHER|Conventional Management and monitoring|Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
214463243|NCT03819933|BEHAVIORAL|Educational intervention|Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
214463244|NCT03576365|BEHAVIORAL|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
214695970|NCT00330720|DEVICE|Emergency Response System (Device)|
214695971|NCT04413435|OTHER|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
215152450|NCT01019083|DRUG|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
215152451|NCT01019083|OTHER|Arsenic|Participant will be selected from the Arsenic Contaminated Area
215152452|NCT01189032|DRUG|DE-089 ophthalmic solution|
215152453|NCT01189032|DRUG|DE-089 ophthalmic solution|
214533854|NCT04082377|PROCEDURE|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
214533855|NCT04082377|PROCEDURE|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
214533856|NCT01395706|PROCEDURE|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
214533857|NCT02264717|PROCEDURE|SPECT|Patients are randomized to either SPECT or Cardiac MRI
214533858|NCT02264717|PROCEDURE|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
214533859|NCT00776984|DRUG|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
215152454|NCT01189032|DRUG|Placebo ophthalmic solution|
215152455|NCT00503815|DRUG|BLI-800|
215152456|NCT00503815|DRUG|Polyethylene glycol 3350 based bowel preparation|
215152457|NCT04924881|DRUG|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
215152458|NCT04924881|OTHER|Placebo granules|Placebo granules once daily for 8 weeks
215152459|NCT04365608|PROCEDURE|Direct laryngoscopy|standard laryngoscope with Macintosh blade
215152460|NCT04365608|PROCEDURE|Vie Scope laryngoscopy|Vie Scope with dedicated bougie stylet
215152461|NCT02476461|DRUG|xiapex|
215152462|NCT02476461|PROCEDURE|percutaneous needle fasciotomy|
215152463|NCT01470326|DRUG|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
215152464|NCT01980667|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
215152465|NCT01980667|DRUG|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
215152466|NCT02196636|DRUG|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
215152467|NCT02196636|DRUG|RO6806127|Administered orally with approximately 240 mL of buffer
215152468|NCT05357248|DEVICE|BT-NCBT-00X|the intervention group will consist of 20 patients to receive the BT-NCBT-00X treatment for 90 days. They will receive a baseline MRI-PDFF, Fibroscan and have the tests repeated at 90 days.
215152469|NCT05153096|DRUG|NBL-015|NBL-015 by intravenous infusion
215152470|NCT01166282|BIOLOGICAL|adalimumab|Adalimumab solution for subcutaneous injection.
215152471|NCT01166282|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
215152472|NCT05417919|OTHER|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
215152473|NCT03311243|PROCEDURE|Non surgical periodontal therapy|
215152474|NCT03311243|DRUG|Chemical plaque control|
215152475|NCT02849899|DRUG|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
215152476|NCT02849899|DRUG|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
215152477|NCT00863226|DEVICE|Resonator Device|Application of Magnetic Fields Using the Resonator Device
215152478|NCT02577718|DRUG|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
215152479|NCT02559375|OTHER|Survey|
215152480|NCT00787358|DRUG|ZT-031|80 ul subcutaneous injection per day
215152481|NCT00787358|OTHER|placebo|80 ul daily subcutaneous injection of vehicle only
215152482|NCT01995838|DRUG|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
215152483|NCT01995838|DRUG|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
215152484|NCT04587427|DRUG|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
215152485|NCT04666220|OTHER|VETC evaluation|We will evaluate VETC presence on tissue specimens
215152486|NCT03903406|DRUG|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
215152487|NCT05423561|PROCEDURE|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
215152488|NCT05902806|DIETARY_SUPPLEMENT|Upgraded tube feed|Total duration of study: 4 weeks; 1 week on current tube feed followed by 2 weeks on upgraded tube feed comparable in energy density and fiber content as their current tube feed. The tube feeding regimen is similar to pre study feeding regimen. There will then be a one week follow up period.
215152489|NCT04301804|DRUG|SHR6390|a selective small-molecule CDK4/6 inhibitor
215152490|NCT01967576|DRUG|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
215152491|NCT05611320|OTHER|Awareness campaign - communications campaign|"How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well."
215152492|NCT05611320|OTHER|Online shopping|Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
215152493|NCT00768456|DRUG|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
215152494|NCT00768456|DRUG|Isotonic NaCl|Local Infiltration with NaCl
214695972|NCT00563836|DRUG|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
215152495|NCT00992472|DRUG|Prochlorperazine suppositories, 25mg|
215152496|NCT00992472|DRUG|Compazine® suppositories, 25mg|
215152497|NCT04254172|DEVICE|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
215152498|NCT00400972|DEVICE|GlideScope videolaryngoscope|
215152499|NCT02902289|DRUG|Ibuprofen 200 mg/5 mL oral suspension|
215152500|NCT02902289|DRUG|MOMENT 200 mg coated tablet|
215152501|NCT06012552|DRUG|Tianeptine|Tianesal 12,5mg
215152502|NCT06012552|DRUG|Placebo|application as in the control group
215152503|NCT01437566|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
215152504|NCT01437566|DRUG|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
215152505|NCT01437566|DRUG|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
215152506|NCT01437566|DRUG|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
214463245|NCT03576365|BEHAVIORAL|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
214695973|NCT04435145|BEHAVIORAL|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
214695974|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
215152507|NCT01437566|DRUG|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
215152508|NCT01302249|DRUG|Latanoprost 0.005%|q.d.
215152509|NCT01302249|DRUG|AR-12286 Ophthalmic Solution 0.5%|
215152510|NCT01302249|DRUG|Timolol maleate ophthalmic solution 0.5%|
215152511|NCT05119361|OTHER|Early Dry protocol|"After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours."
215152512|NCT06284135|OTHER|Michl-stitch|In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
214533860|NCT00776984|DRUG|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
215152513|NCT05465577|OTHER|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
215152514|NCT00409734|BEHAVIORAL|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
215152515|NCT00409734|BEHAVIORAL|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
215152516|NCT03449667|DEVICE|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
215152517|NCT03449667|DEVICE|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
215152518|NCT06035757|DRUG|Bridion 200 MG in 2 ML Injection|Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
215152519|NCT06035757|DRUG|Pyridostigmine Bromide 5 MG/ML|Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
215152520|NCT03515330|OTHER|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
215152521|NCT04651062|DEVICE|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
214533861|NCT00006137|DRUG|enalapril|
215152522|NCT04651062|PROCEDURE|no endocuff|colonoscopy is performed without endocuff.
215152523|NCT05654818|DRUG|Vitamin D|100,000 UI
215152524|NCT05654818|DRUG|Placebo|The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
215152525|NCT04084691|OTHER|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
215152526|NCT04084691|OTHER|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
215152527|NCT04084691|OTHER|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
215152528|NCT04084691|OTHER|Normal meal|\- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
215152529|NCT04084691|OTHER|Normalized meal|"\- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
215152530|NCT04084691|OTHER|Fasting|non meal in the hour before exercise
215152531|NCT02760953|PROCEDURE|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
215152532|NCT02760953|DRUG|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
214533862|NCT01971034|DRUG|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
215152533|NCT03444636|DRUG|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
215152534|NCT03444636|DRUG|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
215152535|NCT00380367|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
214533863|NCT01971034|DRUG|Metformin|850mg, PO, every 8 hours, daily.
214533864|NCT02672137|BEHAVIORAL|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
214533865|NCT02686671|OTHER|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
214695975|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
214695976|NCT04840992|BIOLOGICAL|Placebo for Inhalation|Aerogen Solo
215152536|NCT03281200|DRUG|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
215152537|NCT03281200|DRUG|L01 - Antineoplastic agents|L01 - Antineoplastic agents
215152538|NCT03281200|DRUG|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
215152539|NCT03281200|DRUG|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
215152540|NCT03281200|DRUG|L01XE31 - Nintedanib|L01XE31 - Nintedanib
215152541|NCT00473096|BEHAVIORAL|Informed breast cancer surgical treatment|
215152542|NCT00225732|OTHER|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
215152543|NCT00225732|DRUG|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
215152544|NCT00392769|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
214533866|NCT04383834|DEVICE|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
214533867|NCT01309113|DRUG|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
214533868|NCT03852875|OTHER|Education|Same
214533869|NCT03852875|OTHER|Control|Same
214533870|NCT03644784|DIAGNOSTIC_TEST|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
214533871|NCT03524547|DEVICE|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
214533872|NCT03524547|DEVICE|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
214533873|NCT03709316|DRUG|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
215152545|NCT04601649|BEHAVIORAL|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
215152546|NCT05109143|DRUG|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
214533874|NCT03709316|DRUG|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
214533875|NCT03083093|DIAGNOSTIC_TEST|The initial CTPA will be reviewed|The initial CTPA will be reviewed
214533876|NCT04369300|BEHAVIORAL|Registery Data Collection|Observational Data Collection
215152547|NCT05109143|OTHER|Standard Medical Treatment|Standard Medical Treatment
215152548|NCT01155518|DRUG|testosterone|intramuscular every 2 weeks
215152549|NCT01155518|DRUG|clomiphene|thrice a week
215152550|NCT01155518|DRUG|placebo|intramuscular saline injections every 2 weeks
215152551|NCT01155518|DRUG|placebo|oral
215152552|NCT04981990|PROCEDURE|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
215152553|NCT04981990|PROCEDURE|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
215152554|NCT00326859|DRUG|remifentanil|
215152555|NCT01641185|PROCEDURE|radiation|radiation with protons or carbon ions
215152556|NCT04319588|PROCEDURE|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
215152557|NCT04319588|PROCEDURE|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
215152558|NCT03397810|RADIATION|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
215152559|NCT05744817|BEHAVIORAL|Inspiratory muscle strength training|30 breaths/day against a set resistance
215152560|NCT06254885|PROCEDURE|Equi-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.
215152561|NCT06254885|PROCEDURE|Sub-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
215152562|NCT00210951|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
215152563|NCT04786717|OTHER|core muscle training|The intervention of this group will focus on training the endurance of the core muscle.
215152564|NCT04786717|OTHER|movement control training|Based from the initial test, the subjects will receive either lumbar flexion control exercise or lumbar extension control exercise. They will perform each lumbar movement control exercise in different position. Starting from the lying position, then progressing to sitting, standing with support, and the last level will be standing without support. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
215152565|NCT04786717|OTHER|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, so the subjects will not have any real movement, and the last 7 times they will perform the lumbar motor control exercise literally. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
215152566|NCT00867672|DRUG|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
215152567|NCT00867672|DRUG|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
215152568|NCT00867672|DRUG|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
215152569|NCT01574469|OTHER|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
215152570|NCT01574469|OTHER|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
214533877|NCT00806299|DRUG|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
214533878|NCT00806299|DRUG|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
214533879|NCT00806299|DRUG|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
214695977|NCT04840992|BIOLOGICAL|Placebo|Intramuscular administration
215152571|NCT01702649|DRUG|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
215152572|NCT01702649|DRUG|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
214533880|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
214533881|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
214533882|NCT02311985|OTHER|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
215152573|NCT04058964|BIOLOGICAL|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
215152574|NCT04058964|BIOLOGICAL|Pembrolizumab|Given IV
215152575|NCT00002002|DRUG|Trimethoprim|
214533883|NCT02311985|OTHER|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
214533884|NCT02311985|OTHER|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
215152576|NCT00002002|DRUG|Sulfamethoxazole|
214695978|NCT05253313|OTHER|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
215152577|NCT00002002|DRUG|Leucovorin calcium|
215152578|NCT02503761|DRUG|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
215152579|NCT05429957|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~* MET of the Iliopsoas~* MET of Piriformis muscle~* MET of Quadratus Lumborum muscle~* MET of Erector Spinae muscle"
215152580|NCT05429957|OTHER|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~* Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~* Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~* Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
214695979|NCT00480922|BEHAVIORAL|Low glycemic load diet|Outpatient behavioral counseling
215152581|NCT01850654|GENETIC|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
215152582|NCT01850654|GENETIC|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~* CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~* CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~* CRC study participants diagnosed with CRC \<50 years, regardless of tumor studies or family history~* CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
215152583|NCT01850654|BEHAVIORAL|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
214533885|NCT01570621|PROCEDURE|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
215152584|NCT01850654|OTHER|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
215152585|NCT01850654|BEHAVIORAL|Questionnaire|
215152586|NCT02644655|BIOLOGICAL|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
215152587|NCT03859934|DRUG|Melatonin|Melatonin treatment
215152588|NCT03859934|DRUG|Placebo Oral Tablet|Placebo treatment
215152589|NCT02864784|DRUG|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
215152590|NCT02864784|OTHER|Placebo|microcrystalline cellulose
215152591|NCT02426203|PROCEDURE|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
215152592|NCT02036814|BEHAVIORAL|Program Health Education|
215152593|NCT01736995|BEHAVIORAL|Functional Family Therapy|
215152594|NCT01736995|BEHAVIORAL|Motivational Enhancement Tx/Cognitive Behavioral Tx|
215152595|NCT01736995|BEHAVIORAL|Contingency Management|
215152596|NCT01885598|DRUG|Apixaban|
215152597|NCT01553968|OTHER|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
215152598|NCT00424684|PROCEDURE|collection of blood sample|
215152599|NCT06361069|OTHER|distraction cards, kaleidoscope and finger puppet|"A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions."
215152600|NCT04204889|DRUG|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
215152601|NCT05644158|PROCEDURE|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
215152602|NCT05644158|OTHER|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
215152603|NCT01342159|PROCEDURE|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
215152604|NCT02611583|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation
215152605|NCT05099952|PROCEDURE|Biospecimen Collection|Undergo collection of cheek cell and blood samples
215152606|NCT05099952|OTHER|Counseling|Meet with therapist
215152607|NCT05099952|OTHER|Educational Intervention|Participate in BBT-CI sessions
215152608|NCT05099952|OTHER|Electronic Health Record Review|Medical records are reviewed
215152609|NCT05099952|OTHER|Medical Device Usage and Evaluation|Wear actigraphy watch
215152610|NCT05099952|OTHER|Questionnaire Administration|Ancillary studies
215152611|NCT05950815|DRUG|CD73 Antigen|subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.
215152612|NCT02382432|DRUG|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
214533886|NCT00009789|RADIATION|accelerated conformational radiotherapy|
214533887|NCT04040283|PROCEDURE|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
214533888|NCT06039943|DEVICE|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
214695980|NCT00480922|BEHAVIORAL|Low fat diet|Outpatient behavioral counseling
215152613|NCT02382432|DRUG|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
214695981|NCT02366663|RADIATION|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
214695982|NCT02366663|DRUG|Carmustine|Given IV
214695983|NCT02366663|DRUG|Etoposide|Given IV
214695984|NCT02366663|DRUG|Cytarabine|Given IV
214695985|NCT02366663|DRUG|Melphalan|Given IV
215152614|NCT03511937|BEHAVIORAL|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
215152615|NCT03511937|OTHER|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
215152616|NCT01339143|DRUG|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
215152617|NCT01339143|DRUG|pioglitazone|15mg, QD, PO, 16 weeks
215152618|NCT03275649|OTHER|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
215152619|NCT01249079|OTHER|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
215152620|NCT00561509|DRUG|SSRIs|Use within normal clinical practice
215152621|NCT00561509|DRUG|Dual antidepressants|Use within clinical practice
215152622|NCT02768857|BEHAVIORAL|Sensorimotor reeducation programs|
215152623|NCT00060840|DRUG|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
215152624|NCT00060840|DRUG|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
215152625|NCT04148846|DRUG|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
215152626|NCT04148846|PROCEDURE|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
215152627|NCT04148846|DRUG|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
215152628|NCT04148846|DRUG|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
215152629|NCT04148846|DRUG|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
215152630|NCT04148846|DRUG|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
215152631|NCT04148846|DIETARY_SUPPLEMENT|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
215152632|NCT03783832|OTHER|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
215152633|NCT01655485|OTHER|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
214463246|NCT05437172|PROCEDURE|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
214533889|NCT05687318|DEVICE|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
215152634|NCT03339843|DRUG|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
215152635|NCT05380817|OTHER|Remote Monitoring Program|Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
215152636|NCT00553891|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
215152637|NCT00553891|DRUG|placebo nasal spray|One spray in each nostril once daily for 3 months.
215152638|NCT03570099|DRUG|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
215152639|NCT03570099|OTHER|Historical control cohort|Historical data will be retrieved from quality registries.
215152640|NCT01227993|DRUG|Finasteride|
215152641|NCT03710161|DRUG|Vitamin D|Vitamin D taken in two different dosages daily for six months.
214463247|NCT05437172|PROCEDURE|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
214533890|NCT02958813|BEHAVIORAL|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
214533891|NCT02958813|BEHAVIORAL|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
214533892|NCT01845558|DRUG|Wobenzym® plus|
214533893|NCT01845558|OTHER|Placebo|
214533894|NCT04559516|BEHAVIORAL|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
214533895|NCT04559516|BEHAVIORAL|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
214533896|NCT03298555|BEHAVIORAL|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
214533897|NCT01212484|DRUG|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
214695986|NCT02366663|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
214695987|NCT02366663|BIOLOGICAL|Rituximab|Given IV
214695988|NCT02062528|DIETARY_SUPPLEMENT|omega-3 fatty acids|highly dosed in EPA
215152642|NCT05459883|PROCEDURE|splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation
215152643|NCT00843219|PROCEDURE|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
214463248|NCT03498612|OTHER|Laboratory Biomarker Analysis|Correlative studies
214463249|NCT03498612|BIOLOGICAL|Pembrolizumab|Given IV
214463250|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
214463251|NCT04735458|OTHER|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
214463252|NCT06367296|OTHER|Prolonged resistance exercise training|"Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm."
214463253|NCT04114669|BEHAVIORAL|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
214463254|NCT04114669|BEHAVIORAL|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
214695989|NCT02062528|DIETARY_SUPPLEMENT|placebo|
215152644|NCT00518102|DRUG|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
215152645|NCT00518102|OTHER|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
215152646|NCT05637580|DRUG|Timing of drug administration|The effect of drug administration timing on tumor and lymph node responses was observed.
215152647|NCT03702283|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
215152648|NCT03532204|RADIATION|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
215152649|NCT03532204|DRUG|Chemotherapy|At investigator's discretion
215152650|NCT04615052|OTHER|Exercise training|A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
215152651|NCT02124993|OTHER|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
215152652|NCT00541385|DRUG|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
215152653|NCT00541385|DRUG|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
215152654|NCT06520293|OTHER|Sweet Beverage|A beverage containing different sweet ingredients.
215152655|NCT06344962|DEVICE|Absorbable Suture|3-0 V-Loc
214533898|NCT01212484|DRUG|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
214533899|NCT01170923|DEVICE|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
214533900|NCT01170923|DEVICE|CT|CT performed after 3 cycles of chemotherapy
214533901|NCT00890214|DRUG|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
215152656|NCT06344962|DEVICE|Non-absorbable Suture|3-0 Prolene
215152657|NCT04542837|BIOLOGICAL|KN046|Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
215152658|NCT04542837|DRUG|Lenvatinib|Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW\<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
214533902|NCT00890214|DRUG|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
214533903|NCT05895110|BIOLOGICAL|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
214533904|NCT04595526|PROCEDURE|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
214533905|NCT04595526|PROCEDURE|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
214533906|NCT03697083|OTHER|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
214533907|NCT03697083|OTHER|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
214533908|NCT03697083|OTHER|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
215152659|NCT04717219|OTHER|Blood drawing|Blood will be drawn after inclusion of the participants.
215152660|NCT06237504|DEVICE|SaCoVLM™|Patients will receive general anesthesia with their airways maintained with the SaCoVLM, which is a newer supraglottic airway device with a video port to directly visualize the upper airway.
215152661|NCT06237504|DEVICE|Ambu®Auragain™|Patients will receive general anesthesia with their airways maintained with the Ambu Auragain, which is a conventional 2nd generation supraglottic airway device.
215152662|NCT04387604|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF\>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
215152663|NCT01099332|OTHER|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
215152664|NCT01099332|OTHER|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
215152665|NCT03468140|DRUG|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
215152666|NCT03468140|OTHER|No intervention|Historical control arm
215152667|NCT03313622|BEHAVIORAL|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
215152668|NCT03313622|BEHAVIORAL|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
215152669|NCT03674047|DRUG|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
214463255|NCT03967795|DRUG|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
214463256|NCT03593317|DRUG|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
214463257|NCT03593317|DRUG|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
214463258|NCT02589522|DRUG|Berzosertib|Given IV
214463259|NCT02589522|OTHER|Quality-of-Life Assessment|Ancillary studies
214463260|NCT02589522|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214463261|NCT02589522|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
214463262|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
214463263|NCT06572813|DRUG|Sintilimab|PD-1 antibody
214463264|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
214463265|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
214463266|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
214463267|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
214463268|NCT04593732|DEVICE|STERN FIX (Sternal Stabilization System)|Sternotomy closure with STERN FIX and supplemented with wires
214463269|NCT03800654|BEHAVIORAL|Mindful Action for Pain|MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.
214463270|NCT03800654|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
214463271|NCT04159415|DRUG|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
214463272|NCT04159415|DRUG|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
214463273|NCT04159415|DRUG|High-dose REGN4461|IV infusion loading dose or SC injection QW.
214463274|NCT05571670|DRUG|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
215152670|NCT05293197|DEVICE|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
215152671|NCT06292078|BEHAVIORAL|Instructional Skill-Building Learning Approach (ISLA)|The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
215152672|NCT02981446|DRUG|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
215152673|NCT02981446|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
215152674|NCT04072900|DRUG|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
215152675|NCT04072900|DRUG|Anti-PD-1|3mg/kg, ivgtt, Q2w
215152676|NCT04072900|DRUG|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
215152677|NCT04072900|DRUG|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
215152678|NCT05533736|OTHER|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
215152679|NCT01499355|BIOLOGICAL|BIIB023|
215152680|NCT01499355|BIOLOGICAL|Placebo|
215152681|NCT01499355|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
215152682|NCT01499355|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
215152683|NCT01526733|DRUG|Sham Injection|
215152684|NCT01526733|DRUG|Recombinant human hyaluronidase PH20|
215152685|NCT01526733|DRUG|Insulin aspart|
215152686|NCT01526733|DRUG|Insulin lispro|
215152687|NCT06508190|BEHAVIORAL|continuous positive airway pressure|continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night
215152688|NCT06508190|BEHAVIORAL|free walking exercise and continuous positive airway pressure|patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
215152689|NCT04202601|DRUG|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
215152690|NCT04202601|DRUG|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
215152691|NCT01523912|DEVICE|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
215152692|NCT01626469|DRUG|Captopril|25mg Captopril
215152693|NCT01626469|DRUG|placebo|placebo
215152694|NCT01871935|DRUG|Remifentanil|Anaesthesia with remifentanil/propofol.
215152695|NCT01871935|DRUG|Sufentanil|Anaesthesia with sufentanil/propofol
215152696|NCT03549182|DRUG|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
215152697|NCT03549182|DRUG|placebo treatment|oral administration of placebo (102.3g)
215152698|NCT01599637|DRUG|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
215152699|NCT01599637|DRUG|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
215152700|NCT03460249|OTHER|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
215152701|NCT02565108|DRUG|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
215152702|NCT02565108|DRUG|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
215152703|NCT02565108|DRUG|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
215152704|NCT05755321|OTHER|Skin biopsy|Skin biopsy performed during surgery.
214533909|NCT02573883|DEVICE|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
215152705|NCT04763369|BIOLOGICAL|Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
215152706|NCT04763369|BIOLOGICAL|Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa|Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
214533910|NCT02573883|DRUG|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
214533911|NCT04892602|DIAGNOSTIC_TEST|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
214533912|NCT04919044|OTHER|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
214533913|NCT01544309|DRUG|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)"
214533914|NCT01544309|DRUG|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)"
214533915|NCT02410317|DRUG|Ropivacaine|
214533916|NCT02410317|DRUG|Morphine|
214533917|NCT05292170|OTHER|Heat acclimation|10 consecutive days of heat acclimation
214533918|NCT04959825|DRUG|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
214533919|NCT04959825|DRUG|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
214533920|NCT02671864|OTHER|1: incretin-based therapy|
214533921|NCT02671864|OTHER|2: other antidiabetic|
214533922|NCT01290783|DRUG|Irintoecan|"* Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment."
214533923|NCT01290783|DRUG|HA-Irinotecan solution for Infusion|"* HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment."
214533924|NCT01990911|DEVICE|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
214533925|NCT01990911|DRUG|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
214533926|NCT04695314|DEVICE|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
214533927|NCT04695314|PROCEDURE|Experimental insert|Raised shoe insert, insert used for massage
214533928|NCT04695314|PROCEDURE|Sham insert|Flat shoe insert, insert used for massage
215152707|NCT00453219|PROCEDURE|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
215152708|NCT00453219|PROCEDURE|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
215152709|NCT00453219|GENETIC|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
215152710|NCT00453219|PROCEDURE|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
215152711|NCT00453219|PROCEDURE|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
215152712|NCT00973635|OTHER|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
215152713|NCT06125717|BIOLOGICAL|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
215152714|NCT02873416|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
215152715|NCT02873416|BIOLOGICAL|Precision Cells|Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
215152716|NCT02640287|BIOLOGICAL|Blood or bone marrow samples|
215152717|NCT01887535|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
215152718|NCT01887535|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
215152719|NCT01887535|DRUG|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
215152720|NCT01887535|DRUG|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
215152721|NCT01887535|DRUG|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
214533929|NCT01584271|DEVICE|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
214533930|NCT00118703|DRUG|GW685698X|
214533931|NCT05857514|DRUG|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
215152722|NCT01887535|DRUG|Placebo|Matching placebo will be administered as an oral suspension formulation.
215152723|NCT02963285|OTHER|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
215152724|NCT05021861|DRUG|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
215152725|NCT05021861|DIAGNOSTIC_TEST|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
215152726|NCT05021861|DIAGNOSTIC_TEST|Control group|SYSTEMICALLY HEALTHY FEMALES
215152727|NCT00405600|PROCEDURE|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
215152728|NCT04869826|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD\_2020 universal protocol.
215152729|NCT03698877|DIAGNOSTIC_TEST|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
214533932|NCT05857514|PROCEDURE|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
214533933|NCT06396923|DIAGNOSTIC_TEST|Wingate test|Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
215152730|NCT03382444|PROCEDURE|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
215152731|NCT03382444|DIAGNOSTIC_TEST|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
215152732|NCT01310075|DEVICE|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
215152733|NCT01310075|DEVICE|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
215152734|NCT03154411|DRUG|ABY-029|A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
215152735|NCT02124785|PROCEDURE|Blood sampling|At Years 21 to 25 after their second vaccine dose.
214533934|NCT03292497|PROCEDURE|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
214533935|NCT03292497|PROCEDURE|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
214533936|NCT00087113|DRUG|pemetrexed disodium|
214533937|NCT00953212|DRUG|beta blockers|metoprolol 25mg by mouth every 6 hours
214533938|NCT00953212|DRUG|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
214533939|NCT00953212|DRUG|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
214533940|NCT00004090|DRUG|cisplatin|
214533941|NCT00004090|DRUG|gemcitabine hydrochloride|
214533942|NCT03688022|DRUG|MT-7117|MT-7117
214533943|NCT03688022|DRUG|PPI|Proton pump inhibitor
214533944|NCT03688022|DIETARY_SUPPLEMENT|Acidic beverage|Acidic beverage
214533945|NCT05205252|DRUG|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
214533946|NCT05205252|DRUG|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
214533947|NCT05205252|DRUG|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
214533948|NCT05205252|DRUG|Acalabrutinib|Orally, 100 mg, twice daily.
214533949|NCT05205252|DRUG|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
214533950|NCT05205252|DRUG|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
214533951|NCT05205252|DRUG|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
215152736|NCT01377337|DRUG|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
215152737|NCT02778789|DRUG|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
215152738|NCT02778789|DRUG|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
215152739|NCT03450122|BIOLOGICAL|Aldesleukin|Given SC
215152740|NCT03450122|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
215152741|NCT03450122|DRUG|Cyclophosphamide|Given IV
215152742|NCT03450122|BIOLOGICAL|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
215152743|NCT03052075|OTHER|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
215152744|NCT05349071|DRUG|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
214533952|NCT05205252|DRUG|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
214533953|NCT05205252|DRUG|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
214533954|NCT05205252|DRUG|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
214533955|NCT00067548|DRUG|EKB-569|
214533956|NCT04514172|DEVICE|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
214533957|NCT04514172|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
214533958|NCT01933529|DRUG|ARA 290|ARA 290 is injected s.c. once daily during the study period
214533959|NCT01497340|OTHER|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
215152745|NCT05349071|DRUG|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
215152746|NCT02395081|DIETARY_SUPPLEMENT|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
215152747|NCT02395081|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
214533960|NCT01497340|OTHER|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
214533961|NCT00308919|DRUG|WST09|Treatment with WST09 Vascular Photodynamic therapy
215152748|NCT02395081|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
215152749|NCT04617704|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
215152750|NCT01123902|DEVICE|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
215152751|NCT01123902|DEVICE|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
215152752|NCT00770172|BIOLOGICAL|filgrastim|Given subcutaneously
215152753|NCT01876017|BIOLOGICAL|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
215152754|NCT03835806|OTHER|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
215152755|NCT03835806|OTHER|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
215152756|NCT05807620|OTHER|Gentle Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
214533962|NCT00053768|BIOLOGICAL|filgrastim|
214533963|NCT00053768|DRUG|EPOCH regimen|
214533964|NCT00053768|DRUG|cyclophosphamide|
215152757|NCT05807620|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen (morning and evening, 2x daily).
214463275|NCT05859204|BEHAVIORAL|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
214463276|NCT05859204|BEHAVIORAL|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
214463277|NCT01799265|DEVICE|Somnetics Transcend Auto|
214463278|NCT01799265|DEVICE|Respironics REMstar Auto with C-Flex|
214463279|NCT06448182|DIETARY_SUPPLEMENT|Postbiotic|1 capsule of postbiotic daily in the morning
214463280|NCT06448182|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo daily in the morning
214463281|NCT04900701|OTHER|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
214463282|NCT03459729|DRUG|Antitumor B|Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
214533965|NCT00053768|DRUG|doxorubicin hydrochloride|
214533966|NCT00053768|DRUG|etoposide|
214533967|NCT00053768|DRUG|prednisone|
214533968|NCT00053768|DRUG|vincristine sulfate|
214533969|NCT00053768|RADIATION|radiation therapy|
214533970|NCT00287157|DRUG|Sublingual Tizanidine HCl|
214533971|NCT02970786|DRUG|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
214533972|NCT03796208|BEHAVIORAL|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
214695990|NCT01469494|PROCEDURE|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
215152758|NCT05807620|OTHER|Sunscreen SPF 30|"Neutrogena Ultra Sheer Dry Touch SPF 30. Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an over the counter"
215152759|NCT04171843|GENETIC|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
215152760|NCT04171843|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
215152761|NCT04171843|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
215152762|NCT04171843|DRUG|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
215152763|NCT02099955|DRUG|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
214533973|NCT03796208|BEHAVIORAL|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
214533974|NCT00312234|BEHAVIORAL|Aerobic exercise|
214533975|NCT00312234|BEHAVIORAL|Qigong exercise|
214533976|NCT01808521|DRUG|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
214533977|NCT00953511|GENETIC|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
214533980|NCT01915992|OTHER|blood samples|
214533981|NCT00634218|BEHAVIORAL|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
215152764|NCT04097574|DRUG|NPO-13: l-menthol|20 mL/site
215152765|NCT01223781|BEHAVIORAL|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
215152766|NCT00926861|DEVICE|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
215152767|NCT00926861|DEVICE|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
215152768|NCT02991040|DEVICE|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
215152769|NCT02991040|DEVICE|Revanesse Ultra|Comparator without lidocaine
215152770|NCT02779946|DEVICE|Fibro Scan|
215152771|NCT02779946|GENETIC|PNPLA3|
215152772|NCT00102817|DRUG|somatropin|
215152773|NCT02395159|DEVICE|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
215152774|NCT02395159|OTHER|sterile plaster dressings|standard wound management method of sterile plaster dressings
215152775|NCT04615026|DIAGNOSTIC_TEST|duplex sonography|all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
215152776|NCT03829202|DEVICE|Own mechanical knee|Daily use of own mechanical knee
215152777|NCT03829202|DEVICE|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
215152778|NCT02295618|DEVICE|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
215152779|NCT02295618|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
215152780|NCT05147259|DRUG|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
215152781|NCT06190704|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
215152782|NCT05303311|DRUG|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
215152783|NCT05303311|DRUG|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
215152784|NCT00380783|DRUG|AGN 203818|
215152785|NCT01286480|BEHAVIORAL|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
215152786|NCT03229785|BIOLOGICAL|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
215152787|NCT00183313|BEHAVIORAL|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
215152788|NCT00183313|BEHAVIORAL|Usual care|Usual care includes standard mental health services.
215152789|NCT01267500|PROCEDURE|Non surgical therapy|patching or fusion exercises
215152790|NCT02497352|DIETARY_SUPPLEMENT|flaxseed|
215152791|NCT02497352|BEHAVIORAL|lifestyle modification|
215152792|NCT01024413|DRUG|erlotinib|study arm.erlotinib 150 mg oral till disease progression
215152793|NCT01024413|DRUG|gefitinib|study arm.gefitinib 250 mg oral till disease progression
215152794|NCT02460419|DRUG|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
214533982|NCT00634218|BEHAVIORAL|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
214533983|NCT00634218|BEHAVIORAL|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
214533984|NCT00634218|BEHAVIORAL|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
214533985|NCT00306878|DRUG|Abatacept|
214533986|NCT04192539|DIAGNOSTIC_TEST|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
214533987|NCT04303871|DIAGNOSTIC_TEST|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
214533988|NCT01560585|DRUG|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
214533989|NCT01837589|OTHER|QCT|
214533990|NCT01837589|OTHER|DXA|
214533991|NCT05456308|PROCEDURE|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
215152795|NCT02460419|OTHER|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
215152796|NCT02794532|PROCEDURE|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
215152797|NCT00327600|DRUG|imexon|
215152798|NCT00327600|DRUG|DTIC|
215152799|NCT05151276|BEHAVIORAL|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
215152800|NCT04809480|DIAGNOSTIC_TEST|Fungal rhinosinusitis|Pathology examination
215152801|NCT03931252|DIETARY_SUPPLEMENT|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
215152802|NCT03931252|DIETARY_SUPPLEMENT|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
215152803|NCT01202032|DRUG|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
215152804|NCT02751489|OTHER|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
214533992|NCT04890886|DIAGNOSTIC_TEST|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
215152805|NCT05060601|PROCEDURE|Gracey micro-curettes|Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
215152806|NCT05060601|PROCEDURE|Standard Gracey curettes|After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
215152807|NCT06330558|PROCEDURE|laparoscopic right adrenalectomy|adrenalectomy
215152808|NCT02290769|DEVICE|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
215152809|NCT02290769|DEVICE|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
215152810|NCT00101673|DRUG|vildagliptin|
215152811|NCT05254704|OTHER|TEX-Q-F before scheduled surgery|"The TEX-Q-F questionnaire (French version of the breif version of the TEX-Q) contains 15 questions to assess the patient's overall expectations concerning the surgery.~The first 11 questions concern the patient's expectations regarding the postoperative period: pain and functional recovery. The last 4 questions focus on the patient's hopes for the outcome of the surgery. Each item is scored from 0 to 10, according to the intensity of the level of expectation."
215152812|NCT05366062|DRUG|ERC1671|ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
215152813|NCT05366062|DRUG|GM-CSF|Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
215152814|NCT05366062|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
215152815|NCT05366062|DRUG|Pembrolizumab|A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
215152816|NCT05185713|OTHER|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
215152817|NCT02536963|DEVICE|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
215152818|NCT02536963|OTHER|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
215152819|NCT05083286|DRUG|OnabotulinumtoxinA|Injection of glabellar rhytids
214533993|NCT04890886|DIAGNOSTIC_TEST|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
214533994|NCT04890886|DIAGNOSTIC_TEST|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
214533995|NCT04890886|DIAGNOSTIC_TEST|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
214533996|NCT04890886|DIAGNOSTIC_TEST|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
215152820|NCT05069493|PROCEDURE|simple suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
214533997|NCT02175745|DRUG|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
214533998|NCT02175745|PROCEDURE|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
214533999|NCT02175745|PROCEDURE|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
214534000|NCT02175745|PROCEDURE|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
214534001|NCT01252511|PROCEDURE|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
215152821|NCT05069493|PROCEDURE|mesh|Hiatal hernia repair by tension-free mesh closure
215152822|NCT05451901|PROCEDURE|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
215152823|NCT05451901|PROCEDURE|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
215152824|NCT02728687|DRUG|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
215152825|NCT02728687|DRUG|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
215152826|NCT05701501|DRUG|Vitamin B5 Tablets|The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.
215152827|NCT05701501|DRUG|placebo|The control group was given placebo tablets of the same type based on the standard IBD treatment.
215152828|NCT05503823|DEVICE|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
215152829|NCT03586466|DEVICE|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
215152830|NCT03586466|DRUG|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
215152831|NCT03586466|OTHER|MEMS|Subjects will receive their medication in a MEMS pill bottle.
215152832|NCT00012844|DEVICE|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
215152833|NCT00012844|PROCEDURE|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
215152834|NCT01607684|DEVICE|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
215152835|NCT00904592|DRUG|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
215152836|NCT00904592|DRUG|Placebo Comparator|"Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid"
215152837|NCT02354053|DRUG|Switch to Triumeq|
215152838|NCT02354053|BEHAVIORAL|Adherence support + current ART|
215152839|NCT05404932|DRUG|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
215152840|NCT02668393|DRUG|Docetaxel|
215152841|NCT02668393|DRUG|Nintedanib|Low Dose
215152842|NCT02668393|DRUG|Nintedanib|Medium dose
215152843|NCT02668393|DRUG|Nintedanib|High dose
215152844|NCT02668393|DRUG|Nintedanib|Continuous high dose
215152845|NCT00936780|DEVICE|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
215152846|NCT00309348|OTHER|Weekly measurement of graft flow|
214463283|NCT06182033|BEHAVIORAL|Peer-mediated pivotal response training|Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
214463284|NCT02364557|RADIATION|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~* For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~* For a single liver metastases, patients receive a single fraction of 30 Gy.~* For metastases in the abdominal-pelvic or liver (\>1), patients receive 3 fractions for a total of 45 Gy.~* For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~* For spinal metastases, patients receive 1 fraction of 20 Gy.~* For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~* For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
214463285|NCT02364557|PROCEDURE|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
214463286|NCT03439449|DEVICE|CLEOS software program|Computer-assisted history taking program
215152847|NCT05569278|DRUG|GE200486 0.5M Injection|Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
215152848|NCT06367530|DIAGNOSTIC_TEST|Incidence and survival of trilateral retinoblastoma and the differences globally|The detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.
215152849|NCT04433416|DIAGNOSTIC_TEST|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
215152850|NCT04207632|DRUG|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
215152851|NCT02141204|BIOLOGICAL|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
215152852|NCT02141204|BIOLOGICAL|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
215152853|NCT03333278|DRUG|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
215152854|NCT03333278|DRUG|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
215152855|NCT03333278|DRUG|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
215152856|NCT05695508|DRUG|Teclistamab (Tec)|Subcutaneous administration of Teclistamab
215152857|NCT05695508|DRUG|Daratumumab|Subcutaneous administration of Daratumumab
215152858|NCT05695508|DRUG|Dexamethasone|administered i.v. or orally
214695991|NCT01469494|PROCEDURE|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
214695992|NCT01255046|DRUG|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
214695993|NCT01255046|DRUG|STA-1|300mg/tab, 2 tab/tid for 72 weeks
214695994|NCT01255046|DRUG|placebo|2 tab/tid for 72 weeks
214695995|NCT04871633|DRUG|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
214695996|NCT04871633|DRUG|Conventional|IV Steroids Antibiotics
215152859|NCT05695508|DRUG|Lenalidomide|Administration oral
214534002|NCT04093466|DRUG|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
214695997|NCT06691945|COMBINATION_PRODUCT|Saline delivered using an intrauterine pressure catheter (IUPC)|An intrauterine pressure catheter (IUPC) will be placed in participants after membrane rupture, or at 4 cm if membranes previously ruptured. A 300cc bolus of normal saline will be administered. A continuous rate of 100 cc/hr of normal saline will continue until delivery to prevent Postpartum Hemorrhage. If the IUPC is dislodged, it will be replaced by a trained clinician.
215152860|NCT05695508|DRUG|Bortezomib|Subcutaneous administration
214534005|NCT04116242|OTHER|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
214534006|NCT04116242|OTHER|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
214534007|NCT04116242|OTHER|Health-related Questionnaires|Health-related Questionnaires (Questionnaire\_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
214695998|NCT07073664|PROCEDURE|The surgical side of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES)|Surgery was performed by Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) . Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
214695999|NCT07073664|PROCEDURE|The surgical side of Endoscopic Sinus Surgery (ESS)|Description: Surgery was performed by Endoscopic Sinus Surgery (ESS). Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
214696000|NCT06898294|DIAGNOSTIC_TEST|EIT kidney function assessment|The product under investigation is named Gense EIT-kidney device. This kidney device is a portable and non-invasive imaging modality capable of capturing the cross-sectional bioelectrical impedance distribution of the kidney at multiple current injection frequencies using electrical impedance tomography (EIT). Currently, the kidney device employs a band consisting of 16 equally distributed electrodes around the abdomen. The electrode band is connected to a control unit that switches the electrode stimulation and measurement pairs, then sends the collected measurement to a computational unit for image reconstruction. The images are then post-processed to extract functional kidney images for diagnosis. This kidney device has a large LED screen, allowing the functional images to be produced and visualized.
214696001|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in GCF|The primary intervention will involve the non-invasive collection of GCF samples using Periopaper strips. The strips will be placed into the gingival sulcus for 30 seconds and then stored at -80°C until analysis. The analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
214696002|NCT06897722|DIAGNOSTIC_TEST|IL-17A analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
214696003|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
214696004|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
214696005|NCT06897722|DIAGNOSTIC_TEST|İL-17A analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
214696006|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
214696007|NCT06897722|DIAGNOSTIC_TEST|Periodontal assesment|Comprehensive periodontal assessments will be conducted, including Plaque Index (PI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL).
214696008|NCT03273738|DIAGNOSTIC_TEST|folate level measurement|the level of folate measured in plasma with homocysteine
215152861|NCT05695508|DRUG|Talquetamab|Subcutaneous administration of Daratumumab
215152862|NCT05345652|PROCEDURE|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
215152863|NCT00063765|DRUG|Ciliary Neurotrophic Factor Implant NT-501|
215152864|NCT03869697|DRUG|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
215152865|NCT01091220|BIOLOGICAL|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
215152866|NCT01091220|BIOLOGICAL|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
215152867|NCT00601393|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
215152868|NCT00601393|OTHER|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
215152869|NCT06042062|DEVICE|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
215152870|NCT06042062|DEVICE|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
215152871|NCT01103752|OTHER|no intervention, descriptive study|no intervention, descriptive study
215152872|NCT03487705|OTHER|electromyographic essential tremor|"* Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
215152873|NCT02053376|DRUG|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
215152874|NCT00344409|DRUG|darbepoetin alfa|
215152875|NCT05703711|BEHAVIORAL|mHealer|MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
214463287|NCT03439449|PROCEDURE|Physician taken history|Conventional history taking by physicians
214463288|NCT03134092|OTHER|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
214463289|NCT03134092|OTHER|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
214463290|NCT05844137|BEHAVIORAL|NAFLD Education|NAFLD Education
214463291|NCT05844137|BEHAVIORAL|diet/lifestyle support|diet/lifestyle support
214463292|NCT05844137|DRUG|T2D medication management|T2D medication management
214463293|NCT05844137|DIAGNOSTIC_TEST|clinically-indicated liver testing and care|clinically-indicated liver testing and care
214463294|NCT05775406|DRUG|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
214463295|NCT04196413|DRUG|GD2 CAR T cells|Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
214463296|NCT04196413|DRUG|Fludarabine|Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
214463297|NCT04196413|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
214463298|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
214463299|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
214534008|NCT04116242|OTHER|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
214534009|NCT05022927|DRUG|ERY974|ERY974 vial
214534010|NCT05022927|DRUG|Tocilicumab|Tocilizumab vial
214534011|NCT05022927|DRUG|Atezolizumab|Atezolizumab vial
215152876|NCT02930863|OTHER|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
214463300|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
214463301|NCT03666000|DRUG|IL-2|Specified dose on specified days
214463302|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
215152877|NCT02930863|BEHAVIORAL|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
215152878|NCT04330404|BEHAVIORAL|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
215152879|NCT04330404|BEHAVIORAL|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
215152880|NCT03830541|OTHER|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
215152881|NCT05999357|DRUG|JDQ443|JDQ443 tablets, orally administered
215152882|NCT05241990|BEHAVIORAL|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
215152883|NCT05241990|BEHAVIORAL|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
215152884|NCT02019095|OTHER|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
215152885|NCT02453308|DRUG|ACT|"1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days"
215152886|NCT02453308|DRUG|TACT|"1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
215152887|NCT02963506|OTHER|Placebo|
215152888|NCT02963506|DRUG|Bimekizumab|Bimekizumab in different dosages.
215152889|NCT00066157|DRUG|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
215152890|NCT00066157|DRUG|Medroxyprogesterone|2.5mg tablet daily for 12 months
215152891|NCT00066157|DRUG|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
215152892|NCT00066157|DRUG|Placebo|Placebo tablet daily for 12 months
215152893|NCT03503032|PROCEDURE|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]
215152894|NCT03503032|PROCEDURE|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
215152895|NCT05796934|BEHAVIORAL|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
215152896|NCT06520917|DEVICE|Locator-Positioner (LOPO) Guide Device|Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
214696009|NCT03273738|DIAGNOSTIC_TEST|B12|B12 measurement in blood
215152897|NCT02212782|DRUG|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
215152898|NCT02212782|DRUG|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
215152899|NCT00905866|OTHER|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
215152900|NCT06204198|OTHER|No intervention|No intervention
215152901|NCT05486806|DRUG|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
215152902|NCT05486806|RADIATION|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
215152903|NCT06514066|DRUG|Cannabidiol Oil|The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.
214463303|NCT06176300|BEHAVIORAL|PAR - the SEED Method|The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
214534012|NCT05022927|DRUG|Bevacizumab|Bevacizumab vial
214534013|NCT05632016|PROCEDURE|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
215152904|NCT02999204|DRUG|Vitamin D3|Two different doses of Vitamin D3
215152905|NCT00710697|DRUG|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
215152906|NCT04258267|PROCEDURE|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
215152907|NCT04258267|PROCEDURE|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
215152908|NCT00904137|PROCEDURE|Cast|
215152909|NCT00904137|PROCEDURE|Splint|
215152910|NCT00904137|PROCEDURE|Tape|
215152911|NCT05043662|DIAGNOSTIC_TEST|UroCAD assay, CTU examination and urine cytology|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
214463304|NCT06176300|BEHAVIORAL|PAR-Youth Voices|Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
214463305|NCT06176300|BEHAVIORAL|Emerging Leaders hospital-based intervention|Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
214463306|NCT06126900|OTHER|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
214463307|NCT05094908|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
214463308|NCT02950987|DEVICE|Whole Body MRI|
214534014|NCT04688086|DIAGNOSTIC_TEST|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
214534015|NCT03786003|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
214534016|NCT03786003|PROCEDURE|Thoracotomy|Standard thoracotomy
214534017|NCT02292641|PROCEDURE|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
214696010|NCT07080125|DRUG|Ofev®|Ofev®
215152912|NCT03100552|DIAGNOSTIC_TEST|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
215152913|NCT04657393|PROCEDURE|mechanical ventilation|change of ventilation frequency
215152914|NCT03254797|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
215152915|NCT03254797|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
215152916|NCT00518765|DRUG|Aliskiren|
215152917|NCT00518765|DRUG|Aliskiren plus placebo|
215152918|NCT00518765|DRUG|Aliskiren|
215152919|NCT00518765|DRUG|Aliskiren plus placebo|
215152920|NCT03495089|DIAGNOSTIC_TEST|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
215152921|NCT03495089|DIAGNOSTIC_TEST|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
215152922|NCT03241901|DRUG|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
215152923|NCT03241901|DRUG|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
215152924|NCT03241901|OTHER|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
215152925|NCT06039111|PROCEDURE|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
215152926|NCT02340364|BEHAVIORAL|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
215152927|NCT02340364|BEHAVIORAL|Self-care Education|208 patients randomized to self-care education alone.
215152928|NCT00923572|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
215152929|NCT00750438|DIETARY_SUPPLEMENT|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
215152930|NCT00750438|DIETARY_SUPPLEMENT|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
214534018|NCT05683886|DRUG|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
214534019|NCT05258877|OTHER|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
214534020|NCT02824497|OTHER|No intervention. It's a description study|
214534021|NCT02972814|DEVICE|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
214534022|NCT02972814|DEVICE|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
214534023|NCT02972814|DEVICE|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
214534024|NCT03600922|PROCEDURE|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
215152931|NCT00750438|DIETARY_SUPPLEMENT|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
215152932|NCT04239014|DRUG|Olaparib|Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
215152933|NCT04239014|DRUG|Ceralasertib|Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
215152934|NCT04239014|DRUG|Placebo to match olaparib|Per olaparib
215152935|NCT05002296|PROCEDURE|upper cervical manipulation|rotatory upper cervical manipulation to both sides. The treatment program was conducted for twelve sessions (three sessions per week). Assessment procedures were performed before and after treatment through visual analogue scale (VAS)
215152936|NCT04139213|DRUG|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
215152937|NCT04139213|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
215152938|NCT04139213|OTHER|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
215152939|NCT04139213|DRUG|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
215152940|NCT02753452|BEHAVIORAL|Residential Immersive Life Skills programming|
215152941|NCT02753452|BEHAVIORAL|Non-residential life skills programming|
215152942|NCT01173237|PROCEDURE|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
215152943|NCT01173237|PROCEDURE|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
215152944|NCT01260402|DEVICE|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
215152945|NCT01260402|DEVICE|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
215152946|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
215152947|NCT02284035|DRUG|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
215152948|NCT02284035|DRUG|EFV/TDF/FTC|standard combination therapy
215152949|NCT02284035|DRUG|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
214696011|NCT07084103|BEHAVIORAL|Psychosocial Support Intervention|Participants in the intervention arm will receive a structured psychosocial support program designed for women diagnosed with fetal anomaly. The program includes individual counseling sessions, stress management techniques, emotional support, and educational materials addressing coping strategies and mental well-being. The intervention will be delivered by trained healthcare professionals over sessions during the prenatal period.
215152950|NCT02284035|DRUG|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
215152951|NCT02284035|DRUG|EFV plus ABC/3TC or RPV/TDF/FTC|
214534025|NCT05765409|OTHER|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
214534026|NCT05765409|OTHER|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
214534027|NCT04206384|DEVICE|Ultrasound|Ultimate Contour Body Sculpting Device
214534028|NCT03705988|DEVICE|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
215152952|NCT02284035|DRUG|ATV/r plus ABC/3TC|
215152953|NCT02284035|DRUG|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
215152954|NCT02284035|DRUG|RAL plus ABC/3TC|
215152955|NCT02284035|DRUG|Other ART regimens|
215152956|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
214534029|NCT03705988|DEVICE|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
215152957|NCT04832997|DIAGNOSTIC_TEST|Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)|Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS \>= 3 and PRI-MUS \>= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
215152958|NCT04501770|DRUG|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
215152959|NCT04501770|DRUG|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
214534030|NCT03307083|OTHER|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
215152960|NCT04501770|DRUG|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
214534031|NCT00006436|BIOLOGICAL|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
214534032|NCT00006436|BIOLOGICAL|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
214534033|NCT00006436|DRUG|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
214534034|NCT01299441|DEVICE|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
214534035|NCT00951574|DRUG|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
214534036|NCT00951574|DRUG|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
214534037|NCT03847220|DIAGNOSTIC_TEST|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
214534038|NCT05262504|DEVICE|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
214534039|NCT01958047|DRUG|ASP3652|Oral
214534040|NCT00328276|DRUG|Sarcosine|
214534041|NCT03594045|DRUG|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
214534042|NCT02826759|OTHER|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
214534043|NCT03750500|DEVICE|Biofeedback device|12-week exercise program performed through the device
214534044|NCT03750500|BEHAVIORAL|Education on falls risk|Education on falls risk factors and how to minimize them
214534045|NCT03750500|OTHER|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
214534046|NCT03750500|DIAGNOSTIC_TEST|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
214534047|NCT00942188|DRUG|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
214534048|NCT00942188|DRUG|Placebo|Participants received 2 SC injections weekly for 12 weeks.
214534049|NCT00276016|DRUG|phenylephrine|immediate-release 12 mg capsules for oral administration
214534050|NCT00276016|DRUG|pseudoephedrine|60 mg immediate-release tablets for oral administration
215152961|NCT04501770|DRUG|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
215152962|NCT04501770|DRUG|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
215152963|NCT04501770|DRUG|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
215152964|NCT04501770|DRUG|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
215152965|NCT04501770|DRUG|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
215152966|NCT04845568|BEHAVIORAL|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
214534051|NCT00276016|DRUG|placebo|placebo capsules
215152967|NCT00928408|DRUG|Cinacalcet|
214534052|NCT01507753|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
214534053|NCT01507753|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
214534054|NCT01507753|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
214534055|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
214534056|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
214534057|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
215152968|NCT00776074|DRUG|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
215152969|NCT00776074|DRUG|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
215152970|NCT00923793|DEVICE|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
214534058|NCT00390936|DRUG|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
214534059|NCT05041439|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
215152971|NCT00923793|DEVICE|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
215152972|NCT04078425|DRUG|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
215152973|NCT01930006|DRUG|MGCD265|
215152974|NCT00536744|DEVICE|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
215152975|NCT00536744|OTHER|Sham|Non-energized (inactive - Sham) application + standard of care
215152976|NCT00787644|DRUG|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
215152977|NCT00787644|DRUG|Placebo|Matching placebo (inert tablet)
215152978|NCT01619280|DRUG|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
214534060|NCT03648684|BEHAVIORAL|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
214534061|NCT03648684|BEHAVIORAL|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
215152979|NCT02177565|BIOLOGICAL|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
215152980|NCT00359645|PROCEDURE|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
215152981|NCT06498076|DRUG|Norepinephrine|injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
215152982|NCT06498076|DRUG|Ephedrine|injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
214534062|NCT01378481|DRUG|Vorinostat|Given PO
214534063|NCT01378481|RADIATION|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
214534064|NCT01378481|OTHER|Laboratory Biomarker Analysis|Correlative studies
214534065|NCT01378481|OTHER|Pharmacological Study|Correlative studies
214534066|NCT01378481|PROCEDURE|Therapeutic Conventional Surgery|Undergo neurosurgery
214534067|NCT01182272|DRUG|sorafenib tosylate|
215152983|NCT02119377|OTHER|questionnaire|
215152984|NCT01334450|DEVICE|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
215152985|NCT04302077|OTHER|virtual doctor visit|interactive live-video feed at home through EPIC
214534068|NCT01182272|OTHER|laboratory biomarker analysis|
215152986|NCT04302077|OTHER|Standard care doctor's visit|In person visit as per standard of care
215152987|NCT02638454|PROCEDURE|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
214534069|NCT01182272|PROCEDURE|neoadjuvant therapy|
214534070|NCT01182272|PROCEDURE|therapeutic conventional surgery|
214534071|NCT01431105|DRUG|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
214534072|NCT03572998|DRUG|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
214534073|NCT06620432|PROCEDURE|Low segment hysterotomy|A low segment hysterotomy is a surgical procedure in which an incision is made in the lower segment of the uterus, typically during a cesarean section or other uterine surgeries. This approach is preferred because the lower uterine segment is thinner and less vascular, reducing the risk of bleeding and complications during and after the procedure. The incision is typically horizontal.
215152988|NCT04002102|OTHER|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
215152989|NCT04002102|OTHER|Usual care|Remain in standard care after randomization and educational materials.
215152990|NCT04002102|OTHER|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
215152991|NCT00057720|DRUG|TLK286 HCl for injection|
215152992|NCT00057720|DRUG|topotecan hydrochloride for injection|
215152993|NCT00057720|DRUG|doxorubicin HCl liposome injection|
215152994|NCT00752778|OTHER|pet-scan FDG-F18|
215152995|NCT01538758|OTHER|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
215152996|NCT01538758|OTHER|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
215152997|NCT01073111|DEVICE|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
215152998|NCT01073111|DEVICE|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
214534074|NCT06620432|PROCEDURE|High segment hysterotomy|A high segment hysterotomy is a surgical procedure involving an incision in the upper segment of the uterus.
214534075|NCT06620432|PROCEDURE|Crossed hysterorrhaphy|Crossed hysterorrhaphy is a surgical technique used to close the uterine incision following a hysterotomy, particularly during cesarean sections. In this method, the sutures are placed in a crossed or X-shaped pattern, which helps to evenly distribute tension across the incision site.
214534076|NCT06620432|PROCEDURE|Non-Crossed hysterorrhaphy|Non-crossed hysterorrhaphy is a surgical technique used to close a uterine incision, typically after a hysterotomy, such as during a cesarean section. In this method, the sutures are placed in a linear, parallel fashion rather than in a crossed or X-shaped pattern
214534077|NCT04112355|OTHER|Blood Collection|Blood draw
215152999|NCT01073111|DEVICE|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
215153000|NCT06128759|OTHER|Focusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
215153001|NCT02908672|DRUG|Atezolizumab|Will be administered as per the schedule described in individual arm.
215153002|NCT02908672|DRUG|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
215153003|NCT02908672|DRUG|Cobimetinib|Will be administered as per the schedule described in individual arm.
215153004|NCT02908672|DRUG|Vemurafenib|Will be administered as per the schedule described in individual arm.
215153005|NCT02908672|DRUG|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
214534078|NCT01996397|PROCEDURE|Cardiac resynchronization therapy device implantation|
214534079|NCT06720571|DEVICE|Auricular vagal neuromodulation therapy (aVNT)|The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
214534080|NCT06720571|DEVICE|Sham Auricular vagal neuromodulation therapy (aVNT)|The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.
214534081|NCT01718613|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
214534082|NCT01718613|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
214534083|NCT06090760|BEHAVIORAL|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
215153006|NCT05952882|DRUG|Liraglutide + Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks
215153007|NCT05952882|DRUG|Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
215153008|NCT00005618|DRUG|arsenic trioxide|
215153009|NCT03767413|PROCEDURE|PNF|proprioceptive neuromuscular facilitation training
215153010|NCT03767413|PROCEDURE|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
215153011|NCT02606513|OTHER|MR Urography; CT Urography|
215153012|NCT04819607|OTHER|model of care|Multidisciplinary model of care for BMFS patients.
215153013|NCT03452657|DRUG|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
215153014|NCT03452657|PROCEDURE|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
214696012|NCT07082699|OTHER|antegrade enema|Introduce saline at a flow rate of 40 ml/minute through the distal end of the ileostomy. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
214696013|NCT07082699|OTHER|retrograde enema|Introduce saline at a flow rate of 40 ml/minute through the anus. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
214696014|NCT07081997|COMBINATION_PRODUCT|Palopegteriparatide|Palopegteriparatide is supplied as a solution with a concentration of 0.3 mg/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
215153015|NCT06516536|OTHER|MBI (Mindfulness-Based Intervention)|"Breath-Focused Meditation Approach (5-7 minutes):~They will be guided to observe the flow of air in and out of the nose, noting sensations in the abdomen or chest.~Body scan (7-8 minutes):~Students will be guided through a careful exploration of their body. You'll start with your toes and slowly work your way toward your head, paying attention to the physical sensations in each part of your body.~Simple yoga poses (5-7 minutes):~Students will stand and follow instructions to perform a series of simple poses, such as mountain pose, tree pose, and cat-cow pose."
215153016|NCT06315582|PROCEDURE|Removal of uterine septum with hysteroscopic scissors without electrosurgery.|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
215153017|NCT06315582|PROCEDURE|Hysteroscopic septoplasty utilizing bipolar electrosurgery|Hysteroscopic septoplasty utilizing bipolar electrosurgery
215153018|NCT04800276|OTHER|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
215153019|NCT04800276|OTHER|global muscle strenghtening|global muscle strenghtening
215153020|NCT01685762|DRUG|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
215153021|NCT06975371|OTHER|No drug|No study drug was administered in this non-interventional study.
215153022|NCT06521398|OTHER|Doula Support|Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
215153023|NCT06212726|BEHAVIORAL|InjureFree|The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
214534084|NCT05862467|BEHAVIORAL|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
214534085|NCT05089981|DRUG|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
214534086|NCT05089981|DRUG|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
214534087|NCT00989898|OTHER|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
214534088|NCT00832364|DRUG|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
214534089|NCT00832364|DRUG|Placebo|Placebo capsules
214534090|NCT00832364|BIOLOGICAL|Etanercept|Injectable Biologic
214534091|NCT02628964|DEVICE|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
214534092|NCT00318786|DRUG|biphasic insulin aspart|
214534093|NCT02485314|OTHER|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
214534094|NCT00791297|DRUG|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
214534095|NCT01016223|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
214534096|NCT01016223|DRUG|placebo|Matched placebo swallowed two puffs twice daily
214696015|NCT07082231|OTHER|Blood sample|3 blood samples
214696016|NCT07082231|PROCEDURE|biopsy|3 pairs of biopsy realised during the coloscopy
214696017|NCT07083310|BEHAVIORAL|Health Education|Structured group education focused on breast cancer awareness, risk reduction, and early detection.
214696018|NCT07083310|BEHAVIORAL|Motivational Interviewing|Individual counseling sessions using motivational interviewing to enhance screening behavior.
214696019|NCT07084363|DEVICE|Quantitative monitoring|The TetraGraph TOF monitor will be used to quantitatively assess the TOF-ratio. Quantitative monitoring includes objective measurement of the TOF-ratio, as defined by the ratio between the first and the fourth muscular responses and is quantified by acceleromyography. A TOF twitch response ratio equal or greater to 95% (TOF0.95) will be targeted prior to extubation. If TOF0.95 is not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
214696020|NCT07084363|OTHER|Qualitative monitoring|Clinicians will assess the TOF-ratio. Qualitative monitoring includes subjective assessment of the count and the amplitude of the muscular responses related to neuromuscular block depth. A TOF twitch response count of 4 similarly strong twitches will be targeted prior to extubation. If 4 similarly strong TOF twitch responses are not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
215153024|NCT04163016|DRUG|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
215153026|NCT06612788|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
215153027|NCT05134428|DEVICE|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
214534097|NCT04085705|DIAGNOSTIC_TEST|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
215153028|NCT06716866|DEVICE|temporally-interfering electric field stimulation|Temporally-interfering electric field stimulation is a candidate non-invasive means to stimulate and modulate the nervous system. We do not know of any other trials of this method in epilepsy patients.
215153029|NCT07054723|BEHAVIORAL|Mobile Daily Diary|This study will include a 14-day daily diary survey in which participants will be expected to complete morning (\~5 minutes) and night (\~10 minutes) assessments using mobile phones provided by the research team.
215153030|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a well-established trauma treatment for children ages 3-17 years that demonstrates improved outcomes relative to other active treatments. Originally developed for treatment of childhood sexual abuse, evidence from numerous randomized clinical trials (RCT) demonstrates that TF-CBT is one of the most effective treatments for children with PTSD and/or depression resulting from many forms of child abuse and neglect as well as other traumatic experiences.TF-CBT is rated by California Evidence-Based Clearinghouse for Child Welfare as highly relevant for child welfare and well-supported in improving children's outcomes, including reduced PTSD symptoms, behavior problems, depression, and shame, and improving parental support related to their children's experiences.
214534098|NCT01754532|BIOLOGICAL|Hair Sample|Analysis of hair cortisol levels
214534099|NCT00113269|DRUG|basiliximab|IV
214534100|NCT00113269|DRUG|rabbit anti-thymocyte globulin|IV
215153031|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) augmented with Socialization (S)|The study will compare standard TF-CBT with TF-CBT augmented with Socialization enhancements. TF-CBT+S includes enhancements to address socioecological stress and trauma and provide coping strategies to support positive socialization.
214463309|NCT05261204|DEVICE|Transcatheter Aortic Valve Implantation|Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
214534101|NCT00113269|DRUG|tacrolimus|oral
214463310|NCT05261204|PROCEDURE|Bioprothesis|The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
214463311|NCT05261204|PROCEDURE|Sutureless|The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
214463312|NCT06153420|DRUG|CIN-103|CIN-103 BID
214463313|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
214463314|NCT03466294|DRUG|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
214463315|NCT04200456|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
214463316|NCT04200456|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
214463317|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
214463318|NCT06145386|BEHAVIORAL|Aerobic Exercise and Strength Training|Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
214463319|NCT03778996|DRUG|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
214534102|NCT00113269|DRUG|alemtuzumab|Intravenous (IV)
214534103|NCT00113269|DRUG|mycophenolate mofetil|oral
214534104|NCT00113269|DRUG|steroids|IV and/or oral
214534105|NCT05812586|BIOLOGICAL|SCB-2019/Clover|SCB-2019/Clover Vaccine
214534106|NCT05812586|BIOLOGICAL|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
214534107|NCT05812586|BIOLOGICAL|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
214534108|NCT06462274|OTHER|body sample collection and imaging scan|
214534109|NCT01317823|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
214534110|NCT04947826|PROCEDURE|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
215153032|NCT07059637|OTHER|Multidisciplinary clinic evaluation|The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalizations, COPD exacerbations, or mortality. The approach is different than standard of care COPD treatment because it is informed by quantifying muscle mass and strength (through handgrip strength and bio-impedance) and have strong collaborations with nutrition and pulmonary rehabilitation.
215153033|NCT07059637|OTHER|COPD standard of care|Standard COPD care treatment in an ambulatory post-hospital follow up clinic
215153034|NCT07075770|DEVICE|Combined iTBS-tACS|The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. iTBS and tACS will be synchronized using a BrainTrigger and SIGNAL Software so that both stimulations will start simultaneously
215153035|NCT07075770|DEVICE|iTBS-sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
215153036|NCT07075770|DEVICE|sham iTBS- sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the iTBS sham condition, stimulation was delivered with the coil angled at 90°, with only the edge of the coil resting on the scalp..~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
215153037|NCT07075913|OTHER|Subcostal transverse abdominis plane block|Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
215153038|NCT07075913|OTHER|Erector spinae plane block|Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
215153039|NCT07073573|PROCEDURE|Vital pulp therapy|Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
215153040|NCT07075536|BEHAVIORAL|My Health, My Choice Web-Based Contraceptive Decision Tool|"The My Health My Choice decision tool is a web-based interactive tool designed to educate patients with health conditions about their contraceptive options, elicit their personal preferences and contraceptive concerns, and help them prepare for a contraceptive discussion with their clinician. Patients can compare features of different contraceptive methods side-by-side and grouped by medical risk according to the Center for Disease Control and Prevention U.S. Medical Eligibility Criteria (US MEC). The tool generates an individualized Birth Control Summary for each patient user that records their contraceptive favorites and their questions for the clinician. Clinicians can use the Clinician Version of the tool to review the patient's Birth Control Summary and their medical eligibility for different contraceptive methods per the US MEC guidelines."
214534111|NCT04947826|DRUG|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
214534112|NCT04947826|DRUG|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
215153041|NCT07075536|BEHAVIORAL|Usual Contraceptive Care|Participants will attend clinic visits per routine. Clinicians proceed with usual contraceptive care. All study activities and incentives for participants in the usual contraceptive care arm are the same as for participants in the intervention arm except for those related to the intervention itself.
215153042|NCT07075133|OTHER|Antidiabetic diet (control)|Standard antidiabetic diet
214534113|NCT04947826|DRUG|Placebo|Placebo
214534114|NCT00467298|BEHAVIORAL|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
214534115|NCT00467298|BEHAVIORAL|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
214534116|NCT00467298|BEHAVIORAL|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
214534117|NCT04764201|DRUG|HIP2001|Test drug
214534118|NCT04764201|DRUG|HGP2001|Reference drug
214534119|NCT05651113|OTHER|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
214534120|NCT02718547|DRUG|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
214534121|NCT00636480|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
214534122|NCT00636480|DRUG|ChloraPrep One Step|Administer topically
214534123|NCT00636480|DRUG|Sterile saline|0.9% NaCl solution
214534124|NCT02024659|DRUG|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
214534125|NCT02024659|OTHER|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
214463320|NCT06554405|OTHER|Unilateral Intervention|Treatment plan will be applied to the symptomatic side.
214463321|NCT06554405|OTHER|Bilateral Intervention|Treatment plan will be applied to the symptomatic and nonsymptomatic sides.
214463322|NCT03080987|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
214463323|NCT03080987|DRUG|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
214463324|NCT03080987|DRUG|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
214463325|NCT03080987|OTHER|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
214463326|NCT03080987|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
214463327|NCT06849973|DRUG|Drug: Bionetide|NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
214463328|NCT06849973|DRUG|Placebo|NA-921 (Bionetide) placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
214463329|NCT05176080|DRUG|Famitinib|Famitinib orally, daily or every other day
214463330|NCT05176080|DRUG|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
214463331|NCT05176080|DRUG|Fulvestrant|Fulvestrant
214463332|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1\) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
214463333|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
214463334|NCT02098629|DRUG|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
214463335|NCT02098629|DRUG|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
214463336|NCT02098629|DRUG|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
214463337|NCT05085067|OTHER|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
214463338|NCT04593810|PROCEDURE|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
214463339|NCT04593810|PROCEDURE|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
214463340|NCT07062744|DEVICE|Swan-Ganz IQ Pulmonary Arterial catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂).~These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
214534126|NCT01318317|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
214534127|NCT01318317|BIOLOGICAL|Filgrastim|Given IV
214534128|NCT01318317|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR
214534129|NCT01318317|OTHER|Laboratory Biomarker Analysis|Correlative studies
214534130|NCT01318317|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
214534131|NCT01318317|DRUG|Plerixafor|Given IV
214534132|NCT01318317|BIOLOGICAL|Rituximab|Given IV
214534133|NCT04234945|DRUG|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
214534134|NCT04234945|DRUG|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
215153043|NCT07075133|OTHER|eTRE diet|eTRE for a total duration of 12 weeks. During the eTRE, volunteers will have to eat and drink (meals + snacks, medication) exclusively during an 8-hour period which will extend between 6 a.m. (flexible: or 7 a.m. or 8 a.m.) in the morning and 2 p.m. (depending on the chosen start time: or 3 p.m. or 4 p.m.), which corresponds to a fasting period of 16 hours per day
215153044|NCT07075133|OTHER|Physical activity in the morning|Physical exercise will consist of 3 weekly morning sessions that will combine aerobic and resistance exercises
214534135|NCT06784310|BEHAVIORAL|Medically Tailored Meals|Dare to Care will provide meals each week for 12 weeks tailored for comorbidities. Meals will be provided to both the adult and the child(ren). Meals have been developed with a Registered Dietitian and have been approved through Food Is Medicine Coalition (FMIC). Meals are delivered via Door Dash each week.
214534136|NCT06784310|BEHAVIORAL|Grocery Prescription|Instacart Fresh Funds (for those that need delivery) or Kroger Grocery Rx cards will be issued to each participant per month to be spent on eligible healthy food items (lean protein, lean dairy, fruits, vegetables, eggs, and nuts). For each participating child in the household, they will receive additional funds/per child loaded on their grocery Rx card
214534137|NCT06784310|BEHAVIORAL|Medically Tailored Meals and Grocery Prescription|will receive both tailored MTM meals per week for adult and child(ren) and the GP monthly grocery funds
214534138|NCT06784310|BEHAVIORAL|Nutritional Counseling|30 minutes per week of nutrition counseling and assistance.
214534139|NCT03378037|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
214534140|NCT05484895|BEHAVIORAL|WeTest-WeLink|"WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST."
214534141|NCT05484895|BEHAVIORAL|Control condition|Contact information of local NGO for emergency referrals; free additional HST.
214534142|NCT04978428|DRUG|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
214534143|NCT05045950|DRUG|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
214534144|NCT05045950|RADIATION|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
214534145|NCT04782700|OTHER|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
214534146|NCT01307917|DIETARY_SUPPLEMENT|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
214534147|NCT03738098|BEHAVIORAL|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
215153045|NCT07075133|OTHER|Physical activity in the afternoon|The physical exercise will consist of 3 weekly afternoon sessions that will combine aerobic and resistance exercises.
215153046|NCT07075419|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
214534148|NCT03738098|BEHAVIORAL|GUÍA|GUÍA for the ROR1 visit.
214534149|NCT05540418|OTHER|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
214534150|NCT05493228|DRUG|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
214534151|NCT05493228|DRUG|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
214534152|NCT04018885|DRUG|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
215153047|NCT07075419|DRUG|Penpulimab|Penpulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
215153048|NCT07074574|OTHER|Present odors to participants while recording brain activity using fMRI|Present odors to participants while recording brain activity using fMRI
215153049|NCT04379414|BEHAVIORAL|YES portal|A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.
214534153|NCT04018885|DRUG|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
215153050|NCT06956040|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year to depict suspicious lung nodules
215153051|NCT02392819|DIETARY_SUPPLEMENT|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
215153052|NCT02392819|DIETARY_SUPPLEMENT|Placebo|
215153053|NCT00124553|BEHAVIORAL|Intensive dietary advice|
215153054|NCT06517004|BIOLOGICAL|JWCAR201|Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
215153055|NCT00089401|DRUG|isolated perfusion|
214463341|NCT07062744|DEVICE|Swan-Ganz IQ catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂). These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
214463342|NCT07063394|DEVICE|Group 1|Patients in Group 1 will receive standard anesthesia protocol combined with interactive and immersive Virtual Reality (VR) therapy. This includes both engaging in interactive games that require cognitive and motor tasks, such as slicing objects or solving puzzles, and watching immersive 360-degree videos featuring calming environments like natural landscapes. The VR sessions are designed to distract patients from pain perception and reduce anxiety. The intervention will be administered for 3 sessions per day, each lasting 30-45 minutes, over 5 consecutive postoperative days.
214463343|NCT07063394|DEVICE|Group 2|Patients in Group 2 will receive standard anesthesia protocol combined with passive Virtual Reality (VR) therapy. This involves the use of a VR headset to watch immersive 360-degree videos, such as tranquil natural landscapes or underwater scenes, designed to promote relaxation and reduce anxiety. The VR sessions do not require active participation, allowing patients to passively observe calming environments. The intervention will be administered for 3 sessions per day, lasting 30-45 minutes each, over 5 consecutive postoperative days.
214463344|NCT07062900|BEHAVIORAL|Low-Intensity Physical Activity|"This includes a structured and progressive 8-week physical activity program involving:~Gentle walking~Portable pedal exerciser~Low-intensity resistance exercises (e.g., resistance bands, seated leg press, hip circles)~Supervised sessions with warm-up and cool-down components"
214463345|NCT07062900|BEHAVIORAL|usual care|Standard Medical Management: Participants continued with their prescribed medications and routine clinical follow-ups for congestive heart failure as directed by their healthcare providers.
214463346|NCT07062913|PROCEDURE|Conventional Rehabilitation|A standard rehabilitation program including positioning, range of motion exercises, stretching, strengthening, and conventional transcutaneous electrical nerve stimulation.
214463347|NCT07062913|DEVICE|Contrast Compression Therapy|Contrast compression therapy using a Game Ready® MED4 ELITE device applied to the affected upper extremity with sequential hot and cold phases and pneumatic compression.
214463348|NCT07062913|PROCEDURE|Conventional Rehabilitation|Same standard rehabilitation program as in the control group.
214463349|NCT07062237|OTHER|Ultrashort abstinence|Ultrashort abstinence: producing a sperm sample after 1 hour of abstinence.
214463350|NCT07062237|OTHER|Standard abstinence|Standard abstinence: producing a sperm sample after 2-5 days of abstinence.
214534154|NCT04018885|DRUG|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
215153056|NCT00089401|DRUG|melphalan|
215153057|NCT00089401|PROCEDURE|conventional surgery|
215153058|NCT02029248|OTHER|Quality of life questionnaire|
214534155|NCT03171532|PROCEDURE|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
214534156|NCT03119688|OTHER|Test Product|Micellar cleanser (0.09 ml)
215153059|NCT03734380|BEHAVIORAL|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
215153060|NCT03734380|BEHAVIORAL|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
215153061|NCT03734380|BEHAVIORAL|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
215153062|NCT05760469|OTHER|Screening|Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
215153063|NCT03959267|BEHAVIORAL|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
215153064|NCT01079052|DRUG|Famotidine|Tablets
214534157|NCT03119688|OTHER|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
214696021|NCT07084545|DEVICE|CT LUCIA 621P Intraocular Lens Implantation|The intervention consists of bilateral implantation of the CT LUCIA 621P intraocular lens (IOL) during routine cataract surgery in patients with a history of myopic corneal laser vision correction. The CT LUCIA 621P IOL is an approved, single-piece, hydrophobic acrylic lens designed to provide improved visual quality and refractive stability. Implantation is performed following each investigator's standard surgical procedures, including preoperative preparation, operative technique, and postoperative care. IOL power calculation uses the ZEISS Cataract Workflow platform with the VERACITY system and Barrett True-K with TK formula, incorporating the VERION Optical Coherence (VOC) technology.
214696022|NCT07083336|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
214696023|NCT07082088|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
215153065|NCT00084513|BIOLOGICAL|trastuzumab|
215153066|NCT00084513|DRUG|imatinib mesylate|
215153067|NCT04528966|OTHER|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
215153068|NCT04528966|OTHER|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
215153069|NCT02675673|PROCEDURE|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
214534158|NCT03119688|OTHER|Reference Product|Sterile Water (0.09 ml)
214534159|NCT03119688|OTHER|No Treatment|Unwashed area of the forearm
214534160|NCT00522717|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
214534161|NCT00522717|BEHAVIORAL|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
214534162|NCT06311747|BEHAVIORAL|Oculo-motor exercises|Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
214534163|NCT00890539|DRUG|Methacholine challenge|Clinical and research test used in asthma
214534164|NCT01257399|DRUG|Asacol®|400 mg tablets
214534165|NCT01257399|DRUG|Mesalazine|400mg tablets
214463351|NCT07064252|PROCEDURE|Educational Informed Consent Video|Individualized procedure-specific educational video. Videos are developed by a multidisciplinary collaboration of neurosurgeons, medical educators, and patient advocates. Each video is tailored based on location of the pathology, surgical approach, positioning, anticoagulation intake, and intraoperative adjuncts such as electrophysiology. Each video followes a standardized format covering anatomical considerations, preoperative care, the surgical procedure, and postoperative care including potential complications, expected recovery process, and post-surgery instructions.
214463352|NCT07064252|PROCEDURE|Standard informed consent|Standard informed consent, consisting of an in-person verbal consultation with the responsible neurosurgeon supplemented by written documentation and cranial models when applicable
214463353|NCT07062770|DEVICE|Continuous positive airway pressure (CPAP)|Subjects will be administered either 0, 5 or 10 cmH2O
215153070|NCT02675673|PROCEDURE|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
215153071|NCT04004195|DRUG|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
215153072|NCT00846092|DEVICE|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
215153073|NCT00846092|DEVICE|Near-infrared light (NIR)|"* Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily."
215153074|NCT01071798|DRUG|Rituximab|As prescribed by physician
215153075|NCT01571687|DIETARY_SUPPLEMENT|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
215153076|NCT01571687|DIETARY_SUPPLEMENT|Placebo|Intake of 6 identically appearing tablets daily containing placebo
215153077|NCT01732718|DRUG|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
215153078|NCT01732718|DRUG|Placebo|Matching placebo tablet by mouth daily for 6 weeks
215153079|NCT02111759|PROCEDURE|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
215153080|NCT02111759|PROCEDURE|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
215153081|NCT02569749|OTHER|Berlin and Epworth questionaries|
215153082|NCT02569749|OTHER|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
215153083|NCT02569749|OTHER|Night polygraph / Polysomnography|
214463354|NCT07062770|OTHER|Mask exhaust port flow|Subjects will be administered varying levels of exhaust flow: 35, 23, 18, 13 and 8 L/s
214463355|NCT07062107|PROCEDURE|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery adopts the traditional perfusion system and uses intraoperative optical coherence tomography to assist in observation.
214463356|NCT07062107|PROCEDURE|Phacoemulsification using adaptive fluidics technology|Phacoemulsification surgery adopts the adaptive fluidics system to precisely and dynamically control the pressure and flow rate of the perfusion fluid. During the operation, optical coherence tomography is used to assist in observing the stability of the anterior chamber.
214463357|NCT07064278|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Flexible bronchoscopy to assess airway patency, remove mucous plugs, and collect bronchoalveolar lavage (BAL) fluid for microbiological and cytological analysis.
214463358|NCT07064278|PROCEDURE|Chest CT with Scoring|Chest CT scans at baseline and day 14 to quantitatively assess lesion range, lesion type, pleural effusion, and lymphadenectasis (Total score: 0-13).
214463359|NCT07064278|DIAGNOSTIC_TEST|Monocyte Subpopulation Analysis|Flow cytometry analysis of peripheral blood to phenotype monocyte subsets (Classical, Intermediate, Non-classical) at baseline and day 14 to guide immunomodulatory therapy.
214463360|NCT07064278|DRUG|Azithromycin, Doxycycline, Prednisone|Sequential azithromycin as baseline therapy. Doxycycline (4 mg/kg/day) was used if BAL results confirmed azithromycin resistance. Oral prednisone (1 mg/kg/day for 5 days) was added if intermediate monocytes were \>15%.
214463361|NCT07064278|OTHER|Supportive Care|Management of cough, wheezing, and fever based on clinical symptoms.
214463362|NCT07063888|RADIATION|Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost|Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative.
214463363|NCT06801522|DRUG|0.1% xylometazoline nasal drops|Xylometazoline is direct acting, non selective, adrenergic agonist binding with alpha 1\&2 receptors, used for vasoconstriction to decrease nasal bleeding.
214463364|NCT06801522|DRUG|Adrenaline nasal pack|Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
214463365|NCT06773325|BEHAVIORAL|Buzzy application|Buzzy application during heel prick blood collection
214463366|NCT05335096|BEHAVIORAL|An AI-chatbot-based mHealth intervention|The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
214463367|NCT05335096|BEHAVIORAL|An attention-chatbot-based mHealth intervention|The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
214463368|NCT05335096|BEHAVIORAL|Educational materials|the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
214534166|NCT03226106|BEHAVIORAL|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
214534167|NCT03226106|OTHER|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
214534168|NCT06957353|PROCEDURE|oblique K-wire technique in controlling Calcaneal displacement during osteotomy in flatfoot correction|Under spinal Anaesthesia , patients will placed in lateral decubitus position. A standard lateral incision will be made over the calcaneus, and the osteotomy site will be exposed. An oblique K-wire will be inserted percutaneously into the posterior calcaneus under fluoroscopic guidance to facilitate the desired displacement. Cannulated screws will then be inserted across the osteotomy site to secure the calcaneal fragment. Post-operative care will include a non-weight bearing protocol for six weeks, followed by gradual weight bearing as tolerated.
214534169|NCT04349657|DEVICE|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
214534170|NCT04349657|PROCEDURE|Endarterectomy treatment group|Surgical treatment through endarterectomy
214534171|NCT05249309|DRUG|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
214534172|NCT00721214|DRUG|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
214534173|NCT03067363|DRUG|MOR107|MOR107 solution for injection
214696024|NCT07084532|OTHER|Chewing gum|Dry mouth was diagnosed in the initial assessment of diabetic individuals assigned to the intervention group. Following the assessment, they were asked to chew gum for 15 minutes before each main meal for seven days. Dry mouth was re-evaluated with the Xerostomia Scale seven days later.
214696025|NCT07084532|OTHER|Standart therapy group|The control group was informed about the study. They were then assessed for dry mouth. They were asked to follow their standard treatment. They were warned not to chew gum. A day later, dry mouth was assessed again without any treatment.
215153084|NCT01734603|PROCEDURE|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
215153085|NCT01734603|PROCEDURE|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
215153086|NCT06405724|DRUG|Liposomal bupivacaine|133mg LB 20mL thoracic paravertebral nerve block
215153087|NCT06405724|DRUG|Ropivacaine|0.5% ropivacaine 20mL thoracic paravertebral nerve block
215153088|NCT04115865|DEVICE|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
214534174|NCT03067363|DRUG|Placebo|Solution for injection manufactured to match MOR107 solution for injection
214534175|NCT03067363|OTHER|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
214534176|NCT00184197|DRUG|Botulinum toxin|
214534177|NCT00184197|DRUG|Placebos|
214696026|NCT07078643|PROCEDURE|Superior Hypogastric Plexus Block (SHPB)|Laparoscopic superior hypogastric plexus block with bupivacaine and lidocaine injection near sacral promontory.
214696027|NCT07078643|PROCEDURE|Erector Spinae Plane Block (ESPB)|Erector spinae plane block with ultrasound-guided injection of bupivacaine and lidocaine at T10 level.
214696028|NCT07084662|DRUG|Xinlikang capsules|Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks
214696029|NCT07084662|DRUG|mimic capsules|mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.
214534178|NCT00866164|DEVICE|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
215153089|NCT04052152|DRUG|Anlotinib and Sintilimab injection|Patients will be treated with Anlotinib and Sintilimab injection
215153090|NCT02617472|DEVICE|Pelvic floor exerciser|Daily exercise using the study device
215153091|NCT04553380|DRUG|basic insulin|"1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night."
215153092|NCT06119139|DRUG|3.6 ml 4% Articaine hydrochloride|3.6 ml 4% articaine buccal infiltration
215153093|NCT06119139|DRUG|1.8 ml 4% Articaine hydrochloride|1.8 ml 4% articaine buccal infiltration
215153094|NCT02561468|DRUG|Nefopam|
215153095|NCT02561468|DRUG|Saline|
215153096|NCT03078218|DIAGNOSTIC_TEST|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
214534179|NCT00536081|DRUG|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
214534180|NCT02805036|DEVICE|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
214534181|NCT02805036|DEVICE|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
214534182|NCT01830764|DRUG|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
214534183|NCT00245245|DRUG|recombinant porcine coagulation factor VIII (OBI-1)|
214534184|NCT01058525|PROCEDURE|median nerve block|median nerve block performed using ultrasound guidance
214534185|NCT01058525|PROCEDURE|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
214534186|NCT04950036|DIAGNOSTIC_TEST|Diagnostic Test|The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.
214534187|NCT06454201|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
214534188|NCT06454201|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
215153097|NCT00277654|DRUG|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
215153098|NCT03485872|OTHER|Self-Screening and Referral Information|Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
215153099|NCT03485872|OTHER|Standard Care|Demographic and quality of life questionnaires; standard care provided by participants' GPs
215153100|NCT03323281|OTHER|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
215153101|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and Montanide ISA51|
215153102|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and CpG 7909|
215153103|NCT06048640|DIETARY_SUPPLEMENT|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
215153104|NCT04198051|DRUG|adjuvant chemotherapy|"Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months."
215153105|NCT01888302|DRUG|Cisplatin|Given IV
215153106|NCT01888302|DRUG|Gemcitabine Hydrochloride|Given IV
215153107|NCT01888302|OTHER|Quality-of-Life Assessment|Ancillary studies
215153108|NCT01888302|DRUG|Sirolimus|Given PO
215153109|NCT00847509|DRUG|[F-18]FLT|The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
215153110|NCT02223702|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
215153111|NCT02223702|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
215153112|NCT02223702|DRUG|Moxifloxacin|400 mg, once in a day for 7 days.
214534189|NCT00883636|OTHER|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
214534190|NCT00883636|OTHER|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
214534191|NCT00883636|OTHER|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
214534192|NCT00637247|DRUG|imexon in combination with gemcitabine|875 mg/m\^2 imexon IV + 1000 mg/m\^2 gemcitabine IV
214534193|NCT00637247|DRUG|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m\^2 gemcitabine IV
215153113|NCT06333119|DIAGNOSTIC_TEST|modified rankin scale|"Modified Rankin Scale: The functional status of individuals with stroke is determined by this scale.~Modified Ashworth Scale: It allows determining the severity of spasticity. Tinetti Balance and Gait Scale: This scale helps determine the risk of falling by evaluating balance and gait.~Danish Prostatic Symptom Score: It allows to evaluate the storage and urinary functions of the bladder."
215153114|NCT01227018|DRUG|STA-9090|Given IV
215153115|NCT01227018|RADIATION|Radiologic imaging|radiologic modalities used to evaluate response to treatment
215153116|NCT01227018|PROCEDURE|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
215153117|NCT05922800|DEVICE|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
215153118|NCT05922800|DRUG|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
215153119|NCT00190151|DRUG|ciprofloxacin|
215153120|NCT05273671|DRUG|Nalbuphine|will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
215153121|NCT05273671|DRUG|Dexmedetomidine|will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
215153122|NCT05273671|DRUG|normal Saline|will receive with a saline solution 10 min before the end of surgery
215153123|NCT00921167|DRUG|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
215153124|NCT03921645|DRUG|aerosol antibiotics|use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
214534194|NCT00488319|DRUG|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
214534195|NCT03553485|DEVICE|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
214534196|NCT03553485|DEVICE|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
214534197|NCT03553485|RADIATION|Radiotherapy|Standard treatment for included patients
214534198|NCT04047771|DRUG|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
214534199|NCT04648111|DIAGNOSTIC_TEST|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
214534200|NCT02041221|DRUG|SPARC1316 Dose 1|The subjects will receive SPARC1316.
214534201|NCT02041221|DRUG|Placebo|
214534202|NCT02041221|DRUG|SPARC1316 Dose 2|
215153125|NCT05758636|BEHAVIORAL|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
215153126|NCT01640392|BEHAVIORAL|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
215153127|NCT02164409|PROCEDURE|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
215153128|NCT03613064|OTHER|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
215153129|NCT03511196|DRUG|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
215153130|NCT03511196|DRUG|Abiraterone|Prednisone 5 mg once a day with food.
215153131|NCT03511196|DRUG|Prednisone|Abiraterone 1000 mg daily with empty stomach.
215153132|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 1|Investigational Reflex Test 1
215153133|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 2|Investigational Reflex Test 2
214534203|NCT02041221|DRUG|SPARC1316 Dose 3|
214534204|NCT02041221|DRUG|SPARC1316 Dose 4|
214534205|NCT02041221|DRUG|SPARC1316 Dose 5|
214534206|NCT05220956|BEHAVIORAL|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
214534207|NCT05220956|BEHAVIORAL|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
214534208|NCT00146198|DRUG|ALGRX 4975|
214534209|NCT02716688|DRUG|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
214534210|NCT02716688|RADIATION|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
215153134|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 3|Investigational Reflex Test 3
214534211|NCT04361968|OTHER|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
215153135|NCT06957600|PROCEDURE|Preoperative marking|Applying markings prior to uniport VATS wedge resections helps localize small, potentially early-stage lung tumors. After marking, the patients are positioned laterally and receive general anesthesia with single-lung ventilation. The investigators perform VATS wedge resection using uniportal techniques. The utility incision is made in the 5th intercostal space between the anterior and mid-axillary lines. Insufflation is not typically utilized. The lesion is localized, elevated, and confirmed by palpation. The investigators then staple around the lesion using the Endo GIA™ ultra universal stapler with an Articulating Reload featuring Tri-Staple™ Technology in 45 or 60 mm lengths, choosing purple or black loads based on parenchyma thickness. Finally, the investigators close the wound and place one chest drain in the thoracic cavity, set to active suction of 5-10 cm of water.
214534212|NCT04361968|OTHER|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
214534213|NCT04361968|OTHER|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
214534214|NCT04361968|OTHER|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
214534215|NCT06370117|BEHAVIORAL|Buzzy|Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
214696030|NCT07082972|DRUG|Botulinum toxin injection|Patients will receive a total of 20 units of botulinum toxin type A (Botox) injected into each masseter muscle. The injections will be administered at three standardized sites on each side using a fine needle to ensure accurate delivery. Muscle activity will be recorded using electromyography (EMG) before the injection, and follow-up EMG measurements will be taken at one month and four months post-treatment to evaluate changes in muscle activity and treatment efficacy.
215153136|NCT06257433|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
215153137|NCT03956654|DRUG|Ribociclib|combination of ribociclib and letrozole
214534216|NCT06370117|BEHAVIORAL|Music video listening|Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure.
214534217|NCT06370117|BEHAVIORAL|Buzzy+ Music video listening|60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool. 60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed midway between the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
214534218|NCT05501782|OTHER|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
214534219|NCT02830009|OTHER|Urines samples|24-hour urines will be collected
214534220|NCT02830009|OTHER|Blood sample|
214534221|NCT02646735|DRUG|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
215153138|NCT04068753|DRUG|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
215153139|NCT04068753|DRUG|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
215153140|NCT03935958|DIETARY_SUPPLEMENT|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
215153141|NCT03935958|OTHER|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
215153142|NCT04858048|PROCEDURE|Anesthesia|2 types of anesthesia (general and WALANT) performed during the surgery
215153143|NCT04245865|DRUG|Fluorouracil|2800 mg/m2 iv
215153144|NCT04245865|DRUG|Calcium folinate|400 mg/m2 iv
214696031|NCT07082972|DEVICE|Occlusal splint|Patients with myofascial pain syndrome will receive custom-made occlusal splints to wear during sleep. These splints help reduce abnormal muscle activity and relieve pain by redistributing bite forces. EMG measurements will be taken before and during treatment to monitor changes in muscle activity.
215153145|NCT04245865|DRUG|Oxaliplatin|85 mg/m2 iv
215153146|NCT04245865|DRUG|Bevacizumab|5 mg/kg OR 7.5 mg/kg iv
215153147|NCT04245865|DRUG|Capecitabine|2000 mg/m2 orally daily for two weeks
215153148|NCT04245865|DIETARY_SUPPLEMENT|Tocotrienol|300 mg orally x 3 daily
215153149|NCT04245865|OTHER|Placebo|Placebo orally x 3 daily
215153150|NCT03227640|PROCEDURE|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
215153151|NCT03227640|DEVICE|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
215153152|NCT01912170|DIETARY_SUPPLEMENT|Fish oil|
215153153|NCT01912170|DIETARY_SUPPLEMENT|Flaxseed oil|
215153154|NCT03931369|DRUG|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
214534222|NCT02646735|DRUG|Exemestane 25 mg|Exemestane 25mg will be given once daily.
215153155|NCT04213248|DRUG|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
215153156|NCT00753649|BIOLOGICAL|Infanrix™ hexa|Intramuscular, three doses
214534223|NCT00144378|DRUG|Irinotecan|
215153157|NCT00499616|DRUG|carboplatin|Given IV
215153158|NCT00499616|DRUG|cyclophosphamide|Given IV
215153159|NCT00499616|DRUG|doxorubicin hydrochloride|Given IV
215153160|NCT00499616|DRUG|etoposide|Given orally
214534224|NCT01871168|PROCEDURE|TAP block|Infusion of 0.5-1% lidocaine
214534225|NCT01871168|PROCEDURE|Sham TAP block|Infusion of saline
214534226|NCT02241278|DRUG|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
214534227|NCT02344056|OTHER|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
214534228|NCT02344056|OTHER|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
214534229|NCT02675803|BIOLOGICAL|VAY736|VAY736 treatment
214534230|NCT02675803|BIOLOGICAL|VAY736 placebo|VAY736 placebo
214534231|NCT00875615|DRUG|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
214534232|NCT00875615|DRUG|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
214534233|NCT00875615|DRUG|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
214534234|NCT02483845|DRUG|Natalizumab|
214534235|NCT00002796|DRUG|fluorouracil|Given IV
214534236|NCT00002796|DRUG|sodium phenylbutyrate|Given IV
215153161|NCT00499616|DRUG|topotecan hydrochloride|Given IV
215153162|NCT00499616|DRUG|Isotretinoin|Given orally
215153163|NCT00499616|PROCEDURE|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
215153164|NCT00499616|DRUG|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
215153165|NCT04531930|PROCEDURE|surgery|Colorectal surgery, mainly total proctocolectomy.
215153166|NCT04531930|PROCEDURE|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
215153167|NCT04531930|OTHER|self choosed methods|A patient chooses a method for himself other than surgery.
215153168|NCT02569788|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
215153169|NCT00067730|DRUG|Drotrecogin Alfa (activated)|
215153170|NCT04233723|OTHER|peripheral blood samples|venous puncture
215153171|NCT01241201|DIETARY_SUPPLEMENT|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
215153172|NCT00045617|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
215153173|NCT00045617|BIOLOGICAL|monoclonal antibody GD2 anti-idiotype vaccine|
214534237|NCT00002796|DRUG|indomethacin|Given orally
214534238|NCT00002796|BIOLOGICAL|recombinant interferon gamma|Given subcutaneously
214534239|NCT05466188|DIAGNOSTIC_TEST|CPC|CPC
214534240|NCT00286962|DEVICE|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
214534241|NCT00286962|DEVICE|continuous subcutaneous insulin infusion (CSII) or MDI|
214534242|NCT00870532|DRUG|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
215153174|NCT00045617|DRUG|cisplatin|
215153175|NCT00045617|DRUG|etoposide|
215153176|NCT00045617|RADIATION|radiation therapy|
215153177|NCT06088784|DRUG|ATH-399A|Orally administered drug in capsule form.
215153178|NCT06088784|DRUG|Placebo|Orally administered drug in capsule form.
215153179|NCT03108469|DRUG|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
215153180|NCT03108469|OTHER|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
215153181|NCT01506804|OTHER|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
215153182|NCT00826462|DRUG|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
215153183|NCT00826462|DRUG|Placebo|Injection with sodium chloride at start and at 3 weeks
215153184|NCT00826462|DRUG|Lidocaine|10 mg of lidocaine at start and at 3 weeks
215153185|NCT00826462|OTHER|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
215153186|NCT00826462|DRUG|Naproxen|Naproxen 500 mg bid for 14 days
215153187|NCT06521931|DRUG|PN20|Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
215153188|NCT02955043|BEHAVIORAL|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
215153189|NCT05876000|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for mechanical circulatory support
215153190|NCT01081106|PROCEDURE|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
215153191|NCT00004366|PROCEDURE|Physical therapy|
215153192|NCT01189409|DRUG|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
215153193|NCT01189409|DRUG|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
215153194|NCT04150848|BEHAVIORAL|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
215153195|NCT04150848|BEHAVIORAL|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
215153196|NCT01938716|DRUG|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
215153197|NCT06001957|DIAGNOSTIC_TEST|Whole exome sequencing|"Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described.~Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer."
215153198|NCT00859911|DIETARY_SUPPLEMENT|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
215153199|NCT02238652|BEHAVIORAL|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
214463369|NCT05391230|OTHER|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
214463370|NCT05391230|OTHER|Untreated lesu|Water soaked baby wraps (lesus)
214463371|NCT07062497|DRUG|Rectus Sheath Block|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1%, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
215153200|NCT02238652|BEHAVIORAL|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
215153201|NCT02238652|BEHAVIORAL|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
215153202|NCT02238652|BEHAVIORAL|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
215153203|NCT02238652|BEHAVIORAL|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
215153204|NCT00737815|DIETARY_SUPPLEMENT|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
215153205|NCT00737815|OTHER|Placebo|Inactive placebo pill
215153206|NCT05305404|DRUG|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
215153207|NCT05305404|DRUG|Placebo|oral placebo to be administered once at 11:00PM
215153208|NCT01470950|PROCEDURE|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
215153209|NCT02817568|OTHER|Drawing Blood|Drawing Blood for genetic analysis
215153210|NCT00426244|OTHER|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
215153211|NCT00426244|OTHER|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
215153212|NCT04441918|COMBINATION_PRODUCT|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
215153213|NCT03136848|DRUG|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
215153214|NCT00098813|DRUG|romidepsin|Given IV
215153215|NCT00098813|OTHER|laboratory biomarker analysis|Correlative studies
215153216|NCT00098813|PROCEDURE|positron emission tomography|Correlative studies
215153217|NCT01801228|DRUG|Eplerenone|
215153218|NCT01956929|DRUG|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
215153219|NCT01956929|DRUG|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
215153220|NCT06186193|BEHAVIORAL|MyP|see above: attention exercise based on phone app
214534243|NCT00870532|DRUG|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
214534244|NCT00715637|DRUG|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
214534245|NCT00715637|DRUG|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
214534246|NCT01772823|BEHAVIORAL|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
214534247|NCT01772823|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
214534248|NCT01772823|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
214534249|NCT02345915|OTHER|Blood sample|
214534250|NCT02345915|OTHER|Electrocardiogram|
215153221|NCT05653076|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract|Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
215153222|NCT00710580|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
215153223|NCT00710580|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
215153224|NCT00710580|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
215153225|NCT04884178|DEVICE|Trifocal Preloaded IOL Delivery System|UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.
215153226|NCT01588392|BEHAVIORAL|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
215153227|NCT01588392|BEHAVIORAL|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
215153228|NCT01432925|PROCEDURE|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
215153229|NCT02894736|DEVICE|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
215153230|NCT05297981|PROCEDURE|Erector spinae plane block|The patient will be placed in lateral decubitus position. A high frequency linear probe of a transportable Fuji M-Turbo ultrasound system will be placed on the spinous process at T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the inplane technique,then 0.5 ml/kg of 0.25% bupivacaine will be injected between the muscle and transverse process. The same procedure will be performed bilaterally.
215153231|NCT05297981|PROCEDURE|Quadratus lumborum block|The patient will be placed in the lateral decubitus position. A low frequency curved probe of a transportable Fuji M-Turbo ultrasound system will be placed horizontally in the anterior axillary line midway between the subcostal margin and the iliac crest to identify the triple abdominal muscle layers.A 22-G, 80-mm needle echogenic needle will be inserted in plane relative to the US probe, into the posterior aspect of the QL muscle (between QL and erector spinae muscle); this is known as QLB type 2. Then, 0.5 ml/kg of 0.25% bupivacaine will be injected behind the muscle as a bolus dose. The block will be performed bilaterally.
215153232|NCT04946981|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
215153233|NCT04946981|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
215153234|NCT05147090|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
215153235|NCT05147090|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
215153236|NCT03727256|OTHER|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
215153237|NCT03727256|OTHER|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
215153238|NCT03123952|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
215153239|NCT05029778|DIETARY_SUPPLEMENT|L-arginine 3g + L-Citruline 2 g|receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
215153240|NCT05029778|DRUG|Placebo|receive placebo 3g PO, for 24 h, until birth.
215153241|NCT02670239|PROCEDURE|normothermic ex vivo lung perfusion|
215153242|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
215153243|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
215153244|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
215153245|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
215153246|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
215153247|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
215153248|NCT04424264|DRUG|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
215153249|NCT04424264|DRUG|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
215153250|NCT04424264|DRUG|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
215153251|NCT02807584|DEVICE|ELECT|
215153252|NCT06288100|OTHER|Observation|"1. Measure changes in tibial slope after medial opening wedge High tibial osteotomy in Skeletally mature patient with unicompartmental osteoarthitis and genuvarus knee~2. Evaluate the effect of tibial slope angle change on the clinical outcome at 1 year ."
215153253|NCT04367623|OTHER|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
215153254|NCT02182752|DRUG|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
215153255|NCT02182752|DRUG|Ropivacaine|Interscalene block using ropivacaine
215153256|NCT04316819|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
215153257|NCT04287296|BEHAVIORAL|Wakey!|Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
215153258|NCT02919579|DRUG|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
215153259|NCT02919579|DRUG|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
215153260|NCT02919579|OTHER|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
215153261|NCT02919579|DRUG|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
215153262|NCT01614392|BEHAVIORAL|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
215153263|NCT01614392|BEHAVIORAL|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
214696032|NCT07082972|COMBINATION_PRODUCT|Botulinum toxin + Occlusal splint combined|Patients will receive both botulinum toxin injections (20 units per masseter muscle, injected at three standardized points per side) and will use occlusal splints during sleep. EMG measurements will be conducted before treatment, and at follow-up visits to assess the combined effect of pharmacological and mechanical therapy on muscle activity.
214696033|NCT03732391|DRUG|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
215153264|NCT01657240|DRUG|PRO-118|instill one drop in each eye once a day for 21 days
215153265|NCT01657240|DRUG|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
215153266|NCT05597488|DEVICE|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
215153267|NCT01118000|PROCEDURE|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
214534251|NCT04059497|BEHAVIORAL|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
214534252|NCT04059497|BEHAVIORAL|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w\_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
214534253|NCT05908578|OTHER|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
215153268|NCT06514768|BIOLOGICAL|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
215153269|NCT03683459|DEVICE|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
215153270|NCT01994824|DRUG|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
215153271|NCT03623529|DRUG|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
215153272|NCT03623529|DRUG|Placebo|Placebo Arm
215153273|NCT02212951|DRUG|BIOD-531|
215153274|NCT02212951|DRUG|Humalog Mix 75/25|
215153275|NCT02212951|DRUG|Humulin R U-500|
215153276|NCT00433004|DRUG|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
215153277|NCT03180918|PROCEDURE|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
215153278|NCT05048095|OTHER|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
215153279|NCT04562818|DIAGNOSTIC_TEST|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
215153280|NCT04562818|DIAGNOSTIC_TEST|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
215153281|NCT04562818|DIAGNOSTIC_TEST|Leucocytes|
215153282|NCT03536416|BEHAVIORAL|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
215153283|NCT05522348|PROCEDURE|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|two patient fitted custom made plates will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
215153284|NCT05522348|PROCEDURE|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|one patient fitted custom made plate will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
215153285|NCT01744080|OTHER|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
215153286|NCT01744080|OTHER|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
215153287|NCT04517175|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
215153288|NCT00220636|DRUG|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
215153289|NCT06465407|DIETARY_SUPPLEMENT|Collagen|Participants will consume two 30-g amount of collagen peptides derived from bovine hide (commercially available as Vital Proteins or Peptan) mixed in 300 ml of orange gatorade zero.
215153290|NCT06465407|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume two 30-g amount of pure maltodextrin mixed in 300 ml of orange gatorade zero.
215153291|NCT01169818|DRUG|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
215153292|NCT01119209|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
215153293|NCT01119209|DRUG|Saline|Approved by the Danish Medicines Agency
215153294|NCT05480267|PROCEDURE|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
215153295|NCT03766152|DEVICE|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
215153296|NCT00330967|DRUG|20% Intralipid|lipid infusion
215153297|NCT00539942|DRUG|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
215153298|NCT00539942|DEVICE|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
215153299|NCT01970098|DRUG|KPS-0373, High dose|28 weeks
215153300|NCT01970098|DRUG|KPS-0373, Low dose|28 weeks
215153301|NCT01970098|DRUG|Placebo|28 weeks
215153302|NCT05828485|DRUG|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
215153303|NCT05167643|DRUG|Enituzumab injection+Abesili tablets+Anastrozole tablets|According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
215153304|NCT02616588|BEHAVIORAL|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
215153305|NCT00892983|BEHAVIORAL|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
215153306|NCT00892983|BEHAVIORAL|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
215153307|NCT03448913|PROCEDURE|PECS block|It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
215153308|NCT06211959|BEHAVIORAL|Approach Bias Modification with Implementation Intentions|Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
215153309|NCT05466864|DEVICE|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
215153310|NCT04065737|DRUG|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
215153311|NCT00257257|DRUG|Rimonabant (SR141716)|
215153312|NCT01149668|DRUG|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
215153313|NCT03680846|DEVICE|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
215153314|NCT03680846|OTHER|CMM|Conventional Medical Management
215153315|NCT02029300|OTHER|Fiberoptic Intubation through the nasal route|
215153316|NCT02029300|OTHER|Fiberoptic intubation through the oral route|
215153317|NCT05045378|DRUG|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
215153318|NCT05045378|DRUG|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
214534254|NCT05908578|OTHER|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
214534255|NCT04287634|OTHER|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
214534256|NCT04287634|OTHER|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
214534257|NCT02601105|OTHER|Placebo Vehicle Cream|Lipoderm Cream alone
215153319|NCT05045378|DRUG|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
215153320|NCT05752760|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
215153321|NCT05752760|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
215153322|NCT04533529|DRUG|Seltorexant|Seltorexant tablet will be administered orally once daily.
215153323|NCT04533529|DRUG|Placebo|Matching placebo tablet will be administered orally once daily.
215153324|NCT05084833|BEHAVIORAL|Control|Electronic educational materials
215153325|NCT05084833|BEHAVIORAL|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
215153326|NCT05084833|BEHAVIORAL|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
215153327|NCT03014544|DEVICE|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
214534258|NCT02601105|OTHER|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
214534259|NCT02064309|DEVICE|Beta-Air device for encapsulation of transplanted human islets|
215153328|NCT03014544|DEVICE|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
215153329|NCT03612531|PROCEDURE|Manual Therapy|Receive manual therapy
215153330|NCT01950130|PROCEDURE|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
215153331|NCT06784063|DEVICE|Clareon Vivity Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
215153332|NCT05658913|DRUG|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
215153333|NCT02229344|OTHER|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
215153334|NCT06563804|DRUG|S227928|For administration via intravenous (IV) infusion
215153335|NCT06563804|DRUG|Venetoclax|For oral administration
215153336|NCT04129008|DRUG|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
215153337|NCT04129008|DRUG|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
215153338|NCT03249402|DRUG|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
215153339|NCT03249402|DRUG|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
215153340|NCT06628830|DEVICE|VamosJuntxs App|"Psychoeducational materials (videos, information and interactive exercises) about depression, anxiety and social support~Skills training through information and activities based on the principles of cognitive behavioral therapy (cognitive restructuring, behavioral activation, emotional regulation, problem solving and exposure)"
215153341|NCT06628830|OTHER|Web Conciencia Saludable|mental health psychoeducational campaign (https://concienciasaludable.uchile.cl/)
215153342|NCT02363452|DRUG|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
215153343|NCT04329806|DRUG|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
215153344|NCT04329806|DRUG|Amlodipine 5 MG|Amlodipine 5 MG twice daily
215153345|NCT05017571|DRUG|Colchicine|Colchicine 1 capsule (0.6 mg) per day
215153346|NCT05017571|DRUG|Placebo|Placebo 1 capsule per day
215153347|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
215153348|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
215153349|NCT05258656|BEHAVIORAL|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
215153350|NCT05258656|BEHAVIORAL|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
215153351|NCT04604301|DEVICE|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
215153352|NCT02862431|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
215153353|NCT02862431|DRUG|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
215153354|NCT05361551|PROCEDURE|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
215153355|NCT01897688|BIOLOGICAL|Islet Cell Transplant|
215153356|NCT02636595|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
215153357|NCT03772158|DRUG|Cetirizine 10mg|Chewable tablet
215153358|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
215153359|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
215153360|NCT00099333|DRUG|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
215153361|NCT00099333|DRUG|Insulin|Insulin will be taken according to the subject's current regimen
215153362|NCT00751517|DRUG|Methotrexate|
215153363|NCT00751517|DRUG|Cyclophosphamide|
215153364|NCT04006132|DEVICE|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
215153365|NCT06167733|DEVICE|VERTICA Active device|VERTICA device with a therapeutic RF energy level
215153366|NCT06167733|DEVICE|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
215153367|NCT00880919|DRUG|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
215153368|NCT00880919|DRUG|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
215153369|NCT01291732|DRUG|Matching placebo|single dose of matching placebo
215153370|NCT01291732|DRUG|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
215153371|NCT03968562|DRUG|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
215153372|NCT06255431|DRUG|Ezerra cream|"The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen."
215153373|NCT03085602|BEHAVIORAL|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
215153374|NCT03085602|BEHAVIORAL|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
215153375|NCT03105752|OTHER|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
215153376|NCT02578706|DRUG|Clopidogrel|Clopidogrel 75mg
215153377|NCT02578706|DRUG|Aspirin|81 mg
215153378|NCT02578706|DRUG|Placebo|
215153379|NCT00408200|DRUG|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
215153380|NCT00408200|DEVICE|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
215153381|NCT00578825|DRUG|Lopinavir / Ritonavir plus Ribavirin|
215153382|NCT05641259|DRUG|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
215153383|NCT05641259|DRUG|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
215153384|NCT03646552|DRUG|THX-110|"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."
215153385|NCT01576809|DRUG|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
215153386|NCT02015637|DRUG|Delafloxacin|single dose
215153387|NCT02015637|DRUG|Ceftriaxone|single dose
215153388|NCT03644004|OTHER|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
215153389|NCT00619814|PROCEDURE|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
214534260|NCT03693040|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
214534261|NCT00540384|DRUG|Placebo|Placebo
214534262|NCT00540384|DRUG|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
214534263|NCT04551378|OTHER|Quality-of-Life Assessment|Ancillary studies
214534264|NCT04551378|OTHER|Survey Administration|Complete survey
214534265|NCT02778334|OTHER|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
214534266|NCT00132951|DRUG|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
214534267|NCT00132951|DRUG|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
214534268|NCT04458987|BEHAVIORAL|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
214534269|NCT05452421|DIETARY_SUPPLEMENT|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
215153390|NCT03085264|BEHAVIORAL|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
215153391|NCT05298553|DEVICE|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
215153392|NCT05298553|DEVICE|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
215153393|NCT02961829|DRUG|Maraviroc|antiretroviral intensification
215153394|NCT02961829|DRUG|Dolutegravir|antiretroviral intensification
215153395|NCT02961829|BIOLOGICAL|Dendritic Cell Vaccine|Therapeutic vaccination
215153396|NCT02961829|DRUG|Auranofin|purging
215153397|NCT02961829|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
215153398|NCT02354196|PROCEDURE|CCTA|CT of heart to assess coronary disease
215153399|NCT00087867|DRUG|SCIO-469|two 30-mg capsules three times daily
215153400|NCT00087867|DRUG|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
215153401|NCT01855061|PROCEDURE|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
215153402|NCT01855061|PROCEDURE|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
215153403|NCT01855061|PROCEDURE|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
215153404|NCT01855061|PROCEDURE|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
215153405|NCT06186843|BEHAVIORAL|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
215153406|NCT02922647|DEVICE|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
215153407|NCT02922647|DEVICE|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
215153408|NCT01695304|OTHER|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
215153409|NCT05155267|OTHER|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
215153410|NCT05821062|OTHER|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
215153411|NCT05821062|OTHER|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
215153412|NCT05821062|OTHER|standard ASA therapy|ASA 100 mg daily
215153413|NCT04203186|DRUG|atovaquone-proguanil|Malaria standard treatment regimen
215153414|NCT02122003|DRUG|Sorafenib|Sorafenib 400 mg bid
215153415|NCT05590078|DEVICE|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
215153416|NCT05590078|OTHER|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
215153417|NCT05590078|OTHER|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
215153418|NCT05590078|OTHER|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
215153419|NCT01829906|BEHAVIORAL|Multidisciplinary outpatient programme|
215153420|NCT01829906|BEHAVIORAL|Inpatient lifestyle programme|
215153421|NCT04211909|DRUG|SOF/VEL|400/100 mg FDC tablet orally once daily.
215153422|NCT04211909|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
215153423|NCT04936087|OTHER|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
215153424|NCT03529591|DEVICE|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
214534270|NCT05452421|DIETARY_SUPPLEMENT|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
215153425|NCT03529591|PROCEDURE|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
215153426|NCT05676580|PROCEDURE|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
214534271|NCT01732926|DRUG|Idelalisib|150 mg tablet administered orally twice daily
214534272|NCT01732926|DRUG|Rituximab|375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
214534273|NCT01732926|DRUG|Bendamustine|90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
214534274|NCT01732926|DRUG|Placebo|Tablet administered orally twice daily
214534275|NCT00282698|DRUG|Insulin infusion with a goal|
214534276|NCT02018471|BEHAVIORAL|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
215153427|NCT05676580|OTHER|abstention|No surgery
215153428|NCT04455815|DRUG|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
215153429|NCT03458195|OTHER|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
215153430|NCT06296316|DEVICE|Restorelle Polypropylene Mesh|"The Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse).~Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene."
215153431|NCT02747498|PROCEDURE|Procedure with circumferential pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
215153432|NCT02747498|PROCEDURE|Procedure with linear ablation in addiction to pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
215153433|NCT04106206|DRUG|LY3372689|Administered orally
215153434|NCT04106206|DRUG|Placebo|Administered orally
215153435|NCT04593199|BEHAVIORAL|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
215153436|NCT04593199|BEHAVIORAL|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
215153437|NCT02106390|BIOLOGICAL|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
214534277|NCT05498077|PROCEDURE|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
214534278|NCT06379555|PROCEDURE|Walanpoigne|Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
214534279|NCT04868981|DRUG|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
214534280|NCT04868981|DRUG|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
214534281|NCT00317759|BIOLOGICAL|therapeutic autologous lymphocytes|
214534282|NCT00317759|DRUG|fludarabine phosphate|
214534283|NCT00583050|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
214534284|NCT04205214|BEHAVIORAL|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
214534285|NCT00676897|DRUG|Simvastatin|Simvastatin 40mg PO or NGT
214534286|NCT00676897|DRUG|Placebo|Corn Starch
214534287|NCT02262364|BIOLOGICAL|APS|See above
214534288|NCT02160561|OTHER|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
214534289|NCT00902226|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
214534290|NCT02753764|DRUG|AZD7624|
215153438|NCT02106390|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
214696034|NCT06330844|BEHAVIORAL|Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)|RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.
215153439|NCT04063007|OTHER|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
215153440|NCT03198507|DRUG|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
215153441|NCT03198507|DRUG|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
215153442|NCT04516889|PROCEDURE|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
215153443|NCT05436743|DRUG|K-Y Jelly, Topical Gel soaked packs|Topical Gel used as lubricant
215153444|NCT05436743|OTHER|Water soaked packs|Water soaked packs for reduction of postoperative sore throat
215153445|NCT02980861|PROCEDURE|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
215153446|NCT02980861|PROCEDURE|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
214463372|NCT07062497|DRUG|Rectus Sheath Block with Clonidine|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1% + clonidine 75 mcg, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
214463373|NCT07062172|DIAGNOSTIC_TEST|Low Dose CT Scan|Completed once after screening and eligibility is confirmed.
214463374|NCT06864234|DRUG|Saline (NaCl)|IV 0.9% NaCl (5 ml)
214463375|NCT06864234|DRUG|Metoprolol Tartrate|Metoprolol Tartrate (5 ml of 1 mg/ml solution for injection)
214463376|NCT06852469|DRUG|Lorazepam 1 mg tablet|Lorazepam is an oral medication which is FDA approved to treat anxiety.
215153447|NCT03007693|DRUG|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
215153448|NCT03007693|DRUG|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
215153449|NCT05244135|PROCEDURE|Pulmonary rehabilitation|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
215153450|NCT04857632|DRUG|Statin|atorvastatin 20mg per day for 7 days
215153451|NCT01910935|BEHAVIORAL|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
215153452|NCT00545259|DRUG|AEB071|
215153453|NCT05492682|DRUG|PeptiCRAd-1|All patients will receive PeptiCRAd-1.
215153454|NCT05492682|DRUG|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
215153455|NCT05492682|DRUG|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
215153456|NCT05543642|BIOLOGICAL|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
215153457|NCT05543642|BIOLOGICAL|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
215153458|NCT06667141|DRUG|ACR-2316|ACR-2316 is an experimental drug
215153459|NCT00921518|DRUG|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
215153460|NCT00921518|DRUG|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
215153461|NCT06487494|PROCEDURE|Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures|2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.
215153462|NCT06487494|PROCEDURE|Circumcision wound closure using continuous sutuing|Continuous suturing is the standard following circumcision for wound closure.
215153463|NCT05382949|OTHER|SilverBills Financial and Legal Tech Tool for Caregivers|All subjects will be receiving the Silverbills financial and legal tech tool and a pre-post analysis will be conducted.
215153464|NCT04655794|DRUG|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
215153465|NCT04806555|DIAGNOSTIC_TEST|Compression ultrasound examination|After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
214463377|NCT06852469|DRUG|Placebo tablet|Placebo will match the study drug in mode of administration, color, size, and taste.
214534291|NCT02753764|DRUG|prednisone|oral prednisone 20 mg bid for one week
214534292|NCT02753764|DRUG|Placebo|
214534293|NCT01049984|DRUG|Rasagiline|1mg tablet daily for 18 weeks
214534294|NCT01049984|DRUG|Placebo|one tablet daily for 18 weeks
214534295|NCT03496337|OTHER|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
215153466|NCT05377801|BEHAVIORAL|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
215153467|NCT04781751|DRUG|insulin injection|Carpal tunnel syndrome sonagraphic injection
215153468|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
215153469|NCT06169826|DRUG|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
215153470|NCT06169826|OTHER|Control|Control
215153471|NCT05475925|DRUG|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
215153472|NCT03298906|DRUG|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
215153473|NCT03298906|DRUG|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
215153474|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
215153475|NCT04746235|DRUG|Venetoclax|Given PO
215153476|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 8 Gy|
215153477|NCT02811250|RADIATION|Stereotactic radiotherapy 5 x 8 Gy|
215153478|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 10 Gy|
215153479|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 12 Gy|
215153480|NCT01325636|OTHER|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
215153481|NCT05218655|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
215153482|NCT01269190|PROCEDURE|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
215153483|NCT01269190|PROCEDURE|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
215153484|NCT01269190|DRUG|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
214534296|NCT02968654|PROCEDURE|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
214534297|NCT02968654|PROCEDURE|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
214534298|NCT04435405|OTHER|Observational|video footage analysis of group and individual behavioral processes.
214534299|NCT00000578|DRUG|theophylline|
214534300|NCT00000578|DRUG|beclomethasone|
215153485|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
214534301|NCT02181998|DRUG|Full dose tenecteplase|
214534302|NCT02181998|DRUG|Unfractioned heparin|
215153486|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
215153487|NCT06549348|RADIATION|Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance|Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
215153488|NCT04384692|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
215153489|NCT04384692|DRUG|Busulfan|Given IV
215153490|NCT04384692|DRUG|Cyclophosphamide|Given IV
215153491|NCT04384692|DRUG|Fludarabine|Given IV
215153492|NCT04384692|DRUG|Melphalan|Given IV
215153493|NCT04384692|DRUG|Methotrexate|Given IV
215153494|NCT04384692|DRUG|Mycophenolate Mofetil|Given IV or PO
215153495|NCT04384692|DRUG|Ruxolitinib|Given PO
215153496|NCT04384692|DRUG|Tacrolimus|Given IV and PO
215153497|NCT04384692|RADIATION|Total-Body Irradiation|Undergo TBI
215153498|NCT04384692|PROCEDURE|Computed Tomography|Undergo CT scan
215153499|NCT04384692|PROCEDURE|Echocardiography|Undergo echocardiography
215153500|NCT04384692|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215153501|NCT04384692|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215153502|NCT04384692|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
215153503|NCT06012136|DRUG|VH4004280|VH4004280 will be administered.
215153504|NCT06012136|DRUG|Placebo|Placebo will be administered.
215153505|NCT06012136|DRUG|VH4011499|VH4011499 will be administered.
215153506|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
215153507|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
215153508|NCT03599765|OTHER|Best Practice|Receive routine therapy
215153509|NCT03599765|PROCEDURE|Local Consolidation Therapy|Receive LCT
215153510|NCT05024968|DRUG|Sintilimab|Given by IV
215153511|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
214463378|NCT06807112|OTHER|Intravenously administered secretin|16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.
214463379|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
214463380|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
214463381|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
214463382|NCT06279351|DRUG|Thalidomide+cetuximab+FOLFOX/FOLFIRI|Thalidomide+cetuximab+FOLFOX/FOLFIRI
214463383|NCT06089278|DRUG|300mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
214463384|NCT06089278|DRUG|600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
214463385|NCT06089278|DRUG|TQH2722 injection matching placebo|Placebo without active substance.
214463386|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
214463387|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
214463388|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
214463389|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
214463390|NCT06325657|BIOLOGICAL|Placebp|Placebo
214463391|NCT04527185|DRUG|Endotoxin|Endotoxin 0.4ng/kg i.v.
214463392|NCT06389565|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.
214463393|NCT06389565|OTHER|Change My Story|Change My Story is a narrative game with a choose-your-own-adventure format in which players navigate emotionally difficult experiences along with the character(s) and interact with the virtual environment to choose a narrative path toward the story's conclusion. It will used to address important obstacles in the mental health treatment gap for Y-PLWH.
214463394|NCT04068246|DRUG|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
214463395|NCT04068246|DRUG|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
214463396|NCT04116320|DEVICE|Echopulse|The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
214463397|NCT04116320|DRUG|Poly ICLC|Poly-ICLC is a TLR3 agonist.
214463398|NCT04116320|DRUG|Standard of Care PD-1 Therapy|PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
214463399|NCT06492746|DEVICE|HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring|The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
214463400|NCT06964633|BEHAVIORAL|Kūkākūkā Discussion Sessions|Participants attend a single 2-hour, flip-chart-guided module that integrates a focused health topic (e.g., colorectal cancer screening) with Hawaiian cultural teachings-beginning with an 'ōlelo no'eau (proverb) and guided by trained facilitators-to foster peer discussion, deliver key health information, and assess knowledge via pre- and post-test surveys.
214463401|NCT05678673|DRUG|XL092|Specified doses on specified days
214463402|NCT05678673|DRUG|Nivolumab|Specified doses on specified days
214463403|NCT05678673|DRUG|Sunitinib Malate|Specified doses on specified days
214463404|NCT03533283|DRUG|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
214463405|NCT03533283|DRUG|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
215153512|NCT05957068|BEHAVIORAL|Control|Usual care group.
215153513|NCT03458247|DRUG|Abiraterone acetate standard dose|1000 mg/day
215153514|NCT03458247|DRUG|Abiraterone acetate escalated dose|2000 mg/day
214463406|NCT03533283|DRUG|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
214463407|NCT03533283|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
214534303|NCT02181998|DRUG|Enoxaparin|
215153515|NCT04007029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
215153516|NCT04007029|DRUG|Cyclophosphamide|Given IV
215153517|NCT04007029|DRUG|Fludarabine Phosphate|Given IV
215153518|NCT04007029|BIOLOGICAL|Tocilizumab|Given IV
215153519|NCT02962063|BIOLOGICAL|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
215153520|NCT02962063|DRUG|carboplatin AUC 2/paclitaxel|
215153521|NCT02962063|RADIATION|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
215153522|NCT02962063|PROCEDURE|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
215153523|NCT02962063|DRUG|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
215153524|NCT01923636|OTHER|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
215153525|NCT00241839|DRUG|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
215153526|NCT00241839|DRUG|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
215153527|NCT00241839|DRUG|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
215153528|NCT00241839|DRUG|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
215153529|NCT04031014|DEVICE|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
215153530|NCT04031014|DEVICE|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
215153531|NCT05865431|DRUG|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
215153532|NCT05598801|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
215153533|NCT05204641|BIOLOGICAL|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
215153534|NCT03859687|BIOLOGICAL|Vitamin A supplementation|liquid oral vitamin A supplementation
215153535|NCT03859687|BIOLOGICAL|No vitamin A supplementation|No vitamin A supplementation
215153536|NCT04394234|DRUG|Direct oral anticoagulant (DOACs)|Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
215153537|NCT04394234|DRUG|Warfarin|Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
215153538|NCT05575830|BIOLOGICAL|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
215153539|NCT06284681|BEHAVIORAL|Weight-focused health coaching|Following the definition of structured lifestyle interventions within the current obesity clinical practice guidelines, the weight-focused health coaching intervention will be delivered as a multi-component behavior change intervention intended to produce clinically-important weight loss through consuming a healthy, energy-restricted diet and increasing physical activity.
215153540|NCT06284681|BEHAVIORAL|Weight-neutral health coaching|Dietary and physical activity prescriptions for the weight-neutral health coaching intervention will be similar to the weight-focused intervention except the diet prescription will be designed to fully meet daily estimated energy requirements rather than creating a negative energy balance and producing weight loss. Health coaches will not emphasize changes in body weight as an explicit goal or as a mediator of improved cardiometabolic health. Rather, health coaches will emphasize achieving diet and exercise behavioral goals as a direct means to improving cardiometabolic health independently of changes in body weight.
214463408|NCT03533283|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
214463409|NCT03533283|DRUG|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
214463410|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
214463411|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
214463412|NCT05211180|BEHAVIORAL|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
214534304|NCT02648113|PROCEDURE|Restrictive transfusion|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
214463413|NCT05211180|BEHAVIORAL|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
214534305|NCT02648113|PROCEDURE|Liberal transfusion|transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
215153541|NCT06284681|BEHAVIORAL|Intensify lifestyle approach|Participants identified as non-responders to initial health coaching interventions may be re-randomized to receive a 4-month membership to the local YMCA and health coaches will assist participants in identifying and enrolling in at least 2 weekly group fitness classes at the YMCA.
215153542|NCT06284681|OTHER|Augment with enhanced medical management|Participants identified as non-responders to initial health coaching interventions may be re-randomized to meet with the primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
215153543|NCT03405441|DRUG|JNJ-55375515 Dose Level 1|Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
215153544|NCT03405441|DRUG|JNJ-55375515 Dose Level 2|Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
215153545|NCT03405441|DRUG|JNJ-55375515 Dose Level 3|Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
214463414|NCT05907798|PROCEDURE|LIMA Blood flow|30 minutes after induction
214463415|NCT06804083|DRUG|oral combination of colostrum and Serenoa repens extracts (PROSTYM®)|"The composition of PROSTYM® (per capsule) includes bovine colostrum (30 mg), Serenoa extracts (320 mg), glutathione (30 mg), N-acetyl cysteine (20 mg), Ribes nigrum extracts (50 mg), willow extracts (50 mg), zinc (5 mg), selenium (27.5 micrograms), and vitamin E (6 mg).~Drug administration (1 capsule per day) for 6 months."
214463416|NCT04140903|DRUG|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
214463417|NCT04140903|DRUG|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
214463418|NCT06464510|DRUG|Early Vasopressin|Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
214463419|NCT06464510|DRUG|Norepinephrine and Vasopressin for Rescue|Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
214463420|NCT05385237|DIAGNOSTIC_TEST|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
214463421|NCT04972669|DEVICE|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
215153546|NCT03405441|DRUG|JNJ-55375515 Dose Level 4|Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
215153547|NCT03405441|DRUG|JNJ-55375515 Dose Level 5|Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
215153548|NCT03405441|DRUG|JNJ-55375515 Dose Level 6|Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
215153549|NCT03405441|DRUG|Placebo|All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
215153550|NCT03405441|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
215153551|NCT04808778|DRUG|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
215153552|NCT01719510|OTHER|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~* one swab for GBS detection by real-time PCR~* the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~2. A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
215153553|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
215153554|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
215153555|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
215153556|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
215153557|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
215153558|NCT06053502|OTHER|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
215153559|NCT01512615|OTHER|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
215153560|NCT01512615|OTHER|Control group|Usual care, clinical control as provided by treating heart centre
215153561|NCT02465827|DRUG|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
215153562|NCT02465827|DRUG|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
215153563|NCT02465827|DRUG|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
215153564|NCT05245617|DEVICE|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
215153565|NCT01465919|DRUG|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
215153566|NCT01465919|OTHER|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
215153567|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
215153568|NCT04423302|DIETARY_SUPPLEMENT|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
215153569|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
215153570|NCT00872443|OTHER|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
215153571|NCT02877589|OTHER|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
215153572|NCT02282098|DRUG|Colchicine|Colchicine 0.6mg twice daily
215153573|NCT02282098|DRUG|Placebo|Placebo Colchicine
215153574|NCT00004428|DRUG|CPX|
215153575|NCT01755182|DRUG|approved pharmacologic therapy|
215153576|NCT01755182|PROCEDURE|TAE|after randomization, and after 3 months
214463422|NCT04972669|DEVICE|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
214463423|NCT05258071|DRUG|Pirepemat|Oral use
214463424|NCT05258071|DRUG|Placebo|Oral use
214463425|NCT04468659|DRUG|Lecanemab|IV infusion.
214463426|NCT04468659|DRUG|Placebo|IV infusion.
214463427|NCT06232109|DRUG|Fluvoxamine|Oral
215153577|NCT01447459|BEHAVIORAL|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
215153578|NCT05974124|DEVICE|Povidone-Iodine 0.66%|Povidone-iodine 0.66% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
215153579|NCT05974124|DEVICE|Chlorhexidine 0.02%|Chlorhexidine 0.02% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
215153580|NCT00500513|PROCEDURE|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
215153581|NCT00500513|PROCEDURE|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
215153582|NCT00500513|RADIATION|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
215153583|NCT06208280|DRUG|After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.|"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)"
215153584|NCT06081270|OTHER|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
215153585|NCT00132704|RADIATION|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
215153586|NCT00132704|RADIATION|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
215153587|NCT03135964|DEVICE|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
215153588|NCT00133068|BEHAVIORAL|Computer|Computer intervention only
215153589|NCT00133068|BEHAVIORAL|Reduction in financial barrier|Copay only
215153590|NCT00133068|BEHAVIORAL|Computer intervention & reduction of financial barrier|computer intervention \& copay
215153591|NCT00133068|BEHAVIORAL|Control|No intervention
215153592|NCT00439517|DRUG|UFOX + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
214463428|NCT06232109|DRUG|Itraconazole|Oral
214463429|NCT06232109|DRUG|Paroxetine|Oral
214463430|NCT06232109|DRUG|ASN51|Oral
214463431|NCT04070443|DRUG|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
214463432|NCT04070443|DRUG|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
214463433|NCT05921344|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
214463434|NCT06283511|OTHER|educational workshops|patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme
214463435|NCT04588064|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
214534306|NCT02648113|BIOLOGICAL|red blood transfusion|
214534307|NCT05908305|DRUG|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
215153593|NCT00439517|DRUG|FOLFOX4 + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16"
215153594|NCT01684813|DRUG|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
215153595|NCT01684813|DRUG|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
215153596|NCT00988728|DRUG|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
215153597|NCT00988728|DRUG|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
215153598|NCT00988728|DRUG|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
215153599|NCT03171571|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
215153600|NCT03244839|PROCEDURE|bariatric surgery|bariatric surgery
215153601|NCT02304367|BIOLOGICAL|Burosumab|Solution for subcutaneous injection
215153602|NCT01185665|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulator
215153603|NCT01185665|DEVICE|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
215153604|NCT00554489|BEHAVIORAL|exercise intervention|participation in physical activity intervention program weeks 2 through 5
215153605|NCT04526769|DIAGNOSTIC_TEST|Tear Collection|"A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored."
215153606|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
215153607|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
215153608|NCT04462614|DRUG|Decrease per-dialytic heparin therapy|Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
215153609|NCT03544177|OTHER|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
214534308|NCT03742817|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
214696035|NCT06330844|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)|"ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations."
214463436|NCT05170386|OTHER|Cognitive training Therapy|"Cognitive training Therapy include: Writing the reminiscences~• Solving a table• Writing a letter making a calendar and writing a note about the daily activities on it Facing patients' fears instead of avoiding them.Using role-playing to prepare for potentially problematic interactions with others.Learning to calm one's mind and relax one's body."
214463437|NCT05170386|OTHER|instructive conventional treatment|instructive conventional treatment breathing relaxation exercise inform of diaphragmatic breathing Practice sleep hygiene such as keeping a regular sleep schedule. Get regular exercise. Minimize noise. Minimize light. Manage the temperature so that you're comfortable.
214463438|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
214463439|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
215153610|NCT03544177|OTHER|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
214463440|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
214463441|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
214463442|NCT04457596|BIOLOGICAL|Trastuzumab Emtansine|Given IV
215153611|NCT00199212|DRUG|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
214463443|NCT04457596|DRUG|Placebo Administration|Given PO
214463444|NCT04457596|DRUG|Tucatinib|Given PO
214463445|NCT04457596|OTHER|Questionnaire Administration|Ancillary studies
214463446|NCT04457596|OTHER|Quality-of-Life Assessment|Ancillary studies
214463447|NCT01192048|OTHER|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
214463448|NCT04322864|OTHER|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
214463449|NCT03538899|DRUG|AProArt-CD34|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
214463450|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
214463451|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
214463452|NCT05988788|OTHER|Epigallocatechin-3-gallate|to be used as a root canal irrigant
214463453|NCT05988788|OTHER|sodium hypochlorite|to be used as a root canal irrigant
214463454|NCT05378113|DRUG|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
214463455|NCT05378113|DRUG|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
214463456|NCT06546891|BEHAVIORAL|Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
214463457|NCT05304104|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
214463458|NCT05895838|DRUG|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
214463459|NCT05895838|PROCEDURE|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
214463460|NCT05895838|PROCEDURE|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
214463461|NCT05895838|DRUG|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
214463462|NCT03127007|DRUG|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
214463463|NCT03127007|DRUG|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
214463464|NCT06485687|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
214534309|NCT06354192|BEHAVIORAL|Precision Nudging for Hypertension Management|The hypertension digital health intervention under study combines behavioral science theory with a type of machine learning called reinforcement learning to enable precision nudging: the selection, assembly, and delivery of behavioral science-based messages created to address barriers to, and promote, management of hypertension. The behavioral design process used for the hypertension DHI intentionally includes research on traditionally underserved populations, such as racial and ethnic minorities and people with lower incomes or educational attainment. By including the right ingredients to meet a diverse set of needs and by effectively personalizing the content each individual sees based on their own reactions, the intervention aims to improve health equity by matching each individual to the right behavioral approach.
214534310|NCT06050018|OTHER|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
214534311|NCT06050018|OTHER|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
215153612|NCT02403648|DRUG|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
215153613|NCT02403648|DRUG|Lilly Glucagon|
215153614|NCT02403648|DRUG|Novo Glucagon|
215153615|NCT00526071|DRUG|migalastat HCl|
215153616|NCT04767984|DRUG|Atorvastatin Calcium|Given PO
215153617|NCT04767984|PROCEDURE|Biopsy of Colon|Undergo colonoscopy with biopsy
215153618|NCT04767984|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215153619|NCT04767984|DRUG|Placebo Administration|Given PO
215153620|NCT04767984|OTHER|Questionnaire Administration|Ancillary studies
214463465|NCT05530603|BEHAVIORAL|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
214534312|NCT04574661|OTHER|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
214696036|NCT02389712|DRUG|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
215153621|NCT01168037|DEVICE|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
215153622|NCT01168037|PROCEDURE|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
215153623|NCT05996133|DRUG|Bupivacaine Hcl 0.25% Inj|30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.
215153624|NCT05996133|OTHER|Normal saline|3 mL normal saline
215153625|NCT04229537|BIOLOGICAL|SCT-I10A|200 mg intravenous (IV) on Day 1 of Q3W.
215153626|NCT04229537|BIOLOGICAL|SCT200|6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
215153627|NCT04229537|OTHER|Chemotherapy|Capecitabine and Oxaliplatin.
214463466|NCT05423444|BEHAVIORAL|TF-CBT|evidence-based psychotherapy for trauma in youth
214463467|NCT05423444|BEHAVIORAL|TAU|treatment as usual
214463468|NCT02043678|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
214463469|NCT02043678|DRUG|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
214463470|NCT02043678|DRUG|Abiraterone|1000 mg once daily, oral, with best supportive care
214463471|NCT02043678|DRUG|Prednisone/Prednisolone|5 mg twice daily, oral, with best supportive care
214463472|NCT06499389|PROCEDURE|Systematic and early intensive instrumental respiratory physiotherapy for patients undergoing difficult ventilatory weaning|Patients randomized to this group will receive 3 sessions per day of intensive early respiratory physiotherapy with instrumental techniques from randomization to day 7, before and after any extubation. The strategy will be applied until day 7 of randomization, regardless of the patient's status (intubated or not).
214463473|NCT06499389|PROCEDURE|Protocolized standard-of-care respiratory physiotherapy|Patients in this group will receive standardized and protocolized respiratory physiotherapy to reproduce the usual practices of non-expert centers,1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary
214463474|NCT05522075|BEHAVIORAL|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
214463475|NCT05522075|BEHAVIORAL|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
215153628|NCT04251130|DRUG|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
215153629|NCT03387878|DEVICE|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
215153630|NCT04077723|DRUG|Englumafusp alfa|Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
215153631|NCT04077723|DRUG|Obinutuzumab|"A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III)."
215153632|NCT04077723|DRUG|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
215153633|NCT04077723|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
215153634|NCT05884541|OTHER|TipsbyText Messages|Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
215153635|NCT05021068|OTHER|Postural Assessment|Spinal mouse measurement
214534313|NCT04574661|OTHER|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
214534314|NCT00104975|BIOLOGICAL|alemtuzumab|
214534315|NCT00104975|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214534316|NCT00104975|DRUG|fludarabine phosphate|
214534317|NCT00104975|DRUG|melphalan|
214534318|NCT00104975|DRUG|tacrolimus|
214534319|NCT00104975|DRUG|thiotepa|
214534320|NCT00104975|PROCEDURE|peripheral blood stem cell transplantation|
214534321|NCT04765553|DRUG|NI-0501|emapalumab single i.v infusion (1 mg/kg)
214534322|NCT04765553|DRUG|Saline|Saline single i.v infusion
214534323|NCT03128788|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
214534324|NCT03106298|DRUG|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
214534325|NCT01328808|DRUG|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
214534326|NCT00772655|DRUG|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
214534327|NCT00772655|DRUG|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
214534328|NCT03523325|OTHER|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
214534329|NCT00249119|DRUG|risperidone|
214534330|NCT01486511|PROCEDURE|Liver resection|Hepatectomy including both minor and major.
214534331|NCT01486511|RADIATION|Computed Tomography|Computed Tomography +/- pulmonary angiography
214534332|NCT02396498|DRUG|HIPEC|Using cisplatin in HIPEC plus oral S-1
214534333|NCT06008340|DEVICE|Dual chamber Pacemaker|Anti bradycardia device implanted in patients with complete heart block, the device has 2 leads, one in the RT atrium and the other in RV. The RV lead positioned either apical or septal
214534334|NCT02274623|DRUG|CTAP101 Capsules|escalating doses
214534335|NCT01829828|BEHAVIORAL|No intervention|This is an observational study with no investigational drug administered.
214534336|NCT05738447|BIOLOGICAL|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
214534337|NCT02987322|DIETARY_SUPPLEMENT|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
214534338|NCT01304628|DRUG|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
214534339|NCT04068285|OTHER|Aerobic Exercise|Participants will be making aerobic exercise
214534340|NCT03645005|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
214534341|NCT03645005|BEHAVIORAL|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
214534342|NCT00321321|DRUG|Sulfonylurea|
214534343|NCT02154477|DRUG|intranasal insulin|insulin
214534344|NCT02154477|DRUG|placebo (intranasal saline)|saline
214534345|NCT02209727|DRUG|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
214534346|NCT02673307|BEHAVIORAL|1 chewing gum over 45 minutes|
214534347|NCT02273700|DRUG|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
214534348|NCT03503162|DEVICE|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
214534349|NCT04566198|OTHER|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
214534350|NCT03330717|PROCEDURE|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
214534351|NCT03330717|PROCEDURE|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
214534352|NCT03330717|PROCEDURE|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
215153636|NCT04803552|DEVICE|Overnight sleep study with Sleepiz One and a respiratory polygraphy|"Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~* Thoracic respiratory effort: respiration frequency (BR), respiration curve~* Airflow: respiration frequency (BR), respiration curve~* Body movement: body position~* Blood oxygen saturation (SpO2)~* Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions"
215153637|NCT01328132|DRUG|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
215153638|NCT01328132|DRUG|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
215153639|NCT05744934|DEVICE|LUX-Dx™|Placement of LUX-Dx at the time of stage 1 palliation
215153640|NCT00463515|DRUG|carboplatin/gemcitabine|
215153641|NCT00463515|PROCEDURE|cisplatin/radiation therapy|
215153642|NCT04378543|BIOLOGICAL|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
214534353|NCT06544252|DIETARY_SUPPLEMENT|Low glycaemic index rice-based mixed meal (GI value = 47)|The mixed meal consisted of Basmati rice, chicken, and green-leafy vegetables. The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
214534354|NCT06544252|DIETARY_SUPPLEMENT|High glycaemic index rice-based mixed meal (GI value = 80)|The mixed meal consisted of fragrant rice, chicken, and green-leafy vegetables.The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
214534355|NCT00818870|DRUG|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
214534356|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
214534357|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
214534358|NCT06054919|DRUG|Cholecalciferol|vitamin D3
214534359|NCT05132660|DRUG|Sinemet CR|25 mg carbidopa/100 mg levodopa
215153643|NCT00694642|BIOLOGICAL|Selected CD 133+ cells|Endothelial progenitor cell CD 133
215153644|NCT03829644|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
215153645|NCT05633758|DRUG|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
214534360|NCT05132660|DRUG|placebo|Placebo pill of similar size/shape
214534361|NCT02051985|OTHER|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
214534362|NCT02051985|OTHER|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
214534363|NCT03891641|BEHAVIORAL|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
214534364|NCT03234842|RADIATION|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
214534365|NCT03234842|RADIATION|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
214534366|NCT03234842|DRUG|Chemotherapy|Concurrent weekly chemotherapy at standard doses
214534367|NCT03403556|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
214534368|NCT03403556|DRUG|Monorova|Rosuvastatin 20mg qd for 24 weeks
214534369|NCT06051097|DIAGNOSTIC_TEST|sleep study|over-night polysomnography
214534370|NCT01575483|DRUG|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
215153646|NCT05633758|DRUG|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
215153647|NCT00485810|DRUG|Olanzapine Hydrochloride|
215153648|NCT00080236|DRUG|IDN-6556|
215153649|NCT00080236|DRUG|Placebo|
215153650|NCT05966688|DRUG|SPR720|Multiple oral doses of SPR720 capsules.
215153651|NCT05966688|DRUG|Azithromycin|Multiple oral doses of azithromycin.
215153652|NCT05966688|DRUG|Ethambutol|Multiple oral doses of ethambutol.
215153653|NCT01792752|BEHAVIORAL|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
215153654|NCT01792752|BEHAVIORAL|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
215153655|NCT01792752|BEHAVIORAL|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
215153656|NCT01792752|BEHAVIORAL|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
215153657|NCT01792752|BEHAVIORAL|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
215153658|NCT00776516|DRUG|mirabegron|oral
215153659|NCT00776516|DRUG|rifampin|oral
215153660|NCT00281242|OTHER|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
215153661|NCT00467753|DRUG|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
215153662|NCT00467753|OTHER|Placebo/sugar pill|Dosage similar to active drug
214534371|NCT01561885|OTHER|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
214534372|NCT04659200|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
214534373|NCT01705223|BIOLOGICAL|DNA vaccine|4mg/dose, three doses at week 0,4,8
214534374|NCT01705223|BIOLOGICAL|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
214534375|NCT01705223|BIOLOGICAL|rTV boost|at week 16
214534376|NCT01705223|BIOLOGICAL|rTV boost|at week 24
214534377|NCT01705223|BIOLOGICAL|rTV boost|at week 32
214534378|NCT00841477|BIOLOGICAL|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
214534379|NCT00841477|BEHAVIORAL|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
214696037|NCT02389712|DRUG|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
214696038|NCT02909998|OTHER|Blood sample|Conservation at the end of the blood sample
215153663|NCT01869764|DRUG|omega-3 fatty acid|Given PO
215153664|NCT01869764|OTHER|placebo|Given PO
215153665|NCT01869764|OTHER|laboratory biomarker analysis|Correlative studies
215153666|NCT05442476|OTHER|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
215153667|NCT05442476|OTHER|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
215153668|NCT05442476|OTHER|conventional physiotherapy|conventional physiotherapy
215153669|NCT04235621|OTHER|FSGS/TR-MCD|This is a non-interventional study
215153670|NCT04235621|OTHER|Diabetic Nephropathy (DN)|This is a non-interventional study
215153671|NCT01312532|DEVICE|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
215153672|NCT01312532|DEVICE|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
215153673|NCT01626872|DRUG|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
215153674|NCT01626872|DRUG|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
215153675|NCT01626872|DRUG|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
215153676|NCT01626872|DRUG|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
215153677|NCT05724537|PROCEDURE|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
215153678|NCT02979548|DRUG|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
215153679|NCT02979548|DRUG|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
215153680|NCT02979548|DRUG|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
215153681|NCT05275283|OTHER|PEEP|6 cmH2O of PEEP
215153682|NCT00960999|RADIATION|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
215153683|NCT00960999|RADIATION|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
215153684|NCT01696188|DEVICE|interscalene nerve catheter|
215153685|NCT05114252|DEVICE|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
215153686|NCT05114252|BEHAVIORAL|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
215153687|NCT04350957|DIAGNOSTIC_TEST|Low-dose Imaging|"We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations."
215153688|NCT00302367|DRUG|OROS methylphenidate hydrochloride|
215153689|NCT00302367|DRUG|immediate release methylphenidate hydrochloride|
215153690|NCT01578486|DRUG|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
215153691|NCT02843516|OTHER|No intervention|No intervention
215153692|NCT02504593|DEVICE|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
215153693|NCT01673542|DRUG|Lidocaine-Prilocaine 5%|
214534380|NCT01340040|DRUG|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
214534381|NCT05854771|OTHER|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
214534382|NCT05854771|OTHER|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
214534383|NCT04045522|DRUG|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
215153694|NCT01673542|DRUG|DEXERYL|
215153695|NCT02756286|OTHER|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
215153696|NCT04838470|OTHER|cardiac rehabilitation|multidisciplinary disease management program
215153697|NCT01017302|DRUG|Placebo|Subcutenaous once weekly for 4 weeks
214534384|NCT01636830|DEVICE|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
214534385|NCT04850859|OTHER|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
214534386|NCT04850859|OTHER|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
214534387|NCT01562483|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
214534388|NCT01562483|DRUG|Placebo|Identical to the Namisol arm.
214534389|NCT05167513|DRUG|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
214534390|NCT04064723|DEVICE|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
215153698|NCT01017302|DRUG|Placebo|Single subcutaneous dose in week 5
215153699|NCT01017302|DRUG|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
215153700|NCT01017302|DRUG|RO5095932|Single subcutenaous dose in week 5
215153701|NCT01958164|DRUG|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
215153702|NCT01958164|DRUG|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
215153703|NCT01958164|DRUG|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
215153704|NCT01958164|DRUG|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
215153705|NCT02173899|BIOLOGICAL|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
215153706|NCT02173899|BIOLOGICAL|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
215153707|NCT02173899|BIOLOGICAL|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
215153708|NCT01397968|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
215153709|NCT01397968|DRUG|Placebo|Placebo capsule Placebo tablet
214696039|NCT05286073|PROCEDURE|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
214696040|NCT05331950|OTHER|Office Workers|Office Workers which will be observed/exposed with different task and different factors
214696041|NCT02457182|OTHER|Mindfulness-based Stress Reduction (MBSR)|
214696042|NCT02457182|OTHER|Usual medical therapy|
214696043|NCT01446679|DRUG|atrovastatin|oral
214696044|NCT01895491|BIOLOGICAL|VM206DNA|
214696045|NCT01895491|BIOLOGICAL|VM206Ad|
214696046|NCT05665621|OTHER|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
214696047|NCT02337595|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
214534391|NCT03628456|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
214534392|NCT03628456|DEVICE|Hill-Rom Monarch|High-frequency chest wall oscillation vest
214696048|NCT00823524|BIOLOGICAL|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
215153710|NCT02716480|BEHAVIORAL|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
215153711|NCT02716480|BEHAVIORAL|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
215153712|NCT01698580|OTHER|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
214534393|NCT00557336|DRUG|somatropin|
214534394|NCT00920699|DRUG|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
214534395|NCT01880697|BIOLOGICAL|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
214534396|NCT03709485|OTHER|rectal swab for microbial culture.|Rectal swab and culture.
214534397|NCT00953862|DRUG|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
214534398|NCT03723915|BIOLOGICAL|Pembrolizumab|Given IV
214534399|NCT03723915|BIOLOGICAL|Wild-type Reovirus|Given pelareorep IV
214534400|NCT00989313|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
214696049|NCT05875558|PROCEDURE|M-TACE|Lipiodol combined with microspheres
214696050|NCT03534063|GENETIC|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
214696051|NCT03440255|DEVICE|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
214696052|NCT00834704|DRUG|PEGPH20|PEGylated recombinant human hyaluronidase
214696053|NCT04342182|BIOLOGICAL|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
214696054|NCT00734344|DRUG|Raltegravir|Raltegravir 400 mg. BID
214696055|NCT00734344|DRUG|Efavirenz|600 mg once daily
214696056|NCT00734344|DRUG|Emtricitibine|200mg once daily
214534401|NCT04961983|BEHAVIORAL|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months."
214534402|NCT03696602|DIAGNOSTIC_TEST|bronchial provocation test|
214534403|NCT04612478|BEHAVIORAL|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
214534404|NCT04612478|BEHAVIORAL|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
214534405|NCT06357936|PROCEDURE|nano-fat grafting in chronic limb ischaemia|The nano fat grafting procedure in the clinical trial involves the collection of adipose tissue under tumescent anesthesia, which is a technique to swell and firm the targeted area, through a separate puncture in the anterior abdominal wall. Following the collection, the adipose tissue undergoes a process of cannulation to prepare the nano fat. This prepared material is then injected into the tissues of the foot and leg using standard intramuscular injection needles. The injections are performed in various directions to ensure proper distribution of the nano fat. This method does not require additional drug therapy. It leverages the natural growth factors and stem cells present in adipose tissue, aiming to improve blood flow and tissue regeneration in limbs affected by critical ischemia. The unique aspect of this treatment is its focus on using autologous materials, minimizing the risk of rejection and side effects associated with foreign substances.
214534406|NCT06357936|PROCEDURE|sham comparator|For the clinical trial, a sham procedure would be designed to mimic the nano fat grafting without providing the actual therapeutic intervention. This involve the patient undergoing a similar process with tumescent anesthesia and making a puncture on the anterior abdominal wall. However, instead of harvesting adipose tissue and preparing nano fat, a placebo solution (such as saline) would be injected using the same intramuscular injection technique. The aim of this sham comparator is to assess the psychological and physiological effects of the nano fat grafting procedure itself, by eliminating the potential therapeutic benefits of the nano fat.
214534407|NCT03497221|BEHAVIORAL|Education intervention|The same description of arm Education intervention.
214534408|NCT03497221|BEHAVIORAL|Visual identity campaign|The same description of arm Visual identity campaign.
214534409|NCT00002621|BIOLOGICAL|recombinant interferon alfa|
214534410|NCT04322916|DEVICE|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
214534411|NCT04913623|PROCEDURE|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
214534412|NCT01576913|OTHER|Music listening|Listening to tempo music while cycling in an exercise test
214534413|NCT04317001|DRUG|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
214534414|NCT04317001|DRUG|Placebo|placebo
214534415|NCT00873678|BIOLOGICAL|Whole blood sample|Whole blood sample (10 ml)
214534416|NCT00335374|DRUG|Pardoprunox|12 -42 mg
214534417|NCT01547247|DEVICE|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
214534418|NCT01547247|PROCEDURE|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
214534419|NCT00418418|PROCEDURE|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
214534420|NCT00418418|PROCEDURE|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
214534421|NCT00418418|BIOLOGICAL|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
214534422|NCT00418418|BIOLOGICAL|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
214696057|NCT00734344|DRUG|Tenofovir disoproxil once daily|300mg once daily
214696058|NCT00734344|DRUG|Tenofovir disoproxil twice daily|300mg twice daily
215153713|NCT01698580|OTHER|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
214696059|NCT00000585|DRUG|penicillin|
214696060|NCT04265170|DEVICE|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
214696061|NCT06239506|OTHER|no intervention|no intervention
214696062|NCT01187784|BEHAVIORAL|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
214696063|NCT05841264|BEHAVIORAL|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
214696064|NCT00789191|DRUG|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
214534423|NCT05143879|DIETARY_SUPPLEMENT|Citrulline|3 g/day during 9 weeks
215153714|NCT01698580|OTHER|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
215153715|NCT01698580|OTHER|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
215153716|NCT01698580|OTHER|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
215153717|NCT05326490|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively
215153718|NCT05326490|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
215153719|NCT05326490|DRUG|Metformin hydrochloride|The dosage and administration of metformin hydrochloride remain unchanged before screening
215153720|NCT04129463|DEVICE|Subscleral Trabeculectomy (SST) with Iris incarceration|Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
215153721|NCT04129463|DEVICE|Conventional trabeculotomy|Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
215153722|NCT00828204|DEVICE|single-use autoinjector with a prefilled liquid Avonex syringe|
215153723|NCT00828204|DEVICE|Avonex prefilled syringe via manual IM injection|
215153724|NCT00828204|DRUG|BG9418 (interferon beta-1a)|
215153725|NCT02702791|BEHAVIORAL|Telecoaching|Pedeometer based goals and telecoaching support
215153726|NCT02702791|OTHER|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
215153727|NCT00337480|BEHAVIORAL|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
215153728|NCT04609670|DRUG|[14C]-ALXN2050|A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
215153729|NCT02641288|DRUG|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
215153730|NCT02641288|DRUG|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
215153731|NCT00395031|DRUG|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
214696065|NCT00789191|DRUG|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
214534424|NCT05143879|DIETARY_SUPPLEMENT|Nitrate|300 mg/day during 9 weeks
214534425|NCT05143879|DIETARY_SUPPLEMENT|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
214534426|NCT05143879|DIETARY_SUPPLEMENT|Placebo|3 g/day during 9 weeks
214534427|NCT00626613|DRUG|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
214534428|NCT01650935|BEHAVIORAL|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
214696066|NCT00789191|DRUG|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
214534429|NCT01156402|BEHAVIORAL|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
214534430|NCT01801462|OTHER|Simulation-based training|
214696067|NCT00789191|DRUG|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
214696068|NCT04158089|BEHAVIORAL|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
214696069|NCT01009983|BIOLOGICAL|panitumumab|Given IV
214696070|NCT01009983|DRUG|paclitaxel|Given IV
214696071|NCT01009983|DRUG|carboplatin|Given IV
214696072|NCT01009983|PROCEDURE|laboratory biomarker analysis|Correlative study
214696073|NCT01009983|PROCEDURE|immunohistochemistry staining method|Correlative study
214696074|NCT05632029|DEVICE|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
214696075|NCT05632029|DEVICE|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
214696076|NCT03497429|DRUG|Niraparib|Niraparib capsule
214696077|NCT05522894|DRUG|AK104|10mg/kg IV every 3 weeks (Q3W)
214696078|NCT05522894|DRUG|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
214696079|NCT05522894|DRUG|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
214696080|NCT02101840|DRUG|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
214696081|NCT02101840|DRUG|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
214696082|NCT02101840|DRUG|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
214696083|NCT00506948|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
214696084|NCT00506948|DRUG|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
214696085|NCT00506948|DRUG|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
214696086|NCT00506948|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
214534431|NCT04266002|OTHER|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
214534432|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
214534433|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
214534434|NCT04967586|OTHER|No intervention, questioner only|questioner only
214696087|NCT00917085|BEHAVIORAL|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
214696088|NCT04775472|PROCEDURE|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
214696089|NCT04775472|PROCEDURE|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
214696090|NCT03258047|COMBINATION_PRODUCT|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
214696091|NCT03863067|PROCEDURE|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
215153732|NCT02792530|OTHER|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
215153733|NCT04087850|BEHAVIORAL|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
215153734|NCT04431440|OTHER|silver nanoparticles|effect silver nanoparticles will be examined on multidrug resistant bacteria
215153735|NCT00654771|OTHER|urine collection|clean catch urine collection and catheterized urine collection
215153736|NCT02970162|DRUG|Amifampridine Phosphate|
215153737|NCT02970162|DRUG|Placebo Oral Tablet|
215153738|NCT00612248|OTHER|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
215153739|NCT03760861|DEVICE|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
215153740|NCT03603262|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
215153741|NCT05453591|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
215153742|NCT05221957|DRUG|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
215153743|NCT04960657|DRUG|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
215153744|NCT04960657|DRUG|PACAP38|PACAP38 infusion
214463476|NCT06431997|BEHAVIORAL|Time-limited eating|All participants will be instructed to follow a diet of 1800-2200 kcal/d (45-50% of energy from carbohydrate, 15-20% from protein, 25-30% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
214463477|NCT04855175|DEVICE|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
214463478|NCT04855175|OTHER|Autograft|Patients in this arm will use patient's own bone
214463479|NCT04379596|DRUG|Fluorouracil (5-FU)|5-FU: administered as an IV infusion
214463480|NCT04379596|DRUG|Capecitabine|Capecitabine: administered orally
214463481|NCT04379596|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
214463482|NCT04379596|DRUG|Oxaliplatin|Oxaliplatin: administered as an IV infusion
214463483|NCT04379596|BIOLOGICAL|Trastuzumab|Trastuzumab: administered as an IV infusion
214463484|NCT04379596|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
214463485|NCT04379596|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
214463486|NCT04379596|BIOLOGICAL|Pembrolizumab|Pembrolizumab: administered as an IV infusion
214463487|NCT04379596|BIOLOGICAL|Volrustomig|Volrustomig: administered as an IV infusion
214463488|NCT04379596|BIOLOGICAL|Rilvegostomig|Rilvegostomig: administered as an IV infusion
214463489|NCT06055842|OTHER|over-denture|implant retained overdenture prosthesis.
214463490|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
214463491|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
214463492|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
214534435|NCT03800485|DEVICE|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
215153745|NCT04230031|DRUG|Daratumumab|Experimental
215153746|NCT02302339|DRUG|glembatumumab vedotin|
214463493|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
214463494|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
214463495|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
214463496|NCT04568603|DRUG|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
214534436|NCT05024409|DEVICE|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
215153747|NCT02302339|DRUG|glembatumumab vedotin and varlilumab|
215153748|NCT02302339|DRUG|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
215153749|NCT02302339|DRUG|glembatumumab vedotin and CDX-301|
215153750|NCT01651637|DRUG|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
215153751|NCT01568242|DEVICE|Phacoemlsification|Transurgical measurement of temperature
215153752|NCT02460237|PROCEDURE|Disease Screening|Complete HPV self-test
214463497|NCT05275725|DRUG|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
214463498|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
214463499|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
214463500|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
214463501|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
214463502|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
214463503|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
214463504|NCT03192280|DEVICE|iPhone 7|Smart phone
214463505|NCT06151119|DIAGNOSTIC_TEST|68Ga FAPI PET/CT|68Ga FAPI PET/CT
214463506|NCT03209102|OTHER|Clinical assessment|"* Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~* and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
214463507|NCT03209102|BEHAVIORAL|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
214463508|NCT03209102|OTHER|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
214463509|NCT03209102|BIOLOGICAL|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
214463510|NCT03313076|DRUG|Omega-3 fatty acids (fish oil)|4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
214463511|NCT03313076|DRUG|Vitamin D3 (cholecalciferol)|1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
214463512|NCT03313076|DRUG|Vitamin D3 (cholecalciferol) placebo|1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
214463513|NCT03313076|DRUG|Omega-3 fatty acid placebo|4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
214463514|NCT04119843|DRUG|Mangoral|800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
214463515|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
214463516|NCT06073301|DEVICE|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
214463517|NCT06073301|OTHER|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
214463518|NCT05946070|OTHER|ONKOSIS|ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
214463519|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
214463520|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
214463521|NCT03586414|DIETARY_SUPPLEMENT|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
214463522|NCT03586414|DIETARY_SUPPLEMENT|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
214463523|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
214463524|NCT06029296|DRUG|Diclofenac|100 mg
214463525|NCT06029296|DRUG|Placebo|Sugar pill
214463526|NCT04817644|DRUG|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
214463527|NCT05044689|BEHAVIORAL|Questionnaire|Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
214463528|NCT05044689|DEVICE|Bioimpedance/Body Composition Unit|Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
214534437|NCT05024409|OTHER|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
214534438|NCT04054453|COMBINATION_PRODUCT|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
214534439|NCT01074697|DRUG|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
214534440|NCT01074697|DRUG|Placebo|Saline water
214534441|NCT04723732|DRUG|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
214534442|NCT04723732|DRUG|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
214534443|NCT04723732|DRUG|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
214534444|NCT06035185|PROCEDURE|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
214534445|NCT00604513|OTHER|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
214534446|NCT00604513|OTHER|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
214534447|NCT04007146|DIAGNOSTIC_TEST|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
214534448|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
214534449|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Pain (CBT-P)|
214534450|NCT03195049|DIAGNOSTIC_TEST|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
214534451|NCT05892822|OTHER|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
214534452|NCT05434715|PROCEDURE|Thyroidectomy|removal of the thyroid gland
214534453|NCT04857047|DRUG|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
214534454|NCT04857047|DRUG|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
214534455|NCT02960126|DRUG|Aspirin|
214534456|NCT02960126|DRUG|Clopidogrel|
214534457|NCT05867914|DEVICE|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
214696092|NCT00554463|DRUG|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
214696093|NCT00554463|DRUG|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
214696094|NCT00554463|DRUG|Etoposide|Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
214463529|NCT04243356|BEHAVIORAL|Nurse Encounter Group|Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
214463530|NCT04243356|OTHER|Nurse control group|This group will complete surveys.
214534458|NCT01978236|DRUG|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
214534459|NCT01978236|DRUG|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
214534460|NCT01120288|DRUG|EZN-2968|
214534461|NCT05774171|OTHER|no intervention|no intervention
214534462|NCT04202016|PROCEDURE|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
214534463|NCT00325546|DRUG|Rimonabant (SR141716)|
214534464|NCT00325546|DRUG|Placebo|
214534465|NCT00238498|DRUG|vildagliptin|
214534466|NCT02906696|DRUG|Bosutinib|Given PO
214534467|NCT02906696|OTHER|Laboratory Biomarker Analysis|Correlative studies
214534468|NCT03153098|BEHAVIORAL|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
214696095|NCT00554463|DRUG|Cisplatin|Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
214534469|NCT02785276|DEVICE|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
214534470|NCT02785276|DRUG|Ropivacaine|Commonly used local anaesthetic drug
214534471|NCT02785276|OTHER|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
214534472|NCT02643745|PROCEDURE|Nephrology Intervention|"1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction"
215153753|NCT02460237|OTHER|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
215153754|NCT02460237|OTHER|Informational Intervention|Receive standard instructions and information sheet
215153755|NCT02460237|OTHER|Laboratory Biomarker Analysis|Correlative studies
215153756|NCT02460237|OTHER|Survey Administration|Ancillary studies
215153757|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
215153758|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) Dim light-therapy|\<100 lux for 30 minutes
215153759|NCT04017195|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
215153760|NCT04017195|DRUG|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
215153761|NCT06159777|DRUG|Polyethylene Glycol 3350|\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
215153762|NCT04270266|OTHER|Educational Intervention|Attend educational sessions
215153763|NCT04270266|OTHER|Meditation Therapy|Attend meditation sessions
215153764|NCT04270266|OTHER|Questionnaire Administration|Ancillary studies
214534473|NCT02148653|OTHER|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
214534474|NCT02148653|OTHER|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
214534475|NCT00634920|DRUG|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
214534476|NCT00634920|DRUG|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
214696096|NCT00554463|RADIATION|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
215153765|NCT04264026|DRUG|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
215153766|NCT05519982|BEHAVIORAL|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
215153767|NCT05519982|BEHAVIORAL|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
214534477|NCT00634920|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
214534478|NCT00634920|DRUG|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
214534479|NCT00634920|DRUG|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
215153768|NCT02824614|DIETARY_SUPPLEMENT|E967-Xylitol|
215153769|NCT02824614|DIETARY_SUPPLEMENT|E968-Erythritol|
215153770|NCT03978546|DIAGNOSTIC_TEST|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
215153771|NCT03978546|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
215153772|NCT03978546|DIAGNOSTIC_TEST|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
215153773|NCT00645346|BIOLOGICAL|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
215153774|NCT00645346|BIOLOGICAL|Placebo|Subjects will receive one dose of placebo
215153775|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
215153776|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
215153777|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
215153778|NCT05528315|DRUG|ABX-002|ABX-002
215153779|NCT05528315|DRUG|Placebo|Placebo
215153780|NCT01642589|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
215153781|NCT01642589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
215153782|NCT01703767|BEHAVIORAL|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
215153783|NCT00298558|BEHAVIORAL|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
215153784|NCT06266143|DRUG|Y101D|Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
215153785|NCT06383481|OTHER|Mobile based education|"Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided."
215153786|NCT05127863|BEHAVIORAL|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
215153787|NCT01342016|DRUG|tacrolimus capsule|oral
214534480|NCT03331432|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
214534481|NCT03331432|DIETARY_SUPPLEMENT|Placebo|Taking daily placebo capsules for 4 weeks.
214534482|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
214534483|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
214534484|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
214534485|NCT00819013|BIOLOGICAL|Saline placebo|0.5 mL, Intramuscular
214534486|NCT04232878|DRUG|CVL-936|CVL-936
214534487|NCT04232878|DRUG|Matching Placebo|Placebo matching CVL-936
214534488|NCT04037306|BEHAVIORAL|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
214534489|NCT04037306|BEHAVIORAL|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
214534490|NCT01299298|DRUG|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
214534491|NCT01299298|DRUG|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
214534492|NCT00363649|BIOLOGICAL|GM-K562 cell vaccine|Given by injection
214534493|NCT00363649|BIOLOGICAL|Interferon alfa|Given by injection
214534494|NCT00363649|BIOLOGICAL|Sargramostim|Given by injection
214534495|NCT04885634|DRUG|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
214534496|NCT04885634|DRUG|Placebo|Subcutaneous injection of volume-matched placebo once weekly
214534497|NCT05091554|PROCEDURE|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
215153788|NCT01342016|DRUG|tacrolimus placebo|oral
215153789|NCT01342016|DRUG|leflunomide tablet|oral
215153790|NCT01342016|DRUG|leflunomide placebo|oral
214534498|NCT00112710|DRUG|carboplatin|
214534499|NCT00112710|DRUG|cisplatin|
214534500|NCT00112710|DRUG|gemcitabine hydrochloride|
214534501|NCT00979745|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
214534502|NCT00979745|DRUG|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
215153791|NCT01342016|DRUG|prednisone|oral
215153792|NCT04740372|OTHER|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
215153793|NCT01880138|OTHER|watching animated cartoon before general anesthesia|
215153794|NCT01880138|OTHER|not watching animated cartoon beofre general anaesthesia|
215153795|NCT01185080|DRUG|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
215153796|NCT01185080|DRUG|Placebo|Nasal spray solution, intranasal, three times weekly for one month
214534503|NCT02870751|BIOLOGICAL|TW11681 or TW10722|
214534504|NCT02468310|OTHER|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
214534505|NCT00868764|DRUG|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
214534506|NCT04394312|OTHER|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
214534507|NCT04866706|DEVICE|Visiol|VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.
214534508|NCT02965053|DRUG|EOS789|
214534509|NCT02965053|DRUG|Placebo|
214534510|NCT02965053|DRUG|Renvela|
215153797|NCT01185080|DRUG|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
215153798|NCT04545580|DRUG|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
214696097|NCT04370964|OTHER|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
215153799|NCT04545580|DRUG|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
215153800|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered.
215153801|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered at RP2D regimen.
215153802|NCT02876562|PROCEDURE|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
214463531|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
214463532|NCT05659381|DRUG|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
214463533|NCT05659381|OTHER|No treatment|No treatment with Cisplatin
214463534|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
214463535|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
214463536|NCT03904147|DEVICE|TriClipTM Device|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
214463537|NCT04484727|OTHER|PEEP-step method|By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
214463538|NCT06813469|GENETIC|LRS analysis|Long Read Sequencing (LRS) and High-throughput chromosome conformation capture (Hi-C) analysis to explore and functionally characterize the r(14) event and its impact on the three-dimensional (3D) genomic architecture inside the cells of r(14)S patients
214463539|NCT05775497|BEHAVIORAL|Behavioral weight loss intervention (Online; Rx Weight Loss)|Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
214463540|NCT05775497|BEHAVIORAL|Minority stress intervention|The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
214463541|NCT05775497|BEHAVIORAL|Social support intervention|The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
214463542|NCT05775497|BEHAVIORAL|Negative body image intervention|The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
214463543|NCT05317897|DIAGNOSTIC_TEST|Lung ultrasound examination|45 pediatric patients who will go elective repair of congenital acyanotic heart diseases will be included and will be examined with Lung ultrasound together with arterial blood gases preoperative and postoperative and given a score range from 0-3 according to number of B lines in each region and sensitivity of post-operative lung ultrasound score to extubation within 6 hours was examined.
214463544|NCT04406623|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
214463545|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
215153803|NCT03959176|DRUG|Brimonidine|2 drops administered once in the left eye in both study arms
214534511|NCT00946205|PROCEDURE|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
214534512|NCT00946205|PROCEDURE|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
214534513|NCT01252056|DRUG|Probucol|250mg,Bid
214534514|NCT01252056|DRUG|Probucol and Cilostazol|50-100mg,Bid
215153804|NCT03959176|DRUG|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
215153805|NCT03959176|DRUG|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
215153806|NCT02739061|BEHAVIORAL|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
215153807|NCT02739061|DRUG|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
215153808|NCT02739061|OTHER|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
215153809|NCT05943067|BIOLOGICAL|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
215153810|NCT00002150|DRUG|Celgosivir hydrochloride|
215153811|NCT02808598|BEHAVIORAL|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
215153812|NCT05395975|DEVICE|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
215153813|NCT00567099|DRUG|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
215153814|NCT05287620|DEVICE|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
215153815|NCT04640610|OTHER|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
214463546|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
214463547|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
214463548|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
214463549|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
214463550|NCT05320250|OTHER|Single saliva collection|1 ml of saliva will be collected with Salivette swabs.
214463551|NCT05320250|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects diagnosed with PD will undergo assessments and saliva sampling before starting rehabilitation treatment (T0), at the end of treatment (T1) and 3 months after the end of treatment (T2).
214463552|NCT04885855|DRUG|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
214463553|NCT04885855|DRUG|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
214463554|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
214463555|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
214463556|NCT04828733|PROCEDURE|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
215153816|NCT05012917|OTHER|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
214696098|NCT04370964|OTHER|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
215153817|NCT05012917|OTHER|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
214696099|NCT00215436|DRUG|Formoterol Fumarate|
214696100|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
214696101|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
214463557|NCT05380752|DRUG|TPOXX IV (Tecovirimat Injection, 10 mg/mL)|IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
214463558|NCT04094246|PROCEDURE|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
214463559|NCT04094246|PROCEDURE|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
214463560|NCT05898711|DEVICE|Fish skin graft|Kerecis Fish Skin Graft - SurgiBind
214463561|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
214463562|NCT04233216|DRUG|ISL|ISL 0.75 mg capsule taken by mouth.
214463563|NCT04233216|DRUG|DOR|DOR 100 mg tablet taken by mouth.
214463564|NCT04233216|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
214463565|NCT04233216|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
214463566|NCT04233216|DRUG|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
214463567|NCT03965338|DIAGNOSTIC_TEST|fMRI|Screening
214463568|NCT02298504|DRUG|Mineral Trioxide Aggregate|Vital pulp therapy
214463569|NCT02298504|DRUG|Biodentin|Vital pulp therapy
214463570|NCT02298504|DEVICE|Vitrebond|Vital pulp therapy
214463571|NCT06771908|DIAGNOSTIC_TEST|Conjunctival Swab|CFU/ml by bacterial species before and after prophylaxis.
214463572|NCT04307355|DEVICE|Transcu O2®|Breasts randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
214463573|NCT04307355|OTHER|Tegaderm|A 10 cm × 12 cm Tegaderm TM Film adhesive (3M Healthcare, Minnesota).
214463574|NCT04307355|OTHER|Silagen|A 10 cm × 12 cm silicon sheet (Silagen, New Medical Technology, Inc, Illinois).
214463575|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
214463576|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
214463577|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
214463578|NCT05613036|DRUG|BI 907828|BI 907828
214696102|NCT05152017|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
214696103|NCT04839536|DRUG|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
214696104|NCT00425711|DRUG|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
215153818|NCT06491485|DRUG|Group M (lidocaine with Magnesium sulfate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
214696105|NCT05079867|DEVICE|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
214696106|NCT00762372|DRUG|desflurane|volatile liquid for inhalation
215153819|NCT06491485|DRUG|Group B (lidocaine with Sodium bicarbonate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
214463579|NCT05188222|DRUG|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
214463580|NCT05188222|DRUG|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
214463581|NCT06161974|DRUG|Olutasidenib + TMZ|Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
214463582|NCT05548322|DEVICE|Different surfaces to be touched|The participant will touch various different surfaces and textures, including ones of different temperature and including solids and liquids.
214534515|NCT00414583|OTHER|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
214534516|NCT03247361|OTHER|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
214534517|NCT03247361|OTHER|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
214534518|NCT03247361|OTHER|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
215153820|NCT06491485|DRUG|Group C (lidocaine with saline)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
215153821|NCT05504707|BIOLOGICAL|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
214463583|NCT05548322|BEHAVIORAL|Emotional state change|The emotional state of the participant will be modulated by listening to music.
214463584|NCT05548322|DEVICE|Electrical stimulation|The participant will receive electrical stimulation of single nerve fibers (a few microamps) to artificially excite an individual afferent.
214463585|NCT06008730|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214463586|NCT06008730|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214463587|NCT06008730|OTHER|Radiology, Treatment Planning|Undergo radiation treatment planning
214463588|NCT05843799|DRUG|ILB-202|Single i.v. infusion
214463589|NCT05843799|DRUG|Placebo|Single i.v. infusion
214463590|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 1|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 short hairpin (sh)RNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 1 in the dose escalation phase of the study will receive a fixed number of intramuscular (IM) injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 1.2e13 vg/subject."
214463591|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 2|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 2 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 3.6e13 vg/subject."
214534519|NCT00607997|DRUG|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
214534520|NCT01606891|BEHAVIORAL|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
214534521|NCT03046381|DRUG|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
214696107|NCT00762372|DRUG|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
214696108|NCT00762372|DRUG|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
214696109|NCT03364335|DRUG|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
214696110|NCT03364335|DRUG|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
214696111|NCT03364335|DRUG|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
214696112|NCT03364335|DRUG|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
214696113|NCT03364335|DRUG|Placebo|Placebo
214696114|NCT00695708|BEHAVIORAL|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
214696115|NCT00695708|BEHAVIORAL|Cogpack|Computer-aided cognitive program for cognitive abilities
214696116|NCT00728312|DRUG|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
214696117|NCT00728312|DRUG|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
215153822|NCT05504707|BIOLOGICAL|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
215153823|NCT05557110|DRUG|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
215153824|NCT06654375|PROCEDURE|Endovascular Thrombectomy|"Endovascular thrombectomy (EVT) in this clinical trial involves the mechanical removal of a thrombus from a blocked large cerebral artery using specialized devices like stent retrievers or aspiration catheters. Key distinguishing features of this EVT protocol include:~* Extended Time Window: Unlike standard EVT, which is typically performed within 24 hours after symptom onset, this intervention targets patients presenting beyond 24 hours.~* Collateral Circulation Assessment: Multi-phase CT angiography (CTA) is employed to evaluate collateral flow, prioritizing patients with favorable collateral grades. This selection process helps ensure the identification of patients most likely to benefit from EVT despite the late presentation."
215153825|NCT06654570|DRUG|Intravaginal estrogen during adjuvant letrozole|Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
215153826|NCT04462627|DIAGNOSTIC_TEST|Blood group determination|Determination of the blood group (ABO/LE)
215153827|NCT04462627|DIAGNOSTIC_TEST|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
215153828|NCT04462627|DIETARY_SUPPLEMENT|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
215153829|NCT05903950|DEVICE|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
215153830|NCT05903950|DEVICE|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
215153831|NCT06593548|DRUG|Ivosidenib (AK112)|Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
215153832|NCT06137495|DIAGNOSTIC_TEST|Sensitization to House dust mites|The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
215153833|NCT01104311|PROCEDURE|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
215153834|NCT01104311|PROCEDURE|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
214463592|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 3|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject."
214463593|NCT06185673|GENETIC|BB-301: Dose expansion phase 2a|Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
214463594|NCT03199651|OTHER|Best Practice|Receive usual care
214463595|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
214463596|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
214463597|NCT03199651|OTHER|Laboratory Biomarker Analysis|Correlative studies
214696118|NCT02030444|PROCEDURE|PET-MRI and EBUS-TBNA|
214463598|NCT03199651|OTHER|Medical Chart Review|Undergo medical record abstraction
214463599|NCT03199651|OTHER|Quality-of-Life Assessment|Ancillary studies
214463600|NCT03199651|OTHER|Questionnaire Administration|Ancillary studies
214463601|NCT03199651|BEHAVIORAL|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
214463602|NCT03039751|DRUG|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
214463603|NCT03039751|DRUG|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
214463604|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
214463605|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
214463606|NCT02690558|DRUG|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
214696119|NCT04406935|DEVICE|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
214696120|NCT02884830|DEVICE|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
214696121|NCT05066035|DRUG|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
215153835|NCT06609577|DEVICE|Diaphragm Ultrasound-Guided External Diaphragm Pacing|This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
215153836|NCT05788770|OTHER|FEops HEARTGuide|FEops HEARTGuide added to routine preoperative CT imaging. Results of the computer modelling will be discussed with TAVR implanting team prior to and during the procedure.
215153837|NCT06594432|DRUG|R-CHOP+Z+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
215153838|NCT06594432|DRUG|R-CHOP+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
215153839|NCT03760718|DRUG|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
215153840|NCT03760718|DRUG|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
215153841|NCT03760718|DRUG|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
215153842|NCT05968560|BEHAVIORAL|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
215153843|NCT05968560|BEHAVIORAL|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
215153844|NCT05968560|BEHAVIORAL|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
215153845|NCT05758194|OTHER|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
215153846|NCT05758194|OTHER|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
215153847|NCT07074691|DRUG|Regional Dexamethasone|Patients were generally anesthetized, then a supraclavicular block is given (0.5% bupivacaine + dexamethasone 8 mg regionally), total volume = 20 mL (18 mL 0.5% bupivacaine + 2 mL dexamethasone).
215153848|NCT07074691|DRUG|Intravenous Dexamethasone|Patients were generally anesthetized, and then a supraclavicular block was administered (0.5% bupivacaine), with a total volume of 20 mL (18 mL of 0.5% bupivacaine and 2 mL of normal saline).
214463607|NCT04225273|DEVICE|Sculptra Aesthetic, Lidocaine HCL|No intervention was administered during this extension study.
214463608|NCT04521608|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
214463609|NCT04888832|OTHER|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
214463610|NCT04599504|DRUG|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
214463611|NCT04599504|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
215153849|NCT07075614|BEHAVIORAL|Parent Training Program|"Parent Training Programs are complementary interventions to special education, implemented by parents to support the social, cognitive, and behavioral development of children with autism and other developmental disorders.~Throughout the program, key developmental skills that children are expected to acquire-such as social skills (eye contact, joint attention, play, imitation), language, cognitive, motor, and self-care abilities-are explained using sample photos and simple instructions.~Additionally, the program provides guidance on how to foster secure attachment between parent and child and how to support social-communicative skills through warm, responsive interactions in daily life."
215153850|NCT07074080|OTHER|Performing chest compressions on a mannequin using the foot|Performing chest compressions on a mannequin using the foot
215153851|NCT07074080|OTHER|Performance of standard chest compressions with the upper limbs.|Performance of standard chest compressions with the upper limbs.
215153852|NCT07074470|DRUG|Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|2 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally, W1，60mg，W2，40mg biw，W3，cycle 1； 40mg， biw，cycle 2
215153853|NCT07074470|PROCEDURE|Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning|"TB preconditioning:~Thiotepa intravenous drip 300mg/m2 d-6-d-5; Busulfan: intravenous drip, 0.8mg/kg q6h d-4--d2; followed by autologous peripheral stem cells infusion at day 0"
215153854|NCT07074470|DRUG|Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|4 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally biw, cycle 3-6；
215153855|NCT07074470|RADIATION|Consolidation therapy-whole brain radiation therapy|whole brain radiotherapy: CTV1: 20-30Gy/10fractions GTVp: 25-40Gy/10fractions
215153856|NCT07074470|DRUG|Maintenance treatment-PD-1 monoclonal antibody|PD-1 monoclonal antibody for up to 2 years intravenous infusion, 200mg d1 (21days per cycle)
215153857|NCT07075757|DRUG|Single in situ intra-arterial injection of bevacizumab|3 Escalating doses of an in situ intra-arterial injection of Bevacizumab (5 mg/kg, 7.5 mg/kg, 10 mg/kg)
215153858|NCT07075653|OTHER|Survey using a questionnaire.|Participants fill out a brief survey in which they answer questions about vegetarian diets.
215153859|NCT06927973|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound
214534522|NCT05074771|DEVICE|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
214534523|NCT03975296|PROCEDURE|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
214696122|NCT05066035|DRUG|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
214696123|NCT01445106|DRUG|Nelfinavir|
214696124|NCT01445106|DRUG|Nelfinavir Mesylate|
215153860|NCT07074223|PROCEDURE|Fascial wrapping the site of tendon repair|wrapping the tendon repair site by Pelnac or Fascial graft
215153861|NCT07074223|PROCEDURE|Modified Kestler tendon repair|Modified Kestler tendon repair
215153862|NCT07074223|PROCEDURE|ADM (Pelnac) wrapping of repaired tendon|Modifed kestler tendon repair wrapped by ADM ( Pelnac)
214696125|NCT02483702|OTHER|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
215153863|NCT07074366|BEHAVIORAL|Splint Therapy with Structured Communication|All participants received a stabilization splint for the management of TMDs, combined with a structured counseling protocol delivered by the assigned dentist.
215153864|NCT04510961|OTHER|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
215153865|NCT06932796|BEHAVIORAL|Health Care Provider Stigma Training and Clinic-Based Messaging Campaign|Providers in 10 HIV clinics participated in a 5 session anti-stigma health facility training focused on: 1) raising awareness about stigma and discrimination at the facility; and 2) changing attitudes and behaviors towards women who use drugs and/or trade sex; and 3) building a stigma-free clinic. Each of these clinics also received anti-stigma messaging materials (i.e., pamphlets, posters) to display in their clinics over a 6 month period. Providers received text-based message twice a month during this time to reinforce skills learned during trainings and to empower providers to be stigma change agents. Providers completed pre/post survey assessments.
215153866|NCT00430404|OTHER|Collaborative care (Intervention)|Structured shared care with treatment protocol \& support
215153867|NCT01255436|OTHER|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
215153868|NCT01255436|OTHER|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
215153869|NCT00861562|DRUG|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
215153870|NCT00861562|DRUG|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
215153871|NCT04980144|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
215153872|NCT04980144|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
215153873|NCT03677453|OTHER|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
214696126|NCT02483702|OTHER|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
214696127|NCT02962219|BEHAVIORAL|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
214696128|NCT02962219|BEHAVIORAL|Home Exercise Programme (HEP)|Written advice on exercise at home
214696129|NCT05812469|BEHAVIORAL|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
214463612|NCT03823209|BEHAVIORAL|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
214463613|NCT03823209|BEHAVIORAL|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
214463614|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
214463615|NCT05686395|PROCEDURE|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
214463616|NCT05686395|PROCEDURE|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
214463617|NCT05686395|DRUG|Bupivacaine|bupivacaine 0.25%.
214463618|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & Carbohydrate|Essential amino acid plus whey beverage with added carbohydrate
214463619|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & EAA|Essential amino acid plus whey beverage with added essential amino acid
214463620|NCT05448105|OTHER|My Diabetes Care (MDC)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate diabetes self-care information. In this study, the MDC user-interface was expanded to display additional diabetes health-data, including urine microalbumin and weight/body mass index (BMI) and a Spanish-language version of MDC was available to Spanish-speaking patients with limited English proficiency.
214463621|NCT03358810|DEVICE|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
214463622|NCT06310018|DEVICE|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (treated with a total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours for first 10 patients followed by 50 patients treated with total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
214463623|NCT03965468|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
215153874|NCT00509483|RADIATION|Radioactive iodine|Radioactive iodine preceded by rhTSH
215153875|NCT03404752|DRUG|Peg-Filgrastim|
215153876|NCT00273494|PROCEDURE|Surgery|
215153877|NCT00779350|DRUG|sertraline 100 mg tablets|
215153878|NCT05283941|DIETARY_SUPPLEMENT|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
215153879|NCT04441086|BEHAVIORAL|eMotion|Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
215153880|NCT04441086|BEHAVIORAL|Healthy Living Active Control|The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
215153881|NCT01993121|OTHER|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
215153882|NCT00372593|DRUG|asparaginase|Given intramuscularly
215153883|NCT00372593|DRUG|cytarabine|Given IV
215153884|NCT00372593|DRUG|daunorubicin hydrochloride|Given IV over 6 hours
215153885|NCT00372593|DRUG|etoposide|Given IV over 1-4 hours
215153886|NCT00372593|DRUG|gemtuzumab ozogamicin|Given IV over 2 hours
215153887|NCT00372593|DRUG|mitoxantrone hydrochloride|Given IV over 1 hour
215153888|NCT02980393|BEHAVIORAL|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
215153889|NCT01380821|RADIATION|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
215153890|NCT03353519|OTHER|Primary care model|"Specifically, the intervention will comprise the following components:~1. Structured review of patient needs;~2. A self-management programme (MLAS) for stroke survivors and their carers;~3. A direct point of contact for stroke survivors and carers at the GP surgery;~4. Optimised communication between General Practice staff and specialist services;~5. Service mapping for stroke related needs;~6. Training for General Practice staff."
215153891|NCT04786535|PROCEDURE|Expanded Hemodialysis|"* Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
215153892|NCT04786535|PROCEDURE|High-flux Conventional Hemodialysis|"* Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
214534524|NCT03975296|PROCEDURE|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
215153893|NCT04786535|PROCEDURE|Hemodiafiltration|"* Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
215153894|NCT03534180|OTHER|Laboratory Biomarker Analysis|Correlative studies
215153895|NCT03534180|DRUG|Romidepsin|Given IV
215153896|NCT03534180|DRUG|Venetoclax|Given PO
215153897|NCT01719497|DRUG|[C-11]OMAR|PET radioligand
215153898|NCT06108232|DRUG|Obinutuzumab|Given by IV (vein)
215153899|NCT06108232|DRUG|CC-99282|Given by PO
215153900|NCT01977872|BEHAVIORAL|A worksite activity-diet intervention|
215153901|NCT02370108|DEVICE|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
215153902|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid|2.8mg
215153903|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
214534525|NCT03975296|DRUG|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
214534526|NCT03558282|OTHER|Recession Observation|Soft tissue measurements
214534527|NCT03558282|DIAGNOSTIC_TEST|Crown Contour Observation|Ultrasound measures of implant crown contour.
214696130|NCT05812469|BEHAVIORAL|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
214696131|NCT02440295|PROCEDURE|Lower Extremity Amputation|
215153904|NCT05592002|DEVICE|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
215153905|NCT06783686|DRUG|NV701|eye drop
215153906|NCT06783686|DRUG|Pilocarpine 1.25% Eye drop|eye drop
215153907|NCT05753046|DRUG|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
215153908|NCT05753046|DRUG|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
214534528|NCT04350112|OTHER|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
214534529|NCT06083610|OTHER|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
214534530|NCT00576823|DRUG|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
214534531|NCT05324007|OTHER|Basic Science|This is a basic science experiment to test whether infants' looking time to video stimuli differ according to the race of the individuals shown.
214534532|NCT00409591|DRUG|Maternal and infant nevirapine|"* In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately"
214534533|NCT00409591|DRUG|Maternal placebo and infant nevirapine|"* In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
214534534|NCT00409591|DRUG|Maternal lopinavir+ritonavir|\- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
214534535|NCT00409591|DRUG|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
214534536|NCT02350855|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
214534537|NCT02350855|OTHER|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
214534538|NCT02350855|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
214696132|NCT02440295|DEVICE|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
214696133|NCT02440295|DRUG|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
214534539|NCT00907946|PROCEDURE|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
214534540|NCT03360110|DEVICE|Phoebe test lens|Daily disposable contact lens
214534541|NCT03360110|DEVICE|stenfilcon A lens (control)|Daily disposable contact lens
214534542|NCT00510146|DRUG|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
214534543|NCT00510146|DRUG|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
214534544|NCT00005064|DRUG|bortezomib|Given IV
214534545|NCT03470792|DEVICE|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
214534546|NCT05101915|DRUG|RESP301|Inhaled IMP delivered via nebulisation
214534547|NCT03260803|DRUG|Oligopin|Oligopin ,150 mg ,once daily, 12 week
214534548|NCT03260803|DRUG|Placebo|Placebo,150 mg ,once daily, 12 week
214534549|NCT04189510|DEVICE|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
214534550|NCT04189510|OTHER|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
214534551|NCT03041298|PROCEDURE|MR mammography with Dotarem|
214534552|NCT00134147|DRUG|Inhaled Insulin|
214534553|NCT01930214|DEVICE|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
214534554|NCT04207645|DIAGNOSTIC_TEST|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
214534555|NCT00915577|DRUG|Interferon beta-1a|30mcg, IM once-a-week
214534556|NCT00915577|DEVICE|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
214534557|NCT02132117|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
214534558|NCT02132117|DRUG|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
214534559|NCT04075786|OTHER|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
214696134|NCT02211183|PROCEDURE|Best Repair of torn Rotator Cuff|
214696135|NCT02211183|DEVICE|InSpace™ system|
214534560|NCT03589300|DEVICE|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
214534561|NCT01376297|DRUG|Netupitant and Palonosetron|
214534562|NCT01376297|DRUG|Aprepitant|
214534563|NCT01376297|DRUG|Palonosetron|
214534564|NCT01376297|DRUG|Dexamethasone|
214534565|NCT02569632|BIOLOGICAL|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
214534566|NCT04692090|OTHER|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
214534567|NCT04107597|OTHER|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
214534568|NCT04107597|OTHER|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
214534569|NCT04107597|OTHER|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
214696136|NCT04753138|DEVICE|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
214696137|NCT04753138|DEVICE|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
215153909|NCT05132608|OTHER|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
215153910|NCT04439136|DRUG|Afatinib Dimaleate|Given PO
215153911|NCT05350878|OTHER|Implementation Intervention|Virtual and in-person implementation support
215153912|NCT00433082|BEHAVIORAL|Ramadan Fasting|
215153913|NCT06840262|OTHER|Questionnaire Administration|Ancillary studies
215153914|NCT06840262|PROCEDURE|Regenerative Peripheral Nerve Interface Surgery|Undergo regenerative peripheral nerve interface surgery
215153915|NCT06840262|PROCEDURE|Targeted Muscle Reinnervation|Undergo targeted muscle reinnervation
215153916|NCT06789172|DRUG|OKN4395|OKN4395 oral dosing twice per day
215153917|NCT06789172|COMBINATION_PRODUCT|Pembrolizumab|200 mg IV every 3 weeks
215153918|NCT06789172|OTHER|Fasting|Fasting before first dose of OKN4395
215153919|NCT06789172|OTHER|Fed|Food provided to patient before first OKN4395 dose
215153920|NCT06789172|DRUG|H2 Receptor Antagonist|Famotidine 20 mg IV (as a slow push over 2 minutes) administered 3 hours prior to OKN4395
215153921|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will be provided food to meet the ketogenic diet prescription for the 6-week weight maintenance phase.
215153922|NCT06736028|BEHAVIORAL|Calorie Restriction|Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.
215153923|NCT06736028|BEHAVIORAL|Behavioral Support|Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.
215153924|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will have food provided to meet the standard low-fat diet prescription for the 6-week weight maintenance phase.
214534570|NCT04107597|OTHER|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
214534571|NCT02420405|PROCEDURE|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
214534572|NCT02420405|PROCEDURE|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
214534573|NCT03856814|DEVICE|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
214534574|NCT00413855|PROCEDURE|laparoscopic appendectomy or not (surgery)|
214534575|NCT06570434|DRUG|budoprutug|monoclonal antibody
214534576|NCT01213615|DEVICE|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
214534577|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
214534578|NCT04655742|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
214534579|NCT00466089|DRUG|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
214534580|NCT00142038|DRUG|Docetaxel|
214534581|NCT00142038|DRUG|Capecitabine|
214534582|NCT03352882|DIAGNOSTIC_TEST|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
214696138|NCT02670915|DRUG|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
215153925|NCT06551116|DIAGNOSTIC_TEST|CE-10-IVD|Leftover tumor tissue from a routine biopsy will be sent for analysis.
215153926|NCT06157892|DRUG|disitamab vedotin|Given into the vein (IV; intravenous)
215153927|NCT06157892|DRUG|tucatinib|300mg given twice daily by mouth (orally)
215153928|NCT02997228|DRUG|Atezolizumab|Given IV
215153929|NCT02997228|BIOLOGICAL|Bevacizumab|Given IV
214696139|NCT02670915|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
215153930|NCT02997228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215153931|NCT02997228|PROCEDURE|Computed Tomography|Undergo CT or CT/PET
215153932|NCT02997228|DRUG|Fluorouracil|Given IV
215153933|NCT02997228|DRUG|Leucovorin|Given IV
215153934|NCT02997228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215153935|NCT02997228|DRUG|Oxaliplatin|Given IV
215153936|NCT02997228|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
215153937|NCT02997228|OTHER|Quality-of-Life Assessment|Ancillary studies
215153938|NCT02997228|OTHER|Questionnaire Administration|Ancillary studies
215153939|NCT05393921|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
215153940|NCT03147937|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
215153941|NCT04373720|PROCEDURE|Magnetic Resonance Elastography|Undergo MRE
214534583|NCT04622371|OTHER|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
214534584|NCT05652790|PROCEDURE|Enhanced Rehabilitation Programme|"The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
214534585|NCT05652790|PROCEDURE|Standard Care|Standard care received at usual NHS facility
214534586|NCT03341858|OTHER|no intervention-strictly observational|
214534587|NCT00006104|BIOLOGICAL|trastuzumab|
214534588|NCT00006104|DRUG|docetaxel|
214534589|NCT04573257|OTHER|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
214534590|NCT01545778|DRUG|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
214534591|NCT01545778|DRUG|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
214534592|NCT00002388|DRUG|Abacavir sulfate|
214534593|NCT03029611|DRUG|Carboplatin|Given IV
214534594|NCT03029611|PROCEDURE|Gynecological Surgical Procedure|Undergo cytoreductive surgery
214534595|NCT03029611|OTHER|Laboratory Biomarker Analysis|Correlative studies
214534596|NCT03029611|DRUG|Paclitaxel|Given IV
214534597|NCT03029611|BIOLOGICAL|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
214534598|NCT06646601|OTHER|Intervention of prevention|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
214534599|NCT05104957|OTHER|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
214534600|NCT05104957|OTHER|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
214534601|NCT06647186|PROCEDURE|Non Incised Papillae Surgical Approach|Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.
214696140|NCT02670915|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
214696141|NCT01225367|DEVICE|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
214696142|NCT02573376|BEHAVIORAL|Directly Observed Therapy|
214696143|NCT02573376|BEHAVIORAL|Wirelessly Observed Therapy|
215153942|NCT04373720|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
215153943|NCT03745521|OTHER|no intervention|no intervention
215153944|NCT01025726|BEHAVIORAL|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
214534602|NCT06647186|PROCEDURE|Conventional flap design|"Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures."
214534603|NCT01073774|BEHAVIORAL|Side by side|
214534604|NCT01073774|BEHAVIORAL|couples control condition|
214534605|NCT06647199|PROCEDURE|the plaque index (PI)|Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
214534606|NCT06647199|PROCEDURE|the bleeding index (BI)|Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
214534607|NCT06647199|PROCEDURE|simpliﬁed gingival index(GI),|Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
214534608|NCT00352391|OTHER|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
214534609|NCT03612492|DRUG|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
214534610|NCT03612492|DRUG|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
215153945|NCT01025726|BEHAVIORAL|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
215153946|NCT01025726|BEHAVIORAL|General Health Education|Host community events for chronic disease education
215153947|NCT06006884|PROCEDURE|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
215153948|NCT06006884|DIAGNOSTIC_TEST|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
215153949|NCT06006884|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
214534611|NCT02447380|DRUG|AZD6094|AZD6094 600MG qd
214534612|NCT02447380|DRUG|Docetaxel|Docetaxel 60 mg/m2
215153950|NCT06006884|DIAGNOSTIC_TEST|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
215153951|NCT06006884|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
215153952|NCT03630445|OTHER|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
215153953|NCT03630445|OTHER|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
215153954|NCT03630445|OTHER|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
215153955|NCT03630445|OTHER|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
215153956|NCT03630445|OTHER|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
215153957|NCT02223858|BEHAVIORAL|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
214463624|NCT03965468|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
214463625|NCT03965468|DRUG|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
214463626|NCT03965468|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
214463627|NCT03965468|PROCEDURE|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
214463628|NCT03965468|RADIATION|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
214534613|NCT05246618|DRUG|TUM012|Ex-vivo infusion
214534614|NCT05246618|DRUG|Placebo|Ex-vivo infusion
214534615|NCT05278442|OTHER|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
214534616|NCT03235401|OTHER|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
214534617|NCT06646874|BEHAVIORAL|VR game|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
214534618|NCT06244693|OTHER|No intervention|No intervention
214534619|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
214534620|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
214534621|NCT02841176|OTHER|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
214534622|NCT02841176|BIOLOGICAL|Golimumab|Participants will start monthly Golimumab after their baseline visit
214696144|NCT02022072|DEVICE|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
214534623|NCT04104724|OTHER|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
214534624|NCT00126061|DRUG|Tedisamil sesquifumarate|
214534625|NCT02284802|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
214534626|NCT02857309|DEVICE|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
214534627|NCT02857309|DRUG|Optimal medical therapy|OMT using standard heart failure (HF) drugs
214534628|NCT02134899|DRUG|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
214534629|NCT02134899|DRUG|Calcineurin inhibitors maintenance|Usual treatment
214534630|NCT01849679|OTHER|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
214534631|NCT00000904|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214534632|NCT00000904|BIOLOGICAL|gp160 MN/LAI-2|
214534633|NCT00000904|BIOLOGICAL|ALVAC(1)120(B,MN)GNP (vCP1433)|
214534634|NCT00000904|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214534635|NCT00000904|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214534636|NCT02146729|PROCEDURE|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
214534637|NCT02146729|PROCEDURE|Open Treatment|Midline posterior incision with instrumentation.
214534638|NCT06205576|DEVICE|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
214534639|NCT04748471|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccine
214534640|NCT01174498|DEVICE|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
214534641|NCT01174498|DEVICE|t-VNS Sham stimulation|t-VNS Sham stimulation
214534642|NCT03353155|BEHAVIORAL|Usual Care|
214534643|NCT03353155|BEHAVIORAL|CareHub|
214534644|NCT04615715|BEHAVIORAL|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
214534645|NCT04615715|BEHAVIORAL|Stress Reduction Messaging|Stress Reduction Messaging
214696145|NCT02546427|RADIATION|Helical TomoTherapy (HT)|
214696146|NCT02546427|RADIATION|CyberKnife SBRT|
214696147|NCT02546427|RADIATION|Permanent Prostate Implant (PPI)|
214696148|NCT02546427|RADIATION|HDR brachytherapy|
214696149|NCT06078787|DRUG|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
214696150|NCT02807064|DRUG|Bifidobacteria|0.5 ml per os all days for 2 months
214696151|NCT02807064|DRUG|placebo|0,5 ml per os all days for 2 months
214696152|NCT01142609|BEHAVIORAL|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
215153958|NCT02223858|BEHAVIORAL|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
214463629|NCT03965468|DRUG|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
214463630|NCT04893733|DRUG|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
214463631|NCT04893733|OTHER|STOP AKI protocol|"STOP AKI protocols includes:~S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration"
214463632|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
214463633|NCT04413708|BEHAVIORAL|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
214463634|NCT06053580|DRUG|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
214463635|NCT06053580|DRUG|Placebo|Placebo twice daily for 24 weeks.
214463636|NCT06224283|PROCEDURE|Cryoablation|Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
214463637|NCT03484039|BEHAVIORAL|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
214463638|NCT03484039|BEHAVIORAL|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
214463639|NCT03484039|BEHAVIORAL|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
214463640|NCT03484039|BEHAVIORAL|Stress Management|Some subjects will be enrolled in a stress management course.
214463641|NCT04989413|DRUG|Placebo oral drops|use of placebo for 12 weeks
214463642|NCT04989413|DRUG|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|use of cannabidiol + canabigerol + thc for 12 weeks
214463643|NCT03945552|BEHAVIORAL|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
214463644|NCT04824053|DIETARY_SUPPLEMENT|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
214534646|NCT02864342|DEVICE|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
215153959|NCT06246448|PROCEDURE|Robotic-assisted radical cholecystectomy|Procedure will be performed robotic-assisted
215153960|NCT06246448|PROCEDURE|Open radical cholecystectomy|Procedure will be open
214696153|NCT05871021|RADIATION|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
214696154|NCT03499080|BEHAVIORAL|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
214696155|NCT03499080|BEHAVIORAL|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
214696156|NCT03499080|BEHAVIORAL|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
214696157|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
214696158|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
214534647|NCT02864342|DEVICE|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
214534648|NCT00661466|DRUG|Bupivacaine Collagen Sponge|
214534649|NCT00661466|DRUG|Placebo|placebo
214534650|NCT01192672|BEHAVIORAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
214534651|NCT01192672|BEHAVIORAL|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
214534652|NCT03609671|BEHAVIORAL|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
214534653|NCT03609671|OTHER|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
214696159|NCT05364229|RADIATION|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
215153961|NCT06203847|DRUG|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
215153962|NCT06203847|DRUG|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
214534654|NCT00502983|BEHAVIORAL|Interview|Interview lasting approximately 50 minutes.
214534655|NCT05113485|BEHAVIORAL|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
214534656|NCT05113485|BEHAVIORAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
214463645|NCT04824053|DIETARY_SUPPLEMENT|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
214463646|NCT04824053|DIETARY_SUPPLEMENT|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
214696160|NCT02494778|DRUG|Pridopidine|45 mg BID
214696161|NCT02077985|BEHAVIORAL|Sensory Adapted Dental Environment|See study arm description.
214696162|NCT03617029|DEVICE|Microcoil|Needle localization with microcoil
214696163|NCT03617029|DRUG|Lipiodol|Needle localization with contrast injection
214696164|NCT02963896|DRUG|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
214696165|NCT01617512|DEVICE|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
215153963|NCT04624074|BEHAVIORAL|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
215153964|NCT06113861|DIAGNOSTIC_TEST|Quantiferon Gold|Test for TB infection
215153965|NCT06113861|DIAGNOSTIC_TEST|HIV serology|Test for HIV infection
215153966|NCT06113861|DIAGNOSTIC_TEST|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
215153967|NCT06113861|DIAGNOSTIC_TEST|Chest radiograph|Chest imaging test by traditional X ray
214534657|NCT04087070|DEVICE|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
214534658|NCT01412632|DRUG|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
214534659|NCT02036606|BEHAVIORAL|questionary|
214534660|NCT00183183|BEHAVIORAL|Screening and Brief Intervention|
214534661|NCT01267058|BIOLOGICAL|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
214534662|NCT01267058|BIOLOGICAL|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
214534663|NCT01267058|BIOLOGICAL|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
214534664|NCT01422083|PROCEDURE|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
214534665|NCT05734742|OTHER|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
214534666|NCT05762471|DRUG|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
214534667|NCT05762471|DRUG|Placebo|Patients will receive GSBR-1290 or matching Placebo
214534668|NCT02517125|DEVICE|Transoral robotic-assisted surgery with Da Vinci Xi|
214696166|NCT04117568|OTHER|Blood sampling|Blood sampling at 3-5 occasions per admission
214696167|NCT00418730|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
214696168|NCT02168881|DRUG|Misoprostol|
214696169|NCT02168881|DRUG|Dinoprostone|
214696170|NCT01059396|DRUG|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
214696171|NCT01059396|DRUG|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
214696172|NCT01059396|DRUG|placebo|placebo propranolol / carvedilol
214696173|NCT03705312|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
215153968|NCT06113861|DIAGNOSTIC_TEST|Lung ultrasound|Chest imaging test by ultrasound
215153969|NCT06113861|DIAGNOSTIC_TEST|cell free DNA test|Blood test for TB infection
215153970|NCT03852160|DRUG|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
215153971|NCT03852160|DRUG|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
215153972|NCT03852160|DRUG|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
215153973|NCT03852160|DRUG|Placebo|Participants will receive matching placebo as nasal spray.
215153974|NCT03852160|DRUG|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
214534669|NCT00115817|DRUG|Atorvastatin|
214534670|NCT01246219|DRUG|GH treatment (Genotropin)|4 years treatment with GH
214534671|NCT01246219|DRUG|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
214534672|NCT02301364|DRUG|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
214534673|NCT02901483|DRUG|PEP503|PEP503 will be administered by intratumoral route as slow injection
214534674|NCT02901483|DRUG|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
214534675|NCT02901483|RADIATION|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
214534676|NCT00328380|DRUG|Rifaximin|
214534677|NCT01612767|DEVICE|PRO-Kinetic Energy Stent|Coronary artery stent implant
214534678|NCT06039592|DRUG|Captopril Tablets|0.3mg/kg, tid
214534679|NCT06039592|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
214534680|NCT06039592|DRUG|Spironolactone Tablets|2-4mg/kg, bid
214534681|NCT06039592|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
214534682|NCT06039592|DRUG|Potassium citrate powder|0.06g/kg, tid
214534683|NCT00326703|PROCEDURE|Hypobaric hypoxia|
214696174|NCT03705312|OTHER|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
214696175|NCT05271903|BEHAVIORAL|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
214696176|NCT00450164|PROCEDURE|esofagic varices ligation|
215153975|NCT03852160|DRUG|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
215153976|NCT03852160|DRUG|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
215153977|NCT03852160|DRUG|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
215153978|NCT03852160|DRUG|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
215153979|NCT03852160|DRUG|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
214463647|NCT04824053|DIETARY_SUPPLEMENT|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
214696177|NCT00450164|DRUG|Nadolol|
214696178|NCT00450164|DRUG|Isosorbide mononitrate|
214696179|NCT00450164|DRUG|Prazosin|
214696180|NCT02174861|DRUG|Erenumab|Administered by subcutaneous injection once a month
214696181|NCT01915108|DRUG|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
214696182|NCT04006912|PROCEDURE|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
215153980|NCT03852160|DRUG|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
215153981|NCT04516057|DRUG|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
214463648|NCT04824053|DIETARY_SUPPLEMENT|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
214463649|NCT04824053|DIETARY_SUPPLEMENT|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
214463650|NCT06328439|DRUG|ANS014004|Specification: 7.5mg; 30mg QD/BID Oral
214463651|NCT06367556|BEHAVIORAL|Emotion and Symptom-Focused Engagement (EASE)|EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.
214463652|NCT00313222|DRUG|bosentan|
214463653|NCT03768505|DRUG|Zandelisib (ME-401)|Zandelisib (ME-401) 60 mg
214463654|NCT05688280|DRUG|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
214463655|NCT05714891|DRUG|JDQ443|Dose will be assigned at enrollment
214463656|NCT02216240|OTHER|Paramedic|
214463657|NCT02216240|OTHER|Standard care|
214463658|NCT05358717|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
214463659|NCT05358717|DRUG|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
214463660|NCT05646524|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
214463661|NCT06119464|OTHER|Multimodal Intervention: Education|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
214463662|NCT06119464|OTHER|Multimodal Intervention: Audit and Feedback|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
214463663|NCT06119464|OTHER|Multimodal Intervention: Patient Engagement|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
214463664|NCT06119464|OTHER|Multimodal Intervention: System Changes|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
214463665|NCT03264352|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
214463666|NCT03264352|DRUG|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
214463667|NCT03264352|OTHER|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
215153982|NCT04516057|OTHER|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
214534684|NCT01764698|BEHAVIORAL|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
214534685|NCT01764698|BEHAVIORAL|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
214534686|NCT04717947|PROCEDURE|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
214534687|NCT01707706|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
214534688|NCT02725008|DRUG|Dexamethasone|
214534689|NCT02725008|DRUG|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
215153983|NCT04288661|PROCEDURE|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered, according to the criteria stated above
214534690|NCT02990364|DRUG|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
214534691|NCT02990364|DRUG|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
214534692|NCT02990364|DRUG|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
214534693|NCT04658654|DRUG|Roflumilast|chronic intervention (24 weeks): roflumilast capsule
215153984|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
215153985|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
215153986|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
215153987|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
215153988|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
215153989|NCT00860860|DRUG|TF2|TF2: 75-300 mg
215153990|NCT00860860|DRUG|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
215153991|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
215153992|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
215153993|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
215153994|NCT00055913|BIOLOGICAL|bevacizumab|Given IV
215153995|NCT00055913|DRUG|erlotinib hydrochloride|Given orally
215153996|NCT00055913|OTHER|laboratory biomarker analysis|Correlative studies
215153997|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
215153998|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
215153999|NCT01635296|DRUG|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
215154000|NCT01635296|DRUG|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
215154001|NCT00629070|OTHER|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
215154002|NCT00629070|OTHER|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
215154003|NCT05970289|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
215154004|NCT05970289|DRUG|BRII-835|BRII-835 will be given via subcutaneous injection
214534694|NCT04658654|DRUG|Placebo oral tablet|Pill with inactive ingredients to mimic same appearance of roflumilast capsule
214534695|NCT01149876|OTHER|Nu Skin Product|Thin layer of Nu Skin product applied to face.
214534696|NCT01149876|OTHER|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
214534697|NCT01149876|DRUG|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
214534698|NCT01149876|OTHER|CeraVe moisturizer|Thin layer of CeraVe applied to face.
214534699|NCT03447574|OTHER|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
215154005|NCT03682770|DRUG|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
215154006|NCT03682770|DRUG|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
215154007|NCT03682770|DRUG|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
215154008|NCT02362282|BEHAVIORAL|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
215154009|NCT02362282|BEHAVIORAL|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
215154010|NCT02362282|BEHAVIORAL|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
215154011|NCT01278225|BEHAVIORAL|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
215154012|NCT01278225|BEHAVIORAL|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
215154013|NCT01278225|BEHAVIORAL|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
215154014|NCT03588884|DRUG|Calcifediol Oral Capsule|Capsule, daily
215154015|NCT03588884|DRUG|Calcifediol Oral Product|Capsule, once a month
215154016|NCT03588884|DRUG|Cholecalciferol|Capsule, once a month
215154017|NCT03588884|DRUG|Paricalcitol Oral Capsule|Capsule, daily
215154018|NCT01630876|PROCEDURE|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
214534700|NCT04987034|DEVICE|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
214534701|NCT02968121|DRUG|Brexpiprazole, OPDC-34712|
214534702|NCT04382807|BEHAVIORAL|Counseling|Online delivered group counseling session, providing insights into the tinnitus symptoms
214534703|NCT00513461|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
214534704|NCT00513461|OTHER|placebo|Given PO
214534705|NCT00513461|OTHER|laboratory biomarker analysis|Correlative studies
214534706|NCT00513461|OTHER|immunoenzyme technique|Correlative studies
215154019|NCT01630876|PROCEDURE|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
215154020|NCT06008691|DRUG|"novel MAB (alone or in combination)"|"novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy"
214534707|NCT00513461|OTHER|high performance liquid chromatography|Correlative studies
214534708|NCT00853021|BIOLOGICAL|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
214534709|NCT00853021|BIOLOGICAL|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
214534710|NCT01329419|DRUG|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214534711|NCT05166798|BEHAVIORAL|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
214534712|NCT02920021|DRUG|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
214534713|NCT02920021|DRUG|Placebo|Administered by intravenous infusion
214534714|NCT06348498|DRUG|Jia Shen Tablet|Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
214696183|NCT00218140|DRUG|nicotine transdermal system|
215154021|NCT04814004|DRUG|hCD19.IL15.CAR-iNKT|Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
215154022|NCT06003894|OTHER|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
215154023|NCT06003894|OTHER|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
215154024|NCT02058303|DRUG|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
215154025|NCT02058303|DRUG|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
215154026|NCT05377255|COMBINATION_PRODUCT|16 mg naloxone AP003|4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
215154027|NCT05377255|COMBINATION_PRODUCT|8 mg naloxone NARCAN Nasal Spray|2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
215154028|NCT03644472|DRUG|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
215154029|NCT03644472|DRUG|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
215154030|NCT01907711|DEVICE|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
215154031|NCT00179192|PROCEDURE|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
215154032|NCT00179192|PROCEDURE|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
215154033|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
214534715|NCT05370547|DRUG|Chidamide|"1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
214534716|NCT05370547|DRUG|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
214534717|NCT05370547|BIOLOGICAL|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
215154034|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
215154035|NCT03599089|DRUG|CA-008|single-dose wound infiltration prior to surgical incision closure
215154036|NCT03599089|DRUG|Placebo|single-dose wound infiltration prior to surgical incision closure
215154037|NCT03599089|DRUG|Ketorolac|30mg IV administered intraoperatively
215154038|NCT03599089|DRUG|Acetaminophen|1000mg IV administered intraoperatively
215154039|NCT03599089|DRUG|Oxycodone|5mg PO prn post-surgery
215154040|NCT03599089|DRUG|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
215154041|NCT03214666|DRUG|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day"
215154042|NCT03214666|DRUG|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
215154043|NCT00470275|DRUG|cytarabine|Given IV
215154044|NCT00499148|OTHER|herbal extract; root of woody shrub grown in India/Sri-Lanka|
215154045|NCT00272311|DRUG|Aspirin|Dosage
215154046|NCT04399785|OTHER|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
215154047|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
215154048|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
214696184|NCT01539278|PROCEDURE|Adenotonsillectomy|Tonsils and adenoids are surgically removed
215154049|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
215154050|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
215154051|NCT05274893|DRUG|SYHX2011 and Abraxane®|IV infusion, 260 mg/m\^2
215154052|NCT06214091|PROCEDURE|Gastrointestinal decompression|Gastric tube is inserted within 24-hour severe ischemic stroke attack; gastrointestinal decompression is performed for 48 hours.
215154053|NCT06214091|PROCEDURE|Control|Gastric tube is inserted within 24-hour severe ischemic stroke attack.
214534718|NCT06199206|OTHER|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
214534719|NCT00688077|DRUG|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
214534720|NCT00688077|DRUG|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
214534721|NCT02010398|OTHER|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
214534722|NCT02010398|OTHER|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
214534723|NCT02010398|OTHER|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
214534724|NCT04786756|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
214534725|NCT04001998|DRUG|BLD-2660|Randomized to active product
214534726|NCT00316498|DRUG|OGT918|
214696185|NCT01539278|OTHER|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
214696186|NCT05446623|DRUG|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
214696187|NCT05446623|DRUG|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
215154054|NCT03916900|PROCEDURE|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
215154055|NCT03916900|PROCEDURE|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
215154056|NCT03409016|OTHER|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
215154057|NCT02893397|DEVICE|Activity Monitor|Wear a fitbit
215154058|NCT02893397|BEHAVIORAL|Exercise Intervention|Undergo supervised exercise sessions
215154059|NCT06453889|DEVICE|Multimode thermal therapy|The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
215154060|NCT02442297|BIOLOGICAL|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
214534727|NCT02927652|OTHER|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
214534728|NCT03974698|PROCEDURE|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
214534729|NCT04257942|PROCEDURE|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
214534730|NCT03630965|OTHER|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
214534731|NCT05400226|DRUG|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
214534732|NCT00930683|DRUG|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
214534733|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
214534734|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
214534735|NCT00930683|DRUG|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
214534736|NCT00930683|DRUG|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
214534737|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
214534738|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
214696188|NCT00210080|DRUG|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
214696189|NCT01122628|DEVICE|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
214696190|NCT03309787|BEHAVIORAL|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
215154061|NCT06841887|DIAGNOSTIC_TEST|US acquisitions|US acquisition from two anatomical regions i.e., the non-dominant arm and the neck.
215154062|NCT04169074|DRUG|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
214696191|NCT00130806|DRUG|MK0478 (muraglitazar)|
214696192|NCT00130806|DRUG|Comparator: placebo|
214696193|NCT01469806|DEVICE|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
214696194|NCT03710941|DRUG|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
214696195|NCT03710941|DRUG|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
215154063|NCT04529018|COMBINATION_PRODUCT|[18F]CETO|\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
215154064|NCT06850623|COMBINATION_PRODUCT|Acoustic Cluster Therapy|Drug: PS101; Device: Ultrasound
215154065|NCT06850623|DRUG|Modified FOLFIRINOX|Chemotherapy
215154066|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with analogic guide|coDiagnostix9® planning software
214534739|NCT00930683|DRUG|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
214534740|NCT00930683|DRUG|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
214534741|NCT01145547|DEVICE|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
214534742|NCT04410354|DRUG|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
214696196|NCT05510778|DIETARY_SUPPLEMENT|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
214696197|NCT05510778|OTHER|Placebo|capsules containing \~250 mg cellulose
214696198|NCT03555084|DEVICE|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
214696199|NCT03555084|DEVICE|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
214696200|NCT05765695|PROCEDURE|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
214696201|NCT00314652|DRUG|Buprenorphine transdermal delivery system|
214696202|NCT04980352|OTHER|real world treatment by doctors|real world treatment by doctors
214696203|NCT00484536|DRUG|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
214696204|NCT00484536|DRUG|placebo|capsules, once daily
214696205|NCT00484536|DRUG|CDP323|250 mg Capsules, 500 mg, once daily
214696206|NCT03874624|DIAGNOSTIC_TEST|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
215154067|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with CAD-CAM surgical guide|coDiagnostix9® planning software
214534743|NCT04410354|DRUG|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
214534744|NCT04410354|DRUG|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
214534745|NCT05509283|BEHAVIORAL|Risk Reduction|Letter, patient portal, SMS and/or another modality
214696207|NCT01925638|DRUG|BAY86-9766|
214696208|NCT01925638|DRUG|Ketoconazole|
214696209|NCT05248971|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
214696210|NCT01487096|DRUG|Teriflunomide|"film-coated tablet~oral administration"
214696211|NCT01487096|DRUG|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
214696212|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
214696213|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
215154068|NCT00973804|DRUG|EPOCH-F/R|
215154069|NCT00973804|DRUG|FLAG|
215154070|NCT00973804|DRUG|Transplant Preparative Regimen (Flu/Cy/Mes)|
215154071|NCT00973804|DRUG|GVHD Prophylaxis (tacrolimus and sirolimus)|
215154072|NCT00973804|PROCEDURE|Double Cord Blood Transplantation|
215154073|NCT02546206|DIETARY_SUPPLEMENT|Probiotic Yoghurt|Probiotic yoghurt consumption
215154074|NCT02546206|DIETARY_SUPPLEMENT|Natural Yoghurt|Natural yoghurt consumption
215154075|NCT01184963|DIETARY_SUPPLEMENT|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
215154076|NCT01184963|DIETARY_SUPPLEMENT|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
215154077|NCT01177371|DRUG|busulfan|Given orally
215154078|NCT01177371|DRUG|cyclophosphamide|Given IV
215154079|NCT01177371|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
215154080|NCT01177371|DRUG|methylprednisolone|Given IV or orally
215154081|NCT01177371|DRUG|methotrexate|Given IV
215154082|NCT01177371|DRUG|cyclosporine|Given IV or orally
215154083|NCT04616456|DRUG|[F-18]PBR06|PET radiopharmaceutical
215154084|NCT04616456|DRUG|Verdiperstat|verdiperstat targets microglial inflammation in the brain
215154085|NCT05866809|DRUG|HK-660S|Administered orally
215154086|NCT05866809|DRUG|Placebo|Administered orally
215154087|NCT00318643|DRUG|Mitomycin C|intravesical administration
215154088|NCT00318643|DRUG|Chemophase|intravesical administration
215154089|NCT02601846|OTHER|No intervention|This is an observational study, without any specific intervention.
214534746|NCT06646497|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|"1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative)."
214534747|NCT04155333|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
214534748|NCT00806741|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
214534749|NCT00806741|DRUG|Phenylephrine|1μg/kg/min, infusion period 20 minutes
214534750|NCT00806741|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
215154090|NCT02071394|DRUG|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
214534751|NCT00806741|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
214534752|NCT00806741|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
214534753|NCT00806741|OTHER|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
214534754|NCT05130502|OTHER|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
214534755|NCT05130502|OTHER|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
214534756|NCT06369883|DIAGNOSTIC_TEST|Spine radiography|Posterior-anterior and lateral spine radiography
214534757|NCT00866502|DRUG|sNN0031|Continuous ICV infusion for two weeks
214534758|NCT00866502|DRUG|Placebo|Continous ICV infusion
214534759|NCT02145195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
214534760|NCT02212197|DRUG|leuprolide acetate FluidCrystal® injection depot|
214534761|NCT02212197|DRUG|leuprolide acetate|
215154091|NCT02071394|OTHER|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
215154092|NCT00406484|BEHAVIORAL|Standard drug counseling|Individual drug counseling
215154093|NCT00406484|BEHAVIORAL|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
215154094|NCT02778737|BEHAVIORAL|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
215154095|NCT02778737|BEHAVIORAL|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
215154096|NCT03417154|DRUG|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
215154097|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
215154098|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
214534762|NCT00321529|DEVICE|motion analysis by durometer|
214534763|NCT04030988|DRUG|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
214534764|NCT04030988|DRUG|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
214534765|NCT00346177|BIOLOGICAL|Autologous Stem Cells|Intramyocardial injections
214534766|NCT06454799|BEHAVIORAL|Akupressur|The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
214534767|NCT04641416|DIAGNOSTIC_TEST|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
214534768|NCT01911936|DRUG|LM716|
214534769|NCT02703402|OTHER|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
214696214|NCT03933423|DEVICE|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
214696215|NCT04768335|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
215154099|NCT03915093|OTHER|Educational nursing protocol|It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
215154100|NCT03915093|OTHER|Routine hospital care|The routine care given by physicians and nurses after thoracoscopic surgery
215154101|NCT01519921|DRUG|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
215154102|NCT06561165|DEVICE|Standard HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
215154103|NCT06561165|DEVICE|Multifocal network targeted HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
215154104|NCT06561165|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will have an MRI before or after having HD-tDCS intervention.
215154105|NCT03585738|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
214534770|NCT02703402|OTHER|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
214534771|NCT02551692|DRUG|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
214534772|NCT02551692|DRUG|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
214696216|NCT05015205|OTHER|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
215154106|NCT03585738|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
215154107|NCT03327207|OTHER|Non Interventional|Non Interventional
214696217|NCT05015205|OTHER|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
214696218|NCT02860845|DEVICE|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
214696219|NCT02860845|DRUG|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
214696220|NCT02860845|DRUG|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
214696221|NCT02791971|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
214696222|NCT02791971|BEHAVIORAL|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
214696223|NCT05123898|PROCEDURE|Soft tissue augmentation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
214696224|NCT06018935|OTHER|No intervention|No intervention
214696225|NCT03196193|PROCEDURE|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
214696226|NCT03196193|DEVICE|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
214696227|NCT03196193|DEVICE|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
214696228|NCT03925961|OTHER|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
214696229|NCT02709083|DRUG|Dasatinib|Given orally
215154108|NCT04268667|OTHER|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
214534773|NCT02551692|DRUG|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
214696230|NCT02709083|DRUG|Imatinib Mesylate|Given orally
215154109|NCT02864459|OTHER|Muscular ultrasound|Muscular ultrasound is done before extubation
215154110|NCT05120921|OTHER|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
215154111|NCT05120921|OTHER|Self-management|Providing rehabilitative exercises to patients to do at home
215154112|NCT05120921|OTHER|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
215154113|NCT05120921|OTHER|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
214696231|NCT02709083|DRUG|Nilotinib|Given orally
214696232|NCT05551598|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
214696233|NCT02029352|DRUG|Sinecatechins 10%|
214696234|NCT02029352|DRUG|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
214696235|NCT04262401|BEHAVIORAL|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
214696236|NCT04262401|BEHAVIORAL|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
214696237|NCT00061919|DRUG|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
214696238|NCT00061919|DRUG|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
214696239|NCT00143975|DRUG|Cytarabine|3 g/m2 bid. i.v day 1-3
214696240|NCT00143975|DRUG|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
214696241|NCT00143975|DRUG|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
214696242|NCT00143975|DRUG|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
214696243|NCT04018196|OTHER|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
215154114|NCT05322395|DIAGNOSTIC_TEST|ESC 0/1 hour troponin pathway|randomisation to 0/1 versus 0/3 hour pathway
215154115|NCT02500797|BIOLOGICAL|Ipilimumab|Given IV
215154116|NCT02500797|OTHER|Laboratory Biomarker Analysis|Correlative studies
215154117|NCT02500797|BIOLOGICAL|Nivolumab|Given IV
215154118|NCT02500797|OTHER|Quality-of-Life Assessment|Ancillary studies
215154119|NCT00845117|PROCEDURE|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
214534774|NCT02551692|DRUG|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
214534775|NCT01091519|OTHER|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
214534776|NCT01091519|OTHER|Toviaz(fesoterodine) without educational materials|No educational materials
214534777|NCT05157568|BEHAVIORAL|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
214534778|NCT05157568|BEHAVIORAL|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
215154120|NCT00925457|OTHER|No Intervention|Neither current domperidone nor current PPI
215154121|NCT00925457|DRUG|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
215154122|NCT00925457|DRUG|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
214534779|NCT05157568|BEHAVIORAL|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
214534780|NCT00621946|DRUG|Placebo|Placebo Matching Escitalopram
214534781|NCT00621946|DRUG|Escitalopram|Active Escitalopram
214534782|NCT05253079|OTHER|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
214534783|NCT05253079|OTHER|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
214534784|NCT06585319|DRUG|Collagen-polyvinylpyrrolidone|2 ml intramuscular q24 h
214534785|NCT06585319|DRUG|Pirfenidone 1200 mg|1,200 mg of oral q12 h
214534786|NCT01177228|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
215154123|NCT06440681|OTHER|Providing nutritional counselling|"Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks."
214534787|NCT01177228|DRUG|Placebo|Placebo intravenous infusion
215154124|NCT06440681|OTHER|counseling on physical activity|"Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)"
215154125|NCT01956838|DIETARY_SUPPLEMENT|umami|intraduodenal infusion of umami tastant
215154126|NCT01956838|DIETARY_SUPPLEMENT|bitter|intraduodenal infusion of bitter tastant
214534788|NCT00598858|DRUG|Docetaxel|Given IV
214534789|NCT00598858|DRUG|Prednisone|Given PO
215154127|NCT01956838|DIETARY_SUPPLEMENT|sweet|intraduodenal infusion of sweet tastant
215154128|NCT05777252|OTHER|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
215154129|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
214534790|NCT04887701|DEVICE|Non-hormonal vaginal device therapy|Experimental Active Therapy
215154130|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
215154131|NCT01684293|BEHAVIORAL|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
214534791|NCT04887701|DEVICE|Sham vaginal device therapy|Sham Comparator
214534792|NCT05360342|DRUG|Vitamin K supplement|Single dose of vitamin K supplement
214534793|NCT01592383|DRUG|erlotinib hydrochloride|Given PO
214534794|NCT03861585|OTHER|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
214534795|NCT03861585|OTHER|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
214534796|NCT01128140|BEHAVIORAL|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
214534797|NCT01128140|BEHAVIORAL|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
214534798|NCT04159805|DRUG|TAK-079|TAK-079 subcutaneous injection
214534799|NCT04159805|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
214534800|NCT06053047|DEVICE|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
214534801|NCT05832944|DEVICE|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
214534802|NCT03462368|PROCEDURE|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
214534803|NCT03462368|PROCEDURE|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
214534804|NCT03462368|PROCEDURE|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
214534805|NCT06516692|DIAGNOSTIC_TEST|Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment|Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
214534806|NCT06561256|DRUG|Janus Kinase Inhibitor|Janus Kinase Inhibitor in combination with corticosteroids
214534807|NCT06288256|OTHER|No Intervention|No Intervention
215154132|NCT01684293|BEHAVIORAL|Psychoeducation/games|Psychoeducation/games
215154133|NCT01673737|DRUG|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
215154134|NCT01673737|DRUG|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
215154135|NCT01647347|DRUG|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
215154136|NCT01647347|OTHER|Water|
215154137|NCT04670471|DRUG|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
215154138|NCT04670471|DRUG|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
215154139|NCT02346058|DRUG|Esarin Gel|
215154140|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
215154141|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
215154142|NCT00088764|BEHAVIORAL|Coping skills training|8 sessions of pain and stress coping skills training
215154143|NCT00088764|BEHAVIORAL|Written emotional disclosure|4 sessions of writing about stress
215154144|NCT00088764|BEHAVIORAL|Arthritis education|8 sessions of learning about rheumatoid arthritis
215154145|NCT00088764|BEHAVIORAL|Health behavior writing|4 sessions of writing about various health behaviors
215154146|NCT02902861|DRUG|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
215154147|NCT02902861|DRUG|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
215154148|NCT02289157|DEVICE|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
214534808|NCT04292925|OTHER|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
214534809|NCT04292925|OTHER|Conventional therapy|conventional therapy
214534810|NCT05708976|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
214534811|NCT05708976|DEVICE|Active Whole-Body Hyperthermia (Active WBH)|Active whole-body hyperthermia (active WBH) will be administered by trained research assistants. Preparation for the active WBH session, the active WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 38.5 C.
214534812|NCT05708976|DEVICE|Sham Whole-Body Hyperthermia (Sham WBH)|Sham whole-body hyperthermia (sham WBH) will be administered by trained research assistants. Preparation for the sham WBH session, the sham WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the sham WBH session will minimally impact core body temperature.
214534813|NCT05018949|PROCEDURE|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
214534814|NCT04472442|PROCEDURE|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
214534815|NCT04472442|PROCEDURE|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
214534816|NCT02657018|DEVICE|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
215154149|NCT04782479|PROCEDURE|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
215154150|NCT04033016|BEHAVIORAL|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
214696244|NCT04018196|OTHER|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
215154151|NCT04033016|BEHAVIORAL|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
215154152|NCT04016766|BEHAVIORAL|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
214534817|NCT02657018|OTHER|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
214534818|NCT04975932|OTHER|TACE+ICIs|TACE plus ICIs ( with or without molecular targeted therapies)
214534819|NCT04975932|PROCEDURE|TACE|TACE without combination of ICIs ( with or without molecular targeted therapies)
214534820|NCT02618785|PROCEDURE|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
214534821|NCT05580783|OTHER|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
214534822|NCT05580783|OTHER|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
214534823|NCT05580783|OTHER|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
214534824|NCT04167085|DRUG|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
214534825|NCT04167085|OTHER|Placebo|Matching placebo, twice a day for 2 months
214534826|NCT04177732|DIAGNOSTIC_TEST|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
214534827|NCT04177732|DIAGNOSTIC_TEST|Probing depth|Williams SE manual probe will be used to measure the probing depth
214534828|NCT04177732|DIAGNOSTIC_TEST|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
214534829|NCT04177732|DIAGNOSTIC_TEST|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
214534830|NCT04177732|DIAGNOSTIC_TEST|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
214534831|NCT01890499|DIETARY_SUPPLEMENT|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
214534832|NCT01314014|DRUG|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
214534833|NCT00660764|DRUG|Rosuvastatin|Oral
214534834|NCT00115284|BEHAVIORAL|ABIM asthma practice improvement module|
214534835|NCT02367742|BEHAVIORAL|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
214534836|NCT02367742|BEHAVIORAL|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
214534837|NCT03955952|PROCEDURE|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
214534838|NCT01361789|DRUG|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
214696245|NCT04018196|OTHER|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
214534839|NCT01361789|DRUG|Dexamethasone|8 mg IV
214534840|NCT01361789|DRUG|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
214534841|NCT06326281|PROCEDURE|unilateral external oblique intercostal plane block group|USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours
214534842|NCT06326281|PROCEDURE|unilateral oblique subcostal transversus abdomınıs plane block group|USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours
214534843|NCT06326281|PROCEDURE|Local anesthetic infiltration group|Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours
214534844|NCT06326281|DRUG|Control group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
214534845|NCT03650244|DEVICE|REMEEX implantation|Device implantation
214534846|NCT04643496|PROCEDURE|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
214534847|NCT03527758|DEVICE|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
214534848|NCT05181891|BEHAVIORAL|Contingency Management|Incentives for submitting negative-alcohol urine samples
214696246|NCT04018196|OTHER|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
215154153|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
215154154|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
215154155|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
215154156|NCT04923282|BIOLOGICAL|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
215154157|NCT04923282|BIOLOGICAL|Placebo|Intravenous infusion
215154158|NCT05080335|OTHER|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~1. TRANS- vs CIS-gender female instructors~2. With or without short videos of transgender youth embedded into the didactic \[TV or CV\]; for the group with no embedded videos \[NV\], the same videos will be shown AFTER completion of the post measures)~3. No-intervention control, in which TV will be delivered \*after\* collection of pre/post measures."
215154159|NCT01288261|DRUG|paclitaxel|Given IV
215154160|NCT01288261|BIOLOGICAL|bavituximab|Given IV
214534849|NCT05181891|BEHAVIORAL|Non-contingent control|Incentives for submitting urine samples
214534850|NCT04365738|OTHER|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
214534851|NCT05878249|PROCEDURE|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
214534852|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
214534853|NCT05878249|PROCEDURE|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
214534854|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
214696247|NCT03498417|DIAGNOSTIC_TEST|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
214696248|NCT01697267|BIOLOGICAL|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
214696249|NCT01697267|DRUG|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
215154161|NCT01288261|OTHER|laboratory biomarker analysis|Correlative studies
215154162|NCT01288261|OTHER|pharmacological study|Correlative study
215154163|NCT01415882|DRUG|Cyclophosphamide|Given PO
215154164|NCT01415882|BIOLOGICAL|Daratumumab|Given IV
215154165|NCT01415882|DRUG|Dexamethasone|Given PO or IV
215154166|NCT01415882|DRUG|Ixazomib Citrate|Given PO
215154167|NCT01415882|OTHER|Laboratory Biomarker Analysis|Correlative studies
215154168|NCT02390505|DRUG|Vitamin C|
215154169|NCT02390505|DRUG|Placebo|
215154170|NCT02627976|DEVICE|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
215154171|NCT02983552|OTHER|iPad®|Binocular therapy using a Dig Rush application on an iPad®
215154172|NCT02983552|OTHER|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
215154173|NCT02740452|DEVICE|ligamys technique|Ligamys technique (device) or standard technique
215154174|NCT02740452|OTHER|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
215154175|NCT06353555|DRUG|Euthyrox|Upon discovering low T3 or low T4 levels, administer oral levothyroxine sodium tablets daily. If accompanied by a decrease in TSH, the regimen is 100μg qd (for individuals weighing \<75kg) or 150μg qd (for individuals weighing \>75kg). If not accompanied by a decrease in TSH, the regimen is 50μg qd. However, if thyroid function does not significantly improve within 3 days of medication, the regimen is adjusted to 100μg qd. Treatment should continue until transfer out of the NICU or discharge, with a minimum duration of 7 days.
215154176|NCT06353555|DRUG|Euthyrox|Patient will not receive the oral levothyroxine sodium tablets.
215154177|NCT00163683|BEHAVIORAL|Dietary Therapy|
215154178|NCT00691834|BIOLOGICAL|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
215154179|NCT00691834|BIOLOGICAL|Placebo|Plasma and culture medium (10 ml)
215154180|NCT00623142|DRUG|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
215154181|NCT00357006|DRUG|Estradiol|100 mcg adjunctive transdermal estradiol
215154182|NCT00357006|DRUG|Estradiol|200 mcg adjunctive transdermal estradiol
215154183|NCT00357006|OTHER|placebo|adjunctive transdermal placebo
215154184|NCT04178785|DRUG|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
215154185|NCT05724888|BEHAVIORAL|Peer mentorship and physical activity|Participants will be asked to participate for 12 weeks, attending 3 sessions per week (if in the intervention arm). Session 1 will be a group session that will be about 90 minutes, session 2 will be an individual session with a peer mentor for 20-30 minutes, and session 3 will be a virtual check in with the peer mentor about 15 minutes. The intervention will focus on increasing physical activity through the circle of courage.
215154186|NCT02293317|BIOLOGICAL|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
215154187|NCT02293317|DRUG|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
214534855|NCT03761407|DRUG|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
214534856|NCT03761407|DRUG|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
214534857|NCT03761407|DRUG|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
214534858|NCT03761407|DRUG|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
214534859|NCT03761407|DRUG|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
214696250|NCT00333619|BEHAVIORAL|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
214696251|NCT00333619|BEHAVIORAL|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
214696252|NCT03677310|DRUG|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
215154188|NCT02293317|OTHER|Saline|Placebo
215154189|NCT00976560|DRUG|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
215154190|NCT00976560|OTHER|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
215154191|NCT04152941|DRUG|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
215154192|NCT02356861|DEVICE|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
215154193|NCT05130515|DRUG|Niraparib|Niraparib 200mg po QD, day1\~21
215154194|NCT05130515|DRUG|Anlotinib|Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle
215154195|NCT02132026|DRUG|Denosumab|
215154196|NCT02132026|DRUG|Alendronic Acid|
215154197|NCT02132026|DRUG|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
215154198|NCT02132026|DRUG|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
215154199|NCT00889161|DRUG|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
215154200|NCT00171561|DRUG|valsartan/hydrochlorothiazide|
214534860|NCT05264649|DEVICE|acupuncture|"The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes De Qi reported by patients, needles were restimulated manually and removed after an additional 10 minutes."
214534861|NCT05264649|DRUG|Guizhi-Shaoyao-Zhimu decoction|The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
214534862|NCT07000266|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Standard PCI intervention
215154201|NCT02842489|PROCEDURE|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
215154202|NCT02842489|PROCEDURE|left lateral horizontal position|patients will be horizontally positioned on their left side
215154203|NCT01216189|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
214534863|NCT07000266|DIAGNOSTIC_TEST|Diagnostic Imaging|Cardiac Magnetic Ressonance (CMR) and hospital discharge
214534864|NCT07000266|DEVICE|Device Treatment|SSO2 therapy
214534865|NCT07000266|PROCEDURE|Follow-up at 30 days|Remote (phone) follow-up at 30 days
214534866|NCT07000266|PROCEDURE|Follow-up at 60 days|In person follow-up at 60 days
214534867|NCT07000266|PROCEDURE|Follow-up at 12 months|Remote (phone) follow-up at 12 months
214696253|NCT03677310|DRUG|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
214534868|NCT06310226|DEVICE|Epidural electrical spinal cord stimulator|Epidural electrical spinal cord stimulator turned on vs. turned off
214534869|NCT05152706|OTHER|Aerobic training|Cycling at the aerobic intensity
215154204|NCT04844411|DRUG|JNJ-67835989|JNJ-67835989 will be administered orally.
215154205|NCT04844411|DRUG|Placebo|Matching placebo will be administered orally.
215154206|NCT00888732|DRUG|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
215154207|NCT03210337|DRUG|A-101 Topical Solution|A-101 Topical Solution
215154208|NCT03210337|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
215154209|NCT00125164|DRUG|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
215154210|NCT04536558|DRUG|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
215154211|NCT04536558|DRUG|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
214534870|NCT05152706|OTHER|Photobiomodulation|Photons therapy
214696254|NCT02031822|PROCEDURE|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
215154212|NCT05005117|PROCEDURE|Laparoscopic operation|Operation
215154213|NCT05005117|PROCEDURE|Open operation|Operation
214534871|NCT00153348|BEHAVIORAL|Women's health|
214696255|NCT04311801|DIAGNOSTIC_TEST|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
214696256|NCT01240512|DRUG|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
214696257|NCT02909842|DIETARY_SUPPLEMENT|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
214696258|NCT02909842|DIETARY_SUPPLEMENT|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
214696259|NCT02909842|BIOLOGICAL|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
215154214|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
215154215|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
214696260|NCT05874687|DRUG|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
214534874|NCT03993561|OTHER|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
214534875|NCT02003690|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy
215154216|NCT03773276|DRUG|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses."
214534876|NCT02003690|BEHAVIORAL|Standard of Care Psychotherapy|Standard of Care Psychotherapy
214534877|NCT02003690|OTHER|Pharmacotherapy|Standard of Care Pharmacotherapy
214534878|NCT03480919|DEVICE|Shen Men acupuncture|20-minute acupuncture session
214534879|NCT03480919|PROCEDURE|Epidural injection|Epidural injection for the relief of back pain
214534880|NCT01601717|DRUG|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
214534881|NCT01601717|DRUG|Placebo|Matching placebo pill administered once per day for 10 days.
214534882|NCT03836170|PROCEDURE|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
214534883|NCT06014970|BEHAVIORAL|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
214534884|NCT04807023|BIOLOGICAL|blood sampling|blood sampling
214534885|NCT00315666|DRUG|memantine|
214534886|NCT05546736|BEHAVIORAL|iCanWork Intervention|Participants will receive RTW support from the VRC and OT.
214534887|NCT04322760|DRUG|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
215154217|NCT02127697|DRUG|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
215154218|NCT02127697|DRUG|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
215154219|NCT02127697|DRUG|salbutamol/ albuterol|Taken as rescue medication
214534888|NCT04322760|DRUG|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
214534889|NCT05162196|RADIATION|SBRT|24Gy/3F
214534890|NCT05162196|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
214534891|NCT05162196|DRUG|Niraparib|200mg qd
214534892|NCT04417569|DRUG|hCG|human chorionic gonadotropin
214534893|NCT04417569|DIAGNOSTIC_TEST|Ultrasound|Endometrial thickness monitoring
214534894|NCT04417569|OTHER|Blood test|Progesterone, Luteinizing Hormone, Estradiol
214534895|NCT04596176|OTHER|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
214534896|NCT04596176|OTHER|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
214696261|NCT04446026|DRUG|teneligliptin|teneligliptin 20mg PO qd for 24weeks
214696262|NCT04446026|DRUG|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
214696263|NCT03076866|OTHER|observational follow-up:clinical, radiological et biological|
214696264|NCT04780958|OTHER|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
215154220|NCT02528812|DEVICE|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
215154221|NCT02528812|OTHER|Manual Massage|A massage therapist massaged the participant
215154222|NCT01339052|DRUG|BKM120|
215154223|NCT01339052|PROCEDURE|Surgery|Surgery
215154224|NCT02869568|OTHER|Data collection|
214463668|NCT05078970|BEHAVIORAL|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
215154225|NCT02501577|DEVICE|SAD 1|Placement and fiberoptic control
215154226|NCT02501577|DEVICE|SAD 2|Placement and fiberoptic control
215154227|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
215154228|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
215154229|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
214463669|NCT05078970|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
215154230|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
215154231|NCT00513916|DIETARY_SUPPLEMENT|soy isoflavones|High or low dose of soy isoflavones in the diet.
215154232|NCT03339219|DRUG|Cabozantinib|Cabozantinib tablets
215154233|NCT04623632|DRUG|Transversus abdominus plane block|transversus abdominus plane block using 40 ml of bupivacaine 0.25%
215154234|NCT04623632|DRUG|Transversus abdominus plane placebo|injection of 40 ml of normal saline in the transversus abdominus plane
215154235|NCT00338585|DRUG|alfimeprase|
214463670|NCT05078970|BEHAVIORAL|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
214463671|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
214463672|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
214463673|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
214463674|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
214463675|NCT06254261|DRUG|RAY1225|Administered SC
214463676|NCT06254261|DRUG|Placebo|Placebo
214463677|NCT04032704|DRUG|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
214463678|NCT04032704|DRUG|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
214463679|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (active)|Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
214463680|NCT05842473|BEHAVIORAL|Language therapy|Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
214463681|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (sham)|Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
215154236|NCT05179356|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg given once daily for three months
215154237|NCT05179356|DRUG|Placebo|Matching placebo
215154238|NCT02015962|DRUG|Intravenous potassium chloride|
215154239|NCT02015962|DRUG|Oral potassium chloride|
215154240|NCT05349799|DEVICE|TEOSYAL RHA® 1|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment."
215154241|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
215154242|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
215154243|NCT01917630|DRUG|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
215154244|NCT01917630|DRUG|placebo|
215154245|NCT02955849|DEVICE|SLT laser|Patients will be offered initial SLT laser by doctors
215154246|NCT04472832|DRUG|Placebo for Treatment A|6 tablets matched to mitapivat tablet
215154247|NCT04472832|DRUG|Mitapivat 100 mg|Two 50-mg tablets
215154248|NCT04472832|DRUG|Placebo for Treatment B|4 tablets matched to mitapivat tablet
215154249|NCT04472832|DRUG|Mitapivat 300 mg|Six 50-mg tablets
215154250|NCT04472832|DRUG|Placebo for Treatment C|4 tablets matched to mitapivat tablet
214696265|NCT03915236|DEVICE|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
214696266|NCT03915236|OTHER|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
215154251|NCT04473677|DIAGNOSTIC_TEST|The new qFIT and colonoscopy with pathological examination|Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
215154252|NCT00034580|DRUG|olanzapine|
215154253|NCT00034580|DRUG|risperidone|
215154254|NCT01497496|DRUG|High Dose Methylprednisolone (HDMP)|1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
215154255|NCT01497496|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
215154256|NCT01497496|DRUG|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
215154257|NCT05726708|BEHAVIORAL|E-Learning|On line modules of coaching for parents
215154258|NCT06255613|DEVICE|Belun Ring|The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.
215154259|NCT06255613|DEVICE|Belun Cor|"The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts."
215154260|NCT03330249|DRUG|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
215154261|NCT03330249|DRUG|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
215154262|NCT03330249|RADIATION|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
214463682|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
214463683|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
214696267|NCT01650792|DRUG|Aspirin|
214696268|NCT02042729|DRUG|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
214696269|NCT02042729|DRUG|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
214696270|NCT02042729|DRUG|E2022 Matching Placebo- Current Formula Tape|
214696271|NCT02042729|DRUG|E2022 Matching Placebo- New Formula Tape|
214534897|NCT05052502|OTHER|Case Management and Follow-up|"Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions."
214696272|NCT03496467|COMBINATION_PRODUCT|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
215154263|NCT00675610|BEHAVIORAL|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
215154264|NCT04900727|OTHER|No intervention|No intervention
214696273|NCT03496467|COMBINATION_PRODUCT|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
215154265|NCT01469377|DRUG|Placebo|Placebo was supplied in capsules
215154266|NCT01469377|DRUG|Cariprazine|Cariprazine was supplied in capsules.
215154267|NCT05330299|BEHAVIORAL|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
215154268|NCT01733680|DRUG|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
215154269|NCT01733680|BEHAVIORAL|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
215154270|NCT02681978|DRUG|Ivabradine|Ivabradine 5 mg twice daily
215154271|NCT02681978|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
215154272|NCT05208099|BIOLOGICAL|Blood tests|"For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
215154273|NCT05208099|PROCEDURE|exeresis|"For patients, it will be performed:~\- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
215154274|NCT05208099|PROCEDURE|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin"
215154275|NCT04903613|DRUG|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
215154276|NCT02666625|PROCEDURE|saliva samples|
214463684|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
215154277|NCT02666625|PROCEDURE|blood samples|
215154278|NCT04176484|OTHER|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
215154279|NCT06581549|OTHER|Translation analysis|Bulk GEP analysis, Spatial whole transcriptome analysis, mIF analysis of tumors
215154280|NCT03937999|DRUG|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
215154281|NCT03942120|DRUG|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
215154282|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
215154283|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
215154284|NCT05441813|DRUG|Virgin Coconut Oil|Standard of care with the addition of virgin coconut oil mouth rinse
214463685|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
215154285|NCT06358313|DRUG|Atorvastatin 40mg|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215154286|NCT06358313|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215154287|NCT05745493|BEHAVIORAL|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
215154288|NCT05670301|DIAGNOSTIC_TEST|cytokine and lipidomic profiling|"* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~* Serum amyloid A~* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~* Lipidomics"
215154289|NCT05222269|DRUG|68Ga-PTF|68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
215154290|NCT01182506|BEHAVIORAL|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
215154291|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo electroacupuncture therapy
215154292|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
215154293|NCT02754752|OTHER|Laboratory Biomarker Analysis|Correlative studies
215154294|NCT02754752|OTHER|Quality-of-Life Assessment|Ancillary studies
215154295|NCT02754752|OTHER|Questionnaire Administration|Ancillary studies
215154296|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
215154297|NCT02812420|BIOLOGICAL|Durvalumab|Given IV
215154298|NCT02812420|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
215154299|NCT02812420|BIOLOGICAL|Tremelimumab|Given IV
215154300|NCT06463457|DRUG|Darolutamide|Androgen receptor antagonist, tablet taken orally per protocol.
215154301|NCT06463457|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.
215154302|NCT06800092|DRUG|Sildenafil|Sildenafil, 50mg, daily
215154303|NCT05313945|PROCEDURE|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
215154304|NCT05313945|PROCEDURE|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
215154305|NCT06479213|BEHAVIORAL|REACH Peer Coaching Program|The REACH Peer Coaching Program consists of weekly coaching calls conducted over video teleconference. Coaches will use motivational interviewing to help participants formulate and work towards movement goals.
215154306|NCT06479213|BEHAVIORAL|REACH Mobile Health Application|Participants will use the the REACH mobile health application to set weekly movement goals and log physical activity.
215154307|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
215154308|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
215154309|NCT05699538|BEHAVIORAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
215154310|NCT04030507|DEVICE|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
215154311|NCT05197504|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
215154312|NCT04139798|DRUG|NOV03|100% Perfluorohexyloctane
215154313|NCT04139798|DRUG|Placebo|Saline solution (0.6% sodium chloride solution)
215154314|NCT04187781|DEVICE|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
215154315|NCT02869464|OTHER|Imaging-Ultrasound|Abdominal Ultrasound
215154316|NCT02869464|OTHER|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
215154317|NCT02869464|GENETIC|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
215154318|NCT03381638|DEVICE|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
215154319|NCT03838432|DEVICE|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
215154320|NCT06276946|RADIATION|standard radiotherapy|radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.
215154321|NCT06276946|RADIATION|experimental radiotherapy|radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
215154322|NCT03916913|RADIATION|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
215154323|NCT05286775|OTHER|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~1. 3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~2. 5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~3. \*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~   For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~4. Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~5. Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~6. Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~   * Four weekly applications."
215154324|NCT05286775|OTHER|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
215154325|NCT05414084|DIETARY_SUPPLEMENT|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
215154326|NCT06193356|OTHER|Learning tool|Video based learning tool about detection of endoscopic resection scars and recurrence.
215154327|NCT04269889|DRUG|Eltrombopag|"Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
215154328|NCT05766800|DRUG|Serplulimab|Specified dose on specified days
215154329|NCT05766800|DRUG|Carboplatin|Specified dose on specified days
215154330|NCT05766800|DRUG|Pemetrexed|Specified dose on specified days
215154331|NCT05766800|DRUG|Nab-paclitaxel|Specified dose on specified days
215154332|NCT05766800|DRUG|Liposomal paclitaxel|Specified dose on specified days
214463686|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Condoms & Contraception)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them."
214463687|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
214463688|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Gender & Partner Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
214463689|NCT06223165|BEHAVIORAL|Floreciendo (Foundations)|• Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.
214463690|NCT06148324|BEHAVIORAL|MENTOR Program|"MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week."
214463691|NCT05195840|BEHAVIORAL|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
214463692|NCT05195840|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
214463693|NCT06522256|PROCEDURE|High-resolution anoscopy|"The study includes 2 visits:~* a medical consultation for inclusion~* a proctology consultation including the performance of an AHR associated or not with biopsy sampling"
215154333|NCT05766800|PROCEDURE|Surgery|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
215154334|NCT05766800|RADIATION|Radiotherapy|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
214463694|NCT03647852|DRUG|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
214463695|NCT03647852|DRUG|IVIG|1\. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
215154335|NCT03841279|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
214463696|NCT03647852|DRUG|other basic supportive treatment|"1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d"
214463697|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
214463698|NCT05774639|DRUG|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
214463699|NCT05774639|DRUG|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
214463700|NCT05618756|DIETARY_SUPPLEMENT|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
214463701|NCT05618756|DIETARY_SUPPLEMENT|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
214463702|NCT00664014|DRUG|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
214463703|NCT00664014|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
214463704|NCT05718700|DRUG|Bulevirtide|Administered via subcutaneous (SC) injections
214463705|NCT02861300|DRUG|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
214463706|NCT02861300|DRUG|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
214463707|NCT05338801|OTHER|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
214463708|NCT05338801|OTHER|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
214463709|NCT06502639|OTHER|theraplay program|"A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing."
215154336|NCT05505955|DRUG|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
214463710|NCT06502639|OTHER|conventional physical therapy|conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
214463711|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
214463712|NCT06491030|DEVICE|Align PJK™ TLSO brace|Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.
214463713|NCT06491030|OTHER|Standard of Care|Patients will receive the standard of care postoperative instructions without a brace
214463714|NCT04072458|DRUG|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
214463715|NCT05678179|BEHAVIORAL|Telehealth|Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
214463716|NCT05678179|BEHAVIORAL|In Person (Face-2-Face)|Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
214463717|NCT06138418|PROCEDURE|Neurotomy|Surgical treatment of spastic foot
215154337|NCT05505955|DRUG|Placebo|Subjects took Placebo in Part 1 and Part 2.
215154338|NCT05599945|DRUG|NNC0581-0001|Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
215154339|NCT05599945|DRUG|Placebo (NNC0581-0001)|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
215154340|NCT00095888|DRUG|triapine|Given IV
215154341|NCT00095888|DRUG|gemcitabine hydrochloride|Given IV
214463718|NCT04837222|OTHER|No Intervention|This is a non-interventional study.
214463719|NCT04344678|DRUG|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
214463720|NCT04344678|DRUG|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
214463721|NCT06014983|DIETARY_SUPPLEMENT|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
214463722|NCT06014983|DIETARY_SUPPLEMENT|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
214463723|NCT06062745|DRUG|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
214463724|NCT06062745|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
214463725|NCT06442982|DEVICE|insole-type gait analyzer|Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
214463726|NCT06494787|COMBINATION_PRODUCT|Aliya Pulse Electric Field sysem and pembrolizumab|This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
214463727|NCT02955290|OTHER|Laboratory Biomarker Analysis|Correlative studies
214463728|NCT02955290|BIOLOGICAL|Nivolumab|Given IV
214463729|NCT02955290|BIOLOGICAL|Pembrolizumab|Given IV
214463730|NCT02955290|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
214463731|NCT05222971|DRUG|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
214463732|NCT05222971|DRUG|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
214463733|NCT04974554|BEHAVIORAL|FIT|FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
214463734|NCT04974554|BEHAVIORAL|Home-Based Family Support|Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
215154342|NCT00095888|OTHER|laboratory biomarker analysis|Correlative studies
215154343|NCT00095888|OTHER|pharmacological study|Correlative studies
215154344|NCT02826317|PROCEDURE|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS \>0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS \>0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
215154345|NCT02572908|OTHER|Sourdough wheat bread|
215154346|NCT02572908|OTHER|Regular yeast baked toast bread|
215154347|NCT02572908|OTHER|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
215154348|NCT00120302|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
215154349|NCT00120302|DRUG|Placebo|Matching vehicle cream
215154350|NCT01281514|DRUG|everolimus|Given PO
214534898|NCT05052502|OTHER|Reactive focal mass drug administration (rfMDA)|"Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants."
214534899|NCT03389425|BEHAVIORAL|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
214534900|NCT04668521|OTHER|OVA360|Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
214534901|NCT00004478|DRUG|droxidopa|
215154351|NCT01281514|DRUG|carboplatin|Given IV
214534902|NCT01171183|DRUG|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
214534903|NCT01171183|DRUG|Placebo|Placebo
215154352|NCT01281514|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
215154353|NCT01281514|OTHER|laboratory biomarker analysis|Correlative studies
215154354|NCT00042822|DRUG|romidepsin|
215154355|NCT03102437|DEVICE|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
215154356|NCT03265314|BEHAVIORAL|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
214463735|NCT03133546|DRUG|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
214463736|NCT03133546|DRUG|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
214463737|NCT02974998|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
214463738|NCT02974998|BEHAVIORAL|Standard HTC|Participants received the standard HTC available in South Africa for this population.
214463739|NCT05356286|DEVICE|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
214463740|NCT05947760|DRUG|IV Magnesium Sulfate|Participants will receive IV Magnesium Sulfate intraoperatively.
214463741|NCT05633615|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
214463742|NCT05633615|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214463743|NCT05633615|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
214463744|NCT05633615|DRUG|Cyclophosphamide|Given IV
214463745|NCT05633615|DRUG|Fludarabine|Given IV
214463746|NCT05633615|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214463747|NCT05633615|BIOLOGICAL|Mosunetuzumab|Given IV
214463748|NCT05633615|OTHER|Patient Observation|Undergo observation
214463749|NCT05633615|DRUG|Polatuzumab Vedotin|Given IV
214463750|NCT05633615|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214463751|NCT05633615|BIOLOGICAL|Tisagenlecleucel|Given IV
214463752|NCT06166420|OTHER|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
214463753|NCT06166420|OTHER|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
215154357|NCT03265314|BEHAVIORAL|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
215154358|NCT04308291|DEVICE|MiniMed™ 780G System|Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.
215154359|NCT02134158|DEVICE|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
215154360|NCT00612144|DRUG|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
215154361|NCT00612144|DRUG|Metformin HCl|"Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
215154362|NCT04184700|DIETARY_SUPPLEMENT|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
215154363|NCT04184700|DIETARY_SUPPLEMENT|RHF|Rice hydrolysed formula
215154364|NCT04184700|DIETARY_SUPPLEMENT|SF|Soy formula
215154365|NCT04184700|DIETARY_SUPPLEMENT|EHWF|extensively hydrolysed whey formula
215154366|NCT04184700|DIETARY_SUPPLEMENT|AAF|amino acid based formula
215154367|NCT02643446|BIOLOGICAL|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
215154368|NCT02643446|BIOLOGICAL|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
215154369|NCT04718155|DRUG|Atorvastatin|will receive 40 mg atrorvastatin 2 days
215154370|NCT04718155|OTHER|placebo|will receive 40 mg placebo 2 days
215154371|NCT00003469|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
215154372|NCT03610269|DEVICE|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
215154373|NCT01138449|DRUG|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
215154374|NCT00523302|DEVICE|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
215154375|NCT00523302|DEVICE|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
214463754|NCT04333745|OTHER|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
215154376|NCT03387618|DIAGNOSTIC_TEST|Digital PET/CT imaging|Next generation PET/CT imaging
215154377|NCT04411667|DRUG|Octagam|Standard of Care plus Octagam infusion for 3 days.
215154378|NCT00682123|DIETARY_SUPPLEMENT|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
215154379|NCT01065727|OTHER|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
214463755|NCT04333745|DIETARY_SUPPLEMENT|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
214463756|NCT02152046|PROCEDURE|ROP exam with spring loaded retractor|
214463757|NCT02152046|PROCEDURE|ROP exam with screw retractor|
214463758|NCT06011174|OTHER|survey application|Participants will only be asked to fill out the questionnaires.
214463759|NCT05445375|OTHER|PAD education video|20-min online multi-media video
214463760|NCT05135650|OTHER|Questionnaire Administration|Ancillary studies
214463761|NCT05135650|BIOLOGICAL|Sotrovimab|Given IV
214463762|NCT05135650|PROCEDURE|Biospecimen Collection|Undergo blood and nasal swab sample collection
214463763|NCT06365970|DRUG|Niraparib|An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
214463764|NCT06365970|DRUG|Dostarlimab|An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
215154380|NCT01065727|OTHER|natalizumab|monthly natalizumab during 3 years
215154381|NCT01406782|BIOLOGICAL|rituximab|
214463765|NCT06333561|PROCEDURE|Hepatic arterial infusion chemotherapy|Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
214463766|NCT06333561|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
214463767|NCT06333561|DRUG|Tislelizumab|200mg intravenously every 3 weeks
214463768|NCT06333561|DRUG|Toripalimab|240mg intravenously every 3 weeks
214463769|NCT06333561|DRUG|Sintilimab|200mg intravenously every 3 weeks
214463770|NCT06333561|DRUG|Camrelizumab|200mg intravenously every 3 weeks
214463771|NCT03838263|DRUG|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
214463772|NCT03838263|RADIATION|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
214463773|NCT06501729|OTHER|Kiss|Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.
214463774|NCT05712057|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|high frequency rTMS over the right dlPFC
214463775|NCT05712057|DEVICE|electrical scalp stimulation|electrical scalp stimulation over the right dlPFC
214463776|NCT05712057|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal.
214463777|NCT05712057|BEHAVIORAL|Emotional Awareness Training|Emotional awareness training is a behavioral intervention through which participants learn how to identify and evaluate their emotions and the components that make up each emotion.
215154382|NCT01406782|GENETIC|DNA analysis|
215154383|NCT01406782|GENETIC|gene expression analysis|
215154384|NCT01406782|GENETIC|polymerase chain reaction|
215154385|NCT01406782|OTHER|laboratory biomarker analysis|
215154386|NCT00067002|PROCEDURE|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
215154387|NCT00067002|PROCEDURE|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
215154388|NCT00067002|DRUG|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
215154389|NCT00067002|DRUG|Melphalan|140 mg/m2 by vein on Day -8.
215154390|NCT00067002|DRUG|Thiotepa|5 mg/Kg by vein on Day -7.
215154391|NCT00067002|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
215154392|NCT00067002|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6.
215154393|NCT00067002|DRUG|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
215154394|NCT00067002|RADIATION|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
215154395|NCT04326803|BIOLOGICAL|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
215154396|NCT03483857|BEHAVIORAL|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
215154397|NCT01017198|DRUG|BIIB021 and Food|Assessing the effect of food use on BIIB021
215154398|NCT01017198|DRUG|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
215154399|NCT00522808|DRUG|A-831|
214463778|NCT04442646|BEHAVIORAL|multidisciplinary lessons|the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
214463779|NCT04571255|BEHAVIORAL|Music-Assisted Relaxation|The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
214463780|NCT05642182|DRUG|SFA002|Study drug formula without excipient
214463781|NCT05642182|DRUG|SFA002|Study Drug SFA002 with excipient (Propionate)
214463782|NCT05729438|DIETARY_SUPPLEMENT|BCAA|status of nutrition evaluation after 3 months of BCAA
214463783|NCT01642641|PROCEDURE|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
214463784|NCT01642641|PROCEDURE|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
214463785|NCT01642641|PROCEDURE|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
214534904|NCT02809807|OTHER|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
214534905|NCT02809807|DEVICE|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
215154400|NCT03315663|OTHER|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
215154401|NCT03315663|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
215154402|NCT02733640|DRUG|Pantoprazole|pantoprazole 40 mg once-daily
215154403|NCT02733640|DRUG|Ranitidine|ranitidine 150 mg twice-daily
215154404|NCT02481219|DEVICE|PillCam® COLON 2 procedure-CONTROL|
215154405|NCT02481219|DRUG|Senna tablets|
215154406|NCT02481219|DRUG|PEG|
215154407|NCT02481219|DRUG|Metoclopramide|
215154408|NCT02481219|DRUG|Erythromycin|
215154409|NCT02481219|DRUG|SUPREP oral sulfate solution|
215154410|NCT02481219|DRUG|Bisacodyl|
215154411|NCT02481219|DRUG|SUPREP oral sulfate solution with Gastrografin|
214534906|NCT06400797|OTHER|estimation of patient outcome by health care providers|On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
214534907|NCT00747695|DRUG|Rabeprazole sodium|
214534908|NCT06094335|DEVICE|Virtual reality rehabilitation|Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
214534909|NCT06094335|OTHER|Traditional physical therapy|Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
214534910|NCT00835510|DRUG|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
214534911|NCT00835510|DRUG|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
214534912|NCT00835510|DRUG|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
214534913|NCT04244149|OTHER|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
214534914|NCT05140707|OTHER|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
214534915|NCT02236663|BEHAVIORAL|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
214534916|NCT02236663|BEHAVIORAL|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
214534917|NCT04926441|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
214534918|NCT04578587|DEVICE|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
214534919|NCT05817474|DRUG|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
214534920|NCT05248698|BEHAVIORAL|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
214534921|NCT05248698|OTHER|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
214534922|NCT01904136|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
214534923|NCT01904136|PROCEDURE|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
215154412|NCT02039141|OTHER|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
215154413|NCT00843700|BEHAVIORAL|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
215154414|NCT00843700|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
215154415|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
215154416|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
215154417|NCT02064023|DEVICE|insulin pump|subjects in the experimental arm will administer insulin using a pump
215154418|NCT02064023|OTHER|multiple daily insulin injection|Subjects will continue with usual insulin injections
215154419|NCT01354314|DRUG|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
214534924|NCT01904136|DRUG|Cyclophosphamide|Given IV
214534925|NCT01904136|DRUG|Fludarabine|Given IV
214534926|NCT01904136|OTHER|Laboratory Biomarker Analysis|Correlative studies
215154420|NCT01354314|DRUG|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
215154421|NCT01354314|DRUG|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
215154422|NCT01354314|DRUG|Placebo|One capsule in the morning, three capsules in the evening
215154423|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
215154424|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
215154425|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
215154426|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
214534927|NCT01904136|DRUG|Melphalan|Given IV
214534928|NCT01904136|DRUG|Mycophenolate Mofetil|Given PO
214534929|NCT01904136|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
214534930|NCT01904136|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
214534931|NCT01904136|DRUG|Tacrolimus|Given IV and PO
215154427|NCT03406312|DIAGNOSTIC_TEST|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
215154428|NCT02665390|PROCEDURE|Percutaneous cryoablation|Percutaneous cryoablation
215154429|NCT05924217|OTHER|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
215154430|NCT06459206|DEVICE|Pulse oximeter|Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
215154431|NCT01970293|OTHER|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
215154432|NCT05064215|PROCEDURE|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
215154433|NCT01795053|BEHAVIORAL|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
215154434|NCT01795053|BEHAVIORAL|Placebo open play session|
215154435|NCT02080806|DEVICE|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
215154436|NCT04343742|DRUG|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
215154437|NCT00414336|DRUG|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
215154438|NCT03619382|RADIATION|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
215154439|NCT03619382|RADIATION|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
215154440|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
214463786|NCT05574270|DEVICE|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
214463787|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training|"The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure."
214463788|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage|"Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
214463789|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise|"Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
214463790|NCT02733003|BEHAVIORAL|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
214463791|NCT05719493|OTHER|multicomponent treatment|The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
214463792|NCT06694259|PROCEDURE|Pneumatic retinopexy with transscleral cryopexy|"Pneumatic retinopexy with transscleral cryopexy is a procedure used to treat certain types of rhegmatogenous retinal detachments.~Procedure steps:~Transscleral cryopexy: in this first step, the surgeon uses a cryoprobe applied to the sclera directly over the retinal tear. The cryoprobe emits extreme cold, creating a small, localized freeze that reaches the retina and seals the tear by causing a controlled scar to form. This scar tissue holds the retina in place and prevents further fluid from passing through the tear.~Gas bubble injection: after the cryopexy, a small gas bubble (usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8)) is injected into the vitreous cavity. This bubble applies upward pressure on the retina, gently pressing it against the back wall of the eye, which aids in reattaching the retina.~Head positioning: for several days following the procedure, the patient must keep their head in a specific position so the gas bubble remains aligned with the retinal tear."
214534932|NCT01904136|RADIATION|Total-Body Irradiation|Undergo TBI
214534933|NCT01742845|OTHER|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
214534934|NCT01742845|OTHER|landmark based superfical ropivacaine 4.75 mg/ml injection|
214534935|NCT03300609|BIOLOGICAL|Panitumumab|Given IV
214534936|NCT03300609|DRUG|Oxaliplatin|Given IV
214534937|NCT03300609|DRUG|Leucovorin Calcium|Given IV
214696274|NCT02834546|BIOLOGICAL|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
214696275|NCT04762147|DRUG|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
214696276|NCT04762147|DRUG|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
215154441|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
215154442|NCT01840982|DIETARY_SUPPLEMENT|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
215154443|NCT01840982|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
215154444|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
215154445|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
215154446|NCT02911844|DRUG|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
215154447|NCT04772274|DRUG|Ustekinumab|45 mg, single-dose
215154448|NCT03754998|BEHAVIORAL|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
215154449|NCT05653869|DRUG|APS03118|Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
214534938|NCT03300609|DRUG|Fluorouracil|Given IV
214534939|NCT03300609|DRUG|Capecitabine|Given PO
214534940|NCT03300609|OTHER|Quality-of-Life Assessment|Ancillary studies
214534941|NCT03300609|OTHER|Laboratory Biomarker Analysis|Correlative studies
214534942|NCT03090971|DRUG|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
214534943|NCT03090971|DRUG|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
214534944|NCT05238155|DRUG|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
214534945|NCT01744743|PROCEDURE|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
214534946|NCT00349739|DRUG|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
214534947|NCT00853372|DRUG|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
214534948|NCT00853372|DRUG|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
214534949|NCT04289259|OTHER|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
214696277|NCT05583981|OTHER|Interview|Participate in interview
214696278|NCT00062634|BEHAVIORAL|Female condom skills training|
214696279|NCT03791645|BEHAVIORAL|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
214696280|NCT06552715|DEVICE|Placement of resorbable HAp-based composite|The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
214534950|NCT01821729|DRUG|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
214696281|NCT03904524|BEHAVIORAL|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
214534951|NCT01821729|DRUG|Losartan|Taken orally every day during Phase I for all 8 cycles
214534952|NCT01821729|RADIATION|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
214534953|NCT04278495|DRUG|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
214534954|NCT04278495|DRUG|Placebo|Placebo
214696282|NCT02681055|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
214696283|NCT02695524|OTHER|Scapula-focused exercises|
215154450|NCT03052062|DIETARY_SUPPLEMENT|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
215154451|NCT00478023|DRUG|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
215154452|NCT00478023|DRUG|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
215154453|NCT00478023|DRUG|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
215154454|NCT00478023|DRUG|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
214534955|NCT04166110|DRUG|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
214534956|NCT04166110|DRUG|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
214534957|NCT04950062|OTHER|High Intensity Interval Training|"1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit."
215154455|NCT00478023|DRUG|Placebo|4 - 6 hourly; Total 72 hours
214534958|NCT04950062|OTHER|Intermittent Fasting 16/8 Protocol|Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
214534959|NCT00489528|DRUG|Somatropin; Recombinant human growth hormone (r hGH)|
214534960|NCT04083937|RADIATION|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
214534961|NCT04083937|RADIATION|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
214534962|NCT04083937|RADIATION|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
214534963|NCT06201871|DRUG|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
214534964|NCT03441945|OTHER|magnetic steering|magnetic steering
214534965|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
214534966|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
215154456|NCT03553303|DRUG|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
215154457|NCT00389038|BEHAVIORAL|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
215154458|NCT00389038|BEHAVIORAL|Headache Education|Behavioral Treatment 2 (headache education)
215154459|NCT00389038|DRUG|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
215154460|NCT02978976|DRUG|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
214696284|NCT02695524|OTHER|Motor control exercises|
214696285|NCT02341118|GENETIC|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
214696286|NCT05582265|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214696287|NCT05582265|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214696288|NCT05582265|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214696289|NCT05582265|PROCEDURE|Surgical resection|Standard of care
214696290|NCT05582265|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214696291|NCT05582265|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214696292|NCT05582265|RADIATION|Radiation|Recommended, standard of care
214696293|NCT05582265|DRUG|Carboplatin (neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
215154461|NCT02978976|DRUG|saline|saline placebo injection in the same regimen.
215154462|NCT04588584|OTHER|Survey and Interviews|Survey and Interviews
214534967|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
214534968|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
214534969|NCT05885269|DRUG|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
214534970|NCT05885269|DRUG|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
214534971|NCT03120598|BEHAVIORAL|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
214534972|NCT03120598|BEHAVIORAL|ISF strategy|Implementation \& Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
214534973|NCT02925234|DRUG|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
214534974|NCT02925234|DRUG|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
214534975|NCT02925234|DRUG|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
214534976|NCT02925234|DRUG|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
214534977|NCT02925234|DRUG|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
214534978|NCT02925234|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
214534979|NCT02925234|DRUG|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
214534980|NCT02925234|DRUG|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
214534981|NCT02925234|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
214534982|NCT02925234|DRUG|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
214534983|NCT02925234|DRUG|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
214534984|NCT02925234|DRUG|Afatinib|Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
215154463|NCT01094847|DRUG|DWJ1252|tablet(oral) administration following the schedule of each arm
215154464|NCT01010646|DRUG|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
215154465|NCT01010646|DRUG|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
215154466|NCT01010646|DRUG|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
215154467|NCT00981110|DEVICE|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
215154468|NCT00981110|DEVICE|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
215154469|NCT00402402|PROCEDURE|Tuberculin skin test|
215154470|NCT00402402|PROCEDURE|Quantiferon-TB Gold assay|
215154471|NCT05481086|OTHER|No Interventions|There is no interventions in this study
215154472|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
214534985|NCT02925234|DRUG|Dabrafenib and trametinib|Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
214534986|NCT02925234|DRUG|Ribociclib|Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
214534987|NCT02925234|DRUG|Lenvatinib|Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
214534988|NCT02925234|DRUG|Pembrolizumab|Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
214534989|NCT02925234|DRUG|Durvalumab|Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
214696294|NCT05582265|DRUG|Carboplatin (adjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
215154473|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
215154474|NCT01004991|BIOLOGICAL|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
215154475|NCT01004991|DRUG|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
215154476|NCT01004991|DRUG|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
215154477|NCT01004991|DRUG|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
215154478|NCT01004991|DRUG|prednisone|100 mg PO days 8-12 of each of 6 cycles
215154479|NCT01004991|DRUG|azacytidine|Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
215154480|NCT00107913|DRUG|Doxil|
215154481|NCT02149043|DEVICE|Thermography|Thermographic imaging of the patient's abdomen surface
215154482|NCT02149043|PROCEDURE|Colonoscopy|Endoscopic examination of the colon
215154483|NCT02904278|OTHER|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
215154484|NCT02904278|OTHER|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
215154485|NCT03537521|PROCEDURE|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
214696295|NCT00396240|DRUG|Rosuvastatin|
215154486|NCT01740648|DRUG|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
215154487|NCT01740648|DRUG|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
215154488|NCT01740648|RADIATION|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
215154489|NCT01872416|DEVICE|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
214463793|NCT06694259|PROCEDURE|Pneumatic retinopexy with laser photocoagulation|"Pneumatic retinopexy with laser photocoagulation is a minimally invasive procedure used to repair certain types of rhegmatogenous retinal detachments.~Procedure steps:~Gas bubble injection: a small gas bubble, usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8), is injected into the vitreous cavity which rises and applies pressure to the detached retina, pressing it back against the eye wall and helping to reapproximate the retinal layers.~Laser photocoagulation: once the retina is positioned correctly, laser is used to create small burns around the retinal tear. This laser application causes a mild inflammatory response, creating a scar around the tear and effectively welding the retina to the underlying tissue. This seal prevents fluid from reaccumulating beneath the retina.~Head positioning: following the procedure, the patient must keep their head in a specific position for several days. This positioning ensures that the gas bubble stays aligned with the retinal tear."
214463794|NCT03630211|DRUG|Cyclophosphamide|Stem Cell Mobilization
214463795|NCT03630211|DRUG|Mesna|Stem Cell Mobilization
214463796|NCT03630211|DRUG|Rituximab|Transplantation Conditioning
214463797|NCT03630211|DRUG|Alemtuzumab|Transplantation Conditioning
214534990|NCT02925234|DRUG|Rucaparib|Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
214534991|NCT02925234|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
214534992|NCT02925234|DRUG|Palbociclib|Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
214534993|NCT02925234|DRUG|Crizotinib|Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
214534994|NCT02925234|DRUG|Sunitinib|Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
215154490|NCT03780166|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
214463798|NCT03630211|DRUG|Thiotepa|Transplantation Conditioning
214463799|NCT03630211|DRUG|GM-CSF|Transplantation Conditioning
214696296|NCT00396240|PROCEDURE|Initiatives to improve compliance|
214696297|NCT00621452|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214463800|NCT03630211|DRUG|Intravenous immunoglobulin|Transplantation Conditioning
214463801|NCT03630211|RADIATION|Total Body Irradiation|Transplantation Conditioning
214463802|NCT03630211|DRUG|Anti Thymocyte Globulin|Transplantation Conditioning
214463803|NCT06103188|DRUG|Placebo|The placebo pill will be given to the patients 1 hour prior to their planned surgery.
214463804|NCT06103188|DRUG|Diazepam|Diazepam will be given to the patients 1 hour prior to their planned surgery.
214463805|NCT06103188|DRUG|Melatonin|Melatonin will be given to the patients 1 hour prior to their planned surgery.
214463806|NCT05411159|PROCEDURE|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
214463807|NCT05411159|PROCEDURE|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
214696298|NCT00621452|DRUG|cyclophosphamide|Given IV
215154491|NCT01809340|DRUG|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
215154492|NCT01809340|DRUG|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
214534995|NCT02925234|DRUG|Cabozantinib|Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
214534996|NCT02925234|DRUG|Abemaciclib|Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
214534997|NCT02925234|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
214534998|NCT02925234|DRUG|Atezolizumab and Bevacizumab|Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
214534999|NCT02925234|DRUG|Ipilimumab and nivolumab|Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
214535000|NCT02925234|DRUG|Entrectinib|Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
214535001|NCT02925234|DRUG|Talazoparib|Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
214535002|NCT02925234|DRUG|Dacomitinib|Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
214535003|NCT02925234|DRUG|Lorlatinib|Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
214535004|NCT02925234|DRUG|Erdafitinib|Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
214535005|NCT02925234|DRUG|Alpelisib|Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
214535006|NCT02925234|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
214535007|NCT02925234|DRUG|Pemigatinib|Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
214535008|NCT02925234|DRUG|Selpercatinib|Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
214535009|NCT02925234|DRUG|Tepotinib|Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
214696299|NCT00621452|BIOLOGICAL|aldesleukin|Given subcutaneously
214696300|NCT00621452|GENETIC|polymerase chain reaction|Correlative studies
214696301|NCT00621452|GENETIC|gene rearrangement analysis|Correlative studies
214696302|NCT00621452|PROCEDURE|lymph node biopsy|Optional correlative studies
214696303|NCT00621452|BIOLOGICAL|genetically engineered lymphocyte therapy|Receive genetically modified T cells
214696304|NCT00621452|PROCEDURE|bone marrow aspiration|Optional correlative studies
214696305|NCT00621452|OTHER|flow cytometry|Correlative studies
214696306|NCT00621452|OTHER|laboratory biomarker analysis|Correlative studies
214696307|NCT00621452|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214696308|NCT05059951|DRUG|Immune checkpoint inhibitor|Chemotherapy follow the guild line.
214696309|NCT02155764|DEVICE|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
214696310|NCT02155764|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
214696311|NCT02155764|DEVICE|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
215154493|NCT01809340|DRUG|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
214463808|NCT05813080|DEVICE|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
215154494|NCT00714870|BEHAVIORAL|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
215154495|NCT02331888|DEVICE|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
215154496|NCT00389259|DRUG|Placebo|IV placebo q4h
215154497|NCT03895749|DIETARY_SUPPLEMENT|NEO40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
215154498|NCT04563949|OTHER|Repeat Testing|Repeat Testing with the PLA will be conducted
215154499|NCT00544297|DRUG|PEP005 gel|Two day application, 0.05%
215154500|NCT06045156|DRUG|Tirofiban|Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
215154501|NCT06045156|DRUG|Tirofiban simulant|Tirofiban simulant is placebo packed the same style as tirofiban
215154502|NCT01577888|DEVICE|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
215154503|NCT02275234|OTHER|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
215154504|NCT03121053|DRUG|sodium bicarbonate|
215154505|NCT03121053|DRUG|hypotone saline|
215154506|NCT02357368|DRUG|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
215154507|NCT02357368|DEVICE|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
215154508|NCT02357368|DEVICE|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
215154509|NCT02357368|DEVICE|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
215154510|NCT02894684|DRUG|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
215154511|NCT02894684|DRUG|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
215154512|NCT02639221|DRUG|PXT002331|
215154513|NCT02172885|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
215154514|NCT02377817|DEVICE|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
215154515|NCT02377817|DEVICE|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
215154516|NCT03895840|DRUG|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
214463809|NCT05813080|OTHER|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
214463810|NCT05703971|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
214463811|NCT05703971|BIOLOGICAL|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
214463812|NCT00986856|DRUG|Fucidin® cream|
214463813|NCT03358719|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
214463814|NCT03358719|DRUG|Decitabine|Given IV
214463815|NCT03358719|OTHER|Laboratory Biomarker Analysis|Correlative studies
214463816|NCT03358719|BIOLOGICAL|Nivolumab|Given IV
214696312|NCT00831441|DRUG|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
215154517|NCT05169008|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular injection
215154518|NCT05169008|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
214535010|NCT01011699|DRUG|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
214696313|NCT00831441|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
215154519|NCT05552989|OTHER|this is a non-interventional study|this is a non-interventional study
215154520|NCT00659789|DRUG|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
215154521|NCT00659789|DRUG|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
215154522|NCT01032252|OTHER|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
215154523|NCT01147874|PROCEDURE|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
215154524|NCT02109497|DRUG|PBT2|PBT2 250 mg administered
215154525|NCT00082797|DRUG|leucovorin calcium|
214463817|NCT03358719|DRUG|Poly ICLC|Given SC
214463818|NCT06331598|DRUG|Atezolizumab|A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
214463819|NCT06331598|DRUG|Tiragolumab|A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
214463820|NCT06158646|DEVICE|kinematic knee prosthesis|Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.
214463821|NCT06158646|DEVICE|biomechanic knee prosthesis|A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
215154526|NCT00082797|DRUG|methotrexate|
214463822|NCT01541553|PROCEDURE|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
214463823|NCT01541553|DRUG|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
214463824|NCT01541553|DRUG|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
214463825|NCT05887583|BEHAVIORAL|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
215154527|NCT02360878|DEVICE|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
215154528|NCT01206725|OTHER|Exercise|"1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
214463826|NCT04486833|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
214463827|NCT04486833|DRUG|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
214463828|NCT04486833|DRUG|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
214535011|NCT01011699|DRUG|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
214696314|NCT00169117|BEHAVIORAL|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
214696315|NCT02483104|DRUG|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
214696316|NCT02483104|DRUG|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
215154529|NCT00000288|DRUG|Cotinine fumarate|
215154530|NCT01149018|DRUG|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
215154531|NCT01149018|DRUG|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
215154532|NCT03197896|OTHER|Educational Intervention|Review prostate cancer information
215154533|NCT00251732|DRUG|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
215154534|NCT00251732|DRUG|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
215154535|NCT00251732|DRUG|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
215154536|NCT06400043|OTHER|Cognitive dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.
215154537|NCT06400043|OTHER|Motor dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
215154538|NCT01879098|DIETARY_SUPPLEMENT|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
215154539|NCT01879098|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
214535012|NCT01011699|DRUG|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
214696317|NCT02483104|DRUG|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
215154540|NCT01879098|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
215154541|NCT01879098|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
215154542|NCT00434785|DRUG|AGG-523|
214463829|NCT04632238|BEHAVIORAL|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
214463830|NCT05582681|DIAGNOSTIC_TEST|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
214463831|NCT05582681|OTHER|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
214463832|NCT05582681|DRUG|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
214463833|NCT05894954|DIETARY_SUPPLEMENT|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
214463834|NCT05894954|COMBINATION_PRODUCT|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
214463835|NCT05894954|BEHAVIORAL|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
214463836|NCT05894954|BEHAVIORAL|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
214463837|NCT03623074|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
214463838|NCT03623074|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
214463839|NCT03947814|DRUG|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
214463840|NCT05642780|DRUG|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
214463841|NCT05642780|DRUG|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
214463842|NCT05386030|COMBINATION_PRODUCT|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
214463843|NCT05386030|COMBINATION_PRODUCT|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
214463844|NCT04535349|DIAGNOSTIC_TEST|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
214463845|NCT05597371|OTHER|the use of the platform|the use of the platform
214463846|NCT04525729|DRUG|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
214463847|NCT04525729|DRUG|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
214535013|NCT02517528|DRUG|ABT-450/r/ABT-267|Tablet
214535014|NCT02517528|DRUG|ABT-333|Tablet
214696318|NCT04719676|OTHER|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
214696319|NCT04719676|OTHER|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
214696320|NCT01728753|DRUG|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
214696321|NCT01728753|DRUG|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
214696322|NCT01728753|DRUG|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
214696323|NCT01728753|DRUG|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
214696324|NCT00111917|DRUG|Infliximab|anti-TNF
214696325|NCT00111917|OTHER|Placebo|Placebo infusion
215154543|NCT04798404|OTHER|Multimodal exercise intervention|The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
215154544|NCT02175030|DRUG|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
215154545|NCT02175030|DRUG|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
215154546|NCT05255315|BEHAVIORAL|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
215154547|NCT01637441|PROCEDURE|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
215154548|NCT01637441|PROCEDURE|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
215154549|NCT01521403|DRUG|Metronidazole|3x500 mg/day for 10 days
215154550|NCT01521403|DRUG|Placebo|3x1 tablet per day for 10 days
215154551|NCT03734913|DRUG|ZSP1602|ZSP1602 capsules for oral administration
215154552|NCT02440841|DRUG|fedovapagon|
215154553|NCT02440841|DRUG|Itraconazole|
215154554|NCT02440841|DRUG|rifampicin|
215154555|NCT05136014|OTHER|Collection of surgical waste|collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed
215154556|NCT02817464|DRUG|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
215154557|NCT02817464|DRUG|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
215154558|NCT00885534|DRUG|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
215154559|NCT01075542|DEVICE|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
215154560|NCT01075542|DEVICE|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
215154561|NCT04919798|DEVICE|Non-invasive bladder emptying device|The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
215154562|NCT00540085|DRUG|Rocuronium|0.6 mg/kg given intravenously before intubation
215154563|NCT02453711|DRUG|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
215154564|NCT02453711|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
215154565|NCT02453711|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
215154566|NCT00507143|DRUG|irinotecan|
214535015|NCT02517528|DRUG|ribavirin|Tablet
214535016|NCT02986750|DEVICE|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
214535017|NCT02986750|DEVICE|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
214535018|NCT02986750|DEVICE|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
214535019|NCT02361879|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
214535020|NCT02361879|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
214535021|NCT00668330|DRUG|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
214535022|NCT00668330|DRUG|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
214535023|NCT01672398|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
214535024|NCT02311777|DRUG|Pregabalin|Pregabalin will be given orally during preoperative period
214535025|NCT02311777|DRUG|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
214535026|NCT02311777|DRUG|Placebo|Placebo will be given orally during preoperative period
214535027|NCT00936962|BIOLOGICAL|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
214535028|NCT04551430|DRUG|Cabozantinib|Cabozantinib will be supplied by Exelixis.
214535029|NCT04551430|DRUG|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
214535030|NCT04551430|DRUG|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
215154567|NCT00343096|DRUG|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
215154568|NCT05940090|DEVICE|SkinIO|The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
215154569|NCT01867177|OTHER|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
215154570|NCT01867177|OTHER|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
215154571|NCT01867177|BEHAVIORAL|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
215154572|NCT01033799|OTHER|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
215154573|NCT01033799|OTHER|Non fermented dairy product (control)|
215154574|NCT04071288|PROCEDURE|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
215154575|NCT03008369|OTHER|Laboratory Biomarker Analysis|Correlative studies
215154576|NCT03008369|DRUG|Lenvatinib|Given PO
215154577|NCT03008369|OTHER|Quality-of-Life Assessment|Ancillary studies
214535031|NCT01542398|BEHAVIORAL|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
214535032|NCT02960945|DRUG|CTP-543, 16 mg (2 x 8 mg tablet)|
214535033|NCT02960945|DRUG|Jakafi 15Mg Tablet|
214535034|NCT01692145|DRUG|KCT-0809|
214535035|NCT01692145|DRUG|Placebo|
214535036|NCT02743988|DRUG|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
214535037|NCT01939561|DRUG|Lamotrigine|
214535038|NCT01939561|DRUG|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
214535039|NCT06546358|DRUG|Trazodone|Participants will be randomized to receive either quetiapine or trazodone.
214535040|NCT06546358|DRUG|Quetiapine|Participants will be randomized to receive either quetiapine or trazodone.
214535041|NCT06701019|OTHER|Semi-structured interview/focus group discussion|"All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option."
214535042|NCT06122454|DRUG|Hepenofovir Fumarate Tablets|Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
214535043|NCT05955963|OTHER|Abdominal auscultation|spectral analysis of Bowel sounds
214535044|NCT04087564|OTHER|music intervention|"The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session"
214535045|NCT04795206|OTHER|No Intervention|Administered as specified in the treatment arm.
215154578|NCT02774629|OTHER|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
215154579|NCT06462599|GENETIC|Gene polymorphism from blood samples|"Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation"
214535046|NCT04458220|OTHER|photo and voice obtained|The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
214535047|NCT05500781|BEHAVIORAL|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
214696326|NCT04600050|OTHER|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
214535048|NCT04742062|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
215154580|NCT03873142|BEHAVIORAL|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
215154581|NCT01578876|DEVICE|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
215154582|NCT01292629|DEVICE|iSert 251 intraocular lens|aphakic intraocular lens
215154583|NCT02964091|DRUG|sofosbuvir/ledipasvir|
215154584|NCT00089869|DRUG|olanzapine|
215154585|NCT00089869|DRUG|atomoxetine|
215154586|NCT00089869|DRUG|placebo|
215154587|NCT03863769|OTHER|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
215154588|NCT03172416|DRUG|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
215154589|NCT03172416|DRUG|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
215154590|NCT04241562|OTHER|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
214535049|NCT04742062|OTHER|Placebo|100 mL 0.9% Sodium Chloride solution
214535050|NCT04584333|BEHAVIORAL|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
214535051|NCT03713281|DEVICE|Toric Multifocal etafilcon A with PVP|Investigational
214535052|NCT02010983|OTHER|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
214535053|NCT06509945|OTHER|allogeneic peripheral blood stem cell transplantation|Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
214535054|NCT00320814|DRUG|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
214535055|NCT03736278|OTHER|No intervention|We group the patients according to the outcome (survival vs mortality)
214535056|NCT04573556|DRUG|Lemborexant|Lemborexant oral tablets.
214535057|NCT00320398|DRUG|Fondaparinux|
214535058|NCT01355978|DEVICE|Noninvasive Open Ventilation System|Noninvasive ventilation system
214535059|NCT03206268|DEVICE|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
214535060|NCT03515447|OTHER|Non interventional study|
215154591|NCT01579136|BEHAVIORAL|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
215154592|NCT02064777|DRUG|Tacrolimus|
214535061|NCT04478838|DRUG|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
214535062|NCT04478838|DRUG|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
214535063|NCT04478838|DRUG|paliperidone|3 mg, 6 mg, 9 mg Tablets
214535064|NCT04221958|DEVICE|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
214535065|NCT04150913|DRUG|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
214535066|NCT04150913|DRUG|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
214535067|NCT01245803|DRUG|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
214535068|NCT01245803|DRUG|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
215154593|NCT03229980|DRUG|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
215154594|NCT03229980|DRUG|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
215154595|NCT00704236|DRUG|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
215154596|NCT00704236|DRUG|Placebo|
215154597|NCT04292899|DRUG|Remdesivir|Administered as an intravenous infusion
215154598|NCT04292899|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
215154599|NCT03016052|BEHAVIORAL|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
215154600|NCT01578369|OTHER|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
215154601|NCT01947140|DRUG|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
214535069|NCT05633056|BEHAVIORAL|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
214535070|NCT03472976|OTHER|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
214535071|NCT03472976|DRUG|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
214535072|NCT03472976|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
214535073|NCT00799747|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
214535074|NCT00799747|DRUG|Placebo|placebo
214535075|NCT02546505|OTHER|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
214463848|NCT03387475|DRUG|Deferasirox|iron chelation
214535076|NCT02546505|OTHER|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
214535077|NCT02428218|DRUG|dimethyl fumarate|enteric-coated microtablets
214535078|NCT02428218|DRUG|Placebo|enteric-coated microtablets
214535079|NCT06134583|PROCEDURE|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
214463849|NCT05158374|DRUG|Aspirin tablet|75mg Aspirin once per day
214463850|NCT05158374|DRUG|Metformin|500mg Metformin once per day
214463851|NCT05158374|DRUG|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
214463852|NCT05581017|PROCEDURE|Preoperative biliary drainage|Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
214535080|NCT06134583|PROCEDURE|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
214535081|NCT00215722|DRUG|Cetuximab|
214535082|NCT00039117|BIOLOGICAL|oblimersen sodium|Given IV
214535083|NCT00039117|DRUG|cytarabine|Given IV
214535084|NCT00039117|DRUG|daunorubicin hydrochloride|Given IV
214535085|NCT00039117|OTHER|laboratory biomarker analysis|Correlative studies
214535086|NCT00039117|OTHER|pharmacological study|Correlative studies
214535087|NCT03745378|OTHER|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
214535088|NCT02743299|DEVICE|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
214535089|NCT03298529|OTHER|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
214535090|NCT03298529|OTHER|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
214535091|NCT03298529|OTHER|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
215154602|NCT01947140|DRUG|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
215154603|NCT05053802|COMBINATION_PRODUCT|Microwave ablation plus Camrelizumab|Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
215154604|NCT05053802|DEVICE|Microwave ablation|Tumor received treatment of microwave ablation
215154605|NCT00992797|DRUG|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.
215154606|NCT00992797|OTHER|Orange juice|Orange juice at randomization day and at week 5.
215154607|NCT03695367|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
215154608|NCT03695367|DEVICE|Luer lock applicator|Applicator for instillation.
215154609|NCT03695367|DEVICE|Vial access device|Device for withdrawal of drug product.
215154610|NCT03695367|DRUG|Ibuprofen|Ibuprofen, 600 mg.
215154611|NCT03695367|DRUG|Acetaminophen|Acetaminophen, 1 g.
215154612|NCT03695367|DRUG|Ketorolac|Intraoperative IV ketorolac.
215154613|NCT00559819|DRUG|placebo|Placebo (orange juice), same volume as alcohol
214463853|NCT05605756|DRUG|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
214535092|NCT03298529|OTHER|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
214463854|NCT02789956|DEVICE|Internal vs. external cad cam co/cr framework|
214535093|NCT03298529|OTHER|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
214535094|NCT03298529|OTHER|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
214696327|NCT04600050|OTHER|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
214696328|NCT02854904|DRUG|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
214696329|NCT02854904|DRUG|Placebo|Placebo controlled
215154614|NCT00559819|DRUG|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
215154615|NCT00536419|DRUG|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
215154616|NCT00536419|OTHER|Placebo|Placebo, daily dose, 4 days, oral administration
215154617|NCT01678495|OTHER|Sulfur hexafluoride + ultrasounds|
215154618|NCT01678495|DRUG|Recombinant tissue plasminogen activator|
215154619|NCT05574413|OTHER|Moderate intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
215154620|NCT05574413|OTHER|High intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
215154621|NCT05574413|OTHER|High intensity interval exercise|Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
215154622|NCT05574413|OTHER|Resting (no exercise) control|Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.
215154623|NCT02189733|BIOLOGICAL|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
215154624|NCT05824195|OTHER|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
215154625|NCT02984605|DIETARY_SUPPLEMENT|nutritional meal replacement|1 times a day with bags of nutritional meal replacement + individualized exercise prescription
215154626|NCT03204864|DEVICE|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
215154627|NCT03204864|DEVICE|Conventional CS lead placement|Clinical Practice
215154628|NCT01707199|DRUG|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
215154629|NCT03990727|DIAGNOSTIC_TEST|Retina Analysis-mosaic|Fundus retina pattern study
215154630|NCT03990727|DIAGNOSTIC_TEST|Autofluorescence|Fundus reflectance-functionality
215154631|NCT03990727|DIAGNOSTIC_TEST|OCT- 1 micra|Fine tomography fundus retina
214535095|NCT05548413|BEHAVIORAL|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
214535096|NCT05548413|BEHAVIORAL|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
214535097|NCT00980577|DEVICE|NUUS|Sonosite Micro Maxx
214535098|NCT05479188|DEVICE|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
214535099|NCT05479188|DEVICE|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
214535100|NCT05479188|DEVICE|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
214535101|NCT05479188|DEVICE|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
214535102|NCT04492137|PROCEDURE|Cannulation technique|"Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed"
214535103|NCT02740205|OTHER|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
214535104|NCT03320642|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
214535105|NCT03320642|DRUG|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
214535106|NCT02815735|DEVICE|comfilcon A|contact lens
214535107|NCT02815735|DEVICE|lotrafilcon B|contact lens
215154632|NCT03990727|PROCEDURE|Genotype analysis|Molecular target retina dystrophy analysis
215154633|NCT02353624|BEHAVIORAL|Cycling|Cycling distance of 2880 km in 14 days
215154634|NCT02964169|BEHAVIORAL|Family Planning Support|
215154635|NCT03494998|DIAGNOSTIC_TEST|PAT-POPS|Emergency Department-specific screening tool
215154636|NCT00986037|DRUG|ABT-308|Single IV doses
215154637|NCT00986037|DRUG|ABT-308|Multiple SC doses x 3
215154638|NCT00986037|DRUG|Placebo|Single IV dose
215154639|NCT00986037|DRUG|Placebo|Multiple SC doses x 3
215154640|NCT01117363|OTHER|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
215154641|NCT01497561|DRUG|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
214535108|NCT02253745|DRUG|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
214535109|NCT02253745|DRUG|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
215154642|NCT01497561|DRUG|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
215154643|NCT02967783|DEVICE|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
215154644|NCT02967783|DEVICE|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
215154645|NCT02967783|DEVICE|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
215154646|NCT04610593|BEHAVIORAL|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
215154647|NCT01600170|DRUG|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
215154648|NCT01600170|DRUG|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
214535110|NCT01501747|DRUG|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
214535111|NCT01501747|DRUG|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
214535112|NCT00334139|DRUG|Zoledronic Acid|every 4 weeks for 4 months
214535113|NCT04608032|OTHER|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
214535114|NCT04608032|OTHER|Recovery-Oriented Therapy|The second group will have \[THoR\] Recovery-Oriented Therapy
214535115|NCT00610818|OTHER|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
214535116|NCT01297699|DRUG|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
214535117|NCT01297699|DRUG|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
214535118|NCT04841070|OTHER|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
214535119|NCT00064428|DRUG|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
214535120|NCT00064428|OTHER|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
214535121|NCT00064428|DRUG|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
214535122|NCT00064428|DRUG|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
214535123|NCT04747821|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
214463855|NCT05925608|COMBINATION_PRODUCT|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
214463856|NCT05925608|DIAGNOSTIC_TEST|Diagnostic Catheterization|Left ventricular catheterization with no active therapy
214463857|NCT03987399|OTHER|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
214463858|NCT05458518|PROCEDURE|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
214463859|NCT06779526|OTHER|Heartfulness Meditation|Receiving an orientation session regarding the study, attending once weekly didactic sessions on Zoom for Heartfulness Meditation, and participating in morning and evening meditation for ten to fifteen minutes daily either by themselves or along with the trainer.
214535124|NCT03182296|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
214535125|NCT00048776|DRUG|Pletal|
214535126|NCT04485299|DRUG|Bifluorid 10 ,VOCO|NaF and CaF 10 %
214535127|NCT04485299|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
214535128|NCT06486675|OTHER|education|breastfeeding consultant training
214535129|NCT01852188|OTHER|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
214535130|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
214535131|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
215154649|NCT01974635|DEVICE|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
214463860|NCT04324359|DRUG|SURF-201|One drop twice daily (BID) in the study eye for 16 days.
214463861|NCT04324359|DRUG|Placebo|One drop twice daily (BID) in the study eye for 16 days.
214463862|NCT00070590|DRUG|Bosentan|
214463863|NCT02416258|DRUG|LP0113 aerosol spray|
215154650|NCT04972617|DIAGNOSTIC_TEST|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
215154651|NCT02454842|DRUG|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
214463864|NCT02416258|DRUG|Aerosol spray vehicle|
214463865|NCT02416258|DRUG|LEO 90100 aerosol foam|
214463866|NCT02416258|DRUG|Betamethasone dipropionate aerosol spray|
214463867|NCT02416258|DRUG|Calcipotriol aerosol spray|
214463868|NCT02416258|DRUG|Daivobet® gel|
214463869|NCT04757363|DRUG|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
214463870|NCT04757363|DRUG|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
215154652|NCT01209325|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
214463871|NCT04757363|DRUG|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
214463872|NCT04144023|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
214463873|NCT04144023|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
214463874|NCT04144023|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214463875|NCT04144023|PROCEDURE|Echocardiography|Undergo ECHO
214463876|NCT04144023|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214463877|NCT04144023|PROCEDURE|Biopsy|Undergo biopsy
214463878|NCT02862210|DRUG|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
214463879|NCT02862210|DRUG|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
214463880|NCT04437264|DIETARY_SUPPLEMENT|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
214463881|NCT04437264|DIETARY_SUPPLEMENT|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
214463882|NCT05918744|BEHAVIORAL|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
214463883|NCT06120972|DRUG|Olaparib tablet|Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
214463884|NCT04888702|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214463885|NCT05815953|DEVICE|Polarstem|Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
214463886|NCT05815953|DEVICE|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
214463887|NCT06419621|DRUG|PM8002|PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
214463888|NCT06419621|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
214463889|NCT06419621|DRUG|Placebo|Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
215154653|NCT01209325|OTHER|laboratory biomarker analysis|
215154654|NCT03401814|OTHER|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
215154655|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
215154656|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
215154657|NCT01523041|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
215154658|NCT04061330|DRUG|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
215154659|NCT04061330|DRUG|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
215154660|NCT01638871|BEHAVIORAL|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
215154661|NCT00396253|DRUG|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
215154662|NCT05425940|DRUG|XL092|Supplied as tablets; administered orally daily
215154663|NCT05425940|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
214535132|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
214535133|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
214535134|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
214535135|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
214535136|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
214535137|NCT03740178|DRUG|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
214535138|NCT03740178|DRUG|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
214535139|NCT03740178|DRUG|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
214535140|NCT02876848|OTHER|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~* Contact you over the phone or in person to provide medical advice on how to better take your pills,~* Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
214535141|NCT05786521|DRUG|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
214535142|NCT05786521|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
214535143|NCT00935714|OTHER|Exercise|
214535144|NCT00935714|OTHER|Exercise|
215154664|NCT05425940|DRUG|Regorafenib|Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
215154665|NCT01280708|OTHER|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
215154666|NCT02282514|BIOLOGICAL|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
214535145|NCT03552237|DIETARY_SUPPLEMENT|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
214535146|NCT06477991|DRUG|Tireilizumab（PD-1 inhibitor）|"Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed."
214535147|NCT04658550|OTHER|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
214535148|NCT04658550|OTHER|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
214535149|NCT02651883|BEHAVIORAL|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
215154667|NCT02282514|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
215154668|NCT02282514|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
215154669|NCT02282514|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
215154670|NCT02282514|DRUG|Methylprednisolone|Steroid
214535150|NCT02651883|BEHAVIORAL|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
214535151|NCT04308642|OTHER|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
214535152|NCT04308642|OTHER|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
214535153|NCT01746108|BIOLOGICAL|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
214535154|NCT06435741|DIAGNOSTIC_TEST|99mTc-3PRGD2 Spect-CT scan|Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
214535155|NCT00997932|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
214535156|NCT00468858|OTHER|Placebo|"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
214535157|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
214535158|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
214535159|NCT02497196|DEVICE|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
214696330|NCT04958421|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
214696331|NCT00748085|DEVICE|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
214696332|NCT02363270|PROCEDURE|Ketamine|IV Push or or IV Drip
214696333|NCT04388098|OTHER|Diagnosis of caries experience and periodontal health|
214696334|NCT02311309|OTHER|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.
214696335|NCT02311309|OTHER|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
215154671|NCT02282514|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
214535160|NCT02497196|DEVICE|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
214535161|NCT02497196|DEVICE|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
214535162|NCT02497196|DEVICE|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
214535163|NCT03022383|DEVICE|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
214535164|NCT00004403|DRUG|albendazole|
214535165|NCT00004403|DRUG|dexamethasone|
215154672|NCT02282514|DRUG|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
215154673|NCT01093235|BIOLOGICAL|bevacizumab|
215154674|NCT01093235|DRUG|cyclophosphamide|
215154675|NCT01093235|DRUG|docetaxel|
214535166|NCT00004403|DRUG|phenytoin|
214535167|NCT04137718|OTHER|nonIntervention|nonIntervention
214696336|NCT04703127|DRUG|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
214696337|NCT04703127|DRUG|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
215154676|NCT01093235|DRUG|epirubicin hydrochloride|
215154677|NCT01093235|DRUG|fluorouracil|
215154678|NCT01093235|PROCEDURE|assessment of therapy complications|
215154679|NCT01093235|PROCEDURE|neoadjuvant therapy|
215154680|NCT01093235|PROCEDURE|quality-of-life assessment|
215154681|NCT01093235|PROCEDURE|therapeutic conventional surgery|
215154682|NCT05340478|BEHAVIORAL|Adjunctive Family - Cognitive Behavioral Therapy|AF-CBT provides family members psychoeducation on anxiety and teaches skills to facilitate the recovery of Veterans in the process of completing anxiety treatment.
215154683|NCT01594216|DRUG|Ruxolitinib|
215154684|NCT01594216|DRUG|Exemestane|
215154685|NCT02149901|DRUG|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
215154686|NCT02149901|DRUG|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
215154687|NCT02149901|OTHER|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
215154688|NCT02149901|OTHER|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
215154689|NCT05846737|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
215154690|NCT02550405|BEHAVIORAL|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
215154691|NCT05242198|PROCEDURE|Robotic prostatectomy|patients who will undergo robotic prostatectomy
215154692|NCT00092443|BIOLOGICAL|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
215154693|NCT00092443|BIOLOGICAL|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
215154694|NCT01962350|DEVICE|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
215154695|NCT03651024|DEVICE|ED surgery|The surgical implant for ED treatment
215154696|NCT02441595|BEHAVIORAL|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
215154697|NCT02441595|BEHAVIORAL|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
215154698|NCT01319552|PROCEDURE|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
215154699|NCT01319552|PROCEDURE|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
215154700|NCT02665832|DRUG|DWJ1351|
215154701|NCT02665832|DRUG|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
215154702|NCT04883827|OTHER|Blood collection|20-40 mL of blood to extract cell free DNA
215154703|NCT04883827|OTHER|Urine collection|up to 15 mL of urine to extract cell free DNA
215154704|NCT06079112|DRUG|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
214535168|NCT04853134|DRUG|Proxalutamide|200 mg q.d.
215154705|NCT06079112|DRUG|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
215154706|NCT06273215|DRUG|The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
215154707|NCT01951963|DRUG|Ketamine|
215154708|NCT01951963|DRUG|Morphine|
214535169|NCT04853134|OTHER|Standard of Care|Standard of care as determined by the PI
214535170|NCT05213325|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
214535171|NCT00581464|BEHAVIORAL|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
214535172|NCT00581464|BEHAVIORAL|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
215154709|NCT05285046|OTHER|No intervention|No intervention
215154710|NCT03846492|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
215154711|NCT04961684|DEVICE|Solver Pen|One application per day for 3 months
215154712|NCT04961684|DRUG|Loceryl 5%|One application per week for 3 months
215154713|NCT06802198|PROCEDURE|total hysterectomy|Total hysterectomy (TH) involves the complete removal of the uterus including the cervix
215154714|NCT06802198|PROCEDURE|subtotal hysterectomy|subtotal hysterectomy (STH) preserves the cervix while removing the upper part of the uterus
215154715|NCT02951000|PROCEDURE|platysma suture|
215154716|NCT02951000|PROCEDURE|no platysma suture|
215154717|NCT03141827|DRUG|Insulin|Insulin 40 IU, nasal spray, single dose
215154718|NCT03141827|DRUG|Placebo|Placebo, nasal spray, single dose
215154719|NCT02926885|DEVICE|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
214535173|NCT02730000|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
214535174|NCT02730000|PROCEDURE|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
214535175|NCT05807425|PROCEDURE|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
214535176|NCT04458181|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
214535177|NCT01228721|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
214535178|NCT02801500|DEVICE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
214535179|NCT02801500|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
214535180|NCT00003423|DRUG|asparaginase|
214535181|NCT00003423|DRUG|cyclophosphamide|
214535182|NCT00003423|DRUG|cytarabine|
214535183|NCT00003423|DRUG|daunorubicin hydrochloride|
214535184|NCT00003423|DRUG|dexamethasone|
214535185|NCT00003423|DRUG|etoposide|
214535186|NCT00003423|DRUG|mercaptopurine|
214535187|NCT00003423|DRUG|methotrexate|
214535188|NCT00003423|DRUG|prednisolone|
214535189|NCT00003423|DRUG|thioguanine|
214535190|NCT00003423|DRUG|vincristine sulfate|
214535191|NCT04921878|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
214535192|NCT04550286|BEHAVIORAL|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
214535193|NCT04550286|BEHAVIORAL|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
214535194|NCT06347770|DRUG|Probiotic Blend Oral Tablet|In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
214535195|NCT05047497|DIAGNOSTIC_TEST|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
214535196|NCT06480253|DEVICE|Helmet Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
214535197|NCT06480253|DEVICE|Oronasal Mask Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
214535198|NCT01650727|DRUG|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
214535199|NCT01650727|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
214535200|NCT01709955|DIETARY_SUPPLEMENT|Glucomannan|750 MG of Glucomannan in capsule form
214535201|NCT01709955|OTHER|Placebo|750 mg of Cellulose powder in a capsule form
214696338|NCT05610358|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
214696339|NCT03489993|DIAGNOSTIC_TEST|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
214696340|NCT03489993|DIAGNOSTIC_TEST|FGF23 and klotho|Measured using ELISA's.
214696341|NCT04673136|DEVICE|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
214696342|NCT04673136|OTHER|Colonoscopy|Standard colonoscopy
214535202|NCT04011397|OTHER|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
214535203|NCT04011397|BEHAVIORAL|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
215154720|NCT02926885|DEVICE|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
214535204|NCT00809341|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.
214535205|NCT00809341|DRUG|Cyclophosphamide|750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
214535206|NCT00809341|DRUG|Doxorubicin|50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
214535207|NCT00809341|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
214535208|NCT00809341|DRUG|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
214535209|NCT00809341|DRUG|Ifosfamide|2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
214535210|NCT00809341|DRUG|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
214535211|NCT00809341|DRUG|Etoposide|100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
214535212|NCT00809341|DRUG|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
214535213|NCT00809341|PROCEDURE|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
214535214|NCT00237614|DRUG|intravenous and oral N-acetylcysteine|
214535215|NCT04311385|DIAGNOSTIC_TEST|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
214535216|NCT05197114|OTHER|summerlunch+ At Home Food Skills Program|The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
214535217|NCT01579110|DRUG|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
214535218|NCT01579110|DRUG|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
214535219|NCT05226247|PROCEDURE|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
214535220|NCT01681199|DRUG|Fluvastatin extended release tablet|
214535221|NCT03694626|DEVICE|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
214535222|NCT03694626|DEVICE|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
214696343|NCT01354041|BEHAVIORAL|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
214696344|NCT02338492|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
215154721|NCT02926885|PROCEDURE|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
215154722|NCT00928239|PROCEDURE|laparoscopic sacropexy with mid vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
215154723|NCT00928239|PROCEDURE|laparoscopic sacropexy with caudal vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
215154724|NCT00105781|BEHAVIORAL|Exercise counseling|
215154725|NCT05825378|DRUG|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
215154726|NCT05825378|DRUG|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
215154727|NCT04163211|PROCEDURE|Abdominal drain|A latex-free drain (size 20F)
215154728|NCT04818372|DRUG|CM313-Dose escalation|Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
215154729|NCT04818372|DRUG|CM313|Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
214696345|NCT04625894|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
214696346|NCT04625894|DRUG|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
214696347|NCT01262612|DRUG|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
215154730|NCT04818372|DRUG|Dexamethasone|dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
214696348|NCT01262612|DRUG|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
214696349|NCT02823678|PROCEDURE|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
214696350|NCT00503360|DRUG|SAD448|
214696351|NCT02405585|DRUG|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
214696352|NCT02405585|BIOLOGICAL|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
214696353|NCT02405585|RADIATION|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
214696354|NCT02405585|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
215154731|NCT04818372|DRUG|Lenalidomide|25 mg/day lenalidomide 21 of 28 days cycle
215154732|NCT05775276|PROCEDURE|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
215154733|NCT02772458|OTHER|Dodecanoate acid and saline|Test drink
215154734|NCT05079308|DEVICE|Peripheral sealing device for surgical mask or filtering face piece|The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
215154735|NCT05079308|DEVICE|IIR Surgical mask with Filtering face piece|The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
215154736|NCT01234389|DEVICE|Electrochemical H. pylori detection method|Determination of H. pylori infection.
215154737|NCT01234389|DEVICE|IHC|Determination of H. pylori infection.
215154738|NCT01234389|DEVICE|C13-urea breath test|Determination of H. pylori infection.
215154739|NCT01234389|DEVICE|HUT|Determination of H. pylori infection.
214535223|NCT03694626|DEVICE|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
214535224|NCT03694626|DEVICE|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
214535225|NCT03694626|DEVICE|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
214535226|NCT01219777|DRUG|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
215154740|NCT00069615|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
215154741|NCT00069615|DEVICE|Continuous Glucose Monitoring System™ (CGMS)|
215154742|NCT00241436|DRUG|Anastrozole (ARIMIDEX™)|
215154743|NCT02510508|BEHAVIORAL|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
215154744|NCT02510508|BEHAVIORAL|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
215154745|NCT02510508|OTHER|Non-intervention|Non-intervention
215154746|NCT05667493|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
214696355|NCT03817567|DRUG|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
214696356|NCT06555614|OTHER|Acellular Dermal Matrix(ADM)|A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
214696357|NCT00996021|DRUG|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
214696358|NCT00996021|DRUG|Placebo Suspension|Placebo is a liquid with no drug in it.
214696359|NCT00996021|DRUG|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
215154747|NCT07075497|OTHER|Neuromuscular electrical stimulation (NMES)|NMES is applied during each 10-second isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator delivering biphasic, symmetric rectangular pulses at 50 Hz with a 250 µs pulse width. Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one approximately two finger-breadths below the gluteal fold and the other over the distal third of the muscle belly. Stimulation intensity is individually titrated to each participant's maximal motor threshold-eliciting a strong, yet painless, contraction-and the exact milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs NMES intensity and cues the timing of the 10 s contraction and ensuing 30 s passive stretch.
215154748|NCT07075497|OTHER|Sham Neuromuscular electrical stimulation (NMES)|Sham NMES is delivered during each 10 s isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator with biphasic, symmetric rectangular pulses (50 Hz, 250 µs pulse width). Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one two finger-breadths below the gluteal fold and one over the distal third of the muscle belly. Intensity is individually set to the sensory threshold, defined as the minimal current producing a slight tingling without any visible muscle response; this milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and full knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs the NMES intensity and cues the 10 s contraction timing.
214535227|NCT01219777|DRUG|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
214535228|NCT01219777|DRUG|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
214535229|NCT01743521|DRUG|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
214535230|NCT04510610|DRUG|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
214535231|NCT02678364|DIETARY_SUPPLEMENT|Control eggs|Control eggs containing no additional vitamin D beyond norm
214535232|NCT02678364|DIETARY_SUPPLEMENT|Vitamin D3 eggs|Vitamin D3-biofortified eggs
214535233|NCT02678364|DIETARY_SUPPLEMENT|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
214535234|NCT05154240|DRUG|INS018_055|INS018\_055 is a small molecule compound. INS018\_055 has good solubility in water and was chemically and physically stable at different temperatures.
214535235|NCT05154240|DRUG|Placebo|Placebo
214535236|NCT02954796|DRUG|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
214535237|NCT02106637|DRUG|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
214535238|NCT02106637|DRUG|placebo|placebo
214696360|NCT04133805|DIETARY_SUPPLEMENT|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
214696361|NCT01235286|PROCEDURE|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
214696362|NCT02961686|RADIATION|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
214696363|NCT03916471|DEVICE|Solyx™ SIS System|Single-incision sling system
214696364|NCT03916471|DEVICE|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
214696365|NCT02600000|RADIATION|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
214696366|NCT02600000|DEVICE|Cardiopulmonary test|Assessment of maximal functional capacity
214463890|NCT04760652|BEHAVIORAL|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
214463891|NCT06361056|BEHAVIORAL|Survey|All participants will complete a brief questionnaire.
214463892|NCT06361056|BEHAVIORAL|mHealth app|Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
214463893|NCT06067009|BEHAVIORAL|ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease|ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
214463894|NCT06407037|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
214463895|NCT06407037|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Serratus Posterior Superior Intercostal Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
214463896|NCT04974138|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
214463897|NCT04974138|DRUG|Amlodipine besylate and folic acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
214463898|NCT04974138|DRUG|Amlodipine placebos|An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
214463899|NCT04974138|DRUG|Amlodipine-folic acid placebos|An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
214463900|NCT05741372|DRUG|Rosuvastatin|Rosuvastatin
214463901|NCT05741372|DRUG|Digoxin|Digoxin
214463902|NCT05741372|DRUG|Metformin hydrochlorid|Metformin hydrochloride
214463903|NCT05741372|DRUG|Furosemide|Furosemide
214463904|NCT04601987|BEHAVIORAL|Breastfeeding|Counseling about the maternal health benefits of lactation.
214463905|NCT04601987|BEHAVIORAL|Smokefree Homes|Counseling about the importance of smoke-free homes.
214463906|NCT06696924|OTHER|Reciprocal inhibition|First Subjects will start doing baseline warmup exercises which are mentioned then they will perform reciprocal inhibition of the serratus muscle in supine or side-lying. After identifying the antagonist muscles of the serratus anterior, which are typically the rhomboids or the middle and lower trapezius. Athletes will perform a gentle contraction of the antagonist's muscles by retracting or squeezing their shoulder blades together. While the antagonist muscles are contracting, we will ask the athlete to simultaneously relax and lengthen the serratus anterior muscle. The patient can achieve this by protracting or pushing their shoulder blades forward and away from each other.
214463907|NCT06696924|OTHER|Static stretching|"Subjects will perform 2 stretches~1. Standing Wall Stretch: Stand facing a wall with your feet about hip-width apart. Place their palms on the wall at shoulder height, slightly wider than shoulder-width apart. will Lean their body forward, keeping their arms straight, until feel a stretch in their serratus anterior. Hold the stretch for 15 to 30 seconds, then slowly release. Instead of using a wall or object, the athlete will use their opposite hand to hold the stretched arm in position.~2. Seated Cross-Body Stretch: Sit on the edge of a chair or bench. Cross one arm over your chest, placing your hand on the opposite shoulder. The athlete will use the other hand to gently pull the crossed arm closer to your body, feeling a stretch in the serratus anterior. Hold the stretch for 15 to 30 seconds or more, and then switch sides and repeat."
214463908|NCT06540911|OTHER|Personalized physical back training program|The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
214463909|NCT06540911|OTHER|Non-personalized physical back training program|The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
214463910|NCT05698849|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
214463911|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
214463912|NCT06822894|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine
214463913|NCT01733316|DRUG|RP103|
214463914|NCT01733316|DRUG|Cystagon®|
215154749|NCT07075497|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 30 seconds, followed by a 10-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
215154750|NCT04508491|OTHER|Rhythm control|Rhythm control with medications or any procedure
215154751|NCT04508491|OTHER|Rate control|Rate control
215154752|NCT06482450|OTHER|LetsTalkShots (patient-facing CDS)|LetsTalkShots is a website which provides patients/parents with tailored videos addressing vaccine concerns.
214535239|NCT02975297|DRUG|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
214535240|NCT02975297|DRUG|NRT|Nicotine Patch (21mg) / 24 hours.
214535241|NCT02975297|BEHAVIORAL|Counseling|Brief individual behavioral smoking cessation counseling.
214535242|NCT02975297|DRUG|Placebo|Normal saline.
214535243|NCT03937037|PROCEDURE|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
214535244|NCT00382798|DRUG|RO5024048|
214535245|NCT05864885|DRUG|Minoxidil|Topical formulation applied once a day.
214535246|NCT05501496|PROCEDURE|intramedullary nailing|Flexible intramedullary nailing using 2 nails
214535247|NCT05501496|PROCEDURE|casting|casting with long leg cast
214535248|NCT01655992|DRUG|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
214535249|NCT01655992|DRUG|S1 generic|40mg／m2 bid four weeks on two weeks off
214535250|NCT05291806|OTHER|Reference Product|This intervention is based on white rice.
214535251|NCT05291806|OTHER|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
214535252|NCT05291806|OTHER|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
214535253|NCT05291806|OTHER|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
214535254|NCT00225277|DRUG|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
214535255|NCT00225277|DRUG|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
214535256|NCT06468267|DRUG|Thiotepa|The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
214535257|NCT03432650|DRUG|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
214535258|NCT03432650|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
215154753|NCT06482450|OTHER|LetsTalkShots (provider-facing CDS)|The provider-facing CDS component will propagate patient concerns obtained from LetsTalkShots (and the appropriate talking points to address the talking points) into the electronic health record (EHR) for the provider at the point of care.
214535259|NCT01961674|DIETARY_SUPPLEMENT|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
214535260|NCT00276900|DRUG|Sertraline|
214535261|NCT00822666|DRUG|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
214535262|NCT03772509|OTHER|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
214535263|NCT02923609|BIOLOGICAL|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
214535264|NCT03220165|DRUG|MGL-3196|oral, 100 mg
214535265|NCT00711997|BIOLOGICAL|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
214535266|NCT00945763|DRUG|N1539|30 mg
214535267|NCT00945763|DRUG|placebo|tablets
214535268|NCT00945763|DRUG|N1539|15 mg
214535269|NCT00945763|DRUG|N1539|60 mg
215154754|NCT06482450|OTHER|Appointment Reminder Message|"The regular text message and e-mail appointment reminder includes a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
214535270|NCT00945763|DRUG|Motrin|400 mg
214535271|NCT04731675|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
214535272|NCT00511186|DRUG|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
214535273|NCT00511186|DRUG|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
214535274|NCT04356638|DRUG|Midazolam|Oral Midazolam and intranasal placebo
214535275|NCT04356638|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
214535276|NCT04356638|OTHER|Placebo|Placebo orally and intranasally
215154755|NCT01731431|OTHER|Insulin|
215154756|NCT01731431|DRUG|Glyburide|
214535277|NCT04582669|DRUG|Intralesional Triamcinolone 10 mg/mL|Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
214535278|NCT04582669|DRUG|Intralesional Triamcinolone 20 mg/mL|Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
214535279|NCT04582669|DRUG|Intralesional Triamcinolone 40 mg/mL|Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
214535280|NCT04582669|DRUG|Placebo|Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
214696367|NCT02600000|DEVICE|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
214696368|NCT02600000|DEVICE|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
215154757|NCT04894331|OTHER|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris \& Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
214463915|NCT06116526|DRUG|Dupilumab - Discontinuation|Drug injections are discontinued.
214463916|NCT06116526|DRUG|Dupilumab - Dose Reduction|The drug is given as a subcutaneous injection.
214463917|NCT06116526|DRUG|Dupilumab - Standard Dose|The drug is given as a subcutaneous injection.
214463918|NCT03096028|OTHER|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
214463919|NCT05674786|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
214463920|NCT05213936|DEVICE|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
214463921|NCT05213936|DEVICE|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
214463922|NCT03260023|BIOLOGICAL|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
214463923|NCT03260023|DRUG|Avelumab|Anti PD-L1
214463924|NCT06822088|DRUG|Esketamine|A total of 126 patients undergoing thoracoscopic surgery under elective general anesthesia were randomly divided into three groups: normal saline group (group C), dexmedetomidine group (group D), eschloroacetone group (group E) and dexmedetomidine group (group D), with 42 cases in each group. Group C was continuously injected with the same amount of normal saline, group D was given dextrometin 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery. Group E was given esketamine 0.2 mg/kg 10min before surgery, and maintained at 0.15 mg/kg\*h after intubation until 30min before surgery. Other anesthetic induction and maintenance drugs were consistent among the three groups.
214463925|NCT06822088|DRUG|Dexmedetomidine|group D was given Dexmedetomidine 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery.
214463926|NCT06822088|DRUG|Normal Saline|Group C was continuously injected with the same amount of normal saline,
214463927|NCT06513793|BEHAVIORAL|Roots and Shoots|Four-week intervention involving a self-help guidebook to improve mental wellbeing.
214463928|NCT06513793|BEHAVIORAL|Waiting list|Four-week waiting list period involving treatment as usual.
214463929|NCT06823609|DRUG|QLS1304 tablet|QLS1304 monotherapy dose escalation and expansion
214463930|NCT06413524|DEVICE|Whole-body Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles.
214463931|NCT06413524|DEVICE|Local Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. During the vibration, participants will hold onto the handle to ensure balance stability.
214463932|NCT05535894|PROCEDURE|Ablation of Celiac Ganglion|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
214463933|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
214463934|NCT06778369|PROCEDURE|traingular exclusion technique in mitral valve repair|The prolapsed part of the posterior leaflet is inverted and excluded, not resected toward the left ventricle, and the margins of the prolapsed part are sutured to each other's using proline 5/0, extending from the posterior leaflet edge to the posterior annulus. Then the posterior annulus is reinforced with an annuloplasty band using a treated strip of pericardium. The determination of suitable ring size is subsequently predicated upon the assessment of inter-commissural distance surface area and the anterior leaflet, utilizing sizers that are correlated with typical mitral geometry.
214463935|NCT03058289|DRUG|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."
214463936|NCT03058289|BIOLOGICAL|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
214463937|NCT03058289|BIOLOGICAL|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
214463938|NCT06704204|DRUG|The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks|To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
214463939|NCT02240862|DEVICE|Carotid Artery Stent|Placement of a stent within the carotid artery
215154758|NCT04894331|OTHER|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
215154759|NCT04798768|DEVICE|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
215154760|NCT02997306|PROCEDURE|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
215154761|NCT02997306|PROCEDURE|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
215154762|NCT03748004|BEHAVIORAL|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
214535281|NCT05700578|BEHAVIORAL|Safety Behavior Elimination for Traumatic Stress (SBETS)|This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
214535282|NCT05700578|BEHAVIORAL|Modifiable Behavior Intervention (MoBI)|The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
214535283|NCT04853407|DRUG|LY03005 extended-release tablet|orally once a day
214535284|NCT04853407|DRUG|Placebo|orally once a day
214535285|NCT04052035|PROCEDURE|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
214535286|NCT04693845|BEHAVIORAL|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
214535287|NCT04693845|BEHAVIORAL|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
215154763|NCT03748004|BEHAVIORAL|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
215154764|NCT03688594|DIAGNOSTIC_TEST|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
215154765|NCT03965390|BEHAVIORAL|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
215154766|NCT03290599|OTHER|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
215154767|NCT03207763|DEVICE|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
214535288|NCT06511518|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
214535289|NCT00353093|PROCEDURE|Ultrasonography of the deep vein system of the legs|
214535290|NCT05277090|DRUG|2L of polyethyleneglycol|2L of polyethyleneglycol
214535291|NCT05277090|DIETARY_SUPPLEMENT|inulin|15g inulin per day
214535292|NCT05277090|COMBINATION_PRODUCT|probiotic combination product|"participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
214535293|NCT01430078|DRUG|ASP015K|oral tablet
214535294|NCT01430078|DRUG|ASP015K|solution via oral capsule
214696369|NCT05086185|DIAGNOSTIC_TEST|Kalemic Response to Orange Juice|100% pulp-free orange juice
214696370|NCT05086185|DIETARY_SUPPLEMENT|Kalemic Response to Orange Juice with Fiber|100% pulp-free orange juice with psyllium-based fiber added
214535295|NCT00591409|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
214535296|NCT00591409|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
214535297|NCT03544437|PROCEDURE|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
214535298|NCT00677092|DRUG|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
214535299|NCT00502164|DRUG|AZD2171|
214535300|NCT04737005|PROCEDURE|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
214535301|NCT02716077|RADIATION|FDG PET/CT imaging|
214535302|NCT06371430|DEVICE|Dental Implant insertion and tooth extraction|"The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment."
214535303|NCT05245305|OTHER|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
214535304|NCT01795729|DEVICE|Stent|Coronary revascularization
214535305|NCT01795729|DRUG|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
214535306|NCT01175564|DRUG|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
214535307|NCT01175564|DRUG|Placebo|Placebo tablet, single dose and 6 days repeated dose
214535308|NCT03401723|OTHER|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
214535309|NCT03401723|OTHER|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
214535310|NCT03401723|OTHER|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
214535311|NCT02554422|DEVICE|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
214535312|NCT05047653|DIAGNOSTIC_TEST|RALE score vs. severity score|RALE score vs. severity score and CORADS
214535313|NCT06213519|DRUG|S-1, Oxaliplatin sintilimab HIPEC|"1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."
214535314|NCT02629276|OTHER|neurodynamic testing|
214535315|NCT02714699|DRUG|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
214535316|NCT02714699|DRUG|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
214535317|NCT02714699|DRUG|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
214535318|NCT02716298|DEVICE|fanfilcon A|contact lens
214535319|NCT02716298|DEVICE|lotrafilcon B|contact lens
214696371|NCT05456204|DRUG|Pharmacological cardioversion with Refralon|"1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
214696372|NCT05312710|DRUG|APG-157|Treatment
214696373|NCT00229203|DRUG|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
214535320|NCT00550446|DRUG|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
214535321|NCT00550446|DRUG|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
214535322|NCT00550446|DRUG|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
214535323|NCT00550446|DRUG|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
214535324|NCT00550446|DRUG|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
214535325|NCT00550446|DRUG|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
214535326|NCT00550446|DRUG|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
214535327|NCT05524285|DEVICE|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
214535328|NCT05524285|DEVICE|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
214535329|NCT04052945|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 )."
214535330|NCT04052945|PROCEDURE|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6)."
214535331|NCT03230045|DEVICE|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
214535332|NCT03230045|DEVICE|no treatment|electrodes are attached, but no stimulation is given
214535333|NCT04134715|DRUG|PF-06826647|100 mg tablet
214535334|NCT04134715|DRUG|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
214535335|NCT02246218|DRUG|RAVICTI|
214696374|NCT02382341|DEVICE|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
214696375|NCT01609179|DRUG|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
214696376|NCT06133634|DIETARY_SUPPLEMENT|Fisetin|Fisetin dietary supplement
214535336|NCT04603833|DRUG|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
214535337|NCT04603833|DRUG|SHR3680|Participants will receive SHR3680
214535338|NCT04603833|DRUG|Docetaxel|Participants will receive Docetaxel
214535339|NCT04362098|BEHAVIORAL|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
214535340|NCT04952701|DEVICE|Control lenses|Control Multifocal lenses
214535341|NCT04952701|DEVICE|Test lenses|Test Multifocal lenses
214535342|NCT06295042|OTHER|BREAST-Q Questionnaire|Patient-reported outcome measure
214535343|NCT00301561|PROCEDURE|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited"
214535344|NCT00301561|PROCEDURE|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed"
214535345|NCT02762305|OTHER|RSVP Bone Builders Group Exercise|
214535346|NCT05194475|OTHER|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
214696377|NCT06133634|OTHER|Placebo|Placebo capsules identical in appearance to fisetin capsules
214535347|NCT05194475|OTHER|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
214535348|NCT01789619|DRUG|Extended release tacrolimus (Advagraf®)|
214535349|NCT01013064|DRUG|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
214535350|NCT00001359|DRUG|Penicillin or Placebo|
214535351|NCT05254717|OTHER|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
214535352|NCT04938622|OTHER|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
214535353|NCT04938622|OTHER|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
214535354|NCT04938622|OTHER|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
214535355|NCT04938622|OTHER|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
214535356|NCT04938622|OTHER|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
214535357|NCT04938622|OTHER|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
214535358|NCT02969629|DRUG|Apomorphine|
214535359|NCT02969629|DRUG|Normal Saline|
214535360|NCT01033279|OTHER|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
214535361|NCT03578419|DEVICE|Small-Volume Blood Collection Tubes|Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
214535362|NCT03578419|DEVICE|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
214535363|NCT02696863|BEHAVIORAL|questionnaire|
214535364|NCT00078858|DRUG|fludarabine phosphate|Given IV
214535365|NCT00078858|RADIATION|total-body irradiation|Undergo TBI
214535366|NCT00078858|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
214535367|NCT00078858|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
214535368|NCT00078858|DRUG|cyclosporine|Given PO
214535369|NCT00078858|DRUG|mycophenolate mofetil|Given PO or IV
214535370|NCT00078858|OTHER|laboratory biomarker analysis|Correlative studies
214535371|NCT02115334|BEHAVIORAL|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
214535372|NCT02115334|BEHAVIORAL|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
214535373|NCT02115334|BEHAVIORAL|health education|health education of the children with DD.
214535374|NCT00065819|BEHAVIORAL|HIV Symptom Education Program|
214535375|NCT01104064|DEVICE|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
214535376|NCT01104064|DEVICE|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
214535377|NCT06276101|BIOLOGICAL|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
214535378|NCT04499014|DEVICE|ultrasound|5 days a week, a total of 10 sessions
214535379|NCT05596149|OTHER|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
215154768|NCT03207763|DEVICE|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
215154769|NCT05582083|DRUG|Momelotinib|Momelitinib available as tablets.
215154770|NCT04856813|OTHER|Manual therapy active|massage or ischemic compression with active contraction, tha will be isometric or concentric.
215154771|NCT04856813|OTHER|Manual therapy|massage or isquemic compression without contraction
215154772|NCT04352036|OTHER|no interventional study|no interventional study
215154773|NCT02605122|DRUG|Solithromycin|
214535380|NCT05596149|OTHER|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
214535381|NCT05596149|OTHER|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
214535382|NCT05596149|OTHER|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
214535383|NCT06298968|DRUG|combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab|"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."
214535384|NCT02212301|DEVICE|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
214535385|NCT02212301|DEVICE|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
214535386|NCT02825719|DRUG|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
214535387|NCT02825719|OTHER|Placebo pills|Placebo pills will be prescribed
214535388|NCT02825719|DRUG|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
214535389|NCT02825719|DRUG|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
214696378|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
215154774|NCT02605122|DRUG|Standard of Care|Age- and weight-based dosing as appropriate per sites standard of care.
215154775|NCT06220942|DRUG|Phenylephrine|Pregnant female presented for C.S. after receiving spinal anesthesia, recording the vital data, phenylephrine will be given in a dose of 50 µg IV immediately if the heart rate increases ≥ 20 % of baseline
215154776|NCT04643652|BEHAVIORAL|Noise Reduction Bundle|"Implementation of a bundle of noise reducing interventions. This concerns among other things:~reduction of alarms, phone calls/pagers/ beepers, introduction of a defined period in which there is a reduction of controllable sound (quiet time), etc"
215154777|NCT02945579|RADIATION|Undergo EBRT|Undergo EBRT
215154778|NCT02945579|OTHER|Laboratory Biomarker Analysis|Correlative studies
214535390|NCT04456049|DRUG|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
214535391|NCT03047902|OTHER|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
214535392|NCT03047902|OTHER|Group 2- Parents will not be present for the Questionnaire|
214535393|NCT03927222|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
214535394|NCT03927222|DRUG|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
214696379|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
215154779|NCT02945579|OTHER|Quality-of-Life Assessment|Ancillary studies
215154780|NCT02945579|OTHER|Questionnaire Administration|Ancillary studies
215154781|NCT02945579|RADIATION|Partial Breast Irradiation|Undergo partial breast irradiation
214535395|NCT03927222|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
214535396|NCT03927222|BIOLOGICAL|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
214535397|NCT03927222|BIOLOGICAL|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
214535398|NCT06464614|DRUG|Adebrelimab|Adebrelimab 1200mg，d1，q3w, until disease progression or unacceptable toxicity
214535399|NCT06464614|DRUG|Apatinib|Apatinib 250mg，d1-21，q3w, until disease progression or unacceptable toxicity
214535400|NCT06464614|DRUG|Investigator chosen chemotherapy (ICC)|"Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.~Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or withdrawal due to other reasons; when synchronized with radiotherapy, 625mg/m2, bid, oral, d1-5, qw."
214535401|NCT06464614|RADIATION|Radiotherapy|Radiotherapy mode: IMRT for the primary lesion and SBRT for the metastasis; If the patient has symptoms of dysphagia, the radiation dose is 1.8 Gy×28 F or 2 Gy×25 F, d1-5 5 times a week; If oligometastatic lesions occur in the body: the radiation dose is 8 Gy×5F, d1-5; If oligometastatic lesions occur in the brain, the radiation dose is 7 Gy×5F, d1-5.
214535402|NCT03277417|OTHER|Echocardiography|Imaging of fetal heart and amniotic fluid
214535403|NCT06389929|BEHAVIORAL|Education|In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
214535404|NCT00273351|DRUG|[123I]B-CIT|Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
214535405|NCT01099683|DRUG|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
214535406|NCT01099683|DRUG|Placebo|All subjects will receive rectal suppository containing placebo
214535407|NCT00030303|BIOLOGICAL|recombinant 70-kD heat-shock protein|
214535408|NCT06011928|OTHER|MOPEX Exercise|"Exercises to be done in order:~1. Pelvic tilt in supine position~2. Bridge building~3. Pelvic stretching~4. Ball spin~5. Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
214535409|NCT06011928|OTHER|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
214535410|NCT06011928|OTHER|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
214535411|NCT02057302|DRUG|Xuezhikang capsule|
214535412|NCT00804414|DRUG|SBG|Solution for topical use
214535413|NCT00804414|DRUG|Placebo Comparator|Solutin for topical use
214535414|NCT03122405|DEVICE|RAM sensors|Noninvasive acoustic monitoring device
214535415|NCT00866827|OTHER|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
214535416|NCT00375778|DRUG|memantine (drug)|
214535417|NCT03690284|DEVICE|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
214535418|NCT03690284|DEVICE|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
214535419|NCT01929564|OTHER|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
214535420|NCT01929564|OTHER|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
214535421|NCT02997397|PROCEDURE|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
214696380|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
214696381|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
214696382|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
214696383|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
214696384|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
214535422|NCT02997397|PROCEDURE|tourniquet(-)|
214535423|NCT03231761|OTHER|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
214535424|NCT03231761|OTHER|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
214535425|NCT05240547|OTHER|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
214535426|NCT05240547|OTHER|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
214535427|NCT00001440|PROCEDURE|Autologous T cells|
214535428|NCT00001440|DRUG|Interleukin-2|
214535429|NCT05062837|DRUG|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
214535430|NCT03455218|DRUG|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
214535431|NCT03455218|DRUG|Placebo|INOmax device connected to oxygenator, but no gas is delivered
214535432|NCT03455218|DEVICE|INOmax|All patients will have the INOmax device connected to the oxygenator
214535433|NCT00052325|DIETARY_SUPPLEMENT|mistletoe extract|
214535434|NCT06369857|PROCEDURE|Pectopexy|Suspension of apical organs
214535435|NCT00204516|BIOLOGICAL|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
214535436|NCT00204516|DRUG|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
214535437|NCT00578318|BEHAVIORAL|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
214535438|NCT00913783|DRUG|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
214535439|NCT00913783|DRUG|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
214535440|NCT00866918|DRUG|Arsenic Trioxide|Given IV
214535441|NCT00866918|DRUG|Cytarabine|Given IT or IV
214535442|NCT00866918|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214535443|NCT00866918|DRUG|Idarubicin|Given IV
214535444|NCT00866918|DRUG|Mercaptopurine|Given orally
214535445|NCT00866918|DRUG|Methotrexate|Given orally
214535446|NCT00866918|DRUG|Mitoxantrone Hydrochloride|Given IV
215154782|NCT01560182|GENETIC|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
215154783|NCT03283605|RADIATION|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
215154784|NCT03283605|DRUG|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
215154785|NCT03283605|DRUG|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
215154786|NCT02479308|DRUG|Moxifloxacin|Single administration
215154787|NCT02479308|DRUG|ALKS 5461|Daily administration for a total of 12 dosing days
215154788|NCT02479308|DRUG|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
215154789|NCT02248246|DEVICE|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)"
214535447|NCT00866918|DRUG|Tretinoin|Given orally
214535448|NCT04031118|DEVICE|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
214535449|NCT02486159|DRUG|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
214535450|NCT02486159|PROCEDURE|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
214535451|NCT02053064|GENETIC|SAF-301|
214535452|NCT04611724|DRUG|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
214535453|NCT04069429|RADIATION|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
214535454|NCT04069429|RADIATION|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
214535455|NCT04069429|DRUG|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
214535456|NCT04069429|RADIATION|Planar Images|2 dimensional imaging - whole body planar scans
214535457|NCT04069429|PROCEDURE|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
214535458|NCT03775278|DRUG|PHP-303|Investigational drug
214535459|NCT03775278|OTHER|Placebo|Matching placebo
214535460|NCT00527514|DRUG|Amlodipine|Tablets
214535461|NCT00527514|DRUG|Olmesartan medoxomil plus amlodipine|Tablets
215154790|NCT06067360|DEVICE|IFIS sleeve|IFIS sleeve will be inserted to prevent iris prolapse
215154791|NCT00807001|DRUG|IDX184|oral dose, active or placebo
215154792|NCT00170859|DRUG|Everolimus|
215154793|NCT03542786|DIETARY_SUPPLEMENT|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Lactobacillus plantarum CECT7484~* Lactobacillus plantarum CECT7485~* Pediococcus acidilactici CECT7483"
215154794|NCT03542786|DIETARY_SUPPLEMENT|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Partially Hydrolyzed Guar Gum (PHGG)~* Inulin HPD~* Oat Beta-Glucans~* Pectin~* Inulin Low Protein Diet (LPD)~* Polydextrose~* Maltrodextrins"
215154795|NCT03542786|DIETARY_SUPPLEMENT|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
215154796|NCT00854113|DRUG|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
215154797|NCT00854113|DRUG|Placebo|Placebo to match EGT0001474
215154798|NCT02724618|DRUG|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
215154799|NCT02724618|RADIATION|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
215154800|NCT02724618|DRUG|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
215154801|NCT04001530|DRUG|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
215154802|NCT04001530|DRUG|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
215154803|NCT03206229|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
215154804|NCT03206229|DRUG|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
215154805|NCT02121119|DRUG|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
215154806|NCT02121119|DRUG|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
215154807|NCT03284307|DRUG|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
215154808|NCT03284307|DRUG|Ketamine|20 participants will be administered Ketamine.
214463940|NCT05436314|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
214463941|NCT05436314|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
214535462|NCT01842919|OTHER|Kinesthetics tests|
214535463|NCT01842919|OTHER|Psychological questionnaires|
214696385|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
215154809|NCT03284307|DRUG|Propofol|20 participants will be administered Propofol.
215154810|NCT03284307|DRUG|Midazolam|20 participants will be administered Midazolam.
215154811|NCT03807856|DRUG|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
215154812|NCT03807856|OTHER|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
215154813|NCT06444841|BEHAVIORAL|Digital - Google Calendar|"Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm)."
215154814|NCT06444841|BEHAVIORAL|Paper-based - Memory Support System|The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
215154815|NCT01680029|DEVICE|PBASE-system 2.0|
215154816|NCT04909918|DRUG|Dexamethasone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
214535464|NCT01842919|OTHER|structural Magnetic ResonanceImaging (MRI)|
214535465|NCT05644236|OTHER|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
214535466|NCT00027963|DRUG|gabapentin|
214535467|NCT00027963|OTHER|placebo|
214696386|NCT02315287|DRUG|Pioglitazone|Comparison of two different thiazolidinediones
214696387|NCT02315287|DRUG|Lobeglitazone|Comparison of two different thiazolidinediones
214696388|NCT01241838|DEVICE|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
215154817|NCT04909918|DRUG|Methylprednisolone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
215154818|NCT04683887|DEVICE|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
215154819|NCT02273596|DRUG|ALXN1840|Individualized oral doses of ALXN1840.
215154820|NCT02113137|DRUG|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
214696389|NCT05999474|DRUG|Topical tioconazole|Laser
215154821|NCT02113137|DEVICE|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
215154822|NCT00468962|DRUG|FACOS (functional food)|
215154823|NCT04153396|DRUG|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
215154824|NCT04153396|DRUG|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
215154825|NCT02604160|DRUG|LY3113593|Administered by slow intravenous (IV) infusion.
215154826|NCT02604160|DRUG|Placebo|Administered by slow intravenous (IV) infusion.
215154827|NCT02427997|BEHAVIORAL|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
215154828|NCT02427997|BEHAVIORAL|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
215154829|NCT00785642|DRUG|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
215154830|NCT01596062|DRUG|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
215154831|NCT01596062|DRUG|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
215154832|NCT01596062|DRUG|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
215154833|NCT01596062|DRUG|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
214463942|NCT05436314|OTHER|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
214463943|NCT01674140|DRUG|anastrozole|Given orally
214463944|NCT01674140|DRUG|everolimus|Given PO
214463945|NCT01674140|DRUG|exemestane|Given orally
214463946|NCT01674140|DRUG|goserelin acetate|Given subcutaneously or intramuscularly
214463947|NCT01674140|DRUG|letrozole|Given orally
214463948|NCT01674140|DRUG|leuprolide acetate|Given subcutaneously or intramuscularly
214463949|NCT01674140|DRUG|tamoxifen citrate|Given PO
214463950|NCT01674140|OTHER|placebo|Given PO
214463951|NCT06667739|BEHAVIORAL|IMPACT-L3|The intervention is a physical activity behaviour change intervention: IMproving Physical Activity through Coaching and Technology following Lower Limb Loss (IMPACT-L3). Two theories provide a framework for IMPACT-L3. One is social cognitive theory and the other is self-determination theory. As mHealth solutions have the potential to increase access and improve health outcomes, IMPACT-L3 will be delivered entirely virtually.
214463952|NCT06344026|BIOLOGICAL|ANPD001|Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
214463953|NCT06344026|DEVICE|Custom Device|A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
214463954|NCT05546411|DRUG|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
214463955|NCT05546411|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
214463956|NCT05546411|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
214535468|NCT03230409|BEHAVIORAL|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
214535469|NCT03230409|BEHAVIORAL|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
214535470|NCT03230409|BIOLOGICAL|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
214535471|NCT03230409|BEHAVIORAL|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
214535472|NCT00141908|DRUG|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
214535473|NCT00141908|DRUG|Castor oil|weekly IM injections
214535474|NCT02643953|BEHAVIORAL|Incentives|1\) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
214535475|NCT02643953|BEHAVIORAL|Community|1\) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
214535476|NCT03106935|DRUG|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
214535477|NCT00812838|DRUG|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
214535478|NCT00812838|OTHER|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
214535479|NCT00812838|DRUG|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
214696390|NCT05405296|DEVICE|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
214696391|NCT06029712|DRUG|Heart failure polypill|Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
215154834|NCT01596062|DRUG|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
215154835|NCT04643717|OTHER|Electronic pupillometer analysis|Electronic pupillometer analysis
215154836|NCT02284698|OTHER|Health Education|Heath education will be given through awareness creation \& pamphlet distribution
215154837|NCT02139592|DRUG|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
215154838|NCT01864382|OTHER|Core stability|Core stability 5 days a week during 5 weeks
215154839|NCT01864382|OTHER|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
215154840|NCT00171262|DRUG|Fluvastatin|
215154841|NCT03060980|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
215154842|NCT03060980|DRUG|Empagliflozin (oral)|10 mg/day and 25 mg/day
215154843|NCT03060980|DRUG|Glimepiride (oral)|1-6 mg/day
215154844|NCT03180840|BIOLOGICAL|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
215154845|NCT02648256|OTHER|Polymerase Chain Reaction on Oropharyngeal rinse|
215154846|NCT01278472|DEVICE|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
215154847|NCT01278472|DEVICE|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
215154848|NCT06464237|BEHAVIORAL|Mio-App|The Mio-App aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and motor skills to reduce cognitive and physical long-term sequelae after cancer during adolescence.
214535480|NCT04148521|BEHAVIORAL|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
214535481|NCT01539408|DRUG|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
214535482|NCT01539408|PROCEDURE|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
214535483|NCT06117202|OTHER|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
214535484|NCT01793298|DRUG|ASM-024|Ascending doses of ASM-024
214535485|NCT04933162|DIETARY_SUPPLEMENT|High Protein and Low Fiber Diet|Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.
214535486|NCT04933162|DIETARY_SUPPLEMENT|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
214535487|NCT01245335|DEVICE|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
214535488|NCT01245335|DEVICE|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
214535489|NCT01334762|DRUG|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
214535490|NCT01334762|DRUG|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
214696392|NCT06029712|DRUG|Control Rx|GDMT delivered as individual tablets
214463957|NCT05546411|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
214463958|NCT05546411|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
214535491|NCT01530659|DRUG|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
214535492|NCT01530659|PROCEDURE|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
214696393|NCT05962996|DEVICE|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
214696394|NCT03637192|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214696395|NCT03637192|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214463959|NCT05546411|DRUG|NIS793|Given by intravenous infusion
214463960|NCT05546411|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
214463961|NCT05546411|PROCEDURE|Surgery|Surgical removal of tumor
214463962|NCT02606422|DEVICE|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
214463963|NCT02606422|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
214463964|NCT03828513|DEVICE|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
214463965|NCT03828513|DEVICE|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
214463966|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
214463967|NCT06777537|DRUG|Talniflumate|Talniflumate was administered
214463968|NCT04547595|OTHER|Hypnosis|given by Expert in this method
214535493|NCT01723514|DRUG|Erenumab|Administered by subcutaneous injection once a month
214535494|NCT01723514|DRUG|Placebo|Administered by subcutaneous injection once a month
214535495|NCT00632723|DRUG|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
214535496|NCT01329185|DRUG|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
214535497|NCT01329185|DRUG|Placebo|1 capsule twice a day for 14 days prior to transplant date
214535498|NCT00001941|BIOLOGICAL|daclizumab|
215154849|NCT02429180|OTHER|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
215154850|NCT04085900|BIOLOGICAL|Blood and saliva|Collect blood and saliva samples from participants
215154851|NCT04085900|DIAGNOSTIC_TEST|P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA|Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
215154852|NCT04085900|DIAGNOSTIC_TEST|Fiberoptic endoscopy and biopsy|Screening participants will refer to fiberoptic endoscopy and biospy
215154853|NCT04264481|PROCEDURE|Adductor Canal Block|Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
215154854|NCT04264481|PROCEDURE|Intra-Articular Steroid and Lignocaine Injection|Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
214463969|NCT06571994|BEHAVIORAL|Low Plastic Intervention|Participants will be provided with food that contain no or low plastic and PAC. This is defined as minimally processed (according to NOVA Classification) fresh produce where the supply chain is either known to be free, or likely to be free of plastic contamination. Foods that are canned, pickled, use plastic storage containers will be either avoided or substituted where possible with glass. Participants will also follow guidance concerning the preparation of their food. Plastic utensils used in the preparation of food will be substituted for non-plastic. Commonly used personal care products, e.g., shampoo and soaps, and cleaning products will be replaced with no/low PAC alternatives. Participants will be supplied with a comprehensive schedule, and instructions for the 4-week intervention.
214463970|NCT04597541|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
214463971|NCT05369429|BEHAVIORAL|My Wellbeing Guide|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
214463972|NCT05985148|RADIATION|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
214463973|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number."
214463974|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2"
214463975|NCT06702722|BEHAVIORAL|Enhanced Friendship Bench|Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
214535499|NCT04112277|DRUG|Cumulative morphine consumption|morphine equivalent \[mg\] 24 hours after the procedure
214535500|NCT01336387|DRUG|retinoid 9cUAB30|Given PO
214535501|NCT01336387|OTHER|placebo|Given PO
214535502|NCT01336387|OTHER|pharmacological study|Correlative studies
214535503|NCT01336387|OTHER|laboratory biomarker analysis|Correlative studies
214535504|NCT01336387|OTHER|cancer prevention|Disease prevention
214535505|NCT04577976|DEVICE|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
214535506|NCT05550714|DRUG|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
214535507|NCT05550714|DRUG|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
214535508|NCT06124183|BEHAVIORAL|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
214535509|NCT02241161|OTHER|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
214535510|NCT02241161|OTHER|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
214535511|NCT02241161|OTHER|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
214535512|NCT01527903|DRUG|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
214535513|NCT01527903|DRUG|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
214535514|NCT01723007|OTHER|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
214535515|NCT00014222|BIOLOGICAL|epoetin alfa|40,000 IU
214535516|NCT00014222|BIOLOGICAL|filgrastim|5 mg/kg/d - days 2-13
214535517|NCT00014222|DRUG|cyclophosphamide|75, 600 and 830 mg/m2
214535518|NCT00014222|DRUG|doxorubicin hydrochloride|60 mg/m2
214535519|NCT00014222|DRUG|epirubicin hydrochloride|60 mg/m2
214535520|NCT00014222|DRUG|fluorouracil|500mg/m2
214535521|NCT00014222|DRUG|paclitaxel|175 mg/m2
214535522|NCT01222702|DRUG|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
214696396|NCT03709810|COMBINATION_PRODUCT|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
215154855|NCT06000774|OTHER|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
215154856|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
215154857|NCT06004427|OTHER|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
214535523|NCT01222702|DRUG|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
214535524|NCT01222702|DRUG|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
214535525|NCT01222702|DRUG|Placebo-matching vancomycin|Placebo of vancomycin capsules
214696397|NCT03709810|OTHER|No Adhesive|No adhesive will be applied.
214696398|NCT03065504|DIETARY_SUPPLEMENT|Turmeric|
215154858|NCT06004427|OTHER|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
215154859|NCT05492578|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
215154860|NCT05492578|DRUG|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
215154861|NCT05492578|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
215154862|NCT05492578|DRUG|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
214535526|NCT05270473|PROCEDURE|uterine compressive sutures|uterine compression sutures comaprison
214535527|NCT00799136|DRUG|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
214535528|NCT02134613|OTHER|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
215154863|NCT03497195|DIAGNOSTIC_TEST|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
215154864|NCT06833580|OTHER|The intervention group, who will receive the health belief model-based fall prevention education program|Each participant in this group will receive two in-person individual educational sessions based on the health belief model (HBM).
215154865|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
215154866|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
215154867|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
215154868|NCT06830863|DRUG|ATR04-484|ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use
215154869|NCT06830863|DRUG|Vehicle|Topically applied vehicle.
215154870|NCT00337623|DRUG|Prednisolone|
215154871|NCT06160843|DRUG|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
215154872|NCT02338271|OTHER|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
215154873|NCT05742711|DEVICE|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
215154874|NCT05742711|DEVICE|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
215154875|NCT05240391|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
215154876|NCT05240391|DRUG|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
215154877|NCT05246358|DEVICE|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
215154878|NCT02427308|DRUG|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
214535529|NCT01432522|DRUG|Epinephrine|"1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray"
214535530|NCT06646809|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
214535531|NCT06646809|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214535532|NCT06646809|OTHER|Standard care|Standard care
214535533|NCT04713878|OTHER|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
214535534|NCT02134249|DRUG|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
215154879|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
214535535|NCT02134249|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
214535536|NCT03240458|DEVICE|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
214535537|NCT02113540|DRUG|Atorvastatin|
214535538|NCT03237598|OTHER||
214535539|NCT05753358|OTHER|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
214535540|NCT01841645|DIETARY_SUPPLEMENT|CLA depletion-repletion|
214535541|NCT01424176|DRUG|Dexpramipexole (dose 1)|
214535542|NCT01424176|DRUG|Dexpramipexole (dose 2)|
214535543|NCT03377959|OTHER|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
214535544|NCT03377959|OTHER|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
214535545|NCT00464217|DRUG|ARA-C|
214535546|NCT00464217|DRUG|Idarubicin|
214535547|NCT00464217|DRUG|Leucomax|
214696399|NCT03065504|DIETARY_SUPPLEMENT|Turmeric-containing combination tablet|
214696400|NCT03065504|DIETARY_SUPPLEMENT|Placebo tablets|
214696401|NCT03169452|DEVICE|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
214696402|NCT01053845|OTHER|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
215154880|NCT06003686|BEHAVIORAL|PVA Consumer Guide|"Subject's will receive education on the PVA consumer guide 3 times over the course of the study.~Each session will be approximately 10-15 minutes and will consist of a general review of the nutrition, exercise, and general healthy living guidelines content included."
215154881|NCT06003686|BEHAVIORAL|WebMD|Subject's will receive education on how to navigate the WebMD site and find information on health, exercise and nutrition 3 times over the course of the study. Each session will be approximately 10-15 minutes and will consist of a general review of the health and wellness content available on the website. At study completion, subjects in this group will be provided with the PVA guide and a brief orientation of the nutrition, exercise, and general healthy living guidelines content included in the guide.
215154882|NCT03520855|OTHER|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
215154883|NCT03520855|BEHAVIORAL|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
214535548|NCT05207449|OTHER|Questionnaire|"The questionnaire will include:~1. The demographic data of the patients~2. Chronic disease related questions~3. Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~4. Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~5. Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~6. Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~7. Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
215154884|NCT06047015|COMBINATION_PRODUCT|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
215154885|NCT06047015|COMBINATION_PRODUCT|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
215154886|NCT00214890|DRUG|Tenofovir|300 mg once daily
215154887|NCT00214890|DRUG|Abacavir|600 mg once daily
215154888|NCT02225002|DRUG|CP-870,893|
215154889|NCT03269396|PROCEDURE|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
215154890|NCT01180582|DEVICE|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
215154891|NCT04530383|DRUG|Metformin Hydrochloride|500-1000 mg twice daily
214535549|NCT00640042|DRUG|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
214535550|NCT04665349|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
214535551|NCT05484713|DIAGNOSTIC_TEST|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
214535552|NCT05484713|DEVICE|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
214535553|NCT01240252|DRUG|Human insulin|U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
214535554|NCT06546761|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
215154892|NCT04633005|DRUG|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
215154893|NCT04633005|DRUG|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
215154894|NCT03249116|OTHER|animal-assisted intervention|Interaction with a therapy dog
215154895|NCT03249116|OTHER|active control|Interaction with a stuffed dog
215154896|NCT04110288|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
215154897|NCT04110288|DEVICE|Non-drug coated Device Treatment|
214535555|NCT04343859|DRUG|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
214535556|NCT00519285|DRUG|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
214535557|NCT00519285|DRUG|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
214535558|NCT00519285|DRUG|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
214535559|NCT00519285|DRUG|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
214535560|NCT04400799|DRUG|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
214535561|NCT03443011|RADIATION|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
214535562|NCT02997683|DEVICE|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
214535563|NCT02997683|OTHER|exercises at home on the floor|exercises at home on the floor
214535564|NCT01020747|DRUG|Avastin® (bevacizumab)|Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
215154898|NCT00221117|DEVICE|Neuroprosthesis-FES Therapy|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
214535565|NCT01020747|DRUG|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
215154899|NCT00221117|OTHER|Conventional Ocupational Therapy (COT)|Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
215154900|NCT00766662|DRUG|Sulfadoxine pyrimethamine|
215154901|NCT04299789|OTHER|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
215154902|NCT00713167|DRUG|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
214535566|NCT01222078|BIOLOGICAL|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
214535567|NCT04206709|PROCEDURE|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
214535568|NCT04206709|OTHER|passive pedaling|20 minutes passive pedaling by upper limbs.
214535569|NCT01792778|DEVICE|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
214535570|NCT01792778|DEVICE|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
214535571|NCT01040923|DEVICE|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
214535572|NCT01510132|DRUG|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
214535573|NCT00136682|DRUG|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
214535574|NCT00136682|DRUG|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
214535575|NCT02576327|DRUG|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
214535576|NCT02576327|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
214535577|NCT02576327|DRUG|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
214535578|NCT02970305|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
214535579|NCT02970305|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
214535580|NCT03592823|DRUG|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
214535581|NCT01438515|DRUG|Rifampin|600mg po once daily x 7 days
215154903|NCT00713167|DRUG|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
215154904|NCT03405532|DIAGNOSTIC_TEST|DM-ECC|Diabetes mellitus CPB
214535582|NCT01438515|DRUG|Doxycycline|100mg po twice daily x 7 days
214535583|NCT01438515|OTHER|2% mupirocin ointment|\~ 1cm applied to the anterior nares twice daily for 7 days
214535584|NCT01438515|OTHER|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
214535585|NCT00983892|BEHAVIORAL|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
214535586|NCT00006005|DRUG|thalidomide|
214535587|NCT06017336|OTHER|Inspiratory Muscle Training Group|Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
214535588|NCT06017336|OTHER|Control Group (breathing exercises)|Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
214535589|NCT02220777|DRUG|ASP8477|oral
214535590|NCT02220777|DRUG|omeprazole|oral
214535591|NCT02220777|DRUG|Placebo|oral
214535592|NCT01729923|DRUG|Capecitabine|Given PO
214535593|NCT01729923|DRUG|Celecoxib|Given PO
214535594|NCT01729923|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214535595|NCT01729923|OTHER|Laboratory Biomarker Analysis|Correlative studies
214535596|NCT01729923|OTHER|Quality-of-Life Assessment|Ancillary studies
214535597|NCT01729923|RADIATION|Radiation Therapy|Undergo radiation therapy
214535598|NCT01729923|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
214535599|NCT01729923|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
215154905|NCT02217358|DEVICE|NBI endoscopy|"see in detail description of the study part of the protocol"
215154906|NCT01171482|DRUG|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
215154907|NCT01171482|DRUG|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
215154908|NCT01171482|DRUG|sorafenib|400 mg BID every 28 days
214535600|NCT00808899|DRUG|Temsirolimus|Temsirolimus
215154909|NCT03952975|OTHER|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
215154910|NCT03007225|DRUG|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
215154911|NCT03007225|DRUG|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
214535601|NCT00808899|DRUG|Irinotecan|Irinotecan
214535602|NCT00808899|PROCEDURE|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
214535603|NCT00808899|DRUG|Cyclophosphamide|Cyclophosphamide
214535604|NCT00808899|DRUG|Doxorubicin|Doxorubicin
214535605|NCT00808899|DRUG|Etoposide|Etoposide
214535606|NCT00808899|DRUG|Cisplatin|Cisplatin
214535607|NCT00808899|DRUG|Topotecan|Topotecan
214535608|NCT00808899|PROCEDURE|PBSC|Peripheral Blood Stem Cell Harvest
214535609|NCT00808899|RADIATION|Radiation Therapy|Radiation Therapy
214535610|NCT00808899|DRUG|13-cis-retinoic acid|13-cis-retinoic acid
214535611|NCT04661514|DRUG|Psilocybin|Psilocybin-assisted psychotherapy
214535612|NCT03284528|OTHER|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
214535613|NCT00450398|DRUG|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
214535614|NCT00450398|DRUG|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
214535615|NCT03529084|DRUG|EFG816|It will be administered orally daily.
214535616|NCT03529084|DRUG|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
214535617|NCT04615910|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
214535618|NCT04466410|BIOLOGICAL|XT-150|Single bolus intrathecal injection
214535619|NCT04466410|BIOLOGICAL|Placebo|Placebo is a sterile phosphate-buffered saline
214535620|NCT04338347|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
214535621|NCT02894905|DRUG|AL-335|Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
214535622|NCT03373955|DRUG|pembrolizumab|anti-programmed death 1 (PD-1) antibody
214535623|NCT06135675|DRUG|TNP-2092 capsules|Administration orally.
214535624|NCT06135675|DRUG|Placebo|Administration orally.
214535625|NCT05335343|OTHER|no intervention|no intervention
214535626|NCT04124016|DIETARY_SUPPLEMENT|Inulin|Powder of inulin fractions dissolved into 250 ml of water
214535627|NCT04124016|DIETARY_SUPPLEMENT|green tea extract|Powder of green tea extract dissolved into 200 ml of water
214535628|NCT04124016|DIETARY_SUPPLEMENT|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
214535629|NCT04124016|DIETARY_SUPPLEMENT|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
215154912|NCT02692638|PROCEDURE|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
215154913|NCT02692638|PROCEDURE|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
215154914|NCT03482596|BEHAVIORAL|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
214535630|NCT05459025|BEHAVIORAL|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
214535631|NCT05459025|BEHAVIORAL|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
214535632|NCT02582034|RADIATION|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
215154915|NCT00124436|DRUG|alitretinoin|
215154916|NCT03970317|DEVICE|Broad Band Light|Broad Band Light Device
215154917|NCT01413204|DRUG|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
215154918|NCT01413204|DRUG|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
215154919|NCT01413204|DRUG|Placebo|The patients will receive Placebo orally for 24 weeks.
215154920|NCT01318239|PROCEDURE|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
214535633|NCT02582034|RADIATION|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
214535634|NCT03120949|DRUG|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
214535635|NCT03120949|DRUG|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
214535636|NCT03120949|DRUG|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
214535637|NCT03509142|DEVICE|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
214535638|NCT03466229|DIETARY_SUPPLEMENT|Androferti|
214535639|NCT03466229|DIETARY_SUPPLEMENT|Placebo|
214535640|NCT00988117|DRUG|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
214535641|NCT06224335|DIAGNOSTIC_TEST|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
214696403|NCT04507867|DIETARY_SUPPLEMENT|Nutritional support system (NSS)|"1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
214696404|NCT04507867|OTHER|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
214696405|NCT00228306|BEHAVIORAL|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
214535642|NCT05955547|OTHER|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
215154921|NCT06318013|DIAGNOSTIC_TEST|vitality test|A vitality test will be performed using a vitalometer to check if the drowsiness is gone
215154922|NCT04952948|OTHER|PILATES Training|During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
214535643|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
214535644|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
214535645|NCT00702273|DRUG|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
214535646|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214535647|NCT00702273|DRUG|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
214535648|NCT00702273|DRUG|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214535649|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
214535650|NCT00702273|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
214535651|NCT00702273|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
214535652|NCT00702273|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
214535653|NCT03483597|OTHER|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
214535654|NCT01196247|DRUG|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
214535655|NCT04522778|DEVICE|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
214535656|NCT04522778|OTHER|Traditional Securement Dressing|All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
214535657|NCT01225159|DRUG|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
214535658|NCT01225159|DRUG|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
214535659|NCT02996318|DEVICE|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
214535660|NCT02996318|DEVICE|Sirolimus coated balloon|Sirolimus coated balloon
214535661|NCT05011617|DEVICE|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
214535662|NCT05971017|DIETARY_SUPPLEMENT|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
214535663|NCT05971017|DIETARY_SUPPLEMENT|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
214535664|NCT00312845|DRUG|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
214535665|NCT00312845|DRUG|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
214535666|NCT02659384|DRUG|Bevacizumab|
214535667|NCT02659384|DRUG|atezolizumab|
214535668|NCT02659384|DRUG|acetylsalicylic acid|
214535669|NCT02659384|DRUG|placebo|
214535670|NCT00453934|DEVICE|h-Patch|
215154923|NCT00851058|BEHAVIORAL|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
214696406|NCT02857335|BEHAVIORAL|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
215154924|NCT00851058|BEHAVIORAL|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
214535671|NCT02091297|DRUG|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
214535672|NCT02091297|DRUG|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
214535673|NCT02091297|DRUG|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
214535674|NCT02091297|DRUG|Morphine|
214535675|NCT06646718|PROCEDURE|Close kinetic chain exercise group|●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
214535676|NCT06646718|PROCEDURE|Traditional physical therapy.|●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
214535677|NCT06646770|PROCEDURE|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
214535678|NCT06646770|PROCEDURE|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
214535679|NCT05950776|BIOLOGICAL|MVA-SARS-2-S|Vaccination with MVA-SARS-2-S
214535680|NCT05950776|OTHER|Placebo|Placebo
214535681|NCT01220856|DRUG|Reparixin|Reparixin + immunosuppression
214535682|NCT04088500|BIOLOGICAL|Nivolumab|Specific dose on specific days
214535683|NCT04088500|BIOLOGICAL|Ipilimumab|Specific dose on specific days
214535684|NCT03953378|OTHER|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
214535685|NCT00688051|OTHER|My Life with CF game|Play the game My Life with CF
214535686|NCT02946827|DIETARY_SUPPLEMENT|Balanced low FODMAPs /gluten free diet|
214535687|NCT02946827|DIETARY_SUPPLEMENT|Balanced gluten free diet|
214535688|NCT03421171|OTHER|no intervention|Qualitative research through semi-structured interviews
214535689|NCT03069014|DRUG|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
214535690|NCT03069014|DRUG|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
214535691|NCT03069014|DRUG|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
214535692|NCT00721825|DRUG|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
214535693|NCT00721825|DRUG|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
214535694|NCT04785573|DIETARY_SUPPLEMENT|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
214535695|NCT04743453|DRUG|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
214535696|NCT04743453|DRUG|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
214535697|NCT02722759|OTHER|hemoglobin measurement|
214696407|NCT02983630|OTHER|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
214696408|NCT00510328|DEVICE|Whole Body Vibration|
214696409|NCT00698789|DRUG|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
214696410|NCT00698789|DRUG|INCB019602|20 mg in AM with placebo administration in PM
214696411|NCT00698789|DRUG|INCB019602|5 mg in PM with placebo administration in AM
214696412|NCT00698789|DRUG|INCB019602|20 mg in PM with placebo administration in AM
214696413|NCT00698789|DRUG|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
214696414|NCT00698789|DRUG|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
214696415|NCT00698789|DRUG|Metformin|Stable dose metformin monotherapy
215154925|NCT00851058|BEHAVIORAL|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
215154926|NCT00851058|BEHAVIORAL|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
215154927|NCT00000369|BEHAVIORAL|Individual psychotherapy|
215154928|NCT00000369|DRUG|Lithium carbonate|
214535698|NCT03614286|DIAGNOSTIC_TEST|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
214535699|NCT03821064|OTHER|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
214535700|NCT03002233|DRUG|TRK-820|
214535701|NCT02617667|DRUG|Cyclosporine A|topical ocular, eye drops
214535702|NCT02617667|DRUG|Placebo|topical ocular, eye drops
214535703|NCT03777553|BEHAVIORAL|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
214535704|NCT01554371|DRUG|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
214535705|NCT01554371|DRUG|Cyclophosphamide|Given IV
214535706|NCT02456259|PROCEDURE|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
214535707|NCT03325608|OTHER|POISED Care|Program of dementia care management.
214535708|NCT02188784|DRUG|Polysaccharide Iron Complex 150 mg|Oral Iron
214535709|NCT02188784|DRUG|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
214535710|NCT05634083|DIETARY_SUPPLEMENT|Uremic pateints with itching|Activated charcoal
214535711|NCT04160000|DEVICE|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
214535712|NCT04160000|DRUG|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
214535713|NCT04160000|DEVICE|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
214535714|NCT04160000|DRUG|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
214535715|NCT01789229|OTHER|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
214535716|NCT01789229|OTHER|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
214535717|NCT01789229|OTHER|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
214535718|NCT01789229|OTHER|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
214535719|NCT01789229|OTHER|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
214535720|NCT01789229|OTHER|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
214535721|NCT01789229|OTHER|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
214696416|NCT03670394|DIAGNOSTIC_TEST|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
214696417|NCT04657952|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
214535722|NCT01497951|OTHER|Aminolaevulinic acid|Photodynamic therapy
214535723|NCT01497951|OTHER|Methylcellulose Placebo|Methylcellulose
214535724|NCT02177435|DRUG|Telmisartan|
214535725|NCT02177435|DRUG|Telmisartan/Hydrochlorothiazide|
214535726|NCT02177435|DRUG|Placebo|
214696418|NCT04657952|DRUG|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
214696419|NCT02656758|BEHAVIORAL|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
214696420|NCT00580944|PROCEDURE|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
215154929|NCT04445896|OTHER|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
214696421|NCT04894786|OTHER|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
214696422|NCT04894786|OTHER|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
214696423|NCT06402812|OTHER|Interview|A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
214696424|NCT04818814|BEHAVIORAL|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
214696425|NCT04818814|BEHAVIORAL|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
214696426|NCT06160869|BEHAVIORAL|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
214696427|NCT06160869|COMBINATION_PRODUCT|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
214696428|NCT04096326|DRUG|AGN-151586|AGN-151586 solution for injection.
214696429|NCT04096326|DRUG|Placebo|Placebo solution for injection.
214696430|NCT02004782|DRUG|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
214535727|NCT03614351|DIETARY_SUPPLEMENT|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
214535728|NCT03614351|OTHER|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
214535729|NCT05116865|BIOLOGICAL|HH-120 Dose 1|Dose level 1 of HH-120
214535730|NCT05116865|BIOLOGICAL|HH-120 Dose 2|Dose level 2 of HH-120
214535731|NCT05116865|BIOLOGICAL|HH-120 Dose 3|Dose level 3 of HH-120
214535732|NCT05116865|DRUG|Placebo|Placebo to match
214535733|NCT04531852|OTHER|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
214535734|NCT04531852|BEHAVIORAL|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
214535735|NCT06291597|OTHER|Vaping|Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
214535736|NCT00871455|DRUG|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
214535737|NCT00038961|DRUG|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
214535738|NCT00038961|OTHER|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
215154930|NCT02749084|BIOLOGICAL|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
215154931|NCT05542030|DIAGNOSTIC_TEST|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
214535739|NCT06283563|OTHER|Physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
214535740|NCT06283563|OTHER|No physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
214535741|NCT00035061|DRUG|pemetrexed|
215154932|NCT05542030|DIAGNOSTIC_TEST|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
214535742|NCT00938132|DRUG|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
214535743|NCT01190449|BIOLOGICAL|ofatumumab|Given IV
214535744|NCT02724163|DRUG|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
214696431|NCT02004782|DRUG|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
215154933|NCT05542030|DIAGNOSTIC_TEST|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
215154934|NCT00326430|BEHAVIORAL|Cognitive Therapy, Interpersonal Therapy|
215154935|NCT04922541|DRUG|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
215154936|NCT00120497|DRUG|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
215154937|NCT03828071|PROCEDURE|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
215154938|NCT04652219|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
215154939|NCT02695563|DRUG|Lactoferrin|
215154940|NCT06210217|DRUG|Dobutamine hydrochloride, Injectable|In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.
215154941|NCT06210217|DRUG|0.9% normal saline|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
215154942|NCT01678404|DRUG|131I-rituximab|
215154943|NCT04986319|DIAGNOSTIC_TEST|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
215154944|NCT04475302|BIOLOGICAL|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
215154945|NCT06165315|BEHAVIORAL|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
214535745|NCT02724163|DRUG|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
214535746|NCT02724163|DRUG|Mitoxantrone|DNA-reactive agent
214535747|NCT02724163|DRUG|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
214535748|NCT02724163|DRUG|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
215154946|NCT05857475|DEVICE|CPAP therapy|Continous positive airway pressure therapy
215154947|NCT05857475|OTHER|Control|No CPAP
215154948|NCT04409080|DRUG|REGN7257|Administered by intravenous (IV) infusion, in Part A and B.
215154949|NCT00487656|DRUG|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
215154950|NCT00487656|DRUG|placebo|6 mg/ml ampule solution for injection at .01mg/kg
215154951|NCT00123422|BEHAVIORAL|Breathing retraining|exercise training with computerized training program
215154952|NCT00123422|BEHAVIORAL|Heliox|exercise training with a helium oxygen combination
215154953|NCT00123422|BEHAVIORAL|Exercise|exercise training
215154954|NCT05452343|BIOLOGICAL|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
214535749|NCT02724163|DRUG|Busulfan|Alkylsulfonate
214535750|NCT02724163|DRUG|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
215154955|NCT04555616|BEHAVIORAL|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
215154956|NCT04555616|BEHAVIORAL|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
215154957|NCT04555616|BEHAVIORAL|Placebo|Participants' caregivers will receive a set script of placebo modifications.
215154958|NCT03089281|DEVICE|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
215154959|NCT02796313|BEHAVIORAL|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
215154960|NCT02796313|BEHAVIORAL|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
214535751|NCT05187000|DEVICE|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
214535752|NCT05187000|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
214535753|NCT05442593|OTHER|Plyometric training|Participants will perform: 8 sets of 10 maximal countermovement jumps
214535754|NCT02531399|DEVICE|FDOCT|Measurement of retinal blood velocities
214535755|NCT02531399|DEVICE|LDV|Measurement of retinal blood velocities
214535756|NCT02531399|DEVICE|DVA|Measurement of retinal vessel diameters
214535757|NCT02531399|DEVICE|LSFG|Imaging of retinal blood flow
214535758|NCT05096078|OTHER|Diet|Special diet program for gestational diabetes
214535759|NCT05096078|OTHER|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
214535760|NCT00033943|DRUG|deligoparin|
214535761|NCT03631303|DEVICE|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
214535762|NCT01130311|DRUG|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214535763|NCT01130311|DRUG|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
214535764|NCT01049386|OTHER|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
214535765|NCT01049386|PROCEDURE|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
214535766|NCT02807961|DRUG|ELX-02|Synthetic aminoglycoside
214535767|NCT02807961|DRUG|Placebo|Placebo comparator
214535768|NCT00071877|DRUG|Replagal|
214535769|NCT01028755|DRUG|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
214535770|NCT04298099|DRUG|Ropivacaine|Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
214535771|NCT05348668|DRUG|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
214535772|NCT05955677|DRUG|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
215154961|NCT04490876|PROCEDURE|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
215154962|NCT03101332|BEHAVIORAL|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
215154963|NCT00818701|DRUG|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
215154964|NCT00818701|DRUG|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
215154965|NCT05793268|OTHER|Nuc Discontinuation|Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.
215154966|NCT05793268|DRUG|Entecavir or Tenofovir|Continuation of either entecavir or tenofovir treatment for 3 years
215154967|NCT03419923|DRUG|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
215154968|NCT03419923|DRUG|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
215154969|NCT00409552|BEHAVIORAL|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
215154970|NCT00409552|BEHAVIORAL|VR with flat projection display|VR with flat projection display
215154971|NCT00409552|BEHAVIORAL|non-interactive video with head display|non-interactive video with head display
215154972|NCT00409552|BEHAVIORAL|non-interactive video with with flat projection display|non-interactive video with with flat projection display
215154973|NCT04816669|BIOLOGICAL|BNT162b2|Intramuscular injection
215154974|NCT01852409|DRUG|bevacizumab|
215154975|NCT01229267|BIOLOGICAL|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
215154976|NCT01229267|BIOLOGICAL|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
215154977|NCT02901392|PROCEDURE|AMS-800|Artificial urianry sphincter
215154978|NCT02901392|PROCEDURE|ADVANCE/ADVANCEXP|Male sling
215154979|NCT02901392|PROCEDURE|VIRTUE|Male sling
215154980|NCT02901392|PROCEDURE|INVANCE|Male sling
214535773|NCT05955677|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
214535774|NCT01268098|DRUG|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
214535775|NCT05439473|DIETARY_SUPPLEMENT|Curalin|Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
214535776|NCT00665132|DEVICE|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
215154981|NCT03370900|OTHER|Testing|Participants either received 20 case testing with or without feedback
215154982|NCT02927561|OTHER|Diabetic Retinopathy screening|Diabetic Retinopathy screening
215154983|NCT04913935|DIAGNOSTIC_TEST|Muscle-Skeleton Ultrasonography|postero-anterior radiography
215154984|NCT00919321|BIOLOGICAL|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
215154985|NCT03057483|BIOLOGICAL|Seasonal Influenza vaccine|Seasonal Influenza vaccine
215154986|NCT06287099|DRUG|BRL-101|Subjects will receive a single infusion of BRL-101.
215154987|NCT03016494|DRUG|Co-administration of DWC20155 and DWC20156|
215154988|NCT03016494|DRUG|DWJ1386 Tab.|
215154989|NCT00659737|DRUG|Aprepitant|40mg tablet
215154990|NCT00659737|DRUG|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
215154991|NCT04579939|DIAGNOSTIC_TEST|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
215154992|NCT03578952|DEVICE|TAVR with Evolut R valve|TAVR with Evolut R valve
215154993|NCT00475956|DRUG|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
214535777|NCT00817245|DRUG|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
214535778|NCT02572635|BIOLOGICAL|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
215154994|NCT00475956|DRUG|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
215154995|NCT00697138|DRUG|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
215154996|NCT02291458|DRUG|L-arginine|9 gram L-arginine / day for 6 weeks
215154997|NCT02291458|DRUG|Placebo|9 gram placebo / day for 6 weeks
215154998|NCT02506803|DRUG|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
215154999|NCT04395742|OTHER|Data collection|Only data collection
215155000|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
215155001|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
215155002|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
215155003|NCT01908803|DRUG|AL-60371/AL-817 otic suspension|
215155004|NCT01908803|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
215155005|NCT04312659|DRUG|Infliximab|Participants will be observed who were treated with Infliximab.
215155006|NCT00184301|BEHAVIORAL|inpatient treatment|inpatient treatment during 1 year
215155007|NCT00184301|BEHAVIORAL|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
214535779|NCT02572635|BIOLOGICAL|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
214535780|NCT04311190|OTHER|Family engagement|Physical exercises and simple care tasks
214535781|NCT01727206|DRUG|Tocilizumab|
214535782|NCT00000545|BEHAVIORAL|exercise|
214535783|NCT00000545|BEHAVIORAL|diet|
214535784|NCT04388696|BEHAVIORAL|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
215155008|NCT04791306|OTHER|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
214535785|NCT01055210|DEVICE|Optimisation of VV delay|Programmed VV delay altered on device
214696432|NCT03925311|PROCEDURE|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
215155009|NCT04791306|OTHER|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
215155010|NCT00867815|DRUG|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
215155011|NCT00245752|DEVICE|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
215155012|NCT01305993|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
215155013|NCT05326269|DRUG|Terbutaline|Subcutaneous injection
215155014|NCT02840591|DRUG|Ramelteon|
215155015|NCT02840591|DRUG|Citicoline|
215155016|NCT00120419|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
215155017|NCT03383016|OTHER|Lifestyle questionnaires|
215155018|NCT03383016|DIAGNOSTIC_TEST|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
215155019|NCT05865119|DEVICE|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
215155020|NCT05865119|PROCEDURE|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
215155021|NCT01043367|DIETARY_SUPPLEMENT|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
215155022|NCT01043367|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
215155023|NCT05190497|DEVICE|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
215155024|NCT00306319|DRUG|moxifloxacin|
215155025|NCT01864603|OTHER|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
215155026|NCT01864603|OTHER|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
215155027|NCT01864603|OTHER|Targeted PrEP and Targeted testing interventions|
215155028|NCT01864603|OTHER|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
215155029|NCT01046838|DRUG|Sildenafil|40 mg three times daily for 9 weeks
215155030|NCT01046838|DRUG|Placebo|tablet 3 times daily for 9 weeks
215155031|NCT01107158|BIOLOGICAL|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
215155032|NCT00529867|DRUG|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
215155033|NCT00529867|DRUG|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
215155034|NCT05113069|DRUG|SHR-A1912|SHR-A1912, dose escalation and expansion.
215155035|NCT01900717|DRUG|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
215155036|NCT01900717|DRUG|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
215155037|NCT02446899|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
215155038|NCT02446899|DRUG|Placebo|Intravenous infusion (IV)
214535786|NCT06037239|DRUG|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
214535787|NCT01584011|OTHER|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
214535788|NCT01584011|OTHER|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
214535789|NCT01584011|BEHAVIORAL|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
214535790|NCT01584011|OTHER|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
214535791|NCT06544447|DEVICE|taVNS|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
215155039|NCT03652285|DEVICE|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
215155040|NCT03652285|DEVICE|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
215155041|NCT05832229|DRUG|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
215155042|NCT04259918|PROCEDURE|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
215155043|NCT02192281|OTHER|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
215155044|NCT01610778|DIETARY_SUPPLEMENT|Placebo|
215155045|NCT01610778|DIETARY_SUPPLEMENT|5-aminolevulinic acid phosphate|
215155046|NCT03743857|PROCEDURE|Manual Therapy|AP ankle mobilization
215155047|NCT00003518|DRUG|gemcitabine hydrochloride|
215155048|NCT00003518|DRUG|paclitaxel|
215155049|NCT04946279|OTHER|Best Practice|Receive usual/standard of care
215155050|NCT04946279|OTHER|Informational Intervention|Receive conversation tool
215155051|NCT04946279|OTHER|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
215155052|NCT01615913|DRUG|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
214535792|NCT06544447|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
214535793|NCT04145388|OTHER|online cancer risk assessment|Electronic surveys to collect family cancer history information.
214535794|NCT04145388|OTHER|Usual care|Family cancer history captured by provider during a clinical encounter
214535795|NCT03602248|OTHER|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
214535796|NCT03602248|OTHER|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
214535797|NCT06385613|BEHAVIORAL|Mobile-based stoma care education group|Individuals included in the intervention group will be given mobile-based stoma care trainings before surgery, on the 3rd postoperative day, on the day of discharge, and on the 1st and 3rd months after discharge, and their effectiveness will be measured using data collection forms.
214535798|NCT03215342|BEHAVIORAL|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
214535799|NCT03215342|BEHAVIORAL|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
215155053|NCT01615913|DRUG|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
215155054|NCT01615913|DRUG|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
215155055|NCT04050202|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC) Intervention|ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
215155056|NCT03893942|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
215155057|NCT03893942|OTHER|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
215155058|NCT03893942|OTHER|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
215155059|NCT03893942|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
215155060|NCT03893942|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
215155061|NCT03893942|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
215155062|NCT03893942|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
215155063|NCT03893942|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
215155064|NCT05408442|OTHER|No intervention|No intervention
215155065|NCT01501877|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
215155066|NCT01501877|BEHAVIORAL|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
215155067|NCT00001213|DRUG|Cysteamine|
214535800|NCT00523068|DRUG|Tolterodine|
214535801|NCT00523068|PROCEDURE|tension free vaginal tape|
215155068|NCT06522126|BEHAVIORAL|progressive relaxation exercise|One of the techniques employed to mitigate the prevalence of PMS complaints in women during this period is progressive relaxation exercises (PRE). It is one of the most preferred options due to its simplicity, cost-effectiveness, and reliability. Over the course of numerous years of research, progressive relaxation has been validated as an efficacious approach for regulating muscle tension. These exercises are performed to facilitate the distinction between tension and looseness in the body and to enable the individual to relax on her own in daily life. PRE involves the voluntary, systematic tension and relaxation of large muscle groups in the human body. PRE reduces anxiety levels by reducing muscle tension. It also provides the individual with a sense of profound rest, renewal, and rebirth.
215155069|NCT00149318|OTHER|Biochemical analyses.|Biochemical analyses.
215155070|NCT00908843|OTHER|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
215155071|NCT00908843|OTHER|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
215155072|NCT05801341|DEVICE|Lollipop|An oral lollipop swab will be obtained by placing a flocked swab into the mouth and sucking on the swab for 20 seconds as one would suck on a lollipop
215155073|NCT04583774|OTHER|Prediction error tasks|The intervention involves two tasks, one that involves taste stimuli and another that involves monetary stimuli, and test their impact o brain response in electro encephalography (EEG) and functional magnetic resonance imaging (fMRI)
215155074|NCT04673019|BEHAVIORAL|Nurse AMIE (Addressing Metastatic Individuals Every day)|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
214535802|NCT00085878|DRUG|SB-485232|
214535803|NCT00228098|BEHAVIORAL|Smoking cessation|
214535804|NCT05726266|OTHER|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
214535805|NCT05726266|OTHER|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
214535806|NCT01059188|DRUG|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
214535807|NCT01059188|DRUG|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
214535808|NCT01059188|DRUG|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
215155075|NCT01554241|DIETARY_SUPPLEMENT|D3 2000 IU/day|2000 IU/day D3
215155076|NCT01554241|DIETARY_SUPPLEMENT|D3 4000 IU/day|vitamin D3 4000 IU/day
215155077|NCT01554241|DIETARY_SUPPLEMENT|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
215155078|NCT01554241|DIETARY_SUPPLEMENT|vitamin D3 800 IU/day|vitamin D3 800 IU/day
214535809|NCT01059188|RADIATION|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
214535810|NCT01059188|PROCEDURE|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
214535811|NCT00687245|DRUG|esomeprazole magnesium|capsules, oral, qd, one day
214535812|NCT00970320|OTHER|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
214535813|NCT03345147|OTHER|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
214535814|NCT03345147|OTHER|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
214535815|NCT03587779|DRUG|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
214535816|NCT03587779|DRUG|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
214696433|NCT05239949|OTHER|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
215155079|NCT06104436|BEHAVIORAL|Individualized music playlist|Individualized music playlist composed of preferred music genres sequenced according to the ISO-Principle. It will be played at the state of agitation.
215155080|NCT06104436|BEHAVIORAL|Preferred music|Preferred music is composed of the genres selected by the participants, and to be played at random sequence.
215155081|NCT06104436|BEHAVIORAL|Usual care|Usual technique for calming agitated older adults with dementia
215155082|NCT04599413|OTHER|SURVEY|Pain survey on pianists
215155083|NCT05272501|BEHAVIORAL|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
215155084|NCT04030117|PROCEDURE|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
215155085|NCT04030117|PROCEDURE|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
215155086|NCT00077415|DRUG|gemcitabine hydrochloride|
215155087|NCT00077415|DRUG|triapine|
214535817|NCT02376647|OTHER|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
214696434|NCT05239949|OTHER|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
214696435|NCT05096871|GENETIC|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
214696436|NCT05093413|BEHAVIORAL|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
214696437|NCT05632627|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
214696438|NCT05632627|DRUG|Placebo|Placebo arm
215155088|NCT05591313|BEHAVIORAL|LI-40|Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
215155089|NCT05591313|BEHAVIORAL|MI-30|Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
214535818|NCT02376647|OTHER|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
214535819|NCT04721899|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
214535820|NCT03921242|DRUG|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
214535821|NCT03921242|DRUG|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
214535822|NCT03921242|DRUG|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
214535823|NCT03921242|DRUG|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
214535824|NCT03921242|DRUG|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
214535825|NCT00206739|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
214535826|NCT02491710|DEVICE|Training on low-cost box trainer|
214535827|NCT02491710|DEVICE|Training on standard box trainer|
214696439|NCT03638661|DIETARY_SUPPLEMENT|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
214696440|NCT03638661|DIETARY_SUPPLEMENT|soybean oil|soybean oil used formula
214535828|NCT01093599|BEHAVIORAL|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
214535829|NCT01093599|BEHAVIORAL|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
214535830|NCT01703845|DRUG|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
214535831|NCT01703845|DRUG|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
214535832|NCT01644188|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
214535833|NCT01644188|DRUG|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
214696441|NCT03169023|BEHAVIORAL|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
214696442|NCT03169023|BEHAVIORAL|Enhanced Usual Care Packets|-From the American Cancer Society Website
214535834|NCT01644188|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
214535835|NCT01644188|DRUG|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
214535836|NCT01644188|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
214696443|NCT03169023|OTHER|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
214696444|NCT03169023|OTHER|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
214696445|NCT03169023|OTHER|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
214535837|NCT01087749|DRUG|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
214696446|NCT03169023|OTHER|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
214535838|NCT01087749|DRUG|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
214696447|NCT03169023|OTHER|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
214696448|NCT03169023|BEHAVIORAL|iOTA|-Washington University based intervention
214696449|NCT01238315|BIOLOGICAL|HuCNS-SC|Surgery to implant human CNS stem cells
214696450|NCT00407914|DEVICE|Aquamid|Subcutaneous injection
214696451|NCT00407914|DEVICE|Restylane|Injection in dermis
214696452|NCT01951235|DRUG|Imeglimin|
214696453|NCT01951235|DRUG|Placebo|
214696454|NCT04124536|BEHAVIORAL|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
214696455|NCT02700100|DEVICE|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
215155090|NCT05591313|BEHAVIORAL|HI-16|Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
215155091|NCT02074410|DRUG|OMS643762|
215155092|NCT02074410|DRUG|Placebo|
214535839|NCT01087749|DRUG|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
214535840|NCT00607178|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
214696456|NCT04281342|DRUG|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
214696457|NCT04281342|DRUG|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
214696458|NCT04281342|DRUG|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
214696459|NCT04281342|OTHER|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
214696460|NCT03164512|DRUG|Oral or vaporized cannabidiol|Acute drug exposure
214696461|NCT03164512|DRUG|Placebo|Placebo capsule/vapor
214696462|NCT03314441|BEHAVIORAL|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
214696463|NCT01879176|DEVICE|CytoSorb|
214696464|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
214696465|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
214696466|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
215155093|NCT02306902|DRUG|fenofibrate|130mg, Capsules
215155094|NCT02306902|DRUG|ANTARA® (fenofibrate)|130mg, Capsules
215155095|NCT03835832|OTHER|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
215155096|NCT03314129|BEHAVIORAL|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
215155097|NCT03314129|BEHAVIORAL|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
215155098|NCT03314129|BEHAVIORAL|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
215155099|NCT03314129|BEHAVIORAL|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
215155100|NCT01423747|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
215155101|NCT01423747|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
215155102|NCT01423747|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
215155103|NCT01423747|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
214696467|NCT06142461|DEVICE|PharmaJet Stratis® Needle-Free Injection System|0.5mL dose injection
214696468|NCT06142461|DEVICE|PharmaJet Tropis® Needle-Free Injection System|0.1mL dose injection
214696469|NCT02822534|DRUG|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
214696470|NCT01763021|DRUG|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
214696471|NCT01763021|DRUG|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
215155104|NCT01423747|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
214535841|NCT00607178|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
214535842|NCT03756168|DEVICE|1060nm Diode laser|"All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area."
214535843|NCT01347268|PROCEDURE|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
214535844|NCT01347268|PROCEDURE|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
214535845|NCT05507398|DRUG|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
214535846|NCT00093288|DRUG|bupropion XL|
214535847|NCT01929876|DRUG|Cobimetinib|10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
214535848|NCT01929876|DRUG|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
214535849|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
214535850|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
215155105|NCT01423747|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
215155106|NCT01423747|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
214535851|NCT06302595|DEVICE|MRI-guided prostate biopsy using the needle holder frame.|A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
214535852|NCT02043834|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
214535853|NCT04037345|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
214535854|NCT04037345|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
214535855|NCT04037345|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
214535856|NCT01845649|DRUG|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
214535857|NCT01845649|DRUG|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
214535858|NCT05162898|DRUG|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
214535859|NCT05162898|DRUG|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day
214535860|NCT05162898|DEVICE|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
214535861|NCT05186896|OTHER|Risk perception questionnaire|A questionnaire for risk perception will be developed and administered
214535862|NCT00048503|DRUG|ZARNESTRA, tipifarnib, R115777|
214535863|NCT00148252|DRUG|Mycophenolate mofetil withdrawal|
214535864|NCT00148252|DRUG|Cyclosporione A withdrawal|
214535865|NCT01893853|OTHER|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
214535866|NCT04634955|PROCEDURE|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
214535867|NCT03988998|DRUG|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
214535868|NCT03988998|DRUG|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
214696472|NCT04753242|OTHER|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C\&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C\&L services in the context of pandemics, especially the COVID-19 pandemic.
214696473|NCT04758429|DEVICE|Machine-learning Algorithm|System technology/Software
214696474|NCT05236881|DEVICE|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
214696475|NCT00139425|BEHAVIORAL|Disease Management Assessment|
214696476|NCT01593501|DIETARY_SUPPLEMENT|vitamin D3|pharmaceutical grade D3
214696477|NCT03192072|DIAGNOSTIC_TEST|Host Gene Expression|comparison to retrospective clinical adjudication
214696478|NCT03704441|DRUG|Bupivacaine|bupivacaine dose
214696479|NCT05729425|DEVICE|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
214696480|NCT03653403|DRUG|IDP-126 Gel|Component A
214696481|NCT03653403|DRUG|Control Gel|gel
215155107|NCT01713101|DRUG|Early intravenous tranexamic acid administration|Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.
215155108|NCT01713101|DRUG|placebo|
214535869|NCT03991988|DRUG|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
214535870|NCT03991988|DRUG|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
214535871|NCT04224259|PROCEDURE|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
214535872|NCT04224259|PROCEDURE|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
214535873|NCT00248534|BIOLOGICAL|rituximab|given IV days 1,8, 15 and 22
214535874|NCT00248534|DRUG|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
214535875|NCT00248534|DRUG|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
214535876|NCT01222533|DRUG|Tiotropium medium|Tiotropium inhalation solution medium dose
214535877|NCT01222533|DRUG|Tiotropium low|Tiotropium inhalation solution low dose
214535878|NCT01222533|DRUG|Tiotropium high|Tiotropium inhalation solution high dose
214535879|NCT01222533|DRUG|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
214535880|NCT01222533|DRUG|Tiotropium placebo|Placebo inhalation solution
214535881|NCT05243615|BEHAVIORAL|Guided internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
214535882|NCT05243615|BEHAVIORAL|Stroke rehabilitation mental health education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
214535883|NCT05000099|OTHER|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
214535884|NCT01947517|DEVICE|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
214535885|NCT01947517|DEVICE|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
214535886|NCT04698798|PROCEDURE|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
214535887|NCT02257229|PROCEDURE|Surgical|Surgery only
214535888|NCT02257229|PROCEDURE|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
214535889|NCT02257229|PROCEDURE|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
214535890|NCT05382598|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
214535891|NCT00238953|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214535892|NCT02276638|DEVICE|Specular Microscope Nidek CEM-530|Nidek CEM-530
214535893|NCT02276638|DEVICE|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
214535894|NCT06957262|PROCEDURE|Surgical correction of nasal obstruction|Surgical intervention to correct anatomical nasal obstruction, specifically septal deviation, performed under general anesthesia. The procedure involved the repositioning and reshaping of the deviated nasal septum to improve nasal airflow. The surgery was conducted by an otolaryngologist with experience in nasal airway procedures. No additional medications or postoperative interventions beyond standard care (e.g., saline irrigation, analgesics) were administered. Postoperative assessments occurred 2-3 months after surgery, including evaluations of nasal patency, sleep quality, and aerobic performance using treadmill-based gas exchange measurements.
214535895|NCT06956378|BEHAVIORAL|Instruction Emphasis|The study team will emphasize the questionnaire instructions when asking the second time.
214535896|NCT06957015|DEVICE|EndoAIM|EndoAIM will be used during the withdrawal process of the colonoscopy
214535897|NCT06956326|BEHAVIORAL|Intensive rehab|Frequent moderate-to-high intensity physical therapy, provided by local physiotherapists.
214535898|NCT06956326|BEHAVIORAL|Usual care|Usual care physiotherapy
214535899|NCT06956248|OTHER|Off-label or non-standard systemic therapies|Off-label systemic treatments and/or relevant clinical trials recommended by the NCCS Molecular Tumour Board (MTB).
215155109|NCT01627730|OTHER|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
215155110|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment."
215155111|NCT04195373|BIOLOGICAL|TMV-018 + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC."
214696482|NCT05528874|DIETARY_SUPPLEMENT|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
214696483|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
214535900|NCT06957613|PROCEDURE|Revascularization/Conservative management|Percutaneous Transluminal Angioplasty of Coronary Chronic Total Occlusions via Dedicated Drug Eluting Stents and/or Balloons.
214535901|NCT03629899|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
214696484|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
214696485|NCT06498752|DRUG|PD-1 monoclonal antibody consolidation therapy|PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
214696486|NCT03741725|OTHER|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
214696487|NCT03741725|OTHER|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
214696488|NCT06027931|PROCEDURE|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
215155112|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC."
215155113|NCT06325592|PROCEDURE|surgical timing and operation path|surgical timing; laparoscopic hysterectomy or abdominal hysterectomy
215155114|NCT05593978|BEHAVIORAL|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
215155115|NCT05593978|BEHAVIORAL|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
215155116|NCT03585751|PROCEDURE|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
215155117|NCT03585751|PROCEDURE|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
215155118|NCT03585751|PROCEDURE|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
215155119|NCT00811915|DRUG|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
214535902|NCT00476112|DRUG|Vernakalant Injection 20 mg/mL|
214535903|NCT05683912|DRUG|Aflibercept|Intravitreal aflibercept as used in the routice clinical practice
214535904|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 20mg
214696489|NCT06569147|DRUG|Elranatamab|Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
214696490|NCT00103805|DRUG|levodopa|
214696491|NCT01100996|OTHER|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
214696492|NCT01100996|OTHER|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
214696493|NCT02512068|DRUG|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
214696494|NCT02512068|DRUG|Placebo|Placebo Tablets
214696495|NCT02569411|OTHER|Financial Incentive|money
214696496|NCT06323915|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
214535905|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 5 mg
214535906|NCT00600847|DRUG|placebo|single dose for 7 days, oral
214535907|NCT04865055|OTHER|cyclic merocyanine|long-UVA absorber
214535908|NCT04865055|OTHER|placebo|placebo
214535909|NCT03238807|DRUG|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
214535910|NCT04827589|DRUG|Tirabrutinib|Tablets administered orally
214535911|NCT04827589|DRUG|Placebo|Tablets administered orally
214535912|NCT02418845|DRUG|SYM-1219|
214535913|NCT02418845|DRUG|Placebo|
214535914|NCT00141362|DRUG|Pregabalin|
214535915|NCT06084676|DRUG|Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
214535916|NCT00003693|DRUG|Dolastatin 10|IV bolus once every 3 weeks.
214535917|NCT00526097|DRUG|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
214535918|NCT00526097|DRUG|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
214535919|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract|207 mg curcumin
214535920|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
214535921|NCT03530436|DIETARY_SUPPLEMENT|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
214535922|NCT03530436|DIETARY_SUPPLEMENT|Cyclodextrin complex of curcuminoids|207 mg curcumin
214535923|NCT03530436|DIETARY_SUPPLEMENT|Turmeric oleoresin|207 mg curcumin
214535924|NCT03530436|DIETARY_SUPPLEMENT|Liposomal curcumin|207 mg curcumin
214535925|NCT03530436|DIETARY_SUPPLEMENT|Phytosomal curcumin|207 mg curcumin
214535926|NCT03530436|DIETARY_SUPPLEMENT|Micellar turmeric extract|207 mg curcumin
214535927|NCT02139462|OTHER|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
214535928|NCT02139462|OTHER|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
215155120|NCT03588585|PROCEDURE|Tension|Tension applied to catheter and taped firmly to leg.
215155121|NCT03588585|PROCEDURE|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
215155122|NCT06016777|PROCEDURE|Ultrasound-guided paraspinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided paraspinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
215155123|NCT06016777|PROCEDURE|Ultrasound-guided erector spinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided erector spinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
215155124|NCT06016777|PROCEDURE|Patient-controlled intravenous analgesia pump|Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
215155125|NCT00946621|DRUG|Ramipril 10 mg Capsule (Sandoz)|
214535929|NCT01662037|DRUG|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
214535930|NCT01489917|OTHER|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
214535931|NCT00460564|DRUG|GSK1358820|botulinum toxin type A
214535932|NCT00460564|DRUG|Placebo|Placebo
214535933|NCT03362034|DEVICE|double transfer trays|double trays one soft and one hard
214535934|NCT03362034|DEVICE|single transfer tray|single soft tray
214535935|NCT05758987|BEHAVIORAL|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
214535936|NCT05758987|BEHAVIORAL|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
214535937|NCT06956261|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
214535938|NCT06956261|DRUG|Drug: NW-301D|TCR-T T cell targeting KRAS G12D mutation
214535939|NCT06385847|DRUG|Zoladex|Patients received 3.6 mg subcutaneous Zoladex
214535940|NCT06385847|DRUG|LY01005|Patients received 3.6 mg intramuscular LY01005
214535941|NCT06957561|DRUG|Disitamab Vedotin Injection|Participants will receive Disitamab Vedotin at a dose of 2.0 mg/kg. In the neoadjuvant phase, it will be administered every 2 weeks for 6 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 4 cycles, starting 4-8 weeks after surgery.
214535942|NCT06957561|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Participants will receive Ivonescimab at a dose of 20 mg/kg. In the neoadjuvant phase, it will be administered every 3 weeks for 4 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 9 cycles, starting 4-8 weeks after surgery.
214535943|NCT06957561|PROCEDURE|Radical Cystectomy with Pelvic Lymph Node Dissection|Participants will undergo radical cystectomy with pelvic lymph node dissection 4-6 weeks after the last dose of neoadjuvant treatment.
214535944|NCT06957197|DRUG|Hydrogel with xenograft|vehicle to hold xenograft
214535945|NCT06957197|DRUG|Xenograft|to maintain the socket
214535946|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
214696497|NCT03168256|DRUG|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
215155126|NCT00946621|DRUG|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
215155127|NCT05008965|BIOLOGICAL|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
215155128|NCT05008965|OTHER|Placebo|Formulation buffer
215155129|NCT02974543|DEVICE|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
215155130|NCT02974543|DEVICE|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
215155131|NCT05688475|DRUG|CC-122|Specified dose on specified days
215155132|NCT05688475|DRUG|Dexamethasone|Specified dose on specified days
215155133|NCT00742235|DRUG|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
215155134|NCT03079843|OTHER|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
215155135|NCT03079843|OTHER|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
215155136|NCT04509661|DRUG|LABA/LAMA or Placebo inhalation|Inhaled LABA/LAMA for one year.
215155137|NCT06437743|DEVICE|Nociception Level (NoL) Monitor|The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.
215155138|NCT00133003|DRUG|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
214535947|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
214535948|NCT00511836|DRUG|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
214535949|NCT00511836|DRUG|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
214535950|NCT01540604|DRUG|CRD007|
214535951|NCT03003598|OTHER|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
214535952|NCT03003598|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
214535953|NCT05650541|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
214535954|NCT00721812|DRUG|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
214535955|NCT01936324|DRUG|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
214535956|NCT01936324|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
214535957|NCT05931445|OTHER|e-PRO monitoring|"The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action."
214535958|NCT00884559|OTHER|instruction|Debriefing
214535959|NCT01674517|DRUG|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
214535960|NCT03166046|DEVICE|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
214535961|NCT03166046|DEVICE|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
214535962|NCT03061604|DEVICE|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
214535963|NCT03061604|DRUG|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
215155139|NCT00133003|DRUG|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
215155140|NCT05459844|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
215155141|NCT05459844|DRUG|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
215155142|NCT01237899|DRUG|LY2623091|Administered orally.
215155143|NCT01237899|DRUG|Placebo|Administered orally.
215155144|NCT01237899|DRUG|Eplerenone|Administered orally.
215155145|NCT01051518|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
214696498|NCT03168256|DRUG|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
214696499|NCT03168256|DRUG|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
214696500|NCT03168256|DRUG|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
214696501|NCT00121303|DRUG|cytarabine|
214696502|NCT00121303|DRUG|daunorubicin hydrochloride|
215155146|NCT05897125|OTHER|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
215155147|NCT05897125|BEHAVIORAL|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
215155148|NCT05897125|OTHER|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
215155149|NCT05897125|OTHER|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
215155150|NCT05897125|OTHER|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
215155151|NCT05897125|OTHER|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
215155152|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
215155153|NCT02141438|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
215155154|NCT05835687|DRUG|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
215155155|NCT06249867|DRUG|Darifenacin 7.5 MG Extended Release Oral Tablet|During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.
214535964|NCT03061604|BIOLOGICAL|Blood transfusion|Blood transfusion will be administered to all patients if needed
214535965|NCT03061604|DRUG|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
214535966|NCT05142930|OTHER|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
214696503|NCT00121303|DRUG|gemtuzumab ozogamicin|
214696504|NCT03305094|PROCEDURE|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
214696505|NCT01133431|DRUG|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
214696506|NCT01133431|DRUG|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
214696507|NCT03521687|DRUG|Apremilast|30 mg BID
214696508|NCT03399175|DRUG|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
214696509|NCT04365985|DRUG|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
214696510|NCT04365985|DRUG|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
214696511|NCT04365985|OTHER|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
214535967|NCT05142930|OTHER|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
214535968|NCT06238050|PROCEDURE|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
214535969|NCT00004316|DRUG|capsaicin|
214535970|NCT00004316|DRUG|Placebo|
214696512|NCT02362087|OTHER|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
214696513|NCT03498781|OTHER|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
214696514|NCT03498781|OTHER|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
215155156|NCT06249867|DRUG|Placebo|During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
214535971|NCT00460018|BEHAVIORAL|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
214535972|NCT06951386|DIETARY_SUPPLEMENT|with short-chain fatty acids enriched drink|Oat-based drink enriched with 15 g/L short-chain fatty acids
214535973|NCT06951386|DIETARY_SUPPLEMENT|unenriched oat drink|Oat-based drink
214535974|NCT06956716|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
214535975|NCT06956716|DRUG|Gemcitabine + cisplatin (GP)|As standard chemotherapy (D1, D8 gemcitabine 1000mg/m², intravenous drip for 30 minutes, cisplatin 25mg/m², intravenous drip), once every 3 weeks
214535976|NCT06956716|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion
214535977|NCT06956534|OTHER|Questionnaire and Physical Exam|online digital questionnaire
214535978|NCT06957717|COMBINATION_PRODUCT|cow's milk kefir|group given cow's milk kefir and blood supplement tablets (TTD)
214535979|NCT06957717|COMBINATION_PRODUCT|pasteurized cow's milk|group given pasteurized cow's milk and blood supplement tablets (TTD)
214535980|NCT06951932|DIETARY_SUPPLEMENT|Mediterranean-type diet with MCT supplementation|The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)
214535981|NCT06951932|OTHER|Mediterranean-type food regimen using extra virgin olive oil|The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily
214535982|NCT06048133|DRUG|Gemcitabine|Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
214535983|NCT06048133|DRUG|Cisplatin|Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
214535984|NCT06048133|DRUG|Zimberelimab|Zimberelimab IV: Day 1 and 22 every 42 days
214535985|NCT06048133|DRUG|Quemliclustat|Quemliclustat IV: Day 1, 15, 29 every 42 days
214535986|NCT00943618|DRUG|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
214535987|NCT00943618|DRUG|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
214535988|NCT00943618|OTHER|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
214535989|NCT00943618|BEHAVIORAL|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
214535990|NCT03919955|DRUG|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
214535991|NCT03919955|DRUG|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
214535992|NCT03919955|DRUG|Placebo|Placebo, per mouth, before bed.Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
214535993|NCT06142578|DEVICE|Dermal Filler Device|Injection of device by investigators according to the Instruction For Use (IFU)
214535994|NCT05986084|DRUG|Cabotegravir Injection [Apretude]|Injection
214535995|NCT05120596|DRUG|Pembrolizumab+T3P-Y058-739|intravenous infusion or intratumoural injection
214535996|NCT05120596|DRUG|T3P-Y058-739 (IV)|Intravenous infusion
214535997|NCT05120596|DRUG|T3P-Y058-739 (IT)|Intratumoral use
214535998|NCT06712693|DEVICE|Phonak Audeo Infinio Hearing Aid|Receiver-In-Canal hearing aid type that is coupled with either a custom earmold or a dome.
214535999|NCT06178718|DRUG|TNP-2092 capsules|Administered orally, 100 to 1200 mg
214536000|NCT06178718|DRUG|TNP-2092 placebo capsules|Administered orally
214536001|NCT06045000|DRUG|DC-806|Oral tablets
214536002|NCT06045000|DRUG|[14C]-DC-806|Oral capsules
214536003|NCT05880225|BEHAVIORAL|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
214536004|NCT05880225|BEHAVIORAL|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
215155157|NCT05357950|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
215155158|NCT05357950|DRUG|Placebo|Placebo matches active drug in size, color and taste
215155159|NCT01858025|RADIATION|Pencil Beam scanning Radiation|
215155160|NCT01858025|DRUG|5-fluorouracil|
215155161|NCT01858025|DRUG|Mitomycin-C|
215155162|NCT05035706|PROCEDURE|Biopsy|Undergo biopsy
215155163|NCT05035706|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
215155164|NCT05035706|OTHER|Electronic Health Record Review|Medical records reviewed
215155165|NCT05035706|OTHER|Photography|Photographs taken
214536005|NCT04649671|BEHAVIORAL|Mobile health|"Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit"
214536006|NCT05566886|DEVICE|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
214536007|NCT01660919|DRUG|placebo|
214536008|NCT01660919|DRUG|rosuvastatin|
214536009|NCT00487552|DEVICE|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
214536010|NCT02412111|DRUG|Ivacaftor|
214536011|NCT02412111|DRUG|Tezacaftor/Ivacaftor|
214536012|NCT01543334|BIOLOGICAL|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
214536013|NCT06064045|BEHAVIORAL|Simulation-based team training intervention|"Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~1. Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~2. Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~3. Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~4. Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period)."
214536014|NCT02724293|DRUG|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
214536015|NCT02724293|DRUG|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
214536016|NCT02724293|DRUG|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
214536017|NCT02724293|DRUG|placebo|patients received placebo
214536018|NCT03371277|OTHER|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
214536019|NCT04038697|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
214536020|NCT04038697|PROCEDURE|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
214536021|NCT04038697|PROCEDURE|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
214536022|NCT04578288|PROCEDURE|INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION|The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
214536023|NCT00517842|DRUG|ViNeuro|
214536024|NCT00573456|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
214536025|NCT06316245|OTHER|DASI questionnaire|All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
214536026|NCT00630552|OTHER|Placebo|Inactive dummy of AMG 655.
214536027|NCT00630552|DRUG|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
214536028|NCT00630552|DRUG|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
214536029|NCT04349644|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.
215155166|NCT05201014|DIAGNOSTIC_TEST|NT-pro-BNP|Blood draw
215155167|NCT05201014|DIAGNOSTIC_TEST|Electrocardiogram|electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart
215155168|NCT05201014|DIAGNOSTIC_TEST|Echocardiogram|medical imaging of the heart
215155169|NCT05816850|DIAGNOSTIC_TEST|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
215155170|NCT05816850|DIAGNOSTIC_TEST|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
214536030|NCT06845735|DEVICE|Non-Absorbable Sutures|Non-Absorbable Sutures
214536031|NCT06845735|DEVICE|Absorbable Suture|Absorbable suture
214536032|NCT00522509|DRUG|Floxuridine FUDR|
214536033|NCT05124002|DRUG|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
215155171|NCT06315010|DRUG|Repotrectinib|"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."
215155172|NCT05868239|DEVICE|Aerosol box|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
214536034|NCT05124002|DRUG|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
214536035|NCT03170947|DEVICE|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
214536036|NCT03170947|DEVICE|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
214536037|NCT04826991|DEVICE|Active UV Device|Active water treatment system
214536038|NCT04826991|DEVICE|Inactive UV Device|Inactive water treatment system
214536039|NCT04669002|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
214536040|NCT04669002|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
214536041|NCT06028217|OTHER|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
214536042|NCT00983905|DRUG|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
214536043|NCT00983905|DRUG|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
214536044|NCT04488861|OTHER|Non-interventional cohort study|Non-interventional cohort study
214536045|NCT01114139|DRUG|Ferumoxytol|IV Ferumoxytol
214536046|NCT01114139|OTHER|Placebo|IV Placebo
214536047|NCT03371537|PROCEDURE|Liver debit measure|Mesure of liver debit during hepatectomy
214536048|NCT02250768|BIOLOGICAL|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
214536049|NCT04077697|DIAGNOSTIC_TEST|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
214536050|NCT01389414|DRUG|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
214536051|NCT01389414|DRUG|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
214536052|NCT01169636|DRUG|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
214536053|NCT01169636|DRUG|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
214536054|NCT01169636|DRUG|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
214536055|NCT01169636|DRUG|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
214536056|NCT01169636|DRUG|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
214536057|NCT01169636|DRUG|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
214536058|NCT03088098|DEVICE|LAAO|Left atrial appendage occlusion for stroke prevention
214536059|NCT04111900|BEHAVIORAL|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
214536060|NCT02705625|DRUG|MIV-711|MIV-711 administered orally once daily
214536061|NCT02705625|DRUG|Placebo|Placebo manufactured to mimic MIV-711 capsule.
214536062|NCT02719262|DEVICE|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
214536063|NCT02168231|PROCEDURE|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
215155173|NCT03438461|DRUG|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
215155174|NCT03438461|DRUG|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
215155175|NCT05460000|DRUG|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
215155176|NCT05460000|DRUG|6 cycles chemotherapy|Standard chemotherapy as comparator
214536064|NCT01565317|OTHER|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
214536065|NCT04071509|DEVICE|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
214536066|NCT03680963|PROCEDURE|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
214536067|NCT03680963|PROCEDURE|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
214536068|NCT00494026|DRUG|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
214536069|NCT00494026|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
214536070|NCT00494026|PROCEDURE|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
214536071|NCT04366362|PROCEDURE|Individualised ACL reconstruction|ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
214536072|NCT04366362|PROCEDURE|Conventional ACL reconstruction|ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
214536073|NCT03423368|DEVICE|Libramed|Policaptil Gel Retard
214536074|NCT03423368|DEVICE|Placebo|Placebo-comparator
214536075|NCT04834492|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty in Crowe type 4 developmental dysplasia of the hip.
214536076|NCT00187499|DRUG|Inhaled fluticasone 500 ug BID for 8 weeks|
214536077|NCT00002647|DRUG|verteporfin|
214536078|NCT00002647|PROCEDURE|conventional surgery|
214536079|NCT03507153|PROCEDURE|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
214536080|NCT03507153|PROCEDURE|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
215155177|NCT05661409|DRUG|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
214536081|NCT00518856|OTHER|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
214536082|NCT00518856|OTHER|Standard of care|continued with current standard of care for birth attendants
214536083|NCT05972304|DEVICE|Nasal positive airway System by Vyaire Medical|Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor
214536084|NCT05557071|BEHAVIORAL|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
214536085|NCT00489645|DRUG|placebo|placebo SC during euglycemia
214536086|NCT00489645|DRUG|pramlintide|pramlintide SC during eglycemia
214536087|NCT00489645|DRUG|placebo|placebo during hyperglycemia
214536088|NCT00489645|DRUG|pramlintide|pramlintide SC during hyperglycemia
215155178|NCT05661409|DRUG|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
215155179|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
214536089|NCT06149143|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
214536090|NCT00364390|DRUG|Anginera, a human tissue replacement therapy|
214536091|NCT03238222|BEHAVIORAL|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
214536092|NCT00004039|BIOLOGICAL|recombinant interferon alfa|
214536093|NCT00004039|BIOLOGICAL|rituximab|
214536094|NCT00004039|DRUG|cyclophosphamide|
214536095|NCT00004039|DRUG|doxorubicin hydrochloride|
214536096|NCT00004039|DRUG|prednisone|
214536097|NCT00004039|DRUG|vincristine sulfate|
214536098|NCT06230133|BEHAVIORAL|MBSR intervention|In our study, it is the same to arm description.
214536099|NCT01916798|DRUG|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
214536100|NCT04937205|BEHAVIORAL|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
214536101|NCT02866071|DRUG|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
214536102|NCT02866071|DRUG|Placebo-Comparator|50mg IN Placebo
214536103|NCT06332300|DRUG|Adebelimumab+Famitinib + FOLFIRI+Ariely|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
214536104|NCT04296422|DRUG|NSAIDs or oral contraceptives treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
214536105|NCT04296422|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
214536106|NCT04296422|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
214536107|NCT04865783|PROCEDURE|Saline spray|The saline spray will be applied twice for 1-2 seconds.
214536108|NCT04865783|PROCEDURE|Cryospray|The cryospray will be applied twice for 1-2 seconds.
214536109|NCT03946098|BEHAVIORAL|iCBT|A newly developed iCBT protocol targeting problem gambling.
214536110|NCT04673799|DRUG|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
214536111|NCT04673799|DRUG|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
214536112|NCT03765515|DEVICE|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
214536113|NCT03765515|DEVICE|Q-Fix|Q-Fix
214536114|NCT05858801|DEVICE|PRIMUS|PRIMUS system
214536115|NCT04342598|OTHER|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
214536116|NCT03284125|OTHER|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
214536117|NCT04787289|DRUG|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
214536118|NCT02190552|DEVICE|EmboTrap® Revascularization Device|
214536119|NCT01620307|DRUG|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
214536120|NCT02413606|OTHER|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
214536121|NCT01057251|DRUG|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
214536122|NCT01057251|DRUG|Placebo|5 mg or 20 mg once daily, oral administration
214536123|NCT03788122|OTHER|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
214536124|NCT02637856|DRUG|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
214536125|NCT02637856|DRUG|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
214536126|NCT00784147|DRUG|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
214536127|NCT00784147|DRUG|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
214536128|NCT03343210|DIAGNOSTIC_TEST|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
214536129|NCT03677245|OTHER|Strider Balance Bike|Learning to ride a Strider balance bike
214536130|NCT00440388|DRUG|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
214536131|NCT00440388|DRUG|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
214536132|NCT00814411|BEHAVIORAL|group family planning counseling|group family planning counseling for gynecological patients with unmet need
214536133|NCT00814411|BEHAVIORAL|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
214536134|NCT05596747|DRUG|LY3209590|Administered SC.
214536135|NCT05596747|DRUG|Insulin Glargine|Administered SC.
214536136|NCT04615598|BEHAVIORAL|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
214536137|NCT04615598|BEHAVIORAL|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
214536138|NCT05722405|DRUG|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
214536139|NCT05722405|DRUG|Ixazomib|Ixazomib alone
214536140|NCT05097937|OTHER|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
214536141|NCT05097937|OTHER|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
214536142|NCT05097937|OTHER|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
214536143|NCT03049098|BEHAVIORAL|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
215155180|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
214536144|NCT00907192|BEHAVIORAL|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
214536145|NCT00907192|BEHAVIORAL|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
214536146|NCT01674920|BEHAVIORAL|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
214536147|NCT01982786|RADIATION|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
214536148|NCT01982786|RADIATION|Brachytherapy|Brachytherapy boost
214536149|NCT04544865|DEVICE|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
214536150|NCT04731974|DRUG|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
214536151|NCT04731974|OTHER|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
214536152|NCT04358536|DEVICE|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
214536153|NCT04231162|DIETARY_SUPPLEMENT|Active product|Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
214536154|NCT04231162|DIETARY_SUPPLEMENT|Control product|Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
215155181|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
215155182|NCT06016270|DRUG|hSTC810 400 mg + Paclitaxel|"hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion"
214696515|NCT02221180|DRUG|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
214536156|NCT02476747|OTHER|EMR|performing EMR for patients with small polyp
214536157|NCT02476747|OTHER|CSP|performing CSP for patients with small polyp
214696516|NCT02221180|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
214696517|NCT02221180|DRUG|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
214696518|NCT01962714|BEHAVIORAL|Loving-Kindness Meditation|12-week loving-kindness meditation course
214696519|NCT01962714|BEHAVIORAL|Cognitive Processing Therapy|12-week CPT course
214696520|NCT05738902|OTHER|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
215155183|NCT06016270|DRUG|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
215155184|NCT05316948|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
215155185|NCT02429245|OTHER|Retrospective study|
215155186|NCT06236048|PROCEDURE|MRI scan|7 Tesla MRI scan
215155187|NCT06236048|PROCEDURE|PET-MR scan|18F-fluorodeoxyglucose PET-MR scan
214536158|NCT00005569|DRUG|SLPI (Secretory Leukocyte Protease Inhibitor)|
214536159|NCT05380102|DEVICE|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
214536160|NCT05380102|DEVICE|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
214536161|NCT05380102|DEVICE|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
214536162|NCT03964922|BIOLOGICAL|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
214536163|NCT03964922|BIOLOGICAL|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
214536164|NCT05725044|DIETARY_SUPPLEMENT|Ginsengberry concentrate|Ginsengberry concentrate
214536165|NCT05725044|DIETARY_SUPPLEMENT|Placebo|Placebo
214536166|NCT00591604|DRUG|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
214536167|NCT01209741|DRUG|telcagepant potassium|\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
214536168|NCT01209741|DRUG|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
214536169|NCT01209741|DRUG|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
214696521|NCT04729920|DEVICE|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
214696522|NCT00437333|DRUG|Metformin cloridrate|
214696523|NCT02364167|DRUG|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
214696524|NCT02364167|DEVICE|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
214696525|NCT02364167|OTHER|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
214696526|NCT01151579|DRUG|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
214696527|NCT01151579|DRUG|Albuterol|Nebulized albuterol 2.5mg
214696528|NCT00979446|BEHAVIORAL|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
214696529|NCT00979446|BEHAVIORAL|Self-directed|Received study materials but no phone coaching
214696530|NCT01276457|DRUG|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
214696531|NCT01276457|DRUG|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
215155188|NCT05035420|DEVICE|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
215155189|NCT05035420|DEVICE|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
215155190|NCT05035420|DEVICE|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
214696532|NCT01276457|DRUG|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
214696533|NCT03007017|PROCEDURE|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
214696534|NCT03007017|PROCEDURE|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
214696535|NCT00463658|OTHER|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
215155191|NCT05035420|DEVICE|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
215155192|NCT05035420|DEVICE|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
215155193|NCT05035420|DEVICE|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
214536170|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
214536171|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
214536172|NCT05090475|BEHAVIORAL|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
214536173|NCT02287883|OTHER|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
214536174|NCT06222775|BEHAVIORAL|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
214536175|NCT06222775|BEHAVIORAL|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
214696536|NCT01040208|DRUG|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
214696537|NCT01040208|DRUG|flibanserin 100 mg qhs|100mg qhs
214696538|NCT01040208|DRUG|placebo 2 tablets qhs|50 mg placebo
214696539|NCT01204255|DRUG|lorazepam|Given topically
214536176|NCT06222775|BEHAVIORAL|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
214536177|NCT06222775|BEHAVIORAL|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
214536178|NCT06222775|BEHAVIORAL|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
214536179|NCT06222775|BEHAVIORAL|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
214536180|NCT06222775|BEHAVIORAL|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
214696540|NCT01204255|DRUG|diphenhydramine hydrochloride|Given topically
214696541|NCT01204255|DRUG|haloperidol|Given topically
214696542|NCT01204255|OTHER|questionnaire administration|Ancillary studies
214696543|NCT01204255|OTHER|laboratory biomarker analysis|Correlative studies
214696544|NCT01924052|DRUG|CGRP|Calcitonin-gene-related-peptide (CGRP)
214696545|NCT01098461|BIOLOGICAL|albiglutide|subcutaneous injection of albiglutide
214696546|NCT01098461|BIOLOGICAL|placebo|subcutaneous injection of placebo to match albiglutide
214696547|NCT02019524|BIOLOGICAL|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
214696548|NCT02019524|BIOLOGICAL|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
214696549|NCT02019524|BIOLOGICAL|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
215155194|NCT05842174|DRUG|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
214536181|NCT06222775|BEHAVIORAL|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
214536182|NCT06222775|BEHAVIORAL|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
214536183|NCT06222775|BEHAVIORAL|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
214536184|NCT06222775|BEHAVIORAL|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
214536185|NCT06222775|BEHAVIORAL|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
214536186|NCT03144778|BIOLOGICAL|Durvalumab|Given IV
214536187|NCT03144778|BIOLOGICAL|Tremelimumab|Given IV
214536188|NCT05089604|DRUG|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
214536189|NCT05089604|DRUG|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
214536190|NCT05648136|BIOLOGICAL|blood sample|"Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation"
214536191|NCT05077241|DEVICE|Inspiratory muscle training|Individuals will be instructed to perform a rapid contraction of the inspiratory muscles against a load and sustain it for 2 seconds in each maneuver.
214536192|NCT02110511|OTHER|blended lentils|blended lentils burritto breakfast
214536193|NCT02110511|OTHER|whole lentils|whole lentils breakfast burritto
214536194|NCT02110511|OTHER|no lentils|No lentils control breakfast burritto
214536195|NCT03436030|OTHER|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
214536196|NCT01476124|DRUG|morphine Placebo|Morphine Placebo
214536197|NCT01476124|DRUG|GEn 600 mg|Gabapentin enacarbil 600 mg
214696550|NCT06400563|DEVICE|MRg-NIRS|The trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
215155195|NCT05842174|DRUG|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
215155196|NCT05842174|DRUG|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
214536198|NCT01476124|DRUG|Morphine|morphine extended release 60 mg
214536199|NCT01476124|DRUG|GEn Placebo|Gabapentin enacarbil placebo
214536200|NCT02234635|OTHER|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
214536201|NCT02568878|DRUG|Creatine monohydrate|
214536202|NCT00402584|DRUG|sibutramine|
214536203|NCT00802438|BIOLOGICAL|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
214536204|NCT00245440|DRUG|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
214536205|NCT00245440|DRUG|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
214536206|NCT02833623|BEHAVIORAL|Short-message-based Re-education|
214536207|NCT02833623|BEHAVIORAL|conventional education|
214536208|NCT03705364|OTHER|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
214536209|NCT04016805|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion"
214536210|NCT04016805|DRUG|Umbralisib|"* Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis"
214536211|NCT04016805|DRUG|Ibrutinib|"* Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis"
214536212|NCT04016805|DRUG|Venetoclax|"* BCL-2 inhibitor~* Tablet form, to be taken orally"
214536213|NCT04016805|DRUG|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
214536214|NCT03175198|DRUG|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
214536215|NCT06308185|OTHER|observational study|Observational retrospective study on infants with neonatal seizures
214536216|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
214536217|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
214536218|NCT01512914|DRUG|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
214536219|NCT01512914|DRUG|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
214536220|NCT03903523|DEVICE|Lumen apposing metal stent (LAMS)|Stent positioning
214536221|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
214536222|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
214536223|NCT01540903|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
214536224|NCT01540903|BIOLOGICAL|Saline|Saline
214536225|NCT00302497|DRUG|basiliximab|
214536226|NCT03722693|DEVICE|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
214536227|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
214536228|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
214536229|NCT05191836|OTHER|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
214536230|NCT03382288|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
214536231|NCT05632718|OTHER|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
214536232|NCT03367910|DRUG|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
215155199|NCT04333576|DRUG|Elagolix|Tablet:Oral
214536233|NCT06112522|DRUG|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
214536234|NCT00275145|BEHAVIORAL|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
214536235|NCT00275145|BEHAVIORAL|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
214536236|NCT00275145|BEHAVIORAL|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
214536237|NCT00275145|BEHAVIORAL|Continued Sedentary lifestyle|No changes
214536238|NCT04863638|BIOLOGICAL|3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 42
214536239|NCT04863638|BIOLOGICAL|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 111
214536240|NCT04863638|BIOLOGICAL|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 171
214536241|NCT04863638|BIOLOGICAL|2 doses of vaccine|the schedule of Day 0, 21
214536242|NCT01800578|DEVICE|monitor for depth of hypnosis|"evaluation of depth of hypnosis~\--------------------------------------------------------------------------------"
214536243|NCT01603771|OTHER|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
214536244|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
214536245|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
214536246|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
215155200|NCT04333576|DRUG|Placebo|Tablet:Oral
215155201|NCT04333576|DRUG|Combined Oral Contraceptive|Tablet:Oral
214536247|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
214536248|NCT01193218|DRUG|BI 10773|BI 10773 tablets low dose once a day
215155202|NCT06380270|DIETARY_SUPPLEMENT|Oral probiotic Streptococcus salivarius eK12|Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)
215155203|NCT06380270|OTHER|Placebo|Orally dissolving placebo tablets
215155204|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
215155205|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215155206|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
215155207|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
214463976|NCT06702722|BEHAVIORAL|Enhanced usual care|Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
214463977|NCT03206047|DRUG|Atezolizumab|Given IV
214463978|NCT03206047|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
214463979|NCT03206047|DRUG|Guadecitabine|Given SC
214463980|NCT03206047|OTHER|Laboratory Biomarker Analysis|Correlative studies
214536249|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
214536250|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
214536251|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
215155208|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
214536252|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-high dose once a day
214536253|NCT01193218|DRUG|BI 10773|BI 10773 tablets high dose once a day
214536254|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
214536255|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
214536256|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
214536257|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
214536258|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-low dose once a day
214536259|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
214536260|NCT05993520|OTHER|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
214536261|NCT02869906|OTHER|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
214536262|NCT01271023|DEVICE|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
215155209|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
215155210|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215155211|NCT04553757|OTHER|Survey Administration|Complete survey
215155212|NCT04620070|PROCEDURE|ECPR|Application of prehospital ECPR
215155213|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
215155214|NCT06847724|BIOLOGICAL|CYB704|Intravenous Infusion
214463981|NCT03206047|DRUG|Poly ICLC|Given SC
214463982|NCT05776810|DIAGNOSTIC_TEST|Diagnostic Test: Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
214463983|NCT05776810|DEVICE|Device: Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
214463984|NCT03609021|PROCEDURE|Screening Mammography|Provide bilateral mammogram
214463985|NCT03609021|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214463986|NCT04731818|BIOLOGICAL|ZB-06|ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
215155215|NCT06847724|BIOLOGICAL|Ocrevus-EU|Intravenous Infusion
215155216|NCT06847724|BIOLOGICAL|Ocrevus-US|Intravenous Infusion
214536263|NCT06350708|OTHER|Virtual reality (VR) tracheostomy educational tool|This is an unsupervised VR training packaged designed to train healthcare professionals and their students the management of the paediatric tracheostomy emergency.
214536264|NCT03290222|OTHER|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
214536265|NCT05377645|OTHER|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
214536266|NCT04773730|PROCEDURE|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
214536267|NCT04773730|PROCEDURE|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
215155217|NCT06843759|OTHER|mat pilates|Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises
215155218|NCT06843759|OTHER|reformer pilates|Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star
215155219|NCT04576104|PROCEDURE|Biopsy Procedure|Undergo biopsy
214536268|NCT04733898|OTHER|SamenSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to elicit personal interaction.
214536269|NCT04733898|OTHER|FijnSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to not elicit personal interaction.
214536270|NCT00006010|DRUG|docetaxel|
214536271|NCT00006010|DRUG|gemcitabine hydrochloride|
214536272|NCT00067093|DRUG|SanOrg34006|
214536273|NCT00067093|DRUG|LMW heparin|
214536274|NCT00067093|DRUG|Unfractionated heparin|
214536275|NCT00067093|DRUG|Vitamin K antagonist (VKA)|
214536276|NCT02790112|OTHER|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
214536277|NCT04610632|DIAGNOSTIC_TEST|home pregnancy test|use of home pregnancy test
214536278|NCT00187343|DEVICE|Breast IMRT|
214536279|NCT03811834|DRUG|Mobocertinib|Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
214536280|NCT04183244|PROCEDURE|Erector spinae block|A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
214536281|NCT04183244|PROCEDURE|Infraclavicular subomohyoid (ISO) block|Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
214536282|NCT04114097|DRUG|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
215155220|NCT04576104|DRUG|Extended Release Metformin Hydrochloride|Given PO
214536283|NCT04114097|DRUG|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
214536284|NCT01230762|DRUG|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
214536285|NCT05051215|OTHER||
214536286|NCT01913626|BEHAVIORAL|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
214536287|NCT01242371|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
214536288|NCT01242371|DIETARY_SUPPLEMENT|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
214536289|NCT04444219|OTHER|Breakfast meals|Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
214536290|NCT03183180|DIAGNOSTIC_TEST|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
215155221|NCT04576104|DRUG|Megestrol Acetate|Given PO
215155222|NCT04576104|OTHER|Questionnaire Administration|Ancillary studies
215155223|NCT06232876|DEVICE|Blinded continuous vital sign monitoring|Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
214536291|NCT02620956|OTHER|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
215155224|NCT06232876|DEVICE|Unblinded continuous vital sign monitoring|Continuous ward monitoring with vital signs available to clinicians and investigators.
215155225|NCT04077047|BEHAVIORAL|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
215155226|NCT00461370|DRUG|SRX251|
215155227|NCT05483309|DIAGNOSTIC_TEST|CT scan|Patients receive a CT scan
215155228|NCT05483309|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia
215155229|NCT03933085|BEHAVIORAL|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
215155230|NCT01917162|DEVICE|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
215155231|NCT01917162|DEVICE|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
214463987|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
214463988|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
214536292|NCT04991688|DRUG|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
214536293|NCT00166881|DRUG|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
214463989|NCT04990323|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)
214463990|NCT01705899|DRUG|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
214463991|NCT03329157|OTHER|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
214463992|NCT06277388|DEVICE|Impedance cardiography|The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).
214536294|NCT03188536|OTHER|No Intervention|As it was an observational study, no intervention was administered in this study.
214536295|NCT01108042|DRUG|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
214536296|NCT01748045|DRUG|inhaled nitric oxide|
214536297|NCT01748045|DRUG|Placebo Comparator - nitrogen gas|
214536298|NCT06201637|OTHER|Performance Test|Performance Test
214536299|NCT04311047|DIAGNOSTIC_TEST|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
214536300|NCT02885792|OTHER|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
214536301|NCT02885792|OTHER|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
214536302|NCT02885792|OTHER|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
214536303|NCT02885792|PROCEDURE|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
214536304|NCT02550912|DRUG|Vitamin D3|vitamin D drops for paediatrics
214536305|NCT02550912|OTHER|Placebo|glucose syrup with same taste and color to vitamin D3 drops
214536306|NCT04947436|DEVICE|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
214536307|NCT04947436|DEVICE|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
214536308|NCT04869150|PROCEDURE|radial access coronary angiography|The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
215155232|NCT04336501|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
214536309|NCT00673127|DRUG|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
214536310|NCT02548676|DEVICE|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
214696551|NCT03524105|BEHAVIORAL|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
214696552|NCT03524105|BEHAVIORAL|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
214696553|NCT04358042|OTHER|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
214696554|NCT04358042|OTHER|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
214696555|NCT04358042|OTHER|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
214696556|NCT04358042|OTHER|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
215155233|NCT03617198|BIOLOGICAL|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
215155234|NCT05350774|DRUG|IV normal saline|IV normal saline 250ml for 5 days
215155235|NCT05350774|DRUG|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
215155236|NCT05782179|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
214536311|NCT03779321|OTHER|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
214536312|NCT03719378|OTHER|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
214536313|NCT00359385|DRUG|Alendronate 70mg weekly|70mg weekly
214536314|NCT00169949|DRUG|aripiprazole|
214536315|NCT02681445|DEVICE|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
214536316|NCT02161185|DRUG|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
214536317|NCT06646380|BEHAVIORAL|Multicomponent Training|The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
214696557|NCT06441812|DRUG|SHR-1703 Injection|SHR-1703 Injection
214696558|NCT05256875|OTHER|chemical adherence test, medication adherence questionnaire, pharmacy refill rate|Urine/blood samples will be collected from participants, also they will be asked to complete a medication adherence questionnaire, medication records will also be examined to determine the pharmacy refill rate.
215155237|NCT05782179|BIOLOGICAL|Placebo|Normal Saline 0.9 %
215155238|NCT06580951|PROCEDURE|Regenerative Peripheral Nerve Interface|The RPNI portion of the case will consist of blunt dissection of the cut sensory branches of the intercostal nerves at the T3 and/or T4 levels, with creation of a peripheral nerve interface using a small cuff of dissected pectoralis muscle and 3-0 Monocryl suture. The breast reconstruction will otherwise be performed as per standard protocol.
215155239|NCT06510686|OTHER|İnspiratory muscle training|exercises to strengthen inspiratory muscles
215155240|NCT06510686|OTHER|Core training|exercises to strengthen inspiratory and core muscles
215155241|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
215155242|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time bilateral intracochlear administration using the Akouos Delivery Device.
215155243|NCT01731561|DRUG|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
215155244|NCT01731561|DRUG|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
215155245|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
215155246|NCT04894006|BEHAVIORAL|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
214463993|NCT05347446|PROCEDURE|Hybrid ESD|Method of removing colon lesion
214463994|NCT05347446|PROCEDURE|Non-hybrid ESD|Method of removing colon lesion
214463995|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
214463996|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
214463997|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
214536318|NCT06646380|OTHER|Maintenance|Participants were instructed to maintain daily life activities regarding physical activity.
214536319|NCT06647329|BIOLOGICAL|CAR-T Therapy|CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
214536320|NCT04655014|OTHER|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
214696559|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
214696560|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
214696561|NCT05289804|DEVICE|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
214696562|NCT05289804|DRUG|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
215155247|NCT04894006|BEHAVIORAL|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
215155248|NCT04894006|BEHAVIORAL|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
215155249|NCT05963438|PROCEDURE|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
215155250|NCT06640023|BEHAVIORAL|Z-drug Default Quantity|For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
214463998|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
214463999|NCT05433298|BIOLOGICAL|Mesenchymal stem cell|Administration of advanced cell product
214464000|NCT05433298|OTHER|Placebo|Ringer's lactate, albumin and heparin solution
214464002|NCT06581094|DIETARY_SUPPLEMENT|UCII, glucosamine and curcumin|compound capsules twice daily.
214464003|NCT06581094|DIETARY_SUPPLEMENT|Placebo|Placebo capsules twice daily.
214464004|NCT06611319|DRUG|Prevention of Venous Thromboembolism|Direct oral anticoagulant
214464005|NCT06611319|DRUG|Placebo Oral Tablet|Placebo
214464006|NCT04269200|DRUG|olaparib|Olaparib tablets
214464007|NCT04269200|BIOLOGICAL|durvalumab|Durvalumab by intravenous infusion
214464008|NCT04269200|DRUG|durvalumab placebo|Matching placebo for intravenous infusion
214464009|NCT04269200|DRUG|olaparib placebo|Placebo tablets to match olaparib
214464010|NCT04269200|DRUG|Carboplatin|Standard of care chemotherapy
214464011|NCT04269200|DRUG|Paclitaxel|Standard of care chemotherapy
214464012|NCT06512805|BEHAVIORAL|Routine transport|"1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record."
214464013|NCT06512805|BEHAVIORAL|Post-guideline transfer|"In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0."
214464014|NCT01856478|DRUG|methotrexate|intravenous bolus injection, once weekly
214464015|NCT01856478|DRUG|afatinib|oral intake, once daily
214464016|NCT06827197|DIAGNOSTIC_TEST|Blood test|Blood samples were withdrawn from all the neonates under strict aseptic conditions and stored at -80°C for detecting PGE2 and IL-1β levels. PGE2 and IL-1β concentrations were measured using ELISA.
214464017|NCT04610294|DEVICE|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
215155251|NCT06640023|BEHAVIORAL|Redirection + Accountable Justification|"For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the Encounter Report.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display."
215155252|NCT03255174|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
215155253|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
215155254|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
215155255|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
215155256|NCT04023019|BIOLOGICAL|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
215155257|NCT04023019|BIOLOGICAL|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
215155258|NCT04023019|BIOLOGICAL|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
214464018|NCT04610294|DEVICE|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
214464019|NCT06524492|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
214464020|NCT03064529|BEHAVIORAL|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
214464021|NCT06853262|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
214464022|NCT06853262|OTHER|Sham Manual Protocol|The Sham techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The Sham techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
214464023|NCT06851026|OTHER|Pilates Exercise|Pilates exercises were applied for 8 weeks
214464024|NCT06852001|DEVICE|X-ray stereotactic radiotherapy for brain metastasis|X-ray stereotactic radiotherapy for brain metastasis
214464025|NCT05497440|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
214464026|NCT04430725|PROCEDURE|Computed Tomography with Contrast|Undergo contrast-enhanced CT
214464027|NCT04430725|PROCEDURE|Microwave Ablation|Undergo microwave ablation
214464028|NCT04430725|OTHER|Questionnaire Administration|Ancillary studies
214464029|NCT04430725|PROCEDURE|Wedge Excision|Undergo wedge resection
214464030|NCT06838780|OTHER|No intervention|No intervention for this retrospective study
214464031|NCT02151981|DRUG|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
214696563|NCT05289804|DEVICE|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
214696564|NCT05289804|DEVICE|Sham NITESGON|Sham NITESGON
214696565|NCT00252122|DRUG|Ketamine|Ketamine. 0.2 mg/kg, intravenously
215155259|NCT04023019|BIOLOGICAL|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
215155260|NCT04023019|BIOLOGICAL|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
215155261|NCT04023019|BIOLOGICAL|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
215155262|NCT04339036|DRUG|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
215155263|NCT04339036|DRUG|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
215155264|NCT04339036|COMBINATION_PRODUCT|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
215155265|NCT01854450|OTHER|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
215155266|NCT01854450|OTHER|control|usual obstetrical care
215155267|NCT06137365|DRUG|Cannabis|Cannabis gummy product will be prepared using cannabis flower extract.
215155268|NCT06137365|DRUG|Placebo|Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
215155269|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
215155270|NCT03208296|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
214536321|NCT05153642|PROCEDURE|Microsurgical intervention|The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
214536322|NCT03389997|DIAGNOSTIC_TEST|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
214536323|NCT00372255|BIOLOGICAL|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
214536324|NCT02661503|DRUG|Bleomycin|
215155271|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
215155272|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
215155273|NCT03810651|OTHER|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
214536325|NCT02661503|DRUG|Etoposide|
214536326|NCT02661503|DRUG|Doxorubicin|
214536327|NCT02661503|DRUG|Cyclophosphamide|
214536328|NCT02661503|DRUG|Vincristine|
214536329|NCT02661503|DRUG|Procarbazine|
214536330|NCT02661503|DRUG|Prednisone|
214536331|NCT02661503|DRUG|Brentuximab Vedotin|
215155274|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
214536332|NCT02661503|DRUG|Dacarbazine|
214536333|NCT02661503|DRUG|Dexamethasone|
214536334|NCT04461314|BEHAVIORAL|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
214536335|NCT00086021|PROCEDURE|Acupuncture|
214464032|NCT02151981|DRUG|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
214464033|NCT06842212|DEVICE|Balance Training|balance training exercises performed on the biodex balance system 3 sessions every week for 12 weeks
214536336|NCT04602039|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (Neovite)
214536337|NCT04248036|BEHAVIORAL|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
214536338|NCT00107081|DRUG|ciprofloxacin and amoxicillin|
214536339|NCT00107081|PROCEDURE|Outpatient management|
214536340|NCT00107081|DRUG|i.v. antibiotics|
214536341|NCT00107081|PROCEDURE|inpatient management|
214536342|NCT03987464|BEHAVIORAL|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
214536343|NCT03987464|BEHAVIORAL|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
214536344|NCT03987464|BEHAVIORAL|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
214536345|NCT03987464|BEHAVIORAL|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
214536346|NCT03987464|BEHAVIORAL|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
214536347|NCT01940783|RADIATION|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
214536348|NCT01940783|DEVICE|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
214536349|NCT00944892|DRUG|REGN475|2 Administrations of REGN475 within 24 weeks.
214536350|NCT00944892|OTHER|Placebo|Placebo to match REGN475 doses
214536351|NCT00131547|BEHAVIORAL|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
214536352|NCT03752489|DIAGNOSTIC_TEST|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
214536353|NCT03752489|DIAGNOSTIC_TEST|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
214536354|NCT01692132|DRUG|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
214536355|NCT02149732|BIOLOGICAL|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
214536356|NCT04012099|DRUG|BMT101|Intradermal injection to each of 3 dose-groups.
214536357|NCT05499143|OTHER|Online questionnaire|Online questionnaire impact for DCD - Belgian version
214536358|NCT05930002|DRUG|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
214536359|NCT05930002|DRUG|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
214536360|NCT05930002|DRUG|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
214696566|NCT05986643|BEHAVIORAL|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
214536361|NCT05211453|PROCEDURE|atrioventricular node ablation|atrioventricular node ablation
214536362|NCT00281502|DRUG|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
214536363|NCT02341599|DRUG|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
215155275|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
215155276|NCT05180383|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
214464034|NCT06335823|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
214464035|NCT06335823|DEVICE|Placebo Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
214464036|NCT03850418|DRUG|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
214464037|NCT04737941|PROCEDURE|Endothermal Ablation|Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
214464038|NCT04737941|PROCEDURE|Foam Sclerotherapy|Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
214464039|NCT05759637|DIAGNOSTIC_TEST|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
214464040|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
214464041|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
214464042|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
214464043|NCT01946789|BIOLOGICAL|ALT-803|N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.
214464044|NCT04935359|DRUG|NIS793|Concentrate for solution infusion (Liquid in Vial)
214464045|NCT04935359|DRUG|Nab-paclitaxel|Per locally approved formulation
214464046|NCT04935359|DRUG|Gemcitabine|Per locally approved formulation
214464047|NCT04935359|DRUG|Placebo|Dextrose 5% in water (D5W) solution for infusion
214464048|NCT05997030|DEVICE|low intensity focused ultrasound (LIFU)|Subjects will undergo undergo a single LIFU of the target brain region
214464049|NCT04703179|OTHER|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
214464050|NCT04748601|DRUG|Qudexy XR|Extended-Release Capsule
214464051|NCT04748601|DRUG|Placebo|Qudexy XR Matching capsules
214464052|NCT06489405|OTHER|Horticultural practices|The first week of the program was 'Getting to know horticultural practices', the second week was 'Painting pots', the third week was 'Planting vegetable seedlings', the fourth week was 'Preparing compost', the fifth week was 'Making pressed flowers' and the sixth week was 'Harvesting vegetables'.
214464053|NCT05374798|DEVICE|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
214464054|NCT06833944|OTHER|HIIT intervention program|"The HIIT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 36 minutes). The program will be divided into two phases: phase 1 (adaptation to HIIT training: during the first 4 weeks, the intensity will be progressively increased to ensure the safety and progressive physical conditioning of the patients.~The high-intensity intervals will follow the Norwegian 4 x 4-minute HIIT model: 4 bouts of 4 minutes of high intensity corresponding to a rating of perceived exertion (RPE) 15 to 18 on the Borg 6 to 20 Scale33 and an 85-95%HRmax, interspersed with 3-minute active recovery intervals (RPE of 11 to 13 and 54-69%HRmax). This protocol has been widely applied and is safe in general and in clinical populations. Additionally, this protocol includes the training parameters recently proposed in a recent meta-analysis to maximize the training effects of HIIT on cardiorespiratory fitness (primary outcome)."
214696567|NCT05986643|BEHAVIORAL|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
214696568|NCT04960345|DEVICE|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
214696569|NCT03674203|BIOLOGICAL|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
214696570|NCT01474746|DRUG|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
214696571|NCT01474746|DRUG|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
214696572|NCT00400829|DRUG|eribulin mesylate|Given IV
214696573|NCT02742922|BEHAVIORAL|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
214696574|NCT00396708|DEVICE|myomo e100 neurorobotic elbow brace|
214696575|NCT01766336|DRUG|Group 1 ELND005|
214696576|NCT01766336|DRUG|Group 2 ELND005|
214696577|NCT00901537|DRUG|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
214696578|NCT02605447|DRUG|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
214696579|NCT02605447|DEVICE|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
214696580|NCT02958397|BIOLOGICAL|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214696581|NCT00039195|BIOLOGICAL|filgrastim|
214696582|NCT00039195|BIOLOGICAL|rituximab|
214696583|NCT00039195|DRUG|carboplatin|
214696584|NCT00039195|DRUG|cyclophosphamide|
214696585|NCT00039195|DRUG|doxorubicin hydrochloride|
214696586|NCT00039195|DRUG|etoposide|
214696587|NCT00039195|DRUG|ifosfamide|
214696588|NCT00039195|DRUG|prednisone|
214696589|NCT00039195|DRUG|vincristine sulfate|
214696590|NCT00039195|PROCEDURE|peripheral blood stem cell transplantation|
214696591|NCT00039195|RADIATION|radiation therapy|
214696592|NCT02110121|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
214696593|NCT02110121|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
214696594|NCT06108869|OTHER|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis"
214696595|NCT06108869|OTHER|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
214696596|NCT04308512|DEVICE|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
214696597|NCT02303951|DRUG|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
215155277|NCT06440421|BEHAVIORAL|MTL Labels|The MTL label developed by the United Kingdom (UK) Food Standards Agency (FSA) includes per serving size information and grades each nutrient i.e., energy, sugar, fat, saturated fat, and sodium separately based on recommended thresholds. Green signifies a healthy amount of that nutrient; red signifies an unhealthy amount, and amber signifies that the nutrient levels fall between healthy and unhealthy amounts. Additionally, the label also shows how much of a person's daily allowance for a particular nutrient is met by consuming one serving of the product. Lastly, MTL includes the absolute values of each nutrient per serving of a product and the percentage of an adult's daily reference intake that is met by consuming a serving of this product. These will be displayed on all food and beverage products shown on this version of Bahrain e-Mart.
215155278|NCT05202756|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
214464055|NCT06833944|OTHER|MICT intervention program|"The MICT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 44 minutes). The workout will be performed at RPE 11 to 13 (54-69%HRmax) to provide an isoenergetic workload (same energy expenditure) as the HIIT group.~Each session will include 3 parts: warm-up (5 min), main MICT workout (34 min), and a cool-down (5 min). Warm-up will include mobility, core, and aerobic exercise involving major muscle groups. The main workout (MICT) will include exercises involving major muscle groups using the same materials and rationale as commented on in the HIIT group. The cool-down phase will include aerobic exercise at a lower intensity, stretching, and relaxation exercises (RPE\<11). The highest and average HR and RPE for each session will be registered."
214464056|NCT06840613|OTHER|Myo-Inositol|"Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment"
214464057|NCT06840613|OTHER|Glucophage|"Intervention: Patients in this group will receive 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment."
214464058|NCT06833424|PROCEDURE|Dural venous sinus stenting|40 patients with idiopathic intracranial hypertension according to Modified Dandy Criteria will subjected to Dural venous stenting
214536364|NCT00264823|BEHAVIORAL|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
214536365|NCT02360813|BEHAVIORAL|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
214536366|NCT02360813|OTHER|Treatment as usual|Keep getting usual care.
214536367|NCT02638233|DRUG|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
214536368|NCT05925062|BEHAVIORAL|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
214536369|NCT01540812|DRUG|Vincristine in induction|
214536370|NCT01540812|DRUG|Daunorubicin in induction|
214536371|NCT01540812|DRUG|Prednisone in induction|
214536372|NCT01540812|DRUG|Metotrexato in induction|
214536373|NCT01540812|DRUG|Cytarabine in induction|
214536374|NCT01540812|DRUG|Hydrocortisone in induction|
214536375|NCT01540812|DRUG|Idarubicin in induction-2|
214696598|NCT02303951|DRUG|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
214696599|NCT02303951|DRUG|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
214696600|NCT00944606|DIETARY_SUPPLEMENT|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
214696601|NCT00944606|OTHER|Placebo candy|candy gum drops
214536376|NCT01540812|DRUG|Fludarabine in induction-2|
214536377|NCT01540812|DRUG|Ara-C in induction-2|
214536378|NCT01540812|DRUG|G-CSF in induction-2|
214536379|NCT01540812|DRUG|Dexamethasone in consolidation-1|
214536380|NCT01540812|DRUG|Vincristrine in consolidation-1|
214536381|NCT01540812|DRUG|Metotrexato in consolidation-1|
214536382|NCT01540812|DRUG|PEG-ASP in consolidation-1|
214536383|NCT01540812|DRUG|Dexamethasone in consolidation-2|
214536384|NCT01540812|DRUG|ARA-C in consolidation-2|
214536385|NCT01540812|DRUG|PEG-ASP in consolidation-2|
214536386|NCT01540812|DRUG|Dexamethasone in consolidation-3|
214536387|NCT01540812|DRUG|Vincristine in consolidation-3|
214536388|NCT01540812|DRUG|Metotrexato in consolidation-3|
214696602|NCT03979105|DRUG|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
214696603|NCT01425073|OTHER|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
214536389|NCT01540812|DRUG|PEG-ASP in consolidation-3|
214536390|NCT01540812|PROCEDURE|allogeneic HSCT|
214536391|NCT01540812|PROCEDURE|Allo HSCT with reduced-intensity conditioning|
214536392|NCT04777097|OTHER|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
214536393|NCT05727488|OTHER|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
214536394|NCT04885426|DRUG|low-dose metformin|Metformin Pill 250mg/day
214536395|NCT04885426|DRUG|high-dose metformin|Metformin Pill 500mg/day
214536396|NCT04885426|DRUG|Placebo|Placebo
214536397|NCT05207631|OTHER|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
214536398|NCT05640973|OTHER|Evaluation|Evaluation of ease of use
214536399|NCT05300997|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
214536400|NCT00246610|DRUG|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
214536401|NCT06252090|OTHER|Short term mentalization-based treatment for adolescents (MBT-A)|The general framework of intervention corresponds to the Mentalization-Based Treatment model for adolescents (MBT-A). In this study, the model was adapted to a brief, time-limited format (12 sessions) aimed at both the adolescent and their family. The model retains the main characteristics of Mentalization-Based Therapy, such as the therapist's basic attitude toward actively promoting patients' mentalization, uncertainty of mental states, focus on the here and now, and the use of affect as a mechanism for change.
214536402|NCT00961610|BEHAVIORAL|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
214536403|NCT01215032|DRUG|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
214536404|NCT03021278|OTHER|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
214536405|NCT03021278|OTHER|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
214536406|NCT04158973|OTHER|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
214536407|NCT04158973|OTHER|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
214536408|NCT00456417|DRUG|123-I MNI-187 Injection and Imaging Procedures|
214536409|NCT03002922|DRUG|BAY987517|Sunscreen formula Y65-158
214536410|NCT00686088|DRUG|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
214536411|NCT04915547|OTHER|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
214536412|NCT03420898|OTHER|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
214536413|NCT03156205|BEHAVIORAL|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
215155279|NCT05202756|BEHAVIORAL|EMA Monitoring Only|Safety Planning Intervention; ecological momentary assessment only
215155280|NCT05335915|OTHER|Nicotine|Nicotine pouches will be self-administered
215155281|NCT05335915|OTHER|Cigarette|Cigarette will be smoked
215155282|NCT03603353|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
215155283|NCT03603353|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
215155284|NCT03675321|DEVICE|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
215155285|NCT03675321|DEVICE|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
215155286|NCT00936286|DEVICE|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
215155287|NCT00910416|DRUG|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
215155288|NCT00910416|DRUG|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
215155289|NCT00910416|DEVICE|EEG monitoring|simultaneous monitoring with Bis and Neurosense
215155290|NCT04422158|DIETARY_SUPPLEMENT|Nuun electrolyte tablet|Each table contains 2 grams of carbohydrate and a combination of electrolytes. calcium (13mg, 1%DV), sodium (300mg, 13%DV), potassium (150mg, 3%DV), magnesium (25mg, 6%DV), and chloride (40mg, 2%DV).
215155291|NCT04422158|OTHER|water|water
215155292|NCT04284228|BIOLOGICAL|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
215155293|NCT04442802|PROCEDURE|Percutaneous transluminal angioplasty|Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
215155294|NCT05095948|PROCEDURE|Discussion|Undergo audio recording of clinic conversations
215155295|NCT05095948|OTHER|Electronic Health Record Review|Review of medical records
215155296|NCT05095948|OTHER|Questionnaire Administration|Complete questionnaires
215155297|NCT00825487|DRUG|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
215155298|NCT00343460|DRUG|APF530|Given subcutanously
215155299|NCT00343460|DRUG|dexamethasone|Given IV and orally
215155300|NCT00343460|DRUG|Palonosetron Hydrochloride|Given IV
215155301|NCT00343460|OTHER|placebo|Given subcutanously or IV
215155302|NCT05853991|OTHER|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
215155303|NCT05853991|OTHER|Active comparator|Application of affective touch
215155304|NCT05853991|OTHER|Placebo|Application of static touch
215155305|NCT05938400|DEVICE|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
215155306|NCT01318460|DRUG|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
215155307|NCT01318460|DRUG|Placebo infusion|Twenty-four hour administration of placebo
214536414|NCT03156205|BEHAVIORAL|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
214464059|NCT06820138|DEVICE|Brainsonix Ultrasound Device|This device delivers low intensity focused ultrasound and delivers either active or sham sonication depending upon the transducer pad used.
214464060|NCT06837896|DRUG|QLG1080|Oral administration
214464061|NCT02188264|DRUG|Cyclosporine|Given PO
214464062|NCT02188264|OTHER|Laboratory Biomarker Analysis|Correlative studies
214464063|NCT02188264|OTHER|Pharmacological Study|Correlative studies
214464064|NCT02188264|DRUG|Selumetinib|Given PO
214536415|NCT03156205|BEHAVIORAL|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
214536416|NCT05750277|OTHER|Evening Time-Restricted Eating|Eating between 8am-6pm.
214536417|NCT01818609|BEHAVIORAL|Step reduction|taking less than 1500 steps/d
215155308|NCT06457750|BEHAVIORAL|Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application|Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
215155309|NCT00006340|DRUG|arginine butyrate|
215155310|NCT00006340|DRUG|ganciclovir|
215155311|NCT01397214|DRUG|Megace F|Megace F oral suspension
215155312|NCT01397214|DRUG|Megace OS|Megace oral suspension
215155313|NCT04073108|DIAGNOSTIC_TEST|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
215155314|NCT06138496|DRUG|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
215155315|NCT02549365|DRUG|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
215155316|NCT02549365|PROCEDURE|Surveillance (nasal swabbing) during influenza season|
214464065|NCT03683277|DRUG|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
214464066|NCT06839729|BEHAVIORAL|CEASE+|The intervention will be delivered by the clinician to smoking parents who attend the office visit and to smoking parents not present at the visit via resources sent home with a non-smoking parent. If the smoking parent is present in clinic, the intervention consists of a brief, clinician- delivered motivational intervention that includes messaging around the risks of household smoking, verbal recommendation for establishing home/car smoke-free rules, a printed prescription for nicotine replacement therapy and quitline information, and messaging on the benefits of cessation and a quitline referral. If the smoking parent is not present in clinic, the intervention will include clinician-delivered messaging to the non-smoking parent to share CEASE+ resources with the parent who smokes and an invitation for the parent who smokes to participate in a single call delivered by a culturally-/linguistically-congruent community health worker to connect them to CEASE+ resources.
214464067|NCT06840964|DIETARY_SUPPLEMENT|omega 3 ethyl esters at 90%|2 grams/day of omega 3 capsules will be administered orally, for 12 weeks
214464068|NCT06840964|DIETARY_SUPPLEMENT|Placebo|Mygliol 812
214464069|NCT06840561|DRUG|Local triamcinolone injection combined with fibrin glue spray|TA injection and fibrin glue spray are used in two sessions after ESD immediately (D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity is diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points (0.5ml/point) depending on the defective area. But TA injection should avoid muscular injury place. We check the wound to make sure there is no bleeding or perforation after the TA injection, then spray 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage is depending on the wound area. The key point is that the glue could cover all the injection wound. Seven days later, the protocol is carried out again.
214464070|NCT03502590|DEVICE|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
214464071|NCT05951725|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214464072|NCT05951725|BIOLOGICAL|Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214464073|NCT05951725|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214464074|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214464075|NCT05951725|BIOLOGICAL|DTaP-IPV-Hib|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214464076|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
214696604|NCT04544709|DRUG|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
214696605|NCT05475821|DRUG|ABBV-990|Oral Tablet
214696606|NCT05475821|DRUG|Placebo for ABBV-990|Oral Tablet
214696607|NCT04482491|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
215155317|NCT02718144|DRUG|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
214696608|NCT01503073|DEVICE|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
214696609|NCT04382859|PROCEDURE|Transversus abdominis plane (TAP) block with liposomal bupivacaine|Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
214696610|NCT03628508|OTHER|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
215155318|NCT04315740|OTHER|Particles from candles|Generating fine and ultrafine particles from lit candles
215155319|NCT04315740|OTHER|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
215155320|NCT04315740|OTHER|Clean Air|Nothing but clean air
215155321|NCT02614599|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
215155322|NCT02614599|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
215155323|NCT00194506|BEHAVIORAL|Internet co-management module|
215155324|NCT04366817|BEHAVIORAL|psychological assessment|psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
215155325|NCT02865213|DEVICE|OBA|"The intrusion of posterior teeth using removable appliance OBA."
215155326|NCT02865213|DEVICE|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
214464077|NCT05887401|BEHAVIORAL|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
214464078|NCT05887401|BEHAVIORAL|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
214696611|NCT02172079|OTHER|Real mobilization-with-movement (MWM)|
215155327|NCT02865213|DEVICE|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
215155328|NCT01153334|DRUG|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1\. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
215155329|NCT06511141|DEVICE|Axonics SNM System|To assess clinical outcomes of the Axonics SNM System in the male OAB population.
215155330|NCT02999672|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
215155331|NCT03565497|BEHAVIORAL|Wellness Education Control Condition|As per arm of the same name
215155332|NCT03565497|BEHAVIORAL|Mindfulness Training|As per arm of the same name
215155333|NCT03565497|BEHAVIORAL|Mindfulness Training Plus IE|As per arm of the same name
214464079|NCT05887401|BEHAVIORAL|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
215155334|NCT06684704|OTHER|minimal and high flow anesthesia|Low-flow anesthesia technique is a technique based on the re-breathing of at least half of the gas exhaled in semi-closed systems by returning at least half of the exhaled gas to the patient in the next inspiration.
214464080|NCT05887401|BEHAVIORAL|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
214464081|NCT05887401|BEHAVIORAL|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
214464082|NCT05887401|BEHAVIORAL|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
214464083|NCT05887401|BEHAVIORAL|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
214464084|NCT05887401|BEHAVIORAL|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
214464085|NCT05887401|BEHAVIORAL|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
214464086|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
214464087|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
214464088|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
214464089|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
214464090|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
214464091|NCT00194285|PROCEDURE|FDG-PET Imaging|
215155335|NCT04765891|OTHER|Positional release therapy|Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
215155336|NCT04765891|OTHER|Therapeutic Massage|Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
214536418|NCT05188898|OTHER|MINSD and Hyaluronic acid|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.
214536419|NCT05188898|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
214536420|NCT04631588|DRUG|Botox|Intradermal (ID) injection
214536421|NCT04631588|DRUG|Placebo|Intradermal (ID) injection
214536422|NCT06180863|DRUG|oral azacitidine (CC-486)|Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
214536423|NCT02643511|RADIATION|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
214536424|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
214536425|NCT00640198|BEHAVIORAL|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
214536426|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
214536427|NCT00640198|DRUG|placebo|Placebo
214536428|NCT05934656|OTHER|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
214536429|NCT02924558|OTHER|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
214536430|NCT02924558|OTHER|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
214536431|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
214536432|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
214536433|NCT01474421|DRUG|Placebo|Patients will receive placebo once daily orally for 28 days.
214536434|NCT00949221|DEVICE|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"* group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
214536435|NCT00357318|DRUG|sunitinib malate|Given PO
214536436|NCT00357318|BIOLOGICAL|bevacizumab|Given IV
214536437|NCT00357318|OTHER|pharmacological study|Correlative studies
214536438|NCT00357318|OTHER|laboratory biomarker analysis|Correlative studies
214536439|NCT03524950|DRUG|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
214536440|NCT04270656|PROCEDURE|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
214536441|NCT04270656|PROCEDURE|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
214696612|NCT02172079|OTHER|Sham mobilization-with-movement (MWM)|
214696613|NCT02045212|DRUG|RPh201|SC injection twice a week during 13/26 weeks
214696614|NCT02045212|DRUG|Placebo|SC injection twice a week during 13/26 weeks
214696615|NCT04591795|DRUG|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
214696616|NCT04591795|DRUG|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
214696617|NCT00145249|DRUG|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
215155337|NCT03731676|DEVICE|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
215155338|NCT03731676|DEVICE|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
215155339|NCT03103334|OTHER|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
215155340|NCT03103334|DRUG|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
215155341|NCT00531661|DEVICE|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
215155342|NCT03516630|DRUG|Trazodone 20 mg|Oral drops
215155343|NCT03516630|DRUG|Trazodone 60 mg|Oral drops
215155344|NCT03516630|DRUG|Trazodone 140 mg|Oral drops
215155345|NCT03516630|DRUG|Placebo|Oral drops
215155346|NCT03516630|DRUG|Moxifloxacin 400mg|Tablet
215155347|NCT01814267|OTHER|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed"
215155348|NCT01814267|OTHER|conventional|"conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed"
215155349|NCT02812862|DRUG|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
215155350|NCT02633709|DRUG|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
215155351|NCT02633709|OTHER|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
215155352|NCT02633709|DRUG|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
215155353|NCT05860309|OTHER|quadratous lumborum block|The patient will be placed in the lateral position, after sterilization.. QLB will be done using ultrasound, The probe will be positioned superior to the iliac crest, in the transverse orientation, at the posterior axillary line. The Shamrock sign will be identified at the L4 level, and the insulated nerve block needle will be advanced from posterior to anterior, through the QL muscle, until the needle tip is visualized in the interfascial plane between the QL muscle and psoas muscle. As the correct needle placement is confirmed with 2-3 mL of saline, 20 mL of 0.25% bupivacaine will be injected ensuring that the psoas muscle will be pushed deeply.
215155354|NCT01347619|OTHER|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
215155355|NCT01347619|OTHER|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
215155356|NCT01347619|OTHER|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
215155357|NCT00586417|OTHER|punch biopsy|skin biopsies
214464092|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
214464093|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
214464094|NCT05576155|DRUG|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
214464095|NCT05576155|DRUG|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
214464096|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
214464097|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
214464098|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
215155358|NCT04693624|OTHER|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
215155359|NCT04301505|OTHER|Intervention 1|Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
215155360|NCT04301505|OTHER|Intervention 2|The same checklist will be delivered at the beginning of the study and repeated after 6 months.
215155361|NCT02194985|DRUG|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
215155362|NCT00018083|DRUG|rifabutin|
215155363|NCT00018083|DRUG|isoniazid|
214696618|NCT00145249|DRUG|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
214696619|NCT00403858|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
214696620|NCT00403858|DRUG|Lactulose|
214536445|NCT06009445|DIAGNOSTIC_TEST|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity \_ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
215155364|NCT00018083|DRUG|efavirenz|
214536446|NCT06197113|DEVICE|Magstim Rapid2 Magnetic Stimulator|For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
214536447|NCT00269841|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
214536448|NCT00269841|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
214536449|NCT00269841|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
214536450|NCT01424189|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214536451|NCT01424189|DEVICE|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
214536452|NCT05201170|DRUG|Vehicle Ophthalmic Solution|Ophthalmic Solution
214536453|NCT05201170|DRUG|PL9643 Ophthalmic Solution|Ophthalmic Solution
214536454|NCT05959018|DEVICE|Arrow Three-Lumen Central Venous Catheter|Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
215155365|NCT01131689|DRUG|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
215155366|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
215155367|NCT01775618|BIOLOGICAL|BAY94-9027|Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
214536455|NCT05959018|DEVICE|Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
214536456|NCT00308399|DRUG|Itopride|
214536457|NCT00221481|DRUG|divalproex or olanzapine|
214536458|NCT04682340|DIAGNOSTIC_TEST|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
214536459|NCT05288504|DRUG|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
214536460|NCT05288504|DRUG|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
214696621|NCT04056364|BIOLOGICAL|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
214696622|NCT03224975|OTHER|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
214536461|NCT05455684|DRUG|Aticaprant|Aticaprant will be administered orally as tablets.
214536462|NCT05455684|OTHER|Placebo|Placebo will be administered orally as tablets.
214536463|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram on visit 5 single dose
214536464|NCT01257048|DRUG|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
214536465|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
214536466|NCT05317299|OTHER|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
214536467|NCT03910296|BEHAVIORAL|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
214696623|NCT03188679|DEVICE|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
215155368|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
215155369|NCT02561832|DRUG|Olaparib|tablets taken orally twice daily
215155370|NCT02561832|DRUG|Carboplatin|intravenous injections on day one of each cycle
215155371|NCT02561832|DRUG|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
215155372|NCT02561832|DRUG|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
215155373|NCT05635253|OTHER|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
215155374|NCT05635253|OTHER|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
215155375|NCT02280343|OTHER|evaluated lung function|lung function tests
215155376|NCT03077841|OTHER|Laboratory Biomarker Analysis|Correlative studies
215155377|NCT03077841|RADIATION|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
215155378|NCT03077841|OTHER|Questionnaire Administration|Ancillary studies
215155379|NCT06480084|DIAGNOSTIC_TEST|Continuous Laryngoscopy during Exercise Test (CLE test)|A flexible fiberoptic laryngoscope (Olympus, Tokyo, Japan) is introduced directly through the nose or via a slightly modified Hans Rudolph facemask, and into the pharyngeal space. A modified Bruce protocol with a 60-second incremental intensity step is used (Appendix A) and heart rate is monitored. During the CLE test participants perform incremental exercise on a treadmill until symptom-limiting distress or exhaustion. Forced expiratory flow-volume loops are measured before, during and after the CLE test.
215155380|NCT04103749|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
215155381|NCT02615639|BIOLOGICAL|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
215155382|NCT02615639|DRUG|Entecavir|0.5mg tablet every night by mouth
215155383|NCT02615639|DRUG|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
215155384|NCT02615639|DRUG|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
215155385|NCT02615639|DRUG|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
215155386|NCT02615639|DRUG|Telbivudine|Telbivudine 600mg tablet every day by mouth
214696624|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
214696625|NCT03005977|PROCEDURE|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
214696626|NCT02512692|DEVICE|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
215155387|NCT01070485|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
215155388|NCT03284580|OTHER|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
215155389|NCT03284580|OTHER|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
214464099|NCT03210311|DEVICE|compression|a compression stocking is worn, a garment compression class 2, flat knitted
214464100|NCT05690711|DRUG|HRS8179|HRS8179 injection
214464101|NCT05690711|DRUG|Placebo|physiological saline
214464102|NCT05922722|OTHER|Decision-making tool|The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
214464103|NCT05922722|OTHER|Questionnaire|Questionnaire to assess participant's understanding of the decision-making tool
214464104|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
214464105|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
214464106|NCT06278350|DRUG|D-2570|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
214464107|NCT06278350|DRUG|Placebo|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
214464108|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
214464109|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
214464110|NCT04078191|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214464111|NCT06540456|DRUG|Qutenza® 8% Capsaicin Topical System|Treatment of patients with neuropathic LBP and painful lumbosacral radiculopathy using the Qutenza 8% capsaicin topical system.
214464112|NCT03478215|BIOLOGICAL|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
214464113|NCT03478215|OTHER|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
214464114|NCT06781268|BEHAVIORAL|Life Kinetic Training|Combination of cognitive and physical exercises aimed at improving neuroplasticity, agility, balance, and cognitive functions.
214464115|NCT04032041|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
214464116|NCT04032041|DEVICE|Caliper|Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.
214464117|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
214464118|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
214464119|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
215155390|NCT03284580|OTHER|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
215155391|NCT00768313|DEVICE|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
215155392|NCT00768313|DEVICE|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
215155393|NCT01564576|DRUG|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
215155394|NCT03048578|DRUG|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
214464120|NCT06007664|BEHAVIORAL|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
214464121|NCT04972552|DIETARY_SUPPLEMENT|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
214464122|NCT04972552|OTHER|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
214464123|NCT04972552|OTHER|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
214464124|NCT04972552|OTHER|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
214464125|NCT01275677|DRUG|Cyclophosphamide|Given IV
214464126|NCT01275677|DRUG|Docetaxel|Given IV
214464127|NCT01275677|DRUG|Doxorubicin|Given IV
214464128|NCT01275677|DRUG|Doxorubicin Hydrochloride|Given IV
214696627|NCT02512692|DRUG|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
215155395|NCT03048578|DRUG|Placebo|Subcutaneous Saline Solution
215155396|NCT01096459|PROCEDURE|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
215155397|NCT01052701|DRUG|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)"
215155398|NCT01052701|DRUG|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
215155399|NCT01723319|DEVICE|HBLPADD coil deep TMS|20 daily deep TMS treatment
215155400|NCT01723319|DEVICE|Sham|inactive treatment
215155401|NCT03346980|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
214464129|NCT01275677|OTHER|Laboratory Biomarker Analysis|Correlative studies
214464130|NCT01275677|DRUG|Paclitaxel|Given IV
215155402|NCT02459834|OTHER|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
215155403|NCT02459834|OTHER|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
215155404|NCT02459834|OTHER|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
215155405|NCT06232200|OTHER|ACUPUNCTURE|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
215155406|NCT03021343|DRUG|Colchicine|colchicine given as per trial protocol
215155407|NCT00235365|BEHAVIORAL|meta-cognitive therapy|Meta-cognitive therapy
214696628|NCT02512692|DRUG|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
215155408|NCT00235365|OTHER|waiting list|waiting list control
215155409|NCT00643903|BEHAVIORAL|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
215155410|NCT00643903|BEHAVIORAL|Standard care|Participants will receive standard of care for HIV infections.
215155411|NCT00643903|BEHAVIORAL|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
215155412|NCT00156468|BEHAVIORAL|Provider Prompt|
215155413|NCT00996333|DRUG|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
215155414|NCT02902237|BIOLOGICAL|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
215155415|NCT04749056|BEHAVIORAL|EPAS (electronic psycho-oncological adapative screening program)|"Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested."
214464131|NCT01275677|OTHER|Quality-of-Life Assessment|Ancillary studies
214464132|NCT01275677|BIOLOGICAL|Trastuzumab|Given IV
214464133|NCT05012683|DEVICE|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
214464134|NCT00207636|BEHAVIORAL|Computer Assisted Decision making tool|The intervention consisted of access to a computer tailored decision aid designed to promote informed decision making.
214464135|NCT00335816|DRUG|fluorouracil|Given IV
214464136|NCT00335816|DRUG|leucovorin calcium|Given IV
214464137|NCT00335816|DRUG|oxaliplatin|Given IV
214464138|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
214464139|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
214464140|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
214464141|NCT00335816|GENETIC|DNA analysis|Correlative studies
214464142|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
214464143|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
214464144|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
214464145|NCT04767841|DRUG|Metformin|Metformin 1000mg tablet plus celecoxib 200 mg capsule
214464146|NCT04767841|DRUG|Placebo|Placebo tablet plus celecoxib 200 mg capsule
214464147|NCT06518941|DRUG|Donepezil|Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
214464148|NCT06198426|DRUG|IBI3004|IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
214464149|NCT05002608|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
214464150|NCT05416658|OTHER|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
214464151|NCT06849219|DRUG|Oxcarbazepine|Oxcarbazepine will be started at a dose of 150 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1800 mg per day.
214464152|NCT06849219|DRUG|Carbamazepine|Carbamazepine will be started at a dose of 100 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1200 mg per day.
214464153|NCT06852352|PROCEDURE|Modified deep cervical Lymphatic-Venous Anastomosis|Deep cervical lymph-vein anastomosis surgery, connecting deep cervical lymph input vein vessels to enhance glymphatic-mediated protein clearance
214464154|NCT06393608|DRUG|Epsom salt|Epsom salt solution in water, 25% concentration
214464155|NCT06393608|OTHER|Water|Water
214464156|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
214464157|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
214464158|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
214464159|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
214464160|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
214464161|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
214536468|NCT00148616|DRUG|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
214536469|NCT00148616|DRUG|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
215155416|NCT03088956|OTHER|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
215155417|NCT01301027|DRUG|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
215155418|NCT01301027|DRUG|Placebo|1 pill a day for 26 weeks
215155419|NCT00277732|PROCEDURE|Pharmaceutical care at baseline and follow-up visits over 6 months|
215155420|NCT04919200|DIAGNOSTIC_TEST|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
215155421|NCT03705143|BEHAVIORAL|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
215155422|NCT03705143|BEHAVIORAL|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
215155423|NCT01279785|DRUG|123I-MIP-1072|Single IV dose
214464162|NCT06852417|BEHAVIORAL|Health qigong training|Participants will receive two 60-minute Baduanjin qigong training sessions every week under the instruction and supervision of qualified qigong instructors over 12 weeks (i.e., 24 sessions in total). Baduanjin qigong consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. Instructions on each movement, voice-guide audios, and demonstration videos will be provided for participants' daily self-practice. They will be advised to practice Baduanjin for at least 10 minutes every day.
214464163|NCT03372317|DRUG|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
214464164|NCT06850974|DEVICE|Foley Balloon Catheter|18 French Foley Balloon placed trans-cervically and inflated with 30-60ml of Normal Saline.
214464165|NCT06850974|DRUG|Misoprostol|400 mcg of buccal misoprostol sublingual
215155424|NCT01420952|DRUG|[11C]LY2428703|
215155425|NCT01271985|DRUG|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
215155426|NCT01271985|OTHER|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
215155427|NCT03346694|DEVICE|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
215155428|NCT03346694|DEVICE|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
214464166|NCT06850974|DEVICE|Laminaria|Laminaria will be placed in the cervix according to the following standard formula: Estimated gestational age -10 = number of 5mm laminaria.
214464167|NCT03252834|DIAGNOSTIC_TEST|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
214464168|NCT04818021|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
214464169|NCT04818021|BEHAVIORAL|Facial Skin Stretch|Facial skin stretch
214464170|NCT05655702|OTHER|Community based TB intervention|"* 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts."
214464171|NCT04532346|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
214464172|NCT04409353|DEVICE|Distraction-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Distraction software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
214536470|NCT05218421|DIAGNOSTIC_TEST|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
214536471|NCT05218421|OTHER|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
214536472|NCT05218421|OTHER|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
214536473|NCT03726983|OTHER|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
215155429|NCT03346694|DEVICE|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
215155430|NCT00915616|DRUG|Melatonin|
215155431|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
215155432|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
215155433|NCT00533936|BIOLOGICAL|trastuzumab|
215155434|NCT00533936|DRUG|cyclophosphamide|
215155435|NCT00533936|DRUG|doxorubicin hydrochloride|
215155436|NCT00533936|DRUG|fluorouracil|
215155437|NCT00533936|DRUG|paclitaxel|
215155438|NCT00533936|PROCEDURE|adjuvant therapy|
215155439|NCT00533936|PROCEDURE|conventional surgery|
215155440|NCT00533936|PROCEDURE|neoadjuvant therapy|
215155441|NCT06056479|PROCEDURE|external oblique intercostal block|20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
215155442|NCT03113461|DEVICE|CPAP|non-invasive positive airway pressure applied using an oronasal mask
215155443|NCT05063773|DEVICE|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
215155444|NCT00074490|DRUG|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
215155445|NCT00074490|DRUG|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
215155446|NCT00074490|DRUG|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
215155447|NCT00074490|DRUG|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
215155448|NCT00074490|DRUG|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
215155449|NCT00074490|DRUG|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
215155450|NCT00074490|PROCEDURE|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
215155451|NCT00074490|GENETIC|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
215155452|NCT00074490|DRUG|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
215155453|NCT00074490|PROCEDURE|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
215155454|NCT00074490|DRUG|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
215155455|NCT00074490|GENETIC|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
214464173|NCT04409353|DEVICE|Sham VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Sham software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
214464174|NCT04409353|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
214464175|NCT04409353|DEVICE|Activity Tracker|Participants among all arms will be provided the option to passively wear a Fitbit Charge 4 throughout their 90-day study enrollment period. The Fitbit collects biometric data such as daily steps, heart rate, hours of sleep, stages of sleep, and sleep efficiency.
214464176|NCT04636814|DRUG|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
214464177|NCT04636814|DRUG|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
214464178|NCT04636814|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
214464179|NCT04636814|DRUG|Roflumilast|\- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
214464180|NCT06774820|PROCEDURE|self-blocking tenodesis|the LHB tendon is detached from its origin in the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate later localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
214536474|NCT01600235|DRUG|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
214536475|NCT01208870|BEHAVIORAL|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
214536476|NCT01208870|BEHAVIORAL|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
214536477|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
215155456|NCT03557060|DRUG|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
215155457|NCT05838482|DEVICE|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
215155458|NCT04685889|PROCEDURE|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
214464181|NCT06774820|PROCEDURE|arthroscopic tenodesis|LHB tendon is detached from its origin, and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-lasso loop tenodesis technique. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
214464182|NCT06336863|DIAGNOSTIC_TEST|Allosure and TruGraf|Precision medicine will be employed to withdraw immunosuppression in kidney transplant recipients.
214464183|NCT06336863|OTHER|Immunosuppression Taper|An immunosuppression taper will be employed over a 12-month period for those that are deemed immune quiescent.
214464184|NCT05936905|OTHER|Acupuncture|Acupuncture 1 time per month
214464185|NCT05936905|OTHER|Chiropractic|Chiropractic 1 time per month
214464186|NCT04081103|DRUG|Nexagon® (lufepirsen) High Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
214464187|NCT04081103|DRUG|Nexagon® (lufepirsen) Low Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
214464188|NCT04081103|DRUG|Vehicle|Vehicle is administered topically in the affected eye three (3) times over 28 days.
214464189|NCT04081103|DRUG|Open-label Nexagon® (lufepirsen)|Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
214464190|NCT03833154|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
214464191|NCT03833154|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
214464192|NCT03833154|DRUG|(Osimertinib cohort, single-arm, open-label separate cohort)|Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
214464193|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
214464194|NCT06559553|DRUG|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
214464195|NCT06169527|DRUG|Dupilumab|Dupilumab cohort
214464196|NCT06465381|BEHAVIORAL|Safety Planning Intervention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
214464197|NCT06465381|BEHAVIORAL|Enhanced Usual Care|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
214464198|NCT06465381|BEHAVIORAL|Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
214464199|NCT04732065|DRUG|ONC206|Given orally (PO)
214464200|NCT04732065|RADIATION|Standard of Care Radiation Therapy|Undergo RT
214464201|NCT04732065|PROCEDURE|Optional Proton (1H) MR spectroscopy (MRS)|Optional imaging procedure
214464202|NCT05701657|OTHER|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, nuts/seeds, and olive oil, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
214464203|NCT05701657|OTHER|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
214464204|NCT05701657|OTHER|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, nuts/seeds, dairy and fats/oils, low amounts of fruits, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
214464205|NCT05701657|OTHER|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
214464206|NCT05701657|OTHER|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
214464207|NCT05754203|RADIATION|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
214464208|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
214464209|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
214464210|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
214464211|NCT06274034|OTHER|Survey Administration|Ancillary studies
214464212|NCT06429657|DRUG|Ketamine with propofol|Propofol at a rate of 300 mcg/kg/hr (5 mcg/kg/min) with the addition of ketamine at a rate of 1000-5000 mcg/kg/hr (16.67 - 83.33 mcg/kg/min) (using weight at time of admission) with an additional 2 mg/kg (2000 mcg/kg) bolus of ketamine
214696629|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
215155459|NCT02722499|BEHAVIORAL|High Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65."
215155460|NCT02722499|BEHAVIORAL|Moderate Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85"
215155461|NCT02722499|BEHAVIORAL|Low Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150."
215155462|NCT03841201|DRUG|Lenvatinib|oral
215155463|NCT03841201|DRUG|Nivolumab|iv infusion
215155464|NCT03810911|DRUG|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
215155465|NCT03935763|OTHER|observational disease study|observation of routine clinical practices in mCRC
215155466|NCT03973060|DEVICE|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
215155467|NCT03973060|GENETIC|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
214536478|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
214536479|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
214536480|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
214536481|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
214536482|NCT00945698|DIETARY_SUPPLEMENT|Maize-soy flour|"* No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
214536483|NCT01077622|DRUG|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
214536484|NCT05764577|PROCEDURE|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
215155468|NCT04312724|DEVICE|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
214536485|NCT01133925|DEVICE|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
214536486|NCT01133925|DEVICE|Sirolimus Eluting Stent|Cypher stents implanted in overlap
214536487|NCT01133925|DEVICE|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
214536488|NCT01133925|DEVICE|Zotarolimus eluting stent|Endeavor stents implanted in overlap
214536489|NCT00424177|DRUG|eltrombopag|experimental
214536490|NCT06028399|OTHER|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
214536491|NCT06028399|OTHER|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
214536492|NCT06034964|DRUG|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
214536493|NCT01123512|DEVICE|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
214536494|NCT05712655|OTHER|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
214536495|NCT04022603|DEVICE|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
214536496|NCT06086119|DIAGNOSTIC_TEST|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
214536497|NCT05645809|DEVICE|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
214536498|NCT05645809|DEVICE|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
215155469|NCT02668536|DRUG|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
215155470|NCT02668536|DEVICE|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
215155471|NCT04794569|DRUG|tinzaparin|low molecular weight heparin
215155472|NCT04794569|DRUG|Rivaroxaban|direct oral anticoagulant
215155473|NCT03111628|DRUG|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
215155474|NCT04141436|BEHAVIORAL|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
215155475|NCT04141436|OTHER|Routine clinical procedure|Routine clinical procedure
215155476|NCT02321176|DRUG|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
215155477|NCT01324037|OTHER|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
214536499|NCT06479252|OTHER|Sit-to-Stand Test (STS)|The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
214536500|NCT05699369|OTHER|Digital health interventions|Described in arm descriptions.
214536501|NCT00816153|OTHER|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
214536502|NCT03822377|DRUG|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
214536503|NCT03822377|DRUG|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
214536504|NCT00402636|DEVICE|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
214536505|NCT00402636|DEVICE|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
214536506|NCT04976283|DRUG|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
214536507|NCT04976283|DRUG|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
215155478|NCT03566485|DRUG|Atezolizumab|Given by IV
215155479|NCT03566485|DRUG|Cobimetinib|Given by mouth
215155480|NCT03566485|DRUG|Idasanutlin|Given by mouth
215155481|NCT03641586|DRUG|BGB-283|
215155482|NCT04999852|DEVICE|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
215155483|NCT04999852|BEHAVIORAL|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
215155484|NCT06218797|OTHER|a routine sedation protocol|In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.
215155485|NCT06218797|DRUG|Nebulized with dexmedetomidine|Patients will be received nebulisation with dexmedetomidine 2mcg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
215155486|NCT06959849|DEVICE|Use of robot surgical system|
215155487|NCT06375499|DEVICE|T2769|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
215155488|NCT06375499|DEVICE|Hylo-Forte®|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
215155489|NCT05489523|DRUG|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
215155490|NCT01648686|PROCEDURE|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
215155491|NCT05539898|DEVICE|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
215155492|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
215155493|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
215155494|NCT04379895|DEVICE|Radiofrequency ablation|Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
215155495|NCT04460001|DRUG|Ranibizumab|Intravitreal
215155496|NCT04460001|DRUG|Ranibizumab|Intravitreal
215155497|NCT04460001|DRUG|triamcinolone acetate|intravitreal
215155498|NCT02575586|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
215155499|NCT02575586|DEVICE|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
215155500|NCT02506244|DEVICE|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
215155501|NCT02506244|DEVICE|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
215155502|NCT04521725|DEVICE|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
215155503|NCT04521725|DEVICE|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
215155504|NCT00492258|DRUG|sorafenib tosylate|
214464213|NCT06429657|OTHER|Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam|Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the institutional SOC guidelines.
214464214|NCT06609356|PROCEDURE|Study Visit 1|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
214464215|NCT06609356|DRUG|Placebo|"* T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies."
214464216|NCT06609356|PROCEDURE|Study Visit 2|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
214464217|NCT06609356|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
214464218|NCT04046562|BEHAVIORAL|PAW|Pain and Weight Treatment plus standard of care
214464219|NCT04046562|BEHAVIORAL|Pain Education|Pain Education plus standard of care
214464220|NCT05528536|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
214464221|NCT05528536|OTHER|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
214464222|NCT05528536|OTHER|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
214464223|NCT05528536|OTHER|Treatment as usual|treatment as usual within their community centres
214464224|NCT06469723|OTHER|INFA Program|"Participants will be screened using the INFA Screening tool, comprising of assessments for multiple domains that are part of existing routine admission nursing assessments, including functional decline, delirium, recurrent falls, self-reported hearing and visual impairment questionnaires, malnutrition risk, oral health, and dysphagia screening. Nurse-led protocols will be done to address each identified geriatric syndrome.~Participants with complex cases (defined as delirium and/or high-risk falls) will be referred to the GeriCARE service, with capabilities for performing comprehensive geriatric assessment (CGA) guiding discharge planning. Referrals to geriatricians can be initiated whenever necessary, facilitating access to specialised geriatric medical expertise.~Participants will also receive comprehensive discharge planning and systematic follow-up procedures, done by ward resource nurses."
214464225|NCT06978647|DRUG|YTS109 cell|Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.
214464226|NCT05309291|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode.
214464227|NCT05309291|DEVICE|FX 800 Dialyzer|Dialysis performed in HDF mode.
214464228|NCT06408350|BEHAVIORAL|Text Me, Alexis!|Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
214464229|NCT06982846|DRUG|Retatrutide|Administered SC
214464230|NCT06982846|DRUG|Placebo|Administered SC
215155505|NCT00492258|PROCEDURE|adjuvant therapy|
215155506|NCT01075490|DRUG|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
215155507|NCT01075490|DRUG|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
215155508|NCT01698398|DEVICE|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
215155509|NCT03632850|OTHER|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
215155510|NCT04005131|DEVICE|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
215155511|NCT04005131|DEVICE|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
215155512|NCT05922917|DEVICE|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
215155513|NCT03523988|DRUG|Acetaminophen|Acetaminophen gel capsule
215155514|NCT03523988|DRUG|Ibuprofen|Ibuprofen gel capsule
214536508|NCT04976283|DRUG|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
214536509|NCT00248079|DEVICE|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
215155515|NCT02550639|OTHER|BIOMARKER- elispot test|ELISPOT TEST
214536510|NCT05819775|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
215155516|NCT00654550|DRUG|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
215155517|NCT01065883|BEHAVIORAL|community health worker|community health workers will provide education in the home
215155518|NCT01065883|BEHAVIORAL|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
215155519|NCT02472028|OTHER|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
215155520|NCT02472028|OTHER|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
215155521|NCT05760573|BEHAVIORAL|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
215155522|NCT02272205|OTHER|Retrospective analysis of records|
215155523|NCT01369888|DRUG|Cyclophosphamide|60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
215155524|NCT01369888|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
215155525|NCT01369888|BIOLOGICAL|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
215155526|NCT01369888|DRUG|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
215155527|NCT06005207|DRUG|progesterone vaginal sustained-release gel|90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
215155528|NCT06274515|PROCEDURE|Tumor Tissue and Blood Draw|Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
215155529|NCT02820493|DRUG|vedolizumab|
215155530|NCT04131647|OTHER|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
215155531|NCT04131647|OTHER|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
215155532|NCT05530512|OTHER|electroacupuncture|acupuncture needling and stimulation are applied for 30 min
215155533|NCT05220436|OTHER|DISCOVER workshop programme|See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance \& Commitment Therapy principles.
215155534|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
215155535|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
215155536|NCT02932852|PROCEDURE|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
214464231|NCT05183828|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples
214464232|NCT05183828|DRUG|Letrozole|Given PO
214464233|NCT05183828|OTHER|Questionnaire Administration|Ancillary studies
214464234|NCT05944458|DRUG|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
214464235|NCT05944458|DRUG|Placebo|20 ml normal saline iv every 12 hours
214464236|NCT06856174|DRUG|Transdermal estradiol gel|All participants: Estradiol gel 0.1%, 0.75 grams (corresponding to estradiol 0.75 mg) applied to the skin of the upper thigh once daily for 12 weeks.
214464237|NCT06856174|DRUG|Micronized Progesterone|Participants with intact uterus: Encapsulated micronized progesterone 100 mg orally once daily for 12 weeks.
214464238|NCT06856174|DRUG|Placebo for estradiol gel|All participants: Placebo for estradiol gel 0.1%, 0.75 grams applied to the skin of the upper thigh once daily for 12 weeks.
214464239|NCT06856174|DRUG|Placebo for micronized progesterone|• Participants with intact uterus: Encapsulated placebo for micronized progesterone 100 mg orally once daily for 12 weeks.
214464240|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
214464241|NCT03876626|OTHER|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
214464242|NCT03876626|OTHER|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
214464243|NCT05840172|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
215155537|NCT02932852|PROCEDURE|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
215155538|NCT02840461|DRUG|Ivermectin Cream, 1%|
215155539|NCT02840461|DRUG|Placebo/Vehicle cream|
215155540|NCT02469311|OTHER|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
215155541|NCT02469311|OTHER|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
214536511|NCT03792893|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
214696630|NCT05311280|OTHER|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
214696631|NCT05311280|OTHER|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
215155542|NCT06648044|OTHER|Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie|
215155543|NCT04162678|PROCEDURE|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
215155544|NCT04162678|OTHER|Laboratory Biomarker Analysis|Correlative studies
215155545|NCT04162678|PROCEDURE|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
215155546|NCT04162678|OTHER|Medical Chart Review|Review of medical chart
215155547|NCT05823467|DRUG|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
215155548|NCT05823467|DEVICE|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
215155549|NCT01737502|DRUG|Auranofin|Given PO
215155550|NCT01737502|DRUG|Sirolimus|Given PO
215155551|NCT01737502|OTHER|Laboratory Biomarker Analysis|Correlative studies
215155552|NCT01737502|OTHER|Pharmacological Study|Correlative studies
215155553|NCT04835857|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
215155554|NCT04835857|DEVICE|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
215155555|NCT04835857|DEVICE|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
215155556|NCT03741673|OTHER|Quality-of-Life Assessment|Ancillary studies
215155557|NCT03741673|OTHER|Questionnaire Administration|Ancillary studies
215155558|NCT03741673|RADIATION|Stereotactic Radiosurgery|Undergo SRS
215155559|NCT03819985|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
215155560|NCT03819985|OTHER|Quality-of-Life Assessment|Ancillary studies
215155561|NCT03819985|OTHER|Questionnaire Administration|Ancillary studies
215155562|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
215155563|NCT06262516|PROCEDURE|Nephroureterectomy|Participants will undergo standard-of-care nephroureterectomy for UTUC.
215155564|NCT06262516|PROCEDURE|Lymph Node Dissection|Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
215155565|NCT05307965|DEVICE|Retriever Thrombectomy|The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.
215155566|NCT05307965|PROCEDURE|Percutaneous Coronary Intervention|Standard of care
215155567|NCT05307965|PROCEDURE|Thrombus Aspiration|Standard of care treatment with manual thrombectomy catheter
215155568|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
215155569|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
215155570|NCT05411952|OTHER|No intervention|Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
215155571|NCT05820191|DRUG|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
215155572|NCT04672655|BEHAVIORAL|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
215155573|NCT03224000|PROCEDURE|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
214536512|NCT03792893|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
214696632|NCT03901612|DRUG|Ropivacaine 0.2%|Continuous post operative regional analgesia
214696633|NCT03901612|DRUG|saline 09%|Continuous post operative regional analgesia
214696634|NCT00429377|DRUG|tacrolimus|
214696635|NCT03020901|DRUG|Teicoplanin for Injection|Use Teicoplanin for Injection
214696636|NCT05916833|OTHER|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
214696637|NCT05916833|OTHER|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
214696638|NCT00592397|OTHER|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
214696639|NCT03614091|PROCEDURE|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
214696640|NCT03614091|PROCEDURE|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
214696641|NCT03807739|DRUG|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
214696642|NCT03807739|DRUG|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
214696643|NCT03807739|DRUG|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
214696644|NCT04720508|DIAGNOSTIC_TEST|blood sample collection.|venipuncture procedure
214696645|NCT01186146|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
214696646|NCT01186146|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
214696647|NCT03417180|DRUG|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
214696648|NCT03417180|DEVICE|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
214696649|NCT00899743|GENETIC|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
215155574|NCT03224000|BEHAVIORAL|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
215155575|NCT03224000|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
215155576|NCT03224000|PROCEDURE|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
214696650|NCT00899743|GENETIC|western blotting|western blotting
214696651|NCT00899743|OTHER|immunologic technique|immunologic technique
215155577|NCT03224000|PROCEDURE|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
215155578|NCT03224000|PROCEDURE|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
215155579|NCT03224000|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
215155580|NCT04526418|DEVICE|24/7 EEG™ SubQ system|Electrographic seizure recording sensitivity of an ipsilaterally implanted 24/7 EEG™ SubQ system: proportion of identified ipsilateral seizures as compared to ipsilateral video-EEG during admission to the Epilepsy Monitoring Unit
214696652|NCT00899743|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214536513|NCT00554086|DRUG|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
214696653|NCT04601142|DRUG|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
214696654|NCT01831973|DRUG|Lipotecan|
214696655|NCT05725057|DRUG|AX-158|Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
214696656|NCT05725057|DRUG|Placebo|Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
214696657|NCT04288804|DEVICE|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
214696658|NCT04288804|DEVICE|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
214696659|NCT02284958|BEHAVIORAL|Standard|Back care advice
214696660|NCT02284958|BEHAVIORAL|Walking|Back care advice, individualized 12 week pedometer-driven walking program
214696661|NCT03136081|DIAGNOSTIC_TEST|Candidiasis infection occurence|Candidiasis infection occurence
214696662|NCT01855542|OTHER|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
214696663|NCT01855542|OTHER|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
214696664|NCT01661400|DRUG|Metronomic Cyclophosphamide|
214696665|NCT01661400|DRUG|Thalidomide|
214696666|NCT05146232|OTHER|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
214696667|NCT05146232|OTHER|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
214696668|NCT05146232|OTHER|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
214696669|NCT05146232|OTHER|First postoperative analgesia|IV acetaminophen will be administered every 6 h
214536514|NCT01012596|BEHAVIORAL|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
214536515|NCT06032273|BEHAVIORAL|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
214696670|NCT05146232|OTHER|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
214696671|NCT05723549|DRUG|HCP1803-3|Take it once per period
214696672|NCT05723549|DRUG|RLD2002|Take it once per period
214696673|NCT05723549|DRUG|HCP1904-1|Take it once per period
214696674|NCT04296500|OTHER|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
214696675|NCT01300897|PROCEDURE|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
215155581|NCT05237947|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
215155582|NCT05237947|OTHER|Questionnaire Administration|Ancillary studies
215155583|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
215155584|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
215155585|NCT05741840|BEHAVIORAL|PBT-A|PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
215155586|NCT05741840|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
215155587|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
215155588|NCT00494676|DEVICE|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
215155589|NCT00494676|DEVICE|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
215155590|NCT05816421|BEHAVIORAL|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
214536516|NCT01058083|DRUG|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
214696676|NCT01300897|PROCEDURE|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
215155591|NCT05816421|BEHAVIORAL|Non-Affinity KEEP|Non-Affinity KEEP
215155592|NCT06806709|DEVICE|PIVO-Pro needle-free blood collection device|The PIVO™ Pro Needle-free Blood Collection Device advances a flexible flow tube through the intravenous catheter to access optimal blood draw conditions, overcoming traditional hurdles to collect high-quality, reliable blood samples.
215155593|NCT06451406|DRUG|Selective serotonin re-uptake inhibitor|Patients received selective serotonin re-uptake inhibitor as medical treatment for treatment of premature ejaculate.
215155594|NCT06451406|DRUG|Hyaluronic acid|Patients received injection of glans penis with hyaluronic acid
215155595|NCT04250493|BIOLOGICAL|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
215155596|NCT04250493|BEHAVIORAL|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
215155597|NCT04250493|BEHAVIORAL|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
214536517|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
214536518|NCT01058083|DRUG|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
214536519|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
214536520|NCT01058083|DRUG|Placebo|Placebo, Oral, 0 mg, daily, 28 days
214536521|NCT03161223|DRUG|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
214536522|NCT03161223|DRUG|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
214536523|NCT03161223|DRUG|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
214536524|NCT03161223|DRUG|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
214536525|NCT00747045|OTHER|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
214536526|NCT00496834|DRUG|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
214536527|NCT00496834|DRUG|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
214536528|NCT00496834|DRUG|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
214536529|NCT00496834|DRUG|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
214536530|NCT06291584|OTHER|Exercise|In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
214536531|NCT05699967|OTHER|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
214536532|NCT05159778|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
214536533|NCT05159778|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
214536534|NCT03209297|OTHER|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
214536535|NCT00525200|DRUG|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
214536536|NCT00525200|DRUG|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
214536537|NCT00427245|DRUG|cyclophosphamide|
214536538|NCT00427245|DRUG|goserelin acetate|
214536539|NCT00427245|PROCEDURE|adjuvant therapy|
214536540|NCT00427245|PROCEDURE|fertility assessment and management|
214536541|NCT00427245|PROCEDURE|neoadjuvant therapy|
214536542|NCT03441737|BEHAVIORAL|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
214536543|NCT03441737|BEHAVIORAL|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
214536544|NCT00002855|DRUG|Bicalutamide|
215155598|NCT04250493|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
214536545|NCT00002855|DRUG|Doxorubicin hydrochloride|
214536546|NCT00002855|DRUG|Estramustine Phosphate Sodium|
214536547|NCT00002855|DRUG|Flutamide|
214536548|NCT00002855|DRUG|Ketoconazole|
214536549|NCT00002855|DRUG|Nilutamide|
214536550|NCT00002855|DRUG|Therapeutic Hydrocortisone|
214536551|NCT00002855|DRUG|Vinblastine|
214536552|NCT00002855|PROCEDURE|Conventional Surgery|Surgical castration
214536553|NCT02409121|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
214536554|NCT03212183|BEHAVIORAL|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
214536555|NCT03212183|OTHER|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
214536556|NCT04205500|OTHER|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
214536557|NCT02503488|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
214536558|NCT02503488|BEHAVIORAL|Treatment as Usual|See arm description
214536559|NCT01889771|DRUG|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
214536560|NCT01399502|BEHAVIORAL|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
214536561|NCT05399082|DEVICE|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
215155599|NCT04250493|BIOLOGICAL|Blood sampling|Optional blood sampling for the constitution of a biological collection
214536562|NCT05399082|PROCEDURE|Forceps biopsy|Biopsy forceps used to collect tissue
214536563|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
214536564|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
214536565|NCT02127983|BEHAVIORAL|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
214536566|NCT02127983|BEHAVIORAL|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
214536567|NCT05992519|DIAGNOSTIC_TEST|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
214536568|NCT05335668|PROCEDURE|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
214536569|NCT06632340|PROCEDURE|TUR-BT|Transurethral resection of bladder tumor
214536570|NCT04944784|DRUG|Reldesemtiv|Reldesemtiv Oral Tablet
214536571|NCT04944784|DRUG|Placebo|Placebo Oral Tablet
214536572|NCT05831995|DRUG|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
215155600|NCT07074938|DRUG|Jianmin Daopeng Angong Niuhuang Wan|An Gong Niu Huang Wan comes from JianMin Dapeng.
215155601|NCT07074938|DRUG|Tongrentang Angong Niuhuang Wan|Angong Niuhuang Wan comes from Tongrentang.
215155602|NCT06923488|DRUG|Leflunomide 10mg|Leflunomide 10mg tablet
215155603|NCT06923488|DRUG|Leflunomide 20mg|Leflunomide 20mg tablet
215155604|NCT06923488|DRUG|Decitabine|Decitabine dose of 20 mg/m2
215155605|NCT06938581|OTHER|ERAS Protocol|"The ERAS protocol consists of:~* Day before surgery: Oral carbohydrate drink (evening), Acetaminophen 1000mg (evening), Celecoxib 200mg (morning and evening)~* Morning of surgery: Oral carbohydrate drink (2-4 hours before surgery), Celecoxib 200mg, Acetaminophen 1000mg Additionally, optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed."
215155606|NCT06938581|OTHER|Standard Perioperative Care|Standard perioperative care without ERAS protocol components. Includes routine preoperative instructions and omission of oral carbohydrate drink, celecoxib, and preoperative acetaminophen. Optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed.
215155607|NCT05102253|PROCEDURE|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
214536573|NCT04185038|BIOLOGICAL|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
214536574|NCT03717077|PROCEDURE|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
214536575|NCT02210208|DEVICE|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
214696677|NCT01300897|PROCEDURE|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
214696678|NCT03651193|DIAGNOSTIC_TEST|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
214696679|NCT05304871|DRUG|Cefazolin|infusion
214696680|NCT05304871|OTHER|saline|infusion
214696681|NCT02742077|DEVICE|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
214696682|NCT01544777|DEVICE|Study IOL|Aspheric IOL for correction of aphakia
214696683|NCT01544777|DEVICE|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
214696684|NCT01544777|DEVICE|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
214536576|NCT02210208|DEVICE|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
214536577|NCT01718431|OTHER|test meal|
214536578|NCT01718431|OTHER|reference meal|
214536579|NCT01491542|DEVICE|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
214536580|NCT01491542|DEVICE|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
214536581|NCT02306447|DEVICE|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
214536582|NCT06413264|PROCEDURE|Ultrasonography guided Veress needle insertion for creating pneumoperitoneum|A real-time visualisation of the path of the Veress needle entry by the use of high frequency (13-6 MHz) probe ultrasonography.
214536583|NCT06413264|PROCEDURE|Veress needle will be inserted blindly as a closed technique for creating pneumoperitoneum|The Veress needle is inserted blindly and guided by the resistance of tissues and the click sounds of layers of abdominal wall.
214536584|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
214536585|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
214536586|NCT03840356|OTHER|Postoperative|No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
214536587|NCT00370370|DRUG|bevacizumab|Injection of intravitreal bevacizumab
214536588|NCT00370370|DRUG|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
214536589|NCT04502043|OTHER|Exercise therapy|"* Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises"
214536590|NCT04334447|OTHER|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
214536591|NCT04334447|OTHER|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
214536592|NCT04334447|OTHER|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
214536593|NCT03371121|OTHER|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
214536594|NCT03416569|DRUG|Placebo|placebo skin patch + placebo capsule
214696685|NCT01952197|OTHER|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
214536595|NCT03416569|DRUG|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
214536596|NCT03416569|DRUG|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
214536597|NCT03416569|DRUG|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
214536598|NCT05218746|PROCEDURE|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
214536599|NCT05218746|PROCEDURE|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
214536600|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
214536601|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
214536602|NCT03785626|PROCEDURE|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
214536603|NCT01346462|BEHAVIORAL|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
214536604|NCT04338906|DRUG|Camostat Mesilate|400 mg tid, d1-d7
214536605|NCT04338906|DRUG|Placebo|Instead of Camostat Mesilate, tid, d1-d7
215155608|NCT05102253|PROCEDURE|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
214696686|NCT05746351|DRUG|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
214696687|NCT05746351|DRUG|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
215155609|NCT05102253|OTHER|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
215155610|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
215155611|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
215155612|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
214536606|NCT04338906|DRUG|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
214536607|NCT05995847|BEHAVIORAL|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
214536608|NCT05995847|BEHAVIORAL|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
214536609|NCT02432170|DEVICE|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
214536610|NCT05280743|DRUG|Oxycodone|exposure to opioids after Cesarean Section
214536611|NCT04333732|DRUG|MR or M-M-R II ® vaccine|Education and surveillance plus MR or M-M-R II ® vaccine
214536612|NCT04333732|DRUG|Placebo|Placebo injection
214536613|NCT01310712|DRUG|Oxybutynin|5 mg every 12 hours for 6 weeks
214536614|NCT01310712|DRUG|placebo|placebo twice a day for 42 days.
214696688|NCT05746351|DRUG|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
214696689|NCT03956953|DRUG|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
214536615|NCT06956352|BEHAVIORAL|Adapted Collaborative Care Model (CCM)|Person-centered, recovery supports.
214536616|NCT06956352|BEHAVIORAL|Usual Care Group|Usual care, referral-based.
214536617|NCT01630005|BEHAVIORAL|talk therapy|Psychotherapy
214536618|NCT00855725|OTHER|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
214536619|NCT00855725|OTHER|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
214536620|NCT00855725|OTHER|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
214536621|NCT00855725|OTHER|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
214536622|NCT01625676|OTHER|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
214536623|NCT01625676|OTHER|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
214536624|NCT06031961|DRUG|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
214536625|NCT03176901|BEHAVIORAL|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
214536626|NCT03176901|BEHAVIORAL|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
214536627|NCT05359055|DRUG|SPH3127 tablet|100mg once daily on Day 1 and Day 8
214536628|NCT05359055|DRUG|Itraconazole|200mg once daily from Day 3 to Day10.
214536629|NCT05359055|DRUG|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
214696690|NCT03956953|OTHER|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
214696691|NCT00102453|DRUG|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
214696692|NCT02774226|DRUG|Tetrahydrobiopterin (BH4)|12 week intervention
215155613|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
215155614|NCT05255289|PROCEDURE|Urodynamic investigations before and after an Solyx sling protocol.|Urodynamic investigations (stated above.)
215155616|NCT04195841|PROCEDURE|Z shaped incision|"After local anaesthesia, a mucoperiosteal flap will be elevated at the edentulous ridge with two horizontal incisions placed with a no MB 69 blade, 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. The extend of the incisions should be up to the proximal line angles of the adjacent teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles. A periosteal elevator is used to elevate a full thickness mucoperiosteal flap buccally and lingually to the level of the mucogingival junction, exposing the alveolar ridge of the implant surgical sites.~Endosseous implant placement is done followed by simple interrupted resorbable sutures"
215155617|NCT04195841|PROCEDURE|H shaped incision|"After local anaesthesia, a mucoperiosteal flap is elelevated by placing sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles using a MB 69 blade.~Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth. A full thickness mucoperiosteal flap will be elevated buccally and lingually to the level of the mucogingival junction to expose the alveolar ridge of the implant surgical sites using a periosteal elevator.~Endosseous implant will be placed, followed by simple interrupted resorbable sutures."
215155618|NCT05358353|DEVICE|Bare Temporary Spur Stent System|Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
215155619|NCT00384046|DRUG|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
215155620|NCT00384046|DRUG|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
215155621|NCT03776006|PROCEDURE|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
215155622|NCT04603027|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
215155623|NCT04603027|DRUG|Placebo|Placebo oral capsule
215155624|NCT02831101|DRUG|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
215155625|NCT02831101|DRUG|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
215155626|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
215155627|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
215155628|NCT05259280|OTHER|Wellinks|Digital health and virtual care program for COPD management.
215155629|NCT02611596|DRUG|Ranolazine|24 weeks of the assigned medication
215155630|NCT02611596|DRUG|Placebo|Placebo for 24 weeks
215155631|NCT04805099|DRUG|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
215155632|NCT05404672|OTHER|Aerobic Training|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
215155633|NCT05404672|OTHER|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
215155634|NCT03278054|OTHER|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
215155635|NCT03278054|OTHER|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
214536630|NCT05359055|DRUG|Rifampin|600mg once daily from Day 3 to Day13.
214536631|NCT05611541|BEHAVIORAL|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
214536632|NCT05611541|BEHAVIORAL|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
214696693|NCT02774226|DIETARY_SUPPLEMENT|Antioxidant Cocktail|12 week intervention
215155636|NCT03278054|OTHER|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
214536633|NCT02187367|BIOLOGICAL|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
214536634|NCT04957329|DRUG|Xalatan|Eye drop
214536635|NCT04957329|DRUG|Monoprost|Eye drop
214536636|NCT04984239|BEHAVIORAL|Acceptance and Commitment Therapy for aphasia|The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
214536637|NCT03851380|BEHAVIORAL|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
214536638|NCT03851380|OTHER|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
214536639|NCT03851380|DEVICE|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
214536640|NCT03851380|DEVICE|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
214536641|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
214536642|NCT06956222|OTHER|Hybrid Tele-rehabilitation|"In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under the physiotherapist's supervision, including watching and correcting exercise techniques.~Video session: participants attend video session via Zoom platform (Zoom Video Communications, inc., USA), an accessible internet-based platform from any laptop or mobile device that offers a real-time video and audio communications. Participants will receive a Zoom link with a unique password. During the video session, the physiotherapist accesses from the clinic using a laptop, while participants are based at their home. Participants will receive exercises (attached in the study protocol document) with real time instructions from the physiotherapist. Instructions on downloading and accessing Zoom platform will be given to the participants in the first in-person session to ensure their readiness to access the Zoom platform."
214536643|NCT06956222|OTHER|Standard Rehabilitation|In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under physiotherapist's supervision, including watching and correcting exercise techniques.
214536644|NCT04190225|BEHAVIORAL|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
214536645|NCT06439641|OTHER|Ulcerative colitis Disease Activity Index|QUESTIONNAIRE - Score between 0 to 12, the higher is the worse
214536646|NCT05671978|PROCEDURE|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
214536647|NCT05671978|PROCEDURE|neutral position|The patient was then placed in the netural position
214536648|NCT03728959|OTHER|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
214536649|NCT03728959|OTHER|GIP|Subcutaneous injected GIP
214536650|NCT03728959|OTHER|GLP-2|Subcutaneous injected GLP-2
214536651|NCT03728959|OTHER|Placebo (saline)|Subcutaneous injected Placebo (saline)
214536652|NCT00963443|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
214536653|NCT00963443|DRUG|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
214536654|NCT00963443|DRUG|Placebo|Matching Placebo
214536655|NCT01284309|DRUG|Mirabegron|oral
214536656|NCT01284309|DRUG|Placebo|oral
214536657|NCT00771095|BEHAVIORAL|podcasting|
214536658|NCT01275768|PROCEDURE|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
214536659|NCT03367598|GENETIC|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.
214536660|NCT00389688|DRUG|cisplatin|
214536661|NCT00389688|DRUG|pemetrexed disodium|
214536662|NCT00389688|PROCEDURE|adjuvant therapy|
214536663|NCT00389688|PROCEDURE|conventional surgery|
214536664|NCT00389688|PROCEDURE|neoadjuvant therapy|
214536665|NCT02994784|DRUG|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
214536666|NCT00805597|RADIATION|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
214536667|NCT00805597|RADIATION|no radiation|no radiotherapy
214536668|NCT02363998|DRUG|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
214536669|NCT05417347|OTHER|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
214536670|NCT05417347|OTHER|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
215155637|NCT02688777|BEHAVIORAL|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
214536671|NCT04248907|OTHER|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
214536672|NCT04248907|OTHER|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
214536673|NCT04248907|OTHER|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
214536674|NCT02466243|DRUG|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
214536675|NCT02466243|DRUG|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
214536676|NCT03347266|DRUG|VVZ-149 injections|•VVZ-149 injection
214536677|NCT03347266|DRUG|Placebo|water for injection
214536678|NCT04106570|OTHER|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
214536679|NCT02803671|DEVICE|TFU-NIRS|
214536680|NCT02803671|DEVICE|NIRS|
214536681|NCT02803671|DEVICE|EEG|
214536682|NCT00477464|DRUG|Lapatinib|1250mg once daily
215155638|NCT04986761|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
215155639|NCT03259503|DRUG|Busulfan|Given IV
215155640|NCT03259503|DRUG|Gemcitabine|Given IV
215155641|NCT03259503|DRUG|Melphalan|Given IV
215155642|NCT03259503|DRUG|Olaparib|Given PO
215155643|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
215155644|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
215155645|NCT03259503|BIOLOGICAL|Rituximab|Given IV
214536683|NCT00477464|DRUG|capecitabine|2000mg/m\^2 twice daily (14 days out of 21 days)
214536684|NCT03664206|DIAGNOSTIC_TEST|MRS, conventional TMS and treshold tracking TMS|"Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
214536685|NCT04952779|DRUG|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
214536686|NCT01921907|DRUG|AD17137 topical treatment|
214696694|NCT05769842|DRUG|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
215155646|NCT03259503|DRUG|Vorinostat|Given PO
215155647|NCT03161444|OTHER|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
214536687|NCT01921907|DRUG|Placebo|
214536688|NCT04329546|OTHER|NA (no intervention)|NA (no intervention)
214536689|NCT03647384|DRUG|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
214536690|NCT03647384|DRUG|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
214536691|NCT00639769|DRUG|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
214536692|NCT00639769|DRUG|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
214536693|NCT00072683|DRUG|tolvaptan|
214536694|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
214536695|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
214536696|NCT00863798|DRUG|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
214536697|NCT02418715|OTHER|Water Aerobics Training|
214536698|NCT04238520|BEHAVIORAL|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
214536699|NCT04238520|BEHAVIORAL|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
214536700|NCT01470599|DRUG|CP-690,550|ORAL TABLET, TWICE DAILY
214536701|NCT01470599|DRUG|CP-690,550|ORAL TABLETS, TWICE DAILY
215155651|NCT05936697|DEVICE|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
215155652|NCT05936697|DEVICE|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
215155653|NCT05936697|OTHER|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
215155654|NCT01009216|DRUG|ABT-384|Doses will be administered daily for 5 days.
215155655|NCT02004678|DRUG|DS-1150b|
215155656|NCT02004678|OTHER|Placebo|
215155657|NCT03983811|DRUG|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
215155658|NCT03983811|DRUG|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
215155659|NCT03983811|OTHER|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
214536702|NCT00195442|DRUG|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
214536703|NCT01917006|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
214536704|NCT01917006|DRUG|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
215155660|NCT04655807|DRUG|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
215155661|NCT04655807|DRUG|Placebo|Matching placebo will be administered as SC injection.
215155662|NCT04655807|DRUG|Adalimumab|Adalimumab will be administered as SOC biological therapy.
215155663|NCT04655807|DRUG|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
215155664|NCT05791019|OTHER|Paleolithic diet effect on patients|Efficacy of paleolithic diet in control of blood level of glucose in type 2 DM patients
215155665|NCT04387084|DRUG|Atezolizumab|Given IV
215155666|NCT04387084|DRUG|Avelumab|Given IV
214536705|NCT00624013|DRUG|sertraline|50 mg up to 100 mg daily for 6 months
214536706|NCT00624013|DRUG|Placebo|50 mg up to 100 mg daily for 6 months
214536707|NCT00847132|BEHAVIORAL|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
214536708|NCT00847132|BEHAVIORAL|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
214536709|NCT04651309|OTHER|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
214536710|NCT05987098|DIAGNOSTIC_TEST|BBPA PET examination|A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
214536711|NCT01733589|DRUG|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
214536712|NCT01733589|DRUG|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
214536713|NCT01733589|DRUG|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
214536714|NCT01733589|OTHER|laboratory biomarker analysis|
214536715|NCT01733589|OTHER|CT perfusion imaging|
214536716|NCT06521424|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
214536717|NCT06521424|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214536718|NCT05419310|OTHER|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
214536719|NCT05419310|OTHER|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
214536720|NCT05419310|OTHER|Elastic taping application|Application of elastic taping
214536721|NCT02162017|OTHER|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
215155667|NCT04387084|BIOLOGICAL|Cemiplimab|Given IV
215155668|NCT04387084|BIOLOGICAL|Durvalumab|Given IV
214536722|NCT02162017|OTHER|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
214536723|NCT01939951|DIETARY_SUPPLEMENT|Activation Energy Serum|7 drops or 21 drops twice daily
214536724|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
214536725|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
215155669|NCT04387084|BIOLOGICAL|Nivolumab|Given IV
215155670|NCT04387084|BIOLOGICAL|Pembrolizumab|Given IV
215155671|NCT04387084|OTHER|Quality-of-Life Assessment|Ancillary studies
214536726|NCT04912700|BIOLOGICAL|COVID-19 vaccine|Full or partial reception of vaccine
214536727|NCT01508832|DRUG|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
215155672|NCT04387084|OTHER|Short-Term Fasting|Undergo STF
215155673|NCT04387084|BIOLOGICAL|Dostarlimab|Given IV
214536728|NCT01508832|DRUG|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
214536729|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
214536730|NCT02306083|DRUG|Placebo three times a day|
214536731|NCT02306083|DRUG|glucosamine sulfate 1500 mg three times a day|
214536732|NCT03820570|PROCEDURE|hernia repair|inguinal hernia repair
214536733|NCT00397202|DEVICE|Diva Cup TM|See Detailed Description.
214696695|NCT05769842|DRUG|normal saline|Same dose as propofol.
214696696|NCT02634879|BEHAVIORAL|Incentive Change|
214696697|NCT03698604|PROCEDURE|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
215155674|NCT04387084|BIOLOGICAL|Retifanlimab|Given IV
215155675|NCT04387084|BIOLOGICAL|Toripalimab|Given IV
215155676|NCT04387084|BIOLOGICAL|Tislelizumab|Given IV
215155677|NCT01932437|BIOLOGICAL|ETI-204|monoclonal antibody
215155678|NCT01932437|OTHER|Placebo|Placebo for ETI-204
215155679|NCT01348516|DRUG|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
215155680|NCT01348516|DRUG|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
215155681|NCT05013541|OTHER|No intervention|Observational study, standard record of need to void during cystometry
215155682|NCT03572595|DIAGNOSTIC_TEST|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
215155683|NCT05567718|BEHAVIORAL|Paediatric Anaesthesia Emergence Delirium scale|measure emergence delirium in children
214536734|NCT03412578|PROCEDURE|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
215155684|NCT00448643|RADIATION|Vaginal Brachytherapy|High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
215155685|NCT00448643|DRUG|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
215155686|NCT00448643|RADIATION|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
215155687|NCT05428397|DIAGNOSTIC_TEST|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
215155688|NCT06103253|DIETARY_SUPPLEMENT|a Bla80 group|the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
215155689|NCT04112212|DRUG|Fluorescence molecular imaging procedure using vedolizumab-800CW|First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
215155690|NCT04112212|OTHER|Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW|Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.
215155691|NCT04112212|COMBINATION_PRODUCT|Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab|Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
215155692|NCT00003897|BIOLOGICAL|gp100 antigen|
215155693|NCT00003897|BIOLOGICAL|sargramostim|
215155694|NCT02472067|BEHAVIORAL|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
215155695|NCT01009619|DRUG|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
214536735|NCT02221999|DRUG|Paclitaxel|
214536736|NCT02221999|DRUG|Cisplatin|
214536737|NCT02221999|DRUG|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
215155696|NCT01009619|DRUG|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
215155697|NCT02506413|OTHER|MamaToto Package|"The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers."
215155698|NCT03300596|BEHAVIORAL|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
215155699|NCT03300596|BEHAVIORAL|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
215155700|NCT01620216|OTHER|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
215155701|NCT01620216|DRUG|Dasatinib|Given PO
215155702|NCT01620216|DRUG|Idelalisib|Given PO
215155703|NCT01620216|OTHER|Laboratory Biomarker Analysis|Correlative studies
215155704|NCT01620216|DRUG|Pacritinib|Given PO
215155705|NCT01620216|OTHER|Pharmacological Study|Correlative studies
215155706|NCT01620216|DRUG|Ponatinib|Given PO
215155707|NCT01620216|DRUG|Ponatinib Hydrochloride|Given PO
215155708|NCT01620216|DRUG|Ruxolitinib|Given PO
215155709|NCT01620216|DRUG|Sorafenib|Given PO
214536738|NCT02221999|DRUG|Letrozole|
214536739|NCT03357471|DRUG|e-Device|"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"
214536740|NCT02973802|BIOLOGICAL|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
215155710|NCT01620216|DRUG|Sorafenib Tosylate|Given PO
215155711|NCT01620216|DRUG|Sunitinib|Given PO
215155712|NCT01620216|DRUG|Sunitinib Malate|Given PO
215155713|NCT01172717|DRUG|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
215155714|NCT01419652|OTHER|hold hypoglycemic meds|continue versus hold hypoglycemic medications
215155715|NCT06511401|OTHER|Pharmacogenomic (PGx) results.|These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
214536741|NCT05131711|COMBINATION_PRODUCT|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
214536742|NCT03457974|OTHER|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
214536743|NCT03046797|DEVICE|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
214536744|NCT03046797|DEVICE|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
214536745|NCT02668627|PROCEDURE|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
214536746|NCT04418180|DRUG|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
214536747|NCT04418180|DRUG|Placebo|oral distilled water
214536748|NCT04308213|DEVICE|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
214536749|NCT04561583|DEVICE|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
214536750|NCT04561583|DEVICE|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
214536751|NCT04832581|BEHAVIORAL|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
214536752|NCT04771962|DRUG|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
214696698|NCT03023644|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
214696699|NCT05302739|OTHER|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
214696700|NCT05145504|DIAGNOSTIC_TEST|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
215155716|NCT04796090|OTHER|Clinical assessment|FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
215155717|NCT06109662|DIAGNOSTIC_TEST|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
215155718|NCT06109662|OTHER|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
215155719|NCT04676399|DRUG|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
215155720|NCT04676399|DRUG|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
214536753|NCT02906995|DRUG|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
214536754|NCT00706914|DRUG|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
214536755|NCT00706914|DRUG|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
214536756|NCT00706914|DRUG|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
214536757|NCT00706914|DRUG|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
214696701|NCT04673526|PROCEDURE|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
214696702|NCT04673526|PROCEDURE|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
214696703|NCT02733614|DRUG|SRX246|novel V1a receptor antagonist
214696704|NCT02733614|DRUG|Placebo|matching placebo
214696705|NCT00331370|BEHAVIORAL|GP training and Health Education|
214536758|NCT04214275|OTHER|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
215155721|NCT03115788|OTHER|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
215155722|NCT03115788|OTHER|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
215155723|NCT03115788|OTHER|iPad|
214536759|NCT00087997|DRUG|STA-4783|
214536760|NCT04010383|DIAGNOSTIC_TEST|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
214536761|NCT02025478|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
214536762|NCT06220812|DEVICE|low level laser ,pulsed electromagnetic field .|"LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage."
214536763|NCT00392535|RADIATION|conventional radiotherapy 74 Gy delivered in 37 fractions|
214536764|NCT00392535|RADIATION|hypofractionated radiation therapy 60 Gy in 20 fractions|
214536765|NCT00392535|RADIATION|hypofractionated radiation therapy 57 Gy in 19 fractions|
214536766|NCT02122549|DEVICE|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
214536767|NCT03505255|DRUG|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
214536768|NCT03505255|OTHER|Normal saline|Normal saline 0.9 % is given in the control group
214536769|NCT04868253|DRUG|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
214536770|NCT02943707|PROCEDURE|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
214536771|NCT02943707|DRUG|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
214536772|NCT03364478|PROCEDURE|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
214536773|NCT03364478|PROCEDURE|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
214536774|NCT02609152|DRUG|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
214536775|NCT02609152|DRUG|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
214536776|NCT01721174|PROCEDURE|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
214536777|NCT01721174|PROCEDURE|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
215155724|NCT06095128|DRUG|Vedolizumab|Vedolizumab IV infusions
214536778|NCT05187247|DEVICE|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
214536779|NCT01159483|DRUG|PF-04958242|Administered as specified in the treatment arm
214536780|NCT01159483|DRUG|Placebo|Administered as specified in the treatment arm
214536781|NCT02352077|BIOLOGICAL|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
214536782|NCT01903083|DRUG|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
214536783|NCT01903083|DRUG|Gemcitabine|Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
214536784|NCT01903083|RADIATION|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
214536785|NCT01903083|PROCEDURE|Pancreaticoduodenectomy|Surgical resection.
214536786|NCT03017313|DRUG|LHRH analogues|3-or 6-month formulations
214536787|NCT05987644|DRUG|Alectinib|600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)
214536788|NCT05987644|RADIATION|Stereotactic Radiosurgery|SRS dose varies by brain met size and location
214536789|NCT02156388|BIOLOGICAL|GW003|freeze-dried powder；single SC injection
215155725|NCT06095128|DRUG|Tofacitinib|Tofacitinib Tablets
215155726|NCT06102525|DRUG|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
215155727|NCT06102525|COMBINATION_PRODUCT|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
215155728|NCT06122415|DIAGNOSTIC_TEST|Plasma Amyloid Probability Score 2 (APS 2) score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215155729|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217/nptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215155730|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215155731|NCT06122415|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215155732|NCT06122415|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215155733|NCT05901558|BEHAVIORAL|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
215155734|NCT05901558|BEHAVIORAL|Community intervention|Regular community intervention
215155735|NCT04638660|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
215155736|NCT04638660|DRUG|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
215155737|NCT04965597|DRUG|Treosulfan|Given IV
215155738|NCT04965597|DRUG|Fludarabine Phosphate|Given IV
215155739|NCT04965597|DRUG|Tacrolimus|Given IV and PO
215155740|NCT04965597|DRUG|Methotrexate|Given IV
215155741|NCT04965597|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
215155742|NCT04965597|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
215155743|NCT04965597|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo bone marrow transplant
215155744|NCT04965597|OTHER|Quality-of-Life Assessment|Ancillary studies
215155745|NCT04965597|PROCEDURE|Echocardiography|Undergo ECHO
215155746|NCT04965597|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214536790|NCT03669328|PROCEDURE|locoregional anesthesia|Both groups received locoregional anesthesias
215155747|NCT04965597|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215155748|NCT04965597|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
215155749|NCT04965597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214464244|NCT05840172|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
214464245|NCT05840172|DEVICE|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
214464246|NCT04581564|BEHAVIORAL|Rhythm-based speech therapy app (i.e., Speech Hero)|Participants will be issued a tablet device pre-installed with a rhythm-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
214464247|NCT04581564|BEHAVIORAL|Non-rhythm based (singing) application (conventional speech therapy)|Participants will be issued a tablet device pre-installed with a singing-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
214464248|NCT05098704|DRUG|clopidogrel treatment|75 mg daily during 24 months
214464249|NCT05098704|DRUG|Placebo|75 mg daily during 24 months
214464250|NCT02992704|DRUG|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
215155750|NCT04965597|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
215155751|NCT04965597|PROCEDURE|Computed Tomography|Undergo chest CT
215155752|NCT04991389|DRUG|129-Xe|Inhaled contrast for MRI
215155753|NCT06045754|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
215155754|NCT06045754|DRUG|Adalimumab|Adalimumab subcutaneous injection.
215155755|NCT06045754|DRUG|Ustekinumab|Ustekinumab intravenous infusion.
215155756|NCT06045754|DRUG|Ustekinumab|Ustekinumab subcutaneous injection.
215155757|NCT02343237|PROCEDURE|Osteopathic treatment|osteopathic sessions of 20 minutes
215155758|NCT02343237|PROCEDURE|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
215155759|NCT06637852|BEHAVIORAL|SUFICS-PACT|SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
215155760|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
214536791|NCT03954223|BEHAVIORAL|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)
214536792|NCT03954223|BEHAVIORAL|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
214536793|NCT03954223|DEVICE|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
214536794|NCT02787811|DEVICE|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
214536795|NCT04241809|DIAGNOSTIC_TEST|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
214536796|NCT02932085|DEVICE|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
214536797|NCT03927690|DRUG|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
214536798|NCT03927690|DRUG|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
214536799|NCT01850823|DRUG|placebo|
214536800|NCT01850823|DRUG|Mometasone Nasal Spray|
214696706|NCT03992768|DEVICE|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
214536801|NCT01850823|DRUG|Mometasone nasal spray|
214536802|NCT02200978|DRUG|ATO|Given IV
214536803|NCT02200978|DRUG|RIF|Given orally
214536804|NCT02200978|DRUG|ATRA|Given orally
214696707|NCT04068558|DEVICE|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
215155761|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
214536805|NCT02200978|DRUG|mitoxantrone|Given IV
215155762|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
215155763|NCT05645016|BEHAVIORAL|COEST|Adapted version of our COEST training, targeting Black church members.
215155764|NCT05566561|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
215155765|NCT04729322|PROCEDURE|Biopsy|Undergo biopsy
214536806|NCT02200978|DRUG|Ara-C|Given IV
214536807|NCT02200978|DRUG|MTX|Given orally
214536808|NCT02200978|DRUG|6MP|Given orally
214536809|NCT02200978|OTHER|intrathecal injection|Ara-C and dexamethasone
214536810|NCT02652195|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
214536811|NCT02652195|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
214536812|NCT01751165|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214536813|NCT04601597|DEVICE|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
214536814|NCT02830048|DRUG|Glibenclamide|
214536815|NCT05663164|DRUG|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
214536816|NCT05663164|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
214536817|NCT04026399|OTHER|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
214536818|NCT04026399|BEHAVIORAL|therapy|practice of daily living tasks
214536819|NCT03626077|OTHER|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
214536820|NCT03626077|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
215155766|NCT04729322|PROCEDURE|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
215155767|NCT04729322|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
215155768|NCT04729322|DRUG|Metronidazole|Given PO
214536821|NCT03626077|COMBINATION_PRODUCT|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
214536822|NCT06202911|DRUG|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
214536823|NCT06202911|OTHER|placebo|the control group will receive placebo
214536824|NCT00239096|DRUG|losartan (drug)|
215155769|NCT04729322|DRUG|Neomycin|Given PO
215155770|NCT04729322|BIOLOGICAL|Nivolumab|Given IV
215155771|NCT04729322|BIOLOGICAL|Pembrolizumab|Given IV
215155772|NCT04729322|OTHER|Questionnaire Administration|Ancillary studies
215155773|NCT04729322|DRUG|Vancomycin|Given PO
215155774|NCT06009393|DRUG|SHR-1918|Three administration
215155775|NCT04042337|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
215155776|NCT06196164|PROCEDURE|EUS-BD|We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
215155777|NCT06196164|PROCEDURE|ERCP-BD|We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
215155778|NCT06308718|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
215155779|NCT04120493|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
215155780|NCT04120493|OTHER|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
215155781|NCT01651585|DRUG|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
215155782|NCT06224933|DEVICE|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
215155783|NCT06444256|DRUG|SUVO|Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
215155784|NCT06444256|DRUG|TAU|Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
215155785|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
215155786|NCT04030455|DRUG|Carboplatin|Given IV
215155787|NCT04030455|DRUG|Cisplatin|Given IV
215155788|NCT04030455|DRUG|Docetaxel|Given IV
215155789|NCT04030455|BIOLOGICAL|Pembrolizumab|Given IV
214536825|NCT02888223|BIOLOGICAL|SCT800|
214536826|NCT02888223|BIOLOGICAL|Xyntha|
214536827|NCT05469412|DEVICE|iPad®|Use of Technology.
215155790|NCT06420297|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
214536828|NCT05469412|DRUG|Midazolam|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
214536829|NCT02431455|DEVICE|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
214536830|NCT02431455|DEVICE|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
214536831|NCT05865171|DRUG|IXP|Tablets for oral administration.
214536832|NCT00988533|DRUG|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
214536833|NCT03248141|DRUG|Hemophilia B standard half-life|Benefix
214536834|NCT03248141|DRUG|Hemophilia B extended half-life|Alprolix
214536835|NCT03248141|DRUG|Hemophilia A standard half-life|Xyntha and other standard half-life agents
215155791|NCT05025059|PROCEDURE|Discussion|Participate in coaching sessions
215155792|NCT05025059|OTHER|Exercise Intervention|Perform walking exercise
215155793|NCT05025059|OTHER|Exercise Intervention|Perform strength exercises
215155794|NCT05025059|OTHER|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
215155795|NCT05025059|OTHER|Informational Intervention|Maintain exercise log
215155796|NCT05025059|OTHER|Medical Device Usage and Evaluation|Wear fitness tracker
215155797|NCT05025059|OTHER|Quality-of-Life Assessment|Complete questionnaires
215155798|NCT05025059|OTHER|Questionnaire Administration|Complete questionnaires
215155799|NCT05889845|DRUG|Candin, Intradermal Solution|Injection at the base of the selected wart
215155800|NCT05889845|DRUG|Placebo|Injection at the base of the selected wart
214536836|NCT03248141|DRUG|Hemophilia A extended half-life|Eloctate and Adynovate
214536837|NCT00511277|DRUG|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
214536838|NCT05413863|BIOLOGICAL|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
214536839|NCT05413863|BIOLOGICAL|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
214536840|NCT00661544|DRUG|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
214536841|NCT00661544|DRUG|Melphalan|Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
214536842|NCT00661544|DRUG|Ascorbic Acid|Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
214536843|NCT05105568|BEHAVIORAL|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
214536844|NCT02573649|DEVICE|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
214536845|NCT02573649|DEVICE|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
214536846|NCT03871621|DRUG|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
214536847|NCT03871621|DRUG|Dapagliflozin|Dapagliflozin tablet (10 mg)
214536848|NCT00675792|DRUG|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
214536849|NCT00675792|DRUG|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
214536850|NCT00675792|DRUG|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
214536851|NCT05219578|DRUG|RTX-224|RTX-224 monotherapy
214536852|NCT00943722|BIOLOGICAL|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
214536853|NCT03613636|DIAGNOSTIC_TEST|Enzyme-linked immunospot (ELISpot) assay [Blood]|The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
214536854|NCT00828893|DEVICE|navigation station|navigation station for gestures (carried out under CT) guidance
214536855|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
214696708|NCT04068558|DEVICE|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
214696709|NCT05525767|DRUG|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
214696710|NCT03323918|OTHER|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
215155801|NCT06215677|DRUG|Camrelizumab|Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
215155802|NCT06364774|BIOLOGICAL|ALS20|novel lentiviral vector ALS20
215155803|NCT06228066|DRUG|Lurbinectedin|Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
215155804|NCT06228066|DRUG|Avelumab|Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
215155805|NCT06453265|DRUG|Cebranopadol- 600 ug|"Dose ascending cohorts~\- Cebranopadol 600 ug single dose"
215155806|NCT06453265|DRUG|Cebranopadol- 800ug|"Dose ascending cohorts~\- Cebraopadol 800 ug single dose"
215155807|NCT06453265|DRUG|Cebranopadol- 1000ug|"Dose ascending cohorts~\- Cebranopadol 1000 ug single dose"
215155808|NCT06453265|DRUG|Treatment A:|Cebranopadol, dose determined in Part A
215155809|NCT06453265|DRUG|Treatment B|Oxycodone HCl IR 40 mg
215155810|NCT06453265|DRUG|Treatment C|Placebo
215155811|NCT06453265|DRUG|Qualification|Oxycodone 40mg
215155812|NCT06453265|DRUG|Qualification|Matching Placebo
215155813|NCT03664687|DRUG|Zoledronate|Administered intravenously (IV)
215155814|NCT04879329|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
214536856|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
215155815|NCT04879329|DRUG|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
215155816|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
214536857|NCT04240028|OTHER|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
214536858|NCT01117129|DRUG|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
214536859|NCT01117129|DRUG|placebo|i.v. infusion on day 1 and 15
214536860|NCT01117129|DRUG|methotrexate|10-25 mg weekly
214536861|NCT01117129|DRUG|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
214536862|NCT04640818|DRUG|Cladribine Oral Tablet|Treatment according to the label and medical prescription
214536863|NCT04640818|DRUG|Rituximab|Treatment according to the label and medical prescription
214536864|NCT04640818|DRUG|Ocrelizumab|Treatment according to the label and medical prescription
214536865|NCT02580175|PROCEDURE|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
214536866|NCT02580175|PROCEDURE|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
214536867|NCT04410809|BIOLOGICAL|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
214536868|NCT04410809|OTHER|Placebo|The same composition as the active medication but without the active substance TA-46
214536869|NCT04330378|OTHER|Hospital-at-home|As per experimental arm
214536870|NCT04330378|OTHER|Usual in-hospital care|As per control arm
214536871|NCT02378636|DEVICE|600S|Monofocal Aspheric Intraocular Lens (IOL)
214536872|NCT01036165|DEVICE|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
214536873|NCT03100955|DRUG|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
214536874|NCT03100955|DRUG|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
215155817|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
215155818|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
215155819|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
215155820|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
215155821|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
215155822|NCT04939415|DRUG|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
214536875|NCT06125899|BEHAVIORAL|emhGAP-Age|"* Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources."
214536876|NCT04423172|DEVICE|the new tissue containment system|Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
214536877|NCT01840449|DRUG|Somatuline Autogel® 60, 90 or 120 mg|
214536878|NCT02656849|DRUG|BAY 1000394|
214536879|NCT04434118|DRUG|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
214696711|NCT03323918|OTHER|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
215155823|NCT04939415|DRUG|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
215155824|NCT06344403|DRUG|analgesic|Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.
215155825|NCT06344403|BEHAVIORAL|Tender point infiltration|Lidocaine mixed with diprospan injected into tender points.
215155826|NCT04216524|DRUG|Cyclophosphamide|Given IV
215155827|NCT04216524|DRUG|Cytarabine|Given IT or IV
215155828|NCT04216524|DRUG|Dexamethasone|Given PO or IV
215155829|NCT04216524|DRUG|Doxorubicin|Given IV
215155830|NCT04216524|DRUG|Mercaptopurine|Given PO
215155831|NCT04216524|DRUG|Methotrexate|Given IT, IV, or PO
215155832|NCT04216524|DRUG|Methylprednisolone|Given IV
215155833|NCT04216524|DRUG|Prednisone|Given PO
215155834|NCT04216524|BIOLOGICAL|Rituximab|Given IV
215155835|NCT04216524|BIOLOGICAL|Tagraxofusp-erzs|Given IV
215155836|NCT04216524|DRUG|Venetoclax|Given PO
215155837|NCT04216524|DRUG|Vincristine|Given IV
215155838|NCT02629809|DRUG|Cyclophosphamide|Given IV
215155839|NCT02629809|DRUG|Fludarabine Phosphate|Given IV
214536880|NCT01276613|DRUG|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
214536881|NCT01276613|DRUG|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
214536882|NCT03468179|DIETARY_SUPPLEMENT|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
214536883|NCT03701633|DIAGNOSTIC_TEST|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
214536884|NCT02958241|OTHER|MRI|Supine and weight bearing MRI
214536885|NCT03293836|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
215155840|NCT02629809|DRUG|Ibrutinib|Given PO
215155841|NCT02629809|BIOLOGICAL|Obinutuzumab|Given IV
215155842|NCT06233747|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by licensed nursing assistants or other non-specialist clinicians who provide one-on-one safety supervision during boarding. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy. Given that one-on-one safety supervision is the current standard of care during boarding, I-CARE requires minimal additional resources beyond those already available in acute care hospitals and builds on well established research demonstrating the effectiveness of task-sharing, the redistribution of tasks within the workforce, to address the shortage of mental health professionals.
215155843|NCT01617161|RADIATION|Proton Beam Therapy|5 days per week up to 9 weeks
215155844|NCT01617161|RADIATION|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
215155845|NCT05130580|OTHER|Enhanced Consultation|Attend an enhanced consultation with decision aid
215155846|NCT05130580|OTHER|Standard of Care Consultation|Attend standard of care consultation
215155847|NCT05130580|PROCEDURE|Conventional Imaging|Undergo 2D and 3D torso imaging
215155848|NCT05130580|OTHER|Educational Intervention|Receive educational materials
215155849|NCT05130580|OTHER|Questionnaire Administration|Ancillary studies
215155850|NCT06564792|BEHAVIORAL|Contingency management|Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
215155851|NCT02425293|BEHAVIORAL|asthma patient education|
215155852|NCT05569239|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1.
215155853|NCT05569239|BIOLOGICAL|Saline Solution|One single administration intramuscularly at Day 1.
215155854|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
215155855|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
214536886|NCT03293836|PROCEDURE|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
214536887|NCT04592497|PROCEDURE|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
214536888|NCT05423431|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
214536889|NCT01752764|OTHER|Test product: Salad with a high dosage fat|
215155856|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
214536890|NCT01752764|OTHER|Control product: Salad with low dosage fat|
214536891|NCT02470923|DRUG|Nicotine replacement therapy|
214536892|NCT02470923|BEHAVIORAL|Intensive counseling|
214536893|NCT02470923|BEHAVIORAL|Medical advice|
214536894|NCT01339624|DRUG|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
214536895|NCT01339624|DRUG|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
214536896|NCT03543605|BEHAVIORAL|PROA Experimental|PROA Control plus clinical advice
214536897|NCT03543605|OTHER|PROA Control|PROA Control
214536898|NCT01387815|BIOLOGICAL|Adalimumab|Adalimumab administered by subcutaneous injection.
214536899|NCT04456647|OTHER|Parenteral nutrition|Parenteral nutrition treatment in palliative care
214536900|NCT03082898|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
214536901|NCT02389322|BIOLOGICAL|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
214536902|NCT02389322|BIOLOGICAL|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
214536903|NCT02389322|BIOLOGICAL|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
214536904|NCT02389322|BIOLOGICAL|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
214536905|NCT05616598|DRUG|Sofosbuvir +daclatasvir+ simeprevir+Ribavirin|Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
214536906|NCT00913523|DEVICE|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
214536907|NCT00913523|DEVICE|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
214536908|NCT06164808|DEVICE|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
214536909|NCT00483353|PROCEDURE|Intra-nasal allergen challenge with Phleum pratense.|
214536910|NCT00483353|PROCEDURE|Collection of nasal effluent using filter paper.|
214536911|NCT00483353|PROCEDURE|Measurement of nasal congestion using acoustic rhinometry.|
214536912|NCT02895360|DRUG|BAL101553|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
214536913|NCT02895360|DRUG|BAL101553 at MTD|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
214536914|NCT00916305|OTHER|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
214536915|NCT00916305|OTHER|Unmodified audio video|An audio video with unaltered music
214536916|NCT01844726|DRUG|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
214536917|NCT01844726|DRUG|Placebo|Single injection of placebo (saline)
214536918|NCT05781165|OTHER|Augmented reality|Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
215155857|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
215155858|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
215155859|NCT05733598|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
215155860|NCT05733598|BIOLOGICAL|Bevacizumab|Anti-VEGF therapy.
215155861|NCT05733598|BIOLOGICAL|Atezolizumab|Anti-PD-L1 monoclonal antibody.
215155862|NCT05733598|BIOLOGICAL|Durvalumab|Anti-PD-L1 monoclonal antibody
215155863|NCT05787002|DRUG|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
215155864|NCT05787002|DRUG|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
215155865|NCT03587376|DRUG|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
215155866|NCT03612934|PROCEDURE|Specialist Palliative Care|In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
215155867|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
215155868|NCT05942833|PROCEDURE|Sigmoid resection|Timing of sigmoid resection
215155869|NCT04713241|PROCEDURE|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
215155870|NCT04713241|OTHER|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
215155871|NCT01434199|PROCEDURE|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
214536919|NCT01688817|OTHER|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
214536920|NCT01688817|OTHER|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
214536921|NCT02149524|DRUG|Herceptin (trastuzuamb)|Intravenous administration
214536922|NCT02149524|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
215155872|NCT03715348|DRUG|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
215155873|NCT03715348|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
215155874|NCT02034864|OTHER|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
215155875|NCT02034864|OTHER|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
215155876|NCT01276210|DRUG|sorafenib tosylate|Given PO
215155877|NCT01276210|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
215155878|NCT01276210|OTHER|laboratory biomarker analysis|Correlative studies
215155879|NCT05577299|DEVICE|PET/CT|18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
215155880|NCT06053658|DRUG|Tivozanib|Given by PO
215155881|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
215155882|NCT02239419|PROCEDURE|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
215155883|NCT02239419|PROCEDURE|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
215155884|NCT03525795|DRUG|CPI-1205|Administered orally
214464251|NCT06595862|BEHAVIORAL|EA-Avatar|The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
214464252|NCT05209152|DRUG|AMG 176|Administered as an intravenous (IV) infusion.
214464253|NCT05209152|DRUG|Azacitidine|Administered as an IV infusion or subcutaneous (SC) injection.
214464254|NCT04700072|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214464255|NCT04700072|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
214464256|NCT04700072|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
214464257|NCT06842498|DRUG|FG-3246|FG-3246 will be administered per schedule specified in the arm description.
214464258|NCT04242199|DRUG|INCB099280|INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
214464259|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
214464260|NCT05547542|DRUG|CVL-354|Oral solution/capsule
214464261|NCT05547542|DRUG|[11C]-LY2795050|IV injection
214464262|NCT05547542|DRUG|[11C]-carfentanil|IV injection
214464263|NCT05673187|DRUG|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
214464264|NCT06345755|DRUG|VX-407|Solution or Suspension for oral administration.
214464265|NCT06345755|DRUG|Placebo|Solution or Suspension for oral administration.
214464266|NCT06345755|DRUG|Midazolam|Syrup for oral administration.
214464267|NCT06345755|DRUG|VX-407|Suspension or Tablets for oral administration.
214464268|NCT06867185|DEVICE|Brief Electrical Stimulation Therapy|10-minutes of electrical stimulation to repaired nerve
214464269|NCT06867185|PROCEDURE|Digital Nerve Repair|Standard of care surgical repair of digital nerve injury as determined by health care provider.
214464270|NCT06867835|DRUG|Vyleesi (Bremelanotide Injection)|Single dose of BMT 1.75 mg SC on Day 1
214464271|NCT06872944|DRUG|Melatonin|"Melatonin, or N-acetylmethoxytryptamine, is a hormone secreted by the pineal gland in the brain. Light is the main factor that regulates melatonin production. Melatonin has important biological effects on the body and plays an important role in regulating the sleep wake cycle. Besides circadian rhythm stabilizing, exogenous melatonin has been investigated for other effects such as modulation of blood pressure, body temperature and cortisol control, immune function, and anti-oxidative defense.~Recent studies showed some benefits of perioperative short-acting melatonin in different groups of patients such as quality of recovery after surgery, diminished depressive symptoms and pain score reduction"
214464272|NCT06872944|DRUG|Sugar Coated Tablet|sugar coated tablets will be given to the patients at the night (8 PM) before the procedure and another dose 2 hours before surgery
214464273|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
214464274|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
214464275|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
214464276|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
214464277|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
214464278|NCT07050745|BEHAVIORAL|DADA LINK|"Intervention facilities will receive the DADA-LINK intervention, comprised of:~1. HPV self-sampling: We will provide clinics with HPV self-sampling kits to administer to eligible patients.~2. Care Navigation: One study-supported non-physician care navigator will be assigned to each clinic to support the clinic staff. These trained individuals will be responsible for managing data collection through the mHealth platform to aid the coordination of services and for motivating the clinic staff to adhere to cervical cancer care guidelines.~3. mHealth support for cervical cancer screening and treatment linkage: The WEMA application is a low-cost and highly adaptable open-source application designed for cervical cancer data monitoring and evaluation. Relevant patient information and data on uptake of cervical cancer screening and triage/treatment will be entered in the WEMA platform. The platform will additionally be used to send text messages to patients to facilitate clinic attendance."
214464279|NCT07049497|OTHER|Evaluation of the T cell response in terms of IFN-γ measured by ELISpot|The evaluation of the T cell response will be performed by quantifying the frequencies of SARS-CoV-2-specific T cells producing IFN-γ using an enzyme-linked immunospot assay (ELISpot), with cryopreserved PBMC collected at the designated timepoints (T0, T1, T2, T3, and T4)
214464280|NCT07052006|DRUG|HT-6184|Oral HT-6184
214696712|NCT02290535|PROCEDURE|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
214696713|NCT02290535|PROCEDURE|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
214696714|NCT00920608|DRUG|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
214696715|NCT00920608|DRUG|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
214696716|NCT06282900|OTHER|University students|A cross-sectional study (Level IV evidence) will be conducted at the university (Acibadem University, Turkey). All students at the university will be invited to respond to a self-administered online survey. The survey will be prepared via Google Forms.
214696717|NCT03126539|DRUG|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
214696718|NCT03126539|RADIATION|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
215155885|NCT03525795|DRUG|ipilimumab|Administered intravenously
215155886|NCT00135551|DRUG|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
214464281|NCT04168580|OTHER|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
214536923|NCT03177109|DRUG|5% fluoride varnish|Applied topically as a coating at single point in time
214536924|NCT03177109|DRUG|8% arginine containing paste|Applied topically as a coating at single point in time
214536925|NCT03177109|DRUG|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
215155887|NCT00135551|DRUG|β-blockers|benidipine+β-blockers, titlation scheme
214536926|NCT02717741|DRUG|tafetinib|
215155888|NCT00135551|DRUG|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
214464282|NCT07056764|OTHER|Standard treatment|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
214536927|NCT01416935|OTHER|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
214536928|NCT00777998|PROCEDURE|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> 2 months later: Melphalan plus allogeneic PBSCT~* -\> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~* -\> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10\^6 (MRD) or 5 x 10\^5 (MUD) CD3+ cells per kg BW)~* -\> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Further DLI depending on MRD-measurement"
214536929|NCT00777998|PROCEDURE|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~* -\> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
214536930|NCT00307164|DRUG|NucleomaxX|36 g sachet taken orally three times daily
214536931|NCT00307164|DRUG|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
214536932|NCT01457274|OTHER|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80)."
215155889|NCT00679900|DRUG|eplivanserin (SR46349)|5 mg/day
215155890|NCT00679900|DRUG|lormetazepam|1 mg/day
215155891|NCT02057185|BEHAVIORAL|Study questionnaire|Questionnaire based on work situation of enrolled patients.
215155892|NCT02057185|BEHAVIORAL|SF-36 Questionnaire|Version 1.6
215155893|NCT01314586|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
215155894|NCT05717543|DEVICE|Retro-illuminator|The device Retro-illuminator will be used to photograph the eyes.
215155895|NCT01444040|DEVICE|iStent inject|Implantation of two iStent inject devices
215155896|NCT01444040|DRUG|Travoprost|Travoprost drops
214696719|NCT03126539|PROCEDURE|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
214696720|NCT03864263|OTHER||
214696721|NCT02632110|DRUG|ALA|20% ALA applied to face prior to light treatment
214696722|NCT02632110|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
214696723|NCT02632110|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
214696724|NCT02632110|PROCEDURE|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
214696725|NCT02632110|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
214696726|NCT01266655|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
214696727|NCT01266655|DRUG|Placebo|Placebo
215155897|NCT05445271|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
215155898|NCT04930471|DRUG|Metformin|Treatment with Metformin as prescribed by the treating physician.
215155899|NCT03807206|BEHAVIORAL|Questionnaire|Patient questionnaire
215155900|NCT02797938|DEVICE|Taper guard tube|Taper guard tube was intubated
214696728|NCT03645408|DRUG|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
214696729|NCT03645408|OTHER|Sham injection|Subjects received a sham injection with no study drug.
214696730|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
214696731|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
214696732|NCT05067062|DIETARY_SUPPLEMENT|New Zealand blackcurrant extract|Capsules taken daily or intermittent
215155901|NCT02797938|DEVICE|Cylindrical tube|Cylindrical tube was intubated
215155902|NCT00798993|OTHER|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
215155903|NCT00798993|DRUG|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
215155904|NCT00798993|OTHER|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
215155905|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
215155906|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
215155907|NCT05365425|DRUG|Choline fenofibrate|choline fenofibrate 178.8mg (135mg as fenofibric acid)
215155908|NCT05365425|DRUG|Policosanol|policosanol 10mg
215155909|NCT03239106|DRUG|Apremilast|Apremilast 30 mg BID daily
215155910|NCT06331143|DEVICE|Ultrasound-Guided Mid-Transverse Process to Pleura (MTP) Block|Patients will receive MTP block after induction of anesthesia.
215155911|NCT06331143|DRUG|Morphine|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
214696733|NCT05213468|DEVICE|PainDrainerTM|Self management digital tool for chronic pain
214696734|NCT00516269|DRUG|Methylphenidate|18 mg by mouth daily for 2 weeks
214696735|NCT00516269|DRUG|Placebo|Capsule by mouth daily for 2 weeks
214696736|NCT01907594|DRUG|D-cycloserine|
214696737|NCT01907594|DRUG|Nicotine Replacement Therapy (patch)|
214696738|NCT01907594|BEHAVIORAL|Smoking Cue Exposure|
214696739|NCT01907594|BEHAVIORAL|Progressive Muscle Relaxation|
214696740|NCT01907594|DRUG|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
214696741|NCT00734786|OTHER|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
214696742|NCT04178681|OTHER|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
215155912|NCT06217484|BEHAVIORAL|delayed feedback|participants learn through either immediate or delayed feedback during a computer task
215155913|NCT04591808|DRUG|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
215155914|NCT04591808|DRUG|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
215155915|NCT04591808|DRUG|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
215155916|NCT06405191|BEHAVIORAL|Web based education|The link to the web page was shared with the students in the experimental group (https://inonuhemsirelikesaslari.com, the expired page cannot be accessed at the moment). Theoretical training and application process steps video for IV catheterization and IM injection skills were taken to the students in the experimental group and uploaded to the web page. The students in the experimental group were given a username-password with which they could access the web page, and the access status of the students was followed by the researcher. The researcher was able to see the frequency of each student watching the videos and their scores in online tests. The student who did not watch the videos or did not take the test was interviewed and feedback was given about watching them. Students were able to access the web page as often as they wanted for two weeks.
215155917|NCT05847946|OTHER|Kinesio tape application and Core stabilization home program|Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.
215155918|NCT05847946|OTHER|Core stabilization home program|Core stabilization exercises will be given to the participants as a home exercise program.
215155919|NCT04677088|BIOLOGICAL|TCR-T cells|Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
215155920|NCT01804400|DRUG|QAW039|
214464283|NCT07056764|DEVICE|Standard treatment + Lung vibration device|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
214464284|NCT07058987|BEHAVIORAL|Cardiac Rehabilitation Combined With EECP|This intervention consists of a comprehensive cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support, and lifestyle counseling, combined with enhanced external counterpulsation (EECP) therapy administered according to standard cardiovascular protocols. The combined intervention is designed to improve cardiac function, exercise tolerance, and quality of life in patients with atrial fibrillation.
214536933|NCT04264546|BIOLOGICAL|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
214536934|NCT00583271|DRUG|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
215155921|NCT01804400|DRUG|Montelukast|
215155922|NCT01804400|DRUG|Placebo|
215155923|NCT01591525|BEHAVIORAL|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
215155924|NCT01591525|BEHAVIORAL|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
215155925|NCT01591525|BEHAVIORAL|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
215155926|NCT05474157|OTHER|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
214464285|NCT07058987|OTHER|Routine Medical Care|Participants in the control group will receive standard medical treatment for atrial fibrillation as prescribed by their attending physicians, without enhanced external counterpulsation or structured cardiac rehabilitation. This may include pharmacological therapy, routine clinical monitoring, and general lifestyle advice.
214536935|NCT00583271|DRUG|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
214696743|NCT04178681|OTHER|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
214536936|NCT00190099|DEVICE|Dexamethasone-Eluting Stent|
214536937|NCT02520700|DEVICE|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
215155927|NCT01463449|PROCEDURE|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
214536938|NCT02325362|DRUG|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
215155928|NCT03399552|DRUG|Avelumab|10mg/kg delivered by IV infusion
215155929|NCT03399552|RADIATION|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
215155930|NCT01696539|BEHAVIORAL|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
215155931|NCT01696539|OTHER|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
215155932|NCT00493129|DRUG|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
215155933|NCT04691076|DRUG|Propofol|Propofol is administered by target-controlled infusion
215155934|NCT04691076|DRUG|Esketamine|Esketamine is intravenously administrated
215155935|NCT04691076|DRUG|Fentanyl|Fentanyl is intravenously administrated
215155936|NCT03918564|DEVICE|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
215155937|NCT00783107|DRUG|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
215155938|NCT00783107|DRUG|Placebo|
215155939|NCT01573689|BEHAVIORAL|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
215155940|NCT03626909|OTHER|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
215155941|NCT03626909|OTHER|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
215155942|NCT03626909|OTHER|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
214536939|NCT02325362|DRUG|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
215155943|NCT03626909|OTHER|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
215155944|NCT00194428|BEHAVIORAL|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
214536940|NCT00000677|DRUG|SCH 39304|
215155945|NCT00194428|BEHAVIORAL|Low fat caloric diet|Low fat caloric diet
214536941|NCT04067843|PROCEDURE|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
214536942|NCT05710237|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
214696744|NCT04178681|OTHER|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
215155946|NCT01162642|DIETARY_SUPPLEMENT|Green Tea|Green Tea 4 cups daily
215155947|NCT01162642|OTHER|Placebo|4 cups placebo tea for 6 weeks
215155948|NCT00002496|DRUG|chemotherapy|
215155949|NCT00002496|DRUG|cisplatin|
214464286|NCT07059572|DRUG|Group A- 0.15% Guava leaf extract mouthwash group|Participants will be instructed to rinse with 10 ml of 0.15% Guava Leaf Extract Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing.
214464287|NCT07059572|DRUG|Group B- 0.2% Chlorhexidine mouthwash|"Participants will be instructed to rinse with 10 ml of 0.2% Chlorhexidine Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing."
214464288|NCT07062562|OTHER|Sham (No Treatment)|A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.
214464289|NCT07062562|OTHER|NMES|Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.
214464290|NCT07062562|DIETARY_SUPPLEMENT|Protein bolus (20g)|A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.
214464291|NCT07062562|OTHER|Standard nutrition|Provision of a normal Western standardized diet.
214464292|NCT07062601|DRUG|Etomidate and fentanyl group|In the etomidate-fentanyl group (group A), 0.3 mg/kg etomidate and 4 µg/kg fentanyl were given at the induction of anesthesia, followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the surgery, respectively.
214464293|NCT07062601|DRUG|Etomidate and esketamine group|In the etomidate-esketamine group (group B), induction of anesthesia with 0.3 mg/kg etomidate and 0.5 mg/kg esketamine , followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the operation
214464294|NCT07063992|OTHER|thoracic facet manipulations|"Group A will receive thoracic facet manipulations of the restricted segments between T3 to T9, in the prone position and cephalic direction. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre- and post-intervention observations will be recorded.~Bilateral hypothenar Cross bilateral hypothenar manipulationThese flexibility exercises will be targeted for~* Rhomboid and middle trapezius stretching (2-3 times daily; 3 sets for 30 seconds))~* Pectoralis muscle stretch in a corner (2-3 times daily; 3 sets for 30 seconds)~* Prone on the elbow with upper thoracic extension exercise (2-3 times daily; 3 sets for 30 seconds) .~The postural exercises will be the following~* Postural strengthening/ stabilization with back to a wall. The participant will press their arms into the wall while retracting scapulae.~* Trunk rotation stretching in the sitting position"
214464295|NCT07063992|OTHER|thoracic facet and costovertebral manipulations|"Group B will receive thoracic facet and costovertebral manipulations of the restricted segments between T3 to T9 and ribs 3 to 9 (costovertebral joints), in the prone position. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre and post-intervention observations will be recorded.~Hypothenar Costal Manipulative technique Ilial Hypothenar costal manipulation between T3-T9"
214464296|NCT07062289|PROCEDURE|endoscopic ultrasound-guided portal pressure gradient|This study employs an integrated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG+) protocol uniquely designed for cirrhotic patients with portal vein thrombosis (PVT). Under general anesthesia in the left lateral decubitus position (novel positioning), a linear echoendoscope directs 22G needle puncture of the portal vein and inferior vena cava for direct pressure measurement, with real-time Doppler confirmation to avoid thrombosed vessels. Crucially, this intervention synchronizes diagnostic and therapeutic actions: if high-risk esophageal/gastric varices are identified during EUS, immediate endoscopic therapy (e.g., glue injection) is delivered in the same session. All participants additionally undergo standard hepatic venous pressure gradient (HVPG) measurement via transjugular access within 24 hours, enabling within-patient correlation analysis.
214464297|NCT07063420|OTHER|Experimental Group|Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS) PCM-DSS (n=12)
214464298|NCT07063420|OTHER|Control Group|Continuous Glucose Monitor (CGM) + Usual Care
214464299|NCT07063004|OTHER|Bruegger's Exercise and Upper Thoracic Mobilization|"Bruegger's Exercise: The position will be held for 10 second at first session and then there will be an increment of 2 seconds during each session.~Upper Thoracic Mobilization: Upper thoracic (T1-T6) mobilization (Maitland mobilization (Grade I, II and III; PA glide) applied in prone lying position from via spinous process. Amount of treatment will be 3-4 mobilizations for a vertebra for 30 seconds approximately."
214464300|NCT07063004|OTHER|Standard Physical Therapy|"Isometric exercises will be done for flexors, extensors, rotators, and lateral flexors of the neck. Isometrically contracting working muscle for 5 seconds against patients own hand, which was placed in compliance with the working muscles, with a total of 10 repetitions.~Passive stretching will apply to Upper trapezius, Levator scapulae, Sternocleidomastoid, Scalene, Pectoralis major and minor muscle for 3-5 repetition 10 with 20-30 second hold. Intensity of exercise will be prescribed according to patient's tolerance level. Duration of stretch will 15 to 30 seconds, 3-5repetition and for 10 minutes.~Postero-anterior Maitland mobilization (Grade I \& II) for C1-C2, Maitland lateral PA glide (Grade-III \& IV) for C3-C6. Time of oscillations will be two or three oscillations in a second for one to two minutes."
214696745|NCT00006708|BIOLOGICAL|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
215155950|NCT00002496|DRUG|fluorouracil|
215155951|NCT00002496|PROCEDURE|conventional surgery|
215155952|NCT00002496|RADIATION|low-LET cobalt-60 gamma ray therapy|
215155953|NCT00002496|RADIATION|low-LET electron therapy|
215155954|NCT00002496|RADIATION|low-LET photon therapy|
215155955|NCT04082793|COMBINATION_PRODUCT|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
214536943|NCT05710237|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
214536944|NCT05710237|DRUG|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
214536945|NCT05936008|BEHAVIORAL|Exercise MICT|Standard of care, exercise recommendations for people with stroke
214536946|NCT05936008|BEHAVIORAL|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
214536947|NCT06224400|DRUG|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
214536948|NCT06224400|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
214536949|NCT06224400|DRUG|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
214536950|NCT06224400|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
214536951|NCT03729427|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
214536952|NCT05098015|BEHAVIORAL|Game Changers|8-session group intervention that uses didactic instruction, role plays and experience sharing to empower participants to engage in HIV prevention advocacy.
214696746|NCT00006708|BIOLOGICAL|rituximab|
214696747|NCT00006708|DRUG|carboplatin|
214696748|NCT00006708|DRUG|etoposide|
214696749|NCT00006708|DRUG|ifosfamide|
214696750|NCT03072121|DRUG|Shexiang Baoxin pill|Conventional western medicine \& shexiang baoxin pill
214696751|NCT03072121|DRUG|SBP placebo|Conventional western medicine \& placebo (for shexiang baoxin pill)
214696752|NCT03072121|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
215155956|NCT04082793|COMBINATION_PRODUCT|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
215155957|NCT05370677|GENETIC|ARMS|amplification refractory mutation system
215155958|NCT04843462|DEVICE|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time."
215155959|NCT04843462|DRUG|Esketamine nasal spray|All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
214696753|NCT03072121|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
214696754|NCT03072121|DRUG|Atorvastatin Calcium|10 mg tablet, two tablets each night.
214696755|NCT03072121|DRUG|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
215155960|NCT02682043|DEVICE|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
215155961|NCT05935670|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
215155962|NCT03831750|OTHER|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
215155963|NCT00721383|BEHAVIORAL|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
214464301|NCT07062731|BEHAVIORAL|Supervised pelvic floor muscle exercises|4 months of supervised physiotherapy by a women's health physiotherapists (3 sessions in total)
214464302|NCT07064031|OTHER|Neck Isometrics , TENS and Hot pack|Hot apck and TENS applied for 10min each. Using the same amount of light pressure, gently push your head into your hand as you did before. This time, allow the head to move slowly toward the shoulder against the pressure of the hand. This too can be repeated on the opposite side, forwards, backward, and into left and right rotation
214464303|NCT07063303|OTHER|Intermittent feeding|"Feeding Frequency: Enteral nutrition will be provided every 4 to 6 hours via nasogastric tube.~Feeding Volume: Each session will deliver 240 to 720 mL of enteral formula. Feeding Duration: Each feeding session will last approximately 20 to 60 minutes."
214464304|NCT07063303|OTHER|Continuous feeding|"Feeding Frequency: Enteral nutrition will be administered continuously for 20 hours per day via nasogastric tube.~Feeding Volume: The total daily volume will be divided evenly over the 20-hour infusion period, based on individual nutritional requirements.~Feeding Duration: Each 24-hour cycle includes 20 hours of continuous feeding followed by a 4-hour rest period."
215155964|NCT00721383|BEHAVIORAL|CSBI|Caregiver skill-building
215155965|NCT00140608|DEVICE|Seprapack Sinus Dressing|
215155966|NCT01734616|BEHAVIORAL|Old Exercise|
215155967|NCT01734616|DIETARY_SUPPLEMENT|Old Acute Cocoa|
215155968|NCT01734616|DIETARY_SUPPLEMENT|Old 7 Day Cocoa|
214536953|NCT04183023|GENETIC|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
214464305|NCT07061990|DIAGNOSTIC_TEST|Polysomnography (PSG)|Participants underwent overnight polysomnography for a minimum of 7 hours using an E series polysomnography monitor. The monitoring included electroencephalogram (EEG), eye movement, Holter monitoring, airflow, chest and abdominal respiratory movements, and fingertip oxygen saturation. The results were used to diagnose Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) and calculate the Apnea-Hypopnea Index (AHI) for severity classification.
214464306|NCT07061990|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|A whole-brain scan was performed on all participants using a Philips Ingenia 3.0T MRI scanner. The scanning sequences included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), and Fluid-Attenuated Inversion Recovery (FLAIR). The images were analyzed by two neurologists to identify asymptomatic lacunar infarction and to assess the severity of white matter lesions using the Age-Related White Matter Change (ARWMC) scoring system.
214464307|NCT07061990|DIAGNOSTIC_TEST|Serum Inflammatory Marker Measurement|Fasting venous blood (3mL) was collected from all participants on the day of their brain MRI scan. Serum was separated by centrifugation. Levels of Serum Amyloid A (SAA), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-6 (IL-6) were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) method according to the manufacturer's protocols.
214464308|NCT07063407|DRUG|HS-20093 in combination with Adebrelimab|HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until disease progression or other criteria for termination of treatment are met.
214464309|NCT07062432|BEHAVIORAL|Continuous Comprehensive Nursing System|A multi-faceted nursing plan delivered by trained cardiac nurses, extending from the preoperative phase to 3 months post-discharge. In addition to routine inpatient care, the intervention included: preoperative education and psychological support; postoperative individualized rehabilitation guidance; and a continuous post-discharge program. The post-discharge phase involved structured follow-up (monthly phone calls, one 6-week outpatient visit), ongoing psychological support, reinforcement of education on medication adherence, diet, and activity progression, and guidance on a structured home-based exercise program.
214464310|NCT07062432|OTHER|Routine Postoperative Care|Standard institutional postoperative care for patients after Coronary Artery Bypass Graft (CABG) surgery. This care was primarily focused on the inpatient period and included monitoring of vital signs, wound and drainage tube management, respiratory and circulatory support, and progressive diet guidance. The care concluded with standard discharge instructions and did not include the structured, continuous, or extended follow-up provided to the intervention group.
214464311|NCT07063537|DEVICE|Virtual Reality Visual Field (VR-VF)|Both devices administer a standard visual field test. The Humphrey is the gold standard desk top model and the VR-VF is a virtual reality headset designed to deliver visual field testing
214464312|NCT06765681|OTHER|Diagnosis of both VTE and sepsis|Both diagnoses need to present during ICU stay for case inclusion into this retrospective study
214464313|NCT07062575|DEVICE|ABLE Daily|The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks
214464314|NCT07063875|DRUG|Aldesleukin|IL-2 in combination with Tebentafusp
214464315|NCT07063641|DEVICE|Percutaneous Electrical Nerve Stimulation (PENS)|Ultrasound-guided percutaneous electrical nerve stimulation applied to the suprascapular nerve using a monophasic or biphasic current at 10 Hz frequency and 250 μs pulse width. Intensity is progressively increased to patient tolerance, aiming to induce visible muscle contractions of the supraspinatus and infraspinatus. Duration of the session is 30 minutes.
214536954|NCT03803943|BEHAVIORAL|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
215155969|NCT02888600|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
215155970|NCT02888600|BEHAVIORAL|Health Education|Guided health education and stress management training
215155971|NCT04198688|BEHAVIORAL|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
215155972|NCT01931566|DRUG|Pioglitazone|Pioglitazone SR tablets
215155973|NCT01931566|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets
215155974|NCT05342714|DEVICE|Remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
215155975|NCT04117516|PROCEDURE|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
215155976|NCT04117516|PROCEDURE|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
214464316|NCT07064096|OTHER|cawthorne cooksey exercise|Cawthorne Cooksey exercises -Start with low to moderate intensity. Cawthorne Cooksey exercise Training Phase1-In bed exerercises:- Eye movements: 1)Up and down 2)Side to side 3)Moving finger away from face -Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed -bending forward and backward -turning from side to side. --Shoulder shrugging and circling -Bending forward and picking up objects from the ground - Phase 3 - Standing: -Eye, Head, Shoulder movements -Throwing ball from hand to hand, hand under knee -Switch to sitting to standing and turning around in between. -Phase 4 - Walk: with eyes closed and open: -Across room -Slope and Stairs
214464317|NCT07064096|OTHER|mental imagery|The mental imagery intervention in this study is a structured, guided cognitive training program designed to enhance the effects of vestibular rehabilitation in young adults with unilateral vestibular hypofunction. Mental imagery (MI) involves the internal visualization and mental rehearsal of physical movements without actual motor output, engaging similar neural pathways as actual execution.
214696756|NCT03072121|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
214696757|NCT03072121|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
215155977|NCT04283227|GENETIC|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
215155978|NCT05623917|BEHAVIORAL|Tele-supervised diaphragmatic respiratory exercise|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
215155979|NCT03899922|DRUG|Drugs inducing uveitis|Drugs susceptible to induce uveitis
215155980|NCT04569487|PROCEDURE|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
214464318|NCT07062952|DIETARY_SUPPLEMENT|Salt substitute|Patient consume salt substitutes daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.Salt substitutes (potassium-enriched low-sodium salt, primarily NaCl and KCl) reduce sodium content versus regular salt
214464319|NCT07063160|BEHAVIORAL|Pain|Injection was used to determine the level of pain
214464320|NCT07063160|BEHAVIORAL|Fear of injection|The scale developed determines the fear levels of individuals towards the injection procedure. The scale consists of 14 items. It was developed on a 5-point Likert type, 1-I am not afraid at all, 5- I am very afraid. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of fear increases. Stated in their research that the Cronbach Alpha value for the entire scale was 0.92.
214464321|NCT07063160|BEHAVIORAL|Post-injection satisfaction|The scale developed to determine the satisfaction levels of patients regarding the injection process. The scale was developed in a 5-point Likert type, 1-I am not satisfied at all, 5-I am very satisfied. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of satisfaction increases. Post-injection satisfaction Scale consists of 9 items. In the study conducted, it was determined that the Cronbach Alpha value of the entire scale was 0.895.
214464322|NCT07064460|DEVICE|Physician Modified Endovascular Graft|The participant's surgeon will modify a commercially available graft tailored to their anatomy for their surgery. All components used to create the final device (PMEG), made specifically for each participant and tailored to their individual anatomy, are FDA-approved, although the final graft itself (the PMEG) is considered investigational.
214464323|NCT07063173|DIETARY_SUPPLEMENT|Fruit Bar|Tart Cherry N185
214464324|NCT07063173|DIETARY_SUPPLEMENT|Powdered Drink|Vita Cherry Sport N1244 (FutureCeuticals, Momence, IL)
214464325|NCT07063173|DIETARY_SUPPLEMENT|Commercially available 100% tart cherry juice|100% concentrated Montmorency cherry juice (CherryActive, Sunbury, UK)
214464326|NCT07063173|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
214464327|NCT07064525|DRUG|SPC1001 Low|low-dose combination therapy
214464328|NCT07064525|DRUG|SPC5002|low-dose combination therapy
214464329|NCT07064525|DRUG|SPC5003|low-dose combination therapy
214464330|NCT07064525|DRUG|SPC5004|low-dose combination therapy
214464331|NCT06830239|DRUG|Dostarlimab|"Dostarlimab \[Jemperli GlaxoSmithKline (GSK)\] is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.~Dostarlimab is in clinical development for the treatment of subjects with solid tumors, including those with recurrent/advanced dMMR/MSI-H solid tumors who have progressed on standard of care chemotherapy, as monotherapy or in combination with other agents."
214464332|NCT05619913|DRUG|Eribulin Mesylate|Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
214464333|NCT05619913|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
214464334|NCT05925972|PROCEDURE|Plane block|Plane block application in laparoscopic hysterectomies
214464335|NCT04531709|OTHER|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
214464336|NCT04531709|OTHER|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
214464337|NCT04531709|OTHER|EORTC QLQ C-30|Assess quality of life in cancer patients
215155981|NCT02084407|OTHER|Clinical examination, skin biopsy, blood and urine sampling|
215155982|NCT05824104|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
215155983|NCT06411314|COMBINATION_PRODUCT|Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
215155984|NCT06411314|DRUG|Lactulose 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
215155985|NCT06411314|DRUG|Pimafucin® (natamycin) 100 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
215155986|NCT03382353|DIETARY_SUPPLEMENT|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
215155987|NCT03382353|BEHAVIORAL|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
214536955|NCT03803943|OTHER|No Intervention - Business-as-usual control|Does not receive PICT internvention
214536956|NCT05286242|BIOLOGICAL|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
214536957|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
215155988|NCT03382353|BEHAVIORAL|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
215155989|NCT03382353|BEHAVIORAL|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
215155990|NCT03382353|BEHAVIORAL|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
215155991|NCT04040387|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
215155992|NCT04040387|DEVICE|Sham NightWare|NightWare device not providing interventions
215155993|NCT02622178|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
214464338|NCT04531709|OTHER|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
214464339|NCT06955923|DRUG|Trigger point injection (lidocaine)|A trigger point injection utilizing lidocaine 1% without epinephrine will be injected into several muscles bellies immediately following surgery to halt a trigger point from forming. One group will receive this type of intervention and the sham group will not receive any type of injection.
214464340|NCT06955923|OTHER|Sham Comparator|This arm of the study will not receive any injection.
214464341|NCT05159050|DRUG|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose"
214464342|NCT00963417|OTHER|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
214464343|NCT00963417|PROCEDURE|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
214464344|NCT06787703|BEHAVIORAL|Psychological First Aid Intervention|"Psychological first aid is a compassionate and supportive presence designed to mitigate acute distress and asses the need for continued mental health care. The intervention aims to enhance the compassionate presence, assist with needs and promote adaptive functioning. The intervention encompasses seven main themes (RAPID model, emotion stabilization, self-compassion, reframing, instillation of hope and empowerment) that will be covered through a series of five training exercises conducted on 6 sessions. Each session ranged in duration from 30 to 45 minutes.~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition).~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition). The"
214464345|NCT06377111|DIETARY_SUPPLEMENT|C-PAN|C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
214464346|NCT06377111|BIOLOGICAL|Nivolumab|Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
214464347|NCT06377111|BIOLOGICAL|Ipilimumab|Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
214464348|NCT03491969|DRUG|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
214464349|NCT03491969|DRUG|Placebos|200 mg, po, tid
214536958|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
214536959|NCT04151706|DRUG|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
214536960|NCT04151706|DRUG|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
214536961|NCT04151706|DRUG|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
214536962|NCT04151706|RADIATION|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
214536963|NCT04151706|DRUG|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
214536964|NCT04151706|DRUG|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
214536965|NCT04672499|DRUG|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
214536966|NCT04672499|DRUG|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
214536967|NCT04672499|DRUG|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
214536968|NCT01963442|RADIATION|Chest X-ray|at Day 0, Day 30 and relapse
214536969|NCT01963442|BIOLOGICAL|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
214536970|NCT01963442|DRUG|Augmentin|2 tablets 3 times a day for 5 days from Day 3
214536971|NCT01963442|DRUG|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
214536972|NCT01963442|DRUG|Beta-Lactams|administered from Day 0 to Day 3
214536973|NCT02298855|BEHAVIORAL|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
214536974|NCT02648711|DRUG|CRLX101|infusion CRLX101 weekly
214536975|NCT02648711|DRUG|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
214536976|NCT02648711|DRUG|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
215155994|NCT02622178|DIAGNOSTIC_TEST|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
215155995|NCT03286517|BIOLOGICAL|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
215155996|NCT02188888|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
214536977|NCT02652715|OTHER|Laboratory Biomarker Analysis|Correlative studies
214536978|NCT02652715|OTHER|Quality-of-Life Assessment|Ancillary studies
214536979|NCT02652715|OTHER|Questionnaire Administration|Ancillary studies
214536980|NCT02652715|DIETARY_SUPPLEMENT|Salvia hispanica Seed|Given PO
214536981|NCT00742898|OTHER|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
214536982|NCT00384098|DRUG|CTA018 cream|
214536983|NCT02434523|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
214536984|NCT02434523|OTHER|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
214536985|NCT03487653|BIOLOGICAL|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
214536986|NCT03565302|DRUG|Formoterol|Subjects are treated with daily inhalation of formoterol
214536987|NCT03565302|DRUG|Terbutaline|Subjects are treated with daily inhalation of terbutaline
214536988|NCT03565302|OTHER|Placebo|Subjects are treated with placebo
214536989|NCT00212277|DRUG|Norethindrone,Ethinyl Estradiol|
214536990|NCT01584323|DIETARY_SUPPLEMENT|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
214536991|NCT01584323|DIETARY_SUPPLEMENT|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
215155997|NCT05546632|DIAGNOSTIC_TEST|Blood sampling|Patients will have one blood sampling using one EDTA tube and one Cyto-Chex BCT tube, one after the other
215155998|NCT03306316|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic experimental group
215155999|NCT03306316|DIETARY_SUPPLEMENT|Dextrose Control|Dextrose Control
215156000|NCT06416384|OTHER|Hand Massage Group|The patients in the hand massage application group were asked by the researcher; Hand massage with olive oil was applied 12 times in total, three times a week for four weeks. No application was made to the side with fistula.
215156001|NCT06416384|OTHER|Control Group|Patients in the control group received routine nursing care in the clinic for four weeks.
215156002|NCT00611026|DRUG|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
215156003|NCT00611026|DRUG|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
215156004|NCT00611026|DRUG|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
215156005|NCT01290770|OTHER|blood sample|blood sample at inclusion and 1 month after inclusion
215156006|NCT05019521|DRUG|Danicopan|Oral tablet.
214536992|NCT04167228|DRUG|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with ceftazidime-avibactam.
215156007|NCT05019521|DRUG|Placebo|Oral tablet.
215156008|NCT01481818|DRUG|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
215156009|NCT02881606|DEVICE|Naso-alveolar molding (NAM)|
215156010|NCT02881606|DEVICE|Computer aided design NAM (CAD/NAM)|
215156011|NCT03348059|DRUG|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
215156012|NCT00760617|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
215156013|NCT00760617|BIOLOGICAL|Fluarix|Intramuscular (IM) administration, 1 dose
215156014|NCT01764906|DEVICE|Novosis|
215156015|NCT01764906|PROCEDURE|Iliac crest bone graft|
215156016|NCT05477667|DIAGNOSTIC_TEST|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
215156017|NCT00002630|BIOLOGICAL|filgrastim|
215156018|NCT00002630|DRUG|cyclophosphamide|
215156019|NCT00002630|DRUG|melphalan|
215156020|NCT00002630|PROCEDURE|peripheral blood stem cell transplantation|
214536993|NCT04167228|DRUG|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
215156021|NCT00002630|RADIATION|low-LET cobalt-60 gamma ray therapy|
214536994|NCT05913986|DIETARY_SUPPLEMENT|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
214536995|NCT05913986|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
214536996|NCT01167192|DRUG|Cisplatin|
214536997|NCT01167192|DRUG|Carboplatin|
214536998|NCT01167192|RADIATION|Radiation therapy|
214536999|NCT01167192|PROCEDURE|Mastectomy (recommended but not mandatory)|
214696758|NCT00184106|DRUG|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
215156022|NCT00002630|RADIATION|low-LET photon therapy|
215156023|NCT01129596|DRUG|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
215156024|NCT01732289|GENETIC|genes|Draw blood for genetic screening
215156025|NCT05895812|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
215156026|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
215156027|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
215156028|NCT02421835|DIETARY_SUPPLEMENT|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
215156029|NCT02421835|DIETARY_SUPPLEMENT|Placebo|700 mg Maltodextrin per day
215156030|NCT00662441|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
215156031|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
215156032|NCT04625101|DRUG|Placebo|Non-active dosage form.
215156033|NCT01436435|DEVICE|Jetstream Atherectomy System|Atherectomy
215156034|NCT04150861|DRUG|Follitropin Delta|Solution for Injection, subcutaneous administration
215156035|NCT00575731|BEHAVIORAL|Weight management strategies|
215156036|NCT05577117|DRUG|Dexmedetomidine|drugs are injected with induction of general anesthesia
215156037|NCT03613519|BEHAVIORAL|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
215156038|NCT03613519|BEHAVIORAL|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
215156039|NCT03613519|BEHAVIORAL|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
215156040|NCT02615899|OTHER|Matched: Targeted (specific) balance exercise interventions|
215156041|NCT02615899|OTHER|Mismatched: Untargeted (non-specific) balance exercise interventions|
215156042|NCT05173753|OTHER|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
215156043|NCT05918913|DRUG|Revumenib|Revumenib administered orally every 12 hours.
215156044|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
215156045|NCT03131609|OTHER|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
215156046|NCT03131609|OTHER|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
215156047|NCT03131609|OTHER|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
215156048|NCT03131609|OTHER|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
215156049|NCT02394587|BEHAVIORAL|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
215156050|NCT04434456|DEVICE|CGuard stent implantation|CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
215156051|NCT03929497|DRUG|Lu AF11167|Lu AF11167 - 2 or 4 mg/day; tablets, orally
215156052|NCT01543048|OTHER|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
215156053|NCT02533453|BIOLOGICAL|Bydureon|exenatide once weekly
215156054|NCT01732237|DRUG|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
215156055|NCT01732237|DRUG|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
215156056|NCT01732237|DRUG|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
215156057|NCT02037230|DRUG|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
215156058|NCT02037230|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
215156059|NCT02037230|RADIATION|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
214537000|NCT05416411|BEHAVIORAL|Inspiratory muscle training|Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
214537001|NCT02560389|DRUG|Placebo|Sugar pill packaged to resemble levodopa
214537002|NCT02560389|DRUG|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
214537003|NCT00498615|DRUG|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
214537004|NCT06101472|DEVICE|ASQELIO Toric Biaspheric Monofocal Lens|Intraocular lens implantation in cataract surgery
214537005|NCT04074343|DRUG|TAS-102|Given PO
214537006|NCT04074343|DRUG|Irinotecan|Given IV
214537007|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
214537008|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
214537009|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
214537010|NCT04933799|DRUG|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
214537011|NCT04933799|DRUG|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
214537012|NCT01211444|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
214537013|NCT00687947|DRUG|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
214537014|NCT00484601|DRUG|Ifosfamide|
214537015|NCT00484601|DRUG|Doxorubicin|
215156060|NCT01072643|DRUG|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
214537016|NCT00414258|PROCEDURE|breastfeeding|See detailed description.
214537017|NCT03980132|DRUG|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
214537018|NCT02767518|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
214537019|NCT05624697|PROCEDURE|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
214537020|NCT00000725|DRUG|Interferon alfa-2a|
214537021|NCT00000725|DRUG|Zidovudine|
214537022|NCT00000725|DRUG|Interferon alfa-n1|
214537023|NCT02806817|DRUG|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
214537024|NCT02806817|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
214537025|NCT02806817|OTHER|Normal saline|Use saline as placebo
214537026|NCT05243537|OTHER|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
214537027|NCT00241969|BEHAVIORAL|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
214537028|NCT00241969|BEHAVIORAL|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
214537029|NCT02600585|BIOLOGICAL|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
214537030|NCT02600585|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
215156061|NCT01579929|DRUG|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
215156062|NCT05866523|BEHAVIORAL|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
214537031|NCT03828877|OTHER|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
214537032|NCT04440930|OTHER|White tea|Mouthwash with white tea five to six times a day for nine weeks
215156063|NCT05866523|BEHAVIORAL|Standard of Care|Subject admitted and seen by routine inpatient medical service.
215156064|NCT05438212|PROCEDURE|Brain Surgery|Undergo surgery per standard of care
214537033|NCT04440930|OTHER|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
214537034|NCT01811628|BEHAVIORAL|Questionnaire|Questionnaire completion taking about 10-15 minutes.
214537035|NCT01811628|BEHAVIORAL|Interview|Audio-recorded interview that will last about 1 hour.
214537036|NCT05088538|OTHER|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
214537037|NCT01138761|BEHAVIORAL|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
214537038|NCT05097183|PROCEDURE|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
215156065|NCT05438212|OTHER|Quality-of-Life Assessment|Ancillary studies
215156066|NCT05438212|OTHER|Questionnaire Administration|Ancillary studies
215156067|NCT05438212|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
215156068|NCT05773001|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
215156069|NCT00602017|DRUG|Amlodipine|
215156070|NCT03635073|DRUG|Soticlestat|Soticlestat tablets or mini-tablets.
214537039|NCT05268185|BEHAVIORAL|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
214696759|NCT06199440|DRUG|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
214696760|NCT06199440|DRUG|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
215156071|NCT03404180|PROCEDURE|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
215156072|NCT03404180|DRUG|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
214537040|NCT05268185|BEHAVIORAL|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
214537041|NCT02041312|OTHER|No intervention|No intervention will be needed.
214537042|NCT03087331|OTHER|medication reviews, assessment, recommendations, education.|
214537043|NCT03779477|BEHAVIORAL|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
214537044|NCT06342245|RADIATION|Radiofrequency coblation micro-tenotomy|Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed.
214537045|NCT02886169|OTHER|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
215156073|NCT03404180|PROCEDURE|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
215156074|NCT03404180|PROCEDURE|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
215156075|NCT00732537|DRUG|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
215156076|NCT00732537|DRUG|Oxygen (>90% by hood) - standard therapy|"Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
215156077|NCT05739981|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV
215156078|NCT05739981|DRUG|Carboplatin|Carboplatin AUC 5-6 IV
215156079|NCT05739981|DRUG|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
215156080|NCT05739981|DRUG|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
215156081|NCT06143514|OTHER|No intervention|No intervention
215156082|NCT01286051|DRUG|Follistim administration|adminstation of FSH for ovulation induction
215156083|NCT01286051|DRUG|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
215156084|NCT06140810|OTHER|Lung Recruitment|Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
215156085|NCT03519711|DRUG|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
215156086|NCT01475617|DIETARY_SUPPLEMENT|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
215156087|NCT01475617|DIETARY_SUPPLEMENT|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
215156088|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
215156089|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
215156090|NCT01475617|DIETARY_SUPPLEMENT|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
215156091|NCT01475617|DIETARY_SUPPLEMENT|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
215156092|NCT01366157|GENETIC|microarray analysis|
215156093|NCT01366157|GENETIC|protein expression analysis|
215156094|NCT01366157|OTHER|immunohistochemistry staining method|
215156095|NCT01366157|OTHER|laboratory biomarker analysis|
215156096|NCT03951662|OTHER|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level \>3mg/dL and AST level\>50U/L
215156097|NCT03951662|OTHER|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
214537046|NCT02886169|OTHER|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
214537047|NCT04477356|PROCEDURE|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
214537048|NCT04477356|PROCEDURE|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
214537049|NCT03937232|BEHAVIORAL|Cross-Education|Home exercise program + usual care
214537050|NCT03937232|BEHAVIORAL|Mirror Visual Feedback|Home exercise program + usual care
214537051|NCT03937232|OTHER|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
214537052|NCT03955861|BIOLOGICAL|adalimumab|Subcutaneous injection
214537053|NCT03955861|BIOLOGICAL|Certolizumab|Subcutaneous injection
214537054|NCT03955861|BIOLOGICAL|Etanercept|Subcutaneous injection
214537055|NCT03955861|BIOLOGICAL|Golimumab|Subcutaneous injection
214537056|NCT03955861|BIOLOGICAL|Secukinumab|Subcutaneous injection
214537057|NCT01664897|DRUG|Erlotinib Hydrochloride|Given PO
214537058|NCT01664897|OTHER|Laboratory Biomarker Analysis|Correlative studies
214537059|NCT01203956|DEVICE|SmartFlex|Device used with smartflex engaged.
214537060|NCT01203956|DEVICE|Standard|
214537061|NCT06015685|OTHER|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
214537062|NCT06015685|OTHER|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
214537063|NCT02480777|BIOLOGICAL|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
214537064|NCT04092959|BEHAVIORAL|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
214537065|NCT04092959|BEHAVIORAL|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
214537066|NCT04092959|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
215156098|NCT04788706|OTHER|Low level Laser Therapy and Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
215156099|NCT04788706|OTHER|Placebo Laser and Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
215156100|NCT04788706|OTHER|Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
215156101|NCT04788706|OTHER|Placebo Laser and Placebo Laser plus Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
215156102|NCT03135496|OTHER|Study of endothelial function biological markers|Study of endothelial function biological markers
215156103|NCT05490888|DRUG|PHIN-214 Subcutaneous injection|subcutaneous injection(s) with PHIN-214 terlipressin derivative
215156104|NCT01567267|BEHAVIORAL|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
214537067|NCT06465615|DEVICE|Self-education with dichoptic reading on tablet|"Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books."
214537068|NCT06465615|PROCEDURE|Conventional orthoptic rehabilitation|Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
214537069|NCT06048939|OTHER|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
214696761|NCT06199440|DRUG|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
214696762|NCT05478044|DRUG|Ascorbic acid|Ascorbic acid IV ampoules (20%).
214537070|NCT06048939|OTHER|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
214696763|NCT05478044|OTHER|saline|saline (0.9%)
215156105|NCT01567267|BEHAVIORAL|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
215156106|NCT05289895|OTHER|No intervention|This study was an observational trial without any intervention
214537071|NCT00069277|DRUG|E7389|
214696764|NCT03108144|BEHAVIORAL|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
215156107|NCT00136097|DEVICE|Placement of a silver impregnated central venous catheter|
214696765|NCT04406246|DRUG|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
215156108|NCT02469870|BEHAVIORAL|Autism Parent Trainer (APT)|Experimental condition
215156109|NCT02469870|BEHAVIORAL|Teaching Routines (Control)|Content comparison group.
215156110|NCT01808105|OTHER|Control Formula|Feeding ad libitum
215156111|NCT01808105|OTHER|Experimental Formula 1|Feeding ad libitum
215156112|NCT01808105|OTHER|Experimental Formula 2|Feeding ad libitum
215156113|NCT01808105|OTHER|Human Milk|Feeding ad libitum
214696766|NCT00234858|DRUG|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
214696767|NCT00234858|DRUG|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
214696768|NCT04068467|OTHER|Smartphone App|The application consists of content areas focused on mental health.
214696769|NCT04068467|OTHER|Waitlist Control|Waitlist control
214696770|NCT05518734|DRUG|VX-708|Solution for intravenous (IV) administration.
214696771|NCT05518734|DRUG|Itraconazole|Solution for oral administration.
214696772|NCT05518734|DRUG|Midazolam|Solution for oral administration.
215156114|NCT06406179|BIOLOGICAL|dd-cfDNA-guided|"In groups I and II, the blood sample for dd-cfDNA assay will be taken on D0, just prior to transplantation, for all patients.~in addition, for patients following a dd-cf DNA-guided strategy based on dd-cf DNA ; samples for dd-cf DNA assay will be taken at M3 and M12 visits and at visits for clinical indication (5 maximum) and the blood will be sent to the PARCC technical platform of INSERM UMR 970. By combining the dd-cfDNA level and relevant medical data, an integration report will be sent to the centers to stratify patients into high-risk or low-risk rejection profiles.~If the patient is classified in the low risk of rejection subgroup, he may decide not to perform the biopsy. If the patient is classified in the high risk of rejection subgroup, he may decide to perform the biopsy within 15 days of the sample being taken. the decision to perform the biopsy is left to the discretion of the physician."
214696773|NCT05518734|DRUG|Placebo|Placebo matched to VX-708 for IV administration.
215156115|NCT02410564|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
215156116|NCT02410564|BEHAVIORAL|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
215156117|NCT02039843|OTHER|Emotional Support Dogs|Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized.
215156118|NCT02039843|OTHER|Service Dogs|Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, \& behind).
215156119|NCT03962062|DRUG|Moxidectin|2 mg tablets
215156120|NCT06376331|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
215156121|NCT00954226|DRUG|Erlotinib Hydrochloride|Given PO
215156122|NCT00954226|OTHER|Laboratory Biomarker Analysis|Correlative studies
214537072|NCT03011905|DRUG|Dexamethasone|4 ml DexaGalen 4 mg/ml
214537073|NCT03011905|DRUG|NaCl (Control)|4 ml NaCl 9 mg/ml
214537074|NCT03011905|DRUG|Paracetamol|Premedication and as needed after operation
214537075|NCT03011905|DRUG|EtoriCoxib|Premedication and first 2 postoperative days.
214537076|NCT03011905|DRUG|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
214537077|NCT03011905|DRUG|Ropivacaine|In brachial plexus block
214537078|NCT00175370|DRUG|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
214537079|NCT04209998|DIAGNOSTIC_TEST|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
214537080|NCT02933307|DEVICE|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
214537081|NCT02933307|DEVICE|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
214537082|NCT02230306|DRUG|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
214537083|NCT02230306|DRUG|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
214537084|NCT03127878|OTHER|Exercise|
214696774|NCT01005732|DEVICE|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and \<5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
214696775|NCT02596711|DRUG|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
214696776|NCT02596711|BEHAVIORAL|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
214696777|NCT02596711|OTHER|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
214696778|NCT02596711|BEHAVIORAL|Health Education and Handouts|Participants receive general health education and handouts.
214696779|NCT02596711|BEHAVIORAL|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
214696780|NCT02596711|BEHAVIORAL|Counseling Sessions|Participants attend 3 counseling sessions during the study.
214696781|NCT01552928|DRUG|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
214696782|NCT01552928|DRUG|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
214537085|NCT02026245|DEVICE|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove"
214537086|NCT00002061|DRUG|Inosine pranobex|
214537087|NCT04150471|OTHER|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
214696783|NCT01552928|DRUG|Moxifloxacin|400 mg Moxifloxacin single oral dose
214537088|NCT02442245|DIETARY_SUPPLEMENT|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
214537089|NCT02442245|OTHER|Placebo: Microcrystalline Cellulose|
214537090|NCT02442245|OTHER|Control: No supplementation|
214537091|NCT00626015|BIOLOGICAL|PEP-3-KLH conjugate vaccine|Given intradermally
214537092|NCT00626015|BIOLOGICAL|daclizumab|Given IV
214696784|NCT01552928|DRUG|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
214696785|NCT02558153|DEVICE|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
215156123|NCT00466596|DRUG|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
215156124|NCT02406534|BEHAVIORAL|HRQoL surveys|
215156125|NCT00034268|DRUG|LY900003|
215156126|NCT04927169|DRUG|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
215156127|NCT04927169|DRUG|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
215156128|NCT04245683|PROCEDURE|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
214537093|NCT00626015|DRUG|temozolomide|Given by mouth.
214537094|NCT00626015|OTHER|placebo|Given IV
214537095|NCT00626015|BIOLOGICAL|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
214537096|NCT03010345|DEVICE|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
214537097|NCT03010345|OTHER|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
214537098|NCT02657954|BEHAVIORAL|CCT|10-week Compensatory Cognitive Training
214537099|NCT02657954|BEHAVIORAL|HCE|10-week Holistic Cognitive Education
214537100|NCT04854902|PROCEDURE|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
214537101|NCT04854902|PROCEDURE|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
214537102|NCT04854902|PROCEDURE|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
214537103|NCT00953199|DRUG|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
214696786|NCT02558153|DEVICE|standard PTA|Percutaneous angioplasty performed with a standard balloon
214696787|NCT03218254|DRUG|Methylphenidate|Titration of MTP for treatment of fatigue
214696788|NCT03218254|DRUG|Placebo|Placebo
215156129|NCT04245683|OTHER|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
215156130|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
215156131|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
215156132|NCT00806819|DRUG|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
215156133|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
215156134|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
215156135|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
215156136|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
215156137|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
214537104|NCT00953199|DRUG|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
214537105|NCT05169814|DRUG|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
214537106|NCT05169814|OTHER|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
214537107|NCT05169814|DRUG|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
214537108|NCT05169814|OTHER|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
214537109|NCT00004758|DRUG|carbamazepine|
214537110|NCT00004758|DRUG|corticotropin|
214537111|NCT00004758|DRUG|nitrazepam|
214537112|NCT00004758|DRUG|pyridoxine|
214537113|NCT00004758|DRUG|valproic acid|
214537114|NCT00004758|PROCEDURE|Surgery|
214537115|NCT01006447|BEHAVIORAL|Instructor contact|
214537116|NCT01006447|BEHAVIORAL|Instructor contact|
214537117|NCT00136175|DRUG|Paclitaxel|
214537118|NCT00136175|DRUG|Carboplatin|
214537119|NCT00136175|DRUG|Gemcitabine|
214537120|NCT04801784|PROCEDURE|Increased net ultrafiltration with advanced hemodynamic monitoring|A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.
215156138|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
214696789|NCT01395095|OTHER|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
215156139|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
215156140|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
215156141|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
215156142|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
215156143|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
215156144|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
215156145|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
215156146|NCT02373683|DEVICE|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
215156147|NCT05785442|DRUG|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
215156148|NCT05785442|DRUG|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
215156149|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
215156150|NCT03564678|DRUG|Vitamin B Complex|Given PO
215156151|NCT03028337|RADIATION|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
215156152|NCT03028337|BEHAVIORAL|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
215156153|NCT05932862|DRUG|XL309|XL309 will be administered orally per assigned schedule.
215156154|NCT05932862|DRUG|Olaparib|Olaparib will be administered orally per assigned schedule.
215156155|NCT05095376|DRUG|Lomustine|Given PO
215156156|NCT05095376|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215156157|NCT05095376|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
214537121|NCT04801784|PROCEDURE|Zero or near-zero net ultrafiltration|The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
214537122|NCT03795402|DEVICE|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
214696790|NCT01395095|OTHER|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
215156158|NCT05095376|OTHER|Questionnaire Administration|Ancillary studies
215156159|NCT05095376|DRUG|Temozolomide|Given PO
215156160|NCT03367702|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215156161|NCT03367702|OTHER|Quality-of-Life Assessment|Ancillary studies
215156162|NCT03367702|OTHER|Questionnaire Administration|Ancillary studies
215156163|NCT03367702|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215156164|NCT06487533|DEVICE|EmbracePlus Smartwatch|"The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
215156165|NCT06487533|DEVICE|Corti Sensor|"The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
215156166|NCT05449548|DRUG|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
215156167|NCT05988632|DRUG|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
215156168|NCT05988632|DRUG|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
215156169|NCT04067830|OTHER|Best Practice|Receive usual care
215156170|NCT04067830|PROCEDURE|Laparoscopic Surgery|Undergo laparoscopic surgery
215156171|NCT04067830|OTHER|Quality-of-Life Assessment|Ancillary studies
215156172|NCT04067830|OTHER|Questionnaire Administration|Ancillary studies
215156173|NCT04067830|DEVICE|Respiratory Muscle Training Device|Use power lung device to complete RMT
215156174|NCT04067830|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo video-assisted thoracic surgery
215156175|NCT06374602|DRUG|Pembrolizumab + Lenvatinib|Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
215156176|NCT05055050|DRUG|UGN-201|Intravesical 200 mg /50 ml x 1 dose
215156177|NCT02846519|DRUG|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
214537123|NCT01770314|BEHAVIORAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
214537124|NCT03704649|BEHAVIORAL|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
214537125|NCT04345783|DRUG|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
214537126|NCT06353802|DIAGNOSTIC_TEST|Chronic non-specific neck pain and lumbar reposition sense|"In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times."
214537127|NCT04373356|DEVICE|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
214537128|NCT04373356|DEVICE|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
214537129|NCT06385314|OTHER|Collecting data with oral health related quality of life, dental anxiety and state anxiety|Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
214537130|NCT00801450|DRUG|Triamcinolone acetonide|4 mg
214537131|NCT00801450|DRUG|Triamcinolone acetonide|40 mg
214537132|NCT06129045|BEHAVIORAL|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
215156178|NCT02846519|DRUG|Rifampin|2 capsules (300 mg each) of rifampin.
215156179|NCT04133792|DRUG|Simvastatin 40mg|40 mg orally daily for 5 years.
215156180|NCT04133792|DRUG|Placebo oral tablet|40 mg orally daily for 5 years.
215156181|NCT05869708|DEVICE|Active RS-EFP|A minimum of 10 and up to 15 active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
215156182|NCT05869708|DEVICE|Sham RS-EFP|a minimum of 10 and up to 15 sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
215156183|NCT03604835|OTHER|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
215156184|NCT06416306|BEHAVIORAL|Speech Intervention|The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.
214537133|NCT06129045|BEHAVIORAL|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
214537134|NCT03582150|DEVICE|Remote Monitoring with Ambulatory Detox|"* Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
214537135|NCT03185585|OTHER|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
215156185|NCT05760339|BEHAVIORAL|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
215156186|NCT05760339|DIETARY_SUPPLEMENT|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
215156187|NCT03196453|DIETARY_SUPPLEMENT|Probiotic|probiotic and/or placebo intervention in toddlers
215156188|NCT03150693|DRUG|Allopurinol|Given PO
215156189|NCT03150693|DRUG|Cytarabine|Given IT, IV, SC
215156190|NCT03150693|DRUG|Daunorubicin Hydrochloride|Given IV
215156191|NCT03150693|DRUG|Vincristine Sulfate|Given IV
215156192|NCT03150693|DRUG|Dexamethasone|Given PO or IV
215156193|NCT03150693|DRUG|Pegylated L-Asparaginase|Given IV
215156194|NCT03150693|DRUG|Methotrexate|Given IT, IV, PO
215156195|NCT03150693|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215156196|NCT03150693|DRUG|Cyclophosphamide|Given IV
215156197|NCT03150693|DRUG|Mercaptopurine|Given PO
215156198|NCT03150693|BIOLOGICAL|Rituximab|Given IV
215156199|NCT03150693|DRUG|Doxorubicin|Given IV
215156200|NCT03150693|DRUG|Thioguanine|Given PO
215156201|NCT03150693|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
215156202|NCT03150693|OTHER|Laboratory Biomarker Analysis|Correlative studies
215156203|NCT02987712|OTHER|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
215156204|NCT04016623|DEVICE|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
215156205|NCT04016623|DEVICE|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
215156206|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
215156207|NCT05555069|OTHER|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
215156208|NCT05555069|OTHER|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
215156209|NCT02752165|OTHER|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
215156210|NCT02752165|OTHER|Enhanced Usual Care|Report of symptoms to primary care physician
215156211|NCT00823693|DRUG|Bimosiamose Cream|
215156212|NCT00823693|DRUG|Placebo Cream|
215156213|NCT02285946|PROCEDURE|major spine surgery|
215156214|NCT04765683|OTHER|questionnaire|Survey of views on outpatient consultation format
215156215|NCT05231122|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
215156216|NCT05231122|BIOLOGICAL|Bevacizumab|Given IV
215156217|NCT05231122|BIOLOGICAL|Pembrolizumab|Given IV
215156218|NCT05231122|OTHER|Quality-of-Life Assessment|Ancillary studies
215156219|NCT05231122|OTHER|Questionnaire Administration|Ancillary studies
215156220|NCT06483100|DRUG|Elrantamab|"\- Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15"
215156221|NCT06483100|DEVICE|clonoSEQ|FDA approved MRD testing
214537136|NCT03185585|OTHER|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
214537137|NCT06647316|OTHER|Physiotherapy|The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
214537138|NCT01172899|PROCEDURE|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
214537139|NCT01172899|BEHAVIORAL|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
214537140|NCT00361842|DRUG|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
214537141|NCT03581253|OTHER|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
214537142|NCT03581253|OTHER|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
214537143|NCT03512288|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
215156222|NCT04618653|OTHER|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
214537144|NCT03512288|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
214537145|NCT06585748|DRUG|Lidocaine spray|4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
215156223|NCT01704599|DRUG|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
215156224|NCT00148083|DRUG|Risperdal Consta (drug)|
215156225|NCT00148083|BEHAVIORAL|Social Skills Training|
215156226|NCT05788159|DRUG|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
215156227|NCT05788159|DRUG|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
215156228|NCT02464696|DRUG|Methylprednisolone|IPS cohort only
215156229|NCT02464696|PROCEDURE|Oxygen Therapy|Receive high flow oxygen therapy
214537146|NCT06585748|OTHER|Placebo|No medication/application will be administered as placebo.
215156230|NCT02464696|DEVICE|Positive Air Pressure Device|Undergo NIPPV
215156231|NCT04812652|BEHAVIORAL|Digitally distributed yoga|Yoga distributed through internet.
215156232|NCT05842044|DRUG|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
214537147|NCT04814992|BEHAVIORAL|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
214537148|NCT00601471|OTHER|proximal tibiofibular manipulation|proximal tibiofibular manipulation
214537149|NCT00601471|OTHER|distal tibiofibular manipulation|distal tibiofibular manipulation
214537150|NCT00601471|OTHER|no intervention|no intervention / control
215156233|NCT05842044|DRUG|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
215156234|NCT05842044|DRUG|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
215156235|NCT05842044|DRUG|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
215156236|NCT05842044|DRUG|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
214537151|NCT02108418|DRUG|TG-2349 as the original formulation|single oral dose under fed condition
214537152|NCT02108418|DRUG|TG-2349 as a new capsule formulation|single oral dose under fed condition
214537153|NCT05310344|COMBINATION_PRODUCT|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
214537154|NCT02274519|OTHER|Tai Chi|Arm 1
214537155|NCT02274519|OTHER|Education|Arm 2
214537156|NCT01355471|DRUG|CD07805/47 Gel|applied topically once daily
214537157|NCT01355471|DRUG|Placebo|applied topically once daily
214537158|NCT01102387|DRUG|LAS41003|Once daily, topically
214537159|NCT01102387|DRUG|LAS189962|Once daily, topically
214537160|NCT01102387|DRUG|LAS189961|Once daily, topically
214537161|NCT02345707|DRUG|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
214537162|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
214537163|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
214537164|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
214537165|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
214696791|NCT01395095|OTHER|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
214537166|NCT01594697|DRUG|Metformin|
214537167|NCT06176378|OTHER|traditional pulpotomy|After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
214537168|NCT06176378|DEVICE|diode laser pulpotomy|after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
214537169|NCT05680285|DEVICE|diode lazer|diode laser was applied during the pulpotomy procedure
214537170|NCT05680285|DEVICE|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
214537171|NCT02966418|PROCEDURE|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
214696792|NCT04030104|DEVICE|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
215156237|NCT06212128|COMBINATION_PRODUCT|RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol (Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol)
214537172|NCT02966418|PROCEDURE|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
214537173|NCT05402618|OTHER|No intervention|This is an observational study without any intervention.
214537174|NCT03526471|DEVICE|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
214537175|NCT02542085|PROCEDURE|Laparoscopic repair|operative method
214537176|NCT02542085|PROCEDURE|Hybrid repair|operative method
214537177|NCT00113997|DRUG|REG1|
214537178|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
214537179|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
214537180|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
214537181|NCT01086878|DRUG|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
214696793|NCT04030104|DEVICE|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
214696794|NCT04030104|DEVICE|Mammography|Mammography as available per standard of care
214696795|NCT02270892|DEVICE|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
214696796|NCT03105596|DRUG|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
215156238|NCT06212128|COMBINATION_PRODUCT|LCRT|LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine
214537182|NCT04815785|DEVICE|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
214537183|NCT04520841|DEVICE|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
214537184|NCT04520841|DEVICE|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
214537185|NCT05787171|DEVICE|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
214537186|NCT05787171|DEVICE|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
214537187|NCT05787171|DEVICE|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
214537188|NCT02928809|DEVICE|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
214537189|NCT02928809|OTHER|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
214696797|NCT05126524|OTHER|NO INTERVENTION|Observational study, no intervention performed
215156239|NCT00996398|OTHER|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
215156240|NCT03983356|OTHER|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
215156241|NCT05776823|BEHAVIORAL|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
215156242|NCT05776823|BEHAVIORAL|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
215156243|NCT05776823|BEHAVIORAL|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
215156244|NCT05776823|BEHAVIORAL|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
215156245|NCT03657693|DIAGNOSTIC_TEST|NICU MRI|MRI device that is not FDA approved.
215156246|NCT03657693|DIAGNOSTIC_TEST|Polysomnography|Polysomnography to better determine obstruction index in the airway.
215156247|NCT05268003|DRUG|Ponatinib|Given by PO
215156248|NCT05268003|DRUG|Venetoclax|Given by PO
215156249|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
215156250|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
215156251|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
215156252|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
215156253|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
214537190|NCT06219161|DIETARY_SUPPLEMENT|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
214537191|NCT00691678|DRUG|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
214537192|NCT00691678|DRUG|Glucosamine|500mg glucosamine TID for twenty-four weeks
214537193|NCT05772481|OTHER|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
214537194|NCT04882748|OTHER|ADAMO|Physical therapy provided with or without the help of a robot
214537195|NCT00528710|DIETARY_SUPPLEMENT|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
214537196|NCT01458964|DRUG|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
214537197|NCT02872519|DRUG|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
214537198|NCT02872519|PROCEDURE|Positron Emission Tomography|Undergo scan
214537199|NCT02872519|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
214537200|NCT06158178|DIAGNOSTIC_TEST|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
214537201|NCT02112578|DRUG|Meclizine|25 mg, 3 times per day up to 30 days
214537202|NCT02112578|DRUG|Dimenhydrinate|50 mg, 3 times per day up to 30 days
214696798|NCT06553417|OTHER|Aqua posae and microresyl|"* This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
215156254|NCT05834569|DRUG|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
215156255|NCT05834569|DRUG|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
215156256|NCT04671693|OTHER|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
215156257|NCT02971748|BIOLOGICAL|Pembrolizumab|Given IV
215156258|NCT06193616|DRUG|Octreotide|All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
215156259|NCT04755153|OTHER|Practice Facilitation|Tailored interventions provided by a trained Practice Facilitator
215156260|NCT04755153|OTHER|Non-Practice Facilitation|Implementation support without using Practice Facilitation
215156261|NCT01189643|DRUG|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
215156262|NCT03137199|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
215156263|NCT02389309|DRUG|Cyclophosphamide|Given PO
215156264|NCT02389309|DRUG|Dasatinib|Given PO
215156265|NCT02389309|OTHER|Laboratory Biomarker Analysis|Correlative studies
215156266|NCT02389309|DRUG|Temsirolimus|Given IV
214537203|NCT00733564|DRUG|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
214537204|NCT00733564|DRUG|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
214537205|NCT00733564|DRUG|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
214537206|NCT03030105|DRUG|BPN14770|investigational drug
214537207|NCT03030105|DRUG|BPN14770 placebo|placebo
214537208|NCT03030105|DRUG|Donepezil|comparator
214537209|NCT03030105|DRUG|Donepezil placebo|placebo
214537210|NCT03030105|DRUG|Scopolamine 0.6 MG/ML|cognition impairment
214537211|NCT03030105|DRUG|Scopolamine placebo|placebo
214537212|NCT02277067|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
214537213|NCT02277067|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
214537214|NCT01227928|DRUG|Pazopanib|Pazopanib 800 mg daily for 24 months
214537215|NCT01227928|DRUG|Placebo comparator|Placebo 800 mg daily for 24 months
214537216|NCT01042145|DRUG|Prednisone|2 mgs/kg for 3 days
214537217|NCT01042145|DRUG|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
214537218|NCT01993628|OTHER|Rey figure test|
214537219|NCT01993628|OTHER|MRI|
214696799|NCT06553417|OTHER|Urea 10%|"Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
214696800|NCT04950881|PROCEDURE|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
214696801|NCT04950881|DRUG|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
215156267|NCT06265012|BIOLOGICAL|PHV01|Marburg virus vaccine
214537220|NCT02277392|BIOLOGICAL|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
214537221|NCT02277392|BIOLOGICAL|SB---485232 (Human recombinant Interleukin---18)|
214537222|NCT04721405|DEVICE|Observational Study: No intervention|Observational Study: No intervention
214696802|NCT03563703|DEVICE|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
214696803|NCT03563703|DEVICE|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
214537223|NCT03065439|DIAGNOSTIC_TEST|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
214537224|NCT01462825|DIETARY_SUPPLEMENT|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
214696804|NCT04570657|BIOLOGICAL|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
214696805|NCT04570657|DRUG|Placebo|Participants will receive multiple doses of placebo
215156268|NCT06265012|BIOLOGICAL|Placebo|Lactated Ringer's Solution
215156269|NCT04901715|DRUG|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
215156270|NCT04901715|DIAGNOSTIC_TEST|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 microcurie (µCi) deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive three quarters of the adult dose to account for the smaller lung volume.
214537225|NCT01462825|DIETARY_SUPPLEMENT|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
214537226|NCT06543550|DRUG|Implantable gestrinone|1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
214537227|NCT06543550|DRUG|Oral Dienogest|Administered orally at 2 mg daily
214537228|NCT00016978|DRUG|FOLFOX regimen|
214537229|NCT00016978|DRUG|fluorouracil|
214537230|NCT00016978|DRUG|leucovorin calcium|
214537231|NCT00016978|DRUG|oxaliplatin|
214537232|NCT05613504|OTHER|Acupuncture treatment|"Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
214537233|NCT05613504|OTHER|Sham acupuncture treatment|"Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
214537234|NCT04501978|BIOLOGICAL|LY3819253|Participants are no longer being randomized to this intervention.
214537235|NCT04501978|DRUG|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
214537236|NCT04501978|BIOLOGICAL|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
214537237|NCT04501978|BIOLOGICAL|VIR-7831|Participants are no longer being randomized to this intervention.
214537238|NCT04501978|BIOLOGICAL|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
214537239|NCT04501978|BIOLOGICAL|AZD7442|Participants are no longer being randomized to this intervention.
214537240|NCT04501978|DRUG|MP0420|Participants are no longer being randomized to this intervention.
214537241|NCT04501978|DRUG|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
214537242|NCT00768209|DRUG|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
214537243|NCT00472069|PROCEDURE|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
214537244|NCT01211223|DRUG|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
214537245|NCT00934700|OTHER|Xenon gas|30% Xenon gas inhaled for 24 hours
214537246|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
214537247|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
214537248|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
214537249|NCT01308047|DRUG|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
214537250|NCT02044341|DRUG|AR01|drops administered an needed for pain
214537251|NCT02044341|DRUG|Glycerin ear drops|placebo drops administered for ear pain
214537252|NCT06348745|DEVICE|ultrasound|5\. Transthoracic ultrasound for both right and left diaphragm during inspiration and expiration.
214537253|NCT05027880|BEHAVIORAL|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
214537254|NCT03819842|DIAGNOSTIC_TEST|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
215156271|NCT04013542|BIOLOGICAL|Ipilimumab|Given IV
215156272|NCT04013542|BIOLOGICAL|Nivolumab|Given IV
215156273|NCT04013542|RADIATION|Radiation Therapy|Undergo radiation therapy
215156274|NCT04105166|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
215156275|NCT06567860|BIOLOGICAL|Influenza Fluzone vaccine|Fluzone vaccine administered in both May-June and in September-October for each participant.
215156276|NCT03404193|DRUG|Decitabine|Given IV
215156277|NCT03404193|OTHER|Laboratory Biomarker Analysis|Correlative studies
215156278|NCT03404193|DRUG|Venetoclax|Given PO
215156279|NCT06966804|DRUG|Terazosin|Subject will complete 14-day course of Terazosin
215156280|NCT06966804|DRUG|Tamsulosin|Subject will complete 14-day course of Tamsulosin
214537255|NCT03328910|DEVICE|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
214696806|NCT01731301|DRUG|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
214696807|NCT01731301|DRUG|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
215156281|NCT06125028|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PTF i.v. injection
215156282|NCT06125028|DRUG|[18F]Fluorodeoxyglucose|\[18F\]FDG i.v. injection.
215156283|NCT00580385|OTHER|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
215156284|NCT05359926|OTHER|Experimental|Early urethral foley removal after the surgery
215156285|NCT05359926|OTHER|Active comparator|Delayed urethral foley removal after the surgery
215156286|NCT04022499|BEHAVIORAL|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
215156287|NCT04022499|BEHAVIORAL|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
214537256|NCT02930837|DRUG|alteplase|
214537257|NCT05463445|OTHER|Only observation|No intervention is needed.
214537258|NCT00566345|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
215156288|NCT04988009|OTHER|Electronic Health Record Review|Review of medical chart
215156289|NCT04988009|OTHER|Survey Administration|Complete survey
215156290|NCT04976322|DRUG|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
215156291|NCT02324387|PROCEDURE|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
214537259|NCT00566345|OTHER|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
214537260|NCT00547183|DRUG|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
214696808|NCT01731301|DRUG|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
214696809|NCT04961372|OTHER|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
214537261|NCT00547183|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
214696810|NCT00437606|DRUG|GK Activator (2)|100mg po
214696811|NCT00437606|DRUG|Ethanol|40g po
214696812|NCT04873024|DEVICE|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
214696813|NCT03862690|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
214696814|NCT05006898|COMBINATION_PRODUCT|PBO to control presbyopia symptoms|Low dose PBO to control presbyopia symptoms
214696815|NCT01754220|DRUG|Montelukast|Montelukast is a leukotriene receptor antagonist
215156292|NCT02324387|DRUG|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
215156293|NCT05575401|PROCEDURE|Lateral pharyngoplasty|Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.
215156294|NCT05575401|PROCEDURE|Tonsillectomy|Extracapsular tonsillectomy
215156295|NCT06127303|DRUG|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
215156296|NCT06127303|OTHER|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
215156297|NCT04637867|OTHER|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample"
215156298|NCT03164460|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
215156299|NCT03164460|RADIATION|Proton Radiation|Undergo IMRT/IMPT
215156300|NCT03164460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215156301|NCT05985655|DRUG|GTAEXS617|Administered as specified in the treatment arm.
215156302|NCT05985655|DRUG|SoC|Participants will receive either fulvestrant (breast cancers) or paclitaxel + bevacizumab (HGSOC) as specified in the treatment arm.
215156303|NCT00433043|DRUG|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
215156304|NCT00433043|PROCEDURE|CRT (cardiac resynchronization therapy)|Both arms
215156305|NCT04598074|OTHER|Opioid Package Prototype (OPP)|The Opioid Package Prototype (OPP) is a child-resistant/senior-friendly, calendar-blister packaging of limited pill counts with flat readable billboard space for medication labeling.
215156306|NCT04598074|OTHER|Usual Care (standard amber vial)|The standard amber vial (orange bottle) is the container that medication is normally dispensed in outside of the study.
215156307|NCT03843541|DRUG|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
214537262|NCT00547183|DRUG|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
214537263|NCT01919177|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
214537264|NCT01919177|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
214696816|NCT00134225|DEVICE|Muscle Pattern Recognition (MPR)|
214696817|NCT01072539|DRUG|tigecycline|As prescribed by physician in usual clinical practice
215156308|NCT03843541|DRUG|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
214537265|NCT04636879|OTHER|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
214537266|NCT04636879|OTHER|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
214537267|NCT04636879|OTHER|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
214537268|NCT01393613|DRUG|OPC-34712|Higher dose tablet, once daily, for six weeks,
214537269|NCT01393613|DRUG|OPC-34712|Middle dose tablet, once daily, for six weeks
214537270|NCT01393613|DRUG|OPC-34712|Lower dose tablet, once daily, for six weeks
214537271|NCT01393613|DRUG|Placebo|Placebo, once daily, for six weeks
214537272|NCT02279992|DRUG|Vardenafil|
214537273|NCT02279992|DRUG|Carboplatin|
215156309|NCT03843541|OTHER|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
215156310|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
214537274|NCT01831726|DRUG|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
214537275|NCT05335577|DIAGNOSTIC_TEST|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
214537276|NCT05335577|DIAGNOSTIC_TEST|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
214537277|NCT05335577|DIAGNOSTIC_TEST|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
214537278|NCT03591432|DEVICE|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
214537279|NCT03591432|DEVICE|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
214696818|NCT02577250|DRUG|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
214696819|NCT00348582|DRUG|Ketorolac, Nepafenac|
214696820|NCT04931316|OTHER|antiglaucoma|use antiglaucoma in ocular hypertension
214696821|NCT05685641|DIAGNOSTIC_TEST|Histoplasma Urine Antigen Lateral Flow Antigen test|Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
214696822|NCT05685641|DIAGNOSTIC_TEST|Cryptococcal Lateral Flow Antigen test|Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
214696823|NCT05685641|DIAGNOSTIC_TEST|Tuberculosis-lipoarabinomannan Lateral Flow Antigen test|Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
215156311|NCT05070416|DEVICE|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
215156312|NCT05208450|OTHER|Practice support And Community Engagement (PACE)|A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
215156313|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
215156314|NCT04617925|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
215156315|NCT06186765|DEVICE|Axonics SNM System (Model 4101)|Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
215156316|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.~SSD: NNC0442-0344 A will be administered subcutaneously."
215156317|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.~SSD: Placebo will be administered subcutaneously."
215156318|NCT03400371|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
215156319|NCT03400371|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
215156320|NCT04858035|BEHAVIORAL|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
214537280|NCT04168996|BEHAVIORAL|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
214537281|NCT05173259|BEHAVIORAL|F|The participant will be asked to chew the two-coloured chewing gum naturally.
215156321|NCT04858035|BEHAVIORAL|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
215156322|NCT06274788|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
215156323|NCT06621017|DRUG|ROSE-010 99 mcg|Sub-cutaneous injection of ROSE-010 solution
215156324|NCT06621017|DRUG|Placebo|Sub-cutaneous injection of saline solution
215156325|NCT06621017|DRUG|ROSE-010 150 mcg|Sub-cutaneous injection of ROSE-010 solution
215156326|NCT04123938|OTHER|Pea Protein|Soluble pea protein
215156327|NCT04123938|OTHER|Whey Protein|Whey protein concentrate
215156328|NCT04123938|OTHER|Maltodextrin|Non-protein isocaloric comparator
215156329|NCT05376566|DRUG|Hydrochloric Acid (2 M)|Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
215156330|NCT05376566|DRUG|Normal saline|Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
215156331|NCT04550442|DRUG|Azacitidine|Given IV or SC
215156332|NCT04550442|DRUG|Venetoclax|Given PO
215156333|NCT05555108|BEHAVIORAL|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
215156334|NCT05555108|BEHAVIORAL|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
215156335|NCT06523387|BEHAVIORAL|Pivotal Response Treatment Online (PRT-O) Course|Pivotal Response Treatment - Parent Training
215156336|NCT06971744|DRUG|Hydroxychloroquine|3 x 200 milligram tablets twice daily
215156337|NCT06971744|DRUG|Nelfinavir|2x 625 milligram tablets twice daily
214696824|NCT03446937|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
215156338|NCT06971744|DRUG|Bevacizumab|IV 15 milligram/kilogram every 3 weeks
215156339|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
215156340|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
215156341|NCT06852768|BIOLOGICAL|d-MAPPS|Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.
215156342|NCT06852768|BIOLOGICAL|Placebo|Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.
215156343|NCT06852768|OTHER|PI and Patient Masked|Both the PI and the participant are masked on the drug administered.
215156344|NCT05784480|DIAGNOSTIC_TEST|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
215156345|NCT04693468|DRUG|Axitinib|Given PO
215156346|NCT04693468|DRUG|Crizotinib|Given PO
215156347|NCT04693468|DRUG|Palbociclib Isethionate|Given PO
215156348|NCT04693468|DRUG|Talazoparib Tosylate|Given PO
214537282|NCT05173259|BEHAVIORAL|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
214537283|NCT05173259|BEHAVIORAL|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
215156349|NCT04488055|BEHAVIORAL|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
215156350|NCT04488055|BEHAVIORAL|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
214537284|NCT05173259|BEHAVIORAL|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
214537285|NCT05173259|BEHAVIORAL|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
214537286|NCT05173259|BEHAVIORAL|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
214537287|NCT01379261|PROCEDURE|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
214696825|NCT03446937|DRUG|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
214696826|NCT03446937|DRUG|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
214696827|NCT06053827|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
214696828|NCT00080366|DRUG|1-Octanol|
214696829|NCT02856269|DIETARY_SUPPLEMENT|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
214537288|NCT01618227|DEVICE|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
214537289|NCT01618227|PROCEDURE|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
214537290|NCT02480751|DRUG|Beraprost|
214464350|NCT04404881|DRUG|Bevacizumab (Avastin®)|"* Induction Period (first 3 months of bevacizumab treatment):~  \-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
214537291|NCT02480751|DRUG|Placebo|
214537292|NCT02187445|DRUG|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
214537293|NCT03945851|PROCEDURE|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
214537294|NCT02489721|DEVICE|PICC and Midline|Peripherally inserted central venous catheter
214537295|NCT00110955|DRUG|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
214537296|NCT00110955|DRUG|Placebo|Q3W dosing of placebo
214537297|NCT01716923|BIOLOGICAL|S-303 Red Blood Cells (RBCs) - Test|
214537298|NCT01716923|BIOLOGICAL|Conventional, untreated red blood cells (RBCs) - Control|
215156351|NCT04903080|BIOLOGICAL|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
215156352|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
214464351|NCT03807128|OTHER|Prélèvement sanguin (2*4mL) ou médullaire (2mL)|Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
214464352|NCT03807128|OTHER|Data collection through questionnaires|Collection of quality of life and occupational exposure data via questionnaires
214464353|NCT05267106|DRUG|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
214464354|NCT05968170|DEVICE|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
214464355|NCT03287817|BIOLOGICAL|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells with limited duration of anti-PD1 antibody (pembrolizumab).
214464356|NCT06181227|DRUG|AVD-104|An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
214464357|NCT05882734|DRUG|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
214464358|NCT05882734|DRUG|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
214464359|NCT06359223|DIETARY_SUPPLEMENT|coffee consumption|After cesarean section, patients will be allowed to drink coffee.
214464360|NCT06359223|OTHER|control group|Patients will undergo a routine surgical procedure.
214464361|NCT04867681|BEHAVIORAL|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
214696830|NCT01679080|DRUG|Zoledronic acid|antiresorptive and calcium and vitamin D
214696831|NCT01679080|DRUG|Teriparatide|anabolic and calcium and vitamin D
214537299|NCT00654615|DEVICE|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
214696832|NCT01679080|OTHER|No active treatment|Calcium and vitamin D
215156353|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
215156354|NCT01604330|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
215156355|NCT01604330|DRUG|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
215156356|NCT03217071|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
215156357|NCT03217071|RADIATION|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
215156358|NCT03217071|PROCEDURE|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
215156359|NCT05735951|DRUG|STIRIPENTOL oral administration|"Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
215156360|NCT05382299|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
215156361|NCT05382299|DRUG|Paclitaxel|Administered intravenously
215156362|NCT05382299|DRUG|nab-Paclitaxel|Administered intravenously
215156363|NCT05382299|DRUG|Gemcitabine|Administered intravenously
215156364|NCT05382299|DRUG|Carboplatin|Administered intravenously
215156365|NCT05065008|OTHER|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
215156366|NCT05065008|OTHER|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
215156367|NCT04816513|DRUG|Ustekinumab|Ustekinumab will be administered as SC injection.
215156368|NCT06677905|BEHAVIORAL|web-based spinal cord injury self-management program|"Peer health coaches will be recruited from the United Spinal Connecticut Chapter and SCI BC. They will be at least 5 years post-SCI and will be certified in brief action planning and in Mental Health First Aid.~Online coaching sessions are expected to cover a health-related topic (eg. bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression etc) and a self-management skill topic (eg.action planning, goal setting, problem-solving, mood management, navigating the health care system, communicating with health care providers). To ensure we meet the unique needs of participants, the coach and participant will determine jointly how many sessions to spend on a topic. In addition, coaches will be able to link relevant information and resources contained in the resource library to each session."
215156369|NCT06677905|BEHAVIORAL|Peer support|Existing peer support program from the United Spinal Connecticut Chapter or SCI BC
215156370|NCT05991154|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
215156371|NCT03214510|DRUG|Bupivacaine|Given via thoracic epidural catheter or TAP block
215156372|NCT03214510|DRUG|Fentanyl|Given via thoracic epidural catheter
215156373|NCT03214510|DRUG|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
215156374|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of thoracic epidural catheter
215156375|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
215156376|NCT03214510|DRUG|Liposomal Bupivacaine|Given via TAP block
215156377|NCT03214510|BEHAVIORAL|Questionnaire|Ancillary studies
215156378|NCT05938322|OTHER|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates \< 30g/day, 1.2g-1.5g protein/kg/day and lipids \> 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
214537300|NCT00654615|PROCEDURE|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
214537301|NCT05372471|OTHER|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
214537302|NCT05372471|OTHER|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
214537303|NCT06574633|BEHAVIORAL|In-person therapy|Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
215156379|NCT05938322|OTHER|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
215156380|NCT02978612|DRUG|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
215156381|NCT05344313|DIETARY_SUPPLEMENT|Ensure Plus Advance|as in the arm description of the intervention
215156382|NCT05764642|DRUG|Definity|Ultrasound contrast agent administered intravenously
215156383|NCT05764642|DIAGNOSTIC_TEST|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
215156384|NCT06371755|DEVICE|Ultrasound examination with REMS technology|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
215156385|NCT03870672|DEVICE|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
215156386|NCT03870672|DEVICE|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
215156387|NCT03870672|DEVICE|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
215156388|NCT03870672|DEVICE|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
215156389|NCT04595474|DEVICE|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
215156390|NCT05987007|DEVICE|Acoustic slow-wave activity enhancement|The acoustic enhancement of slow-wave activity will be conducted using the Dreem2 headband. This device utilizes five dry-EEG electrodes (O1, O2, FpZ, F7, and F8), a 3D accelerometer, and a pulse oximeter to detect slow-wave activity and generates acoustic stimulation of slow-waves to augment slow-wave sleep.
215156391|NCT05987007|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia (CBTI) is a well-established first-line or complimentary treatment for insomnia which consists of cognitive and behavioral modifications, including addressing maladaptive sleep-related behaviors, controlling sleep environment, and limiting time spent in bed.
214537304|NCT06574633|BEHAVIORAL|Telehealth therapy|Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
214537305|NCT01794650|DIETARY_SUPPLEMENT|Meal composition|
214537306|NCT02623686|OTHER|Aroma Therapy Massage and Inhalation Patch|
214537307|NCT06212765|DRUG|L-citrulline|to take 1 pod a day for 45 days
214537308|NCT00701506|DEVICE|Patterned Electrical Neuromuscular Stimulation|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings"
214537309|NCT00701506|DEVICE|Placebo PENS|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
214537310|NCT03463538|PROCEDURE|arthroscopic capsular release|surgical release of shoulder joint capsule
214537311|NCT03463538|PROCEDURE|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
214537312|NCT02592486|BIOLOGICAL|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
214537313|NCT02592486|BIOLOGICAL|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
214537314|NCT02978846|OTHER|Clinical Observation|Undergo side effects evaluation using cards
214537315|NCT06453161|OTHER|Post-operative acute kidney injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
214537316|NCT02511171|OTHER|Cranial osteopathic manipulative therapy|
214537317|NCT01283971|DRUG|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
214537318|NCT01283971|DRUG|adalimumab|Adalimumab 40 mg SC every 2 weeks.
214537319|NCT01283971|DRUG|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
214537320|NCT01283971|DRUG|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
214537321|NCT01283971|DRUG|methotrexate|Methotrexate 10-25 mg weekly.
214537322|NCT01283971|DRUG|folate|Folate at least 5 mg weekly.
214537323|NCT01108484|BEHAVIORAL|Exercise|Supervised exercise: Three 90-minutes sessions per week.
214537324|NCT01108484|BEHAVIORAL|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
214537325|NCT01108484|BEHAVIORAL|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
214537326|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
214696833|NCT06179550|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214696834|NCT06179550|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215156392|NCT05458219|DRUG|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
215156393|NCT02847338|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
215156394|NCT02847338|DRUG|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
215156395|NCT02847338|DRUG|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
214537327|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
214537328|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
214537329|NCT01502371|DRUG|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
214537330|NCT01502371|DRUG|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
214537331|NCT01502371|DRUG|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
214537332|NCT05182671|OTHER|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
214537333|NCT02791126|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
214537334|NCT02791126|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
214537335|NCT02552693|OTHER|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
214537336|NCT06196229|OTHER|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
214537337|NCT06196229|OTHER|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
215156396|NCT02847338|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
215156397|NCT06595875|OTHER|m-tapa block|Patients in Group M were placed in the supine position. After skin antisepsis with 5% povidone-iodine, a sterile drape was placed. The high-frequency (8-13 MHz) linear ultrasound (USG) probe was covered with a sterile sheath, and the transversus abdominis, internal oblique, and external oblique muscles were identified at the 10th costal margin in the sagittal plane at the costochondral angle. The probe was angled sagittally to visualize the costochondral angle at the edge of the 10th rib and to display the posterior surface of the rib cartilage in the midline. Using an in-plane technique, a 22-gauge, 100-millimeter (mm) Stimuplex A peripheral nerve block needle was advanced cranially, and the needle tip was directed towards the posterior surface of the 10th costal cartilage. After negative aspiration, 20 mL of 0.25% bupivacaine was injected under the lower surface of the costal cartilage. The same procedure was repeated on the opposite side.
214537338|NCT06045871|PROCEDURE|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
214537339|NCT03074045|DRUG|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
214537340|NCT03074045|DRUG|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
215156398|NCT06361303|DEVICE|SNOO Bassinet|This is a non-interventional, prospective observational and descriptive active surveillance study of a cohort of individuals who have purchased or rented a SNOO for use with their infant.
214537341|NCT03216252|BIOLOGICAL|samples|Blood samples, oral smear and urine
214537342|NCT04421118|OTHER|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
215156399|NCT02607709|PROCEDURE|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
215156400|NCT02607709|PROCEDURE|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
215156401|NCT06603805|PROCEDURE|MAST group|
215156402|NCT06603805|PROCEDURE|breast-conserving surgery plus adjuvant radiotherapy|Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
215156403|NCT06589115|OTHER|Blood Flow Restriction Cuff|The standardized exercises will be performed while wearing a blood flow restriction cuff.
215156404|NCT06589115|OTHER|Physical Therapy|Standard physical therapy
215156405|NCT05287906|OTHER|Water|Each subject will receive one control and three treatments in the crossover design. The control contains water only.
214537343|NCT02864199|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
215156406|NCT05287906|OTHER|Glucose|Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
214537344|NCT02864199|DRUG|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
214537345|NCT02598934|DRUG|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
214537346|NCT01618071|DIETARY_SUPPLEMENT|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
214537347|NCT02672514|DEVICE|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
214537348|NCT02672514|DEVICE|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
214537349|NCT05313815|RADIATION|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
214537350|NCT04133259|DRUG|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
214537351|NCT04133259|DRUG|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
214537352|NCT02579278|OTHER|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
214537353|NCT02579278|OTHER|Blood sample (mrEMVI negative patient)|
214537354|NCT05087329|BEHAVIORAL|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
214537355|NCT03049306|DRUG|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
215156407|NCT05287906|OTHER|Steviol Glycosides|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
215156408|NCT05287906|OTHER|Steviol Glycosides plus glucose|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
215156409|NCT05287906|OTHER|Rebaudioside A|A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
215156410|NCT02279706|OTHER|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
214537356|NCT03049306|DRUG|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
214537357|NCT03352661|OTHER|Collect retrospectively data|Collect retrospectively data
214537358|NCT03600519|DEVICE|NOTAL OCT V2.5|AMD Patients
214537359|NCT04364503|DEVICE|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
214537360|NCT02154347|DRUG|KAD-1229|
214537361|NCT02154347|DRUG|Placebo|
214537362|NCT02154347|DRUG|Insulin|
214537363|NCT03799354|OTHER|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
214537364|NCT03799354|OTHER|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
214537365|NCT00282061|DRUG|Melatonin|
214537366|NCT01356121|DRUG|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
214537367|NCT01356121|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
214537368|NCT01607099|PROCEDURE|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
215156411|NCT06841198|DEVICE|spinal cord transcutaneous stimulation|"Stimulation, using the Neostim-5 (Cosyma Ltd.), a 5-channel electrical stimulator, will be administered throughout the study period, beginning shortly after the injury and continuing at regular intervals until one year post-spinal cord injury. It will be performed in two settings:~1. During seated mapping to identify stimulation sites (potentially T7/8, T11/12, L1/2, and S1/2) and determine stimulation parameters (e.g., frequency, pulse wave, amplitude) that elevate systolic blood pressure (SBP) and maintain it within the target range of 110-120 mmHg.~2. During 70-degree tilt tests to elicit an orthostatic response (a drop in blood pressure accompanied by symptoms)."
215156412|NCT00487461|DRUG|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
215156413|NCT00487461|DRUG|Placebo|Placebo tablet
214537369|NCT00884884|DRUG|Double Placebo|1 capsule daily
214696835|NCT01389622|OTHER|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
214696836|NCT01389622|OTHER|acupuncture|random points + digital pressure
214696837|NCT00325286|DRUG|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
214696838|NCT00115804|DRUG|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
214696839|NCT06376266|COMBINATION_PRODUCT|nutritional supplements|a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
214696840|NCT02226042|BEHAVIORAL|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
214696841|NCT05241015|OTHER|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
214696842|NCT05241015|OTHER|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
215156414|NCT00487461|DRUG|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
215156415|NCT06821178|BEHAVIORAL|Acute stress manipulation|Youth will be randomly assigned to the HS (high stress) or LS (low stress) TSST-M condition. The objective activities will be identical in the HS and LS conditions but the context will vary. The HS condition will be highly evaluative. The researcher will tell youth that they are being videotaped in order to code their behaviors later. The observers will maintain neutral expressions, provide instructions in a neutral tone, and avoid eye contact. In the LS condition, evaluative components are removed \[31, 53\]. Observers will be introduced as new, and the videotaping will be explained as a check to ensure that the observers follow instructions. The observers will appear disorganized while giving instructions, smile, and maintain an open body posture and eye contact.
215156416|NCT06855277|DRUG|AAA817|AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.
215156417|NCT06855277|DRUG|ARPI|Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.
214696843|NCT02683915|PROCEDURE|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
214696844|NCT05399238|DEVICE|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
214696845|NCT02294721|DEVICE|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
214696846|NCT02294721|DEVICE|The CPREazy|feedback device-1
214696847|NCT02294721|DEVICE|TrueCPR|feedback device -2
214696848|NCT02294721|DEVICE|The CPR PRO APP|feedback device -3
215156418|NCT06855277|DRUG|Standard of Care|Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel.
214696849|NCT02294721|DEVICE|The CardioPump|feedback device- 4
214537370|NCT00884884|DRUG|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
214537371|NCT00884884|DRUG|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
214537372|NCT00884884|DRUG|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
214537373|NCT00884884|DRUG|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
214537374|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
214537375|NCT00884884|DRUG|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
214537376|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
214537377|NCT00884884|DRUG|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
214537378|NCT00884884|DRUG|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
214537379|NCT01568021|OTHER|No Intervention|No intervention was administered in this study.
214537380|NCT02473913|DRUG|Milk Thistle|
214537381|NCT02473913|DRUG|Placebo|
214537382|NCT00584376|DRUG|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
214537383|NCT00584376|DRUG|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
214537384|NCT03159065|OTHER|Bilberry|Fruit beverage with bilberry and fermented oatmeal
214537385|NCT03159065|OTHER|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
214537386|NCT03159065|OTHER|Mango|Fruit beverage with mango and fermented oatmeal
214537387|NCT03159065|OTHER|Beetroot|Fruit beverage with beetroot and fermented oatmeal
214537388|NCT03159065|OTHER|Rose hip|Fruit beverage with rose hip and fermented oatmeal
214537389|NCT03159065|OTHER|Glucose drink|A reference glucose drink
215156419|NCT06601790|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
214537390|NCT00204100|DEVICE|Surface Functional Electrical Stimulation|
214537391|NCT02130271|DRUG|Radioactive dye|The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
214537392|NCT02130271|RADIATION|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
214537393|NCT02130271|OTHER|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
214537394|NCT01772381|DRUG|Dexamethasone|Long acting corticosteroid
214537395|NCT04145089|DEVICE|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
215156420|NCT06601790|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
214537396|NCT05051683|PROCEDURE|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
214537397|NCT04458012|DIAGNOSTIC_TEST|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
214537398|NCT02094547|DIETARY_SUPPLEMENT|New infant formula|New infant formula
214537399|NCT02094547|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
214537400|NCT02094547|DIETARY_SUPPLEMENT|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
214537401|NCT04939324|BIOLOGICAL|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
214537402|NCT05753319|OTHER|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
214537403|NCT04739189|BEHAVIORAL|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
214537404|NCT04739189|BEHAVIORAL|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
215156421|NCT05767749|DRUG|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
215156422|NCT05767749|DRUG|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
215156423|NCT05767749|DRUG|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
214537405|NCT04739189|BEHAVIORAL|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
214537406|NCT06538519|PROCEDURE|total hip replacement using lateral approach|In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
214537407|NCT06538519|PROCEDURE|total hip replacement using anterior approach|the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
214537408|NCT06538519|DEVICE|gait analysis at 6wks, 3 months and 18 months|gait analysis done in the gait lab at the mentioned postoperative periods
214537409|NCT06415071|OTHER|No intervention|Exposures of interest would be clearly defined according to a specific research question and identified from the database
215156424|NCT06611956|OTHER|No intervention (observational study)|No intervention (observational study)
215156425|NCT07001943|OTHER|enteral nutrition|We'll use an enteral nutrition intervention with intact protein formulations. Initiate nasogastric tube feeding at 20ml/h and continue for 24 hours. Adjust feeding strategies based on patients' SMA blood flow reactivity.
214537410|NCT01202383|BEHAVIORAL|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
215156426|NCT04708067|DRUG|Bintrafusp Alfa|Given IV
215156427|NCT04708067|PROCEDURE|Biopsy|Undergo biopsy
215156428|NCT04708067|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215156429|NCT07007182|DRUG|SOX regimen|"The SOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral S-1 (tegafur/gimeracil/oteracil) 40-60 mg twice daily, taken on days 1-14 followed by 7 days off, in a 21-day cycle.~Experimental arm: 3 cycles before surgery, 5 cycles after surgery. Control arm: up to 8 cycles as standard systemic therapy."
215156430|NCT07007182|DRUG|CAPEOX regimen|"The CAPEOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral capecitabine 1000 mg/m² twice daily on days 1-14, repeated every 3 weeks (q3w), up to 8 cycles.~Used as a standard chemotherapy option in the control arm, with or without PD-1 inhibitor according to PD-L1 CPS score."
215156431|NCT07007182|DRUG|PD-1 inhibitor|"A PD-1 inhibitor is administered intravenously at a fixed dose of 200 mg every 3 weeks.~It is combined with SOX in the experimental arm (CPS ≥1 patients) during conversion and adjuvant phases, and with CAPEOX or SOX in the control arm (CPS ≥1 patients).~Maintenance PD-1 inhibitor continues for up to 1 year or until disease progression or unacceptable toxicity."
215156432|NCT07007182|RADIATION|Para-aortic lymph node radiotherapy (IMRT to station 16)|"Intensity-modulated radiotherapy (IMRT) is delivered postoperatively to the para-aortic (station 16) nodal basin.~Elective nodal basin: 45-50 Gy in 25 fractions Positive nodes: 56-60 Gy in 25 fractions Radiotherapy is given concurrently with oral capecitabine or S-1 as radiosensitizers."
215156433|NCT07007182|DRUG|Capecitabine / S-1 (radiosensitizer during IMRT)|"During para-aortic IMRT, patients receive concurrent oral capecitabine 825 mg/m² twice daily on radiation days, or oral S-1 dosed according to body surface area.~These agents are used as radiosensitizers during postoperative radiotherapy."
215156434|NCT05002218|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
215156435|NCT05002218|BEHAVIORAL|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
215156436|NCT06868537|BEHAVIORAL|Launching! to adulthood group therapy|Participants will be in a 12-week therapy program that includes weekly group sessions and individual coaching.
215156437|NCT06868537|BEHAVIORAL|standard of care|Participants will receive a list of resources
215156438|NCT07013474|DRUG|ibuzatrelvir|tablet
215156439|NCT07013474|DRUG|remdesivir|injection, for intravenous use
215156440|NCT07013474|DRUG|placebo for ibuzatrelvir|tablet
215156441|NCT07013474|DRUG|placebo for remdesivir|injection, for intravenous use
215156442|NCT06619080|DRUG|Genicular nerve block with bupivacaine and corticosteroids|"\- GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
215156443|NCT06619080|DRUG|Genicular nerve block with bupivacaine|"\- GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
215156444|NCT06619080|DRUG|Genicular nerve block with saline|"\- GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
215156445|NCT06874439|OTHER|WHO QualityRights program|"The WHO's QualityRights program involves an assessment, called observation, of mental health care services by an ephemeral multidisciplinary team, which provides feedback and recommendations for improving care practices. The observation team, trained in the QualityRights (QR) methodology, includes mental health professionals, researchers, legal experts, and management staff from mental health organizations. Each team always incorporates at least one expert by experience and one informal caregiver or family member. Participation in the program is voluntary and initiated at the request of healthcare facilities.~The observation is structured into three stages:~1. Site preparation~2. On-site observation~3. Restitution of observation report and follow-up"
215156446|NCT07028853|DRUG|Mevrometostat|Oral continuous
215156447|NCT07028853|DRUG|Placebo|Oral continuous
215156448|NCT07028853|DRUG|Enzalutamide|Oral continuous
215156449|NCT07037238|DRUG|Everolimus 10mg daily|An oral mTOR inhibitor
215156450|NCT06705686|DRUG|(R)-9bMS|(R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
215156451|NCT07042100|BIOLOGICAL|Dose level (DL)1|Administered IV every 3 weeks
215156452|NCT07042100|BIOLOGICAL|DL2|Administered IV every 3 weeks
214537411|NCT01202383|BEHAVIORAL|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
215156453|NCT07042100|BIOLOGICAL|DL3|Administered IV every 3 weeks
215156454|NCT07042100|BIOLOGICAL|DL4|Administered IV every 3 weeks
215156455|NCT07042100|BIOLOGICAL|DL5|Administered IV every 3 weeks
215156456|NCT06721507|DRUG|tirzepatide|Participants will be educated on dietary and lifestyle changes. Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary. Dose escalation will proceed per package directions if instructed by study team at follow up visits.
215156457|NCT06721507|BEHAVIORAL|Standard of Care|Participants will be educated on dietary and lifestyle changes
215156458|NCT07038356|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
215156459|NCT07038356|DRUG|Placebo|Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
215156460|NCT06369233|DEVICE|MegaShield®-SP|MegaShield®-SP application Lumbar discectomy or laminectomy
214537412|NCT03188809|PROCEDURE|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
214537413|NCT03188809|PROCEDURE|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
214537414|NCT03216941|DRUG|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
214537415|NCT00655369|DRUG|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
214537416|NCT00655369|DRUG|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
214537417|NCT00655369|DRUG|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
214537418|NCT00655369|DRUG|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
214537419|NCT00655369|DRUG|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
214537420|NCT00655369|DRUG|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
214537421|NCT00601133|OTHER|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
214537422|NCT00601133|OTHER|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
214537423|NCT00601133|BEHAVIORAL|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
214537424|NCT00601133|BEHAVIORAL|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
214537425|NCT02209688|DRUG|ESR 1150 CL|
214537426|NCT02209688|DRUG|Placebo|
214537427|NCT02007759|DEVICE|VitalStim|This group will receive active VitalStim treatment.
214537428|NCT02007759|DEVICE|Sham VitalStim|This group will receive a sham VitalStim intervention.
214537429|NCT00005058|PROCEDURE|ultrasound imaging|
214537430|NCT04106453|PROCEDURE|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
214537431|NCT04106453|PROCEDURE|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
214537432|NCT04438330|OTHER|Nickel sulfate hexahydrate|Patch test
214537433|NCT03754764|BIOLOGICAL|Specificity CD38 CAR-T Cells|1\) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
214537434|NCT01531907|OTHER|Study visit procedures|"Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
214537435|NCT00605566|DRUG|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
215156461|NCT06369233|DEVICE|Guardix-SP Plus|Guardix-SP Plus application Lumbar discectomy or laminectomy
214537436|NCT00605566|DRUG|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
214537437|NCT06107049|DIETARY_SUPPLEMENT|BLa80|During the experiment, the subjects took a packet of probiotics every day, and the sleep condition, anxiety level and memory level of the subjects were evaluated by questionnaires and ability tests. The questionnaire included PSQI Pittsburgh Sleep Quality Index scale, ISI Insomnia Severity Index Scale and GSRS gastrointestinal symptom Score scale.
214537438|NCT00945113|BEHAVIORAL|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
214537439|NCT05787145|BEHAVIORAL|Let's Discuss Health Group|Use of the Let's Discuss Health website to prepare four medical encounters with the radiation oncologist throughout the radiation care trajectory.
214537440|NCT00207402|DRUG|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
214537441|NCT04156399|OTHER|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
214537442|NCT03440047|DEVICE|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
214537443|NCT01181609|DRUG|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
214537444|NCT04813497|DIAGNOSTIC_TEST|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
214537445|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
214537446|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
214537447|NCT01333111|DRUG|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
214537448|NCT02471456|OTHER|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
214537449|NCT02471456|OTHER|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
214537450|NCT04732871|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
214537451|NCT02267265|OTHER|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
214537452|NCT02267265|OTHER|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
214537453|NCT04256369|COMBINATION_PRODUCT|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
214537454|NCT02697838|DRUG|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
214537455|NCT02697838|DRUG|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens"
214537456|NCT02594046|OTHER|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
214537457|NCT00384865|DRUG|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
214537458|NCT00384865|DRUG|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
214537459|NCT00384865|DRUG|Placebo|Placebo, taken orally, once a day for 6 months
214464362|NCT03457402|BEHAVIORAL|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
214464363|NCT06530511|DRUG|Polatuzumab vedotin|Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;
214464364|NCT06530511|DRUG|Rituximab|Rituximab: 375 mg/m2, IV Drip infusion, D1
214537460|NCT02582398|OTHER|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
214464365|NCT06530511|DRUG|Orelabrutinib|Orelabrutinib: 150 mg/time, qd, po, D1-21
214696850|NCT04234815|BEHAVIORAL|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
214696851|NCT04234815|BEHAVIORAL|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
214696852|NCT01300611|DRUG|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
214696853|NCT01300611|DRUG|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
214696854|NCT01752842|DRUG|Fenofibrate|
214696855|NCT01752842|DRUG|Placebo for fenofibrate|
214696856|NCT04169334|BEHAVIORAL|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
214464366|NCT06806397|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
214464367|NCT06211413|OTHER|no intervention|no intervention
214464368|NCT05667857|BEHAVIORAL|Integrative neurocognitive remediation therapy|Integrative Neurocognitive Remediation Therapy is a clinical program of 12 weeks (1 day/week) that combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of adapted physiotherapy, acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and information sessions on cognition, fatigue, nutrition and physical exercise.
214464369|NCT05839080|BEHAVIORAL|Gardens to Bellis|In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
214464370|NCT05839080|BEHAVIORAL|No intervention|Pupils are not receiving any intervention
214464371|NCT06801197|COMBINATION_PRODUCT|MI-Coach: ED Mobile App|The MI-Coach: ED mobile app is a self-guided intervention designed to enhance motivation and readiness for treatment in adults with eating disorders. The app includes seven sequential modules based on motivational interviewing (MI) principles, addressing ambivalence, self-acceptance, compassionate motivation, behavior change goals, sustain and change talk, commitment language, and relapse prevention. Each module incorporates interactive content, including educational videos, articles, and exercises, tailored to support motivation across a range of eating disorder diagnoses. The app is designed to be user-friendly and scalable, providing an accessible, cost-effective solution for individuals on waitlists for formal eating disorder treatment.
214464372|NCT06801977|GENETIC|Genome-wide genotyping|Whole blood from the participants was used to extract DNA for genotyping.
214464373|NCT05560971|DIETARY_SUPPLEMENT|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
214464374|NCT05560971|OTHER|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
214464375|NCT06798168|BIOLOGICAL|Combining bacteriophage therapy with antibiotics for a case with hip PJI|The treatment plan is to treat the patient with weekly intra-articular injections of a personalized phage therapy cocktail (QDP-PSA-011) for 3 consecutive weeks. This will be associated with antibiotics for 6 weeks.
214464376|NCT06800560|OTHER|MenoScale|Menopause symptom questionnaire
214464377|NCT06800560|OTHER|Greene Climacteric Scale|Menopause symptom questionnaire
214464378|NCT06800560|OTHER|RAND 36-Item Health Survey 1.0|Quality of life questionnaire
214537461|NCT02582398|OTHER|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
214537462|NCT00485550|DRUG|Atomoxetine Hydrochloride|
214537463|NCT00485550|DRUG|Methylphenidate Hydrochloride|
214537464|NCT00485550|DRUG|Placebo|
214537465|NCT00006145|DRUG|Valganciclovir|
214464379|NCT06800560|OTHER|PREDICT-FFQ-v1|Food frequency questionnaire
214537466|NCT03990142|DIAGNOSTIC_TEST|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
214537467|NCT00482898|DRUG|MK0359|
214537468|NCT00640744|DRUG|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
214537469|NCT01935596|DRUG|ropivacaïne|spinal anesthesia.
214537470|NCT01935596|DRUG|lévobupivacaïne|
214537471|NCT00077597|DRUG|epoetin|3 times a week iv, as prescribed.
214537472|NCT00077597|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
214696857|NCT06203496|DIAGNOSTIC_TEST|Blood sample|Blood sample
214696858|NCT01625598|PROCEDURE|Photography of the retina|Every subject will undergo photography of the retina in both eyes
214696859|NCT01625598|PROCEDURE|Retinal photography|"Device~Subjects will have photography of both eyes"
214537473|NCT04871347|DRUG|TWP-101|IV infusion
214537474|NCT03294941|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
214537475|NCT05338541|DRUG|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
214696860|NCT01683071|DRUG|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
214696861|NCT01683071|DRUG|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
214696862|NCT01683071|DRUG|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
214696863|NCT01683071|DRUG|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
215156462|NCT06887634|OTHER|Rebozo and Maternal Procedures|"Combination of FLI and side-lying release SLR and Rebozo technique in a pre-specified order:~1\) FLI for 30 seconds repeated for 3 subconsequent contractions; 2) SLR for 30 seconds repeated for 3 consequent contractions; 3) Rest with free maternal postures for 15 minutes; 4) 15 minutes of Rebozo on maternal pelvis (women on hands and knees); 5) Rest with free maternal postures for 15 minutes; 6) 15 minutes of Rebozo on the side of the fetal spine (supine women).~Duration of the intervention ranges between 90 and 105 minutes. The intervention will start within thirty minutes after randomization; it can be interrupted at any time if needed. It will be considered performed when the proposed sequence is completed. After completion of the sequence, women will be allowed to move freely and adopt different postures. No FLI or SLR procedures or the Rebozo technique will be further allowed until sonographic assessment of the fetal head is performed at 3 hour and thirty after randomization"
215156463|NCT06887634|OTHER|Control|Standard of care, including upright, semi-recumbent, lateral recumbent, and hands-and-knees position. They will not receive forward-leaning inversion (FLI) and side-lying release (SLR) and Rebozo technique. the control group will continue to adopt maternal postures with no possibility of performing the FLI or SLR procedures or the Rebozo technique until sonographic assessment of fetal head position is completed at 3 hours and thirty after randomization.
214464380|NCT05260112|OTHER|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
214464381|NCT06803420|DEVICE|Portable, ultra-low-field MRI scanner|"This study evaluates a portable, ultra-low-field MRI scanner (the Hyperfine Swoop) combined with artificial intelligence (AI) to detect brain abnormalities.~Patients undergoing a standard brain MRI scan will be invited to have an additional portable MRI scan within 30 days of their clinical scan. The portable MRI scan will take approximately 60 minutes, using multiple imaging sequences, including T2-weighted scans.~The AI system will then analyse the portable MRI images and categorise them as normal or abnormal. The results will be compared with expert neuroradiologist reports from standard MRI scans to validate accuracy.~This intervention aims to assess whether portable MRI with AI can provide a low-cost, accessible alternative to standard MRI, potentially improving triage and reducing waiting times for patients requiring urgent brain imaging."
214464382|NCT06301412|DEVICE|hypothermia|hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
214464383|NCT06798935|PROCEDURE|autologous platelet-rich stroma|Autologous platelet-rich stroma, which is the combined product of stromal vascular fraction and platelet-rich plasma
214464384|NCT06058169|DEVICE|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
214464385|NCT06803290|DRUG|VHX-896|Oral tablet
214464386|NCT06802848|DRUG|Xeligekimab injection|This is a real-world study. All treatment regimens are developed and implemented through detailed communication between patients and their treating clinicians. Treatment recommendations are consistent with the medication's prescribing information and treatment guidelines. The recommended dosing for xeligekimab is 200 mg at weeks 0, 2, 4, 6, 8, 10, and 12, followed by every 4 weeks thereafter. Each 200 mg dose is given in 2 separate 100 mg subcutaneous injections. The preferred injection site is the abdomen. Upper arms or thighs are recommended as alternative sites.
214464387|NCT06802926|DRUG|Colchicine|Oral Colchicine 0.5mg qd for 1 year
214464388|NCT03400826|DRUG|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
214464389|NCT03400826|DRUG|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
214464390|NCT06803433|DEVICE|Aligners|Lower arch in office aligners.
214537476|NCT00702650|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
214696864|NCT03121183|DEVICE|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
214696865|NCT03121183|BEHAVIORAL|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
215156464|NCT07048041|OTHER|Functional Assessment Battery|Participants completed a series of validated patient-reported outcome questionnaires (Oxford Hip Score, WOMAC, SF-12) and physical performance tests (Timed Up and Go, Four Square Step Test, 4-Meter Gait Speed Test) during a single outpatient assessment session. No therapeutic or invasive interventions were performed.
215156465|NCT06053684|DEVICE|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
215156466|NCT06053684|DEVICE|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
215156467|NCT06727500|BEHAVIORAL|HIIT plus plyometric training|"The HIIT plus plyometric training will perform two weeks of exercise adaptation involving 25 minutes of MICT at 65% of maximal heart rate (HRmax) and 5 minutes of jumps in place at 5 - 6 of the EPinfant scale of Perceived exertion. The HIIT plus plyometric training will perform 15 minutes of HIIT and 5 minutes of jumps each session. The HIIT phase will be performed in a work recovery intensity at 85 and 50% of the HRmax. The work phase of jumps will be performed all out, and the recovery phase will be performed at 5 - 6 of the EPinfant scale of perceived exertion. The work: recovery bouts will be progressed from 1:4 (15 seconds: 60 seconds) at weeks 3-6, to 1:3 (15 seconds: 45 seconds) at weeks 7-9, and to 1:3 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured."
215156468|NCT06727500|BEHAVIORAL|HIIT|The HIIT group will perform two weeks of exercise adaptation involving 30 minutes of moderate-intensity continuous training (MICT) at 65% of the maximal heart rate (HRmax) reached in the maximal oxygen consumption test. The HIIT group will perform 20 minutes of HIIT each session, with a work: recovery intensity at 85% and 50% of HRmax, respectively. The work: recovery bouts will be progressed from 1:4 (15 seconds:60 seconds) at weeks 3-6, to 1:3 (15 seconds:45 seconds) at weeks 7-9, and to 1:2 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured.
215156469|NCT03516617|DRUG|Acalabrutinib|Given PO
215156470|NCT03516617|OTHER|Laboratory Biomarker Analysis|Correlative studies
215156471|NCT03516617|BIOLOGICAL|Obinutuzumab|Given IV
215156472|NCT03516617|OTHER|Patient Observation|Undergo observation
215156473|NCT03516617|OTHER|Quality-of-Life Assessment|Ancillary studies
215156474|NCT05603312|GENETIC|AAV-GAD Low Dose|Bilateral infusion of AAV-GAD low dose
215156475|NCT05603312|GENETIC|AAV-GAD High Dose|Bilateral infusion of AAV-GAD high dose
215156476|NCT05603312|PROCEDURE|Sham Surgery|Sham infusion
215156477|NCT05289947|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
215156478|NCT05289947|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
214464391|NCT06803433|DEVICE|Lingual braces|Lingual braces bonded to the lower anterior teeth
214464392|NCT06803433|DEVICE|Active fixed lingual wire|A customized 14 Niti lingual wire customized to the lingual surface of the lower anterior teeth and secured with ligature wires.
214464393|NCT03994367|OTHER|High animal protein isolate|Increased dietary protein content from animal protein isolates
214464394|NCT03994367|OTHER|High animal protein whole food|Increased dietary protein content from animal protein whole food
214464395|NCT03994367|OTHER|High plant protein isolate|Increased dietary protein content from plant protein isolates
214464396|NCT03994367|OTHER|High plant protein whole food|Increased dietary protein content from animal protein whole food
214464397|NCT03854227|DRUG|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
214464398|NCT03854227|DRUG|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
214464399|NCT03854227|DRUG|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
214464400|NCT06268535|DRUG|Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023|Disproportionality analysis studying the association between cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.
214464401|NCT03668236|DRUG|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
214464402|NCT05374681|OTHER|Medical treatment|Medical treatment alone
214464403|NCT05374681|OTHER|Surgical treatment|Surgical treatment alone
214464404|NCT05374681|OTHER|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
214464405|NCT06447480|DRUG|ISOtretinoin 5 MG|"The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended."
214464406|NCT06447480|DRUG|Topical cream|Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
214464407|NCT05295030|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
215156479|NCT06739941|OTHER|Oat fiber (BG-OS)|Beta-glucan oligosaccharide (BG-OS) is beta-glucan predominant, dietary fiber obtained by extracting oat fiber from oat grain and applying a food-grade depolymerization process to shorten the polysaccharide chain length of the fiber. BG-OS retains the fiber structure of oat fiber but has a shorter chain length, which makes it water soluble and easily formulated into any food.
215156480|NCT07053826|DEVICE|Penile Traction Device|Patients will be randomized into one of two groups: penile traction therapy 30 min 3x/day x 3 months, or control (no treatment). Preoperative erectile function surveys will be recorded in the EMR per standard of care. Following randomization, patients allocated to the treatment arm will be instructed how to use the device properly. Patients in the treatment arm will record a daily journal of use of the device (Appendix 1). After a minimum of 3 months, patients in the treatment arm will return for their scheduled procedure. Control arm patients will be scheduled directly for an OR date.
215156481|NCT07053826|PROCEDURE|Inflatable Penile Prosthesis Implantation|Implantation of a three-component inflatable penile prosthesis.
215156482|NCT07055438|PROCEDURE|Ultrasound guided Rectus sheath block|After receiving general anesthesia, bilateral ultrasound guided rectus sheath block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
214464408|NCT05295030|OTHER|Kieember Infant formula, Ruibuen®|Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited
214464409|NCT05295030|OTHER|Yashili Infant formula, Ruibuen®|Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
214464410|NCT04863378|BEHAVIORAL|Walking conversational reminiscence|Triadic walking with prompted conversational reminiscence
214464411|NCT03798093|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
214464412|NCT03798093|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
214464413|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
214464414|NCT05330351|DIAGNOSTIC_TEST|Gastric Ultrasound|The investigators will compare gastric fluid volume as determined by ultrasound pre-induction vs. gastric volume aspirated via an orogastric tube post-intubation. The results will be stratified into low risk, moderate risk and high risk for aspiration based on ultrasound exam by an investigator off-line.
214464415|NCT03818880|DEVICE|Novel spectacle lens design|Spectacle lens to control progression of myopia
214464416|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
214464417|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
214464418|NCT06134336|OTHER|Interview|No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
214464419|NCT03132506|OTHER|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
214464420|NCT06132282|BEHAVIORAL|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
214464421|NCT03850964|DRUG|Pazopanib|gel capsule, with 25mg-similar fills
214464422|NCT03850964|DRUG|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
214464423|NCT06557330|DRUG|Bendamustine|Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
214464424|NCT06557330|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
214464425|NCT03397303|OTHER|elastography measurements|elastography measurements
214464426|NCT06771934|BIOLOGICAL|Allergen-specific immunotherapy(AIT)|"Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks."
215156483|NCT07055438|PROCEDURE|ultrasound guided external oblique intercostal plane block|After receiving general anesthesia, bilateral ultrasound guided external oblique intercostal plane block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
215156484|NCT07053059|DRUG|Obecabtagene autoleucel|given by Infusion
215156485|NCT07076849|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum 299v|Probiotic
215156486|NCT07076849|OTHER|Placebo Capsule(s)|Placebo control
215156487|NCT05016505|BEHAVIORAL|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
215156488|NCT05016505|BEHAVIORAL|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
215156489|NCT04274530|BEHAVIORAL|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
215156490|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
215156491|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
215156492|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
215156493|NCT07090213|OTHER|Survey using a questionnaire|Eighty women, determined by the number of questions times the rule of 10, will be asked to fill out the Pelvi-Perineal Surgery Sexuality Questionnaire - PPSSQ and Female Sexual Function Index (FSFI) questionnaires and will be asked to fill out the PPSSQ again 7 days later for test-retest reliability.
215156494|NCT06927635|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
215156495|NCT06927635|OTHER|Systemic therapy|Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
215156496|NCT04985565|OTHER|Dietary Intervention|Participate in Mediterranean diet
215156497|NCT04985565|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
215156498|NCT07103382|DIETARY_SUPPLEMENT|Attapulgite|Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.
215156499|NCT07103382|DIETARY_SUPPLEMENT|Placebo|Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.
215156500|NCT07096193|DRUG|GS-4321|Administered subcutaneous (SC) or intravenously IV
215156501|NCT07096193|DRUG|GS-4321 Placebo|Administered SC
214537477|NCT02732002|PROCEDURE|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
214696866|NCT06866028|DEVICE|Real-time fNIRS neurofeedback from Turbo-Satori|Activity in the target brain region measured by fNIRS in real-time will undergo processing on Turbo-Satori (BrainVoyager; Maastricht, Netherlands) to infer changes in oxygenated blood activity in the target brain region and relayed to the task program for visual feedback.
214696867|NCT06866028|DEVICE|Yoked sham feedback from Turbo-Satori|Previous data acquired from another individual in the experimental group will be loaded into Turbo-Satori (BrainVoyager; Maastricht, Netherlands) software for preprocessing in real-time and relayed to the task program for visual feedback.
214696868|NCT02558738|DEVICE|ear spray|
215156502|NCT07096193|DRUG|GS-4321|Administered SC
215156503|NCT06915025|DRUG|IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)|100 mg/m2 IP given weekly during frontline treatment
215156504|NCT06915025|DRUG|Paclitaxel|175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment
215156505|NCT06915025|DRUG|Carboplatin|AUC 6 IV given every 21 days for 6 cycles during frontline treatment
215156506|NCT06915025|DRUG|Olaparib|Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
215156507|NCT06915025|DRUG|Niraparib|Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt.
215156508|NCT07110116|OTHER|Alternate nostril breathing with Incentive Spirometery|Participants in experimental group were instructed to close their left nostril by left index finger and inhale through their right nostril for six seconds, then closing the right nostril and holding breath for six seconds. Afterward, they exhaled through the left nostril slowly for six seconds. Next, they inhaled through left nostril, keeping the right nostril closed for six seconds then hold the breath by closing both nostrils for six seconds subsequently, and then exhaled through the right nostril, keeping the left closed for six seconds repeating these steps several times for 10 minutes
215156509|NCT07110116|OTHER|Incentive spirometery|The control group participants were asked to do breathing exercise with incentive spirometry. The subject is asked to create a tight seal around the mouthpiece and asked to inhale deeply and slowly and the subject would observe the flow meter for visual feedback of his/her effort. At the end of the inspiration the subject is asked to sustain the inhalation 2-3 seconds to facilitate the Inspiratory hold. Subject relaxes the seal around the mouthpiece and exhales. Normal breathing is taken, then the exhalation phase in the incentive spirometry is done and the whole cycle is repeated 5 - 10 times thrice a day over a period 6 weeks
215156510|NCT06882317|OTHER|Long Term Follow-Up|No intervention is administered on this study. Subjects who have received CLBR001 autologous CAR-T cells in a primary Calibr treatment trial will be followed long term in line with FDA guidance.
215156511|NCT07132281|BEHAVIORAL|Language activities active inference|Participants will join reading or writing activities and come up with their own inference about wording or plots.
215156512|NCT07132281|BEHAVIORAL|Language activities passive|Participants will join reading or writing activities and will be given step-by-step explanations about the wording and plots.
215156513|NCT07132281|BEHAVIORAL|Board Games|Participants will play board games with each other.
215156514|NCT06934044|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle.
215156515|NCT06934044|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
215156516|NCT07143903|OTHER|artificial application|The conceptual framework for this study proposes that an AI-powered labor monitoring application, designed to track contractions, analyze symptoms, provide educational resources, and utilize predictive analytics, will enhance maternal experience by increasing perceived control, reducing anxiety, and boosting confidence during the first stage of labor. These improvements in maternal experience are expected to mediate positive outcomes, including higher maternal satisfaction, lower stress levels, and timely interventions when necessary, ultimately leading to better fetal outcomes, such as higher Apgar scores and reduced NICU admissions. The framework hypothesizes that expectant mothers using the AI application will have a more empowered labor experience compared to those receiving traditional monitoring, with measurable benefits for both mothers and their newborns.
215156517|NCT07141225|PROCEDURE|Off-Clamp Sutureless Technique|During the procedure, the renal artery and its branches are not clamped. The tumor is completely resected with a gross margin of 0.5-1 cm from its edge. Monopolar or bipolar electrocautery is used for hemostasis during resection. Following tumor removal, the renal resection bed is subjected to meticulous hemostasis, followed by the application of hemostatic agents without suture closure.
215156518|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
215156519|NCT07145255|DRUG|ADC|MBRC-201 ADC
215156520|NCT07145502|BIOLOGICAL|Allogeneic MSC infusions (IV)|Optional T-reg therapy (experimental/compassionate-use basis)
215156521|NCT07139795|BEHAVIORAL|Mindful eating and movement|Group mindful eating sessions will be conducted once per week, one hour per session, for eight weeks. Participants will be encouraged to attend at least two, 45-minute yoga sessions per week.
215156522|NCT07144033|DIETARY_SUPPLEMENT|Butyrate and Taurine|This dose of butyrate is chosen to maximize any treatment effect in postoperative pain. Butyrate was reported to be safe at this dose for a prolonged period of 8 weeks. The dose of taurine is considered safe according to the European Food Safety Authority and was used in previous human perioperative trials. A human pharmacokinetic study showed that after taking 4g taurine (32 mmol) orally, plasma taurine levels reached a peak level of 86 mg/L (or 0.7 mmol/L) at 1.5 hours, exceeding the physiological plasma taurine level (0.01-0.1 mmol/L), which is needed to exert its pharmacological benefits.
215156523|NCT07144033|OTHER|Placebo|indistinguishable placebo capsules will be administered orally after enrolment on the day before surgery, followed by daily administration for three months after surgery.
215156524|NCT07144748|OTHER|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
215156525|NCT07144215|DRUG|Dexmedetomidine 3 mcg|Patient received spinal injection of dexmedetomidine 3 mcg.
215156526|NCT07144215|DRUG|Dexmedetomidine 4 mcg|Patient received spinal injection of dexmedetomidine 4 mcg.
214537478|NCT05051423|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
214537479|NCT05897983|OTHER|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
214537480|NCT05184777|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
214537481|NCT03993457|DRUG|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
214537482|NCT03993457|DRUG|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
214537483|NCT01605656|BEHAVIORAL|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
214537484|NCT01605656|BEHAVIORAL|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
214537485|NCT01605656|BEHAVIORAL|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
214537486|NCT00037115|DRUG|interferon beta 1a|
214537487|NCT00037115|DRUG|methotrexate|
214537488|NCT00037115|DRUG|methylprednisolone|
214537489|NCT00072605|DRUG|VRC-EBODNA012-00-VP|
214537490|NCT03752242|DRUG|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
214537491|NCT05803148|PROCEDURE|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
214537492|NCT05803148|DRUG|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
214537493|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
214537494|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
214537495|NCT05656612|OTHER|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
214537496|NCT05574751|OTHER|Titanium tacker|Mesh fixation with Titanium tacker
214537497|NCT05574751|OTHER|Polypropylene 0|Mesh was sutured and fixed with polypropylene 0
214537498|NCT03219177|BEHAVIORAL|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
214537499|NCT03219177|OTHER|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
214537500|NCT02171884|OTHER|Sample of cord blood|
214537501|NCT02171884|OTHER|Sample of placenta|
214537502|NCT00005997|DRUG|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
214537503|NCT02518347|DIETARY_SUPPLEMENT|FDS-Strawberry|Natural frozen and dried strawberries
214537504|NCT02518347|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
214537505|NCT05758103|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)|Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
214537506|NCT05463731|DRUG|Remternetug (IV)|Administered IV
214537507|NCT05463731|DRUG|Remternetug (SC)|Administered SC
214537508|NCT05463731|DRUG|Placebo|Administered IV or SC
214537509|NCT01617798|DRUG|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
214537510|NCT01617798|DRUG|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
214537511|NCT01475461|DRUG|Placebo|double-dummy placebo tablets administered once-daily for 84-days
214537512|NCT01475461|DRUG|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
214537513|NCT01475461|DRUG|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
214537514|NCT01475461|DRUG|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
214537515|NCT01475461|DRUG|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
214537516|NCT01475461|DRUG|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
214537517|NCT04676633|DRUG|STP705|Investigational Product
214537518|NCT01061853|DRUG|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
214537519|NCT01061853|DRUG|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
214537520|NCT00141713|DRUG|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
214537521|NCT03911908|COMBINATION_PRODUCT|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
214696869|NCT05092971|DEVICE|Shock or startle device|Shock and startle devices were used as aversive stimulus (shock and startle)
214696870|NCT03166436|PROCEDURE|Radiofrequency ablation|radiofrequency ablation
214696871|NCT03166436|PROCEDURE|Biliary stenting|biliary stenting
214537522|NCT03194854|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
214537523|NCT01271036|DEVICE|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
214537524|NCT01093170|DRUG|RNA-144101|Intravitreous administration of RNA-144101
214537525|NCT02512861|DRUG|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs"
214537526|NCT02512861|DRUG|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs"
214537527|NCT01269255|DRUG|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy"
214537528|NCT02347969|DIETARY_SUPPLEMENT|X34|Dietary supplement named X34
214537529|NCT05286086|BEHAVIORAL|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
214537530|NCT04008056|OTHER|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
214537531|NCT03180554|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
214537532|NCT03180554|OTHER|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
214537533|NCT01362283|OTHER|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
214537534|NCT02107547|PROCEDURE|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
214537535|NCT02107547|PROCEDURE|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
214537536|NCT01774019|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
214537537|NCT05146661|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
214537538|NCT03891498|DRUG|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
214537539|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
214537540|NCT02160470|BEHAVIORAL|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
214537541|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
214537542|NCT02160470|BEHAVIORAL|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
214537543|NCT03206476|BEHAVIORAL|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
214537544|NCT03206476|BEHAVIORAL|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
214537545|NCT04774783|DEVICE|Low-Level Laser Therapy|The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
214537546|NCT03104777|BEHAVIORAL|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
214537547|NCT02883179|DRUG|lidocaine injection|anhydrous solution
214537548|NCT02883179|DRUG|lidocaine-prilocaine cream|topical cream
214537549|NCT06642363|DRUG|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"
214537550|NCT06642363|DRUG|Placebo|The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
215156527|NCT07144215|DRUG|Dexmedetomidine 5 mcg|Patient received spinal injection of dexmedetomidine 5 mcg.
215156528|NCT07144215|DRUG|Dexmedetomidine 6 mcg|Patient received spinal injection of dexmedetomidine 6 mcg.
215156529|NCT07144215|DRUG|Bupivacain hyperbaric 0.5% 12.5 mg|Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg
215156530|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156531|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Not Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156532|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156533|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156534|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156535|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Not Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
214537551|NCT02179710|BEHAVIORAL|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
214537552|NCT03503487|OTHER|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
214537553|NCT00694733|DRUG|Placebo injection|Normal saline injection IM monthly for 4 months
214537554|NCT00694733|DRUG|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
214537555|NCT00694733|DRUG|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
214537556|NCT00694733|DRUG|placebo|Placebo Cream 1ml applied twice daily for four months
214696872|NCT02306187|DRUG|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
214696873|NCT06260072|DRUG|magnesium and riboflavin supplement|Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
214696874|NCT05549141|OTHER|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
215156536|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156537|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
215156538|NCT07146958|OTHER|Chia seeds|Chia seeds will be added to soup and bread recipes.
215156539|NCT07146958|OTHER|Hemp seeds|Hemp seeds will be added to soup and bread recipes.
215156540|NCT07146958|OTHER|Placebo|The placebo will be food items that are not enriched with the intervention products.
215156541|NCT06947161|DRUG|Gengigel|Throat pack will be soaked with gengigel, and post operatively, will see if there is any presence of sore throat, severity of sore throat. 10 mlm of gengigel, in liquid form will be used to soak the throat pack. 30 patients will receive gengigel spray soaked throat pack, and control group will receive normal saline soaked throat pack
215156542|NCT07148934|DIAGNOSTIC_TEST|Smartphone seismographic recording and Bed Based Ballistocardiographic recordings|A short recording of heart rhythm using a smartphone and bed-based ballistocardiogram.
215156543|NCT07142044|DRUG|EC5026 oral tablet|Oral soluble epoxide hydrolase inhibitor
215156544|NCT07142044|DRUG|Placebo|Matching oral placebo
215156545|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin|Participants received Whole wheat muffin once a day
215156546|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)
215156547|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)
215156548|NCT07147296|PROCEDURE|ARC-IM System Implantation|Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
215156549|NCT07147296|DEVICE|ARC-IM Therapy (active)|The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
215156550|NCT07147296|DEVICE|ARC-IM Therapy (sham)|The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation (after 3 months of sham stimulation) at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
215156551|NCT06955468|BEHAVIORAL|Priming Survey|13-item priming survey assessing patients' goals, treatment preferences, and disease understanding.
215156552|NCT07144839|OTHER|Data Collection Throughout Pregnancy and Delivery|Participants will receive monitoring by ultrasound and blood tests at three time points during pregnancy, and delivery and neonatal data will be collected.
215156553|NCT07147114|DRUG|Combination therapy|Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
215156554|NCT07147114|DRUG|Monotherapy|Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
214537557|NCT00694733|DRUG|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
214537558|NCT05985083|DRUG|IMM47|IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
214537559|NCT03214250|DRUG|APX005M|Administer intravenously once every 28-day Cycle
215156555|NCT07146763|BEHAVIORAL|Prescribing Feedback|Automated prescribing feedback messages are delivered to clinician prescribers in participating emergency departments. Messages are based on Geriatric Emergency Medication Safety Recommendations (GEMS-Rx) recommendations and include aspirational norms and benchmark comparisons. Depending on study arm, feedback is sent either from a credible peer messenger or through an anonymous messenger system.
215156556|NCT07150585|DEVICE|Ultrasonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the Ultra X device (Eighteeth) with ultrasonic tips.
215156557|NCT07150585|DEVICE|Sonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using an EDDY sonic activation tip (VDW, Munich, Germany)
215156558|NCT07150585|DEVICE|Laser Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the LightWalker (Fotona, Ljubljana, Slovenia) Er:YAG laser device in SWEEPS mood
214537560|NCT03214250|DRUG|Nivolumab|Administer intravenously twice every 28-day cycle
215156559|NCT07152912|DRUG|Isoflurane|Patients will receive general anesthesia and maintenance by isoflurane.
215156560|NCT07152912|DRUG|Sevoflurane|Patients will receive general anesthesia and maintenance by sevoflurane.
215156561|NCT07154875|PROCEDURE|Assisted Hatching|Laser-assisted zona drilling performed either on Day-3 or Day-5 of culture, depending on randomization arm.
215156562|NCT07148206|DRUG|Dronabinol Capsules|Dronabinol is a synthetic form of THC. Dronabinol is eliminated in a biphasic manner, with an initial half-life of 25-36 hours.
215156563|NCT07148206|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is an oral solution (100 mg/mL) which rapidly appears in plasma, reaches peak plasma concentration in 3-4 hours and has a half-life of 18-32 hours.
215156564|NCT07148206|OTHER|Placebo Dronabinol|Placebo capsules
215156565|NCT07148206|OTHER|Placebo Epidiolex|Placebo oral solution
215156566|NCT07158333|DEVICE|Mobile Cardiac Telemetry (MCT System)|MCT System without data transmission
215156567|NCT07157072|OTHER|Corrective rigid taping|Rigid taping used to correct pelvic torsion in patients with CAI
215156568|NCT07157696|DEVICE|High-Flow Nasal Cannula (HFNC) Oxygen Therapy|"Type: Device / Procedure~Description: Humidified high-flow nasal cannula oxygen therapy delivered via a home device. Provides warmed (37°C), humidified air and supplemental oxygen at ≥30 L/min, titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use the device for ≥8 hours per day, preferably overnight.~Special Features: Integrated remote monitoring system that automatically records flow, FiO₂, SpO₂, heart rate, and usage time, transmitting data to a secure cloud platform for clinical follow-up."
215156569|NCT07157696|DEVICE|Oxygen therapy|"Type: Device / Procedure~Description: Standard long-term oxygen therapy delivered through conventional low-flow systems (e.g., nasal cannula or mask). Oxygen is titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use oxygen for ≥8 hours per day, preferably overnight.~Special Features: No humidification, high-flow delivery, or remote monitoring capabilities."
215156570|NCT07157059|BEHAVIORAL|Doula Care|Participants assigned to the Doula care group received care from the doula pre, during, and post delivery.
215156571|NCT07157592|OTHER|Ventrogluteal IM Injection tecnique|"Ventrogluteal IM injection technique:~During IM injection into the ventrogluteal region:~* The entrance angle of the needle is 90º.~* The 25-gauge (1-inch) syringe is held with the active hand as if holding a pen, and no hand change is made during the injection.~* The needle is rapidly inserted into the skin and withdrawn at the same angle 5 seconds after the injection.~* The drug is injected for 5 seconds/mL without blood aspiration during injection.~* Light pressure is applied to the area after injection, with no massage performed.~To evaluate the appropriateness of the application ventrogluteal IM injection technique, the opinions were obtained of five experts in nursing principles and child health and disease nursing."
215156572|NCT07156175|DRUG|SAR444336|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
215156573|NCT07156175|DRUG|Placebo|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
215156574|NCT07157501|BEHAVIORAL|Accupressure|Acupressure will be applied by pressing in circular movements on the acupoint with the thumb finger first in clock wise and then anti-clock wise direction. The finger must remain at the same point on the skin and be moved in small circles
215156575|NCT07157501|OTHER|Aromatherapy inhaler|The lavender inhalation application will be explained to the children and their mothers. Two drops of 100% pure organic lavender oil will poured on a cotton. The cotton will have fixed by the child at 5 cm distance from his or her nose and will asked to breathe slowly for 10-15 minutes
215156576|NCT07157436|OTHER|Non-interventional study|observational study. non-interventional
215156577|NCT07158268|DRUG|HSK47388|HSK47388 tablets will be administered orally, once a day
215156578|NCT07157124|OTHER|Dynamic Visual Noise (DVN)|DVN is a brief visual array of patterns of flickering black and white dots. In alignment with prior literature, the DVN array will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares that will change at a rate of 640 frames per second. The DVN will be 30 seconds in duration, though participants will be able to keep watching for as long as desired by restarting the video of the array.
215156579|NCT07157124|OTHER|Static Visual Noise (SVN)|SVN is similar to DVN, but refers to a static (or still) image of an array of black and white squares. The SVN will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares. SVN has been used in previous working memory-loading studies as a control for DVN. Similar to the DVN, participants in the control group will view the SVN for at least 30 seconds (but they will be able to keep viewing it for as long as desired).
214537561|NCT03214250|DRUG|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
214537562|NCT03214250|DRUG|Gemcitabine|Administer intravenously 3 times every 28-day cycle
214537563|NCT04503837|PROCEDURE|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
214537564|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
214537565|NCT02264964|PROCEDURE|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
214537566|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
214537567|NCT02264964|PROCEDURE|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
214537568|NCT00848068|OTHER|FID 114657|artificial tears
214537569|NCT00848068|OTHER|OPTIVE Lubricant Eye Drops|artificial tears
214537570|NCT00508534|DRUG|SB-751689|
214537571|NCT04747210|BEHAVIORAL|contextual one-on-one coaching|Training workshop and coaching one-on-one
214537572|NCT04747210|BEHAVIORAL|Trainig workshop|Ten-hour training workshop.
214537573|NCT04157023|DEVICE|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
214537574|NCT05923502|DRUG|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
214537575|NCT03643497|DRUG|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
214537576|NCT02217488|DRUG|DG3173|
214537577|NCT02217488|DRUG|Placebo|
214537578|NCT00931008|DRUG|SID530, Taxotere|75mg/m2
214537579|NCT02428816|OTHER|MRI acquisition|MRI acquisitions
214537580|NCT02428816|BEHAVIORAL|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
214537581|NCT03065478|DIETARY_SUPPLEMENT|OnLife|Daily dosing of dietary supplement OnLife
214537582|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
214537583|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
214537584|NCT00616577|DRUG|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
214537585|NCT05203224|DRUG|Dornase Alfa|Intravenous Dornase alfa
214537586|NCT03801681|DIAGNOSTIC_TEST|ECG holter monitoring|patients will be monitored using ECG-holter
214537587|NCT02239861|BIOLOGICAL|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
214537588|NCT02652377|DRUG|EDP-494|10, 100 and 200 mg capsules
214537589|NCT02652377|DRUG|Placebo|placebo to match EDP-494
214537590|NCT02292485|BEHAVIORAL|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
214537591|NCT01376050|DEVICE|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
214537592|NCT01376050|DEVICE|Placebo Laser|Placebo Laser has no therapeutic output emitted.
214537593|NCT01553227|DEVICE|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
214537594|NCT03463577|OTHER|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
214537595|NCT05694533|DRUG|INDV-2000|Capsules administered orally twice a day
214696875|NCT05549141|OTHER|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
215156580|NCT07157891|BIOLOGICAL|MSC-Derived Secretome|The secretome will be collected from cultured MSCs under sterile, GMP-compliant conditions and concentrated to retain bioactive molecules. It will be injected into the affected knee under ultrasound guidance.
215156581|NCT07157891|BIOLOGICAL|MSC-Derived Secretome + Autologous PRGF|MSC-derived secretome will be collected from mesenchymal stem cell cultures under sterile, GMP-compliant conditions. Autologous PRP will be prepared from the participant's own peripheral blood using a standardized single-spin centrifugation method and combined with 10% calcium chloride to activate growth factors. Both components will be mixed and administered into the affected joint under ultrasound guidance.
214537596|NCT05694533|DRUG|Midazolam|Midazolam syrup administered orally on Days 1 and 15
214537597|NCT00292981|DRUG|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
214537598|NCT02073253|OTHER|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
214537599|NCT05008263|DIAGNOSTIC_TEST|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
214537600|NCT05008263|DIAGNOSTIC_TEST|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
214696876|NCT00798213|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
214537601|NCT00610025|PROCEDURE|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
214537602|NCT05755217|DIETARY_SUPPLEMENT|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
214537603|NCT05755217|DIETARY_SUPPLEMENT|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
215156582|NCT07156487|DEVICE|Digital Anesthesia with SleeperOne 5|For both maxillary and mandibular teeth, 1.7 mL of Ultracaine D-S Fort carpule (4% articaine with 1:200,000 epinephrine) was administered in two stages (gingival and intraosseous injection) using a computer-controlled intraosseous anesthesia system with a 30-gauge, 9 mm Effitec needle.
215156583|NCT07156487|DEVICE|Infiltration Anesthesia with a Metal Cartridge Syringe|For maxillary teeth, buccal infiltration is performed using a metal carpule syringe and a 30G, 16 mm Effitec needle (Dental Hi Tec, France); after aspiration, Ultracaine D-S Fort is slowly injected over 1 minute.
214537604|NCT00594178|DEVICE|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
214537605|NCT06042023|DEVICE|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
214537606|NCT04427878|PROCEDURE|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
214537607|NCT02172950|BIOLOGICAL|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
214537608|NCT00496626|BIOLOGICAL|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
214537609|NCT00496626|BIOLOGICAL|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
214537610|NCT03080662|DEVICE|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
214537611|NCT03080662|DEVICE|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
214537612|NCT02795715|DEVICE|tDCS|
214537613|NCT02795715|BEHAVIORAL|training|
214537614|NCT02541045|DRUG|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
214537615|NCT02541045|OTHER|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
214537616|NCT00611715|DRUG|erlotinib hydrochloride|OSI-774 150 mg/day
214537617|NCT00611715|DRUG|letrozole|Letrozole 2.5 mg/day
214537618|NCT00611715|GENETIC|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
214537619|NCT00611715|OTHER|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
214537620|NCT00611715|OTHER|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
214537621|NCT00291239|BEHAVIORAL|partial sleep deprivation|
214537622|NCT00107978|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
214537623|NCT00107978|DRUG|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
215156584|NCT07156487|DEVICE|Mandibular Block Anesthesia with a Metal Cartridge Syringe|For mandibular teeth, the injection site is dried, and a 27G, 35 mm Effitec needle (Dental Hi Tec, France) is inserted between the pterygomandibular raphe and internal oblique ridge, aligned with contralateral molars. After aspiration, Ultracaine D-S Fort is slowly injected over 1 minute using a traditional metal carpule syringe, following the standard mandibular block technique.
215156585|NCT07156981|BEHAVIORAL|Physiotherapy|The treatment program will include patient education, lifestyle recommendations, breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks.
214537624|NCT02003378|DEVICE|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
214537625|NCT02003378|DEVICE|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
214537626|NCT01016418|DIETARY_SUPPLEMENT|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
214537627|NCT03738306|OTHER|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
214537628|NCT03738306|OTHER|Conventional Physiotherapy|therapeutic exercise; physical agents
214537629|NCT00727415|DRUG|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
214537630|NCT00727415|DRUG|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
214537631|NCT00727415|DRUG|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
214537632|NCT04864717|DRUG|Doxycycline 100mg po once daily x 6 months|active intervention
214537633|NCT04864717|DRUG|Isotretinoin 40 mg po once daily x 6 months|active intervention
214537634|NCT02005393|DEVICE|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
214537635|NCT03510806|DIETARY_SUPPLEMENT|Supplement|dietary supplement contain protein from milk and fruit extract
214537636|NCT03510806|OTHER|Placebo|color, taste, and calorie-matched placebo
214696877|NCT00798213|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
214696878|NCT00202631|DEVICE|Surface Functional Electrical Stimulation|
215156586|NCT07156162|OTHER|Videos: Taste vs Health|Participants in this intervention will watch taste and health focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
214537637|NCT03060213|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
214537638|NCT03016949|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
214537639|NCT03016949|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
214537640|NCT00664183|DRUG|Vitreosolve|Intravitreal injection
214537641|NCT04761692|BEHAVIORAL|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
214537642|NCT04761692|BEHAVIORAL|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
214537643|NCT04761692|BEHAVIORAL|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
214537644|NCT04191148|DRUG|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
214537645|NCT04191148|DRUG|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
214537646|NCT01637285|BIOLOGICAL|PF-04856883|Dose A
214537647|NCT01637285|BIOLOGICAL|PF-04856883|Dose B
214537648|NCT01637285|BIOLOGICAL|PF-04856883|Dose C
214537649|NCT01637285|BIOLOGICAL|PF-04856883|Dose D
214537650|NCT03135613|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
214537651|NCT05410119|BEHAVIORAL|8-week Resilience Group Psychotherapy|Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
214537652|NCT05410119|OTHER|Usual care|Usual care means treating as usual, such as regular home visit.
214537653|NCT00016445|DRUG|growth hormone|
214537654|NCT03696888|BEHAVIORAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
214537655|NCT03696888|BEHAVIORAL|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
214537656|NCT06546514|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
214537657|NCT02090998|PROCEDURE|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
214537658|NCT02090998|DRUG|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
214537659|NCT00085111|BIOLOGICAL|bevacizumab|Given IV
214537660|NCT00374088|DRUG|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
214537661|NCT00374088|DRUG|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
214537662|NCT01148498|DRUG|solanezumab|400mg administered once intravenously
214537663|NCT04156347|DRUG|Episcleral Topotecan|Transscleral Topotecan
214537664|NCT04963946|DRUG|Stop ACA|discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
214537665|NCT04963946|DRUG|ACA Continuation|continuation of acalabrutinib at the same dose
214537666|NCT01799109|DRUG|Magnesium Sulfate & albuterol|
214537667|NCT01799109|DRUG|albuterol|
214537668|NCT01799109|DRUG|magnesium|
215156587|NCT07156162|OTHER|Health vs. Taste|Participants in this intervention will watch health and taste focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
215156588|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
215156589|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
214696879|NCT03766087|PROCEDURE|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
214696880|NCT02020031|DRUG|Vancomycin|
214696881|NCT05693090|DRUG|Tipifarnib|Oral administration
214696882|NCT05693090|DRUG|Osimertinib|Oral administration
214696883|NCT03750071|BIOLOGICAL|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
215156590|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
215156591|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
215156592|NCT07156214|OTHER|Assessment of markers of oxidative stress in peripheral blood samples|Participants will perform serial blood samples at interval of 12 months to compare levels of markers of oxidative stress
215156593|NCT07157371|OTHER|Supervised structured aerobic exercise training|Supervised structured aerobic exercise plan will be conducted in gym by the physiotherapist
215156594|NCT07157371|OTHER|Walk|Females with PCOS will be instructed to do a walk at home with medications
215156595|NCT07156747|OTHER|Visual Analog Scale|The Visual Analog Scale (VAS) is a linear instrument employed to measure perceived pain intensity, spanning from 0 (indicating no pain) to 10 (representing the most severe pain), where patients indicate the level that most accurately represents their experience.
215156596|NCT07156747|OTHER|State-Trait Anxiety Inventory|The STAI is a self-administered questionnaire with two parts: STAI-1 measures state anxiety, representing a transient emotional state triggered by a particular circumstance, while STAI-2 examines trait anxiety, denoting a consistent predisposition to experience anxiety across diverse situations.
215156597|NCT07156747|OTHER|Video|watching video on Digital Platfrom (for example, Youtube)
215156598|NCT07156747|OTHER|Image|Prostate biopsy information with images
215156599|NCT07156968|DRUG|Bupivacaine-fentanyl|A peripheral intravenous (IV) catheter will be inserted, and a 7 mL kg-1 crystalloid infusion will be initiated. The patients will be premedicated with 0.03 mg kg-1 midazolam IV. Heart rate and peripheral oxygen saturation (SpO2) will be monitored continuously; systolic, diastolic, and mean arterial pressure (MAP) will be measured noninvasively at 5 min intervals during the procedure and at 15 min intervals during the post anesthesia care unit (PACU) stay. The baseline values will be recorded. Nasal oxygen 2 L min-1 will be administered during the whole procedure
215156600|NCT07156617|PROCEDURE|Interventional therapy|Interventional therapy
215156601|NCT07156617|DRUG|Systemic therapy|Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab
214537669|NCT06416332|OTHER|group A: in face to face live therapeutic exercise|"In group A: in face to face live therapeutic exercise the program and its progressivity will be determined and performed for life according to the progress of the patient, with a frequency of sessions twice a week, session duration 45 minutes, following the recommended dosage of exercise according to clinical guidelines, while the total duration of the intervention will be eight weeks. You will be instructed to perform the program at home, 3 times a week. The standardized exercise program to be followed by this group will include :~1. Exercises to strengthen the hip and knee muscles through isometric contractions and resistance exercises using elastic bands.~2. Balance and neuromuscular coordination exercises."
214537670|NCT06416332|OTHER|group B: telerehabilitation program|In group B: telerehabilitation program, the therapeutic exercise program will follow the same structure, which was mentioned above. The differentiation in the intervention of this group will be that the explanation of the exercises, their presentation, monitoring and information of the participants will be done through the telerehabilitation platform and special data processing software. The intervention time remains the same, with the physical therapist during these 45 minutes of the session , to evaluate the data on the patients progress by receiving the information through the software and to inform the patient of any changes in the progressivity of the exercise program. The other parameters of the intervention remain the same, as in person exercise.
214537671|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
214537672|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
214537673|NCT02282306|BEHAVIORAL|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
215156602|NCT07157462|DIETARY_SUPPLEMENT|Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species)|The probiotic powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
215156603|NCT07157462|DIETARY_SUPPLEMENT|Placebo Powder for Oral Solution|The placebo powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
215156604|NCT07158008|PROCEDURE|Nissen-Sleeve Gastrectomy (N-SG)|Laparoscopic Nissen-Sleeve Gastrectomy is a modification of standard sleeve gastrectomy that incorporates an anti-reflux procedure. The greater curvature of the stomach is mobilized and short gastric vessels are divided. A segment of the gastric fundus is preserved and passed behind the distal esophagus to create a 360-degree wrap (Nissen fundoplication) around the lower esophageal sphincter. The crura of the diaphragm are approximated if necessary. Following fundoplication, the remainder of the stomach is resected longitudinally over a 40 French bougie using a linear stapling device, creating a tubular gastric conduit. This approach aims to achieve weight loss while providing a functional anti-reflux barrier and maintaining gastrointestinal continuity.
214537674|NCT01274559|DRUG|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
214696884|NCT03750071|BIOLOGICAL|Avelumab|Monoclonal anti-PD-L1 Antibody
214696885|NCT00171028|DRUG|valsartan|
214696886|NCT02214485|BEHAVIORAL|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
214696887|NCT02214485|BEHAVIORAL|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
214696888|NCT03992209|OTHER|Standard care|Usual operating room practice
214696889|NCT03992209|OTHER|Protocolized care|Hand washing per protocol
215156605|NCT07158008|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Laparoscopic Roux-en-Y Gastric Bypass is a standard bariatric procedure that combines gastric restriction with intestinal bypass. A small proximal gastric pouch is created using linear staplers, completely separating it from the gastric remnant. A 100 cm alimentary (Roux) limb of jejunum is measured from the ligament of Treitz and anastomosed to the gastric pouch (gastrojejunostomy) using a linear stapler. A jejunojejunostomy is then performed 150 cm distal to the gastrojejunostomy to connect the biliopancreatic limb to the alimentary limb, restoring intestinal continuity. The mesenteric defects are closed to reduce the risk of internal hernia. This procedure promotes weight loss and has established effectiveness in reducing gastroesophageal reflux symptoms.
215156606|NCT07158008|PROCEDURE|Sleeve Gastrectomy (SG)|Laparoscopic Sleeve Gastrectomy is a restrictive bariatric procedure involving longitudinal resection of the stomach to create a tubular gastric conduit. The greater curvature is mobilized and short gastric vessels are divided. Using a bougie as a guide, the stomach is divided with a linear stapling device from the antrum to the angle of His, removing approximately 75-80% of gastric volume, including most of the fundus. This reduces stomach capacity and ghrelin production, promoting weight loss while maintaining gastrointestinal continuity.
215156607|NCT07156578|DRUG|Bivamelagon|daily dose of oral bivamelagon
215156608|NCT07156955|BEHAVIORAL|Electrical stimulation cue|A single 30-minute session is provided. Electrodes are attached to the cubital fossa, and stimulation is delivered at a frequency that increases up to 70 Hz as the elbow joint approaches the target angle. Target angles are set between 0 degrees and 120 degrees, based on each participant's available range of motion determined during the initial assessment. Participants adjust their elbow joint angle to match the provided target angle using feedback from the electrical stimulation. When the elbow joint angle matches the target angle, the maximum frequency is applied to the cubital fossa. Participants match their elbow joint angle to the target angle based on the given frequency.
215156609|NCT07156955|BEHAVIORAL|Visual stimulation cue|A single 30-minute session is provided. The difference between the current elbow joint angle and the pre-set target angle is displayed on a screen using two colored needles (a red needle for the target angle and a black needle for the current elbow joint angle). The target angle is set within each participant's available range of motion based on the initial assessment. Participants continue the intervention by adjusting their elbow angle using the visual feedback. When the elbow joint angle matches the target angle, the two needles overlap. Based on this visual cue, participants adjust their elbow joint angle to match the target angle.
215156610|NCT07156955|BEHAVIORAL|No cue|A single 30-minute session is provided. The target angle is determined within each participant's available range of motion based on the initial assessment. Throughout the session, participants receive verbal feedback from the assessor and adjust their elbow joint angle accordingly to match the target angle.
215156611|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain)
215156612|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)
215156613|NCT07157748|DRUG|Fufang E'jiao Jiang|Oral solution; 20 mL TID for 90 days;
215156614|NCT07157748|DRUG|Matching Placebo|Oral solution; 20 mL TID for 90 days;
215156615|NCT00892346|PROCEDURE|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
214537675|NCT01274559|DRUG|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
214537676|NCT03757078|DRUG|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
214537677|NCT03757078|DRUG|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
214537678|NCT01013506|DRUG|IGF-1R inhibitor OSI-906|Given orally
214537679|NCT01013506|DRUG|erlotinib hydrochloride|Given orally
214696890|NCT01159509|BEHAVIORAL|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
214696891|NCT05718206|DEVICE|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
214696892|NCT04282070|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
214696893|NCT04282070|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
214696894|NCT04282070|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
214696895|NCT04282070|DRUG|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
214537680|NCT01013506|DRUG|goserelin|Given subcutaneously
214537681|NCT01013506|DRUG|letrozole|Given orally
214696896|NCT04438772|OTHER|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
214696897|NCT03297307|BEHAVIORAL|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
214696898|NCT02458157|DRUG|Furosemide (Furix)|"* Loading dose: 40 mg I.V.~* Infusion rate 40 mg/h~* Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
215156616|NCT06355180|DRUG|Esketamine|The experimental group will receive intravenous esketamine hydrochloride. Participants will be asked to fast for 8 hours prior to administration. On treatment days, esketamine will be administered at a dose of 0.2 mg/kg, diluted in 0.9% sodium chloride solution. The infusion rate will be controlled with an infusion pump or syringe pump to ensure a minimum administration duration of 40 minutes. Treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks, totaling six sessions. For participants demonstrating intolerance to either the dose of 0.2 mg/kg or the six-session regimen, investigators could modify the treatment protocol based on efficacy and safety assessments.
215156617|NCT06355180|DEVICE|Electroconvulsive therapy|The control group will receive ECT. Prior to each session, participants will undergo safety evaluations and concomitant medication adjustments. Following an 8-hour fast and bladder evacuation, other preoperative preparations include intravenous administration of anticholinergic agents, short-acting anesthetics, and muscle relaxants. Electrodes will be placed unilaterally on the non-dominant hemisphere, with the seizure threshold determined via titration. The treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks (six sessions in total). The protocol permitted regimen modifications for participants unable to tolerate the full course, based on efficacy and safety assessments.
214537682|NCT03535805|BEHAVIORAL|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (\>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
214537683|NCT03535805|BEHAVIORAL|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
214537684|NCT04267471|BEHAVIORAL|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
214537685|NCT04267471|BEHAVIORAL|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
214537686|NCT04223128|PROCEDURE|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
214537687|NCT03623477|BEHAVIORAL|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
214537688|NCT03623477|BEHAVIORAL|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
214537689|NCT05554783|DIAGNOSTIC_TEST|Trendelenburg position|Positioning the patient with head 15 degrees down
214537690|NCT00171418|DRUG|Tegaserod|
214537691|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
214537692|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
214537693|NCT04031573|DRUG|Placebo|Placebo will be administered via the enteral route, every 12 hours.
214537694|NCT04262609|RADIATION|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
214537695|NCT04683328|BIOLOGICAL|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
214537696|NCT04683328|BIOLOGICAL|SCTA01 Placebo|The excipients of SCTA01
214537697|NCT05629247|DIAGNOSTIC_TEST|Systematic screening of immune deficiency|Systematic screening of immune deficiency with blood tests
214537698|NCT00069381|BEHAVIORAL|Psychotherapy treatment|
214537699|NCT02971228|DRUG|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
214537700|NCT02971228|DRUG|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
214537701|NCT02971228|DRUG|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
214537702|NCT02971228|DEVICE|iPhone-based bionic pancreas|An experimental device.
214537703|NCT02971228|DEVICE|iLet-based bionic pancreas|An experimental device.
215156618|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
214537704|NCT02066610|OTHER|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
214537705|NCT02066610|OTHER|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
214537706|NCT02066610|OTHER|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
214537707|NCT02066610|OTHER|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
214537708|NCT00721032|PROCEDURE|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
214537709|NCT00721032|DRUG|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD"
214537710|NCT00678977|DRUG|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
215156619|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
215156620|NCT01077050|DEVICE|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
215156621|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
214537711|NCT00678977|DRUG|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
214537712|NCT00678977|DRUG|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
214537713|NCT06215287|OTHER|Physician survey|Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
214537714|NCT03315234|GENETIC|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
214537715|NCT01003145|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
214696899|NCT02458157|OTHER|Continuous renal replacement therapy (CRRT)|"* Initiated in case of contraindications or inadequate effect of furosemide.~* Fluid removal is started at 2 ml/kg/h~* The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
214537716|NCT02602795|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
214537717|NCT02602795|BEHAVIORAL|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
214537718|NCT03478046|OTHER|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
214537719|NCT01664923|DRUG|Enzalutamide|160 mg, daily, by mouth.
214537720|NCT01664923|DRUG|Bicalutamide|50 mg, daily, by mouth
214696900|NCT02458157|OTHER|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~* Mottling beyond the edge of kneecaps~* Hypotension (MAP \< 50) resistant to inotropes and vasopressors~* Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~1. Fluid removal is paused~2. A crystalloid fluid bolus of 250-500 ml is given~3. Circulatory status is reevaluated within 30 minutes~4. Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~5. Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
215156622|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
215156623|NCT02310204|BEHAVIORAL|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
215156624|NCT02310204|OTHER|standard psoriasis care alone|
215156625|NCT03894813|DRUG|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
215156626|NCT03894813|DRUG|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
215156627|NCT00080444|DRUG|aprepitant|aprepitant capsules
215156628|NCT00080444|DRUG|ondansetron|ondansetron IV preparation
215156629|NCT00080444|DRUG|dexamethasone|dexamethasone tablets
215156630|NCT00080444|DRUG|placebo to aprepitant|Matching placebo to aprepitant capsules
215156631|NCT00080444|DRUG|placebo to dexamethasone|Matching placebo to dexamethasone tablets
215156632|NCT00080444|DRUG|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
215156633|NCT05523778|PROCEDURE|placement of pancreatic duct stents before enucleation surgery|Advance placement of pancreatic stents endoscopically
214537721|NCT03354234|OTHER|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
214537722|NCT03354234|OTHER|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
214537723|NCT03354234|OTHER|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
214537724|NCT03354234|DEVICE|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
214537725|NCT03354234|DEVICE|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
214537726|NCT01940406|PROCEDURE|Stimulation procedure|Device
214537727|NCT01977183|DIETARY_SUPPLEMENT|MSPrebiotic|Potato Resistant Starch
214537728|NCT01977183|DIETARY_SUPPLEMENT|Placebo|Placebo - Corn Starch
214537729|NCT02182232|DRUG|BIBF 1120|
214537730|NCT02182232|DRUG|Paclitaxel|
214537731|NCT02182232|DRUG|Carboplatin|
214537732|NCT01377168|DRUG|oral naltrexone|
214537733|NCT01377168|DRUG|Placebo pill|
214537734|NCT01217619|DRUG|erlotinib|erlotinib 150mg/d continuously for 56 days
214537735|NCT04226937|OTHER|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
214537736|NCT00220909|DRUG|Lansoprazole|
214537737|NCT01401114|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
214537738|NCT02856490|DEVICE|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
214537739|NCT02856490|DEVICE|InTone|A genital device using electric muscle stimulation to treat incontinence.
214537740|NCT06325345|BEHAVIORAL|Gut-directed hypnotherapy|Eight session gut-directed hypnotherapy for IBS symptoms adapted from the evidence-based Manchester protocol for treatment of IBS.
214537741|NCT06325345|OTHER|Standard Medical Therapy|Standard medical treatment will be administered by board certified gastroenterologists
214537742|NCT04703257|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
214537743|NCT04703257|DRUG|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
215156634|NCT05523778|PROCEDURE|Direct enucleation surgery|Patients will receive direct enucleation surgery
215156635|NCT04002492|BEHAVIORAL|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
215156636|NCT01619969|DRUG|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
215156637|NCT01619969|DRUG|placebo|Capsules of identical appearance containing starch
215156638|NCT01213199|DRUG|Adapalene|Adapalene Gel 0.3%
215156639|NCT03083873|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
215156640|NCT03083873|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
215156641|NCT06125080|DRUG|Utidelone|Utidelone (30 mg/m2, days 1-5, every 3 weeks)
215156642|NCT06125080|DRUG|Tirelizumab|Tirelizumab（200mg, day1, every 3 weeks）
214537744|NCT03039881|DEVICE|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
214537745|NCT03774212|DEVICE|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
214537746|NCT03359226|PROCEDURE|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
214537747|NCT02934945|DRUG|budesonide 160μg/formoterol 4.5μg|SMART regimen
214537748|NCT03700372|DEVICE|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
214537749|NCT00030537|DRUG|erlotinib hydrochloride|
214537750|NCT02134366|DRUG|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
214537751|NCT02134366|DRUG|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
214537752|NCT02134366|DRUG|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
214537753|NCT03409731|DEVICE|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
214537754|NCT04171947|DEVICE|Matuzalem ovule|vaginal ovule with 2 mg tea extract
214537755|NCT04171947|DEVICE|Vehicle ovule|polyethylene glycol vaginal ovule
214537756|NCT02205541|DRUG|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
214537757|NCT02205541|DRUG|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
214537758|NCT01537185|OTHER|Placebo|3 cohorts of normal saline injection
214537759|NCT01537185|BIOLOGICAL|SPWCV+Alum 100 mcg|3 injections 28 days apart
214537760|NCT01537185|BIOLOGICAL|SPWCV+Alum 600 mcg|3 injections 28 days apart
214537761|NCT01537185|BIOLOGICAL|SPWCV+Alum 300 mcg|3 injections 28 days apart
214537762|NCT00892944|DRUG|AZD2516|Fractionated single oral dose
214537763|NCT06157528|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients were treated with abarelix prior to the examination
214537764|NCT00784745|DRUG|Dexamethasone|2mg morning and night for 5 days.
214537765|NCT05018897|BEHAVIORAL|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
214537766|NCT05018897|BEHAVIORAL|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
214537767|NCT03131349|DIAGNOSTIC_TEST|serum zinc and iron|history ,examination,investigations
214537768|NCT00965120|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
214537769|NCT00965120|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
214537770|NCT00965120|DRUG|Placebo (saline)|Systemic infusion of placebo (saline).
214537771|NCT03052712|BEHAVIORAL|social cognition|battery of tests of social cognition
214537772|NCT05117879|PROCEDURE|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
214537773|NCT00251888|DRUG|campto (irinotecan)|
214537774|NCT00251888|DRUG|cisplatin (cisplatyl)|
214537775|NCT02780505|DRUG|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
214537776|NCT02780505|DRUG|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
214537777|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
214537778|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
214537779|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
214537780|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
215156643|NCT06125080|DRUG|Bevacizumab|Bevacizumab(7.5mg/kg, day1, every 3 weeks)
215156644|NCT01677377|DRUG|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
214696901|NCT02458157|OTHER|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~* Hyperkalaemia (p-K+ \> 6 mmol/l)~* Severe metabolic acidosis attributable to AKI (pH \< 7.25 and standard base excess \< -10 mmol/l) resistant to IV bicarbonate infusion~* Severe respiratory failure with PaO2/FiO2 \< 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~* Progressive azotaemia and a blood urea nitrogen (BUN) \> 25 mmol/l."
215156645|NCT01677377|DRUG|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
214537781|NCT05549999|DIAGNOSTIC_TEST|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
215156646|NCT05250388|PROCEDURE|Arthroscopic Bankart repair|Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
215156647|NCT00296699|DRUG|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~\* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
214537782|NCT04016402|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
214537783|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
214537784|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
214537785|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 0
214537786|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
214537787|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
214537788|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 4
214537789|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
214537790|NCT01264445|BIOLOGICAL|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
214537791|NCT00480155|BIOLOGICAL|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
214537792|NCT00480155|OTHER|Placebo|
214537793|NCT00005946|BIOLOGICAL|filgrastim|
214537794|NCT00005946|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214696902|NCT02625324|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
215156648|NCT03975478|PROCEDURE|Gastric bypass|The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.
215156649|NCT03975478|PROCEDURE|Sleeve gastrectomy|The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
215156650|NCT02932371|DEVICE|ECOM™.|
215156651|NCT02932371|DEVICE|Trans-esophageal echography|
215156652|NCT01284335|DRUG|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
215156653|NCT01284335|DRUG|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
215156654|NCT01284335|DRUG|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
215156655|NCT01284335|DRUG|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
214537795|NCT00005946|DRUG|cyclophosphamide|
214537796|NCT00005946|DRUG|etoposide|
214537797|NCT04617236|BEHAVIORAL|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
214537798|NCT02938897|BEHAVIORAL|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
214537799|NCT02938897|BEHAVIORAL|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
214537800|NCT02938897|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
214537801|NCT05891652|PROCEDURE|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
214537802|NCT06278337|GENETIC|genetic restrospective study|it is not an interventional study but observational
214537803|NCT00827775|DRUG|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
214537804|NCT02151578|OTHER|home/community case management|
214537805|NCT00479843|BEHAVIORAL|Nutritional programme|
214696903|NCT02823041|BEHAVIORAL|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
214537806|NCT00663273|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
214537807|NCT04912154|PROCEDURE|Rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture
214537808|NCT05425225|OTHER|Low level LASER therapy|Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
214537809|NCT05425225|OTHER|Conventional physical therapy|Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
214537810|NCT02427958|DRUG|Leuprorelin|Suspension for injection.
214537811|NCT05896540|BEHAVIORAL|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
214537812|NCT00854152|DRUG|GDC-0980|Escalating repeating dose
214537813|NCT01401036|DEVICE|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
214537814|NCT01401036|PROCEDURE|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
214537815|NCT02679547|OTHER|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
214696904|NCT02823041|BEHAVIORAL|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
214696905|NCT02823041|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
214696906|NCT02823041|BEHAVIORAL|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
214696907|NCT01828918|GENETIC|microRNAs|
214696908|NCT01124201|OTHER|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
215156656|NCT01284335|DRUG|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
214696909|NCT00316381|PROCEDURE|Autologous bone marrow-derived stem cells|
214696910|NCT02307539|PROCEDURE|Psychosocial Assessment and Care|Undergo PCPI
214696911|NCT02307539|OTHER|Palliative Therapy|Undergo PCPI
214696912|NCT02307539|OTHER|Quality-of-Life Assessment|Undergo QOL assessment
214696913|NCT02307539|OTHER|Questionnaire Administration|Undergo questionnaire administration
215156657|NCT01284335|DRUG|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
215156658|NCT02656693|BEHAVIORAL|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
214537816|NCT03696641|OTHER|glazed lithium disilicate crowns|glazing of IPS e.max crowns
214537817|NCT03696641|OTHER|polished lithium disilicate crowns|polishing of IPS e.max crowns
214537818|NCT03271177|DEVICE|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
214537819|NCT03271177|DEVICE|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
214537820|NCT00372177|RADIATION|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
214537821|NCT03410108|DRUG|Brigatinib|Brigatinib tablet
214696914|NCT05585086|OTHER|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
214696915|NCT04982510|DEVICE|complete denture|3D printed complete denture
214696916|NCT05602012|BEHAVIORAL|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
214696917|NCT04377334|BIOLOGICAL|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
214696918|NCT02065596|DRUG|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
214696919|NCT02065596|PROCEDURE|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
214696920|NCT01196650|DRUG|IN 10 003 formulation A|
214696921|NCT01196650|DRUG|IN 10 003 formulation B|
214696922|NCT01196650|DRUG|Placebo capsules|
214696923|NCT05025735|DRUG|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
214696924|NCT00625898|DRUG|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
215156659|NCT02656693|BEHAVIORAL|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
215156660|NCT00994968|DRUG|cyclophosphamide|
215156661|NCT00994968|DRUG|docetaxel|
215156662|NCT00994968|DRUG|doxorubicin hydrochloride|
215156663|NCT00994968|DRUG|tegafur-gimeracil-oteracil potassium|
215156664|NCT00994968|PROCEDURE|neoadjuvant therapy|
215156665|NCT00994968|PROCEDURE|therapeutic conventional surgery|
215156666|NCT01403597|DEVICE|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
215156667|NCT00842751|DRUG|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
215156668|NCT00842751|OTHER|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
215156669|NCT00842751|DRUG|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
215156670|NCT00842751|DRUG|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
215156671|NCT00842751|OTHER|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
215156672|NCT00693901|BEHAVIORAL|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
215156673|NCT00693901|BEHAVIORAL|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
215156674|NCT03319758|PROCEDURE|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
215156675|NCT01628666|DRUG|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
215156676|NCT01628666|DRUG|Conventional|Cefazolin preoperative
215156677|NCT04535778|BEHAVIORAL|COMPASS|An 11 module, therapist-supported online CBT program.
215156678|NCT04535778|BEHAVIORAL|Standard charity resources|Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
214537822|NCT04080063|OTHER|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
214537823|NCT01009138|BEHAVIORAL|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement"
214537824|NCT01009138|BEHAVIORAL|Standard Diabetes Education|"Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
214537825|NCT00151697|DRUG|Novomix 30|
215156679|NCT02269267|DRUG|Imatinib (Stopping their TKI)|Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
215156680|NCT02269267|DRUG|Dasatinib (Stopping their TKI)|Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
215156681|NCT02269267|DRUG|Nilotinib (Stopping their TKI)|Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
215156682|NCT02269267|DRUG|Bosutinib (Stopping their TKI)|Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
215156683|NCT03470844|BEHAVIORAL|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
215156684|NCT03470844|BEHAVIORAL|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
215156685|NCT03470844|OTHER|fMRI|Brain volume, chemical markers, functional outcome
215156686|NCT03470844|BEHAVIORAL|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
215156687|NCT03016000|DRUG|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
215156688|NCT03016000|OTHER|Observation|Just observation
215156689|NCT00482066|DRUG|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
215156690|NCT03620877|BEHAVIORAL|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
215156691|NCT03773796|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
215156692|NCT03053167|DRUG|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
215156693|NCT03053167|DRUG|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
214537826|NCT00151697|DRUG|Novorapid and Amaryl|
214537827|NCT00151697|DRUG|Lantus|
214537828|NCT03240497|BEHAVIORAL|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\]."
214537829|NCT03240497|BEHAVIORAL|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
214537830|NCT05184621|OTHER|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
214537831|NCT06310798|BEHAVIORAL|Inter-professional team test|"Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff."
214537832|NCT03092245|DRUG|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
214537833|NCT03092245|DRUG|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
214537834|NCT05999019|PROCEDURE|robotic surgery|robotic surgery
214537835|NCT01491763|DRUG|Imatinib|600 mg p.o. from day 1 until consolidation
214537836|NCT04356625|DIAGNOSTIC_TEST|MEPic|"* patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
214537837|NCT02765386|DEVICE|Hybrid fittings for cochlear implant recipients|
214537838|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
214537839|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
214537840|NCT04692298|OTHER|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
214537841|NCT03233347|DRUG|Brentuximab Vedotin|Given IV
214537842|NCT03233347|DRUG|Dacarbazine|Given IV
214537843|NCT03233347|DRUG|Doxorubicin|Given IV
214537844|NCT03233347|OTHER|Laboratory Biomarker Analysis|Correlative studies
214537845|NCT03233347|BIOLOGICAL|Nivolumab|Given IV
214537846|NCT03233347|DRUG|Vinblastine|Given IV
214537847|NCT04578899|DEVICE|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
214537848|NCT00177684|DRUG|Amphotericin B|
214537849|NCT00548002|DRUG|trovafloxacin and levofloxacin|Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
214537850|NCT03168698|DRUG|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
214537851|NCT03168698|DRUG|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
214537852|NCT02830828|OTHER|Investigation of precision pinch grip control|
214537853|NCT04124783|DEVICE|Cooling Bolero|A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
214537854|NCT00238719|DRUG|Venlafaxine ER|
214537855|NCT01013740|DRUG|Vinorelbine|Vinorelbine
214537856|NCT01013740|DRUG|Lapatinib|Lapatinib
214537857|NCT01013740|DRUG|Capecitabine|Capecitabine
214537858|NCT03159078|DRUG|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
215156694|NCT01158599|BIOLOGICAL|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
214537859|NCT01137747|DRUG|Carfilzomib|
214537860|NCT02940210|DEVICE|Mediclore® (adhesion barrier)|
214537861|NCT03781245|OTHER|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
214537862|NCT02725398|DRUG|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
214537863|NCT02725398|DRUG|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
215156695|NCT05906290|OTHER|Multigenerational eHealth Intervention for Grandparents and Grandchildren|Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
214537864|NCT02725398|DRUG|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
214537865|NCT04164862|DEVICE|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
214537866|NCT00338949|DRUG|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
214537867|NCT00338949|DRUG|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
214537868|NCT05655039|OTHER|Rehabilitation|Stroke Rehabilitation Program
214537869|NCT04324658|DEVICE|Lactiplus|capsules containing L. gasseri LA806
214537870|NCT05527743|OTHER|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
214537871|NCT05527743|OTHER|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
214537872|NCT03232034|DIETARY_SUPPLEMENT|Calcium Citrate|1000 mg calcium as calcium citrate
214537873|NCT03232034|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
215156696|NCT04161703|PROCEDURE|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
215156697|NCT04161703|PROCEDURE|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A \& B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
215156698|NCT00590772|DRUG|montelukast|10 mg po each day (compared to placebo for 2 weeks)
215156699|NCT00590772|DRUG|placebo|placebo for 2 weeks
215156700|NCT03993067|PROCEDURE|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
215156701|NCT03993067|PROCEDURE|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
214537874|NCT03232034|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
214537875|NCT05417464|OTHER|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
214537876|NCT00251264|PROCEDURE|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
214537877|NCT00251264|PROCEDURE|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
214537878|NCT04281693|DIAGNOSTIC_TEST|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
214537879|NCT04281693|DIAGNOSTIC_TEST|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
214537880|NCT02819219|DIETARY_SUPPLEMENT|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
214537881|NCT02819219|OTHER|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
214537882|NCT01944449|DIETARY_SUPPLEMENT|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
214537883|NCT01944449|DIETARY_SUPPLEMENT|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
214537884|NCT01944449|DIETARY_SUPPLEMENT|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
214537885|NCT01501227|DEVICE|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
214537886|NCT01501227|OTHER|Conventional endotracheal tube|Sham Comparator
214537887|NCT04785716|DRUG|Niraparib|Niraparib provided through the patient access program
214537888|NCT01419938|DEVICE|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
214537889|NCT01419938|DEVICE|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
214537890|NCT04550559|PROCEDURE|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
215156702|NCT02543424|BEHAVIORAL|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
215156703|NCT06182956|DEVICE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
215156704|NCT06182956|DEVICE|Nasal high-flow oxygen therapy|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
215156705|NCT06182956|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
215156706|NCT03360318|DEVICE|elbow cast|elbow cast
215156707|NCT03360318|DEVICE|Removable elbow brace|Removable elbow brace
215156708|NCT01173289|RADIATION|External Beam Radiotherapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~* Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~* Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~* Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~* The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
215156709|NCT01833156|DEVICE|MoistureMeterD|measuring erythema size and the dielectric constant values
215156710|NCT03805659|DEVICE|HD-tDCS|High-Dose transcranial Direct Current Stimulation
215156711|NCT03805659|DEVICE|Sham|Sham sessions (no electric current)
214537891|NCT06189989|BEHAVIORAL|The group to which a care package was applied in addition to the clinical routine care protocol)|"Intervention Group:~* Immediately after the newborn's admission to the intensive care unit, mechanical ventilation mode, physiological parameters, blood gas results and descriptive characteristics of the baby were recorded in the Data Collection and Daily Monitoring Form.~* In addition to the routine care practices of the clinic (every 3 hours / 8 times a day), the newborn's temporary tachypnea care package was applied. Postural drainage, percussion and vibration were applied 4 times a day for an average of 10-15 minutes.~* Mechanical ventilation mode and physiological parameters were recorded one hour after 4 daily maintenance applications.~* Blood gas parameters were evaluated immediately before and 1 hour after the newborn was separated from mechanical ventilation.~* Physiological parameters were recorded again 1 hour after the first routine nursing care after the newborn was separated from mechanical ventilation."
214537892|NCT02382523|DRUG|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
214537893|NCT01491906|BEHAVIORAL|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
214537894|NCT00025662|DRUG|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
214537895|NCT00025662|DRUG|Isolex system|CD34 selection/ T cell depletion used this system
214537896|NCT01686490|BEHAVIORAL|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
214537897|NCT01686490|BEHAVIORAL|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
214537898|NCT04518761|PROCEDURE|Elective surgery|Any patient who needs to undergo an elective surgery.
214537899|NCT05052749|OTHER|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
214537900|NCT05052749|OTHER|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
214537901|NCT01043198|GENETIC|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~* Standardized screening with :~* radiological (hands, feet, spine ; and renal ultrasonography)~* biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
214537902|NCT06647251|PROCEDURE|Q-MODE : radiofrequency ablation up to 50W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W."
214537903|NCT06647251|PROCEDURE|Q-MODE+ : radiofrequency up to 90W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W."
215156712|NCT03243292|OTHER|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
215156713|NCT02228837|DIETARY_SUPPLEMENT|Pear|
215156714|NCT02228837|DIETARY_SUPPLEMENT|Placebo|
215156715|NCT03188497|DRUG|Lobaplatin|Lobaplatin for Injection
215156716|NCT03188497|DEVICE|linear accelerator|Medical linear accelerator
214696925|NCT00625898|DRUG|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
215156717|NCT04099264|OTHER|Personalized music|Patients in the intervention group will listen to personalized music from the Musicare application
215156718|NCT04099264|OTHER|Audio Books|Patients in the active comparator group will listen to audio books
215156719|NCT04800172|DRUG|Roflumilast|administration of roflumilast 500 mcg tablet once daily for 3 months.
215156720|NCT04800172|DRUG|placebo|administration of placebo tablet once daily for 3 months.
215156721|NCT03768648|OTHER|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
215156722|NCT03768648|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
215156723|NCT03768648|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
215156724|NCT03768648|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
215156725|NCT03768648|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
215156726|NCT00796419|DRUG|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
215156727|NCT00796419|DRUG|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
215156728|NCT01250145|DRUG|LY333334|Transdermal patch
215156729|NCT01250145|DRUG|Placebo|Transdermal patch
215156730|NCT04491513|DIAGNOSTIC_TEST|Computed tomography angiography|Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
215156731|NCT00082862|BIOLOGICAL|recombinant interferon alfa|
214537904|NCT06647251|PROCEDURE|Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part."
214537905|NCT06646081|PROCEDURE|Greater Occipital Nerve Block|The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
214537906|NCT06646081|PROCEDURE|Stellate Ganglion Block|The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
214696926|NCT00625898|DRUG|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
214696927|NCT00625898|DRUG|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
215156732|NCT00082862|DRUG|cisplatin|
215156733|NCT00082862|DRUG|gemcitabine hydrochloride|
214696928|NCT00625898|DRUG|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
214696929|NCT00625898|DRUG|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
214696930|NCT00625898|DRUG|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
215156734|NCT00082862|PROCEDURE|hyperthermia treatment|
215156735|NCT02513927|DRUG|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
215156736|NCT02513927|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
215156737|NCT04455464|DRUG|Midodrine Oral Tablet|Midodrine will be given 10 mg for one time only.
215156738|NCT02964013|BIOLOGICAL|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
215156739|NCT02964013|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
215156740|NCT02964013|DRUG|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
215156741|NCT02964013|DRUG|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
215156742|NCT02964013|BIOLOGICAL|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
215156743|NCT02964013|DRUG|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
215156744|NCT02964013|DRUG|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
215156745|NCT01404936|DRUG|Interferon-2A|4 (x106 IU/m\^2) subcutaneously on days 1-4.
215156746|NCT01404936|DRUG|Adriamycin|25 mg/m\^2 by vein on day 4.
215156747|NCT01404936|DRUG|Bleomycin|10 mg/m\^2 by vein on day 4.
215156748|NCT01404936|DRUG|Velban|6 mg/m\^2 by vein on day 4.
215156749|NCT01404936|DRUG|Dacarbazine|375 mg/m\^2 by vein on day 4.
215156750|NCT00156676|DEVICE|Body-weight supported treadmill|
215156751|NCT00156676|DEVICE|Lokomat|
214537907|NCT02934815|OTHER|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
214696931|NCT01374763|DRUG|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
214696932|NCT01374763|DRUG|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
214696933|NCT04923620|DRUG|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
214696934|NCT04923620|RADIATION|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
214696935|NCT01832012|OTHER|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
214696936|NCT01832012|OTHER|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
214696937|NCT01116687|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
215156752|NCT00156676|DEVICE|Body-weight supported treadmill|
214537908|NCT02068196|PROCEDURE|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
214537909|NCT02068196|DRUG|Ipilimumab|
214537910|NCT00478998|DRUG|Tamsulosin|
214537911|NCT01113164|DRUG|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
214537912|NCT00525018|DEVICE|contact heat evoked potential stimulator|
214537913|NCT00582114|DRUG|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
214537914|NCT00582114|DRUG|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
214537915|NCT02640222|DRUG|VKA|
214537916|NCT02640222|DRUG|Apixaban|
214537917|NCT02640222|DRUG|dabigatran|
214537918|NCT02640222|DRUG|rivaroxaban|
215156753|NCT00156676|DEVICE|Lokomat|
214537919|NCT06140914|DIAGNOSTIC_TEST|Proteomics, miRNA studies and studies of blood cells from blood samples|This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
214537920|NCT05388097|OTHER|Managed Services|coordination of care and assistance with community resources (food, transportation)
214537921|NCT05848453|DRUG|BAP5191|Placebo
214537922|NCT05217355|DRUG|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
214537923|NCT05217355|DRUG|Placebo|Placebo will be injected into the Glabellar line
214537924|NCT02958475|BEHAVIORAL|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
214537925|NCT02958475|BEHAVIORAL|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
214696938|NCT01116687|OTHER|laboratory biomarker analysis|Correlative studies
214696939|NCT00424528|DRUG|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
214696940|NCT00424528|DRUG|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
214696941|NCT00424528|DRUG|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
214696942|NCT00424528|DRUG|Placebo|Placebo inhalation solution and placebo inhalation powder
214696943|NCT01734980|PROCEDURE|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
214696944|NCT03294408|DIAGNOSTIC_TEST|multimodal imaging|
214696945|NCT02221271|DRUG|NPB-01|
214696946|NCT00109304|BIOLOGICAL|VEE 3526|
214696947|NCT03824548|OTHER|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
215156754|NCT01398306|OTHER|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
215156755|NCT01368328|DIETARY_SUPPLEMENT|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
215156756|NCT01460043|DRUG|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
215156757|NCT01460043|DRUG|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
215156758|NCT04267913|DRUG|Dexamethasone|Given IV
215156759|NCT04267913|DRUG|Docetaxel|Given IV
215156760|NCT04267913|BIOLOGICAL|Ramucirumab|Given IV
215156761|NCT04267913|DRUG|Sapanisertib|Given PO
215156762|NCT05960721|DRUG|Rivaroxaban 15mg|QD
215156763|NCT05960721|DRUG|Aspirin 100mg|QD
215156764|NCT05960721|DRUG|Clopidogrel 75mg|QD
215156765|NCT05960721|DRUG|Rivaroxaban 10mg|QD
215156766|NCT05960721|DRUG|Rivaroxaban 2.5mg|B.I.D
215156767|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
215156768|NCT01192802|DRUG|albendazole|single 1 tablet of 400 mg of albendazole
215156769|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
215156770|NCT02185859|DRUG|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
215156771|NCT02185859|DRUG|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
215156772|NCT02185859|DRUG|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
215156773|NCT01069900|DRUG|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
215156774|NCT01069900|DRUG|Ertapenem|For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
215156775|NCT01069900|DRUG|Amoxicillin/Clavulanate|Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
215156776|NCT01069900|DRUG|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
215156777|NCT01069900|DRUG|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
215156778|NCT01069900|DRUG|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
215156779|NCT06343480|DRUG|Labour Induction|the use of misoprostol sublingual for labour induction compared with oxytocin titration in parturients with prelabour membrane rupture at term.
214537926|NCT02958475|BEHAVIORAL|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
214537927|NCT06088797|OTHER|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
214537928|NCT06088797|OTHER|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
214537929|NCT06088797|OTHER|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
214537930|NCT06088797|OTHER|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
214696948|NCT01208701|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
214537931|NCT06088797|OTHER|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
214537932|NCT06088797|OTHER|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
214537933|NCT06088797|OTHER|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
214537934|NCT05432700|OTHER|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
214537935|NCT05643313|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
214537936|NCT02604342|DRUG|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
214537937|NCT02604342|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
214537938|NCT02604342|DRUG|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
214537939|NCT03053635|DRUG|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
214537940|NCT00130728|DRUG|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
214537941|NCT00130728|DRUG|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
214537942|NCT00130728|DRUG|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
214696949|NCT01208701|DRUG|Unikalk|1 tablet Unikalk pr day for 5 days
214696950|NCT02201381|DRUG|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
214537945|NCT05457322|BEHAVIORAL|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
214537946|NCT05457322|BEHAVIORAL|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
214537947|NCT01398644|OTHER|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
214537948|NCT01561456|DRUG|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
214537949|NCT01561456|DRUG|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
214537950|NCT00600301|DRUG|Triamcinolone Acetonide and Bevacizumab|
214537951|NCT02787759|OTHER|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
215156780|NCT02642315|DRUG|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
214537952|NCT02787759|OTHER|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
214537953|NCT01582412|DRUG|Isavuconazole|oral
214537954|NCT01582412|DRUG|digoxin|oral
214537955|NCT00119795|BEHAVIORAL|Exercise|Increase Physical Activity to 150 min/wk
214537956|NCT00119795|BEHAVIORAL|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
214537957|NCT00119795|BEHAVIORAL|Health Education Control|Lectures on information relevant to successful aging
214537958|NCT00383591|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
214537959|NCT00383591|BIOLOGICAL|Engerix-B|
214537960|NCT02196168|DRUG|Cisplatin|Given IV
214537961|NCT02196168|OTHER|Laboratory Biomarker Analysis|Correlative studies
214537962|NCT02196168|OTHER|Pharmacological Study|Correlative studies
214537963|NCT02196168|OTHER|Placebo|Given PO
214537964|NCT02196168|DRUG|WEE1 Inhibitor AZD1775|Given PO
214696951|NCT01975077|DRUG|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
215156781|NCT02525770|DEVICE|radiostereometric analysis (RSA)|
215156782|NCT02687191|BIOLOGICAL|PF-05230907|PF-05230907 IV bolus injection
215156783|NCT05218291|OTHER|Yoga Practice|In this study, the yoga initiative to be made for the caregivers in the experimental group consists of breathing, meditation and yoga poses.
215156784|NCT05218291|OTHER|Ongoing caregivers|Caregivers included in the control group, who did not apply any yoga intervention, will be observed as caregivers.
215156785|NCT00022022|DRUG|docetaxel|
215156786|NCT00022022|PROCEDURE|quality-of-life assessment|
215156787|NCT02230514|DRUG|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
215156788|NCT02230514|OTHER|autologous iliac crest|Autologous iliac crest in association with surgery
215156789|NCT02230514|PROCEDURE|Surgery|Standard surgery for non-union fractures
215156790|NCT03093571|DEVICE|Auricular stimulation|Auricular stimulation with indwelling fixed needles
214537965|NCT00511498|DRUG|Sildenafil|50 mg daily at bedtime
214537966|NCT00053378|DRUG|paricalcitol injection (Zemplar)|
214537967|NCT00053378|BEHAVIORAL|Effects on calcium regulation|
214537968|NCT00053378|BEHAVIORAL|Administration of elemental Ca during hypocalcemic ICU pts.|
214537969|NCT03703843|DEVICE|ARTUS MONO|Temporarily implant and activation of the medical device
214537970|NCT04538222|OTHER|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
214537971|NCT03618706|RADIATION|Involved-field radiotherapy|After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
214537972|NCT04303546|DEVICE|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
214537973|NCT05768737|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214537974|NCT00739076|BEHAVIORAL|Virtual Reality|Using Virtual Reality for pain control
214537975|NCT04886817|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
214537976|NCT02914171|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
214537977|NCT02914171|DEVICE|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
214537978|NCT03998501|BEHAVIORAL|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
214537979|NCT04972539|DRUG|AJU-A51 Tab.|Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
214537980|NCT04972539|DRUG|A51R1 Tab. and A51R2 Tab.|Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
214537981|NCT02595606|DRUG|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
214537982|NCT02881047|DEVICE|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
214537983|NCT02881047|RADIATION|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
214537984|NCT02881047|DIAGNOSTIC_TEST|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
215156791|NCT03093571|BEHAVIORAL|Relaxation|Progressive muscle relaxation
215156792|NCT03536117|BIOLOGICAL|MTBVAC|Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
215156793|NCT03536117|BIOLOGICAL|BCG|Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
214537985|NCT01810276|OTHER|Saline|400 mL of Saline will be given intravenously over 2 hours once
214537986|NCT01810276|OTHER|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
214537987|NCT01454232|OTHER|stools sampling|stools sampling at baseline, 1, 3 and 12 months
214537988|NCT01454232|OTHER|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
214537989|NCT01687868|DRUG|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
214537990|NCT02895321|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
214537991|NCT02895321|OTHER|Colgate, Protection Caries|a fluorine-based toothpaste gels
214537992|NCT02895321|OTHER|Placebo gel|a glycerin and water gel
215156794|NCT05647161|DEVICE|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
215156795|NCT05647161|DEVICE|No Intervention|Control Group
215156796|NCT04870489|COMBINATION_PRODUCT|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
215156797|NCT04870489|DEVICE|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
215156798|NCT03771170|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
215156799|NCT03771170|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
215156800|NCT00248963|DRUG|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
214696952|NCT00223691|DRUG|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
215156801|NCT04044170|DRUG|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
214696953|NCT00223691|DRUG|Acarbose|25-100 mg, PO. Single dose.
215156802|NCT00865410|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
215156803|NCT00865410|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
215156804|NCT00790140|DIETARY_SUPPLEMENT|Prosure|This is an enteral tube feed with 125 kcals \& 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
215156805|NCT00790140|DIETARY_SUPPLEMENT|Ensure Plus|This is a standard enteral tube feed with 150 kcals \& 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
214537993|NCT03936764|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing."
214537994|NCT03028012|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
214537995|NCT03028012|DRUG|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
214537996|NCT03028012|DRUG|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
214537997|NCT00099203|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
214537998|NCT00099203|DRUG|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
214696954|NCT00223691|DRUG|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
214696955|NCT00223691|DRUG|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
214696956|NCT00223691|DRUG|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
214696957|NCT00223691|DRUG|placebo|PO.Single dose.
214696958|NCT00223691|DRUG|Modafinil|50-400 mg PO. Single dose
214696959|NCT00223691|DRUG|Octreotide|5-50 µg, S.C. Single dose.
214696960|NCT00223691|OTHER|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
214696961|NCT00223691|DRUG|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
214696962|NCT00223691|DRUG|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
214696963|NCT00223691|DRUG|Tranylcypromine|5 - 40 mg PO. Single dose
214696964|NCT00223691|DRUG|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
214696965|NCT00223691|DRUG|Celecoxib|50-200 mg PO. Single dose
214696966|NCT00223691|DRUG|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
215156806|NCT00662675|DRUG|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
215156807|NCT00662675|DRUG|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
215156808|NCT04986436|DRUG|HS-10360|Single or multiple dose(s) of HS-10360
215156809|NCT04986436|DRUG|Placebo|Single or multiple dose(s) of Placebo
215156810|NCT04330729|DRUG|Acetylsalicylic acid|Se arm description
215156811|NCT05143372|DEVICE|Vibrolung|Vibroacoustic respiratory therapy
214696967|NCT00223691|DRUG|Methylphenidate|5 or 10 mg PO. Single dose.
214696968|NCT00223691|DRUG|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
214696969|NCT00223691|DRUG|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
214696970|NCT00223691|DRUG|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
214696971|NCT00223691|DIETARY_SUPPLEMENT|Bovril|6-10 g, PO. Single dose.
215156812|NCT03310489|BEHAVIORAL|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
215156813|NCT03310489|BEHAVIORAL|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
215156814|NCT00176956|PROCEDURE|Skin Biopsy|Skin biopsy.
215156815|NCT00422864|DRUG|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
215156816|NCT00422864|DRUG|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
215156817|NCT00422864|DRUG|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
214537999|NCT03181282|BEHAVIORAL|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
214538000|NCT00270647|DIETARY_SUPPLEMENT|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
214538001|NCT00270647|DIETARY_SUPPLEMENT|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
214538002|NCT00270647|DIETARY_SUPPLEMENT|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
214538003|NCT00270647|DIETARY_SUPPLEMENT|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
214538004|NCT03020056|DRUG|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
214538005|NCT03020056|PROCEDURE|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
214538006|NCT02624375|DRUG|Zoster Vaccine Live|
214538007|NCT02606097|DRUG|regorafenib|
214538008|NCT04897685|BEHAVIORAL|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
214538009|NCT00569010|DRUG|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days
214538010|NCT00569010|DRUG|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)"
214538011|NCT04525456|DIETARY_SUPPLEMENT|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
214538012|NCT06194812|OTHER|Pain Catastrophizing scale|"Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked."
214538013|NCT00331708|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
214538014|NCT00148135|DRUG|Carboplatin|
214538015|NCT00148135|DRUG|Gemcitabine|
214538016|NCT00148135|DRUG|Capecitabine|
214696972|NCT00223691|DRUG|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
214696973|NCT00223691|DRUG|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
214696974|NCT00223691|DRUG|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
215156818|NCT00422864|PROCEDURE|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
215156819|NCT02052076|BEHAVIORAL|Meal pattern|
214538017|NCT03745586|DRUG|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
214538018|NCT03745586|DRUG|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
214538019|NCT02508597|OTHER|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
214538020|NCT02484547|DRUG|Aducanumab (BIIB037)|Low dose
214538021|NCT02484547|DRUG|Aducanumab (BIIB037)|High dose
214538022|NCT02484547|DRUG|Placebo|Placebo
214538023|NCT04287140|OTHER|Bolus fluid administration|1000 ml of 0.9% normal saline bolus over one hour
214538024|NCT00001123|DRUG|Ribavirin|
214538025|NCT01813305|DRUG|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
214538026|NCT01813305|DRUG|CSTC1 Matched vehicle|
214538027|NCT01515722|BEHAVIORAL|Health education intervention (HEI)|"* \<Part 1\> Understanding OAB~* \<Part 2\> Behavioral/lifestyle modification~* \<Part 3\> Bladder training~* \<Part 4\> Understanding antimuscarinics"
214538028|NCT02736955|DRUG|Valbenazine|
214538029|NCT05337488|OTHER|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
214538030|NCT05050526|BEHAVIORAL|Real-time videoconference-based Exercise program|12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
214538031|NCT02286687|OTHER|Laboratory Biomarker Analysis|Correlative studies
214538032|NCT02286687|OTHER|Pharmacological Study|Correlative studies
214538033|NCT02286687|DRUG|Talazoparib|Given PO
214538034|NCT01665599|DRUG|Testosterone gel (FE 999303)|
214538035|NCT03705533|DRUG|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
214538036|NCT03705533|DRUG|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
214696975|NCT00223691|DEVICE|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
215156820|NCT04254328|DEVICE|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
215156821|NCT04254328|DEVICE|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
215156822|NCT03353337|BEHAVIORAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
215156823|NCT03353337|BEHAVIORAL|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
215156824|NCT05633316|DEVICE|Investigational device named ICSIA|Oocytes will undergo intracytoplasmic sperm injection using the ICSIA (the investigational) device.
215156825|NCT05633316|DEVICE|Manual ICSI|Oocytes will undergo intracytoplasmic sperm injection using the ICSI manual protocol
215156826|NCT02516540|BEHAVIORAL|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
215156827|NCT03940768|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
215156828|NCT03940768|DIETARY_SUPPLEMENT|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
215156829|NCT00381290|BEHAVIORAL|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
214538037|NCT03953209|DRUG|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
214538038|NCT03953209|DRUG|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
214696976|NCT00223691|DEVICE|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
214696977|NCT04083898|BIOLOGICAL|Isatuximab|Isatuximab will be administered on a 28-day cycle
214696978|NCT04083898|DRUG|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
214696979|NCT04083898|DRUG|Prednisone|Prednisone will be administered on a 28-day cycle as follows
214696980|NCT01825980|DRUG|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
214696981|NCT01825980|DRUG|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
214696982|NCT01825980|DRUG|Placebo|Placebo
214696983|NCT04470128|DRUG|Stage I: HSK21542 0.5 μg/kg|intravenous injection
214696984|NCT04470128|DRUG|Stage I: HSK21542 1 μg/kg|intravenous injection
215156830|NCT00381290|BEHAVIORAL|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
215156831|NCT03089164|DIAGNOSTIC_TEST|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
215156832|NCT01089517|DRUG|E10030 plus Lucentis|once a month intravitreal injection
215156833|NCT01089517|DRUG|Lucentis|10 mg/mL intravitreal injection monthly
215156834|NCT00272896|DRUG|Vasoactive intestinal peptide|
215156835|NCT00752440|OTHER|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
215156836|NCT04860544|PROCEDURE|RED BLOOD CELLS TRANFUSION|
214538039|NCT03953209|DRUG|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
214538040|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
214696985|NCT04470128|DRUG|HSK21542 0.5 μg/kg|intravenous injection
214696986|NCT04470128|DRUG|HSK21542 1 μg/kg|intravenous injection
214696987|NCT04470128|DRUG|HSK21542 2 μg/kg|intravenous injection
215156837|NCT01658644|OTHER|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
215156838|NCT01571544|DEVICE|Thermal suit|Thermal suit
215156839|NCT01571544|OTHER|Conventional clothing|Conventional clothing
215156840|NCT06359444|OTHER|Combined aerobic + strength training|"Participants will follow a combination of endurance and strength training for 14 weeks.~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
214696988|NCT04470128|DRUG|Placebo|intravenous injection
214696989|NCT00609453|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
215156841|NCT06359444|OTHER|Combined strength + HIIT training|"6 weeks of endurance training and strength training, 8 weeks of strength training and HIIT.~Participants will follow the same combination of endurance and strength training for the first six weeks, to build up to a baseline level of physical fitness. They will then switch to eight weeks of a combination of strength training and High Intensity Interval Training (HIIT).~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
215156842|NCT01343641|DRUG|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
215156843|NCT01343641|DRUG|Placebo|Inactive Pill used as a comparator
215156844|NCT01305590|OTHER|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
215156845|NCT01819818|DRUG|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
215156846|NCT04461067|DIAGNOSTIC_TEST|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
215156847|NCT06073145|DEVICE|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
215156848|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
215156849|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
215156850|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
215156851|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
214538041|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
214538042|NCT04548297|OTHER|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
214538043|NCT03878290|BEHAVIORAL|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
214538044|NCT00897754|GENETIC|gene expression analysis|
214538045|NCT00897754|GENETIC|protein expression analysis|
214538046|NCT00897754|GENETIC|reverse transcriptase-polymerase chain reaction|
214538047|NCT00897754|OTHER|immunoenzyme technique|
214538048|NCT00897754|OTHER|immunohistochemistry staining method|
214538049|NCT00897754|OTHER|immunologic technique|
214538050|NCT02876003|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
214696990|NCT00371111|DRUG|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
214696991|NCT00371111|DRUG|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
214696992|NCT00247260|DEVICE|32P BioSilicon|
214696993|NCT02395653|DRUG|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
215156852|NCT01774656|DRUG|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
214538051|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
214538052|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
214538053|NCT02843425|OTHER|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
214538054|NCT02843425|OTHER|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
214538055|NCT01262742|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214538056|NCT01262742|DRUG|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214538057|NCT01262742|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214538058|NCT01262742|DRUG|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214538059|NCT01262742|DRUG|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214538060|NCT06500858|OTHER|Exercise Intervention|Receive a welcome package with exercise equipment
214538061|NCT06500858|OTHER|Exercise Intervention|Participate in virtual-exercise sessions
214538062|NCT06500858|OTHER|Exercise Intervention|Receive access to optional drop-in classes
214696994|NCT00040014|DRUG|exemestane|
215156853|NCT04877951|BEHAVIORAL|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
215156854|NCT01168219|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
215156855|NCT01168219|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
215156856|NCT01168219|DRUG|Azacitidine|Given SC or IV
215156857|NCT01168219|DRUG|Busulfan|Given IV
215156858|NCT01168219|DRUG|Fludarabine Phosphate|Given IV
215156859|NCT01168219|OTHER|Laboratory Biomarker Analysis|Correlative studies
215156860|NCT01168219|DRUG|Methotrexate|Given IV
215156861|NCT01168219|OTHER|Pharmacological Study|Correlative studies
215156862|NCT01168219|DRUG|Tacrolimus|Given PO or IV
215156863|NCT05584319|DRUG|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
215156864|NCT04797624|PROCEDURE|Gastric cancer surgery|Appropriate gastric cancer surgery types for the convenient patients
215156865|NCT05189041|OTHER|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
215156866|NCT06131476|DRUG|Blink® Tears eye drops|Control Drops
215156867|NCT06131476|DRUG|Investigational lipid eye drops|Test Drops
215156868|NCT05680532|DIETARY_SUPPLEMENT|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
215156869|NCT05680532|OTHER|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
215156870|NCT01292824|DRUG|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
215156871|NCT01368224|DIETARY_SUPPLEMENT|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
215156872|NCT04992858|DRUG|CT053PTSA|CT053PTSA will be administered orally once a day
215156873|NCT06455046|DRUG|AK104|PD-1/CTLA-4 bispecific antibody
215156874|NCT06455046|DRUG|Recombinant Human Adenovirus 5 Injection|Recombinant Human Adenovirus 5 Injection
215156875|NCT04740138|BEHAVIORAL|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
215156876|NCT05165693|OTHER|Experimental Formula|Diabetes-specific study formula
214538063|NCT06500858|OTHER|Health Promotion and Education|Receive monthly newsletters
214538064|NCT06500858|OTHER|Internet-Based Intervention|Receive access to online fitness buddy matching program
214538065|NCT06500858|OTHER|Physical Activity|Participate in a walking program
214696995|NCT03308162|BEHAVIORAL|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
214696996|NCT02469532|DEVICE|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
215156877|NCT05165693|OTHER|Test Meal|Instant oatmeal
215156878|NCT00347373|DRUG|Tonalin Conjugated linoleic acid (dietary supplement)|
215156879|NCT02736890|DRUG|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
215156880|NCT02736890|DRUG|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
215156881|NCT02490020|BIOLOGICAL|mesenchymal stem cell|
215156882|NCT03089762|BIOLOGICAL|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
215156883|NCT04748198|PROCEDURE|Intracorneal ring segment implantation|Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
215156884|NCT05795608|DEVICE|respiratory exercise with incentive spirometry|Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
214538066|NCT06500858|OTHER|Questionnaire Administration|Ancillary studies
214696997|NCT02469532|DEVICE|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
214696998|NCT01757756|DRUG|Pf-05175157|200-mg administered twice daily for 14 days
214696999|NCT01757756|DRUG|placebo|placebo administered twice daily for 14 days
214697000|NCT01757756|DRUG|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
215156885|NCT06025968|BEHAVIORAL|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
215156886|NCT06025968|BEHAVIORAL|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
215156887|NCT05819827|OTHER|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
215156888|NCT04149756|OTHER|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
215156889|NCT02584010|OTHER|Silicon-based aerosol|Apply twice a day over the postoperative scar
215156890|NCT02584010|OTHER|Silicon-based gel|Apply twice a day over the postoperative scar
215156891|NCT04160754|BEHAVIORAL|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
215156892|NCT04160754|BEHAVIORAL|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
215156893|NCT02873702|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
215156894|NCT02873702|DRUG|Lansoprazole|Lansoprazole capsules.
215156895|NCT02873702|DRUG|Placebo|Dexlansoprazole placebo-matching capsules.
215156896|NCT03164239|BEHAVIORAL|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
215156897|NCT00583895|DRUG|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
214538067|NCT06448104|OTHER|Dry needling and immersive virtual reality|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~The procedure will be carried out simultaneously with the use of immersive virtual reality distraction software, applied through MetaQuest 2 virtual reality glasses. This procedure consists of immersive visualization (video and sound images that represent scenes related to relaxation).~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
214538068|NCT06448104|OTHER|Dry needling|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
214538069|NCT00927550|DRUG|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
214538070|NCT00927550|DRUG|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
214538071|NCT01837797|DRUG|Placebo|Once daily, tablets, orally
215156898|NCT00583895|DRUG|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
214538072|NCT01837797|DRUG|Brexpiprazole 1 mg|once daily dose, tablets, orally
214538073|NCT01837797|DRUG|Brexpiprazole 3 mg|once daily dose, tablets, orally
214538074|NCT01993576|DRUG|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
214538075|NCT04547166|DRUG|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
214538076|NCT04547166|DRUG|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
214538077|NCT05745181|BIOLOGICAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
214538078|NCT01705145|DRUG|Ivacaftor|
214538079|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
214538080|NCT05253911|DRUG|TUKYSA®|tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
214538081|NCT04700397|DIAGNOSTIC_TEST|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
214538082|NCT01574014|BEHAVIORAL|CBGT|Cognitive-behavioral group therapy
214538083|NCT01574014|DRUG|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
214538084|NCT01574014|DRUG|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
214538085|NCT00051103|DRUG|Investigational Cancer Drug|
214538086|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
214538087|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
214538088|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
214538089|NCT02083679|DRUG|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
214538090|NCT04528290|DRUG|Ozanimod|Ozanimod capsule formulation of 0.92mg
214538091|NCT04528290|DRUG|Ozanimod|Ozanimod, granule formulation of 0.92mg
214538092|NCT02176837|DRUG|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
214538093|NCT05971277|DEVICE|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
214538094|NCT00468065|DEVICE|VeinViewer|Veinveiwer is used to view veins subQ
214538095|NCT00468065|DEVICE|Veinviewer|near infrared light reveals veins subcutaneously
214538096|NCT04766047|DRUG|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
214538097|NCT02053740|DRUG|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
214538098|NCT02053740|DRUG|Routine western medicine|
214538099|NCT00159549|BEHAVIORAL|education and training program|
214538100|NCT00592735|PROCEDURE|laparoscopic gastric banding|standard surgical procedure
214538101|NCT02618863|DEVICE|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
214538102|NCT06170229|BEHAVIORAL|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
214538103|NCT06170229|BEHAVIORAL|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
214538104|NCT00618917|GENETIC|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
214538105|NCT00618917|DRUG|carboplatin|Chemotherapy to stop the growth of tumor cells.
214538106|NCT00618917|DRUG|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
214538107|NCT00618917|RADIATION|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
214538108|NCT01849913|OTHER|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
214538109|NCT01849913|OTHER|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
214538110|NCT05481398|OTHER|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
214538111|NCT04017637|BEHAVIORAL|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
214538112|NCT01503164|DEVICE|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
214538113|NCT01503164|BEHAVIORAL|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
214538114|NCT05404217|OTHER|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
214538115|NCT05404217|OTHER|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
214538116|NCT05980819|OTHER|Sustainability lecture and opportunity to create a project|Pure education
214538117|NCT02348372|DRUG|GSK1278863A Placebo|Matching size, shape and color
214538118|NCT02348372|DRUG|GSK1278863A|A round, biconvex, white film coated tablet
214538119|NCT04088136|BEHAVIORAL|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
214538120|NCT04088136|BEHAVIORAL|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
214538121|NCT05363098|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
214538122|NCT01420900|DEVICE|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
214538123|NCT01420900|DEVICE|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
214538124|NCT01199445|DIETARY_SUPPLEMENT|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
214538125|NCT06140576|DRUG|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
214538126|NCT06140576|DRUG|Nab-paclitaxel|Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
214538127|NCT06140576|DRUG|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
214538128|NCT01669720|DRUG|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
214538129|NCT04634812|DRUG|KBP-5074|a single oral dose of \[14C\]-KBP-5074
214697001|NCT02021825|DRUG|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
214697002|NCT05069805|PROCEDURE|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
214697003|NCT05069805|PROCEDURE|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
214697004|NCT00234819|DRUG|Bazedoxifene/Conjugated Estrogen|
214538130|NCT06289855|OTHER|MDS-UPDRS|"Movement disorder society- unified Parkinson disease rating scale (MDS-UPDRS) for Parkinson's disease.~Movement disorder society- non motor rating scale (MDS-NMS) Cognitive assessment using Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog)~Using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale:~Timed up and go: originally aimed to clinically evaluate dynamic balance in elderly people during the performance of a task MR imaging of the brain will be performed with a 1.5T MR imaging scanner Assessment of Cortical excitability and unhibition by NIHON KOHDEN- neuropack2"
214538131|NCT05095233|BEHAVIORAL|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
214538132|NCT05095233|DEVICE|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
214538133|NCT02756299|OTHER|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
214538134|NCT02756299|OTHER|Standard Support|General information about OSA and PAP treatment at baseline
214538135|NCT02934893|OTHER|Medication Management Clinic|referral to medication management clinic from primary care
214538136|NCT02934893|OTHER|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
214538137|NCT00356213|PROCEDURE|sleeve gastrectomy|laparoscopic sleeve gastrectomy
214538138|NCT00356213|PROCEDURE|Roux-Y-gastric bypass|laparoscopic gastric bypass
214538139|NCT04013932|BEHAVIORAL|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
214538140|NCT05859009|PROCEDURE|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
214538141|NCT05859009|DRUG|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
214538142|NCT00730210|DRUG|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
214538143|NCT00730210|DRUG|b:placebo|100 microgram placebo subcutaneous a day for 6 months
214697005|NCT02453438|OTHER|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
214697006|NCT00483158|DRUG|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
214697007|NCT03736629|DRUG|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
214697008|NCT03736629|DRUG|Placebo|Placebo
214697009|NCT00151125|DRUG|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
214697010|NCT00151125|DRUG|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
214697011|NCT00151125|DRUG|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
214538144|NCT04337034|BEHAVIORAL|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
214538145|NCT04337034|PROCEDURE|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
214538146|NCT06304597|DRUG|Imfinzi|Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
214538147|NCT06304597|DRUG|Opdivo|Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
214538148|NCT02785575|OTHER|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
214538149|NCT03604289|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
214538150|NCT03604289|DRUG|Saline|Saline will be used as the placebo comparator
214697012|NCT06293677|DRUG|Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 40 mg/kg q6 h eGFR 150-199 : 30 mg/kg q4h eGFR 200-299 : 40 mg/kg q4h eGFR \&amp;gt;/= 300 : 40 mg/kg q4h~Piperacillin-tazobatam dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 150 mg/kg q6 h eGFR 150-199 : 120 mg/kg q4h eGFR 200-299 : 150 mg/kg q4h eGFR \&amp;gt;/= 300 : 180 mg/kg q4h~The maximum doses for the antibiotic prescription before the first drug monitoring will be 2gr of MER every 4 hours and 4gr of PIP every 4 hours.~The duration of infusion will be set to 2 h."
214697013|NCT06293677|DRUG|Standard dosages of piperacillin-tazobactam or meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR\> 50 : 40mg/kg q8h eGFR 25-49 : 40mg/kg q12h eGFR 15-24 : 20mg/kg q12h~Piperacillin-tazobactam :~eGFR \>50 : 100mg/kg q6h eGFR 20-49 : 50mg/kg q6h eGFR 15-29 : 50 mg/kg q8h"
214538151|NCT03043170|DEVICE|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
214538152|NCT02923817|BIOLOGICAL|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
214697014|NCT03522194|DRUG|Sevoflurane|Anesthesia maintenance with Sevoflurane
214697015|NCT03522194|DRUG|Propofol|Anesthesia maintenance with Propofol
214697016|NCT00129194|DRUG|KP-1461|
215156899|NCT00426413|DRUG|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
215156900|NCT06385626|DIETARY_SUPPLEMENT|Raspberry leaf tea|10 g of raspberry leaf tea
215156901|NCT03638765|BIOLOGICAL|DCVax-Direct|activated, autologous dendritic cells
214538153|NCT02626689|OTHER|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
214538154|NCT02626689|OTHER|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
214538155|NCT05773209|DEVICE|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
214538156|NCT05795309|DEVICE|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
214538157|NCT02746237|DRUG|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
214538158|NCT02746237|DRUG|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
214538159|NCT01550783|OTHER|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
214538160|NCT01550783|OTHER|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
214538161|NCT01550783|OTHER|Questionnaire Administration|Ancillary studies
214538162|NCT01550783|PROCEDURE|Screening Method|Undergo standard of care Pap test screening
214538163|NCT01550783|PROCEDURE|Screening Method|Undergo home-based HPV screening
215156902|NCT03762317|DRUG|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
215156903|NCT03762317|DRUG|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
215156904|NCT03443570|DRUG|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
215156905|NCT03443570|DRUG|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
215156906|NCT05475756|DEVICE|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
215156907|NCT05475756|DEVICE|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
215156908|NCT01039376|BIOLOGICAL|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
215156909|NCT01039376|OTHER|Observation|Observation/Safety Evaluation
215156910|NCT03252925|DRUG|N-Acetylcysteine|50mg/Kg.d, oral
215156911|NCT03252925|DRUG|Placebo Oral Tablet|50mg/Kg.d, oral
215156912|NCT03261427|DRUG|Lyrica 150Mg Capsule|150 mg oral administered (BID)
215156913|NCT03261427|DRUG|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
214538164|NCT04029792|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
214538165|NCT04029792|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
214538166|NCT06591767|DIETARY_SUPPLEMENT|Quercetin|200 mg supplemental Quercefit®
214538167|NCT06591767|COMBINATION_PRODUCT|Berberol K®|"Berberine Phytosome® 730 mg~\+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"
214697017|NCT03900806|BEHAVIORAL|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
214697018|NCT00003809|BIOLOGICAL|cetuximab|
214697019|NCT00003809|DRUG|cisplatin|
214697020|NCT03853512|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
214697021|NCT03853512|OTHER|Semisolid vaseline|Product is applied to the other side of the inguinal region.
214697022|NCT00825019|DRUG|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
214538168|NCT04229706|DRUG|High dose Xiang Ju Ru Pi Ning capsule|xingjurupining capsule,8 capsule,tid,3 months.
214538169|NCT04229706|DRUG|Low dose Xiang Ju Ru Pi Ning capsule|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
214538170|NCT04229706|DRUG|Xiang Ju Ru Pi Ning capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
214538171|NCT04981184|DEVICE|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
214538172|NCT03972397|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
214538173|NCT03972397|DRUG|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
214538174|NCT03972397|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
214538175|NCT05079906|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
214538176|NCT05079906|DEVICE|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
214538177|NCT02169778|BEHAVIORAL|Intermittent energy restricted diet|
214538178|NCT02169778|BEHAVIORAL|Continuous energy restricted diet|
214538179|NCT01649037|DRUG|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h."
214538180|NCT01649037|DRUG|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
214538181|NCT00788047|DRUG|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
214538182|NCT00788047|DRUG|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
214538183|NCT05908539|BEHAVIORAL|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
214538184|NCT05908539|BEHAVIORAL|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
214697023|NCT00825019|DRUG|placebo|oral administration in 12h intervals
214697024|NCT00825019|DRUG|paroxetine|oral administration of 20 mg/day
214697025|NCT04676542|OTHER|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
214697026|NCT02320968|OTHER|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
214697027|NCT06304675|OTHER|no intervention|no intervention
214697028|NCT00967226|DRUG|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
214697029|NCT00967226|DRUG|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
214697030|NCT03476382|DEVICE|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
214697031|NCT01768338|DRUG|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
214697032|NCT00505804|DRUG|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
215156914|NCT02225691|DEVICE|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
215156915|NCT02873494|DEVICE|PHYSIOFLOW - PF05 Lab1TM|
215156916|NCT04655352|DIETARY_SUPPLEMENT|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
215156917|NCT06441916|DRUG|Dabigatran Etexilate Capsules 150 mg|Dabigatran Etexilate
215156918|NCT03181737|BEHAVIORAL|Covivio/Relaxio|Informations already included in arm/group descriptions.
214538185|NCT05908539|BEHAVIORAL|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
214538186|NCT05908539|BEHAVIORAL|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
214538187|NCT04633785|OTHER|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
214538188|NCT06355037|DRUG|Quercetin|quercetin 1000mg d1-d3, qw
214538189|NCT06355037|DRUG|Dasatinib|Dasatinib 50mg d1-d3, qw
214538190|NCT06355037|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
214538191|NCT05264142|DRUG|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
214538192|NCT05264142|DRUG|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
214538193|NCT05264142|DRUG|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
214538194|NCT06625645|COMBINATION_PRODUCT|Modified triple antibiotic paste (TAP) mixed with chlorehexidine|M-TAP with CHX 2%
214538195|NCT06625645|COMBINATION_PRODUCT|Modified Triple Antibiotic Paste mixed with saline|M-TAP mixed with saline
214538196|NCT06625645|COMBINATION_PRODUCT|Calcium Hydroxide mixed with chlorohexidine Intracanal medication|calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
214538197|NCT06625645|COMBINATION_PRODUCT|calcium hydroxide mixed with saline as intracanal medication|calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
214697033|NCT00505804|DRUG|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
214697034|NCT06342570|OTHER|There is no Intervention name to describe.|There is no Intervention name to describe.
215156919|NCT03498404|RADIATION|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
215156920|NCT03498404|OTHER|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
215156921|NCT05593068|PROCEDURE|MRI|Pancreatic MRI
215156922|NCT06109961|DRUG|Oxygen Gas for Inhalation|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
215156923|NCT06109961|OTHER|Standard of care|The accepted standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission.
215156924|NCT03408704|OTHER|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~1. The Swedish guidelines~2. Example of cases~3. Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
215156925|NCT05676021|BEHAVIORAL|motivational interview|motivational interview-based health education
215156926|NCT00163813|PROCEDURE|Early jejunal feeding (using frictional NJ tube)|
215156927|NCT00163813|PROCEDURE|Standard feeding (using nasogastric [NG] tube)|
215156928|NCT01765972|DEVICE|etafilcon A with Lacreon|contact lens with Lacreon
215156929|NCT01765972|DEVICE|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
215156930|NCT01765972|DEVICE|etafilcon A with print|contact lens with print
215156931|NCT01765972|DEVICE|Spectacles (habitual)|Spectacles
214538198|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
214538199|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
214538200|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
215156932|NCT04326283|DRUG|Trametinib (0.5 mg)|0.5 mg/day
215156933|NCT04326283|DRUG|Trametinib (1 mg)|1 mg/day
215156934|NCT04326283|DRUG|Riluzole (100 mg)|100 mg/day (50 mg twice)
215156935|NCT04520646|DRUG|Empagliflozin|empagliflozin of 10mg/day is added on the basis of primary care
215156936|NCT05282602|OTHER|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
215156937|NCT05282602|OTHER|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
214538201|NCT06632834|DRUG|simvastatin therapy|Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
214538202|NCT06332391|DEVICE|Exercise-similar cardiac pacing|Cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
214538203|NCT06332391|DEVICE|Sham cardiac pacing|Simulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
214538204|NCT05958147|BIOLOGICAL|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
214538205|NCT00143598|DEVICE|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
214538206|NCT00143598|DEVICE|Knee-length, placebo stocking|Worn daily for two years
214538207|NCT05576012|BIOLOGICAL|SOL-116|Participants will receive SC injection in a double-blind manner
214538208|NCT05576012|BIOLOGICAL|Placebo|Participants will receive SC injection in a double-blind manner
215156938|NCT04303676|OTHER|Virtual Practice Facilitation with e-Learning|"Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
214697035|NCT00714298|OTHER|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
214697036|NCT05275296|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
214538209|NCT00420147|DEVICE|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
214538210|NCT00420147|DEVICE|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
214538211|NCT00610805|OTHER|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
214538212|NCT00610805|OTHER|Usual Care|Participants will receive usual care per their primary care physician.
214538213|NCT03900715|DRUG|Luspatercept|Luspatercept
214538214|NCT00771238|DEVICE|P500 Mattress|Study mattress
214538215|NCT01878383|DEVICE|Genexpert assay|
214538216|NCT03464383|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
214538217|NCT03464383|OTHER|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
214538218|NCT03464383|OTHER|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
214538219|NCT04505345|BEHAVIORAL|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
214697037|NCT03516955|DRUG|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
214697038|NCT00605722|DRUG|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
214697039|NCT00605722|DRUG|erlotinib (Tarceva)|150 mg orally (po) daily.
214538220|NCT04505345|BEHAVIORAL|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
214538221|NCT01709396|RADIATION|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
214538222|NCT04260464|DRUG|PF-06700841|A single dose of 30 mg PF-06700841 will be administered on Day 1
214538223|NCT06465992|DRUG|Exparel 266 MG Per 20 ML Injection|20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
214538224|NCT06465992|DRUG|Bupivacaine Hcl 0.75% Inj|10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
214697040|NCT03300219|BEHAVIORAL|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
214697041|NCT03909932|OTHER|Observational study : no intervention|Observational study : only exporting data
214697042|NCT02526719|PROCEDURE|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
214697043|NCT02530606|PROCEDURE|Photoacoustic Imaging|Undergo PAI
214697044|NCT01155297|BEHAVIORAL|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
214538225|NCT06465992|DRUG|Dexamethasone|1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
214697045|NCT01155297|BEHAVIORAL|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
214538226|NCT05084599|DRUG|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
214538227|NCT05084599|DRUG|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
214538228|NCT05390996|OTHER|dental implant placement|dental implant placement by using a different drilling techniques
215156939|NCT04303676|OTHER|Virtual Practice Facilitation without e-Learning|"Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
215156940|NCT05697185|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
214538229|NCT02895243|OTHER|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
214538230|NCT04069533|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
214538231|NCT04390412|RADIATION|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
214538232|NCT03384147|DIETARY_SUPPLEMENT|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
214538233|NCT03384147|OTHER|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
214538234|NCT04724096|DIAGNOSTIC_TEST|Oxygen Enhanced MRI scan|Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.
214538235|NCT00514488|DRUG|STI571 (400 mg/day; or 800 mg/day)|
214538236|NCT01395849|DRUG|Salmeterol and Fluticasone|
214538237|NCT03607617|OTHER|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
214538238|NCT00695136|DRUG|Donepezil hydrochloride|
214538239|NCT00695136|BEHAVIORAL|Increase REM sleep percentage|
214538240|NCT03469492|DRUG|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
214538241|NCT03469492|BEHAVIORAL|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
214538242|NCT03469492|DIETARY_SUPPLEMENT|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
214538243|NCT01726049|DRUG|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
214538244|NCT01726049|DRUG|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
214538245|NCT03912974|DRUG|Escitalopram|see 'arm description'
214697046|NCT00488579|DRUG|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
214697047|NCT00914602|DRUG|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
214697048|NCT00914602|DRUG|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
214538246|NCT03912974|DRUG|Placebo oral capsule|see 'arm description'
214538247|NCT02925936|OTHER|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
214538248|NCT02925936|OTHER|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
214538249|NCT05279534|DIETARY_SUPPLEMENT|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
214538250|NCT05279534|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
214538251|NCT04410939|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
214538252|NCT02331810|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214538253|NCT02331810|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214538254|NCT04249050|DIETARY_SUPPLEMENT|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
214538255|NCT01811498|DRUG|Bevacizumab|
214697049|NCT00914602|DRUG|Carbidopa Pill|
214697050|NCT00849251|DRUG|cyclophosphamide|Given IV or PO
214697051|NCT00849251|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214697052|NCT00849251|DRUG|bortezomib|Given IV
214697053|NCT00849251|DRUG|dexamethasone|Given IV or PO
215156941|NCT01742117|DRUG|Clopidogrel|One 75 mg tablet per day by mouth for one year
215156942|NCT01742117|DRUG|Ticagrelor|One 90 mg tablet twice per day by mouth for one year
215156943|NCT04623853|DEVICE|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
215156944|NCT03925779|DRUG|Dexmedetomidine|dexmedetomidine sedation
215156945|NCT03925779|DRUG|Propofol|propofol sedation
215156946|NCT03925779|DRUG|Remifentanil|Remifentanil sedation
215156947|NCT00674713|OTHER|Acupuncture|
215156948|NCT00674713|DRUG|Ondansetron|
215156949|NCT00674713|DRUG|Physiological saline solution|
215156950|NCT00674713|OTHER|Sham acupuncture|
214538256|NCT04595942|DRUG|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
214538257|NCT04595942|DRUG|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
214538258|NCT04595942|BEHAVIORAL|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
214538259|NCT01688453|BEHAVIORAL|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
214538260|NCT01688453|BEHAVIORAL|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
214538261|NCT00008320|DRUG|ceramide|
214538262|NCT00349570|DEVICE|Xtract Aspiration Catheter|
214538263|NCT03887247|BEHAVIORAL|E-mail Alert|Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
214697054|NCT05446025|DIAGNOSTIC_TEST|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
214697055|NCT02702518|DRUG|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
214697056|NCT02702518|DRUG|Vehicle|Drug vehicle 4 times a day for 8 weeks
215156951|NCT00674713|DRUG|Ondansetron|
215156952|NCT00674713|OTHER|Acupuncture at P6 point|
215156953|NCT00674713|DRUG|Physiological saline solution|
215156954|NCT00674713|OTHER|Sham acupuncture|
215156955|NCT05733117|DRUG|Vitamin D|cholecalciferol
215156956|NCT05069272|OTHER|Bakuchiol and Ethyl Linoleate|A synergistic combination of Bakuchiol and Ethyl Linoleate
215156957|NCT05069272|OTHER|Vehicle|No actives
215156958|NCT02730780|DIETARY_SUPPLEMENT|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
215156959|NCT02730780|DIETARY_SUPPLEMENT|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
215156960|NCT05540587|DRUG|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
215156961|NCT05540587|DRUG|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
215156962|NCT00673738|DRUG|Cetuximab|"* Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
215156963|NCT00673738|RADIATION|Conformal Thoracic Radiotherapy (CTRT)|"* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \>1,000 and platelets \>75,000) required. Patient may be delayed for a max. of 2 weeks. If \> 2 week delay occurs, patient will come off study."
215156964|NCT02705066|DIETARY_SUPPLEMENT|Citicoline supplement|
215156965|NCT02705066|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
215156966|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
215156967|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
215156968|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
215156969|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
215156970|NCT03830892|OTHER|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
215156971|NCT03830892|OTHER|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
215156972|NCT05486624|OTHER|Reiki|Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
214538264|NCT05528822|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
214538265|NCT05528822|PROCEDURE|ultrasound-guided pericapsular nerve group (PENG) block|A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
214538266|NCT03320395|DEVICE|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
214538267|NCT06114134|DIETARY_SUPPLEMENT|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
214538268|NCT06114134|DIETARY_SUPPLEMENT|Placebo|Placebo
214538269|NCT02806505|DRUG|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
214538270|NCT02377323|OTHER|MACFIMS|Cognitive evaluation of 50 participants
214538271|NCT02377323|OTHER|MSQoL-54|Quality of life questionnaires
214538272|NCT06410339|DIAGNOSTIC_TEST|Ultrasound|ultrasound of flexor tendons on hands
214697057|NCT01042613|PROCEDURE|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
214697058|NCT01042613|PROCEDURE|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
215156973|NCT01499277|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
215156974|NCT01499277|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
215156975|NCT01499277|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
215156976|NCT02814552|OTHER|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
215156977|NCT02814552|OTHER|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
215156978|NCT04661579|BIOLOGICAL|Malaria Vaccine RTS,S/AS01E|RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.
215156979|NCT04661579|BIOLOGICAL|Abhayrab rabies vaccine|Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.
215156980|NCT04661579|DRUG|Dihydroartemisinin-piperaquine (DHA/Pip)|"Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites."
214538273|NCT06338436|DEVICE|Proton Radiation Therapy System (ProBeam)|All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
214538274|NCT04334668|DIETARY_SUPPLEMENT|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
214538275|NCT04334668|OTHER|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
214538276|NCT02416713|DEVICE|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
214538277|NCT02416713|OTHER|Education Only|No active intervention, educational materials will be provided
214538278|NCT01798862|PROCEDURE|Endometrial injury by hysteroscopy or pipelle sampling|
214538279|NCT01798862|PROCEDURE|Proceed to COH directly|
214538280|NCT04853498|DRUG|TQB3720|This is an androgen receptor antagonists.
214538281|NCT00034853|DRUG|meloxicam oral suspension|
214538282|NCT00034853|DRUG|naproxen oral suspension|
214538283|NCT06049069|DIAGNOSTIC_TEST|physical activity in stroke|physical activity in stroke
214538284|NCT02979171|DEVICE|Laryngeal Mask Airway Classic|
214538285|NCT01722045|DRUG|Intravitreal Aflibercept Injection (IAI)|
214538286|NCT04332432|DRUG|belapectin|intravenous
214538287|NCT02219698|DRUG|Ibuprofen|
214538288|NCT02219698|DRUG|Paracetamol|
214538289|NCT06103643|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency breech birth.
214538290|NCT01339299|DRUG|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
214538291|NCT01339299|DRUG|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
214538292|NCT05155891|DEVICE|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
214538293|NCT05155891|PROCEDURE|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
214538294|NCT03339271|BEHAVIORAL|Technology-Enhanced Support|The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.
214538295|NCT03339271|BEHAVIORAL|Usual Care Support|The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.
214538296|NCT00263211|DRUG|Plavix|
214538297|NCT00263211|DRUG|Aspirin|
214697059|NCT00165841|DRUG|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
214538298|NCT06134947|OTHER|Echocardiographic examination|"Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~* Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE \<-2 Z Score is considered abnormal .~* Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler \<-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś)."
214538299|NCT00002492|DRUG|cisplatin|
214538300|NCT00002492|DRUG|doxorubicin hydrochloride|
214538301|NCT00002492|DRUG|isolated limb perfusion|
214538302|NCT00002492|PROCEDURE|conventional surgery|
214538303|NCT00002492|RADIATION|brachytherapy|
214538304|NCT00002492|RADIATION|radiation therapy|
214538305|NCT05649189|DIAGNOSTIC_TEST|telomere length measure|length of telomere between two groups
214538306|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
214538307|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
214538308|NCT00760513|DRUG|OMACOR|4 grammes daily, oral capsule
214538309|NCT00760513|DRUG|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
214538310|NCT00327353|DRUG|formoterol (TURBOHALER)|
214538311|NCT00327353|DRUG|Salmeterol (DISKUS)|
215156981|NCT04661579|DRUG|Artemether / Lumefantrine|"Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy."
215156982|NCT04661579|DRUG|Primaquine|One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
215156983|NCT05118659|PROCEDURE|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
215156984|NCT05118659|PROCEDURE|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
215156985|NCT00605787|DRUG|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
215156986|NCT03493217|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
215156987|NCT01743859|DRUG|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
215156988|NCT01743859|DRUG|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
215156989|NCT01743859|OTHER|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
215156990|NCT00604799|DEVICE|Talent Thoracic Stent Graft|TEVAR
214697060|NCT05208203|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
214697061|NCT06129396|OTHER|Aerobic exercise|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with HR at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
214697062|NCT06129396|OTHER|Video-watching|The video-watching group will be asked to watch a nature documentary for 30 mins
214538312|NCT02727257|PROCEDURE|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
214538313|NCT00097838|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
214538314|NCT00097838|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
214697063|NCT00796094|OTHER|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
214697064|NCT00487084|DRUG|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
214697065|NCT00487084|DRUG|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
214697066|NCT00487084|DRUG|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
215156991|NCT02532738|DRUG|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
215156992|NCT02532738|BIOLOGICAL|MSC treatment 01|Injection of 3×10E6/kg of MSC
215156993|NCT02532738|BIOLOGICAL|MSC treatment 02|Injection of 6×10E6/kg of MSC
215156994|NCT02532738|OTHER|NS|Injection of NS
215156995|NCT03752437|DIAGNOSTIC_TEST|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
215156996|NCT03752437|DRUG|Heparin|300 IU of heparin
214538315|NCT02854371|DRUG|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
214538316|NCT02854371|DRUG|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
214697067|NCT04583111|DRUG|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
214538317|NCT06018688|DRUG|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
214697068|NCT04583111|DRUG|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
214697069|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
214538318|NCT06018688|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
214538319|NCT03089736|BEHAVIORAL|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
214538320|NCT03089736|BEHAVIORAL|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
214538321|NCT03089736|OTHER|Treatment as usual (TAU)|pharmacological treatment + advices
214538322|NCT01572298|DEVICE|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
214538323|NCT01572298|DEVICE|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
214538324|NCT04467346|DRUG|Ped-TMZ|Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
214538325|NCT03893006|DEVICE|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
214538326|NCT00816647|PROCEDURE|Patellofemoral stabilizing surgery|Comparison of surgical techniques
214697070|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
214697071|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
214538327|NCT06547385|DRUG|ONO-4578|Specified dose on specified days
214538328|NCT06547385|DRUG|ONO-4538|Specified dose on specified days
214538329|NCT06547385|DRUG|Capecitabine|Specified dose on specified days
214538330|NCT06547385|DRUG|Oxaliplatin|Specified dose on specified days
214538331|NCT06547385|DRUG|Fluorouracil|Specified dose on specified days
214538332|NCT06547385|DRUG|Calcium Levofolinate Hydrateb|Specified dose on specified days
214538333|NCT06547385|DRUG|Bevacizumab|Specified dose on specified days
214538334|NCT05451797|DEVICE|Implant of WiSE-CRT with intracardiac pacemaker|Implant of two cardiac devices
214538335|NCT03787420|OTHER|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
214538336|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
214538337|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
214538338|NCT00908349|DRUG|Oxcarbazepine XR|Open Label Study
214538339|NCT05328310|DRUG|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
214538340|NCT02459405|PROCEDURE|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
214538341|NCT02459405|DEVICE|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
214538342|NCT01937195|DEVICE|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
214538343|NCT05354713|DRUG|NVP-1805|NVP-1805 (80/10/20.8mg)
214538344|NCT05354713|DRUG|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
214538345|NCT05594004|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
214538346|NCT05594004|DEVICE|Sonic electric toothbrush|Sonic electric toothbrush used twice daily
214538347|NCT05594004|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
214538348|NCT01097499|DEVICE|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
214538349|NCT03617068|DRUG|Cocos Nucifera Whole|Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
214538350|NCT03617068|DRUG|Cocos Nucifera Whole|For dermatopharmacokinetic evaluation using tape/ skin stripping
214538351|NCT03834623|DRUG|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
214538352|NCT03834623|DRUG|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
214538353|NCT00458354|DEVICE|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
214538354|NCT00458354|PROCEDURE|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
214538355|NCT03189147|PROCEDURE|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
214697072|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
214697073|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
214538356|NCT03189147|PROCEDURE|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
214538357|NCT05316909|OTHER|Breastfeeding Simulation|In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.
214697074|NCT00254293|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
214538358|NCT00867178|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
214538359|NCT00867178|DRUG|Carboplatin|Given IV
214538360|NCT00867178|DRUG|Cisplatin|Given IV
214538361|NCT00867178|DRUG|Cyclophosphamide|Given IV
214538362|NCT00867178|DRUG|Etoposide Phosphate|Given IV
214538363|NCT00867178|DRUG|Isotretinoin|Given PO
214538364|NCT00867178|OTHER|Laboratory Biomarker Analysis|Correlative studies
214538365|NCT00867178|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
214538366|NCT00867178|DRUG|Thiotepa|Given IV
214538367|NCT00867178|DRUG|Vincristine Sulfate|Given IV
214538368|NCT00867178|DRUG|Vorinostat|Given PO
214538369|NCT02813083|OTHER|No intervention (observational)|No intervention (observational)
214697075|NCT05566652|DEVICE|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
214697076|NCT05566652|DRUG|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
214697077|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
214697078|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
214697079|NCT02230878|DRUG|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
214697080|NCT02230878|DRUG|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
214697081|NCT02230878|DRUG|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
214538370|NCT04028817|DEVICE|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
214538371|NCT04028817|DEVICE|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
214538372|NCT01338974|GENETIC|gene expression analysis|
214538373|NCT01338974|GENETIC|proteomic profiling|
214538374|NCT01338974|OTHER|flow cytometry|
214538375|NCT01338974|OTHER|laboratory biomarker analysis|
214538376|NCT00384605|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
214538377|NCT00384605|DRUG|placebo|Placebo capsule once daily. Treatment for 52 weeks.
214538378|NCT06424730|OTHER|Feasibility Interview|One audio-recorded interview with the participants lasting about 30-minutes
214538379|NCT06424730|BEHAVIORAL|Team Based Equity Conscious Telemedicine Hypertension Intervention|Will provide blood pressure monitor connected to a telehealth application. Patients will be asked to measure home blood pressure once daily. Will intensify medications as needed based on blood pressure measurement. Trained nurses or pharmacists will provide 4 self-management telephone calls (up to 30 minutes per call) to patients to address hypertension knowledge, medication adherence, healthy eating, physical activity, weight management, stress management, tobacco and alcohol use, and sleep apnea (with referrals if needed). Will support needs relevant in blood pressure control using locally available resources via community health worker and social workers.
214538380|NCT06424730|BEHAVIORAL|Usual Care|Usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
214538381|NCT06957067|BEHAVIORAL|CPT Skills|CPT trainings recommend that if an individual is experiencing challenges with the CPT protocol (e.g., ambivalence about continuing treatment or struggling with completing homework), the provider can apply the skills of CPT to that particular problem. Those skills include problem solving and cognitive restructuring to identify and alter maladaptive underlying beliefs. The purpose of this work is to address the individual's underlying problem or problematic beliefs to improve the individual's attitudes about CPT and/or improve the individual's compliance with treatment activities. The therapist's end-goal is to keep the individual moving forward in the CPT protocol.
214538382|NCT06957067|BEHAVIORAL|Cognitive Processing Therapy|"CPT is a 12-session, cognitive-behavioral treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to prior trauma. The goal is to build a new understanding of prior trauma in order to limit the negative influence trauma and it's reminders have on individuals' daily lives. The treatment involves education about PTSD and skill building to identify and challenge maladaptive, trauma-related thinking through Socratic questioning and worksheets that teach individuals to challenge this thinking themselves. Later sessions focus on specific themes that are difficult for individuals with PTSD and can keep individuals stuck in their symptoms. Themes include safety, trust, control, self-esteem, and intimacy.~Although the skills utilized in CPT may be used to respond to challenges individuals have with participating in CPT, the effectiveness of these strategies has not been explicitly tested."
214538383|NCT06957067|BEHAVIORAL|Present Centered Therapy|"PCT was developed as a comparator for active TFT, so protocol length typically matches the comparator. PCT focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to life difficulties and stress, and emotional support and validation. Its hypothesized mechanisms are increased interpersonal connection and mastery in managing life stressors. Therapist skills include validation, support, and reflective listening. The first 2 sessions provide an overview and rationale for PCT. Subsequent sessions focus on topics participants choose and are less structured. Participants use a daily diary to record any concerning problems or issues they experience during the week. These diaries are used to select session topics."
214538384|NCT06957067|BEHAVIORAL|Shared Decision Making|Shared decision making (SDM) is widely considered the best model for achieving patient-provider agreement on treatment plans and an ethical imperative for decision making. SDM is a communicative process in which patients and their provider personalize treatment approaches to the individual, their situation, and the problems that they are experiencing. Providers and patients engage in a shared deliberation of meaningful treatment alternatives, including pros and cons, how choices align or misalign with values, and patients' abilities to complete the plans under consideration.
215156997|NCT02804152|BEHAVIORAL|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
215156998|NCT04541459|DEVICE|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
215156999|NCT04541459|DEVICE|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
215157000|NCT04566926|DRUG|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
215157001|NCT04566926|DRUG|Placebo|Participant will receive matching placebo.
215157002|NCT04300621|DRUG|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
215157003|NCT04300621|DRUG|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
215157004|NCT04300621|DRUG|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
215157005|NCT04300621|DRUG|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
215157006|NCT00792168|DRUG|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
214538385|NCT06957067|BEHAVIORAL|Measurement Based Care|"Investigators will compare methods of identifying individuals experiencing challenges in CPT. Investigators will use self-report measures administered each week during treatment to identify individuals who may be struggling in during CPT and compare two approaches to cut scores on these measures to classify individuals as in need of intervention. Investigators will also use behavioral indices to determine if veterans are in need of intervention, including homework compliance and session attendance. One approach will liberally classify many individuals as in need of intervention (Catchall), while the other will take a more targeted approach (Targeted)."
214538386|NCT06787482|DIETARY_SUPPLEMENT|ACE Retino|1 ml sublingually self administer / 4 times/day for 6 months
214538387|NCT06957340|DEVICE|Low-Intensity Transcranial Ultrasound Stimulation|"LITUS is conducted using the UE880C model from RuAo Medical Technology Co., Ltd. (Beijing). The parameters are set as follows:Frequency: 800(1+10%) kHz,Pulse repetition period: 25 ms,Duty cycle: 50%,Output power: 1.2 W,Maximum output power duration: 0.6 W,Effective sound intensity: 0.4 W/cm².During treatment, the patient is placed in a quiet room and asked to relax in a seated position. Three ultrasound probes are coated with a coupling agent and positioned on the patient's forehead.The total treatment duration is 20 minutes.~The upper limb rehabilitation virtual training is used by the EM-BURT02-01 model from Eston.The affected limb is fixed to the robotic arm. Each treatment session consists of two virtual games (such as Airplane Battle, Mosquito Smasher, and other motion-based games).Each game lasts for 10 minutes, totaling 20 minutes of treatment. Treatment is administered 5 times a week."
214538388|NCT06957340|DEVICE|sham TUS|In the sham group, the machine only operates for 30 seconds, then stopping. Due to the physical characteristics of ultrasound, this stimulation cannot be perceived.Treatment is administered 5 times a week.
214538389|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM)|The tPBM-2.0 device consists of a therapeutic laser console (that produces laser energy as NIR), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap). tPBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead at the standard scalp location \~12 minutes per day, 3 days per week, for 6 weeks (18 total sessions).
214538390|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM) in sham mode|The tPBM-2.0 device consists of a therapeutic laser console (which will be in sham mode, which does not produce laser energy), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap).
214538391|NCT06957132|DEVICE|Audiogram|"Either the patient can be proposed to perform the audiogram during their long-term consultation, or they will be contacted by the physician to come especially for the project and realize the audiogram.~iAudiogram is an Artificial Intelligence (AI) - automated audiometry platform (https://iaudiogram.com/), certified CE (European conformity).~This examination will be performed once within the study."
214538392|NCT06957288|OTHER|Mindfulness-based psychoeducation|The aim of psychoeducation is to reduce the death anxiety of nurses and to increase their awareness of death by providing them with information about the death experience they are secondarily exposed to (1- Death process and death anxiety, 2- Effects of the death process on the individual and family, 3- Coping with the death process, 4- Effects of the death process on caregiving nurses, 5- Awareness of death, 6- Nursing care and emotional competence during the death process). Therefore, it will be evaluated whether the implemented psychoeducation program reduces the intended death anxiety and creates awareness about death. This study will be conducted to examine the effect of a 6-week, 12-session mindfulness-based group psychoeducation program given to nurses on death anxiety and death awareness levels.
214538393|NCT06956885|DRUG|Discontibuation of oral ULT|Patients will stop the ULT at D0. They will have an US scan to look for urate deposits at each visit.
214538394|NCT06956885|DRUG|Maintenance of ULT|Patients will continue their ULT according to the recommendations of the Eular and French Society of Rheumatology, to maintain their SUA levels below 60 mg/l.
214538395|NCT06956820|DEVICE|Medication Management Center|The MMC that provides patient centred information on drug-drug interactions and pharmaco-genetics affecting personal polytherapy. The MMC will show a selection of high quality publicly available information such as details on different types of medications, including their uses, side effects and instructions for use, in the language of the patient. This information is targeted at an individual patient's medication profile to inform patients to better understand and deal with their personal health information, with regard to drug therapy. Patients in the Netherlands, Slovenia and Greece also will receive their PGx profile to further personalise the MMC experience.
214538396|NCT06956196|BIOLOGICAL|Stapokibatrt|Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)
214538397|NCT06956196|OTHER|Placebo|Placebo of matching volume，Subcutaneous injection(SC)
214538398|NCT06957470|PROCEDURE|Total Intravenous Anesthesia|It is a general anesthesia technique performed through a combination of intravenous agents administered intravenously by various methods.
214538399|NCT03479125|DIAGNOSTIC_TEST|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
214538400|NCT03447275|OTHER|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
214697082|NCT02230878|DRUG|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
214538401|NCT05119634|OTHER|whole body vibration training|participants will receive whole body vibration training 3 days in a week and for 8 weeks
214538402|NCT05119634|OTHER|home based exercises|participants will receive a home based exercise program for 8 weeks
214538403|NCT04363619|DIAGNOSTIC_TEST|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
215157007|NCT00792168|OTHER|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
214538404|NCT03099408|DRUG|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
214538405|NCT03099408|DRUG|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
214538406|NCT01045863|DRUG|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
214538407|NCT01045863|DRUG|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
214538408|NCT01045863|DRUG|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
215157008|NCT02968108|DRUG|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
215157009|NCT05575167|DRUG|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
214538409|NCT01045863|DRUG|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
214538410|NCT01045863|DRUG|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
214538411|NCT05397366|DIAGNOSTIC_TEST|Task Specific Training|"Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side."
214538412|NCT05397366|DIAGNOSTIC_TEST|Neurodevelopmental Training|"Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways."
214538413|NCT03046368|BEHAVIORAL|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
214538414|NCT00478647|BIOLOGICAL|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
214538415|NCT01741389|DRUG|"Melatonin (Circadin)"|
214538416|NCT05634798|OTHER|no intervention|There is no intervention in this study.
214538417|NCT06142981|BIOLOGICAL|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
214538418|NCT04378647|DRUG|Induction with Brentuximab vedotin (BV)|3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
214538419|NCT04378647|DRUG|Induction without Brentuximab Vedotin|3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
214538420|NCT04378647|DRUG|Consolidation with Brentuximab Vedotin|Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
214538421|NCT06546540|DRUG|Telitacicept|160mg，once weekly
214538422|NCT01452737|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
214538423|NCT01452737|DRUG|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
215157010|NCT06845501|DIETARY_SUPPLEMENT|purine-rich diet|diet to achieve a purine intake of 160mg/d
215157011|NCT04730271|DEVICE|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
215157012|NCT01890603|OTHER|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
215157013|NCT01890603|OTHER|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
215157014|NCT00891670|DRUG|cilostazol|100mg twice daily for at least 1 month
215157015|NCT00891670|DRUG|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
215157016|NCT00891670|DRUG|aspirin|aspirin 100mg
215157017|NCT05140720|BIOLOGICAL|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval \> 1 month Group 3: 2 doses, dose interval \> 2 months"
214697083|NCT02230878|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
214697084|NCT01602926|PROCEDURE|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
214697085|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
214697086|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
214697087|NCT03986008|DRUG|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
214697088|NCT03986008|DRUG|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
214697089|NCT04717193|DRUG|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
214697090|NCT04717193|PROCEDURE|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
214697091|NCT02638896|DRUG|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
214697092|NCT02638896|DRUG|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
214697093|NCT02638896|DRUG|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
214697094|NCT02638896|DRUG|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
214697095|NCT01161082|DRUG|REGN727(SAR236553)|subcutaneous
214697096|NCT02814864|DRUG|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
214697097|NCT02568345|DRUG|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
214697098|NCT03170479|DIETARY_SUPPLEMENT|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
215157018|NCT06531551|OTHER|The group to which Acupressure will be applied in each fraction|Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
215157019|NCT06371001|OTHER|disease|Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
215157020|NCT06053567|BEHAVIORAL|Aerobic Exercise|Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
215157021|NCT06053567|BEHAVIORAL|Counseling|Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
215157022|NCT06053567|DRUG|Nicotine patch|On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
215157023|NCT03564379|DRUG|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
215157024|NCT03564379|DRUG|Placebo|Matching placebo tablet will be administered orally.
215157025|NCT04954833|DEVICE|EMO-200|TEST Lens
215157026|NCT04954833|DEVICE|EMO-118|CONTROL Lens
215157027|NCT01487343|BEHAVIORAL|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
214538424|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
214538425|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
214538426|NCT03448705|BIOLOGICAL|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
214538427|NCT01522703|DRUG|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
214538428|NCT01522703|DRUG|Placebo|Alfalfa Sprouts
214538429|NCT02525081|DRUG|Ramipril (ACE-inhibitor)|up to 10 mg
214538430|NCT02525081|DRUG|placebo|up to 10 mg
214538431|NCT06957093|OTHER|artificial intelligence|The platform will also monitor the medical and lifestyle data of the patients every two weeks,offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform.
214538432|NCT06957093|OTHER|Routine diagnosis and treatment group for diabetes|There is no limit to the number of outpatient visits for the control group; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team (endocrinologist and nutritionist) objectively conducttheir diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.
214538433|NCT01755546|DRUG|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
214538434|NCT04127071|PROCEDURE|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
214538435|NCT04127071|PROCEDURE|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
214538436|NCT04820647|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
214538437|NCT00362375|BEHAVIORAL|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
214538438|NCT00362375|BEHAVIORAL|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
214538439|NCT06469567|OTHER|Patient Counselling|Doctor's counselling using Culturally-responsive pamphlet
214538440|NCT02083601|BEHAVIORAL|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
214538441|NCT02083601|BEHAVIORAL|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
214538442|NCT06956365|PROCEDURE|Group-C|100 iu carbetosin administered to carbetocin group
214538443|NCT06956365|PROCEDURE|Group-O|In cesarean surgery, 5 IU of oxytocin will be administered after the baby delivered.
214538444|NCT03902509|DRUG|Pirfenidone|pirfenidone capsule made in China
214538445|NCT03902509|DRUG|basic treatment|glucocorticoid and expectant treatment etc.
214538446|NCT06830772|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
214538447|NCT06830772|OTHER|Active comparator|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
214538448|NCT06956898|OTHER|Mindfulness Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
214538449|NCT06956898|OTHER|Haptonomy Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
214538450|NCT06735807|BEHAVIORAL|Generated AI-based intervention (Emohaa)|Participants will complete the intervention process by interacting with the Wechat applet. Participants will be required to complete a 6-week self-help therapy. Participants will be required to have a 30-minute dialogue including input and reflection time with Emohaa each week simultaneously with group ACT. Participants are free to dialogue with Emohaa for the rest of the week. An independent research assistant will monitor the intervention process from the platform. If the corresponding dialogue is not completed on time each week, the participant will be reminded via WeChat to complete this session before the start of the next session in the following week.
214538451|NCT06735807|BEHAVIORAL|group ACT|A 6-week group ACT intervention. Each group has 6-10 participants. Each session is one hour.
214538452|NCT06735807|BEHAVIORAL|wailist (delayed intervenion)|During the intervention period, participants in the WLG were only required to complete the appropriate assessments without receiving any intervention. Upon completion of the 15-day follow-up assessment, participants in the WLG could be free to choose to receive one of the two interventions. The intervention will be the same as the corresponding experimental group.
214538453|NCT06957184|PROCEDURE|bladder dissection in placenta accreta spectrum|"All caesarean sections will be performed by a surgeon who has experience in performing caesarean hysterectomy in both groups.~* Scrubbing the abdomen as usual.~* Subumblical midline skin incision versus Pfannenstiel incision will be chosen according to site of the placenta and previous surgeries.~* In group A careful bladder dissection will be done before uterine incision with ensuring hemostasis, uterine incision will be done above the placenta, after delivering the baby awaiting for placental separation if not proceeding for caesarean hysterectomy.~* In group B uterine incision will be done above the placenta and after delivering the baby awaiting for placental separation if not proceeding to caesarean hysterectomy and dissecting bladder just before clamping uterine artery."
214697099|NCT03170479|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
214697100|NCT00852189|DRUG|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
214697101|NCT00852189|DRUG|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
214697102|NCT00852189|DRUG|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
214697103|NCT03311399|OTHER|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
214697104|NCT03311399|OTHER|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
214697105|NCT02640144|DRUG|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
214697106|NCT02640144|DRUG|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
214697107|NCT00743457|DEVICE|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
214697108|NCT04273126|BEHAVIORAL|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
214697109|NCT01807195|OTHER|contrast medium usage|
214697110|NCT02871193|DRUG|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
214697111|NCT02871193|DRUG|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
215157028|NCT04108637|PROCEDURE|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
215157029|NCT03358524|DRUG|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
215157030|NCT03358524|DRUG|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
215157031|NCT00552435|DEVICE|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
215157032|NCT04243616|DRUG|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
214697112|NCT02871193|OTHER|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
214697113|NCT04031404|DEVICE|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
215157033|NCT04243616|DRUG|Paclitaxel|80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
215157034|NCT04243616|DRUG|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
214538454|NCT06399991|BEHAVIORAL|Champion strategy|The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
214538455|NCT06399991|BEHAVIORAL|Adapted LOCI leadership and climate alignment strategy plus champion strategy|The LOCI strategy involves engaging with district health leadership through data and feedback, leadership development trainings, coaching, and alignment strategy activities to align leadership and climate in support of implementing the evidence-based mental health package. The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
214538456|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
214538457|NCT05213429|OTHER|non interventional study|non interventional
214538458|NCT02948569|DRUG|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
214538459|NCT06328140|DRUG|Lurasidone|Daily medication treatment
214538460|NCT06328140|DRUG|FDA Approved antidepressant treatment|Daily treatment with an FDA approved antidepressant
214538461|NCT05145439|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
214538462|NCT04668365|DRUG|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
214538463|NCT04668365|DRUG|Zanubrutinib|160mg twice daily continuous oral administration.
214538464|NCT04668365|DRUG|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214538465|NCT04668365|DRUG|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214538466|NCT04668365|DRUG|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214538467|NCT04668365|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214538468|NCT01009762|BIOLOGICAL|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
214538469|NCT04294524|OTHER|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
214538470|NCT04695886|OTHER|Community-delivered Integrated Malaria Elimination (CIME) intervention model|"Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral."
214538471|NCT02995382|PROCEDURE|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
214538472|NCT02624869|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214538473|NCT06091839|OTHER|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
214538474|NCT05471804|DIETARY_SUPPLEMENT|Sceletium tortuosum|Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
214538475|NCT00974389|BIOLOGICAL|bevacizumab|
214538476|NCT00974389|DRUG|tegafur-gimeracil-oteracil potassium|
215157035|NCT04243616|DRUG|Doxorubicin|60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
215157036|NCT04243616|DRUG|Cyclophosphamide|600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
215157037|NCT00287378|DRUG|omalizumab|omalizumab as per weight and IgE
215157038|NCT05290285|DIETARY_SUPPLEMENT|Amino-Ther Pro|Food supplements
215157039|NCT05290285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215157040|NCT03008200|DEVICE|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
215157041|NCT03698097|OTHER|patient satisfaction survey|Patient survey completed in a paper or survey monkey based internet version accessible via a QR code or link
215157042|NCT02689440|DRUG|Dasatinib|Given PO
215157043|NCT02689440|OTHER|Laboratory Biomarker Analysis|Correlative studies
215157044|NCT02689440|DRUG|Venetoclax|Given PO
215157045|NCT03835949|DRUG|TJ004309|Antibody to CD73
215157046|NCT03835949|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
215157047|NCT01526304|OTHER|no intervention|No intervention, only observational study
214538477|NCT02813213|PROCEDURE|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
214538478|NCT02813213|PROCEDURE|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
214538479|NCT00632385|DRUG|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
214538480|NCT05707715|DEVICE|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
214538481|NCT06371469|BEHAVIORAL|PHeBAC|Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
214538482|NCT06371469|BEHAVIORAL|Control Group|Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
214538483|NCT03669198|DIAGNOSTIC_TEST|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
214538484|NCT02341586|OTHER|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
214538485|NCT02341586|DIETARY_SUPPLEMENT|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
214538486|NCT02341586|OTHER|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
214538487|NCT02603705|DRUG|Oxycodone extended-release|
214538488|NCT05282238|DIAGNOSTIC_TEST|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
215157048|NCT00782847|BEHAVIORAL|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
215157049|NCT05083117|DRUG|XW001|It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
215157050|NCT05083117|DRUG|Placebo|It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
215157051|NCT04885777|DRUG|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
215157052|NCT04885777|OTHER|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
214538489|NCT03376555|DIETARY_SUPPLEMENT|Low sodium no cheese|Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese 8 days
214538490|NCT03376555|DIETARY_SUPPLEMENT|Low sodium cheese|Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
214538491|NCT03376555|DIETARY_SUPPLEMENT|High sodium no cheese|Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese 8 days
214538492|NCT03376555|DIETARY_SUPPLEMENT|High sodium cheese|Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
214538493|NCT03660397|PROCEDURE|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
214538494|NCT03660397|DRUG|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
214538495|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
214538496|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
214538497|NCT05803083|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
214538498|NCT01435707|OTHER|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
214538499|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
214538500|NCT01435707|OTHER|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
214538501|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
214538502|NCT03801187|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
214538503|NCT03801187|PROCEDURE|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
214538504|NCT03801187|PROCEDURE|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
214538505|NCT03637647|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
214538506|NCT04867707|DRUG|Zanamivir|5 days of treatment with 10mg zanamivir inhaler BID
214538507|NCT02142634|DRUG|Budesonide granules 9 mg|per day
214538508|NCT02142634|DRUG|Placebo granules|per day
214538509|NCT05231278|DEVICE|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
214538510|NCT05305677|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
214538511|NCT05305677|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
214538512|NCT05815823|OTHER|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
214538513|NCT05815823|OTHER|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
214538514|NCT00163007|PROCEDURE|Nutritional support|
214538515|NCT00812721|OTHER|Preservative Free Saline|One drop will be instilled into each eye once
214538516|NCT00812721|OTHER|Optive|One drop will be instilled into each eye once
214538517|NCT00812721|OTHER|Refresh Moderate/Severe|One drop will be instilled into each eye once
214538518|NCT00812721|OTHER|Systane|One drop will be instilled into each eye once
214538519|NCT00812721|OTHER|Systane Ultra|One drop will be instilled into each eye once
214538520|NCT03917537|GENETIC|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
214538521|NCT00514800|BEHAVIORAL|Intervention - a validated home BP monitor and support from the specialist nurse|
214538522|NCT00514800|BEHAVIORAL|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
214538523|NCT04797598|OTHER|Virtual reality group|This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment
214538524|NCT04797598|OTHER|Cyclic training group|This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
214538525|NCT03596242|OTHER|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
214538526|NCT03596242|BEHAVIORAL|blood pressure control education|standard blood pressure control education given during visits
214538527|NCT06788691|DRUG|Luspatercept|Administered at 1 mg/kg once every 3 weeks
214538528|NCT02509312|DRUG|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
214538529|NCT02509312|DRUG|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
214538530|NCT03616860|DEVICE|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
214538531|NCT01705405|DEVICE|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
214538532|NCT00969969|DEVICE|Arthrodesis|arthrodesis using screws and/or a plate
214538533|NCT00969969|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
214538534|NCT06114485|BEHAVIORAL|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
214538535|NCT06114485|BEHAVIORAL|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
214538536|NCT03373851|DEVICE|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
214538537|NCT04441827|OTHER|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
214538538|NCT04184349|DRUG|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
214538539|NCT04184349|DRUG|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
214538540|NCT04051242|DEVICE|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
214538541|NCT00000770|DRUG|Nevirapine|
214538542|NCT00000770|DRUG|Zidovudine|
214538543|NCT00000770|DRUG|Didanosine|
214538544|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
214538545|NCT06315426|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
214538546|NCT06315426|BIOLOGICAL|Placebo|Placebo
214538547|NCT05259358|OTHER|exercise|exercises that increase muscular endurance
214538548|NCT01522677|DRUG|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
214538549|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
214538550|NCT00093132|DRUG|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
214538551|NCT00611299|DIETARY_SUPPLEMENT|BB-12 and CRL 431|
214538552|NCT05371145|BIOLOGICAL|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
214538553|NCT04716218|PROCEDURE|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
214538554|NCT00704171|PROCEDURE|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
214538555|NCT00704171|DEVICE|PleuraSeal Lung Sealant System|
214538556|NCT06386445|OTHER|Serum metabolomics sequencing|Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
214538557|NCT00237354|DRUG|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
214538558|NCT01874665|DRUG|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
214538559|NCT05763654|DEVICE|Linovera emulsion|Apply Linovera emulsion in clinical routine
214538560|NCT03277885|OTHER|chronic pain|work related chronic pain
214538561|NCT00078728|BEHAVIORAL|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
214538562|NCT00078728|BEHAVIORAL|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
214538563|NCT06133868|DRUG|Lavender and Chamomile Essential Oils|essential oils
214538564|NCT02780102|OTHER|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
214538565|NCT02780102|DRUG|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
214538566|NCT02780102|OTHER|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
214538567|NCT03463434|DEVICE|Air Fluidized Therapy|AFT bed used for pressure injury treatment
214538568|NCT03463434|DEVICE|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
215157053|NCT03746119|OTHER|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
215157054|NCT03746119|OTHER|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
214538569|NCT02471482|OTHER|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
214538570|NCT05238363|DRUG|HLX07|HLX07 1500mg ivgtt Q3W
214538571|NCT05225207|OTHER|Non-interventional|No intervention will be administered.
214538572|NCT04269434|OTHER|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
214538573|NCT05098691|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
214538574|NCT03548493|DRUG|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
214538575|NCT03548493|DRUG|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
214538576|NCT03548493|DRUG|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
214538577|NCT01685125|DRUG|abiraterone acetate|Given PO
215157055|NCT03372681|PROCEDURE|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
214538578|NCT01685125|DRUG|dasatinib|Given PO
215157056|NCT03372681|PROCEDURE|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
215157057|NCT03655249|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
215157058|NCT03655249|DRUG|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
215157059|NCT02023697|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
215157060|NCT00845897|DRUG|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
215157061|NCT00845897|DRUG|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
215157062|NCT05569070|OTHER|Guided Young United Parents! Website Intervention|Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.
215157063|NCT05569070|OTHER|Nutrition Website|Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
215157064|NCT00629889|DRUG|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
215157065|NCT00629889|DRUG|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
215157066|NCT03904693|DRUG|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
215157067|NCT03904693|DRUG|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
215157068|NCT03904693|DRUG|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
215157069|NCT03904693|DRUG|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
215157070|NCT03904693|DRUG|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
215157071|NCT03904693|DRUG|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
215157072|NCT00887211|DEVICE|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
215157073|NCT00887211|DEVICE|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
215157074|NCT04593537|OTHER|No intervention|This is an observational study, no intervention is involved
215157075|NCT04752904|DEVICE|ClearSight System|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem
214538579|NCT01685125|DRUG|prednisone|Given PO
214538580|NCT04485754|OTHER|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
214538581|NCT04485754|OTHER|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
214538582|NCT00277199|DRUG|Abatacept|
214538583|NCT04962698|BEHAVIORAL|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
214538584|NCT04962698|BEHAVIORAL|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
214538585|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
214538586|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
214538587|NCT04962698|BEHAVIORAL|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
214538588|NCT04962698|BEHAVIORAL|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
214538589|NCT04962698|BEHAVIORAL|Rest|Subjects will rest without a task.
214538590|NCT02906280|DEVICE|EBUS-TBNA needle|tissue sampling
214538591|NCT00165334|DRUG|Cetuximab|
214538592|NCT00165334|DRUG|Vinorelbine (Navelbine)|
214697114|NCT04826458|DEVICE|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
215157076|NCT01809743|DRUG|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
215157077|NCT01809743|DRUG|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
215157078|NCT01809743|DRUG|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
214538593|NCT00853229|DRUG|pregabalin|pregabalin 150mg twice daily for 4 weeks
214538594|NCT00264563|BEHAVIORAL|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
214538595|NCT00264563|BEHAVIORAL|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
214538596|NCT00429442|DRUG|Simvastatin|80 mg once daily
214538597|NCT00429442|DRUG|placebo|calcium tablets once daily
214538598|NCT04477993|DRUG|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
214538599|NCT04477993|OTHER|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
214697115|NCT04826458|OTHER|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
214697116|NCT03768531|DRUG|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
214697117|NCT03768531|DRUG|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
215157079|NCT01809743|DRUG|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
215157080|NCT01809743|DRUG|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
215157081|NCT00060619|BEHAVIORAL|thermal biofeedback|
215157082|NCT00060619|BEHAVIORAL|relaxation training|
214538600|NCT01006499|DRUG|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
214538601|NCT01700322|PROCEDURE|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
214538602|NCT01700322|DRUG|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
214538603|NCT01700322|DRUG|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
214538604|NCT01700322|DRUG|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
214538605|NCT02361398|OTHER|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
215157083|NCT00060619|BEHAVIORAL|cognitive coping skills|
215157084|NCT00060619|BEHAVIORAL|parent education|
215157085|NCT00068419|DRUG|tamoxifen citrate|Given orally
215157086|NCT00068419|DRUG|sulindac|Given orally
215157087|NCT00068419|OTHER|laboratory biomarker analysis|Correlative studies
215157088|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
214538606|NCT02208037|DRUG|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
214697118|NCT04850716|OTHER|non-intervention|non-intervention
214697119|NCT01626352|DRUG|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
214697120|NCT01626352|DRUG|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
214697121|NCT02797704|DRUG|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
214697122|NCT02150473|DRUG|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
214697123|NCT02150473|DRUG|Placebo|Placebo the same amount as adalimumab
214538607|NCT02208037|DRUG|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
214538608|NCT02208037|DRUG|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
214538609|NCT02208037|DRUG|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
214538610|NCT02208037|DRUG|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
214538611|NCT02208037|DRUG|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
214538612|NCT02208037|DRUG|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
214538613|NCT02208037|DRUG|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
214538614|NCT03201900|DRUG|E2007|Oral tablet
214538615|NCT04752033|DRUG|Morphine|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
214538616|NCT04752033|DRUG|Hydromorphone|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
214538617|NCT02790775|DRUG|Anti-VEGF in quadrant 1|
214538618|NCT02790775|DRUG|Anti-VEGF in quadrant 2|
214538619|NCT02790775|DRUG|Anti-VEGF in quadrant 3|
214538620|NCT02790775|DRUG|Anti-VEGF in quadrant 4|
214538621|NCT05352971|OTHER|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
214538622|NCT05953831|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
214538623|NCT05953831|DRUG|Placebo|Placebo to CDR132L
214538624|NCT02673554|DRUG|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
214538625|NCT02673554|DRUG|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
214538626|NCT02673554|PROCEDURE|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
214538627|NCT02673554|PROCEDURE|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
214538628|NCT01043445|DIETARY_SUPPLEMENT|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
214538629|NCT01043445|DIETARY_SUPPLEMENT|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
214538630|NCT01043445|DIETARY_SUPPLEMENT|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
214697124|NCT01064193|PROCEDURE|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative."
214697125|NCT01064193|PROCEDURE|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
214697126|NCT02673892|OTHER|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
214697127|NCT01734486|DRUG|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
214697128|NCT01734486|DRUG|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
214697129|NCT06196957|COMBINATION_PRODUCT|pursed lip breathing|pursed lip breathing
215157089|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
215157090|NCT00973232|DRUG|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
215157091|NCT00973232|DRUG|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
215157092|NCT00973232|DRUG|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
215157093|NCT00973232|DRUG|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
214538631|NCT05326698|PROCEDURE|Medtronic NIM Eclipse for evoked potentials recording|Recording of somesthetic and motor evoked potentials during endoscopic posterior cervical foraminotomy.
214538632|NCT03634306|DEVICE|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
214538633|NCT03634306|PROCEDURE|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
214697130|NCT00052884|BIOLOGICAL|filgrastim|
214697131|NCT00052884|DRUG|amifostine trihydrate|
214697132|NCT00052884|DRUG|melphalan|
214697133|NCT00052884|PROCEDURE|bone marrow ablation with stem cell support|
214697134|NCT00052884|PROCEDURE|peripheral blood stem cell transplantation|
214697135|NCT02796391|DRUG|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
214697136|NCT02796391|BEHAVIORAL|One on One Counseling|All participants will receive One on One Counseling.
214697137|NCT01427283|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
214697138|NCT01427283|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
214697139|NCT01427283|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
215157094|NCT00973232|DRUG|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
215157095|NCT04674761|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
215157096|NCT04674761|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
214538634|NCT00375765|DRUG|Dutasteride|
214538635|NCT00776659|OTHER|Aromasin|Non-Interventional study design.
214697140|NCT05674344|DEVICE|Masimo Temperature device|Non-invasive temperature device
214697141|NCT00798655|DRUG|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
214697142|NCT00798655|DRUG|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
214538636|NCT04185987|OTHER|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
214697143|NCT00798655|RADIATION|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
214697144|NCT03119844|OTHER|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
214538637|NCT04185987|OTHER|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
214538638|NCT04185987|OTHER|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
214697145|NCT03119844|OTHER|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
215157097|NCT05283772|BEHAVIORAL|Development of eye tracker for simulation training in nursing|"Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks."
215157098|NCT04466670|DRUG|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
215157099|NCT04466670|DRUG|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
215157100|NCT02354430|BEHAVIORAL|Water-exercise|"1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises."
214538639|NCT04185987|OTHER|AO twisted ended ligature wire|AO twisted ended ligature wire application
214538640|NCT02909309|DEVICE|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
214538641|NCT01292577|BEHAVIORAL|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
214538642|NCT01292577|BEHAVIORAL|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
214538643|NCT00119938|BEHAVIORAL|Access to online patient portal|
214538644|NCT03104283|DRUG|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
214538645|NCT04889859|PROCEDURE|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
214538646|NCT04889859|PROCEDURE|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
214538647|NCT05498454|BEHAVIORAL|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
214538648|NCT05090605|GENETIC|DNA analysis|GWAS
214538649|NCT00995384|PROCEDURE|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
214538650|NCT04863820|DIAGNOSTIC_TEST|cutaneous silent period|form of Nerve conduction studies
214697146|NCT03119844|OTHER|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
214538651|NCT01339962|OTHER|Non-interventional|Non-interventional (retrospective chart reviews)
214538652|NCT01667172|DEVICE|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
214538653|NCT01903369|DEVICE|Shear Wave Elastography|Shear wave elastography
214697147|NCT03754062|DRUG|Placebo - Cap|Administration of Placebo by pill.
214697148|NCT03754062|DRUG|L-dopa|Administration of L-dopa by pill.
214538654|NCT02192723|DRUG|Typical antipsychotic|Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
214538655|NCT02192723|DRUG|Risperidone|2\~6mg/day, twice per day, 8 weeks
214538656|NCT02192723|DRUG|Olanzapine|Olanzapine, 400\~750mg/day, twice per day, 8 weeks
214538657|NCT02192723|DRUG|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
214538658|NCT02192723|DEVICE|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
214538659|NCT02192723|DRUG|Ziprasidone|Ziprasidone 80\~160mg/day, twice per day, 8 weeks
214538660|NCT06287086|DRUG|BRL-101 autologous hematopoietic stem and progenitor cells injection|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
214538661|NCT03789812|DEVICE|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
214697149|NCT03754062|DRUG|Haloperidol|Administration of Haloperidol by pill.
214697150|NCT03720821|BEHAVIORAL|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
214538662|NCT03789812|DEVICE|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
214538663|NCT03789812|DEVICE|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
214538664|NCT03789812|DEVICE|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
214538665|NCT06392893|COMBINATION_PRODUCT|Meat product without additives and allergens|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of meat products without additives and allergens (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
214538666|NCT06392893|COMBINATION_PRODUCT|Commercial meat product|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of commercial meat products (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
214538667|NCT03184506|OTHER|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
214538668|NCT03184506|OTHER|no warming|patients were covered only with two layers of cotton blanket
214538669|NCT03247738|DRUG|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
214538670|NCT03247738|OTHER|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
214538671|NCT03613324|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
214538672|NCT02314104|DRUG|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
214538673|NCT03569605|BEHAVIORAL|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
214538674|NCT03569605|BEHAVIORAL|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
215157101|NCT06327880|DRUG|PF-07054894 or placebo|multiple oral doses of PF-07054894 for 14 days
215157102|NCT01809119|PROCEDURE|Partial nephrectomy|
215157103|NCT02773576|DRUG|Risperidone implant|
214538675|NCT06499688|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214538676|NCT06499688|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214697151|NCT00960934|DRUG|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
215157104|NCT01804127|DRUG|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
215157105|NCT01237197|DRUG|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
215157106|NCT01237197|DRUG|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
215157107|NCT02374749|BEHAVIORAL|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
214538677|NCT06499688|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214538678|NCT02670499|DEVICE|CPM|Used to aid in recovery from TKR
214538679|NCT02670499|DEVICE|GAPFLEX|Used to aid in the recovery of TKR
214538680|NCT04875897|DEVICE|keepMED PAP device|The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).
214538681|NCT02080377|DRUG|Glibenclamide|
214538682|NCT02080377|DRUG|Insulin|
215157108|NCT02374749|BEHAVIORAL|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
214538683|NCT04540562|OTHER|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
214538684|NCT06015906|DEVICE|Plenum® Guide|Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.
214538685|NCT06015906|DEVICE|Plenum® Oss|Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.
214538686|NCT06015906|PROCEDURE|Tooth extraction|Tooth extraction and subsequent surgical procedure of guided bone regeneration.
214538687|NCT03632005|DEVICE|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
214538688|NCT03632005|OTHER|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
214538689|NCT01743105|PROCEDURE|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
214538690|NCT01743105|PROCEDURE|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
214538691|NCT03961997|DRUG|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
214538692|NCT03961997|DRUG|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
214538693|NCT03961997|DRUG|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
214538694|NCT05477303|OTHER|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
214538695|NCT05073549|BEHAVIORAL|Collaborative Antimicrobial Stewardship Program (ASP)|"The collaborative ASP interventions will be implemented from October 1st, 2021 to September 30th, 2023 in all participating NICUs.~The collaborative ASP interventions include two levels of interventions that will be delivered at the NICU level: the NICU-targeted ASP program and collaborative quality improvement interventions to facilitate implementation of the ASP.~The core elements of the NICU-targeted ASP program include the establishment of ú ASP leader and team, development of the facility-specific antibiotic guidelines, checklist-led audit and feedback, and staff education.~The collaborative quality improvement interventions include data feedback and benchmarking, a potential 'better practice' list on neonatal antibiotic use, implementation using Plan-Do-Study-Act cycles and collaborative learning."
214538696|NCT04811898|BIOLOGICAL|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
214538697|NCT04312412|PROCEDURE|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
214538698|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
214538699|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
214538700|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
214538701|NCT01582503|DRUG|placebo|Subcutaneous repeating dose
214538702|NCT03530462|DRUG|rituximab|375 mg/m2 weekly for 4 weeks
214538703|NCT03530462|DRUG|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
214538704|NCT03530462|DRUG|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
214538705|NCT03530462|DRUG|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
214538706|NCT05566392|DIAGNOSTIC_TEST|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
214538707|NCT02835092|OTHER|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
214538708|NCT02835092|OTHER|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
214538709|NCT02835092|OTHER|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
214538710|NCT05840562|DRUG|Capsaicin|Application of capsaicin patches 179 mg
214538711|NCT05840562|DRUG|Duloxetine|Administration of duloxetine
214538712|NCT03630263|OTHER|Raw Corn Starch|Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
214697152|NCT00960934|DRUG|Placebo|Dose-matched oral placebo to MK-5442
214538713|NCT03630263|OTHER|No Raw Corn Starch|200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
214538714|NCT05383625|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
214538715|NCT05383625|DRUG|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
214538716|NCT05383625|DRUG|Saline|intralesional into the largest warts every two weeks
214538717|NCT00047749|DRUG|Prialt (ziconotide)|
214538718|NCT04805047|BEHAVIORAL|education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
214538719|NCT03197077|PROCEDURE|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
214538720|NCT03197077|PROCEDURE|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
214538721|NCT03197077|PROCEDURE|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
214538722|NCT03197077|DRUG|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
214538723|NCT03197077|DRUG|Follitropin beta|Daily injection (three days) of follitropin beta
214538724|NCT03197077|DRUG|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
214538725|NCT02767609|DEVICE|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
214538726|NCT05603065|DRUG|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m\^2D1 + paclitaxel 150mg/m\^2D1 Q3W 3 cycles
214538727|NCT05603065|DRUG|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
214538728|NCT00025506|OTHER|Laboratory Biomarker Analysis|Correlative studies
214538729|NCT00025506|DRUG|Thalidomide|Given orally
214538730|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
214538731|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
214538732|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
214538733|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
214538734|NCT01321723|DRUG|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
214538735|NCT01321723|DRUG|Placebo|
214538736|NCT01321723|DRUG|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
214538737|NCT02250690|DEVICE|experimental group - tDCS|
214538738|NCT02250690|DEVICE|Control group (tDCS sham)|
214538739|NCT05223972|OTHER|Schroth Treatment|Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise
214538740|NCT05623371|BEHAVIORAL|Training leaders in leading well-being and the psychosocial working environment|"The intervention comprises five training modules with practice in small groups in between. Training will take place over 5 months. The training will be received in groups of 20 and the training will be facilitated by 2 facilitators. Central themes of the training are:~1. Self-care and well-being of the manager and how to cope with stress as a manager.~2. Employee well-being and reducing risk-factors in the psychosocial working environment of employee mental health problems~3. Enhancing protective factors social social support and a healthy team climate~4. Responding to employees at risk and how to handle difficult conversations and procedures on return to work~5. Managing well-being in employees during organizational change and final reflections~The training will comprise video material and in person training of competencies and behaviors in group settings.~The waitlist control group will receive an offer of a webinar and written information."
214538741|NCT05623371|BEHAVIORAL|The offer of a webinar and written material|The offer of a webinar plus written material
214538742|NCT04310683|OTHER|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
214538743|NCT04310683|OTHER|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
215157109|NCT01160822|BIOLOGICAL|Canakinumab|Intra-articular injection
214538744|NCT03331926|DRUG|Xiapex|Follow-up of effect of treatment
214538745|NCT02011217|OTHER|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
214538746|NCT02011217|OTHER|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
214538747|NCT02011217|OTHER|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
214697153|NCT00960934|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
215157110|NCT01160822|DRUG|Placebo to canakinumab|Intra-articular injection
215157111|NCT01160822|DRUG|Naproxen|Tablets for oral administration
215157112|NCT01160822|DRUG|Placebo to Naproxen|Tablets for oral administration
215157113|NCT04772560|DEVICE|Precision1 for Astigmatism|Daily disposable soft toric contact lens
215157114|NCT04772560|DEVICE|Precision1 Sphere|Daily disposable soft spherical contact lens
214538748|NCT02947841|OTHER|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
214538749|NCT02947841|OTHER|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
214538750|NCT03551431|DIAGNOSTIC_TEST|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
215157115|NCT01439828|DRUG|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
215157116|NCT00000596|DRUG|prednisone|
215157117|NCT00000596|DRUG|cyclophosphamide|
215157118|NCT00000596|DRUG|dapsone|
214538751|NCT00713206|DEVICE|Dental Implant (Osseotite)|Root form titanium dental implant
214538752|NCT00276666|DRUG|cisplatin|
214538753|NCT00276666|DRUG|lomustine|
215157119|NCT03692104|DIAGNOSTIC_TEST|transrectal ultrasound|Use of US for post implant quality assessment
215157120|NCT00707941|DRUG|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
215157121|NCT00707941|DRUG|Placebo|"Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
215157122|NCT00314795|DRUG|Peginesatide|Peginesatide injection
214538754|NCT00276666|DRUG|vincristine sulfate|
214538755|NCT00276666|PROCEDURE|adjuvant therapy|
214538756|NCT00276666|RADIATION|radiation therapy|
214538757|NCT05623813|OTHER|Postoperative education|provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
214538758|NCT05336617|PROCEDURE|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
214538759|NCT01838486|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
214538760|NCT00347399|DRUG|bevacizumab intravitreal injection|
214538761|NCT00347399|PROCEDURE|verteporfin photodynamic therapy|
214538762|NCT05158023|DRUG|Placebo Comparator|Sterile solution for subcutaneous injection
214538763|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
214538764|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
214538765|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
214538766|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
214538767|NCT02737111|BEHAVIORAL|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
214538768|NCT02737111|BEHAVIORAL|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
214538769|NCT02737111|BEHAVIORAL|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
214538770|NCT02737111|BEHAVIORAL|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
214697154|NCT00960934|DIETARY_SUPPLEMENT|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
214697155|NCT03639012|DIETARY_SUPPLEMENT|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
215157123|NCT03871218|BIOLOGICAL|Hyaluronic acid group|Applicaton of topical Hyaluronic acid
215157124|NCT01493167|OTHER|limb casting/splinting|ankle and arm cast
215157125|NCT04717336|OTHER|Sodium Chloride|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
215157126|NCT04717336|OTHER|Placebo|placebo capsules
215157127|NCT03200080|DRUG|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
215157128|NCT03200080|DRUG|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
215157129|NCT03200080|DRUG|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
215157130|NCT03200080|DRUG|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
215157131|NCT04053803|DRUG|IMR-687|Oral administration of once daily IMR-687
215157132|NCT04497623|DEVICE|Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours|Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
215157133|NCT00209612|DRUG|Taxol|Day1,15 X mg/m2, IV (in the vein)
215157134|NCT00209612|DRUG|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
215157135|NCT06804005|BEHAVIORAL|Music group|Music will be sung continuously in an area equipped with a sound system so that subjects can listen comfortably without headphones, and will be performed with the participation of students and peer support. Each intervention activity will last approximately 60 minutes.
215157136|NCT06804005|BEHAVIORAL|mandala group|In the mandala coloring activity, they will be asked to choose the picture they want from the mandala coloring booklets and color it however they want. This activity will take approximately 60 minutes.
215157137|NCT01500720|DRUG|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
215157138|NCT01500720|DRUG|Topotecan|Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
215157139|NCT06044077|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
215157140|NCT06044077|BIOLOGICAL|control pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp
215157141|NCT02439437|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
215157142|NCT02624986|DRUG|Idasanutlin|Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
215157143|NCT02624986|DRUG|Obinutuzumab|Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
215157144|NCT02624986|DRUG|Rituximab|Participants received a fixed dose of rituximab, 375 mg/m\^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m\^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
215157145|NCT02527421|DRUG|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
215157146|NCT05624970|BEHAVIORAL|aerobic training , tobacco cessation and nutritional advices|"1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months"
214697156|NCT03721393|DEVICE|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
214697157|NCT01844622|OTHER|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
214538771|NCT02737111|BEHAVIORAL|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
214697158|NCT05004142|DRUG|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
215157147|NCT05624970|BEHAVIORAL|tobacco cessation and nutritional advices|Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
214538772|NCT02901236|PROCEDURE|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
214538773|NCT02901236|DRUG|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
214538774|NCT02901236|DRUG|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
214538775|NCT02561806|DRUG|Ixekizumab|Administered SC
214538776|NCT02561806|DRUG|Ustekinumab|Administered SC
214538777|NCT02561806|DRUG|Placebo|Administered SC
214538778|NCT04055415|BIOLOGICAL|adipose derived mesenchymal stem cells|The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
214538779|NCT04055415|DRUG|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
214538780|NCT05075512|DRUG|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
214538781|NCT03516045|DRUG|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
214538782|NCT06040047|OTHER|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
214538783|NCT06040047|OTHER|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
214538784|NCT06311643|OTHER|Postpartum back massage in study group|Effleurage massage from shoulders toward lower back
214538785|NCT02062112|OTHER|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
214538786|NCT05887141|BEHAVIORAL|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
214538787|NCT05887141|BEHAVIORAL|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
214697159|NCT05004142|DRUG|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
214697160|NCT01000779|DRUG|Propranolol|upto 320mg/day maximum
215157148|NCT02281513|OTHER|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
215157149|NCT02281513|OTHER|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
215157150|NCT02281513|OTHER|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
215157151|NCT01879358|DEVICE|Drug-eluting stent|
215157152|NCT02116205|BIOLOGICAL|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
214697161|NCT01000779|DEVICE|multi band ligator for esophageal varices|to obliterate esophageal varices
214697162|NCT05852678|OTHER|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
214697163|NCT00839878|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
215157153|NCT02116205|BIOLOGICAL|Placebo|0.9% sodium chloride
214538788|NCT04314388|OTHER|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
214538789|NCT04314388|OTHER|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
214538790|NCT00458146|DRUG|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
214538791|NCT05765747|DRUG|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
214538792|NCT05765747|DRUG|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
214538793|NCT01427049|DEVICE|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
214538794|NCT00941642|DRUG|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
214538795|NCT00941642|DRUG|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
214538796|NCT04038749|DRUG|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
214538797|NCT04038749|DRUG|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
214538798|NCT04038749|OTHER|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
214538799|NCT03449862|OTHER|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
214538800|NCT02547441|DRUG|CLS001 (Omiganan)|Topical gel
214538801|NCT02547441|DRUG|Vehicle|Vehicle Gel
214538802|NCT04128800|DRUG|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
214538803|NCT01859611|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
214538804|NCT02671214|OTHER|Control|100 g high fibre flour
214538805|NCT02671214|OTHER|Active 2|98 g high fibre flour + 2 g guar gum
214538806|NCT02671214|OTHER|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
214538807|NCT02671214|OTHER|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
214538808|NCT02671214|OTHER|Active 5|96 g high fibre flour + 4 g guar gum
214538809|NCT02671214|OTHER|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
214538810|NCT02671214|OTHER|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
214538811|NCT02671214|OTHER|Active 8|94 g high fibre flour + 6 g guar gum
214538812|NCT02671214|OTHER|Active 9|98 g high fibre flour + 2 g konjac mannan
214538813|NCT02671214|OTHER|Active 10|96 g high fibre flour + 4 g konjac mannan
214538814|NCT02671214|OTHER|Active 11|100 g low fibre flour
214538815|NCT02671214|OTHER|Active 1|85 g high fibre flour + 15 g legume flour
215157154|NCT02116205|DEVICE|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
214538816|NCT01322009|DRUG|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
214538817|NCT01322009|DRUG|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
214538818|NCT00229710|DRUG|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
214538819|NCT04169451|DRUG|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
214538820|NCT01657877|DRUG|Calcium sodium phosphosilicate|CSP high percentage weight by weight
214538821|NCT01657877|DRUG|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
214538822|NCT01657877|DRUG|Placebo|No CSP and no fluoride
214538823|NCT05573100|DRUG|CU06-1004|CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
214538824|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
214538825|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
214697164|NCT02156492|DRUG|Evacetrapib|Administered orally.
214697165|NCT02156492|DRUG|Simvastatin|Administered orally.
214697166|NCT02156492|DRUG|Atorvastatin|Administered orally.
214697167|NCT04010890|BEHAVIORAL|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
214538826|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
215157155|NCT02447523|PROCEDURE|Elective abdominal surgery|
215157156|NCT05557188|OTHER|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
215157157|NCT05557188|OTHER|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
214538827|NCT01241006|DRUG|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
214538828|NCT01241006|DRUG|Prednisone|Prednisone 60mg PO q day for 5 days
214538829|NCT03818243|BEHAVIORAL|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
215157158|NCT00569959|OTHER|fasting 12+ hours|fasting 12+ hours
215157159|NCT00569959|OTHER|Non-fasting|Non-fasting
215157160|NCT05700019|BEHAVIORAL|Pinkwashed Advertisements|Real advertisements from alcoholic beverage companies' social media accounts that contain messaging or other features that associate the alcohol company with breast cancer awareness or research.
215157161|NCT05700019|BEHAVIORAL|Control - Standard Advertisements|Real advertisements from the same alcoholic beverage companies' social media accounts that do not contain messaging or other features associated with breast cancer awareness or research.
215157162|NCT05006638|DRUG|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
215157163|NCT05006638|DRUG|Atropine|a drug used as an antidote for some types of pesticides
215157164|NCT05006638|DRUG|Toxogonin|a drug used as an antidote for some types of pesticides
215157165|NCT05006638|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
215157166|NCT02219425|PROCEDURE|endometrial biopsy|
215157167|NCT02541604|DRUG|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
215157168|NCT05819801|OTHER|Non-fasting|Instructing patients to eat before their local-only procedure
215157169|NCT05819801|OTHER|Fasting|Instructing patients to fast before their local-only procedure
215157170|NCT05342883|DEVICE|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
215157171|NCT02568267|DRUG|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
215157172|NCT04194437|DEVICE|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
215157173|NCT04920578|DRUG|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
215157174|NCT04920578|OTHER|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
215157175|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
214538830|NCT00830609|DRUG|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)
214538831|NCT00830609|DRUG|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks
214538832|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 24 weeks
214538833|NCT00830609|DRUG|ribavirin|ribavirin 800 mg/day for 24 weeks
215157176|NCT04232228|OTHER|No intervention|No intervention was used in this study.
215157177|NCT00930033|PROCEDURE|Nephrectomy|Current surgery
215157178|NCT00930033|OTHER|Sunitinib alone|Sunitinib alone without nephrectomy
215157179|NCT05023486|DRUG|NP-G2-044 Monotherapy|1600 mg QD, 2000mg QD, and 2100 mg QD
215157180|NCT05023486|DRUG|Anti-PD-1 Therapy|previously initiated per standard of care, at a dose and frequency in accordance with the package insert
215157181|NCT05023486|DRUG|NP-G2-044 Combination therapy|1600 mg QD or 2100 mg QD
215157182|NCT04033497|DEVICE|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
214538834|NCT00830609|DRUG|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
214697168|NCT05254613|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
214538835|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
214538836|NCT02108626|DRUG|Nicotine|E-Cigarette with nicotine cartridge
214538837|NCT02108626|DRUG|Placebo|E-Cigarette with 0mg nicotine cartridge
214538838|NCT02025855|DRUG|Methadone|
214538839|NCT02025855|DRUG|Placebo|
214538840|NCT04777825|OTHER|Heart rate variability biofeedback training (Symbiocenter)|12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training
214538841|NCT04777825|OTHER|psychoeducation session|Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
214538842|NCT01388062|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
214538843|NCT01189422|DRUG|teplizumab or placebo|infusion or injection
214538844|NCT00992719|BIOLOGICAL|Inactivated H1N1 Vaccine|H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
214538845|NCT02872311|BIOLOGICAL|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
214538846|NCT02872311|BIOLOGICAL|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
214538847|NCT02872311|BIOLOGICAL|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
214538848|NCT02872311|BIOLOGICAL|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
214697169|NCT05254613|DRUG|Placebo|Placebo will be administered as SC infusion(s).
214697170|NCT03248245|OTHER|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
214697171|NCT03248245|OTHER|TAU|Ordinary practices related to interprofessional team collaboration
214697172|NCT06371651|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing creatine and guanidinoacetic acid
214697173|NCT06371651|DIETARY_SUPPLEMENT|Placebo|Inert substance
214697174|NCT02413619|PROCEDURE|Vitrectomy|Vitrectomy
214697175|NCT02413619|PROCEDURE|Cataract surgery|Cataract surgery
214697176|NCT02413619|PROCEDURE|Combined surgery|Combined vitrectomy and cataract surgery at the same time
214538849|NCT04721288|OTHER|Active communication through Reboot application|Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
214538850|NCT04721288|OTHER|Generic communication through Reboot application|Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
214538851|NCT05903677|OTHER|magnesium levels|Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
214538852|NCT04241783|OTHER|descriptive|correlation
214538853|NCT04161547|DRUG|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
214697177|NCT05524870|OTHER|Mobilization|Movement with mobilization plus exercise
214697178|NCT04903184|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
214697179|NCT04903184|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
214697180|NCT05835245|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
214697181|NCT05835245|DRUG|Sintilimab|a PD-1 immune check inhibitor
214697182|NCT05835245|DRUG|Lenvatinib|Lenvatinib capsules
214697183|NCT02387372|DRUG|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
214697184|NCT02387372|DRUG|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
214697185|NCT01434641|OTHER|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
215157183|NCT05754281|DEVICE|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
215157184|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
215157185|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
215157186|NCT05579847|OTHER|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
215157187|NCT05579847|BEHAVIORAL|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
215157188|NCT05579847|BEHAVIORAL|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
215157189|NCT05579847|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
215157190|NCT05579847|BEHAVIORAL|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
215157191|NCT03000660|DRUG|Venetoclax|Venetoclax at one of four escalating doses
215157192|NCT03000660|DRUG|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
215157193|NCT05091372|DRUG|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
215157194|NCT05091372|DRUG|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
215157195|NCT06655779|DIAGNOSTIC_TEST|Acoustic Detection of Blood Flow|Subject will have the acoustic device scoring performed prior to a Coronary CTA. No treatment decisions will be based upon the acoustic device score.
215157196|NCT06655662|OTHER|β-globin restored autologous hematopoietic stem cells|Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
214538854|NCT04161547|DRUG|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
214538855|NCT04161547|DRUG|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
214538856|NCT04161547|DRUG|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
214538857|NCT03904875|OTHER|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
214538858|NCT06478810|OTHER|Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy|For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
214538859|NCT00257764|BEHAVIORAL|behavioral swallowing exercises/ strategies|
214538860|NCT00383864|DRUG|Pegylated interferon and ribavirin|
214538861|NCT04620031|DRUG|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
214538862|NCT04620031|DRUG|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
214538863|NCT02186314|DEVICE|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
215157203|NCT00427765|DRUG|Busulfan|Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
215157204|NCT00427765|DRUG|Melphalan|70 mg/m\^2 IV for 2 Days
215157205|NCT06980948|GENETIC|ST-503|Genomic Medicine
215157206|NCT06980948|PROCEDURE|Sham (No Treatment)|Sham Procedure
215157207|NCT06982131|DRUG|RO7795081|RO7795081 will be administered orally during Periods 3, 4, and 5, according to the protocol.
215157208|NCT06982131|DRUG|Placebo|Placebo will be administered orally during Periods 3, 4, and 5, according to the protocol.
215157209|NCT06982131|DRUG|Rosuvastatin|A single 10 mg dose of rosuvastatin (ROS) will be taken on Day 1 of Period 1 and on Day 1 of Period 4.
215157210|NCT06982131|DRUG|Pitavastatin|A single 1 mg dose of pitavastatin (PIT) will be taken on Day 1 of Period 2 and on Day 1 of Period 5.
215157211|NCT05044468|DRUG|Lidocaine|Given via injection
215157212|NCT05044468|DRUG|Liposomal Bupivacaine|Given via injection
215157213|NCT05044468|OTHER|Questionnaire Administration|Ancillary studies
215157214|NCT06812312|OTHER|PCR Trainning|A two-hour training intervention was conducted by a CPR-B instructor. The first 30 minutes were dedicated to explaining how to recognize a cardiopulmonary arrest, the correct technique for chest compressions, ventilations, and AED use. The remaining 90 minutes were for practical application of the intervention. This was conducted with five CPR-B training torsos (Little Anne QCPR training mannequin, Laerdal) and a simulated AED for CPR training (AED Practi-Trainer - Bilingual, WNL). Both theoretical and practical training were provided by a basic life support instructor from the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC), instructing participants under the 2021 European Resuscitation Council (ERC) recommendations.
215157215|NCT06654609|COMBINATION_PRODUCT|Insoles for Foot|Assess the condition of foot ulcers in patients, beginning with creating a cast of the affected foot. After the initial rectification, necessary modifications are made to prepare the rough insole. The size and fit of the insole are then carefully checked against the patient's foot. I use local silicone materials, secured with lady socks or stockinette to ensure the insole stays in place and provides durability.
214697186|NCT02767453|PROCEDURE|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
214538864|NCT02186314|DEVICE|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
214538865|NCT02604797|DRUG|Nalbuphine|patient-controlled intravenous analgesia
214538866|NCT02604797|DRUG|Sufentanil|patient-controlled intravenous analgesia
214538867|NCT02604797|DRUG|flurbiprofen axetil|patient-controlled intravenous analgesia
214538868|NCT02604797|DRUG|ramosetron|patient-controlled intravenous analgesia
214538869|NCT05863013|OTHER|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
214538870|NCT00001383|DRUG|PSC 833|
214538871|NCT00001383|DRUG|paclitaxel|
214538872|NCT00322140|DRUG|CDDO|
214538873|NCT02206945|BEHAVIORAL|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
214538874|NCT02206945|BEHAVIORAL|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
214538875|NCT00511797|DRUG|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
214538876|NCT00511797|DRUG|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
215157216|NCT04301193|DEVICE|Quantra Analyzer|Subject's blood samples will be manipulated in the lab and will be tested with the Quantra Analyzer. After obtaining blood from each patient, the blood was diluted to varying dilutions to obtain different fibrinogen concentrations. This way, 89 samples were prepared from the blood from 13 patients. Each sample was analyzed for fibrinogen concentration in the lab using conventional technology. Additionally each sample was used to measure Quantra variables such as clot stiffness (CS), and fibrinogen contribution to clot stiffness (FCS).
215157217|NCT05723276|DRUG|Psilocybin|Psilocybin 25mg PO
215157218|NCT06817239|DRUG|Esketamine|Esketamine (1mg/ml) will be administered at a loading dose of 0.2 mg/kg, namely at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with a formulation consisting of esketamine 50mg and sufentanil 200 μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
215157219|NCT06817239|DRUG|Normal saline|Normal saline will be administered at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with sufentanil 200μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
215157220|NCT04746183|DRUG|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
215157221|NCT04746183|DRUG|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
215157222|NCT04746183|DRUG|Nitazoxanide|"CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
214538877|NCT00511797|DRUG|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
214538878|NCT00511797|DRUG|Placebo|Placebo
214538879|NCT03989583|OTHER|Infrared thermography|Temperature observation in foot and footwear in healthy children
214538880|NCT00056329|DRUG|Vitamin E|1,000 international units twice daily for three years
214538881|NCT00056329|DRUG|multivitamin|once daily for three years
214538882|NCT00056329|DRUG|Placebo|Placebo twice daily for three years
214538883|NCT03974100|BIOLOGICAL|GP2411|60 mg /mL subcutaneous injection every 6 months
214538884|NCT03974100|BIOLOGICAL|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
214538885|NCT03847922|DRUG|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
214538886|NCT03847922|DRUG|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
214538887|NCT03847922|OTHER|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
214538888|NCT02941419|BIOLOGICAL|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
214538889|NCT04758546|DIAGNOSTIC_TEST|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
214538890|NCT02169921|DEVICE|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
214538891|NCT02019641|OTHER|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
214538892|NCT02019641|OTHER|Education|Weekly education
214538893|NCT00001677|DRUG|Methotrexate|
214538894|NCT00001677|DRUG|Fludarabine|
214538895|NCT00373022|BEHAVIORAL|exercise intervention|
214538896|NCT00373022|OTHER|flow cytometry|
214538897|NCT00373022|OTHER|laboratory biomarker analysis|
214538898|NCT00373022|PROCEDURE|management of therapy complications|
214538899|NCT00373022|PROCEDURE|psychosocial assessment and care|
214538900|NCT00373022|PROCEDURE|quality-of-life assessment|
214538901|NCT03398421|DRUG|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
214538902|NCT03398421|DRUG|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
215157223|NCT04746183|DRUG|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
215157224|NCT04746183|DRUG|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
214538903|NCT02236702|OTHER|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
214538904|NCT05188313|DRUG|Trastuzumab|Intravenous administration of study drug
214538905|NCT05188313|DRUG|Pertuzumab|Intravenous administration of study drug
214538906|NCT05188313|DRUG|Paclitaxel|Intravenous administration of study drug
214538907|NCT05188313|DRUG|Carboplatin|Intravenous administration of study drug
214538908|NCT06173232|DEVICE|Camera Imaging|Camera Imaging
214538909|NCT05644535|DIAGNOSTIC_TEST|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
214538910|NCT05644535|DIAGNOSTIC_TEST|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
214538911|NCT05644535|DIAGNOSTIC_TEST|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
214538912|NCT04973514|PROCEDURE|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
214538913|NCT01463514|PROCEDURE|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
214538914|NCT01463514|PROCEDURE|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
214538915|NCT05557149|DEVICE|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
214538916|NCT05557149|BEHAVIORAL|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
214538917|NCT05557149|DEVICE|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
214538918|NCT02384278|BEHAVIORAL|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
215157225|NCT04746183|DRUG|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
214697187|NCT02767453|PROCEDURE|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
214697188|NCT03983928|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214697189|NCT03983928|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
215157226|NCT04746183|DRUG|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
215157227|NCT04746183|DRUG|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
214538919|NCT02114983|OTHER|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
214538920|NCT04593706|DRUG|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
214538921|NCT04593706|DRUG|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
214538922|NCT04593706|DRUG|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
214538923|NCT04593706|DRUG|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
215157228|NCT04746183|DRUG|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
215157229|NCT04746183|DRUG|ALG-097558|ALG-097558 600 mg Twice a day (BD) for 5 days
215157230|NCT04746183|DRUG|ALG-097558 and Remdesivir|ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.
215157231|NCT04746183|DRUG|NHS standard of care as per COVID-19 treatment guidelines|NHS standard of care as per COVID-19 treatment guidelines
215157232|NCT06289907|DIETARY_SUPPLEMENT|Bonafide-HF3.0|Take 2 capsules once daily in the mornings with food
215157233|NCT06289907|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
215157234|NCT05301790|DEVICE|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
215157235|NCT00560352|DRUG|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
215157236|NCT00560352|DRUG|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD
215157237|NCT00560352|DRUG|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
214538924|NCT00545571|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
214538925|NCT04255121|DRUG|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
214538926|NCT04255121|DRUG|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
214697190|NCT04875949|PROCEDURE|Immunoabsorption/plasmapheresis procedure|
214538927|NCT05413837|DIAGNOSTIC_TEST|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
214538928|NCT05413837|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
214538929|NCT03269695|DRUG|PF-06687234|SC QW
215157238|NCT02471937|BIOLOGICAL|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
215157239|NCT06526793|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
215157240|NCT06824727|OTHER|Baseline cell blood counts|Obtain one peripheral blood sample from participants who have severe thrombocytopenia defined as 30,000 platelets/mcl or less
215157241|NCT06123741|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
215157242|NCT06123741|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
214697191|NCT00848549|DRUG|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
214538930|NCT03269695|DRUG|Placebo|SC QW
214538931|NCT04114812|OTHER|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
214538932|NCT04114812|OTHER|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
214538933|NCT03643757|PROCEDURE|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
214538934|NCT03643757|DRUG|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
214538935|NCT05851664|DEVICE|intubation by direct laryngoscopy|intubation using a direct laryngoscopy type macintosh
214538936|NCT05851664|DEVICE|Intubation by videolaryngoscopy|Intubation using a videolaryngoscope type McGrath
214538937|NCT01100918|DEVICE|BiV ICD|Biventricular ICD
214538938|NCT01100918|DEVICE|ICD|Implantable Defibrillator
214538939|NCT02024750|BEHAVIORAL|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
214538940|NCT06213064|BEHAVIORAL|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
214697192|NCT00848549|DRUG|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
214697193|NCT05740449|DRUG|Decitabine|intravenous
214697194|NCT05740449|DRUG|Venetoclax|oral
214538941|NCT05230030|BEHAVIORAL|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
214697195|NCT05740449|DRUG|Navitoclax|oral
214697196|NCT05740449|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
214697197|NCT03921138|OTHER|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
214697198|NCT06095752|OTHER|blood viscosity , albumin / fibrinogen ratio and red cell distribution|In multiple myeloma patients ,we get blood viscosity , albumin / fibrinogen ratio and red cell distribution directly after confirmed diagnosis to determine the prognosis of the disease in association with these tests results
214697199|NCT05338281|DEVICE|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
214697200|NCT01013168|PROCEDURE|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
214697201|NCT00544011|BIOLOGICAL|bevacizumab|
214697202|NCT00544011|DRUG|capecitabine|
214697203|NCT00544011|DRUG|fluorouracil|
214697204|NCT00544011|DRUG|irinotecan hydrochloride|
214697205|NCT00544011|OTHER|diagnostic laboratory biomarker analysis|
215157243|NCT03384134|OTHER|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
215157244|NCT06601595|DRUG|TNF inhibitors|tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
215157245|NCT06601595|DRUG|conventional ibd medical treatment|Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
215157246|NCT01857492|DEVICE|tDCS|
215157247|NCT01857492|BEHAVIORAL|Meditation|Both Active and SHAM groups will receive Meditation.
215157248|NCT06609499|DEVICE|Flexible-tip Bougie|The device is used for intubation and then the manikin is ventilated
215157249|NCT06609499|DEVICE|Gum-elastic Bougie|The device is used for intubation and then the manikin is ventilated
215157250|NCT06609694|DEVICE|Portable oxygen concentrator Inogen G5 model|The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
215157251|NCT06984952|PROCEDURE|ERAS protocol|The ERAS protocol includes pre-admission patient education through audiovisual materials; reduction of perioperative fasting duration with preoperative carbohydrate loading and early postoperative oral intake; multimodal prophylaxis for postoperative nausea and vomiting; early removal of surgical drains and intravenous lines; early mobilization; and multimodal analgesia aimed at minimizing postoperative opioid use. The detailed protocol used in this study has been published previously \[https://doi.org/10.5230/jgc.2025.25.e27\].
215157252|NCT06608901|DRUG|REGN7544|Administered per the protocol
215157253|NCT06608901|DRUG|PB|Administered per the protocol
215157254|NCT06862206|OTHER|benralizumab|non-interventional
215157255|NCT06861049|DIETARY_SUPPLEMENT|Psychobiotic Supplement|Lactobacillus helveticus R0052 Bifidobacterium bifidum R0071 Bifidobacterium longum R0175
215157256|NCT06861049|DIETARY_SUPPLEMENT|Placebo Supplement|Maltodextrin
215157257|NCT03708003|DRUG|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
215157258|NCT03708003|DRUG|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
215157259|NCT04434937|DRUG|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
215157260|NCT06993233|DRUG|CIT-013 high dose|subcutaneous injection
215157261|NCT06993233|DRUG|CIT-013 medium dose|subcutaneous injection
215157262|NCT06993233|DRUG|Placebo|subcutaneous injection
215157263|NCT06993831|BEHAVIORAL|Virtual Reality-based psychotherapy|"A manualized, modularized, Virtual Reality-based intervention comprising 10 sessions of 1 hour each. The VR therapy aims at enhancing anticipatory pleasure and positive emotions by amplifying exposure and reactivity towards social environments and rewarding activities using a highly elaborate VR software. The VR exposure comprises several different virtual social environments (e.g., a bus, a café, a park etc.) In a tailored treatment approach, therapists will guide participants to train focusing on positive stimuli, engage in activities, experience social rewards, and practice expressing emotions through body language.~The therapy focuses on increasing the awareness of positive outcomes that may influence motivation. The therapy deploys activity appraisal/re-appraisal intended to enhance the salience of future opportunities for reward and desire for such rewards, thus targeting reward anticipation processes and promoting enjoyable daily-life activities."
215157264|NCT02968212|DRUG|Clofazimine|All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
215157265|NCT02968212|OTHER|sugar pill|All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
215157266|NCT00563472|DRUG|estetrol|10 mg orally per day for 28 days
215157267|NCT00563472|DRUG|estetrol|20 mg orally per day for 28 days
215157268|NCT00563472|DRUG|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
215157269|NCT00563472|DRUG|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
215157270|NCT02141828|DRUG|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
215157271|NCT04756232|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
215157272|NCT04756232|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
215157273|NCT06591338|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
215157274|NCT06591338|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
214538942|NCT04225000|OTHER|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
215157275|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
215157276|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
215157277|NCT06599918|DRUG|Nicotinamide|Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
215157278|NCT06599918|DRUG|Placebo|Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
215157279|NCT00024622|DRUG|18F-Fluoro-L-dopa|
215157280|NCT00024622|DRUG|O-15 Water|
215157281|NCT06592209|BEHAVIORAL|Sedentary Breaks|Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
214538943|NCT04225000|OTHER|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
214538944|NCT05012943|BIOLOGICAL|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
214538945|NCT05012943|OTHER|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
214538946|NCT05012943|BIOLOGICAL|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
214538947|NCT01027663|DIETARY_SUPPLEMENT|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
214538948|NCT01349036|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
214538949|NCT04830878|DRUG|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
214538950|NCT05582590|DRUG|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
214538951|NCT05582590|DRUG|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
214538952|NCT05582590|BIOLOGICAL|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
214538953|NCT00000636|DRUG|Isoniazid|
214538954|NCT00000636|DRUG|Pyrazinamide|
214538955|NCT00000636|DRUG|Pyridoxine hydrochloride|
214538956|NCT00000636|DRUG|Rifampin|
214538957|NCT04003961|OTHER|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
214538958|NCT04218552|DRUG|AD209|PO, Once daily(QD), 8weeks
214538959|NCT04218552|DRUG|Amlodipine low|PO, Once daily(QD), 8weeks
214538960|NCT04218552|DRUG|Amlodipine high|PO, Once daily(QD), 8weeks
214538961|NCT04218552|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
214538962|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
215157282|NCT07013747|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: suspension for injection Route of administration: intramuscular
215157283|NCT07013747|OTHER|Placebo|Pharmaceutical form: liquid solution for injection Route of administration: intramuscular
214538963|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
214538964|NCT05729204|OTHER|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
214538965|NCT00032747|DRUG|Vasopressin V2 Receptor Antagonist|
214538966|NCT01449747|DRUG|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
214538967|NCT05818995|DRUG|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
215157284|NCT00924027|RADIATION|High Dose Radiation (HDR) Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
214538968|NCT04344665|OTHER|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
214538969|NCT02896101|DRUG|Pimecrolimus Cream, 1%|
214538970|NCT02896101|DRUG|Elidel® (pimecrolimus) Cream|
214538971|NCT02896101|DRUG|Placebo of Pimecrolimus Cream, 1%|
214538972|NCT03605368|BEHAVIORAL|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
214538973|NCT03605368|BEHAVIORAL|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
214538974|NCT03605368|BEHAVIORAL|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
214538975|NCT06002321|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.
214538976|NCT06002321|DIAGNOSTIC_TEST|Laboratory Test|BNP, NT-proBNP and renal function.
214538977|NCT01125566|DRUG|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
214538978|NCT01125566|DRUG|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
214538979|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
214538980|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
214538981|NCT00998829|OTHER|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
214538982|NCT01825317|DEVICE|NeuroAD|synchronized TMS+COGNITIVE TRAINING
214538983|NCT01825317|DEVICE|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
214538984|NCT05046106|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
214538985|NCT05046106|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
214538986|NCT02214771|DRUG|Fidaxomicin|oral
214538987|NCT02214771|DRUG|Treatment for CDI other than fidaxomicin Type|Oral
214538988|NCT06646133|DIAGNOSTIC_TEST|3D camera weight estimate|Weight estimation using 3D camera system
214538989|NCT06646133|DIAGNOSTIC_TEST|Standard methods of weight estimation|Standard methods of weight estimation will be used
214538990|NCT01684111|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
214538991|NCT01684111|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
214538992|NCT05577663|OTHER|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
215157285|NCT00924027|DIAGNOSTIC_TEST|MRI|When deemed necessary.
214538993|NCT05577663|PROCEDURE|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
214538994|NCT05577663|PROCEDURE|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
214538995|NCT02001467|OTHER|Simulation-based training|
214538996|NCT05105425|DIETARY_SUPPLEMENT|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
214538997|NCT05105425|DIETARY_SUPPLEMENT|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
214538998|NCT03129971|PROCEDURE|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
214538999|NCT03129971|PROCEDURE|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
214539000|NCT03151551|DRUG|Ixekizumab|Administered SC
214539001|NCT03151551|DRUG|Adalimumab|Administered SC
214539002|NCT04131699|DEVICE|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
214539003|NCT00514813|DRUG|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
214539004|NCT02224352|DEVICE|Functional neuromuscular electrical stimulation|
214539005|NCT02979613|DRUG|TAF|25 mg tablet administered orally once daily
214539006|NCT02979613|DRUG|TDF|300 mg tablet administered orally once daily
214539007|NCT02979613|DRUG|TAF Placebo|Tablet administered orally once daily
214539008|NCT02979613|DRUG|TDF Placebo|Tablet administered orally once daily
214539009|NCT03134274|DEVICE|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
214539010|NCT05590806|OTHER|Direct composite build-ups|Direct composite build-ups application
214539011|NCT03369314|DRUG|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
214539012|NCT00169962|DRUG|rhDNAse (pulmozyme)|
214539013|NCT01138098|BIOLOGICAL|Engerix™-B|Intramuscular, single dose
214539014|NCT04186884|OTHER|Quality-of-Life Assessment|Ancillary studies
214539015|NCT04186884|OTHER|Questionnaire Administration|Complete questionnaires
214539016|NCT05320861|DRUG|[14C]SJP-0008|Single oral dose of \[14C\]SJP-0008
214539017|NCT01075100|DRUG|Ixabepilone|20 mg/m2 on Days 1 and 8
214539018|NCT01075100|DRUG|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
214539019|NCT05308199|OTHER|thoracic manipulation|thoracic manipulation for unlocking of facet joints
214539020|NCT05308199|OTHER|muscle enegy technique|to release muscle spasm of cervical musces
214539021|NCT02250183|DEVICE|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
214539022|NCT02250183|DEVICE|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
214539023|NCT01497678|DEVICE|Extracellular Matrix|Extracellular Matrix
214539024|NCT03096977|DIAGNOSTIC_TEST|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
214539025|NCT03096977|DEVICE|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
214539026|NCT03096977|DEVICE|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
214539027|NCT03096977|DEVICE|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
215157286|NCT00924027|DIAGNOSTIC_TEST|CT|Obtained based on the sites of target, as clinical situation dictates and at each follow-up to determine local control.
215157287|NCT00924027|DIAGNOSTIC_TEST|PET Scan|When deemed necessary.
215157288|NCT07022743|DRUG|Imatinib|Imatinib is a first-line tyrosine kinase inhibitor which is used in the management of chronic myeloid leukaemia. It will be used by all the patients in the 3 arms of the study (Groups A, B and C)
215157289|NCT07022743|DRUG|Artesunate|Artesunate has been established to reverse resistance to some chemotherapeutic agents. patients in 2 arms of the study (Groups B and C) will be given artesunate at 4mg/kg (not exceeding 200mg daily) in combination with imatinib
214539028|NCT03096977|DEVICE|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
214539029|NCT03862105|OTHER|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
214539030|NCT04599387|OTHER|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
215157290|NCT06872775|OTHER|Blood draws to assess RNA expression levels|None. Standard of Care (SOC) only.
215157291|NCT07031557|DEVICE|EchoStation Implementing REMS Technology|Ultrasound-based densitometry used for the prevention, diagnosis, and monitoring of bone health status and fracture risk at reference anatomical sites (femur and spine), including all patient categories.
215157292|NCT07031557|OTHER|Nutritional and Fracture Risk Assessment Questionnaires|Questionnaires regarding Calcium Intake, dietary habits assessment (Predimed), and Algorithm for Fracture Risk in Women of Childbearing Age (AFEF) developed by the Fragility Fracture Observatory (OFF)
215157293|NCT07031765|BIOLOGICAL|exHSC|Ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) at a targeted dose of 2.5 x 106 cells/kg (or maximal achievable dose, with a minimum deliverable dose of 1/10 target dose; max dose 1.0 x 108 total cells for patients ≥40kg).
215157294|NCT07031765|DRUG|Nivolumab|Nivolumab 3mg/kg once every 2 weeks, max dose 240mg. Nivolumab will be administered on day 1 and day 15 of each cycle for a total of 10 cycles. Nivolumab may continue for a total two years of therapy, at the discretion of the treating team.
215157295|NCT07031765|PROCEDURE|Resection or biopsy|Patients must be candidates for standard of care surgical resection or biopsy.
215157296|NCT07039136|OTHER|Virtual Reality Mirror Therapy|"Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. Data from participants' right forearms will be collected using Leap Motion tracking. In the virtual reality environment, both the original and mirrored forearms will be displayed within the participants' field of view.~The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement."
215157297|NCT07039136|OTHER|Conventional Mirror Therapy|Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement.
215157298|NCT07039136|OTHER|Sham Virtual Reality|Participants will experience pre-recorded virtual environments while seated and wearing a virtual reality headset, without interacting with the environment. The virtual reality application will be used for 10 minutes at the end of each session of conventional mirror therapy.
215157299|NCT06883240|DRUG|Von Willebrand Factor Concentrates|Used according to local labeling or local treatment guidelines.
215157300|NCT06883240|DRUG|Von Willebrand Factor Concentrates and Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
215157301|NCT06883240|DRUG|Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
215157302|NCT06883240|DRUG|Recombinant Activated Factor VII|Used according to local labeling or local treatment guidelines.
215157303|NCT06883240|DRUG|Activated Prothrombin Complex Concentrate|Used according to local labeling or local treatment guidelines.
215157304|NCT07039591|DEVICE|Pro-type IVR|Women will test three non-medicated IVRs on two one-day clinic visits (two on the first day, one on the second day) by manipulating them, vaginally inserting each ring and then performing a controlled set of tasks simulating routine daily activities with the ring in the vagina.
215157305|NCT04962412|OTHER|"Standard care bundle"|"The management for AKI patients were performed by implementing a standard care bundle suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline."
214539031|NCT04599387|OTHER|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
214539032|NCT02453477|GENETIC|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
214539033|NCT03282799|DRUG|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
214539034|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat|
214539035|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
214539036|NCT01811329|DIETARY_SUPPLEMENT|Palm fat|
214539037|NCT01811329|DIETARY_SUPPLEMENT|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
214539038|NCT05088733|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
214539039|NCT05088733|OTHER|Routine medical care|Routine medical care
214539040|NCT01068405|DRUG|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
214539041|NCT01068405|DRUG|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
214539042|NCT05970783|DRUG|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
214539043|NCT05970783|OTHER|Placebo|Placebo 0.2g tid p.o.
215157306|NCT06712797|BEHAVIORAL|Physical Activity (PA)|"Participants will receive a Fitbit (Inspire 3, Google LLC, Mountain View, CA, USA) to encourage and self-monitor Physical Activity (PA) using active minutes, which approximate moderate-to-vigorous PA.~Fitbits will be synced to a HIPAA-compliant platform created by Moffitt's Biostatistics and Bioinformatics Shared Resource (BBSR).~Study personnel will view active minutes to provide individualized feedback and encourage progression. Weekly feedback will encourage participants to increase active minutes by 10% until achieving ≥ 150 minutes to meet cancer prevention recommendations.~Participants who reach ≥ 150 active minutes will be encouraged to maintain or exceed recommendations."
215157307|NCT06712797|BEHAVIORAL|Nutrition (N)|"Participants will undergo counseling at baseline (T0) to address nutritional symptoms and provide targets for daily calories and protein following a Mediterranean diet. This diet includes a high intake of vegetables, legumes, fruits, and unsaturated fatty acids, low intake of saturated fatty acids, and a moderately high intake of fish.~Total caloric intake will be calculated. A standard breakdown of 40% carbohydrates, 30% fats and 30% protein will be used. Individuals will review this calculation during their office encounters and follow these values using the FitBit, application, which will adjust to their daily energy expenditure.~Additional counseling (in-person or via Zoom) will occur at baseline (T0) + 12 weeks to gauge progress toward calorie and protein targets, monitor weight change, and guide dietary changes.~Participants will log daily food intake and self-monitor progress toward calorie and protein goals."
215157308|NCT06883344|DEVICE|Automated insulin delivery (AID) system|An AID system incorporates data from a continuous glucose monitor (CGM) to automatically adjust the amount of insulin delivered by an insulin pump via an algorithm that incorporates multiple factors, including predicted glucose level in the next 30-60 minutes, target glucose level, and recent insulin delivery.
215157309|NCT06883344|OTHER|Intravenous (IV) insulin|Variable rate IV insulin infusions are used in most labor/delivery units as the standard of care for glycemic management for pregnant people with T1D. A continuous rate of IV insulin is infused, with manual rate adjustments made based on current glucose level and hospital-specific protocols.
215157310|NCT06743243|DRUG|Tegoprazan|Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.
215157311|NCT06743243|DRUG|Famotidine|Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
214539044|NCT05797883|DRUG|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
214539045|NCT03194945|DRUG|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
214539046|NCT03194945|DRUG|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
214539047|NCT03194945|DRUG|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
214539048|NCT03194945|DRUG|CSII alone|No OHA is given after short-term intensive CSII
214539049|NCT06817993|BEHAVIORAL|Rejection and Acceptance Feedback|Participants will be administered cues of peer acceptance and rejection from virtual peers during an fMRI task. In the CHAT-I task, they will be chosen or not chosen to discuss various topics with a virtual peer. In the TBO Task, they will receive a high or low number of likes relative to the other photos displayed of peers. They will also view comments on their posts from peers, which may have positive, negative, or neutral content.
214539050|NCT00637325|DRUG|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
214539051|NCT03501888|BEHAVIORAL|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
214539052|NCT03501888|BEHAVIORAL|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
214539053|NCT02585141|DEVICE|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
214539054|NCT02585141|PROCEDURE|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
214539055|NCT02585141|DRUG|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
214539056|NCT02546778|DEVICE|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
214539057|NCT00498758|DEVICE|APOS System - biomechanical wedge shoe|
214539058|NCT03769077|DEVICE|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
214539059|NCT04438369|PROCEDURE|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
214539060|NCT06055972|OTHER|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~1. Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~2. Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~3. For patients with CAC\>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~4. Links to American Heart Association (AHA) and phone number for study research coordinator."
214539061|NCT03379428|DRUG|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
214539062|NCT03379428|DRUG|Ibrutinib 560 mg|560 mg by mouth daily
214539063|NCT03379428|DRUG|Ibrutinib 840 mg|840 mg by mouth daily
214539064|NCT03379428|DRUG|Ibrutinib 420 mg|420 mg by mouth daily
215157312|NCT06743243|DRUG|Placebo|Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.
214539065|NCT05241197|OTHER|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
214539066|NCT05241197|OTHER|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
214539067|NCT04817657|BIOLOGICAL|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.
214539068|NCT02960256|DEVICE|ekocardiogram test|ekocardiogram test
214539069|NCT03751553|DRUG|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
214539070|NCT00092521|BIOLOGICAL|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
214539071|NCT00092521|BIOLOGICAL|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
214539072|NCT00092521|BIOLOGICAL|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
214697206|NCT03996109|BEHAVIORAL|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 6 months. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
214697207|NCT03996109|BEHAVIORAL|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 6 months. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
215157313|NCT05372354|DRUG|CC-92480|Specified dose on specified days
215157314|NCT05372354|DRUG|Tazemetostat|Specified dose on specified days
215157315|NCT05372354|DRUG|BMS-986158|Specified dose on specified days
214539078|NCT05588947|OTHER|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
214539079|NCT05588947|OTHER|Active Control|Life After Stroke educational video
214539080|NCT05706636|DRUG|oral mini pulse|5mg / week oral dexamethasone
214539081|NCT05706636|DRUG|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
214539082|NCT05706636|DEVICE|targeted phototherapy|twice weekly targeted excimer light sessions
214539083|NCT03475056|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
214539084|NCT06090175|OTHER|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
214539085|NCT06090175|OTHER|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
215157316|NCT05372354|DRUG|Trametinib|Specified dose on specified days
215157317|NCT05372354|DRUG|Dexamethasone|Specified dose on specified days
215157318|NCT06890312|PROCEDURE|Administration of heparin after sheath insertion|Administration of heparin after sheath insertion
214539086|NCT04415827|DIAGNOSTIC_TEST|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
214539087|NCT04678908|DRUG|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
214539088|NCT01833208|OTHER|Laboratory Biomarker Analysis|Correlative studies
214539089|NCT01833208|RADIATION|Radiation Therapy|Undergo single-fraction radiation therapy
214539090|NCT01921361|DRUG|Levobupivacaine|Intrathecal 3ml (15 mg)
214539091|NCT01921361|DRUG|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
215157319|NCT06890312|PROCEDURE|Administration of heparin prior to sheath insertion|Administration of heparin prior to sheath insertion
214539092|NCT01921361|DRUG|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
214697208|NCT01842841|DRUG|velaglucerase alfa|15-60 U/kg, EOW
214697209|NCT01418053|DRUG|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
214697210|NCT01418053|DRUG|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
214697211|NCT05963048|DRUG|Rituximab|IV infusion 1000 mg
214697212|NCT05963048|DRUG|IL6 inhibitor|6 mg/kg I V infusion monthly
214697213|NCT02860637|OTHER|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
214697214|NCT02094053|DRUG|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
214697215|NCT02094053|DRUG|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
215157320|NCT07057908|PROCEDURE|Video Laryngoscope Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngoscope under general anesthesia. After induction, a standard bougie will be advanced through the vocal cords under video guidance, and the endotracheal tube will be railroaded over the bougie into the trachea.~The primary outcome will be intubation time, measured from insertion of the device until confirmation of successful tracheal intubation. Additional parameters such as intubation success rate, ease of insertion, and complications (e.g., desaturation, airway trauma, failed attempts) will also be recorded. No extra procedures will be performed beyond routine airway management."
214539093|NCT01921361|DRUG|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
214539094|NCT01932762|DRUG|Grazoprevir|100 mg every day (QD) orally
214539095|NCT01932762|DRUG|Elbasvir|50 mg QD orally
214539096|NCT01932762|DRUG|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
214539097|NCT03795168|DEVICE|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
214539098|NCT03795168|DEVICE|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
214539099|NCT04361383|OTHER|control group|the patient will receive general anesthesia
214539100|NCT04361383|PROCEDURE|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
214539101|NCT04361383|PROCEDURE|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
214539102|NCT02332304|PROCEDURE|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
214539103|NCT00837590|DRUG|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
214539104|NCT00837590|DRUG|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
214539105|NCT05470270|DRUG|Hydroxycarbamide|Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
214539106|NCT02851849|DRUG|LGD-6972-5 mg|5 mg LGD-6972 QD
214539107|NCT02851849|DRUG|LGD-6972-10 mg|10 mg LGD-6972 QD
214539108|NCT02851849|DRUG|LGD-6972-15 mg|15 mg LGD-6972 QD
214539109|NCT02851849|OTHER|Placebo|Placebo QD
214539110|NCT01101334|DRUG|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
214539111|NCT01101334|DRUG|erlotinib|Erlotinib; One 150mg tablet administered once daily
214539112|NCT05550597|DRUG|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
214539113|NCT05550597|DRUG|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
214539114|NCT03344016|OTHER|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
214539115|NCT00940654|OTHER|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
214539116|NCT01384383|DRUG|GS-5885|GS-5885 30 mg tablet administered orally once daily
214539117|NCT01384383|DRUG|GS-9451|GS-9451 200 mg tablet administered orally once daily
214539118|NCT01384383|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214697216|NCT02094053|DRUG|Placebo|placebo (oral) once daily, for 24 weeks
214697217|NCT03809221|DRUG|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
214697218|NCT05352906|DIAGNOSTIC_TEST|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
214539119|NCT01384383|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
214697219|NCT04629898|BEHAVIORAL|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
214697220|NCT01902953|DRUG|Lymphoseek and VBD Sln dissection|See detailed description of study design
214539120|NCT06310083|PROCEDURE|Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy|The study's Participants Were Randomly classified in two groups Interventional Group, applied for Submucosal Resection Turbinoplasty and the controlled group who were applied for Partial Inferior Turbinectomy
214539121|NCT01004029|DRUG|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
214539122|NCT01004029|DRUG|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
214539123|NCT03864341|BEHAVIORAL|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
215157321|NCT07057908|PROCEDURE|Video Laryngeal Mask Airway (SaCoVLM) Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngeal mask airway (SaCoVLM) under general anesthesia. After successful placement of the device, a standard bougie will be inserted through the SaCoVLM's dedicated lumen, and an endotracheal tube will be advanced over the bougie into the trachea under video guidance.~The primary outcome will be intubation time, defined as the duration from device insertion to confirmation of successful intubation. Secondary outcomes include intubation success rate, ease of insertion, and complications such as desaturation, trauma, or failed attempts. As both techniques are part of routine practice, no additional risks will be introduced."
215157322|NCT07057791|DRUG|Ivonescimab 10 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 10 mg/kg intravenous (IV) on Day 1 followed by carboplatin area under the curve (AUC) 5 IV on Day 1 and etoposide 100 milligrams per square meter (mg/m²) IV on Day 1, 2 and 3 followed by maintenance ivonescimab 10 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
215157323|NCT07057791|DRUG|Ivonescimab 20 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 20 mg/kg IV on Day 1 followed by carboplatin AUC 5 IV on Day 1 and etoposide 100 mg/m² IV on Day 1, 2 and 3 followed by maintenance ivonescimab 20 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
214539124|NCT03864341|BEHAVIORAL|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
214539125|NCT03864341|BEHAVIORAL|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
214539126|NCT03353142|OTHER|Equal Breathing|"* Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
214539127|NCT00154427|DRUG|activated recombinant human factor VII|
214539128|NCT03901443|OTHER|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
214539129|NCT06351462|OTHER|Spermogram|Spermogram will be proposed to men
214539130|NCT06351462|OTHER|Hospital Anxiety and Depression Scale (HADS)|Anxiety and depression will be evaluated 10 years after HSCT
214539131|NCT06351462|OTHER|SF36 Quality of life questionnaire|Quality of life will be evaluated 10 years after HSCT
214539132|NCT06351462|OTHER|Psychologist interview|During a follow-up visit
214539133|NCT06351462|OTHER|Optional sera banking|One in the study
214539134|NCT06351462|OTHER|Optional DNA banking|Once in the study
214539135|NCT01338805|DRUG|BGG492|
214539136|NCT04325009|DRUG|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
214539137|NCT04325009|DRUG|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
214697221|NCT01248130|DRUG|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
214539138|NCT04780984|DRUG|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
214539139|NCT04780984|DRUG|Placebo|Placebo comparator
214539140|NCT00127400|BEHAVIORAL|anger management therapy|
214539141|NCT04067349|OTHER|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
214539142|NCT03184597|DIAGNOSTIC_TEST|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
214539143|NCT01597583|BEHAVIORAL|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
214539144|NCT04927962|OTHER|Questionnaires|For youth: self-reported questionnaires (on oral quality of life, bullying and cyberbullying, dental anxiety) and routine clinical examination for adolescents. For one parent: self-reported questionnaires (on perceived oral quality of life of their child and on their own dental anxiety).
214539145|NCT00542932|OTHER|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
215157324|NCT07054333|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
215157325|NCT07051733|BEHAVIORAL|Health Information Literacy Enhancement|"Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows:~1. Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory: ① Strengthening skills related to Health Information Literacy; ② Training on Medication Management Skills; ③ Practice of Self-Monitoring Skills; ④ Education on Diet and Exercise Management Knowledge.~2. Health Behavior Motivation Management Based on the Health Empowerment Theory: ① Personalized Goal Setting; ② Behavioral Incentives and Feedback; ③ Construction of Peer Support Networks; ④ Demonstration Effect of Role Models.~3. Health Management Support System Based on the Health Empowerment Theory: ① Online Dynamic Monitoring; ② Family-Community Collaborative Support; ③ Digital Monitoring Platform; ④ Continuous Supply of Resources."
214539146|NCT01138371|PROCEDURE|LDL Apheresis|LDL Apheresis
214539147|NCT05932706|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
214539148|NCT05932706|DEVICE|sham high definition transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
214539149|NCT04387045|BEHAVIORAL|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
214539150|NCT02135822|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
214539151|NCT02135822|DRUG|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
214539152|NCT04317534|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
214539153|NCT04470843|DRUG|Acetazolamide|Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
214539154|NCT04470843|OTHER|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
214539155|NCT03953456|DRUG|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
214539156|NCT03953456|DRUG|Placebo|Placebo is a coated tablet for oral administration, once daily
214539157|NCT05720377|DEVICE|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
214539158|NCT03550053|DEVICE|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
214539159|NCT05158283|DEVICE|chocolate balloon|chocolate balloon dilatation
214539160|NCT05158283|DEVICE|plain balloon|plain balloon dilatation
214539161|NCT00997711|DEVICE|Cypher|Sirolimus-eluting stents
214539162|NCT03080818|DIETARY_SUPPLEMENT|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
214539163|NCT03080818|OTHER|Placebo|2 placebo capsules per day for 90 days
214539164|NCT04831047|DRUG|Oxymetazoline hydrochloride 0.1% ophthalmic solution|One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
214539165|NCT04831047|DRUG|Placebo|One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
214539166|NCT05141227|PROCEDURE|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates \& screws
214539167|NCT05141227|PROCEDURE|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov \& minimal fixation of the articular surface using cannulated screws through mini open approaches
214539168|NCT00612352|DRUG|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
214539169|NCT04531306|OTHER|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
214539170|NCT02161406|DRUG|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
215157326|NCT06883305|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
215157327|NCT06883305|OTHER|Placebo|Placebo subcutaneous injection
215157328|NCT06795048|DRUG|Faricimab|Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
215157329|NCT07068295|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
215157330|NCT07068295|DRUG|Insulin Aspart|Insulin aspart will be administered subcutaneously.
215157331|NCT05904028|DRUG|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
215157332|NCT05904028|DEVICE|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
215157333|NCT06813781|DRUG|AZD5004|Dose 1
215157334|NCT02415621|DRUG|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
215157335|NCT06654245|BEHAVIORAL|Telephone based interview|Receive SHAREDCare navigator calls
215157336|NCT06654245|OTHER|Survey using a questionnaire.|Ancillary studies
215157337|NCT06654245|OTHER|Electronic health record review|Ancillary studies
215157338|NCT06654245|OTHER|Referral|Receive standard of care automated referrals
215157339|NCT06843772|OTHER|ergonomic training|will receive ergonomic training.
215157340|NCT06843772|OTHER|exercise|People who will receive an exercise program. Participants will receive ergonomic training along with the exercise program.
214539171|NCT02161406|DRUG|Placebo|125 mg of Placebo
214539172|NCT04428008|DRUG|Thymalfasin|Synthetic 28 amino acid peptide
214539173|NCT02450890|DRUG|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
214539174|NCT02450890|DRUG|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
214539175|NCT01979289|OTHER|computerized cognitive remediation|
214539176|NCT01979289|OTHER|computerized cognitive remediation:Control|
214539177|NCT03888222|DRUG|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
214539178|NCT03888222|DRUG|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
214697222|NCT05041478|PROCEDURE|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
214697223|NCT05041478|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
215157341|NCT06775301|DIAGNOSTIC_TEST|Hyfe Cough Monitoring System|Smartwatch-based cough monitoring
214539179|NCT05747612|OTHER|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
214539180|NCT01612247|DRUG|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
214697224|NCT06205225|BEHAVIORAL|Text4HF|Behavioral text messages about heart failure self-care
214697225|NCT06205225|BEHAVIORAL|MyApps|consumer mobile health apps and devices for heart failure self-care
214697226|NCT06205225|BEHAVIORAL|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
215157342|NCT07074301|BEHAVIORAL|Caregiver Training Program|The intervention consists of a two-month structured education program including two face-to-face sessions and a mobile application. The training content covers PEG care, stoma and tube management, enteral nutrition, drug administration via tube, and troubleshooting complications.
215157349|NCT06585410|DRUG|Cemiplimab|Administered per protocol
215157350|NCT06585410|PROCEDURE|Standard of care|Primary surgery
214697227|NCT06205225|BEHAVIORAL|Enhanced Usual Care|Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
214697228|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
214697229|NCT00305643|DRUG|Capecitabine|Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
214697230|NCT00305643|DRUG|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
214697231|NCT00305643|PROCEDURE|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
214697232|NCT00305643|DRUG|Placebo|Oral placebo twice daily on days 1-21
215029381|NCT00876941|BEHAVIORAL|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
214539181|NCT01875341|DEVICE|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
214539182|NCT01875341|DEVICE|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
214539183|NCT01969045|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
214539184|NCT01969045|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
214539185|NCT02034162|DRUG|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
214539186|NCT02034162|DRUG|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
214539187|NCT04556409|DEVICE|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
214539188|NCT04556409|DEVICE|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
214539189|NCT04556409|OTHER|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
214539190|NCT01042249|OTHER|Pelvic Floor Muscle training|12 week training program including home exercises
214539191|NCT03379545|DIAGNOSTIC_TEST|3-dimensional (3D) magnetic resonance (MR) imaging|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
214539192|NCT03379545|DIAGNOSTIC_TEST|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
214539193|NCT06118242|OTHER|Use of oral care solutions|Oral care solutions to be used: Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid
214539194|NCT01445795|DRUG|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
214539195|NCT01445795|DRUG|Placebo QD Fasted|Placebo capsule QD fasted x7 days
214539196|NCT01445795|DRUG|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
214539197|NCT01445795|DRUG|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
214539198|NCT01445795|DRUG|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
214539199|NCT01445795|DRUG|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
214539200|NCT01445795|DRUG|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
214539201|NCT01445795|DRUG|Placebo BID Fasted|Placebo BID fasted x7 days
214697233|NCT04087343|BEHAVIORAL|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
214697234|NCT04087343|BEHAVIORAL|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
214697235|NCT04064320|BEHAVIORAL|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
214697236|NCT04980976|DEVICE|Blind insertion technique|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
215157351|NCT06101797|OTHER|Remote supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised by video call. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
215157352|NCT06101797|OTHER|In-person supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised at a physiotherapy clinic. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
215157353|NCT06904664|OTHER|Individualized temperature health risk early warning and risk factor management|Receive individualized temperature health risk warning and prevention risk factor management information for stroke through the application
214539202|NCT01445795|DRUG|ribavirin|
214539203|NCT04224454|OTHER|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
214539204|NCT00571077|DEVICE|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
214539205|NCT02607202|DRUG|nab-paclitaxel|
214539206|NCT02607202|DRUG|Carboplatin|
214539207|NCT02607202|DRUG|Gemcitabine|
214539208|NCT01095159|DEVICE|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
214539209|NCT01095159|DEVICE|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
214539210|NCT05380128|GENETIC|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
214539211|NCT03271749|OTHER|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
215157354|NCT06904664|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
215157355|NCT06904664|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
215157356|NCT07097428|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
215157357|NCT02153229|RADIATION|Photodynamic Therapy|
215157358|NCT02153229|PROCEDURE|Radical Pleurectomy|
215157359|NCT02153229|RADIATION|Chemotherapy|
214539212|NCT00263497|DEVICE|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
214539213|NCT03458728|DRUG|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
214539214|NCT04453163|PROCEDURE|Vertebroplasty|Patient will undergo a surgery in percutaneous vertebroplasty
214539215|NCT02999737|BIOLOGICAL|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
214539216|NCT02999737|BIOLOGICAL|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
214539217|NCT02077205|BEHAVIORAL|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
214539218|NCT06957678|DIAGNOSTIC_TEST|Artificial Intelligence-Based Predictive Model for Lymph Node Metastasis|The intervention is an artificial intelligence-based predictive model developed using preoperative multimodal data, including contrast-enhanced CT images, preoperative histopathological findings, and clinical features. The model is designed to predict (1) the presence or absence of lymph node metastasis, (2) the specific lymph node stations involved, and (3) the individual lymph nodes involved. Each lymph node's metastatic status is confirmed by serial pathological sectioning of surgically retrieved nodes, ensuring a highly accurate reference standard for model training and validation. This distinguishes the intervention from traditional imaging-based assessments and from other AI models that do not use individually validated lymph node pathology.
214539219|NCT04553445|BEHAVIORAL|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
214539220|NCT04553445|BEHAVIORAL|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
214539221|NCT00244907|DIETARY_SUPPLEMENT|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
214539222|NCT01134471|DEVICE|Ostene|applied to sternal surface
214539223|NCT01134471|DEVICE|Bonewax|applied to sternal surface
214539224|NCT05444036|DRUG|Ketamine|compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
215157360|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
215157361|NCT04806464|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
215157362|NCT07092670|DRUG|Dabrafenib + Trametinib|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
215157363|NCT07092670|DRUG|Pembrolizumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
215157364|NCT07092670|DRUG|Nivolumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
215157365|NCT07092670|OTHER|Observation|Patients who will not initiate adjuvant therapy, but will undergo observation (due to refusal, comorbidities, other reasons).
215157366|NCT07098143|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
215157367|NCT06904326|OTHER|Postoperative dynamic radiography|Participants will perform a dynamic radiography 3 months after lumbar decompression surgery under UBE to study vertebral instability
215157368|NCT03995134|COMBINATION_PRODUCT|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
215157369|NCT07100522|DEVICE|Hearing aid in spectacle frame form factor|"eyewear frames embedded with groundbreaking technology which seamlessly integrate an air conduction hearing aid (over-the-counter OTC, in the United States) intended to amplify sound for adult users (18yrs and older) with a perceived mild to moderate hearing impairment. Nuance Audio Glasses may, if necessary, be used in association with prescription lenses for those adults who also require correction of visual defects. Nuance Audio Glasses can be worn all day and can be easily configured via the App to adapt to any situation, from business meetings to family time."
215157370|NCT07100522|DEVICE|hearing aid|Hearing aid in spectacle frame form factor
215157371|NCT07100587|BEHAVIORAL|Ketogenic diet|A structured, equicaloric ketogenic diet providing approximately 1200 kcal/day, consisting of high fat (70-80 g/day), moderate protein (80-90 g/day), and very low carbohydrate intake (20-30 g/day), primarily from non-starchy vegetables. The diet is administered for 3 consecutive weeks to induce nutritional ketosis. A sugar-free multivitamin supplement is provided throughout the intervention.
214697237|NCT04980976|DEVICE|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique
215157372|NCT07100587|BEHAVIORAL|Mediterranean diet|A structured Mediterranean diet administered for 3 weeks following a 2-week transition phase. The diet provides approximately 1200 kcal/day and emphasizes plant-based foods, extra virgin olive oil as the main fat source, moderate consumption of fish, dairy products, and whole grains, with limited red meat and processed foods.
214539225|NCT03204500|COMBINATION_PRODUCT|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
214539226|NCT03204500|DRUG|Placebos|Administered orally under the same conditions
214539227|NCT01626729|BEHAVIORAL|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
214539228|NCT01626729|BEHAVIORAL|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
214539229|NCT01626729|BEHAVIORAL|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
214539230|NCT01626729|BEHAVIORAL|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
214539231|NCT01626729|BEHAVIORAL|No label control group|No label control group
214539232|NCT02703753|BEHAVIORAL|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
214539233|NCT06301347|BEHAVIORAL|Learning through Play Plus|Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
214539234|NCT05897528|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
214539235|NCT06418399|OTHER|cancer patients|Patients aged between 18 and 80 years with cancer-related pain lasting for more than 3 months will be included.
214539236|NCT01913899|OTHER|Occupational/ physical therapy|
214539237|NCT01913899|OTHER|Mirror therapy|\- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
214539238|NCT00694798|BIOLOGICAL|Mycobacterium w|Immunomodulator
214539239|NCT04759846|DRUG|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
214539240|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
214539241|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
214539242|NCT03239418|DEVICE|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
214539243|NCT03239418|DEVICE|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
214539244|NCT01377792|DRUG|Hypertonic saline|comparison of different dosages of drug
214539245|NCT04291209|DRUG|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
214539246|NCT06456606|PROCEDURE|before prone position|It was evaluated with transesophageal echocardiography
214539247|NCT06456606|PROCEDURE|the first hour of prone position|It was evaluated with transesophageal echocardiography
214539248|NCT06456606|PROCEDURE|the first hour of returning to the supine position|It was evaluated with transesophageal echocardiography
214539249|NCT02148510|DEVICE|Monobloc|Construction fitted to upper and lower jaw
214539250|NCT02148510|DEVICE|Bibloc|Biblock construction
214539251|NCT03563625|PROCEDURE|Caudal block|Caudal block/bupivacaine 0.25%
214539252|NCT03563625|PROCEDURE|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
214539253|NCT03563625|DRUG|Bupivacaine|bupivacaine
214539254|NCT04340765|DRUG|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
214539255|NCT02367430|BEHAVIORAL|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
214697238|NCT03134651|DEVICE|Monitoring brain function|
214697239|NCT03134651|DRUG|propofol|
214697240|NCT02106455|DRUG|Sodium risedronate|Sodium risedronate tablets
214697241|NCT02974387|DRUG|Fluorometholone(FML)|
214697242|NCT02974387|DRUG|Loteprednol (Lotemax)|
214539256|NCT04674254|DRUG|Bevacizumab Injection|Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
214539257|NCT04674254|PROCEDURE|Targeted retinal photocoagulation|Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
214539258|NCT04674254|PROCEDURE|Standard pan-retinal photocoagulation|Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
214539259|NCT03234998|DEVICE|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
214539260|NCT03234998|DEVICE|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
214539261|NCT03234712|DRUG|ABBV-321|Intravenous infusion
214539262|NCT01520337|DEVICE|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
214539263|NCT01759147|PROCEDURE|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
214697243|NCT03398122|PROCEDURE|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
214697244|NCT03398122|DRUG|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
214539264|NCT04285047|OTHER|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
214539265|NCT02904785|DEVICE|Extracorporeal Shock Waves|
214539266|NCT02904785|DEVICE|Sham Extracorporeal Shock Waves|
214539267|NCT02904785|OTHER|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
214539268|NCT05876169|PROCEDURE|Orthognathic surgery|Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
214539269|NCT05648396|OTHER|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
214539270|NCT01851707|DRUG|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
214539271|NCT01851707|DRUG|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
214539272|NCT05421156|PROCEDURE|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
214539273|NCT05421156|PROCEDURE|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
214697245|NCT00541138|DRUG|carboplatin|CBDCA AUC=3
214539275|NCT04582305|DRUG|Bleomycin|Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
214539276|NCT04582305|DRUG|Normal saline|Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
214539277|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
214539278|NCT05407987|DRUG|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
214539279|NCT05407987|DRUG|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
214539280|NCT04456244|OTHER|Evaluation of the static posture|Photographing from the back, front and side with ADIBAS posturography in standing position
214539281|NCT05031468|BIOLOGICAL|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
214697246|NCT00541138|DRUG|tamoxifen citrate|Tamoxifen 100mg bid
214697247|NCT00541138|DRUG|topotecan hydrochloride|Topotecan 0.75 g/m2/d
214697248|NCT00541138|OTHER|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
214697249|NCT00718289|OTHER|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
215157373|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste +ozone therapy application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Periodontal paste (Coe-pak) will be applied to the area left for secondary healing after ozone therapy (activated oxygen (Cure 09 Active Oxygen))
215157374|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Only periodontal paste will be applied after the surgery.
215157375|NCT04347629|BEHAVIORAL|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
215157376|NCT07103967|BEHAVIORAL|Calorie information manipulation|The intervention will be administered by changing the information presenting to participants at point-of-choice when ordering alcoholic drinks and bar snacks. When alcohol calorie information is present, participants will see the calorie content of alcohol products on menus and at other point-of-choice locations. When it is not present, this information will be absent.
215157377|NCT07103967|BEHAVIORAL|Serving size manipulation|The intervention will be administered by changing the availability of alcoholic drinks. When serving sizes are reduced, participants will only be able to order 2/3 pint of 1/2 servings of beer, and 125 ml servings of wine. When serving sizes are not reduced, participants will be able to order 1 pint servings or 1/2 servings of beer, and 175 ml or 125 ml servings of wine.
215157378|NCT04044872|DIAGNOSTIC_TEST|[1-13C]pyruvate along with MRI imaging|\[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
215157381|NCT06922617|BEHAVIORAL|Switching to E-Cigarette|Participants will receive twelve weeks of e-cigarette products with instructions to switch completely at switch date
215157382|NCT06922617|DRUG|Quitting using Medication|Participants will receive twelve weeks of FDA approved medication, combination NRT, with instructions to quit smoking cigarettes at quit date
215157383|NCT06922617|BEHAVIORAL|Counseling|Participants will recieve brief weekly counseling to support their quit or switch attempt from cigarettes.
214697250|NCT00718289|OTHER|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
215029382|NCT00876941|BEHAVIORAL|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
215029383|NCT05212207|OTHER|CGM, smartwatch, and electronic diary|Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
215029384|NCT01779414|OTHER|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
215157384|NCT06557798|DEVICE|Any commercially available transcatheter aortic valve|Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
215157385|NCT06557798|PROCEDURE|Surgical explantation and aortic valve replacement|Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
215157386|NCT06557798|OTHER|Conservative management|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
215157387|NCT04695977|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
215157388|NCT04695977|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
215157389|NCT06931158|DRUG|Open-label Placebo|Open-label placebo pill for 21 days at 2 per day
215157390|NCT06931158|BEHAVIORAL|Standard Rationale|Scientific rationale about the placebo effect
215157391|NCT06931158|BEHAVIORAL|Mindfulness|Mindfulness based rationale
214539282|NCT03993496|DIAGNOSTIC_TEST|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation"
214539283|NCT00858247|DIETARY_SUPPLEMENT|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
214539284|NCT03171116|OTHER|none intervention|it is not an interventional study; it is an observational study
214539285|NCT05648318|DRUG|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
214539286|NCT05648318|DRUG|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
214539287|NCT05375383|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214539288|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214539289|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214539290|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214539291|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
214539292|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
214539293|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
214539294|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
214539295|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214539296|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214697251|NCT05166746|DRUG|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
215029385|NCT01554709|DEVICE|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
214539297|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214539298|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214539299|NCT00500981|PROCEDURE|Volume challenge|
214539300|NCT00500981|PROCEDURE|Ultrasound evaluation of internal jugular vein|
214697252|NCT05166746|OTHER|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
215029386|NCT06200948|OTHER|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
214539301|NCT00176475|BIOLOGICAL|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
214539302|NCT00176475|BIOLOGICAL|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
214539303|NCT00337285|DRUG|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
214539304|NCT00210678|BEHAVIORAL|No intervention|No treatment is given to the patients as this is an observational study.
214539305|NCT00553605|DRUG|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
214539306|NCT00553605|DRUG|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
214539307|NCT05671744|OTHER|Cell-based non-invasive prenatal testing|Blood sampling
214539308|NCT00448773|BEHAVIORAL|Online education|
214539309|NCT04208347|DRUG|Apatinib 250mg|Apatinib 250mg
214539310|NCT04208347|DRUG|Camrelizumab|Camrelizumab 200mg
214539311|NCT04208347|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
214539312|NCT04208347|DRUG|Apatinib 500mg|Apatinib 500mg
214539313|NCT00003185|BIOLOGICAL|autologous tumor cell vaccine|
214539314|NCT00003185|BIOLOGICAL|sargramostim|
214539315|NCT00003185|BIOLOGICAL|tumor-draining lymph node lymphocyte therapy|
214539316|NCT00003185|DRUG|cyclophosphamide|
214539317|NCT00003185|PROCEDURE|conventional surgery|
214539318|NCT04567797|DEVICE|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
214539319|NCT04567797|DEVICE|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
214539320|NCT04567797|DEVICE|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
214539321|NCT04567797|DEVICE|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
214539322|NCT02226497|DEVICE|Health Telemonitoring|Use home telemonitoring device
215029387|NCT06200948|OTHER|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
215029388|NCT01577407|DRUG|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
215029389|NCT00800826|DRUG|dexmedetomidine|
215029390|NCT02190500|OTHER|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
214697253|NCT02756975|DEVICE|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
214697254|NCT02756975|DEVICE|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
214697255|NCT01478438|DEVICE|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
214697256|NCT06490198|DRUG|OBI-833/OBI-821|"OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy."
214697257|NCT00316342|DEVICE|Back supports|
214539323|NCT02226497|OTHER|Quality-of-Life Assessment|Ancillary studies
214697258|NCT01293149|DRUG|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
214697259|NCT01293149|DRUG|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
214697260|NCT04159077|DRUG|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
214697261|NCT04159077|DRUG|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
214697262|NCT03102216|DIAGNOSTIC_TEST|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
215157392|NCT06931158|BEHAVIORAL|Control Rationale|Basic epidemiological information about chronic pain to achieve structural equivalence for the control groups
214539324|NCT02226497|OTHER|Questionnaire Administration|Ancillary studies
214539325|NCT02226497|PROCEDURE|Supportive Care|Receive standard outpatient supportive care
214539326|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
214539327|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
214539328|NCT03596463|OTHER|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
214539329|NCT06407583|BEHAVIORAL|ProMIO2.0 program|"ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)"
214539330|NCT03481556|DRUG|Melphalan flufenamide (Melflufen)|Intravenous infusion
214539331|NCT03481556|DRUG|Dexamethasone|Oral tablets
214539332|NCT03481556|DRUG|Bortezomib|Subcutaneous administration
214539333|NCT03481556|DRUG|Daratumumab|Intravenous infusion
214539334|NCT04067908|OTHER|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
214539335|NCT01797133|PROCEDURE|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
214539336|NCT01797133|PROCEDURE|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
214697263|NCT03102216|DIAGNOSTIC_TEST|CBC|Complete Blood Count
214697264|NCT03102216|DIAGNOSTIC_TEST|ECG|ElectroCardioGram
214697265|NCT03102216|DIAGNOSTIC_TEST|Lodox|Low dose x-ray
214697266|NCT00095368|DRUG|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
214697267|NCT02531464|OTHER|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
214697268|NCT02190747|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
214697269|NCT02190747|DRUG|Placebo|
214697270|NCT04906408|DEVICE|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
214697271|NCT04906408|DEVICE|Prineo|Incisions will be dressed with Prineo
214697272|NCT04906408|DRUG|Traditional|Incisions will be dressed with bacitracin/xeroform
214697273|NCT06388993|DEVICE|Bone Marrow Collection|Comparing the two collection systems for bone marrow aspirate
214697274|NCT01480141|DRUG|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
214697275|NCT05188612|COMBINATION_PRODUCT|Observational (registry)|Observational (Patient Registry)
215157393|NCT03105713|OTHER|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
215157394|NCT06935422|DEVICE|Ultrasound|Measuring cerebroplacental ratio discordance in monochorionic twins at 16-20 Weeks of gestation
215157395|NCT07136168|BEHAVIORAL|Health dialogue|"1. Pre-visit 20 minutes including timed-up and go (TUG) walking test, length, weight, blood pressure, and blood tests ( HbA1C, PEth)~2. Structured health dialogue by a dedicated nurse practitioner for about 60 minutes covering living conditions, activity, everyday function, lifestyle habits and formation of a plan for improved health and referral to physician, physiotherapist or other primary care worker when appropriate~3. Follow-up call at 3 months with the nurse practitioner for evaluation and adjustment of the plan"
215157396|NCT07145034|DRUG|Prosman|Prosman, the study drug is prepared from the gummy extract (pygeum) from the Indian plum tree Prunus domestica and is available in various dosage forms. Originally, pygeum, was obtained from the African prune tree bark (Prunus africanum) and was used for the treatment of various urinary problems.
214539337|NCT01085812|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
214539338|NCT01085812|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily.
214539339|NCT05470959|OTHER|ACTIVA bioactive|bioactive ionic resin composite
214539340|NCT05470959|OTHER|Riva LC|resin-modified glass ionomer
214539341|NCT01101997|DEVICE|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
214539342|NCT02953028|DEVICE|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
214539343|NCT02953028|DEVICE|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
214539344|NCT03588819|RADIATION|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
214539345|NCT02943642|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
214539346|NCT02943642|DRUG|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
214539347|NCT00509457|BIOLOGICAL|GV 1001 Telomerase peptide|
214539348|NCT00126139|DRUG|Abciximab|
214539349|NCT02176564|DRUG|inhaled bronchodilator|
214539350|NCT01196585|PROCEDURE|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
214539351|NCT01196585|PROCEDURE|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
214539352|NCT05789550|DIAGNOSTIC_TEST|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"1. Full clinical history with detailed history about T2DM (its duration and treatment).~2. Full medical examination, including BMI using the formula: weight (kg)/height (m2).~3. Laboratory investigation, including the following:~   1. Complete blood picture.~  2. Fasting blood sugar (FBS).~  3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~  4. HbA1c.~  5. Kidney function tests (serum creatinine and blood urea).~  6. Liver function tests (serum albumin, ALT, and AST).~  7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
214539353|NCT00269997|DRUG|epoetin alfa|
214539354|NCT00503217|DRUG|Tryptorelin|
214539355|NCT05130346|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
214539356|NCT03565692|BIOLOGICAL|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR"
214539357|NCT03565692|BIOLOGICAL|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
214539358|NCT03453203|OTHER|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
214539359|NCT03336697|DIAGNOSTIC_TEST|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
214697276|NCT02318732|BEHAVIORAL|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
215157397|NCT07145034|OTHER|Placebo|Placebo matched to the Prosman
215157398|NCT06953466|DRUG|QRX003, 4% Lotion|QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)
214539360|NCT01035047|OTHER|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
214539361|NCT04061863|DRUG|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
214539362|NCT02669407|PROCEDURE|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
214539363|NCT02669407|DRUG|regional nerve block with a local anesthetic (Lidocaine)|
214539364|NCT05512078|PROCEDURE|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
214539365|NCT01391429|BEHAVIORAL|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
214539366|NCT00791739|DRUG|trazodone, pregabalin|"* phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
214539367|NCT00878293|DRUG|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
214539368|NCT00878293|DRUG|MS Continus®|60 mg, capsule, once daily
214539369|NCT00878293|DRUG|Placebo|liquid formulation and capsule, once daily
214539370|NCT00910325|PROCEDURE|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
214539371|NCT06215417|PROCEDURE|Rotator cuff repair|Arthroscopic rotator cuff repair augmented with graft.
214539372|NCT01113671|DRUG|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
214539373|NCT01113671|DRUG|Placebo|includes inactive Ingredients
214539374|NCT04988399|OTHER|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
214539375|NCT03634839|DRUG|Flavoring Agents|Flavor of e-liquid - sweet or tobacco
214539376|NCT03634839|DRUG|Nicotine|Nicotine level (36 mg/ml)
214539377|NCT00350298|BIOLOGICAL|GS-CDA1/MDX-1388|One Intravenous dose
214539378|NCT00350298|BIOLOGICAL|normal saline|One Intravenous dose
214539379|NCT05969405|PROCEDURE|Laparoscopic staging|Laparoscopic staging
214539380|NCT05969405|PROCEDURE|Robotic staging|Robotic staging
214539381|NCT05969405|PROCEDURE|Laparotomic staging|Laparotomic staging
214539382|NCT02571998|DRUG|Omiganan (CLS001) Topical Gel|
214539383|NCT02571998|DRUG|Vehicle Topical Gel|
214539384|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
214539385|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
214539386|NCT02447432|BIOLOGICAL|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
214539387|NCT02647788|DRUG|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
214539388|NCT02647788|DRUG|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
214539389|NCT04198948|DRUG|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
214539390|NCT04198948|DRUG|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
214539391|NCT04198948|DRUG|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
214539392|NCT00130078|DRUG|1.0% C31G SAVVY vaginal gel|
214539393|NCT06438692|PROCEDURE|VOM ethanol chemical ablation and 2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
214539394|NCT06438692|PROCEDURE|2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
215029391|NCT02230982|DRUG|nintedanib|soft gelatin capsule
215029392|NCT04120870|DRUG|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
215029393|NCT04120870|DRUG|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
215029394|NCT00004103|DRUG|cisplatin|
215029395|NCT00004103|DRUG|floxuridine|
215029396|NCT00004103|DRUG|irinotecan hydrochloride|
215029397|NCT00004103|PROCEDURE|adjuvant therapy|
215029398|NCT00004103|PROCEDURE|conventional surgery|
215029399|NCT00004103|PROCEDURE|neoadjuvant therapy|
215029400|NCT00213070|DRUG|Miglitol|
215029401|NCT00000307|DRUG|Naltrexone|
215029402|NCT02896205|DRUG|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
215029403|NCT02896205|DRUG|Placebo|Subjects will be given matching placebo for 6 months
215029404|NCT01259531|DRUG|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
215029405|NCT06541119|OTHER|Selective Peroneus longus excercise|Weight bearing peroneus longus exercise
215029406|NCT06541119|OTHER|Conventional physical therapy programme|"* Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs"
215029407|NCT02104934|PROCEDURE|Adductor Canal Block|
215029408|NCT04076332|OTHER|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
214539395|NCT00607061|PROCEDURE|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
214539396|NCT00233389|DRUG|Rebamipide|
214539397|NCT03740477|DIAGNOSTIC_TEST|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
214539398|NCT00913068|PROCEDURE|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
214539399|NCT00913068|PROCEDURE|standard post op pain control|opiates
214539400|NCT04622475|BIOLOGICAL|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
214539401|NCT00003912|DRUG|carboplatin|
214539402|NCT00003912|DRUG|cisplatin|
214539403|NCT00003912|DRUG|doxorubicin hydrochloride|
214539404|NCT00003912|PROCEDURE|conventional surgery|
214539405|NCT03948399|DEVICE|Duplex scanning of carotid arteries|Measurement of carotid arteries
214539406|NCT03948399|DEVICE|ABI measurement|ankle brachial index (ABI) assessment
214539407|NCT05333575|BEHAVIORAL|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
214539408|NCT05333575|BEHAVIORAL|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
214539409|NCT00302159|PROCEDURE|adjuvant therapy|
214539410|NCT00302159|DRUG|Temozolomide|Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
214539411|NCT00302159|DRUG|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
214539412|NCT00302159|RADIATION|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
214539413|NCT02754336|BEHAVIORAL|Cogmed Robomemo, working memory training|
214539414|NCT02754336|BEHAVIORAL|Othmer, neurofeedback|
214539415|NCT03019198|DRUG|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
214539416|NCT03019198|DRUG|Placebo - Concentrate|
214539417|NCT04021225|DEVICE|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
214539418|NCT04021225|DEVICE|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
214539419|NCT04021225|DEVICE|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
214539420|NCT04758676|OTHER|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
214539421|NCT04758676|OTHER|Standard of care|Study subjects will receive the current standard of care.
214539422|NCT02794714|DRUG|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
214539423|NCT02794714|DRUG|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
214539424|NCT01380288|DRUG|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
214539425|NCT05595811|OTHER|outcome following surgery|
214539426|NCT02928471|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
215029409|NCT02367885|DRUG|TAK-850 0.5 mL injection|TAK-850 injection
215029410|NCT02367885|DRUG|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
215029411|NCT06059950|BEHAVIORAL|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
215029412|NCT01602484|DEVICE|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
215157399|NCT07156448|BEHAVIORAL|Multicomponent Exercise Program|Participants in the intervention group received a structured, multicomponent exercise program consisting of resistance training, stretching, and walking. The program began on the second day of hospitalization and continued until discharge, with a frequency of five sessions per week. Each session lasted approximately 30 minutes, including about 20 minutes of resistance and stretching exercises targeting major muscle groups through functional movements (e.g., sit-to-stand, leg flexion-extension) and flexibility exercises for the upper arms, back, and posterior legs, performed in 2 to 3 sets of 8 to 12 repetitions. Each session also incorporated approximately 10 minutes of walking, with intensity adjusted according to individual tolerance.
215157400|NCT07156513|PROCEDURE|Epidural Pulsed Radiofrequency|Pulsed radiofrequency applied via a guidable epidural catheter electrode (Cosman RCE-E401519-P), advanced through the sacral hiatus to the target lumbar or sacral root (L5 and/or S1) under fluoroscopic guidance. Parameters: 45 V, 2 Hz, 20 ms pulses, applied at a single location with continuous temperature monitoring (≤42°C). Procedure performed with Cosman C4 generator.
215157401|NCT07156513|DRUG|Betamethasone (Epidural Corticosteroid Injection)|Epidural injection of 12 mg betamethasone diluted in 8 ml sterile saline, administered via the sacral hiatus under fluoroscopic guidance.
215157402|NCT07157826|DEVICE|Guided Imagery Application|"Guided Imagery Intervention:~Scenario-based guided imagery, one of the guided imagery techniques, will be utilized. The scenario will be developed with input from experts to promote functional recovery. Expert opinions will be obtained from a psychologist and a psychiatric nurse. The scenario will begin with breathing exercises and continue with the safe place technique. Patients will be instructed to listen to the audio recording using headphones in an environment free from disturbances, to set their phones to airplane mode, and to inform their relatives not to interrupt them before starting the session. Headphones will be provided by the researcher for each patient. After the content of the audio recordings is created during the initial session, it will be recorded via phone and transferred as a file to the patients' phones, with instructions on how to use it. The audio recording will last approximately 15 to 20 minutes and will include relaxing, soft background music."
215157403|NCT07158424|PROCEDURE|Serious games|Participants in the experimental groups engage in daily sessions of serious games from the Vana Vital Platform (Super Surfer, Hungry Woo, Paddle Waddle, Woo's Wonderful World Adventure). Each child will for 30 minutes per day over 10 training days.
215157404|NCT07158424|PROCEDURE|Intensive rehabilitation|"Participants receive their intensive rehabilitation program, which includes:~30 minutes of physical therapy (PT) 20 minutes of occupational therapy 5 minutes of spinal manipulative therapy 60 minutes of full-body massage with reflexotherapy 15 minutes of joint mobilization 15 minutes of treadmill gait training (with or without suspension) 15 minutes of strength training 30 minutes of group rhythmic gymnastics"
215157405|NCT07158424|PROCEDURE|Physical therapy|Participants receive an additional 30 minutes of physical therapy (PT)
215157406|NCT07156864|DRUG|1/10 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/10 therapeutic dose of the study drug (parenteral administration).
215157407|NCT07156864|DRUG|1/2 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/2 therapeutic dose of the study drug (parenteral administration).
215157408|NCT07156864|DRUG|full therapeutic dose|15 volunteers + 3 replacement volunteers will recieve full therapeutic dose of the study drug (parenteral administration).
215157409|NCT07156864|DRUG|Patients with a verified diagnosis of COVID-19|10 volunteers with a verified diagnosis of COVID-19 will recieve full therapeutic dose of the study drug (parenteral administration).
215157410|NCT07156812|DEVICE|Custome made 3D PEEK plate|Custome made 3D PEEK plate
215157411|NCT07156812|DEVICE|3D Titanium plate|Pre-bent 3D Titanium plate
215157412|NCT07157345|DRUG|PDR001|This drug was packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus
215157413|NCT07157657|BIOLOGICAL|Surgical implantation with standard (DRM) or photosynthetic dermal regeneration matrices (PDRM) in same patient.|Under sterile conditions and appropriate anesthesia, standard dermal regeneration matrices (DRMs) and photosynthetic dermal regeneration matrices (PDRMs), containing live photosynthetic microalgae, are implanted in separate wound areas or in anatomically distinct wounds on the same patient. Each site is then covered with a transparent adhesive dressing. In the experimental (PDRM) area, a light-emitting dressing is applied to stimulate photosynthesis and promote localized oxygen production.
215157414|NCT07157657|PROCEDURE|Autologous split-thickness skin grafting over implanted matrices|Approximately 21 days after the initial intervention, and once the wound bed meets predefined grafting criteria based on clinical evaluation, an autologous dermo-epidermal skin graft is performed.
215157415|NCT07156877|PROCEDURE|Pulsed Field Ablation (PFA) with VOLT Catheter|Participants in this arm will undergo pulmonary vein isolation (PVI) using the VOLT catheter, a novel single-shot ablation device that delivers pulsed field energy (a non-thermal ablation method). The catheter features a balloon-in-basket design and enables electro-anatomical mapping. The procedure is performed under conscious sedation or general anesthesia and follows standard PVI protocols adapted for the PFA technology.
214697277|NCT06583876|DEVICE|Coriofix System|Treatment of functional mitral regurgitation by reducing the mitral valve annular area through ablation of the posterior annulus.
214697278|NCT02000141|PROCEDURE|Endoscopic Mucosal Resection|
214697279|NCT04906902|DRUG|Acalabrutinib|Tablet taken by mouth twice daily
214697280|NCT00377533|DEVICE|wheelchair rear anti-tip device|assistive device
214697281|NCT05800431|DEVICE|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
214697282|NCT04786951|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
214697283|NCT04786951|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
214697284|NCT04786951|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
214697285|NCT04804891|BIOLOGICAL|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
215157416|NCT07156877|PROCEDURE|Thermal Ablation (Radiofrequency or Cryoablation)|"Participants in this arm will receive PVI using established thermal ablation techniques, either:~* Radiofrequency ablation, a point-by-point technique using heat delivered through a catheter tip guided by mapping systems, or~* Cryoballoon ablation, which uses freezing energy delivered via a balloon catheter.~The choice between RF and cryoablation is at the discretion of the treating physician, in line with standard care."
215157417|NCT07156656|PROCEDURE|Conventional treatment|Beside the using of Sivelestat Sodium or placebo, all postoperative care will adhere to each center's standard protocols for type A aortic dissection.
215157418|NCT07156656|DRUG|Sivelestat sodium|The daily dose (4.8 mg/kg) is diluted in 48 mL of 0.9 % saline and administered as a continuous intravenous infusion over 24 hours at 2 mL/h (equivalent to 0.2 mg/kg/h) for 72 consecutive hours.
215157419|NCT07156656|DRUG|Placebo|An equal volume of placebo-containing only the excipients of sivelestat sodium and diluted to 48 mL with 0.9 % saline-will be infused at 2 mL/h for 72 consecutive hours.
215157420|NCT07157033|DRUG|XER-001|XER-001 (Amifostine for nasoduodenal delivery)
215157421|NCT07156682|DRUG|QL1706|neoadjuvant administered at a dose of 5 mg/kg, intravenous infusion, every three weeks (Q3W), on day 1 of each cycle, 4 cycles
215157422|NCT07156682|DRUG|XELOX|Oxaliplatin 130 mg/m² by intravenous infusion on Day 1; Capecitabine 850-1000 mg/m² orally twice daily (morning and evening) from Day 1 to Day 14; 4 Cycles in total.
214539427|NCT03635840|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
214539428|NCT05660330|BEHAVIORAL|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
214539429|NCT00466713|DRUG|Rosiglitazone therapy|
214539430|NCT02815059|DRUG|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
214539431|NCT02815059|DRUG|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
214539432|NCT02815059|DRUG|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
214539433|NCT02125136|DRUG|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
214539434|NCT02125136|DRUG|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
214539435|NCT05195892|DRUG|Treatment A|Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
214539436|NCT05195892|DRUG|Treatment B|Single oral dose of alpelisib granule at 50 mg in fed state
214539437|NCT05195892|DRUG|Treatment C|Single oral dose of alpelisib granule at 50 mg in fasted state
214539438|NCT03413215|BEHAVIORAL|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
214539439|NCT05082623|OTHER|Music|Music medicine
214539440|NCT05082623|OTHER|Earplug|Earplug with noise cancelling
214539441|NCT04339023|DRUG|Open-Label Placebo|in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
214539442|NCT04339023|OTHER|treatment as usual|usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
214539443|NCT00470405|DRUG|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
215157423|NCT07157579|DIAGNOSTIC_TEST|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.
215157424|NCT07156604|DRUG|Vebreltinib Enteric Capsules|treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery.
214539444|NCT00470405|DRUG|pemetrexed disodium|a novel antifolate with multiple targets.
214539445|NCT01411449|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
214697286|NCT03607838|DRUG|SI-6603|SI-6603 will be injected into an intervertebral disc.
214697287|NCT03607838|DRUG|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
214697288|NCT04023513|OTHER|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
214697289|NCT04023513|OTHER|Control, no intervention|No Intervention, control
214697290|NCT04023513|OTHER|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
214697291|NCT04023513|OTHER|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
214697292|NCT01266434|DRUG|Simvastatin|10 mg once daily for 8 weeks
214697293|NCT01266434|DRUG|B1-6-12|1 tablet once daily for 8 weeks
214697294|NCT00312299|DEVICE|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
214697295|NCT00312299|DEVICE|Round edge PMMA IOL|Round edge PMMA IOL
214539446|NCT06456086|BIOLOGICAL|stimulation with EB virus|stimulation with EB virus
214539447|NCT03409562|BEHAVIORAL|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
214539448|NCT03409562|BEHAVIORAL|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
214539449|NCT05159986|PROCEDURE|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
214539450|NCT05159986|OTHER|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
214539451|NCT04991350|DRUG|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
214539452|NCT04991350|DRUG|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
214697296|NCT00312299|DEVICE|Acrysof IOL|Acrysof IOL
214697297|NCT00312299|DEVICE|square Edge PMMA IOL|Square edge PMMA intra ocular lens
214697298|NCT00312299|DEVICE|Square Edge PMMA IOL|Square Edge PMMA IOL lens
214697299|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
214697300|NCT02287012|OTHER|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
214697301|NCT04352322|DIETARY_SUPPLEMENT|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
214697302|NCT04352322|DIETARY_SUPPLEMENT|Placebo|oral solution with no active ingredients
214697303|NCT03192527|DRUG|KN015|experimental drug
214697304|NCT03192527|DRUG|Placebo|Comparator.
214697305|NCT03192527|DRUG|Triptorelin|The drug is used for down-regulation of endogenous FSH.
214697306|NCT04058262|OTHER|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
214697307|NCT04058262|OTHER|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
214697308|NCT04058262|OTHER|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
214697309|NCT04058262|OTHER|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
214697310|NCT05629533|DEVICE|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
214697311|NCT00187239|DEVICE|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
214697312|NCT04393636|OTHER|Digital cardiac Counseling|"* Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling."
214697313|NCT01576016|DEVICE|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
214697314|NCT01576016|DEVICE|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
214697315|NCT02191709|DRUG|Dextromethorphan syrup|
214697316|NCT02191709|DRUG|Dextromethorphan soft pastilles|
215029413|NCT01602484|DEVICE|Bulk splint supplies|Applying splint by using the bulk splint supplies
215157425|NCT07158138|OTHER|Digital yoga intervention|Digital yoga intervention
214697317|NCT04718181|DRUG|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
214697318|NCT04718181|DRUG|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
214697319|NCT05834803|PROCEDURE|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
214539453|NCT02414347|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214539454|NCT03626831|DRUG|Evolocumab Prefilled Syringe|Injection of study drug
214539455|NCT03626831|DRUG|Placebos|Injection of placebo
214539456|NCT00117897|DRUG|pegfilgrastim|
214539457|NCT00117897|DRUG|Filgrastim|
214539458|NCT00766402|DRUG|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
214539459|NCT00766402|DRUG|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
214539460|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
214539461|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
214539462|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
214539463|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
214539464|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
214539465|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
214539466|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
214539467|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
214539468|NCT00726713|OTHER|Metanx (a medical food)|Metanx one tablet twice a day
214539469|NCT00726713|OTHER|Metanx placebo|Metanx placebo one tablet twice a day
214539470|NCT06258733|BEHAVIORAL|Lay-led FL workshops|Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.
214539471|NCT06258733|BEHAVIORAL|Expert-led workshops|Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
214539472|NCT05260554|DRUG|Fosfomycin|In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
214539473|NCT05260554|DIETARY_SUPPLEMENT|Cranberry|In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
214539474|NCT01233999|DRUG|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
214539475|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
214539476|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
214539477|NCT02367105|DRUG|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
214539478|NCT02367105|OTHER|Lifestyle Therapy|Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
214539479|NCT02367105|DRUG|Placebo|Placebo gel for testosterone
214539480|NCT03895502|DRUG|12-month Edoxaban|Prescription of Edoxaban for 12 months
214539481|NCT03895502|DRUG|3-month Edoxaban|Prescription of Edoxaban for 3 months
214539482|NCT01721083|PROCEDURE|Procedure: Z-track|Subject received immunization by z-track
214539483|NCT01721083|PROCEDURE|Procedure: Bunch|Subject receives immunization by bunch method.
214539484|NCT04588675|DIAGNOSTIC_TEST|MRI|the patients will underwent dobutamine stress cardiac MRI
214539485|NCT05350124|DRUG|Ascorbic acid|vitamin C (200 mg) capsule
214539486|NCT05350124|DRUG|Tocopherol|vitamin E (400 IU) capsule
214539487|NCT05350124|DRUG|Placebo capsule|Placebo one pill only
214539488|NCT05350124|DRUG|Placebo capsule|Placebo two pills only
214539489|NCT00024323|DRUG|cisplatin|
214539490|NCT00024323|DRUG|triapine|
214539491|NCT02684799|DRUG|Cenicriviroc|
214539492|NCT02684799|DRUG|Omeprazole|
214539493|NCT02684799|DRUG|Famotidine|
214539494|NCT03771222|BIOLOGICAL|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
214539495|NCT03840109|BEHAVIORAL|Questionnaire 1a|Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214697320|NCT05834803|PROCEDURE|Sham treatment|Optimal medical therapy and sham treatment.
215157426|NCT07156227|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215157427|NCT07156227|DRUG|Camonsertib|Given PO
214708739|NCT06195098|OTHER|Nutritional educational intervention|The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
215157428|NCT07156227|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214539496|NCT03840109|BEHAVIORAL|Questionnaire 1b|Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539497|NCT03840109|BEHAVIORAL|Questionnaire 2a|Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539498|NCT03840109|BEHAVIORAL|Questionnaire 2b|Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539499|NCT03840109|BEHAVIORAL|Questionnaire 3a|Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539500|NCT03840109|BEHAVIORAL|Questionnaire 3b|Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539501|NCT03840109|BEHAVIORAL|Questionnaire 4a|Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539502|NCT03840109|BEHAVIORAL|Questionnaire 4b|Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
214539503|NCT00889837|DRUG|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
214539504|NCT00889837|DRUG|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
214539505|NCT00047177|DRUG|Oxaliplatin|
214539506|NCT01001962|DRUG|empagliflozin|ACTIVE TREATMENT FOR DIABETES
214539507|NCT01001962|DRUG|Metformin|ACTIVE TREATMENT FOR DIABETES
214539508|NCT03231969|DRUG|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
214539509|NCT03231969|DRUG|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
214539510|NCT03231969|DRUG|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
214539511|NCT03231969|DRUG|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
214539512|NCT03109509|BEHAVIORAL|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
214708740|NCT02771457|DRUG|Infliximab at weeks 0,2, and 6|
215157429|NCT07156227|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215157430|NCT07156227|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215157431|NCT07158385|OTHER|Standard test meal (SM)|Participants were given a standard breakfast meal with a fat and protein content similar to their daily intake. Insulin was administered according to their individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
214539513|NCT03109509|BEHAVIORAL|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
214539514|NCT00129649|BEHAVIORAL|Telephone reminder call|
214539515|NCT06511375|OTHER|sprint training|sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
214539516|NCT06511375|OTHER|Power Training|"GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week."
214539517|NCT05739110|BEHAVIORAL|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
214539518|NCT02735590|DRUG|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
214539519|NCT02735590|DRUG|Rifapentine|Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
214539520|NCT01532635|RADIATION|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
214539521|NCT01532635|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
214539522|NCT01532635|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
214539523|NCT01532635|DRUG|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
214539524|NCT01532635|DRUG|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
214539525|NCT01532635|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
214539526|NCT00905034|DRUG|Methotrexate|200 mg/m\^2 by vein on days 1 and 15.
214539527|NCT00905034|DRUG|Vincristine|1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
214539528|NCT00905034|DRUG|PEG-l-asparaginase|2500 International units/m\^2 by vein on days 2 and 16
214539529|NCT00905034|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
214539530|NCT00905034|DRUG|Rituximab|Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
214539531|NCT00004265|DRUG|paclitaxel|
215157432|NCT07158385|OTHER|High fat high protein meal-carbohydrate counting (HFHP)|On the high-fat, high-protein meal-carbohydrate counting test day (HFHP), participants were given a high-fat and high-protein breakfast. Insulin was administered according to the individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
214539532|NCT00394589|DRUG|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
214539533|NCT00394589|DRUG|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
214539534|NCT00394589|DRUG|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
214539535|NCT05209724|BEHAVIORAL|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
214539536|NCT04081389|DRUG|Celecoxib|Given PO
214539537|NCT04081389|DRUG|Cyclophosphamide|Given IV
214539538|NCT04081389|DRUG|Doxorubicin|Given IV
214539539|NCT04081389|DRUG|Doxorubicin Hydrochloride|Given IV
214539540|NCT04081389|DRUG|Paclitaxel|Given IV
214539541|NCT04081389|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
214539542|NCT04081389|DRUG|Rintatolimod|Given IV
214539543|NCT03707847|DRUG|Crizotinib|250mg, BID, PO
214539544|NCT03707847|DRUG|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
214539545|NCT03707847|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
214539546|NCT06428877|OTHER|analyzed on the post-operative scanner|analyzed on the post-operative scanner
214539547|NCT01089309|DRUG|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
214539548|NCT05914415|OTHER|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
214539549|NCT02582385|OTHER|in-situ cytokine expression|
214539550|NCT04191876|OTHER|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
214539551|NCT02173145|DRUG|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
214539552|NCT02173145|DRUG|placebo|Placebo will be given 3 times a wek over a period of 3 months.
214539553|NCT02897089|DEVICE|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
214539554|NCT01114672|DRUG|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
214539555|NCT01114672|DRUG|Placebo|oral placebo once weekly
214539556|NCT03411993|DIAGNOSTIC_TEST|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
214539557|NCT04693910|OTHER|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
214539558|NCT03371745|PROCEDURE|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
214539559|NCT03371745|PROCEDURE|Cryopreservation|Rapid freezing using vitrification
214539560|NCT03371745|PROCEDURE|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
214539561|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
214539562|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
214539563|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
214539564|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
214539565|NCT03304756|DRUG|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
214539566|NCT06226298|DEVICE|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
214539567|NCT06226298|BEHAVIORAL|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
214539568|NCT02550483|OTHER|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214539569|NCT02550483|OTHER|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214708741|NCT02771457|DRUG|Infliximab at weeks 0,4, and 8|
214708742|NCT02771457|DRUG|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
215157433|NCT07158385|OTHER|High fat high protein meal-fat counting (HFHP-a)|On the high-fat, high-protein meal-fat-counting test day (HFHP-a), participants were given a high-fat and protein breakfast. In addition to their individual carbohydrate/insulin ratio, insulin was administered based on fat counting (1 unit for every 15 g of fat after the first 15 g of fat in the meal). In this method, the insulin dose calculated based on their individual carbohydrate/insulin ratio was delivered via insulin pump as a standard bolus, while the insulin dose calculated based on their fat count was delivered as a 4 hour extended bolus.
215157434|NCT07158385|OTHER|High fat high protein meal-fat and protein counting (HFHP-b)|On the high-fat, high-protein meal-fat and protein counting test day (HFHP-b), participants were given a high-fat and protein breakfast. In addition to the individual carbohydrate/insulin ratio, insulin was administered according to the adapted Pankowska Algorithm (1 FPU for every 100 kcal after the first 200 kcal of the meal). In this method, the insulin dose calculated based on the individual carbohydrate/insulin ratio was delivered as a standard bolus by an insulin pump, while the insulin dose calculated based on the fat and protein count was delivered as a spread over 4 hours.
215157435|NCT07158177|DEVICE|Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.|both of the patient's eyes will be implanted: 1 CPO and the other APO
215157436|NCT07158177|DEVICE|Clareon Panoptix|both of the patient's eyes will be implanted: 1 CPO and the other APO
215157437|NCT07156383|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first line treatment for Insomnia. Participants will receive weekly CBT-I during which they will receive the tools to improve their sleep.
215157438|NCT07157098|DEVICE|asymmetrical high-flow nasal cannula|high-flow nasal oxygen therapy via asymmetrical nasal prongs
215157439|NCT07157098|DEVICE|non-invasive ventilation with standard mask|non-invasive ventilation with standard oronasal mask, clinically used in the participting site
215157440|NCT07157098|DEVICE|non-invasive ventilation with a new mask|non-invasive ventilation with a new mask design, with under-nose, bridge-free design
215157441|NCT07157293|BEHAVIORAL|Online Motivation Enhancing Intervention|This is a online intervention that will ask participants to review and complete 30 minutes of material each week.
215157442|NCT07156266|PROCEDURE|Kegal Exercise|"Dead Bugs:Participants will begin by lying on their backs with their arms extended overhead and legs bent at a 90-degree angle. While engaging their core muscles, they will gradually lower their arms and legs toward the floor, then return to the starting position.~Bridging Exercise: Lying on their backs with knees bent and feet flat on the ground, participants will gently raise their hips upward while activating the pelvic floor muscles, then slowly lower them back to the starting position."
214539570|NCT02550483|OTHER|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214539571|NCT01163955|OTHER|Time to fatigue|5 minutes while playing video games
214539572|NCT01135082|BIOLOGICAL|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
214539573|NCT00934414|DRUG|Technosphere Insulin Inhalation Powder|30U
214539574|NCT04472988|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
214539575|NCT04472988|OTHER|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
214539576|NCT04472988|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
214539577|NCT03091582|BEHAVIORAL|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
214539578|NCT03091582|BEHAVIORAL|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
214539579|NCT03091582|BEHAVIORAL|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
214539580|NCT01710800|DRUG|Esomeprazole|
214539581|NCT01710800|DRUG|placebo|
214539582|NCT00900783|DRUG|valacyclovir|1 gram, three times a day for seven days
214539583|NCT00900783|DRUG|FV-100|400 mg, once daily, for seven days
214539584|NCT00900783|DRUG|FV-100|200 mg, once daily, for seven days
214539585|NCT00900783|DRUG|Valacyclovir placebo|three times a day, for seven days
214539586|NCT00900783|DRUG|FV-100 placebo|once daily, for seven days
214539587|NCT01963715|DRUG|IMGN289|
214539588|NCT00144846|DRUG|albuterol sulfate inhalation aerosol|
214708743|NCT00141934|DRUG|AD 452|
214708744|NCT01689766|DRUG|Technetium Tc 99m EC20|
214539589|NCT04520074|DRUG|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
214539590|NCT00341471|PROCEDURE|Risk Behavior Prevention Intervention Program|
215157443|NCT07156266|PROCEDURE|Squats Exercise|"Sumo Squats: Participants will stand with their feet placed wider than shoulder-width apart and toes pointing outward. They will then squat down, keeping their backs straight and their weight on their heels, pause briefly at the bottom, and return to a standing position.~Narrow Squats: With their feet set shoulder-width apart and toes pointing forward or slightly outward, participants will lower their bodies into a squat position while keeping their backs straight and their weight centered in the heels. After a brief pause, they will return to a standing position."
215157444|NCT07157423|DRUG|Eptacog alfa (NovoSeven)|Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)
215157445|NCT07157488|BEHAVIORAL|Conventional Physical Therapy With Dual Task Training|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Conventional PT (20 min): Wide leg squatting, hip flexion/extension, hip abduction/adduction, knee extension/flexion with ankle weights (Uysal et al., 2024).~Dual Task Training (20 min): Balance activities (semi-tandem stance, tiptoe, heel stance, one-leg stance, line walking) with cognitive activities (verbal fluency, simple math, memory recall, daily routine recall)."
215157446|NCT07157488|BEHAVIORAL|Dual Task Training With Vestibular Stimulation|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Dual Task Training (20 min): Same as Intervention 1 (balance + cognitive tasks).~Vestibular Stimulation (20 min): Sliding activity on physio roll (10 repetitions) and vertical bouncing on physio roll for 10 minutes (Parashar et al., 2017)."
215157447|NCT07156279|BEHAVIORAL|EFT(Emotional Freedom Technique)|EFT is a behavioral intervention in which participants tap with their fingertips on specific acupressure points while focusing on a target issue. The technique is non-invasive, painless, and simple to apply. Sessions also include the use of positive affirmations during tapping.
215157448|NCT07157358|BEHAVIORAL|standardized audio hypnosis recordings for healthy children at primary school|8 different audio hypnosis recordings hat chidlren will listen too at a daily basis (one recording per day)
215157449|NCT07158411|DRUG|Vimseltinib|Administered orally
215157450|NCT07158411|DRUG|Metformin|Administered orally
215157451|NCT07156903|OTHER|Interview|Patients and their care-givers will be asked to participate in interviews
215157452|NCT07158190|BIOLOGICAL|Vaccine|Vaccine TAK003 administration
215157453|NCT07158398|DRUG|Vimseltinib|Administered orally
215157454|NCT07158398|DRUG|Rosuvastatin|Administered orally
214539591|NCT01672593|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
214539592|NCT01672593|DRUG|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
214539593|NCT01672593|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
214539594|NCT01672593|PROCEDURE|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
214539595|NCT02146092|PROCEDURE|Incentive spirometry|
214539596|NCT02146092|OTHER|Physiotherapy|Standard of care exercise training and supervision
214539597|NCT04240236|PROCEDURE|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
214539598|NCT04240236|OTHER|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
214539599|NCT04745936|OTHER|Style curve similar to natural curvature of endotracheal tube|Stylet curvature is made similar to the natural curvature of endotracheal tube for intubation using C-MAC videolaryngoscope.
214539600|NCT04745936|OTHER|Style curve similar to hockey stick shape|Stylet curvature is made similar to hockey stick shape for intubation using C-MAC videolaryngoscope.
214539601|NCT04383145|DEVICE|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
214539602|NCT00696553|OTHER|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
214539603|NCT00696553|BEHAVIORAL|Nutrition plus Exercise|Nutrition plus Exercise
214539604|NCT00498095|PROCEDURE|Renal biopsy|
214539605|NCT05143112|BIOLOGICAL|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
214708745|NCT00520299|DRUG|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
215157455|NCT07157306|DRUG|Gecacitinib Combined With Donafenib and PD-1 Inhibitor|Subjects were enrolled and started receiving treatment with Gecacitinib (100mg, Bid, po) for 7 consecutive days; thereafter, they were treated with PD-1 antibody (Q3W, iv) and Donafenib (200mg, Bid, po), counting the day of infusion of PD-1 monoclonal antibodies as C1D1, with each cycle lasting 3 weeks. Subsequent treatments involved administering Gecacitinib for 1 week before each infusion of PD-1.
214539606|NCT06538467|OTHER|Hip extension exercise with inertial load|Hip extension exercise with inertial load
214539607|NCT06538467|OTHER|Hip extension exercise with gravitational load|Hip extension exercise with gravitational load
215157456|NCT07156344|DIAGNOSTIC_TEST|Progression and Outcome of Intracranial Atherosclerosis|"Progression and Outcome of Intracranial Atherosclerosis is the primary endpoint; all others are secondary endpoints. Stroke defined as any stroke and new ipsilateral stroke (including ischemic and hemorrhagic stroke) associated with vascular stenosis."
215157457|NCT07158203|DEVICE|CADx simultaneously|The investigators showed the CADx suggestion during the 15-second playback of the video
215157458|NCT07158203|BEHAVIORAL|CADx delayed|During the 15-seconds polyp video the CADx suggestion appear only in the last 3 seconds of the video
215157459|NCT07158164|DRUG|Fluorouracil injection|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
215157460|NCT07158164|DRUG|Xeloda|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
215157461|NCT07157722|DRUG|Iron chelating intervention|JADENU is indicated for the treatment of chronic iron overload due to blood transfusions.
215157462|NCT07157722|DRUG|N Acetyl cysteine 600mg|N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.
215157463|NCT07157722|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha lipoic acid (ALA) 600 mg will be administered orally once daily for 12 weeks.
215157464|NCT07154186|OTHER|Coronary Angiographic Assessment|Coronary angiographic assessment will be performed for all patients.
215157465|NCT07151508|DEVICE|Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age|"Secukinumab was administered in a weight-adapted dosing regimen equivalent to that used in clinical trials for psoriasis: 75 mg for less than 25 kg,150 mg for 25 to 50 kg, and 300 mg for greater than 50 kg at baseline and weeks1,2,3, and 4 and monthly there after.~Dupilumab was administered at a dose dependent on the patient's weight and age in accordance with the instructions."
215157466|NCT07158489|DRUG|Gemcitabine + Ivonescimab|"The trial combines two Investigational Medicinal Products (IMPs):~* Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC).~* Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation."
215157467|NCT07158437|BIOLOGICAL|SL-325|DR3 blocking antibody
215157468|NCT07158437|OTHER|Placebo (Normal Saline)|Normal saline
215157469|NCT07156422|PROCEDURE|A scalp biopsy using a 4 mm punch in the retroauricular hair zone|a scalp biopsy using a 4 mm punch in the retroauricular hair zone under local anesthesia
215157470|NCT07156422|OTHER|a general health questionnaire|a general health questionnaire : demographics, history, treatment, smoking, alcohol consumption, phototype.
215157471|NCT07156422|OTHER|Questionnaires concerning their sensitive scalp|"* The characteristics of a sensitive scalp (location, chronicity, triggering and soothing factors, use of cosmetics, etc.)~* Sensitive Scalp Score (3S)~* Impact on quality of life: BoSS questionnaire~* Impact of pruritus on quality of life (ItchyQol)"
215157472|NCT07157761|BEHAVIORAL|Buit in de klas|The program is taught by a trusted teacher of the students (for example, their mentor). The program consists of a lesson of about one hour. It includes a short film and an interactive chat box that allows students to chat with the main character of the film. In addition, there is a guideline for discussing the topic in the classroom and information on where to find help.
215157473|NCT07156565|DRUG|[Ac 225]RTX-2358|\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group (3 total) will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it is appropriate to allow the next group to proceed.
215157474|NCT07156565|DIAGNOSTIC_TEST|[Cu64]LNTH-1363S|\[Cu64\]LNTH-1363S is a investigational radioactive diagnostic imaging agent to demonstrate that the tumor expresses Fibroblast Activation Protein. An imaging test is performed after a single injection with \[Cu64\]LNTH-1363S 13-35 days before the first administration of study drug \[AC225\]RTX-2358 to confirm that the sarcoma has FAP expression.
215157475|NCT07157956|DRUG|CVL006 combined with pemetrexed and carboplatin|CVL006 combined with pemetrexed and carboplatin
215157476|NCT07157956|DRUG|CVL006 in combination with SKB264|CVL006 in combination with SKB264
215157477|NCT07157956|DRUG|CVL006 in combination with DS-8201|CVL006 in combination with DS-8201
215157478|NCT07157956|DRUG|CVL006 in combination with Enfortumab Vedotin|CVL006 in combination with Enfortumab Vedotin
214539608|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-PreF-A vaccine|B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
214708746|NCT01807091|DRUG|Chemotherapy|Receive outpatient induction chemotherapy
214708747|NCT03267589|DRUG|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
214708748|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121 without MF59®
214708749|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241 without MF59®
215157479|NCT07156942|BEHAVIORAL|Story-Based Digital Game|Participants in this arm played a story-based digital game during their regular hemodialysis sessions. The game was administered once per week, with each session lasting approximately 10 to 15 minutes, over a 4-week period. The game was accessed via an online platform and designed to educate patients on dietary choices, fluid management, and dialysis self-care through interactive storytelling and decision-making tasks.
215157480|NCT07156799|DRUG|Kaempferol Gel|Local topical application of Kaempferol gel into the implant site during one-stage delayed implant placement to enhance peri-implant bone healing and osseointegration.
215157481|NCT07158320|BEHAVIORAL|Relaxation training|In Jacobson's progressive muscle relaxation method, the first step is to make various muscle groups contract, to realize what it feels like to contract in this body area; The second step is to release these contracted muscle groups and notice how a relaxed muscle feels as the contraction subsides. During the exercise, the contraction is continued for 5 seconds. After the contraction, the muscles are relaxed for 10-15 seconds and in the meantime, rest is provided. Before starting the training, the person is taught the correct breathing technique and is asked to use the correct breathing technique throughout the practice. The practice should be done calmly without haste. During the practice, people should choose clothes that they can feel comfortable in. The practice should be applied in a quiet, dim environment where people can feel comfortable. It can also be performed with the eyes closed.
215157482|NCT07156305|BEHAVIORAL|Protective Behavioral Strategies|Participants receive psychoeducation about protective behavioral strategies and are asked to choose three strategies that they do not already engage in regularly but would be willing to start using more.
215157483|NCT07156305|BEHAVIORAL|Goal-Setting|Participants receive psychoeducation about protective behavioral strategies and goal-setting. They are asked to choose three strategies that they do not already engage in regularly and identify two goals related to each strategy.
215157484|NCT07157813|BEHAVIORAL|Structured Health Dialogue|"Health Screening (Approx. 15-20 minutes):~Measurement of height, weight, BMI, and waist-to-hip ratio Blood pressure recording Collection of fasting blood samples to assess glucose, cholesterol, and triglyceride levels~Health and Lifestyle Questionnaire:~Self-reported assessment of physical activity, dietary habits, alcohol and tobacco use, psychosocial stress, and family history of cardiovascular disease~Creation of an Individualized Health Curve:~Visual summary of the patient's current cardiovascular risk factors, showing how these factors interact and where improvement is needed~Structured Health Dialogue (60-90 minutes):~A one-on-one conversation between the participant and a trained nurse using principles of motivational interviewing Focused on identifying personal health goals, enhancing motivation for lifestyle change, and discussing possible support strategies Tailored Health"
215157485|NCT07156240|BEHAVIORAL|Experimental I (SDT)|SDT-based course aiming to inmprove professionals operational interpersonal qualities
215157486|NCT07156240|BEHAVIORAL|Experimental II (Hedonic)|Hedonic-based course aiming to inmprove professionals operational interpersonal qualities
215157487|NCT07156240|OTHER|Control group|FITT-VP bases course aiming to improve exercise prescription
215157488|NCT07156253|DRUG|SYN818 and Olaparib will be administered|Patients will orally receive SYN818 and Olaparib
215157489|NCT07157683|OTHER|Biospecimen collection|"If a blood sample is drawn as part of standard care, up to six additional EDTA tubes (42 mL max) will be collected for research.~In addition, the following optional samples may be collected, depending on investigator assessment and/or patient preference:~* Saliva sample (if no blood draw is performed)~* Urine sample~* Stool sample"
215157490|NCT07157150|BEHAVIORAL|Free Play SSG|Other current and former name(s) or alias(es), if any, different from the Intervention Name(s), that the sponsor has used publicly to identify the intervention(s), including, but not limited to, past or present names such as brand name(s), or serial numbers
215157491|NCT07157150|BEHAVIORAL|Controlled Pass|Participants train in 3v3 and 4v4 football games under Controlled Pass rules for 8 weeks.
215157492|NCT07156994|OTHER|No Intervention: Observational Cohort|Participants will be followed digitally using the LCC app. They will complete questionnaires about their health status and do voice recordings on their own rhythm during the entire study duration.
215157493|NCT07156292|OTHER|Observational study, not interventional|Observational study, not interventional
215157494|NCT07157709|OTHER|non-pharmacological interventions|Care staff collaborate with residents to select the most suitable non-pharmacological intervention from the designated toolkit to reduce pain. It is imperative to pay attention to the resident's preferences and to ascertain which intervention they would like to attempt.
215157495|NCT03474965|DRUG|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
215157496|NCT07157332|PROCEDURE|Bariatric Sleeve Surgery|Participants undergo a restrictive bariatric procedure called sleeve gastrectomy, performed by experienced surgeons. This procedure involves surgical reduction of the stomach size to aid in weight loss. The study observes outcomes related to iron metabolism, body composition, and biochemical markers over six months post-surgery. No additional interventions or treatments are applied as part of the study protocol; the surgery is part of routine clinical care.
215157497|NCT03229941|PROCEDURE|Blood Transfusion|Blood Transfusion
215157498|NCT03847428|DRUG|Durvalumab|Durvalumab IV (intravenous)
215157499|NCT03847428|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
214539609|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-F-B365 vaccine|B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
214539610|NCT06546423|DRUG|Placebo|Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
214708750|NCT05664334|BIOLOGICAL|Placebo|Diluent
214708751|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, without MF59®
214708752|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, without MF59®
214708753|NCT05664334|BIOLOGICAL|IVX-241|225 mcg of IVX-241, without MF59®
214708754|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, with MF59®
214708755|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241, with MF59®
214697321|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
215157500|NCT03847428|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
215157501|NCT01671917|OTHER|Educational and exercise program|"* 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour"
215157502|NCT01671917|OTHER|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
215157503|NCT02759718|BIOLOGICAL|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
215157504|NCT00880243|DRUG|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
215157505|NCT03253861|OTHER|No intervention|No intervention
215157506|NCT03696459|DRUG|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
215157507|NCT03696459|DRUG|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
215157508|NCT03696459|DRUG|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
215157509|NCT03696459|DRUG|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
214539611|NCT02586415|PROCEDURE|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
214539612|NCT02586415|DEVICE|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
214539613|NCT02586415|DEVICE|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
214539614|NCT02586415|DEVICE|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System \[026, 032, 041\] Penumbra System Separator Flex \[026, 032, 041, 054\] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 \& ACE68"
214539615|NCT02586415|DEVICE|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
214539616|NCT00639899|PROCEDURE|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
214539617|NCT01756144|DEVICE|rhBMP-2|
214539618|NCT00329563|DRUG|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
214539619|NCT04982627|BEHAVIORAL|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
214539620|NCT04982627|BEHAVIORAL|OUD Education & Treatment Resources|The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
214539621|NCT03451409|OTHER|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
214539622|NCT03451409|OTHER|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
214539623|NCT03708705|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
214539624|NCT04216485|BEHAVIORAL|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
214539625|NCT04216485|BEHAVIORAL|Standard Care|Standard prenatal care on diet, nutrition and physical activity
214539626|NCT00196534|DRUG|Human Thrombin|
214539627|NCT00196534|DRUG|Bovine Thrombin|
214539628|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
214539629|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
214539630|NCT04770909|BEHAVIORAL|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
214539631|NCT01423708|DRUG|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
214539632|NCT01037062|DRUG|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
214539633|NCT03385577|BEHAVIORAL|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
214539634|NCT03991598|OTHER|Exercise program|Exercise program in communities / Exercise program at home
214539635|NCT03562429|DRUG|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
214539636|NCT03562429|DRUG|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
214539637|NCT03094962|OTHER|Motion capture|Capture kinematics of finger movements
214539638|NCT03094962|DIAGNOSTIC_TEST|MR scan|Capture MR images of hand and fingers in three postures
214539639|NCT03094962|DIAGNOSTIC_TEST|CT scan|Capture CT images of hand and fingers in three postures
214539640|NCT01585298|DRUG|FTY720|
214539641|NCT05072262|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml
214539642|NCT05072262|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex)
214539643|NCT04400344|OTHER|No intervention|No intervention
214539644|NCT05294718|PROCEDURE|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
214539645|NCT05294718|PROCEDURE|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
214539646|NCT05132855|BIOLOGICAL|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
214539647|NCT05132855|BIOLOGICAL|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
214539648|NCT05132855|BIOLOGICAL|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
214539649|NCT04707456|OTHER|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
214539650|NCT04131010|DEVICE|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
214539651|NCT06115239|OTHER|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
214539652|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
214539653|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
214539654|NCT04545476|OTHER|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
214539655|NCT04545476|OTHER|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
214708756|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, with MF59®
214539656|NCT03143296|OTHER|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
214539657|NCT04827186|PROCEDURE|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
214539658|NCT04024514|OTHER|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
214539659|NCT04024514|OTHER|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
214539660|NCT04237714|BEHAVIORAL|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
214539661|NCT01980524|DRUG|acipimox|
214539662|NCT01980524|DRUG|Placebo Oral Capsule|
214539663|NCT00680147|BEHAVIORAL|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
214539664|NCT03440983|DEVICE|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
214539665|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
214539666|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
214539667|NCT02044614|OTHER|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
214539668|NCT03318783|DRUG|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
214539669|NCT03318783|DRUG|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
214539670|NCT01246050|OTHER|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
214539671|NCT01246050|OTHER|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
214539672|NCT01355822|DRUG|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
214539673|NCT01355822|DRUG|Placebo control|orally, twice daily
214539674|NCT04560023|OTHER|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
214539675|NCT05426161|DRUG|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
214539676|NCT00216957|PROCEDURE|Coronary bypass surgery without cardiopulmonary bypass|
214539677|NCT01154270|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
214539678|NCT02878460|OTHER|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
214697322|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214697323|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214539679|NCT02878460|OTHER|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
214539680|NCT03770052|DRUG|duvie|take the intervention drug once daily according to the randomized groups
214539681|NCT04006236|OTHER|Experimental Infant Formula|Feed Ad Libitum
214539682|NCT04006236|OTHER|Control Infant Formula|Feed Ad Libitum
214539683|NCT04647305|OTHER|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
214539684|NCT04647305|OTHER|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
214539685|NCT02415283|DEVICE|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
214539686|NCT05810441|OTHER|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
214539687|NCT04469062|DRUG|Mirikizumab IV|Administered IV
214539688|NCT04469062|DRUG|Mirikizumab SC|Administered SC
214539689|NCT04469062|DRUG|Vedolizumab IV|Administered IV
214697324|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214539690|NCT04469062|DRUG|Placebo IV|Administered IV
214539691|NCT04469062|DRUG|Placebo SC|Administered SC
214539692|NCT00639314|PROCEDURE|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
214539693|NCT00639314|PROCEDURE|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
214539694|NCT01233414|BEHAVIORAL|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
214539695|NCT01233414|OTHER|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
214539696|NCT04035577|BEHAVIORAL|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
214539697|NCT02056002|OTHER|Usual Care|\- Standard CPAP educational training
214539698|NCT02056002|OTHER|Peer-Buddy System|"* Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~\- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy"
214539699|NCT02056002|OTHER|Usual Care|\- Educational Brochures
214539700|NCT02056002|OTHER|Usual Care|\- Educational DVD videos mailed to participant
214708757|NCT05664334|OTHER|MF59®|MF59® as an adjuvant
214539701|NCT02591862|DRUG|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
214539702|NCT00705562|OTHER|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
214539703|NCT01313624|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
214539704|NCT01313624|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
214539705|NCT00104637|DRUG|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
214539706|NCT00104637|DRUG|Placebo|25 mg po tid
214539707|NCT01619462|BIOLOGICAL|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
214539708|NCT00505414|DRUG|Tapentadol in the Titration Phase|
214539709|NCT00505414|DRUG|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
214539710|NCT00505414|DRUG|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
214539711|NCT00505414|DRUG|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
214539712|NCT00505414|DRUG|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
214539713|NCT04660578|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
214539714|NCT03411798|DRUG|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
215157510|NCT03696459|DRUG|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
215157511|NCT03696459|DRUG|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
215157512|NCT03696459|DRUG|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
215157513|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
215157514|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
215157515|NCT01214096|DRUG|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
215157516|NCT01214096|DRUG|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
215157517|NCT00003182|DRUG|cisplatin|
215157518|NCT00003182|DRUG|gemcitabine hydrochloride|
215157519|NCT05426603|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
215157520|NCT05426603|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
215157521|NCT03198624|DRUG|HTL0018318|Part A single dose Part B five doses
214539715|NCT01684618|PROCEDURE|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
214539716|NCT04012658|OTHER|No intervention|No intervention
214539717|NCT00527150|DRUG|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
214539718|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
214708758|NCT01081821|DRUG|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
214697325|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214697326|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
215157522|NCT03198624|DRUG|Placebo oral capsule|Part B only
215157523|NCT06519721|DRUG|Lenvatinib Combined with VIC-1911|"Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months."
214539719|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
214539720|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
214539721|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
214539722|NCT02599493|DRUG|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
214539723|NCT05060835|OTHER|Virtual assistants offering medical recommendations to health care profesionals|the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
214539724|NCT01560871|BEHAVIORAL|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
214539725|NCT01560871|BEHAVIORAL|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
214539726|NCT05853692|DEVICE|Zinc Gluconate|Three times a day (spray)
214539727|NCT05853692|DEVICE|Sodium Bicarbonate|Five times a day (rinse)
214539728|NCT05318235|OTHER|No intervention|No intervention
214539729|NCT00746109|PROCEDURE|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
214539730|NCT00746109|PROCEDURE|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
214708759|NCT01081821|DRUG|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
214708760|NCT06059300|DIAGNOSTIC_TEST|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
214539731|NCT04158271|DEVICE|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
214539732|NCT04158271|DEVICE|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
214539733|NCT04158271|DEVICE|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
214539734|NCT06480435|OTHER|Chest physical Therapy|Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful
215157524|NCT00006118|DRUG|cisplatin|
215157525|NCT00006118|DRUG|gemcitabine hydrochloride|
214539735|NCT06480435|OTHER|Lungs squeezing technique|"It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase"
214539736|NCT01010997|DEVICE|Foresee Home|using the Foresee home device
214539737|NCT02187289|DEVICE|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
214539738|NCT02187289|DEVICE|Compression Sleeve, daytime wear|
214539739|NCT02187289|DEVICE|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
214539740|NCT01003262|OTHER|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
214539741|NCT01003262|OTHER|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
214539742|NCT03591627|DIAGNOSTIC_TEST|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
214539743|NCT00644878|DRUG|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
214539744|NCT00630136|BEHAVIORAL|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
214539745|NCT02625753|DRUG|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
214539746|NCT02625753|DRUG|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
214539747|NCT02625753|DRUG|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
214539748|NCT05879562|DIAGNOSTIC_TEST|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
214539749|NCT00037895|PROCEDURE|Ambulation training|
214539750|NCT04389346|PROCEDURE|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
214539751|NCT04389346|PROCEDURE|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
214697327|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
215157526|NCT00006118|DRUG|paclitaxel|
215157527|NCT05040113|DRUG|CBP-307|CBP-307 capsules oral administration
215157528|NCT00684060|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
215157529|NCT00684060|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
215157530|NCT04917341|DIAGNOSTIC_TEST|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
215157531|NCT06523101|DRUG|PJ009|Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.
215157532|NCT06523101|DRUG|Placebo|Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.
214539752|NCT01293799|BEHAVIORAL|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
214539753|NCT04071093|OTHER|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
214539754|NCT00948610|DRUG|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
214539755|NCT05549167|DRUG|Sirolimus|Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
214539756|NCT06104579|OTHER|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
214539757|NCT00796393|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
214539758|NCT00796393|DIETARY_SUPPLEMENT|Starch of potato|1 pill per day for 12 weeks
214539759|NCT04310176|DRUG|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
214697328|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214539760|NCT04310176|DRUG|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
214539761|NCT04310176|DRUG|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
214539762|NCT04310176|DRUG|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
214539763|NCT04310176|DRUG|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
214539764|NCT04310176|DRUG|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
214539765|NCT02649361|DRUG|Anlotinib|Anlotinib p.o. qd
214539766|NCT02649361|DRUG|Placebo|Placebo p.o. qd
214539767|NCT01395511|DEVICE|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
214539768|NCT00591591|DEVICE|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
214539769|NCT03121612|DEVICE|CPAP|CPAP therapy
214697329|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214697330|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
214697331|NCT01390116|DIETARY_SUPPLEMENT|Aged garlic extract|2 aged garlic extract capsules taken twice daily
214697332|NCT01390116|DIETARY_SUPPLEMENT|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
214697333|NCT02488551|DEVICE|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
214697334|NCT02488551|OTHER|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
214697335|NCT03963245|BEHAVIORAL|Meaningful Activities and Recovery|"MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
214697336|NCT03963245|BEHAVIORAL|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
214697337|NCT05238467|OTHER|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
214697338|NCT02005848|BIOLOGICAL|Alpha-1 Antitrypsin|
214539770|NCT00579449|BEHAVIORAL|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
214539771|NCT00579449|BEHAVIORAL|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
214697339|NCT02005848|OTHER|Placebo|Placebo
214697340|NCT02191423|DRUG|Oxytocin|administered pre-fMRI assessment
214697341|NCT02191423|DRUG|placebo|administered pre-fMRI assessment
214539772|NCT03889054|BEHAVIORAL|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
215157533|NCT03751657|DRUG|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
215157534|NCT03751657|DRUG|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
215157535|NCT03751657|DRUG|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
215157536|NCT03751657|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
215157537|NCT03751657|DRUG|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
215157538|NCT03751657|DRUG|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
215157539|NCT03162913|DIETARY_SUPPLEMENT|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
215157540|NCT03162913|OTHER|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
215157541|NCT02600819|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
215157542|NCT02600819|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
215157543|NCT01097031|OTHER|Infusion Intermittent|
215157544|NCT03712423|DRUG|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
215157545|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
215157546|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
215157547|NCT04797559|PROCEDURE|SZMN Block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
215157548|NCT02631590|DRUG|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
215157549|NCT02631590|DRUG|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
215157550|NCT02631590|DRUG|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
215157551|NCT02904954|DRUG|Durvalumab|Intravenously
214539773|NCT01270698|DRUG|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
214539774|NCT00616330|DRUG|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
214539775|NCT00616330|DRUG|clindamycin phosphate|semi solid, single dose
214539776|NCT00616330|DRUG|butoconazole nitrate|semi solid, single dose
214539777|NCT05028946|DRUG|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
214539778|NCT02085902|DRUG|Ropivacaine|
214539779|NCT04455685|OTHER|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
214697342|NCT02191423|BEHAVIORAL|Dyadic psychotherapy|
215157552|NCT02904954|OTHER|Durvalumab plus SBRT|Intravenously plus radiotherapy
215157553|NCT01857817|DRUG|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
215157554|NCT01857817|DRUG|Placebo|The placebo capsules will be prepared to match the active drug.
215157555|NCT02383212|DRUG|Cemiplimab|
215157556|NCT02383212|RADIATION|Hypofractionated radiotherapy|
215157557|NCT02383212|DRUG|Cyclophosphamide|
215157558|NCT02383212|DRUG|Docetaxel|
215157559|NCT02383212|DRUG|Carboplatin|
215157560|NCT02383212|DRUG|GM-CSF|
214539780|NCT03949712|DEVICE|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
214539781|NCT03949712|DEVICE|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
214539782|NCT03530488|DRUG|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
215157561|NCT02383212|DRUG|Paclitaxel|
215157562|NCT02383212|DRUG|Pemetrexed|
214539783|NCT03530488|PROCEDURE|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
214539784|NCT01419977|DRUG|Placebo|Normal saline solution, administered by nursing staff once daily
215157563|NCT05097963|DEVICE|Endoscopic Ultrasound Shear Wave Elastography|Software to determine stiffness of liver for evaluating liver fibrosis.
215157564|NCT01450332|DEVICE|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
215157565|NCT02146534|DRUG|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
215157566|NCT02146534|DRUG|Placebo|placebo will be taken PO BID
215157567|NCT02787629|PROCEDURE|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
215157568|NCT02787629|PROCEDURE|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
215157569|NCT02295670|DEVICE|Vividtrac|video-laryngoscopy
215157570|NCT02295670|DEVICE|MIL|direct-laryngoscopy
215157571|NCT01851759|DRUG|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
215157572|NCT01851759|DRUG|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
214539785|NCT01419977|DRUG|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
214539786|NCT02447276|DRUG|REGN475|
214539787|NCT02447276|DRUG|Placebo|
214539788|NCT03108976|OTHER|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
215029414|NCT03842280|DEVICE|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
215029415|NCT04326738|DRUG|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
215029416|NCT04326738|DRUG|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
215029417|NCT04824677|OTHER|Hospital treatment of COVID disease|Hospital treatment of COVID disease
215029418|NCT03910595|OTHER|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
215029419|NCT00011635|DRUG|Silymarin (milk thistle)|
215029420|NCT05236023|BEHAVIORAL|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
215029421|NCT06642740|OTHER|Platelet count|divide into two groups based on platelet count
215029422|NCT06563570|OTHER|yoga (online)|8-week online yoga practices, 2 days a week
215029423|NCT03578315|DEVICE|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
215029424|NCT06642272|DRUG|Empagliflozin 10 MG|Once daily
215029425|NCT06642272|DRUG|Dapagliflozin 10 MG|Once daily
215029426|NCT06216288|OTHER|Repeated back extension exercise (McKenzie)|repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
215029427|NCT06216288|DEVICE|Mechanical traction|The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
215029428|NCT03729609|DRUG|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
215029429|NCT06639776|DIAGNOSTIC_TEST|Questionnaire|"All erection prosthesis placements in post-phalloplasty transgender and gender non-conforming individuals at Ghent University Hospital from start of the gender clinic until June 2023 will be evaluated. All patients that are at least 6 months after erection prosthesis placement and currently have a functioning prosthesis in place are eligible and will be contacted. Upon inclusion and informed consent, the patient's medical files will be used to gather all necessary underlying medical information that is relevant to this study. will receive an email asking them to complete a questionnaire for themselves. At the end of this questionnaire the patient will be asked if they have a sexual partner and if this partner is willing to participate as well. After affirmation, the partner will be contacted in the same way.~Patients will receive a series of questionnaires reviewing recent sexual activity, sexual preference, satisfaction with the erectile prosthesis and quality partner relationship."
215029430|NCT06640660|DEVICE|Mindlenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
215029431|NCT06640660|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
215157573|NCT00859456|DRUG|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
215157574|NCT00337675|DRUG|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
215157575|NCT00337675|DRUG|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
215157576|NCT00337675|DRUG|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
215157577|NCT04518189|DRUG|lidocaine patch|lidocaine patch applied 3 hours before the procedure
215157578|NCT04518189|DRUG|Sham patch|Sham patch applied 3 hours before the procedure
215157579|NCT04633044|DIETARY_SUPPLEMENT|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
215157580|NCT04633044|DIETARY_SUPPLEMENT|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
215157581|NCT05521399|DIAGNOSTIC_TEST|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
215157582|NCT05521399|DIAGNOSTIC_TEST|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
214539789|NCT03108976|OTHER|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
214539790|NCT03108976|OTHER|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
214539791|NCT00137020|DRUG|ziprasidone|
214539792|NCT03040830|DRUG|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
214539793|NCT02950181|DEVICE|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
214539794|NCT04011423|OTHER|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
215157583|NCT05521399|DIAGNOSTIC_TEST|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
215157584|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
215157585|NCT04033458|DRUG|JNJ-64140284|Participants will receive JNJ-64140284 orally.
215157586|NCT04239248|DIETARY_SUPPLEMENT|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy."
215157587|NCT04239248|DIETARY_SUPPLEMENT|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
215157588|NCT04141839|BEHAVIORAL|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
215157589|NCT06055439|BIOLOGICAL|CHM-2101 CAR-T cells|Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
215157590|NCT05761886|OTHER|telehealth-based clinical pharmacy intervention|The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity
214539795|NCT04011423|OTHER|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
214539796|NCT05564546|PROCEDURE|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
214539797|NCT05564546|PROCEDURE|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
214539798|NCT05564546|OTHER|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* …"
215157591|NCT04751006|OTHER|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
215157592|NCT04751006|OTHER|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
215157593|NCT03230370|OTHER|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
215157594|NCT03230370|OTHER|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
215157595|NCT05155514|PROCEDURE|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
215157596|NCT01491607|BIOLOGICAL|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
215157597|NCT01708785|BEHAVIORAL|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
215157598|NCT01708785|BEHAVIORAL|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
215157599|NCT01708785|BEHAVIORAL|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
215157600|NCT01708785|BEHAVIORAL|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
215157601|NCT01317277|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
214539799|NCT05564546|OTHER|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
214539800|NCT05674292|DEVICE|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
214539801|NCT01841112|DRUG|Placebo|Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
214539802|NCT01841112|DRUG|BI-409306 25 milligram (mg) SD|Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
214539803|NCT01841112|DRUG|BI-409306 50 mg SD|Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
214539804|NCT01841112|DRUG|BI-409306 100 mg SD|Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
214539805|NCT01841112|DRUG|BI-409306 100 mg MD|Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
214539806|NCT05168137|DRUG|Low-dose colchicine|prescribed colchicine 0.6 mg/day
214539807|NCT05168137|DRUG|Placebo|Placebo of colchicine
214539808|NCT00177762|BEHAVIORAL|behavior weight loss|
214539809|NCT03302442|OTHER|Non interventional study|Not applicable - Non interventional Study
214539810|NCT04247269|OTHER|Enteral Tube Feeding|Enteral tube feeding
214539811|NCT03245177|BIOLOGICAL|Pembrolizumab|Anti-PD-1 antibody
214539812|NCT03245177|RADIATION|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
214539813|NCT06319651|OTHER|Lower Limb Resistance Band Exercises|"* Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening"
214539814|NCT06319651|OTHER|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
214539815|NCT03219671|DRUG|Nivolumab|nivolumab 240mg every 2 weeks
214539816|NCT03219671|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
215157602|NCT01317277|BEHAVIORAL|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
215157603|NCT00774566|PROCEDURE|PV-Isolation RF|Radiofrequency
215157604|NCT00774566|PROCEDURE|PV-Isolation Cryo|Cryo-Balloon
215157605|NCT02074683|PROCEDURE|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
215157606|NCT02074683|PROCEDURE|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
214539817|NCT03981718|PROCEDURE|Fat grafting|Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
214539818|NCT02680197|DRUG|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
215157607|NCT00852852|BEHAVIORAL|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
214539819|NCT00878553|DRUG|placebo|tablet at bedtime
215157608|NCT00912795|BEHAVIORAL|SMS Turkey|"6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
215157609|NCT04595981|DRUG|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
215157610|NCT00232726|DRUG|CP-4055 (ELACYT)|
215157611|NCT01075685|BEHAVIORAL|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
215157612|NCT01075685|BEHAVIORAL|Minimum information|"This intervention includes:~* information about hazardous drinking~* an alcohol diary"
215157613|NCT02037685|BEHAVIORAL|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~* Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~* Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
215157614|NCT02037685|OTHER|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
215157615|NCT01255683|DRUG|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
214539820|NCT00878553|DRUG|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
214539821|NCT00947141|DRUG|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR \>200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
214539822|NCT00947141|OTHER|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
215157616|NCT03470298|PROCEDURE|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
215157617|NCT04570319|DIETARY_SUPPLEMENT|Probiotic Bths-08|A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
215157618|NCT04570319|DIETARY_SUPPLEMENT|Placebo|A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
215157619|NCT05361148|OTHER|no interventions will be used|This is a cohort study with no interventions.
215157620|NCT02858362|DRUG|Ezutromid|Administered orally.
215157621|NCT06266832|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
215157622|NCT06266832|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1, Q3W
215157623|NCT06266832|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W
215157624|NCT06266832|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
215157625|NCT06266832|PROCEDURE|Biopsy|local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
215157626|NCT04945928|PROCEDURE|Surgery|Participants having been evaluated as operable after receiving first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) will receive surgery.
215157627|NCT00735267|DRUG|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
215157628|NCT03842189|DRUG|M281|Participants will receive once weekly intravenous (IV) infusions of M281
215157629|NCT03061006|DRUG|Dabigatran Etexilate|150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.
215157630|NCT03061006|DRUG|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
215157631|NCT01391052|DRUG|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
215157632|NCT01391052|OTHER|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
215157633|NCT04738461|OTHER|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
215157634|NCT04738461|OTHER|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
215157635|NCT04738461|OTHER|Home Exercise Group|The same exercise program applied to telerehabilitation group.
214539823|NCT00947141|DRUG|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
214539824|NCT00947141|OTHER|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
214539825|NCT00592462|PROCEDURE|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
214539826|NCT03253068|DRUG|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
214539827|NCT03866447|DRUG|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
214539828|NCT03866447|DRUG|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
214539829|NCT05009381|DEVICE|Stylage XXL at enrollment|Injection in the chin at enrollment
214539830|NCT05009381|DEVICE|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
214539831|NCT00220480|DRUG|escitalopram|10 to 30 mg / day
215157636|NCT02991976|PROCEDURE|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
215157637|NCT01262989|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
215157638|NCT01262989|DRUG|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
215157639|NCT06835933|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is most commonly performed bariatric/metabolic surgery. LSG is performed in patients with obesity and/or obesity-related comorbidities. During LSG, the stomach was resected from 5 cm proximal to the pylorus to the angle of His, guided by a 36-French bougie. In patients with hiatal hernia, concomitant HHR was also performed with LSG using non-absorbable sutures. Routine oral potassium-competitive acid blocker (PCAB) was prescribed for 3 months after surgery and the discontinuation of PCAB was determined based on GERD symptoms at the 3-month visit.
215157640|NCT02557880|BEHAVIORAL|Sleep Application Diary|Tool used to document sleep hygiene.
215157641|NCT02557880|BEHAVIORAL|Treatment As Usual|Sleep hygiene counseling
215157642|NCT06003270|DRUG|Quercetin 1000 mg|Active comparator
215157643|NCT06003270|DRUG|Quercetin 500 MG|Active comparator
214539832|NCT02504749|PROCEDURE|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
215157644|NCT06003270|DRUG|Placebo|Placebo comparator
215157645|NCT04551534|DRUG|DNL201|Oral dose(s)
215157646|NCT04551534|DRUG|Placebo|Oral dose(s)
214539833|NCT03625453|DRUG|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
214539834|NCT03625453|DRUG|Placebo|Part 1: 8 weeks with daily administration
214539835|NCT04276298|DRUG|Metronidazole cream|10% metronidazole applied rectally
214539836|NCT04276298|DRUG|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
214539837|NCT04276298|DRUG|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
214697343|NCT02667860|PROCEDURE|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
215157647|NCT02961738|BEHAVIORAL|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
214539838|NCT04276298|DRUG|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
214539839|NCT03739333|OTHER|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
214539840|NCT00461123|DRUG|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
214539841|NCT00461123|DRUG|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
214539842|NCT02692287|DEVICE|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
214539843|NCT04377412|OTHER|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
214539844|NCT01228305|OTHER|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
214539845|NCT04807283|DEVICE|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
214539846|NCT00177372|DRUG|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
214539847|NCT05955755|OTHER|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
214539848|NCT04252170|DEVICE|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
214539849|NCT05076136|OTHER|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
214539850|NCT05076136|OTHER|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
214539851|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
214539852|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
214697344|NCT02667860|PROCEDURE|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
214697345|NCT02667860|DEVICE|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
215157648|NCT05529797|OTHER|Veovita-VR|Veovita-VR is a VR intervention with positive emotional stimuli and positive behavioral activation designed to reduce depressive symptoms in people with at least moderate depressive symptoms. In the VR session, the participants stay in a beautiful environment (island, sandy beach, beautiful scenery). They can engage in activities that are perceived as positive (climbing, treasure hunting, listening to music, building sandcastles). The session has a length of approx. 30 minutes. Participants are free to continue to engage with any treatment they require during the duration of the study.
214539853|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
214539854|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
214539855|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
214539856|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
214539857|NCT03075098|DEVICE|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
214539858|NCT00702546|DRUG|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
214539859|NCT00702546|BIOLOGICAL|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
214539860|NCT00702546|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
214539861|NCT00702546|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
214539862|NCT00702546|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
214539863|NCT00702546|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
214539864|NCT00702546|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
214539865|NCT00702546|BIOLOGICAL|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
214697346|NCT02667860|DEVICE|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
215157649|NCT02273804|DRUG|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
214539866|NCT01982175|BIOLOGICAL|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~\--------------------------------------------------------------------------------"
214539867|NCT05639998|BIOLOGICAL|COVAXIN(BBV152)|COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
214539868|NCT05639998|BIOLOGICAL|BBV154 Intranasal Vaccine|BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
215157650|NCT02273804|DRUG|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
214539869|NCT00876499|BEHAVIORAL|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
214539870|NCT05566509|PROCEDURE|Breast excision|some patient had minimal excision, some had maximal excision.
214697347|NCT05851508|DRUG|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
214697348|NCT05851508|DRUG|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
215157651|NCT05688722|PROCEDURE|Supine position|Patients preoxygenated in supine position before endotracheal intubation
215157652|NCT05688722|PROCEDURE|20 degree head elevation position|Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
215157653|NCT05688722|PROCEDURE|30 degree head elevation position|Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
214539871|NCT01475422|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
214539872|NCT01475422|BEHAVIORAL|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
214539873|NCT03714542|OTHER|Pre- and postoperative MRI|
214539874|NCT02675218|OTHER|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
214539875|NCT04234503|BEHAVIORAL|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
214539876|NCT00037661|DRUG|INS365 Ophthalmic Solution|
214539877|NCT02483598|DRUG|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
214539878|NCT02483598|DRUG|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
214539879|NCT00520871|DRUG|Blueberry juice|
214539880|NCT03633864|BIOLOGICAL|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
214539881|NCT03180008|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
214539882|NCT03180008|BEHAVIORAL|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
214539883|NCT03769298|DRUG|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
214539884|NCT02540343|OTHER|questionnaires|fill out all questionnaires twice
214539885|NCT00833183|DRUG|MAL|80 mg/g cream one administration with incubation for 90 minutes
214539886|NCT00609323|DRUG|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
214539887|NCT00609323|DRUG|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
214539888|NCT04836234|OTHER|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
214539889|NCT04228354|DRUG|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
214539890|NCT05928858|DRUG|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
214539891|NCT05928858|DRUG|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
214539892|NCT05896696|DEVICE|BeShape One|Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
214539893|NCT00406406|DRUG|SKI-606|
214539894|NCT01517607|OTHER|Mesalazine|Patient's treated with oral Mesalazine
214539895|NCT03304613|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
214697349|NCT04834973|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
214697350|NCT04834973|DRUG|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
214697351|NCT00002358|DRUG|Sorivudine|
214697352|NCT02517827|DEVICE|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
214697353|NCT02517827|PROCEDURE|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
214539896|NCT03304613|BEHAVIORAL|Promoting Resilience through Innovative Self-Management|Already noted.
214539897|NCT02185677|OTHER|Clinical evaluation|
214539898|NCT02185677|OTHER|neuropsychological battery test|
214539899|NCT02185677|OTHER|MRI|
214539900|NCT02185677|OTHER|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
215157654|NCT05688722|PROCEDURE|45 degree head elevation position|Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
215157655|NCT02922049|OTHER|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
215157656|NCT02877992|PROCEDURE|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
214539901|NCT05308277|DEVICE|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
214539902|NCT01988298|DRUG|Ibuprofen|Ibuprofen 400 mg each 8 hours
214539903|NCT01988298|DRUG|Acetaminophen|Control group
214539904|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
214539905|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
214539906|NCT00390078|BIOLOGICAL|MVA-mBN32|3 immunizations: 1x 10E8\_TCID50 MVA-mBN32
214539907|NCT00390078|BIOLOGICAL|IMVAMUNE|3 immunizations: 1x 10E8\_TCID50 IMVAMUNE
214539908|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
214539909|NCT05901155|DEVICE|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
214539910|NCT04597970|DRUG|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
215157657|NCT05355246|OTHER|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
215157658|NCT05355246|OTHER|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
214539911|NCT02080403|DRUG|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
214697354|NCT04866303|DIAGNOSTIC_TEST|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
214697355|NCT00783211|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
214697356|NCT00783211|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
214697357|NCT00783211|DRUG|placebo|placebo, once daily for 15 days
214697358|NCT05120960|DRUG|tepotinib|Given by PO
214697359|NCT05120960|DRUG|tepotinib plus osimertinib|Given by PO
214697360|NCT00923234|DRUG|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
214697361|NCT00923234|DRUG|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
215157659|NCT04904393|DEVICE|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
215157660|NCT03858309|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
215157661|NCT03858309|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
215157662|NCT02813577|DEVICE|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
215157663|NCT00663091|DRUG|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
215157664|NCT00663091|DRUG|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
215157665|NCT00663091|DRUG|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
214697362|NCT00064129|BIOLOGICAL|Ipilimumab|Given IV
214697363|NCT00064129|OTHER|Laboratory Biomarker Analysis|Correlative studies
214697364|NCT00064129|OTHER|Pharmacological Study|Correlative studies
214697365|NCT00064129|BIOLOGICAL|Sargramostim|Given SC
214697366|NCT03209635|DIETARY_SUPPLEMENT|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
214697367|NCT03209635|DIETARY_SUPPLEMENT|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
214697368|NCT01163253|DRUG|CP-690,550|5 mg oral BID
214697369|NCT01163253|DRUG|CP-690,550|10 mg oral BID
214697370|NCT05649618|BIOLOGICAL|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
214697371|NCT05649618|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
214697372|NCT05649618|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214697373|NCT05649618|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
214697374|NCT01188564|DRUG|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
214697375|NCT01188564|DRUG|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
214697376|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
214697377|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
214697378|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
214708761|NCT01354613|DRUG|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
214539912|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
214539913|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
214539914|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
214539915|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
214539916|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
214539917|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
214539918|NCT06105762|OTHER|Ketogenic Diet|The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
214539919|NCT00103532|BEHAVIORAL|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
214539920|NCT00103532|BEHAVIORAL|Standard care|Participants will receive standard care plus referrals at three months post-baseline
214539921|NCT06198699|DIETARY_SUPPLEMENT|Jing Si Herbal Tea|Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water
214539922|NCT06198699|DIETARY_SUPPLEMENT|Barley Tea|Consuming Barley Tea for three months; twice per day with each time 600 ml barley tea consumption
214539923|NCT05064644|OTHER|Product that contains plant stanol ester|Product with active ingredient
214539924|NCT05064644|OTHER|Placebo product|Product without active ingredient
214539925|NCT04710186|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
214539926|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
214539927|NCT02654899|OTHER|Placebo|Placebo
214539928|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
214539929|NCT02668198|DEVICE|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
214539930|NCT02668198|DEVICE|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
214708762|NCT01354613|DRUG|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
214708763|NCT03255265|OTHER|no interventions|no interventions
214708764|NCT00250185|DRUG|Sodium Nitrate|
214539931|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
214539932|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
214539933|NCT02668198|PROCEDURE|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
214539934|NCT02826798|DRUG|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
214539935|NCT02826798|DRUG|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
214539936|NCT02826798|DRUG|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
214539937|NCT02826798|DRUG|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
214539938|NCT02826798|DRUG|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
214539939|NCT02435576|RADIATION|Radiotherapy (primary or postoperative)|
214539940|NCT02330276|DRUG|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
214539941|NCT04460729|DRUG|Capmatinib|400 mg administered orally twice daily
214539942|NCT05731505|BEHAVIORAL|theory-based education-consulting|Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
214539943|NCT01955759|DRUG|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
214539944|NCT01955759|DRUG|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
214708765|NCT00250185|DRUG|Acetylcholine|
214539945|NCT01955759|DRUG|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
214539946|NCT01986114|DRUG|SM-13496|
214539947|NCT00664105|DRUG|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
214539948|NCT00664105|DRUG|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
214539949|NCT00664105|RADIATION|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
214539950|NCT06240429|DIETARY_SUPPLEMENT|Collagen|Daily doses of 10 g collagen peptide supplementation
214539951|NCT00683059|DRUG|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
214539952|NCT00220545|PROCEDURE|Laparoscopic ovarian diathermy|
214539953|NCT04212780|DEVICE|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
214539954|NCT04212780|PROCEDURE|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
214539955|NCT04212780|PROCEDURE|standard ET DBS|Single Lead VIM
214539956|NCT04212780|PROCEDURE|ipsilateral VO|second lead in the ipsilateral VO
214539957|NCT05498922|PROCEDURE|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9\_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
214539958|NCT04581408|DRUG|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
214539959|NCT05097209|DRUG|Camrelizumab|Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
214539960|NCT05097209|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
214539961|NCT05097209|DRUG|Induction Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
214539962|NCT05097209|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
214539963|NCT05097209|DRUG|Concurrent cisplatin|Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214539964|NCT04633954|DRUG|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
214539965|NCT04702893|DRUG|Nintedanib|150 or 100 milligrams (mg) of nintedanib, when 150 mg is not tolerated, twice daily, administered 12 hours apart, according to the approved label.
214539966|NCT06956183|OTHER|Control (Standard treatment)|In control group participants will take one hour conventional physiotherapy including stretching, strengthening, balance and gait exercises in each session.
214539967|NCT06956183|OTHER|Vestibular exercise|In vestibular group (study group) participant will take 40 minutes conventional physiotherapy including stretching, strengthening, balance and gait exercises, and 20 minutes vestibular exercises including head and gaze stabilization, occulomotor, head turning and balance exercises in different postures.
214539968|NCT02988297|DRUG|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
214539969|NCT02988297|DRUG|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
214539970|NCT05611749|DRUG|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
214539971|NCT05611749|OTHER|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
214539972|NCT04469465|DRUG|Danicopan|Oral tablet
214539973|NCT04469465|DRUG|Placebo|Oral tablet
214539974|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
214539975|NCT06130059|DRUG|Low Dose Colchicine|Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
214539976|NCT06130059|DRUG|Placebo|Placebo
214539977|NCT01951378|DEVICE|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
214708766|NCT01047748|DRUG|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
214708767|NCT01047748|DRUG|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
214539978|NCT01951378|DEVICE|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
214539979|NCT01951378|DRUG|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
214539980|NCT00487318|DRUG|standard of care|peginterferon/RBV
214539981|NCT00487318|DRUG|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
214539982|NCT01620970|DRUG|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
214539983|NCT00021047|DRUG|capecitabine|
214539984|NCT00021047|DRUG|carboplatin|
214539985|NCT00021047|DRUG|epirubicin hydrochloride|
214539986|NCT06624839|BIOLOGICAL|Human papillomavirus (HPV) vaccine, 9-valent|0.5 ml intramuscular injection
214539987|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
214539988|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
214539989|NCT03277677|DRUG|Normal saline|for resuscitation in sepsis patients
214539990|NCT03277677|DRUG|Ringer's Acetate|for resuscitation in sepsis patients
214539991|NCT06190288|OTHER|Transitional care model|A newly developed care model to support frail older adults during their transition from hospital to home.
214539992|NCT06553807|OTHER|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
214539993|NCT05264272|OTHER|Prospective serological assays|"1. Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~2. BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
214539994|NCT05264272|OTHER|Retrospective serological assays|"1. Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~2. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
214539995|NCT03437941|DRUG|CORT125281|CORT125281 is supplied as capsules for oral dosing
214539996|NCT03437941|DRUG|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
214539997|NCT03437941|DRUG|Placebo|Placebo capsules to match the appearance of the CORT125281
214539998|NCT04949854|DEVICE|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
214539999|NCT04949854|DEVICE|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
214540000|NCT05907317|DEVICE|Cerebral oximetry monitoring device|Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.
214540001|NCT05907317|OTHER|Usual care|Treatment as usual
214540002|NCT04331132|DRUG|Tolvaptan 15 MG|vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
214540003|NCT04692805|DEVICE|coils|EUS-guided injection of coils
214540004|NCT04692805|DRUG|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
214540005|NCT00002716|DRUG|dexamethasone|
214540006|NCT00002716|DRUG|floxuridine|
214540007|NCT00002716|DRUG|fluorouracil|
214540008|NCT00002716|DRUG|leucovorin calcium|
214540009|NCT00002716|PROCEDURE|laparotomy|
214540010|NCT00002716|PROCEDURE|conventional surgery|
214540011|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
214697379|NCT02492997|DEVICE|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
214697380|NCT02492997|OTHER|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
214697381|NCT04357119|PROCEDURE|One-anastomosis gastric bypass|"Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision."
214697382|NCT03972358|DRUG|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
214697383|NCT03972358|DRUG|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
214697384|NCT04886999|BEHAVIORAL|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
214697385|NCT00000875|DRUG|Indinavir sulfate|
215029432|NCT06642129|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
214540012|NCT01038453|OTHER|placebo tablet|placebo 2 tablet, once a day,
214540013|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
214540014|NCT05328024|DRUG|Immunotherapy|anti-PD1
214540015|NCT01354249|DIETARY_SUPPLEMENT|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
214540016|NCT01660256|DRUG|OPC-12759|Instillation, 4 times/day for 4 weeks
214540017|NCT01660256|DRUG|Placebo|
214540018|NCT02582268|DEVICE|intrauterine device TCu 380A|
214540019|NCT02582268|RADIATION|Trans-abdominal sonography|
214540020|NCT06027229|BIOLOGICAL|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
214540021|NCT03491215|DRUG|Ruxolitinib|All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
214540022|NCT01855347|DEVICE|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
214540023|NCT01984762|PROCEDURE|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
214540024|NCT01984762|PROCEDURE|sleeve gastrectomy|SG = sleeve gastrectomy
214540025|NCT04585737|DRUG|Dolutegravir / Lamivudine Pill|Experimental
214540026|NCT04585737|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
214540027|NCT01848067|DRUG|Alisertib|Given PO
214540028|NCT01848067|DRUG|Abiraterone acetate|Given PO
214540029|NCT01848067|DRUG|Prednisone|Given PO
214540030|NCT06512220|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
214540031|NCT06512220|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
214540032|NCT00058942|DEVICE|home drinking water treatment device|
214540033|NCT00541671|DRUG|Saline|10 c of saline
214540034|NCT00541671|DRUG|Phenergan|Physician ordered dose
214540035|NCT00551135|DRUG|Pregabalin|150 mg BID
214540036|NCT00551135|DRUG|placebo|Placebo
214540037|NCT00551135|DRUG|Pregabalin|75 mg BID
214540038|NCT00551135|DRUG|Pregabalin|25 mg BID
214540039|NCT01202409|DRUG|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
214540040|NCT05917548|DEVICE|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
214540041|NCT05917548|BEHAVIORAL|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
214697386|NCT00000875|DRUG|Diphenhydramine hydrochloride|
214697387|NCT00000875|DRUG|Lymphocytes, Activated|
214697388|NCT00000875|DRUG|Lamivudine|
214697389|NCT00000875|DRUG|Zidovudine|
215157666|NCT06132815|DEVICE|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
215157667|NCT06132815|OTHER|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
215157668|NCT06132815|OTHER|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
214540042|NCT05781997|DIAGNOSTIC_TEST|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by \>0.50D.
214540043|NCT03096197|DEVICE|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
214540044|NCT03096197|DEVICE|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
214540045|NCT02913170|DIETARY_SUPPLEMENT|Nattokinase|
214540046|NCT02913170|DIETARY_SUPPLEMENT|Placebo|
214540047|NCT01115283|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
214540048|NCT01115283|BEHAVIORAL|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
214540049|NCT01115283|BEHAVIORAL|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
214540050|NCT06443424|DEVICE|ultrasound device|usage of ultrasound device in pediatric airway asessment
214540051|NCT02949856|DEVICE|Mallinckrodt, COVIDIEN|
214540052|NCT02949856|DEVICE|Endotracheal tube, Unomedica|
214540053|NCT00145483|DRUG|Sildenafil|
214540054|NCT01004185|DRUG|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM
214540055|NCT01004185|DRUG|Asacol 400 mg|17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
214540056|NCT00574483|DRUG|quinacrine|100 mg day
214540057|NCT06433440|BIOLOGICAL|PVRV|Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
214540058|NCT02788526|PROCEDURE|Adjuvant TACE|1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
214540059|NCT02788526|PROCEDURE|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
214540060|NCT03962517|DEVICE|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
214540061|NCT03962517|OTHER|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
214540062|NCT01649505|DRUG|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
214540063|NCT01649505|PROCEDURE|breast reconstruction|Undergo sharp dissection technique
214540064|NCT01649505|PROCEDURE|breast reconstruction|Undergo electrocoagulation dissection technique
214540065|NCT03396211|DRUG|Apatinib|Apatinib tablets
214540066|NCT03396211|DRUG|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
214540067|NCT04932226|DEVICE|cloth mask|Buff bandana double layer worn over nose and mouth
214540068|NCT04932226|DEVICE|surgical mask|standard surgical mask
214540069|NCT04932226|DEVICE|FFP2 respirator|filtering facepiece 2 respirator
214540070|NCT02296203|DRUG|cetuximab|
214540071|NCT02296203|DRUG|irinotecan|
214540072|NCT03526978|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
214540073|NCT03526978|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
214540074|NCT06235853|DIAGNOSTIC_TEST|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
214540075|NCT06235853|DIAGNOSTIC_TEST|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
214540076|NCT02440737|OTHER|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
214540077|NCT02440737|OTHER|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
214540078|NCT02440737|PROCEDURE|Psychosocial Assessment and Care|Undergo the NEST intervention
214540079|NCT02440737|OTHER|Questionnaire Administration|Ancillary studies
214540080|NCT00171366|DRUG|amlodipine/benazepril|
214540081|NCT04546022|DRUG|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
214540082|NCT00188825|OTHER|placebo|
214540083|NCT00188825|DRUG|basiliximab|
214540084|NCT06483685|DRUG|Radiopharmaceuticals drugs|radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
214540085|NCT02153190|DEVICE|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
214540086|NCT02153190|DEVICE|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
214540087|NCT03334877|DIAGNOSTIC_TEST|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
214540088|NCT04709978|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
214540089|NCT04709978|DIAGNOSTIC_TEST|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
214540090|NCT04709978|DIAGNOSTIC_TEST|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
214540091|NCT04709978|DIAGNOSTIC_TEST|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
214540092|NCT04709978|DIAGNOSTIC_TEST|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
214540093|NCT04709978|DIAGNOSTIC_TEST|Lung Ultrasound|To image the lungs (ED participants only)
214540094|NCT04709978|DIAGNOSTIC_TEST|Respiratory Function Tests|To measure respiratory pressures.
214540095|NCT01046591|PROCEDURE|Polysomnography|Overnight sleep studies will be performed on all children.
214540096|NCT00002971|DRUG|O6-benzylguanine|
214540097|NCT04604470|OTHER|Decision tool|no intervention.
214540098|NCT05041725|DRUG|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
214540099|NCT01272323|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
214540100|NCT01272323|BIOLOGICAL|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
214540101|NCT01272323|BIOLOGICAL|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
214540102|NCT01172639|DRUG|Methotrexate|Methotrexate tablet
214540103|NCT01172639|DRUG|Sulfasalazine|Sulfasalazine tablet
214540104|NCT01172639|DRUG|Leflunomide|Leflunomide tablet
214540105|NCT01172639|DRUG|Prednisone|Prednisone tablet
214540106|NCT00070343|BIOLOGICAL|oblimersen sodium|
214540107|NCT00070343|DRUG|dacarbazine|
214540108|NCT03110263|OTHER|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
214540109|NCT03110263|OTHER|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
214540110|NCT05469113|DRUG|Repaglinide|Administered orally.
214540111|NCT05469113|DRUG|Selpercatinib|Administered orally.
214540112|NCT01516853|DEVICE|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
214540113|NCT05708300|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
214540114|NCT02142998|OTHER|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
214540115|NCT02142998|OTHER|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
214540116|NCT00495872|DRUG|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
214540117|NCT00495872|DRUG|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
214540118|NCT00495872|DRUG|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
214540119|NCT00495872|DRUG|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
214697390|NCT00000875|DRUG|Acetaminophen|
214540120|NCT00495872|DRUG|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
214540121|NCT00495872|DRUG|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
214540122|NCT00495872|DRUG|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
214540123|NCT03500666|DEVICE|Robot|Robot lateral neck lymph node dissection
214540124|NCT03500666|DEVICE|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
214540125|NCT04745377|DIAGNOSTIC_TEST|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
214540126|NCT00720369|DRUG|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
214540127|NCT00469456|DRUG|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
214540128|NCT00469456|DRUG|placebo|Placebo oral administration twice daily for 12 weeks
214540129|NCT02880683|DEVICE|NeuroTronik CANS Therapy System|
214540130|NCT05560750|PROCEDURE|Frenotomy|Releasing the tongue-tie with scissors
214540131|NCT05560750|PROCEDURE|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
214540132|NCT04379817|DIAGNOSTIC_TEST|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
214540133|NCT04367077|BIOLOGICAL|MultiStem|intravenous infusion
214540134|NCT04367077|BIOLOGICAL|Placebo|intravenous infusion
214540135|NCT01136447|PROCEDURE|Ultrasound|Block catheter will be introduced using ultraosound
214540136|NCT05139823|PROCEDURE|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
214540137|NCT02163798|BEHAVIORAL|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
215157669|NCT06132815|OTHER|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
215157670|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
214540138|NCT02163798|BEHAVIORAL|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
215157671|NCT01446055|DEVICE|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
215157672|NCT01446055|DEVICE|Ficoll conventional cell processing method|Comparison of different cell processing methods
214540139|NCT01487902|DRUG|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
214540140|NCT01487902|DRUG|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
214540141|NCT02606383|DRUG|Dapaconazole|
214540142|NCT02606383|DRUG|Ketoconazole|
214540143|NCT05307263|PROCEDURE|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
214540144|NCT05307263|PROCEDURE|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
214540145|NCT05964361|BIOLOGICAL|IL15-transpresenting WT1-targeted Dendritic Cell Vaccine|IL15/IL15Ra/WT1 DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered every 2 weeks (+- 3 days) for a total of 6 administrations.
214540146|NCT06007105|BEHAVIORAL|SUCCEED Community-Based Intervention|"The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach."
214697391|NCT00000875|DRUG|Aldesleukin|
214540147|NCT03752255|OTHER|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
214540148|NCT00000850|DRUG|Indinavir sulfate|
214540149|NCT00000850|DRUG|Sargramostim|
214540150|NCT04731142|DEVICE|Huma|Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
214540151|NCT04731142|BEHAVIORAL|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals."
214697392|NCT06373172|OTHER|virtual simulation-based education program|"We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module."
214697393|NCT00469404|DRUG|Buprenorphine|
214697394|NCT00568880|DRUG|bortezomib|bortezomib 1.0-1.3mg/m2 IV
214697395|NCT00568880|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg pill
214697396|NCT01450046|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
215157673|NCT06360120|DRUG|Atorvastatin 40 Mg Oral Tablet|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215157674|NCT06360120|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215157675|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215157676|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
215157677|NCT00668889|DRUG|Lactic acid (Dermacid)|
215157678|NCT02780752|DRUG|hymecromone|Oral Hymecromone
215157679|NCT00573300|PROCEDURE|Phlebotomy|Single blood draw
215157680|NCT04931706|OTHER|Magnetics Assisted by Singe port|Use of magnet for assistance through the surgery, and a novel approach as it is single port
215157681|NCT00160901|DRUG|two complex naturopathic add-on therapies, leaflet 5-a-day|
215157682|NCT05066932|OTHER|Additionnal blood samples|Additionnal blood samples
215157683|NCT02131649|DEVICE|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
215157684|NCT02627261|BIOLOGICAL|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
215157685|NCT06519851|OTHER|suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%|postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
215157686|NCT06519851|OTHER|Interscalene block with 20 ml bupivacaine 0.25%|postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
215157687|NCT03370978|BEHAVIORAL|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
215157688|NCT02921841|BEHAVIORAL|D*STAR|
214540152|NCT04731142|BEHAVIORAL|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
215157689|NCT02921841|BEHAVIORAL|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
215157690|NCT04413006|BEHAVIORAL|Self-Compassion for Chronic Pain Virtual Group Treatment Program|6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
215157691|NCT02233361|BEHAVIORAL|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
214540153|NCT04731142|OTHER|Standard of care|Normal primary care service provided to matched control group.
214540154|NCT05538416|PROCEDURE|Posterior Lumbar Interbody Fusion (PLIF)|Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
214540155|NCT03892551|OTHER|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
214540156|NCT03892551|OTHER|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
214540157|NCT03892551|OTHER|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
214540158|NCT03892551|DIAGNOSTIC_TEST|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
214540159|NCT03892551|OTHER|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
214540160|NCT03892551|OTHER|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
214540161|NCT03892551|OTHER|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
214540162|NCT02316288|BEHAVIORAL|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
214540163|NCT02316288|BEHAVIORAL|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
214540164|NCT01168245|DEVICE|Sham-NICE-System|sham TMS and sham cognitive training
214540165|NCT01168245|DEVICE|NICE-System|TMS combined with cognitive training
214540166|NCT02785731|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
214540167|NCT02785731|PROCEDURE|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
214540168|NCT02785731|PROCEDURE|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
214540169|NCT00595647|DEVICE|Drug eluting stent|Implantation of stent
214540170|NCT00595647|DEVICE|Bare metal stent|Implantation of stent
214540171|NCT01624298|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
215157692|NCT04238897|DEVICE|soft contact lens|
214540172|NCT02840916|PROCEDURE|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
214540173|NCT02840916|PROCEDURE|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
214540174|NCT02121743|DEVICE|strattice|use of a strattice
215157693|NCT05266170|DEVICE|aerobic and anaerobic exercises|"\[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1\. Fitness exercise program with EX1"
215157694|NCT04730232|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
214540175|NCT02121743|PROCEDURE|No strattice|no use of a strattice
214540176|NCT02259062|OTHER|Music with brief mindfulness intervention|Music listening with mindfulness therapy
214540177|NCT02259062|OTHER|Music listening alone|
214540178|NCT02259062|OTHER|Audiobook listening|
214540179|NCT01168336|DRUG|Betahistine standard formulation|betahistine 24 mg tablets
214540180|NCT01168336|DRUG|Betahistine Extended Release formulation|betahistine 32 mg tablets
214540181|NCT01168336|DRUG|Placebo|matching placebo
214540182|NCT00739609|DRUG|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
214540183|NCT01832454|OTHER|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
215157695|NCT04730232|DRUG|Nab-paclitaxel|Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
214697397|NCT00579501|DRUG|Trabectedin|Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
215157696|NCT00555516|OTHER|EW02|"1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
215157697|NCT01782391|DEVICE|Stimulation|
215157698|NCT01782391|DEVICE|SHAM|no stimulation
215157699|NCT01470118|DRUG|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
215157700|NCT01470118|DRUG|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
215157701|NCT01470118|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
215157702|NCT00785382|DRUG|Placebo|Lactulose Placebo
215157703|NCT00785382|DRUG|Pregabalin 150 mg|150 mg Q12H x 2 doses
215157704|NCT00111852|DRUG|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
215157705|NCT00111852|DRUG|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
215157706|NCT00111852|DRUG|Placebo|Dose-Match Placebo, intravenous administration.
215157707|NCT05475080|DRUG|Antiplatelet Drug|Any antiplatelet drug or combination
215157708|NCT05475080|DRUG|Anticoagulant|Any anticoagulante
215157709|NCT05475080|PROCEDURE|Endovascular|Angioplasty +- stent
215157710|NCT05475080|PROCEDURE|Surgery|Endarterectomy
215157711|NCT00285623|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
215157712|NCT02458326|OTHER|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
215157713|NCT02458326|OTHER|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
215157714|NCT04036396|BEHAVIORAL|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
215157715|NCT04036396|BEHAVIORAL|Usual Care plus Customized Referrals|Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
215157716|NCT00606437|PROCEDURE|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
215157717|NCT03212313|DRUG|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
215157718|NCT03097809|OTHER|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
215157719|NCT03839797|BEHAVIORAL|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
215157720|NCT03839797|BEHAVIORAL|Standard Health Education|Standard Health Education
215157721|NCT01516086|DRUG|Fluticasone Propionate (FP)|FP Inhalation BID
215157722|NCT01053780|OTHER|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
215157723|NCT01053780|BEHAVIORAL|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
214540184|NCT00345800|DRUG|Sodium Oxybate (Xyrem)|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
214540185|NCT03807817|OTHER|Alcohol administration|Amount of alcohol to be administered.
214540186|NCT03807817|OTHER|Placebo|Placebo Alcohol
214540187|NCT03807817|OTHER|No Alcohol|No Alcohol
214540188|NCT00135577|DRUG|alvimopan|
214540189|NCT00135577|DRUG|placebo|
214540190|NCT00142545|DRUG|apomorphine HCl injection|
214540191|NCT00408798|DRUG|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
214540192|NCT04409522|DRUG|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
214540193|NCT04409522|DRUG|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
214540194|NCT06224010|OTHER|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
214540195|NCT04678765|PROCEDURE|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
214540196|NCT04678765|PROCEDURE|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
214540197|NCT00639977|OTHER|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
214540198|NCT00639977|OTHER|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
215157724|NCT06458478|OTHER|Hyper-oxygenated gel|Novox drop is a medical device (CE certified, class II b, non-invasive) based on oxygen-enriched olive oil (Excipients: Mint essential oil (2%), Stevia extract (1%)). Mechanism of action: facilitate the healing process by creating, thanks to the release of reactive oxygen species (ROS), a microenvironment favorable to the activation of the microcirculation and at the same time unfavorable to the proliferation of pathogens. Furthermore, it has a film-forming, protective, barrier and soothing action thanks to its oily nature.
215157725|NCT06458478|OTHER|glycerin based gel|The placebo consists of a viscous, colorless and transparent gel, based on glycerin (Conformity:FUI).
215157726|NCT00775593|DRUG|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.~Induction therapy~\- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
215157727|NCT00775593|DRUG|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.~Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.~Induction therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.~Maintenance therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
215157728|NCT00531791|DRUG|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
215157729|NCT00531791|DRUG|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
214540199|NCT03723122|BEHAVIORAL|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
214540200|NCT04961632|DRUG|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
214540201|NCT04961632|DRUG|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
215157730|NCT02067676|BIOLOGICAL|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
214540202|NCT03862209|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
214540203|NCT02800447|DRUG|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14
214540204|NCT02800447|DRUG|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
214540205|NCT01127321|OTHER|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
214540206|NCT01127321|BIOLOGICAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
214540207|NCT01127321|BIOLOGICAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
214540208|NCT01127321|BIOLOGICAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
214540209|NCT01127321|BIOLOGICAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
214540210|NCT02107742|PROCEDURE|Normal speed lidocaine injection|30 seconds
214540211|NCT02107742|PROCEDURE|Slow lidocaine injection|speed 45 seconds
214540212|NCT02107742|PROCEDURE|Fast lidocaine injection|speed 15 seconds
214540213|NCT02874573|DRUG|Tocilizumab|Investigational agent
214540214|NCT02874573|DRUG|Normal saline|Placebo
214540215|NCT01849445|PROCEDURE|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
214540216|NCT01849445|OTHER|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
214540217|NCT00719043|BIOLOGICAL|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
214540218|NCT00719043|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
214540219|NCT00719043|BIOLOGICAL|Placebo|Administered as an intramuscular (IM) injection
214540220|NCT06344806|BEHAVIORAL|Gamified Breastfeeding Education|Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
214540221|NCT01588366|DRUG|Placebo|Administered orally
214540222|NCT01588366|DRUG|LY2409021|Administered orally
214540223|NCT03520062|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for \~6 weeks
214540224|NCT04991636|PROCEDURE|Angioscan|"La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen."
214540225|NCT06009744|DRUG|Low-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
214540226|NCT06009744|DRUG|High-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
215157731|NCT02067676|DRUG|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
215157732|NCT04712630|PROCEDURE|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
215157733|NCT04712630|PROCEDURE|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
215157734|NCT02164708|BEHAVIORAL|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
215157735|NCT04440865|OTHER|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
215157736|NCT04440865|OTHER|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
215157737|NCT01243580|DRUG|Ortho-Cyclen|Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
215157738|NCT01243580|DRUG|AG200-15|AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
215157739|NCT02689362|DRUG|Evogliptin|1 tablet per day
215157740|NCT02689362|DRUG|Sitagliptin|1 tablet per day
215157741|NCT02689362|DRUG|Placebo Evogliptin|1 tablet per day
214697398|NCT00579501|DRUG|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
214697399|NCT01549743|DRUG|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
214697400|NCT01549743|DRUG|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
214697401|NCT01549743|DRUG|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
214697402|NCT03191006|DEVICE|MEI BIN insoles|insoles
215157742|NCT02689362|DRUG|Placebo Sitagliptin|1 tablet per day
215157743|NCT00000400|DRUG|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
215157744|NCT00000400|DRUG|alendronate|70 mg/week by oral route
215157745|NCT03159039|OTHER|Conventional Physiotherapy|
214540227|NCT04077814|DEVICE|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
214540228|NCT04077814|DEVICE|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
214540229|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
214540230|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
214540231|NCT00000447|DRUG|naltrexone (Revia)|
214540232|NCT00000447|DRUG|nicotine replacement patch|
214540233|NCT06009172|OTHER|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
214540234|NCT03245619|DRUG|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
214540235|NCT03245619|DRUG|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
215157746|NCT03159039|OTHER|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
215157747|NCT02039024|DRUG|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
215157748|NCT04660565|DRUG|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
214540236|NCT04212975|OTHER|joint lavage with dextrose|joint lavage with dextrose
214540237|NCT03202485|DEVICE|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
214540238|NCT03202485|DEVICE|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
214540239|NCT05605561|OTHER|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
214540240|NCT04360798|OTHER|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
214540241|NCT04360798|OTHER|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
214540242|NCT06486727|DEVICE|Redtouch|675-nm laser
214540243|NCT00000349|DRUG|Flupenthixol|
214697403|NCT01370057|DEVICE|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
214697404|NCT02598466|DRUG|Abatacept|
214697405|NCT06261099|OTHER|control + working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
214697406|NCT01672437|OTHER|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
214697407|NCT03025217|BEHAVIORAL|Total Lifestyle Coaching (TLC)|
214697408|NCT01897181|DEVICE|Hearing aids|Using hearing aids for 12 months
214697409|NCT04585217|PROCEDURE|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
214697410|NCT00620971|DRUG|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
214697411|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
214697412|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
214697413|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
214697414|NCT00620971|DRUG|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
214697415|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
214697416|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
214697417|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
214697418|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
214697419|NCT01165593|OTHER|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
214697420|NCT04069156|DEVICE|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
214697421|NCT04069156|DRUG|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
214697422|NCT04069156|DRUG|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
214697423|NCT03864718|PROCEDURE|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
214697424|NCT03689062|PROCEDURE|induction of labor|oxytocin intravenous drip
214697425|NCT03689062|PROCEDURE|follow up|hospitalization and antibiotics
214697426|NCT04875338|DRUG|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
214697427|NCT04875338|DRUG|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
214540244|NCT03171935|DEVICE|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
214540245|NCT03171935|DEVICE|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 \>92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 \>96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
214540246|NCT03171935|DEVICE|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
214540247|NCT06072963|DRUG|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
214697428|NCT04875338|DRUG|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
214697429|NCT01953536|DRUG|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
214697430|NCT01953536|DRUG|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m\^2.
214697431|NCT01953536|DRUG|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
214697432|NCT01953536|DRUG|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
215029433|NCT06434493|RADIATION|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
215029434|NCT06434493|DRUG|Concurrent oral capecitabine chemotherapy|All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
215029435|NCT06434493|DRUG|Cisplatin & Gemcitabine intravenous chemotherapy|Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
215029436|NCT06434493|PROCEDURE|Orthotropic Liver Transplant|If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
215029437|NCT04540471|OTHER|music|MT group receives additional music therapy
215029438|NCT04540471|OTHER|comprehensive in-patient education program|comprehensive in-patient education program
215029439|NCT06639048|BEHAVIORAL|Questionnaire|Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
215029440|NCT05264454|DEVICE|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
214540248|NCT06072963|DRUG|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
215157749|NCT04660565|DRUG|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
215157750|NCT02177071|DRUG|INFLIXIMAB|
214540249|NCT06072963|OTHER|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
214540250|NCT06072963|OTHER|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
215157751|NCT02177071|DRUG|AZATHIOPRINE|
214540251|NCT06479200|BEHAVIORAL|VR-guided mindfulness|The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.
215157752|NCT02177071|DRUG|MERCAPTOPURINE|
215157753|NCT02177071|DRUG|Methotrexate|
215157754|NCT02730013|BEHAVIORAL|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
215157755|NCT06403345|BEHAVIORAL|Green Activity Program|See arm description.
215157756|NCT01048034|DRUG|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
215157757|NCT01048034|DRUG|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
215157758|NCT04293822|DRUG|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
215157759|NCT04293822|DRUG|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
215157760|NCT03238495|DRUG|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
215157761|NCT03238495|DRUG|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
215157762|NCT04153552|DIETARY_SUPPLEMENT|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
214540252|NCT06479200|OTHER|Sham VR|The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
214540253|NCT00155883|DRUG|Taxteral|
214540254|NCT00155883|DRUG|5-Fluorouracil|
214540255|NCT00155883|DRUG|Leucovorin|
214697433|NCT01953536|DRUG|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
214697434|NCT04215523|DRUG|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
215157763|NCT03283514|OTHER|Complete denture|questionnaire
215157764|NCT04853017|DRUG|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
215157765|NCT03460262|DEVICE|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
215157766|NCT03460262|DEVICE|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
215157767|NCT02483962|OTHER|Gelatine capsule|Gelatine capsules containing no active ingredients.
214697435|NCT04215523|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
214697436|NCT05143762|DRUG|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
215157768|NCT02483962|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
215157769|NCT03667456|PROCEDURE|Self-rehabilitation by digital support|Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
215157770|NCT00636493|DEVICE|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
215157771|NCT04411732|DEVICE|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
215157772|NCT04411732|DIAGNOSTIC_TEST|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
214540256|NCT05168514|OTHER|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
214540257|NCT00143741|DRUG|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
214540258|NCT06478732|OTHER|health services|Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
214540259|NCT02768077|DRUG|Melatonin(Circadin®)|
214540260|NCT02768077|DRUG|Placebo|
214697437|NCT05143762|DRUG|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
214697438|NCT05143762|DRUG|normal Saline|patients will receive placebo 10 ml normal saline IV.
214540261|NCT04237675|PROCEDURE|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
214540262|NCT05297253|DEVICE|telescopic overdenture|fixed implant retained prostheses
214540263|NCT02878421|DEVICE|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
214540264|NCT02878421|OTHER|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
214697439|NCT00692510|DRUG|AZD3480|Capsule, oral, dose once daily, 7 days
214697440|NCT00692510|DRUG|Placebo|Capsule, oral, dose once daily, 7 days
214697441|NCT00692510|DRUG|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
214540265|NCT02878421|OTHER|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
214540266|NCT00114543|PROCEDURE|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
214697442|NCT01254513|DRUG|Docetaxel every 3 weeks + Prednisone|"* Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
214697443|NCT01254513|DRUG|Docetaxel weekly+ Prednisone|"* Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
214540267|NCT00114543|PROCEDURE|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
214540268|NCT00114543|PROCEDURE|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
214540269|NCT00114543|PROCEDURE|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
214697444|NCT03379012|DRUG|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
215157773|NCT04411732|DIAGNOSTIC_TEST|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
215157774|NCT04411732|DIAGNOSTIC_TEST|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
215157775|NCT05985369|OTHER|Controlled diet and resistance exercise|Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
214540270|NCT03671239|BEHAVIORAL|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
214540271|NCT03671239|BEHAVIORAL|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
214540272|NCT03671239|BEHAVIORAL|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
214540273|NCT00690378|DRUG|NXL104/ceftazidime|125mg/500mg TID
214540274|NCT00690378|DRUG|Imipenem/Cilastatin|4 x daily
214540275|NCT02757313|DRUG|Low dose THC marijuana|
214540276|NCT02757313|DRUG|High dose THC marijuana|
214540277|NCT02757313|DRUG|Placebo marijuana|
214540278|NCT02238964|DEVICE|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
214540279|NCT02238964|PROCEDURE|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
214540280|NCT02949232|DRUG|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
214540281|NCT02949232|DRUG|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
214540282|NCT04019249|BEHAVIORAL|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
214540283|NCT02987998|DRUG|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
214540284|NCT02987998|DRUG|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
214540285|NCT02987998|DRUG|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
214540286|NCT02987998|DRUG|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
214540287|NCT01335321|DRUG|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
214540288|NCT01335321|DRUG|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
214540289|NCT01051102|DRUG|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
214540290|NCT01051102|DRUG|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
214540291|NCT01627470|DEVICE|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
214540292|NCT05269927|DIAGNOSTIC_TEST|EEG|resting state EEG
214540293|NCT05269927|DIAGNOSTIC_TEST|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
214540294|NCT05269927|DIAGNOSTIC_TEST|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
214540295|NCT05269927|OTHER|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
214540296|NCT05717517|DEVICE|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
214540297|NCT02801409|DRUG|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
214540298|NCT02801409|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
214540299|NCT05689281|BEHAVIORAL|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
214540300|NCT05167032|BEHAVIORAL|Cognitive Multisensory Rehabilitation (CMR)|The goal of CMR is to restore proprioception (i.e., sense of joint position and movement), body awareness, and awareness of the paralyzed limbs and trunk in space, in order to improve sensory and motor function. For example, CMR tasks will have the participant solve exercises related to: (i) where the legs are situated in space; where the legs are in relation to the pelvis and the upper part of the body (ii) the dimensions and length of the legs, the dimension of the pelvis, and sensation of the pelvis as a central body reference. (iii) the relationship between the left and right side of the body, and the relationship between the pelvis and the feet. Further, improvements in touch and pressure sensation are obtained with (v) texture discrimination tasks, and (vi) discrimination of sponges with varying resistance. Given the importance of sensory feedback for movement, sensory improvements create the opportunity for motor recovery to occur.
214540301|NCT05167032|BEHAVIORAL|Adaptive fitness|The Courage Kenny Rehabilitation Institute centers provide access to state-of- the-art adaptive gym equipment in their fitness center to promote fitness and recreation. Equipment includes treadmills, elliptical, NuSteps, SciFit upper body ergometers, Ski Erg and Rowing Machine, Upright and recumbent stationary bicycles, chest press, rear row, leg extension, leg curl, leg press, uppertone, free weights, and kettlebells. The equipment is spaced to allow for movement and is accessible for use from a wheelchair. They allow for transfers and caregiver assistance.
215157776|NCT03293368|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
215157777|NCT03293368|DRUG|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
215157778|NCT00505349|BEHAVIORAL|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
214540302|NCT06406998|OTHER|Pre-existing atherosclerotic cardiovascular disease|Presence of pre-existing atherosclerotic cardiovascular disease
214540303|NCT00487526|PROCEDURE|duodenal jejunal bypass|
214540304|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
214540305|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
214540306|NCT04650659|DIAGNOSTIC_TEST|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
214540307|NCT04650659|DIAGNOSTIC_TEST|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
214697445|NCT00893048|DRUG|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
214697446|NCT00893048|DRUG|Placebo Oral Tablet|Placebo
214697447|NCT02548572|DEVICE|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
214697448|NCT01426607|DEVICE|AMO|
214697449|NCT00126178|BIOLOGICAL|HSPPC-96|
215157779|NCT01802138|BIOLOGICAL|Activated T lymphocyte|intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
215157780|NCT02009280|DRUG|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
215157781|NCT02009280|DRUG|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
215157782|NCT03393988|DRUG|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
215157783|NCT03393988|PROCEDURE|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
215157784|NCT03393988|DRUG|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
215157785|NCT04680182|PROCEDURE|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
214540308|NCT04650659|DIAGNOSTIC_TEST|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
214540309|NCT04650659|DIAGNOSTIC_TEST|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
214540310|NCT04650659|DIAGNOSTIC_TEST|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
214540311|NCT04650659|DIAGNOSTIC_TEST|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
214540312|NCT03420261|BIOLOGICAL|0.9% saline|Fluid administration
214540313|NCT03420261|BIOLOGICAL|HES 130/0.4|Fluid administration
214540314|NCT05808855|PROCEDURE|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
214540315|NCT05808855|PROCEDURE|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
214540316|NCT03100864|DRUG|Spesolimab|12 weeks treatment
214540317|NCT02101658|OTHER|clinic-based weight measurements|
214540318|NCT01648036|DRUG|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
214540319|NCT01648036|DRUG|Dalteparin|Dose 5000 IU, subcutaneous, daily
214540320|NCT01732341|DEVICE|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
214540321|NCT01732341|DEVICE|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~\--------------------------------------------------------------------------------"
214540322|NCT05612841|OTHER|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
214540323|NCT02277197|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
214540324|NCT02277197|DRUG|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
214540325|NCT02749136|DRUG|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
214540326|NCT06471907|PROCEDURE|erector spinae plane block|fascial plane injection using ultrasound
214540327|NCT03713697|BEHAVIORAL|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
214540328|NCT03713697|BEHAVIORAL|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
214540329|NCT03713697|BEHAVIORAL|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
214540330|NCT02115919|DRUG|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
215157786|NCT03126513|PROCEDURE|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
215157787|NCT00019201|OTHER|cytology specimen collection procedure|
215157788|NCT00019201|OTHER|immunohistochemistry staining method|
215157789|NCT00019201|OTHER|sputum cytology|
214540331|NCT02115919|DRUG|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
214540332|NCT02368899|OTHER|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
214540333|NCT02368899|OTHER|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
214540334|NCT02828163|OTHER|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
214540335|NCT02828163|DRUG|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
214540336|NCT01344499|PROCEDURE|Carbon dioxide|standard pneumoperitoneum with 100% CO2
214540337|NCT01344499|PROCEDURE|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
214540338|NCT01344499|DRUG|Adept|instillation of 1 liter of fluid at the end of laparoscopy
214540339|NCT01344499|DRUG|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
214540340|NCT02945371|BEHAVIORAL|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
214540341|NCT02945371|BEHAVIORAL|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
214540342|NCT02792647|DRUG|Placebo|Administered orally
214540343|NCT02792647|DRUG|IX-01|Administered orally
214540344|NCT05066919|PROCEDURE|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
214540345|NCT05066919|OTHER|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
214540346|NCT02715427|OTHER|Conventional care|
214540347|NCT02715427|OTHER|Enhanced recovery|
214540348|NCT00846768|DRUG|BI 1744 CL|
214540349|NCT02931578|OTHER|Glucose100|
214540350|NCT02931578|OTHER|Glucose50|
215157790|NCT00019201|PROCEDURE|bronchoscopic and lung imaging studies|
215157791|NCT00019201|PROCEDURE|bronchoscopy|
215157792|NCT00019201|PROCEDURE|comparison of screening methods|
215157793|NCT00019201|PROCEDURE|endoscopic biopsy|
215157794|NCT02164461|BIOLOGICAL|Axalimogene filolisbac|
214540351|NCT02931578|OTHER|Glucose42|
214540352|NCT02931578|OTHER|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
214540353|NCT02276209|DRUG|Dasotraline|Dasotraline 4 mg once daily
214540354|NCT02276209|DRUG|Dasotraline|Dasotraline 6 mg once daily
214540355|NCT02276209|OTHER|Placebo|Placebo once daily
214540356|NCT01328210|PROCEDURE|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
214540357|NCT03849768|DRUG|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214540358|NCT03849768|DRUG|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214540359|NCT00716547|DRUG|ketoprofen in Diractin®|50 mg (b.i.d.)
214540360|NCT00716547|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
214540361|NCT00716547|DRUG|Placebo|b.i.d.
214540362|NCT00716547|DRUG|celecoxib|100 mg (b.i.d.)
214540363|NCT04620369|DRUG|Placebo Administration|Instill isotonic nasal saline intranasally
214540364|NCT04620369|OTHER|Questionnaire Administration|Ancillary studies
214540365|NCT04620369|DRUG|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
214540366|NCT05082844|RADIATION|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
214540367|NCT03399838|DRUG|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
214540368|NCT03399838|DRUG|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
215157795|NCT06160648|OTHER|Management according to Mechanical Diagnosis and Therapy|MDT management is based on the patient response to repeated end range movements.
214540369|NCT02174614|BEHAVIORAL|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
214540370|NCT02174614|BEHAVIORAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
214540371|NCT02174614|BEHAVIORAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
214540372|NCT05267678|OTHER|No intervention|This is an observational study without any intervention
214540373|NCT03467698|DEVICE|Active tDCS|Real stimulation
214540374|NCT03467698|DEVICE|Sham tDCS|Sham stimulation
214540375|NCT00912223|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
214540376|NCT02138656|OTHER|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
214540377|NCT02138656|OTHER|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
214540378|NCT03980197|OTHER|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
214540379|NCT03980197|OTHER|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
214540380|NCT04751136|DRUG|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
214540381|NCT05784766|DIAGNOSTIC_TEST|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
214540382|NCT05784766|OTHER|routine care|medical review
214540383|NCT01991145|PROCEDURE|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
214540384|NCT01991145|BIOLOGICAL|Erythropoietin alfa|
214540385|NCT01991145|OTHER|Rehabilitation|Active rehabilitation
214540386|NCT01991145|PROCEDURE|Placebo UCB|
214540387|NCT01991145|BIOLOGICAL|Placebo EPO|
214540388|NCT03903497|DEVICE|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
215157796|NCT06160648|OTHER|Management according to the Cervical Spine Clinical Practice Guidelines|CPG management is based on clinical research regarding management of people with neck pain.
214540389|NCT01099579|DRUG|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
214540390|NCT01099579|DRUG|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
214540391|NCT01099579|DRUG|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
214540392|NCT01099579|DRUG|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
215157797|NCT01814241|DRUG|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
215157798|NCT02100696|DRUG|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
214540393|NCT00909532|DRUG|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
214540394|NCT00909532|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
214540395|NCT01711398|DRUG|Drug|
214540396|NCT00750451|DRUG|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
214540397|NCT00750451|DRUG|crinone 8% gel|routine luteal phase support with progesterone gel
214540398|NCT01020214|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
214540399|NCT01020214|DRUG|Benicar HCT® Tablets 40 mg/25 mg|
214540400|NCT01226836|OTHER|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
214540401|NCT05792761|DRUG|Peginterferon alfa-2b combined and ETV|"Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks."
214540402|NCT00932295|OTHER|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
214540403|NCT00932295|OTHER|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
214540404|NCT00932295|OTHER|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
214540405|NCT00932295|OTHER|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
215157799|NCT02100696|DRUG|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
215157800|NCT00078897|DRUG|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
214540406|NCT00859976|DEVICE|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
214540407|NCT00859976|DEVICE|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
214540408|NCT01912989|BEHAVIORAL|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
214540409|NCT00192426|BIOLOGICAL|CAIV-T|
214540410|NCT03288077|OTHER|Tryptophan|Beverage including tryptophan
214540411|NCT01398462|DRUG|CWP232291|IV Infusion
214540412|NCT04500028|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.
214540413|NCT04500028|DRUG|Placebo Comparator|3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
214540414|NCT06078098|OTHER|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
214540415|NCT00603083|DRUG|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
214540416|NCT00603083|DRUG|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
214540417|NCT01341847|PROCEDURE|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
214540418|NCT01341847|PROCEDURE|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
215157801|NCT05867498|BEHAVIORAL|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
215157802|NCT05867498|BEHAVIORAL|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
214697450|NCT01670409|RADIATION|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
214697451|NCT01670409|DRUG|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
214697452|NCT02596152|OTHER|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
214540419|NCT01791777|BEHAVIORAL|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
214540420|NCT03428464|DRUG|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
215157803|NCT03865381|DEVICE|Onduo App|The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
215157804|NCT05343728|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
214540421|NCT03428464|OTHER|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
214540422|NCT01157377|DRUG|AGN-214868|AGN-214868 injected into the bladder.
214540423|NCT01157377|DRUG|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
214540424|NCT03220997|DIETARY_SUPPLEMENT|Vitaflow Preload|Carbohydrate loading drink
214540425|NCT03834207|DEVICE|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
214540426|NCT04186052|BIOLOGICAL|BCMA-CART cells|Target BCMA chimeric antigen receptor T cell infusion
214540427|NCT05051475|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
214540428|NCT05051475|PROCEDURE|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
214540429|NCT04959500|DRUG|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
214540430|NCT04959500|DRUG|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
214540431|NCT04959500|RADIATION|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
214540432|NCT04959500|DRUG|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
214540433|NCT00080041|DRUG|Motexafin Gadolinium Injection|
214540434|NCT06401785|DIETARY_SUPPLEMENT|Hydrogen capsules|In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
214540435|NCT00927901|DRUG|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
214540436|NCT00927901|DRUG|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
214540437|NCT00927901|DRUG|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
214540438|NCT00927901|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
214697453|NCT02596152|OTHER|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
214697454|NCT05133804|DRUG|Methylphenidate|Ritalin 10mg
214697455|NCT05133804|DRUG|Reboxetine|Reboxetine 4mg
214697456|NCT05133804|DRUG|Placebo|Placebo matched to Reboxetine
214697457|NCT05133804|DRUG|Placebo|Placebo matched to Ritalin
214697458|NCT02208024|RADIATION|Stereotactic Body Radiation Therapy|
214697459|NCT02296437|OTHER|Transcranial direct current stimulation combined with cognitive training|
214697460|NCT05667792|DEVICE|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
214540439|NCT03299413|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
214540440|NCT01430208|PROCEDURE|resectoscopy|hysteroscopy for myomas G0 and/or polyps
214540441|NCT00483080|DRUG|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
214540442|NCT05980962|PROCEDURE|Inferior oblique anteriorization|symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
214540443|NCT05980962|PROCEDURE|Inferior oblique anteriorization together with unliateral resction|asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
214540444|NCT01306006|BIOLOGICAL|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
215157805|NCT05343728|DIAGNOSTIC_TEST|Standard coagulation profile laboratory examination|Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
215157806|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
215157807|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
215157808|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
215157809|NCT04713007|BEHAVIORAL|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
215157810|NCT04713007|BEHAVIORAL|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
215157811|NCT03824145|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
214540445|NCT00334971|PROCEDURE|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
214540446|NCT05665413|DEVICE|TENS|strocking technique, HOT PACK and Ergon instrument
214540447|NCT03989921|OTHER|no intervention. observational study|no intervention. observational study
214540448|NCT02882841|OTHER|Biopsies, stool and blood collection|
215157812|NCT03824145|BEHAVIORAL|Attention Control|"The attention control participants will receive a home/work organization intervention:~Following completion of the attention control home/work organization program and 16-week assessment, women will receive the lifestyle program."
215157813|NCT02606084|DRUG|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
215157814|NCT05268497|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
215157815|NCT05268497|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
215157816|NCT05268497|DRUG|Antidepressant|Antidepressant will be administered orally.
215157817|NCT04003038|PROCEDURE|Negative Pressure Wound Therapy|Receive wound care with NPWT
215157818|NCT04003038|PROCEDURE|Wound Care Management|Receive wound care with a standard dressing (bandage)
215157819|NCT04451187|DRUG|Seltorexant Dose 1|Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
215157820|NCT04451187|DRUG|Seltorexant Dose 2|Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
215157821|NCT04451187|DRUG|Placebo|Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
215157822|NCT04451187|DRUG|Zopiclone|Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
215157823|NCT04565119|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
215157824|NCT04223349|DRUG|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
215157825|NCT04223349|DRUG|Placebo|Matching placebo in capsule will be administered orally.
215157826|NCT05796141|BEHAVIORAL|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
215157827|NCT05796141|BEHAVIORAL|Dyadic Action Planning|Participants will develop dyadic action plans together.
215157828|NCT05796141|BEHAVIORAL|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
215157829|NCT05796141|BEHAVIORAL|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
215157830|NCT05796141|BEHAVIORAL|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
215157831|NCT03959878|DEVICE|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
215157832|NCT02858505|DRUG|27 mg elemental iron|
214540449|NCT06480877|DIAGNOSTIC_TEST|Taking a swab from periodontal pockets or gingival sulci|Swabs for next generation sequencing were taken with paper points as described earlier.
214540450|NCT02383407|DEVICE|Medtronic Deep Brain Stimulation|
214540451|NCT03739255|DEVICE|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
214540452|NCT03739255|DEVICE|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
214540453|NCT00984698|BEHAVIORAL|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
214540454|NCT00984698|BEHAVIORAL|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
214540455|NCT00040820|DRUG|oxaliplatin|
214540456|NCT01263925|DRUG|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
214540457|NCT01263925|DRUG|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
214540458|NCT01263925|DRUG|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
214540459|NCT01263925|DRUG|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
214540460|NCT05804682|PROCEDURE|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
214540461|NCT05804682|PROCEDURE|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
214540462|NCT00904709|DRUG|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
214540463|NCT04583462|DRUG|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
214540464|NCT04583462|DRUG|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
214540465|NCT03029819|BEHAVIORAL|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
214540466|NCT03029819|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
214540467|NCT03029819|BEHAVIORAL|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
215157833|NCT02858505|DRUG|54 mg elemental iron|
214540468|NCT03029819|DRUG|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
214540469|NCT05851040|OTHER|Observation study|Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
214540470|NCT05436210|OTHER|foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test|Patients will be evaluated only observationally without intervention by foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test
214540471|NCT01989923|OTHER|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
214540472|NCT01989923|DEVICE|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
214540473|NCT03536702|OTHER|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
214540474|NCT03536702|OTHER|Independent Writing - Control Group|This group will receive a book for a self writing session.
214540475|NCT02998619|RADIATION|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
215157834|NCT04793022|DRUG|TIVA with Propofol|Total intravenous anesthesia with propofol
215157835|NCT04793022|DRUG|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
215157836|NCT03099278|DRUG|Ezetimibe|Ezetimibe 20 mg oral daily
215157837|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
214540476|NCT03559829|DEVICE|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
214540477|NCT01536197|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
214540478|NCT01536197|PROCEDURE|Gastric banding|Laparoscopic adjustable gastric banding
214540479|NCT01536197|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy surgery
214540480|NCT02690337|DRUG|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
214540481|NCT00698555|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
214540482|NCT00698555|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214540483|NCT05694962|RADIATION|Low-Dose Radiation Therapy|1.5Gy single treatment of whole-lung radiation therapy
214540484|NCT04507633|BEHAVIORAL|ROMA therapy(reminiacence therpy, orientation, music, and art)|An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
214540485|NCT01962311|PROCEDURE|lumbar puncture|lumbar puncture at enrollment in study
214540486|NCT03478410|PROCEDURE|Epicardial fat biopsy|A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
214540487|NCT00249171|DRUG|risperidone|
214540488|NCT04522206|DRUG|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
214540489|NCT02650466|DEVICE|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
214540490|NCT02741258|DEVICE|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
214540491|NCT02741258|DRUG|skin cream|cream to treat skin erythema due to radiotherapy
214540492|NCT05760911|BEHAVIORAL|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
214540493|NCT05886946|OTHER|ABG|ABG
214540494|NCT02547597|DRUG|Carvedilol|
214540495|NCT02547597|DRUG|Atenolol|
214540496|NCT03682198|DEVICE|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
214540497|NCT03682198|DRUG|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
214540498|NCT03682198|DRUG|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
214540499|NCT00890890|DRUG|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
214540500|NCT00890890|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
214540501|NCT01726517|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
214540502|NCT01726517|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214540503|NCT05160571|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
214540504|NCT01588210|OTHER|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
214540505|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
214540506|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
214540507|NCT00573651|OTHER|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
214540508|NCT00398723|DEVICE|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
214540509|NCT01674803|DEVICE|Orsiro|biodegradable polymer sirolimus eluting stent
214697461|NCT05667792|OTHER|Pediatric Rehabilitation|Bobath therapy
214697462|NCT02207556|DRUG|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."
214697463|NCT03712332|BEHAVIORAL|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
214540510|NCT01674803|DEVICE|Synergy|biodegradable polymer everolimus eluting stent
214540511|NCT01674803|DEVICE|Resolute Integrity|durable polymer zotarolimus-eluting stent
214697464|NCT01405118|DRUG|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
214697465|NCT03558555|DRUG|Acetaminophen IV Soln|1000mg of IV acetaminophen
214697466|NCT03558555|DRUG|Oral Acetaminophen|oral acetaminophen 975mg pills
214697467|NCT03558555|DRUG|Placebo Pills|placebo match to acetaminophen
214697468|NCT03558555|DRUG|Saline|Intravenous saline
214697469|NCT01958125|DEVICE|gammaCore|Vagal stimulation
214697470|NCT01800279|OTHER|Physiotherapy Protocol|"Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
214697471|NCT01800279|OTHER|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
214697472|NCT06269289|OTHER|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
214697473|NCT06269289|OTHER|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
214697474|NCT02503774|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
214697475|NCT02503774|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
214540512|NCT01695447|PROCEDURE|duct-to-mucosa|
214697476|NCT04114513|DIETARY_SUPPLEMENT|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
214697477|NCT04114513|DIETARY_SUPPLEMENT|Inulin|BENEO-Orafti, white powder 5 weeks intervention
214697478|NCT04114513|DIETARY_SUPPLEMENT|Pectin|BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention
214697479|NCT04114513|DIETARY_SUPPLEMENT|Beta-glucan|Tate \& Lyle, white powder 5 weeks intervention
214697480|NCT04114513|DIETARY_SUPPLEMENT|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
214697481|NCT00956215|DRUG|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
214697482|NCT00956215|DRUG|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
214697483|NCT00194025|DRUG|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
214697484|NCT00004418|DRUG|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
214697485|NCT03768141|PROCEDURE|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
214697486|NCT05877651|BIOLOGICAL|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
214697487|NCT05848050|PROCEDURE|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
214697488|NCT05782296|DEVICE|TrueLabor|Non invasive monitoring device
214697489|NCT04804033|DRUG|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
214697490|NCT04804033|DRUG|Placebo|Matching placebo softgel capsule.
215157838|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
215157839|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
215157840|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
214540513|NCT01695447|PROCEDURE|invagination|
214540514|NCT01695447|DEVICE|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
214540515|NCT03051893|DRUG|Chronocort|Modified formulation of hydrocortisone
214540516|NCT03765164|DIAGNOSTIC_TEST|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
214540517|NCT03765164|OTHER|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
214540518|NCT01351337|PROCEDURE|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
214540519|NCT05630378|BEHAVIORAL|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
214540520|NCT05630378|OTHER|waiting group|Patients receive no intervention
214540521|NCT04149587|DRUG|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
214540522|NCT05266625|BEHAVIORAL|BT-001|"Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
214540523|NCT05266625|OTHER|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
214540524|NCT01495676|OTHER|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~* In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~* In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
214540525|NCT01495676|OTHER|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
214540526|NCT04137861|OTHER|Bioceramics|root repair material
214540527|NCT03747627|DIAGNOSTIC_TEST|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
214540528|NCT05154032|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
214697491|NCT06177184|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
215157841|NCT06398509|BEHAVIORAL|Control|The control intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The control intervention focuses on home safety, home management of common childhood illnesses, and promotion of language development.
214540529|NCT05128734|DRUG|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
214697492|NCT04917835|DEVICE|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
214697493|NCT00307515|DRUG|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
214540530|NCT05128734|DRUG|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
214540531|NCT05275023|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously.
214540532|NCT05275023|DRUG|PD-1 inhibitor|PD-1 inhibitor will be administered as IV infusion.
214540533|NCT05275023|DRUG|Tenofovir Disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
214697494|NCT00307515|DEVICE|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
214697495|NCT05974085|DRUG|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
214697496|NCT04772664|DIETARY_SUPPLEMENT|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
214697497|NCT04772664|DIETARY_SUPPLEMENT|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
214697498|NCT00836680|DEVICE|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
214697499|NCT00308438|DRUG|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
214697500|NCT03866863|OTHER|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
214540534|NCT05275023|DRUG|Tenofovir Alafenamide|TAF film-coated tablets will be administered orally.
214697501|NCT06554470|DRUG|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
214697502|NCT06554470|DRUG|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
214697503|NCT00025532|OTHER|iodine I 131 monoclonal antibody CC49-deltaCH2|
214540535|NCT05275023|DRUG|Entecavir|ETV film-coated tablets will be administered orally.
214540536|NCT05338151|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
214540537|NCT05338151|BEHAVIORAL|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
214540538|NCT05338151|BEHAVIORAL|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
214540539|NCT04500847|DRUG|Emtriva Capsule|200mg daily oral dose
214540540|NCT04500847|DRUG|Placebo|200mg daily oral dose
214540541|NCT00812123|DRUG|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
214697504|NCT02130427|DIAGNOSTIC_TEST|CT scan|Weekly 3D/4D CT scan
214697505|NCT04719169|DIAGNOSTIC_TEST|Dynamic MRI enema|Dynamic MRI enema
214697506|NCT04719169|DIAGNOSTIC_TEST|Fluoroscopic enema|Fluoroscopic enema
214697507|NCT02310971|BIOLOGICAL|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
214697508|NCT00258427|BIOLOGICAL|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
214697509|NCT00258427|BIOLOGICAL|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
214697510|NCT00258427|DRUG|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
214697511|NCT00258427|DRUG|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
214697512|NCT00258427|DRUG|fludarabine phosphate|35 mg/m\^2 intravenously (IV) on Days -5 through -2.
214697513|NCT00258427|DRUG|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
215157842|NCT06398509|BEHAVIORAL|Futuros Fuertes 2.0|The Futuros Fuertes 2.0 intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The Futuros Fuertes 2.0 intervention focuses on optimal infant feeding, screen time, and sleep practices.
214540542|NCT00812123|DRUG|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
214540543|NCT00812123|DRUG|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
214540544|NCT00812123|DRUG|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
214540545|NCT00812123|PROCEDURE|Protocol biopsies|protocol kidney biopsies at month one and three
214540546|NCT01820910|DRUG|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
215157843|NCT05677568|DEVICE|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
215157844|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
214540547|NCT04562896|DEVICE|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
214540548|NCT06188624|DRUG|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
214540549|NCT04689828|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
214540550|NCT04689828|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
214540551|NCT04689828|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
214540552|NCT04689828|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
214540553|NCT03797989|BIOLOGICAL|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
214540554|NCT02852811|OTHER|Group education|Intervention involving two education session with topics common in menopause transition.
214540555|NCT01653249|BIOLOGICAL|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
214540556|NCT04052997|DRUG|Camidanlumab Tesirine|Intravenous Infusion
214540557|NCT04958941|BEHAVIORAL|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
214540558|NCT00287547|DRUG|CTLA4Ig / Abatacept|
214540559|NCT06416319|DEVICE|Daily Activity Goal and Feedback|The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.
214540560|NCT05103098|DRUG|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214540561|NCT05103098|DRUG|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214540562|NCT00968006|DRUG|Sitagliptin|100 mg once daily for 4 weeks
214540563|NCT04652011|PROCEDURE|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
214540564|NCT04652011|PROCEDURE|osteopathic manipulative treatment|Osteopathic manipulative treatment
214540565|NCT04652011|DRUG|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
214540566|NCT05971628|PROCEDURE|RAPID procedure|RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma
214540567|NCT05959161|PROCEDURE|DBS|We observed the prognostic changes of patients after DBS surgery
214540568|NCT05212311|DEVICE|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
214540569|NCT05212311|DEVICE|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
214697514|NCT00258427|BIOLOGICAL|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
214697515|NCT04648423|DRUG|Sodium Oxybate|solution for oral administration
214697516|NCT04648423|DRUG|Placebo|solution for oral administration
215157845|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
214540570|NCT05212311|DEVICE|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
214540571|NCT05212311|OTHER|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
214540572|NCT03560414|PROCEDURE|simple plasma exchange|simple plasma exchange treatment
214540573|NCT03560414|PROCEDURE|conventional PDF treatment group|conventional PDF treatment group
214540574|NCT03560414|PROCEDURE|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
214540575|NCT02942368|DEVICE|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
214540576|NCT02453516|PROCEDURE|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
214540577|NCT02453516|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
214540578|NCT02453516|DRUG|ropivacaine|Drug indicated for regional anesthesia
214540579|NCT02453516|DRUG|epinephrine|Drug indicated to prolong the action of regional anesthesia
214540580|NCT02453516|OTHER|sterile saline|Neutral injection (no drug involved)
214540581|NCT01024036|DRUG|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
214540582|NCT01024036|DRUG|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
214540583|NCT01024036|DRUG|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
214540584|NCT00644735|DRUG|Esomeprazole|
215157846|NCT02765750|BEHAVIORAL|No message|The headphones will be placed on patient's ears but no message will be played.
215157847|NCT06474026|DEVICE|ExAblate 4000 Type 2.1|"In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments."
215157848|NCT00690781|DIETARY_SUPPLEMENT|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
214540585|NCT00644735|DRUG|Lansoprazole|
214540586|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
214540587|NCT00396214|DRUG|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
214540588|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
214540589|NCT01939821|BEHAVIORAL|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
214540590|NCT01939821|BEHAVIORAL|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
214540591|NCT06584825|DEVICE|Enhanced Vitals Monitoring|"For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first)."
214540592|NCT04032119|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
214540593|NCT04032119|DRUG|Epinephrine|Epinephrine
214540594|NCT05930132|PROCEDURE|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
214540595|NCT05930132|PROCEDURE|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
214540596|NCT03459612|DRUG|Lasmiditan|Administered orally
214540597|NCT03459612|DRUG|Placebo|Administered orally
214540598|NCT03459612|DRUG|Diphenhydramine|Administered orally
214540599|NCT05230095|BEHAVIORAL|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
214540600|NCT05230095|BEHAVIORAL|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
214540601|NCT03979547|BEHAVIORAL|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
214540602|NCT03628690|DEVICE|BandGrip|Topical skin closure device
214540603|NCT03628690|DEVICE|Suture|Wound closure
214540604|NCT05511558|DRUG|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
214540605|NCT03246399|DRUG|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
214540606|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
214540607|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
214540608|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
214540609|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
214540610|NCT04017897|DRUG|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
214540611|NCT03282578|DEVICE|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
214540612|NCT03282578|DEVICE|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
214540613|NCT05261230|BEHAVIORAL|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
214540614|NCT05261230|BEHAVIORAL|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
214540615|NCT02570256|BEHAVIORAL|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
214540616|NCT02570256|BEHAVIORAL|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
214540617|NCT02570256|BEHAVIORAL|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
214540618|NCT04318314|DIAGNOSTIC_TEST|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
215157849|NCT00690781|DIETARY_SUPPLEMENT|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
214540619|NCT03397316|PROCEDURE|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
214540620|NCT03965221|BEHAVIORAL|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
214540621|NCT03965221|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
214540622|NCT04130581|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
214540623|NCT01032356|DEVICE|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
214540624|NCT04344756|DRUG|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
214540625|NCT04440059|DRUG|ICP-022|ICP-022 at a dose of 150mg PO QD
214540626|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
214540627|NCT05940831|BEHAVIORAL|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
214540628|NCT05940831|BEHAVIORAL|Control|Routine care/ information giving
214540629|NCT00604188|DRUG|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
214540630|NCT00604188|DRUG|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
214540631|NCT04360434|DRUG|NI006|NI006 will be administered intravenously
214540632|NCT04360434|DRUG|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
214540633|NCT06254300|BEHAVIORAL|Exercise Training|The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
214540634|NCT03427008|OTHER|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
214540635|NCT04452409|DEVICE|low level laser|The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
214540636|NCT04452409|OTHER|Mediterranean diet|recommend healthy diet component evaluated periodically by 24 hour recall
214540637|NCT00857740|BEHAVIORAL|Education|Education about the neurophysiology of pain
214540638|NCT01218425|DRUG|Methylphenidate 40 mg|Oral dose 40 mg
214540639|NCT01218425|DRUG|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
214540640|NCT01218425|DRUG|Domperidon 10 mg|Domperidon 10 mg
214540641|NCT03167047|PROCEDURE|Caudal block|Caudal epidural
214697517|NCT05474690|DRUG|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|"Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle."
214540642|NCT03167047|PROCEDURE|Nerve Block|Peripheral nerve block
214540643|NCT03167047|DRUG|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
214540644|NCT02850718|DRUG|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
214540645|NCT02850718|DRUG|Oral Sildenafil|50 mg oral sildenafil (Viagra)
214540646|NCT04956614|DEVICE|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
214540647|NCT02291809|BIOLOGICAL|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
214540648|NCT01214681|DIETARY_SUPPLEMENT|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
214540649|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
214540650|NCT01214681|DIETARY_SUPPLEMENT|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
214540651|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
214540652|NCT05850182|BEHAVIORAL|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
214540653|NCT04303442|PROCEDURE|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
214540654|NCT02530398|DRUG|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
214540655|NCT03524768|DIAGNOSTIC_TEST|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
214540656|NCT01817712|BEHAVIORAL|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
214540657|NCT01817712|BEHAVIORAL|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
214540658|NCT04498988|OTHER|Observational study without interventions|
214540659|NCT06153498|DRUG|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
214540660|NCT05904756|DEVICE|framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone|evaluation of patient satisfaction and oral healty related quality of life
214540661|NCT05571306|OTHER|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
214540662|NCT00097669|DRUG|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo|multivitamin
214540663|NCT00097669|OTHER|Placebo|
214540664|NCT04666376|OTHER|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
214540665|NCT05822128|OTHER|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
214540666|NCT03094455|OTHER|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
214540667|NCT02111720|BEHAVIORAL|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
214540668|NCT02111720|BEHAVIORAL|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
214540669|NCT03674762|DEVICE|Microgrooved dental implants|Dental Implant placement
214540670|NCT05554926|DRUG|AEF0117|2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
214540671|NCT05226039|BEHAVIORAL|Moderate intensity acute exercise bout|The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
214540672|NCT00281047|DRUG|FP-10|
214540673|NCT03111797|DRUG|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
214540674|NCT03111797|OTHER|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
214540675|NCT05988034|DRUG|Avacopan|Administered orally.
214540676|NCT05988034|DRUG|Moxifloxacin|Administered orally.
214540677|NCT05988034|DRUG|Placebo for avacopan|Administered orally.
214697518|NCT05474690|DRUG|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)|Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
214697519|NCT04958863|OTHER|Surgical mask|Use of a surgical mask during test
214697520|NCT04958863|OTHER|Polyester reusable mask|Use of a polyester reusable mask during test
214697521|NCT05589116|OTHER|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
214697522|NCT00409201|DRUG|reboxetine adjuvant therapy|
214540678|NCT05988034|DRUG|Placebo for moxifloxacin|Administered orally.
214540679|NCT01260207|OTHER|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
214540680|NCT01190722|DRUG|etoricoxib|120 mg once daily for the 1st 6 postoperative days
214540681|NCT01190722|DRUG|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
214540682|NCT04643093|DRUG|Pitavastatin|Pitavastatin, QD
214540683|NCT04643093|DRUG|Ezetimibe|Ezetimibe, QD
214540684|NCT04643093|DRUG|1PC111|1PC111, QD
214540685|NCT00352378|DRUG|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
214540686|NCT00102271|DRUG|Oxypurinol|
214540687|NCT00102271|DRUG|Sodium Nitrite|
214540688|NCT00356759|DRUG|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
214540689|NCT01752010|OTHER|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
214540690|NCT01752010|DEVICE|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
214540691|NCT01752010|DEVICE|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
214540692|NCT03750526|BEHAVIORAL|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
214540693|NCT03750526|BEHAVIORAL|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
214540694|NCT03750526|BEHAVIORAL|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
214540695|NCT03750526|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
214540696|NCT03269747|DRUG|Prednisone|2 tablets of Prednisone 20 Mg in the morning
214540697|NCT03269747|DRUG|Placebo|2 Placebo tablets in the morning
214540698|NCT03115229|BEHAVIORAL|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
214540699|NCT06010550|RADIATION|Magnetic resonance imaging|Brain magnetic resonance imaging
214540700|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
214540701|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
214540702|NCT04817033|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
214540703|NCT04817033|DRUG|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
214540704|NCT06320847|DIAGNOSTIC_TEST|rPPG|A pulse oximeter and blood pressure cuff will be applied on the study patient by the study team member (research coordinators). At the same time, vital signs from Nervotec's rPPG technology will be recorded via the laptop and webcam. Synchronous measurement process of heart rate, respiration rate, pulse oximetry, heart rate variability and blood pressure estimates using Nervotec rPPG technology will take place for a duration of 3 minutes.
214540705|NCT05648604|BEHAVIORAL|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardening mentor twice monthly, and attending a gardening informational workshop once monthly.
214540706|NCT04702399|DEVICE|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
214540707|NCT01965041|DRUG|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
214540708|NCT01134718|DRUG|TMC435 (G006)|one morning dose of 150 mg
214540709|NCT01134718|DRUG|TMC435 (F021)|one morning dose of 150 mg
214540710|NCT01134718|DRUG|TMC435 (G007)|one morning dose of 150 mg
214540711|NCT04236245|DEVICE|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
214540712|NCT04151771|OTHER|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
214540713|NCT04151771|OTHER|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
214540714|NCT00474383|DRUG|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
214540715|NCT00474383|DRUG|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
214540716|NCT00926302|DRUG|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
214540717|NCT00926302|DRUG|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
214540718|NCT02998918|DIETARY_SUPPLEMENT|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
214540719|NCT02998918|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
214540720|NCT00977795|DRUG|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
214540721|NCT05910697|OTHER|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
214540722|NCT03500835|BEHAVIORAL|App|"1. 6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~2. Daily Weigh In~3. App based reminders~4. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months."
214540723|NCT03500835|BEHAVIORAL|Coaching|"1. 6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~2. Daily Weighing~3. Daily Text messages from Coach~4. Weekly 15 minute phone meetings with Coach~5. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent"
214540724|NCT03500835|BEHAVIORAL|Clinic: Modified KidsNFitness|"1. 6 month in-clinic, evidence-based, multi-disciplinary intervention~2. 90 minute sessions, in clinic that occur every month for 6 months~3. Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months."
214540725|NCT02364609|DRUG|Afatinib Dimaleate|Given PO
214540726|NCT02364609|BIOLOGICAL|Pembrolizumab|Given IV
214540727|NCT00487799|DRUG|Ularitide|
214540728|NCT03393065|OTHER|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
214540729|NCT03642288|DRUG|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
214540730|NCT00443599|DRUG|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
214540731|NCT00443599|OTHER|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
214540732|NCT03110692|BEHAVIORAL|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
214540733|NCT01952106|OTHER|play computer game|
214540734|NCT00615355|RADIATION|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
214540735|NCT00615355|DEVICE|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
214540736|NCT06336941|DEVICE|Ultrasound|Ultrasonographic scan with a 70 MHz probe
214540737|NCT01119534|DRUG|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
214540738|NCT01119534|DRUG|guaiacol suppository|2 times per day
214540739|NCT01119534|DRUG|Guaifenesin syrup|4.19 mL - 4 in 4 hours
214540740|NCT03594578|BEHAVIORAL|Episodic future thinking|Prospective thinking intervention
214540741|NCT03594578|BEHAVIORAL|Episodic recent thinking|Sham episodic thinking
214540742|NCT00220571|DEVICE|Coronary Angioplasty (PTCA)|
214540743|NCT01974661|BIOLOGICAL|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
214540744|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
214540745|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale|"Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line"
214540746|NCT01286376|DIETARY_SUPPLEMENT|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
214540747|NCT01286376|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
214540748|NCT05655624|OTHER|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
214540749|NCT05655624|OTHER|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
214540750|NCT05197153|BIOLOGICAL|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
214540751|NCT05197153|BIOLOGICAL|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
214540752|NCT05197153|BIOLOGICAL|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
214540753|NCT05197153|BIOLOGICAL|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
214540754|NCT04551222|DRUG|probenecid|1 gr. orally of probenecid twice daily for 180 days
214540755|NCT04551222|DRUG|Placebo|identical tablets to probenecid
214540756|NCT04396847|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
214540757|NCT04396847|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
214697523|NCT01073280|PROCEDURE|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
215029441|NCT05098821|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
215029442|NCT06049160|DRUG|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
215029443|NCT06641700|DIAGNOSTIC_TEST|diagnosed with gastric cancer|Pathological biopsy confirmed the diagnosis of gastric cancer.
215029444|NCT06637085|DEVICE|LLLT|low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .
214540758|NCT04214327|BEHAVIORAL|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
214540759|NCT04214327|BEHAVIORAL|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
214540760|NCT04214327|BEHAVIORAL|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
214697524|NCT04987853|DIAGNOSTIC_TEST|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire"
214697525|NCT04987853|DIAGNOSTIC_TEST|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2\. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3\. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4\. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
214697526|NCT04987853|DIAGNOSTIC_TEST|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
214697527|NCT04987853|DIAGNOSTIC_TEST|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
214697528|NCT05532098|PROCEDURE|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
214697529|NCT05532098|PROCEDURE|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
214697530|NCT00543569|DRUG|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
214697531|NCT00543569|DRUG|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
214697532|NCT00543569|DRUG|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
214697533|NCT00543569|DRUG|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
214697534|NCT00543569|DRUG|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
214697535|NCT00204997|PROCEDURE|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
214697536|NCT03194152|DIETARY_SUPPLEMENT|Peanut|Dietary Supplement: Peanut
214697537|NCT03194152|DIETARY_SUPPLEMENT|Control|Dietary Supplement: High carbohydrate snacks
214697538|NCT04019275|BEHAVIORAL|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
215029445|NCT06637085|OTHER|traditional physical therapy|traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
215029446|NCT06637085|DEVICE|ACU TENSE|Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
215029447|NCT06639685|DIAGNOSTIC_TEST|MRI|MR Fingerprinting and ASL
215029448|NCT04409431|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
215157850|NCT00690781|DIETARY_SUPPLEMENT|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
215157851|NCT00690781|DIETARY_SUPPLEMENT|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
215157852|NCT00369265|DRUG|Lansoprazole|Lansoprazole 30mg twice daily
215157853|NCT00369265|DIETARY_SUPPLEMENT|Sugar pill|placebo twice daily
215157854|NCT06174415|DEVICE|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
215157855|NCT02736318|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
215157856|NCT01140126|DRUG|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
215157857|NCT00078546|BIOLOGICAL|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
215157858|NCT00078546|BIOLOGICAL|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
215157859|NCT04859933|PROCEDURE|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
215157860|NCT04859933|PROCEDURE|AV-node ablation|Right sided ablation of the AV-node
215157861|NCT01847027|DRUG|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
215157862|NCT01847027|DRUG|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
215157863|NCT01320917|DEVICE|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
215157864|NCT01320917|DEVICE|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
214540761|NCT02331199|DEVICE|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
214540762|NCT02331199|DEVICE|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
214540763|NCT01699737|DRUG|JTT-851|
214540764|NCT01699737|DRUG|Glimepiride|Encapsulated Glimepiride tablets
214540765|NCT01699737|DRUG|Placebo for Active|
214540766|NCT01699737|DRUG|Placebo for comparator|
215157865|NCT00986765|DRUG|Lovenox® (enoxaparin)|Injectable solution 4000 UI
215157866|NCT00986765|DRUG|Aspegic ® (Aspirin)|100 mg/day
214540767|NCT06251999|DRUG|fospropofol sedation|Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
214540768|NCT06251999|DRUG|Propofol|propofol
214540769|NCT06391437|DIAGNOSTIC_TEST|Extraction of blood sample|Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.
214540770|NCT01749267|PROCEDURE|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
214540771|NCT03455205|DRUG|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
214540772|NCT03455205|DRUG|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
214540773|NCT02861196|PROCEDURE|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
214540774|NCT02250599|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
214540775|NCT02250599|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
214540776|NCT02250599|DRUG|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
214540777|NCT02382562|BEHAVIORAL|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
214540778|NCT03533777|PROCEDURE|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
214540779|NCT03533777|OTHER|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
214540780|NCT03533777|DEVICE|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
214540781|NCT03533777|DRUG|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
215029449|NCT06565286|PROCEDURE|inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias|compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
214540782|NCT00143026|DRUG|carbidopa, levodopa, entacapone|
214540783|NCT04759430|OTHER|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
214540784|NCT04759430|OTHER|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
214540785|NCT02202109|BEHAVIORAL|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
214540786|NCT02202109|BEHAVIORAL|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
214540787|NCT01361958|DRUG|NOMAC|
214540788|NCT05606198|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
214540789|NCT00803777|DEVICE|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
214540790|NCT04634370|BIOLOGICAL|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
214540791|NCT00002463|DRUG|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
214540792|NCT00002463|DRUG|Leucovorin Calcium|
214540793|NCT00002463|DRUG|Mechlorethamine Hydrochloride|
214540794|NCT00002463|DRUG|Methotrexate|
214540795|NCT00002463|DRUG|Prednisone|
214540796|NCT00002463|DRUG|Procarbazine Hydrochloride|
214540797|NCT00002463|DRUG|Vincristine Sulfate|
214540798|NCT00002463|PROCEDURE|Conventional Surgery|
214540799|NCT00927524|DRUG|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
214540800|NCT00927524|DRUG|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
214540801|NCT03163706|BEHAVIORAL|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
214540802|NCT01861639|DEVICE|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
214540803|NCT01861639|DEVICE|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
214540804|NCT01861639|DEVICE|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
214540805|NCT01861639|DEVICE|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
214540806|NCT01861639|DEVICE|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
214540807|NCT01861639|DEVICE|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
214540808|NCT02369861|DRUG|ST266|Topical ocular application 4 times per day
214540809|NCT02369861|DRUG|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
214540810|NCT01256671|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
214540811|NCT04431245|DRUG|Entecavir|Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.
215157867|NCT05022576|DIAGNOSTIC_TEST|Robotic arm assisted PSMA PET/CT guided prostate biopsy|The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
215157868|NCT02181088|BIOLOGICAL|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10\^9 vp
215157869|NCT02181088|BIOLOGICAL|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10\^10 vp
215157870|NCT02181088|BIOLOGICAL|MVA RH5 low dose|MVA RH5 at 1 x 10\^8 pfu
215157871|NCT02181088|BIOLOGICAL|MVA RH5 full dose|MVA RH5 at 2 x 10\^8 pfu
215157872|NCT04667221|DEVICE|Active transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.
215157873|NCT04667221|DEVICE|Sham transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
215157874|NCT03278171|BEHAVIORAL|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
215157875|NCT00030914|DRUG|medroxyprogesterone|
215157876|NCT00030914|DRUG|venlafaxine|
215157877|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
215157878|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2.5mg po daily
215157879|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
215157880|NCT03054532|DRUG|Durvalumab|Durvalumab intravenous 1500 mg
215157881|NCT03054532|DRUG|Lenali|Lenalidomide oral 20 mg/day
215157882|NCT03854279|DEVICE|tonsillar dissection|The tonsils will be removed by bizact device
215157883|NCT06351007|OTHER|Nutritional education and psychological intervention|"In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting"
215157884|NCT06351007|OTHER|Standard care|"The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml"
215157885|NCT06116370|PROCEDURE|Rezum procedure|In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.
214540812|NCT00902798|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
214540813|NCT00902798|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
214540814|NCT04505475|PROCEDURE|Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)|single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
214540815|NCT00846508|DRUG|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
214540816|NCT00438178|DRUG|Obatoclax mesylate (GX15-070MS)|
215157886|NCT06116370|PROCEDURE|B-TURP procedure|In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
215157887|NCT05463484|DRUG|Test composition Saliactive® (olive product, betaine and xylitol)|Fluoridated toothpaste with Saliactive®.
215157888|NCT05463484|DRUG|Placebo|Fluoridated toothpaste without Saliactive®.
215157889|NCT05463484|DRUG|Control|Commercial Fluoridated toothpaste for gingivitis with zinc citrate.
215157890|NCT03937622|OTHER|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
215157891|NCT02873377|DRUG|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
215157892|NCT02873377|DRUG|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
215157893|NCT02873377|OTHER|Smoking Quitline Referral|Fax referral to the State smoking Quitline
215157894|NCT02873377|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
215157895|NCT01586572|DRUG|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
215157896|NCT01586572|DRUG|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
215157897|NCT01773213|PROCEDURE|Ice-water-test|
215157898|NCT04951609|DRUG|Seltorexant|Participants will receive a single oral dose of seltorexant.
215157899|NCT04951609|DRUG|Placebo|Participants will receive matching placebo orally.
215157900|NCT04573582|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
215157901|NCT02925299|DEVICE|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
215157902|NCT02925299|DEVICE|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
215157903|NCT03313167|OTHER|Non-interventional|Non-interventional
215157904|NCT03980704|DRUG|IMPACT|Administration of oral immunostimulating oral supplement
215157905|NCT03980704|DRUG|resource protein|Administration of oral high-protein oral supplement
215157906|NCT02610114|OTHER|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
214540817|NCT06080360|OTHER|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
214540818|NCT05068921|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
215157907|NCT02610114|OTHER|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
215157908|NCT02376153|DEVICE|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
215157909|NCT02376153|DEVICE|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
215157910|NCT04496583|OTHER|Fluid depletion strategy|The fluid depletion strategy will be individualized depending on the response to the standardized furosemide test (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) with a urinary output (UO) cutoff of 200 ml at 2 hours. The desired depletion endpoint will be targeted by using diuretics (40 mg q6h iv initially, adjusting dose by UO) or ultrafiltration (UF) if UO \<200 ml/2h
215157911|NCT06347120|PROCEDURE|nasogastric tube|nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.
215157912|NCT06347120|OTHER|NOM without NGT insertion|intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h
215157913|NCT05955781|PROCEDURE|Spinal Mobilization With Leg Movement|spinal mobilization with leg movement is the intervention given to experimental group. This technique involves applying pressure to the relevant spinous process while the patient moves their limb through the previously restricted range of motion. It is assumed that the restriction of movement is due to a spinal issue but it does not always indicate nerve damage as spinal movement is necessary for limb movement beyond a certain point. The goal is to address any spinal mechanical limitations and there may also be potential effects on the nerves.
214540819|NCT04171245|OTHER|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
214540820|NCT04171245|DEVICE|Sleep tracking equipment|Tracking sleep using equipment
214540821|NCT02450695|DEVICE|rTMS|
215157914|NCT05955781|PROCEDURE|Spinal Mobilization|The patients will be given Spinal mobilization transverse glide(kaltenborn glide) on the effected spinous process. The total time duration will be 25-30 minutes.
215157915|NCT05955781|PROCEDURE|Conventional treatment|Participants will be given Hot pack for 15 minutes, TENS for 10 minutes
214540822|NCT03624387|OTHER|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
215157916|NCT02407600|DRUG|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
215157917|NCT02407600|DRUG|Placebo|
215157918|NCT02129127|DEVICE|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
215157919|NCT01817270|BIOLOGICAL|Live Attenuated Varicella Vaccine|
215157920|NCT04044001|DRUG|BTZ-043|BTZ-043 (250mg per tablet)
215157921|NCT04044001|DRUG|Rifafour e-275®|Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
215157922|NCT04044001|DRUG|Probe Drug Cocktail|"A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg"
215157923|NCT04044001|DRUG|Dolutegravir 50mg Tab|1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
215157924|NCT06091683|PROCEDURE|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
215157925|NCT05244252|DRUG|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
215157926|NCT05244252|DRUG|Bupivacaine|bupivacaine
215157927|NCT02185482|BEHAVIORAL|Physician Supported Care|
215157928|NCT02185482|OTHER|Usual care|
215157929|NCT06370429|OTHER|Progressive Relaxation Exercises, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
215157930|NCT05115149|DEVICE|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
215157931|NCT05115149|PROCEDURE|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
215157932|NCT05115149|PROCEDURE|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
215157933|NCT05115149|DEVICE|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
215157934|NCT05115149|PROCEDURE|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
215157935|NCT04041167|DRUG|alpha lipoic acid|alpha lipoic acid treatment
215157936|NCT04041167|DRUG|Saline|No alpha lipoic acid treatment
215157937|NCT05000255|BEHAVIORAL|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
215157938|NCT05000255|BEHAVIORAL|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
215157939|NCT00218842|BEHAVIORAL|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
215157940|NCT01448980|PROCEDURE|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
215157941|NCT01448980|PROCEDURE|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
215157942|NCT03771313|DRUG|Ceftaroline|Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
215157943|NCT04336878|BEHAVIORAL|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
215157944|NCT01339572|DRUG|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~1. Pre-apheresis peripheral blood CD34+ count \<20 cells/μL on day 5.~2. Estimated CD34+ cell collection is \< 25% of target cell dose after 1 day of apheresis.~3. Estimated CD34+ cell collection is \< 50% of target cell dose after 2 days of apheresis."
215157945|NCT01339572|DRUG|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID."
215157946|NCT06403332|BEHAVIORAL|brief intervention|The intervention for cohort A (intervention arm) based on brief intervention on alcohol consumption performed by a psycologist, medical visit peformed by an hepatologist including assessment of underlying liver disease with non invasive test (i.e Fibroscan and lab work).
215157947|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
214540823|NCT03969576|PROCEDURE|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
214540824|NCT03969576|PROCEDURE|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
214540825|NCT05828849|BEHAVIORAL|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
214540826|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
214540827|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
214540828|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
214540829|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
214540830|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
214540831|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
214540832|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
214540833|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
214540834|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
214540835|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
214540836|NCT04729842|PROCEDURE|Axillary Brachial plexus block|Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
214540837|NCT01501292|OTHER|Fixation and staining|Fixation and staining by MitiTracker Green FM
214540838|NCT01501292|OTHER|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
214697539|NCT01182948|BEHAVIORAL|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
214697540|NCT01182948|BEHAVIORAL|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
214697541|NCT02020096|PROCEDURE|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
214540839|NCT01042717|DRUG|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
214540840|NCT01788475|DRUG|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
214540841|NCT02619214|DRUG|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
214540842|NCT02619214|DRUG|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
214540843|NCT00749242|OTHER|orthopedic brace|antalgic drugs and orthopedic brace
214697542|NCT02020096|PROCEDURE|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
214697543|NCT03338517|OTHER|Helium Neon Laser|
214697544|NCT01143168|BIOLOGICAL|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
214697545|NCT05176431|DEVICE|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
214697546|NCT05176431|DEVICE|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
214697547|NCT05176431|DEVICE|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
214540844|NCT00749242|DEVICE|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
214540845|NCT00564148|DRUG|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
214540846|NCT01508637|OTHER|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
214540847|NCT01508637|OTHER|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
214540848|NCT01508637|DRUG|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
214540849|NCT01508637|DRUG|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
214540850|NCT06085053|DRUG|TQA3038 injection|TQA3038 is an injection.
214540851|NCT06085053|DRUG|TQA3038 injection matching placebo|Placebo injection contains no active substance.
214540852|NCT01122875|DRUG|MFGR1877S|Intravenous repeating dose
214540853|NCT03132662|DIETARY_SUPPLEMENT|Omega-3|3 gr/day of Omega-3
214540854|NCT03132662|DIETARY_SUPPLEMENT|Very Low Calorie Diet|4 servings/day Optifast
214540855|NCT04199468|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
214540856|NCT04199468|DRUG|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
214540857|NCT04199468|DRUG|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
214540858|NCT04199468|DRUG|Placebo Ketamine|A placebo dose given intravenously (IV)
214540859|NCT01333553|DEVICE|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
214697548|NCT03259997|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
214697549|NCT03259997|DIETARY_SUPPLEMENT|Placebo|Placebo
214697550|NCT06554028|DRUG|chemotherapy TP regimen combined with Tislelizumab|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel"
214697551|NCT01070602|PROCEDURE|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
214697552|NCT00213252|DRUG|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
214697553|NCT00213252|DRUG|Prednisolone|Six daily doses of oral prednisolone
214697554|NCT00673478|DRUG|Tiotropium+Salmeterol|
214697555|NCT00673478|DRUG|Salmeterol|
214697556|NCT00673478|DRUG|Tiotropium|
214697557|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
214697558|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
214697559|NCT02428530|OTHER|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
214697560|NCT00037635|DRUG|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
214697561|NCT00037635|DRUG|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
214697562|NCT04596280|PROCEDURE|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
214697563|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
214697564|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
214697565|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
214697566|NCT01268423|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
214697567|NCT01268423|PROCEDURE|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
214540860|NCT03006185|DEVICE|Ablative Fractional Carbon Dioxide (CO2) Laser|One 50 cm2 test area was randomized to pretreatment using a fractional 2940 nm Er:YAG laser (Joule®; Sciton Inc., Palo Alto, CA, USA). To remove hyperkeratosis, a fully-ablative 4 mm handpiece was optionally applied, followed by a single pass of a fractional Profrax 430 handpiece for all AKs. Subsequent field treatment consisted of a single pass of the Profrax 430 handpiece over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
214540861|NCT03006185|DEVICE|Microdermabrasion|Another adjacent 50 cm2 test area was exposed to microdermabrasion using an MD pad with 58.5 µm-diameter particles (Ambu® Skin Prep Pads 2121M; Ambu A/S, Ballerup, Denmark). Lesion-directed treatment consisted of an increasing number of swipes concentrated to AK lesions. During field treatment, multiple swipes were applied in perpendicular directions over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
214540862|NCT02828397|DRUG|REGN2222|
214540863|NCT01306539|PROCEDURE|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
214540864|NCT03984513|BEHAVIORAL|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
214540865|NCT03984513|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
214540866|NCT02169557|DRUG|Fexinidazole|
214697568|NCT02918409|DRUG|Colistin|
214697569|NCT02918409|DRUG|Tobramycin|
214697570|NCT00123916|DRUG|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
215157948|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
214540867|NCT01468077|DRUG|Tocilizumab|8 mg/kg infusion
214540868|NCT00345709|BEHAVIORAL|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
214540869|NCT05327036|OTHER|collect information about all participants|collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
214540870|NCT03921489|PROCEDURE|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
214540871|NCT00761956|DEVICE|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
214540872|NCT00761956|DEVICE|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
214540873|NCT03008109|DRUG|EGFR-TK Inhibitor|
214540874|NCT03437135|DIAGNOSTIC_TEST|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
214697571|NCT00123916|DRUG|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
214697572|NCT03117062|OTHER|occlusal reduction|relief of occlusion following endodontic treatment
214697573|NCT06531070|DIETARY_SUPPLEMENT|Nitrate|"A four-day supplementation period, separated by one week including a 3-day washout period between conditions will be applied before conducting strength and endurance assessments~Days 1 to 3 the randomly assigned supplement (N, NC, or PLA) will be ingested 2 hr before a standard low-volume training session including 3 sets of 8 to 10 reps of squat and deadlift using a very light load (e.g., own body mass) and flexibility exercises following by 5 min of running at self-paced intensity rated as light (12) with the rating of perceived exertion Borg Scale.~Day 4: the assigned supplement will be ingested 2.5 h before the assessments~Assessment of strength and endurance will be conducted"
215157949|NCT00553371|OTHER|biomarker analysis|
214540875|NCT00525928|DRUG|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
214540876|NCT03234361|DIETARY_SUPPLEMENT|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
214540877|NCT03234361|DIETARY_SUPPLEMENT|Low Phosphate Phase|2 capsules of sodium chloride.
214540878|NCT03421977|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
214540879|NCT06789965|PROCEDURE|SADI-S|In the case of SADI-S, the complete dissection of the antrum and the first portion of the duodenum is performed up to the limit of the gastroduodenal artery. The right gastric artery is dissected, clipped, and sectioned at its root. A vertical gastrectomy is created using a 38F Foucher tube with staplers. Next, the duodenum is sectioned with a stapler, and the resection of the greater gastric curvature is completed. Then, from the left side of the patient, 250 cm is measured from the ileocecal valve, where the duodenoileal anastomosis will be performed. This anastomosis is carried out with the surgeon positioned again between the patient's legs. A manual end-to-side anastomosis with two layers of monofilament is performed. Finally, the vertical gastrectomy and the duodenoileal anastomosis are verified using intraoperative endoscopy or a methylene blue and air test. The gastrectomy specimen is removed through the left pararectal trocar incision. A drain will only be placed in cases of s
214540880|NCT06789965|PROCEDURE|RY-GBP|In the case of RY-GBP, first, the lesser gastric curvature is dissected between the cardia and the angular incisura, accessing the gastric transcavity. A horizontal gastric transection is performed using the first firing of a stapler. A gastric reservoir is created through successive firings with a 38F Foucher tube stapler. Next, 100 cm of the biliopancreatic limb is measured, where the manual or semi-mechanical gastrojejunostomy will be performed, with an end-to-side anastomosis using a stapler and manual closure of the loop. Then, 150 cm of the alimentary limb is measured, and a side-to-side jejunojejunostomy is created. A section is made between the two anastomoses. The mesenteric opening and the Petersen space are closed with a continuous non-absorbable suture. The anastomosis is verified using intraoperative endoscopy or a methylene blue and air test. A drain will only be placed in cases of special technical difficulty or intraoperative complications.
214540881|NCT06956313|DEVICE|Hydraulic Pressure Lifting Technique|Hydraulic Pressure Lifting Technique
214540882|NCT06956313|DEVICE|Piezo-Surgical Lifting Technique|Piezo-Surgical Lifting Technique
214540883|NCT05258955|OTHER|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
214540884|NCT05258955|DRUG|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
214540885|NCT03024996|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
214697574|NCT04054843|DIAGNOSTIC_TEST|Afamin|Plasma maternal afamin levels
214697575|NCT04790266|DIAGNOSTIC_TEST|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
214697576|NCT00275925|DRUG|Oxcarbazepine|
214697577|NCT00781599|DRUG|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
214697578|NCT00781599|BEHAVIORAL|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
215157950|NCT00553371|PROCEDURE|computed tomography|
215157951|NCT06139367|DRUG|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
215157952|NCT02864056|OTHER|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
214697579|NCT00781599|BEHAVIORAL|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
214697580|NCT04888234|DRUG|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
214697581|NCT05640674|DRUG|Ibuprofen|Non-opioid
214697582|NCT05640674|DRUG|Hydrocodone/acetaminophen|Opioid
215157953|NCT00793013|DEVICE|Volume-Cycled Assist-Control (AC) mode|"1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40%~2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~4. Inspiratory to Expiratory ratio set at 1:1 to 1:3~5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol~7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
214540886|NCT03024996|OTHER|Placebo|Placebo matching to atezolizumab q3w
214540887|NCT00372346|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
214540888|NCT01885923|DEVICE|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
214540889|NCT01792388|DIETARY_SUPPLEMENT|Vitamin D|Capsule Form
214540890|NCT01792388|DIETARY_SUPPLEMENT|Soya Bean oil|Capsule form
214540891|NCT03060382|DEVICE|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
214540892|NCT03060382|BIOLOGICAL|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
214540893|NCT02627768|DRUG|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
214540894|NCT03362541|BEHAVIORAL|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
214540895|NCT03362541|BEHAVIORAL|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
214540896|NCT03232710|DRUG|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
214540897|NCT03232710|DRUG|abilify|Aripiprazol orodispersible tablets 10mg
214540898|NCT06956911|DEVICE|traditional cardiac rehabilitation with early low resisted exercise with blood flow restriction|Traditional cardiac rehabilitation and early low resisted exercise with 0.5 kilogram in form of bilateral upper limb exercise (elbow flexion and extension,wrist flexion and extension ) with external pressure applied with pressure cuff which determined by 40% of systolic blood pressure which applied on the proximal part of the arm,the frequency of exercise is once per day for 14 consecutive day and intensity determined by rate of perceived exertion scale
214540899|NCT06956911|DEVICE|traditional cardiac rehabilitation|Diaphragmatic and costal breathing exercise, active assisted to active range of motion,percussion,splinted cough,early mobility, upper limb exercise with breathing and incentive spirometer
214540900|NCT02263040|BIOLOGICAL|Fluzone High-Dose|Influenza vaccine
214540901|NCT02263040|BIOLOGICAL|Fluzone (standard dose)|Influenza vaccine
214540902|NCT02828345|OTHER|Specimen Collection|
214540903|NCT04564521|DRUG|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
214540904|NCT04564521|DRUG|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
214540905|NCT01479270|DRUG|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
214540906|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate.|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF
214540907|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
214540908|NCT03570151|OTHER|no intervention|no intervention will be done
214540909|NCT00030823|BIOLOGICAL|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
214540910|NCT00030823|BIOLOGICAL|QS21|
214540911|NCT01488955|DRUG|Ibuprofen|400 mg oral once a day from day 0 for 3 days
214540912|NCT01488955|DRUG|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
214540913|NCT03102489|DRUG|BP101|Nasal spray
214540914|NCT03102489|DRUG|Placebo|Nasal spray
214540915|NCT05019170|BEHAVIORAL|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
214697583|NCT05640674|DRUG|Acetaminophen|Non-opioid
214697584|NCT01202721|DRUG|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
214697585|NCT01202721|DRUG|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
214697586|NCT02626845|DRUG|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
214697587|NCT02626845|OTHER|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
215157954|NCT00793013|DEVICE|Airway Pressure Release Ventilation (APRV) mode|"1. Ventilation uses Drager Model X1~2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~3. Time periods for the high \& low pressure levels can be set independently~4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min~7. If spontaneous breathing is achieved,level of sedation will be decreased~8. If spontaneous respirations are \>20 breaths/min, sedation will be increased~9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
215157955|NCT01850758|PROCEDURE|Regenexx SD|stem cell treatment
214540916|NCT05019170|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
215157956|NCT01850758|OTHER|Exercise Therapy|exercise therapy control
215157957|NCT04083768|DEVICE|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
215157958|NCT05109195|OTHER|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
214540917|NCT00706771|DRUG|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
214540918|NCT00706771|DRUG|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
214540919|NCT06456476|DIAGNOSTIC_TEST|ERCP|ERCP used only if needed in some patients
214540920|NCT01509261|DRUG|Ilaprazole|20mg/Tap, QD
214540921|NCT01509261|DRUG|Lansoprazole|30mg/Tap, QD
214540922|NCT03513744|DIETARY_SUPPLEMENT|human milk oligosaccharides|mixture of five different human milk oligosaccharides
214540923|NCT01083199|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
214540924|NCT00269932|DRUG|levofloxacin|
214540925|NCT01830062|OTHER|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
214540926|NCT01830062|OTHER|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
214540927|NCT04415645|DRUG|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
214540928|NCT04333147|BIOLOGICAL|Otilimab (GSK3196165)|GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
214540929|NCT04333147|DRUG|csDMARD(s)|Stable dose of csDMARD(s) as standard of care (SoC).
214540930|NCT00303927|DRUG|capecitabine|
214540931|NCT02106195|DRUG|Belumosudil|
214540932|NCT03215953|DEVICE|cast shoe|ankle-high, custom-made, well-moulded cast shoe
214540933|NCT03215953|DEVICE|removable walker|Prefabricated especially designed for relieving load on the foot
215157959|NCT04628325|DRUG|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
215157960|NCT03950297|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
215157961|NCT02210494|DRUG|Secretrol|
214540934|NCT04157192|OTHER|Real acupuncture|The patient will be treated for migraine with real acupuncture.
214540935|NCT04157192|OTHER|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
214540936|NCT04027959|DIETARY_SUPPLEMENT|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
214540937|NCT06957522|OTHER|face to face rehabilitation|"The face-to-face rehabilitation program will be delivered in a clinical setting to infants aged 0-6 months with congenital muscular torticollis (CMT). It is based on neurodevelopmental treatment (NDT) principles and consists of:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities to promote the development of symmetrical movement~Environmental modification suggestions for the home setting~Parent/caregiver education and training~Sessions will be conducted twice per week, 30 minutes per session, over a total of 8 weeks.~In addition, an individualized home exercise program will be prescribed for each infant based on their specific needs. Frequency and duration of the home exercises may vary accordingly."
214540938|NCT06957522|OTHER|telerehabilitation|"The telerehabilitation program provides the same therapeutic content as the face-to-face rehabilitation group but will be delivered remotely via the Zoom video conferencing platform. The program will be applied to infants aged 0-6 months with congenital muscular torticollis (CMT) and is based on neurodevelopmental treatment (NDT) principles, including:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities for symmetrical movement development~Environmental modification suggestions~Parent/caregiver education and guidance~Sessions will be conducted via live video calls, twice per week, 30 minutes per session, for 8 weeks.~Each family will also receive an individualized home exercise program, with its frequency and duration adapted to the infant's needs."
214540939|NCT06957041|PROCEDURE|Intertransverse process block|The patient(s) will receive a pre-induction Intertransverse process block as pilot study
214540940|NCT06956872|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
214540941|NCT06956872|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
214540942|NCT06956872|OTHER|Printed Nutrition Pamphlet|After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose. Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions.
215157962|NCT06380413|OTHER|Tai Chi Chuan Plus Walking|Participants perform a 12-week program with two weekly sessions on non-consecutive days. The sessions last 75 min (5 min of warm-up, 45 min of Tai Chi Chuan (TCC), 20 min of walking, and 5 min of cool-down). The intervention occurs at the School of Physical Education, Federal University of Pelotas. The TCC section occurs in a mirrored dance studio, while walking occurs on an indoor sports court. The TCC sections are based on the simplified Yang 16-movement form. Over the 12 weeks, participants learn the fundamentals and basic principles of TCC and practice the 16 movements. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
215157963|NCT06380413|OTHER|Walking|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. The sessions last 30 minutes (5 minutes of warm-up, 20 minutes of walking, and 5 minutes of cool-down) throughout the intervention period. The intervention occurs in an indoor sports court at the School of Physical Education, Federal University of Pelotas. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
215157964|NCT03820895|DIAGNOSTIC_TEST|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
215157965|NCT02967224|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214540943|NCT06957054|OTHER|Any|Any
214540944|NCT04182633|COMBINATION_PRODUCT|vancomycin, Miralax, intestinal microbiota|vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
214540945|NCT04182633|COMBINATION_PRODUCT|placebo vancomycin, Miralax, placebo intestinal microbiota|placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
214540946|NCT06329401|DRUG|AP01|Oral inhalation solution
214540947|NCT06329401|OTHER|Placebo|Placebo oral inhalation solution
214540948|NCT06529718|DRUG|Ivonescimab|20 mg/kg IV infusion every 3 weeks
214540949|NCT06529718|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks
214540950|NCT06633757|DRUG|RCT1100|mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
214540951|NCT03939182|DRUG|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
214540952|NCT03939182|DRUG|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
214540953|NCT04743934|DRUG|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
214540954|NCT04743934|DRUG|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
214697588|NCT04090905|OTHER|Standard clinical monitoring|Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
214697589|NCT04090905|DIAGNOSTIC_TEST|Holter monitoring|Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
214540955|NCT04743934|DRUG|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
214540956|NCT04472845|RADIATION|1 week RT|RT will be delivered over 1 week
214540957|NCT04472845|RADIATION|2 week RT|RT will be delivered over 2 week
214540958|NCT02578888|OTHER|Palliative Therapy|Palliative Therapy
214540959|NCT02578888|OTHER|Palliative Therapy + idiographic|Ancillary studies
214540960|NCT05869045|OTHER|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
214697590|NCT01403701|BEHAVIORAL|Physical therapy|pelvic floor physical therapy
214697591|NCT05271422|DEVICE|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
214697592|NCT05271422|DEVICE|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
214697593|NCT05360355|PROCEDURE|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
215157966|NCT02967224|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214540961|NCT05013515|DRUG|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
214540962|NCT05764551|DIAGNOSTIC_TEST|Serum DNA methylation|Serum DNA methylation
214540963|NCT05900180|BEHAVIORAL|Speech Therapy|Delivery of speech therapy services
214540964|NCT05559879|DRUG|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
214540965|NCT06140901|DIAGNOSTIC_TEST|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
214540966|NCT06013865|DRUG|Empagliflozin|SGLT2 Inhibitor
214697594|NCT06409091|DEVICE|Medium weight or Heavy weight mesh|Patients received a hernia repair with one of the two groups
214697595|NCT01650818|OTHER|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
214697596|NCT01650818|OTHER|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
214697597|NCT00089479|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
214697598|NCT00089479|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
214697599|NCT00089479|DRUG|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
215157967|NCT02967224|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
215157968|NCT02967224|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
215157969|NCT02967224|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
215157970|NCT02062619|BEHAVIORAL|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
215157971|NCT02062619|OTHER|Real tDCS|Real tDCS 20 minutes per session, three times per week
215157972|NCT02062619|OTHER|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
215157973|NCT01939769|OTHER|Exercise - Low-intensity exercise|
215157974|NCT01939769|OTHER|Exercise - High-intensity exercise|
215157975|NCT01497223|DRUG|MGCD290|1 Oral Dose Administration
215157976|NCT01420211|DRUG|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
215157977|NCT01420211|DEVICE|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
214540974|NCT06956846|DRUG|insulin eye drops|Use of topical insulin eye drops following a standard excimer laser photo-refractive keratecotmy in myopic/astigmatic patients, in order to examine its efficacy in promoting corneal epithelial healing and patient comfort
214540975|NCT06956846|DRUG|Artificial tears eye-drops|The other arm receiving only artificial tears
214540976|NCT06956924|DIAGNOSTIC_TEST|CCTA|The data acquisition protocol was tailored to each patient's heart rate and rhythm. Specifically, a prospectively ECG-triggered volume scan was used to account for heart rates and rhythms, capturing predefined scanning areas during R-R intervals, especially in instances of frequent ectopic beats or irregular heart rates noted during pre-scan ECG monitoring. Imaging system parameters included a gantry rotation time of 0.275 seconds, collimation of 0.5 mm, tube voltage settings ranging from 100 kV to 120 kV, and a tube current-time product between 200 mAs and 450 mAs, with adjustments based on the patient's BMI.
214540977|NCT05854667|DRUG|Treatment as Usual plus Placebo|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
214540978|NCT05854667|DRUG|Treatment as Usual plus Placebo plus Contingency Management|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
214540979|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01)|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15)."
214540980|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13."
214540981|NCT06630624|DRUG|IP-001|Intra-tumoral injection of IP-001 following ablation (MWA or IRE).
214540982|NCT00408928|DRUG|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
214540983|NCT06309576|BEHAVIORAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
214540984|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
214540985|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
215157978|NCT04473469|DEVICE|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
215157979|NCT00004101|BIOLOGICAL|apolizumab|
215157980|NCT01030926|DRUG|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
215157981|NCT01030926|DRUG|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
215157982|NCT02565667|DEVICE|KOL|KOL staple was used for rectal anastomosis
215157983|NCT02565667|DEVICE|traditional staple|traditional staple was used for rectal anastomosis
215157984|NCT02985528|OTHER|further diagnostic|further diagnostic procedures - mainly CHEST CT -
215157985|NCT01627288|RADIATION|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
215157986|NCT04910841|DEVICE|CGM GUARDIAN 2|continuous blood glucose monitoring system
215157987|NCT04130503|DEVICE|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
215157988|NCT04130503|BEHAVIORAL|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
215157989|NCT02015910|DRUG|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
215157990|NCT02015910|DRUG|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
215157991|NCT00909298|DRUG|TTP889|300 mg
215157992|NCT00909298|DRUG|Placebo|Placebo
215157993|NCT04615377|BEHAVIORAL|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
215157994|NCT04615377|OTHER|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
215157995|NCT00792220|PROCEDURE|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
215157996|NCT00792220|PROCEDURE|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
214697600|NCT03212846|OTHER|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
214697601|NCT01053117|OTHER|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
214697602|NCT04665791|BIOLOGICAL|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
214697603|NCT01547468|PROCEDURE|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
214697604|NCT01547468|PROCEDURE|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
214697605|NCT01094717|DRUG|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
214697606|NCT01094717|DEVICE|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
214697607|NCT01094717|DRUG|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
214697608|NCT01094717|DEVICE|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
214697609|NCT02276716|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
214697610|NCT00126399|DRUG|doxycycline|
214697611|NCT03529136|BIOLOGICAL|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
214697612|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
214697613|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
214697614|NCT02836535|BEHAVIORAL|qualitative interviews|
214697615|NCT04429685|DRUG|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
214697616|NCT04429685|DRUG|Saline (placebo)|Saline (placebo)
214697617|NCT05528224|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
214697618|NCT05528224|OTHER|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
214697619|NCT05528224|DRUG|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
215029450|NCT06638697|OTHER|Free walking|The free walking training program will last 32 weeks. The intensity of the training will be controlled by the scale of perceived exertion (Borg). The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
214540986|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
214540987|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
214540988|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
214540989|NCT00522743|DRUG|growth hormone and gonadotropin-releasing hormone agonist|GH \& GNRHa treatment
214540990|NCT00522743|DRUG|growth hormone|GH treatment
214540991|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
214540992|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
214540993|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
214540994|NCT03212677|OTHER|Placebo|Cornstarch
214540995|NCT06573346|OTHER|Cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
215157997|NCT05211843|OTHER|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
215157998|NCT05211843|OTHER|Apple juice|apple juice
215157999|NCT05925868|BEHAVIORAL|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
214540996|NCT06255626|DRUG|CD40.RBDv vaccin (SARS-Cov2 Vaccin)|1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
214540997|NCT03480295|DEVICE|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
214540998|NCT03480295|DEVICE|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
214540999|NCT00314418|PROCEDURE|Colonoscopy in the prone position|
214541000|NCT04214613|PROCEDURE|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
214541001|NCT03163043|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
214541002|NCT01854736|DRUG|Grazax|GRAZAX
214541003|NCT01854736|OTHER|Placebo|Placebo
214541004|NCT06177899|PROCEDURE|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
214541005|NCT00385099|DRUG|GW876008|
214541006|NCT05735743|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
214541007|NCT06078566|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
214541008|NCT03194867|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214541009|NCT03194867|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214541010|NCT00464945|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
214541011|NCT04943354|BEHAVIORAL|Taking a person's venous blood|Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
214541012|NCT03831854|DRUG|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).
214541013|NCT03831854|DRUG|Placebo|300 mg of oral Placebo
214541014|NCT03831854|DRUG|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
214541015|NCT01828086|BIOLOGICAL|CJM112|Monoclonal antibody
214541016|NCT01828086|BIOLOGICAL|Secukinumab|Monoclonal antibody
214541017|NCT01828086|OTHER|Placebo|Liquid for subcutaneous injection without active drug.
214541018|NCT05253859|OTHER|No intervention|Registry study: No intervention
214541019|NCT03067545|OTHER|Step rate increase|increase the step rate during running by 10% steps per minute
214697620|NCT03395275|BEHAVIORAL|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
215158000|NCT00983658|DRUG|huMAb OX40L|Intravenous repeating dose
215158001|NCT00983658|DRUG|placebo|Intravenous repeating dose
215158002|NCT03830307|DEVICE|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
215158003|NCT05408546|DRUG|TS23|Monoclonal antibody to a2-antiplasmin
215158004|NCT05408546|DRUG|Placebo|Placebo
215158005|NCT03056196|DIAGNOSTIC_TEST|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
215158006|NCT02181244|OTHER|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
214541020|NCT04293952|OTHER|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
214541021|NCT04293952|OTHER|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
215158007|NCT02181244|OTHER|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
214541022|NCT03813732|PROCEDURE|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
214541023|NCT05624788|OTHER|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
214697621|NCT03395275|BEHAVIORAL|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
214697622|NCT02797691|OTHER|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
214697623|NCT02797691|OTHER|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
214697624|NCT05821621|OTHER|no intervention|observational study : there is no intervention
214697625|NCT05259267|BEHAVIORAL|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
214697626|NCT05259267|BEHAVIORAL|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
214697627|NCT03198754|DEVICE|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
215158008|NCT04254185|PROCEDURE|Simple decompression|Surgical technique
215158009|NCT04254185|PROCEDURE|Subcutaneous anterior transposition|Surgical technique
215158010|NCT00740857|DRUG|placebo|2 placebo gels capsules delivered as a single dose.
215158011|NCT00740857|DRUG|ibuprofen Formulation 1|2 marketed ibuprofen gels
215158012|NCT00740857|DRUG|ibuprofen Formulation 2|2 marketed ibuprofen gels
215158013|NCT05809297|DEVICE|Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®|According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
214541024|NCT02161198|DIETARY_SUPPLEMENT|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
214541025|NCT02161198|DIETARY_SUPPLEMENT|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
214697628|NCT03198754|DEVICE|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
214697629|NCT00503880|BIOLOGICAL|filgrastim|subcutaneously one day prior to treatment
214697630|NCT00503880|DRUG|clofarabine|single IV dose over 1 hour daily for 5 days
214697631|NCT00503880|DRUG|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
214697632|NCT00503880|GENETIC|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
214697633|NCT00503880|PROCEDURE|biopsy|bone marrow biopsy
214697634|NCT05311293|DIAGNOSTIC_TEST|Endoscopy|Observe the extent of colonic lesions and obtain intestinal mucosal samples
214697635|NCT04399512|PROCEDURE|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
214697636|NCT02129335|OTHER|stress|stress level and survival
215158014|NCT05809297|DRUG|Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer|The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
215158015|NCT03227419|DRUG|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
214541026|NCT03305809|DRUG|LY3154207|Administered orally.
214541027|NCT03305809|DRUG|Placebo|Administered orally.
214541028|NCT00816556|DRUG|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
214541029|NCT00816556|DRUG|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
215158016|NCT03227419|DRUG|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection."
215158017|NCT03433040|DRUG|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
214541030|NCT00816556|DRUG|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
214541031|NCT05418413|DEVICE|CTB|conventional Twin-block (CTB) will be comprised of maxillary and mandibular removable appliances having the labial bows, adam's clasps, and with no incisal capping.
214541032|NCT05418413|DEVICE|ETB|will be comprised of maxillary and mandibular removable 1.5-mm biocryl sheet will be adapted separately on maxillary and mandibular casts with help of vacuum machine, and Acrylic bite blocks with the inclined plane will be fabricated on biocryl sheets sim
214541033|NCT02438371|DRUG|Nifedipine|
214541034|NCT02438371|DRUG|Indomethacin|
214541035|NCT03546816|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
214541036|NCT03546816|DRUG|Placebo Tablets|Placebo Tablets
214541037|NCT01161446|BEHAVIORAL|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
214541038|NCT01161446|DEVICE|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
214541039|NCT03065933|DRUG|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
214541040|NCT04959578|DRUG|Recombinant human erythropoietin|Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
214541041|NCT04959578|DRUG|Darbepoetin Alfa|Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
214541042|NCT05952947|BIOLOGICAL|HRYZ-T101 Injection|On day 1, the TCR-T cells will be administered intravenously.
215158018|NCT03532451|DRUG|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
215158019|NCT03532451|DRUG|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
214541043|NCT05952947|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
214541044|NCT05719402|PROCEDURE|non-interventional prospective cross-sectional observational study|to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD
214541045|NCT02330562|DRUG|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
214541046|NCT02330562|DRUG|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
214541047|NCT06488638|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days|commercially available beetroot juice dietary nitrate supplement
215158020|NCT01214733|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
215158021|NCT00249899|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
215158022|NCT00249899|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
215158023|NCT02785523|DRUG|Ganoderma Spore Lipids|
215158024|NCT02785523|DRUG|Placebo|
215158025|NCT02785523|DRUG|Chemotherapy|
215158026|NCT00135499|DRUG|Rituximab|375 mg/m², D1, 4 cycles
215158027|NCT00135499|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
215158028|NCT00135499|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
215158029|NCT00135499|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
214541048|NCT04173702|DIAGNOSTIC_TEST|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
214541049|NCT00258362|DRUG|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
214541050|NCT00258362|DRUG|docetaxel|75 mg/m\^2 on Day 1 of each course
214541051|NCT00258362|RADIATION|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
214541052|NCT00051038|DRUG|Entecavir|
215158030|NCT00135499|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
215158031|NCT00135499|DRUG|Prednisone|60 mg, D1-D5, 4 cycles
215158032|NCT00135499|DRUG|Prednisone|40 mg, D1-D5, 4 cycles
215158033|NCT00135499|DRUG|Doxorubicin|50 mg/m², D1, 4 cycles
215158034|NCT00135499|DRUG|Cyclophosphamide|750 mg/m², D1, 4 cycles
215158035|NCT00135499|DRUG|Vincristine|1.4 mg/m², D1, 4 cycles
215158036|NCT05045495|DIAGNOSTIC_TEST|Sucrose Hydrogen Methane Breath Test|Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
215158037|NCT05744843|BEHAVIORAL|exercise|cardiovascular and lower limb strengthening exercise programme
215158038|NCT05744843|PROCEDURE|Deep venous stenting|Planned surgical intervention
215158039|NCT03846908|OTHER|MCT|patients will receive fat load with MCT
214541053|NCT04481646|DIAGNOSTIC_TEST|Face mask sampling|Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
214697637|NCT05630430|PROCEDURE|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
214541054|NCT00568698|DRUG|Hydroxyurea|
214541055|NCT00568698|DRUG|Placebo to match hydroxyurea|
214697638|NCT02979730|OTHER|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
214697639|NCT02979730|OTHER|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
214697640|NCT03772938|BIOLOGICAL|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
214697641|NCT04229550|BEHAVIORAL|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
214697642|NCT02951390|OTHER|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
214697643|NCT06399640|DRUG|Eltanexor|Eltanexor will be taken by mouth
214697644|NCT06399640|DRUG|Venetoclax|Venetoclax will be taken by mouth
214697645|NCT06399640|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214697646|NCT06399640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214697647|NCT05670964|DEVICE|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
214697648|NCT05670964|DEVICE|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
215158040|NCT03846908|OTHER|SFA|patients will receive fat load with SFA
215158041|NCT03846908|OTHER|MUFA|patients will receive fat load with MUFA
214541056|NCT02412449|DRUG|AKB-6548 tablet, reference formulation given in the fasted state|
214541057|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fasted state.|
214541058|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fed state|
214541059|NCT00947232|BEHAVIORAL|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
214697649|NCT05678413|PROCEDURE|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
214697650|NCT05678413|PROCEDURE|DVIU|DVIU
214697651|NCT00190203|PROCEDURE|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
214697652|NCT00190203|PROCEDURE|hemicraniectomy|hemicraniectomy
214697653|NCT06065267|DRUG|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
214697654|NCT06065267|DRUG|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
215158042|NCT01055431|OTHER|Control bread|Control bread
215158043|NCT01055431|OTHER|Teff Bread|Teff bread
215158044|NCT01175499|DEVICE|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
215158045|NCT01175499|DEVICE|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
215158046|NCT05744674|DRUG|HR18034|HR18034 228mg/342mg/456mg
214697655|NCT02681380|OTHER|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
214697656|NCT02681380|OTHER|Control group|No session will be planned for the participants.
214697657|NCT00093080|DRUG|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
214697658|NCT02786589|BIOLOGICAL|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
214697659|NCT02831075|BIOLOGICAL|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
214697660|NCT02831075|BIOLOGICAL|saline|
214697661|NCT01132989|DRUG|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
214697662|NCT03367065|RADIATION|Dynamic contrast enhanced computerised tomography|
214541060|NCT00947232|BEHAVIORAL|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
214541061|NCT00765154|DRUG|darunavir|two 400mg tablets (800mg) once daily
214697663|NCT06118567|DRUG|Nitrous oxide|Nitrous oxide gas.
214697664|NCT06118567|DRUG|Room Air|Room Air
214697665|NCT05941858|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resource document
214697666|NCT05941858|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
214697667|NCT05941858|OTHER|Internet-Based Intervention|Receive access to WaQi/Tai Chi program
214697668|NCT05941858|OTHER|Survey Administration|Ancillary studies
214697669|NCT05941858|OTHER|Tai Chi|Practice Tai Chi
214697670|NCT06217536|DRUG|Lurbinectedin|Given intravenously (IV)
214697671|NCT06217536|RADIATION|Radiotherapy|Conventionally fractionated radiotherapy or external beam radiation
214697672|NCT06217536|PROCEDURE|Non-investigational surgery|Non-investigational surgical procedure on tumor tissue
214541062|NCT00765154|DRUG|ritonavir|one 100mg capsule once daily
214541063|NCT03042364|OTHER|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
214541064|NCT01765738|DEVICE|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
214541065|NCT05601427|PROCEDURE|aACB|The patient will undergo a pre-operative single-shot, ultrasound-guided ACB performed by an anaesthesiologist skilled in regional anaesthesia techniques. The ACB will be performed in a dedicated block room, immediately prior to administration of a spinal anaesthetic.
214697673|NCT02098460|DRUG|Atorvastatin, Probucol, Cilostazol|
214697674|NCT03484000|BEHAVIORAL|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
214697675|NCT06184269|DRUG|BR1017-1|One tablet administered alone
214697676|NCT06184269|DRUG|BR1017-1A|One tablet administered alone
214697677|NCT06184269|DRUG|BR1017-1B|One tablet administered alone
215158047|NCT05744674|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
215158048|NCT01519167|DRUG|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
215158049|NCT01519167|DRUG|Midazolam|0.025 - 2 mg/kg IV
214541066|NCT05601427|PROCEDURE|sACB|The patient will undergo an intraoperative single-shot ACB performed by the treating surgeon following placement of the TKA components.
214697678|NCT06626139|DRUG|Psilocybin|Healthy participants will receive up to 25 mg psilocybin.
214697679|NCT06626139|BEHAVIORAL|Context 1|Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
214697680|NCT06626139|BEHAVIORAL|Context 2|Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
214697681|NCT06626139|DRUG|Placebo|Healthy participants will receive an inactive placebo.
214697682|NCT03216551|DIAGNOSTIC_TEST|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
214697683|NCT06108323|BEHAVIORAL|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
214697684|NCT06108323|BEHAVIORAL|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
214697685|NCT03571620|DRUG|Q301 Cream|1.0% or 1.4% Q301 Cream
214697686|NCT03571620|DRUG|Vehicle|Vehicle Control
214697687|NCT06693063|OTHER|Data collection|Some data will be collected for all patients included: medical and family history, chest pain data and medical care data
214697688|NCT06692257|BEHAVIORAL|Observation|To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
214697689|NCT06692231|BEHAVIORAL|Pharmacist intervention|Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
214697690|NCT06692777|DIETARY_SUPPLEMENT|Bergavit|Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
214697691|NCT06692777|DIETARY_SUPPLEMENT|Placebo|Subjects will take capsule equivalent amount of maltodextrin for 4 months.
214697692|NCT06692049|PROCEDURE|Gonadectomy|Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
214697693|NCT05112016|PROCEDURE|Total mesorectal excision for rectal cancer|
214697694|NCT00382096|DRUG|Vildagliptin|
215158050|NCT01519167|DRUG|Fentanyl|0.5 - 3 mcg/kg IV
214541067|NCT01184885|DRUG|Hyper-CVAD|"* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
214541068|NCT01184885|DRUG|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
214541069|NCT06374082|OTHER|WhatsApp message|"Participants in the intervention group will receive 3 WhatsApp messages per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205). These messages are about the core content of the course, including (1) Knowledge Themes: harmfulness of smoking and benefits of quitting, the fundamentals of nicotine addiction, smoking cessation counselling with the 5A model, and pharmacotherapy for smoking cessation; (2) Attitude Themes: nurses' role in smoking cessation and the importance of smoking cessation; and (3) Practice Themes: practical advice on counseling techniques, communication skills by motivational interviewing, local smoking cessation resources for referral.~Participants in the control group will receive 3 WhatsApp messages about generic mental health information per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205)."
214541070|NCT01162135|DRUG|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
215158051|NCT00557713|DRUG|bevacizumab|"1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
215158052|NCT02654769|DRUG|Ingenol Mebutate (Picato®)|Brand product
215158053|NCT02654769|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
215158054|NCT02654769|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
215158055|NCT02602210|DRUG|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
215158056|NCT02602210|DRUG|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
215158057|NCT00556504|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
215158058|NCT00556504|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
215158059|NCT00556504|DRUG|Ribavirin|conventional treatment of Hepatitis C
215158060|NCT00556504|DRUG|Placebo|Placebo, without acting ingredient.
215158061|NCT02932241|BEHAVIORAL|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
215158062|NCT05808543|OTHER|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
215158063|NCT05808543|OTHER|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
214541071|NCT02002962|PROCEDURE|radiofrequency ablation|
214541072|NCT02002962|DRUG|Botulinum Toxin Type A injection|
214697695|NCT00382096|DRUG|Metformin|
214697696|NCT00382096|DRUG|Vildagliptin + Metformin|
214697697|NCT05928806|DRUG|Botensilimab|Botensilimab 75mg IV
214697698|NCT05928806|DRUG|Balstilimab|Balstilimab 450mg IV
214697699|NCT05928806|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV
214697700|NCT05928806|DRUG|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
214697701|NCT06490354|DEVICE|Lightback group|Use of the patented Lightback device to relax the gluteal musculature and prevent hamstring injuries.
214697702|NCT06490354|OTHER|Conventional treatment|Conventional treatment to relax the gluteal musculature and prevent hamstring injuries.
214697703|NCT04588883|BEHAVIORAL|Kuja Pamoja - HIV|Information has been provided in the treatment arm description.
214697704|NCT07027228|OTHER|Using virtual reality glasses or listening to music|Donors in the intervention group will be randomly assigned and shown relaxing nature images through virtual reality glasses.
214541073|NCT01325597|OTHER|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
215158064|NCT02546518|DEVICE|Moniri Otovent|Please see Arm Description.
215158065|NCT02546518|DEVICE|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
215158066|NCT00158496|DRUG|pegylated interferon alpha2a|
215158067|NCT00158496|DRUG|ribavirin|
215158068|NCT00565188|DRUG|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
215158069|NCT02401789|DEVICE|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
215158070|NCT04711226|DRUG|AT-1501|AT-1501 IV infusion
214541074|NCT01325597|OTHER|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
214541075|NCT01325597|OTHER|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
214541076|NCT01325597|OTHER|Control group|No intervention
214541077|NCT04347785|PROCEDURE|carotid endarterectomy|shunt
214541078|NCT02902653|DRUG|Oral misoprostol|hourly titrated misoprostol
214541079|NCT02902653|DRUG|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
214541080|NCT02902653|DRUG|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
214541081|NCT05225636|PROCEDURE|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
214541082|NCT01316887|DRUG|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
214541083|NCT01316887|DRUG|125mcg once-daily GSK573719|GSK573719
214541084|NCT01316887|DRUG|Placebo once-daily|inactive
214541085|NCT03121495|DIAGNOSTIC_TEST|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
214541086|NCT04092049|OTHER|lollipop|chewing lollipop for 10 minutes
214541087|NCT00813098|DRUG|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
214541088|NCT00813098|DRUG|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
214541089|NCT00813098|DRUG|Placebo|Matching placebo dosing with daily oral intake
214541090|NCT03732976|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
214541091|NCT03732976|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
214541092|NCT04129047|DRUG|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
214541093|NCT04129047|DRUG|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
214541094|NCT04517383|PROCEDURE|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
214541095|NCT04517383|PROCEDURE|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
214541096|NCT01809899|BEHAVIORAL|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
214541097|NCT01809899|BEHAVIORAL|Consent as Usual|Routine informed consent procedures
214541098|NCT03564834|PROCEDURE|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
214541099|NCT03564834|PROCEDURE|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
214541100|NCT02462343|OTHER|walk tests|
214541101|NCT02089412|DRUG|E2006|
214541102|NCT01068288|PROCEDURE|Laparoscopic or open appendectomy|
214541103|NCT01068288|PROCEDURE|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
214541104|NCT03361098|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
214541105|NCT03361098|DRUG|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
214541106|NCT03361098|OTHER|placebo exenatide|placebo b.i.d. exenatide
214541107|NCT03361098|OTHER|placebo dapagliflozin|placebo tablets dapagliflozin
214541108|NCT02298049|OTHER|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
214541109|NCT02298049|DEVICE|MRI|
214541110|NCT01301703|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
214541111|NCT03470545|DRUG|mavacamten|mavacamten capsules
214541112|NCT03470545|DRUG|Placebo|placebo oral capsule
214541113|NCT01143545|BIOLOGICAL|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
214541114|NCT01143545|DRUG|Celecoxib|400 g po bid
214697705|NCT07027228|OTHER|Using listening to music|Donors in the intervention group will be randomly assigned and will listen to relaxing music.
215158071|NCT04297527|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
215158072|NCT04297527|PROCEDURE|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
215158073|NCT05486377|DRUG|Remimazolam besylate|Remimazolam besylate TIVA
215158074|NCT00882817|OTHER|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
215158075|NCT01039883|DRUG|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
215158076|NCT01039883|DRUG|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
215158077|NCT02561338|DRUG|HMS5552|75mgQD
215158078|NCT02561338|DRUG|HMS5552|100mgQD
215158079|NCT02561338|DRUG|HMS5552|50mgBID
215158080|NCT02561338|DRUG|HMS5552|75mgBID
215158081|NCT02561338|OTHER|Placebo|QD/BID
215158082|NCT03384862|DIETARY_SUPPLEMENT|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
215158083|NCT03384862|DIETARY_SUPPLEMENT|Placebo|Placebo pills, with same appearance as intervention pills.
215158084|NCT03384862|DIETARY_SUPPLEMENT|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
215158085|NCT02978599|DRUG|AVL-3288|daily for 5 days
215158086|NCT02978599|DRUG|Placebo|daily for 5 days
215158087|NCT00533676|DRUG|MK0524A, /Duration of Treatment : 8 Weeks|
215158088|NCT00533676|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
215158089|NCT04236609|DEVICE|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
215158090|NCT04236609|DEVICE|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
215158091|NCT04200352|DRUG|TEV-50717|Oral tablets are 6, 9, and 12 mg.
215158092|NCT02135926|DEVICE|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
215158093|NCT02135926|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
215158094|NCT00474591|DRUG|Fondaparinux|
215158095|NCT04690452|BEHAVIORAL|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
215158096|NCT04371393|BIOLOGICAL|Remestemcel-L|administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
215158097|NCT04371393|DRUG|Placebo|administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
215158098|NCT01147913|BEHAVIORAL|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
214541115|NCT01143545|DRUG|cyclophosphamide|50 mg po bid
214541116|NCT05155488|OTHER|No Intervention|This is a non-interventional study.
214541117|NCT03354910|BEHAVIORAL|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
214541118|NCT03354910|BEHAVIORAL|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
214541119|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
215029451|NCT06638697|OTHER|Nordic walking|The Nordic walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
215158099|NCT01147913|BEHAVIORAL|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
214697706|NCT06693245|PROCEDURE|VAS scores of the puncture|All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
214697707|NCT06692647|DRUG|MK-4318|Oral administration
215158100|NCT05689580|DIETARY_SUPPLEMENT|Ketogenic diet|The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
214541120|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
214541121|NCT00002547|DRUG|busulfan|
214541122|NCT00002547|DRUG|cyclophosphamide|
214541123|NCT00002547|DRUG|cyclosporine|
214541124|NCT00002547|DRUG|cytarabine|
214541125|NCT00002547|DRUG|methotrexate|
214541126|NCT00002547|PROCEDURE|allogeneic bone marrow transplantation|
214541127|NCT00002547|PROCEDURE|syngeneic bone marrow transplantation|
214541128|NCT05142839|PROCEDURE|EUS-CD|EUS-guided choledochoduodenostomy
214541129|NCT05142839|PROCEDURE|EUS-GEA|EUS-guided gastroenterostomy
214541130|NCT04674878|OTHER|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
214541131|NCT04674878|OTHER|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
214541132|NCT02584881|OTHER|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
214541133|NCT02875002|DRUG|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.
214541134|NCT02875002|DRUG|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
214541135|NCT00133055|BEHAVIORAL|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
214697708|NCT06692647|DRUG|Diltiazem|Oral administration
214697709|NCT00975702|PROCEDURE|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
214541136|NCT00133055|BEHAVIORAL|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
214541137|NCT02312206|DRUG|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
214541138|NCT02312206|OTHER|Placebo|Placebo
214541139|NCT01154062|DRUG|Pazopanib|Pazopanib tablet
214541140|NCT02627898|DRUG|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
214541141|NCT02627898|DRUG|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
214541142|NCT00585975|DRUG|bromfenac ophthalmic solution|sterile opthalmic solution
214541143|NCT00507156|PROCEDURE|Standard primary PCI|Acute re-opening of the occluded coronary artery
214541144|NCT00507156|PROCEDURE|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
214541145|NCT00120575|PROCEDURE|hemofiltration|
214541146|NCT01558323|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
214541147|NCT02869945|GENETIC|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
214541148|NCT02869945|OTHER|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
214541149|NCT02869945|OTHER|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
214541150|NCT03619798|DEVICE|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
214541151|NCT04205656|BIOLOGICAL|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
214541152|NCT04205656|BIOLOGICAL|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
214541153|NCT04205656|OTHER|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
215158101|NCT05689580|DIETARY_SUPPLEMENT|Balanced diet|Balanced diet
215158102|NCT00452972|DRUG|Spinal Anesthesia|
215158103|NCT06471348|DRUG|Bupivacaine liposome injectable suspension|EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.
215158104|NCT06471348|DRUG|Bupivacaine Hydrochloride and Epinephrine Injection|Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).
215158105|NCT03816293|DEVICE|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
215158106|NCT06307197|DEVICE|HAAL platform|"The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices.~The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors."
215158107|NCT00233064|BIOLOGICAL|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
215158108|NCT00233064|BIOLOGICAL|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
215158109|NCT06328413|DEVICE|photobiomodulation|Photobiomodulation application at different extraoral and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
215158110|NCT06328413|OTHER|Leukocyte and Platelet Rich Fibrin|Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
215158111|NCT03508908|DIAGNOSTIC_TEST|HIV-1 RNA testing|During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
214541154|NCT06547671|OTHER|Employment of a confort room to help in anxiety and agitation moments.|Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
214541155|NCT01238393|DRUG|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
214541156|NCT01007006|DEVICE|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
214541157|NCT03984175|PROCEDURE|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
214541158|NCT03082612|BEHAVIORAL|Faith-Based African American Cancer Survivorship Storytelling Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
214541159|NCT04456712|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
214541160|NCT04456712|DRUG|Levofloxacin 750 MG|antibiotic
214541161|NCT05370729|DRUG|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
214541162|NCT05975632|DEVICE|Device: Self testing Potassium device|"Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test"
214541163|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
214541164|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
214541165|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
214541166|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
214697710|NCT05745402|BEHAVIORAL|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
215158112|NCT03456310|DIAGNOSTIC_TEST|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
215158113|NCT04251403|DIAGNOSTIC_TEST|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
215158114|NCT06120361|DIAGNOSTIC_TEST|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
214541167|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
214541168|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
214541169|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
214541170|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
214541171|NCT01336205|DRUG|NKTR-118|25 mg oral tablet once daily
214541172|NCT01336205|DRUG|Usual care|As prescribed by the investigator
214541173|NCT03629470|OTHER|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
214541174|NCT03629470|OTHER|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
214541175|NCT01006616|DRUG|Navarixin|Navarixin 10 mg and 30 mg capsules
214541176|NCT01006616|DRUG|Placebo|Placebo to navarixin capsules
214541177|NCT01006616|DRUG|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
214541178|NCT03157908|DEVICE|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
214541179|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
214541180|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
214541181|NCT01008163|DRUG|YY-351|comparison of different dosages of drug
214541182|NCT01008163|DRUG|Placebo|comparison of different dosages of drug
214541183|NCT00462111|DRUG|Indometacin|
214541184|NCT02333266|OTHER|Candidemia|
214541185|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
214541186|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
214541187|NCT03943836|BEHAVIORAL|Music|Patients in the music group will listen to classical music during their dental procedure.
214541188|NCT02049112|DEVICE|Salivary equivalent|14-day treatment with salivary equivalent sticks
214541189|NCT02049112|DEVICE|Aequasyal|14-day treatment with Aequasyal oral spray
214541190|NCT02049112|DEVICE|Biotene|14-day treatment with Biotene oral spray
214541191|NCT01061190|DRUG|Propranolol|oral application of 160 mg Propranolol for 30 days
214541192|NCT00336817|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
214541193|NCT00336817|DRUG|CellCept|CellCept 500mg or 1000mg BID for 90 days
214541194|NCT03672175|DRUG|SAGE-217|SAGE-217 hard gelatin capsules.
214541195|NCT03672175|DRUG|Placebo|SAGE-217 matched placebo hard gelatin capsules.
214541196|NCT06284434|DRUG|Liposomal Bupivacaine|Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
214541197|NCT06284434|DRUG|Bupivacain|Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
214541198|NCT06284434|DRUG|Epinephrine|Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
214541199|NCT03675412|DIETARY_SUPPLEMENT|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
214541200|NCT01846403|DEVICE|Semi-quantitative urine pregnancy test|
215158115|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215158116|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215158117|NCT06120361|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
215158118|NCT06120361|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
214697711|NCT06898762|OTHER|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.
214697712|NCT06898060|DRUG|QLG2128|Recommended dosage is 80 μg subcutaneously once daily，52week
214697713|NCT06898060|DRUG|Teriparatide Injection|Recommended dosage is 20μg subcutaneously once daily，52week
214697714|NCT01739777|BIOLOGICAL|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
214697715|NCT01739777|OTHER|Controls|Autologous Serum will administrated as placebo
214697716|NCT01968187|DRUG|FE 992097|"Each spray pump actuation delivered a 50 μL volume of solution that contained 1.6 mg carbetocin (FE 992097); each dose consisted of 3 spray pump actuations in each nostril that delivered a total of 9.6 mg carbetocin.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
214697717|NCT01968187|DRUG|Placebo|"Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
214697718|NCT06898801|OTHER|Just-in-time video training|"A Just-in-time educational video was designed and produced by the investigating team. Content of the video includes;~* Environmental set up and patient positioning~* Equipment preparation including stylet insertion~* Description of internal anatomy of airway~* Suggested instructional language for supervisors~* Example footage of an intubation~* Tips and common pitfalls~* Guidance for intubation assistant on how to perform cricoid pressure"
214697719|NCT02813798|DRUG|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
214541201|NCT01028612|RADIATION|thermal ablation with external beam radiation|thermal ablation with external beam radiation
214541202|NCT00089830|DRUG|MSI-1256F (Squalamine Lactate)|
214541203|NCT02482935|DRUG|Abemaciclib|Administered orally
214541204|NCT04668703|PROCEDURE|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
214541205|NCT01337375|DRUG|peginterferon alfa 2a [Pegasys]|sc weekly
214541206|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv weekly
214541207|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|sc twice weekly
214541208|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv twice weekly
214541209|NCT03414047|DRUG|Prexasertib|Administered IV
214541210|NCT02813993|OTHER|Health educational video|
214541211|NCT00438139|DRUG|Dronabinol|
214541212|NCT00270036|DRUG|epoetin alfa|
214541213|NCT00510939|DRUG|Tipifarnib plus Bortezomib|
214541214|NCT02542098|DRUG|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
214541215|NCT01946555|DRUG|Morphine|
214541216|NCT01946555|DRUG|Fentanyl|
214541217|NCT01946555|DRUG|Methadone|
214541218|NCT01946555|DRUG|Buprenorphine|
214541219|NCT01946555|DRUG|Oxycodone|
214541220|NCT01946555|DRUG|Hydromorphone|
214541221|NCT01946555|DRUG|Tapentadol|
214541222|NCT03003806|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
214541223|NCT03003806|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
214541224|NCT04974723|DRUG|Abaloparatide|Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
214541225|NCT04974723|DRUG|Teriparatide|Teriparatide subcutaneous (TPTD; Forteo®)
214541226|NCT03712592|OTHER|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
214697720|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 without Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
214697721|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 with Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
214697722|NCT06831344|DRUG|Vonoprazan (Reference)|Vonoprazan will be administered orally as a tablet
214697723|NCT06929754|OTHER|Lip bumper|Lip bumper appliance will be given as intervention to Lip bumper group
215158119|NCT06120361|DIAGNOSTIC_TEST|MRI and CT of the brain|Structural brain imaging
215158120|NCT06120361|DIAGNOSTIC_TEST|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
215158121|NCT03263559|PROCEDURE|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
215158122|NCT03263559|DRUG|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
214541227|NCT03251612|DRUG|Based on sensitivity analysis|"* 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin"
214541228|NCT00197223|BIOLOGICAL|Influenza vaccine|
214541229|NCT03421405|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
214541230|NCT06019065|DRUG|AJA001|AJA001
214541231|NCT06019065|OTHER|Placebo|Placebo
214541232|NCT03292523|OTHER|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
214541233|NCT02053883|DRUG|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
214541234|NCT02053883|DRUG|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
214541235|NCT04672798|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
214541236|NCT04672798|BEHAVIORAL|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
214541237|NCT01636622|DRUG|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
214541238|NCT01636622|DRUG|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
214541239|NCT01636622|DRUG|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
214541240|NCT03040609|BEHAVIORAL|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
214541241|NCT03040609|BEHAVIORAL|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
214541242|NCT03040609|BEHAVIORAL|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
214541243|NCT00019695|DRUG|alendronate sodium|
214541244|NCT00019695|DRUG|ketoconazole|
214541245|NCT02000128|DEVICE|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
214541246|NCT02000128|OTHER|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
214541247|NCT02244268|DRUG|ALNA®|
214541248|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
214541249|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
214541250|NCT03854019|DRUG|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
214541251|NCT03854019|DRUG|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
214541252|NCT00060437|DRUG|perifosine|
214541253|NCT00229762|BEHAVIORAL|phone call from nurses - informational only|
214541254|NCT04811326|RADIATION|NB-UVB|radiation
214541255|NCT04811326|DRUG|Latanoprost|eye drops
214541256|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
214541257|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
214541258|NCT00561899|DRUG|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
214541259|NCT00561899|DRUG|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
214541260|NCT00561899|DRUG|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
214541261|NCT00429897|DRUG|Bendroflumethiazide 2.5mg - 5mg|
214541262|NCT00429897|DRUG|Amiloride 20-40mg|
214541263|NCT00429897|DRUG|Spironolactone 50-100mg|
214541264|NCT00429897|DRUG|Frusemide 20-40mg|
214541265|NCT00429897|DRUG|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
214541266|NCT04576845|OTHER|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
215158123|NCT03263559|DRUG|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
214541267|NCT03197025|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
214541268|NCT03197025|BIOLOGICAL|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
214541269|NCT00217022|OTHER|Placebo|Placebo, 3 tablets daily
214541270|NCT00217022|DRUG|Budesonide|9 mg daily (three tablets)
215158124|NCT03263559|DRUG|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
214541271|NCT04056793|OTHER|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
214541272|NCT04718233|DRUG|Sildenafil 25Mg Tablet|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
214541273|NCT04718233|DRUG|Placebo Oral Tablet|placebo will be administered orally in patients with recurrent pregnancy loss
214541274|NCT03913169|OTHER|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
214541275|NCT05730998|DIETARY_SUPPLEMENT|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
214541276|NCT05730998|DIETARY_SUPPLEMENT|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
214541277|NCT03521518|DIAGNOSTIC_TEST|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
214541278|NCT04662437|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
214541279|NCT03579238|PROCEDURE|CV4|The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
214541280|NCT03579238|PROCEDURE|touching|the clinician allows the participant's head to rest quietly upon his open palms on a table.
214541281|NCT00316368|DEVICE|Ethicon TPW32 60 cm (pacing wires x 2)|
214541282|NCT02505893|BIOLOGICAL|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
214541283|NCT02505893|DRUG|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
214541284|NCT02505893|DRUG|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
214541285|NCT02505893|DRUG|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
214541286|NCT01341249|DRUG|Experimental DW224aa|DW224aa tablet, single dose
214541287|NCT01341249|DRUG|Experimental DW224a|DW224a capsule, single dose
215158125|NCT03263559|DRUG|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
215158126|NCT03263559|DRUG|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
215158127|NCT03263559|RADIATION|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
215158128|NCT03263559|DRUG|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
215158129|NCT05444257|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
214541288|NCT01187745|OTHER|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
214541289|NCT02592499|DEVICE|HM III|
214541290|NCT02592499|OTHER|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
214541291|NCT00156923|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
214541292|NCT00156923|DRUG|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
214541293|NCT04699097|DRUG|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
214541294|NCT04295018|DRUG|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
214541295|NCT00757978|DRUG|memantine|memantine 10mg twice a day
214541296|NCT00757978|DRUG|placebo|1 capsule of placebo twice a day
214541297|NCT02625571|BEHAVIORAL|Phase-based treatment of sexual behavior problems of children|
214541298|NCT01689467|DIETARY_SUPPLEMENT|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
214541299|NCT01689467|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
214541300|NCT02777242|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
215158130|NCT06019000|COMBINATION_PRODUCT|CYR-064|CYR-064 is a nasal solution.
215158131|NCT01881828|DRUG|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
215158132|NCT01881828|OTHER|oral placebo|
215158133|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
215158134|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
215158135|NCT04638543|DRUG|ABP-671|ABP-671 Tablet
214541301|NCT02508779|BEHAVIORAL|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
214541302|NCT02508779|OTHER|Routine Care|Participants will continue to receive care from their clinician.
214541303|NCT03306693|BEHAVIORAL|Emotional skills|2-hour 3 group sessions
214541304|NCT03306693|BEHAVIORAL|Relaxation and talking group|2-hour 3 group sessions
214541305|NCT05029349|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
214541306|NCT03262155|BIOLOGICAL|Blood test|
214541307|NCT01898442|DRUG|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
214541308|NCT01898442|DRUG|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
214541309|NCT01898442|DRUG|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
214541310|NCT05178979|BEHAVIORAL|Training for HIV care providers (effect on provider outcomes)|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
214541311|NCT00611728|DRUG|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 \& 1/2 hrs on 1st day of each cycle \& then again on days 14 \& 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 \& continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height \& weight. Irinotecan will be given intravenously over 90 min on days 1, 14 \& 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, \& then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, \& then within 1 week prior to completion of every other cycle."
214541312|NCT03788954|OTHER|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
215158136|NCT04638543|DRUG|Placebo|Placebo
215158137|NCT04915612|DRUG|Gemtuzumab Ozogamicin|Given IV
214541313|NCT05394883|BEHAVIORAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
214541314|NCT05394883|BEHAVIORAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
214541315|NCT01768741|PROCEDURE|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
214541316|NCT01768741|PROCEDURE|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
214541317|NCT02189577|DRUG|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
214541318|NCT02189577|DRUG|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
214541319|NCT02836054|PROCEDURE|lumbar puncture (LP)|
214541320|NCT02836054|PROCEDURE|brain MRI|
215158138|NCT04915612|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215158139|NCT01120964|DRUG|Intravenous L-Citrulline|
215158140|NCT01120964|DRUG|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
215158141|NCT01003769|DRUG|Lenalidomide|Given PO
215158142|NCT01003769|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
215158143|NCT01003769|OTHER|Laboratory Biomarker Analysis|Correlative studies
215158144|NCT03747861|DEVICE|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
215158145|NCT00826202|DRUG|D-serine|60 mg/kg/day
215158146|NCT00826202|OTHER|Placebo|Inert Placebo
214541321|NCT02338427|OTHER|Immunohistochemistry|
214541322|NCT02338427|OTHER|Proteomic analysis|
214541323|NCT03035318|DEVICE|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
214541324|NCT03035318|DEVICE|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
214541325|NCT03035318|DEVICE|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
214541326|NCT03035318|DEVICE|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
215158147|NCT01440777|BEHAVIORAL|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~* Daily articles~* Daily activities to help get the sleep you need~* Daily sleep improvement recommendations~* Audio recorded relaxation exercises~* Daily e-mails from your program coach~* Personal progress charts~* An online sleep log and daily sleep score"
215158148|NCT04045028|DRUG|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
215158149|NCT04045028|DRUG|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
215158150|NCT04045028|DRUG|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
215158151|NCT04045028|DRUG|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
215158152|NCT02545088|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
215158153|NCT02545088|OTHER|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
215158154|NCT02545088|OTHER|2nd control group|The 2nd control group will not receive an intervention.
215158155|NCT04932408|OTHER|Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.|A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
215158156|NCT02831972|DRUG|AG120|
215158157|NCT02831972|DRUG|Itraconazole|
215158158|NCT00619710|DRUG|Meropenem|Intravenous
215158159|NCT00619710|DRUG|Imipenem-cilastatin|Intravenous
215158160|NCT04237116|BIOLOGICAL|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
214541327|NCT03035318|DEVICE|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
214541328|NCT01095913|DRUG|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
215158161|NCT04237116|BIOLOGICAL|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
215158162|NCT04690023|PROCEDURE|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
214541329|NCT03990298|DIAGNOSTIC_TEST|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
214541330|NCT06234813|OTHER|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
214541331|NCT06234813|OTHER|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
214697724|NCT00052169|DRUG|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
215158163|NCT04690023|PROCEDURE|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
215158164|NCT04690023|DRUG|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
215158165|NCT04690023|DRUG|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
214541332|NCT06234813|OTHER|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
214541333|NCT06234813|OTHER|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
214541334|NCT06234813|OTHER|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
214541335|NCT04116281|OTHER|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
214541336|NCT05609799|OTHER|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
214541337|NCT01317706|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
214541338|NCT02261298|DRUG|ONO-4538|
214541339|NCT01675310|DRUG|medical nutrition therapy + metformin|
214541340|NCT01675310|BEHAVIORAL|Medical nutrition therapy|medical nutrition therapy
214541341|NCT02004106|DRUG|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
214541342|NCT06192030|OTHER|Prediction model|We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
214541343|NCT00506272|PROCEDURE|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
214541344|NCT00506272|PROCEDURE|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
214541345|NCT02980705|DRUG|SUNPG1622 I dose|Injection
214541346|NCT02980705|DRUG|Placebo dose|Injection
214541347|NCT01005368|GENETIC|fluorescence in situ hybridization|
214541348|NCT01005368|GENETIC|mutation analysis|
214541349|NCT01005368|GENETIC|nucleic acid sequencing|
214541350|NCT01005368|GENETIC|polymerase chain reaction|
214541351|NCT01005368|GENETIC|western blotting|
214541352|NCT01005368|OTHER|flow cytometry|
214541353|NCT01005368|OTHER|laboratory biomarker analysis|
214541354|NCT01721746|BIOLOGICAL|BMS-936558|
214541355|NCT01721746|DRUG|Dacarbazine|
214541356|NCT01721746|DRUG|Carboplatin|
214541357|NCT01721746|DRUG|Paclitaxel|
214541358|NCT01659671|PROCEDURE|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
214541359|NCT05428111|DIAGNOSTIC_TEST|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
214541360|NCT04358068|DRUG|Hydroxychloroquine (HCQ)|Administered orally
214541361|NCT04358068|DRUG|Azithromycin (Azithro)|Administered orally
214541362|NCT04358068|DRUG|Placebo for Hydroxychloroquine|Administered orally
214541363|NCT04358068|DRUG|Placebo for Azithromycin|Administered orally
214541364|NCT03887169|DRUG|Methionine|Administration of methionine from D1 to D60
214541365|NCT03887169|DRUG|Vitamin B12, B9, B6, C supplementation|In case of hyperhomocysteinemia
214541366|NCT03887169|DIAGNOSTIC_TEST|Methionine/homocysteine Dosage|Plasma concentration control of methionine and homocysteine from D0 to D75
214541367|NCT03887169|DIAGNOSTIC_TEST|Thoracic CT scan|At D60
214541368|NCT03887169|DIAGNOSTIC_TEST|Abdominal and liver ultrasound.|At D60
214541369|NCT03887169|DIAGNOSTIC_TEST|Brain MRI|In case of abnormal neurological examination
214541370|NCT05605288|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
214541371|NCT02411708|DRUG|SANGUINATE|Single two-hour infusion of SANGUINATE
214541372|NCT02411708|DRUG|Placebo|Single two-hour infusion of placebo
214541373|NCT00237211|DRUG|Letrozole|
214541374|NCT02032264|OTHER|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
214541375|NCT02032264|OTHER|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
214697725|NCT01448291|DRUG|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
214697726|NCT06929247|PROCEDURE|Pulpotomy using Neoputty Mineral Trioxide Aggregate|Pulpotomy (Test Group): Removal of coronal pulp followed by Neoputty MTA placement and restoration.
214697727|NCT06929247|PROCEDURE|single visit pulpectomy using metapex|pulpectomy: removal of radicular pulp followed by metapex placement and final restoration
214697728|NCT04095286|DRUG|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
214697729|NCT04095286|DRUG|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
214697730|NCT05906641|DIETARY_SUPPLEMENT|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
214697731|NCT06392256|PROCEDURE|Non surgical therapy|Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.
214697732|NCT06392256|PROCEDURE|Free gingival Grafting|In the PM-NS-FGG group, soft tissue augmentation using a free gingival graft will be performed.
214697733|NCT02310633|BEHAVIORAL|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
214697734|NCT02310633|BEHAVIORAL|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
214697735|NCT02310633|BEHAVIORAL|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
214697736|NCT05006521|DRUG|KN-002|KN-002 dry powder inhaler
214697737|NCT02397603|DRUG|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
214697738|NCT02397603|DRUG|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
214697739|NCT02210104|DRUG|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
214697740|NCT02210104|DRUG|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
214697741|NCT02210104|BIOLOGICAL|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
214697742|NCT01086046|DRUG|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
214697743|NCT02243917|DRUG|CB-5083|
214697744|NCT00810459|DEVICE|Trilogy Ventilator|Exposure to one hour on the Trilog ventilator
214697745|NCT00810459|DEVICE|Standard of Care|Exposure of one hour on the Participants prescribed ventilator
214697746|NCT00040547|DRUG|Farnesyl Protein Transferase Inhibitor|
214697747|NCT05274828|DEVICE|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
214697748|NCT05517356|PROCEDURE|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
214697749|NCT02906956|BEHAVIORAL|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
214697750|NCT02604810|BIOLOGICAL|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
214697751|NCT02604810|BIOLOGICAL|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
214697752|NCT03201367|DRUG|Rivaroxaban|Rivaroxaban 10 mg/12 hour
214697753|NCT03201367|OTHER|symptomatic therapy for ascites, abdominal pain|
214697754|NCT00796042|OTHER|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
215158166|NCT06428968|DRUG|160 units nasal insulin spray|Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.
215158167|NCT03690297|DEVICE|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
215158168|NCT00829504|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
215158169|NCT00829504|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg
215158170|NCT03212144|OTHER|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
214541376|NCT03133078|OTHER|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
214541377|NCT03133078|OTHER|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
214541378|NCT05005325|OTHER|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
214697755|NCT00796042|OTHER|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
214541379|NCT05005325|OTHER|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
214541380|NCT06382571|DRUG|Renin-Angiotensin System Inhibitor|
214541381|NCT02886598|DRUG|degarelix|
214541382|NCT00945399|PROCEDURE|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
214541383|NCT00945399|PROCEDURE|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
214541384|NCT00831012|BIOLOGICAL|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
214541385|NCT00774423|DRUG|Riluzole|50 mg per day during 24 months
214541386|NCT00239681|DRUG|Rosuvastatin|Oral
214541387|NCT00239681|OTHER|Placebo|Oral
214541388|NCT04055610|DEVICE|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
214541389|NCT02447718|BIOLOGICAL|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
214697756|NCT01125657|DRUG|YM150|oral
214697757|NCT01047046|OTHER|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
214697758|NCT00488995|DRUG|CP-675,206|
214697759|NCT05000814|DEVICE|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
214697760|NCT06249256|BIOLOGICAL|Fast CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
214697761|NCT04084938|PROCEDURE|Prostate operation or prostate artery embolization|As described above.
214541390|NCT02447718|BIOLOGICAL|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
214541391|NCT02447718|BIOLOGICAL|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
214541392|NCT03599622|DRUG|BMS-986165|Specified dose on specified days
214541393|NCT03599622|OTHER|Placebo|Specified dose on specified days
214541394|NCT04891471|RADIATION|Stereotactic RadioTherapy|To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).
214541395|NCT04891471|RADIATION|Whole Brain Irradiation|To irradiate the entire brain, site of at least 5 parenchymal metastasis.
214541396|NCT01003171|DRUG|MCS-2 soft-gel capsule|MCS-2 30 mg/day
214541397|NCT05874778|DRUG|6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy|All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
214541398|NCT05874778|RADIATION|Radiotherapy beyond standard R-CHOP Chemotherapy|Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
214541399|NCT03579433|DEVICE|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
214541400|NCT03579433|OTHER|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
214541401|NCT03579433|DEVICE|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
214541402|NCT00468130|DRUG|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
214697762|NCT04848454|DRUG|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
214697763|NCT04092816|BEHAVIORAL|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
214697764|NCT06209814|DEVICE|Conventional denture|Patients in this group received conventional maxillary and mandibular complete dentures. The patients used these dentures for 45 days. Then, the conventional maxillary denture was replaced by open faced denture with soft acryl resin wing.
214697765|NCT06209814|DEVICE|Maxillary open-faced denture|Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
214697766|NCT06483763|OTHER|SmokerFace App from the Education Against Tobacco (EAT) program|The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
214697767|NCT06483763|OTHER|The use of standardized school-based educational module|This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
214697768|NCT02278640|DEVICE|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
214697769|NCT04082468|DIAGNOSTIC_TEST|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T \& B lymphocyte panel at above time points
214697770|NCT01159626|DRUG|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
214697771|NCT01159626|DRUG|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
214697772|NCT01159626|DRUG|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
214697773|NCT01159626|DRUG|Placebo|Oral single dose as matching placebo
214697774|NCT01159626|DRUG|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
214697775|NCT01159626|DRUG|Placebo|Oral multiple doses as matching placebo for 7 days
214697776|NCT04389398|DEVICE|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
214697777|NCT00506571|DRUG|S-1, irinotecan, oxaliplatin|
214697778|NCT01313520|DRUG|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
214697779|NCT01313520|DRUG|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
214697780|NCT04824417|DRUG|Itraconazole 200 mg|Control
214697781|NCT04824417|DRUG|Voriconazole 200mg|Comparator
214697782|NCT04534036|DIETARY_SUPPLEMENT|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
214697783|NCT04534036|OTHER|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
214697784|NCT00148850|DRUG|Pioglitazone|
215158171|NCT03212144|OTHER|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
215158172|NCT02841904|DEVICE|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
215158173|NCT06052319|DEVICE|Care4Today® Connect CAD-PAD Mobile Application|Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
215158174|NCT05949021|DRUG|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
215158175|NCT05462379|PROCEDURE|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
214541403|NCT00468130|DRUG|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
214541404|NCT00436956|PROCEDURE|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
214697785|NCT02776956|DRUG|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
214697786|NCT02776956|DRUG|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
214697787|NCT01541527|BIOLOGICAL|blood test|One blood test entering in the usual follow-up of the patient
214697788|NCT02156232|PROCEDURE|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
214697789|NCT02156232|PROCEDURE|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
214697790|NCT00697658|DRUG|Paliperidone ER|6 mg tablet once daily, variable treatment length.
214697791|NCT03209440|BEHAVIORAL|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
214697792|NCT03209440|BEHAVIORAL|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
214697793|NCT03209440|BEHAVIORAL|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
214697794|NCT03493867|DEVICE|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
214697795|NCT02658344|BIOLOGICAL|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
214697796|NCT02658344|DRUG|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
214697797|NCT00845546|DRUG|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
214697798|NCT01864824|DRUG|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
214697799|NCT01864824|DRUG|Placebo|Placebo
214697800|NCT00390247|DRUG|thalidomide|
214697801|NCT04762407|DRUG|HGP1910|Take it once per period.
214697802|NCT04762407|DRUG|HGP1909|Take it once per period.
214697803|NCT04762407|DRUG|HCP1903|Take it once per period.
214697804|NCT01507844|DEVICE|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
214697805|NCT03333330|DRUG|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
214697806|NCT04874467|PROCEDURE|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
214697807|NCT02690207|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
214697808|NCT02712177|BIOLOGICAL|4CMenb|
214697809|NCT02712177|BIOLOGICAL|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
214697810|NCT02712177|BIOLOGICAL|conjugated pneumococcal vaccine|
214697811|NCT02712177|BIOLOGICAL|MMRV|
214697812|NCT01002053|PROCEDURE|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
214697813|NCT00484965|PROCEDURE|Coronary stenting|
214697814|NCT00127530|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
214697815|NCT00127530|DRUG|Placebo|sugar pill, twice a day (b.i.d.)
215029452|NCT06638697|OTHER|Dance|The Dance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
215158176|NCT03882255|DRUG|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
215158177|NCT03882255|DRUG|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
215158178|NCT03882255|DRUG|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
215158179|NCT03532828|OTHER|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
215158180|NCT05687500|DRUG|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
215158181|NCT05687500|BIOLOGICAL|Pharmacokinetics study|"* For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);~* For subsequent patients included during phase II:~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment~* 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.~* In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution."
214541405|NCT00436956|DRUG|AZD2171|20 mg oral daily for 28 days
214541406|NCT00436956|DRUG|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
214541407|NCT01316965|BEHAVIORAL|Multifaceted prevention program HELP(Hospital Elder Life Program)|"* A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
214541408|NCT02460536|BEHAVIORAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
214541409|NCT02460536|BEHAVIORAL|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
214541410|NCT02460536|BEHAVIORAL|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
214541411|NCT02460536|BEHAVIORAL|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
214541412|NCT02782572|OTHER|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
214541413|NCT00103636|PROCEDURE|Extending peripheral intravenous (IV) cannula dwell times|
214541414|NCT05330052|DEVICE|Agilik|The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
214541415|NCT06014047|PROCEDURE|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
214541416|NCT06014047|PROCEDURE|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
214541417|NCT00000902|DRUG|Ritonavir|
214541418|NCT00000902|DRUG|Nelfinavir mesylate|
214697816|NCT05138874|BEHAVIORAL|Trending Feedback|Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
215158182|NCT05687500|BIOLOGICAL|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized
215158183|NCT05687500|BIOLOGICAL|Routine biological monitoring|"If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.~Transaminases and hemostasis will be done only in case of clinical indication before the first administration."
215158184|NCT01746836|OTHER|Laboratory Biomarker Analysis|Blood draws.
215158185|NCT01746836|DRUG|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
215158186|NCT01746836|OTHER|Quality-of-Life Assessment|Surveys completed.
214541419|NCT00000902|DRUG|Nevirapine|
214541420|NCT00000902|DRUG|Lamivudine|
214541421|NCT00000902|DRUG|Stavudine|
214697817|NCT05138874|BEHAVIORAL|Benchmark Peer Comparison Feedback|Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
214697818|NCT05138874|BEHAVIORAL|Private Commitment|Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
214541422|NCT00000902|DRUG|Zidovudine|
214541423|NCT00000902|DRUG|Zalcitabine|
214541424|NCT00000902|DRUG|Didanosine|
214697819|NCT05138874|BEHAVIORAL|Public Commitment|Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
214541426|NCT02038998|DEVICE|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
214541427|NCT05336513|OTHER|Diet Control|Diet following mediterranean principles, for 15 weeks
214541428|NCT05336513|OTHER|Diet anti-inflammatory|Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
214541429|NCT00406900|PROCEDURE|Treatment of metastatic disease|
214541430|NCT02542423|OTHER|Endocan blood test samples|
214541431|NCT03827850|DRUG|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
214541432|NCT04683341|DRUG|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.
214541433|NCT01006889|DRUG|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
214541434|NCT01177995|BEHAVIORAL|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
214697820|NCT00000993|DRUG|Zidovudine|
214697821|NCT04633057|DRUG|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
214697822|NCT04633057|DRUG|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
214697823|NCT04348656|BIOLOGICAL|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
215158187|NCT05030883|BEHAVIORAL|Source of news|The main intervention was the source of the news that was shown to participants
214541435|NCT04128462|DRUG|MNK-6105|L-Ornithine Phenylacetate for IV infusion
214541436|NCT04128462|DRUG|Placebo|Matching placebo for IV infusion
214541437|NCT04128462|DRUG|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
214541438|NCT04228406|DRUG|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
214541439|NCT02505477|DRUG|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
214541440|NCT02505477|OTHER|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
214541441|NCT04188756|OTHER|Exercise|High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
214541442|NCT04243642|DEVICE|IntelliSpace Cognition|Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.
214541443|NCT01130168|DRUG|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
214541444|NCT01130168|DRUG|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
214541445|NCT01130168|DRUG|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
214697824|NCT01935362|DIETARY_SUPPLEMENT|Citrus supplement|
214697825|NCT01935362|DIETARY_SUPPLEMENT|Placebo|
214697826|NCT05764356|GENETIC|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
214697827|NCT05764356|OTHER|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
215158188|NCT03896269|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215158189|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
215158190|NCT06345794|DRUG|Itraconazole|Administered orally.
215158191|NCT06345794|DRUG|Fluconazole|Administered orally.
214541446|NCT05252936|OTHER|COVID-19 vaccine social media campaign exposure|A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
214541447|NCT03715868|OTHER|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
215158192|NCT06345794|DRUG|Carbamazepine|Administered orally.
215158193|NCT05978713|DRUG|Tirzepatide|Administered SC
215158194|NCT05307692|DRUG|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
214541448|NCT00430742|DRUG|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
214541449|NCT00430742|DRUG|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
214541450|NCT03935061|OTHER|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
214541451|NCT05427019|PROCEDURE|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
214541452|NCT05427019|PROCEDURE|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
214541453|NCT05157737|OTHER|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
214541454|NCT05157737|OTHER|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
214541455|NCT05157737|OTHER|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
214541456|NCT01702519|DRUG|nicotine|nicotine transdermal patch
214541457|NCT01795859|DRUG|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
214541458|NCT01795859|DRUG|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
214541459|NCT03738397|BIOLOGICAL|Upadacitinib|Extended release tablet
214541460|NCT03738397|BIOLOGICAL|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
214541461|NCT03738397|DRUG|Placebo to dupilumab|Placebo administered as a subcutaneous injection
214541462|NCT03738397|DRUG|Placebo to upadacitinib|Tablet
214541463|NCT04530877|BIOLOGICAL|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
214541464|NCT04530877|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
214541465|NCT02592681|PROCEDURE|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
214541466|NCT02592681|PROCEDURE|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
214541467|NCT02592681|PROCEDURE|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
214541468|NCT00904722|DRUG|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
215158195|NCT05307692|DRUG|Placebo|Matching placebo will be administered orally as a tablet.
215158196|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
215158197|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
215158198|NCT05413135|DRUG|ARO-APOC3|ARO-APOC3 Injection
215158199|NCT05209074|DRUG|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
214541469|NCT00904722|DRUG|Rituximab|Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
214541470|NCT03862261|OTHER|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services."
214541471|NCT01748123|DRUG|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
215158200|NCT05209074|DRUG|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
215158201|NCT04223193|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
215158202|NCT04223193|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
215158203|NCT03151486|DRUG|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
215158204|NCT03151486|DRUG|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
215158205|NCT03151486|DRUG|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
215158206|NCT03151486|DRUG|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
215158207|NCT03151486|DRUG|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
215158208|NCT03151486|DRUG|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
215158209|NCT03151486|DRUG|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
215158210|NCT03151486|DRUG|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
215158211|NCT03151486|DRUG|Placebo|Participants will receive matching placebo in all cohorts.
215158212|NCT03393884|BIOLOGICAL|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
215158213|NCT03393884|DRUG|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
215158214|NCT03393884|DRUG|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
215158215|NCT05660954|DRUG|Cabozantinib|"* All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose."
215158216|NCT05407064|DRUG|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
215158217|NCT05407064|OTHER|Placebo|A substance that is designed to have no therapeutic value.
215158218|NCT01552434|BIOLOGICAL|Bevacizumab|Given IV
215158219|NCT01552434|BIOLOGICAL|Cetuximab|Given IV
215158220|NCT01552434|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215158221|NCT01552434|OTHER|Pharmacological Study|Optional correlative studies
215158222|NCT01552434|DRUG|Temsirolimus|Given IV
214541472|NCT01748123|DRUG|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
214541473|NCT00855322|OTHER|Gym exercise group intervention|Gym based circuit class
214541474|NCT00855322|OTHER|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
214541475|NCT00855322|OTHER|Control group|No intervention
214697828|NCT05764356|OTHER|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
214697829|NCT04030780|DIETARY_SUPPLEMENT|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
214697830|NCT04030780|OTHER|Placebo|similar capsules administered twice daily
215158223|NCT01552434|DRUG|Valproic Acid|Given PO
214541476|NCT04759950|BEHAVIORAL|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
214541477|NCT04759950|BEHAVIORAL|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
214541478|NCT04759950|BEHAVIORAL|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
215158224|NCT05112289|DIAGNOSTIC_TEST|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
215158225|NCT05989204|BIOLOGICAL|TmCD19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
215158226|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
215158227|NCT03374475|DRUG|JNJ-42847922 20mg|Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
215158228|NCT03374475|DRUG|JNJ-42847922 40mg|Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
215158229|NCT03374475|DRUG|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
215158230|NCT05994261|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
215158231|NCT04817163|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
215158232|NCT04817163|BEHAVIORAL|Professionally-administered booster face-to-face CBT-I sessions|"Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment."
215158233|NCT02003924|DRUG|Enzalutamide|160 mg by mouth once daily
215158234|NCT02003924|DRUG|Placebo|Sugar pill to mimic enzalutamide
215158235|NCT05684172|DRUG|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
215158236|NCT05684172|OTHER|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
215158237|NCT02212535|DRUG|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
214541479|NCT00296023|BIOLOGICAL|anti-thymocyte globulin|
214541480|NCT00296023|BIOLOGICAL|filgrastim|
214541481|NCT00296023|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214541482|NCT00296023|DRUG|busulfan|
214541483|NCT00296023|DRUG|fludarabine phosphate|
214541484|NCT00296023|DRUG|methotrexate|
214541485|NCT00296023|DRUG|tacrolimus|
214541486|NCT00296023|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214541487|NCT00296023|PROCEDURE|peripheral blood stem cell transplantation|
215158238|NCT01711554|BIOLOGICAL|Dinutuximab|Given IV
215158239|NCT01711554|DRUG|Isotretinoin|Given PO
215158240|NCT01711554|OTHER|Laboratory Biomarker Analysis|Correlative studies
215158241|NCT01711554|DRUG|Lenalidomide|Given PO
215158242|NCT01711554|OTHER|Pharmacological Study|Correlative studies
215158243|NCT02405702|OTHER|restrospective study|
215158244|NCT05696717|DRUG|Ampreloxetine|Oral tablet, QD
215158245|NCT05696717|DRUG|Placebo|Oral tablet, QD
215158246|NCT06209580|DRUG|AMT-253 for injection|Administered intravenously
215158247|NCT02498691|BIOLOGICAL|Biological collection|Blood and saliva samples, placenta and cord blood collection
215158248|NCT06015022|DRUG|Epigallocatechin gallate (EGCG)|EGCG is a green tea-derived catechin
215158249|NCT06015022|OTHER|Placebo|Placebo in the same capsule with the experimental agent (EGCG).
215158250|NCT05186805|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
215158251|NCT04693767|DEVICE|Mechanical thrombectomy|"1. Clot specimen collection~2. Extracranial blood collection"
215158252|NCT04693767|OTHER|Minimally invasive surgery|"1. Clot specimen collection~2. Arterial blood collection"
215158253|NCT00065572|DRUG|ZD6126|
215158254|NCT00065572|DRUG|Placebo|
215158255|NCT03071419|BEHAVIORAL|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
215158256|NCT02022124|DRUG|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
215158257|NCT03012399|BEHAVIORAL|Hypnosedation|Undergo hypnosedation
215158258|NCT03012399|OTHER|Questionnaire Administration|Ancillary studies
215158259|NCT03012399|BEHAVIORAL|Verbal Support|Speak with min-body specialist
215158260|NCT06555601|DRUG|UCB3101|Study participants will receive UCB3101 as prespecified in each cohort.
215158261|NCT06555601|DRUG|Placebo|Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
215158262|NCT07115121|DRUG|Intravenous Ferric Carboxymaltose|Patients were given ferric carboxymaltose as a maximum single dose of 1000 mg diluted in 250 mL of sterile 0.9% normal saline as a slow infusion over 45 minutes.
215158263|NCT07115121|DRUG|Intravenous Iron Sucrose|Patients received intravenous injections of iron sucrose complex, which contained 200 mg of elemental iron (equivalent to 2 ampoules of 5 ml), mixed in 100 ml of 0.9% normal saline and infused over a period of 30 minutes every other day for up to 5 doses.
214541488|NCT04241887|PROCEDURE|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
214541489|NCT04241887|PROCEDURE|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
214541490|NCT04360083|OTHER|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
214541491|NCT04360083|OTHER|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
214541492|NCT01413022|DRUG|Oxaliplatin|
214541493|NCT01413022|DRUG|Irinotecan|
215158264|NCT03023345|DEVICE|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
214541494|NCT01413022|DRUG|Leucovorin|
215158265|NCT07120295|DEVICE|Dragonfly™ Digital Pancreaticobiliary System|Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.
215158266|NCT06653179|PROCEDURE|Sacral Erector Spinae Plane Block|The patient is placed in the prone positionon a procedure table. The sacral region is exposed, and the area is prepped with antiseptic solution under sterile conditions. The ultrasound high-frequency linear transducer is placed transversely over the sacrum. The sacral cornua are typically seen as bony structures adjacent to the sacral hiatus, appearing as two hyperechoic structures. Rotate the ultrasound probe to a sagittal position over the sacrum to align with the fourth and fifth sacral vertebrae. Under continuous ultrasound guidance, block needle is inserted in-plane with the ultrasound probe. Direct the needle through the soft tissue towards the plane between the erector spinae muscle and the sacrum. After confirming needle placement, the injectate mixture of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is administered. A total volume of 10 mL is injected, and real-time ultrasound is used to observe the spread of the injectate within the target tissue plane.
214541495|NCT01413022|DRUG|Fluorouracil|
214541496|NCT01413022|OTHER|laboratory biomarker analysis|Correlative studies
214541497|NCT01413022|OTHER|flow cytometry|Correlative studies
214541498|NCT01413022|OTHER|immunohistochemistry staining method|Correlative studies
214541499|NCT01413022|OTHER|pharmacological study|Correlative studies
214541500|NCT01413022|DRUG|PF-04136309|
214541501|NCT02251340|BEHAVIORAL|Eczema Care Plan|
214541502|NCT00567983|DRUG|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
214541503|NCT00567983|DRUG|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
214541504|NCT01187810|DRUG|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
214541505|NCT01187810|DRUG|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
214541506|NCT01187810|DRUG|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
214541507|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
214541508|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
214541509|NCT00631397|DEVICE|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
214541510|NCT04319614|DRUG|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
214541511|NCT04319614|DRUG|Placebos|100 ml of saline will be administered in the beginning of the procedure.
214541512|NCT01891656|BEHAVIORAL|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
214541513|NCT01891656|BEHAVIORAL|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
214541514|NCT01891890|DRUG|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
214541515|NCT01891890|DRUG|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
214541516|NCT01891890|DRUG|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
214541517|NCT05656963|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
214541518|NCT04429035|DIETARY_SUPPLEMENT|Vitamin K2|Administration of 300 μg Vitamin K2 (MQ7) daily p.o
214541519|NCT04429035|DIETARY_SUPPLEMENT|Placebo|Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
214541520|NCT00279877|PROCEDURE|Kyphoplasty|kyphoplasty
214541521|NCT01938898|OTHER|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project"
214541522|NCT01143883|OTHER|Silverlon|Silverlon dressings are gauze impregnated with silver ions
214541523|NCT01143883|OTHER|Standard of Care Dressing|Standard dry gauze dressing
214541524|NCT03515200|DRUG|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
214541525|NCT03515200|DRUG|Intrathecal Triple Therapy|Given intrathecally (IT).
214541526|NCT03515200|DRUG|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
214541527|NCT03515200|DRUG|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
214541528|NCT03515200|DRUG|Dasatinib|Given orally or nasogastrically (NG).
214541529|NCT03515200|DRUG|Doxorubicin|Given intravenously (IV).
214541530|NCT03515200|DRUG|Ruxolitinib|Given orally or nasogastrically (NG).
214541531|NCT06076824|DRUG|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
214541532|NCT06076824|OTHER|Placebo|Saline solution
214541533|NCT01137877|OTHER|Milk based infant formula powder|milk based infant formula ad lib
214541534|NCT01137877|OTHER|Investigational Infant Formula #1|Milk based infant formula ad lib
214541535|NCT01137877|OTHER|Investigational Infant Formula #2|Milk based infant formula powder ad lib
214541536|NCT01137877|OTHER|Human Milk|Human milk ad lib
215158267|NCT06653179|PROCEDURE|Caudal Epidural Injection|The patient is positioned in the prone position on the procedure table, and the sacral region is exposed and prepped with antiseptic solution under sterile conditions. The fluoroscope is positioned laterally to visualize the sacral hiatus. Under fluoroscopic guidance, the block needle is inserted through the skin and advanced toward the sacral hiatus. Continuous fluoroscopy is used to ensure correct needle placement, typically visualized at the level of the sacral canal. After confirming the appropriate position with contrast media, the injectate consisting of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is slowly administered, with a total volume of 10 mL. During injection, careful monitoring of the needle position is performed to avoid intravascular injection. After the procedure, patients are monitored for potential complications such as hypotension and allergic reactions.
214541537|NCT04833244|BEHAVIORAL|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
214541538|NCT04833244|BEHAVIORAL|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
214541539|NCT05021822|PROCEDURE|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
214541540|NCT03185702|GENETIC|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
214541541|NCT05799521|DRUG|Optate|Alkaline Buffer
214541542|NCT05799521|DRUG|Placebo|Normal Saline
214541543|NCT05865925|DRUG|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
214541544|NCT03539133|OTHER|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
214541545|NCT00806598|DRUG|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients \>55 years receive 2.5 mg/kg/day for 5 days"
214541546|NCT00806598|DRUG|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
214541547|NCT00806598|DRUG|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
214541548|NCT00806598|DRUG|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
214541549|NCT03540290|PROCEDURE|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
214541550|NCT04896684|BIOLOGICAL|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
214541551|NCT03055546|DRUG|Oxytocin|intranasal administration of oxytocin
214541552|NCT03055546|DRUG|Placebo|intranasal administration of placebo
214541553|NCT02188394|DRUG|Anesthetic blockades with bupivacaine|
214541554|NCT02188394|DRUG|Isotonic saline injection|
214541555|NCT05200325|OTHER|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
214541556|NCT04665362|DRUG|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
214541557|NCT01729845|DRUG|Cytarabine|Given IV
214541558|NCT01729845|DRUG|Decitabine|Given IV
214541559|NCT01729845|DRUG|Etoposide|Given IV
214541560|NCT01729845|OTHER|Laboratory Biomarker Analysis|Correlative studies
214541561|NCT01729845|DRUG|Mitoxantrone Hydrochloride|Given IV
214541562|NCT01576198|GENETIC|DNA analysis|
214541563|NCT01576198|GENETIC|nucleic acid amplification|
214541564|NCT01576198|OTHER|diagnostic laboratory biomarker analysis|
214541565|NCT01576198|OTHER|medical chart review|
214541566|NCT02294097|PROCEDURE|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
214541567|NCT02759926|DRUG|Denatonium benzoate|
214541568|NCT02759926|DRUG|Quinine hydrochloride|
214541569|NCT02759926|DRUG|Tap water|
214541570|NCT03455777|DRUG|AKCEA-ANGPTL3-LRX|Single open-label cohort
214541571|NCT03843398|PROCEDURE|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
214541572|NCT03843398|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
214697831|NCT04003077|DEVICE|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
214697832|NCT01453569|DRUG|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
215029453|NCT06638697|OTHER|Physical exercise for cognition|The Physical exercise for cognition training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
214541573|NCT05168098|OTHER|board game comparison|The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
214541574|NCT05168098|OTHER|olfactory stimulation intervention|The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
214541575|NCT05115292|BIOLOGICAL|BJ-005|dosed with intravenous infusion
214541576|NCT01029236|OTHER|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
214541577|NCT03448536|DRUG|Naproxen Sodium, (Aleve, BAY117031)|220 mg \*2 tablets, orally, single dose
214541578|NCT03448536|DRUG|Acetaminophen (Tylenol Extra Strength)|500 mg \*2 caplets, orally, single dose
214541579|NCT00592189|PROCEDURE|blood draw|blood collection
214541580|NCT05476510|DRUG|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
214541581|NCT05006222|DRUG|Enzyme Replacement Agent|Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
214541582|NCT01779453|DRUG|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
214541583|NCT01779453|DRUG|Placebo|Placebo once daily for 8 weeks
214541584|NCT01779453|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
214541585|NCT04016116|DRUG|Pembrolizumab|Pembrolizumab IV every 3 weeks
214541586|NCT04016116|DRUG|Ruxolitinib|Ruxolitinib po days 1-21
214541587|NCT03242668|PROCEDURE|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
214541588|NCT03242668|PROCEDURE|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
214541589|NCT03242668|DRUG|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
214541590|NCT03421639|DRUG|GnRH analog (11.25mg Leuprolide acetate)|11.25 Leuprolide acetate only one administration
214541591|NCT03421639|DRUG|Aromatase inhibitor and GnRH analog|1mg/day of Anastrazole for 3 months
214541592|NCT03421639|DRUG|Aromatase and GnRH analog (11.25mg Leuprolide acetate)|Leuprolide acetate 11.25mg only one
214541593|NCT02528851|PROCEDURE|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
214541594|NCT01191554|DRUG|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
214697833|NCT01453569|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
214697834|NCT01453569|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
214697835|NCT00418964|PROCEDURE|Single bundle hamstring|Single bundle hamstring
214697836|NCT00418964|PROCEDURE|Double bundle hamstring|Double bundle hamstring
214697837|NCT00418964|PROCEDURE|Bone patellar tendon bone|Bone patellar tendon bone
214697838|NCT00937560|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
214697839|NCT00937560|DRUG|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
214697840|NCT00937560|DRUG|Carboplatin|Carboplatin was supplied locally in commercial batches.
215029454|NCT06638697|OTHER|Balance|The Balance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
214697841|NCT05912309|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
214697842|NCT05912309|BEHAVIORAL|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
214697843|NCT05912309|BEHAVIORAL|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
214697844|NCT02373241|DRUG|Losartan|Standard dosing
215158268|NCT03181048|PROCEDURE|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
215158269|NCT03181048|PROCEDURE|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
214541595|NCT03783546|DEVICE|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
214541596|NCT03783546|OTHER|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
214541597|NCT05107752|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
214541598|NCT05107752|DRUG|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
214541599|NCT03909282|PROCEDURE|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
214541600|NCT03909282|RADIATION|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
214541601|NCT04243798|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
214541602|NCT04243798|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214541603|NCT06276517|OTHER|questionnaire|self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
214541604|NCT06276517|OTHER|SS-QoL|49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
214541605|NCT06276517|OTHER|SF-36|multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
214541606|NCT06276517|OTHER|CIQ-R|16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
214541607|NCT06276517|DIAGNOSTIC_TEST|BREFF|rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
214541608|NCT06276517|DIAGNOSTIC_TEST|MoCA|MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
214541609|NCT06276517|OTHER|IADL|8 questions rated from 0 to 1 to assess functional outcome
214697845|NCT02373241|DRUG|Losartan|Experimental dosing
214697846|NCT03719326|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
214697847|NCT03719326|DRUG|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
214541610|NCT06276517|OTHER|mMRS|mMRS score from 0 to 4 to assess functional outcome
214541611|NCT06276517|OTHER|PCL-5|To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
214541612|NCT06276517|OTHER|Brief-Cope|28-question self-questionnaires to study patients' coping strategies
214541613|NCT03900429|DRUG|MGL-3196|Tablet
214541614|NCT03900429|DRUG|Placebo|Matching Tablets
214541615|NCT03900429|PROCEDURE|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
214541616|NCT00557349|DRUG|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
214541617|NCT00557349|DRUG|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
214541618|NCT02316392|DRUG|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
214541619|NCT00057044|BEHAVIORAL|education and reminder|
214541620|NCT04811339|DRUG|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
214541621|NCT04811339|OTHER|Placebo oral tablet without BSS|Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
214541622|NCT02827032|DEVICE|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
214541623|NCT01547624|OTHER|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
214541624|NCT01411098|RADIATION|3-dimensional conformal radiation therapy|Undergo 3D-CRT
214541625|NCT01411098|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
215158270|NCT01315652|BEHAVIORAL|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
215158271|NCT01315652|BEHAVIORAL|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
215158272|NCT05902715|DEVICE|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
215158273|NCT06597123|BEHAVIORAL|Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training|Basic participants will participate in two motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool (Real-time Evaluation of Dialogue in Motivational Interviewing), and both the spirit of MI and presence of bias as measured by Dougall GPT.
215158274|NCT06597123|BEHAVIORAL|Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training|Plus participants will participate in four motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool, and both the spirit of MI and presence of bias as measured by Dougall GPT.
215158275|NCT06586710|OTHER|Assessment activation of interferon pathway|"* Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed."
214541626|NCT01411098|DRUG|cisplatin|Given IV
214541627|NCT01411098|DRUG|etoposide|Given IV
214541628|NCT04183010|BEHAVIORAL|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise"
214541629|NCT01124071|BEHAVIORAL|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
214541630|NCT01124071|BEHAVIORAL|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
214541631|NCT02851875|OTHER|Registry|
214697848|NCT03719326|DRUG|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
214697849|NCT03719326|DRUG|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
214697850|NCT00451750|DRUG|Cortisol|20 mg for 3 times
214697851|NCT03072641|DIETARY_SUPPLEMENT|ProBion Clinica|
214541632|NCT06468189|DEVICE|transcranial direct stimulation|Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
214541633|NCT06468189|DEVICE|Sham treatment|The same device used for stimulation will be used, but no stimulation will be given.
214541634|NCT02878369|PROCEDURE|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
214541635|NCT00360477|PROCEDURE|Floseal|Bioglue that seals the kidney
214541636|NCT00360477|PROCEDURE|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
214541637|NCT00360477|PROCEDURE|Fascial Stitch|Stitch that closes the kidney
214541638|NCT02536742|DRUG|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
214541639|NCT02536742|DRUG|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
214541640|NCT03916822|DIAGNOSTIC_TEST|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
214541641|NCT02349945|DRUG|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
214541642|NCT03450668|DEVICE|mOm incubator|24 hour usage of test incubator
214541643|NCT03450668|DEVICE|standard incubator|standard incubator
214541644|NCT04751682|BIOLOGICAL|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.
214541645|NCT04751682|BIOLOGICAL|Placebo|Placebo
214541646|NCT05933889|GENETIC|Molecular Analysis|Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples
214541647|NCT05933889|OTHER|Radiomic/ Morphological analysis|Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
214541648|NCT03559790|DRUG|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
214541649|NCT04338789|OTHER|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
214541650|NCT01656213|DEVICE|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
214541651|NCT00844337|DRUG|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
214541652|NCT00844337|DRUG|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
214541653|NCT00844337|DRUG|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
214541654|NCT04301570|DEVICE|Ultrasound device|"The measurement of bone age is performed via ultrasound with the Ultrasound System for Bone Age Assessment (BAUS) from Sonic Bone (SonicBone Medical Ltd., Rishon Lezion, Israel)."
214541655|NCT04301570|RADIATION|XR|The measurement of bone age is performed via imaging procedure via X-ray (Röntgengerät, Stadler SE 4600, Littau, CH) of the left hand.
214697852|NCT03935087|DIAGNOSTIC_TEST|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
214541656|NCT04629443|DRUG|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
214541657|NCT01704443|BEHAVIORAL|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
214541658|NCT01704443|OTHER|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
214541659|NCT04476836|OTHER|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
214541660|NCT01547117|RADIATION|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
214697853|NCT04622787|OTHER|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
214697854|NCT03364608|DRUG|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
215158276|NCT06982716|DEVICE|Lexie Lumen Hearing Aids|The Lexie Lumens (Lexie Hearing) are self-fitting wireless air conduction hearing aids consisting of 16 channels, wide-dynamic-range compression technology, feedback reduction, Bluetooth connectivity and programming, digital noise reduction, and a directional microphone array. These hearing aids will be sourced at a cost of $240 USD per pair as this study will be conducted in low-income settings. The hearing aids allow for Bluetooth in-situ hearing aid fitting using the Lexie proprietary fitting algorithm that is based on the NAL/NL2 algorithm from a smartphone application (Lexie Hearing) based on the four hearing thresholds tested. These digital hearing aids were designed for use by adults over the age of 18 years with known or self-perceived mild-to-moderate hearing loss. The Lexie Lumens are behind-the-ear (BTE) hearing aids powered by replaceable batteries. Individuals can conduct an in-situ hearing test via the hearing aids for customized amplification or select a minimal gain.
215158277|NCT06982716|DEVICE|Go Ultra Hearing Aids|Go Ultras (GoHearing) are rechargeable, BTE pre-set hearing aids with advanced audio features, digital sound processing and Bluetooth-streaming capabilities. Designed for adults with mild-to-moderate hearing loss, these hearing aids have four unique programs that the user can manually change to ensure optimal listening comfort. These devices have both program and volume memory functions, as well as noise and wind noise reduction. Go Ultras will be sourced at a cost of less than $130 USD per pair, as this study will be conducted in low-income settings.
215158278|NCT04973683|DRUG|AL101|Given IV
214541661|NCT01547117|RADIATION|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
215158279|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214541662|NCT01547117|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
215158280|NCT04626362|OTHER|Cranberry juice|Cranberry juice cocktail is a product of Ocean Spray Cranberries, Inc.
215158281|NCT06589024|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
215158282|NCT06589024|OTHER|Sleep Hygiene Education|Access to sleep hygiene education materials
215158283|NCT06655506|COMBINATION_PRODUCT|ERAS group|This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
215158284|NCT06655506|COMBINATION_PRODUCT|Control group|This group will include patients that do not follow the predetermined criteria of ERAS protocols
215158285|NCT06654453|PROCEDURE|Thrombectomy|Manual thrombectomy followed by Percutaneous Coronary Intervention (PCI), a procedure involving mechanical removal of thrombus before stent placement in coronary arteries to restore blood flow in STEM
215158286|NCT06654453|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.
215158287|NCT06813963|DRUG|Topical Minoxidil（5%） to the scalp.|The patient will apply 5% Minoxidil topical solution to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
215158288|NCT06813963|DRUG|Placebo|The patient will apply placebo to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
214541663|NCT01547117|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
214541664|NCT01265043|OTHER|Oral hygiene intervention|Oral health promotion intervention
215158289|NCT01916044|OTHER|Ultrasound|Measure of Uterine Segment by Ultrasound
214541665|NCT06322147|DRUG|Doublet or triplet chemotherapy combined with cetuximab|"chemotherapy+cetuximab combination therapy，chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h)."
214541666|NCT02024295|DRUG|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
214541667|NCT02024295|DRUG|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
214541668|NCT02024295|DRUG|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
214541669|NCT03021551|DEVICE|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
214697855|NCT03364608|DRUG|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
214697856|NCT03364608|OTHER|Placebo MDI|Placebo MDI (2 actuations)
214697857|NCT03364608|DRUG|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
214697858|NCT03364608|DRUG|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
215158290|NCT04777175|DRUG|immunity therapy|The patient receives immunotherapy
214541670|NCT00882076|DRUG|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
215158291|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
215158292|NCT06065345|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
214541671|NCT00882076|DRUG|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
214541672|NCT00882076|DRUG|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
214541673|NCT01777126|OTHER|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
214541674|NCT01777126|OTHER|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
214541675|NCT02751047|OTHER|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
214541676|NCT02751047|OTHER|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
214541677|NCT06487143|DRUG|Triptorelin pamoate（15mg）|Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
214541678|NCT06487143|DRUG|Triptorelin acetate （3.75mg）|Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
214697859|NCT02982304|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation Electrode
214541680|NCT00565266|DRUG|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
214541681|NCT00565266|DRUG|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
214541682|NCT00565266|DRUG|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
214697860|NCT00410501|DRUG|Indacaterol (QAB149)|
214697861|NCT01438749|DRUG|Placebo|Single dose
214697862|NCT01438749|DRUG|RO4917838|Single doses (3 dose levels)
214697863|NCT01438749|DRUG|diazepam|Single dose
214697864|NCT02239770|DRUG|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
214697865|NCT02239770|DRUG|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
215158293|NCT06593743|DRUG|Perianal NRL001 Gel 3 strengths|A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.
214541683|NCT02131727|BEHAVIORAL|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
214541684|NCT02131727|BEHAVIORAL|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
215158294|NCT06593743|DRUG|Intraanal NRL001 Gel 2 strengths|A single application of 3.0% or 1.0% Gel
215158295|NCT06593743|DRUG|Intrarectal NRL001 Gel|A single application of 1.0% Gel
215158296|NCT06593743|DRUG|NRL001: 10mg suppository|NRL001 10mg suppository applied to rectum.
215158297|NCT06170411|DEVICE|Elexir (program1)|The Elexir is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as Trigeminal Nerve Stimulation. The Elexir will deliver trigeminal nerve stimulation.
215158298|NCT06170411|DEVICE|sham device|The sham device will deliver sham trigeminal nerve stimulation.
215158299|NCT06011551|DEVICE|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
215158300|NCT06011551|OTHER|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
215158301|NCT04917757|DIAGNOSTIC_TEST|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
215158302|NCT06595680|DRUG|Medialipide 20% perfusion|Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
215158303|NCT06595680|DRUG|NaCl 0,9%|Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
215158304|NCT06595680|BIOLOGICAL|Blood sample|Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.
215158305|NCT06860867|DEVICE|PerQdisc|PerQdisc Artificial Implant
215158306|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
215158307|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
215158308|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
215158309|NCT06995924|OTHER|Educational Intervention|Complete self-directed interactive education
214541685|NCT02977247|OTHER|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
214541686|NCT02977247|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
214541687|NCT02088554|DEVICE|Model 400 aortic valve bioprosthesis|
214541688|NCT06331104|GENETIC|gene expression levels|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
215158310|NCT06995924|OTHER|Electronic Health Record Review|Ancillary studies
215158311|NCT06995924|OTHER|Internet-Based Intervention|Receive access to CTAC
215158312|NCT06995924|BEHAVIORAL|Patient Navigation|Receive patient navigation services
215158313|NCT06995924|OTHER|Survey Administration|Ancillary studies
215158314|NCT06863220|OTHER|Intravesical Ozone Therapy|Patients received 50 mL ozonated saline (20-40 µg/mL) intravesically twice weekly for 3 weeks.
215158315|NCT06863220|OTHER|Placebo (Normal Saline)|Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.
215158316|NCT06863220|OTHER|Control|Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.
215158317|NCT00114517|DRUG|17B-estradiol|Oral 17B-estradiol 1 mg daily
215158318|NCT00114517|OTHER|Placebo|Matching oral 17B-estradiol placebo daily
215158319|NCT03669341|OTHER|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
215158320|NCT03669341|OTHER|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
215158321|NCT02544100|OTHER|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
215158322|NCT02587637|DEVICE|Dorsal root ganglion (DRG) stimulation|The role the DRG plays in the development and maintenance of chronic pain, we have developed a neurostimulator system for the management of chronic intractable pain by electrically stimulating the DRG
215158323|NCT06602726|DRUG|REGN1908|Administered per the protocol
215158324|NCT06602726|DRUG|REGN1909|Administered per the protocol
215158325|NCT06602726|DRUG|Placebo|Administered per the protocol
215158326|NCT06678269|DRUG|Abemaciclib|The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
215158327|NCT06678269|RADIATION|Radiation Therapy|27Gy in 3 daily fractions or 30Gy in 5 daily fractions completed entirely within 28 days of simulation via stereotactic body radiotherapy (SBRT).
215158328|NCT07129811|PROCEDURE|Stellate Ganglion Block|The stellate ganglion is located in front of the anterior tubercle of the C6 vertebra. An ultrasound-guided intervention will be performed from the affected side and 2 cc of 1% lidocaine will be injected.
215158329|NCT06347926|PROCEDURE|Questionnaires given before and after photobiomodulation|Questionnaires given at 1 month, 6 months and 12 months
214541689|NCT04411134|BIOLOGICAL|E7 TCR|Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
214541690|NCT04205955|OTHER|Best Practice|Receive healthy living education via phone call
214541691|NCT04205955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet modification coaching via phone call
214541692|NCT04205955|OTHER|Message|Receive motivational messages via email and/or text message
214541693|NCT04205955|OTHER|Quality-of-Life Assessment|Ancillary studies
214541694|NCT04205955|OTHER|Questionnaire Administration|Ancillary studies
214541695|NCT03898960|DEVICE|NIMBUS Device|NIMBUS Geometric Clot Extractor
214541696|NCT00548847|BIOLOGICAL|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
214541697|NCT00548847|BIOLOGICAL|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
214541698|NCT04059887|DRUG|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
214541699|NCT02271659|RADIATION|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
214541700|NCT02271659|RADIATION|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
214541701|NCT04199455|DRUG|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
214541702|NCT04199455|DRUG|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
214541703|NCT03757871|DEVICE|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
214541704|NCT03790904|OTHER|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214541705|NCT03790904|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214541706|NCT03790904|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214541707|NCT01927107|DIETARY_SUPPLEMENT|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
214541708|NCT02119949|BEHAVIORAL|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
214541709|NCT02119949|BEHAVIORAL|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
214541710|NCT01896453|PROCEDURE|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
214541711|NCT01896453|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
214541712|NCT01550432|DIETARY_SUPPLEMENT|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
214541713|NCT01550432|DIETARY_SUPPLEMENT|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
214541714|NCT01550432|OTHER|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
214541715|NCT02466698|PROCEDURE|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
215158330|NCT06262178|BEHAVIORAL|Parenting-STAIR Modular (PSTAIR-M)|12-16 PSTAIR-M treatment sessions (approximately 12-16 weeks).
215158331|NCT06262178|BEHAVIORAL|Treatment as Usual (TAU)|Weekly treatment sessions of an established EBT. The total number of sessions/weeks will be determined by the EBT and clinic protocols.
214541716|NCT02466698|DRUG|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
214541717|NCT02466698|DRUG|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
214541718|NCT02466698|DRUG|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
214541719|NCT01086384|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
214697866|NCT05441137|BEHAVIORAL|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
214697867|NCT05441137|BEHAVIORAL|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
214697868|NCT03195855|OTHER|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
214541720|NCT01086384|DRUG|Fluticasone furoate|Inhaled corticosteroid
214541721|NCT06356623|OTHER|1|this is not an intervention study
214541722|NCT02077725|OTHER|interdisciplinary polypharmacy clinic visit|
214541723|NCT01196819|DEVICE|Firehawk|Implantation of Firehawk drug eluting stent
214541724|NCT01196819|DEVICE|Xience V|Implantation of Xience V drug eluting stent
214697869|NCT04377594|PROCEDURE|Radio frequency ablation|Two different radio frequency ablation procedures
214697870|NCT02546674|DRUG|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
214697871|NCT02892565|OTHER|Blood sample|
214697872|NCT00588250|OTHER|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
214697873|NCT03147274|BEHAVIORAL|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
214697874|NCT02520518|DRUG|Dapagliflozin|
214697875|NCT02520518|DRUG|Placebo|
214697876|NCT02520518|BEHAVIORAL|Weight maintenance|
214697877|NCT02520518|BEHAVIORAL|Ad libitum dietary intake|
214541725|NCT05350488|OTHER|Informational Interview|Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.
214697878|NCT02520518|BEHAVIORAL|Dietary restriction|
215158332|NCT07012005|DRUG|BPN14770|BPN14770 will be administered per schedule specified in the arm description.
215158333|NCT07074769|DEVICE|Evaluation of speech-in-noise intelligibility and listening effort|The speech in noise testing will be performed in lab settings; the listening effort evaluated trough a standardized questionnaire
215158334|NCT06762444|BEHAVIORAL|Speech-language pathologist (SLP) protocol|The SLP intervention protocol consists of six components, all of which will be implemented by the treating speech-language pathologist
215158335|NCT03460977|DRUG|Mervometostat (PF-06821497)|Oral continuous
215158336|NCT03460977|DRUG|Enzalutamide|Oral continuous
215158337|NCT07082816|DRUG|Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution|Investigational ophthalmic solution
215158338|NCT07082816|DRUG|Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution|Commercially available ophthalmic solution
215158339|NCT07087314|DRUG|SG301 Subcutaneous injection|Subcutaneous injection every weeks (QW\*6),subsequently, administer it once every two weeks for a total of three times (Q2W\*3). The total number of doses is nine.
215158340|NCT03487432|DEVICE|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
214541726|NCT05350488|OTHER|Focus Group|Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
214541727|NCT01694888|OTHER|lecture|Teaching documentation skill using lecture method
214541728|NCT04988776|OTHER|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
214541729|NCT04988776|OTHER|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
214541730|NCT03416413|PROCEDURE|Ambulatory phlebectomy|Minor surgery to remove varicose vein tributaries
214541731|NCT03416413|DRUG|Foam sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
215158341|NCT03487432|DEVICE|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
215158342|NCT06901700|OTHER|Experimental Group|Total 40\~60 minutes, 3 sessions per week in alternate day for 8 weeks, total 24 sessions 5 min warm up and 5 min cool down Power training (using body weight as resistance): hip flexor, hip extensor, hip adductor, hip abductor, knee flexor, ankle plantarflexor, hip external rotator, hip internal rotator, knee extensor, ankle dorsiflexor, ankle invertor, ankle evertor
214541732|NCT01776359|DIETARY_SUPPLEMENT|High Protein|2.4g/kg of protein
214541733|NCT01776359|DIETARY_SUPPLEMENT|Low Protein|1.2g/kg of protein
214541734|NCT03840265|PROCEDURE|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
214541735|NCT02250534|OTHER|Very low nicotine content cigarettes|
214541736|NCT04236232|DIAGNOSTIC_TEST|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
214541737|NCT03716388|BIOLOGICAL|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
214541738|NCT03716388|DRUG|Mesalamine Granules|Mesalamine granules 4 grams a day
214541739|NCT03716388|OTHER|Placebo infusion|Water with food grade colour to resemble fecal slurry
215158343|NCT06901700|OTHER|control group|Health education
215158344|NCT06905197|DRUG|DZD6008|Daily dose of DZD6008
215158345|NCT05693649|BEHAVIORAL|No Direct Patient Outreach|Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
215158346|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Colonoscopy Only|Patient will receive direct outreach including an order to schedule and complete colonoscopy.
215158347|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Sequential Choice|Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
215158348|NCT05693649|BEHAVIORAL|Visit-Based Nudge/Text|Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
214541740|NCT03716388|OTHER|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
214697879|NCT01518426|DEVICE|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
214697880|NCT05315232|OTHER|survey and interview|qualitative assessment
214697881|NCT05678192|DRUG|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
214697882|NCT05678192|DRUG|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
214697883|NCT04251689|DRUG|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
214697884|NCT04251689|DRUG|Placebo|0.9% normal saline 100 ml
214697885|NCT02215408|BEHAVIORAL|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
214541741|NCT04044703|DRUG|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
214541742|NCT03527498|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
214541743|NCT03527498|BEHAVIORAL|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
214541744|NCT02804451|DEVICE|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
214541745|NCT02804451|DEVICE|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
214541746|NCT02804451|DEVICE|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
214541747|NCT02804451|DEVICE|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
214541748|NCT01806935|DEVICE|DC086|
214541749|NCT01806935|DEVICE|Placebo|
214541750|NCT02305745|OTHER|Observational|
214697886|NCT02665364|BIOLOGICAL|IFNα-Kinoid|
214697887|NCT02665364|OTHER|Placebo|
214697888|NCT02665364|OTHER|ISA 51 VG|
214697889|NCT02521688|PROCEDURE|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
214697890|NCT00987922|DEVICE|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
214697891|NCT03888391|DEVICE|Active TNS|
214697892|NCT00301028|BIOLOGICAL|Cetuximab|Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
214697893|NCT00301028|DRUG|Carboplatin|AUC 2 weekly for 6 courses.
215158349|NCT05693649|BEHAVIORAL|No Nudge/Text|Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
215158350|NCT01805076|PROCEDURE|Breast surgery|
215158351|NCT01805076|PROCEDURE|Magnetic resonance imaging|
215158352|NCT01805076|PROCEDURE|Mammography|
214541751|NCT00850486|DEVICE|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
214541752|NCT03045809|DIAGNOSTIC_TEST|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
214541753|NCT02725567|DRUG|IVA|Granules in sachet for oral administration.
214541754|NCT05780905|DRUG|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
214541755|NCT05780905|OTHER|Placebo|Placebo
214541756|NCT06064370|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy for pheochromocytoma
214541757|NCT02198261|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
214541758|NCT04397146|DIETARY_SUPPLEMENT|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
214541759|NCT00115947|DRUG|Terlipressin|
214541760|NCT03974789|DIAGNOSTIC_TEST|Blood test|Plasma cortisol level test
214541761|NCT03974789|DIAGNOSTIC_TEST|24-hour Urine test|Urinary free cortisol test
214697894|NCT00301028|DRUG|Paclitaxel|135 mg/m\^2 weekly for 6 courses.
214697895|NCT00301028|PROCEDURE|Conventional Surgery|Following induction in second part of study.
214697896|NCT00301028|RADIATION|Radiation Therapy|Following induction in second part of study.
214697897|NCT02848339|DRUG|aspirin|aspirin desensitization
214697898|NCT03736954|BEHAVIORAL|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
214697899|NCT00000150|PROCEDURE|Subfoveal Choroidal Neovascularization Removal|
214697900|NCT06179615|OTHER|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
215158353|NCT05943106|BIOLOGICAL|Durvalumab|Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
214541762|NCT03974789|DIAGNOSTIC_TEST|Saliva swab|salivette® for salivary cortisol quantification
214541763|NCT03974789|DIAGNOSTIC_TEST|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
214541764|NCT02929719|DRUG|Test.|gel
214541765|NCT02929719|DRUG|Aczone Gel 5%|gel
214541766|NCT02929719|DRUG|Placebo|gel
214541767|NCT00519064|BIOLOGICAL|Adjuvanted influenza vaccine|
214541768|NCT00945451|DEVICE|CK|Cyberknife Irradiation
214541769|NCT00255944|BEHAVIORAL|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
214541770|NCT00255944|BEHAVIORAL|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
214541771|NCT03124550|BEHAVIORAL|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
214541772|NCT01129115|BEHAVIORAL|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
214541773|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
214541774|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
214541775|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
214697901|NCT06179615|OTHER|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
215158354|NCT05943106|BIOLOGICAL|BCG|Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
215158355|NCT06901466|DRUG|Experimental: Rivaroxaban monotherapy|Rivaroxaban monotherapy
215158356|NCT06901466|DRUG|Active Comparator: Rivaroxaban+Aspirin|Rivaroxaban+Aspirin
214541776|NCT00001234|GENETIC|human glucocerebrosidase cDNA|
214541777|NCT00247702|DRUG|warfarin|
215158357|NCT07113990|PROCEDURE|Active EA|Participants will receive electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable sterile needles will be inserted at standardized acupoints to achieve de qi, then connected to an electroacupuncture device for 30 minutes per session.
215158358|NCT07113990|PROCEDURE|Sham EA|Participants will receive sham electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable blunt needles will be placed at the same acupoints without skin penetration or electrical stimulation, with the electroacupuncture device turned on but delivering no current, for 30 minutes per session.
214541778|NCT04626271|DEVICE|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
214541779|NCT04626271|DEVICE|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
214541780|NCT05951621|OTHER|Qigong|An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
215158359|NCT07113990|DEVICE|Active rTMS|Participants will receive high-frequency rTMS to the ipsilesional M1 area once daily for 2 consecutive weeks (total 10 sessions). Stimulation will be delivered with a MagPro R30 stimulator at 10 Hz, 1600 pulses per session, 4-second trains with 41-second inter-train intervals.
215158360|NCT06922591|DRUG|TNG462|MTA cooperative PRMT5 inhibitor
215158361|NCT06922591|DRUG|RMC-9805|RAS(ON) G12D selective covalent inhibitor
214541781|NCT05951621|BEHAVIORAL|guidance of nutrition and exercise|Provide health promotion and guidance to participants on diet and physical exercise
214541782|NCT02735798|DRUG|MM-302|
214541783|NCT02735798|DRUG|Trastuzumab|
214541784|NCT03120299|DRUG|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
214541785|NCT03120299|DRUG|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
214697902|NCT00423735|DRUG|Dasatinib|Given PO
214541786|NCT00005845|DRUG|tipifarnib|Given PO
214541787|NCT00005845|OTHER|laboratory biomarker analysis|Correlative studies
214541788|NCT00005845|OTHER|pharmacological study|Correlative studies
214541789|NCT01963572|OTHER|SG will be screened every time when they visit the clinics.|
214541790|NCT01797978|DRUG|Intravenous methylene blue administration|Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
214541791|NCT01797978|DRUG|Placebo|
214697903|NCT00423735|OTHER|Pharmacological Study|Correlative studies
215158362|NCT06922591|DRUG|RMC-6236|RAS(ON) multi-selective inhibitor
214697904|NCT05839431|BEHAVIORAL|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
214697905|NCT02040818|DRUG|tigecycline, N-acetylcysteine, heparin combination|
214541792|NCT05431725|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
214697906|NCT02040818|DEVICE|guide-wire exchange|
214697907|NCT00439673|DRUG|5-Azacytidine|
215158363|NCT05756855|BEHAVIORAL|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
215158364|NCT06932458|PROCEDURE|Retroperitoneal Lymph Node Dissection|Open bilateral nerve-sparing RPLND.
215158365|NCT07135895|DEVICE|Artix Thrombectomy System|Treatment of lower extremity arterial occlusions using the Artix Thrombectomy System.
215158366|NCT05020184|DRUG|Cimetidine|Oral Cimetidine 800mg twice daily.
215158367|NCT05020184|DRUG|Placebo|Placebo twice daily
214541793|NCT05431725|BIOLOGICAL|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
214541794|NCT04627441|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
214541795|NCT04627441|DEVICE|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
214541796|NCT04597099|DRUG|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
214541797|NCT04597099|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
214541798|NCT04597099|DRUG|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
214541799|NCT04597099|DRUG|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
214541800|NCT06240546|DRUG|LPM6690176|Administered orally
214541801|NCT03877952|DRUG|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
214541802|NCT04157218|DEVICE|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
214541803|NCT04157218|DEVICE|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
214541804|NCT01747837|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
214541805|NCT05579665|BIOLOGICAL|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
214541806|NCT05579665|BIOLOGICAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
214541807|NCT05579665|DRUG|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
214541808|NCT01728207|DRUG|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
214541809|NCT00751634|DEVICE|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
214541810|NCT03184818|OTHER|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
214697908|NCT00439673|DRUG|Valproic Acid|
214697909|NCT00439673|DRUG|ATRA|
214697910|NCT05851339|OTHER|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
214697911|NCT05487053|PROCEDURE|Single-shot adductor canal block|Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
214697912|NCT05487053|PROCEDURE|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
214697913|NCT00446485|DRUG|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
214697914|NCT00446485|DRUG|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
214697915|NCT00446485|DRUG|placebo|placebo during 6 months
215158368|NCT06303063|DEVICE|SINOMED IAS Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
215158369|NCT06303063|DEVICE|Neuroform Atlas Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
215158370|NCT04951947|DRUG|JS201 combine with Lenvatinib|JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
215158371|NCT03708783|PROCEDURE|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
214541811|NCT04730076|PROCEDURE|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
214541812|NCT04730076|PROCEDURE|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
214541813|NCT00001083|DRUG|Indinavir sulfate|
214541814|NCT00001083|DRUG|Ritonavir|
214541815|NCT00001083|DRUG|Nevirapine|
214541816|NCT00001083|DRUG|Lamivudine|
214541817|NCT00001083|DRUG|Stavudine|
214541818|NCT00001083|DRUG|Zidovudine|
214541819|NCT02815137|OTHER|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
214541820|NCT01171300|OTHER|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
214541821|NCT01171300|OTHER|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
214541822|NCT05674383|PROCEDURE|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
214541823|NCT05674383|PROCEDURE|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
214541824|NCT02162914|DRUG|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
215158372|NCT02641561|DRUG|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
215158373|NCT02641561|DRUG|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
215158374|NCT02641561|DRUG|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
215158375|NCT02641561|DRUG|Placebo|Placebo would be a suppository 50 mg x 2
214541825|NCT02162914|DRUG|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
214541826|NCT00010842|DRUG|Ginkgo biloba|
214541827|NCT00010842|DRUG|Alpha-lipoic acid|
214541828|NCT00010842|DRUG|Vitamin E/Selenium|
214541829|NCT00010842|DRUG|Essential fatty acids|
214541830|NCT01435798|DRUG|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
214541831|NCT01253447|DRUG|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
214541832|NCT01253447|OTHER|laboratory biomarker analysis|Correlative studies
214541833|NCT04048798|OTHER|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
214541834|NCT04048798|OTHER|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
214541835|NCT03450148|OTHER|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
214541836|NCT03450148|OTHER|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
215158376|NCT03340324|BIOLOGICAL|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
214541837|NCT04207697|BIOLOGICAL|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
214541838|NCT00817336|DRUG|D Serine|60 mg/kg/day
214541839|NCT00817336|DRUG|Placebo|oral
214541840|NCT02449083|PROCEDURE|MRI|MRI
214541841|NCT02449083|PROCEDURE|coronary angiography|coronary angiography
214541842|NCT02299427|BEHAVIORAL|dog safety|use of dog safety website at home for about 2 weeks
214541843|NCT02299427|BEHAVIORAL|transportation safety|use of transportation safety website at home for about 2 weeks
214541844|NCT04187430|BEHAVIORAL|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
214541845|NCT04187430|BEHAVIORAL|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
214541846|NCT03123419|BEHAVIORAL|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
215158377|NCT00702715|DRUG|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
214541847|NCT01554293|DRUG|Matching placebo|Matching Placebo, single dose
214541848|NCT01554293|DRUG|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
214541849|NCT02032108|BEHAVIORAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
214541850|NCT02108652|DRUG|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
214541851|NCT01603342|DRUG|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
214541852|NCT01603342|DRUG|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
214541853|NCT01481519|DRUG|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
214541854|NCT01481519|DRUG|Artificial Tears|artificial tears 1 drop, 4 times per day
214541855|NCT05241054|DRUG|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
214541856|NCT05241054|DRUG|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
214541857|NCT05241054|DRUG|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
214541858|NCT05241054|DRUG|Fentanyl|fentanyl 1 microgram.kg
214541859|NCT05241054|DRUG|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
214541860|NCT05241054|PROCEDURE|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
214541861|NCT05241054|DRUG|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
214541862|NCT05241054|DRUG|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
214541863|NCT05241054|OTHER|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
214541864|NCT05241054|DRUG|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
214541865|NCT03311269|DEVICE|ClariVein RES|ClariVein system
214541866|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
214541867|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
214541868|NCT04151823|DRUG|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
214541869|NCT04151823|DRUG|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
214541870|NCT04151823|OTHER|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
214541871|NCT04151823|OTHER|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
214541872|NCT05756049|OTHER|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
214541873|NCT02929706|GENETIC|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
214541874|NCT01182181|DRUG|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
214541875|NCT01182181|DRUG|Anastrozole (Arimidex®)|1 mg Tablets
214541876|NCT01940289|DEVICE|Algometric meter readings for perception of pain|
214541877|NCT04760197|OTHER|no intervention|no intervention
214541878|NCT04826497|DRUG|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
214541879|NCT04826497|DRUG|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
214541880|NCT01280383|DEVICE|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
214541881|NCT06128213|DRUG|NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
214541882|NCT03756064|DRUG|Pyrotinib|Pyrotinib: 400mg orally daily
214541883|NCT03756064|DRUG|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
214541884|NCT03756064|DRUG|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
214697916|NCT05271396|OTHER|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
214697917|NCT00654784|DRUG|idebenone|idebenone 450 mg/day (150 mg three times a day)
214697918|NCT00654784|DRUG|placebo|
214697919|NCT02070406|DRUG|cyclophosphamide|Given IV
214697920|NCT02070406|DRUG|fludarabine phosphate|Given IV
215158378|NCT04314297|DRUG|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
215158379|NCT01827423|DEVICE|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
215158380|NCT06831825|COMBINATION_PRODUCT|YAP101 (AAV9-Sav-shRNA)|YAP101 delivered using YAPCATH-101
215158381|NCT04466709|OTHER|none intervention type|This is an observational study, no intervention
214541885|NCT03756064|DRUG|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
214541886|NCT03756064|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
214541887|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
214541888|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
214541889|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
214541890|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
214541891|NCT01086618|DRUG|systemic chemotherapy|
214541892|NCT01086618|PROCEDURE|adjuvant therapy|
214541893|NCT01086618|PROCEDURE|quality-of-life assessment|
214541894|NCT01086618|PROCEDURE|therapeutic conventional surgery|
214541895|NCT03758456|BIOLOGICAL|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
214541896|NCT00000232|DRUG|Buprenorphine|
214541897|NCT05940714|BEHAVIORAL|Video participants|Showing a video of oral hygiene intructions
214541898|NCT05065697|OTHER|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
214541899|NCT04152395|OTHER|EVAR|Patients undergoing EVAR
214541900|NCT03028259|OTHER|lab results|Comparison of lab results
214541901|NCT04815473|PROCEDURE|Valvulotomy|Valvulotomy of the venous valves
214541902|NCT04307641|BEHAVIORAL|2 Page Information Sheet|2 page information sheet about medication abortion
214697921|NCT02070406|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
214541903|NCT02597036|DRUG|LY3127804|Administered IV
214541904|NCT02597036|DRUG|Ramucirumab|Administered IV
214541905|NCT02597036|DRUG|Paclitaxel|Administered IV
214541906|NCT04522583|DIAGNOSTIC_TEST|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
214541907|NCT03101033|DEVICE|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
214541908|NCT03101033|DRUG|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
214541909|NCT03101033|DRUG|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
214541910|NCT03101033|DRUG|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
214541911|NCT00938990|DRUG|Etomidate|
214541912|NCT00938990|DRUG|Midazolam|
215158382|NCT01452932|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
215158383|NCT01452932|OTHER|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
215158384|NCT03055130|OTHER|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
215158385|NCT02082119|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
215158386|NCT03263663|DRUG|targeted substance according to the avatar model|individualized second line treatment
215158387|NCT01350401|GENETIC|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
215158388|NCT01773759|BEHAVIORAL|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
215158389|NCT02869737|DEVICE|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
215158390|NCT01047605|DRUG|Neurapas balance|6 tablets single dose
215158391|NCT01047605|DRUG|Pascoflair 425 mg|3 tablets , single dose
215158392|NCT01047605|DRUG|P-Tabletten weiß|3 tablets, single dose
215158393|NCT05345340|OTHER|Telemedicine|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days)."
214541913|NCT04244422|OTHER|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
214541914|NCT06192719|OTHER|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
214541915|NCT02830256|OTHER|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
214541916|NCT04964778|DEVICE|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
214541917|NCT05458154|OTHER|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
214697922|NCT02070406|BIOLOGICAL|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
214697923|NCT02070406|BIOLOGICAL|aldesleukin|Given SC
214697924|NCT02070406|RADIATION|fludeoxyglucose F 18|Correlative studies
214697925|NCT02070406|PROCEDURE|positron emission tomography|Correlative studies
214697926|NCT02070406|OTHER|laboratory biomarker analysis|Correlative studies
214697927|NCT01954251|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214697928|NCT01954251|BIOLOGICAL|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
214697929|NCT02877355|DRUG|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
214697930|NCT04996472|BEHAVIORAL|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
214697931|NCT04996472|BEHAVIORAL|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
215158394|NCT05345340|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
214541918|NCT02564718|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
214541919|NCT02283021|OTHER|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
214541920|NCT02767102|OTHER|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
214697932|NCT00877669|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
215158395|NCT02840799|DRUG|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
215158396|NCT02840799|DRUG|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
215158397|NCT02586558|OTHER|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
215158398|NCT02586558|OTHER|Reference group|Ready-to-feed infant formula to be fed ad libitum
215158399|NCT03160235|RADIATION|Magnetic resonance imaging|
214697933|NCT00877669|PROCEDURE|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
214697934|NCT01899859|DRUG|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
214697935|NCT01899859|DRUG|Placebo|GR-MD-02 Placebo
214697936|NCT01345344|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
214697937|NCT01345344|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
214697938|NCT02665923|OTHER|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
214697939|NCT05108220|DIETARY_SUPPLEMENT|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
214697940|NCT01413841|DRUG|Nasal oxygen|3 l oxygen
214697941|NCT01413841|DRUG|Regular nasal air|3 l nasal air
214697942|NCT02701686|BEHAVIORAL|quit immediately (QI)|advise to quit immediately using the AWARD model
215158400|NCT03160235|DEVICE|EEG|
215158401|NCT03160235|DEVICE|NIRS|
214697943|NCT02701686|BEHAVIORAL|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
214697944|NCT00104078|DRUG|MYO-029|
214697945|NCT02864940|DEVICE|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
214541921|NCT02767102|OTHER|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
214541922|NCT02089438|DRUG|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
214541923|NCT02089438|DRUG|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
214541924|NCT02089438|DRUG|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
214697946|NCT02864940|DEVICE|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
214697947|NCT01722487|DRUG|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
214697948|NCT01722487|DRUG|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
215158402|NCT04990804|DRUG|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
215158403|NCT04990804|DRUG|Opioid-Free Postoperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
215158404|NCT01326338|DRUG|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
215158405|NCT04611399|BEHAVIORAL|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
215158406|NCT04611399|OTHER|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
215158407|NCT01886599|DRUG|Asunaprevir|
215158408|NCT06278441|OTHER|Kangaroo care and White noise|CG newborns underwent routine heel lancing, and no intervention was performed.
215158409|NCT01137201|PROCEDURE|Suturing of mesenteric defects|
215158410|NCT01014351|DRUG|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
215158411|NCT01014351|DRUG|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
215158412|NCT01014351|DRUG|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
214541925|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation I
214541926|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation II
214541927|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation III
214541928|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation IV
214541929|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation V
214541930|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation VI
214541931|NCT00937521|BIOLOGICAL|Control|Control
214541932|NCT00937521|BIOLOGICAL|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
214541933|NCT03322241|OTHER|overall wellness|Wellness lab testing
214541934|NCT03494855|DEVICE|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
214541935|NCT00198302|DRUG|Aurexis®|
214541936|NCT05234775|DRUG|lerodalcibep|300 mg of each drug given SC as single dose
214541937|NCT04346485|PROCEDURE|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
214541938|NCT04346485|PROCEDURE|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
214541939|NCT04346485|PROCEDURE|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
214541940|NCT05771025|PROCEDURE|Hepatectomy|Patients in the hepatectomy group receive liver resection.
214541941|NCT05181397|DRUG|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
214541942|NCT03503383|BEHAVIORAL|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
214541943|NCT03503383|BEHAVIORAL|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
214541944|NCT03949465|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
214541945|NCT04515628|DRUG|Rosuvastatin|Specified dose on specified days
214541946|NCT04515628|DRUG|Branebrutinib|Specified dose on specified days
214541947|NCT06301971|DRUG|Emraclidine|Oral solution/suspension
214541948|NCT05803642|DRUG|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
214541949|NCT05803642|DRUG|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
214541950|NCT04353817|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
214541951|NCT04353817|DRUG|IVA|Tablet for oral administration qd in the evening.
214541952|NCT04353817|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
214541953|NCT04353817|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
214541954|NCT01438762|BEHAVIORAL|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
214541955|NCT01438762|OTHER|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
214541956|NCT05474898|OTHER|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
214541957|NCT05474898|OTHER|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
214541958|NCT05474898|OTHER|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
214541959|NCT02868372|DRUG|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
214541960|NCT02781298|DIETARY_SUPPLEMENT|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
214541961|NCT02781298|DIETARY_SUPPLEMENT|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
214541962|NCT01518088|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to study foods
214541963|NCT04226898|BIOLOGICAL|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
214541964|NCT04226898|BIOLOGICAL|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
214541965|NCT00142688|BEHAVIORAL|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
214541966|NCT00142688|BEHAVIORAL|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
214541967|NCT00770588|DRUG|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
214541968|NCT00770588|DRUG|Placebo|To match Gefitinib
214541969|NCT06176898|DEVICE|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
214541970|NCT01114308|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
214541971|NCT01114308|DRUG|placebo implant|Implant contains ethylene vinyl acetate
214541972|NCT01114308|DRUG|Buprenorphine|sublingual buprenorphine/naloxone tablets
214541973|NCT01711346|BIOLOGICAL|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
214541974|NCT01711346|BIOLOGICAL|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
214541975|NCT05294406|DRUG|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
214541976|NCT00516828|DRUG|cytarabine|subcutaneously twice daily from Day 1 to 10
214541977|NCT00012662|BEHAVIORAL|Diabetes Self Management Education|
214541978|NCT06545578|OTHER|low-level laser therapy|The Low-level laser (LLL) pain-relief instrument RG-300IB (code E22), manufactured in China, was utilized for low-level laser therapy (LLLT) in Group A . The therapy employed a wavelength of 830 nm (near infrared) and involved careful skin contact hygiene at specified positions, 2.5 and 3.5 cm laterally from the spinous process (L4, L5, or S1) and one distal level segment. The laser operated at a repetition rate of 5,000, with a power density of 300 mW/cm2 and a power output of 10 mW. Each point received 3 J of energy, resulting in a density of 3 J/cm2, with four points. The spot size was 1 cm, and each point received a 30-second treatment. The energy was administered three times per week for four weeks
214541979|NCT06545578|OTHER|TENS|TENS Intelect Advanced device (Chattanooga, Mouguerre, France). The parameters for TENS stimulation included a frequency range of 60-80 Hz, a pulse width of 50-80 ms, and an intensity of 10-30 mA. Before commencing therapy, patients were provided information regarding the therapeutic approach and any potential adverse effects. During the procedure, two channels (four electrodes) were employed, with one set placed on the right and one on the left paraspinal muscles at the level of L2-L4. Active electrodes from the other channels were affixed 1.5 cm laterally to the spine, while passive electrodes were positioned 3 cm away. TENS therapy was utilized for 30 minutes in Group B, and the intensity of the pain and discomfort was adjusted to the patient's tolerance level.
214541980|NCT06545578|OTHER|motor control exercises|Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.
214541981|NCT05809336|DRUG|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
214541982|NCT05809336|DRUG|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
214541983|NCT03712384|OTHER|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
214541984|NCT00002597|DRUG|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
215158413|NCT01760785|DRUG|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
215158414|NCT01760785|DRUG|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
215158415|NCT05768022|OTHER|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
215158416|NCT05768022|OTHER|placebo|placebo taping
214541985|NCT00002597|DRUG|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
214541986|NCT00002597|DRUG|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
214697949|NCT02175771|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
214697950|NCT02175771|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
215158417|NCT06220760|DIAGNOSTIC_TEST|Ultrasound|The use of US to calculate placenta accreta index
214697951|NCT02175771|DRUG|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
214697952|NCT02175771|DRUG|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
215158418|NCT01193257|DRUG|Orteronel|Orteronel tablets
215158419|NCT01193257|DRUG|Prednisone|Prednisone tablets
215158420|NCT01193257|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
215158421|NCT00732407|DRUG|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
215158422|NCT00732407|DRUG|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
215158423|NCT04188444|BIOLOGICAL|Blood test|20 ml of blood, three times
215158424|NCT04206280|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
214541987|NCT00002597|RADIATION|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
215158425|NCT04206280|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
215158426|NCT00921895|DEVICE|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
215158427|NCT03332680|BIOLOGICAL|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
214541988|NCT04502836|BEHAVIORAL|Preliminary psychological intervention|psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
214697953|NCT02175771|DRUG|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
215029455|NCT06638697|OTHER|Aquatic physiotherapy|The Aquatic Physiotherapy training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
215158428|NCT03332680|BIOLOGICAL|Standard control medium|Embryos placed in this medium prior to transfer
215158429|NCT05224167|DRUG|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
215158430|NCT05224167|DRUG|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
215158431|NCT00618345|DRUG|everolimus|
215158432|NCT00618345|GENETIC|DNA analysis|
215158433|NCT00618345|GENETIC|protein analysis|
214541989|NCT01682746|DRUG|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
214541990|NCT00332826|DRUG|Technosphere Insulin|
214541991|NCT02812875|DRUG|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
214541992|NCT01494545|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
214541993|NCT01447199|BEHAVIORAL|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
214541994|NCT04933981|DIAGNOSTIC_TEST|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
214541995|NCT02485899|BIOLOGICAL|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
214541996|NCT02485899|DEVICE|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
214541997|NCT01918371|DRUG|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
214541998|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214541999|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214542000|NCT05238649|BIOLOGICAL|SARS-Cov-2 Vaccine Inactivated|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214542001|NCT02219399|DIETARY_SUPPLEMENT|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
214542002|NCT02219399|DIETARY_SUPPLEMENT|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
214542003|NCT02219399|DIETARY_SUPPLEMENT|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
214542004|NCT02838576|DRUG|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
214697954|NCT02581111|DRUG|Naloxone|Naloxone 8-mg IV bolus
214697955|NCT02581111|DRUG|Normal saline|
214697956|NCT03364673|OTHER|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
215158434|NCT00618345|GENETIC|western blotting|
215158435|NCT00618345|OTHER|flow cytometry|
215158436|NCT00618345|OTHER|laboratory biomarker analysis|
215158437|NCT00618345|PROCEDURE|biopsy|
215158438|NCT03227783|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
215158439|NCT00662298|DRUG|prednisolone|40mg of prednisolone once a day for 14 days
215158440|NCT05061043|OTHER|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
215158441|NCT05061043|OTHER|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
215158442|NCT02847676|PROCEDURE|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
215158443|NCT06260722|DRUG|Retatrutide|Administered SC.
215158444|NCT06260722|DRUG|Semaglutide|Administered SC.
214542005|NCT02838576|DRUG|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
214542006|NCT03595423|PROCEDURE|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
214542007|NCT05809102|PROCEDURE|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
214542008|NCT01642095|OTHER|Laboratory Biomarker Analysis|Correlative studies
214542009|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
214542010|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
214542011|NCT02455999|DRUG|Placebo|Placebo eye drops administration for 10 consecutive days
214542012|NCT01382862|OTHER|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
214542013|NCT03415399|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
214542014|NCT03384771|BEHAVIORAL|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
214542015|NCT01036243|DIETARY_SUPPLEMENT|test formula 1|hydrolyzed formula with probiotics
214542016|NCT01036243|DIETARY_SUPPLEMENT|test formula 2|acidified hydrolyzed formula
214542017|NCT01036243|DIETARY_SUPPLEMENT|test formula 3|hydrolyzed formula without probiotics
214542018|NCT01036243|DIETARY_SUPPLEMENT|reference formula|standard infant formula
214542019|NCT05752045|DEVICE|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
214542020|NCT01095133|DRUG|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
214542021|NCT01095133|DRUG|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
214542022|NCT03494465|PROCEDURE|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
214542023|NCT03494465|DRUG|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
214542024|NCT00238992|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214542025|NCT02206932|DRUG|Sofosbuvir + Simeprevir|
214542026|NCT02143063|BEHAVIORAL|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
214542027|NCT02143063|BEHAVIORAL|prize contingency management on a variable interval schedule for cocaine abstinence|
214542028|NCT02143063|BEHAVIORAL|standard care|
214542029|NCT02509988|DIETARY_SUPPLEMENT|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
214542030|NCT02509988|DIETARY_SUPPLEMENT|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
214542031|NCT03245463|OTHER|Educational handout|The educational handout will include information on self-management strategies.
215158445|NCT05585944|DIAGNOSTIC_TEST|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
215158446|NCT04768608|DRUG|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
215158447|NCT05296395|OTHER|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
215158448|NCT05296395|OTHER|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
215158449|NCT04657094|DRUG|Acalabrutinib|Given PO
215158450|NCT03437590|DRUG|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
215158451|NCT03437590|DRUG|[18F]-JNJ-64413739|\[18F\]-JNJ-64413739 fluid for injection administered intravenously.
215158452|NCT05709093|DRUG|Lemzoparlimab+Azacitidine (AZA)|"1. Lemzoparlimab is administered by intravenous (IV) infusion once a week at a dose of 30 mg/kg in 28-day treatment cycles~2. Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles."
215158453|NCT05709093|DRUG|Azacitidine (AZA)|AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.
215158454|NCT05393102|OTHER|No interventions|No interventions
215158455|NCT03888417|DEVICE|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
215158456|NCT02817009|BEHAVIORAL|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
215158457|NCT02817009|BEHAVIORAL|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
215158458|NCT02817009|BEHAVIORAL|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
215158459|NCT00578149|DRUG|Bevacizumab|
215158460|NCT00578149|DRUG|Carboplatin|
214542032|NCT03245463|OTHER|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
214542033|NCT03245463|DRUG|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
215158461|NCT00578149|DRUG|Paclitaxel|
215158462|NCT05033704|DRUG|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
215158463|NCT01621802|BIOLOGICAL|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
215158464|NCT01621802|BIOLOGICAL|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
215158465|NCT01621802|BIOLOGICAL|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
215158466|NCT01621802|BIOLOGICAL|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
215158467|NCT05909657|OTHER|questionnaires (surveys)|Mixed-methods study. Both the qualitative interview guides and the questionnaire surveys are adapted from the Sickle Cell Disease Implementation Consortium (SCDIC) project which is a multicentre study occurring in the United States.
214542034|NCT03582345|PROCEDURE|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1\. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
214542035|NCT04482192|COMBINATION_PRODUCT|Thoracic paravertebral block|After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
214542036|NCT04482192|DRUG|Systemic analgesia|Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
214697957|NCT03364673|OTHER|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
215158468|NCT02948634|DEVICE|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
215158469|NCT02948634|DEVICE|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
215158470|NCT02595489|DIETARY_SUPPLEMENT|vitamin D3|Daily oral supplement provided by study investigators
215158471|NCT02449148|OTHER|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
215158472|NCT06168916|DIAGNOSTIC_TEST|PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.
215158473|NCT00475696|DRUG|Duloxetine|
214697958|NCT02232087|DRUG|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
214697959|NCT02232087|DRUG|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
214697960|NCT02446353|DRUG|Apetrol ES / Megace|Sequences of administered drugs
214697961|NCT01367301|DRUG|paclitaxel|Given IV
214542037|NCT06029985|DIAGNOSTIC_TEST|Hysteroscopic Follow Up|Office hysteroscopy was carried out to detect the scar site, performed with a 4-mm, continuous-flow operative hysteroscope by vaginoscopic approach, without analgesia or anesthesia. Distension of the uterus was obtained using a normal solution as distension medium, dispensed by an electronic suction/irrigation pump. This can maintain a constant intrauterine pressure of around 30-40 mmHg, balancing an irrigation flow of 200 mL/min with a vacuum of 0.2 bars, necessary to avoid overdistension of the muscle fibers and patient discomfort. The use of this distension medium allows blood or mucus to be washed out from the pouch if necessary.
214542038|NCT02782611|BEHAVIORAL|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
214542039|NCT00623363|DRUG|piclozotan|piclozotan, intravenous (IV) infusion
214542040|NCT00623363|DRUG|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
214542041|NCT00853736|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
214542042|NCT00853736|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
214542043|NCT02332083|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
214542044|NCT02332083|DEVICE|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
214542045|NCT02332083|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
214542046|NCT02332083|DEVICE|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
214542047|NCT04711486|DRUG|Contraloid acetate|Oral administration of drug substance capsules
214542048|NCT04711486|DRUG|Placebo|Oral administration of placebo without any exipients.
214542049|NCT05172986|BEHAVIORAL|Follow-up patient program|An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
214542050|NCT00511771|DRUG|Tegaserod|Tegaserod maleate
214542051|NCT06105112|DEVICE|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
214697962|NCT01367301|DRUG|carboplatin|Given IV
215158474|NCT02664571|DEVICE|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
215158475|NCT02664571|DEVICE|MRI scan|Subjects will have an MRI scan at inclusion.
215158476|NCT02664571|BIOLOGICAL|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
214542052|NCT06105112|DEVICE|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
214542053|NCT04581252|DEVICE|Non-invasive cardiac system|Non-invasive cardiac system
214542054|NCT05343208|DIAGNOSTIC_TEST|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
214542055|NCT04848376|DEVICE|(1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L|As long as there are patients using the above device, conduct questionnaire interview.
214542056|NCT01473615|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
214697963|NCT01367301|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
214697964|NCT01367301|RADIATION|brachytherapy|Undergo HDR brachytherapy
214697965|NCT01367301|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
215158477|NCT04073979|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
215158478|NCT03062540|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
215158479|NCT03062540|DRUG|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
214697966|NCT01367301|OTHER|laboratory biomarker analysis|Correlative studies
214697967|NCT06296433|OTHER|VR rehabilitation|VR software application containing education, exergames, therapeutic exercises and relaxation sections.
214697968|NCT06296433|OTHER|VR video application|VR software application that plays 2D nature videos
214697969|NCT01628094|DRUG|RO5024048|
214697970|NCT01628094|DRUG|RO5190591|
214697971|NCT01628094|DRUG|RO5466731|
214697972|NCT01628094|DRUG|ribavirin [Copegus]|
214697973|NCT01628094|DRUG|ritonavir|
214697974|NCT02504268|DRUG|Abatacept|
214697975|NCT02504268|DRUG|Methotrexate|
214542057|NCT01140282|OTHER|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
214542058|NCT01140282|PROCEDURE|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
214542059|NCT01140282|PROCEDURE|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
214542060|NCT01140282|BEHAVIORAL|exercise intervention|12 week exercise intervention
214542061|NCT06402214|OTHER|Lombard test|In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
214542062|NCT03499262|BEHAVIORAL|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
214542063|NCT03962322|OTHER|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
214542064|NCT04120142|OTHER|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
214542065|NCT04120142|OTHER|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
214542066|NCT04115852|BEHAVIORAL|fmri|functional magnetic resonance imaging
214542067|NCT00718471|DRUG|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
214542068|NCT00718471|DRUG|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
214542069|NCT04919733|DEVICE|Fluoroscopy reduction|To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
214542070|NCT05655455|BEHAVIORAL|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
214542071|NCT05655455|BEHAVIORAL|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
214542072|NCT00869271|PROCEDURE|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
214542073|NCT00869271|PROCEDURE|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
214697976|NCT02504268|OTHER|Abatacept Placebo|
214697977|NCT02504268|OTHER|Methotrexate Placebo|
214697978|NCT03957655|BIOLOGICAL|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
214697979|NCT05126706|BEHAVIORAL|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
214697980|NCT06070116|DRUG|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
214697981|NCT06070116|DRUG|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
214697982|NCT06070116|DRUG|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
214697983|NCT06070116|DRUG|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
214697984|NCT00229164|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|
215029456|NCT06638697|OTHER|Multicomponent gymnastics|The Multicomponent Gymnastics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
214542074|NCT02584036|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
214542075|NCT02584036|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
214542076|NCT02584036|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
214542077|NCT01719588|DRUG|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
214542078|NCT06263439|DIAGNOSTIC_TEST|Throat/buccal swab sample|The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
214542079|NCT00179257|DRUG|sertraline (Zoloft)|
214542080|NCT00460668|BEHAVIORAL|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
214542081|NCT02572115|BEHAVIORAL|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
214542082|NCT02572115|BEHAVIORAL|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
214542083|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
214542084|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
215158480|NCT05070715|OTHER|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
215158481|NCT05844488|DEVICE|PrecivityAD|Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
215158482|NCT01897818|DEVICE|communication system P300 Speller|
215158483|NCT00004802|DRUG|dichlorphenamide|
214542085|NCT01069328|DRUG|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
214542086|NCT01069328|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenously
214542087|NCT01069328|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
214542088|NCT01069328|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenously
214542089|NCT01069328|DRUG|Paclitaxel|Paclitaxel 200 mg/m² intravenously
214542090|NCT01069328|DRUG|Carboplatin|Carboplatin AUC 6 intravenously
214542091|NCT04215315|OTHER|Retrospective observation|Case note and imaging review
214542092|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
214542093|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
214542094|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
214542095|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
214542096|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
214542097|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
214542098|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
214542099|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
214542100|NCT04470570|OTHER|Cross-Education|1\) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
214542101|NCT04470570|OTHER|Blood-Flow Restriction Training|1\) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
214542102|NCT03654768|DRUG|Bosutinib|Given PO
214542103|NCT03654768|DRUG|Dasatinib|Given PO
214542104|NCT03654768|OTHER|Laboratory Biomarker Analysis|Correlative studies
214542105|NCT03654768|DRUG|Nilotinib|Given PO
214542106|NCT03654768|DRUG|Ruxolitinib|Given PO
214542107|NCT03654768|DRUG|Imatinib|Given PO
214542108|NCT02844530|DRUG|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
214542109|NCT02844530|DRUG|chemotherapy/ immunotherapy|
214542110|NCT03065998|DRUG|Opipramol|PO
214542111|NCT03065998|DRUG|Baclofen|PO
214542112|NCT00001509|DRUG|IFN-alpha with retinoic acid|
214542113|NCT02669615|DRUG|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
214542114|NCT02867098|DRUG|XmAb5871|
214542115|NCT01492621|DRUG|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
214542116|NCT01880437|DRUG|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
214542117|NCT01880437|DRUG|vismodegib|Cohorts 1 and 2: 150 mg orally daily
214542118|NCT04454099|DIAGNOSTIC_TEST|4 kind of FOBT and colonoscopy with pathological examination|Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
215158484|NCT01474252|DRUG|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
215158485|NCT01936441|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
215158486|NCT01936441|BEHAVIORAL|Menopause Education Control (MEC)|See Experimental Arm Description
214542119|NCT02801864|DEVICE|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
214542120|NCT02801864|DEVICE|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
214542121|NCT02801864|OTHER|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
214542122|NCT00823836|DRUG|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
214542123|NCT00823836|DRUG|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
214542124|NCT03713320|DRUG|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
214542125|NCT03713320|DRUG|Vorinostat|Daily doses of vorinostat throughout study treatment period
214542126|NCT04967183|DIAGNOSTIC_TEST|Annual FIT|"Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas)."
214542127|NCT04967183|PROCEDURE|Endoscopic surveillance.|First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
214542128|NCT04421339|DIETARY_SUPPLEMENT|Melatonin|Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
215158487|NCT03128125|OTHER|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
215158488|NCT03128125|OTHER|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
215158489|NCT03128125|OTHER|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
215158490|NCT05062499|DEVICE|Active TENS|electrical stimulation
215158491|NCT05062499|DEVICE|Sham TENS|no stimulation
215158492|NCT03052400|DRUG|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
215158493|NCT03052400|DRUG|Placebo|Matching placebo
215158494|NCT00555061|DRUG|Retapamulin Ointment, 1%|1% Ointment
215158495|NCT01873534|DRUG|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
215158496|NCT03929380|OTHER|Squat protocol|60% of 1RM weight for 100 squat reps
215158497|NCT02309905|DEVICE|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
215158498|NCT03548181|BEHAVIORAL|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
215158499|NCT00951613|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
215158500|NCT02527603|PROCEDURE|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
215158501|NCT02527603|PROCEDURE|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
215158502|NCT02527603|DRUG|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
215158503|NCT03291964|DIAGNOSTIC_TEST|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
214542129|NCT04421339|OTHER|Placebo|Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
214542130|NCT02109666|DRUG|Abatacept|
214542131|NCT02271230|DRUG|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
214542132|NCT02271230|DIETARY_SUPPLEMENT|Fish oil (EPA/DHA) alone|1 g/d fish oil
214542133|NCT02271230|DRUG|Vitamin D alone|2000 IU vitamin D
214542134|NCT02271230|OTHER|Placebo|Vitamin D placebo and fish oil placebo
214542135|NCT00530998|PROCEDURE|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
214542136|NCT00530998|PROCEDURE|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
214542137|NCT00503503|DRUG|Enbrel (etanercept)|
214542138|NCT04065126|BEHAVIORAL|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
214542139|NCT04065126|BEHAVIORAL|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
214542140|NCT01551069|DRUG|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
214542141|NCT01551069|DRUG|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
214542142|NCT05513183|PROCEDURE|Intraoperative blood and peritoneal fluid samplings during HIPEC|"\- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
214542143|NCT02168322|DEVICE|collagen membrane|bovine collagen membrane used for selective tissue regeneration
214542144|NCT02168322|DEVICE|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
214542145|NCT04022577|BEHAVIORAL|Adherence Therapy|Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
214542146|NCT04022577|BEHAVIORAL|control group|The control group received routine care
214542147|NCT00004922|DRUG|irinotecan hydrochloride|
214542148|NCT06102564|BEHAVIORAL|Group schematherapy|Brief group schematherapy for mothers with young children (age 0-5) focused on attachment relations between mother and child
214542149|NCT00066846|BIOLOGICAL|bevacizumab|
214542150|NCT00066846|DRUG|fluorouracil|
214542151|NCT00066846|DRUG|leucovorin calcium|
214542152|NCT03874936|DRUG|Dexamethasone 24mg Solution for Injection|Administrated i.v.
214542153|NCT03874936|DRUG|Saline Solution for Injection|administrated i.v.
214542154|NCT02121327|OTHER|disease management|disease management program include self management education
214542155|NCT02121327|OTHER|usual care|usual care group receive regular outpatient treatment
215158504|NCT05145218|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
215158505|NCT05145218|DRUG|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
215158506|NCT05145218|DRUG|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
215158507|NCT05776095|PROCEDURE|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
215158508|NCT05776095|DEVICE|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
215158509|NCT00485134|BIOLOGICAL|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
214542156|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
214542157|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
214542158|NCT03537235|DEVICE|Libramed|
214542159|NCT03537235|DEVICE|Placebo|
214542160|NCT04354168|BEHAVIORAL|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
214542161|NCT03042299|DRUG|TAK-536|TAK-536 granules.
214542162|NCT03042299|DRUG|TAK-536|TAK-536 tablet.
214542163|NCT00607464|DEVICE|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
214542164|NCT01438840|DRUG|Avatrombopag|
214542165|NCT01438840|DRUG|Placebo|
214542166|NCT01438840|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
214542167|NCT01582373|BEHAVIORAL|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
214542168|NCT05401383|DEVICE|Lumevis (IIa class)|intake of Lumevis 30 minutes before EGDS
214542169|NCT03062345|OTHER|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
214542170|NCT03062345|OTHER|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
214542171|NCT02594410|DEVICE|stent|patients receiving renal artery stenting for renal artery atherosclerosis
214542172|NCT02594410|DRUG|Aspirine|100mg Qd
214542173|NCT02594410|DRUG|Clopidogrel|75mg Qd
214542174|NCT02594410|DRUG|Lercanidipine|10-20mg Qd
214542175|NCT03004586|DEVICE|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
214542176|NCT03004586|DEVICE|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
214542177|NCT03004586|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
214542178|NCT02942342|PROCEDURE|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
214542179|NCT02062645|DRUG|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
214542180|NCT02912754|DRUG|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
214542181|NCT02912754|DRUG|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
214542182|NCT02804399|DRUG|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
214542183|NCT02804399|DRUG|rifampin|600 mg QD from day 1 to day 12 in period 2.
214542184|NCT01362647|PROCEDURE|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
214542185|NCT01362647|PROCEDURE|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
214542186|NCT01372007|DRUG|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
214542187|NCT01372007|DRUG|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
214542188|NCT03763149|BIOLOGICAL|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
214542189|NCT05549947|DRUG|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
214542190|NCT05549947|DRUG|Placebo|Treatment group D：placebo
215158510|NCT00485134|BIOLOGICAL|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
214542191|NCT06148402|DRUG|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
214542192|NCT03553290|DEVICE|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
214542193|NCT03553290|PROCEDURE|Control|Mechanical debridement alone
214542194|NCT02297685|DEVICE|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
214542195|NCT02297685|DEVICE|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
214542196|NCT02297685|DEVICE|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
214542197|NCT03201237|OTHER|Action observation training|Each child observed a task video and then performed a task
214542198|NCT01774305|DRUG|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
214542199|NCT01774305|DRUG|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
214542200|NCT04797117|DIAGNOSTIC_TEST|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
214542201|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
214542202|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
214542203|NCT04211389|DRUG|ARQ-151 0.3% cream|ARQ-151 0.3% cream
214542204|NCT04211389|DRUG|ARQ-151 vehicle cream|ARQ-151 vehicle cream
214542205|NCT04627454|PROCEDURE|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
214542206|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid|
214542207|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid formulation|
214542208|NCT02209103|DIETARY_SUPPLEMENT|Identical looking placebo|
214542209|NCT02717182|OTHER|interviews|interviews
214542210|NCT03062696|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
214542211|NCT00692458|DRUG|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
215158511|NCT00485134|BIOLOGICAL|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
215158512|NCT00485134|OTHER|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
215158513|NCT00002213|DRUG|Abacavir sulfate|
215158514|NCT00002213|DRUG|Amprenavir|
215158515|NCT00002213|DRUG|Efavirenz|
215158516|NCT01780064|BEHAVIORAL|interviews with a psychologist|interviews with a psychologist
215158517|NCT01780064|BEHAVIORAL|Questionnaires|Questionnaires
215158518|NCT00473304|DEVICE|Johnson&Johnson Acuevue daily disposable lenses|
215158519|NCT03620864|OTHER|Motor Control Exercises|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
215158520|NCT03620864|OTHER|Motor Control Exercise Plus Neurodynamic Intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
215158521|NCT00970684|BIOLOGICAL|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
215158522|NCT00970684|DRUG|docetaxel|75 mg/m2 on day 1
215158523|NCT00970684|DRUG|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
215158524|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
215158525|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
215158526|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
215158527|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
214542212|NCT00692458|DRUG|Comparator: placebo|placebo; oral, once daily for approximately 60 months
214542213|NCT02001142|OTHER|Exercise|single session of exercise
214542214|NCT04246853|DEVICE|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
214542215|NCT00953316|OTHER|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
214542216|NCT00333190|DEVICE|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
214542217|NCT00484692|DRUG|sustained-release bupropion (Zyban(R))|
214542218|NCT00484692|BEHAVIORAL|Psychodynamic Model Training (R) = PDM(R)|
214542219|NCT05608031|OTHER|Pittsburgh sleep quality index (PSQI) scale|Pittsburgh Sleep Quality Index (PSQI) (6), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), was used to evaluate sleep quality over the last month.
214542220|NCT02394249|BEHAVIORAL|Physical activity regime|Information already included in arm descriptions
214542221|NCT03165578|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
214542222|NCT03165578|OTHER|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
214542223|NCT06540885|DRUG|Palonosetron (Group P)|Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia
215158528|NCT01146327|DRUG|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
215158529|NCT05432089|DRUG|Intranasal Oxytocin|24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
215158530|NCT03257319|DRUG|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
215158531|NCT03257319|DRUG|IV placebo|Patient in arm A will receive 1 to 6 injection
214542224|NCT06540885|DRUG|Granisetron (Group G)|Group G participants will receive IV Granisetron 1mg at the start of wound closure
214542225|NCT00840671|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
215158532|NCT03257319|DEVICE|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
215158533|NCT03257319|DRUG|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
214542226|NCT00840671|DRUG|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
215158534|NCT03777748|DEVICE|dental implants and stud attachments|
215158535|NCT01123551|DRUG|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
214542227|NCT00456378|DEVICE|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
214542228|NCT00456378|PROCEDURE|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
214542229|NCT01773876|DRUG|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
214542230|NCT01773876|DRUG|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
214542231|NCT02964546|OTHER|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
214542232|NCT01560195|DRUG|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
214542233|NCT01560195|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
214542234|NCT01560195|DRUG|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
214542235|NCT04009109|DRUG|Lenalidomide|Induction and Maintenance
214542236|NCT04009109|DRUG|Ixazomib|Induction and Only Maintenance Arm B
214542237|NCT04009109|DRUG|Daratumumab Injection|Induction and Only Maintenance Arm B
214542238|NCT04009109|DRUG|Dexamethasone|Induction and Only Maintenance Arm B
214542239|NCT02357264|DEVICE|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
214542240|NCT05528263|DEVICE|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
214542241|NCT05528263|OTHER|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
214542242|NCT03623373|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
214542243|NCT03623373|DRUG|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m\^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
214542244|NCT03623373|DRUG|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
214542245|NCT03623373|DRUG|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
214542246|NCT03623373|PROCEDURE|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
214542247|NCT03623373|PROCEDURE|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
214542248|NCT03623373|PROCEDURE|Oral rinse|-Baseline
214542249|NCT03623373|PROCEDURE|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
214542250|NCT00020709|DRUG|cisplatin|Given IV
214542251|NCT00020709|DRUG|docetaxel|Given IV
214542252|NCT00020709|DRUG|etoposide|Given IV
214542253|NCT00020709|DRUG|gefitinib|Given orally
214542254|NCT00020709|RADIATION|radiation therapy|Undergo radiation therapy
214542255|NCT00020709|OTHER|placebo|Given orally
214542256|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
215158536|NCT01123551|DRUG|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
214542257|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
214542258|NCT00087555|DRUG|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
214542259|NCT04797520|DEVICE|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
214542260|NCT04797520|DEVICE|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
215158537|NCT03030976|DRUG|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
215158538|NCT03030976|DRUG|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6\~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
214542261|NCT02856061|BEHAVIORAL|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
214542262|NCT05833776|PROCEDURE|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
214542263|NCT05226988|DEVICE|robot-assisted|Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
214542264|NCT05226988|DEVICE|Conventional rehabilitation intervention|Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
214542265|NCT00193596|DRUG|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
214542266|NCT00193596|DRUG|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
214542267|NCT00193596|DRUG|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
214542268|NCT00193596|DRUG|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
214542269|NCT00193596|DRUG|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
214542270|NCT03168399|DIETARY_SUPPLEMENT|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
214542271|NCT00620633|BIOLOGICAL|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
214542272|NCT05551936|DRUG|Bendamustine|90 mg/m\^2 IV Days 1-2, Cycles 1-3
214542273|NCT05551936|DRUG|Rituximab|375 mg/m\^2 IV Day 1 Cycles 1-6
214542274|NCT05551936|DRUG|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
214542275|NCT01062971|DRUG|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
214542276|NCT04823364|OTHER|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
214542277|NCT01759238|DRUG|Capecitabine|825mg/m2 per os bid
214542278|NCT01759238|DRUG|Bevacizumab|7.5 mg/kg
214542279|NCT01759238|RADIATION|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
214542280|NCT00230945|BEHAVIORAL|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
214542281|NCT00641836|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
214542282|NCT04882189|DIAGNOSTIC_TEST|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
214542283|NCT01949883|DRUG|CPI-0610|
214542284|NCT02261285|DRUG|ONO-4538|
214542285|NCT02760485|DRUG|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
214542286|NCT02760485|DRUG|ibrutinib|
214542287|NCT03880825|DRUG|Metformin 500 mg Oral Tablet|single dose
214542288|NCT03880825|DRUG|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
214542289|NCT02702336|BEHAVIORAL|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
214542290|NCT01182207|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
214542291|NCT01182207|DRUG|YAZ®|3 mg/0.02 mg Tablets
214542292|NCT01087814|DRUG|Efavirenz|Subject will take efavirenz for 5 days.
215158539|NCT05631483|DEVICE|DAISe|Use of the DAISe Thrombectomy Device
214542293|NCT01087814|DRUG|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
214542294|NCT02050698|PROCEDURE|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
215158540|NCT02888678|BEHAVIORAL|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
214542295|NCT02050698|PROCEDURE|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
215158541|NCT02888678|BEHAVIORAL|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
215158542|NCT03574012|DEVICE|Monitoring Device|Use Fitbit tracker
215158543|NCT03574012|OTHER|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
215158544|NCT03574012|OTHER|Informational Intervention|Receive general health and fitness information from clinician
215158545|NCT03574012|OTHER|Questionnaire Administration|Ancillary studies
214542296|NCT05685953|BIOLOGICAL|DNA vaccine OC-007|Plasmid DNA vaccine
214542297|NCT05685953|OTHER|Placebo|0.9% NaCl solution
214542298|NCT04842526|DRUG|Anlotinib and irinotecan combined with temozolomide|Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
214542299|NCT04201704|OTHER|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
214542300|NCT04201704|OTHER|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
214542301|NCT04201704|OTHER|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
214542302|NCT04201704|OTHER|Platelets volume|For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
214542303|NCT04089839|OTHER|Non-Interventional|Non-Interventional
214542304|NCT01161628|DRUG|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
214542305|NCT03436550|PROCEDURE|mpMRI|Multiparametric MRI
214542306|NCT03436550|PROCEDURE|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
214542307|NCT06183671|DRUG|JX09 or placebo SAD|For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
214542308|NCT06183671|DRUG|JX09 or placebo MAD|For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
214542309|NCT06183671|DRUG|JX09|For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
214542310|NCT06413017|DRUG|Nimotuzumab|Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
214542311|NCT06413017|DRUG|ICIs(Immune checkpoint inhibitors)|Use it as it is describe in the instructions from the specification
214542312|NCT04103502|DEVICE|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
214542313|NCT04103502|DEVICE|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
214542314|NCT00571337|DRUG|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
214542315|NCT05832619|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
214542316|NCT05832619|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
214542317|NCT05832619|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
214542318|NCT02778906|DRUG|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
214542319|NCT02778906|DRUG|Placebo|Administration of the comparator s.c. weekly in comparable to verum
214542320|NCT01589549|BIOLOGICAL|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
214542321|NCT04363710|OTHER|Low Calorie Diet|800-1000 Kcal/day
214542322|NCT04641117|OTHER|Exercise|Walking and Power Training
214542323|NCT06360952|DEVICE|Tasso+ CBC|Novel blood collection device
215158546|NCT00481091|DRUG|ABT-263|Tablet; Oral
215158547|NCT00006119|DRUG|hydroxyurea|
214542324|NCT01232400|DRUG|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached."
214542325|NCT00865137|DRUG|Tacrolimus, modified release|Oral
214542326|NCT00321490|DRUG|Quetiapine fumarate|
214542327|NCT00321490|DRUG|Duloxetine|
214542328|NCT02240797|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
214542329|NCT03906604|PROCEDURE|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
214542330|NCT02915562|OTHER|exercise|
214542331|NCT00523952|DRUG|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
214542332|NCT03482947|DRUG|ultrasonography-guided TAP block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
214542333|NCT03482947|DRUG|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
214542334|NCT04629937|OTHER|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
215158548|NCT05198440|DEVICE|non-invasive neuromodulation|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
215158549|NCT05198440|DEVICE|electroencephalography|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
215158550|NCT05198440|DEVICE|anatomical MRI|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
215158551|NCT03975244|BEHAVIORAL|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
215158552|NCT04294680|DEVICE|Cryotherapy|see opiate sparing description
215158553|NCT01453985|PROCEDURE|Full-Thickness-Gastroplication|
215158554|NCT01296672|DRUG|Finasteride|Finasteride 5mg every day by mouth for 3 months
215158555|NCT01296672|DRUG|Placebo|Placebo every day by mouth for 3 months
215158556|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
215158557|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
215158558|NCT06230237|BEHAVIORAL|Smiling is fun + professional support|"Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.~While they do the online program, they will receive periodically professional support. The professional support will be contacts of 20 minutes long, will take place every two weeks and will last 3 months."
215158559|NCT06230237|BEHAVIORAL|Smiling is fun|Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.
214542335|NCT02081937|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|
214542336|NCT00302926|PROCEDURE|energy restriction and maintenance|
214542337|NCT01977027|OTHER|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
214542338|NCT04459221|DRUG|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
214542339|NCT00080522|BEHAVIORAL|Monitoring by HIV-trained primary care nurses|
214542340|NCT00080522|BEHAVIORAL|Community-based directly observed therapy (DOT)|
214542341|NCT00080522|DRUG|stavudine|
214542342|NCT00080522|DRUG|lamivudine|
214542343|NCT00080522|DRUG|efavirenz|
214542344|NCT00080522|DRUG|zidovudine|
214542345|NCT00080522|DRUG|didanosine|
214542346|NCT00080522|DRUG|lopinavir/ritonavir|
214542347|NCT03339947|OTHER|Questionnaire|
214542348|NCT02391077|OTHER|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
214708930|NCT06605430|DRUG|Medical Cannabis|The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.
215158560|NCT04027608|OTHER|Reinforcing value of HED and LED foods in response to snack food monotony|Each child will be asked to eat two different snack foods over the course of two weeks each. The RRV of that food (vs alternative reinforcer) will be tested and baseline and post exposure. Increases in RRv for food after monotony will be considered sensitization to that food. All children will be followed to observe weight change over time for 2 years each.
215158561|NCT06208475|OTHER|Resistance exercise|Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
215158562|NCT03176537|DRUG|Testosterone gel|Androgel (50mg testosterone), gel, daily
215158563|NCT03176537|DRUG|Placebos|Placebo, gel, daily
215158564|NCT02592057|DRUG|SOF|SOF tablets administered orally once daily based on approved prescribing information
215158565|NCT02453347|DEVICE|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
215158566|NCT00613275|OTHER|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
215158567|NCT00201513|BEHAVIORAL|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
215158568|NCT00201513|BEHAVIORAL|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
215158569|NCT00201513|BEHAVIORAL|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
215158570|NCT00986011|OTHER|questionnaire administration|
215158571|NCT00986011|OTHER|study of socioeconomic and demographic variables|
215158572|NCT00986011|OTHER|survey administration|
215158573|NCT00986011|PROCEDURE|study of high risk factors|
215158574|NCT00207285|BEHAVIORAL|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
215158575|NCT00207285|PROCEDURE|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
215158576|NCT01386970|DRUG|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
215158577|NCT04330313|PROCEDURE|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
215158578|NCT04330313|PROCEDURE|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
214542349|NCT02391077|OTHER|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
214542350|NCT02391077|OTHER|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
214542351|NCT01463228|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
215158579|NCT04330313|PROCEDURE|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
215158580|NCT04330313|PROCEDURE|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
215158581|NCT04881942|OTHER|e-Vapor Product A|e-Vapor product XL25F
215158582|NCT04881942|OTHER|e-Vapor Product B|e-Vapor product XL40CB
215158583|NCT04881942|OTHER|e-Vapor Product C|e-Vapor product XL35WM
215158584|NCT04881942|OTHER|e-Vapor Product D|e-Vapor product XL40MB
215158585|NCT01049542|DRUG|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
215158586|NCT01224951|DRUG|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
215158587|NCT02939807|DRUG|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
215158588|NCT00097656|OTHER|multi-center, randomized, controled periodontal therapy|periodontal therapy
215158589|NCT06395467|BEHAVIORAL|InTEGRA|"Session topics are as follows: Parent Info Session - Informational and Q\&A format; Motivation Building- Addressing AA/NA Expectancies and Experiences; AA/NA Expectancies and Treatment Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management (AA/NA and Hungry, Angry, Lonely, Tired HALT; Effective Communication (Sharing at AA/NA meetings; getting a sponsor); Depression Management; Using AA/NA for enhancing Social Support and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse"
215158590|NCT06395467|BEHAVIORAL|MET/CBT|Session topics are as follows: Motivation Building Session; Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management; Effective Communication; Depression Management; Enhancing the Social Support Network and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse
215158591|NCT04230252|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
215158592|NCT05227170|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
215158593|NCT05227170|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
214542352|NCT01463228|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
214542353|NCT03226301|DRUG|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
214542354|NCT03226301|DRUG|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
214542355|NCT03226301|DRUG|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
214542356|NCT00715117|DRUG|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
214542357|NCT00715117|OTHER|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
214542358|NCT04966559|DRUG|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
214542359|NCT04966559|DRUG|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
214542360|NCT03954288|DIAGNOSTIC_TEST|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
215158594|NCT05741164|PROCEDURE|Biopsy|Undergo tumor biopsy
215158595|NCT05741164|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214542361|NCT01652859|DRUG|Liposomal Amphotericin B|
214542362|NCT01652859|DRUG|AmBisome|
214542363|NCT06546059|DEVICE|narrow band ultraviolet-B|vitiligo patients will recevie twice sessions per week
214542364|NCT04292080|DRUG|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
214542365|NCT04292080|OTHER|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
215158596|NCT05741164|PROCEDURE|Computed Tomography|Undergo CT scan
215158597|NCT05741164|BIOLOGICAL|Pembrolizumab|Given IV
215158598|NCT05741164|DRUG|Propranolol|Given PO
215158599|NCT05741164|OTHER|Questionnaire Administration|Ancillary studies
215158600|NCT02905851|OTHER|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
215158601|NCT02905851|OTHER|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
214542366|NCT05028036|OTHER|Personalized lifestyle treatment program|"The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program."
214542367|NCT01338376|BEHAVIORAL|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration"
215158602|NCT02333617|OTHER|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
215158603|NCT02333617|OTHER|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
215158604|NCT02333617|OTHER|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
215158605|NCT02333617|OTHER|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
215158606|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
215158607|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
215158608|NCT03828201|DRUG|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
214542368|NCT01338376|BEHAVIORAL|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration"
214542369|NCT01338376|DRUG|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
214542370|NCT02332200|OTHER|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
214542371|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
214542372|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (monthly)|
214542373|NCT00471172|BEHAVIORAL|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
214542374|NCT00471172|BEHAVIORAL|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
214542375|NCT00471172|BEHAVIORAL|Self help|
214542376|NCT01454388|OTHER|breakfast|
214542377|NCT00169845|DIETARY_SUPPLEMENT|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
214542378|NCT00169845|DIETARY_SUPPLEMENT|Placebo|Provided by Roche Vitamins Inc
214542379|NCT00176059|DRUG|intravenous immunoglobulins (IVIG)|
214542380|NCT00176059|PROCEDURE|kidney transplantation|
214542381|NCT01482429|OTHER|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
214542382|NCT03747809|DEVICE|CIEDs Remote Monitoring System|Cardiac device remote monitoring system
214708931|NCT05119088|OTHER|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
214708932|NCT01267604|DRUG|Recombinant FSH (rFSH)|225IU
215158609|NCT03828201|DRUG|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
215158610|NCT03828201|DRUG|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
215158611|NCT03828201|DRUG|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
215158612|NCT03828201|DRUG|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
215158613|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
215158614|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
215158615|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
215158616|NCT01349959|DRUG|Azacitidine|Given SC
215158617|NCT01349959|DRUG|Entinostat|Given PO
215158618|NCT01349959|OTHER|Laboratory Biomarker Analysis|Correlative studies
215158619|NCT01349959|OTHER|Pharmacological Study|Correlative studies
214542383|NCT02759796|PROCEDURE|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
214542384|NCT02759796|PROCEDURE|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
214542385|NCT05032846|PROCEDURE|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
214542386|NCT05032846|OTHER|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
214542387|NCT04567810|DRUG|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
214542388|NCT04567810|DRUG|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
214542389|NCT04286763|DIAGNOSTIC_TEST|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
214542390|NCT02311088|DRUG|Caffeine|
214542391|NCT02311088|DRUG|Placebo|
214542392|NCT05819047|DEVICE|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
214542393|NCT05739539|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
214542394|NCT05739539|DIAGNOSTIC_TEST|spectral domain optical coherence tomography|optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
214542395|NCT00503607|DRUG|BLI-800|
215158620|NCT02675634|DEVICE|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
215158621|NCT02675634|DEVICE|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
215158622|NCT02675634|DEVICE|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
215158623|NCT01652534|DRUG|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
215158624|NCT01652534|DRUG|Placebo|Sugar Pill
215158625|NCT03965481|RADIATION|Dynamic Enhanced CT|Undergo standard CECT
215158626|NCT03965481|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI scan
215158627|NCT03965481|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI scan
215158628|NCT00261820|DRUG|tacrolimus|
214542396|NCT00503607|DRUG|Polyethylene glycol 3350 based bowel preparation|
214542397|NCT00250978|DRUG|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
214542398|NCT01458847|DRUG|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
214697985|NCT03475576|OTHER|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
214542399|NCT01458847|DRUG|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
214697986|NCT04677621|OTHER|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
214697987|NCT04677621|OTHER|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
214697988|NCT05075967|OTHER|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks \[BTAN\]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
214697989|NCT05075967|BEHAVIORAL|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~* HIV/sexually transmitted infections (STI) testing promotion~* PrEP (and general HIV prevention) awareness and promotion~* Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
214542400|NCT01458847|DRUG|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
214697990|NCT05075967|BEHAVIORAL|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
214708933|NCT01267604|DIETARY_SUPPLEMENT|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
214708934|NCT01668381|PROCEDURE|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
214708935|NCT05386472|DRUG|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
214708936|NCT05386472|DRUG|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
214542401|NCT05563090|OTHER|Questionnaires+Tongue diagnosis+Pulse diagnosis|Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
214542402|NCT02399397|PROCEDURE|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
215158629|NCT00261820|DRUG|mycophenolate mofetil|
215158630|NCT00261820|DRUG|methylprednisolone|
215158631|NCT00261820|DRUG|prednisolone|
215158632|NCT00261820|DRUG|sirolimus|
214542403|NCT02399397|PROCEDURE|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
214542404|NCT02399397|PROCEDURE|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
214542405|NCT02399397|DRUG|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
214542406|NCT02399397|PROCEDURE|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
215158633|NCT01085994|OTHER|Literature search|Literature search followed by systematic review and meta-analysis
215158634|NCT00731302|DRUG|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
214542407|NCT06394609|OTHER|double loaded knotted suture anchor|arthroscopic bankart repair by using double loaded knotted suture anchor
214542408|NCT06394609|OTHER|double grand knot|arthroscopic bankart repair by using double grand knot
214542409|NCT00383409|DRUG|multivitamins|
214542410|NCT00383409|DRUG|placebo|
215158635|NCT02663401|BEHAVIORAL|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
215158636|NCT03082625|DRUG|Transdermal Magnesium|Magnesium
215158637|NCT03082625|DRUG|Placebo|
215158638|NCT05997303|OTHER|Continuous norepinephrine infusion via an infusion pump|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
215158639|NCT05997303|OTHER|Manual bolus norepinephrine administration|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
215158640|NCT04140513|RADIATION|Fludeoxyglucose F-18|Given via injection
215158641|NCT04140513|PROCEDURE|Positron Emission Tomography|Undergo dPET
215158642|NCT03067714|OTHER|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
215158643|NCT03067714|OTHER|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
215158644|NCT00905801|OTHER|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
215158645|NCT00201188|BEHAVIORAL|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
215158646|NCT05163626|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
215158647|NCT02757716|OTHER|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
214542411|NCT05079594|OTHER|Mother voice|"Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale."
214542412|NCT05079594|OTHER|White noise|"Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed."
214542413|NCT05714423|PROCEDURE|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
214542414|NCT05714423|PROCEDURE|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
214542415|NCT05176691|DRUG|HMPL-760|Administered orally QD for 28-day cycles
214542416|NCT05376371|OTHER|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
214542417|NCT04680637|DRUG|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
214542418|NCT04680637|DRUG|Placebo|Administered as a subcutaneous (SC) injection.
215158648|NCT02328638|BEHAVIORAL|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
215158649|NCT02328638|BEHAVIORAL|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
215158650|NCT03860259|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
215158651|NCT03860259|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
215158652|NCT05482100|DIAGNOSTIC_TEST|Patients monitored with OmniGraf testing|This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
215158653|NCT05512156|OTHER|Supervised Toothbrushing|"* Recruitment, consent, and Questionnaires (Behaviors, Quality of Live, Cost Analysis) distribution.~* Inclusion \& Exclusion Criteria Applied~* Baseline Dental examination~* Toothbrushes \& Toothpastes Home and school use packs delivery-Colgate (six pack per child a year- child soft toothbrush with a1450ppm fluoridated toothpaste))~* Supervised teachers training~* Three months intervals monitoring visits~* 12months Follow up and Questionnaires (Behaviours) distribution~* Endpoint dental Examination and Questionnaires (Behaviours, Quality of Live, Cost Analysis) distribution"
215158654|NCT00811018|DRUG|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
215158655|NCT03792906|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
215158656|NCT03792906|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
215158657|NCT03792906|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
215158658|NCT03792906|DRUG|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
215158659|NCT04420104|PROCEDURE|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
215158660|NCT04420104|DRUG|iv analgesia|iv contromal
214542419|NCT04680637|OTHER|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
214542420|NCT03477825|DIETARY_SUPPLEMENT|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
214542421|NCT03477825|DIETARY_SUPPLEMENT|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
214542422|NCT03477825|DIETARY_SUPPLEMENT|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
214542423|NCT03277560|OTHER|No Intervention as it is an observational study|No Intervention as it is an observational study
214542424|NCT01822145|DEVICE|ICD|
214542425|NCT02037256|DRUG|bortezomib|Given IV
214542426|NCT02037256|BIOLOGICAL|filgrastim|Given SC
214542427|NCT02037256|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
214542428|NCT05250960|DEVICE|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
214542429|NCT00951678|OTHER|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
214542430|NCT04544592|DRUG|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF-19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
214708937|NCT02317341|DRUG|Ketamine|Single intravenous dose
214708938|NCT02317341|DRUG|Placebo (saline)|Given intravenously over 40 minutes
214708939|NCT02317341|DRUG|Ketamine|Single intravenous dose given over 40 minutes
215158661|NCT00162019|DRUG|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
215158662|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
215158663|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
215158664|NCT04978298|OTHER|Placebo|Placebo
215158665|NCT04978298|DRUG|Rasigiline|Rasigiline
214708940|NCT02317341|DRUG|Midazolam|Given intravenously over 40 minutes
215158666|NCT04978298|DRUG|Phenelzine|Phenelzine
215158667|NCT04978298|DRUG|Ozanimod|Ozanimod
215158668|NCT04495920|DRUG|CGB-S-100|Alcohol and choline geranate
215158669|NCT00272532|DRUG|Thiocolchicoside|
215158670|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
214542431|NCT06187064|OTHER|Mobile Van Clinic|The investigators will implement a pilot clinic one evening per week, with the primary goal of measuring a community-based extension of SHE Clinic's impact on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). The clinic will be dispatched with a driver, nurse, physician, and research assistant. The van clinic will be outfitted with space to obtain a confidential history and physical exam and include a space for sample collection. In addition to standard of care, the investigators will provide participants with rapid point-of-care HIV and STI testing, and HIV PrEP and MOUD counseling and prescriptions.
214542432|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
214542433|NCT01547221|DRUG|clotrimazole|single application of 1%clotrimazole ear drop
214542434|NCT01547221|DRUG|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
214542435|NCT05834023|DRUG|Bupivacaine-Lidocaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
214542436|NCT05834023|DRUG|Bupivacaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
214542437|NCT04055259|BEHAVIORAL|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
214542438|NCT04055259|BEHAVIORAL|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
214542439|NCT02336256|PROCEDURE|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
214542440|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
214542441|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
214542442|NCT06782217|BIOLOGICAL|VENOX|Treatment with allergy vaccine againts Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
214542443|NCT04360785|DRUG|Methotrexate|Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
214542444|NCT00930956|DIETARY_SUPPLEMENT|Resistant Starch|30 g of carbohydrate per Arm
214542445|NCT05258591|DEVICE|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
214542446|NCT05068947|DRUG|GV101|GV101 administered once orally.
214542447|NCT05068947|DRUG|Placebo|Matched placebo
214542448|NCT03700905|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
214542449|NCT03700905|RADIATION|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
214542450|NCT03700905|DRUG|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
214542451|NCT03700905|DRUG|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
214542452|NCT03700905|DRUG|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
214542453|NCT02444780|PROCEDURE|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
214542454|NCT03755973|DRUG|CFA|Long-acting exogenous ovarian stimulation
214542455|NCT03755973|DRUG|rFSH|Daily rFSH
214542456|NCT03755973|PROCEDURE|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
214542457|NCT03755973|PROCEDURE|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
214542458|NCT00497874|BEHAVIORAL|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
214542459|NCT03020953|OTHER|Exercise + Estrogen|12 weeks resistance training and estrogen patches
214542460|NCT03020953|OTHER|Exercise + Placebo|12 weeks resistance training and placebo patches
214542461|NCT05475847|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
214542462|NCT00014287|DRUG|gemcitabine hydrochloride|
214542463|NCT00548756|PROCEDURE|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
214542464|NCT00548756|OTHER|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
214542465|NCT00548756|BEHAVIORAL|Questionnaire|Questionnaire taking 40 minutes to complete.
214542466|NCT03061058|DRUG|Docetaxel|intraperitoneal and/or intravenous
214542467|NCT03061058|DRUG|Oxaliplatin|intravenous
214542468|NCT03061058|DRUG|Cisplatin|intraperitoneal
214542469|NCT03061058|DRUG|Irinotecan|intraperitoneal and/or intravenous
214542470|NCT03061058|DRUG|Pemetrexed|intraperitoneal and/or intravenous
214542471|NCT03061058|DRUG|S1|oral
214542472|NCT04486976|DEVICE|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
215158671|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
215158672|NCT01662609|PROCEDURE|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
214542473|NCT04486976|DEVICE|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
214542474|NCT02246881|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
214542475|NCT05175469|DIAGNOSTIC_TEST|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
214542476|NCT02295176|DIETARY_SUPPLEMENT|Armolipid Plus|
214542477|NCT02295176|DIETARY_SUPPLEMENT|Placebo|
214542478|NCT03718377|PROCEDURE|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
214542479|NCT03718377|PROCEDURE|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
214542480|NCT02185105|DEVICE|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
214542481|NCT02185105|DEVICE|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
214542482|NCT01789840|DEVICE|Embosphere Microspheres|
214542483|NCT01789840|PROCEDURE|TURP|
214542484|NCT00883974|BEHAVIORAL|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
214542485|NCT04154800|DRUG|BMS-986209|Specified Dose on Specified Days
214542486|NCT04154800|OTHER|BMS-986209 Placebo|Specified Dose on Specified Days
214542487|NCT04154800|DRUG|Itraconazole|Specified Dose on Specified Days
214542488|NCT04154800|DRUG|Diltiazem|Specified Dose on Specified Days
214542489|NCT02234947|PROCEDURE|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
214542490|NCT04843579|DRUG|Selinexor|Given as 60 mg oral capsule
214542491|NCT04843579|DRUG|Clarithromycin|Given as 500 mg oral capsule
214542492|NCT04843579|DRUG|Pomalidomide|Given as 4 mg oral capsule
214542493|NCT04843579|DRUG|Dexamethasone|Given as 40 mg oral capsule
214708941|NCT02317341|DRUG|Midazolam(placebo)|Given intravenously over 40 minutes
215158673|NCT00271453|DRUG|Durogesic® (fentanyl transdermal drug delivery system)|
214542494|NCT01755910|OTHER|Left thoracic paravertebral block|
214542495|NCT01755910|OTHER|Right thoracic paravertebral block|
214542496|NCT04587986|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
214542497|NCT04009629|BEHAVIORAL|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
214542498|NCT05879003|DEVICE|novel brace with neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on scapular muscles and adductor muscle
214542499|NCT05879003|BEHAVIORAL|scapular and adductor exercise|The symptomatic rotator cuff tear subjects conduct scapular and adductor exercise
214542500|NCT02825186|DRUG|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
214542501|NCT02825186|DRUG|Dexamethasone 0.1%|
214542502|NCT04398368|DRUG|Gemcitabine Hydrochloride|Given intravesically
214542503|NCT00004146|RADIATION|radiation therapy|Undergo radiotherapy
214542504|NCT00004146|DRUG|carboxyamidotriazole|Given orally
214542505|NCT00004146|OTHER|pharmacological study|Correlative studies
214542506|NCT02808975|DRUG|Placebo|Subcutaneous injections administered as described in arm description
214542507|NCT02808975|DRUG|Adalimumab|Subcutaneous injections administered as described in arm description
214542508|NCT01672138|PROCEDURE|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
214542509|NCT01672138|PROCEDURE|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
215158674|NCT01976091|GENETIC|SRP-9004|Isolated Limb Infusion (ILI)
215158675|NCT03042819|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
215158676|NCT03042819|DRUG|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
215158677|NCT01802996|DRUG|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
215158678|NCT04565639|DEVICE|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
215158679|NCT00934362|DRUG|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
215158680|NCT00934362|DRUG|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
214542510|NCT01672138|PROCEDURE|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
214542511|NCT02421549|DEVICE|Unpaired remote monitoring transmitter|
214542512|NCT06957704|DRUG|ketamine|Ketamine will be administered as adjunctive therapy at an initial dose of 0.5 mg/kg via subcutaneous injection, twice weekly for four weeks, under double-blind conditions. Dose adjustments between 0.5 and 1.0 mg/kg will be based on depressive symptoms, efficacy, and tolerability. All procedures will occur at the Ketamine Clinic of Federal University of São Paulo.
214542513|NCT06957704|DRUG|Midazolam|Midazolam will be administered subcutaneously twice weekly for four consecutive weeks, also under double-blind conditions. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
214542514|NCT06956729|PROCEDURE|Proximal Femoral Guided Growth.|"Proximal Femoral Guided Growth (PFGG) is performed under general anesthesia with the patient in a supine position on a radiolucent table. The surgical field is prepared from the abdomen to the feet. Anatomical landmarks on the femur and femoral neck are marked to guide the procedure.~A smooth guidewire (4.0-7.0 mm) is introduced parallel to the table and advanced to the lateral quarter of the femoral neck.~A 1-2 cm incision is made along the lateral femur, allowing access to the vastus lateralis muscle.~Fluoroscopic control is used to ensure precise guidewire placement in the proximal femoral epiphysis in both anteroposterior (AP) and lateral views.~The lateral cortex is drilled, and a fully threaded cannulated screw is inserted, ensuring at least three threads reach the epiphysis for effective growth modulation.~Final fluoroscopic verification is performed to confirm proper screw placement and rule out joint penetration. Continuous fluoroscopy is used if necessary.~The guidewire is r"
214542515|NCT06956729|PROCEDURE|Standard prophylactic treatment for Hips at Risk of Dislocation.|"Both groups will receive standard prophylactic treatment for HRD, which consists of soft tissue release procedures based on clinical indication and functional level (GMFCS classification):~Adductor Tenotomy - Percutaneous or open technique, depending on contracture severity.~Psoas Tenotomy - Intrapelvic approach for GMFCS levels I-III and IV (ambulatory). Lesser trochanter approach for GMFCS levels IV-V (non-ambulatory). Additional tenotomies may be performed as needed, targeting muscles contributing to hip displacement and contractures.~Botulinum toxin type A may be administered to specific muscle groups if clinically indicated.~Postoperative immobilization includes:~Hip abduction wedge Knee immobilizers in extension Ankle-foot orthoses (AFOs), based on individual patient needs~The goal of this intervention is to reduce spastic muscle imbalance, improve hip stability, and delay or prevent hip dislocation in children with spastic CP and HRD."
214542516|NCT06957301|PROCEDURE|Intrathecal Fentanyl Group (F)|Group fentanyl (F), an injection of bupivacaine 0.5% (3.5 ml) + fentanyl 0.5 ml (25 μg) will be administered intrathecally.
214542517|NCT06957301|PROCEDURE|intrathecal dexmedetomidine group(D)|Group dexmedetomidine( D), dexmedetomidine will be first diluted in normal saline to obtain a dose of 5 μg in 0.5 ml. Then, an injection of bupivacaine 0.5% (3.5 ml) + dexmedetomidine 0.5 ml (5 μg) will be administered intrathecally. Drug will be administered over 10 seconds (s) using 5 cc syringes with cephalad orientation of the spinal needle bevel.
214542518|NCT06956807|COMBINATION_PRODUCT|VB-C01 cellularised patch|surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure
214542519|NCT04996368|DRUG|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
214542520|NCT03602586|DRUG|Epacadostat|Given PO
214542521|NCT03602586|BIOLOGICAL|Pembrolizumab|Given IV
215158681|NCT05500404|DIAGNOSTIC_TEST|Ultrasound measurment of placental thickness|The maximum placental thickness in the lower uterine segment will obtained using trans-abdominal ultrasound scan. For the image to be deemed suitable, a midline sagittal section of the lower uterine segment (with the implanted placenta) and the cervical canal, with the intervening urinary bladder will be required (Bhide et al., 2019). The measurement will be performed by a researcher who will be blinded to the final diagnosis.
215158682|NCT02906176|DRUG|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
215158683|NCT02906176|DRUG|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
215158684|NCT00679796|PROCEDURE|Varicella (chickenpox) lesion sampling|
215158685|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
215158686|NCT00006205|DRUG|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
215158687|NCT00006205|DRUG|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
215158688|NCT00006205|DRUG|Placebo + cognitive behavioral therapy|placebo
215158689|NCT00006205|DRUG|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
215158690|NCT05910190|DRUG|Use of buprenorphine with FAO > 30 OME|Patients will receive buprenorphine with concurrent FAO \>30 OME and be assessed for withdrawal, pain, and other symptoms.
215158691|NCT05910190|BEHAVIORAL|CPM Rx application use|The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
214697991|NCT05075967|BEHAVIORAL|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~* HIV, PrEP, nPEP, other HIV prevention options and ART education~* Adherence to PrEP, ART and medical care~* HIV/STI testing~* New HIV diagnosis~* Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~* Self-care~* Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~* Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
214697992|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
214697993|NCT04141215|BIOLOGICAL|BIOBank bone paste|BIOBank bone paste (PPT322)
214697994|NCT04141215|BIOLOGICAL|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
214697995|NCT06230835|BEHAVIORAL|Intervention Group|Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
214697996|NCT00861861|DRUG|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
214697997|NCT00861861|DRUG|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
214697998|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
214697999|NCT05378607|BEHAVIORAL|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
214698000|NCT05378607|BEHAVIORAL|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
215029457|NCT06638697|OTHER|Water aerobics|The Water Aerobics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
215029458|NCT06638697|OTHER|Hydroposture|The Hydroposture training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
215029459|NCT06638697|OTHER|deep water walking|The deep water walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
215029460|NCT06638697|OTHER|Weight training|The weight training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
214542522|NCT03292445|PROCEDURE|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
215029461|NCT06638697|OTHER|Mat pilates|The MAt pilates program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
215030338|NCT05612945|OTHER|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
215158692|NCT02415478|OTHER|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
215158693|NCT03527732|DRUG|Albendazole|Monotherapy of albendazole (400 mg)
214698001|NCT05378607|BEHAVIORAL|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
214698002|NCT05378607|BEHAVIORAL|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
214698003|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
214698004|NCT05378607|BEHAVIORAL|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
214698005|NCT05378607|BEHAVIORAL|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
214698006|NCT05746884|PROCEDURE|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
214698007|NCT05746884|PROCEDURE|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
214698008|NCT04732819|BEHAVIORAL|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team."
214698009|NCT01318473|DEVICE|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
214698010|NCT00209170|BEHAVIORAL|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
214698011|NCT00209170|DRUG|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
214698012|NCT00209170|DRUG|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
214698013|NCT04010786|DRUG|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
214698014|NCT04010786|DRUG|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
214698015|NCT02352610|PROCEDURE|LRTI|
214698016|NCT02352610|DEVICE|Biotenodesis Screw|
214698017|NCT03097224|BEHAVIORAL|Prehabilitation|Four weeks of tele-supervised prehabilitation
214698018|NCT02108600|DRUG|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
214698019|NCT01175967|OTHER|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
214698020|NCT01175967|OTHER|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
214698021|NCT01175967|OTHER|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
214698022|NCT01175967|OTHER|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
214698023|NCT01389648|OTHER|Pre Operative|Pre operative chest physiotherapy treatment
215158694|NCT03527732|DRUG|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
215158695|NCT05241548|PROCEDURE|BMAC on PCL Scaffold|Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
215158696|NCT00509613|DRUG|Sorafenib|
215158697|NCT00509613|DRUG|Sirolimus|
215158698|NCT02280408|OTHER|Placebo|Normal saline placebo.
215158699|NCT02280408|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
215158700|NCT06134024|PROCEDURE|Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections|During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
214542523|NCT03292445|DRUG|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover \>10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
214542524|NCT02371720|BEHAVIORAL|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
214542525|NCT03372590|OTHER|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
214542526|NCT03372590|OTHER|Standard of care|Standard NICU care
214542527|NCT04721782|OTHER|smoking|to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
214542528|NCT02713971|DEVICE|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
214542529|NCT02713971|OTHER|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
214542530|NCT03819751|PROCEDURE|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
214542531|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
214542532|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
214542533|NCT01382498|DRUG|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
214542534|NCT01382498|DRUG|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
214542535|NCT03257098|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
214542536|NCT03691545|BEHAVIORAL|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
214542537|NCT03305887|DEVICE|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
214542538|NCT03305887|DEVICE|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
214542539|NCT03305887|DEVICE|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
214542540|NCT03305887|DEVICE|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
214542541|NCT05395364|BEHAVIORAL|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
214542542|NCT05276271|DIAGNOSTIC_TEST|the blood sample test results|Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.
214542543|NCT04427176|DEVICE|ARFC mask|Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
214542544|NCT00682227|BIOLOGICAL|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
214542545|NCT01459146|DRUG|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
214542546|NCT01459146|DRUG|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
214542547|NCT01459146|DRUG|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
214542548|NCT02646709|DRUG|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
214542549|NCT02646709|DRUG|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
214542550|NCT02646709|DRUG|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
214542551|NCT02646709|DRUG|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
214542552|NCT01347372|BEHAVIORAL|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
214542553|NCT06421077|DEVICE|transauricular auricular vagus nerve stimulation|transauricular auricular vagus nerve stimulation
214542554|NCT02166970|DEVICE|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
214542555|NCT06072040|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
214542556|NCT00848510|BIOLOGICAL|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
214542557|NCT01399762|DEVICE|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
214542558|NCT00891046|DRUG|Canakinumab|Canakinumab
214698024|NCT03150095|BEHAVIORAL|Health coaching|Patients will work with a health coach by telephone
214698025|NCT02506296|DRUG|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
214698026|NCT02506296|DEVICE|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
214698027|NCT02815241|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
215158701|NCT06134024|PROCEDURE|Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only|During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
215158702|NCT00629369|DEVICE|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
215158703|NCT04482452|PROCEDURE|Colonoscopy|Diagnostic colonoscopy will be performed
214542559|NCT02166476|DRUG|Meropenem-Vaborbactam|Meropenem-vaborbactam
214542560|NCT02166476|DRUG|Piperacillin-Tazobactam|Piperacillin-tazobactam
214542561|NCT02166476|DRUG|Levofloxacin|Levofloxacin
214542562|NCT02166476|DRUG|Saline|Saline
214542563|NCT00004060|DRUG|exatecan mesylate|
214542564|NCT05869695|OTHER|OSPRO-ROS Questionnaire|Completion of questionnaires
214542565|NCT05869695|OTHER|OSPRO-YF Questionnaire|Completion of questionnaires
214542566|NCT01076244|PROCEDURE|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
214542567|NCT05828758|DRUG|Amoxicillin|Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
214542568|NCT05828758|OTHER|Placebo|Distilled water 0.2 ml/kg by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
215158704|NCT01092117|DEVICE|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
215158705|NCT02827929|BEHAVIORAL|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
215158706|NCT01081964|DRUG|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
215158707|NCT01081964|DRUG|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
215158708|NCT01081964|DRUG|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
214542569|NCT02939846|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
214542570|NCT06956482|DRUG|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine for five days (day 1 to day 5) at a daily dose of 300mg/Kg
214542571|NCT06956482|DRUG|Prednisolone|prednisolone 40 mg/day for a total of 30 days
214542572|NCT06956482|DRUG|Placebo of N-acetylcysteine|Placebo of N-acetylcysteine for five days (day 1 to day 5)
214542573|NCT06956482|DRUG|Placebo of Prednisolone|Placebo of prednisolone for 30 additional days
214542574|NCT06956482|DRUG|Prednisolone|prednisolone (tapering dose) for 30 additional days
214542575|NCT04525599|BIOLOGICAL|ASP3772|Intramuscular (IM) injection
214542576|NCT04525599|BIOLOGICAL|PCV13|Intramuscular injection
214542577|NCT01808131|DRUG|Lesinurad|Tablets, 200 mg QD
214698028|NCT04032171|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
214698029|NCT04032171|DRUG|Avonex®|Participants received avonex® IM injection once a week.
214698030|NCT04032171|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
214698031|NCT04032171|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
214698032|NCT02124707|DRUG|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
214542578|NCT01808131|DRUG|Lesinurad|Tablets, 400 mg QD
214542579|NCT05337098|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
214542580|NCT02034019|DRUG|Dexamethasone|
214542581|NCT02034019|DRUG|Punctum Plug|
214542582|NCT05833841|DIAGNOSTIC_TEST|Surface Electromyography and Video fluoroscopy|Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
214542583|NCT04523207|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
214542584|NCT04523207|DRUG|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
214542585|NCT04523207|DRUG|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
214542586|NCT05262010|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
214542587|NCT05262010|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
214542588|NCT06956976|PROCEDURE|Dissection of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), and dissecting the lymph nodes at the root of the inferior mesenteric artery (IMA).
214542589|NCT06956976|PROCEDURE|Preservation of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), but preserving the lymph nodes at the root of the inferior mesenteric artery (IMA).
214542590|NCT06956274|OTHER|Preoperative Telehealth|Conduct a preoperative telehealth consultation with a Certified Wound, Ostomy, and Continence Nurse (WOCN) to provide patient education on post-surgical care expectations.
214542591|NCT06956274|OTHER|Measure Ostomy Output|Patients will be sent home with a measuring container (graduated container) and will measure their ostomy output every 12 hours and record it in a pad that will be provided to them.
215158709|NCT03072004|DEVICE|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
215158710|NCT03072004|DEVICE|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
214542592|NCT06954194|BEHAVIORAL|Explicit intervention (Shape Coding+syntactic priming)|For explicit intervention, a syntactic priming task will be preceded by explicit teaching of the target structure using the Shape Coding scheme adapted to be age- and language (Cantonese)-appropriate. A different set of 10 sentences will be used for teaching in each explicit intervention session, with five sentences used as exemplars for the experimenter to explain the target structure, and the remaining five sentences for children to practice. The syntactic priming session will be presented as a game to sustain the children's interest and to disguise the purpose of the study. Each intervention session will contain 40 pairs of prime-target pictures, 40 pairs of control-target pictures, and 20 pairs of filler pictures, randomly presented to the experimenter and child and controlled by the experimenter. In total, there are 500 doses of SRC-O sentences (50 sentences x10 sessions).
214542593|NCT06954194|BEHAVIORAL|Implicit intervention (syntactic priming only)|For implicit intervention, the same 10 sessions of syntactic priming will be provided to the children without explicit instruction of the SRC-O structure using the Shape Coding System. Nonetheless, to make the exposure and dosage as comparable as possible between the two groups, children in the implicit intervention group will also receive 10 listening sessions before the syntactic priming sessions. During the listening sessions, the same sets of sentences used in the explicit instruction sessions will be presented and the children will be instructed to listen closely as the tutor reads aloud the SRC-O sentence. Each listening session will be followed by a syntactic priming session that is identical to that of the explicit intervention group. In total, there are also 500 doses of SRC-O sentences (50 sentences x10 sessions).
214542594|NCT06956573|OTHER|aorta imaging|Retrospective analysis of imaging data (echocardiography and/or cardiac MRI) in adult patients with Fabry disease to assess ascending aortic diameters.
214542595|NCT06956599|DRUG|test toothpaste|A commercially available fluoride toothpaste
214542596|NCT06956599|DRUG|Control toothpaste|A commercially available fluoride toothpaste
214542597|NCT03113383|DEVICE|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
214542598|NCT02122172|DRUG|afatinib dimaleate|Given PO
214542599|NCT02122172|OTHER|laboratory biomarker analysis|Correlative studies
214542600|NCT02738957|BEHAVIORAL|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
214542601|NCT02849405|DEVICE|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
214542602|NCT06145789|OTHER|standing powered wheelchair evaluation|standing powered wheelchair evaluation
214542603|NCT03062449|DRUG|L-Serine|Gummy containing L serine dose
214542604|NCT03062449|OTHER|Placebo Gummy|Gummy with no dosing of L Serine
214698033|NCT02124707|DRUG|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
214698034|NCT02124707|DRUG|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
214698035|NCT01692353|OTHER|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
214542605|NCT03765398|BEHAVIORAL|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
214542606|NCT02989571|DRUG|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
214542607|NCT02989571|DRUG|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
214698036|NCT06357260|DRUG|Pregabalin and Carbamazepine|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
214698037|NCT06357260|DRUG|Carbamazepine|Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
214698038|NCT03861546|BEHAVIORAL|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
214698039|NCT04654091|PROCEDURE|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
214698040|NCT04654091|PROCEDURE|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
214698041|NCT02815176|OTHER|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
214698042|NCT00261248|BIOLOGICAL|Immunization with inactivated bacteria|
214698043|NCT00974051|DRUG|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
214698044|NCT00974051|OTHER|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
214698045|NCT00974051|OTHER|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
214698046|NCT06410599|DRUG|Ketamine|Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
215158711|NCT03710083|DEVICE|Guardian™ Sensor (3)|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
215158712|NCT04155580|DRUG|ASTX660|Capsule for oral administration
215158713|NCT04155580|DRUG|ASTX727|Tablet for oral administration
215158714|NCT03993106|DRUG|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
215158715|NCT04059315|OTHER|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
215158716|NCT05300763|DEVICE|senofilcon A prototype|Test
215158717|NCT05300763|DEVICE|Dailies Total 1|Control
215158718|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
215158719|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
214542608|NCT02168283|COMBINATION_PRODUCT|treatment arm|Hypertonic peritoneal dialysis cycles
214542609|NCT02168283|BEHAVIORAL|Control arm|Dietary counseling
214542610|NCT05688683|OTHER|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
215158720|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
215158721|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
215158722|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
215158723|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
215158724|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
215158725|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
215158726|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
215158727|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
214698047|NCT06410599|DRUG|Placebo|Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
214698048|NCT06410599|BEHAVIORAL|CBASP|In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
214698049|NCT06410599|BEHAVIORAL|TAU|Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
214698050|NCT00950079|DRUG|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
214698051|NCT00950079|DRUG|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
214698052|NCT02882763|OTHER|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
214698053|NCT00555048|BIOLOGICAL|alemtuzumab|
214698054|NCT00555048|DRUG|busulfan|
214698055|NCT00555048|DRUG|cyclophosphamide|
214698056|NCT00555048|DRUG|methotrexate|
215158728|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
215158729|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
214542611|NCT03463551|DRUG|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
214542612|NCT03463551|OTHER|0.9% NaCl|Placebo
214698057|NCT00555048|DRUG|tacrolimus|
215158730|NCT05862168|DRUG|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
215158731|NCT05862168|DRUG|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
215158732|NCT05862168|DRUG|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
214542613|NCT03863132|DEVICE|TAVR|Repair of defective aortic valve by microsurgical Intervention.
214542614|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
214542615|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
214542616|NCT06381648|DIAGNOSTIC_TEST|LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)|A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
214542617|NCT06548217|DRUG|ONO-4538HSC|ONO-4538HSC will be administered subcutaneously once every 4 weeks.
214542618|NCT05317559|BEHAVIORAL|room light|The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
214542619|NCT01178307|BEHAVIORAL|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
214542620|NCT01178307|BEHAVIORAL|Interview|Each interview will take approximately 30 minutes.
214542621|NCT01178307|BEHAVIORAL|MDASI-GIST Questionnaire|Every 4 weeks for one year
214542622|NCT02976168|OTHER|12° head down tilt|supine head down tilt
214542623|NCT00636662|OTHER|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
214698058|NCT00555048|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214698059|NCT00555048|PROCEDURE|peripheral blood stem cell transplantation|
214698060|NCT00183950|DRUG|Noscapine|
214698061|NCT04766138|DEVICE|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
214698062|NCT00986310|DRUG|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
214698063|NCT00986310|DRUG|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
214698064|NCT00943982|DRUG|Interferon Gamma 1-b|
214698065|NCT03190096|PROCEDURE|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
214698066|NCT03090373|DEVICE|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
214708942|NCT03516409|DIETARY_SUPPLEMENT|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
214542624|NCT02429908|DEVICE|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
214542625|NCT02178930|OTHER|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
214542626|NCT03051425|DIETARY_SUPPLEMENT|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
214542627|NCT03051425|DIETARY_SUPPLEMENT|Placebo|120 mL of low-fat milk
214542628|NCT00459914|DEVICE|cpap treatment during sleep|CPAP
214542629|NCT00252083|BEHAVIORAL|Popular Opinion Leader|
214542630|NCT02053610|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
214542631|NCT02053610|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
214542632|NCT02053610|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
214542633|NCT00197795|BIOLOGICAL|"Meningococcal outer membrane vesicle vaccine MenBVac"|
214542634|NCT05435989|DIAGNOSTIC_TEST|Reduced extended high-frequency audibility|This study examines the effects of low-pass filtering speech on speech perception.
214542635|NCT02585297|OTHER|no intervention|
214542636|NCT01122563|DRUG|Solifenacin|oral
214542637|NCT06367634|DEVICE|injection in NLF|TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin
214542638|NCT05286294|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
214542639|NCT01798979|DRUG|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
214542640|NCT01798979|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
214542641|NCT04297592|DRUG|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
214542642|NCT04297592|DRUG|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
214542643|NCT04297592|DRUG|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
214542644|NCT00698282|DRUG|AZD1981|Oral tablet, 250 mg single dose
214542645|NCT00698282|DRUG|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
215158733|NCT05862168|DRUG|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
214542646|NCT00698282|DRUG|Placebo|
214542647|NCT03568812|DRUG|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
214542648|NCT03568812|OTHER|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
214542649|NCT05602623|DEVICE|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
214542650|NCT06086041|PROCEDURE|cochlear implant|cochlear implant
214542651|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
214542652|NCT02617979|OTHER|SAFECARE at Home customized lessons|
214542653|NCT01296763|DRUG|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
214542654|NCT01296763|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
214542655|NCT01296763|DRUG|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
214542656|NCT01296763|DRUG|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
214542657|NCT01296763|DRUG|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
214542658|NCT05508269|GENETIC|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
214542659|NCT05508269|PROCEDURE|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
214542660|NCT05032404|DEVICE|BNT103|BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.
214542661|NCT03462043|COMBINATION_PRODUCT|ND0612|s.c. infused
214542662|NCT03462043|COMBINATION_PRODUCT|CLES|Carbidopa-Levodopa Enteral Suspension.
214542663|NCT04921137|OTHER|No endocrine therapy|No endocrine therapy given
214542664|NCT04921137|OTHER|Endocrine therapy|Endocrine therapy given for at least 5 years
214542665|NCT04461769|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
214542666|NCT01869114|DRUG|Sirolimus|Given PO
214542667|NCT01869114|DRUG|Azacitidine|Given IV
215158734|NCT02170415|DRUG|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
215158735|NCT02170415|OTHER|Pain education|Participant will receive a pain education leaflet
215158736|NCT02170415|BEHAVIORAL|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
214542668|NCT05808127|BEHAVIORAL|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
214542669|NCT05673733|OTHER|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
214542670|NCT05673733|OTHER|exergaming training|Group B will receive only exergaming training
214542671|NCT00543062|DRUG|Inhaled placebo|Inhaled Staccato placebo (0 mg)
214542672|NCT00543062|DRUG|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
214542673|NCT00543062|DRUG|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
215158737|NCT02170415|PROCEDURE|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
214542674|NCT00543062|DRUG|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
214542675|NCT00543062|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
214542676|NCT03703726|DIETARY_SUPPLEMENT|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
214542677|NCT03703726|DIETARY_SUPPLEMENT|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
214542678|NCT03703726|DIETARY_SUPPLEMENT|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
214542679|NCT03703726|DIETARY_SUPPLEMENT|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
215158738|NCT02170415|OTHER|Daily visits from pain team whilst in hospital|
215158739|NCT05008406|OTHER|Satisfaction|Students Satisfaction
215158740|NCT05284526|OTHER|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
215158741|NCT01903980|OTHER|No intervention. It is a retrospective study|No intervention. It is a retrospective study
215158742|NCT05433844|DRUG|Reference Drug or Test Drug|"Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
215158743|NCT02606149|BEHAVIORAL|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
214542680|NCT03703726|DIETARY_SUPPLEMENT|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
214542681|NCT03703726|DIETARY_SUPPLEMENT|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
214542682|NCT03703726|DIETARY_SUPPLEMENT|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
214542683|NCT05923346|OTHER|GLUTLEARN|"The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management."
214542684|NCT01642953|DIETARY_SUPPLEMENT|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
214542685|NCT04654962|PROCEDURE|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
215158744|NCT02606149|BEHAVIORAL|Standard of information|
215158745|NCT01594528|OTHER|pain tests|pain induction with pressure application or ischemia on the arm
215158746|NCT04004871|DRUG|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
215158747|NCT04004871|RADIATION|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
215158748|NCT04588454|OTHER|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
215158749|NCT04154527|OTHER|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
215158750|NCT01828151|DEVICE|Noninvasive ventilation mask|
215158751|NCT04625517|PROCEDURE|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
215158752|NCT04625517|DRUG|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
215158753|NCT00441064|DRUG|Aliskiren|
215158754|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
215158755|NCT00953056|BIOLOGICAL|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
215158756|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
215158757|NCT00953056|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
215158758|NCT00903188|DRUG|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
215158759|NCT00903188|DRUG|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
215158760|NCT01842217|PROCEDURE|FES-PET|
215158761|NCT02575157|OTHER|No intervention|No intervention
215158762|NCT03962504|BEHAVIORAL|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
215158763|NCT02943434|OTHER|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
214542686|NCT05095428|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
214542687|NCT05095428|BEHAVIORAL|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
214542688|NCT01439854|DRUG|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
214542689|NCT01439854|DRUG|Placebo|Patients are treated with placebo
214542690|NCT03020030|DRUG|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
214542691|NCT03020030|DRUG|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
214542692|NCT03020030|DRUG|Cyclophosphamide|Standard of Care
214542693|NCT03020030|DRUG|CYTARABINE|Standard of Care
214542694|NCT03020030|DRUG|DASATINIB|Standard of Care
214542695|NCT03020030|DRUG|DEXAMETHASONE|Standard of Care
214542696|NCT03020030|DRUG|Dexrazoxane|Standard of Care
214542697|NCT03020030|DRUG|Doxorubicin|Standard of Care
214542698|NCT03020030|DRUG|ETOPOSIDE|Standard of Care
214542699|NCT03020030|DRUG|HYDROCORTISONE|Standard of Care
214542700|NCT03020030|DRUG|LEUCOVORIN CALCIUM|Standard of Care
214542701|NCT03020030|DRUG|MERCAPTOPURINE|Standard of Care
214542702|NCT03020030|DRUG|METHOTREXATE|Standard of Care
214542703|NCT03020030|DRUG|NELARABINE|Standard of Care
214542704|NCT03020030|DRUG|Vincristine|Standard of Care
214542705|NCT02409095|BIOLOGICAL|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
214542706|NCT02409095|DEVICE|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
214542707|NCT02409095|OTHER|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
214542708|NCT00712647|DRUG|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard \& Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
214542709|NCT00712647|OTHER|Placebo|Two placebos, one each/day
214542710|NCT00328562|DRUG|ZD1839 (Iressa)|
214542711|NCT00328562|RADIATION|Thoracic Radiotherapy|
214542712|NCT06640296|DRUG|Liposomal Amphotericin B (LAmB)|collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
214542713|NCT06298708|BIOLOGICAL|Mevac-A vaccine|"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."
214542714|NCT06298708|BIOLOGICAL|Havrix 720 Junior|"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."
214542715|NCT06566261|BIOLOGICAL|ABA-101|ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
214542716|NCT00839566|PROCEDURE|Ablation|AV-node ablation
214542717|NCT00839566|OTHER|Rate Control|Rate control by drug
214542718|NCT03509961|DIAGNOSTIC_TEST|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
214542719|NCT03509961|DRUG|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
214542720|NCT02941848|DRUG|HGP0816|
215158764|NCT04276948|DIETARY_SUPPLEMENT|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
215158765|NCT01077076|DRUG|Zegerid|Zegerid taken once daily for 11 days.
215158766|NCT01077076|DRUG|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
215158767|NCT01077076|OTHER|Placebo|Placebo taken once daily for 11 days.
215158768|NCT06134804|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
214542721|NCT02941848|DRUG|HGP1404|
214542722|NCT02941848|DRUG|HCP1306|
214542723|NCT01863797|OTHER|Early induction|
215158769|NCT06134804|BIOLOGICAL|Placebo|Placebo will be administered as an IM injection.
215158770|NCT06134804|BIOLOGICAL|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
214542724|NCT01863797|OTHER|Expectant mamagement|
214542725|NCT01176318|DRUG|Erdosteine|capsule 300mg twice daily for 10 days
214542726|NCT01176318|DRUG|Placebo|placebo capsule, twice daily for 10 days
214542727|NCT04014790|DRUG|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
214542728|NCT04014790|DRUG|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
214542729|NCT06242938|PROCEDURE|Early intensive antihypertensive treatment|"1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.)."
214542730|NCT04608136|BEHAVIORAL|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
214542731|NCT04847245|DRUG|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
214542732|NCT04847245|DRUG|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
215158771|NCT01646229|OTHER|Polymyxin-B hemoperfusion|
215158772|NCT01646229|OTHER|Control|
215158773|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
215158774|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
215158775|NCT01976741|DRUG|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
215158776|NCT06170099|RADIATION|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
215158777|NCT06170099|DEVICE|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
215158778|NCT00889720|DRUG|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
215158779|NCT04565704|DEVICE|Biopsy imaged by Optical imaging device.|
214542733|NCT04847245|DRUG|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
214542734|NCT04847245|DRUG|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
214542735|NCT04213677|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
215158780|NCT00670306|DRUG|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
215158781|NCT01327482|DRUG|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
214542736|NCT04213677|DRUG|Placebo|Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
214542737|NCT05146115|OTHER|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
214542738|NCT05070832|PROCEDURE|Deep Hyperthermia|Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
214542739|NCT02720211|DEVICE|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
214542740|NCT02720211|DEVICE|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
214542741|NCT05080205|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
214542742|NCT05311553|PROCEDURE|Zona pellucida thinning|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
214542743|NCT05311553|PROCEDURE|Zona pellucida drilling|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
215158782|NCT00476229|DRUG|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
215158783|NCT00476229|RADIATION|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
215158784|NCT00476229|PROCEDURE|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
215158785|NCT00476229|DRUG|Rituximab|375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
215158786|NCT05699694|DIETARY_SUPPLEMENT|StemRegen product|"Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible:~Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance."
215158787|NCT06338969|OTHER|Carbohydrate Restriction after a Gastric Bypass|"All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates."
215158788|NCT01776216|OTHER|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
215158789|NCT01776216|OTHER|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
215158790|NCT04510441|OTHER|Nil intervention|Nil intervention; retrospective cohort study
215158791|NCT02069860|DEVICE|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
215158792|NCT03375697|DRUG|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
214542744|NCT04648826|DEVICE|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
214542745|NCT04648826|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
214542746|NCT04648826|DRUG|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
215158793|NCT03375697|DRUG|Placebo|Subjects will receive matching placebo intravenously.
214542747|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
214542748|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
214542749|NCT05203861|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
214542750|NCT05203861|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
214542751|NCT05061199|PROCEDURE|approach of anastomosis|The approach of anastomosis
214542752|NCT00207818|DEVICE|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
214542753|NCT01610960|DEVICE|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
214542754|NCT01610960|DEVICE|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
215158794|NCT00773214|BEHAVIORAL|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
215158795|NCT04338802|DRUG|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
214542755|NCT04849689|BEHAVIORAL|Whole-food, plant-based lifestyle|"The WFPB lifestyle program included:~1. Nutrition/plant-based food (energy intake: at least 90% of whole-food, plant-based diet and ≤ 10% of energy intake from plant-based meal replacements (PBMR) and dietary supplements (e.g., vitamin B12, D, and EPA and DHA omega-3 fatty acids).~2. Physical activity (habitual; organized and other).~3. Support system (lectures, workshops and individual nutrition counselling, grocery shopping assistance, cooking classes, regular measurements body composition, food logging, regular medical monitoring)."
214542756|NCT01240889|DRUG|Fluticasone|nasal spray
214542757|NCT01240889|DRUG|Fluticason|2 sprays per day in each nostril
214542758|NCT01793636|DRUG|AZD2014|AZD2014 vs Everolimus
214542759|NCT01793636|DRUG|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
214542760|NCT00976690|DRUG|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
214542761|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
214542762|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
214542763|NCT01010204|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
214542764|NCT01010204|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
214542765|NCT05875454|DIAGNOSTIC_TEST|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
214542766|NCT00424788|PROCEDURE|Plasma exchange|
214542767|NCT00424788|DRUG|natalizumab treatment|
214542768|NCT01513330|DEVICE|SenSura Mio|Ostomy product - 1 piece closed bag
214698067|NCT04460417|BEHAVIORAL|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
215158796|NCT04338802|OTHER|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
215158797|NCT02196662|DRUG|IBD98-M:|single adiministration
215158798|NCT02196662|DRUG|IBD98-M without HA|single adiministration
215158799|NCT02196662|DRUG|Delzicol|single adiministration
215158800|NCT05821881|OTHER|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
215158801|NCT04995952|BEHAVIORAL|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
214698068|NCT04460417|BEHAVIORAL|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
214698069|NCT01831206|PROCEDURE|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
214542769|NCT01513330|DEVICE|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
214542770|NCT01519778|DRUG|TR701 FA|1 tablet 200 mg once daily
214542771|NCT00207753|DRUG|albendazole vs. combined albendazole/ivermectin treatment|
214542772|NCT00703183|DRUG|ACU-4429|administered as a single dose, orally
214542773|NCT00703183|DRUG|matching placebo|administered as a single dose, orally
214698070|NCT03013244|BEHAVIORAL|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
214698071|NCT02236949|BEHAVIORAL|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
214698072|NCT00542724|DRUG|VIAject™|Dosage as individually required
215158802|NCT04995952|BEHAVIORAL|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
215158803|NCT00545636|OTHER|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
215158804|NCT03174730|BEHAVIORAL|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
215158805|NCT03174730|BEHAVIORAL|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
215158806|NCT04485351|OTHER|no intervention|no intervention
215158807|NCT01032889|DRUG|Deoxycholic acid injection|
214542774|NCT01603433|DEVICE|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
214542775|NCT01592812|DEVICE|electrical muscle stimulation|Duration of the stimulation 20 minutes
214698073|NCT00542724|DRUG|Regular Human Insulin|Dosage as individually required
214698074|NCT00668200|DRUG|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
214698075|NCT00668200|DIETARY_SUPPLEMENT|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
214698076|NCT00668200|DIETARY_SUPPLEMENT|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
214698077|NCT01244347|DRUG|folic acid|
215158808|NCT01032889|DRUG|Placebo|Phosphate buffered saline placebo for injection
215158809|NCT00857688|DRUG|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
214542776|NCT01858051|DIETARY_SUPPLEMENT|Cholecalciferol|
214542777|NCT01858051|DIETARY_SUPPLEMENT|Placebo|
214542778|NCT04136600|DRUG|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
214698078|NCT01244347|DRUG|folic acid|
214698079|NCT02646267|DRUG|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
214698080|NCT02646267|DRUG|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
214698081|NCT02646267|DRUG|dabigatran etexilate|110mg, twice a day, oral
214698082|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
214698083|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
214698084|NCT02299063|DRUG|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
214698085|NCT02299063|DRUG|0.9% NaCl|
214698086|NCT01362686|DRUG|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
215158810|NCT00857688|OTHER|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
214698087|NCT01362686|DRUG|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
214698088|NCT01362686|DRUG|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
214698089|NCT01613547|DRUG|Amoxicillin|80 mg/kg/day for 7 days
214698090|NCT01613547|DRUG|Placebo|7 days
214698091|NCT01552187|DRUG|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
215158811|NCT00618228|DRUG|Balsalazide|
214542779|NCT04136600|DRUG|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
214542780|NCT01657799|DRUG|Veliparib|Veliparib capsules for oral administration
214542781|NCT01657799|DRUG|Placebo|Placebo to veliparib capsules for oral administration
214542782|NCT01657799|RADIATION|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
214542783|NCT06011278|OTHER|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
214542784|NCT05963009|DRUG|baxdrostat (formerly CIN-107) oral solution|5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
214542785|NCT03922152|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
214542786|NCT02449057|OTHER|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
214542787|NCT05142579|OTHER|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
214542788|NCT05142579|OTHER|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
214542789|NCT03084276|OTHER|High-fat meal|High-fat meal
214542790|NCT03084276|OTHER|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
214542791|NCT02871583|PROCEDURE|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
214542792|NCT02871583|PROCEDURE|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
214542793|NCT05147337|DRUG|E2511|E2511 tablets.
214542794|NCT05147337|DRUG|Placebo|E2511 matched placebo tablets.
214542795|NCT02543099|DRUG|policosanol|Patients will receive policosanol 20mg Qd
214542796|NCT02543099|DRUG|placebo|Patients will receive placebo 20mg Qd;
214542797|NCT05928468|BIOLOGICAL|LYB002V14|Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.
214542798|NCT05928468|BIOLOGICAL|LYB002V14A|Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.
215158812|NCT02094157|DRUG|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
214542799|NCT05928468|BIOLOGICAL|LYB002CA|Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
215158813|NCT02094157|DRUG|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
215158814|NCT02411097|PROCEDURE|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
214698092|NCT01552187|DRUG|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
214698093|NCT01767870|PROCEDURE|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
214698094|NCT01767870|PROCEDURE|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
215158815|NCT01849731|OTHER|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
215158816|NCT01849731|OTHER|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
215158817|NCT03800940|PROCEDURE|Fistulography and trans-drain occlusion|"1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
215158818|NCT03800940|PROCEDURE|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
215158819|NCT00993148|DRUG|maraviroc|150 mg tab by mouth once daily for 96 weeks
215158820|NCT00993148|DRUG|darunavir|800 mg tab by mouth once daily for 96 weeks
215158821|NCT00993148|DRUG|ritonavir|100 mg capsule by mouth once daily for 96 weeks
215158822|NCT02905890|DRUG|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
215158823|NCT02905890|DEVICE|Condoms|Latex male condoms
215158824|NCT01318980|DRUG|GSK2190915 100mg milled tablet|Taken orally
215158825|NCT01318980|DRUG|[14C] radiolabelled GSK2190915 solution|Microtracer solution
215158826|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
215158827|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
215158828|NCT01318980|DRUG|GSK2190915 100mg enteric-coated tablet.|Taken orally
215158829|NCT01989494|DEVICE|Pedometer|All groups will receive a pedometer to measure their daily steps
214542800|NCT04212754|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
214542801|NCT00412880|DRUG|BI 2536|Intravenous Infusion
214542802|NCT05995652|PROCEDURE|elastography|elastography
214542803|NCT02830542|DRUG|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
214542804|NCT02830542|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
214542805|NCT06296004|DEVICE|Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S|"Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US"
214542806|NCT03265015|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
214542807|NCT03265015|OTHER|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas.
214542808|NCT06001151|DRUG|Cadonilimab|Patients receive cadonilimab (10mg/kg) every 3 weeks.
214542809|NCT06001151|DRUG|Pemetrexed|Patients receive pemetrexed (500mg/m2) every 3 weeks.
214542810|NCT06001151|DRUG|Carboplatin|Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
214542811|NCT05471440|DRUG|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
214542812|NCT05471440|DRUG|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
214542813|NCT05471440|DRUG|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
214542814|NCT05471440|DRUG|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
214542815|NCT04977115|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
214542816|NCT04977115|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
214542817|NCT05500833|OTHER|Multidimentional observation scale (MDP)|Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later
214542818|NCT04398901|OTHER|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
214542819|NCT06214624|BEHAVIORAL|Two types of exercise interventions|"* HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
214542820|NCT03297398|DRUG|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
214542821|NCT03297398|DRUG|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
214542822|NCT03297398|OTHER|Placebo|Placebo
214542823|NCT04866433|PROCEDURE|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
214542824|NCT04866433|PROCEDURE|Music|Play the same music in both ears through headphones during sedation
214542825|NCT04866433|PROCEDURE|Control|Just wear headphones during sedation
214542826|NCT06555770|BEHAVIORAL|müzik müdahalesi|One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
214542827|NCT04106713|BEHAVIORAL|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
214542828|NCT04106713|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
214542829|NCT04106713|BEHAVIORAL|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
214542830|NCT02988349|OTHER|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
214542831|NCT02772718|DRUG|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
215158830|NCT04558840|PROCEDURE|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
215158831|NCT05976763|DRUG|Zanubrutinib|Given PO
215158832|NCT05976763|BIOLOGICAL|Rituximab|Given IV
214542832|NCT02772718|DRUG|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
214542833|NCT02772718|DRUG|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
214708943|NCT03516409|DIETARY_SUPPLEMENT|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
215158833|NCT05976763|OTHER|Patient Observation|Undergo observation
215158834|NCT05976763|PROCEDURE|Bone Marrow Biopsy|undergo bone marrow biopsy
215158835|NCT05976763|OTHER|Fludeoxyglucose F-18|Given IV
214542834|NCT02772718|DRUG|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
214542835|NCT04335747|OTHER|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
214542836|NCT02895334|BEHAVIORAL|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
214542837|NCT04431752|RADIATION|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
214542838|NCT05965739|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
214542839|NCT05965739|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
214542840|NCT05965739|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
214542841|NCT05965739|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
214542842|NCT05965739|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
214542843|NCT06105931|BIOLOGICAL|Hyperinsulinemic-euglycemic clamp|Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.
214542844|NCT06105931|OTHER|High Fat Mixed Meal Tolerance Test|After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.
214542845|NCT05054465|DRUG|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
214542846|NCT05054465|DRUG|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
214542847|NCT03587519|PROCEDURE|Early|Early ileostomy closure
214542848|NCT03587519|PROCEDURE|Late|Late ileostomy closure
214542849|NCT03431480|BIOLOGICAL|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
214542850|NCT00252018|BEHAVIORAL|Daily intake of broccoli sprouts|
214542851|NCT00237861|DRUG|risperidone|
214542852|NCT00237861|DRUG|olanzapine|
214542853|NCT00237861|DRUG|quetiapine|
214542854|NCT05185297|OTHER|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
214542855|NCT06380647|DRUG|Intravenous Acyclovir|Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
214542856|NCT00151905|DRUG|3 % hypertonic saline|
214542857|NCT01397500|DRUG|Genotropin|Genotropin administered sc once a day by patient or caregiver.
214542858|NCT01397500|DRUG|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
214542859|NCT04768868|DRUG|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
214542860|NCT03211585|DEVICE|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
215158836|NCT05976763|PROCEDURE|Positron Emission Tomography|Undergo PET
215158837|NCT05976763|PROCEDURE|Computed Tomography|Undergo CT
215158838|NCT05976763|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215158839|NCT05976763|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
215158840|NCT05976763|PROCEDURE|Colonoscopy|Undergo colonoscopy
215158841|NCT05976763|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215158842|NCT05976763|OTHER|Questionnaire Administration|Ancillary studies
215158843|NCT03388710|RADIATION|XRay|Xray to confirm the location of the endotracheal tube
215158844|NCT00472030|DRUG|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
214542861|NCT02394964|OTHER|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
214542862|NCT00250640|DRUG|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
214542863|NCT00643435|BEHAVIORAL|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
214542864|NCT00643435|BEHAVIORAL|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
214542865|NCT01984671|BEHAVIORAL|Mobile Pain Coping Skills Training|
214542866|NCT05580198|DIAGNOSTIC_TEST|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
214542867|NCT01470729|OTHER|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
214542868|NCT02876029|OTHER|Reference|the reference product used
214542869|NCT02876029|OTHER|Test product|The test Product used
214542870|NCT04049370|OTHER|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
214542871|NCT05921487|BEHAVIORAL|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
215158845|NCT00472030|DRUG|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
215158846|NCT02668978|DEVICE|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
215158847|NCT02668978|PROCEDURE|Standard surgical technique|Lung resuturing or restapling
215158848|NCT02838394|PROCEDURE|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
215158849|NCT02838394|OTHER|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
215158850|NCT06849258|DEVICE|FloStent|Flexible cystoscopy to deploy medical device used to treat BPH
215158851|NCT06849258|DEVICE|Sham (Control)|Flexible Cystoscopy without deployment of medical device used to treat BPH
215158852|NCT06451757|DRUG|Sonlicromanol|Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks
215158853|NCT06451757|DRUG|Placebo|Oral administration of 100 mg placebo twice daily during 52 weeks
214542872|NCT01772563|DRUG|volasertib|Solution for infusion
214542873|NCT01772563|DRUG|itraconazole|capsules
214542874|NCT04068051|DRUG|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
214542875|NCT05779917|BIOLOGICAL|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
214542876|NCT04817605|OTHER|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
214542877|NCT04380428|OTHER|No Intervention. Observational study.|No Intervention. Observational study.
214542878|NCT01192776|PROCEDURE|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
214542879|NCT00736125|DEVICE|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
214542880|NCT00736125|DEVICE|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
214542881|NCT03107507|DRUG|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
214542882|NCT03107507|DRUG|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
214542883|NCT02181907|DRUG|UH-AC 62 XX tablet|
214542884|NCT02181907|DRUG|UH-AC 62 XX capsule|
214542885|NCT04374383|DRUG|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
214542886|NCT04374383|DRUG|LASER assisted SRP|LASER assisted SRP will be carried
215158854|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
214542887|NCT00026182|BIOLOGICAL|rituximab|Given IV
214542888|NCT00026182|BIOLOGICAL|recombinant interleukin-12|Given SC
214542889|NCT00026182|OTHER|laboratory biomarker analysis|Correlative studies
214542890|NCT00026182|OTHER|questionnaire administration|Ancillary studies
214542891|NCT00026182|PROCEDURE|quality-of-life assessment|Ancillary studies
214542892|NCT04614571|DIETARY_SUPPLEMENT|Gluten Powder|Administered orally daily for 14 days
214542893|NCT05138250|DRUG|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
214542894|NCT05793307|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
214542895|NCT00000983|DRUG|Zidovudine|
214708944|NCT00823940|DRUG|GSK1362885|5 - 100mg of GSK1362885 or placebo
215158855|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
214542896|NCT02905409|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
214698095|NCT04042675|DIAGNOSTIC_TEST|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
215158856|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
214542897|NCT02567305|OTHER|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
214542898|NCT02719041|OTHER|Immunohistochemistry staining method|
214542899|NCT02877732|DEVICE|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
214542900|NCT02877732|OTHER|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
214542901|NCT02877732|OTHER|DEM|Participant will be asked to read list of numbers out loud from a card
214698096|NCT00311558|BIOLOGICAL|recombinant interferon alfa-2b|SSG x 5 week
215158857|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
215158858|NCT01422343|PROCEDURE|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
215158859|NCT03461588|RADIATION|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
215158860|NCT03461588|RADIATION|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
215158861|NCT02178137|DRUG|Diacerien|
215158862|NCT02178137|DRUG|Glucosamine/Chondroitin|
215158863|NCT02178137|DRUG|Placebo|
215158864|NCT02267837|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
215158865|NCT01006993|DEVICE|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
215158866|NCT00912197|DIETARY_SUPPLEMENT|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
215158867|NCT00912197|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
215158868|NCT06073561|OTHER|learning curve of Underwater mucosectomy|Patients will be submitted to underwater mucosectomy (U-EMR)
215158869|NCT01209533|DRUG|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
215158870|NCT04373252|BIOLOGICAL|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
215158871|NCT04288284|PROCEDURE|Curative resection of colorectal cancer|
214542902|NCT02877732|OTHER|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
214542903|NCT02877732|OTHER|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
214698097|NCT00311558|DRUG|sodium stibogluconate|SSG \& IFN
214698098|NCT00311558|DRUG|SSG & interferon|1 arm study with SSG \& interferon
214698099|NCT03096223|DRUG|KHK4083|IV administration
214698100|NCT03477526|PROCEDURE|Pulmonary rehabilitation program|3 weeks, ...
214698101|NCT02566941|DEVICE|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
214698102|NCT02108951|DRUG|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
214698103|NCT02176395|DRUG|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
214708945|NCT00823940|DRUG|GSK1362885|100 - 600mg or placebo
214708946|NCT00823940|DRUG|Glucagon|0.5mg IV bolus
215158872|NCT03422094|BIOLOGICAL|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
215158873|NCT03422094|BIOLOGICAL|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
215158874|NCT03422094|BIOLOGICAL|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
215158875|NCT03422094|PROCEDURE|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
215158876|NCT03422094|PROCEDURE|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
215158877|NCT06268977|DRUG|SGLT2 inhibitor|a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
215158878|NCT02538354|DIETARY_SUPPLEMENT|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
215158879|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
215158880|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
215158881|NCT03801044|DIAGNOSTIC_TEST|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
214542904|NCT01938313|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem."
214542905|NCT01938313|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed"
214698104|NCT02176395|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
214698105|NCT02176395|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
214698106|NCT04247750|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
214698107|NCT00718666|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
214542906|NCT00353886|PROCEDURE|TONI-3|
214542907|NCT00353886|PROCEDURE|WRAT-3|
214542908|NCT00353886|PROCEDURE|Connor's Rating Scales PRS & TRS|
214698108|NCT04779671|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
214698109|NCT04779671|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
214698110|NCT00516425|BIOLOGICAL|pegfilgrastim|
214698111|NCT00516425|DRUG|cyclophosphamide|
214698112|NCT00516425|DRUG|doxorubicin hydrochloride|
214698113|NCT00516425|DRUG|epirubicin hydrochloride|
214698114|NCT00516425|GENETIC|proteomic profiling|
214698115|NCT00516425|OTHER|diagnostic laboratory biomarker analysis|
214698116|NCT00516425|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
214698117|NCT00516425|OTHER|pharmacological study|
214542909|NCT00353886|PROCEDURE|Peabody Picture Vocabulary Test|
214542910|NCT00353886|PROCEDURE|Children's Memory Scale|
214542911|NCT00353886|PROCEDURE|WISC-3|
214542912|NCT00353886|PROCEDURE|Behavioral Assessment System for Children PRS & TRS|
214542913|NCT06194682|PROCEDURE|Anterior cruciate ligament reconstruction|Anterior cruciate ligament arthroscopic reconstruction
214542914|NCT03225976|DEVICE|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
214542915|NCT03225976|DEVICE|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
214542916|NCT03231332|OTHER|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
214542917|NCT03666195|COMBINATION_PRODUCT|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
214698118|NCT00516425|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
214698119|NCT00516425|PROCEDURE|adjuvant therapy|
214698120|NCT06576102|OTHER|Persisting SARS-CoV-2 infection|Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients defined as the persistence or the recurrence of symptoms and signs (fever, dyspnea, hypoxemia, changes on chest-X ray or CT scan) and positive SARS-CoV-2 PCR ≥ 21 days after the time 0 (day of the first test positive for SARS-CoV-2 infection)
214698121|NCT00920036|DEVICE|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
214698122|NCT00670397|DRUG|HPPH|IV
214698123|NCT04510350|OTHER|Biomarkers analysis|Genetic analysis of regions of interest
214698124|NCT03326830|DEVICE|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
214698125|NCT03326830|DEVICE|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
214698126|NCT02298478|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
214708947|NCT00823940|DRUG|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
214542918|NCT04919070|BEHAVIORAL|Connect for Caregivers|The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.
214542919|NCT03815864|DIAGNOSTIC_TEST|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
214542920|NCT01648595|DRUG|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
214542921|NCT02493465|DRUG|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
214542922|NCT00890799|DEVICE|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
214542923|NCT00890799|PROCEDURE|surgery|Patient in this group received open surgical repair of pmVSD.
214542924|NCT00380965|DRUG|Cesamet™ (nabilone)|
214542925|NCT03211728|DRUG|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
214542926|NCT03211728|DRUG|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
214542927|NCT06062615|PROCEDURE|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
214542928|NCT06062615|PROCEDURE|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
214542929|NCT06062615|DEVICE|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
214542930|NCT02632812|DRUG|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
214542931|NCT02632812|DRUG|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
214542932|NCT02632812|DRUG|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
214542933|NCT01998971|DRUG|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
214542934|NCT01998971|DRUG|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
214542935|NCT01998971|DRUG|Pomalidomide|Administered orally in accordance with product labeling and local standards.
214542936|NCT01998971|DRUG|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
214542937|NCT01998971|DRUG|Melphalan|Administered orally in accordance with product labeling and local standards.
214542938|NCT01998971|DRUG|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
214542939|NCT01998971|DRUG|Thalidomide|Administered orally in accordance with product labeling and local standards.
214542940|NCT01998971|DRUG|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
214542941|NCT01998971|DRUG|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
214542942|NCT01998971|DRUG|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
214542943|NCT01998971|DRUG|Lenalidomide|Administered orally in accordance with product labeling and local standards.
214542944|NCT01998971|DRUG|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
214542945|NCT03732820|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
214542946|NCT03732820|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
214542947|NCT00451828|DRUG|Simvastatin|40mg/day
214542948|NCT06254755|DEVICE|mechanical thrombectomy|mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
214542949|NCT03381469|PROCEDURE|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs \> 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
214542950|NCT03381469|PROCEDURE|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
214542951|NCT00590525|PROCEDURE|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
214542952|NCT06317402|OTHER|malnutrition questionary|At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
214542953|NCT03683550|PROCEDURE|SLNE with preoperative hybrid SPECT/CT|Single-photon emission computed tomography/computed tomography (SPECT/CT) provides complementary functional and anatomical information and has been shown to be superior to planar imaging in a number of indications. It can provide valuable information before sentinel lymph node biopsy and advocate its use in a range of tumors such as truncal and head and neck melanomas.
214542954|NCT03683550|PROCEDURE|Standard SLNE|"The current gold standard for detection and targeted extirpation of the sentinel lymph node (SLN) is preoperative lymphoscintigraphy.~Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy."
214542955|NCT00992992|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
214542956|NCT01130649|DEVICE|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
214542957|NCT01804010|DRUG|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
214698127|NCT01467908|DEVICE|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
214698128|NCT01652248|PROCEDURE|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
214698129|NCT02636348|DIETARY_SUPPLEMENT|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
214698130|NCT02636348|DIETARY_SUPPLEMENT|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
215158882|NCT03801044|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
215158883|NCT03801044|RADIATION|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
214542958|NCT05399368|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
214542959|NCT05399368|OTHER|Placebo|Nonactive placebo tablet
214542960|NCT02398045|OTHER|Computerised CBT for OCD|Computerised CBT for OCD
215158884|NCT03801044|DIAGNOSTIC_TEST|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
214542961|NCT01854307|PROCEDURE|Pneumoperitoneum and SVV/PPV|
214542962|NCT00832000|DRUG|Mexiletine|200 mg three times a day; in pill form
214542963|NCT00832000|DRUG|Placebo|Placebo three times a day; in pill form
214542964|NCT01383239|OTHER|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
214698131|NCT03342196|DRUG|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
214698132|NCT03342196|DRUG|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
214698133|NCT03342196|DRUG|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
214698134|NCT05449496|BEHAVIORAL|Dietary Education Curriculum|Curriculum of dietary education and group-based counseling to encourage whole-food plant-based eating
214698135|NCT02690233|PROCEDURE|Elective Surgery|Elective laparoscopic inguinal hernia repair
214698136|NCT05434247|DEVICE|Needle choice|The type of needle use was the only intervention
214542965|NCT01383239|OTHER|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
214542966|NCT02610621|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
214542967|NCT04679740|DEVICE|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
214542968|NCT03845075|DRUG|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
214542969|NCT03845075|DRUG|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
214542970|NCT02654613|OTHER|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
214542971|NCT05393622|DEVICE|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
214542972|NCT05278013|OTHER|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
214542973|NCT02400814|DRUG|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
214542974|NCT02400814|RADIATION|Stereotactic Body Radiation Therapy|Undergo SAR
214698137|NCT00932152|DRUG|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
214698138|NCT00932152|DRUG|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
214698139|NCT00932152|DRUG|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
214698140|NCT00932152|DRUG|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
214698141|NCT00421343|DRUG|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
214698142|NCT00421343|DRUG|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
214542975|NCT02539238|OTHER|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
214542976|NCT00935259|DRUG|Simvastatin|40 mg once daily for 2 weeks
214542977|NCT00935259|DRUG|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
214542978|NCT04795583|DRUG|Prednisone|Prednisone 25 mg capsules
214542979|NCT04795583|DEVICE|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
214542980|NCT00904683|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
214542981|NCT00904683|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
214542982|NCT00992121|DRUG|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
214542983|NCT00992121|DRUG|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
214542984|NCT00992121|DRUG|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
214542985|NCT05531890|DRUG|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
214542986|NCT05531890|DRUG|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
214698143|NCT00421343|BEHAVIORAL|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
214698144|NCT01580592|DRUG|Omalizumab|150mg, s.c., every 4 weeks
214698145|NCT01580592|DRUG|Omalizumab|300mg, s.c., every 4 weeks
214698146|NCT01580592|DRUG|Placebo|Placebo, s.c., every 4 weeks
214542987|NCT05531890|DRUG|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
214542988|NCT05531890|DRUG|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
214542989|NCT05531890|DRUG|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
214542990|NCT05531890|DRUG|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
214542991|NCT04582513|OTHER|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
214542992|NCT02798692|BIOLOGICAL|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
214542993|NCT02798692|BIOLOGICAL|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
214542994|NCT02798692|BIOLOGICAL|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
214542995|NCT02798692|BIOLOGICAL|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
214542996|NCT02877264|DRUG|vapendavir 132 mg capsule|
214542997|NCT02877264|DRUG|vapendavir 264 mg tablet|
214542998|NCT02877264|DRUG|vapendavir 24 mg/mL oral suspension|
214542999|NCT02951169|OTHER|No intervention|No intervention. Treatment are accordance with clinical practice.
214543000|NCT06801171|OTHER|cognitive stimulation|12 sessions (one per week for 12 weeks) in group of cognitive stimulation
214543001|NCT06801171|OTHER|mixed intervention|12 sessions (one per week for 12 weeks) in group of mixte stimulation (yoga, cognitive behavioral therapy, mindfullness meditation, positive psychology)
214543002|NCT05354310|COMBINATION_PRODUCT|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
214543003|NCT03585283|OTHER|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
215158885|NCT03801044|DIAGNOSTIC_TEST|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
215158886|NCT01615029|DRUG|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
214543004|NCT03585283|OTHER|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
214543005|NCT02605096|PROCEDURE|MRI|Magnetic Resonance Imaging Scan
214543006|NCT02605096|PROCEDURE|X-ray|X-ray exam (conventional radiography)
214543007|NCT01860547|DIETARY_SUPPLEMENT|Bilberries|Frozen bilberries, 100 g/d
214543008|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
214543009|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
214543010|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
214543011|NCT03856047|DRUG|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
214543012|NCT03856047|DRUG|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
214543013|NCT03856047|DRUG|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
214543014|NCT03856047|DRUG|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
214543015|NCT00000370|BEHAVIORAL|Cognitive behavior therapy|
214543016|NCT00000370|BEHAVIORAL|Performance-based exposure therapy|
214543017|NCT00000370|BEHAVIORAL|Psychosocial intervention|
214543018|NCT00673556|DRUG|alefacept|Intramuscular (IM)
214543019|NCT00673556|DRUG|placebo|Intramuscular (IM)
214543020|NCT03599336|PROCEDURE|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
214543021|NCT03599336|OTHER|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
215158887|NCT01615029|DRUG|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
215158888|NCT01615029|DRUG|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
215158889|NCT01615029|DRUG|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
215158890|NCT03194230|OTHER|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
215158891|NCT05285605|DRUG|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
214543022|NCT02734186|DRUG|Praziquantel|Anthelminthic
214543023|NCT02205099|DRUG|SKL15508|
214543024|NCT02205099|DRUG|Placebo|
214543025|NCT02713737|DEVICE|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.
214543026|NCT02713737|DEVICE|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
214543027|NCT00171795|DRUG|Rivastigmine|
214543028|NCT02419963|PROCEDURE|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
214543029|NCT02419963|OTHER|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
214543030|NCT02419963|OTHER|Stool Sample|Stool sample to evaluate microbiome fingerprint.
214543031|NCT03177681|OTHER|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
214543032|NCT03177681|OTHER|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
214543033|NCT03177681|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
214543034|NCT03177681|DEVICE|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
214543035|NCT03177681|OTHER|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
214543036|NCT02609802|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
214543037|NCT02609802|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
214543038|NCT02023905|DRUG|Everolimus|everolimus at 10 mg daily continuously
214543039|NCT02023905|DRUG|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
214543040|NCT01135030|PROCEDURE|Total knee|Primary Total knee
214543041|NCT02377011|BEHAVIORAL|Problem solving cognitive behaviour therapy (PS CBT)|
214543042|NCT02878759|DEVICE|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
214543043|NCT04315116|DRUG|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 \& day10 .
214543044|NCT04315116|DRUG|Loperamide|Loperamide 4 mg bid from day 7 to day 13
214543045|NCT05313906|DRUG|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
214543046|NCT04035330|COMBINATION_PRODUCT|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
214543047|NCT04035330|COMBINATION_PRODUCT|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
214543048|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
215158892|NCT01326104|BIOLOGICAL|TTRNA-xALT|TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.
215158893|NCT01326104|BIOLOGICAL|TTRNA-DCs|TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.
215158894|NCT04794816|OTHER|Questionnaire Administration|Complete questionnaire
215158895|NCT00735488|OTHER|Observational|Summary of data
215158896|NCT01745458|DRUG|SB-659032|
215158897|NCT01745458|DRUG|Placebo|Matched placebo
214543049|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
214543050|NCT05526456|PROCEDURE|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
214543051|NCT00874497|DRUG|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
214543052|NCT00874497|DRUG|placebo|Placebo for 104 weeks (2 years)
214543053|NCT04842409|RADIATION|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
215158898|NCT01287741|DRUG|Rituximab|Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
215158899|NCT01287741|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
215158900|NCT01287741|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
215158901|NCT01287741|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
215158902|NCT01287741|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
215158903|NCT01287741|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
215158904|NCT02773316|DRUG|MR902|
214543054|NCT00521443|PROCEDURE|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
214543055|NCT02937896|DRUG|Desmopressin|40 micrograms Nasal Desmopressin.
214543056|NCT02937896|DRUG|Ketorolac|30mg intravenous Ketorolac.
214543057|NCT02937896|DRUG|Normal Saline|1cc intravenous Normal Saline.
214543058|NCT02937896|DRUG|Normal Saline|4 puffs nasal Normal Saline.
214543059|NCT06102226|DIAGNOSTIC_TEST|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
214543060|NCT01017263|DRUG|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
214543061|NCT05918393|BEHAVIORAL|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
214543062|NCT05177783|BEHAVIORAL|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
214543063|NCT05177783|BEHAVIORAL|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
214543064|NCT00227123|DRUG|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
214543065|NCT05736731|BIOLOGICAL|A2B530|Autologous logic-gated Tmod CAR T-cells
214543066|NCT05736731|DIAGNOSTIC_TEST|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
214543067|NCT03235362|DRUG|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
214543068|NCT03235362|DRUG|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
214543069|NCT03235362|DRUG|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
214543070|NCT04419363|DRUG|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
214543071|NCT04340856|PROCEDURE|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
214543072|NCT04340856|DRUG|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
214543073|NCT00176410|DRUG|fluvastatin|40mg fluvastatin daily
215158905|NCT02773316|DRUG|IR morphine sulphate|
215158906|NCT02861885|OTHER|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
215158907|NCT04421027|DRUG|Baricitinib|Given orally
215158908|NCT04421027|DRUG|Placebo|Given orally
215158909|NCT06096467|BEHAVIORAL|Comprehension Exercise Training|Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
215158910|NCT06096467|DIETARY_SUPPLEMENT|Placebo milk|Placebo milk: 8 g. protein for each serving and provided immediately after the CET session
214543074|NCT00984438|DRUG|BCNU Wafer|Implantable during surgical resection into the tumor bed
214543075|NCT00984438|DRUG|Irinotecan|IV every 2 weeks for up to one year
214543076|NCT00984438|DRUG|Bevacizumab|IV every 2 weeks for up to one year
214543077|NCT05192564|OTHER|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
214543078|NCT05192564|OTHER|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
214543079|NCT01200927|OTHER|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
214543080|NCT06330987|DEVICE|electrocardiograph|Ten standard derivation electrodes were used to acquired FANTE registrations. The peripheral electrodes (Left (L), Right (R) and Foot (F)) were placed on the maternal abdomen in a triangle around the navel (orange) with lower apex, while the precordial ones (C1, C2, C3, C4, C5, C6) were put on an external circle. The Neutral electrode was on the right side of the patient abdomen. The software was configured so that the system acquired and wrote on disk 8 signals (2 bipolar and 6 referenced to the centroid of the three L, R and F leads) at 1000 sps with a resolution of 0.763uV. This high resolution is needed to resolve the very small voltage changes related to fetal cardiac activity.
214543081|NCT01818427|BIOLOGICAL|infusion of 2 units of plasma|infusion of 2 units of plasma
214543082|NCT02420041|PROCEDURE|Active comparator: Fluoroscopic Guided SIJ injection|"* Needle entry point is in the lower one-third of the SIJ~* Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~* Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~* 1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~* Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~* Patient observed in recovery bay for 20 minutes and then discharged home"
214543083|NCT02420041|PROCEDURE|Ultrasound Guided Sacroiliac Joint Injection|"* Sterile preparation (with chlorhexidine) and drape~* Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~* 3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~* Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~* After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~* Patient observed in recovery bay for 20 minutes and then discharged home"
214543084|NCT02420041|DEVICE|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
214543085|NCT02420041|DEVICE|SonoSite S-nerve|
214543086|NCT02420041|DEVICE|iohexol|
214543087|NCT02420041|DRUG|triamcinolone/lidocaine|
214543088|NCT03324971|OTHER|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
214543089|NCT00103272|DRUG|tanespimycin|Given IV
214543090|NCT00103272|DRUG|bortezomib|Given IV
214543091|NCT00665223|DRUG|ACR16|Capsules will be swallowed whole with water.
214543092|NCT00665223|DRUG|Placebo|Capsules will be swallowed whole with water.
214543093|NCT01278615|OTHER|Laboratory Biomarker Analysis|Correlative studies
214543094|NCT01278615|DRUG|Selumetinib|Given PO
214543095|NCT04117815|DEVICE|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
214543096|NCT04117815|OTHER|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
214543097|NCT00040898|DIETARY_SUPPLEMENT|Sho-saiko-to|
215158911|NCT06096467|DIETARY_SUPPLEMENT|Protein Supplement|Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
215158912|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q14 day schedule
215158913|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q21 day schedule
215158914|NCT02844868|DEVICE|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
214543098|NCT03602222|BEHAVIORAL|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
214543099|NCT03602222|BEHAVIORAL|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
214543100|NCT04195932|OTHER|Exercise training|
214543101|NCT01657643|DIETARY_SUPPLEMENT|Probiotics|
214543102|NCT01657643|DIETARY_SUPPLEMENT|placebo|
214543103|NCT05188872|DIAGNOSTIC_TEST|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
214543104|NCT00905359|PROCEDURE|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
214543105|NCT00905359|PROCEDURE|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
214543106|NCT00146510|BEHAVIORAL|HealtheLifestyle Program|
214543107|NCT00146510|BEHAVIORAL|step counters with monthly feedback on logs|
214543108|NCT05665322|PROCEDURE|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
214543109|NCT05665322|PROCEDURE|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
214543110|NCT01073319|OTHER|Placebo|Administration of placebo pill
214543111|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
214543112|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
214543113|NCT00809913|DRUG|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
214543114|NCT00027976|DRUG|celecoxib|
214543115|NCT00027976|DRUG|Placebo|
214543116|NCT01152476|DRUG|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
214543117|NCT01152476|DRUG|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
214543118|NCT02654132|DRUG|Elotuzumab|
214543119|NCT02654132|DRUG|Pomalidomide|
214543120|NCT02654132|DRUG|Dexamethasone|
214543121|NCT03201536|DEVICE|conventional Suture|Sutures
214543122|NCT03201536|DEVICE|Zip3|wound closure device
214543123|NCT01682798|DIETARY_SUPPLEMENT|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
214543124|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
214543125|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
214543126|NCT02572440|PROCEDURE|Sorin XTRA/Sorin Group,|
214543127|NCT06270277|DIAGNOSTIC_TEST|Pediatric Quality of Life Inventory (PedsQL)|Questionnaire
214543128|NCT06270277|DIAGNOSTIC_TEST|Strengths and Difficulties Questionnaire (SDQ)|Questionnaire
214698147|NCT03591679|DRUG|Oxytocin|20 units by slow intravenous drip injection
214543129|NCT02739776|DEVICE|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
214543130|NCT00894998|BIOLOGICAL|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
214543131|NCT00894998|BIOLOGICAL|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
214543132|NCT05612451|PROCEDURE|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
214543133|NCT05612451|OTHER|non-setting calcium hydroxide|non-setting calcium hydroxide
214543134|NCT05612451|OTHER|modified triple antibiotic paste|modified triple antibiotic paste
214543135|NCT00083330|DRUG|VRC-HIVADV014-00-VP|
214543136|NCT03379558|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
214543137|NCT05441098|OTHER|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
214543138|NCT01031849|DRUG|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
214543139|NCT01749163|BIOLOGICAL|Saline|
214543140|NCT01749163|BIOLOGICAL|GIP|
214543141|NCT01749163|BIOLOGICAL|GLP-1|
214543142|NCT04855357|BEHAVIORAL|Resident counselling|One hour, one-on-one counseling for residents
214543143|NCT04855357|BEHAVIORAL|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
214543144|NCT04783103|DEVICE|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
214543145|NCT03272529|OTHER|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
214708948|NCT06480188|DEVICE|deep brain stimulation|Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
215158915|NCT02844868|DEVICE|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
215158916|NCT04593862|OTHER|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
215158917|NCT03756324|DRUG|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
215158918|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
215158919|NCT03756324|BEHAVIORAL|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
215158920|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
215158921|NCT05374603|DRUG|Savolitinib|Savolitinib combine with Durvalumab
215158922|NCT05374603|DRUG|Durvalumab|savolitinib plus durvalumab
215158923|NCT05036733|DRUG|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
215158924|NCT04466007|DRUG|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
215158925|NCT04466007|DRUG|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
215158926|NCT04466007|DRUG|Placebos|0,9% physiological saline
215158927|NCT05750732|BEHAVIORAL|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
215158928|NCT06946810|BEHAVIORAL|Combined visits-based transition|In this arm, patients experience a gradual transition involving joint consultations where both pediatric and adult gastroenterologists are present. This includes at least one combined visit at the pediatric clinic and one at the adult clinic, allowing for collaborative care and direct communication between all parties during the transition process.
215158929|NCT06946810|BEHAVIORAL|Letter-based transition|In this arm, patients are transitioned from pediatric to adult gastroenterology care through a referral system where the pediatrician prepares a comprehensive clinical report that accompanies the patient to their first adult gastroenterology appointment. The transition occurs without joint visits between pediatric and adult specialists.
214543146|NCT03272529|OTHER|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
214543147|NCT03272529|OTHER|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
214543148|NCT05376904|DRUG|HR18034|HR18034 low dose
214543149|NCT05376904|DRUG|HR18034|HR18034 midium dose
214543150|NCT05376904|DRUG|HR18034|HR18034 high dose
214543151|NCT05376904|DRUG|ropivacaine HCl.|ropivacaine HCl.
214543152|NCT00621192|DRUG|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
214543153|NCT04426435|DRUG|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
214543154|NCT04706793|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
214698148|NCT03591679|PROCEDURE|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
214698149|NCT06516666|BEHAVIORAL|Music|"Participants went through four stages. In the rest stage, they were instructed to relax. In the neutral control stage, they watched an informative video about plastic injection molding. In the sadness induction stage, they viewed sad clips from either Hachi: A Dog's Tale or My Brother and Sister, with the order randomized across participants. In the music intervention stage, they listened to the cheerful Cuckoo Waltz. Each stage lasted for about 6 minutes.~The interventions for the two groups were exactly same.~PS: On the basis of the PHQ-9, this HAMD interview was conducted to further group the participants. So, following the experimental protocol, participants who scored ≥ 5 on the PHQ-9 measure underwent the HAMD interview, while the remaining individuals were simply interviewed about their feelings during the experiment."
214698150|NCT00783341|DRUG|GAP-134|
214698151|NCT00783341|DRUG|placebo|
214698152|NCT01205672|DRUG|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
214698153|NCT04043338|DRUG|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
214698154|NCT04043338|DRUG|Placebo|Placebo supplied as matching capsules or tablets
214698155|NCT00564954|DRUG|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
215158930|NCT06947018|BEHAVIORAL|Adolescent Girls' and Boys' Empowerment Program|"The program was developed based on a social behavioural change (SBC) approach in order to change attitudes and behaviours of the participants, consisting of the following main activities on a 6 - 8 week cycle.~* Girls' Empowerment Training: Workshops comprise six sessions of approximately 80 minutes each, held separately with girls aged 12-15 and 16-18 years in groups of approximately 12-20 adolescents on a range of life skill themes.~* Boys' Awareness Raising Training: Similar to the girls' training, four workshops are organized for boys aged 12-15 and 16-18 years, in separate sessions, with similar length and group size.~* Awareness Raising Seminars to Caregivers: Caregivers (e.g., mothers, fathers) are invited to a one-time seminar focused on the negative outcomes of child marriage and role of caregivers in preventing child marriage, lasting approximately one hour and conducted separately for fathers and mothers to eventually influence social norms in the family and communities."
214543155|NCT04706793|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
214543156|NCT00087945|DRUG|Abacavir sulfate|
214543157|NCT00087945|DRUG|Abacavir sulfate, lamivudine, and zidovudine|
214543158|NCT05395923|PROCEDURE|Suture|The pressure application will be applied before the incision on the palate.
214543159|NCT05395923|PROCEDURE|No Suture CTG -Control|A graft will be taken from the palate before the procedure is applied.
214543160|NCT03191071|DIAGNOSTIC_TEST|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
214543161|NCT03191071|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
214543162|NCT03191071|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
214543163|NCT03191071|DIAGNOSTIC_TEST|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
214543164|NCT02868671|OTHER|acupuncture|
214543165|NCT02868671|OTHER|sham acupuncture|
214698156|NCT00564954|DRUG|Placebo|orally once a day for 7 days
215158931|NCT06946836|DRUG|AK104|Eligible patients will be randomly assigned in a 1:1 ratio to either the PD-1 combined with chemotherapy group or the AK104 monotherapy group. Treatment will be administered every 3 weeks, with patients undergoing three preoperative treatment cycles before surgery.
215158932|NCT06343987|BEHAVIORAL|Physical Activity|12-week physical activity program with training 3 times a week. The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
215158933|NCT06164795|DRUG|Zoledronate|intravenous infusion
214543166|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)
214543167|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
214543168|NCT01477736|DRUG|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
214543169|NCT01477736|DRUG|Botulinum toxin A|300 U intradetrusor injection
214543170|NCT03672799|BEHAVIORAL|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
214543171|NCT03672799|OTHER|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
214543172|NCT02893098|DRUG|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
214543173|NCT02893098|DRUG|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
214543174|NCT01283022|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214543175|NCT01993277|DEVICE|Nexalin Brain Stimulator|
214543176|NCT01993277|DEVICE|Fischer Wallace Stimulator|
214543177|NCT01993277|DEVICE|David Delight Stimulator|
214543178|NCT01993277|BEHAVIORAL|Relaxation Therapy|
214543179|NCT03062085|OTHER|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
214543180|NCT02461862|BEHAVIORAL|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
214543181|NCT02461862|PROCEDURE|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
214543182|NCT02461862|PROCEDURE|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
214543183|NCT01085383|DRUG|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
214543184|NCT04686292|DIAGNOSTIC_TEST|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
214543185|NCT01874509|BEHAVIORAL|Check Your Drinking|
214543186|NCT01874509|BEHAVIORAL|Alcohol Help Centre|
214543187|NCT02601209|DRUG|Pazopanib|Given PO
214543188|NCT02601209|DRUG|Pazopanib Hydrochloride|Given PO
214543189|NCT02601209|DRUG|Sapanisertib|Given PO
215158934|NCT06164795|DRUG|Denosumab|subcutaneous injection
214543190|NCT03439618|OTHER|time-restricted feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
214543191|NCT03439618|OTHER|continuous feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
214543192|NCT02599922|BIOLOGICAL|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
214543193|NCT01390142|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
214543194|NCT01390142|PROCEDURE|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
214543195|NCT01390142|PROCEDURE|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
214543196|NCT02925845|DEVICE|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
214543197|NCT02970097|DRUG|20ml bolus of 0.5% ropivicaine|local anesthetic
215158935|NCT06164795|DRUG|Teriparatide|subcutaneous injection
215158936|NCT06164795|DRUG|Romosozumab|subcutaneous injection
214543198|NCT02970097|DRUG|10 ml of 0.5% ropivicaine|local anesthetic
214543199|NCT02970097|DRUG|Midazolam|1-2 mg of medication given intravenously before nerve block
214543200|NCT02970097|DRUG|Fentanyl|50-100 mcg of medication given intravenously before nerve block
215158937|NCT06164795|DRUG|Abaloparatide Injection (80 mcg)|daily subcutaneous injection
215158938|NCT06044727|PROCEDURE|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
215158939|NCT06044727|PROCEDURE|Conventional subgingival instrumentation|Conventional subgingival instrumentation
215158940|NCT05014256|BEHAVIORAL|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
215158941|NCT04253691|DEVICE|Virtual Reality Mediated Relaxation|Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
214543201|NCT05247697|DRUG|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
214543202|NCT05247697|DRUG|Placebo oral tablet once daily at bedtime|Matching placebo
214543203|NCT05995093|OTHER|no intervention|no intervention
214543204|NCT01314599|DRUG|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
214543205|NCT03636373|DRUG|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
214543206|NCT03636373|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
214543207|NCT02150395|OTHER|music therapy|
214543208|NCT00572533|OTHER|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
214543209|NCT00572533|OTHER|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
214543210|NCT01586481|DEVICE|SANIDIAB|off-loading shoe
214543211|NCT01586481|DEVICE|BAROUK|old shoe
214543212|NCT03679897|DRUG|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
214543213|NCT03679897|DRUG|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
214543214|NCT03382769|DEVICE|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
214543215|NCT04228198|PROCEDURE|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
214543216|NCT02888379|DRUG|TOP1288|
214543217|NCT02888379|DRUG|Placebo (for TOP1288)|
214543218|NCT01126320|DEVICE|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
214543219|NCT01126320|DEVICE|routine mechanical ventilator|routine mechanical ventilation
214543220|NCT00557531|DEVICE|BL-1040|2 mL of BL-1040
214543221|NCT04196543|OTHER|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra\_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
214543222|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
214543223|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
214543224|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
214543225|NCT02313337|OTHER|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
215158942|NCT06655844|DEVICE|Sana Pain Reliever|The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).
215158943|NCT06655844|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
215158944|NCT06654180|DEVICE|Orthokeratology|Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.
215158945|NCT06654180|DEVICE|defocus-incorporated multiple segment lenses (DIMS) spectacles|It is the special lenses with peripheral lots of tiny segments of plus lenses around the center
215158946|NCT06654180|DEVICE|DISK|SVS
214543226|NCT02313337|OTHER|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
215158947|NCT06654180|DEVICE|Single-focus spectacles|Myopic Glasses with mono-focus in each eye
214543227|NCT02313337|OTHER|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
215158948|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
215158949|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
215158950|NCT06590584|OTHER|Patients with obesity|Six-Minute Pegboard and Ring Test: It will be used to evaluate upper extremity exercise capacity. There are 20 rings on 4 iron bars on the board used and patients will be asked to attach the rings with both hands, first from top to bottom and then from bottom to top. At the end of the six minutes, the total number of rings attached will be recorded. Heart rate, blood pressure, respiratory rate, dyspnea and fatigue will be evaluated according to the Modified Borg Scale before and after the test.
215158951|NCT06590649|BEHAVIORAL|Household-level effects|At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). The household participants will be analyzed side by side with the index participants.
215158952|NCT02987387|DEVICE|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
215158953|NCT06600087|BEHAVIORAL|Questionnaire|Standardized self-administered questionnaire specifically designed for this study.
215158954|NCT02930018|DRUG|Nerinetide (NA-1), 2.6 mg/kg|Single intravenous infusion of nerinetide over 10 ± 1 minutes
215158955|NCT02930018|DRUG|Placebo|Placebo Comparator: Placebo
215158956|NCT06646731|DEVICE|cryoneurolysis|Peripheral nerve cryoneurolysis of the foot
215158957|NCT06646731|DEVICE|sham cryoneurolysis|a sham probe will be placed percutaneously proximal to target nerves. No cryoneurolysis will be given.
215158958|NCT06667011|BEHAVIORAL|Feedback|learning conversation between trainee and teacher lasting 5 to 10 minutes at the end of each working day
215158959|NCT06591403|OTHER|the index and middle fingers of each participant&amp;#39;s active hand|A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
215158960|NCT06858904|DIETARY_SUPPLEMENT|Placebo|Non- calorically sweetened Water
215158961|NCT06858904|DIETARY_SUPPLEMENT|ConcenTrace|1.25 milliliter of concentrace per liter
214543228|NCT02313337|OTHER|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
214543229|NCT02313337|DRUG|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
215158962|NCT06858904|DIETARY_SUPPLEMENT|ZeroLyte|Beverage with 1 pack of ZeroLyte per 500 milliliter of water
214543230|NCT02313337|PROCEDURE|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
214543231|NCT02313337|DRUG|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
214543232|NCT00835185|BIOLOGICAL|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
214543233|NCT00835185|DRUG|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
214543234|NCT00835185|DRUG|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
214543235|NCT00835185|DRUG|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
214543236|NCT01844713|BEHAVIORAL|Workbook|Subjects will read a workbook about sun protection
214543237|NCT04999605|DRUG|AK112 low dose|AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
215158963|NCT06602947|OTHER|Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation|"1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
215158964|NCT07000357|DRUG|AZD0780|Participants will receive oral AZD0780 once daily
215158965|NCT07000357|DRUG|Placebo|Participants will receive oral placebo once daily
215158966|NCT06599281|OTHER|Physiotherapy|The physical therapy program was applied for 3 months, 6 days a week, 2 sessions per day, and an average session duration of 45 minutes. Each neurodevelopmental exercise and proprioceptive exercise was applied for 10 minutes, and stretching exercises were applied for 45 seconds and 3 repetitions. The exercises included functional rotation, sitting with or without arm support, crawling, kneeling, half kneeling, standing up by holding on, and sequencing exercises. Stretching exercises were mostly positional stretches aimed at lateral flexion of the spine.
215158967|NCT04528303|GENETIC|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
214543238|NCT04999605|DRUG|AK112 medium dose|AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
214543239|NCT04999605|DRUG|AK112 high dose|AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
214543240|NCT01337206|DEVICE|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
214543241|NCT01337206|PROCEDURE|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
214543242|NCT04042025|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
215158968|NCT04528303|GENETIC|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
215158969|NCT06614790|DRUG|Niraparib 200/300 MG|"We expect to enroll approximately 300 patients from about 10 sites. Treatment part of study.~Part I- looking retrospectively at the time period JAN 2021-MAR 2023. The retrospective data will include patients who are enrolled in niraparib treatment:~* under the EAP (started in JAN 2021, in continuation)~* under the B.50 drug program, which began in January 2022 Of note, the retrospective multi-center observational study will involve about 30 patients treated with niraparib in EAP (FIGO III R0 after PDS included) and patients who were treated with niraparib before starting RWE (about 120 pts) (JAN 2021- MAR 2023) by the drug program B.50 which has been started to adapt on 1st of Jan, 2022.~FIGO III PDS to R0 patients are included to this study. Part II- looking prospectively at the time period APR 2023 to DEC 2025. The prospective data will include patients who are enrolled in niraparib treatment under the B.50 drug program.~The prospective multi-center observational study will i"
215158970|NCT06530394|DIETARY_SUPPLEMENT|Greek yogurt|Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.
215158971|NCT05799872|BEHAVIORAL|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.
215158972|NCT05799872|BEHAVIORAL|Psychoeducational and Behavioral Therapy (PBT)|The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
215158973|NCT05748600|DRUG|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
215158974|NCT05748600|DRUG|Placebo|administration of placebo tablet
214543243|NCT03793322|DRUG|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
214543244|NCT01530087|DEVICE|CASTLE barrier|Prototype barrier to be used in place of current two piece device
214543245|NCT03896074|DRUG|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
215158975|NCT07134738|DRUG|Dimolegin|Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily.
215158976|NCT07134660|PROCEDURE|Liposomal Bupivacaine intercostal nerve block|Ultrasound-guided intercostal nerve block with liposomal bupivacaine 266 mg (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
215158977|NCT07134660|PROCEDURE|Bupivacaine Hydrochloride intercostal nerve block|Ultrasound-guided intercostal nerve block with 0.25% bupivacaine hydrochloride (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
215158978|NCT07134660|OTHER|Standard Postoperative Analgesia|No intercostal nerve block. Patients receive standard postoperative analgesia consisting of an intravenous patient-controlled opioid pump per institutional protocol.
214543246|NCT03896074|DRUG|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
214543247|NCT01324700|DRUG|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
214543248|NCT01324700|DRUG|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
214543249|NCT01324700|DRUG|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
214543250|NCT01324700|DRUG|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
214543251|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
214543252|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
214543253|NCT03108638|BEHAVIORAL|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
214543254|NCT02220218|DRUG|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
214543255|NCT02220218|DRUG|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
214543256|NCT02220218|DRUG|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
214543257|NCT02640170|OTHER|Registry|
214543258|NCT00661713|BIOLOGICAL|rMenB+OMV NZ|
214543259|NCT00661713|BIOLOGICAL|Placebo|
214543260|NCT04605744|BEHAVIORAL|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
214543261|NCT06172114|PROCEDURE|Alveolar ridge preservation using sticky bone|In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
214543262|NCT01837498|DRUG|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
214543263|NCT01837498|DRUG|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
214543264|NCT01828385|DRUG|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
214543265|NCT01828385|DRUG|Saline|Saline + rocuronium + sugammadex
215158979|NCT07127432|DEVICE|The Storytelling Caterpillar|The Storytelling Caterpillar is a plastic toy measuring 19.5 × 5.5 × 25.5 cm and is recommended for use in children aged 1-6 years. It is designed in the form of a storybook and includes interactive f
215158980|NCT06865079|DRUG|TPX-100 200mg, Once weekly for 4 weeks|"TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 \& 4) to a single target knee of the subject for 4 injections.~TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection."
215158981|NCT06865079|OTHER|PBS|PBS / placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections
215158982|NCT06866691|DRUG|levetiracetam|levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days
214543266|NCT02893488|DRUG|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
214543267|NCT02893488|DRUG|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
214543268|NCT02893488|DRUG|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
214543269|NCT01606423|DRUG|Placebo|Administered orally, single dose
214543270|NCT01606423|DRUG|LY2409021|Administered orally, single dose
214543271|NCT05588544|PROCEDURE|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
214543272|NCT04080713|DRUG|Budesonide|Budesonide 9 mg prolonged release tablet
214543273|NCT06957665|DEVICE|T-scan Assisted Occlusal Adjustment with Stabilization Splint|Participants were treated with a custom-fabricated stabilization splint (Michigan-type) whose occlusion was adjusted using the T-scan system (Tekscan, Norwood, MA, USA) to measure and optimize occlusal force distribution. The T-scan system was used in conjunction with articulating paper to guide occlusal refinement until bilateral force balance was achieved.
214543274|NCT06957652|DEVICE|DBMM-C plus Resorbable collagen membrane|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, followed by coverage with a resorbable collagen membrane. The flaps will then be coronally advanced and stabilized over the biomaterials.
214543275|NCT06957652|DEVICE|DBMM-C|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, and then the flaps will be coronally advanced and stabilized over the graft material.
214543276|NCT00416598|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
214543277|NCT00416598|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
214543278|NCT00416598|DRUG|Busulfan|Given IV
214543279|NCT00416598|DRUG|Cytarabine|Given IV
214543280|NCT00416598|DRUG|Daunorubicin Hydrochloride|Given IV
214543281|NCT00416598|DRUG|Decitabine|Given IV
214543282|NCT00416598|DRUG|Etoposide|Given IV
214543283|NCT00416598|BIOLOGICAL|Filgrastim|Given SC
214543284|NCT00416598|OTHER|Laboratory Biomarker Analysis|Correlative studies
214543285|NCT00416598|OTHER|Pharmacological Study|Correlative studies
214543286|NCT04692545|DIETARY_SUPPLEMENT|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
214543287|NCT01347671|DRUG|GRT6005|25µg/day once daily
214543288|NCT01347671|DRUG|GRT6005|75 µg/day once daily
214543289|NCT01347671|DRUG|GRT6005|200 µg/day once daily
214543290|NCT01347671|DRUG|Matching Placebo|Once daily
214543291|NCT04907279|DRUG|Aripiprazole Once-Monthly (AOM)|Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.
214543292|NCT03082937|DRUG|3 mg [14C]-A4250 capsule|Each subject will receive a single administration of 3 mg \[14C\]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
214543293|NCT05567107|OTHER|massage|Classical foot massage was applied by the researcher with efflorescence, superficial friction and petrissage techniques for 10 minutes on each foot.
214543294|NCT00429143|RADIATION|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
214543295|NCT00429143|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
214543296|NCT00429143|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
215158983|NCT06866691|DRUG|lacosamide|lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days
215158984|NCT06675643|OTHER|Non-Interventional Study|Non-Interventional study
215158985|NCT04077879|DRUG|ASP1617|Oral
215158986|NCT04077879|DRUG|Placebo|Oral
214543297|NCT00429143|DRUG|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
214543298|NCT00429143|DRUG|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
214543299|NCT00429143|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
214543300|NCT03427060|DRUG|Coversin|Coversin - 22.5mg followed by 45mg for 6 months.
214543301|NCT00216047|DRUG|PTK787|PTK787 daily
215158987|NCT07008469|DRUG|Del-desiran (AOC 1001)|Del-desiran will be administered by intravenous (IV) infusion.
215158988|NCT06681402|DRUG|FLAMOD|FLAMOD (GMP-grade flagellin) inhalation
215158989|NCT06681402|DRUG|Placebo|Placebo inhalation
215158990|NCT06625034|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215158991|NCT06625034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215158992|NCT06625034|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
215158993|NCT06625034|PROCEDURE|Positron Emission Tomography|Undergo PET
214543302|NCT00216047|DRUG|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*
214543303|NCT00631345|BEHAVIORAL|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
214543304|NCT00631345|OTHER|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
214543305|NCT00631345|BEHAVIORAL|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
214543306|NCT00631345|BEHAVIORAL|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
215158994|NCT06625034|OTHER|Questionnaire Administration|Ancillary studies
215158995|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive human-driven treatment planning
215158996|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive RapidPlan treatment planning
215158997|NCT05038098|PROCEDURE|Gastrectomy|Undergo surgery
215158998|NCT05038098|DRUG|Indocyanine Green|Given peritumorally
215158999|NCT05038098|OTHER|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
215159000|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
215159001|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
215159002|NCT03644511|DRUG|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
215159003|NCT03644511|DRUG|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
215159004|NCT03578783|DRUG|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
215159005|NCT03578783|DRUG|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
215159006|NCT06556810|DRUG|Atibuclimab (IC14)|Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
215159007|NCT06398444|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
215159008|NCT02226731|DEVICE|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
214543307|NCT02579824|DRUG|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
214543308|NCT02866396|DRUG|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
214543309|NCT02866396|OTHER|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
214543310|NCT02075619|DRUG|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
214543311|NCT02075619|DRUG|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
214543312|NCT02075619|DRUG|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
214543313|NCT05967182|DRUG|Pembrolizumab|Given by IV (vein)
214543314|NCT05967182|DRUG|Gemcitabine|Given by IV (vein)
214543315|NCT05967182|DRUG|Cisplatin|Given by IV (vein)
214543316|NCT05429255|BEHAVIORAL|Aerobic Exercise|Bicycle training
214543317|NCT05429255|BEHAVIORAL|Exergame Training|Nintendo Wii
214543318|NCT04200898|DEVICE|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
214543319|NCT00810342|BEHAVIORAL|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
214543320|NCT00810342|BEHAVIORAL|physical activity standard|standard print and website information on how to become more active
214543321|NCT04144647|OTHER|Single testing session|"All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off."
214543322|NCT03360578|DEVICE|Garmin|A commercial grade health wearable
214543323|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
214543324|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
214543325|NCT04178447|DRUG|Glepaglutide|Single dose of Glepaglutide 10 mg
214543326|NCT04486313|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
214543327|NCT04486313|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
214543328|NCT04486313|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
214543329|NCT04719715|DIAGNOSTIC_TEST|Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays|Measurement and evaluation of the ANCA testing
214543330|NCT02865551|DEVICE|Foley catheter|Extended bladder catheterization after epidural anesthesia.
214543331|NCT02865551|DEVICE|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
214543332|NCT02865551|DRUG|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
214543333|NCT04815343|DEVICE|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
214543334|NCT04636645|OTHER|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
214543335|NCT04636645|OTHER|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
215159009|NCT02226731|DEVICE|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
214543336|NCT04636645|OTHER|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
215159010|NCT06690905|DRUG|Piperacillin-tazobactam administered in a prolonged infusion|For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.
215159011|NCT06690905|DRUG|Piperacillin-tazobactam administered in a standard infusion|For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
215159012|NCT07018492|DRUG|BPN14770|Administered as specified in the treatment arm.
215159017|NCT04549298|OTHER|No interventions|No interventions - observational study
215159018|NCT03543917|COMBINATION_PRODUCT|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
215159019|NCT06248996|RADIATION|Hyperfractionated radiotherpy|83.0 Gy in 68 fractions, 1.22 Gy per fraction, two daily fractions, five days per week to the primary tumour volume (GTVT\_83.0). To the primary tumour with an added margin (PTVT\_74.8) and to neck node metastases (PTVN\_74.8) the prescribed dose will be 74.8 Gy in 68 fractions, 1.10 Gy per fraction twice daily. To elective neck nodes (PTV 54.4) the prescribed dose will be 54.4 Gy in 68 fractions, 0.80 Gy per fraction twice daily.
215159020|NCT06248996|RADIATION|Control group|68.0 Gy in 34 fractions, 2.00 Gy per fraction per day, five or six days per week to tumour volumes and 54.4 Gy in 34 fractions, 1.60 Gy per fraction to elective neck nodes.
215159021|NCT05458713|DEVICE|Laser acupuncture|Irradiate acupoints with low power laser
215159022|NCT06628206|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
215159023|NCT06628206|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
215159024|NCT06623292|OTHER|Motivational interviewing-based breastfeeding education|This program includes breastfeeding motivational interviewing consisting of a total of 4 sessions and breastfeeding education consisting of one session.
215159025|NCT06691035|DRUG|Elacestrant|"345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)"
215159026|NCT06691035|BIOLOGICAL|DC1 native/mutated ESR1|"2.0-5.0 x 10 (20-50 million) cells (Injections in groin nodes (or accessible breast tumor if available) weekly with DC1 for eight consecutive weeks, alternating between native ESR1 DC1s and mutated ESR1 DC1s.~Mutated ESR1 DC1s on week 1 followed by native ESR1 DC1s on week 2, alternating during the initial vaccination series and the subsequent booster phase.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses."
215159027|NCT06203132|DRUG|Doravirine + tenofovir DF + lamivudine|Oral administration
215159028|NCT06203132|DRUG|Dolutegravir + tenofovir DF + lamivudine or emtricitabine|Oral administration
215159029|NCT07022275|DIETARY_SUPPLEMENT|Hemp protein powder|Agoge Universal Hemp Protein Powder - A certified cannabinoid-free hemp protein powder.
215159030|NCT06325813|DEVICE|Active repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.
215159031|NCT06325813|DEVICE|Sham repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
215159032|NCT06223373|DEVICE|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
215159033|NCT06223373|DEVICE|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
215159034|NCT03632473|DIAGNOSTIC_TEST|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
214543337|NCT03560570|BIOLOGICAL|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
214543338|NCT03560570|OTHER|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
215159035|NCT06874205|DRUG|11C-JMJ-129|Injected IV followed by PET scanning
215159036|NCT05283031|DIAGNOSTIC_TEST|Modified Diurnal Tension Curve|The modified diurnal tension curve (mDTC), an alternative that involves IOP measurements every 2 or 3 hours during office hours, is more feasible and may provide better information regarding the IOP profile than single IOP measurements.
215159037|NCT04087109|OTHER|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
214543339|NCT01496365|DRUG|DS-5565 tablet|5mg and 10mg tablets
214543340|NCT01496365|DRUG|pregabalin capsule|75mg and 150mg over-encapsulated
214543341|NCT01496365|DRUG|Placebo tablet|
214543342|NCT01496365|DRUG|placebo capsule|
215159038|NCT06715670|DRUG|Zibotentan|Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
215159039|NCT06722118|DRUG|Dexamethasone IV|IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
215159040|NCT06722118|OTHER|Placebo|Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
215159041|NCT06726148|DRUG|ECI830|Experimental
215159042|NCT06726148|DRUG|ribociclib|Approved medication
215159043|NCT06726148|DRUG|fulvestrant|Approved medication
215159044|NCT06466421|DRUG|Fexofenadine|Fexofenadine 60 mg orally once daily for 3 months
215159045|NCT06466421|DRUG|Gabapentin|100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
214543343|NCT03017937|DEVICE|Q-collar|capture ultrasound images at each pressure point
214543344|NCT02706951|DRUG|Methotrexate|Capsule; Oral
214543345|NCT02706951|DRUG|Upadacitinib|Tablet; Oral
214543346|NCT02706951|DRUG|Placebo Upadacitinib|Tablet; Oral
214543347|NCT02706951|DRUG|Placebo Methotrexate|Capsule; Oral
214543348|NCT01843777|BEHAVIORAL|Standard-of-Care|the standard of care in audiologic practice
214543349|NCT01843777|BEHAVIORAL|Treatment|motivational interviewing
214543350|NCT04324190|BEHAVIORAL|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
214543351|NCT04324190|BEHAVIORAL|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
214543352|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
214543353|NCT06838169|BEHAVIORAL|Virtual reality glasses|virtual reality glasses application
214543354|NCT06838169|BEHAVIORAL|breathing exercise|breathing exercise app
214543355|NCT01821105|PROCEDURE|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
214543356|NCT01821105|PROCEDURE|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
214543357|NCT01821105|RADIATION|fludeoxyglucose F 18|Given IV
214543358|NCT01821105|PROCEDURE|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
214543359|NCT02978677|RADIATION|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
214543360|NCT02978677|RADIATION|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
214543361|NCT02978677|RADIATION|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
214543362|NCT01834612|DEVICE|CM1500|blood volume monitor
214543363|NCT04700059|BEHAVIORAL|Virtual perinatal home visiting|10 perinatal home visits
214543364|NCT02846064|PROCEDURE|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
214543365|NCT04883060|DEVICE|midline localizer|a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
214543368|NCT03193242|OTHER|Electronic Asthma Management System: eAMS|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
214543369|NCT03539068|BEHAVIORAL|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive::~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider)."
214543370|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
214543371|NCT01300442|OTHER|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
215159046|NCT05122455|DRUG|ASA|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
214543372|NCT01300442|OTHER|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
214543373|NCT01146977|OTHER|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
215159047|NCT05122455|DRUG|Clopidogrel|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
214543374|NCT01146977|OTHER|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
214543375|NCT01124968|OTHER|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
214543376|NCT01777334|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
214543377|NCT01777334|DRUG|Tiotropium 18 mcg|Inhalation Powder
214543378|NCT05888844|DRUG|INCB099280|Administered as specified in the treatment arm description.
214543379|NCT05216042|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
214543380|NCT05216042|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
214543381|NCT05216042|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
214543382|NCT05216042|OTHER|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
214543383|NCT05361811|BEHAVIORAL|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
214543384|NCT05361811|BEHAVIORAL|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
214543385|NCT03672019|BEHAVIORAL|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
214543386|NCT04488666|DEVICE|npSIMS|incisional NPWT
214543387|NCT05117840|DEVICE|Low-dose CT scan|Standard of care screening for individuals at high-risk of lung cancer
214543388|NCT05948423|OTHER|Tisue Flossing Technique|"Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted."
214543389|NCT04740723|DEVICE|iRF System Renal Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery
214543390|NCT00491621|PROCEDURE|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
214543391|NCT06332898|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
214543392|NCT06332898|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214543393|NCT01896180|DRUG|ALZ-1101|ALZ-1101 Ophthalmic Solution
214543394|NCT01896180|DRUG|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
214543395|NCT00520624|DEVICE|inspiratory muscle strength training|
214543396|NCT00520624|PROCEDURE|Surgery|
214543397|NCT03546387|OTHER|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
214543398|NCT03546387|OTHER|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
214543399|NCT03546387|OTHER|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
214543400|NCT03546387|OTHER|Grooved Pegboard Test|Measures dexterity
214543401|NCT03546387|OTHER|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
214543402|NCT03359564|PROCEDURE|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
214543403|NCT05896189|BEHAVIORAL|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.
215159048|NCT05122455|DRUG|Edoxaban|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
215159049|NCT06896994|DRUG|esketamine group|In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.
215159050|NCT06896994|DRUG|control group|receiving the combination of pregabalin and duloxetine
215159051|NCT05336383|DRUG|Radiation Therapy|Given by Infusion
215159052|NCT05185661|BEHAVIORAL|eHealth education|"eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education"
215159053|NCT06890416|BIOLOGICAL|RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE|Intramuscular injection
214543404|NCT05896189|BEHAVIORAL|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
215159054|NCT06890416|BIOLOGICAL|HZ/su VACCINE|intramuscular injection
215159055|NCT07062003|PROCEDURE|Biopsy Procedure|Undergo biopsy
215159056|NCT07062003|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215159057|NCT07062003|PROCEDURE|Computed Tomography|Undergo CT
215159058|NCT07062003|OTHER|Medical Device Usage and Evaluation|Undergo MBRT with tungsten slit collimator
215159059|NCT07062003|RADIATION|Minibeam Radiation Therapy|Undergo MBRT with tungsten slit collimator
215159060|NCT06762054|DRUG|Continue DTG-based antiretroviral therapy|Participants will continue on DTG-based ART after enrollment for up to 12 months
215159061|NCT06762054|BEHAVIORAL|Enhanced adherence counselling|Participants with VL ≥200 copies/mL will undergo enhanced adherence counselling
215159062|NCT07062783|OTHER|Breathing exercise|Volunteers participating in the study who were included in the experimental group performed breathing exercises every day for three weeks. They were taught to focus their attention on the hand on their abdominal area while breathing slowly through their nose and to increase abdominal movement while reducing chest movement. They were warned that during inspiration, as air filled their lungs, the hand on their abdomen should rise upward and the hand on their chest should not move excessively. Participants continued the training until they performed the exercise correctly. The diaphragmatic breathing exercise was performed for 10 minutes in the supine position during the first week, in the semi-sitting and/or sitting position during the second week, and in the standing position during the final week.
214543405|NCT06962020|DRUG|first-line biologic：IFX|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
214543406|NCT06962020|DRUG|first-line biologic:VDZ|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
214543407|NCT04070768|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
214543408|NCT04070768|DRUG|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
215159063|NCT07062783|OTHER|Aerobic Exercise|The ratios determined as reference values for walking training in healthy adults (reference value for women = (2.11\*height) - (2.29\*body weight) - (5.78\*age) + 667 meters - reference value for men = (7.57\*height) - (1.76\*body weight) - (5.0 2\*age) - 309 meters) was performed at 80% intensity for at least 30 minutes on at least 3 days a week for 3 weeks. Aerobic exercise was considered for 3 weeks to facilitate adaptation to exercise and sustainability.
215159064|NCT06890897|DRUG|Esketamine group|Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients
215159065|NCT06890897|DRUG|PRF group|Patients in the control group will receive PRF+standardized treatment
214543409|NCT06531304|DEVICE|Lokomat Robot Assisted Gait Training|Patients will underwent 12 RAGT training sessions (3 times/week for 4 consecutive weeks, 45 min each including the time for wearing the harness and the exoskeleton) with the Lokomat device as add-on to conventional regimen (5 times/week, 80 min each). The Lokomat is a technologically advanced robot-assisted gait training device. Patients are supported in a harness above a treadmill while the robotic device assists the movements of their legs to provide physiological gait. As treatment progresses, weight bearing is increased and assistance from the robotic legs is reduced, requiring the patient to gradually assume greater responsibility for movements needed during walking.
214543410|NCT04685447|PROCEDURE|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
214543411|NCT04685447|PROCEDURE|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
214543412|NCT05204069|DRUG|Instillation of cyclopentolate|Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
214543413|NCT04599855|DRUG|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
214543414|NCT04599855|DRUG|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
214543415|NCT04599855|DRUG|Placebo|Matching placebo will be self administered as nasal spray.
214543416|NCT06134622|DRUG|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
214543417|NCT06134622|DRUG|Intravenous thrombolysis plus placebo|placebo (saline)
214543418|NCT00951964|DRUG|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
214543419|NCT00951964|DRUG|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
214543420|NCT02165397|DRUG|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
214543421|NCT02165397|DRUG|Placebo|Participants will receive placebo capsules orally.
214543422|NCT02165397|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV.
214543423|NCT01836016|DRUG|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
214543424|NCT01836016|DRUG|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
214543425|NCT01836016|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
214543426|NCT01836016|DRUG|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
214543427|NCT01836016|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
214543428|NCT01836016|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
214543429|NCT01836016|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
214543430|NCT01836016|DRUG|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
214543431|NCT01855477|PROCEDURE|Histological biopsy procedure|
214543432|NCT05387837|DRUG|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
214698157|NCT04619121|DEVICE|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
215159066|NCT04829240|BEHAVIORAL|Veterans Anxiety Skills Training Intervention|Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms
215159067|NCT04829240|BEHAVIORAL|PCMHI Usual Care|Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
215159068|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
215159069|NCT05731544|DRUG|BMF-219|Investigational Product
215159070|NCT06823180|DRUG|Hydromorphone hydrochloride low dose|15min before the end of the operation, 0.1mg hydromorphone hydrochloride was injected into the epidural space in the low-dose group for preemptive analgesia.
215159071|NCT06823180|DRUG|Hydromorphone hydrochloride high dose|15min before the end of the operation, 0.3mg hydromorphone hydrochloride was injected into the epidural space in the high-dose group for preemptive analgesia.
215159072|NCT06823180|DRUG|0.9% sodium chloride|15min before the end of the operation, 0.9% sodium chloride injection was given in the control group.
215159073|NCT04888988|OTHER|Best Practice|Receive standard of care
215159074|NCT04888988|OTHER|Exercise Counseling|Meet with certified exercise instructor
215159075|NCT04888988|OTHER|Exercise Intervention|Participate in the EXCAP program
215159076|NCT04888988|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215159077|NCT04888988|OTHER|Neuropathy Assessment|Undergo tactile sensitivity test
215159078|NCT04888988|OTHER|Questionnaire Administration|Ancillary studies
215159079|NCT07084168|BEHAVIORAL|Educational videos|Educational videos about genetic testing will be provided. Subjects will be asked to view one of three videos (an endometrial cancer/Lynch Syndrome video or a longer or shorter version of an ovarian cancer video) relevant to their cancer diagnosis and genetic testing.
215159080|NCT07084168|BEHAVIORAL|Survey|Subjects will be asked to complete a brief satisfaction survey.
215159081|NCT07142395|PROCEDURE|Immediate skin closure|After laparotomy wounds will be closed primarily using no. 1 vicryl suture
214543433|NCT04921553|OTHER|Data collection and quality of life questionnaire|"* Data collection from the medical file~* Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
214543434|NCT00424554|DRUG|temozolomide|"Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
214543435|NCT02956083|OTHER|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
214543436|NCT02956083|OTHER|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
214543437|NCT02956083|OTHER|saline|Saline - no brand name
214543438|NCT00000177|DRUG|Estrogen|
214543439|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
214543440|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
214543441|NCT04493697|DEVICE|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
214543442|NCT04493697|DEVICE|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
215159082|NCT07142395|PROCEDURE|Delayed primary closure|Deeper layers of wound will be closed after surgery and loose mattress sutures will be applied to skin with prolene. After three to five days of daily dressing with bactericidal solution, the skin will be closed
215159083|NCT06938464|DIETARY_SUPPLEMENT|Probiotics|Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid
215159084|NCT06938464|DIETARY_SUPPLEMENT|Placebo|placebo with similar appearance and smell but not containing probiotics
215159085|NCT06940778|OTHER|No Interventions|no interventions
215159086|NCT02844309|DRUG|Thalidomide|thalidomide 50-150 mg per night
214543443|NCT00236184|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
214543444|NCT00236184|OTHER|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
215159087|NCT02713464|BEHAVIORAL|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
214543445|NCT01579721|PROCEDURE|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
215159088|NCT07144163|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth
215159089|NCT07144163|DRUG|Placebo|Placebo, tablets, once daily by mouth
215159090|NCT07141251|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
215159091|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
215159092|NCT04193189|BIOLOGICAL|HEPLISAV-B|Administered by IM injection
214543446|NCT03689439|DIAGNOSTIC_TEST|bone scintigraphy|bone scintigraphy
214543447|NCT02599688|OTHER|Observation only|No intervention in this study.
214543448|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
214543449|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
214543450|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
214543451|NCT01476813|DRUG|Comparator|comparison of different dosages of drug versus comparator
214543452|NCT01841697|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
214543453|NCT01841697|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
214543454|NCT01841697|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
214543455|NCT01841697|DRUG|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
214543456|NCT01841697|DRUG|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
214543457|NCT01841697|DRUG|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
214543458|NCT00000319|DRUG|Buprenorphine|
214543459|NCT04874623|OTHER|Collection of peripheral blood mononuclear cells|Analysis of specific memory B cells in CDI patients
214543460|NCT04696133|OTHER|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
214543461|NCT04696133|OTHER|sensory integration|"* Tactile stimulation~* Proprioceptive stimulation"
214543462|NCT02492698|DIETARY_SUPPLEMENT|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
214543463|NCT02492698|DIETARY_SUPPLEMENT|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
214543464|NCT06801717|DEVICE|KTP Laser Therapy|Participants will receive full face treatments with 532 nm KTP laser for 3 sessions at 8-12 weeks apart. Laser therapy will be conducted in person. Each laser treatment session will last up to 10 minutes.
214543465|NCT06801717|DEVICE|Radiofrequency microneedling|Participants will receive unilateral facial treatments with radiofrequency microneedling device for 3 sessions at 8-12 weeks apart. Radiofrequency microneedling will be conducted in person. Each treatment session will last up to 1 hour.
214543466|NCT06026475|PROCEDURE|Goal directed Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining SVV below 11
214543467|NCT06026475|PROCEDURE|Conventional Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining CVP between 8-12 cms H20
214543468|NCT00756457|DEVICE|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
214543469|NCT00756457|OTHER|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
214543470|NCT00756457|OTHER|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
214543471|NCT05911178|RADIATION|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesicle density."
214543472|NCT05911178|RADIATION|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
214543473|NCT05911178|RADIATION|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topography of tau deposition."
214543474|NCT05911178|RADIATION|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
214543475|NCT01973062|BIOLOGICAL|rituximab|Given IV
214543476|NCT01973062|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
214543477|NCT04288206|DRUG|Cefazolin|intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
214543478|NCT04288206|DRUG|normal saline|intravenous normal saline placebo
215159093|NCT04193189|BIOLOGICAL|ENGERIX-B|Administered by IM injection
215159094|NCT01650597|DRUG|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
215159095|NCT01650597|DRUG|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
215159096|NCT01650597|DRUG|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
214543479|NCT03019081|DRUG|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
214543480|NCT03019081|OTHER|placebo|placebo
214543481|NCT03889873|BEHAVIORAL|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
214543482|NCT02113410|BEHAVIORAL|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
214543483|NCT02113410|BEHAVIORAL|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
214543484|NCT01028872|DEVICE|Intraocular lens|
214543485|NCT01028872|DEVICE|Intraocular lens|
214543486|NCT01028872|DEVICE|Intraocular lens|
214543487|NCT04682561|BEHAVIORAL|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
214543488|NCT02205775|DRUG|Atorvastatin|80 + 40 mg pre PCI
214543489|NCT02205775|DRUG|Rosuvastatin|40 + 40 mg before PCI
214543490|NCT02205775|DRUG|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
214543491|NCT02205775|DRUG|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
214543492|NCT02205775|DRUG|placebo|twice before PCI
214543493|NCT01612273|DRUG|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
214543494|NCT01612273|DRUG|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
214543495|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
214543496|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
214543497|NCT01309477|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
214543498|NCT02518815|DEVICE|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
214543499|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
214543500|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
214543501|NCT03919409|DRUG|TS-161|TS-161 capsules
214543502|NCT03919409|DRUG|TS-161 Placebo|TS-161 matching placebo capsules
215159097|NCT00108199|BEHAVIORAL|Problem-Solving Training|
215159098|NCT00108199|BEHAVIORAL|Work-Related Social Skills Training|
215159099|NCT06947252|DIAGNOSTIC_TEST|Oral food challenge test|Oral food challenge test at home or in the hospital
215159100|NCT06947785|OTHER|Combined Neural Mobilization with Manual myofascial Release|Combined neural mobilization with manual myofascial release will be provided to each subject.
215159101|NCT06947785|OTHER|Neural Mobilization|neural mobilization will be provided to each subject.
215159102|NCT06947785|OTHER|Manual Myofascial Release|Manual myofascial release will be provided to each subject.
215159103|NCT06947915|OTHER|Co-design workshop|Co-design workshops to develop the implementation model
215159104|NCT06947915|OTHER|Survey|Survey of care staff knowledge and confidence
215159105|NCT06947915|OTHER|Interview|Interview to explore care staff experience of the falls management support
215159106|NCT06945965|PROCEDURE|Injectable platelet-rich fibrin (i-PRF) scaffold|The separated plasma and platelets form a light-yellow-colored layer, which is situated at the top of the tube. This is then aspirated using a syringe with a needle (partially active injectable form).
215159107|NCT06945965|PROCEDURE|platelet-rich fibrin (PRF)scaffold|The fibrin clot was removed from the test tube with sterile tweezers, then cut into fragments, then placed incrementally in the canal space below the CEJ using hand pluggers (without prior induction of apical bleeding).
215159108|NCT06945965|PROCEDURE|blood clot (BC) scaffold|A sterile saline-soaked cotton pellet was placed into the canal 2 mm below the orifice for 15 minutes to form a blood clot.
215159109|NCT00387985|DRUG|MOA-728|
215159110|NCT07150455|OTHER|Echocardiographic Assessment (2D Speckle Tracking)|All participants will undergo standardized 2D echocardiographic examination including Global Longitudinal Strain (GLS) measurement. No drug or device intervention is applied.
215159111|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
215159112|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
215159113|NCT07157410|OTHER|Machinable lithium-disilicate ceramic onlay (IPS e.max CAD)|Single indirect onlay restoration milled from an IPS e.max CAD block and crystallized according to the manufacturer's Instructions for Use, then adhesively luted on a randomized molar under.
214543503|NCT02196805|DRUG|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
214543504|NCT02196805|DRUG|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
214543505|NCT04915131|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
215159114|NCT07157410|OTHER|Pressed lithium-disilicate ceramic onlay (IPS e.max Press)|Single indirect onlay restoration heat-pressed from an IPS e.max Press ingot and then adhesively luted on a randomized molar under rubber-dam isolation.
214543506|NCT00251056|DRUG|mannitol|120mg BD
214543507|NCT00251056|DRUG|mannitol|40 mg BD
214543508|NCT00251056|DRUG|mannitol|240mg BD
215159115|NCT07157410|OTHER|Machinable composite onlay (BRILLIANT Crios)|Single indirect onlay restoration milled from a BRILLIANT Crios block and then adhesively luted on a randomized molar under rubber-dam isolation.
215159116|NCT07156734|DEVICE|Neuromuscular Electrical Stimulation|Studies in healthy individuals have demonstrated that NMES applied to the quadriceps of one limb induces short-term increases in strength and neural drive in the contralateral homologous muscle. Since these effects have only been observed in healthy individuals, it is essential to investigate whether similar responses occur in ACL patients.
215159117|NCT07158372|DIAGNOSTIC_TEST|AI-assisted Intraoperative Anatomy Analysis|This is a prospective study on patients aged 18 years or more diagnosed with laparoscopic cholecystectomy. We will collect information such as laparoscopic cholecystectomy videos and procedure type, excluding patients who did not undergo surgery at the original hospital or whose videos were blurry.
214543509|NCT00251056|DRUG|mannitol|400mg BD
214543510|NCT01910883|DRUG|Finafloxacin i.v. solution 200 mg|
214543511|NCT01910883|DRUG|Finafloxacin i.v. solution 400 mg|
214543512|NCT01910883|DRUG|Finafloxacin i.v. solution 600 mg|
214543513|NCT01910883|DRUG|Finafloxacin i.v. solution 800 mg|
214543514|NCT01910883|DRUG|Finafloxacin i.v. solution 1000 mg|
214543515|NCT01910883|DRUG|Placebo i.v. solution|
214543516|NCT00364377|DRUG|Sitagliptin|100 mg once daily
214543517|NCT00364377|OTHER|Placebo|once daily for duration of the study
214543518|NCT00822770|DRUG|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
214543519|NCT00822770|DRUG|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
214543520|NCT00822770|DRUG|Fludarabine|Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
214543521|NCT00822770|DRUG|Busulfan|Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.
214543522|NCT00822770|PROCEDURE|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
214543523|NCT00822770|DRUG|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
214543524|NCT00930345|DRUG|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
214543525|NCT00051623|DRUG|Infliximab|
215159118|NCT07157007|DRUG|Ratutrelvir (83-0060) non-randomised|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
215159119|NCT07157007|DRUG|Paxlovid|Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)
215159120|NCT07157007|DRUG|Ratutrelvir (83-0060)|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
215159121|NCT07157969|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
215159122|NCT07157969|DRUG|Pembrolizumab|200 mg intravenously every three weeks
215159123|NCT07157969|DRUG|Atezolizumab|1200 mg intravenously every three weeks
214698158|NCT04619121|DEVICE|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
214698159|NCT03471767|DRUG|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
214698160|NCT03471767|DRUG|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
214698161|NCT05371990|OTHER|Determination of Eating habits|Questionnaire
215159124|NCT07157969|DRUG|Bevacizumab|15mg/kg intravenously every three weeks
215159125|NCT07157969|DRUG|Camrelizumab|200 mg intravenously every three weeks
215159126|NCT07157969|DRUG|Apatinib|250mg once daily
215159127|NCT07157969|PROCEDURE|TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
215159128|NCT07157969|PROCEDURE|HAIC|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
215159129|NCT07157969|PROCEDURE|DEB-TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
214543526|NCT01975298|DRUG|Laquinimod|Oral Administration
214543527|NCT01975298|DRUG|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
214543528|NCT03286309|DEVICE|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
214543529|NCT05140083|DRUG|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
214543530|NCT02818998|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
214543531|NCT02193659|DIETARY_SUPPLEMENT|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
214543532|NCT06499662|OTHER|Vagus Nerve Neurodynamics|This intervention involves passive cervical movements designed to enhance vagus nerve functionality.
214543533|NCT06499662|OTHER|Guided Breathing|This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.
215159130|NCT07158099|DRUG|Methylconalamin Injection(WP205)|25 mg intramuscular injection in the upper-arm deltoid
215159131|NCT07158099|DRUG|Methylconalamin for Injection|25 mg intramuscular injection in the upper-arm deltoid
215159132|NCT07157384|DIETARY_SUPPLEMENT|Low calorie meal replacement plan|intervention provided to both arms in 2 out of the 3 study phases: Phase 1 (total dietary replacement) and Phase 2 (food re-introduction)
215159133|NCT07157384|BEHAVIORAL|Diabetes self management education|intervention provided to both arms throughout study conducted as in-person session and telephone sessions
215159134|NCT07157384|DEVICE|Intermittently scanned continuous glucose monitoring|intervention provided to the intervention arm only: isCGM + LCMR + DSME
215159135|NCT07157384|DEVICE|capillary blood glucose monitoring|intervention provided to the control arm only: CBG + LCMR + DSME
214543534|NCT06499662|OTHER|Manual Therapy|This intervention includes suboccipital inhibition techniques applied during the session.
214543535|NCT05069298|DIETARY_SUPPLEMENT|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
214543536|NCT02906475|OTHER|standardized skin care regimen|"Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed"
214698162|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
214698163|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
214698164|NCT00657852|DRUG|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
214698165|NCT00657852|DRUG|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
214698166|NCT00678587|DRUG|Eltrombopag|75 mg, once daily, oral
214698167|NCT00678587|DRUG|Placebo|placebo, once daily, oral
214698168|NCT01747278|DRUG|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
214698169|NCT02763878|PROCEDURE|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
215159136|NCT07158294|OTHER|Peripheral blood withdrawal for BCR::ABL1 mutations testing|Peripheral blood samples taken from patients treated according to clinical practice with resistance to imatinib or 2GTKI therapy according to the ELN recommendations will be shipped to one of the reference laboratories and analyzed by ddPCR using Bio-Rad ADS assays and reagents. Samples will be analyzed in batches of suitable size. ddPCR results will be compared with NGS results. In patients positive for mutations below 20% by ddPCR (low level mutations) peripheral blood sample(s) will be collected every 3 months at subsequent follow-up visits to monitor the kinetics of mutations in relation to therapy continuation or change.
214543537|NCT04787432|BEHAVIORAL|Salutogenic Frailty Prevention Program|"Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources."
214543538|NCT04560478|DEVICE|Pro Seal Sealant|Sealant was reapplied every 3 months
214543539|NCT04560478|DEVICE|MI Varnish|Fluoride varnish was applied every 4-6 weeks
214543540|NCT02444468|DEVICE|Flowtron ACS800|Flowtron ACS800 and bandage
214543541|NCT02444468|OTHER|Bandage|Bandage only
214543542|NCT05040945|PROCEDURE|Traditional corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
214543543|NCT05040945|PROCEDURE|Flapless corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
214543544|NCT00926380|DRUG|denosumab|denosumab: 60 mg SC every 6 months
214543545|NCT00926380|DRUG|teriparatide|teriparatide: 20 mcg SC QD
214543546|NCT05264701|OTHER|Physiotherapist supervised exercise training|Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.
214543547|NCT05264701|OTHER|Exercise training via phone app|Exercise training for 12 weeks will be given over the developed phone application.
214543548|NCT05264701|OTHER|Physical activity recommendations|The program will be consist of 12 weeks of physical activity recommendations.
214543549|NCT00565838|PROCEDURE|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
214543550|NCT03533205|DIAGNOSTIC_TEST|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
214543551|NCT06404983|OTHER|Opioid Free Anaesthesia (OFA)|Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
214543552|NCT06404983|OTHER|Conventional General Anaesthesia (CGA)|Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
214543553|NCT02045290|DRUG|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
214543554|NCT02045290|DRUG|Placebo|
214543555|NCT00632021|BEHAVIORAL|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
214543556|NCT04624945|DIAGNOSTIC_TEST|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
214543557|NCT04394195|OTHER|measurement of circulating sFlt1 concentration|blood circulating sFlt1 concentration will be determined
214543558|NCT00480064|DRUG|Lomustine, intermediate dose cytarabine|
214543559|NCT00458393|DRUG|daily TDF/FTC|daily oral medication
215159137|NCT07156695|PROCEDURE|Deep Marginal Elevation (DME)|Deep Marginal Elevation (DME) is performed by elevating the deep margin of Class II cavities using resin-modified glass ionomer cement (RMGIC), followed by adhesive bonding and placement of a nanofilled composite resin restoration. This procedure improves accessibility of the restorative margin, enhances marginal sealing, and facilitates plaque control.
215159138|NCT07158021|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215159139|NCT07158021|OTHER|Electronic Health Record Review|Ancillary studies
214543560|NCT00458393|DRUG|Placebo|daily oral medication
214543561|NCT02486419|OTHER|Outdoor weather|Seasonal changes in temperature
215159140|NCT07158021|DRUG|Goserelin|Given SC
214543562|NCT00788164|BIOLOGICAL|TA-HPV|Given intramuscularly
214543563|NCT00788164|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
214543564|NCT00788164|DRUG|imiquimod|Given topically
214543565|NCT01690923|DEVICE|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
214543566|NCT01690923|DEVICE|Pillows mask|Nasal pillows mask (Swift FX)
214543567|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
214543568|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
214543569|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
214543570|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
214543571|NCT04148118|BIOLOGICAL|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
214543572|NCT04148118|BIOLOGICAL|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
214543573|NCT04148118|BIOLOGICAL|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
214543574|NCT01101061|DRUG|Romosozumab|Administered by subcutaneous injection
214543575|NCT01101061|DRUG|Placebo|Administered by subcutaneous injection
214543576|NCT04846855|DRUG|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
214543577|NCT06164015|DIAGNOSTIC_TEST|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
214543578|NCT02615678|DEVICE|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
214543579|NCT05585177|DRUG|Growth hormone|3 months of growth hormone treatment (2 units daily)
214543580|NCT06315101|DRUG|Chinese Herbal Medicine|Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
214543581|NCT05506215|DEVICE|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
214543582|NCT05506215|DEVICE|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
214543583|NCT00455845|DEVICE|Levonorgestrel IUD|levonorgestrel IUD
214543584|NCT06488885|BEHAVIORAL|Elderly care training|The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
214543585|NCT00857233|DRUG|Memantine|20 mg oral tablets once daily
214543586|NCT04517942|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
214543587|NCT04517942|OTHER|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
214543588|NCT05997459|DRUG|Pemigatinib|Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
214543589|NCT05052710|DRUG|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
214543590|NCT05052710|DRUG|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
214543591|NCT03820869|OTHER|Family Training|Family Training
214543592|NCT03820869|OTHER|Occupational Therapy|Occupational Therapy
214543593|NCT05043883|DEVICE|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
214543594|NCT06478901|DEVICE|Echocardiography|Echocardiography assited by Artificial intelligence
214543595|NCT03181906|OTHER|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
214543596|NCT01587118|DRUG|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
214543597|NCT01041768|PROCEDURE|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
214543598|NCT02033473|DRUG|Apelin|An apelin clamp in which an apelin infusion will be administered
214543599|NCT02033473|DRUG|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
214543600|NCT03598881|OTHER|Treatment|
214543601|NCT05002530|DRUG|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214698170|NCT02763878|PROCEDURE|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
214543602|NCT05002530|DRUG|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214543603|NCT05002530|OTHER|Standard therapy|Standard therapy
214543604|NCT00263575|DRUG|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
215159141|NCT07158021|DRUG|Leuprolide|Given IM
215159142|NCT07158021|OTHER|Questionnaire Administration|Ancillary studies
214543605|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
214543606|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
214543607|NCT00299598|DEVICE|alkylated polyethylenimine nanoparticles antibacterial evaluation|
214543608|NCT00224978|DRUG|Chloroquine|
214543609|NCT04560062|OTHER|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
214543610|NCT05744583|OTHER|Packed red cell transfusion|Type O RhD negative packed red cell transfusion during prehospital emergency care
214543611|NCT05744583|OTHER|Whole blood transfusion|Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
214543612|NCT04532762|DEVICE|nasal spray|Application of a nasal spray
214543613|NCT06108453|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
214543614|NCT06108453|DRUG|Rifampicin|Co-administration of methotrexate and rifampicin
214543615|NCT02164006|DRUG|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
214543616|NCT02577588|BIOLOGICAL|re-activated T cells|autologous reactivated T cells against p53
214543617|NCT02622711|BEHAVIORAL|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
214543618|NCT02622711|BEHAVIORAL|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
215159143|NCT07157241|DIETARY_SUPPLEMENT|Intervention|omega-3 capsules with a concentration of 1000 mg/day for three months (NOW Foods- Ultra omega-3 500 EPA/250 DHA).
215159144|NCT07157241|DIETARY_SUPPLEMENT|Control group (placebo)|corn oil capsule /day for 3 months
215159145|NCT07158034|DEVICE|Lenire Device|The Lenire device is a non-invasive stimulation system designed to reduce the symptoms of chronic subjective tinnitus. It includes a controller that is connected to headphones for sound delivery to the ears and a mouthpiece that provides mild electrical stimulation to the surface of the tongue. Users are recommended to use the device for 60 minutes daily, either in two consecutive 30-minute sessions or at different times throughout the day, for a minimum of 36 hours.
215159146|NCT07157085|OTHER|Comprehensive treatment|Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
215159147|NCT07157020|PROCEDURE|ommaya capsule implantation technique|Intervention criteria: Low-threshold intervention group and high--threshold intervention group
214543619|NCT02622711|BEHAVIORAL|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
214543620|NCT02622711|BEHAVIORAL|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
214543621|NCT03118245|DEVICE|AuraGain|After anesthetic induction, AuraGain is inserted in children
214543622|NCT03118245|DEVICE|I-gel|After anesthetic induction, I-gel is inserted in children
214543623|NCT04587583|BEHAVIORAL|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
214543624|NCT01586975|DRUG|Clopidogrel|Clopidogrel 75 mg QD
214543625|NCT01586975|DRUG|Aspirin 81 mg|Aspirin 81mg QD
214543626|NCT01586975|DRUG|Aspirin >300 mg|Aspirin \>300 mg QD
214543627|NCT00239447|DRUG|Tiotropium|
214543628|NCT00239447|DEVICE|HandiHaler|
214543629|NCT00239447|DEVICE|Respimat SMI|
214543630|NCT06183411|BEHAVIORAL|Assessment|"* Observations using two valid, observational instruments (MABC-2 and ToM test-R) that each child completes once at random.~* A demographic and developmental questionnaire is completed once by the parent/guardian at recruitment.~* Standardized questionnaires (Coordination Questionnaire For Parents (CVO), Social Responsiveness Scale second edition (SRS-2), Strengths and Difficulties Questionnaire (SDQ) and Theory of Mind Behavior Checklist (ToMBC)) are also questioned once to parent/guardian for data collection."
214543631|NCT02136771|DIETARY_SUPPLEMENT|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
214543632|NCT02136771|DIETARY_SUPPLEMENT|Placebo|
214698171|NCT02002806|OTHER|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
214698172|NCT02002806|OTHER|Placebo Injection|
214698173|NCT03650686|OTHER|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
215159148|NCT07158502|DRUG|TauroPace Cohort|"After sterile opening of the vial, the entire content of TauroPace™ will be poured into single-use sterile trays. Following skin incision, the surgical site will be irrigated with 5 mL of TauroPace™ solution.~The leads, device generator, and fixation sutures will then be thoroughly wiped using sterile gauze soaked in the solution. Once the leads are connected to the generator, the entire system will be treated again with TauroPace™ before being inserted into the pocket.~At the end of the procedure, the final surgical site will be irrigated once more with an additional 5 mL of TauroPace™ using a sterile syringe. A full 100 mL vial of the solution will be used for each patient, ensuring continuous antimicrobial coverage throughout the procedure.~Excess solution will be gently removed prior to surgical wound closure."
215159149|NCT07156773|DRUG|XJN010 Nasal Spray|"In the XJN010 Nasal Spray group, subjects will receive XJN010 Nasal Spray，Based on the frequency of the off periods experienced by Parkinson's patients."
214543633|NCT05482490|PROCEDURE|Maintenance protocol for the hygiene of implant supported prosthesis|Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
214543634|NCT04758052|OTHER|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
214543635|NCT00741832|DEVICE|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
214543636|NCT00741832|OTHER|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
214543637|NCT01728623|DRUG|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
214543638|NCT03842631|DRUG|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
214543639|NCT05559632|PROCEDURE|osteotomy for implant placement|preparing the bone for implant placement
214543640|NCT06061380|OTHER|no intervation taken|
214543641|NCT00672282|DRUG|Bicalutamide|150mg p.o. daily
214543642|NCT00672282|DRUG|Placebo|
214543643|NCT02957695|DEVICE|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
214543644|NCT02957695|DEVICE|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
214543645|NCT00243022|DRUG|Boswellia serrata extract|given orally
214543646|NCT00243022|DIETARY_SUPPLEMENT|cyanocobalamin|given orally
214543647|NCT02787447|DRUG|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
214543648|NCT02787447|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
214543649|NCT02787447|DRUG|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
214543650|NCT03297476|DIAGNOSTIC_TEST|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
214543651|NCT00479219|DRUG|GSI-953|
214543652|NCT00479219|OTHER|Placebo|
214543653|NCT01380977|BEHAVIORAL|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
214543654|NCT01390441|BIOLOGICAL|MK-8808|MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
214543655|NCT01390441|BIOLOGICAL|MabThera® (rituximab)|MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
214543656|NCT01390441|DRUG|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
214543657|NCT01390441|BIOLOGICAL|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
214543658|NCT01390441|DRUG|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
214543659|NCT01390441|DRUG|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
214543660|NCT01390441|DRUG|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
214543661|NCT06307067|DIAGNOSTIC_TEST|Urine dipstick|Urine dipstick is a point of care test that can be performed on the urine in the public health center.
214543662|NCT04901845|OTHER|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
214543663|NCT02001909|DRUG|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
214543664|NCT02001909|DRUG|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
214543665|NCT03517111|BEHAVIORAL|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
215159150|NCT07156773|DRUG|Placebo|"In the XJN010 Nasal Spray blank preparation group, subjects will receive XJN010 Nasal Spray blank preparation, Based on the frequency of the off periods experienced by Parkinson's patients ."
215159151|NCT07157943|OTHER|Abridge AI Scribe|"Users will have access to the Abridge AI scribe software, either integrated into Epic Haiku (Abridge Inside) or via standalone app that send information back to Epic (Abridge Integrated)."
214543666|NCT03517111|BEHAVIORAL|Substance use prevention only|Parenting program focusing only on substance use prevention
215159152|NCT07157943|OTHER|DAX Copilot|Users will have access to DAX Copilot integrated into Epic Haiku or via standalone app.
215159153|NCT07156643|DRUG|Anlotinib and bempegaldesleukin|"Subjects will receive concurrent anlotinib, bempegaldesleukin, and radiotherapy, followed by maintenance therapy with anlotinib, bempegaldesleukin, and chemotherapy.~Concurrent Radiotherapy Phase:~Anlotinib: 10 mg orally once daily on days 1-14, every 3 weeks (q3w), for 2 cycles during radiotherapy.~Bempegaldesleukin: 1200 mg IV on day 1, q3w, for 2 cycles during radiotherapy. Radiotherapy: Delivered once daily, with a total biological effective dose (BED) of 36-100 Gy. Techniques may include conventional fractionation or stereotactic body radiotherapy (SBRT), as determined by the investigator.~Maintenance Phase:~Chemotherapy: Doxorubicin 40 mg/m² IV day 1 + ifosfamide 1.2-2.4 g/m² IV days 1-5 per 21-day cycle for 4-6 cycles.~Anlotinib: 10 mg orally once daily on days 1-14, q3w. Bempegaldesleukin: 1200 mg IV on day 1, q3w."
214543667|NCT03517111|BEHAVIORAL|Academic success program|Program focusing on academic success and college acceptance
215159154|NCT07158359|BEHAVIORAL|chewing gum mastication|chewing gum mastication
215159155|NCT07156357|DIAGNOSTIC_TEST|Surface Electromyography|Tests performed to evaluate swallowing function
214543668|NCT06171035|OTHER|3D-printed high-fidelity craniofacial manikin model education|Slide-based presention plus 3D printed model
214543669|NCT06171035|OTHER|Traditional model education|Slide-based presention plus traditional model
214543670|NCT00887029|DRUG|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
215159156|NCT07156357|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|Assessment of swallowing function
215159157|NCT07156318|BEHAVIORAL|2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome|Drumming lessons consisting of how to use hands to drum on djembe drum, using alternating hands to drum, drumming to a metronome and to music.
215159158|NCT07156318|BEHAVIORAL|Lessons after measurement|Receiving lessons after the two lab visits should still offer any possible positive effects to participants while still allowing us to compare the Control group children's behaviors to those of the Experimental group.
214543671|NCT00887029|DRUG|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
214543672|NCT01514955|RADIATION|Gold seeds insertion to detect movements at pelvis|
215159159|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version A|Qualia Iron Version A manufactured by Qualia Life Sciences
214543673|NCT01514955|RADIATION|Image guided MRI based RT (IMRT+Brachytherapy)|
214543674|NCT02039544|DRUG|Xuebi formula|
214543675|NCT02039544|DRUG|placebo|
214543676|NCT00004072|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
214543677|NCT00004072|DRUG|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
214543678|NCT06302725|PROCEDURE|Vaginal self sampling detecting HPV|IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
215159160|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version B|Qualia Iron Version B manufactured by Qualia Life Sciences
214543679|NCT02944396|DRUG|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
214543680|NCT02944396|DRUG|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
214543681|NCT02944396|DRUG|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
214543682|NCT02944396|DRUG|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
214543683|NCT02944396|DRUG|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
214543684|NCT03592004|OTHER|neoadjuvant chemotherapy|neoadjuvant chemotherapy
215159161|NCT07156526|DIETARY_SUPPLEMENT|Placebo|Rice powder
215159162|NCT07158255|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
214698174|NCT03650686|OTHER|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
214698175|NCT03650686|OTHER|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
214698176|NCT00895518|BEHAVIORAL|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
214698177|NCT03806179|DRUG|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
214698178|NCT03806179|DRUG|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
214698179|NCT02310828|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
214698180|NCT02310828|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
214698181|NCT00116857|DRUG|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
214698182|NCT00116857|DRUG|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
214698183|NCT03998475|BEHAVIORAL|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
214698184|NCT02375633|DRUG|DW-330SR2|
214543686|NCT04769375|OTHER|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
214543687|NCT04769375|OTHER|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
214543688|NCT04769375|OTHER|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
214543689|NCT04192864|PROCEDURE|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
214543690|NCT04192864|PROCEDURE|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
214543691|NCT06401837|BEHAVIORAL|Circadian based acupressure application|Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
214543692|NCT05457166|DEVICE|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
214543693|NCT01580683|DRUG|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
214698185|NCT02375633|DRUG|Pelubiprofen|
214698186|NCT04507477|BIOLOGICAL|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
214698187|NCT04217889|OTHER|Questionnaire|Short questionnaire that can be completed during the usual consultation.
214698188|NCT01952730|BIOLOGICAL|GVAX|
214698189|NCT02076321|DRUG|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
214698190|NCT02076321|DRUG|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
214543694|NCT01580683|OTHER|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
215159163|NCT07158255|OTHER|Exercise training|In addition to electrotherapy, the patients in the study group will receive 15 sessions (45 minutes, 5 days a week, for 3 weeks) of exercise training consistent with the literature. Exercise training includes programs to increase joint range of motion and mobility at the pain threshold and to restore functionality. Following electrotherapy, upper extremity normal range of motion exercises, anterior and posterior capsule stretching exercises, pendulum exercises, wand exercises, isometric training in 3 planes, and isotonic strengthening exercises will be applied. Five exercises will be selected each day, performed under the supervision of a physiotherapist. A 2-minute rest period will be provided after each exercise, followed by a transition to the next exercise. Care will be taken to perform the exercises within the pain threshold and to ensure that the pain does not exceed a VAS score of 2.
215159164|NCT07157397|BEHAVIORAL|Plant-Focused Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics to guide patients to consume a diet emphasising plant-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
215159165|NCT07157397|BEHAVIORAL|Standard Renal Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics based on current guideline recommendations, to guide patients to consume a diet emphasising animal-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
214543695|NCT01398098|DRUG|Sodium phosphate|32 tablets
214543696|NCT04438382|BIOLOGICAL|Infliximab|Given IV
214543697|NCT04438382|BIOLOGICAL|Intravenous Immunoglobulin Therapy|Given IV
214543698|NCT04438382|DRUG|Prednisone|Given IV or PO
214543699|NCT04438382|DRUG|Methylprednisolone|Given IV or PO
214543700|NCT02698306|DRUG|Dexamethasone|Dexamethasone
214543701|NCT02698306|DRUG|Diclofenac Sodium|Diclofenac Sodium
214543702|NCT04181489|DRUG|Sintilimab|Sintilimab 200mg d0
214543703|NCT04181489|DRUG|Rituximab|Rituximab 375 mg/m2 d0
214543704|NCT04181489|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
214543705|NCT04181489|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
214543706|NCT04181489|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
214543707|NCT04181489|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
214543708|NCT02418962|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
214543709|NCT02418962|OTHER|Normal Saline|0.9% Sodium chloride solution for injection
214543710|NCT00027703|DRUG|gemcitabine hydrochloride|Given IV
214543711|NCT00027703|DRUG|cisplatin|Given IV
214543712|NCT00027703|BIOLOGICAL|bevacizumab|Given IV
214543713|NCT00027703|OTHER|placebo|Given IV
214543714|NCT00027703|OTHER|laboratory biomarker analysis|Correlative studies
214543715|NCT01284712|BIOLOGICAL|blood sample|blood sample coming from therapeutic bleeding in hospital
214543716|NCT06497790|DIAGNOSTIC_TEST|BJH-SDS Screenint Test|The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)
214543717|NCT06497790|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists
214543718|NCT00336336|DRUG|n-3 PUFA|1 g die per os
214543719|NCT00336336|DRUG|Rosuvastatin|10 mg die per os
214543720|NCT00336336|DRUG|Placebo|1 gram c. per os
214543721|NCT00336336|DRUG|Placebo|10 mg c. per os
214543722|NCT05438134|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
214543723|NCT05213442|DIAGNOSTIC_TEST|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
214543724|NCT02920255|OTHER|Diagnostic|Measurement of spinal tilt
214543725|NCT01781832|DEVICE|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
214543726|NCT01440010|RADIATION|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
214698191|NCT06502756|DEVICE|SOBER, mobile Application providing digital CBT|SOBER is a software application (Android) that delivers cognitive behavioral therapy (CBT) in a structured and interactive manner. It analyzes patterns in participants\&#39; lifestyles to identify problematic behaviors related to their alcohol consumption. By providing tailored guidance and support, the app aims to help individuals make sustainable changes, ultimately reducing hazardous drinking. This approach combines the principles of CBT with the convenience and accessibility of digital technology, offering a personalized experience to support the reduction of alcohol consumption.
214698192|NCT00790738|DRUG|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
214698193|NCT00790738|DRUG|placebo|placebo
214698194|NCT05622383|OTHER|aromatherapy|aromatherapy,
214698195|NCT05622383|OTHER|music concert|music concert
214698196|NCT05622383|OTHER|aromatherapy and music concert,|aromatherapy and music concert,
214698197|NCT04767633|DRUG|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
214698198|NCT03013205|PROCEDURE|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
214698199|NCT03013205|PROCEDURE|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
214698200|NCT03013205|PROCEDURE|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
214543727|NCT01163474|OTHER|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
214543728|NCT01280604|DRUG|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
214543729|NCT01313169|OTHER|EMR Reminder|EMR reminders displayed
214543730|NCT01313169|OTHER|EMR Reminder + Panel management|EMR Reminder + Panel management
214543731|NCT02757820|DEVICE|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
214543732|NCT02757820|DEVICE|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
214543733|NCT02757820|DEVICE|Air-Q|Patients will be anesthetized using Air-Q\_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
214543734|NCT05889962|PROCEDURE|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
214543735|NCT05889962|PROCEDURE|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
214543736|NCT02830529|BEHAVIORAL|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
214543737|NCT02830529|BEHAVIORAL|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
214543738|NCT03432390|DEVICE|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
214543739|NCT03432390|DEVICE|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
214543740|NCT01472614|DRUG|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
214543741|NCT03144297|OTHER|Lumbar puncture|diagnostic lumbar puncture
214543742|NCT03144297|OTHER|BOD POD (air-displacement plethysmography)|Assessment of body fat
214543743|NCT03720223|DRUG|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
214698201|NCT03013205|PROCEDURE|Physiotherapy|
214698202|NCT02136199|OTHER|Active Implementation of ShareEBM Toolkit|
214698203|NCT02136199|OTHER|Passive Dissemination of Share EBM|
214698204|NCT01357915|PROCEDURE|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
214698205|NCT01357915|BIOLOGICAL|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
214698206|NCT00305253|DEVICE|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
214698207|NCT00240552|DRUG|fosamprenavir|
214698208|NCT00240552|DRUG|Telzir®|
214698209|NCT00671580|DRUG|PZ-601|750 mg
214698210|NCT00671580|DRUG|PZ-601|1000 mg
214698211|NCT00671580|DRUG|Standard of Care|as directed
214698212|NCT02393573|DRUG|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
214698213|NCT02393573|DRUG|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
214698214|NCT02068131|DRUG|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
214698215|NCT02068131|DRUG|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
214698216|NCT03298191|DRUG|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
214543744|NCT04810897|OTHER|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
214543745|NCT05702541|DEVICE|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
214543746|NCT05702541|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
214543747|NCT05702541|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
214543748|NCT02519946|OTHER|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
214543749|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
214543750|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
214543751|NCT05825222|DIETARY_SUPPLEMENT|Placebo|One Capsule to be consumed twice a day
214543752|NCT02807610|DRUG|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
214543753|NCT02807610|DRUG|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
214543754|NCT02807610|DRUG|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
214543755|NCT03873454|DEVICE|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
214543756|NCT03873454|DEVICE|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
214543757|NCT03873454|OTHER|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
214543758|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
214543759|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
214543760|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
215159166|NCT07156838|OTHER|bioflex crown|A preformed bioflex crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area, bioflex crown fitting and proper occlusion will be checked then it will be cemented using type-I glass ionomer cement, Any excess cement will be removed.
214543761|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
215159167|NCT07156838|OTHER|zerconia crown|"Occlusal reduction will be done by 1-1.5 mm using coarse football shaped diamond bur following the natural occlusal anatomy.~Interproximal contacts will be opened with a tapered fissure bur. The proximal space should be enough to permit the chosen crown to fit passively.~The molar will be trimmed down circumferentially 0.5-1.25 mm as needed with the use of tapered diamond burs.~•About 1 to 2 mm subgingival preparation will be done to achieve a feather-edge finish line.~Prepared tooth should be free from any blood or saliva. Try-in will be done using the pink crowns, to check the occlusion and Passive fit of the crown.~The zirconia crown will be luted with type I glass ionemer cement. Consistent firm finger pressure will be applied during cementation, Any excess cement will be removed, and proper occlusion will be verified"
214543762|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
214543763|NCT05429593|DRUG|Semaglutide|Tablet given orally
214543764|NCT05429593|DRUG|Dapagliflozin|Tablet given orally
214543765|NCT05429593|DRUG|Semaglutide/dapagliflozin|Tablet given orally
214543766|NCT04718636|DRUG|Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)|Daily
214543767|NCT04718636|DRUG|CC-99677|Daily
214543768|NCT00322686|DRUG|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
214543769|NCT00322686|DRUG|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
214543770|NCT02961478|DRUG|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
214698217|NCT03298191|DRUG|Ritodrine|Those women will be given Ritodrine for tocolysis
214543771|NCT05928949|OTHER|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
214543772|NCT05302297|DRUG|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
214698218|NCT03298191|DRUG|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
214698219|NCT02800473|DEVICE|Strorz (commercial)|
214698220|NCT02800473|DEVICE|CyPaM2 (experimental)|
214543773|NCT05260593|DEVICE|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
214543774|NCT05260593|DEVICE|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
214543775|NCT05260593|DEVICE|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
214543776|NCT05260593|OTHER|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
215159168|NCT07156838|OTHER|stainless steel crown|"An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement.~Any excess cement will be removed, and proper occlusion will be verified"
215159169|NCT07156539|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
215159170|NCT07156539|DRUG|Dulaglutide Injection|Dulaglutide injected subcutaneously once weekly
215159171|NCT07157631|DRUG|tranexamic acid|In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
215159172|NCT07157631|DRUG|0.9 % saline|In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
215159173|NCT07156396|DEVICE|SleeperOne®, dental Hitec, France|SleeperOne® is a computerized local anesthetic delivery system used to deliver 3% mepivacaine following application of 20% benzocaine topical gel. It is designed to reduce injection pain and improve comfort during pediatric dental procedures.
215159174|NCT07156396|PROCEDURE|Conventional Infiltration|Local anesthetic (3% mepivacaine) will be administered using a conventional dental syringe after the application of 20% benzocaine topical anesthetic.
215159175|NCT07156552|BEHAVIORAL|Resistance exercise training and protein supplementation|"The intervention consists of two components:~1. Resistance Exercise Training Participants will engage in a 24-week resistance training program. This program includes one supervised session per week supervised by a qualified kinesiologist, complemented by two to three additional unsupervised sessions per week performed at home.~2. Protein Supplementation~Participants will receive daily protein supplements for a total duration of 12 weeks. The dosage will be progressively increased:~* 20 grams per day during weeks 1-4~* 40 grams per day during weeks 5-8~* 60 grams per day during weeks 9-12 After the 12-week supplementation period, participants will receive additional dietary counseling sessions with a dietitian. These sessions aim to support the maintenance of adequate protein intake through dietary intake."
215159176|NCT07158346|DRUG|L03RD1|1 tablet of L03RD1
215159177|NCT07158346|DRUG|L03RD2|2 tablets of L03RD2
215159178|NCT07158346|DRUG|CT-L03|1 tablet of CT-L03
215159179|NCT07156591|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention during esophagogastroduodenoscopy
215159180|NCT07157995|BEHAVIORAL|BALANCE Building Active LIving and Addressing Needs for Caregiver Empowerment|The Balance intervention will include individual visits by a Caregiver Navigator and group sessions with other participants, led by the caregiver navigator. The focus will be on future planning, resources for unmet needs and support and socialization.
215159181|NCT07156435|DRUG|Vyxeos 44 MG / 100 MG Liposome Injection|Vyxeos®/CPX-351 will be infused in 90 minutes on day 1, 3 and 5 only, 3 hours after the end of clofarabine (if administered on the same day).
215159182|NCT07156435|DRUG|Clofarabine|Clofarabine infusion will be given according to the assigned dose level, over 2 hours IV, daily on day 2-6 (for 5 consecutive days).
215159183|NCT07156669|DEVICE|Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG)|Patients will receive ECLS treatment using the Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG) during ground-based inter-hospital patient transport and/ or stationary treatment according to their intended use and local standards/ requirements.
215159184|NCT07157475|DRUG|Treatment with SGLT2 inhibitors (flozins)|Patients received SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as part of their routine clinical care during the 12-month follow-up period after elective or urgent lower limb revascularization procedures. The study does not assign treatment; medication use occurred independently of the study protocol.
215159185|NCT07157735|DRUG|dapansutrile|Dapansutrile tablets administered for 26 weeks, starting at 1,000 mg daily (500 mg twice daily) for 4 weeks, escalated to 2,000 mg daily (1,000 mg twice daily) thereafter.
214543777|NCT00136370|DRUG|Chlorhexidine|
214543778|NCT00136370|PROCEDURE|Birth canal wipe|
214543779|NCT00136370|PROCEDURE|sterile water external genital wipe|
214543780|NCT01408745|DEVICE|Sternumfix|sternotomy closure with Sternumfix
214543781|NCT01408745|PROCEDURE|steel wire|sternotomy closure with steel wire
214543782|NCT00299923|DRUG|Peginterferon alfa-2a, Ribavirin, Amantadine|
214543783|NCT00980590|DEVICE|Airway Scope|Tracheal intubation by Airway Scope
214543784|NCT00980590|DEVICE|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
214698221|NCT02819115|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
215159186|NCT07157735|DRUG|placebo|Matched placebo tablets administered for 26 weeks, admistered as per the active treatment.
215159187|NCT07156409|DEVICE|Peripheral Embolization Coil System|Primarily used to block or reduce the blood flow velocity in the peripheral vascular system
214543785|NCT00136279|BEHAVIORAL|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
214543786|NCT03850275|DIETARY_SUPPLEMENT|Intervention/treatment|Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
214543787|NCT04816864|DIAGNOSTIC_TEST|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
214543788|NCT05422989|DIAGNOSTIC_TEST|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
214543789|NCT03478137|BEHAVIORAL|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
214543790|NCT00672451|DIETARY_SUPPLEMENT|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
214543791|NCT00672451|DIETARY_SUPPLEMENT|placebo|placebo titrated up to 6 pills daily as patient tolerates
214543792|NCT00375531|BEHAVIORAL|Mindfulness Meditation (MfM)|
214543793|NCT02689453|BIOLOGICAL|IL-15 plus|Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
214543794|NCT02689453|BIOLOGICAL|alemtuzumab|Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
214543795|NCT01425177|PROCEDURE|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
214543796|NCT05222100|DIAGNOSTIC_TEST|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
215159188|NCT05170919|DRUG|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
215159189|NCT05170919|DRUG|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
215159190|NCT06030752|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
215159191|NCT05106426|BEHAVIORAL|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
215159192|NCT05106426|BEHAVIORAL|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
214543797|NCT00661843|OTHER|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
214543798|NCT04211077|OTHER|Date collection|Data collection from national SNIIRAM and PMSI database
215159193|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
214543799|NCT04206085|DEVICE|Viveve - Active|Radiofrequency and Cryogen-Cooling
214543800|NCT04206085|DEVICE|Viveve - Cryogen-Alone|Cryogen-Cooling
214543801|NCT04206085|DEVICE|Viveve - Sham|Sham
214543802|NCT00763451|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214543803|NCT00763451|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214543804|NCT00763451|DEVICE|Pen auto-injector|
214543805|NCT00763451|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
214543806|NCT00453024|PROCEDURE|Pericardial graft & tissue glue|
214543807|NCT00453024|PROCEDURE|scleral flap & sutures|
214543808|NCT04258657|DRUG|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
214543809|NCT06021587|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
214543810|NCT06021587|DRUG|No Levosimendan|Without Levosimendan Infusion
215159194|NCT02685267|DRUG|Docetaxel|
215159195|NCT02685267|DRUG|Enzalutamide|
215159196|NCT02685267|DRUG|Prednisone|
215159197|NCT02042872|DRUG|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
214698222|NCT01785810|DRUG|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
214543811|NCT04089072|DRUG|Methylene Blue|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
214698223|NCT01750632|PROCEDURE|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
215159198|NCT05203900|DIETARY_SUPPLEMENT|Infant formula with Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
215159199|NCT05203900|DIETARY_SUPPLEMENT|Infant formula without Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
215159200|NCT03270579|DRUG|[18F]JNJ-64511070|An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
215159201|NCT02832362|DRUG|Carbomer 980|Test product containing 0.5% carbomer 980 gel
215159202|NCT02832362|OTHER|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
215159203|NCT06155396|DRUG|Disitamab Vedotin|2.0 mg/kg IV every 2 weeks
215159204|NCT06155396|DRUG|Zimberelimab|240mg IV every 2 weeks
215159205|NCT00229385|DRUG|Ziprasidone|40-80 mg BID
215159206|NCT03795246|PROCEDURE|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
214543812|NCT04089072|DRUG|Phenylephrine|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
214543813|NCT04135508|DRUG|BAT1406|40mg/0.8ml
214543814|NCT04135508|DRUG|Humira|40mg/0.8ml
214543815|NCT04741737|PROCEDURE|reSLNB arm|Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
214543816|NCT01473992|DEVICE|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
214543817|NCT01473992|DEVICE|Otto Bock Genium|Study knee.
214543818|NCT00003428|DRUG|arzoxifene hydrochloride|
214543819|NCT02673411|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
215159207|NCT03795246|BIOLOGICAL|Biological Test|"Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL"
215159208|NCT03795246|PROCEDURE|Pelvic Ultrasound|Antral Follicles Count
215159209|NCT00696917|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
215159210|NCT00696917|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
215159211|NCT04800770|DIAGNOSTIC_TEST|4C mortality score|4C mortality score and phosphate levels
214543820|NCT00725543|BIOLOGICAL|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
214543821|NCT06336798|DRUG|Pioglitazone 30mg|Study participants will take Pioglitazone 30 mg PO daily
215159212|NCT03007641|BEHAVIORAL|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
215159213|NCT03007641|BEHAVIORAL|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
215159214|NCT04730661|DIAGNOSTIC_TEST|Sit to stand test|"The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~* If SpO2 \<90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~* SpO2 \<90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~* SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge."
215159215|NCT00667108|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
215159216|NCT00667108|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
215159217|NCT00667108|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
215159218|NCT04384133|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
215159219|NCT04384133|DIAGNOSTIC_TEST|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
214543822|NCT06336798|DRUG|Placebo|Study participants will take a placebo PO daily
214543823|NCT06336798|DIAGNOSTIC_TEST|Labs|Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
214698224|NCT04289246|DEVICE|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
214698225|NCT03429816|PROCEDURE|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
214698226|NCT02310139|PROCEDURE|Colonoscopy|
214698227|NCT01737567|OTHER|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
214543824|NCT04741854|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
214543825|NCT05594589|DRUG|Lemborexant|Lemborexant oral tablet.
214543826|NCT05594589|OTHER|PBO|Lemborexant-matched PBO tablet.
214543827|NCT03200444|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
214698228|NCT01737567|OTHER|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
214698229|NCT04213287|DRUG|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
215159220|NCT04384133|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
215159221|NCT04384133|DIAGNOSTIC_TEST|Thorax Computed Tomography|Computed tomography is a radiological examination.
215159222|NCT04384133|DIAGNOSTIC_TEST|Chest X Ray|Chest X ray is a radiological examination.
215159223|NCT04384133|DIAGNOSTIC_TEST|Blood eosinophil level|A tube of blood will be drawn from the participant.
215159224|NCT04384133|OTHER|CAT|It consists of 8 questions.
215159225|NCT04384133|OTHER|mMRC|It is the scale used to measure the severity of shortness of breath.
215159226|NCT00094484|DRUG|Cinacalcet HCl|
215159227|NCT04136015|DRUG|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
215159228|NCT04900532|DIETARY_SUPPLEMENT|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
215159229|NCT04900532|DIETARY_SUPPLEMENT|Placebo|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
215159230|NCT01027806|DRUG|Montelukast|1 pill per day for 4 months
215159231|NCT06231771|DRUG|Allogeneic mesenchymal stem cells (MSCs)|Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
215159232|NCT06231771|DRUG|Normal Saline|Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
215159233|NCT00295386|BEHAVIORAL|Cognitive behavior therapy (CBT)|
215159234|NCT00295386|DRUG|Zopiclone|
215159235|NCT01186172|DRUG|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
215159236|NCT01186172|DRUG|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
215159237|NCT00409669|DEVICE|Barraquer tonometer|barraquer tonometer
215159238|NCT01264705|DRUG|bavituximab (0.3 mg/kg) and sorafenib|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
215159239|NCT01264705|DRUG|bavituximab (1.0 mg/kg ) and sorafenib|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
215159240|NCT01264705|DRUG|bavituximab (3.0 mg/kg) and sorafenib|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
215159241|NCT04096599|OTHER|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
215159242|NCT04096599|OTHER|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
215159243|NCT00367614|DRUG|pantoprazole|
214543828|NCT03200444|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
214543829|NCT03200444|OTHER|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
214543830|NCT03200444|OTHER|P-4|Newly developed adhesive P-4
214543831|NCT03200444|OTHER|P-15|Newly developed adhesive P-14
214543832|NCT03200444|OTHER|P-16|Newly developed adhesive P-8
214698230|NCT04213287|OTHER|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
214698231|NCT04213287|OTHER|IPACK|Drug: bupivacaine 20 ml 0,025%
214698232|NCT04213287|OTHER|PAI|Drug: bupivacaine 30 ml 0,025%
215159244|NCT00068861|DRUG|metformin XR|
215159245|NCT00068861|DRUG|clomiphene citrate|
214543833|NCT05949567|OTHER|urodynamic exam in sitting and lying position|Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
214543834|NCT05347212|DRUG|Nivolumab|Given by IV
214698233|NCT04213287|OTHER|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
214698234|NCT00666133|DEVICE|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
214698235|NCT02214199|OTHER|Manipulative Therapy Techniques|
214698236|NCT02214199|OTHER|Home Exercises|
214698237|NCT04654000|PROCEDURE|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
214543835|NCT05347212|DRUG|Relatlimab|Given by IV
214543836|NCT05787249|BEHAVIORAL|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
214543837|NCT05787249|BEHAVIORAL|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
214543838|NCT03688997|OTHER|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
214543839|NCT02168478|DRUG|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
214543840|NCT02168478|OTHER|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
214543841|NCT02168478|OTHER|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
214543842|NCT05160311|DRUG|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
214543843|NCT05160311|DEVICE|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
214698238|NCT04654000|PROCEDURE|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
214543844|NCT04219917|OTHER|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
214543845|NCT01233271|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
214543846|NCT04793581|DEVICE|Atherectomy|Directional atherectomy of lesions below the knee.
214543847|NCT00723918|DRUG|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
214543848|NCT00723918|DRUG|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
214543849|NCT00723918|DRUG|SAB placebo|an inactive substance
214698239|NCT03587480|PROCEDURE|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
214698240|NCT03587480|PROCEDURE|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
214698241|NCT00823849|DRUG|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
214698242|NCT00823849|DRUG|Probucol|250 mg Bid, PO after breakfast and dinner.
214698243|NCT00823849|DRUG|Cilostazol+Probucol|
215159246|NCT02682862|DRUG|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
215159247|NCT02682862|DRUG|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
214698244|NCT00823849|OTHER|Control Group|Routine treatment
214698245|NCT03125655|DIAGNOSTIC_TEST|Inflammatory markers|
214698246|NCT05151328|DRUG|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
214698247|NCT02985268|DEVICE|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
215159248|NCT03823313|BEHAVIORAL|SCAI (Spiritual Care Assessment and Intervention)|4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
215159249|NCT02981615|DRUG|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
215159250|NCT02981615|DRUG|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
215159251|NCT06434142|PROCEDURE|implant overdenture|Following the two-stage surgical protocol, two dental implant fixtures with a length of 10 mm and a diameter of 3.7 mm were inserted at the canine area of the mandibular alveolar ridge.
214543850|NCT00723918|DRUG|Methadone placebo|Methadone placebo
214698248|NCT02985268|DRUG|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
214698249|NCT02985268|DEVICE|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
214698250|NCT04709302|BIOLOGICAL|COVID-19|Patients diagnosed with a COVID-19 infection
214543851|NCT05122741|DRUG|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
214543852|NCT05122741|DRUG|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
214543853|NCT00000959|DRUG|Isoniazid|
214698251|NCT04709302|BIOLOGICAL|HIV|Patients diagnosed HIV-positive
214698252|NCT04709302|DRUG|ART|Patients on ART
214698253|NCT01366066|DEVICE|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
215159252|NCT05593263|PROCEDURE|surgical correction of astigmatism with cataract|The Steep meridian will be identified and marked, relaxing limbal / corneal incisions will be designed according to it.
215159253|NCT00539864|BIOLOGICAL|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
215159254|NCT00539864|BIOLOGICAL|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
215159255|NCT02565784|DEVICE|Restylane|Facial tissue augmentation
215159256|NCT02565784|DEVICE|Perlane|Facial tissue augmentation
215159257|NCT02267876|DEVICE|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
215159258|NCT02267876|PROCEDURE|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
215159259|NCT03439384|DEVICE|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
215159260|NCT00578734|DRUG|Lucinactant|Slow intra-tracheal instillation
215159261|NCT00578734|OTHER|Sham Comparator|Slow intra-tracheal instillation
215159262|NCT02417506|OTHER|E-OA-07 (Lanconone)|
215159263|NCT02417506|DRUG|Ibuprofen|
215159264|NCT00580528|BEHAVIORAL|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
214543854|NCT00000959|DRUG|Pyridoxine hydrochloride|
214543855|NCT05479747|DRUG|post operative analgesics|post-operative pain killer
214543856|NCT06414005|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)
214543857|NCT06414005|OTHER|Placebo (Saline)|Ultrasound-guided intratendinous placebo injection
214543858|NCT03618810|DRUG|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
214543859|NCT03618810|DRUG|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
215159265|NCT00580528|BEHAVIORAL|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
215159266|NCT06146283|COMBINATION_PRODUCT|Jamar Hydraulic Hand Dynamometer|"This device measures hand grip strength. The individual should be in an upright sitting position. There should be no arm support on the sitting surface. ...~The knee angle should be 90 degrees. Elbow angle should be 90 degrees. The wrist should be held without deviation. The measurement should be performed 3 times with an interval of 10 seconds."
215159267|NCT05083858|OTHER|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
214543860|NCT03845023|DRUG|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
214543861|NCT03845023|DRUG|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
214543862|NCT03845023|DRUG|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
214543863|NCT03845023|DRUG|Placebo|Placebo oral capsule administered before sleep
214543864|NCT01691547|DRUG|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
214543865|NCT01691547|DRUG|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
214543866|NCT01691547|DRUG|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
214543867|NCT01691547|DRUG|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
214543868|NCT04061070|OTHER|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
214543869|NCT04061070|OTHER|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
214543870|NCT05696223|OTHER|Ultrasound|Doppler mesure
214543871|NCT00371995|DRUG|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
214543872|NCT04422977|DIAGNOSTIC_TEST|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
214543873|NCT05193747|OTHER|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
214543874|NCT03310398|BEHAVIORAL|NeuroImaging|standard anatomical and functional imaging
214698254|NCT05971004|DEVICE|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
214698255|NCT05971004|DRUG|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
214698256|NCT03734367|BEHAVIORAL|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
214698257|NCT04523441|OTHER|Focus group|Holding of a focus group by a sociologist
214698258|NCT04523441|OTHER|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
215159268|NCT05083858|OTHER|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
215159269|NCT05083858|OTHER|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
215159270|NCT04202419|DEVICE|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
215159271|NCT01745822|DRUG|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
215159272|NCT01745822|DRUG|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
214543875|NCT03310398|BEHAVIORAL|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
214543876|NCT05124821|DEVICE|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
214543877|NCT03462537|DEVICE|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
214543878|NCT03462537|DEVICE|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
214698259|NCT00157937|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
214698260|NCT00157937|DRUG|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
214698261|NCT05918874|OTHER|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
214698262|NCT04289415|BEHAVIORAL|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
215159273|NCT00251043|BEHAVIORAL|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
215159274|NCT00251043|BEHAVIORAL|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
215159275|NCT03550352|DRUG|TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)|Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
214698263|NCT03432052|PROCEDURE|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
214543879|NCT03462537|DEVICE|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
214543880|NCT04250688|DEVICE|Ekso Training with FES|
214543881|NCT05585736|DRUG|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
214543882|NCT01743976|DRUG|Donepezil|donepezil 5 mg once daily for 6 weeks
214543883|NCT01743976|DRUG|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
214543884|NCT01985646|PROCEDURE|surgery treatment|one staged pull-through left-colectomy
214543885|NCT01985646|BEHAVIORAL|anal dilation|anal dilation
214543886|NCT01985646|BEHAVIORAL|colonic lavage|colonic lavage
214543887|NCT01985646|DRUG|oral probiotic|oral probiotic
214543888|NCT02072421|PROCEDURE|PCI|
214543889|NCT02151071|DEVICE|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
214543890|NCT02151071|DEVICE|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
214543891|NCT03691142|OTHER|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
214543892|NCT03096756|DRUG|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
214543893|NCT03096756|DRUG|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
214543894|NCT03096756|OTHER|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
214543895|NCT03096756|OTHER|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
214543896|NCT03096756|OTHER|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
214543897|NCT03096756|OTHER|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
214698264|NCT00091702|BIOLOGICAL|Cold-adapted live attenuated influenza vaccine (FluMist)|
214698265|NCT00091702|BIOLOGICAL|Inactivated influenza vaccine (IAIV)|
214698266|NCT01479374|DRUG|AL-4943A ophthalmic solution|
214698267|NCT01479374|DRUG|AL-4943A vehicle|Inactive ingredients used as placebo
214698268|NCT01479374|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
214698269|NCT03616327|DEVICE|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
214698270|NCT05900011|BEHAVIORAL|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
215159276|NCT03550352|DRUG|TN-C200M2 oral capsules (CBD 200 mg)|Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
214698271|NCT04365439|BIOLOGICAL|Blood plasma|Convalescent plasma after COVID-19
214698272|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
214698273|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
214698274|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
214698275|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
214698276|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
214698277|NCT01045772|DRUG|rilonacept|160mg of rilonacept 1x/week
214698278|NCT05086289|DRUG|LY3526318|Administered orally
214698279|NCT05086289|DRUG|Placebo|Administered orally
214698280|NCT05059548|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
214698281|NCT02237157|DRUG|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
214698282|NCT02145091|DRUG|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
214698283|NCT02145091|DRUG|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
214698284|NCT02145091|DRUG|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
214698285|NCT02145091|DRUG|Placebo|An oral placebo (lactose pill).
214543898|NCT03096756|OTHER|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
214543899|NCT03096756|DRUG|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
214543900|NCT00847158|PROCEDURE|phacoemulsification alone|phacoemulsification alone
214543901|NCT00847158|DEVICE|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
214543902|NCT05019703|BIOLOGICAL|Atezolizumab|Given IV
214543903|NCT05019703|DRUG|Cabozantinib|Given PO
214543904|NCT02302703|OTHER|low FODMAP diet vs Gluten free diet|
214543905|NCT02554383|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
214543906|NCT02554383|DRUG|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
214543907|NCT01965106|DRUG|QPI-1007 Injection|1.5 mg QPI-1007 Injection
215159277|NCT00544700|BIOLOGICAL|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
215159278|NCT00544700|OTHER|no maintenance|No treatment until progression
215159279|NCT05339867|BEHAVIORAL|Prevent Maternal Mortality using Mobile technology (PM3)|"PM3: The app will include:~1. integrated self-management and tailored health messaging feature~2. support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~3. multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~4. a feature that will update women on maternal and reproductive health policies that impact women."
215159280|NCT00943072|BIOLOGICAL|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
215159281|NCT00943072|DRUG|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
214543908|NCT01965106|DRUG|(including placebo)|Sham injection procedure
214543909|NCT00420225|DEVICE|Low-weight prolypropylene mesh|
214543910|NCT02918292|DRUG|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
214543911|NCT02918292|DRUG|Fludarabine|Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.
214698286|NCT05071560|OTHER|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
214698287|NCT03623126|OTHER|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
214698288|NCT05407090|DIETARY_SUPPLEMENT|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
215159282|NCT00030459|DRUG|cisplatin|
215159283|NCT00030459|DRUG|mitomycin C|
215159284|NCT00030459|DRUG|vinblastine sulfate|
214698289|NCT05407090|DIETARY_SUPPLEMENT|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
214698290|NCT04777643|DRUG|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
214698291|NCT04777643|OTHER|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
214698292|NCT02621879|PROCEDURE|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
214698293|NCT01996748|DRUG|DF277|Two administrations daily for 7 days
215159285|NCT00030459|DRUG|vinorelbine tartrate|
215159286|NCT04930341|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
215159287|NCT06421103|DRUG|Indocyanine Green (ICG)|Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
214543912|NCT02918292|DRUG|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
214543913|NCT02918292|RADIATION|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
215159288|NCT05815875|COMBINATION_PRODUCT|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
215159289|NCT05815875|OTHER|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
214543914|NCT02918292|PROCEDURE|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
214543915|NCT02918292|DRUG|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
214543916|NCT02918292|DRUG|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
214543917|NCT02918292|DRUG|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.
214543918|NCT01801982|OTHER|non-interventional|non-interventional
214543919|NCT01966978|DRUG|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
214543920|NCT01966978|DRUG|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
214543921|NCT01966978|DRUG|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
214543922|NCT01966978|DRUG|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
214543923|NCT00476528|BEHAVIORAL|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
214543924|NCT00476528|BEHAVIORAL|Reality Orientation|A quasiexperimental study
214543925|NCT01185171|DRUG|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
214543926|NCT00002406|DRUG|Indinavir sulfate|
214543927|NCT03772093|DEVICE|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
214543928|NCT03772093|OTHER|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
214543929|NCT03518242|DRUG|Cyclophosphamide|Given PO
214543930|NCT03518242|DRUG|Methotrexate|Given PO
214543931|NCT03518242|DRUG|Capecitabine|Given PO
214543932|NCT03518242|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
214543933|NCT01493999|DRUG|Clopidogrel reloading|Up to three times 600 mg clopidogrel
214543934|NCT01493999|DRUG|Prasugrel|60 mg prasugrel in patients with HPR
214543935|NCT01869140|DEVICE|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
214543936|NCT00282945|DRUG|Rosiglitazone|
214543937|NCT00282945|DRUG|Metformin|
214543938|NCT00223210|DRUG|Quetiapine|Active Quetiapine
214543939|NCT00223210|DRUG|PLacebo|Placebo
214543940|NCT00727506|DRUG|BIBW 2992|BIBW 2992 once daily
214543941|NCT00727506|DRUG|TMZ|TMZ 21/28
215159290|NCT04976907|DEVICE|Contactless vital sign information collection|Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
214543942|NCT00727506|DRUG|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
214543943|NCT05716776|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
214543944|NCT01555398|DIETARY_SUPPLEMENT|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
214543945|NCT00149617|DRUG|Buspirone|
214543946|NCT02394522|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
214543947|NCT02394522|DEVICE|Active Ingredient|Transfluthrin (Active ingredient)
214543948|NCT02394522|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
214543949|NCT04373837|BEHAVIORAL|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
214543950|NCT04373837|OTHER|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
214543951|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
214543952|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
214543953|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
214543954|NCT01440413|BIOLOGICAL|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
214543955|NCT02450097|OTHER|Caloric restriction|
214543956|NCT04414631|DRUG|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
214543957|NCT04322812|DEVICE|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index \[WPI\] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
214543958|NCT04322812|DEVICE|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
214543959|NCT03492710|BIOLOGICAL|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
214698294|NCT01996748|DRUG|Placebo|Two administrations daily for 7 days
214698295|NCT02456376|PROCEDURE|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
214698296|NCT02456376|PROCEDURE|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
214698297|NCT04711876|BIOLOGICAL|Cytokine level in blood and CSF|Measure of cytokine level
214543960|NCT01089296|OTHER|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
214543961|NCT02207036|BEHAVIORAL|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
214543962|NCT02207036|BEHAVIORAL|Smokefree.gov|referral to the NCI Smokefree.gov website
214543963|NCT03561597|BEHAVIORAL|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
214543964|NCT01692093|DIETARY_SUPPLEMENT|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
214543965|NCT01692093|DIETARY_SUPPLEMENT|Placebo|Placebo
214543966|NCT02460055|DEVICE|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
214543967|NCT02460055|DRUG|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
214543968|NCT02460055|DRUG|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
214543969|NCT02460055|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
214543970|NCT02460055|DRUG|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
214543971|NCT02460055|DRUG|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
214543972|NCT00940862|BIOLOGICAL|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
214543973|NCT00940862|DEVICE|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
214543974|NCT00940862|OTHER|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
214543975|NCT03545412|DEVICE|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
214543976|NCT03783689|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
214543977|NCT04996940|DEVICE|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette"
214543978|NCT01931982|DRUG|Victoza|
214543979|NCT03975842|OTHER|Sinonasal and otologic evaluation|"At onset, each participant had:~* sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~* otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
214543980|NCT04399343|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
214543981|NCT04399343|DRUG|Normal saline|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
214543982|NCT01805245|BEHAVIORAL|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
214543983|NCT05692219|BEHAVIORAL|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
214543984|NCT05692219|BEHAVIORAL|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
214543985|NCT04182347|OTHER|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
214543986|NCT01255761|BIOLOGICAL|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
214543987|NCT05167084|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
214543988|NCT05167084|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
214543989|NCT05167084|DRUG|Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg
214543990|NCT05167084|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8
214543991|NCT03616483|OTHER|This is a non-interventional trial|This is a non-interventional trial
214543992|NCT01255956|DEVICE|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
214543993|NCT01255956|DEVICE|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
214543994|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
214543995|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
214543996|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
214543997|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
214543998|NCT05355129|DRUG|TT-00920|Tablets
214543999|NCT05355129|DRUG|TT-00920 Placebo|Tablets
214544000|NCT01539577|DRUG|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
214544001|NCT01437488|DRUG|Cabazitaxel|"* Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
214544002|NCT01437488|DRUG|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
214544003|NCT01437488|PROCEDURE|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
214544004|NCT01437488|BIOLOGICAL|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
214544005|NCT05392491|OTHER|No intervention|No intervention. It is an observational study
214698298|NCT02130258|DEVICE|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
214698299|NCT02130258|PROCEDURE|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
215159291|NCT05971576|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
215159292|NCT03774056|DRUG|HC-1119|oral
215159293|NCT00552188|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
215159294|NCT00552188|DRUG|Placebo|oral dosing, 1 time daily for 24 weeks
215159295|NCT03717870|PROCEDURE|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
215159296|NCT03717870|PROCEDURE|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
215159297|NCT03717870|PROCEDURE|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
215159298|NCT03867370|DRUG|Toripalimab (JS001 )|Given IV
215159299|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
215159300|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
214544006|NCT05063331|PROCEDURE|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
214544007|NCT05063331|PROCEDURE|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
214544008|NCT00669734|BIOLOGICAL|Falimarev|Given intratumorally or SC
214544009|NCT00669734|BIOLOGICAL|Inalimarev|Given SC
214544010|NCT00669734|OTHER|Laboratory Biomarker Analysis|Correlative studies
214544011|NCT00669734|BIOLOGICAL|Sargramostim|Given SC
214544012|NCT01717586|DRUG|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
214544013|NCT01717586|DRUG|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
214544014|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
214544015|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
214544016|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
214698300|NCT03150108|DRUG|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
214698301|NCT03150108|DRUG|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
214698302|NCT03150108|DRUG|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
214698303|NCT05923489|DIAGNOSTIC_TEST|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
214698304|NCT05923489|DIAGNOSTIC_TEST|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
215159301|NCT04475042|DRUG|Dapagliflozin|10mg od
215159302|NCT04475042|DRUG|Placebo|Placebo
214544017|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
214544018|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
214544019|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
214544020|NCT04356807|PROCEDURE|Reflex Locomotion Therapy|The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
214544021|NCT04356807|PROCEDURE|Passive Joint Mobilizations|Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
214544022|NCT04356807|PROCEDURE|Massage|Soft massage with soft pressures in limbs, tactile stimulation and no motion.
214544023|NCT06391398|BEHAVIORAL|Stoma care education with the Stoma Care Training Belt|Stoma care education
214544024|NCT06339463|BEHAVIORAL|Self-Distancing Intervention|"In the Self Distancing Intervention condition, participants will be instructed to describe the exposure task from a self-distanced perspective (e.g., Emily is going to touch the spider)."
214544025|NCT06339463|BEHAVIORAL|First-person self-talk|"Youth will be randomized to a BAT with a control condition. In this arm, participants will be instructed to describe the exposure task from a self-immersed perspective (e.g., I'm going to touch the spider)"
214544026|NCT05213234|BEHAVIORAL|Chronotherapy|Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
214544027|NCT06014827|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214544028|NCT06014827|PROCEDURE|Computed Tomography|Undergo CT or PET/CT scan
214544029|NCT06014827|DRUG|Osimertinib|Given PO
214544030|NCT06014827|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214544031|NCT06014827|RADIATION|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
214544032|NCT06014827|OTHER|Survey Administration|Ancillary study
214544033|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
214544034|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
214544035|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
214544036|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
214544037|NCT04284397|DRUG|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
214544038|NCT04284397|OTHER|Control|All participants will be tested with no treatment.
214544039|NCT05505084|PROCEDURE|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
214544040|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
214544041|NCT04560712|OTHER|Best Practice|Undergo usual care
214544042|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
214544043|NCT03947918|BEHAVIORAL|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
214544044|NCT03947918|BEHAVIORAL|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
214544045|NCT05289908|DRUG|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
214544046|NCT05289908|DRUG|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
214544047|NCT05289908|DRUG|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
214544048|NCT05289908|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
214544049|NCT05289908|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
214544050|NCT06124131|BEHAVIORAL|Financial incentive for colorectal cancer screening|$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
214544051|NCT06124131|BEHAVIORAL|Financial incentive for flu shot|$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
214544052|NCT06124131|BEHAVIORAL|Financial incentive for COVID-19 shot|$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
214544053|NCT01628640|OTHER|Laboratory Biomarker Analysis|Correlative studies
214544054|NCT01628640|OTHER|Pharmacological Study|Correlative studies
214544055|NCT01628640|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
214544056|NCT03783871|DEVICE|Microwave ablation|Subjects will be treated with microwave ablation.
214544057|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
214544058|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
214544059|NCT06636942|DEVICE|Intermittent pneumatic compression|Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
214544060|NCT05663528|PROCEDURE|orotracheal intubation|Clinical and laboratory data will be collected from patients who are intubated after 48 hours of admission to the intensive care unit
215159303|NCT05008900|RADIATION|Salvage radiotherapy|Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.
215159304|NCT03887702|OTHER|Best Practice|Receive best practice
215159305|NCT03887702|DRUG|Entecavir|Given PO
215159306|NCT03887702|DRUG|Tenofovir Alafenamide|Given PO
215159307|NCT03887702|DRUG|Tenofovir Disoproxil Fumarate|Given PO
214544061|NCT05916235|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
214544062|NCT04797767|DRUG|Cladribine|Given IV
215159308|NCT00522236|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
215159309|NCT04432727|DEVICE|Flexitouch Plus with Cellular Connectivity (FT-CC)|Daily use of FT-CC
215159310|NCT01617226|DRUG|Azacitidine|Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
215159311|NCT01617226|DRUG|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
215159312|NCT00107640|BEHAVIORAL|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
214544063|NCT04797767|DRUG|Cytarabine|Given IV
214544064|NCT04797767|DRUG|Mitoxantrone|Given IV
215159313|NCT02447224|DRUG|1 gm IV ertapenem at enrollment|
214544065|NCT04797767|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
214544066|NCT04797767|DRUG|Venetoclax|Given PO
214544067|NCT04797767|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214544068|NCT04797767|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214544069|NCT04797767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214544070|NCT06369363|DRUG|Placebo|Subjects will be assigned to 1 week of transdermal placebo patch.
214544071|NCT06369363|DRUG|Estradiol|Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
214544072|NCT06131203|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
214544073|NCT05443880|BEHAVIORAL|Exercise|The exercise intervention will focus on working the core muscles, starting with low-intensity isometric contraction of the core muscles that stabilize the trunk; increasing intensity by performing functional tasks (phase 1: independent isometric contraction of transversus-abdominis and multifidus, phase 2: co-contraction and functional tasks of the deep trunk muscles; phase 3: functional task with load; phase 4: functional task with unstable surface)
214698305|NCT05804006|OTHER|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
215159314|NCT02447224|DRUG|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
215159315|NCT02447224|PROCEDURE|Appendectomy|
214544074|NCT05443880|BEHAVIORAL|Exercise + mindfulness|The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group (using appreciative inquiry) and a Mindfulness practice. Participants will be provided with workbooks, audios with guided meditations, and instructions for practice at home. In addition, the Exercise + mindfulness intervention will include the exercise program described in the exercise intervention.
214544075|NCT05443880|OTHER|Control group|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks.
214544076|NCT04594733|DRUG|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
214544077|NCT04594733|DRUG|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
214544078|NCT04670770|DRUG|Drug - SHR1459|Oral Tablets taken once daily for 52 weeks
215159316|NCT00927914|DRUG|Ranirestat|Ranirestat 40 mg tablets
214544079|NCT01898715|DRUG|ATR-101|
214544080|NCT06646224|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
214544081|NCT06646796|OTHER|Yoga|Yoga with certified teacher, 3 times a week during 3 months.
214544082|NCT00277342|PROCEDURE|measurement of lipid-induced hepatic insulin resistance|
214544083|NCT00885326|DRUG|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
214698306|NCT03293277|DRUG|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
214698307|NCT03293277|DRUG|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
215159317|NCT00927914|DRUG|Placebo|Placebo tablets
215159318|NCT04196387|DIAGNOSTIC_TEST|urine culture|urine culture and antibiotic susceptibility test
215159319|NCT03347292|DRUG|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
214698308|NCT03293277|DRUG|Intranasal Placebo|Intranasal Placebo
214698309|NCT03293277|DRUG|Intravenous Placebo|Intravenous Placebo
214698310|NCT01341379|DRUG|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
214698311|NCT06317857|OTHER|Centio Forte|A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
215159320|NCT03347292|DRUG|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
214544084|NCT00885326|DRUG|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
214544085|NCT00885326|DRUG|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
214544086|NCT00796627|GENETIC|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
214544087|NCT00796627|OTHER|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
214544088|NCT02055456|DRUG|Nandrolone Decanoate|
214698312|NCT01368159|DEVICE|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
214698313|NCT01975935|DRUG|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
214698314|NCT01975935|DRUG|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
215159321|NCT00458224|BEHAVIORAL|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
215159322|NCT01456624|DRUG|Megace|800mg
215159323|NCT01456624|DRUG|DW-ES(B)|625mg
215159324|NCT05002244|DRUG|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
215159325|NCT05002244|DRUG|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
215159326|NCT05002244|DRUG|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
215159327|NCT03543787|COMBINATION_PRODUCT|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
215159328|NCT03137264|DRUG|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
215159329|NCT01675544|PROCEDURE|Electrocardiogram|EKG voltage changes between admission and discharge
214544089|NCT01804998|PROCEDURE|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
214544090|NCT01804998|PROCEDURE|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
214544091|NCT02647645|DEVICE|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
214544092|NCT02647645|PROCEDURE|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
214544093|NCT02647645|DEVICE|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
214544094|NCT03588598|DRUG|SHC014748M|a selective PI3Kδ inhibitor
214544095|NCT00507806|DRUG|perflutren lipid microsphere|
214544096|NCT01832662|OTHER|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
215159330|NCT01675544|PROCEDURE|Six minute walk test|
215159331|NCT02789267|OTHER|Regular dietary support|Systematic and regular dietary support after radiotherapy
215159332|NCT03118661|OTHER|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
215159333|NCT03118661|PROCEDURE|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
214544097|NCT01832662|OTHER|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
214544098|NCT01832662|OTHER|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
214544099|NCT00801411|DRUG|cyclophosphamide|Given IV
214544100|NCT00801411|DRUG|docetaxel|Given IV
214544101|NCT00801411|DRUG|doxorubicin hydrochloride|Given IV
214544102|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
214544103|NCT00169975|DEVICE|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
214698315|NCT05111496|RADIATION|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
214698316|NCT02388061|DRUG|Tenecteplase|
215159334|NCT02817932|DRUG|Ranolazine|
214544104|NCT00658840|DRUG|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
214544105|NCT00658840|RADIATION|Localization, simulation and immobilization|"Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
214544106|NCT02230462|OTHER|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
214544107|NCT04584879|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
214544108|NCT04584879|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
214544109|NCT04584879|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
214544110|NCT04626986|PROCEDURE|microwave ablation|Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
214544111|NCT04626986|PROCEDURE|breast conserving surgery|The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
214544112|NCT05484232|PROCEDURE|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
214544113|NCT00356811|DRUG|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
214698317|NCT02388061|DRUG|Tissue Plasminogen Activator|
214698318|NCT02358330|OTHER|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
214544114|NCT00356811|DRUG|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
214544115|NCT00503724|DRUG|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
214544116|NCT05442086|BEHAVIORAL|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24-27 minutes
214544117|NCT05442086|BEHAVIORAL|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
214698319|NCT03253991|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
215159335|NCT05317091|OTHER|Laughter yoga practiced|"In this study, 8 sessions of laughter yoga were applied to the nurses in the experimental group as an intervention, twice a week for 4 weeks. Due to the Covid-19 pandemic; Laughter Yoga sessions were held on the web through the 'ZOOM' program.~For this reason, it is recommended that the laughter yoga sessions be done with a group and that the group should consist of at least five people in order to provide group dynamics. Sessions are planned according to the days and hours that nurses can attend. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday-Saturday between 20:00-21:00. The nurses were constantly contacted (whatsapp, phone) to ensure that they attend the sessions regularly and that there is no interruption in the sessions. No experiment was performed on the control group during the study. However, after the research, a 4-week laughter yoga was given to the nurses who wanted it."
215159336|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing stretching
215159337|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing Ai Chi
215159338|NCT05178368|PROCEDURE|Surgical/ Transcatheter aortic valve replacement|The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
215159339|NCT00502411|DRUG|Doxorubicin|17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
214544118|NCT02386839|DRUG|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
214544119|NCT02101983|DRUG|Cytosine Arabinoside|
214544120|NCT03190629|DEVICE|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
214544121|NCT03190629|DEVICE|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
214544122|NCT04251546|DIAGNOSTIC_TEST|p2PSA|p2PSA test(for calculation of PHI)
214544123|NCT04251546|DIAGNOSTIC_TEST|Ultrasonic parameters|Ultrasonic parameters(TPV)
214544124|NCT04251546|DIAGNOSTIC_TEST|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
214544125|NCT04038671|DEVICE|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
214544126|NCT04038671|DEVICE|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
215159340|NCT00502411|RADIATION|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
215159341|NCT04561726|OTHER|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
215159342|NCT04561726|OTHER|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
215159343|NCT00215176|DRUG|modafinil|
215159344|NCT04502940|DIAGNOSTIC_TEST|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
215159345|NCT00947440|DRUG|ABT-072|See arm description for more information
214544127|NCT04038671|DEVICE|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
214544128|NCT04840498|BEHAVIORAL|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
214544129|NCT05756179|DRUG|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
214544130|NCT04783987|OTHER|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
214544131|NCT06862011|BEHAVIORAL|control group|Only surveys will be filled out.
214544132|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
215159346|NCT04882345|DRUG|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
215159347|NCT00899496|OTHER|immunological diagnostic method|
215159348|NCT00899496|OTHER|physiologic testing|
214544133|NCT06738316|BEHAVIORAL|Simulation|Simulation of a patient safety incident in practice. The simulation closely replicates the workplace experience.
214544134|NCT06831929|BEHAVIORAL|Intervention Arm|Within the intervention clinics, parents of patients between the ages of 10-12 (who are eligible for the HPV vaccine) will receive a culturally tailored customized HPV vaccine message and testimonial video from a patient/survivor of an HPV associated cancer (e.g., oropharyngeal, or cervical) via the MyChart patient portal. Parents will also receive a personal call from the research coordinator to remind them that their child is due for the HPV vaccine. If the parent is interested in scheduling the HPV vaccine appointment during this call, the research coordinator will transfer the parent to UC Davis appointment call center to schedule the appointment. Also, primary care team members will receive a semi-annual learn at lunch workshop focused on strategies to introduce the HPV vaccine to parents and how to address concerns from vaccine hesitant parents. Workshop content will be tailored/adapted to include patient/parent cultural considerations.
214544135|NCT04314492|PROCEDURE|Tonsillectomy|Intracapsular removal of tonsillar tissue (\>90%) with coblation
214544136|NCT01803347|DRUG|◦Drug: ASCs. + fibrin glue|Experimental group
214544137|NCT01803347|DRUG|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
214544138|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
214544139|NCT06933628|PROCEDURE|Patient-Specific Titanium Plates|Custom 3D-printed titanium fixation plates and cutting guides
214544140|NCT06933628|PROCEDURE|3D-Printed Intermediate Splint|CAD/CAM-fabricated occlusal splint for maxillary positioning
214544141|NCT06939413|DEVICE|Continuous glucose monitor (CGM)|The glucose data from the CGM will help participants to understand the effect of lifestyle and medications on their glucose levels. The glucose levels from the CGM will be remotely monitored. Outreach will be made to participants not reaching glycemic goals. Appropriate adjustments in treatment regimen will be made based on the glucose data obtained from CGM and RPM
214544142|NCT06945289|BEHAVIORAL|Let's Know!|This intervention is modified from a whole-classroom intervention by LARRC, 2018 and modified by Hogan et al. used in a larger NIH R01 investigation. We are examining the efficacy of the first two units used by Hogan et al.
214544143|NCT06944236|OTHER|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
214544144|NCT06945588|BEHAVIORAL|Music listening|Happy music group listened to happy music (major mode with a tempo of \>120 beats per minute).
214544145|NCT06945588|BEHAVIORAL|Music listening|Sad music group listened to sad music (minor mode with a tempo of \<80 beats per minute).
214544146|NCT06944652|OTHER|Stretching|Stretching of the plantar flexors or the shoulder joint
214544147|NCT06944301|DIAGNOSTIC_TEST|blood sampling|measuring troponine preoperative and postoperative first and second day
214544148|NCT06945705|DRUG|furmonertinib combined with anlotinib|furmonertinib: 160 mg po qd Anlotinib: 8 mg per day, orally administered.The treatment cycle is every 3 weeks, with each cycle lasting 21 days. Anlotinib are taken on Days 1-14 of each cycle.
214698320|NCT05103319|OTHER|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
215159349|NCT05272345|PROCEDURE|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
215159350|NCT00581880|BEHAVIORAL|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
214544149|NCT06944834|DEVICE|Implant|Implantation of the device and follow-up
214544150|NCT06945510|DEVICE|PCT detection|Clinicians will prescribe PCT tests every day for enrolled patients, with assigning a dedicated person monitoring the daily PCT results. Once the PCT \<0.5 ng/ml or ΔPCT (drop from the peak value) \>80%, the clinicians will receive a notification and will strictly adhere to guidelines and PCT values to adjust antibiotic prescriptions.
214544151|NCT00826228|DRUG|teriparatide|teriparatide 20ug daily sc for 6 months
214544152|NCT00826228|OTHER|weight-bearing|device assisted walking
214544153|NCT04385758|OTHER|Diabetes-REM Program|A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
214544154|NCT05999890|DRUG|Tapentadol Hydrochloride|Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
214544155|NCT04169191|DRUG|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
214698321|NCT03599141|BEHAVIORAL|Trust-building Self-management Together|Trust building plus depression self-management
215159351|NCT00108875|BIOLOGICAL|Survivin peptide vaccine|
215159352|NCT00484848|DEVICE|Vortex port and Celsite port|
215159353|NCT03393247|DRUG|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
215159354|NCT03393247|DRUG|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
215159355|NCT02296372|DEVICE|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
214544156|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
214544157|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
214544158|NCT00296738|DEVICE|SPECT/CT|GE INFINIA HAWKEYE
214544159|NCT00903760|DRUG|Decitabine|Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
214544160|NCT00903760|DRUG|Clofarabine|Clofarabine 10 mg/m\^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
214698322|NCT03599141|BEHAVIORAL|Depression Management|Traditional depression self-management
215159356|NCT05917678|OTHER|Repositioning Therapy|Caregivers will be instructed how to increase tummy time activities and reshape their infant's heads using at-home methods to direct their attention to the non-preferred side.
215159357|NCT05917678|DEVICE|Cranial Remolding Orthosis|A custom cranial remolding orthosis (FDA Class II device) will be made to fit affected infants. this should be worn 23 hours per day and the Orthotist needs to be seen regularly for adjustments until the head shape is resolved.
215159358|NCT00689260|DEVICE|easypod|Subjects is aware that the device records injection information that can be viewed by user
215159359|NCT00689260|DEVICE|easypod|Subjects is not aware that the device records injection information that can be viewed by user
215159360|NCT06466018|DIAGNOSTIC_TEST|Schirmer test paper|"This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved."
215159361|NCT01870934|DEVICE|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
215159362|NCT04381546|OTHER|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
215159363|NCT05780424|BIOLOGICAL|BRII-196|BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
215159364|NCT05780424|BIOLOGICAL|BRII-198|BRII-198 is a fully human IgG-1 mAb derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
215159365|NCT05780424|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
215159366|NCT05780424|BIOLOGICAL|Remdesivir|Antiviral agent
215159367|NCT00476008|DRUG|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
215159368|NCT00476008|DRUG|Placebo|One tablet placebo morning and evening (BID) for 12 months
215159369|NCT03970044|DRUG|Exenatide 2 MG|Glucagon-like peptide-1 receptor
215159370|NCT03970044|DRUG|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
215159371|NCT04988360|DEVICE|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
215159372|NCT04988360|DEVICE|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
215159373|NCT01170247|DRUG|Ketamine|Intranasal Ketamine (100 mg/mL)
215159374|NCT01170247|DRUG|Ketamine|Intramuscular Ketamine
215159375|NCT01934647|DRUG|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
215159376|NCT01901796|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
215159377|NCT01075308|DRUG|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
214544161|NCT02711319|DEVICE|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
214544162|NCT02711319|DEVICE|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
214544163|NCT04287283|OTHER|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
214544164|NCT00260247|DRUG|carbamazepine oxcarbazepine|
214544165|NCT00959777|DRUG|DA-3031|
214544166|NCT00959777|DRUG|Filgrastim|
214544167|NCT01197612|DRUG|pulmicort|applied to nasal packing after surgery
214544168|NCT02371772|OTHER|Training|Patients were trained to monitor INR and dose warfarin
214544169|NCT02723097|BEHAVIORAL|3 RP|
214544170|NCT02475304|DRUG|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
214698323|NCT00041613|GENETIC|INGN 201|
214698324|NCT03218423|DEVICE|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
214698325|NCT02274584|GENETIC|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
214698326|NCT01280890|BEHAVIORAL|Staff training using VIPS|Staff training using the VIPS framework
214698327|NCT01280890|BEHAVIORAL|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
214698328|NCT01280890|BEHAVIORAL|Control group|Filmed traditional Lectures will be given to care staff
214698329|NCT04032743|OTHER|ICU treatment|any treatment available by ICU
214698330|NCT04615962|DRUG|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
214698331|NCT04615962|DRUG|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
214698332|NCT04615962|DRUG|SNG100|A combination of low potency steroid and skin barrier repair agent
214698333|NCT03126929|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
214698334|NCT00807846|DRUG|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
214698335|NCT00807846|DRUG|Naproxen|Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
214698336|NCT02692339|DRUG|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
214544171|NCT02475304|DRUG|Placebo|
214544172|NCT01845805|DRUG|oral azacitidine|
214698337|NCT02692339|DRUG|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
214698338|NCT04152525|OTHER|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
214698339|NCT01081873|DRUG|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
214698340|NCT03011840|OTHER|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
214698341|NCT05224401|DRUG|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
214698342|NCT05224401|DRUG|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
214698343|NCT05745896|OTHER|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
214698344|NCT05745896|OTHER|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
214698345|NCT00441558|DRUG|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
214544173|NCT01845805|OTHER|Observation|
214544174|NCT03852108|OTHER|Comfort Care|Face, Hand and body care for 15 to 45 minutes
214544175|NCT01295203|BEHAVIORAL|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
214544176|NCT03082755|DRUG|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
214544177|NCT03082755|DRUG|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
214544178|NCT00673608|DRUG|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
214544179|NCT01674322|DRUG|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
214698346|NCT03340792|DEVICE|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
214698347|NCT04426123|DRUG|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
214698348|NCT04426123|OTHER|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
214698349|NCT01165021|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
214698350|NCT01165021|DRUG|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
214698351|NCT01165021|DRUG|Folic Acid|Administered orally.
214698352|NCT01165021|DRUG|Vitamin B12|Administered Intramuscular injection.
214698353|NCT01165021|DRUG|Dexamethasone|Administered orally.
214698354|NCT02491073|OTHER|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
214698355|NCT05275153|OTHER|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
214698356|NCT02274324|DIETARY_SUPPLEMENT|different diets|3 different diets: A\\B\\C
214698357|NCT00175084|BEHAVIORAL|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
214698358|NCT00924976|BEHAVIORAL|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
214698359|NCT03192982|DEVICE|A-V impulse 6000 Series|foot pad and pump
214544180|NCT00130845|DRUG|Octreotide Acetate in Microspheres|
214544181|NCT00130845|DRUG|Placebo|
214544182|NCT04864366|DRUG|Tenofovir Alafenamide 25 MG [Vemlidy]|TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
214544183|NCT06544850|OTHER|experimental group|Oswestry Low Back Pain Questionnaire will be used to assess functional limitations in daily life activities of patients with low back pain. Recognize mobile application will be used to assess lateralization performance. Evaluation will be made with hand, foot and back modules of this application. Reaction time and accuracy given at the end of the application will be recorded. The most accurate response instruction will be given in the shortest possible time. Visual Analog Scale (VAS) will be used to measure general pain status of patients. Tampa Kinesiophobia Scale will be used to assess fear of movement. Pain catastrophizing level will be assessed with Pain Catastrophizing Scale. Two-point discrimination device will be used to assess two-point discrimination. Central Sensitization Inventory will be used for central sensitization findings.
214544184|NCT06544850|OTHER|control group|Healthy volunteer participants who meet the inclusion criteria will be evaluated with the tests applied to the experimental group
214544185|NCT06484374|PROCEDURE|Robot-assisted minimally invasive treatment|An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
214544186|NCT01509443|OTHER|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
214544187|NCT02419768|OTHER|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
214544188|NCT02738905|DRUG|Rifaximin|One 550 mg tablet taken orally two times a day.
214544189|NCT00960609|PROCEDURE|Ultrasound guided liver resection|
214544190|NCT03927898|DRUG|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
214544191|NCT03927898|RADIATION|Stereotactic Body Radiotherapy|Participants receive SBRT (BED\>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
214544192|NCT06547463|OTHER|nasal oxygenation device|Use of the nasal oxygenation device on one of the two nights during which polysomnography will be performed.
214544193|NCT02472002|BIOLOGICAL|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~* Registry Type: autologous~* Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~* Route of administration: endomyocardial injection~* Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
214544194|NCT05099289|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
214544195|NCT00954005|DRUG|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
214544196|NCT03596398|GENETIC|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
214544197|NCT06330935|DRUG|Tranexamic Acid (TXA)|30 patients will be randomized to A arm and 30 patients to B arm
214544198|NCT06330935|DRUG|Normal saline|30 patients will be randomized this arm C
214544199|NCT03414528|DIAGNOSTIC_TEST|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
214544200|NCT01118559|DRUG|YM150|oral
214544201|NCT06957457|BEHAVIORAL|Exercise|The exercise program lasts 32 minutes in total. The first 6 (six) minutes of this program consists of warm-up exercises. Active exercise time is 21 (twenty-one) minutes. Relaxation exercises consist of 5 (five) minutes of relaxation exercises. exercise was accompanied by music. it consists of warm-up exercise and relaxation sections.
214544202|NCT06957457|BEHAVIORAL|Control (Standard treatment)|do nothing
214544203|NCT06957691|DRUG|fezolinetant - reference formulation|Daily oral administration of fezolinetant at a dose of 45 mg
214544204|NCT06957691|DRUG|Placebo|Daily oral administration of placebo
214544205|NCT06401278|DEVICE|Transcutaneous electrical acupoint stimulation|"It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)"
214544206|NCT06401278|DEVICE|Transcutaneous electrical nerve stimulation (group b):|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
214544207|NCT00656032|OTHER|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
214544208|NCT00656032|OTHER|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
214544209|NCT00466609|DRUG|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
214544210|NCT00466609|DRUG|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
214544211|NCT00466609|DRUG|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
214544212|NCT03553381|OTHER|hypocaloric balanced diet|
214544213|NCT02638688|OTHER|ultrasound|
214544214|NCT02755701|DRUG|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
214544215|NCT02755701|DRUG|Placebo|Placebo will be administered in the same way
214544216|NCT03142347|PROCEDURE|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
214544217|NCT03142347|PROCEDURE|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
214544218|NCT01266746|PROCEDURE|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
214544219|NCT00848796|DRUG|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
214544220|NCT01226732|DRUG|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
214544221|NCT01226732|DRUG|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
214544222|NCT02594449|DRUG|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
214544223|NCT00942747|DRUG|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
214544224|NCT00589303|DRUG|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone"
214544225|NCT00589303|DEVICE|AV Node ablation and device implant|"Pacing Systems:~* Enpusle Premarket Approval Number (PMA#) P980035~* EnRhythm PMA# P980035~* Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~\- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~* EnTrust PMA# P980016~* Virtuoso PMA# P980016~ICD CRT Pacing Systems:~* InSync Maximo PMA# P980016~* InSync Sentry PMA# P890003~* Concerto PMA# P980016"
214544226|NCT04840342|DRUG|Eplerenone|Dose escalations of eplerenone 50, 100, or 200mg
214544227|NCT04840342|DRUG|Amlodipine|Dose escalations of amlodipine 2.5, 5, or 10mg
214544228|NCT06164535|DRUG|Control group|35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
214544229|NCT06164535|DRUG|DPP-4 inhibitor group|35 T2DM patients will be given DPP-4 I once or twice daily
214544230|NCT06164535|DRUG|DPP-4 inhibitor + metformin group|35 T2DM patients will be given DPP-4 I + metformin once or twice daily
214544231|NCT01618370|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
214544232|NCT05015582|DEVICE|Pre op upper body forced air warming (32˚C)|Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
214544233|NCT05015582|DEVICE|Pre op lower body forced air warming (32˚C)|lower body forced air warming at ambient (32˚C) for at least 30 minutes
214544234|NCT05015582|DEVICE|Pre op fluids (45˚C)|fluids from warmed cabinet set at 45˚C
214544235|NCT05015582|DEVICE|Intra op upper body forced air warming (32˚C)|Use of upper body forced air warming intra-operative at ambient (32˚C)
214544236|NCT05015582|DEVICE|Intra op fluids at room temperature|IV fluids at room temperature
214544237|NCT05015582|DEVICE|Intra op upper body forced air warming at (32˚C)|upper body forced air warming intra-operative at ambient (32˚C)
214544238|NCT05015582|DEVICE|Intra op upper body forced air warming at (42˚C)|upper body forced air warming intra-operative at ambient (42˚C)
214544239|NCT05015582|DEVICE|Intra op lower body forced air warming at (32˚C)|Lower body forced air warming intra-operative at ambient (32˚C)
214544240|NCT05015582|DEVICE|Intra op lower body forced air warming at (42˚C)|Lower body forced air warming intra-operative at ambient (42˚C)
214544241|NCT05015582|DEVICE|Intra op fluid (42˚C)|IV fluids with hotline fluid warmer set at 42˚C
214544242|NCT04367480|DEVICE|Placebo Administration|Wear placebo TENS device
214698360|NCT03192982|DEVICE|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
215159378|NCT04049409|DRUG|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
214544243|NCT04367480|OTHER|Questionnaire Administration|Ancillary studies
214544244|NCT04367480|DEVICE|Transcutaneous Electrical Nerve Stimulation|Wear active TENS device
214544245|NCT00529477|OTHER|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
214544246|NCT00529477|OTHER|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
214544247|NCT00529477|OTHER|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
214544248|NCT00166946|PROCEDURE|foreskin from healthy adults for organotypic culture|
214544249|NCT01156740|DRUG|Penicillin G, Benzathine|IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg)
214544250|NCT01156740|DRUG|Amoxicillin|750 mg/QD
214544251|NCT01561677|DEVICE|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
214698361|NCT01419665|BIOLOGICAL|GP2013|Type: Biological/Vaccine
214698362|NCT01419665|BIOLOGICAL|rituximab|Type: Biological/Vaccine
214698363|NCT03738566|DEVICE|Esophageal self-dilation therapy|Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
214544252|NCT01561677|DEVICE|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
214698364|NCT03738566|PROCEDURE|Endoscopic therapy with esophageal dilation|A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
215159379|NCT04049409|DRUG|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
214544253|NCT03024892|PROCEDURE|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
214544254|NCT03024892|PROCEDURE|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
214544255|NCT03024892|PROCEDURE|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
214544256|NCT03024892|PROCEDURE|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
214544257|NCT03034850|PROCEDURE|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size \> 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
214544258|NCT00304382|BIOLOGICAL|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
214544259|NCT00304382|BIOLOGICAL|Pneumovax|0.5 ml IM one time
214544260|NCT03038035|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
214544261|NCT03038035|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
214544262|NCT03503929|DEVICE|LaparoGuard System|Adjunctive safety system for laparoscopic surgery
214544263|NCT00524186|DRUG|fluorouracil|Given IV
214544264|NCT00524186|DRUG|irinotecan hydrochloride|Given IV
214544265|NCT00524186|DRUG|leucovorin calcium|Given IV
214544266|NCT00524186|DRUG|sunitinib malate|Taken Orally
214544267|NCT00524186|OTHER|flow cytometry|Correlative Study
214544268|NCT00524186|OTHER|pharmacological study|Correlative Study
214544269|NCT00253331|DRUG|topical organogel with nitroglycerin|
214544270|NCT04351698|DRUG|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
214544271|NCT04351698|OTHER|Oral Placebo|Inert chewable tablet with no therapeutic value
214544272|NCT00419302|DRUG|Technosphere/Insulin|
214544273|NCT03832972|OTHER|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
214544274|NCT01780454|DRUG|MEDI-507|T-Cell Depleting Agent
214544275|NCT01780454|DRUG|Rituximab|B-Cell Depleting Agent
214544276|NCT01780454|RADIATION|Total Body Irradiation|Bone Marrow Depletion
214544277|NCT01780454|RADIATION|Thymic Irradiation|
214544278|NCT04385576|DEVICE|Aerosol Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
214544279|NCT04385576|DEVICE|Intubation Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
214544280|NCT03651557|DRUG|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
214544281|NCT03651557|DRUG|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
214544282|NCT03651557|DRUG|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
214544283|NCT00068172|DRUG|PI-88|
214544284|NCT05055947|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
214544285|NCT00749697|OTHER|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
214544286|NCT03549091|DIAGNOSTIC_TEST|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
214544287|NCT03549091|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
214544288|NCT00672685|DIETARY_SUPPLEMENT|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
214544289|NCT00672685|BEHAVIORAL|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
214544290|NCT00672685|DRUG|Placebo|OMEGA-3 placebo
214544291|NCT06956859|BEHAVIORAL|Paternal Skin to skin applicated to newborns|Paternal Skin to skin applicated to newbornsin the intervention group for 45 minutes. Routine care will be applied to the newborns in the control group. Father Descriptive Information Form, Newborn Descriptive Information Form, Skin-to-Skin Contact Monitoring Form (Newborn/Father), Newborn Comfort
214544292|NCT03088540|DRUG|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
214544293|NCT03088540|DRUG|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
214544294|NCT03088540|DRUG|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
214544295|NCT03088540|DRUG|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
214544296|NCT03088540|DRUG|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
214544297|NCT03088540|DRUG|cemiplimab|Patients will be administered cemiplimab as per protocol.
214544298|NCT06360926|DEVICE|SuperSonic® Ultrasound System|SuperSonic® Ultrasound System equipped with new software iterations used with a new probe and CE marked probes. The new software and probe are the new study investigational device not CE marked
214544299|NCT05427526|PROCEDURE|intraocular lens implantation|Lens surgery during or before vitrectomy surgery.
214544300|NCT00730015|DRUG|Matching Placebo|Oral, once daily
214544301|NCT00730015|DRUG|Linaclotide|Oral, once daily
214544302|NCT00330356|BEHAVIORAL|Low Salt Diet versus High salt diet|
214544303|NCT01335906|OTHER|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
214544304|NCT02608736|DRUG|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
214544305|NCT02608736|DRUG|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
215159380|NCT04321135|BEHAVIORAL|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
215159381|NCT04321135|BEHAVIORAL|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
215159382|NCT02537158|DRUG|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
215159383|NCT02537158|PROCEDURE|TACE|TACE group patients will accept TACE therapy once at a month after resection.
214544306|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
214544307|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
214544308|NCT04290377|DEVICE|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
214544309|NCT04290377|OTHER|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
214544310|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
214544311|NCT05724199|OTHER|Placebo|SC injection
214544312|NCT06391736|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
214544313|NCT06564285|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
214544314|NCT06564285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214544315|NCT02731911|DRUG|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
214544316|NCT01458925|DEVICE|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
214544317|NCT04120376|BEHAVIORAL|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
214544318|NCT03270800|BIOLOGICAL|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
214544319|NCT03270800|BIOLOGICAL|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
214544320|NCT05728190|OTHER|steril/salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose. Green food coloring was added (one drop of food coloring to 5 ml of sterile/saline water) to make sterile/saline water similar to lavender oil.
215159384|NCT00264758|DEVICE|Conventional hemodialysis|Three times per week in-center hemodialysis
215159385|NCT00264758|DEVICE|Frequent hemodialysis|Six times per week in-center hemodialysis
215159386|NCT04385693|PROCEDURE|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
214544321|NCT05728190|OTHER|Lavender essential oil|Five days seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
214544322|NCT02379143|OTHER|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
214544323|NCT03790709|DRUG|High dose ANAVEX2-73|Oral capsule
214544324|NCT03790709|DRUG|Mid dose ANAVEX2-73|Oral capsule
214544325|NCT03790709|DRUG|Placebo oral capsule|Oral capsule
215159387|NCT04385693|PROCEDURE|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
215159388|NCT05576545|DEVICE|The Breast Cancer Self-Care App|The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
215159389|NCT02044107|BEHAVIORAL|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
214544326|NCT01954433|PROCEDURE|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
214544327|NCT01954433|PROCEDURE|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
214544328|NCT01954433|PROCEDURE|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~1. RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~2. RISA with FCR-Ligament modified according to Weilby~3. RISA with APL-Ligament (abductor pollicis longus ligament)~4. RISA with Graftjacket modified according to Weilby~5. Resection arthroplasty"
214544329|NCT06120647|DIETARY_SUPPLEMENT|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
214698365|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
214698366|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
215159390|NCT02975232|BEHAVIORAL|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
215159391|NCT02975232|BEHAVIORAL|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
215159392|NCT01528202|DIETARY_SUPPLEMENT|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
215159393|NCT01528202|DIETARY_SUPPLEMENT|Fruit juice cordial|fruit flavoured juice concentrate
215159394|NCT02058745|BEHAVIORAL|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
215159395|NCT02058745|BEHAVIORAL|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
214698367|NCT06473337|DIAGNOSTIC_TEST|Blood sample|Serum blood sample for Vitamin D testing
215029462|NCT01532739|BEHAVIORAL|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
215029463|NCT06160245|OTHER|exercise therapy|core stabilization exercises
214544330|NCT01114451|PROCEDURE|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
214544331|NCT05921669|BEHAVIORAL|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
214544332|NCT04697953|DRUG|brolucizumab|Pre-filled Syringes for intravitreal injection
214698368|NCT05169645|OTHER|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale"
214698369|NCT02583945|PROCEDURE|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
214698370|NCT02934776|DEVICE|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
214698371|NCT02302794|PROCEDURE|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
214698372|NCT02302794|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
214698373|NCT05320458|OTHER|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
214698374|NCT01229488|DEVICE|Intervention|Project was withdrawn before starting. There were no interventions
214698375|NCT01540916|OTHER|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
214698376|NCT01540916|OTHER|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
214698377|NCT06006858|BIOLOGICAL|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
214698378|NCT01655823|DRUG|Placebo|Sham treatment acting as control arm
214698379|NCT01655823|DRUG|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
215029464|NCT05789251|DIAGNOSTIC_TEST|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
214544333|NCT00420875|DEVICE|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
214544334|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
214544335|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
214544336|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
214544337|NCT01648153|OTHER|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
214544338|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
214544339|NCT02922205|DEVICE|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
214544340|NCT03419676|DEVICE|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
214544341|NCT04799769|DEVICE|Percutaneous arterial closure device|Large hole percutaneous arterial closure device
214544342|NCT05425407|DIETARY_SUPPLEMENT|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
214544343|NCT05425407|DIETARY_SUPPLEMENT|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
214544344|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
214698380|NCT04539249|DRUG|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
215159396|NCT02058745|BEHAVIORAL|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
214544345|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
214544346|NCT01403870|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
214544347|NCT06016699|OTHER|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
214544348|NCT03085199|PROCEDURE|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
214544349|NCT03113747|BIOLOGICAL|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
214544350|NCT00240214|DRUG|sirolimus|Tablet, dosage is determined by trough level
214544351|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
214544352|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
214544353|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
214544354|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
214544355|NCT05921097|DIAGNOSTIC_TEST|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
214544356|NCT05921097|DIAGNOSTIC_TEST|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
214544357|NCT05921097|DIAGNOSTIC_TEST|2-point discrimination tasks|2-point discrimination tasks
214544358|NCT05921097|DIAGNOSTIC_TEST|NC-Stat DPNCheck|NC-Stat DPNCheck
214544359|NCT05921097|DIAGNOSTIC_TEST|QST|QST
214544360|NCT05921097|DIAGNOSTIC_TEST|Biothesiometry|Biothesiometry
214544361|NCT01542346|PROCEDURE|subcutaneous adaption|
214544362|NCT03932578|DRUG|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
214544363|NCT03932578|DRUG|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
214544364|NCT02674269|DRUG|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
214544365|NCT02674269|DRUG|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
214544366|NCT02674269|DEVICE|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
214544367|NCT04451447|PROCEDURE|The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
214544368|NCT04451447|PROCEDURE|Saline test (routine test)|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
214544369|NCT00040287|BEHAVIORAL|smoking cessation program|
214544370|NCT00040287|BEHAVIORAL|weight control program|
214544371|NCT02007200|OTHER|Laboratory Biomarker Analysis|Correlative studies
214544372|NCT02007200|DRUG|Soy Isoflavones|Given PO
214544373|NCT02007200|OTHER|Survey Administration|Ancillary studies
214544374|NCT00393653|PROCEDURE|N-of-1 prescription method|
214544375|NCT04339660|BIOLOGICAL|UC-MSCs|1\*10E6 UC-MSCs /kg body weight suspended in 100mL saline
214544376|NCT04339660|OTHER|Placebo|100mL saline intravenously
214544377|NCT00648687|BEHAVIORAL|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
214544378|NCT02911194|DIETARY_SUPPLEMENT|a2 milk|replace all milk with a2 milk
214544379|NCT02911194|DIETARY_SUPPLEMENT|a1 containing milk|use a1 containing milk
214544380|NCT04040049|GENETIC|FLT190|Gene Therapy product.
215159397|NCT04854447|DEVICE|Single-Vision Spectacles|Spectacle correction for myopia treatment
215159398|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
215159399|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
214544381|NCT03310671|PROCEDURE|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm"
214544382|NCT03253432|OTHER|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
214544383|NCT06008223|DRUG|vitamin B6|The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
214544384|NCT06008223|DRUG|0.9% sodium chloride solution|That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
214544385|NCT00534053|OTHER|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
214698381|NCT04539249|DRUG|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
214544386|NCT06074692|COMBINATION_PRODUCT|Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)|Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
214544387|NCT00297843|PROCEDURE|allergen challenge (grass pollen), nasal lavage|
214544388|NCT03851081|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214544389|NCT03851081|OTHER|Quality-of-Life Assessment|Ancillary studies
214544390|NCT03851081|DRUG|Vincristine Sulfate Liposome|Given IV
214544391|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
214544392|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
214544393|NCT05282836|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
214544394|NCT04182113|DEVICE|1 Hz rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
214544395|NCT04182113|DEVICE|Sham rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
214544396|NCT04563598|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
214698382|NCT02462304|PROCEDURE|End-Point-Management grid laser|
214544397|NCT04563598|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
214544398|NCT01526837|DRUG|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
214544399|NCT05194163|DRUG|MW150|oral-delivered capsule of study drug
214544400|NCT05194163|DRUG|Placebo|oral delivered capsule matched to study drug capsule
214544401|NCT01186731|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
214544402|NCT05029011|DEVICE|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
214544403|NCT03236610|DRUG|tenofovir monotherapy|switching to tenofovir monotherapy
214544404|NCT03236610|DRUG|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
214544405|NCT02561208|OTHER|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
214544406|NCT01159951|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
214544407|NCT06064747|DEVICE|LF-rTMS|"LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);"
214544408|NCT06064747|DEVICE|Sham stimulation|Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
214544409|NCT03002142|DEVICE|Hearing aids|Phonak Audéo B-R (Target V 5.0)
214544410|NCT03002142|DEVICE|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
214544411|NCT06269159|OTHER|Concept mapping: brainstorm|"Group health care providers:~* Duration: 1.5 hour for HCP via zoom session~* Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~* Duration: online survey (REDCAP) of approx. 10 minutes~* Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?"
214698383|NCT02462304|DRUG|ranibizumab|
214698384|NCT02462304|DRUG|Bevacizumab|
214698385|NCT00187837|PROCEDURE|SW|Stepwise removal of carious tissue in 2 stages
214698386|NCT00187837|PROCEDURE|DCE|one complete excavation
215029465|NCT03794947|PROCEDURE|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
215029466|NCT03794947|PROCEDURE|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
214544412|NCT06269159|OTHER|Concept mapping: clustering and rating|"The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~* Duration: flexible use of the online tool (available for two weeks)~* The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~* Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks."
214698387|NCT04799405|DEVICE|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
214698388|NCT05430451|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
214698389|NCT05430451|BEHAVIORAL|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
214544413|NCT01041989|BEHAVIORAL|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
214544414|NCT01041989|BEHAVIORAL|Exercise|Guided muscle strength training and aerobic exercise.
214544415|NCT01041989|BEHAVIORAL|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
214544416|NCT01041989|OTHER|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
214544417|NCT01409005|DRUG|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1\~21~Interval: every 4 weeks"
214544418|NCT04176289|DIAGNOSTIC_TEST|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI\> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
214544419|NCT02634047|DEVICE|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
214544420|NCT02634047|DEVICE|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
214544421|NCT01667406|DRUG|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
214544422|NCT01667406|DRUG|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
214544423|NCT01667406|DRUG|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
214544424|NCT01667406|DRUG|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
214544425|NCT01667406|DRUG|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
214544426|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
214698390|NCT05430451|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
214698391|NCT05430451|BEHAVIORAL|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
214544427|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
214544428|NCT04752800|DEVICE|Direct Current Transcranial Stimulation - tDCS|Intervenção Ativa
214544429|NCT04752800|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham Intervention
214544430|NCT00981708|DRUG|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
214544431|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
214544432|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
214544433|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
214698392|NCT05430451|BEHAVIORAL|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
214698393|NCT05430451|BEHAVIORAL|SMS|SMS on follow-up survey reminders
214544434|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
214698394|NCT04612062|DRUG|CEE321|CEE321 administered to all subjects
214698395|NCT04946136|OTHER|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
214698396|NCT02434627|DRUG|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
214544435|NCT00943787|PROCEDURE|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
214544436|NCT03792347|DRUG|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
214544437|NCT04597346|DEVICE|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
214544438|NCT03306004|OTHER|Questionare|
214544439|NCT00589537|OTHER|questionnaire administration|
214544440|NCT00589537|PROCEDURE|computed tomography|
214544441|NCT00589537|PROCEDURE|magnetic resonance imaging|
214544442|NCT00589537|PROCEDURE|quality-of-life assessment|
214544443|NCT01288209|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
214544444|NCT01288209|DRUG|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
214544445|NCT01288209|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
214544446|NCT05213546|OTHER|Aerobic exercise training|bicycle ergometer exercise training
214544447|NCT01015677|DRUG|MK-6913|
214544448|NCT01015677|DRUG|17-β estradiol|
214544449|NCT01015677|DRUG|Placebo to MK-6913|
214544450|NCT01015677|DRUG|Placebo to 17-β estradiol|
214544451|NCT01015677|DRUG|MK-6913 25 mg|
214544452|NCT06464952|DIETARY_SUPPLEMENT|Resistant potato starch|Prebiotic
214544453|NCT06464952|DIETARY_SUPPLEMENT|Powdered cellulose|Active comparator
214544454|NCT00293345|DRUG|gemcitabine hydrochloride|
214544455|NCT00293345|DRUG|triapine|
214544456|NCT01755676|DRUG|Orlistat 60 mg|1 tablet 3 times a day
214544457|NCT01755676|OTHER|Placebo|1 tablet 3 times a day
214544458|NCT02232399|DRUG|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
214544459|NCT02232399|DRUG|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
214544460|NCT00814008|DRUG|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
214544461|NCT00814008|DRUG|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
214544462|NCT04623762|OTHER|Yoga|yoga application
214544463|NCT03091322|DEVICE|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
214544464|NCT03064152|DEVICE|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
214544465|NCT00751322|OTHER|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
214544466|NCT00751322|OTHER|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
214698397|NCT01849835|PROCEDURE|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
214698398|NCT01849835|PROCEDURE|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
214698399|NCT04062851|OTHER|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
215029467|NCT04869384|OTHER|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
215029468|NCT04869384|OTHER|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
215029469|NCT03421353|DRUG|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
215029470|NCT03421353|DRUG|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
215029471|NCT03421353|DRUG|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
215029472|NCT03421353|DRUG|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
214544467|NCT05317455|DRUG|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
214544468|NCT05429047|BIOLOGICAL|Tozinameran|Tozinameran during pregnancy
214544469|NCT05429047|OTHER|COVID-19|SARS-CoV-2 infection during pregnancy
214544470|NCT05429047|OTHER|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
214544471|NCT04083924|OTHER|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
214544472|NCT00209664|DRUG|irinotecan|
214544473|NCT00209664|DRUG|S-1|
214544474|NCT00601432|DRUG|levofloxacin oral solution|
214544475|NCT01986296|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
214544476|NCT05759286|BEHAVIORAL|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
214544477|NCT05759286|BEHAVIORAL|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
214544478|NCT05759286|BEHAVIORAL|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
214544479|NCT05558436|DIAGNOSTIC_TEST|Genome-wide methylation profiling|Detection for colorectal tumor-specific ctDNA methylation biomarkers
214544480|NCT04487353|OTHER|Labor mechanism application developed with virtual reality technology (VRT-LMA)|"In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups."
214544481|NCT01646385|DRUG|etanercept|use as per routine clinical practice
214544482|NCT01646385|DRUG|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
214544483|NCT00206297|DRUG|Pramlintide|
214544484|NCT04338412|DEVICE|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
214544485|NCT00289575|DEVICE|MBCP|
214544486|NCT04719299|BEHAVIORAL|Tell-Play-Do|Using smart phone application
214544487|NCT04719299|BEHAVIORAL|Tell-Show-Do|Using traditional behavior management technique
214544488|NCT00508495|DRUG|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
214544489|NCT00508495|DRUG|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
214544490|NCT00508495|DRUG|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
214544491|NCT01495351|DRUG|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
214544492|NCT04627051|DEVICE|Atherectomy and balloon angioplasty|Atherectomy and balloon angioplasty of arterial-venous graft stenosis
214544493|NCT05758805|DEVICE|mini-invasive esophagoscopy|mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
214544494|NCT05758805|DEVICE|HP-SD AF ablation by a CF sensing catheter|AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
214544495|NCT01076790|DRUG|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
214544496|NCT01076790|DRUG|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
214544497|NCT05264779|OTHER|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
214544498|NCT03895528|DRUG|Lonafarnib|Farnesyl transferase inhibitor
214544499|NCT01112436|DRUG|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
214544500|NCT01112436|DRUG|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
214698400|NCT05056454|BEHAVIORAL|Online therapy with coaching within STAND|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
214544501|NCT04812743|BEHAVIORAL|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
214544502|NCT04061135|PROCEDURE|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
214544503|NCT01216072|DRUG|Fingolimod|0.5 mg/day oral capsule
214544504|NCT01216072|DRUG|Standard MS DMTs|
214544505|NCT04175561|OTHER|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
214544506|NCT02440334|DRUG|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
214544507|NCT05856136|DRUG|Fentanyl Injection|Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
214544508|NCT05567757|BIOLOGICAL|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
214544509|NCT05289661|DRUG|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
214544510|NCT05289661|DRUG|Topical Placebo|topical Placebo
214544511|NCT05425264|OTHER|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
214544512|NCT03322553|DEVICE|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
214544513|NCT01435148|PROCEDURE|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
214544514|NCT05306444|DRUG|CLN-418|Intravenous (IV) administration
214544515|NCT03915769|DRUG|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
214544516|NCT03915769|OTHER|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
214544517|NCT04266444|DEVICE|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
214544518|NCT04294667|DRUG|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
214544519|NCT04294667|OTHER|Placebo|Subjects will receive placebo at prespecified time-points.
214544520|NCT04058236|OTHER|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
214544521|NCT04058236|OTHER|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
214544522|NCT04799418|DEVICE|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
214544523|NCT01785147|DRUG|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
214544524|NCT01785147|DRUG|Placebo|
214544525|NCT00244647|DRUG|RESTEN-MP|
214544526|NCT00136110|DRUG|Sodium Valproate|
214544527|NCT05109000|DRUG|Sodium Chloride 0.9% Inj|10 mL subcutaneous injection into one randomized anterior thigh of subject
214544528|NCT05109000|DRUG|Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)|10 mL subcutaneous injection into the contralateral anterior thigh of subject
214544529|NCT01601912|DRUG|Atomoxetine|40 mg, 1 application
214544530|NCT01601912|DRUG|Citalopram|20 mg, 1 application
214544531|NCT03349411|DIAGNOSTIC_TEST|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
214544532|NCT03349411|DIAGNOSTIC_TEST|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
214544533|NCT03349411|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
214544534|NCT03349411|DIAGNOSTIC_TEST|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
214544535|NCT03349411|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
214544536|NCT03349411|DIAGNOSTIC_TEST|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
214544537|NCT03349411|DIAGNOSTIC_TEST|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
214544538|NCT00004254|DRUG|raltitrexed|
214544539|NCT03563313|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.
214544540|NCT03563313|DEVICE|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
214544541|NCT00952848|OTHER|questionnaire administration|Pain Rating Score
214544542|NCT00952848|OTHER|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
214544543|NCT00952848|OTHER|Quality of Life instrument|Uniscale 0-100 scale global quality of life
214544544|NCT00952848|DEVICE|MC5-A Scrambler device|Electrical stimulation for 60 minutes
214544545|NCT01447862|DRUG|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
214544546|NCT01447862|DRUG|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
214544547|NCT03655665|DRUG|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
214698401|NCT05056454|BEHAVIORAL|Clinical care within STAND|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
214698402|NCT05056454|OTHER|Perinatal Psychiatric Care|Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
214544548|NCT05514171|PROCEDURE|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
214544549|NCT04749498|OTHER|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
214544550|NCT04749498|OTHER|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
214544551|NCT04749498|OTHER|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
214544552|NCT04749498|OTHER|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
214544553|NCT00537329|DRUG|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
214544554|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
214698403|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler|
214698404|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
214698405|NCT02162485|DRUG|Seretide Diskus|
214698406|NCT02162485|DRUG|Seretide Diskus with charcoal|
214698407|NCT00626912|PROCEDURE|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
214698408|NCT02849912|OTHER|questionnaire|
214698409|NCT05381376|DIAGNOSTIC_TEST|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
214544555|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
214544556|NCT03886597|OTHER|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
214544557|NCT00574600|BIOLOGICAL|SAAVI DNA-C2 vaccine|DNA vaccine
214544558|NCT00574600|BIOLOGICAL|SAAVI MVA-C vaccine|Boost vaccine
214544559|NCT00574600|BIOLOGICAL|Placebo|Placebo vaccine
214544560|NCT01530386|DRUG|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
214544561|NCT01658956|DRUG|GCSF administration on days 8 and 12 after chemotherapy|
214544562|NCT02049515|DRUG|IPI-145|PI3K Inhibitor
214544563|NCT02049515|DRUG|Ofatumumab|Monoclonal antibody
214544564|NCT02100683|DEVICE|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
214544565|NCT05946122|DRUG|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
214544566|NCT05946122|DRUG|placebo drug|tablet resembles atorvastatin
214698410|NCT05381376|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
214544567|NCT02425241|BIOLOGICAL|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
214544568|NCT02425241|BIOLOGICAL|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
214544569|NCT02425241|BIOLOGICAL|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10\^8 pfu at week 20
214544570|NCT02425241|DRUG|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
214544571|NCT02425241|OTHER|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
214698411|NCT00002157|DRUG|Thalidomide|
214698412|NCT01609803|OTHER|laboratory biomarker analysis|Correlative studies
214544572|NCT02660268|OTHER|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
214544573|NCT06248112|DRUG|Sacubitril and Valsartan-Test product|Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
214544574|NCT06248112|DRUG|Sacubitril and Valsartan-Reference product|Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
214544575|NCT01308268|DRUG|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (\>= 2 years old) single dose, PO
214544576|NCT04011293|BIOLOGICAL|CNCT19|0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
214544577|NCT01902498|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
214544578|NCT01902498|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
214544579|NCT01902498|DRUG|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
214544580|NCT01363310|DRUG|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
214544581|NCT01363310|DRUG|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
214544582|NCT03049345|PROCEDURE|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
214544583|NCT03049345|DRUG|Radioactive Tracers|see above
214544584|NCT03049345|DRUG|Methylene Blue 20 MG/ML|see above
214544585|NCT01640171|PROCEDURE|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
214544586|NCT01640171|DRUG|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
214544587|NCT01640171|DRUG|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
214544588|NCT01640171|DRUG|Acuvail|Anti-inflammatory drop given after treatment
214544589|NCT01640171|DRUG|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
214698413|NCT02088684|DRUG|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
214544590|NCT02444728|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
214544591|NCT02444728|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
214544592|NCT02444728|DRUG|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
214544593|NCT02444728|DRUG|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
214544594|NCT01792843|BEHAVIORAL|data|"* comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features"
214544595|NCT05749861|DRUG|CKD-348(5)|QD, PO
214544596|NCT05749861|DRUG|CKD-828, D097, D337|QD, PO
214544597|NCT02138253|DRUG|IDN-6556|
214544598|NCT02138253|DRUG|Placebo|Placebo control
214544599|NCT03967912|BEHAVIORAL|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
214544600|NCT04376112|OTHER|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
214544601|NCT04376112|OTHER|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
214544602|NCT04648098|OTHER|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
214698414|NCT02088684|DRUG|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
214698415|NCT02088684|DRUG|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
214544603|NCT06454305|OTHER|Active cycle of breathing technique|Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing. Secretions are moved into the central airways during the forceful expiratory exercise that follows The three stages of ACBT
214544604|NCT06454305|OTHER|Blow Bottle Technique|A 1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly, Breath in through nose and out through mouth, Blowing enough water is bubbled, Short Breaks for 2 to 3 mints, When mucus rises up get out of it by coughing or huffing
214544605|NCT01426113|DRUG|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
214698416|NCT02088684|DRUG|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
215159400|NCT02746224|PROCEDURE|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
215159401|NCT02746224|PROCEDURE|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
215159402|NCT01916291|DRUG|Propess insertion group|
215159403|NCT05710445|OTHER|Augmented Reality|Mixed reality smart glasses will be used to view a virtual monitor which mirrors the ultrasound screen in real-time.
215159404|NCT02862353|BIOLOGICAL|blood sample|15 ml of blood
215159405|NCT01862692|BEHAVIORAL|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
215159406|NCT01862692|BEHAVIORAL|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
215159407|NCT04596436|OTHER|no intervention|no intervention
214544606|NCT01426113|DRUG|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
215159408|NCT06531889|OTHER|classical physiotherapy program|Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
215159409|NCT06531889|OTHER|Core Stabilization Exercises|The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
214544607|NCT01426113|DRUG|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
214544608|NCT00224029|DRUG|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
214698417|NCT02074579|DRUG|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
214698418|NCT02074579|DRUG|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
214698419|NCT05602259|DIAGNOSTIC_TEST|induced sputum|After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
214698420|NCT05602259|DIAGNOSTIC_TEST|lung biopsy|As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
214698421|NCT05602259|DIAGNOSTIC_TEST|bronchoalveolar lavage|When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
214544609|NCT03357978|DIAGNOSTIC_TEST|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
214544610|NCT03357978|DIAGNOSTIC_TEST|blood draw|Blood samples are taken from sober patients
214544611|NCT03357978|DIAGNOSTIC_TEST|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
214544612|NCT03357978|DIAGNOSTIC_TEST|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
214544613|NCT03357978|DIAGNOSTIC_TEST|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
214544614|NCT01793077|DRUG|Depo-Eligard®|Subcutaneous
214544615|NCT03043482|DRUG|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
214544616|NCT03043482|DRUG|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
214544617|NCT03043482|DRUG|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
214544618|NCT02051569|DIETARY_SUPPLEMENT|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
214544619|NCT02316262|PROCEDURE|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
214544620|NCT05364034|OTHER|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
214698422|NCT05602259|DIAGNOSTIC_TEST|blood draw|As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
214698423|NCT02473159|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
214698424|NCT02315937|PROCEDURE|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
215159410|NCT03546868|DRUG|[18F]FSPG|Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
215159411|NCT03758300|OTHER|Radiofrequency|See previous page
215159412|NCT03820700|BEHAVIORAL|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
215159413|NCT03820700|BEHAVIORAL|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
215159414|NCT03820700|BEHAVIORAL|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
215159415|NCT00874926|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
214544621|NCT04470869|OTHER|Phone call|The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
215159416|NCT02816827|DIETARY_SUPPLEMENT|AG-01|Product to increase mental alertness
215159417|NCT02816827|DIETARY_SUPPLEMENT|AG-05|Product to increase mental alertness
215159418|NCT02816827|DIETARY_SUPPLEMENT|AG-06|Product to increase mental alertness
215159419|NCT02816827|DIETARY_SUPPLEMENT|AG-07|Product to increase mental alertness
215159420|NCT00514748|PROCEDURE|DIEP|flap survival, operation time, flap complications, donor site morbidity.
215159421|NCT00514748|PROCEDURE|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
215159422|NCT04193072|BEHAVIORAL|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
215159423|NCT03209739|OTHER|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
215159424|NCT02727439|OTHER|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
215159425|NCT00506636|BEHAVIORAL|Tissue engineering for hair follicle regeneration|
215159426|NCT01385397|OTHER|Preceptorship and virtual community|
214698425|NCT00952237|DRUG|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
214698426|NCT00952237|DRUG|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
214698427|NCT01778088|DRUG|I-131-CLR1404 Injection|
214698428|NCT06156111|DEVICE|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
215159427|NCT02799251|OTHER|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
214698429|NCT06156111|DEVICE|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
214698430|NCT00123851|DRUG|Tarceva (OSI-774)|
214698431|NCT00123851|DRUG|Capecitabine|
215159428|NCT02785796|OTHER|CV4|
215159429|NCT02785796|OTHER|SHAM TECHNIQUE|
215159430|NCT06138860|OTHER|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
215159431|NCT06138860|OTHER|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
215159432|NCT05300438|DRUG|TSN084|Oral tablets
215159433|NCT00792571|DRUG|Beraprost Sodium Modified Release|
215159434|NCT01949467|DRUG|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
215159435|NCT02836639|DRUG|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
215159436|NCT02836639|DRUG|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
215159437|NCT02836639|DRUG|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
215159438|NCT04473742|BIOLOGICAL|Blood collection|4 EDTA tubes for 24 mL blood collection
215159439|NCT04473742|BIOLOGICAL|Blood sample|2 drying tubes for 12 mL blood collection
215159440|NCT04473742|BIOLOGICAL|Blood sample|1 drying tube for 6 mL blood collection
214544622|NCT06210061|DRUG|Propofol-Fentanyl|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
214544623|NCT06210061|DRUG|Propofol-Fentanyl-Dexmedetomidine|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
214544624|NCT06210061|DRUG|Propofol-Fentanyl-Sevoflurane|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
214698432|NCT00123851|DRUG|Oxaliplatin|
214698433|NCT02998554|DRUG|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
214698434|NCT02998554|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
215159441|NCT05055492|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
215159442|NCT00994344|DRUG|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
215159443|NCT00994344|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
214544625|NCT02872012|DEVICE|Cryoanesthesia device|The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
214544626|NCT02872012|DRUG|Lidocaine|Lidocaine applied to the non-cryoanesthesia eye.
214544627|NCT05715736|DRUG|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
214544628|NCT05715736|DRUG|Placebo|0.90% Normal Saline only
214544629|NCT05331976|DIAGNOSTIC_TEST|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
214544630|NCT05414383|DEVICE|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
214544631|NCT03336099|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique"
214544632|NCT02573545|DEVICE|Planning@IFE and Standard@IFE Software|
214544633|NCT02573545|DEVICE|MR Syngo (Numaris/4) software|
214544634|NCT04690478|DEVICE|Electronic remote blood pressure monitor|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
214544635|NCT04690478|DEVICE|Ordinary household electronic sphygmomanometer|One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
214544636|NCT04690478|DEVICE|Office electronic sphygmomanometer|One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
214544637|NCT01210378|DRUG|Nitroglycerin patch|Nitroglycerin patch
215159444|NCT06476639|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound monitoring|Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
214698435|NCT06187844|PROCEDURE|Inguinal exploration|Inguinal exploration will be done for all the included patients.
214698436|NCT06187844|PROCEDURE|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
214698437|NCT04496596|DRUG|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
214698438|NCT04496596|DRUG|Placebo|Placebo
215159445|NCT03104660|DEVICE|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
215159446|NCT02465554|PROCEDURE|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
215159447|NCT05767879|DRUG|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
215159448|NCT04619160|DRUG|Propofol|TCI 4 µg/mL start until BIS-value of 50
215159449|NCT04619160|DRUG|Sevoflurane|start 1 MAC, until BIS-value of 50
214544638|NCT01498562|DRUG|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
214698439|NCT01999413|DRUG|OMEGAVEN|AML Study treatment induction phase
215029473|NCT03421353|DRUG|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
214544639|NCT01498562|DRUG|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
214544640|NCT05005299|DRUG|Venetoclax|Venetoclax is administered as an oral tablet once daily.
214544641|NCT05005299|DRUG|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
214544642|NCT05005299|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
214698440|NCT01999413|DRUG|Daunorubicin|AML Study treatment induction phase
214698441|NCT01999413|DRUG|Cytarabine|AML Study treatment induction phase
214698442|NCT03407196|DRUG|Forxiga|Oral antidiabetics
214698443|NCT06516939|DRUG|bFGF|Half-face randomized control
214698444|NCT06516939|DRUG|Bovine Basic Gel|Bovine Basic Gel
214698445|NCT05580055|DIAGNOSTIC_TEST|Affinity|Blood Analyser
215029474|NCT03421353|DRUG|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
215029475|NCT03421353|DRUG|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
215029476|NCT02754297|DRUG|177Lu-Octreotate|"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
215159450|NCT02490969|PROCEDURE|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
215159451|NCT01638442|DRUG|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
215159452|NCT01638442|DRUG|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~\--------------------------------------------------------------------------------"
215029477|NCT06268847|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
215159453|NCT06395337|DRUG|[111In]In-DOTA-ANTI-CEA antibody injection|tracer injection
214544643|NCT05445063|BIOLOGICAL|Autologous iPSC-derived RPE|Autologous transplantation of iPSC-derived RPE
214544644|NCT03833362|DRUG|Narlaprevir|yellow film-coated 100 mg. tablets
214544645|NCT03833362|DRUG|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
214544646|NCT03833362|DRUG|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
214544647|NCT03833362|DRUG|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
214544648|NCT03833362|DRUG|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
214544649|NCT03833362|DRUG|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b"
214544650|NCT04731350|DEVICE|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
214544651|NCT04731350|DEVICE|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
214544652|NCT04731350|OTHER|Exercise|strengthening exercise
214544653|NCT02754193|OTHER|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
214544654|NCT04416932|PROCEDURE|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
214544655|NCT02484989|OTHER|Surviellance card|
214544656|NCT00499928|DRUG|SB-751689|
214544657|NCT01764308|DIETARY_SUPPLEMENT|Omega-3|1200mg twice a day for 24 weeks
214544658|NCT01764308|DIETARY_SUPPLEMENT|Placebo|4 tablets twice a day for 24 weeks
214544659|NCT06345326|OTHER|Greater occipital nerve block|The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
215029478|NCT06268847|DIETARY_SUPPLEMENT|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
215029479|NCT06268847|DIETARY_SUPPLEMENT|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
215029480|NCT06040255|DRUG|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
215159454|NCT06395337|RADIATION|SPECT/CT scan|abdominal and thoracic SPECT/CT scan
215159455|NCT06395337|PROCEDURE|Resection surgery|oncological resection surgery will be performed extended with the use of dual-modality imaging.
215159456|NCT05400382|BEHAVIORAL|Mindfulness|Meditation training to help reduce stress and reactivity to pain and other stressors.
215159457|NCT01615536|PROCEDURE|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
215159458|NCT01615536|PROCEDURE|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
215159459|NCT03236376|OTHER|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
215159460|NCT03236376|OTHER|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
215159461|NCT05762068|OTHER|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
215159462|NCT02850913|DRUG|Doxycycline|"* 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
215159463|NCT02850913|OTHER|Placebo|\- Placebo (matching capsules containing no active ingredients)
215159464|NCT04857320|COMBINATION_PRODUCT|Human insulin|Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
214544660|NCT02489409|DRUG|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
214544661|NCT02489409|DRUG|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
214544662|NCT02489409|DRUG|Navelbine|40 mg/d, iv, d1, 8
214544663|NCT02489409|DRUG|Platinum|30 mg/m2, iv 3h, d1-3
214544664|NCT02489409|DRUG|Xeloda Tablets:|2 000 mg/m2, po, d1-14
215029481|NCT02997085|DEVICE|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
215159465|NCT00452816|BEHAVIORAL|Workplace Solutions Consulting approach|"Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation"
215159466|NCT00452816|BEHAVIORAL|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
215159467|NCT03260751|DIETARY_SUPPLEMENT|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
215159468|NCT03260751|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
215159469|NCT03713346|OTHER|Lactose free milk|Single dose of lactose free milk
215159470|NCT03713346|OTHER|Jersey milk|Single dose of jersey milk
215159471|NCT03713346|OTHER|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
215159472|NCT03713346|OTHER|High A2 β-casein milk|Single dose of A2 β-casein milk
215159473|NCT02405377|PROCEDURE|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
215159474|NCT02405377|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
215159475|NCT02405377|DRUG|0.9% sodium chloride ﬂuid administration|
215159476|NCT02405377|DEVICE|5-French catheter|
214544665|NCT04063046|DRUG|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
214544666|NCT04063046|DRUG|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
214544667|NCT00020722|BIOLOGICAL|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
214544668|NCT00020722|DRUG|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
214544669|NCT00020722|DRUG|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
214544670|NCT00020722|PROCEDURE|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
214544671|NCT00020722|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
215159477|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
215159478|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
215159479|NCT05773170|DRUG|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
214698446|NCT04610034|BEHAVIORAL|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
214698447|NCT04610034|OTHER|Care as usual|The control arm will receive usual care, which implies no systematic support.
214698448|NCT03132480|OTHER|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
214544672|NCT02238106|DRUG|Salmeterol medium dose|
214544673|NCT02238106|DRUG|Salmeterol low dose|
214544674|NCT02238106|DRUG|Salmeterol high dose|
214544675|NCT02238106|DRUG|Serevent® Diskus®|
214698449|NCT00127062|OTHER|Oxford street|2 h walk around Oxford street
215159480|NCT03790696|DEVICE|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
215159481|NCT02956200|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
214544676|NCT02238106|DRUG|Placebo HandiHaler®|
214698450|NCT00127062|OTHER|Hyde park|2 h walk around Hyde park
214698451|NCT01727050|DEVICE|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
214698452|NCT01727050|DEVICE|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
215159482|NCT04743986|BIOLOGICAL|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
215159483|NCT04743986|DRUG|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
214544677|NCT02238106|DRUG|Placebo Diskus®|
214544678|NCT02087215|DRUG|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
214544679|NCT02087215|DRUG|Placebo|
214544680|NCT03260933|OTHER|No intervention given. This is a qualitative interview study|This is a qualitative interview study
214698453|NCT02641366|DEVICE|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
214698454|NCT02641366|PROCEDURE|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
215159484|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%"
215159485|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
215159486|NCT03353506|BIOLOGICAL|LFMT|Lyophilized fecal microbiota transplant
215159487|NCT03353506|BIOLOGICAL|LSFF|Lyophilized sterile fecal filtrate
214544681|NCT04370535|DEVICE|cellulose|The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks.
214544682|NCT04370535|DEVICE|PMA-zeolite|The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks.
214544683|NCT04909671|DEVICE|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
214544684|NCT04909671|OTHER|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
214544685|NCT05367206|DRUG|Albumin-Bound Paclitaxel|260mg/m2 q3w \*2 circles
214544686|NCT05367206|DRUG|Carboplatin|AUC 5-6 q3w \* 2 circles
214544687|NCT04850235|DRUG|Nab paclitaxel|Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
214698455|NCT02641366|PROCEDURE|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
214544688|NCT04767334|DEVICE|Anti-Gravity Treadmill|"Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
214544689|NCT02725528|DRUG|collagenase injection|injection
214544690|NCT02725528|PROCEDURE|limited palmar fasciectomy|surgery
214544691|NCT05442346|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
214544692|NCT00177021|DRUG|Aldara Cream 5%|
214544693|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
214544694|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
214544695|NCT02569957|DRUG|Acetylcysteine|Given IV and PO
214544696|NCT02960971|PROCEDURE|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
214544697|NCT03990636|DRUG|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
214544698|NCT03276390|BEHAVIORAL|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
214544699|NCT01410864|DEVICE|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
214544700|NCT01410864|OTHER|Control|Devices or drugs used to seal the dura (other than DuraSeal)
214544701|NCT02900235|DRUG|MT-3995|
214544702|NCT02864823|PROCEDURE|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
214544703|NCT00827398|BIOLOGICAL|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
214544704|NCT04839055|DRUG|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
214544705|NCT04839055|DRUG|Abiraterone|Abiraterone
214544706|NCT04642547|DRUG|Lenvatinib and Gefitinib|"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral."
214544707|NCT02635386|DRUG|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
214544708|NCT02635386|DRUG|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
214544709|NCT02635386|DRUG|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
214544710|NCT02635386|DRUG|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
214544711|NCT02635386|DRUG|Phentermine /Topiramate (PHEN/ TPM) ER|PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
214544712|NCT00444262|PROCEDURE|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
214544713|NCT00444262|DRUG|VOLUVEN and others solute|VOLUVEN and others solute
214544714|NCT02468908|DRUG|Molgramostim|
214544715|NCT02468908|DRUG|Placebo|
214544716|NCT04226092|DEVICE|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
214544717|NCT04226092|DEVICE|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
214544718|NCT02530788|DRUG|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
214544719|NCT02530788|DRUG|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
214544720|NCT05820113|DEVICE|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
214544721|NCT05710289|BIOLOGICAL|Immune Responses|To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510\_004 study.
214544722|NCT00715689|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214544723|NCT00715689|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214544724|NCT00715689|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214544725|NCT00715689|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214544726|NCT00715689|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214544727|NCT00715689|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214544728|NCT00715689|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214544729|NCT00715689|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214544730|NCT01209598|DRUG|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
214544731|NCT01209598|DRUG|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
214544732|NCT02719743|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
214544733|NCT02063581|DRUG|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
214544734|NCT02063581|DRUG|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
214544735|NCT01971281|DEVICE|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
214544736|NCT01971281|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
214544737|NCT01971281|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
214544738|NCT05742048|DIAGNOSTIC_TEST|traumatic patient suspect to have long bone fracture between 18 - 65 years old|Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
214544739|NCT04606147|PROCEDURE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
214544740|NCT04606147|PROCEDURE|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
214544741|NCT02287233|DRUG|Venetoclax|Venetoclax will be taken orally once daily.
214544742|NCT02287233|DRUG|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
214544743|NCT02846493|DRUG|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
215029482|NCT02997085|DEVICE|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
215029483|NCT01809769|BIOLOGICAL|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
215029484|NCT01809769|BIOLOGICAL|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
215029485|NCT01809769|BIOLOGICAL|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
215029486|NCT03528733|DEVICE|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
215029487|NCT01829451|OTHER|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~\--------------------------------------------------------------------------------"
215029488|NCT02510586|DRUG|Sevoflurane|administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
214544744|NCT02846493|DRUG|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
214544745|NCT04113057|OTHER|Remote Coaching|In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
214544746|NCT04730674|DRUG|tetracycline mixed with xylocaine|10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
214544747|NCT04921579|PROCEDURE|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
214544748|NCT04921579|PROCEDURE|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
214544749|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 1 application|
214544750|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 2 applications|
214544751|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 1 application|
214544752|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 2 applications|
214544753|NCT05194228|BEHAVIORAL|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
214544754|NCT05432505|OTHER|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
214544755|NCT03772613|DRUG|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
214544756|NCT02478385|OTHER|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
214544757|NCT05698862|DIETARY_SUPPLEMENT|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
214544758|NCT05698862|DIETARY_SUPPLEMENT|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
214698456|NCT04048525|PROCEDURE|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
214544759|NCT03243500|DRUG|Atracurium|5mg in 1 ml normal saline
214544760|NCT03243500|DRUG|Lidocaine 2%|
214544761|NCT03243500|DRUG|Bupivacaine 0.5%|
214544762|NCT03243500|DRUG|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
214544763|NCT03243500|PROCEDURE|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
215029489|NCT00784615|PROCEDURE|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
214544764|NCT01867970|DEVICE|Tool|"The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
215029490|NCT03982173|DRUG|Tremelimumab|tremelimumab 75mg
215029491|NCT03982173|DRUG|Durvalumab|Durvalumab 1500mg
214544765|NCT01867970|BEHAVIORAL|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
215159488|NCT03599219|BIOLOGICAL|sample|confirmation of platelet dysfunction
215159489|NCT03436082|DEVICE|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
214544766|NCT01427738|DRUG|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
214544767|NCT01427738|DRUG|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
214544768|NCT04185922|DEVICE|Hemopatch|As stated in Hemopatch arm description
214544769|NCT02731456|OTHER|altitude exposure|altitude exposure
214544770|NCT05314374|DIETARY_SUPPLEMENT|Ileocolonic-release conjugated bile acid|500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
214544771|NCT05314374|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient. 500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
214544772|NCT06003699|BEHAVIORAL|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
214544773|NCT02658175|DRUG|Volanesorsen|300 mg volanesorsen administered via SC injection.
214544774|NCT02351336|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. \- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. \- CL measurement using 2D ultrasound ( in cm)"
214544775|NCT00895388|BEHAVIORAL|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
214544776|NCT05111743|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
214544777|NCT00841230|DRUG|Deanxit|Deanxit 1x/day
214544778|NCT00841230|DRUG|Lactose placebo|Lactose used as placebo
214544779|NCT02719756|DRUG|Metformin|Metformin tablets 1000 mg
214544780|NCT02719756|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets
215029492|NCT01533987|DIETARY_SUPPLEMENT|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
214544781|NCT02719756|DRUG|Metformin up-titration|
214544782|NCT04580498|DRUG|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
214544783|NCT04580498|DRUG|SHR-1701|Drug: SHR-1701 30mg/kg
214544784|NCT06140394|OTHER|diode laser|low level diode therapy
214544785|NCT06140394|OTHER|non surgical scaling|non surgical scaling using ultrasonic
214544786|NCT00827736|PROCEDURE|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
214544787|NCT00827736|DRUG|ISDN ointment|application of ISDN 1% ointment 6 times a day
214544788|NCT00827736|DRUG|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
215029493|NCT01869673|DEVICE|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
214544789|NCT05399615|DIAGNOSTIC_TEST|VOX|Breath biopsy
215029494|NCT01869673|DEVICE|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
215029495|NCT04998630|DEVICE|Extracorporeal shockwave therapy|Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
215029496|NCT04687930|DRUG|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
215029497|NCT04687930|DRUG|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
215029498|NCT04311307|BIOLOGICAL|[6,6-2H2]glucose|Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
215029499|NCT06192563|DRUG|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
215029500|NCT00492544|BIOLOGICAL|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
215029501|NCT01704157|DEVICE|Cryo-Touch III|Study treatment at Day 0.
214544790|NCT01126697|DRUG|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
214544791|NCT04574232|DRUG|knee intra-articular infiltration with Triamcinolone acetonide|knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
214544792|NCT05936918|OTHER|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
214544793|NCT05936918|OTHER|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
214544794|NCT00002722|DRUG|cisplatin|
214544795|NCT00002722|DRUG|fluorouracil|
214544796|NCT00002722|DRUG|leucovorin calcium|
214544797|NCT04805957|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
214544798|NCT05802771|PROCEDURE|surgical resection|surgical resection of the lung cancer
215159490|NCT04867304|OTHER|Patient education about chronic pancreatitis.|"Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters."
215159491|NCT01079299|DEVICE|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
215159492|NCT03145870|OTHER|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
215159493|NCT04043858|DRUG|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
215159494|NCT03473509|OTHER|CKD Registry|Health Service intervention
215159495|NCT01818011|DRUG|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
215159496|NCT01818011|DRUG|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
215159497|NCT01818011|DRUG|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
215159498|NCT01818011|DRUG|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
215159499|NCT01818011|DRUG|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
214544799|NCT04342312|PROCEDURE|Pulmonary vein isolation|Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.
214544800|NCT01594645|PROCEDURE|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
214544801|NCT01214421|DRUG|Tolvaptan|Tablets of 15 or 30 mg
214544802|NCT02744339|DRUG|Riociguat|Adempas up-titrated to max. 1.5mg TID
214698457|NCT04048525|PROCEDURE|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
215159500|NCT01818011|DRUG|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
215159501|NCT01818011|DRUG|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
215159502|NCT03791957|OTHER|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
215159503|NCT02049593|DRUG|PARP inhibitor BMN-673|Given PO
215159504|NCT02049593|DRUG|temozolomide|Given PO
215159505|NCT02049593|DRUG|irinotecan hydrochloride|Given IV
215159506|NCT02049593|OTHER|pharmacological study|Correlative studies
215159507|NCT02049593|OTHER|laboratory biomarker analysis|Correlative studies
214544803|NCT02744339|DRUG|Placebo|Placebo sham-titrated TID
214544804|NCT04297072|DRUG|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
214544805|NCT04297072|DRUG|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
214544806|NCT06457685|DEVICE|Pulse Intravascular Lithotripsy (Pulse IVL)|The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
214544807|NCT00542412|DRUG|Riluzole|
214544808|NCT00985270|DRUG|Rifampicin|
214544809|NCT00985270|DRUG|Placebo|
214544810|NCT03391856|DRUG|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
214544811|NCT03391856|OTHER|supportive therapy|prophylactic platelet transfusion was given when platelet count \<20000/ul
214544812|NCT05888610|BEHAVIORAL|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
214544813|NCT03928392|BEHAVIORAL|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
214544814|NCT03928392|BEHAVIORAL|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
214544815|NCT00509405|DRUG|potassium citrate|6 times 10 mEq per day, oral for 24 months
214544816|NCT06266598|DRUG|Metformin|Only obese children with insulin resistance were treated with metformin.
214544817|NCT06202768|OTHER|data collection|data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
214544818|NCT05784922|OTHER|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
215159508|NCT03498937|DEVICE|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
215159509|NCT03498937|DEVICE|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
215159510|NCT01931319|DRUG|Intravenous baclofen|
215159511|NCT02637492|OTHER|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
215159512|NCT00950859|DRUG|GSK1349572 (Cohort I)|50 mg once daily
215159513|NCT00950859|DRUG|GSK1349572 (Cohort II)|50 mg twice daily
215159514|NCT04896086|DRUG|VRC-GENADJ0110-AP-NV (Adjuplex)|Adjuplex is a sterile, pyrogen-free adjuvant solution produced by the VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline. Adjuplex adjuvant was mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B.
214544819|NCT05874310|GENETIC|FT-002|Comparison of different dosages of FT-002
214544820|NCT04191408|PROCEDURE|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
214544821|NCT04749407|GENETIC|biomarker detection|PBMC and ctDNA analysis
214698458|NCT03780556|DRUG|Lornoxicam and mepridine|compare the effect of each to control pain
215159515|NCT04896086|BIOLOGICAL|Flucelvax|Flucelvax is an inactivated influenza vaccine licensed for the 2020-2021 season.
214544822|NCT03465943|DRUG|Ringer|1L of Ringer's solution as a preload in one group.
214544823|NCT03465943|DRUG|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
214544824|NCT01621789|OTHER|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
214544825|NCT00104767|DRUG|celecoxib|
214544826|NCT00550212|DRUG|neratinib|HKI-272, Single-dose capsule and solution
214544827|NCT05768399|DIAGNOSTIC_TEST|The level of biomarkers in Peripheral blood|All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
214544828|NCT01493037|DEVICE|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
214544829|NCT02900898|OTHER|Dynamic exercise and Mediterranean diet|DE, MD
214544830|NCT02900898|OTHER|Dynamic exercise|DE
214544831|NCT02900898|OTHER|Mediterranean diet|MD
214544832|NCT02900898|OTHER|Control|Control
214544833|NCT05144399|OTHER|Accelerated antibiotic treatment|"E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
214544834|NCT05144399|OTHER|Standard treatment length|"E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
214698459|NCT02953782|DRUG|Magrolimab|Administered intravenously
214698460|NCT02953782|DRUG|Cetuximab|Administered intravenously
214698461|NCT02357849|DRUG|Aripiprazole|see arm description
214698462|NCT02357849|DRUG|Fluoxetine|see arm description
214698463|NCT05072717|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
214698464|NCT02711215|DIAGNOSTIC_TEST|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
214544835|NCT02321267|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
214544836|NCT04115189|DRUG|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
214698465|NCT02711215|DRUG|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
214698466|NCT02711215|DRUG|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
214698467|NCT02711215|DRUG|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
214698468|NCT04508673|OTHER|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
214698469|NCT04691752|OTHER|Audit|Audit from clinical records
214698470|NCT01477190|DRUG|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
215159516|NCT04896086|DRUG|VRC-FLUMOS0111-00-VP (FluMos-v1)|FluMos-v1 investigational vaccine is composed of engineered pentameric promoters based on C. albicans lumazine synthase assembled with 20 trimeric promoters displaying HA ectodomains. It contains hemagglutinin (HA) proteins from the following 4 influenza strains: A/Idaho/07/2018, A/Perth/1008/2019, B/Colorado/06/2017 and B/Phuket/3073/2013.
215159517|NCT02917642|DEVICE|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
215159518|NCT02917642|DEVICE|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
215159519|NCT00458978|DRUG|Cediranib Maleate|Given orally
215159520|NCT00458978|OTHER|Laboratory Biomarker Analysis|Correlative studies
215159521|NCT02765581|DEVICE|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
215159522|NCT02765581|DEVICE|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
215159523|NCT02765581|BEHAVIORAL|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
215159524|NCT04396561|DRUG|Paravertebral group (group P):|"In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels."
215159525|NCT02249832|DEVICE|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
215159526|NCT03357588|OTHER|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
215159527|NCT03357588|OTHER|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
215159528|NCT04437134|OTHER|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
215159529|NCT04437134|OTHER|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
215159530|NCT03398083|DRUG|THC|THC capsule
215159531|NCT03398083|DRUG|Alprazolam|Alpraxolam capsule
215159532|NCT03398083|DRUG|Placebo oral capsule|Sugar pill capsule
215159533|NCT03398083|DRUG|CBD|CBD capsule
214544837|NCT02581059|DRUG|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
215159534|NCT05576636|BEHAVIORAL|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
215159535|NCT05576636|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
215159536|NCT01635426|DRUG|Aspirin|Aspirin 75 mg daily for 2 months after meals
215159537|NCT01635426|DRUG|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
215159538|NCT05212818|DRUG|TF0023|Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
215159539|NCT03765034|BEHAVIORAL|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
214544838|NCT02581059|DIETARY_SUPPLEMENT|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
214544839|NCT02392104|DRUG|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
214544840|NCT01582698|BIOLOGICAL|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
214544841|NCT03239327|DRUG|Misoprostol|
214544842|NCT04887506|DRUG|TAVT-45|250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
214544843|NCT04887506|DRUG|Zytiga|500 mg tablet, two tablets administered once daily
214544844|NCT04887506|DRUG|Prednisone|mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
214544845|NCT04460833|DEVICE|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
214544846|NCT01999777|DRUG|USL261|
214544847|NCT01999777|DRUG|Placebo|
214544848|NCT04238013|OTHER|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
214544849|NCT04238013|OTHER|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
214544850|NCT03666806|BIOLOGICAL|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
214544851|NCT02394665|RADIATION|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
214544852|NCT02394665|DRUG|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle."
215159540|NCT03765034|BEHAVIORAL|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
215159541|NCT00229567|DRUG|Lidocaine infusion plus ketamine injection|
215159542|NCT00717704|DRUG|ixabepilone|by vein once every 3 weeks
215159543|NCT00717704|DRUG|Dasatinib|by mouth once daily
215159544|NCT04000854|DRUG|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
215159545|NCT02516969|RADIATION|Stereotactic Body Radiotherapy|Radiation
215159546|NCT03398499|DEVICE|VIOFOR (Med & Life)|Device: VIOFOR (Med \& Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
215159547|NCT04216264|BEHAVIORAL|Standard response|Parents pick from a menu of behavior changes
215159548|NCT04216264|BEHAVIORAL|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
215159549|NCT00701883|DRUG|Placebo|2 capsules, once a day for 8 weeks
214544853|NCT02394665|BEHAVIORAL|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
214544854|NCT02394665|RADIATION|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
215159550|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
215159551|NCT00701883|DRUG|MBX-8025|2 capsule, once daily for 8 weeks
214544855|NCT02394665|RADIATION|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
214544856|NCT02394665|DEVICE|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
214544857|NCT06445088|DIAGNOSTIC_TEST|VCA-IgA, EBNA1-IgA, and EBV-DNA|Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
214544858|NCT06445088|DIAGNOSTIC_TEST|EBV C Promoter Methylation Detection in nasopharyngeal swab samples|Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
214544859|NCT02906722|DRUG|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
214544860|NCT02906722|DRUG|Intravenous placebo|administration once, twice or 3 times per day according to renal function
214544861|NCT02906722|DRUG|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
214544862|NCT02906722|DRUG|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
214544863|NCT03170843|DEVICE|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
214544864|NCT01774136|BEHAVIORAL|Enhanced HIV and MCH training for CHW|
214544865|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
214544866|NCT06019364|OTHER|Whole blood transfusion|Transfusion of whole blood in a situation with acute bleeding according to routine practice.
214544867|NCT04669769|OTHER|interview|telephone interview
214544868|NCT05473936|BEHAVIORAL|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
214544869|NCT05161741|DRUG|Insulin|Human rDNA Insulin (Insuget, local brand of Getz Pharma)
214544870|NCT01957540|DRUG|Ticagrelor|
214544871|NCT01957540|DRUG|Prasugrel|
214544872|NCT06050447|PROCEDURE|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
214544873|NCT06050447|PROCEDURE|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
214544874|NCT06050447|PROCEDURE|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
214544875|NCT06050447|PROCEDURE|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
214544876|NCT06050447|PROCEDURE|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
214544877|NCT06050447|PROCEDURE|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
215159552|NCT00701883|DRUG|Atorvastatin|2 capsules, once daily for 8 weeks
214544878|NCT06050447|PROCEDURE|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
215159553|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
215159554|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
215159555|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
214544879|NCT03860090|DEVICE|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
214544880|NCT03860090|DEVICE|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
214544881|NCT03860090|PROCEDURE|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
214544882|NCT03860090|PROCEDURE|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
214544883|NCT02227797|DRUG|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
214544884|NCT05421767|PROCEDURE|nerve stimulation guided renal denervation procedure|RNS-in
214544885|NCT05849623|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
214544886|NCT05849623|PROCEDURE|Cold Endoscopic Mucosal Resection (C-EMR)|C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
214544887|NCT05849623|PROCEDURE|Underwater Endoscopic Mucosal Resection (U-EMR)|U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
214544888|NCT01386723|DRUG|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
215159556|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
215159557|NCT01111799|PROCEDURE|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
215159558|NCT04320589|DRUG|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
215159559|NCT04320589|DRUG|General anesthetic|1\) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
215159560|NCT00967421|DRUG|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
215159561|NCT00967421|DRUG|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
215159562|NCT00967421|OTHER|Placebo drink|Placebo drink containing no alcohol + placebo pill
215159563|NCT02563067|DRUG|QAW039|QAW039 150 mg once daily
215159564|NCT02563067|DRUG|QAW039|QAW039 450 mg once daily
215159565|NCT02563067|DRUG|Placebo|Placebo once daily
215159566|NCT04212962|BEHAVIORAL|Transitional care model (TCM)|Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient
215159567|NCT04212962|BEHAVIORAL|Usual care|usual hospital discharge and post-discharge care
215159568|NCT02495519|DRUG|Imatinib|Imatinib 400 mg/day until disease progression
215159569|NCT00970996|DRUG|Temozolomide|250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
215159570|NCT00970996|DRUG|Abraxane|100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
214544889|NCT03411785|OTHER|CPC+ model|CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
214544890|NCT01280851|PROCEDURE|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
214544891|NCT01696786|PROCEDURE|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
214544892|NCT03506347|DRUG|Vancomycin|Antibiotic
214544893|NCT04877613|DRUG|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
214544894|NCT04877613|DRUG|Fludarabine|Lymphodepletion
214544895|NCT04877613|DRUG|Cyclophosphamide|Lymphodepletion
214544896|NCT03960853|PROCEDURE|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
214544897|NCT03960853|PROCEDURE|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
214544898|NCT04741594|DEVICE|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
214544899|NCT05613088|DRUG|MORAb-202|Specified dose on specified days
214544900|NCT05613088|DRUG|Paclitaxel|Specified dose on specified days
214544901|NCT05613088|DRUG|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
214544902|NCT05613088|DRUG|Topotecan|Specified dose on specified days
215159571|NCT00970996|DRUG|Cisplatin|20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
215159572|NCT00970996|BIOLOGICAL|Interleukin-2|9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
215159573|NCT00970996|BIOLOGICAL|Interferon alpha 2b|5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
215159574|NCT03873818|BIOLOGICAL|Ipilimumab|Given IV
215159575|NCT03873818|BIOLOGICAL|Pembrolizumab|Given IV
215159576|NCT00839319|DRUG|Acyline|300 ug/kg subcutaneous injections on Day 1.
215159577|NCT00839319|OTHER|placebo hCG (no active ingredient)|placebo hCG
214544903|NCT06163651|BEHAVIORAL|Parent-Child Assistance Program - One-Year Version|Case managers work closely with parents over the course of one year, meeting them in their own homes when possible, to help them set goals and take advantage of available resources.
215159578|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
215159579|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
215159580|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
215159581|NCT00839319|DRUG|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
215159582|NCT04014868|DEVICE|Nasal high-flow|See arm description.
215159583|NCT04014868|OTHER|Sham nasal high-flow|See arm description.
215159584|NCT02444767|DRUG|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
214544904|NCT03127839|PROCEDURE|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
214544905|NCT03127839|PROCEDURE|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
214544906|NCT03127839|BEHAVIORAL|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
214544907|NCT03912532|BIOLOGICAL|NGM282|NGM282
214698471|NCT01477190|DRUG|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
214698472|NCT02399839|DRUG|lomitapide|As prescribed by Physician.
214698473|NCT06495307|DRUG|rhPRG4|Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
214698474|NCT04095988|PROCEDURE|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
214698475|NCT04095988|PROCEDURE|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
214698476|NCT01121159|PROCEDURE|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
214698477|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
214698478|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
214698479|NCT05844800|PROCEDURE|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
214698480|NCT05844800|DRUG|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
214698481|NCT03468699|COMBINATION_PRODUCT|Autologous BMMC transplantation|Stem cell transplantation
215159585|NCT00774267|DRUG|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
214698482|NCT04901403|OTHER|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
214698483|NCT04901403|OTHER|Home visiting|Parents as Teachers home visiting program
214698484|NCT00043875|DRUG|lamotrigine|
215159586|NCT00774267|DRUG|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
215159587|NCT00774267|DRUG|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
214544908|NCT03912532|OTHER|Placebo|Placebo for NGM282
214698485|NCT05280041|BEHAVIORAL|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
214698486|NCT05678985|BEHAVIORAL|Choose to Move|As described under study arm description.
215159588|NCT00774267|DRUG|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
214544909|NCT03851835|DRUG|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
214544910|NCT03851835|DRUG|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24-hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
214544911|NCT05424003|DRUG|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
214544912|NCT05424003|DRUG|Placebo|Placebo solution injected weekly for 72 weeks
214698487|NCT05239559|DEVICE|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
215159589|NCT03544333|DEVICE|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
215159590|NCT05631613|PROCEDURE|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
214544913|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
215159591|NCT02335788|DEVICE|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
215159592|NCT03363490|BEHAVIORAL|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
215159593|NCT03363490|BEHAVIORAL|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
215159594|NCT03363490|BEHAVIORAL|Health education|All four groups of patient will receive two times of health education in the first week.
215159595|NCT04021641|DIAGNOSTIC_TEST|Speech recognition in noise|Measurement of speech recognition performance in noise
215159596|NCT02110043|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
215159597|NCT02110043|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
215159598|NCT05844007|BEHAVIORAL|Trauma-Informed Yoga|Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
214544914|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
214544915|NCT04461158|BEHAVIORAL|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
214544916|NCT04068649|RADIATION|Palliative Radiation Therapy|Undergo palliative RT
214544917|NCT04068649|OTHER|Quality-of-Life Assessment|Ancillary studies
214544918|NCT04068649|OTHER|Questionnaire Administration|Ancillary studies
214544919|NCT04068649|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214544920|NCT05357092|DEVICE|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
214544921|NCT03059004|BEHAVIORAL|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
214544922|NCT03059004|BEHAVIORAL|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
214544923|NCT03059004|BEHAVIORAL|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
214544924|NCT03059004|BEHAVIORAL|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
214544925|NCT05901987|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
214544926|NCT04199052|BEHAVIORAL|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
214544927|NCT05824910|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
214544928|NCT05882357|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
214544929|NCT05882357|DRUG|IVA|Granules for oral administration
214544930|NCT03569891|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
214544931|NCT03569891|BIOLOGICAL|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
214698488|NCT05989490|OTHER|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
215159599|NCT01039519|DRUG|Ganetespib|Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
214544932|NCT06944886|OTHER|Active Static Stretching Exercise Combined with Breathing Exercise (Experimental Group)|"Participants in the intervention group performed active static stretching exercises using a pictorial exercise booklet. The booklet contained a series of self-directed stretching postures targeting major muscle groups. Each stretch was held in a static position without external assistance, encouraging the participant to engage and maintain the stretch voluntarily.~Each stretch was held for 30 seconds and repeated 3 times per muscle group. The targeted areas included the hamstrings, quadriceps, calves, hip flexors, and shoulders."
214544933|NCT02689947|DEVICE|Restylane Silk|
214544934|NCT01315015|OTHER|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
214544937|NCT04959526|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
214544938|NCT06839196|OTHER|VR and first aid training|"Intervention Stages:~Stage 1: Descriptive Information Form and the Home Accident Awareness Questionnaire for Parents of Children with Special Needs will be administered to the parents as pre-tests.~Stage 2: A total of 100 parents will participate in the virtual reality simulation scenarios, organized into four separate groups of 25 for implementation.~Stage 3: Balance assessments for children will be conducted using the Children's Balance Assessment Form, the Tinetti Balance and Gait Assessment, and the Nintendo Wii Fit Balance Board.~Stage 4: Each group of 25 participants will receive hands-on training at three different stations focusing on basic first aid and home accidents, delivered by nurses, and transfer training provided by physiotherapists.~Stage 5: Post-tests will be administered to the parents using the Home Accident Awareness Questionnaire for Parents of Children with Special Needs."
214544939|NCT04340180|DRUG|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
214544940|NCT04340180|DRUG|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
214544941|NCT06538298|OTHER|Multimodal Exercise Program with Gamification|A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
214544942|NCT04178811|DEVICE|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
214544943|NCT00815919|DRUG|bortezomib|Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
214544944|NCT00815919|DRUG|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
214544945|NCT05520723|DRUG|Sacituzumab govitecan|"Upon meeting all selection criteria, patients enrolled in the single-arm study will receive the combination of: sacituzumab govitecan and prophylaxis (loperamide and G-CSF).~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle . This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision."
214544946|NCT05520723|DRUG|Loperamide|Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
214544947|NCT05520723|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
214544948|NCT03833804|OTHER|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
214544949|NCT06802081|DRUG|Tirzepatide|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
214544950|NCT06802081|DRUG|Placebo|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
215159600|NCT04901780|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
215159601|NCT04901780|OTHER|cross body stretch|crossbody stretch performed by an individual
215159602|NCT03419559|BIOLOGICAL|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
215159603|NCT03419559|DRUG|Durvalumab|PD-L1 antagonist monoclonal antibody
215159604|NCT03046862|DRUG|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
214544951|NCT05575063|DEVICE|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
214544952|NCT05575063|DEVICE|Control Healon EndoCoat|Ophthalmic Viscoelastic device
214544953|NCT06266442|OTHER|Whole genome sequencing testing|Whole genome sequencing
214698489|NCT01691352|PROCEDURE|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
215159605|NCT03046862|DRUG|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
215159606|NCT03046862|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks
215159607|NCT03046862|DRUG|Cisplatin|Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
215159608|NCT04323657|DRUG|TC-110 T Cells|TC-110 T Cells
215159609|NCT04323657|DRUG|Fludarabine|Flu/Cy Lymphodepletion
215159610|NCT04323657|DRUG|Cyclophosphamide|Flu/Cy Lymphodepletion
215159611|NCT01994096|DRUG|Caspofungin|
214544954|NCT03965780|OTHER|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
214544955|NCT00175591|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
214544956|NCT03134261|DIAGNOSTIC_TEST|WB-MRI|scanning methods
214544957|NCT03134261|DIAGNOSTIC_TEST|SPECT-CT|scanning methods
214544958|NCT03134261|DIAGNOSTIC_TEST|Cholin-PET-CT|scanning methods
214544959|NCT03134261|DIAGNOSTIC_TEST|PSMA-PET-CT|
214544960|NCT04795076|DIETARY_SUPPLEMENT|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
214544961|NCT00758823|DEVICE|Paranix|pediculicide product
214544962|NCT04417400|BEHAVIORAL|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
214544963|NCT02360800|PROCEDURE|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
214544964|NCT02360800|PROCEDURE|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
214544965|NCT01198847|BEHAVIORAL|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
214544966|NCT05047978|OTHER|Cow's milk protein infant formula|A routine cow's milk-based infant formula
214544967|NCT05047978|OTHER|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
214544968|NCT03406650|DRUG|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
214544969|NCT03220685|BIOLOGICAL|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
214544970|NCT04198922|DRUG|Acalabrutinib|Given PO
214544971|NCT04198922|OTHER|Questionnaire Administration|Ancillary studies
214544972|NCT05523414|BEHAVIORAL|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
214544973|NCT06223841|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q3w
214544974|NCT01716091|PROCEDURE|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
214544975|NCT05098652|BEHAVIORAL|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
214544976|NCT01321983|OTHER|Inspiratory muscular training - IMT|
214544977|NCT06945614|DRUG|Xenon gas inhalation|Administration of xenon gas in the mixture with oxygen for the period of time via inhalation
214544978|NCT05824169|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
214544979|NCT05532735|BIOLOGICAL|ANXV|ANXV (Human recombinant Annexin A5 protein)
215159612|NCT05112952|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
214544980|NCT02275013|DRUG|Levosimendan|
215159613|NCT05231512|OTHER|Respiratory Music Therapy Protocol|Participants will engage in eight (8) 45-minute virtual music therapy groups containing up to 6 participants over the course of 8 weeks. Within these groups, participants will be invited to use instruments provided including a Yamaha recorder and a Grover Trophy slide whistle. 45 minute virtual music therapy sessions facilitated by board-certified music therapy will consist of music-assisted relaxation through music visualization, followed by gentle pulmonary exercise via wind instrumental playing, and concluding with group singing.
215159614|NCT06520410|DEVICE|Pars plana vitrectomy with a 18 mm short vitrector|Using the shorter 18 mm vitrector for various pediatric vitreoretinal surgeries
215159615|NCT00995293|DRUG|DOCETAXEL|Intravenous
215159616|NCT00995293|DRUG|CISPLATIN|Intravenous
215159617|NCT00995293|DRUG|5-FLUOROURACIL|Intravenous
214544981|NCT04845490|DRUG|Mitomycin|Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
214544982|NCT04845490|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
214544983|NCT00717548|BEHAVIORAL|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
214544984|NCT02336100|DEVICE|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
214544985|NCT03614676|PROCEDURE|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
214544986|NCT03614676|PROCEDURE|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
214544987|NCT03614676|OTHER|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
214544988|NCT03614676|PROCEDURE|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
214544989|NCT03614676|OTHER|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
214544990|NCT02807974|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
214544991|NCT03423810|DRUG|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
214544992|NCT04775147|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
214544993|NCT04239599|RADIATION|Hypofractionated IMRT Radiation treatment|
214544994|NCT00733395|DIETARY_SUPPLEMENT|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
214544995|NCT00733395|DIETARY_SUPPLEMENT|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
214544996|NCT00609856|DRUG|pioglitazone|tablet, 30 mg, once daily, 26 weeks
214544997|NCT00609856|DRUG|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
214544998|NCT04259697|OTHER|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
214544999|NCT04259697|OTHER|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
214545000|NCT01641653|OTHER|Normal saline|Normal saline 2cc. one dose prior to OR
214545001|NCT01641653|DRUG|Midazolam|1-2.5 mg
214545002|NCT02825251|DRUG|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
214545003|NCT02825251|DRUG|insulin aspart|Injected s.c. /subcutaneously (under the skin)
214545004|NCT01511497|BIOLOGICAL|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
214545005|NCT01511497|OTHER|Normal saline|Intravenous, normal saline
214545006|NCT03890198|BIOLOGICAL|LCAR-C182A cells|Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
214545007|NCT06282211|DRUG|Ondansetron Oral Soluble Pellicles|patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.
214545008|NCT01726569|BEHAVIORAL|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
214545009|NCT01726569|OTHER|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
214545010|NCT06141200|DRUG|NW Roselle|NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
214545011|NCT06141200|DRUG|Captopril 25Mg Tab|Active Comparator
214545012|NCT02812992|DRUG|Nab-paclitaxel|
214545013|NCT02812992|DRUG|Gemcitabine|
214545014|NCT02812992|OTHER|Best Supportive Care|
214545015|NCT01792531|BEHAVIORAL|Parent training group|The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
214545016|NCT01792531|BEHAVIORAL|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
214545017|NCT01792531|BEHAVIORAL|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
214545018|NCT01176461|BIOLOGICAL|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
214545019|NCT01176461|BIOLOGICAL|NY-ESO-1|NY-ESO-1 peptide vaccine
214545020|NCT01176461|BIOLOGICAL|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
214545021|NCT01176461|BIOLOGICAL|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
214545022|NCT01176461|DRUG|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
214698490|NCT01691352|PROCEDURE|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
214698491|NCT01536119|BEHAVIORAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
214698492|NCT06678347|BEHAVIORAL|Leadership for recovery|The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
214698493|NCT03266666|BEHAVIORAL|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
214545023|NCT01176461|BIOLOGICAL|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
214698494|NCT03266666|OTHER|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
214698495|NCT00470652|DEVICE|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
214698496|NCT05986032|DIAGNOSTIC_TEST|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
214698497|NCT04304755|DRUG|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
214698498|NCT04304755|DRUG|Placebos|NaCl 0.9%
214698499|NCT06692465|DRUG|GT20029 Tincture|5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
215159618|NCT00551278|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
215159619|NCT03859583|DIETARY_SUPPLEMENT|Capsaicin|4 tsp of cayenne in a breakfast omelette
214545024|NCT01992367|DRUG|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
214545025|NCT00009906|DRUG|Imatinib Mesylate|Given orally
214545026|NCT03484494|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
214545027|NCT00512616|DRUG|Ceftriaxone|
214545028|NCT03550079|PROCEDURE|fixation|treated with different fixation method
214545029|NCT00487825|DRUG|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
214545030|NCT00487825|DRUG|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
214545031|NCT00487825|DRUG|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
214545032|NCT00122486|DRUG|Tenofovir Disoproxil Fumarate|
214545033|NCT00671710|DRUG|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
214545034|NCT02192593|BEHAVIORAL|Computer CBT|
214545035|NCT01993771|PROCEDURE|Surgery with general anaesthesia.|
214545036|NCT01993771|PROCEDURE|Raw EEG|
214545037|NCT05113797|DIAGNOSTIC_TEST|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
214545038|NCT05113797|BEHAVIORAL|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
214545039|NCT03815383|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
215159620|NCT03859583|DIETARY_SUPPLEMENT|Control|breakfast omelette without cayenne pepper
215159621|NCT03847506|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
214545040|NCT02549417|DRUG|KHK7580|Oral administration
214545041|NCT04669743|OTHER|Ozone exposure|Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
214545042|NCT02779348|DRUG|BIA 3-202|Nebicapone tablets 200 mg
214545043|NCT02779348|DRUG|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
214545044|NCT00249782|DRUG|Vehicle control, 2x/day|
214545045|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 2x/day|
214545046|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day|
214545047|NCT00249782|DRUG|MetroGel® (metronidazole gel), 1.0% 1x/day|
214545048|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
214545049|NCT01473745|PROCEDURE|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
214545050|NCT01473745|PROCEDURE|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
214545051|NCT02230722|BEHAVIORAL|Motivational Interviewing|
214545052|NCT02230722|BEHAVIORAL|Attention Control|
214545053|NCT03225898|OTHER|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
214545054|NCT03225898|OTHER|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
214545055|NCT05895708|OTHER|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
214545056|NCT05895708|OTHER|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
214545057|NCT01639742|DEVICE|New texture round breast implants|Breast implant surgery
214545058|NCT02531867|BIOLOGICAL|Asfotase Alfa|
214545059|NCT02977299|DRUG|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
214545060|NCT02977299|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
214545061|NCT02977299|DRUG|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
214545062|NCT04515407|OTHER|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
214545063|NCT04515407|OTHER|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
214545064|NCT04515407|OTHER|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
214545065|NCT03996265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214545066|NCT03996265|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
214545067|NCT03996265|OTHER|Placebo Administration|Given PO
214545068|NCT03996265|OTHER|Quality-of-Life Assessment|Ancillary studies
214545069|NCT03996265|OTHER|Questionnaire Administration|Ancillary studies
214545070|NCT05221138|DRUG|VV116|VV116 oral tablets, 400mg
214545071|NCT01190644|DRUG|Sotatercept|single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
214545072|NCT01452568|DRUG|Aspirin|150mg/daily for three months, starting day after surgery
214545073|NCT01452568|DRUG|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
214545074|NCT02366143|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
215159622|NCT03847506|DRUG|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
215159623|NCT03847506|DRUG|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
215159624|NCT01571518|DRUG|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
214545075|NCT02366143|DRUG|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
214545076|NCT02366143|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
214545077|NCT02366143|DRUG|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
214545078|NCT00373919|DRUG|intravenous (IV) administration of erythromycin|
214545079|NCT06326879|OTHER|No intervention|Questionnaires compilation and sample collection
214545080|NCT00807703|PROCEDURE|Select Stim|Select Stim: see summary
214545081|NCT04411186|PROCEDURE|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
214545082|NCT04411186|PROCEDURE|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 \>94%"
214545083|NCT04912310|DEVICE|Argon laser peripheral iridoplasty|Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
215159625|NCT01571518|DRUG|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
215159626|NCT05428657|OTHER|EC Brain After-school Program|"* Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet"
215159627|NCT05428657|OTHER|conventional intervention|Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
215159628|NCT05669261|PROCEDURE|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
215159629|NCT05669261|BIOLOGICAL|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
215159630|NCT06241391|DIAGNOSTIC_TEST|PSMA PET-CT|Prostate Specific Membrane Antigen PET-CT
214545084|NCT02244138|BEHAVIORAL|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
214545085|NCT03376035|OTHER|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
214545086|NCT04945447|OTHER|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
214545087|NCT05815615|DEVICE|Plasmapheresis|Plasma donation at different frequencies
214545088|NCT00167154|DRUG|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
214545089|NCT04992754|BEHAVIORAL|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
214545090|NCT04339712|DRUG|Anakinra|In case of diagnosis of MAS treatment with anakinra
214545091|NCT04339712|DRUG|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
214545092|NCT03480113|BEHAVIORAL|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
214545093|NCT03480113|BEHAVIORAL|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
214545094|NCT06146192|DRUG|Colchicine|colchicine 1-2 mg/day
214545095|NCT00171236|DRUG|Fluvastatin|
214545096|NCT03985436|BEHAVIORAL|Trek for Surgical Success|Cognitive behavioral therapy for pain
214545097|NCT05571826|BEHAVIORAL|telerehabilitation|No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
214545098|NCT01026298|OTHER|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
214545099|NCT00575042|DRUG|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
214545100|NCT01053247|DRUG|0416|Topical 0416 test product applied twice daily for 2 weeks
214545101|NCT01053247|DRUG|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
214545102|NCT01053247|DRUG|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
214545103|NCT03038269|BEHAVIORAL|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
214545104|NCT01240538|BIOLOGICAL|wild-type reovirus|Given IV
214545105|NCT01240538|DRUG|cyclophosphamide|Given PO
214545106|NCT01240538|OTHER|laboratory biomarker analysis|Correlative studies
214545107|NCT01240538|OTHER|pharmacological study|Correlative studies
214545108|NCT05383638|OTHER|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
214545109|NCT03575949|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214545110|NCT03575949|OTHER|Fludeoxyglucose F-18|Given IV
214545111|NCT03575949|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
215159631|NCT05346666|DRUG|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
215159632|NCT02744404|DEVICE|POC EID|
215159633|NCT01022528|DRUG|Dexamethasone (0.1 mg/kg)|
214545112|NCT05616377|OTHER|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
214545113|NCT05616377|OTHER|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
214545114|NCT00273286|BEHAVIORAL|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
214545115|NCT05783713|OTHER|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
214545116|NCT00726271|DIETARY_SUPPLEMENT|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
214545117|NCT01663558|DRUG|imiquimod|
215159634|NCT01022528|DRUG|Dexamethasone (0.2 mg/kg)|
215159635|NCT01022528|OTHER|Saline|
215159636|NCT02644603|PROCEDURE|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
215159637|NCT00385437|BEHAVIORAL|Driving Simulator Testing|
215159638|NCT00385437|DRUG|Mirtazapine Treatment|
215159639|NCT05453669|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
215159640|NCT02089893|DEVICE|Fundus photography|Non-mydriatic fundus photographs
215159641|NCT02583737|PROCEDURE|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
214545118|NCT01663558|PROCEDURE|ablative|
214545119|NCT04718311|DRUG|Oral lichen clinical Healing evaluation|Treatments were topically applied for 5 days
214545120|NCT00319800|DRUG|Gefitinib|
214545121|NCT00319800|DRUG|Irinotecan|
214545122|NCT04795336|DRUG|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
214545123|NCT04795336|OTHER|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
214545124|NCT00008281|DRUG|FOLFOX regimen|
214545125|NCT00008281|DRUG|fluorouracil|
214545126|NCT00008281|DRUG|leucovorin calcium|
214545127|NCT00008281|DRUG|oxaliplatin|
214545128|NCT00619268|DRUG|Temsirolimus|25 mg once per week administered intravenously
214545129|NCT00619268|DRUG|Bevacizumab|10 mg/kg \* 1 time /2 weeks administered intravenously
214545130|NCT00619268|DRUG|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
214545131|NCT00619268|DRUG|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
214545132|NCT01278147|BEHAVIORAL|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
214545133|NCT02209844|DRUG|BI 44847|
214545134|NCT02209844|DRUG|Placebo|
214545135|NCT06304467|BEHAVIORAL|Contingency Management|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
214545136|NCT04901832|OTHER|Intradialytic stretching exercises|Exercises performed actively and passively to reduce or prevent muscle cramps during hemodialysis procedure.
214545137|NCT04800939|OTHER|Acupressure|The experimental group will start with HT7 points and continue with SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
214545138|NCT04800939|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the HT7 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
214545139|NCT02112890|OTHER|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
214545140|NCT03898700|BEHAVIORAL|strength based coaching|strength based and solution focused coaching
214545141|NCT04692701|DEVICE|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
214545142|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
214545143|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
214545144|NCT03637413|DIETARY_SUPPLEMENT|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
214545145|NCT04432545|BIOLOGICAL|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
215159642|NCT02583737|PROCEDURE|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
215159643|NCT00594243|BEHAVIORAL|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
215159644|NCT00594243|OTHER|Wait-list control|No treatment given.
214545146|NCT03023722|DRUG|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
215159645|NCT00351052|DRUG|Pimecrolimus|Pimecroliums cream 1 % bid.
215159646|NCT00351052|DRUG|Placebo|Vehicle control (placebo) bid.
215159647|NCT00429728|DRUG|GW876008|
215159648|NCT00808080|BIOLOGICAL|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
215159649|NCT02935439|OTHER|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
215159650|NCT05545540|OTHER|Musical Neurostimulation|Daily exposure to musical composition found to have antiseizure properties
215159651|NCT05545540|OTHER|Placebo Musical Neurostimuloation|Daily exposure to musical composition found NOT to have antiseizure properties
214545147|NCT02061878|DRUG|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
214545148|NCT02061878|DRUG|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
214545149|NCT00582725|DRUG|R-CHOP+GM-CSF|addition of GM-CSF
214545150|NCT00068432|DRUG|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
214545151|NCT00068432|DRUG|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
214545152|NCT03616964|DRUG|Baricitinib|Administered orally.
214545153|NCT03616964|DRUG|Placebo|Administered orally
214545154|NCT03126071|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
214545155|NCT03126071|DRUG|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
214545156|NCT03126071|DRUG|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
214545157|NCT03126071|DRUG|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
214545158|NCT04520568|COMBINATION_PRODUCT|High flow nasal cannula|using sedation with the HFNC F\&P AIRVOTM 2 to maintain oxygenation
214545159|NCT04520568|COMBINATION_PRODUCT|CONTROL|using general anaesthesia with one lung ventilation (OLV) technique
214545160|NCT00478283|OTHER|survey administration|
214545161|NCT00568841|DRUG|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
214545162|NCT00568841|PROCEDURE|FDG-/FLT-PET|
214545163|NCT01450293|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
214545164|NCT01450293|BIOLOGICAL|AdCH63 ME-TRAP, MVA ME-TRAP|5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
214545165|NCT00656201|DRUG|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
214545166|NCT00656201|DRUG|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
214545167|NCT00850122|DRUG|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
214545168|NCT01928693|DRUG|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
214545169|NCT01928693|DRUG|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
214545170|NCT01928693|DRUG|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
214545171|NCT01193998|OTHER|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
214545172|NCT01193998|OTHER|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
214545173|NCT02515006|OTHER|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
214545174|NCT02551211|PROCEDURE|blood drawn|blood drawn
214545175|NCT02551211|PROCEDURE|surgical resection of cancer|
214545176|NCT05875649|COMBINATION_PRODUCT|CLAG|Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
214545177|NCT05250765|DEVICE|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
214545178|NCT05250765|DEVICE|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
215159652|NCT03072108|DIETARY_SUPPLEMENT|Bonolive|2 caps per day of Bonolive
215159653|NCT03072108|DIETARY_SUPPLEMENT|Placebo|2 caps per day of Placebo
215159654|NCT00423917|BIOLOGICAL|bevacizumab|
215159655|NCT00423917|DRUG|fulvestrant|
215159656|NCT05555420|DEVICE|SRP+Laser|Non-surgical periodontal therapy in combination with Laser
215159657|NCT03664596|DIETARY_SUPPLEMENT|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
215159658|NCT03664596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
215159659|NCT05344404|DIETARY_SUPPLEMENT|Nicotinamide Riboside|3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
214545179|NCT02165410|PROCEDURE|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
214545180|NCT02165410|PROCEDURE|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
214545181|NCT02165410|PROCEDURE|Resting state MRI|This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.
214698500|NCT06692465|DRUG|GT20029 matching placebo|5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
214545182|NCT02165410|PROCEDURE|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
214545183|NCT02165410|PROCEDURE|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
214545184|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
214545185|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
214545186|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
214545187|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
214545188|NCT01081847|OTHER|Placebo|PLacebo: Isotonic saline solution
214545189|NCT05744102|DIAGNOSTIC_TEST|MRI Image|MRI sequences
214545190|NCT04194047|OTHER|Transfusion|RBC transfusion (1 unit)
214545191|NCT04194047|OTHER|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
214545192|NCT01052363|DRUG|Bevacizumab, CA4P|
214545193|NCT03752177|DRUG|LY3415244|Administered IV
214545194|NCT00286988|DRUG|Topiramate|
214545195|NCT03687008|BEHAVIORAL|Cognitive Computer Based Intervention|25 sessions \[each 30-45 minutes, 5 days a week / for 5 weeks\], supervised by trained coaches
214545196|NCT03049670|DEVICE|latent available chlorine (LAC)|local application on the necrotic infected tissue
214545197|NCT02931422|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
214545198|NCT01421212|BIOLOGICAL|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
214545199|NCT02641587|OTHER|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
214545200|NCT02641587|OTHER|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
214545201|NCT01165177|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
214545202|NCT01165177|BIOLOGICAL|Placebo|Intramuscular injection
214545203|NCT06546085|BEHAVIORAL|Exercise|Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.
214698501|NCT06693297|DEVICE|Immediate loading of early placed implants|Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.
214698502|NCT06693297|DEVICE|Conventional loading of early placed implants|Definitive loading of early placed implants upon successful osteointegration (after 8 weks)
214698503|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
214698504|NCT02487901|DEVICE|drill|making gutter with drill
214698505|NCT01073696|DRUG|granisetron IV|IV
214698506|NCT01073696|DRUG|granisetron patch|patch
214545204|NCT00610909|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
214545205|NCT00610909|DRUG|Placebo|Placebo
214545206|NCT05864677|DRUG|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
214545207|NCT00867737|DRUG|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
214545208|NCT00867737|DRUG|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
214545209|NCT03963427|PROCEDURE|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
214545210|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
214545211|NCT04626804|OTHER|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
215029502|NCT06042816|PROCEDURE|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
215159660|NCT05344404|DIETARY_SUPPLEMENT|Placebo|Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
215159661|NCT04909073|DRUG|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
215159662|NCT00093379|DRUG|Capecitabine|825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
215159663|NCT00093379|DRUG|Oxaliplatin|50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
215159664|NCT00093379|RADIATION|Radiation Therapy (XRT)|Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
215159665|NCT02921178|OTHER|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
215159666|NCT04651842|DEVICE|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
215159667|NCT03565328|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
215159668|NCT03897517|DIETARY_SUPPLEMENT|Proprietary Botanical Blend|Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
215159669|NCT03897517|DIETARY_SUPPLEMENT|Placebo|Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
215159670|NCT05494424|BEHAVIORAL|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
215159671|NCT05255809|OTHER|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
215159672|NCT05255809|OTHER|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
215159673|NCT00025480|DRUG|carboplatin|
215159674|NCT00025480|DRUG|paclitaxel|
215159675|NCT00025480|DRUG|tipifarnib|
215159676|NCT00025480|RADIATION|radiation therapy|
215159677|NCT05753696|DRUG|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
215159678|NCT05753696|DRUG|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
214545212|NCT00915083|DRUG|Amrubicin|40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
214545213|NCT01642147|DEVICE|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
214545214|NCT01642147|PROCEDURE|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
214545215|NCT01642147|PROCEDURE|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
214545216|NCT01642147|PROCEDURE|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
214545217|NCT01642147|PROCEDURE|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
215159679|NCT02285608|OTHER|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
214545218|NCT00579709|BIOLOGICAL|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell \>4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
214545219|NCT02488083|DEVICE|Ultrashape|circumference reduction
215159680|NCT00400270|PROCEDURE|Breathing and relaxation exercises: the Papworth Method|
215159681|NCT05466617|BEHAVIORAL|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
214545220|NCT01636583|DEVICE|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
214545221|NCT01636583|DEVICE|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
214545222|NCT01636583|OTHER|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
214545223|NCT03040245|BEHAVIORAL|Whiplash book|
214545224|NCT05492968|DRUG|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
214545225|NCT05492968|DRUG|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
214545226|NCT05492968|DRUG|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
214545227|NCT01852032|RADIATION|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
214545228|NCT01852032|RADIATION|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
214545229|NCT05036954|DEVICE|EyeBrid Excel hybrid lenses|new lenses
214545230|NCT05679999|DIAGNOSTIC_TEST|CIMT (Carotid artery intima media thickness measurement)|Carotid artery intima media thickness measurement with ultrasound
214545231|NCT04962451|DRUG|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
214545232|NCT04962451|DRUG|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
214545233|NCT01275599|DRUG|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
215159682|NCT04254770|DEVICE|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
215159683|NCT04254770|DEVICE|Marketed Power Toothbrush|Marketed Power Toothbrush
215159684|NCT01490905|OTHER|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
215159685|NCT01490905|DRUG|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
215159686|NCT01490905|DRUG|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
215159687|NCT01338454|DRUG|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
215159688|NCT05156021|DRUG|anti-VEGF|To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
215159689|NCT02682225|DRUG|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
214545234|NCT01275599|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
214545235|NCT01979263|OTHER|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
214545236|NCT01979263|OTHER|Placebo Computer Task|Computer task that does not actively modify attention bias
214545237|NCT04540445|OTHER|Pupillary Assessment|Pupillary assessment with handheld pupillometer
215159690|NCT02682225|DRUG|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
214545238|NCT03210519|DIETARY_SUPPLEMENT|Eleutherococcus senticosus|taken orally once/day for 90 days
214545239|NCT03210519|OTHER|Placebo|taken orally once/day for 90 days
214545240|NCT05452551|OTHER|Myotonometric measurement|MyotonPRO is a non-invasive myotonometer used to evaluate the viscoelastic properties of soft tissues. Data collection will be carried out by three researchers experienced in the use of myotonometer. Before the evaluations, participant and repeated measurement information for both researchers will be recorded on the device. All assessments will be made bilaterally. The first researcher will perform two measurements 30 minutes apart from the measurement point standardized with MyotonPRO to evaluate the plantar mechanical properties. Then, the second researcher will take two measurements with MyotonPRO from the same point with 30 minutes intervals. One day later, the first researcher will measure again from the same reference point once.
214545241|NCT06450236|DRUG|Perampanel 10 MG|1 tablet of Perampanel Tablets 10mg
214545242|NCT06450236|DRUG|Fycompa 10Mg Tablet|1 tablet of Perampanel Tablets 10mg
214545243|NCT04351269|DEVICE|CanGaroo Envelope|CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
214545244|NCT04351269|DEVICE|TYRX Envelope|TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
214545245|NCT04676789|DRUG|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
214545246|NCT04676789|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
214545247|NCT04676789|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
214545248|NCT03186586|DRUG|Ulipristal acetate|5mg/day/five days
214545249|NCT03186586|DRUG|Placebo|Placebo one pill a day for 5 days at the bleeding episode
215159691|NCT02682225|DRUG|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
215159692|NCT02682225|DRUG|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
215159693|NCT02682225|DRUG|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
215159694|NCT01396447|DRUG|Placebo|Placebo was supplied in capsules.
214545250|NCT05141396|OTHER|Telehealth- enabled support for SAT/SBT adherence|Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
214545251|NCT05141396|OTHER|Usual audit and feedback for SAT/SBT adherence|Usual audit and feedback
215159695|NCT01396447|DRUG|Cariprazine|Cariprazine was supplied in capsules.
214545252|NCT02838537|DRUG|Exposure to Triptan|
214545253|NCT02838537|DRUG|Exposure to Ergot|
214545254|NCT04513353|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
214545255|NCT04513353|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
214545256|NCT04030689|OTHER|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
214545257|NCT00535938|OTHER|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
214545258|NCT04154969|OTHER|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
214545259|NCT04154969|OTHER|conventional Physiotherapy|conventional Physiotherapy
214545260|NCT03598699|DRUG|AXR-159|AXR-159 Ophthalmic Solution
214545261|NCT03598699|DRUG|Vehicle|AXR-159 Ophthalmic Solution Vehicle
214545262|NCT01921647|DRUG|YH4808|
214545263|NCT01921647|DRUG|Nexium|
214545264|NCT01921647|DRUG|Amoxicillin|
214545265|NCT01921647|DRUG|clarithromycin|
214545266|NCT05893589|OTHER|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
215159696|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
215159697|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
215159698|NCT03080896|DEVICE|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
215159699|NCT03080896|DEVICE|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
215159700|NCT00476853|DRUG|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
215159701|NCT03868813|BEHAVIORAL|Semi-structured Interview|One-on-one semi-structured interviews
215159702|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
215159703|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
215159704|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
215159705|NCT04860388|PROCEDURE|closed eruption technique|The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
215159706|NCT05216744|DRUG|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
214545267|NCT04412083|BEHAVIORAL|PPA Tele-Savvy Pilot Intervention|We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
214545268|NCT02429479|BEHAVIORAL|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
214545269|NCT02429479|BEHAVIORAL|Standard advance care planning|This is a online simple living will form.
214545270|NCT05802927|OTHER|DSF|Diabetes-specific formula
214545271|NCT05802927|OTHER|Breakfast 1|Noodle Soup
214545272|NCT05802927|OTHER|Breakfast 2|Glutinous rice
214545273|NCT00890578|PROCEDURE|adhesive to suture|surgical closure
214545274|NCT02422732|OTHER|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
214545275|NCT02422732|RADIATION|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
214545276|NCT02422732|GENETIC|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
214545277|NCT04218474|PROCEDURE|Evaluation Of Cross Mental Nerve Transfer In Restoration Of Chin &Lip Sensation Post Inferior Alveolar Nerve Injury|-sural nerve harvest ,and use it as conduit between injured mental nerve and the normal one
215159707|NCT05216744|DRUG|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
214545278|NCT01543022|DEVICE|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
214545279|NCT01543022|PROCEDURE|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
214545280|NCT00912210|DIETARY_SUPPLEMENT|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
214545281|NCT00912210|DIETARY_SUPPLEMENT|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
214545282|NCT02229578|DRUG|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
214545283|NCT02229578|DRUG|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
214545284|NCT06956677|DEVICE|Novel UE rehabilitation device training|The novel UE rehabilitation device training includes the single-joint exercise and dual-joint exercise, each performed 20 repetitions per set, for a total of 5 sets with 30-second rest intervals between sets.
214545285|NCT06956677|OTHER|The UE functional training|The UE functional training focuses on the affected arm, incorporating exercises such as push-pull boxes (standing or seated), alternating push-pull boxes, and hand-crank exercises.
214545286|NCT06956677|OTHER|Conventional occupational therapy|Conventional occupational therapy
214545287|NCT02357602|DRUG|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
214545288|NCT05411263|DIAGNOSTIC_TEST|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
214545289|NCT04611347|DRUG|CBD|Topical CBD application for thumb basal joint osteoarthritis.
214545290|NCT04611347|DRUG|Shea Butter|Placebo Shae Butter for comparison
214545291|NCT01184534|BEHAVIORAL|Video|5 minute multimedia presentation (video)
214545292|NCT01184534|BEHAVIORAL|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
214545293|NCT06043453|OTHER|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
214545294|NCT05860569|GENETIC|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
214545295|NCT03656276|BEHAVIORAL|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
214545296|NCT05398549|OTHER|Conventional Physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise
214545297|NCT05398549|OTHER|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
214545298|NCT05394090|DIAGNOSTIC_TEST|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
214545299|NCT05575570|DEVICE|EVAR|EVAR stent graft and embolization material CE marked.
214545300|NCT00749359|DRUG|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
214545301|NCT00754598|DEVICE|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
214545302|NCT04053569|DIETARY_SUPPLEMENT|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
214545303|NCT04533828|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
214545304|NCT00157898|DRUG|MK0826; ertapenem sodium|
214545305|NCT00157898|DRUG|Comparator: ceftriaxone + metronidazole|
214545306|NCT04295330|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
214545307|NCT04295330|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
215159708|NCT05367635|DRUG|SKB315 for injection|SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
214545308|NCT05480462|BIOLOGICAL|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
214545309|NCT05480462|BIOLOGICAL|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
215159709|NCT05461508|BIOLOGICAL|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
215159710|NCT05461508|OTHER|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
215159711|NCT02214394|OTHER|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
215159712|NCT02214394|DEVICE|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
215159713|NCT00578292|DRUG|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
215159714|NCT00578292|DRUG|Fludarabine|30mg/m2 Day -5 through Day -2
215159715|NCT00578292|DRUG|Campath 1H|Per institutional guidelines Days -5 through -2
215159716|NCT00578292|DRUG|Cyclophosphamide|50 mg/kg Days -5 through -2
214545310|NCT05088109|DIAGNOSTIC_TEST|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
214545311|NCT04539067|DRUG|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
214545312|NCT05156515|DIAGNOSTIC_TEST|68Ga-THP-APN09|APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
214545313|NCT00394420|BEHAVIORAL|Telephone Quitline|
214545314|NCT02276534|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention.
214545315|NCT02276534|BEHAVIORAL|Delayed Intervention|
214545316|NCT02085473|BIOLOGICAL|Tralokinumab 300 mg|Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
214545317|NCT04486599|DEVICE|Electromagnetic Navigation|The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
214545318|NCT00272350|DRUG|Steroids|
214545319|NCT00272350|DRUG|ZD6474|
214545320|NCT00741208|DIETARY_SUPPLEMENT|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
214545321|NCT05703152|OTHER|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
214545322|NCT00088647|DRUG|MST-997|
214545323|NCT00435955|PROCEDURE|High dose chemotherapy with autologous transplantation|
214545324|NCT00435955|DRUG|Rituximab|
214545325|NCT00532246|DRUG|raloxifene|
214545326|NCT00532246|DRUG|Placebo|
214545327|NCT04799847|DRUG|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
214545328|NCT00752245|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
214545329|NCT00752245|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
214545330|NCT00752245|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
214545331|NCT04964895|OTHER|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
214545332|NCT04703400|OTHER|anonymous survey|anonymous survey with 25 mandatory questions
214545333|NCT06314139|DEVICE|continuous theta-burst stimulation (cTBS)|Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
214545334|NCT04912713|OTHER|Stress group|This group will perform the MAST stress protocol
214545335|NCT04912713|OTHER|Control group|This group will perform the MAST control protocol
214545336|NCT01727661|BEHAVIORAL|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
214545337|NCT01727661|BEHAVIORAL|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
215159717|NCT00578292|DRUG|MESNA|10 mg/kg x 5 Days -5 through -2
215159718|NCT01756170|DRUG|paclitaxel|
215159719|NCT01756170|DRUG|cisplatin|
215159720|NCT01756170|RADIATION|Radiotherapy|
215159721|NCT05989451|BEHAVIORAL|Dialectical behavior therapy (DBT)|The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
215159722|NCT04726969|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
215159723|NCT04726969|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
215159724|NCT04726969|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
215159725|NCT00856518|DEVICE|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
214545338|NCT01727661|BEHAVIORAL|quality of life|assessing quality of life using short-forum 36 (questionnaire)
214545339|NCT01613963|DRUG|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
214545340|NCT04776902|BEHAVIORAL|Survey|Patients will fill a questionary with 8 questions.
214545341|NCT02386878|BEHAVIORAL|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
214545342|NCT02386878|BEHAVIORAL|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
214545343|NCT01407276|DRUG|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
214545344|NCT01544504|DRUG|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
214545345|NCT06420050|BEHAVIORAL|Instagram Intervention|The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
214545346|NCT03035110|BEHAVIORAL|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
214545347|NCT01982409|BIOLOGICAL|Live Attenuated Varicella Vaccine|
214698507|NCT06889714|DEVICE|ultrasonography|Right thigh length (between the right femur greater trochanter and patella) was measured and recorded while the patients were lying supine. A linear transducer (Philips Affiniti 50, Philips Medical Systems, Seattle, WA, United States) was used for ultrasonographic measurements. The rectus femoris (RF) and vastus intermedius (VI) were visualized with the feather-touch technique after a generous amount of ultrasound gel was sprayed in the center of the right thigh, and the thickness of the muscles was determined and recorded using ultrasonography software. After these measurements, the rectus femoris-to-thigh length ratio (RF/B), vastus intermedius-to-thigh length ratio (VI/B), and total muscle thickness-to-thigh length ratio (T/B) were calculated and recorded.
215159726|NCT00856518|DEVICE|Sham|The same device just like the EMST but does not provide a load on the target muscle group
215159727|NCT02977962|BEHAVIORAL|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
215159728|NCT02977962|OTHER|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
215159729|NCT02933684|DRUG|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
215159730|NCT02933684|BEHAVIORAL|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
215159731|NCT02933684|DRUG|Placebo|Administered in pill form.
215159732|NCT04849559|DRUG|Tradipitant|Tradipitant Capsule
215159733|NCT04849559|DRUG|Placebo|Placebo Capsule
215159734|NCT00947193|DRUG|Ataluren|Oral powder
215159735|NCT05765513|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
215159736|NCT00805337|DEVICE|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
215159737|NCT04553042|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
215159738|NCT04601467|DRUG|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
214545348|NCT02446613|OTHER|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
214545349|NCT04171349|DRUG|Articaine|Vial
214545350|NCT04171349|DRUG|Dexmedetomidine|Vial
214545351|NCT04695704|DRUG|Montelukast|10 mg oral montelukast once daily for 28 days
214545352|NCT04695704|OTHER|placebo|10 mg oral placebo once daily for 28 days
214545353|NCT06422442|BEHAVIORAL|Threat-related stimulus exposure|Participants will view threat-related stimuli (words or faces) paired with nonthreat matches in three related experimental paradigms.
214545354|NCT04302129|PROCEDURE|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
214545355|NCT04302129|DRUG|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
214545356|NCT02612506|DRUG|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
214545357|NCT02612506|DRUG|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
214545358|NCT01062269|DRUG|Cholestyramine|Cholestyramine 4 grams one time dose
214545359|NCT01062269|DRUG|Cholestyramine|Cholestyramine 12 grams one dose, one day
214545360|NCT01062269|DRUG|Tang|Tang one dose one day
214698508|NCT06892119|DRUG|Celrixafor|Use a reduced-dose of generic plerixafor
214698509|NCT06890624|DRUG|cmFOLFOXIRI plus PD-1 inhibitor|cmFOLFOXIRI: oxaliplatin 85 mg/m² , irinotecan 150 mg/m², folinic acid 400 mg/m², 5-FU 2400 mg/m² continuous 46h infusion, repeat once every 2 weeks. PD-1 inhibitor 200mg, repeat once every 2 weeks.
214698510|NCT06890624|DRUG|mFOLFOX6|mFOLFOX6: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hours, repeat once every 2 weeks.
214698511|NCT00002340|DRUG|Atovaquone|
214698512|NCT00002340|DRUG|Pentamidine isethionate|
214698513|NCT06892938|DIAGNOSTIC_TEST|Atrial Fibrillation Identification|Identification of atrial fibrillation by device.
215159739|NCT04601467|DRUG|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
215159740|NCT06311617|DIAGNOSTIC_TEST|Optical coherence tomography|Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
215159741|NCT02105961|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
215159742|NCT02105961|DRUG|Placebo|Sterile 0.9percent sodium chloride solution
215159743|NCT00005062|RADIATION|radiation therapy|
215159744|NCT05613465|DRUG|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
215159745|NCT05613465|DRUG|Placebo|Placebo is packaged in the same package as the drug
215159746|NCT02349217|BEHAVIORAL|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
215159747|NCT02349217|BEHAVIORAL|Self-Help Materials|Participants and partner receive self-help materials.
215159748|NCT02349217|BEHAVIORAL|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
214545361|NCT04805450|PROCEDURE|ES before fully covered SEMS placement|
214545362|NCT04805450|PROCEDURE|no ES before fully covered SEMS placement|
214545363|NCT00085566|DRUG|everolimus|
214545364|NCT00085566|DRUG|gefitinib|
214545365|NCT00296010|DRUG|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
214545366|NCT00296010|DRUG|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
214545367|NCT00296010|DRUG|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
214545368|NCT00296010|PROCEDURE|adjuvant therapy|
214545369|NCT00296010|RADIATION|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
214545370|NCT04553588|OTHER|Disposal pouch|Medication Disposal Pouch
214545371|NCT06454045|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
214545372|NCT00745498|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
214545373|NCT04073797|DRUG|Inclisiran|Inclisiran 284 mg, one injection
214698514|NCT06899269|DEVICE|robotic resection with Da Vinci Xi|robotic resection with Da Vinci Xi
214545374|NCT04073797|DIAGNOSTIC_TEST|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
214545375|NCT04073797|DRUG|Colchicine|Colchicine 500 mcg tablet once daily
214545376|NCT04592081|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
214545377|NCT05891145|DRUG|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
214545378|NCT05891145|DRUG|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
214545379|NCT04762303|OTHER|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
214545380|NCT05701241|DRUG|Somatostatin analog|Somatostatin analog treatment every 4 weeks
214545381|NCT05979428|DRUG|NNC0491-6075|NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
214545382|NCT05979428|DRUG|Placebo|Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
214545383|NCT00079755|DRUG|SGN-30 (anti-CD30 mAb)|
214545384|NCT05500079|DEVICE|Wrist splint|A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.
214545385|NCT05500079|OTHER|Pulsed radiofrequency current|Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
214545386|NCT02775305|BEHAVIORAL|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
214545387|NCT03174782|DRUG|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
214545388|NCT03174782|DRUG|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
214545389|NCT00424567|PROCEDURE|Fracture surgery|
214545390|NCT00424567|DRUG|Cultured Bone Marrow Tissue|
214545391|NCT04378374|OTHER|Food-1|Baked food made of lentil flour
214545392|NCT04378374|OTHER|Food-2|Baked food made of lentil flour and wheat flour
214545393|NCT04378374|OTHER|Food-3|Baked food made of wheat flour
214545394|NCT04378374|OTHER|Food-4|Potable water (energy and carbohydrate-free control)
214545395|NCT06140342|BEHAVIORAL|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
214545396|NCT00778921|DRUG|Amlodipine 10 mg|Amlodipine 10 mg
214545397|NCT00778921|DRUG|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
214545398|NCT00778921|DRUG|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
214545399|NCT00184379|BEHAVIORAL|Psychoeducation|Structured disorder-related educational program for relatives
215159749|NCT02349217|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
215159750|NCT02349217|BEHAVIORAL|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
215159751|NCT02349217|PROCEDURE|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
215159752|NCT02349217|BEHAVIORAL|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
215159753|NCT05252091|DRUG|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
215159754|NCT02970903|DEVICE|VitalPAD|VitalPAD prototype device
215159755|NCT02970903|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
215159756|NCT04306861|DIAGNOSTIC_TEST|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
215159757|NCT00299169|BEHAVIORAL|N of 1 Trials|N of 1 Trials of statin therapy
214545400|NCT03754790|DRUG|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214545401|NCT00299806|DRUG|Aliskiren|
214545402|NCT04805073|DRUG|Promethazine|1cc 25mg/ml Promethazine (study medication)
215159758|NCT00075257|DRUG|DVS-233 SR|
215159759|NCT01790997|DRUG|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
215159760|NCT01790997|DRUG|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
215159761|NCT01790997|DRUG|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
215159762|NCT02428725|OTHER|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
214545403|NCT04805073|DRUG|Placebo|1cc 0.9% Sodium Chloride (placebo)
214545404|NCT03178045|OTHER|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
214545405|NCT03178045|OTHER|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
214545406|NCT00450138|DRUG|ZD6474 (vandetanib)|once daily oral dose
214545407|NCT00450138|DRUG|Cisplatin|intravenous infusion
214545408|NCT00450138|RADIATION|Radiation|radiation of head and neck
214545409|NCT02991586|BEHAVIORAL|Dialectical Behaviour Therapy|Group of families
214545410|NCT04802304|OTHER|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
214545411|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).
214545412|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).
214545413|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
214545414|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
214545415|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
214545416|NCT00133575|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
214545417|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
214545418|NCT00005599|DRUG|bryostatin 1|
214545419|NCT00005599|DRUG|paclitaxel|
214545420|NCT04086238|DRUG|Decitabine|Capsules containing a combination of decitabine and THU
214545421|NCT02119338|DRUG|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
215159763|NCT02096640|PROCEDURE|Type of surgical teqnique for tracheostomy|
215159764|NCT01492335|BEHAVIORAL|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
214545422|NCT05907642|OTHER|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
214545423|NCT01078922|DRUG|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
214545424|NCT04721964|DIETARY_SUPPLEMENT|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
215159765|NCT01492335|BEHAVIORAL|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
215159766|NCT00000903|DRUG|Indinavir sulfate|
215159767|NCT00000903|DRUG|Lamivudine/Zidovudine|
215159768|NCT00000903|DRUG|Nelfinavir mesylate|
215159769|NCT00000903|DRUG|Efavirenz|
215159770|NCT04988243|OTHER|All aortic valve products on the market|"1. Subjects with severe aortic valve stenosis~2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~4. Be able to contact the subjects or their legal guardians / relatives;~5. The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
215029503|NCT06042816|PROCEDURE|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
214545425|NCT04583644|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
214545426|NCT04021082|DRUG|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
214545427|NCT04434001|DRUG|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
214545428|NCT04434001|DRUG|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
214545429|NCT04434001|BIOLOGICAL|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
214545430|NCT04429802|DRUG|Prucalopride|Orally administered
214545431|NCT04429802|DRUG|Placebo|Orally administered
214545432|NCT05260099|DEVICE|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
214545433|NCT02706847|DRUG|Placebo|Tablet; Oral
214545434|NCT02706847|DRUG|Upadacitinib|Tablet; Oral
214545435|NCT00675584|DRUG|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
214545436|NCT00675584|DRUG|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
214545437|NCT01174264|OTHER|Pharmacological Study|Correlative studies
214545438|NCT01174264|DRUG|Vismodegib|Given PO
214545439|NCT00645580|DRUG|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
214545440|NCT01298882|DRUG|Diacerein|
214545441|NCT01298882|OTHER|Placebo|
214545442|NCT02872389|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
214545443|NCT02872389|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
214545444|NCT04679155|BEHAVIORAL|Eating Time Restriction|early vs late time of day restriction
214545445|NCT01510353|DEVICE|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
214545446|NCT00541905|DRUG|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
214545447|NCT04088929|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
214545448|NCT00358007|DEVICE|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
214545449|NCT04237285|OTHER|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
215029504|NCT04853121|PROCEDURE|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
215029505|NCT04853121|PROCEDURE|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
214545450|NCT02058836|DRUG|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
214545451|NCT02058836|PROCEDURE|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
214545452|NCT03376750|BEHAVIORAL|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
214545453|NCT00470028|DEVICE|Transcranial Magnetic Stimulation|
214545454|NCT02609542|OTHER|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
215159771|NCT01995188|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
215159772|NCT01995188|DRUG|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
215159773|NCT01995188|DRUG|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
215159774|NCT02471599|PROCEDURE|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
215159775|NCT02471599|OTHER|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
215159776|NCT01572285|PROCEDURE|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
214545455|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
214545456|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
214545457|NCT02903303|OTHER|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
214545458|NCT06119152|BEHAVIORAL|DESA|Intervention group is monitored via remote bp monitoring and telehealth device.
214545459|NCT02802397|OTHER|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
214545460|NCT04902469|BEHAVIORAL|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
214545461|NCT04902469|BEHAVIORAL|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
215029506|NCT01683812|DEVICE|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
215029507|NCT06021132|DEVICE|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
215029508|NCT06094738|DRUG|Relacorilant under fasted conditions|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
215159777|NCT01572285|PROCEDURE|Sham|Sham procedure using a non-penetrating needle
215159778|NCT02052388|DRUG|Daptomycin|Active Comparator
215029509|NCT06094738|DRUG|Relacorilant after a high-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
215029510|NCT06094738|DRUG|Relacorilant after a low-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
215159779|NCT02052388|DRUG|Brilacidin|Experimental Drug
215029511|NCT00141011|DRUG|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
215029512|NCT00141011|DRUG|Placebo|0.6 mL/kg/hr
215029513|NCT04357470|OTHER|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
215029514|NCT01623947|DIETARY_SUPPLEMENT|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
215029515|NCT01623947|DIETARY_SUPPLEMENT|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
215029516|NCT01623947|DIETARY_SUPPLEMENT|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
214545462|NCT05735665|DIAGNOSTIC_TEST|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
214545463|NCT05735665|DIAGNOSTIC_TEST|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
214545464|NCT01508338|DIETARY_SUPPLEMENT|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
214545465|NCT01508338|DIETARY_SUPPLEMENT|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
214545466|NCT01508338|DIETARY_SUPPLEMENT|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
214545467|NCT01508338|DIETARY_SUPPLEMENT|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
214545468|NCT06234553|PROCEDURE|surgery of pituitary adenomas|evaluate pathological type and treatment effect after treatment
214545469|NCT01115608|OTHER|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
214545470|NCT00843427|BEHAVIORAL|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
214545471|NCT04767724|DEVICE|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
214545472|NCT04201899|DIETARY_SUPPLEMENT|No intervention - pure observation|Phosphate administration (yes or no)
214545473|NCT03798873|DEVICE|FeelWell™ Compression garment|"Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back."
214545474|NCT03798873|BEHAVIORAL|Increase Mobility|Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
214545475|NCT00547534|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4, 8, 11
214545476|NCT00547534|DRUG|bendamustine|90 mg/m\^2 days 1 and 4
214545477|NCT00547534|DRUG|rituximab|375 mg/m\^2 day 1
214545478|NCT04330651|PROCEDURE|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
214545479|NCT03747887|BEHAVIORAL|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
214545480|NCT03747887|OTHER|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
214545481|NCT05668299|DEVICE|TrachFlush|See detailed description previously entered.
214545482|NCT00164268|BEHAVIORAL|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
214545483|NCT01348152|DRUG|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
214545484|NCT01348152|DRUG|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
214545485|NCT01303250|DRUG|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
214545486|NCT01303250|DRUG|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
214545487|NCT02286453|DRUG|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
214545488|NCT02286453|DRUG|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
214545489|NCT00861822|OTHER|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
214545490|NCT02891642|DEVICE|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
215029517|NCT00270556|DRUG|tenofovir disoproxil fumarate|
215029518|NCT00270556|DRUG|Abacavir|
215029519|NCT01505855|DRUG|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
215029520|NCT00605189|DEVICE|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
215029521|NCT00605189|DEVICE|Powered Suction Pump|continuous gauze based negative pressure wound therapy
215029522|NCT00605189|DEVICE|MWT|moist wound therapy
215029523|NCT05516875|DRUG|JM-010|JM-010
214545491|NCT02111863|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
215159780|NCT03173183|DRUG|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
214545492|NCT02111863|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
214545493|NCT02111863|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
214545494|NCT02111863|BIOLOGICAL|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
214545495|NCT04402697|OTHER|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
214545496|NCT00569543|OTHER|high performance liquid chromatography|urine analysis
214545497|NCT00569543|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
214545498|NCT00569543|OTHER|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
214545499|NCT00569543|OTHER|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
214545500|NCT05515783|DRUG|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
214545501|NCT05515783|DRUG|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
214545502|NCT03879174|DRUG|Pembrolizumab + Tamoxifen|"The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage."
214545503|NCT04121780|BIOLOGICAL|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
214545504|NCT04121780|OTHER|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
214545505|NCT00304772|DRUG|Fluconazole|400mg/day
215159781|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
214545506|NCT00304772|DRUG|Micafungin|150mg/day
214545507|NCT01044992|RADIATION|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
214545508|NCT01044992|DRUG|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
214545509|NCT02718222|DEVICE|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
214545510|NCT03045913|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
215159782|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
214545511|NCT00561106|DRUG|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
214545512|NCT00561106|DRUG|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
214545513|NCT05295394|DRUG|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
214545514|NCT01807429|DRUG|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
214545515|NCT01807429|DRUG|Morphine|morphine 0.05 mg/kg
214545516|NCT02737423|DRUG|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
214545517|NCT04321122|PROCEDURE|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
214545518|NCT02688530|DRUG|IV Saline|
215159783|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
214545519|NCT02688530|DRUG|IV Dexamethasone 4mg|
214545520|NCT02688530|DRUG|IV Dexamethasone 6mg|
214545521|NCT02688530|DRUG|IV Dexamethasone 8mg|
215159784|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
215159785|NCT05080699|DIETARY_SUPPLEMENT|Peptamen Intense VHP, Nestlé Health Science, Switzerland|An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
215159786|NCT01328067|DEVICE|Exablate 2100|MRgFUS
214545522|NCT01919515|DEVICE|ZR Crown|This is an esthetic primary molar crown.
214545523|NCT01919515|DEVICE|Stainless Steel Crown|This is a conventional stainless steel crown.
214545524|NCT01658020|DRUG|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
214545525|NCT01658020|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
214545526|NCT00001107|DRUG|Fluconazole|
214545527|NCT00001107|DRUG|AmBisome|
214545528|NCT00364364|DRUG|Radiolabeled humanized PAM4 IgG|
214545529|NCT02897999|BIOLOGICAL|QBKPN|QBKPN Site Specific Immunomodulators
214545530|NCT02897999|OTHER|Placebo|Placebo
214545531|NCT06430671|DRUG|CLS12311 low|Peptide-coupled Red Blood Cells (RBCs)
214545532|NCT06430671|DRUG|CLS12311 medium|Peptide-coupled Red Blood Cells (RBCs)
214545533|NCT06430671|DRUG|CLS12311 high|Peptide-coupled Red Blood Cells (RBCs)
214698515|NCT06897761|DEVICE|Interactive Digital Respiratory Game|With the development of technology and digitalization, Digital Respiratory Games (DRG) offer an alternative solution. DRGs, with their difficulty levels, provide a platform for progression, offering a fun and engaging experience that enhances patient adherence to therapy through storytelling and user interaction. The absence of a locally made DRG in Turkey, despite the chronic respiratory diseases impact, has led to the need for an interactive DRG with personalized features. The developed interactive DRG and device will be Turkey first interactive DRG example, designed to respond to different respiratory maneuvers. The developed DRG and device will detect the lung volume and flow rates and allow for the real-time execution of maneuvers within the Active Cycle of Breathing Techniques (ACBT) in a playful environment.
214698516|NCT06897761|OTHER|home-based exercise training|Patients in the home-based exercise training group will be asked to perform the active breathing techniques cycle, which is an airway clearance technique, twice a day, 7 days a week, for 20 minutes each, for 8 weeks and to follow the program that includes physical activity recommendations. Patients who use mucolytic and/or nebulized drugs such as hypertonic saline or mannitol will be instructed to perform nebulization before performing the active breathing techniques cycle.
214698517|NCT06898008|OTHER|Assessment of socio-demographic, anthropometric, psychometric and clinical characteristics|age, sex and place of residence, socioeconomic level, education, anthropometric data, first-degree family history, screen time, physical activity time, sleep time, comorbidity, drug treatments, education, total IQ, results of Epworth, CDI, ISI, ADHD, CONNERS, SCSC, Horne and Ostberg questionnaires, hearing aids, referring professional, melatonin dosage, ferritinemia, etiology of sleepiness
214698518|NCT03120780|DRUG|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
215159787|NCT01328067|PROCEDURE|Myomectomy|Non-Hysteroscopic Myomectomy
215159788|NCT04571567|DRUG|Secukinumab|Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
215159789|NCT04202172|PROCEDURE|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography"
215159790|NCT00617968|DRUG|DOCETAXEL|
215159791|NCT02516852|OTHER|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
215159792|NCT00459186|DRUG|RAD001|Daily for two weeks
215159793|NCT00459186|DRUG|Docetaxel|Infusion once per cycle
215159794|NCT00459186|DRUG|Prednisone|Prednisone 5 mg by mouth twice daily
215159795|NCT04681976|BEHAVIORAL|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
215159796|NCT01632124|OTHER|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
215159797|NCT04316988|DIAGNOSTIC_TEST|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
214545534|NCT06430671|DRUG|uncoupled RBCs|autologous Red Blood Cells (RBCs)
214545535|NCT04364685|OTHER|Walking on soft-sand|The participants are required to walking on sand for 30 minutes. Walking is self-paced.
214545536|NCT04364685|OTHER|Walking on Levelled Surface|The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
214545537|NCT05470361|PROCEDURE|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
214545538|NCT02621554|DIETARY_SUPPLEMENT|resveratrol supplementation|6 months of resveratrol supplementation
214545539|NCT02621554|DIETARY_SUPPLEMENT|Placebo|6 months of placebo intake
214545540|NCT02353871|BIOLOGICAL|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
215159798|NCT01485172|DRUG|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
215159799|NCT01485172|DRUG|placebo monotherapy|placebo as monotherapy in Parkinson's disease
215159800|NCT02549924|DRUG|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
215159801|NCT02549924|DRUG|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
215159802|NCT00974480|OTHER|Redermic|Cosmetic cream formulation 609637 43.
215159803|NCT00974480|DRUG|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
215159804|NCT04372940|DRUG|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
215159805|NCT04372940|OTHER|Saline Irrigation|Saline will serve as the control.
215159806|NCT00050362|DRUG|Rofecoxib and Bupivacaine|
215159807|NCT02302014|OTHER|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
215159808|NCT00540332|DRUG|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
215159809|NCT00540332|DRUG|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
215159810|NCT05998057|OTHER|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~* Standing Hip Out 3 sets of 30sec~* 90-90 Hip Stretch 3 sets of 30 seconds~* World's Greatest Stretch 3 sets of 30 seconds~* Star Excursion 3 sets of 5 reps~* Side Jumps+ Balance 3 sets of 10 reps~* Forward Hops + Balance 3 sets of 10 reps~* Squat 3 sets of 10 reps~* Squat Jump 3 sets of 10 reps~* Jumping Spider Push-up 3 sets of 10 reps~* Double Leg Vertical Jump 3 sets of 10 reps~* Broad Jumps 3 sets of 10 reps~* Lateral Box Shuffles 3 sets of 10 reps~* Plank 3 sets of 30 seconds~* Side Plank 3 sets of 30 seconds~* Bird Dog 3 sets of 10 reps~* Glute Bridge 3 sets of 10 reps~* Single Leg Glute Bridge 3 sets of 10 reps~* Single Toe Raises 3 sets of 30sec~* Nordic Hamstrings 3 sets of 10 reps~* Monster Walk 3 sets of 10 reps"
214545541|NCT02353871|DRUG|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
214545542|NCT00571896|DRUG|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
214698519|NCT03120780|DRUG|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
214698520|NCT05265845|BEHAVIORAL|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
214698521|NCT05265845|BEHAVIORAL|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
214698522|NCT04260022|DRUG|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
215159811|NCT05998057|OTHER|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
215159812|NCT00495014|DRUG|GSK376501|
215159813|NCT00495014|DRUG|Placebo|
214698523|NCT04260022|DRUG|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
214698524|NCT04211155|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
214698525|NCT04211155|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
214698526|NCT06898840|OTHER|Fruit drink|Commercially available fruit drinks or smoothies
214698527|NCT06897865|OTHER|survey|SURVEY
215159814|NCT00709865|DRUG|tonapofylline|IV
215159815|NCT00709865|DRUG|Placebo|IV
215159816|NCT03311698|BEHAVIORAL|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
215159817|NCT01901913|DEVICE|MD-bolus calculator for pre-meal bolus|
215159818|NCT01901913|DEVICE|No MD-bolus calculator for pre-meal bolus|
214698528|NCT06898827|PROCEDURE|IVR using the Morpheus Programme|Patients in the intervention group will receive 20 mins of immersive therapy during cardiac rehabilitation
214545543|NCT00571896|DRUG|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
214698529|NCT06898827|PROCEDURE|Cardiac Rehabilitation control group|Cardiac rehabilitation but no IVR
214545544|NCT00115336|DRUG|Intravenous Ketorolac|Intravenous ketorolac
214545545|NCT00115336|DRUG|Ibuprofen|Ibuprofen, taken orally
214545546|NCT02526186|DEVICE|Battlefield Auricular Acupuncture|
214545547|NCT04115267|RADIATION|Radiotherapy|Combined modality
214545548|NCT02854397|OTHER|blood sample|
214545549|NCT01674452|BEHAVIORAL|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
214545550|NCT01674452|BEHAVIORAL|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
214545551|NCT01951521|RADIATION|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
214545552|NCT00695825|DIETARY_SUPPLEMENT|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
214545553|NCT00695825|DIETARY_SUPPLEMENT|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
214545554|NCT01700283|BEHAVIORAL|exercise education and walking program|12-week moderate intensity walking program
214545555|NCT00910260|PROCEDURE|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
214545556|NCT01287845|DRUG|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
214545557|NCT01287845|DRUG|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
214545558|NCT01527162|DEVICE|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
214545559|NCT01527162|OTHER|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
214698530|NCT06898138|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
214698531|NCT06898697|DRUG|Epidural fentanyl|Fentanyl will be injected in the epidural space by the surgeon one or two levels above the surgical site.
214698532|NCT06898697|DRUG|epidural midazolam|midazolam will be injected in the epidural space by the surgeon one or two levels above the surgical site.
214698533|NCT02471664|DEVICE|Mitral Loop Cerclage Annuloplasty|
214698534|NCT03872583|OTHER|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
215029524|NCT04758988|OTHER|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
215029525|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
215159819|NCT04659213|DEVICE|esolution catheter|esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
215159820|NCT02920242|DRUG|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
215159821|NCT02920242|DRUG|Rifaximin (Xifaxan)|200 mg tablet administered orally
215159822|NCT02920242|DRUG|Placebo|Matching Placebo tablet administered orally
215159823|NCT04815148|DRUG|MH004 Ia(0.1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
215159824|NCT04815148|DRUG|MH004 Ia(0.3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
215159825|NCT04815148|DRUG|MH004 Ia(1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
214545560|NCT04147559|DEVICE|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
214545561|NCT02121912|DEVICE|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
214545562|NCT02121912|DEVICE|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
214545563|NCT02842983|DRUG|Esmolol|conventional management plus esmolol infusion
215159826|NCT04815148|DRUG|MH004 Ia(3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
214545564|NCT00231764|DRUG|daclizumab|
214545565|NCT03542162|BIOLOGICAL|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
214545566|NCT03667937|COMBINATION_PRODUCT|CUTIMED|Hydrophobic Dressing
214545567|NCT03667937|OTHER|AQUACEL silver|Silver Dressing
214545568|NCT04599907|DEVICE|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
215159827|NCT04815148|DRUG|MH004 Ib-1(0.1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
215159828|NCT04815148|DRUG|MH004 Ib-1(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
215159829|NCT04815148|DRUG|MH004 Ib-1(1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
215159830|NCT04815148|DRUG|MH004 Ib-2(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
215159831|NCT04815148|DRUG|MH004 Ib-2(1%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
215159832|NCT04815148|DRUG|MH004 Ib-2(3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
215159833|NCT03338738|DIAGNOSTIC_TEST|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
215159834|NCT05159336|DEVICE|tACS for auditory hallucinations via single arm|a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
215159835|NCT04496570|PROCEDURE|periodontal therapy|Non surgical periodontal therapy was performed to patients with peridontitis
215159836|NCT02876536|DEVICE|TENS|The effect of TENS device will be compared in case and control groups.
215159837|NCT05865041|DRUG|Farudodstat|Farudodstat tablets administered orally
215159838|NCT05865041|DRUG|Placebo|Placebo tablets administered orally
214545569|NCT04599907|DEVICE|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
214545570|NCT04599907|DEVICE|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
214545571|NCT06547047|BEHAVIORAL|Speed, Agility, and Quickness (SAQ) Training|The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.
214545572|NCT06547047|BEHAVIORAL|Regular Training|Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
214545573|NCT03635736|OTHER|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
214545574|NCT05696925|OTHER|Motor Imagery|Motor imagery (MI) is a cognitive process that involves the ability to perform an action mentally, without the need to perform the movement itself. The perspective that the person uses to imagine can be: internal perspective (first person - imagines himself/herself), which relates to the person's view of the content of the images or to his/her kinesthetic sensation - the person imagines the movement being performed, as if feeling the movement of the action; or external perspective (third person - imagines another person), which relates to the visual imagination of scenes outside the person.
214545575|NCT05696925|OTHER|Action Observation|Action observation consists of watching another person acting, or doing a motor task, on video or in real-time.
214545576|NCT05696925|OTHER|Exoskeletons|The term Brain-Machine Interface (BMI) refers to systems that capture brain activity signals, translating them into computer commands to control external devices, with the robotic exoskeletons. The electrodes are positioned on the skull cap.
215159839|NCT03679520|OTHER|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care"
215159840|NCT03679520|OTHER|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood"
215159841|NCT01419288|OTHER|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
215159842|NCT02880436|OTHER|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
215159843|NCT01409811|DRUG|zoledronic acid|Given IV
215159844|NCT01409811|OTHER|laboratory biomarker analysis|Correlative studies
215159845|NCT01409811|PROCEDURE|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
215159846|NCT01942733|DRUG|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
215159847|NCT00922012|DEVICE|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
215159848|NCT00634101|DEVICE|nelfilcon A|contact lens
215159849|NCT00634101|DEVICE|narafilcon A|contact lens
215159850|NCT04506099|DEVICE|TINS Active protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
214545577|NCT05696925|OTHER|Execution of the Action|In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
214545578|NCT04585100|DRUG|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
214545579|NCT04585100|DRUG|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
214545580|NCT04585100|DRUG|Placebo|Placebo BID for 28 days
214545581|NCT04585100|DRUG|FM101 150 mg|FM101 (150 mg) BID for 28 days
214545582|NCT04585100|DRUG|FM101 300 mg|FM101 (300 mg) BID for 28 days
214545583|NCT00370643|DRUG|human regular insulin|
214698535|NCT03872583|OTHER|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
214698536|NCT02678988|DEVICE|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
214545584|NCT02635178|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
214545585|NCT02635178|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
214545586|NCT03192969|DRUG|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
214545587|NCT03192969|OTHER|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
214545588|NCT03192969|DRUG|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
214545589|NCT03780010|DRUG|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
214545590|NCT05774041|DEVICE|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
214545591|NCT05196880|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
215159851|NCT04506099|DEVICE|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
215159852|NCT01098513|DRUG|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
215159853|NCT01098513|DRUG|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
215159854|NCT01098513|DRUG|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
215159855|NCT00822549|DRUG|intravenous morphine titration|intravenous morphine titration
215159856|NCT03373396|DIAGNOSTIC_TEST|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
215159857|NCT05861167|BIOLOGICAL|selective intensive induction therapy based on ustekinumab clinical decision-making tools|At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
215159858|NCT00885222|DEVICE|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
215159859|NCT01543633|DRUG|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
215159860|NCT06519695|BEHAVIORAL|Multicomponent exercises|Performed exercise three times a week, one time at a community health service station and two times at home
215159861|NCT01632618|BEHAVIORAL|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
214545592|NCT04431219|BIOLOGICAL|LIS1|LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
214545593|NCT01466790|DRUG|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
214545594|NCT01466790|DRUG|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
215159862|NCT01632618|BEHAVIORAL|Passive control intervention|Passive physical therapy approach to low back pain
214545595|NCT01466790|DRUG|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
214545596|NCT00311246|DRUG|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
214545597|NCT00220623|DRUG|antidepressant medications, flexible drug choice|
214545598|NCT00220623|BEHAVIORAL|CBT, Psychodynamic or Supportive Psychotherapy|
214545599|NCT03557242|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
214545600|NCT03557242|OTHER|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
214545601|NCT03557242|OTHER|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
214545602|NCT00495092|DRUG|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
214545603|NCT00495092|DRUG|Biperiden|Biperiden 2-4 mg/d p.o.
214545604|NCT00495092|DRUG|Placebo|Placebo + Placebo
214545605|NCT02242643|BIOLOGICAL|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
214545606|NCT02242643|BIOLOGICAL|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
214545607|NCT04342988|DRUG|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
214545608|NCT04172012|BIOLOGICAL|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
214545609|NCT04172012|OTHER|Placebo|Placebo mixture
214545610|NCT01888809|BEHAVIORAL|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
214545611|NCT01888809|BEHAVIORAL|Screening and referral|
214545612|NCT02351713|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
214545613|NCT03638921|DRUG|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
214545614|NCT03753243|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
214545615|NCT03753243|DRUG|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
214545616|NCT02183077|DRUG|Meloxicam gel|
214545617|NCT02183077|DRUG|Meloxicam tablet|
214545618|NCT05858398|BIOLOGICAL|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
214545619|NCT01251887|DIETARY_SUPPLEMENT|Linoleic Acid|
214545620|NCT01251887|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|
214545621|NCT01251887|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|
214545622|NCT02633397|DRUG|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
214545623|NCT02633397|DRUG|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
214545624|NCT02275299|DRUG|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
214545625|NCT02275299|DRUG|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
214545626|NCT02275299|DRUG|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
214545627|NCT03595878|RADIATION|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
214545628|NCT03595878|RADIATION|Standard WBRT|Standard Whole Brain Radiation Therapy
214545629|NCT04673357|DRUG|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
214545630|NCT04673357|DRUG|Placebo|Matching placebo will be administered as SC injection.
214545631|NCT06577649|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)
214545632|NCT06577649|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
214545633|NCT03313895|BEHAVIORAL|Aerobic & Cognitive Training (ACT)|ACT stands for combined aerobic exercise and cognitive training.
214545634|NCT03313895|BEHAVIORAL|Cycling Only|Cycling on a recumbent stationary cycle
214545635|NCT03313895|BEHAVIORAL|Cognitive Training Only|Engage in cognitive training on a computer
214545636|NCT03313895|BEHAVIORAL|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
214545637|NCT05488119|BEHAVIORAL|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
214545638|NCT04823117|OTHER|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
214545639|NCT05131789|PROCEDURE|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
214545640|NCT03668223|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
214545641|NCT01103232|PROCEDURE|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
214545642|NCT01103232|PROCEDURE|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
214545643|NCT03036124|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
214545644|NCT03036124|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
214545645|NCT04938934|BEHAVIORAL|Lipids infusion|Lipids infusion via intestinal tube
214545646|NCT04938934|BEHAVIORAL|Sham infusion|Sham infusion via intestinal tube
214545647|NCT06632236|DRUG|Amivantamab|Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
214545648|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
214545649|NCT05274100|DRUG|Risankizumab|Intravenous Infusion
214545650|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
214545651|NCT02660112|DRUG|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
214545652|NCT04919382|BIOLOGICAL|Atezolizumab|Given IV
214545653|NCT04919382|DRUG|Temozolomide|Given PO
214545654|NCT06816498|DRUG|nL-LMNB1-001|Personalized antisense oligonucleotide
214545655|NCT04322955|DRUG|Cabozantinib|2 x 20 mg capsules taken orally daily
214545656|NCT04322955|DRUG|Nivolumab|480mg IV on first day of each 28-day cycle
214545657|NCT04322955|PROCEDURE|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
214545658|NCT05945615|DRUG|Oxymetazoline 0.1% (Pf) Oph Soln Ud|"Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis."
214545659|NCT05945615|OTHER|Preservative free lubricating drops|Over the counter ophthalmic lubricating drop.
214545660|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
214545661|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
214545662|NCT05660031|PROCEDURE|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
214545663|NCT05660031|PROCEDURE|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
214545664|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
214545665|NCT06860971|DRUG|AL2846 Capsules|AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET).
214545666|NCT06860971|DRUG|AL2846 Placebo|AL2846 Placebo without drug substance.
214545667|NCT06518720|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
214545668|NCT06615284|DRUG|Atorvo+™ (Arm1)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
214545669|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 2)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
214545670|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 3)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
214545671|NCT05414019|OTHER|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
214545672|NCT05414019|OTHER|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
214545673|NCT05414019|OTHER|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
214545674|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
214545675|NCT06619210|DRUG|HL231 Dose 1/2/3/4|HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
214545676|NCT06611696|DRUG|Avacopan, prednisolone and rituximab|Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.
214545677|NCT06611696|DRUG|Prednisolone and rituximab|Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
214545678|NCT06626711|DRUG|Propofol|Propofol as a part of total venous anesthesia
214545679|NCT06626711|DRUG|Sevoflurane|Sevoflurane as a part of intravenous anesthesia
214545680|NCT06694155|DIETARY_SUPPLEMENT|Whey Protein Isolate Crossover|This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
214545681|NCT06694155|DIETARY_SUPPLEMENT|Placebo|1 week of Non-whey protein Placebo supplement
214698537|NCT02678988|DEVICE|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
214698538|NCT02678988|DRUG|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
214545682|NCT01729715|BEHAVIORAL|Internet|
214545683|NCT01729715|BEHAVIORAL|DVD|
214545684|NCT00610571|DRUG|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
214545685|NCT06707883|DRUG|TQC2731 injection|TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)
214545686|NCT06707883|DRUG|TQC2731 Placebo|TQC2731 Placebo without drug substance.
214545687|NCT06888427|OTHER|Questionnaires|With the help of a questionnaires, determination of postoperative sleep quality
214545688|NCT06724510|DEVICE|HIFU treatment with ULTRAFOMER MPT|The high-intensity focused ultrasound (HIFU) treatment, which is the primary intervention being evaluated for efficacy and safety in eyebrow lifting.
214545689|NCT06765902|DRUG|N-803|A subcutaneous injection of an IL-15 superagonist.
214545690|NCT06765902|DRUG|ETBX-071|A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.
214545691|NCT06765902|DRUG|M-CENK|An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
214545692|NCT06326554|BEHAVIORAL|Virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2)|Study nurse will offer a palliative care clinic visit referral alongside usual cancer care to participants who report moderate to high symptom burden.
214545693|NCT06893406|DIAGNOSTIC_TEST|Cervical MRI|Participants whose history and physical exam indicate signs or symptoms of cervical myelopathy will be scheduled for a cervical MRI.
214545694|NCT06893406|OTHER|History & Physical Exam|A history and physical exam to evaluate for specific signs and symptoms of cervical myelopathy will be performed.
214698539|NCT06898931|BEHAVIORAL|Dialect Interpreting Training|The intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments.
214698540|NCT06701331|DRUG|Placebo|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
214698541|NCT06701331|DRUG|Upadacitinib|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
214698542|NCT06755125|OTHER|Kinesio Taping|Patients in Group A was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with kinesio taping. Kinesio tape was applied directly to the muscle with 50% stretching.During the treatment, kinesio tape will be applied to the patients twice a week, eight times in total.
214698543|NCT06755125|OTHER|Dry Needling|Patients in Group B was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with dry needling.During the treatment, dry needling was applied to the patients twice a week, eight times in total.
214698544|NCT06898034|OTHER|Ultrasound|Postpartum ultrasound exam
214698545|NCT01620632|PROCEDURE|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
214545695|NCT06773000|DIETARY_SUPPLEMENT|XR™ Recovery Supplement|Participants will receive a total daily dosage of 59.2 grams of XR™ Recovery Supplement orally, divided into two doses of 29.6 grams each (or two pouches). The dosing regimen will begin upon hospital admission and continue for three weeks post-operatively.
214545696|NCT06773000|DIETARY_SUPPLEMENT|XR Carbohydrate Loading Supplement|2 packets of XR Carbohydrate Loading will be administered the evening before surgery and one packet on the day of surgery up to 2 hours prior to the scheduled operating time. The powder will be mixed with 14 oz of room temperature water only until dissolved then may be served over ice for desired temperature of consumption by the participant.
214545697|NCT05501665|PROCEDURE|Biospecimen Collection|Correlative studies
214545698|NCT05501665|DRUG|Carboplatin|Given carboplatin
214545699|NCT05501665|PROCEDURE|Computed Tomography|Undergo PET/CT
214698546|NCT06898554|OTHER|The structured balance training protocol|The structured balance training protocol consists of 7 exercises including balance and hop stabilization exercises for athletes with chronic ankle instability.
214698547|NCT05085028|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
214698548|NCT04552535|DRUG|Second line (2L) afatinib|Afatinib
214698549|NCT04552535|DRUG|Second line chemotherapy|Chemotherapy
214698550|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
214698551|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
215159863|NCT00192634|DRUG|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
214545700|NCT05501665|OTHER|Fludeoxyglucose F-18|Given IV
214545701|NCT05501665|DRUG|Nab-paclitaxel|Given nab-paclitaxel
214545702|NCT05501665|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
214545703|NCT05501665|DRUG|Pemetrexed|Given pemetrexed
214545704|NCT05501665|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214545705|NCT05501665|RADIATION|Radiation Therapy|Undergo radiation therapy
214545706|NCT05501665|OTHER|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
214545707|NCT05501665|BIOLOGICAL|Ipilimumab|Given Ipilimumab
214545708|NCT05501665|BIOLOGICAL|Nivolumab|Given Nivolumab
214545709|NCT05501665|BIOLOGICAL|Cemiplimab|Given Cemiplimab
214545710|NCT05501665|BIOLOGICAL|Atezolizumab|Given Atezolizumab
214545711|NCT06761781|OTHER|Augmented Reality|"Each participant will receive a standard trial consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Each session will consist of 2-10 exercises selected by the trainer from a pool of 46 exercises. The selected exercises will be tailored based on the participant's condition and progress. The exercise pool will be designed as comprehensively as possible to cover the upper limb (22 exercises and lower limb (7 exercises) motor functions, balance ability (11 exercises), or/and coordination (6 exercises).~Each exercise with a duration ranging from 3 to 23 min, and will be determined by a set of parameters that can be adjusted to the individuals dynamically according to the participant's performance."
214698552|NCT06930352|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214698553|NCT06930352|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
214698554|NCT06930352|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
214698555|NCT06930352|DRUG|Cytarabine|Given cytarabine
214698556|NCT06930352|PROCEDURE|Echocardiography Test|Undergo ECHO
214698557|NCT06930352|DRUG|Hydroxyurea|Given hydroxyurea
214698558|NCT06930352|PROCEDURE|Leukapheresis|Undergo leukapheresis
214698559|NCT06930352|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214698560|NCT06930352|OTHER|Questionnaire Administration|Ancillary studies
214698561|NCT06930352|DRUG|Ziftomenib|Given PO
214698562|NCT05756673|DRUG|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
214698563|NCT05756673|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
214698564|NCT05756673|DRUG|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
214698565|NCT05756673|DEVICE|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
214698566|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner (NP) located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, heart rate (HR), respiration rate (RR), SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
214698567|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
214698568|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
214698569|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
215159864|NCT00192634|DRUG|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
215159865|NCT01636518|PROCEDURE|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
215159866|NCT00842322|BEHAVIORAL|high fluid intake|fluid intake of 4 litres per day
215159867|NCT00842322|BEHAVIORAL|normal fluid intake|Fluid intake of 2 litres per day
214545712|NCT06761781|OTHER|Traditional Training|Each participant will receive a Traditional training based on Task oriented training consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Exercises will be tailored based on the participant's condition and progress. The exercises will cover the upper limb, lower limb, motor functions, balance ability and coordination.
214545713|NCT06775730|DRUG|Ensitrelvir|Ensitrelvir will be administered per schedule specified in the arm description.
214545714|NCT06494904|DRUG|Buprenorphine|All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
214545715|NCT06320717|OTHER|Blood sample|To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
214545718|NCT03716765|DIETARY_SUPPLEMENT|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
214545719|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
214545720|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
214545721|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
215159868|NCT05213767|DRUG|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
214545722|NCT06525636|DRUG|KK8123|Subcutaneous administration
214545723|NCT06857474|PROCEDURE|Bristle Brush Polishing|After ultrasonic scaling, teeth will be polished using a bristle brush attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
214545724|NCT06857474|PROCEDURE|Rubber Cup Polishing|After ultrasonic scaling, teeth will be polished using a rubber cup attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
214545725|NCT06857474|PROCEDURE|Air Polishing|After ultrasonic scaling, teeth will be polished using sodium bicarbonate air polishing with an air polishing device in a circular motion for 10 seconds.
214545726|NCT06857474|PROCEDURE|Ultrasonic Scaling|Teeth in the control group will undergo ultrasonic scaling only, with no additional polishing procedures.
214545727|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
214545728|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
214545729|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
214545730|NCT06907628|DRUG|SHR-3792 Injection|SHR-3792 injection.
214545731|NCT06829836|BEHAVIORAL|Hight intensity interval training|Participants assigned to this intervention group will complete 6 supervised HIIT sessions over 2 weeks.
214545732|NCT06829836|BEHAVIORAL|Cyclic Hyperventilation with Retention|Participants of this intervention group will complete a total of 10 remote guided breathing sessions on Zoom over 2 weeks.
214545733|NCT06044649|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
214545734|NCT06044649|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
214545735|NCT06044649|BEHAVIORAL|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
214545736|NCT06044649|OTHER|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
214698570|NCT05108805|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleuce given by IV
214545737|NCT06933901|PROCEDURE|Oocyte retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
214545738|NCT06936683|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy|"Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy~1. Site selection: For patients with limited lesions, the lesion segment was chosen; For patients with diffuse lesions, the right middle lobe or left upper lobe tongue should be severed.~2. Injecting physiological saline: After the top of the bronchoscope is embedded in the target bronchial segment or subsegment opening, 37 ℃ or room temperature physiological saline is rapidly injected through the operating channel, with a total volume of 60-120ml, injected in batches (20-50ml each time).~3. Negative pressure suction: After injecting physiological saline, immediately use appropriate negative pressure (generally recommended below 100mmHg) to suction and obtain BALF, with a total recovery rate of ≥ 30%.~4. BALF collection: Specimens used for pathogen analysis need to be collected in sterile containers; Cytological analysis requires the selection of plastic containers or siliconized glass containers to reduce cell adhesion."
214545739|NCT06936683|DIAGNOSTIC_TEST|throat Swab|"A throat swab is a diagnostic sampling technique used to collect microbial specimens from the oropharynx and tonsillar areas. The standardized procedure involves:~1. Positioning the patient with their head tilted slightly backward;~2. Using a sterile, synthetic-fiber swab with a plastic shaft (avoiding calcium alginate or wooden shafts);~3. Vigorously rubbing the swab over both tonsillar pillars and the posterior pharyngeal wall while avoiding contact with the tongue, teeth, or uvula;~4. Immediately placing the swab into appropriate transport media viral/bacterial);~5. Maintaining cold chain (2-8°C) for specimen transport if required."
214545740|NCT06943001|BEHAVIORAL|Fit24+|This is a digital diabetes prevention program for adolescents that leverages a Fitbit device, rule-based chatbot, and eLearning platform to deliver a comprehensive nutrition and physical activity lifestyle intervention to Hispanic adolescents with obesity.
214545741|NCT06945874|DIAGNOSTIC_TEST|Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french version|"The RCSQ questionnaire translated into French (RCSQ-F) will be distributed to intensive care patients who meet the inclusion and non-inclusion criteria and who have given their informed consent to participate in the study.~The questionnaire will be distributed on two occasions: at the first visit and on the day of discharge from intensive care for survivors, or at the latest on the 14th day of hospitalisation.~Patients' use of the questionnaire will enable internal validation (primary objective) by exploratory factor analysis."
214698571|NCT05108805|DRUG|Cyclophosphamide|Given IV
214698572|NCT05108805|DRUG|Fludarabine|Given IV
214698573|NCT05687695|OTHER|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
214698574|NCT05687695|OTHER|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
214698575|NCT05083156|OTHER|Diet Change|Observation Cohort will be observed for treatment response to elimination of cow's milk
214698576|NCT00216775|DRUG|interferon-alfa-2b and ribavirin|
214698577|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
214698578|NCT04367025|DRUG|Camrelizumab|Camrelizumab: 200mg,iv drip for 1h,d1,q3w
214698579|NCT04367025|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
214698580|NCT04367025|DRUG|S1|S-1:40\~60mg Bid, d1\~14, q3w;
214698581|NCT04745286|DRUG|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
214698582|NCT04745286|DRUG|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
214698583|NCT02199106|DEVICE|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
214545742|NCT06944990|BEHAVIORAL|Meta self-efficacy internet intervention|The meta self-efficacy intervention is a three-week program comprised of activities designed to enhance meta self-efficacy (the ability to leverage self-efficacy sources). The intervention is contextualized to young employees.
214545743|NCT06944990|BEHAVIORAL|Placebo|The placebo condition contains educational material delivered with the same modality as in the experimental condition.
214545744|NCT06944275|PROCEDURE|Blood draw for thromboelastography - admission|Two blood samples will be collected at admission for thromboelastography using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
214545745|NCT06944275|PROCEDURE|Blood draw for thromboelastography - follow-up|Two blood samples will be collected 3 - 7 days after initial thromboelastography for follow-up analysis using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
214545746|NCT06944275|PROCEDURE|Blood draw for transcriptomic analysis|One blood sample will be collected at admission for transcriptomic analysis. Blood sample will be collected into a PAXgene® RNA tube and analysed using nanopore sequencing to characterise the viral and host transcriptome.
214545747|NCT06944275|OTHER|Data collection - clinical/demographic/epidemiological data|Routine clinical/demographic/epidemiological data will be collected at admission and throughout hospitalisation. This will relate to clinical presentation (day of illness at presentation, presenting symptoms); demographics and epidemiology (age, gender, site of infection); clinical course during hospitalisation (maximum level of care, dialysis use, blood product use, survival outcome).
214698584|NCT02199106|DEVICE|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
214698585|NCT02462733|BEHAVIORAL|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
214698586|NCT02462733|BEHAVIORAL|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
214698587|NCT01954472|BEHAVIORAL|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
214698588|NCT01954472|BEHAVIORAL|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
214698589|NCT03294928|OTHER|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
215159869|NCT05261698|OTHER|Home-based Exercise Manual|in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
215159870|NCT05261698|OTHER|Conventional PT|In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
215159871|NCT00838513|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
215159872|NCT05952609|OTHER|Surefil One|Ion-releasing restoration
214545748|NCT06944275|OTHER|Data collection - routine laboratory parameters|Data on routine laboratory parameters will be collected throughout hospitalisation. These will relate to laboratory clotting parameters (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer); liver function tests (aspartate aminotransferase, alanine aminotransferase); laboratory haematology parameters (haemoglobin, white cell count, blood film); laboratory biochemistry parameters (urea, creatinine); viral load.
214545749|NCT06944275|OTHER|Severity score calculation|A severity score will be assigned to each patient based on clinical and laboratory data at admission according to a pre-defined scoring system.
214545750|NCT06945601|DRUG|ICI monotherapy or combinations of chemo- immunotherapy|ICI monotherapy or combinations of chemo- immunotherapy
215159873|NCT05952609|OTHER|Cention N|Ion-releasing restoration
215159874|NCT05952609|OTHER|Bulkfil resin composite|resin composite (No ion-release)
215159875|NCT05988606|BEHAVIORAL|15 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 1 round of high-intensity interval training
215159876|NCT05988606|BEHAVIORAL|43 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 5 rounds of high-intensity interval training
215159877|NCT05988606|OTHER|Hot environment|Participants exercised in a hot environment, \~ 35 °C, \~40% relative humidity.
215159878|NCT05988606|OTHER|Temperate environment|Participants exercised in a temperate environment, \~ 22 °C, \~40% relative humidity.
215159879|NCT02416622|BIOLOGICAL|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
215159880|NCT00139477|DRUG|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
215159881|NCT00139477|BEHAVIORAL|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
215159882|NCT00139477|BEHAVIORAL|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
215159883|NCT01491984|DEVICE|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
215159884|NCT01491984|DEVICE|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
215159885|NCT05162937|BIOLOGICAL|IL-17A antibody|Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
215159886|NCT04095429|BEHAVIORAL|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
215159887|NCT04095429|BEHAVIORAL|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
215159888|NCT01613898|BIOLOGICAL|Blood tests|Blood tests
215159889|NCT00482989|BIOLOGICAL|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
215159890|NCT00482989|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
215159891|NCT00250289|DEVICE|a mucosal sticker with herbal formula|
215159892|NCT01580215|DEVICE|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
215159893|NCT00973713|DRUG|RAD001|10mg/d
215159894|NCT00102583|DRUG|Subconjunctival Cyclosporine Implant|
215159895|NCT00573144|DRUG|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
215159896|NCT00573144|DRUG|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
214545751|NCT06944873|BIOLOGICAL|Blood test 4 EDTA tubes|Blood test 4 EDTA tubes for biological check-up
214545752|NCT06944782|DIAGNOSTIC_TEST|Electromyography (EMG) of the Oropharynx|The transmembranous electromyography (tmEMG) probe is a disposable single-use bipolar recording device with the sensor configured with two electrodes located at the distal end of the probe in a parallel orientation. Unlike conventional EMG probes that are designed to be inserted into the muscle, the tmEMG probe is placed on the surface of the muscle similar to a surface electrode; the tip of the probe is approximately the size of a ball point pen, which allows us to record from the smaller muscles inside the mouth. Recordings will be taken from the genioglossus and palatoglossus in the mouth bilaterally. Recordings will be taken while the subject performs various maneuvers such as shallow breathing, deep breathing, and pressing their tongue against the side of their mouth.
214545753|NCT06944392|DIETARY_SUPPLEMENT|Pumpkin Seed Extract|This is the only intervention
215159897|NCT01968655|BIOLOGICAL|OBI-1|OBI-1 is a B domain deleted recombinant porcine factor VIII
215159898|NCT02124317|DRUG|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
215159899|NCT02124317|DRUG|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
215159900|NCT02114073|DRUG|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
215159901|NCT02114073|DRUG|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
214698590|NCT02572895|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
214545754|NCT06940986|BEHAVIORAL|Empowered Relief|ER is provided in a single, 2-hour session delivered remotely by trained instructors. ER has two main components: didactics and skills acquisition as outlined below. The ER class is administered virtually. The class includes the didactic and skill acquisition content. At the end of the class participants receive tangible items including the self-crafted, personalized catastrophizing cessation plan, a guided relaxation response audio file, and an electronic copy of the didactic class content.
214545755|NCT06940986|BEHAVIORAL|Move to Health|The M2H intervention is delivered virtually by trained health coaches using a 6-step process. The administration of M2H begins with an initial session with follow-up sessions scheduled every 1-2 weeks for up to 8 weeks or until the participant is ready to transition to self-management.
214545756|NCT06940986|OTHER|Usual Care as determined by primary care provider|Patients will receive care as determined by their primary care provider, with no input or control by the research team.
214545757|NCT06945146|DRUG|Ponatinib|Ponatinib treatment will be initiated per usual treatment procedure at 45 mg once daily p.o., which will be gradually decreased to 30 mg and 15 mg according to the predefined criteria based on responsiveness to treatment and AEs in the course of the treatment.
214545758|NCT06944249|DRUG|NaCl (placebo)|During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.
214545759|NCT06944249|DRUG|Verteporfin Injection|During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.
214545760|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
214545761|NCT03865290|DRUG|Placebo|Oral matched placebo
214698591|NCT06041646|DRUG|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
214698592|NCT05674201|COMBINATION_PRODUCT|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
215159902|NCT04593264|OTHER|Self-guided pre-habilitation exercise program|A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
215159903|NCT04593264|OTHER|Traditional pre-habilitation|Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
214698593|NCT06355401|DRUG|Tamoxifen 20mg|maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
214545762|NCT02425345|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
215159904|NCT02090842|DIETARY_SUPPLEMENT|Ca-caseinate|
215159905|NCT02090842|DIETARY_SUPPLEMENT|Maltodextrin|
214545763|NCT04761367|OTHER|Physical activity. Physical Activity program is performed in a group in a gym|The intervention groups will be trained in a gyms under the direct supervision of a graduate trainer. All subjects will be requested to choose an additional third day of the week to carry out at least one of the following activities: walking, cycling or swimming
214545764|NCT04099485|OTHER|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
214545765|NCT00206856|DEVICE|Triage® B-Type Natriuretic Peptide (BNP) Test|
214698594|NCT00828334|DEVICE|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
214698595|NCT04972734|BIOLOGICAL|premature newborns developing a NEC|weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
214698596|NCT04972734|BIOLOGICAL|premature newborns without NEC|weekly Blood sample and daily Stools sample during 12 weeks
215159906|NCT02090842|DIETARY_SUPPLEMENT|Whey protein isolate|
215159907|NCT02625909|DRUG|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
215159908|NCT02625909|DRUG|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
214545772|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
214545773|NCT00698347|DEVICE|M2a-Magnum™ Hip System|
214545774|NCT00297804|DEVICE|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
214545775|NCT00297804|DEVICE|Control stent|control stent
214545776|NCT02764099|BEHAVIORAL|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
214545777|NCT00873262|DRUG|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
214545778|NCT00873262|DRUG|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
214545779|NCT00823537|PROCEDURE|therapeutic electrical stimulation|
214545780|NCT01530581|PROCEDURE|G-PB Transplant|G-PB Transplant
214545781|NCT01530581|PROCEDURE|G-BM Transplant|G-BM Transplant
214545782|NCT02531854|DRUG|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
214545783|NCT02531854|DRUG|Pemetrexed|Chemotherapy
214545784|NCT05987020|OTHER|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
214545785|NCT03371147|OTHER|CancerLife|CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
214545786|NCT06474195|BEHAVIORAL|Cue based intervention|The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.
215159909|NCT04310189|PROCEDURE|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
214545787|NCT06474195|BEHAVIORAL|Treatment as Usual|This group will not get any intervention but the usual treatment all assessments will continue
214545788|NCT04650698|DRUG|Tranexamic acid (TXA) injection|IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
214545789|NCT00616824|PROCEDURE|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
214545790|NCT00616824|PROCEDURE|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
214545791|NCT02672449|RADIATION|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
214545792|NCT00585871|DRUG|clonidine|0.1 mg tid
214545793|NCT00585871|DRUG|metoprolol|25 mg tid
214545794|NCT04814602|DRUG|Proglumide|CCK receptor antagonist
214545795|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active episodic thinking task
215159910|NCT01701947|BIOLOGICAL|Hemoleven|Replacement therapy
214545796|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active future thinking priming task
215159911|NCT00329355|DRUG|sumatriptan succinate/naproxen sodium|
215159912|NCT00483977|DRUG|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
215159913|NCT00483977|DRUG|Placebo|Placebo: oral for 2 weeks.
215159914|NCT00483977|DRUG|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
214698597|NCT05747755|BEHAVIORAL|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
214698598|NCT00517335|PROCEDURE|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
214698599|NCT00801853|DRUG|Aerovant|Aerovant 1mg bid (dry powder)
214545797|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control episodic future thinking task
214545798|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control future thinking priming task
214545799|NCT04297332|OTHER|Informational Intervention|Provided with Forever Free relapse prevention booklet
214545800|NCT04297332|DRUG|Nicotine Replacement|Receive nicotine patches, gum, or lozenges
214545801|NCT04297332|OTHER|Telephone-Based Intervention|Receive coaching call
214545802|NCT01593930|OTHER|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
214545803|NCT01593930|OTHER|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
214545804|NCT01593930|OTHER|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
214545805|NCT01593930|OTHER|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
214545806|NCT03527641|BEHAVIORAL|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
214545807|NCT03527641|BEHAVIORAL|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
214545808|NCT03527641|BEHAVIORAL|Physical Activity|Physical fitness activities for teens
214545809|NCT03527641|BEHAVIORAL|Health Education|Health knowledge curriculum for adolescents
214545810|NCT03527641|BEHAVIORAL|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
214545811|NCT03527641|BEHAVIORAL|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
214545812|NCT02559401|OTHER|MRI|
214545813|NCT02559401|OTHER|Neurocognitive battery|
214545814|NCT02209753|DRUG|BIRB 796 BS, low dose|
214545815|NCT02209753|DRUG|BIRB 796 BS, medium dose 1|
214545816|NCT02209753|DRUG|BIRB 796 BS, medium dose 2|
214545817|NCT02209753|DRUG|BIRB 796 BS, high dose|
214545818|NCT02209753|DRUG|Placebo|
214545819|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
214545820|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
214545821|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
214545822|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
214545823|NCT01181245|DRUG|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
214545824|NCT02069197|OTHER|Ketogenic diet|ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.
214545825|NCT02069197|DRUG|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
214698600|NCT00801853|DRUG|Aerovant|Aerovant 3mg bid (dry powder)
214698601|NCT00801853|DRUG|Aerovant|Aerovant 10mg bid (dry powder)
214698602|NCT00801853|OTHER|placebo|placebo control (dry powder)
214698603|NCT05940727|OTHER|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
214698604|NCT05940727|OTHER|No macroalgae consumption|The participants exclude any macroalgae products from their diet
214698605|NCT06482554|DRUG|Lumateperone 42 mg|Standard treatment with lumateperone
214545826|NCT02069197|OTHER|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
214545827|NCT03422861|DRUG|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
214545828|NCT03422861|DRUG|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
214545829|NCT00979186|DEVICE|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
214545830|NCT00307047|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214545831|NCT00307047|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214545832|NCT00379769|DRUG|Rosiglitazone|Rosiglitazone maximum 8 mg per day
214545833|NCT00379769|DRUG|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
214545834|NCT00379769|DRUG|Metformin|Metformin maximum permitted daily dose .
214545835|NCT01718951|DRUG|golimumab|golimumab
214545836|NCT01718951|DRUG|Pamidronate|pamidronate
214698606|NCT06482554|DRUG|Risperidone 2 mg|Standard treatment with other antipsychotic drugs
214698607|NCT04825145|OTHER|Pregnancy|Pregnancies complicated by preeclampsia
214698608|NCT00343291|BIOLOGICAL|Cetuximab|Administered intravenously
214698609|NCT00343291|BIOLOGICAL|Bevacizumab|Administered intravenously
214698610|NCT00343291|DRUG|Paclitaxel|Administered intravenously
214698611|NCT00343291|DRUG|Carboplatin|Administered intravenously
214545837|NCT00406614|BEHAVIORAL|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
214545838|NCT00855790|OTHER|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
214545839|NCT03249870|DRUG|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~* First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~* Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
214545840|NCT02149238|DIETARY_SUPPLEMENT|flavanol|
214545841|NCT02149238|DIETARY_SUPPLEMENT|methylxanthine|
214545842|NCT02149238|DIETARY_SUPPLEMENT|flavanol + methylxanthine|
214545843|NCT01144390|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
214545844|NCT01144390|DRUG|methadone maintenance treatment|methadone maintenance treatment
214545845|NCT03778294|PROCEDURE|Computed Tomography|Undergo PET/CT
214545846|NCT03778294|OTHER|Fluorodopa F 18|Given IV
214545847|NCT03778294|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214545848|NCT03778294|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
214545849|NCT03778294|RADIATION|Proton Beam Radiation Therapy|Receive proton beam RT
214545850|NCT03778294|OTHER|Quality-of-Life Assessment|Ancillary studies
214545851|NCT03778294|OTHER|Questionnaire Administration|Ancillary studies
214545852|NCT03778294|DRUG|Temozolomide|Drug
214545853|NCT05366543|DIAGNOSTIC_TEST|Visual acuity measurement|Visual acuity will be measured using autorefractometer after cycloplegic eye drops 3 times and glasses will be prescribed for those who are needed.
214698612|NCT05250830|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
214698613|NCT05250830|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
214698614|NCT03689413|DRUG|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
214698615|NCT06324279|DEVICE|Transvaginal ultrasound|Transvaginal ultrasound will be used to see the presence of cervical sliding sign
215159915|NCT02367833|DRUG|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
215159916|NCT02367833|DRUG|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
215159917|NCT02367833|DRUG|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
215159918|NCT03001817|DRUG|K-877|
214698616|NCT06324279|DRUG|Misoprostol 200mcg Tab|Induction of labor by misoprostol
214698617|NCT05097248|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
214698618|NCT05097248|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
215159919|NCT03001817|DRUG|Fenofibrate|
215159920|NCT03001817|DRUG|Placebo (for K-877)|
215159921|NCT03001817|DRUG|Placebo (for Fenofibrate)|
214545854|NCT06173011|DRUG|QL2107|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
214545855|NCT06173011|DRUG|Keytruda®(china)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
214545856|NCT06173011|DRUG|Keytruda®(US)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
214545857|NCT01115686|DRUG|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
214545858|NCT01115686|DRUG|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
214545859|NCT03774290|DRUG|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
214545860|NCT03774290|DRUG|Placebo oral capsule|Oral gelatine capsule
214545861|NCT02388347|DRUG|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
214545862|NCT02388347|BIOLOGICAL|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
214545863|NCT02388347|BIOLOGICAL|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
214545864|NCT02388347|BIOLOGICAL|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
214698619|NCT05097248|DRUG|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
214545865|NCT02388347|BIOLOGICAL|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
214545866|NCT05089747|BIOLOGICAL|Blood sampling for biomarker analysis (microRNA, circulating DNA…)|From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
214698620|NCT00884052|DRUG|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
214698621|NCT00884052|DRUG|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
214698622|NCT03569306|DEVICE|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
214698623|NCT03569306|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
214698624|NCT00839423|DRUG|Placebo|capsules, daily, orally
214698625|NCT00839423|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
214698626|NCT00839423|DRUG|Venlafaxine XL|capsules, daily, orally
214698627|NCT01071096|DRUG|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
214545867|NCT05440604|OTHER|Fortified milk|Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
214698628|NCT01071096|DRUG|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
214698629|NCT05265143|OTHER|bolus/intermittant feeding|sequential randomization
214698630|NCT05429229|DRUG|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
214698631|NCT05429229|DRUG|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
214698632|NCT05429229|DRUG|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
214698633|NCT03831815|DRUG|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
214698634|NCT01954069|DEVICE|Semi-quantitative pregnancy test|
214698635|NCT05871229|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
214698636|NCT05871229|OTHER|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
214545868|NCT00986596|DIETARY_SUPPLEMENT|vitamin D3|4000 IU once daily by mouth for 4 months
214698637|NCT02637440|PROCEDURE|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
215159922|NCT00035932|DRUG|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
215159923|NCT00035932|DRUG|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
214545869|NCT00986596|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
214545870|NCT01177956|BIOLOGICAL|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
214545871|NCT01177956|DRUG|Cisplatin|Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
214545872|NCT01177956|DRUG|5-Fluorouracil|Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
214545873|NCT04935216|PROCEDURE|Laparoscopic|Laparoscopic resection of the pancreas has become widely accepted in the treatment of lesions which are benign or of low-grade malignancy
214698638|NCT02637440|PROCEDURE|Angio guided PCI|Patients receive PCI without FFR measurement
214698639|NCT02262884|DEVICE|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
215159924|NCT00035932|DRUG|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
214698640|NCT02262884|DEVICE|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
214698641|NCT03377244|BEHAVIORAL|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
214698642|NCT03377244|BEHAVIORAL|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
214698643|NCT03377244|BEHAVIORAL|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
214545874|NCT02089139|DEVICE|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
214545875|NCT02089139|OTHER|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks"
214545876|NCT03662269|DRUG|indomethacin|indomethacin (75mg, bid, po, 14days)
214545877|NCT03662269|DRUG|Placebo|placebo (75mg, bid, po, 14days)
214545878|NCT03662269|DRUG|Omeprazole|placebo (20mg, qd, po, 14days)
214545879|NCT04923490|BEHAVIORAL|state and trait anxiety scale levels|"While the STAI-I anxiety level is scored as (1) never, (2) somewhat, (3) frequently, and (4) almost always, the scoring options in STAI-II are (1) almost never, (2) sometimes, (3) most of the time, and (4) almost always."
214545880|NCT00277368|OTHER|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
214545881|NCT02820597|DEVICE|ClariFix device|
214698644|NCT00756886|DRUG|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
215159925|NCT03501108|OTHER|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
215159926|NCT03494907|DRUG|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
215159927|NCT03494907|OTHER|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
215159928|NCT03494907|OTHER|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
215159929|NCT03494907|DRUG|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
215159930|NCT05389995|DRUG|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
215159931|NCT05389995|DRUG|Crystal light|7 days crystal light followed by 24 hour urine collection
215159932|NCT05389995|DRUG|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
215159933|NCT02321709|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
215159934|NCT02321709|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
215159935|NCT00567814|DRUG|Metyrapone|Twice daily
215159936|NCT00567814|DRUG|Oxazepam|Twice Daily
215159937|NCT00567814|DRUG|Placebo|Twice daily
215159938|NCT01459497|RADIATION|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
215159939|NCT01459497|RADIATION|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
215159940|NCT00722306|DRUG|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
215159941|NCT02502617|DIETARY_SUPPLEMENT|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
214545882|NCT03118167|DIETARY_SUPPLEMENT|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
215159942|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
215159943|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
215159944|NCT05358769|DIETARY_SUPPLEMENT|Incoxil food supplement and pelvic floor muscle exercise|"Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.~Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity."
215159945|NCT05358769|OTHER|Pelvic floor muscle exercise|Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
214545883|NCT03118167|DIETARY_SUPPLEMENT|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
214545884|NCT03118167|OTHER|Placebo|Edible starches 0.35g, edible capsule
214545885|NCT03118167|OTHER|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
214545886|NCT00566813|DRUG|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
214545887|NCT00566813|DRUG|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
214545888|NCT01863628|OTHER|aerobic exercise|
214545889|NCT01863628|OTHER|psychoeducation|
214698645|NCT00756886|DRUG|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
214698646|NCT05435144|DIETARY_SUPPLEMENT|Elderberry|European black elderberry extract
214698647|NCT05435144|OTHER|Placebo|Inactive placebo
214545890|NCT05633498|OTHER|Book|Self-help book describing advice to cope with shift work
214545891|NCT05633498|OTHER|Sleep hygiene|Basic sleep hygiene advice on a piece of paper
214545892|NCT03544645|OTHER|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
214545893|NCT03544645|OTHER|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
214545894|NCT01636908|DRUG|Sunitinib|50 mg once daily, oral use, 14 days
214545895|NCT01636908|DRUG|Sorafenib|400 mg, twice daily, oral use, 14 days
214545896|NCT01636908|DRUG|Erlotinib|150 mg once daily, oral use, 14 days
214545897|NCT01636908|DRUG|Everolimus|10 mg once daily, oral use, 14 days
214545898|NCT01636908|DRUG|Lapatinib|1250 mg once daily, oral use, 14 days
214545899|NCT01636908|DRUG|Dasatinib|100 mg once daily, oral use, 14 days
214545900|NCT01636908|DRUG|Pazopanib|800 mg once daily, oral use, 14 days
214545901|NCT01636908|DRUG|Vemurafenib|960 mg twice daily, oral use, 15-21 days
214545902|NCT01636908|PROCEDURE|tumor biopsy|
214545903|NCT01636908|PROCEDURE|skin biopsy (optional)|
214545904|NCT02857075|OTHER|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
214545905|NCT06330493|DEVICE|PCB|Paclitaxel coated PTA balloon catheter
214545906|NCT06330493|DEVICE|PTA|Non-coated FDA cleared (US) or CE-marked (EU) standard percutaneous transluminal angioplasty balloon catheter
214545907|NCT01229774|DRUG|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
214545908|NCT01229774|DRUG|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
214545909|NCT02772328|BEHAVIORAL|Peer Mentor|comparison of communication training to equal attention control
214545910|NCT04303507|DRUG|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
214545911|NCT04303507|DRUG|Placebo|Placebo
215159946|NCT03292367|PROCEDURE|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
215159947|NCT03179319|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
215159948|NCT03651401|DEVICE|Scapular muscle endurance test|The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
215159949|NCT03651401|OTHER|Pain intensity|"Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20."
214545912|NCT00701909|DRUG|Morphine plus Ketamine|Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV
214545913|NCT00701909|DRUG|Morphine plus Saline (placebo)|Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
214545914|NCT00663975|DRUG|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
214545915|NCT00158197|BEHAVIORAL|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
214545916|NCT04012619|DRUG|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
214545917|NCT04435964|DRUG|Immunotherapy|Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
214545918|NCT01629212|DRUG|Tiropramide HCl 100mg|
214545919|NCT01629212|DRUG|Octylonium bromide 20mg|
214545920|NCT02666664|DRUG|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
214545921|NCT02666664|DRUG|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
214545922|NCT00720564|DRUG|arsenic trioxide|
214545923|NCT00720564|DRUG|temozolomide|
214545924|NCT00720564|PROCEDURE|adjuvant therapy|
214545925|NCT00720564|RADIATION|intensity-modulated radiation therapy|
214545926|NCT00720564|RADIATION|radiation therapy|
214545927|NCT01053481|DIETARY_SUPPLEMENT|vitamin D|Vitamin D supplement
214545928|NCT01053481|BEHAVIORAL|exercise program (rebounding on a trampoline)|40 days at 30 min/d
215159950|NCT03651401|DEVICE|Upper Limb Functional Performance|The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
214545929|NCT05000632|BEHAVIORAL|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
214545930|NCT05000632|BEHAVIORAL|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
214545931|NCT02836288|DRUG|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
214545932|NCT02836288|OTHER|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
214545933|NCT02867683|OTHER|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
214545934|NCT00971997|DRUG|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
214545935|NCT02425540|DEVICE|Pelvic MRI|
214545936|NCT01385748|DRUG|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
214545937|NCT01385748|DRUG|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
214545938|NCT01385748|DRUG|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
214545939|NCT03243240|DIAGNOSTIC_TEST|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
214545940|NCT02022111|BEHAVIORAL|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
214545941|NCT02022111|BEHAVIORAL|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
214698648|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
214698649|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
214698650|NCT04303793|DEVICE|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
214698651|NCT00099788|DRUG|Ranolazine|IV to oral transition.
214698652|NCT00099788|DRUG|Placebo|IV to oral transition.
215159951|NCT00267566|BEHAVIORAL|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
215159952|NCT05766696|PROCEDURE|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
214545942|NCT02022111|OTHER|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
214545943|NCT02022111|OTHER|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
214545944|NCT02022111|OTHER|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
214545945|NCT06199154|DRUG|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
214545946|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
214545947|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
214545948|NCT01699464|DRUG|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
214545949|NCT05543239|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes."
214545950|NCT05543239|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)|"Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes."
214545951|NCT04644211|DRUG|Ruxolitinib|Pill taken by mouth.
214545952|NCT02434757|DRUG|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
214545953|NCT02147847|BEHAVIORAL|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
214545954|NCT02147847|BEHAVIORAL|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
214545955|NCT01266018|DRUG|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
214545956|NCT04183998|OTHER|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
214545957|NCT05801445|BEHAVIORAL|Occupation-based activity|Painting large-scale canvas
215159953|NCT05766696|PROCEDURE|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
215159954|NCT00416221|DRUG|Lexapro, an antidepressant medicine|
214545958|NCT05801445|BEHAVIORAL|Body-Weight Exercise|Body-weight exercises designed for older adults
214545959|NCT03167151|DRUG|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
214545960|NCT06197659|OTHER|Liberal Fluid Grubu|Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
214545961|NCT06197659|OTHER|Restrictive Fluid Group|Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
214545962|NCT00560157|DIETARY_SUPPLEMENT|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
214545963|NCT02098447|DEVICE|PrimeStim|
214545964|NCT03145012|DRUG|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
215159955|NCT00416221|BEHAVIORAL|Physical Activity|
215159956|NCT00416221|BEHAVIORAL|Mood Management Skills|
215159957|NCT00416221|BEHAVIORAL|Personalized support from a Family Nurse Practitioner|
214545965|NCT04955977|OTHER|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
214545966|NCT04955977|OTHER|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
214698653|NCT02664207|PROCEDURE|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
214698654|NCT06352099|DIETARY_SUPPLEMENT|Dietary supplement with micronised diosmin, hesperidin and herbal extracts|Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
214698655|NCT05357326|DRUG|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
214698656|NCT05357326|DEVICE|Orthokeratology|wear orthokeratology at night while sleeping
214698657|NCT05357326|DRUG|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
214698658|NCT00757770|BIOLOGICAL|Rotarix|Two oral doses.
215159958|NCT00356304|BEHAVIORAL|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
215159959|NCT00356304|BEHAVIORAL|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
215159960|NCT06422897|OTHER|anterior segment optical coherence tomography|surgically treated corneal perforation by amniotic membrane graft and platelet rich plasma clot is assessed by anterior segment optical coherence tomography 1 month postoperative
214698659|NCT00757770|BIOLOGICAL|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
214698660|NCT02529293|DRUG|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
214698661|NCT02529293|DRUG|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
214698662|NCT04959253|COMBINATION_PRODUCT|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
214698663|NCT04959253|COMBINATION_PRODUCT|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
214698664|NCT03279302|DRUG|Glepaglutide|Solution for injection
214698665|NCT04203563|BEHAVIORAL|Strong People Strength Training|A community-based progressive strength training program
214698666|NCT05781971|DIETARY_SUPPLEMENT|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
214698667|NCT05781971|BEHAVIORAL|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
214698668|NCT05781971|DIETARY_SUPPLEMENT|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
214698669|NCT04453696|BEHAVIORAL|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
214698670|NCT03501745|BEHAVIORAL|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
214698671|NCT01490762|DRUG|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
214698672|NCT01490762|DRUG|Regular Human Insulin|Subcutaneous injection
214698673|NCT01044680|DIETARY_SUPPLEMENT|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
214698674|NCT01044680|DIETARY_SUPPLEMENT|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
214698675|NCT02252237|BIOLOGICAL|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
214698676|NCT01911299|DIETARY_SUPPLEMENT|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
214698677|NCT01911299|DIETARY_SUPPLEMENT|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
214698678|NCT00941889|DRUG|Saline|0.5 ml
214698679|NCT00941889|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
215159961|NCT02731105|DRUG|Acnatac® Gel left face|topical application
215159962|NCT02731105|DRUG|Epiduo® Gel right face|topical application
214545967|NCT00709501|BEHAVIORAL|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
214545968|NCT00709501|BEHAVIORAL|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
214545969|NCT02470689|DRUG|Diacerin cream|Diacerin tablet solubule in ultraphil cream
214545970|NCT06957028|OTHER|Diabetes Treatment|"Management will include an unblinded CGM sensor worn 24/7, GDM specific nutrition information, training on using CGM in daily glucose management to achieve euglycemia (maximizing time 63-140 mg/dL \[3.5-7.8 mmol/L\]).~Visits (which could be telehealth) per usual obstetrical care for glycemia management (expected to be about every 4 weeks for most participants) and weekly glycemic management with review of CGM data by site and by central CGM Resource Center for flagged cases.~Participants not receiving glucose lowering medication by 24-28 weeks will undergo OGTT per usual obstetrical management and those with positive OGTT will be treated for GDM per usual clinic routine and continue to wear an unblinded CGM."
214545971|NCT06957028|OTHER|Usual Care Group|"The control group will receive usual obstetrical care at the clinical center. A general pregnancy nutrition information handout will be provided to each participant and a blinded CGM sensor will be placed at routine obstetrical care visits and worn for 10-14 days each time throughout the pregnancy beginning between 18-22 weeks' gestation.~At 18-22 weeks, blinded CGM data will be reviewed to assess if participant has ≥25% time \>140 mg/dL to determine if an early OGTT or glycemic management is required. Site clinicians will be unblinded to the masked CGM data for participants with CGM data ≥25% time \>140 mg/dL and those participants may be treated as those with a positive OGTT.~An OGTT will be performed at \~24-28 weeks per the clinic's usual routine and those with positive OGTT will be treated for GDM per usual clinic routine. If real-time CGM is to be used, then unblinded study CGM sensors can be used instead of blinded sensors for the duration of the study."
214545972|NCT00950196|DRUG|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
214545973|NCT01439386|PROCEDURE|Catheter ablation|PVAI with or without CTI ablation
214545974|NCT01439386|PROCEDURE|Catheter ablation|CTI ablation only
214545975|NCT03984877|DIAGNOSTIC_TEST|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
214545976|NCT02023359|DRUG|Everolimus and exemestane|
214545977|NCT01615172|PROCEDURE|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
214698680|NCT01010711|DIETARY_SUPPLEMENT|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
214698681|NCT02590523|DRUG|Vancomycin|Intracameral vancomycin injection during cataract surgery
214698682|NCT02590523|DRUG|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
214698683|NCT02590523|DRUG|Placebo|Intracameral placebo injection with BSS during cataract surgery
214698684|NCT04020094|COMBINATION_PRODUCT|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
214698685|NCT01236742|DEVICE|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
214698686|NCT01236742|DEVICE|single-vision glasses|daily wear of spectacle glasses to correct vision
214698687|NCT06169371|DRUG|Abemaciclib|Week 1 50mg orally BID
214698688|NCT06169371|DRUG|Abemaciclib|Week 2 100mg orally BID
214698689|NCT06169371|DRUG|Abemaciclib|Week 3+ 150mg orally BID
215159963|NCT02731105|DRUG|Acnatac® Gel right face|topical application
215159964|NCT02731105|DRUG|Epiduo® Gel left face|topical application
214698690|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
215159965|NCT02475694|OTHER|No intervention|No treatment
215159966|NCT04539769|PROCEDURE|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
215159967|NCT04539769|PROCEDURE|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
215159968|NCT04539769|PROCEDURE|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
215159969|NCT05605886|DRUG|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
215159970|NCT05605886|DRUG|placebo|placebo
215159971|NCT00574522|RADIATION|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
215159972|NCT03703193|OTHER|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
215159973|NCT03703193|OTHER|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
215159974|NCT01486095|DEVICE|AXXESS + Biomatrix Biolimus Eluting stent|NAP
214545978|NCT01021709|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
214545979|NCT03037047|DRUG|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
214545980|NCT03037047|DRUG|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
214545981|NCT06776172|PROCEDURE|Extended Pelvic Lymph Node Dissection|Extended pelvic lymph node dissection during radical prostatectomy
214545982|NCT01458522|DRUG|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
214545983|NCT01458522|DRUG|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
214545984|NCT05526365|OTHER|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
214545985|NCT05184270|DEVICE|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
214545986|NCT05775159|DRUG|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
214545987|NCT05775159|DRUG|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
214545988|NCT05775159|DRUG|Lenvatinib|Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
214545989|NCT05775159|DRUG|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
214545990|NCT05775159|DRUG|Gemcitabine|1000 mg/m2, IV infusion
214545991|NCT05775159|DRUG|Cisplatin|25 mg/m2, IV infusion
214545992|NCT00709397|OTHER|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
214545993|NCT02684123|DRUG|Apremilast|Subjects will get drug or placebo
214545994|NCT02684123|DRUG|Placebo|
214545995|NCT00516139|DRUG|Lamotrigine|Open-label
214545996|NCT00513201|DRUG|lyspro|
214698691|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
214698692|NCT03517683|OTHER|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
214698693|NCT03517683|OTHER|High speed|speed of intrathecal injection will be 1ml in 5 seconds
214698694|NCT05521932|OTHER|endometrium collected|endometrium tissue collected following adhesiolysis surgery
214698695|NCT03993964|DRUG|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
214698696|NCT00703833|DRUG|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
215159975|NCT01486095|DEVICE|Culotte technique with Xience V or Xience Prime stents|NAP
214698697|NCT00703833|DRUG|Placebo (unspecified)|matching placebo
215159976|NCT05465252|DIETARY_SUPPLEMENT|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
214545997|NCT00513201|DRUG|regular insulin|
214698698|NCT00288834|BEHAVIORAL|dysphagia rehabilitation|
214698699|NCT03277144|DEVICE|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
214698700|NCT03277144|OTHER|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
215159977|NCT05465252|DIETARY_SUPPLEMENT|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
215159978|NCT01210404|DRUG|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
214545998|NCT04770870|DEVICE|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
214545999|NCT04872023|OTHER|Blood and bone marrow sampling|Blood and bone marrow sampling
214546000|NCT00517036|DIETARY_SUPPLEMENT|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
214546001|NCT00517036|DIETARY_SUPPLEMENT|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
215159979|NCT00946283|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
215159980|NCT00063843|BIOLOGICAL|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
215159981|NCT05079243|BIOLOGICAL|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
214546002|NCT00517036|DIETARY_SUPPLEMENT|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
214546003|NCT06790082|DRUG|[68Ga]Ga-FAPI-46 PET/CT|"Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment."
214698701|NCT01922284|BIOLOGICAL|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
214698702|NCT01922284|BIOLOGICAL|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
215159982|NCT04422483|OTHER|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
214698703|NCT01922284|BIOLOGICAL|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
215159983|NCT00666016|DRUG|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
215159984|NCT06214234|PROCEDURE|Band ligation|Band ligation in variceal bleeding
214698704|NCT01922284|BIOLOGICAL|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
214698705|NCT06390254|OTHER|Resilience-Enhancing Nursing Suppor|The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
214698706|NCT04698213|DRUG|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
215159985|NCT05106764|OTHER|No intervention|This is non-interventional study.
215159986|NCT06554366|DEVICE|GentleWave|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the GentleWave procedure will be performed
215159987|NCT06554366|DEVICE|EdgePro laser irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the EdgePro procedure will be performed
215159988|NCT06554366|DEVICE|Irrisafe passive ultrasonic irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the passive ultrasonic irrigation procedure will be performed
214546004|NCT00990951|DRUG|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
214546005|NCT03422445|DRUG|Apatinib|Apatinib：500mg/d，qd，po，d1-28
214546006|NCT03422445|DRUG|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
214546007|NCT00676104|DEVICE|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
214546008|NCT06252012|BEHAVIORAL|Mobile application|The mobile application will be designed as a health assistant for women aged between 30-65 to encourage healthy choices and positively develop their behaviors regarding the prevention of cancer. Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study
214546009|NCT05244369|OTHER|Only TENS|Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump
214546010|NCT05244369|PROCEDURE|Acupuncture+TENS|acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
214546011|NCT01419340|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
214546012|NCT06292390|OTHER|Pet Therapy|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy.
214546013|NCT03382561|DRUG|Carboplatin|Given IV
214546014|NCT03382561|DRUG|Cisplatin|Given IV
215159989|NCT04393454|DRUG|Sirolimus 2mg Tablet|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
214546015|NCT03382561|DRUG|Etoposide|Given IV
214546016|NCT03382561|BIOLOGICAL|Nivolumab|Given IV
214546017|NCT01131104|DRUG|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
214546018|NCT01282528|BIOLOGICAL|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
214546019|NCT03121820|DRUG|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
214546020|NCT03121820|DRUG|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
214546021|NCT05496153|BEHAVIORAL|Adaptive posture-balance cardiac rehabilitation exercise|The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
214546022|NCT04681053|DRUG|Ivermectin Powder|\- Administration through inhalation (6mg) BID for 3 days
215159990|NCT01224145|DRUG|5x5cm bupivacaine collagen sponges|
215159991|NCT02230033|DRUG|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
215159992|NCT02230033|DRUG|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
214546023|NCT04985578|OTHER|Dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
214546024|NCT04985578|OTHER|Sham dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
214546025|NCT02805478|OTHER|There is no intervention|This is a prospective observational cohort study without any intervention
214546026|NCT06373796|DEVICE|Echographic scan|Liver ultrasound exam
214546027|NCT03740243|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone tablet or film
214546028|NCT03740243|DRUG|Buprenorphine|Buprenorphine tablet
214546029|NCT02370251|DRUG|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB \<2 mg/dL) occurs.
214546030|NCT05643040|OTHER|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
214546031|NCT05643040|OTHER|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
214546032|NCT05643040|OTHER|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
214546033|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
214546034|NCT06108206|OTHER|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)"
214546035|NCT03012529|DRUG|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
215159993|NCT02230033|DRUG|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
214546036|NCT03012529|DRUG|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
214546037|NCT06348134|DRUG|Trastuzumab emtansine|A chemotherapy drug.
214546038|NCT06348134|DRUG|Pertuzumab Injection|A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
214546039|NCT06348134|DRUG|Docetaxel|A chemotherapy drug.
214546040|NCT06348134|DRUG|Tamoxifen|A medication used to treat breast cancer.
214698707|NCT04698213|DRUG|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
214698708|NCT02411201|DRUG|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
214698709|NCT04929340|OTHER|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
214698710|NCT04929340|OTHER|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
214698711|NCT01260467|DRUG|memantine|10 milligrams orally twice a day
214698712|NCT02256332|DIETARY_SUPPLEMENT|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
214698713|NCT02256332|DIETARY_SUPPLEMENT|High dose plant based ingredient|Reference food with high dose of plant based ingredient
214698714|NCT02256332|DIETARY_SUPPLEMENT|Reference food format|Reference food without plant-based ingredient
214698715|NCT01774344|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
214698716|NCT01774344|DRUG|Placebo|Placebo tablets matching in appearance
214698717|NCT05618496|DEVICE|Sodium Hyaluronate Lyophilizate|Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
214698718|NCT05905211|OTHER|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
214698719|NCT00734773|BIOLOGICAL|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
214698720|NCT00734773|DRUG|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
215159994|NCT06217640|DIAGNOSTIC_TEST|Dual X Ray Absorptiometry|"* Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength"
215159995|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
214546041|NCT06348134|DRUG|Letrozole|A medication used to treat breast cancer.
214698721|NCT00734773|DRUG|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
214698722|NCT00734773|DRUG|Motexafin gadolinium|"* Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
214698723|NCT00734773|DRUG|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
214546042|NCT06348134|DRUG|Goserelin|A hormone therapy drug.
214546043|NCT02453061|DRUG|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
214546044|NCT02453061|DRUG|Placebo|Safflower oil orally administered at 1g/kg/day
214546045|NCT01985815|DEVICE|VC/VS stimulation|
214546046|NCT00151398|DRUG|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
214546047|NCT00151398|DRUG|Donepezil|10 mg donepezil QD dosed up to 40 weeks
214546048|NCT04546802|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
215159996|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
215159997|NCT01111578|DEVICE|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
215159998|NCT04199130|BEHAVIORAL|BrainHQ|"BrainHQ is a web-based brain-training program. The investigators will assign participants to attention specific modules that they will complete at home with the goal of restoring attentional functions lost through injury via repetitive tasks of graded difficulty."
215159999|NCT04199130|BEHAVIORAL|Goal Management Training|"This is a manualized, interactive, metacognitive-strategy training designed to promote a mindful approach to complex real-life tasks and reduce lapses in attention via implementation of compensatory mechanisms for monitoring tasks."
214546049|NCT03003377|DEVICE|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
214546050|NCT03003377|DEVICE|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
214546051|NCT02411617|DEVICE|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
214546052|NCT01276769|DRUG|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
214546053|NCT01276769|DRUG|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
214546054|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
214546055|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
214546056|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
214546057|NCT01958242|OTHER|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
214546058|NCT00371059|DRUG|Memantine|Memantine 10mg BD
214546059|NCT00371059|DRUG|Placebo|Placebo 10 mgs BD
214546060|NCT02557126|DRUG|URC102|
214546061|NCT02557126|DRUG|Placebo|
214546062|NCT03562390|DRUG|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
214546063|NCT00919945|OTHER|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
214546064|NCT00919945|OTHER|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
214546065|NCT01970254|OTHER|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
215160000|NCT05751564|BIOLOGICAL|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw \& inject MSC intra-articular therapy
215160001|NCT05751564|BIOLOGICAL|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
214546066|NCT01970254|OTHER|Survey Administration|Ancillary studies
214546067|NCT03042403|OTHER|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
214546068|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
214546069|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
214546070|NCT01179776|DRUG|Ilomedin|Ilomedin
214546071|NCT01179776|DRUG|Placebo|i.v saline
214546072|NCT01179776|DRUG|Ilomedin|
214546073|NCT01179776|DRUG|Ilomedin and standard low dose treatment|
214546074|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
214546075|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
214546076|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
214546077|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
214546078|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
214546079|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
214546080|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
214546081|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
214546082|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
214546083|NCT02593383|DRUG|Placebo|
214546084|NCT02342990|OTHER|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
214546085|NCT02342990|OTHER|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
214546086|NCT01481688|OTHER|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
214546087|NCT01481688|OTHER|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
214546088|NCT05577325|BEHAVIORAL|control group will be followed without health education|After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
214546089|NCT06375486|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)
214546090|NCT04387877|DEVICE|Graston|"Graston technique will be applied on the lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~For the first 2 weeks; dorsolumbar stabilization, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
214546091|NCT04387877|OTHER|Sham|"Sham graston technique will be applied on lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied by partially touching the skin overlying the muscle or fascia region via ultrasound gel with the flat part of the Graston instrument so as not to provide any activity of the fascia) For the first 2 weeks; dorsolumbar stabilization, counting on spot, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
214546092|NCT00284232|BEHAVIORAL|Use and interpretation of blood glucose results|
214546093|NCT00284232|DRUG|Insulin dosing based on SMBG chart and education|
214546094|NCT00000490|PROCEDURE|jejunoileal bypass|
214546095|NCT00000490|BEHAVIORAL|diet, fat-restricted|
214546096|NCT02270671|BEHAVIORAL|ABMT|Attention Bias Modification Training
214546097|NCT02270671|OTHER|Placebo|Placebo Training
214546098|NCT02713399|DEVICE|Optical Coherence Tomography|
214546099|NCT00476242|DRUG|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
214546100|NCT00476242|DRUG|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
214546101|NCT00916708|PROCEDURE|Intensive/Low-Risk follow up (IA G1; IA G2)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months~\* clinical visit with gynecological exploration"
214546102|NCT00916708|PROCEDURE|Intensive/High-Risk follow up (≥ IA G3)|"\- First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~\- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~\* clinical visit with gynecological exploration"
214546103|NCT00916708|PROCEDURE|Minimalist/Low-Risk follow up (IA G1; IA G2)|"\- First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
214546104|NCT00916708|PROCEDURE|Minimalist/High-Risk follow up (≥ IA G3)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
214698724|NCT00734773|DRUG|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
214698725|NCT00734773|RADIATION|Radiation therapy|Given at weeks 11 through 16.
214698726|NCT05491057|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
214698727|NCT02370355|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
214698728|NCT02370355|OTHER|Laboratory Biomarker Analysis|Correlative studies
214698729|NCT04343079|DIAGNOSTIC_TEST|PET CT|measurement of surgical margins during lumpectomy
214698730|NCT06093763|PROCEDURE|Group without bone grafting|Open wedge corrective osteotomy and plate fixation without bone grafting.
214698731|NCT06093763|PROCEDURE|Group with bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
214698732|NCT03777371|OTHER|Anti HIV Seropositive Pregnant Women|
214698733|NCT01442740|PROCEDURE|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
214698734|NCT06534814|DIAGNOSTIC_TEST|AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)|The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.
214698735|NCT06105424|PROCEDURE|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
214698736|NCT04641312|DRUG|LY3457263|Administered SC
215160002|NCT02460796|OTHER|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
214546105|NCT02693704|DEVICE|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
214546106|NCT03624153|BEHAVIORAL|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
214698737|NCT04641312|DRUG|Dulaglutide|Administered SC
214546107|NCT03624153|BEHAVIORAL|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
214698738|NCT04641312|DRUG|Placebo|Administered SC
214698739|NCT00285974|DEVICE|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
214698740|NCT01353937|DRUG|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
214698741|NCT03939806|DRUG|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
214698742|NCT03939806|DRUG|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
214698743|NCT04995328|OTHER|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
214698744|NCT01023412|DIETARY_SUPPLEMENT|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
215160003|NCT04319692|DIETARY_SUPPLEMENT|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
215160004|NCT04319692|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks.
215160005|NCT02260180|DRUG|A-101|Topical Solution
215160006|NCT00942097|DRUG|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
215160007|NCT00942097|DRUG|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
214546108|NCT02070770|DIETARY_SUPPLEMENT|Very low calorie diet|
214546109|NCT02070770|OTHER|Standard weight loss diet|
214546110|NCT06474065|PROCEDURE|Myomectomy|Patients submitted to operation of fibroids removal
214546111|NCT01819142|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
214698745|NCT04114500|DIAGNOSTIC_TEST|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
214698746|NCT00674830|BEHAVIORAL|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
214698747|NCT00674830|BEHAVIORAL|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
214698748|NCT00674830|BEHAVIORAL|placebo|usual care
214698749|NCT00456729|DRUG|Metronidazole|
214698750|NCT00456729|PROCEDURE|Blood tests|
214698751|NCT05825209|DRUG|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
214698752|NCT05825209|DRUG|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
214698753|NCT05209412|DEVICE|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
214546112|NCT01472029|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
214546113|NCT01472029|DRUG|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
214546114|NCT01306123|DRUG|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
214546115|NCT01306123|DRUG|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
214546116|NCT02700854|OTHER|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE \> -5 mmol/L in arterial blood gas samples
214546117|NCT04283708|PROCEDURE|Submental liposuction|Advancement Genioplasty With Submental Liposuction
214546118|NCT02689570|OTHER|observational|no interventions; observational study
214546119|NCT03144544|PROCEDURE|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
214546120|NCT05063695|OTHER|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
214546121|NCT01578213|DRUG|Imatinib mesylate|"* Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use"
214546122|NCT00399841|DEVICE|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
214546123|NCT02356796|OTHER|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
214546124|NCT02356796|OTHER|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
214546125|NCT01383811|OTHER|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
214546126|NCT01383811|OTHER|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
214546127|NCT05469724|OTHER|Role of ct pulmonary angiography in diagnosis of pulmonary embolism|Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery
214546128|NCT00639327|DRUG|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
214546129|NCT00639327|DRUG|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
214546130|NCT06060483|DEVICE|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
214698754|NCT05209412|DEVICE|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
214698755|NCT05209412|DRUG|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
214698756|NCT05209412|DRUG|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
214546131|NCT01585441|DRUG|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
214546132|NCT01585441|DRUG|Placebo|Capsule with no active ingredients to mimic finasteride
214546133|NCT01448369|DEVICE|Blephasteam|10 minute treatment twice daily
214546134|NCT01448369|DEVICE|EyeGiene|10 minute treatment, twice daily
214546135|NCT01448369|DEVICE|Hot compresses|10 minute treatment, twice daily
214546136|NCT05352945|DEVICE|HyPNOS self-hypnosis mask from DREAMINZZ|"The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections"
214546137|NCT05221177|BEHAVIORAL|TR-30|Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
214546138|NCT05221177|BEHAVIORAL|TR-45|Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
214546139|NCT03043430|DRUG|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
214546140|NCT03043430|DRUG|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
214546141|NCT01803334|OTHER|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
214546142|NCT03792490|DRUG|Fasudil|Fasudil hydrochloride hydrate IV solution
214546143|NCT03792490|DRUG|Placebo|Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
214546144|NCT03486483|OTHER|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
214546145|NCT03405077|BEHAVIORAL|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
214546146|NCT03487198|DRUG|Brexpiprazole|Brexpiprazole 2-3mg/day
214546147|NCT03487198|DRUG|Placebo|Placebo 2-3 mg/day
214546148|NCT02775838|DRUG|Indocyanine green|perioperative application of Indocyanine green (ICG)
214546149|NCT02140736|DRUG|Epoetin biosimilar|
214546150|NCT02274077|DRUG|EXPAREL|
214546151|NCT02274077|DRUG|Normal Saline|
214546152|NCT00311415|BIOLOGICAL|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
214546153|NCT01054378|PROCEDURE|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
214546154|NCT02367352|DRUG|Alisertib|Alisertib tablets
214546155|NCT02367352|DRUG|Paclitaxel|Paclitaxel intravenous solution
214546156|NCT05525507|COMBINATION_PRODUCT|Conditioning and Stem cell infusion|Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
214546157|NCT05021445|COMBINATION_PRODUCT|plates based exercises|12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
214546158|NCT05021445|COMBINATION_PRODUCT|conventional exercises|12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
214546159|NCT00174447|DRUG|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
214546160|NCT04400968|PROCEDURE|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen \[FT2\], uterus \[FT5\], sympathetic \[HI4\], kidney \[CS6\], heart \[CI4\], endocrine \[IT2\] and thalamus \[PC2\].
214546161|NCT04400968|PROCEDURE|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
214546162|NCT04400968|PROCEDURE|Auricular therapy Placebo group|Sham auricular therapy
214546163|NCT04400968|PROCEDURE|kinesio tape Placebo group|Sham kinesio tape
214546164|NCT00907764|DRUG|regadenoson|400 ug, IV
214546165|NCT01437423|BIOLOGICAL|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
214546166|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
214546167|NCT02164019|PROCEDURE|long-stem cemented hemiarthroplasty (LSCH)|
214546168|NCT02164019|PROCEDURE|intramedullary nailing (IMN)|
214546169|NCT02164019|BEHAVIORAL|questionnaires|
214546170|NCT04695652|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
214546171|NCT04695652|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
214698757|NCT05209412|DRUG|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
214546172|NCT05282251|DRUG|Intrapleural bupivacine nebulization|Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
214546173|NCT05282251|DRUG|Intravenous paracetamol and ketorolac|Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
214698758|NCT01397552|DRUG|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
214698759|NCT01397552|DRUG|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
214546174|NCT00497666|DRUG|Rosiglitasone (retrospective observation)|
214546175|NCT00232219|DRUG|Fish oil|
214546176|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
214546177|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
214546178|NCT02695147|PROCEDURE|TAVI|
214698760|NCT04905199|PROCEDURE|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
214698761|NCT05966844|BEHAVIORAL|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
214698762|NCT00286390|PROCEDURE|Acupuncture|
214698763|NCT00001940|DRUG|Voriconazole|
214698764|NCT03096002|BEHAVIORAL|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
214698765|NCT06186635|OTHER|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
214698766|NCT06186635|OTHER|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
214698767|NCT03934892|DIAGNOSTIC_TEST|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
214698768|NCT02346500|DEVICE|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
214698769|NCT02425007|DEVICE|Incentive spirometry|
214698770|NCT03377010|OTHER|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
214698771|NCT03377010|OTHER|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
214546179|NCT04739410|DRUG|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
214546180|NCT06484868|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
214698772|NCT05696171|PROCEDURE|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
214698773|NCT05696171|PROCEDURE|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
214698774|NCT04138030|PROCEDURE|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
214698775|NCT04138030|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
214698776|NCT02423434|OTHER|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
214546181|NCT02639806|DRUG|Sevoflurane|
214546182|NCT02639806|DRUG|Lidocaine|
214546183|NCT04142099|BEHAVIORAL|skin to skin contact 60 min group|Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
214546184|NCT04142099|BEHAVIORAL|skin to skin contact 20min group|Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
214698777|NCT05211011|DRUG|Fosfomycin|Infectofos 5 g
214546185|NCT02114762|PROCEDURE|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
214546186|NCT01383447|DRUG|entinostat|Given PO
214546187|NCT01383447|DRUG|imatinib mesylate|Given PO
214546188|NCT01383447|OTHER|laboratory biomarker analysis|Correlative studies
214546189|NCT01383447|OTHER|pharmacological study|Correlative studies
214546190|NCT01383447|GENETIC|western blotting|Correlative studies
214546191|NCT01383447|OTHER|immunohistochemistry staining method|Correlative studies
214546192|NCT01383447|OTHER|flow cytometry|Correlative studies
214546193|NCT01383447|GENETIC|polymerase chain reaction|Correlative studies
214546194|NCT01383447|OTHER|high performance liquid chromatography|Correlative studies
214546195|NCT01383447|OTHER|mass spectrometry|Correlative studies
214546196|NCT02738645|OTHER|pneumonia|
214546197|NCT01409122|DRUG|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
214546198|NCT01409122|DRUG|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
214546199|NCT01409122|DRUG|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
214546200|NCT01409122|DRUG|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
214546201|NCT01409122|DRUG|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
214546202|NCT00254969|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
214546203|NCT03839810|OTHER|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
214546204|NCT04515056|DRUG|Papain 10 µg|The area will be exposed to 10 µg of papain.
214546205|NCT04515056|DRUG|Papain 50 µg|The area will be exposed to 50 µg of papain.
214546206|NCT04515056|DRUG|Papain 100 µg|The area will be exposed to 100 µg of papain.
214546207|NCT04515056|OTHER|Vehicle|The area will be exposed to vehicle
214546208|NCT04515056|DRUG|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
214546209|NCT04515056|DRUG|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
214546210|NCT04515056|DRUG|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
214546211|NCT04515056|OTHER|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
214546212|NCT00633945|DRUG|Lenalidomide|
214546213|NCT04908345|DRUG|Methadone|Used at induction and during surgery
214546214|NCT04908345|DRUG|Fentanyl|Used at induction and during surgery
214546215|NCT01192789|DRUG|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
214546216|NCT01192789|OTHER|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
214546217|NCT01579643|PROCEDURE|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~2. The host cornea bed will be prepared with an excimer laser.~3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
214546218|NCT01579643|PROCEDURE|Penetrating Keratoplasty (KP)|"1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~2. The donor cornea is then sutured where the patient's cornea was."
214546219|NCT01928667|OTHER|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
214546220|NCT06545318|DEVICE|Density Gradient Centrifugation|Sperm separation with density gradients
214546221|NCT06545318|DEVICE|CA0 chamber|Sperm separation with a novel device
214546222|NCT04528823|OTHER|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
214546223|NCT04528823|OTHER|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
214546224|NCT01487187|PROCEDURE|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
214546225|NCT01487187|PROCEDURE|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
214546226|NCT01861977|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
214698778|NCT04004533|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
214698779|NCT00300651|BEHAVIORAL|Cognitive Behavioral Therapy|
214698780|NCT04941352|BEHAVIORAL|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
215160008|NCT04037696|BEHAVIORAL|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
214546227|NCT01861977|BEHAVIORAL|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
214546228|NCT03865953|DRUG|LAT8881|LAT8881 oral capsule
214546229|NCT03865953|DRUG|Placebo|Placebo oral capsule
214546230|NCT03936842|BEHAVIORAL|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
214546231|NCT03936842|BEHAVIORAL|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
214546232|NCT02028286|DRUG|CLS001|
214546233|NCT02392754|DEVICE|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
214546234|NCT00882115|DRUG|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
214546235|NCT01271504|DRUG|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
214546236|NCT01271504|DRUG|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
214546237|NCT02552147|DRUG|Transdermal nicotine|
214546238|NCT02552147|OTHER|Transdermal placebo|
214546239|NCT04467645|OTHER|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
214546240|NCT02375347|OTHER|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
214546241|NCT01514851|DRUG|Lanthanum carbonate (BAY77-1931)|
214546242|NCT01514851|DRUG|Calcium carbonate|
214546243|NCT05828836|DRUG|Allopurinol Tablet|allopurinol300mg once daily
214546244|NCT05828836|DRUG|Placebo|placebo once daily
214546245|NCT04513743|DIAGNOSTIC_TEST|24/7 EEG™ SubQ|24/7 EEG™ SubQ device will be worn by each subject for 365 nights
214546246|NCT04737837|DRUG|lacosamide|lacosamide as first add on therapy
214546247|NCT06442696|OTHER|Health Education: Healthy Choices Program|Six session for students and school personel
214546248|NCT01545947|DRUG|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
214546249|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
214698781|NCT00734734|BIOLOGICAL|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
214698782|NCT01735617|DRUG|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
214546250|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
214546251|NCT00114296|DIETARY_SUPPLEMENT|omega-3 fatty acid|
214698783|NCT02344407|BIOLOGICAL|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
214698784|NCT02344407|BIOLOGICAL|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
214546252|NCT04181112|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT using retention enema
214546253|NCT02034097|DRUG|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
214546254|NCT02034097|DRUG|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
214546255|NCT03502577|BIOLOGICAL|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
214546256|NCT03502577|DRUG|Cyclophosphamide|Given IV
214546257|NCT03502577|DRUG|Fludarabine|Given IV
214546258|NCT03502577|DRUG|Gamma-Secretase Inhibitor LY3039478|Given PO
214546259|NCT03502577|OTHER|Laboratory Biomarker Analysis|Correlative studies
214546260|NCT03502577|OTHER|Pharmacokinetic Study|Correlative studies
214546261|NCT03673995|DIETARY_SUPPLEMENT|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
214546262|NCT00696488|DRUG|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
214546263|NCT01159522|DRUG|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
214546264|NCT01758744|DRUG|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
214546265|NCT03672942|BEHAVIORAL|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
214546266|NCT03672942|BEHAVIORAL|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
214546267|NCT03672942|BEHAVIORAL|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
214546268|NCT02595320|DRUG|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
214546269|NCT02191904|OTHER|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
214546270|NCT00085397|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
214546271|NCT00085397|BIOLOGICAL|gp100 antigen|Given IV
214546272|NCT00085397|BIOLOGICAL|therapeutic autologous dendritic cells|Given IV
214546273|NCT05923645|DEVICE|Transcranial magnetic stimulation (Hf rTMS)|"TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
214546274|NCT02806843|DEVICE|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
214546275|NCT01096576|DRUG|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
214546276|NCT01096576|DRUG|placebo|orally twice daily for 5 days
214546277|NCT01502592|PROCEDURE|Cryoablation|"OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*"
214546278|NCT01502592|BIOLOGICAL|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
214698785|NCT02344407|BIOLOGICAL|Placebo|
214698786|NCT03348111|DEVICE|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
214546279|NCT00358982|DRUG|MGCD0103|MGCD0103 administered orally three times per wek
214698787|NCT06063408|BEHAVIORAL|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
214698788|NCT06063408|BEHAVIORAL|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
214698789|NCT06473493|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
214698790|NCT04853524|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
214698791|NCT04853524|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
214698792|NCT05181319|OTHER|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
214698793|NCT05346913|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
214698794|NCT03147339|OTHER|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
214698795|NCT02498756|BIOLOGICAL|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
214698796|NCT02498756|DRUG|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
214698797|NCT00992784|BIOLOGICAL|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
214698798|NCT00992784|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
214698799|NCT04228692|PROCEDURE|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
214698800|NCT04228692|DEVICE|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
215160009|NCT04037696|BEHAVIORAL|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
215160010|NCT01043289|OTHER|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
214546280|NCT02768350|PROCEDURE|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
214546281|NCT02768350|PROCEDURE|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
214546282|NCT05196971|DRUG|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
214546283|NCT05196971|DRUG|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
214546284|NCT05834868|DRUG|THDB0206 Injection|Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.
214546285|NCT05834868|DRUG|Insulin Lispro Injection|Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
214698801|NCT01869751|DRUG|Prucalopride|Treatment with prucalopride for slow-transit constipation
214698802|NCT02570763|DEVICE|Active tDCS stimulation|
215160011|NCT00611403|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
214698803|NCT02570763|DEVICE|Sham tDCS stimulation|
214698804|NCT05415046|PROCEDURE|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
214698805|NCT01231360|OTHER|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
215160012|NCT00611403|DRUG|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
215160013|NCT03945604|DRUG|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
215160014|NCT05127746|DRUG|Aricept 5mg Tablet|1 tablet once daily
215160015|NCT05127746|DRUG|Aricept 10mg Tablet|1 tablet once daily
215160016|NCT05127746|DRUG|DA-5207 A|1 patch once weekly
215160017|NCT05127746|DRUG|DA-5207 B|1 patch once weekly
215160018|NCT00536445|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
215160019|NCT00407056|DRUG|Difluprednate Ophthalmic Emulsion|
215160020|NCT02325869|DEVICE|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
215160021|NCT01812668|DRUG|cabozantinib-s-malate|Given PO
215160022|NCT01812668|RADIATION|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
215160023|NCT01812668|PROCEDURE|positron emission tomography|Undergo 18F PET/FMAU PET scan
214546286|NCT02830282|OTHER|Blood Collection|
214546287|NCT00501683|DRUG|Radiolabelled GSK189075|
214546288|NCT04623606|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
214546289|NCT02853487|DEVICE|Actigraphy|An actigraph from Philips
214546290|NCT02853487|OTHER|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
214546291|NCT02031536|DRUG|everolimus|Given PO
214546292|NCT02031536|OTHER|placebo|Given PO
214546293|NCT04530578|DRUG|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
214546294|NCT04530578|DRUG|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
214546295|NCT06370442|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 100mcg
214546296|NCT06370442|DRUG|Lorazepam|0.5mg IV
214546297|NCT06370442|DRUG|Haloperidol|0.5mg IV
214546298|NCT06028490|BIOLOGICAL|GR1802 injection-1|subcutaneous，dose\*1
214546299|NCT06028490|BIOLOGICAL|GR1802 injection-2|subcutaneous，dose\*2
214546300|NCT06028490|BIOLOGICAL|Placebo|subcutaneous，dose\*2
214546301|NCT04449237|OTHER|music therapy|music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
214546302|NCT00905047|DRUG|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
214546303|NCT00905047|DRUG|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
214546304|NCT04201145|DRUG|Pembrolizumab|IV, predetermined dosage, twice per cycle
214546305|NCT04201145|DRUG|Defactinib|Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
214546306|NCT04678778|BEHAVIORAL|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
214546307|NCT00799955|PROCEDURE|Placebo block|100 micrograms of spinal morphine
214546308|NCT00799955|PROCEDURE|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
214546309|NCT03180944|DRUG|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
214546310|NCT03180944|DRUG|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
214546311|NCT03180944|DRUG|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
214546312|NCT03180944|DRUG|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
214546313|NCT03180944|DRUG|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
214546314|NCT04530604|DRUG|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (\>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
214546315|NCT06360211|DRUG|BAY2927088|Oral administration
214546316|NCT06360211|DRUG|Midazolam|Oral administration
214546317|NCT05442450|DRUG|oral semaglutide|Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
214546318|NCT04093388|DIAGNOSTIC_TEST|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
215160024|NCT01812668|OTHER|pharmacological study|Correlative studies
214546319|NCT04093388|DIAGNOSTIC_TEST|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
215160025|NCT01812668|OTHER|laboratory biomarker analysis|Correlative studies
215160026|NCT04534816|DIAGNOSTIC_TEST|Indocyanine Green|Perfusion assessments
215160027|NCT00632788|OTHER|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
215160028|NCT03636464|OTHER|Blood collection|Pharmacokinetics
215160029|NCT01643421|OTHER|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
215160030|NCT03708354|DRUG|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
215160031|NCT03708354|DRUG|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
215160032|NCT03059355|BIOLOGICAL|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
215160033|NCT03059355|BIOLOGICAL|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
215160034|NCT03059355|OTHER|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
215160035|NCT04966663|DRUG|Nivolumab|Antineoplastic agent
215160036|NCT04966663|DRUG|Pemetrexed|Antineoplastic agent
215160037|NCT04966663|DRUG|Gemcitabine|Antineoplastic agent
215160038|NCT04966663|DRUG|Cisplatin|Antineoplastic agent
215160039|NCT04966663|DRUG|Carboplatin|Antineoplastic agent
215160040|NCT04966663|PROCEDURE|ctDNA blood test|Blood will be collected for ctDNA testing
215160041|NCT02375061|BEHAVIORAL|e-BPS|
215160042|NCT02375061|BEHAVIORAL|Daily Activities|
215160043|NCT01595022|DRUG|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
215160044|NCT01595022|DRUG|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
215160045|NCT01595022|DRUG|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
214546320|NCT00762645|DRUG|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
214546321|NCT00762645|DRUG|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
214546322|NCT02128698|DIETARY_SUPPLEMENT|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
214546323|NCT02128698|DIETARY_SUPPLEMENT|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
214546324|NCT02128698|BEHAVIORAL|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
214546325|NCT02128698|BEHAVIORAL|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
214546326|NCT00095043|DRUG|MK0928, gaboxadol|
214546327|NCT00095043|DRUG|Comparator: placebo|
214546328|NCT03272711|DRUG|Vortioxetine 10 mg|
214546329|NCT03272711|BEHAVIORAL|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
214546330|NCT02998398|OTHER|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
214546331|NCT00002498|DRUG|CMF regimen|
214546332|NCT00002498|DRUG|cyclophosphamide|
214546333|NCT00002498|DRUG|fluorouracil|
214546334|NCT00002498|DRUG|methotrexate|
214546335|NCT00002498|DRUG|mitoxantrone hydrochloride|
214546336|NCT03634722|DEVICE|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
214546337|NCT03581669|DEVICE|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
214546338|NCT05434585|BIOLOGICAL|ABO1009-DP|Vaccine
214546339|NCT05434585|BIOLOGICAL|ABO-CoV.617.2|Vaccine
214698806|NCT01231360|OTHER|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
214698807|NCT04561921|DRUG|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
214546340|NCT05434585|OTHER|Placebo|Placebo
214546341|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
214546342|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
214546343|NCT02326259|OTHER|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
214698808|NCT04561921|DRUG|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
214698809|NCT05186766|DEVICE|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
214546344|NCT02149706|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
214546345|NCT02149706|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
214546346|NCT03434028|DRUG|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
214546347|NCT03434028|OTHER|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
214546348|NCT02712970|PROCEDURE|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
214698810|NCT03453021|DRUG|Mepolizumab|
214698811|NCT02035982|DRUG|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
214546349|NCT02712970|PROCEDURE|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
214546350|NCT02712970|PROCEDURE|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
214698812|NCT02035982|DRUG|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
214698813|NCT00398957|DRUG|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
214698814|NCT02432248|DRUG|Dehydroepiandrosterone|75mg/day, PO for 90 days
214698815|NCT02432248|OTHER|placebo(medical starch)|75mg/day, PO for 90 days
214698816|NCT02795546|DRUG|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
214698817|NCT02795546|BIOLOGICAL|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
214698818|NCT01363713|DRUG|DE-114 ophthalmic solution|
214698819|NCT03173586|OTHER|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
215160046|NCT03032302|DIETARY_SUPPLEMENT|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
215160047|NCT03032302|DIETARY_SUPPLEMENT|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
214546351|NCT02712970|PROCEDURE|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
214546352|NCT05928663|OTHER|double surgical gloves|In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
214546353|NCT05928663|OTHER|single surgical gloves|MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
214698820|NCT02051725|OTHER|Active life-style intervention|
214698821|NCT00399594|PROCEDURE|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
214698822|NCT00399594|PROCEDURE|B|LV lead placement in standard (lateral / posterolateral) position.
214698823|NCT03798249|OTHER|Gluten|Tereos
214698824|NCT03798249|OTHER|Placebo|Nestlé Health Science
214698825|NCT03747744|OTHER|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
214698826|NCT04157647|DEVICE|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
214698827|NCT04157647|DEVICE|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
214698828|NCT01658579|DRUG|HOE901-U300 (new formulation of insulin glargine)|
214698829|NCT01658579|DRUG|Lantus (insulin glargine)|
214698830|NCT01717703|DIETARY_SUPPLEMENT|Water|
214698831|NCT01717703|DIETARY_SUPPLEMENT|Fruit drink|
214698832|NCT01717703|DIETARY_SUPPLEMENT|Cola|
214698833|NCT01717703|DIETARY_SUPPLEMENT|1% chocolate milk|
214698834|NCT03702530|BIOLOGICAL|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
214698835|NCT03702530|OTHER|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
214698836|NCT03702530|BIOLOGICAL|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
214698837|NCT00576251|DRUG|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
214698838|NCT00576251|DRUG|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
215160048|NCT01204008|PROCEDURE|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
215160049|NCT01204008|PROCEDURE|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
215160050|NCT03860818|OTHER|Health services delivery|Technology-enabled pharmacist intervention
215160051|NCT03126344|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
215160052|NCT03126344|DEVICE|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
215160053|NCT03126344|DEVICE|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
215160054|NCT00620932|BEHAVIORAL|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
215160055|NCT01811056|DRUG|Mifepristone|Mifepristone use outside of the center
215160056|NCT00593476|OTHER|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
215160057|NCT00593476|OTHER|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
215160058|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
215160059|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
215160060|NCT01785173|PROCEDURE|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
215160061|NCT01785173|PROCEDURE|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
215160062|NCT02975362|OTHER|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
215160063|NCT02975362|OTHER|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
215160064|NCT05204303|DIAGNOSTIC_TEST|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
215160065|NCT05204303|OTHER|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
215160066|NCT05204303|OTHER|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
215160067|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
215160068|NCT05367492|DRUG|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
215160069|NCT05367492|DRUG|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
215160070|NCT05367492|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
214546354|NCT05115708|PROCEDURE|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
214546355|NCT05115708|PROCEDURE|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
214546356|NCT01702870|PROCEDURE|Magnetic Resonance Imaging|
214546357|NCT04753944|DIETARY_SUPPLEMENT|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
214546358|NCT04753944|DIETARY_SUPPLEMENT|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
214546359|NCT03729713|OTHER|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
214698839|NCT05682586|BIOLOGICAL|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
214698840|NCT05682586|DRUG|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
214698841|NCT03026335|BEHAVIORAL|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
214698842|NCT03026335|BEHAVIORAL|Control|Business as usual with students in non-itervened schools
214698843|NCT01368666|DEVICE|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
214698844|NCT01889654|OTHER|Venous blood sampling|
214698845|NCT01434381|BIOLOGICAL|Pfs25-EPA/Alhydrogel|
214546360|NCT03729713|OTHER|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
214546361|NCT02578498|DIETARY_SUPPLEMENT|High carbohydrate intake|Carbohydrate intake \< 50 gram
214546362|NCT02578498|DIETARY_SUPPLEMENT|Low carbohydrate intake|Carbohydrate intake \> 250 gram
214546363|NCT02037776|DRUG|Rikkunshito|\- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
214546364|NCT02037776|DRUG|Rikkunshito placebo|\- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
214546365|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
214546366|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
214546367|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214546368|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214546369|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
214698846|NCT01769417|DRUG|Placebo|Placebo
214698847|NCT01769417|DRUG|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
214698848|NCT01987167|DRUG|ACTHAR|Injectable Gel
214546370|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
214546371|NCT00763594|BEHAVIORAL|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
214698849|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
214698850|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
214698851|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
214698852|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
214698853|NCT05383729|OTHER|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
214698854|NCT05383729|OTHER|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
214698855|NCT03703830|DEVICE|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
214698856|NCT03703830|OTHER|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
214546372|NCT00763594|BEHAVIORAL|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
214546373|NCT04131764|DIAGNOSTIC_TEST|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
214698857|NCT03703830|DEVICE|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
214546374|NCT03230825|DRUG|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
214546375|NCT03230825|OTHER|Expectant management|No intervention and a follow up visit a wewk later
214546376|NCT03575676|DRUG|SOM3355 100mg BID|Oral
214546377|NCT03575676|DRUG|SOM3355 200mg BID|Oral
214546378|NCT03575676|DRUG|Placebo BID|Oral
214698858|NCT03703830|DEVICE|Cerebello-spinal direct current stimulation|Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
214698859|NCT03703830|DEVICE|Sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
214698860|NCT00003539|BIOLOGICAL|trastuzumab|
215160071|NCT05367492|BEHAVIORAL|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
215160072|NCT01088048|DRUG|Idelalisib|Idelalisib tablet administered orally
215160073|NCT01088048|DRUG|Rituximab|Rituximab administered intravenously
215160074|NCT01088048|DRUG|Bendamustine|Bendamustine administered intravenously
215160075|NCT01088048|DRUG|Ofatumumab|Ofatumumab administered intravenously
215160076|NCT01088048|DRUG|Fludarabine|Fludarabine administered orally
215160077|NCT01088048|DRUG|Everolimus|Everolimus administered orally twice daily until disease progression
215160078|NCT01088048|DRUG|Bortezomib|Bortezomib administered as a subcutaneous injection
215160079|NCT01088048|DRUG|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
215160080|NCT01088048|DRUG|Lenalidomide|Lenalidomide administered orally
215160081|NCT01851603|DEVICE|AVL-3288|Drug
215160082|NCT01851603|DRUG|Placebo|Identical diluent to that used for AVL-3288
215160083|NCT06529926|OTHER|Observational|Only classical physiotherapy application for 4 weeks.
215160084|NCT06529926|OTHER|IASTM Technique Application|IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
215160085|NCT05799248|DRUG|rhPSMA-7.3 (18F)|Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
215160086|NCT01804738|OTHER|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
215160087|NCT01804738|OTHER|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
215160088|NCT01588418|DRUG|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
215160089|NCT01588418|DRUG|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
215160090|NCT01374503|BIOLOGICAL|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
215160091|NCT01374503|BIOLOGICAL|Placebo|single or multiple i.v. administration
214546379|NCT01850537|DEVICE|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
214546380|NCT02626247|DIETARY_SUPPLEMENT|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
214546381|NCT02626247|OTHER|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
214698861|NCT00003539|DRUG|paclitaxel|
214698862|NCT05607940|PROCEDURE|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
214698863|NCT05607940|PROCEDURE|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
215160092|NCT00772317|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
215160093|NCT01374230|PROCEDURE|Total knee arthroplasty|Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
215160094|NCT00333762|DEVICE|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
215160095|NCT00333762|DEVICE|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
214698864|NCT00240188|PROCEDURE|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
214698865|NCT00240188|PROCEDURE|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
214698866|NCT06022978|PROCEDURE|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
214698867|NCT06022978|PROCEDURE|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
214698868|NCT05564286|DRUG|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
214698869|NCT05564286|DRUG|tropisetron|All patients received tropisetron 5mg on day 1.
214698870|NCT05564286|DRUG|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
214698871|NCT01434888|DRUG|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
214698872|NCT01434888|DRUG|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
214698873|NCT01434888|DRUG|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
214546382|NCT00552864|DRUG|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
214546383|NCT00552864|DRUG|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
214546384|NCT06338085|OTHER|emotional liberation technique|In this intervention, with the technique taught by the researcher, women will self-administer the practice of lightly touching certain points 5 days and 1 time per week for 8 weeks. A whatsup group will be created by the researcher. A reminder message will be sent from this group to do the practice 1 time every day.
214546385|NCT01568385|DRUG|TAK-438|
214546386|NCT02832349|OTHER|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
214546387|NCT05678686|OTHER|Active Comparator: Routine Exercise Group|Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.
214546388|NCT05678686|OTHER|Experimental: PNF Exercise|In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.
214546389|NCT05678686|OTHER|Experimental: CTAR Exercise|In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
214546390|NCT03892005|PROCEDURE|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
214546391|NCT01279837|BEHAVIORAL|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
214546392|NCT04413422|DRUG|type of hypnotic used for induction of general anesthesia|
214698874|NCT04715308|PROCEDURE|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
214698875|NCT04526756|PROCEDURE|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
214698876|NCT00220766|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
214698877|NCT00220766|DRUG|Dextrose, 5% in Water|
214698878|NCT00247182|BEHAVIORAL|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
214698879|NCT00247182|BEHAVIORAL|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
215160096|NCT06067152|DEVICE|EIT measurement|Evaluation of mechanical ventilation and ventilation distribution through EIT. Mechanical ventilation is set by the physician according to clinical protocolized criteria
214698880|NCT00247182|BEHAVIORAL|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
214698881|NCT02923752|DEVICE|MRI|Contrast-enhanced MRI
214698882|NCT03140995|BEHAVIORAL|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
214698883|NCT02077387|BEHAVIORAL|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
214698884|NCT02077387|BEHAVIORAL|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
214698885|NCT04838106|OTHER|Not applicable as observational study|Not applicable as observational study.
214698886|NCT01514188|DRUG|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
214698887|NCT01514188|DRUG|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
214698888|NCT05624684|DIAGNOSTIC_TEST|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
214698889|NCT04667806|BEHAVIORAL|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
214698890|NCT01019486|DRUG|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
214698891|NCT01019486|DRUG|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
214698892|NCT03026413|PROCEDURE|pulmonary vein antrum modification|
214546393|NCT05803681|DEVICE|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
214546394|NCT05803681|OTHER|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
214546395|NCT05354882|BEHAVIORAL|Physical activity program|The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing
214546396|NCT00873327|DRUG|piperacillin-tazobactam|"6 doses intravenously at the following doses:~Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6"
214546397|NCT04147858|DRUG|NYX-2925|NYX-2925 administered orally
214546398|NCT04147858|DRUG|Placebo|Placebo administered orally
214698893|NCT05203276|DRUG|Envafolimab|300mg，SC，Q3W，d1
214698894|NCT05203276|DRUG|Endostar|210mg，CIV，Q3W，d1-3
214698895|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
214698896|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
214698897|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
214698898|NCT01277341|DRUG|Placebo Nasal Spray|nasal spray
214698899|NCT02932332|OTHER|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
214698900|NCT02932332|OTHER|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
214698901|NCT02932332|OTHER|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
214698902|NCT02932332|OTHER|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
214698903|NCT03134313|DEVICE|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
214698904|NCT04115618|RADIATION|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
214698905|NCT05913284|DRUG|Methadone|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
214698906|NCT05913284|DRUG|Morphine|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
214698907|NCT05373706|BEHAVIORAL|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
214698908|NCT04729491|DRUG|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
214698909|NCT04729491|DRUG|Azithromycin|Azithromycin 500mg/day for 05 days
214698910|NCT04729491|DRUG|Nitazoxanide|500mg twice daily for 06 days
214698911|NCT04729491|DRUG|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
214698912|NCT03216317|BEHAVIORAL|Intervention Group|Isometric handgrip training consisting of four series
214698913|NCT03144323|BEHAVIORAL|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
214698914|NCT05553626|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
214698915|NCT05553626|DEVICE|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
214698916|NCT02981277|DRUG|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
214546399|NCT02780895|DRUG|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
214546400|NCT00751660|OTHER|laboratory biomarker analysis|
214546401|NCT00751660|OTHER|screening questionnaire administration|
214546402|NCT00751660|PROCEDURE|bronchoscopic and lung imaging studies|
214546403|NCT00751660|PROCEDURE|computed tomography|
214546404|NCT00751660|PROCEDURE|endoscopic biopsy|
214546405|NCT00751660|PROCEDURE|quality-of-life assessment|
214546406|NCT01554722|PROCEDURE|Needle placement|In plane versus out of plane needle placement techniques
214546407|NCT01486381|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
214546408|NCT01191008|DRUG|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
214546409|NCT03060018|DEVICE|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
214546410|NCT03786744|BIOLOGICAL|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
214546411|NCT03786744|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
214546412|NCT06263075|PROCEDURE|Intraoperative monitoring|"ANESTHESIOLOGICAL MANAGEMENT accords to usual practice. Participants underwent preoperative fasting (3 h for breast milk, 4 h for formula milk, and 1 h for clear liquids), no premedication, induction and maintenance by sevoflurane, fentanyl boluses for analgesia, mechanical ventilation (PEEP 4 cm H2O, target tidal volume 6-8 ml/Kg, end tidal CO2 32-40 mmHg), 10 ml/Kg/h of intraoperative fluids. Scalp block is performed before surgery.~MONITORING DURING SURGERY: monitor devices routinely used are connected to the participant: Dräger Infinity Delta XL®, Masimo® for pulse oximetry (Rainbow SET), regional cerebral oximetry (O3TM), and (optional) brain function monitoring (Masimo® SedLine). Arterial blood gas test is sampled at the anesthesiologist's discretion. After the artery catheterization, the MostCare® system is simultaneously connected to the patient monitoring devices. Data are collected every 3 minutes, 6 minutes for the noninvasive blood pressure measurement."
214546413|NCT04905849|BEHAVIORAL|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=\> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=\> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=\> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
214546414|NCT04905849|BEHAVIORAL|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
214546415|NCT04430257|OTHER|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
214546416|NCT04430257|BEHAVIORAL|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
214546417|NCT04430257|BEHAVIORAL|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
214546418|NCT04430257|BEHAVIORAL|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
214546419|NCT04430257|OTHER|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
214546420|NCT04430257|OTHER|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
214546421|NCT05010850|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
214546422|NCT05010850|PROCEDURE|Stoma Creation|Protective ileostomy
214546423|NCT02810873|DEVICE|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
214698917|NCT02981277|DRUG|Spray as you go|Lignocaine delivery using Spray as you go method
214698918|NCT04684914|BIOLOGICAL|HepTcell|Intramuscular injection
214698919|NCT04684914|DRUG|Placebo|Intramuscular injection
214698920|NCT06471998|DRUG|Sodium Chloride injection|"Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard treatment including stage I and II analgesics and physiotherapy in line with the recommendations of the French National Authority for Health.~At each session, 250ml to 500ml of physiological serum will be injected subcutaneously using a Meso-Kit-Perfuser\* or injection octopus positioned by the nurse according to the injection points defined by the investigating physician during the inclusion visit, with a dermographic tracer for surgical use."
214698921|NCT06313437|DRUG|Revumenib|Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
214698922|NCT06313437|DRUG|Midostaurin|Kinase inhibitor, capsule taken orally per protocol.
214546424|NCT02810873|DEVICE|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
214546425|NCT02810873|RADIATION|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
214546426|NCT02810873|DRUG|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
214546427|NCT00838929|DRUG|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
214546428|NCT00838929|RADIATION|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
214546429|NCT06181474|OTHER|ESAS|Observation of symptoms
214546430|NCT05362344|PROCEDURE|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
214546431|NCT04683510|OTHER|Navigation - Study Specific - Researcher Voice|The intervention is delivered over the telephone
214546432|NCT04683510|OTHER|Navigation - Study Specific - Cancer Survivor Voice|The intervention is delivered over the telephone
214546433|NCT04683510|OTHER|Navigation - Research General - Researcher Voice|The intervention is delivered over the telephone
214546434|NCT04683510|OTHER|Navigation - Research General - Cancer Survivor Voice|The intervention is delivered over the telephone
214546435|NCT04683510|OTHER|Brochure - Study Specific - Researcher Voice|The invention is mailed to the participant in a brochure.
214546436|NCT04683510|OTHER|Brochure - Study Specific - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
214546437|NCT04683510|OTHER|Brochure - Research General - Researcher Voice|The invention is mailed to the participant in a brochure.
214546438|NCT04683510|OTHER|Brochure - Research General - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
214698923|NCT06313437|DRUG|Cytarabine|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
214546439|NCT05365178|DRUG|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
214546440|NCT05365178|DRUG|Placebo|It is a placebo
214546441|NCT05365178|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
214546442|NCT06188559|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
214546443|NCT01076998|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
214546444|NCT01076998|OTHER|Refresh PM Ointment|1 drop in each eye, one time
214546445|NCT03764033|BEHAVIORAL|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
214546446|NCT03764033|BEHAVIORAL|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
214546447|NCT03522389|PROCEDURE|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
214698924|NCT06313437|DRUG|Daunorubicin|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
214698925|NCT03410927|DRUG|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
214698926|NCT05843110|OTHER|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
214546448|NCT03522389|PROCEDURE|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
214546449|NCT03522389|OTHER|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
214546450|NCT05368350|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
214546451|NCT05118854|DRUG|AMG 510|Given by IV
214546452|NCT05118854|DRUG|Cisplatin|Given by IV
214546453|NCT05118854|DRUG|Carboplatin|Given by IV
214698927|NCT03357809|PROCEDURE|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
214698928|NCT02566330|DEVICE|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
214698929|NCT00239772|BEHAVIORAL|Cognitive Processing Therapy|
214546454|NCT05118854|DRUG|Pemetrexed|Given by IV
214546455|NCT00814645|DRUG|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
214546456|NCT00814645|DRUG|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
214546457|NCT02257918|DRUG|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
214546458|NCT02257918|DRUG|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
214698930|NCT00239772|BEHAVIORAL|Prolonged Exposure Therapy|
214698931|NCT02841787|BEHAVIORAL|iCBT for late life depression|
214698932|NCT00607958|DRUG|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
214698933|NCT06418776|OTHER|Intensive therapy|Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
215160097|NCT06067152|DEVICE|Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial|"SRMs will be performed with a standardized ventilation protocol. Patient will be sedated, paralyzed and ventilated in pressure controlled mode, FIO2 to obtain SPO2\> 92%, RR 25, I:E =1:1.5. Alarm of pressure limit will be set at 35 cmH2O. The ventilator will be equipped with inspiratory and expiratory hold taste. Inspiratory and expiratory occlusion will be held for 5 seconds, data will be stored and analyzed with the ventilator own tool.~Decremental PEEP trial will start if plateau pressure 30 cmH2O will be reached or end inspiratory transpulmonary pressure will exceed 28 cmH2O value. Once reached this level of plateau or transpulmonary pressure, PEEP will be reduced in three steps from 12, 10 and finally to 8 cmH2O every 20 minutes"
214546459|NCT05082207|OTHER|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
215160098|NCT06067152|DEVICE|Setting of EIT-guided mechanical ventilation|Mechanical ventilation is set according to EIT measurement
214546460|NCT05082207|OTHER|sham group|a deflated cuff placed on the upper arm for 30 min
214546461|NCT02014883|DRUG|GLUT1 DS|
214698934|NCT06418776|OTHER|Low intensity therapy|Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
214698935|NCT00207103|DRUG|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
214698936|NCT00207103|DRUG|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
214698937|NCT00207103|DRUG|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
214698938|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
214698939|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
214698940|NCT00207103|DRUG|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
214698941|NCT01763268|BIOLOGICAL|Trivivac vaccine|Trivalent MMR vaccine
214698942|NCT03965832|DEVICE|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
214698943|NCT03965832|DEVICE|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
215160099|NCT06067152|DEVICE|Reevaluation after 24 h|Evaluation of mechanical ventilation and ventilation distribution through EIT after 24h of ventilation EIT-guided
215160100|NCT01847326|DRUG|carboplatin|Given IV
215160101|NCT01847326|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214546462|NCT02422225|DEVICE|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention\]~* Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~* Stimulation site \<Experimental group\>~  * Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~ * Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~ * Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit \<Control group\> Sham stimulation"
214546463|NCT02422225|DEVICE|Sham Eldith DC-STIMULATOR|
214546464|NCT06215859|DRUG|MR-107A-02|tablet
214546465|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
214546466|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
214546467|NCT04170491|DIAGNOSTIC_TEST|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
214546468|NCT05432921|BEHAVIORAL|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
214698944|NCT01521234|BEHAVIORAL|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
214698945|NCT04253977|BEHAVIORAL|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
215160102|NCT01847326|DRUG|fluorouracil|Given IV
214698946|NCT04253977|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
214698947|NCT01657448|DRUG|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
214698948|NCT01657448|DRUG|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
214698949|NCT00348634|DRUG|Tegaserod|
214698950|NCT02820376|OTHER|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
214698951|NCT01205555|DEVICE|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day."
215160103|NCT01847326|DRUG|hydroxyurea|Given PO
214698952|NCT00498108|DRUG|Rotigotine|
214698953|NCT02864537|OTHER|Training|Patients were trained to measure INR and dose warfarin
214698954|NCT04811248|OTHER|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
214698955|NCT00580177|PROCEDURE|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
214698956|NCT00580177|PROCEDURE|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
214698957|NCT00580177|PROCEDURE|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
214546469|NCT04403906|DIAGNOSTIC_TEST|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
214698958|NCT00853333|DRUG|dexmedetomidine|
214698959|NCT00853333|DRUG|midazolam|
214698960|NCT00853333|DRUG|propofol|
214698961|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with investigational device
214698962|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with reference device
214698963|NCT00917306|DRUG|PEP005 Gel|0.05% two day treatment
214698964|NCT01614236|DRUG|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
214698965|NCT01614236|DRUG|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
214698966|NCT04770987|OTHER|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
215160104|NCT01847326|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
215160105|NCT01847326|RADIATION|radiation therapy|Undergo radiation therapy
215160106|NCT01847326|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
215160107|NCT01847326|OTHER|laboratory biomarker analysis|Correlative studies
215160108|NCT01330108|DRUG|ambrisentan|ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
214546470|NCT05612646|PROCEDURE|Acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
214546471|NCT05612646|PROCEDURE|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
214546472|NCT02930252|DEVICE|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
214546473|NCT02930252|DEVICE|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
214546474|NCT00002740|BIOLOGICAL|filgrastim|
214546475|NCT00002740|DRUG|carboplatin|
214546476|NCT00002740|DRUG|cyclophosphamide|
214546477|NCT00002740|DRUG|doxorubicin hydrochloride|
214546478|NCT00002740|DRUG|etoposide|
214546479|NCT00002740|DRUG|mesna|
214546480|NCT00002740|DRUG|vincristine sulfate|
214546481|NCT00002740|PROCEDURE|conventional surgery|
214546482|NCT00002740|PROCEDURE|peripheral blood stem cell transplantation|
214546483|NCT00002740|RADIATION|low-LET cobalt-60 gamma ray therapy|
214546484|NCT00002740|RADIATION|low-LET photon therapy|
214546485|NCT02923193|DEVICE|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
214546486|NCT02923193|DRUG|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
214546487|NCT06061224|BEHAVIORAL|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
214546488|NCT01812798|OTHER|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
214546489|NCT02328586|OTHER|Group Acupuncture|
214698967|NCT04419285|BEHAVIORAL|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
214698968|NCT04419285|BEHAVIORAL|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
214546490|NCT00449345|PROCEDURE|Blood test for Quantiferon-GOLD assay|
214546491|NCT00003495|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214698969|NCT04419285|BEHAVIORAL|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
215160109|NCT00243269|BEHAVIORAL|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
214546492|NCT02634814|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
214546493|NCT02634814|OTHER|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
214546494|NCT02634814|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
215160110|NCT02437708|PROCEDURE|REP with L-PRF|
215160111|NCT02437708|PROCEDURE|REP|
215160112|NCT02437708|BIOLOGICAL|stem and progenitor cells|
215160113|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counseling A|Krill powder capsules
215160114|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counselling B|Placebo capsules
215160115|NCT00857714|DRUG|lapatinib|1500 mg lapatinib for 14-21 days
214546495|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA."
214546496|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
214546497|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
214546498|NCT03766373|COMBINATION_PRODUCT|Drug: OP0201 20mg|OP0201
214546499|NCT03766373|COMBINATION_PRODUCT|Drug: Placebo 0mg|Placebo
214546500|NCT06201546|PROCEDURE|TAP block group|TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
214546501|NCT06201546|PROCEDURE|m-TAPA block group|m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
214546502|NCT03750253|OTHER|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
214546503|NCT00004448|DRUG|omega-3 fatty acids|
214546504|NCT00004448|DRUG|prednisone|
214546505|NCT00004448|DRUG|Placebo|
214546506|NCT03298269|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
214546507|NCT03298269|BEHAVIORAL|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
214546508|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
214546509|NCT02324478|PROCEDURE|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
214546510|NCT06976424|DRUG|Eflornithine Topical|Eflornithine cream will be applied to the face of group B female patients
214546511|NCT06976424|RADIATION|Instense pulsed light|Intense pulse light will be applied to the face of patient of Group A on areas having increase hair. Patient will be called for a followup every month for next session.
214546512|NCT06976424|DRUG|Eflornithine Topical|Eflornithine will be given to group A patient along with intense pulsed light and results will be compared to group B who recieved only Eflornithine cream
215160116|NCT03085797|DRUG|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
215160117|NCT03085797|DRUG|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
215160118|NCT03085797|DRUG|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
215160119|NCT00545272|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
215160120|NCT00545272|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
214546513|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
214546514|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
214546515|NCT05441982|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
214546516|NCT00915785|DRUG|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
214546517|NCT03494985|DEVICE|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
214546518|NCT03494985|DEVICE|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
214546519|NCT03494985|DEVICE|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
214546520|NCT03494985|OTHER|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
214546521|NCT00581841|OTHER|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
215160121|NCT00545272|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
215160122|NCT00545272|DRUG|placebo to formoterol|Placebo AEROLIZER® device
215160123|NCT00545272|DRUG|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
215160124|NCT02049541|DRUG|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
214698970|NCT05280431|DEVICE|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects (on a plane or in the space)~* exergames.~A subset of exercises is defined based on the patient's capability."
214698971|NCT05280431|DEVICE|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
214698972|NCT05280431|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Occupational therapy exercises~* Constraint-induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training"
214698973|NCT03029650|DRUG|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
214698974|NCT03029650|DRUG|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
214698975|NCT01449201|DRUG|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
214698976|NCT01875367|DRUG|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
214698977|NCT01875367|DRUG|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
214698978|NCT01875367|DRUG|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
214698979|NCT02987348|DRUG|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
214698980|NCT02987348|DRUG|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
214698981|NCT02987348|DRUG|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
214698982|NCT00256087|DRUG|Probiotic Lactobacillus|
215160125|NCT02049541|BIOLOGICAL|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
215160126|NCT02049541|OTHER|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
215160127|NCT02049541|OTHER|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
214698983|NCT00256087|OTHER|Lactose Powder|
214698984|NCT05683652|DEVICE|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
214698985|NCT00230529|DRUG|infliximab|
214698986|NCT02754830|DRUG|LY3303560 - IV|Administered IV
214698987|NCT02754830|DRUG|Saline Solution - IV|Administered IV
215160128|NCT01837823|DRUG|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
215160129|NCT00865540|DRUG|prednisolone acetate 1%|1 drop every 8h two days before surgery
214698988|NCT02754830|DRUG|LY3303560 - SC|Administered SC
214698989|NCT05418062|BEHAVIORAL|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
215160130|NCT00865540|DRUG|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
215160131|NCT00865540|DRUG|nepafenac 0.1%|1 drop every 8h two days before surgery
215160132|NCT00865540|DRUG|methylcellulose 0.5%|1 drop every 8h two days before surgery
215160133|NCT00792493|DRUG|ORM-12741|Alternating panel multiple dose escalation
215160134|NCT00927004|DRUG|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
215160135|NCT00927004|DRUG|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
215160136|NCT00047164|BIOLOGICAL|ipilimumab|
215160137|NCT04466579|OTHER|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
215160138|NCT04466579|OTHER|Standard care|Standard anesthesiology care according to the protocol of the study
215160139|NCT03848182|DRUG|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
215160140|NCT03848182|BIOLOGICAL|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
215160141|NCT01697514|DRUG|LY2940680|Capsule administered orally.
215160142|NCT01697514|DRUG|LY2940680|Powder administered orally (may be sprinkled on soft food).
215160143|NCT04841642|OTHER|MANUAL THERAPY|The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
214546522|NCT06297031|OTHER|heat application|• Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
214546523|NCT05742568|DRUG|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
214546524|NCT05742568|DRUG|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
214546525|NCT05742568|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
214546526|NCT05742568|DRUG|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
214546527|NCT05742568|DRUG|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
214546528|NCT05742568|DRUG|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
214546529|NCT06028594|DRUG|Pozelimab|Subcutaneous (SC) administration
214698990|NCT02634931|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
214698991|NCT04533815|BEHAVIORAL|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
214698992|NCT05146583|PROCEDURE|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
214546530|NCT06028594|DRUG|Cemdisiran|Subcutaneous (SC) administration
214698993|NCT05146583|PROCEDURE|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
214698994|NCT06041295|BEHAVIORAL|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
214698995|NCT06102642|BIOLOGICAL|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
215160144|NCT04841642|OTHER|THERAPEUTIC EXERCISE|"The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
215160145|NCT01132781|DRUG|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
214698996|NCT03312712|RADIATION|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
214698997|NCT03312712|OTHER|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
215160146|NCT01132781|DRUG|Placebo (Placebo Group)|200 mg twice daily of placebo drug
214546531|NCT00244686|DRUG|Mepolizumab|open label investigational product
214546532|NCT06194032|DRUG|Baxdrostat|Participants will receive baxdrostat as two separate doses.
214546533|NCT06194032|DRUG|Placebo|Participants will receive baxdrostat matching placebo.
214546534|NCT06194032|DRUG|Moxifloxacin|Participants will receive a single dose moxifloxacin
214546535|NCT05424094|BEHAVIORAL|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
214546536|NCT04359264|OTHER|Cash transfer|Cash transfer of $1000
214546537|NCT04274699|DIAGNOSTIC_TEST|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
214546538|NCT02282059|DRUG|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
214698998|NCT03312712|OTHER|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
214698999|NCT03312712|DIAGNOSTIC_TEST|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
215160147|NCT02686723|OTHER|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
214546539|NCT03115671|DIETARY_SUPPLEMENT|Vayarin|Vayarin capsule
215160148|NCT02936648|OTHER|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
215160149|NCT00306826|DRUG|pioglitazone|
215160150|NCT00306826|DRUG|simvastatin|
215160151|NCT00306826|DRUG|pioglitazone + simvastatin|
214546540|NCT04156893|BIOLOGICAL|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
214546541|NCT05900986|DRUG|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
214546542|NCT05900986|DRUG|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
214546543|NCT05900986|DRUG|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
214546544|NCT05900986|DRUG|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
214546545|NCT04498754|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
214546546|NCT04498754|BEHAVIORAL|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
214546547|NCT01793662|PROCEDURE|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
214546548|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
214546549|NCT04906954|OTHER|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
214546550|NCT06022055|OTHER|Blood and tissue collection|"Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research."
214546551|NCT05708313|BEHAVIORAL|lifestyle modification|Participants will undergo an exercise program designed by AHH
214546552|NCT04979156|PROCEDURE|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
214546553|NCT06334640|DIAGNOSTIC_TEST|Three questionaires|Berlin, Pittsburgh and Epworth tests administered during study visit
214546554|NCT05619822|BEHAVIORAL|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES\_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
214546555|NCT05619822|BEHAVIORAL|TAU|Treatment as usual
214546556|NCT05093504|DEVICE|Sham comparator|Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit
214546557|NCT05093504|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
214546558|NCT02574351|BIOLOGICAL|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
214546559|NCT00439361|DRUG|Bortezomib|1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
214546560|NCT00439361|DRUG|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
214546561|NCT00439361|DRUG|Etoposide|100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
214546562|NCT00439361|DRUG|Ifosfamide|5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
214546563|NCT00439361|DRUG|Mesna|5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
215160152|NCT00004554|DRUG|naltrexone (Revia)|100mg/day
215160153|NCT00004554|DRUG|sertraline (Zoloft)|200mg/day
215160154|NCT00004554|DRUG|Placebo|Placebo
215160155|NCT01934595|DIETARY_SUPPLEMENT|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
214699000|NCT01562366|DEVICE|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
214699001|NCT01562366|PROCEDURE|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
214699002|NCT01220986|PROCEDURE|Liver biopsy|0, 30, 60, 90 min post inflow-division
214699003|NCT04222933|DEVICE|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
214699004|NCT04222933|DEVICE|Classical cryotherapy|application of an ice bag
214699005|NCT06250517|DEVICE|EVLP|The right lung will be perfused for 3h with EVLP
214699006|NCT06250517|DEVICE|Cold preservation|The left lung will be cold preserved as usual protocol
214699007|NCT02082314|PROCEDURE|RFA Vertebroplasty|
214699008|NCT02951988|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
214699009|NCT02951988|DRUG|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
214699010|NCT03053596|DEVICE|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
214699011|NCT00307060|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
214699012|NCT00307060|DRUG|losartan / Duration of Treatment: 6 weeks|
214699013|NCT02955654|BEHAVIORAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
214699014|NCT02955654|DRUG|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
214699015|NCT02955654|BEHAVIORAL|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
214546564|NCT06276114|DEVICE|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
214546565|NCT04684771|DIETARY_SUPPLEMENT|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
214546566|NCT04684771|DIETARY_SUPPLEMENT|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
214546567|NCT02394925|DEVICE|Multifocal Test Contact lens|Used in a daily wear modality
214546568|NCT02134847|OTHER|SCS intervention schedule|
214546569|NCT04592809|DRUG|Ketamine Hydrochloride|infused over a 40 minute period
214546570|NCT04592809|DRUG|Midazolam Hydrochloride|infused over a 40 minute period
214546571|NCT02272244|BEHAVIORAL|Decision Support & Navigation|
214546572|NCT02272244|BEHAVIORAL|Standard|
214546573|NCT03430661|DRUG|ACT-246475|Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
214546574|NCT03430661|DRUG|Clopidogrel|Tablet for oral administration (300 or 600 mg)
214699016|NCT05836818|OTHER|Question (Q)|Flu vaccine acceptance question: a question asked of participants about their willingness to accept a flu vaccine
214699017|NCT05836818|OTHER|Messaging (M)|Flu vaccine educational materials -videos and flyers containing flu vaccine educational information
214699018|NCT01951014|OTHER|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
214699019|NCT04702555|DRUG|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
214699020|NCT02580916|OTHER|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
214699021|NCT05930392|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
214546575|NCT03430661|DRUG|Prasugrel|Tablet for oral administration (60 mg)
214546576|NCT03430661|DRUG|Placebo|Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
214546577|NCT03430661|DRUG|Ticagrelor|Tablet for oral administration (180 mg)
214546578|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
214699022|NCT05930392|PROCEDURE|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
214699023|NCT03977727|DRUG|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
214699024|NCT03977727|DRUG|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
214699025|NCT03977727|DEVICE|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
215160156|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
214546579|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
214546580|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
214546581|NCT00151827|DRUG|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
214546582|NCT00151827|DRUG|Losartan|Medications are taken once daily before breakfast with water.
214546583|NCT00151827|DRUG|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
214546584|NCT03670277|DEVICE|etafilcon A|Test Soft Contact Lens
214546585|NCT03670277|DEVICE|Habitual Orthokeratology Lenses|CONTROL
214546586|NCT00702598|BEHAVIORAL|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
214546587|NCT00702598|BEHAVIORAL|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
214546588|NCT04339374|DEVICE|Photoacoustic imaging, photoacoustic microscopy|-Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise -The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers -The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)
214546589|NCT04339374|DEVICE|Endorectal photoacoustic imaging probe|-An endorectal imaging device using coregistered photoacoustic and ultrasound imaging has been constructed. This probe is used to perform in vivo imaging among patients with rectal pathology intraoperatively.
214546590|NCT04339374|OTHER|Reader Performance|After initial training, the study surgeon will grade the lesion as either PAM/US non-cCR or PAM/US cCR at the time of PAM/US imaging. The study radiologist, blinded from the surgeon's read, will also grade the lesion based on MRI. PAM/US-CNNs provide a real-time imaging tool to assist the reader team in diagnosis. The pathological outcomes of the patients will be assessed based on Tumor Regression Score by standard pathologic evaluation. The study will evaluate the effect of the assistance of PAM/US-CNNs for trained readers on their performance i.e. sensitivity and specificity of their diagnosis of rectal cancers from images obtained from the testing cohort of (Group 2) patients.
214546591|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
214546592|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
214546593|NCT00212992|PROCEDURE|Fixed lower-energy defibrillation|Every shock administered at 150 J
214546594|NCT00212992|PROCEDURE|Escalating higher-energy defibrillation|First shock administered at 200 J, second shock at 300 J, all subsequent shocks at 360 J
215160157|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
214546595|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
214546596|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
214546597|NCT00578578|DIETARY_SUPPLEMENT|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
214546598|NCT05954182|BEHAVIORAL|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
214546599|NCT02774668|OTHER|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
214546600|NCT02774668|OTHER|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
214546601|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
214546602|NCT03906032|DEVICE|TFNA IM Nail|IM nail
214546603|NCT03906032|DEVICE|Sliding hip screw|SHS surgical fixation
214546604|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
214546605|NCT06242925|DEVICE|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
214546606|NCT06371586|DRUG|Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy|Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
214546607|NCT06859398|OTHER|Ocular Topography and Wavefront Aberrometry|Eyescan with Pentacam AXL Wave
214546608|NCT05347485|DRUG|Cilta-cel|Cilta-cel will be administered as an IV infusion.
214546609|NCT05347485|DRUG|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
214546610|NCT05423041|DIAGNOSTIC_TEST|BOSS Imaging|Biomechanical Imaging of Cornea and Lens
214546611|NCT00541151|DEVICE|MiniArc|sling system
215160158|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
215160159|NCT03479164|OTHER|Ultra Low-Dose CT|Ultra Low-Dose CT
215160160|NCT02914301|DEVICE|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
215160161|NCT02914301|DEVICE|Placebo|No Mobile App, Usual care
215160162|NCT04765267|DIETARY_SUPPLEMENT|Zinc sulphate heptahydrate|Dietary supplements
215160163|NCT03213171|BEHAVIORAL|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
215160164|NCT03213171|BEHAVIORAL|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
215160165|NCT01145677|DRUG|Topiramate|Topiramate 100-300 mg/day orally twice per day
215160166|NCT05067699|DIAGNOSTIC_TEST|Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)|The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
215160167|NCT00549068|DRUG|Risedronate Sodium (Actonel)|
215160168|NCT06392399|DEVICE|cooled radiofrequency ,|In Cooled RF, after placement of the introducer needle, the 18 gauge internally cooled RF electrode is used for 90 seconds at a temperature of 60°C.
215160169|NCT06392399|DEVICE|conventional radiofrequency|In conventional RF group lesion will be performed at 80°C for 120 seconds.
214546612|NCT04886518|DRUG|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
214546613|NCT04886518|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
214546614|NCT03034096|DRUG|Propofol|Maintenance of general anesthesia with propofol infusion
214546615|NCT03034096|DRUG|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
215160170|NCT06392399|DEVICE|neurolysis of ganglion|In neurolytic block, Once the position of the needle tip confirmed, 4 - 6 mL of 8% phenol in saline will be injected followed by 1 mL of saline to avoid the deposition of phenol within the intervertebral disc material.
215160171|NCT04981535|DEVICE|Head box during upper gastrointestinal endoscopy|"็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy."
215160172|NCT04192383|RADIATION|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
215160173|NCT00126334|PROCEDURE|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
215160174|NCT05941195|OTHER|Psychoeducation|"In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included."
215160175|NCT03870243|DEVICE|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
215160176|NCT03870243|DEVICE|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
215160177|NCT02165267|BIOLOGICAL|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
215160178|NCT02165267|BIOLOGICAL|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
214546616|NCT06735482|BEHAVIORAL|Therapeutic play program|Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
214546617|NCT05896644|OTHER|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
214546618|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
214546619|NCT06899711|DEVICE|External Cranial Prosthesis|The external cranial prosthesis is a 3D printed external plate that approximates patients' post-craniectomy skull defect. The prosthesis is made from the same material used in other external Craniofacial prostheses. Patients will be counseled on securing it properly and comfortably on their scalp. Patients will be asked to wear this prosthesis as much as possible until Cranioplasty takes place. After Cranioplasty, the participant will be asked to stop wearing the prosthesis.
214546620|NCT03733899|DIAGNOSTIC_TEST|Local Anesthesia|Minims Proxymetacaine hydrochloride Eye Drops
214546621|NCT03733899|DIAGNOSTIC_TEST|Placebo|Sodium Chloride Solution
214546622|NCT06945770|BEHAVIORAL|POLSIS|web based smoking cessation psycho-education
215160179|NCT02165267|BIOLOGICAL|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
215160180|NCT01782248|OTHER|Questionnary and IRM|
214546623|NCT06945770|DRUG|routine service delivery(Nicotine Replacement Theraphy, Cytisine)|routine smoking cessation service delivery
214546624|NCT06944366|OTHER|Imagery intervention|Imagery rescripting or imaginal exposure
214546625|NCT06945445|DRUG|SLN12140|SLN12140 for sc injection or IV infusion
214546626|NCT06945445|OTHER|Placebo|Placebo for sc injection or IV infusion
214546627|NCT02604563|OTHER|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
214546628|NCT02604563|OTHER|Activities of Daily Living Questionnaire|"* 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
215160181|NCT03893461|RADIATION|x|Stereotactic body radiation therapy for localized NSCLC
214546629|NCT02604563|OTHER|Instrumental Activities of Daily Living, subscale of the OARS|"* 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
214546630|NCT02604563|OTHER|Karnofsky Self-reported Performance Rating Scale|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
214546631|NCT02604563|OTHER|Number of Falls|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
214546632|NCT02604563|OTHER|Physical Health Section, subscale of the OARS|"* 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death"
214546633|NCT02604563|OTHER|MOS Social Activity Survey|"* 4 items about social activity~* Baseline and no more frequently than every 6 months until death"
214546634|NCT02604563|OTHER|Unintentional Weight Loss|"* 2 items about nutrition~* Baseline and no more frequently than every 6 months until death"
214546635|NCT02604563|GENETIC|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
215160182|NCT03504176|OTHER|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
215160183|NCT04956913|DEVICE|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
215160184|NCT04956913|DEVICE|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
215160185|NCT05751018|DRUG|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
215160186|NCT02088138|DEVICE|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
214546636|NCT02604563|GENETIC|Buccal Swab|"* Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death"
214546637|NCT02604563|OTHER|Heart Health and Smoking History from BRFSS questionnaire|"* 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death"
215160187|NCT02088138|DEVICE|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
215160188|NCT02137915|BIOLOGICAL|Human Central Nervous System Stem Cells|
215160189|NCT01576900|BEHAVIORAL|SyBeMeP (Systemized Behavioural Modification education Program)|"* Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
215160190|NCT03622918|DRUG|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
215160191|NCT03622918|DRUG|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
215160192|NCT01923272|DEVICE|AlphaCore Device|Active stimulation to the vagal nerve
215160193|NCT01923272|DEVICE|AlphaCore|Active AlphaCore treatment
215160194|NCT05202340|OTHER|No intervention|No intervention
215160195|NCT05106699|RADIATION|proton plus carbon ion radiation|All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
215160196|NCT01757353|BEHAVIORAL|BASICS motivational interview|
215160197|NCT01757353|BEHAVIORAL|BASICS plus normative enhancement motivational interview|
215160198|NCT01757353|BEHAVIORAL|Self-directed: Information only|
215160199|NCT00436345|DRUG|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
215160200|NCT00436345|DRUG|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
215160201|NCT04660097|DRUG|Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer|This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
215160202|NCT00842491|DRUG|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
215160203|NCT00842491|DRUG|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
215160204|NCT00842491|DRUG|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
215160205|NCT03609606|DRUG|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
215160206|NCT03609606|DRUG|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
215160207|NCT03609606|DRUG|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
215160208|NCT06319950|DRUG|Furmonertinib|Furmonertinib, 160mg po qd
214546638|NCT02604563|OTHER|Gait Speed|"* Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death"
214546639|NCT02604563|OTHER|Grip Strength|"* Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death"
214546640|NCT02604563|OTHER|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
214546641|NCT02604563|OTHER|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
214546642|NCT02604563|PROCEDURE|Optional bone marrow biopsy|-1 optional bone marrow biopsy
214546643|NCT02604563|PROCEDURE|Blood draw for trauma measurements|-For Arm E only
214546644|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
214546645|NCT00616590|OTHER|medical chart review|
215160209|NCT06319950|DRUG|Osimertinib|Osimertinib，80mg po qd
214546646|NCT00616590|OTHER|questionnaire administration|
214546647|NCT00616590|PROCEDURE|fatigue assessment and management|
214546648|NCT00616590|PROCEDURE|quality-of-life assessment|
214546649|NCT03243097|DEVICE|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
214699026|NCT03551301|OTHER|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
214699027|NCT00918476|DRUG|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
214699028|NCT03448718|DRUG|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
214699029|NCT04355312|DIAGNOSTIC_TEST|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
214699030|NCT02661607|PROCEDURE|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
214699031|NCT02661607|DEVICE|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
214699032|NCT02661607|PROCEDURE|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
214699033|NCT06499545|OTHER|Pressure release|Release of pre-pressure at the latent trigger point of flexor digitorum brevis
214699034|NCT06499545|OTHER|Non emision Laser|Non emision laser in Flexor digitorum brevis latent trigger point
214699035|NCT04834882|OTHER|Data collection (|online survey
214699036|NCT00862966|OTHER|citrate|comparison of different catheter lock solutions
214699037|NCT00862966|OTHER|heparin|comparison of different lock solutions
214699038|NCT00150371|DRUG|atorvastatin|
214699039|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
214699040|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
214699041|NCT05990764|OTHER|Placebo|"placebo~Once a day"
214546650|NCT03243097|DEVICE|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
214546651|NCT03243097|DEVICE|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
214699042|NCT01982604|DRUG|TI-Inhalation Powder A|Inhaled Insulin
214546652|NCT04350099|OTHER|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
214546653|NCT05249647|OTHER|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
214546654|NCT05249647|OTHER|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
214546655|NCT04446806|DRUG|Ruxolitinib|Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore
214546656|NCT02895919|OTHER|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
214546657|NCT00113815|DRUG|topiramate|15 mg/kg/day
214546658|NCT00113815|DRUG|topiramate|5 mg/kg/day
214699043|NCT01982604|DRUG|TI-Inhalation Powder B|Inhaled Insulin
214699044|NCT03037658|OTHER|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
214699045|NCT04190784|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
214699046|NCT04190784|OTHER|Placebo stretching|The therapist maintains the same manual contact without stretching force.
214699047|NCT05080179|BEHAVIORAL|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
214699048|NCT05080179|BEHAVIORAL|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
214699049|NCT05080179|BEHAVIORAL|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
214699050|NCT05080179|BEHAVIORAL|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
214699051|NCT03945045|PROCEDURE|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
214699052|NCT03945045|PROCEDURE|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
214699053|NCT02848300|DRUG|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
214699054|NCT02848300|DRUG|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
214699055|NCT00143221|DRUG|Viagra|
214699056|NCT00143221|DRUG|Placebo|
214699057|NCT00603980|DRUG|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
214699058|NCT00603980|DRUG|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
214546659|NCT00113815|DRUG|topiramate|25 mg/kg/day
214699059|NCT00603980|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
214699060|NCT00603980|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
215160210|NCT05358613|BEHAVIORAL|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
215160211|NCT05114642|DEVICE|Skeletal Class III Malocclusion Treatment with Face Mask Group|Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
214546660|NCT00113815|DRUG|placebo|placebo
214546661|NCT04420039|DEVICE|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
214546662|NCT04560751|DRUG|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
214546663|NCT04560751|PROCEDURE|TACE|TACE will be performed as needed.
214546664|NCT04445298|DIAGNOSTIC_TEST|Transepidermal water loss|We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
214699061|NCT00603980|DRUG|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
214699062|NCT00603980|DRUG|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
214699063|NCT00603980|DRUG|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
214699064|NCT00603980|DRUG|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
214699065|NCT00603980|DRUG|Oral placebo qualifying session|Qualifying control session (oral placebo)
214699066|NCT03986346|DEVICE|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
214699067|NCT03986346|OTHER|standardized care|the scar will receive standardized care such as scar massage.
214699068|NCT01957826|OTHER|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
214699069|NCT01957826|OTHER|placebo intervention|placebo administration
214699070|NCT02683525|DRUG|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
214699071|NCT01660087|DEVICE|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
214699072|NCT06117800|OTHER|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
214699073|NCT04265586|BEHAVIORAL|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
214546665|NCT04445298|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
214546666|NCT04445298|DIAGNOSTIC_TEST|Blood draw|We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
214546667|NCT04445298|DIAGNOSTIC_TEST|Bacterial PCR swab|Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
214546668|NCT02859077|DRUG|EGFR-TKI|EGFR-TKI (gefitinib)
214546669|NCT02859077|DRUG|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
214546670|NCT02859077|DRUG|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
214546671|NCT06119347|DRUG|AntiVEGF|anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
214699074|NCT04265586|BEHAVIORAL|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
214699075|NCT06377800|OTHER|navicular mobilization along conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
215160212|NCT01067092|BEHAVIORAL|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
214546672|NCT06119347|DRUG|ICIs|immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
214546673|NCT00234598|PROCEDURE|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
214546674|NCT00234598|PROCEDURE|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
214546675|NCT00234598|PROCEDURE|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
214546676|NCT02852356|DEVICE|MIRI-TL Incubator|MIRI-TL Timelapse incubator
214546677|NCT01689363|DRUG|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
214546678|NCT01689363|DRUG|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
214546679|NCT01689363|DRUG|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
214546680|NCT02104505|DRUG|Gamma Tocopherol 700 mg capsules,|2 capsules daily
214546681|NCT02104505|DRUG|Placebo|Safflower oil capsules
214546682|NCT06137612|DIAGNOSTIC_TEST|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
214546683|NCT02665585|PROCEDURE|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
214546684|NCT02859064|DRUG|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
214546685|NCT02859064|DEVICE|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
214546686|NCT01076764|DRUG|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546687|NCT01076764|DRUG|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546688|NCT01076764|DRUG|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546689|NCT01076764|DRUG|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546690|NCT01076764|DRUG|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546691|NCT01076764|DRUG|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
214546692|NCT02448498|BEHAVIORAL|Exercise Intervention|
214546693|NCT04928807|COMBINATION_PRODUCT|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
214546694|NCT02155049|DRUG|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
214546695|NCT00404885|DRUG|Placebo|PO BID
214546696|NCT00404885|DRUG|LX211|0.2 mg/kg, twice a day (BID)
214546697|NCT00404885|DRUG|LX211|0.4 mg/kg, twice a day (BID)
214546698|NCT00404885|DRUG|LX211|0.6 mg/kg, twice a day (BID)
214546699|NCT04142411|DRUG|Insulin|Ultrasound guided perineural injection therapy (PIT)
214546700|NCT04142411|DRUG|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
214546701|NCT04142411|DEVICE|Ultrasound|Philips Neuromuscular Ultrasound
214546702|NCT02414009|DRUG|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
214699076|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
214699077|NCT02114567|OTHER|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
214699078|NCT00158548|DRUG|SP, chloroquine, amodiaquine, primaquine, artesunate|
215160213|NCT01067092|BEHAVIORAL|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
214699079|NCT01912430|BEHAVIORAL|ICC (Integrated Care Coaching) Intervention Group|
214699080|NCT01627067|DRUG|Everolimus|10 mg by mouth once daily.
214699081|NCT01627067|DRUG|Exemestane|25 mg by mouth once daily.
215160214|NCT01175083|BIOLOGICAL|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
215160215|NCT01175083|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
215160216|NCT01175083|BIOLOGICAL|Polio Sabin|4 oral doses
215160217|NCT01623713|DRUG|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
215160218|NCT01623713|DRUG|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
214699082|NCT01627067|DRUG|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
214699083|NCT04972344|DIAGNOSTIC_TEST|Ionized magnesium|Assessment of ionized magnesium level
214699084|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
215160219|NCT02467686|BEHAVIORAL|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
215160220|NCT02467686|BEHAVIORAL|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
215160221|NCT02467686|BEHAVIORAL|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
214699085|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
214699086|NCT00711269|DRUG|Placebo|
214699087|NCT00711269|DRUG|Risperidone|
214699088|NCT00537550|DRUG|Vincristine|Steroids pre-treatment
214699089|NCT00537550|DRUG|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
214699090|NCT01700517|OTHER|Spinal anesthesia|spinal anesthesia
215160222|NCT02467686|DRUG|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
215160223|NCT02467686|DRUG|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
215160224|NCT02467686|DRUG|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
215160225|NCT00254384|DRUG|Cisplatin|Given IV
214546703|NCT02414009|DRUG|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
214546704|NCT02414009|DRUG|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
214546705|NCT02414009|DRUG|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
214699091|NCT01700517|OTHER|Femoral nerve block|Femoral nerve block
214699092|NCT01700517|OTHER|sciatic nerves block|sciatic nerves block
214699093|NCT02215993|DRUG|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
214699094|NCT02215993|DRUG|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
214699095|NCT00926796|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
214699096|NCT00926796|DRUG|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
214699097|NCT00926796|DRUG|Gemifloxacin|One 320 mg tablet administered orally.
214699098|NCT05414708|BEHAVIORAL|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
215160226|NCT00254384|DRUG|Docetaxel|Given IV
215160227|NCT00254384|DRUG|Erlotinib|Given PO
215160228|NCT00254384|DRUG|Erlotinib Hydrochloride|Given PO
215160229|NCT00254384|OTHER|Laboratory Biomarker Analysis|Correlative studies
215160230|NCT03482960|DRUG|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses."
215160231|NCT03482960|DRUG|PFP|"* Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
215160232|NCT05855148|PROCEDURE|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
215160233|NCT00267813|DRUG|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
215160234|NCT01783704|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
215160235|NCT01783704|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
215160236|NCT01783704|BEHAVIORAL|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
215160237|NCT02056262|OTHER|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
215160238|NCT02056262|BIOLOGICAL|Saliva sampling|A saliva sample will be harvested.
215160239|NCT02056262|BIOLOGICAL|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
215160240|NCT04159311|OTHER|Osteopathy|testing osteopathy Vs Treating osteopathy
215160241|NCT04407949|OTHER|CPAP Treatment|Comparing events from the CPAP device with the events scored in PSG
215160242|NCT02637830|OTHER|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
215160243|NCT02637830|OTHER|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
215160244|NCT02637830|OTHER|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
215160245|NCT00475306|DRUG|metoclopramide 10 mg|an anti-emetic medication
215160246|NCT00475306|DRUG|Diphenhydramine 25 mg|used for prophylaxis against akathisia
215160247|NCT00475306|DRUG|Placebo|placebo
215160248|NCT00475306|DRUG|Metoclopramide 20 mg|Metoclopramide 20 mg
215160249|NCT02812251|DRUG|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
215160250|NCT02812251|DRUG|Placebo|Matching placebo will be administered.
215160251|NCT00985361|DIETARY_SUPPLEMENT|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
215160252|NCT00985361|DIETARY_SUPPLEMENT|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
215160253|NCT01716052|DRUG|placebo|Lactulose
215160254|NCT01716052|DRUG|Ibuprofen|
215160255|NCT01042041|DRUG|sorafenib tosylate|Given orally
214546706|NCT02414009|DRUG|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
214546707|NCT00321685|BIOLOGICAL|Bevacizumab|Given IV
214546708|NCT00321685|DRUG|Capecitabine|Given PO
215160256|NCT01042041|DRUG|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
215160257|NCT01042041|DRUG|cisplatin|Given via transarterial/hepatic chemoembolization
215160258|NCT01042041|DRUG|mitomycin C|Given via transarterial/hepatic chemoembolization
215160259|NCT01042041|PROCEDURE|transarterial chemoembolization|
215160260|NCT01042041|PROCEDURE|hepatic artery embolization|
215160261|NCT03383341|DIETARY_SUPPLEMENT|Cricket Protein Powder|Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
214546709|NCT00321685|DRUG|Fluorouracil|Given IV
214546710|NCT00321685|DRUG|Leucovorin Calcium|Given IV
214546711|NCT00321685|DRUG|Oxaliplatin|Given IV
214546712|NCT00321685|RADIATION|Radiation Therapy|Undergo radiotherapy
214546713|NCT00321685|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214546714|NCT04470661|DIAGNOSTIC_TEST|Ultrasonography|"Point-of-care ultrasound:~1. Kidney length and echogenity,~2. Bladder scanning~3. VCI measures~4. Lung B lines and effusion~5. Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
214546715|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
214546716|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
214699099|NCT01628016|BEHAVIORAL|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
214699100|NCT01341652|BIOLOGICAL|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
214699101|NCT01341652|BIOLOGICAL|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
214699102|NCT02801162|DEVICE|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
214699103|NCT02801162|DEVICE|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
214699104|NCT06263634|OTHER|Hand exercises|30-45 minutes of home exercises consisting of stretching, mobility and strengthening
214699105|NCT02410707|DRUG|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
214699106|NCT02410707|DRUG|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
214699107|NCT02410707|DRUG|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
215160262|NCT03383341|OTHER|Placebo control|Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
214699108|NCT04975971|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
214699109|NCT03502252|BEHAVIORAL|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
215160263|NCT05437497|DRUG|Remimazolam Injection|The experimental group was sedated with remimazolam
215160264|NCT05437497|DRUG|Propofol Injection|The control group was sedated with propofol
215160265|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
214546717|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
214546718|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
214546719|NCT05203705|DRUG|Enoxaparin|Enoxaparin, for 12 days
214546720|NCT05286463|COMBINATION_PRODUCT|bee venom gel phonophoresis|a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
214546721|NCT05286463|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
215160266|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
215160267|NCT04056832|PROCEDURE|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
214546722|NCT04066517|PROCEDURE|SBRT|Multimodal-imaging guided SBRT for VT ablation.
214546723|NCT05815537|OTHER|Low-Reverberation|The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.
214546724|NCT05815537|OTHER|High-Reverberation|The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
214546725|NCT02573272|DRUG|eslicarbacepine|
214546726|NCT02619526|DRUG|Nebivolol|Nebivolol 10mg, once a day
214546727|NCT02619526|DRUG|Carvedilol|Carvedilol 25mg, twice a day
214699110|NCT03798912|COMBINATION_PRODUCT|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
214699111|NCT01260766|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
214699112|NCT01260766|DEVICE|Placebo Patch|same as active patch
214699113|NCT04926194|BIOLOGICAL|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
214699114|NCT02460757|OTHER|Laryngoscopy|Observation of glottic width in different arms
214699115|NCT06266273|OTHER|No intervention|No intervention
214699116|NCT02645058|PROCEDURE|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
214699117|NCT02645058|PROCEDURE|ESWL|Treatment by extracorporeal shock waves lithotripsy
214699118|NCT02645058|DEVICE|Rigid and flexible ureteroscope|
214699119|NCT02645058|DEVICE|Lithotripter|
214699120|NCT02645058|DEVICE|Holmium laser|
214699121|NCT02645058|DEVICE|Basket for fragment removal|
214699122|NCT02645058|PROCEDURE|General or spinal anesthesia|
214699123|NCT02645058|DRUG|Intravenous pain medication|If required by the patient
214546728|NCT04533009|PROCEDURE|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
214546729|NCT00172939|PROCEDURE|foreskin from healthy adults|
214546730|NCT01019239|PROCEDURE|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
214546731|NCT01019239|PROCEDURE|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
214546732|NCT00127842|DRUG|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
214699124|NCT02645058|DEVICE|X-ray|To focus the stone
214699125|NCT02645058|DEVICE|Ultrasound|To focus the stone
214699126|NCT00632463|BIOLOGICAL|RI-001|Dose 1
214699127|NCT00632463|BIOLOGICAL|RI-001|Dose 2
214699128|NCT00632463|BIOLOGICAL|RI-001|Placebo
214699129|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699130|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699131|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699132|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699133|NCT00586924|DRUG|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699134|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
214699135|NCT05339724|OTHER|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
214699136|NCT03185455|OTHER|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
214699137|NCT03010995|DRUG|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
214699138|NCT03483506|DRUG|BI 1467335|Film-coated tablet
214699139|NCT03483506|DRUG|BI 1467335 (C-14) intravenous solution|Intravenous solution
214546733|NCT01589926|DEVICE|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
214546734|NCT01589926|DEVICE|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
214699140|NCT02634918|OTHER|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
214699141|NCT05250271|OTHER|15 g dextrose|15 g dextrose tablets
214699142|NCT05250271|OTHER|5 g dextrose|5 g dextrose tablets
214699143|NCT05250271|OTHER|Protein bar|5 g carbohydrates + 10 g protein
214699144|NCT00002207|DRUG|Stavudine|
214699145|NCT00002207|DRUG|Didanosine|
214699146|NCT05140005|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
214699147|NCT00392262|DRUG|valsartan + amlodipine|
214699148|NCT05742672|OTHER|ABDOMINAL MASSAGE APPLICATION|"* Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue."
214699149|NCT06553534|OTHER|SAMURAI PICU Bundle|"The proposed multifaceted SAMURAI PICU Bundle is an intervention with the following core elements: 1) PICU Warning Tool: an automated clinical decision support (CDS) tool to provide a non-interruptive interprofessional predictive alert, 2) twice daily safety huddles with unit leadership, and 3) bedside assessment including the care team and patient's family to complete and display a bedside mitigation plan to prevent deterioration. This intervention combines the automated accurate prediction of the PICU Warning Tool with the use of provider intuition or a gut feeling from huddles to improve decision making at the bedside. Peripheral elements and possible adaptations will be suggested during Aim 1 and additional peripheral elements may be added by local sites after discussion with the PI through a user-centered design approach."
214546735|NCT01898780|PROCEDURE|pancreaticojejunostomy with horizontal mattress suture|
214699150|NCT04892758|DRUG|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
215160268|NCT04056832|PROCEDURE|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
215160269|NCT05048511|BIOLOGICAL|vitamin D estimation|Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
215160270|NCT04790565|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
215160271|NCT03742752|OTHER|Enteral nutrition|administration of enteral nutrition
214546736|NCT01898780|PROCEDURE|pancreaticojejunostomy with interrupted suture|
214546737|NCT04253938|OTHER|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
214546738|NCT01289132|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
214546739|NCT01289132|DRUG|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
214546740|NCT01289132|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
214546741|NCT01289132|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
214546742|NCT01289132|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
214699151|NCT04892758|DRUG|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
214699152|NCT03071536|DRUG|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
214699153|NCT02000713|OTHER|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
214699154|NCT02000713|OTHER|Clinical Exam|Brief neurological exam will be performed.
214699155|NCT02817815|DEVICE|Electrocardiogram (ECG)|
214699156|NCT02817815|BIOLOGICAL|Blood sampling from the cephalic vein|
214699157|NCT02817815|BIOLOGICAL|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
214699158|NCT02817815|BIOLOGICAL|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
214699159|NCT02817815|PROCEDURE|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
214699160|NCT02817815|BIOLOGICAL|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
215160272|NCT03742752|OTHER|Parenteral nutrition|administration of parenteral nutrition
215160273|NCT02405442|DRUG|Andecaliximab|Andecaliximab administered via subcutaneous (SC) injection
215160274|NCT02405442|DRUG|Placebo|Placebo to match andecaliximab administered via SC injection
215160275|NCT03521778|OTHER|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~1. Triggerbands - therapist put a pressure by the thumb along the presented pathway.~2. Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~3. Folding Distortions - therapist conduct traction or compression of the affected joint.~4. Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~5. Cylinder Distortions - therapist compress and stretch by the hands affected area.~6. Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
214546743|NCT01289132|DRUG|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
214546744|NCT01289132|DRUG|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
214546745|NCT00000469|DRUG|aspirin|
214546746|NCT00000469|DRUG|lovastatin|
214546747|NCT03436303|DRUG|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
214546748|NCT03436303|DRUG|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
214546749|NCT03436303|DRUG|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
214546750|NCT03554720|DEVICE|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
214546751|NCT03554720|DEVICE|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
214546752|NCT01638390|DEVICE|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
214546753|NCT00551850|DRUG|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
214546754|NCT00143104|DRUG|Inhaled insulin|
214546755|NCT04397211|PROCEDURE|Angiography-derived FFR|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~\*Criteria for revascularization: Angiography-derived FFR ≤ 0.80"
214546756|NCT04397211|PROCEDURE|IVUS|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3\< MLA ≤ 4mm2 \& Plaque burden \> 70%"
214546757|NCT05996367|RADIATION|Single-dose involved-site radiotherapy|Single-dose of 8 Gy at involved-site radiotherapy
214546758|NCT01377389|DRUG|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
214546759|NCT01377389|DRUG|Leuprolide|7.5 mg intramuscular once a month for 8 months
214708949|NCT06965907|OTHER|Kinesio Taping|The participant will be seated upright in a chair with the elbow flexed at 90 degrees. The forearm under examination will be placed in a pronated position, and the wrist will be maintained in a neutral position. I-shaped kinesio taping will be applied as described by Mohammadi et al. Prior to taping, the extensor surface will be cleaned using a cotton swab moistened with alcohol. The tape length will be measured from a point 2 cm distal to the lateral epicondyle to the radial styloid process. Each end of the tape will be 2 cm in length (totaling 4 cm for both ends). To achieve 35% tension, the following formula will be used: (L - 4) / 1.35 + 4. In this formula, L represents the total length of the tape, 4 is the combined length of the two tape ends, and 1.35 corresponds to the factor required to achieve the desired 35% tension.
215160276|NCT03521778|OTHER|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
215160277|NCT03521778|OTHER|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
215160278|NCT04342507|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
215160279|NCT04342507|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
215160280|NCT02950467|DRUG|Psilocybin|One individual oral psilocybin treatment session
215160281|NCT02950467|BEHAVIORAL|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
214546760|NCT01377389|DRUG|Goserelin|3.6 mg subcutaneous once a month for 8 months
214546761|NCT01377389|DRUG|Degarelix|80 mg subcutaneous once a month for 8 months
214546762|NCT02611453|OTHER|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
214546763|NCT02882997|BEHAVIORAL|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
214546764|NCT02882997|BEHAVIORAL|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
214546765|NCT05572749|DIETARY_SUPPLEMENT|Crocus Kozanis|In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.
214546766|NCT05572749|DIETARY_SUPPLEMENT|Placebo of Crocus Kozanis|Placebo of Crocus Kozanis
214546767|NCT05572749|DRUG|Metformin|Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
214546768|NCT05519553|OTHER|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
214546769|NCT02788266|PROCEDURE|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
214546770|NCT02788266|PROCEDURE|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
214546771|NCT02788266|PROCEDURE|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
214546772|NCT06957379|DRUG|Letrozole|Oral administration at a dose of 2.5 mg once daily for a 4-week cycle
214546773|NCT06957379|DRUG|Anastrozole|Oral administration at a dose of 1 mg once daily for a 4-week cycle
214546774|NCT06957379|DRUG|Exemestane|Oral administration at a dose of 25 mg once daily with a meal every 4 weeks
214699161|NCT06033339|OTHER|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
214699162|NCT05506592|OTHER|dermatological product|cosmetic shampoo
214546775|NCT06957379|DRUG|Fulvestrant|Fulvestrant: IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
214546776|NCT06957379|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
214546777|NCT04684667|DRUG|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
214546778|NCT03236532|DIETARY_SUPPLEMENT|Glutamine and exercise|
214546779|NCT03236532|DIETARY_SUPPLEMENT|Maltodextrin and exercise|
214546780|NCT04334616|DEVICE|Video Laryngocope|VDL used for VDL arm
214699163|NCT00997048|PROCEDURE|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
214699164|NCT00997048|PROCEDURE|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
214699165|NCT01656681|DIETARY_SUPPLEMENT|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
214546781|NCT04334616|DEVICE|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
214699166|NCT01656681|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
214699167|NCT00129350|PROCEDURE|Pulmonary rehabilitation programme|
214699168|NCT06484439|DRUG|Ketorolac|10 mg PO q 6h scheduled
214699169|NCT06484439|DRUG|Oxycodone|5 mg PO PRN
214699170|NCT06484439|DRUG|Acetaminophen|650 mg q 6h scheduled
215160282|NCT06014398|DIAGNOSTIC_TEST|Dynamic testing of Pituitary Function|"Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1\].~Dynamic testing of pituitary function:~* Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~* Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency."
215160283|NCT00551057|BEHAVIORAL|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
215160284|NCT02223845|OTHER|Music|Self-selected music played via headphones
215160285|NCT03476590|PROCEDURE|new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine|"The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations."
214546782|NCT00628277|BEHAVIORAL|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
214546783|NCT00628277|BEHAVIORAL|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
214546784|NCT04885348|BEHAVIORAL|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
214546785|NCT04885348|BEHAVIORAL|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
214546786|NCT02375451|OTHER|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
214699171|NCT06484439|DRUG|Ibuprofen|600 mg PO scheduled q6h
214699172|NCT06484439|DRUG|Hydrocodone|5 mg hydrocodone PO PRN q6h
214699173|NCT02520622|BEHAVIORAL|Digital photographs loaded onto a mobile device|
214699174|NCT02520622|BEHAVIORAL|Skin exam reminders|
214699175|NCT02520622|BEHAVIORAL|Social support network|
214699176|NCT05054673|OTHER|universal adhesive|PALFIQUE universal adhesive
214699177|NCT05054673|OTHER|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
214699178|NCT02902744|DRUG|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
214546787|NCT01439867|DRUG|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
214546788|NCT01439867|DRUG|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
214546789|NCT04003766|DIAGNOSTIC_TEST|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
214546790|NCT00807105|DEVICE|H-coil dTMS|treatment with deep TMS stimulation.
214699179|NCT01269372|DEVICE|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
214699180|NCT01269372|DEVICE|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
214699181|NCT03798444|RADIATION|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
214699182|NCT03798444|RADIATION|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
214699183|NCT01463904|PROCEDURE|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
214699184|NCT04146467|DEVICE|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
214699185|NCT02163304|OTHER|Sucrose|
214699186|NCT02163304|OTHER|Artificial Sweetner|
214699187|NCT02163304|OTHER|Tasteless Solution|
214699188|NCT02202096|OTHER|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
214699189|NCT02202096|OTHER|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
214699190|NCT02202096|OTHER|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
215160286|NCT05349565|OTHER|CONVENTIONAL PHYSICAL THERAPY|"High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes"
215160287|NCT05349565|OTHER|MUSCLE ENERGY TECHNIQUE|"Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes"
215160288|NCT00267787|OTHER|genetic analysis|standard of care
215160289|NCT05546580|DRUG|Iadademstat|iadademstat oral solution
215160290|NCT05546580|DRUG|Gilteritinib Oral Tablet|120 mg Gilteritinib
215160291|NCT01171560|PROCEDURE|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
215160292|NCT03275350|DRUG|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
215160293|NCT03275350|OTHER|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
214546791|NCT00421629|BEHAVIORAL|After-sales service and supportive supervision (AfterSS)|
214699191|NCT02202096|OTHER|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
214699192|NCT02202096|OTHER|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
214699193|NCT02202096|OTHER|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
214699194|NCT02202096|OTHER|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
214699195|NCT02202096|OTHER|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
214546792|NCT00421629|BEHAVIORAL|Prospective reimbursement (PR)|
214546793|NCT00421629|BEHAVIORAL|Both (AfterSS and PR)|
214546794|NCT05058053|OTHER|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
214546795|NCT04889469|PROCEDURE|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
214546796|NCT01003119|BEHAVIORAL|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
214699196|NCT02202096|OTHER|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
214699197|NCT02202096|OTHER|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
214699198|NCT02202096|OTHER|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
214699199|NCT03689504|DIETARY_SUPPLEMENT|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
214699200|NCT03689504|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
214699201|NCT03689504|BEHAVIORAL|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
214699202|NCT01114958|DRUG|Cisplatin, Thiosulfate|Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
214546797|NCT00334542|DRUG|simvastatin|24-28 weeks of simvastatin
214546798|NCT03095170|BEHAVIORAL|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
215160294|NCT06251882|OTHER|injection|10ml D5W injection for MP patients
214546799|NCT03095170|BEHAVIORAL|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
214546800|NCT03095170|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
214546801|NCT03095170|BEHAVIORAL|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
214546802|NCT03095170|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
214546803|NCT06261957|DRUG|Salbutamol HFA-134a|100 microgram (μg) (ex-valve) at 30-second intervals per actuation
214546804|NCT06261957|DRUG|Salbutamol HFA-152a|100 μg (ex-valve) at 30-second intervals per actuation
214546805|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
214546806|NCT06011200|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
214546807|NCT06011200|BIOLOGICAL|MSPV4|1 dose of MSPV4 on Day 0
214546808|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
214546809|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
214699203|NCT04103255|OTHER|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
215160295|NCT05262049|OTHER|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
214546810|NCT00013611|DRUG|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
214699204|NCT06185218|OTHER|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
214699205|NCT00621855|DRUG|placebo|matched placebo
214699206|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
214699207|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
214699208|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
214699209|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
214699210|NCT02537379|DRUG|SOF|SOF 400 mg tablets administered orally once daily
215160296|NCT05262049|OTHER|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
214546811|NCT00236262|DEVICE|ventilatory strategies with pressure|
214546812|NCT00002430|DRUG|Indinavir sulfate|
214546813|NCT00002430|DRUG|Nelfinavir mesylate|
214546814|NCT00002430|DRUG|Lamivudine|
214699211|NCT02537379|DRUG|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
214699212|NCT05557955|OTHER|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
214699213|NCT03731364|DRUG|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
215160297|NCT05262049|OTHER|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
215160298|NCT01707576|BEHAVIORAL|consultation 10 days later|new depression screening
215160299|NCT06426589|OTHER|Resistence training and mediterranean diet|"Resistance training. Subjects assigned to the experimental group participated in resistance program twice a week (on Tuesdays and Thursdays) for a period of 12 weeks, totaling 24 sessions of 60 minutes each. Each session during this time was divided into three clearly differentiated parts: i) 5-minute warm-up comprised of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise.~Mediterranean Diet. In addition to the resistance intervention, the experimental group received a Mediterranean diet protocol based on the study by Ismail et al. \[34\] with the following meal plan: i) carbohydrates constituted 50% of daily intake; ii) fats repre-sented 35%; and iii) proteins accounted for 15%."
215160300|NCT01668862|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
215160301|NCT01668862|DRUG|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
215160302|NCT02560077|OTHER|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
215160303|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
215160304|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
214546815|NCT00002430|DRUG|Stavudine|
214546816|NCT02407210|DRUG|azilsartan|
214546817|NCT02407210|DRUG|Olmesartan medoxomil|
214546818|NCT06277180|PROCEDURE|Surgery|Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.
214546819|NCT06277180|PROCEDURE|Surgery|68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.
214699214|NCT03731364|DRUG|Placebo|Placebo
214699215|NCT00233259|BEHAVIORAL|Mediterranean Diet|Mediterranean dietary program
214699216|NCT00233259|BEHAVIORAL|Physical Activity|Physical activity program
214699217|NCT00233259|BEHAVIORAL|Stress Management|Stress management program
214699218|NCT00233259|BEHAVIORAL|Social Support|Social support
214699219|NCT00233259|BEHAVIORAL|Smoking Cessation|Smoking cessation program
214699220|NCT00233259|OTHER|Control group|Usual Diabetes Care Control group
214699221|NCT03262532|OTHER|Web-base simulator|Training manipulation of TEE using a Web-based simulator
214699222|NCT03262532|OTHER|No web-base simulator|Training manipulation of TEE with out a web-base simulator
214699223|NCT01250093|DEVICE|acupuncture|
214699224|NCT01368393|PROCEDURE|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
214699225|NCT01368393|PROCEDURE|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
214699226|NCT02467647|DRUG|Thalidomide|
214699227|NCT02467647|DRUG|HLJDT|
214699228|NCT03579953|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
215160305|NCT04207541|BEHAVIORAL|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
214546820|NCT03234946|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
214699229|NCT03579953|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214699230|NCT06425783|PROCEDURE|Warmed Blood Transfusion|"The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K."
214699231|NCT00006054|DRUG|anti-thymocyte globulin|
214699232|NCT00006054|DRUG|busulfan|
214699233|NCT00006054|DRUG|cyclophosphamide|
214546821|NCT04855942|DEVICE|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
214546822|NCT04855942|DEVICE|physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
214546823|NCT03435146|COMBINATION_PRODUCT|3HP plus DTG +2NRTIs|"* HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~* LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)"
214699234|NCT00006054|DRUG|cyclosporine|
214699235|NCT00006054|DRUG|etoposide|
214699236|NCT00006054|DRUG|methotrexate|
214699237|NCT00006054|DRUG|methylprednisolone|
214699238|NCT00006054|DRUG|prednisone|
214699239|NCT00006054|PROCEDURE|Allogeneic Bone Marrow Transplantation|
214699240|NCT01914705|PROCEDURE|Landmark Procedure|Using Landmarks to guide SCVC placement
214699241|NCT01914705|PROCEDURE|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
214699242|NCT01934192|DRUG|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
214699243|NCT01934192|DRUG|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
214699244|NCT01934192|DRUG|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
214699245|NCT01934192|DRUG|Placebo IV|Placebo will be administered IV every 6 hours
214699246|NCT01760824|DRUG|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
215160306|NCT04119830|BIOLOGICAL|Pembrolizumab|Given IV
214699247|NCT01760824|DRUG|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
214699248|NCT00347763|PROCEDURE|10% permethrin in water applied as low volume spray|
215160307|NCT04119830|OTHER|Questionnaire Administration|Ancillary studies
215160308|NCT04119830|DRUG|Rintatolimod|Given IV
215160309|NCT02817529|DEVICE|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
214699249|NCT01189435|DRUG|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
214699250|NCT04208763|DRUG|Imipenem|Inj Imipenem 1gm i.v. TDS
214699251|NCT04208763|DRUG|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
214699252|NCT04208763|DRUG|GMCSF|Inj GM-CSF 500mcg s.c. OD
214699253|NCT04208763|DRUG|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
214699254|NCT03627910|DIETARY_SUPPLEMENT|symbiotic|Feed supplementation
214699255|NCT03627910|DIETARY_SUPPLEMENT|zinc and arginine|Feed supplementation
214699256|NCT02771249|DRUG|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
214699257|NCT02771249|DRUG|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
214699258|NCT02771249|DRUG|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
214699259|NCT02771249|DIETARY_SUPPLEMENT|Pyridoxine|
214699260|NCT04887103|OTHER|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
214699261|NCT05689658|BEHAVIORAL|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
214699262|NCT05689658|BEHAVIORAL|Diet|Hypocaloric diet prescription
214699263|NCT05328921|DRUG|Antihypertensive Agents|Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
215160310|NCT02817529|DEVICE|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
215160311|NCT00504946|DRUG|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
215160312|NCT00504946|DRUG|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
214546824|NCT04025268|BEHAVIORAL|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
214546825|NCT04025268|BEHAVIORAL|Standard of Care|Standard of prenatal care
214546826|NCT02431052|DRUG|Olumacostat Glasaretil|
214546827|NCT02431052|OTHER|Vehicle|
214546828|NCT04029805|COMBINATION_PRODUCT|Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
214546829|NCT04029805|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
214546830|NCT02094898|DRUG|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
214546831|NCT04312932|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
214546832|NCT04312932|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
214546833|NCT01714167|GENETIC|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
214546834|NCT05455372|DRUG|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
214546835|NCT02875145|PROCEDURE|Cataract surgery|
214546836|NCT03520075|DRUG|ASTX029|PiB
214546837|NCT03520075|DRUG|ASTX029|Tablet
214546838|NCT01947712|DIETARY_SUPPLEMENT|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
214546839|NCT01947712|DIETARY_SUPPLEMENT|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
214546840|NCT00073398|BIOLOGICAL|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
214546841|NCT05382039|DEVICE|Transcutaneous Electrical Nerve Stimulation|High frequency sensory transcutaneous electrical nerve stimulation
214546842|NCT01432626|DRUG|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
214546843|NCT03895697|DRUG|dasiglucagon|Glucagon analogue
214546844|NCT00932971|DRUG|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
215160313|NCT00504946|DRUG|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
215160314|NCT00504946|DRUG|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
215160315|NCT00504946|DRUG|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
215160316|NCT00114790|RADIATION|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
215160317|NCT05279573|DIETARY_SUPPLEMENT|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
215160318|NCT05279573|OTHER|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
215160319|NCT01900418|BEHAVIORAL|Walk with Ease|An evidence-based walking program
215160320|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
215160321|NCT02663544|OTHER|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
215160322|NCT02663544|OTHER|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
214546845|NCT00932971|DRUG|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
214546846|NCT00981539|PROCEDURE|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
214546847|NCT01234883|DRUG|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
214546848|NCT01234883|DRUG|saline|IV solutions dosed as clinically indicated for rehydration
214546849|NCT00316433|DRUG|Irinotecan (CPT-11)|
214546850|NCT00316433|DRUG|Oxaliplatin (Eloxatin)|
214546851|NCT01601613|DRUG|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
214546852|NCT01601613|DRUG|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
214699264|NCT05328921|DRUG|Antihistaminics|Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
214699265|NCT05277649|OTHER|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
214699266|NCT03354819|BEHAVIORAL|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
214699267|NCT03354819|BEHAVIORAL|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction"
214699268|NCT00100633|DRUG|CpG7909 oligodeoxynucleotides (ODN)|
214699269|NCT00100633|BIOLOGICAL|Hepatitis B virus vaccine|
214546853|NCT00979693|DRUG|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
214546854|NCT00979693|DRUG|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
214699270|NCT03641209|DRUG|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
215160323|NCT02663544|OTHER|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
214546855|NCT01742299|DRUG|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
214546856|NCT05889949|DRUG|Sorafenib|oral sorafenib
214546857|NCT05889949|DRUG|Lenvatinib|oral lenvatinib
214546858|NCT01535001|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
214546859|NCT01535001|BEHAVIORAL|Information|"Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet."
214546860|NCT01535001|DRUG|Paracetamol|1 g x 4/day
214546861|NCT01535001|DRUG|Burana|400 mg x 3/day for three weeks
215160324|NCT00926029|DRUG|Fluoride|Brush twice daily
215160325|NCT00926029|DRUG|Triclosan, fluoride|Brush twice daily
215160326|NCT00926029|OTHER|Metal salt|Brush twice daily
215160327|NCT00635258|DRUG|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
215160328|NCT00635258|DRUG|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
214546862|NCT01535001|DRUG|Pantoprazole|20mg x 1/day for three weeks
214699271|NCT03641209|OTHER|Placebo|Half physiological saline solution as the non-active placebo solution
214699272|NCT03057457|DEVICE|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
214699273|NCT01600768|DRUG|Beta-Lactams|infusion time: 30 mins or 1 hr
214546863|NCT01535001|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
214699274|NCT01600768|DRUG|Beta-Lactams|infusion time 4 hrs
214699275|NCT01597427|DRUG|Clonidine|Administration of 2 μg/kg of intravenous clonidine
214699276|NCT01597427|DRUG|Placebo|Injection of placebo solution.
214699277|NCT02952326|PROCEDURE|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
214699278|NCT02952326|PROCEDURE|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
214708950|NCT06965907|OTHER|Sham Taping|The participant will be seated in a chair with the forearm resting comfortably. The tape will be applied to the middle of the forearm without any tension. The taping will be performed from the medial to the lateral direction.
214708951|NCT03102177|DRUG|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
214708952|NCT04328922|OTHER|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
214708953|NCT04328922|OTHER|Placebo capsuls|capsules of glycerol and saline (placebo).
214546864|NCT01535001|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
214546865|NCT01535001|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
214546866|NCT03182998|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
214546867|NCT03182998|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
214546868|NCT03182998|OTHER|Best Practice|Undergo usual care
214546869|NCT03182998|OTHER|Quality-of-Life Assessment|Ancillary studies
214546870|NCT03182998|OTHER|Questionnaire Administration|Ancillary studies
214546871|NCT03182998|OTHER|Survey Administration|Ancillary studies
214546872|NCT03182998|OTHER|Laboratory Biomarker Analysis|Correlative studies
214546873|NCT00126659|PROCEDURE|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
214546874|NCT00126659|DRUG|sorafenib tosylate|Given orally
214546875|NCT00126659|OTHER|laboratory biomarker analysis|Correlative studies
214546876|NCT02272361|OTHER|laparoscopic sacrocolpopexy|
214546877|NCT02272361|OTHER|vaginal mesh surgery|
214546878|NCT06547567|BEHAVIORAL|Motivational Interviewing|In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
214546879|NCT01013961|BIOLOGICAL|alemtuzumab|Given IV
214546880|NCT01013961|BIOLOGICAL|rituximab|Given IV
214546881|NCT01006525|DRUG|zolpidem|placebo or zolpidem (10mg)daily for one year
214546882|NCT02866669|BEHAVIORAL|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
214546883|NCT02866669|BEHAVIORAL|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
214546884|NCT02866669|BEHAVIORAL|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
214546885|NCT03796078|PROCEDURE|Maxillomandibular advancement|Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
215160329|NCT06317129|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted.
214546886|NCT03796078|PROCEDURE|monomaxillary surgery (isolated MaxS)|Monomaxillary surgery (Isolated MaxS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
214546887|NCT03796078|PROCEDURE|monomandibullary surgery (MandS)|Monomandibullary surgery (Isolated MandS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
214546888|NCT02097186|PROCEDURE|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
214546889|NCT02296749|DRUG|Sirolimus|Sirolimus tablets 2 mg
214546890|NCT01375751|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214546891|NCT01375751|BIOLOGICAL|Placebo|d by subcutaneous injection
214546892|NCT02980523|DRUG|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
214546893|NCT02980523|DRUG|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
214546894|NCT02980523|DRUG|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
214546895|NCT02980523|DRUG|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
214546896|NCT00540943|DRUG|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
214546897|NCT00540943|DRUG|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
214546898|NCT00540943|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
215160330|NCT05106153|DRUG|Suvorexant|Suvorexant will be administered orally as per assigned treatment sequence.
215160331|NCT05106153|DRUG|Zolpidem|Zolpidem will be administered orally as per assigned treatment sequence.
215160332|NCT05106153|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
214546899|NCT00132197|BEHAVIORAL|Cognitive Behavioral Therapy|1\. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
214546900|NCT00132197|PROCEDURE|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
214546901|NCT04789343|OTHER|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
214546902|NCT04412525|DEVICE|vitrectomy (27G gauge or larger needle)|vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
214546903|NCT00730613|BIOLOGICAL|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
214546904|NCT00730613|GENETIC|gene expression analysis|At the time of excess pathology samples documenting response/relapse
214546905|NCT00730613|OTHER|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
214546906|NCT04699045|OTHER|No active intervention|
214546907|NCT00131963|DRUG|cyclophosphamide|Given IV
214546908|NCT00131963|DRUG|doxorubicin|Given IV
214546909|NCT00131963|DRUG|paclitaxel|Given IV
214546910|NCT02884037|DRUG|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
214546911|NCT00037206|DRUG|Anidulafungin, VER002|
214546912|NCT05241132|DRUG|Tislelizumab plus chemotherapy|"1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
214546913|NCT03469726|DIAGNOSTIC_TEST|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
214699279|NCT05775744|OTHER|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
214699280|NCT01605591|PROCEDURE|the DLT bending to the right|bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
214699281|NCT01605591|PROCEDURE|the DLT bending to the left|bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
214546914|NCT02412579|OTHER|None - Standard of Care|
215160333|NCT05106153|DRUG|Placebo|Placebo will be administered orally as per assigned treatment sequence.
215160334|NCT00971815|DRUG|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
215160335|NCT00971815|DRUG|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
214546915|NCT02968706|DEVICE|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
214546916|NCT02968706|DEVICE|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
215160336|NCT05618691|DRUG|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
215160337|NCT05618691|OTHER|Placebo|Placebo will be administered to subjects in the placebo group
214546917|NCT02968706|OTHER|Patient satisfaction questionnaire|Questionnaire
214546918|NCT04575181|DRUG|NNC0268-0965|For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
214546919|NCT04575181|DRUG|Insulin glargine|For s.c. injection once daily for 26 weeks
215160338|NCT02385643|BEHAVIORAL|SmartPhone Support System|
215160339|NCT03031080|DEVICE|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
215160340|NCT02522663|OTHER|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
214546920|NCT04575181|DRUG|Placebo (NNC0268-0965)|For s.c. injection once daily for 26 weeks
214546921|NCT04575181|DRUG|Placebo (insulin glargine)|For s.c. injection once daily for 26 weeks
214546922|NCT01202799|DRUG|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
214546923|NCT01202799|DRUG|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
214546924|NCT01202799|DRUG|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
214546925|NCT01943682|DRUG|CPX-351|Comparison of Different doses of drug
214546926|NCT05472103|BEHAVIORAL|ergonomics surgical workshop|ergonomics surgical workshop
214546927|NCT03888599|BEHAVIORAL|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
215160341|NCT02541396|DRUG|Wafermine|35 or 70 mg ketamine in a sublingual wafer
215160342|NCT02541396|DRUG|Oxycodone|5 mg oxycodone capsule
215160343|NCT02541396|DRUG|Placebo|Placebo capsule or placebo wafer
215160344|NCT06518408|DRUG|Cabotegravir Injectable Product|long-acting regimen dosed every 2-months
215160345|NCT06518408|DRUG|Rilpivirine Injectable Product|long-acting regimen dosed every 2-months
215160346|NCT02966444|OTHER|MUFA-rich HF Meal|
215160347|NCT02966444|OTHER|PUFA-rich HF Meal|
214546928|NCT00959010|DIETARY_SUPPLEMENT|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
214546929|NCT00959010|DIETARY_SUPPLEMENT|Placebo|capsules containing middle chain triglycerides
214546930|NCT02743897|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
214546931|NCT02743897|DRUG|Mavyret|Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
214546932|NCT03815253|OTHER|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
214546933|NCT00590226|DRUG|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
214546934|NCT00590226|DRUG|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
214546935|NCT01547598|DRUG|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
214546936|NCT01547598|DRUG|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
214546937|NCT01547598|DRUG|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
214546938|NCT00371176|BEHAVIORAL|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
214546939|NCT00371176|DRUG|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
214546940|NCT00371176|OTHER|Placebo pill|
214546941|NCT00635401|DRUG|Varenicline|0.5 mg BID for 7 weeks
214546942|NCT01573949|DRUG|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
214546943|NCT00777634|OTHER|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
214546944|NCT02423889|RADIATION|Radiotherapy|
214546945|NCT02229227|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
214546946|NCT02229227|DRUG|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
214546947|NCT01349452|DRUG|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
214546948|NCT01349452|DRUG|Artificial tear|Artificial tear 5 times per day
214546949|NCT05383339|OTHER|Blood collection|\- 56mL blood collected additionally to routine care
214546950|NCT06428864|DEVICE|Plaster cast|Wearing a Garchois brace produced after a plaster cast
214546951|NCT06428864|DEVICE|3D Scanning|Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
214546952|NCT05775783|PROCEDURE|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
214546953|NCT04071301|DEVICE|TENA SmartCare Change Indicator|"Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
214546954|NCT06475794|OTHER|Patients with osteoporosis group|Pain, Q angle, muscle strength and foot posture will be evaluated.
214546955|NCT06475794|OTHER|Patients with osteoarthritis group|Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
214546956|NCT01114347|DIETARY_SUPPLEMENT|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
214546957|NCT01114347|DIETARY_SUPPLEMENT|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
215160348|NCT02966444|OTHER|SFA-rich HF Meal|
215160349|NCT01347411|PROCEDURE|CPAP|Treatment with CPAP
215160350|NCT00540852|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
215160351|NCT04937465|OTHER|No intervention done|No intervention was done. This was an observational study.
215160352|NCT02566369|DRUG|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
214699282|NCT04469374|OTHER|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
214699283|NCT04469374|OTHER|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
214699284|NCT03095521|DRUG|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
214699285|NCT03095521|DRUG|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
214699286|NCT03259490|DRUG|Empagliflozin/linagliptin/metformin HCl|Once daily
214699287|NCT03259490|DRUG|Empagliflozin|Once daily
214699288|NCT03259490|DRUG|Linagliptin|Once daily
214699289|NCT03259490|DRUG|Metformin HCl|Once daily
215160353|NCT02566369|DRUG|Placebo cream|Placebo cream applied once daily for 12 weeks
215160354|NCT03472261|DRUG|Botulinum toxin type A|Dysport
215160355|NCT03472261|OTHER|Upper extremity orthoses|Twister
215160356|NCT03472261|OTHER|Home exercise program|Specific exercises for pronation deformity
214699290|NCT03675438|OTHER|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
214546958|NCT03917745|BEHAVIORAL|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
214699291|NCT02822404|DIETARY_SUPPLEMENT|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
214699292|NCT05298696|DRUG|Cilostazol|Cilostazol 100 mg twice daily
214546959|NCT00419289|BEHAVIORAL|follow-up rehabilitation of participants with COPD|
214699293|NCT05298696|DRUG|Placebo|Placebo twice daily
214546960|NCT00548743|BEHAVIORAL|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
214546961|NCT00548743|BEHAVIORAL|Usual care|usual care for identification and management of postpartum depression
214699294|NCT01963208|DRUG|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
214699295|NCT01963208|DRUG|Placebo|placebo
214699296|NCT00448916|DRUG|Pregabalin|Orally-administered pregabalin
214699297|NCT06348407|DRUG|IgE monoclonal antibody|omalizumab
214546962|NCT02480699|BIOLOGICAL|Recurring blood sample|
214546963|NCT02480699|OTHER|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
214699298|NCT03521193|DEVICE|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
214699299|NCT03900754|DRUG|Oxytocin|Intranasal administration of oxytocin
214699300|NCT03900754|DRUG|Placebo|Placebo
215160357|NCT00558649|BIOLOGICAL|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
214546964|NCT05186311|DEVICE|Capillary Blood Collection System|Test Blood Sample Collection
214546965|NCT04901923|DRUG|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
214546966|NCT04901923|DRUG|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
214699301|NCT01810042|DRUG|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
214699302|NCT03707158|BEHAVIORAL|Therapist-Led CBT (telehealth, office-based, or hybrid)|Participants receiving therapist-led CBT will participate in therapist-led (telehealth or office-based) CBT treatment for up to 20 weeks. Weekly therapist-led treatment sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
214708954|NCT02452268|DRUG|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
215160358|NCT06193668|BEHAVIORAL|High-fat overnutrition|Overnutrition: 40% higher lipid consumption per day than required
215160359|NCT06193668|BEHAVIORAL|Normocaloric macronutrient-balanced nutrition|"Normocaloric, macronutrient-balanced nutrition:~Calories requirement for weight maintenance \[(kcal/d) 55% carbohydrates, 15% proteins, 30% fat\]"
215160360|NCT04154189|DRUG|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
215160361|NCT04154189|DRUG|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
214546967|NCT00883298|DRUG|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 \& 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 \& 5 every 28-day cycle
214546968|NCT04072705|DRUG|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
214546969|NCT01355276|DRUG|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
214546970|NCT01355276|DRUG|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
214546971|NCT05646147|DEVICE|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
214546972|NCT02125279|DRUG|Calcitriol|
214546973|NCT03178344|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
214546974|NCT03178344|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
214546975|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
214546976|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
214546977|NCT01537692|DRUG|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
214546978|NCT01948674|BEHAVIORAL|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
214546979|NCT01126034|OTHER|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record"
214546980|NCT00567840|DRUG|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
214546981|NCT01850589|OTHER|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~* Chantix (varenicline) GlaxoSmithKline,~* Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
214546982|NCT00823953|DRUG|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
214546983|NCT00823953|OTHER|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
214546984|NCT00111995|DRUG|Aranesp®|
214546985|NCT06058715|PROCEDURE|Transverse Abdominal Plan block (TAP block)|Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane and after placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, 20 ml of ropivacaine 0.25% is injected bilaterally. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.
214546986|NCT01392703|DRUG|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
214546987|NCT01392703|DRUG|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
214546988|NCT01392703|DRUG|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
214546989|NCT06319157|DEVICE|minimal access breast reconstruction with a latissimus dorsi muscle flap|minimal access breast reconstruction with a latissimus dorsi muscle flap
214546990|NCT06319157|DEVICE|conventional breast reconstruction with a latissimus dorsi muscle flap|conventional breast reconstruction with a latissimus dorsi muscle flap
214546991|NCT03714659|DEVICE|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
214546992|NCT04468230|DRUG|Nicotine Transdermal Patch|Nicotine Treatment Condition
214699303|NCT03707158|BEHAVIORAL|Guided Online CBT|Participants receiving guided online CBT will complete an online, self-paced, standardized and digitalized CBT program for up to 20 weeks with 8 modules, with adjunctive therapist phone support for supportive accountability. The self-administered treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
214546993|NCT00417053|BIOLOGICAL|filgrastim|
214546994|NCT00417053|DRUG|busulfan|
214546995|NCT00417053|DRUG|carboplatin|
214546996|NCT00417053|DRUG|cyclophosphamide|
214546997|NCT00417053|DRUG|doxorubicin hydrochloride|
214546998|NCT00417053|DRUG|etoposide phosphate|
214546999|NCT00417053|DRUG|melphalan|
214547000|NCT00417053|DRUG|vincristine sulfate|
214547001|NCT00417053|PROCEDURE|autologous bone marrow transplantation|
214547002|NCT00417053|PROCEDURE|bone marrow ablation with stem cell support|
214547003|NCT00417053|PROCEDURE|conventional surgery|
214699304|NCT06689059|OTHER|Multimodal Data Integration and Multi-Task Learning|This study utilizes a multimodal data integration and multi-task learning approach to predict perioperative events after hip replacement surgery. By combining various data types, including demographics, surgical details, medical history, and lab results, the model enhances prediction accuracy for outcomes like AKI, blood transfusion needs, and ICU transfers. The use of ensemble learning algorithms such as CatBoost optimizes the platform's performance, offering a unique method for clinical decision support.
214547004|NCT00417053|PROCEDURE|peripheral blood stem cell transplantation|
214547005|NCT00417053|RADIATION|radiation therapy|
214547006|NCT00839384|DEVICE|Advisa IPG|Implantable Pulse Generator will be implanted
214547007|NCT02503098|BEHAVIORAL|Recovery Record adaptive smartphone application|
214547008|NCT02503098|BEHAVIORAL|Recovery Record standard smartphone application|
214547009|NCT03090750|DRUG|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
214547010|NCT03090750|DRUG|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
214547011|NCT03090750|OTHER|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
214699305|NCT06874374|DEVICE|Closed-loop tACS|Individual alpha tACS
215160362|NCT04154189|DRUG|Etoposide|Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
214547012|NCT02691988|OTHER|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
214547013|NCT02691988|OTHER|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
214547014|NCT03091816|DEVICE|Computed Tomography Perfusion Imaging|Undergo DPCT
214547015|NCT03091816|OTHER|Laboratory Biomarker Analysis|Correlative studies
214547016|NCT03091816|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214547017|NCT00415701|DRUG|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
214547018|NCT00415701|DRUG|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
214547019|NCT00415701|DRUG|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
215160363|NCT04154189|DRUG|Lenvatinib|Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
215160364|NCT02050893|DRUG|sedatives(Midazolam and Propofol)|
214547020|NCT00415701|DRUG|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
214547021|NCT00415701|OTHER|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
214547022|NCT02454504|DRUG|sugammadex|
214547023|NCT02454504|DRUG|Neostigmine|
214547024|NCT05860621|BEHAVIORAL|Brief Physical Activity Counselling|The brief physical activity counselling program will comprise 8 sessions (120 minutes each), every fifteen days, addressing the following themes: reasons to change, an introduction to the PAC-WOMAN program and principles, types of physical activity and their benefits, strategies on how to become more active and less sedentary, how to safely practice exercise at home, the importance of social support for doing more physical activity, barriers and facilitators for becoming more active, development of coping plans and strategies to overcome those barriers, establishing SMART goals, self-monitoring, medical aspects related to symptom management in breast cancer survivors, body image and self-acceptance, sharing experiences with role models, and re-evaluating action plans. It will be delivered in a need-supportive interpersonal climate, according to Self-Determination Theory principles.
214547025|NCT05860621|BEHAVIORAL|Structured Exercise Program|The structured exercise program was informed by the most recent guidelines for exercise prescription and safe practice in cancer populations. A supervised program of 32 sessions (over 4 months), lasting 90 min each, and taking place twice a week, was developed. The program combines aerobic, strength and mobility exercises, and is organized in four mesocycles, with progressive intensity, always adapted according to participants' initial assessments and evolution throughout the weeks. Once every 15 days, a thematic group class will be offered to participants, so that they can experiment and discover new physical activities, and more easily maintain regular practice in the future.
214547026|NCT04381923|DEVICE|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (Sp02) remains \< 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
214547027|NCT04381923|DEVICE|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (SpO2) remains \< 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
214547028|NCT05933785|PROCEDURE|transanal endoscopic ISR|perform ISR using laparoscopy through transanal port
214547029|NCT01560845|PROCEDURE|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
214699306|NCT06874374|DEVICE|Sham Comparator|Sham stimulation
214699307|NCT06693414|OTHER|Tailored health promotion education|14 weeks tailored education
214699308|NCT06693414|OTHER|Routine nursing education|14 weeks nursing education
215160365|NCT04048772|BEHAVIORAL|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
215160366|NCT04048772|OTHER|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
215160367|NCT04609462|PROCEDURE|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
215160368|NCT04609462|PROCEDURE|High flow nasal cannula|Breathing support with High-flow nasal cannula
215160369|NCT04727372|OTHER|Questionnaire|A structured questionnaire will be served to each participant of study after getting the verbal consent from him for inclusion into the study
215160370|NCT00748904|DRUG|Rifaximin|400 mg orally
214547030|NCT01560845|PROCEDURE|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
214547031|NCT02839005|OTHER|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
214547032|NCT02839005|OTHER|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
214547033|NCT04202445|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
214547034|NCT01371422|OTHER|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
214547035|NCT01371422|OTHER|Saline|Ultrasonography and local infiltration of saline will only be performed
214547036|NCT04560374|DEVICE|crochet octopus|Delivering crochet octopus to the hands of the neonates
214547037|NCT02274090|DRUG|Placebo gel|Placebo gel consist of drug without the active component.
214547038|NCT02274090|DRUG|1% Metformin gel|Metformin gel consist of active component.
214547039|NCT05783609|DRUG|Epcoritamab|T-cell bispecific antibody, via subcutaneous injection
214547040|NCT05783609|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, via IV infusion
214547041|NCT03721705|DEVICE|Renew NCP-5|Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
215160371|NCT00748904|DRUG|Lactulose|20 grams titrate to 2-3 bowel movements in one day
215160372|NCT06268756|OTHER|Data collection|Data collection
214547042|NCT03105063|DIAGNOSTIC_TEST|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
214547043|NCT04471545|PROCEDURE|Pectoral nerve block type II|A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided
214547044|NCT05194670|DEVICE|enhanced depth of focus IOL|Acunex Vario AN6V, enhanced depth of focus IOL
214547045|NCT05194670|DEVICE|monofocal IOL|Acunex AN6, monofocal IOL
214547046|NCT06291064|DRUG|Cyclophosphamide|Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
214547047|NCT06291064|DRUG|Epirubicin|Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
214547048|NCT06291064|DRUG|Docetaxel|Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
214547049|NCT06291064|DRUG|Carboplatin|Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
214547050|NCT06291064|PROCEDURE|Breast Surgery|Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
214547051|NCT06291064|DRUG|Capecitabine|Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
214547052|NCT06046833|DEVICE|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
214547053|NCT06046833|OTHER|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
215160373|NCT02170103|PROCEDURE|percutaneous intervention (PCI)|Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
215160374|NCT02170103|DRUG|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
215160375|NCT02170103|PROCEDURE|Ultrasound|Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
215160376|NCT03680326|DEVICE|OCT|only OCT
215160377|NCT04079309|BEHAVIORAL|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
215160378|NCT01287312|PROCEDURE|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
215160379|NCT00631943|DRUG|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
214547054|NCT05139290|BEHAVIORAL|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
214547055|NCT05868941|DEVICE|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
214547056|NCT03908892|DRUG|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
214547057|NCT03908892|DRUG|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
214547058|NCT05698251|BEHAVIORAL|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
214547059|NCT01441219|DEVICE|Colon 2|Ingest one colon 2 capsule
214547060|NCT00389272|DRUG|Ibuprofen, acetaminophen|
214547061|NCT00181506|PROCEDURE|dose escalation (radiotherapy treatment schedule)|
214547062|NCT01746147|OTHER|No intervention and study treatment|
214547063|NCT03721172|DRUG|Apremilast|Apremilast, oral, twice daily
215160380|NCT04223219|DRUG|Fentanyl|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
215160381|NCT04223219|DRUG|Fentanyl, Propofol|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
215160382|NCT04223219|DRUG|Dexmedetomidine, Ketamine, Magnesium sulfate|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
215160383|NCT04980092|OTHER|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
215160384|NCT01526759|DIETARY_SUPPLEMENT|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
215160385|NCT01526759|DIETARY_SUPPLEMENT|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
214547064|NCT03721172|OTHER|Placebo|Placebo, oral, twice daily
214547065|NCT03204162|OTHER|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
214547066|NCT00092183|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
214547067|NCT00092183|DRUG|Comparator: ondansetron / Duration of Treatment: 3 days|
214547068|NCT02719288|OTHER|CLARIX® CORD 1K graft|
214547069|NCT06441864|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Partners will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.
214708955|NCT02452268|DRUG|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
214708958|NCT00685529|DRUG|Racemic formoterol|12 µg of racemic formoterol fumarate BID
214547070|NCT06183541|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
214547071|NCT00157794|DEVICE|Search AV+ algorithm|
214699309|NCT06691334|DEVICE|PRP injection|Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
214699310|NCT06691334|DEVICE|Hifu procedure and PRP injection|Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
214699311|NCT06693466|OTHER|Facial expression block|Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.
214699312|NCT06693466|OTHER|Conditioned pain modulation block|The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).
214699313|NCT06693466|OTHER|Pain facilitation block|Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.
214699314|NCT06696820|DRUG|PCSK9 inhibitors combined with atorvastatin/rosuvastatin|A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
214699315|NCT06696820|DRUG|Atorvastatin/Rosuvastatin|Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
214699316|NCT02773238|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214699317|NCT02773238|PROCEDURE|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
214699318|NCT02773238|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
214699319|NCT02773238|OTHER|Laboratory Biomarker Analysis|Correlative studies
214699320|NCT02773238|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214699321|NCT02773238|RADIATION|Radiation Therapy|Undergo functional avoidance radiation therapy
214699322|NCT02773238|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
214699323|NCT02773238|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
214547072|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
214547073|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
214547074|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
214547075|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
214547076|NCT00148668|DRUG|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
214547077|NCT00148668|DRUG|Navelbine|Weekly injections given starting week 3 and ending week 14
214547078|NCT00148668|DRUG|Taxotere|Given every three weeks starting week 3 and ending on week 14
214699324|NCT02773238|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
214699325|NCT05790811|OTHER|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
214699326|NCT05790811|OTHER|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
214699327|NCT06693232|PROCEDURE|Mobile micro-learning|Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
214699328|NCT06419517|DEVICE|EMG-triggered ES|The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
214699329|NCT06419517|OTHER|Pelvic Floor Muscle Training|Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
214699330|NCT04850703|DEVICE|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
214699331|NCT04850703|DRUG|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
214699332|NCT04850703|COMBINATION_PRODUCT|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
214699333|NCT04850703|DIAGNOSTIC_TEST|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
214699334|NCT04527354|DRUG|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
214699335|NCT04527354|DRUG|Placebo|Participants will receive Placebo once a day during 4 weeks
214699336|NCT06717282|BEHAVIORAL|visual rehabilitation for ophthalmic compliance|contextual, behavioral, and cognitive-based program for ophthalmic compliance
214547079|NCT00148668|DRUG|Carboplatin|Given every three weeks starting week 3 and ending on week 14
215160386|NCT05911685|DEVICE|SeaLA™ left atrial appendage occluder|"1. Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~2. Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~3. Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~4. Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
215160387|NCT03367078|DEVICE|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
215160388|NCT03367078|OTHER|Usual care|Usual care of DOC patients
215160389|NCT04133688|DEVICE|ASC|mobile app
215160390|NCT02138448|BEHAVIORAL|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
215160391|NCT00244543|DRUG|R89674 (generic name not yet established)|
215160392|NCT00158964|DEVICE|EASYTRAK 4 STEERABLE LV lead|
215160393|NCT04316091|DRUG|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
215160394|NCT04316091|DRUG|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
215160395|NCT02133690|BIOLOGICAL|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
215160396|NCT02133690|OTHER|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
215160397|NCT02193503|OTHER|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
215160398|NCT05724095|OTHER|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
215160399|NCT05724095|OTHER|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
214547080|NCT03052660|DRUG|Midazolam|Oral administration preoperatively
214547081|NCT03052660|DRUG|Placebo oral capsule|Oral administration preoperatively
214547082|NCT01914081|OTHER|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
214547083|NCT01914081|OTHER|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
214547084|NCT04589299|BIOLOGICAL|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
214547085|NCT03005990|OTHER|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
214547086|NCT02417441|DEVICE|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
214547087|NCT01180504|RADIATION|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
214547088|NCT06331455|DRUG|Durvalumab|Two doses of durvalumab (1500 mg IV)
214547089|NCT06331455|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
214547090|NCT03748862|OTHER|Taper Plan|Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
214547091|NCT01951768|DRUG|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
214547092|NCT01951768|DRUG|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
214708959|NCT00685529|DRUG|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
214547093|NCT03080142|DRUG|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
214708960|NCT00685529|DRUG|Racemic formoterol|24 µg of racemic formoterol fumarate BID
214699337|NCT06717282|BEHAVIORAL|Using contextual, behavioral, and cognitive-based stragegies to develop training programs|"Key Features of the Intervention:~1. Contextual Adaptation: Participants practice ophthalmic examination procedures in a simulated clinical environment to familiarize themselves with real-world conditions.~2. Behavioral Strategies: Positive reinforcement, such as rewards (snacks, toys, or videos), is used to encourage participation and cooperation during sessions.~3. Cognitive Support: Animated materials and interactive exercises are employed to teach the concepts required for visual tests, with take-home tasks for generalization.~4. Individualized Goals: Individualized training plans and objectives are established collaboratively with caregivers based on participants' cognitive and behavioral profiles.~Duration and Frequency:~Six sessions, each lasting one hour, are conducted biweekly, with flexibility based on caregiver availability."
214699338|NCT04255550|DIAGNOSTIC_TEST|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
214699339|NCT03260205|DRUG|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
214699340|NCT03260205|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
214699341|NCT03260205|DRUG|SPD489|SPD489
214699342|NCT06898216|DEVICE|Steerable FANS|This device is designed for flexible ureteroscopy procedures in patients with lower pole renal stones ≤2 cm. It features an active deflection mechanism that enables independent adjustment to enhance access into the lower pole calyx. The description focuses solely on the device and does not include procedural details already provided in the arm description.
214699343|NCT06898216|DEVICE|Conventional FANS|This device is intended for use in flexible ureteroscopy for lower pole renal stone management. It relies on passive deflection provided by the flexible ureteroscope for navigation into the lower pole calyx. The description is limited to the device characteristics without duplicating procedural details from the arm description.
214699344|NCT06897540|DEVICE|Upper endoscopy|View mucosa of esophagus with upper endoscope
214699345|NCT06898567|OTHER|Right Lateral Position|Participants rested for 10 minutes in a fully seated position, leaning their backs on a chair, without crossing their legs and placing their feet parallel to the floor. During this time, the arm to be measured was kept at heart level.
214699346|NCT06898567|OTHER|Left Lateral Position|Left Lateral Position
214699347|NCT06898567|OTHER|Semi Fowler Position (45° Fowler)|Semi Fowler Position (45° Fowler)
214699348|NCT06898372|DRUG|JAK Inhibitor|The retrospective analysis will examine the effects of Janus Kinase 1/2 (JAK1/2) inhibitors, such as Baricitinib and Ruxolitinib, on neurological symptoms and brain MRI.
214699349|NCT06897449|BEHAVIORAL|Positive psychological intervention|Each week consists of two modules, focusing on different techniques and methods from positive psychology, aimed at improving athletes' mental health and performance.
214699350|NCT06897449|OTHER|Introduction to Positive Psychology Poster|The poster serves as an introductory resource, summarizing key concepts of positive psychology in an accessible format.
214699351|NCT06898021|DIAGNOSTIC_TEST|3DStent|Coronary interventions will be performed according to the standard of care, which includes IVUS guidance. In patients undergoing stent implantation, a 3DStent image acquisition will be done followed by IVUS.
214699352|NCT06898359|RADIATION|Radioimmunotherapy|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles)
214699353|NCT02362308|OTHER|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
214699354|NCT02362308|DRUG|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
215160400|NCT05724095|OTHER|electrodes attached|electrodes are attached to area of acupoints
214547094|NCT03080142|DRUG|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
214547095|NCT03567044|DIAGNOSTIC_TEST|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
214699355|NCT04689750|DIAGNOSTIC_TEST|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
214699356|NCT06111053|OTHER|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
214699357|NCT06111053|OTHER|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
214699358|NCT06111053|OTHER|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
215160401|NCT02861001|DEVICE|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
214699359|NCT06111053|OTHER|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
215160402|NCT02861001|DEVICE|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
215160403|NCT02283827|DRUG|BIA 2-093|
215160404|NCT02283827|DRUG|Phenytoin|
215160405|NCT02411890|PROCEDURE|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
214547096|NCT06544356|OTHER|No intervention, questionnaire filled out|Mother introductory information form, Health Literacy Scale, Knowledge and Attitude Scale about Newborn Screenings were completed.
215160406|NCT02411890|PROCEDURE|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
214699360|NCT03059563|DRUG|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
214699361|NCT03059563|OTHER|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
214699362|NCT05301322|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine
214547097|NCT02328079|DRUG|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
214547098|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
214547099|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
214699363|NCT05301322|OTHER|Placebo|Placebo
214699364|NCT05301322|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV
214699365|NCT01345097|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty
214699366|NCT06897891|COMBINATION_PRODUCT|Acupuncture combined with core stability training|All patients were given routine health education guidance and core stability training. Acupuncture group combined with core stability training
214699367|NCT06897891|COMBINATION_PRODUCT|Dragon Tank joint core stability training|All patients were given routine health education guidance and core stability training. Huolong Tank group adopts Huolongcan combined core stability training
214699368|NCT06897553|BEHAVIORAL|ACT-based group therapy|"ACT-based group therapy based on the manual Living Well with Neurological Conditions published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members."
214699369|NCT06899139|OTHER|Orthokeratology Lens Wear|"Orthokeratology Lens Wear~Intervention Type:~Device~Description:~Participants will wear gas-permeable orthokeratology (OK) lenses overnight for a minimum of 8 hours per night. Lenses are designed to reshape the cornea temporarily to reduce refractive error and slow axial elongation. This intervention is administered to both the experimental and control groups."
214699370|NCT06899139|DEVICE|Repeated Low-Level Red-Light Therapy Intervention Type: Device Description: Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a no|"Description:~Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a non-invasive light-emitting device. Each session will last no more than 3 minutes, with a minimum interval of 4 hours between sessions. The therapy is administered under parental supervision and aims to enhance myopia control in conjunction with orthokeratology."
214699371|NCT05803889|OTHER|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
214699372|NCT05803889|OTHER|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
214699373|NCT05917457|OTHER|balance coordination and strengthening training|"The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group.~Study group: Low vision children were given balance, coordination training and general strengthening training with sandbags for 70 minutes 3 days a week (5-minute warm-up phase, 20-minute balance training, 20-minute coordination training, 20-minute strengthening training and 5-minute cooling phase) for 8 weeks."
215160407|NCT02411890|PROCEDURE|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
215160408|NCT02411890|PROCEDURE|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
214547100|NCT00983853|BIOLOGICAL|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
214547101|NCT00983853|DRUG|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
214547102|NCT00983853|DRUG|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
214547103|NCT03946202|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
214547104|NCT05534932|DEVICE|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
214547105|NCT02509520|DIETARY_SUPPLEMENT|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
214547106|NCT02346929|OTHER|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
214547107|NCT01632189|DRUG|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
214547108|NCT00485953|DRUG|risedronate|risedronate 35 mg per week
214547109|NCT03496077|OTHER|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
214547110|NCT01673789|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
214547111|NCT03736538|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
214547112|NCT03736538|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
214547113|NCT05034939|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
214547114|NCT05034939|DEVICE|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
214547115|NCT00489801|OTHER|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
214547116|NCT05681273|DRUG|Chiglitazar|Chiglitazar 48mg
214547117|NCT05681273|DRUG|Empagliflozin|Empagliflozin 10mg
214547118|NCT05681273|DRUG|Atorvastatin|Atorvastatin 20mg
214699374|NCT06816420|OTHER|Cold Application|The effects of local cold application on pain and vital signs during port catheter needle insertion will be studied in this group.
214699375|NCT06892652|OTHER|Supportive care measures|shared decision making with patients and families to receive specialist palliative care
214699376|NCT01369316|PROCEDURE|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
214699377|NCT01369316|PROCEDURE|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
214547119|NCT05681273|DRUG|Valsartan|Valsartan 160mg
214547120|NCT00551499|DEVICE|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
214547121|NCT03910777|DIAGNOSTIC_TEST|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
214547122|NCT04267055|DEVICE|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
214547123|NCT05465759|OTHER|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
214699378|NCT04939077|BIOLOGICAL|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
214699379|NCT02551133|DRUG|dexamethasone|1 hour before surgery
214547124|NCT03515304|DRUG|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
214547125|NCT03515304|DRUG|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
214547126|NCT04042818|DIAGNOSTIC_TEST|Rehabilitative Ultrasound|Ultrasound imagining
214699380|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation active stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
214699381|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation sham stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
214699382|NCT06898268|DRUG|Metoclopramide|Patients were prescribed metoclopramide twice a day for one week.
214699383|NCT06898268|DRUG|Ondansetron|Patients were put on oral ondansetron in BD doses for one week.
214547127|NCT00483028|DRUG|donezepil (Aricept)|
214547128|NCT00301483|DRUG|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
214699384|NCT06899048|DIAGNOSTIC_TEST|residual neuromuscular block risk prediction score|it is a clinical tool designed to estimate the likelihood of residual neuromuxcular blockade in postoperative patients
214699385|NCT04611711|DRUG|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
214699386|NCT04611711|DRUG|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
214699387|NCT01877382|DRUG|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
215160409|NCT03733886|DEVICE|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
214699388|NCT01877382|DRUG|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
214699389|NCT00649467|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
214699390|NCT00649467|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
214699391|NCT03829332|BIOLOGICAL|Pembrolizumab|IV infusion
214699392|NCT03829332|DRUG|Lenvatinib|oral capsule
214699393|NCT03829332|DRUG|Placebo for lenvatinib|oral capsule
214699394|NCT06930326|OTHER|intradermal exosome|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
214699395|NCT06930326|OTHER|0.9 % NaCl|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
214699396|NCT05050721|OTHER|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
214699397|NCT04065880|OTHER|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
215160410|NCT01599988|DIETARY_SUPPLEMENT|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
214547129|NCT00301483|OTHER|Standard of Care|Standard Therapy
214547130|NCT06086678|OTHER|Conventional physical therapy|"1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise."
214547131|NCT06086678|OTHER|Hydrotherapy|"1. Water walking exercise.~2. Forward lunges exercise.~3. Single leg balance exercise.~4. Side stepping exercise.~5. Push ups exercise.~6. Standing knee lifts exercise."
214699398|NCT04065880|OTHER|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
214699399|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
214699400|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
214699401|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
214699402|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
214699403|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
214699404|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
214699405|NCT01996202|DRUG|Ipilumimab|
214699406|NCT01996202|RADIATION|Radiation|
214699407|NCT02808533|DRUG|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
215160411|NCT01599988|DIETARY_SUPPLEMENT|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
215160412|NCT02147561|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
215160413|NCT04799093|DIAGNOSTIC_TEST|EyeBOX|Eye-Tracking based diagnostic
215160414|NCT06222788|DEVICE|Convertible Plasma Jet|NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
215160415|NCT05727852|DIAGNOSTIC_TEST|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
214699408|NCT02808533|OTHER|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
214699409|NCT02592603|DEVICE|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
214699410|NCT06355557|OTHER|AI enabled ultrasound system for self-directed learning|use of the AI enabled ultrasound system for self-directed learning
214699411|NCT06355557|OTHER|Simulator for self-directed learning|use of the simulator for self-directed learning
214699412|NCT06355557|OTHER|traditional with human instructors|Medical students who are randomised to this arm
214699413|NCT00746031|DRUG|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
214699414|NCT00746031|DRUG|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
214699415|NCT02973464|DRUG|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
214547132|NCT06086678|OTHER|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
214547133|NCT00678483|DRUG|rimonabant (SR141716)|once daily
214547134|NCT01980602|PROCEDURE|Supervised Exercise program|
214699416|NCT02973464|DRUG|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
214699417|NCT05641818|OTHER|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
214699418|NCT04752189|BEHAVIORAL|Enhanced Replicating Effective Programs (Enhanced REP)|Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.
214699419|NCT04752189|BEHAVIORAL|Standard implementation|The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
214699420|NCT03422133|OTHER|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
214699421|NCT04134325|BIOLOGICAL|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
214699422|NCT04134325|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
214699423|NCT05374551|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
214699424|NCT06302309|OTHER|Psychological intervention|The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
214699425|NCT02198651|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
214699426|NCT02198651|OTHER|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
214699427|NCT02115113|DRUG|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
214699428|NCT02115113|DRUG|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
214699429|NCT01011036|DRUG|clobazam|test substance
214699430|NCT01011036|DRUG|clonazepam|positive control
214699431|NCT01011036|DRUG|tolterodine|active placebo
215160416|NCT05727852|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
215160417|NCT05727852|DIAGNOSTIC_TEST|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
215160418|NCT02829567|BEHAVIORAL|Motivational interviewing|
215160419|NCT00262626|DRUG|Intraocular pressure reduction|
215160420|NCT00262626|PROCEDURE|Argon laser trabeculoplasty|
215160421|NCT00262626|PROCEDURE|Trabeculectomy|
214547135|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
214547136|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
214547137|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
214547138|NCT00745771|DRUG|Diractin|
214547139|NCT00745771|DRUG|Diractin|
214547140|NCT05036525|DEVICE|HANBIO BarriGel|an anti-adhesive product
214547141|NCT06213324|DRUG|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
214547142|NCT06213324|DRUG|Placebo|Normal saline delivered intravenously
214547143|NCT04162002|DRUG|Restylane® Lyft|Filler Injection
214699432|NCT01967524|DRUG|botulinum toxin A + ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
214699433|NCT01967524|DRUG|Ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
214699434|NCT05719051|DRUG|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
214547144|NCT01873326|DRUG|Paclitaxel|
214547145|NCT01873326|DRUG|Ifosfamide|
214547146|NCT01873326|DRUG|Cisplatin|
214547147|NCT01873326|DRUG|Mesna|
214547148|NCT01873326|DRUG|Bleomycin|
214547149|NCT01873326|DRUG|Etoposide|
214547150|NCT01013545|BEHAVIORAL|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
214699435|NCT05724017|BEHAVIORAL|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
214699436|NCT00383578|DRUG|Vildagliptin 100 mg qd|
214699437|NCT00383578|DRUG|Metformin 1500 mg daily|
215160422|NCT02952443|BEHAVIORAL|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
215160423|NCT02952443|BEHAVIORAL|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
214547151|NCT02927015|OTHER|Purple Majesty potato chips|Purple Majesty potato chips
214547152|NCT02927015|OTHER|Mountain Rose potato chips|Mountain Rose potato chips
214547153|NCT02927015|OTHER|White potato chips|White potato chips
214547154|NCT02927015|OTHER|Crackers|Crackers
214547155|NCT03848884|BEHAVIORAL|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
214547156|NCT02947100|DRUG|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
214547157|NCT01093443|DRUG|ovarian stimulation|rFSH with GnRH antagonists
214547158|NCT01093443|DRUG|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
214547159|NCT04706689|BEHAVIORAL|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
214547160|NCT04706689|BEHAVIORAL|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
214547161|NCT00621205|BEHAVIORAL|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
214547162|NCT00025909|PROCEDURE|Leukapheresis|
214547163|NCT02402322|BEHAVIORAL|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
214547164|NCT02402322|BEHAVIORAL|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
214547165|NCT06035536|DEVICE|Symphony™ plus Off-loading|Application of Symphony™
214547166|NCT06035536|DEVICE|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
214547167|NCT00530582|DRUG|progesterone|300mg progesterone /placebo each for 21 days
214547168|NCT04442347|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
214547169|NCT04442347|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
214547170|NCT01408810|DRUG|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
214547171|NCT05400837|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
214547172|NCT02472145|DRUG|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/\[m\^2\]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
214547173|NCT02472145|DRUG|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
214547174|NCT05297344|PROCEDURE|direct pulp capping|direct pulp capping
214547175|NCT05297344|PROCEDURE|pulpotomy|pulpotomy
214547176|NCT03567642|DRUG|Osimertinib|Osimertinib 80mg daily
214547177|NCT03567642|DRUG|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
214547178|NCT03567642|DRUG|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
214547179|NCT05833659|PROCEDURE|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
214547180|NCT01828866|BEHAVIORAL|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
214547181|NCT01828866|BEHAVIORAL|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring"
214547182|NCT05100810|OTHER|Natural History Study|Longitudinal assessment of disease progression of Angelman syndrome in patients
214547183|NCT01080326|DEVICE|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
214547184|NCT04189055|DRUG|Cetuximab|Cetuximab 500mg/m² IV, day 1
214547185|NCT04189055|DRUG|Irinotecan|Irinotecan 180mg/m² IV, day 1
214547186|NCT04097847|DRUG|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
214547187|NCT06002646|DRUG|Formocresol|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
214547188|NCT06002646|DRUG|Sodium Hypochlorite Solution|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
214547189|NCT06002646|DEVICE|Diode laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.
214547190|NCT06002646|DEVICE|Er,Cr:YSGG laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
214547191|NCT00074295|BIOLOGICAL|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
214547192|NCT04443478|PROCEDURE|Radical gastrectomy with dissection of lower mediastinal lymph node|Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
214699438|NCT05246241|DEVICE|magnetic resonance imaging|Preoperative magnetic resonance imaging
214547193|NCT01296555|DRUG|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
214547194|NCT01296555|DRUG|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
214547195|NCT01296555|DRUG|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
214547196|NCT01296555|DRUG|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
214547197|NCT05762419|DRUG|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
214547198|NCT05762419|DEVICE|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
214547199|NCT02008071|BEHAVIORAL|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
214547200|NCT02008071|BEHAVIORAL|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
214547201|NCT03998722|DEVICE|Vagivital|Vagivital once Daily for 12 weeks
214547202|NCT05489562|DEVICE|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
214547203|NCT03452683|BEHAVIORAL|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
214547204|NCT06300983|BEHAVIORAL|Psychoeducative|The intervention consiste of 5 sessions (Table 1), with each lasting 100 minutes and delivered on a weekly basis. Individual meetings will be conducted with each participant prior to starting the group work. These were considered pre-intervention sessions, during which patients provided informed consent to participate in the study and the first assessment tests were administered.
214547205|NCT06300983|BEHAVIORAL|Placebo|The control group, which do not receive any psychoeducative intervention
214547206|NCT04563299|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
214699439|NCT01708707|DRUG|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
214699440|NCT01708707|DRUG|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
214699441|NCT02485548|DRUG|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
214699442|NCT02485548|DRUG|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
214699443|NCT02485548|DRUG|Cisplatin|All patients will receive concurrent cisplatin.
214699444|NCT02485548|RADIATION|IMRT|All patients will receive IMRT
214699445|NCT00089271|DRUG|alvespimycin hydrochloride|Given IV
214699446|NCT00089271|OTHER|laboratory biomarker analysis|Correlative studies
214699447|NCT01313364|DEVICE|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
214699448|NCT03700788|DRUG|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
214699449|NCT03700788|DRUG|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
214699450|NCT02622724|DRUG|Interferon beta-1a|Investigational drug
214699451|NCT02622724|DRUG|Placebo|Placebo for investigational drug
214547207|NCT04563299|DRUG|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
214547208|NCT03531554|DIETARY_SUPPLEMENT|ketone ester drink|395 mg of ketone ester/kg
214547209|NCT03531554|BEHAVIORAL|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
214547210|NCT03531554|PROCEDURE|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
214699452|NCT02345824|DRUG|Ribociclib|CDK4/6 INHIBITOR
214699453|NCT00296725|DRUG|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
214699454|NCT00296725|DRUG|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
214699455|NCT05098548|PROCEDURE|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
215160424|NCT05818969|BEHAVIORAL|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
215160425|NCT04635540|BEHAVIORAL|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
214547211|NCT03531554|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
214547212|NCT04457817|DEVICE|CRI|Monitoring via CRI
214547213|NCT01617499|BEHAVIORAL|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
214547214|NCT06333977|DRUG|LC542019|oral dose, once daily
214547215|NCT06333977|DRUG|Placebo|matching placebo
214547216|NCT01183442|DRUG|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
214547217|NCT05502822|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
215160426|NCT05263778|DRUG|Bempedoic Acid / Ezetimibe Oral Tablet|Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
215160427|NCT05263778|DRUG|Placebo|Matching placebo by mouth once daily for 12 weeks
215160428|NCT00528593|DRUG|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
215160429|NCT04578236|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
215160430|NCT04578236|DRUG|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
214547218|NCT05502822|DEVICE|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
214547219|NCT01355640|OTHER|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
214547220|NCT01355640|OTHER|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
214547221|NCT05554042|DIAGNOSTIC_TEST|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
214547222|NCT05175300|DEVICE|Prosthesis with CoPXE couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
214547223|NCT05175300|DEVICE|Prosthesis with CoC torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
214547224|NCT03212755|DIAGNOSTIC_TEST|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
214547225|NCT04288414|DIAGNOSTIC_TEST|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
214547226|NCT04452591|BIOLOGICAL|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
214547227|NCT04452591|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
214547228|NCT05759377|DEVICE|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
214547229|NCT03817723|RADIATION|c-arm cholangiography|
214547230|NCT05964959|OTHER|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
214547231|NCT05964959|OTHER|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
214547232|NCT05643898|BEHAVIORAL|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
214699456|NCT05734326|DEVICE|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA \[18\].
214699457|NCT05478330|DRUG|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
214699458|NCT05478330|DRUG|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
214699459|NCT02997384|OTHER|Information|information of women about their risk of breast cancer and the screening methods recommended for them
214699460|NCT05425875|PROCEDURE|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure \<100 mmHg
214699461|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
214699462|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
214699463|NCT00356863|BEHAVIORAL|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
214699464|NCT01850862|OTHER|Collective group exercise program in patients with KOA|
214699465|NCT01850862|OTHER|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
214699466|NCT03101059|PROCEDURE|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
214699467|NCT00394238|PROCEDURE|Ultrasonographic imaging|
214699468|NCT06048926|DRUG|Carrelizumab|200 mg/time, iv, Q3W
214699469|NCT06048926|DRUG|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
214699470|NCT06048926|DRUG|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
214699471|NCT06048926|RADIATION|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
214699472|NCT05577091|GENETIC|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
214699473|NCT02637024|RADIATION|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
215160431|NCT03691194|DIETARY_SUPPLEMENT|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
215160432|NCT03691194|DIETARY_SUPPLEMENT|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
215160433|NCT02874976|DEVICE|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
215160434|NCT02874976|DEVICE|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
214547233|NCT04263805|OTHER|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
214547234|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
214547235|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
214547236|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
214547237|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
214547238|NCT01046422|DRUG|Placebo|Capsule, Oral, 0mg, Daily, 28 days
214547239|NCT01046422|DRUG|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
214547240|NCT01052389|DRUG|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
214547241|NCT01052389|DRUG|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
214547242|NCT01052389|DRUG|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
214547243|NCT00677768|OTHER|No intervention|Sample collection
214547244|NCT00409409|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214547245|NCT00409409|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214547246|NCT04012723|DEVICE|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
214547247|NCT04296045|DIETARY_SUPPLEMENT|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
214547248|NCT04296045|DIETARY_SUPPLEMENT|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
214547249|NCT01200498|DRUG|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
214699474|NCT02637024|RADIATION|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
214699475|NCT05283863|DEVICE|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
215160435|NCT02874976|DEVICE|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
215160436|NCT02874976|DEVICE|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
215160437|NCT03336112|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
215160438|NCT03336112|OTHER|Information program|Information program delivered by the Internet during 5 weeks.
215160439|NCT01191762|DRUG|sevelamer carbonate|2400 mg with each meal for 4 weeks
215160440|NCT01191762|DRUG|placebo|3 tablets with each meal
215160441|NCT03554564|BEHAVIORAL|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
215160442|NCT03554564|OTHER|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
215160443|NCT02679118|DEVICE|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
215160444|NCT00005035|DRUG|oxaliplatin|
215160445|NCT00984997|PROCEDURE|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
215160446|NCT00984997|RADIATION|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
215160447|NCT00984997|DRUG|Cisplatin|50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
215160448|NCT00984997|DRUG|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
215160449|NCT00984997|RADIATION|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
214547250|NCT05281289|OTHER|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
214547251|NCT05281289|OTHER|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
214547252|NCT05281289|OTHER|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
214547253|NCT02247843|BIOLOGICAL|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
214547254|NCT01989949|DRUG|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
214547255|NCT03980990|DRUG|Metformin|Continuation of Metformin
214547256|NCT01087515|OTHER|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
214699476|NCT05283863|DEVICE|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
214699477|NCT03520439|DRUG|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
215160450|NCT06384118|BEHAVIORAL|Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study|Based on IMB health education theory Questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; hypoglycemia knowledge promotion on the second day; Peer experience sharing on the third day; access to WeChat group and knowledge pushing on the fourth day; hypoglycemia-related lectures and practical teaching on the fifth day, face-to-face teaching and development of blood glucose management plan. Hypoglycemia knowledge contest on the day before discharge; One week, two weeks and three weeks after discharge for WeChat push or phone call; WeChat push, phone call and questionnaire.
215160451|NCT00746057|BIOLOGICAL|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
215160452|NCT00505401|BIOLOGICAL|recombinant HIV-1 Tat protein|
215160453|NCT02003599|DEVICE|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
215160454|NCT02003599|DEVICE|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
214547257|NCT04756206|DRUG|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
214547258|NCT04756206|DRUG|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
214547259|NCT00966030|DRUG|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
214547260|NCT00966030|DRUG|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
214547261|NCT04040998|BEHAVIORAL|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
214547262|NCT03380364|DEVICE|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
214547263|NCT00820664|DRUG|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
214547264|NCT00820664|DRUG|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
214547265|NCT00820664|DRUG|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
214547266|NCT05967078|DEVICE|ExerG|"The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training."
214547267|NCT04657562|DRUG|Tacrolimus|Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
214547268|NCT04657562|DIAGNOSTIC_TEST|Unbound tacrolimus measurement|Unbound tacrolimus measurement in plasma ultrafiltrate.
214547269|NCT04657562|DIAGNOSTIC_TEST|CYP3A4 and CYP3A5 genotyping|DNA purification and genotyping
214547270|NCT03137706|PROCEDURE|Biospecimen Collection|Undergo fresh tumor tissue collection
214547271|NCT03137706|OTHER|Laboratory Biomarker Analysis|Correlative studies
214547272|NCT03137706|OTHER|Laboratory Procedure|Tissue stiffness and cell viability analysis
214547273|NCT03970499|PROCEDURE|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
214547274|NCT02163707|DRUG|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
214547275|NCT03635086|BIOLOGICAL|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
214547276|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
214547277|NCT03635086|BIOLOGICAL|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
214699478|NCT03520439|DRUG|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
214699479|NCT00267371|DEVICE|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
214547278|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.
214547279|NCT03635086|OTHER|Placebo|Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
214547280|NCT03000348|DRUG|Cysteamine|Oral Cysteamine Capsule
214547281|NCT03000348|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
214547282|NCT06034899|DRUG|BMS-986196|Specified dose on specified days
214547283|NCT02429986|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
214547284|NCT04353206|BIOLOGICAL|Multiple Doses of Anti-SARS-CoV-2 convalescent plasma|Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
214547285|NCT00458588|OTHER|physiologic testing|
214547286|NCT00458588|OTHER|questionnaire administration|
214547287|NCT00458588|PROCEDURE|breast imaging study|
214547288|NCT00458588|PROCEDURE|dual x-ray absorptometry|
214547289|NCT00458588|PROCEDURE|evaluation of cancer risk factors|
214547290|NCT00458588|PROCEDURE|magnetic resonance imaging|
214547291|NCT04042077|DRUG|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
214547292|NCT04042077|DRUG|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
214547293|NCT04042077|DRUG|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
214547294|NCT04042077|DRUG|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
214547295|NCT04042077|DRUG|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
214547296|NCT00387699|BIOLOGICAL|bevacizumab|
214547297|NCT00387699|DRUG|cisplatin|
214547298|NCT00387699|DRUG|etoposide|
214547299|NCT00387699|RADIATION|radiation therapy|
214547300|NCT02661633|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
214547301|NCT02661633|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
214547302|NCT01367444|DRUG|SAR422459|"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
214547303|NCT03159351|DEVICE|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
214547304|NCT03159351|DEVICE|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
214547305|NCT00298675|DRUG|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
214547306|NCT00298675|DRUG|irinotecan|Irinotecan administered weekly, IV.
214547307|NCT04502797|BEHAVIORAL|Electronic Patient Visit Assessment (ePVA)|The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
214547308|NCT05196451|BEHAVIORAL|Rehabilitation based on CBT principles|Cf. arm description
214699480|NCT00267371|DRUG|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
214699481|NCT00590915|DRUG|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
214699482|NCT01216592|OTHER|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
214547309|NCT05597423|OTHER|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
214547310|NCT05597423|OTHER|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
214547311|NCT03995342|DIETARY_SUPPLEMENT|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
214547312|NCT03995342|DIETARY_SUPPLEMENT|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
214547313|NCT01932268|DRUG|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
214547314|NCT02442193|OTHER|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
214547315|NCT02188537|DRUG|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
214547316|NCT02188537|DRUG|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
214547317|NCT02188537|DRUG|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
214547318|NCT00513747|BIOLOGICAL|rituximab|Given IV over 4 hours
214547319|NCT00513747|DRUG|fludarabine phosphate|Given IV over 30 minutes
214547320|NCT01198106|DRUG|scopolamine|0.6 mg
214547321|NCT01198106|DRUG|cinnarizine|50 mg
214547322|NCT02409446|DIETARY_SUPPLEMENT|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
214547323|NCT02365103|OTHER|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
214547324|NCT02365103|OTHER|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
214547325|NCT02365103|OTHER|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
214547326|NCT02365103|OTHER|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
214547327|NCT05578430|DRUG|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
214547328|NCT05578430|PROCEDURE|TACE|TACE will be performed per institutional standard of care.
214699483|NCT04068064|PROCEDURE|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
214547329|NCT05578430|PROCEDURE|Surgery|Surgery will be performed per institutional standard of care.
214547330|NCT00943046|DEVICE|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
214547331|NCT00827554|DRUG|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
214547332|NCT00827554|PROCEDURE|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
214699484|NCT04068064|PROCEDURE|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
214699485|NCT02241044|DEVICE|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
214547333|NCT01084226|DIETARY_SUPPLEMENT|Rye-2008|
214699486|NCT02241044|DEVICE|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
214699487|NCT04061681|BEHAVIORAL|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
214699488|NCT03424889|DRUG|Xylometazoline|Nasal administration of Xylometazoline
214699489|NCT03424889|DRUG|Saline|Nasal administration of 0.9% Saline
214699490|NCT04044209|DRUG|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
214547334|NCT06260488|PROCEDURE|Endovascular surgery|routine endovascular surgery and FPAS harvesting from amputated limbs to evaluate the technical feasibility of histological segmentation by the FPAS algorithm from CT
214699491|NCT04044209|DRUG|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
214699492|NCT03712345|DRUG|IFX-1 low dose|Single IV infusions of IFX-1
214699493|NCT03712345|DRUG|IFX-1 high dose|Single IV infusions of IFX-1
214699494|NCT03712345|DRUG|Placebo|Placebo
214547335|NCT02271022|OTHER|Non-Interventional Study|Non-Interventional Study
214547336|NCT03639727|DIAGNOSTIC_TEST|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
214547337|NCT03639727|DIAGNOSTIC_TEST|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
214547338|NCT00884897|DRUG|Oxytocin|Oxytocin given as 20 IU BID
214547339|NCT00884897|DRUG|Placebo|Placebo given as 20 IU BID
214547340|NCT01980004|DIETARY_SUPPLEMENT|Potassium Citrate Supplementation|20 mEq taken twice daily
214547341|NCT01980004|OTHER|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
214547342|NCT03375736|DEVICE|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
214547343|NCT04452136|DRUG|68GA PSMA-HBED-CC|Given IV
214547344|NCT01236352|DRUG|BMS-911543|
214547345|NCT01282515|DRUG|clobetasol propionate 0,05% ointment|continuously daily treatment for 6 weeks
214547346|NCT01282515|DRUG|hexaminolevulinate|one PDT treatment
214547347|NCT00001649|DRUG|Valaciclovir|
214547348|NCT04786613|OTHER|Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
214547349|NCT04786613|OTHER|Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
214547350|NCT04786613|OTHER|Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection|"Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
214547351|NCT00105105|DRUG|Mifepristone|
214547352|NCT01545557|DEVICE|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
214547353|NCT00487032|DRUG|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
214547354|NCT00487032|DRUG|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
214547355|NCT00487032|DRUG|Prazosin hydrochloride|Prazosin 1mg one dose only
214547356|NCT00487032|DRUG|Placebo to Prazosin|Placebo 1 tablet one dose only
214547357|NCT04488042|OTHER|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
214547358|NCT04488042|OTHER|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
214547359|NCT06152679|OTHER|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
214547360|NCT04032912|DIAGNOSTIC_TEST|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
214547361|NCT00332969|DRUG|Octreotide|
215160455|NCT06227793|BEHAVIORAL|pharmaceutical intervention|Individuals randomized to the intervention group will undergo monthly pharmaceutical consultations for health education, initiated after randomization. There will be three in-person consultations, starting in month 1 with monthly spacing, scheduled by the pharmacist in the office, except for the first consultation, which will be scheduled by the pharmacist over the phone after randomization. These consultations will be part of the intervention study's educational process and will take place between the initial and final assessments. The educational process scripts for each consultation include a pharmaceutical follow-up form and an inhalation technique assessment form. Once the consultation is completed, the patient will also receive, via WhatsApp and/or email according to their preference, an educational video demonstrating the step-by-step inhalation technique based on their prescribed treatment.
215160456|NCT04518267|BEHAVIORAL|Structured clinical interview|A structured clinical interview will be performed at enrollment.
215160457|NCT04518267|BEHAVIORAL|Psychological questionnaires|Several psychological questionnaires will be performed at enrollment.
214547362|NCT01368237|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
214547363|NCT01963169|BEHAVIORAL|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
214547364|NCT01963169|BEHAVIORAL|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
214547365|NCT04975503|OTHER|Observing cardiovascular risk factors|Documenting the presence or absence of CVD risk factors in each participant.
214547366|NCT05026489|GENETIC|G6PD gene deficiency|we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
214547367|NCT05404555|OTHER|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
214547368|NCT06464315|PROCEDURE|Functional Substrate-Only Mapping without VT Induction|In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
214547369|NCT06464315|PROCEDURE|Standard-of-Care Mapping/Imaging|Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
214547370|NCT06316700|DIETARY_SUPPLEMENT|Nutritional supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
214547371|NCT06316700|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214699495|NCT02765633|DRUG|Cangrelor|
215160458|NCT06193226|OTHER|Cryotherapy|"Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure.~The spray's nozzle of the Cryogun spray -50 ◦C was situated 1 cm away from the skin's surface and applied on the oral lesion for 30 seconds. Each freezing cycle lasted 10 to 30 seconds, with the subsequent 60-second thaw interval lasting twice as long as the freezing time. The ice ball that formed during freezing was totally melted before the subsequent freezing process could begin.~The application process should went from the core out to the edges. The management of lesions that are too big to be frozen by a single spray requires many overlapping treatments of liquid nitrogen. Mucoceles and erosive lichen planus took 30 to 50 seconds to freeze, whereas fibromas and leukoplakia took 60 to 70 seconds."
214547372|NCT04101565|BEHAVIORAL|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
214547373|NCT06267911|OTHER|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
215160459|NCT02279264|DEVICE|RightSpot Infant pH Indicator|pH indicator
214547374|NCT06114277|OTHER|ETCO2 levels|Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in group 1.
214547375|NCT06114277|OTHER|Patients with high ETCO2 levels|Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
214547376|NCT02023775|DEVICE|Melody valve implantation|
214547377|NCT04942158|PROCEDURE|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
214547378|NCT04942158|PROCEDURE|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
214547379|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
214547380|NCT04913948|OTHER|No intervention|No intervention
214547381|NCT03652571|DRUG|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
214547382|NCT03652571|DRUG|Placebo|Placebo
214547383|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
214547384|NCT00170261|DEVICE|Use of an Implantable Loop Recorder|
214547385|NCT01068210|BEHAVIORAL|Aerobic Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
214547386|NCT01068210|BEHAVIORAL|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
214547387|NCT01068210|BEHAVIORAL|Resistance Training|The ultimate goal for resistance training alone is 3 resistance training session/week at an intensity above 50% to 85% of 1-RM for 30-60 minutes/session. Resistance trainings will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Participants will be progressively trained to perform two to three sets of 75-85% of maximal strength.
214547388|NCT01068210|BEHAVIORAL|Aerobic and Resistance Training|The ultimate goal will be three combined exercise sessions per week at an intensity above 50% VO2speak and above 50% 1-RM for aerobic and resistance training, respectively for 30-90 minutes/session.
214547389|NCT05549609|BIOLOGICAL|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
214547390|NCT05549609|OTHER|Vehicle|CryoStor CS10 cryomedium
214547391|NCT06279728|DRUG|Datopotamab deruxtecan|6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
214547392|NCT00170300|DEVICE|Implantable Cardiac Resynchronisation (pacing) device|
214547393|NCT02591719|DEVICE|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
214547394|NCT02591719|DEVICE|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
214547395|NCT02591719|DEVICE|MagPro magnetic stimulator (LF rTMS)|"Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session"
214547396|NCT05446584|DEVICE|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
214547397|NCT01476163|DRUG|migalastat HCl 150 mg|150 mg capsule
214547398|NCT01476163|DRUG|migalastat HCl 20 mg|20 mg dispersible tablets; dosing will be based on body weight
214547399|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
214547400|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
214547401|NCT05842928|BEHAVIORAL|PARTNER intervention|"The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)"
214547402|NCT05842928|BEHAVIORAL|Control intervention|The control intervention only comprises a pharmacy visit with brown bag review.
214547403|NCT06853340|BIOLOGICAL|blood sampling|Patients with septic shock will have three differents times of blood sampling and of clinical and biological statements. Healthy volunteers will have a unique visit to collect clinical data and blood samples.
214547404|NCT05304208|BIOLOGICAL|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
214547405|NCT06356610|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
214547406|NCT06356610|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
214547407|NCT06356610|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
214547408|NCT06356610|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
214547409|NCT06356610|OTHER|Reference Product E|Use of Reference Product E in controlled use and ad libitum use sessions
215160460|NCT03898557|BEHAVIORAL|Provision of HIV self-test with Commitment and planning prompts|The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
215160461|NCT03898557|BEHAVIORAL|Provision of HIV self-test|This arm will receive a HIV self-test
214547410|NCT06356610|OTHER|Reference Product F|Use of Reference Product F in controlled use and ad libitum use sessions
214547411|NCT06531538|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine.
214547412|NCT06531538|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
214547413|NCT05939570|OTHER|Interview|Prospective, semi-structured, qualitative interview.
214547414|NCT05709327|OTHER|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
214547415|NCT06402006|PROCEDURE|PENG block|pericapsular nerve group block
214547416|NCT06402006|PROCEDURE|LFCN block|Lateral femoral cutaneous nerve block
214547417|NCT06402006|PROCEDURE|ESP block|Erector spinae plane block
214547418|NCT03789084|BEHAVIORAL|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
214547419|NCT03789084|BEHAVIORAL|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
214547420|NCT03423160|OTHER|None--observational|Observational study of behavior and electrical brain activity
214547421|NCT05834907|BEHAVIORAL|Circle of Security Parenting|"COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs."
214547422|NCT05834907|BEHAVIORAL|Little Talks|Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
214547423|NCT05990387|DRUG|Mirabegron|Dose-response effect on thermogenesis
214547424|NCT05990387|DRUG|Placebo|Placebo control condition
214547425|NCT05840510|DRUG|Adagrasib|KRAS G12C inhibitor
214547426|NCT05840510|DRUG|nab-Sirolimus|mTOR inhibitor
214547427|NCT04750577|DRUG|Placebo matching BI 685509|film-coated tablet
214547428|NCT04750577|DRUG|BI 685509|film-coated tablet
214699496|NCT06375980|OTHER|Intraoperative Mechanical Ventilation Strategies|The intervention involves the management of mechanical ventilation during major abdominal surgery. This includes the adjustment of ventilation parameters such as tidal volume, respiratory rate, peak pressure, positive end-expiratory pressure (PEEP), and inspiratory flow rate. The aim is to optimize ventilation strategies to reduce the risk of postoperative pulmonary complications
214699497|NCT03839017|DEVICE|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
214699498|NCT02842112|OTHER|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
214699499|NCT00649441|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
214547429|NCT04934605|PROCEDURE|Cochlear implantation|Cochlear implantation
214547430|NCT04980378|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
214547431|NCT00056810|DRUG|4-aminopyridine (4-AP)|
214547432|NCT00428025|DRUG|diclofenac|100 mg diclofenac rectal suppository
214547433|NCT00428025|DRUG|placebo|similar shape and size suppository
214547434|NCT02496598|PROCEDURE|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
214547435|NCT02496598|DRUG|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
214547436|NCT02337452|OTHER|Questionnaire Administration|Ancillary studies
214547437|NCT02337452|BEHAVIORAL|Web Site|Communicate via family outreach program website
214547438|NCT05092698|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
214547439|NCT05092698|DIETARY_SUPPLEMENT|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
214547440|NCT01084993|DRUG|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
214547441|NCT01084993|DRUG|Heparin|70 U/kg
214547442|NCT04266847|DEVICE|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
214547443|NCT05783999|DEVICE|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
214547444|NCT05947266|BEHAVIORAL|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
214547445|NCT03371823|OTHER|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
214699500|NCT00649441|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
214547446|NCT03371823|DRUG|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
215160462|NCT02519985|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
215160463|NCT06245980|DRUG|SGLT2 inhibitor|According to whether SGLT2i was used
215160464|NCT04456855|PROCEDURE|Locoregional surgery|Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
215160465|NCT03238430|DRUG|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
215160466|NCT03238430|DRUG|Morphine PCA|a postoperative Morphine PCA
215160467|NCT03238430|DRUG|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
215160468|NCT01829152|DEVICE|CHM|
215160469|NCT02507700|PROCEDURE|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
214547447|NCT01876615|DRUG|YH4808|experimental drug
214547448|NCT01876615|DRUG|Diclofenac|Depain tablet 25mg
214547449|NCT01876615|DRUG|YH4808+Diclofenac|
214547450|NCT01633476|DRUG|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
214547451|NCT02145169|DRUG|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
214547452|NCT01670071|DRUG|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
214547453|NCT01670071|DRUG|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
214547454|NCT04708483|DEVICE|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
214547455|NCT01263054|DEVICE|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
214547456|NCT01263054|OTHER|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
214547457|NCT03616795|DRUG|LY3154207|Administered orally
214547458|NCT03616795|DRUG|[14C]-LY3154207|Administered orally
214547459|NCT06110065|DRUG|CT-guided Pudendal Nerve Cryoneurolysis|CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
214699501|NCT02943265|OTHER|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
214699502|NCT06138327|DRUG|BMN 255|Oral Capsule
214699503|NCT06138327|DRUG|Placebo|Oral Capsule
214699504|NCT01479959|DEVICE|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
215160470|NCT02507700|DRUG|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
215160471|NCT02507700|DEVICE|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
215160472|NCT02507700|OTHER|Plaster cover|Plaster cover will be used to control group for sham procedure
215160473|NCT02507700|DRUG|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
215160474|NCT02507700|OTHER|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
215160475|NCT02743104|DRUG|Ketamine|
215160476|NCT02743104|DRUG|Propofol|
214547460|NCT06110065|DRUG|Percutaneous image-guided cryoneurolysis|Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
214547461|NCT00668785|DRUG|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
214547462|NCT05587452|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is performed to identify whether the patient has colorectal adenoma or cancer
214547463|NCT05587452|DIAGNOSTIC_TEST|Test of ctDNA methylation|A specified panel is used to detect the site of methylation of ctDNA in plasma
214547464|NCT05587452|DIAGNOSTIC_TEST|Test of characteristics of ctDNA fragment|Low pass whole genome sequencing is used to detect the characteristics of ctDNA fragment
214547465|NCT00078143|BEHAVIORAL|Behavior Therapy|
214547466|NCT04001738|OTHER|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
215160477|NCT02743104|DRUG|midazolam and atropine|
215160478|NCT02743104|DRUG|Lidocaine|
215160479|NCT02364635|DRUG|icosabutate|Single dose at each dose levet
215160480|NCT03331640|DRUG|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
215160481|NCT03331640|DRUG|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
214547467|NCT04516005|PROCEDURE|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
214699505|NCT03294668|BEHAVIORAL|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
214699506|NCT03294668|OTHER|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
214699507|NCT02853006|BIOLOGICAL|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
214699508|NCT02853006|PROCEDURE|Biopsy|
214699509|NCT02853006|PROCEDURE|Excised tissues|
214699510|NCT00000118|DEVICE|Sustained-Release Intraocular Drug Delivery System|
214699511|NCT05754697|OTHER|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
214699512|NCT05754697|OTHER|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
214699513|NCT05754697|OTHER|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
215160482|NCT05676840|PROCEDURE|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
215160483|NCT00947687|DRUG|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
215160484|NCT00947687|DRUG|Placebo|
215160485|NCT02453204|BEHAVIORAL|Sitting|
215160486|NCT02453204|BEHAVIORAL|Standing|
214547468|NCT04243512|BEHAVIORAL|Time-restricted eating|Restrict food and beverage intake (except water) to a 10-hour window
214547469|NCT02908984|BEHAVIORAL|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
214547470|NCT02908984|OTHER|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
214699514|NCT03933514|OTHER|Plaque control|Children were instructed about the hygiene procedures
214699515|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
214699516|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
214699517|NCT02003729|DEVICE|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
215160487|NCT02453204|BEHAVIORAL|Walking|
215160488|NCT04098484|OTHER|Control Trial|Participants will abstain from exercise throughout a 3-month period
215160489|NCT04098484|OTHER|Exercise Trial|Participants will execute a 3-month exercise training program
215160490|NCT00038818|BIOLOGICAL|CD8 Depleted Donor Lymphocyte|
214547471|NCT03863860|DRUG|Fluzoparib capsules|Fluzoparib capsules
214547472|NCT03863860|DRUG|Placebo capsules|Placebo capsule
214699518|NCT02640066|OTHER|acupuncture|
214699519|NCT00485589|DRUG|Methotrexate|Oral repeating dose
214699520|NCT00485589|DRUG|Ocrelizumab|Intravenous repeating dose
214699521|NCT00485589|DRUG|Placebo|Intravenous repeating dose
214699522|NCT02585999|DEVICE|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
214699523|NCT02155361|DRUG|Topical Citrullus colocynthis fruit oil (1%)|
215160491|NCT00710541|DEVICE|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
215160492|NCT04968769|OTHER|ischemic compression|manual therapy
215160493|NCT04968769|OTHER|kinesio taping|elastic therapeutic taping
214699524|NCT02155361|DRUG|Topical vehicle oil|
214699525|NCT05126745|DEVICE|color flow Doppler ultrasonography|Doppler ultrasonography
214699526|NCT00249639|BEHAVIORAL|Contingency management|Rewards valued $1-$100
214699527|NCT02104999|DEVICE|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
214699528|NCT00003856|DRUG|temoporfin|
215160494|NCT04968769|OTHER|exercise|posture exercises
215160495|NCT02796261|DRUG|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
215160496|NCT02796261|DRUG|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
215160497|NCT02796261|DRUG|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
215160498|NCT03812276|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
215160499|NCT01043913|DRUG|Guarana extract|Guarana extract 50mg q12 hours for 21 days
215160500|NCT01384149|DEVICE|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
215160501|NCT01384149|DEVICE|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
215160502|NCT01614691|DRUG|SPARC1203|Active
215160503|NCT01614691|DRUG|Placebo|Placebo
215160504|NCT00002751|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
215160505|NCT02283762|DRUG|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
215160506|NCT02283762|DRUG|Placebo|Sham-titration
215160507|NCT05037799|DRUG|Rb-82 Radioisotope|Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
215160508|NCT02501395|OTHER|No intervention, observational|
215160509|NCT05237089|OTHER|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
215160510|NCT05237089|OTHER|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
215160511|NCT05237089|OTHER|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
215160512|NCT00299390|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
214547473|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
214547474|NCT04762069|DRUG|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
214547475|NCT04762069|DRUG|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
214547476|NCT06944470|DRUG|Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma|"Carboplatin Injection:~One dose of carboplatin AUC 5 IV on Day 1 of each 3-week cycle.~Cisplatin injection:~Cisplatin 75 mg/m2 IV on Day 1 of every 3-week cycle.~Paclitaxel injection:~175 mg/m2 IV on Day 1 of each 3-week cycle.~Pemetrexed Injection:~Pemetrexed 500 mg/m2 IV on Day 1 of each 3-week cycle."
214547477|NCT06944470|PROCEDURE|surgery|Subjects with surgical indications will undergo radical surgery for NSCLC，within 4-6 weeks after the last dose of neoadjuvant therapy.
214547478|NCT06944470|RADIATION|Radiochemotherapy|If radical surgery is not suitable after MDT evaluation, the subjects will receive comprehensive treatment mainly based on radiotherapy.
214547479|NCT06944470|DRUG|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days.
214699529|NCT01922778|PROCEDURE|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
214699530|NCT06057636|BEHAVIORAL|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
214699531|NCT06057636|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
214464427|NCT06771934|BIOLOGICAL|omalizumab|Omalizumab Treatment Protocol: The dosage and administration frequency (once every 2 weeks or once every 4 weeks) of omalizumab were determined based on the patients' pretreatment serum total IgE (kU/L), age, and body weight (kg). Each dosage ranged from 15 to 600 mg and was administered subcutaneously. If the dosage was ≤ 150 mg, it was injected subcutaneously at 1 site; otherwise, it was injected subcutaneously at 1 to 4 sites respectively. After the first 3 injections, patients were observed in the hospital for at least 2 hours, and after the 4th and subsequent injections, they were observed for at least 30 minutes. During the treatment period, the background medications for asthma control were adjusted according to the patient's condition.
214547480|NCT05535413|DRUG|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
214547481|NCT01390597|GENETIC|DNA analysis|
214547482|NCT01390597|GENETIC|cytogenetic analysis|
214547483|NCT01390597|GENETIC|gene mapping|
214547484|NCT01390597|GENETIC|mutation analysis|
214547485|NCT01390597|GENETIC|polymerase chain reaction|
214547486|NCT01390597|OTHER|laboratory biomarker analysis|
214699532|NCT00066118|DEVICE|Dental amalgam restorations|
214699533|NCT00799929|OTHER|in vitro fertilization (IVF/ICSI)|
214699534|NCT01369849|DRUG|Akt Inhibitor MK2206|Given PO
214547487|NCT06432972|OTHER|Pulmonary Rehab|Prehab will include 2, one-hour sequential sessions of PR per day as is standard, however this intervention will increase the frequency from 2 days to 4 days per week, for 2 weeks, thus completing 16 sessions of PR prior to surgery. An exercise prescription will be written by the medical director based on initial 6MWD, age, height, weight, and co-morbidities, as is standard of care. Prior to each session, patients are evaluated for symptoms and vital signs are measured. Exercise will include 30 minutes of warm-up and upper and lower extremity resistance training, either against gravity or with resistance bands as appropriate. Exercise will then move to the open gym, where patients utilize endurance equipment of their choosing, such as a treadmill or recumbent bicycle. As with traditional PR, participants will be given online education videos regarding lung health to complete at home, with a supplementary video on breathing techniques to reduce atelectasis from pain.
214699535|NCT01369849|DRUG|Bendamustine Hydrochloride|Given IV
214547488|NCT06184659|DRUG|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
214547489|NCT06184659|DRUG|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
214547490|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine (TIVc)|
214547491|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
214547492|NCT05202873|DIAGNOSTIC_TEST|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.
214547493|NCT04474444|OTHER|attendance by ambulance crew|hear, attendance, convey
214547494|NCT02070679|DRUG|Vitamin E|
214699536|NCT01369849|OTHER|Laboratory Biomarker Analysis|Correlative studies
214699537|NCT01369849|BIOLOGICAL|Rituximab|Given IV
214699538|NCT03661450|DIAGNOSTIC_TEST|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
214699539|NCT02924688|DRUG|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
214699540|NCT02924688|DRUG|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
214699541|NCT02924688|DRUG|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
214699542|NCT02924688|DRUG|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
214699543|NCT02924688|DRUG|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
214699544|NCT02924688|DRUG|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
215160513|NCT03233984|BEHAVIORAL|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
215160514|NCT06316024|DIETARY_SUPPLEMENT|water|The participants drink 240 mL of water approximately 6-8 hours after surgery
214547495|NCT00966264|DRUG|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
214547496|NCT00966264|PROCEDURE|Hysterectomy|operation
214547497|NCT06486142|DRUG|Afatinib/Dacomitinib|Second-generation EGFR-inhibitors
215160515|NCT06316024|DIETARY_SUPPLEMENT|juice/sport drink group|The participants drink 240 mL of juice/sport drink approximately 6-8 hours after surgery
214547498|NCT06486142|DRUG|Osimertinib|Third-generation EGFR-inhibitor
214547499|NCT01246999|BIOLOGICAL|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
215160516|NCT06316024|DIETARY_SUPPLEMENT|Chewing gum group|The participants eat chewing gum approximately 6-8 hours after surgery
215160517|NCT03565419|DEVICE|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
215160518|NCT00202878|DRUG|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
214547500|NCT01246999|BIOLOGICAL|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
214547501|NCT01246999|BIOLOGICAL|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
214547502|NCT01246999|BIOLOGICAL|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
214547503|NCT03811990|BEHAVIORAL|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
214547504|NCT01867047|DRUG|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
214547505|NCT01867047|DRUG|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
214547506|NCT00746629|BEHAVIORAL|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
214547507|NCT04309695|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
214547508|NCT04702516|DRUG|Ozempic|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
214547509|NCT04702516|DRUG|Placebo|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
214547510|NCT06378697|DRUG|AK111|Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.
214547511|NCT06378697|DRUG|Placebo+AK111|Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
214547512|NCT02517814|DIETARY_SUPPLEMENT|Vitamin D|
214547513|NCT00003622|DRUG|paclitaxel|
214547514|NCT00003622|DRUG|vinorelbine tartrate|
214547515|NCT03089996|PROCEDURE|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
214547516|NCT03089996|PROCEDURE|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
214699545|NCT02924688|DRUG|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
214699546|NCT02924688|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
214699547|NCT02924688|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
215160519|NCT00202878|DRUG|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
215160520|NCT00202878|DRUG|Placebo for simvastatin 40 mg|one or two tablets orally daily
214547517|NCT03089996|DEVICE|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
215160521|NCT00202878|DRUG|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
215160522|NCT03146299|PROCEDURE|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
215160523|NCT03284281|DEVICE|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
215160524|NCT03284281|DEVICE|Sham Tragus stimulator|No stimulation will be performed
215160525|NCT04101942|BEHAVIORAL|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
215160526|NCT02334462|BIOLOGICAL|Pfs230D1M-EPA/Alhydrogel|
215160527|NCT02334462|BIOLOGICAL|Pfs25M-EPA/Alhydrogel|
214547518|NCT03089996|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
214547519|NCT04536389|PROCEDURE|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
214547520|NCT04476212|OTHER|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
214547521|NCT00349466|DRUG|CF101|Orally CF101 1mg
214547522|NCT00349466|DRUG|Placebo|Orally matching Placebo
214547523|NCT00170274|DEVICE|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
214547524|NCT00170274|DEVICE|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
214547525|NCT03058380|OTHER|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
214547526|NCT02364596|BIOLOGICAL|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
214547527|NCT02364596|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
214547528|NCT01536587|DRUG|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
214547529|NCT05858255|BEHAVIORAL|Exergaming|Please see Arms description.
214547530|NCT02354651|OTHER|Diaphragm conditioning via phrenic nerve stimulation|Diaphragm pacing will be prescribed by the patient's clinical team.
215160528|NCT02334462|DRUG|TWINRIX|
215160529|NCT02334462|DRUG|Menactra|
215160530|NCT00685568|DRUG|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
215160531|NCT00685568|OTHER|placebo|Orally, twice daily for 3 months
215160532|NCT02439502|DEVICE|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
215160533|NCT05755243|DEVICE|glucose sensor|skin biopsy (punch)
215160534|NCT04462588|DRUG|Cipro 400 MG in 200 ML Injection|medical tratment group
215160535|NCT04462588|DRUG|Flagyl I.V. RTU|medical tratment group
215160536|NCT04462588|PROCEDURE|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
215160537|NCT02083913|BEHAVIORAL|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
215160538|NCT04724824|DEVICE|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
215160539|NCT04724824|DEVICE|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
215160540|NCT02030236|DEVICE|Cooling|Temperature reached Duration of exposure to cold.
214547531|NCT05369949|DRUG|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
214547532|NCT05369949|OTHER|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
214547533|NCT05708547|BIOLOGICAL|Blood samples|at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1
214547534|NCT05708547|PROCEDURE|myocardial tissue samples|use of usually harvested right auricular tissue
214547535|NCT05708547|OTHER|Data collection|pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital
214547536|NCT00645177|DRUG|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
214547537|NCT00645177|DRUG|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
214547538|NCT00645177|DRUG|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
214547539|NCT03430544|DRUG|Cariprazine Oral Capsule [Vraylar]|Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
214547540|NCT03430544|DRUG|Placebo oral capsule|PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
214547541|NCT02986191|PROCEDURE|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
214547542|NCT02986191|PROCEDURE|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
214547543|NCT04696393|DRUG|Mitapivat tablet|Oral tablets
214547544|NCT00577070|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
214547545|NCT04682782|DRUG|Esketamine|Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .
214547546|NCT04682782|DRUG|Saline|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
214547547|NCT02939339|DEVICE|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
214547548|NCT02939339|DEVICE|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
214547549|NCT01515943|OTHER|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
214547550|NCT01515943|PROCEDURE|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
214547551|NCT01515943|OTHER|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
214547552|NCT01515943|PROCEDURE|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~* Weeks 1-4: View the target through prism flippers~* Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~* Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
214547553|NCT01535651|BEHAVIORAL|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
215160541|NCT00602758|BEHAVIORAL|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
214547554|NCT03930329|BEHAVIORAL|MBRP group|same as arm description
214547555|NCT02204020|DRUG|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
214547556|NCT05163795|PROCEDURE|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
214547557|NCT01951404|DRUG|Allopurinol|
214547558|NCT01951404|DRUG|Placebo (for allopurinol)|
214547559|NCT06956456|OTHER|Supervised Multicomponent Training Protocol|"Supervised Multicomponent Training Protocol~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
214547560|NCT06956456|OTHER|Non-Supervised Home-Based Multicomponent Training Protocol|"Participant will receive a personalized exercise plan tailored to their fitness level.~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
214547561|NCT04435444|OTHER|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
214547562|NCT04435444|OTHER|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
214547563|NCT05224843|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
214547564|NCT05834192|OTHER|Backward treadmill walking|Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
214547565|NCT05834192|OTHER|Lower extremity cross training|"For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down."
214547566|NCT03684876|PROCEDURE|diuretic use|use of diuretic
214547567|NCT02806492|OTHER|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
215160542|NCT00602758|BEHAVIORAL|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
215160543|NCT02028208|DIAGNOSTIC_TEST|Ammoniated mercury|Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
215160544|NCT02028208|DIAGNOSTIC_TEST|Aluminum chloride and aluminum lactate|Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
215160545|NCT02028208|DIAGNOSTIC_TEST|Sodium tetrachloropalladate|Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
215160546|NCT02820948|DRUG|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
215160547|NCT03034070|DIAGNOSTIC_TEST|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
215160548|NCT04344561|OTHER|Postural Positioning|Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
215160549|NCT01914341|OTHER|Music|Live music played on the pentatonically tuned children's harp
215160550|NCT03563183|OTHER|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
215160551|NCT06204835|DRUG|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
214547568|NCT02806492|OTHER|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
214547569|NCT02806492|OTHER|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
214547570|NCT02806492|OTHER|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
214547571|NCT02806492|OTHER|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
214547572|NCT02422680|PROCEDURE|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
214547573|NCT06830850|DRUG|HRS-5041 Single dose of HRS-5041 orally administered|HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.
214547574|NCT04663477|DIAGNOSTIC_TEST|patient-completed Caprini Risk Score|The participants will be asked to complete patient-completed Caprini Risk Score
214547575|NCT00540462|PROCEDURE|gastric bypass|
214547576|NCT00540462|PROCEDURE|sleeve gastrectomy|
214547577|NCT02294747|DEVICE|Sliding Hip Screw with Trochanteric Stabilization Plate|
214547578|NCT02294747|DEVICE|Sliding Hip Screw without Trochanteric Stabilization Plate|
214547579|NCT00157781|DEVICE|Medtronic AT500|
214547580|NCT01135654|OTHER|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
214547581|NCT00322244|PROCEDURE|Massage Therapy|
214547582|NCT03415243|DRUG|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters \[mcL\]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel \[MBq\] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
214547583|NCT03415243|DRUG|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi\[4MBq\]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
214699548|NCT02924688|DEVICE|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
215160552|NCT02296983|BIOLOGICAL|VSV-ZEBOV|VSV-ZEBOV
215160553|NCT03801031|DRUG|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
215160554|NCT03801031|DRUG|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
215160555|NCT05068882|DIETARY_SUPPLEMENT|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
215160556|NCT05068882|DIETARY_SUPPLEMENT|High-protein nutrition|Oral nutrition with high-protein content
215160557|NCT05068882|DIETARY_SUPPLEMENT|Standard nutrition|Oral nutrition with standard ingredients
214547584|NCT05360498|BEHAVIORAL|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
214547585|NCT05360498|BEHAVIORAL|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
214547586|NCT02616159|OTHER|Oatmeal|
214547587|NCT03258320|DRUG|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
214547588|NCT01245140|DRUG|alitretinoin|to receive verum (20 patients)
214547589|NCT01245140|DRUG|Placebo|to receive placebo (10 patients)
214547590|NCT05863767|OTHER|Baduanjin sequential therapy|Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.
214547591|NCT05863767|OTHER|Conventional Therapy|Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
214547592|NCT06960980|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. During phase 1 of each training session, on a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During phase 2 of each training session, teens will complete five 5-minute simulated drives using a fixed-base driving simulator. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
214547593|NCT06960980|BEHAVIORAL|VR-FOCAL+|Weekly for 5 weeks, teens complete a training program designed to train teens to limit the length of glances away from the roadway. The training has two phases, each of which will be administered using immersive virtual reality. The first phase will have teens switch between the upper half of a virtual reality screen which will play a simulated video drive while the bottom half contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During the second phase of each session, teens will complete five 5-minute simulated drives in a virtual reality environment where teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
214547594|NCT02766127|OTHER|Veritise Flow|Self-adhering composite
214547595|NCT02766127|OTHER|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
214547596|NCT02766127|OTHER|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
214547597|NCT02766127|OTHER|Flor-Opal® Varnish|fluoride-based varnish
214547598|NCT04526093|OTHER|Medical Cannabis|Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
214547599|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
214547600|NCT06492603|DEVICE|Ultrasonography|Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).
214547601|NCT06492603|DEVICE|The MyotonPRO Device|The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues
214547602|NCT04836559|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
214547603|NCT04836559|DRUG|Placebo|Placebo will be administered orally.
214547604|NCT02635360|DRUG|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
214547605|NCT02635360|RADIATION|Brachytherapy|Radiation is done for standard clinical care purposes.
214547606|NCT02635360|DRUG|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
214547607|NCT04602377|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
214547608|NCT05230537|DRUG|Iptacopan (LNP023)|oral capsules
214547609|NCT05230537|DRUG|Placebo|oral capsules
215160558|NCT04265105|DRUG|fluticasone-vilanterol|LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
215160559|NCT04265105|DRUG|Standard Preparation|inhaled SABA or Inhaled corticosteroid
215160560|NCT00830297|DRUG|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
215160561|NCT00830297|DRUG|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
215160562|NCT00610454|DRUG|Levetiracetam|
215160563|NCT00616785|DRUG|cisplatin|
215160564|NCT00616785|DRUG|etoposide|
214547610|NCT05413005|COMBINATION_PRODUCT|ECP regular-intensity arm|"* Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
214547611|NCT05413005|COMBINATION_PRODUCT|ECP accelerated-intensity arm|"* Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks"
214547612|NCT05413005|BIOLOGICAL|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
214547613|NCT04516369|GENETIC|voretigene neparvovec|Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
214547614|NCT04978350|BEHAVIORAL|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
214547615|NCT03807609|OTHER|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214547616|NCT03807609|OTHER|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214547617|NCT03807609|OTHER|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214547618|NCT05364580|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
214547619|NCT05364580|BIOLOGICAL|Botox®|Botulinum toxin Type A
214547620|NCT04264715|DEVICE|405nm light|In this room, surgeries will be performed under ambient light including the wavelength 405nm
214547621|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
214547622|NCT04573660|DEVICE|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
214547623|NCT04573660|DEVICE|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
214547624|NCT04573660|DEVICE|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
214547625|NCT04573660|DEVICE|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
214547626|NCT04573660|DEVICE|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
214547627|NCT04573660|DEVICE|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
214547628|NCT04573660|DEVICE|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
214547629|NCT04573660|DEVICE|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
214547630|NCT04573660|DEVICE|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
214547631|NCT05574296|DRUG|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
214547632|NCT05574296|OTHER|Usual care|Usual care post-ECPR event, including targeted temperature management.
215160565|NCT00616785|DRUG|irinotecan hydrochloride|
215160566|NCT00616785|RADIATION|radiation therapy|
215160567|NCT02497742|OTHER|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
215160568|NCT00486291|DRUG|VI-0521|phentermine 15mg/topiramate 100mg
215160569|NCT00486291|DRUG|Placebo|matched placebo
215160570|NCT01209702|BIOLOGICAL|tocilizumab|Administered intravenously (iv) every 4 weeks
214547633|NCT05867017|OTHER|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
214547634|NCT05582772|OTHER|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
214547635|NCT05582772|OTHER|RSM intervention|Telephone-based, symptom management of patients with cancer
214547636|NCT05582772|OTHER|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
214547637|NCT04796220|DEVICE|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
214547638|NCT04796220|OTHER|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
214547639|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
214547640|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
214547641|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214547642|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
214547643|NCT06151899|OTHER|Kinesio taping with angle and tension|Kinesio taping by applying angle and tension to back muscle
214547644|NCT05634876|BIOLOGICAL|UB-312 Injection|UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.
214547645|NCT05634876|BIOLOGICAL|Placebo Injection|Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
214547646|NCT06062212|PROCEDURE|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
214547647|NCT03593278|DRUG|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
215160571|NCT01209702|DRUG|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
215160572|NCT04220476|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
215160573|NCT04220476|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
215160574|NCT04220476|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
215160575|NCT02163603|PROCEDURE|Pelvic osteotomy|
215160576|NCT02121821|BEHAVIORAL|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
215160577|NCT00010829|BEHAVIORAL|American Heart Association Step 1 diet|
214547648|NCT05844930|DRUG|Corticosteroid|Triamcinolone 20 mg (1cc)
214547649|NCT05844930|OTHER|ActiveMatrix|1cc ActiveMatrix (Skye Biologics, Inc.)
215160578|NCT00010829|BEHAVIORAL|American Heart Association Step 2 diet + 10 g/day flax seed|
215160579|NCT00010829|BEHAVIORAL|Macrobiotic dietary intervention|
214547650|NCT05844930|DRUG|Lidocaine|Lidocaine 10 mg/mL (5cc)
215160580|NCT03934099|DRUG|LC350189 formulated capsule|Xanthine Oxidase Inhibitor
214547651|NCT06001008|OTHER|PQA|PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
214547652|NCT02078726|DRUG|Glucagon|glucagon (hormone produced by the body) administered through IV
214547653|NCT04400292|OTHER|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
214547654|NCT04400292|DEVICE|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
214547655|NCT04400292|PROCEDURE|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
214547656|NCT02130245|PROCEDURE|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
215160581|NCT03934099|DRUG|Placebo|Matching placebo
215160582|NCT02380469|BEHAVIORAL|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
215160583|NCT03739034|BEHAVIORAL|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
215160584|NCT02010450|OTHER|Wearable Blanket (Sleep Sack)|
215160585|NCT02010450|OTHER|Incentive Item|
214699549|NCT02924688|DEVICE|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
214699550|NCT02790554|DEVICE|Moyo strap-on|Continous monitoring
214699551|NCT02790554|DEVICE|Hand-held Doppler|Intermittent monitoring
214699552|NCT03687138|OTHER|24h urin sample|The samples will analyzed by proteomic techniques
214699553|NCT01661166|DRUG|Fesoterodine|4 mg
214699554|NCT01661166|DRUG|Placebo oral tablet|Placebo
214547657|NCT02130245|PROCEDURE|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
214547658|NCT01296009|DRUG|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
214547659|NCT02383992|DRUG|3% H2O2 solution|
214547660|NCT02383992|DRUG|0.9% normal saline|
214547661|NCT06182345|PROCEDURE|spray skin|autologous skin cell suspension combined with skin graft
214547662|NCT06182345|PROCEDURE|skin graft|skin graft
214547663|NCT02484378|DRUG|CER-001|Engineered pre-beta HDL particle
214547664|NCT02484378|DRUG|Placebo|Normal saline
214547665|NCT02605486|DRUG|Palbociclib|
214547666|NCT02605486|DRUG|Bicalutamide|
214547667|NCT05765435|OTHER|12-week exercise and walking program|The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.
214547668|NCT05765435|DEVICE|NMES|Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.
214547669|NCT05765435|DEVICE|FES|Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
214547670|NCT02761798|DEVICE|Automated Mobile Interactive Audiometer|iPad game
214547671|NCT03836573|BEHAVIORAL|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
214547672|NCT00333905|PROCEDURE|Ischemic exercise training|
214547673|NCT03834389|BEHAVIORAL|Case- based Learning|critical thinking, self efficacy, focus group interview
214547674|NCT01467310|DRUG|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
214547675|NCT05172492|DEVICE|Endocare|Endocare will be administred through a virtual reality headseat used one to twice a day.
214547676|NCT05172492|DEVICE|Digital control|Digital control will be administred through a virtual reality headseat used one to twice a day.
214547677|NCT04377854|OTHER|Observation. No intervention per se.|Observation. No intervention (no collection of blood).
214547678|NCT04377854|OTHER|2) Observation and collection and of blood sample|All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
214547679|NCT00166062|PROCEDURE|Screening patients for IPV|
214547680|NCT01597843|OTHER|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
214699555|NCT00174785|DRUG|dronedarone (SR33589)|oral administration (tablets)
214547681|NCT02701062|DEVICE|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
214547682|NCT02701062|DRUG|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
214547683|NCT00517049|DRUG|PRO95780|Intravenous repeating dose
214547684|NCT00517049|DRUG|rituximab|Intravenous repeating dose
214699556|NCT00174785|DRUG|placebo|oral administration (tablets)
214699557|NCT01314976|DRUG|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
214699558|NCT01314976|DRUG|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
214699559|NCT00274768|DRUG|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
214699560|NCT00120289|DRUG|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
214699561|NCT00120289|DRUG|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
214699562|NCT05871593|GENETIC|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
214547685|NCT03363347|DRUG|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
214547686|NCT02677077|DRUG|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
214547687|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from animal sources.|Diet was prescribed to the participant and menus and recipes were also provided.
214547688|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from plant sources.|Diet was prescribed to the participant and menus and recipes were also provided.
214547689|NCT00121121|BIOLOGICAL|Lipopeptides LIPO-4|
214547690|NCT03823144|DEVICE|Diagnostic Microscopy|Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
214547691|NCT03823144|DRUG|Fluorescein Sodium Injection|Given IV as part of IVM procedure
214547692|NCT04952363|DEVICE|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
214547693|NCT04952363|DEVICE|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
214547694|NCT00337753|BEHAVIORAL|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
214547695|NCT00337753|BEHAVIORAL|Wait-list|subjects assigned to wait-list condition for six-weeks
214547696|NCT05988242|OTHER|Primrose oil|group A will take primrose oil
214547697|NCT05988242|OTHER|Lavender oil|group B will take lavender oil
214547698|NCT05988242|OTHER|placcebo|this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
214547699|NCT00697398|OTHER|Transcranial stimulation|Stimulation to white
214547700|NCT00697398|OTHER|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
214547701|NCT01973140|DRUG|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
214547702|NCT01973140|DRUG|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
214547703|NCT05600140|BEHAVIORAL|Viewing strategy training|Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.
214547704|NCT02738528|OTHER|Mental practice and brushing guidance in patients with Parkinson Disease|
214547705|NCT02162498|BEHAVIORAL|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
214547706|NCT04434248|DRUG|Favipiravir|200 mg coated tablets
214547707|NCT04434248|DRUG|Standard of Care|Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
214547708|NCT05633069|OTHER|Datas analysed by medical records|"Datas analysed by medical records : pupillary parameters: pupillary diameter and pupillary diameter variation. heart rate, the blood pressure, the Behavioral Pain Scale (BPS) pain score before and during painful procedures.~The pupillary parameters were recorded with the AlgiScan® pupillometer (iDMed, Marseille, France), which allows the recording of Pupillary Diameter (PD) variations at the patient's bed at a sampling frequency of 67 hertz."
214547709|NCT03033303|BIOLOGICAL|Hu3F8|Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
214547710|NCT03033303|DRUG|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
214547711|NCT03033303|DRUG|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
214547712|NCT05627869|PROCEDURE|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
214547713|NCT05627869|PROCEDURE|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
214547714|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
214547715|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 1)
214547716|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 15)
214699563|NCT02285712|DEVICE|Vascular ultrasound system|
214699564|NCT03214926|DEVICE|Moving Through Glass intervention|
214699565|NCT03619291|OTHER|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
214699566|NCT03619291|OTHER|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
214699567|NCT03619291|OTHER|control|physical inactivity, reading sports science literature, total duration 15 minutes
214547717|NCT05252845|BIOLOGICAL|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
215160586|NCT02476266|OTHER|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
215160587|NCT04088058|DRUG|GXHPC1|autologous ADSCs
215160588|NCT04783090|DRUG|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
215160589|NCT00528450|DRUG|arsenic trioxide|
215160590|NCT00528450|DRUG|idarubicin|
215160591|NCT00528450|DRUG|tretinoin|
215160592|NCT04710472|DEVICE|Mentora App|"Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria."
215160593|NCT02909543|OTHER|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
215160594|NCT00126490|BIOLOGICAL|Aldesleukin|Given subcutaneously
215160595|NCT00126490|BIOLOGICAL|Bevacizumab|Given IV
215160596|NCT00126490|OTHER|Laboratory Biomarker Analysis|Correlative studies
215160597|NCT02305810|DRUG|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
215160598|NCT00654433|BIOLOGICAL|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
215160599|NCT01931371|PROCEDURE|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
215160600|NCT01931371|PROCEDURE|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
215160601|NCT05118880|OTHER|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
215160602|NCT05606471|DRUG|Semaglutide Pen Injector [Ozempic]|Glucagon-like peptide 1 (GLP-1) receptor agonist
215160603|NCT05606471|DIETARY_SUPPLEMENT|Very-low Calorie Diet|Total meal replacement with a limit of 800 kilocalories per day
214547718|NCT05252845|DRUG|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
214547719|NCT05252845|DRUG|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
214547720|NCT04731259|DRUG|ATR-04|ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
215160604|NCT00045318|DRUG|exatecan mesylate|
215160605|NCT04796194|COMBINATION_PRODUCT|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
215160606|NCT04574635|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215160607|NCT06480487|BEHAVIORAL|Feedback provided face to face|Feedback will be provided face-to-face.
215160608|NCT06480487|BEHAVIORAL|Feedback provided by electronic mail|Feedback will be provided by electronic mail.
215160609|NCT06480487|BEHAVIORAL|Feedback provided by researchers|Feedback will be provided by researchers.
215160610|NCT06480487|BEHAVIORAL|Feedback provided by authoritative bodies|Feedback will be provided by authoritative bodies.
215160611|NCT06480487|BEHAVIORAL|Feedback provided with peer comparision|Feedback will be provided with peer comparison.
214547721|NCT04731259|OTHER|Placebo|Placebo
214547722|NCT02061059|OTHER|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
214547723|NCT02061059|OTHER|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
214547724|NCT02061059|OTHER|standard|patient wears shoes produced with standard method
214547725|NCT02061059|OTHER|with measurements|patient wears shoes produced with plantar pressure measurements
214547726|NCT06022068|DRUG|Sirolimus|7 mg taken once per week during 26 weeks.
214547727|NCT06474299|DRUG|Varenicline|0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
214547728|NCT06474299|DRUG|Nicotine patch|Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
214547729|NCT06474299|BEHAVIORAL|Dual Focused Cessation Counseling|Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
214547730|NCT06474299|BEHAVIORAL|Smoking Focused Cessation Counseling|Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
214547731|NCT06474299|OTHER|Counseling Intensity: 1 Session|Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).
214547732|NCT06474299|OTHER|Counseling Intensity: 4 Sessions|Participants assigned to intensive counseling will have four, 15-20-minute sessions.
214547733|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
214547734|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
214547735|NCT00781937|DRUG|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
214547736|NCT00781937|DRUG|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
214547737|NCT01263249|PROCEDURE|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
214547738|NCT01263249|PROCEDURE|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
214547739|NCT04920747|DRUG|Taxane|docetaxel or paclitaxel
214547740|NCT02967276|DRUG|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
214547741|NCT02967276|DRUG|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
214547742|NCT04698915|DRUG|Drug GC4711|15 Minute IV Infusion
214547743|NCT04698915|DRUG|Placebo|15 Minute IV Infusion
214547744|NCT02992847|OTHER|Unenhanced MRI|
214547745|NCT03964051|DRUG|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
214547746|NCT02379962|OTHER|no intervention|
214547747|NCT00298688|DRUG|Gefitinib|
214547748|NCT00234897|DRUG|adalimumab|
214547749|NCT01150045|DRUG|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
214547750|NCT01150045|DRUG|5-fluorouracil|Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.
214547751|NCT01150045|OTHER|placebo|Patients receive placebo administered by mouth, once daily.
214547752|NCT01150045|DRUG|oxaliplatin|Patients receive 85 mg/m\^2 intravenous over two hours.
214547753|NCT01150045|DRUG|leucovorin|Patients receive 400 mg/m\^2 intravenous over two hours.
214547754|NCT03167853|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
214547755|NCT00791193|DRUG|Paliperidone ER|
214547756|NCT01430637|GENETIC|DNA analysis|
214547757|NCT01430637|GENETIC|RNA analysis|
214547758|NCT01430637|GENETIC|gene expression analysis|
214547759|NCT01430637|GENETIC|mutation analysis|
214547760|NCT01430637|GENETIC|nucleic acid sequencing|
214547761|NCT01430637|GENETIC|polymerase chain reaction|
214547762|NCT01430637|OTHER|laboratory biomarker analysis|
214547763|NCT01430637|OTHER|pharmacogenomic studies|
214547764|NCT02838784|OTHER|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
214547765|NCT02838784|PROCEDURE|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
214547766|NCT00370110|DRUG|Itopride 100 mg|100 mg three times daily
214547767|NCT00370110|OTHER|Placebo|
214547768|NCT00370110|DRUG|Itopride 200 mg|200 mg three times daily
214547769|NCT03124693|DEVICE|Rainbow DCI pulse oximeter sensor|
214547770|NCT06109597|OTHER|75 g glucose tolerance test|Pregnant patient who visited obstetric clinic , who did 75 g glucose tolerance test
214547771|NCT04253847|PROCEDURE|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
214547772|NCT04253847|PROCEDURE|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
214547773|NCT01907932|DEVICE|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
214547774|NCT04658563|OTHER|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
214547775|NCT01114490|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
214547776|NCT05052918|BEHAVIORAL|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
214547777|NCT02735304|OTHER|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
214547778|NCT04225741|BEHAVIORAL|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
214547779|NCT01790295|DRUG|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
214547780|NCT05215691|PROCEDURE|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
214547781|NCT05215691|PROCEDURE|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
214547782|NCT06516679|DRUG|Consolidation #4(without daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
214547783|NCT06516679|DRUG|Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
214699568|NCT01932931|DIETARY_SUPPLEMENT|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
214699569|NCT00651612|DRUG|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
214699570|NCT00651612|DRUG|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
215160612|NCT06480487|BEHAVIORAL|Feedback provided without peer comparision|Feedback will be provided without peer comparision.
214547784|NCT06516679|DRUG|Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation"
214547785|NCT01908751|PROCEDURE|Sliding Hip Screw|
214547786|NCT01908751|PROCEDURE|Cancellous Screws|
214547787|NCT01908751|DRUG|Vitamin D|
214547788|NCT01908751|DRUG|Vitamin D Placebo|
214547789|NCT02489734|DRUG|sevoflurane|extubation when end-tidal concentration of sevoflurane \< 0.5%
214547790|NCT02489734|DRUG|Sevoflurane|extubation when end-tidal concentration of sevoflurane \>= 0.5%
214547791|NCT03597373|OTHER|reintubation|Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
214547792|NCT00179738|DRUG|CC5013|
214547793|NCT04594837|DEVICE|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
214547794|NCT04594837|OTHER|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
214547795|NCT04594837|DEVICE|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
214547796|NCT04594837|DEVICE|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
214547797|NCT00092053|DRUG|Placebo|tablets
215160613|NCT00975780|OTHER|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
215160614|NCT00975780|OTHER|Usual oral care|Usual oral care and feeding positioning
214547798|NCT00092053|DRUG|ibandronate|50 mg tablets
214547799|NCT00420784|DRUG|Telaprevir|tablet
214547800|NCT00420784|DRUG|Ribavirin|tablet
214547801|NCT00420784|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
214547802|NCT00420784|DRUG|Matching Placebo|Tablet
214547803|NCT00002838|BIOLOGICAL|Filgrastim (G-CSF)|
214547804|NCT00002838|DRUG|Cyclophosphamide|
214547805|NCT00002838|DRUG|Fludarabine Phosphate|
214547806|NCT00002838|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
214547807|NCT02322086|DRUG|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
214547808|NCT00148408|DRUG|Montelukast|
214547809|NCT00148408|BEHAVIORAL|Education|
215160615|NCT02699606|DRUG|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
214547810|NCT04884919|DEVICE|Regular Gauze|Regular gauze
214547811|NCT04884919|DEVICE|Chitosan Dressing|Dressing made of chitosan material
214547812|NCT05487235|DRUG|GDC-1971|Capsule or tablet administered orally.
214547813|NCT05487235|DRUG|Atezolizumab|Administered as IV infusion.
214547814|NCT05487235|DRUG|Omeprazole|Administered orally as tablet or capsule in the acid-reducing agent assessment.
214547815|NCT03845270|DRUG|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
214547816|NCT05679804|OTHER|validity and realibility of scale|Turkish validity and realibility of Bipolar Recovery Questionnare
214547817|NCT04081077|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
214547818|NCT04081077|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
214547819|NCT04081077|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
214547820|NCT04081077|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
214547821|NCT04081077|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
214547822|NCT04709653|OTHER|Occupation-based nursing program|"First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille."
214547823|NCT04709653|OTHER|Control Group|Routine nursing care
214547824|NCT05053880|DRUG|ACT001|Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
214547825|NCT05053880|DRUG|ACT001 + Pembrolizumab|Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
214547826|NCT04205357|DRUG|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
214547827|NCT03603639|DRUG|Placebo|Participants will receive E2730-matched placebo capsule, orally.
214547828|NCT03603639|DRUG|E2730|Participants will receive E2730 capsule, orally.
214547829|NCT04345380|OTHER|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
214547830|NCT04345380|OTHER|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
214547831|NCT04345380|OTHER|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
214547832|NCT02934204|DRUG|methotrexate|
214547833|NCT02934204|DRUG|temozolomide|
214547834|NCT00607672|DRUG|Placebo|Placebo
214547835|NCT00607672|DRUG|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
214547836|NCT00607672|DRUG|Candesartan|Candesartan 16mg/d
214547837|NCT00951470|OTHER|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
214547838|NCT00951470|OTHER|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
214547839|NCT00951470|OTHER|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
214547840|NCT04944667|DIAGNOSTIC_TEST|TAVR planning|TAVR planning without VR vs after VR
214547841|NCT02900950|PROCEDURE|Multicolour inking specimens|
215160616|NCT01056016|OTHER|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
214547842|NCT02900950|PROCEDURE|Monocolour inking specimens|
215160617|NCT03948945|RADIATION|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
214547843|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
214547844|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/kg every three days.
214547845|NCT01436747|DRUG|Paricalcitol|2 micrograms daily, peroral, 24 weeks
214547846|NCT01436747|DRUG|Placebo|2 micrograms daily, peroral, 24 weeks
214547847|NCT04817423|OTHER|No intervention|No intervention
214547848|NCT04576793|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
214547849|NCT04576793|DRUG|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
214547850|NCT04576793|DRUG|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
214547851|NCT04576793|PROCEDURE|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
214547852|NCT04714463|PROCEDURE|Implant-based breast reconstruction|All types of implant based breast reconstructions
214547853|NCT04714463|PROCEDURE|Autologous breast reconstruction|All types of autologous breast reconstructions
214547854|NCT04714463|PROCEDURE|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
214547855|NCT06003881|DRUG|Pozelimab|Subcutaneous (SC) administration
214547856|NCT01968889|OTHER|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
214547857|NCT00532168|DRUG|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
214547858|NCT00532168|DRUG|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
214547859|NCT00532168|DRUG|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
214547860|NCT02137577|PROCEDURE|DEB catheter|DEB catheter (trade name: Litos/Tulip)
214547861|NCT02137577|PROCEDURE|common PTA balloon catheter|common PTA balloon catheter
214547862|NCT03016598|DRUG|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
214547863|NCT03016598|DRUG|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
214547864|NCT06566183|PROCEDURE|Guideline-directed medical therapy (GDMT)|Participants receive guideline-directed medical therapy (GDMT).
214547865|NCT06566183|PROCEDURE|Coronary artery bypass grafting (CABG)|Participants receive coronary artery bypass grafting (CABG).
214699571|NCT05551338|OTHER|Serious games|The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.
215160618|NCT01695759|DRUG|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
215160619|NCT01695759|DRUG|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
214547866|NCT06566183|PROCEDURE|Percutaneous coronary intervention (PCI).|Participants receive percutaneous coronary intervention (PCI).
214547867|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
214547868|NCT05980416|DRUG|Ramucirumab (CYRAMZA®)|VEGFR2 inhibitor
214547869|NCT05980416|DRUG|Dostarlimab|anti-PD-1 antibody
214547870|NCT01954225|OTHER|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
214547871|NCT02952196|DRUG|drug administration|administering drug to patient with amphetamine addiction
214547872|NCT04051918|BEHAVIORAL|Piano Training|Cognitive training via music learning
214547873|NCT04924049|OTHER|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
214547874|NCT03913559|DRUG|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
214547875|NCT03913559|DRUG|Methotrexate|Intrathecal (IT) therapy
214547876|NCT03913559|DRUG|Hydrocortisone|Intrathecal (IT) therapy
214547877|NCT03913559|DRUG|Cytarabine|Intrathecal (IT) therapy
214547878|NCT03913559|DRUG|Diphenhydramine|1 mg/kg (max 50 mg) IV
214547879|NCT03913559|DRUG|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
214547880|NCT03913559|DRUG|Methylprednisolone|1 mg/kg IV x 1
214547881|NCT03200652|DIETARY_SUPPLEMENT|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
214547882|NCT00996502|DRUG|Docetaxel|"Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
214699572|NCT05034471|DEVICE|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
214699573|NCT03677895|DRUG|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
214699574|NCT00882102|DRUG|Decitabine|Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
214547883|NCT00996502|DRUG|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
215160620|NCT00950820|DRUG|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
214547884|NCT00996502|DRUG|Erlotinib|200 mg of Erlotinib PO daily days 2-16
214547885|NCT00996502|DRUG|Prednisone|5 mg of Prednisone PO bid
215160621|NCT00950820|DRUG|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
215160622|NCT04976582|DEVICE|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
215160623|NCT05656144|DEVICE|Cadonilimab|AK104, 6mg/kg, Q2W
215160624|NCT05494515|PROCEDURE|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
215160625|NCT00241189|DRUG|rapamycin|
215160626|NCT00241189|DRUG|methotrexate|
215160627|NCT04805398|BIOLOGICAL|CM310|300 mg every two weeks
215160628|NCT04805398|BIOLOGICAL|Placebo|300 mg every two weeks
215160629|NCT03051178|DEVICE|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
215160630|NCT04749992|PROCEDURE|Polysomnographic examination in sleep laboratory (PSG measurement)|Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
215160631|NCT04202042|OTHER|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
215160632|NCT04202042|OTHER|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
215160633|NCT02270294|OTHER|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
214547886|NCT01198483|PROCEDURE|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
214547887|NCT01198483|PROCEDURE|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
214547888|NCT06477861|OTHER|calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity|calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)
215160634|NCT02270294|OTHER|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
214547889|NCT02167919|DEVICE|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
214547890|NCT05986045|OTHER|Quality of Life|ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
214547891|NCT00119652|DRUG|quetiapine fumarate (Seroquel)|
214547892|NCT00119652|DRUG|paroxetine|
214547893|NCT00119652|BEHAVIORAL|mood stabilizing activity|
214547894|NCT03662646|OTHER|no intervention performed- observational only|no intervention performed- observational only
214547895|NCT00549978|DRUG|Cilostazol|cilostazol, then cilostazol/probucol
214699575|NCT00882102|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.
214699576|NCT01944969|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
215160635|NCT03769610|OTHER|Inpatient Foley catheter|
215160636|NCT03769610|OTHER|Outpatient Foley catheter|
214547896|NCT00549978|DRUG|Probucol|Probucol probucol/ cilostazol
214547897|NCT03943017|OTHER|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
214547898|NCT00037713|BIOLOGICAL|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.
214547899|NCT05488288|PROCEDURE|Mesh repair|Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
214547900|NCT05488288|PROCEDURE|Suture repair|The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
214547901|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
214547902|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
214699577|NCT00310388|DRUG|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
214699578|NCT02560831|BEHAVIORAL|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
214699579|NCT02560831|BEHAVIORAL|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
214699580|NCT05089344|DRUG|Growth Hormone|growth hormone
214547903|NCT00022815|DEVICE|Tissue ultrafiltration|
214699581|NCT05089344|DRUG|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
214699582|NCT01864798|DRUG|Denosumab|
214699583|NCT01587573|OTHER|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
214699584|NCT03411707|DIAGNOSTIC_TEST|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
214699585|NCT03518099|BIOLOGICAL|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
215160637|NCT05918471|DIETARY_SUPPLEMENT|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
214699586|NCT00868959|DRUG|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
214699587|NCT03341897|PROCEDURE|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
214699588|NCT04759014|OTHER|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
214699589|NCT00961337|BIOLOGICAL|Trivalent inactivated influenza vaccine|one dose
214699590|NCT04302103|BIOLOGICAL|RC18 160mg|subcutaneous injection
214699591|NCT04302103|BIOLOGICAL|RC18 240 mg|subcutaneous injection
214699592|NCT04479917|DRUG|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
214699593|NCT04479917|DRUG|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
214699594|NCT03948308|BIOLOGICAL|blood sample|blood sample before, during and after infection treatment
214699595|NCT05543460|PROCEDURE|MARPE with Corticopunctures|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
214699596|NCT05543460|DEVICE|MARPE|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
214699597|NCT04512469|DEVICE|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
215160638|NCT01598506|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
215160639|NCT03873792|DIAGNOSTIC_TEST|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
215160640|NCT00001027|DRUG|Pentamidine isethionate|
215160641|NCT03846206|DIETARY_SUPPLEMENT|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
214699598|NCT03038659|DEVICE|Penile Duplex|Measuring intima media thickness
214699599|NCT05511675|DEVICE|cold application|ISO-BALL
214699600|NCT04284943|PROCEDURE|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
214699601|NCT04284943|PROCEDURE|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
214699602|NCT04284943|PROCEDURE|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
214699603|NCT05516693|OTHER|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
215160642|NCT04249986|BEHAVIORAL|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
215160643|NCT02891135|OTHER|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
215160644|NCT05915156|OTHER|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
214699604|NCT02558556|DEVICE|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
214699605|NCT02558556|OTHER|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
214699606|NCT05831618|OTHER|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
214699607|NCT05831618|OTHER|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
214699608|NCT02205827|OTHER|Single-arm|collection of blood for assessment of whole blood clotting time
215160645|NCT05741749|DEVICE|Socket Seal Abutment|Customized Healing Abutment
215160646|NCT03420352|DIAGNOSTIC_TEST|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
215160647|NCT00946387|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
215160648|NCT00946387|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
215160649|NCT00995800|DRUG|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
215160650|NCT03855059|DRUG|Placebos|This will be a saline solution of given IV or perineural.
215160651|NCT03855059|DRUG|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
215160652|NCT03005405|PROCEDURE|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
215160653|NCT03005405|PROCEDURE|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
215160654|NCT03005405|PROCEDURE|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
215160655|NCT02087696|DRUG|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
215160656|NCT04292418|DRUG|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
215160657|NCT02268175|DRUG|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
215160658|NCT02268175|DRUG|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
215160659|NCT02268175|DRUG|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
215160660|NCT02268175|DRUG|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
215160661|NCT01681719|DEVICE|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
215160662|NCT01681719|DEVICE|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
215160663|NCT01681719|DEVICE|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
215160664|NCT04080167|BEHAVIORAL|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
215160665|NCT04080167|BEHAVIORAL|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
215160666|NCT05711563|OTHER|Observational study|Observational study
215160667|NCT04893304|DEVICE|co2 laser|types of laser
215160668|NCT03639909|PROCEDURE|sweating function|Sweating dysfunction by Sudoscan
214547904|NCT04593823|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
214699609|NCT02367534|PROCEDURE|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
214699610|NCT03677817|DRUG|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
214699611|NCT03677817|DRUG|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
214699612|NCT05102149|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
214699613|NCT05102149|DRUG|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
214699614|NCT05102149|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
214699615|NCT05102149|DRUG|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
214699616|NCT01933165|DEVICE|LipiView|
214699617|NCT05402098|PROCEDURE|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
214699618|NCT05402098|PROCEDURE|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
214699619|NCT00848250|DRUG|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
214699620|NCT00848250|OTHER|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
214699621|NCT03277300|DIETARY_SUPPLEMENT|dietary supplement|good dietary supplement for critically ill patients
214699622|NCT05108610|OTHER|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
215160669|NCT03639909|PROCEDURE|Cardiovascular function|Cardiovascular (CV) tests
215160670|NCT00295373|DRUG|Rosuvastatin|
215160671|NCT00295373|BEHAVIORAL|Exercise Training|
215160672|NCT03414931|DRUG|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
215160673|NCT03414931|DRUG|Sertraline|Use of SSRI as an active comparator
214699623|NCT05108610|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
214699624|NCT03497442|DRUG|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
214699625|NCT03497442|DRUG|Placebo Vehicle Gel|Vehicle Gel
214699626|NCT05628025|OTHER|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
214699627|NCT02535832|DRUG|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
215160674|NCT03414931|DRUG|Placebo - Cap|Use of placebo as a comparator
215160675|NCT01957046|DRUG|Laxative|
215160676|NCT04030273|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
215160677|NCT05779189|BEHAVIORAL|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
215160678|NCT05779189|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
215160679|NCT04518358|BEHAVIORAL|Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges|During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
214547905|NCT03511690|BEHAVIORAL|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
214699628|NCT02535832|DRUG|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
214547906|NCT01061099|BIOLOGICAL|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
214699629|NCT00914043|GENETIC|gene expression analysis|
214699630|NCT00914043|GENETIC|microarray analysis|
214699631|NCT00914043|GENETIC|polymerase chain reaction|
214699632|NCT00914043|GENETIC|polymorphism analysis|
214699633|NCT00914043|GENETIC|reverse transcriptase-polymerase chain reaction|
214699634|NCT00914043|OTHER|biologic sample preservation procedure|
215160680|NCT05346068|DEVICE|OPN™ NCB Super High Pressure PCI Balloon|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
215160681|NCT05346068|DEVICE|Shockwave™ C2 IVL Catheter|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
214547907|NCT00742326|DRUG|Pioglitazone|45 mg/daily
214547908|NCT00742326|DRUG|Placebo|one capsule daily
214547909|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
214547910|NCT00922688|DRUG|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
214547911|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
214547912|NCT00385307|DRUG|amibegron (SR58611A)|
214547913|NCT00828555|OTHER|Vaccination Program|Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis
214547914|NCT00034554|BIOLOGICAL|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5\* patient safely completing the 2nd vaccination at the lower dose level.
214547915|NCT03218566|DEVICE|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
214547916|NCT03569215|BEHAVIORAL|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
214547917|NCT00573547|DRUG|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
214547918|NCT05861765|DRUG|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
214547919|NCT05861765|DRUG|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
214547920|NCT00443209|DRUG|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
214547921|NCT00443209|DRUG|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
214547922|NCT00443209|DRUG|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
214547923|NCT00443209|DRUG|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
214547924|NCT00443209|DRUG|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
214547925|NCT00443209|DRUG|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
214547926|NCT04522661|PROCEDURE|Vitrectomy|Vitrectomy within 48 hours of randomisation
214547927|NCT04522661|PROCEDURE|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
214547928|NCT03219762|DRUG|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
214699635|NCT00914043|OTHER|enzyme-linked immunosorbent assay|
214699636|NCT00914043|OTHER|laboratory biomarker analysis|
214699637|NCT00914043|PROCEDURE|fatigue assessment and management|
214699638|NCT00246948|PROCEDURE|Active conservative treatment of sciatica|
214699639|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
214547929|NCT05564481|BEHAVIORAL|diabetes education and parent coaching support|Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
214547930|NCT03115398|BEHAVIORAL|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
214547931|NCT03735953|DIAGNOSTIC_TEST|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
214547932|NCT03427983|PROCEDURE|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
214547933|NCT03427983|PROCEDURE|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
214547934|NCT03922607|DRUG|ABBV-157|ABBV-157 will be administered orally as capsule
214547935|NCT03922607|DRUG|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
214547936|NCT02602483|DRUG|Ibuprofen|
214547937|NCT02602483|DRUG|Magnesium|
214547938|NCT02602483|DRUG|Ascorbic Acid|
214547939|NCT02602483|DRUG|Placebo|
214547940|NCT05426993|OTHER|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
214547941|NCT01151514|OTHER|Nephrologist referral|Nephrologist specialty, renal replacement therapy
214547942|NCT01486368|DRUG|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
214547943|NCT01628692|DRUG|Daclatasvir|Tablets, oral, 30 mg, once daily
214547944|NCT01628692|DRUG|Simeprevir|Capsule, oral, 150 mg, once daily
214699640|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
215160682|NCT05915481|DRUG|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
214547945|NCT01628692|DRUG|Ribavirin|Tablets, oral, 500-600 mg, twice daily
214547946|NCT03959852|DRUG|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
214547947|NCT03959852|COMBINATION_PRODUCT|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
214547948|NCT03959852|DRUG|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
214547949|NCT05760521|OTHER|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
214547950|NCT03640247|DRUG|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
214547951|NCT03640247|DRUG|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
214547952|NCT01651533|BEHAVIORAL|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
214547953|NCT01651533|BEHAVIORAL|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
214547954|NCT05976230|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
214547955|NCT04657601|DEVICE|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
214547956|NCT03585686|DRUG|Vemurafenib|vemurafenib 20 mg/kg/day
214547957|NCT03585686|DRUG|Cytarabine|100 mg/m2/12 h, days 1-5
214547958|NCT03585686|DRUG|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
214547959|NCT02716363|DEVICE|Rotational Atherectomy by Rotablator|
214547960|NCT00643318|RADIATION|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being \> 2 cms from the carina and \> 2 cms from the right and left mainstem bronchus and/or \> 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
214547961|NCT02472054|DRUG|Alemtuzumab|
214547962|NCT02472054|DRUG|Methyl Prednisolone (MP)|
214547963|NCT02472054|DRUG|Cyclosporin A (CSA)|
214547964|NCT05277077|OTHER|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
214699641|NCT02331615|DEVICE|SHAM|no meaningful stimulation will be given
214699642|NCT04342039|DRUG|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
214699643|NCT04342039|OTHER|Placebo|2 sprays each nostril daily on days as indicated in the timeline
214699644|NCT05875220|OTHER|No intervention|No intervention
215160683|NCT05915481|RADIATION|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
214547965|NCT05277077|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
214547966|NCT00080860|GENETIC|microarray analysis|
214547967|NCT00080860|OTHER|immunohistochemistry staining method|
214547968|NCT00080860|PROCEDURE|conventional surgery|
214699645|NCT03657914|PROCEDURE|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
214699646|NCT04969497|DRUG|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
214699647|NCT04969497|DRUG|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
214699648|NCT04969497|DRUG|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
215160684|NCT03530124|BIOLOGICAL|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
215160685|NCT03530124|BIOLOGICAL|DTaP|ACIP Recommended vaccine
214547969|NCT00080860|PROCEDURE|lymphangiography|
214699649|NCT01893658|DRUG|Omalizumab|administration of a single dose together with the standard treatment
214699650|NCT01893658|DRUG|Prednisone|standard treatment
214547970|NCT00080860|PROCEDURE|radionuclide imaging|
214547971|NCT00080860|PROCEDURE|sentinel lymph node biopsy|
214547972|NCT00080860|RADIATION|technetium Tc 99m sulfur colloid|
214699651|NCT05515822|DRUG|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
214699652|NCT05515822|DRUG|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
214699653|NCT05515822|DRUG|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
214699654|NCT02938585|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
214699655|NCT02938585|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
214699656|NCT03427905|PROCEDURE|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
214699657|NCT03427905|PROCEDURE|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
214699658|NCT01850745|OTHER|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
214547973|NCT02126462|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|
214547974|NCT02126462|BIOLOGICAL|Na-GST-1/Alhydrogel®|
214699659|NCT02511951|PROCEDURE|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
214699660|NCT00304317|DRUG|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
214699661|NCT00304317|OTHER|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
214699662|NCT03457103|DEVICE|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
215160686|NCT03530124|BIOLOGICAL|HBV|ACIP Recommended vaccine
215160687|NCT03530124|BIOLOGICAL|IPV|ACIP Recommended vaccine
215160688|NCT03530124|BIOLOGICAL|Hib|ACIP Recommended vaccine
215160689|NCT03192553|BEHAVIORAL|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
215160690|NCT03192553|BEHAVIORAL|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
215160691|NCT03192553|BEHAVIORAL|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
215160692|NCT03192553|BEHAVIORAL|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
215160693|NCT04436848|OTHER|This is a non-interventional study|This is a non-interventional study
214547975|NCT02126462|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
214547976|NCT02196077|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
214547977|NCT02196077|DRUG|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
214699663|NCT03457103|DEVICE|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
214699664|NCT00213980|DRUG|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
214699665|NCT05798169|OTHER|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
214699666|NCT06175650|PROCEDURE|Cardiac surgery|Cardiac surgery of all types
214699667|NCT01313026|PROCEDURE|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
214699668|NCT03129581|BEHAVIORAL|Dietary Counseling|Counseling to only eat during a restricted amount of time.
214699669|NCT00798694|DRUG|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
214699670|NCT00798694|DRUG|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
214699671|NCT05117229|DEVICE|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
214699672|NCT04169724|BEHAVIORAL|Calm Meditation|10 minutes per day of meditation via the Calm app.
214699673|NCT00258089|DRUG|Levofloxacin|
214699674|NCT00228254|DRUG|Zinc (12.5 mg/day)|
214699675|NCT00228254|DRUG|vitamin A 10,000 IU per week|
215160694|NCT06313918|OTHER|High intensity training (HIT)|Please see information already included in the arm descriptions.
215160695|NCT01047553|DRUG|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
214699676|NCT04424355|DIAGNOSTIC_TEST|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
214699677|NCT05233449|DEVICE|NoL monitor|NoL monitor : non invasive, adhesive digital device
214699678|NCT05233449|PROCEDURE|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
214699679|NCT03730883|PROCEDURE|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
215160696|NCT01583296|BEHAVIORAL|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
214699680|NCT03730883|PROCEDURE|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
214699681|NCT02351258|DEVICE|70% Isopropyl alcohol embedded caps|Protective cap on central lines
214699682|NCT02351258|OTHER|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care"
215160697|NCT01583296|BEHAVIORAL|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
215160698|NCT01063283|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 intravenously over 10 minutes
215160699|NCT01063283|DRUG|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
215160700|NCT01063283|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
215160701|NCT01063283|DRUG|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
215160702|NCT02111304|DRUG|iOWH032|
215160703|NCT03613961|DRUG|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
214699683|NCT01724125|OTHER|personal electronic medical record|
214699684|NCT00611897|DRUG|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
214699685|NCT00611897|DRUG|placebo and ketamine|placebo N-acetylcysteine
214699686|NCT05508438|DEVICE|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
214699687|NCT01699620|PROCEDURE|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
214699688|NCT02488096|DEVICE|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
214699689|NCT02488096|DEVICE|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI."
214699690|NCT03768830|BEHAVIORAL|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
214699691|NCT02393118|DEVICE|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
214699692|NCT04441736|DEVICE|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
215160704|NCT05343624|DEVICE|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
215160705|NCT01120717|DRUG|QVA149|capsules for inhalation, delivered by an SDDPI
215160706|NCT01120717|DRUG|Placebo|capsules for inhalation, delivered by an SDDPI
215160707|NCT03117140|DRUG|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
215160708|NCT03117140|DRUG|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
214699693|NCT05653297|DEVICE|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
214699694|NCT03184857|PROCEDURE|open maxillary sinus lifting|biopsy of the region 6 months later
214699695|NCT00110318|PROCEDURE|Manual therapy and therapeutic exercise|
214699696|NCT00110318|PROCEDURE|Corticosteroid injections|
215160709|NCT03117140|DRUG|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
215160710|NCT03117140|DRUG|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
214699697|NCT04185441|DRUG|Tanzânia association|Tanzânia association capsule
214699698|NCT04185441|DRUG|Omnic Ocas|Tamsulosin 0,4 mg
214699699|NCT04185441|OTHER|Omnic Ocas placebo|Tamsulosin placebo
214699700|NCT04185441|OTHER|Tanzânia association placebo|EMS association placebo
214699701|NCT02731807|DIETARY_SUPPLEMENT|Dose A: TA-65 24mg, powder|
214699702|NCT02731807|DIETARY_SUPPLEMENT|Dose B: TA-65, 8mg, powder|
214699703|NCT02731807|DIETARY_SUPPLEMENT|Dose C: TA-65 3.2mg, capsule|
214699704|NCT02731807|DIETARY_SUPPLEMENT|Dose D: TA-65 8mg, capsule|
214699705|NCT02731807|DIETARY_SUPPLEMENT|Dose E: TA-65 32mg, capsule|
214699706|NCT01089582|OTHER|No intervention|
214699707|NCT00637715|DRUG|Alfuzosin|
214699708|NCT06085261|BEHAVIORAL|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
214699709|NCT06085261|BEHAVIORAL|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
214699710|NCT00375635|PROCEDURE|mFPSA treatment|
214699711|NCT00195767|DRUG|divalproex sodium|
214699712|NCT06419647|BEHAVIORAL|Intervention|Daily mood tracking tasks
214699713|NCT04715256|BEHAVIORAL|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
214699714|NCT04715256|GENETIC|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
214699715|NCT04715256|DIAGNOSTIC_TEST|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
214699716|NCT03055403|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
214699717|NCT03055403|DRUG|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
214699718|NCT05051865|DRUG|camrelizumab|camrelizumab combined with SHR1020 for advanced melanoma
214699719|NCT05051865|DRUG|SHR1020|camrelizumab combined with SHR1020 for advanced melanoma
214699720|NCT03445897|DRUG|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
214699721|NCT05157451|OTHER|Quality of Life|Ancillary studies
214699722|NCT05157451|OTHER|Questionnaire Administration|Ancillary studies
214699723|NCT05157451|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214699724|NCT05157451|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Given via injection
214699725|NCT02225873|OTHER|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
214699726|NCT02225873|OTHER|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
214699727|NCT05500924|OTHER|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
214699728|NCT00862849|DRUG|Insulin Lispro|
214699729|NCT00862849|DRUG|Regular Human Insulin|
214699730|NCT00862849|DRUG|rHuPH20|
214699731|NCT01621672|DRUG|Revlimid|10 mg/day in the morning same time each day
214699732|NCT05102396|DRUG|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
214699733|NCT05102396|DRUG|Topical placebo spray|Participants will receive topical placebo spray.
214699734|NCT05102396|DRUG|Oral oxybutynin|Participants will receive oxybutynin (tablets).
215160711|NCT01493076|DEVICE|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
215160712|NCT03465969|DRUG|tacrolimus|oral
215160713|NCT02403440|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
214547978|NCT02196077|DRUG|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
215160714|NCT01267214|DRUG|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
215160715|NCT01267214|PROCEDURE|Osteotomy alone|no injection
215160716|NCT01145976|DRUG|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
215160717|NCT01145976|DRUG|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
215160718|NCT02640456|BIOLOGICAL|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
215160719|NCT02640456|PROCEDURE|Type of surgery|Surgical approach and complications.
215160720|NCT02640456|BIOLOGICAL|Biochemistry|Amylase concentration i pus aspirates.
215160721|NCT02640456|BIOLOGICAL|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
215160722|NCT02019797|DRUG|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
215160723|NCT01637129|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
215160724|NCT01637129|DEVICE|Sham Magnetic Stimulation|Sham Magnetic Stimulation
215160725|NCT02504216|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
215160726|NCT02504216|DRUG|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
215160727|NCT02544516|OTHER|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
215160728|NCT02544516|OTHER|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
215160729|NCT03061396|OTHER|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
215160730|NCT03061396|OTHER|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
214547979|NCT02196077|DRUG|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
214547980|NCT02196077|DRUG|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
214547981|NCT05592977|DEVICE|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
214547982|NCT03316807|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
214699735|NCT04415567|DRUG|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
214699736|NCT05535127|DIAGNOSTIC_TEST|"Palpation with  laryngeal handshake technique"|Information alredy included
215160731|NCT02591225|DRUG|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
214547983|NCT03316807|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
214547984|NCT05713162|BEHAVIORAL|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
214547985|NCT06191081|PROCEDURE|lymphaticovenous anastomosis|lymphaticovenous anastomosis
214547986|NCT02046512|DIETARY_SUPPLEMENT|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
214547987|NCT02046512|OTHER|Placebo|Sugar pill
215160732|NCT02591225|DRUG|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
214547988|NCT06544681|PROCEDURE|Coronary stenting with planned drug eluting stent (DES).|Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.
214547989|NCT06056271|DEVICE|AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation
214547990|NCT02781311|DRUG|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
214547991|NCT02781311|DRUG|Placebo|Placebo tablets, orally, BID for 24 weeks.
214547992|NCT02781311|DRUG|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
214547993|NCT01335945|PROCEDURE|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
214547994|NCT01299142|DRUG|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
214547995|NCT01056263|DRUG|axitinib: observational study|Non-interventional observational study
214547996|NCT03612076|OTHER|Global cost of management of PJI|estimation of the global cost to manage PJI with 2-step exchange over 3 years
214547997|NCT01262092|DRUG|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
214547998|NCT00891553|PROCEDURE|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
214547999|NCT00006462|DRUG|gemcitabine hydrochloride|
214548000|NCT04831879|DEVICE|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
214548001|NCT03543553|OTHER|This is not an intervention study|This is not an intervention study
214548002|NCT04312542|PROCEDURE|Measurement of Biomarkers|Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.
214548003|NCT05906706|DRUG|dupilumab|Subcutaneous (SC) administration
214548004|NCT05884489|BEHAVIORAL|A gamified smartphone app-based eating behaviour intervention|All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
214548005|NCT01885169|BIOLOGICAL|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
214548006|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
214548007|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
214548008|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
214548009|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
214548010|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
214548011|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
214548012|NCT06194331|BEHAVIORAL|iCHART/cASAP|When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.
214548013|NCT06194331|BEHAVIORAL|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
214548014|NCT04929184|BEHAVIORAL|Speech and non-speech tasks|Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
214548015|NCT03814200|DRUG|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
214548016|NCT03814200|DRUG|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
214548017|NCT03814200|DRUG|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
214548018|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
214548019|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
214548020|NCT05422144|DEVICE|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
214699737|NCT05535127|DIAGNOSTIC_TEST|Palpation strategy plus sequential ultrasound|Information alredy included
214548021|NCT05422144|DEVICE|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
214548022|NCT05673967|OTHER|Non-Interventional|No study treatment will be administered on this study.
214548023|NCT05688852|DRUG|VTX958|Dose A VTX958
214548024|NCT05688852|DRUG|VTX958|Dose B VTX958
214548025|NCT05688852|DRUG|VTX958 Placebo|Placebo
214548026|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
214548027|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
214548028|NCT04925258|BEHAVIORAL|SPACE Parenting Program|The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online \~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
214548029|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
214548030|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
214548031|NCT05255380|BEHAVIORAL|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
214548032|NCT05255380|BEHAVIORAL|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
214548033|NCT05365802|DRUG|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
214548034|NCT05365802|PROCEDURE|Computed Tomography|As part of PET/CT scan
214548035|NCT05365802|PROCEDURE|Positron Emission Tomography|As part of PET/CT scan
214548036|NCT05365802|PROCEDURE|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
214548037|NCT06028438|DRUG|Placebo|Placebo will be administered intravenously.
214548038|NCT06028438|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
214548039|NCT06028438|DRUG|Certolizumab|Certolizumab will be administered subcutaneously.
214699738|NCT05535127|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
214699739|NCT04619264|DRUG|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
214548040|NCT00699842|DRUG|Lenalidomide|"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"
214548041|NCT03491267|DRUG|Retinoic acid|The study team will treat skin with topical retinoic acid
214548042|NCT03491267|DEVICE|Laser|The study team treat skin with a surface laser.
214548043|NCT03491267|DRUG|Sham treatment|No drug will be given
214548044|NCT03491267|DEVICE|Sham treatment|No laser treatment will be given
214548045|NCT06166056|DRUG|CHF6333|CHF6333 Part I SAD; CHF6333 Part II MD.
214548046|NCT06166056|DRUG|CHF6333 Placebo|Placebo Part I SAD; Placebo Part II MD.
214548047|NCT06132828|DRUG|DR30206|Subjects receive DR30206 intravenously
214548048|NCT03751501|PROCEDURE|Indocyanine green-Guided Targeted Laser photocoagulation|Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
214548049|NCT03751501|PROCEDURE|Sham laser|Therapeutic procedure used in ophthalmology
214548050|NCT03355976|DRUG|Nivolumab|240mg flat dose every 2 weeks
214548051|NCT03355976|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
214548052|NCT06191042|DRUG|si-544|Subcutaneous injection in the abdomen
214548053|NCT06191042|DRUG|Placebo|Subcutaneous injection in the abdomen
214548054|NCT04253262|DRUG|Rucaparib|Rucaparib (PO twice daily continuous)
214548055|NCT04253262|DRUG|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
214548056|NCT04468607|DRUG|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
214548057|NCT04734015|BEHAVIORAL|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
215160733|NCT02451709|DEVICE|Activated Smartinhaler or Smartturbo|Medication reminder alarms
215160734|NCT02451709|OTHER|Feedback of adherence data|Review of adherence data with action planning
214548058|NCT06544772|DEVICE|Pivot cigarette smoking cessation program|The Pivot cigarette smoking cessation program comprises a mobile personal breath carbon monoxide sensor (Pivot Breath Sensor) and a smartphone app (Pivot app) with in-app asynchronous SMS text-based coaching with a certified human tobacco cessation coach.
214548059|NCT03641456|DRUG|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
214548060|NCT03641456|DRUG|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
214548061|NCT03641456|DRUG|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
214548062|NCT03023423|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
214548063|NCT03023423|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
214548064|NCT03001622|BIOLOGICAL|IFX-1|chimeric, monoclonal antibody
214548065|NCT03454659|PROCEDURE|Craniotomy|Extracting the part of the sculpt
214548066|NCT00280865|DRUG|Tesaglitazar|
214548067|NCT00280865|DRUG|Pioglitazone|
214548068|NCT00280865|BEHAVIORAL|Dietary and Lifestyle Modification Counseling|
214548069|NCT02854618|OTHER|additional blood sample|
214548070|NCT06972212|DRUG|suzetrigine 100mg|Suzetrigine is an inhibitor of the NaV1.8 voltage-gated sodium channel and FDA approved for the treatment of moderate-to-severe acute pain in adults
214548071|NCT06972212|OTHER|Placebo|biologically inactive placebo comparator
215160735|NCT02451709|DEVICE|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
214548072|NCT02335645|OTHER|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
214548073|NCT01498783|DRUG|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
214548074|NCT03512197|DRUG|Midostaurin|Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
214548075|NCT03512197|DRUG|Placebo|Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
214699740|NCT04619264|PROCEDURE|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
215160736|NCT00862082|DRUG|PR104 550 mg/m^2 + sorafenib|550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
214548076|NCT03512197|DRUG|Chemotherapy|Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
214548077|NCT03445117|OTHER|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
214548078|NCT03842436|DEVICE|Digital pill|Digital pills over encapsulating Truvada
214699741|NCT03182400|BEHAVIORAL|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
214699742|NCT03182400|BEHAVIORAL|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
215160737|NCT00862082|DRUG|PR104 770 mg/m^2 + sorafenib|770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
215160738|NCT02608671|PROCEDURE|Skin adhesive tape|
215160739|NCT05161013|DIAGNOSTIC_TEST|LINFU™|A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.
215160740|NCT01383343|BIOLOGICAL|Bevacizumab|Given IV
215160741|NCT01383343|DRUG|Fluorouracil|Given IV
215160742|NCT01383343|DRUG|Irinotecan Hydrochloride|Given IV
215160743|NCT01383343|DRUG|Leucovorin Calcium|Given IV
215160744|NCT01383343|DRUG|Sorafenib Tosylate|Given PO
215160745|NCT04949321|OTHER|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
215160746|NCT00517855|BIOLOGICAL|PRTX-100 (Staphylococcal protein A)|
214548079|NCT03842436|DRUG|Truvada|Truvada prescribed with digital pills for PrEP
214548080|NCT05256810|DRUG|ALN-XDH|ALN-XDH administered by SC injection
214548081|NCT05256810|DRUG|Placebo|Placebo administered by SC injection
214548082|NCT01688310|PROCEDURE|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
214699743|NCT04820543|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
214548083|NCT01688310|PROCEDURE|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
214548084|NCT01071837|DRUG|APG101|400mg weekly as intravenous infusion
214699744|NCT03943953|BEHAVIORAL|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners."
214699745|NCT01835613|OTHER|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
214548085|NCT01071837|PROCEDURE|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
214548086|NCT04865692|OTHER|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
214548087|NCT04865692|OTHER|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
214699746|NCT01102218|DRUG|Erythropoietin|Standard of Care
214699747|NCT01102218|DRUG|Erythropoietin|Standard of Care
214699748|NCT01102218|DRUG|Pentoxifylline|400 mg qd po for 6 months
214699749|NCT03832439|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
214699750|NCT03832439|DIETARY_SUPPLEMENT|microcrystalline cellulose|Placebo
214548088|NCT00284193|DRUG|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
214548089|NCT00284193|DRUG|FEIBA- Activated Prothrombin Complexes|
214548090|NCT03668171|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
214548091|NCT05205564|OTHER|This is a cross-sectional research design.|No intervention will be involved in the study.
214548092|NCT03214536|PROCEDURE|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
214548093|NCT03214536|DRUG|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
214548094|NCT03214536|PROCEDURE|Spine surgery|Surgery of lumbar spine
214548095|NCT03214536|PROCEDURE|anesthesia|general anesthesia
214548096|NCT01155076|DIETARY_SUPPLEMENT|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
214548097|NCT01155076|DIETARY_SUPPLEMENT|Placebo|Placebo taken twice a day for 8 weeks
214548098|NCT05568368|OTHER|No intervention|no intervention
214548099|NCT03330964|OTHER|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
214548100|NCT02675049|DRUG|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
214548101|NCT02675049|DRUG|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
214699751|NCT00803543|DRUG|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
214699752|NCT00803543|DRUG|Placebo|Dosage: Two tablets once a day for 24 weeks
214699753|NCT03299738|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
215160747|NCT02486185|OTHER|SCREENING TEST|"* Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
215160748|NCT02256709|DRUG|BIBP 5371 CL tablet|single rising daily doses
214548102|NCT02675049|DRUG|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
214548103|NCT02675049|DRUG|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
214548104|NCT06021938|DEVICE|Immersive virtual reality (IVR) & Music therapy|The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
214548105|NCT05716529|OTHER|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
214548106|NCT06038851|PROCEDURE|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~* The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~* The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~* In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
214548107|NCT06038851|PROCEDURE|Femoral Triangle Block (FTB)|"* The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
214548108|NCT06038851|PROCEDURE|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
214548109|NCT03514381|DRUG|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)"
214548110|NCT01902186|DRUG|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
214548111|NCT01902186|DRUG|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
214548112|NCT03259399|GENETIC|detection of genotype|detection of genotype by next generation sequencing
214548113|NCT03843294|BIOLOGICAL|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
214699754|NCT01154179|OTHER|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
214699755|NCT00289185|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
214699756|NCT00289185|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
214699757|NCT00289185|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
214699758|NCT01199055|DRUG|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
214548114|NCT03843294|DRUG|Nivolumab|Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
214548115|NCT06382389|DRUG|EMONO|Exposure of Emono via facial mask
214548116|NCT06382389|DRUG|Medical air|exposure to Medical Air
214548117|NCT05087836|DEVICE|Sensor at forehead area|NIRS sensor attached at forehead area.
214548118|NCT05087836|DEVICE|Sensor at temporal area|NIRS sensor attached at temporal area.
214548119|NCT02180347|DEVICE|Contact lenses|
214548120|NCT03796000|PROCEDURE|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
214699759|NCT01199055|DRUG|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
214699760|NCT01199055|DRUG|Paclitaxel|Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
214699761|NCT01152736|DRUG|Nicotine|2 mg Single-dose
214699762|NCT00505232|DRUG|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy."
214699763|NCT02930369|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
214699764|NCT05603507|OTHER|inspiratory muscle training|training done with a pressure threshold-loading device
214699765|NCT05603507|OTHER|pulmonary rehabilitation|Circuit training of aerobic and resistive exercise
214699766|NCT02297113|DEVICE|Macintosh blade|conventional endotracheal intubation
214548121|NCT00556647|PROCEDURE|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
214548122|NCT00556647|PROCEDURE|conventional diagnosis|out-patient diagnosis
215160749|NCT02256709|DRUG|BIBP 5371 CL solution|
215160750|NCT02256709|OTHER|High fat, high caloric breakfast|
215160751|NCT02256709|DRUG|Placebo tablet|
215160752|NCT02256709|DRUG|BIBP 5371 CL tablet high dose|
215160753|NCT02256709|DRUG|Placebo drinking solution|
215160754|NCT02256709|DRUG|BIBP 5371 CL tablet low dose|
215160755|NCT00388193|DRUG|RITUXIMAB|375 mg/m2/d day 1
215160756|NCT04421703|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
215160757|NCT02598583|BIOLOGICAL|ALXN1210|Participants were administered ravulizumab as an IV infusion every 4 weeks.
215160758|NCT05785676|DEVICE|Filter implantation|Implantation of OATF ALN vena cava filter
215160759|NCT02422459|BEHAVIORAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
215160760|NCT02093819|DRUG|Placebo to BI 416970|single rising doses
215160761|NCT02093819|DRUG|BI 416970|single rising doses
215160762|NCT05334212|DEVICE|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
215160763|NCT02267798|OTHER|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
215160764|NCT02267798|DEVICE|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
215160765|NCT00925925|OTHER|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
215160766|NCT05829369|OTHER|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
215160767|NCT05829369|OTHER|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
215160768|NCT05829369|OTHER|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
215160769|NCT05569590|DRUG|Propolis|Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
215160770|NCT05569590|DRUG|hydrogen peroxide 35%|hydrogen peroxide 35%
214548123|NCT05120154|OTHER|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
214548124|NCT05120154|BEHAVIORAL|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
214548125|NCT00554645|BEHAVIORAL|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
214699767|NCT02297113|DEVICE|C-MAC videolaryngoscope|
214699768|NCT05046678|DIAGNOSTIC_TEST|Control|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
215160771|NCT05569590|OTHER|fluoride varnish|fluoride varnish
215160772|NCT02152956|BIOLOGICAL|Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
215160773|NCT02152956|BIOLOGICAL|Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160774|NCT02152956|BIOLOGICAL|Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160775|NCT02152956|BIOLOGICAL|Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160776|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160777|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
214548126|NCT00554645|OTHER|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
214699769|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontally healthy|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
215160778|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160779|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160780|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160781|NCT02152956|DRUG|Ruxolitinib|Oral inhibitor of JAK kinase
215160782|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
215160783|NCT02445794|DRUG|Low dose cohort|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
215160784|NCT02445794|DRUG|High dose cohort|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
215160785|NCT01900210|BEHAVIORAL|WaySafe|
215160786|NCT02677519|DRUG|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
215160787|NCT05226637|DEVICE|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
215160788|NCT05226637|DEVICE|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
215160789|NCT04945057|DEVICE|Mindpax monitoring system|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
215160790|NCT00530387|DRUG|19 organic sunscreen filters and 5 topical NSAIDs|
215160791|NCT03904992|OTHER|Progressive web app|Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
215160792|NCT02433470|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
215160793|NCT04381182|DEVICE|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
215160794|NCT02467634|BIOLOGICAL|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
215160795|NCT01996761|DRUG|porcine brain peptide (Cerebrolysin)|
215160796|NCT01996761|DRUG|Placebo|
215160797|NCT06020872|OTHER|Health literacy program|Health literacy program was the health education related to healthy plate.
215160798|NCT02869659|BEHAVIORAL|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
215160799|NCT02869659|BEHAVIORAL|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
215160800|NCT02081885|PROCEDURE|Tricalcium Phosphate / Chitosan|
215160801|NCT02081885|PROCEDURE|Autologous Graft|
215160802|NCT03159962|DEVICE|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
215160803|NCT03159962|DEVICE|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
215160804|NCT00835562|PROCEDURE|Non-surgical management|Non-surgical management (physiotherapy and self-training)
215160805|NCT00835562|PROCEDURE|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
215160806|NCT00835562|PROCEDURE|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
215160807|NCT05922865|DEVICE|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
215160808|NCT05922865|BEHAVIORAL|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
214548127|NCT02398032|DEVICE|CPAP nasal|During the night
214548128|NCT02398032|DEVICE|sham CPAP nasal|During the night
214699770|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
214699771|NCT05046678|DIAGNOSTIC_TEST|Smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
214548129|NCT05074199|PROCEDURE|W-plasty/Linear closure|"The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material."
214548130|NCT01310699|DEVICE|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
214548131|NCT05436015|OTHER|Virtual nature-based intervention|"Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor"
215160809|NCT03239561|DRUG|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
215160810|NCT06230900|OTHER|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
215160811|NCT06230900|COMBINATION_PRODUCT|14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
215160812|NCT02758184|DEVICE|ROTEM-based coagulation monitoring|
214548132|NCT00936598|DRUG|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or \> 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
214548133|NCT00936598|DRUG|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
214548134|NCT03293069|DRUG|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
214548135|NCT03293069|DRUG|Placebo Oral Tablet|the placebo twice daily morning and evening.
215160813|NCT02758184|PROCEDURE|Spine surgery|
215160814|NCT04079140|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
215160815|NCT04079140|DRUG|placebo|one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
214548136|NCT02413814|BEHAVIORAL|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
214548137|NCT02413814|BEHAVIORAL|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
214699772|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
214699773|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
214699774|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
214699775|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
214699776|NCT05417659|OTHER|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
214699777|NCT05398276|BEHAVIORAL|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
214699778|NCT05398276|BEHAVIORAL|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
214699779|NCT01260376|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
214699780|NCT01908959|BEHAVIORAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
214548138|NCT01158989|DEVICE|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
214548139|NCT00127361|BEHAVIORAL|doula training|
214548140|NCT00926575|DRUG|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
214548141|NCT00926575|DRUG|Placebo|Two tablets QID for 50 days
214548142|NCT02405897|DEVICE|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
214548143|NCT02405897|DEVICE|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
214548144|NCT05761340|PROCEDURE|Helfer skin tap injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~2. After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~3. After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~4. During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~5. After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~6. After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke"
214548145|NCT05761340|PROCEDURE|Standard Injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~2. After determining the injection site, prepare the skin with alcohol.~3. Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~4. After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~5. Remove the syringe needle 10 seconds after the drug is consumed"
214548146|NCT06018038|DIAGNOSTIC_TEST|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
214548147|NCT03278743|OTHER|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
214548148|NCT01179503|DIETARY_SUPPLEMENT|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
214548149|NCT01179503|DIETARY_SUPPLEMENT|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
214548150|NCT00273208|BEHAVIORAL|10 week behavioral intervention program|
214548151|NCT01267669|DRUG|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
214548152|NCT01267669|DRUG|Placebo|Emergency EVL plus placebo infusion for 5 days
214548153|NCT03893110|PROCEDURE|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
214548154|NCT05026268|PROCEDURE|intracorporeal anastomosis|"intracorporeal stapled side-to-side isoperistaltic anastomosis"
214548155|NCT00333255|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|
214548156|NCT00428337|BIOLOGICAL|EP-1233|DNA-HIV-recombinant vaccine
214548157|NCT00428337|BIOLOGICAL|MVA-mBN32|HIV-recombinant viral vaccine
214548158|NCT01939301|DRUG|Inhaled Nitric Oxide|Nitric Oxide + oxygen
214548159|NCT01939301|DRUG|Sham|Nitrogen + Oxygen
214548160|NCT00490698|DRUG|Zoledronate|4 mg IV Once Every 4 Weeks
214548161|NCT00490698|DRUG|Atorvastatin|20 mg PO Daily
214548162|NCT02201901|DRUG|SOF/VEL|400/100 mg tablets administered orally once daily
214548163|NCT02201901|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214548164|NCT01907269|BEHAVIORAL|Video-based Intervention|Video clips delivered by DVD and Internet
214548165|NCT01654068|RADIATION|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
214548166|NCT03358238|BEHAVIORAL|Weekly review|Each week in the study, an interviewer will review manic and depressive symptoms self-reported by a participant and patterns of activity, sleep, and heart rate collected by the participant's activity tracker.
214548167|NCT03358238|OTHER|No weekly review|An interviewer will not review self-report symptoms and patterns collected from an activity tracker.
214548168|NCT01227616|DRUG|Ferumoxytol|IV Ferumoxytol
214548169|NCT01227616|DRUG|Iron Sucrose|IV Iron Sucrose
214548170|NCT04277507|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
214548171|NCT04618380|DIAGNOSTIC_TEST|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
214548172|NCT00611169|DRUG|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
214548173|NCT05137925|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
214548174|NCT05137925|BEHAVIORAL|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
214548175|NCT03128528|DRUG|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
214548176|NCT03128528|DRUG|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
214548177|NCT01431950|DRUG|fluticasone furoate|Inhaled corticosteroid
214548178|NCT01431950|DRUG|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
214548179|NCT03210649|DRUG|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14
214548180|NCT03210649|DRUG|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
214548181|NCT04749355|DRUG|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
214548182|NCT03297762|BEHAVIORAL|gamification|incentives/rewards and contact between standard visits
214548183|NCT03297762|BEHAVIORAL|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
214548184|NCT01611961|DRUG|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
214548185|NCT01611961|DRUG|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
214548186|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
214548187|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
214548188|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
214548189|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
214548190|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
214548191|NCT05767177|OTHER|Glucemia following Mixed Meal Test|On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.
214699781|NCT06065358|PROCEDURE|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
214548192|NCT05767177|OTHER|Enteroscopy - mucosal ketogenic activity as well as glucose transport|On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
214548193|NCT05647109|OTHER|No intervention|No intervention
214548194|NCT04323046|BIOLOGICAL|Nivolumab|Given IV
214548195|NCT04323046|OTHER|Quality-of-Life Assessment|Ancillary studies, given in person or online
214548196|NCT04323046|OTHER|Questionnaire Administration|Ancillary studies, given in person or online
214548197|NCT05123612|BEHAVIORAL|Fiber|Additional 20 grams of fiber/day.
214548198|NCT05123612|BEHAVIORAL|Fermented Foods|6 servings of fermented foods/day
214548199|NCT02884492|DRUG|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
214548200|NCT02884492|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
214548201|NCT04577573|DEVICE|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
214548202|NCT04577573|DEVICE|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
214548203|NCT05455203|BEHAVIORAL|ADAPT-ITT|ADAPT-ITT is an implementation framework that guides adaptation of evidence-based interventions (EBI) for specific settings/populations. It will be used to adapt target interventions with a Family and Community Advisory Board. It has 8 phases: (1) Assess the risk profile of Black families in Paterson and East Orange, (2) Adopt or adapt an EBI, (3) Administer novel methods with families and children to facilitate the adaptation process, (4) Plan on what aspects of the EBI need to be adapted/how best to evaluate the adapted EBI, (5) Identify additional experts to assist in the adaptation process, (6) Integrate material from experts to adapt the EBI, (7) Train staff to implement the adapted intervention, and (8) Test the adapted intervention. Given time and financial constraints, five phases will be completed at the end of the pilot study. Qualitative data collected from individual dyad interviews will be used to inform the data.
214548204|NCT05706844|DRUG|Spinal anesthesia|plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal
214548205|NCT05706844|DRUG|General anaesthesia|Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously
214548206|NCT06608966|BEHAVIORAL|Epilepsy Journey web-based modules|Participants assigned to Epilepsy Journey modules will independently review web-based EJ modules focused on executive functioning skills. The modules cover 10 topic areas: Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Participants will complete 10 modules (\~15-30 minutes each session) within a 14-week time frame. The goal is to complete one module per week.
214548207|NCT06608966|BEHAVIORAL|Telehealth with a therapist|Therapist will cover 10 areas of executive functioning during telehealth sessions, including Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Telehealth sessions with a therapist will occur via HIPAA-compliant videoconference (e.g. Microsoft Teams) each week ideally over the course of 14 weeks.
214548208|NCT06590675|DRUG|Chlorhexidine Gluconate (CHG)|A locally-prepared CHG formulation as a 1% or 2% solution
214699782|NCT02040883|DRUG|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
214699783|NCT02040883|DRUG|Tandospirone|Tandospirone，30mg per day
214699784|NCT01410266|OTHER|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
214699785|NCT00423618|RADIATION|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
214548209|NCT06682650|BEHAVIORAL|NPT-PLA|"NPT-PLA was developed and initially tested in 5 European countries in the EU-funded RESTORE study. PLA Participatory Learning in Action is a set of participatory research techniques in which participants use democratic processes to identify key actions needed to achieve a specific goal e.g. implementation of a tested decision making tool such as I2; and prioritize which of these need to be acted upon first and subsequently (in which order). Normalization Process Theory (NPT) is combined with PLA to help implementation teams using PLA to assess organization capacity and readiness to enact the selected action steps vis-a-vis NPT constructs, iteratively. These are coherence does everyone understand what needs to be done?; Cognitive participation Does everyone who needs to act 'buy in' to take action; collective action Is everyone who needs to act taking steps to make the change?'; and reflexive monitoring After the step has been taken, has it had the desired impact on the goal?"
214548210|NCT06682650|BEHAVIORAL|Usual Quality Improvement|Usual quality improvement includes principles of continuous quality improvement, such as Plan-Do-Study-Act cycles, to implement a specific goal. In this study, 'usual QI' methods already in use in 'active comparator' arm will be documented during the baseline assessment of clinical workflows in clinics assigned to that arm; and will be provided with a 'preset protocol' to implement the study shared decision-making tool (I2). Processes that implementation teams in these clinics use to achieve implementation will be documented.
214548211|NCT05275972|DRUG|Ripasudil|Topical Ripasudil 0.4%
214548212|NCT05275972|DRUG|Placebo|Topical Placebo
214548213|NCT06882720|BEHAVIORAL|Exercise|Cardiorespiratory exercises include walking at a normal pace for 30 minutes three times a week, or three 10-minute sessions. The resistance exercises involve five leg muscle strengthening exercises, including knee extensors, knee flexors, hip adductors, ankle plantar flexors, and ankle dorsolflexors, performed 8-10 times, 1-2 sets, 3 times a week, with 1 day intervals in between. Balance training includes 12 exercises such as kneeling, walking backwards, walking and turning, walking sideways, tandem standing (heel-toe standing), tandem walking (heel-toe walking), standing on one leg, walking on the heel, and walking on the tip of the foot. Only 1 set of 1 exercise, 3 times a week, 1 day interval in between. Add 4 upper body strength exercises and 4 lower body strength exercises to the OEP, using water bottles and elastic bands as AIDS. Each movement is completed 8-12 times, 1-3 sets, 3 times a week, 1 day apart.
214548214|NCT06719986|DRUG|Nalmefene HCl injection|Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
214548215|NCT06719986|DRUG|Naloxone HCl intranasal|Naloxone 4 mg for intranasal (IN) administration
214548216|NCT06726408|OTHER|Neuromonitoring with 10 electrodes|"In case of no parental objection, the clinician may begin neuromonitoring according to standard indications. The number of electrodes applied to the child's skull will be 10 electrodes (8 recording electrodes, 1 reference electrode, and 1 ground electrode) instead of the current 5.~The intensivist will analyze the quantitative EEG trace as they currently do but will also have access to additional tools for seizure detection support (CDSA and seizure detection software) and targeted review of part of the recording by a neurophysiologist in case of doubt. Access to the neurophysiologist will be available during current working hours on weekdays. Data will be collected in 12-hour periods."
214548217|NCT06915285|DIAGNOSTIC_TEST|Automated software for malarial retinopathy detection|"ASPIRE mobile application (App) software is intended to perform computer-aided detection of malarial retinopathy (MR) in digital retinal images of clinically diagnosed cerebral malaria (CM) patients under 21 years of age, to be used by a healthcare provider (user) with basic training, in primary care settings such as healthcare clinics and hospitals. The mobile Application hosts a software module developed using Deep-Learning algorithms to analyze digital retinal images of diagnosed CM patients for features suggestive of malarial retinopathy. ASPIRE requires at least four adequate quality retinal images (as determined by the image quality analysis software) captured from a patient to process it for MR detection. ASPIRE outputs a screening result of Malarial retinopathy detected or Malarial retinopathy not detected to the user. ASPIRE software is designed and validated to perform at clinically acceptable sensitivity and specificity in the detection of MR."
214548218|NCT06728787|DEVICE|Robot-Assisted Gait Training|15 sessions of robot-assisted gait training(LOKOMAT)+ 15 session of usual treatment for a total of 30 sessions in three weeks. 45 minutes for each session.
214548219|NCT07043777|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|Bilateral modified catheter antegrade cerebral perfusion technique applied during acute type A aortic dissection repair; avoids additional right-axillary incision while providing continuous cerebral flow.
214548220|NCT07043777|PROCEDURE|Conventional Brain Perfusion|Conventional cerebral perfusion strategy (e.g., standard bilateral antegrade cerebral perfusion) used during arch repair according to surgeon preference.
214548221|NCT06717815|DRUG|IPG11406|"Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed."
214548222|NCT06921213|DRUG|Linezolid (LZD)|Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
214548223|NCT06921213|DRUG|Amoxicillin|Ten day course. Oral Linezolid dosed at 50mg/kg twice a day.
214548224|NCT06921213|DRUG|Benzathine Penicillin G|Single IM dose 50,000iu/kg
214548225|NCT06721494|DRUG|Methamphetamine|Methamphetamine HCl for intravenous administration
214548226|NCT06721494|DRUG|Sterile Saline|Sterile Saline for intravenous administration
214548227|NCT06721494|DRUG|CS-1103|CS-1103 for intravenous administration
215160816|NCT02564835|OTHER|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
215160817|NCT02564835|OTHER|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
214548228|NCT07049224|OTHER|Meat diet|Participants will be subjected to a 10-day diet containing meat and animal products. During the interventional period participants will perform unilateral lower limb resistance exercise.
214548229|NCT07049224|OTHER|Plant diet|Participants will be subjected to a 10-day diet containing plant products. During the interventional period participants will perform unilateral lower limb resistance exercise.
215160818|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 500 mg/m\^2 IV over 2 hours every other week
215160819|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 750 mg/m\^2 IV over 3 hours every other week
215160820|NCT05812729|BEHAVIORAL|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
215160821|NCT01420094|DRUG|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter \[mL\]) between 1-4 hours post dental surgery.
215160822|NCT01420094|DRUG|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
215160823|NCT01420094|DRUG|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
215160824|NCT01432483|DRUG|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
215160825|NCT04723797|OTHER|Physical activity|Physical activity program consisting of running and/or cycling
215160826|NCT05167825|DRUG|Macitentan|Macitentan will be administered orally as a tablet.
215160827|NCT00610298|DEVICE|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
215160828|NCT00488683|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
215160829|NCT00488683|BIOLOGICAL|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
215160830|NCT00488683|BIOLOGICAL|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
215160831|NCT00488683|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
215160832|NCT00488683|BIOLOGICAL|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
215160833|NCT06600945|OTHER|Cataract surgery|With local anesthetic in peribulbar anesthesia
215160834|NCT04509726|DRUG|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
215160835|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from optoelectronic system|The raw data acquired from motion capture system were processed with Smart Analyzer software (BTS Bioengineering, Milano, Italy). First, the 3D data were filtered and interpolated in case of missing data for short time. Then spatial-temporal parameters (cycle duration, cadence, gait speed, stance phase, swing phase, double-support phase, stride length and step width) and conventional kinematic parameters of traditional Davis marker-set protocols were computed.
215160836|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from markerless system|The two videos were elaborated using OpenPose that returns a set of 25 2D keypoints coordinates for body pose estimation for each video. Key-points were located in relevant body landmarks and it were used to determine the 2D Cartesian coordinates on the sagittal plane and on the frontal plane. The data calculated with routines were filtered and interpolated in case of missing data. With respect to kinematic parameters, the segment and joint angles were measured from the estimated feature points of each joint. Spatiotemporal gait parameters were calculated using successive heel strike and toe-off events.
215160837|NCT04743765|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
215160838|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
215160839|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
215160840|NCT04291573|DEVICE|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
215160841|NCT04291573|DEVICE|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
215160842|NCT04706026|OTHER|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
215160843|NCT04706026|OTHER|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
215160844|NCT04810052|BEHAVIORAL|Behavioral Intervention|Perform 1 nice thing
215160845|NCT04810052|BEHAVIORAL|Behavioral Intervention|Write a letter or note of gratitude
215160846|NCT04810052|BEHAVIORAL|Behavioral Intervention|Track daily activities
215160847|NCT04810052|OTHER|Interview|Ancillary studies
215160848|NCT04810052|OTHER|Quality-of-Life Assessment|Ancillary studies
215160849|NCT04810052|OTHER|Questionnaire Administration|Ancillary studies
215160850|NCT06176365|DRUG|Survodutide|once weekly subcutaneous injection
214548230|NCT07050524|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Participants assigned to the experimental group will receive Omega-3 fatty acids supplementation as part of their treatment regimen. The Omega-3 supplementation will consist of high-quality fish oil capsules, providing a daily dose of \[specific dosage, e.g., 2000 mg of EPA and DHA combined\], taken orally. This supplementation will commence concurrently with the initiation of neoadjuvant immunotherapy and will continue throughout the treatment period.
214548231|NCT07050524|DRUG|Neoadjuvant Immunotherapy|"Participants in both the experimental and control groups will receive neoadjuvant immunotherapy designed to stimulate the body's immune response against locally advanced gastric and gastroesophageal junction adenocarcinomas. The specific regimen will involve administration of \[specific immunotherapeutic agents, e.g., pembrolizumab, nivolumab, etc.\] in accordance with established clinical protocols.~The neoadjuvant immunotherapy will be administered through intravenous infusion, typically starting \[specify timeline, e.g., 4-6 weeks\] prior to surgical resection of the tumor. Treatment cycles will be scheduled every \[specify interval, e.g., 2 or 3 weeks\], depending on the specific agent used and participant response."
214548232|NCT07050134|DRUG|DR10624 Injection；|"The experimental group(Trial Drug)~* Name: DR10624 Injection (referred to as DR10624)~* Specification: 60mg (1mL)/vial~* Active Ingredient: DR10624~* Route of Administration: Subcutaneous injection~* Packaging: Vial~* Expiry Date: See the drug label~* Storage Conditions: 2\~8℃, protected from light~* Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd.~* Supplier: Zhejiang Daor Biotechnology Co., Ltd."
214548233|NCT07050134|DRUG|DR10624 Injection Placebo (referred to as placebo)|(The control group)Placebo: Name: DR10624 Injection Placebo (referred to as placebo) Specification: 0mg (1mL)/vial (no active ingredient) Main Component: Normal saline Route of Administration: Subcutaneous injection Packaging: Vial Expiry Date: See the drug label Storage Conditions: 2\~8℃, protected from light Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. Supplier: Zhejiang Daor Biotechnology Co., Ltd.
214548234|NCT07049835|DRUG|Ilioinguinal/iliohypogastric Nerve Block|15cc 0.25% of Bupivacaine + Dexamethasone 8 mg 2cc
214548235|NCT07049835|OTHER|Ilioinguinal/iliohypogastric with Placebo Block|17 cc of Placebo
214548236|NCT07051135|DEVICE|"HablaRÉ: Emotional Reasoning bias correction training"|"The HablaRÉ bias correction training for Emotional Reasoning consists of ten online, self-administered sessions that last no more than 30 minutes each. These courses include practice tasks in addition to textual and audio-visual content. The explanation of ER bias, motivation to change, emotional psychoeducation, and the distinction between emotionally biassed and objective information are all addressed."
214548237|NCT07050316|DRUG|CBT101|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
214548238|NCT07050316|DRUG|Placebo|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
214548239|NCT07050849|BEHAVIORAL|Slackline Training|This intervention consisted of a six-week supervised slackline training program designed to improve core stability, physical performance, and dynamic balance. Participants in the intervention group performed 18 sessions (3 sessions per week, 45 minutes each) using a Gibbon-brand slackline (12.5 meters in length, 50 mm wide). The training protocol included a structured progression of 11 exercises, ranging from assisted standing to unassisted long walks and dynamic movements on the slackline. All sessions were conducted under the supervision of a licensed physiotherapist to ensure participant safety and training fidelity. Exercises were adapted weekly to increase difficulty, challenge motor control, and stimulate neuromuscular adaptation.
214548240|NCT07049666|DEVICE|Bag-valve mask|A BVM equipped with an oxygen reservoir, coupled with a correctly fitted oronasal mask was used.
214548241|NCT07049666|DEVICE|Noninvasive mechanical ventilation|Preoxygenation was conducted over a three-minute period using NIMV employing a properly fitted oronasal mask. This was facilitated by a mechanical ventilator operating in pressure support mode. The preoxygenation protocol entailed the administration of 100% FiO2, applying Positive End-Expiratory Pressure set at 5 cmH2O, delivering breaths at a frequency of 15 per minute, and providing a tidal volume ranging between 6 to 8 ml/kg of body weight.
214548242|NCT07050602|BEHAVIORAL|Health Belief Model Nursing Intervention|Participants received a one-year health belief model nursing intervention. This included: comprehensive assessment and psychological interventions (Perceived Susceptibility); education on OSAHS risks and consequences (Perceived Severity); weekly weight/blood pressure monitoring, dietary/exercise guidance, sleep posture correction aids, and a daily health diary (Perceived Benefits); and regular phone follow-ups (2-3 times/week for 0-8 weeks post-discharge, bi-weekly up to 1 year) for support and addressing difficulties (Perceived Barriers).
214548243|NCT07050602|BEHAVIORAL|Routine Care|Participants received routine postoperative care for OSAHS for one year, including general education, dietary and exercise guidance. Post-discharge monitoring was conducted via monthly phone calls.
215160851|NCT06176365|DRUG|Placebo matching survodutide|once weekly subcutaneous injection
215160852|NCT06422923|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
214699786|NCT02432040|DRUG|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
214548244|NCT07049302|COMBINATION_PRODUCT|Conventional Risk Factor Assessment|Participants in Group 1 will undergo evaluation for conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS
214548245|NCT07049302|COMBINATION_PRODUCT|Non-Conventional Risk Factor|Participants in Group 2 will be assessed for non-conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS).
214699787|NCT02432040|DRUG|Placebo|Placebo tablets, made to look like the interventional drug
214699788|NCT01147575|DIETARY_SUPPLEMENT|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
214699789|NCT01147575|DIETARY_SUPPLEMENT|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
214699790|NCT04051151|BEHAVIORAL|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
214699791|NCT01919905|DIETARY_SUPPLEMENT|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
214699792|NCT04245527|DEVICE|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
214699793|NCT04050098|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
214699794|NCT04050098|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
214699795|NCT02379754|DRUG|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
214699796|NCT04081597|DRUG|Star-101|Administered orally
214699797|NCT04081597|DRUG|Placebo|Administered orally
214699798|NCT03590522|GENETIC|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
214699799|NCT03440853|BEHAVIORAL|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
214699800|NCT03440853|OTHER|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
214699801|NCT03226132|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
214699802|NCT03226132|BEHAVIORAL|Repeated Contact|Repeated Contact
214548246|NCT07050446|DRUG|Vizol S DIGI EYE eye drops|1 drop 4 times a day
214548247|NCT07050446|DRUG|0,9% saline solution, eye drops|1 drop 4 times a day
214548248|NCT07049146|PROCEDURE|EUS-guided tissue glue/coil injection|Under linear array endoscopic ultrasound (EUS), puncture GVs with a 19G/22G needle, deploy coils, and inject 1-2ml tissue glue until blood flow in GVs disappears (or inject glue directly if coils are unsuitable). Treat moderate-to-severe esophageal varices (EVs) with band ligation during or after the procedure.
214548249|NCT07049146|PROCEDURE|BRTO|Establish vascular access via the femoral or internal jugular vein, occlude gastrorenal shunts with a balloon catheter, and inject sclerosant foam. Treat moderate-to-severe EVs with band ligation within 5 days post-procedure.
214699803|NCT05344976|BIOLOGICAL|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
214699804|NCT01351402|PROCEDURE|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
214699805|NCT03214692|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
214699806|NCT00003450|BIOLOGICAL|Ad5CMV-p53 gene|
214699807|NCT02705508|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
214699808|NCT02705508|DRUG|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
214699809|NCT02705508|DRUG|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
214699810|NCT02705508|RADIATION|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
214699811|NCT04416126|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
214699812|NCT04416126|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
214699813|NCT03633227|DRUG|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
214548250|NCT07050901|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Kolcaba's Nursing Care Applications Based on Comfort Theory were carried out individually; each application was planned for one and a half hours, one day a week and for 8 weeks, and each session was carried out for each individual through home visits. The topics of Nursing Care Based on Kolcaba's Comfort Theory were; Physical Care Practices (2 weeks), Psychospiritual Care Practices (2 weeks), Environmental Care Practices (2 weeks) and Sociocultural Care Practices (2 weeks).
214548251|NCT07049601|OTHER|Insulin Therapy|The effect of this intervention on HbA1c leading to either tight glycemic control HbA1c less than 7% or less tight glycemic control HbA1c less than 7.5%
214548252|NCT07049601|OTHER|Antidiabetic therapy, lifestyle modification|Individualized adjustments in antidiabetic therapy, lifestyle modification, and monthly clinical follow-up.
214548253|NCT07050043|DRUG|Nivolumab 40mg|Nivolumab is an immunotherapy medicine used to treat several cancers, including lung cancer.
214548254|NCT07050043|DRUG|Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel|Cisplatin, carboplatin, pemetrexed, paclitaxel, Gemcitabine, and docetaxel are chemotherapy drugs used to treat various types of cancer, including non-small cell lung cancer.
214548255|NCT07049913|DEVICE|Gore® TAG® Thoracic Aortic Branch Stent Graft System|Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance.
214548256|NCT07049718|DEVICE|whole body vibration|Whole-body vibration (WBV) is a training method that uses mechanical vibration and external resistance loading to stimulate the body, causing muscle vibration and increasing central nervous system adaptations (Rittweger, 2010).
214548257|NCT07050017|BEHAVIORAL|The study will investigate how different amounts of protein (0 g, 15 g, and 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.|The study will investigate how different amounts of protein (carbohydrate control drink : 0 g, reguler milk : 15 g, and high-protein milk : 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.
214548258|NCT07049549|BIOLOGICAL|Injectable PRF|Autologous injectable platelet-rich fibrin (i-PRF) will be prepared from venous blood using low-speed centrifugation and administered subgingivally to the test quadrants following full-mouth scaling and root planing.
214548259|NCT07049549|OTHER|Plasebo (Sterile Saline)|sterile saline solution will be administered subgingivally to the control quadrants following full-mouth scaling and root planing (SRP).
214548260|NCT06741280|DEVICE|Profilm Mouth Sores|Daily applications of the product as soon as a mouth sore appears, until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
214548261|NCT07050277|DRUG|Intrathecal Morphine|Intrathecal morphine
214548262|NCT07050277|DRUG|No Intrathecal Morphine|No Intrathecal Morphine
214548263|NCT06743321|BEHAVIORAL|Speech-to-speech Voice-Cloning Care (SVCC)|After patients in the intervention group were transferred to the ICU, the SVCC intervention was initiated. It is administered three times daily: in the morning, at noon, and in the evening. The SVCC intervention includes three types of activities: awakening, reassurance, and preparatory exercises for the removal of the endotracheal tube (ETT). Before each intervention is carried out, the clinical status of the participants must be assessed to determine whether they are suitable for SVCC and to decide on the specific content of the intervention. Once the removal of the ETT is implemented, the SVCC intervention will no longer be carried out.
214548264|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,500 participants. There is no medication or non-medication treatment or intervention provided by this study.
214548265|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered by intravenous drip, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
214548266|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered via intravenous drip at a fixed frequency and cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study occurs. The dose for each administration will be calculated based on the body weight measured prior to administration. The dosing regimen (dosing frequency and interval) for subsequent studies may be adjusted based on prior data. The intravenous drip duration should be ≥ 90 minutes for the first dose and may be adjusted to ≥ 30 minutes for subsequent doses if the first dose is well tolerated.
214699814|NCT03633227|DRUG|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
214699815|NCT01276665|PROCEDURE|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
214699816|NCT01276665|PROCEDURE|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
214699817|NCT01069523|DRUG|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
214548267|NCT06943911|BEHAVIORAL|AI Chatbot for Breast Cancer Patient Education and Empowerment|The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.
214548268|NCT06944756|OTHER|Global Postural Reeducation|"Two stretching postures were maintained for 10 minutes each.~* In order to stretch the posterior muscle chain(the supine posture with hip ﬂexion, which stretches the posterior muscle chain) the patient lay in the supine position with the occipital, lumbar, and sacral spine stabilized, with the lower limbs at 90° hip flexion, and performed gradual knee extensions, and dorsiﬂexion of the ankle.~* In order to stretch the anterior muscle chain (the supine posture with leg extension, which progressively stretches the anterior muscle chain) the patient lay in the supine position with the upper limbs abducted at 30° and the forearms supine.. Hips were flexed, abducted, and laterally rotated, with the soles of the feet touching each other. Gradually, respecting the patient's limits, the lower limbs were extended as much as possible and adduction of the upper limbs."
214548269|NCT06944756|OTHER|Scapular Stabilization Exercises|"1\) Push up plus and 2) press up, were selected in reference to a study for scapular stabilization.~During the 5-week intervention training, sets of repetitions were increased progressively. In the ﬁrst week participants performed 3 sets of each exercise (10 repetitions × 10-second duration each) and worked up to a maximum of 5 sets of 10 repetitions in the last weeks of the intervention."
214548270|NCT06945692|PROCEDURE|patient specific reconstruction plates|Use of patient specific reconstruction plates on the 3-D virtually-generated defect using Artificial Intelligence.
214548271|NCT06944457|DRUG|MPD-1|It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.
214548272|NCT06945497|BEHAVIORAL|Art Therapy|The art therapy program will include different weekly experientials to explore mindfulness, establish safety, cultivate relaxation, find strength, honor self-identity, and cultivate community. Art media will include markers, colored pencils, fabrics, watercolors, collage, and yarn.
214548273|NCT06945497|BEHAVIORAL|Yoga/Mindfulness|The yoga/mindfulness curriculum will explore consciousness (awareness of self and others), compassion, confidence, courage, and community. Each week, new movement and breathing exercises will be learned.
214548274|NCT06945003|BEHAVIORAL|Exercise Intervention|Those assigned to the intervention group will be invited to attend one of three group activity sessions with their parent/guardian that will occur at one of Ulster University's sport centres. Three group activity sessions will be delivered separately for each cohort (i.e Primary, Post-Primary and those with an Intellectual Disability) and their respective parent/guardian.) Parents/guardians and their child will then meet one-to-one with Professor Frank Casey, a paediatric cardiologist, will discuss with them, their child's results from their cardiopulmonary exercise test and from wearing their activity monitor. Using these results, alongside their age and diagnosis and likes and dislikes, Professor Casey will provide an individualised physical activity recommendation plan for each child that will be safe and beneficial to them, to be implemented at home over 12-weeks.
214548275|NCT06945133|OTHER|Clinical testing|"Intervention includes :~* Surface EMG to measure inhibition of the VM and the rectus femoris (RF) on the injured and non-injured sides during attempts at voluntary contractions of the knee extensor muscles.~* Myotonometry to measure the stiffness of the semimembranosus and biceps femoris (long head) on the injured and non-injured sides under resting conditions"
214548276|NCT06944808|OTHER|Sham-BFR + EMS|Daily passive sham-BFR with a fixed pressure of 20mmHg in combination with electrical stimulation of the m. vastus lateralis and mediales
214548277|NCT06944808|OTHER|BFR + EMS|Daily passive BFR with an individual pressure of 80% of the limb occlusion pressure in combination with electrical stimulation of the m. vastus lateralis and mediales
214548278|NCT06944496|BIOLOGICAL|Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine|Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W
214548279|NCT06944496|BIOLOGICAL|Tislelizumab+Oxaliplatin+Capecitabine|Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 130 mg/m², IV, D1, Q3W; Capecitabine: 1000 mg/m², po, BID, D1-D14, Q3W
214548280|NCT06945029|DEVICE|Ambu Aura Gain|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric population.
214548281|NCT06945029|DEVICE|Laryseal Pro|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric
214548282|NCT06938269|DRUG|MWN109 tablet|Strength: 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.
214548283|NCT06938269|DRUG|Placebo|Administration: Oral.
214699818|NCT01069523|DRUG|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
215160853|NCT04446468|BEHAVIORAL|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
214699819|NCT01419483|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
214699820|NCT02724774|BEHAVIORAL|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
215160854|NCT04446468|OTHER|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
214548284|NCT06948227|OTHER|Daily Living Activities (ADL) Training Program|After the 1st assessment, activities that the investigators frequently use in daily life such as eating and brushing our teeth and activities that are appropriate for the age group of the participants and that affect their participation such as throwing a ball or playing games will be implemented with the therapist for 6 weeks. During the session, the therapist will provide practical training so that the participants can do the activities correctly and will provide a demonstration of the activity, observe whether the child compensates while performing the movements during all these activity steps and will make corrections for the movements that he/she compensates for. At the same time, the therapist will give reinforcing verbal affect for the activity skills that the participants do correctly in order to increase their motivation during the session. The 2nd Assessment will be made at the end of the 6th week in order to analyze the change during the 6-week period.
214548285|NCT06948227|OTHER|Social Robot Application|The basic daily life activities that the Social Robot can perform, such as eating and brushing teeth, and the ball throwing activity that affects their participation, will be coded into the robot by engineers. 1. The evaluations will be applied as in the other group, and occupational therapy sessions for upper extremity skills will be applied with the Social Robot Nao accompanied by a therapist for 6 weeks. In this group, the robot will show the selected activities to the children according to the activity application steps during the session and then ask the child to apply them. The verbal feedback that the Social Robot Nao will use will be determined and applied by the therapist. At the end of the 6th week, the second evaluations will be made and the 6-week developments of the participants in this group will be analyzed. Each session will be applied once a week for 40 minutes.
214548286|NCT06950502|PROCEDURE|transversus abdominis plane block|Transversus abdominis plane block was performed with the patient lying in the supine position via an oblique subcostal approach from the anterior abdominal wall. After skin asepsis of the anterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the linear ultrasound probe was placed parallel to the subcostal border at the level of the xiphoid bone and the subcutaneous fat tissue, rectus abdominis muscle and transversus abdominis muscle were visualized, respectively. A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
214548287|NCT06950502|PROCEDURE|Quadratus Lumborum Block (QLB)|Quadratus lumborum block; after the patient was lying in the lateral decubitus position and skin asepsis of the posterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the ultrasound probe was moved from the level of the iliac crest to the 4th lumbar vertebra and the quadratus lumborum muscle was visualized on the transverse process of the 4th lumbar vertebra at the point where the anterior abdominal wall muscles end. The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
214548288|NCT06950502|DRUG|quadratus lumborum block using bupivacaine|The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
214548289|NCT06950502|DRUG|transversus abdominis plane block using bupivacaine|A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
214548290|NCT06947512|DEVICE|Seleggo Test|Seleggo Test is a computerized procedure to identify the personalized visual and auditory parameters facilitating reading and writing for each participant. By applying these parameters to the visualization and to the TTS software during reading of school texts, the participants are expected to be facilitated in reading and understanding the text.
214548291|NCT00233753|DEVICE|Cordis Neurovascular Self-Expanding Stent|
214548292|NCT06546137|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing of genomic DNA extracted from buccal swab
214548293|NCT00903071|BEHAVIORAL|Real PPL|See above arm description
214548294|NCT00903071|BEHAVIORAL|Sim PPL|See above arm description
215160855|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
215160856|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
215160857|NCT05459298|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
215160858|NCT05459298|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
214548295|NCT06245213|DRUG|ANAVEX3-71 oral capsules|ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
215160859|NCT05459298|OTHER|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
215160860|NCT04986670|BEHAVIORAL|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
215160861|NCT04986670|OTHER|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
215160862|NCT04986670|BEHAVIORAL|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
215160863|NCT04986670|OTHER|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
214548296|NCT06245213|DRUG|Placebo oral capsules|The placebo comparator for the study.
214548297|NCT05992922|DRUG|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice a day
214548298|NCT05992922|DRUG|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice a day
214548299|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
214548300|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
214548301|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
214548302|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
214548303|NCT06388317|BEHAVIORAL|Adaptive Step Goal (Intervention)|Receiving automated personalized daily step goals,
214548304|NCT06388317|BEHAVIORAL|Static Step Goal (Control)|Receiving personalized static daily step goals.
214548305|NCT01918592|DEVICE|MRI/acetate-PET imaging|
214548306|NCT04608747|OTHER|Tahini|Fifty grams of tahini were consumed by 20 healthy males
214548307|NCT03153150|DRUG|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548308|NCT03153150|DRUG|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548309|NCT03153150|DRUG|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548310|NCT03153150|DRUG|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548311|NCT03153150|DRUG|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548312|NCT03153150|DRUG|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548313|NCT03153150|DRUG|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
214548314|NCT03055169|GENETIC|genetic analysis|
214548315|NCT03055169|BIOLOGICAL|blood and stools samples|
214548316|NCT04698746|PROCEDURE|Pericapsular nerve group block|PENG block will be made with 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml NaCl under US-guidance
214548317|NCT04698746|PROCEDURE|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
214699821|NCT06130852|BEHAVIORAL|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
214699822|NCT01043354|BEHAVIORAL|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
215160864|NCT04986670|BEHAVIORAL|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
215160865|NCT04986670|BEHAVIORAL|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
215160866|NCT06007846|DRUG|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
215160867|NCT02082418|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
215160868|NCT02082418|DIETARY_SUPPLEMENT|Whey|commercially available whey protein
215160869|NCT02082418|DIETARY_SUPPLEMENT|Casein|commercially available casein protein
215160870|NCT05691517|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215160871|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215160872|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
215160873|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
215160874|NCT06501586|DRUG|SGB-3908|SGB-3908 for sc injection
215160875|NCT06501586|OTHER|SGB-3908-Matching placebo|Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
215160876|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
215160877|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
215160878|NCT05627362|DRUG|Elafibranor 80 mg|Oral Tablet
215160879|NCT05627362|DRUG|Elafibranor 120 mg|Oral Tablet
215160880|NCT05627362|DRUG|Placebo Matched to Elafibranor 80 mg|Oral Tablet
215160881|NCT05627362|DRUG|Placebo Matched to Elafibranor 120 mg|Oral Tablet
215160882|NCT02079740|PROCEDURE|Biopsy Procedure|Undergo biopsy
215160883|NCT02079740|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215160884|NCT02079740|PROCEDURE|Computed Tomography|Undergo conventional CT or PET/CT
214548318|NCT04707950|DRUG|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
214548319|NCT04707950|DRUG|Oxytocin|both groups will be given oxytocin as a standard management
214548320|NCT02555553|BEHAVIORAL|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
214548321|NCT04596995|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
214548322|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
214699823|NCT01043354|BEHAVIORAL|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
214548323|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
214548324|NCT06432114|BEHAVIORAL|Sensory Awareness Program (SAP)|SAP is a new rehabilitation program for people with severe mental health problems. SAP aims to help the target group manage anxiety outburst and live an active life through sensory modulation techniques.
214548325|NCT06432114|OTHER|Treatment as usual (TAU)|Treatment as usual is standard psychiatric care for the target group.
214548326|NCT02701998|BEHAVIORAL|mHealth-Enhance Physical Activity Intervention|
215160885|NCT02079740|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215160886|NCT02079740|BIOLOGICAL|Navitoclax|Given PO
215160887|NCT02079740|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215160888|NCT02079740|DRUG|Trametinib|Given PO
215160889|NCT02328014|DRUG|Acalabrutinib|Oral
215160890|NCT02328014|DRUG|ACP-319|Oral
215160891|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
215160892|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
215160893|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
215160894|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
215160895|NCT01734473|DIETARY_SUPPLEMENT|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
215160896|NCT03723551|DRUG|Afabicin|Administered intravenously and orally.
215160897|NCT03723551|DRUG|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
214548327|NCT02701998|OTHER|Physical Activity Intervention|
214548328|NCT04058470|DRUG|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
214548329|NCT04058470|DRUG|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
214548330|NCT01377298|DRUG|Pazopanib|200mg/tablet, 800mg/day PO.
214548331|NCT00590564|DRUG|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
214548332|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
214548333|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
214548334|NCT01791998|PROCEDURE|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
215160898|NCT04939051|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215160899|NCT04939051|PROCEDURE|Esophageal Biopsy|Undergo esophageal biopsy, brushings and gastric aspirate
215160900|NCT04939051|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
215160901|NCT04939051|PROCEDURE|Liver Ultrasonographic Elastography|Undergo liver ultrasound with elastography
215160902|NCT04939051|BIOLOGICAL|Obeticholic Acid|Given PO
214548335|NCT01791998|PROCEDURE|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
214548336|NCT02344875|DRUG|FYU-981, (Oral single dosing)|
214548337|NCT00194324|DRUG|Miconazole nitrate|
214548338|NCT00194324|PROCEDURE|Magnetic resonance imaging|
214548339|NCT00194324|BEHAVIORAL|Moderate levels of exercise|
214548340|NCT03051399|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
214548341|NCT03051399|DIETARY_SUPPLEMENT|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
214548342|NCT00925392|DRUG|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
214548343|NCT00925392|DRUG|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
214699824|NCT01043354|BEHAVIORAL|attention placebo intervention|6 monthly counseling sessions about general health topics
215160903|NCT04939051|DRUG|Placebo Administration|Given PO
215160904|NCT04939051|OTHER|Questionnaire Administration|Ancillary study
215160905|NCT01274338|BIOLOGICAL|Ipilimumab|Given IV
215160906|NCT01274338|OTHER|Quality-of-Life Assessment|Ancillary studies
215160907|NCT01274338|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
215160908|NCT04811014|DRUG|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
215160909|NCT04811014|BEHAVIORAL|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
215160910|NCT04811014|BEHAVIORAL|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
215160911|NCT04811014|BEHAVIORAL|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
215160912|NCT04811014|BEHAVIORAL|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
214548344|NCT05657756|DEVICE|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
214548345|NCT01434680|BIOLOGICAL|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
214548346|NCT01434680|BIOLOGICAL|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
214548347|NCT01434680|BIOLOGICAL|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
214548348|NCT04819061|OTHER|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
214548349|NCT04819061|OTHER|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
214548350|NCT05161793|DEVICE|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
214548351|NCT03947008|OTHER|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
214548352|NCT00214253|DRUG|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
214548353|NCT04617249|PROCEDURE|median anesthesia|giving median anesthesia
214548354|NCT04617249|PROCEDURE|paramedian anesthesia|giving paramedian anesthesia
214548355|NCT05163223|BIOLOGICAL|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
214548356|NCT05163223|DRUG|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
214548357|NCT05163223|DRUG|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
214548358|NCT05163223|DRUG|Pembrolizumab|Q3W; IV infusion
214548359|NCT05163223|DRUG|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
215160913|NCT04811014|BEHAVIORAL|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
215160914|NCT03493945|BIOLOGICAL|M7824|1,200 mg intravenous (IV) once every 2 weeks.
214548360|NCT04082351|DIETARY_SUPPLEMENT|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
214548361|NCT04082351|DIETARY_SUPPLEMENT|ordinary water|Ordinary bottled water
214548362|NCT05730114|DRUG|Antiplatelet Drug|anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
214548363|NCT02997332|DRUG|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
214548364|NCT02997332|DRUG|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
214548365|NCT02997332|DRUG|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
214699825|NCT00863837|DRUG|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
214699826|NCT00863837|DRUG|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
215160915|NCT03493945|DRUG|N-803|8-15 mcg/kg subcutaneous every 2 weeks.
215160916|NCT03493945|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
215160917|NCT03493945|BIOLOGICAL|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of modified vaccinia Ankara (MVA)-Bavarian Nordic (BN)-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 months.
215160918|NCT03493945|DRUG|Epacadostat|600 mg orally twice daily (1200 MG total).
215160919|NCT03493945|DRUG|Acetaminophen|Antipyretic medication, orally, prior to infusion, up to 650mg.
214548366|NCT02997332|DRUG|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
215160920|NCT03493945|DRUG|Ibuprofen|Antipyretic medication, orally, prior to infusion, up to 600mg.
214548367|NCT00467415|BEHAVIORAL|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
214548368|NCT00467415|BEHAVIORAL|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
214548369|NCT03597984|RADIATION|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~\- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
214548370|NCT02833805|DRUG|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
214548371|NCT02833805|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
214548372|NCT02833805|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
214548373|NCT02833805|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
214548374|NCT02833805|DRUG|Tacrolimus|Start on Day 5 through Day 365
214548375|NCT02833805|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
214548376|NCT00983749|DEVICE|Full-pressure ECP|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
214548377|NCT00983749|DEVICE|Sham-pressure ECP|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
214548378|NCT02656550|PROCEDURE|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
214548379|NCT01177761|PROCEDURE|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
214548380|NCT01952847|OTHER|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
214548381|NCT01952847|DRUG|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
214548382|NCT01952847|BEHAVIORAL|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
214548383|NCT01598103|DRUG|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
214548384|NCT01598103|DRUG|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
214548385|NCT05227781|DIETARY_SUPPLEMENT|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
214548386|NCT05227781|DIETARY_SUPPLEMENT|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
214548387|NCT01907906|DEVICE|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
214548388|NCT06352073|DRUG|Dupilumab|300mg weekly subcutaneous injection
214548389|NCT04451811|DRUG|OPL-002|Spray dried dispersion and tablet formulation
214548390|NCT00708851|OTHER|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
214699827|NCT04836455|BEHAVIORAL|The FDA's The REal Cost vaping prevention ads - Health harms theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
215160921|NCT03493945|DRUG|Naproxen|Antipyretic medication, orally, prior to infusion, up to 500mg.
215160922|NCT03493945|OTHER|Benadryl|50mg orally prior to infusion.
215160923|NCT03493945|DIAGNOSTIC_TEST|EKG|Baseline and principal investigator discretion.
215160924|NCT03493945|DIAGNOSTIC_TEST|Bone scan|Restaging every 12 weeks.
214548391|NCT00708851|DEVICE|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
214548392|NCT00448006|DEVICE|Allium Biliary Stent|device
214548393|NCT00448006|DEVICE|allium biliary stent|allium biliary stent
214548394|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
214548395|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
214548396|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
214548397|NCT00121667|DRUG|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
214548398|NCT00121667|DRUG|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
214548399|NCT01453023|DRUG|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
214548400|NCT01453023|DRUG|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
214548401|NCT02879383|PROCEDURE|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
214548402|NCT02879383|PROCEDURE|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
214548403|NCT05332678|DRUG|SLS-005 - Once Weekly|Please see Arm description.
215160925|NCT03493945|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Every 12 weeks after start of therapy.
215160926|NCT03493945|DIAGNOSTIC_TEST|MRI|If clinically indicated.
214699828|NCT04836455|BEHAVIORAL|The FDA's The Real Cost vaping prevention ads - Addiction theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.
215160927|NCT03477942|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10\^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
215160928|NCT06373146|DRUG|Tirzepatide|Administered SC
215160929|NCT06373146|DRUG|Mibavademab|Administered SC
215160930|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
215160931|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
215160932|NCT05152823|BIOLOGICAL|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
215160933|NCT03959891|DRUG|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
215160934|NCT03959891|DRUG|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
215160935|NCT03959891|DRUG|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
215160936|NCT03959891|DRUG|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
215160937|NCT06781762|OTHER|N/A (Usual Care)|BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
215160938|NCT06835049|DRUG|Doxorubicin|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Doxorubicin will be given at a dose of 75 mg/m2 Body surface area (BSA) on day 1 of each cycle as a intravenous infusion over 15 minutes.
215160939|NCT06835049|DRUG|Ifosfamide|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Ifosfamide will be given at a dose of 3 g/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 9 g/m2 BSA, as an intravenous infusion of 3 g/m2 daily over 4 hours.
214699829|NCT04836455|BEHAVIORAL|Neutral vaping ads|Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
214699830|NCT05525338|DRUG|Alectinib|In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
214699831|NCT01986634|PROCEDURE|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
214699832|NCT02860806|DRUG|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
214699833|NCT02860806|DRUG|Placebo|Intravenous infusion of matching placebo.
214699834|NCT03886142|PROCEDURE|radiofrequency|radiofrequency of the genicular nerves
214699835|NCT03886142|PROCEDURE|platelet rich plasma injection|intra articular injection of platelet rich plasma
214699836|NCT01886131|OTHER|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
214699837|NCT04698590|DEVICE|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
214699838|NCT04698590|DEVICE|Traditional Scleral Lenses|Traditional scleral lenses
214699839|NCT06411119|DEVICE|Meta Oculus Quest 2™ Virtual Reality Exergaming|Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
214699840|NCT05609123|DIAGNOSTIC_TEST|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
215160940|NCT06835049|DRUG|Dacarbazine|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Dacarbazine will be given at a daily dose of 300 mg/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 900 mg/m2 BSA, as an intravenous infusion over 30 minutes.
215160941|NCT06835049|OTHER|Hyperthermia|Hyperthermia (HT) sessions are scheduled on days 1 and 3 of each chemotherapy cycle. The duration of the preheating phase is always 30 minutes. Together with the treatment phase of 60 minutes, the duration of a HT session is uniformly 90 minutes (Total treatment time). On days 2, chemotherapy will be applied without HT.
214699841|NCT04615689|OTHER|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
215160942|NCT06835049|RADIATION|Radiotherapy|"Radiotherapy (RT) treatment should start ideally 19 days after last chemotherapy dose received (range -4 / +7), preferably on a Monday to omit that the last RT fractions will be applied directly after the weekend. Start of RT can be postponed up to 14 days due to medical reasons without violating treatment protocol.~Patients will preferably receive normofractionated RT to a total dose of 50 Gy in 25 fractions of 2 Gy over 5 weeks23.~Alternatively, patients can receive a moderate hypofractionated RT to either a total dose of 42.75 Gy in 15 fractions of 2.85 Gy over 3 weeks or a total dose of 42 Gy in 14 fractions of 3 Gy over 2 weeks and four days41. The respective total treatment time changes respectively.~The RT treatment should be delivered once daily except on weekends."
214548404|NCT05332678|DRUG|SLS-005 - Twice Weekly|Please see Arm description.
215160943|NCT06835049|PROCEDURE|Surgery|"Standard of care surgical resection must be done by an experienced sarcoma surgeon. All lesions of the trunk and extremities will be resected after total neoadjuvant treatment with chemotherapy, HT and RT.~Surgery will take place preferentially 6 weeks (+/- 2 weeks) after end of radiation."
215160944|NCT06785272|DRUG|magnesium sulfate|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
214548405|NCT04829123|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
214548406|NCT04829123|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
214548407|NCT00312585|PROCEDURE|Acupuncture|
214548408|NCT00312585|PROCEDURE|Sham comparator|
214548409|NCT00637468|DRUG|Intravenous injection of heparin|
214548410|NCT00637468|DRUG|Intravenous injection of acetazolamide|
214548411|NCT00637468|PROCEDURE|Local intra-arterial fibrinolysis|
214548412|NCT00637468|PROCEDURE|Globe massage|
214548413|NCT00637468|DRUG|Topical use of beta-blocker|
214548414|NCT00637468|DRUG|Isovolaemic haemodilution|
214548415|NCT00637468|DRUG|Acetylsalicylic acid|
214548416|NCT02480647|DRUG|Levonorgestrel|20μg/day.
214548417|NCT02480647|DRUG|Etonogestrel|20μg/day.
214548418|NCT01721889|RADIATION|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
214548419|NCT05104255|PROCEDURE|Spinal anesthesia|Twins delivered under under spinal anesthesia
214699842|NCT04798885|BEHAVIORAL|GAIN 2.0|1\) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
214699843|NCT05300100|BEHAVIORAL|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
214699844|NCT01662700|DRUG|Artesunate|
214699845|NCT01662700|DRUG|Chloroquine|
215160945|NCT06785272|DRUG|Normal Saline|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
215160946|NCT04269902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215160947|NCT04269902|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215160948|NCT04269902|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215160949|NCT04269902|PROCEDURE|Computed Tomography|Undergo CT
214548420|NCT05104255|PROCEDURE|General anesthesia|Twins delivered under general anesthesia
214548421|NCT01953445|DRUG|paclitaxel|
214548422|NCT01953445|DRUG|BKM120|
214548423|NCT01338753|OTHER|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
214548424|NCT04577131|BEHAVIORAL|Weekly check-in|Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
214548425|NCT01627262|DRUG|Mesalamine|3x1000mg mesalamine granules per day
214548426|NCT01627262|DRUG|Placebo|3x1000mg placebo granules per day
214548427|NCT02018653|DRUG|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
214548428|NCT02018653|OTHER|Placebo|1 by mouth every 6 hours for up to 6 days.
214548429|NCT02018653|BEHAVIORAL|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
214548430|NCT03699189|BEHAVIORAL|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
214548431|NCT00195377|DRUG|Etanercept|
214548432|NCT00349414|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|
214548433|NCT00349414|PROCEDURE|Conventional Transscleral Cyclophotocoagulation|
214548434|NCT06311370|OTHER|Observation|Observed by trained staff and wearing a sensor watch
214548435|NCT02677870|DRUG|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
214548436|NCT02677870|OTHER|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
214548437|NCT02710227|OTHER|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
214548438|NCT04889027|DIAGNOSTIC_TEST|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
214548439|NCT00648999|DRUG|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
214548440|NCT05518695|DRUG|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
214548441|NCT00015080|DRUG|Naltrexone|
214548442|NCT04375267|DRUG|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
214548443|NCT03188367|DIAGNOSTIC_TEST|Gluten or placebo capsules|Administration of gluten or placebo capsules
214548444|NCT01893047|BEHAVIORAL|live music|live harp music
214548445|NCT01893047|BEHAVIORAL|recorded music|recorded harp music
214548446|NCT03343093|BEHAVIORAL|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
214548447|NCT03343093|BEHAVIORAL|Control|usual care, surveys every 3 months
214548448|NCT03042832|BEHAVIORAL|LOCI|Leadership development with coaching and organizational change support
214548449|NCT03042832|BEHAVIORAL|Internet Based Webinar Leadership Training|Internet Based Webinar Leadership Training
214548450|NCT01108315|OTHER|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
214548451|NCT05950451|OTHER|No intervention|No intervention is led during this descriptive study
214548452|NCT01139359|DRUG|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
214548453|NCT01139359|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
214548454|NCT04990778|DRUG|Eprenetapopt|Given IV
214548455|NCT04990778|DRUG|Venetoclax|Given PO
214548456|NCT03833791|BEHAVIORAL|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
214548457|NCT03833791|BEHAVIORAL|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
214548458|NCT02664597|PROCEDURE|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
214548459|NCT02664597|OTHER|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
214548460|NCT04918004|BEHAVIORAL|Sleep Hygiene|"1. One-to-one sleep hygiene training, the content of which was created by the researchers,~2. A brochure containing 10 lifestyle changes related to sleep hygiene"
214548461|NCT03055962|DRUG|E2609|tablet
214548462|NCT03055962|DRUG|Placebo|tablet
214699846|NCT06208982|DIAGNOSTIC_TEST|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
214699847|NCT01064024|DRUG|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
214699848|NCT01064024|DRUG|Placebo|Tablets, every 8 hours for 48 hours
214548463|NCT02610075|DRUG|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
214548464|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
215160950|NCT04269902|BIOLOGICAL|Obinutuzumab|Given IV
215160951|NCT04269902|OTHER|Questionnaire Administration|Ancillary studies
215160952|NCT04269902|DRUG|Venetoclax|Given PO
215160953|NCT05473143|OTHER|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
215160954|NCT05473143|OTHER|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
214548465|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
214548466|NCT04652388|BEHAVIORAL|Nutritional counseling|Nutritional counseling about mediterranean diet
214548467|NCT04510480|OTHER|Observational study without specific intervention|Observational study with standard cardiac arrest approach
214548468|NCT00506805|DRUG|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
214548469|NCT05641779|DEVICE|pigtail|pigtail catheter insertion in chest in the pleural cavity
214548470|NCT05948969|OTHER|Decision support|"This implementation strategy will include the clinician education of the previous arm and apply audit and feedback of prior care to inform recommendations for future care. These suggestions will encompass 5 different domains based on eligibility and potential opportunity for an SGLT2i, GLP-1RA, angiotensin converting enzyme inhibitors (ACEi)/angiotensin-receptor blockers (ARB), antiplatelet or antithrombotic therapy, and statin therapy. The incorporation of clinical decision support technology will be utilized to identify tailored opportunities for each CV risk reduction based on guideline recommendations for individual patients. Clinicians will be presented prompts with patient-specific recommendation(s) for further optimization of cardioprotective agents. These prompts will be conveyed by a Study Coordinator to responsible clinicians. The follow-up clinical prompts will be based on auditing of updated clinical parameters and medication use."
214548471|NCT05948969|OTHER|Facilitated referral to a cardiometabolic team-based center|Each site will have access to clinicians caring for patients in structured, multidisciplinary cardiometabolic centers. Clinicians caring for patients randomized to this intervention strategy will receive a facilitated referral via the EHR together). If the clinician approves the referral, the patient will be referred to this local team-based comprehensive risk factor management clinic. All patients randomized to this group will be considered in this group whether or not a visit to the cardiometabolic center is completed.
214548472|NCT00003704|DRUG|capecitabine|
214548473|NCT00003704|RADIATION|radiation therapy|
214548474|NCT05428280|OTHER|Physiotherapy|Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise
214548475|NCT05428280|OTHER|Muscle Energy technique|Muscle Energy Technique (MET) is a technique that was developed in 1948 by Fred Mitchell, Sr, D.O\[1\]. It is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.
214548476|NCT05428280|OTHER|Myofacial mobilization|It is a type of gentle, constant massage that releases tightness and pain throughout your myofascial tissues
214548477|NCT06846775|DIAGNOSTIC_TEST|DNA-methylation testing in patient-collected urine and vaginal samples|DNA-methylation testing of methylation markers CDO1, GHSR and ZIC1 for patient-collected vaginal samples and GHSR, CDH13 and SST for patient-collected urine samples.
214548478|NCT02003677|DRUG|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
215160955|NCT06041503|DRUG|Pembrolizumab|Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
215160956|NCT06041503|DRUG|Enfortumab vedotin|EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
215160957|NCT06335303|DRUG|BI 1819479|BI 1819479
215160958|NCT06335303|DRUG|Placebo matching BI 1819479|Placebo matching BI 1819479
215160959|NCT06325709|DRUG|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
215160960|NCT06325709|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
215160961|NCT06325709|DRUG|Palifermin|Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
214548479|NCT02003677|DRUG|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
214548480|NCT00448526|BEHAVIORAL|low protein diet|
214699849|NCT03476785|BEHAVIORAL|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
214699850|NCT03476785|BEHAVIORAL|Yoga|Subjects will perform strength and flexibility exercises.
214699851|NCT01633996|PROCEDURE|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
214699852|NCT02504476|DRUG|AMG 581|Active drug
214699853|NCT02504476|DRUG|Placebo|Placebo
214699854|NCT02504476|DRUG|Midazolam|Interaction
214699855|NCT01160952|DRUG|itraconazole|the two groups are defined by different treatment duration
214699856|NCT04752579|OTHER|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
214699857|NCT00217867|BEHAVIORAL|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
215160962|NCT06325709|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
214699858|NCT01743339|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
214699859|NCT01743339|BEHAVIORAL|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
214699860|NCT02069496|BIOLOGICAL|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
214699861|NCT02010216|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
214699862|NCT06553196|BEHAVIORAL|MATAspire Web-app|Substance misuse prevention education and adaptive coping skills
214699863|NCT03104335|DRUG|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
214699864|NCT05162950|DIAGNOSTIC_TEST|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
214699865|NCT05162950|BEHAVIORAL|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
214699866|NCT04136613|DEVICE|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
214699867|NCT06182813|OTHER|Beta auditory beats (Group A)|Beta auditory beats for 25 min and then perform alternate wall toss test.
214699868|NCT06182813|OTHER|white noise (Group B)|Involves participants receiving White noise for 25 min and then perform alternate wall toss test.
214699869|NCT01717664|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
214699870|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
215160963|NCT06325709|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.
215160964|NCT06325709|DRUG|Sirolimus|Immunomodulating agent: Daily oral dosing beginning Day -1 for approximately 3 to 6 months to prevent an immune response to the protein expressed by the BE HSPCs.
215160965|NCT06528093|DRUG|BI 765883|BI 765883
215160966|NCT06528093|DRUG|gemcitabine|gemcitabine
215160967|NCT06528093|DRUG|nab-paclitaxel|nab-paclitaxel
214548481|NCT05508815|DRUG|Modified Zhiwang Decoction Combined with methotrexate|Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
214548482|NCT05508815|DRUG|Methotrexate|Methotrexate(7.5-15mg, once a week) for 12 weeks.
214548483|NCT00292344|DRUG|Rifaximin and loperamide|
214548484|NCT01821768|PROCEDURE|Sentinel Lymph Node Biopsy|
214548485|NCT04413370|DIAGNOSTIC_TEST|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
215160968|NCT06005493|DRUG|AZD5863|T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
215160969|NCT06433765|OTHER|No intervention|No intervention
215160970|NCT05997446|DEVICE|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
215160971|NCT06694454|DRUG|azacytidine|"Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2."
215160972|NCT06694454|DRUG|carboplatin|Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160973|NCT06694454|DRUG|paclitaxel|Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160974|NCT06694454|DRUG|durvalumab|Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160975|NCT06694454|DRUG|cisplatin|Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160976|NCT06694454|DRUG|gemcitabine|Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160977|NCT06694454|DRUG|pemetrexed|Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
215160978|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
215160979|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.6cm circles, attached to a digitimer.
215160980|NCT05016882|DRUG|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
215160981|NCT05016882|DRUG|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
215160982|NCT05016882|DRUG|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
215160983|NCT05016882|DRUG|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
215160984|NCT05016882|DRUG|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
215160985|NCT05016882|DRUG|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
215160986|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
215160987|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
215160988|NCT05665426|OTHER|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
215160989|NCT05665426|OTHER|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
214548486|NCT00325598|RADIATION|Partial Breast Irradiation (PBI)|
214548487|NCT00502502|BEHAVIORAL|Questionnaire|Weekly questionnaires lasting about 30 minutes.
214548488|NCT04723290|DIAGNOSTIC_TEST|Serological tests for SARS Cov-2|Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
214548489|NCT05288829|DRUG|ALXN1210 SC|All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
214548490|NCT05288829|DRUG|ALXN1210 IV|All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
215160990|NCT05902871|DEVICE|External Automatic Glaucoma Laser|Trans-limbal, direct selective laser trabeculoplasty (DSLT) instrument that directs laser energy through the sclera around the limbus overlying the trabecular meshwork and treats 360 degrees of the angle is treated simultaneously
215160991|NCT05902871|PROCEDURE|Direct Selective Laser Trabeculoplasty|Surgical procedure that utilizes a laser to improve fluid drainage in the eye and reduce intraocular pressure
215160992|NCT04651504|OTHER|Colorectal Cancer Toolkit|The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
214548491|NCT05288829|DRUG|Placebo|All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
214548492|NCT06144593|OTHER|Dietary macronutrient composition|Intermittent carbohydrate restriction
214548493|NCT04874558|DIAGNOSTIC_TEST|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
214548494|NCT06023251|OTHER|Clinical Nutrition|"Nutritional care plan implementation, including~* A step-up and step-down nutritional protocol guided by caloric and protein ratio~* Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~* Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~* Dedicated and specialized dietician and nurse involvement~* Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition."
214548495|NCT02520583|DIETARY_SUPPLEMENT|Lactic acid bacteria and bifidobacteria|
214548496|NCT02520583|OTHER|Placebo|
214548497|NCT05046925|PROCEDURE|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
214548498|NCT05046925|PROCEDURE|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
214548499|NCT01375998|DRUG|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
214548500|NCT04382235|DEVICE|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
214548501|NCT03567135|DRUG|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
214548502|NCT03567135|DRUG|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
214548503|NCT04958720|PROCEDURE|Surgery|Surgery
214548504|NCT04958720|DRUG|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
214548505|NCT04958720|RADIATION|Radiotherapy|Radiotherapy
214548506|NCT00519545|BEHAVIORAL|Prayer|Data collection on physiological biomarkers
214548507|NCT05666817|OTHER|breastfeeding education|"Mothers in the intervention group will be given breastfeeding training after the pre-test application. The content of breastfeeding education is as follows;~* General information about breastfeeding,~* General information about breast milk and the benefits of breast milk,~* Benefits of breastfeeding for mother and baby,~* How the baby should be held during breastfeeding, the baby's position,~* Effective breastfeeding positions for the mother,~* Ensuring that the baby holds the breast correctly,~* Providing the correct breastfeeding technique,~* Breast milking and storage conditions,~* The necessity and benefits of continuing breastfeeding."
214548508|NCT06320002|BEHAVIORAL|Communication Intervention for fecal ostomy surgery|This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
214548509|NCT00819702|OTHER|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
214548510|NCT00272259|PROCEDURE|Participants will interact with up to two small robots and a visual display|
214548511|NCT02474043|BEHAVIORAL|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
214548512|NCT02474043|BEHAVIORAL|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
214548513|NCT00508989|DRUG|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
214548514|NCT00508989|DRUG|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
214548515|NCT00508989|DRUG|L-NMMA|
214548516|NCT00508989|DRUG|Acetylcholine|
214548517|NCT02640105|OTHER|Neurological clinical examination|Diagnostic and description of cluster headache
214548518|NCT02640105|OTHER|Psychological clinical examination|Scale and questionnaires
214548519|NCT02640105|OTHER|Questionnaires|Psychopathological and cognitive questionnaires
214548520|NCT02640105|OTHER|Blood sample|Blood sample for DNA collection
214548521|NCT02640105|OTHER|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
214548522|NCT03945643|DRUG|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
214548523|NCT03945643|OTHER|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
214548524|NCT00047541|DRUG|Alcon Investigational Agent|
214548525|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
214548526|NCT02413593|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214548527|NCT02413593|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214548528|NCT05856578|DRUG|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
214548529|NCT05856578|DRUG|Canagliflozin|Canagliflozin 100mg po qd
214548530|NCT01607931|BEHAVIORAL|Exercise|1 hour of cycling at 50% of maximum power output
214548531|NCT05828563|DIAGNOSTIC_TEST|Blood sample test|Blood sample will be taken to determine immunological indices
214548532|NCT04696783|DRUG|Esomeprazole Magnesium Enteric-coated Tablets|Nexium taken once every 2 days plus lifestyle adjustment
214548533|NCT04696783|BEHAVIORAL|Lifestyle adjustment|Lifestyle adjustment
214548534|NCT03536078|OTHER|home phototherapy|
215160993|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
215160994|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
215160995|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
214548535|NCT05542121|DEVICE|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
214548536|NCT05542121|OTHER|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
214548537|NCT02669134|OTHER|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
214548538|NCT03968068|PROCEDURE|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
214548539|NCT03968068|PROCEDURE|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
215160996|NCT06391099|OTHER|Best Practice|Undergo standard of care diet
215160997|NCT06391099|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
214548540|NCT03344406|OTHER|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
214548541|NCT03344406|OTHER|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
214548542|NCT03344406|OTHER|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
214548543|NCT03344406|OTHER|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
214548544|NCT03344406|OTHER|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
214548545|NCT03344406|OTHER|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
214548546|NCT05530330|DIAGNOSTIC_TEST|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
214548547|NCT05815706|DEVICE|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
214548548|NCT00080990|DRUG|alvocidib|Given IV
214548549|NCT00080990|DRUG|fluorouracil|Given IV
214548550|NCT00080990|DRUG|oxaliplatin|Given IV
214548551|NCT00080990|DRUG|leucovorin calcium|Given IV
215160998|NCT06391099|PROCEDURE|Computed Tomography|Under CT
215160999|NCT06391099|OTHER|Dietary Intervention|Undergo ketogenic diet
215161000|NCT06391099|OTHER|Educational Activity|Receive coaching support
215161001|NCT06391099|OTHER|Glucose Measurement|Undergo blood glucose testing
215161002|NCT06391099|OTHER|Ketone Measurement|Undergo ketone measurement
215161003|NCT06391099|OTHER|Questionnaire Administration|Ancillary studies
215161004|NCT06218914|BIOLOGICAL|NT-112: Autologous, engineered T Cells targeting KRAS G12D|NT-112 targets KRAS G12D in the context of HLA-C\*08:02
215161005|NCT06218914|BIOLOGICAL|AZD0240: Autologous, engineered T Cells targeting KRAS G12D|AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02
214548552|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
214548553|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
214548554|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
214548555|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
214548556|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
214548557|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
214548558|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
214548559|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
214548560|NCT01607528|DIETARY_SUPPLEMENT|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
214548561|NCT01607528|DIETARY_SUPPLEMENT|Placebo|A similar looking and tasting powder with no active substances
214548562|NCT02319863|PROCEDURE|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
214548563|NCT02319863|PROCEDURE|hepatectomy (rapid ligating)|
214548564|NCT02726477|DRUG|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
214548565|NCT02726477|DRUG|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
214548566|NCT00501956|DRUG|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
214548567|NCT03112447|PROCEDURE|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
214548568|NCT03112447|PROCEDURE|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
214548569|NCT05783687|DIAGNOSTIC_TEST|NCC-Sp Assay|Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.
214548570|NCT01125462|OTHER|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
214548571|NCT04666363|OTHER|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
214548572|NCT00134771|DRUG|Nutrient enriched infant formula|
214548573|NCT00723125|DRUG|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
214548574|NCT00723125|DRUG|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
214548575|NCT00723125|DRUG|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
214548576|NCT05290012|OTHER|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
214548577|NCT02839785|DRUG|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
214548578|NCT02839785|DRUG|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
214548579|NCT04969809|DIAGNOSTIC_TEST|Ultrasound of the jugular veins|Ultrasound of the jugular veins to assess the thickness of the carotid intima media
214548580|NCT04969809|DIETARY_SUPPLEMENT|addition of phenylalanine-free protein substitutes|addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
214548581|NCT02880839|DEVICE|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
214548582|NCT02880839|DEVICE|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
214548583|NCT02880839|DEVICE|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
214548584|NCT03497715|DRUG|Ibuprofen lysine|Test 1
214548585|NCT03497715|DRUG|Ibuprofen Sodium|Test 2
214548586|NCT03497715|DRUG|Ibuprofen|Test 3
214548587|NCT03497715|DRUG|Ibuprofen (Nurofen)|Reference 1
214548588|NCT03497715|DRUG|Ibuprofen (Wockhardt)|Reference 2
214548589|NCT03446638|DRUG|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
214548590|NCT03446638|DRUG|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count \> 500/ microliter for 3 days.
214548591|NCT03446638|DRUG|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
214548592|NCT03446638|DRUG|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
214548593|NCT03446638|OTHER|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
214548594|NCT03446638|DEVICE|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
214548595|NCT06487663|PROCEDURE|TACE with ICI|Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
214548596|NCT02676609|DEVICE|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
214548597|NCT05247008|OTHER|Thyme honey|"* Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
214548598|NCT03258671|DRUG|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
214548599|NCT03258671|RADIATION|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
214548600|NCT05359692|BIOLOGICAL|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
214548601|NCT05359692|BIOLOGICAL|retifanlimab|retifanlimab will be administered via IV Q4W
214548602|NCT06544369|BIOLOGICAL|COVID-19 vaccin|injection
214548603|NCT02119897|DEVICE|Low Level Light Therapy|
214548604|NCT01512797|DRUG|Sitagliptin phosphate|100 mg/day orally
214548605|NCT01512797|OTHER|Placebo|1 Placebo Pill per day
214548606|NCT05972798|OTHER|Omega-3 fatty acids|2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
214699871|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
214699872|NCT02986893|BEHAVIORAL|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
214699873|NCT02986893|BEHAVIORAL|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
214699874|NCT06081998|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
214699875|NCT06081998|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
214699876|NCT04915677|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
214699877|NCT04915677|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
214548607|NCT05972798|OTHER|Soybean oil|Soybean oil in patients with LLD
214548608|NCT04582747|DIAGNOSTIC_TEST|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
214548609|NCT00433875|DRUG|AMG 714|
214548610|NCT01895036|DRUG|Naltrexone|
214548611|NCT05950100|DEVICE|Virtual reality group|"It is composed of the physiotherapeutic procedures usually used in the hospital applied by the institution's physiotherapist, and the immersive virtual reality therapy that will be conducted by a third researcher (blind to the sampling and evaluations). Physiotherapeutic consultations will have the conventional duration offered by the Institution and therapy with virtual reality will last 10 minutes, using the game Aviãozinho. Both interventions will have a frequency of 2x a day (morning and afternoon shifts), during the period of 4 days."
214548612|NCT00776022|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
214699878|NCT04186000|BIOLOGICAL|Ad26.ZEBOV vaccine|The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
214548613|NCT01945398|OTHER|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
215161006|NCT06183580|OTHER|neurofeedback training involving dACC|"Participants are pseudorandomized to the dACC group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the dACC. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase dACC neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
215161007|NCT06183580|OTHER|neurofeedback training involving amygdala|"Participants are pseudorandomized to the rAMY group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the rAMY. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase rAMY neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
214699879|NCT05688579|DRUG|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
215161008|NCT05422339|DEVICE|The MapHabit system (MHS)|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
215161009|NCT02757638|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
214548614|NCT01945398|OTHER|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
214548615|NCT03482752|DRUG|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
214548616|NCT05750836|OTHER|Specific nursing support|"* 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
214548617|NCT05750836|OTHER|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
214548618|NCT04947514|DRUG|Tranexamic acid|Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
214548619|NCT04947514|OTHER|Placebo (topical saline)|The untreated breast will receive topical saline.
214548620|NCT01080300|DRUG|Gabapentin Extended Release|Gabapentin ER 1800mg daily
214548621|NCT01080300|DRUG|Placebo|Sugar pill
214548622|NCT01807182|BIOLOGICAL|Aldesleukin|Given IV
214548623|NCT01807182|DRUG|Cyclophosphamide|Given IV
214548624|NCT01807182|DRUG|Fludarabine Phosphate|Given IV
214548625|NCT01807182|OTHER|Laboratory Biomarker Analysis|Correlative studies
214548626|NCT01807182|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
214548627|NCT00924222|DRUG|Sevoflurane|Sedation with sevoflurane
214548628|NCT00924222|DRUG|Propofol|Sedation on intensive care unit with propofol
214548629|NCT00369096|DRUG|bemiparin 3500 IU/day|
214699880|NCT05688579|OTHER|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
214548630|NCT01991847|BEHAVIORAL|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
214548631|NCT04467892|DRUG|methylprednisolone|received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
214548632|NCT04467892|DRUG|Methyl Prednisolonate|received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
214548633|NCT04467892|DEVICE|ventilators|all patients in both groups will be ventilated with CMV for 2 weeks
214548634|NCT05191147|DIETARY_SUPPLEMENT|Dietary supplement|We will study dietary supplement consumption among pregnant women
214548635|NCT04636762|PROCEDURE|Radiation Therapy|Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions\>3:whole brain radiotherapy PTV:30Gy/10F.
214699881|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
214699882|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
214699883|NCT03060603|DRUG|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
214699884|NCT00896987|DRUG|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
214699885|NCT00896987|DRUG|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
214699886|NCT04167306|DRUG|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
214699887|NCT04167306|DRUG|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
215161010|NCT02537613|DRUG|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
215161011|NCT02537613|DRUG|Ibrutinib|Ibrutinib given once daily by mouth
215161012|NCT06542497|DRUG|0.75% phentolamine ophthalmic solution|Once daily dosing
215161013|NCT06542497|DRUG|Placebo|Once daily dosing
215161014|NCT05527834|DRUG|VNRX-7145|Single oral dose
215161015|NCT05527834|DRUG|Ceftibuten|Single oral dose
215161016|NCT05979272|BEHAVIORAL|Treatment as usual|Treatment as Usual at the local family court, which includes a brief, computerized motivation enhancement intervention. All CINI youth will receive TAU, regardless of condition.
215161017|NCT05979272|BEHAVIORAL|Teen Empowerment through Computerized Health (TECH) app|An adjunct smartphone app (i.e., TECH) developed to support TAU. All participants randomly assigned to TAU+TECH will receive the TECH app.
215161018|NCT06295159|DRUG|Nivolumab|Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
215161019|NCT06295159|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
215161020|NCT06295159|DRUG|Ipilimumab|Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
215161021|NCT04319198|DRUG|Sacituzumab Govitecan-hiy|Administered intravenously
215161022|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (WT/OMI BA.2)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.2\]
214548636|NCT00791375|BEHAVIORAL|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
214548637|NCT03444740|OTHER|ICIQ-FLUTS, ADMN-20|Questionnaire
214548638|NCT03026647|PROCEDURE|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
214548639|NCT01776008|DRUG|Akt Inhibitor MK2206|Given PO
214548640|NCT01776008|DRUG|Anastrozole|Given PO
214548641|NCT01776008|DRUG|Goserelin Acetate|Given SC
214548642|NCT01776008|OTHER|Laboratory Biomarker Analysis|Correlative studies
214548643|NCT01776008|PROCEDURE|Neoadjuvant Therapy|Given before standard-care surgery
214548644|NCT01776008|OTHER|Pharmacological Study|Correlative studies
214548645|NCT01776008|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard-care surgery
214548646|NCT03614806|DIAGNOSTIC_TEST|Simultaneous Transcutaneous and End-tidal CO2 measurements|Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement
214548647|NCT00813982|DEVICE|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
214548648|NCT00813982|DEVICE|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
214548649|NCT04444843|DRUG|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
214548650|NCT04458818|PROCEDURE|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
214548651|NCT00926081|BEHAVIORAL|Supervised exercise training|A standardized supervised exercise training program
214548652|NCT02799355|DRUG|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
214548653|NCT02999243|BEHAVIORAL|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
214548654|NCT02999243|BEHAVIORAL|Harm reduction education|Both arms will receive harm reduction education
214548655|NCT03513068|DEVICE|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
214548656|NCT00478205|DRUG|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
214548657|NCT00478205|DRUG|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
214699888|NCT04167306|OTHER|Placebo for varenicline|Capsules for oral use
214548658|NCT01808183|DEVICE|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
214548659|NCT04003194|OTHER|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
214699889|NCT04167306|OTHER|Placebo for bupropion|Capsules for oral use
214699890|NCT05596968|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
214699891|NCT00840944|DRUG|somatropin|somatropin 0.050 mg/kg/day
214699892|NCT00840944|DRUG|triptorelin|triptorelin 3.75 mg each month
214548660|NCT04003194|OTHER|Green Beans - control|The control was 1/2 cup of green beans each day.
214548661|NCT03451708|DEVICE|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
214548662|NCT04810468|OTHER|Anthropometric measurment|Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
214699893|NCT06244940|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
214699894|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
214699895|NCT01513226|OTHER|Cycled light|lights on at daytime, lights off at nighttime
214548663|NCT01010087|DRUG|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
214548664|NCT05837299|DRUG|IMC008|allowing 10% dose error
214548665|NCT02682940|DEVICE|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
214548666|NCT00175747|DRUG|Inhaled Budesonide 800 µg twice daily|
214548667|NCT00405938|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
214548668|NCT00405938|DRUG|Anastrozole|anastrozole (1 mg orally daily)
214548669|NCT00405938|DRUG|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
214548670|NCT02264782|OTHER|Computer-Assisted Intervention|Complete PreView
214548671|NCT02264782|OTHER|Computer-Assisted Intervention|Watch an educational video
214548672|NCT02264782|OTHER|Questionnaire Administration|Ancillary studies
214699896|NCT00383422|DRUG|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
214548673|NCT01854606|DRUG|AEB071|a Protein Kinase C Inhibitor
214548674|NCT01854606|DRUG|Everolimus|mTOR inhibitor
214548675|NCT01915797|OTHER|blood and tumor samples|all tumor pathology associated with anomaly of development
214548676|NCT01587482|PROCEDURE|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
214548677|NCT00003477|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
214548678|NCT04610411|DEVICE|surgical navigation|surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software
214548679|NCT04610411|OTHER|standard surgical method|standard surgical method established at the institution
214548680|NCT02580747|BIOLOGICAL|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
214548681|NCT05671497|DRUG|Cilostazol 100 MG|An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
214548682|NCT05671497|DRUG|conventional synthetic antirheumatic drugs|methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
214699897|NCT00383422|DRUG|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
214699898|NCT02562248|OTHER|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
214699899|NCT02562248|OTHER|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
214699900|NCT03179514|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
214699901|NCT03179514|DRUG|Lipid Regulating Drugs|Mainly including statins
214699902|NCT03179514|DRUG|Coronary Vasodilator|Mainly including nitrates
214699903|NCT03179514|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
214699904|NCT02136121|DEVICE|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
214699905|NCT03670914|DIAGNOSTIC_TEST|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
214699906|NCT02029508|PROCEDURE|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
214699907|NCT02029508|PROCEDURE|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
215161023|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.1)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.1\]
215161024|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
215161025|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
215161026|NCT05472038|BIOLOGICAL|BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BNT162b6 Wild Type and BNT162b6 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
214699908|NCT02029508|PROCEDURE|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
214699909|NCT00340314|PROCEDURE|Circumferential Pulmonary Vein Ablation|
215161027|NCT05472038|BIOLOGICAL|BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BNT162b7 Wild Type and BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
215161028|NCT05472038|BIOLOGICAL|BNT162b7 Monovalent (OMI BA.4/BA.5)|BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
215161029|NCT05470140|BIOLOGICAL|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
215161030|NCT05303519|DRUG|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
215161031|NCT05303519|DRUG|Placebo|Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
214699910|NCT00340314|DRUG|Antiarrhythmic Drug Therapy|
214699911|NCT05829616|DRUG|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
214548683|NCT05575297|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
214548684|NCT05575297|DRUG|Rifampicin Sodium|Co-administration of methotrexate and rifampicin
214548685|NCT05575297|DRUG|Febuxostat Tablets|Co-administration of methotrexate and febuxostat
214548686|NCT02777645|OTHER|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
214548687|NCT01575873|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months
214548688|NCT01575873|DRUG|Placebo for risendronate|Administered orally once a day
214548689|NCT01575873|DRUG|Risendronate|Administered orally once a day
214548690|NCT01575873|DRUG|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
214699912|NCT04284956|PROCEDURE|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
214699913|NCT06281886|DRUG|Induction Immunotherapy-Toripalimab|Toripalimab 240mg iv. drip, Q3W, 2 cycles
214699914|NCT06281886|DRUG|Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
214699915|NCT06281886|RADIATION|Radiotherapy|Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
214699916|NCT06281886|DRUG|Apatinib|Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
214699917|NCT06281886|DRUG|Capecitabine|Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
214699918|NCT02626572|DRUG|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
214699919|NCT02626572|DRUG|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
214699920|NCT02626572|DRUG|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
214699921|NCT02626572|DRUG|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
214548691|NCT04625010|OTHER|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
214548692|NCT04625010|OTHER|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
214548693|NCT00820261|OTHER|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
214548694|NCT03235206|OTHER|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
214548695|NCT04684433|OTHER|Data extraction from medical files|Data extraction from medical files
214699922|NCT04743700|PROCEDURE|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
214548696|NCT04910633|OTHER|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~* Age~* Gender~* Cancer type~* Cancer Stage~* Cancer Treatment~* COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~* Living Status~* Attribution of Mortality to COVID status~* Comorbidities"
214548697|NCT01680081|OTHER|Adenosine stress dynamic CT perfusion|
214699923|NCT04743700|PROCEDURE|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
214548698|NCT01850030|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
214548699|NCT01850030|DRUG|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
214548700|NCT01850030|DRUG|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
214548701|NCT01850030|DRUG|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
214548702|NCT00463853|PROCEDURE|Autologous stem cell therapy|
214699924|NCT02426554|DIETARY_SUPPLEMENT|DDU-supplement|DDU: Vitamin D, DHA, Uridine
214699925|NCT02426554|DIETARY_SUPPLEMENT|Placebo supplement|
214699926|NCT00323505|DRUG|Pegylated Interferon|
214548703|NCT00463853|PROCEDURE|CABG|
214699927|NCT00323505|DRUG|Interferon-alpha2a|
214548704|NCT00463853|RADIATION|CMRI|
214699928|NCT03247205|BEHAVIORAL|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
214699929|NCT00946777|OTHER|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
214699930|NCT02678234|DRUG|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
214699931|NCT01737840|DRUG|Pantoprazole|33 patients
214699932|NCT01737840|DRUG|Ranitidine|33 patients
214699933|NCT05249816|BIOLOGICAL|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
214699934|NCT05249816|BIOLOGICAL|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
214699935|NCT02787434|OTHER|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
214699936|NCT03714035|OTHER|no intervention|no intervention
214699937|NCT01006863|DRUG|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
214548705|NCT02920840|DEVICE|Intermittent theta-burst stimulation|see associated arm/group description
214548706|NCT02920840|DEVICE|Negative-peak-triggered-TMS|see associated arm/group description
214548707|NCT02920840|DEVICE|Open-loop replay TMS|see associated arm/group description
214548708|NCT05620615|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
214548709|NCT05567042|OTHER|No intervention|No intervention
214548710|NCT01407055|BEHAVIORAL|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
214548711|NCT01407055|BEHAVIORAL|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
214548712|NCT02931305|DRUG|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
214548713|NCT02931305|DRUG|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
214548714|NCT02263807|PROCEDURE|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
214548715|NCT02263807|PROCEDURE|Control|Arthroscopy followed by active rehabilitation
214548716|NCT04107753|BEHAVIORAL|Brief counseling based on the 5As model|"It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~1. ASK: every patient should be asked whether he/she is or is not a smoker;~2. ADVICE: the patient is advised to quit in a strong, clear and personalized way;~3. ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~4. ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~5. ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses."
214548717|NCT05006118|DRUG|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of \[12C\]-rodatristat ethyl and \[14C\]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
214548718|NCT04678739|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
214548719|NCT04678739|DRUG|Tocilizumab|Actemra IV Infusion
214548720|NCT00279188|PROCEDURE|Guiding therapy by bronchial hyperrsponsiveness|
214548721|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
214548722|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
214548723|NCT00762476|DRUG|3804-250A|"* topical product~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
214699938|NCT01006863|DRUG|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
214699939|NCT01006863|DRUG|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
214699940|NCT02118610|DRUG|L-tetrahydropalmatine (30mg)|Active comparator
214699941|NCT02118610|DRUG|Sugar pill|Placebo
214699942|NCT04989010|DRUG|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
214548724|NCT00762476|DRUG|3804-291|"* topical~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
214699943|NCT00504335|DRUG|BIO 300 Capsules|
214699944|NCT01641549|PROCEDURE|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
214699945|NCT01641549|DRUG|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
214548725|NCT00992342|DRUG|PF-03893787|oral solution, 5 mg, QD for 14 days
214699946|NCT01758666|DRUG|Methotrexate,Calcium folinate|
214548726|NCT00992342|DRUG|PF-03893787|oral solution, 15 mg, QD for 14 days
214548727|NCT00992342|DRUG|PF-03893787|oral solution, 50 mg, QD for 14 days
214548728|NCT02116569|DRUG|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
214548729|NCT05253768|BIOLOGICAL|Fecal microbiota transplant (FMT)|"Patients will randomized to a fecal microbiota transplantation by using a nasointestinal tube for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
214699947|NCT03105700|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
215029526|NCT02129972|DEVICE|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
214548730|NCT05253768|OTHER|normal saline and glycerin/food coloring|"Patients will receive an equivalent volume of normal saline and glycerin/food coloring via a nasointestinal tube (sham transplantation) for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of placebo FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
214548731|NCT05444946|DRUG|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
214548732|NCT05444946|DRUG|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
214548733|NCT06517238|OTHER|There is no intervention|Observal Study.There is no intervention
214548734|NCT05072652|OTHER|Neuromuscular Electrical Stimulation|Participants in this group will perform twice daily neuromuscular electrical stimulation training sessions of the quadriceps muscles (specifically, the vastus lateralis and rectus femoris) or the immobilized left leg.
214548735|NCT05072652|OTHER|Action Observation + Mental Imagery|Participants in this group will perform daily action observation + mental imagery training via video and audio recordings.
214548736|NCT06017908|DEVICE|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
214548737|NCT05784610|DEVICE|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
214548738|NCT05784610|DEVICE|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
214548739|NCT02708381|OTHER|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
214548740|NCT02266342|DEVICE|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
214548741|NCT05323019|BEHAVIORAL|Psychotherapy|Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.
214699948|NCT06197932|OTHER|Routine exercise and running training|impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
214699949|NCT06197932|OTHER|Big Toe Strengthening Exercise|impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
214548742|NCT05323019|BEHAVIORAL|Treatment as Usual|Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
214548743|NCT05323019|DRUG|Intranasal Ketamine (esketamine)|Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
214548744|NCT01258621|PROCEDURE|Laparoscopy|Laparoscopic distal pancreatectomy
214699950|NCT04773899|DIAGNOSTIC_TEST|Procedure : Multimodal microvascular assessment at study inclusion|"* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy."
214699951|NCT03637699|BEHAVIORAL|Positive Psychology|5-week positive psychology intervention
214699952|NCT04662242|DRUG|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
215161032|NCT05455814|BEHAVIORAL|Shambhavi Madamudra Kriya|The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
215161033|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
215161034|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
215161035|NCT03837483|GENETIC|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
214548745|NCT00965497|DRUG|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
214548746|NCT05005702|OTHER|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
214548747|NCT02799641|DRUG|Diazepam|5 mg Diazepam
214548748|NCT02799641|DRUG|Lidocaine|2 ml of 2% lidocaine
214548749|NCT02799641|OTHER|Placebo pill|Placebo pill
214548750|NCT02799641|OTHER|Placebo injection|Placebo injection
214548751|NCT00001905|DRUG|Interferon gamma|
214548752|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
214548753|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
214548754|NCT03931759|DIAGNOSTIC_TEST|laparoscopic surgery|patients with diabetes mellitus in laparoscopic surgery
214548755|NCT02892643|PROCEDURE|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
215161036|NCT05636501|OTHER|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
215161037|NCT05636501|OTHER|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
215161038|NCT02792166|PROCEDURE|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
214548756|NCT02892643|PROCEDURE|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
214548757|NCT03620097|DIETARY_SUPPLEMENT|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
214548758|NCT03620097|OTHER|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
214548759|NCT05034068|DRUG|0.15% bezaydamine hydrochloride.|0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
214548760|NCT05034068|DEVICE|low power laser with a wavelength of 870 nm|the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
214548761|NCT00178347|RADIATION|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
214548762|NCT05146089|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
215161039|NCT02792166|PROCEDURE|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
215161040|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
215161041|NCT06044259|PROCEDURE|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
215161042|NCT06044259|PROCEDURE|Conventional hemiarch replacement|Coventional open hemiarch replacement
215161043|NCT05867979|DIAGNOSTIC_TEST|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
215161044|NCT06134934|OTHER|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
215161045|NCT06134934|OTHER|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
215161046|NCT05374616|GENETIC|Observation|Retrospective and prospective Natural History Study
215161047|NCT05109975|DRUG|Debio 0123|Debio 0123 orally during 21-day treatment cycles.
215161048|NCT03648905|DRUG|13N-Ammonia|a perfusion imaging agent
215161049|NCT03648905|DRUG|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
214548763|NCT05146089|OTHER|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
214548764|NCT05146089|DRUG|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
214548765|NCT05146089|OTHER|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
214548766|NCT03127670|DRUG|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
214548767|NCT02965105|DEVICE|Coloplast Test Catheter|This is a newly developed intermittent catheter
214548768|NCT02965105|DEVICE|Speedicath|This is a marketed Catheter which is used as comparator
214548769|NCT02214953|DRUG|BI 11634 ER formulation A|
214548770|NCT02214953|DRUG|BI 11634 ER formulation B|
214548771|NCT02214953|DRUG|BI 11634 ER formulation M|
214548772|NCT02214953|DRUG|BI 11634 ER formulation C|
214548773|NCT02214953|DRUG|BI 11634 IR tablet|
214548774|NCT03180567|DIAGNOSTIC_TEST|Genetic Mutations|By next generation sequencing
214699953|NCT04662242|DRUG|normal saline|normal saline 100ml iv infusion for 7 days
214699954|NCT04619875|OTHER|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
214699955|NCT04619875|OTHER|SG1|SG1 is a novel glycan
214699956|NCT04619875|OTHER|Lactulose|Lactulose is a synthetic dissacharide
214699957|NCT04070352|DRUG|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
214699958|NCT01237106|OTHER|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
215029527|NCT06640790|OTHER|Case Group|Root canal treated were categorized based on the AAE case difficulty assessment form. Endodontic mishaps investigated included over-instrumentation, working length loss, underfilling, overfilling, apical transportation, instrument fracture, and perforation.
215161050|NCT03648905|DRUG|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
215029528|NCT06539442|DEVICE|Versius Surgical System|Urological minimal access surgery performed with Versius Surgical System
215161051|NCT03648905|DRUG|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
215161052|NCT05998369|BEHAVIORAL|Empowered Relief for Youth|The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
214548775|NCT02952521|PROCEDURE|Blood Draw|CA125 and ctDNA
214548776|NCT02952521|PROCEDURE|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
214548777|NCT04510181|DIETARY_SUPPLEMENT|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
214548778|NCT02181153|OTHER|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
214548779|NCT02499523|PROCEDURE|THR with conventional technique|THR with conventional technique.
214548780|NCT02499523|PROCEDURE|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
214548781|NCT03701048|PROCEDURE|Cesarean Section|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
214548782|NCT01267240|DRUG|Capecitabine|Given PO
214548783|NCT01267240|DRUG|Vorinostat|Given PO
214548784|NCT02638103|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
214548785|NCT02638103|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
214548786|NCT00505154|DRUG|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
214548787|NCT00505154|DRUG|placebo|placebo
214548788|NCT01770795|DRUG|Genexol-PM/Gemcitabine|
214548789|NCT01731964|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
214699959|NCT00403559|DRUG|Elidel|
214699960|NCT00403559|DRUG|Ketoconazole Cream|
214699961|NCT00100724|BIOLOGICAL|rPA102|
214699962|NCT04270994|DRUG|Misoprostol|
214699963|NCT01253421|DRUG|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
214699964|NCT01253421|DRUG|placebo|single-dose placebo capsule
214699965|NCT03553433|DRUG|Apremilast 30mg|Anti-psoriatic drug
214699966|NCT03553433|DRUG|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
214699967|NCT03584854|DRUG|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
215029529|NCT05546307|OTHER|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
215029530|NCT05546307|OTHER|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
214699968|NCT03584854|DRUG|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
214699969|NCT00059722|DRUG|ZD6474|
214699970|NCT00059722|DRUG|Placebo|
214548790|NCT01731964|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
214548791|NCT00214747|DRUG|Vehicle gel formulations|
214548792|NCT05864404|DRUG|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
214548793|NCT05864404|DRUG|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
214548794|NCT05520853|RADIATION|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
214548795|NCT02292472|DRUG|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
214548796|NCT02292472|DRUG|Placebos|Inject intramuscularly once in visit 2
214699971|NCT00059722|DRUG|ZD1839|
214699972|NCT02200367|BEHAVIORAL|e-mental health collaborative programme|
214699973|NCT02200367|OTHER|Usual Care|
214699974|NCT03331094|PROCEDURE|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
214699975|NCT03331094|PROCEDURE|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
214699976|NCT06336551|BEHAVIORAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
214699977|NCT00121992|DRUG|Docetaxel|
214548797|NCT02037620|DEVICE|5-6-5 Specify electrode|
214548798|NCT02037620|DEVICE|Restore Advance Pulse Generator|
214548799|NCT04198389|PROCEDURE|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
214699978|NCT00121992|DRUG|5-fluorouracil|
214699979|NCT00121992|DRUG|Doxorubicin|
214699980|NCT00121992|DRUG|Cyclophosphamide|
214699981|NCT02085876|OTHER|2 additional MRI sequences|
214699982|NCT02085876|OTHER|An additional blood sample|
214699983|NCT00024076|PROCEDURE|radiofrequency ablation|
214548800|NCT01031498|DRUG|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
214699984|NCT05671601|DIAGNOSTIC_TEST|Automatic picture recognition|A machine that processes photographs automatically taken
214548801|NCT01031498|DRUG|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
214699985|NCT05671601|DIAGNOSTIC_TEST|Manual Assessment Group|Manual recognition of pictures
214699986|NCT00087737|DRUG|DVS-233 SR|
214699987|NCT00087737|DRUG|Venlafaxine ER|
214699988|NCT05604469|DIAGNOSTIC_TEST|Isolation of skin microbiota|Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
214699989|NCT02266082|OTHER|No intervention|There is no intervention in this study.
214699990|NCT03092869|OTHER|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
214699991|NCT03092869|OTHER|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
214699992|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
214699993|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
214548802|NCT02933086|OTHER|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
214548803|NCT02933086|OTHER|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
214548804|NCT01005797|DRUG|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
214548805|NCT00171912|DRUG|imatinib mesylate|
214548806|NCT01810523|BEHAVIORAL|Narrative|Narrative form as described above.
214548807|NCT01810523|BEHAVIORAL|Control|Blank piece of paper
214548808|NCT00631267|PROCEDURE|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
214548809|NCT00631267|PROCEDURE|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
214548810|NCT02825342|DRUG|Citalopram|
214548811|NCT02471989|DIETARY_SUPPLEMENT|Low-FODMAP diet|
214548812|NCT02471989|DIETARY_SUPPLEMENT|GERD diet|
214548813|NCT01827046|DRUG|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
214548814|NCT03143738|PROCEDURE|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
214548815|NCT03143738|PROCEDURE|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
214548816|NCT03143738|PROCEDURE|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
214548817|NCT04454034|PROCEDURE|arthroscopic synovectomy|arthroscopic synovectomy
214548818|NCT02734004|DRUG|Olaparib|Olaparib
214548819|NCT02734004|DRUG|MEDI4736|MEDI4736
214548820|NCT02734004|DRUG|Bevacizumab|Bevacizumab
214548821|NCT00889967|DRUG|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
214548822|NCT00889967|DRUG|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
214548823|NCT00889967|DRUG|Placebo|Placebo once daily by inhalation for 28 days
214548824|NCT04796675|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
214548825|NCT01294436|DRUG|Dapagliflozin|Oral Dose 5 or 10 mg
214548826|NCT03153813|DRUG|capsaicin 8% patches (Qutenza)|
214548827|NCT03153813|OTHER|Placebo patches|
214548828|NCT05946694|OTHER|intubation in manikin|Evaluation of 3 videolaryngoscopes under simulated out-of-hospital conditions by people without clinical experience on a manikin model
214699994|NCT02753829|OTHER|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
214548829|NCT02595775|OTHER|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
214548830|NCT02595775|OTHER|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
214548831|NCT02595775|OTHER|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
214548832|NCT02595775|OTHER|A/F report alone|
214548833|NCT05973123|BEHAVIORAL|Group Nature Outings|A 6 week nature-based intervention for pediatric anxiety. Every other week group outings for families in nature, alternating with every other week nature-based goals for families at home.
214548834|NCT05973123|BEHAVIORAL|Family Outings|6 weeks of weekly outings into nature. These will be supported by the research team through a weekly text message and written materials on skill building and activities to do outdoors.
214548835|NCT01018108|PROCEDURE|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
214548836|NCT01018108|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
214548837|NCT01018108|OTHER|Questionnaire Administration|Ancillary study
214548838|NCT01018108|OTHER|Laboratory Biomarker Analysis|Correlative Study
214548839|NCT02343289|DRUG|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
214548840|NCT02343289|DRUG|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
214548841|NCT00822146|DEVICE|CRT|classified
214548842|NCT04737265|OTHER|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
214548843|NCT00535093|DEVICE|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
214548844|NCT01379456|PROCEDURE|physiotherapy|exercises, 20 sessions over 10 weeks
214548845|NCT02802358|PROCEDURE|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
214548846|NCT05037253|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
214548847|NCT02482610|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
214548848|NCT02482610|OTHER|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
214548849|NCT02482610|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
214548850|NCT02928211|DEVICE|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
214548851|NCT02928211|DRUG|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
214548852|NCT02928211|RADIATION|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
214548853|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
214548854|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
214548855|NCT03547245|BIOLOGICAL|DPBS Sucrose|Placebo
214548856|NCT02296892|DRUG|Remimazolam|For induction and maintenance of sedation
214548857|NCT02296892|DRUG|Placebo|Inactive control arm
214548858|NCT02296892|DRUG|Midazolam|For induction and maintenance of sedation
214548859|NCT04565262|DRUG|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
214548860|NCT00585078|DRUG|Capecitabine|
214548861|NCT00585078|DRUG|Oxaliplatin|
214548862|NCT06542406|DEVICE|Endotracheal intubation|The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
214548863|NCT01018732|BIOLOGICAL|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
214548864|NCT01536171|OTHER|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
214548865|NCT02745639|RADIATION|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
214548866|NCT02745639|DRUG|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
214548867|NCT04198571|DRUG|Zinforo (ceftaroline fosamil)|IV Solution
214548868|NCT04253119|DRUG|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
214548869|NCT02653209|DRUG|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
214548870|NCT02653209|DRUG|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
214548871|NCT02653209|DRUG|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
214548872|NCT04268056|DIAGNOSTIC_TEST|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
214548873|NCT02874599|PROCEDURE|Dental restoration|Damaged teeth will be restored
215161053|NCT06338917|BEHAVIORAL|Moderate-to-vigorous intensity physical activity program (+moviMENT)|The intervention comprises 16 weeks of group based High Intensity Interval Training (HIIT), with transition to individual community based Vigorous Intermittent Lifestyle Physical Activity (VILPA) over the next 12 weeks - for a total intervention period of 28 weeks.
214548874|NCT06543563|DRUG|esketamine|After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
214548875|NCT06543563|DRUG|normal Saline|After the craniotomy, a continuous infusion of normal saline at a rate of 0.3 ml/kg/h is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
214548876|NCT05474547|BEHAVIORAL|Meditation|Students will meditate for 30 min every day for 10 days
214548877|NCT00288951|DRUG|Travoprost 0.004% with and without BAK|
214548878|NCT02165826|DRUG|Roflumilast|Roflumilast tablets
214548879|NCT02165826|DRUG|Roflumilast Placebo|Roflumilast placebo-matching tablets
214548880|NCT02165826|DRUG|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
214548881|NCT00597142|DEVICE|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~* Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~* Lesion length ≤15mm~* Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~* RVD 4.0-7.0mm"
214548882|NCT00005964|BIOLOGICAL|filgrastim|
214548883|NCT00005964|DRUG|cyclophosphamide|
214548884|NCT00005964|DRUG|doxorubicin hydrochloride|
215161054|NCT05452928|DRUG|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
215161055|NCT05452928|DRUG|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
215161056|NCT06333665|OTHER|Whether there is type 2 diabetes mellitus before surgery|Patients were grouped according to whether they had type 2 diabetes mellitus before surgery
215161057|NCT05403034|PROCEDURE|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
215161058|NCT04206319|DRUG|Radium-223|an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
214548885|NCT00005964|DRUG|etoposide|
214548886|NCT00005964|DRUG|prednisone|
214548887|NCT00005964|DRUG|vincristine sulfate|
214548888|NCT00160082|DRUG|Xepol|
214548889|NCT02119247|DEVICE|CHF 6001 dry powder for inhalation via NEXThaler®|
214548890|NCT02119247|DEVICE|CHF 6001 DPI capsules for inhalation via Aerolizer|
214548891|NCT02562898|DRUG|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
214548892|NCT02562898|DRUG|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
214548893|NCT02562898|DRUG|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
214548894|NCT05810805|OTHER|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
214548895|NCT02876952|OTHER|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
214548896|NCT02876952|OTHER|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
214548897|NCT02876952|OTHER|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
214548898|NCT02876952|OTHER|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
214548899|NCT01936467|DEVICE|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
214548900|NCT01936467|DEVICE|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
214548901|NCT06212089|DRUG|TR-012001|A single dose of TR-012001 will be administered.
214548902|NCT06212089|OTHER|Placebo|A single dose of placebo will be administered.
215161059|NCT04206319|DRUG|18F Sodium Fluoride|18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
215161060|NCT06176196|DRUG|VX-548|Tablets for oral administration.
215161061|NCT06176196|DRUG|Placebo|Tablets for oral administration.
214699995|NCT02618980|OTHER|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
215161062|NCT06601998|OTHER|Blood samples and Oropharyngeal swab|Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)
215161063|NCT06601998|OTHER|Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms|"* Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max"
215161064|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
215161065|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
215161066|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
214699996|NCT01316991|DIETARY_SUPPLEMENT|Chewing Gum|chewing gum will be provided
214699997|NCT01316991|DIETARY_SUPPLEMENT|No Gum|no chewing gum will be provided
215161067|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
215161068|NCT06533111|OTHER|Epic Health Record semi-structured handoff cognitive aid|Epic Health Record cognitive aid will be used for intraoperative anesthesia handoff
214699998|NCT02649543|PROCEDURE|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
214699999|NCT02649543|PROCEDURE|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
214700000|NCT02649543|PROCEDURE|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
214700001|NCT03711994|OTHER|Alkantis|cold therapy pack placed on the wound post operatively
214700002|NCT02779192|DRUG|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
214700003|NCT02779192|DRUG|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
214700004|NCT02779192|DRUG|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
214548903|NCT01774045|DRUG|PDC-1421|
214548904|NCT01774045|DRUG|Placebo|
214548905|NCT04034849|RADIATION|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
214548906|NCT04034849|RADIATION|Placebo|Device turned off
214548907|NCT00315679|DRUG|Pentoxifylline (also known as oxpentifylline)|
214548908|NCT04547023|BEHAVIORAL|Fasting before gestational diabetes screen|Fasting for at least 6 hours before 1-hour gestational diabetes screen.
214548909|NCT04547023|BEHAVIORAL|Per oral intake of food and drink|Per oral intake of food and drink within 2 hours of gestational diabetes screen
214548910|NCT04129476|BEHAVIORAL|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
214548911|NCT04041973|DRUG|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
214548912|NCT04041973|DIETARY_SUPPLEMENT|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
214700005|NCT03926767|OTHER|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
214700006|NCT03926767|OTHER|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
214700007|NCT03926767|OTHER|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
214548913|NCT00250432|DRUG|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
214548914|NCT02788071|DIETARY_SUPPLEMENT|FMT capsules|25 capsules per day for 12 days
214548915|NCT02788071|DIETARY_SUPPLEMENT|FMT placebo|25 capsules per day for 12 days
214548916|NCT02568670|OTHER|clinical signs|to remove the peripheral venous catheter according clinical signs
214548917|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
214548918|NCT01011868|DRUG|BI 10773 low dose|BI 10773 low dose
214548919|NCT01011868|DRUG|BI 10773 high dose|BI 10773 high dose
214548920|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
214548921|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
214548922|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
214548923|NCT04319146|PROCEDURE|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
214548924|NCT01002716|BIOLOGICAL|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
214548925|NCT04214353|DIAGNOSTIC_TEST|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
214548926|NCT04214353|DIAGNOSTIC_TEST|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
214548927|NCT03764995|OTHER|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
214548928|NCT03764995|OTHER|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
214700008|NCT03926767|OTHER|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
214700009|NCT06521957|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
214548929|NCT03764995|OTHER|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
214548930|NCT00830687|DEVICE|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
214548931|NCT02760901|DRUG|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
214548932|NCT02760901|DRUG|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
214548933|NCT02760901|DRUG|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
214548934|NCT02760901|DRUG|saline|saline hydration 2500 ml before cisplatin therapy
214548935|NCT02760901|DRUG|Cisplatin|patients with tumours already prescribed cisplatin
214548936|NCT01663038|DRUG|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
214548937|NCT01663038|DRUG|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
214548938|NCT01663038|DRUG|Aspirin|
214548939|NCT05226676|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
214548940|NCT00627354|DRUG|etoposide|
214548941|NCT00627354|DRUG|mitoxantrone hydrochloride|
214548942|NCT00627354|DRUG|prednisone|
214700010|NCT00389740|DRUG|MK0217, /Duration of Treatment : 12 Months|
214548943|NCT00627354|DRUG|vinorelbine tartrate|
214548944|NCT02039895|RADIATION|HITS|Helical irradiation of the total skin by helical tomotherapy
214548945|NCT03981497|PROCEDURE|Microwave ablation (MWA)|Thermal ablation
214548946|NCT05438836|RADIATION|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
214548947|NCT03525470|BIOLOGICAL|Water|150 mil of water was drunk on two occasions
214548948|NCT03525470|OTHER|No drink|Although body weight lost no drink consumed
214548949|NCT00855855|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
214548950|NCT04518904|OTHER||
214548951|NCT01655303|DRUG|Propranolol|
214548952|NCT01655303|DRUG|Metoprolol|
214548953|NCT01655303|DRUG|Verapamil|
214548954|NCT01655303|DRUG|Diltiazem|
214548955|NCT00652509|BEHAVIORAL|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
214548956|NCT00652509|BEHAVIORAL|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
214548957|NCT02400775|DRUG|Azilsartan|Azilsartan tablets
214700011|NCT00389740|DRUG|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
214700012|NCT04200716|BEHAVIORAL|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
215161069|NCT06533111|OTHER|Usual care|Epic Health Record cognitive aid will not be used for intraoperative anesthesia handoff
215161070|NCT05005403|DRUG|Azirkitug|Intravenous (IV) Infusion
214700013|NCT04200716|BEHAVIORAL|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
214700014|NCT00747838|PROCEDURE|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
214700015|NCT01343134|DEVICE|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
214700016|NCT06555237|DRUG|Trametinib tablet|Trametynib orally once daily in 0,025mg/kg dose
214700017|NCT06555237|DRUG|Standard therapy|Disopiramide and Beta blockers orally
214700018|NCT00004038|BIOLOGICAL|Ad5CMV-p53 gene|
214700019|NCT00004038|DRUG|chemotherapy|
214700020|NCT03166865|BIOLOGICAL|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
214700021|NCT03166865|OTHER|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
214700022|NCT02683226|DRUG|Vipdomet|
214700023|NCT02683226|DRUG|Incresync|
214548958|NCT00328575|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
214548959|NCT02694042|BEHAVIORAL|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
214548960|NCT03784820|BEHAVIORAL|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
214700024|NCT05439694|DRUG|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
214700025|NCT00022035|BIOLOGICAL|trivalent influenza vaccine|
214700026|NCT05059418|DRUG|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
214700027|NCT05059418|DRUG|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
214700028|NCT05059418|OTHER|Placebo|Mouth rinse with no capsaicin
214548961|NCT03784820|BEHAVIORAL|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
214548962|NCT04517240|OTHER|endoscopy|upper and lower endoscopy and fecal calprotectin test
214548963|NCT05638347|DRUG|HRS-7085 tablets|Single oral administration
214548964|NCT05638347|DRUG|Placebo tablet|Single oral administration
214548965|NCT00736411|PROCEDURE|acupuncture|16 treatments over 8 weeks
214548966|NCT00736411|PROCEDURE|IVF|one 4 week IVF cycle
214548967|NCT04501393|OTHER|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
214700029|NCT03106506|PROCEDURE|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
214700030|NCT04387136|DRUG|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
214700031|NCT06043206|PROCEDURE|Bariatric Surgery|Bariatric Surgery
214700032|NCT01788306|DRUG|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
214700033|NCT04839770|DEVICE|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
214700034|NCT06224881|DRUG|Ascorbic acid|2 gm every 8hrs for 4 days
214700035|NCT01463865|DRUG|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
214700036|NCT01463865|DRUG|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
214700037|NCT01485926|DRUG|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
214700038|NCT01485926|DRUG|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
214700039|NCT05542329|DEVICE|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
215161071|NCT05005403|DRUG|Budigalimab|Intravenous (IV) Infusion
215161072|NCT05005403|DRUG|Bevacizumab|Intravenous (IV) Infusion
215161073|NCT06492174|DEVICE|AGENT DCB 40 mm|Drug coated PTCA balloon catheter 40 mm size
214548968|NCT05321199|DRUG|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
214548969|NCT04539223|DRUG|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
214548970|NCT06067607|OTHER|eye gaze technology|eye gaze technology and software activities
214548971|NCT05536206|DEVICE|Wireless and continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
214548972|NCT03554031|DRUG|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
215161074|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
215161075|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
215161076|NCT04754321|RADIATION|External Beam Radiation Therapy|Undergo EBRT
215161077|NCT04754321|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
215161078|NCT04754321|BIOLOGICAL|Pembrolizumab|Given IV
215161079|NCT04754321|OTHER|Quality-of-Life Assessment|Ancillary studies
215161080|NCT04754321|PROCEDURE|Salvage Surgery|Undergo salvage surgery
215161081|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
215161082|NCT05240742|OTHER|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
214548973|NCT03573193|OTHER|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
214548974|NCT05652439|OTHER|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
214548975|NCT03439358|DRUG|Magnesium Sulfate|Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
214548976|NCT03439358|OTHER|Normal Saline|Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
214548977|NCT00794170|BEHAVIORAL|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
214548978|NCT00658606|DRUG|alefacept|IM
214548979|NCT00658606|PROCEDURE|Narrow Band UVB Phototherapy|UVB Phototherapy
214548980|NCT04217772|DEVICE|Optical Coherence Tomography Angiography|A device testing the vascular density in the retina
214548981|NCT05393089|DRUG|AGN-190584|Eye drops
214548982|NCT05393089|DRUG|Vehicle|Eye drops
214548983|NCT06430229|PROCEDURE|Volume controlled ventilation (VCV) mode|"Patients to be ventilated with VCV mode were placed on respiratory support (Dräger Primus) with a breathing rate that would provide 8 ml/kg tidal volume, 5 cmH2O PEEP, and 30-35 mmHg end-tidal carbon dioxide concentration (etCO2) level.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
214548984|NCT06430229|PROCEDURE|Pressure controlled ventilation (PCV) mode|"Appropriate peak inspiratory pressure was set to create a tidal volume of 8 ml/kg in patients who would be ventilated with PCV mode. The number of breaths (Dräger Primus) was adjusted to provide an end-tidal carbon dioxide concentration (etCO2) level of 30-35 mmHg. PEEP was set to 5 cmH2O.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
214548985|NCT05097391|BEHAVIORAL|Warm-up (5 minutes)|Participants will benefit from passive stretches of hamstrings, calf muscles including a range of motion (ROM) exercise to the lower limbs as mat exercises.
214548986|NCT05097391|BEHAVIORAL|Conventional physiotherapy exercise (15 minutes)|The conventional treatments will be active-assisted and free active exercises to the lower limbs on the mat for five (5) minutes. This will be followed by strength training such as sit-to-stand exercises for five (5) minutes and squatting exercises for five (5) minutes prior to the over-ground training.
214548987|NCT05097391|BEHAVIORAL|Over-ground training with lower limb loading (15-25 minutes)|"Participants will perform the over-ground training exercise with an external 1.5kg load on the paretic lower limb placed 2cm above the ankle joint. Before commencing the over-ground training, all the participants will observe a pre-exercise rest period of about two (2) minutes during which their heart rate and blood pressure measurements will be recorded.~The over-ground training will involve the patients walking within a demarcated path. Each participant will be instructed to stand and walk 15meters to and fro for five (5) minutes after which they will be asked to stop and rest for two (2) minutes. The over ground training exercise will be repeated 3 times in the first 2 weeks of the training (15 minutes); 4 times in weeks 3-4 of the training (20 minutes); and 5 times in weeks 5-8 of the training (25 minutes)."
214548988|NCT06426602|DEVICE|mindBEAGLE daily device use|If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
214548989|NCT06601140|DEVICE|EMOCARE software|Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
214548990|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
214548991|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
214548992|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
214548993|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
214548994|NCT05520528|BEHAVIORAL|Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia|The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
214548995|NCT04112186|BEHAVIORAL|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
214548996|NCT04112186|BEHAVIORAL|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
214548997|NCT03025308|DRUG|Filgotinib|Tablet(s) administered orally once daily
214548998|NCT03025308|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
214548999|NCT06267092|OTHER|No treatment given|Participants will not get any medicine during this study.
214549000|NCT06267092|DRUG|Cagrilintide and Semaglutide|Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
214549001|NCT06267092|DRUG|Placebo|Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
214549002|NCT01908777|OTHER|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
214549003|NCT04511234|DEVICE|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
214549004|NCT04511234|DEVICE|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
214549005|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
214549006|NCT06314438|BEHAVIORAL|Family Care Project|Caregivers will be administered the Family Care Project workbook.
214549007|NCT04800783|DIAGNOSTIC_TEST|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
214549008|NCT01972945|PROCEDURE|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
214549009|NCT01972945|PROCEDURE|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
214549010|NCT00365547|BIOLOGICAL|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
214549011|NCT00365547|DRUG|topotecan hydrochloride|Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
214549012|NCT00198003|BEHAVIORAL|Educational program to address patients' expectations|
214549013|NCT00546247|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
214549014|NCT01258647|DIETARY_SUPPLEMENT|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
214549015|NCT00205647|DRUG|Oral N-acetycystein (NAC)|
214549016|NCT00728000|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
214700040|NCT04434820|DEVICE|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
214700041|NCT02278289|DEVICE|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
214700042|NCT02278289|PROCEDURE|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
214700043|NCT03733873|DRUG|Desmopressin|take desmopressin for 3 months
214700044|NCT03733873|DRUG|Suoquan|take Suoquan mixture for 3 months
214700045|NCT01029886|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly
214700046|NCT01029886|DRUG|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
214700047|NCT04123717|DRUG|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
214700048|NCT02569619|BEHAVIORAL|Activity Intervention|
214700049|NCT02569619|BEHAVIORAL|Healthy Diet Intervention|
214700050|NCT03734081|DEVICE|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
214700051|NCT03734081|DEVICE|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
214700052|NCT01553916|DRUG|Lithium Carbonate|
215161083|NCT05895461|BEHAVIORAL|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
215161084|NCT05895461|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
215161085|NCT02107989|DEVICE|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
215161086|NCT02107989|DEVICE|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
215161087|NCT06406465|DRUG|Belinostat|400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status
215161088|NCT06406465|DRUG|Cisplatin|60 mg/m\^2 IV over 60 minutes on day 2
215161089|NCT06406465|DRUG|Etoposide|80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
215161090|NCT06230965|PROCEDURE|Lung protective ventilation strategy|They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
214549017|NCT00728000|DRUG|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
214549018|NCT00728000|DRUG|Erlotinib|100mg/day PO on days 1-14 and 15-28
214549019|NCT01287728|DRUG|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
214700053|NCT01553916|RADIATION|Prophylactic cranial irradiation|
214700054|NCT03936517|DRUG|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
214700055|NCT03936517|DRUG|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
214700056|NCT00583323|DRUG|Lomotil|Orally 10ml of Lomotil
214700057|NCT00583323|OTHER|Normal saline|10 ml orally
215161091|NCT06787131|DRUG|ZE50-0134 or placebo|The patients will receive ZE50-0134 or placebo.
215161092|NCT06787131|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg once daily (QD) on Day 1 and Day 2.
215161093|NCT06787131|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg twice per day.
214549020|NCT05435911|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
214549021|NCT05435911|DRUG|Flumazenil|Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
214549022|NCT05435911|DRUG|Propofol|Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
214549023|NCT02693951|DRUG|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
214549024|NCT04444934|OTHER|histological examination|Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
214549025|NCT00196352|DRUG|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
214549026|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
214549027|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
214549028|NCT02033447|OTHER|Magnetic Nanoparticle Injection|
214549029|NCT00000951|DRUG|Fluconazole|
214549030|NCT06545461|OTHER|Fruits and Vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups daily of F+V provided in weekly allotments. Amount provided will be that calculated for the participant multiplied times number of household members to assure participants eat the prescribed amount and do not share with household members.
214549031|NCT06545461|OTHER|Sodium Bicarbonate (NaHCO3)|Participants will receive 0.3 mEq/kg bw/day NaHCO3 tablets to match the alkali provided by F+V given to F+V participants. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in two divided oral doses.
214549032|NCT06545461|OTHER|Usual Care|Participants will receive standard medical care but no additional alkali (F+V nor NaHCO3).
214549033|NCT06851806|DRUG|Palivizumab 15 mg/kg|Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection
214549034|NCT04827745|DRUG|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
214549035|NCT04447833|DRUG|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
214549036|NCT06646653|DEVICE|Alma System|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
214549037|NCT06646913|DEVICE|Transcutaneous Electrical Nerve Stimulation|Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
214549038|NCT05924386|PROCEDURE|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
214549039|NCT05924386|PROCEDURE|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
214549040|NCT03170518|DRUG|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
214549041|NCT03170518|DRUG|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
214549042|NCT03170518|DRUG|Placebo|Matching placebo tablet will be administered orally once-daily.
214549043|NCT04428476|BIOLOGICAL|Deramiocel (CAP-1002)|Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months
214549044|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
214549045|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
214549046|NCT03189173|DEVICE|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
214549047|NCT03189173|DRUG|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
214549048|NCT03189173|OTHER|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
214549049|NCT03189173|OTHER|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
214549050|NCT00546078|BIOLOGICAL|Cervarix™|Intramuscular injection, one or three doses
214549051|NCT04637516|DEVICE|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
214549052|NCT00135785|DRUG|Bupropion|
214549053|NCT00135785|DRUG|Placebo|
214549054|NCT02068378|DEVICE|CMPE Optical Sensor Device|Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
214549055|NCT04455607|BEHAVIORAL|perturbation training|A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
214549056|NCT02325830|DEVICE|Carillon Mitral Contour System|Percutaneous mitral valve repair
214549057|NCT05688163|OTHER|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
214549058|NCT05688163|OTHER|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
214549059|NCT05996978|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
214549060|NCT00101998|DRUG|alvimopan|
214549061|NCT00101998|DRUG|placebo|
214549062|NCT06171022|OTHER|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
214549063|NCT06171022|OTHER|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
214549064|NCT04306146|DRUG|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
214549065|NCT04306146|DRUG|Placebos|Capsules
214549066|NCT06294197|OTHER|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
214549067|NCT02387697|DEVICE|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
214549068|NCT00129142|DRUG|Toremifene Citrate|
214549069|NCT02910843|DRUG|Regorafenib|"* Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
214549070|NCT02910843|DRUG|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
214549071|NCT02910843|RADIATION|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
214549072|NCT02910843|PROCEDURE|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
214549073|NCT03772769|DIAGNOSTIC_TEST|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
214549074|NCT03772769|DIAGNOSTIC_TEST|Microbial culture|Standard diagnosis by microbial culture.
214549075|NCT02314689|DRUG|Intravenous (IV) citrulline|
214549076|NCT01261247|DRUG|panobinostat|Given orally
214549077|NCT01261247|OTHER|laboratory biomarker analysis|Correlative studies
214549078|NCT01261247|GENETIC|western blotting|Correlative studies
214549079|NCT01261247|GENETIC|DNA analysis|Correlative studies
214549080|NCT01261247|OTHER|flow cytometry|Correlative studies
214549081|NCT01261247|OTHER|pharmacological study|Correlative studies
214549082|NCT01261247|OTHER|immunohistochemistry staining method|Optional correlative studies
214549083|NCT01855711|DRUG|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
214700058|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
215161094|NCT03857919|DEVICE|TearCare|The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.
215161095|NCT03857919|DEVICE|LipiFlow|The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
215161096|NCT05369208|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.
215161097|NCT06956209|DEVICE|Direct Bladder Wall Stimulation|The Akyva System is an implantable device intended to electrically stimulate the bladder muscle that controls bladder emptying or urination
215161098|NCT05622708|DRUG|Secukinumab|Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.
214549084|NCT04588766|OTHER|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
214549085|NCT04588766|OTHER|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
214549086|NCT03534583|OTHER|Sudarshan Kriya Yoga|Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
214549087|NCT03534583|OTHER|Health Enhancement Program|Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
214549088|NCT02559310|DRUG|lefamulin|antibacterial agent
214549089|NCT02559310|DRUG|Moxifloxacin|antibacterial agent
214549090|NCT02559310|DRUG|Linezolid|antibacterial agent
214549091|NCT00895726|DRUG|APD209|Oral tablets twice per day for 56 days
214549092|NCT01740154|PROCEDURE|transcranial magnetic stimulation|Undergo TMS
214549093|NCT01740154|PROCEDURE|electromyography|Undergo EMG
214549094|NCT01740154|OTHER|survey administration|Ancillary studies
214549095|NCT01740154|DRUG|sunitinib malate|Given PO
214549096|NCT01815853|RADIATION|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy \[Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle (non-concurrent); Oxaliplatin 100 mg/m² IV on Day 1 + Capecitabine 825 mg/m² orally BID on Days 1-14 of a 21-day cycle (concurrent chemoradiotherapy)\]
214549097|NCT01815853|DRUG|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
214549098|NCT01815853|PROCEDURE|R0 D2 Gastrectomy|
214549099|NCT01815853|DRUG|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
214549100|NCT06282640|DRUG|Vitamin D|Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
214549101|NCT06476938|OTHER|Gene PilotLX|eHealth decision making tool regarding tumor genomic profiling
214549102|NCT00551746|DIETARY_SUPPLEMENT|Purple Grape Juice|Grape Juice
214549103|NCT03514316|PROCEDURE|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
214549104|NCT03514316|PROCEDURE|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
215161099|NCT05622708|DRUG|Placebo|Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.
215161100|NCT05622708|DRUG|Secukinumab|"Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.~Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c."
215161101|NCT02531880|DRUG|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
214549105|NCT03514316|PROCEDURE|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
214549106|NCT04161651|DEVICE|eversense|eversense CGM
214549107|NCT01893489|OTHER|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
215161102|NCT02446262|BEHAVIORAL|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
214549108|NCT03267810|DEVICE|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
214549109|NCT03267810|OTHER|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
214549110|NCT04371237|DEVICE|Compression sleeve|From foot to hip/groin on both legs with only 1 leg connected to pneumatic pump for 1 hour
214700059|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
214700060|NCT04972487|DRUG|Tofersen|Administered as intrathecal bolus injection
214700061|NCT06273306|DEVICE|IMIDOC|Patient´s Mobile App for recording clinical data
214549111|NCT04371237|DEVICE|Heat therapy|Custom leg garment with one leg heated by circulating hot water approx 40 degrees C, the other leg approx 32 degrees C (thermoneutral) for 1 hour
214549112|NCT04371237|OTHER|Glycogen-depleting exercise session|Prolonged intermittent high intensity running (LIST protocol)
214549113|NCT04371237|OTHER|Nutrient Intake (beverage)|Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher
214549114|NCT04371237|PROCEDURE|Skeletal muscle biopsy|Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
214549115|NCT00140374|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
214549116|NCT01775293|DEVICE|Non-absorbable polypropylene mesh|"2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
214549117|NCT05654623|DRUG|ARV-471|orally, once daily on a 28-day continuous dosing schedule
214549118|NCT05654623|DRUG|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
214549119|NCT00624910|DRUG|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
214549120|NCT00624910|DRUG|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
214549121|NCT06171555|DEVICE|CTM|decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
214549122|NCT06171555|DRUG|Celestone|standard of care
214549123|NCT01947322|DRUG|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
214549124|NCT05989594|BEHAVIORAL|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
214549125|NCT05989594|BEHAVIORAL|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
214549126|NCT00778245|DRUG|cefprozil 500mg tablets|
214549127|NCT05792098|PROCEDURE|percutaneous dilatational tracheostomy (PDTS)|Tracheostomy made by percutaneous dilatational technique
214549128|NCT05792098|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound verification of guidewire position
214549129|NCT05792098|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopic control of guidewire position
214549130|NCT01149122|DRUG|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
214549131|NCT01149122|DRUG|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
214549132|NCT04669379|BEHAVIORAL|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
214549133|NCT05472064|OTHER|Persona: Primary care doctor|The chatbot persona is a Black woman who is a primary care doctor.
214549134|NCT05472064|OTHER|Persona: Breast cancer survivor|The chatbot persona is a Black woman who is a breast cancer survivor.
214700062|NCT03089216|PROCEDURE|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
214549135|NCT05472064|OTHER|Communication Style: Direct|The chatbot messages are characterized by commands and direct addresses (''you'').
214549136|NCT05472064|OTHER|Communication Style: Indirect|"The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's)."
214549137|NCT05831137|PROCEDURE|shorter cryoanalgesia|duration time of cryoanalgesia
214549138|NCT02185547|DRUG|Zoloft|Sertraline treatment 25 mg
214549139|NCT02185547|BEHAVIORAL|ICBT|Internet behavioral cognitive therapy only
214549140|NCT04661943|DRUG|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
214549141|NCT04930497|PROCEDURE|vestibular socket technique with bone grafting|a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral
214549142|NCT04930497|PROCEDURE|vestibular socket technique without bone grafting|the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
214549143|NCT06096584|PROCEDURE|Triple Injection Perisartorius block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata"
214549144|NCT06096584|PROCEDURE|Dual sub sartorial block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB."
214549145|NCT06096584|PROCEDURE|Femoral triangle block|Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.
214549146|NCT06096584|PROCEDURE|Distal adductor canal block|Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.
214549147|NCT06096584|PROCEDURE|Suprasartorial plane block|Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
214549148|NCT03328377|DIAGNOSTIC_TEST|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
214549149|NCT00043069|DIETARY_SUPPLEMENT|calcium carbonate|
214549150|NCT00043069|DIETARY_SUPPLEMENT|cholecalciferol|
214549151|NCT00043069|DRUG|Estrogen Antagonists|
214549152|NCT00043069|DRUG|risedronate sodium|
214549153|NCT00043069|OTHER|placebo|
214549154|NCT01227291|DRUG|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
214549155|NCT05311254|DRUG|Fosfomycin Calcium|Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.
214549156|NCT05574283|PROCEDURE|Erector spinae plane block and transmuscular quadratus lumborum block|"All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side"
214549157|NCT05230719|PROCEDURE|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
214549158|NCT03349619|DRUG|Resveratrol plus Carboxymethyl-β-Glucan|Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
214549159|NCT03349619|DRUG|Placebo|Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
214549160|NCT02737826|DRUG|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
214549161|NCT02737826|DRUG|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
214549162|NCT02737826|DRUG|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
214549163|NCT02737826|DRUG|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
214549164|NCT01340248|DRUG|Dilatrend 64mg capsule|"1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
214549165|NCT03430622|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
214549166|NCT03430622|OTHER|TAU|This group will be on their routine care and will not be given any intervention
214549167|NCT05614440|DRUG|Local anesthetic + tramadol hydrochloride|Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block
214549168|NCT05614440|DRUG|Only local anesthetic|Using articain HCL for inferior alveolar nerve block
214549169|NCT02432664|DRUG|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
214549170|NCT02432664|DRUG|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
214549171|NCT02432664|DRUG|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
214549172|NCT02432664|DRUG|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
214549173|NCT02432664|DRUG|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
214549174|NCT02432664|DRUG|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
214549175|NCT05838963|DIAGNOSTIC_TEST|CTQ-SSS scores|"The CTQ-SSS is a self-reported questionnaire that measures the severity of symptoms related to carpal tunnel syndrome, including pain, numbness, tingling, and weakness in the hand and wrist.~Participants in this study will complete the CTQ-SSS and other functional measures that include:~1. demographic information~2. hand dominance~3. Boston Carpal Tunnel Questionnaire (BCTQ)~4. nerve conduction studies (NCS) to measure median nerve conduction velocity (NCV), distal motor latency (DML), and sensory nerve action potential (SNAP) amplitude, Compound muscle action potential (CMAP) amplitude.~5. Hand grip strength~Outcomes will be measured at baseline, 3 months, 6 months, and 12 months.~The primary outcome will be progression to carpal tunnel release surgery, and logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for this outcome, adjusted for potential confounding factors such as age, sex, and baseline symptom severity."
214549176|NCT01973153|BEHAVIORAL|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
214549177|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
214549178|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
214549179|NCT03880253|DRUG|CTP-692|Placebo or CTP-692
214549180|NCT01060397|BEHAVIORAL|Extended Brief Intervention|Frames motivational interviewing approach
214549181|NCT01060397|BEHAVIORAL|Control|Usual care
214549182|NCT02790697|OTHER|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
214549183|NCT00919451|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
214549184|NCT02539849|DIETARY_SUPPLEMENT|FOS|
214549185|NCT02539849|DRUG|Adalimumab|
214549186|NCT00129935|DRUG|Docetaxel|
214549187|NCT00129935|DRUG|Capecitabine|
214549188|NCT00129935|DRUG|Epirubicin|
214549189|NCT00129935|DRUG|Cyclophosphamide|
214549190|NCT04055428|DRUG|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
214549191|NCT04055428|DRUG|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
214549192|NCT04055428|OTHER|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
214549193|NCT04055428|DIETARY_SUPPLEMENT|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
214549194|NCT04055428|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
214549195|NCT01820520|DRUG|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
214549196|NCT02047162|DRUG|Bismuth subsalicylate|
214549197|NCT02047162|OTHER|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
214549198|NCT02783573|DRUG|Lanabecestat|Administered orally
214549199|NCT02783573|DRUG|Placebo|Administered orally
215161103|NCT02446262|BEHAVIORAL|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
215161104|NCT02446262|BEHAVIORAL|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
214549200|NCT01896765|BEHAVIORAL|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
214549201|NCT01896765|OTHER|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
214549202|NCT05656755|OTHER|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
214549203|NCT05656755|OTHER|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
214549204|NCT03514615|PROCEDURE|Incision|A skin incision will be made on the medial aspect of the upper arm.
214549205|NCT03514615|DRUG|Active gel|The incision site on one arm will be dosed with the active gel.
214549206|NCT03514615|DRUG|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
214549207|NCT03112915|PROCEDURE|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
214549208|NCT03112915|PROCEDURE|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
214549209|NCT05157945|DRUG|ALTO-300 PO Tablet|One tablet daily
214549210|NCT02517177|OTHER|Parabolic flight|
214549211|NCT02517177|OTHER|Cardiovascular parameters measurements|
214549212|NCT00233662|DRUG|Alefacept|
214549213|NCT02503826|DRUG|Sufentanil|low dose
214549214|NCT02503826|DRUG|Sufentanil|moderate dose
214549215|NCT02503826|DRUG|Sufentanil|high dose
214549216|NCT02503826|DRUG|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
214549217|NCT02503826|DRUG|propofol|
214549218|NCT02503826|DRUG|cisatracurium|
214549219|NCT02760563|DRUG|BAY 987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
214549220|NCT01378806|BEHAVIORAL|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
214549221|NCT04204382|DRUG|Levofloxacin Injection|Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
214549222|NCT04204382|DRUG|Compound Kushen Injection（CKI）|CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
214549223|NCT00159263|DRUG|Placebos|Dry powder inhaler
214549224|NCT00159263|DRUG|Formoterol Inhalant Powder|12ug
214549225|NCT00159263|DRUG|Budesonide Powder|Inhaler
214549226|NCT00159263|DRUG|Budesonide and Formoterol Product|Combination Inhaler, Symbicort
214549227|NCT04834713|OTHER|clinical classification of HFRS|Based upon clinical classification of HFRS , the patients were classified into four types
214549228|NCT01375413|BEHAVIORAL|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
214549229|NCT02858453|DRUG|AQX-1125 100 mg|Synthetic SHIP1 activator
214549230|NCT02858453|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
214549231|NCT02858453|DRUG|Placebo|Appearance and weight matched placebo tablets
214549232|NCT04349007|DIETARY_SUPPLEMENT|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
214549233|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
214549234|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use plus Milk|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
214549235|NCT02989090|OTHER|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
214549236|NCT02989090|OTHER|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
214549237|NCT04519593|PROCEDURE|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
214549238|NCT04519593|PROCEDURE|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
214549239|NCT01964846|DIETARY_SUPPLEMENT|Resveratrol, curcumin|
214549240|NCT01964846|DIETARY_SUPPLEMENT|Placebo|
214549241|NCT00372736|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
214549242|NCT00372736|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
214549243|NCT00372736|GENETIC|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs \> 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs \> 5 x ULN1
214549244|NCT00372736|GENETIC|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
214549245|NCT00372736|OTHER|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
214549246|NCT00372736|OTHER|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
214549247|NCT00372736|OTHER|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
214549248|NCT00372736|OTHER|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
214549249|NCT01012245|OTHER|no intervention|
214549250|NCT06814197|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy for Procrastination|This intervention incorporates Motivational Interviewing (e.g., open-ended questions, affirmations, reflective listening, summarising) and Cognitive Behavioural Therapy (e.g., cognitive restructuring) techniques in natural conversations instead of having a fully manualised programme. This approach resembles coaching instead of traditional therapy to build therapeutic relationships naturally and keep clients engaged with genuine human connection.
214549251|NCT00174694|DRUG|Telithromycin|
214549252|NCT04429282|DRUG|ibuprofen|Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
214549253|NCT04429282|DRUG|Placebo|Placebo
214549254|NCT00158067|DEVICE|external Responsive Neurostimulator (eRNS) System|
214549255|NCT02797522|DRUG|ARC-521 Injection|
214549256|NCT02797522|OTHER|Placebo|0.9% normal saline
214549257|NCT02797522|DRUG|antihistamine|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
215161105|NCT02446262|BEHAVIORAL|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
214549258|NCT02797522|DRUG|acetaminophen|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
214549259|NCT02797522|DRUG|entecavir|Participants take entecavir OR tenofovir daily throughout the study.
214549260|NCT02797522|DRUG|tenofovir|Participants take entecavir OR tenofovir daily throughout the study.
214549261|NCT00004940|DRUG|cysteine hydrochloride|
214549262|NCT06541769|DEVICE|Limb hypothermia|Limb hypothermia with special gel-gloves
214549263|NCT06541769|DEVICE|Limb compression|compression with sterile one way Latex gloves. Size measured for every Patient individually
214549264|NCT00725712|DRUG|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
214549265|NCT04398329|DRUG|HTX-034|HTX-034, low dose
214549266|NCT04398329|DRUG|HTX-034|HTX-034, high dose
214549267|NCT04398329|DEVICE|Luer lock applicator|Applicator for instillation
214549268|NCT04398329|DRUG|Bupivacaine HCl|Bupivacaine HCl, 50 mg
214549269|NCT03020069|DEVICE|CGMS Device|
214549270|NCT03020069|OTHER|No Device|
214549271|NCT05799469|DRUG|Envafolimab|SC
214549272|NCT05799469|DRUG|Cisplatin|IV infusion
214700063|NCT03089216|PROCEDURE|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
214700064|NCT03089216|PROCEDURE|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
214700065|NCT03089216|PROCEDURE|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
214700066|NCT03089216|DRUG|8% arginine and calcium carbonate|using during all the treatment.
214700067|NCT05942157|OTHER|Therapeutic Drug Monitoring (TDM)|Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
214700068|NCT01985009|DEVICE|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
214700069|NCT06254027|DEVICE|Forte|One application per day for a complete treatment period.
214700070|NCT06254027|DEVICE|Active Cover Light|One application per day for a complete treatment period.
214549273|NCT05799469|RADIATION|External Beam Radiotherapy (EBRT)|45-50.4Gy
214549274|NCT05799469|RADIATION|Brachytherapy (BT)|Performed according to clinically required dose
214700071|NCT06254027|DRUG|Loceryl|One application per week for a complete treatment period.
214700072|NCT00001165|DRUG|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
214700073|NCT02263482|OTHER|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
215161106|NCT01581580|DEVICE|Medtronic Activa Tremor Control System|Medtronic DBS Therapy delivers electrical stimulation to an area in the brain to help treat Parkinson's Disease, dystonia, and essential tremor.
214549275|NCT02655289|DEVICE|Modulated TENS|"* Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
214549276|NCT02655289|DEVICE|Placebo TENS|"* Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
214549277|NCT01605682|DIETARY_SUPPLEMENT|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
214549278|NCT01475305|DRUG|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
214549279|NCT01475305|DRUG|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
214549280|NCT04826276|OTHER|smoking abstinence|participants will be asked to not smoke for at least 12 hours
214549281|NCT04826276|OTHER|smoking satiety|participants will be asked to smoke as usual
214549282|NCT01142167|PROCEDURE|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
214549283|NCT01142167|PROCEDURE|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
214549284|NCT04239131|OTHER|Skin prick test|a Skin prick test is planned in all patients
214549285|NCT02509949|DRUG|Dexmedetomidine|
214549286|NCT02509949|DRUG|Saline|
214700074|NCT02263482|OTHER|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
214700075|NCT02263482|OTHER|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
214549287|NCT01561482|DRUG|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
214549288|NCT01561482|DRUG|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
214549289|NCT01872481|DEVICE|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
214549290|NCT01872481|DEVICE|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
214549291|NCT00757224|BEHAVIORAL|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
214549292|NCT02960503|DRUG|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
214549293|NCT02960503|OTHER|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
214549294|NCT00132678|DRUG|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
214549295|NCT00132678|DRUG|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
214549296|NCT03815370|DEVICE|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
214549297|NCT03815370|DEVICE|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
214549298|NCT01758679|BIOLOGICAL|Licartin and CIK|Licartin and CIK
214549299|NCT05711277|DIETARY_SUPPLEMENT|Standard milkshake ONS (Fortisip Compact Protein)|Two 125ml bottles of standard ONS administered a day for two days
214549300|NCT05711277|DIETARY_SUPPLEMENT|High protein, fortified, ice cream|Two 80g servings of N-ICE CREAM administered a day for two days
214549301|NCT00953147|DRUG|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
214549302|NCT00953147|DRUG|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
214549303|NCT00953147|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
214549304|NCT01367847|BEHAVIORAL|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon \& Forehand) for parents of 3 to 8 y.o. children with externalizing problems
214549305|NCT01367847|BEHAVIORAL|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
214549306|NCT06277505|COMBINATION_PRODUCT|Take prebiotics and probiotics|Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
214549307|NCT06277505|BEHAVIORAL|lifestyle guidance|lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
214549308|NCT03215147|DIAGNOSTIC_TEST|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6\~8 weeks later.
215029531|NCT04427670|OTHER|Group intervention|Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.
214549309|NCT03428308|OTHER|Screening|Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
214549310|NCT03428308|OTHER|Treatment|Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
214549311|NCT04511624|DRUG|IBI112 dose1|Drug: IBI112 SC dose1 Drug:placebo
214549312|NCT04511624|DRUG|IBI112 dose2|Drug: IBI112 SC dose2 Drug:placebo
214549313|NCT04511624|DRUG|IBI112 dose3|Drug: IBI112 SC dose3 Drug:placebo
214549314|NCT04511624|DRUG|IBI112 dose4|Drug: IBI112 SC dose4 Drug:placebo
214549315|NCT04511624|DRUG|IBI112 dose5|Drug: IBI112 IV dose5 Drug:placebo
214700076|NCT00991380|BEHAVIORAL|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
214700077|NCT00991380|BEHAVIORAL|Usual Care|Control
214700078|NCT01003080|DEVICE|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
214700079|NCT01003080|OTHER|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
214700080|NCT00007904|BIOLOGICAL|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.
214700081|NCT00007904|DRUG|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
214700082|NCT00007904|DRUG|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
214700083|NCT00007904|DRUG|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
214700084|NCT00007904|DRUG|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
215161107|NCT01581580|PROCEDURE|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
214549316|NCT04511624|DRUG|IBI112 dose6|Drug: IBI112 SC dose6 Drug:placebo
214549317|NCT04511624|DRUG|IBI112 dose7|Drug: IBI112 IV dose7 Drug:placebo
214549318|NCT06957314|OTHER|Hospital-at-Home/HAH|After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence
214549319|NCT04665609|DRUG|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
214549320|NCT04665609|DRUG|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
214549321|NCT04432792|OTHER|Questionnaire|Study survey participants will be administered 3 online surveys.
214549322|NCT01949636|OTHER|Functional Magnetic Resonance Imaging|
214549323|NCT02781805|DRUG|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
214549324|NCT01613690|DRUG|NVA237|NVA237 is administered via a BREEZHALER device
214549325|NCT05205070|BIOLOGICAL|Rosnilimab|humanized monoclonal antibody
214549326|NCT05205070|BIOLOGICAL|Placebo|Placebo solution
214549327|NCT01949181|PROCEDURE|Lung surgery|
214549328|NCT03148522|DRUG|Escitalopram|receive escitalopram
214549329|NCT03148522|DRUG|Duloxetine|receive duloxetine
214549330|NCT03148522|DRUG|Mirtazapine|receive mirtazapine
214549331|NCT05665569|DEVICE|Flourish HEC, which contains BioNourish|The Flourish HEC vaginal hygiene system comprises Balance intimate wash used daily, BioNourish vaginal moisturizing gel used daily, and BiopHresh homeopathic vaginal suppository containing probiotics, used once every 3 days. In addition, for all therapy requiring insertion in the clinic or at home, or for sex if desired, BioNude personal lubricant will be used. These four products are intended to allow the vaginal microbiome to self-correct by supporting the vaginal environment in terms of providing pH, osmolality, and lactic acid levels that match those in a healthy vagina.
214549332|NCT05665569|OTHER|Routine pelvic physical therapy|Routine pelvic physical therapy may include external and internal manual techniques, exercises, diaphragmatic breathing exercises, and other modalities.
214549333|NCT02276105|OTHER|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
214549334|NCT02856516|OTHER|Boost Glucose Control (A)|Oral nutrition supplement
214549335|NCT02856516|OTHER|Boost Glucose Control (B)|Oral nutrition supplement
214549336|NCT02856516|OTHER|Boost Original|Oral nutrition supplement
214549337|NCT00487955|PROCEDURE|Resting Energy Expenditure examination|
214549338|NCT03289559|DRUG|GnRH antagonist|
214549339|NCT03289559|DRUG|Aromatase Inhibitors|
214549340|NCT03289559|DRUG|Testosterone gel|
214549341|NCT05308394|OTHER|No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.|Each participant will provide a blood and fecal sample.
214549342|NCT02056626|DRUG|carvedilol|
214549343|NCT02834767|DEVICE|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
214549344|NCT02834767|DEVICE|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
214549345|NCT02622555|DRUG|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
214549346|NCT00863512|DRUG|cisplatin|Given IV
214549347|NCT00863512|DRUG|docetaxel|Given IV
214549348|NCT00863512|DRUG|gemcitabine hydrochloride|Given IV
214700085|NCT00007904|PROCEDURE|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
214700086|NCT00007904|RADIATION|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
214700087|NCT04915924|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
214549349|NCT00863512|DRUG|pemetrexed disodium|Given IV
214549350|NCT00863512|DRUG|vinorelbine tartrate|Given IV
214549351|NCT00863512|PROCEDURE|standard follow-up care|Standard care
214549352|NCT02259660|DEVICE|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
214549353|NCT02259660|DEVICE|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
214549354|NCT05153928|DRUG|Norethisterone acetate|Norethisterone acetate for 5 months
214549355|NCT03527797|OTHER|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
214549356|NCT00000877|DRUG|Indinavir sulfate|
214549357|NCT00000877|DRUG|Rifabutin|
214549358|NCT02015507|DRUG|ivacaftor|
214549359|NCT02015507|DRUG|VX-661|
214549360|NCT02015507|DRUG|ciprofloxacin|
214549361|NCT00078338|DRUG|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
214549362|NCT00078338|DRUG|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
214549363|NCT00642525|PROCEDURE|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
214549364|NCT04047277|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
214549365|NCT00640770|DEVICE|balloon angioplasty|balloon angioplasty
214549366|NCT00640770|DEVICE|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
214549367|NCT02037477|DRUG|Vonoprazan|Vonoprazan tablets
214549368|NCT02037477|DRUG|Esomeprazole|Esomeprazole capsules
214549369|NCT02037477|DRUG|Rabeprazole sodium|Rabeprazole sodium tablets
214549370|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Wonderlab Product|Chew two tablets of Wonderlab Product for phase 1 (day 1)
214549371|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Placebo|Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
214549372|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Placebo|Chew two tablets of placebo for phase 1 (day 1)
214549373|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Wonderlab Product|Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
214549374|NCT00756041|DRUG|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
214549375|NCT00005977|BIOLOGICAL|filgrastim|Given IV
214549376|NCT00005977|DRUG|cyclophosphamide|Given IV
214549377|NCT00005977|DRUG|cytarabine|Given IV
214549378|NCT00005977|DRUG|dexamethasone|Given IV
214549379|NCT00005977|DRUG|doxorubicin hydrochloride|Given IV
214549380|NCT00005977|DRUG|etoposide|Given IV
214549381|NCT00005977|DRUG|ifosfamide|Given IV
214549382|NCT00005977|DRUG|leucovorin calcium|Given IV
214549383|NCT00005977|DRUG|methotrexate|Given IV
214549384|NCT00005977|DRUG|vincristine sulfate|Given IV
214549385|NCT02292862|PROCEDURE|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant."
214549386|NCT00218231|DRUG|300 mg/day bupropion-sr|300 mg/day for 1 week
214549387|NCT00218231|DRUG|0 mg/day bupropion-sr|0 mg/day bupropion-sr
214549388|NCT00633269|DRUG|AZD2281|100mg Oral Dose
214549389|NCT05026021|BIOLOGICAL|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion), M6 visit (6 months after inclusion) and M12 visit (12 months after inclusion).
214700088|NCT04286542|DIAGNOSTIC_TEST|Cold, dry air|Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
214700089|NCT03497026|DEVICE|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
214700090|NCT01968954|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
214700091|NCT01968954|OTHER|Placebo|subcutaneous injection, every 2 weeks for 12 months
214700092|NCT00434122|DRUG|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
214700093|NCT00434122|DRUG|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
214700094|NCT04474119|DRUG|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
214549390|NCT01211301|BEHAVIORAL|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
214549391|NCT01211301|OTHER|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 \& 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean \& Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are \>70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 \& 1 Plan. The Medifast 5 \& 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean \& Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 \& 1 Plan.
214549392|NCT04264377|PROCEDURE|Bronchoscopy|Bronchoscopy for retrieval of airway cells
214549393|NCT02511444|OTHER|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
214549394|NCT04110925|GENETIC|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
214549395|NCT04110925|OTHER|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
214549396|NCT04110925|OTHER|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease \[ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents\], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
214549397|NCT02961257|DRUG|cabazitaxel|"* Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used"
214549398|NCT02961257|DRUG|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
214549399|NCT02961257|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
214549400|NCT00463905|PROCEDURE|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
214549401|NCT01632826|DRUG|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
214549402|NCT02165553|DIETARY_SUPPLEMENT|Hibiscus sabdariffa calyces extract as a cold drink|
214549403|NCT03366532|OTHER|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
214549404|NCT02963675|OTHER||external unexposed reference group
214549405|NCT03743779|BEHAVIORAL|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q\&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
214549406|NCT04360720|DRUG|Antiplatelet Monotherapy|"All subjects randomized to the Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to the Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12."
214549407|NCT01673022|DRUG|IC Green|IC Green
214549408|NCT01955187|DRUG|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
214549409|NCT01955187|DRUG|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
214549410|NCT01955187|DRUG|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
214549411|NCT01955187|DRUG|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
214549412|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab Prefilled Syringe|Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
214549413|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab AI|AI for SC injection self-administration of rocatinlimab.
214549414|NCT04843410|OTHER|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
214700095|NCT04474119|DRUG|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
214700096|NCT00881855|DRUG|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
214700097|NCT00881855|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
214700098|NCT01288508|DIETARY_SUPPLEMENT|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
214549415|NCT04843410|OTHER|The routine care|Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
214549416|NCT02778672|OTHER|Thermal imaging of infant's chest with a mobile phone|
214700099|NCT01288508|DIETARY_SUPPLEMENT|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
215161108|NCT05473429|DEVICE|TSA2 Thermosensory Stimulator|TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
214549417|NCT05267795|BEHAVIORAL|Experimentally-induced pain|Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
214549418|NCT02552017|DEVICE|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
214549419|NCT05439330|DEVICE|MRI of teeth and surrounding structures|included above
214549420|NCT02975063|BEHAVIORAL|A&T IYCF intervention|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
214549421|NCT05603364|COMBINATION_PRODUCT|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
214549422|NCT05603364|OTHER|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
214549423|NCT03587766|DRUG|Fexinidazole|Drug: fexinidazole (FEXI)
214549424|NCT03587766|DRUG|Placebo Oral Tablet|Drug: fexinidazole
214549425|NCT01454739|DRUG|rFVIIIFc|Administered as specified in the treatment arm.
214549426|NCT03564197|OTHER|18F-PD-L1|18F-PD-L1 PET/CT scan
214549427|NCT06242769|DRUG|Stannous Fluoride Toothpaste (SnF)|test
214549428|NCT06242769|DRUG|Colgate Fluoride Toothpaste (CDC)|negative control
214549429|NCT02015988|DRUG|Fenofibrate|
214549430|NCT02015988|DRUG|Simvastatin|
214549431|NCT01784523|DRUG|Hydroxychloroquine|
214549432|NCT03908567|DRUG|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
214549433|NCT03908567|DRUG|Oral Tablet|Oral dosing with tablets 3 times a day
214549434|NCT03908567|OTHER|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
214549435|NCT00326053|DRUG|Budesonide/formoterol|
214549436|NCT04621253|DRUG|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
214549437|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
214549438|NCT05146206|OTHER|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
214549439|NCT04964245|DEVICE|accelometer|the respiration parameters are measured using an accelometer.
214549440|NCT04964245|DEVICE|thermographic camera|the respiration parameters are measured using an thermographic camera.
214549441|NCT04964245|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
214549442|NCT04964245|DEVICE|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
214549443|NCT04344210|BEHAVIORAL|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
214549444|NCT06407609|DIETARY_SUPPLEMENT|Curcuma and boswellia extracts plus low fodmap diet|Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability
214549445|NCT06407609|OTHER|Low Foodmap diet|such as lactose or gluten free diet in the last 6 months
214549446|NCT04482153|DEVICE|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
214549447|NCT04484389|OTHER|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
214549448|NCT04484389|OTHER|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
214549449|NCT06489275|BEHAVIORAL|Building Financial Wellness|In addition to receiving services as usual, subjects attend financial literacy classes and booster sessions.
214549450|NCT06489275|OTHER|Services as Usual|Subjects continue to receive services as usual.
214549451|NCT02039648|OTHER|Rumex acetosa L. extract|
214549452|NCT02039648|OTHER|Placebo|
214549453|NCT02577003|DRUG|Ipragliflozin|50 mg tablet administered orally
214549454|NCT02577003|DRUG|Placebo|Placebo to ipragliflozin tablet administered orally
214549455|NCT02577003|DRUG|Sitagliptin|Background medication; 50 mg tablet administered orally
214700100|NCT06359743|PROCEDURE|Quadratus Lamborum versus superior hypogatric|Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
214549456|NCT02786004|DEVICE|Full Field Digital Mammography|
214700101|NCT06600178|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10mg oral
214549457|NCT02786004|DEVICE|Digital Breast Tomosynthesis|
214700102|NCT06600178|DRUG|Placebo|Placebo tablet given to subject vs. active drug.
214700103|NCT00497016|DRUG|atorvastatin 80 mg|
214700104|NCT02675153|DRUG|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
214700105|NCT04191577|DRUG|CVN424 Low Dose|CVN424
214700106|NCT04191577|DRUG|CVN424 High Dose|CVN424
215161109|NCT05509582|DRUG|fostamatinib|Subjects will receive fostamatinib at the same dose as the dose they receive at the time of rollover. The dose could be reduced to 100mg daily, 150 mg daily, 100 mg twice a day if a dose-limiting adverse event occurred. After the initial 12 weeks on the extended access (total of 24 weeks of treatment), subjects will have the option to start tapering fostamatinib if they are maintaining hematologic recovery. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response, defined as Hb\<9g/dL and/or PLT\< 30 X 10\^9/L can increase their dose to next higher dose. Once count stabilization again occurs, a slow dose reduction to next lowest dose (100mg or 150mg) can be performed to identify the lowest dose necessary to keep counts over these thresholds.
215161110|NCT04752592|DIAGNOSTIC_TEST|SeroSelectTB rapid TB test|The SeroSelectTB test is a rapid blood-based immunochemical lateral flow assay for the detection of active tuberculosis.
214549458|NCT01833689|DIETARY_SUPPLEMENT|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
214549459|NCT02185898|OTHER|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
214549460|NCT02185898|OTHER|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
215161111|NCT05889182|DRUG|Upadacitinib|Oral Tablets
215161112|NCT05889182|DRUG|Placebo|Oral Tablets
214549461|NCT02185898|OTHER|Electronic cigarette #1|Electronic cigarette
214549462|NCT02185898|OTHER|Electronic cigarette #2|Electronic cigarette
214549463|NCT02185898|OTHER|Electronic cigarette #3|Electronic cigarette
214549464|NCT02185898|OTHER|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
214549465|NCT03258736|PROCEDURE|inguinal hernia surgery|repair of inguinal hernia
214549466|NCT01502046|DRUG|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
214549467|NCT01502046|DRUG|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
214549468|NCT05671354|DEVICE|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
214549469|NCT02835027|PROCEDURE|Open versus endovascular surgery|Treatment for acute ischemia
214549470|NCT05878912|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
214700107|NCT04191577|DRUG|Placebo|Placebo
214700108|NCT03655717|DRUG|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
214700109|NCT03655717|DRUG|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
214700110|NCT03655717|DRUG|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
214700111|NCT03655717|DRUG|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
214700112|NCT01185249|PROCEDURE|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
214700113|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
214700114|NCT00634959|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
214700115|NCT00634959|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
214700116|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
214700117|NCT00634959|OTHER|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
214700118|NCT02470052|DEVICE|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
214700119|NCT05518175|DEVICE|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
214700120|NCT05518175|DEVICE|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
214700121|NCT05518175|DEVICE|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
214700122|NCT04363437|DRUG|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
215161113|NCT01961557|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
215161114|NCT06609239|DRUG|Lunsekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
214700123|NCT04363437|DRUG|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
214549471|NCT04787237|OTHER|VST and immediate implants|One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
214700124|NCT01890070|DIETARY_SUPPLEMENT|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
214549472|NCT04787237|OTHER|Buser technique and early implants placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
214549473|NCT01677299|DRUG|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
214549474|NCT01677299|DRUG|EFB0026 (metformin immediate-release)|Active comparator
214549475|NCT01517997|PROCEDURE|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
214549476|NCT01517997|PROCEDURE|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
214549477|NCT04860440|DEVICE|GeneActiv wrist worn accelerometer|Wrist worn device worn for 7 days
214549478|NCT03723577|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
214549479|NCT03931993|BIOLOGICAL|Placebo comparator|
214549480|NCT03931993|BIOLOGICAL|Grass MATA MPL|
214549481|NCT03835962|DEVICE|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
214549482|NCT00737828|OTHER|Perioperative care pathway guided by CPX results|"* AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
214549483|NCT02813902|DRUG|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
214549484|NCT02813902|OTHER|Sugar Pill|A pill that appears similar to the supplement
214549485|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
214549486|NCT00676845|DRUG|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
214549487|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
214549488|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
214549489|NCT06486337|DRUG|CMOP±R|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
214700125|NCT01890070|DIETARY_SUPPLEMENT|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
214700126|NCT01890070|DIETARY_SUPPLEMENT|Red wine|Italian Organic Red Wine
215161115|NCT05108428|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
215161116|NCT05108428|RADIATION|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
215161117|NCT05108428|DRUG|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
214700127|NCT01890070|DIETARY_SUPPLEMENT|Olive Oil|Italian Organic Olive Oil
214700128|NCT01890070|DIETARY_SUPPLEMENT|Wild mixed greens|Italian organic wild mixed greens
214700129|NCT01890070|DIETARY_SUPPLEMENT|Chestnut|Italian Organic Chestnut
214700130|NCT01890070|OTHER|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
214700131|NCT01290120|DRUG|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
215161118|NCT06269640|DEVICE|Septal Scoring Along Midline Endocardium|Transcatheter ventricular myotomy called SEptal Scoring Along the Midline Endocardium (SESAME) that relies on intramyocardial guidewire navigation and transcatheter electrosurgery
214549490|NCT00787072|DRUG|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
214549491|NCT00787072|DRUG|Placebo|Oral suspension
215161119|NCT05668949|DRUG|TTI-101|Given by PO
215161120|NCT05668949|DRUG|Pembrolizumab|Given by IV (vein)
214549492|NCT04312256|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
214549493|NCT00559377|OTHER|18F-fluoromisonidazole|Undergo \^18F FMISO PET scan
214549494|NCT00559377|RADIATION|fluorodeoxyglucose F 18|Undergo \^18F FDG PET scan
214549495|NCT00559377|PROCEDURE|positron emission tomography|Undergo \^18F-FMISO and \^18F FDG PET scan
214549496|NCT00559377|OTHER|tissue oxygen measurement|Undergo \^18 F FMISO PET and \^18F FDG PET
214549497|NCT00940875|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
214549498|NCT00940875|DRUG|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
214549499|NCT00940875|DRUG|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
214549500|NCT04976647|DRUG|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
214700132|NCT04682834|DRUG|Sulopenem Etzadroxil/Probenecid|Individual Patients
214700133|NCT01388582|DEVICE|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
214700134|NCT01388582|DEVICE|Implanon|60 mcg/day contraceptive implant
214700135|NCT01388582|DRUG|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
215161121|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.
215161122|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505
215161123|NCT05987241|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
215161124|NCT05987241|OTHER|cfDNA or ctDNA Measurement|Undergo ctDNA surveillance
214549501|NCT04976647|DRUG|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
214549502|NCT04976647|DRUG|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
214549503|NCT00490945|DRUG|VEC-162|
214549504|NCT05857254|OTHER|Patient with chronic intestinal failure|"The negociation component will be assessed during an office visit with the help of forms, by the difference between  ideal  parenteral nutrition prescription proposed by prescriber and the  final  prescription, that the patient ultimately receives at the end of the office visit.~The compliance component will be assessed by a telephone interview, 8 weeks after the office visit."
214549505|NCT04329572|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
214549506|NCT04329572|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
214549507|NCT04266353|DIETARY_SUPPLEMENT|Resveratrol (RSV)|Participants will receive Resveratrol at 150 mg daily for 6 weeks.
214549508|NCT03334253|DRUG|Atropine|Daily 0.01% atropine eyedrops
214549509|NCT03334253|OTHER|Placebo Eyedrops|Daily placebo eyedrops
214549510|NCT01882153|BEHAVIORAL|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, \& Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
214549511|NCT01882153|BEHAVIORAL|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
214549512|NCT01882153|BEHAVIORAL|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
214549513|NCT03263247|BEHAVIORAL|Memory Training|
214549514|NCT03263247|BEHAVIORAL|Psychoeducation|
214549515|NCT03263247|BEHAVIORAL|Alphabet search|
214700136|NCT01388582|DEVICE|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
214700137|NCT01388582|DEVICE|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
214700138|NCT06434103|DRUG|SHR-A1921；Adebrelimab；SHR-8068；carboplatin|SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
214700139|NCT00920595|DRUG|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
214700140|NCT05522712|DEVICE|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
214700141|NCT05522712|DEVICE|Incentive spirometer user|"1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets."
215161125|NCT05987241|PROCEDURE|Computed Tomography|Undergo CT
214700142|NCT05522712|PROCEDURE|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
214549516|NCT02324777|DRUG|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
215161126|NCT05987241|PROCEDURE|Cystoscopy|Undergo cystoscopy
215161127|NCT05987241|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161128|NCT05987241|BIOLOGICAL|Nivolumab|Given IV
215161129|NCT05987241|OTHER|Questionnaire Administration|Ancillary studies
215161130|NCT05987241|BIOLOGICAL|Relatlimab|Given IV
215161131|NCT05588141|DRUG|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
215161132|NCT02089217|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy
215161133|NCT02089217|DEVICE|Carotid Stenting (CAS)|Carotid stenting
215161134|NCT02089217|OTHER|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
215161135|NCT02089217|OTHER|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
215161136|NCT06422806|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161137|NCT06422806|PROCEDURE|Diagnostic Imaging Testing|Undergo standard imaging scans
215161138|NCT06422806|DRUG|Doxorubicin|Given IV
215161139|NCT06422806|PROCEDURE|Echocardiography Test|Undergo ECHO
215161140|NCT06422806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
215161141|NCT06422806|BIOLOGICAL|Pembrolizumab|Given IV
215161142|NCT06687616|DEVICE|SynerGI|Standardized 8-week CBT program, used for 20-30 minutes per week
215161143|NCT06687616|DEVICE|Sham VR|Distraction-based VR program with 2D nature videos to be used for 8 weeks, 2-2 times a week for 10 minutes
214549517|NCT02324777|DEVICE|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
215161144|NCT06832696|DEVICE|RUF-D|"We have developed a simplified fluid removal device (RUF-D) to address the challenges that patients face with being unable to remove the fluid they need with standard dialysis. Participants 01-09 will receive one week of baseline observation (three HD treatments) with two weeks of supervised intervention using RUF-D post HD on Mondays and Wednesdays for up to six hours (total three-week study).~Participants 10-18 will receive one week of baseline observation, two weeks of intervention (identical to cohort one above), with an additional week of intervention (total four weeks) where participants will be fitted with the RUF-D (ensuring functionality) before going home with the device in operation for up to six hours twice weekly."
214549518|NCT01359839|BEHAVIORAL|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
214549519|NCT00203047|DRUG|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
214549520|NCT00203047|DRUG|Placebo|Placebo for prednisone given daily
214549521|NCT00203047|DRUG|Prednisone|Prednisone 1250 mg taken daily
214549522|NCT01446146|BEHAVIORAL|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
215161145|NCT05510895|DRUG|Binimetinib|Triplet combination administered neoadjuvant and adjuvant, depending on TRG
214549523|NCT01446146|BEHAVIORAL|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
214549524|NCT01580904|BEHAVIORAL|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
214549525|NCT00872001|DRUG|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
214549526|NCT00872001|DRUG|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
214549527|NCT00340704|DRUG|tamsulosin hydrochloride|oral
214549528|NCT04197167|PROCEDURE|Hysteroscopy|Diagnostic procedure
215161146|NCT05998031|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
214549529|NCT04197167|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
214549530|NCT02214511|BEHAVIORAL|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
214549531|NCT02214511|BEHAVIORAL|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
214549532|NCT00890292|DRUG|JNJ-31001074|
214549533|NCT00980642|DEVICE|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
214549534|NCT00980642|DEVICE|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
214549535|NCT00980642|DEVICE|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
214549536|NCT05020145|BIOLOGICAL|BNT162b2 (Tozinameran)|Covid-19 Vaccine
214549537|NCT00220064|DRUG|Irinotecan, 5-Fluorouracil, Leucovorin|
214549538|NCT00167232|DRUG|Naltrexone|
214549539|NCT00376415|DRUG|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
214700143|NCT06692387|BEHAVIORAL|Step count increase with the use of a motivational application|The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
214700144|NCT01208038|DRUG|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
214700145|NCT06692478|BEHAVIORAL|Exercise regimen|"Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups."
214700146|NCT06693791|DRUG|Romiplostim N01|Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
214700147|NCT02300077|DRUG|methadone|Escalating dose of methadone up to .3mg/kg.
214700148|NCT02300077|DRUG|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
214700149|NCT05824637|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
214700150|NCT05824637|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
214700151|NCT05998954|PROCEDURE|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
214700152|NCT05998954|PROCEDURE|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
214700153|NCT06712511|OTHER|Caffeine content|Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.
214700154|NCT00486538|DRUG|ABT-869|One oral dose daily.
214700155|NCT04250740|OTHER|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
214700156|NCT04250740|OTHER|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
215161147|NCT05998031|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
214700157|NCT04250740|OTHER|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
215161148|NCT04424303|DRUG|Tofacitinib|Observational study
214549540|NCT00376415|DRUG|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
214549541|NCT03313141|DIAGNOSTIC_TEST|Ultrasound|Volitional and non volitional respiratory tasks
214549542|NCT00531726|DEVICE|DBS of Cg25|
214549543|NCT04970290|DEVICE|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
214549544|NCT00494468|DRUG|Zolpidem|
214549545|NCT03333161|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
214549546|NCT00564616|DEVICE|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
214700158|NCT05669534|BEHAVIORAL|community-friendly health recovery program|Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
214700159|NCT05669534|DRUG|Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis|Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
214700160|NCT06795399|DRUG|OPC-131461|OPC-131461 will be administered as oral tablets.
214700161|NCT06795399|DRUG|Placebo|OPC-131461 matched placebo will be administered as oral tablets.
214700162|NCT01966575|DRUG|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
214700163|NCT01743963|BEHAVIORAL|Decision support|Clinical pharmacists mediated computerized decision support
214700164|NCT01743963|BEHAVIORAL|Usual Care|clinicians typical apporach for GID monitering
214700165|NCT02170805|DRUG|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
214549547|NCT02239744|BEHAVIORAL|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
214549548|NCT03653923|BEHAVIORAL|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
214700166|NCT02170805|DRUG|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
214700167|NCT02170805|DRUG|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
214700168|NCT02170805|DRUG|Pantoprazole|Pantoprazole 40 mg
214549549|NCT03618004|OTHER|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
214549550|NCT03618004|OTHER|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
214549551|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
214549552|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
214549553|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
214549554|NCT05252832|PROCEDURE|Superficial Cervical Plexus Block|Location of injection for block.
214549555|NCT05252832|PROCEDURE|Local Infiltrate|Local infiltration location.
214549556|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
214700169|NCT06898086|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation using the CE-certified Myval™ transcatheter heart valve series
214700170|NCT06897995|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participants in the exercise groups were trained five times a week for six weeks. The regimen began with a 5-min warm-up and ended with a 5-min cool-down, both at 40% of heart rate reserved (HRR). The circuit training participants were trained for three bouts of 10-min moderate-intensity exercise (60% of HRR) with 1-min rest intervals at a stationary ergometer, a rowing machine, and an elliptical trainer, respectively. The cycling training group was trained on an ergometer for three bouts of 10-min cycling on a stationary ergometer.
214700171|NCT06898164|OTHER|This study does not involve any interventions|This study does not involve any interventions
214700172|NCT06346028|DEVICE|Brainsway H4 deep rTMS coil and Brainsway stimulator system|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC."
215029532|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
215029533|NCT06487936|DEVICE|TransLoc 3D SI Joint Fusion System|Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
214549557|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
214549558|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic RFA assisted TE|
214700173|NCT06899334|DRUG|LSD|A moderate to high oral dose of 150 µg LSD will be administered followed by 20 mg intravenous ketanserin after 3 h
214700174|NCT06899334|DRUG|Psilocybin|A moderate to high oral dose of 30 mg psilocybin will be administered followed by 20 mg intravenous ketanserin after 3 h
214700175|NCT06899334|DRUG|DMT|A moderate to high, dose-escalating, intravenous infusion up to 2 mg/min DMT will be administered followed by 20 mg intravenous ketanserin after 3 h
214700176|NCT06899334|DRUG|Placebo|An oral and an intravenous placebo will be administered followed by 20 mg intravenous ketanserin after 3 h
214700177|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
214700178|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
214700179|NCT06381414|BEHAVIORAL|Observation|"Identify the prevalence of early wear in primary dentition, using Childhood Early Oral Aging Syndrome (CEOAS) index.~The CEOAS index involves scores of 0 to 3 for the assessment of tooth wear and dental management, whereas scores of I, II and III are used concomitantly in cases of the presence of enamel defects."
214700180|NCT01196169|DRUG|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
214700181|NCT01196169|DRUG|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
214700182|NCT03637842|DRUG|Lorcaserin|Lorcaserin XR 20mg per day
214700183|NCT03637842|DRUG|Placebo oral capsule|Placebo
214549559|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic partial nephrectomy|
214700184|NCT00002058|DRUG|Clofazimine|
214700185|NCT04691063|DRUG|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
214700186|NCT04691063|DRUG|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
214700187|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
214700188|NCT04054349|OTHER|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
214700189|NCT02814357|OTHER|Control (market standard)|
214700190|NCT02814357|OTHER|wheat flour|
214700191|NCT02814357|OTHER|chickpea flour|
214700192|NCT02814357|OTHER|guar gum|
214700193|NCT02814357|OTHER|barley|
214549560|NCT04653428|DEVICE|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
214549561|NCT03922789|DIAGNOSTIC_TEST|6 minute walking test|change of 6MWT pre to post pulmonary rehabilitation
214549562|NCT06509360|DEVICE|Feelee app|Adolescents uses the Feelee app for 4-weeks in addition to treatment as usual in the forensic outpatient setting. The use of Feelee involves: submitting one emoji every day and allow the Feelee app to read the following passive data from the health app on the smartphone: number of steps and number of hours of sleep. The collected Feelee data will be presented in a dashboard in the Feelee app itself which will be discussed by the clinician in the weekly treatment session (in case the adolescents agreed to show the Feelee data to the clinician).
214549563|NCT06007196|DEVICE|non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)|Intraoperative cardiac output will be measured using the non-invasive device (Task Force CORE(R) and Task Force CARDIO(R) and will be compared with the invasive thermodilution method (PiCCO).
214700194|NCT02860533|DEVICE|cuff device|Measurement of blood pressure during stress testing with cuff device
214700195|NCT02860533|DEVICE|iphone|Measurement of blood pressure during stress testing with iPhone
214700196|NCT00259220|DRUG|erythomycin|erythomycin
214700197|NCT00259220|PROCEDURE|gastric lavage alone|gastric lavage alone
214700198|NCT00259220|PROCEDURE|erythromycine and gastric lavage|erythromycine and gastric lavage
214700199|NCT03003403|BEHAVIORAL|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
214700200|NCT00847938|DRUG|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
214700201|NCT00847938|DRUG|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
214549564|NCT02844452|DEVICE|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
214700202|NCT00847938|DRUG|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
214700203|NCT00795353|DRUG|Amevive exposure|Commercial alefacept prescribed by Physician
214700204|NCT02595047|PROCEDURE|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
214700205|NCT04231955|DIAGNOSTIC_TEST|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
214700206|NCT04231955|OTHER|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
214700207|NCT04231955|OTHER|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
214700208|NCT04231955|OTHER|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
214700209|NCT04718584|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
214700210|NCT00587444|DRUG|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
214700211|NCT00587444|DRUG|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
215029534|NCT02697448|DRUG|propofol|Participant receives propofol as anesthetic for cardiac ablation.
215029535|NCT02697448|DRUG|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
215029536|NCT05473715|DRUG|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
215029537|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Active Treatment questionnaire|Electronic questionnaire to be administered to patients in active treatment.
215029538|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Survivors questionnaire|Electronic questionnaire to be administered to cancer survivors.
214700212|NCT00587444|DRUG|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
214549565|NCT02844452|DEVICE|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
214549566|NCT05521711|OTHER|Food|Commercially available powders or liquids
214549567|NCT02792595|OTHER|Negative Control|Untreated area
214549568|NCT02792595|OTHER|Positive Control|High SPF Standard P3/SPF 15
214549569|NCT02792595|OTHER|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
214700213|NCT03525457|PROCEDURE|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
215161149|NCT06558552|OTHER|transcutaneous pulsed radiofrequency|Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.
214700214|NCT00000248|DRUG|Pergolide|
214700215|NCT01891760|DEVICE|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
214700216|NCT01891760|DEVICE|Profore|Four-layer compression bandaging therapy.
214700217|NCT02312076|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
214700218|NCT02494388|PROCEDURE|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
214700219|NCT06187623|OTHER|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
215161150|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)'|A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
214549570|NCT02792595|OTHER|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
214549571|NCT02792595|OTHER|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
214549572|NCT02792595|OTHER|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
214549573|NCT02792595|OTHER|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
215029539|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Palliative Care questionnaire|Electronic questionnaire to be administered to patients in palliative care.
215029540|NCT06511024|OTHER|Blood sample|Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
215029541|NCT02886962|BIOLOGICAL|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
215029542|NCT02886962|DRUG|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
215161151|NCT05712317|BEHAVIORAL|Exergame Intervention|8-week exergame-based intervention 3x per week
215161152|NCT05712317|BEHAVIORAL|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
214549574|NCT02792595|OTHER|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
214549575|NCT02792595|OTHER|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
214549576|NCT02792595|OTHER|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
214549577|NCT04955899|DEVICE|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
214549578|NCT06405412|OTHER|MUST malnutrition score|MUST malnutrition score
214549579|NCT03453047|DIAGNOSTIC_TEST|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
215161153|NCT03547947|DEVICE|Medacta Shoulder System|Total Shoulder Arthroplasty
214549580|NCT03453723|PROCEDURE|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
214549581|NCT03453723|DRUG|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
214549582|NCT04197076|DRUG|anti-PD-1 or anti-PD-L1|immunotherapy anti-PD-1 or anti-PD-L1
214549583|NCT04197076|DRUG|EGFR-TKI, ALK inhibitor, ROS1 inhibitor|targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
214700220|NCT06187623|OTHER|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
214700221|NCT05398393|DRUG|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
214700222|NCT05398393|DRUG|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
214700223|NCT05136378|DRUG|Low Dose Selenious Yeast Tablets|Low dose of Selenious Yeast Tablets
214700224|NCT05136378|DRUG|High Dose Selenious Yeast Tablets|High Dose Selenious Yeast Tablets
214700225|NCT03018912|OTHER|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?"
214700226|NCT03034759|OTHER|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
214700227|NCT04350190|DRUG|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
214700228|NCT04350190|DRUG|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
214700229|NCT00374855|DRUG|PPAR alpha|
214549584|NCT04197076|DRUG|investigator decided|chemotherapy
214549585|NCT01598077|DRUG|LJM716|
214549586|NCT05174598|DRUG|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
214549587|NCT05174598|DRUG|Calcipotriol Ointment 50 micrograms/g|Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
214549588|NCT05174598|OTHER|Placebo|Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
214549589|NCT01889576|DIETARY_SUPPLEMENT|Magnesium Oxide|
214549590|NCT00246090|DRUG|E7389|E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
214549591|NCT03867162|BIOLOGICAL|Live Attenuated Tularemia Vaccine|Subjects will be vaccinated with a bifurcated needle; approximately 0.06 mL of the reconstituted vaccine will be placed on the volar surface of the forearm and applied by multiple puncture.
214700230|NCT00374855|DRUG|Hydrochlorothiazide|
214700231|NCT00374855|DRUG|Placebo|
214700232|NCT05194046|DRUG|JP-1366 20mg 1capsule|will be orally administered
214700233|NCT05194046|DRUG|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
214700234|NCT05194046|DRUG|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
214700235|NCT03264794|DRUG|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
214700236|NCT03264794|DRUG|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
214700237|NCT03264794|DRUG|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
214700238|NCT02581358|OTHER|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
214700239|NCT01734096|OTHER|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
214700240|NCT01734096|DRUG|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
214700241|NCT03550287|DIETARY_SUPPLEMENT|Experimental product|10 g/day
214700242|NCT03550287|DIETARY_SUPPLEMENT|Placebo product|10 g/day
214700243|NCT03286712|DRUG|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
214700244|NCT03532581|OTHER|Indocyanine Green Solution|Given Subcutaneous injection
214700245|NCT03532581|PROCEDURE|Lymphangiography|Undergo lymphangiography
214700246|NCT00111579|BIOLOGICAL|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
214700247|NCT00111579|OTHER|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
214700248|NCT03082989|DEVICE|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
214700249|NCT03082989|OTHER|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
214700250|NCT03508661|OTHER|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
214700251|NCT01807260|PROCEDURE|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
214700252|NCT04520828|OTHER|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
214700253|NCT04124692|DEVICE|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
214700254|NCT03427541|PROCEDURE|Surgeries|Surgeries
214700255|NCT00050999|DRUG|ONTAK|
214700256|NCT06160037|BEHAVIORAL|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
214700257|NCT06160037|BEHAVIORAL|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
214700258|NCT02294149|DRUG|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
214700259|NCT02294149|DRUG|placebo|
214700260|NCT04471064|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
215161154|NCT06056310|DRUG|Xevinapant|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
215161155|NCT06056310|DRUG|Cisplatin|Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
215161156|NCT06056310|RADIATION|intensity-modulated radiation therapy (IMRT)|Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
215161157|NCT03729115|PROCEDURE|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
215161158|NCT06363929|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
214700261|NCT03391687|DIAGNOSTIC_TEST|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
214700262|NCT05923476|DRUG|Lithium|Placebo + ECT
214700263|NCT02370498|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
214700264|NCT02370498|DRUG|paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
214700265|NCT03656120|DRUG|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
214700266|NCT03656120|DRUG|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
214700267|NCT03656120|DRUG|placebo control group|Participants only take placebos for 12 weeks during the research.
215161159|NCT04121806|OTHER|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
215161160|NCT04803370|OTHER|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
214549592|NCT05427227|DEVICE|EV-array detection|Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
214549593|NCT03402074|BEHAVIORAL|Group hypnosis|5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
214549594|NCT04633850|DRUG|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
214700268|NCT00319228|DRUG|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
214700269|NCT02488616|OTHER|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
214700270|NCT02488616|OTHER|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
214700271|NCT02488616|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
214700272|NCT02488616|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
214700273|NCT02488616|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
214700274|NCT04411212|DRUG|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
214700275|NCT04411212|OTHER|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
214700276|NCT03812523|DRUG|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
214700277|NCT03812523|DRUG|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
214700278|NCT05941169|PROCEDURE|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
214700279|NCT03466021|DRUG|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
214700280|NCT03466021|DRUG|Placebo|Matching injection
214700281|NCT04494464|OTHER|No intervention|
214700282|NCT02156869|OTHER|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
215161161|NCT04803370|OTHER|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
214549595|NCT04633850|DRUG|Bupivacain|"Bupivacaine dose according to weight. \<60 kg: Total dose 100mg 60-90kg: Total dose 150mg \>90kg: Total dose 200mg~Given once at the end of surgery."
214549596|NCT04091035|OTHER|To describe the incidence of disease and evaluate risk factors|Se above
214549597|NCT05312346|DIAGNOSTIC_TEST|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
214549598|NCT02320513|OTHER|Wearing activty monitoring device (Fitbit Flex)|
214700283|NCT01908517|BEHAVIORAL|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
214700284|NCT00367198|DIETARY_SUPPLEMENT|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
215161162|NCT05775796|DRUG|Serplulimab and Chemotherapy|Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
214549599|NCT02320513|DEVICE|Fitbit Flex|
214549600|NCT03731923|DIAGNOSTIC_TEST|Biannual ultrasonography|Biannual liver ultrasonography for HCC surveillance, without contrast agent.
214549601|NCT03731923|DIAGNOSTIC_TEST|Annual abbreviated liver MRI|Abbreviated liver MRI using standard dose of extracellular contrast agent (Dotarem, Guerbet, France) on weight-based dosing. Table time targets 10 minutes.
215161163|NCT06527079|OTHER|Opioid Tapering Pathway Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
214549602|NCT00515788|DRUG|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
215161164|NCT05495932|DIAGNOSTIC_TEST|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
215161165|NCT05370430|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
214549603|NCT00515788|DRUG|Temozolomide|100 mg/m\^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
214549604|NCT02595372|DRUG|Omeprazole|
214549605|NCT02842437|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
214549606|NCT02842437|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
214549607|NCT00500344|DRUG|Lucentis (ranibizumab)|intravitreal injection
214549608|NCT00270192|BEHAVIORAL|individual lactation counseling and educational material|
214549609|NCT00270192|BEHAVIORAL|educational material alone|
214549610|NCT00270192|BEHAVIORAL|routine antenatal care without educational intervention|
214549611|NCT04527484|DRUG|SHR-1314|each group subjects will be given different formulations of SHR-1314
214549612|NCT05334043|DRUG|CuminUP30|7 capsules, 500 mg / capsule
214549613|NCT05334043|DRUG|Curcumin capsules|5 capsules, 450 mg / capsule
214549614|NCT00953615|DRUG|Thalidomide|Titrate to 400 mg daily for 6 months
214549615|NCT05639608|PROCEDURE|SCALING|SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
214549616|NCT03132675|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
214549617|NCT03132675|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
214549618|NCT03132675|DEVICE|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
214549619|NCT05350046|DEVICE|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
214549620|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
214549621|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
214549622|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
214549623|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
214549624|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
214549625|NCT02016378|BEHAVIORAL|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
214549626|NCT02016378|BEHAVIORAL|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
214549627|NCT02817061|DEVICE|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
214549628|NCT02389764|DRUG|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
214549629|NCT02389764|BEHAVIORAL|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
214549630|NCT05167890|DIETARY_SUPPLEMENT|Coffee|Coffee 3 times per day
214549631|NCT05167890|DIETARY_SUPPLEMENT|Orange juice|Orange juice 3 times per day
214549632|NCT00583947|DRUG|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
214549633|NCT00583947|DRUG|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
214549634|NCT04833478|BEHAVIORAL|Anxiety|Techniques used to reduce anxiety in paediatric patients.
214549635|NCT03019419|DRUG|Perampanel|4mg/d or 8mg/d
214549636|NCT03019419|DRUG|placebo|placebo
214549637|NCT00869947|DEVICE|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
214549638|NCT00869947|OTHER|No device|
214549639|NCT00486252|OTHER|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
215161166|NCT02675647|DRUG|Heparin, IV route, based on patients body weights (UI/kg)|
215161167|NCT02675647|PROCEDURE|Cardiopulmonary bypass|
215161168|NCT02675647|DRUG|Protamin administration|
214549640|NCT00788242|DRUG|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
214549641|NCT00788242|DRUG|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
214549642|NCT01210651|BEHAVIORAL|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
214549643|NCT01210651|BEHAVIORAL|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
214700285|NCT02909569|DRUG|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
214700286|NCT01399749|OTHER|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
214700287|NCT05250193|DEVICE|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
214700288|NCT05250193|DEVICE|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
214700289|NCT01122030|DRUG|Naldemedine|Tablets or solution for oral administration
214700290|NCT01122030|DRUG|Placebo|Tablets or solution for oral administration
214700291|NCT06155760|DRUG|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
214700292|NCT06155760|OTHER|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
214700293|NCT06155760|DRUG|Placebo|Placebo
214700294|NCT02275767|DEVICE|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
214700295|NCT02275767|DEVICE|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
214700296|NCT02275767|DEVICE|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
214700297|NCT06118580|DRUG|Alcohol (Ethanol)|95% Ethanol diluted in Grape-flavored drink
214700298|NCT06118580|DRUG|Placebo|Grape-flavored drink
214700299|NCT04323761|DRUG|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
214700300|NCT05433194|BIOLOGICAL|ABO1009-DP|Vaccine
214700301|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
214700302|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
214700303|NCT04497298|BIOLOGICAL|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
214700304|NCT04497298|OTHER|Placebo|Physiological saline solution (0.9% NaCl)
214700305|NCT05779579|DRUG|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
214700306|NCT05779579|DRUG|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
214700307|NCT05779579|DRUG|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
214700308|NCT05779579|DRUG|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
214700309|NCT05779579|DRUG|Placebo|Dose level A of placebo
214700310|NCT05469477|BEHAVIORAL|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
214700311|NCT05469477|BEHAVIORAL|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
214700312|NCT05469477|BEHAVIORAL|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
214700313|NCT05469477|BEHAVIORAL|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
214700314|NCT05469477|BEHAVIORAL|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
214700315|NCT05469477|BEHAVIORAL|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
214549644|NCT05405699|BEHAVIORAL|digitalized group psychoeducation|"Problem Solving Approach based problem solving skills psychoeducation's session topics of eight weeks are as follows:~1. Introduction and warm-up,~2. Problem orientation-identifying the problem,~3. Identifying prior problems-Which do I want to start from?~4. Recognizing the losses caused by problems and complaints,~5. Setting reachable and realistic goals,~6. Generating alternatives -What can I do?~7. Regulating emotions,~8. Experimenting and exploring. The main outcomes of each session were determined, and sessions were completed in approximately one hour as a semi-structured interactive group training according to group dynamics.~Three days a week for eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. Participants were connected to the live broadcast of the research team and interacted via text messages."
214549645|NCT02314351|DRUG|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
214700316|NCT05469477|BEHAVIORAL|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
214700317|NCT04274660|BEHAVIORAL|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
214700318|NCT03600948|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
214700319|NCT02525419|BEHAVIORAL|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
214700320|NCT02525419|BEHAVIORAL|HP-IF|High Protein, Intermittent Fast
214549646|NCT02314351|DRUG|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
214549647|NCT02314351|DRUG|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
214549648|NCT01976572|DRUG|colestilan|
214549649|NCT01976572|DRUG|candesartan|
214549650|NCT04246398|OTHER|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
214700321|NCT02525419|BEHAVIORAL|HH|Heart Healthy
214700322|NCT04518982|DRUG|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
214700323|NCT04518982|DRUG|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
214700324|NCT01453998|BIOLOGICAL|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
214700325|NCT01453998|BIOLOGICAL|Prevenar 13|Single co-administered dose, intramuscular into left thigh
214700326|NCT01453998|BIOLOGICAL|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
214700327|NCT05911815|RADIATION|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
214700328|NCT04761172|PROCEDURE|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
214700329|NCT05334680|DEVICE|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
214700330|NCT04915664|DEVICE|Pessary|Use of Pessary as treatment of POP
214549651|NCT04246398|OTHER|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
214549652|NCT03070704|DRUG|insulin degludec/liraglutide|Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
214549653|NCT03472989|DEVICE|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
214549654|NCT03472989|DEVICE|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
214700331|NCT05861804|PROCEDURE|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
214700332|NCT05521217|DIAGNOSTIC_TEST|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
215029543|NCT04381806|DRUG|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
215029544|NCT06043011|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
215029545|NCT06078930|DIAGNOSTIC_TEST|Tongue imaging, tougue coating, saliva, gastric juice, and feces|Tongue images, coating, saliva, gastric juice, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
215029546|NCT05277532|BEHAVIORAL|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
214549655|NCT03472989|BEHAVIORAL|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
214549656|NCT03472989|BEHAVIORAL|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
214549657|NCT06049368|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
214549658|NCT00141999|BIOLOGICAL|hepatitis B vaccine|
214549659|NCT00382525|DEVICE|Cardiac Rhythm Management device|
214549660|NCT04134884|DRUG|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
214549661|NCT04134884|DRUG|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
214549662|NCT02592707|DRUG|Satoreotide tetraxetan|Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
214549663|NCT02592707|OTHER|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
214549664|NCT02592707|OTHER|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
214549665|NCT03358368|DEVICE|Vitalscan|Vitalscan is a magnetocardiograph device
214549666|NCT05615688|PROCEDURE|Pain Intensity following Placement of Orthodontic Separators|Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
214549667|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
214549668|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
214549669|NCT00721929|PROCEDURE|MRI|Magnetic Resonance Imaging
214549670|NCT00469859|DRUG|cytarabine|given IV
214549671|NCT00469859|DRUG|idarubicin|Given IV
214549672|NCT00469859|DRUG|lestaurtinib|Given orally
214549673|NCT02214680|DRUG|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
214549674|NCT02214680|DRUG|Timolol|0.5% eye drop
214549675|NCT05172752|OTHER|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
215161169|NCT04365569|BEHAVIORAL|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1\. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
215161170|NCT06381180|DRUG|Tetrahydrocannabinol|Plant cannabis that will be smoked
215161171|NCT06381180|DRUG|Cannabidiol|Plant cannabidiol that will be smoked
215161172|NCT06381180|DRUG|Placebo|Plant will be smoked.
215161173|NCT04634578|DRUG|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
215161174|NCT02838069|BIOLOGICAL|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
215161175|NCT02838069|BIOLOGICAL|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
215161176|NCT02838069|OTHER|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
215161177|NCT01176006|PROCEDURE|Reduced-intensity hematopoietic stem cell|stem cell transplant
215161178|NCT01176006|DRUG|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
214549676|NCT05172752|OTHER|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
214549677|NCT04404166|BEHAVIORAL|PINGS 2|Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
214549678|NCT06195865|PROCEDURE|DIEP-flap|Breast reconstruction with a deep inferior epigastric perforator flap
214549679|NCT06195865|PROCEDURE|Implant|Breast reconstruction with an implant-based technique
214700333|NCT03268694|BEHAVIORAL|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
214700334|NCT03268694|BEHAVIORAL|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
214700335|NCT03268694|BEHAVIORAL|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
214700336|NCT00598169|BIOLOGICAL|rituximab|375mg/m2 on Day 1
214700337|NCT00598169|DRUG|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
214700338|NCT00598169|DRUG|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
214549680|NCT04560621|BEHAVIORAL|Managed Problem Solving (MAPS)|MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
214549681|NCT06434116|DEVICE|Immersive virtual reality|"The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection."
214549682|NCT04511247|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
214549683|NCT04511247|DEVICE|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
214700339|NCT00598169|DRUG|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
214700340|NCT00598169|DRUG|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
214700341|NCT00598169|DRUG|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
214700342|NCT00598169|GENETIC|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
214700343|NCT00598169|GENETIC|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
214700344|NCT04109872|DRUG|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
214700345|NCT03574935|DRUG|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
214700346|NCT03574935|DRUG|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
214549684|NCT04092660|BEHAVIORAL|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits"
214549685|NCT04092660|DEVICE|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
214549686|NCT04855734|BEHAVIORAL|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
214549687|NCT03701581|DRUG|4-Aminopyridine|FDA-approved tablets.
214549688|NCT03701581|OTHER|Placebo|Placebo will be tooled to look similar to the study drug.
214549689|NCT05789433|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
214549690|NCT05789433|BEHAVIORAL|Progressive stretching|Statistic stretching of eight major muscle groups
214549691|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
214549692|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
214549693|NCT06015256|BIOLOGICAL|blood sample|Blood sample (56mL) taken in a heparin tube
214549694|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
214549695|NCT04577209|DEVICE|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
214549696|NCT05260320|OTHER|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
214549697|NCT06823947|DRUG|Placebo|Placebo is administered single dose or multiple dose by SC injection.
214700347|NCT05572827|BEHAVIORAL|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
214700348|NCT02056717|DRUG|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
215161179|NCT01176006|DRUG|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
215161180|NCT01176006|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
215161181|NCT01176006|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
215161182|NCT01176006|PROCEDURE|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
215161183|NCT01176006|PROCEDURE|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
215161184|NCT05910528|DRUG|Afimkibart|Afimkibart will be administered during the Induction, Maintenance and OLE period.
214549698|NCT06823947|DRUG|KK3910|KK3910 is administered single dose or multiple dose by SC injection.
214549699|NCT04402840|PROCEDURE|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
214549700|NCT05954286|DRUG|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
214549701|NCT05954286|DRUG|Placebo (PO)|Oral Capsules
214700349|NCT02056717|DRUG|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
214700350|NCT04798391|DRUG|Dexamethasone|Steroids and analgesics
214700351|NCT04021394|DIAGNOSTIC_TEST|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
214700352|NCT04021394|DIAGNOSTIC_TEST|Parsortix CTC platform|EMT-independent platform
214700353|NCT02011126|DRUG|Imetelstat Sodium|Given IV
214700354|NCT02011126|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214700355|NCT05279989|OTHER|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
214549702|NCT05263960|BIOLOGICAL|CM350 group1|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
214549703|NCT05263960|BIOLOGICAL|CM350 group2|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
214549704|NCT05263960|BIOLOGICAL|CM350 group3|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
214549705|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
214549706|NCT02538198|DRUG|Lenalidomide|
214549707|NCT03780647|OTHER|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
214549708|NCT05237869|DEVICE|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
214549709|NCT05237869|OTHER|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
214549710|NCT04557280|COMBINATION_PRODUCT|Selatogrel|A single subcutaneous injection of 16 mg.
214549711|NCT04557280|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
214549712|NCT01991925|OTHER|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
214549713|NCT05902897|DEVICE|Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.|Heart Valve Replacement
214549714|NCT02520310|DEVICE|AVJ-514|Patients receiving AVJ-514 device
214549715|NCT01340014|DRUG|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
214549716|NCT01340014|DRUG|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
214549717|NCT02270307|DRUG|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
214549718|NCT02270307|BIOLOGICAL|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
214549719|NCT01237847|BEHAVIORAL|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
214549720|NCT01237847|BEHAVIORAL|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
214549721|NCT01237847|BEHAVIORAL|Wait list comparison group|Wait list comparison group to receive intervention at later point.
214549722|NCT01769430|OTHER|Observational Study of influenza aerosol shedding -- No Intervention|No intervention -- observational study only
214549723|NCT06655649|DIETARY_SUPPLEMENT|Ketone-IQ (1,3 Butanediol)|Ketone-IQ (1,3 Butanediol) 20 or 40 g will be ingested (open-label) before bedtime.
214549724|NCT06903312|PROCEDURE|Deferred Cytoreductive Nephrectomy + medical treatment|Patients randomized to Deferred Cytoreductive Nephrectomy can be treated with one among radical nephrectomy; partial nephrectomy or lumpectomy. Patients will continue to receive the ongoing medical treatment before the randomization.
214549725|NCT06903312|RADIATION|Radiotherapy + medical treatment|Patients randomized to RT should be treated with single shot of 25 Gy (or with multiple fractions with equivalent biological dose). Patients will continue to receive the ongoing medical treatment before the randomization.
214549726|NCT06903312|DRUG|Medical therapy|Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab.
214549727|NCT06587958|DIETARY_SUPPLEMENT|Fermented plant-based foods|Participants will daily consume five different types of fermented plant-based foods, in addition to their habitual diet.
214549728|NCT06587958|DIETARY_SUPPLEMENT|Non-fermented plant-based foods|Participants will daily consume five different types of non-fermented plant-based foods, in addition to their habitual diet.
214549729|NCT06587958|OTHER|Habitual diet|Participants will follow their habitual diet.
214549730|NCT00155532|PROCEDURE|3 mm-punch biopsies of the skin|
214549731|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
214549732|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
214549733|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
214549734|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
214549735|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
214549736|NCT04529811|DRUG|Rifaximin Novel Formulation|Rifaximin Novel Formulation
214549737|NCT04529811|DRUG|Placebo|Placebo
214549738|NCT01754987|DRUG|Ascorbic Acid + Sorafenib|
214549739|NCT01754987|DRUG|Sorafenib|
214549740|NCT06005675|DEVICE|Intervention|No study treatments will be administered during this study.
214549741|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
214549742|NCT05131477|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214549743|NCT05131477|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214549744|NCT06595368|PROCEDURE|Vimala massage|The massage will be given three times per day, each lasting 15 minutes and planned one hour after the first feeding of each shift.
214549745|NCT06595368|PROCEDURE|Hydrotherapy|Hydrotherapy will be applied two times per day before feeding, each lasting 5-10 min.
214700356|NCT05279989|OTHER|Health Information Videos|Participants will receive videos of health information.
214700357|NCT00514202|DRUG|Placebo|matched placebo
214700358|NCT00514202|DRUG|Dextroamphetamine SR|60 mg/day
214700359|NCT02671942|DRUG|Roflumilast|
214700360|NCT02671942|DRUG|Placebo|
214700361|NCT01486784|DRUG|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
214700362|NCT03985072|DRUG|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
214700363|NCT04472364|DEVICE|HemoPill Acute ®|Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
214700364|NCT00776399|DEVICE|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
214700365|NCT04022174|BEHAVIORAL|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
214549746|NCT02194829|DRUG|AZD1775|Given PO
214549747|NCT02194829|DRUG|Gemcitabine|Given IV
214549748|NCT02194829|DRUG|Nab-paclitaxel|Given IV
214549749|NCT06336512|DIAGNOSTIC_TEST|ELISA|Estimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy .
214549750|NCT02536495|DRUG|Docetaxel|Given IV
214549751|NCT02536495|OTHER|Laboratory Biomarker Analysis|Correlative studies
214700366|NCT04022174|BEHAVIORAL|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
214700367|NCT04022174|BIOLOGICAL|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
214700368|NCT04022174|BEHAVIORAL|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
214700369|NCT03631862|DRUG|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
214700370|NCT03631862|DRUG|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
214700371|NCT03491553|DRUG|Selgantolimod|Tablet(s) administered orally once weekly
214700372|NCT03491553|DRUG|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
214700373|NCT03491553|DRUG|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
214700374|NCT05673863|BEHAVIORAL|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
214700375|NCT06282497|RADIATION|Optimised neck CTV|neck CTV delineation extends from the lateral process of C1
214700376|NCT06282497|RADIATION|standard neck CTV|neck CTV delineation extends from skull base
215029547|NCT05544760|OTHER|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
215029548|NCT03577470|DRUG|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
215029549|NCT04965064|DRUG|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
215029550|NCT05498870|DRUG|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
214549752|NCT02536495|OTHER|Pharmacological Study|Correlative studies
214549753|NCT02536495|DRUG|Selinexor|Given PO
214549754|NCT06819904|BEHAVIORAL|Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE)|Participants will receive the ACT treatment. It is comprised of three processes: Open Up, Be Present, and Do What Matters. Each of these is further sub-divided, for a total of six core processes. These processes include, but are not limited to, present moment awareness, de-fusion, and committed action. This group will also receive targeted vestibular therapy and standardized behavioral management strategies (physical activity, sleep, hydration, and nutrition prescription). Participants will also receive usual care at the discretion of each site's treating providers. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
215029551|NCT05498870|DRUG|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
215029552|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
215029553|NCT05407441|DRUG|Tazemetostat|oral, twice daily, dosage per protocol
214549755|NCT06819904|BEHAVIORAL|Usual Care Vestibular Rehabilitation|Participants will receive usual care at the discretion of each site's treating providers, excluding any components associated with ACT. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
214549756|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1, 5, 9, and 13 months.
214549757|NCT05176626|BEHAVIORAL|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
214700377|NCT03327753|BEHAVIORAL|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
214700378|NCT03327753|BEHAVIORAL|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
214700379|NCT01156610|BEHAVIORAL|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
214700380|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
214700381|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
214700382|NCT00131040|DRUG|Aprotinin|
214700383|NCT04176055|DRUG|Haloperidol|haloperidol intervention
214700384|NCT03608553|DEVICE|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
214700385|NCT05102708|OTHER|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
214700386|NCT01594138|OTHER|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
214700387|NCT04425421|OTHER|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
214700388|NCT06226506|DRUG|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
214700389|NCT06226506|DRUG|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
215029554|NCT05407441|DRUG|Nivolumab|IV, dosage and schedule per protocol
215029555|NCT05407441|DRUG|Ipilimumab|IV, dosage and schedule per protocol
215029556|NCT01690533|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
215029557|NCT02919618|RADIATION|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
215161185|NCT06169319|BIOLOGICAL|Collagenase Clostridium Histolyticum (CCH)|Biologic: Intrafascial injection
215161186|NCT06169319|BIOLOGICAL|Placebo|Intrafascial injection
215161187|NCT04264572|OTHER|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
214549758|NCT05176626|DRUG|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
214549759|NCT06600607|DRUG|pregabalin 300 mg|pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain
214549760|NCT06600607|OTHER|Placebo|biologically inactive placebo comparator
214549761|NCT01124838|DRUG|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
214549762|NCT01124838|DRUG|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
214549763|NCT01124838|DRUG|Placebo|Administered by subcutaneous injection
214549764|NCT03708796|DIAGNOSTIC_TEST|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
214549765|NCT06857929|BEHAVIORAL|energy reduced Mediterranean diet (25% caloric restriction) plus physical activity program|An intensive multifactorial lifestyle intervention involving monthly individual and group sessions during 6 months. Participants will be asked to follow a Mediterranean diet with a 25% reduction in energy and a physical activity program based on WHO recommendations to achieve a moderate physical activity level.
214549766|NCT06857929|BEHAVIORAL|Usual Care|Participants in the control group will be asked to follow general recommendations to adhere to a healthy lifestyle, as indicated in the clinical guidelines of general practitioners and nurses for adults with metabolic syndrome
214549767|NCT06859138|OTHER|Manual Therapy|Manual therapy techniques including massage, trigger point pressure, muscle stretching and joint mobilization.
214549768|NCT06859138|OTHER|Splint therapy|Dental splint used for temotoromandibular disorders treatment
214549769|NCT06670768|DIAGNOSTIC_TEST|Stress Dynamic MPI SPECT|BMI standardized radiopharmaceutical injection in pharmacological stress (dipyridamole or adenosine) is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
214549770|NCT06670768|DIAGNOSTIC_TEST|Stress Static MPI SPECT|30-60 minutes after stress dynamic SPECT imaging is performed, an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
214549771|NCT06670768|DIAGNOSTIC_TEST|Rest Dynamic MPI SPECT|3 hours after the stress phase, the rest phase is also recorded. A radiopharmaceutical injection with a three-fold dose at rest is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
214549772|NCT06670768|DIAGNOSTIC_TEST|Rest Static MPI SPECT|30-60 minutes after rest, dynamic SPECT imaging is performed, and an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
214549773|NCT06670768|DIAGNOSTIC_TEST|Cardiac CT|Within 30 days of MPI SPECT imaging, a cardiac CT is performed for every patient, including a native calcium-scoring scan and a coronary CT angiography as a reference standard. A photon-counting detector CT is used.
214549774|NCT00000505|DRUG|tissue plasminogen activator|
214549775|NCT00000505|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214549776|NCT04182997|DRUG|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
214549777|NCT04182997|DRUG|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
214549778|NCT06989541|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous immune globulin replacement
214549779|NCT06989541|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous immune globulin replacement
214549780|NCT04297618|DRUG|Xiidra|Xiidra (lifitegrast 5% ophthalmic solution)
214700390|NCT03838068|BIOLOGICAL|Biodentine|Biodentine is considered a calcium silicate cement
215161188|NCT04264572|BEHAVIORAL|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
215161189|NCT03993873|DRUG|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
215161190|NCT02639273|DRUG|Nalmefene|Active Drug
215161191|NCT02639273|OTHER|Placebo|Single Dose Placebo
215161192|NCT04772378|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
215161193|NCT03595683|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks.
215161194|NCT03595683|BIOLOGICAL|EDP1503|Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).
215161195|NCT06168799|DRUG|Ilofotase alfa|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
215161196|NCT06168799|DRUG|Placebo|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
214549781|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
214549782|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
214549783|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
214549784|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
214700391|NCT03838068|BIOLOGICAL|mineral trioxide aggregate|calcium based silicate cement
214700392|NCT03838068|PROCEDURE|cervical pulpotomy|coronal pulp tissue was removed till the orifice
214700393|NCT03838068|DRUG|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
214700394|NCT03240393|DRUG|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
214700395|NCT00473837|DRUG|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
214700396|NCT00473837|DRUG|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
214700397|NCT02941913|DRUG|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
214700398|NCT04703348|DIAGNOSTIC_TEST|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities."
214700399|NCT01755494|DRUG|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
214700400|NCT01755494|DRUG|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
214700401|NCT01755494|DRUG|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
214700402|NCT01755494|DRUG|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
214700403|NCT01755494|DRUG|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
214700404|NCT06061887|OTHER|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
214700405|NCT01769261|OTHER|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
214700406|NCT01769261|OTHER|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
214700407|NCT01769261|OTHER|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
214700408|NCT00817401|DEVICE|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
214700409|NCT01136421|DRUG|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
214549785|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
214549786|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
214549787|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
214549788|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
214549789|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
214549790|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
214549791|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
214700410|NCT01136421|DRUG|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
214700411|NCT05779332|OTHER|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
214700412|NCT00720421|DRUG|AZD7325|AZD7325 10 mg oral 2 capsules
214700413|NCT00720421|DRUG|AZD7325|AZD7325 1 mg oral 2 capsules
214700414|NCT00720421|DRUG|AZD7325|AZD7325 Placebo oral 2 capsules
214700415|NCT00720421|DRUG|Lorazepam|Lorazepam 1 mg oral 2 tablets
214700416|NCT00720421|DRUG|Lorazepam|Lorazepam Placebo oral 2 tablets
214700417|NCT01165151|BEHAVIORAL|behavioral weight loss program|weekly, group-based lifestyle weight loss program
214700418|NCT01821820|OTHER|Pistachios|
214549792|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
214549793|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
214700419|NCT05585892|OTHER|Elaboration and individual mailed feedback|see above
214700420|NCT02497157|DRUG|Oxaliplatin (L-OHP)|
214700421|NCT02497157|DRUG|Irinotecan hydrochloride hydrate (CPT-11)|
214700422|NCT02497157|DRUG|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
214700423|NCT02497157|DRUG|Levofolinate calcium (l-LV)|
214700424|NCT02497157|DRUG|Bevacizumab (Bmab)|
214700425|NCT04729582|BIOLOGICAL|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
214700426|NCT04729582|OTHER|Placebo|Placebo is the injection solution without muscle stem cells.
214700427|NCT03184298|OTHER|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
214700428|NCT03184298|OTHER|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
214700429|NCT03184298|OTHER|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
214700430|NCT02019394|DRUG|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
214700431|NCT04650958|PROCEDURE|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
214700432|NCT03914495|DIETARY_SUPPLEMENT|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
214700433|NCT03914495|DIETARY_SUPPLEMENT|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
214700434|NCT06195384|BIOLOGICAL|Neoantigen mRNA Vaccine|Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
214700435|NCT03628430|PROCEDURE|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
214700436|NCT03628430|PROCEDURE|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
214700437|NCT03628430|PROCEDURE|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
214700438|NCT00488592|BIOLOGICAL|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
215029558|NCT02592863|DRUG|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
215029559|NCT02592863|DRUG|Placebo|Patients will take placebo 3 times per day for 12 weeks
215029560|NCT02743221|DRUG|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
215029561|NCT02743221|DRUG|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
215029562|NCT06134401|DEVICE|saline|nebulised
215029563|NCT04962113|OTHER|TUBE BATH|Wrap Tube Baht (immersion)
215029564|NCT04503616|DRUG|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
215029565|NCT04770285|DEVICE|CT-152 - Digital Therapeutic|CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
214549794|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
214549795|NCT06858540|BEHAVIORAL|Unified protocol for transdiagnostic treatment of emotional disorders in adolescents|The blended UP-A includes 8 weekly modules, 6 of which (Module 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (module 8), each with an expected duration of 90 minutes.
214549796|NCT06604754|OTHER|Assigned Intervention for VR Training|In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.
214549797|NCT06604754|OTHER|Assigned Intervention for Traditional Physical Therapy Training|In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.
214549798|NCT07002294|OTHER|Transfer to specialty care|Interfacility transport and treatment at the specialty care hospital
214549799|NCT07002294|OTHER|Usual care|Hospitalization and treatment at the closest appropriate facility
214549800|NCT06669975|DRUG|AP402 (Part 1 Dose esclation)|Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
214549801|NCT06669975|DRUG|AP402 (Part 2 Dose Expansion)|After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
214549802|NCT04466566|OTHER|Saline|Saline will serve as the control
214549803|NCT04466566|BIOLOGICAL|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
214549804|NCT06546150|BIOLOGICAL|RE002 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
214549805|NCT06998667|BEHAVIORAL|Standard Heat Illness Prevention Measures|Standard CAL-OSHA workplace heat illness prevention interventions, which require availability of cool, potable water; availability of shade when temperatures exceed 80F; and encouragement of rest for cool down breaks
214549806|NCT06998667|OTHER|Cooling bandana|Cooling bandana embedded with a polymer to slow evaporation
214549807|NCT06998667|OTHER|Cooling glove|Cooling glove with ability to circulate cool water interface with palmar skin
214549808|NCT03534011|PROCEDURE|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
214549809|NCT03534011|DEVICE|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
214549810|NCT07009548|DRUG|Cytogam|CytoGam 150 mg/kg intravenously (IV) administered as a single dose
214549812|NCT05388435|DRUG|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
214549813|NCT01688011|DRUG|Luspatercept|Prescribed by treating physician as per product label.
214549814|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
214549815|NCT06627335|DRUG|TCS|Topical corticosteroid
214549816|NCT07014852|OTHER|Traditional Country Foods|Participants will receive weekly distributions of traditional foods, including caribou and fish. Guided conversations will explore changes in dietary habits, emotional well-being, and cultural connections
214549817|NCT07014852|BEHAVIORAL|Cultural Workshops|Weekly workshops led by Elders will focus on traditional country food, food preparation, and sharing practices, enhancing cultural identity and community bonds. Participants will also engage in cultural camps where they will be led by Elders in land based teachings on country food.
214549818|NCT05890963|DRUG|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
214549819|NCT05890963|DRUG|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
214549820|NCT05890963|DRUG|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
214549821|NCT05419388|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
214549822|NCT02325583|DRUG|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
214549823|NCT02325583|DRUG|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
214549824|NCT06875154|PROCEDURE|Valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy or minitoracothomy Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium or from peripheral access. Left ventricle was vented through the right superior pulmonary vein.~In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion.. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
214549825|NCT03687593|DEVICE|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
214549826|NCT07024160|DRUG|MT1011|MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.
214700439|NCT00488592|BIOLOGICAL|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
214700440|NCT00488592|DRUG|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
214700441|NCT00488592|BIOLOGICAL|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
214549827|NCT07024160|DRUG|Placebo|This intervention contains no active ingredients
214700442|NCT05600647|DEVICE|Electromagnetic Field therapy with an exercise program|"1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
214700443|NCT05600647|OTHER|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
214700444|NCT05393076|DRUG|Linerixibat|Linerixibat dose and administration as per study intervention.
214700445|NCT05651217|DEVICE|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
214700446|NCT05651217|DEVICE|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
214700447|NCT03707964|OTHER|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
214700448|NCT03707964|OTHER|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
214700449|NCT00327548|BEHAVIORAL|guided imagery|
214700450|NCT00135837|DRUG|Verteporfin for injection|
214549828|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
214549829|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
214700451|NCT02074774|DEVICE|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
214700452|NCT02074774|OTHER|Manual control|Standard practice of manually titrating FiO2 as needed.
214700453|NCT05475912|OTHER|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
215161197|NCT04752774|BIOLOGICAL|IPN10200|Powder and solvent for solution for injection
215161198|NCT04752774|DRUG|Placebo|Powder and solvent for solution for injection
215161199|NCT04752774|BIOLOGICAL|Dysport|Powder for solution for injection
215161200|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
215161201|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
215161202|NCT02674152|DRUG|BI 836880|BI 836880
215161203|NCT06255782|GENETIC|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
215161204|NCT03410667|BEHAVIORAL|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
215161205|NCT03410667|BEHAVIORAL|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
214549830|NCT07031180|OTHER|educational video|"The experimental educational intervention will consist of professional video recordings that will cover the following topics:~1. Disease knowledge (VLU)~2. Medication management~3. The importance of compression therapy~4. Diet and physical activity The video recordings' contents will result from a review of the literature and guidelines, which will be later reviewed by a panel of experts in VLU. The video will be recorded by experienced video-maker and by a group of volunteers who will be the actors."
215161206|NCT03410667|BEHAVIORAL|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
214549831|NCT07031180|OTHER|educational pamphlet (standard educational intervention)|The educational brochure is an educational intervention already in use at the setting involved in the study.
214549832|NCT07030218|PROCEDURE|Office hysteroscopy|In office hysteroscopy will utilize 1.9-2.9 mm hysteroscopes (primarily Bettocchi) by the technique of vaginoscopy, without anesthesia or up to level 3a analgesia, in accordance with International Consensus Statement for Recommended Terminology Describing Hysteroscopic Procedures. The choice of distension medium and hysteroscope is left to the operator's discretion. A nurse positioned at the head of the patient will record signs and symptoms of VVR/VVS.
214549833|NCT07031544|DEVICE|deep brain stimulation|Deep Brain Stimulation (DBS) involves the use of stereotactic techniques to implant microelectrodes into specific target nuclei within the brain through minimally invasive surgery. These electrodes are connected via leads to a subcutaneously implanted pulse generator, typically placed beneath the clavicle. By delivering low-intensity electrical pulses, DBS suppresses abnormal intracranial neural activity, thereby alleviating symptoms. Long-term stimulation can also induce neuroplastic changes in neural networks and neurotransmitter systems, contributing to the restoration of neurological function.
214549834|NCT07033572|PROCEDURE|Endoscopic Hemithyroidectomy with Central-Neck Dissection|Gas-less axillo-breast approach (trans-axillary + peri-areolar), carbon-dioxide-free working space, removing dominant thyroid lobe plus level VI lymph nodes; intra-operative neuromonitoring used throughout.
214549835|NCT07033572|PROCEDURE|Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule|17-gauge internally-cooled electrode, 0.7 cm active tip, power 40 W; moving-shot technique under real-time ultrasound until hyperechoic halo fully covers ≤ 7 mm papillary microcarcinoma ≥ 2 mm from posterior capsule; same anesthesia session as surgery.
214549836|NCT07037589|PROCEDURE|investigation setting (cystoscopy + CTU + cytology)|Observational study. All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for acute macroscopic hematuria.
214549837|NCT07037589|PROCEDURE|Cystoscopy - CTU - cytology (if needed)|All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for atypical or chronic presentations of macroscopic hematuria.
214549838|NCT06880406|OTHER|MMSE and blood draw|Each patient will be evaluated by Mini-Mental State Examination (MMSE) and will have a blood draw
214549839|NCT06727799|DIAGNOSTIC_TEST|Docking Assessment / Observation|One eye of each subject will have corneal marks placed and will be docked at the study visit.
214549840|NCT06753331|COMBINATION_PRODUCT|DSP-1083 implantation|DSP-1083 subjects will receive 2.7M viable cells per hemisphere; 5.4M total cell dose as implants.
214549841|NCT06753331|PROCEDURE|Sham surgery treatment|Sham surgery subjects will undergo a partial thickness burr hole surgical procedure on each side of the skull with no DSP-1083 administration.
214549842|NCT06751407|PROCEDURE|Single level SPSIPB|The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.
214700454|NCT04930211|DRUG|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
214700455|NCT00825955|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
214700456|NCT00825955|OTHER|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
214700457|NCT00825955|PROCEDURE|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
215161207|NCT03410667|BEHAVIORAL|Aim 3|This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
215161208|NCT06363383|BIOLOGICAL|MB-001|Oral, delayed release formulation of a biologic drug
215161209|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
215161210|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
215161211|NCT06047444|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
214549843|NCT06751407|PROCEDURE|Two-level SPSIPB|In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
214549844|NCT05704049|DRUG|Isatuximab|Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
214549845|NCT05704049|DRUG|Carfilzomib|Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
214549846|NCT05704049|DRUG|Dexamethasone|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
214549847|NCT05704049|DRUG|Dexamethasone IV|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
214549848|NCT05704049|DRUG|Montelukast|Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
214549849|NCT05704049|DRUG|Acetaminophen|Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
214549850|NCT05704049|DRUG|Diphenhydramine|Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
214549851|NCT05704049|DRUG|Methylprednisolone|Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
214549852|NCT06903741|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-acetyl-aspartyl-glutamate
214549853|NCT06906783|PROCEDURE|Transtibial Pull Out Method|The Transtibial Pull-Out Repair is a surgical technique used to fix posterior root tears of the meniscus, particularly in the medial meniscus. This method restores the hoop stress mechanism of the meniscus, which is essential for knee stability and function.
214549854|NCT06906783|PROCEDURE|Suture Anchor Method|The Suture Anchor Technique is an alternative to the Transtibial Pull-Out Method for repairing posterior meniscal root tears, especially in the medial meniscus. Instead of using a tibial tunnel, this technique fixes the meniscal root directly to the native footprint using suture anchors.
214549855|NCT06817967|DEVICE|PSNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
214549856|NCT06817967|DEVICE|ISNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
214549857|NCT06914050|DRUG|Adebrelimab|Induction therapy：Adebrelimab, 1200mg, d1, q3w, 2 cycles; Maintenance therapy：Adebrelimab, 1200mg, d1, q3w, until disease progression or unbearable toxicity.
214549858|NCT06914050|DRUG|EC/EP|Chemotherapy: standard chemotherapy EC/EP
214549859|NCT06914050|RADIATION|SBRT|8Gy\*3
214549860|NCT06914050|RADIATION|Chest radiotherapy|Chest radiotherapy: conventional fractionation mode 2Gy QD total dose 60Gy or 1.5Gy BID total dose 45Gy, according to the patient's physical condition, concurrent EP or EC chemotherapy can be considered
214700458|NCT01453309|PROCEDURE|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
214700459|NCT01453309|PROCEDURE|No Cell Saver|Cell Saver will not be available during surgery
214700460|NCT03672877|BEHAVIORAL|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
214700461|NCT03384225|DRUG|Cladribine|
214700462|NCT03384225|DRUG|Fludarabine|
214700463|NCT03384225|DRUG|Busulfan|
214700464|NCT03384225|DRUG|Cytarabine|
214700465|NCT05895227|PROCEDURE|Oocyte retrieval|
214549861|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
214549862|NCT03506672|OTHER|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
214549863|NCT03506672|OTHER|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
214700466|NCT05008588|BIOLOGICAL|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
214700467|NCT05008588|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
214700468|NCT05008588|PROCEDURE|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
214700469|NCT05903391|DEVICE|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
214700470|NCT05903391|DEVICE|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
214700471|NCT03420716|DIETARY_SUPPLEMENT|yogurt|
214700472|NCT00005096|DRUG|docetaxel|
214700473|NCT06616766|DRUG|YH42946|YH42946
214549864|NCT06931535|DEVICE|remote ischemic conditioning|The cuff of the remote ischemic conditioning device was placed on both upper arms (at the same position as blood pressure measurement) and inflated to 200 mmHg. The treatment protocol consisted of 5 cycles of 5-minute inflation followed by 5-minute deflation, performed twice daily. The treatment duration was 8-12 consecutive days.
214549865|NCT06934694|DEVICE|Instrument-Assisted Soft Tissue Mobilization|Participants will receive a single session of instrument-assisted soft tissue mobilization (IASTM) applied to the gastrocnemius muscle using a stainless-steel instrument. The treatment consists of longitudinal and transverse strokes targeting both the medial and lateral heads of the muscle. The procedure will be performed by a trained clinician, following a standardized protocol lasting approximately 5 minutes. The goal is to induce mechanical and neuromodulatory effects on muscle tissue. This intervention is designed to assess acute changes in muscle stiffness (via shear-wave elastography) and ankle dorsiflexion range of motion (via the weight-bearing lunge test).
214549866|NCT06938568|OTHER|Personalized back exercises|"The study intervention is a 12-week personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
214549867|NCT06938568|OTHER|Non-personalized back exercises|"The active control intervention is a 12-week non-personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
214549868|NCT06939907|DEVICE|Nexpowder™|Nexpowder™ hemostatic powder
214700474|NCT01595737|DRUG|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
214700475|NCT01595737|DRUG|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
214700476|NCT01726920|DRUG|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
214700477|NCT01726920|DRUG|naratriptan|Tablets containing naratriptan 2,5 mg
214700478|NCT01726920|DRUG|naproxen|Tablets containing naproxen 500 mg
214700479|NCT02260102|DRUG|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
214549869|NCT06941506|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has three phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
214549870|NCT06941506|OTHER|Control|Participants maintain their routine activities.
214549871|NCT06941714|OTHER|Perturbation|Jack is attached to force plates and it is used to give perturbation when participants are standing on force platform. Balance is assessed after perturbation and readings will be taken through HRV and GSR.
214700480|NCT00374153|BEHAVIORAL|Feedback|Online personal feedback report
214700481|NCT00374153|BEHAVIORAL|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
214700482|NCT00374153|BEHAVIORAL|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
214700483|NCT06422351|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
214700484|NCT04196361|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound as part of routine physical examination
214700485|NCT05342129|OTHER|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
214700486|NCT03930212|DRUG|Progesterone|received rectal progesterone suppositories 400 mg once daily
214700487|NCT03930212|DRUG|Placebos|received placebo suppositories rectally once daily.
214700488|NCT04593940|DRUG|Infliximab|study drug or matching placebo
214700489|NCT04593940|DRUG|Abatacept|study drug or matching placebo
214700490|NCT04593940|DRUG|Remdesivir|Standard of Care
214700491|NCT04593940|DRUG|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
214700492|NCT02077634|DRUG|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
215161212|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections."
214549872|NCT06941714|OTHER|Working Memory Task|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants are asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher. while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
214549873|NCT06941714|OTHER|Visual and Verbal Fluency Task|Modified Stroop test or Stroop color word test: Participants are asked to name the color of ink that each word is printed. The test will appear on screen while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
214549874|NCT06940843|BEHAVIORAL|Hopeful and Healthy Living (HHL)|The HHL intervention is a 16-week long, manualized group intervention. Classes will be held weekly for 90 minutes. The class covers 15 topics centered on building social connections, developing healthy lifestyle routines around eating, exercise, and sleep. Each class will target one social skill (i.e. starting conversations) and one cognitive self-management strategy (i.e. memory tips), which will be taught and practiced in class. Each class also includes a facilitated exercise component and individually tailored take home application activity.
214549875|NCT06945666|DRUG|Combined therapy of Iguratimod and tofacitinib|This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.
214549876|NCT06944327|PROCEDURE|MANAGEMENT CARE|Administration of the sealing element after canalization and initial treatment of the device, prior to fixation with a suture system and a 7-day vs. 14-day cadence test.
214549877|NCT06944327|OTHER|traditional care|Traditional cure administration with sutureless device fixation every 7 days
214549878|NCT06945068|BIOLOGICAL|GB261|GB261 will be dosed according to the assigned group.
214549879|NCT06944184|DEVICE|Intraarticular microdialysis|The intervention decive is placed during the routine surgery to remove the infected knee prosthesis and implantation of the static cement spacer. A microdialysis catheter is implemented to generate continious intra-articular samples of the knee joint. To ensure complete removal and no damage of the membrane it is inserted via a regular drainage tube. The catheter membrane is placed intra-articularly next to the spacer and continious to an outlet tube for sample collection.
214549880|NCT06944613|DEVICE|Augmented reality-based programme/Microsoft Hololens version 2|Participants play two exergames, the aim of this process is to engage cognitive double tasks
214549881|NCT06945679|DRUG|CPLE|It will be a double-blind study,CPLE and Placebo will be marked as either Group A or Group B.Half of the patients will receive Group A and other half will receive Group B drug along with standard treatment according to national guideline,Each participant will receive either CPLE or Placebo,500 mg 2 capsules three times daily for 5 days and will be followed up daily upto study day 5.
214549882|NCT06945679|DRUG|Placebo|"The patients will be assigned to visually matched placebo 2 capsule t.i.d for 5 days The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR). On receipt, the medications will be stored in a secure area at room temperature. Enrolled patients will receive CPLE or placebo for 5 days.~Clinical data will be captured on structured case report forms."
214549883|NCT06944418|OTHER|observation|observation
214549884|NCT06945302|DIETARY_SUPPLEMENT|Intervention Group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
214549885|NCT06945302|DIETARY_SUPPLEMENT|Control group (placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
214700493|NCT02077634|DRUG|abiraterone acetate + prednisone|ormon therapy will be stopped
214700494|NCT00180596|DEVICE|Contak heart failure devices|
214700495|NCT03989219|PROCEDURE|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
214700496|NCT03246217|BEHAVIORAL|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
214700497|NCT03246217|BEHAVIORAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
214700498|NCT03246217|BEHAVIORAL|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
214700499|NCT04331873|DIAGNOSTIC_TEST|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
214700500|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
214700501|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
215161213|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections."
215161214|NCT05556512|DRUG|Tirzepatide|Administered SC
215161215|NCT05556512|DRUG|Placebo|Administered SC
215161216|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
215161217|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
215161218|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
215161219|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
215161220|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
215161221|NCT04563143|OTHER|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
215161222|NCT03925025|DRUG|Magnesium Sulfate|Treatment in addition to standard therapy
215161223|NCT03925025|DRUG|Nimodipine|Treatment in addition to standard therapy
215161224|NCT02153957|BEHAVIORAL|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
215161225|NCT03298243|BEHAVIORAL|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
215161226|NCT05267262|DRUG|R3R01|R3R01 administered orally for 12 weeks
215161227|NCT05181592|DRUG|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
215161228|NCT03017820|PROCEDURE|Biopsy|Undergo tumor biopsy
214549886|NCT06945315|PROCEDURE|RALP (Robotic-assisted radical prostatectomy)|Robotic-assisted radical prostatectomy (RALP) is a standard surgical procedure for managing localized prostate cancer that focuses on prostate anatomy and surrounding structures to enable personalized surgeries. The procedure incorporates nerve-sparing techniques through careful dissection of the neurovascular bundle and can use a thermal and traction-free dissection to improve functional outcomes, particularly erectile function.
214549887|NCT06945315|DRUG|SAFE (Saline assisted fascial engorgement)|SAFE (Saline assisted fascial engorgement) an innovative technique to achieve enhanced nerve-sparing outcomes among patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). Essentially a new method of hydro dissection, SAFE involves an injection of 30 cc of normal saline solution between the layers of the periprostatic fascia after early release of the neurovascular bundle. This injection effectively pushes the nerves away from the prostate, enabling a dissection of the prostate that is atraumatic vis a vis the neural hammock.
214549888|NCT06944288|PROCEDURE|total knee replacement|The Orthopedic Surgeon will remove the damaged cartilage and bone then implant the new metal and plastic knee to restore the alignment and function of your knee. The surgical procedure takes about 1-2 hours on average. While in case of infection, an antibiotic cement is inserted, which will be removed with the subsequent prosthetic implant surgery. Finally, prosthetic components can be more filling, depending on the amount of bone that is previously removed.
214549889|NCT06944015|OTHER|normal saline|After completion of surgery, Study Group patients underwent intraperitoneal irrigation with 30 mL/kg of normal saline at 37C infused under the right hemidiaphragm. Patients were placed in Trendelenburg position and reverse Trendelenburg position, to allow contact between the liquid and all abdominal structures, including the diaphragm and surgical wounds. At the end of the procedure, all the introduced liquid was carefully removed.
214549890|NCT06945471|BEHAVIORAL|1) Face-to-face, and 2) Computer-mediated motivational type interviews|
214549891|NCT06945185|PROCEDURE|Intervention Group A Conventional Physical Therapy|"Active Range of Motion Exercises: (5-10 reps with 2 sets) Finger bends, finger spreads, finger to thumb opposition, thumb to palm stretches, palm up and down, wrist rotation, wrist bends, elbow bends, shoulder shrugging and shoulder rotation.~Strengthening Exercises: (10-15 reps 2 sets weight 500 ml to 1L water bottle). Finger pinch, power grip, finger spread, pushing movement, wrist curls, roll and squeeze, bicep curls, side arm raise, lifting objects to a height, pulling resistance band.~Coordination Exercises: (10-15 reps 2 sets) finger to finger, finger to doctor's finger, finger to nose, holding and lifting coins, buttoning, holding and lifting coins, alternate hand movement, closing and opening hand."
214700502|NCT04671316|DRUG|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
214700503|NCT03759457|DEVICE|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
214700504|NCT01449591|DRUG|BFH772 1% ointment|
214700505|NCT01449591|DRUG|Vehicle ointment|
214700506|NCT01449591|DRUG|Noritate® 1% cream|
214700507|NCT01096849|DRUG|levofloxacin|
214700508|NCT01096849|DRUG|plazomicin|
214700509|NCT01096849|DRUG|placebo|
215161229|NCT03017820|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161230|NCT03017820|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215161231|NCT03017820|PROCEDURE|Computed Tomography|Undergo SPECT/CT
215161232|NCT03017820|DRUG|Cyclophosphamide|Given IV
215161233|NCT03017820|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215161234|NCT03017820|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
215161235|NCT03017820|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215161236|NCT03017820|BIOLOGICAL|Cemiplimab|Given IV
215161237|NCT03017820|DRUG|Ruxolitinib|Given PO
215161238|NCT04389437|PROCEDURE|Ophthalmological exam|OCT-A and AO
214549892|NCT06945185|PROCEDURE|Intervention Group B Motor Imagery with Conventional Physical Therapy|"1. Subjects will be asked to sit comfortably on a chair with a backrest. A Quiet environment is ensured for proper concentration of subject .Take deep breaths for 2-3 min to relax.~2. Subjects will be asked to close their eyes and imagine the training scene for each task for 5 min while listening to the therapist 's voice describing the motion.~3. The non-paralysis part of the body's movement was imagined first and then the movement of the paralysis part was imagined.~4. Upon completion of the mental practice for the first activity, the subject will be given a comfortable break.~Motor Imagery Training:~Week 1-2: Approaching and holding a cup, turning book pages and grasping pencil to write.~Week 3-4: wiping desk, turning door handle and drinking water from cup. Week 5-6: pressing light switch on and off, turning faucet and putting card in wallet.~Week 7-8: folding towel, brushing teeth and brushing hair. Imagine for 30 sec 2-3 repetitions."
214549893|NCT06944093|BEHAVIORAL|audio book|Listen to a audio book
214700510|NCT03412318|DEVICE|Twisted file|Use of twisted file during cleaning and shaping of root canals
214700511|NCT03412318|DEVICE|Mpro|Use of Mpro during cleaning and shaping of root canals
214700512|NCT04460690|DEVICE|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
214700513|NCT03154632|DEVICE|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
214549894|NCT06944561|DIAGNOSTIC_TEST|Culture and identify Mycobacterium tuberculosis from patient faeces|When faecal samples have been identified only by a pseudo-anonymised label they will be transferred to the designated secure collection point (Vaccine Institute). Professor Tim Bull will then be informed of their availability and will collect and transport to the research laboratory, located in the same building, making a log of all samples received. All samples will then be processed by the research laboratory as defined in the sample processing protocol. Culture result data will be obtained and stored on a secure password protected PC Excel file for collation and archiving by the chief analyst.
214549895|NCT06945393|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
214700514|NCT03154632|DEVICE|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
214700515|NCT01542359|OTHER|Yogic practice|breathing, meditation, physical postures
214700516|NCT01542359|OTHER|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
215029566|NCT04770285|DEVICE|Sham|Sham mobile app was used by the participants as per the schedule specified in the respective arm.
215029567|NCT05943496|DRUG|Acalabrutinib|Given PO
215029568|NCT05943496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215029569|NCT05943496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
215029570|NCT05943496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
215029571|NCT05943496|PROCEDURE|Computed Tomography|Undergo CT scan
215029572|NCT05943496|PROCEDURE|Echocardiography|Undergo ECHO
215029573|NCT05943496|BIOLOGICAL|Obinutuzumab|Given IV
215029574|NCT05943496|OTHER|Questionnaire Administration|Ancillary studies
215029575|NCT05943496|BIOLOGICAL|Tafasitamab|Given IV
215029576|NCT03766399|DRUG|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
215029577|NCT03766399|DRUG|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
215029578|NCT05809583|DRUG|Ozanimod|Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
214549896|NCT06944028|PROCEDURE|Selective excavation|Partial removal of carious dentine, soft carious tissue is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, and a permanent restoration is placed on the tooth.
214700517|NCT00174707|DRUG|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
214700518|NCT00174707|DRUG|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
214700519|NCT00174707|DRUG|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
214549897|NCT06944028|PROCEDURE|Stepwise excavation|Partial removal of carious dentine is performed, soft dentine is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, application of a provisional restoration. After approximately 3-5 months, the provisional restoration is removed, and any remaining carious dentine is further removed until firm dentine is reached. A permanent restoration is then applied.
214549898|NCT06944405|DEVICE|Mechanocardiography|Using mechanocardiography for the detection of signs of heart failure.
214549899|NCT06945211|PROCEDURE|LOW INTENSITY TASK ORIENTED MIRROR THERAPY|"Group A Low Intensity Task Oriented Mirror Therapy will be administered for 2 and half hour per week for 30 min a day, 10 rep five times a week for 8 weeks.~Task-oriented Activities for Group A:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 30 min with 10 reps per day for 8 consecutive weeks."
214549900|NCT06945211|PROCEDURE|High Intensity Task Oriented Mirror Therapy|"Group B High Intensity Task Oriented Mirror Therapy will be administered for 5 hours per week for 60 min a day, 20 rep five times a week for 8 weeeks. The mode of mirror therapy will be unilateral as subjects will perform movement only on unaffected arm.~Task-oriented Activities for Group B:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 60 min with 20 reps per day for 8 consecutive weeks"
214549901|NCT06937463|BEHAVIORAL|Rehabilitation|This is a study on the recovery of physical function in bed patients through a digital rehabilitation exercise system
214549902|NCT06945848|DRUG|Acetazolamide|Acetazolamide will be maintained and weight loss will be recommended
214549903|NCT06945848|DEVICE|Stent (Tentos 4F or Precise ProRX)|Transverse venous sinus will be stented by neuroradiological intervention
214549904|NCT06944431|DEVICE|Continuous Passive Motion (CPM)|Continuous passive motion was applied to the left ankle joint for 60 minutes per day using a motorized CPM device. The therapy was initiated within 48 ho
214549905|NCT06945731|DEVICE|TMS|20 sessions 10 Hz rTMS
214549906|NCT06945731|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS
214549907|NCT06944691|OTHER|Major depressive disorder scale|Pass HDRS to patient taking PrEP to study prevalence of Major Depressive Disorder
214549908|NCT06944730|BEHAVIORAL|Structural Exercise|Multi-joint limb movement with force vector through the spine. The spine is held at neutral position
214549909|NCT06944730|BEHAVIORAL|Isolated Trunk Exercise|Holding the spine in neutral position with no limb movement, with static loading through the spine
214549910|NCT06944730|BEHAVIORAL|Back school|Patient education that has been proven to not be effective and has been used as control in past low back pain intervention studies
214549911|NCT03439475|BIOLOGICAL|AMG 714|
214549912|NCT06940895|DRUG|Sirolimus 0.2%|sirolimus 0.2% gel
214549913|NCT06944574|BEHAVIORAL|Guided online intervention|"The intervention combines a one-hour in-person workshop with a four-week app-based program tailored to elite athletes. The workshop focuses on sleep education and individual motivation setting. Athletes then complete seven self-paced audio modules via the 7-Schläfer app, covering strategies to improve sleep quality. Weekly reminder emails reinforce motivation. Unlike other interventions, this program is fully integrated into the elite sport context, emphasizes behavioral change through personalized goal-setting, and includes no therapist contact, ensuring scalability. No control group is included in this one-arm pre-post design."
214700520|NCT02024893|OTHER|Observational study|"Observation and type of data collected are listged in detail under 'description"
214700521|NCT03870126|OTHER|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
214700522|NCT00242580|DRUG|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
214700523|NCT00242580|DRUG|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
214700524|NCT00242580|DRUG|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
214700525|NCT01232894|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
214700526|NCT01232894|DRUG|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
214700527|NCT02328989|DEVICE|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
214700528|NCT00235339|BEHAVIORAL|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
215161239|NCT04389437|PROCEDURE|Blood pressure measurement|Blood pressure measurement before the ophthalmological exam
215029579|NCT04100993|OTHER|No intervention used|No intervention used
215029580|NCT06445439|DEVICE|Pacing rate of 80 bpm|Pacing rate of 80 bpm
215029581|NCT06445439|DEVICE|Pacing rate of 60 bpm|Pacing rate of 60 bpm
214700529|NCT00235339|BEHAVIORAL|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
214700530|NCT04546386|PROCEDURE|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
214700531|NCT04720586|PROCEDURE|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
214700532|NCT04720586|PROCEDURE|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
214700533|NCT03970395|OTHER|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
215161240|NCT06121492|DRUG|Branched-chain amino acid|In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
215161241|NCT06121492|DRUG|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
215161242|NCT06768671|DRUG|Sonelokimab|Open label
214549914|NCT06944665|DEVICE|Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture theory|Based on the theory of wrist and ankle needles, transcutaneous electrical nerve stimulation is a kind of analgesic treatment device that combines wrist and ankle needles with transcutaneous electrical nerve stimulation, and can be worn on the human wrist and ankle. Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture Theory uses low-frequency electronic pulses to stimulate the entry point of the wrist-ankle needle, which has the advantages of easy to wear, concentration of the treatment site, safety of the treatment, and no needles.
214549915|NCT06945822|OTHER|Blood sample|"For febrile patients with confirmed (group 1) or refuted (group 2) diagnosis of leptospirosis:~\- At D0, D1, D3 and D15 a 20-ml blood sample~For healthy patients (group 3):~\- At D0 and D15: a 20-ml blood sample"
214549916|NCT06945822|OTHER|Urine Sample|For all participants, a 5-ml urine sample at D0
214549917|NCT06945055|BEHAVIORAL|FAMES|225 dyads (family member/support persons and individuals receiving services for psychosis) will be recruited over a period of 30 months. Family member/support persons will be connected to a family peer for a period of 12 weeks who will use the cultural formulated interview to develop rapport and identify unique cultural needs which can inform treatment and resource identification. Participants will receive brief contact, family psychoeducation, and be connected to an online family resource group where they can receive additional support from certified peers and other family member/support persons.
214549918|NCT06945055|BEHAVIORAL|Control|participants will receive 12 weeks of automated communication which contain positive messaging, appointment reminders, links to community resources, and coping skills.
214549919|NCT06945367|BEHAVIORAL|Active Learning-Based Research Methods Course|A four-month educational intervention based on active learning strategies, delivered as part of a Research Methods course for fourth-year undergraduate students in physiotherapy. The intervention included weekly group activities focused on literature retrieval, critical appraisal, oral presentations, peer feedback, and structured formative assessments using rubrics. The aim was to improve beliefs, attitudes, perceived skills, and frequency of use of evidence-based practice.
214549920|NCT06944847|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
214549921|NCT06944847|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
214549922|NCT06944054|OTHER|Group 1|Every 2 hours, the heat probes were replaced. Hypoallergenic patches were removed with a silicone-based spray used in the clinic. The application continued for 24 hours. In total, 12 heat probe displacements were made to different points in the abdominal, chest or lower extremity region. Heat probe stabilising tapes were attached to different points in a clockwise direction. At the end of 24 hours, the skin conditions of the newborns were re-evaluated with scales and recorded. This application continued for 3 days.
214549923|NCT06944587|DRUG|Chemotherapy|The choice of chemotherapy regimen follows national guidelines, preferably mFOLFIRINOX or gemcitabine-nab-paclitaxel.
214549924|NCT06944587|DIAGNOSTIC_TEST|Radiology|PET/CT is optional. PET/CT will be offered as a part of the diagnostic work up at baseline and one additional scan after a minimum of two months of chemotherapy.
214549925|NCT06944587|PROCEDURE|Pancreatectomy|Surgery is scheduled within 4 weeks after the last neoadjuvant infusion. Resection will be performed as a standard or pylorus-preserving pancreatoduodenectomy (PD), distal pancreatectomy (DP) with splenectomy, or total pancreatectomy (TP) with splenectomy, and with or without venous or arterial resection and reconstruction.
214700534|NCT03970395|OTHER|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
214700535|NCT03970395|OTHER|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
215161243|NCT03760523|DRUG|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
214700536|NCT05314218|DEVICE|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~* Exploration procedures for diagnosis alone~* Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
214700537|NCT00062114|BIOLOGICAL|rituximab|
215161244|NCT04934722|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
214549926|NCT06944587|PROCEDURE|Endoscopy|Endoscopic ultrasound fine-needle biopsy to establish the diagnosis with histopathology and to obtain an adequate sample for molecular pathology (KRAS status (mutation or wild type), microsatellite instability (MSI)).
214549927|NCT06945757|OTHER|Physical Exercise|"Patients will participate in the routine rehabilitation program for 12 weeks, consisting of two 1h30 one-to-one sessions per week of physical activity administered by experienced physical therapist. Both sessions of the week are tailored to the need of the individual participant and are typically structured as follow:~* 10 minutes of warming up by light exercises~* 20 minutes of coordination exercises~* 20 minutes of strengths exercises~* 20 minutes of mobility exercises~* 10-15 minutes of cool down and stretching~Patients will further benefit during the 12-weeks program of several individual encounters with a psycho-oncologist, a nurse specialized in cognitive support and a nutritionist. Furthermore, a dietician will conduct an introductory evaluation, several intermediate evaluations and a final evaluation on nutritional status and habits of the patients."
214549928|NCT06944132|PROCEDURE|Excision of the pterygium|The surgical procedure involved excision of the pterygium, including the fibrovascular head and associated conjunctival tissue, followed by bare sclera closure using an autologous conjunctival graft harvested from the superior bulbar conjunctiva. The graft was secured in place using either fibrin glue or 8-0 absorbable sutures. In Group B, 0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
214549929|NCT06944132|DRUG|Post-operative application of CsA|Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.
214549930|NCT06944132|DRUG|Intra-operative application of MMC|0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
214549931|NCT06944769|OTHER|Group A myofascial technique|"Group A with MET (latissimus dorsi), myofascial release (thoracolumbar fascia) and posterior oblique sling strengthening it will be a six-week protocol, with sessions conducted five times a week for 30-40 minutes, focusing on posterior oblique sling activation. Week 1: Myofascial release (thoracolumbar fascia, 60-90 sec), MET (latissimus dorsi, 7-10 sec isometric + 30-sec stretch, 5 reps), glute max strengthening (prone hip extensions, 10-sec holds ×5; bilateral bridges, 5-sec holds ×5).~Week 2: Prone hip extension (3-kg resistance), arm extension (1-kg dumbbell, 5-sec holds ×5), bird-dog (5-sec holds ×10, 1 set).~Weeks 3-4: Prone hip extensions (5-sec holds ×10), single-leg bridges (5-sec holds ×10), twice daily.~Weeks 5-6: Increased intensity to 10-sec holds ×10 reps"
214549932|NCT06944769|OTHER|Group B posterior sling exercises|A six-week conservative protocol, was conducted five times weekly for 30-40 minutes, focuses on core stability exercises. Week 1 includes static stretching of the latissimus dorsi (30-second hold, 3 reps) and prone hip extensions with knee flexed at 90° (5-second hold, 10 reps). By Week 2, bird-dog exercises are introduced (5-second hold, 10 reps per side). In Weeks 3-6, these exercises are maintained to provide a stable baseline for comparison with Group A's more intensive protocol. The latissimus dorsi stretch is performed 2-3 times daily for improved flexibility.
214549933|NCT06944977|BEHAVIORAL|Anticipatory guidance and postnatal home visits|Anticipatory guidance to pregnant women, followed by scheduled home visits at 6, 12, and 18 months
214549934|NCT06944977|BEHAVIORAL|Anticipatory guidance|Postnatal anticipatory guidance
214549935|NCT06944743|PROCEDURE|Transurtheral Resection of prostate ( TURP)|"TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones).~The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria."
214549936|NCT06944210|OTHER|'Rosy Red Valencia' sweet orange|The participants consume 2 'Rosy Red Valencia' sweet oranges daily for 4 weeks
214549937|NCT06944210|OTHER|'Olinda Valencia' sweet oranges|The participants consume 2 'Olinda Valencia' sweet oranges daily for 4 weeks
214549938|NCT06945835|BEHAVIORAL|Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.|Partticipants will be performing supported and unsupported walking, free weights, rowing, cycling, resistance bands, adaptive bikes and body weight exercises.
214549939|NCT06944938|PROCEDURE|Non-Surgical Periodontal Treatment|Participants in this arm received standard non-surgical periodontal treatment, including scaling and root planing, without any additional supplementation or dietary modification.
214549940|NCT06944938|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants in this arm received standard periodontal treatment along with a daily probiotic supplement (1 capsule/day, containing 10⁹ CFU of Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis) for six consecutive weeks.
214700538|NCT00062114|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214700539|NCT00125190|DRUG|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
214700540|NCT04076150|DEVICE|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
214700541|NCT03927508|DRUG|r-tPA|Pulse spray and infusion
214700542|NCT03927508|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
215161245|NCT04934722|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
214549941|NCT06944938|OTHER|Probiotic Supplementation + Personalized Diet|Participants in this arm received standard periodontal treatment, the same probiotic protocol as the probiotic group, and a personalized anti-inflammatory diet. The diet was developed by a clinical dietitian and emphasized high-fiber, antioxidant-rich, and prebiotic foods. Consumption of refined carbohydrates, added sugars, and trans fats was restricted.
214700543|NCT03482323|BEHAVIORAL|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
214700544|NCT03482323|BEHAVIORAL|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
214700545|NCT04257955|BEHAVIORAL|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
214700546|NCT02266186|BEHAVIORAL|Traditional Cognitive behavioural therapy|Therapist supported live therapy
214700547|NCT02266186|BEHAVIORAL|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
214700548|NCT01015482|DRUG|Remifentanil|Remifentanil Infusion
214700549|NCT01015482|DRUG|Midazolam|Midazolam Infusion
214700550|NCT00575952|DRUG|Cisplatin|Given IV or IP
215161246|NCT04934722|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
214700551|NCT00575952|DRUG|Doxorubicin Hydrochloride|Given IV
214700552|NCT00575952|BIOLOGICAL|Filgrastim|Given SC
214700553|NCT00575952|DRUG|Paclitaxel|Given IV or IP
214700554|NCT00575952|BIOLOGICAL|Pegfilgrastim|Given SC
214700555|NCT05198752|DRUG|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
214700556|NCT05595785|BEHAVIORAL|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
214700557|NCT05595785|BEHAVIORAL|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
215161247|NCT04934722|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
215161248|NCT06097143|OTHER|Flowable Giomer|Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.
214700558|NCT01892098|DIETARY_SUPPLEMENT|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
214700559|NCT01892098|DIETARY_SUPPLEMENT|Placebo|Cellulose pill given as placebo
214549942|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
214549943|NCT02726945|OTHER|Placebo|Placebo Control
214549944|NCT06945562|DEVICE|collagen cone (resorbable material used for socket sealing )|The test group include those sites enrolled for placement of immediate dental implant (N=8) with application of collagen cone
214700560|NCT03972124|DRUG|CBD 100 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
214700561|NCT03972124|DRUG|CBD 200 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
214700562|NCT03972124|DRUG|Placebo|Soft-gel capsules containing placebo
214700563|NCT04793386|DIAGNOSTIC_TEST|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
214700564|NCT00813514|GENETIC|VEGF genotyping|blood sample for gene analysis
214700565|NCT02510170|OTHER|no intervention|
214700566|NCT03791359|OTHER|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
214700567|NCT05924906|DRUG|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
214700568|NCT00432952|BEHAVIORAL|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
214700569|NCT00516633|BEHAVIORAL|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
214700570|NCT00127504|DRUG|Rifampin|
214700571|NCT00127504|DRUG|Azithromycin|
214700572|NCT00929734|DRUG|Rosuvastatin|10mg tablets, once daily in three months
214700573|NCT00929734|DRUG|Placebo|1 tablet, once daily in three months
214700574|NCT04073940|BEHAVIORAL|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
214700575|NCT00980980|DRUG|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
215161249|NCT06097143|OTHER|Flowable Nano-filled composite with S-PRG barrier coat|"Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries."
215161250|NCT06097143|OTHER|Flowable Nano-filled composite|Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
214549945|NCT06945562|PROCEDURE|Placement of Immediate Dental Implant Only|Participants will receive placement of an immediate dental implant without any additional material (N=8).
214549946|NCT06950840|DRUG|Acetaminophen|Acetaminophen 1 g IV once
214549947|NCT06950840|DRUG|dipyrone|Dipyrone IV 1 g once
214549948|NCT06950944|DEVICE|Theranova 500|Participants will dialysis by Theranova 500 dialyzer during study period, the dialyzer will reprocessing with standard hospital protocol and dialyzer will check before use in dialysis session.
214549949|NCT06949982|COMBINATION_PRODUCT|experimental group x-MAP|hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.
214549950|NCT06949982|DRUG|Regorafenib (BAY 73-4506)|Regorafenib 160 mg PO daily on days 1-21, every 28 days OR 1st cycle: Regorafenib 80 mg PO daily on days 1-7, followed by 120 mg PO daily on days 8-14, followed by 160 mg PO daily on days 15-21, every 28 days, 2nd and subsequent cycles: Regorafenib 160 mg PO daily on days 1-21, every 28 days
214549951|NCT06950008|OTHER|Educational Intervention|Receive links to informational websites
214549952|NCT06950008|BEHAVIORAL|Patient Navigation|Receive patient navigator phone calls
214549953|NCT06950008|OTHER|Survey Administration|Ancillary studies
214549954|NCT06950008|BEHAVIORAL|Telephone-Based Intervention|Receive patient navigator phone calls
214549955|NCT06261619|DEVICE|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
214549956|NCT05363189|PROCEDURE|Venous augmentation|Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
214549957|NCT05363189|PROCEDURE|Traditional ERAS (enhanced recovery after surgery) protocol|Pre-, peri-, and post-operative care as described in the ERAS protocol
214549958|NCT05363189|PROCEDURE|Sahlgrenska recovery protocol|Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
214549959|NCT05363189|PROCEDURE|No venous augmentation|Traditional deep inferior epigastric artery perforator flap (DIEP)
214549960|NCT03728985|DEVICE|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
214549961|NCT03778502|DRUG|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
214549962|NCT01882413|OTHER|No intervention|No intervention
214700576|NCT03172520|DEVICE|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
215161251|NCT06474871|DEVICE|Khymeia®-Virtual Reality rehabilitation System (VRRS EVO SYSTEM or COMPACT VRRS ENGINE)|fully immersive VR software created by clinicians and experts specialized in cognitive rehabilitation. Khymeia Devices are Medical Class 1 devices according to MDR. VRRS systems consist of a central process unit, complete with a capacitive touch screen LCD monitor.
214549963|NCT00243906|DRUG|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
214549964|NCT00243906|PROCEDURE|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS \>/= 10) treated within 3 hours of symptoms onset.
214549965|NCT00269906|DRUG|Abciximab|
214549966|NCT00269906|DRUG|Placebo|
214549967|NCT06051110|DEVICE|Combined risk score|Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
214549968|NCT06051110|OTHER|Usual care|Prehospital risk stratification by EMS protocols
214549969|NCT06051110|DEVICE|point-of-care troponin|Prehospital risk stratification by the use of a POC-troponin
214549970|NCT01895790|DEVICE|Pancreatic Duct Stent Placement|
215161252|NCT06474871|BEHAVIORAL|Traditional cognitive training (TCT)|face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits
215161253|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
215161254|NCT04174924|PROCEDURE|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
215161255|NCT05778071|COMBINATION_PRODUCT|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
215161256|NCT05778071|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
215161257|NCT05704829|DRUG|Trastuzumab deruxtecan|T-DXd i.v.
215161258|NCT05704829|DRUG|Standard-of-Care|Chemotherapy+T+P
215161259|NCT04229979|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
215161260|NCT04229979|DRUG|Azacitidine|injection
215161261|NCT04229979|DRUG|Venetoclax|tablet
215161262|NCT04229979|DRUG|Decitabine|injection
215161263|NCT04229979|DRUG|Cytarabine|injection
214549971|NCT01442922|OTHER|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
214549972|NCT01442922|OTHER|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
214549973|NCT00554996|DEVICE|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
214549974|NCT01606371|DRUG|Placebo|Administered orally
214549975|NCT01606371|DRUG|LY2409021|Administered orally
214549976|NCT06044246|BIOLOGICAL|PRF membrane|Placing implant with PRF membrane treatment
214549977|NCT02796768|OTHER|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
214549978|NCT02796768|OTHER|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
214549979|NCT00785837|OTHER|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
214549980|NCT00000416|OTHER|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
214549981|NCT02560753|DRUG|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
214549982|NCT05835271|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
214549983|NCT03944642|BEHAVIORAL|Breastfeeding support|Breastfeeding self-efficacy enhancing through professional support
214549984|NCT03795857|BEHAVIORAL|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
214549985|NCT02881372|OTHER|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
214549986|NCT04358432|DRUG|AK102|Administered by subcutaneous injection
214549987|NCT04358432|DRUG|Placebos|Administered by subcutaneous injection
214549988|NCT04358432|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
214549989|NCT03587337|OTHER|POEM|Pt. are going to submit a POEM procedure.
214549990|NCT02820545|OTHER|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
214549991|NCT02820545|OTHER|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
214549992|NCT02344589|DRUG|Lidocaine|used for the active blocks
214549993|NCT02344589|DRUG|Saline|used for the placebo-block
214549994|NCT03501810|DEVICE|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
214549995|NCT00502268|DRUG|Doxercalciferol administration|Doxercalciferol administration
214549996|NCT00502268|DRUG|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
214549997|NCT04879212|OTHER|PCIA +Acupuncture group:|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6)
214549998|NCT02172911|BIOLOGICAL|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
214549999|NCT02172911|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
214550000|NCT05641116|OTHER|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
214550001|NCT05641116|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
214550002|NCT05995509|PROCEDURE|Micro-osteo-perforations|small perforations drilled in Alveolar bone, adjacent to site of tooth movement.
214550003|NCT02567851|DRUG|Brentuximab Vedotin|Monoclonal antibody drug conjugate
214550004|NCT03313492|BEHAVIORAL|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~1. A mobile version of the site~2. Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~3. Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
214550005|NCT03313492|BEHAVIORAL|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
214550006|NCT03313492|BEHAVIORAL|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
214550007|NCT01682551|DRUG|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
214550008|NCT01682551|DRUG|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
214550009|NCT03640572|DIAGNOSTIC_TEST|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
214550010|NCT02614378|PROCEDURE|air insufflation|modulated air insufflation of the ear canal
214550011|NCT02614378|PROCEDURE|placebo|no air will be introduced in the ear canal
214550012|NCT04211311|OTHER|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
214550013|NCT02622399|BEHAVIORAL|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
214550014|NCT01037426|OTHER|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information"
214550015|NCT05992896|DRUG|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
214550016|NCT05992896|DRUG|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
214550017|NCT00580489|DRUG|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
214550018|NCT02559427|OTHER|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
214550019|NCT02559427|OTHER|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
214550020|NCT05022537|DEVICE|retrograde nephrostomy|this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
214550021|NCT05022537|DEVICE|antegrade nephrostomy|this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
214550022|NCT01606319|DRUG|Acetaminophen|15 mg/kg every 6 hours as needed
214550023|NCT01606319|DRUG|Ibuprofen|9.4 mg/kg every 6 hours as needed
214550024|NCT05692869|DRUG|Propranolol|Administered orally.
214550025|NCT05692869|DRUG|Pseudoephedrine|Administered orally.
214550026|NCT05692869|DEVICE|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
214550027|NCT05692869|OTHER|No Intervention|No intervention during this period (Control Period)
214550028|NCT00966563|DRUG|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
214550029|NCT00966563|DRUG|Placebo|
215161264|NCT04229979|OTHER|Observation|palliative management
214550030|NCT01449786|DRUG|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
214550031|NCT01449786|DRUG|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
215161265|NCT04229979|BIOLOGICAL|GM-CSF|subcutaneous injection
214700577|NCT03172520|DEVICE|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
214700578|NCT00135486|BIOLOGICAL|MenC-TT|
214700579|NCT00135486|BIOLOGICAL|Hib-MenC-TT|
214700580|NCT06011746|DRUG|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
214700581|NCT06011746|DRUG|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
214700582|NCT02410850|DEVICE|Oral Appliance|Mandibular Advancement Splints
214700583|NCT06473285|DRUG|Drug: Esketamine (Continuous infusion)|Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.
214700584|NCT01912937|DEVICE|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
214700585|NCT03218982|BEHAVIORAL|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
214700586|NCT02237976|BEHAVIORAL|Self-hypnosis|
214700587|NCT02237976|BEHAVIORAL|Routine practice|
214700588|NCT00740168|DRUG|bevacizumab treatment|single infusion 10 mg/kg
214700589|NCT03227562|DRUG|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
214700590|NCT00414960|DRUG|Enzastaurin|500 mg po QD for 6 months
214700591|NCT00414960|DRUG|Placebo|po QD for 6 months
215161266|NCT04229979|OTHER|Montanide|adjuvant
214700592|NCT05346601|DRUG|Chiauranib|50mg po only once
214700593|NCT04897282|DIAGNOSTIC_TEST|UCRI|Biomarker panel and algorithm
214700594|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
215161267|NCT04512144|BEHAVIORAL|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
214700595|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
214700596|NCT01062594|OTHER|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
215161268|NCT02720445|DRUG|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
214700597|NCT01062594|OTHER|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
214700598|NCT01062594|OTHER|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
214700599|NCT02675894|DEVICE|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
214550032|NCT01449786|OTHER|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
214550033|NCT05639452|OTHER|Data collection for developing an algorithm for an Early Warning Score|Data collection of patient parameters (heart rate, respiratory rate, clinical outcomes (death, transfer to intensive care unit, adverse events like sepsis, infection, heart attack))
214700600|NCT02675894|DEVICE|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
214700601|NCT03768791|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
215161269|NCT02720445|DRUG|Placebo Patch|Matching placebo patches worn during waking hours.
214550034|NCT06378723|OTHER|Balance Tests|With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured
214550035|NCT03608059|DRUG|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
214550036|NCT03608059|DRUG|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
215161270|NCT05035030|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
215161271|NCT04472949|DRUG|Durvalumab|Durvalumab: 1500 mg iv
215161272|NCT04472949|DRUG|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
215161273|NCT04472949|DRUG|etoposide|Etoposide: 100 mg/m2 iv
215161274|NCT04472949|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
215161275|NCT04554277|BIOLOGICAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
214550037|NCT03608059|DRUG|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
214550038|NCT04646369|BEHAVIORAL|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
214550039|NCT04646369|BEHAVIORAL|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
214550040|NCT04646369|BEHAVIORAL|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
214550041|NCT00620269|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
214550042|NCT00620269|DRUG|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
214550043|NCT00620269|DRUG|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 \& 8 every 3 weeks X 2 cycles
214550044|NCT00620269|RADIATION|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
214550045|NCT01124097|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
214550046|NCT01124097|DRUG|Placebo|Tablets will be used.
214550047|NCT01782521|PROCEDURE|No primer|Primer not used when bonding orthodontic brackets
214550048|NCT01748305|BEHAVIORAL|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
214550049|NCT01754415|DEVICE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
214550050|NCT01821937|DRUG|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
214550051|NCT01821937|DRUG|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
214550052|NCT03193463|DRUG|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
214550053|NCT03193463|DRUG|Topotecan (>8cc)|In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
214550054|NCT03193463|DEVICE|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
214550055|NCT03193463|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
214550056|NCT03193463|DRUG|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
214550057|NCT01139788|DRUG|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
214550058|NCT05772143|PROCEDURE|Percutaneous discectomies under CT|Percutaneous discectomies under CT guidance to treat lumbar disc herniations resistant to conservative treatment and nerve root infiltrations.
214700602|NCT03768791|OTHER|SCS is switched on|Spinal cord stimulator is on
214550059|NCT01795599|DRUG|Mifegyne ®|
214550060|NCT01795599|DRUG|Gymiso®|
214550061|NCT05344677|OTHER|Trendelenburg Position|Group 1 (trendlenburg position group) in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period.
214550062|NCT05344677|OTHER|Warm Pad Application|• Group 2 (warm pad application group) in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
214550063|NCT05344677|BEHAVIORAL|Deep Breathing Exercise|• Group 3: (deep breathing group) the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers.
214550064|NCT02153905|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
214700603|NCT03164226|DEVICE|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
214550065|NCT02153905|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
214550066|NCT02153905|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
214550067|NCT02153905|BIOLOGICAL|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
214700604|NCT01763281|DRUG|CRH|
214700605|NCT01763281|DRUG|Placebo|
214700606|NCT05881772|OTHER|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
214700607|NCT05855317|OTHER|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
214550068|NCT04455022|OTHER|Bedside blood culture bottles weighing combined with educational interventions.|Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
214550069|NCT01717079|PROCEDURE|Sham rTMS|120 pulses 0.2Hz
214550070|NCT01717079|PROCEDURE|rTMS|120 pulses 0.2Hz
214550071|NCT00193479|DRUG|Cyclophosphamide|Cyclophosphamide
214700608|NCT05691634|PROCEDURE|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
214700609|NCT05691634|OTHER|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
214700610|NCT00058734|BIOLOGICAL|Dendritic Cells Pulsed with HIV antigens|
214700611|NCT03745196|DRUG|PC945|Study drug under investigation
214700612|NCT03745196|DRUG|Placebo|Placebo control
214700613|NCT01412658|DIETARY_SUPPLEMENT|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
214700614|NCT01412658|DIETARY_SUPPLEMENT|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
214700615|NCT04863014|DRUG|evinacumab|Intravenous infusion every 4 weeks (Q4W)
214700616|NCT04863014|OTHER|Placebo|Intravenous infusion Q4W
214700617|NCT01473810|BIOLOGICAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
214700618|NCT01473810|BIOLOGICAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
214700619|NCT01473810|BIOLOGICAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
214700620|NCT01473810|BIOLOGICAL|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
214700621|NCT05180110|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
214700622|NCT05180110|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
214700623|NCT06430112|DRUG|Liposomal Bupivacaine|After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
214700624|NCT06430112|DRUG|Ropivacaine|Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
214700625|NCT00832546|DRUG|Placebo|
214700626|NCT00832546|DRUG|Oral NGX426 (Powder in solution)|
214700627|NCT01683110|DRUG|cabozantinib|
214700628|NCT03464123|OTHER|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
214700629|NCT02602938|DRUG|Aspirin|Take aspirin (100mg) orally once a day for 2 months
214700630|NCT04301921|OTHER|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
214700631|NCT04301921|OTHER|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
214700632|NCT02223455|OTHER|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
214550072|NCT00193479|DRUG|Mitoxantrone|Mitoxantrone
214550073|NCT00193479|DRUG|Vincristine|Vincristine
214550074|NCT00193479|DRUG|Prednisone|Prednisone
214550075|NCT00193479|DRUG|Rituximab|Rituximab
214550076|NCT01862497|DRUG|Carvedilol vs. Prazosin|
214550077|NCT02784743|DRUG|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
214550078|NCT04830189|DEVICE|shoulder sling|Patients were used shoulder slings
214700633|NCT04423614|OTHER|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
214550079|NCT04830189|DEVICE|forearm sling|Patients were used forearm slings
214550080|NCT03685682|BIOLOGICAL|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
214550081|NCT00867698|DRUG|AST-120|AST-120
214550082|NCT04541368|DRUG|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
214550083|NCT03667118|DIETARY_SUPPLEMENT|Food Supplement|A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
214550084|NCT01304498|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
214550085|NCT01304498|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
214550086|NCT00894504|DRUG|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
215161276|NCT06798649|OTHER|The intervention in the GESTACOR study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs).|"This is aimed at assessing whether such feedback can encourage the adoption of healthier lifestyles and enhance adherence to preventive treatments, thereby potentially reducing the incidence of postpartum hypertension and other cardiovascular diseases.~Components of the Intervention:~Vascular Imaging:~Women in the intervention group undergo advanced vascular imaging using ultrasound technology to detect the presence of arterial plaques vs. no information about vascular images in the standard manag group.~The images are analyzed to assess the extent of vascular health, focusing on areas typically affected by cardiovascular risks such as the carotid arteries.~Feedback Delivery:~Detailed results from the vascular imaging are provided to the participants in a comprehensible format by healthcare professionals specialized in cardiovascular health.~This feedback session includes a thorough explanation of the findings, highlighting areas of concern and potential risks."
215161277|NCT02843165|DRUG|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
215161278|NCT02843165|RADIATION|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
215161279|NCT06161532|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
215161280|NCT06161532|DRUG|Atezolizumab|Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
215161281|NCT02982694|DRUG|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
215161282|NCT02982694|DRUG|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
214550087|NCT00894504|DRUG|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
214550088|NCT00894504|DRUG|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
214550089|NCT04706858|DIETARY_SUPPLEMENT|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
214550090|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
214550091|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
214550092|NCT00259571|DRUG|retarded release phosphatidylcholine|2g daily, given orally QTD
214550093|NCT01834586|DRUG|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
214550094|NCT00219245|DRUG|Rivastigmine|
214550095|NCT00168493|DRUG|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
214550096|NCT00440245|DRUG|salbutamol|200 micrograms salbutamol from MDI
214550097|NCT04867109|OTHER|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
214550098|NCT04867109|DIAGNOSTIC_TEST|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
214550099|NCT02722811|DRUG|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
214550100|NCT02722811|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
214550101|NCT04537598|PROCEDURE|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
214550102|NCT04537598|PROCEDURE|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
214550103|NCT04041830|BEHAVIORAL|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
214550104|NCT04041830|BEHAVIORAL|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
214550105|NCT01667549|OTHER|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
214550106|NCT00375622|DRUG|Tamoxifen|
215161283|NCT06790966|COMBINATION_PRODUCT|Combination Treatment of PDS0101 and Pembrolizumab|"* Pembrolizumab (IV) every 3 weeks for up to 35 Cycles~* PDS0101 (SC) during Cycles 1, 2, 3, 4, and 12"
215161284|NCT06790966|DRUG|Pembrolizumab Monotherapy|Pembrolizumab (IV) every 3 weeks for up to 35 cycles.
215161285|NCT05262855|DRUG|[68Ga]FAPI-46|\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
214550107|NCT02552459|DRUG|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
214550108|NCT02552459|DRUG|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
214550109|NCT02552459|DRUG|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
214550110|NCT02552459|DRUG|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
214550111|NCT04155970|OTHER|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
214550112|NCT04155970|OTHER|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
214550113|NCT02637102|OTHER|Not applicable - observational study|
214550114|NCT01883284|OTHER|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
214700634|NCT04423614|OTHER|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
214700635|NCT03817255|OTHER|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
214700636|NCT03817255|OTHER|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
214700637|NCT02408055|DRUG|TA-8995|
214550115|NCT05790525|DRUG|Standard bismuth quadruple|Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
214550116|NCT03174665|OTHER|No intervention|
214550117|NCT04210843|DRUG|Ligelizumab|"For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.~Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.~The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period."
214550118|NCT01749098|DRUG|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
214550119|NCT01749098|DRUG|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
214550120|NCT01749098|DRUG|Placebo|Placebo capsule orally administered on Days 1 - 5
214700638|NCT01321502|DRUG|famciclovir|500 mg tablet
214700639|NCT02137590|DIETARY_SUPPLEMENT|Spanish Black Radish product|
214700640|NCT01948284|PROCEDURE|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
214700641|NCT01948284|PROCEDURE|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
214700642|NCT01948284|DEVICE|Suction Unit|
215161286|NCT05564247|BEHAVIORAL|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
215161287|NCT06785948|DEVICE|active-tDCS|"2mA stimulation (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
214550121|NCT01749098|DRUG|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
214550122|NCT02844777|DRUG|Placebo|200 mg applied once-daily for 28 days
214550123|NCT02844777|DRUG|5% VDA-1102|200 mg applied once-daily for 28 days
214550124|NCT02844777|DRUG|10% VDA-1102|200 mg applied once-daily for 28 days
214550125|NCT00150618|DRUG|SPD503 (1 mg)|
214550126|NCT00150618|DRUG|SPD503 (2 mg)|
214550127|NCT00150618|DRUG|SPD503 (3 mg)|
214550128|NCT00150618|DRUG|SPD503 (4 mg)|
214550129|NCT00150618|DRUG|Placebo|
214550130|NCT03758495|OTHER|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
214550131|NCT00609401|DRUG|Nexavar (Sorafenib)|400 mg bid
214550132|NCT00609401|DRUG|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
214550133|NCT01132469|PROCEDURE|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
214700643|NCT06015802|OTHER|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
214700644|NCT01889966|DRUG|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
214700645|NCT00632190|OTHER|fluorophotometry|
214700646|NCT00632190|PROCEDURE|colposcopic biopsy|
214700647|NCT00632190|PROCEDURE|colposcopy|
214700648|NCT00632190|PROCEDURE|light-scattering spectroscopy|
214700649|NCT03386656|DRUG|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
214700650|NCT03386656|OTHER|Saline Solution|Placebo
215161288|NCT06785948|DEVICE|Sham-tDCS|"No intensity applied (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
214550134|NCT00663637|DEVICE|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
214550135|NCT03214445|PROCEDURE|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
214550136|NCT03214445|PROCEDURE|Sealing margins with seal|Seal the margin of restoration with sealant without filler
214550137|NCT04748536|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
214550138|NCT04748536|DRUG|Placebo|Matching placebo for IRL201104
214550139|NCT00947323|DRUG|Simvastatin|simvastatin 20 daily for six months.
214550140|NCT00947323|DRUG|Placebo|
214550141|NCT03993275|DEVICE|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
214550142|NCT05336175|DRUG|Angiotensin 1-7|"A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
214550143|NCT05336175|DRUG|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
214550144|NCT01012947|BEHAVIORAL|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
214550145|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
214550146|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
214550147|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
214550148|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
214550149|NCT01078961|DRUG|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
214550150|NCT01078961|DRUG|sorafenib|400mg taken orally twice a day
214550151|NCT00382447|DEVICE|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
214550152|NCT00382447|DEVICE|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
214550153|NCT04344951|DRUG|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
214550154|NCT01791413|DRUG|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
214550155|NCT04711083|DIAGNOSTIC_TEST|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of \> 4%), the percentage of oximetry sleep time spent with a SpO2 of \< 90%, and the total oximetry time. Recordings were classified as normal (\< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (\> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
214550156|NCT06129032|PROCEDURE|Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation|"a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision"
214550157|NCT06129032|PROCEDURE|Group QUADRATUS LUMBORUM BLOCK (QLB)|quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
215161289|NCT06145373|DRUG|Fitusiran (SAR439774)|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
215161290|NCT06145373|BIOLOGICAL|Clotting factor concentrates (CFC) or bypassing agents (BPA)|Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
215161291|NCT06145373|BIOLOGICAL|Antithrombin concentrate (ATIIIC)|Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
215161292|NCT06145373|BIOLOGICAL|Emicizumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
215161293|NCT06784752|RADIATION|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)
215161294|NCT06784752|DRUG|Octreotide LAR|"Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W."
215161295|NCT04967833|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
215161296|NCT03770390|PROCEDURE|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
215161297|NCT04840589|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214700651|NCT01155648|DEVICE|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
214700652|NCT01155648|DEVICE|Chest wall compression for ten minutes in chest|
214700653|NCT01611129|BEHAVIORAL|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
214700654|NCT02515617|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
215161298|NCT04840589|PROCEDURE|Biopsy Procedure|Undergo a biopsy
215161299|NCT04840589|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161300|NCT04840589|PROCEDURE|Computed Tomography|Undergo a CT scan
215161301|NCT04840589|BIOLOGICAL|Ipilimumab|Given IV
215161302|NCT04840589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161303|NCT04840589|BIOLOGICAL|Nivolumab|Given IV
215161304|NCT04840589|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
215161305|NCT04840589|PROCEDURE|X-Ray Imaging|Undergo x-ray
214550158|NCT05693077|BIOLOGICAL|10E4 NTCD spores|in capsule for oral ingestion.
214550159|NCT05693077|BIOLOGICAL|10E7 NTCD spores|in capsule for oral ingestion.
214550160|NCT05693077|OTHER|placebo|in capsule for oral ingestion.
214550161|NCT05693077|DRUG|Vancomycin Oral Capsule|4 times a day 250mg
215161306|NCT06456463|DRUG|Tagraxofusp|Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.
214550162|NCT01566097|DEVICE|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~1. Information on the risk of continued smoking and benefits of cessation~2. Messages that address common misbeliefs regarding smoking cessation services and medications~3. Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~1. Behavioral only~2. Nicotine replacement therapy~3. Bupropion~4. Varenicline"
214550163|NCT03294824|OTHER|blood sample|peripheral blood samples are collected
214550164|NCT00855413|DRUG|Darunavir|800 mg orally once daily
214550165|NCT00855413|DRUG|Ritonavir|100 mg orally once daily
214550166|NCT00855413|DRUG|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
214550167|NCT00825305|BIOLOGICAL|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
214550168|NCT00825305|BIOLOGICAL|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
214550169|NCT04016272|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
214550170|NCT04016272|DEVICE|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
215161307|NCT06456463|DRUG|Venetoclax|Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.
215161308|NCT06456463|DRUG|Azacitidine|Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
215161309|NCT04305431|BEHAVIORAL|Cooking Intervention|90-minute culinary education sessions.
215161310|NCT06395129|DEVICE|Low dead-space syringes/needles|LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.
214550171|NCT00004251|DRUG|letrozole|2.5 mg of letrozole per day
214550172|NCT03617289|DRUG|Magnesium Sulfate|
214550173|NCT03617289|DRUG|D5W|
214550174|NCT03190512|OTHER|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
214550175|NCT05143164|DEVICE|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
214550176|NCT05143164|DRUG|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
214550177|NCT02493946|BIOLOGICAL|Botulinum toxin type A|
214550178|NCT02493946|DRUG|Placebo|
214550179|NCT00003664|BIOLOGICAL|aldesleukin|
214550180|NCT00003664|BIOLOGICAL|recombinant interferon alfa|
214550181|NCT00003664|DRUG|fluorouracil|
214550182|NCT00003664|DRUG|gemcitabine hydrochloride|
214550183|NCT00435747|DRUG|PARECOXIB SODIUM|
215161311|NCT06395129|DEVICE|Hepatitis C Antibody Rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
215161312|NCT06395129|DEVICE|HIV rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
215161313|NCT06202144|DEVICE|Noninvasive support|Noninvasive respiratory support delivered through a helmet
215161314|NCT03687723|DEVICE|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
214550184|NCT03272737|PROCEDURE|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study \[37\]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
214550185|NCT03272737|PROCEDURE|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of \< 0.,9 m/s (Guralnik, 1994).
214550186|NCT03272737|DEVICE|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
214550187|NCT03272737|DEVICE|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity \[33\]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ \* distance travelled by the pulse wave (m) / transit time(s)."
214550188|NCT03272737|DEVICE|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
214550189|NCT03272737|DEVICE|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
214550190|NCT03272737|DEVICE|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
214550191|NCT03272737|DIAGNOSTIC_TEST|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
214550192|NCT03272737|OTHER|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
214550193|NCT03473210|DRUG|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
214550194|NCT03473210|DRUG|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
214550195|NCT03473210|PROCEDURE|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
214550196|NCT03783676|DRUG|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
214550197|NCT03783676|DRUG|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
214550198|NCT01239784|BEHAVIORAL|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
215161315|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
215161316|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
215161317|NCT03173937|BIOLOGICAL|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn(TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn(TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
215161318|NCT03173937|DEVICE|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
215161319|NCT04984356|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
215161320|NCT04926818|DRUG|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
215161321|NCT04926818|DRUG|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
214700655|NCT02515617|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
214700656|NCT04633473|BEHAVIORAL|SIB-Time Web-Application Tool|Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
215161322|NCT04926818|DRUG|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
215161323|NCT04926818|OTHER|Fingolimod placebo|Fingolimod matching placebo capsule
215161324|NCT04926818|OTHER|Siponimod placebo|Siponimod matching placebo tablet
215161325|NCT04926818|OTHER|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
214550199|NCT01244165|DEVICE|Cytrix|
214550200|NCT01244165|OTHER|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
214550201|NCT03355209|DRUG|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
214550202|NCT03355209|DRUG|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
214550203|NCT03747406|PROCEDURE|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
214550204|NCT03747406|PROCEDURE|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
214550205|NCT00431613|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
214550206|NCT00431613|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
214550207|NCT00431613|DRUG|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
214550208|NCT00431613|RADIATION|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
214550209|NCT00431613|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
214700657|NCT05637723|OTHER|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
215161326|NCT05059210|BEHAVIORAL|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
215161327|NCT06072170|DRUG|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
214550210|NCT03135990|BEHAVIORAL|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
214550211|NCT05000047|DEVICE|3D ear scanner|A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.
215161328|NCT06072170|DRUG|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
215161329|NCT04438525|DIAGNOSTIC_TEST|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
215161330|NCT04438525|OTHER|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
214700658|NCT05637723|OTHER|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
214700659|NCT00211718|DRUG|intra-articular botulinum toxin type a|
214700660|NCT04378920|DRUG|LEAF-4L6715|LEAF-4L6715
215161331|NCT05440643|BIOLOGICAL|Peanut SLIT-tablet|Peanut extract
215161332|NCT05440643|OTHER|Placebo|Placebo
215161333|NCT06797089|DEVICE|Oral appliance therapy plus scaling and root planing on left or right of mouth|This device opens the upper airway by bringing the mandible forward to improve breathing during sleep. The mouth shield minimizes mouth breathing to optimize salivary function. Scaling and root planing (deep cleaning of all teeth requiring it).
214700661|NCT02421744|BEHAVIORAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
214550212|NCT05000047|OTHER|Conventional silicon ear impressions|A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
214550213|NCT05776290|BIOLOGICAL|Hyaluronic Acid|This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
214700662|NCT02421744|BEHAVIORAL|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
214550214|NCT05329168|DRUG|Tonabacase (LSVT-1701)|4.5 or 6.0 mg/kg IV once daily for 4 days
214700663|NCT00511524|DRUG|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
214700664|NCT00511524|DRUG|[carbonyl-^11C]GW842166|\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
214700665|NCT00815906|DRUG|SBI-087|IV, Single dose
214700666|NCT00815906|DRUG|SBI-087|IV, Single dose
214700667|NCT00815906|DRUG|SBI-087|SC, Single dose
214700668|NCT00815906|DRUG|SBI-087|SC, Single dose
214550215|NCT02445651|DIETARY_SUPPLEMENT|Intravenous and Oral n-acetyl cysteine|
214550216|NCT04855045|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
214550217|NCT03544294|DEVICE|Xience alpine, ultimaster, resolute onyx, synergy|PCI will be performed
214550218|NCT01583504|PROCEDURE|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
214550219|NCT01583504|PROCEDURE|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
214550220|NCT01583504|BEHAVIORAL|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
214550221|NCT03452215|BEHAVIORAL|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
214550222|NCT03452215|BEHAVIORAL|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
214550223|NCT01075477|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
214550224|NCT00160277|DRUG|Moxonidine|
214550225|NCT00508209|DRUG|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
214550226|NCT05822492|PROCEDURE|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
214550227|NCT05822492|PROCEDURE|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
214700669|NCT05291949|DEVICE|ATLASense RAPHAEL PolyMonitor|All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
214700670|NCT05255913|DRUG|Nanosilver|preventive material for arresting caries
214700671|NCT05255913|DRUG|Silver diamine fluoride|preventive material for arresting caries
214700672|NCT00264849|DRUG|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
214700673|NCT00264849|OTHER|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
214700674|NCT01757613|DRUG|AK 3012|cutaneous use twice a day
214700675|NCT04679259|DIAGNOSTIC_TEST|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
215161334|NCT05406414|BEHAVIORAL|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems"
215161335|NCT05406414|BEHAVIORAL|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
215161336|NCT06795412|DRUG|PYX-201|Intravenous (IV) infusion.
215161337|NCT06795412|DRUG|pembrolizumab|IV infusion.
215161338|NCT06792708|DRUG|LUMRYZ|Prescribed for narcolepsy in accordance with product label.
215161339|NCT05413304|DRUG|pre-operative abemaciclib|pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
215161340|NCT05413304|DEVICE|Device for Cerebral Fluid Dialysate Collection|post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
215161341|NCT05413304|DEVICE|Ashion Analytics GEM ExTra|resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
215161342|NCT05413304|DRUG|abemaciclib + temozolomide|abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
215161343|NCT05265624|BEHAVIORAL|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
214550228|NCT05822492|OTHER|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
214700676|NCT04679259|DIAGNOSTIC_TEST|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
214700677|NCT04679259|DIAGNOSTIC_TEST|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
215161344|NCT05265624|BEHAVIORAL|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
215161345|NCT03995966|BEHAVIORAL|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
215161346|NCT03995966|BEHAVIORAL|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
215161347|NCT06840002|DRUG|SHR-A1811|SHR-A1811.
215161348|NCT06840002|DRUG|Carboplatin|Carboplatin.
215161349|NCT06840002|DRUG|Bevacizumab|Bevacizumab.
215161350|NCT06840002|DRUG|Oxaliplatin for Injection|Oxaliplatin for injection.
215161351|NCT06840002|DRUG|Paclitaxel injection|Paclitaxel injection.
215161352|NCT06840002|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injetction.
215161353|NCT06840002|DRUG|Adebrelimab Injection|Adebrelimab injection.
214700678|NCT05618899|OTHER|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
215161354|NCT06958835|DRUG|Linezolid 600 mg|linezolid 600 mg tablets (twice a day for 5 days)
215161355|NCT06958835|DRUG|Placebo|Placebo tablets (twice a day for 5 days)
215161356|NCT04147884|DEVICE|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
215161357|NCT06690775|DRUG|TORL-1-23|2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
215161358|NCT06690775|DRUG|TORL-1-23|3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
214550229|NCT01727505|DEVICE|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
214550230|NCT01727505|DEVICE|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
214550231|NCT02847390|OTHER|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
214550232|NCT02878603|BIOLOGICAL|Caplacizumab|
214550233|NCT02878603|OTHER|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
214550234|NCT00866489|PROCEDURE|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
214550235|NCT01551368|DRUG|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
214550236|NCT01551368|DRUG|Placebo|Identical inactive tablets.
214550237|NCT05010876|DRUG|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
214550238|NCT05010876|DRUG|Icatibant Injection|a single injection of 30 mg subcutaneously
214550239|NCT05010876|OTHER|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
214550240|NCT01543542|RADIATION|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
214550241|NCT02469155|DRUG|ITI-007|
214550242|NCT02469155|DRUG|Risperidone|
214550243|NCT02469155|DRUG|Placebo|
214550244|NCT00004077|DRUG|cisplatin|
214550245|NCT00004077|DRUG|ifosfamide|
214550246|NCT00004077|DRUG|paclitaxel|
214550247|NCT03202680|OTHER|USDA Style Diet|USDA style healthy diet, low in saturated fats.
214550248|NCT03202680|OTHER|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
214550249|NCT04969705|DRUG|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
214550250|NCT04557358|OTHER|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
215161359|NCT06690775|DRUG|TORL-1-23|3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
215161360|NCT06690775|DRUG|Pegfilgrastim (drug)|6.0 mg subcutaneous injection on Day 4 of each cycle.
215161361|NCT05809752|BIOLOGICAL|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
215161362|NCT06840015|DEVICE|Airpod Pro as hearing assistive technology|All participants will use and evaluate four types of assistive technology: hearing aids, Airpod pro 2nd and 3rd generation, dedicated wireless remote microphones, and Smartphone wireless remote microphone.
214550251|NCT04557358|OTHER|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
214550252|NCT04557358|OTHER|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
214550253|NCT04557358|OTHER|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
214700679|NCT05618899|OTHER|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
214700680|NCT01621152|OTHER|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
214700681|NCT01621152|OTHER|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
214700682|NCT05197673|BEHAVIORAL|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
214700683|NCT05392894|PROCEDURE|Haploidentical stem cell transplantation|Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
214700684|NCT05392894|OTHER|Standard medical care|Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
215161363|NCT04064983|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
215161364|NCT06840171|OTHER|Mandala coloring|Mandala group will participate in 8 sessions of mandala application. Mandala Coloring Application will be applied to the Intervention group 2-3 times a week for 3 weeks. Mandala application will be done by the researcher and feedback about the mandala will be received from the patients at the end of each session. Data collection forms will be applied before the mandala painting application starts and after the mandala painting application ends (after the 8th session).
215161365|NCT06287463|DRUG|DCC-3084|Administered orally
215161366|NCT06039579|DRUG|VH4004280|VH4004280 was administered as tablets orally at Day 1.
215161367|NCT06039579|DRUG|VH4011499|VH4011499 was administered as tablets orally at Day 1 and Day 6.
215161368|NCT06039579|DRUG|VH4004280 Matching Placebo|VH4004280 Matching Placebo was administered as tablets orally at Day 1.
214550254|NCT04557358|OTHER|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
214700685|NCT02713191|DRUG|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
215161369|NCT06039579|DRUG|VH4011499 Matching Placebo|VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
215161370|NCT06039579|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
215161371|NCT04699890|OTHER|Blood sampling, questionnaires and specific exams|Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
214550255|NCT00358644|DRUG|Decitabine|20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
214550256|NCT04154852|DRUG|Adalimumab|
214550257|NCT04154852|DRUG|Methotrexate|
214550258|NCT04154852|DRUG|Placebo|Placebo to replace adalimumab
214550259|NCT04154852|DRUG|Folic Acid|
214550260|NCT04515498|DEVICE|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
214550261|NCT00246935|DRUG|Roflumilast|
214550262|NCT00911651|DRUG|Salbutamol|400 µg inhalation once
214700686|NCT02713191|DRUG|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
214700687|NCT02713191|OTHER|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
214700688|NCT02713191|DRUG|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
214700689|NCT02713191|DRUG|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
214700690|NCT01770873|BEHAVIORAL|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
215161372|NCT06088472|BIOLOGICAL|TIL injection|Autologous tumor infiltrating lymphocyte injection
215161373|NCT06794541|DRUG|Eravacycline 2mg/kg|intravenous (IV) infusion
215161374|NCT06794541|DRUG|Eravacycline 1.5mg/kg|intravenous (IV) infusion
214550263|NCT00911651|DRUG|ipratropium bromide|80 µg inhalation once
214550264|NCT05845203|DIAGNOSTIC_TEST|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
215161375|NCT05652504|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 Pf sporozoites (PfSPZ) produced by Sanaria Inc. PfSPZ Vaccine is manufactured in compliance with Good Manufacturing Practice (GMP) regulations (21 Code of Federal Regulations \[CFR\] 21), that is described in detail in Investigational New Drug (IND) 13969. Manufacture of PfSPZ Vaccine is performed in Sanaria s Clinical Manufacturing Facility (CMF) in Rockville, Maryland, USA.
214700691|NCT04569331|PROCEDURE|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
214700692|NCT04569331|PROCEDURE|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
214700693|NCT01982773|BEHAVIORAL|Virtual Hope Box Smartphone App|Smartphone app
214550265|NCT03477357|DEVICE|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
214700694|NCT01982773|BEHAVIORAL|Enhanced Treatment as Usual|Printed materials
214700695|NCT01097473|PROCEDURE|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
214700696|NCT05902546|OTHER|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
214700697|NCT05902546|OTHER|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
214700698|NCT04724382|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
214550266|NCT06146764|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Integrated scoring method and up-and-down scoring method
214550267|NCT00599274|DRUG|Interferon beta-1a|injection once a week
214550268|NCT00599274|DRUG|Interferon beta-1a|injection three times a week
214550269|NCT03876470|OTHER|Hepatitis C treatment as chosen by provider|Participants' providers will determine the type of HCV treatment as appropriate.
214550270|NCT03327831|DRUG|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
214550271|NCT01081275|BEHAVIORAL|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
214550272|NCT01081275|BEHAVIORAL|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
214550273|NCT02866032|DRUG|MOB015B|
214550274|NCT02866032|DRUG|Ciclopirox 80 mg/g|
214550275|NCT03889847|DEVICE|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
214550276|NCT03889847|DEVICE|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
214550277|NCT02838134|OTHER|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
214550278|NCT02838134|OTHER|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
214700699|NCT04724382|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
214700700|NCT01424826|DRUG|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
214700701|NCT01424826|DRUG|Rifampicin|\< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days \> 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
214550279|NCT04545333|DIAGNOSTIC_TEST|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
214550280|NCT04674189|BIOLOGICAL|CVnCoV Vaccine|Intramuscular injection
214550281|NCT04674189|DRUG|Placebo|Intramuscular injection
214550282|NCT01357642|DRUG|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
214550283|NCT01357642|DRUG|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
214550284|NCT01357642|DRUG|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
214550285|NCT06502392|OTHER|Assessment of creatine phosphokinase|Assessment will be done through collecting a blood sample.
214550286|NCT06502392|OTHER|Assessment of pelvic floor muscle strength|Assessment will be done by a biofeedback.
214550287|NCT00111267|BEHAVIORAL|vitamin B12 supplementation|
214550288|NCT00111267|BEHAVIORAL|vitamin B12 + folic acid combined supplementation|
214550289|NCT06031831|OTHER|airway anomalies|with or without airway anomalies
214550290|NCT04240249|BEHAVIORAL|Constructive self-assertiveness program via the internet|"Participants will get one chapter a week to work with. All chapters are presented on web pages and include information and exercises and end with homework assignments."
214700702|NCT01424826|DRUG|Raltegravir|800 mg bd for 4 days
214700703|NCT01952457|DEVICE|Zilver PTX|
214700704|NCT01952457|DEVICE|prosthetic bypass|
214700705|NCT01804322|OTHER|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
214700706|NCT01804322|OTHER|usual care|usual care according to the participating Epilepsy Centers
214700707|NCT02388022|DEVICE|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
214700708|NCT05415540|OTHER|Questionnaires|Subjects included in the study will answer questionnaires
214700709|NCT03408548|PROCEDURE|Scaling root planning|Periodontal treatment
214700710|NCT03408548|DIETARY_SUPPLEMENT|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
214700711|NCT03408548|OTHER|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
214700712|NCT06520319|DRUG|68Ga-MGS5|Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
214550291|NCT03981939|OTHER|No intervention|This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.
214550292|NCT01564277|DRUG|rasburicase|Given IV
214550293|NCT01564277|DRUG|allopurinol|Given PO
214550294|NCT04489108|DRUG|Tranexamic acid|Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
214550295|NCT04489108|OTHER|Standard Medical Treatment|Standard Medical Treatment
214700713|NCT03294681|DEVICE|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
215161376|NCT05652504|OTHER|PfSPZ Diluent|The diluent for PfSPZ Vaccine is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA) and is termed PfSPZ Diluent (or Diluent). The PfSPZ Diluent was manufactured in compliance with GMP by Sanaria, Inc. (9800 Medical Center Dr., Rockville, MD, USA), or Sanaria s contractor Emergent Biosolutions (https://www.emergentcdmo.com/). Each lot of PfSPZ Diluent is issued a Certificate of Analysis (CoA) and is also placed on a stability program. HSA used in PfSPZ Diluent is a licensed product which is approved for parenteral, IV administration to humans and is purchased by Sanaria, Inc. from CSL Behring, Bern, Switzerland.
214550296|NCT04489108|OTHER|Placebo|isotonic solution (saline)
214550297|NCT05403931|DEVICE|Low level laser therapy|Omega XP is the particular device producing low level laser therapy and has been in use for therapeutic purposes to treat different musculoskeletal conditions.
214550298|NCT02847481|PROCEDURE|fecal microbiota transplantation|fecal microbiota transplantation
214550299|NCT02847481|DRUG|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
214700714|NCT04922619|DEVICE|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
214700715|NCT04922619|DEVICE|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
214700716|NCT04626843|OTHER|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
214700717|NCT01959737|PROCEDURE|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
214550300|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
214550301|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
214550302|NCT03643549|DRUG|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
214550303|NCT03643549|DRUG|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
214550304|NCT01851551|DRUG|Vincristine Sulfate Liposome Injection plus rituximab|
214550305|NCT01637077|DRUG|pregabalin|Given PO
214550306|NCT01637077|DRUG|placebo|Given PO
214700718|NCT04757909|DIAGNOSTIC_TEST|Monthly Haemoglobinometry|"Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary."
214700719|NCT01948388|DRUG|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
214700720|NCT01836887|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
214700721|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
214700722|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
214550307|NCT01637077|OTHER|questionnaire administration|Ancillary studies
214550308|NCT04833413|DRUG|Continuous intensive insulin therapy|After initial intensive insulin therapy in hospital, patients were grouped according to different treatment regimens within 6 months of discharge
214550309|NCT04796311|DIAGNOSTIC_TEST|blood samples|T cells, B cells and cytokines testing
214550310|NCT01896622|DRUG|Ritonavir|Impact on dabigatran PK/PD
214550311|NCT01896622|DRUG|Cobicistat|Impact on dabigatran PK/PD
214550312|NCT01098916|RADIATION|Home X-rays|X-rays examinations performed at home
214550313|NCT01098916|RADIATION|X-rays in hospital|
214550314|NCT02275208|PROCEDURE|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
214550315|NCT03979534|OTHER|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
214550316|NCT04937322|PROCEDURE|Interventional Endoscopy procedures|• All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
214550317|NCT01552759|PROCEDURE|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
214550318|NCT01552759|BEHAVIORAL|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
214550319|NCT01552759|BEHAVIORAL|Test meal|Subjects are presented with an ad libitum buffet meal.
214550320|NCT00794924|DIETARY_SUPPLEMENT|VSL#3|one sachet per day, for 45 consecutive days
214700723|NCT05341505|BEHAVIORAL|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
214700724|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
215029582|NCT03981055|DEVICE|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
215161377|NCT05652504|DRUG|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
215161378|NCT02929303|DRUG|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
214550321|NCT00794924|DIETARY_SUPPLEMENT|placebo|one sachet per day, for 45 consecutive days
214550322|NCT01594970|DRUG|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
214550323|NCT05788692|DEVICE|electric tootbrush|Participants will brush twice per day with an electric toothbrush
214550324|NCT05788692|DEVICE|manual toothbrush|Participants will brush twice per day with a manual toothbrush
214550325|NCT05788692|DEVICE|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
214550326|NCT04794153|DIETARY_SUPPLEMENT|whole food sources|Foods selected are naturally high in protein and consumed by the general population as part of a meal.
214550327|NCT03053453|PROCEDURE|Spinal Surgery|TKA under standard of care spinal surgery.
214550328|NCT03053453|DEVICE|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
214550329|NCT03332784|DRUG|TAK-925|TAK-925 Intravenous Infusion
214550330|NCT03332784|DRUG|Placebo|TAK-925 Placebo Intravenous Infusion
214550331|NCT02727153|OTHER|"Ultra E.R.A.S."|
214550332|NCT02727153|OTHER|Classic E.R.A.S.|
214550333|NCT06047574|OTHER|This study does not involve any interventions|This study does not involve any interventions
215161379|NCT04998604|DRUG|Dupilumab|solution for injection subcutaneous
215161380|NCT04998604|DRUG|Omalizumab|solution for injection subcutaneous
214550334|NCT04922177|PROCEDURE|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
214550335|NCT04922177|PROCEDURE|Direct restoration|Restoration using a Glass Ionomer Cement
214550336|NCT06180213|DIAGNOSTIC_TEST|FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.
214550337|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
214550338|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
214550339|NCT00600470|BEHAVIORAL|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
214550340|NCT00600470|BEHAVIORAL|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
214700725|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
214550341|NCT03306420|DRUG|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
214550342|NCT01893476|OTHER|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
214700726|NCT03280641|DRUG|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
215161381|NCT04998604|DRUG|Placebo|solution for injection subcutaneous
215161382|NCT06654050|DRUG|alrizomadlin|Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.
215161383|NCT02362438|GENETIC|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
215161384|NCT04663997|DRUG|177Lu-PSMA-617|IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
215161385|NCT04663997|DRUG|Docetaxel|75mg/m2 IV every 3 weeks maximum 12 cycles
215161386|NCT06102902|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
215161387|NCT06102902|PROCEDURE|Biopsy Procedure|Undergo biopsy
215161388|NCT06102902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215161389|NCT06102902|BIOLOGICAL|Cetuximab|Given IV
215161390|NCT06102902|PROCEDURE|Computed Tomography|Undergo CT
215161391|NCT06102902|PROCEDURE|Echocardiography Test|Undergo ECHO
215161392|NCT06102902|DRUG|Encorafenib|Given PO
215161393|NCT06102902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161394|NCT06102902|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214550343|NCT05320510|DIETARY_SUPPLEMENT|Se-yeast|The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214550344|NCT05320510|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214700727|NCT03280641|DRUG|Warfarin Sodium|Target INR:1.6-3.0
214700728|NCT02260245|BEHAVIORAL|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
214700729|NCT03365427|OTHER|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
214700730|NCT05763160|DRUG|RZL-012|Ready to use drug product for injection into the subcutaneous fat
214700731|NCT06080776|DRUG|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
214700732|NCT06080776|DRUG|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
214700733|NCT00417976|DRUG|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
215161395|NCT06834074|DRUG|NVL-655|Drug: NVL-655
215161396|NCT04047628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|"1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
215161397|NCT04047628|BIOLOGICAL|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab"
215161398|NCT05022550|DEVICE|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
215161399|NCT06735209|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
215161400|NCT06735209|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) Challenge consists of cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ Challenge (7G8) contains a laboratory malaria clone derived from Brazil.
215161401|NCT06735209|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
215161402|NCT06014684|BEHAVIORAL|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
214700734|NCT00417976|DRUG|Bevacizumab|10 mg/kg every 2 weeks.
214700735|NCT00417976|DRUG|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
215161403|NCT05304351|BIOLOGICAL|Amezosvatein Antigen High Dose Arm A|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
214550345|NCT04518046|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
214700736|NCT04547894|DRUG|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
214700737|NCT00032968|DRUG|Buprenorphine/naloxone|
214550346|NCT04518046|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
214550347|NCT04518046|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
214550348|NCT03157245|DIAGNOSTIC_TEST|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
214550349|NCT06121804|DRUG|Immunosuppressive Agents|Prescribing immunosuppressive agents
214550350|NCT00122213|BEHAVIORAL|Behavior change on physical activity and diet|
214550351|NCT05887739|DIAGNOSTIC_TEST|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
214550352|NCT00953732|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
214550353|NCT01500993|DRUG|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
214550354|NCT01500993|DRUG|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
214550355|NCT02498236|DRUG|Intranasal Oxytocin|
214550356|NCT06023810|BEHAVIORAL|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
214550357|NCT00806637|PROCEDURE|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
214550358|NCT00806637|PROCEDURE|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
214550359|NCT00383123|BIOLOGICAL|Fluarix™|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
214550360|NCT00383123|BIOLOGICAL|Fluzone|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
214550361|NCT01814072|BEHAVIORAL|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
214550362|NCT01814072|BEHAVIORAL|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
214550363|NCT01814072|BEHAVIORAL|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
214550364|NCT01814072|BEHAVIORAL|Text Messages|Participants will receive regular text messages
214550365|NCT01814072|BEHAVIORAL|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
214550366|NCT01814072|BEHAVIORAL|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
214700738|NCT00706667|DRUG|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
214700739|NCT04348591|BEHAVIORAL|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
215161404|NCT05304351|BIOLOGICAL|Amezosvatein Antigen Low Dose Arm B|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161405|NCT05304351|BIOLOGICAL|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161406|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm D|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161407|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm F|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
214550367|NCT06406699|BEHAVIORAL|Pain Reprocessing Therapy (PRT)|PRT is a psychological intervention for chronic pain patients with a primary nociplastic component. PRT aims to help patients reconceptualize their pain as a non-dangerous signal that is not indicative of tissue pathology or structural abnormality. Through decreasing the threat level of their chronic pain, the pain itself can also resolve.
214550368|NCT03833895|DRUG|Norepinephrine|0.05ug/kg/min Norepinephrine during Cesarean Section Operation
214550369|NCT03833895|DRUG|Phenylephrine|0.25ug/kg/min phenylephrine during Cesarean Section Operation
214550370|NCT03833895|DRUG|Ringer's Solution|3 ml/kg/min of LR was administrated according to standard weight.
214550371|NCT01568125|DRUG|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
214550372|NCT04049981|DEVICE|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
215029583|NCT03981055|DEVICE|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
215161408|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm H|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161409|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm J|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161410|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm L|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
215161411|NCT04704661|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
215161412|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161413|NCT04704661|DRUG|Ceralasertib|Given PO
215161414|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215161415|NCT04704661|PROCEDURE|Echocardiography Test|Undergo ECHO
214550373|NCT02336425|DRUG|QGE031|QGE031 120 mg per 1 mL liquid in vial
214550374|NCT02336425|DRUG|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
214550375|NCT04499612|PROCEDURE|Cardiac implantable electronic device implantation.|Patients who have indications will receive cardiac implantable electronic device implantation.
214550376|NCT04499612|PROCEDURE|Cardiac implantable electronic device replace.|Patients who have indications will receive cardiac implantable electronic device replace.
214550377|NCT04499612|DIAGNOSTIC_TEST|Duplex ultrasound.|Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
214550378|NCT04499612|DIAGNOSTIC_TEST|Echocardiography.|Patients will undergo an ultrasound examination of the heart.
214550379|NCT04499612|DIAGNOSTIC_TEST|Blood sampling.|Patients will be taken venous blood to determine the studied markers of hemostasis system.
214550380|NCT00656747|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
214550381|NCT00656747|DRUG|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
214550382|NCT01836172|DRUG|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
214550383|NCT00978562|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
214550384|NCT00978562|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
214550385|NCT00978562|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
215161416|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215161417|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215161418|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214550386|NCT00978562|DRUG|Gadolinium|Given IV
214550387|NCT02250053|OTHER|Exercise|
214550388|NCT00175539|BEHAVIORAL|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
215161419|NCT06709521|DRUG|Iohexol|Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)
215161420|NCT00001160|DRUG|68-Gallium Dotatate|For evaluation risk/benefit evaluation
215161421|NCT01273168|DRUG|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
215161422|NCT01631617|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
215161423|NCT01631617|DRUG|Cephalexin|500 mg orally every 8 hours for 14 days
214550389|NCT06479928|OTHER|delivery mode|Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.
214550390|NCT03230604|DEVICE|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
214550391|NCT03230604|DEVICE|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
215161424|NCT01631617|DRUG|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
215161425|NCT01631617|OTHER|Sodium hypochlorite|6 % dilute bleach
214700740|NCT04348591|DEVICE|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
214700741|NCT05753280|DRUG|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
214700742|NCT04246580|PROCEDURE|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
215161426|NCT01631617|OTHER|Placebo capsules|Capsule orally every 8 hours daily for 14 days
215161427|NCT01631617|OTHER|Placebo Sodium hypochlorite|Three times a week for 14 days
215161428|NCT05382494|DRUG|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
215161429|NCT05382494|DRUG|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
215161430|NCT06822543|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
214550392|NCT06311305|PROCEDURE|Early Laparoscopic cholecystectomy|laparoscopic cholecystectomy early after ERCP with assessing the risks and complications
215161431|NCT06822543|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload and a cleavable linker.
215161432|NCT06822543|DRUG|Carboplatin|Carboplatin is a platinum compound chemotherapy used to treat lung cancer with a known safety profile. For more details on specific indications refer to the approved product label.
215161433|NCT06465368|DRUG|PF-07220060|PF-07220060 given as tablet by mouth twice a day for 14 days.
215161434|NCT06465368|DRUG|letrozole|Letrozole given as tablet by mouth once a day for 14 days
214550393|NCT01782690|DRUG|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
214550394|NCT01782690|DRUG|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
214700743|NCT01778127|BEHAVIORAL|Activity Monitor|Measurement of physical activity.
214700744|NCT01778127|BEHAVIORAL|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
214700745|NCT01778127|BEHAVIORAL|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
214700746|NCT00093860|DRUG|Propranolol|
214550395|NCT04121897|OTHER|Therapist Education and Massage for Parents of Extremely Preterm Infants|"TEMPO includes these components:~* Early Parent Education Session~* Weekly Parent Education Sessions~* Infant Massage Parent Education Sessions~* Discharge Parent Education Session~* Parent Education Post-Discharge~* Bi-weekly emails (or texts)~* 2 Month Follow-up Massage Review Session"
214550396|NCT04614168|PROCEDURE|Stepped hyperinsulinaemic-hypoglycaemic clamp study|Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
214700747|NCT01218789|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
214700748|NCT00143260|DRUG|Viagra (Sildenafil Citrate) 100 mg|
214700749|NCT01348425|DEVICE|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
214700750|NCT01348425|DEVICE|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
214700751|NCT03509272|DEVICE|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
214700752|NCT02104804|DRUG|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
214700753|NCT02104804|DRUG|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
214700754|NCT04482868|PROCEDURE|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
214700755|NCT00668304|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
214700756|NCT04347317|PROCEDURE|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
214700757|NCT04347317|PROCEDURE|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
215161435|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection."
215161436|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty."
215161437|NCT05665491|BEHAVIORAL|HabitWorks|Smartphone app-delivered interpretation bias intervention
215161438|NCT05665491|BEHAVIORAL|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
215161439|NCT06465719|PROCEDURE|Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System|Basal ganglion hemorrhage patients will be operated on hematoma puncture and aspiration with Tract-based AI Robot Guiding System
215161440|NCT06465719|DRUG|Patients will be managed with guideline-based medications|Patients will be managed with guideline-based medications without surgery
214550397|NCT04614168|DEVICE|Insulin pump|Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
214550398|NCT04614168|DEVICE|Continuous glucose monitor|Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
214700758|NCT03430817|DRUG|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
214550399|NCT04614168|OTHER|Low carbohydrate diet|30-40g of carbohydrate per main meal portion.
214700759|NCT03430817|DRUG|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
214700760|NCT02942849|DRUG|r-hFSH|As per standard clinical practice
214700761|NCT02038218|DRUG|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
214700762|NCT03722784|DEVICE|Invigor A (test)|silicone hydrogel lens
214700763|NCT03722784|DEVICE|Invigor B (control)|silicone hydrogel lens
214700764|NCT03615911|BIOLOGICAL|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
214700765|NCT04593693|DEVICE|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
214700766|NCT01390961|DRUG|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
214550400|NCT04614168|DEVICE|Blinded continuous glucose monitor|Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
214550401|NCT04614168|PROCEDURE|Stable isotope studies- D2 Glucose and D5 Glycerol|These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
214700767|NCT04377061|DIAGNOSTIC_TEST|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
214700768|NCT03455309|BIOLOGICAL|NDV-3A|Single dose administered by intramuscular injection
214700769|NCT03455309|BIOLOGICAL|Placebo|Single dose administered by intramuscular injection
214700770|NCT05941351|PROCEDURE|flap fixation|flap fixation using running or interrupted sutures
214700771|NCT04123756|BEHAVIORAL|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
214700772|NCT03832153|PROCEDURE|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
214700773|NCT03374553|DEVICE|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
214700774|NCT03374553|DEVICE|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
214700775|NCT02385877|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
214700776|NCT02385877|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
214700777|NCT03411265|OTHER|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
215029584|NCT03981055|OTHER|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
214700778|NCT01337063|OTHER|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
214550402|NCT06123689|DEVICE|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine."
214700779|NCT00644254|PROCEDURE|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
214700780|NCT03713931|DIAGNOSTIC_TEST|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
214700781|NCT04202653|DRUG|ETV|entecavir 0.5 mg qd
214550403|NCT06123689|DEVICE|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
214700782|NCT04202653|DRUG|TQ-A3334|TQ-A3334 po qw
214700783|NCT04202653|DRUG|TQ-B2450|TQ-B2450 q3w iv
214700784|NCT04511026|DRUG|Lymphoseek|Radioactive diagnostic agent
214550404|NCT06074562|DRUG|LY3556050|Administered orally.
214550405|NCT06074562|DRUG|Placebo|Administered orally.
214550406|NCT04471909|DEVICE|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
214700785|NCT04511026|DEVICE|Single Photon Emission Computed Tomography (SPECT)|Imaging test
214700786|NCT04511026|DRUG|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
214700787|NCT04511026|DEVICE|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
214700788|NCT03825094|DEVICE|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
214700789|NCT05491694|DRUG|Toripalimab|Toripalimab 240mg
214700790|NCT05491694|DRUG|Epirubicin|90mg/m2，IVD，q3w
214700791|NCT05491694|PROCEDURE|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
214700792|NCT05491694|DRUG|Cyclophosphamide|600mg/m2，IVD，q3w
214700793|NCT05491694|DRUG|Carboplatin|AUC 5，IVD，q3w
214700794|NCT05491694|DRUG|Nab-paclitaxel|260mg/m2，IVD，q3w
214700795|NCT05319080|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
214700796|NCT05350566|DIETARY_SUPPLEMENT|Olive leaf extract|A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water before exercise.
214700797|NCT05350566|DIETARY_SUPPLEMENT|Placebo|A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water before exercise.
214700798|NCT00239486|DRUG|Pramipexole|
214700799|NCT03518814|OTHER|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
214700800|NCT00465491|DRUG|picoplatin|IV picoplatin 150mg/m2 q3wk
214700801|NCT00465491|OTHER|best supportive care|best supportive care
214700802|NCT00751114|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
214700803|NCT00751114|DRUG|Sitagliptin|Oral administration. 100 mg film-coated tablets.
214700804|NCT00751114|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
214700805|NCT00292448|DRUG|Ba 679 BR Respimat|
214700806|NCT00292448|DRUG|Tiotropium (Spiriva) inhalation capsule 18 ug|
214700807|NCT01571648|DRUG|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
214700808|NCT01423773|DEVICE|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
214700809|NCT01423773|DEVICE|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
215029585|NCT03411044|DEVICE|Fitmore Hip Stem|
214550407|NCT05763342|DEVICE|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
214550408|NCT04946942|BEHAVIORAL|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
214550409|NCT04946942|BEHAVIORAL|Usual Care|Attendance at primary care appointments as usual.
214550410|NCT04907357|DEVICE|rTMS|Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
214550411|NCT04907357|DEVICE|Sham (Placebo)|Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
214550412|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
214550413|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
214550414|NCT03921944|DIAGNOSTIC_TEST|CT scan of the shoulders|studies of both operative and nonoperative shoulders
214550415|NCT04216888|DRUG|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
214550416|NCT04505436|DRUG|HM15211|A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes
214550417|NCT04505436|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
214550418|NCT06054009|BEHAVIORAL|Brief CBT|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
214550419|NCT06457191|DRUG|Roflumilast|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
214550420|NCT06457191|DRUG|Placebo|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
214550421|NCT06457191|DEVICE|Intermittent theta-burst stimulation transcranial magnetic stimulation|Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.
214550422|NCT06457191|DEVICE|Continuous theta-burst stimulation transcranial magnetic stimulation|Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.
214550423|NCT05368155|BEHAVIORAL|Brief ACT for Pelvic Pain|The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
214550424|NCT00040495|DRUG|Pantoprazole|
214550425|NCT05035797|PROCEDURE|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
215029586|NCT03276273|DEVICE|recording of Bispectral Index|recording of Bispectral Index
215029587|NCT03453541|DRUG|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
215029588|NCT03453541|DRUG|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
215029589|NCT04978467|DEVICE|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
215029590|NCT05325242|DEVICE|Embozene particles|Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
215029591|NCT06264596|DRUG|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
215029592|NCT06264596|PROCEDURE|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
215029593|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
215029594|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
215029595|NCT06269406|OTHER|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
215029596|NCT04726527|DRUG|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
214700810|NCT01423773|DEVICE|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
214700811|NCT01755468|DRUG|Intermittent insulin therapy|
214700812|NCT01755468|DRUG|Continuous metformin|
214700813|NCT04212286|DIAGNOSTIC_TEST|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
214700814|NCT00747396|OTHER|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
214700815|NCT02648724|DRUG|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
214700816|NCT00042484|PROCEDURE|Community-level intervention & policy change|
214700817|NCT03076190|BEHAVIORAL|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
214700818|NCT04224285|OTHER|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
214700819|NCT01892319|DRUG|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
214700820|NCT01892319|DRUG|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
214700821|NCT04070170|DEVICE|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
214700822|NCT04070170|PROCEDURE|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
214700823|NCT05896618|DEVICE|TPA|1\. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
214700824|NCT05896618|DEVICE|Nance appliance|2\. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
214700825|NCT03488121|BEHAVIORAL|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
214700826|NCT03488121|BEHAVIORAL|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
214700827|NCT00332800|DRUG|Nutritional Supplementation|
214700828|NCT04452227|OTHER|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
214700829|NCT01471704|DRUG|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
214700830|NCT01471704|DRUG|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
214700831|NCT01471704|DRUG|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
214700832|NCT01527019|DRUG|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
214700833|NCT01527019|DRUG|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
215029597|NCT04726527|DEVICE|Positron Emission Tomography|PET Scan for brain imaging
215029598|NCT00523107|DRUG|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
215029599|NCT00523107|DRUG|Placebo|500 ml normal saline t.i.w. per week
215029600|NCT05665751|DRUG|TLC-3595 Dose 1|Tablets administered orally
215029601|NCT05665751|DRUG|TLC-3595 Dose 2|Tablets administered orally
215029602|NCT05665751|DRUG|Placebo|Tablets administered orally
215029603|NCT04458766|BEHAVIORAL|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
215029604|NCT05811832|OTHER|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
215029605|NCT06291987|DRUG|Ivosidenib|Ivosidenib will be given at assigned dose once daily.
215029606|NCT06291987|DRUG|Ruxolitinib|Ruxolitinib will be given at assigned dose twice daily.
215029607|NCT06129877|DEVICE|CHAMP App|CHAMP App software platform will have been used in other research studies to be included in the Feeding difficulties repository
215029608|NCT06639581|DEVICE|20 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
215029609|NCT06639581|DEVICE|30 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
214700834|NCT01527019|DRUG|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
214700835|NCT00422409|PROCEDURE|Endoscopic stenting|
214700836|NCT03329651|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
214700837|NCT03329651|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
215161441|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
214700838|NCT03030911|DRUG|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
214700839|NCT03030911|DRUG|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
214700840|NCT03030911|DRUG|Fentanyl|The drug will be administered in both groups
214700841|NCT03030911|DEVICE|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
214700842|NCT00406783|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
214700843|NCT00406783|DRUG|Placebo|Placebo tablet, once daily for 15 days
215029610|NCT06639581|DEVICE|40 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
215161442|NCT05951777|BIOLOGICAL|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
215161443|NCT05951777|DRUG|Normal Saline|Sterile Saline Solution 0.9%
215161444|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
215161445|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
214550426|NCT05035797|PROCEDURE|Usual care|Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
214550427|NCT01948076|DEVICE|resident with GE vscan|resident with GE vscan
214550428|NCT04966065|DEVICE|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
214550429|NCT04896788|BIOLOGICAL|Monitoring of the immune response|Blood sample at 3,6,12,18 and 24 months in order to assess the blood level of anti-S1 / RBD anticoprs
215029611|NCT06639646|DIETARY_SUPPLEMENT|Probiotics supplements|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
215029612|NCT06639646|DIETARY_SUPPLEMENT|Health diet|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
215029613|NCT06639867|DEVICE|VR-based home physiotherapy|VR-based home physiotherapy
215029614|NCT06639867|OTHER|Standard physiotherapy care|Standard physiotherapy care as prescribed by the treating physiotherapist
214550430|NCT01745276|DEVICE|Biphosfonate|External pins coated by biphosfonate.
214550431|NCT01745276|DEVICE|Hydroxylapatit|External pins coated by Hydroxylapatit.
214700844|NCT00064350|DRUG|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
214700845|NCT00064350|DRUG|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
214700846|NCT03256474|OTHER|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
214700847|NCT03751592|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
214700848|NCT00808730|PROCEDURE|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
214700849|NCT03360539|BEHAVIORAL|Nurse-Family Partnership|
214550432|NCT00521859|DRUG|Cloretazine|800 mg/m\^2 by vein daily
214550433|NCT00521859|DRUG|Fludarabine|25 mg/m\^2 by vein daily x 5 Days
214550434|NCT04141722|BEHAVIORAL|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
214550435|NCT04141722|BEHAVIORAL|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
214700850|NCT02787330|BEHAVIORAL|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
214700851|NCT02787330|BEHAVIORAL|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
214700852|NCT06553430|BEHAVIORAL|aerobics exercises|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
214550436|NCT03995225|BEHAVIORAL|Smartband automatic smoking detection combined with brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
214700853|NCT00608439|DRUG|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
214700854|NCT00608439|OTHER|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
214700855|NCT00939224|DEVICE|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
214700856|NCT03069846|DEVICE|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
214700857|NCT00012012|DRUG|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
214700858|NCT00012012|DRUG|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
214700859|NCT00012012|RADIATION|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
214700860|NCT00012012|RADIATION|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
214700861|NCT04785391|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
215029615|NCT06639191|DRUG|[177Lu]Lu-AKIR001|"Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq."
215029616|NCT06637748|PROCEDURE|Echocardiography|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)"
215029617|NCT06637748|PROCEDURE|Electrocardiography|"Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval"
215029618|NCT06638437|BEHAVIORAL|Cognitive-behavioral therapy|"The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process"
215161446|NCT04493372|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
214550437|NCT04264975|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
214550438|NCT03799419|BEHAVIORAL|Cognitive bias modification for interpretation bias|Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
214550439|NCT03799419|BEHAVIORAL|Psychoeducation|Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
214550440|NCT03799419|BEHAVIORAL|Approach avoidance training|Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, \& Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).
214700862|NCT05231174|OTHER|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
214700863|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
214700864|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
214700865|NCT02034474|DRUG|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
214700866|NCT02034474|DRUG|Placebo|intravenously via iv drip over 60 min
214700867|NCT01391819|OTHER|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
214700868|NCT01391819|PROCEDURE|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
214700869|NCT00001251|DRUG|Mafosfamide|
215161447|NCT05874479|DEVICE|Active PAC|The active PAC will contain HEPA filters inside the device.
215161448|NCT05874479|DEVICE|Sham PAC|The sham PAC will contain no HEPA filters inside the device.
215161449|NCT05412927|DEVICE|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
214700870|NCT00050791|DRUG|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
214700871|NCT00050791|BEHAVIORAL|Very Low Calorie Diet|placebo injections
214700872|NCT00691262|DRUG|tacrolimus ointment|transdermal
215161450|NCT05632887|OTHER|no intervention|no intervention
215161451|NCT05828823|DEVICE|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
215161452|NCT05828823|OTHER|Hemodialysis thrice weekly|Conventional hemodialysis regimen
214700873|NCT01522040|DRUG|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
214700874|NCT01522040|DRUG|Placebo|Simple saline drip, without active drug
215161453|NCT04613440|OTHER|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
215161454|NCT04613440|OTHER|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
215161455|NCT04613440|OTHER|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
215161456|NCT04613440|OTHER|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
215161457|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
214700875|NCT01795287|PROCEDURE|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
214700876|NCT01795287|PROCEDURE|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
215161458|NCT05835141|OTHER|OCT Imaging|Each participant will receive imaging of the inferior sectors of the iridocorneal angle at 150°, and 180°, and 210° with the swept-source ANTERION AS-OCT system under standardized light and dark lighting conditions by a trained research technician
214550441|NCT03799419|BEHAVIORAL|Inactive sham approach avoidance training|Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
214550442|NCT05663905|DRUG|Ambroxol Hydrochloride|IV ambroxol hydrochloride 30mg TDS as adjunct therapy to standard therapy for severe pneumonia in ICU for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour.
214550443|NCT05663905|OTHER|Standard Therapy|Standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC). This includes antibiotics stewardship and supportive therapy.
214550444|NCT04443959|BEHAVIORAL|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
214550445|NCT05592184|OTHER|Exercise|The experimental protocol begins with the assessment of self-perceived pain intensity and perceived exertion when using different intensities of elastic resistance, during wrist flexion and extension, at a controlled speed of 1.5sec/ phase. To assess the intensity at which they will work, participants will perform 2 repetitions and will be allowed a rest of 60s between sets until they obtain a score of 3 on the Borg CR10 scale. Exercises should be performed with the subject's available ROM. Participants are asked to move their body and trunk as little as possible and to perform the exercise smoothly, without stopping or accelerating. The exercise will be performed in a seated position, with the back supported by the backrest and the forearm resting on a table, with the shoulders and elbows bent at 90o, leaving the wrist free, with the elastic bands held under the feet (stepping on them).
214550446|NCT01390350|DRUG|Canakinumab|150mg subcutaneous injections on day 0
214550447|NCT01390350|DRUG|Placebo|150mg subcutaneous injections on day 0
214550448|NCT01044927|OTHER|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
214550449|NCT01044927|OTHER|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
214550450|NCT03542110|DRUG|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
214550451|NCT03542110|DRUG|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
214550452|NCT05261841|OTHER|Standard care for T2D patients, Smartwatch|No intervention, observational study
214550453|NCT01137669|BIOLOGICAL|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
214550454|NCT01137669|OTHER|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
214550455|NCT02975791|OTHER|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
214550456|NCT02975791|PROCEDURE|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
214550457|NCT02565550|DIETARY_SUPPLEMENT|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
214550458|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
214550459|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
214550460|NCT04673045|DEVICE|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
214550461|NCT04673045|DEVICE|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
214550462|NCT00693433|DRUG|dexamethasone|Given orally
214550463|NCT00693433|DRUG|temsirolimus|Given IV
214550464|NCT00693433|OTHER|laboratory biomarker analysis|Correlative studies
214550465|NCT05680324|PROCEDURE|Monsplasty|liposuction assisted monsplasty
214700877|NCT04475822|BEHAVIORAL|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
214700878|NCT04475822|BEHAVIORAL|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
214700879|NCT04475822|BEHAVIORAL|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
214700880|NCT04291872|OTHER|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
214700881|NCT04597619|OTHER|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
214700882|NCT04914741|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
214700883|NCT04914741|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
214700884|NCT04914741|DRUG|Doxorubicin|Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
214700885|NCT04914741|DRUG|Vincristine|Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
214550466|NCT00569192|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
214550467|NCT00569192|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
214550468|NCT00569192|DRUG|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
214550469|NCT05015725|DIAGNOSTIC_TEST|Quality of life assessment, biochemical measures|"Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to \~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels."
214550470|NCT04765410|DIAGNOSTIC_TEST|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
214550471|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
214550472|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
214550473|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing every 2 weeks~* Intravenous injection"
214550474|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing weekly~* Intravenous injection"
214550475|NCT06544564|DEVICE|Membrane Wrap™|Membrane Wrap™
214700886|NCT04914741|DRUG|Prednisolone|Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
214700887|NCT04914741|DRUG|Glofitamab|Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
214700888|NCT04914741|DRUG|Polatuzumab vedotin|Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
214550476|NCT06544564|OTHER|Standard of Care|SOC treatment will be defined as: 1) debridement of non-viable, necrotic tissue, 2) application of Biologic as the primary, wound covering, 3) application of a dressing over Biologic that maintains moisture balance, 4) application of a Class 3 high compression system, and 5) wrapping with a covering dressing
214550477|NCT00723385|DIETARY_SUPPLEMENT|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
214550478|NCT00723385|OTHER|Placebo|Administration of placebo for 12 weeks with repeated D measurements
214550479|NCT06770972|BEHAVIORAL|Family Foundations|The FF intervention is 9 sessions, 5 in the prenatal period and 4 in the postpartum period.
214550480|NCT05365399|DEVICE|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
214550481|NCT00691600|DRUG|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
214550482|NCT00691600|DRUG|Placebo|Placebo caps or suspension every 12 hours for 10 days
214700889|NCT04015414|DRUG|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
214700890|NCT04015414|DRUG|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
214700891|NCT03172858|DEVICE|Intracervical balloon catheter|cervical ripening balloon
214700892|NCT03172858|DRUG|Oxytocin|medication used to induce contractions
214700893|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
214700894|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
214700895|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
214700896|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|control biscuit on a daily basis for 8 months
214700897|NCT00261170|DRUG|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
214700898|NCT00261170|OTHER|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
214700899|NCT01547910|DIETARY_SUPPLEMENT|Fish Oil|Fish oil given in supplementary dose
214550483|NCT04687098|DRUG|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
214550484|NCT04687098|DRUG|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~\- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
214550485|NCT04687098|DRUG|G-CSF|"* Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7."
214550486|NCT04687098|PROCEDURE|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
214550487|NCT04687098|PROCEDURE|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
214550488|NCT04687098|PROCEDURE|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
214550489|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
214550490|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
214550491|NCT02643147|DRUG|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
214550492|NCT02600078|DEVICE|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
214550493|NCT02600078|OTHER|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
214550494|NCT02600078|OTHER|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
214550495|NCT02600078|OTHER|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
214550496|NCT02737813|DRUG|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
214550497|NCT02737813|DRUG|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
214550498|NCT06559839|OTHER|Vestibulocortical Stimulation|50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
214550499|NCT00405119|DRUG|AH23844 (lavoltidine)|
214550500|NCT00405119|DRUG|NEXIUM (esomeprazole)|
214550501|NCT00405119|DRUG|ZANTAC (ranitidine)|
214550502|NCT03169998|DEVICE|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
214550503|NCT05511337|OTHER|Caloric restriction and control oxalate and citrate foods|Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.
214550504|NCT05511337|OTHER|Caloric restriction|Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan
214550505|NCT05511337|OTHER|Real-life intervention with control oxalate and citrate foods|Decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.
214550506|NCT06024915|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
214550507|NCT06024915|DRUG|Itraconazole capsule|Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
214550508|NCT06024915|DRUG|Rifampicin Capsule|Rifampicin is a strong inducer of CYP3A.
214550509|NCT05238753|DEVICE|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
214550510|NCT00161265|PROCEDURE|tissue procurement|tissue procurement
214550511|NCT03866096|OTHER|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
214550512|NCT03866096|OTHER|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
214550513|NCT00958542|PROCEDURE|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
214550514|NCT02132871|DEVICE|Impedance cardiography Physioflow ®|
214550515|NCT05224661|OTHER|Prospective determination of the clinical utility of measurable residual disease (MRD) testing|Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
214550516|NCT04124471|BEHAVIORAL|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
214700900|NCT02117596|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
214700901|NCT00278772|DRUG|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
214700902|NCT00278772|OTHER|Placebo|oral dose, placebo
214700903|NCT01745601|DRUG|escitalopram 10 mg|Reference product
214700904|NCT01745601|DRUG|escitalopram 10 mg|Test product
214550517|NCT05261412|OTHER|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
214550518|NCT05261412|OTHER|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
214550519|NCT01972997|DEVICE|SENSIMED Triggerfish|
214550520|NCT02132715|BEHAVIORAL|Resistance Exercise|
214550521|NCT02132715|BEHAVIORAL|KAATSU exercise|
214700905|NCT00391417|DRUG|estradiol gel|
214700906|NCT01656317|OTHER|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
214700907|NCT04433624|OTHER|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
214700908|NCT00657124|DIETARY_SUPPLEMENT|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
214700909|NCT00657124|DIETARY_SUPPLEMENT|Placebo|placebo
214700910|NCT00245193|BEHAVIORAL|Motivationally-Enhanced Interpersonal Psychotherapy|
214550522|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
214550523|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
214550524|NCT02574325|DRUG|Placebo|Control
214550525|NCT02574325|DRUG|ARI-3037MO|Treatment
214700911|NCT04359082|DIETARY_SUPPLEMENT|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
214700912|NCT04359082|OTHER|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
214700913|NCT03912025|OTHER|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
214700914|NCT02969434|OTHER|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
214700915|NCT00607438|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
214700916|NCT00607438|DRUG|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
214700917|NCT00383214|DRUG|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
214700918|NCT00383214|OTHER|Placebo|Intravenous
214700919|NCT00206895|PROCEDURE|Photodynamic therapy|
214700920|NCT02633995|PROCEDURE|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
214700921|NCT04152005|OTHER|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
215029619|NCT06642285|PROCEDURE|Non Invasive Respiratory Support bundle|premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning
214700922|NCT03577912|PROCEDURE|TAP block administered by Surgery|TAP block administered by Surgery
214700923|NCT03577912|PROCEDURE|TAP block administered by Anesthesia|TAP block administered by Anesthesia
214700924|NCT02304315|BIOLOGICAL|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
214700925|NCT02304315|BIOLOGICAL|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
214700926|NCT03201952|DRUG|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
214700927|NCT03201952|DRUG|Placebos|Ileostomy administration of 5cc saline placebo once
214700928|NCT00092066|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
215029620|NCT06638788|OTHER|Knee extension|Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
215029621|NCT06637397|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
214700929|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
214700930|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
214700931|NCT06888843|DRUG|Capecitabine|Capecitabine 2000mg/m2 from day 1 to 14
214550526|NCT01607541|BEHAVIORAL|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
214550527|NCT01607541|BEHAVIORAL|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
214550528|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
214700932|NCT06888843|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on day 1, cycle of 21 days
214700933|NCT00002057|DRUG|Nystatin|
214550529|NCT03358472|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
214550530|NCT03358472|DRUG|Epacadostat|Epacadostat administered orally twice daily.
214550531|NCT03358472|DRUG|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
214550532|NCT03358472|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
214550533|NCT03358472|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
214550534|NCT03358472|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
214550535|NCT03732677|DRUG|Durvalumab|Anti- PD-L1 Antibody
214550536|NCT03732677|DRUG|Cisplatin|Chemotherapy Agent
214550537|NCT03732677|DRUG|Gemcitabine|Chemotherapy agent
214700934|NCT06897917|DRUG|Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets|"1. Calculate the total opioid dosage administered to the patient in the previous 24 hours and convert it to an equivalent dose of oxycodone/naloxone sustained-release tablets(Mimeixin).~2. Based on the principle of incremental dosing, calculate the total dosage to be administered on the day of enrollment, divide it into two portions, and administer one portion every 12 hours (q12h).~3. In case of breakthrough pain during treatment, administer an equivalent dose of immediate-release morphine or other medications equivalent to 10%-20% of the 24-hour background dosing for relief.~4. If the number of breakthrough pain events exceeds 2 in a day after dosing, adjust the dosage again based on the incremental dosing principle. Adjustments should be made every 1-2 days, with each adjustment increasing the dose by a gradient of 5 mg/2.5 mg or 10 mg/5 mg of oxycodone/naloxone sustained-release tablets, twice daily, and so on. The maximum daily dose of oxycodone should not exceed 160 mg."
214700935|NCT06898723|DRUG|Shenfu Injection|The treatment will utilize Ginseng and Aconite Injection, which primarily consists of Red Ginseng and Aconite
214700936|NCT06898645|DEVICE|navigated iTBS (Intermittent theta-burst stimulation) targeting the cerebellum|1,800 pulses per session for unilateral cerebellum, 50-minute intersession interval, 80% resting motor threshold, total 75600 pulse number.
214700937|NCT05902754|DIETARY_SUPPLEMENT|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
214700938|NCT05902754|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
214550543|NCT04013971|OTHER|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
214550544|NCT04013971|OTHER|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
214550545|NCT04013971|OTHER|Control Condition|Participants will complete a control walk with out feedback.
214550546|NCT05853900|DEVICE|ReMMi-D Digital Therapeutic|Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
214700939|NCT05022771|DRUG|PMG1015 Dose 1|Dose level 1 of PMG1015
214700940|NCT05022771|DRUG|PMG1015 Dose 2|Dose level 2 of PMG1015
214700941|NCT05022771|DRUG|PMG1015 Dose 3|Dose level 3 of PMG1015
214700942|NCT05022771|DRUG|PMG1015 Dose 4|Dose level 4 of PMG1015
214700943|NCT05022771|DRUG|PMG1015 Dose 5|Dose level 5 of PMG1015
214550547|NCT05129410|DRUG|Mycophenolate Mofetil|"1. Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. MMF1.5g-2.0g/d"
214550548|NCT05194033|DIETARY_SUPPLEMENT|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
214550549|NCT05194033|DIETARY_SUPPLEMENT|Placebo daily|Placebo 1 time/day for 7 consecutive days
214550550|NCT03040947|OTHER|Cardiovascular Magnetic Resonance|
214700944|NCT05022771|DRUG|PMG1015 Dose 6|Dose level 6 of PMG1015
214700945|NCT05022771|DRUG|Placebo|Placebo to match
214700946|NCT05022771|DRUG|PMG1015 Dose 7|Dose level 7 of PMG1015
215161459|NCT00539071|DRUG|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
215161460|NCT00539071|DRUG|long acting injectable risperidone, Conventional Dose Group|Study dose remains 50 mg for the length of the study.
215161461|NCT00539071|DRUG|long acting injectable risperidone, High Dose Group|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
215161462|NCT02443077|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
215161463|NCT02443077|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
215161464|NCT02443077|DRUG|Carmustine|Given IV
215161465|NCT02443077|DRUG|Cyclophosphamide|Given IV
215161466|NCT02443077|DRUG|Cytarabine|Given IV
215161467|NCT02443077|DRUG|Etoposide|Given IV
215161468|NCT02443077|DRUG|Ibrutinib|Given PO
215161469|NCT02443077|OTHER|Laboratory Biomarker Analysis|Correlative studies
215161470|NCT02443077|DRUG|Melphalan|Given IV
215161471|NCT02443077|OTHER|Pharmacogenomic Study|Correlative studies
215161472|NCT02443077|OTHER|Placebo Administration|Given PO
215161473|NCT06208163|PROCEDURE|Chiropractic|Chiropractic spinal adjustments
215161474|NCT06846320|DRUG|ABBV-932|Oral Capsule
214550551|NCT04286854|DIAGNOSTIC_TEST|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
214550552|NCT05928533|OTHER|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
214550553|NCT04500600|OTHER|Quality-of-Life Assessment|Ancillary studies
214550554|NCT04500600|OTHER|Questionnaire Administration|Complete questionnaire
214700947|NCT00088803|GENETIC|molecular genetic technique|
214700948|NCT00088803|GENETIC|polymerase chain reaction|
214700949|NCT00088803|GENETIC|polymorphism analysis|
214700950|NCT00657631|BEHAVIORAL|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999)."
214700951|NCT02763904|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
214700952|NCT02763904|OTHER|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
214700953|NCT06068361|DIAGNOSTIC_TEST|EEG|32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap
214700954|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
214700955|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
214700956|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
215161475|NCT06846320|DRUG|Placebo for ABBV-932|Oral Capsule
215161476|NCT06846320|DRUG|Antidepressant Therapy (ADT)|Standard of care
215161477|NCT06553456|DRUG|Recombinant Human Serum Albumin|The experimental drug was administered at a dose of 20 g/ day for 7 days.
215161478|NCT06553456|DRUG|Human Serum Albumin|The positive control drug was administered at a dose of 20 g/ day for 7 days.
215161479|NCT06846541|DRUG|Open-Label ESK-001|Open-Label ESK-001
215161480|NCT06846541|DRUG|Blinded ESK-001|Blinded ESK-001 during Randomized Treatment Withdrawal Period
215161481|NCT06846541|DRUG|Placebo|Placebo during Randomized Treatment Withdrawal Period
215161482|NCT05726396|DRUG|RMT|A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
214700957|NCT00808249|DRUG|Placebo|2 tablets taken twice a day for 28 days
215161483|NCT05726396|DRUG|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
215161484|NCT03674814|DRUG|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
215161485|NCT03674814|DRUG|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
214550555|NCT04554212|DEVICE|Blood Flow Restriction Training|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
214550556|NCT04554212|DEVICE|Sham Blood Flow Restriction Training|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
214550557|NCT05216198|OTHER|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
214550558|NCT06521268|OTHER|Inspiratory muscle training|Inspiratory muscle training
214550559|NCT06521268|OTHER|Decongestive treatment|Decongestive treatment
214550560|NCT01965509|DRUG|PEX168 or placebo|injection has to administered subcutaneously weekly
214550561|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D
214550562|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
214550563|NCT00809679|DRUG|T-62 Dose 1|Capsule dosage form 100 mg bid
214700958|NCT06826976|OTHER|sensory electrical stimulation|peripheral sensory electrical stimulation on median, ulnar, and radial nerves of affected upper limb, simultaneously with Task Specific Training program which included four subtests of Action Research Arm Test scale.
215161486|NCT06308055|OTHER|Data Acquisition|Develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module.
215161487|NCT05029882|DRUG|ABBV-400|Intravenous (IV) Infusion
215161488|NCT05029882|DRUG|Trifluridine/Tipiracil|Oral Tablet
215161489|NCT05029882|DRUG|Bevacizumab|IV Infusion
215161490|NCT05757141|DRUG|Fosigotifator|Oral Use
215161491|NCT06481306|DRUG|BMS-986470|Specified dose on specified days
215161492|NCT06481306|DRUG|Placebo|Specified dose on specified days
214550564|NCT00809679|DRUG|T-62 Dose 2|Capsule dosage form 200 mg bid
214550565|NCT00809679|OTHER|Placebo|Capsule dosage form placebo bid
214550566|NCT04157036|DRUG|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
214550567|NCT04157036|DRUG|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
214550568|NCT01864460|BEHAVIORAL|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
214550569|NCT00257114|DRUG|bortezomib|
214700959|NCT06826976|OTHER|task specific training program|received task specific training program only. Patients were tested pre and post treatment by Grip dynamometer, Pinch dynamometer, Digital goniometer and Action Research Arm Test Scale (ARAT).
214700960|NCT05834764|DRUG|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
214700961|NCT04838925|DEVICE|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
214700962|NCT06897709|PROCEDURE|Classic Approach in Laparoscopic Appendectomy|underwent laparoscopic appendectomy using the standard approach
214700963|NCT06897709|PROCEDURE|Stump first Approach in Laparoscopic Appendectomy|Stump first Approach in Laparoscopic Appendectomy
214700964|NCT06137521|PROCEDURE|Coronary angiography|
214550570|NCT06380179|DEVICE|THOR3 training + Photobiomodulation Therapy (PBMT)|"PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball."
214550571|NCT06380179|DEVICE|THOR3 training + sham PBMT|Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
214550572|NCT06547788|OTHER|Mitral valve repair with creation of an 8 mm inter-atrial shunt|Mitral valve repair with creation of an 8 mm inter-atrial shunt
214550573|NCT03429166|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation|A non-trauma-focused treatment
214550574|NCT03429166|BEHAVIORAL|Present Centered Therapy|A non-trauma-focused treatment
214700965|NCT00479557|BIOLOGICAL|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
215161493|NCT02792270|OTHER|Caloric Restriction Diet|"Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein."
214700966|NCT00479557|BIOLOGICAL|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
214700967|NCT00479557|BIOLOGICAL|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
214700968|NCT00479557|DRUG|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
215161494|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
214550575|NCT00344032|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214550576|NCT00344032|BIOLOGICAL|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214550577|NCT02000778|DRUG|EC17|
214550578|NCT06590558|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214550579|NCT06590558|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214550580|NCT06590558|PROCEDURE|Computed Tomography|Undergo CT
214550581|NCT06590558|DRUG|Eribulin Mesylate|Given IV
214550582|NCT06590558|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214550583|NCT06590558|DRUG|Tolinapant|Given PO
214550584|NCT06590558|PROCEDURE|X-Ray Imaging|Undergo chest X-ray
214550585|NCT03746509|DEVICE|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
214550586|NCT03746509|DEVICE|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
214550587|NCT06590168|PROCEDURE|Socket Preservation by vestibular socket therapy|Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
214550588|NCT06590168|PROCEDURE|Socket Preservation by icecream cone technique|Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
214550589|NCT06267807|DIAGNOSTIC_TEST|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
214550590|NCT00755456|DRUG|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
214550591|NCT00755456|DRUG|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
214550592|NCT05009199|DRUG|[18F]MNI-444|Subjects will undergo PET imaging using \[18F\]MNI-444.
214700969|NCT00002344|DRUG|Azithromycin|
214700970|NCT01594294|DEVICE|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
214700971|NCT01594294|DEVICE|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
214700972|NCT01594294|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
214700973|NCT01594294|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
214700974|NCT01594294|DEVICE|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
214700975|NCT01422278|OTHER|Rehabilitation|Three weeks of rehabilitation in Hospital.
214700976|NCT04524286|OTHER|Interviews only.|Interviews will be conducted with childbearing women and midwives.
214700977|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
215161495|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
215161496|NCT06047457|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
215161497|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections."
214550593|NCT06819098|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
214550594|NCT06819098|OTHER|Isometric Multicomponent Training|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Isometric training: Gradual progression of 8 isometric exercises targeting major muscle groups, such as wall squats, isometric bicep curls, lateral raises, and rows (1-3 sets, 30 seconds per exercise, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
214550595|NCT00730821|DRUG|BIBW 2992|
214550596|NCT00730821|DRUG|BIBF 1120|
214550597|NCT03539029|PROCEDURE|Surgery|Surgical fracture fixation
214550598|NCT03539029|PROCEDURE|Conservative treatment|immobilisation with plaster cast
214550601|NCT02706249|DRUG|Enoxaparin|
214550602|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Active|Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
214550603|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Sham|Wearable device programmed to deliver sham stimulation.
214550604|NCT05101993|DEVICE|AtriClip|Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
214550605|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
214550606|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
214550607|NCT03920176|DIAGNOSTIC_TEST|Computed tomography coronary angiography|CTCA \>64 detector row scanner
214550608|NCT03920176|OTHER|ASSIGN Score|ASSIGN Cardiovascular Risk Score
214550609|NCT06030986|DIAGNOSTIC_TEST|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
214550610|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
214550611|NCT06820528|BEHAVIORAL|Occupational Therapy|Formal therapy with a certified hand therapist, weekly for 6 weeks
214550612|NCT06820528|BEHAVIORAL|Home Exercise Program|A booklet on hand exercises to complete following surgery, including range of motion and strengthening exercises
214550613|NCT06600373|BEHAVIORAL|Mindful Walking meditation|Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.
214550614|NCT06600373|BEHAVIORAL|physical education group class|120 minutes physical education group class about volleyball.
214550615|NCT06056128|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
214550616|NCT04067271|OTHER|Analyze changes in intestinal microbiome|Descriptive Analysis
214550617|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
214550618|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
214550619|NCT04513977|OTHER|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
214550620|NCT02390661|DEVICE|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
214550621|NCT06658873|OTHER|Proximal arterial cannulation|Radial arterial cannulation from the proximal part of the artery 5 cm proximal to the level of the styloid process.
214700978|NCT05136248|PROCEDURE|intraarticular injection|Ultrasound-guided intraarticular injection
214700979|NCT05136248|PROCEDURE|peng block|Ultrasound-guided PENG block
214700980|NCT00061126|DRUG|ABX-EGF|
215161498|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections."
215161499|NCT02199665|DRUG|selinexor|Given PO
215161500|NCT02199665|DRUG|carfilzomib|Given IV
215161501|NCT02199665|DRUG|dexamethasone|Given PO or IV
214550622|NCT06658873|OTHER|Distal arterial cannulation|Radial arterial cannulation from the distal part of the artery at the styloid process.
214550623|NCT06856863|BEHAVIORAL|Test of personality : questionnary|The questionnary Temperament and Character Inventory (TCI) describes personality through temperament traits governed by the individual's neurobiological systems and predetermined by heredity; and character traits shaped by social and cognitive experience
214550624|NCT04166396|DRUG|Resveratrol|500 mg resveratrol, BID
214550625|NCT04166396|DRUG|NR|500 mg NR BID
214550626|NCT04166396|DIETARY_SUPPLEMENT|Placebo|Placebo
214550627|NCT06872684|DEVICE|Surpass Elite with Guardian Flow Diverter System|The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeter (mm) and ≤ 6.0 mm and located on the Internal Carotid Artery (ICA) or its branches.
214550628|NCT04893850|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
214550629|NCT04893850|BEHAVIORAL|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
214550630|NCT06537271|COMBINATION_PRODUCT|experimental group|Autism awareness, breastfeeding cessation and toilet training knowledge and attitude training guide and weekly training content animation videos will be prepared for the experimental group and uploaded via WhatsApp and training will be provided. All participants will be interviewed face to face before the training and the necessary information about our study will be provided. Feedback will be received from the researcher regarding the videos, and participants in the study will be able to ask their questions via WhatsApp and share digital content in a digital environment. Evaluation will be made by conducting group work with individuals. Reminders such as mobile phone messages will be used. Training will be carried out within an 8-week program. Each week, training videos on the topics prepared in line with the training guide will be prepared and shared via WhatsApp. Feedback will be received by creating interactive communication environments.
214550631|NCT06537271|COMBINATION_PRODUCT|Control Group|After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of the training, survey forms will be filled out by the researcher for the control group and post-test data will be collected.
214550632|NCT02065882|DRUG|BT524 (Part I)|Single intravenous infusion of 70 mg BT524 per kg body weight.
214550633|NCT02065882|DRUG|BT524 (Part II)|Single or repetitive intravenous infusion(s) of BT524, depending on the severity of the disorder, location and extent of the bleeding and patient's clinical condition. Dosage based on individual body weight and fibrinogen level.
214550634|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
214550635|NCT06618794|OTHER|Recovery Legal Care|These patients will receive support from our HVIP standard of care (Violence Recovery Program) plus our Medical Legal Partnership (Recovery Legal Care) for additional legal support to address health-harming legal needs and public benefits.
214550636|NCT06618794|OTHER|HVIP Standard of Care|These patients will receive HVIP standard of care (Violence Recovery Program Support)
214550637|NCT06869824|DIETARY_SUPPLEMENT|Minayo Iron-rich Nutritional Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
214550638|NCT06869824|DIETARY_SUPPLEMENT|Common Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
214550639|NCT02775006|DRUG|Docetaxel|75mg/m2
214550640|NCT02775006|DRUG|Erlotinib|150mg/day
214550641|NCT07017478|DRUG|LSD|The serotonin 2A receptor agonist LSD
214550642|NCT07017478|DRUG|Placebo|Distilled water
214550643|NCT06710899|DRUG|Methenamine Hippurate 1g BD|Methenamine Hippurate 1g BD for 6 months
214550644|NCT06710899|DRUG|Methenamine Hippurate 1g BD + Vitamin C 1g BD|Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
214550645|NCT07041619|DEVICE|Intersection short-pulse (ISP) stimulation|The intervention aims to terminate pathological brain oscillations (i.e. epileptiform activity) in patients.
214550646|NCT06881264|DRUG|HR17031 injection|HR17031 injection
214550647|NCT06881264|DRUG|insulin glargine|insulin glargine
214550648|NCT07039669|DRUG|611|611 subcutaneous (SC) injection
214550649|NCT07039669|DRUG|Placebo|placebo Q2W, subcutaneous (SC) injection
214550650|NCT07039864|DIAGNOSTIC_TEST|protein bar first|Take protein bar(after one week fried eggs intake) to evaluate the size of the gallbladder with ultrasound
214550651|NCT07039864|DIAGNOSTIC_TEST|fried eggs first|Take fried eggs (after one week protein bar intake) to evaluate the size of the gallbladder with ultrasound
214550652|NCT05944614|OTHER|Magnetic Resonance imaging (MRI) examination|3D CINE and 4 dimensional (4D) flow MRI sequence
214550653|NCT07044466|BEHAVIORAL|CBT4CBT-Buprenorphine|CBT4CBT-Buprenorphine is an evidence-based, Internet-delivered cognitive behavioral therapy program for individuals prescribed buprenorphine by a medical provider. It includes eight 30-minute modules.
214700981|NCT03180359|BIOLOGICAL|Recommended vaccine scheme according to French Vaccine Schedule 2015|"* BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
214700982|NCT05864443|PROCEDURE|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
214550654|NCT07045428|DRUG|68Ga-GP-01 Injection|A certain mass dose of 68Ga-GP-01 will be used in this study, and the radiation dose will be no more than, enabling all participants will receive a radiation dose of 5±2 mCi in the study.
214550655|NCT07044583|BEHAVIORAL|Opioid Educational Video|The video includes information on (1) how to consume appropriate over-the-counter pain medication alongside opioids for optimal pain control, (2) how prescribed opioids should be used only to treat pain related to the surgery, and (3) the proper disposal of unused opioids. The video was created through the University of Utah Office of Patient Experience. Feedback regarding the educational content was provided by surgeons, pain management physicians, and pharmacists throughout the process.
214550656|NCT06921746|DIAGNOSTIC_TEST|Urine Microbiological and Metabolomic Analysis|Microbiological and metabolomic analysis of a urine sample will be performed in the study subjects, before and after the end of the treatment.
214550657|NCT07049588|OTHER|Quantitative neuromuscular MRI|Quantification of biomarkers as fat fraction, magnetization Transfer Ratio, muscular volume, relaxation time T2
214550658|NCT07049588|OTHER|Skin biopsy|Performed on the arm or index finger, depending on patient age
214550659|NCT07049588|OTHER|Clinical scores|ONLS, CMTES-R, CMT-Peds, CMT-FOM
214550660|NCT07049588|OTHER|Blood test|10 ml sample
214550661|NCT07049588|OTHER|Patient Report Outcomes Measures|pCMT-QoL, EVA, WALK-12, PGI-c, SF-12
214550662|NCT07048990|BEHAVIORAL|Empowerment Group Therapy|Empowerment is a manualized, culturally sensitive treatment program. The treatment is based on a modular principle that transdiagnostically targets major symptom domains (e.g. stress, depression, anxiety), and can be flexibly adapted to individual mental health conditions of clients who participate in this program. The intervention is designed as a psychological group intervention for resource-limited settings and scalable for different formats (i.e. in-person, online, hybrid) to be feasible under the unstable conditions of war (e.g. missile attacks, power outrages). Key therapeutic elements are psychoeducation, emotion regulation strategies, problem solving and building coping skills. The activation of individual and culture-specific resources as well as building self-help skills are at focus of the treatment.
214550663|NCT07049471|BEHAVIORAL|Swallowing Exercise and Maneuver Program for Older Adults with Dysphagia|The intervention is a structured swallowing exercise and maneuver program designed specifically for older adults with oropharyngeal dysphagia in nursing homes. It combines four evidence-based techniques: Masako Maneuver, Chin Tuck Against Resistance (CTAR), Supraglottic Swallow, and Super-Supraglottic Swallow. The program was delivered by nurses using video-guided instructions and was conducted three times daily before meals for six weeks. Unlike interventions targeting post-stroke dysphagia, this program focuses on non-stroke-related swallowing difficulties in frail elderly populations residing in long-term care facilities.
214700983|NCT03761719|OTHER|No intervention|No intervention
214700984|NCT01869166|BIOLOGICAL|CART-EGFR|
214700985|NCT01745991|DEVICE|CoSeal spray|
214700986|NCT02623036|DRUG|Equivalent dose enalapril|Chronotherapy with enalapril.
214700987|NCT02623036|DRUG|Equivalent dose lisinopril|Chronotherapy with lisinopril
214700988|NCT02509494|BIOLOGICAL|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
214700989|NCT02509494|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
214700990|NCT02509494|BIOLOGICAL|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
214700991|NCT02509494|BIOLOGICAL|Placebo|0.9% saline for injection.
214700992|NCT06039917|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
214700993|NCT06039917|OTHER|Manually remind the patients|Medical staff remind patients to review manually.
214700994|NCT04900480|OTHER|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
214700995|NCT02692313|DRUG|Epinephrine|Dose response of epinephrine infusion
214700996|NCT02692313|OTHER|Saline infusion|Placebo
214700997|NCT06532253|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
214700998|NCT05680194|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
214700999|NCT05680194|DRUG|Bisphosphonate|Bisphosphonate
214701000|NCT05507645|DRUG|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
214701001|NCT05507645|DRUG|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
214701002|NCT00088569|DRUG|0-15 Water|
214701003|NCT00313027|RADIATION|PET scan|
214701004|NCT06051981|DRUG|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
214701005|NCT06051981|DRUG|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
214701006|NCT06051981|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
214550664|NCT07050069|DEVICE|Transcranial Magnetic Stimulation (TMS) Device / Respiratory Training Device|Participants received group-specific interventions 5 days/week for 4 weeks.
214550665|NCT07049393|DIAGNOSTIC_TEST|Road traffic accident (RTA) victims(SAQ)|"Road traffic accident (RTA) victims present with respiratory and/or cardiac complications. a self-administered questionnaire.~Patients transported to healthcare facilities in District Karak using emergency transport systems.Road traffic accident (RTA) victims presenting with respiratory and/or cardiac complications."
214701007|NCT06051981|DRUG|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
214701008|NCT01540968|BEHAVIORAL|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
214701009|NCT06171672|OTHER|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
214701010|NCT03424577|DRUG|H3B-6527|Oral capsule
214701011|NCT02142257|PROCEDURE|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
214701012|NCT02142257|DEVICE|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
214701013|NCT03682939|BIOLOGICAL|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
214701014|NCT03682939|BIOLOGICAL|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
214701015|NCT03182413|DRUG|Placebo|
214701016|NCT03182413|DRUG|Modafinil|
214701017|NCT03182413|DRUG|THN102|
214701018|NCT03305757|DRUG|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
214701019|NCT03305757|PROCEDURE|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
214701020|NCT03305757|PROCEDURE|Conventional|Conventional closure after mastectomy
214701021|NCT06402903|OTHER|Observation|"The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties)."
214701022|NCT04415619|PROCEDURE|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
214701023|NCT06017778|DEVICE|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
214701024|NCT06017778|OTHER|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
214701025|NCT02800772|DIETARY_SUPPLEMENT|acetic acid|
214701026|NCT02800772|DIETARY_SUPPLEMENT|saline|
214701027|NCT02299713|DEVICE|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
214701028|NCT02151799|PROCEDURE|Abdominoplasty and liposuction|
214701029|NCT00251277|DRUG|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
215029622|NCT06637397|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
214701030|NCT05668468|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
214701031|NCT05668468|OTHER|Placebo cellulose capsule|Daily cellulose capsule
214701032|NCT04205578|DRUG|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
214701033|NCT04205578|DRUG|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
214701034|NCT02286492|DRUG|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
214701035|NCT04307836|DEVICE|Renal Denervation|Renal Denervation: DENEX system
214701036|NCT02319096|OTHER|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
214701037|NCT02370940|OTHER|High phytate intake|
214701038|NCT02370940|OTHER|Low phytate intake|
214701039|NCT02607332|DRUG|Paclitaxel|
214701040|NCT04438252|DIAGNOSTIC_TEST|ICDAS II|Index for caries detection
214701041|NCT04438252|DEVICE|CariScan Pro|Device for early caries detection
214701042|NCT04438252|RADIATION|Digital Radiograpgy|Device for digital x-ray imaging
214701043|NCT03227965|BIOLOGICAL|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
214701044|NCT02915107|DEVICE|BioFreedom|PCI with BioFreedom
214701045|NCT02915107|DEVICE|Orsiro|PCI with BioFreedom
214550666|NCT07049237|BEHAVIORAL|Evidence-Based Nursing Under Quantitative Assessment Strategy (EB-NQAS)|A multifaceted nursing program using the Edmonton Symptom Assessment Scale (ESAS) for quantitative symptom assessment to guide personalized, evidence-based care plans. Interventions included tailored strategies for pain management (graded, music therapy, heat, opioids), fatigue (supervised walking, sleep optimization), nausea/vomiting prevention (prophylactic antiemetics, ginger, dietary advice), and psychological support (cognitive-behavioral therapy). Care plans were dynamically monitored and adjusted.
214550667|NCT07049237|BEHAVIORAL|Routine Nursing Care|Standard hospital oncology nursing care including health education, general psychological support (weekly 15-minute sessions), dietary guidance based on nutritional risk screening, and verbal instructions for managing common adverse effects.
214550668|NCT07050615|PROCEDURE|Continuous suturing|In this group, episiotomy repair was done using the continuous suturing.
214550669|NCT07050615|PROCEDURE|Interrupted suturing|In this group, episiotomy repair was done using the interrupted suturing.
214550670|NCT07050485|DIETARY_SUPPLEMENT|PoZibio|1 gummy once daily
214550671|NCT07050485|DIETARY_SUPPLEMENT|Inert placebo|1 gummy once daily
214550672|NCT07046637|DEVICE|Inspiratory muscle fatigue group|The subjects will perform deep inspirations against a threshold device with varying resistances
214550673|NCT07046637|DEVICE|Inspiratory muscle warm-up group|The subjects will perform deep inspirations against a threshold device with varying resistances
214550674|NCT07045792|PROCEDURE|Body Awareness Therapy|Individuals trained for body awareness therapy.
214550675|NCT07050394|DRUG|CD-GA-102|CD-GA-102 will be administered intravenously at 50 μg per dose, with dosing scheduled at 2 weeks (±3 days) and 4 weeks (±3 days) after the initial dose, followed by maintenance therapy every 3 weeks (±3 days). Dosing intervals may be adjusted based on participant tolerability and safety. After receiving at least two doses of CD-GA-102 monotherapy and completing safety assessments, participants may be offered combination therapies, as determined by the investigator.
214550676|NCT07050329|DEVICE|Electrocautery|Axillary dissection was done through bipolar electrocautery
214550677|NCT07050329|DEVICE|Ultrasonic dissector|Axillary dissection was done through ultrasonic dissector.
214550678|NCT07049250|BEHAVIORAL|Evidence-Based Nursing Intervention under Quantitative Evaluation Strategy|A multifaceted nursing program incorporating comprehensive risk assessment, dynamic risk stratification, psychological and cognitive interventions (including cognitive-behavioral techniques, peer mentoring, family counseling), systematic complication prevention strategies (including prophylactic antiemetics, dietary guidance, infection control), and sleep optimization protocols.
214550679|NCT07049250|BEHAVIORAL|Routine Nursing Care|Standard disease education on chemotherapy side effects and self-management, personalized exercise guidance, and medication adherence counseling. Delivered in 30-minute sessions twice weekly for two months.
214701046|NCT02477293|DRUG|Hyeonggaeyeongyo-tang|
214701047|NCT00474162|DRUG|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
214701048|NCT00474162|DRUG|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
214701049|NCT02871401|DRUG|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
214701050|NCT02871401|DRUG|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
214701051|NCT01120379|DEVICE|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
214701052|NCT02344420|PROCEDURE|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
214701053|NCT02344420|BEHAVIORAL|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
214701054|NCT02344420|PROCEDURE|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
214701055|NCT02344420|BEHAVIORAL|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
215029623|NCT06637579|OTHER|universal exercise unit therapy with task oriented strength training|Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.
215029624|NCT06637579|OTHER|Task-oriented training for gross motor functioning|Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
215029625|NCT06639295|DRUG|611|611 subcutaneous (SC) injection.
215029626|NCT06639295|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214550680|NCT07050004|BEHAVIORAL|SMOKING|Patients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle
214550681|NCT07050940|DIETARY_SUPPLEMENT|Postbiotic|postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day
214701056|NCT05336006|OTHER|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
214701057|NCT05336006|OTHER|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
214701058|NCT06047899|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
214701059|NCT06047899|OTHER|Placebo|mannitol formulated for oral administration (capsules)
214701060|NCT01590862|DEVICE|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
214550682|NCT07050940|DRUG|AntiPD1|Antibody to PD1 approved for standard of care
214550683|NCT07048886|DRUG|Rocklatan (netarsudil 0.02% and latanoprost 0.005%)|Additional intraocular eye pressure lowering post-Hydrus
214550684|NCT07048886|DRUG|Systane|Placebo Comparator (artificial tears)
214550685|NCT07049406|DIAGNOSTIC_TEST|Structured Pre-tested|This will analyzed forthe differences in cultural perceptions and their Influence on health-seeking behavior.
214550686|NCT07049770|DIETARY_SUPPLEMENT|Eczeva supplementation|Intervention contains 0.2g of eczefolia extracts, and 0.01g of rice ceramides as main active ingredients.
214550687|NCT07048899|DRUG|Chlorhexidine|Intraperitoneal irrigation with Irrisept solution
214550688|NCT07048899|DRUG|Normal Saline|Intraperitoneal irrigation with normal saline
214701061|NCT02334670|DRUG|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
214550689|NCT07051096|DEVICE|A novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium.|This device will be provided on top of routine post-operative management and standard delirium reduction measures. It has proven effective in a previous clinical trial by reducing agitation and unscheduled medications. It displays nature-driven responsive imagery through an available mobile screen/device for the first 7 days after surgery or discharge, whichever comes first. The imagery adapts in real-time to the participant's movement and sound. The device will be placed at the foot of the bed while the patient is awake and may be interrupted at the discretion of the patient, bedside RN or attending physician.
214550690|NCT07051096|PROCEDURE|Routine post-operative management and standard delirium reduction measures.|Examples of routine post-operative care are sleep optimization, avoidance of delirium-promoting medications, orientation, and mobilization.
214550691|NCT07050342|OTHER|Personalized Nutrition-Based Psychosomatic Care|This intervention involves personalized, nutrition-focused care provided in a specialized outpatient clinic for individuals with psychosomatic and mental health conditions. The care model integrates nutritional counseling, education on gut-brain interactions, and patient-centered support to promote psychological well-being and reduce stress. No experimental drugs or diets are administered. Instead, the intervention focuses on individualized recommendations based on clinical assessments and ongoing routine laboratory markers (e.g., inflammatory markers, vitamin levels). Participants also receive guidance aimed at improving dietary habits and resilience within a biopsychosocial framework. The intervention is part of regular clinical care and not blinded or randomized.
214550692|NCT07051083|DIAGNOSTIC_TEST|Risk Stratification|Risk Stratification for Assessing Muscle Infiltration in Bladder Cancer.
214550693|NCT07050888|DIETARY_SUPPLEMENT|Inulin (prebiotic, fermentable fiber)|inulin (prebiotic, fermentable fiber)
214550694|NCT07050888|DIETARY_SUPPLEMENT|Placebo|placebo (matodextrin)
214550695|NCT07049185|DRUG|QL1706 Plus Celecoxib Group|QL1706 (anti-PD-1/CTLA-4 bispecific antibody) will be administered at 5 mg/kg by intravenous infusion every 3 weeks. Celecoxib 200 mg will be taken orally twice daily starting on Day 1 of each 3-week treatment cycle. Treatment continues until disease progression, intolerable toxicity, or for a maximum of 2 years.
214550696|NCT07050095|OTHER|Virtual Reality Group|Patient will undergo virtual reality (VR) immersion using oculus.
214550697|NCT07050095|DRUG|Midazolam Group|Patient will receive midazolam premedication only.
214550698|NCT07050979|OTHER|Goal-Directed Fluid Therapy (GDFT)|This arm administers fluid and vasopressor therapy based on SVV (less than 15%) and CI (\>2.6 L/min/m²) targets using the Pressure Recording Analytical Method (PRAM) system with the help of intra-arterial pressure monitoring method. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
214550699|NCT07050979|OTHER|Conventional Fluid Therapy|This arm administers fluid and vasopressor therapy based on targets of Mean Arterial Pressure (MAP) 65-95 mmHg and hourly urine output minimum of 0.5 mL/kg/hr. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
214550700|NCT07049003|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of the Deep Cerebellar Nuclei
214550701|NCT05775523|DRUG|No intervention|No intervention
214550702|NCT07050992|PROCEDURE|Laser posterior nasal nerve neurolysis|Posterior nasal nerve ablation using laser is performed through an angled nasal probe at 20 degrees and a 90-degree endoscope to deliver laser energy to the posterior nasal nerve area. The thermal energy is conducted to the middle meatus and the posterior superior part of the inferior turbinate, targeting the area supplied by the posterior nasal nerve. The ablation continues until there is widespread mucosal blanching and the formation of at least one continuous brown eschar
214550703|NCT07050992|PROCEDURE|Sham surgery|The same laser surgical instrument is used to enter the nasal cavity for a sham procedure with minimal dosage. The energy setting uses the lowest limit of 0.5W with intermittent emission (0.01 second emission with 1 second rest), and the emission mode is Super Pulse to reduce heat dispersion. It is applied to the mucosal surface without blood supply at the lower edge of the middle turbinate for 2 minutes on each side, totaling only 1.2 seconds of cumulative laser emission. Compared to the experimental group using 2W energy with continuous irradiation for 2 minutes, the total energy release difference in the sham surgery group is only 1/400 of the experimental group (2W120sec/0.5W1.2sec). This is to produce the sound, light, and tactile effects of the laser, but without sufficient energy transfer to cause high-temperature mucosal changes and tissue alterations, serving as a high-quality sham surgery control group.
214550704|NCT01507077|DRUG|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
214550705|NCT01507077|DRUG|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
214550706|NCT07049055|DRUG|E-EDV-D682|"E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptors via single chain bispecific antibodies (BsAb).~E-EDV-D682 packages a chemotherapeutic payload PNU159682 into the EDV which targets the epidermal growth factor (EGFR) on cancer cells via a BsAb."
215029627|NCT06640127|PROCEDURE|Sinus lifting and implant placement with osteotomes|Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion
214550707|NCT07049055|DRUG|EDV-GC|EDV-GC is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different drugs. EDV-GC packages the immunomodulatory adjuvant aplha-galactosyl ceramide (GC) into the EDV and is designed to recruit anti-tumor immune cells.
215029628|NCT06640127|PROCEDURE|Sinus lifting and implant placement with specifically designed drills|Sequential drills were used for sinus membrane elevation and implant insertion
215161502|NCT05456841|BEHAVIORAL|Empathic Communication Skills (ECS) training|"The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
215161503|NCT05456841|OTHER|Standard of Care participant interaction|Standard of Care participant interaction
214701062|NCT03560635|BEHAVIORAL|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
214701063|NCT03162055|DRUG|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
215161504|NCT06445062|DRUG|RMC-6236|Oral tablet
215161505|NCT06445062|DRUG|mFOLFOX6 regimen|IV infusion
214701064|NCT03162055|DRUG|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
214701065|NCT00855257|DRUG|Acid Nicotinique|
214701066|NCT00855257|DRUG|Placebo|
215161506|NCT06445062|DRUG|bevacizumab|IV infusion
215161507|NCT06445062|DRUG|mFOLFIRINOX regimen|IV infusion
215161508|NCT06445062|DRUG|cetuximab|IV infusion
215161509|NCT06445062|DRUG|gemcitabine|IV infusion
214550708|NCT07049055|DRUG|Gemcitabine|Gemcitabine in combination with nab-paclitaxel is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
214550709|NCT07049055|DRUG|Nab paclitaxel.|Nab-paclitaxel in combination with gemcitabine is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
214701067|NCT02493322|DRUG|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
215161510|NCT06445062|DRUG|nab-paclitaxel|IV infusion
215161511|NCT06445062|DRUG|RMC-9805|Oral Tablet
215161512|NCT05013736|DEVICE|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
215161513|NCT05013736|BEHAVIORAL|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
214550710|NCT07050953|OTHER|focused cardiac ultrasound|A focused cardiac ultrasound will be performed to measure the dimensions of ascending aorta
214550711|NCT07050914|DEVICE|McGrath Video Laryngoscope|A video laryngoscope.
214550712|NCT07050914|DEVICE|Macintosh Laryngoscope|A classic laryngoscope.
214550713|NCT07050498|DEVICE|Virtual reality|"Virtual reality hypnosis software applications are Class I medical devices according to Rule 12 of Directive 93/42/EC. They allow, through a virtual reality headset and headphones, to immerse the patient in a hypnotic sound and visual environment. Several visual scenarios can be proposed, allowing the patient to virtually travel to a beach, the seabed, on an alpine walk, etc.).~The HypnoVR Biofeedback virtual reality device is provided by the HypnoVR company."
214550714|NCT07050498|PROCEDURE|Usual Care Group|Routine preoperative procedure (local anesthesia)
214550715|NCT07049458|DRUG|CHO-A04|CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.
214550716|NCT07048977|PROCEDURE|Needle-Knife Precut Papillotomy over Pancreatic Stent|If the papilla was treated with three unintended MPD cannulations, a needle-knife precut papillotomy with a small incision over a pancreatic stent (NKP-SIPS)
214550717|NCT07048977|PROCEDURE|Transpancreatic Sphincterotomy|TPS was performed as Goff reported; in short, after cannulation of the pancreatic duct was achieved, a pull-sphincterotome on a guidewire was used to cut the septum between the bile and pancreatic ducts along the direction from 11 o'clock to 12 o'clock. After that, the pancreatic stent is placed first, and the sphincterotomy is extended to expose the biliary lumen, and the biliary duct can be cannulated.
214550718|NCT07050147|DEVICE|Nasal high flow|3 sonographic measurements after use of 30 minutes
214550719|NCT07050147|DEVICE|NIV|3 sonographic measurements after 30 minutes use
214550720|NCT07050199|PROCEDURE|Emergency laparotomy|Emergency laparotomy
214550721|NCT06581536|BEHAVIORAL|Yes and Know curriculum|Yes and Know is fully virtual intervention that integrates group-based education with digital tools to support young people ages 14 to 19 by increasing their relationship and healthy life skills. The curriculum focuses on sexual and reproductive health; healthy relationships; life skills; and educational and career success. It is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
214550722|NCT06581536|BEHAVIORAL|Nutrition Education for Adolescents|Youth will receive a fully virtual intervention that integrates group-based education with digital tools focused on adolescent nutrition and wellness. The curriculum is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
214550723|NCT06421155|OTHER|MRF with neurocognative studies|Magnetic Resonance Imaging is used to assess the risk of neurocognitive side effects in pediatric and AYA patients with acute leukemia receiving chemotherapy and participants will also be asked to complete a neurocognitive battery designed by Cogstate and administered on iPad in a simple gaming format
214550724|NCT06861712|RADIATION|SBRT|The experimental group will first receive SBRT (Stereotactic Body Radiotherapy) for the primary tumor and positive lymph nodes (prescribed dose: 6 Gy × 3 fractions, once every other day).
214701068|NCT02493322|DRUG|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
214701069|NCT02493322|DRUG|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
214701070|NCT03480958|DEVICE|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
214701071|NCT03480958|OTHER|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
214701072|NCT03480958|OTHER|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
214701073|NCT04758598|DEVICE|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
214701074|NCT04758598|DEVICE|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
214701075|NCT01617655|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
214701076|NCT01617655|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
214701077|NCT01617655|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
215161514|NCT05013736|DEVICE|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
214550725|NCT06861712|DRUG|Docetaxel, Cisplatin, Toripalimab|Toripalimab 240mg (free medicine) + Docetaxel 75mg/m2 + Cisplatin 75mg/m2, q3w for 3 courses
214550726|NCT06861712|PROCEDURE|Radical resection surgery|Radical resection surgery
214550727|NCT06861712|RADIATION|IMRT ± chemotherapy/toripalimab|According to the preoperative staging and postoperative pathological characteristics, all patients will receive postoperative radiotherapy with or without cisplatin-based chemotherapy. Additionally, patients can choose whether to continue maintenance therapy with toripalimab after surgery.
214550728|NCT03835273|OTHER|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
214701078|NCT00438893|DIETARY_SUPPLEMENT|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
214701079|NCT01252641|BIOLOGICAL|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
214701080|NCT01113996|BEHAVIORAL|Protein supplementation and strength training|Protein supplementation and strength training
214701081|NCT01113996|DIETARY_SUPPLEMENT|Protein supplementation|Protein supplementation
214701082|NCT00891163|DRUG|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
214701083|NCT00891163|DRUG|Placebo Patch|placebo
214701084|NCT01974986|OTHER|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
214701085|NCT01974986|OTHER|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
214701086|NCT01974986|OTHER|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
214701087|NCT03685552|OTHER|Prog: Purify-2|"Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
214701088|NCT00348842|PROCEDURE|Newcastle Virus|
214701089|NCT00286364|DRUG|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
214701090|NCT06289842|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
214701091|NCT04011124|DRUG|Fluzoparib|single dose on Day 1 and Day 12
214550729|NCT03835273|OTHER|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
214550730|NCT03835273|OTHER|Questionnaires|Three validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and LASORS questionnaire.
214550731|NCT04447131|OTHER|venipuncture in peripheral vein|single vacuum venipuncture in peripheral vein
214550732|NCT06715371|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE)|"Transthoracic echocardiography (TTE) is a non-invasive imaging technique performed by placing an ultrasound transducer on the chest to obtain detailed heart images. TTE is conducted preoperatively on awake patients within two weeks prior to cardiac surgery, following ASE chamber quantification guidelines.~Transesophageal echocardiography (TEE) is an invasive imaging technique where an ultrasound transducer is placed in the esophagus, providing closer and clearer images of the heart. TEE is performed intraoperatively under general anesthesia as part of routine care."
214701092|NCT04011124|DRUG|Rifampicin|QD on Day 5-14 for 10 days
214701093|NCT02277522|BIOLOGICAL|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
214701094|NCT02173392|DRUG|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
214701095|NCT03737422|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
214701096|NCT03737422|OTHER|control|no supplementation
214701097|NCT00080886|BIOLOGICAL|rituximab|
214701098|NCT00080886|DRUG|carmustine|
214701099|NCT00080886|DRUG|cytarabine|
214701100|NCT00080886|DRUG|etoposide|
214701101|NCT00080886|DRUG|melphalan|
214701102|NCT00080886|PROCEDURE|autologous bone marrow transplantation|
214701103|NCT00080886|PROCEDURE|peripheral blood stem cell transplantation|
214701104|NCT05137730|DRUG|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
214701105|NCT02394808|DEVICE|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
214701106|NCT02394808|DEVICE|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
214701107|NCT05479266|OTHER|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
214701108|NCT05479266|OTHER|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
214701109|NCT03792165|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
214701110|NCT03792165|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
214701111|NCT04605939|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
214701112|NCT04605939|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
214701113|NCT06120959|OTHER|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
215029629|NCT06641960|DRUG|Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
215029630|NCT06641960|PROCEDURE|Traditional treatment|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
215029631|NCT06641648|DRUG|NK cell|Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
215029632|NCT06639022|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
215029633|NCT06639022|PROCEDURE|Erector spinae plane block|"Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214550733|NCT04165746|OTHER|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
214550734|NCT04165746|BEHAVIORAL|Caregiving Intervention|During AVI an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. During that meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. AVI is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. The AVI methodology was selected to be used as a method of caregiving intervention with the study participants due to its demonstrated results in its use with children in contexts of social vulnerability, as well as families included in the child protection system. This will be the first time that AVI is being used in foster and institutional care in Brazil.
214550735|NCT07050537|PROCEDURE|Constant oxygen concentration protocols in embryo culture|Participants were randomly assigned to constant (5%) oxygen concentration group and received different blastocyst culture protocols.
214701114|NCT06120959|OTHER|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
214701115|NCT03269890|PROCEDURE|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
214550736|NCT07050537|PROCEDURE|Sequential oxygen concentration protocols in embryo culture|Participants were randomly assigned to sequential (5%-2%) oxygen concentration group and received different blastocyst culture protocols.
214550737|NCT02600897|DRUG|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
214701116|NCT03269890|PROCEDURE|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
214701117|NCT04422106|DIAGNOSTIC_TEST|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
214701118|NCT06157047|PROCEDURE|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
214701119|NCT02922192|DRUG|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
214701120|NCT03723005|DEVICE|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
214701121|NCT03723005|DEVICE|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
214701122|NCT03265743|OTHER|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
214701123|NCT02789605|DRUG|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
214701124|NCT02789605|DRUG|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
215029634|NCT06639022|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
215029635|NCT06637696|OTHER|Blood Culture Bundle|In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
215029636|NCT06640218|DEVICE|sealer activation with Eddy sonic and AF max|activation of sealer after cleaning and shaping, before the obturation
215029637|NCT06640218|OTHER|without AF max or Eddy sonic sealer activation|sealer without activation
215029638|NCT06640270|DEVICE|Diabetes Treatment|Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
215029639|NCT06637683|COMBINATION_PRODUCT|LiveSpo COLON|LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
215029640|NCT06637683|OTHER|Routine treatment|The standard internal medicine treatment protocol of the hospital
214550738|NCT02600897|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
214550739|NCT02600897|DRUG|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
214550740|NCT02600897|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
214550741|NCT01945814|DRUG|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
214550742|NCT01945814|DRUG|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
214550743|NCT00157846|DEVICE|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
214550744|NCT06892327|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
214550745|NCT06830733|GENETIC|ARI0002h|"* Treatment with ARI0002h cells~* Other names: CARTBCMA\_J22.9-h:CD8TM:4-1BB:CD3. Adult differentiated autologous T cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory domain and the CD3z signalling domain that has been humanized."
214550746|NCT06837103|DEVICE|Intermittently Scanned Continuous Glucose Monitor|intervention used by the isCGM and isCGM+Coaching groups
214550747|NCT05203471|OTHER|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
214701125|NCT04724733|BEHAVIORAL|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
214701126|NCT04724733|BEHAVIORAL|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
214701127|NCT03341923|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
214701128|NCT03341923|DEVICE|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
214701129|NCT05501288|DRUG|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
214701130|NCT05501288|DRUG|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
214701131|NCT01742078|DRUG|LY2541546 - IV|Administered IV
214701132|NCT01742078|DRUG|LY2541546 - SC|Administered SC
215029641|NCT06645301|BIOLOGICAL|Group A|BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
215029642|NCT06645301|BIOLOGICAL|Group B|BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
215029643|NCT06644586|OTHER|videolaryngoscopy|The patients intubated with video laryngoscopy
215029644|NCT06644586|OTHER|Direct Laryngoscopy|The patients intubated with direct laryngoscopy
214701133|NCT01742078|DRUG|Placebo|Administered IV or SC
214701134|NCT04580394|DRUG|AD109|Oral administration before bed
215161515|NCT06578897|DEVICE|3D Metal Tibial and Femoral cones|"* To collect retrospective clinical outcomes and data on revision TKAs using Medacta GMK Revision with 3D metal tibial and femoral cones~* Evaluate the patient reported functionality of the operated knee~* Evaluate the clinical and radiological performance~* Evaluate safety of the cones~* Evaluate survivorship of revisions using tibial and femoral cones"
215161516|NCT06248619|BIOLOGICAL|Teprotumumab|SC injection
215161517|NCT06248619|OTHER|Placebo|SC injection
215161518|NCT06206031|DEVICE|Intraosseous ultrasonography at tibia before, during, and after a physiological vascular stimulation (venous occlusions, arterial occlusion, handgrip)|"Timing for sub-protocol 1 (performed twice with 2-to-10-day interval): donning in supine position - rest 5 minutes - venous occlusion to 40 mmHg 3 minutes - rest 10 minutes - arterial occlusion to 200mmHg 2 minutes - post-occlusion period 10 minutes - rest 10 minutes - static handgrip 30% Maximum Voluntary Force 3 minutes - recovery 2 minutes and doffing.~Timing for sub-protocol 2 (performed once). First, two sequences of intraosseous ultrasonography are performed in 45° head-up tilt position, with 10-minutes rest between sequences: donning and rest 5 minutes - occlusion to 80 mmHg 2 minutes - rest 10 minutes - occlusion to 180 mmHg 2 minutes - rest 10 minutes. During the first sequence, ultrasonography probe is positioned between middle and lower third of tibia for cortical bone measurement; during the second - at distal epiphysis of the tibia for trabecular bone measurement. After ultrasonography, subject is sitting down for 10 minutes for computed tomography."
214550748|NCT06804213|BEHAVIORAL|Mobile health app with positive psychological activities|Mobile health app with step tracking, sleep tracking, and positive psychological activities
214550749|NCT03377517|RADIATION|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
214550750|NCT06823765|OTHER|Large Language Model Clinical Decision Support|A Large Language Model (LLM) integrated into the clinic's Electronic Medical Record system provides real-time feedback on patient assessments. Community Health Extension Workers first create a standard SOAP note, submit it to the LLM, and receive detailed feedback and key recommendations. They can then update their assessment based on this feedback. All final treatment decisions are made by Medical Officers who independently evaluate patients.
214550751|NCT06898476|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
214550752|NCT06898476|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
214550753|NCT06840769|DRUG|Fosnetupitant 235 mg solution|Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration
214550754|NCT06840769|DRUG|Akynzeo solution|235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution
214550755|NCT05780177|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|Participants in this arm will receive 4 sessions (30-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
214550756|NCT05780177|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|Participants in this arm will receive 4 sessions (30-60 minutes) of progressive muscle relaxation training called PMRT.
214550757|NCT04550676|BEHAVIORAL|HIIT (intervention)|Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
214701135|NCT04580394|DRUG|Atomoxetine|Oral administration before bed
214701136|NCT04580394|DRUG|R-oxybutynin|Oral administration before bed
214701137|NCT04580394|DRUG|Placebo|Oral administration before bed
214701138|NCT04580394|DIAGNOSTIC_TEST|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
214701139|NCT02276521|BIOLOGICAL|Cervarix®|All groups will received one dose of Cervarix® vaccine
214701140|NCT02010437|DRUG|Sodium Tetradecyl Sulphate (STS)|
214701141|NCT02307071|DEVICE|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
214701142|NCT00642746|DRUG|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
214701143|NCT00642746|DRUG|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
214701144|NCT00642746|DRUG|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
214701145|NCT00642746|DRUG|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
214701146|NCT00642746|DRUG|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
214701147|NCT05249985|DEVICE|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
214701148|NCT05249985|DIETARY_SUPPLEMENT|Protein|Participants will consume a daily protein supplement
214701149|NCT01204333|DRUG|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
214550758|NCT04550676|BEHAVIORAL|CME (active control)|Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
214550759|NCT06816264|DRUG|HRS-5346|HRS-5346
214550760|NCT06816264|DRUG|Placebo|Placebo
214550761|NCT04802161|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214550762|NCT04802161|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
214550763|NCT04802161|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214550764|NCT04802161|DRUG|Pomalidomide|Given PO
214550765|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
214550766|NCT06735456|OTHER|Mandala|The patient will undergo mandala painting during 1 session of chemotherapy.
214550767|NCT06880627|BEHAVIORAL|Brain Boost group|There will be 8 group educational sessions over an 8-week program period to learn strategies for improving cognitive function. Participants will also be asked to engage in 20 minutes, at least 5 times per week online game-like cognitively stimulating activities to improve cognitive health. In addition, surveys will be completed as certain timepoints.
214550768|NCT06880627|OTHER|Waitlist group|This group will continue to receive usual health and care routines. Participants will be asked to complete surveys at certain timepoints that are the same as the boost group. After the 6-month follow-up, participants will receive the intervention materials, which include 8 weekly educational session recordings with slides, 8 weeks' subscription to online brain games, and biweekly online office hours. The office hours, hosted by the principal investigator and a trained patient co-facilitator, will give participants a chance to discuss participant's progress and ask questions.
214550769|NCT05899816|DRUG|Rocatinlimab|Subcutaneous (SC) injection
214550770|NCT05899816|DRUG|Placebo|SC injection
214701150|NCT01204333|DRUG|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
214701151|NCT00507598|OTHER|No intervention|Correlative study collecting serum and tissue samples
214701152|NCT01811355|DRUG|Mexiletine|Sodium channel blocker
214701153|NCT01811355|DRUG|Placebo|Placebo
214701154|NCT05728671|DRUG|IP2015|Test drug
214550771|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
214550772|NCT06753110|DEVICE|OPRA transhumeral|Skeletal anchorage of amputation prostheses.
214550773|NCT06910059|OTHER|Observational|It is a observational study and patients with pacing indications who plan to receive Micra AV implantation will be recruited. No intervention procedure will be performed.
214550774|NCT06911112|DRUG|NBI-1065845|NBI-1065845 tablets
214550775|NCT06911112|DRUG|Placebo|Matching placebo tablets
214550776|NCT06913140|DRUG|Erector Spinae plane Block|Patients received (20ml) plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath at the level of the second thoracic segment (T2)
214550777|NCT06913140|DRUG|Costoclavicular block|Patients received (20ml) plain bupivacaine 0.25% injected in the costoclavicular space lateral to axillary artery.
214701155|NCT03337152|DRUG|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
214701156|NCT03337152|DRUG|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
214701157|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
214701158|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
214701159|NCT00071422|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
214701160|NCT05862558|DEVICE|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
214701161|NCT02662985|DRUG|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
214701162|NCT02662985|DRUG|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
214701163|NCT01807715|OTHER|survey|Survey before procedure to obtain demographic information and contraceptive information
214701164|NCT02480179|DEVICE|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
214701165|NCT04301687|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
214550778|NCT06913140|DRUG|Control group|Patients received sham block
214550779|NCT06918158|OTHER|Mobilization with Movement|"Mobilization with Movement~* The proximal row of carpals glides passively radially.~* Active thumb and wrist movements superimposed on the glide.~Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction"
214550780|NCT06918158|OTHER|Joint Specific Manipulation|"Joint Specific Manipulation~* High-velocity, low-amplitude thrust to the first carpometacarpal joint~* Radiocarpal wrist mobilization .Grade III-IV applied at end range. 2. Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction Ergonomics modifications"
214550781|NCT06871904|DRUG|Metformin Hydrochloride 500Mg Tablet|"Metformin 500 mg is being tested for its potential role in treating oral submucous fibrosis (OSF) due to its antifibrotic and anti-inflammatory effects. This intervention will be administered orally at a dose of 500 mg twice daily (OD) for a specified 6 months treatment period for Group 2 .~Metformin activates AMPK (AMP-activated protein kinase), which inhibits TGF-β signaling and collagen deposition, reducing fibrosis and inflammation.~Distinction from Other Arms: Unlike Pirfenidone, which directly targets profibrotic cytokines, Metformin modulates metabolic pathways to exert antifibrotic effects. The Control Group will receive supportive care for OSF."
214550782|NCT06871904|DRUG|Pirfenidone (PFD)|"Pirfenidone 200 mg (Pirfibet by Mactor Pharma, Pakistan) is an antifibrotic drug being tested for its potential role in treating oral submucous fibrosis (OSF). This intervention will be administered orally at a dose of 200 mg, twice daily for a specified treatment period which will be 6 months for Group 3 .~Pirfenidone modulates fibrotic pathways by inhibiting TGF-β and collagen synthesis, reducing fibrosis progression.~Distinction from Other Arms: Unlike Metformin, which has antifibrotic effects via AMPK activation, Pirfenidone specifically targets profibrotic cytokines. The Control Group will receive either a supportive care for OSF"
214550783|NCT06871904|DRUG|Beclomaethasone and Vitamin E|"The Supportive Care Group will receive Beclomethasone mouthwash (three times daily) and Vitamin E 400 mg (once daily) as part of supportive care for oral submucous fibrosis . This intervention serves as a comparison group to evaluate the efficacy of Metformin and Pirfenidone.~Beclomethasone is a topical corticosteroid that reduces inflammation and provides symptomatic relief in OSF.~Vitamin E is an antioxidant that may help reduce oxidative stress and improve tissue healing.~Distinction from Other Arms:~Unlike Pirfenidone and Metformin, which target fibrosis at the molecular level, Beclomethasone + Vitamin E primarily focus on symptom relief.~This arm will serve as an active comparator to determine whether the antifibrotic effects of Metformin and Pirfenidone provide superior therapeutic benefits."
214550784|NCT06844903|OTHER|Pulsed ultrasound at acupuncture points|The experimental group will receive pulsed ultrasound at bilateral acupuncture points of St29, Sp6 and unilateral acupuncture points on Ren4 and Ren5 in addition to standard care program for 12 weeks.
214550785|NCT06844903|OTHER|Placebo ultrasound at acupuncture points|The placebo group will receive the same but in Placebo manner for 12 weeks.
214550786|NCT06844903|OTHER|Standard care program|All participants in both groups will be given an info brochure, that included advice on a healthy diet as a low-carbohydrate and high-protein diet, high dietary fiber, and less saturated fat in addition to engagement in aerobic exercise, fast walking for at least 30 - 45 min, 3 days a week for 12 weeks.
214550787|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
214701166|NCT04301687|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
214701167|NCT02862223|DIETARY_SUPPLEMENT|Neoprinol|
214701168|NCT01134757|BIOLOGICAL|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
214701169|NCT04886193|DRUG|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"* FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
214701170|NCT06804304|BEHAVIORAL|Music-based telerehabilitation|The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).
215161519|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
215161520|NCT06546189|DIETARY_SUPPLEMENT|OMNi BiOTiC® 41167|"The product OMNi BiOTiC® 41167 contains lactobacillus strains"
215161521|NCT06546189|OTHER|Placebo|Placebo
215161522|NCT05052801|DRUG|Bemarituzumab|Intravenous (IV) infusion
215161523|NCT05052801|DRUG|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
215161524|NCT05052801|DRUG|Placebo|IV infusion
215161525|NCT06561074|DRUG|Decitabine|Given by vein
215161526|NCT06561074|DRUG|Venetoclax|Given by mouth
215161527|NCT06561074|DRUG|Calaspargase pegol-mknl|Given by vein
215161528|NCT05127057|OTHER|PRIME Parkinson Care|A novel model of care
215161529|NCT05127057|OTHER|Usual Care|Usual NHS Care
215161530|NCT05963568|DRUG|Polycap|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
214550788|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
214550789|NCT06848335|BEHAVIORAL|Remote Physical Activity Intervention|The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6, with maintenance doses in months 8 and 10. Mailings include motivation-matched physical activity manuals, tip sheets (on stretching, boredom, places to be active, etc.) and computer expert system-tailored PA feedback reports which draw from a bank of over 330 messages addressing psychosocial and environmental factors affecting PA. Participants receive one interactive text message on PA (goal setting and tips for increasing PA) daily for the first 6 months and weekly for months 7-12.
214550790|NCT06848335|BEHAVIORAL|Mindfulness Enhanced Remote Physical Activity Intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Attention Matched Enhanced Remote PA intervention or Mindfulness enhanced remote Physical Activity intervention. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals. For the Mindfulness enhanced remote Physical Activity intervention participants will receive additional messaging and support to manage their stress through incorporating evidence based MBSR and mindful movement into their daily routine.
214550791|NCT06848335|BEHAVIORAL|Attention Matched Enhanced Remote PA intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Mindfulness enhanced remote Physical Activity intervention or the Attention Matched Enhanced Remote PA intervention as described here. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals.
214550792|NCT06945081|OTHER|Preparation of forearm molds with SILFLO® silicone|Preparation of forearm molds with SILFLO® silicone (MONADERM, Monaco), CE-marked and already used routinely in dermocosmetics. These molds will, then, be analyzed.
214550793|NCT05350969|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
214550794|NCT05350969|DRUG|Placebo to CDR132L|Placebo to CDR132L
214550795|NCT03963869|OTHER|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
214550796|NCT04376151|OTHER|Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'|The intervention has been described in the arm/group descriptions.
214550797|NCT02593877|DEVICE|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
214550798|NCT02369471|DRUG|GWP42006|
214550799|NCT02369471|DRUG|Placebo|
214550800|NCT03318029|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
214550801|NCT03318029|DIETARY_SUPPLEMENT|Placebo|rice flour with no vitamin D
214550802|NCT03659162|DRUG|Azole Antifungal|oral gel \& injections
214550803|NCT03176264|DRUG|PDR001|400 mg every 4 weeks
214550804|NCT03176264|DRUG|bevacizumab|5 mg/kg every 2 weeks
214550805|NCT03176264|DRUG|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
214550806|NCT06055504|OTHER|Control Strategy|ICDs will be implanted in all patients according to current recommendations
214701171|NCT02493426|DRUG|Intranasal Oxytocin|
214701172|NCT02493426|DRUG|Placebo|
215161531|NCT05947305|PROCEDURE|Surgical Blade|Using a 15c blade to de-epithelialize the soft tissue extra-orally
215161532|NCT05947305|PROCEDURE|Mucotome|Using Megagen Mucotome to de-epithelialize the soft tissue intra-orally
214550807|NCT06055504|OTHER|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
214550808|NCT00010153|DRUG|fulvestrant|
214550809|NCT00010153|PROCEDURE|conventional surgery|
214550810|NCT04184453|DRUG|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
214550811|NCT04219995|DRUG|methylprednisolone sodium succinate|Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
214550812|NCT04219995|OTHER|Placebo|The placebo used in this study will be simple syrup.
214550813|NCT04149938|DRUG|Lidocaine topical system 1.8%|
214550814|NCT04149938|DRUG|Lidocaine patch 5%|
214550815|NCT05378334|DRUG|ICI|PD-1 inhibitors selected by clinicians based on patients' condition
214550816|NCT05378334|DRUG|Chemotherapy|AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
214550817|NCT05378334|DRUG|Placebo|The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
214550818|NCT05378334|DRUG|Bone-protecting and Mass-dispersesing Decoction|Chinese Herbal Formula,also named as HGXJT
214550819|NCT03602300|DRUG|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
214550820|NCT03602300|DRUG|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
214550821|NCT05495321|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
214550822|NCT03258723|BEHAVIORAL|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
214550823|NCT03258723|DRUG|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
214550824|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
214550825|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
214550826|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
214550827|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
214550828|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
214550829|NCT01235000|BIOLOGICAL|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
214550830|NCT04591379|DRUG|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
214701173|NCT06450691|PROCEDURE|biopsy|skin biopsy and blood sampling
214550831|NCT06177951|OTHER|NICU Discharge Passport|"The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns."
214550832|NCT06177951|OTHER|NICU Infant Care Class|The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
214550833|NCT02693197|DRUG|T-817MA|A single oral dose of 448 mg
214550834|NCT05214547|DEVICE|Focal VibrationTherapy|Myovolt delivers oscillatory mechanical vibration of focussed frequency and low amplitude to stimulate physiological benefits in soft tissues. Myovolt is non-aggressive and gentle to the body so can be safely targeted. Digitally tuned to transmit a discrete vibration frequency range between 30 - 100Hz for effective neuromuscular stimulation.
214701174|NCT02408796|DRUG|OTO-201|
215161533|NCT05947305|PROCEDURE|Diamond Bur|Using a surgical diamond bur to de-epithelialize the soft tissue intra-orally
214550835|NCT04765878|DEVICE|RespirAq Humidification|Humidifier
214550836|NCT01614353|OTHER|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
214550837|NCT01614353|OTHER|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
214550838|NCT05454345|DRUG|Sitafloxacin|In our Intervention group, sitafloxacin replace the ethambutol, 200mg/d
215161534|NCT05947305|PROCEDURE|Er:YAG Laser|Using an Er:YAG Laser to de-epithelialize the soft tissue intra-orally
215161535|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
215161536|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
215161537|NCT04914663|BEHAVIORAL|Exercise training|Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
215161538|NCT04471961|GENETIC|Exome sequencing in pediatrics cancers|This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
215161539|NCT06270953|DEVICE|Dozee Pro NX|Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements
215161540|NCT05512377|DRUG|brigimadlin|brigimadlin
215161541|NCT06462092|DRUG|Sacituzumab Govitecan|Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
215161542|NCT06462092|DRUG|Pemetrexed|Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).
215161543|NCT04336722|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
214550839|NCT05454345|DRUG|SMZ/TMP|In our The three-month Rifapentine\&Isoniazid\&Pyrazinamide\&Sitafloxacin\&SMZ/TMP-containing regimen, Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin, SMZ 80mg/kg/d, TMP16mg/kg/d
214550840|NCT05454345|DRUG|Rifampin|Rifampin is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, Rifampin 600mg (8-12mg/kg/d)
214550841|NCT05454345|DRUG|Pyrazinamide|Pyrazinamide is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 2000mg (20-30mg/kg/d)
214550842|NCT05454345|DRUG|Rifapentine|In our Intervention group, rifapentine replace rifampin, 600mg/d
214550843|NCT05454345|DRUG|Isoniazid|Isoniazid is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 300mg (4-6mg/kg/d)
214550844|NCT05454345|DRUG|Ethambutol|Ethambutol is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 1200mg (15-25mg/kg/d)
214550845|NCT05454345|DRUG|Moxifloxacin|Moxifloxacin is a fourth-generation fluoroquinolone with potent activity against M. tuberculosis in vitro and in vivo, 400mg (7.5-10mg/kg/d)
214550846|NCT02979106|OTHER|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
214550847|NCT00157768|DEVICE|Implantable cardioverter defibrillator|
214550848|NCT06958848|DEVICE|16 F chest tube|Insertion of 16F chest tube
214550849|NCT06958848|DEVICE|24 F chest tube|Insertion of 24F chest tube
214550850|NCT06958848|PROCEDURE|Early removal|Removal 2-6h after end of skin closure
214550851|NCT06958848|PROCEDURE|Standard removal|Removal 1day postoperative
214550852|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
214550853|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
214550854|NCT06145750|DIAGNOSTIC_TEST|Ability to order FirstLook™|FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
214550855|NCT06145750|OTHER|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
214550856|NCT06314971|OTHER|Tw1CE|A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
215161544|NCT04336722|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
215161545|NCT05895344|RADIATION|Proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
215161546|NCT05895344|RADIATION|Photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
214550857|NCT04488250|OTHER|Robot Therapy|Robot Therapy
214550858|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
214550859|NCT05323630|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
214550860|NCT00943345|DRUG|indometacin|"* capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
214550861|NCT05989828|BIOLOGICAL|Aldesleukin|Given IV
214550862|NCT05989828|BIOLOGICAL|Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|Given IV
214550863|NCT05989828|PROCEDURE|Biopsy|Undergo biopsy of breast tumor
214550864|NCT05989828|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214550865|NCT05989828|PROCEDURE|Computed Tomography|Undergo CT scan
214550866|NCT05989828|DRUG|Cyclophosphamide|Given IV
214701175|NCT04716192|OTHER|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
214550867|NCT05989828|PROCEDURE|Echocardiography|Undergo ECHO
214550868|NCT05989828|DRUG|Fludarabine|Given IV
214550869|NCT05989828|PROCEDURE|Leukapheresis|Undergo leukapheresis
214550870|NCT05989828|PROCEDURE|Magnetic Resonance Imaging|Undergo breast MRI
214550871|NCT05989828|PROCEDURE|Mammogram|Undergo mammogram
214550872|NCT05989828|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214550873|NCT05989828|PROCEDURE|Ultrasound Imaging|Undergo ultrasound of breast
214550874|NCT00044746|DRUG|Piperacillin/Tazobactam|
214550875|NCT00448877|DEVICE|fNIR light emitting and sensing device|
214550876|NCT00592293|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
214550877|NCT00223301|DRUG|Mycophenolate Mofetil (cellcept)|
214550878|NCT00066651|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
214550879|NCT04632043|OTHER|Endotracheal intubation|Endotracheal intubation
214550880|NCT02820064|PROCEDURE|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
214550881|NCT01710059|BEHAVIORAL|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
214550882|NCT01710059|BEHAVIORAL|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
214550883|NCT01710059|BEHAVIORAL|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
214550884|NCT01710059|BEHAVIORAL|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
214550885|NCT00944229|DRUG|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
214550886|NCT00944229|DRUG|Placebo|4 capsules of placebo every 24 hours
215029645|NCT06232993|OTHER|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
214550887|NCT03708237|DRUG|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
214550888|NCT03708237|DRUG|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
214550889|NCT03708237|DRUG|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
214550890|NCT03922022|BEHAVIORAL|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
214550891|NCT02022722|DRUG|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
214550892|NCT02022722|PROCEDURE|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
215161547|NCT03563248|DRUG|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
215161548|NCT03563248|DRUG|Losartan|Losartan is a drug that is used to lower blood pressure
215161549|NCT03563248|DRUG|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
215161550|NCT03563248|RADIATION|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
215161551|NCT03563248|PROCEDURE|Surgery|definitive surgical resection
215161552|NCT06049095|DRUG|LTG-001|Oral doses
215161553|NCT06049095|DRUG|Placebo|Oral doses
215161554|NCT00260442|BEHAVIORAL|Resistance Training|12 weeks, 3 times a week whole body resistance training
215161555|NCT00260442|BEHAVIORAL|Sedentary|Absence of physical activity
214550893|NCT06305442|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
214550894|NCT06305442|DIETARY_SUPPLEMENT|Ready-to-Use Supplementary Food|RUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above.
214550895|NCT02530710|DRUG|Q203|
214550896|NCT02530710|DRUG|Placebo|
214550897|NCT06512844|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Intervention|The MBSR training program consist of 8-week group session with the duration of 45-60 minutes each. Participants of the experimental group were given Mindfulness based stress reduction intervention in which they practice different mindfulness techniques. Each week focused on motor, cognitive and emotional issues of students with physically disabled. All the techniques also included psycho education
214550898|NCT00162617|DRUG|Red blood cell transfusion|
214550899|NCT04584892|DRUG|Turoctocog alfa|Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
214550900|NCT03209869|BIOLOGICAL|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
214550901|NCT03209869|BIOLOGICAL|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
214550902|NCT04292470|DRUG|Amitriptyline|Amitriptyline tablet
214550903|NCT00421655|DRUG|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
214550904|NCT04073342|GENETIC|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
214550905|NCT04654910|BEHAVIORAL|PROMIS Score Explanation|The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
214550906|NCT04654910|BEHAVIORAL|Placebo|Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
214701176|NCT04716192|OTHER|Myofascial release technique & Ultrasound|"Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
214701177|NCT04428684|DRUG|Pepti 3.6 mg|Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
214701178|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
214701179|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
214701180|NCT00987233|DRUG|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
215161556|NCT06770582|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214550907|NCT02906020|DRUG|venglustat GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
214550908|NCT02906020|DRUG|Placebo|Pharmaceutical form: capsule Route of administration: oral
215161557|NCT06770582|DRUG|Cisplatin|Given IV
215161558|NCT06770582|PROCEDURE|Computed Tomography|Undergo CT
215161559|NCT06770582|DRUG|Fluorouracil|Given IV
214550909|NCT04232904|PROCEDURE|Transversus abdominous plane block (TAP Block)|TAP block which is a peripheral nerve block preferred to postoperative pain management.
214550910|NCT06466278|DRUG|Icosapent ethyl|2dd2
214550911|NCT06466278|DRUG|Placebo|2dd2
215161560|NCT06770582|DRUG|Gemcitabine|Given IV
215161561|NCT06770582|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161562|NCT06770582|DRUG|Mitomycin|Given IV
215161563|NCT06770582|BIOLOGICAL|Pembrolizumab|Given IV
215161564|NCT06770582|OTHER|Questionnaire Administration|Ancillary studies
215161565|NCT06770582|RADIATION|Radiation Therapy|Undergo radiation therapy
214550912|NCT04061369|OTHER|Low fat meal|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
214550913|NCT04061369|OTHER|Moderate fat meal|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
214550914|NCT04061369|OTHER|High fat meal|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
214550915|NCT04061369|OTHER|High fat liquid meal|Liquid meal that is high (60% of energy) in fat calories.
214550916|NCT06092320|OTHER|Simulation on Pediatric Status Epilepticus|The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.
215161566|NCT04701983|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
214550917|NCT06092320|OTHER|Didactic Lecture on Pediatric Status Epilepticus|The participants will complete a lecture on pediatric status epilepticus
214701181|NCT04195269|DRUG|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
214701182|NCT04802980|DRUG|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
214701183|NCT04802980|DRUG|Oxaliplatin|Oxaliplatin is an anti-tumor drug
214550918|NCT03508947|DRUG|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
214550919|NCT03508947|DRUG|Placebo|Sodium Chloride
214550920|NCT00463671|DRUG|N-acetylcysteine|
214550921|NCT00218608|DRUG|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
214550922|NCT01384812|DRUG|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
214550923|NCT01384812|DRUG|isoton sodium chloride|intravenous injection for 25 min
214550924|NCT03504345|DRUG|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
214550925|NCT05330988|DEVICE|anodal transcranial direct current stimulation (a-tDCS)|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
214550926|NCT05330988|DEVICE|sham stimulation|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
214550927|NCT05371366|DEVICE|ASD closure with the novel occluder (ReAces)|Transcatheter closure atrial septal defect with the novel occluder (ReAces)
214550928|NCT05371366|DEVICE|ASD closure with normal occluder|Transcatheter closure atrial septal defect with normal occluder
214550929|NCT00258752|BEHAVIORAL|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
214550930|NCT00258752|OTHER|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
214550931|NCT00258752|OTHER|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
214550932|NCT05820399|DIETARY_SUPPLEMENT|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
214550933|NCT05820399|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
214550934|NCT06370845|COMBINATION_PRODUCT|Inhalation - Natural Odour|Inhalation of 50 uL of a natural odour via nasal septum mini-inhaler.
214550935|NCT06370845|COMBINATION_PRODUCT|Inhalation - Placebo|Inhalation of 50 uL of Placebo via nasal septum mini-inhaler.
214550936|NCT01543997|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
214550937|NCT01543997|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
214550938|NCT05724238|DIETARY_SUPPLEMENT|Traditional Herbal Supplements (Kuan Sin Yin)|Astragalus-based Kuan Sin Yin
214550939|NCT05724238|DIETARY_SUPPLEMENT|Placebo|Placebo starch powder with 10% Kuan Sin Yin
214550940|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
214550941|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
214701184|NCT04802980|DRUG|Capecitabine|Capecitabine is an anti-tumor drug
214701185|NCT04802980|DRUG|Paclitaxel|Paclitaxel is an anti-tumor drug
214701186|NCT04802980|DRUG|Gemcitabine|Gemcitabine is an anti-tumor drug
215161567|NCT04701983|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
214550942|NCT04803747|DRUG|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
214701187|NCT04802980|DRUG|Cisplatin|Cisplatin is an anti-tumor drug
214701188|NCT04802980|DRUG|Carboplatin|Carboplatin is an anti-tumor drug
214701189|NCT01947608|DRUG|LDK378|750 mg. orally
214701190|NCT02775552|BEHAVIORAL|A&T community-based interventions|"1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   \- Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   \- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families"
214550943|NCT04803747|DRUG|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
214550944|NCT05688553|DEVICE|Flexi-bar|two groups, experimental group intervention Flexi-bar with balance and strength training
214550945|NCT05688553|OTHER|balance and strength training|the control group intervention only balance and strength training
214550946|NCT02926222|DRUG|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
214550947|NCT02926222|DRUG|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
214550948|NCT01898377|DRUG|Imatinib mesylate, Mycophenolate mofetil|
214550949|NCT00241488|DRUG|Rosuvastatin|
214550950|NCT06271876|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
214550951|NCT01173276|OTHER|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
214550952|NCT01720576|DRUG|REGN1033 (SAR391786)|
214550953|NCT01720576|DRUG|Placebo|
214550954|NCT02438553|DEVICE|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
214701191|NCT02775552|BEHAVIORAL|Mass media|Radio campaign - radio drama series, spots, and jingles
214550955|NCT02438553|DEVICE|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
214550956|NCT02878694|BIOLOGICAL|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
214550957|NCT04974333|DEVICE|Mobile health application on phone|Patients will use a mobile app on their smart phones
214550958|NCT01609426|GENETIC|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
214550959|NCT05661435|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
214550960|NCT00390520|DRUG|Vildagliptin|
214550961|NCT00960362|DRUG|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
214550962|NCT00960362|DRUG|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
214550963|NCT05903157|BEHAVIORAL|Control Group: Delivery of a health literacy flyer|"A health literacy flyer was delivered, by e-mail, in the first week of the intervention (the flyer contained its original source - the European Centre for Disease Prevention and Control). Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and follow-up moments (3 and 6 months after the intervention)."
214550964|NCT05903157|BEHAVIORAL|Experimental Group: Weekly group sessions for weight management|"The eHealth intervention was designed based on: i) the Health Action Process Approach determinants, ii) the Health Belief Model constructs, and iii) behaviour change techniques (BCT, Taxonomy v1, by Michie et al., 2013) to implement healthy behaviours.~The intervention consists of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, are led by the psychologist responsible for the study. Whatsapp groups were created, to share experiences, knowledge, doubts, fears...~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and in follow-up moments (3 and 6 months after the intervention)."
214550965|NCT04340947|OTHER|Very low nicotine cigarette: menthol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
214550966|NCT04340947|OTHER|Very low nicotine cigarette: non-mentol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
214550967|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Ketamine
214550968|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Normal Saline
214550969|NCT05478382|DRUG|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
214701192|NCT01294891|OTHER|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
214701193|NCT02242994|DEVICE|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
214550970|NCT05478382|DRUG|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
214701194|NCT02242994|DEVICE|Experimental App|Participant receives experimental app to test speed and error rate of communication.
214550971|NCT02092532|DRUG|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
214550972|NCT02092532|PROCEDURE|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
214550973|NCT04127903|OTHER|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
214550974|NCT03181347|PROCEDURE|RYGB|Roux-en-Y Gastric Bypass
214550975|NCT03181347|PROCEDURE|SG|Sleeve Gastrectomy
214550976|NCT03181347|BEHAVIORAL|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
214550977|NCT03293459|PROCEDURE|Shunt Occlusion|Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
214550978|NCT03293459|DIETARY_SUPPLEMENT|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
214550979|NCT05655923|BIOLOGICAL|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
214550980|NCT05655923|BIOLOGICAL|xenograft bone substitute|Xenograft bone substitutes in all Groups
214550981|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
214550982|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
214550983|NCT02385383|DRUG|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
214550984|NCT02385383|OTHER|Standard Care|Standard Care in a historical control cohort
214550985|NCT00884650|DRUG|oral analgesic|per clinical standard of care
214550986|NCT00884650|DRUG|intravenous analgesic per pump|per clinical standard of care
214550987|NCT00919204|DRUG|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
214550988|NCT03907267|DRUG|Taurine Solution|Taurine Solution
214550989|NCT03907267|DIETARY_SUPPLEMENT|Normal Saline|Normal Saline
214550990|NCT00398281|DRUG|dutasteride|Given orally
214550991|NCT00398281|OTHER|placebo|Given orally
214701195|NCT01711684|DRUG|Diphenylcyclopropenone (DPCP)|Topical application of study drug
214701196|NCT04880538|PROCEDURE|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
214701197|NCT02017236|DRUG|Volitinib|600mg Volitinib ,single dose,oral
214701198|NCT01674244|BEHAVIORAL|Integrative Exercise|
214550992|NCT04603742|DRUG|Anakinra|100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
214550993|NCT04603742|DRUG|0.9% Saline|The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
214550994|NCT00003058|DRUG|troglitazone|
214550995|NCT00531622|DRUG|saredutant (SR48968)|oral administration, capsules
214550996|NCT00531622|DRUG|escitalopram|oral administration, capsules
214550997|NCT00531622|DRUG|placebo|oral administration, capsules
214550998|NCT05688618|DIETARY_SUPPLEMENT|Enteroccocus Facieum and Agave Inulin|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
214550999|NCT05688618|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
214551000|NCT01517204|DEVICE|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
214551001|NCT01517204|DEVICE|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
214551002|NCT00880022|DEVICE|Flexitouch System|( 10 to 30 treatments depending on group assignment)
214551003|NCT04476940|BEHAVIORAL|COVID-19 Breastfeeding Support|Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
214551004|NCT02154906|DEVICE|DFDBA|
214551005|NCT02154906|DEVICE|autologous platelet rich fibrin|
214701199|NCT01674244|BEHAVIORAL|Monitor Only Waitlist|
214551006|NCT03681743|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214701200|NCT01025817|DRUG|Everolimus and tacrolimus|"Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels"
214701201|NCT01025817|DRUG|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
214701202|NCT04261387|DRUG|LUT014 Gel|Topical application qd for 28 days
214701203|NCT04261387|DRUG|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
214701204|NCT06067412|DRUG|Levetiracetam|Efficacy in fits
214701205|NCT06067412|DRUG|Phenytoin|Efficacy in fits
214701206|NCT00173693|BEHAVIORAL|exercise for strength, balance, health education|
214551007|NCT03755011|DEVICE|white noise|Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
214551008|NCT03755011|BEHAVIORAL|usual care|normal ICU activity noise
214551009|NCT03903718|DRUG|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
214551010|NCT03903718|BIOLOGICAL|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
214551011|NCT03903718|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
214551012|NCT06433895|OTHER|Manual Therapy|Manual Therapy
214551013|NCT06433895|OTHER|Exercise|Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
214701207|NCT03482141|DEVICE|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
214701208|NCT00731848|DIETARY_SUPPLEMENT|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
214701209|NCT04182256|DEVICE|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
214701210|NCT06414538|OTHER|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application."
214701211|NCT06414538|OTHER|Classic Method Group|After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
214701212|NCT00005023|BIOLOGICAL|HER-2/neu peptide vaccine|
214701213|NCT00005023|BIOLOGICAL|sargramostim|
214701214|NCT03471481|OTHER|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
214701215|NCT02107430|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
214701216|NCT02107430|RADIATION|Standard radiotherapy|radiotherapy
214701217|NCT02377271|DRUG|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
215161568|NCT06141408|BEHAVIORAL|MPowerment PrEP Promotion Intervention|"In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection, promoting self-acceptance of sexual identity, teaching skills for navigating healthcare, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour activities focused on the aforementioned goals."
215161569|NCT02356159|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m\^2 intravenous (IV) day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
214551014|NCT03069144|DRUG|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214551015|NCT03069144|DRUG|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214551016|NCT03709108|OTHER|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
214551017|NCT02634424|DEVICE|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
214701218|NCT02377271|DRUG|placebo|treatment by bosentan or placebo is randomized
214701219|NCT06166355|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
214701220|NCT06166355|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
214701221|NCT06166355|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
214701222|NCT02210871|DRUG|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
214701223|NCT03375905|DEVICE|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
214701224|NCT05739812|DEVICE|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
214701225|NCT06293664|OTHER|α-MSH infusion|Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
214701226|NCT06293664|OTHER|Placebo solutions|Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
214701227|NCT02660333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin - 11g/day
214701228|NCT02660333|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharide - 11g/day
214701229|NCT02660333|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
214701230|NCT00305851|PROCEDURE|Music Therapy|Undergo therapeutic music video therapy
214701231|NCT00305851|PROCEDURE|Psychosocial Assessment and Care|Undergo books on tape therapy
214551018|NCT01594827|DRUG|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
214551019|NCT01594827|DRUG|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
214551020|NCT01594827|DRUG|Rifampin|"Oral Rifampin by mouth for 28 days~1. \>45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily"
214551021|NCT01594827|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. \>45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)"
214551022|NCT01594827|DRUG|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
214551023|NCT01594827|DRUG|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
214701232|NCT00305851|OTHER|Quality-of-Life Assessment|Ancillary studies
214701233|NCT02344069|DRUG|Fibrinogen|Human fibrinogen concentrate as a injection
214701234|NCT02344069|DRUG|Placebo|Saline 0.9% as a injection
214701235|NCT01422811|BEHAVIORAL|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
214551024|NCT01594827|DRUG|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
214551025|NCT04480606|BEHAVIORAL|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
214551026|NCT02291822|DRUG|Gadobenate Dimeglumine|gadolinium contrast agent
214701236|NCT01422811|OTHER|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
214701237|NCT03348852|DEVICE|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
214701238|NCT01035242|BEHAVIORAL|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
214701239|NCT01035242|BEHAVIORAL|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
214701240|NCT05943327|DRUG|Lu AG06474|Oral Solution
214701241|NCT05943327|DRUG|Placebo|Oral Solution
214701242|NCT05943327|DRUG|Lu AG06474|Capsule
214701243|NCT04735367|DRUG|palbociclib plus letrozole|palbociclib plus letrozole
214701244|NCT01688167|BEHAVIORAL|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
215161570|NCT02356159|DRUG|Conditioning chemotherapy|Fludarabine:30 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m\^2 per day IV infusion over 2 hours on Days 6, -5, -4, -3. Mesna: 1200 mg/m\^2 per day IV infusion, daily on days 6, -5, -4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3.
215161571|NCT02356159|DRUG|TMS|Tacrolimus: 0.02 mg/kg, start day 3. Continue intravenous (IV) or by mouth (PO). Taper will begin at day +60 if no acute graft-versus-host disease (GVHD) then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m\^2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
215161572|NCT02356159|DRUG|FLAG|Fludarabine: 25 mg/m\^2 per day intravenous (IV) over 30 minutes, daily on days 1-5 Cytarabine: 2,000 mg/m\^2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy.
215161573|NCT02356159|DRUG|EPOCH-F|"Fludarabine: 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days 1-4. Etoposide: 50 mg/m\^2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin: 10 mg/m\^2/day continuous intravenous (CIV), days 1-4. Vincristine: 0.4 mg/m\^2 per day continuous IV infusion over 24 hours daily on days 1-4.~Cyclophosphamide: 750 mg/m\^2 IV infusion over 30 minutes on day 5. Prednisone: 60 mg/m\^2 per day by mouth (PO) daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV."
214551027|NCT02484664|DRUG|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
214551028|NCT05625347|DRUG|single dose (100 mg) of ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
214551029|NCT05625347|DRUG|single dose (162 mg) of non-enteric-coated chewable aspirin tablets|orally administered
214551030|NCT06072976|DIETARY_SUPPLEMENT|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
214551031|NCT06072976|DIETARY_SUPPLEMENT|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
214551032|NCT01615549|PROCEDURE|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
214551033|NCT00297947|DRUG|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
214551034|NCT00297947|DRUG|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
214551035|NCT02768883|BEHAVIORAL|Respira Sano|The intervention is all three components: clinic + home + community.
214551036|NCT02603692|OTHER|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
214551037|NCT03471377|OTHER|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
214551038|NCT03471377|OTHER|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
214551039|NCT00047723|DRUG|minocycline|
214551040|NCT06106867|PROCEDURE|External pressure to the palm|During the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages of the labor process, palm external pressure was applied to the pregnant women in the experimental group.
214701245|NCT00435032|PROCEDURE|early appendectomy|Appendectomy within 24 hours of admission
214701246|NCT00435032|PROCEDURE|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
214701247|NCT05010993|DIAGNOSTIC_TEST|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
214701248|NCT05010993|DIAGNOSTIC_TEST|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
214701249|NCT05010993|DIAGNOSTIC_TEST|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
214701250|NCT02528968|BEHAVIORAL|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
214701251|NCT01599754|DRUG|Axitinib|Axitinib 5 mg twice daily
214701252|NCT01599754|DRUG|Placebo|Placebo twice daily
214701253|NCT03002116|OTHER|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
215161574|NCT02356159|PROCEDURE|Hematopoietic stem cell transplant|Hematopoietic stem cell transplant
215161575|NCT02356159|DRUG|Palifermin|Escalating doses of palifermin given during transplant phase.
215161576|NCT02356159|DRUG|Acetaminophen|Before each infusion of rituximab as indicated.
215161577|NCT02356159|DRUG|Diphenhydramine|Before each infusion of rituximab as indicated.
214551041|NCT05090189|OTHER|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
214701254|NCT04059445|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
214701255|NCT04059445|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
214701256|NCT05459389|OTHER|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
214551042|NCT00016224|DRUG|thalidomide|
214551043|NCT03768622|PROCEDURE|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
214551044|NCT03768622|PROCEDURE|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
214551045|NCT04211090|DRUG|Camrelizumab|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
214551046|NCT04211090|DRUG|Pemetrexed|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
214551047|NCT04211090|DRUG|Carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
214551048|NCT06186297|DIETARY_SUPPLEMENT|Cranberry extract|polyphenol PAC-1
214551049|NCT02030002|DEVICE|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
214551050|NCT02030002|DEVICE|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
214551051|NCT04566562|DIAGNOSTIC_TEST|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
214551052|NCT04566562|DIAGNOSTIC_TEST|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
214551053|NCT04566562|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory Markers
214551054|NCT00512486|BIOLOGICAL|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~* 0.03 mg/kg intravenous injection~* 0.1 mg/kg intravenous injection~* 0.3 mg/kg intravenous injection~* 1.0 mg/kg intravenous injection~* 3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
214701257|NCT00475462|DRUG|metoprolol|
214701258|NCT00475462|DRUG|conventional treatment|
214701259|NCT06064786|DIAGNOSTIC_TEST|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
214701260|NCT05686616|DRUG|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
214701261|NCT01380158|DEVICE|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
214701262|NCT02325635|OTHER|Educational Training|Intervention/Training offered to endoscopists only.
214701263|NCT03739463|DIETARY_SUPPLEMENT|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
214701264|NCT03739463|DIETARY_SUPPLEMENT|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
214701265|NCT03670641|DRUG|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
214701266|NCT03670641|DRUG|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
214701267|NCT03670641|DEVICE|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
214701268|NCT00347555|BIOLOGICAL|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
214701269|NCT00347555|DRUG|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
214701270|NCT00347555|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
214701271|NCT03018626|DRUG|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
214701272|NCT03018626|DRUG|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
214701273|NCT03018626|DRUG|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
214701274|NCT03018626|DRUG|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
214701275|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
214701276|NCT03018626|DRUG|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
214701277|NCT03018626|DRUG|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
214701278|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
214701279|NCT03018626|DRUG|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
214701280|NCT03018626|DRUG|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
214701281|NCT01319643|DRUG|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
214701282|NCT02960048|DEVICE|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
214701283|NCT02960048|DEVICE|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
214701284|NCT04229589|OTHER|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
214551055|NCT03504722|BEHAVIORAL|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
214551056|NCT03504722|BEHAVIORAL|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
214551059|NCT04079205|DEVICE|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
214551060|NCT04079205|BEHAVIORAL|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
214551061|NCT01418404|OTHER|Noxious TS|hot, cold alternately, noxious TS in study A
214551062|NCT01418404|OTHER|Innocuous TS|warm, cool alternately, Innocuious TS in study A
214551063|NCT01418404|OTHER|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
214551064|NCT01418404|OTHER|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
214551065|NCT01418404|OTHER|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
214551066|NCT01418404|OTHER|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
214701285|NCT02007330|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
214701286|NCT02007330|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
214701287|NCT03571334|DRUG|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
215161578|NCT02356159|DRUG|Prednisone|For engraftment syndrome.
215161579|NCT02356159|DRUG|Epinephrine|Emergency medication as indicated.
215161580|NCT02356159|OTHER|IV Saline|Before each infusion of rituximab as indicated.
215161581|NCT02356159|DIAGNOSTIC_TEST|ECG|As indicated.
215161582|NCT02356159|DIAGNOSTIC_TEST|ECHO|As indicated.
215161583|NCT02356159|DIAGNOSTIC_TEST|MUGA|As indicated.
214551067|NCT05256212|OTHER|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
215161584|NCT02356159|DIAGNOSTIC_TEST|DEXA|As indicated.
215161585|NCT02356159|DIAGNOSTIC_TEST|CT chest|As indicated.
215161586|NCT02356159|DIAGNOSTIC_TEST|PET|As indicated.
215161587|NCT02356159|DIAGNOSTIC_TEST|MRI|As indicated.
215161588|NCT02356159|PROCEDURE|BM aspirate|As indicated.
215161589|NCT02356159|PROCEDURE|BM biopsy|As indicated.
215161590|NCT02356159|PROCEDURE|Lumbar puncture|As indicated.
215161591|NCT06525220|DRUG|Petosemtamab|MCLA-158
215161592|NCT06525220|DRUG|Pembrolizumab|Humanized Antibody
214701288|NCT03571334|DRUG|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
214701289|NCT03744884|BEHAVIORAL|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
215161593|NCT05443126|DRUG|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
215161594|NCT04175613|DRUG|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
215161595|NCT00861705|BIOLOGICAL|Bevacizumab|Given IV
215161596|NCT00861705|DRUG|Carboplatin|Given IV
214551068|NCT03935256|DRUG|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 \& Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 \& Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 \& 7 concurrent with radiotherapy
214551069|NCT03935256|RADIATION|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
214551070|NCT06427733|BIOLOGICAL|Placebo comparator|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
214701290|NCT05145075|OTHER|Survey|Patients are asked to fill in a survey concerning teleconsultations
214701291|NCT05115500|DRUG|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
214701292|NCT01457859|DRUG|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
214701293|NCT01457859|OTHER|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
214701294|NCT05717452|DIETARY_SUPPLEMENT|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
215161597|NCT00861705|DRUG|Cyclophosphamide|Given IV
214551071|NCT06427733|BIOLOGICAL|Active Comparator|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
214551072|NCT03396068|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
214551073|NCT03396068|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
215161598|NCT00861705|DRUG|Doxorubicin Hydrochloride|Given IV
215161599|NCT00861705|OTHER|Laboratory Biomarker Analysis|Correlative studies
215161600|NCT00861705|DRUG|Paclitaxel|Given IV
215161601|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
215161602|NCT05708599|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
214701295|NCT05717452|DIETARY_SUPPLEMENT|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
214701296|NCT04445493|DEVICE|MindRhythm Harmony|Passive recording of the head pulse
214701297|NCT00118482|DRUG|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
214701298|NCT06151366|OTHER|non interventional|non interventional
214701299|NCT01241669|DRUG|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
214701300|NCT01241669|DRUG|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
214701301|NCT05745324|PROCEDURE|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
214701302|NCT04791683|OTHER|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
214701303|NCT02702427|BIOLOGICAL|virus-specific T-Cells|infusion
215161603|NCT06375460|BEHAVIORAL|Focused App Prompt|Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).
215161604|NCT06375460|BEHAVIORAL|No App Prompt|No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.
214701304|NCT05201183|COMBINATION_PRODUCT|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
214701305|NCT03513965|BEHAVIORAL|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
214551074|NCT04315805|OTHER|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
214551075|NCT00470197|DRUG|alvocidib|Given IV
214551076|NCT00470197|DRUG|cytarabine|Given IV
214551077|NCT00470197|DRUG|mitoxantrone hydrochloride|Given IV
214551078|NCT00470197|OTHER|pharmacological study|Correlative study
214701306|NCT03513965|BEHAVIORAL|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
214701307|NCT00029991|DRUG|Gingko Biloba (Herb)|
214701308|NCT05799443|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
214701309|NCT05799443|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
214701310|NCT05799443|DRUG|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
214701311|NCT05799443|RADIATION|SBRT|8-10Gy×5F，QOD
214701312|NCT02643186|DRUG|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
215161605|NCT06375460|BEHAVIORAL|Outreach for Missing Data|For participants randomized to proactive outreach, after 3 or more days of missing CGM data, the study team will reach out to participants by phone and/or text message to troubleshoot and support participants in re-connecting with CGM and apps. For participants randomized to not receive proactive outreach, participants will be instructed to reach out to the study team at their discretion when help is needed related to CGM or app connection.
214551079|NCT05201053|DIAGNOSTIC_TEST|Exploratory for different markers|Test biomarkers for development of mild, moderate or severe disease
214551080|NCT02388152|DRUG|Lu AF20513, low dose|
214551081|NCT02388152|DRUG|Lu AF20513, medium dose|
214551082|NCT02388152|DRUG|Lu AF20513, high dose|
214551083|NCT02388152|DRUG|Lu AF20513, double high dose|
214551084|NCT05292053|DRUG|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
214701313|NCT02643186|PROCEDURE|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
214551085|NCT04788745|DRUG|Trimetazidine Dihydrochloride|Oral tablet, twice-daily
214701314|NCT00469755|DRUG|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
214701315|NCT00469755|DRUG|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
214551086|NCT05807906|OTHER|virtual reality application|The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
214551087|NCT01592045|BIOLOGICAL|ch14.18 -NCI|25 mg/m\^2/day IV for four consecutive days
214551088|NCT01592045|BIOLOGICAL|ch14.18-UTC|17.5 mg/m\^2/day IV for four consecutive days
214551089|NCT01592045|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.
214551090|NCT01592045|BIOLOGICAL|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.
214551091|NCT01592045|DRUG|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
214551092|NCT01395004|DRUG|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
214551093|NCT02395419|DEVICE|Orotracheal intubation with Totaltrack|
214551094|NCT02395419|DEVICE|Orotracheal intubation with Airtraq|
214551095|NCT03994731|BIOLOGICAL|Pegloticase|IV pegloticase 8 mg Q2W
214551096|NCT03994731|DRUG|methotrexate|Oral MTX 15 mg weekly
214551097|NCT03994731|DRUG|placebo|Oral placebo for MTX
214551098|NCT03994731|DIETARY_SUPPLEMENT|folic acid|Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
214551099|NCT03994731|DRUG|gout flare prophylaxis regimen|Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
214551100|NCT03994731|DRUG|fexofenadine|For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
214551101|NCT03994731|DRUG|acetaminophen|For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
214701316|NCT00469755|DRUG|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
214701317|NCT04788108|DRUG|Dydrogesterone|Dydrogesterone tablet
214701318|NCT04788108|DRUG|Placebo|Placebo tablet
214701319|NCT02734719|DEVICE|Bonestim|Bonestim is the multipad electrical stimulation device.
214551102|NCT03994731|DRUG|methylprednisolone|For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
214551103|NCT03186001|DRUG|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
214551104|NCT04966026|OTHER|No inervention|No inervention
214551105|NCT00500968|PROCEDURE|stent|ERCP guided stent insertion before transection of the gland
214551106|NCT00500968|PROCEDURE|Distal pancreatectomy|conventional distal pancreatectomy
214551107|NCT06042972|OTHER|Questionnaire including Edinburgh postnatal depression scale, Patient Health Questionnaire 2 and background variables|"Patients meeting the inclusion criteria will be recruited by health professionals who have agreed to participate in the study.~Patients must fill out an anonymous self-questionnaire which will consist of 2 tests aimed to help diagnose postpartum depression, recommended in France by the Haute Autorité de Santé (HAS), and background variables.~The self-questionnaire will be given back by the patient in a sealed envelope. Each questionnaire will only be filled out once per patient."
214551108|NCT04249570|OTHER|Povidone iodine|
214551109|NCT03849703|BEHAVIORAL|Full Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
214551110|NCT03849703|BEHAVIORAL|Full Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
214701320|NCT00334932|DRUG|bortezomib|
214701321|NCT00334932|DRUG|melphalan|
214701322|NCT00334932|DRUG|pegylated liposomal doxorubicin hydrochloride|
214701323|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
214701324|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
214701325|NCT02128763|DRUG|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
214701326|NCT02128763|DRUG|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
214701327|NCT03319615|BEHAVIORAL|Dietary energy restriction|
215029646|NCT06232993|OTHER|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
215161606|NCT00210223|PROCEDURE|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
215161607|NCT05423977|DRUG|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
214551111|NCT03849703|BEHAVIORAL|Partial Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
214551112|NCT03849703|BEHAVIORAL|Partial Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
215161608|NCT06418152|BEHAVIORAL|Multi-modal treatment|Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
215161609|NCT03653507|DRUG|zolbetuximab|Zolbetuximab were administered as a minimum 2-hour IV infusion.
214551113|NCT00027391|DRUG|Albuterol|
215161610|NCT03653507|DRUG|oxaliplatin|Oxaliplatin were administered as a 2-hour IV infusion.
214551114|NCT00027391|DRUG|Oxandrolone|
214551115|NCT00793247|DRUG|PRU-PLA-PRU-PLA|
215161611|NCT03653507|DRUG|capecitabine|Capecitabine were administered orally twice daily (bid).
214551116|NCT00793247|DRUG|PLA-PRU-PLA-PRU|
214551117|NCT00793247|DRUG|PLA-PRU-PRU-PLA|
214551118|NCT00793247|DRUG|PRU-PLA-PLA-PRU|
214551119|NCT02968238|BEHAVIORAL|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
214551120|NCT02968238|BEHAVIORAL|Yoga|10 weeks of biweekly yoga sessions (N = 20)
214551121|NCT02516865|DEVICE|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
214551122|NCT02516865|DEVICE|Ankle weights|Worn during typical daily activities.
214551123|NCT01070576|OTHER|no intervention|no intervention
214551124|NCT00830323|DRUG|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
214551125|NCT00830323|DRUG|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
214551126|NCT00830323|DRUG|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
214551127|NCT03585088|DEVICE|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score \<=60.
214551128|NCT03142269|PROCEDURE|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
214551129|NCT04709458|BIOLOGICAL|TBX-2400|Hematopoietic stem cells transplantation
214551130|NCT04853615|DRUG|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
215161612|NCT03653507|DRUG|placebo|Placebo were administered as a minimum 2-hour IV infusion.
215161613|NCT04284839|DRUG|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
214551131|NCT00675532|BEHAVIORAL|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
214551132|NCT00675532|BEHAVIORAL|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
214551133|NCT01749852|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
214551134|NCT01749852|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
214551135|NCT06146478|DRUG|Thalidomide|Thalidomide given at an average dose of 1.5mg/kg/day
214551136|NCT02868840|BEHAVIORAL|Tai Chi exercise|exercise twice a week each for one hour
214551137|NCT02868840|BEHAVIORAL|symptom management|sending text message weekly to manage symptoms related to stroke
214551138|NCT02410005|DIETARY_SUPPLEMENT|Calcitriol|
214551139|NCT02410005|DRUG|Losartan|
214551140|NCT04043897|DRUG|Rifaximin 550mg|Rifaximin 550mg
214551141|NCT00737503|BIOLOGICAL|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
214551142|NCT03424070|OTHER|Shoulder Roll|The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.
214551143|NCT03424070|OTHER|No shoulder roll (placebo)|Placebo
215161614|NCT04284839|DRUG|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
215161615|NCT03190941|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
215161616|NCT03190941|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
215161617|NCT03190941|BIOLOGICAL|Anti-KRAS G12V mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
214551144|NCT05101512|BEHAVIORAL|Questionnaires on quality of life after surgery|Patient has to answer different questionnaire about quality of life, pain, functional scores
214551145|NCT00887770|DRUG|AZD5672|12 x 50mg tablet, oral, single dose
215161618|NCT03190941|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
214701328|NCT05242549|BEHAVIORAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
214701329|NCT04868591|OTHER|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
214701330|NCT04868591|OTHER|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
214701331|NCT04102878|DRUG|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
214701332|NCT04102878|PROCEDURE|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
214701333|NCT04102878|PROCEDURE|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
214701334|NCT04102878|OTHER|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
214701335|NCT04102878|OTHER|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
214701336|NCT04102878|PROCEDURE|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
214701337|NCT05449613|DRUG|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
214701338|NCT05449613|OTHER|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
214701339|NCT02921919|DRUG|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
214701340|NCT03206242|OTHER|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
214701341|NCT03612180|DRUG|Metoprolol Succinate|Pharmacokinetics
215161619|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
215161620|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
214551146|NCT00887770|DRUG|Moxifloxacin|1 x 400mg capsule, oral, single dose
214551147|NCT00887770|DRUG|placebo|12 x matched to AZD5672 50 mg tablet
214551148|NCT00887770|DRUG|AZD5672|3 x 50mg tablet, oral. single dose
214551149|NCT00887770|DRUG|placebo|9 x matched to AZD5672 50mg tablet
214551150|NCT00887770|DRUG|placebo|1 x matched to Moxifloxacin capsule
215161621|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
215161622|NCT05463666|OTHER|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
214551151|NCT02361086|DRUG|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
214551152|NCT02562157|RADIATION|HYALURONIQUE ACIDE|Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
214551153|NCT00609947|DEVICE|Endeavor Zotarolimus-Eluting Coronary Stent|
215161623|NCT01445509|DRUG|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
214551154|NCT03088774|OTHER|Information material|Online web-application developed together with patients with low back pain
214551155|NCT02478437|PROCEDURE|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
214551156|NCT02478437|PROCEDURE|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
214551157|NCT03863145|DRUG|CB-03-10|CB-03-10, 100 mg capsule for oral use
214551158|NCT01721733|DRUG|Placebo|
214551159|NCT01721733|DRUG|EPI-743 15 mg/kg|
214551160|NCT01721733|DRUG|EPI-743 5 mg/kg|
214551161|NCT04977570|DRUG|SYHA1805 tablets|Oral tablets of SYHA1805 with three pre-designed doses
214551162|NCT04977570|DRUG|Placebo|Oral tablets of placebo with matching doses
214701342|NCT04353921|OTHER|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
214701343|NCT00547378|DEVICE|InterStim|
214701344|NCT00547378|DRUG|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
214701345|NCT02508688|PROCEDURE|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
214701346|NCT04922515|OTHER|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
214701347|NCT05041452|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameters
214701348|NCT02871115|OTHER|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
214701349|NCT02871115|OTHER|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
214551163|NCT02963948|BEHAVIORAL|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
214551164|NCT02963948|BEHAVIORAL|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
214551165|NCT02963948|BEHAVIORAL|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
214551166|NCT02675257|BEHAVIORAL|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
214551167|NCT02675257|BEHAVIORAL|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
214551168|NCT02675257|BEHAVIORAL|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
214551169|NCT02675257|BEHAVIORAL|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
214551170|NCT02675257|BEHAVIORAL|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
214551171|NCT02675257|BEHAVIORAL|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
214551172|NCT02675257|BEHAVIORAL|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
214551173|NCT02675257|BEHAVIORAL|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
214551174|NCT02675257|BEHAVIORAL|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
214551175|NCT02675257|BEHAVIORAL|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
214551176|NCT02675257|BEHAVIORAL|Sports, activities and exercise|Education on sports, activities and exercise
214701350|NCT04105244|BEHAVIORAL|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
214701351|NCT02112994|DRUG|Sebelipase Alfa|IV infusion of sebelipase alfa
214701352|NCT01525927|DRUG|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
214701353|NCT01525927|RADIATION|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
214701354|NCT01525927|RADIATION|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
214701355|NCT03684291|PROCEDURE|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
214701356|NCT02768194|DEVICE|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
214701357|NCT02768194|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
214701358|NCT02768194|OTHER|Mineral water|Commercially available mineral water
214701359|NCT06553066|DRUG|Deep neuromascular blockage|"maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
214701360|NCT06553066|DRUG|Moderate neuromascular blockage|maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
214701361|NCT05787912|DEVICE|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
214551177|NCT02675257|BEHAVIORAL|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
214551178|NCT02675257|BEHAVIORAL|Diabetes complications|Education on diabetes complications
214701362|NCT05787912|OTHER|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
214701363|NCT06128590|DEVICE|Photobiomodulation|"Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups."
214701364|NCT06128590|DRUG|Mepivacaine hydrochloride in combination with epinephrine|"The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure."
214701365|NCT06128590|DEVICE|Photobiomodulation simulation|The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
214701366|NCT04873284|DRUG|fosaprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV"
214701367|NCT04873284|DRUG|aprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg)."
214701368|NCT04873284|DRUG|Granisetron plus dexamethasone|Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
214701369|NCT00764959|DEVICE|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
214701370|NCT05611359|PROCEDURE|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
214701371|NCT05611359|DRUG|Chemotherapy|Chemotherapy
214701372|NCT00975195|DRUG|tiotropium inhalation|
214701373|NCT00975195|DRUG|salmeterol xinafoate|
214701374|NCT00975195|DRUG|fluticasone propionate|
214701375|NCT00975195|DRUG|placebo matched for fluticasone propionate|
214701376|NCT04108585|PROCEDURE|HFO therapy|HFO therapy from mechanical ventilation
214701377|NCT04108585|PROCEDURE|CPAP therapy|CPAP therapy from mechanical ventilation
214701378|NCT03509337|DIAGNOSTIC_TEST|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
214701379|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
214701380|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
214701381|NCT03251287|DRUG|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
214701382|NCT03251287|DRUG|Placebo|Single dose of oral matching placebo
214701383|NCT03251287|DIAGNOSTIC_TEST|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
214701384|NCT03251287|DIAGNOSTIC_TEST|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
215161624|NCT01445509|DRUG|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
215161625|NCT02729519|PROCEDURE|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
214551179|NCT02675257|BEHAVIORAL|Social aspects of living with diabetes|Education on social aspects of living with diabetes
214551180|NCT01528319|DEVICE|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
214551181|NCT04849767|OTHER|Questionnaire|Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
214551182|NCT04148989|OTHER|Code Sepsis protocol (full implementation)|Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
214551183|NCT03812029|DRUG|Vonafexor|Oral tablets
214551184|NCT03812029|OTHER|Placebo|Oral tablets
214551185|NCT04701723|OTHER|cardiac coherence|standard care associated to cardiac coherence training during 3 months
214551186|NCT05627453|OTHER|Arm-in-arm gait training|An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
214551187|NCT05627453|OTHER|Normal gait training|An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
214551188|NCT03149042|DIAGNOSTIC_TEST|CCTA|Diagnostic Test
214551189|NCT02600390|BIOLOGICAL|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
214551190|NCT04046458|BEHAVIORAL|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
214551191|NCT04046458|OTHER|No EHR alert|No change to EHR function; no alert visible to providers
214551192|NCT03840005|DRUG|Ursonorm|Ursodeoxycholic acid
214551193|NCT03471858|DEVICE|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
214551194|NCT03471858|DRUG|Prostaglandins|Prostin will be used in the control arm.
214551195|NCT02257476|DRUG|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
214701385|NCT01782456|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
214701386|NCT01608724|DRUG|Saxagliptin|oral, 5 mg once a day (Q.D.)
214701387|NCT01989234|DRUG|YKP10811|
214701388|NCT01989234|DRUG|Placebo|
214701389|NCT00426517|DRUG|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
214551196|NCT02257476|DRUG|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
214551197|NCT05451667|DRUG|YJ001 for Spray Use|YJ001 (active ingredient)
214551198|NCT05451667|DRUG|Placebo of YJ001 for Spray Use|Hydroxypropyl Methylcellulose
214701390|NCT00426517|DRUG|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
214701391|NCT00426517|DRUG|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
214701392|NCT00426517|DRUG|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
214701393|NCT00426517|DRUG|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
214701394|NCT00077519|DRUG|tipifarnib|
214701395|NCT00077519|RADIATION|radiation therapy|
214701396|NCT00873808|DRUG|clodronate disodium|
214701397|NCT00873808|DRUG|demeclocycline hydrochloride|
214551199|NCT05724927|BEHAVIORAL|Animal assisted activity|The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
214551200|NCT00657735|DEVICE|H-Coil deep TMS|20 daily deep rTMS treatments
214551201|NCT00657735|DEVICE|sham|inactive treatment
214551202|NCT04267068|BEHAVIORAL|Growth Mindset and Modifiable Risk Factor Information|15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
214551203|NCT04267068|BEHAVIORAL|Control|30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
214551204|NCT06544603|DEVICE|Multiwave Locked System (MLS) laser|Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)
214551205|NCT00790205|DRUG|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
214551206|NCT00790205|DRUG|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
214551207|NCT05906797|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
214551208|NCT05054569|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
214551209|NCT03321279|BEHAVIORAL|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
214551210|NCT01206699|DRUG|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
214551211|NCT01206699|DRUG|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
214551212|NCT04937920|BIOLOGICAL|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
214701398|NCT00873808|DRUG|ibandronate sodium|
214701399|NCT00873808|DRUG|tetracycline hydrochloride|
214701400|NCT00873808|DRUG|zoledronic acid|
214701401|NCT00873808|OTHER|laboratory biomarker analysis|
214701402|NCT00873808|PROCEDURE|adjuvant therapy|
214701403|NCT00873808|PROCEDURE|computed tomography|
214701404|NCT00873808|PROCEDURE|dual x-ray absorptiometry|
214701405|NCT01824173|OTHER|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
214701406|NCT01824173|OTHER|Aerobic exercise|Moderate intensity for 45 minutes
214701407|NCT05391568|OTHER|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
214701408|NCT05391568|OTHER|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
214551213|NCT04937920|BIOLOGICAL|Aqueous gel|Topical application on skin affected with tinea versicolor
214551214|NCT00226122|DRUG|Indomethacin|Indomethacin capsules 50 mg
214551215|NCT03209947|DIAGNOSTIC_TEST|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
214701409|NCT06447324|DEVICE|Fender Mate matrix system|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
214701410|NCT06447324|DEVICE|T-band matrix|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
214701411|NCT04837534|BEHAVIORAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
214701412|NCT04837534|BEHAVIORAL|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
214701413|NCT06146296|BIOLOGICAL|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
214701414|NCT06146296|BIOLOGICAL|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
214701415|NCT06148896|BEHAVIORAL|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
214701416|NCT06148896|BEHAVIORAL|GrEx|Group physiotherapy exercise
214701417|NCT04255836|DRUG|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
214701418|NCT04255836|DRUG|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
214701419|NCT04255836|RADIATION|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
214701420|NCT00099359|DRUG|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
214701421|NCT00099359|DRUG|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams"
214701422|NCT00099359|DRUG|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams"
214701423|NCT00099359|DRUG|Nelfinavir (NFV)|200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
214701424|NCT03019770|BEHAVIORAL|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
214701425|NCT05138406|OTHER|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
214701426|NCT05138406|OTHER|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
214701427|NCT03614442|OTHER|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
214701428|NCT04627298|BEHAVIORAL|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
214551216|NCT01046045|DRUG|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
214551217|NCT01356771|OTHER|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma"
214551218|NCT06186947|OTHER|No intervention|Participants are not subjected to any specific intervention.
214551219|NCT03644524|BEHAVIORAL|Heat therapy|Regular hot tub use
214551220|NCT06429982|DRUG|Dexamethasone|Steroid five day treatment
214551221|NCT06429982|DRUG|Placebo|Placebo control group
214551222|NCT03085056|DRUG|Trametinib|trametinib orally 2mg daily during each 4 week cycle
214551223|NCT03085056|DRUG|Paclitaxel|paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
214551224|NCT02394652|DRUG|Metformin|Metformin is an antidiabetic agent given orally.
214551225|NCT02394652|DRUG|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
214551226|NCT02394652|DRUG|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
214701429|NCT01123577|OTHER|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
214701430|NCT01546389|BIOLOGICAL|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
214701431|NCT01546389|DRUG|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
214551227|NCT06555393|DIETARY_SUPPLEMENT|Egg White Powder|"Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption."
214701432|NCT01822691|DRUG|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
214701433|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with less ≤ 3mm from each other.|Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.
214701434|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with > 3mm from each other.|Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
214701435|NCT02756650|DRUG|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
214701436|NCT01897922|OTHER|An investigational infant formula containing a probiotic source|
214701437|NCT01897922|OTHER|Control: Marketed routine infant formula|
214701438|NCT03920826|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
214701439|NCT03920826|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
214701440|NCT05415852|DEVICE|Laser|Laser
214701441|NCT02727270|OTHER|No Intervention - Observational Study|No Intervention - Observational Study
214701442|NCT01260935|PROCEDURE|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
214701443|NCT01260935|PROCEDURE|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
214701444|NCT02742350|DEVICE|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
214701445|NCT03371160|DEVICE|Nutriplace™ System|The Nutriseal™ Nutriplace™ System is an electromagnetic tracking system for feeding tube placement designed to aid qualified operators in the placement of the Nutriseal™ Enteral Feeding Tube™ into the stomach or small intestine.
214701446|NCT04078672|PROCEDURE|NOTAL-OCT V3.0|AMD and DR patients
215161626|NCT05840302|DEVICE|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
215161627|NCT05840302|OTHER|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
215161628|NCT03074487|DEVICE|Near-infrared spectroscopy|
214551228|NCT04229810|PROCEDURE|STD-02|Conventional standardized ventilatory approach.
214701447|NCT00780169|DRUG|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"
214551229|NCT04229810|PROCEDURE|iOLA-iHFNC|Indivudualized perioperative open lung ventilatory approach.
214551230|NCT00525278|DRUG|Levocetirizine dihydrochloride|
214701448|NCT02998060|PROCEDURE|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
214701449|NCT02998060|DEVICE|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
215161629|NCT03074487|DEVICE|Long loop reflex measurements|
215161630|NCT05616650|DRUG|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
215161631|NCT05616650|RADIATION|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
214551231|NCT05505370|DEVICE|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
214701450|NCT02998060|DEVICE|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
214551232|NCT06771830|DEVICE|Pediatric eCART|Integration of the pediatric version of electronic Cardiac Arrest Risk Triage as a clinical decision support tool within Epic for use by clinicians
214551233|NCT05580497|DEVICE|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
214701451|NCT01022567|PROCEDURE|Appendicectomy|Standard appendicectomy
214701452|NCT01022567|DRUG|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
214701453|NCT03858062|DEVICE|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
214701454|NCT03858062|DEVICE|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
214701455|NCT03177980|DRUG|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
214701456|NCT03177980|DRUG|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
214701457|NCT05272527|BEHAVIORAL|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
214701458|NCT01317667|BIOLOGICAL|RVEc|
214701459|NCT00603434|DRUG|OROS-MPH|18 mg bid on days 1 and 2
214701460|NCT00603434|DRUG|OROS-MPH|27mg bid on days 3 and 4
214551234|NCT03632083|DEVICE|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
214551235|NCT03632083|DEVICE|Lite Contact Lens Solution|Lite Contact Lens Solution
214551236|NCT03632083|DEVICE|fanfilcon A soft contact lens|fanfilcon A soft contact lens
214701461|NCT00603434|DRUG|OROS-MPH|35 mg bid on days 5-9
214701462|NCT02381496|DRUG|ACT-453859 1 mg|Capsule
214701463|NCT02381496|DRUG|ACT-453859 3 mg|Capsule
214701464|NCT02381496|DRUG|ACT-453859 10 mg|Capsule
214701465|NCT02381496|DRUG|ACT-453859 30mg|Capsule
214701466|NCT02381496|DRUG|ACT-453859 100 mg|Capsule
214551237|NCT03632083|DEVICE|comfilcon A soft contact lens|comfilcon A soft contact lens
214551238|NCT00504283|DRUG|Toradol|
214551239|NCT00504283|DRUG|Morphine|
214551240|NCT04012086|OTHER|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
214551241|NCT02281123|OTHER|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
214551242|NCT03569592|BEHAVIORAL|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
214551243|NCT00265720|OTHER|Control|Written materials only
214551244|NCT00265720|OTHER|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
214551245|NCT00265720|BEHAVIORAL|one on one education|one on one education with a health educator
214551246|NCT00265720|BEHAVIORAL|Group education|Education in a small group
214551247|NCT01531101|BEHAVIORAL|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
214551248|NCT04777110|DRUG|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
214551249|NCT04777110|OTHER|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
214551250|NCT05006326|DRUG|68Ga-PSMA|Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
214551251|NCT05006326|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
214551252|NCT05006326|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
214551253|NCT04092452|DRUG|PF-06650833|400 mg QD
214551254|NCT04092452|DRUG|PF-06700841|45 mg QD
214551255|NCT04092452|DRUG|PF-06826647|400 mg QD
214551256|NCT04092452|DRUG|Placebo|placebo
214701467|NCT02381496|DRUG|ACT-453859 300 mg|Capsule
214701468|NCT02381496|DRUG|ACT-453859 800 mg|Capsule
214701469|NCT02381496|OTHER|Placebo|Matching ACT-453859 placebo capsule
214701470|NCT02381496|DRUG|Setipiprant 500 mg|Capsule
214701471|NCT02381496|DRUG|Setipiprant 1000 mg|Capsule
214701472|NCT00394290|DEVICE|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
214701473|NCT02720016|BEHAVIORAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
214551257|NCT03463499|DRUG|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
214551258|NCT04368845|DEVICE|Telerehabilitation|The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
214551259|NCT02127125|DRUG|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
214551260|NCT02127125|DRUG|Synbiotic|Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
214701474|NCT02720016|BEHAVIORAL|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
214701475|NCT02720016|BEHAVIORAL|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
214701476|NCT00354263|BIOLOGICAL|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
214701477|NCT00354263|BIOLOGICAL|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
214701478|NCT04793763|OTHER|traditional therapeutic exercises|group A will receive traditional exercises
214701479|NCT04793763|OTHER|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
215161632|NCT06270498|DIETARY_SUPPLEMENT|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 24 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-16 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 24 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 24 weeks"
214551261|NCT02127125|DRUG|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
214551262|NCT01356563|BEHAVIORAL|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
214551263|NCT02493842|DEVICE|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
214551264|NCT02736279|DRUG|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
214551265|NCT03869177|OTHER|Implementation support program|"The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures"
214551266|NCT02184299|DRUG|Nevirapine|
214551267|NCT02184299|DRUG|Prednisone|
214551268|NCT02296216|DEVICE|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
214551269|NCT02353468|DRUG|Bortezomib|Given IV
214551270|NCT02353468|DRUG|Lenalidomide|Given PO
214551271|NCT02353468|DRUG|Dexamethasone|Given PO or IV
214551272|NCT00729638|DRUG|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
214551273|NCT00729638|DRUG|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
214551274|NCT02793310|PROCEDURE|DMEK|The intervention group will receive cornea transplantation by DMEK
214551275|NCT02793310|PROCEDURE|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
214551276|NCT00825539|DRUG|AQW051|
214701480|NCT04793763|OTHER|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
214701481|NCT05607017|DRUG|Losartan|Taken Orally
214701482|NCT05607017|RADIATION|Radiation Therapy|Photon Radiation Therapy
214701483|NCT04374110|OTHER|Clinical data|Clinical characteristics from medical records
214701484|NCT05403749|BIOLOGICAL|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
214701485|NCT05403749|DRUG|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
214551277|NCT00825539|DRUG|Placebo|
214551278|NCT02344342|DEVICE|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
214551279|NCT02344342|OTHER|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
214551280|NCT05105048|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline
214551281|NCT05105048|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214551282|NCT04857567|BEHAVIORAL|TSC program (Three Self-Commitment program)|"1. Self-Competence program~   \- A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   \- A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
214551283|NCT00848484|DRUG|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
214551284|NCT00848484|DRUG|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
214551285|NCT04375553|OTHER|Aerobic exercise|Intradialytic aerobic exercise
214551286|NCT02526498|RADIATION|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
214701486|NCT05403749|BIOLOGICAL|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
214551287|NCT02526498|RADIATION|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
214551288|NCT02526498|OTHER|Questionnaire Administration|Ancillary studies
214551289|NCT04192110|DRUG|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
214551290|NCT05808296|OTHER|Lavander oil Aromatherapy|Lavander oil Aromatherapy
214551291|NCT05808296|OTHER|Saline Solution|Saline solution application
214701487|NCT00605410|DRUG|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
214701488|NCT00605410|DRUG|placebo|Matched placebo
214701489|NCT03740412|BEHAVIORAL|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
214701490|NCT03752606|BIOLOGICAL|TACHOSIL GROUP|
215029647|NCT06232993|OTHER|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
214551292|NCT00002145|DRUG|Foscarnet sodium|
214551293|NCT01907698|BEHAVIORAL|Vaginal intercourse|vaginal intercourse at least twice a week
215029648|NCT01787747|DRUG|AVP-786 Dose 1|
215029649|NCT01787747|DRUG|AVP-786 Dose 2|
215029650|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 1|
214551294|NCT03151746|DRUG|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
214551295|NCT03151746|DRUG|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
214551296|NCT01059305|DRUG|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
214551297|NCT00290901|DRUG|Tramadol Hydrochloride 50mg|
214551298|NCT00290901|DRUG|Celebrex 200mg|
214551299|NCT01234415|DEVICE|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
214551300|NCT00785954|DRUG|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
214551301|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
214551302|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
215029651|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 2|
215029652|NCT01787747|DRUG|AVP-786 Dose 2/Q Dose 2|
215029653|NCT01787747|DRUG|AVP-923|
215029654|NCT02671292|BEHAVIORAL|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
214701491|NCT02049749|BEHAVIORAL|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
214551303|NCT03109236|DRUG|GCSF|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
214551304|NCT03109236|PROCEDURE|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10\^6 and up to 50-100 x 10\^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
214551305|NCT00153985|DRUG|Busulfex|Given once daily for 4 days
214551306|NCT00153985|DRUG|Fludarabine|Given intravenously once daily for 4 days
214551307|NCT00153985|DRUG|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
214551308|NCT00153985|PROCEDURE|Stem Cell Transfusion|Performed three days after the end of chemotherapy
214701492|NCT03696303|OTHER|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
214701493|NCT02213302|DRUG|placebo administration|
214701494|NCT02213302|DRUG|midazolam intravenous administration|
214701495|NCT00389103|BIOLOGICAL|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
214701496|NCT04515043|DRUG|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
214701497|NCT02862821|OTHER|HR-EEG|
214701498|NCT03282708|OTHER|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
214701499|NCT05890287|DRUG|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
214701500|NCT04501679|DRUG|Nemolizumab|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
214701501|NCT04501679|DRUG|Placebo|Participants received matching placebo as SC injection.
214701502|NCT01977079|OTHER|procalcitonin|
214701503|NCT03365479|DRUG|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
214701504|NCT04979832|DRUG|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
214701505|NCT00978809|OTHER|Epley maneuver|
214701506|NCT00978809|OTHER|Semont maneuver|
214701507|NCT05444478|PROCEDURE|Microwave ablation|only microwave ablation for tumor
214701508|NCT05444478|DRUG|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
214701509|NCT01879956|OTHER|Craft Activities|There is no intervention method used to perform the task.
215161633|NCT06270498|OTHER|Placebo|"Placebo pills will be identical in shape, form and color of SI tablets; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin C.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
214551309|NCT02595099|OTHER|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
214551310|NCT02102412|BIOLOGICAL|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
214551311|NCT00535379|DRUG|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
214701510|NCT01879956|BEHAVIORAL|OGI Method|metacognitive approach to assess executive functions.
214701511|NCT00186056|DRUG|Mifepristone|Glucocorticoid antagonist
214701512|NCT00186056|DRUG|Placebo Oral Tablet|Inactive placebo tab
214701513|NCT03661489|DRUG|Remimazolam|For induction and maintenance of general anesthesia
214701514|NCT03661489|DRUG|Propofol|For induction and maintenance of general anesthesia
214701515|NCT04086069|DEVICE|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
214701516|NCT00647868|DRUG|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
214701517|NCT01182389|PROCEDURE|Robotic VT Ablation|Robotic VT Ablation
214701518|NCT01182389|OTHER|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
214701519|NCT00910429|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
214701520|NCT05872594|DIAGNOSTIC_TEST|Online questionnaire|data will be collected remotely on the online platform Qualtrics
214701521|NCT00067314|DRUG|Edotecarin|
215161634|NCT06549764|BEHAVIORAL|Youth Aware of Mental Health|Help-seeking and literacy increasing intervention
215161635|NCT02781922|GENETIC|Autologous cardiac stem cells (JRM-001)|3x 10\^5 cells/kg, single treatment
215161636|NCT05858320|OTHER|SmartHF application|Adaptive medication recommendations that can be shared with the participants HF provider.
215161637|NCT00497380|DIETARY_SUPPLEMENT|Arginine|Oral nutritional supplement
215161638|NCT04794972|DRUG|GNC-039|Administration by intravenous infusion.
215161639|NCT06413108|DRUG|TB31F|transmission-blocking monoclonal antibody TB31F
214551312|NCT01225497|PROCEDURE|Standard eccentric exercise|"Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain."
214551313|NCT01225497|PROCEDURE|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
214701522|NCT03998020|OTHER|scale of severity|assessment of the severity of the sleep disorders by scale
214701523|NCT03998020|GENETIC|blood sample|Genetical study, serum and sample
214701524|NCT05672966|BIOLOGICAL|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
214701525|NCT05672966|BIOLOGICAL|Placebo|0.5mL, Intramuscular
214701526|NCT02128282|DRUG|CX-4945|API powder-in-capsule in 200 mg strength.
214701527|NCT02128282|DRUG|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
214701528|NCT02128282|DRUG|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
214701529|NCT02273557|DRUG|Asasantin ER (new formulation I - low)|
214701530|NCT02273557|DRUG|Asasantin ER (new formulation III - medium)|
214701531|NCT02273557|DRUG|Asasantin ER (new formulation II - high)|
214701532|NCT02273557|DRUG|Asasantin ER (present commercial formulation)|
214701533|NCT04412382|DIAGNOSTIC_TEST|NETosis markers|"NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed."
214701534|NCT04417725|OTHER|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
214701535|NCT06082648|DEVICE|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
214701536|NCT06082648|DEVICE|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
214701537|NCT04846348|COMBINATION_PRODUCT|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
214701538|NCT01941524|DRUG|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
214701539|NCT01941524|DRUG|Beractant instillation|aEEG and NRs monitoring during beractant instillation
214701540|NCT04110418|DRUG|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
214701541|NCT03543306|DRUG|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
214701542|NCT05007249|PROCEDURE|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
214701543|NCT01287533|DRUG|Ibandronate|monthly dosage of ibandronate 150mg
214701544|NCT01287533|DRUG|Placebo|monthly dosage of placebo
214701545|NCT00053261|PROCEDURE|management of therapy complications|
214701546|NCT05764278|OTHER|exercise|exercise group: first bed exercise after 0\~24hr onset ; sit at bed after 24\~48hr onset control group: first bed exercise after 24\~48hr onset ; sit at bed after 48\~72hr onset
214701547|NCT03939351|DIAGNOSTIC_TEST|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
214701548|NCT02749877|BEHAVIORAL|Working Memory Training|(Training Details already described above)
214701549|NCT02749877|BEHAVIORAL|Physical Training|(Training Details already described above)
214701550|NCT05217992|OTHER|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
214701551|NCT05360420|DIAGNOSTIC_TEST|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
214701552|NCT02476591|BEHAVIORAL|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
214701553|NCT05766865|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
214701554|NCT05766865|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
214701555|NCT01502982|DRUG|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
214701556|NCT01322646|DEVICE|CarChipPro|On board driving monitor
214701557|NCT01322646|BEHAVIORAL|Driver's Education|10 Session License to Learn Program.
214701558|NCT01322646|BEHAVIORAL|STEER Program|8-session behavioral parent training and teen social skills/communication training program
214701559|NCT01322646|OTHER|Driving Simulator Practice|Practice Driving on a driving simulator
214701560|NCT00283530|PROCEDURE|Tumor biopsy|
214701561|NCT02047630|DRUG|Generic latanoprost|
214701562|NCT02047630|DRUG|Brand-name latanoprost|
214701563|NCT03569865|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
215161640|NCT06413108|OTHER|Normal saline|normal saline as control (placebo)
215161641|NCT06183359|OTHER|SIP|compare the SIP group versus the ACT group
214551314|NCT02097303|DRUG|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
214551315|NCT05051969|BEHAVIORAL|Remote Mindfulness-Based Stress Reduction Program|Enrolled participants will participate in a remote-delivered (online with audio and video) Mindfulness-Based Stress Reduction (MBSR) program. MBSR is a well established behavioral health intervention consisting of 10-sessions lasting 2.5 hours, with one session lasting 7.5 hours in an all-day retreat format over a 2-month period.
214551316|NCT03530748|PROCEDURE|Endovascular therapy and Imaging Acquisition|"1. Endovascular repair for renal artery stenosis;~2. Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
214551317|NCT01983423|DEVICE|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
214551318|NCT01715883|DRUG|Sodium Nitrite|Same as the details in Arm Description.
214551319|NCT00854204|DRUG|TMC114; TMC41629|
214551320|NCT00356005|DRUG|azithromycin plus artesunate|
214701564|NCT02358369|DRUG|Bimatoprost|Bimatoprost sustained release Ocular Insert
214701565|NCT02358369|DRUG|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
214701566|NCT02358369|DEVICE|Placebo Ocular Insert|Placebo ocular insert OU.
214551321|NCT00356005|DRUG|Artesunate|
214551322|NCT00251342|PROCEDURE|Edinburgh Postnatal Depression Scale|
214551323|NCT01806012|DEVICE|Sealing tissue with the Enseal device|
214551324|NCT01806012|PROCEDURE|Conventional supracervical hysterectomy|
214551325|NCT00005637|DRUG|carmustine|
214551326|NCT00005637|DRUG|temozolomide|
214551327|NCT03928223|OTHER|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
214551328|NCT00950482|PROCEDURE|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
214701567|NCT02358369|DRUG|Placebo Eye Drops|Placebo eye drops BID OU.
214701568|NCT04872335|OTHER|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
215161642|NCT04408885|OTHER|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
215161643|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
215161644|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
215161645|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
215161646|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
215161647|NCT02839551|PROCEDURE|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
215161648|NCT05418764|OTHER|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
214551329|NCT00950482|OTHER|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
214551330|NCT00950482|OTHER|WC|Waiting Group
214551331|NCT03017742|DEVICE|Pulse Oximeter|
214551332|NCT00537342|BIOLOGICAL|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
214551333|NCT04038242|OTHER|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
214701569|NCT04872335|OTHER|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included\_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
215161649|NCT05365659|DRUG|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
215161650|NCT05440851|OTHER|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
214701570|NCT01783717|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
214701571|NCT03627858|DRUG|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
214701572|NCT04465396|DRUG|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
214701573|NCT04465396|DEVICE|Syringe Injection|Teduglutide was administered using syringe.
214701574|NCT04465396|DEVICE|Pen injector|Teduglutide was administered using pen injector.
214701575|NCT02607358|OTHER|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
214701576|NCT00204334|DRUG|darbopoeitin|
214701577|NCT00547638|DEVICE|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
215161651|NCT05440851|OTHER|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
215161652|NCT05440851|OTHER|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
215161653|NCT05440851|OTHER|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
215161654|NCT05440851|DRUG|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
214551334|NCT02975102|DEVICE|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
214551335|NCT02975102|DEVICE|Vismed® Multi Eye Drops|Vismed® Multi 3 to 6 times per day for 3 months.
214551336|NCT00154687|DRUG|Paclitaxel, Cisplatin, 5-Fluorouracil|
214551337|NCT05741190|DEVICE|Pentacam Imaging|Imaging of the corneal surface
214551338|NCT03952442|OTHER|standardized nutrition education|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
214551339|NCT03952442|OTHER|routine nutrition education|Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
214551340|NCT02883036|OTHER|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
214701578|NCT00547638|DEVICE|cyanoacrylate|Topical Skin Adhesive
214701579|NCT02821455|PROCEDURE|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
215161655|NCT05440851|DRUG|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
215161656|NCT05440851|DRUG|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
214551341|NCT02883036|OTHER|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
214551342|NCT03330613|DIAGNOSTIC_TEST|PAEDS|pediatric emergency delirium scale
214551343|NCT03330613|PROCEDURE|TIVA|Total intravenous anesthesia with propofol
214551344|NCT03330613|PROCEDURE|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
214551345|NCT06061237|OTHER|Aerobic Thai dance exercise|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
214551346|NCT05941117|COMBINATION_PRODUCT|stretching exercises|stretching exercises for Hamstring, quadriceps and calf muscle for both lower limbs of the same patients. each exercise was repeated 5 times and each repetition hold for 30 seconds in the same session.
214551347|NCT05941117|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation|it is one of the electrical stimulation modalities which is used to relief pain, each patient receive it on both knees every session.
214551348|NCT05941117|COMBINATION_PRODUCT|weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of weight bearing from standing position each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
214551349|NCT05941117|COMBINATION_PRODUCT|Non-weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of non-weight bearing from lying and setting positions each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
214551350|NCT04492813|DRUG|Pharmacokinetic of propofol and remifentanil|Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
214551351|NCT00208247|BEHAVIORAL|Cognitive behavioral psychotherapy|
214551352|NCT04160806|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
214551353|NCT02649205|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
214551354|NCT04069585|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
214551355|NCT04069585|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
214551356|NCT04560647|OTHER|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
214551357|NCT04560647|OTHER|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
214551358|NCT02272829|BEHAVIORAL|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
214551359|NCT02272829|OTHER|Health Education|
214551360|NCT01636245|BIOLOGICAL|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
214551361|NCT01636245|BIOLOGICAL|placebo|placebo, two doses, 28 days interval
214551362|NCT02089555|PROCEDURE|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
214551363|NCT02089555|PROCEDURE|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
214551364|NCT02089555|PROCEDURE|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
214551365|NCT01783132|DEVICE|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
214551366|NCT03688776|OTHER|1805AA|A moist snuff product
214551367|NCT03688776|OTHER|1805AB|A moist snuff product
214551368|NCT02614690|PROCEDURE|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
214701580|NCT04198324|PROCEDURE|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
214701581|NCT04198324|PROCEDURE|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
214701582|NCT02357641|OTHER|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
214701583|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
214551369|NCT02614690|PROCEDURE|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
214551370|NCT02614690|PROCEDURE|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
214551371|NCT01441635|DRUG|Elagolix|Elagolix tablets
214551372|NCT01441635|DRUG|Placebo|Matching placebo tablets
214551373|NCT01441635|DRUG|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
214551374|NCT01441635|DRUG|Estradiol|1.0 mg micronized estradiol tablets administered once a day
214551375|NCT01441635|DRUG|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
214551376|NCT01658111|DEVICE|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
214551377|NCT01658111|PROCEDURE|Traditional physiotherapy|Active or passive exercises.
214551378|NCT03470636|DEVICE|HeartLight X3|Pulmonary vein isolation
214551379|NCT05037643|PROCEDURE|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
214551380|NCT03827447|DRUG|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
214701584|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
215161657|NCT05440851|DRUG|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
215161658|NCT05440851|DRUG|Usual care with fludrocortisone|Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
214551381|NCT03827447|DRUG|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
214551382|NCT01825577|DRUG|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
214551383|NCT02975076|DRUG|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
214551384|NCT02975076|DRUG|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
214551385|NCT02975076|DRUG|Aspirin|
214551386|NCT02975076|DRUG|Clopidogrel|
214551387|NCT02975076|DRUG|placebo of clopidogrel|
214551388|NCT05390177|BEHAVIORAL|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
214701585|NCT05751486|BIOLOGICAL|Toripalimab /JS001|JS001 IV (if applicable) .
214701586|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
214551389|NCT01358331|DRUG|MK-8353|Administered orally twice daily for 28 days for each cycle
214701587|NCT01378936|BEHAVIORAL|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
214701588|NCT01378936|BEHAVIORAL|Motivational Interview only|45 minute Motivational Interview session
215161659|NCT05440851|DRUG|Usual care without fludrocortisone|Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
215161660|NCT05440851|DRUG|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
215161661|NCT05440851|DRUG|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
215161662|NCT05440851|OTHER|PEEP-20|fixed high positive end-expiratory pressure at 20 cmH2O
215161663|NCT05440851|OTHER|PEEP-AOP|positive end-expiratory pressure set according to airway opening pressure
215161664|NCT05440851|OTHER|PEEP-10|fixed lower positive end-expiratory pressure at 10 cmH2O
214701589|NCT02461836|DRUG|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
214701590|NCT02461836|RADIATION|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
214701591|NCT01665521|OTHER|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
215161665|NCT05440851|OTHER|VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation|Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
215161666|NCT05440851|OTHER|Electrical impedance tomography (EIT)|Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
215161667|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
215161668|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
214551390|NCT00064142|DRUG|halofuginone hydrobromide|Applied topically
214551391|NCT00064142|OTHER|placebo|Applied topically
214551392|NCT00064142|OTHER|laboratory biomarker analysis|Correlative studies
214551393|NCT00064142|OTHER|pharmacological study|Correlative studies
214551394|NCT00639522|DRUG|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
214551395|NCT02895932|RADIATION|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
214551396|NCT02700360|DIETARY_SUPPLEMENT|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
215161669|NCT04643457|DRUG|UCB9741|\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
215161670|NCT04643457|DRUG|Intravenous Placebo|\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
215161671|NCT04643457|DRUG|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
215161672|NCT06432738|DRUG|ZL-82|This group of subjects take ZL-82
215161673|NCT06432738|DRUG|ZL-82 placebo|This group of subjects take ZL-82 placebo
215161674|NCT03327974|OTHER|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~\- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
214551397|NCT02700360|DRUG|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
214551398|NCT02985359|DIETARY_SUPPLEMENT|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
214701592|NCT01642836|BEHAVIORAL|MMM|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
214701593|NCT01642836|BEHAVIORAL|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
214701594|NCT00274872|DRUG|fluorouracil|
214701595|NCT00274872|DRUG|leucovorin calcium|
214701596|NCT00274872|DRUG|oxaliplatin|
214701597|NCT00306774|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
214701598|NCT00306774|DIETARY_SUPPLEMENT|Placebo|Placebo capsule per day for 2 years
214701599|NCT03309267|PROCEDURE|Intercostal block|Intercostal block +patient controlled analgesia
214701600|NCT03309267|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
215161675|NCT03838562|OTHER|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
215161676|NCT03838562|OTHER|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
215161677|NCT05894434|BEHAVIORAL|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
215161678|NCT05894434|BEHAVIORAL|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
215161679|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo CARE
215161680|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo standard stretching program
215161681|NCT03284346|OTHER|Laboratory Biomarker Analysis|Correlative studies
215161682|NCT03284346|OTHER|Polar heart rate monitor|Receive Polar heart rate monitor
215161683|NCT03284346|OTHER|Quality-of-Life Assessment|Ancillary studies
215161684|NCT03284346|OTHER|Questionnaire Administration|Ancillary studies
215161685|NCT02875548|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
215161686|NCT04014920|DEVICE|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
215161687|NCT04014920|DEVICE|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
214551399|NCT02985359|BEHAVIORAL|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
214551400|NCT04600388|DEVICE|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
215161688|NCT06136624|DRUG|Opevesostat|Administered orally
215161689|NCT06136624|DRUG|Abiraterone acetate|Administered orally
215161690|NCT06136624|DRUG|Enzalutamide|Administered orally
215161691|NCT06136624|DRUG|Hydrocortisone|Administered orally or IM as a rescue medication
215161692|NCT06136624|DRUG|Fludrocortisone acetate|Administered orally
214551401|NCT00788970|BEHAVIORAL|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
214551402|NCT02337621|OTHER|No intervention|
214551403|NCT03346005|DEVICE|Aeonose|An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
214551404|NCT06018662|OTHER|A medication management mobile application|A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
214551405|NCT01055704|DRUG|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
214551406|NCT01055704|DRUG|Codeine only|30 mg taken orally four times daily for 5 days
214551407|NCT01055704|DRUG|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
214551408|NCT01055704|DRUG|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
214551409|NCT01969851|DRUG|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
214551410|NCT01971151|BEHAVIORAL|Exposure therapy|"Treatment protocol:~1\) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
215161693|NCT06136624|DRUG|Prednisone|Administered orally
214551411|NCT01133080|DRUG|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
215161694|NCT06136624|DRUG|Dexamethasone|Administered orally as rescue medication
215161695|NCT05799274|DRUG|RAD301 ([68Ga]-RAD301)|A single dose of 68Ga-RAD301 of 150 +/- 50 MBq (\~4mCi) administered as a slow bolus injection over 2-5 minutes
215161696|NCT04936542|BIOLOGICAL|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
214551412|NCT01133080|DRUG|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
214551413|NCT05029453|DRUG|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
214551414|NCT02731079|DEVICE|Covidien iDrive|Surgery performed with Covidien powered stapler
215161697|NCT04936542|BIOLOGICAL|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
215161698|NCT04302324|DRUG|Daratumumab SC|Given as 1800mg via injection
214551415|NCT02731079|DEVICE|Ethicon Echilon|Surgery performed with Ethicon powered stapler
214551416|NCT00065624|DRUG|lipoic acid|
214551417|NCT04727177|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive biological stimulation technique born in the middle of 1980's.
214551418|NCT04351308|DRUG|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)"
214551419|NCT04351308|DRUG|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
214551420|NCT04351308|DRUG|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
214551421|NCT00452140|BIOLOGICAL|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
214551422|NCT00536653|DRUG|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
214551423|NCT00536653|DRUG|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
214551424|NCT00536653|DRUG|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
214551425|NCT02694445|OTHER|observation|The study is non-interventional.
214551426|NCT00763464|PROCEDURE|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
214551427|NCT00763464|PROCEDURE|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
214551428|NCT04196634|OTHER|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
214551429|NCT04640740|PROCEDURE|hip arthroplasty|two different approaches of total hip arthroplasty
214551430|NCT04792177|BEHAVIORAL|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
214551431|NCT01540942|DIETARY_SUPPLEMENT|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;\[W=weight（Kg）；H=height（cm）；A=age（year）\]
214551432|NCT01540942|OTHER|surgery|bowel resection
214551433|NCT04248478|OTHER|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
214701601|NCT01184716|OTHER|Vitamin D fortification|Bread and milk fortified with vitamin D3
215161699|NCT04302324|DRUG|Clarithromycin|Given as 500mg oral capsule
215161700|NCT04302324|DRUG|Pomalidomide|Given as 4mg oral capsule
215161701|NCT04302324|DRUG|Dexamethasone|Given as 20mg IV and 20mg or 40mg oral tablets
215161702|NCT05758077|DEVICE|Selective Cytopheretic Device|"The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation."
215161703|NCT05758077|OTHER|Standard of Care|Standard of care CKRT for the subject's condition, as appropriate
215161704|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
215161705|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
215161706|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
215161707|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
215161708|NCT06304441|DRUG|Osimertinib|Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
214701602|NCT00885417|DRUG|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
214701603|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (low dose)|The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
215161709|NCT06304441|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
215161710|NCT05108233|OTHER|Survey Administration|Complete survey
215161711|NCT05325866|DRUG|Bemarituzumab|Intravenous (IV) infusion.
214701604|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (high dose)|The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
214701605|NCT06350058|BIOLOGICAL|Placebo|Aluminum hydroxide adjuvant.
214701606|NCT01838967|DRUG|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
215161712|NCT04079387|DEVICE|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
214551434|NCT04248478|OTHER|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
214551435|NCT05615584|DIAGNOSTIC_TEST|Quantitative mass spectrometry assay|ORX-A determination by quantitative mass spectrometry
214551436|NCT00292968|BEHAVIORAL|Computer based care|
214551437|NCT00292968|BEHAVIORAL|Telephone counseling|
214551438|NCT00292968|BEHAVIORAL|Group visits|
214551439|NCT00292968|BEHAVIORAL|Usual care|
214551440|NCT03122470|DEVICE|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
214551441|NCT03122470|PROCEDURE|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
214551442|NCT01722279|PROCEDURE|Bariatric surgery|
214551443|NCT03913572|PROCEDURE|Injection of adipose-derived stem cells into perianal fistula|The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
214551444|NCT03570268|OTHER|Experimental Group: Education|Participants in the experimental intervention group received an educational program and tailored home exercises.
215161713|NCT04079387|DEVICE|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
215161714|NCT05972967|BIOLOGICAL|OMS906|Biological: OMS906
215161715|NCT06393439|DIAGNOSTIC_TEST|Virtual reality motor task|After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.
215161716|NCT05873543|OTHER|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|"The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms."
214551445|NCT03570268|OTHER|Control Group: Usual care|Participants allocated to the control group received stretching exercises.
214551446|NCT00566891|DRUG|tirofiban|tirofiban high dose bolus 25µ/Kg
214551447|NCT00566891|DRUG|Clopidogrel|
214551448|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 14
214551449|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 23
214551450|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 8
214551451|NCT05594602|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
214701607|NCT01838967|DRUG|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
214701608|NCT01838967|DRUG|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
214701609|NCT01838967|DRUG|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
214701610|NCT01838967|DRUG|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
214701611|NCT01838967|DRUG|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
214701612|NCT00796601|DRUG|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
214701613|NCT00796601|DRUG|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
215161717|NCT05673993|BIOLOGICAL|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
215161718|NCT05673993|BIOLOGICAL|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
215161719|NCT05673993|DRUG|Placebo|Subjects will be given subcutaneous placebo once a week.
215161720|NCT06353386|DRUG|Opevesostat|Oral Tablet
214701614|NCT03054467|DRUG|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
214701615|NCT03054467|DRUG|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
214551452|NCT05594602|DRUG|Carbamazepine|Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
214551453|NCT05594602|DRUG|Quinidine|Subjects will receive quinidine BID Days 5-12
214551454|NCT01661764|DRUG|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
214551455|NCT01661764|DRUG|Oleic Acid|Placebo
214551456|NCT00763490|PROCEDURE|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
214551457|NCT00763490|DRUG|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
214551458|NCT00763490|RADIATION|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
214551459|NCT00763490|DRUG|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
214551460|NCT00763490|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) \< 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
214551461|NCT03808792|DIAGNOSTIC_TEST|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
214551462|NCT04906681|DEVICE|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
214551463|NCT01357122|DEVICE|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
214551464|NCT01357122|PROCEDURE|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
214551465|NCT01430468|PROCEDURE|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
214551466|NCT02700659|OTHER|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
214551467|NCT03072524|DIAGNOSTIC_TEST|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
214551468|NCT04592159|DRUG|Nabiximols|oromucosal spray
214551469|NCT04592159|DRUG|Placebo|oromucosal spray
214551470|NCT04625959|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
215161721|NCT06353386|DRUG|Olaparib|Oral Tablet
214551471|NCT04625959|BEHAVIORAL|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
214551472|NCT04625959|BEHAVIORAL|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
214551473|NCT04625959|BEHAVIORAL|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
214551474|NCT04625959|BEHAVIORAL|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
214551475|NCT05674162|BEHAVIORAL|Unobserved|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.
214551476|NCT05674162|BEHAVIORAL|Observed|Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.
214551477|NCT05674162|RADIATION|Unobserved & Measured|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
215161722|NCT06353386|DRUG|Docetaxel|IV Infusion
215161723|NCT06353386|DRUG|Cabazitaxel|IV Infusion
215161724|NCT06353386|DRUG|Fludrocortisone acetate|Oral Tablet
215161725|NCT06353386|DRUG|Dexamethasone|Oral Tablet
215161726|NCT06353386|DRUG|Prednisone|Oral Tablet
215161727|NCT02946346|OTHER|vaginal sampling|
214701616|NCT03911336|DRUG|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
214551478|NCT04662229|DEVICE|Eco-guided Percutaneous Electrical Stimulation|Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
214551479|NCT04662229|DEVICE|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
214551480|NCT00391703|BEHAVIORAL|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
214551481|NCT00391703|BEHAVIORAL|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
214551482|NCT03394131|DRUG|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
214701617|NCT03911336|DRUG|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
214701618|NCT03911336|DRUG|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
214701619|NCT03594487|DRUG|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
214701620|NCT03594487|PROCEDURE|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
214701621|NCT03594487|OTHER|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
214701622|NCT01336556|PROCEDURE|Oral appliance|Anterior mandibular repositioner: used for two months
214701623|NCT05027516|DRUG|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
214551483|NCT03394131|DRUG|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
214551484|NCT03394131|OTHER|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
214701624|NCT05027516|DRUG|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
214701625|NCT05982223|PROCEDURE|Acupuncture|The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214701626|NCT05982223|PROCEDURE|Mind-body therapy|The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214701627|NCT05982223|PROCEDURE|Touch therapy|The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214701628|NCT05982223|PROCEDURE|Movement therapy|The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214701629|NCT05982223|DIETARY_SUPPLEMENT|Herbal supplements|The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214701630|NCT05982223|BEHAVIORAL|Emotional treatment|The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
214551485|NCT00012753|PROCEDURE|Automated telephone health status assessments with nurse follow-up.|
214551486|NCT04874753|OTHER|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
214701631|NCT00119730|DRUG|Fludarabine|Given on days 1-3 of each 28-day cycle
214701632|NCT00119730|DRUG|Mitoxantrone|Given on day 1 of each 28-day cycle
214701633|NCT00119730|DRUG|Rituximab|Given on day 1 of each 28-day cycle
214551487|NCT03470259|DRUG|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
214551488|NCT03470259|DEVICE|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
214701634|NCT00119730|DRUG|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
214701635|NCT02523820|DRUG|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
214701636|NCT02523820|DRUG|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
214551489|NCT03470259|DEVICE|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
214551490|NCT03570723|PROCEDURE|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
214551491|NCT03570723|PROCEDURE|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
214551492|NCT00329680|DIETARY_SUPPLEMENT|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
214701637|NCT02072720|DRUG|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
214701638|NCT03374748|OTHER|N/A - observational study|N/A - observational study
214701639|NCT05913141|OTHER|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
214701640|NCT02207595|DRUG|UCB5857|"* Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
214701641|NCT02207595|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
214701642|NCT00379197|DRUG|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
214701643|NCT00379197|PROCEDURE|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
214701644|NCT06099691|BEHAVIORAL|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
214701645|NCT01451034|PROCEDURE|WHYX cancer group|WHYX cancer diagnosed by pathologic report
214701646|NCT02365584|DRUG|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
214701647|NCT01557218|OTHER|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
214701648|NCT01557218|OTHER|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
214701649|NCT01557218|OTHER|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
214701650|NCT01557218|OTHER|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
214701651|NCT01557218|OTHER|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
214701652|NCT01557218|OTHER|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
214701653|NCT01557218|OTHER|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
214701654|NCT01557218|OTHER|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
214701655|NCT03548038|OTHER|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
214551493|NCT00329680|DIETARY_SUPPLEMENT|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
214551494|NCT06533488|OTHER|Perceptual learning module|Perceptual learning module providing feedback on the most relevant image for clinical practice in a spinal ultrasound video.
214551495|NCT06533488|OTHER|Control|Participants in the control group will view the same videos as participants in the intervention group without feedback on the best image.
214701656|NCT03136770|DIETARY_SUPPLEMENT|CK-30|Compound K 600 mg
214701657|NCT03136770|DIETARY_SUPPLEMENT|Red ginseng extracts|Red ginseng extracts 2.94 g
214701658|NCT00349752|BIOLOGICAL|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
214701659|NCT00349752|OTHER|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
214701660|NCT03052842|DRUG|C16G2 Strip|Antimicrobial Peptide
214701661|NCT03052842|OTHER|Placebo Strip|Placebo
214701662|NCT01973452|DRUG|Dexmedetomidine|
214701663|NCT01973452|DRUG|Placebo|
214701664|NCT06206278|DRUG|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
214551496|NCT00115518|DRUG|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
214551497|NCT02583529|DEVICE|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
214551498|NCT02583529|DEVICE|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
214551499|NCT02847039|GENETIC|Blood samples|Blood samples at baseline.
214551500|NCT05011344|OTHER|Blood sample|Seroneutralization and Elisa tests
214551501|NCT04176731|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
214551502|NCT02984007|BEHAVIORAL|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
214551503|NCT02984007|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
214551504|NCT03556800|DRUG|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel"
214551505|NCT00276198|DIETARY_SUPPLEMENT|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
214551506|NCT00276198|DIETARY_SUPPLEMENT|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
214551507|NCT03518567|DRUG|Smoked marijuana cigarettes: High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose \[6% THC\])
214551508|NCT01884220|OTHER|There are no interventions in this study.|
214551509|NCT04686682|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
214551510|NCT04686682|DRUG|JAB-8263|RP2D dose, orally Q2D with 28 days each cycle
214551511|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
214701665|NCT02193815|DRUG|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
214701666|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 4% solution
214701667|NCT02193815|DRUG|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
214701668|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 2% Ointment
214701669|NCT02193815|DRUG|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
214701670|NCT02193815|DRUG|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
214551512|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
214551513|NCT01320878|DRUG|distilled water|distilled water 2 ml per session
214701671|NCT01320111|DRUG|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
214551514|NCT03124147|DEVICE|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
214551515|NCT02401971|DRUG|Thalidomide|Given orally
214551516|NCT02401971|DRUG|CPT-11|Given Ivgtt
214551517|NCT03013140|DRUG|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%"
214551518|NCT03013140|PROCEDURE|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
214701672|NCT01320111|DRUG|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
214551519|NCT01383330|DRUG|megace|800mg
214551520|NCT01383330|DRUG|DW-ES(A)|625mg
214551521|NCT01383330|DRUG|DW-ES(B)|625mg
214551522|NCT00603811|BIOLOGICAL|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
214551523|NCT00603811|BIOLOGICAL|Placebo|Placebo
214551524|NCT02803099|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
214551525|NCT00617929|BIOLOGICAL|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
214551526|NCT00617929|BIOLOGICAL|rituximab|administered 375 mg/m\^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
214551527|NCT00617929|DRUG|clofarabine|administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
214551528|NCT00617929|PROCEDURE|stem cell transplantation|administered on Day 0 per institutional guidelines.
214551529|NCT04355936|DRUG|Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.|Control arm will receive standard care.
214551530|NCT04479072|DRUG|Aspirin 81 mg|Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
214551531|NCT04479072|DRUG|Placebo|Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
214551532|NCT00107523|DRUG|cytarabine|
214701673|NCT04580251|PROCEDURE|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
214551533|NCT00107523|DRUG|idarubicin|
214551534|NCT00107523|DRUG|pravastatin|
214551535|NCT01035541|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
214551536|NCT01309698|DRUG|Vildagliptin (LAF237)|
214551537|NCT01309698|DRUG|Voglibose|
214551538|NCT01309698|DRUG|Vildagliptin and Voglibose|
214551539|NCT00724386|DRUG|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
214551540|NCT00724386|DRUG|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
214551541|NCT00724386|DRUG|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
214551542|NCT00724386|RADIATION|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
214551543|NCT01638845|PROCEDURE|continuous perineural catheter|continuous perineural catheter
214551544|NCT02808247|DRUG|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
214551545|NCT02808247|DRUG|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
214551546|NCT06339749|DIAGNOSTIC_TEST|blood pressure|Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
214551547|NCT06339749|OTHER|Clinical protocols for preeclampsia risk screening|"In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester."
214551548|NCT06156917|DIAGNOSTIC_TEST|diagnostic accuracy|Aims of the present project are: to investigate the relationship between incident PD dementia and multimodal parameters as cardiovascular autonomic dysfunction, altered cerebral glucose metabolism, and genetic biomarkers; development of an algorithm predictive for PD-related dementia, combining the rele- vant multidimensional parameters under study; longitudinal follow-up of clinical and cognitive status in PD patients with and without dementia along four years.
214551549|NCT00533364|DRUG|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
214701674|NCT01789853|BEHAVIORAL|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
214551550|NCT01426347|DRUG|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
214551551|NCT01426347|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
214551552|NCT05102058|DRUG|Magnesium-Dexmedetomidine|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
214551553|NCT05987254|PROCEDURE|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
214551554|NCT05987254|PROCEDURE|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
214551555|NCT01292304|DRUG|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
214551556|NCT00002341|DRUG|Itraconazole|
214551557|NCT01476605|PROCEDURE|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
214551558|NCT01476605|PROCEDURE|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
214551559|NCT01476605|PROCEDURE|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
214551560|NCT02809560|PROCEDURE|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
214551561|NCT00614562|DEVICE|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
214551562|NCT02280876|DRUG|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."
214701675|NCT01789853|BEHAVIORAL|Conventional Physical Therapy|Regular physical therapy for 8 weeks
214701676|NCT02990897|BEHAVIORAL|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
214701677|NCT00661245|DEVICE|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
214701678|NCT00661245|DEVICE|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
214551563|NCT02280876|DRUG|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"
214551564|NCT00000685|DRUG|Zidovudine|
214551565|NCT05516043|PROCEDURE|Implantation with POLYTHESE®|thoracic vascular surgery, abdominal vascular surgery and peripheral vascular surgery
214551566|NCT01422473|DEVICE|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
214551567|NCT04174209|BEHAVIORAL|Cylinder|Patients who receive the Jackson Cross Cylinder Method
214551568|NCT04174209|BEHAVIORAL|Dial|Patients who receive the Astigmatic Dial Technique Method.
214551569|NCT04174209|BEHAVIORAL|Slit|Patients who receive the Stenopeic slit Method.
214551570|NCT00223275|DRUG|Naltrexone|
214551571|NCT00029224|DRUG|zoledronic acid|
214551572|NCT05521997|DRUG|Telaglenastat|-800 mg twice per day by mouth
214551573|NCT05521997|RADIATION|Radiation treatment|"* Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
214551574|NCT05521997|DRUG|Cisplatin|"* Standard of care~* Weekly administration of cisplain"
214551575|NCT06481163|DRUG|Telacebec|The test product will be supplied as Telacebec 100mg tablets.
214551576|NCT01609777|PROCEDURE|SBAR|situation, background, assessment, recommendation
214551577|NCT02304081|DRUG|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
214551578|NCT02304081|DRUG|Placebo for Saxagliptin|
214551579|NCT01151423|BIOLOGICAL|Caplacizumab|"* Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session."
214551580|NCT01151423|BIOLOGICAL|Placebo|"* Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session."
214551581|NCT01249508|OTHER|nutrition label|
214551582|NCT05331469|DRUG|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
214701679|NCT00016198|DRUG|FOLFOX regimen|
214701680|NCT00016198|DRUG|fluorouracil|
214701681|NCT00016198|DRUG|leucovorin calcium|
214701682|NCT00016198|DRUG|oxaliplatin|
214701683|NCT02725827|OTHER|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
214701684|NCT02725827|OTHER|Control medium|The usual embryo transfer medium used in the study centres.
214701685|NCT02472691|DRUG|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
214701686|NCT02472691|DRUG|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
214701687|NCT02472691|BIOLOGICAL|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
214701688|NCT03896880|DIAGNOSTIC_TEST|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar"
214701689|NCT03896880|OTHER|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
214701690|NCT03896880|OTHER|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
214551583|NCT02772237|BIOLOGICAL|Riboflavin|Riboflavin 400mg daily
214551584|NCT02772237|BIOLOGICAL|Placebo|
214551585|NCT01515852|PROCEDURE|general anesthesia in stereotactic biopsy|stereotactic biopsy
214551586|NCT01515852|PROCEDURE|local anesthesia in stereotactic biopsy|stereotactic biopsy
214551587|NCT02984254|DEVICE|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
214551588|NCT02984254|DEVICE|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
214551589|NCT02984254|DEVICE|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
214551590|NCT02984254|DEVICE|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
214551591|NCT02984254|DEVICE|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
214551592|NCT02984254|DEVICE|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
214551593|NCT02984254|DEVICE|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
214701691|NCT03896880|OTHER|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
214701692|NCT00070980|PROCEDURE|Massage therapy|
214701693|NCT02027168|OTHER|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
214701694|NCT02604862|OTHER|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
214551594|NCT01675349|BIOLOGICAL|Prick test Chenopodium album allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
214551595|NCT05225987|BEHAVIORAL|Postpartum Nurse Navigation Program based care|In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times.
214701695|NCT02604862|OTHER|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
214701696|NCT00234572|DRUG|Lanreotide (Autogel formulation)|
214701697|NCT00002386|DRUG|Indinavir sulfate|
214701698|NCT00002386|DRUG|Lamivudine|
214701699|NCT00002386|DRUG|Stavudine|
214701700|NCT00002386|DRUG|Zidovudine|
214701701|NCT00002386|DRUG|Zalcitabine|
214701702|NCT00002386|DRUG|Didanosine|
215161728|NCT06634901|OTHER|Health Literacy Educational Session- Comparator|During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
214551596|NCT02671110|BEHAVIORAL|Transforming Your Life|See Transforming Your Life Arm
214551597|NCT02671110|BEHAVIORAL|Diabetes Prevention Program|See Diabetes Prevention Program Arm
214551598|NCT03188653|OTHER|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
214551599|NCT03188653|OTHER|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
214551600|NCT03188653|OTHER|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
214551601|NCT03188653|OTHER|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
214701703|NCT01333696|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
214701704|NCT05759845|DRUG|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
214551602|NCT03188653|OTHER|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
214551603|NCT03188653|OTHER|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
214551604|NCT03188653|OTHER|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
214551605|NCT06239415|OTHER|observation|Observation for 1 year of patients suffering from symptomatic peripheral atherosclerotic disease of the lower limb, with or without chronic ischemic heart disease, and indication for treatment with rivaroxaban 2.5 mg bid and acetylsalicylic acid 100 mg.
214551606|NCT04328103|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
214701705|NCT05759845|DRUG|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
214701706|NCT05759845|DRUG|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
214701707|NCT05294211|DEVICE|M•care™ System|The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
214701708|NCT05294211|DEVICE|Cardiotocography (CTG)|A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
215161729|NCT06634901|BEHAVIORAL|Health Literacy Educational Session|The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
215161730|NCT05769582|BIOLOGICAL|Anti-BK polyomavirus (AntiBKV)|"Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85."
215161731|NCT06247215|OTHER|Religious leaders|Religious leaders who have experience providing pastoral or spiritual care to Chinese Americans living in Chicago
215161732|NCT06247215|OTHER|Chinese Americans|Chinese Americans living in Chicago.
215161733|NCT06247215|OTHER|Chinese Americans with end-of-life care discussions|Chinese Americans who have experience discussing end-of-life care decisions with others.
214551607|NCT04328103|BEHAVIORAL|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
214551608|NCT00962806|BEHAVIORAL|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
214551609|NCT00962806|BEHAVIORAL|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
214701709|NCT01012505|OTHER|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
214551610|NCT04652661|DRUG|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
214551611|NCT04652661|DRUG|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
214551612|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|Low Dose- 70g bar
214701710|NCT03902782|PROCEDURE|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
214701711|NCT03902782|PROCEDURE|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
214701712|NCT03902782|PROCEDURE|Sham ESP block|As described earlier
215161734|NCT06247215|OTHER|Chinese Americans with chronic diseases|Chinese Americans who are diagnosed with cancer, hypertension, or heart disease and their family caregivers
214551613|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|High Dose- 100g bar
215161735|NCT06343285|DEVICE|Encora Therapeutics Tremor Reduction Device|The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.
215161736|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
215161737|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
215161738|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
214551614|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
214551615|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|High dose: 100g bar
214551616|NCT00691249|DIETARY_SUPPLEMENT|Shredded Wheat|70g bar
214551617|NCT03498352|PROCEDURE|Thoracic surgery|Lung resection surgery
214551618|NCT05794477|BIOLOGICAL|Adebrelimab|Specified dose on specified days
214551619|NCT05794477|BIOLOGICAL|SHR-1802|Specified dose on specified days
214551620|NCT05794477|DRUG|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214551621|NCT05794477|DRUG|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214551622|NCT01498315|OTHER|Ultrasound examination|Ultrasound examination following hysterectomy
214551623|NCT03033758|OTHER|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
214551624|NCT04554537|BEHAVIORAL|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
214551625|NCT04554537|BEHAVIORAL|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
214551626|NCT03763045|DRUG|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
214551627|NCT03763045|DRUG|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
214551628|NCT03763045|OTHER|Placebo|Placebo tablet.
214551629|NCT06630221|DRUG|Eltrombopag (EPAG)|50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)
214551630|NCT07047586|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214551631|NCT07047586|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214551632|NCT07050420|OTHER|Training|Education on Child Abuse and Neglect
214551633|NCT07049120|DEVICE|ZENFLEX Pro™ Peripheral Drug-eluting Stent System|The ZENFLEX Pro™ Peripheral Drug-eluting Stent System will be implanted in patients with femoropopliteal artery lesions to evaluate safety and efficacy outcomes. The device is designed to provide mechanical support and deliver antiproliferative drug locally to reduce restenosis. The procedure will be performed via standard endovascular techniques.
214701713|NCT03902782|PROCEDURE|Sham Intercostal block|As described earlier
214701714|NCT03902782|DRUG|Bupivacaine-epinephrine|As described earlier
214701715|NCT03902782|DRUG|Dexamethasone injection|As described earlier
214551634|NCT07049965|PROCEDURE|Suture ligation|Participants will undergo laparoscopic appendectomy in which the base of the appendix is ligated using intracorporeal suturing with absorbable material. This is the conventional technique used to prevent stump leakage.
214551635|NCT07049965|DEVICE|Harmonic Scalpel|Participants will undergo laparoscopic appendectomy where the base of the appendix is sealed and divided using the harmonic scalpel. This ultrasonic energy-based device cuts and coagulates tissue simultaneously, potentially reducing operative time and blood loss.
214701716|NCT03902782|DRUG|Normal saline|As described earlier
214701717|NCT03946826|DRUG|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
214701718|NCT03946826|DRUG|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
214701719|NCT03946826|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
214701720|NCT00804739|OTHER|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
214701721|NCT04668001|DEVICE|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
215161739|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
215161740|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
215161741|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
215161742|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
214551636|NCT07049016|OTHER|restoring the MIH affected young permanent molars using Direct nanohybrid flowable composite|(Shofu)is a bioactive flowable nano-hybrid restorative with a newly developed patented nanofiller. It is indicated for all classes including occlusal and cusp. It has all of the Giomer Technology attributes, anti-bacterial, acid neutralization, and fluoride release and recharge, with improved handling and effortless polishing, and maintains a long-lasting shine. Beautifil Flow Plus X has the strength, durability, and aesthetics of a hybrid composite.
214551637|NCT07049016|OTHER|restoring the MIH affected young permanent molars using IPS e.max CAD|glass-ceramic-based restorations still offer the best translucency and esthetic qualities. The novel generation of lithium disilicate-based materials as IPS e.max CAD provides standard thickness and quick fabrication. Moreover, the adhesive technique used with this restoration type significantly raises its mechanical properties.
214551638|NCT07049094|DRUG|scalp nerve block with 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution|Using 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution for scalp nerve block
214551639|NCT07049094|DRUG|scalp nerve block with 0.50% hydrochloride bupivacaine|Using 0.50% hydrochloride bupivacaine for scalp nerve block
214551640|NCT07050667|DEVICE|Cold atmospheric plasma|Treatment of chronic wounds with cold plasma
214551641|NCT07050667|DEVICE|Placebo treatment|Treatment of chronic wounds with the placebo device
214551642|NCT07050875|DEVICE|ABLE Exoskeleton|Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.
214551643|NCT07049614|DIAGNOSTIC_TEST|Diabetic Patients|"This group consists of 66 adult diabetic patients (Type 1 or Type 2) undergoing elective general surgical procedures. These patients will be managed as per standard clinical protocols, including preoperative evaluation, glycemic control assessment (via recent HbA1c and blood glucose levels), and administration of prophylactic broad-spectrum antibiotics-typically second-generation cephalosporins and metronidazole.~Postoperative follow-up will be conducted on Day 1, Day 7, and Day 14 to monitor for the development of surgical site infections (SSIs), which will be classified by the unit chief as superficial, deep, or organ/space infections."
214551644|NCT07049614|DIAGNOSTIC_TEST|Non-Diabetic Patients|This group includes 66 adult non-diabetic patients undergoing elective general surgical procedures at DHQ Hospital, Dera Ismail Khan. These participants will serve as the comparison group for evaluating the incidence and characteristics of postoperative surgical site infections (SSIs). All patients will receive standard preoperative assessments and prophylactic antibiotics (second-generation cephalosporins with metronidazole) as per institutional protocols. Postoperative follow-up will be carried out on Day 1, Day 7, and Day 14, and SSIs, if any, will be classified based on CDC criteria into superficial, deep, or organ/space infections
214551645|NCT06742333|DRUG|Bimekizumab|Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
214551646|NCT06742333|DRUG|Clobetasol|Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
214701722|NCT04668001|DEVICE|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
214701723|NCT02927340|DRUG|Lorlatinib|
214701724|NCT03769324|DIAGNOSTIC_TEST|Osmolarity Test|Osmolarity Test
214701725|NCT00838916|BIOLOGICAL|albiglutide|albiglutide weekly injection
214701726|NCT00838916|DRUG|insulin glargine|insulin glargine
214701727|NCT04696458|DIETARY_SUPPLEMENT|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
214701728|NCT04696458|OTHER|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
214701729|NCT04398199|DRUG|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
214701730|NCT04398199|RADIATION|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
214701731|NCT04961099|DRUG|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
214701732|NCT05038033|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
214551647|NCT06854393|DRUG|0.00025% Lacripep ophthalmic solution and Placebo|Participant will receive Lacripep in one eye and placebo in the other eye at the same time.
214701733|NCT05038033|BEHAVIORAL|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
214551648|NCT04103996|DIAGNOSTIC_TEST|Ultrasound|Sonographic measurements (diaphragm, abdominal muscle, and quadriceps thickness) will be acquired when listed for lung transplantation. Sonographic measurements will be recorded on a daily basis for up to 1 week after transplantation (while the patient remains intubated).
214551649|NCT04103996|DIAGNOSTIC_TEST|Respiratory function measurements|Maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) will be acquired after listing for lung transplantation. After transplant, MIP will be recorded once patients are eligible for a trial of spontaneous breathing and weekly thereafter. MEP will also be recorded at ICU discharge.
215161743|NCT05046834|OTHER|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
215161744|NCT05046834|OTHER|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
214701734|NCT04558788|DIAGNOSTIC_TEST|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
214701735|NCT04134585|OTHER|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
214551650|NCT04330690|DRUG|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
214551651|NCT04330690|DRUG|Imatinib|400 mg enterally daily for 14 days plus standard of care
214551652|NCT04330690|DRUG|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
214551653|NCT04330690|DRUG|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
214551654|NCT04330690|DRUG|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
214551655|NCT05389553|OTHER|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
214701736|NCT01842607|BIOLOGICAL|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
214701737|NCT02518152|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
215161745|NCT06189157|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
214551656|NCT00380315|DRUG|AG1321001(drug)|
214551657|NCT04200469|DIAGNOSTIC_TEST|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
214551658|NCT04946578|DIETARY_SUPPLEMENT|Prebiotic|6 weeks of prebiotic supplementation twice a day
214551659|NCT04946578|OTHER|Placebo|6 weeks of maltodextrin supplementation twice a day
214551660|NCT02177253|DRUG|Ipratropium bromide / Salbutamol|
214551661|NCT02177253|DRUG|Placebo Inhalation solution|
214551662|NCT02177253|DRUG|Ipratropium bromide|
214551663|NCT02177253|DRUG|COMBIVENT Inhalation Aerosol|
214551664|NCT02177253|DRUG|Placebo Inhalation Aerosol|
214551665|NCT02288169|BEHAVIORAL|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
214551666|NCT02288169|BEHAVIORAL|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
214551667|NCT03427697|DEVICE|Virtual reality and accommodation relax techniques in combination|The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
214701738|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
215161746|NCT04842929|DEVICE|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
215161747|NCT06344377|DIETARY_SUPPLEMENT|Betaine|Betaine supplemented for 8 weeks
215161748|NCT06344377|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
215161749|NCT06012656|DEVICE|MiniMAX|Total or Partial Hip Arthroplasty
215161750|NCT06275815|OTHER|Sit Together and Read (STAR)|Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.
214701739|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
214701740|NCT02193256|DRUG|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
214701741|NCT02193256|DRUG|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
214701742|NCT02193256|DRUG|Placebo|
215161751|NCT06275815|BEHAVIORAL|Monetary Reward|Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).
215161752|NCT06275815|BEHAVIORAL|Text Encouragement|Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
215161753|NCT03774238|OTHER|FMD analysis|Blood sample and vascular exploration.
215161754|NCT05641896|DRUG|[18F]FAPI-74 PET/CT|\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
215161755|NCT02867423|DEVICE|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
215161756|NCT05080946|DRUG|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
214551668|NCT02356627|OTHER|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
214551669|NCT03192462|BIOLOGICAL|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
214551670|NCT00294411|PROCEDURE|elective cesarean section|
214551671|NCT00279253|DRUG|clonidine (drug) intravenously|
214551672|NCT01030393|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
214551673|NCT05442268|PROCEDURE|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
214551674|NCT05442268|PROCEDURE|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
214551675|NCT05925257|OTHER|ePRO application and proactive clinical care with nurses.|The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
214551676|NCT02419417|DRUG|BMS-986158|Specified dose on specified days
214551677|NCT02419417|BIOLOGICAL|Nivolumab|Specified dose on specified days
214701743|NCT06317077|OTHER|PAP therapy setting|Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
214701744|NCT06317077|OTHER|exclusive use of Löwenstein Medical full face masks|Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
214701745|NCT01398033|DEVICE|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
214701746|NCT01398033|DEVICE|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
215161757|NCT05080946|DRUG|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
215161758|NCT05211154|DRUG|Diclofenac Potassium 50Mg/Pkt Oral Pwdr|Treatment for an acute, moderate to severe migraine attack
215161759|NCT05211154|DRUG|Rimegepant 75 MG|Treatment for an acute, moderate to severe migraine attack
215161760|NCT06049797|DRUG|Fezolinetant|Oral
215161761|NCT06049797|DRUG|Paroxetine|Oral
215161762|NCT06049797|DRUG|Citalopram|Oral
215161763|NCT06049797|DRUG|Escitalopram|Oral
215161764|NCT06049797|DRUG|Desvenlafaxine|Oral
214551678|NCT01764893|OTHER|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
214701747|NCT01945333|BEHAVIORAL|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
214701748|NCT04224428|DRUG|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
214551679|NCT01764893|OTHER|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
214551680|NCT00078377|DRUG|Armodafinil|Armodafinil 250 mg once daily in the morning
214701749|NCT04224428|DRUG|Placebo oral tablet|lactose oral tablet
214701750|NCT02880397|DRUG|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
214701751|NCT02880397|DRUG|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
215161765|NCT06049797|DRUG|Venlafaxine|Oral
215161766|NCT06049797|DRUG|Gabapentin|Oral
215161767|NCT06049797|DRUG|Clonidine|Oral
215161768|NCT06049797|DRUG|Pregabalin|Oral
215161769|NCT06049797|DRUG|Oxybutynin|Oral
215161770|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
215161771|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
215161772|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
215161773|NCT04300335|OTHER|Individual Exercise|Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
215161774|NCT04300335|OTHER|Group Exercise|Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
214551681|NCT00078377|DRUG|Armodafinil|Armodafinil 150 mg once daily in the morning
214551682|NCT00078377|DRUG|Placebo|Matching placebo tablets once daily
214551683|NCT01757951|PROCEDURE|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
214701752|NCT01884857|DRUG|Metoprolol Succinate ER Tablets 50 mg|1\* 50 mg tablet once a day
214701753|NCT01884857|DRUG|'TOPROL-XL®' ER Tablets 50 mg|1 \* 50 mg tablet per day
214701754|NCT05405036|OTHER|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
214701755|NCT02547116|DRUG|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
215161775|NCT04665843|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
215161776|NCT04665843|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
215161777|NCT04665843|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214551684|NCT01757951|PROCEDURE|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
214551685|NCT04601324|DRUG|Fluticasone Propionate|Participants will be required to use fluticasone propionate nasal spray twice daily.
214551686|NCT04601324|DRUG|Azelastine hydrochloride and fluticasone propionate|Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
214551687|NCT04601324|DRUG|Rupatadine|Rupatadine once daily for a total of 2 weeks.
214551688|NCT03554408|DRUG|10-1074-LS|Subcutaneous injection of 10-1074-LS
214551689|NCT03554408|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS
214551690|NCT03554408|DRUG|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
214701756|NCT00379262|DRUG|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
214701757|NCT00379262|DRUG|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
214701758|NCT00379262|DRUG|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
214701759|NCT00972127|DRUG|Neramexane|25 mg or 2x25mg tablets
214701760|NCT02001675|DEVICE|magnetic resonance imaging (MRI)|
214701761|NCT02001675|DEVICE|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
214701762|NCT05651893|BEHAVIORAL|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
214701763|NCT05651893|BEHAVIORAL|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
215161778|NCT02508012|OTHER|Immuno monitoring|treatment optimization
215161779|NCT03294863|DEVICE|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
214551691|NCT03554408|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
214551692|NCT03231124|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
214551693|NCT03231124|DRUG|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
214551694|NCT00233480|DRUG|atorvastatin|atorvastatin 10mg PO QD
214551695|NCT00233480|DRUG|placebo|matched placebo Qd x 3 months
214701764|NCT01965236|DIETARY_SUPPLEMENT|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
214551696|NCT00581893|DRUG|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
214551697|NCT00581893|DRUG|Placebo oral capsule|Placebo
214551698|NCT04697134|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
214551699|NCT00863759|PROCEDURE|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
214701765|NCT01965236|DIETARY_SUPPLEMENT|Placebo|
214551700|NCT03437889|OTHER|Cold Stimulus (Ice)|The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
214701766|NCT00675103|DRUG|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
214701767|NCT03600714|DRUG|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
214701768|NCT03600714|DRUG|Lonafarnib|Oral prenylation inhibitor
215161780|NCT03294863|OTHER|Standard of Care|Without the embrace Scar Therapy Device
214551701|NCT00278447|BEHAVIORAL|Chronic Disease Management for substance abuse|Referral to primary medical care \& longitudinal, multidisciplinary care for persons with substance dependence.
214551702|NCT00278447|BEHAVIORAL|Standard care|Referral to primary medical care for persons with substance dependence.
214701769|NCT03600714|DRUG|Ritonavir|Booster of lonafarnib action
214701770|NCT03894774|BEHAVIORAL|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
214701771|NCT03894774|OTHER|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
214701772|NCT06170801|BEHAVIORAL|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
215161781|NCT06799000|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
215161782|NCT06799000|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
215161783|NCT06799000|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
214551703|NCT02774811|DRUG|Prostaglandin analogue|Topical therapy
214551704|NCT02774811|PROCEDURE|Selective laser trabeculoplasy|Laser therapy into drainage angle
214551705|NCT02774811|DEVICE|laser|
215161784|NCT06799000|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
215161785|NCT06838000|BIOLOGICAL|PCV21|Investigational pneumococcal conjugate vaccine
215161786|NCT06838000|BIOLOGICAL|20vPCV|20-valent pneumococcal conjugate vaccine
215161787|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
215161788|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
214551706|NCT05071638|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks who suffer BPD and also stored cord blood are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg).
214551707|NCT02120001|DEVICE|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
214551708|NCT02039076|DRUG|avatrombopag|
215161789|NCT06307652|DRUG|balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
215161790|NCT06307652|DRUG|balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
214551709|NCT00174837|DRUG|Tirapazamine|in combination with cisplatin and concomitant radiation
214551710|NCT00174837|DRUG|Cisplatin|with concomitant radiation
214551711|NCT06216652|OTHER|downhill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
214551712|NCT06216652|OTHER|uphill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
214551713|NCT06216652|OTHER|walking with no incline|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
214701773|NCT06170801|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
214701774|NCT03431701|OTHER|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
214701775|NCT03431701|OTHER|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
215161791|NCT06307652|DRUG|dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
214701776|NCT03431701|OTHER|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
214701777|NCT03449316|BEHAVIORAL|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
215161792|NCT06449924|DEVICE|Endotracheal tube|Endotracheal Tube Inserted to the Level of the Hypopharynx
215161793|NCT06637631|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
215161794|NCT06637631|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
215161795|NCT02879604|OTHER|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
215161796|NCT02879604|OTHER|Usual|Usual care
215161797|NCT05312879|DRUG|VX-147|Tablets for oral administration.
214551714|NCT01913145|DEVICE|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
214551715|NCT05407831|GENETIC|Genetic|Calculate MODY probability
214701778|NCT02006264|DRUG|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
214701779|NCT02006264|DRUG|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
214701780|NCT05846295|OTHER|ESTIMATE|An online educational module consisting of a video tutorial and feedback during a questionnaire
215161798|NCT05312879|DRUG|Placebo|Tablets for oral administration.
215161799|NCT05256901|DRUG|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or more.
215161800|NCT05256901|DRUG|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
215161801|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
215161802|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
215161803|NCT02908425|OTHER|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
215161804|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastroenterologic tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
215161805|NCT06461897|DRUG|Upadacitinib|Oral Tablet or Oral Solution
215161806|NCT06461897|DRUG|Dupilumab|Subcutaneous Injection
214551716|NCT05407831|BEHAVIORAL|Social habits|Alcohol vs Smoking vs Drug use
214551717|NCT05407831|OTHER|Perinatal stress|Survey
214551718|NCT00498472|PROCEDURE|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is \>3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
214551719|NCT03981848|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
214551720|NCT04958577|DEVICE|Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)|This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
214551721|NCT04465266|DRUG|Tolperisone|tablets
214701781|NCT02164513|DRUG|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
214701782|NCT02164513|DRUG|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
214701783|NCT02164513|DRUG|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
214701784|NCT06150690|OTHER|No intervention|The participants did not receive any study-specific intervention
214701785|NCT06270693|PROCEDURE|Endodontic treatment|Root canal treatment
214701786|NCT03984331|DEVICE|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
214701787|NCT03984331|DEVICE|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
214701788|NCT00945074|OTHER|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
215161807|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
214701789|NCT00945074|OTHER|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
214701790|NCT00945074|OTHER|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
214701791|NCT00006248|DRUG|cisplatin|
214701792|NCT00006248|DRUG|fluorouracil|
214701793|NCT00006248|DRUG|paclitaxel|
214701794|NCT04786041|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
214701795|NCT01185145|RADIATION|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
214701796|NCT01185145|RADIATION|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
215161808|NCT00642980|DRUG|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
214551722|NCT04912830|PROCEDURE|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
214551723|NCT00004139|DRUG|docetaxel|
214551724|NCT00004139|DRUG|gemcitabine hydrochloride|
214551725|NCT00004139|DRUG|irinotecan hydrochloride|
214701797|NCT03503149|OTHER|no intervention|observational study
214551726|NCT02387151|DRUG|mesenchymal stromal cells|2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
214701798|NCT06467604|BEHAVIORAL|Surveys|Participants will be provided electronic surveys at 3 timepoints throughout study.
214701799|NCT06467604|OTHER|Indirect Calorimetry|Participants will receive indirect calorimetry at 3 time points throughout the study.
214701800|NCT06467604|OTHER|Body composition|Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.
214701801|NCT06467604|OTHER|Anthropometrics|Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.
214701802|NCT05841602|OTHER|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
214701803|NCT01510808|PROCEDURE|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
214701804|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT - Active comparator|Consumation of 200 mL of tea infusion (VitalPLANT) in the morning 30 min before breakfast for one week
214701805|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT + Helichrysum Italicum - Experimental product|Consumation of 200 mL of tea infusion VitalPLANT + Helichrysum Italicum in the morning 30 min before breakfast for one week
214701806|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
215161809|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
215161810|NCT00781612|DRUG|Docetaxel|Docetaxel will be administered as per local prescribing information.
215161811|NCT00781612|DRUG|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
215161812|NCT00781612|DRUG|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
214551727|NCT00790400|DRUG|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
214551728|NCT00790400|DRUG|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
214551729|NCT00641680|DRUG|Budesonide|
214551730|NCT00641680|DRUG|Fluticasone propionate|
214551731|NCT00641680|DRUG|Placebo|
214551732|NCT03745677|BEHAVIORAL|Advanced and Integrated MicroSystems (AIMS) interventions|Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
214551733|NCT02436291|DEVICE|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
214551734|NCT04315753|OTHER|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
214551735|NCT00317018|BEHAVIORAL|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
214551736|NCT00725335|PROCEDURE|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
214551737|NCT00725335|PROCEDURE|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
214551738|NCT03513926|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
214551739|NCT03592043|DEVICE|MitraClip|Transcatheter Mitral Valve Repair with MitraClip
214551740|NCT05305170|DIAGNOSTIC_TEST|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
214551741|NCT00230750|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
214701807|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
215161813|NCT00781612|DRUG|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
214551742|NCT00230750|DRUG|Placebo|Saline placebo.
215161814|NCT00781612|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
214551743|NCT02679326|DEVICE|Therapeutic ultrasound|
214551744|NCT00949377|DRUG|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
215161815|NCT00781612|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
215161816|NCT06188741|DRUG|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
214551745|NCT00949377|DRUG|Placebo|Normal saline
214551746|NCT00295815|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
214551747|NCT00295815|DRUG|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
214551748|NCT02784457|DRUG|Cetrorelix|
214551749|NCT01784120|DRUG|Doxorubicin/Genexol-PM|
214551750|NCT04415320|DRUG|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
214551751|NCT03355339|DEVICE|Binasal occlusion|Binasal occlusion glasses
214551752|NCT03355339|DEVICE|No binasal occlusion|Non-occluded glasses
214551753|NCT03941600|BEHAVIORAL|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
215161817|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
215161818|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
215161819|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
215161820|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
214701808|NCT01987388|OTHER|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
214701809|NCT01987388|OTHER|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
214551754|NCT03941600|BEHAVIORAL|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
214551755|NCT04489290|DEVICE|D005 Vaginal Mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
214701810|NCT01987388|OTHER|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
214701811|NCT01987388|OTHER|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
214551756|NCT04489290|OTHER|Placebo|Placebo
214701812|NCT03308981|DEVICE|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
214701813|NCT03308981|OTHER|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
214701814|NCT01628250|PROCEDURE|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
214701815|NCT01628250|PROCEDURE|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
215161821|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
215161822|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
215161823|NCT06012240|DRUG|Upadacitinib|Oral Tablets
214551757|NCT05518474|OTHER|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
214551758|NCT00910897|DRUG|Velcade-Dexamethasone|
214551759|NCT00910897|DRUG|Velcade-Thalidomide-Dexamethasone|
214551760|NCT02356705|DRUG|Midazolam|midazolam 0.2 mg/kg given intranasally
214551761|NCT02356705|DRUG|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
214701816|NCT06824064|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
214701817|NCT06824064|DRUG|Placebo|Placebo to Match RBS2418
214701818|NCT04008407|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
215161824|NCT06012240|DRUG|Placebo|Oral Tablets
215161825|NCT05815342|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
215161826|NCT06798402|DRUG|Ciprofloxacin (BAYO9867)|Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).
214551762|NCT02356705|DRUG|saline placebo|intranasal saline given as placebo
214551763|NCT00005593|DRUG|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
214551764|NCT00005593|DRUG|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
214551765|NCT00005593|DRUG|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
214551766|NCT06146777|DRUG|Pembrolizumab|Intravenous infusion
214551767|NCT06146777|DRUG|Placebo|Intravenous infusion
214551768|NCT01107899|DRUG|clopidogrel|taken orally, day one, single dose
214551769|NCT01107899|DRUG|prasugrel|taken orally, day one, single dose
214551770|NCT03689751|OTHER|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
214551771|NCT03689751|OTHER|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
214551772|NCT00605488|PROCEDURE|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
214551773|NCT04425590|DRUG|DLBS1033|DLBS 1033 490 mg tablet 3 times daily
214551774|NCT04425590|DRUG|Aspirin|Aspirin 100 mg tablet once daily
214551775|NCT04425590|DRUG|Statin|Atorvastatin 20 mg tablet once daily
214551776|NCT04425590|DRUG|Vit B12|Vit B12 100 mg tablet three times daily
214551777|NCT00974259|DEVICE|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (\> 20 mm Hg) or pBrO2 (\< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
214551778|NCT00974259|DEVICE|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
214551779|NCT04893681|OTHER|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
214551780|NCT04893681|OTHER|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
214551781|NCT06024278|BEHAVIORAL|Caregiver educational videos for African American caregivers|The intervention will be culturally tailored education videos for African American caregivers receiving hospice services.
214551782|NCT06024278|BEHAVIORAL|Caregiver educational videos for Puerto Rican caregivers|The intervention will be culturally tailored education videos for Puerto Rican caregivers receiving hospice services.
214551783|NCT00776477|DRUG|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
214551784|NCT00776477|DRUG|aspirin|aspirin 100mg daily
214551785|NCT03177720|DRUG|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
214551786|NCT03177720|DRUG|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
214551787|NCT03112109|OTHER|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
214551788|NCT00561717|DRUG|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
214551789|NCT00561717|DRUG|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
214551790|NCT00561717|DRUG|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
214701819|NCT04008407|PROCEDURE|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
215161827|NCT06798402|DRUG|sodium stibogluconate (Pentostam)|Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
215161828|NCT02770092|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
215161829|NCT05353439|PROCEDURE|Biopsy Procedure|Undergo biopsy
214551791|NCT00561717|DRUG|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
214551792|NCT02957955|BEHAVIORAL|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
214551793|NCT00283283|BIOLOGICAL|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
214551794|NCT00867100|DRUG|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
214551795|NCT00867100|DRUG|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
214551796|NCT00867100|DRUG|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
214551797|NCT00867100|DRUG|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
214551798|NCT04556812|PROCEDURE|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
214551799|NCT04556812|PROCEDURE|soft-tissue surgery|traditional soft-tissue surgery
214551800|NCT02765789|DEVICE|Immunoadsorption (Immunosorba)|Immunoadsorption as an alternative to plasma exchange
214551801|NCT01810939|DRUG|Patiromer|
214551802|NCT01810939|DRUG|Placebo|
214701820|NCT06897631|DEVICE|Robot-Assisted Tai Chi Training|This intervention involves robot-assisted Tai Chi training for upper limb rehabilitation, delivered in a seated position to ensure participant safety and comfort. Each 60-minute session consists of a 5-minute warm-up/preparation phase, followed by three 15-minute segmented functional training phases incorporating Tai Chi-inspired movements to target upper limb coordination, range of motion, and strength recovery, interspersed with two 5-minute rest intervals. The protocol is administered 5 times per week over 4 weeks, with robotic assistance tailored to guide functional upper limb trajectories while minimizing compensatory movements.
214701821|NCT06897631|BEHAVIORAL|Conventional rehabilitation training|This intervention follows evidence-based clinical guidelines for post-stroke upper limb rehabilitation, focusing on therapist-guided task-oriented training that integrates activities of daily living (ADL) such as table wiping and clothes hanging. Sessions emphasize progressive functional integration, with exercises adjusted weekly based on patient performance. Training is delivered in 60-minute sessions (1 session/day), 5 days per week over 4 weeks, under direct therapist supervision to ensure proper movement patterns and safety.
214701822|NCT06898489|COMBINATION_PRODUCT|Yu-Tone Music Intervention|SLE patients undergo a structured Yu-tone music listening program (30 minutes daily, 5 days per week, with each cycle lasting 8 weeks, for a total of 3 cycles
214701823|NCT06898489|DRUG|Conventional pharmacotherapy|Standard SLE medications (e.g., hydroxychloroquine, glucocorticoids).
214701824|NCT01019772|BIOLOGICAL|LBVH0101 (Hib vaccine)|
215161830|NCT05353439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214551803|NCT02963090|DRUG|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
214701825|NCT01019772|BIOLOGICAL|Hiberix™ Vaccine|
214551804|NCT02963090|DRUG|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
214551805|NCT05065606|DIAGNOSTIC_TEST|Dual-energy computed tomography|Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively
214701826|NCT01570933|DEVICE|NivNava|Non-invasive Nava ventilation mode on nasal cannula
214701827|NCT01570933|DEVICE|Cpap|nasal Cpap on nasal cannula
214551806|NCT02944929|OTHER|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
214551807|NCT02484586|DEVICE|Etafilcon A|Prototype lens material
214551808|NCT02484586|DEVICE|Etafilcon A|Control lens for presbyope group
214551809|NCT02484586|DEVICE|Nelfilcon A|Control lens for presbyope group
214551810|NCT02484586|DEVICE|Nesofilcon A|Control lens for presbyope group
214551811|NCT02484586|DEVICE|Nelfilcon A|Control lens for non-presbyope group
214551812|NCT02484586|DEVICE|Etafilcon A|Control lens for non-presbyope group
214551813|NCT02484586|DEVICE|Somofilcon A|Control lens for presbyope group
214551814|NCT02484586|DEVICE|58% Poly-HEMA|Control lens for presbyope group
214551815|NCT02484586|DEVICE|Omafilcon A|Control lens for non-presbyope group
215161831|NCT05353439|PROCEDURE|Computed Tomography|Undergo CT scan
215161832|NCT05353439|BIOLOGICAL|Pembrolizumab|Given IV
215161833|NCT05353439|DRUG|Tazemetostat Hydrobromide|Given PO
215161834|NCT05353439|DRUG|Topotecan Hydrochloride|Given IV
214551816|NCT01375673|OTHER|Exercise|Walking Strength Training Bicycling
214551817|NCT03953131|PROCEDURE|Computed Tomography|Undergo PET/CT
214551818|NCT03953131|RADIATION|Gallium Ga 68-DOTATATE|Given IV
214551819|NCT03953131|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214551820|NCT06417034|DEVICE|Game Software|The software is interfaced with a modified version of Frets on Fire (FOF)-an open source computer game similar to Guitar Hero.
214551821|NCT01863147|DRUG|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
214551822|NCT00374751|DRUG|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
214708961|NCT02086721|DRUG|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
214551823|NCT00513162|DRUG|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
214551824|NCT00513162|DRUG|Etoposide|25 - 50 mg/m\^2 By Mouth Daily
214551825|NCT03059277|DRUG|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
214551826|NCT02700542|OTHER|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
214551827|NCT06198270|OTHER|Closed Kinetic Chain Exercise|Closed chain exercise plan of 5 exercises, 10reps x 3sets of each, 3 days in a week for 4-weeks, all values measured before and after 4-weeks.
214551828|NCT06198270|OTHER|Neuromuscular Training with K Tape|Neuromuscular training plan of 5 exercises, 10reps x 3sets of each, 3 days in a week, for 4-weeks, all values measured before and after 4-weeks. Just After the session k-tape applied.
214551829|NCT04770727|BEHAVIORAL|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
214551830|NCT03995927|OTHER|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
214551831|NCT03995927|OTHER|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
214551832|NCT01660386|DRUG|Sitagliptin|100mg po once
214551833|NCT01660386|DRUG|Saxagliptin|5mg po once
214551834|NCT01660386|DRUG|Glimepiride|2mg po once
214551835|NCT01660386|DRUG|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
214551836|NCT04340661|DIETARY_SUPPLEMENT|BIOintestil|Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)
214551837|NCT04340661|DIETARY_SUPPLEMENT|PLACEBO|Cornstarch
214551838|NCT03843853|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
214551839|NCT03843853|DRUG|S-1|S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14
214551840|NCT03843853|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg d1
214551841|NCT05127759|DRUG|HLX208|HLX208 450mg bid po
214551842|NCT00008476|DRUG|Capsaicin|
214551843|NCT06273449|DEVICE|Group 3 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing
214551844|NCT06273449|DEVICE|Group 2 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
214551845|NCT00137410|DRUG|Celebrex|
214551846|NCT06485583|OTHER|Constraint-induced movement therapy|is a rehabilitation technique used to improve motor function in people who have had a stroke or other neurological conditions. CIMT restricts the use of the unaffected limb, typically with a mitt or sling, to encourage the use of the affected limb.
214551847|NCT06485583|OTHER|Neurodevelopmental Treatment|Therapy, is a rehabilitation approach used to address movement and motor control deficits in people with neurological illnesses such as stroke, cerebral palsy, or traumatic brain injury.
214551848|NCT02036437|DRUG|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
214551849|NCT02036437|DRUG|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
214551850|NCT05678283|DRUG|[14C]CC-90010|Specified dose on specified days
214708962|NCT02306239|DRUG|Terlipressin|
214551851|NCT05678283|DRUG|CC-90010|Specified dose on specified days
214551852|NCT05044923|DEVICE|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
214551853|NCT02349152|DRUG|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
214551854|NCT02349152|DRUG|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
214551855|NCT04873427|GENETIC|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
214551856|NCT06074705|DRUG|DS-1471a|Intravenous administration on Day 1 of each 28-day cycle
214551857|NCT02054676|RADIATION|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~* Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~* Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
214701828|NCT06332027|DIAGNOSTIC_TEST|Hystro-Salpingo-Foam-Sonography (HYFOSY)|antibiotic prophylaxis oral azithromycin 500 mg per day 3 days the patient lie in dorsal lithotomy cervix visualized by Cusco speculum, cleaned with betadine 7% 6-Fr pediatric Foley's balloon catheter will be introduced into the cervical canal inflated with 2 ml of saline to prevent backflow of contrast through the cervix TV-US probe will be introduced,The foam will be created by mixing 3-4ml of 2% rialocaine gel (lidocaine hydrochloride 2%, Riadh Pharma,Saudi Arabia) with 16-17 ml of saline shaking the mixture between two syringes until a whitish suspension 20ml of lidocaine foam infused into uterine cavity observing the flow in each fallopian tube using greyscale and power Doppler (PD) 2D ultrasound Foam flow over the whole length of the tube fimbrial outflow, or peritoneal spillage of contrast provided evidence of tubal patency Patients observed for15-30 min for any complication or increase in pain Comparison between results and that of laparoscopy in operative list
214701829|NCT01031485|DIETARY_SUPPLEMENT|Milk peptides and plant sterols|
214701830|NCT01031485|OTHER|Placebo|
214701831|NCT03036111|DRUG|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
214701832|NCT03036111|PROCEDURE|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
214701833|NCT05496218|DIAGNOSTIC_TEST|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
214701834|NCT03807076|OTHER|GIP-A|GIP-A
214701835|NCT03807076|OTHER|Placebo|Placebo
214701836|NCT01005056|DRUG|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
214701837|NCT01481909|DRUG|Rupatadin|20 mg, 28 days over 60 days
214701838|NCT00003595|BIOLOGICAL|filgrastim|
214701839|NCT00003595|BIOLOGICAL|rituximab|
214701840|NCT00003595|DRUG|CHOP regimen|
214701841|NCT00003595|DRUG|cyclophosphamide|
214701842|NCT00003595|DRUG|doxorubicin hydrochloride|
214701843|NCT00003595|DRUG|prednisone|
214701844|NCT00003595|DRUG|vincristine sulfate|
214701845|NCT05128526|BEHAVIORAL|exercise|Short foot exercises without respiratory exercises
214701846|NCT05128526|BEHAVIORAL|respiratory|Short foot exercises with respiratory exercises
214701847|NCT05578768|OTHER|No intervention|Patients will receive standard of care.
214701848|NCT00067821|DRUG|2-Flourodeoxyglucose|
214701849|NCT00582699|BEHAVIORAL|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
214701850|NCT04575831|BEHAVIORAL|Exercise, Nutrition, and Palliative Symptom Management|"1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
214701851|NCT02277340|PROCEDURE|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
214701852|NCT00647257|DRUG|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
214701853|NCT00647257|DRUG|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
214701854|NCT02066519|BEHAVIORAL|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
214701855|NCT00425126|DRUG|Epoetin Alfa|
214701856|NCT04560140|BEHAVIORAL|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
214551858|NCT02054676|PROCEDURE|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~* implant drill slippage deeper than planned;~* implant threads coverage;~* etc."
214551859|NCT02054676|DEVICE|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
214551860|NCT02054676|RADIATION|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
214551861|NCT02054676|DRUG|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
214701857|NCT04589962|OTHER|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
214701858|NCT02560493|BEHAVIORAL|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
214701859|NCT03073213|DRUG|Ixekizumab|Administered as subcutaneous (SC) injection
214701860|NCT00961662|DRUG|D-Tagatose|powder to be dissolved in water prior to dosage.
214701861|NCT02670460|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
214701862|NCT01560897|DRUG|Oral C13|Ingestion of C13 and follow up of the ureogenesis
214701863|NCT05539105|PROCEDURE|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
214701864|NCT05539105|PROCEDURE|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
214701865|NCT05539105|PROCEDURE|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
214701866|NCT02517593|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
214701867|NCT04290481|OTHER|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
214701868|NCT05204511|OTHER|endurance training|endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 30-60 minutes per session
214701869|NCT05204511|OTHER|concurrent training|combination of endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 20-40 minutes per session and resistance training of moderate intensity performing 2-3 sets of leg press, leg curls, chest press and seated horizontal rows
214701870|NCT05271110|PROCEDURE|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
214701871|NCT00280150|BIOLOGICAL|bevacizumab|Given IV
214701872|NCT00280150|DRUG|carboplatin|Given IV
214701873|NCT00280150|DRUG|erlotinib hydrochloride|Given orally
214701874|NCT00280150|DRUG|paclitaxel|Given IV
214701875|NCT00280150|RADIATION|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
214701876|NCT05020093|PROCEDURE|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
214701877|NCT05020093|PROCEDURE|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
214701878|NCT02732340|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
214701879|NCT02829866|DEVICE|AMIStem-H|
214701880|NCT03303040|OTHER|Electrical stimulation of hemidiaphragm|Electrical impulses
214701881|NCT03379506|DRUG|EBR/GZR FDC Tablet|Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
214551862|NCT02054676|PROCEDURE|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
214701882|NCT03379506|DRUG|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
214701883|NCT03379506|DRUG|Grazoprevir Oral Granules|Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
214701884|NCT03379506|DRUG|Elbasvir Oral Granules|Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
214701885|NCT00020566|BIOLOGICAL|dactinomycin|Given IV
214701886|NCT00020566|DRUG|busulfan|Given orally and IV
214701887|NCT00020566|DRUG|doxorubicin hydrochloride|Given IV
214701888|NCT00020566|DRUG|etoposide|Given IV
214701889|NCT00020566|DRUG|ifosfamide|Given IV
214701890|NCT00020566|DRUG|melphalan|Given orally and IV
214701891|NCT00020566|DRUG|vincristine sulfate|Given IV
214701892|NCT00020566|PROCEDURE|autologous hematopoietic stem cell transplantation|Given IV
214701893|NCT00020566|PROCEDURE|conventional surgery|Given to patients deemed to require it
214701894|NCT00020566|RADIATION|radiation therapy|Given to patients deemed to require it
214701895|NCT00565656|DRUG|BEVACIZUMAB|Administration of Bevacizumab
214551863|NCT02605746|DRUG|ceritinib 750mg|
214551864|NCT05932147|OTHER|Pilates exercise|"1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise."
214551865|NCT05932147|OTHER|Manual lymphatic massage|"procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes."
214701896|NCT03006471|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
214701897|NCT03006471|DRUG|Placebo - Cap|one per day before breakfast during 12 weeks.
214701898|NCT00556192|DRUG|rituximab|"1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
214701899|NCT02534194|OTHER|Image acquisition|Images of baby's face (including ear) and feet
214701900|NCT02480894|DRUG|BMS-663068|BMS-663068
214701901|NCT02480894|DRUG|Maraviroc|Maraviroc
214701902|NCT03309592|DRUG|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
214701903|NCT03309592|DRUG|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
214701904|NCT00866268|DEVICE|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
214701905|NCT00866268|DEVICE|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
214701906|NCT04375241|OTHER|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
214701907|NCT03699449|DRUG|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
214701908|NCT03699449|DRUG|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
214701909|NCT03699449|DRUG|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
214708963|NCT02306239|DRUG|Norepinephrine|
214708964|NCT06076200|DRUG|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
214708965|NCT01504971|OTHER|symptom questionaire|GerdQ questionaire
214708966|NCT01504971|PROCEDURE|pH monitoring|24-hour pH monitoring
214708967|NCT01504971|PROCEDURE|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
214708968|NCT01504971|DRUG|rabeprazole|10mg, bid, p.o.
214551866|NCT06009042|DRUG|IVIG 20g/d|The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
214551867|NCT06009042|DRUG|IVIG 10g/d|The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
214551868|NCT03804216|OTHER|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
214551869|NCT06155097|DRUG|transversus thoracis muscle plane block (TTP)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.
214551870|NCT06155097|DRUG|parasternal intercostal nerve block (PSI block)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
214551871|NCT03670251|PROCEDURE|Blood sampling|Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
214551872|NCT03272503|DRUG|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
214551873|NCT03272503|DRUG|Placebo Oral Tablet|Identical matching placebo lactose tablets
214551874|NCT00979953|DRUG|ADL5859|
214551875|NCT00979953|DRUG|ADL5747|
214551876|NCT00979953|DRUG|Oxycodone CR|
214551877|NCT00979953|DRUG|Placebo|
214551878|NCT01634269|DEVICE|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
214551879|NCT05625932|DRUG|Tinzaparin|Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.
214551880|NCT01173978|BEHAVIORAL|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
214551881|NCT01173978|OTHER|No intervention|
214551882|NCT02847442|DRUG|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
214551883|NCT02847442|DRUG|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
214551884|NCT06359496|OTHER|No intervention factor|No intervention factor
214551885|NCT00865852|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
214551886|NCT00865852|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
214551887|NCT02987647|OTHER|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
214551888|NCT02987647|OTHER|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
214551889|NCT02987647|OTHER|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
214551890|NCT02987647|OTHER|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
214551891|NCT03038204|PROCEDURE|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
214551892|NCT04510298|DRUG|SP-624|Oral Capsule
214551893|NCT04510298|DRUG|Placebo|Oral Capsule
214551894|NCT00824330|BEHAVIORAL|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
214551895|NCT00577135|DRUG|Furosemide-Q12 hour bolus|Q12 hours bolus
214551896|NCT00577135|DRUG|Furosemide-Continuous Infusion|Continuous infusion
214551897|NCT00577135|DRUG|Furosemide-Low Intensification|1x oral dose
214551898|NCT00577135|DRUG|Furosemide-High Intensification|2.5x oral dose
214551899|NCT03904940|DEVICE|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
214551900|NCT03904940|DEVICE|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
214551901|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
215161835|NCT05779605|DEVICE|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
215161836|NCT05779605|DEVICE|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
215161837|NCT06513351|BEHAVIORAL|Novel PPH Risk Prediction Model - Comparator Arm B|Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
215161838|NCT03811015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161839|NCT03811015|DRUG|Cisplatin|Given IV
215161840|NCT03811015|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215161841|NCT03811015|PROCEDURE|Echocardiography Test|Undergo ECHO
215161842|NCT03811015|OTHER|Fludeoxyglucose F-18|Receive FDG
215161843|NCT03811015|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215161844|NCT03811015|BIOLOGICAL|Nivolumab|Given IV
214551902|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
214551903|NCT05410093|DRUG|Resveratrol|Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
214551904|NCT05410093|DRUG|Vitamin E|Take vitamin E at a dose of 100 mg per day for three months
214551905|NCT06463236|OTHER|Guiding treatment|Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
214551906|NCT06463236|OTHER|empirical therapy|Experiential treatment by grassroots doctors
214551907|NCT02909465|DRUG|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
214551908|NCT02909465|DRUG|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
214551909|NCT02909465|DRUG|placebo|distilled water
214551910|NCT02909465|DRUG|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
214551911|NCT02238249|DRUG|Alesion®|Dry Syrup
214551912|NCT04250779|DEVICE|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
214551913|NCT04250779|BEHAVIORAL|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
214551914|NCT00046306|DRUG|Antioxidants|
214551915|NCT06470477|DRUG|Guideline-based treatment|Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
214551916|NCT04118413|OTHER|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
214551917|NCT03321110|OTHER|Placebo|Placebo (dextrin)
214551918|NCT03321110|DIETARY_SUPPLEMENT|Coenzyme Q10|150 mg or 300 mg
214551919|NCT02497846|DEVICE|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
214551920|NCT05580835|DIAGNOSTIC_TEST|PET MRI with PSMA|A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
214701910|NCT03699449|DRUG|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
214701911|NCT03699449|DRUG|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
214701912|NCT03699449|DRUG|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
214551921|NCT01621243|DRUG|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
214551922|NCT01621243|DRUG|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
214551923|NCT01621243|DRUG|placebo|Placebo will be dosed daily
214551924|NCT01621243|DRUG|Necuparanib|Necuparanib will be dosed daily
214701913|NCT02586077|DRUG|Exparel|
214701914|NCT03117530|DRUG|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
214701915|NCT03852914|DEVICE|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
214701916|NCT04417114|DRUG|Rosuvastatin|Statin
214701917|NCT00606814|DRUG|IPI-504, docetaxel|"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
214701918|NCT04248400|OTHER|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
214701919|NCT04248400|OTHER|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
214701920|NCT04342520|OTHER|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
214701921|NCT06027073|BIOLOGICAL|omalizumab|adding omalizumab to anti asthmatic therapy
214701922|NCT03450525|OTHER|No intervention|No intervention
214701923|NCT06197048|BEHAVIORAL|Nutritional counseling|"The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments.~The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases."
214701924|NCT02581865|DRUG|NBI-98854|
215161845|NCT03811015|OTHER|Patient Observation|Undergo observation
214701925|NCT02581865|DRUG|Placebo|
214701926|NCT01376726|BIOLOGICAL|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
215029655|NCT02671292|OTHER|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
215161846|NCT03811015|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214551925|NCT04392492|DEVICE|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
215161847|NCT02674347|DRUG|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
215161848|NCT02674347|DRUG|Placebo|IV matching the Investigational drug
214551926|NCT05847049|OTHER|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
214551927|NCT01607879|DRUG|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
214551928|NCT01607879|OTHER|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
215161849|NCT04960072|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214701927|NCT01376726|BIOLOGICAL|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
215161850|NCT04280497|DRUG|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
214551929|NCT02607787|BEHAVIORAL|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
214551930|NCT02607787|OTHER|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
214551931|NCT04089397|DEVICE|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
214551932|NCT05689892|OTHER|Decision Coach Sessions|"Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors."
214551933|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
214551934|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
214551935|NCT03728751|PROCEDURE|Dry needling|Paravertebral dry needling C7-T4. Total of 8 needles.
214551936|NCT00915824|OTHER|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
214551937|NCT02579590|DRUG|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
214551938|NCT02579590|DRUG|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
214551939|NCT02579590|DRUG|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
214701928|NCT01993615|PROCEDURE|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
215029656|NCT05994300|RADIATION|Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy|"Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2"
215029657|NCT02262663|DRUG|Vilaprisan (BAY1002670)|
215161851|NCT03015896|OTHER|Laboratory Biomarker Analysis|Correlative studies
215161852|NCT03015896|DRUG|Lenalidomide|Given PO
214551940|NCT04627610|OTHER|Rectal prolapse, rectocele and elytrocele|Recurrence of dyschesia on rectal prolapse, rectocele and elytrocele
214551941|NCT01546246|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
214551942|NCT05492305|DRUG|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
214551943|NCT03516305|DRUG|Staccato Alprazolam 1 mg|alprazolam I mg administered via the Staccato hand-held inhaler device system.
214551944|NCT05260879|BEHAVIORAL|Diabetes prevention program|Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
214551945|NCT05230953|BIOLOGICAL|mRNA1273 vaccine|fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM
214551946|NCT01891019|DRUG|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
215029658|NCT04148209|DRUG|PF-07081532|Participants will receive single ascending doses PF-07081532
215029659|NCT04148209|DRUG|Placebo|Participants will receive placebo
214551947|NCT03498703|DRUG|Azathioprine Pill|Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
215029660|NCT01344655|DRUG|Atimos®|Formoterol 12 μg pMDI
215029661|NCT01344655|DRUG|Serevent™|Salmeterol 25 µg pMDI
215161853|NCT03015896|BIOLOGICAL|Nivolumab|Given IV
214551948|NCT03498703|DRUG|Placebo Oral Tablet|Placebo tablets
214551949|NCT02406248|DRUG|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
214551950|NCT03444402|DRUG|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
214551951|NCT03444402|DRUG|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
214551952|NCT03444402|DRUG|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
214551953|NCT04699942|DEVICE|Conventional (low flow) oxygen delivery via nasal cannula|Conventional (low flow) oxygen delivery via nasal cannula or face mask for 20 minutes
214551954|NCT04699942|DEVICE|Revoxa Oxygen Rebrearther|Oxygen delivery via Revoxa Oxygen Rebreather device for 20 minutes
214551955|NCT01351168|DRUG|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
214551956|NCT01351168|DRUG|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
214551957|NCT01351168|DRUG|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
214551958|NCT01351168|DRUG|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
214551959|NCT02614612|DRUG|Itacitinib (200 mg)|
214551960|NCT02614612|DRUG|Itacitinib (300 mg)|
214551961|NCT02614612|DRUG|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
214551962|NCT04223544|DIAGNOSTIC_TEST|Influenza POC and laboratory testing|Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
214551963|NCT00590655|BEHAVIORAL|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
214551964|NCT00590655|BEHAVIORAL|weight loss programme|
214701929|NCT01993615|PROCEDURE|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
214701930|NCT03483766|DEVICE|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
214701931|NCT03224585|DRUG|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
214701932|NCT03224585|DRUG|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
214551965|NCT02194504|OTHER|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
214551966|NCT02194504|OTHER|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
214551967|NCT00569114|DRUG|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
214551968|NCT02917772|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
214551969|NCT03102866|OTHER|Best Practice|Receive usual care
214551970|NCT03102866|BEHAVIORAL|Exercise Intervention|Undergo aerobic and strength training exercise
214701933|NCT00254735|DRUG|quetiapine fumarate|
214701934|NCT00254735|DRUG|SSRI/Clomipramine|
214701935|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
214701936|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
215029662|NCT01344655|DRUG|Placebo|placebo
214551971|NCT03102866|OTHER|Quality-of-Life Assessment|Ancillary studies
214701937|NCT01175213|BIOLOGICAL|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
214701938|NCT00813618|DRUG|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
214701939|NCT00813618|DRUG|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
214701940|NCT00813618|DRUG|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
214701941|NCT02897869|DRUG|POL7080|7 doses of POL7080 alone over 2.5 days
214701942|NCT02897869|DRUG|Amikacin|3 doses of Amikacin alone over 2.5 days
214701943|NCT02897869|DRUG|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
214701944|NCT03036423|BEHAVIORAL|Online video education|
214701945|NCT03036423|BEHAVIORAL|Computerized mental exercises|
214551972|NCT03102866|OTHER|Questionnaire Administration|Ancillary studies
214551973|NCT02643628|PROCEDURE|Microneedling|
214551974|NCT02643628|DEVICE|Microneedling followed by Bellafill treatment|
214551975|NCT02016209|DRUG|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
214551976|NCT04484584|OTHER|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
214551977|NCT03450499|DRUG|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
214551978|NCT03450499|DRUG|Placebo|the analgesic requirement will be calculated in placebo group.
214551979|NCT01729468|DRUG|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
214551980|NCT01729468|DRUG|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
214551981|NCT05585918|BEHAVIORAL|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
214551982|NCT05585918|BEHAVIORAL|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
214551983|NCT01617122|BIOLOGICAL|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
214551984|NCT00967083|BEHAVIORAL|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
214551985|NCT03338647|DRUG|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
214701946|NCT03235817|OTHER|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
214701947|NCT03235817|DEVICE|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
214701948|NCT03235817|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
214551986|NCT03338647|RADIATION|SBRT|High precision radiation therapy to the liver tumor(s)
214551987|NCT02686099|DEVICE|SternaLock 360|Sternal closure with SternaLock 360
214551988|NCT02686099|DEVICE|Wire Cerclage|Sternal closure with standard wire cerclage
214551989|NCT02432833|DRUG|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
214551990|NCT02432833|DRUG|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
214551991|NCT02432833|DRUG|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
214551992|NCT03645148|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
214551993|NCT03645148|OTHER|GM-CSF|immune adjuvant
214701949|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
214701950|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
214701951|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
214701952|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
214701953|NCT00388258|DRUG|Alvimopan|
214701954|NCT01921634|OTHER|Modified Pathologic Analysis|
214701955|NCT01965418|DRUG|Fufang Biejia Ruangan Tablet|
214701956|NCT01965418|DRUG|Placebo|
214701957|NCT01245764|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
214701958|NCT01245764|BIOLOGICAL|Placebo|
214701959|NCT05388019|OTHER|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
214701960|NCT05388019|BEHAVIORAL|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
214701961|NCT00003476|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
214551994|NCT00003626|DRUG|dolastatin 10|
214551995|NCT03509246|DRUG|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
214701962|NCT04973891|DRUG|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
214701963|NCT04973891|DRUG|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
214701964|NCT04493957|BEHAVIORAL|ACCOMPAGNE Education Program|"The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop"
214551996|NCT05196282|OTHER|Smoking cessation|Patients are forced to stop smoking
214701965|NCT04493957|BEHAVIORAL|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
214551997|NCT06383650|DRUG|Acetylsalicylic Acid|Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
214551998|NCT02712749|DEVICE|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
214551999|NCT02712749|DEVICE|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
214552000|NCT01139853|DEVICE|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
214552001|NCT03119545|BEHAVIORAL|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
214552002|NCT03438682|DEVICE|Essure|Essure hysteroscopic sterilization
214552003|NCT03438682|PROCEDURE|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
214552004|NCT03438682|DEVICE|Intrauterine Device (IUD)|Intrauterine Device (IUD)
214552005|NCT00706654|DRUG|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
214701966|NCT02500368|DEVICE|silicone hydrogel lens (test)|contact lens
214701967|NCT02500368|DEVICE|enfilcon A lens (control)|contact lens
214701968|NCT03674658|DRUG|Propafenone|oral, TID
214701969|NCT02621619|DRUG|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
214701970|NCT02621619|DRUG|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
214701971|NCT04568018|DRUG|Surfactant|Inhalation of surfactant emulsion at 150 mg
214701972|NCT05566288|DRUG|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
214701973|NCT05566288|DRUG|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
214701974|NCT05566288|DRUG|Moxifloxacin|400 mg tablets
214552006|NCT00706654|DRUG|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
214552007|NCT00706654|DRUG|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
214552008|NCT00706654|DRUG|Placebo depot|Placebo depot was supplied in lyophilized vials.
214552009|NCT00706654|DRUG|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
214552010|NCT03034590|OTHER|questionnaire|
215029663|NCT05258292|DEVICE|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
215029664|NCT05258292|DRUG|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
215029665|NCT05258292|OTHER|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
215029666|NCT05258292|OTHER|Ovulation kits|Ovulation testing will be done using ovulation kits
215029667|NCT05258292|DEVICE|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
215029668|NCT05258292|OTHER|Keenoa|Food intake will be assessed using the Keenoa phone application
214701975|NCT03956329|OTHER|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
214552011|NCT00657462|OTHER|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
214552012|NCT00335751|PROCEDURE|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
214552013|NCT02117986|DRUG|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
214552014|NCT06160661|DEVICE|mandibular saggital split osteotomy|orthognathic surgery
214552015|NCT06062524|DEVICE|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
214552016|NCT03400683|DRUG|Misoprostol|200 microgram misoprostol in sublingual every four hours for a maximum of five doses
214552017|NCT03400683|DRUG|Letrozole|15mg( letrozole 2.5mg) on three successive day
214552018|NCT03400683|PROCEDURE|Foley's catheter|transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions
214552019|NCT03937141|DRUG|ADU-S100|intratumoral
214552020|NCT00335101|DRUG|Iodixanol, Ioversol, Iopromide|
214552021|NCT04779437|BEHAVIORAL|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
214552022|NCT04779437|BEHAVIORAL|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
214552023|NCT01035268|PROCEDURE|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
214552024|NCT00002439|DRUG|Alitretinoin|
214552025|NCT04729205|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
214552026|NCT00625300|DEVICE|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
214701976|NCT03956329|OTHER|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
214701977|NCT03663140|DIAGNOSTIC_TEST|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
215029669|NCT05258292|OTHER|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
214701978|NCT05381558|DRUG|Triamcinolone Injection|local injection in sinus tarsi
214701979|NCT00745381|OTHER|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
214701980|NCT05289206|OTHER|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
214701981|NCT02911623|DEVICE|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
214701982|NCT06028425|DRUG|LOXO-783|Administered orally.
214701983|NCT04137419|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic strains
214701984|NCT04137419|OTHER|Placebo|Similar to ProlacSan lozenges in taste in colour
215029670|NCT01969409|DRUG|Rituximab|i.v. rituximab given on two occasions 14 days apart.
215029671|NCT01969409|DRUG|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
214552027|NCT00625300|DEVICE|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
214552028|NCT00594022|DEVICE|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
214552029|NCT00594022|DEVICE|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
214552030|NCT05780086|DRUG|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
214552031|NCT05926869|DRUG|Clindamycin and Dapsone gel for 03 months|Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
214552032|NCT04944498|PROCEDURE|Modified Tarsorrhaphy|A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip
214552033|NCT04944498|PROCEDURE|Gold Weight Implant|Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
214701985|NCT03626740|OTHER|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
214701986|NCT03626740|OTHER|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
214701987|NCT00351169|DRUG|Quetiapine SR|
214701988|NCT00351169|DRUG|Escitalopram|
214701989|NCT03098524|PROCEDURE|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
215029672|NCT01446523|DRUG|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
214701990|NCT03098524|PROCEDURE|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
215029673|NCT01446523|DRUG|Lactulose|Syrup 30 ml BD for 12 weeks
215029674|NCT01840072|OTHER|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
215029675|NCT02946983|OTHER|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
215029676|NCT02946983|OTHER|Control|Intragastric administration of distilled water
214552034|NCT03194997|OTHER|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
214552035|NCT03194997|OTHER|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
214701991|NCT03098524|PROCEDURE|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
215161854|NCT04319276|DRUG|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
215161855|NCT04319276|DRUG|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
215161856|NCT04319276|DRUG|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
214552036|NCT05396508|PROCEDURE|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
214552037|NCT05396508|PROCEDURE|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
214552038|NCT01001390|DEVICE|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
214552039|NCT02626442|OTHER|Exercise|6 month group exercise class
214552040|NCT01246089|DRUG|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
214552041|NCT05284630|OTHER|Exercise follow up with mobile application|Exercises will be followed by mobile application. Electrotherapy will be performed.
214552042|NCT05284630|OTHER|Home-Based Exercise Program followed by paper booklet|Exercise will be followed by paper booklet. Electrotherapy will be performed.
214552043|NCT05284630|PROCEDURE|Electrotherapy|Electrotherapy will be performed.
214552044|NCT06117423|DRUG|Adalimumab-680LT|First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.
214552045|NCT06117423|OTHER|Control|Fluorescence Molecular Imaging was performed to enable the visualisation and detection of fluorescence signals.
214552046|NCT00673907|OTHER|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
214552047|NCT02510833|BEHAVIORAL|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
214552048|NCT02510833|BEHAVIORAL|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
214552049|NCT03690427|OTHER|Traditional hookah smoking|Charcoal-heated hookah smoking
214552050|NCT03690427|OTHER|Electronic hookah vaping|Electronic hookah bowl inhalation
215161857|NCT04319276|DRUG|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
215161858|NCT04319276|DRUG|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
215161859|NCT04319276|DRUG|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
215161860|NCT06229691|BEHAVIORAL|30 minute treadmill walk|"Participants will walk on a treadmill at their preferred speed for 30 minutes. One minute challenge periods will occur at minutes 7, 17, and 27, when the treadmill speed will increase by 50%. This walk will induce a magnitude of muscle fatigue corresponding to an individual participant's fatigability."
214552051|NCT01906697|PROCEDURE|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
214552052|NCT01906697|PROCEDURE|middle turbinate resection|middle turbinate resection
214552053|NCT01906697|PROCEDURE|middle turbinate medialization|middle turbinate medialization
214552054|NCT00831077|DRUG|ORM-14540|i.v.
214552055|NCT00831077|DRUG|ORM-12741|i.v.
214552056|NCT01120873|DRUG|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
214552057|NCT02251236|DRUG|Stribild|To be administered orally, once daily with food.
214552058|NCT02251236|DRUG|Genvoya|To be administered orally, once daily with food.
214552059|NCT01151215|DRUG|AZD8931|Tablet, oral, bd
214552060|NCT01151215|DRUG|anastrozole|Tablet, oral, od
214552061|NCT01151215|DRUG|Placebo|Tablet, oral
214552062|NCT00136643|DRUG|Invisible Condom®|
214552063|NCT00118612|BIOLOGICAL|Tree MATA MPL - Therapeutic Regimen|600, 1600, 4000, 4000 SU/0.5 mL
214701992|NCT00781963|BEHAVIORAL|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
214701993|NCT00781963|BEHAVIORAL|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
214701994|NCT04656392|DIAGNOSTIC_TEST|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
215161861|NCT05692323|OTHER|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
215161862|NCT04244942|DEVICE|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
214552064|NCT00118612|BIOLOGICAL|Tree MATA MPL - Intermediate dose|300, 600, 1600, 1600 SU/0.5 mL
214552065|NCT00118612|BIOLOGICAL|Tree MATA MPL - Low dose|300, 300, 300, 300 SU/0.5 mL
214552066|NCT00118612|BIOLOGICAL|Placebo|L-tyrosine 2% w/v , 4 injections
214552067|NCT02968615|BEHAVIORAL|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
214552068|NCT03002298|BEHAVIORAL|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
214552069|NCT03002298|BEHAVIORAL|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
214552070|NCT03002298|BEHAVIORAL|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
214552071|NCT03002298|BEHAVIORAL|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
214552072|NCT01721954|DRUG|FOLFOX6m|
214552073|NCT01721954|DEVICE|SIR-Spheres microspheres|
214552074|NCT00351572|PROCEDURE|Cell Search Assay|
214552075|NCT00727740|DRUG|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
214552076|NCT00727740|DRUG|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
214552077|NCT04591171|PROCEDURE|n-of-1 trial guided clinical decision making|The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
214552078|NCT03266718|BEHAVIORAL|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
214552079|NCT05725772|OTHER|Location of Visit|Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
214552080|NCT00653731|BEHAVIORAL|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
214552081|NCT00653731|BEHAVIORAL|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
214552082|NCT00653731|BEHAVIORAL|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
214552083|NCT00653731|BEHAVIORAL|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
214552084|NCT00509132|DRUG|trodusquemine|
214552085|NCT00098527|DRUG|romidepsin|Given IV
214552086|NCT00098527|OTHER|laboratory biomarker analysis|Correlative studies
214552087|NCT00867971|OTHER|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
214552088|NCT02840864|DEVICE|Sonography assisted breast surgery|
214552089|NCT01465945|PROCEDURE|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
214552090|NCT01465945|PROCEDURE|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
214552091|NCT03353597|BIOLOGICAL|Plasma Transfusion|All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
214552092|NCT04122547|DRUG|Roflumilast|Active drug
214552093|NCT04122547|DRUG|Placebo|Placebo one tablet oral od
214552094|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214552095|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214552096|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214552097|NCT02956837|DRUG|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214701995|NCT05855395|DRUG|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
215161863|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
215161864|NCT04809025|DEVICE|endoscopy|gastroscope
214552098|NCT06297044|OTHER|Neuropsychological assessment|"* APACS assessing various aspects of pragmatic communication abilities;~* SET assessing cognitive and emotional theory of mind;~* COAST assessing functional communication impairments in daily activities and their impact on the quality of life after the illness onset;~* PWB assessing the individual's perceived quality of life and psychological well-being;~* other neuropsychological assessment tools depending on the participant's pathology and routinely used in the clinical practice within the Institution."
214552099|NCT06003205|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
215161865|NCT04809025|PROCEDURE|Surgery|radical gastrectomy
214701996|NCT05278286|BEHAVIORAL|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
215161866|NCT06581328|DRUG|Vedolizumab IV|Vedolizumab IV infusion
215161867|NCT06581328|DRUG|Vedolizumab SC|Vedolizumab SC injection
215161868|NCT04756648|DRUG|CT0180 Cells|Five dose levels were tentatively determined.
215161869|NCT05727878|DRUG|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
215161870|NCT05727878|DRUG|KPI-012 Vehicle|KPI-012 formulation with no active drug
215161871|NCT06091254|DRUG|Odronextamab|Administered by intravenous infusion (IV)
214552100|NCT00196391|DRUG|DR-2021a|1 capsule daily for 10 days
215161872|NCT06091254|DRUG|Rituximab|Rituximab will be administered by IV, or subcutaneously (SC)
214552101|NCT00196391|DRUG|DR-2021b|1 capsule daily for 10 days
214552102|NCT00196391|DRUG|DR-2021c|1 capsule daily for 10 days
214552103|NCT00196391|DRUG|DR-2021d|1 capsule daily for 10 days
214552104|NCT00196391|DRUG|DR-2021e|1 capsule daily for 10 days
214552105|NCT00196391|OTHER|Placebo|1 matching placebo capsule for 10 days
214552106|NCT02597712|DRUG|YF476|gastrin receptor antagonist
214552107|NCT02597712|DRUG|YF476 placebo|placebo
214552108|NCT01803581|OTHER|X92001327|
214552109|NCT01803581|OTHER|RID shampoo|
214552110|NCT00002068|DRUG|Fluconazole|
214552111|NCT00002068|DRUG|Amphotericin B|
214552112|NCT04760262|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
214552113|NCT04760262|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
214552114|NCT00263653|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
214552115|NCT02224547|RADIATION|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
214701997|NCT05278286|BEHAVIORAL|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
214701998|NCT00680953|DRUG|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
214552116|NCT05276089|BEHAVIORAL|Video message|"The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses:~1. I would like to reduce my opioid medication with support.~2. I understand this video but I want to continue my current dose.~3. I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information."
214701999|NCT00680953|DRUG|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
214702000|NCT00680953|DRUG|Alendronate sodium hydrate|Oral tablet once a week for 24 months
214702001|NCT03057951|DRUG|Empagliflozin|once daily
214702002|NCT03057951|DRUG|Placebo|once daily
215029677|NCT04077320|BEHAVIORAL|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
215161873|NCT06091254|DRUG|Cyclophosphamide|Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
215161874|NCT06091254|DRUG|Doxorubicin|Administered by IV as part of CHOP chemotherapy
214552117|NCT03327272|DRUG|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
214552118|NCT03327272|DRUG|Saline|Administration of saline at surgical site prior to incision closure
214552119|NCT00001072|BIOLOGICAL|ALVAC-HIV MN120TMGNP (vCP300)|
214552120|NCT00001072|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214552121|NCT00001072|BIOLOGICAL|rgp120/HIV-1 SF-2|
214552122|NCT02637323|DRUG|FX006 32 mg|Single 5 mL IA injection
214552123|NCT02637323|DRUG|TCA IR 40|Single 1 mL IA injection
214552124|NCT03176004|OTHER|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
214552125|NCT00555243|PROCEDURE|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
214552126|NCT00555243|PROCEDURE|Traditional Surgical Education|Traditional surgical teaching (no simulator)
214552127|NCT00129753|DRUG|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
214552128|NCT00268372|DRUG|cisplatin|
214552129|NCT00268372|DRUG|docetaxel|
214552130|NCT00268372|DRUG|5-fluorouracil|
214552131|NCT00268372|PROCEDURE|surgery|
214552132|NCT00268372|RADIATION|radiation therapy|
214552133|NCT06254170|DIETARY_SUPPLEMENT|Euterpe Edulis juice|The preparation will be obtained with the same methods already well established in previous studies (SCHULZ et al., 2016.; MENDES et al., 2021). Participants will receive commercial samples of juçara (E.edulis) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
214552134|NCT06254170|DIETARY_SUPPLEMENT|Placebo|Participants will receive 250 ml of water + purple dye + pectin (control) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
214552135|NCT01397279|BIOLOGICAL|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
214552136|NCT01397279|BIOLOGICAL|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
214702003|NCT02064205|DIETARY_SUPPLEMENT|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
214702004|NCT02064205|DIETARY_SUPPLEMENT|glucose syrup|Glucose syrup is used a control product for the polydextrose
214702005|NCT03904784|BEHAVIORAL|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
214702006|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
214702007|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
214702008|NCT00696436|DRUG|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
214702009|NCT00696436|DRUG|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
214702010|NCT00696436|DRUG|Placebo|Matching placebo, orally, once daily for up to six weeks.
214702011|NCT01967472|DRUG|amodiaquine-artesunate (AQAS) fixed-dose|
214702012|NCT01967472|DRUG|Artemether-lumefantrine combination (AL) dispersable|
215161875|NCT06091254|DRUG|Vincristine|Administered by IV as part of CHOP, and CVP chemotherapy
214702013|NCT03405493|BEHAVIORAL|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
214702014|NCT03405493|BEHAVIORAL|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
214702015|NCT04859478|DIAGNOSTIC_TEST|Dual energy / spectral portal venous chest computed tomography|Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
214702016|NCT03095716|OTHER|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
214702017|NCT02062463|DRUG|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
214702018|NCT02062463|DRUG|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
214702019|NCT01079533|BEHAVIORAL|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
214552137|NCT06126679|PROCEDURE|1-year dietary and physical activity intervention of childhood obesity|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The participants in the intervention group are advised and motivated to increase their regular daily physical activity and to reduce sedentary habits. They have one group session for the training in the gymnasium with physical education instructor. The physical education instructor gives a voluntary lecture for parents about increasing physical activity and reducing sedentary time."
214702020|NCT01079533|BEHAVIORAL|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
214702021|NCT01605344|DRUG|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
215161876|NCT06091254|DRUG|Prednisone/prednisolone|Administered orally (PO) as part of CVP chemotherapy
214552138|NCT00513708|BEHAVIORAL|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
214552139|NCT00513708|BEHAVIORAL|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
214552140|NCT03377296|OTHER|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
214552141|NCT03377296|PROCEDURE|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
214552142|NCT05719753|DEVICE|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
214552143|NCT05719753|DEVICE|Standard Care|Bard Catheter
214552144|NCT00292097|PROCEDURE|Early tracheostomy|early conversion - less than or equal to 72 hours
214552145|NCT00292097|PROCEDURE|Late tracheostomy|Late conversion (10-14 days)
214552146|NCT00689182|PROCEDURE|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
214552147|NCT04017338|DRUG|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
214552148|NCT04017338|DRUG|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
214552149|NCT04017338|DEVICE|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
214552150|NCT02164903|OTHER|QoL Survey Booklet|
214552151|NCT02754362|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
214552152|NCT02754362|BIOLOGICAL|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
214702022|NCT01605344|DRUG|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
214702023|NCT01911013|PROCEDURE|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
214702024|NCT01911013|DEVICE|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
214552153|NCT02754362|DRUG|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
214552154|NCT02754362|DRUG|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
214552155|NCT05212753|DEVICE|Conventional physical therapy|Hot packs or hot water bags are superficial warming agents that will be used to heat muscle tissue, reduce muscle spasms and pain sensation. TENS is a pain reliever application.
214552156|NCT05212753|OTHER|Lumbar stabilization exercises|Training about the concepts of stabilization and abdominal bracing is given before starting the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface. The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
214552157|NCT05212753|OTHER|Breathing exercises|Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During diaphragmatic breathing, attention is focused on the correct abdominal breathing. The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over-breathing. This intervention also includes Sleep Hygiene education to the subjects,
214552158|NCT01059162|DEVICE|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
214552159|NCT01162486|DRUG|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552160|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552161|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552162|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552163|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552164|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
214552165|NCT01790919|BEHAVIORAL|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
214552166|NCT03308175|DEVICE|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
214552167|NCT03308175|DEVICE|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
214552168|NCT02588872|BIOLOGICAL|Platelet-rich Plasma (PRP)|
214552169|NCT02588872|BIOLOGICAL|Hyaluronic Acid|
214552170|NCT00607581|DRUG|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
214552171|NCT00607581|DRUG|lenalidomide|lenalidomide: 15 mg orally on days 1-21
214552172|NCT00607581|DRUG|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
214552173|NCT06453070|OTHER|No intervention was made|No intervention was made
214552174|NCT06273280|PROCEDURE|SOC|Physician-guided GDMT up-titration
214552175|NCT06273280|PROCEDURE|Protocolized up-titration|Renal-based protocolized GDMT up-titration
214552176|NCT01998789|DRUG|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
214552177|NCT01998789|DRUG|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
214552178|NCT05105776|DEVICE|Galvanic stimulation|Galvanic stimulation during physiotherapy sessions
214552179|NCT05114343|BEHAVIORAL|Exercise|Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.
214552180|NCT04781270|DRUG|mFOLFOXIRI regimen|oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
214552181|NCT04781270|DRUG|mFOLFOX regimen|oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
214552182|NCT04781270|DRUG|Bevacizumab|5 mg/kg on day 1
214552183|NCT02464605|BIOLOGICAL|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
214552184|NCT04277884|DRUG|Firibastat|Oral administration 2×250 mg capsules bid
214552185|NCT04277884|DRUG|Placebo|Oral administration 2 capsules bid
214702025|NCT01911013|DEVICE|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
214702026|NCT03937258|DRUG|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
214702027|NCT03937258|DRUG|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
214702028|NCT01889628|DIETARY_SUPPLEMENT|Liquid-based Nutritional Formulae and liquid glucose|
214702029|NCT03363217|DRUG|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
214702030|NCT00307424|DEVICE|AutoCPAP|
214702031|NCT00307424|DEVICE|FixCPAP|
214702032|NCT00921882|PROCEDURE|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
214702033|NCT00707655|DRUG|Zalutumumab|Eight weekly infusions
214702034|NCT02733406|OTHER|Target Controlled Infusion|
214702035|NCT02733406|OTHER|Velocity Controlled Infusion|
214702036|NCT02925663|BEHAVIORAL|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
214552186|NCT01093469|DRUG|Atopiclair Nonsteroidal Cream|
214552187|NCT01093469|OTHER|Aquaphor Healing Ointment|
214552188|NCT01093469|DRUG|EpiCeram|
214702037|NCT03353753|DRUG|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
214552189|NCT03274895|DRUG|PHMB 0.08%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
214552190|NCT03274895|DRUG|Propamidine 0.1%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
214552191|NCT03274895|DRUG|placebo|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
214552192|NCT03274895|DRUG|PHMB 0.02%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
214552193|NCT06086288|DRUG|Pembrolizumab, Etoposide, Cisplatin or Carboplatin|Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg
214552194|NCT03037203|DRUG|JZP-110|75 mg, 150 mg, 300 mg
214702038|NCT03353753|DRUG|Placebo Oral Tablet|Placebo
214702039|NCT01733901|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
214552195|NCT03037203|OTHER|Placebo|
214552196|NCT01549834|DRUG|ABT-126|Low Dose
214552197|NCT01549834|DRUG|ABT-126|High Dose
214552198|NCT01549834|DRUG|placebo|Placebo
214552199|NCT03949400|OTHER|Exercise therapy and education.|Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
214702040|NCT01733901|PROCEDURE|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
214702041|NCT02979301|DRUG|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
214702042|NCT00983840|OTHER|Family Eats|8-session web-based program on healthy eating for African American families
214702043|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared calcium hydroxide in to the root canals|Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.
214552200|NCT02546297|DRUG|Symbicort|drug are used for 12 months
214552201|NCT02546297|DRUG|Spiriva|drug are used for 12 months
214552202|NCT04239677|PROCEDURE|Conventional crystalloid solution-based priming|CPB circuit is also prepared with crystalloid solution-based priming in all participants (same as the RAP group). In this group (control group), CPB is initiated with antegrade priming (conventional priming).
214552203|NCT04239677|PROCEDURE|Retrograde autologous priming|CPB circuit is prepared with crystalloid solution-based priming in all participants. In RAP group, retrograde autologous priming is performed by displacing the crystalloid priming volume of arterial and venous lines via passive exsanguination of native blood prior to CPB initiation.
214552204|NCT04356534|OTHER|plasma therapy using convalescent plasma with antibody against SARS-CoV-2|convalescent patient plasma plus routine local standard of care
214552205|NCT04356534|OTHER|Routine care for COVID-19 patients|local standard of care which include antivirals and supportive care
214552206|NCT05714605|BEHAVIORAL|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
214552207|NCT05616676|BEHAVIORAL|Brief digital imagery-competing task|"First session guided by a researcher: A memory cue followed by playing a computer game with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session."
215161877|NCT06091254|DRUG|Bendamustine|Administered by IV as part of chemotherapy (Rituximab-Bendamustine)
215161878|NCT06388941|DRUG|Iptacopan|LNP023 administered orally
214552208|NCT05616676|BEHAVIORAL|Brief digital music-listening task|"First session guided by a researcher: Information about the composer's music followed by listening to classical music.~Option to engage in self-administered/guided sessions after the first session."
214552209|NCT05616676|OTHER|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events.
214552210|NCT04237532|DRUG|Intranasal Dexmedetomidine|The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.
214702044|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared double antibiotic paste in to the root canals|Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.
214702045|NCT05581706|DIAGNOSTIC_TEST|Taking standart periapical radiography with film holder|"Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up."
214702046|NCT05581706|OTHER|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
214702047|NCT00055536|DRUG|natalizumab|
214702048|NCT00709917|DRUG|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
214702049|NCT03444194|PROCEDURE|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
214702050|NCT04536649|RADIATION|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
214702051|NCT03148626|OTHER|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
214552211|NCT04237532|DRUG|Sublingual Dexmedetomidine|The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.
214552212|NCT01004523|GENETIC|fluorescence in situ hybridization|
214552213|NCT01004523|GENETIC|loss of heterozygosity analysis|
214702052|NCT03148626|OTHER|Control|Usual Education
214552214|NCT01004523|GENETIC|polymerase chain reaction|
214552215|NCT01004523|OTHER|flow cytometry|
214552216|NCT01004523|OTHER|immunohistochemistry staining method|
214702053|NCT03179579|PROCEDURE|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
214702054|NCT03179579|PROCEDURE|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
214702055|NCT04994652|DEVICE|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
214702056|NCT04994652|DEVICE|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
214702057|NCT04173871|DEVICE|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
215161879|NCT06388941|DRUG|Placebo|Matching placebo administered orally
214552217|NCT01173068|DRUG|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
214552218|NCT05170815|PROCEDURE|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
214552219|NCT00020761|DRUG|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
214552220|NCT00020761|DRUG|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
214552221|NCT03908593|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
214552222|NCT04662983|DEVICE|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
214552223|NCT01584518|DRUG|Furosemide|Based on clinical standard per clinician
215161880|NCT06388941|DRUG|Rituximab|Standard of care
215161881|NCT05439837|PROCEDURE|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
215161882|NCT05439837|PROCEDURE|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
215161883|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
215161884|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
214552224|NCT02761863|OTHER|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
214552225|NCT05974683|DRUG|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
214552226|NCT05974683|DRUG|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
214552227|NCT03557606|PROCEDURE|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
214552228|NCT04792398|DRUG|Incobotulinumtoxin A (BTX A) Xeomin®|Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
214552229|NCT04751240|BEHAVIORAL|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
214552230|NCT01495910|DRUG|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
214552231|NCT06237777|GENETIC|SKG0106 intravitreal injection dose level 1, 2 or 3|SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
214552232|NCT02134509|BEHAVIORAL|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
214552233|NCT02134509|BEHAVIORAL|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
214702058|NCT06481657|OTHER|train with oxygen and without oxygen enrichment (placebo).|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
214552234|NCT04502992|BEHAVIORAL|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
214702059|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
214552235|NCT03229486|DRUG|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
215161885|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
214552236|NCT03229486|DRUG|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
214552237|NCT01228877|OTHER|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
214552238|NCT05578508|DRUG|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
214552239|NCT01512550|PROCEDURE|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
214552240|NCT01512550|PROCEDURE|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
214552241|NCT01512550|DEVICE|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
214552242|NCT01485107|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
214552243|NCT00002264|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
214552244|NCT01461005|DEVICE|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
214552245|NCT05284955|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
214552246|NCT05284955|DRUG|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
214552247|NCT05672771|BEHAVIORAL|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
214552248|NCT05672771|BEHAVIORAL|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
214552249|NCT05672771|BEHAVIORAL|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
214552250|NCT05672771|BEHAVIORAL|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
214552251|NCT06051071|DEVICE|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
214552252|NCT03374293|RADIATION|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
214552253|NCT03374293|DRUG|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
214552254|NCT01838954|DEVICE|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
214552255|NCT00760747|DRUG|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
214552256|NCT01443923|DRUG|Boceprevir|
214552257|NCT01443923|DRUG|Peg-Interferon-alfa 2B|
214552258|NCT01443923|DRUG|Ribavirin|
214702060|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
214702061|NCT03106948|DRUG|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
214702062|NCT03106948|DRUG|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
215161886|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
214552259|NCT02083289|DRUG|ONO-9054|
214552260|NCT02083289|DRUG|Latanoprost|
214552261|NCT01403649|BEHAVIORAL|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
214702063|NCT03106948|DRUG|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
214702064|NCT05186909|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
214702065|NCT05186909|OTHER|Placebo|Placebo
214552262|NCT01403649|OTHER|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
214552263|NCT01666093|PROCEDURE|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
214552264|NCT00983112|DRUG|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
214552265|NCT00983112|DRUG|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
214552266|NCT01021371|BEHAVIORAL|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
214552267|NCT03702387|PROCEDURE|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
214552268|NCT03999632|OTHER|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
214552269|NCT02784964|BIOLOGICAL|Elixcyte 8 ml|ADSC 6.4\*10\^7 cells, allogeneic injection
214552270|NCT02784964|DEVICE|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
214552271|NCT02784964|BIOLOGICAL|Elixcyte 4 ml|ADSC 3.2\*10\^7 cells, allogeneic injection
214702066|NCT01372371|BIOLOGICAL|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
214702067|NCT01372371|BIOLOGICAL|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
214702068|NCT01372371|BIOLOGICAL|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
214552272|NCT02784964|BIOLOGICAL|Elixcyte 2 ml|ADSC 1.6\*10\^7 cells, allogeneic injection
214552273|NCT04811144|DEVICE|Er:YAG dental laser|To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
214702069|NCT00363051|DRUG|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
214702070|NCT00363051|DRUG|Octreotide Depot|
214702071|NCT02028585|DIETARY_SUPPLEMENT|Low-fat milk group|
214702072|NCT06118164|BEHAVIORAL|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
214702073|NCT06118164|BEHAVIORAL|pursing- lip breathing|pursing- lip breathing
214702074|NCT06118164|BEHAVIORAL|aerobic walking exercise|aerobic walking exercise
214702075|NCT00131677|DRUG|tenofovir disoproxil fumarate|study product taken daily
214702076|NCT00131677|DRUG|placebo|study product taken daily
214552274|NCT02529423|DIETARY_SUPPLEMENT|Multi-nutrient supplement|"* Omega 3 fatty acids~* Folic acid~* Calcium~* Selenium~* Vitamin D3"
214552275|NCT02529423|BEHAVIORAL|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood-related snacking) and helpful food-related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
214552276|NCT02529423|OTHER|Placebo|Placebo pills identical in look and taste but including no active ingredients
214552277|NCT00061425|DRUG|radiolabeled epratuzumab|
214702077|NCT06024213|PROCEDURE|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
214702078|NCT06024213|DRUG|indocyanine green|Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
214702079|NCT06024213|DRUG|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
214702080|NCT06024213|DRUG|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
214702081|NCT00280319|BEHAVIORAL|interpersonal psychotherapy for groups|psychotherapy
214702082|NCT00280319|BEHAVIORAL|creative play therapy|consisted of play activities
214702083|NCT02411383|DEVICE|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
214552278|NCT05360628|DRUG|D-0120 in combination with Allopurinol|noted above
214552279|NCT03566979|DRUG|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
214552280|NCT03566979|DRUG|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
214552281|NCT03566979|DRUG|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
214702084|NCT02720653|PROCEDURE|Endoscopic sinus surgery|
214552282|NCT03566979|DRUG|Placebo tablet|2 placebo tablets
214552283|NCT03941899|OTHER|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
214552284|NCT05253599|DEVICE|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
214552285|NCT05253599|DEVICE|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
214552286|NCT05253599|OTHER|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
214552287|NCT01856517|DRUG|Clonidine|
214552288|NCT01856517|DRUG|Placebo|
214552289|NCT05961540|OTHER|Conventional care|"1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
214552290|NCT05961540|BEHAVIORAL|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD."
214702085|NCT03711877|DEVICE|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
214702086|NCT03711877|DEVICE|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
215161887|NCT04599088|OTHER|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
215161888|NCT04198792|OTHER|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
215161889|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
215161890|NCT06426953|OTHER|No intervention|No intervention
215161891|NCT05549323|DRUG|PF-07054894|Oral
215161892|NCT05549323|DRUG|Placebo|Placebo
215161893|NCT05821660|OTHER|Five-day hypocaloric and ketogenic programme|Dietary intervention
215161894|NCT05268640|PROCEDURE|Double-level cervical cerclage|two cervical sutures + regimen of antibiotics + indomethacin + progesterone
215161895|NCT05268640|PROCEDURE|Single-level cervical cerclage|single cervical suture + regimen of antibiotics + indomethacin + progesterone
214552291|NCT00219479|DRUG|Phenytoin (Dilantin) levels during change in enteral feeding|
214552292|NCT03035669|BEHAVIORAL|Mindfulness group|8 week program
215161896|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
215161897|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
214552293|NCT03035669|BEHAVIORAL|Reading group|8 week program
215161898|NCT03972865|OTHER|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
215161899|NCT06403436|DRUG|TT125-802|TT125-802 administered orally
214552294|NCT00565071|DEVICE|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
214552295|NCT03321253|DEVICE|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
214702087|NCT06183632|BIOLOGICAL|blood sampling|3 x 7mL EDTA blood tubes
214702088|NCT03703687|BEHAVIORAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
214552296|NCT00480051|DEVICE|Cardiac Resynchronization Pacing|
214552297|NCT00098397|DRUG|romidepsin|Given IV
214552298|NCT00098397|OTHER|laboratory biomarker analysis|Optional correlative studies
214552299|NCT03659331|DIETARY_SUPPLEMENT|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
214552300|NCT00902811|DRUG|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
214552301|NCT00902811|DRUG|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
214552302|NCT00902811|DRUG|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
214552303|NCT00902811|DRUG|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group \<6yrs of age, a subdivision according to weight is made
214552304|NCT00902811|DRUG|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
214702089|NCT00205699|DRUG|risperidone|randomized to begin 12 week trial of risperidone
214702090|NCT00205699|DRUG|olanzapine|randomized to begin 12 week trial of olanzapine
214702091|NCT00205699|DRUG|aripiprazole|randomized to 12 week trial of aripiprazole
214702092|NCT06348953|OTHER|selective caries removal and conventional non-bioactive restorative system|conventional dental restorative adhesive and resin based composite
214702093|NCT06348953|OTHER|selective caries removal and bioactive restorative system|bioactive dental restorative resin based system
214702094|NCT02644837|DEVICE|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
214702095|NCT02644837|DEVICE|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
215161900|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
215161901|NCT04918186|DRUG|BA3011|IV
215161902|NCT04918186|DRUG|BA3021|IV
215161903|NCT04918186|DRUG|ENB003|IV
215161904|NCT04918186|DRUG|Toripalimab|IV
215161905|NCT06336382|DIAGNOSTIC_TEST|Tau PET imaging scan|Subjects will be scanned with novel tau PET tracer \[18F\] PI-2620 to determine whether neurofibrillary tangle pathology is present.
215161906|NCT06209619|PROCEDURE|Biopsy|Undergo biopsy
215161907|NCT06209619|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161908|NCT06209619|PROCEDURE|Computed Tomography|Undergo PET/CT
215161909|NCT06209619|DRUG|Golcadomide|Given PO
215161910|NCT06209619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215161911|NCT06209619|BIOLOGICAL|Rituximab|Given IV
215161912|NCT04870437|OTHER|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
215161913|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
215161914|NCT06780670|DRUG|Investigators choice of SoC|The control treatment in Phase III is investigator's choice of SoC
215161915|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
215161916|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
215161917|NCT06780670|DRUG|AAA817|Investigational treatment is the Dose B of AAA817
215161918|NCT04926519|OTHER|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
214552305|NCT04622098|PROCEDURE|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci."
214552306|NCT00303706|PROCEDURE|Endoscopic Radial Artery Harvest|
214552307|NCT06222242|BEHAVIORAL|mychoiceTM|mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
214552308|NCT00000104|PROCEDURE|ERP measures of attention and memory|
214552309|NCT02901847|OTHER|PAD tailored care|PAD tailored care
214552310|NCT02498262|OTHER|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
214552311|NCT02781649|DRUG|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
214552312|NCT02781649|DRUG|Ribavirin|Ribavirin 1200 mg/d (\> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses
214702096|NCT02644837|DEVICE|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
214702097|NCT02644837|DEVICE|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
214702098|NCT02644837|DEVICE|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
214702099|NCT02644837|DEVICE|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
214702100|NCT02644837|DEVICE|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
214702101|NCT02644837|DEVICE|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
214702102|NCT02521909|DEVICE|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
215161919|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
215161920|NCT06441006|DRUG|Bedaquiline|Frequency: daily Route of administration: oral
215161921|NCT06441006|DRUG|Linezolid|Frequency: daily Route of administration: oral
215161922|NCT06441006|DRUG|Pretomanid|Frequency: daily Route of administration: oral
214552313|NCT02781649|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily
214552314|NCT03714568|DRUG|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
214552315|NCT03714568|DRUG|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
214552316|NCT01722747|BEHAVIORAL|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
214702103|NCT02521909|DEVICE|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
214702104|NCT02521909|DEVICE|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
214702105|NCT02970227|OTHER|Observation|None, observation only
214702106|NCT03945734|BEHAVIORAL|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
215161923|NCT06441006|DRUG|Moxifloxacin|Frequency: daily Route of administration: oral
214552317|NCT01642433|DRUG|Placebo|Placebo capsules, 3x daily
214552318|NCT01642433|DRUG|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
214552319|NCT00323206|BIOLOGICAL|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
215161924|NCT06441006|DRUG|Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 24 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest international guidelines and the local SOC.
215161925|NCT05109936|DRUG|Adenuric|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
215161926|NCT06367387|DRUG|Patient-Oriented Dosing (POD)|"Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference."
214552320|NCT00323206|PROCEDURE|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
214552321|NCT04099654|OTHER|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
214552322|NCT04099654|OTHER|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
214552323|NCT02690844|DRUG|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
214552324|NCT02690844|DRUG|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
214552325|NCT02690844|DRUG|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
214552326|NCT05440747|OTHER|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
214552327|NCT02761447|OTHER|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
214552328|NCT02761447|OTHER|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
214552329|NCT00781495|DEVICE|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
214552330|NCT01082237|DRUG|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
214552331|NCT01066715|DRUG|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
214552332|NCT01066715|DRUG|Placebo|Sterile solution subcutaneously administered monthly for 6 months
214552333|NCT06319183|DRUG|Salbutamol|We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
214552334|NCT01303315|DEVICE|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
214552335|NCT01889069|DRUG|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
214552336|NCT01889069|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
214552337|NCT01889069|DRUG|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
214552338|NCT01889069|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
214552339|NCT01889069|DRUG|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
214552340|NCT01889069|DRUG|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
215161927|NCT06367387|BEHAVIORAL|Pain Self-Management (PSM)|"Pain self-management (PSM) is a manualized behavioral intervention consisting of 12 sessions, comprising 6 group and 6 individual sessions. The first session will be individual, followed by a group session, and then alternating weekly for the remainder of the intervention.~Individual sessions will be led by a staff Interventionist trained in the pain self-management intervention. The interventionist will guide participants through a PSM study manual, providing education, teaching associated skills, and assisting with goal setting.~Group sessions will be led by a Peer Facilitator who has experience with chronic pain, opioid use disorder, and buprenorphine treatment. These sessions will not have specific content but will serve as supportive forums for participants to discuss their experiences with the intervention, share tips for managing chronic pain, and provide mutual support."
215161928|NCT06367387|BEHAVIORAL|Usual Care|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions."
215161929|NCT06367387|DRUG|Standard Buprenorphine Dosing Condition|Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
215161930|NCT05754216|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
215161931|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
215161932|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
215161933|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
215161934|NCT05117541|OTHER|Interview|Participate in interviews
215161935|NCT05117541|PROCEDURE|Biospecimen Collection|Undergo collection of hair samples
215161936|NCT05117541|OTHER|Electronic Health Record Review|Medical records are reviewed
214552341|NCT03352154|DIAGNOSTIC_TEST|P300 - Auditory long latency potential|Perform the P300 exams.
214552342|NCT01888549|DRUG|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
214552343|NCT01888549|DRUG|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
214552344|NCT01888549|DRUG|placebo|
214552345|NCT00544232|DRUG|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
214552346|NCT00544232|DRUG|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
214552347|NCT01228175|DRUG|Placebo|25mg look alike riboflavin tablets to match active study medication.
214552348|NCT01228175|DRUG|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
214552349|NCT00108745|OTHER|Clinical Observation|Undergo observation
214552350|NCT00108745|OTHER|Laboratory Biomarker Analysis|Correlative studies
214552351|NCT00108745|DRUG|Paclitaxel|Given IV
214552352|NCT00108745|DRUG|Paclitaxel Poliglumex|Given IV
214552353|NCT00108745|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214552354|NCT00307476|DEVICE|Rusch Nasopharyngeal Airway|For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
214552355|NCT02421536|OTHER|Vibrogent Smartphone Application|
214552356|NCT00665093|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
214552357|NCT00665093|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
215161937|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
215161938|NCT05955456|OTHER|No intervention|No intervention is applied to participants. The risk calculator score is not released to the participants or care providers. Participants are followed up for risk calculator accuracy and recalibration.
214702107|NCT02574858|DRUG|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
214702108|NCT05924516|BEHAVIORAL|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
214702109|NCT02357953|OTHER|Measurement of cardiac index|
214702110|NCT06191120|RADIATION|[18F]-ALF-FAPI-74 PET/CT scan|Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.
214552358|NCT03302390|PROCEDURE|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than \<3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
214552359|NCT00723749|DRUG|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
214552360|NCT04621461|DIETARY_SUPPLEMENT|Zinc Sulfate 220 MG|220mg once daily for 5 days
214552361|NCT04621461|DRUG|Placebo|Once daily for 5 days
214552362|NCT00135681|DRUG|nedocromil budesonide|
214552363|NCT03203837|OTHER|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
214552364|NCT00002489|BIOLOGICAL|dactinomycin|
214552365|NCT00002489|BIOLOGICAL|filgrastim|
214552366|NCT00002489|DRUG|carboplatin|
214552367|NCT00002489|DRUG|cyclophosphamide|
214552368|NCT00002489|DRUG|doxorubicin hydrochloride|
214552369|NCT00002489|DRUG|etoposide|
214552370|NCT00002489|DRUG|leucovorin calcium|
214552371|NCT00002489|DRUG|methotrexate|
214552372|NCT00002489|DRUG|vincristine sulfate|
214552373|NCT00002489|PROCEDURE|conventional surgery|
214552374|NCT00455741|DRUG|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
214552375|NCT00455741|DRUG|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
214552376|NCT01727869|DRUG|REGN1400|
214552377|NCT01727869|DRUG|Erlotinib|
214552378|NCT01727869|DRUG|Cetuximab|
214552379|NCT01079910|DRUG|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
214552380|NCT01079910|DRUG|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
214552381|NCT04699760|DIETARY_SUPPLEMENT|Fish Oil|8 weeks, 2.2 G EPA/day
214552382|NCT04699760|DIETARY_SUPPLEMENT|Placebo|Placebo
214552383|NCT01635023|DRUG|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
214552384|NCT01635023|DRUG|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
214552385|NCT01635023|DRUG|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
214552386|NCT01635023|DRUG|AZD6244 Dosing Period 4|Treatment B
214552387|NCT00989547|OTHER|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
214552388|NCT02903017|DRUG|Tranexamic acid 5%|Via nasogastric tube, 100 mL
214552389|NCT02903017|DRUG|Placebo|Via nasogastric tube, 100 mL
214702111|NCT05619679|OTHER|Kidney Transplantation|Kidney transplantation
214552390|NCT03028597|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
214552391|NCT03028597|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
214552392|NCT01606410|OTHER|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
214552393|NCT02332902|DRUG|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
214552394|NCT00984191|RADIATION|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
214702112|NCT00992732|DRUG|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
214702113|NCT00992732|DRUG|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
215029678|NCT04077320|BEHAVIORAL|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
215029679|NCT05844319|OTHER|tele-education|The treatment of the patients will be carried out by tele-education method.
215029680|NCT03078868|DEVICE|Magnetic Resonance Scanner|MRI
215029681|NCT03314896|PROCEDURE|Laparoscopic surgery|
215029682|NCT03170986|BEHAVIORAL|Multisectoral agriculture and Microfinance Intervention|
215029683|NCT03285360|COMBINATION_PRODUCT|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
214552395|NCT04682132|DIAGNOSTIC_TEST|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
214552396|NCT02043743|BIOLOGICAL|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
214552397|NCT03998449|BIOLOGICAL|Vaccination against cholera|Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
214552398|NCT01160627|OTHER|Hydration|Saline hydration
214552399|NCT01160627|DRUG|Acetylcysteine|Acetylcystein tablets for 2 days
214552400|NCT01160627|DRUG|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
214552401|NCT01160627|DRUG|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
214552402|NCT04865042|DRUG|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
214552403|NCT04865042|DRUG|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
214552404|NCT05345730|DIAGNOSTIC_TEST|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
214552405|NCT05614518|DRUG|Sodium Fluoride F-18 Injection|Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
214552406|NCT05614518|DRUG|Technetium[99mTc] Methylenediphosphonate Injection|Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
214552407|NCT03742375|DIAGNOSTIC_TEST|HPV genotyping|Quantitative HPV genotyping on anal swab
214552408|NCT05879237|DRUG|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
214552409|NCT05879237|DRUG|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
214552410|NCT00574418|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
214702114|NCT05353101|DRUG|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
214702115|NCT05353101|DRUG|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
214702116|NCT01541267|DRUG|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
214702117|NCT05491655|DEVICE|High Intensity His Bundle pacing|All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
214702118|NCT01192217|PROCEDURE|Modified thoracoscopic technique|Two-port thoracoscopic technique
214702119|NCT01192217|PROCEDURE|Axillary mini-thoracotomy|Axillary mini-thoracotomy
214702120|NCT04430660|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
214702121|NCT04430660|DEVICE|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
214702122|NCT03071705|DRUG|Metformin|500 mg PO BID
214552411|NCT02848768|DRUG|Sunitinib|
214552412|NCT01245374|DEVICE|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
214552413|NCT02762188|DEVICE|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
214552414|NCT02623998|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
214552415|NCT02623998|DRUG|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
214552416|NCT02623998|BEHAVIORAL|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
214702123|NCT03071705|DRUG|TKI|standard dose
214702124|NCT04922749|BEHAVIORAL|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
215029684|NCT03285360|COMBINATION_PRODUCT|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
214702125|NCT06290947|DEVICE|BFR Cuffs for Intervention Group|"The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes."
214702126|NCT06290947|OTHER|Standard Walking Training Program|"The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention."
214702127|NCT04264767|PROCEDURE|Blood collection|Peripheral blood collection via routine venipuncture
214702128|NCT03019224|PROCEDURE|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
214702129|NCT03019224|PROCEDURE|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
214552417|NCT00935532|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
215161939|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
215161940|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
215161941|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
215161942|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
214552418|NCT00935532|DRUG|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
214552419|NCT06211777|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214552420|NCT06211777|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
215161943|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
215161944|NCT03415412|DEVICE|IBond Universal|Adhesive systems
215161945|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
215161946|NCT05671835|DRUG|TTI-101|Orally via a tablet.
215161947|NCT05671835|DRUG|Placebo|Orally via a tablet.
214552421|NCT06211777|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214552422|NCT02227992|BIOLOGICAL|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
214552423|NCT02227992|DEVICE|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
214552424|NCT01935752|OTHER|blood samples|blood samples
214552425|NCT01935752|OTHER|vascular echotracking|endothelial function study and virtual histology study
215161948|NCT04822181|DRUG|Semaglutide|Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
215161949|NCT04822181|DRUG|Placebo|Placebo administrated subcutaneously (under the skin) once weekly.
214552426|NCT06236633|PROCEDURE|Ischemic preconditioning|Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).
214552427|NCT06236633|PROCEDURE|Arteriogram|The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).
214552428|NCT02592915|DRUG|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
214552429|NCT02592915|OTHER|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
214552430|NCT05445947|BEHAVIORAL|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
214552431|NCT02715141|BEHAVIORAL|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
214552432|NCT00658294|OTHER|Stop treatment|
214552433|NCT00223509|DRUG|Lamotrigine|
214552434|NCT03354468|BEHAVIORAL|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
214702130|NCT03019224|PROCEDURE|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
214552435|NCT02380053|DRUG|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
214552436|NCT02380053|DRUG|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
214552437|NCT00178854|DRUG|Risperidone|
214702131|NCT03019224|PROCEDURE|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
214552438|NCT00001046|BIOLOGICAL|MF59|
214552439|NCT00001046|BIOLOGICAL|rgp120/HIV-1 SF-2|
214552440|NCT05044676|OTHER|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
214552441|NCT06020950|OTHER|Control|Low-calorie diet with the use of placebo pearls (containing sunflower oil)
214552442|NCT06020950|DIETARY_SUPPLEMENT|Omega-3 supplementation|Low-calorie diet with the use of marine omega-3 pearls (containing 1200 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid/day)
214702132|NCT03019224|PROCEDURE|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
214702133|NCT03019224|DRUG|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
214702134|NCT03019224|PROCEDURE|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
214702135|NCT03337555|DEVICE|McGrath|McGrath videolaryngoscope
214552443|NCT06020950|OTHER|Chia seed|Low-calorie diet with the consumption of 30 grams of powdered chia seeds
214552444|NCT04954326|DRUG|Lyophilized S95014|"Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
214552445|NCT04954326|DRUG|Liquid S95014|"Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
214552446|NCT06289595|DEVICE|PBM Ortho device|Device emits light for photobiomodulation (light therapy).
214552447|NCT02038387|BEHAVIORAL|normocaloric low cholesterol diet|
214552448|NCT03329677|OTHER|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
214702136|NCT03337555|DEVICE|Pentax|Pentax videolaryngoscope
214702137|NCT03337555|DEVICE|Macintosh|Macintosh direct laryngoscope
214702138|NCT02093234|BEHAVIORAL|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
214702139|NCT02093234|BEHAVIORAL|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
214702140|NCT02093234|BEHAVIORAL|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
214702141|NCT00286130|DRUG|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
214702142|NCT00286130|DRUG|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
214552449|NCT04982575|DRUG|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
214552450|NCT04982575|DRUG|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
214552451|NCT04982575|DRUG|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
214552452|NCT04982575|DRUG|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
214552453|NCT04108624|OTHER|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
214552454|NCT04108624|DEVICE|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
214702143|NCT00286130|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
214702144|NCT06390917|DEVICE|PVA recognition function|Ventilator with the function of identify and judge PVAs
214702145|NCT01866878|DEVICE|equipment rehabilitation stereognosis|
214702146|NCT01866878|DEVICE|TENS|
214702147|NCT04258046|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
214702148|NCT00789269|DRUG|rhubarb|14 days of rhubarb
214702149|NCT00789269|DRUG|placebo|14 days of placebo
215161950|NCT05537220|DRUG|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
215161951|NCT05537220|DRUG|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
214702150|NCT03284255|DEVICE|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
214702151|NCT03284255|DEVICE|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
214702152|NCT05883553|DEVICE|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
214702153|NCT05638763|DRUG|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
214702154|NCT05638763|DRUG|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
214702155|NCT00091845|DRUG|AVI-4020 Injection|
214702156|NCT02875847|DIETARY_SUPPLEMENT|HMO1|
214702157|NCT02875847|DIETARY_SUPPLEMENT|HMO2|
214702158|NCT02875847|DIETARY_SUPPLEMENT|Dextropur|
214702159|NCT01962519|DIETARY_SUPPLEMENT|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
214702160|NCT02462941|DRUG|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
214702161|NCT02462941|PROCEDURE|Cardiac catheterization|(non-experimental) standard procedure
214702162|NCT04314479|BEHAVIORAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
214702163|NCT02095236|BEHAVIORAL|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
214702164|NCT04807036|DEVICE|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
214702165|NCT01310816|DRUG|IPI-926|Oral
214702166|NCT01310816|DRUG|Placebo Arm|oral placebo
214702167|NCT02808741|DRUG|F901318 SDD|Pharmacokinetics area under curve
214702168|NCT02808741|DRUG|F901318 IR|Pharmacokinetics area under curve
214702169|NCT02808741|DRUG|F901318 IR Fasting|Pharmacokinetics area under curve
214702170|NCT02808741|DRUG|F901318 IR Fed|Pharmacokinetics area under curve
214702171|NCT03225716|DRUG|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
214702172|NCT03225716|DRUG|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
214702173|NCT04574388|OTHER|open label placebo|open label placebo pill
214552455|NCT00475228|DRUG|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem
214552456|NCT00338988|DRUG|Capecitabine|1500 mg/m\^2 PO twice daily x 14 days.
214552457|NCT00338988|DRUG|Oxaliplatin|130 mg/m\^2 IV over 2 hours on day 1 of cycle.
214552458|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
214552459|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
214552460|NCT03855176|DRUG|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
214552461|NCT00403910|DRUG|Canrenone|
214552462|NCT04721015|DRUG|ABBV-637|Intravenous (IV) Infusion
214552463|NCT04721015|DRUG|Docetaxel|Intravenous (IV) Infusion
214552464|NCT04721015|DRUG|Osimertinib|Oral Tablets
214702174|NCT03665428|DRUG|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
214702175|NCT03665428|DRUG|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
214702176|NCT00377910|DRUG|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
214702177|NCT00120653|DRUG|Metoclopramide|
214702178|NCT00283998|PROCEDURE|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
214702179|NCT03709524|DEVICE|Airtraq + fiberoptic|video laryngoscope with a monitor
214702180|NCT03709524|DEVICE|Airtraq|video laryngoscope with a monitor
214702181|NCT03709524|DEVICE|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
214552465|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
214552466|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
214702182|NCT05991674|DIAGNOSTIC_TEST|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
214702183|NCT01114373|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
214702184|NCT01114373|DRUG|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
214702185|NCT01504386|PROCEDURE|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
214702186|NCT01504386|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
214702187|NCT02484612|BEHAVIORAL|acute exercise|
214702188|NCT03110146|DEVICE|EnSite Precision|Ablation procedure
214702189|NCT00934427|DRUG|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
215029685|NCT01706315|DRUG|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
215029686|NCT01706315|DRUG|Placebo|Matching placebo will be available
215029687|NCT00099905|DRUG|vildagliptin|
215029688|NCT05949892|BEHAVIORAL|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
215029689|NCT00421967|DRUG|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
215029690|NCT00421967|DRUG|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
215029691|NCT01652404|BEHAVIORAL|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
214702190|NCT00934427|DRUG|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
214552467|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
214552468|NCT07047456|PROCEDURE|Time of umbilical cord blood infusion|Randomization of patients according to the time of umbilical cord blood infusion
214702191|NCT03255993|DRUG|SPH3127 50mg|SPH3127 50mg
214552469|NCT07050303|OTHER|Mobile Application Developed Based on Social Cognitive Theory|Measuring the Benefits of a 3-Month Mobile Application Use in Hypertension Patients
214552470|NCT07049211|DEVICE|Individualized online stimulation|The individualized online stimulation group will calculate precise targets based on the collected multimodal MRI (structural images, resting-state/task-state functional images, and diffusion tensor imaging), plan the coil position and placement angle of TMS through electric field simulation, and achieve individualized intervention. At the same time, when patients receive TMS treatment, they are matched with specific upper limb motor tasks. When the task starts autonomously, TMS stimulation is triggered by acceleration-EMG feedback. When the task stops or is completed, TMS stimulation also stops immediately according to the acceleration-EMG feedback to achieve real-time effects.
214702192|NCT03255993|DRUG|SPH3127 100mg|SPH3127 100mg
214552471|NCT07049211|DEVICE|Non-individualized online stimulation|In the non-individualized online stimulation group, patients receive TMS treatment synchronized with task training. However, the targeting uses traditional positioning methods, i.e., determining the target with a positioning cap instead of precise target localization.
214552472|NCT07049211|DEVICE|Sham stimulation|In the individualized online sham stimulation group, patients receive TMS treatment combined with specific tasks. The stimulation targets are the same as those in the online stimulation group, all determined by precise target localization, except that a sham stimulation coil is used for TMS stimulation.
214552473|NCT07049029|BEHAVIORAL|PREP-Y|The intervention is a series of behavioral health/psychoeducational modules that the participant will learn from. Participants will use the information discussed and overall impact on physical activity engagement, chronic pain management, and quality of life will be measured
214702193|NCT03255993|DRUG|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
214702194|NCT03255993|DRUG|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
214702195|NCT01608399|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
214702196|NCT01827930|DRUG|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
214702197|NCT01827930|DRUG|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
214702198|NCT01827930|DRUG|Imatinib Mesylate|Imatinib Mesylate for CP CML
214702199|NCT03991884|DRUG|Etoposide|Given IV
214702200|NCT03991884|DRUG|Doxorubicin|Given IV
214702201|NCT03991884|DRUG|Vincristine|Given IV
214702202|NCT03991884|DRUG|Prednisone|Given PO or IV
214702203|NCT03991884|DRUG|Cyclophosphamide|Given IV
214702204|NCT03991884|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214702205|NCT04799951|OTHER|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
214702206|NCT01784952|DIETARY_SUPPLEMENT|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
214702207|NCT06192953|OTHER|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
214702208|NCT01365377|OTHER|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
215161952|NCT06446882|DEVICE|Personalized treatment according to molecular diagnosis with HER2DX|"Patients with HER2DX high-risk disease:~* Neoadjuvant treatment:~  * High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~ * Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.~ * Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.~* Adjuvant treatment:~  * pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).~ * No pCR at surgery: T-DM1 per 14 cycles.~Patients with HER2DX low-risk disease:~* Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~* Adjuvant treatment will be according to the pCR status at surgery:~  * pCR at surgery: trastuzumab or no adjuvant treatment.~ * No pCR at surgery: trastuzumab or T-DM1."
214552474|NCT07050459|DRUG|SIM0686|Administered intravenously
214552475|NCT07050459|DRUG|SIM0686|Administered intravenously
214552476|NCT06735820|DRUG|APG-115|Combination therapy of APG-115 and Selumetinib
214552477|NCT06735820|DRUG|Selumetinib|Combination therapy of APG-115 and Selumetinib
214702209|NCT03585192|OTHER|Skin Group|"1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
214702210|NCT03585192|OTHER|Warmer Group|"1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
214702211|NCT01653158|DRUG|CP-751,871|"CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
214552478|NCT07050108|OTHER|neurodynamic mobilization|the patients will receive neurodynamic mobilization in the form of opening technique which include; static opening and dynamic opening. also, sliding and tensioning technique+ selected physical therapy program
214552479|NCT07050108|OTHER|mulligan therapy|sustained natural apophyseal glide SNAGs are mobilisation techniques and are used as part of the Mulligan Concept+ selected physical therapy program The patient position is stitting on the edage of the plenth non weight bearing position. The therapist will stand behind the patient, the therapist will apply SNAG for 3 repetitions during the initial screening session,the patient will be asked to lean forwared while applying the technique .the therapist apply onle from fove to seven repetitions.patients who experienced no worsening or showed improvement of pain and ROM were considered good indication for the effectivness of treatment .
214552480|NCT07050108|OTHER|selected physical therapy program|"The program of therapeutic exercises consisted of upper and lower back exercises. Each exercise will repeat from ten to thirty times, three repetitions in three sets with rest one to two minutes between the sets. The repetition of each exercise vary according to the physical ability of each patient.~Lower back strengthening exercises: From prone lying position, the patient will asked to raise one lower limb then the other then both lower limbs+ TENS and US"
214552481|NCT06371976|OTHER|Blood sampling|Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.
214552482|NCT06371976|OTHER|Vital status|Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.
214552483|NCT02107976|DIETARY_SUPPLEMENT|Vitamin E|400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
214552484|NCT02107976|DIETARY_SUPPLEMENT|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
214552485|NCT06205498|DRUG|acalabrutinib|patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
214552486|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
214552487|NCT04748042|DRUG|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
214552488|NCT04748042|DRUG|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
214552489|NCT04748042|RADIATION|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
214552490|NCT04748042|BIOLOGICAL|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
214552491|NCT04748042|DRUG|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
214702212|NCT01653158|DRUG|Docetaxel|Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
214702213|NCT02469792|PROCEDURE|Liposuction|
214702214|NCT02469792|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
214702215|NCT02469792|PROCEDURE|Arthroscopic surgery|
214702216|NCT02469792|OTHER|Intraarticular administration of autologous ADRC|
214702217|NCT04659434|DRUG|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
214702218|NCT03497234|DIAGNOSTIC_TEST|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
214702219|NCT03415763|DRUG|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
215029692|NCT01652404|BEHAVIORAL|Conventional treatment|The antibiotics duration will be determined by treating physician.
215029693|NCT01758120|DRUG|prednisone plus cyclophosphamide|"1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
215029694|NCT01758120|DRUG|Prednisone alone|"1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
215029695|NCT03327129|PROCEDURE|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
215029696|NCT02311504|DEVICE|OCT examination|
215029697|NCT01648933|RADIATION|Rubidium PET|Myocardial Perfusion Imaging
214702220|NCT03415763|DRUG|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
215161953|NCT06446882|OTHER|Treatment by physician´s choice, blinded to the diagnostic HER2DX test results|Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
214552492|NCT06538844|DRUG|Intravenous infusion of human albumin|Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
214552493|NCT06538844|DRUG|Saline|Equivalent volume of isotonic saline control
215161954|NCT01701674|DRUG|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
214552494|NCT04383847|BEHAVIORAL|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
214552495|NCT01161381|DEVICE|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
214552496|NCT01225380|DRUG|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
214552497|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
214552498|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
214552499|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
214552500|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
214552501|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
214552502|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
214552503|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
214552504|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
214552505|NCT01225380|DRUG|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
214552506|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
214702221|NCT06322524|DEVICE|Gamma sensory flicker|participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
214702222|NCT00421603|DRUG|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
214702223|NCT00421603|DRUG|Placebo|Placebo
214552507|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), 48 weeks
214552508|NCT03931746|DEVICE|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
214552509|NCT05454813|DEVICE|Wetness Sensing System Validation|Participants will use the Wetness Sensing System in a simulated setting in the sitting, supine and side position (participants are randomized to either the left or right side position).
214552510|NCT02758743|DRUG|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
214552511|NCT02758743|DRUG|Placebo|Placebo with no active substance will not have the effect on intervention device.
214552512|NCT04678531|DRUG|Swabs containing tea tree oil and chamomile oil|Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
214552513|NCT04678531|DRUG|Baby shampoo|Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
214552514|NCT00910286|OTHER|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
214552515|NCT04949802|DEVICE|ViaLase Laser|ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
214552516|NCT02473965|DRUG|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
214552517|NCT02473965|DRUG|Placebo|
214552518|NCT03848039|BIOLOGICAL|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
214552519|NCT03848039|DRUG|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
214702224|NCT00765128|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
214702225|NCT00765128|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
214702226|NCT02217228|DEVICE|Sebacia microparticles and laser|
214702227|NCT02217228|DEVICE|Vehicle suspension and laser|
214702228|NCT02217228|DEVICE|Sebacia microparticles without laser|
214702229|NCT02709928|DRUG|TD-0714|
214702230|NCT02709928|DRUG|Placebo|
214552520|NCT01183390|DRUG|Anastrozole|1 mg Tablets
214552521|NCT01183390|DRUG|Anastrozole|1 mg Tablets
214552522|NCT03816761|DRUG|Fast-acting insulin aspart|In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
214552523|NCT03816761|DEVICE|iLet™|The bionic pancreas including pigtail adapters, used in insulin-only configuration
214552524|NCT04400110|DRUG|Amoxicillin and Clavulanic Acid in Oral Dose Form|50 mg/kg three times daily administered orally
214552525|NCT03384303|OTHER|Standardized meal test|Preoperatively and postoperatively standardized meal test
214552526|NCT04920266|DEVICE|Smart Cap, running and fitness exercisers only|Bottle cap
214552527|NCT04920266|DEVICE|Sweat Patch, all subjects- running, fitness, cycling|Regional contralateral forearm patch
214552528|NCT04920266|DEVICE|Reference sweat patch, all subjects - running, fitness, cycling|Regional contralateral forearm patch
214702231|NCT00965783|OTHER|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
214702232|NCT00965783|OTHER|Extension|Bedtime is extended by 2 hours per night for 4 nights
214552529|NCT04920266|OTHER|Bottle Scale, all subjects - running, fitness, cycling|Bottle weight
214552530|NCT01174069|PROCEDURE|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
214702233|NCT03335956|DRUG|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
214702234|NCT03335956|DRUG|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
214702235|NCT03335956|DRUG|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
214702236|NCT03335956|DRUG|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
214702237|NCT03335956|DRUG|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
214702238|NCT03335956|DRUG|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
214702239|NCT03335956|DRUG|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
214702240|NCT03335956|DRUG|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
214702241|NCT03335956|DRUG|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
214702242|NCT03335956|DRUG|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
214702243|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
214702244|NCT03335956|DRUG|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
214702245|NCT03335956|DRUG|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
214702246|NCT03335956|DRUG|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
214702247|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
214702248|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
214702249|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
214702250|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
215029698|NCT05536115|DEVICE|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
214552531|NCT00128297|DRUG|Pamidronate|
214552532|NCT02952859|OTHER|Irreversible electroporation|
214552533|NCT01507649|BEHAVIORAL|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
214552534|NCT01255254|PROCEDURE|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
214552535|NCT01240551|DRUG|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
214552536|NCT00398190|BEHAVIORAL|Control|Standard anti-tobacco programming
214552537|NCT00398190|BEHAVIORAL|Media Literacy|Anti-smoking media literacy curriculum intervention
214552538|NCT04331483|OTHER|Physical activity program|"Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge."
214552539|NCT04266015|DIETARY_SUPPLEMENT|Enteral nutrition formula|Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
214552540|NCT05648487|DRUG|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy."
214552541|NCT04403542|DEVICE|Lehfilcon A contact lens|Investigational silicone hydrogel contact lens
214702251|NCT01157052|OTHER|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)"
214702252|NCT01866761|PROCEDURE|Periodontal treatment|
214702253|NCT03444870|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
214702254|NCT03444870|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
214702255|NCT02284685|BEHAVIORAL|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
214702256|NCT00046176|DRUG|abacavir/lamivudine|
214702257|NCT00046176|DRUG|abacavir|
214702258|NCT00046176|DRUG|lamivudine|
214702259|NCT05783193|DRUG|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
214702260|NCT05783193|DRUG|Placebo|Placebo capsules
214702261|NCT02209311|PROCEDURE|Oral mucosa biopsy|
214702262|NCT02209311|PROCEDURE|Sinus lift with implantation of tissue engineered construction|
214702263|NCT02209311|DEVICE|Dental implant|
214702264|NCT03090464|OTHER|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
214702265|NCT01560221|BEHAVIORAL|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
214702266|NCT01560221|DRUG|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
214702267|NCT01560221|DRUG|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
214552542|NCT04403542|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
214552543|NCT02981927|OTHER|Physical inactivity|
214552544|NCT03191513|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
214702268|NCT04248790|BEHAVIORAL|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
214702269|NCT02912598|DEVICE|Mallinckrodt™ Endobronchial Tube|
214702270|NCT02912598|DEVICE|Fuji Uniblocker™|
214702271|NCT02912598|DEVICE|ETView VivaSight™-SL+EB|
214702272|NCT02912598|DEVICE|COOK© Arndt Endobronchial Blocker|
214702273|NCT05263817|BIOLOGICAL|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
214702274|NCT06386809|DEVICE|TAVNS|TAVNS is a recently introduced treatment involving transcutaneous electrical stimulation of the auricular branch of the vagus nerve with VAGUSTIM device.
214702275|NCT06386809|OTHER|Exercise program|Rocabado 6x6 exercises will be applied in our study. Rocabado exercise, which is the most commonly used exercise method in the literature, is a set of exercises for the craniocervical and craniomandibular system.
214702276|NCT01583985|OTHER|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
214702277|NCT01583985|OTHER|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
214702278|NCT05261880|OTHER|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
214702279|NCT05261880|OTHER|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
214702280|NCT06554002|OTHER|Control|Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
214702281|NCT06554002|OTHER|Treatment|Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
214552545|NCT03191513|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
214552546|NCT03191513|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
214552547|NCT03325790|DRUG|200mg SPI-1005 BID|Active: low dose
214552548|NCT03325790|DRUG|400mg SPI-1005 BID|Active: high dose
214552549|NCT03325790|OTHER|Placebo|Placebo Comparator
214552550|NCT05864651|OTHER|Tele-exercise program|The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program
214552551|NCT05864651|OTHER|Conventional Fencing Exercise|The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite \& Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
214552552|NCT04198155|RADIATION|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
214552553|NCT01730950|BIOLOGICAL|bevacizumab|Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.
214552554|NCT01730950|RADIATION|radiation therapy|Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
214552555|NCT00336518|DRUG|peginterferon alfa-2a|
214552556|NCT00336518|DRUG|ribavirin|
214702282|NCT03598738|DRUG|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
214702283|NCT04198103|DEVICE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
214702284|NCT00101491|BEHAVIORAL|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
214702285|NCT00701155|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
214702286|NCT05677191|DEVICE|Proximal Femoral Nail|open reduction
214702287|NCT05677191|COMBINATION_PRODUCT|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
214702288|NCT02658201|DEVICE|MRI|Ultrafast MRI to assess constipation
214552557|NCT06249997|DRUG|Leniolisib|The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
214552558|NCT00006501|PROCEDURE|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
214552559|NCT04091698|DRUG|Co-Enzyme Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
214552560|NCT05591053|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
214552561|NCT05168462|DRUG|Reduced noradrenaline use|Reduced noradrenaline by using a lower MAP target
214552562|NCT02080962|RADIATION|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
214552563|NCT02080962|RADIATION|40 Gy in 10 fractions|tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
214552564|NCT04317378|DEVICE|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
214552565|NCT03689634|DEVICE|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
215161955|NCT01701674|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging \[MRI\] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
215161956|NCT01701674|DRUG|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
214552566|NCT00243594|BIOLOGICAL|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
214702289|NCT01170702|DRUG|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
214702290|NCT01170702|DRUG|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
214702291|NCT01170702|DRUG|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
214702292|NCT01170702|DRUG|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
214702293|NCT02590887|DIETARY_SUPPLEMENT|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
214702294|NCT01682577|DRUG|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
215161957|NCT01701674|DRUG|Cyclophosphamide as Part of Lymphodepletion|
214552567|NCT00396695|PROCEDURE|Blood test|
214552568|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
214552569|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
214552570|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
214552571|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
214552572|NCT00667459|DEVICE|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
214552573|NCT00667459|DEVICE|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
214552574|NCT04822779|DEVICE|Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands|"Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
214552575|NCT04822779|OTHER|Placebo|"Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
214552576|NCT04851158|DEVICE|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
215161958|NCT01701674|DRUG|Fludarabine as Part of Lymphodepletion|
214552577|NCT04851158|DEVICE|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
214552578|NCT05174533|OTHER|Data collection|electrocardiogram
214552579|NCT05914870|OTHER|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~* 10 minutes of joint mobility exercises and dynamic stretching.~* 20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~* 20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~* 10 minutes of cool down and static stretching."
214552580|NCT05914870|OTHER|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
214552581|NCT02155270|PROCEDURE|Corneal precut 600µm|
214552582|NCT02155270|PROCEDURE|Corneal stabincision|
214552583|NCT02568397|DRUG|Lanabecestat|Administered orally
214552584|NCT02568397|DRUG|Dabigatran etexilate|Administered orally
214552585|NCT03708497|DRUG|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
214552586|NCT03708497|DRUG|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
214552587|NCT03708497|DRUG|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
214552588|NCT03863977|DRUG|Dexamethasone|After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
214552589|NCT03863977|DRUG|Bupivacaine|After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
214552590|NCT03647904|BEHAVIORAL|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
214552591|NCT01627535|OTHER|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
214552592|NCT06155188|PROCEDURE|applying of FLU+CY post-HSCT|The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
214552593|NCT00721201|DRUG|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
214552594|NCT00821262|DRUG|sevoflurane|
214552595|NCT00821262|DRUG|propofol|
214552596|NCT03715777|DRUG|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
214552597|NCT05169892|PROCEDURE|Aquablation|Aquablation
214552598|NCT01200342|DRUG|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
214552599|NCT01200342|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
214552600|NCT01200342|DRUG|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
214552601|NCT05459155|OTHER|Synapse medicine platform|Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
214552602|NCT02748889|DRUG|Carboplatin|Standard chemotherapy
214552603|NCT02748889|DRUG|Etoposide|Standard chemotherapy
214552604|NCT02748889|BIOLOGICAL|MPDL3280A|Experimental biologic
214552605|NCT04747223|OTHER|Run Gait Retraining|Running step rate will be retrained by real-time biofeedback via a watch accelerometer. Recent literature showed that performing gait retraining by altering step rate reduces loading rates and joint stress that are associated with lower extremity injuries (Wilson et al 2014, Lenhart et al 2014, Heidersheit et al 2011).
214552606|NCT03065140|OTHER|Training or detraining|A period of detraining or a supervised exercise program.
214702295|NCT01682577|DRUG|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
215161959|NCT01701674|DRUG|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
214552607|NCT04546217|COMBINATION_PRODUCT|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
214552608|NCT04546217|DEVICE|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
214552609|NCT00258739|DRUG|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
214552610|NCT00258739|OTHER|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
214552611|NCT02086318|OTHER|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
214552612|NCT00297921|DRUG|tandutinib|
214552613|NCT03684564|DRUG|Rivaroxaban|Oral tablet 15 mg twice daily for 24 months
214552614|NCT03684564|DRUG|Warfarin|Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
214552615|NCT05314270|DIAGNOSTIC_TEST|Diagnostic tests|Diaagnostic tests for all pt diagnosed as Non-B Non-C Liver Cirrhosis
214552616|NCT00598845|PROCEDURE|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
214552617|NCT02223910|PROCEDURE|Neurofeedback training of functional connectivity|
214552618|NCT05429242|OTHER|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
214552619|NCT05141851|DEVICE|Implants with 0,7 mm threads|Implants were placed, with threads of 0.7 mm in the location of premolars and molars.
214552620|NCT05141851|DEVICE|Implants with 0.3 mm threads|Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
214552621|NCT04358770|DRUG|Clocortolone Pivalate|Cream, 0.1%
214552622|NCT05083390|DRUG|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
214552623|NCT04292704|RADIATION|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m
214552624|NCT04292704|DRUG|Clotrimazole|Clotrimazole vaginal tablets
214552625|NCT00570284|DRUG|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
214552626|NCT03235700|OTHER|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
214552627|NCT03235700|OTHER|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
214552628|NCT02550938|DEVICE|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
214552629|NCT05102877|DEVICE|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
215161960|NCT01701674|BIOLOGICAL|Adoptive Cell Therapy with TIL|
215161961|NCT06417814|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
215161962|NCT06417814|DRUG|Osimertinib|Osimertinib will be administered orally.
214552630|NCT02294357|DRUG|Carfilzomib|
214552631|NCT02294357|DRUG|Dexamethasone|If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
214702296|NCT01951690|DRUG|defactinib (VS-6063)|
214702297|NCT02729948|OTHER|Survey Administration|Ancillary studies
215161963|NCT06417814|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
215161964|NCT06417814|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
214702298|NCT02729948|DEVICE|Tethered Capsule Endoscope|Undergo TCE
214702299|NCT03798184|PROCEDURE|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
214702300|NCT01677507|DRUG|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
214702301|NCT00005812|DRUG|temozolomide|
214702302|NCT00571688|DRUG|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
215161965|NCT06417814|DRUG|Cisplatin|Cisplatin will be administered as IV infusion.
215161966|NCT01199978|RADIATION|Fractionated proton radiation|Given daily for approximately 5.5 weeks
215161967|NCT01199978|DRUG|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
215161968|NCT06526286|OTHER|Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)|Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.
215161969|NCT04534205|BIOLOGICAL|BNT113|IV injection
214552632|NCT02294357|DRUG|Prednisone|f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
214552633|NCT02294357|DRUG|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
214552634|NCT02294357|DRUG|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
214552635|NCT02294357|DRUG|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
214552636|NCT04411004|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
214552637|NCT04411004|BEHAVIORAL|5-point Likert scale|Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
214552638|NCT04131816|BEHAVIORAL|HeartHome|The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
214552639|NCT01860599|BEHAVIORAL|Exercise|150 minutes of moderate exercise per week
214552640|NCT01860599|BEHAVIORAL|Without exercise|Pre-study activity level (i.e. no exercise)
214552641|NCT03854747|OTHER|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
214552642|NCT01484431|DRUG|Tadalafil- Tablet or Oral suspension|Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
214552643|NCT01703728|OTHER|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
214552644|NCT03085836|DRUG|TAK-438|TAK-438 tablets.
214702303|NCT00571688|DRUG|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
214702304|NCT04362449|COMBINATION_PRODUCT|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
214702305|NCT04362449|COMBINATION_PRODUCT|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
214702306|NCT04761029|OTHER|RIIS|unilateral Rhomboid intercostal and subserratus block
214702307|NCT04761029|DRUG|Tramadol|intravenous patient-controlled analgesia (tramadol)
214702308|NCT00870285|RADIATION|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
214702309|NCT02603354|DRUG|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
214702310|NCT06446414|BEHAVIORAL|Choose to Move|As described under study arm description
214702311|NCT04343209|DIAGNOSTIC_TEST|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
214702312|NCT04343209|DRUG|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
214702313|NCT03428802|OTHER|Laboratory Biomarker Analysis|Correlative studies
214702314|NCT03428802|BIOLOGICAL|Pembrolizumab|Given IV
215161970|NCT04534205|BIOLOGICAL|Pembrolizumab|IV infusion
215161971|NCT04071236|DRUG|Avelumab|Given IV
215161972|NCT04071236|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215161973|NCT04071236|PROCEDURE|Bone Scan|Undergo bone scan
214552645|NCT03683992|DEVICE|Triathlon total knee system|Implantable
214552646|NCT01004887|OTHER|diagnostic laboratory biomarker analysis|
214552647|NCT00894400|PROCEDURE|catheter ablation|catheter ablation using radiofrequency energy
214552648|NCT04559321|PROCEDURE|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
214552649|NCT03251092|DRUG|PTI-808|Active
214552650|NCT03251092|DRUG|Placebo|Placebo
214552651|NCT03251092|DRUG|PTI-428|Active
214552652|NCT03251092|DRUG|PTI-801|Active
214702315|NCT00282269|PROCEDURE|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
214552653|NCT04374747|BEHAVIORAL|Dietary Counseling|The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
214552654|NCT02751749|BEHAVIORAL|Unified Protocol|
214552655|NCT05464407|DIETARY_SUPPLEMENT|Cubitan|2 bottles of Cubitan daily, for 12 weeks.
214702316|NCT02524756|PROCEDURE|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
214702317|NCT02524756|PROCEDURE|laparoscopic radical hysterectomy (type III/C2).|
214702318|NCT04161274|PROCEDURE|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
214708969|NCT04260061|DEVICE|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
214708970|NCT03997929|DIAGNOSTIC_TEST|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
215161974|NCT04071236|PROCEDURE|Computed Tomography|Undergo CT
215161975|NCT04071236|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161976|NCT04071236|DRUG|Peposertib|Given PO
215161977|NCT04071236|OTHER|Questionnaire Administration|Ancillary studies
215161978|NCT04071236|RADIATION|Radium Ra 223 Dichloride|Given IV
214708971|NCT03483116|BIOLOGICAL|RV3-BB|Oral administration
214708972|NCT03483116|BIOLOGICAL|Placebo|Oral administration
214708973|NCT02703987|OTHER|Fermented infant milk formula|
214708974|NCT02703987|OTHER|Non-fermented infant milk formula|
215161979|NCT05604170|DRUG|Ganaxolone|GNX will be administered.
215161980|NCT04727307|DRUG|Atezolizumab (neoadjuvant)|Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
215161981|NCT04727307|PROCEDURE|Percutaneous Radiofrequency|Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
215161982|NCT04727307|DRUG|Bevacizumab (adjuvant)|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
215161983|NCT04727307|DRUG|Atezolizumab (adjuvant)|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
215161984|NCT05561556|DIETARY_SUPPLEMENT|MitoQ|One 20mg capsule daily for 8 weeks
215161985|NCT01362803|DRUG|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
215161986|NCT06952816|DEVICE|Emily.AI|EMILY.AI is composed of an O2 regulating valve together with an intelligent system, EDGE computing, which allows the automation in the regulation of O2 and its customization.
214552656|NCT01065467|DRUG|LBH589|Taken orally three times per week.
214552657|NCT01888874|DRUG|GLPG0634|GLPG0634 capsules.
214552658|NCT01888874|DRUG|Placebo|Placebo capsules.
214552659|NCT04897204|PROCEDURE|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
214552660|NCT04897204|PROCEDURE|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
214552661|NCT03550469|DEVICE|Computer-assisted Oxygen Weaning|Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
214702319|NCT04161274|PROCEDURE|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
214702320|NCT04161274|PROCEDURE|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
214702321|NCT04161274|PROCEDURE|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
214702322|NCT04538885|BIOLOGICAL|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
214702323|NCT00190983|DRUG|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
214702324|NCT02856685|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
214702325|NCT02287402|DRUG|AO-128|AO-128 tablet
214702326|NCT01284270|OTHER|Cardiac MRI|Cardiac MRI
214702327|NCT02182141|DRUG|BIBF 1120 ES|
214702328|NCT01844830|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
214702329|NCT01844830|DRUG|Placebo|Inactive ingredients supplied in identical nasal sprayer
214702330|NCT04247815|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
214702331|NCT04247815|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
214702332|NCT04247815|DRUG|Methotrexate|7.5 mg to 25 mg weekly
214702333|NCT05859048|DIAGNOSTIC_TEST|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
214702334|NCT05859048|DIAGNOSTIC_TEST|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
214702335|NCT05859048|DIAGNOSTIC_TEST|electrocardiogram|tracing of electrical cardiac activity of the heart
214702336|NCT05859048|OTHER|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
214702337|NCT02170649|DRUG|BIA 2-093|
214552662|NCT05037747|BEHAVIORAL|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
214552663|NCT01060891|DRUG|colimycin|
214552664|NCT02763215|DRUG|Standard of Care Medications|Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
214552665|NCT00347698|DRUG|intravitreal injection of bevacizumab|
214552666|NCT00347698|PROCEDURE|panretinal photocoagulation|
214552667|NCT04420247|DRUG|Chloroquine|5 days of treatment with Chloroquine + Standard Care
214552668|NCT04420247|DRUG|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
214702338|NCT01916616|BEHAVIORAL|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
214702339|NCT00502320|DRUG|Ramelteon|one 8 mg tablet at bed for up to 4 months
214702340|NCT00502320|DRUG|Placebo|one tablet at bedtime for up to 4 months
214702341|NCT03734952|RADIATION|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
214702342|NCT03734952|DRUG|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
214552669|NCT04420247|OTHER|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
214552670|NCT00903825|PROCEDURE|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (\< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
214552671|NCT00903825|PROCEDURE|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
215161987|NCT06819176|DRUG|Lenacapavir|Lenacapavir (Sunlenca) is a prescription drug approved by the Food and Drug Administration (FDA) for the treatment of people living with multidrug-resistant HIV. Lenacapavir is always used as part of a combination ART regimen. Participants will receive lenacapavir at 927 mg by subcutaneous injection (2x1.5 mL injections) on day 0 and 600 mg orally (2x300 mg tablets) on days 0 and 1, followed by 927 mg by subcutaneous injection (2x1.5 mL injections) at weeks 24 and 48.
215161988|NCT03866382|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215161989|NCT03866382|PROCEDURE|Bone Scan|Undergo bone scan
215161990|NCT03866382|DRUG|Cabozantinib S-malate|Given PO
215161991|NCT03866382|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
214552672|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
214552673|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
214552674|NCT05302440|DEVICE|remote real-time health monitoring system with ring-like sensor|The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
214552675|NCT00475644|DRUG|Enzastaurin|Administered orally
214552676|NCT02858570|BIOLOGICAL|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
214552677|NCT02858570|BIOLOGICAL|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
214552678|NCT03969680|BIOLOGICAL|Auotologous BMSCs plus autologous PRP|30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
214552679|NCT03969680|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
214552680|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
214552681|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
214552682|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneous
214552683|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
214552684|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
214702343|NCT03734952|PROCEDURE|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
214702344|NCT03734952|RADIATION|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
214702345|NCT04849819|DRUG|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
214702346|NCT00796133|DRUG|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
214702347|NCT05511818|DIETARY_SUPPLEMENT|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
214552685|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
214702348|NCT04810585|DRUG|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
214702349|NCT01508494|DRUG|Galantamine|16 mg galantamine daily P/O
214702350|NCT01508494|DRUG|placebo|placebo
214702351|NCT03213977|DRUG|R-DA-EPOCH|R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
214702352|NCT03213977|DRUG|R-CEOP90|R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
214552686|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
214552687|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneously
214702353|NCT04731623|DRUG|ION904|ION904 will be administered by SC injection.
214552688|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
214552689|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
214552690|NCT00600327|DEVICE|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
214702354|NCT04731623|DRUG|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
214702355|NCT02854553|PROCEDURE|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
214702356|NCT02854553|PROCEDURE|rectus sheath block|ultrasound guided rectus sheath block
214702357|NCT01932281|DIETARY_SUPPLEMENT|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
214702358|NCT01932281|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
214702359|NCT00344955|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
214702360|NCT04220385|OTHER|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
214702361|NCT04220385|OTHER|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
214552691|NCT00600327|DEVICE|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
214552692|NCT03063684|DEVICE|Fractional / Pixel CO2 Laser|"The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application."
214552693|NCT01155414|OTHER|Hydrolysate based infant formula|Infant formula ad lib
214552694|NCT01155414|OTHER|Investigational Infant Formula A|Investigational infant formula ad lib
214552695|NCT01155414|OTHER|Investigational Infant Formula B|Investigational infant formula ad lib
214552696|NCT00790387|DRUG|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
214552697|NCT00790387|DRUG|Tirofiban|
214552698|NCT00790387|DRUG|unfractionated heparin|
214552699|NCT05147870|PROCEDURE|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
214552700|NCT05147870|PROCEDURE|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
214552701|NCT00429013|DEVICE|Tongue Display Unit|lingual electric stimulation
214552702|NCT04395170|BIOLOGICAL|COVID-19 convalescent plasma|Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
214552703|NCT04395170|BIOLOGICAL|Anti-COVID-19 human immunoglobulin|"Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met."
214552704|NCT04395170|DRUG|Standard (specific) therapy for COVID-19|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
214552705|NCT06381167|PROCEDURE|Endoscopic Decompressive Laminectomy|the patients will undergo block randomization for either endoscopic or microscopic decompression
214552706|NCT01853501|PROCEDURE|Autologous fat grafting|ADSC ovary injection
214552707|NCT01976273|DEVICE|1064nm Q-switch Laser|
214552708|NCT01976273|OTHER|Glycolic Acid Peels|
214552709|NCT02571088|OTHER|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
214552710|NCT06156553|BEHAVIORAL|PULSE school-based intervention|"PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?"
214552711|NCT00725270|DRUG|Mifepristone|600 mg of mifepristone
214552712|NCT00725270|DRUG|Placebo Oral Tablet|Placebo comparator
214552713|NCT02980042|DRUG|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
214552714|NCT02980042|DRUG|Rituximab|A chimeric monoclonal antibody against CD20.
214552715|NCT02958605|DEVICE|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
214552716|NCT02958605|DEVICE|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
214552717|NCT02301377|DEVICE|Spiro PD personal spirometer|
214552718|NCT04962529|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
214552719|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom.|Ingredients: celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
214552720|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
214552721|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
214552722|NCT05594329|OTHER|Control instant noodle soup|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
214702362|NCT03332901|OTHER|this is an observational study, no intervention required|this is an observational study, no intervention required
214702363|NCT03755284|OTHER|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
215161992|NCT03866382|PROCEDURE|Echocardiography Test|Undergo echocardiography
214552723|NCT05640492|BEHAVIORAL|Metacognitive Training for Depression in Later Life (MCT-Silver)|"MCT-Silver consists of eight modules, each of which begins with psychoeducational and normalizing elements. A mastery is presented through examples and exercises, and the fallibility of human cognition is discussed and illustrated. In a second phase, the pathological extremes of each cognitive bias are highlighted and the participant is shown how the exacerbation of (normal) thinking biases can lead to problems in daily life. It is intended with this exercise that participants learn how to identify and mitigate cognitive traps. Dysfunctional coping strategies (social isolation and negative thoughts) are highlighted, and suggestions for replacing them with adaptive strategies are given. Homework assignments are distributed at the end of each session (Schneider et al., 2018)."
214552724|NCT05549492|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present."
214552725|NCT06062004|PROCEDURE|Small Incision Lenticule Extraction (SMILE)|"All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~* Cap thickness of 120 μm~* Cap diameter of 1 mm larger than the lenticule diameter~* Cap side cut angle 70°~* 3 mm incision positioned at 100° and angled at 45°~* Transition zone of 0.1 mm and clearance of 0.5 mm~* Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm"
214552726|NCT05410080|DIAGNOSTIC_TEST|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
214552727|NCT00769600|DRUG|Itraconazole|Itraconazole 200 mg once daily
214552728|NCT00769600|DRUG|Pemetrexed|Pemetrexed every 21 days.
214552729|NCT02673632|DRUG|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
214552730|NCT03798275|DIETARY_SUPPLEMENT|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
214552731|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with double-lumen tube)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, a double-lumen tube will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
214552732|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with endobronchial blocker)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, endotracheal tube-bronchial blocker will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
214552733|NCT03205670|PROCEDURE|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
214702364|NCT05468723|DEVICE|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses \[which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)\] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
214702365|NCT05091294|OTHER|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
214702366|NCT04556370|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
214702367|NCT04556370|DRUG|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
214702368|NCT02769351|DEVICE|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
214702369|NCT02813759|OTHER|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
214702370|NCT02813759|OTHER|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
214702371|NCT05723315|DRUG|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
214702372|NCT04683107|OTHER|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
214702373|NCT04683107|OTHER|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
214702374|NCT02881983|OTHER|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
214708975|NCT02360553|BEHAVIORAL|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
214708976|NCT02360553|BEHAVIORAL|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
214708977|NCT06980077|PROCEDURE|Biopsy Procedure|Undergo biopsy
214708978|NCT06980077|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214708979|NCT06980077|PROCEDURE|Computed Tomography|Undergo CT
215029699|NCT06205693|PROCEDURE|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
215161993|NCT03866382|BIOLOGICAL|Ipilimumab|Given IV
214702375|NCT04786132|OTHER|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
214702376|NCT04786132|OTHER|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
214552734|NCT01473277|DRUG|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
214552735|NCT00269412|DRUG|Rifaximin|
214552736|NCT04342143|DEVICE|Blood pressure and ultrasound assessment|No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
214552737|NCT01653938|BEHAVIORAL|video decision aid|
214552738|NCT04237389|PROCEDURE|Ablation Index Guided endocardial catheter radiofrequency ablation|Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
214552739|NCT04237389|PROCEDURE|minimally invasive thoracoscopic surgical epicardial ablation.|"Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA."
214552740|NCT02749097|DRUG|SHR0534|
214552741|NCT02749097|DRUG|Placebo|
214552742|NCT05917353|DIETARY_SUPPLEMENT|Hinex Jelly|"1. Name: Hinex Jelly~2. Dosage form: Semi-solid jelly/ A-114001297-00000-2~3. Dose(s): 300g/pack (per serving)~4. Dosing schedule: one pack (serving) per day~5. Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food."
214552743|NCT02349997|OTHER|no interventions|This is an observational study and no intervention applied.
214552744|NCT06297720|BEHAVIORAL|Oral hydration|"* Researchers moisten the patient's throat with a wet cotton swab. If no nausea or vomiting occurs after five minutes, proceed to the next stage.~* Provide an ice cube of potable water for the patient to hold in their mouth. If no nausea or vomiting occurs after ten minutes, proceed to the next stage.~* Offer 10-20ml of potable water for the patient to drink under medical supervision. If no nausea or vomiting occurs and the patient requests more water, administer 10-20ml every ten minutes, assessing for any adverse effects each time. The total water intake should not exceed 500ml."
214552745|NCT05916703|DIAGNOSTIC_TEST|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
214552746|NCT01125033|DRUG|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
214552747|NCT01125033|DRUG|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
214552748|NCT01125033|DRUG|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
214552749|NCT01125033|DRUG|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
214552750|NCT03473353|OTHER|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
214552751|NCT01483144|DRUG|Eflornithine|Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
214552752|NCT01483144|DRUG|Eflornithine Placebo|Eflornithine placebo \[three tablets orally once a day\]
214552753|NCT01483144|DRUG|Sulindac 150 MG|Sulindac \[one tablet orally once a day\]
214552754|NCT01483144|DRUG|Sulindac placebo|Sulindac placebo \[one tablet orally once a day\]
214552755|NCT05959798|PROCEDURE|High power short duration ablation|Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
214552756|NCT06056843|OTHER|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.|Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
214552757|NCT02460575|BIOLOGICAL|Lactobacillus reuteri 17938|probiotic
214552758|NCT02460575|BIOLOGICAL|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
214702377|NCT04380974|PROCEDURE|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
214552759|NCT02883595|DRUG|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
214552760|NCT02883595|OTHER|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
214552761|NCT00734136|PROCEDURE|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
214552762|NCT00734136|PROCEDURE|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
214552763|NCT03192345|BIOLOGICAL|SAR439459|"Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion"
214552764|NCT03192345|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
214552765|NCT02499939|BEHAVIORAL|Standard Care|Education and home exercises
214552766|NCT02499939|OTHER|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
214552767|NCT03251729|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
214552768|NCT03251729|DRUG|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
214552769|NCT02339623|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound~2. \- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~3. \- CL measurement using 2D ultrasound"
214552770|NCT03663907|PROCEDURE|Telemonitoring|"The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily."
214552771|NCT01901822|PROCEDURE|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
214552772|NCT01901822|PROCEDURE|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
214552773|NCT01278706|PROCEDURE|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
214708980|NCT06980077|BIOLOGICAL|Ivonescimab|Given IV
214708981|NCT06980077|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214708982|NCT06980077|OTHER|Questionnaire Administration|Ancillary studies
214552774|NCT05519566|DIAGNOSTIC_TEST|Retrograde Urethrogram|Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram
214552775|NCT04940364|DRUG|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
214552776|NCT04940364|DRUG|Cemdisiran|Administered SC per protocol
214552777|NCT03158909|DEVICE|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
214552778|NCT03158909|OTHER|Orientation about space and time|Information and orientation about space and time, given every night.
214552779|NCT02211547|DEVICE|Epic 10 Diode Laser by Biolase Inc.|
214552780|NCT02211547|OTHER|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
214552781|NCT00425607|DRUG|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
214552782|NCT00079339|RADIATION|radiation therapy|Undergo radiotherapy
214552783|NCT00079339|DRUG|tipifarnib|Given orally
214552784|NCT02563548|DRUG|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
214552785|NCT02563548|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
214552786|NCT06109610|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
214552787|NCT05332470|DRUG|Lamivudine and Dotiravir Sodium Tablets|3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)
214552788|NCT02453243|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
214552789|NCT02453243|BEHAVIORAL|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
214552790|NCT00520845|DRUG|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
214552791|NCT00520845|DRUG|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
214552792|NCT00520845|DRUG|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
214552793|NCT00520845|OTHER|laboratory biomarker analysis|Blood collection
214552794|NCT02946671|BIOLOGICAL|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
214552795|NCT02946671|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
214702378|NCT04380974|PROCEDURE|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
214702379|NCT04380974|DRUG|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
214702380|NCT03083509|OTHER|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
214702381|NCT03083509|OTHER|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
214702382|NCT03083509|OTHER|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
214702383|NCT05397483|BEHAVIORAL|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
214702384|NCT05397483|BEHAVIORAL|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
214708983|NCT03267771|DRUG|Progesterone Suppositories Vaginal|progesterone vaginal suppository
214552796|NCT01233661|OTHER|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
214552797|NCT05573581|DRUG|Botox|Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
214552798|NCT05096039|DRUG|Sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
214552799|NCT05096039|DRUG|ACEI or ARB and no sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
214552800|NCT03267446|DEVICE|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
214702385|NCT00084929|PROCEDURE|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
214702386|NCT06443476|PROCEDURE|Tenting abutment technique|To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible.
214702387|NCT06443476|PROCEDURE|Tent pole technique|using the Tent pole technique to gain bone vertical and horizontal loss
214702388|NCT00913133|DRUG|Desirudin|Desirudin SC 15mg q12h
214552801|NCT03453697|DEVICE|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
214552802|NCT02294851|DRUG|BMS-986168|
214552803|NCT02294851|DRUG|BMS-986168 Placebo|
214552804|NCT01686867|DEVICE|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
214552805|NCT01189110|DEVICE|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
214552806|NCT02420249|BEHAVIORAL|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
214552807|NCT04710199|DRUG|Maraviroc experimental group|300-milligram dose of the drug two times daily , oral way. During 14 days.
214552808|NCT04710199|OTHER|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
214552809|NCT01210326|PROCEDURE|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
214552810|NCT01210326|PROCEDURE|testicular sperm extraction|testicular sperm extraction
214702389|NCT06003257|OTHER|stainless steel crown|stainless steel full coverage crown for deciduous teeth
214702390|NCT06003257|OTHER|zirconia crown|zirconia full coverage crown for deciduous teeth
214702391|NCT06003257|OTHER|fiberglass crown|fiberglass full coverage crown for deciduous teeth
214702392|NCT02892838|DEVICE|mobile bearing knee system for total knee arthroplasty|
214702393|NCT02892838|DEVICE|fixed bearing total knee prosthesis|
214702394|NCT05380934|DRUG|TQH3821 tablets|TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
214702395|NCT05380934|DRUG|TQH3821 tablets (Placebo)|TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
214702396|NCT05380934|DRUG|Methotrexate tablets|Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
214552811|NCT01210326|PROCEDURE|testicular sperm aspiration|testicular sperm aspiration
214552812|NCT01322191|DRUG|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
214552813|NCT03274453|DRUG|Ketamine|0.12 mg/kg/hr of ketamine post surgery
214702397|NCT01404026|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
214552814|NCT03274453|DRUG|Saline|Saline will be administered at the same rate as the ketamine infusion.
214552815|NCT00390260|DRUG|MK0966 / Duration of Treatment: 1 Days|
214702398|NCT02175173|DRUG|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
214702399|NCT03645772|OTHER|Exercise intervention|12-week progressive training intervention
214702400|NCT04020146|OTHER|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
214702401|NCT06490419|DEVICE|Electrolipolysis|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute."
214708984|NCT03267771|DRUG|Dydrogesterone Oral Tablet|oral progesterone drug
214702402|NCT06490419|DEVICE|ultrasound cavitation|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes."
214552816|NCT00390260|DRUG|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
214552817|NCT00390260|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
214552818|NCT02503319|DRUG|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
214552819|NCT02503319|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
214552820|NCT02503319|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
214552821|NCT00583466|DRUG|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
214552822|NCT00583466|DRUG|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
214702403|NCT00777231|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
214552823|NCT00583466|DRUG|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
214552824|NCT01732549|DRUG|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
214552825|NCT01732549|DRUG|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
214552826|NCT01516749|DRUG|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
214702404|NCT02118857|OTHER|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
214702405|NCT01548898|DEVICE|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
214552827|NCT00351377|DRUG|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
214552828|NCT00333749|BIOLOGICAL|Drinking or rinsing the mouth 2-3 times for 1 day|
214552829|NCT00333749|BIOLOGICAL|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
214552830|NCT01476683|DRUG|Racecadotril|Film-coated tablet
214552831|NCT01476683|DRUG|Racecadotril|Racecadotril Powder Blend
214552832|NCT01476683|DRUG|Racecadotril|Marketed Capsule
214552833|NCT01476683|DRUG|Racecadotril|Marketed Film-coated Tablet
214552834|NCT03432468|DRUG|Valsartan 1|the high dose of valsartan
214702406|NCT00398385|DRUG|cisplatin|
214552835|NCT03432468|DRUG|Valsartan 80 mg|a single dose of valsartan
214552836|NCT04035980|BEHAVIORAL|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
214552837|NCT04076462|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
214552838|NCT04076462|DRUG|Matching placebo|Matching placebo for CAM2029
214552839|NCT02932930|PROCEDURE|QLB bloc|
214552840|NCT02932930|DRUG|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
214552841|NCT02932930|DRUG|0.9% normal saline|0,2ml/kg of 0.9% normal saline
214552842|NCT04231045|DEVICE|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
214552843|NCT00662597|DRUG|ASA404|
214552844|NCT00662597|DRUG|Placebo|
214552845|NCT00662597|DRUG|carboplatin|
214552846|NCT00662597|DRUG|Paclitaxel|
214552847|NCT05317676|DRUG|Palmitoylethanolamide|2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
214552848|NCT05317676|DRUG|Placebo|2-month supply of placebo will be given upon discharge. Placebo will taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
214552849|NCT04324216|OTHER|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
214552850|NCT02036138|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
214702407|NCT00398385|DRUG|gemcitabine hydrochloride|
214552851|NCT02036138|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
214552852|NCT02036138|DRUG|Advanced Medical Therapy|
214552853|NCT02209090|PROCEDURE|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
214552854|NCT02209090|PROCEDURE|maternal free positions|At least 40 minutes each hour during labour
214552855|NCT00168389|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
214552856|NCT00168389|OTHER|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
214552857|NCT02935803|PROCEDURE|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
214702408|NCT00398385|PROCEDURE|adjuvant therapy|
214702409|NCT00398385|PROCEDURE|conventional surgery|
214702410|NCT00398385|PROCEDURE|neoadjuvant therapy|
214552858|NCT02723227|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
214552859|NCT02723227|BEHAVIORAL|Referral to Social Services|
214552860|NCT04828941|DEVICE|Electronic Headache Diary|The electronic headache diary is an app-based diary that permits the registration of headaches, their acute treatment and their associated work incapacity. It also permits real-time monitoring of these data.
214552861|NCT04828941|DEVICE|Paper Diary|The paper diary permits the registration of the same variables as the electronic diary in paper format.
214552862|NCT05217667|DRUG|ARO-ANG 3 Injection|Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
214552863|NCT05997628|OTHER|Detection of NAD+/NADH concentration of Peripheral Blood Samples|Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.
214552864|NCT01183039|OTHER|Training|20 sessions of training
214552865|NCT01661608|DEVICE|Using the EOS for gastric restriction|
214552866|NCT00001039|DRUG|Ethambutol hydrochloride|
214702411|NCT00731393|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
214702412|NCT00731393|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
214552867|NCT00001039|DRUG|Clarithromycin|
214702413|NCT04233359|PROCEDURE|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
214702414|NCT04233359|PROCEDURE|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
214702415|NCT05055167|DRUG|Envafolimab|single agent, 300mg Q3W IH until disease progressed
214702416|NCT06515769|DIAGNOSTIC_TEST|TERMOGRAPHY|Obtaining an image of the foot using a thermographic camera
214702417|NCT03284008|OTHER|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
214702418|NCT03284008|OTHER|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
214702419|NCT05673473|RADIATION|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
214702420|NCT05256056|DRUG|Bupivacain|efficacy of bupivacaine in different volumes
214702421|NCT00077610|DRUG|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
214702422|NCT00077610|DRUG|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
214552868|NCT05063877|DRUG|Placebo|Matched placebo
214552869|NCT05063877|DRUG|EQU-001|EQU-001 in 10 mg and 20 mg capsules
214552870|NCT03735043|DEVICE|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
214552871|NCT02897505|BEHAVIORAL|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
214552872|NCT03045705|BEHAVIORAL|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
214702423|NCT00077610|DRUG|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
214702424|NCT04068311|OTHER|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
214552873|NCT03045705|BEHAVIORAL|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
214552874|NCT00016588|DRUG|Tenofovir disoproxil fumarate|
214552875|NCT02727244|PROCEDURE|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
214702425|NCT01634321|DRUG|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
214708985|NCT03267771|DEVICE|doppler ultrasound|pulsed doppler ultrasound
215161994|NCT03866382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215161995|NCT03866382|BIOLOGICAL|Nivolumab|Given IV
214702426|NCT03921255|OTHER|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
214702427|NCT02245451|DRUG|Tipranavir|
214702428|NCT02245451|DRUG|Ritonavir|
214702429|NCT02245451|DRUG|Methadone|
214702430|NCT00126789|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
214702431|NCT01921946|DRUG|Fimasartan|
214702432|NCT01921946|DRUG|Rosuvastatin|
214702433|NCT04008901|DRUG|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
214702434|NCT04008901|DRUG|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
214552876|NCT02493062|DEVICE|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
214552877|NCT02805712|OTHER|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
214552878|NCT02805712|OTHER|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
214552879|NCT04355377|OTHER|Non intervention|Non intervention
214552880|NCT04487678|DIETARY_SUPPLEMENT|Ketone ester supplement|Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
214552881|NCT02964702|DEVICE|Thrombectomy Device T-01|
214552882|NCT02492230|DEVICE|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
214552883|NCT02492230|DRUG|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
214552884|NCT00872209|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
214552885|NCT00872209|DRUG|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
214702435|NCT01943422|DRUG|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
214702436|NCT01943422|DRUG|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
214552886|NCT02849613|OTHER|Adipose Derived Stem Cells|
214552887|NCT02849613|OTHER|Vehicle media|
214552888|NCT02106962|DRUG|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
214552889|NCT02106962|OTHER|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
214552890|NCT00280215|DRUG|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
214552891|NCT00280215|DRUG|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
214552892|NCT00280215|DRUG|Placebo|Patients will receive placebo for 24 months
214552893|NCT03845140|DRUG|L-PZQ ODT 50 mg/kg|Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
214702437|NCT05282446|DRUG|INV-202|tablet
214702438|NCT05282446|DRUG|Placebo|matching tablet
214702439|NCT03925194|DRUG|Anakinra|Application of Anakinra once daily for 28 days
214702440|NCT02660619|OTHER|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
214702441|NCT01853111|BIOLOGICAL|Interleukin-2|
214702442|NCT04124042|BIOLOGICAL|XT-150|plasmid DNA
214702443|NCT04124042|DRUG|Placebo|Placebo is a sterile phosphate-buffered saline
215161996|NCT03866382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
215161997|NCT06521086|DIETARY_SUPPLEMENT|Nutrition Supplements - Fresubin KCAL Drinks|Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
214552894|NCT03845140|DRUG|Biltricide®|Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.
214552895|NCT03845140|DRUG|L-PZQ ODT 60 mg/kg|Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
214552896|NCT05043922|DRUG|CYH33|a Selective PI3Kα Inhibitor
214552897|NCT04053998|PROCEDURE|Pancreaticoduodenectomy with portal vein resection|Pancreatic surgery with vein resection to achieve disease clearance.
214552898|NCT02986945|BEHAVIORAL|Resiliency App|
214552899|NCT04324905|DRUG|HIP1802|Test drug
214552900|NCT04324905|DRUG|HGP1705|Reference drug
214702444|NCT04895605|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
214552901|NCT00013585|DRUG|Selegiline hydrochloride|
214552902|NCT02885662|DRUG|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
214552903|NCT04211259|DRUG|Loratadine|Given PO
214552904|NCT04211259|OTHER|Placebo|Given PO
214552905|NCT04211259|OTHER|Questionnaire Administration|Ancillary studies
214552906|NCT04550819|PROCEDURE|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
214702445|NCT04895605|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
214552907|NCT04550819|PROCEDURE|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
214552908|NCT03054337|DRUG|Vadadustat|
214552909|NCT03054337|DRUG|Placebo|
214552910|NCT00200070|DEVICE|Spinal Cord Stimulation|
214552911|NCT01150461|DRUG|losartan|Losartan 50 mg b.i.d
214552912|NCT01150461|DRUG|placebo|Placebo b.i.d.
214552913|NCT01681992|BIOLOGICAL|Priorix|Subjects receive one dose of either minimum (Inv\_MMR\_Min) or medium (Inv\_MMR\_Med) potency lot at Day 0 and a dose of separate potency lot (Inv\_MMR\_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
214552914|NCT01681992|BIOLOGICAL|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
214702446|NCT02143193|BEHAVIORAL|Skin-to-Skin Contact|
214552915|NCT01681992|BIOLOGICAL|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
214552916|NCT01681992|BIOLOGICAL|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
214552917|NCT01681992|BIOLOGICAL|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
214552918|NCT01327612|DRUG|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
214552919|NCT01327612|BIOLOGICAL|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
214552920|NCT01327612|BIOLOGICAL|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
214552921|NCT01327612|BIOLOGICAL|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
214552922|NCT01276808|PROCEDURE|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
214552923|NCT01276808|PROCEDURE|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
214552924|NCT04014244|DRUG|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
214552925|NCT04014244|PROCEDURE|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
214552926|NCT02838979|DIETARY_SUPPLEMENT|First Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
214552927|NCT02838979|OTHER|Washout (3 weeks)|No study product is taken prior to beginning crossover
214552928|NCT02838979|DIETARY_SUPPLEMENT|Second Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
214702447|NCT02628249|DIETARY_SUPPLEMENT|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
214702448|NCT02628249|DIETARY_SUPPLEMENT|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
214702449|NCT02628249|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
214702450|NCT02628249|DIETARY_SUPPLEMENT|Essential amino acids|Essential amino acids modeled after egg protein.
214702451|NCT02628249|DIETARY_SUPPLEMENT|Non essential amino acids|Non essential amino acids modeled after egg protein.
214702452|NCT00139139|BIOLOGICAL|Hepatitis A vaccine|
214702453|NCT04172753|RADIATION|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
214552929|NCT01415934|OTHER|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
214702454|NCT04172753|DIAGNOSTIC_TEST|Imaging on the MR Linac|Only imaging performed on the MR Linac
214552930|NCT03750864|BEHAVIORAL|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance \& Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
214552931|NCT02403518|DEVICE|Freedom Spinal Cord Stimulator System|
214552932|NCT00692731|DIETARY_SUPPLEMENT|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
214552933|NCT00692731|OTHER|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
214552934|NCT03488680|BEHAVIORAL|Behavior change communication|Behavior change communication about optimal complementary feeding
214552935|NCT01762904|OTHER|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
214552936|NCT01762904|OTHER|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
214552937|NCT01967069|DRUG|DFD01 Spray|
214552938|NCT01967069|DRUG|Vehicle Spray|
214552939|NCT03609268|DEVICE|microwave ablation (MWA)|microwave ablation (MWA) for recurrent small liver cancer
214552940|NCT03609268|RADIATION|stereotactic body radiotherapy (SBRT)|stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
214552941|NCT01028677|DRUG|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
214702455|NCT01228942|DEVICE|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
214702456|NCT03676153|OTHER|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
214702457|NCT03676153|OTHER|Integrative medicine treatment program|Integrative medicine treatment program
214552942|NCT01028677|OTHER|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
214552943|NCT03414021|DIAGNOSTIC_TEST|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
214552944|NCT00452907|DRUG|Artesunate|oad, per os, 3 days of treatment
214552945|NCT00452907|DRUG|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
214552946|NCT00452907|DRUG|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
214552947|NCT00959686|DRUG|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
214552948|NCT01267773|BEHAVIORAL|Integrated Treatment|
214702458|NCT01947959|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
214702459|NCT01947959|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
214702460|NCT04782037|DRUG|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
214552949|NCT06179147|OTHER|cervical traction|Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
214552950|NCT02594787|DIETARY_SUPPLEMENT|Phosphorus|
214552951|NCT02594787|DIETARY_SUPPLEMENT|Placebo|
214552952|NCT02345590|DRUG|Eplerenone|25mg of eplerenone
214552953|NCT04688177|DEVICE|Body Composition|The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
214552954|NCT04688177|DEVICE|Heart rate variability|After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
215161998|NCT06961084|DRUG|Iodine-124|Given Orally
215161999|NCT06961084|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Combination of PET and CT imaging
215162000|NCT05663320|OTHER|virtual educational based transition intervention self-paced|study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced
215162001|NCT06510556|DEVICE|Ablation Treatment|Subjects scheduled to undergo endocardial mapping and ablation therapy in the treatment of persistent atrial fibrillation or paroxysmal atrial fibrillation. Ablation of the pulmonary veins will be performed; ablation of the left atrial posterior wall, mitral isthmus (MI), LA roof line and/or cavo-tricuspid isthmus (CTI) is at the discretion of the investigator.
215162002|NCT06507748|DEVICE|AlgometRx Nociometer|Novel objective pain measurement device
215162003|NCT04267848|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215162004|NCT04267848|DRUG|Carboplatin|Given IV
215162005|NCT04267848|DRUG|Cisplatin|Given IV
215162006|NCT04267848|PROCEDURE|Computed Tomography|Undergo CT
215162007|NCT04267848|PROCEDURE|Echocardiography Test|Undergo ECHO
215162008|NCT04267848|DRUG|Gemcitabine Hydrochloride|Given IV
215162009|NCT04267848|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214552955|NCT04688177|DEVICE|Grip Strength|The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
214552956|NCT04688177|DEVICE|Exhale Carbon Monoxide Concentration|Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
214552957|NCT04688177|DEVICE|Pulmonary Function Test|Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
214552958|NCT04688177|DEVICE|Respiratory Muscle Function|Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
214552959|NCT04688177|BEHAVIORAL|Fagerström Test for Nicotine Dependence|Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
214552960|NCT04688177|BEHAVIORAL|Seven-Day Physical Activity Recall Questionnaire|Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
214702461|NCT03442829|BEHAVIORAL|Sweet food consumption|Sweet food consumption at breakfast
214702462|NCT03442829|BEHAVIORAL|Non-sweet food consumption|Non-sweet food consumption at breakfast
215162010|NCT04267848|OTHER|Observation Activity|Undergo observation
215162011|NCT04267848|DRUG|Paclitaxel|Given IV
215162012|NCT04267848|BIOLOGICAL|Pembrolizumab|Given IV
214702463|NCT06809933|OTHER|Digital Health Mobile App|"A digital health technology (DHT) called Move by Sword Health, which utilizes a mobile app displaying tailored and recommended exercise options, wearable technology (Move wearable or equivalent), and a web-based platform monitored by a physical therapist who will provide individual support"
215162013|NCT04267848|DRUG|Pemetrexed Disodium|Given IV
215162014|NCT04267848|OTHER|Questionnaire Administration|Ancillary studies
215162015|NCT05112601|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and/or blood samples
214552961|NCT04688177|DEVICE|Cardiopulmonary exercise testing|Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
214552962|NCT00354757|DRUG|rabeprazole|
214552963|NCT00256022|DRUG|Lactobacillus Probiotic|
214552964|NCT00256022|OTHER|Lactose Powder|
214552965|NCT02301338|OTHER|Usual care|
214552966|NCT02301338|OTHER|Phone Calls|
214552967|NCT03638076|DRUG|GLS4|Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
214552968|NCT03638076|DRUG|RTV|Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
214552969|NCT00025077|BIOLOGICAL|filgrastim|
214552970|NCT00025077|DRUG|carboplatin|
215162016|NCT05112601|PROCEDURE|Computed Tomography|Undergo CT
214552971|NCT00025077|DRUG|cyclophosphamide|
214552972|NCT00025077|DRUG|thiotepa|
214552973|NCT00025077|PROCEDURE|conventional surgery|
214552974|NCT00025077|PROCEDURE|peripheral blood stem cell transplantation|
214552975|NCT00025077|RADIATION|radiation therapy|
214552976|NCT02906826|DEVICE|Video game|Video game operated by performing therapy correctly
214552977|NCT00529880|DRUG|Fludarabine , cytarabine|
214552978|NCT02777437|DRUG|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
214552979|NCT02806362|DRUG|Ombitasvir/paritaprevir/ritonavir|Tablet
214552980|NCT01739257|BEHAVIORAL|Medical Lecture|
215162017|NCT05112601|BIOLOGICAL|Ipilimumab|Given IV
215162018|NCT05112601|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215162019|NCT05112601|BIOLOGICAL|Nivolumab|Given IV
215162020|NCT05256225|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215162021|NCT05256225|DRUG|Carboplatin|Given IV
215162022|NCT05256225|PROCEDURE|Computed Tomography|Undergo CT
215162023|NCT05256225|PROCEDURE|Echocardiography Test|Undergo ECHO
215162024|NCT05256225|RADIATION|High-Dose-Rate Vaginal Cuff Brachytherapy|Undergo vaginal brachytherapy
215162025|NCT05256225|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
215162026|NCT05256225|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162027|NCT05256225|DRUG|Paclitaxel|Given IV
215162028|NCT05256225|OTHER|Survey Administration|Ancillary studies
215162029|NCT05256225|DRUG|Trastuzumab/Hyaluronidase-oysk|Given SC
214552981|NCT01739257|BEHAVIORAL|Dramatic Reading|
214552982|NCT03820297|BEHAVIORAL|10 sessions of ASGI|10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
214552983|NCT04496323|OTHER|EE Golf|Exercise in Golf and Playing 9 holes
214552984|NCT02470676|DEVICE|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
214552985|NCT02470676|DRUG|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
214702464|NCT06809933|OTHER|Virtual Support Group|An institutional, virtual peer support group session will include a maximum of 5 participant per group
214702465|NCT06809933|OTHER|Health Coaching|The facilitated group and discussions sessions will be led by a University of California, San Francisco (UCSF) certified health coach (CHC), following a pre-specified agenda and provided virtually
214702466|NCT06809933|OTHER|Wearable Activity Tracker|A wearable device to track participant activity
214702467|NCT06809933|OTHER|Handouts|A handout with exercise recommendations for those with cancer in accordance with national guidelines
214702468|NCT01740037|OTHER|Specialized outpatient AF Clinic|
214702469|NCT01740037|OTHER|Usual Care|
214702470|NCT03506399|DRUG|Lanabecestat|Administered orally
214702471|NCT03506399|DRUG|Oral Contraceptive|Administered orally
214702472|NCT03108651|OTHER|Case|Motivational message will be administrated.
214702473|NCT00014664|BIOLOGICAL|apolizumab|
214702474|NCT05202093|DEVICE|Oclean electric toothbrush A|Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks
214702475|NCT05202093|DEVICE|Oral B manual toothbrush|Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks
215162030|NCT05675410|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214702476|NCT05202093|DEVICE|Oclean electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
214702477|NCT01498237|DEVICE|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
214702478|NCT01498237|PROCEDURE|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
214552986|NCT01661205|DEVICE|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
214552987|NCT00287443|PROCEDURE|Oral Glucose tolerance test|
214552988|NCT00287443|PROCEDURE|Whole body protein turnover|
214552989|NCT00287443|PROCEDURE|IV glucose tolerance test|
214552990|NCT00287443|PROCEDURE|Indirect Calorimetry|
214702479|NCT00205296|BEHAVIORAL|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
214702480|NCT04694547|OTHER|There is no intervention, as this is a survey study|Survey
214702481|NCT05725382|DEVICE|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
214702482|NCT04629612|PROCEDURE|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
215162031|NCT05675410|BIOLOGICAL|Bleomycin Sulfate|Given IV
215162032|NCT05675410|DRUG|Brentuximab Vedotin|Given IV
215162033|NCT05675410|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
215162034|NCT05675410|DRUG|Cyclophosphamide|Given IV
215162035|NCT05675410|DRUG|Dacarbazine|Given IV
215162036|NCT05675410|DRUG|Doxorubicin Hydrochloride|Given IV
215162037|NCT05675410|DRUG|Etoposide|Given IV
215162038|NCT05675410|DRUG|Etoposide Phosphate|Given IV
215162039|NCT05675410|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
214552991|NCT00287443|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
214552992|NCT00287443|PROCEDURE|Growth Hormone Stimulation Test|
214552993|NCT00775411|DRUG|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
214552994|NCT00775411|BIOLOGICAL|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
214552995|NCT00202189|DRUG|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
214552996|NCT01111253|DRUG|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
214552997|NCT05563389|DRUG|Atorvastatin 20mg|active arm
214552998|NCT05563389|DRUG|Placebo|placebo arm
214552999|NCT01445119|DRUG|Enzastaurin (LY317615)|
215162040|NCT05675410|RADIATION|Involved-site Radiation Therapy|Undergo ISRT
215162041|NCT05675410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET-MRI
214553000|NCT01445119|DRUG|Carboplatin|
214553001|NCT05387967|DRUG|Sacubitril/valsartan|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
214702483|NCT02635152|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
214702484|NCT02635152|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
214702485|NCT02028546|PROCEDURE|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
214702486|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
214702487|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
214702488|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
214702489|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
214702490|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
214702491|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
215162042|NCT05675410|BIOLOGICAL|Nivolumab|Given IV
215162043|NCT05675410|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
215162044|NCT05675410|DRUG|Prednisolone|Given PO
215162045|NCT05675410|DRUG|Prednisone|Given PO
215162046|NCT05675410|DRUG|Procarbazine Hydrochloride|Given PO
214553002|NCT04358718|PROCEDURE|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
214553003|NCT04358718|PROCEDURE|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
214553004|NCT00346905|DRUG|Enteryx|
214553005|NCT02393742|DRUG|Sodium nitrite|
214553006|NCT02393742|DRUG|Placebo|
214553007|NCT01167790|PROCEDURE|buccal cavity examination|autofluorescence examination
214553008|NCT00224744|DEVICE|ultracision|Surgery by Ultracision
214553009|NCT00224744|DEVICE|classical lymphadenectomy|classical lymphadenectomy
214702492|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
214702493|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
214702494|NCT04498533|OTHER|forearm strap (counterforce brace)|
214702495|NCT04498533|OTHER|Kinesio tape application|
214702496|NCT03286088|DIAGNOSTIC_TEST|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
214702497|NCT03286088|DIAGNOSTIC_TEST|Cardiac Magnetics Resonance|imaging as standard practice
214702498|NCT03286088|DIAGNOSTIC_TEST|MitraClip|imaging as standard practice
214702499|NCT03233100|OTHER|FMT|fecal microbiota transplantation
214553010|NCT04191421|BIOLOGICAL|Siltuximab|Given IV
214553011|NCT04191421|BIOLOGICAL|Spartalizumab|Given IV
214702500|NCT03036332|BEHAVIORAL|Aerobic interval training|Carried out 3 times per week for 16 weeks
214702501|NCT01029002|DRUG|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
214702502|NCT01029002|OTHER|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
214702503|NCT03623139|BEHAVIORAL|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
214702504|NCT03623139|BEHAVIORAL|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
214702505|NCT03696264|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
214702506|NCT00702052|DRUG|Everolimus|Everolimus tablets
214702507|NCT01577160|DRUG|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
214702508|NCT01551758|DRUG|FF/VI|FF/VI
214702509|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
214702510|NCT02296996|DRUG|Dabrafenib + Trametinib|
214708986|NCT00426556|DRUG|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
215162047|NCT05675410|OTHER|Questionnaire Administration|Ancillary studies
215162048|NCT05675410|DRUG|Vinblastine Sulfate|Given IV
215162049|NCT05675410|DRUG|Vincristine Sulfate|Given IV
215162050|NCT05564390|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
215162051|NCT05564390|DRUG|Azacitidine|Given IV or SC
215162052|NCT05564390|OTHER|Best Practice|Receive SOC treatment
215162053|NCT05564390|PROCEDURE|Biopsy Procedure|Undergo biopsy
215162054|NCT05564390|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or buccal swab samples
215162055|NCT05564390|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215162056|NCT05564390|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215162057|NCT05564390|DRUG|Busulfan|Given IV
215162058|NCT05564390|PROCEDURE|Chest Radiography|Undergo chest x-ray
215162059|NCT05564390|PROCEDURE|Computed Tomography|Undergo CT
215162060|NCT05564390|DRUG|Cytarabine|Given
215162061|NCT05564390|DRUG|Daunorubicin Hydrochloride|Given IV
215162062|NCT05564390|DRUG|Decitabine and Cedazuridine|Given PO
215162063|NCT05564390|PROCEDURE|Echocardiography Test|Undergo ECHO
214553012|NCT05569421|DRUG|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
214553013|NCT05569421|DRUG|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
214553014|NCT06690372|OTHER|virtual reality exercise|"Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced."
214702511|NCT02804880|BEHAVIORAL|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
214702512|NCT02804880|BEHAVIORAL|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
214553015|NCT05424835|DRUG|SHR-A1811|SHR-A1811 4.8mg/kg
214553016|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
214553017|NCT05424835|DRUG|SHR-A1811|SHR-A1811 6.4mg/kg
214553018|NCT03111095|OTHER|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
214553019|NCT04709588|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml every night for 14, 28 days
214553020|NCT04709588|DIETARY_SUPPLEMENT|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
214553021|NCT05631041|DRUG|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
214553022|NCT05770960|DRUG|Naloxegol|Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
214553023|NCT05770960|DRUG|codeine phosphate|Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
214553024|NCT05770960|OTHER|Placebo|Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
214553025|NCT03242512|BIOLOGICAL|TK006|Subcutaneous injection
214702513|NCT02804880|BEHAVIORAL|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
214553026|NCT06311903|DRUG|Low dose of Norepinephrine (NE)|Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure \>70 mmHg)\] followed by low dose of NE (0.05-0.2 μg/kg/min).
214553027|NCT06311903|DRUG|High dose of Norepinephrine (NE)|Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
214702514|NCT02804880|OTHER|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
214702515|NCT02804880|OTHER|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
214702516|NCT02804880|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
214702517|NCT02804880|OTHER|12-page booklet|12-page smoking cessation self-help booklet
214702518|NCT03000816|RADIATION|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
214702519|NCT00101192|BIOLOGICAL|cetuximab|
214702520|NCT00101192|DRUG|cisplatin|
214702521|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review.
214702522|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review
214702523|NCT02421367|BIOLOGICAL|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
214553028|NCT00504075|BIOLOGICAL|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
214553029|NCT05035147|DRUG|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
214553030|NCT03120429|BEHAVIORAL|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
214553031|NCT03120429|BEHAVIORAL|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
214553032|NCT01186705|DRUG|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
214702524|NCT02840058|OTHER|Biological samples|blood and tumor tissue samples
214702525|NCT02840058|DRUG|Anti PD1/PDL1 treatment|
214702526|NCT02027116|BIOLOGICAL|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
214553033|NCT01258257|PROCEDURE|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
214553034|NCT00767429|DEVICE|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
214553035|NCT04544150|OTHER||
214553036|NCT03730506|DEVICE|Intra oral scanner|computer guided implant
214702527|NCT02623634|BEHAVIORAL|Position, waveform|different positions and waveform
214702528|NCT04604236|BEHAVIORAL|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
214702529|NCT04604236|BEHAVIORAL|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
214702530|NCT01465711|PROCEDURE|All abdominal surgical procedures|Laparotomy, Laparoscopy
214702531|NCT01465711|PROCEDURE|Intubation|Ventilatory support
214702532|NCT01465711|RADIATION|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
214702533|NCT03562585|DIAGNOSTIC_TEST|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
214702534|NCT05528497|OTHER|VR+|Use of a virtual reality helmet during ovocyte retrieval
214553037|NCT04079634|DEVICE|Esophageal warming|Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
214553038|NCT04079634|DEVICE|Control|Standard temperature probe monitoring
214553039|NCT04659564|DEVICE|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
214553040|NCT03106753|DRUG|Bupivacaine|intrathecal bupivacaine 7.5 mg
214553041|NCT03106753|DRUG|Terbutaline|0.25 mg Terbutaline subcutaneously
214553042|NCT04991376|DIAGNOSTIC_TEST|Blood-specific miRNA levels|Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.
214553043|NCT01178008|PROCEDURE|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
214553044|NCT01178008|PROCEDURE|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
214553045|NCT04867447|DIAGNOSTIC_TEST|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE)."
214702535|NCT00672529|DIETARY_SUPPLEMENT|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
215029700|NCT01435356|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
215029701|NCT01435356|BIOLOGICAL|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
215029702|NCT00265499|PROCEDURE|Skeletonization of the internal thoracic artery|
215029703|NCT03196479|DRUG|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
214702536|NCT01334372|BEHAVIORAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
214702537|NCT02657668|BEHAVIORAL|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
214702538|NCT00239317|DRUG|Tamusulosin|
214702539|NCT03720730|OTHER|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
214702540|NCT01795222|DRUG|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
214553046|NCT04351945|PROCEDURE|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
214553047|NCT03924102|DRUG|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with \[11C\] Acetate.
214553048|NCT03423329|DRUG|Brufen|Brufen Syrup
214553049|NCT03423329|DRUG|Cital|Cital Cyrup
214553050|NCT03423329|DRUG|Placebo for Brufen|Sansovit Syrup
214553051|NCT02833298|BEHAVIORAL|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
214553052|NCT02833298|BEHAVIORAL|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
214553053|NCT01434745|DRUG|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
214553054|NCT01434745|DIETARY_SUPPLEMENT|Lactose|Lactose will be administered in a capsule formula.
214553055|NCT02522988|BEHAVIORAL|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
214553056|NCT00537121|DRUG|fluorouracil|Given IV
214553057|NCT00537121|DRUG|irinotecan hydrochloride|Given IV
214553058|NCT00537121|DRUG|leucovorin calcium|Given IV
214553059|NCT00537121|DRUG|vorinostat|Taken Orally
214553060|NCT00537121|OTHER|pharmacological study|Correlative Study
214553061|NCT00543153|BEHAVIORAL|Interview|Interview lasting approximately 30-45 minutes.
214553062|NCT04245345|DEVICE|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
214553063|NCT01782768|DEVICE|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
214553064|NCT06243237|PROCEDURE|Acupuncture|Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
214553065|NCT06243237|PROCEDURE|Sham Acupuncture(Superficial Acupuncture)|Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
214702541|NCT01795222|DRUG|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
214702542|NCT02238496|PROCEDURE|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
214702543|NCT02238496|DRUG|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
214702544|NCT02238496|DRUG|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
214702545|NCT05755334|DRUG|Ropivacaine|Administration of Ropivacaine
214702546|NCT00753935|DRUG|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
214553066|NCT04559178|OTHER|Fluid challenge|fluid challenge administration when patient is in the gray zone
214553067|NCT00780455|DRUG|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
214553068|NCT00780455|DRUG|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
214553069|NCT00961506|PROCEDURE|LESS cholecystectomy|LESS cholecystectomy
214553070|NCT00961506|PROCEDURE|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
214553071|NCT04943471|OTHER|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
214553072|NCT01335347|BIOLOGICAL|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
214553073|NCT01335347|BIOLOGICAL|Placebo control|Capsules of the same size and shape as experimental groups
214702547|NCT00753935|DRUG|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
214553074|NCT02225262|RADIATION|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
214553075|NCT02609672|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
214553076|NCT02609672|OTHER|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
214553077|NCT03392168|DRUG|ARQ-151 cream 0.5%|0.5% active concentration
214553078|NCT03392168|DRUG|ARQ-151 cream 0.15%|0.15% active concentration
214553079|NCT03392168|DRUG|ARQ-151 vehicle cream|Vehicle cream
214553080|NCT02437942|OTHER|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
214553081|NCT00684905|DRUG|bicalutamide|
214702548|NCT04807543|DRUG|17-hydroxyprogesterone caproate|intramuscular injection weekly
215162064|NCT05564390|DRUG|Enasidenib|Given PO
214702549|NCT04807543|DRUG|Castor Oil|intramuscular injection weekly
215162065|NCT05564390|DRUG|Fludarabine|Given IV
215162066|NCT05564390|DRUG|Gemtuzumab Ozogamicin|Given IV
214702550|NCT02817152|PROCEDURE|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
214702551|NCT02817152|DEVICE|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
214702552|NCT01441921|DIETARY_SUPPLEMENT|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
214702553|NCT01441921|OTHER|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
214702554|NCT02776657|OTHER|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
214702555|NCT02776657|DEVICE|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
214553082|NCT00684905|DRUG|leuprolide acetate|
214553083|NCT00684905|PROCEDURE|adjuvant therapy|
214553084|NCT00684905|PROCEDURE|neoadjuvant therapy|
214553085|NCT00684905|PROCEDURE|quality-of-life assessment|
214553086|NCT00684905|RADIATION|brachytherapy|
214553087|NCT01121705|DRUG|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
214702556|NCT02776657|PROCEDURE|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
214702557|NCT02242825|DRUG|Micardis®|
214702558|NCT02242825|DRUG|MicardisPlus®|
214702559|NCT06281782|OTHER|topical retinoids and platalet rich plasma|We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
214702560|NCT00578799|DIETARY_SUPPLEMENT|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
214702561|NCT00578799|DIETARY_SUPPLEMENT|placebo|placebo capsules (potato starch
214702562|NCT03790462|OTHER|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected."
215162067|NCT05564390|DRUG|Gilteritinib|Given PO
215162068|NCT05564390|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215162069|NCT05564390|DRUG|Melphalan|Given IV
215162070|NCT05564390|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162071|NCT05564390|PROCEDURE|Mutation Carrier Screening|Undergo rapid genetic testing
215162072|NCT05564390|DRUG|Olutasidenib|Given PO
215162073|NCT05564390|DRUG|Placebo Administration|Given PO
214553088|NCT06089005|DEVICE|Instrument Assisted Soft Tissue Mobilization device|Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
214553089|NCT04600986|OTHER|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
214553090|NCT02770729|DRUG|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
214553091|NCT02770729|DRUG|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
214553092|NCT00401258|DRUG|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
214553093|NCT02469142|PROCEDURE|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
214553094|NCT00521157|DRUG|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
215162074|NCT05564390|PROCEDURE|Positron Emission Tomography|Undergo PET
215162075|NCT05564390|RADIATION|Total-Body Irradiation|Undergo total body irradiation
215162076|NCT05564390|DRUG|Venetoclax|Given PO
215162077|NCT06066138|DRUG|Atezolizumab|Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.
215162078|NCT05528809|OTHER|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
215162079|NCT00060541|PROCEDURE|Laboratory tests|
215162080|NCT00060541|PROCEDURE|Radiological exams|
215162081|NCT06274749|DIETARY_SUPPLEMENT|Urolithin A|Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.
214553095|NCT02497989|OTHER|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
214553096|NCT02497989|OTHER|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
214553097|NCT01328353|OTHER|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
214553098|NCT00343070|DRUG|Oral administration of escitalopram during 8 weeks|
214553099|NCT00360295|DRUG|Azithromycin SR|
214553100|NCT04309591|DEVICE|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
214553101|NCT04743531|BEHAVIORAL|HEROs|Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
214553102|NCT05299255|DRUG|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
214553103|NCT05299255|DRUG|Placebo|the placebo as control group.
214553104|NCT01788293|OTHER|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports \[Cannesson et al., 2008; Zimmermann et al., 2010\].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
214553105|NCT05165927|DEVICE|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
214553106|NCT02800551|RADIATION|dose-intensified image-guided SBRT using simultaneous integrated boost|
214553107|NCT02800551|RADIATION|External 3-dimensional conformal radiotherapy (3D-CRT)|
214553108|NCT04317261|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
214553109|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
214553110|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
214553111|NCT04380883|DEVICE|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
214553112|NCT04380883|DEVICE|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
214553113|NCT06069453|DEVICE|Hyaluronic Acid (HA) sodium salt and Hydeal-D|intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
214553114|NCT03289702|DRUG|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
214553115|NCT03289702|DRUG|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
214553116|NCT01405677|BIOLOGICAL|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
214553117|NCT01405677|BIOLOGICAL|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
214553118|NCT01405677|BIOLOGICAL|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
214553119|NCT02907437|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
214553120|NCT02907437|DRUG|Placebo|(200 mg/day)
214553121|NCT02907437|OTHER|Probiotics|(450 mg/day)
214553122|NCT04268537|DRUG|PD-1 blocking antibody+standard treatment|After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
215162082|NCT06274749|DIETARY_SUPPLEMENT|Placebo|The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.
214553123|NCT04268537|DRUG|Thymosin+standard treatment|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
214553124|NCT04268537|OTHER|standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
214553125|NCT03722511|DIETARY_SUPPLEMENT|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
214553126|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
214553127|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
214553128|NCT00120809|DRUG|Sulfadoxine-pyrimethamine|
214553129|NCT05588583|DEVICE|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~* a soft silicone wound contact layer (Safetac)~* a flexible absorbent pad of compressed polyurethane foam~* an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
214553130|NCT05301998|OTHER|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
214553131|NCT03828188|DIETARY_SUPPLEMENT|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
214553132|NCT03828188|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
214553133|NCT01544634|DRUG|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
214553134|NCT01544634|DRUG|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
215162083|NCT05080998|DIAGNOSTIC_TEST|CxBladder Monitor/Monitor+|CxBladder Monitor/Monitor+ is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
215162084|NCT06588556|BEHAVIORAL|ICUconnect|ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.
214553135|NCT01544634|DRUG|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
214553136|NCT01544634|DRUG|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
214553137|NCT00288223|DRUG|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
214553138|NCT00808002|DRUG|Raltegravir|Raltegravir 400 mg every 12 hours
214553139|NCT00808002|DRUG|Maraviroc|Maraviroc 300 mg every 12 hours
214553140|NCT00808002|DRUG|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
214553141|NCT04423419|PROCEDURE|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
214553142|NCT04423419|PROCEDURE|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
214553143|NCT04423419|OTHER|IV analgesia|IV analgesia
214553144|NCT05765201|OTHER|High IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
214553145|NCT05765201|OTHER|Low IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
214553146|NCT00844597|DRUG|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
214702563|NCT06162260|PROCEDURE|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
214702564|NCT04079894|OTHER|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
214702565|NCT04079894|DEVICE|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
215162085|NCT06588556|OTHER|Usual care|Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
215162086|NCT05652478|DRUG|Tenofovir alafenamide|25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.
215162087|NCT05652478|DRUG|Dolutegravir|50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
214553147|NCT02670122|DEVICE|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
214553148|NCT01262547|DEVICE|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
214553149|NCT01262547|PROCEDURE|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
215162088|NCT04266093|DRUG|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol.
215162089|NCT05652465|DEVICE|Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)|Device described in protocol
215162090|NCT05767021|DRUG|Mirikizumab|Administered IV
215162091|NCT05767021|DRUG|Mirikizumab|Administered Subcutaneously (SC)
215162092|NCT04181060|BIOLOGICAL|Bevacizumab|Given IV
215162093|NCT04181060|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215162094|NCT04181060|PROCEDURE|Computed Tomography|Undergo CT
214553150|NCT01299311|BEHAVIORAL|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
214553151|NCT01299311|BEHAVIORAL|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
214553152|NCT02762903|PROCEDURE|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
214553153|NCT02762903|PROCEDURE|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
214553154|NCT02762903|DEVICE|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
214553155|NCT05962190|BEHAVIORAL|Diet|High fat (\~60% of total energy intake) diet enriched with either SFA or UFA
214553156|NCT00243074|DRUG|cediranib maleate|Given orally
214553157|NCT00243074|OTHER|laboratory biomarker analysis|Correlative studies
214553158|NCT04033965|GENETIC|Corellation of Mutations, TILs and Age in Breast Cancer|
214553159|NCT02909933|DRUG|liraglutide|
214553160|NCT02909933|DRUG|metformin and liraglutide|
214553161|NCT05321849|OTHER|Echocardiography guide|Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
214553162|NCT06012981|BEHAVIORAL|ACT|"The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree."
214553163|NCT00542204|BEHAVIORAL|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
214553164|NCT00664534|DRUG|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
214553165|NCT00664534|DRUG|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
214553166|NCT05421468|OTHER|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
214553167|NCT03041792|DRUG|Liraglutide|Liraglutide
214553168|NCT03041792|OTHER|Placebo|Placebo
214553169|NCT05078177|DRUG|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
214553170|NCT01535027|DRUG|teriparatide|teriparatide 20 ug/day, sc.
214553171|NCT01535027|DRUG|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
214553172|NCT01535027|DRUG|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
214553173|NCT01857336|OTHER|infusion of G-CSF mobilized peripheral harvest|
214553174|NCT00851565|PROCEDURE|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~1. Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~2. Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~3. High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~4. High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
214553175|NCT00851565|PROCEDURE|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
215162095|NCT04181060|PROCEDURE|Echocardiography Test|Undergo ECHO
214553176|NCT04978090|DEVICE|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
214553177|NCT01337362|PROCEDURE|Insulin clamp|Patients will be exposed to low bloodsugar
214553178|NCT06239233|PROCEDURE|Laparoscopic cholecystectomy|"The surgeon makes small incisions in the abdominal wall, usually around the navel.~Trocars (hollow tubes) are inserted through these incisions to provide access for the laparoscope and specialized instruments.~A laparoscope, a thin tube with a light and camera, is inserted through one of the trocars. It allows the surgical team to visualize the abdominal cavity on a monitor.~The surgeon carefully identifies the gallbladder and the cystic duct, which connects the gallbladder to the common bile duct.~The cystic duct and artery are clipped and cut to disconnect the gallbladder from the biliary system. This step ensures the safe removal of the gallbladder.~The surgeon gently detaches the gallbladder from the liver bed and removes it through one of the small incisions.~Any bleeding vessels are sealed, and the small incisions are closed with stitches or surgical glue."
215162096|NCT04181060|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214553179|NCT05030051|DEVICE|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
214553180|NCT04263987|PROCEDURE|Moses laser enucleation of prostate|Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
214553181|NCT04565002|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
214553182|NCT00035386|PROCEDURE|trans-right ventricular alcohol septal ablation (TRVASA)|
214553183|NCT03344068|RADIATION|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
214553184|NCT03344068|DRUG|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
214553185|NCT03344068|DIETARY_SUPPLEMENT|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
214553186|NCT00373451|DRUG|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)
214553187|NCT00373451|DRUG|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
214553188|NCT00373451|DRUG|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
214553189|NCT01508663|DEVICE|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
214553190|NCT01508663|DRUG|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
214553191|NCT00735280|DRUG|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
214702566|NCT05894473|OTHER|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
214702567|NCT03282357|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
214702568|NCT03282357|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection
215162097|NCT04181060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162098|NCT04181060|DRUG|Osimertinib|Given PO
215162099|NCT05563844|DRUG|PM 8.4 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
215162100|NCT05563844|DRUG|PM 11.2 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
215162101|NCT02423057|DRUG|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
215162102|NCT04036032|OTHER|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
215162103|NCT03181867|DRUG|18F-DCFPyL|Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
214702569|NCT04635072|DRUG|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
214702570|NCT06365814|OTHER|enhanced recovery after surgery|ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
214702571|NCT06365814|OTHER|conventional perioperative management|conventional perioperative management
214702572|NCT00642655|DRUG|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
214702573|NCT01586156|DRUG|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
214702574|NCT01586156|DRUG|placebo|Placebo will be taken twice daily for 6 months
214702575|NCT04096352|BEHAVIORAL|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
214702576|NCT04096352|BEHAVIORAL|Indirect Method|Information on voice function and voice hygiene.
214702577|NCT06063252|BEHAVIORAL|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
214702578|NCT03754283|DEVICE|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
214702579|NCT00002833|BIOLOGICAL|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
215162104|NCT03181867|DRUG|18F-FDG|Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.
215162105|NCT03181867|DRUG|PSMA-11|For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
214702580|NCT00002833|DRUG|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
214702581|NCT00002833|DRUG|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
214702582|NCT00002833|DRUG|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
215162106|NCT06833008|DRUG|IPN01195|IPN01195 will be administered at assigned dose level.
215162107|NCT04929470|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
215162108|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
215162109|NCT06237335|OTHER|Placebo|Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
215162110|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
215162111|NCT06237335|DRUG|RCT2100|RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
215162112|NCT05250063|DRUG|LUM-201|Administered orally once daily
214702583|NCT00002833|DRUG|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
214702584|NCT00002833|DRUG|Idarubicin|IV Days -6, -5 and -4.
215162113|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
215162114|NCT03032172|DRUG|Risdiplam|Risdiplam will be administered orally once daily.
214702585|NCT00002833|DRUG|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
214702586|NCT00002833|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
214702587|NCT04872816|DEVICE|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
214702588|NCT01015664|DRUG|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
214702589|NCT01015664|DRUG|cisplatin|75 mg/m2 IV over 60 minutes on day 1
214702590|NCT01015664|DRUG|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
215162115|NCT06692907|OTHER|B7A (ETEC challenge strain)|A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.
215162116|NCT06692907|BIOLOGICAL|CssBA|A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.
215162117|NCT06692907|BIOLOGICAL|dmLT|An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.
214702591|NCT01156038|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
214553192|NCT03138642|RADIATION|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
214553193|NCT02786472|BEHAVIORAL|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
214553194|NCT02786472|BEHAVIORAL|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
214553195|NCT02786472|BEHAVIORAL|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
214553196|NCT02786472|BEHAVIORAL|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
214702592|NCT03936816|OTHER|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
214702593|NCT01032993|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
214702594|NCT01032993|OTHER|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
214702595|NCT01446601|DEVICE|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
214702596|NCT02121756|DRUG|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
214702597|NCT02121756|DRUG|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
214702598|NCT03976115|DRUG|DDO-3055|Oral
214702599|NCT03976115|DRUG|Placebos|Oral
214702600|NCT03120481|OTHER|no intervation|no intervention
214702601|NCT00154167|DRUG|NV-101 (phentolamine mesylate solution)|
214702602|NCT04982159|OTHER|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
214553197|NCT04051086|BIOLOGICAL|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples"
214553198|NCT04051086|BIOLOGICAL|Urine and blood samples|"Only one visit for each participant~* Medical history~* Urine and blood samples"
214553199|NCT02727569|DEVICE|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
214553200|NCT02727569|DEVICE|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
214553201|NCT02727569|DEVICE|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
214553202|NCT00439192|DRUG|ELB245|
214553203|NCT00439192|DRUG|Tolterodine|
214553204|NCT03862014|DEVICE|SDF+KI|Molar with MIH will be treated with SDF+KI
214553205|NCT03862014|DEVICE|SDF+KI+GIC(SMART)|Molar with MIH will be treated with SDF+KI+GIC(SMART)
214702603|NCT04147871|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
214702604|NCT04147871|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
214702605|NCT06168500|PROCEDURE|Test group|3.0mm diameter implant
214702606|NCT06168500|PROCEDURE|Control group|4.0 diameter implant + guided bone regeneration
214702607|NCT04741334|DRUG|direct anticoagulant|exposure to direct anticoagulant
214702608|NCT04741334|DRUG|antiplatelet drugs|exposure to antiplatelet drugs
214702609|NCT04741334|DRUG|Dicumarols|exposure to dicumarols
214702610|NCT03878524|DRUG|Abemaciclib|Given PO
214702611|NCT03878524|DRUG|Abiraterone|Given PO
214702612|NCT03878524|DRUG|Afatinib|Given PO
214702613|NCT03878524|BIOLOGICAL|Bevacizumab|Given IV
214553206|NCT02963662|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
214553207|NCT02963662|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
214553208|NCT01731223|BEHAVIORAL|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
214553209|NCT02834299|BEHAVIORAL|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
214553210|NCT02834299|BEHAVIORAL|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
214553211|NCT02834299|BEHAVIORAL|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
214553212|NCT03655743|DEVICE|LASIK, PRK, Phacoemulsification|"Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive\_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification"
214553213|NCT03075527|DRUG|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
214553214|NCT03075527|DRUG|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
214553215|NCT07024017|DEVICE|Foam roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
214553216|NCT07024017|OTHER|dynamic stretch|"10 different exercises will be performed over a 13-meter distance, with a 10-second rest period between exercises.~During the session, participants will receive verbal feedback to ensure proper posture and technique. Exercises will be video recorded and shared with participants for review and consistency."
214553217|NCT07029919|BEHAVIORAL|PATH-S app|PATH-S will use casual gaming and intermittent reinforcement techniques to encourage high risk teens to adopt and persist with personalized habits to improve sleep.
214553218|NCT07030686|BEHAVIORAL|Exercise|Exercise following completion of active treatment for the primary index cancer
214553219|NCT07034027|BEHAVIORAL|Project WAVE (Wise Awareness of Visiting Emotions)|Project WAVE is an online, self-directed single-session intervention designed to foster emotional nonreactivity skills in young adults aged 18-29.
214553220|NCT07034027|BEHAVIORAL|Emotionally Neutral Writing Control|The control condition is an online, self-directed single-session activity that includes an emotionally neutral writing task.
214553221|NCT06707402|BEHAVIORAL|WALK|The intervention covers a personalized 24-week progressive brisk walking program. The program consists of moderate to high-intensity walking (i.e., 55-85% maximal heart rate) performed as both continuous and interval training sessions 2-3 times/week lasting 30-60 min/session. Four individually supervised sessions will be conducted in the first 2 weeks, while 1 supervised group session will be received bi-weekly. Furthermore, the group will receive an activity tracker and monthly telephone calls will be offered to adjust the intensity of the program (if necessary), clarify any questions regarding the intervention, and give verbal motivation. At the baseline assessment and at week 12, during a group training session, the figure of 8 walk test will be conducted to gain insigh tinto the current status of the training program. Lastly, after completion of the baseline test, the participants are given a brief educational session (walking advice) on recommended guidelines for physical activity
214553222|NCT06707402|BEHAVIORAL|ACTIVE|Will receive an activity tracker is provided alongside monthly telephone calls and walking advice after the baseline test. Similar to WALK, 3 telephone calls are provided during the follow-up period.
214553223|NCT06707402|BEHAVIORAL|CON|Receives a brief educational session (walking advice) is provided at baseline, after which no further contacts are made.
214553224|NCT06926673|DRUG|Dostarlimab|Dostarlimab will be administered
214553225|NCT06926673|DRUG|Belrestotug.|Belrestotug will be administered
214553226|NCT06926673|DRUG|Nelistotug|Nelistotug will be administered.
214702614|NCT03878524|DRUG|Bicalutamide|Given PO
214702615|NCT03878524|PROCEDURE|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
214553233|NCT07049367|DIAGNOSTIC_TEST|Hand Function Improvement|Finger Extension and Tripod Grip as Indicators of Hand Function Improvement in Subacute Stroke Patients
214553234|NCT07049419|DEVICE|Provision of an environmental control system|Part of standard clinical care for patients referred to the NHS Lothian environmental control service.
214553235|NCT07044778|OTHER|Questionnaire|An online Questionnaire designed by Google Forms will be shared on social media for medical students in Egypt to fill
214553236|NCT07049510|BEHAVIORAL|Experimental: Experimental: Combating violence against women|"After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.~8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test."
214553237|NCT07048873|DRUG|Dexmedetomidine|IV dexmedetomidine
214553238|NCT07048873|DRUG|Ketamine|IV ketamine
214553239|NCT07048873|DRUG|Saline (control group)|no drugs
214702616|NCT03878524|DRUG|Bortezomib|Given IV
214553240|NCT07051031|DRUG|Nuvaxovid (NVX-CoV2705)|COVID-19 vaccination
214553241|NCT07051031|DRUG|Pfizer-BioNTech COVID-19 vaccine|COVID-19 vaccination
214553242|NCT07050966|PROCEDURE|Group A (Active Comparator) 1. Mulligan's Spinal Mobilization with Leg Movement (SMWLM) 2.Lower Limb Neurodynamic Mobilization|This group will receive Mulligan's Spinal Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set). This protocol is given to the patient for a total of 6 sessions (1 session per day).
214553243|NCT07050966|PROCEDURE|Group B (Experimental) 1. Maitland's Lumbar Rotation Mobilization 2.Lower Limb Neurodynamic Mobilization|This group will receive Maitland's Lumbar Rotation Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set).This protocol is given to the patient for a total of 6 sessions (1 session per day).
214553244|NCT07049874|DIETARY_SUPPLEMENT|Huel|Ready to eat huel foods. Containing 2 ready to drink shakes, one savoury meal pack and meal replacement powder. Consumption amounts were based on energy needs of each person
214553245|NCT01551797|DRUG|Paracetamol 500 mg|Standard Paracetamol formulation
214553246|NCT01551797|DRUG|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
214553247|NCT01551797|DRUG|Paracetamol 750 mg|Paracetamol Sustained Release formulation
214553248|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
214553249|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
214553250|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
214553251|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
214702617|NCT03878524|DRUG|Cabazitaxel|Given IV
214702618|NCT03878524|DRUG|Cabozantinib|Given PO
214702619|NCT03878524|DRUG|Capecitabine|Given PO
214702620|NCT03878524|DRUG|Carboplatin|Given IV
214702621|NCT03878524|DRUG|Celecoxib|Given PO
214702622|NCT03878524|DRUG|Cobimetinib|Given PO
214702623|NCT03878524|DRUG|Copanlisib|Given IV
214553252|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
214553253|NCT06181370|OTHER|placebo|placebo inhaled drug
214553254|NCT04873882|DEVICE|Acoustic ventilation|"1. Placement and removal of the esophageal stethoscope~2. Connection of a microphone to the esophageal stethoscope outside of and removed from the patient's body at the location on the figure above Connection fo monaural earpiece.~3. Digital breath sound real-time monitoring will be collected as .wav files from the device with no identifiable elements and the data from the device will be downloaded onto a desktop and we will keep and store the data on a secure departmental server.~4. Additional monitoring schedule includes evaluation of breath sounds with a conventional stethoscope every 30 minutes intraoperatively, at the start of one-lung ventilation, at the return to two-lung ventilation and prior to extubation and during any changes on the digital breath sounds recording monitor."
214553255|NCT00500032|PROCEDURE|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
214702624|NCT03878524|DRUG|Dabrafenib|Given PO
214553256|NCT02358668|DRUG|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
214553257|NCT02358668|DRUG|BTI320 matching placebo|Placebo
214553258|NCT04057573|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214553259|NCT04057573|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214553260|NCT05855525|BEHAVIORAL|Experience sampling|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
214553261|NCT04856735|OTHER|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
214702625|NCT03878524|DRUG|Dacomitinib|Given PO
214702626|NCT03878524|DRUG|Darolutamide|Given PO
214702627|NCT03878524|DRUG|Dasatinib|Given PO
214702628|NCT03878524|DRUG|Doxorubicin|Given IV
214702629|NCT03878524|BIOLOGICAL|Durvalumab|Given IV
214702630|NCT03878524|DRUG|Enasidenib|Given PO
214702631|NCT03878524|DRUG|Entrectinib|Given PO
214702632|NCT03878524|DRUG|Enzalutamide|Given PO
214702633|NCT03878524|DRUG|Erlotinib|Given PO
214702634|NCT03878524|DRUG|Everolimus|Given PO
214702635|NCT03878524|DRUG|Fluorouracil|Given IV
214702636|NCT03878524|DRUG|Idelalisib|Given PO
214702637|NCT03878524|DRUG|Imatinib|Given PO
214702638|NCT03878524|BIOLOGICAL|Ipilimumab|Given IV
214702639|NCT03878524|DRUG|Lenvatinib|Given PO
214702640|NCT03878524|DRUG|Leucovorin|Given IV
214702641|NCT03878524|DRUG|Lorlatinib|Given PO
214702642|NCT03878524|DRUG|Losartan|Given PO
214702643|NCT03878524|DRUG|Nab-paclitaxel|Given IV
214702644|NCT03878524|DRUG|Neratinib|Given PO
214702645|NCT03878524|BIOLOGICAL|Nivolumab|Given IV
214702646|NCT03878524|DRUG|Olaparib|Given PO
214702647|NCT03878524|DRUG|Oxaliplatin|Given IV
214702648|NCT03878524|DRUG|Palbociclib|Given PO
214702649|NCT03878524|DRUG|Panobinostat|Given PO
214702650|NCT03878524|BIOLOGICAL|Pembrolizumab|Given IV
214702651|NCT03878524|BIOLOGICAL|Pertuzumab|Given IV
214702652|NCT03878524|DRUG|Ponatinib|Given PO
214553262|NCT04856735|OTHER|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
214553263|NCT04856735|OTHER|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
214553264|NCT03455998|OTHER|questionnaires|
214553265|NCT03064945|DEVICE|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
214553266|NCT02592213|PROCEDURE|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
214553267|NCT03348410|BEHAVIORAL|Motivational interviewing|Motivational interviewing with insurance officer
214553268|NCT00693979|DEVICE|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
214553269|NCT05609604|DEVICE|tDCS|Electric current will be delivered to the pre-frontal cortex for 30 minutes.
214553270|NCT05609604|DEVICE|Shame- No current|
214553271|NCT03987971|OTHER|acupuncture|Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
214553272|NCT05436405|PROCEDURE|Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb|"Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases."
214702653|NCT03878524|OTHER|Quality-of-Life Assessment|Ancillary studies
214702654|NCT03878524|DRUG|Regorafenib|Given PO
214553273|NCT02702778|DRUG|Delayed-Release (DR) Prednisone|delayed release prednisone
214553274|NCT02702778|DRUG|Immediate Release (IR) Prednisone|standard prednisone
214553275|NCT01317875|DRUG|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
214553276|NCT01145989|DRUG|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
214553277|NCT02328118|DRUG|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
214553278|NCT02328118|DRUG|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
214553279|NCT01002677|BEHAVIORAL|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
214553280|NCT01002677|BEHAVIORAL|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
214553281|NCT00551330|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily
214553282|NCT00551330|DRUG|Placebo|One tablet of placebo once daily
214553283|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
214553284|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
214702655|NCT03878524|DRUG|Ruxolitinib|Given PO
214553285|NCT01762332|OTHER|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
214702656|NCT03878524|DRUG|Sirolimus|Given PO
214702657|NCT03878524|DRUG|Sorafenib|Given PO
214702658|NCT03878524|DRUG|Sunitinib|Given PO
214702659|NCT03878524|DRUG|Trametinib|Given PO
214702660|NCT03878524|BIOLOGICAL|Trastuzumab Emtansine|Given IV
214702661|NCT03878524|DRUG|Tretinoin|Given PO
214702662|NCT03878524|DRUG|Vemurafenib|Given PO
214702663|NCT03878524|DRUG|Venetoclax|Given PO
214702664|NCT03878524|DRUG|Vismodegib|Given PO
214702665|NCT03878524|DRUG|Vorinostat|Given PO
214702666|NCT02619318|BEHAVIORAL|Balancing Everyday Life (BEL)|
214702667|NCT02619318|BEHAVIORAL|Care as usual (generally standard occupational therapy)|
214702668|NCT02176590|BEHAVIORAL|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
215162118|NCT06692907|OTHER|Placebo|Placebo
215162119|NCT06303193|DRUG|pacritinib|Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
215162120|NCT06058377|PROCEDURE|Biospecimen Collection|Undergo optional collection of tissue and/or blood
215162121|NCT06058377|DRUG|Cyclophosphamide|Given IV
215162122|NCT06058377|DRUG|Doxorubicin|Given IV
215162123|NCT06058377|BIOLOGICAL|Durvalumab|Given IV
215162124|NCT06058377|OTHER|Genetic Testing|Undergo MammaPrint testing
214553286|NCT05003492|COMBINATION_PRODUCT|Combination therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
214553287|NCT05003492|RADIATION|Photodynamic therapy|After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.
214553288|NCT05003492|DRUG|Standard therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
214553289|NCT03744013|DEVICE|Fortiva® 1mm|Post mastectomy immediate reconstruction
214553290|NCT00601263|DRUG|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
214553291|NCT06066411|OTHER|Massage Ball|The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
214553292|NCT03466047|DIETARY_SUPPLEMENT|Protein stomach|encapsulated protein stomach
214553293|NCT03466047|DIETARY_SUPPLEMENT|Protein distal small intestine|encapsulated protein distal small intestine
214553294|NCT03466047|DIETARY_SUPPLEMENT|CHO stomach|encapsulated CHO stomach
214553295|NCT03466047|DIETARY_SUPPLEMENT|CHO distal small intestine|encapsulated CHO distal small intestine
214553296|NCT03466047|DIETARY_SUPPLEMENT|Fat stomach|encapsulated Fat stomach
214553297|NCT03466047|DIETARY_SUPPLEMENT|Fat distal small intestine|encapsulated Fat distal small intestine
214553298|NCT00402012|DRUG|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
214553299|NCT03211234|DRUG|2.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
214553300|NCT03211234|DRUG|4.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
214553301|NCT03211234|DRUG|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
214553302|NCT01619189|BIOLOGICAL|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
214553303|NCT01619189|PROCEDURE|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
214553304|NCT01457638|PROCEDURE|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
214553305|NCT01457638|PROCEDURE|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
214553306|NCT02747823|BIOLOGICAL|CBT124|1 mg/kg IV infusion
214553307|NCT02747823|BIOLOGICAL|EU Sourced Avastin®|1 mg/kg IV infusion
214553308|NCT02747823|BIOLOGICAL|US Sourced Avastin®|1 mg/kg IV infusion
214553309|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
214553310|NCT02271984|DRUG|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
214553311|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
214553312|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
214553313|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
214553314|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
214553315|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
214553316|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
214553317|NCT03620539|OTHER|Lifestyle intervention|Sauna bathing
214553318|NCT03814577|DIAGNOSTIC_TEST|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
214702669|NCT02176590|OTHER|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
214702670|NCT03719482|DRUG|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
214702671|NCT00583440|BEHAVIORAL|12-step facilitation|12 weekly individual 12-step facilitation sessions
214702672|NCT00583440|BEHAVIORAL|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
215162125|NCT06058377|PROCEDURE|Mammography|Undergo mammography
215162126|NCT06058377|DRUG|Paclitaxel|Given IV
214702673|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
214702674|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
214702675|NCT02472119|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-free diet
214702676|NCT02935114|DRUG|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
214702677|NCT02935114|DRUG|35% hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
214702678|NCT02693795|OTHER|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
214702679|NCT02693795|OTHER|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
214702680|NCT01970514|DEVICE|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
214702681|NCT04254783|DRUG|Risankizumab|Intravenous (IV) infusion
214702682|NCT04254783|DRUG|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
214702683|NCT03215654|OTHER|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
214702684|NCT03490357|PROCEDURE|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
214702685|NCT03490357|PROCEDURE|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
214702686|NCT05235217|DRUG|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
214702687|NCT05235217|DRUG|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
214702688|NCT02370017|BIOLOGICAL|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
214702689|NCT00523406|PROCEDURE|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
214702690|NCT05246176|DEVICE|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
214702691|NCT00632541|DRUG|Sorafenib|Sorafenib 200mg po daily
214702692|NCT00632541|DRUG|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
214702693|NCT00632541|OTHER|Imaging|Imaging every third cycle
214702694|NCT04949178|OTHER|No intervention|This is an observational study.
214702695|NCT04822272|DEVICE|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
214702696|NCT02338791|DEVICE|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
214702697|NCT03195062|OTHER|Test meal|Liquid test meal (fructose+glucose)
215162127|NCT06058377|OTHER|Quality-of-Life Assessment|Ancillary studies
214553319|NCT03814577|DIAGNOSTIC_TEST|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
214553320|NCT03814577|DEVICE|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
214553321|NCT03814577|OTHER|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
214553322|NCT04160442|BEHAVIORAL|Carevive CarePlanning System|Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
214553323|NCT01978951|BEHAVIORAL|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
214553324|NCT01978951|BEHAVIORAL|Conventional CKD care|group counselling about optimal diets for CKD patients
214553325|NCT01400360|OTHER|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
214553326|NCT04821557|DIETARY_SUPPLEMENT|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
214553327|NCT04821557|DIETARY_SUPPLEMENT|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
214553328|NCT01423591|DRUG|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
214553329|NCT01423591|DRUG|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
214702698|NCT01450956|DRUG|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
214702699|NCT01450956|OTHER|Control|Patients will receive only oxygen and air through oxygenator
214702700|NCT01179347|DRUG|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
214702701|NCT01179347|DRUG|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
214702702|NCT00305747|DRUG|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
214702703|NCT02692456|DEVICE|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
215162128|NCT04530565|PROCEDURE|Biospecimen Collection|Correlative studies
215162129|NCT04530565|BIOLOGICAL|Blinatumomab|Given IV
215162130|NCT04530565|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215162131|NCT04530565|DRUG|Cyclophosphamide|Given IV
214553330|NCT02772939|DEVICE|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
214553331|NCT00664963|DEVICE|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
214553332|NCT00664963|DEVICE|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
214553333|NCT03245905|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
214553334|NCT00003391|BIOLOGICAL|monoclonal antibody muJ591|
214553335|NCT01376453|DRUG|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
214553336|NCT01376453|DRUG|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.
214553337|NCT01376453|RADIATION|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
214702704|NCT02692456|DEVICE|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
215162132|NCT04530565|DRUG|Cytarabine|Given IV or IT
215162133|NCT04530565|DRUG|Dasatinib|Given PO
215162134|NCT04530565|DRUG|Dexamethasone|Given PO or IV
215162135|NCT04530565|DRUG|Doxorubicin Hydrochloride|Given IV
215162136|NCT04530565|PROCEDURE|Echocardiography Test|Undergo ECHO
215162137|NCT04530565|PROCEDURE|Electrocardiography|Undergo ECG
215162138|NCT04530565|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
215162139|NCT04530565|DRUG|Mesna|Given IV
215162140|NCT04530565|DRUG|Methotrexate|Given IV or IT
215162141|NCT04530565|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162142|NCT04530565|DRUG|Ponatinib Hydrochloride|Given PO
215162143|NCT04530565|DRUG|Prednisone|Given PO
215162144|NCT04530565|DRUG|Vincristine Sulfate|Given IV
215162145|NCT06072131|DRUG|Belinostat Injection|Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
215162146|NCT06072131|DRUG|Pralatrexate Injection|Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
215162147|NCT06072131|DRUG|CHOP|CHOP is the comparator arm
215162148|NCT06072131|DRUG|COP|COP is given in combination with Pralatrexate
215162149|NCT06412510|OTHER|Prehabilitation|"Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy"
215162150|NCT03822897|RADIATION|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
215162151|NCT03822897|DRUG|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
214553338|NCT02277054|DEVICE|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
214553339|NCT00777075|DRUG|L-arginine|
214553340|NCT00777075|DRUG|Placebo|
214553341|NCT04465799|BEHAVIORAL|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
214553342|NCT04465799|BEHAVIORAL|ENTREN-F|ENTREN intervention for children + family intervention.
214553343|NCT04465799|BEHAVIORAL|Control group|Behavioral modification of habits
214553344|NCT05091177|DIAGNOSTIC_TEST|Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation|Use relevant instruments for inspection
214553345|NCT05461287|DRUG|QLS31904|QLS31904 ONLY
214553346|NCT02936726|BEHAVIORAL|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
214553347|NCT02936726|BEHAVIORAL|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
214553348|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
214553349|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
214553350|NCT05135676|DEVICE|Blinded CGM|A masked CGM sensor will be worn
214553351|NCT05135676|DEVICE|real-time CGM|An unmasked CGM sensor will worn
214553352|NCT06341777|BEHAVIORAL|Audio-visual training (AVT) telerehabilitation|Participants are trained at home, with remote supervision, for 3 weeks (5 days/week, 2 hours/day) using an audio-visual device suitable for telerehabilitation (AVDESK, Linari Medical). Specifically, visual stimuli (LEDs) appear on a semicircular panel, either alone or paired with an acoustic cues, at different eccentricities. Stimuli to the blind visual field (70%) and intact visual field (30%) are presented in random sequence. Patients are trained to scan the visual field by shifting their gaze (from the central fixation point) towards the visual target (with or without sounds), without head movements, and to report its presence by pressing the response key.
214702705|NCT06376838|DEVICE|DLMR01|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
214702706|NCT06376838|DEVICE|Rejuran|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
215162152|NCT04325425|DRUG|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
215162153|NCT04325425|DRUG|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
215162154|NCT00875849|BIOLOGICAL|cetuximab|
215162155|NCT00875849|DRUG|cisplatin|
215162156|NCT00875849|RADIATION|radiation therapy|
215162157|NCT06104592|RADIATION|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
215162158|NCT06104592|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
215162159|NCT06430385|DRUG|ION440|ION440 will be administered by intrathecal bolus (ITB) injection.
215162160|NCT06430385|PROCEDURE|Sham procedure|An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
215162161|NCT06361667|OTHER|Arts|Arts (music, cinema, dance).
215162162|NCT06330402|OTHER|Hypertonic saline injection|0.25 mL injection with hypertonic saline (7%) to the infrapatellar fat pad.
215162163|NCT06330402|OTHER|Isotonic saline injection|Control injection with 0.25 mL isotonic saline (0.9%) to the infrapatellar fat pad.
214702707|NCT04616495|PROCEDURE|Liver transplantation|Chemotherapy and liver transplantation
214702708|NCT03342937|DRUG|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
215162164|NCT05375071|OTHER|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
214702709|NCT00369967|DRUG|NuvaRing|Initiation of NuvaRing for contraception
214702710|NCT01677624|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
214702711|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
214702712|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg|
214702713|NCT03536598|DRUG|Valsartan 160 mg + Rosuvastatin 20 mg|
214702714|NCT03296852|DIAGNOSTIC_TEST|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
214702715|NCT03296852|DRUG|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
214702716|NCT03230617|DEVICE|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
214702717|NCT04625361|DRUG|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
214702718|NCT05459792|PROCEDURE|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
214702719|NCT05459792|PROCEDURE|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
214702720|NCT05459792|PROCEDURE|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
214702721|NCT05994586|DIETARY_SUPPLEMENT|AP029 mix|Polyphenol-rich plant extracts Twice a day
214553353|NCT03633292|DRUG|Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)|"Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use."
214702722|NCT05994586|OTHER|Placebo|Twice a day
214702723|NCT01743872|PROCEDURE|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
214702724|NCT01743872|PROCEDURE|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
215162165|NCT05375071|OTHER|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
215162166|NCT05111626|DRUG|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
215162167|NCT05111626|DRUG|Nivolumab|Nivolumab will be administered as IV infusion.
215162168|NCT05111626|DRUG|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
215162169|NCT05111626|OTHER|Placebo|Placebo will be administered as IV infusion.
215162170|NCT04644497|PROCEDURE|ACL-reconstruction|Surgery technique in skeletally immature patients
214553354|NCT03633292|DRUG|Master formula of aloe vera gel 80%|Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
214553355|NCT00266123|DRUG|Sirolimus|
214553356|NCT06451640|DRUG|210mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
214702725|NCT01743872|PROCEDURE|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
215162171|NCT06441968|BIOLOGICAL|MPV/S-2P|A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.
215162172|NCT04087889|BIOLOGICAL|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
215162173|NCT04055311|BEHAVIORAL|Cancer Resource Information Support (CRIS)|Intervention support is patient initiated and accessed as needed
214553357|NCT06451640|DRUG|420mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
214553358|NCT06334315|DRUG|Desogestrel / Ethinyl Estradiol Pill|Standard pill packs containing 21 active pills and 7 placebo pills
214553359|NCT03061422|OTHER|Xylitol|caries prevention chewing gum
214553360|NCT03061422|OTHER|xylitol with bicarbonate|caries prevention chewing gum
214553361|NCT03061422|OTHER|paraffin|chewing gum
214553362|NCT03867695|DRUG|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
214553363|NCT03867695|DRUG|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
214553364|NCT02912390|PROCEDURE|Cerclage|Macdonald cerclage placed in standard fashion
214553365|NCT02912390|OTHER|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
214553366|NCT05104489|BIOLOGICAL|AdimrSC-2f|IM injection
214553367|NCT03405090|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
214553368|NCT03405090|DRUG|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
214553369|NCT01508949|DRUG|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
214553370|NCT01508949|DRUG|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
214553371|NCT05306249|DRUG|CBD LGP 50|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
214553372|NCT05306249|DRUG|Placebo|Patients will receive the MCT oil placebo without CBD until the end of week 12.
215162174|NCT04055311|BEHAVIORAL|Usual Care Enhanced|Usual care is enhanced with the addition of the NCI Facing Forward brochure
215162175|NCT04660812|DRUG|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
214553373|NCT04548284|DRUG|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
214553374|NCT04267965|PROCEDURE|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
214553375|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
214553376|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|
214553377|NCT01049451|DRUG|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
214553378|NCT01049451|DRUG|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
215162176|NCT04660812|DRUG|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
215162177|NCT04660812|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
215162178|NCT04660812|DRUG|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
215162179|NCT04660812|DRUG|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
215162180|NCT04660812|DRUG|Regorafenib|Regorafenib is administered as part of standard chemotherapy regimen
214553379|NCT00547612|OTHER|high performance liquid chromatography|
214553380|NCT00547612|OTHER|pharmacological study|
214553381|NCT00547612|RADIATION|[18F]-labeled substance P antagonist receptor quantifier|
214553382|NCT02162004|PROCEDURE|Continuous Correction|
214553383|NCT03997487|OTHER|TOFTEE|Smartphone app for taking quality images of conjunctivae
214553384|NCT00218114|DRUG|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
214553385|NCT00218114|DRUG|Placebo|Participants will be on matching placebo.
214553386|NCT03821103|BEHAVIORAL|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
214553387|NCT03821103|BEHAVIORAL|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
214553388|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
214553389|NCT01345864|DRUG|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
214553390|NCT01345864|DRUG|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
214702726|NCT01743872|PROCEDURE|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
214702727|NCT02388841|RADIATION|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
214702728|NCT04777578|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
214702729|NCT01221688|PROCEDURE|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
214702730|NCT01221688|PROCEDURE|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
214553391|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
214553392|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
214553393|NCT00370864|BIOLOGICAL|H5N1 pandemic influenza vaccine|
214553394|NCT05969301|OTHER|Specific spinal exercises for idiopathic scoliosis|The spinal esercises mainly include: active self-correction, strengthening spinal deep muscles while maintaining self-correction, segmentary stretching involving the limbs and back muscles, and postural task-oriented exercises (e.g. walking, standing, sitting).
214553395|NCT00348270|DEVICE|Tecnis Z9000 intraocular lens|
214553396|NCT00348270|DEVICE|MA60 intraocular lens|
214553397|NCT02799459|PROCEDURE|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
214553398|NCT02799459|PROCEDURE|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
214553399|NCT04307940|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg per tablet, two tablets (440 mg), intake a single dose orally.
214553400|NCT04307940|DRUG|Hydrocodone/Acetaminophen|5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
214553401|NCT04307940|DRUG|Placebo|two tablets, intake a single dose orally.
214553402|NCT04517097|BIOLOGICAL|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
214553403|NCT01644864|DRUG|0.375% ROPIVACAINE|
214553404|NCT01644864|DRUG|placebo|
214553405|NCT02535039|DRUG|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery
214553406|NCT02535039|OTHER|Physiological saline|The same volume of physiological saline will be given in Placebo group
214702731|NCT03016026|PROCEDURE|ERAS|Undergo an ERAS program
214702732|NCT02858154|OTHER|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
214702733|NCT02858154|OTHER|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
214702734|NCT05720442|DRUG|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
214702735|NCT05720442|DRUG|Mosapride Citrate|The mosapride citrate tablets will be administrated.
214553407|NCT04233112|DRUG|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
214553408|NCT04233112|DEVICE|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
214702736|NCT05207306|PROCEDURE|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
214702737|NCT05670405|OTHER|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R."
214702738|NCT01543139|DRUG|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
214702739|NCT01543139|DRUG|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
214553409|NCT04233112|DEVICE|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
214553410|NCT04233112|DRUG|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
214553411|NCT04624243|DRUG|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
214553412|NCT04624243|DRUG|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
214553413|NCT04624243|DRUG|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
214553414|NCT04624243|DRUG|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
214553415|NCT04169321|DRUG|Single Arm|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
214702740|NCT01543139|DRUG|Valproate|Valproate: Week0-8: 300mg/day
214702741|NCT05962918|OTHER|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
214702742|NCT00611221|PROCEDURE|Massage|Massage therapy by an RMT during labour
214702743|NCT00611221|PROCEDURE|Massage|Massage by anyone else, eg. husband, nurse, doula
214702744|NCT05990036|OTHER|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
214702745|NCT00218426|DRUG|naltrexone implant|naltrexone implant is 1000 mg naltrexone
215162181|NCT02444429|DRUG|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
215162182|NCT02444429|OTHER|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
215162183|NCT02444429|OTHER|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
215162184|NCT05018585|BIOLOGICAL|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
214553416|NCT06737861|OTHER|Group A|Participants will perform Buerger exercises three times daily, with each session including three cycles. Additionally, they will receive Whole Body Vibration therapy at a frequency of 25 Hz, three times per week. Each WBV session will last 12 minutes, divided into four 3-minute bouts, aiming to improve pain, balance, and lower limb circulation in diabetic peripheral neuropathy patients.
214553417|NCT06737861|OTHER|Group B|Participants will perform Buerger exercises three times daily, with each session consisting of three cycles. This exercise regimen is aimed at assessing its effectiveness on pain, balance, and circulation in diabetic peripheral neuropathy patients, serving as a comparison to the combined intervention with WBV therapy.
214702746|NCT00218426|DRUG|oral naltrexone|oral naltrexone 50 mg/day
214702747|NCT00218426|DRUG|oral placebo naltrexone|oral placebo naltrexone resembles active medication
214702748|NCT00218426|DRUG|placebo implant|placebo implant resembles active medication
214702749|NCT02952703|BEHAVIORAL|brief pre-delivery smoking cessation counseling|
214702750|NCT02952703|BEHAVIORAL|additional pre-delivery smoking cessation counseling|
214702751|NCT02952703|BEHAVIORAL|post- delivery smoking cessation counseling|
214553418|NCT05543174|DRUG|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
214553419|NCT06523140|DEVICE|Boracare remote monitoring solution|Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
214553420|NCT05281874|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
214702752|NCT02952703|BEHAVIORAL|incentives|
214702753|NCT04535154|OTHER|No interventions|No interventions
214702754|NCT01830816|DRUG|Ixazomib|Ixazomib capsules
214702755|NCT00518232|DRUG|OROS-methylphenidate|
214702756|NCT04437030|DEVICE|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
214702757|NCT04509804|OTHER|non-interventional|non-interventional
214702758|NCT06051825|DIAGNOSTIC_TEST|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
214702759|NCT00830115|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
214702760|NCT05340322|DEVICE|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
214702761|NCT00139607|DRUG|Paracoxib|
214702762|NCT04779632|DIETARY_SUPPLEMENT|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
215162185|NCT05018585|DIETARY_SUPPLEMENT|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
215162186|NCT05018585|BIOLOGICAL|Placebo|Placebo for Diamyd, Alhydrogel® only
215162187|NCT06307821|DIETARY_SUPPLEMENT|Probiotic|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
214702763|NCT04779632|DIETARY_SUPPLEMENT|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
214702764|NCT00352950|DRUG|AMG 954/Panitumumab|
214702765|NCT04826913|DEVICE|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
214553421|NCT05281874|BEHAVIORAL|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
214553422|NCT05281874|BEHAVIORAL|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
214553423|NCT04074720|PROCEDURE|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
214553424|NCT04074720|OTHER|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
214553425|NCT04074720|OTHER|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
214553426|NCT03489252|DEVICE|Monitoring Device|Wear Fitbit Charge 3
214553427|NCT06156059|DRUG|Oral Bedtime Melatonin|100 mg oral suspension or capsule given at bedtime
214553428|NCT06156059|DRUG|Placebo suspension or capsule|Indistinguishable suspension or capsule
214553429|NCT01546506|DRUG|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
214553430|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation alone|Ablation of the pulmonary veins for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
214553431|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation|Ablation of the pulmonary veins and the left atrium posterior wall for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
214553432|NCT00953771|DRUG|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
214553433|NCT00248352|BEHAVIORAL|Consultation with Endocrinologist|
214553434|NCT00248352|BEHAVIORAL|Counseling from Dietician|
214553435|NCT00248352|BEHAVIORAL|Counseling from Diabetes Educator|
214553436|NCT06842628|OTHER|Savoring|"Participants will follow an e-savoring training for 3 weeks. The first week will be focused on savoring past positive experiences (positive reminiscence and life lessons); the second week will be focused on savoring the present (absorption during an activity and writing a letter of gratitude to a significant person); and the third week will be focused on savoring the future (anticipating positive future events and making kind gestures to a significant person). After each activity, they will be guided to reflect and savor the positive emotions that emerge from the activity.~The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
214702766|NCT05897112|DRUG|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
214702767|NCT05897112|DRUG|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
214553437|NCT06842628|OTHER|Positive Emotional Induction|"Participants will follow a positive emotional induction training for 3 weeks, with 2 exercises per week.~The first week, they will listen to a piece of music and watch a video that elicits positive emotions; the second week, they will do an activity that they particularly enjoy in solitude and listen to a narrative about gratitude; the third week, they will listen to a narrative about hope and carry out an activity they like with a loved one. The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
214553438|NCT05950334|DRUG|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
214553439|NCT05950334|DRUG|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
214553440|NCT05950334|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
214553441|NCT05950334|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
214553442|NCT05950334|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
214553443|NCT03356392|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
214553444|NCT04896008|DRUG|Sotatercept|SC injection
214553445|NCT04896008|OTHER|Placebo|Placebo-matched SC injection
214553446|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
214553447|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
214553448|NCT03309540|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
214553449|NCT03223779|DRUG|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
214553450|NCT03223779|RADIATION|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
214553451|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
214553452|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
214553453|NCT04587128|DRUG|Panitumumab|Epidermal growth factor receptor inhibitor, anti-neoplastic
214553454|NCT04587128|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor, anti-neoplastic
214553455|NCT04587128|DRUG|Irinotecan|anti-neoplastic, chemotherapy drug
214702768|NCT03050216|BIOLOGICAL|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
214702769|NCT01726712|OTHER|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
214702770|NCT00635557|DRUG|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
214702771|NCT06060756|OTHER|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire"
214702772|NCT01207388|DRUG|Blinatumomab|Continuous intravenous infusion
214702773|NCT01885078|DRUG|Baricitinib|Administered orally
214702774|NCT01885078|DRUG|Placebo|Administered orally
214702775|NCT04146571|DRUG|Ensartinib|Oral, ALK inhibitor
214702776|NCT04622085|DEVICE|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
214702777|NCT04622085|DEVICE|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
214702778|NCT02466568|DRUG|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
214702779|NCT02466568|BIOLOGICAL|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
214702780|NCT03662633|DIAGNOSTIC_TEST|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
214553456|NCT04587128|DRUG|FOLFIRI Protocol|folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab
214553457|NCT04587128|DRUG|Bevacizumab|Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)
214553458|NCT01933243|DRUG|Fish oil|Participants will take 4 capsules daily
214702781|NCT03662633|DIAGNOSTIC_TEST|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
214553459|NCT01933243|DRUG|Placebo pill|Participants will take 4 capsules daily
215029704|NCT03196479|DRUG|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
214553460|NCT06476132|DRUG|Belumosudil|Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
214553461|NCT06476132|DRUG|Placebo for Belumosudil|Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
214553462|NCT06316986|DIAGNOSTIC_TEST|pH indication with NGPOD|"The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach."
214553463|NCT06564077|OTHER|Eldoa technique with conventional therapy|"is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
214553464|NCT06564077|OTHER|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
214553465|NCT04027413|DIETARY_SUPPLEMENT|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
214553466|NCT04027413|DIETARY_SUPPLEMENT|preOp|(100% carbohydrate).
214553467|NCT01270828|DRUG|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
214553468|NCT01270828|DRUG|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
214702782|NCT04917497|DRUG|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
214702783|NCT01546285|DEVICE|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
214702784|NCT03979027|DIETARY_SUPPLEMENT|Breakfast: ready-to-eat-cereal and milk|
214708987|NCT00426556|DRUG|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
215029705|NCT00205985|DEVICE|Scaphoid screw|Conservative treatment versus application of scaphoid screw
215029706|NCT03270228|OTHER|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
215029707|NCT03236545|OTHER|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
215029708|NCT03236545|OTHER|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
214553469|NCT03195361|DEVICE|SRS - Self Retaining Support system|
214553470|NCT04845399|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
214553471|NCT06456385|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The intervention applied is called transcutaneous auricular vagus nerve stimulation (taVNS) which administers electrical stimulation at the ear which targets the auricular branch of the vagus nerve.
214553472|NCT06456385|DEVICE|Sham Auricular Stimulation|The sham auricular stimulation administers electrical stimulation at the ear lobe which has less auricular branch of the vagus nerve.
214553473|NCT02643264|OTHER|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
214553474|NCT02643264|OTHER|Sham rTMS|Sham stimulation with the same regimen as active treatment
214553475|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
214553476|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
214553477|NCT06490302|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear
214553478|NCT06490302|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear
215029709|NCT01481610|DRUG|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
215029710|NCT01481610|DRUG|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
214702785|NCT03492645|BEHAVIORAL|Telephone-and technology-facilitated treatment protocol|"1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
214702786|NCT03492645|BEHAVIORAL|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
214702787|NCT02750904|BEHAVIORAL|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
214702788|NCT02750904|BEHAVIORAL|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
214702789|NCT02942316|DEVICE|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure"
214702790|NCT02417467|OTHER|Nicotine E-Cigarette|
214702791|NCT02417467|OTHER|Non-Nicotine E-Cigarette|
214702792|NCT02417467|BEHAVIORAL|Counseling|
214702793|NCT01690169|DRUG|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
215029711|NCT03855540|DIAGNOSTIC_TEST|ECHOcardiography|"ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease"
214553479|NCT00015847|BIOLOGICAL|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
214553480|NCT00015847|DRUG|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
214553481|NCT00636415|DRUG|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
214553482|NCT05044507|DEVICE|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
214553483|NCT05044507|DEVICE|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
214702794|NCT01690169|DRUG|placebo|A single dose of oral placebo administered.
214702795|NCT00613418|DEVICE|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
214702796|NCT01806636|DEVICE|PneumRx Coil System|
215029712|NCT03855540|DIAGNOSTIC_TEST|Peripheral blood samples for plasmatic biomarkers|"1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499"
215029713|NCT03855540|DIAGNOSTIC_TEST|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
215029714|NCT03855540|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
215029715|NCT03855540|DIAGNOSTIC_TEST|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
215029716|NCT02386956|OTHER|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
215029717|NCT02386956|OTHER|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
215029718|NCT02386956|OTHER|Control|10 minutes with the patient lying on a machine off of magnetotherapy
215029719|NCT02318433|DRUG|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
215029720|NCT02318433|DRUG|Saline|
215029721|NCT00437073|DRUG|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
215029722|NCT00437073|DRUG|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
215029723|NCT00437073|DRUG|lapatinib|lapatinib administered 1250mg once daily orally
215029724|NCT00860496|DRUG|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
214553484|NCT01877148|DEVICE|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
214553485|NCT01877148|BEHAVIORAL|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
214553486|NCT00709228|DRUG|PegIntron|1.5 ug/kg/week
214553487|NCT00709228|DRUG|Rebetol|800-1200 mg/day
214553488|NCT00975468|OTHER|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
215162188|NCT06307821|DIETARY_SUPPLEMENT|Placebo|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
215162189|NCT06561295|OTHER|Later Morning Timing of Spontaneous Breathing Trials|Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
215162190|NCT06848842|DRUG|Ivonescimab plus chemotherapy|Ivonescimab, 20mg/kg, D1, Q3W; Oxaliplatin, 130mg/m2, D1, Q3W; Capecitabine, 1000mg/m2, BID, D1-D14, Q3W
215162191|NCT06849687|DEVICE|Whole body vibration|Participants will be asked to sit on an chair without armrests close to the platform and will be asked to perform 90° shoulder flexion, bend both elbows slightly, flex the trunk forwards and place both hands on the platform.
215162192|NCT06849687|DEVICE|Sham Whole body vibration|Participants will receive the vibration with the device turned off.
215162193|NCT06849687|OTHER|Strengthening exercises|Participants will use elastic resistance for the finger extension and flexion exercises, and ball to strength wrist flexors for two sets of 10 repetitions within a training session.
215162194|NCT06146257|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
214553489|NCT01007110|DIETARY_SUPPLEMENT|DHA|Docosahexaenoic Acid (DHA) from algal oil
214553490|NCT01007110|OTHER|Placebo|Placebo capsule
214553491|NCT05984927|GENETIC|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
214553492|NCT05970705|DRUG|Regorafenib|this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
214553493|NCT05970705|DRUG|Trifluridine/Tipiracil|this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
214553494|NCT06427889|DRUG|Canoderm|humectant
214553495|NCT06427889|DRUG|Oviderm|humectant + antimicrobial
215162195|NCT06850415|DEVICE|Siriraj gastrointestinal transit capsule|The Siriraj gastrointestinal transit capsule is a local made colonic transit capsule. Each capsule contains 6 circular-shaped radiopaque markers.
215162196|NCT06850415|DEVICE|Sitz-Markers|The standard Sitzmark colonic capsule containing 24 ring-shaped radiopaque markers.
215162197|NCT04885998|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
214553496|NCT06427889|DRUG|Decubal|Non-humectant
214553497|NCT03422575|DRUG|Etoricoxib 120Mg Film-coated Tablet|One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
214553498|NCT03422575|DRUG|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)|One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
214553499|NCT04776642|OTHER|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
214553500|NCT04776642|OTHER|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
214553501|NCT04776642|OTHER|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
214553502|NCT05614726|DIETARY_SUPPLEMENT|575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase|A multi-strain probiotic blend
214553503|NCT02580929|RADIATION|radiotherapy|radiotherapy before surgery
214553504|NCT04747600|PROCEDURE|surgical resection|surgical resection
214553505|NCT02870972|DRUG|BCX7353|Plasma kallikrein inhibitor
214553506|NCT02870972|DRUG|Placebo|
214553507|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553508|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
215162198|NCT04885998|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
215162199|NCT06272812|BIOLOGICAL|MTBVAC|Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
215162200|NCT06272812|BIOLOGICAL|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
214553509|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553510|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553511|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553512|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553513|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
214553514|NCT03901001|DRUG|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
214553515|NCT03901001|DRUG|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
214553516|NCT04497389|BIOLOGICAL|Human Amniotic Fluid|Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
214553517|NCT02179177|DRUG|Apixaban|Drug is taken by mouth twice a day for 6 months
214553518|NCT02179177|DRUG|Placebo|
215162201|NCT05230433|DIETARY_SUPPLEMENT|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
215162202|NCT04211818|BEHAVIORAL|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
215162203|NCT04211818|BIOLOGICAL|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
215162204|NCT03427593|GENETIC|FACS analyses|FACS analyses
214553519|NCT04038918|OTHER|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
214553520|NCT04038918|OTHER|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
214553521|NCT02582294|OTHER|Questionnaire|
214702797|NCT03579550|PROCEDURE|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
215029725|NCT00860496|DRUG|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
214553522|NCT01845506|DEVICE|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
214553523|NCT01845506|DEVICE|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
214553524|NCT00325689|DRUG|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
214553525|NCT00325689|DRUG|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
214553526|NCT05444608|BEHAVIORAL|Breast milk olfactory stimulation|Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
214553527|NCT05444608|BEHAVIORAL|White noise auditory stimulation|Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
214702798|NCT02404883|OTHER|Online Decision-Aid Tool|
214702799|NCT04091230|DEVICE|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
215029726|NCT04434183|DEVICE|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
215029727|NCT03774381|DIETARY_SUPPLEMENT|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
215029728|NCT03774381|DIETARY_SUPPLEMENT|Control group|160 mg of placebo is orally administered per day for 12 weeks.
215162205|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
215029729|NCT00020683|DRUG|incyclinide|High dose given orally
215029730|NCT00020683|DRUG|incyclinide|Low dose given orally
215029731|NCT00020683|OTHER|laboratory biomarker analysis|Correlative studies
215162206|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
215162207|NCT04497584|DRUG|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
215162208|NCT05358249|DRUG|JDQ443|KRAS G12C inhibitor, oral
215162209|NCT05358249|DRUG|trametinib|MEK inhibitor, oral
215162210|NCT05358249|DRUG|Ribociclib|CDK4/6 inhibitor, oral
215162211|NCT05358249|BIOLOGICAL|cetuximab|EGFR inhibitor, intravenous
214553528|NCT03025750|BIOLOGICAL|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
214553529|NCT03025750|BIOLOGICAL|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
214553530|NCT01037556|DRUG|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
214553531|NCT02079324|BIOLOGICAL|GX-051|intratumoral injection
214553532|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
214553533|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
214553534|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
214553535|NCT04619602|DRUG|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
214553536|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214553537|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214553538|NCT04697927|OTHER|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
214553539|NCT04334278|BEHAVIORAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
214553540|NCT04334278|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
214553541|NCT02418936|DEVICE|gene diagnostic kit|
214553542|NCT00170183|DRUG|Nesiritide|
214553543|NCT01981005|DRUG|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
214553544|NCT03023553|BIOLOGICAL|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
214553545|NCT03023553|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
214553546|NCT03526653|OTHER|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
214553547|NCT03526653|OTHER|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
214553548|NCT03526653|OTHER|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
214553549|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
214553550|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
214553551|NCT05187429|DRUG|Saline|Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
214553552|NCT03020459|PROCEDURE|peeling-reposition|"After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively."
214553553|NCT03020459|PROCEDURE|peeling|After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.
214553554|NCT03020459|DRUG|Brilliant Blue G|We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
214553555|NCT03020459|OTHER|postoperative posture|Patients of both two groups need to keep prone position for two weeks after the operation.
214553556|NCT03020459|DEVICE|Constellation 23-gauge vitrectomy system|All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
214553557|NCT05090527|DIAGNOSTIC_TEST|Risk stratification|advanced penicillin challenge after risk stratification
214553558|NCT04829747|DRUG|Atogepant|Oral Tablet
214553559|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
214553560|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with infloran \[Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)\] and Bifidobacteria bifidum \[(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)\]; Laboratorio Farmaceutico S.I.T S.r.I ITALY\] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
215029732|NCT00219414|DEVICE|Adacolumn Apheresis System|
215029733|NCT05764928|DRUG|BLEX 404|BLEX 404 Oral Liquid, PO, BID
215029734|NCT02394574|OTHER|Clean Cookstove|Ethanol
214553561|NCT06159179|PROCEDURE|Medical thoracoscopy|Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic. A Flex-rigid thoracoscope will be inserted through the trocar cannula in the rigt or left mid axillary line of the hemithorax
214553562|NCT02922283|DEVICE|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
214553563|NCT02922283|PROCEDURE|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
215162212|NCT02723929|DEVICE|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
215162213|NCT02723929|DEVICE|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
215162214|NCT04453657|DEVICE|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
215162215|NCT03496805|DRUG|MGE|The patients will take 4 capsules by mouth BID (twice daily).
214553564|NCT02922283|DEVICE|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
214553565|NCT02922283|PROCEDURE|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
214553566|NCT02330094|DRUG|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
214553567|NCT02330094|DRUG|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
214553568|NCT00787306|BEHAVIORAL|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
214553569|NCT04361812|DRUG|HS632|Subcutaneous injection of HS632
214553570|NCT04361812|DRUG|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
214553571|NCT02667106|DRUG|RX0041-2|Pharmacokinetic study
214553572|NCT02790879|OTHER|Transition pediatric - adult|
214553573|NCT04199286|PROCEDURE|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
214553574|NCT02339597|PROCEDURE|Automatic Positive Airway Pressure (APAP) initiation|
214553575|NCT03445533|DRUG|Ipilimumab|Arm A: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.
214553576|NCT03445533|DRUG|Tilsotolimod with Ipilimumab|IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24. WITH (Arm B): Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11. in combination with tilsotolimod
214553577|NCT01168947|OTHER|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
214553578|NCT02615509|RADIATION|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
214708988|NCT00426556|DRUG|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
214708989|NCT03673696|DRUG|HEC74647PA Capsule|Capsule administered orally once daily
214708990|NCT03673696|DRUG|placebo|Matching Placebo Capsule
214708991|NCT02814695|DIETARY_SUPPLEMENT|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
214708992|NCT02814695|DIETARY_SUPPLEMENT|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
214553579|NCT02617953|DEVICE|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
214553580|NCT02617953|DEVICE|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
214553581|NCT02617953|DEVICE|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
214553582|NCT02714712|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
214553583|NCT03920098|OTHER|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level \>100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels \> 92 mg/dL and/or plasma glucose levels \> 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose \>100 mg/dL and/or \> 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
214553584|NCT05182307|DEVICE|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
214553585|NCT05272709|DRUG|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
214553586|NCT05272709|DRUG|Darolutamide|Darolutamide will be administered orally, twice daily, for up to 12 months.
214553587|NCT04548986|DEVICE|Aktiia.product|The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
214553588|NCT03622255|PROCEDURE|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
214553589|NCT03622255|PROCEDURE|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
214553590|NCT00778232|DRUG|Gabapentin tablets 800 mg|
214553591|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
214553592|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
214553593|NCT04310332|DRUG|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
214553594|NCT04310332|DRUG|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
214553595|NCT01783340|DRUG|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
215162216|NCT03496805|OTHER|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
215162217|NCT03496805|OTHER|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
215162218|NCT04347603|PROCEDURE|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
215162219|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
215162220|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
214553596|NCT01783340|DRUG|Placebo|Placebo capsules will be administered at each immunization
214553597|NCT01783340|BIOLOGICAL|Immunization with falciparum|three inoculations with 5 infected mosquito bites
215162221|NCT05244447|OTHER|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
214553598|NCT05494970|OTHER|Accompaniment by the dental assistant.|"Inclusion visit (before radiotherapy treatment):~* oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~* a written information guide on oral hygiene will be given to the patient.~* the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient."
214553599|NCT00012064|BIOLOGICAL|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
214553600|NCT00703339|DRUG|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~* Cohort 1: dosed at 3 breaths (18 mcg)~* Cohort 2: dosed at 6 breaths (36 mcg)~* Cohort 3: dosed at 9 breaths (54 mcg)~* Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
214553601|NCT04492059|DEVICE|Blood flow restriction augmented physical therapy|Using a blood flow restriction cuff during physical therapy. It is a pressurized cuff that is used to decrease the amount of oxygen that is available to the muscle during exercise. This stimulates the muscle to believe it is in an anoxic state and can produce greater strength and hypertrophy with fewer reps and less weight which would mean less stress on a surgically repaired tendon.
214553602|NCT04492059|OTHER|Physical therapy|Completing traditional physical therapy.
214553603|NCT00945672|BIOLOGICAL|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
214553604|NCT00945672|BIOLOGICAL|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
214553605|NCT00945672|DRUG|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
214553606|NCT04505839|DRUG|STP1002|Oral capsule, QD
214553607|NCT00968526|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
214553608|NCT05214664|PROCEDURE|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~* The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~* The Surgery practitioner starts the surgical procedure.~* In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
214553609|NCT06179121|OTHER|DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease|Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S\&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.
214553610|NCT02134938|DIETARY_SUPPLEMENT|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
214553611|NCT04801732|OTHER|mulligan thoracic Sustained Natural Apophyseal Glides|"Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment."
214553612|NCT04801732|OTHER|traditional treatments|"includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles)."
214553613|NCT04201873|BIOLOGICAL|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
214553614|NCT04201873|BIOLOGICAL|Pembrolizumab|Given IV
214553615|NCT04201873|OTHER|Placebo Administration|Given IV
214553616|NCT04201873|DRUG|Poly ICLC|Given IM
214553617|NCT00566540|DRUG|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
215029735|NCT02394574|OTHER|Traditional Cookstove|Firewood / Kerosene
215029736|NCT02115529|DRUG|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
214702800|NCT01396239|DRUG|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
214553618|NCT00566540|DRUG|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
214553619|NCT00566540|RADIATION|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
214553620|NCT00566540|PROCEDURE|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
214553621|NCT03926195|DRUG|Filgotinib|200-mg tablet administered orally once daily
214553622|NCT03926195|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
215162222|NCT04058431|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
214553623|NCT03926195|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
214553624|NCT02373540|DEVICE|Algovita Spinal Cord Stimulation system|
214702801|NCT01396239|OTHER|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
214702802|NCT05122195|OTHER|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
214702803|NCT05140395|DIAGNOSTIC_TEST|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
214702804|NCT01895452|DRUG|ALKS 9072, Low Dose|Intramuscular injection, given monthly
215162223|NCT04058431|OTHER|Control- No Intervention|This group will refrain from getting OMT while in the study.
215162224|NCT06522568|BEHAVIORAL|MyMammogram|An online breast cancer screening decision aid
215162225|NCT06522568|OTHER|Provider communication|Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
214702805|NCT01895452|DRUG|ALKS 9072, High Dose|Intramuscular injection, given monthly
214702806|NCT03212664|OTHER|exercise|physical therapy exercises
214702807|NCT05582161|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
214702808|NCT01523561|BEHAVIORAL|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
214702809|NCT00828685|PROCEDURE|CRPP|Closed reduction, percutaneous pinning
214702810|NCT00828685|PROCEDURE|ORIF|Open reduction, internal fixation
214702811|NCT03591094|DRUG|PTI-428|Active
214702812|NCT03591094|DRUG|Placebo|Placebo
215162226|NCT03636295|DRUG|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
214702813|NCT04902534|DRUG|Naoqingzhiming Tablets (contains echinacoside 180mg)|Single dose escalation and multiple dose escalation
214702814|NCT04902534|DRUG|placebo of Naoqingzhiming Tablets (without echinacoside)|Single dose escalation and multiple dose escalation
214702815|NCT06061042|BEHAVIORAL|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
214702816|NCT06061042|BEHAVIORAL|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
214702817|NCT02466165|BEHAVIORAL|Physical exercise|
214702818|NCT05654766|DIAGNOSTIC_TEST|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
214702819|NCT05654766|DIAGNOSTIC_TEST|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
214702820|NCT04037917|DEVICE|CorNeat EverPatch|Covering Ophthalmic Implants
215162227|NCT04514952|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
214553625|NCT01236378|DRUG|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
214553626|NCT03882151|DIAGNOSTIC_TEST|electrical source imaging|automated analysis of surface EEG with electrocal source imaging
214553627|NCT03724253|DRUG|[68Ga]-NeoBOMB1|\[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
214553628|NCT01290276|DRUG|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
214553629|NCT01290276|DRUG|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
214553630|NCT01290276|DRUG|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
214553631|NCT01290276|DRUG|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
214553632|NCT04785118|DRUG|Hyoscine N Butylbromide|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
214553633|NCT04785118|DRUG|Ondansetron|Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
214553634|NCT04785118|DRUG|Saline|Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
214553635|NCT00447590|DEVICE|LAP-BAND System|Restriction of food intake
214553636|NCT00527761|DRUG|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
214553637|NCT00527761|DRUG|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
214553638|NCT00527761|DRUG|Temodar|150 mg by mouth (PO) on Days 1 - 5.
214553639|NCT01689857|DEVICE|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
214553640|NCT01689857|DEVICE|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
214553641|NCT01035853|DRUG|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
214553642|NCT03555253|BEHAVIORAL|Resilience-Based Program for Support Partners of PwMS|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
214553643|NCT02639455|BEHAVIORAL|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
214553644|NCT04052815|BEHAVIORAL|Diabetes prevention program culturally tailored|Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
214553645|NCT03944655|DRUG|Strepsils Anaesthetic Formula|Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
214553646|NCT03944655|DIETARY_SUPPLEMENT|Clear Mint Drops|Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
214553647|NCT03965442|DRUG|Control|Patients who underwent mastectomy under standard general anesthesia
214553648|NCT03965442|DRUG|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
214553649|NCT05105087|DRUG|Perflubutane Microbubble|Given subdermally
214553650|NCT05105087|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo ultrasound
214553651|NCT02171299|PROCEDURE|Wound infiltration with local anaesthetic|
214553652|NCT02171299|DRUG|Ropivacaine|
214553653|NCT02330770|DRUG|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
214553654|NCT02330770|DRUG|GnRHa then HCG (single low-dose)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
214553655|NCT02330770|DRUG|GnRHa then HCG (multiple low-doses)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
214702821|NCT02831842|DRUG|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
215029737|NCT02115529|DRUG|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
215029738|NCT06473714|DEVICE|tDCS|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will be made at 1,5mA
215029739|NCT06473714|DEVICE|SHAM|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will not be made. The electrodes are placed on the skull and a slight but non-continuous intensity is applied.
214553656|NCT04631731|DIAGNOSTIC_TEST|Blood screening|Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
214553657|NCT04631731|DIAGNOSTIC_TEST|Tissue screening|Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.
214553658|NCT06179745|COMBINATION_PRODUCT|EEG-based brain-computer interface|EEG-based brain-computer interface detecting the patient's EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient.
214553659|NCT06179745|COMBINATION_PRODUCT|Sham EEG-based brain-computer interface|Fake (Sham) EEG-based brain-computer interface which outputs a decision at random about whether EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient are currently detected.
214553660|NCT06179745|DEVICE|Functional Electrical Stimulation|Neuromuscular stimulation of several upper limb muscles (elbow extensors, hand extensors/flexors) to effectuate reach, grasp and release movements of the affected upper limb.
214553661|NCT06179745|DEVICE|Active hand orthosis|Active hand orthosis effectuating reach, grasp and release movements of the affected uppe r limb.
214553662|NCT01914770|DRUG|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
214553663|NCT01914770|DRUG|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
214553664|NCT01914770|DRUG|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
214553665|NCT04700553|DEVICE|Localized muscle vibration|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
214553666|NCT04700553|OTHER|Conventional physiotherapy intervention|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
214702822|NCT02831842|DRUG|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
214702823|NCT02831842|DRUG|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
214553667|NCT04113070|DEVICE|Anthropometric measuring|To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
214553668|NCT04113070|OTHER|Growth environment evaluation|The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
214553669|NCT05614622|DRUG|Cyclopentolate Hydrochloride 1.0% eye drops|A short-acting mydriatic agent
214553670|NCT01736540|DEVICE|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2\*, respectively).
214553671|NCT06122922|DRUG|Hyperpolarized Xe129|Hyperpolarized Xenon Gas
214553672|NCT01991327|DRUG|Androxal|
214553673|NCT01991327|DRUG|Placebo|
214553674|NCT00479882|DRUG|Comparator: simvastatin|
214553675|NCT00479882|DRUG|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
214553676|NCT00479882|DRUG|Placebo|
214553677|NCT00479882|DRUG|MK-0524B|
214553678|NCT05084339|DIAGNOSTIC_TEST|CGM|blinded CGM used at 4 different time points in pregnancy
214553679|NCT02129868|DEVICE|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
214553680|NCT03728270|DEVICE|Patient Specific Titanium Eminoplasty|"* The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl"
214553681|NCT03728270|PROCEDURE|Inlay Autogenous Bone Graft|"\* Steps to harvest the bone graft:~* Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~* To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis."
214553682|NCT03738475|DRUG|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
214553683|NCT03738475|DRUG|Placebo|Administered intravenously on days 1 and 8.
214553684|NCT01083953|DRUG|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
214553685|NCT01083953|DRUG|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
214553686|NCT02694367|OTHER|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
214553687|NCT04060693|DEVICE|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
214702824|NCT06299579|DRUG|GD-11 for injection test group|The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
214702825|NCT06299579|DRUG|Placebo control group|The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
214702826|NCT04072185|OTHER|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
215029740|NCT03123679|RADIATION|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"1. Patient referred to radiotherapy treatment are evaluated with a baseline PFT \[Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)\].~2. RT simulation at the radiotherapy department and treatment planning.~3. Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~4. Radiotherapy."
215029741|NCT05321745|OTHER|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
215029742|NCT03731572|OTHER|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
215029743|NCT03731572|OTHER|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
215029744|NCT01275300|DRUG|Aspirin|
215029745|NCT01275300|DRUG|Placebo|
215029746|NCT01275300|DRUG|Niacin|
215029747|NCT03227549|PROCEDURE|Direct Superior Approach|Total hip arthroplasty using direct superior approach
215029748|NCT03227549|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
215029749|NCT03227549|PROCEDURE|Posterior Approach|Total Hip Arthroplasty using posterior approach
215029750|NCT02333474|BIOLOGICAL|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
214702827|NCT03280069|DEVICE|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
214702828|NCT04238884|DRUG|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
214702829|NCT04238884|DRUG|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
214702830|NCT04315493|DRUG|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
214702831|NCT04315493|DRUG|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
214702832|NCT05098158|OTHER|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
214702833|NCT04379934|DIETARY_SUPPLEMENT|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
214702834|NCT05380674|BEHAVIORAL|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
214702835|NCT04702217|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
214702836|NCT06110299|DIAGNOSTIC_TEST|air injection|delination of the ureter and pelvis by injecting air under C-ARM
214553688|NCT03836859|DRUG|rhNGF 20μg/mL|"Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days."
214553689|NCT03836859|OTHER|Placebo|Vehicle: formulation containing L-methionine as excipient.
214702837|NCT01023438|OTHER|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
214553690|NCT05575817|BEHAVIORAL|Web Based Patient Tutorial on Prolonged Grief Disorder Therapy|"The patient tutorial will contain 9 modules, each designed to be used flexibly in conjunction with Prolonged Grief Disorder Therapy (PGDT) telehealth sessions with the therapist. Each module takes about 15-30 minutes to complete. The patient tutorial consists of information about grief and adaptation to loss, including a description of seven healing milestones that are the focus of PGDT and an explanation of prolonged grief and how to understand it. In addition, the tutorial has descriptions of the procedure, goals and rationale for a series of in-session therapeutic exercises to be undertaken with the therapist, as well as descriptions and encouragement to participate in interim therapeutic activities (i.e., homework) assigned by the therapist after each treatment session. The tutorial also contains a self-assessment component for each module that can be completed by the patient and shared with the therapist."
214702838|NCT01023438|OTHER|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
214702839|NCT03827590|DRUG|Test|three times a day for five days
214702840|NCT03827590|DRUG|Active Comparator Control 1|three times a day for five days
214702841|NCT03827590|DRUG|Active Comparator Control 2|three times a day for five days
214702842|NCT03827590|DRUG|Placebo|three times a day for five days
214702843|NCT03350178|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
214702844|NCT02928926|OTHER|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
214702845|NCT01204697|DRUG|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
214702846|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
214702847|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally as monotherapy
214702848|NCT02333591|DRUG|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
214702849|NCT02333591|DRUG|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
214702850|NCT02333591|DRUG|Saline|Infused intravenously for 2,5 hours.
214702851|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
214702852|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
214702853|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
214702854|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
214702855|NCT01205451|DRUG|Botulinum toxin type A|Botulinum toxin type A
214702856|NCT03777202|PROCEDURE|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
214702857|NCT03777202|PROCEDURE|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
214702858|NCT05279105|BEHAVIORAL|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
214553691|NCT01667809|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
214553692|NCT01667809|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
214553693|NCT02159040|DRUG|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
214553694|NCT02159040|DRUG|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
214553695|NCT00054678|DRUG|MyoCell™|
214553696|NCT00054678|DEVICE|MyoCath™|
214553697|NCT01972932|DIETARY_SUPPLEMENT|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
214553698|NCT01972932|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
214553699|NCT02676843|DRUG|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
214553700|NCT00759642|DRUG|lapatinib|lapatinib 1500 mg PO daily
214553701|NCT05333822|DIETARY_SUPPLEMENT|Bashan|a vegetable plant based compound drink add after three meals for 14 days
214553702|NCT05333822|OTHER|water|water as placebo
214553703|NCT03867539|OTHER|Differing pain management strategy|"The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
214553704|NCT04545528|BEHAVIORAL|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
214553705|NCT01340001|PROCEDURE|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
214553706|NCT05335200|DIAGNOSTIC_TEST|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
214553707|NCT06377085|DRUG|Placebo for the AZA 10mg/m^2|Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.
214553708|NCT06377085|DRUG|Placebo for the AZA 20mg/m^2|Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.
215162228|NCT05852509|BEHAVIORAL|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
215162229|NCT05852509|BEHAVIORAL|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
215162230|NCT05710380|OTHER|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
214553709|NCT06377085|DRUG|Placebo for the AZA 35mg/m^2|Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.
215162231|NCT05710380|RADIATION|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
214553710|NCT06377085|DRUG|Placebo for the AZA 75mg/m^2|Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.
214553711|NCT06377085|DRUG|5-Azacytidine 10mg/m^2|5-Azacytidine 10mg/m\^2, one-time subcutaneous injection
214553712|NCT06377085|DRUG|5-Azacytidine 20mg/m^2|5-Azacytidine 20mg/m\^2, one-time subcutaneous injection
214553713|NCT06377085|DRUG|5-Azacytidine 35mg/m^2|5-Azacytidine 35mg/m\^2, one-time subcutaneous injection
214553714|NCT06377085|DRUG|5-Azacytidine 75mg/m^2|5-Azacytidine 75mg/m\^2, one-time subcutaneous injection
214553715|NCT00004178|BIOLOGICAL|therapeutic autologous lymphocytes|
214553716|NCT00884416|DRUG|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
214553717|NCT02803593|BEHAVIORAL|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
214553718|NCT02803593|BEHAVIORAL|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
215162232|NCT05710380|PROCEDURE|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
215162233|NCT04725916|OTHER|Showering|Patients will be instructed to shower after surgery with drains in place
214553719|NCT00005871|DRUG|fluorouracil|
214553720|NCT00005871|DRUG|rubitecan|
214553721|NCT00302523|DRUG|Tacrolimus|FK506,0.1mg/kg/d
214553722|NCT01993849|DRUG|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
214553723|NCT01993849|OTHER|Placebo|Placebo, designed to match in appearance to NAC
214553724|NCT00480675|PROCEDURE|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
214553725|NCT00480675|PROCEDURE|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
214553726|NCT02023749|DIETARY_SUPPLEMENT|Nut group|
214553727|NCT05450536|OTHER|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
214553728|NCT06411509|OTHER|TC plus active rTMS|The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.
214553729|NCT06411509|OTHER|Tai Chi plus sham rTMS|Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.
214553730|NCT06411509|BEHAVIORAL|TC-alone|Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down
214553731|NCT06411509|BEHAVIORAL|Low intensity physical exercise|To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
214553732|NCT00927498|DRUG|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
214553733|NCT00927498|DRUG|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
214553734|NCT05289219|BEHAVIORAL|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
214553735|NCT00728299|DRUG|PomWonderful Juice|8 oz per day each day for 78 weeks
214553736|NCT00728299|DRUG|Placebo juice|8 oz per day for 78 weeks
214553737|NCT04430803|DIETARY_SUPPLEMENT|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
214553738|NCT04430803|OTHER|Control Water|A glass of tap water
214553739|NCT03659383|COMBINATION_PRODUCT|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
214553740|NCT02735434|BEHAVIORAL|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
215162234|NCT04725916|OTHER|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
215162235|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
215162236|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
215162237|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
215162238|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
215162239|NCT03946215|OTHER|Each participant will perform:|Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
215162240|NCT06081114|DIETARY_SUPPLEMENT|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
214553741|NCT02735434|OTHER|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
214553742|NCT00499278|BEHAVIORAL|Rehabilitation after joint replacement surgery|
214553743|NCT05773911|DEVICE|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
214553744|NCT05773911|DEVICE|Reciprocal Chitosan brush|Reciprocal Chitosan brush
214553745|NCT05584605|BEHAVIORAL|Aerobic treadmill training|The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
214553746|NCT05584605|BEHAVIORAL|Stretching exercise|Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
214553747|NCT03924115|DEVICE|Transmedial Psychoeducational Program to improve adherence full or partial (PS)|Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
214553748|NCT04088045|DEVICE|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
214553749|NCT03443414|DRUG|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
214553750|NCT03443414|DRUG|Placebo|Placebo solution
214553751|NCT02704013|DRUG|Oxybutynin|Anticholinergic
214553752|NCT06485739|DRUG|Irinotecan liposomes combined with cisplatin/carboplatin|Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
215162241|NCT00876200|DRUG|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
214702859|NCT02383680|BIOLOGICAL|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
214702860|NCT00560222|DIETARY_SUPPLEMENT|bovine lactoferrin|1gm of lactoferrin will be given each day
215162242|NCT00876200|DRUG|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
215162243|NCT05108870|DRUG|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
214553753|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
214553754|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
214553755|NCT01079247|OTHER|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
214553756|NCT01079247|OTHER|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
214553757|NCT00000598|BEHAVIORAL|diet, fat-restricted|
214553758|NCT00000598|BEHAVIORAL|exercise|
214702861|NCT00560222|DIETARY_SUPPLEMENT|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
215162244|NCT05108870|DRUG|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
215162245|NCT05108870|DRUG|Carboplatin|Chemotherapy drug.
215162246|NCT05108870|DRUG|Paclitaxel|Chemotherapy drug.
215162247|NCT05108870|PROCEDURE|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
215162248|NCT05948943|DRUG|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 0-5 years of age will receive dose 3 of alpelisib"
214702862|NCT01499719|BEHAVIORAL|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
215162249|NCT05948943|DRUG|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
214702863|NCT02732353|DIETARY_SUPPLEMENT|Minced beef|Cow meat protein supplement
214702864|NCT02732353|DIETARY_SUPPLEMENT|Hydrolyzed beef|Cow meat protein supplement
214702865|NCT03409419|DRUG|[18F] CFA|pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
214553759|NCT04569019|OTHER|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
214553760|NCT04380077|PROCEDURE|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
214553761|NCT04380077|PROCEDURE|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
214553762|NCT02660515|PROCEDURE|Additional wrist arthroscopy|
214702866|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
214702867|NCT02131545|DRUG|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
214702868|NCT02131545|DRUG|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
214702869|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
214702870|NCT02825147|DRUG|Pegaspargase|
214702871|NCT02825147|DRUG|Methotrexate|
214553763|NCT02660515|PROCEDURE|ORIF|
215029751|NCT02333474|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
215029752|NCT01003327|DEVICE|I-gel|intubation with I-gel airway
214553764|NCT00940745|DEVICE|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
214553765|NCT00940745|DRUG|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
214553766|NCT01389089|BEHAVIORAL|ice gel pack|ice gel pack combined with elevation
214553767|NCT01389089|OTHER|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
214553768|NCT01389089|DEVICE|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
214553769|NCT01708434|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
214553770|NCT01181791|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
214553771|NCT01181791|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
214553772|NCT05692583|DIAGNOSTIC_TEST|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
214553773|NCT05490212|OTHER|Single Molecule Array (SiMoA)|The Single Molecule Array (SiMoA), capable of quantifying multiple salivary cytokines from a single sample source at a femtoscale level. The SiMoA platform has been adapted to detect up to nine inflammatory biomarkers, including CRP, PCT, tumor necrosis factor α (TNF α) and ILs 1ß, 6, and 8 in neonatal saliva.
214553774|NCT02165995|PROCEDURE|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
214553775|NCT02165995|PROCEDURE|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
214702872|NCT02825147|DRUG|Dexamethasone|
214702873|NCT02825147|DRUG|Etoposide|
214702874|NCT02825147|RADIATION|radiotherapy|
214702875|NCT01040338|DRUG|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
214702876|NCT01194869|DRUG|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
214702877|NCT01194869|DRUG|Cisplatin|75 mg/m² given IV
214702878|NCT01194869|DRUG|Paclitaxel|175 mg/m² given IV
214702879|NCT00900445|DRUG|Daunorubicin Hydrochloride|Given IV
214702880|NCT00900445|OTHER|Pharmacological Study|Correlative studies
214702881|NCT00900445|DRUG|Prednisolone|Given orally
214702882|NCT00900445|DRUG|Prednisone|Given orally
214702883|NCT00900445|DRUG|Vincristine Sulfate|Given IV
214702884|NCT04859972|DIAGNOSTIC_TEST|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
214702885|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
214702886|NCT00313950|BIOLOGICAL|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
214702887|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
215029753|NCT01003327|DEVICE|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
214553776|NCT06154928|OTHER|Drinking Warm Water Intervention|Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
214553777|NCT02103114|DRUG|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay"
214702888|NCT05971953|OTHER|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
214702889|NCT05971953|OTHER|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
214702890|NCT03154151|BEHAVIORAL|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
214702891|NCT03154151|BEHAVIORAL|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
214702892|NCT06169930|OTHER|This was an observational study without any intervention|This was an observational study without any intervention
214702893|NCT05221788|PROCEDURE|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
214702894|NCT03368131|DRUG|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
214702895|NCT03368131|DRUG|Capecitabine|825\~1000mg/m2 bid d1-14
215029754|NCT04014192|DRUG|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
215029755|NCT04014192|DRUG|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
215029756|NCT04014192|DRUG|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
214553778|NCT02103114|OTHER|Placebo|Normal saline placebo
214553779|NCT05553093|DRUG|Tirzepatide|Tirzepatide ih qw
214553780|NCT05553093|DRUG|Insulin Glargine|6 IU ih qd
214553781|NCT04883112|DEVICE|Magnetic Tape®|Magnetic tape® is applied without creating any tension over low back
214553782|NCT04883112|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension over low back
214553783|NCT03883464|OTHER|Diet|Restriction in postoperative fat diet
214553784|NCT03773913|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
215029757|NCT00951639|DIETARY_SUPPLEMENT|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
215029758|NCT00951639|PROCEDURE|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
215029759|NCT00951639|DIETARY_SUPPLEMENT|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
215029760|NCT04412746|DRUG|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
215029761|NCT03014115|DIETARY_SUPPLEMENT|combination ARA + DHA|combination ARA + DHA supplemented infant formula
215029762|NCT03014115|DIETARY_SUPPLEMENT|DHA|DHA supplemented infant formula
214553785|NCT06497803|OTHER|Nurse-Led Body Protection Education|"Based on BST and Safe Touches education programs and in line with the studies conducted in the literature on children who are not visually impaired, NLBPE was created by the researchers (Akgul et al., 2021; Citak-Tunc et al., 2018; Pulido, 2019; Wurtele, 2007). The program aims to teach visually impaired children how to protect the private parts of their bodies, to distinguish between good and bad touch, to distinguish between good and bad secrets, to say no, scream, and ask for help when necessary. As education tools, dolls and distress whistles were used. In order for children to learn the private parts of their bodies, a doll was used. The practice of Say No, Scream, Run, and Blow Your Whistle While Running in order for the students to protect their body from bad touch was applied by the students one by one firstly, and in groups later."
214553786|NCT06497803|OTHER|Reminder Education Brochure|The brochure was prepared in line with the NLBPE and included what is a good touch and a bad touch, how to distinguish a good touch from a bad touch, examples of good touch and bad touch, and what to do when encountered with a bad touch (Say No, Scream, Run, and Blow Your Whistle While Running). The brochure, the content of which was prepared by the researcher, was translated into Braille Alphabet by a visually impaired teacher working at the school where the research was conducted, before it was distributed to the intervention group members.
214553787|NCT01530737|DRUG|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
214553788|NCT01530737|OTHER|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
214553789|NCT03933462|DEVICE|InnoSpire Go|Participants will use for 30 days.
214553790|NCT03933462|DEVICE|Jet Nebulizer|Participants will use for 30 days.
214553791|NCT00276835|BIOLOGICAL|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
214553792|NCT00276835|DIETARY_SUPPLEMENT|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
214553793|NCT03131947|OTHER|HIV positive patients|As above
214553794|NCT02465736|DRUG|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
215162250|NCT05106361|BEHAVIORAL|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
215162251|NCT05106361|BEHAVIORAL|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
215162252|NCT05031780|DRUG|Mitapivat|Mitapivat tablets
214553795|NCT02465736|DRUG|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
214553796|NCT02465736|RADIATION|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
214553797|NCT02465736|PROCEDURE|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
214553798|NCT02465736|DRUG|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
214553799|NCT02465736|DRUG|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
214553800|NCT02767752|DIETARY_SUPPLEMENT|T-ChOS|
214553801|NCT02767752|DRUG|Gemcitabine|
214553802|NCT02767752|DIETARY_SUPPLEMENT|Placebo|
214702896|NCT03368131|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
215162253|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
215162254|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 100 mg tablets
215162255|NCT06399692|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
214553803|NCT02767752|DRUG|Capecitabine|
214553804|NCT04692467|DRUG|Amlodipine 5mg|Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
214702897|NCT03368131|RADIATION|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
214702898|NCT05957497|BIOLOGICAL|Biological samples transport and analysis|Biological samples transport and analysis
214702899|NCT01921933|DEVICE|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
214702900|NCT03773926|DEVICE|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
215162256|NCT06399692|PROCEDURE|Percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
215162257|NCT06431386|BEHAVIORAL|Behavioural Activation (BA) Therapy|Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.
214702901|NCT01707329|DRUG|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
214702902|NCT01707329|DRUG|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
214702903|NCT02941341|DRUG|r-hFSH|As per standard practice
214702904|NCT01684475|DRUG|CJH1 (CLR4001)|
214702905|NCT02331524|BEHAVIORAL|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
214702906|NCT02331524|OTHER|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
214702907|NCT00790179|PROCEDURE|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
215162258|NCT06431386|DRUG|Esketamine|Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
215162259|NCT01368588|RADIATION|radiation therapy|Undergo RT using IMRT or 3D-CRT
215162260|NCT01368588|RADIATION|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
215162261|NCT06013995|DRUG|BMS-986326|Specified dose on specified days
215162262|NCT06013995|OTHER|Placebo for BMS-986326|Specified dose on specified days
215162263|NCT05292963|OTHER|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
214553805|NCT05262452|DEVICE|ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system|Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound
214553806|NCT05262452|DRUG|FOLFIRINOX regimen|"a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis"
214702908|NCT00030615|DRUG|decitabine|Given IV
214702909|NCT00030615|OTHER|pharmacological study|Correlative studies
214702910|NCT00030615|OTHER|laboratory biomarker analysis|Correlative studies
214702911|NCT03908710|OTHER|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
214702912|NCT05960110|DRUG|Fluoride varnish|Fluoride varnish 26200 ppm
214702913|NCT05960110|DRUG|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
215162264|NCT04705038|BEHAVIORAL|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
215162265|NCT06027151|DRUG|1ml of 1% metronidazole gel|Subgingivally at baseline visit
214553807|NCT01160237|BIOLOGICAL|PandemrixTM|One dose intramuscular injection
214553808|NCT01160237|BIOLOGICAL|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
214553809|NCT00422734|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
214553810|NCT00422734|DRUG|Placebo|placebo tablet taken by mouth once a day for 12 weeks
214553811|NCT00169247|DRUG|cetuximab|
214553812|NCT00169247|DRUG|Cisplatin|
214553813|NCT00169247|PROCEDURE|Radiotherapy 70 Gy, 35 fractions|
214553814|NCT02400008|PROCEDURE|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
214553815|NCT01831037|OTHER|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (\>50% of cases).
214553816|NCT01831037|OTHER|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
214553817|NCT02441998|OTHER|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
214553818|NCT01445327|OTHER|Specimen collection|
214553819|NCT03431753|DIAGNOSTIC_TEST|PSA, STHLM3 and mpMRI for PC detection|"Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination."
215162266|NCT06027151|DRUG|1ml of 2% minocycline gel|sub gingivally at baseline visit
215162267|NCT06027151|DRUG|1ml of combination of 1% metronidazole gel and 2% minocycline|subgingivally at baseline visit
215162268|NCT04154943|DRUG|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
215162269|NCT06349759|DRUG|phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist|Once daily dosing
215162270|NCT06349759|DRUG|Placebo|Once daily dosing
215162271|NCT00872625|DRUG|cyclophosphamide|
215162272|NCT00872625|DRUG|docetaxel|
215162273|NCT00872625|DRUG|epirubicin hydrochloride|
215162274|NCT00872625|DRUG|fluorouracil|
215162275|NCT00872625|PROCEDURE|neoadjuvant therapy|
215162276|NCT00872625|PROCEDURE|therapeutic conventional surgery|
215162277|NCT00872625|RADIATION|hypofractionated radiation therapy|
215162278|NCT00872625|RADIATION|image-guided radiation therapy|
215162279|NCT00872625|RADIATION|radiation therapy|
215162280|NCT00872625|RADIATION|stereotactic radiosurgery|
215162281|NCT02869867|OTHER|refrigerated cushion|refrigerated cushion
215162282|NCT06494488|DRUG|EPA|Fish oil
215162283|NCT06494488|DRUG|DHA|Fish oil
214553820|NCT05219838|DRUG|Lu AG06466|Lu AG06466 will be administered per dose and schedule specified in the arm description.
214553821|NCT06031636|DRUG|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
214553822|NCT06031636|DRUG|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
214553823|NCT04193423|OTHER|Neck extensors training versus deep cervical flexors training, compared to a control group.|"During the first month, the participants of the experimental groups will come at Rehabilitation Service to do the exercises individually and supervised by the physiotherapist and to received the conventional treatment (10 minutes of infrared heat, 10 minutes of massage and 15 minutes of TENS). The last six months, they will perform daily home exercises.~* A-group: the degrees respect to the floor in wich each participant can hold the craniocervical extension and the cervicothoracic extension during 5 seconds will bo measured with the BDI.~* B-group: Using an air-filled pressure sensor placed behind the neck, the physiotherapist will identify the target level that the patient can hold steadily a craniocervical flexion (CCF) for 5 seconds in a controlled manner. They will train following the protocol described by Jull et al.~Of each of this exercises, they will perform 10 isometric contractions, at the corresponding degrees or target level, of 10 seconds with a rest of 3-5 seconds."
214553824|NCT02432651|DRUG|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
214553825|NCT02432651|DRUG|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
214553826|NCT02432651|DRUG|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
214553827|NCT02432651|DRUG|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
214553828|NCT05317442|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"
214702914|NCT04584853|DRUG|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
215162284|NCT02015013|BIOLOGICAL|Filgrastim|10 microgram/kg daily for 5 days, Subcutaneous injection.
215162285|NCT02015013|DRUG|Plerixafor|IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
215162286|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody.
215162287|NCT06960577|DRUG|Methotrexate|Chemotherapy agent.
215162288|NCT06960577|DRUG|Vinblastine|Chemotherapy agent
215162289|NCT06960577|DRUG|Doxorubicin|Chemotherapy agent
215162290|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
215162291|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody
215162292|NCT06960577|DRUG|Gemcitabine|Chemotherapy agent
215162293|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
215162294|NCT05800665|DRUG|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
215162295|NCT05956626|DRUG|OCU410ST|Subretinal Administration of OCU410ST
215162296|NCT03626662|DRUG|AMG 890|Ascending Single Doses of AMG 890
215162297|NCT03626662|DRUG|Placebo|Calculated volume to match experimental drug.
215162298|NCT06046287|DRUG|Daratumumab and hyaluronidase-fihj|subucatneous, fixed dose 1800mg combination drug product containing rHuPH20 drug substance (2000 U/mL) and daratumumab drug substance (120 mg/mL) will be administered weekly for the first 8 weeks, and then every 2 weeks from week 9 to week 24.
215162299|NCT03431584|DRUG|infiltration of corticosteroids|infiltration of corticosteroids
215162300|NCT03431584|DRUG|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
215162301|NCT05665608|DEVICE|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
215162302|NCT05665608|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
214553829|NCT01824589|DEVICE|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
214553830|NCT01824589|DEVICE|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
214702915|NCT04584853|DRUG|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
214702916|NCT00546793|BIOLOGICAL|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
214702917|NCT05480254|OTHER|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
214702918|NCT05743751|DEVICE|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
214702919|NCT05743751|DEVICE|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
214702920|NCT01174953|DRUG|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
214708993|NCT02814695|DIETARY_SUPPLEMENT|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
215162303|NCT03841617|DRUG|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
215162304|NCT03841617|RADIATION|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
215162305|NCT03841617|RADIATION|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
215162306|NCT03841617|OTHER|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
214553831|NCT03388476|DIAGNOSTIC_TEST|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
214553832|NCT04513093|OTHER|Aromatherapy Massage|The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
214553833|NCT03104010|DRUG|Somatropin Injection|Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
214553834|NCT02521714|DRUG|Lenalidomide|
214553835|NCT06415110|DEVICE|Allosync Expand|Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)
214553836|NCT02718261|DRUG|Pantoprazole|
214553837|NCT02718261|DRUG|Saline 0.9% (matching placebo)|
214553838|NCT00368875|DRUG|vorinostat|Given orally
214553839|NCT00368875|DRUG|paclitaxel|Given IV
214553840|NCT00368875|BIOLOGICAL|bevacizumab|Given IV
214553841|NCT01613144|DEVICE|OsseoScrew Spinal Fixation System|Surgical intervention
214553842|NCT04118881|OTHER|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
214553843|NCT02259023|OTHER|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
214553844|NCT02259023|OTHER|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
214553845|NCT04766723|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214553846|NCT04766723|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214553847|NCT00213200|DRUG|morphine, amethocaine|
214553848|NCT02865512|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
214702921|NCT03874754|OTHER|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
214702922|NCT02449408|OTHER|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
214702923|NCT00368498|DRUG|teicoplanin|
214702924|NCT04321252|DRUG|KAE609|"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
214702925|NCT04321252|DRUG|Placebo|matching placeo for iv administration
214702926|NCT03004469|DRUG|P-3074|
214702927|NCT03004469|DRUG|Finasteride|
215162307|NCT05140226|BEHAVIORAL|Physical Training|Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.
215162308|NCT05140226|BEHAVIORAL|Cognitive-Physical Training|Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
215162309|NCT05154214|PROCEDURE|Adenotonsillectomy|Removal of tonsils and adenoids
215162310|NCT05154214|PROCEDURE|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
215162311|NCT03039855|DEVICE|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
215162312|NCT04111978|DRUG|Letrozole 2.5mg|Aromatase inhibitor
215162313|NCT04111978|OTHER|Placebo|Placebo tablet of Femara
215162314|NCT04930094|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg
215162315|NCT04930094|OTHER|Placebo|Placebo
215162316|NCT04930094|BIOLOGICAL|Secukinumab 150 mg|Secukinumab
215162317|NCT03767244|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
215162318|NCT03767244|DRUG|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
215162319|NCT03767244|DRUG|Placebo|Participants will receive matching placebo oral tablets daily.
215162320|NCT06349317|COMBINATION_PRODUCT|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|"1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle)."
215162321|NCT06556147|BIOLOGICAL|VXB-241 60 mcg (Low Dose)|VXB-241 low dose, single, IM injection.
215162322|NCT06556147|BIOLOGICAL|VXB-241 120 mcg (Medium Dose)|VXB-241 medium dose, single, IM injection.
215162323|NCT06556147|BIOLOGICAL|VXB-241 240 mcg (Medium-high Dose)|VXB-241 medium-high dose, single, IM injection.
215162324|NCT06556147|BIOLOGICAL|VXB-241 480 mcg (High Dose)|VXB-241 high dose, single, IM injection.
214553849|NCT05932953|OTHER|questionary|questionary about cutaneous tolerance
214553850|NCT01522690|OTHER|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
214553851|NCT00359047|BEHAVIORAL|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
214702928|NCT03004469|DRUG|P-3074 Vehicle|
214702929|NCT03004469|DRUG|Finasteride Placebo|
214553852|NCT00359047|BEHAVIORAL|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
214702930|NCT05429177|DRUG|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
214553853|NCT02078492|DRUG|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
214553854|NCT02078492|DRUG|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
214553855|NCT02078492|DRUG|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
214553856|NCT02080546|PROCEDURE|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
214553857|NCT02080546|PROCEDURE|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
214702931|NCT02325817|DEVICE|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
214702932|NCT02325817|DEVICE|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
215162325|NCT06556147|BIOLOGICAL|VXB-241 240 mcg|VXB-241 240 mcg (RSV preF 120 mcg + hMPV preF 120 mcg) (based on 1 month post 1st IMP injection results) single, IM injection.
215162326|NCT06556147|OTHER|Placebo|Placebo, single, IM injection.
215162327|NCT06556147|BIOLOGICAL|Arexvy 120 mcg|Arexvy 120 mcg, single, IM injection.
215162328|NCT06132958|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of sacituzumab tirumotecan by IV infusion
215162329|NCT06132958|DRUG|Doxorubicin|60 mg/m\^2 of doxorubicin by IV Infusion
215162330|NCT06132958|DRUG|Paclitaxel|80 mg/m\^2 of paclitaxel by IV infusion
215162331|NCT06132958|DRUG|Nab-paclitaxel|100 mg/m\^2 of nab-paclitaxel by IV infusion
215162332|NCT06284525|DEVICE|Ankle resistance and biofeedback|An ankle exoskeleton will provide stance phase resistance and a plantar pressure biofeedback system will encourage late stance push-off.
215162333|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
215162334|NCT02362035|DRUG|Acalabrutinib|Orally Administered (PO)
215162335|NCT02362035|DRUG|Pembrolizumab|Intravenous Administered (IV)
214553858|NCT02080546|DEVICE|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
214702933|NCT00259740|DRUG|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
214702934|NCT03051087|DRUG|Ganirelix acetate|
214702935|NCT04197544|PROCEDURE|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
215162336|NCT05717647|OTHER|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
215162337|NCT04063215|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
215162338|NCT06518798|BEHAVIORAL|Fasting Mimicking Diet|Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
215162339|NCT03844815|DRUG|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
215162340|NCT03844815|DRUG|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
215162341|NCT05026645|PROCEDURE|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
214702936|NCT05432674|COMBINATION_PRODUCT|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
214702937|NCT01841957|PROCEDURE|ISBCS|same-day cataract surgery
214702938|NCT01841957|PROCEDURE|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
214702939|NCT00799344|DEVICE|Catania Stent|coronary stent implantation
214702940|NCT03411057|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
214702941|NCT03411057|OTHER|Control|Standard of care including an educational video.
214702942|NCT06323694|BEHAVIORAL|quality of life|data collection through questionnaire and interview
214702943|NCT04841720|DRUG|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
215162342|NCT05026645|PROCEDURE|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
215162343|NCT05026645|PROCEDURE|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
214553859|NCT02683499|PROCEDURE|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
214553860|NCT04905368|OTHER|SS-POR11|Topical composition containing probiotic strains derived from human skin (SS-POR11). Participants will be instructed to apply it topically to face, twice weekly for the duration of the trial.
214553861|NCT03212768|PROCEDURE|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
214553862|NCT03510767|DRUG|TQ-B3525|TQ-B3525 p.o. qd
214553863|NCT05790070|DIETARY_SUPPLEMENT|Betaine|3g/ twice daily (separated by \~12 hours) betaine anhydrous
214553864|NCT05790070|OTHER|Placebo|3g/ twice daily (separated by \~12 hours) cellulose placebo
214553865|NCT06442124|DIAGNOSTIC_TEST|Electromyography (EMG)|The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction
214553866|NCT04288349|PROCEDURE|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
214553867|NCT04288349|DRUG|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
214553868|NCT04288349|DRUG|epinephrine + saline|epinephrine + saline
214553869|NCT03570762|PROCEDURE|hybrid percutaneous intervention|
214553870|NCT01715207|DRUG|Aliskiren|
214553871|NCT01715207|DRUG|Atenolol|
214702944|NCT04841720|DRUG|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
214702945|NCT04841720|DRUG|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
214702946|NCT03445754|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
214702947|NCT03445754|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
214702948|NCT00041691|DRUG|hMN14 (labetuzumab)|
214702949|NCT05061797|DIETARY_SUPPLEMENT|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
214702950|NCT05061797|DIETARY_SUPPLEMENT|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
214702951|NCT02692170|BIOLOGICAL|CVI-HBV-001|Investigational Product
214702952|NCT02692170|BIOLOGICAL|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
214702953|NCT04092998|PROCEDURE|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
214702954|NCT03685045|PROCEDURE|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
215162344|NCT06315751|DRUG|Gemlapodect|Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.
215162345|NCT06315751|DRUG|Placebo|Administered in the form of oral capsules with inert ingredients.
215162346|NCT05943652|DIAGNOSTIC_TEST|Neurological examination|A neurological examination following a protocol to detect positive signs of functional neurological disorders.
214702955|NCT04354779|DIAGNOSTIC_TEST|a specifically designed self-administered questionnaire|The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
214702956|NCT01887782|DEVICE|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
214702957|NCT01887782|DEVICE|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
214702958|NCT03296293|OTHER|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
214702959|NCT03296293|OTHER|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
215162347|NCT05943652|DIAGNOSTIC_TEST|Anamnesis|"A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?"
214553872|NCT04996433|BEHAVIORAL|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
214553873|NCT04996433|BEHAVIORAL|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
214553874|NCT04996433|BEHAVIORAL|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
214553875|NCT04996433|BEHAVIORAL|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
214553876|NCT04996433|BEHAVIORAL|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
214553877|NCT04996433|BEHAVIORAL|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
214553878|NCT04996433|BEHAVIORAL|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
214553879|NCT04996433|BEHAVIORAL|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
214702960|NCT03296293|OTHER|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
214702961|NCT00838006|DEVICE|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
214702962|NCT00838006|DEVICE|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
214702963|NCT00838006|DEVICE|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
214702964|NCT03654755|DRUG|ASN002|Daily dose of ASN002 for up to 110 weeks
214702965|NCT03058172|OTHER|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
214702966|NCT03058172|OTHER|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
214702967|NCT03111355|DIETARY_SUPPLEMENT|Brazil nut|one nut a day for 2 months, no intervention for 2 months
214702968|NCT05301023|OTHER|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
214702969|NCT05301023|OTHER|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
214702970|NCT04663984|BEHAVIORAL|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
214702971|NCT02000518|RADIATION|external beam radiotherapy|
214702972|NCT04027101|DRUG|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
214702973|NCT04027101|DRUG|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
214702974|NCT03703271|DRUG|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
214702975|NCT03703271|PROCEDURE|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
214702976|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
214702977|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
214702978|NCT00032838|DRUG|Yohimbine|
214702979|NCT02882815|DEVICE|IrisFIT PFO Occluder|
214702980|NCT01792245|DEVICE|Phototherapy|
214702981|NCT00307242|DRUG|Adefovir Dipivoxil|
214702982|NCT02835677|BEHAVIORAL|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
215162348|NCT05943652|DIAGNOSTIC_TEST|Neuropsychological testing|"Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests"
215162349|NCT05943652|DIAGNOSTIC_TEST|Questionnaires|"* Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)"
215162350|NCT05943652|DIAGNOSTIC_TEST|Tremor recording|Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
215162351|NCT06520202|DRUG|rhPRG4 (450 µg/mL)|1-2 drops of rhPRG4 450 µg/mL solution in both eyes
215162352|NCT06520202|DRUG|Vehicle|Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
214553880|NCT04996433|BEHAVIORAL|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
214553881|NCT04996433|BEHAVIORAL|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
214553882|NCT04996433|DRUG|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant."
214553883|NCT00833378|DRUG|Eltrombopag|Eltrombopag 100 mg single oral dose
215162353|NCT06245681|DRUG|gender affirming hormone therapy|both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
215162354|NCT06228625|BEHAVIORAL|Conventional Exercise Group|"* Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep."
215162355|NCT06228625|BEHAVIORAL|Body Awareness Training Group|"* Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing."
214553884|NCT00833378|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
214553885|NCT00833378|DRUG|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
214553886|NCT00996606|DRUG|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
214553887|NCT00996606|DRUG|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
214702983|NCT06152419|DEVICE|Questionnaire|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
214702984|NCT05821348|DIAGNOSTIC_TEST|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
214553888|NCT00167206|PROCEDURE|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
214553889|NCT00167206|PROCEDURE|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
214553890|NCT00167206|PROCEDURE|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
214553891|NCT00167206|DRUG|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
214553892|NCT00532870|OTHER|laparoscopic|
215162356|NCT06228625|BEHAVIORAL|Rehabilitative Game Exercise Group|"* Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge."
215162357|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
214553893|NCT00545649|BEHAVIORAL|Exercise and education|
214553894|NCT00545649|BEHAVIORAL|Education|
214553895|NCT00305344|PROCEDURE|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
214553896|NCT00305344|BIOLOGICAL|Cord blood|Develop Cord blood vaccine
214553897|NCT04047173|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
214553898|NCT04047173|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual, no more than 2 times.
214553899|NCT05235282|DEVICE|IQoro|An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
214553900|NCT05235282|OTHER|Usual care for swallowing function|Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
214553901|NCT02803281|OTHER|Frailty Assessment|Various physiologic and frailty assessment tests
214553902|NCT00632502|DRUG|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
214553903|NCT00632502|DRUG|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
214553904|NCT00632502|DRUG|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
214553905|NCT05053971|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214702985|NCT02705768|DRUG|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
214702986|NCT02705768|DRUG|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
214702987|NCT03453190|COMBINATION_PRODUCT|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
214702988|NCT02994095|BEHAVIORAL|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
214708994|NCT02814695|DIETARY_SUPPLEMENT|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
214553906|NCT05053971|PROCEDURE|Core Biopsy|Undergo core needle biopsy
214553907|NCT05053971|DRUG|Entinostat|Given PO
214553908|NCT05777109|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
214553909|NCT05777109|DRUG|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
214553910|NCT00921947|BIOLOGICAL|VAX102|Universal M2e influenza vaccine
214553911|NCT03097406|PROCEDURE|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
214553912|NCT03097406|PROCEDURE|Global Advantage|A total shoulder prosthesis used for osteoarthritis
214553913|NCT03097406|PROCEDURE|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
214553914|NCT03097406|PROCEDURE|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
214553915|NCT05239715|DIAGNOSTIC_TEST|Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement
214553916|NCT00947947|BEHAVIORAL|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
214553917|NCT06032507|PROCEDURE|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
214553918|NCT00912145|DRUG|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
214553919|NCT01022411|DIETARY_SUPPLEMENT|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
214553920|NCT01103921|OTHER|Glucose|25% dose at 2-week intervention assigned to subjects.
214702989|NCT00722709|DRUG|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
214702990|NCT00722709|DRUG|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
214702991|NCT06168370|RADIATION|CT guided strategy|"1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
214702992|NCT03934710|DRUG|Placebo|Drug will be administered in solution form
214702993|NCT03934710|DRUG|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
215162358|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
215162359|NCT06240780|OTHER|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
214702994|NCT03934710|DRUG|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
214708995|NCT02814695|DIETARY_SUPPLEMENT|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
215162360|NCT06240780|OTHER|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
214553921|NCT01103921|OTHER|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
214553922|NCT01103921|OTHER|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
214553923|NCT01103921|OTHER|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
214553924|NCT03496376|OTHER|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
214553925|NCT03496376|OTHER|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
214553926|NCT00391339|DRUG|Bryophyllum p.|
214553927|NCT03489876|DEVICE|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
214553928|NCT03489876|PROCEDURE|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
215162361|NCT05570851|BEHAVIORAL|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
215162362|NCT05570851|BEHAVIORAL|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
215162363|NCT06337188|DEVICE|Experimental AAC|Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
214553929|NCT04714398|BEHAVIORAL|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
214553930|NCT04714398|BEHAVIORAL|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
214553931|NCT00681668|DRUG|Quetiapine|150-800 mg, oral, twice a day (bid)
214553932|NCT01786304|PROCEDURE|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
214553933|NCT02466347|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
214553934|NCT02466347|DRUG|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
214553935|NCT01301599|DRUG|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
214553936|NCT01301599|DRUG|alpha blocker monotherapy|alpha blocker monotherapy group
214553937|NCT01301599|DRUG|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
214553938|NCT06231537|DIAGNOSTIC_TEST|Visual oral examination|"Oral preventive examinations in the three groups will be conducted over a one-year period. Individuals with oral injuries will be referred to stomatology, aligning with the existing protocol. Histopathological examinations of the biopsied lesions will be performed at the Oral Pathology Laboratory of the Faculty of Dentistry at the Federal University of Rio de Janeiro, following the established procedures.~Users diagnosed with malignancy will be directed to receive treatment at the reference hospital, with monitoring carried out by the Basic Health Unit responsible for coordinating care, in accordance with the current protocol.~In addition to histopathological examinations, the Faculty of Dentistry will be available to conduct a physical examination and biopsy if the user is not attended to by the Municipal Health Department. This additional resource ensures comprehensive care for individuals who may not have immediate access to municipal health services."
214702995|NCT04250376|DEVICE|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
214553939|NCT02476942|DRUG|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
214553940|NCT02476942|DRUG|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
214553941|NCT03648528|DRUG|cholecalciferol|
214553942|NCT03648528|DRUG|placebo|
214553943|NCT02280512|DEVICE|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
214553944|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
214553945|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
214553946|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
214702996|NCT05124795|DRUG|IMU-935|IMU-935 capsules
214702997|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214702998|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214702999|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214703000|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214703001|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214703002|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214703003|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214703004|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214703005|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214553947|NCT02209181|DRUG|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
214553948|NCT02538315|DRUG|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
214703006|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214703007|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214703008|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214553949|NCT02546947|OTHER|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
214703009|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
214703010|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
214703011|NCT01219517|OTHER|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
214703012|NCT03685370|PROCEDURE|LOS|placement of epidural catheters with LOS technique
214703013|NCT03685370|PROCEDURE|X-ray placement|placement of epidural catheters with x-ray guide
214703014|NCT05545579|OTHER|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
214703015|NCT05545579|OTHER|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
214703016|NCT02482441|DRUG|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
214703017|NCT02482441|DRUG|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
214703018|NCT01481090|PROCEDURE|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
214703019|NCT04116476|DRUG|MT-7117|Single Dose of MT-7117
214553950|NCT02548078|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
214553951|NCT02548078|BIOLOGICAL|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
214553952|NCT01657747|OTHER|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
214553953|NCT04727983|DEVICE|Electrotherapy|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS) (NMES group)
214553954|NCT04727983|DEVICE|Sham Electrotherapy|The second group will be given sham NMES in addition to LSS (SHAM ES group)
214553955|NCT03000790|DEVICE|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
215162364|NCT06337188|DEVICE|Generic AAC|Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
215162365|NCT05985681|PROCEDURE|Biospecimen Collection|Undergo blood sample and vaginal swab collection
215162366|NCT05985681|BIOLOGICAL|HPV16 RG1 VLP Vaccine|Given IM
215162367|NCT05985681|OTHER|Questionnaire Administration|Ancillary studies
214703020|NCT02863939|DEVICE|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
214703021|NCT02863939|OTHER|exercise|
214703022|NCT00257491|DRUG|Telmisartan|
214703023|NCT00257491|DRUG|Telmisartan/HCTZ|
214703024|NCT02473003|BEHAVIORAL|high intensity exercise|high intensity exercise 80-90%
214703025|NCT02473003|BEHAVIORAL|low/medium intensity exercise|low/medium intensity exercise 40-50%
214703026|NCT02473003|BEHAVIORAL|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
214703027|NCT02471001|BIOLOGICAL|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
214703028|NCT05425485|BEHAVIORAL|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
214703029|NCT05068193|DRUG|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
214703030|NCT05068193|DRUG|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
215162368|NCT05985681|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
214553956|NCT00920647|OTHER|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
214703031|NCT03647436|OTHER|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
214553957|NCT00920647|DRUG|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
214553958|NCT00920647|DRUG|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
214553959|NCT00920647|DRUG|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
214553960|NCT05716568|OTHER|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
214553961|NCT03128671|BEHAVIORAL|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
214553962|NCT03630406|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal Tactile Imaging
214553963|NCT01215578|DRUG|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
214553964|NCT00157235|DRUG|Tiotropium bromide|
214553965|NCT04072445|DRUG|Irinotecan|Given IV
214553966|NCT04072445|DRUG|Irinotecan Hydrochloride|Given IV
214553967|NCT04072445|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214553968|NCT04788342|DEVICE|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
214553969|NCT04980079|PROCEDURE|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
214553970|NCT04980079|PROCEDURE|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
214553971|NCT04641962|DRUG|Bocidelpar|Oral
214553972|NCT04641962|DRUG|Placebo|Oral
214553973|NCT02281500|BIOLOGICAL|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
214553974|NCT02125071|OTHER|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
214553975|NCT01562106|PROCEDURE|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
214553976|NCT02869256|OTHER|Practices evaluation|Practices evaluation
214553977|NCT00862836|DRUG|Vandetanib|100mg doses orally, once daily
214553978|NCT00320229|DRUG|abciximab|
214553979|NCT04001335|DIAGNOSTIC_TEST|Dental Broach|Dental broach, RDT and PCR
214553980|NCT04568863|DRUG|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
214553981|NCT04568863|DRUG|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
214553982|NCT05132894|OTHER|Osteopathic Assessment|As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
214553983|NCT02413281|DRUG|ALKS 5461|Sublingual tablets, single administration
214553984|NCT02413281|DRUG|Buprenorphine|Sublingual tablets, single administration
214553985|NCT02413281|DRUG|Placebo|Sublingual tablets, single administration
214553986|NCT00203034|DRUG|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
214553987|NCT00203034|DRUG|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
214553988|NCT00203034|OTHER|Placebo|oral placebo once daily
214553989|NCT01376154|DRUG|Lamivudine|
214553990|NCT04463680|DRUG|Rifampin 600 MG|Administered daily for 2 weeks
214553991|NCT01690468|DRUG|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
214553992|NCT01690468|DRUG|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
214553993|NCT02171247|DRUG|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
214553994|NCT02171247|DRUG|Visipaque 320|Visipaque 320 is standard protocol.
214553995|NCT00938405|DRUG|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
214553996|NCT00938405|DRUG|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
214553997|NCT05389605|OTHER|No intervention was undertaken|This was an observational study, no intervention was done.
214553998|NCT05239598|DRUG|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
214553999|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
214554000|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
214554001|NCT04391543|OTHER|Experimental session|"* comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index"
214554002|NCT00160550|DRUG|Levetiracetam|
214554003|NCT04295850|DRUG|Aspirin 81 mg|Aspirin 81mg daily PO
214554004|NCT06488443|BEHAVIORAL|Yoga|Participants in yoga arm will receive intervention from an instructor who would be trained in the intervention by the yoga adviser.All the yoga exercises selected for this study are low-impact and involve highly controlled movements. All yoga exercises will be taught and supervised by a skilled yoga-instructor. The yoga-instructor will take great care to emphasize to participants that they should not go beyond their usual range of motion/comfort for any of the yoga exercises.
214554005|NCT06488443|BEHAVIORAL|WHO 5As model intervention|"WHO 5As model to help patients ready to quit. The five major steps to intervention are the 5 A's: Ask, Advise, Assess, Assist, and Arrange."
214554006|NCT06480331|PROCEDURE|Ultrasound-guided fistuloplasty|Radiation free fistuloplasty
214554007|NCT06480331|PROCEDURE|Fluoroscopy-guided fistuloplasty|Conventional fistuloplasty
214554008|NCT05730491|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|Participants assigned to this group will complete an online program with 3 core skills, which will include strategies to promote wellness behaviors, use adaptive cognitive coping strategies, model wellness behaviors for their children, and determine when it is appropriate to take further action re: potential illness in their child. The website is interactive and self-guided. All participants will have access to the same resources and content, although based on responses to quizzes and skills practice questions, the automated feedback may differ slightly. The website includes treatment modules that share content via text, images, videos and recordings, a skills library that includes audio recordings of relaxation exercises, infographics to support skills practice, and behavioral assignments to record skills practice and receive automated feedback. Participants will review their knowledge at the end of each treatment module with brief quizzes.
214554009|NCT05730491|BEHAVIORAL|Attention Education Control|Participants assigned to the control group will receive access to a web program and complete 3 modules focused on child health and safety behaviors, such as sports and water safety. These participants will review written/visual content on the above topics, take quizzes to test knowledge gained, and will be provided with brief assignments to increase child safety behaviors. All participants assigned to the control group will have access to the same educational content.
214554010|NCT02712190|DEVICE|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
214554011|NCT03556787|DEVICE|BPI 1000013 (Dr Scholls Insole)|Full length foam insole
214554012|NCT05251675|BEHAVIORAL|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
214554013|NCT05251675|BEHAVIORAL|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
214554014|NCT01398696|PROCEDURE|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
214554015|NCT01398696|PROCEDURE|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
214554016|NCT01550055|DRUG|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
214554017|NCT01550055|DRUG|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
215162369|NCT04103983|DEVICE|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
214554018|NCT01181453|DEVICE|Dermagraft|Weekly application of Dermagraft(R) with standard care
214554019|NCT01181453|OTHER|Comparator|Weekly application of standard care
214554020|NCT04224168|DIETARY_SUPPLEMENT|Green Beans|Please see arm group Green beans for description
214554021|NCT04224168|DIETARY_SUPPLEMENT|Liquid Pectin|Please see arm group liquid pectin for description
214554022|NCT05790005|OTHER|therapeutic play|2 days after the operation, 1 hour before the dressing, a warm-up game will be played with the child in the playroom of the pediatric surgery service, aiming to put the organs prepared by the researcher in their correct places on the picture for the first 10 minutes. Then, the teddy bear, which is given the appearance of an operation area by sewing a zipper on his stomach, will be given to the child and he will be asked to make the first dressing of the teddy bear. therapeutic game, in which the dramatization method is used, will last 20 minutes. During the 30-minute play practice, the child's questions will be answered.
214554023|NCT06853938|DEVICE|Myoelectric prosthesis|The interventions in this study are (1) an enhanced muscle training protocol and (2) fitting with a myoelectric (muscle signal-controlled) prosthetic device after receiving an osseointegrated implant and targeted muscle reinnervation.
214554024|NCT06555939|BEHAVIORAL|Collaborative Care Model|The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.
214703032|NCT04779944|OTHER|other|questionnaire
214554025|NCT06555939|BEHAVIORAL|Promoting Resilience in Stress Management|PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
214554026|NCT04732845|BIOLOGICAL|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
214554027|NCT04732845|DRUG|Fludarabine|25 mg/m2 daily from day -5 to -3
214554028|NCT04732845|DRUG|Cyclophosphamide|60mg/Kg on day -6
214554029|NCT05115045|DIAGNOSTIC_TEST|plasmatic SARS-CoV-2 RNA quantification|plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
214554030|NCT02474849|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
214554031|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 1 combined with antidepressant medication|The self-composed musical piece Five Elements Music 1 was selected to intervene with the patients, with the songs primarily based on the Gong tone and Zhi tone in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
214554032|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 2 combined with antidepressant medication|The self-composed musical piece Five Elements Music 2 was selected to intervene with the patients, with the songs primarily based on the Shang mode (A) and Yu (E) mode in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
214554033|NCT07048938|OTHER|No Intervention: Observational Cohort|No intervention will be applied to healthy people
214554034|NCT05823012|DRUG|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
214554035|NCT07050251|BEHAVIORAL|Mentoring Intervention Delivery|The intervention will utilize a culturally specific, socio-emotional learning (SEL) curriculum, adapted based on feedback from the focus groups. The intervention will consist of 10 weekly mentoring sessions lasting 1 hour each. Licensed clinicians will lead sessions and will also serve as mentors.
214554036|NCT07050797|BEHAVIORAL|Individualised whole-school intervention, developed using data sharing and co-design.|Individualised whole-school intervention, developed using data sharing and co-design.
214554037|NCT05165940|BEHAVIORAL|Treatment As Usual|Care Coordination Treatment as usual with a VA mental health treatment coordinator
214554038|NCT05165940|BEHAVIORAL|New Health Services Intervention|The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
214554039|NCT06920914|OTHER|Low-potassium, ultra-processed diet|A diet restricted in potassium, primarily composed of industrially processed foods such as packaged snacks and processed meals.
214554040|NCT06920914|OTHER|Low-potassium, minimally processed diet|A diet restricted in naturally occurring potassium, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods.
214554041|NCT06920914|OTHER|Normal potassium-rich, minimally processed diet|A diet with normal potassium content, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods, rich in naturally occurring potassium, following a Mediterranean-style pattern.
214554042|NCT06920914|OTHER|Normal potassium-rich, ultra-processed diet|A diet with normal potassium content, primarily composed of industrially processed foods such as packaged snacks and processed meals
214554043|NCT00170287|PROCEDURE|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
214554044|NCT00170287|DEVICE|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
215162370|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
214554045|NCT06938776|BEHAVIORAL|Musical Toy (Xylophone)|Children in this group will play with a colorful xylophone toy for 5 minutes before and during peripheral intravenous cannulation. A nurse (researcher) will assist the child in playing with the toy to distract them from the procedure. The toy will be cleaned between uses. This non-pharmacological method aims to reduce pain and fear.
214554046|NCT06938776|OTHER|Standard Care (in control arm)|Children in this group will receive routine peripheral intravenous cannulation according to standard hospital protocols. No distraction or behavioral intervention will be applied.
214554047|NCT06941701|OTHER|Mild-intensity physical fatigue|Participants will undergo mild-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 50-60% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
214554048|NCT06941701|OTHER|Moderate-intensity physical fatigue|Participants will undergo Moderate-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 60-70% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
214554049|NCT06941701|OTHER|High-intensity physical fatigue|Participants will undergo High-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 70-80% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce sufficient physiological stress while maintaining safety and feasibility for all participants.
214554050|NCT06945484|OTHER|Precision Exercise Regimen for Cancer Care (PERCC)|PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually
214554051|NCT06945744|OTHER|Standard Treatment|The control group followed a standard diabetic habitual diet
214554052|NCT06945744|DEVICE|Carbohydrate|"Eligible participants provided informed consent and underwent baseline assessments, including demographics, medical history, insulin doses, and fasting blood samples for HbA1c and lipid profile. Participants used the FreeStyle Libre 2 sensor, with AGP data collected bimonthly. The primary outcome was Time in Range (TIR, 70-180 mg/dL), while secondary outcomes included TAR, TBR, GV%, GMI, HbA1c, and BMI.~A registered dietitian provided structured CHOC-BC education. The intervention group used the CHOC-BC app, validated against expert-calculated carbohydrate counts, while the control group followed standard diabetes education. Virtual follow-ups occurred bimonthly for three months. At study completion, HbA1c, lipid profile, insulin doses, weight, and AGP data were collected for comparison."
214554053|NCT02401659|DEVICE|CareLinK|
214554054|NCT06947499|BIOLOGICAL|LBVD|Intramuscular injection into the anterolateral area of the thigh
214554055|NCT06947499|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine|Intramuscular injection into the anterolateral area of the thigh
214554056|NCT06952907|OTHER|Femoral artery catheterization for continuous invasive arterial blood pressure monitoring|Femoral artery catheterization allow for continuous invasive arterial blood pressure monitoring.
214554057|NCT06952907|OTHER|Radial artery catheterization for continuous invasive arterial blood pressure monitoring|Radial artery catheterization allows for continuous invasive arterial blood pressure monitoring
214554058|NCT06952452|DRUG|Bevacizumab|The dosage for each intravitreal injection is 1.25mg of BVZ in 0.05ml
214554059|NCT06952452|DRUG|Ranibizumab Ophthalmic|The dosage for each intravitreal injection contains 0.5mg of RBZ in 0.05ml
214554060|NCT00769457|DEVICE|Access Arm|Active OptiVol-System with CareAlert via CareLink
214554061|NCT01686139|BIOLOGICAL|ABMD-MSC|10-20 x 10\^6 cells/20mL
214554062|NCT05120037|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
214554063|NCT00730548|BEHAVIORAL|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
214554064|NCT05654233|DRUG|Sulodexide|The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
214554065|NCT02646787|BEHAVIORAL|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
214554066|NCT02646787|BEHAVIORAL|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
214554067|NCT01109511|DRUG|naloxone|
214554068|NCT01109511|DRUG|oxycodone|
214554069|NCT01381575|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
214554070|NCT05078541|PROCEDURE|Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor|"The Procedure~1. Injection of local subcutaneous and pericapsular anaesthesia~2. Needle radiofrequency ablation under ultrasound guidance~3. Patients should communicate with operating surgeon upon excessive heat or pain~4. The procedure usually lasts 30-45 minutes"
215162371|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
215162372|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
215162373|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
215162374|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
214554071|NCT01920477|BIOLOGICAL|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
214554072|NCT01920477|BIOLOGICAL|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
214554073|NCT04086277|PROCEDURE|Continuous Intrapartum Support|Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
214703033|NCT02415764|BEHAVIORAL|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
214703034|NCT03886831|DRUG|PRT543|PRT543 will be administered orally
214703035|NCT01180114|BEHAVIORAL|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
214703036|NCT01180114|OTHER|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
214703037|NCT01758965|OTHER|PPI|monotherapy of PPI
214703038|NCT01758965|OTHER|H2RA and surgicel|combination therapy of H2RA and surgicel
214703039|NCT03696706|RADIATION|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
214703040|NCT03696706|RADIATION|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
214703041|NCT06348810|BEHAVIORAL|Dual-task training|The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
214703042|NCT06348810|BEHAVIORAL|Cognitive training|Participants only receive cognitive tasks
214703043|NCT06348810|BEHAVIORAL|Motor training|Participants only receive motor tasks
214703044|NCT06348810|OTHER|Usual care|assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
214703045|NCT00259441|DRUG|Simvastatin|
214703046|NCT02861755|BEHAVIORAL|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
214554074|NCT01443403|DRUG|Placebo|Matching placebo tablets administered orally once a day.
214554075|NCT01443403|DRUG|Naldemedine|Naldemedine tablets administered orally once a day.
214554076|NCT00557557|DRUG|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
214554077|NCT00557557|DRUG|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
214554078|NCT03563326|BIOLOGICAL|CAR-T cells targeting EpCAM|Biological: CAR-T cells targeting EpCAM
214554079|NCT03563326|BIOLOGICAL|Chemotherapy|Chemotherapy: determined by medical Oncologist
214554080|NCT01529489|OTHER|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
214554081|NCT01529489|OTHER|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
214554082|NCT01529489|OTHER|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
214554083|NCT01529489|OTHER|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
214554084|NCT02916550|BEHAVIORAL|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
214703047|NCT02861755|BEHAVIORAL|5-week Emotion Reporting|
214703048|NCT01595659|BEHAVIORAL|Passenger|Driving with risk accepting or risk averse passenger
214703049|NCT04000919|DRUG|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
214703050|NCT04000919|DRUG|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
214703051|NCT04000919|DRUG|Placebo oral tablet|Placebo
214703052|NCT04000919|DRUG|Carbidopa|Carbidopa (50mg)
214703053|NCT03051724|OTHER|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
214554085|NCT06509399|OTHER|care package|"Before the patients in the application group started to be observed, the nurses working in the clinic were trained about the risk assessment, skin assessment, incontinence management, nutrition assessment, positioning, support surfaces and injuries caused by the devices in the BP content to be used in the prevention of IU. After the trainings given to the nurses were completed, care was given to the patients in the practice group in accordance with BP. In addition, patient information was collected from patient information files, nurse observation forms and hospital automation system. In the evaluation step, full compliance with the 7 compliance steps specified in the BP was sought. If any one of these parameters was incomplete, the others were considered as incomplete.~The patients in the control group were followed up for 30 days until the determined number of patients was reached and their data were collected."
214554086|NCT00249938|DRUG|Minute Maid Heart Wise orange juice|
214703054|NCT00947752|DRUG|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
214703055|NCT00947752|DRUG|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
214703056|NCT04846166|DIAGNOSTIC_TEST|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
214554087|NCT00249938|DRUG|Welchol|
214554088|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
214554089|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
214554090|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
214554091|NCT01681277|DRUG|Placebo to BI 113608 PIB qd|powder for oral solution
214554092|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
214554093|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
214554094|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
214554095|NCT01681277|DRUG|BI 113608 PIB qd|powder for oral solution
214554096|NCT00803192|DRUG|Famotidine Tablets, 40 mg|
214554097|NCT04592094|DEVICE|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
214554098|NCT01913457|RADIATION|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
214554099|NCT00474526|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|
214554100|NCT00474526|BIOLOGICAL|DTaP-IPV-HBV|
214554101|NCT00474526|BIOLOGICAL|Hib|
214554102|NCT00474526|BIOLOGICAL|Rotavirus|
214554103|NCT00474526|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|
214554104|NCT00474526|BIOLOGICAL|HAV|
214554105|NCT00474526|BIOLOGICAL|MMR-V|
214554106|NCT00474526|BIOLOGICAL|DTaP|
214554107|NCT06523296|PROCEDURE|Adults with Alzheimer's disease|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
214554108|NCT06523296|PROCEDURE|Adults with Myasthenia|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
214554109|NCT06523296|OTHER|Healhty controls|Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
214554110|NCT04093089|DEVICE|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
214554111|NCT04093089|DEVICE|Bionode IOP Lowering System|Control: No stimulation
214554112|NCT05614492|BEHAVIORAL|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
214554113|NCT05614492|BEHAVIORAL|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
214554114|NCT05614492|BEHAVIORAL|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
214554115|NCT03076905|DRUG|F901318|Evaluation of AUC0-t
214554116|NCT06317324|OTHER|Different treatments|NSCLC patients receive the treatment of SBRT
214554117|NCT02793739|PROCEDURE|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
214554118|NCT06190106|OTHER|Cognitive Behavioral Therapy (Psychotherapeutic Intervention)|A psychotherapeutic intervention CBT is given to assess the improvement and betterment in mental health and to assess the reduction of Psychiatric symptoms like depression, anxiety and stress
214554119|NCT00453167|DRUG|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
214554120|NCT00453167|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
214554121|NCT04144712|DRUG|Caffeine Citrate|study rate of occurrence of Apnea of Prematurity between the 2 groups
214703057|NCT04846166|DIAGNOSTIC_TEST|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
214554122|NCT03773575|DEVICE|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
214554123|NCT03222505|DEVICE|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
214554124|NCT03222505|OTHER|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
214554125|NCT06108518|DRUG|Carvedilol|Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
214554126|NCT01504776|DRUG|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
214554127|NCT01504776|DRUG|Bortezomib|
214554128|NCT06044506|DRUG|Autologous Natural Killer Cell Therapy|The therapy will be administered intravenously
214554129|NCT06044506|DEVICE|Clinimacs Plus|The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
214554130|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Spontaneous partner notification practices collected one month after STIs diagnosis"
214554131|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Experiences with partner notification and use of STI testing following notification"
214554132|NCT03063151|DIAGNOSTIC_TEST|Surface Electromyography (EMG)|
214554133|NCT03285607|BIOLOGICAL|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
214554134|NCT03285607|DRUG|Doxorubicin|-Standard of care
214554135|NCT03285607|DRUG|Cyclophosphamide|-Standard of care
214703058|NCT04973410|DIAGNOSTIC_TEST|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
214554136|NCT03285607|DRUG|Paclitaxel|-Standard of care
214554137|NCT03285607|PROCEDURE|Bone marrow aspirate|-Time of enrollment and at time of surgery
214554138|NCT03285607|PROCEDURE|Peripheral blood samples|-Time of enrollment and at time of surgery
214554139|NCT03285607|PROCEDURE|Tumor tissue|-Time of enrollment and at time of surgery
214703059|NCT04973410|DIAGNOSTIC_TEST|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
214703060|NCT01933256|DRUG|HIP2B|
214703061|NCT01933256|DRUG|Placebo|
214703062|NCT05750134|OTHER|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
214703063|NCT05750134|OTHER|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
214703064|NCT03763903|OTHER|3D training|Skills (FLS tasks) training using 3D visualization
214703065|NCT03763903|OTHER|2D training|Skills (FLS tasks) training using 2D visualization
214554140|NCT05629299|BIOLOGICAL|Samples|Men will give semen, saliva, skin, urine and blood specimens
214554141|NCT02224404|DEVICE|Fast Gelling Dressing (Exufiber)|
214554142|NCT01251770|DRUG|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
214554143|NCT01251770|DRUG|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
214554144|NCT00088933|DRUG|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
214703066|NCT02357797|DRUG|Vortioxetine|
214703067|NCT02357797|OTHER|Placebo|
214554145|NCT00088933|DRUG|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
214554146|NCT00088933|DRUG|docetaxel|Given IV
214554147|NCT00088933|DRUG|sargramostim|Given subcutaneously
214554148|NCT06331637|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal Anastomosis (IPAA)
214554149|NCT06331637|PROCEDURE|Double-stapled anastomosis|Restorative proctectomy with Tdouble-stapled Ileal Pouch-Anal Anastomosis (IPAA)
214554150|NCT02895204|DIETARY_SUPPLEMENT|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
214554151|NCT02895204|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin
214554152|NCT05364567|DRUG|cholecalciferol (vitamin D3)|The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.
214703068|NCT04154696|PROCEDURE|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
214703069|NCT00469846|PROCEDURE|L-arginine supplementation in a medical food|
214703070|NCT00469846|PROCEDURE|Vitamin C and E supplementation in a medical food|
214703071|NCT06259773|DIAGNOSTIC_TEST|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
214703072|NCT02418533|DRUG|menotropin|Menopur is used for controlled ovarian stimulation (COH)
214554153|NCT05364567|PROCEDURE|Phototherapy|The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
214554154|NCT01346631|OTHER|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
214554155|NCT02514239|DRUG|BI 836909|Intravenous Infusion of BI 836909.
214554156|NCT02613377|OTHER|Blood transfusion|
214554157|NCT01124383|PROCEDURE|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
214554158|NCT01124383|PROCEDURE|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score \< 4.
214554159|NCT02597335|RADIATION|Spectro-MRI|Spectro-MRI for D-2HG detection
214554160|NCT02597335|OTHER|Dosage of free circulating plasmatic DNA|
214554161|NCT02597335|OTHER|Dosage of D-2HG in the urine|
214703073|NCT02418533|DRUG|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
214703074|NCT00128583|BIOLOGICAL|polyvalent melanoma vaccine|
214703075|NCT04627012|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214703076|NCT04627012|DRUG|Opdivo|3mg/mg intravenously every 3 weeks
214554162|NCT05692700|OTHER|aromatherapy|essential oil application by inhalation
214554163|NCT05692700|OTHER|Placebo|Placebo essential oil
214554164|NCT02381093|OTHER|Modified BLS course|BLS using CI
214703077|NCT04627012|DRUG|Camrelizumab|200mg intravenously every 3 weeks
214554165|NCT02381093|OTHER|Standard BLS Course|Usual BLS teaching
214554166|NCT05266443|DIETARY_SUPPLEMENT|Lactobacillus containing cultured milk drink|Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
214554167|NCT05266443|DIETARY_SUPPLEMENT|Placebo cultured milk drink|The placebo prepared was identical to the probiotic-containing product in terms of color, taste and packaging. However, there is no trace of live microorganism in this product.
214703078|NCT04627012|DRUG|Keytruda|200mg intravenously every 3 weeks
214703079|NCT04627012|DRUG|Toripalimab|240mg intravenously every 3 weeks
214703080|NCT04627012|DRUG|Sintilimab|200mg intravenously every 3 weeks
214703081|NCT04627012|DRUG|Tislelizumab|200mg intravenously every 3 weeks
214703082|NCT02742857|BIOLOGICAL|BQ-A Peptide Extract|BQ-A Peptide Extract
214703083|NCT02742857|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells
214703084|NCT02742857|DEVICE|Transcranial Laser Therapy|Transcranial Laser Therapy
214703085|NCT02742857|DEVICE|Median Nerve Stimulator|Median Nerve Stimulator
214703086|NCT01360762|DRUG|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
214703087|NCT00059618|DRUG|PS-341 (Bortezomib)|Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
214703088|NCT00059618|DRUG|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
214703089|NCT03420443|DIETARY_SUPPLEMENT|Oat bran|45 g oat bran.
214703090|NCT03420443|DIETARY_SUPPLEMENT|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
214703091|NCT03420443|DIETARY_SUPPLEMENT|No oral supplementation|No oral supplementation.
214703092|NCT01408667|DRUG|TRC150094|50 mg Tablets once a day
214703093|NCT01408667|OTHER|Placebo|Tablets once daily
214703094|NCT02196987|OTHER|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
214703095|NCT02196987|OTHER|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
214703096|NCT03841487|DEVICE|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
214703097|NCT00262977|BEHAVIORAL|Electronic prompt plus patient-directed intervention|
214554168|NCT03668639|DRUG|Akynzeo|Weekly administration of akynzeo for five weeks.
214554169|NCT03668639|DRUG|Dexamethasone|Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
214554170|NCT00107887|DRUG|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
214703098|NCT00262977|BEHAVIORAL|Electronic prompt to clinician to prescribe aspirin|
214703099|NCT05613842|DRUG|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
214703100|NCT06314165|OTHER|music medicine practice|Music medicine will be applied
214703101|NCT00799500|OTHER|Screening|Weekly vaginal pH
214703102|NCT04511819|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
214703103|NCT04511819|DRUG|Placebo oral tablet|Placebo will be administered with food when possible.
214703104|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
214703105|NCT04953117|DEVICE|Restore DEB|subjects receiving Restore DEB
214703106|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
214703107|NCT00163072|DRUG|transdermal Megace|oral vs transdermal levels
214703108|NCT05790473|DIAGNOSTIC_TEST|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
214703109|NCT04448093|PROCEDURE|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
214554171|NCT00107887|DRUG|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
214554172|NCT02260713|BIOLOGICAL|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
214554173|NCT05691946|PROCEDURE|Kinesiology Taping|The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.
214554174|NCT05691946|PROCEDURE|Placebo Taping|The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.
214554175|NCT02320526|BEHAVIORAL|Control|
214554176|NCT02320526|BEHAVIORAL|Continuous walking|
214703110|NCT03522701|BEHAVIORAL|CBTI|Refer to the arm description
214703111|NCT00467025|DRUG|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
214703112|NCT00467025|DRUG|Sorafenib|400 mg PO BID
214703113|NCT00467025|DRUG|AMG 386 placebo IV|AMG 386 placebo IV
214703114|NCT01940510|DRUG|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
214703115|NCT01940510|DRUG|rifampin|Multiple doses Days 8-16 and Days 17-20
214703116|NCT03756740|OTHER|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
214703117|NCT03756740|OTHER|control|subjects will receive the LBP exercises as printed pictures on paper
214703118|NCT00003225|DRUG|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
214703119|NCT00003225|DRUG|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
214703120|NCT04675606|BEHAVIORAL|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
214703121|NCT04675606|BEHAVIORAL|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
214554177|NCT02320526|BEHAVIORAL|Interval walking|
214554178|NCT01906983|OTHER|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
214554179|NCT00306813|DRUG|Revlimid|
214554180|NCT00263237|DRUG|STA-5326|
214554181|NCT04009031|DEVICE|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
214703122|NCT02287701|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
214703123|NCT03930641|DRUG|RTH258|6 mg in prefilled syringe
214703124|NCT03849976|BEHAVIORAL|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
214708996|NCT04591496|BEHAVIORAL|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
214554182|NCT03714698|OTHER|Pilates exercise group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
214554183|NCT03714698|OTHER|Control Group|The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
214554184|NCT05293405|DIAGNOSTIC_TEST|18F-DPA-714 PET|TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET
214554185|NCT06508489|BIOLOGICAL|SAR443579|Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
214554186|NCT06508489|DRUG|venetoclax|Pharmaceutical form :Film coated tablet Route of administration: oral
214703125|NCT02181010|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
214703126|NCT02060318|DRUG|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
214703127|NCT04468334|DEVICE|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
214703128|NCT03247413|DRUG|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
214703129|NCT03247413|DRUG|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
214703130|NCT00513097|BEHAVIORAL|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
214703131|NCT00513097|BEHAVIORAL|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
214703132|NCT00513097|BEHAVIORAL|Survey|On-line evaluations and questionnaires
214554187|NCT06508489|DRUG|azacitidine|Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
214703133|NCT00844649|DRUG|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m\^2 administered by intravenous infusion
214703134|NCT00844649|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
214703135|NCT00804375|DRUG|2PX|cutaneous solution to be applied twice daily for 84 days
214703136|NCT00804375|DRUG|Placebo|cutaneous solution to be applied twice daily for 84 days
215162375|NCT05834244|DRUG|Azacitidine|Given by IV (vein)
215162376|NCT05834244|DRUG|Venetoclax|Given by PO
215162377|NCT05834244|DRUG|NK Cells|Given by IV (vein)
214554188|NCT06794008|DRUG|BCMA-CD19 CAR-T therapy|Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.
214554189|NCT03132532|DRUG|Carboplatin|Chemotherapy
214554190|NCT03132532|DRUG|Cisplatin|Chemotherapy
214554191|NCT03132532|DRUG|Etoposide|Chemotherapy
214554192|NCT03132532|DRUG|Paclitaxel|Chemotherapy
214554193|NCT03132532|DRUG|Pemetrexed|Chemotherapy
214554194|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
214554195|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
214554196|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
214703137|NCT00424294|DRUG|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
214703138|NCT00424294|DRUG|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
214554197|NCT04951999|OTHER|Blood sampling|For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
214554198|NCT04596982|OTHER|Placement of IMPELLA®|ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
214703139|NCT00424294|DRUG|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
214703140|NCT04694105|DRUG|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
214703141|NCT04694105|DRUG|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
214703142|NCT04694105|DRUG|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
214703143|NCT03831308|DIAGNOSTIC_TEST|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
215162378|NCT04497727|OTHER|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
215162379|NCT06643884|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
215162380|NCT06643884|DEVICE|SCS Microinjector|Suprachoroidal Injection Device
215162381|NCT06643884|DEVICE|Laser|Laser Administration
215162382|NCT06022393|BEHAVIORAL|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
215162383|NCT06022393|BEHAVIORAL|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
214554199|NCT03381872|PROCEDURE|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~1. Intravascular imaging arm~2. Angiography arm~   * Definition of Complex Lesions~     1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~    2. Chronic total occlusion (≥3 months) as target lesion~    3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~    4. Implanted stent length ≥38mm~    5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~    6. Multiple stent needed (≥3 more stent per patient)~    7. In-stent restenosis lesion as target lesion~    8. Severely calcified lesion (encircling calcium in angiography)~    9. Ostial coronary lesion (LAD, LCX, RCA)"
214554200|NCT03381872|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
214554201|NCT03381872|DEVICE|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden \<50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: \[1\] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~\[2\] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
214554202|NCT03381872|DEVICE|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
214554203|NCT06079294|OTHER|FDG PET|Brain FDG PET performed 3 months after treatment initiation
214554204|NCT06479382|DEVICE|ETX-4143 2.0|Treatment of the eye with the ETX-4143 2.0 device
214703144|NCT03411772|PROCEDURE|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
214554205|NCT03475186|DRUG|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
214554206|NCT03104075|BIOLOGICAL|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
214554207|NCT03104075|BIOLOGICAL|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
214703145|NCT03411772|PROCEDURE|Bariatric surgery|Bariatric surgery will be conducted
214703146|NCT05688501|OTHER|descriptiv group|no intervention
214703147|NCT04352595|DRUG|Hemay808|Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
214703148|NCT00554892|PROCEDURE|bowel preparation|oral laxatives, retrograde enemas
214554208|NCT04024462|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
214703149|NCT00554892|PROCEDURE|no preparation bowel|no preparation bowel
214703150|NCT03855748|OTHER|Healthy group|"Subjects undergo the following activities:~1. Walking~2. Jogging (8-11 km/h)~3. Maximal 5 meters sprint acceleration~4. Single leg drop jump from 35 cm height~5. Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~6. Maximal change of direction at 45, 135, 180 degrees~7. Single-leg cross-country skiing exercise"
214703151|NCT03346447|OTHER|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
214703152|NCT04397718|DRUG|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
214703153|NCT04397718|OTHER|Saline|09% Saline
214554209|NCT04024462|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
214703154|NCT03953261|DRUG|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
214703155|NCT00679718|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
214703156|NCT03714906|PROCEDURE|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
214703157|NCT01693055|DEVICE|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
214703158|NCT04004078|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
214703159|NCT01797965|DRUG|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
214703160|NCT00361127|DRUG|isotonic saline infusion|
214703161|NCT00994656|DEVICE|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
214703162|NCT05312931|OTHER|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
214703163|NCT03522493|DEVICE|"Yaalom Katom"|Full face Gas mask
214703164|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
214703165|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
214554210|NCT04024462|DRUG|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
214554211|NCT04024462|DRUG|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
214554212|NCT04024462|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
214554213|NCT04024462|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
214554214|NCT04024462|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
214554215|NCT04024462|RADIATION|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
214554216|NCT04024462|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
214554217|NCT04557995|PROCEDURE|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
214554218|NCT06215378|DRUG|Antagonization of heparin with protamine sulfate|A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
214554219|NCT02135562|DIETARY_SUPPLEMENT|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
214554220|NCT02135562|OTHER|Informational Material|Receive carbohydrate reintroduction handout
214703166|NCT00656734|BIOLOGICAL|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
214703167|NCT04195100|DRUG|Pilocarpine Ophthalmic Solution|"1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
214703168|NCT00976950|DRUG|Tipranavir|
215162384|NCT06644768|DRUG|valemetostat tosylate|Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
215162385|NCT06644768|DRUG|pembrolizumab|One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
215162386|NCT06641414|DRUG|Lisaftoclax (APG-2575)|QD, oral administration.
214554221|NCT02135562|OTHER|Dietary Education|Receive education on nutrition label reading for carbohydrates
214554222|NCT02135562|DIETARY_SUPPLEMENT|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
214554223|NCT02135562|OTHER|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
214554224|NCT00713986|PROCEDURE|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
214554225|NCT00713986|PROCEDURE|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
214554226|NCT00713986|PROCEDURE|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
214703169|NCT00976950|DRUG|ritonavir|low-dose
214703170|NCT04722484|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
214703171|NCT05044585|OTHER|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
214703172|NCT02674672|DEVICE|VenaTech® (VenaTech Retrievable Filter)|
214703173|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to starchy meal|
214703174|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to liquid|
214703175|NCT02168296|DIETARY_SUPPLEMENT|No Plant-based ingredient|
214703176|NCT04325945|DEVICE|Low level laser therapy|808nm low level laser therapy on acupuncture points
214708997|NCT04591496|BEHAVIORAL|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
215162387|NCT06641414|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection.
215162388|NCT06641414|OTHER|Placebo|QD, oral administration.
215162389|NCT05875168|DRUG|DS-3939a|One IV infusion Q3W on Day 1 of each 21-day cycle
215162390|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
215162391|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
215162392|NCT06003426|DRUG|BMS-986278|Specified dose on specified days
215162393|NCT06003426|DRUG|BMS-986278 Placebo|Specified dose on specified days
214554227|NCT00713986|PROCEDURE|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
214554228|NCT00041652|DRUG|hMN14 (labetuzumab)|
214554229|NCT02585323|BEHAVIORAL|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
214554230|NCT02585323|BEHAVIORAL|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
214554231|NCT06157567|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
214708998|NCT06139536|DRUG|BAT4706 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
215162394|NCT04260126|COMBINATION_PRODUCT|Pembrolizumab (KEYTRUDA®) and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
215162395|NCT06644625|OTHER|Blood draw for the laboratory assessment|Screening blood sample collection to test for MGUS
215162396|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
214554232|NCT05234840|DRUG|platelet rich plasma|1\. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
214554233|NCT05234840|DRUG|Triamcinolone|40 mg triamcinolone with 1% lidocaine, total of 2 ml
214554234|NCT03065075|DRUG|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
214554235|NCT01022541|DRUG|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
214554236|NCT01022541|DRUG|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
214554237|NCT01022541|DRUG|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
214554238|NCT01022541|PROCEDURE|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
214554239|NCT04687462|DEVICE|1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
214554240|NCT02988323|OTHER|Cervicovestibular Physio (CV PT)|See description in CVPT arm
214554241|NCT02988323|OTHER|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
214554242|NCT02988323|OTHER|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
214554243|NCT00789360|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
214554244|NCT00789360|DRUG|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
214554245|NCT03806283|PROCEDURE|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
214554246|NCT04400487|DRUG|Voxelotor|500 mg Tablet, Oral, With or Without Food
214554247|NCT01929824|OTHER|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
214554248|NCT05330598|DEVICE|Connected Catheter|The Connected Catheter System is a replaceable wireless urinary prosthesis that is indicated for bladder emptying in male patients who have impaired bladder emptying due to chronic Urinary Retention. The Connected Catheter resides fully internally in the male lower urinary tract (urethra and bladder neck) and remains in place for up to 7 days before removal.
214554249|NCT01802905|GENETIC|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
214554250|NCT02908295|DRUG|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
214554251|NCT02908295|DRUG|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
214554252|NCT02735928|DEVICE|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (\< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
214554253|NCT00412412|DRUG|CNF2024|Oral doses of CNF2024 as specified in the protocol.
214554254|NCT00412412|DRUG|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
214554255|NCT05408195|DEVICE|CHATBOT use|Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
214554256|NCT06373198|OTHER|standard of care|An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.
214703177|NCT00304915|BEHAVIORAL|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
214703178|NCT03411577|OTHER|Behavioral Intervention|
214703179|NCT00160992|BIOLOGICAL|Melan-A analog peptide|
214703180|NCT05984810|PROCEDURE|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
214703181|NCT06271928|DRUG|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
214703182|NCT02557412|DEVICE|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
214703183|NCT02557412|BEHAVIORAL|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
215162397|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
215162398|NCT06643611|BEHAVIORAL|Continuous Glucose Monitor|Patient will be provided a continuous glucose monitor. Pharmacist will provide information regarding how to best manage type 2 diabetes.
214554257|NCT02963012|OTHER|ultrasound examination|
214554258|NCT06328218|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
214554259|NCT00022659|BIOLOGICAL|bevacizumab|Given IV
214554260|NCT00022659|OTHER|laboratory biomarker analysis|Correlative studies
214554261|NCT03559062|DRUG|TEZ/IVA|Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
214554262|NCT03559062|DRUG|IVA|Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
214554263|NCT03559062|DRUG|Placebo|Placebo matched to TEZ/IVA FDC
214554264|NCT03559062|DRUG|Placebo|Placebo matched to IVA
214554265|NCT04490759|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214554266|NCT05176938|PROCEDURE|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients of the group will be placed supine and elevate arm to the head, Serratus intercostal plane block will be with the probe in the midaxillary line, The subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction after giving 3 ml lidocaine locally. In-plane technique was used until the tip of the needle placed between the serratus anterior muscle and the external intercostals muscle a volume of 20 ml plain bupivacaine will be injected.
214703184|NCT02557412|OTHER|Conventional treatment|Hygiene and diet recommendations on sleep
214703185|NCT03882346|COMBINATION_PRODUCT|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
214554267|NCT05176938|PROCEDURE|Ultrasound guided Erector Spinae plane Block (ESPB)|The patient will be placed in setting position and a superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation, 3 cm lateral to the T4 spinous process. An 8-cm 22-gauge spinal needle will be inserted in cephalic direction after giving 3 ml lidocaine locally until the needle tip hit the transverse process of T4 under ultrasound image visualization, then the needle will be withdrawn slowly to be within the interfacial plane below the erector spinae muscle, then the anesthetic mixture will be injected here. Successful injection will be evidenced by visible linear free spread (cranially and caudally) of injectate below the muscle.
214554268|NCT03073252|OTHER|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
214554269|NCT03073252|OTHER|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
214554270|NCT05927857|DRUG|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
214703186|NCT00646841|DRUG|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
214703187|NCT02982538|BEHAVIORAL|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
214703188|NCT02982538|BEHAVIORAL|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
214703189|NCT01728883|DEVICE|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
214554271|NCT05927857|DRUG|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
214554272|NCT05927857|DRUG|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
214703190|NCT06678867|DRUG|5-ALA (Gliolan)|Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery
214703191|NCT05424991|BEHAVIORAL|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
214554273|NCT00872053|DEVICE|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
214554274|NCT00872053|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
214554275|NCT00426127|DRUG|Docetaxel|
214554276|NCT00426127|DRUG|Liposomal Doxorubicin|
214554277|NCT00426127|DRUG|Enoxaparin|
214554278|NCT02370264|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214703192|NCT01486004|DRUG|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
214703193|NCT01486004|DRUG|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
214554279|NCT02370264|OTHER|Questionnaire Administration|Ancillary studies
214554280|NCT02370264|OTHER|Medical Chart Review|Ancillary studies
214554281|NCT03990740|PROCEDURE|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
214554282|NCT06116747|BEHAVIORAL|Intervention|Support for fathers of preterm infants
214554283|NCT00663585|BEHAVIORAL|Vipassana Meditation|12 day retreat where participants learn to meditate
214554284|NCT03610672|BEHAVIORAL|OD prevention/response training|Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
214554285|NCT03610672|BEHAVIORAL|OD prevention/response training + PI mobile application|Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
214554286|NCT05778942|DEVICE|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
214554287|NCT02465918|DEVICE|motor cortex stimulation (Change of Stimulation Timing)|
214554288|NCT05399901|OTHER|Electromyographic biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
214554289|NCT05399901|OTHER|M-mode US biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
214554290|NCT02264119|DRUG|Lefradafiban tablet|
214554291|NCT02264119|DRUG|Pantoprazole tablet|
214554292|NCT02264119|DEVICE|Lefradafiban double chamber sachet|
214554293|NCT01249846|DRUG|PerioChip ®|
214554294|NCT02318615|PROCEDURE|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
214554295|NCT01277692|DRUG|GSK2336805 10mg|single dose once daily
214554296|NCT01277692|DRUG|GSK2336805 30mg|single dose once daily
214554297|NCT01277692|DRUG|GSK2236805 100mg|single dose once daily
214554298|NCT01277692|DRUG|GSK2236805 200mg|single dose once daily
214554299|NCT01277692|DRUG|GSK2236805 10mg|repeat dose once daily for 7 days
214554300|NCT01277692|DRUG|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
214703194|NCT06382363|PROCEDURE|POC-cHbA1c testing|The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
214703195|NCT01066195|DRUG|iressa|iressa 250mg per day every day
214703196|NCT01066195|DRUG|alimta|alimta 500mg/m2 every 3 weeks
214703197|NCT00156910|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
214703198|NCT00156910|OTHER|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
214554301|NCT01277692|DRUG|GSK2236805 5mg|single dose in HCV infected patients
214554302|NCT01277692|DRUG|GSK2236805 30mg|single dose in HCV infected patients
214554303|NCT01277692|DRUG|GSK2236805 100mg|single dose in HCV infected patients
214554304|NCT00458952|DRUG|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
214554305|NCT03099902|DIAGNOSTIC_TEST|Lung function|Spirometry test
214554306|NCT03099902|DIAGNOSTIC_TEST|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
214554307|NCT03099902|DIAGNOSTIC_TEST|Urinary testing|Urinary nicotine and cotinine detection
214554308|NCT03937102|PROCEDURE|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
214554309|NCT03937102|PROCEDURE|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
214554310|NCT03831542|BEHAVIORAL|direct follicular aspiration|direct follicular aspiration
214554311|NCT03831542|BEHAVIORAL|follicular flushing|follicular flushing
214554312|NCT06404853|DIETARY_SUPPLEMENT|Manna|"Administration is by the oral route according to weight at a dosage of 1 g/kg/day, dissolved in a glass of water, up to a maximum of 30 g. Administration should be repeated every 24 h for 8 weeks, accompanied by plenty of hydration.~In case an effective dosage is achieved (evacuation within 72 h) it will be maintained until the end of the study. If evacuation has not occurred after 72 h, evacuative enema and increased dosage to 1.5 g/kg/day will be indicated. If further evacuative enema is needed, product administration will be discontinued and classical polyethylene glycol therapy will be started as per guidelines."
214554313|NCT05048238|DRUG|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
214554314|NCT04648137|DIAGNOSTIC_TEST|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
214554315|NCT04648137|DIAGNOSTIC_TEST|Control intervention: Placebo|Identical placebo (only mannitol) capsules
214554316|NCT02657499|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
214554317|NCT00158704|DRUG|Hepsera|
214554318|NCT02261077|DRUG|Hyoscine butylbromide|
214554319|NCT02261077|DRUG|Placebo|
214554320|NCT01702857|BIOLOGICAL|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
214703199|NCT04069741|OTHER|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
214703200|NCT04069741|BEHAVIORAL|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
214703201|NCT01021852|DRUG|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
214703202|NCT01021852|DRUG|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
214703203|NCT04137133|DIAGNOSTIC_TEST|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
215162399|NCT06643611|BEHAVIORAL|Usual Care|Routine physician office visits and hemoglobinA1c every 3 for those with HbA1c outside goal and every 6 months for those with HbA1c within goal. Medication regimens managed by physicians, nurse practitioners, and physician assistants. Patients are sent reminders on the phone prior to their visits or when they are due for a visit or any physical examination.
214554321|NCT01702857|BIOLOGICAL|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
214703204|NCT04693442|OTHER|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling \& scar assessment questionnaires
214703205|NCT01763463|DRUG|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
214703206|NCT01763463|DRUG|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
214703207|NCT02581319|PROCEDURE|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
214703208|NCT04717141|OTHER|Selective nerve block|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~\- Clinical and instrumental post-botulinum toxin injection evaluation."
214554322|NCT01702857|OTHER|Phosphate buffered saline|
214554323|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
214554324|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with AS01E adjuvant|
214554325|NCT06034691|BIOLOGICAL|pcsk9 inhibitor|The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
214703209|NCT05300243|DIAGNOSTIC_TEST|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
215162400|NCT05916950|DEVICE|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
215162401|NCT06325683|PROCEDURE|Biopsy Procedure|Undergo biopsy
215162402|NCT06325683|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215162403|NCT06325683|DRUG|Lomustine|Given PO
215162404|NCT06325683|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214554326|NCT01627015|OTHER|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
214554327|NCT01627015|OTHER|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
214554328|NCT00692549|DEVICE|ultrasound|
214554329|NCT01730378|BIOLOGICAL|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
214554330|NCT01730378|BIOLOGICAL|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
214554331|NCT01746589|DEVICE|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
214554332|NCT05238831|DRUG|Alectinib|Given orally (PO)
214554333|NCT05238831|DRUG|Alpelisib|Given PO
214554334|NCT05238831|DRUG|Anastrozole|Given PO
214554335|NCT05238831|BIOLOGICAL|Atezolizumab|Given IV
214554336|NCT05238831|BIOLOGICAL|Bevacizumab|Given IV
214554337|NCT05238831|PROCEDURE|Biopsy|Undergo tissue biopsy
214554338|NCT05238831|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214554339|NCT05238831|DRUG|Capecitabine|Given PO
214554340|NCT05238831|DRUG|Carboplatin|Given IV
214554341|NCT05238831|DRUG|Cobimetinib|Given PO
214554342|NCT05238831|DRUG|Entrectinib|Given PO
214703210|NCT05950347|DEVICE|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
214703211|NCT05950347|DEVICE|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
214703212|NCT03820037|DRUG|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
215162405|NCT06325683|BIOLOGICAL|Nivolumab|Given IV
214703213|NCT03820037|DRUG|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
214703214|NCT04991844|BEHAVIORAL|Intervention Group|Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
214703215|NCT02154126|DEVICE|Continuous Glucose Monitoring Device (Senseonics)|
214703216|NCT00073814|DRUG|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
214703217|NCT00073814|DRUG|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
214554343|NCT05238831|DRUG|Eribulin|Given IV
214554344|NCT05238831|DRUG|Fulvestrant|Given by injection
214554345|NCT05238831|BIOLOGICAL|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given phesgo SC
214703218|NCT00073814|DRUG|Placebo|Placebo MDI QID
214703219|NCT06365671|OTHER|autologous stem-cell transplantation|high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
215162406|NCT06325683|BIOLOGICAL|Relatlimab|Given IV
215162407|NCT06325683|PROCEDURE|Surgical Procedure|Undergo surgery
215162408|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
215162409|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
215162410|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
215162411|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
214554346|NCT05238831|DRUG|Irinotecan|Given IV
214554347|NCT05238831|DRUG|Letrozole|Given PO
215162412|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
214554348|NCT05238831|DRUG|Nab-paclitaxel|Given IV
214554349|NCT05238831|DRUG|Niraparib|Given PO
214554350|NCT05238831|DRUG|Olaparib|Given PO
214554351|NCT05238831|DRUG|Paclitaxel|Given IV
214554352|NCT05238831|DRUG|Palbociclib|Given IV
214554353|NCT05238831|BIOLOGICAL|Pertuzumab|Given subcutaneously (SC)
214554354|NCT05238831|OTHER|Quality-of-Life Assessment|Ancillary studies
214554355|NCT05238831|BIOLOGICAL|Trastuzumab|Given SC
214554356|NCT05238831|BIOLOGICAL|Trastuzumab Emtansine|Given intravenously (IV)
214554357|NCT05238831|DRUG|Vemurafenib|Given PO
214554358|NCT05238831|DRUG|Vinorelbine|Given IV
214554359|NCT05238831|DRUG|Vismodegib|Given PO
214554360|NCT03160846|DRUG|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
214554361|NCT02565433|OTHER|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
214554362|NCT02450812|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
214554363|NCT02443753|DEVICE|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
214703220|NCT06365671|DRUG|Relmacabtagene autoleucel (relma-cel)|relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
215162413|NCT06577766|DRUG|NNC0638-0355|NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
215162414|NCT06577766|DRUG|Placebo (NNC0638-0355)|Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
215162415|NCT04250194|DEVICE|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
215162416|NCT04250194|DEVICE|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
215162417|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
215162418|NCT06462222|DRUG|Toripalimab, pemetrexed|Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
214554364|NCT00955708|DEVICE|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
214554365|NCT04490577|OTHER|Pilates exercises|Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.
214554366|NCT04490577|OTHER|Whole body vibration|Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
214554367|NCT01016262|DRUG|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
214554368|NCT01016262|DRUG|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
214554369|NCT01016262|DRUG|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
214554370|NCT05338125|PROCEDURE|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
214554371|NCT00458081|DRUG|Rimonabant|20 mg once per day + slightly reduced calorie diet
214554372|NCT00458081|DRUG|Placebo|placebo once per day + slightly reduced calorie diet
214554373|NCT00514579|PROCEDURE|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
214554374|NCT01405651|DRUG|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
214554375|NCT01405651|DRUG|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
214554376|NCT03776305|DRUG|Imipenem|1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
214554377|NCT03364777|OTHER|emotional state|anxiety or depression state evaluated by emotional scale
214554378|NCT01458054|DRUG|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
214554379|NCT01458054|DRUG|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
214554380|NCT05616299|DEVICE|BrightPoint|Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.
214554381|NCT01076777|BEHAVIORAL|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
214554382|NCT01076777|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
214554383|NCT00737477|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
214554384|NCT05977205|OTHER|No interventions, observational study|Not applicable, no interventions, observational study
214703221|NCT00712322|DRUG|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
214703222|NCT03760848|DRUG|Aramchol|Aramchol 600 mg
214703223|NCT03760848|DRUG|Midazolam|Midazolam 2 mg
214703224|NCT03760848|DRUG|Atorvastatin|atorvastatin 40 mg
214703225|NCT03054948|DRUG|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
214703226|NCT03054948|DRUG|Standard therapy|In most cases standard therapy will be IntraLipid.
214703227|NCT02687230|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
215162419|NCT06577441|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
214554385|NCT04966975|OTHER|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
214703228|NCT02687230|DRUG|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
214703229|NCT03523221|DRUG|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
214703230|NCT02001116|OTHER|Quality Improvement intervention|"1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
214703231|NCT01887587|DRUG|MLN9708|
214703232|NCT01887587|DRUG|Vincristine|
215162420|NCT06577441|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215162421|NCT06577441|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215162422|NCT06577441|DRUG|Decitabine and Cedazuridine|Given PO
215162423|NCT06577441|DRUG|Enasidenib|Given PO
215162424|NCT05426733|DRUG|Odevixibat|Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
215162425|NCT05501236|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
214703233|NCT01887587|DRUG|Doxorubicin|
214703234|NCT01887587|DRUG|Dexamethasone|
214703235|NCT05630170|DEVICE|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
214703236|NCT05430711|DRUG|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
214703237|NCT05171582|PROCEDURE|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
214703238|NCT05171582|PROCEDURE|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
214554386|NCT04139382|OTHER|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
214703239|NCT00057460|DRUG|Talampanel|
214703240|NCT01974726|OTHER|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
214703241|NCT01974726|OTHER|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
214703242|NCT01974726|OTHER|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
214703243|NCT01974726|OTHER|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
214703244|NCT01974726|OTHER|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
214708999|NCT06139536|DRUG|BAT1308 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
214709000|NCT00497354|DRUG|Variation in volume of local anesthetic|
214709001|NCT00497354|PROCEDURE|Ultrasound-guided interscalene brachial plexus block|
214709002|NCT02238288|DRUG|Aminocaproic acid|Crushed tablet in the dental socket
214554387|NCT04139382|OTHER|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
214554388|NCT00002475|BIOLOGICAL|allogeneic tumor cell vaccine|
214554389|NCT00002475|BIOLOGICAL|autologous tumor cell vaccine|
214554390|NCT00002475|BIOLOGICAL|recombinant interferon alfa|
214554391|NCT00002475|BIOLOGICAL|recombinant interferon gamma|
214554392|NCT00002475|BIOLOGICAL|sargramostim|
214554393|NCT00002475|DRUG|cyclophosphamide|
214554394|NCT01024153|BEHAVIORAL|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
214554395|NCT05872191|OTHER|No intervention|There is no intervention to be administered, only collection of data through various tests and questionnaires.
214554396|NCT04538846|OTHER|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
215162426|NCT03755297|OTHER|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
214554397|NCT01370655|DRUG|MK-7145|
214554398|NCT01370655|DRUG|Hydrochlorothiazide (HCTZ)|
215162427|NCT04516967|DRUG|Avatrombopag|Oral avatrombopag tablet or sprinkle capsule
214554399|NCT01370655|DRUG|Placebo to MK-7145|
214554400|NCT01370655|DRUG|Placebo to HCTZ|
214554401|NCT00296257|DRUG|SMP-114|
214554402|NCT03477487|BIOLOGICAL|XT-150|Human IL-10 variant transgene in a plasmid DNA vector
214554403|NCT03733353|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbial
214554404|NCT03733353|DRUG|Placebo oral capsule|Placebo
214554405|NCT03733353|DRUG|Placebo oral tablet|Placebo
214554406|NCT02872558|OTHER|Acute Otitis Media Choice Decision Aid|Decision Aid
214554407|NCT02872558|OTHER|Usual Care|Usual Care
214554408|NCT00581477|DRUG|Droxidopa Oral Product|Droxidopa administered in increasing dosages up to 300 mg
214554409|NCT05695560|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
214554410|NCT00562458|DRUG|anastrozole|
214554411|NCT03248544|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
214709003|NCT02238288|OTHER|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
214709004|NCT02238288|DRUG|lidocaine and epinephrine|2%
214709005|NCT02238288|DRUG|Paracetamol|750 mg
214709006|NCT03931395|DIETARY_SUPPLEMENT|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
214709007|NCT03931395|OTHER|Standard of Care|Patients will receive standard post operative medications per surgeon
214554412|NCT03248544|OTHER|control|No intervention
214554413|NCT02323958|OTHER|acupoint stimulation|stimulation is given at acupoints
214554414|NCT02323958|OTHER|non-acupoint stimulation|stimulation is given at acupoints
214554415|NCT02323958|OTHER|electrode attached|electrodes are attached to skin
215162428|NCT04516967|DRUG|Placebo|Placebo comparator tablet or sprinkle capsule
215162429|NCT06441786|BEHAVIORAL|A metacognitive group therapy of depression and anxiety in youth with autism|"The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions."
215162430|NCT03954145|PROCEDURE|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
214554416|NCT02323958|DEVICE|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
214554417|NCT02660645|DRUG|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
214554418|NCT02660645|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
214554419|NCT02069366|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.
214554420|NCT02069366|DRUG|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
214554421|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
214554422|NCT02838992|DRUG|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
214554423|NCT02838992|DRUG|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
214554424|NCT02838992|DRUG|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
214554425|NCT02838992|BIOLOGICAL|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
214554426|NCT06250790|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
214554427|NCT06287151|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
214554428|NCT06287151|DRUG|Clonidine|Clonidine is an alpha-2-agonist which is commonly used as an adjunct in spinal anesthesia and caudal anesthesia to improve both the quality and duration of blockade.
214554429|NCT06287151|DRUG|Sevoflurane|5.3. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
214554430|NCT05418127|DIETARY_SUPPLEMENT|Active|Traditionally-fermented coconut milk kefir
214703245|NCT01974726|OTHER|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
214703246|NCT01974726|OTHER|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
214703247|NCT01974726|OTHER|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
214703248|NCT01974726|OTHER|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
214703249|NCT01016691|DRUG|High Dose Drug Device|device inserted for 4 days
214703250|NCT01016691|DRUG|Low Dose Drug Device|device inserted for 4 days
214703251|NCT01016691|DRUG|Placebo Device|device inserted for 4 days
214703252|NCT01016691|DRUG|bimatoprost 0.03%|one drop in each eye on one day only
214703253|NCT01731613|DIETARY_SUPPLEMENT|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
214703254|NCT01398072|DRUG|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
214703255|NCT01398072|DRUG|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
214554431|NCT05418127|OTHER|Placebo|Solution of Calcium Carbonate and coconut extract
214703256|NCT01398072|DRUG|Doxycycline|An oral dose of 100 mg once daily.
214703257|NCT01398072|DRUG|Placebo|Oral dose of one table once daily.
214703258|NCT06281145|BEHAVIORAL|Heart-rate variability biofeedback intervention|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
214703259|NCT01794247|DRUG|Magnesium sulfate|
214703260|NCT01794247|DRUG|Fentanyl|
214703261|NCT01794247|DRUG|Lidocaine|
214703262|NCT02793895|DEVICE|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
214703263|NCT02793895|OTHER|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
214709008|NCT05966246|DRUG|Arm I : Experimental (Prucalopride succinate group)|Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
214709009|NCT05966246|DRUG|Arm II : Control (Mosapride citrate group)|Control gourp taking mosapride citrate from day 1 day 5 after surgery
214554434|NCT02735746|RADIATION|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
214554435|NCT02735746|RADIATION|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
214554436|NCT02735746|RADIATION|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
214554437|NCT02735746|DEVICE|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
214703264|NCT02793895|DEVICE|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
214703265|NCT02438215|DRUG|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
214703266|NCT03354702|OTHER|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
215162431|NCT03954145|PROCEDURE|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
214703267|NCT03354702|OTHER|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
215162432|NCT04517799|DRUG|Epidiolex|"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
215162433|NCT04517799|DRUG|placebo oral solution|"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
215162434|NCT06001788|DRUG|Ziftomenib|Oral administration
214554438|NCT00245180|BEHAVIORAL|Diet|
214554439|NCT00245180|BEHAVIORAL|Exercise|
215162435|NCT06001788|DRUG|Fludarabine|Intravenous infusion
215162436|NCT06001788|DRUG|Idarubicin|Intravenous infusion
215162437|NCT06001788|DRUG|Cytarabine|Intravenous Infusion
215162438|NCT06001788|DRUG|Gilteritinib|Oral administration
215162439|NCT06001788|BIOLOGICAL|Granulocyte colony-stimulating factor|Subcutaneous injection
215162440|NCT03065335|DRUG|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
215162441|NCT03065335|OTHER|Placebo|Placebo comparator
215162442|NCT03065335|DEVICE|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
215162443|NCT03065335|DEVICE|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
215162444|NCT06049017|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
215162445|NCT06049017|DRUG|Placebo|Placebo tablet will be administered orally.
215162446|NCT06049953|DRUG|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
215162447|NCT06049953|DRUG|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
215162448|NCT06049953|OTHER|No Medication|Non-psychotropic medications
214554440|NCT03119233|DEVICE|DETOUR System|The DETOUR System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
214554441|NCT05850195|OTHER|non invasive ventilation|compare indices and diaphragmatic ultrasonography for prediction of NIV failure in acute RF patients
214554442|NCT02035618|OTHER|Exercises|Strengthening and stretching
214554443|NCT02035618|OTHER|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
214554444|NCT04701346|OTHER|Low SAA diet|Diet with low content of methionine and cysteine
214554445|NCT04701346|OTHER|High SAA diet|Diet with high content of methionine and cysteine
214554446|NCT04151836|OTHER|Exercise education|"weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects."
214554447|NCT02228902|DRUG|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
214554448|NCT02228902|DRUG|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
214554449|NCT06240819|OTHER|Sleeper Stretch|They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position
214554450|NCT06240819|OTHER|Cross Body Stretch|They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
214554451|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
214554452|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
214554453|NCT02057575|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
214554454|NCT02057575|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
214554455|NCT04389034|DRUG|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
214554456|NCT00332462|DRUG|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
214703268|NCT02802878|DEVICE|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
214703269|NCT02802878|DEVICE|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
215162449|NCT05460715|DEVICE|Quadra P anteverted|"* Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~* Assessment of functional recovery by gait analysis study~* Collect the rate of complications throughout the course of the study"
215162450|NCT06801899|PROCEDURE|Total pancreatectomy (TP)|The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head.
215162451|NCT06801899|PROCEDURE|Partial pancreaticoduodenectomy (PD)|The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
214703270|NCT00536978|DRUG|ARA-C|100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
214703271|NCT00536978|DRUG|BCNU|300 mg/m\^2 IV Over 1 Hour for 1 Day
214703272|NCT00536978|DRUG|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
214703273|NCT00536978|DRUG|Cyclophosphamide|1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
214554457|NCT00332462|DRUG|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
214554458|NCT01643044|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
214703274|NCT00536978|DRUG|Etoposide|100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
214703275|NCT00536978|DRUG|Fludarabine|30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
214703276|NCT00536978|DRUG|Melphalan|100 mg/m\^2 IV Over 30 Minutes for 1 Day.
214703277|NCT00536978|DRUG|Rituximab|375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
214554459|NCT01643044|BEHAVIORAL|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
214554460|NCT05169840|OTHER|Genetic Risk Score for Coronary Artery Disease|Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)
214554461|NCT02451176|DEVICE|Davol Bard Soft Mesh synthetic|soft mesh synthetic
214554462|NCT02451176|DEVICE|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
214554463|NCT02472340|PROCEDURE|Muscle Biopsy|Muscle Biopsy
214703278|NCT00536978|OTHER|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
214703279|NCT00536978|RADIATION|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
214703280|NCT00536978|DRUG|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
214703281|NCT00536978|DRUG|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
214703282|NCT00536978|PROCEDURE|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
214703283|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
215162452|NCT02245997|RADIATION|External beam radiotherapy|
215162453|NCT02245997|RADIATION|proton beam RT|
214554464|NCT03884322|OTHER|Prepod|the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.
214554465|NCT03884322|PROCEDURE|Joint compression exercises|Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
214703284|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
214703285|NCT02638805|DRUG|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
214703286|NCT02638805|DRUG|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
214703287|NCT05232422|BEHAVIORAL|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
214703288|NCT03364426|OTHER|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
214703289|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
214703290|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
214703291|NCT03477617|OTHER|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
214703292|NCT03477617|COMBINATION_PRODUCT|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
214703293|NCT02149056|BEHAVIORAL|observation|
215162454|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
215162455|NCT02227251|DRUG|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
215162456|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
214703294|NCT02149056|OTHER|Impaired Glucose Tolerance|Impaired Glucose Tolerance
214703295|NCT02852148|DEVICE|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
214703296|NCT04228120|BEHAVIORAL|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
215162457|NCT03570749|DRUG|Baricitinib|Administered orally.
215162458|NCT03570749|DRUG|Placebo|Administered orally.
215162459|NCT04046536|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
215162460|NCT04046536|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
214554466|NCT04061876|DRUG|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
214554467|NCT04061876|DRUG|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
214554468|NCT03080168|DEVICE|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
214554469|NCT06169072|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
214554470|NCT06169072|DEVICE|Technetium99|Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
214703297|NCT00916370|DEVICE|Core size Xience Prime|Core size includes a range of stent sizes.
215162461|NCT06009926|DRUG|Acetaminophen|Given PO
215162462|NCT06009926|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215162463|NCT06009926|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
215162464|NCT06009926|DRUG|Placebo Administration|Given PO
215162465|NCT06009926|OTHER|Questionnaire Administration|Ancillary studies
215162466|NCT06009926|OTHER|Training|Undergo flashover training
215162467|NCT06229353|BIOLOGICAL|Gardasil 9|Prevent HPV-associated diseases and cancers
215162468|NCT05251948|DRUG|Atezolizumab|Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
215162469|NCT05251948|DRUG|Capecitabine|Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
215162470|NCT05251948|DRUG|Oxaliplatin|Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
215162471|NCT05251948|DRUG|Tiragolumab|Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
215162472|NCT05837897|DRUG|Vedolizumab IV|Vedolizumab IV infusion
214703298|NCT00916370|DEVICE|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
214703299|NCT01344837|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214703300|NCT01344837|OTHER|Immunohistochemistry Staining Method|Correlative studies
214703301|NCT01344837|OTHER|Medical Chart Review|Correlative studies
215162473|NCT05837897|DRUG|Placebo|Vedolizumab placebo-matching IV infusion
215162474|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
215162475|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)/RIV|Combination of BNT162b2 (Omi XBB.1.5) and RIV
215162476|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|Licensed COVID-19 vaccine
215162477|NCT06237049|BIOLOGICAL|RIV|Licensed recombinant influenza vaccine
214554471|NCT04278027|BEHAVIORAL|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
214554472|NCT01835405|DEVICE|LiquiBand Flex|
214554473|NCT01835405|DEVICE|Dermabond Advanced|
214554474|NCT01835405|DEVICE|Sutures (Prolene)|
214554475|NCT05108753|OTHER|Procedure/Surgery|Transanal Total Mesorectal Excision
214554476|NCT02042027|DRUG|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
214554477|NCT03897231|OTHER|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
214554478|NCT03578588|DRUG|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
214554479|NCT00021424|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|
214554480|NCT02974400|BEHAVIORAL|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
214554481|NCT03423927|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
214554482|NCT01735175|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
214703302|NCT01344837|GENETIC|Microarray Analysis|Correlative studies
214703303|NCT01344837|OTHER|Study of Socioeconomic and Demographic Variables|Correlative studies
214703304|NCT01344837|GENETIC|Western Blotting|Correlative studies
214703305|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
214703306|NCT00501215|BEHAVIORAL|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
214703307|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
214703308|NCT00501215|BEHAVIORAL|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
214703309|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
214703310|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
215162478|NCT06237049|OTHER|Normal saline placebo|Normal saline (solution for injection)
215162479|NCT04941573|COMBINATION_PRODUCT|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
215162480|NCT02651948|PROCEDURE|Transperineal, MRI-guided, prostate biopsy|
215162481|NCT02651948|PROCEDURE|Transrectal prostate biopsy (TRB):|
215162482|NCT03005925|DEVICE|Smartphone|Smartphone application coupled with a hand dynamometer
215162483|NCT03005925|OTHER|physical follow up|regular visits with the specialist
215162484|NCT06170619|DEVICE|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
215162485|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
215162486|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
214554483|NCT01735175|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
214554484|NCT02885584|DEVICE|High frequency percussive ventilation|
214554485|NCT01336049|DRUG|Nimotuzumab|Nimotuzumab 200mg/week
214554486|NCT05833646|DEVICE|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
214554487|NCT05833646|DEVICE|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
214554488|NCT05833646|DEVICE|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
214554489|NCT01956604|DRUG|Clonidine|
214554490|NCT01956604|DRUG|Placebo|
214554491|NCT05431218|DRUG|Cholecalciferol Liquid|daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
214554492|NCT05762952|DRUG|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
214703311|NCT01892618|DRUG|Prevenar 13|13-valent pneumococcal conjugated vaccine
214703312|NCT01892618|DRUG|Pneumovax|23-valent pneumococcal polysaccharide vaccine
214554493|NCT05762952|DRUG|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
214554494|NCT06228716|DEVICE|Training with hybrid simulation method|Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher. The application was considered successful if they completed all application steps correctly from start to finish. The training took approximately 40 minutes. After the practical training, the individuals' questions, if any, were answered and the training was terminated.
214703313|NCT05120999|DEVICE|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
214703314|NCT01290133|DRUG|GW597599|Single dose IV infusion
214703315|NCT01290133|DRUG|Placebo|Single dose IV infusion
214703316|NCT04586868|BEHAVIORAL|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
214703317|NCT04586868|BEHAVIORAL|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
214554495|NCT06228716|OTHER|Broshure|Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training. After the training, any questions the individuals had were answered and the training was ended.
214554496|NCT01853475|DRUG|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
214554497|NCT01853475|DRUG|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
214554498|NCT01853475|DRUG|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
214554499|NCT01853475|DRUG|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
214554500|NCT05531071|DEVICE|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
214554501|NCT05531071|PROCEDURE|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
214703318|NCT04586868|BEHAVIORAL|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
214703319|NCT04669314|PROCEDURE|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
214703320|NCT01604304|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
215162487|NCT06799533|DRUG|PF-08046031|Given into the vein (IV; intravenous)
214703321|NCT01604304|PROCEDURE|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
214703322|NCT03898869|DIAGNOSTIC_TEST|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
215162488|NCT06120075|DRUG|AB801|Administered as specified in the treatment arm
215162489|NCT06120075|DRUG|Docetaxel|Administered as specified in the treatment arm
215162490|NCT05055700|BEHAVIORAL|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
215162491|NCT05623982|DRUG|GNC-038|Administration by intravenous infusion
215162492|NCT05136196|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
215162493|NCT05136196|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215162494|NCT05136196|DRUG|Cabozantinib S-malate|Given PO
215162495|NCT05136196|PROCEDURE|Computed Tomography|Undergo CT scans
215162496|NCT05136196|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
215162497|NCT05136196|BIOLOGICAL|Nivolumab|Given IV
214554502|NCT05531071|COMBINATION_PRODUCT|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
214554503|NCT04570696|OTHER|NON INTERVENTIONAL|NON INTERVENTIONAL
214554504|NCT02470780|DRUG|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
214554505|NCT02470780|DRUG|Placebo|Placebo matching Rifaximin treatment.
214554506|NCT01023958|DRUG|BI 6727, IV infusion|phase II
214554507|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
214554508|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
214554509|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
214554510|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
215162498|NCT05627128|OTHER|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
215162499|NCT04387552|BEHAVIORAL|Prenatal Safe Sleep Mobile Health (mHealth) Messaging|Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.
215162500|NCT04387552|BEHAVIORAL|Prenatal Breastfeeding Mobile Health (mHealth) Messaging|Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.
215162501|NCT04387552|BEHAVIORAL|Postnatal Safe Sleep Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.
215162502|NCT04387552|BEHAVIORAL|Postnatal Breastfeeding Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
215162503|NCT04104672|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
214703323|NCT03311490|DEVICE|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
214703324|NCT05339243|OTHER|ES 1|Two capsules orally once daily after breakfast for 84 days
214703325|NCT05339243|OTHER|HT ES1|Two capsules orally once daily after breakfast for 84 days
214703326|NCT05339243|OTHER|Placebo|Two capsules orally once daily after breakfast for 84 days
214703327|NCT00610376|BEHAVIORAL|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
214703328|NCT00610376|BEHAVIORAL|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
214703329|NCT03550131|BEHAVIORAL|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
214703330|NCT03550131|BEHAVIORAL|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
214703331|NCT06288958|OTHER|Quality of Life and social participation in Italian children with CP|CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
214703332|NCT00717366|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
214703333|NCT06553950|DRUG|Botox injection|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle."
214554511|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
214703334|NCT06553950|DRUG|Mandibular stabilization splint|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
214703335|NCT06553950|DRUG|Muscle relaxant|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
215162504|NCT04104672|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
215162505|NCT04104672|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
215162506|NCT04104672|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
215162507|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
215162508|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
215162509|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
215162510|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
215162511|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
215162512|NCT03264547|DRUG|Pertuzumab|Every 3 weeks
215162513|NCT03264547|DRUG|Trastuzumab|Every 3 weeks
215162514|NCT03264547|DRUG|Docetaxel|Every 3 weeks
215162515|NCT03264547|DRUG|Paclitaxel|Every week
214554512|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
214554513|NCT05824000|DEVICE|Eye drops for itchy and water eyes|Ocular drops for itchy and watery eyes
214554514|NCT02859090|PROCEDURE|tonsillectomy|
214554515|NCT02859090|BIOLOGICAL|blood sample|
214554516|NCT01301040|DRUG|epirubicin, cyclophosphamide, docetaxel|"* Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
215162516|NCT03264547|DRUG|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
215162517|NCT05159427|DRUG|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
215162518|NCT05159427|DRUG|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
215162519|NCT05159427|DRUG|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
215162520|NCT05159427|DRUG|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
215162521|NCT03826043|DIAGNOSTIC_TEST|Blood sample analysis|Thrombophilia, blood count and coagulation count
214703336|NCT04476355|OTHER|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
214554517|NCT04766359|DRUG|Albumin-Bound Paclitaxel|Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.
214554518|NCT05005962|DEVICE|Neurothrombectomy|Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
214554519|NCT00605332|DEVICE|inferior vena cava filter|Crux Biomedical IVC Filter
214554520|NCT05701878|BEHAVIORAL|SMARTest mobile app for COVID-19 self-testing|The mobile app has self-testing features and information with regard to self-testing and COVID-19.
214554521|NCT01359787|DRUG|Mapracorat|Daily topical application
215162522|NCT06799741|DRUG|AV-1 100 mg|"human monoclonal antibody (mAb) intravenous solution~or"
214554522|NCT01359787|DRUG|Vehicle without active|Daily topical application
215162523|NCT06799741|DRUG|AV-1 300 mg|"human monoclonal antibody (mAb) intravenous solution~or"
215162524|NCT06799741|DRUG|AV-1 900 mg|"human monoclonal antibody (mAb) intravenous solution~or"
215162525|NCT06799741|DRUG|Placebo|(0.9% saline intravenous solution) 12:2
215162526|NCT06212661|DRUG|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
214554523|NCT04851639|OTHER|Wolverhampton Assessment Tool|a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
215162527|NCT06212661|DRUG|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
215162528|NCT06212661|DRUG|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
215162529|NCT06212661|DRUG|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
215162530|NCT06212661|DRUG|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
215162531|NCT06212661|DRUG|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
214554524|NCT06189885|DRUG|Cefazolin with Daptomycin|For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.
214554525|NCT06189885|DRUG|Cefazolin with vancomycin|Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
214554526|NCT01932476|DIETARY_SUPPLEMENT|Gluten Challenge|Three-day gluten containing dietary challenge.
214554527|NCT01932476|DIETARY_SUPPLEMENT|Sham Challenge|Three-day sham (gluten free) dietary challenge
214554528|NCT03982212|DRUG|Copaxone|"* Agent: Glatiramer acetate (Copaxone®)~* Dose: 40 mg~* Route: Intratumoral injection~* Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
214554529|NCT03145922|OTHER|Observational Study|Observational study utilizing bronchoscopy, and imaging
214554530|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
214554531|NCT02656589|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
214703337|NCT00230100|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
215162532|NCT06212661|DRUG|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
215162533|NCT06212661|DRUG|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
215162534|NCT05054790|BIOLOGICAL|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
215162535|NCT04069091|BEHAVIORAL|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
214554532|NCT02656589|DRUG|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
214703338|NCT00230100|BEHAVIORAL|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
214554533|NCT01424462|DRUG|A|Single dose treatment IR formulation
214554534|NCT01424462|DRUG|B|Low Extended release single dose
214554535|NCT01424462|DRUG|C|Medium extended release formulation
215162536|NCT06631313|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
214554536|NCT01424462|DRUG|D|High extended release rate single dose
214554537|NCT03080493|DRUG|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
214554538|NCT03080493|DRUG|Placebo oral capsule|Packaged identical to gabapentin dosing
214554539|NCT03080493|DRUG|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
214554540|NCT00801463|DRUG|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
214554541|NCT05347862|OTHER|Control group|At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.
214703339|NCT05939596|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
214703340|NCT05939596|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
215162537|NCT04835805|DRUG|Belvarafenib|Twice daily (BID), continuous dosing
215162538|NCT04835805|DRUG|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
215162539|NCT04835805|DRUG|Nivolumab|Once every 4 weeks (Q4W)
215162540|NCT05454943|BEHAVIORAL|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
215162541|NCT05454943|BEHAVIORAL|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
215162542|NCT05454943|BEHAVIORAL|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
215162543|NCT05454943|BEHAVIORAL|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
215162544|NCT04638647|BIOLOGICAL|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
215162545|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
215162546|NCT05588453|BIOLOGICAL|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
214554542|NCT05347862|OTHER|Physical activity promotion|"The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study."
214554543|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
214554544|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
214554545|NCT00755417|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
214554546|NCT06055946|DEVICE|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
214554547|NCT02362503|DRUG|BMS-663068|BMS-663068
214554548|NCT02362503|OTHER|Placebo|Placebo
214554549|NCT00813722|BEHAVIORAL|phone call|patients received or not phone calls to give orientation abou treatment
214703341|NCT04727502|DRUG|Duloxetine|duloxetine
214703342|NCT04727502|DRUG|Pregablin|Pregablin
214703343|NCT02141802|BEHAVIORAL|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
215162547|NCT05588453|DRUG|Temozolomide|Given PO
215162548|NCT03701308|PROCEDURE|Biospecimen Collection|Undergo blood collection
215162549|NCT03701308|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
215162550|NCT03701308|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215162551|NCT03701308|DRUG|Cytarabine|Given IV
215162552|NCT03701308|DRUG|Daunorubicin|Given IV
215162553|NCT03701308|PROCEDURE|Echocardiography Test|Undergo ECHO
215162554|NCT03701308|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162555|NCT03701308|DRUG|Uproleselan|Given IV
215162556|NCT00903110|DRUG|Increlex®|Increlex® (mecasermin \[rDNA origin\] injection), 10 mg/ml solution for injection, 40-120mcg/kg BID or 0,04 to 0,12 mg/kg BID, as prescribed by physician
214554550|NCT00813722|DRUG|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
214554551|NCT00813722|DRUG|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
214554552|NCT02306590|DIETARY_SUPPLEMENT|Calogen|
214554553|NCT02306590|DIETARY_SUPPLEMENT|Placebo|
214554554|NCT06456489|DRUG|Solumedrol|125 mg methylprednisolone intravenous pulse on 2 consecutive days
214703344|NCT02141802|BEHAVIORAL|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
214703345|NCT00235690|PROCEDURE|Blood draws|PK samples obtained around a clinical dosing of colistin
214703346|NCT00235690|OTHER|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
214703347|NCT03378726|DIETARY_SUPPLEMENT|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
214703348|NCT03378726|BEHAVIORAL|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
214703349|NCT03378726|BEHAVIORAL|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
214703350|NCT03378726|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
214554555|NCT05636228|DRUG|INV-102|INV-102 Ophthalmic Solution
214554556|NCT05636228|DRUG|Vehicle|Vehicle Ophthalmic Solution
214554557|NCT04197479|DRUG|Placebo|Matching tablets
214554558|NCT04197479|DRUG|Resmetirom|Tablet
215162557|NCT06126666|DRUG|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
214554559|NCT06355323|OTHER|Blood test|Blood test
214703351|NCT03378726|BEHAVIORAL|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
214703352|NCT01167465|OTHER|Moussik Diaper Rash Mousse|To be used as instructed
215162558|NCT04459156|DIETARY_SUPPLEMENT|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
214554560|NCT06355323|OTHER|chest CT scan|chest CT scan
214554561|NCT05143138|DEVICE|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
214554562|NCT00164710|DRUG|sulfadoxine-pyrimethamine|
214554563|NCT00164710|DRUG|amodiaquine plus sulfadoxine-pyrimethamine|
214554564|NCT00164710|DRUG|amodiaquine plus artesunate|
214554565|NCT00164710|DRUG|chlorproguanil-dapsone plus artesunate|
214554566|NCT00164710|DRUG|lumefantrine-artemether|
214554567|NCT00002668|BEHAVIORAL|Observation|
214554568|NCT00002668|BEHAVIORAL|Educational Intervention and Behavioral Skills Training|
214554569|NCT02627378|OTHER|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
214554570|NCT02627378|OTHER|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
214554571|NCT01497106|BEHAVIORAL|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
214554572|NCT01497106|BEHAVIORAL|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
214554573|NCT02353416|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
214554574|NCT02353416|OTHER|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
214554575|NCT01518907|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
214554576|NCT00760344|DRUG|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
214554577|NCT00760344|DRUG|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
214703353|NCT01167465|OTHER|Desitin Creamy Ointment|To be used as instructed
214703354|NCT01200615|BEHAVIORAL|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
214703355|NCT01317615|DRUG|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
214703356|NCT01317615|DRUG|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
214703357|NCT01317615|DRUG|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
214703358|NCT00005847|BIOLOGICAL|recombinant interferon alfa|
214703359|NCT00005847|DRUG|estramustine phosphate sodium|
214703360|NCT00005847|DRUG|isotretinoin|
214703361|NCT00005847|DRUG|mitoxantrone hydrochloride|
214703362|NCT00005847|DRUG|paclitaxel|
214703363|NCT00005847|DRUG|vinorelbine ditartrate|
214703364|NCT02049801|DRUG|MEK inhibitor MEK162|Given PO
214703365|NCT02049801|DRUG|idarubicin|Given IV
214703366|NCT02049801|DRUG|cytarabine|Given IV
215162559|NCT04459156|DIETARY_SUPPLEMENT|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
214703367|NCT02049801|OTHER|pharmacological study|Correlative studies
214703368|NCT02049801|OTHER|laboratory biomarker analysis|Correlative studies
214703369|NCT04813536|OTHER|the Standard Shiftwork Index questionnaire|"1. Biographical information: This includes personal data (e.g., age, sex, marital status, and domestic situations), shift details (e.g., shift start and end times), organization of shiftwork, and general job satisfaction~2. Sleep and fatigue: Measures the effect of shiftwork on perceived sleep quality and quantity and fatigue"
214703370|NCT04813536|OTHER|complete blood picture|5ml blood to estimate changes of total leucocytic count, Hemoglobin, eosinophilic, monocyte
214703371|NCT04813536|OTHER|lipid profile|5ml blood to estimate changes of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and HDL-C
214703372|NCT02859493|DEVICE|Saccharomyces cerevisiae|
214554578|NCT00760344|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
214554579|NCT00760344|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
214554580|NCT00760344|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
214554581|NCT00760344|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
214554582|NCT00377988|DRUG|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
214554583|NCT00377988|DRUG|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
214554584|NCT02977286|DRUG|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
214554585|NCT02977286|DRUG|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
214554586|NCT02977286|DRUG|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
214554587|NCT02977286|DRUG|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
214554588|NCT02977286|DRUG|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
214554589|NCT02977286|DRUG|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
214554590|NCT02977286|DRUG|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.
214554591|NCT02977286|DRUG|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
214703373|NCT02859493|DEVICE|Placebo|
214703374|NCT05601024|BEHAVIORAL|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
214703375|NCT00321425|PROCEDURE|brachial plexus block|
214703376|NCT00321425|PROCEDURE|ultrasound guidance|
214703377|NCT00321425|PROCEDURE|electrical nerve stimulation|
214703378|NCT01380444|PROCEDURE|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
214703379|NCT01380444|PROCEDURE|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
214703380|NCT00255086|DRUG|Memantine|10mg Memantine
214703381|NCT00255086|DRUG|Placebo pill|10mg placebo pill
214554592|NCT00038480|DRUG|Lopinavir/Ritonavir|
214554593|NCT04218747|BEHAVIORAL|VA 365 Demonstration Benefits|Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
214554594|NCT05021471|OTHER|biofeedback|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
214554595|NCT05021471|OTHER|hamstrings stretching|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
214554596|NCT03516097|BEHAVIORAL|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
214703382|NCT00191074|DRUG|somatropin, rDNA origin, for injection|
214554597|NCT03516097|DEVICE|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
214554598|NCT04346810|OTHER|Patient management suffering of coronavirus infection|Welle-being and stress of the caregivers
214554599|NCT03325777|BEHAVIORAL|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
214554600|NCT03325777|BEHAVIORAL|SHAM Training|SHAM Training
214554601|NCT01013142|DRUG|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
214554602|NCT01013142|DRUG|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
214554603|NCT01013142|DRUG|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
214554604|NCT01055236|DRUG|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
214554605|NCT00786643|DRUG|5-Fluorouracil|5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
214554606|NCT00786643|DRUG|Leucovorin (LV)|Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
214554607|NCT00786643|DRUG|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
214554608|NCT00786643|DRUG|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
214554609|NCT06798753|DEVICE|Occlusion Balloon Catheter|The occlusion balloon catheter (OBC) is a type of ureteral catheter equipped with a small inflatable balloon at its tip. When inflated, the balloon can help prevent the migration of stone fragments.
214554610|NCT06798753|DEVICE|5FR Ureteral Catheter|The 5FR ureteral catheter (5FR-UC) is an open-ended small-caliber tube inserted at the beginning of PCNL to facilitate visualization of the collecting system using fluoroscopy and assist with renal access.
215162560|NCT03770429|DRUG|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
215162561|NCT06545916|DRUG|Sunobinop|1 tablet taken orally at bedtime
215162562|NCT06545916|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
215162563|NCT06085833|DIAGNOSTIC_TEST|Nanomechanical Phenotype Test|The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
215162564|NCT06484062|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215162565|NCT06484062|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214554611|NCT04011007|PROCEDURE|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
214554612|NCT02145845|DEVICE|Injectable SIS|Injectable SIS
214554613|NCT06342336|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
214554614|NCT05210075|BEHAVIORAL|Mindful with your Baby program|The training Mindful with your baby consists of eight weekly 2-h sessions, plus a follow-up session 8 weeks later. The first and the fifth sessions are with the mothers only. The rest of the sessions are with both mothers and babies present. The sessions are finished by explaining the new home practices. Home practice consists of reading handouts about mindfulness and mindful parenting for mothers with a baby, formal and informal meditation practice.
214554615|NCT00711308|DRUG|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
214554616|NCT00711308|DRUG|acenocoumarol|acenocoumarol for 6 months
214709010|NCT05100108|BEHAVIORAL|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
215162566|NCT06484062|DRUG|Cirtuvivint|Given PO
215162567|NCT06484062|DRUG|Decitabine and Cedazuridine|Given PO
215162568|NCT06484062|PROCEDURE|Echocardiography Test|Undergo ECHO
215162569|NCT06484062|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162570|NCT05303467|DEVICE|TheraSphere GBM|Single treatment of TheraSphere GBM device
215162571|NCT04187443|DRUG|MS-553|MS-553
214703383|NCT04260334|OTHER|Preoperative Education|The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
214554617|NCT01099917|DRUG|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
214554618|NCT02850042|BEHAVIORAL|Occupation-based practice (OBP)|
214554619|NCT02850042|BEHAVIORAL|Modified-constraint induced therapy (m-CIT)|
214554620|NCT00980746|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
214554621|NCT00980746|DRUG|Placebo|oral route
214554622|NCT01025505|DRUG|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
214554623|NCT01025505|DRUG|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
214703384|NCT02969850|DIETARY_SUPPLEMENT|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
214554624|NCT02990468|DRUG|BMX-001|Subcutaneous injection.
214554625|NCT02990468|RADIATION|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
214554626|NCT02990468|DRUG|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
214703385|NCT02969850|OTHER|Placebo|Subjects in this group will receive a placebo.
214703386|NCT02969850|DIETARY_SUPPLEMENT|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
214703387|NCT05830513|DEVICE|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
214703388|NCT04000555|DRUG|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
214703389|NCT04000555|OTHER|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
214703390|NCT05770050|OTHER|No intervention|No intervention
214554627|NCT02136368|BEHAVIORAL|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
214554628|NCT02136368|BEHAVIORAL|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
214554629|NCT02136368|BEHAVIORAL|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
214554630|NCT02335905|DRUG|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
214554631|NCT04296747|DRUG|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
214554632|NCT04296747|PROCEDURE|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
214554633|NCT04296747|RADIATION|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
214554634|NCT03345745|DIAGNOSTIC_TEST|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
214554635|NCT04641169|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
214703391|NCT02074306|DEVICE|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
214703392|NCT02074306|DEVICE|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
214703393|NCT03270150|DEVICE|BTL-899|BTL-899
214703394|NCT01670214|PROCEDURE|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
214703395|NCT05534204|PROCEDURE|Silk suture|Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
214703396|NCT05534204|PROCEDURE|Polyester suture|Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
214703397|NCT01906866|DRUG|Circadin 2/5/10 mg|Circadin 2/5/10 mg. Active arm
214703398|NCT01906866|DRUG|Placebo|Control arm
214554636|NCT03435731|COMBINATION_PRODUCT|Dual Therapy|Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
214554637|NCT01485120|DEVICE|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
214554638|NCT04210999|OTHER|Homebased resistance training|Resistance training at home instructed via a smart phone training app
214554639|NCT04210999|OTHER|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
214554640|NCT01649154|PROCEDURE|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
214554642|NCT03058393|OTHER|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
214554643|NCT04771377|DIETARY_SUPPLEMENT|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
214554644|NCT01817920|BEHAVIORAL|integrated multidisciplinary fall prevention program|
214554645|NCT02567708|DRUG|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
214703399|NCT01428518|DRUG|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
214703400|NCT04045236|OTHER|Registry|Data collection
214703401|NCT01984879|OTHER|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
214554646|NCT02567708|DRUG|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
214554647|NCT05761613|DEVICE|CeraShield Endotracheal Tube|An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
214554648|NCT05761613|DEVICE|Endotracheal tube with subglottic secretion drainage|An endotracheal tube with subglottic secretion drainage
214554649|NCT03993210|DEVICE|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
214554650|NCT03993210|DEVICE|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
214703402|NCT02977013|DIAGNOSTIC_TEST|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
214554651|NCT03993210|DEVICE|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
214554652|NCT02405598|DRUG|Salbutamol|"1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
214554653|NCT02495766|DRUG|XCEL-MC-ALPHA|Single infusion
214554654|NCT02495766|DRUG|Placebo|Single infusion
214703403|NCT06553443|DEVICE|Angioplasty of all peripheral AVF stenosis|All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
214554655|NCT06026930|DEVICE|low-level laser therapy|LLLT and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
214554656|NCT00022945|DRUG|Iodine-131 Anti-B1 Antibody|
214554657|NCT00022945|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
214554658|NCT01193010|PROCEDURE|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
214554659|NCT01193010|PROCEDURE|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
214554660|NCT04325633|DRUG|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
214554661|NCT04325633|DRUG|2: Standard of care|Standard of care
214554662|NCT04970719|DRUG|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
214554663|NCT04970719|DRUG|Dexamethasone|and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
214554664|NCT04970719|DRUG|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
214554665|NCT02463045|DRUG|TOP1288|
214554666|NCT04053062|BIOLOGICAL|LIGHT-PSMA-CART cells|LIGHT-PSMA-CART cells will be given IV at split doses
214703404|NCT03783052|DEVICE|SmartPill in fasted state|SmartPill administration in fasted state
214703405|NCT03783052|DEVICE|SmartPill in fed state|SmartPill administration in fed state
214703406|NCT03783052|OTHER|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
214703407|NCT03783052|OTHER|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
214703408|NCT06373042|DRUG|Intraarterial and intravenous tirofiban|Intraarterial and intravenous tirofiban after endovascular thrombectomy
214703409|NCT06373042|DRUG|Intraarterial and intravenous placebo|Intraarterial and intravenous placebo after endovascular thrombectomy
214703410|NCT02640352|DIETARY_SUPPLEMENT|Probi Defendum|
214703411|NCT02640352|DIETARY_SUPPLEMENT|Placebo|
214709011|NCT00139620|DRUG|Tarceva, erlotinib, OSI-774|
214703412|NCT02913352|PROCEDURE|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
214703413|NCT02913352|PROCEDURE|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
214703414|NCT02851433|DRUG|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
214703415|NCT02851433|DRUG|total intravenous anaesthesia with Propofol.|
214554667|NCT01798342|DIETARY_SUPPLEMENT|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
214554668|NCT01798342|DIETARY_SUPPLEMENT|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
214554669|NCT02655926|PROCEDURE|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
214554670|NCT00643292|DRUG|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
214554671|NCT00643292|DRUG|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
214554672|NCT01391637|BIOLOGICAL|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
214554673|NCT03600025|BIOLOGICAL|Typbar-TCV vaccine|vaccine will receive intramuscularly
214554674|NCT05988723|OTHER|ELISA kits|Making biochemical measurements with the ELISA kit
214554675|NCT01154140|DRUG|treatment|crizotinib 250mg orally continuous twice daily dosing
214554676|NCT01154140|DRUG|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
214554677|NCT02721992|OTHER|No intervention|No intervention
214554678|NCT04039373|DRUG|BMS-986256|specified dose on specified days
214554679|NCT04039373|DRUG|Mycophenolate Mofetil|specified dose on specified days
214554680|NCT03969134|BIOLOGICAL|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
214554681|NCT03969134|OTHER|Placebo|The placebo will be injected intramuscularly into the arm.
214703416|NCT04729556|DEVICE|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
214703417|NCT00438399|DRUG|C. propionate - Corticosteroid 1|Twice daily application
214703418|NCT00438399|DRUG|C. propionate- Corticosteroid 2|Twice daily application
214554682|NCT05315570|OTHER|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
214554683|NCT00571181|DEVICE|Closed-loop system|Automatic delivery of propofol and remifentanil
214554684|NCT00571181|DEVICE|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
214554685|NCT00211380|DRUG|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
214703419|NCT00438399|DRUG|C. propionate -Corticosteroid 3|Twice daily application
214703420|NCT00438399|DRUG|Corticosteroid 1- C. propionate|Twice daily application
214703421|NCT00438399|DRUG|Corticosteroid 2 - C. propionate|Twice daily application
214703422|NCT00438399|DRUG|Corticosteroid 3 - C. propionate|Twice daily application
214703423|NCT05355727|OTHER|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
214554686|NCT03452852|DEVICE|PICO|NPWT with PICO (Smith and Nephew)
214554687|NCT03452852|OTHER|Coban 2 lite|Compression bandaging with Coban 2 lite
214703424|NCT04575272|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
214703425|NCT03420326|BEHAVIORAL|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
214703426|NCT00231244|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
214703427|NCT02568124|DRUG|Tranexamic Acid|
214703428|NCT02568124|DRUG|Placebo|
214703429|NCT05739877|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
214703430|NCT05739877|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
214703431|NCT06679517|PROCEDURE|TAVI|Clinical follow-up up to 10 years of patients undergoing TAVI
214703432|NCT00004363|DRUG|chlorpropamide|
214703433|NCT00004363|DRUG|desmopressin|
214554688|NCT04571190|BEHAVIORAL|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
214554689|NCT00478192|DRUG|Conivaptan|premix bag
214554690|NCT00478192|DRUG|Placebo|premix bag
214554691|NCT01818531|DRUG|Adductor canal block|
214554692|NCT01818531|DRUG|Lumbar plexus block|
214554693|NCT03664102|DEVICE|Cor Knot|Heart valve replacement with or without the use of automated fastener device Cor Knot
214554694|NCT05967325|PROCEDURE|Stromal Vascular Fraction (SVF) combined with Functional self-assembling peptide nanofiber hydrogels|Transplantation of SVF and biomimetic nanohydrogel
214554695|NCT01243788|DRUG|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
214703434|NCT04653818|DRUG|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
214703435|NCT04371952|DRUG|Doxycycline|comparison of doxycycline 200 mg/day to placebo
214703436|NCT04371952|DRUG|Placebo|Placebo : lactose, 380 mg/gélule
214703437|NCT04504370|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
214703438|NCT04504370|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
214703439|NCT00854178|DRUG|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
214703440|NCT04365998|DEVICE|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
214703441|NCT01530438|OTHER|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
215162572|NCT05014412|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214554696|NCT00477490|DRUG|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
214554697|NCT00477490|DRUG|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
214554698|NCT05788627|DRUG|Tap water|Oral lactulose in a dose of 30ml BD and tap water enema 1000ml BD
214554699|NCT05788627|DRUG|Lactulose|Oral lactulose in a dose of 30ml BD and lactulose enema (300ml lactulose and 700ml water) in a dose of 1000ml BD.
214703442|NCT05868096|OTHER|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
214703443|NCT05868096|OTHER|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
214703444|NCT05807386|BEHAVIORAL|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
214703445|NCT02428452|BEHAVIORAL|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
215162573|NCT06449027|DRUG|T Leuprolide Injectable Emulsion|Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
215162574|NCT06449027|DRUG|Leuprorelin Acetate Microspheres for Injection|Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
214554700|NCT05226936|DIAGNOSTIC_TEST|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
214554701|NCT04489277|DEVICE|Endovascular Arch Procedures|Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
214554702|NCT04012177|DIETARY_SUPPLEMENT|Balanced-energy protein (BEP)|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
214554703|NCT04012177|DRUG|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
214554704|NCT04012177|DRUG|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
214554705|NCT04012177|DRUG|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
214554706|NCT02812056|DRUG|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
214554707|NCT02812056|DRUG|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
215162575|NCT04551469|BEHAVIORAL|music|Music intervention for 30 minutes
214554708|NCT06376877|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.
214554709|NCT06376877|PROCEDURE|Sham transcranial magnetic stimulation|The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
214554710|NCT00358020|DRUG|THALIDOMIDE|
214554711|NCT00358020|DRUG|BORTEZOMIB|
214554712|NCT01646177|DRUG|Placebo|Administered SC
214554713|NCT01646177|DRUG|50 mg etanercept|Administered SC
214554714|NCT01646177|DRUG|80 mg ixekizumab|Administered SC
214554715|NCT00580060|BIOLOGICAL|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
214554716|NCT02931370|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
214554717|NCT03615053|OTHER|Implementation of WAPPS-Hemo personalized dosing regimen|Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
214554718|NCT02204657|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
214554719|NCT00061594|DRUG|rhuFab V2 (ranibizumab)|
214554720|NCT01653054|PROCEDURE|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
214554721|NCT01582230|DRUG|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
214554722|NCT01582230|DRUG|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
214554723|NCT05610124|OTHER|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214554724|NCT05610124|OTHER|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214554725|NCT05610124|OTHER|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214554726|NCT05610124|OTHER|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214554727|NCT05610124|OTHER|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214703446|NCT05636371|OTHER|Written Communication|Written patient care updates provided to families of ICU patients each day
215162576|NCT06551454|DEVICE|Smart Textile Solution Biofeedback Method|The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.
215162577|NCT03181256|PROCEDURE|Biospecimen Collection|Undergo collection of sputum
214554728|NCT05610124|OTHER|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
214554729|NCT03482089|PROCEDURE|Cystoprostatectomy|Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
214554730|NCT03482089|RADIATION|external beam radiotherapy|Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
214554731|NCT00802347|DRUG|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
214554732|NCT00802347|DRUG|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
214554733|NCT03697122|DEVICE|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
214554734|NCT03663062|DIAGNOSTIC_TEST|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
214554735|NCT02334280|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
214554736|NCT04988789|DRUG|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
214554737|NCT04623749|PROCEDURE|US|Percutaneous Ultrasound guided FNAC
214554738|NCT04623749|PROCEDURE|EUS|Endoscopic Ultrasound guided FNAC
214554739|NCT03586908|DRUG|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
214554740|NCT05844059|OTHER|Validated questionnaires|BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
214554741|NCT01305239|DRUG|Aromasin|Aromasin 25 mg daily.
214554742|NCT01512316|DRUG|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
214554743|NCT01512316|DRUG|Lactose pill|one dose, 2hrs prior to fmri
214554744|NCT01512316|GENETIC|Saliva sample|Buccal cell material will be sampled from all participants on day3
214554745|NCT01512316|OTHER|Functional neuroimaging (fMRI)|
214554746|NCT00211224|DRUG|Riluzole|
214554747|NCT05756296|PROCEDURE|Therapeutic hypothermia|whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
214554748|NCT00209404|DRUG|Iodixanol 320 mg I/Ml|
214554749|NCT03362385|OTHER|Patients with OSA based on sleep study|Polysomnography or Polygraphy
214554750|NCT03362385|OTHER|Patients without OSA based on sleep study|Polysomnography or Polygraphy
214554751|NCT06380452|DRUG|5% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
214554752|NCT06380452|DRUG|10% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
214554753|NCT01690377|BIOLOGICAL|PDC or myDC|PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.
214554754|NCT00334334|BIOLOGICAL|Pneumococcal (vaccine)|
214554755|NCT02858128|OTHER|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
214554756|NCT00832468|OTHER|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
214554757|NCT00832468|OTHER|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
215162578|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of nasal epithelium
215162579|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of buccal epithelium
215162580|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of blood
215162581|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of urine
215162582|NCT03181256|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
214554758|NCT02954705|OTHER|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
214554759|NCT04626349|OTHER|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
214554760|NCT04626349|OTHER|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
214554761|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/folic acid|
214554762|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/placebo|
214554763|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 1|2 capsules taken daily for 30 days
214554764|NCT05510050|DIETARY_SUPPLEMENT|Control|2 capsules taken daily for 30 days
214554765|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 2|2 capsules taken daily for 30 days
214554766|NCT02704650|PROCEDURE|fluid sample|taking a vaginal fluid sample
214554767|NCT02307045|DRUG|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
214554768|NCT02307045|DRUG|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
214554769|NCT03487965|DIETARY_SUPPLEMENT|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
214554770|NCT03487965|DIETARY_SUPPLEMENT|High dose Polyphenol|botanical supplement with 13 mg polyphenol
214554771|NCT03487965|DIETARY_SUPPLEMENT|Placebo Control|inert tablet made to mimic the experimental tablets
214554772|NCT05590429|OTHER|Blood transfusion|No intervention
214554773|NCT00561145|OTHER|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
214554774|NCT03181490|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
214554775|NCT01909297|DEVICE|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
214554776|NCT01909297|DEVICE|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
214554777|NCT01909297|DEVICE|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
214554778|NCT00102024|DRUG|Unconjugated IDEC-159|
214554779|NCT00102024|DRUG|111In-IDEC-159|
214554780|NCT00102024|DRUG|90Y-IDEC-159|
214554781|NCT03910322|DIETARY_SUPPLEMENT|Bif195|Two different doses of the bacterial strain Bif195 is compared to placebo
214554782|NCT03910322|DIETARY_SUPPLEMENT|Placebo|Placebo
214554783|NCT05396937|RADIATION|Multifocal Stereotactic Radiotherapy|Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
214554784|NCT05396937|DRUG|Atezolizumab Injection [Tecentriq]|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
214554785|NCT05396937|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
214554786|NCT00402051|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
214554787|NCT00402051|DRUG|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
214554788|NCT00402051|DRUG|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
214554789|NCT03242343|DEVICE|VasQ|An external support device for AV fistula
214554790|NCT04618367|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
214554791|NCT04618367|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214554792|NCT04618367|DRUG|Sintilimab|200mg intravenously every 3weeks
214554793|NCT02204553|DRUG|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
214554794|NCT03507907|OTHER|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
215162583|NCT03181256|PROCEDURE|Computed Tomography (CT)|Undergo chest CT
215162584|NCT03181256|OTHER|Laboratory Biomarker|Correlative studies
215162585|NCT05624749|DRUG|ianalumab|ianalumab s.c. monthly
215162586|NCT05624749|DRUG|placebo|placebo s.c. monthly
215162587|NCT06680817|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
215162588|NCT00885066|DRUG|capecitabine|
215162589|NCT00885066|DRUG|erlotinib hydrochloride|
215162590|NCT00885066|DRUG|gemcitabine hydrochloride|
215162591|NCT06074588|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
214554795|NCT03507907|OTHER|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
214554796|NCT02142153|DRUG|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile"
214554797|NCT02142153|DRUG|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
214554798|NCT00618579|DRUG|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
214554799|NCT03749135|DRUG|Dupilumab|anti-IL4-Receptor alpha
214554800|NCT03749135|DRUG|Placebo|Placebo
214554801|NCT02928731|OTHER|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
214554802|NCT02928731|OTHER|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
214554803|NCT03257527|BEHAVIORAL|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
214554804|NCT03257527|BEHAVIORAL|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
214703447|NCT04574609|DEVICE|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~* for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~* during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
214703448|NCT04116450|PROCEDURE|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
214703449|NCT03334396|DRUG|Baricitinib|Administered orally.
214703450|NCT03334396|DRUG|Placebo|Administered orally.
214703451|NCT04212858|GENETIC|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
214703452|NCT01149642|DIETARY_SUPPLEMENT|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
214703453|NCT01149642|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
214703454|NCT04026854|BEHAVIORAL|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
214703455|NCT04914377|DRUG|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
214554805|NCT02338063|BEHAVIORAL|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
214554806|NCT02338063|BEHAVIORAL|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
214554807|NCT02604823|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
214554808|NCT05863468|DEVICE|ArchSinus implantation|Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
214703456|NCT02910544|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
214703457|NCT06243341|DIETARY_SUPPLEMENT|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
215162592|NCT06074588|DRUG|Docetaxel|75 mg/m\^2 of docetaxel by IV Infusion
214554809|NCT04529005|DRUG|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP \< 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
214554810|NCT03520218|DEVICE|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
214554811|NCT02170545|OTHER|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
214554812|NCT01791972|DRUG|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
214554813|NCT01791972|DRUG|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
214554814|NCT02539316|DRUG|Smoflipid|
214554815|NCT02539316|DRUG|Médialipides|
214703458|NCT04966884|DRUG|JAK Inhibitor|"1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months."
214703459|NCT03629041|DEVICE|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
214703460|NCT03629041|DEVICE|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
214703461|NCT01858610|DRUG|Irbeasartan/hydrochlorothiazide|
214703462|NCT01858610|DRUG|Irbesartan|
214554816|NCT03605888|BEHAVIORAL|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
214554817|NCT00797888|BEHAVIORAL|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
214554818|NCT00570908|DRUG|sunitinib|Sutent
214554819|NCT00570908|DRUG|capecitabine|concurrently
214554820|NCT00570908|RADIATION|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
214554821|NCT03497403|PROCEDURE|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
214554822|NCT03497403|PROCEDURE|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
214554823|NCT00987662|DRUG|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.
214554824|NCT00987662|DRUG|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
214554825|NCT03694977|DRUG|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
214554826|NCT00346853|DRUG|4-Methylpyrazole|15 mg/kg dose
215162593|NCT06074588|DRUG|Pemetrexed|500 mg/m\^2 of pemetrexed by IV infusion
214554827|NCT00346853|OTHER|saline|
214554828|NCT01474629|DIETARY_SUPPLEMENT|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
214554829|NCT01474629|DIETARY_SUPPLEMENT|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
214554830|NCT00132275|DRUG|Amoxicillin potassium clavulanate|
214554831|NCT00002377|DRUG|Valganciclovir|
214554832|NCT00002377|DRUG|Ganciclovir|
214703463|NCT01858610|DRUG|Hydrochlorothiazide|
214703464|NCT00757926|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
214703465|NCT00757926|OTHER|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
214703466|NCT03230474|DRUG|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
214703467|NCT03230474|DRUG|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
214703468|NCT03041909|DRUG|GBT440|Oral drug
214703469|NCT02366754|DEVICE|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
214703470|NCT02366754|DEVICE|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
214703471|NCT01853436|DEVICE|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
214703472|NCT00592553|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
214703473|NCT00592553|DRUG|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
214703474|NCT03326154|OTHER|No intervention, observational|Observation
214554833|NCT02880943|DRUG|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
214554834|NCT01250795|BIOLOGICAL|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
214554835|NCT01250795|OTHER|Saline|
214554836|NCT03455270|DRUG|G1T48|oral SERD
214554837|NCT03455270|DRUG|Palbociclib|CDK 4/6 Inhibitor
214554838|NCT03287895|BEHAVIORAL|Decision Support|A two-part intervention to help patients make better decisions about CPR
214703475|NCT04127734|PROCEDURE|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
214703476|NCT05782166|BEHAVIORAL|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
214703477|NCT05782166|BEHAVIORAL|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
214703478|NCT02379390|DRUG|Cabazitaxel XRP6258|
214703479|NCT02379390|DRUG|Ezalutamide|
214703480|NCT02379390|DRUG|Abiraterone acetate|
214703481|NCT02379390|DRUG|Prednisone|
214703482|NCT02451436|BEHAVIORAL|Sleep and Media Use Intervention|
214703483|NCT02451436|BEHAVIORAL|Study Skills Control Group|
214554839|NCT05191602|DIAGNOSTIC_TEST|drainge fluid|including bilirubin
214554840|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
214554841|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder Extra Strength|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
214554842|NCT05521243|DIETARY_SUPPLEMENT|Placebo|"The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor"
214554843|NCT00602849|DRUG|Sertraline|
214703484|NCT05107349|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
214703485|NCT05164679|BEHAVIORAL|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
214703486|NCT05780593|OTHER|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
214554844|NCT06106139|DIETARY_SUPPLEMENT|Strict ketogenic diet group|the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
214554845|NCT06106139|DIETARY_SUPPLEMENT|Cyclic ketogenic diet group|"the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group."
214554846|NCT06106139|DIETARY_SUPPLEMENT|Autonomous ketogenesis group|Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
214554847|NCT01930097|OTHER|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
214554848|NCT01213524|BEHAVIORAL|sensorimotor replacement|denicotinized cigarettes
214554849|NCT01213524|DRUG|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
214703487|NCT05780593|OTHER|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
215162594|NCT04360395|BEHAVIORAL|Gait Therapy|The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
214554850|NCT01213524|DRUG|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
214554851|NCT01213524|OTHER|usual brand smoking|participant smokes usual brand of cigarette
214554852|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
214703488|NCT03160664|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214703489|NCT03160664|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
214703490|NCT03160664|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
214703491|NCT06233734|DEVICE|The Lokomat (Hocoma, Zurich, Switzerland).|The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
214554853|NCT00630734|DRUG|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
214554854|NCT00630734|DRUG|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
214554855|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
214554856|NCT00630734|OTHER|Washout|Washout (no medication) on days 5-11.
214554857|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
214703492|NCT03699852|RADIATION|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
214703493|NCT03699852|OTHER|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
214703494|NCT01255306|OTHER|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day"
214703495|NCT01255306|DRUG|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
215162595|NCT05930158|OTHER|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
215162596|NCT05930158|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
215162597|NCT06230159|BEHAVIORAL|Non-menthol Cigarette Smoking|Smoke a non-menthol cigarette
215162598|NCT06230159|BEHAVIORAL|Menthol Cigarette Smoking|Smoke a menthol cigarette
214554858|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
214554859|NCT06152224|DEVICE|The Leva Pelvic Health System|The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
214554860|NCT05306886|OTHER|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
215162599|NCT06230159|BEHAVIORAL|Synthetic Cooling Agent Cigarette Smoking|Smoke a synthetic cooling agent cigarette
215162600|NCT06230159|BEHAVIORAL|Usual Brand Cigarette Smoking|Smoke usual brand cigarette
215162601|NCT06230159|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
215162602|NCT06230159|OTHER|Questionnaire Administration|Survey questionnaires
215162603|NCT06230159|DIAGNOSTIC_TEST|Nasal Epithelial Lining Fluid|Nasal strip inserted into the nare to collect nasal epithelial lining fluid.
215162604|NCT02361983|DEVICE|Double lumen tube|Patients managed with a double lumen tube for one lung ventilation
215162605|NCT02361983|DEVICE|Bronchial blocker|Patients managed with a bronchial blocker for one lung ventilation
215162606|NCT02659930|DRUG|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
215162607|NCT02659930|DRUG|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
215162608|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
215162609|NCT06823141|DEVICE|Virtual reality immersion|The study intervention, defined by the use of a virtual reality, exclusively takes place during the pre-oxygenation period where the patient is exposed to a virtual reality immersion scenario.
215162610|NCT06272487|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
215162611|NCT06272487|DRUG|Placebo|Placebo administered by SC injection
215162612|NCT05578092|DRUG|MRTX0902|SOS1 inhibitor
215162613|NCT05578092|DRUG|MRTX849|KRAS G12C inhibitor
215162614|NCT02669225|OTHER|[18F]florbetaben|PET radiotracer to image Amyloid beta (AB) load in human brain.
215162615|NCT06016842|DRUG|Elafibranor|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
214554861|NCT05306886|OTHER|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
214554862|NCT06246929|BEHAVIORAL|MBCT+w|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
214554863|NCT06246929|BEHAVIORAL|ALED|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
214554864|NCT05362045|DRUG|Mavacamten|Specified dose on specified days
214554865|NCT00281320|DRUG|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
214554866|NCT05291377|OTHER||
214554867|NCT01647945|DRUG|Placebo|placebo pill
214554868|NCT01647945|DRUG|FK506 level < 2 ng/ml|FK506 goal trough blood level \< 2 ng/ml
214554869|NCT01647945|DRUG|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
214554870|NCT01647945|DRUG|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
214554871|NCT02902770|DRUG|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
214554872|NCT02902770|DRUG|Ketorolac Tromethamine|IV ketorolac 30mg push
214554873|NCT02902770|DRUG|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
214554874|NCT02902770|DRUG|Normal Saline Push|Normal Saline Push Placebo
215162616|NCT06016842|OTHER|Matched 80 mg placebo|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
215162617|NCT04475939|DRUG|Niraparib|Niraparib will be administered.
215162618|NCT04475939|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
215162619|NCT04475939|DRUG|Placebo|Matching placebo will be administered
214554875|NCT06184035|DRUG|[177Lu]Lu-SN201|Intravenous infusion
214554876|NCT03958006|DEVICE|Cochlear implant|Tumor resection with cochlear implant
214554877|NCT02755129|OTHER|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
214554878|NCT02755129|OTHER|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
215162620|NCT04595266|DRUG|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
215162621|NCT04595266|BIOLOGICAL|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
215162622|NCT04595266|DRUG|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
215162623|NCT05980949|DRUG|KarXT|KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
215162624|NCT05980949|DRUG|KarX-EC|Specified dose on specified days
215162625|NCT03583710|DRUG|Cisplatin|Given IV
215162626|NCT03583710|DRUG|Etoposide|Given IV
214703496|NCT04613102|DRUG|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
214703497|NCT01016548|BIOLOGICAL|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
214703498|NCT04873076|DEVICE|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
215162627|NCT03583710|DRUG|Mitotane|Given PO
215162628|NCT03583710|OTHER|Quality-of-Life Assessment|Ancillary studies
215162629|NCT02101775|DRUG|Adavosertib|Given PO
214703499|NCT01279304|RADIATION|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
214703500|NCT01279304|RADIATION|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
214703501|NCT01279304|RADIATION|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
214703502|NCT04724304|DIAGNOSTIC_TEST|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
214554879|NCT02755129|OTHER|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
214554880|NCT02755129|OTHER|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
214554881|NCT02755129|OTHER|Reveal LINQ accelerometer|Walking exercises test
214554882|NCT02755129|OTHER|3D accelerometer|Walking exercises test
214554883|NCT01447576|DRUG|ADT|Once daily dosing during the duration of the study.
214554884|NCT01447576|DRUG|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
214554885|NCT00557661|DRUG|CD-NP|24 hr intravenous infusion
214554886|NCT04382846|DRUG|Nitazoxanide|Nitazoxanide
214554887|NCT01530893|DIETARY_SUPPLEMENT|Flavanone - supplement|acute single optimal dose
214554888|NCT01530893|OTHER|Flavanone - food|acute single dose
214554889|NCT01530893|OTHER|Flavanone - placebo|acute single dose (flavanone free)
214703503|NCT04724304|DIAGNOSTIC_TEST|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
214703504|NCT03608891|DEVICE|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
214703505|NCT03608891|DEVICE|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
214709012|NCT03548974|BEHAVIORAL|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
214709013|NCT03548974|BEHAVIORAL|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
215162630|NCT02101775|DRUG|Gemcitabine Hydrochloride|Given IV
215162631|NCT02101775|OTHER|Laboratory Biomarker Analysis|Correlative studies
215162632|NCT02101775|OTHER|Pharmacological Study|Correlative studies
215162633|NCT02101775|OTHER|Placebo Administration|Given PO
215162634|NCT02101775|OTHER|Questionnaire Administration|Ancillary studies
214554890|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - supplement|acute single optimal dose
214554891|NCT01530893|OTHER|Isoflavone - food|acute single optimal dose
214554892|NCT01530893|OTHER|Isoflavone - placebo|acute single dose (isoflavone free)
214554893|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
214554894|NCT01530893|DIETARY_SUPPLEMENT|Flavan-3-ol - supplement|acute single optimal dose
214554895|NCT01530893|OTHER|Flavan-3-ol - food|acute single optimal dose
214554896|NCT01530893|OTHER|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
214554897|NCT01530893|DIETARY_SUPPLEMENT|Anthocyanin - supplement|acute single optimal dose
214554898|NCT01530893|OTHER|Anthocyanin - food|acute single optimal dose
214554899|NCT01530893|OTHER|Anthocyanin - placebo|acute single dose (anthocyanin free)
214554900|NCT00146445|BEHAVIORAL|Peer Mentoring Intervention|
214554901|NCT00975676|OTHER|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
214554902|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
214554903|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
214554904|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
214554905|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
214554906|NCT01712269|PROCEDURE|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
215162635|NCT06781385|DRUG|Intra-arterial Tenecteplase|One-time dose of intra-arterial tenecteplase post-thrombectomy
215162636|NCT06781385|DRUG|Intra-arterial Saline|One-time dose of intra-arterial saline post-thrombectomy
215162637|NCT03650673|DIAGNOSTIC_TEST|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
215162638|NCT05758480|BIOLOGICAL|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
215162639|NCT05758480|OTHER|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
214554907|NCT03697694|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
214703506|NCT00436319|PROCEDURE|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
214703507|NCT05360823|OTHER|Birth ball|Exercises for childbirth
214703508|NCT05360823|OTHER|Squatting|Exercises for childbirth
214703509|NCT01283997|OTHER|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
214703510|NCT01283997|DRUG|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
214703511|NCT05820009|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
214703512|NCT05820009|DEVICE|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
214709014|NCT00225212|DRUG|Rituximab 375 mg/m2|
215162640|NCT02243592|OTHER|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
215162641|NCT03535350|DRUG|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
215162642|NCT03535350|RADIATION|Radiation|2Gy x 30minutes for 6 weeks.
215162643|NCT03535350|DRUG|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
215162644|NCT05353452|BEHAVIORAL|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
215162645|NCT05353452|BEHAVIORAL|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
215162646|NCT06804057|OTHER|Blood Collection|Blood will be collected for the subjects who are willing to participate in the optional biorepository
214554908|NCT03697694|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
214554909|NCT00343993|DEVICE|noninvasive positive pressure ventilation|
214554910|NCT02579772|DRUG|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
214554911|NCT02579772|DRUG|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
214554912|NCT03876106|DRUG|LUT014|Topical
214554913|NCT03850132|BEHAVIORAL|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~1. Drawing forward narratives about the pre- and post-loss experience.~2. Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~3. Validating/acknowledging emotional responses.~4. Assessing the need for specific information and recommendations regarding bereavement.~5. The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
214554914|NCT05038540|PROCEDURE|Scaling and root planing|Phase 1 periodontal therapy
214554915|NCT02416245|DIETARY_SUPPLEMENT|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
215162647|NCT06324045|OTHER|Deprescribing|"1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient."
214554916|NCT02416245|OTHER|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
214554917|NCT06064656|OTHER|Non-Interventional|No study treatment will be administered in this study.
214554918|NCT06855719|OTHER|Training in high-fidelity simulation and knowledge of care protocols in patients with multimorbidity and heart failure|Participants will perform an individual simulation as nurses related to the patient profile in their home (pretest and postest). After each simulation, each participant will receive a recording of their simulation, and both individual and group debriefings will be conducted. In addition, they will be trained in scientific evidence and international and national protocols regarding the care of these patients in the context of home health nursing.
214554919|NCT07049757|OTHER|Smoking cessation education|Quit Smoking for a Healthy Family (QS) and Smokefree Family Living (SFL) education sessions to promote smoking cessation and reduce tobacco smoke exposure.
214554920|NCT07049757|BEHAVIORAL|Survey Administration|Administered for ancillary studies
214554921|NCT07049757|BEHAVIORAL|Telephone-Based Intervention|Participants will receive follow-up calls
214554922|NCT07049757|PROCEDURE|Urine Specimen Collection|Undergo urine sample collection at baseline
214554923|NCT07049757|OTHER|Silicone Wrist Band|Non-smoking family/household members will wear a silicone wristband for 2 days at each assessment for ancillary studies
214554924|NCT07049757|OTHER|Interview|Selected participants will take part in an interview for ancillary studies
214554925|NCT07049757|OTHER|Focus Group|Participants will review and comment on materials under development to be used in randomized clinical trial.
214554926|NCT07050680|OTHER|Dietary intervention|Single dose of commercially available Oat food test meal
214554927|NCT07050810|DEVICE|TheraClean|Begins after Week 0 visit and continues through Week 8. Participants will take at least 3 baths/week (20-30 minutes each bath) but may bathe daily, if desired.
214554928|NCT07051109|DEVICE|multimodal analgesia via dual-chamber PCA|combination of fentanyl and ketorolac through dual-chamber PCA
214554929|NCT07051109|DEVICE|single regimen (only fentanyl)|fentanyl only through dual-chamber PCA
214554930|NCT06853613|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
214554931|NCT06853613|OTHER|Aerobic Training Protocol|"Each training session will include an initial 10-minute muscle activation phase (low-intensity walking, Borg = 10-11) to increase heart rate, improve muscle blood flow, and prepare the major joints for the next work phase.~main exercise period (40-minute):~25 minutes of progressive aerobic exercises (controlled and rhythmic jumping jacks, step-ups on a sturdy platform (such as a low step or stable surface), standing knee raises (alternating legs), fast side steps or side leg raises).~15 minutes of walking, exercises will be performed at an intensity to ensure that perceived exertion (RPE) will remain between 13 and 15 points on the Borg Scale (6-20). Progression over the weeks will be by maintaining intensity in this range.~Cool down period: breathing and stretching exercises on all major muscle groups."
214554932|NCT06904261|DRUG|Migalastat HCl 20 mg|Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.
215162648|NCT03396666|OTHER|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
215162649|NCT02945800|DRUG|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
214554933|NCT02928705|PROCEDURE|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
215162650|NCT02945800|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m\^2 intravenously (IV)
215162651|NCT06178159|DRUG|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
215162652|NCT06178159|DRUG|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
215162653|NCT06178159|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
215162654|NCT01812694|BEHAVIORAL|Enhanced standard care|Standard prenatal care plus education
215162655|NCT01812694|BEHAVIORAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
214554934|NCT02928705|PROCEDURE|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
214554935|NCT03319940|DRUG|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
214554936|NCT03319940|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
214554937|NCT03319940|DRUG|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
214554938|NCT03710122|DRUG|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
214703513|NCT06041685|PROCEDURE|local warming|local warming on the site for arterial catheterization using forced air warmer
214703514|NCT00078988|BIOLOGICAL|filgrastim|Given IV
214703515|NCT00078988|DRUG|carboplatin|Given IV
214703516|NCT00078988|DRUG|etoposide|Given IV
214703517|NCT00078988|DRUG|isotretinoin|Given IV
214703518|NCT00078988|DRUG|thiotepa|Given IV
214703519|NCT00078988|PROCEDURE|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
215162656|NCT03502447|DEVICE|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
215162657|NCT03502447|DEVICE|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
215162658|NCT06565390|DEVICE|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
215162659|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
214703520|NCT00078988|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
214703521|NCT04890106|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
215162660|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
215162661|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
215162662|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
214554939|NCT03710122|OTHER|Placebo|Placebo for Vancomycin
214554940|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a gambling task evaluated
214554941|NCT04715984|OTHER|Neural stimulation|Neural stimulation will be delivered during a gambling task and its impact on task performance quantified
214703522|NCT04890106|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
214703523|NCT02017899|BIOLOGICAL|S. sonnei 1790GAHB|
214554944|NCT05636774|DRUG|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
214554945|NCT05636774|DRUG|Placebo|Placebo tables / infusion
214703524|NCT02017899|BIOLOGICAL|Placebo|
214703525|NCT04617899|DIAGNOSTIC_TEST|Intravascular imaging|Use of imaging catheter
214703526|NCT01812070|BEHAVIORAL|ACT|
215162663|NCT06207123|DRUG|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
215162664|NCT06207123|DRUG|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
215162665|NCT06207123|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
214554946|NCT01446120|DRUG|NPH-Insulin Injection|
214554947|NCT01446120|DRUG|Insulin loaded Orally Dissolved Films (insulin-ODF|
214554948|NCT03572881|DEVICE|Endocardial mapping|An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
214703527|NCT01812070|BEHAVIORAL|CBT|
214703528|NCT03367442|OTHER|no intervention|no intervention
214703529|NCT05349942|DEVICE|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
214703530|NCT00961870|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
214703531|NCT01106482|OTHER|Serology blood draw|Blood draw only, no vaccine
214554949|NCT03557645|DEVICE|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
214554950|NCT03557645|DEVICE|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
214554951|NCT03557645|DEVICE|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
214554952|NCT06325917|BEHAVIORAL|what's app ongoing support|"daily educational messages and reminders sent through WhatsApp. The educational material related to diabetes self-management behaviors (AADE7 Self-Care Behaviors, diabetes and genetics, and endocrinology center, also the Ministry of Health in Jordan diabetes.~individual bidirectional communication between the participants and the investigator, which will allow participants to seek advice and get free-of-charge feedback and consultation."
214554953|NCT06325917|BEHAVIORAL|usual care|monthly visit and follow-up at the diabetes education clinic by a diabetes nurse specialist providing DSMES
214554954|NCT03078569|DRUG|Testosterone gel|treatment with testosterone gel
214554955|NCT02319473|OTHER|JAC Registry|patients who received acute reperfusion therapy
214703532|NCT02299648|OTHER|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
214703533|NCT05453448|DRUG|tenofovir alafenamide|Antiviral therapy
214703534|NCT05453448|DRUG|Entecavir|entecavir
214703535|NCT04907422|DIAGNOSTIC_TEST|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
214703536|NCT04907422|DIAGNOSTIC_TEST|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
214703537|NCT02967484|DEVICE|acupuncture|"1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
214703538|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
214554956|NCT03402698|DIETARY_SUPPLEMENT|cholecalciferol|supplementation at a dose 1000 IU/d
214703539|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
214703540|NCT04178135|DRUG|rLH|rLH supplement from day 1 of stimulation
214703541|NCT04178135|DRUG|rLH|rLH supplement from day 6 of stimulation
214703542|NCT02533661|OTHER|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
215162666|NCT06207123|DRUG|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
215162667|NCT06207123|DRUG|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
215162668|NCT04956978|OTHER|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
214554957|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
214554958|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
214554959|NCT03080948|BEHAVIORAL|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
214554960|NCT03080948|OTHER|Saliva samples|Germline DNA analysis
214703543|NCT03969836|DEVICE|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
214703544|NCT02020460|DEVICE|Subdural trial lead|
214703545|NCT02020460|DEVICE|Epidural trial lead|
214703546|NCT05533333|BEHAVIORAL|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
214703547|NCT01812486|RADIATION|dose de escalation|
214703548|NCT01812486|RADIATION|standard dose|
214703549|NCT02541448|DEVICE|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
214703550|NCT02858687|OTHER|Nasopharyngeal swab|
214703551|NCT00241163|PROCEDURE|Fibrinogen (human) + thrombin (human) (TachoSil)|
214703552|NCT00168324|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
214703553|NCT00168324|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
214703554|NCT00168324|OTHER|Sham Injection|Sham injection on Day 0.
214703555|NCT04781452|OTHER|standard treatment|there ist no Intervention but our standart Treatment in the center
214554961|NCT05248477|OTHER|Premex Protocol|"This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents."
214554962|NCT06223360|DRUG|Low Dose Benfotiamine|300mg benfotiamine capsules (BID, twice a day)
214554963|NCT06223360|DRUG|High Dose Benfotiamine|600mg benfotiamine capsules (BID, twice a day)
214554964|NCT06223360|DRUG|Placebo|Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
214554965|NCT05319015|DRUG|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
214554966|NCT05319015|DRUG|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
214554967|NCT05319015|PROCEDURE|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
214554968|NCT05319015|DRUG|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
214554969|NCT01385046|BEHAVIORAL|Project Fit|physical activity and nutrition education
214554970|NCT01817322|DRUG|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
214554971|NCT01817322|DRUG|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
214554972|NCT01817322|DRUG|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
214703556|NCT01187836|DRUG|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
214554974|NCT00993005|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
214554975|NCT00993005|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
214554976|NCT01848613|DRUG|Vinorelbine|
214554977|NCT00132899|DRUG|Methotrexate|Methotrexate and infliximab combination
214554978|NCT00132899|DRUG|Placebo|Placebo and infliximab combination therapy.
214554979|NCT03388268|DRUG|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
214554980|NCT03388268|DRUG|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
214554981|NCT03388268|DEVICE|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
214554982|NCT03388268|DEVICE|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
214554983|NCT05420233|DIAGNOSTIC_TEST|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
214554984|NCT00176982|DRUG|Hydroxychloroquine|
214703557|NCT01187836|DRUG|Placebo|Placebo administered for 14 hours.
214703558|NCT01619592|DEVICE|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
214703559|NCT00142402|DRUG|Modafinil|
214703560|NCT03372629|DRUG|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
215162669|NCT05126277|DRUG|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
215162670|NCT05126277|DRUG|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
215162671|NCT05126277|DRUG|placebo s.c.|placebo s.c. q4w in addition to SoC
214703561|NCT03372629|DRUG|Placebo oral capsule|Placebo capsules matching ID-085 capsules
214703562|NCT05518669|DEVICE|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
214703563|NCT00377585|BIOLOGICAL|Fluarix|
214703564|NCT00377585|BIOLOGICAL|adjuvanted influenza vaccine|
214703565|NCT03181841|DRUG|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
214703566|NCT03181841|DRUG|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
214703567|NCT01747811|DEVICE|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
214703568|NCT01747811|DEVICE|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
214703569|NCT03393468|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
214703570|NCT03012633|DEVICE|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
214703571|NCT04004377|OTHER|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
214703572|NCT01337167|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
214554985|NCT05867823|BEHAVIORAL|OcuApp|The participants will have instaled a mobile aplication (OcuApp) by a member of the researchs team who will teach them how to use it. The person must register the activities they carry out throughout a week and mark each one of them with a punctuation (from 1 to 5) related to the meaning of the following dimensions: identity, pleasure, competence, importance and value of the activity by other people.The application also allows to collect other information such as where the activity takes place, its duration, and the people with whom it is carried out. Also, at the end of the week, the application will ask users about their perceived occupational balance. All the information registered in the mobile application will be returned to the person in a dynamic and understandable way. Based on this, the person can establish two goals to accomplish. In this sense, OcupApp will offer personalized recommendations based on the objectives to be achieved related to the dimensions of meaning.
214703573|NCT01337167|BIOLOGICAL|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
214703574|NCT01337167|BIOLOGICAL|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
214703575|NCT01337167|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
214703576|NCT01337167|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
214703577|NCT01337167|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
214703578|NCT01337167|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
215162672|NCT05707962|DRUG|Magnesium sulfate|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
214703579|NCT01337167|BIOLOGICAL|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
214703580|NCT05378022|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
214703581|NCT05378022|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
214703582|NCT00812240|DRUG|Masitinib|
215162673|NCT05523817|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
215162674|NCT04641247|DRUG|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
214703583|NCT00812240|DRUG|Imatinib|imatinib 400 mg or 600 mg per day, per os
215162675|NCT05707247|DEVICE|software|"The experimental medical device is a prototype software. It is a patient interface.~The device comes in the form of a smartphone with a touch screen"
215162676|NCT03025386|OTHER|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
214703584|NCT03833817|BEHAVIORAL|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
214703585|NCT03713957|DRUG|GRF6021|GRF6021 for IV infusion
214703586|NCT03713957|OTHER|Placebo|Placebo for IV infusion
214703587|NCT02504177|DRUG|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
214703588|NCT02504177|DRUG|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
214703589|NCT00884221|DRUG|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
214709015|NCT02718391|BIOLOGICAL|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
214703590|NCT00884221|DRUG|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
214703591|NCT02757092|OTHER|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
214703592|NCT03363919|DEVICE|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
214703593|NCT03363919|DEVICE|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
214703594|NCT01771536|OTHER|Decision Aid|
214703595|NCT00989404|DRUG|Zanamivir|Rotahaler placebo 10mg BID 5 days
215162677|NCT03025386|OTHER|Electroencephalography|Mesure of the mismatch negativity wave
215162678|NCT05078944|DEVICE|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
215162679|NCT05078944|DEVICE|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
215162680|NCT05078944|DRUG|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
214554986|NCT05867823|BEHAVIORAL|Three-part work|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities to control anxiety and depression. After providing this information, any doubts in this regard will be answered.
214554987|NCT05067595|PROCEDURE|Colonoscopy|Undergo lower FMT via colonoscopy
214554988|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Given upper FMT PO or via post-pyloric or NG feeding tube
214554989|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
214554990|NCT05067595|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
214554991|NCT05067595|OTHER|Survey Administration|Ancillary studies
214554992|NCT05067595|PROCEDURE|Biospecimen Collection|Undergo tissue, stool, stool swabs, and blood sample collection
215162681|NCT04770324|DEVICE|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
215162682|NCT05667246|OTHER|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
215162683|NCT05667246|OTHER|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
215162684|NCT04294043|DRUG|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
214554993|NCT04076709|PROCEDURE|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
214554994|NCT05357976|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
214554995|NCT00783276|DRUG|SYN115|100 mg single dose
214554996|NCT00783276|DRUG|PLACEBO|PLACEBO
214554997|NCT02696876|DEVICE|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
214554998|NCT02696876|PROCEDURE|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
214554999|NCT04673266|DRUG|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
214555000|NCT03518190|DEVICE|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
214703596|NCT00989404|DRUG|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
214555001|NCT02812095|PROCEDURE|Refeeding|when amount of feeding reach to 120mL/kg a day,
214703597|NCT00989404|DRUG|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
214555002|NCT06556433|BEHAVIORAL|Financial Incentive Rewards|Participants in the Rewards Group will have abstinence reinforced through escalating financial incentives.
214555003|NCT03956251|PROCEDURE|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
214555004|NCT03956251|PROCEDURE|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
214555005|NCT00371384|PROCEDURE|massage|UP to 10 massages over 10 weeks
214555006|NCT04392024|DEVICE|Triumf|Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
214555007|NCT02385058|DRUG|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
214703598|NCT01565434|OTHER|CR1 impact|
214703599|NCT02627833|OTHER|observation|Record lung function, Lung clearance index, inflammatory status
214703600|NCT01367314|DRUG|NVC-422|Dermal Gel applied 3 times per day for 7 days
214703601|NCT03717116|DIAGNOSTIC_TEST|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
214703602|NCT02255617|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
214703603|NCT03357666|DRUG|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
215162685|NCT06079736|DRUG|PGN-EDO51|IV infusion
215162686|NCT06349538|DIAGNOSTIC_TEST|Clinical examination, blood draw, cerebral MRI, sonography, tremor analysis, OCT, olfactory mucosa swab.|see previous descriptions
215162687|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
214555008|NCT02385058|DRUG|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
214555009|NCT02385058|DRUG|Placebo|Placebo tablet orally once starting on Day 21.
214555010|NCT00547014|DRUG|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
214555011|NCT00547014|DRUG|52364 3 mg|3 mg capsule single dose administered orally as a single dose
214555012|NCT00547014|DRUG|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
214555013|NCT00547014|DRUG|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
215162688|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
215162689|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
214555014|NCT00547014|DRUG|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
214555015|NCT00547014|DRUG|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
214555016|NCT00547014|DRUG|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
214555017|NCT05050825|OTHER|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
214555018|NCT01249495|PROCEDURE|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
214555019|NCT03680547|OTHER|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
214555020|NCT02575716|DEVICE|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
214703604|NCT03357666|DRUG|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
214703605|NCT03357666|DRUG|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
214703606|NCT03357666|DRUG|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
214703607|NCT03357666|DRUG|Placebo|Vaginal administration, two tablets once a day for 7 days
214703608|NCT02174016|DIETARY_SUPPLEMENT|Ketogenic diet|
214703609|NCT01646398|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
214703610|NCT01646398|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
214703611|NCT01051115|DRUG|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
214703612|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
214703613|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
214703614|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
214703615|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
214703616|NCT02185248|BEHAVIORAL|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
214709016|NCT00879983|DRUG|azithromycin (Zithromax)|"1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg"
214555021|NCT05743881|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214555022|NCT05743881|BIOLOGICAL|mRNA-1365|Sterile liquid for injection
214555023|NCT05743881|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) solution for injection
214555024|NCT05743881|DRUG|Nimenrix|Solution for injection
214555025|NCT03923517|DEVICE|RHAPSODY online program and MEET online sessions|"internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings."
214555026|NCT04220398|DRUG|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
214555027|NCT04220398|DRUG|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
214555028|NCT04220398|PROCEDURE|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
214555029|NCT04056988|DRUG|Perflutren Lipid Microsphere|Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
214555030|NCT01079351|DRUG|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
214555031|NCT00557908|DRUG|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
215162690|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
215162691|NCT06489028|DRUG|allo-APZ2-CVU|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
215162692|NCT06489028|DRUG|Placebo|Placebo
215162693|NCT04847063|DRUG|Mitomycin C|Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
214555032|NCT02819167|OTHER|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
214555033|NCT01516255|DRUG|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
214555034|NCT01516255|DRUG|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
214555035|NCT01516255|DRUG|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
214555036|NCT01516255|DRUG|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
214555037|NCT01516255|PROCEDURE|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
214555038|NCT01516255|PROCEDURE|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
214555039|NCT03455257|BEHAVIORAL|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
214555040|NCT03299049|DRUG|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
214555041|NCT03299049|DRUG|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
214703617|NCT03943108|DIAGNOSTIC_TEST|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
214703618|NCT03125161|DRUG|HAI|HAI
214703619|NCT03125161|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
214703620|NCT01039818|RADIATION|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
214703621|NCT01039818|RADIATION|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
214703622|NCT02559557|OTHER|Educational Intervention|Participate in focus groups
214703623|NCT02559557|OTHER|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
214703624|NCT02559557|OTHER|Quality-of-Life Assessment|Answer questionnaires
214703625|NCT02559557|OTHER|Questionnaire Administration|Answer questionnaires
214703626|NCT06280612|OTHER|Pet therapy|The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
214703627|NCT01144195|DRUG|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
214703628|NCT03327519|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
214703629|NCT03327519|BEHAVIORAL|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
214703630|NCT01913171|OTHER|Exercise|
214703631|NCT05494983|OTHER|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
214703632|NCT05494983|OTHER|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
214703633|NCT05494983|OTHER|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
215162694|NCT04847063|DRUG|Cisplatin|Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
215162695|NCT04847063|PROCEDURE|Heated Intraperitonial Chemotherapy|Heated Intraperitonial Chemotherapy (HIPEC) with with standardized doses of chemotherapeutic agents as indicated by the subject's Arm assignment
214555042|NCT03299049|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
214555043|NCT03299049|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
214555044|NCT03310034|DIETARY_SUPPLEMENT|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
214555045|NCT03310034|DIETARY_SUPPLEMENT|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
214555046|NCT01637805|BIOLOGICAL|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
214555047|NCT05559970|DRUG|Inhalational sedation|Inhalational sedation with isoflurane for 12 hours
214555048|NCT05559970|DRUG|Convention sedation|Conventional sedation receiving analgosedation with fentanyl
214703634|NCT04595357|PROCEDURE|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
214709017|NCT00879983|DRUG|azithromycin (Zithromax)|"1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g"
214555049|NCT05737862|DIETARY_SUPPLEMENT|Moringa oleifera capsules|In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
214555050|NCT05737862|DIETARY_SUPPLEMENT|iron and folic acid supplements|In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
214555051|NCT03165487|OTHER|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
214555052|NCT03165487|OTHER|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
214555053|NCT05869318|OTHER|ECIG own|Participants will vape using their own ecig device
214555054|NCT05869318|OTHER|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
214703635|NCT01933204|OTHER|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
214703636|NCT01933204|DRUG|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
214703637|NCT01033604|PROCEDURE|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
214703638|NCT01033604|PROCEDURE|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
214703639|NCT04154995|DIAGNOSTIC_TEST|Venipuncture|Blood testing at 3, 6 and 12 months
214703640|NCT04154995|DIAGNOSTIC_TEST|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
214555055|NCT01901419|DRUG|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
214555056|NCT03683303|BEHAVIORAL|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
214703641|NCT01603979|BIOLOGICAL|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
214703642|NCT00574119|DRUG|spironolactone|spironolactone 50 mg daily for 6 months
215162696|NCT04847063|DRUG|Doxorubicin|Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
215162697|NCT04847063|DRUG|Oxaliplatin|Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
214555057|NCT03683303|BEHAVIORAL|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
214555058|NCT02296502|OTHER|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
214555059|NCT02639039|DRUG|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
214555060|NCT02639039|PROCEDURE|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
214703643|NCT02860754|OTHER|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
214703644|NCT04084132|PROCEDURE|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
214703645|NCT03008733|OTHER|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
214703646|NCT03008733|OTHER|Electro myography surface nerves|Electro myography surface nerves
214703647|NCT05359406|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
214703648|NCT01780909|DRUG|Paromomycin Sulfate Fasted State|
214555061|NCT03621462|DEVICE|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
214555062|NCT06061822|DIAGNOSTIC_TEST|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
214555063|NCT03712878|RADIATION|Total-Body Irradiation|Undergo TBI
215162698|NCT04847063|DRUG|5-Fluorouracil|Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
214555064|NCT03712878|PROCEDURE|Donor Lymphocyte Infusion|Given IV
214555065|NCT03712878|DRUG|Cyclophosphamide|Given IV
214555066|NCT03712878|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214555067|NCT03712878|DRUG|Tacrolimus|Given IV
214555068|NCT03712878|DRUG|Mycophenolate Mofetil|Given IV
214555069|NCT05677386|DIAGNOSTIC_TEST|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
214555070|NCT05677386|OTHER|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
214555071|NCT02051062|BIOLOGICAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
214555072|NCT05525247|DRUG|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
214555073|NCT05525247|COMBINATION_PRODUCT|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
214555074|NCT04699968|DRUG|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
214555075|NCT04699968|DRUG|SHR-1701|SHR -1701, Intravenous
214703649|NCT01780909|DRUG|Paromomycin Sulfate Fed State|
215162699|NCT04847063|DRUG|Sodium Thiosulfate|Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
214555076|NCT06503484|DEVICE|Brain-computer interface|Patients will perform kinesthetic motor imagery of the affected upper extremity in response to auditory cues from the BCI system. The averaged oxygenated hemoglobin (HbO) level, extracted from optimal channels identified during the localizer session, will serve as signal intensity. This intensity, quantified as percent signal change relative to baseline, will trigger neurofeedback when reaching a predefined threshold. Visual feedback, delivered via the digital mirror therapy system, will guide patients to perform observational imitation tasks using bilateral upper extremities. Each session will include 5-6 movements tailored to the patient's functional performance. After observational imitation training, patients will practice functional adaptation tasks in a virtual environment, where they apply learned movements to functional activities. Sessions will last approximately 75 minutes.
214555077|NCT06503484|DEVICE|Sham brain-computer interface|In the sham group, patients will wear a similar headset equipment as those in the BCI group. However, the visual feedback provided through the digital mirror therapy system will not be based on their own brain activity. Instead, it will be derived from the brain activity of a participant in the BCI group using the simulation mode of Turbo-Satori. Patients in the sham group will receive constant visual feedback, with a fixed duration of 60 seconds for motor imagery, regardless of their actual brain signals. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback, and practice functional adaptation tasks after observational imitation training. The sham training will also last for around 75 minutes per session.
214555078|NCT05271344|DIETARY_SUPPLEMENT|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
214555079|NCT03142854|DRUG|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
215162700|NCT04362826|BIOLOGICAL|Novel probiotic|Investigational novel probiotic
215162701|NCT04362826|OTHER|Placebo|Placebo for probiotic
215162702|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
214555080|NCT03142854|DRUG|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
214555081|NCT05121389|DRUG|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
214555082|NCT03274115|DEVICE|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
214555083|NCT06832540|DRUG|[14C]TJ0113|Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.
214555084|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
214555085|NCT06444490|BEHAVIORAL|General Approach Instruction|Oral health instruction focused more broadly on the different topics of oral diseases and oral hygiene care.
214555086|NCT06444490|BEHAVIORAL|Personalised Technique Instruction|Oral health instruction based on the specific needs of each participant.
214555087|NCT00064649|DEVICE|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
214555088|NCT00064649|DEVICE|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
214555089|NCT00064649|DRUG|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
214555090|NCT04112706|DRUG|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
214555091|NCT05257447|DRUG|Baclofen 20 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
214703650|NCT01780909|DRUG|Paromomycin Sulfate w/ domperidone|
214703651|NCT01780909|DRUG|Paromomycin Sulfate w/ loperamide HCl|
214709018|NCT03438578|DEVICE|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
214709019|NCT03052439|OTHER|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
214709020|NCT01519063|DRUG|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
215162703|NCT03748966|DRUG|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
214555092|NCT05257447|DRUG|Chlorzoxazone 500 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
214555093|NCT05257447|DRUG|Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet|Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
214555094|NCT04706936|BIOLOGICAL|anti-BCMA CAR-T|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
214703652|NCT04256304|BEHAVIORAL|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
214555095|NCT04706936|DRUG|Cyclophosphamid|300mg/m2/d
214555096|NCT04706936|DRUG|Fludarabine|30mg/m2/d
214703653|NCT03114878|OTHER|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
214703654|NCT03114878|BEHAVIORAL|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
214703655|NCT06429423|BEHAVIORAL|Acute exercise low intensity|"A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
214703656|NCT06429423|BEHAVIORAL|Acute exercise moderate intensity|"A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
214703657|NCT02766595|OTHER|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
214703658|NCT02562872|DRUG|DSM265|DSM265 400 mg single oral dose
214703659|NCT02562872|DRUG|Placebo|Placebo to match DSM265, single oral dose
214703660|NCT02562872|BIOLOGICAL|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
214703661|NCT02562872|BIOLOGICAL|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
214703662|NCT06392750|BEHAVIORAL|Collection of tumor tissue specimens|Collection of tumor tissue specimens during surgery
214555097|NCT01667926|DRUG|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
214555098|NCT01667926|DRUG|Placebo|
214703663|NCT03434418|DRUG|osimertinib|80 mg oral administration daily
215162704|NCT05789758|OTHER|No Intervention|Administered as specified in the treatment arm.
215162705|NCT04024943|DEVICE|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
214555099|NCT03572647|DRUG|Eritromax|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
214555100|NCT03572647|DRUG|Eprex|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
214555101|NCT00558922|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
214555102|NCT05311722|DRUG|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
214555103|NCT05311722|DRUG|Ketamine|Ketamine
214555104|NCT05311722|DRUG|Tramadol|Tramadol
214555105|NCT01750970|OTHER|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
214555106|NCT04486625|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
214555107|NCT04486625|DRUG|Aztreonam-Avibactam|675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
214555108|NCT04245553|DIAGNOSTIC_TEST|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
214555109|NCT03360734|DRUG|First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
214555110|NCT05396651|OTHER|low fodmap diet|elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners
214555111|NCT05396651|OTHER|NICE guidelines for IBS|"follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks."
214555112|NCT02422576|OTHER|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
214555113|NCT02422576|OTHER|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
214555114|NCT02422576|OTHER|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
214555115|NCT02422576|OTHER|Thicken Up clear: TUC|
214555116|NCT01798875|DRUG|oral metformin|
214555117|NCT01798875|DRUG|oral contraceptive|
214703664|NCT03434704|DRUG|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.
214703665|NCT03434704|PROCEDURE|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
214703666|NCT03434704|DRUG|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
214703667|NCT03434704|DRUG|Primary antifungal prophylaxis|Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
214703668|NCT04276129|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
214703669|NCT04276129|OTHER|post-surgical CHX mouth-rinses indication|CHX mouth-rinses (0.12%) will be indicated 2 times/day after the surgical procedure
214703670|NCT01956240|PROCEDURE|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
214703671|NCT01956240|PROCEDURE|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
214555118|NCT03429777|DEVICE|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
214555119|NCT04226989|BIOLOGICAL|CT-RD06|CT-RD06 cell injection by intravenous infusion
214555120|NCT04557267|DRUG|low-dose|Dosage 1
214555121|NCT04557267|DRUG|Middle-dose|Dosage 2
214555122|NCT04557267|DRUG|Higher-dose|Dosage 3
214555123|NCT04557267|DRUG|Placebo|Placebo
214555124|NCT01205022|DRUG|irinotecan hydrochloride|Given IV
214555125|NCT01205022|DRUG|leucovorin calcium|Given IV
214555126|NCT01205022|DRUG|fluorouracil|Given IV
214555127|NCT01205022|BIOLOGICAL|bevacizumab|Given IV
214555128|NCT01205022|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
214555129|NCT01205022|OTHER|laboratory biomarker analysis|Correlative studies
214555130|NCT01431820|DRUG|Luliconazole Solution, 10%|Topical
214555131|NCT01431820|DRUG|Vehicle Solution|Topical
214555132|NCT00002385|DRUG|Fozivudine tidoxil|
214555133|NCT03283475|PROCEDURE|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
214555134|NCT00777738|DRUG|BORTEZOMIB|"* Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~* For responding patients : up to 6 cycles~* For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
214555135|NCT03613389|DIETARY_SUPPLEMENT|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
214709021|NCT01519063|DRUG|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
214555136|NCT02084758|DIETARY_SUPPLEMENT|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
214555137|NCT02084758|DIETARY_SUPPLEMENT|Placebo supplementation|7 days of supplementation with sodium chloride solution
214703672|NCT02540096|OTHER|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
214555138|NCT02701881|DEVICE|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
214555139|NCT02701881|DEVICE|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
214555140|NCT05106777|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
214555141|NCT03774615|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
214555142|NCT04227145|BEHAVIORAL|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
214555143|NCT05034172|OTHER|Clinical follow-up|"Clinical Follow-up:~demographic data and history,~* Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only);~* Family history - Neurological examination:~* Diagnosis Clinical examination;~* Rating scales specific to the pathology under investigation;~* Cerebral MRI (optional)~* Biological samples (optional)"
214555144|NCT03404895|DEVICE|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
214555145|NCT03404895|DEVICE|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
214703673|NCT02540096|OTHER|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
214703674|NCT02982486|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
214555146|NCT04651140|BEHAVIORAL|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
214555147|NCT00666900|DRUG|Low Strength IDP-107|Once a day for 12 weeks
214555148|NCT00666900|DRUG|High Strength IDP-107|Once a day for 12 weeks
214555149|NCT00666900|DRUG|Placebo Comparator|Once a day for 12 weeks
214555150|NCT02976077|BEHAVIORAL|RC2S+|new cognitive remediation program
214555151|NCT02976077|BEHAVIORAL|active comparator|cognitive remediation program
214555152|NCT01833377|DIETARY_SUPPLEMENT|caraway sample|
214555153|NCT01833377|DIETARY_SUPPLEMENT|placebo|
214555154|NCT05942820|DRUG|BWC0977|SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
214555155|NCT05942820|DRUG|Placebo|"SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977"
214555156|NCT04127981|DIAGNOSTIC_TEST|18F-FDG PET + Dexa Scan|18F-FDG PET will be compared with Dexa Scan result within and between arms.
214703675|NCT02982486|DRUG|Nivolumab|Ninolumab 240 mg IV every 2 weeks
214703676|NCT02092441|OTHER|Alcohol prep pad group|Subjects inhale scent of alcohol pad
214703677|NCT02092441|OTHER|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
214709022|NCT04990661|BEHAVIORAL|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
215162706|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
215162707|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
214555157|NCT04161053|DRUG|Rifaximin|Rifaximin 550 mg twice daily for 6 months
214555158|NCT04161053|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
214555159|NCT01478451|BEHAVIORAL|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
214555160|NCT01478451|OTHER|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
214555161|NCT04802889|OTHER|scanning electron microscopy|scanning electron microscopy of the сentral retina and preretinal structures
214555162|NCT00703495|DEVICE|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
214555163|NCT04467918|DRUG|Cannabidiol|Already described
214555164|NCT04467918|OTHER|PLACEBO|Already described
214555165|NCT02872805|OTHER|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
214555166|NCT02872805|BEHAVIORAL|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
214555167|NCT05444634|BEHAVIORAL|Distraction Card|"Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do."
214555168|NCT05444634|BEHAVIORAL|Stress Ball|Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
214555169|NCT01908504|OTHER|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
214555170|NCT04905953|DRUG|Neostigmine|Intrathecal injection of two doses of neostigmine (10 \& 20 mic) during spinal anesthesia for cesarean section.
214555171|NCT01202149|DEVICE|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
214555172|NCT01088984|DRUG|Bendamustine|
214703678|NCT03609736|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|"* A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~* After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~* Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~* At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
214703679|NCT04485117|DEVICE|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
215162708|NCT03731832|DRUG|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
214555173|NCT00623259|BIOLOGICAL|MVA-mBN120B|
214555174|NCT04523675|DIETARY_SUPPLEMENT|N-acetylcysteine|Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
214555175|NCT04523675|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
214555176|NCT00115908|DRUG|Albuferon|
214555177|NCT00115908|DRUG|Ribavirin|
214555178|NCT00115908|DRUG|PEG-IFNalfa2a|
214555179|NCT03745742|OTHER|HRV measurement|"Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~* Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App."
214555180|NCT03591484|RADIATION|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
214555181|NCT03591484|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
214703680|NCT04485117|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
214703681|NCT04485117|DRUG|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
214703682|NCT04485117|DRUG|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
214703683|NCT05365009|DIAGNOSTIC_TEST|Multidisciplinary aproach|regular tests
215162709|NCT03731832|DRUG|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
214555182|NCT03591484|PROCEDURE|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
214555183|NCT03591484|PROCEDURE|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
214555184|NCT00004551|DRUG|nicotine replacement patch|
214555185|NCT00004551|BEHAVIORAL|mood management|
214555186|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
214555187|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
214555188|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant|Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
214555189|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant Placebo|Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
214555190|NCT04855006|OTHER|No intervention|Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
214555191|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536|2 capsules od
214555192|NCT01201577|DIETARY_SUPPLEMENT|Active hexose correlated compound (AHCC)|One capsule tds
214555193|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
214555194|NCT01201577|DIETARY_SUPPLEMENT|Corn starch placebo capsule|One capsule tds and two capsules od
214555195|NCT01201577|DRUG|Azithromycin|250mg od
214555196|NCT01225653|DRUG|Latanoprost|Topical application
214703684|NCT00600028|DRUG|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
214703685|NCT00600028|DRUG|Placebo|Placebo 50-100 mg by mouth per day
214703686|NCT04658420|DRUG|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
214703687|NCT04658420|OTHER|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
214703688|NCT02072772|BEHAVIORAL|Positively Smoke Free group treatment|See Arm Description
214555197|NCT02244970|OTHER|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
214555198|NCT02244970|OTHER|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
214555199|NCT01982305|PROCEDURE|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
214555200|NCT01982305|PROCEDURE|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
214703689|NCT02072772|BEHAVIORAL|Standard Care|See Arm Description
214555201|NCT06530004|DRUG|Rituximab|B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
214555202|NCT04707664|DRUG|Sargramostim|All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
214703690|NCT03172481|DRUG|PRC-063 oral capsules|Daily dose
214703691|NCT03172481|DRUG|Placebo oral capsules|Daily dose
214703692|NCT05043246|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
214703693|NCT00484549|PROCEDURE|Blood sample|Ischemic stroke hospitalized
214703694|NCT00648141|DRUG|Celecoxib|200 mg oral capsule once daily for 12 weeks
214703695|NCT00648141|DRUG|Celecoxib|200 mg oral capsule twice daily for 12 weeks
214703696|NCT00648141|DRUG|Diclofenac|75 mg oral capsule twice daily for 12 weeks
214703697|NCT03768895|RADIATION|MRI|"The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI."
214703698|NCT01699412|DRUG|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
214703699|NCT01699412|DRUG|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
214703700|NCT01957709|OTHER|Laboratory Biomarker Analysis|Correlative studies
214555203|NCT04707664|DRUG|Placebo|All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
214555204|NCT04730141|OTHER|Patient mobilization with pre-operative mobilization training and mobilization protocol|Postoperative mobilization for the first 24 hours
214555205|NCT04246164|DEVICE|HD-tDCS combined with CT|HD-tDCS treatments will be administered during a cognitive training session.
214555206|NCT04246164|DEVICE|sham HD-tDCS combined with CT|sham-HD-tDCS treatments will be administered during a cognitive training session.
214555207|NCT03134677|DRUG|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
214555208|NCT03134677|DRUG|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
214555209|NCT01549704|DRUG|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
214555210|NCT01549704|DRUG|Saline|please see intervention description for ropivacaine
214555211|NCT00427505|DRUG|Deferasirox|
214555212|NCT03546153|BEHAVIORAL|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
214555213|NCT04553562|DEVICE|Acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
214555214|NCT04553562|DEVICE|Sham acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
214555215|NCT00090155|DRUG|MK0869, aprepitant|
214555216|NCT00090155|DRUG|Comparator: ondansetron IV|
214555217|NCT03691077|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
214555218|NCT00167804|BEHAVIORAL|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
214555219|NCT04660136|BIOLOGICAL|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
214555220|NCT05476315|OTHER|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
214555221|NCT05034406|DRUG|2% Lidocaine|6 mL of 2% lidocaine injected at the trocar insertion site.
214555222|NCT05034406|DRUG|0.5% levobupivacaine|6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
214555223|NCT05529680|OTHER|Scapular mobilization and Scapular strengthening exercises|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
214555224|NCT05529680|OTHER|Conventional physical therapy program|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
214555225|NCT05509049|OTHER|Precision nudging|Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
214555226|NCT05509049|OTHER|Standard of care|Standard of care communication (e.g., personalized letters and patient portal notices)
214555227|NCT00506246|DRUG|Propofol|"* intravenous (total intravenous anaesthesia)~* induction and maintenance"
214703701|NCT01957709|BIOLOGICAL|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
214555228|NCT00699153|DRUG|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
214709023|NCT04426370|OTHER|Observational|Physical examination and questionnaires
214709024|NCT05080959|DRUG|CPL-01|Subjects will receive a single dose
214709025|NCT05080959|DRUG|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
214709026|NCT05080959|DRUG|Placebo|Subjects will receive a single dose
215162710|NCT03731832|DRUG|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
214555229|NCT00699153|DRUG|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
214555230|NCT04663412|OTHER|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
214555231|NCT02344264|DRUG|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
214555232|NCT02344264|DRUG|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
214555233|NCT03054051|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
214555234|NCT03485664|PROCEDURE|tooth extraction|tooth extraction
214555235|NCT00089960|DRUG|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
214555236|NCT02412735|DRUG|Rexlemestrocel-L|Rexlemestrocel-L injection
214555237|NCT02412735|DRUG|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
214555238|NCT02412735|DRUG|Placebo|Saline control solution
214555239|NCT03523026|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
214555240|NCT03523026|OTHER|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
214555241|NCT03523026|OTHER|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
214703702|NCT02433860|BEHAVIORAL|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery."
214555242|NCT03236623|OTHER|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
214555243|NCT02456519|OTHER|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
214555244|NCT00234702|DRUG|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
214555245|NCT00234702|DRUG|Placebo|Placebo
214555246|NCT02468362|PROCEDURE|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
214555247|NCT02468362|PROCEDURE|open intersphincteric resection|
214555248|NCT00140010|DRUG|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
214555249|NCT04743609|DIAGNOSTIC_TEST|nasopharyngeal samples|rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
214555250|NCT05528523|OTHER|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
214555251|NCT00136877|PROCEDURE|(adeno)tonsillectomy|
214555252|NCT00703417|DEVICE|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
215162711|NCT03731832|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
214555253|NCT00703417|DEVICE|Computed Tomography|CT scan of the lower back and hip
214555254|NCT00703417|DEVICE|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
214555255|NCT01409551|PROCEDURE|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
214555256|NCT01409551|PROCEDURE|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
214555257|NCT02521363|DEVICE|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.
214555258|NCT02521363|DRUG|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
214555259|NCT02552628|DEVICE|"Medtronic, Activa® PC on"|
214555260|NCT02552628|DEVICE|"Medtronic, Activa® PC off"|
214555261|NCT03561298|DRUG|BGB-3111 and Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
214555262|NCT06791239|OTHER|Thoracic squeeze technique|The Thoracic Squeeze Technique is a manual therapy method used primarily in respiratory physiotherapy to improve lung expansion, enhance respiratory function, and facilitate secretion clearance in patients with respiratory conditions.
214555263|NCT06791239|OTHER|Manual diaphragmatic release technique|The Manual Diaphragmatic Release Technique is a soft tissue manipulation technique used to improve the mobility, function, and efficiency of the diaphragm. It is commonly applied in physiotherapy, particularly in respiratory, musculoskeletal, and manual therapy practices, to address breathing dysfunctions, postural imbalances, and associated pain or discomfort.
214555264|NCT04975841|DEVICE|Adipose Derived Regenerative Cells|"The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility."
214555265|NCT03494153|OTHER|Non applicable - Non interventional study|Non interventional study
214555266|NCT06797674|DRUG|MK-7602|Capsule
214555267|NCT06797674|DRUG|Efavirenz|Tablet
214555268|NCT03374488|DRUG|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
214555269|NCT03374488|DRUG|Epacadostat|Epacadostat administered orally twice daily.
214703703|NCT03678376|OTHER|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
214703704|NCT02928380|DEVICE|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
214703705|NCT02928380|DEVICE|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
214555270|NCT03374488|DRUG|Placebo|Matching placebo administered orally twice daily.
214555271|NCT06398847|DEVICE|Virtual Reality headset|Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.
214555272|NCT06291766|DEVICE|FreeStyle Libre 2, continous glucose monitoring|The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
214555273|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
214703706|NCT05720273|DRUG|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
214703707|NCT00474825|DRUG|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
214555274|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
214555275|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
214555276|NCT06522204|DRUG|%5 Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
214555277|NCT05878236|DIAGNOSTIC_TEST|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
214555278|NCT05154981|BEHAVIORAL|Education communication skills (ECS) training|Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
214555279|NCT05154981|BEHAVIORAL|Partners in School|Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
214703708|NCT00474825|DRUG|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
214703709|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
214703710|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
214703711|NCT00671723|DRUG|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
214703712|NCT00671723|DRUG|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
214703713|NCT00671723|DRUG|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
214555280|NCT04495153|BIOLOGICAL|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
214555281|NCT06509100|DEVICE|Device: Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
214555282|NCT05163405|DRUG|Bortezomib|Self-administration of subcutaneously Velcade.
214555283|NCT05973656|DRUG|Alcohol|Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
214555284|NCT05973656|PROCEDURE|Biospecimen Collection|Undergo saliva, mouthwash, and cheek brush collection
214703714|NCT01969942|BIOLOGICAL|allogeneic stem cell transplantation|
214703715|NCT01969942|DRUG|Clyclophosphamide|
214703716|NCT01969942|DRUG|Fludarabina|
214703717|NCT01969942|DRUG|Busulfan|
214703718|NCT01969942|DRUG|Melphalan|
214703719|NCT00390494|PROCEDURE|Hysterectomy|
214703720|NCT00390494|PROCEDURE|Myomectomy|
214703721|NCT00390494|PROCEDURE|Uterine Fibroid Embolization|
214703722|NCT03310437|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
214703723|NCT05682313|DIAGNOSTIC_TEST|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
214703724|NCT04051476|OTHER|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
214703725|NCT04051476|OTHER|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
214703726|NCT04051476|OTHER|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
214703727|NCT04051476|OTHER|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
214555285|NCT05973656|PROCEDURE|Breath Test|Undergo breathalyzer testing
214555286|NCT05949320|OTHER|e-Motivational Interviewing|"This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes."
214555287|NCT06090721|DRUG|DMT310|Topical Powder
214555288|NCT06090721|DRUG|Placebo|Placebo Topical Powder
214555289|NCT04101955|PROCEDURE|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
214555290|NCT04101955|PROCEDURE|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
215162712|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
214555291|NCT01480063|DRUG|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
214555292|NCT00142090|DRUG|3% Hypertonic saline|
214703728|NCT04992039|OTHER|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling."
214703729|NCT03388996|DIAGNOSTIC_TEST|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
215162713|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
214703730|NCT01885858|BEHAVIORAL|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
214703731|NCT01885858|BEHAVIORAL|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
214703732|NCT01362218|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
214703733|NCT01362218|DRUG|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
214555293|NCT00142090|DRUG|Placebo|Normal saline
214555294|NCT04654949|OTHER|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
214555295|NCT01757197|DRUG|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
214555296|NCT01735903|PROCEDURE|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
214555297|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
214555298|NCT02453984|OTHER|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
214703734|NCT01680978|DRUG|aleglitazar|150 mcg orally daily, 6 weeks
215162714|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
215162715|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
215162716|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
215162717|NCT06465888|OTHER|egg whites|Participants will eat four egg whites daily for the 4-week study
215162718|NCT06465888|OTHER|whole eggs|Participants will eat two eggs daily for the 4-week study
214555299|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
214555300|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
214555301|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
214555302|NCT00776906|DEVICE|Advance® 18PTX® Balloon Catheter|
214555303|NCT00776906|DEVICE|Advance® 18LP Balloon Catheter|
214555304|NCT05530577|DRUG|Semaglutide|Semaglutide (subcutaneous)
214555305|NCT05530577|DRUG|Sham/placebo|Sham subcutaneous injection
214555306|NCT03181659|PROCEDURE|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
214555307|NCT03181659|PROCEDURE|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
214555308|NCT06088498|BEHAVIORAL|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
214703735|NCT01680978|DRUG|placebo|orally daily, 6 weeks
214703736|NCT05415345|BIOLOGICAL|Cecolin|Bivalent HPV Vaccine
214703737|NCT05415345|BIOLOGICAL|Hecolin|Hepatitis E vaccine
214703738|NCT01755312|DEVICE|Medication reminder|Medication reminder
214703739|NCT03317249|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram
215162719|NCT06465888|OTHER|Omega-3 eggs|Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.
215162720|NCT06465888|OTHER|egg yolk|Participants will eat four egg yolks daily for the 4-week study
214703740|NCT03317249|DIAGNOSTIC_TEST|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
215162721|NCT06424444|DRUG|Reproxalap ophthalmic solution (0.25%)|Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks
214703741|NCT03317249|DIAGNOSTIC_TEST|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
215162722|NCT06424444|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
214703742|NCT03317249|DIAGNOSTIC_TEST|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
214703743|NCT03317249|OTHER|Echocardiogram|optional (for non-IST participants only)
214703744|NCT05889351|DRUG|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
214703745|NCT05889351|DRUG|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
214703746|NCT05889351|DRUG|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
214703747|NCT01610076|OTHER|Code Status Video|"10 minute video about Code Status"
215162723|NCT03695601|OTHER|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
215162724|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
215162725|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
215162726|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
215162727|NCT06541886|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
214555309|NCT06088498|BEHAVIORAL|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
214555310|NCT06088498|BEHAVIORAL|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
214555311|NCT01503762|OTHER|Mirror therapy|mirror therapy
214555312|NCT01503762|OTHER|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
214555313|NCT05005377|PROCEDURE|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
214555314|NCT05005377|PROCEDURE|Socket Preservation with Freeze-Dried Bone Allograft|The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
214555315|NCT05428995|DEVICE|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
214555316|NCT05428995|DEVICE|Airtraq videolaryngoscope.|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
214555317|NCT03374943|DRUG|KB004|KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
214555318|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 25 mg.
214555319|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 50 mg.
214555320|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 75 mg.
214555321|NCT00903500|BEHAVIORAL|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
214555322|NCT04949256|BIOLOGICAL|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
214555323|NCT04949256|DRUG|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
214555324|NCT04949256|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
214555325|NCT04949256|DRUG|5-FU|4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
214555326|NCT04949256|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
214555327|NCT04949256|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
215162728|NCT03949153|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
215162729|NCT03949153|PROCEDURE|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
215162730|NCT03949153|DRUG|Ipilimumab Injection|In situ injection with ipilimumab at D2.
214555328|NCT04949256|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
214555329|NCT04949256|DRUG|Paclitaxel|175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
214555330|NCT04634474|BEHAVIORAL|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
214555331|NCT02417649|BIOLOGICAL|Placebo|"1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
214555332|NCT02417649|BIOLOGICAL|Ismigen|"1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
214555333|NCT00804505|DEVICE|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
214555334|NCT00804505|DEVICE|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
214555335|NCT06147492|PROCEDURE|transanal total mesorectal excision|a transanal bottom-up approach was employed for the TME procedure
214703748|NCT05189158|DIAGNOSTIC_TEST|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
214703749|NCT05189158|DIAGNOSTIC_TEST|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
215162731|NCT05932680|OTHER|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
215162732|NCT05158218|BEHAVIORAL|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
215162733|NCT05158218|BEHAVIORAL|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
215162734|NCT04479267|DRUG|Prednisone|Given PO
215162735|NCT04479267|DRUG|Prednisolone|Given IV
214555336|NCT06147492|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic Total Mesorectal Excision
214555337|NCT05832151|DRUG|CIN-102 Dose 15mg or 10mg|2 capsules twice daily for 12 weeks
214555338|NCT05832151|DRUG|Placebo|2 capsules twice daily for 12 weeks
215162736|NCT04479267|DRUG|Methylprednisolone|Given IV
215162737|NCT04479267|BIOLOGICAL|Rituximab|Given IV
215162738|NCT04479267|DRUG|Polatuzumab Vedotin|Given IV
215162739|NCT04479267|DRUG|Cyclophosphamide|Given IV
215162740|NCT04479267|DRUG|Doxorubicin Hydrochloride|Given IV
215162741|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
214555339|NCT05976776|BEHAVIORAL|The Childbirth and Parenthood Preparation Education|"The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions)."
214555340|NCT01461889|OTHER|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
214555341|NCT01461889|OTHER|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
214555342|NCT04765917|OTHER|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Strengthening exercises for weakened muscles in upper and lower limbs muscle.~* Strengthening exercises for back and abdominal muscles.~* Stretching exercises for tight muscles in upper and lower limbs.~* Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Jumping in place and jumping a board."
214555343|NCT04765917|OTHER|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
214555344|NCT04283539|DRUG|systemic corticosteroid or biologic|Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
214555345|NCT01706705|DEVICE|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
214555346|NCT01706705|OTHER|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
214555347|NCT01706705|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
214555348|NCT06179225|BEHAVIORAL|HMD AR|Older adults will wear head mounted display to engage in collaborative augmented reality activities: sharing a meal, playing board games, and decorating home.
214555349|NCT06179225|BEHAVIORAL|2-D AV|Older adults will use 2-D AV to engage with family members at a distance.
214555350|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg IV of Remimazolam Tosilate, Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1mg/kg/h
214555351|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection
214555352|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
214555353|NCT04773067|BIOLOGICAL|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
214555354|NCT04773067|BIOLOGICAL|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
215162742|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
215162743|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
215162744|NCT05970172|DRUG|Roxadustat|Oral
215162745|NCT04565691|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
215162746|NCT03190954|DRUG|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
215162747|NCT03190954|DRUG|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
215162748|NCT03190954|DRUG|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
215162749|NCT05805202|OTHER|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
215162750|NCT06387082|DRUG|HMPL-506|HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
215162751|NCT05886582|DRUG|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
215029763|NCT05226195|OTHER|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
215162752|NCT05886582|DRUG|Placebo|Placebo drug
215162753|NCT06348771|BEHAVIORAL|monounsaturated fatty acids (MUFA) peanut meal|mixed meal tolerance test and postprandial measurements
215162754|NCT06423365|OTHER|Virtual Statin Management (VSM)|"VSM is a web-based decision aid to help manage statin therapy after experiencing muscle pain perceived to be caused or worsened by their statin therapy. The introduction will feature a brief explanation of the tool and what they can expect. The modules are:~1. General education (lipids, heart disease, medications)~2. Side effects (causes, diagnosis).~3. Statin modifications. VSM will guide patients to understand their lipid-lowering options, particularly their statin options that may best match patients' stated preferences.~4. ASCVD risk \& statin benefit. Finally, the VSM experience will end by providing the patient with a summary of the results of their use of the tool, which can be used during discussions with their healthcare provider. The information gathered from the VSM will remain confidential and will not be disclosed to anyone other than the patient."
215162755|NCT06357403|DIAGNOSTIC_TEST|Anti-factor Xa activity calibrated for enoxaparin|Anti-factor Xa activity calibrated for enoxaparin
215162756|NCT05431127|DEVICE|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
215162757|NCT04825626|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
215162758|NCT06406361|BEHAVIORAL|online stress management program|"-Nurses should have an idea about stress management program Awareness develops about the importance of attending sessions regularly. Nurses have information about the training program. Joint session dates are determined. The educator makes statements about himself and education. The benefits of education for nurses are explained. Nurses are informed about the general rules of education. The importance of regular attendance at sessions is emphasized. Privacy rules and limits are determined. The necessity of completing homework is explained. Nurses are enabled to share their feelings and thoughts. Ensuring that nurses are able to recognize stress and reactions to stress and identify sources of stress in individual and business life.~Being informed about the effects of stress and negative workload perception Being able to recognize the tension created by stress in the body Learning breathing and deep relaxation techniques to reduce or eliminate symptoms of stress"
215162759|NCT06570915|DRUG|Daratumumab Injection|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
214555355|NCT03540745|DEVICE|TES Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
214555356|NCT03540745|DEVICE|TES-SHAM Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
214555357|NCT02088957|DRUG|Brivaracetam intravenous solution|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use"
214555358|NCT02088957|DRUG|Brivaracetam oral tablets|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use"
214555359|NCT02088957|DRUG|Phenytoin intravenous solution|"* Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use"
214555360|NCT02088957|DRUG|Phenytoin oral tablets|"* Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use"
214555361|NCT04420429|PROCEDURE|Descemet membrane endothelial keratoplasty (DMEK)|All participants underwent DMEK surgery
214555362|NCT00095277|DRUG|Darbepoetin Alfa|
214555363|NCT04370015|DRUG|Hydroxychloroquine|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
214555364|NCT04370015|DRUG|Placebo oral tablet|• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
214555365|NCT04567381|OTHER|Enhanced Services|In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.
214555366|NCT04567381|OTHER|Treatment as Usual|Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
214555367|NCT05022433|PROCEDURE|UVC insertion|To compare two formulae namely UN-1 and Shukla method to estimate the UVC insertion length in achieving optimum UVC tip position.
215029764|NCT00146822|DEVICE|ENDOTAK RELIANCE G lead|
215029765|NCT02522273|DEVICE|EKF Diagnostics 'SensPoint' Lactate Meter|
215029766|NCT05706350|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
214555368|NCT06344468|OTHER|Early Mobilization|Essentially, early mobilization practices consist of two parts: in-bed and out-of-bed. In-bed mobilization; Active-passive joint range of motion (ROM) Exercises include raising the head in bed, turning in bed, in-bed exercises and sitting at the end of the bed. Out-of-bed mobilization includes the process of transferring from bed to chair, standing up, and returning to bed after standing up. In studies conducted on cardiac surgery, the early mobilization period is the first 12 hours.
214555369|NCT04890405|PROCEDURE|Standardized FMT|The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.
214555370|NCT04890405|COMBINATION_PRODUCT|Precision Flora Transplantation|The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
214555371|NCT06415136|DEVICE|SeaSpine Shoreline|The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
214555372|NCT00780728|DRUG|Sildenafil|
215162760|NCT05779423|DRUG|Ipilimumab|Monoclonal antibody administered through intravenous infusion
215162761|NCT05779423|DRUG|Nivolumab|Monoclonal antibody administered through intravenous infusion
215162762|NCT05779423|PROCEDURE|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
215162763|NCT05971251|DRUG|Loncastuximab Tesirine and Acalabrutinib|Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
215162764|NCT05159960|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
214555373|NCT01939353|DRUG|CTN SR|CTN SR tablets
214555374|NCT01939353|DRUG|Placebo|CTN SR-matching placebo tablets
214555375|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
214555376|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
214555377|NCT01342198|DRUG|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
214555378|NCT03337438|OTHER|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
214555379|NCT03337438|OTHER|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
214555380|NCT04980222|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
214555381|NCT04980222|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
214555382|NCT04980222|DRUG|Doxorubicin|Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
215162765|NCT03307616|BIOLOGICAL|Ipilimumab|Given IV
214555383|NCT04980222|DRUG|Vincristine|Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
214555384|NCT04980222|DRUG|Prednisone|Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
214555385|NCT04980222|DRUG|Rituximab|Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
214555386|NCT04980222|DRUG|Cyclophosphamide|Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
214555387|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
214555388|NCT02413645|BIOLOGICAL|TriMix_100|100 μg of TriMix in
215162766|NCT03307616|BIOLOGICAL|Nivolumab|Given IV
214555389|NCT02413645|BIOLOGICAL|TriMix_300|300 μg of TriMix in
214555390|NCT02413645|BIOLOGICAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
214555391|NCT02413645|BIOLOGICAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
214555392|NCT02413645|BIOLOGICAL|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
215162767|NCT03307616|RADIATION|Radiation Therapy|Undergo radiation therapy
215162768|NCT00690560|BIOLOGICAL|rituximab|
214555393|NCT00874731|DRUG|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
214555394|NCT00874731|DRUG|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
214555395|NCT00874731|DRUG|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
215162769|NCT00690560|DRUG|cyclophosphamide|
215162770|NCT00690560|DRUG|doxorubicin hydrochloride|
215162771|NCT00690560|DRUG|prednisone|
215162772|NCT00690560|DRUG|vincristine sulfate|
215162773|NCT00690560|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214555396|NCT01506440|PROCEDURE|cognitive assessment|Given cognitive assessments
214555397|NCT01506440|PROCEDURE|quality-of-life assessment|Ancillary studies
214555398|NCT00186017|DRUG|Olanzapine/Zyprexa|Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
214555399|NCT00538772|OTHER|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
215162774|NCT04614129|DIAGNOSTIC_TEST|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
215162775|NCT04175938|DEVICE|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
214555400|NCT06518811|OTHER|Video-Based Exercise Programme|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided. The participants were used exercise balls and resistance bands distributed by the researchers according to exercise programme.
214555401|NCT02132832|DRUG|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
214555402|NCT02132832|DRUG|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
214555403|NCT06290245|DEVICE|PEP Buddy|It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O
214555404|NCT06290245|OTHER|aerobic exercise|Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
214555405|NCT04968431|OTHER|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
214555406|NCT04968431|OTHER|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
214555407|NCT05411172|BEHAVIORAL|Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses|"The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice."
214703750|NCT01518712|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
214703751|NCT01518712|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
214703752|NCT04102735|DEVICE|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
214703753|NCT04102735|DEVICE|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
214703754|NCT02043405|BEHAVIORAL|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
214703755|NCT02043405|BEHAVIORAL|Weight loss Only Intervention|Weight loss Only Intervention
214703756|NCT02035150|DIETARY_SUPPLEMENT|Oatmeal|A breakfast consisting of oatmeal
214703757|NCT02035150|DIETARY_SUPPLEMENT|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
214703758|NCT02035150|DIETARY_SUPPLEMENT|No Breakfast|A breakfast consisting of plain water
214703759|NCT03448861|DEVICE|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
214703760|NCT01107405|DRUG|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
214703761|NCT01107405|DRUG|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
214703762|NCT01107405|DRUG|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
214703763|NCT01107405|DRUG|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
214703764|NCT01107405|DRUG|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
214703765|NCT01404442|DRUG|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
214703766|NCT01404442|DRUG|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
214703767|NCT01404442|DRUG|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
214703768|NCT01759498|DIETARY_SUPPLEMENT|HYDRO|
214703769|NCT01759498|DIETARY_SUPPLEMENT|ACTIVE|
214703770|NCT01759498|DIETARY_SUPPLEMENT|HYDRO 2|
214555408|NCT02646020|DRUG|Aprepitant|aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
214555409|NCT02646020|DRUG|Desloratadine|Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
214555410|NCT02646020|DRUG|Placebo of aprepitant|Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
214555411|NCT02646020|DRUG|Placebo of desloratadine|Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
214555412|NCT05688631|OTHER|Dietary antioxidant intake|Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.
214555413|NCT02931253|DRUG|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
214555414|NCT03157297|DEVICE|MARVEL algorithm|Software download into implanted Micra device
214555415|NCT01132820|DRUG|Cediranib Maleate|Given PO
214555416|NCT01132820|OTHER|Laboratory Biomarker Analysis|Correlative studies
214555417|NCT06166550|BEHAVIORAL|Parent's Emotional Intelligence Network|A two-day in-person training session will be arranged for the participating parents at least one week apart. The psychologists will conduct the training session on emotional intelligence. A training of the trainer manual will be developed to train the psychologists. The training session will include a power point presentation and certain group and individual activities to practice emotional intelligence. The participants will also be given a diary and a mobile app in order to practice emotional intelligence at home.
214555418|NCT06166550|DEVICE|Mobile App|A mobile app (MonKotha) has been developed along with user manual. It contains different videos, audios, and texts related to emotional intelligence. It also provides a communication platform where users can communicate through texts and upload documents.
214555419|NCT06166550|DEVICE|Diary|A diary (Onuvutir Diary) is also developed that contain different practice materials regarding emotional intelligence. It is a personal diary given to the participants to take to home.
214555420|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
214555421|NCT05017051|BEHAVIORAL|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
214555422|NCT05017051|BEHAVIORAL|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
214555423|NCT05017051|DEVICE|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
214555424|NCT05017051|OTHER|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
214555425|NCT02026492|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
214555426|NCT02026492|OTHER|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
214555427|NCT02026492|OTHER|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
214555428|NCT01048697|DRUG|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
214555429|NCT03033940|RADIATION|Observational use of fluoroscopy|
214555430|NCT00409526|DRUG|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
214555431|NCT00667394|BIOLOGICAL|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
214555432|NCT00667394|DRUG|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
214555433|NCT00667394|PROCEDURE|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
214555434|NCT03837951|OTHER|Figure-of-eight tape measure measurements on both hands|Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.
214555435|NCT03837951|OTHER|Volumeter measurements|Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
214555436|NCT05369559|COMBINATION_PRODUCT|Mini bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
214555437|NCT05369559|DIAGNOSTIC_TEST|passive leg rising test|Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
214555438|NCT05000216|BIOLOGICAL|Moderna mRNA-1273|Administration: One dose administered intramuscularly.
214555439|NCT05000216|BIOLOGICAL|BNT162b2|Administration: One dose administered intramuscularly.
214555440|NCT05000216|BIOLOGICAL|Ad26.COV2.S|Administration: One dose administered intramuscularly.
214555441|NCT05000216|DRUG|Continue IS (MMF or MPA)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
215029767|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
214555442|NCT05000216|DRUG|Continue IS (MTX)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
214555443|NCT05000216|BIOLOGICAL|Continue IS (B cell depletion therapy)|Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.
214555444|NCT05000216|BIOLOGICAL|Monovalent [B.1.351] CoV2 preS dTM-AS03|One dose administered intramuscularly
214555445|NCT05000216|DRUG|Withhold IS (MMF or MPA)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
214555446|NCT05000216|DRUG|Withhold IS (MTX)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
214555447|NCT05000216|DRUG|Withhold IS (B cell depletion therapy)|Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
214555448|NCT05000216|BIOLOGICAL|Moderna mRNA-1273, Bivalent|Administration: One dose administered intramuscularly.
214555449|NCT05000216|BIOLOGICAL|BNT162b2, Bivalent|Administration: One dose administered intramuscularly.
214555450|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
214555451|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
214555452|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
214555453|NCT06771765|OTHER|Chia Seeds|Chia seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
214555454|NCT06771765|OTHER|Hemp Seeds|Hemp seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
214555455|NCT06771765|OTHER|Control (placebo) group|This intervention is a lunch meal made from standard recipes. This intervention is the placebo control intervention.
214555456|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 1|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
214555457|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 2|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
214703771|NCT03555188|DRUG|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
214703772|NCT02090985|PROCEDURE|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
214555458|NCT06253884|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
214555459|NCT06181071|OTHER|Distal Muscle Fatigue Protocol|Initially, sociodemographic data, muscle viscoelastic properties, foot plantar pressure, and static and dynamic balance are assessed. Additionally, the strengths of the plantar flexor and dorsiflexor muscles are evaluated. After these assessments, the heel raise exercise will be implemented in this protocol. Firstly, dominant leg, the heel raise exercise will be performed for 3 sets with the knees in full extension until the individual reaches fatigue. Subsequently, the heel raise exercise will be conducted for another 3 sets with the knee in flexion until the individual reaches fatigue. Following these exercises, Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
214703773|NCT05096013|OTHER|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
214703774|NCT02069236|OTHER|G6PD Test|All subjects are tested by multiple G6PD tests
214703775|NCT02128984|DIETARY_SUPPLEMENT|Symbiotic Formula with DHA and antioxidants|6 months intervention.
214703776|NCT02128984|DIETARY_SUPPLEMENT|Standard Formula|6 months intervention.
214703777|NCT05287607|DIAGNOSTIC_TEST|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
214703778|NCT03987334|OTHER|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
214703779|NCT03987334|OTHER|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
214703780|NCT04003753|OTHER|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
214703781|NCT01010854|DRUG|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
215162776|NCT05984979|OTHER|Standardized meal|The participants will receive a standardized meal for breakfast
215162777|NCT06340958|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
215162778|NCT06340958|DRUG|Placebo|1 tablet of placebo administered once daily
215162779|NCT06500624|DRUG|Pizotifen|Each subject will be given 0.5mg pizotifen with 10-20mg escitalopram in patients with depressive disorder
214555460|NCT06181071|OTHER|Proximal Muscle Fatigue Protocol|One week after the application of the distal muscle fatigue protocol, the same individuals will undergo the proximal fatigue protocol. In this protocol, individuals will perform, dominant leg, a single-leg squat exercise targeting the fatigue of the hip flexor and extensor muscles. Prior to this exercise, the viscoelastic properties of the muscles, foot plantar pressure, static and dynamic balances, as well as the strengths of the hip flexor and extensor muscles will be assessed. Then, individuals will perform the single-leg squat exercise, 3 sets. When the individual indicates fatigue, the set will conclude, allowing a 30-second rest between sets. Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
214555461|NCT02874014|RADIATION|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
214555462|NCT04763226|DRUG|BMS-986308|Specified dose on specified days
214555463|NCT04763226|OTHER|Placebo (for BMS-986308)|Specified dose on specified days
214555464|NCT04763226|DRUG|Furosemide|Specified dose on specified days
214555465|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
214555466|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
214555467|NCT04161729|DRUG|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
214555468|NCT04161729|DRUG|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
214555469|NCT00485277|BIOLOGICAL|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
215162780|NCT01886872|DRUG|Bendamustine Hydrochloride|Given IV
215162781|NCT01886872|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215162782|NCT01886872|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
215162783|NCT01886872|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214555470|NCT03586791|PROCEDURE|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
214555471|NCT03586791|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
214555472|NCT03586791|PROCEDURE|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
214555473|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
214555474|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
214555475|NCT06381986|DRUG|SHJ002|Topical ophthalmic
214555476|NCT06381986|OTHER|Vehicle|Topical ophthalmic
214555477|NCT05039073|DRUG|Brentuximab Vedotin|Given IV
214555478|NCT05039073|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
214555479|NCT05039073|BIOLOGICAL|Nivolumab|Given IV
214555480|NCT05039073|OTHER|Quality-of-Life Assessment|Ancillary studies
214555481|NCT05039073|OTHER|Questionnaire Administration|Ancillary studies
214555482|NCT03129126|DRUG|LP-10|Intravesical tacrolimus
214555483|NCT06533319|DRUG|sofosbuvir/velpatasvir|Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.
214555484|NCT01527747|DRUG|Saxagliptin|5 mg daily
214555485|NCT02377167|PROCEDURE|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
214555486|NCT06359418|DEVICE|Acupuncture|The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
214555487|NCT06359418|DEVICE|Sham acupuncture|The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
214555488|NCT03032718|BEHAVIORAL|Whole-body vibration training|Whole-body vibration exercise
215162784|NCT01886872|PROCEDURE|Computed Tomography|Undergo CT
215162785|NCT01886872|DRUG|Ibrutinib|Given PO
215162786|NCT01886872|OTHER|Laboratory Biomarker Analysis|Correlative studies
215162787|NCT01886872|OTHER|Quality-of-Life Assessment|Ancillary studies
215162788|NCT01886872|BIOLOGICAL|Rituximab|Given IV
215162789|NCT04908397|DIETARY_SUPPLEMENT|L-carnitine|supplement provided twice a day for 2 weeks
214555489|NCT05161598|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
214555490|NCT00578162|BEHAVIORAL|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
214555491|NCT05138289|OTHER|Total Plaque Volume|Compare total plaque volume with IVUS obtained during ICA (invasive coronary angiography)
214555492|NCT04222777|DIAGNOSTIC_TEST|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
214555493|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing to start with home respiratory polygraphy (APNIA)
214555494|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
214555495|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)
214555496|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
214555497|NCT00462878|DRUG|Meropenem|antibiotic
214555498|NCT00462878|DRUG|Vancomycin|Antibiotic
214555499|NCT00462878|DRUG|Teicoplanin|Antibiotic
214555500|NCT02345109|DEVICE|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
214555501|NCT02345109|DEVICE|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
214555502|NCT03992391|BEHAVIORAL|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
214555503|NCT00905905|DRUG|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
214555504|NCT00905905|DRUG|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
214555505|NCT01484600|DRUG|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
214703782|NCT02762019|DEVICE|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
214555506|NCT01484600|DRUG|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
214555507|NCT06372704|DEVICE|HIFEM|All patients had a total of 6 sessions lasting 28 minutes, twice a week, sitting on an electromagnetic chair (BTL EMSELLA®, BTL Industries Inc, Boston, MA, USA).
214555508|NCT03106454|DRUG|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
214555509|NCT03106454|DRUG|Norethindrone|Norethindrone 1.05mg
214555510|NCT06378684|DRUG|Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555511|NCT06378684|DRUG|Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555512|NCT06378684|DRUG|Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555513|NCT06378684|DRUG|Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555514|NCT06378684|DRUG|Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555515|NCT06378684|DRUG|Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
214555516|NCT02207855|DRUG|Chloroprocaine|
214555517|NCT01285700|DRUG|Lamazym|ERT, infusion weekly
214555518|NCT05861245|RADIATION|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~* For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~* For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
214555519|NCT05905159|BEHAVIORAL|ABM|Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures
214555520|NCT05905159|BEHAVIORAL|Control|Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
214555521|NCT05969860|PROCEDURE|Clinical Encounter|Receive treatment in clinic
214555522|NCT05969860|OTHER|Home Health Encounter|Receive at-home treatment
214555523|NCT05969860|OTHER|Quality-of-Life Assessment|Ancillary studies
214703783|NCT02762019|DEVICE|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
214703784|NCT04562545|DEVICE|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
214703785|NCT04562545|DEVICE|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
214703786|NCT00002545|DRUG|carmustine|
214703787|NCT00002545|RADIATION|low-LET photon therapy|
214555524|NCT05969860|OTHER|Questionnaire Administration|Ancillary studies
214703788|NCT02655445|PROCEDURE|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
214703789|NCT02655445|PROCEDURE|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
214703790|NCT02655445|PROCEDURE|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
214703791|NCT00530530|DRUG|ASP8825|oral
214555525|NCT04773925|BEHAVIORAL|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
214555526|NCT06423950|OTHER|Peds Evolutionary Tumor Board (pedsETB)|The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
214703792|NCT00530530|DRUG|Placebo|oral
214703793|NCT02791880|PROCEDURE|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
214703794|NCT01949727|OTHER|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
214555527|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
214703795|NCT04646473|BEHAVIORAL|SweetGoals app|App offers goal setting and feedback
214703796|NCT04646473|BEHAVIORAL|Coaching|Web health coaching
214703797|NCT04646473|BEHAVIORAL|Incentives|Financial incentives for meeting goals
214703798|NCT02858973|DRUG|Q203|
214703799|NCT02858973|DRUG|Placebo|
214703800|NCT02430428|DEVICE|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
215162790|NCT04261894|BEHAVIORAL|OPTIMIZE|The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
214555528|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
214703801|NCT01666691|DRUG|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
214703802|NCT01666691|DRUG|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
214703803|NCT00797069|OTHER|standard nutritional product (medical food)|once during crossover
214703804|NCT00797069|OTHER|nutritional product for diabetes (medical food)|once during crossover
214703805|NCT00797069|OTHER|diabetes specific experimental nutritional product (medical food)|once during crossover
214703806|NCT05533255|OTHER|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
214703807|NCT05533255|OTHER|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
215162791|NCT04264442|DRUG|Losmapimod|Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
215162792|NCT03644615|OTHER|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
215162793|NCT03644615|OTHER|Usual care|No intervention on the patients
215162794|NCT03744429|OTHER|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
215162795|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
215162796|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
215162797|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
215162798|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
214703808|NCT00664755|DRUG|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
215162799|NCT06028022|DRUG|Placebo Administration|Given PO
215162800|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
214703809|NCT00664755|DEVICE|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
215162801|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
215162802|NCT03044587|DRUG|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
214555529|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
214555530|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
214555531|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
214555532|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
214555533|NCT02562144|DRUG|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
214555534|NCT02562144|DRUG|Placebo|Cutaneous placebo before intravenous cannulation.
214555535|NCT04533048|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
214555536|NCT04533048|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
214555537|NCT03329300|BEHAVIORAL|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
214555538|NCT02264262|OTHER|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
214555539|NCT03004404|DRUG|Placebo|Placebo
214555540|NCT03004404|DRUG|BI 730357|powder for reconstitution of an oral solution (PfoS)
214555541|NCT03004404|DRUG|BI 730357|BI 730357 film-coated tablet
214555542|NCT01336998|DIETARY_SUPPLEMENT|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
214555543|NCT01937975|DRUG|Grazoprevir|100 mg oral tablet administered once a day for 10 days
214555544|NCT01937975|DRUG|Elbasvir|50 mg oral tablet administered once a day for 10 days
214555545|NCT06327776|OTHER|Serum and saliva biomarkers|2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.
214555546|NCT02522728|DEVICE|Triathlon CR|Implantation of Knee Prosthesis
214703810|NCT04094766|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
214703811|NCT04574921|OTHER|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
214703812|NCT04574921|OTHER|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
214703813|NCT02500602|DRUG|doxazosin|active medication
215162803|NCT03044587|DRUG|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
215162804|NCT05804370|DRUG|Gleolan|Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
214555547|NCT02522728|DEVICE|Triathlon PS|Implantation of Knee Prosthesis
214555548|NCT02028325|DRUG|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
214555549|NCT06102447|DRUG|Netopitam Palonosetron capsules and dexamethasone|On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
214703814|NCT02500602|DRUG|placebo|placebo pill
214703815|NCT00347035|DRUG|brimonidine|
214703816|NCT01918787|DEVICE|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
214703817|NCT02271867|PROCEDURE|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
214703818|NCT01926847|DRUG|Riociguat (Adempas, BAY63-2521)|
214703819|NCT01926847|DRUG|Placebo|
214703820|NCT00098020|DRUG|Isotretinoin|
214703821|NCT02823600|DEVICE|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
214703822|NCT01309867|DEVICE|Investigational Toric Lens|Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
214703823|NCT01309867|DEVICE|PureVision Toric Lens|Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
214703824|NCT04975542|OTHER|Osteopathic Manipulative Medicine|Manipulative therapies based on Osteopathic principles.
214703825|NCT04975542|OTHER|Sham|Light touch techniques to mimic to osteopathic treatment.
214703826|NCT01840228|DRUG|Micronized progesterone suppository|
214703827|NCT01954888|PROCEDURE|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
214555550|NCT04852913|OTHER|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
214555551|NCT04852913|OTHER|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
214555552|NCT00914745|DRUG|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
214555553|NCT02949245|PROCEDURE|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
214555554|NCT01266161|DRUG|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
214555555|NCT01266161|DRUG|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
214555556|NCT00003564|DRUG|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
214555557|NCT00003564|DRUG|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
214555558|NCT06091059|DIAGNOSTIC_TEST|Ultrasound MRI fusion|Fused MRI images with direct ultrasound guidance
214555559|NCT06439732|DEVICE|Acumen IQ cuff|Use of Acumen IQ cuff for haemodynamic monitoring
214555560|NCT01224522|PROCEDURE|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
214555561|NCT01224522|PROCEDURE|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
214555562|NCT04467047|BIOLOGICAL|Mesenchymal Stromal Cells infusion|Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
214555563|NCT03828890|OTHER|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
214555564|NCT06215209|OTHER|position|patients will be in supine position and prone position
214555565|NCT05930808|DRUG|First Test Concor (Fasted)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
214555566|NCT05930808|DRUG|First Reference Concor (Fasted)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
214555567|NCT05930808|DRUG|First Test Concor (Fed)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
214555568|NCT05930808|DRUG|First Reference Concor (Fed)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
214555569|NCT01436305|DRUG|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
214555570|NCT01436305|DRUG|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
214555571|NCT01436305|BIOLOGICAL|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication\[s\])
214555572|NCT01436305|DRUG|Short-term Tac|Short-term (3 months)
214555573|NCT01436305|DRUG|tacrolimus|maintenance
215162805|NCT05756751|DEVICE|Device: Impella 5.5 with SmartAssist|Patients who are deemed high-risk due to low preoperative ejection fraction undergoing cardiac surgery with cardiopulmonary bypass (CPB) which will be supported by the Impella 5.5 System.
214555574|NCT01436305|BIOLOGICAL|Belatacept|maintenance
214555575|NCT01436305|DRUG|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
214555576|NCT03563066|DRUG|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.
214555577|NCT03563066|DRUG|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
214703828|NCT01954888|PROCEDURE|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
214703829|NCT03915912|BEHAVIORAL|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
214555578|NCT01049438|DRUG|nasal mupirocin|twice daily for 10 days
214555579|NCT01049438|DRUG|topical 3% hexachlorophene body wash|daily for 10 days
214555580|NCT01049438|DRUG|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
214555581|NCT05884814|BEHAVIORAL|Morning exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
214555582|NCT05884814|BEHAVIORAL|Afternoon exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
214555583|NCT05884814|BEHAVIORAL|Habitual physical activity levels|Participants will be asked to maintain their normal activity levels
214703830|NCT02017613|DRUG|RP6530|Escalating doses starting at 25 mg BID
214555584|NCT05390814|DRUG|PET-MRI|\[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
214555585|NCT02281162|OTHER|Blood Draw|Blood Draw
214555586|NCT02813044|DRUG|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
214555587|NCT02813044|DRUG|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
214555588|NCT00751543|RADIATION|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
214555589|NCT01322737|PROCEDURE|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
214555590|NCT02019862|DEVICE|TRJ® Total Hip Arthroplasty|
214703831|NCT03475901|OTHER|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
214703832|NCT06335498|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
214555591|NCT02876445|OTHER|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
214555592|NCT02926287|OTHER|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
214703833|NCT06335498|DEVICE|Periodic ECG triggered measurement|Subject triggers AFGen1 to perform an extended measurement during wear period
214555593|NCT02740738|DEVICE|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
214555594|NCT02740738|DEVICE|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
214555595|NCT02309671|DRUG|FE 999049|
214555596|NCT02309671|DRUG|follitropin beta|
214703834|NCT02356146|DRUG|Tacrolimus C12|
214703835|NCT00047307|DRUG|alvocidib|Given IV
214703836|NCT00047307|DRUG|gemcitabine hydrochloride|Given IV
214703837|NCT00047307|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
214703838|NCT00047307|OTHER|laboratory biomarker analysis|Correlative studies
214703839|NCT03494426|PROCEDURE|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
214555597|NCT04574817|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
214555598|NCT05070364|DRUG|Peginterferon Lambda-1a|Immunomodulator
214555599|NCT00795223|DRUG|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
214703840|NCT03494426|DRUG|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
215162806|NCT05523453|BEHAVIORAL|Processing of Positive Memories Technique (PPMT)|PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.
214555600|NCT00795223|DRUG|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
214555601|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
214555602|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
214555603|NCT03124654|BEHAVIORAL|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
214555604|NCT05071053|DRUG|Ramucirumab (CYRAMZA®)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
214555605|NCT05071053|DRUG|Tusamitamab ravtansine (SAR408701)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
214555606|NCT03071237|PROCEDURE|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
214555607|NCT02019186|DIETARY_SUPPLEMENT|Vitamin C|\<30 kg 250 mg 30-60 kg 500 mg \>60 kg 750 mg
214555608|NCT02019186|DIETARY_SUPPLEMENT|Vitamin E|\<30 kg 100 IU, 30-60 kg 200 IU, \>60 kg 300 IU
214703841|NCT04353336|DRUG|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
214703842|NCT04733846|OTHER|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
214703843|NCT01160653|DEVICE|FES-IM|implantable Functional Electrical Stimulation
214703844|NCT01160653|OTHER|Cognitive training|training of impaired cognitive processes
215162807|NCT05523453|BEHAVIORAL|Supportive Counseling (SC)|SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
214555609|NCT05858684|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
214555610|NCT00289250|DRUG|Sulfadoxine-pyrimethamine|
214555611|NCT00289250|DRUG|Sulfadoxine-pyrimethamine plus artesunate|
214555612|NCT01871337|BEHAVIORAL|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
214555613|NCT01937169|BEHAVIORAL|Motor Task|A motor task executed for 30 minutes after drug adminidtration
214555614|NCT01937169|DRUG|Levodopa tablet|
214555615|NCT01937169|BEHAVIORAL|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
214555616|NCT01937169|DRUG|Placebo pill|
214555617|NCT01081886|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
214555618|NCT01081886|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
214555619|NCT05392647|DRUG|Hetrombopag|All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (\>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
214555620|NCT00108251|DRUG|Eplerenone|aldosterone receptor blocker
214555621|NCT00108251|DRUG|Placebo|matching placebo
214555622|NCT00654797|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
214555623|NCT05083845|PROCEDURE|Same blocks with different local anesthetic volume|Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
214555624|NCT02834338|DEVICE|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
214555625|NCT00459797|DEVICE|Conventional (reusable) Glidescope|
214555626|NCT00459797|DEVICE|Single-use Glidescope videolaryngoscope|
214555627|NCT03573869|PROCEDURE|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
214555628|NCT06511492|OTHER|No intervention in this study|No intervention in this study
214555629|NCT04670445|OTHER|Educational Video and QPL List|The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.
214555630|NCT04670445|OTHER|Usual Care|Surveys
214555631|NCT00798252|DRUG|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
214555632|NCT00798252|DRUG|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
214555633|NCT00798252|DRUG|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
215029768|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
215162808|NCT00382707|DEVICE|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
215162809|NCT04979806|DRUG|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
214555634|NCT00798252|DRUG|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
214555635|NCT00798252|DRUG|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
214555636|NCT00798252|DRUG|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
214555637|NCT04148651|DEVICE|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
214555638|NCT00003877|BIOLOGICAL|filgrastim|
214555639|NCT00003877|DRUG|carboplatin|
214555640|NCT00003877|DRUG|cyclophosphamide|
214555641|NCT00003877|DRUG|paclitaxel|
214555642|NCT00003877|DRUG|thiotepa|
214555643|NCT00003877|PROCEDURE|in vitro-treated bone marrow transplantation|
214555644|NCT00003877|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214555645|NCT01602510|DRUG|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
214555646|NCT01602510|DRUG|Placebo|Placebo
214555647|NCT05262751|DRUG|Ofev®|Ofev®
214555648|NCT05262751|DRUG|Nintedanib formulation 1|Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
214555649|NCT05262751|DRUG|Nintedanib formulation 2|Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
215029769|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
215029770|NCT05706350|DIETARY_SUPPLEMENT|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
215162810|NCT04979806|DRUG|Meropenem|1 g IV q8h
214555650|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
214555651|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
214555652|NCT02656719|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
214555653|NCT02656719|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
214555654|NCT04127097|OTHER|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
214555655|NCT03185884|OTHER|Control|control carbohydrate blend
214555656|NCT03185884|OTHER|Experimental|experimental carbohydrate blend
214555657|NCT03519204|DEVICE|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
214555658|NCT03519204|OTHER|No-treatment Control|No-treatment was administered.
214555659|NCT02144103|OTHER|Subtenon administration of autologous ADRC|
214555660|NCT02144103|PROCEDURE|Liposuction|
214555661|NCT02144103|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
214555662|NCT03832842|DIAGNOSTIC_TEST|Blood sample|Blood sample
214703845|NCT00759746|BEHAVIORAL|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
214703846|NCT00759746|BEHAVIORAL|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
214709027|NCT03765255|OTHER|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
215162811|NCT04904367|PROCEDURE|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
215162812|NCT04904367|PROCEDURE|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
214555663|NCT05089045|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
215162813|NCT04941482|BEHAVIORAL|Periodic health check program for post-stroke|The stroke survivors were assessed for their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months using specific scales.
215162814|NCT04941482|BEHAVIORAL|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises were designed and guided for each patient, and they were followed up by the daily online report.
215162815|NCT04941482|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
215162816|NCT04941482|DEVICE|Functional near-infrared spectroscopy|The fNIRS devices served as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measurement by fNIRS could detect various mental disorders such as depression, anxiety, schizophrenia early through cognitive tasks.
215162817|NCT04132414|DIAGNOSTIC_TEST|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
214555664|NCT04341129|DRUG|Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)|To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
214555665|NCT03377686|DIAGNOSTIC_TEST|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
214555666|NCT05446753|DIETARY_SUPPLEMENT|Animal-based meats|Animal-based meats from beef, pork and chicken
214555667|NCT05446753|DIETARY_SUPPLEMENT|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
214555668|NCT04419233|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
214555669|NCT00806481|DRUG|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
214555670|NCT00806481|DRUG|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
214555671|NCT04549818|DEVICE|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
214555672|NCT04553055|OTHER|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
214555673|NCT03678090|DRUG|tPA standard dosage|Tissue plasminogen activator 25mg dosage
214555674|NCT03678090|DRUG|tPA low dosage|Tissue plasminogen activator 2.5mg
214555675|NCT05946720|OTHER|Training including aggression and the use of BVC.|After obtaining verbal consent from the nurses who met the inclusion criteria of the study before the pre-test was applied to the nurses, the nurses who volunteered to participate in the study were randomized within their own clinic using the simple randomization method. For this, after the data collection form was distributed before the pre-test, the nurses were asked to write the letter that came to them on the data collection form and not forget it. In order for nurses to be included in the training or comparison group, the letter A, written on the closed papers in the box prepared for simple randomization, represents the Education group, and the letter B represents the comparison group.
214555676|NCT06128096|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."
214703847|NCT00759746|BEHAVIORAL|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
214703848|NCT05364983|DEVICE|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
214703849|NCT05364983|DEVICE|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
214703850|NCT03398733|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
214703851|NCT01148563|DEVICE|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
214703852|NCT00442676|DRUG|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
214703853|NCT00442676|DRUG|Placebo|Gelatin capsules of lactose
214703854|NCT05240638|DEVICE|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
214703855|NCT01879319|BIOLOGICAL|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
214703856|NCT01879319|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
214703857|NCT00854256|PROCEDURE|Canaloplasty|Canaloplasty surgery
214703858|NCT00854256|PROCEDURE|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
214703859|NCT02611063|DRUG|fostamatinib|100mg qd, 150mg qd, or 100mg bid
214555677|NCT04301895|BEHAVIORAL|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
214555678|NCT04301895|DRUG|Remifentanil infusion|10 minute remifentanil infusion
214555679|NCT03335436|DRUG|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
214555680|NCT03335436|DRUG|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
214703860|NCT06119451|BEHAVIORAL|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
214703861|NCT04392336|OTHER|Trust/Respect feedback|This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
214703862|NCT01500018|DRUG|TC-5214|Single oral dose of 2 mg
214703863|NCT01500018|DRUG|TC-5214 Placebo|Single oral dose
214703864|NCT01500018|DRUG|Ketamine|Single oral dose of 100 mg
214703865|NCT01500018|DRUG|Phentermine|Single oral dose of 45 mg
214555681|NCT02627118|DEVICE|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
214555682|NCT02627118|DEVICE|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
214703866|NCT01500018|DRUG|TC-5214|Single oral dose of 8 mg
214703867|NCT01500018|DRUG|TC-5214|Single oral dose of 16 mg
214703868|NCT01500018|DRUG|Phentermine|Single oral dose of 90 mg
214703869|NCT03985748|DEVICE|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
214703870|NCT03985748|DEVICE|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
214703871|NCT00740324|DRUG|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
214703872|NCT00740324|DRUG|NPO-11|NPO-11 after administration of NPO-11
214703873|NCT00740324|DRUG|NPO-11|1 mg glucagons after administration of NPO-11
214703874|NCT05262582|PROCEDURE|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
214555683|NCT03965715|DEVICE|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
214703875|NCT05262582|PROCEDURE|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
214703876|NCT02327221|DRUG|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
215162818|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
214555684|NCT03133832|DRUG|Companion Tablet|Chinese-made drug for schistosomiasis treatment
214555685|NCT06306469|OTHER|Meditation practice|physical and breathing exercises
214555686|NCT03274973|DRUG|Zomacton|Injection
214555687|NCT06457243|DEVICE|Closed-loop cTBS stimulation based on addiction induced states|We conducted a longitudinal controlled study of closed-loop cTBS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed loop cTBS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
214555688|NCT06068764|DRUG|Etomidate|The type of general anesthesia induction agent for CABG surgery
214555689|NCT06068764|DRUG|Propofol|The type of general anesthesia induction agent for CABG surgery
214555690|NCT06117553|PROCEDURE|thorough flushing|The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
214555691|NCT04385706|BEHAVIORAL|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
214555692|NCT02126852|DEVICE|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
214555693|NCT02126852|DEVICE|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
214703877|NCT02327221|DRUG|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
214703878|NCT05865873|BEHAVIORAL|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
214703879|NCT00101621|DRUG|M40403|
214703880|NCT03146221|OTHER|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
214703881|NCT00250991|DRUG|activase|
214703882|NCT00250991|DRUG|integrilin|
214703883|NCT01756872|PROCEDURE|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
214703884|NCT05191355|BIOLOGICAL|blood test|Blood spot collection for sampling
214555694|NCT02126852|DEVICE|Electromyography (EMG)|Neuromuscular monitoring
214555695|NCT03900910|OTHER|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
214555696|NCT03900910|OTHER|Execution of the program|Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
214555697|NCT04212351|GENETIC|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
214555698|NCT01572740|DRUG|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
214703885|NCT03155633|OTHER|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
214703886|NCT03155633|OTHER|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
214703887|NCT04496648|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
214703888|NCT04496648|PROCEDURE|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
214703889|NCT06122987|DRUG|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
214703890|NCT05308615|DIETARY_SUPPLEMENT|Rhea® Health Tone|Rhea® Health Tone
214703891|NCT04103398|COMBINATION_PRODUCT|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
214709028|NCT01583452|OTHER|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
214555699|NCT01572740|DRUG|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
214555700|NCT01572740|DRUG|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
214555701|NCT01289210|DRUG|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
214555702|NCT01224834|DRUG|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
214703892|NCT04103398|PROCEDURE|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
214703893|NCT03302208|DRUG|Pregabalin|Pregabalin capsule 150 mg oral
214703894|NCT03302208|DRUG|Placebo|Placebo
214703895|NCT00794014|PROCEDURE|Conservative strategy|"* Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup."
214703896|NCT00794014|PROCEDURE|Aggressive strategy|"* Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup."
214703897|NCT00003157|DRUG|cisplatin|
214703898|NCT00003157|DRUG|gemcitabine hydrochloride|
214703899|NCT00003157|RADIATION|radiation therapy|
214703900|NCT03688945|PROCEDURE|Art Therapy|Attend art viewing sessions
214703901|NCT03688945|OTHER|Best Practice|Receive standard of care
214703902|NCT03688945|OTHER|Questionnaire Administration|Ancillary studies
214703903|NCT02617017|DRUG|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
214703904|NCT02617017|DRUG|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
214703905|NCT03886701|DRUG|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
214703906|NCT03886701|DRUG|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
214703907|NCT03886701|DRUG|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
214703908|NCT00846261|DEVICE|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
214703909|NCT03611322|DRUG|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
214703910|NCT03611322|DRUG|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
214703911|NCT03611322|DRUG|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
214703912|NCT03611322|DEVICE|DV3372|DV3372 device will be used for administration of semaglutide
214703913|NCT03611322|DEVICE|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
214703914|NCT05562024|BIOLOGICAL|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
214703915|NCT05225220|DEVICE|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
214703916|NCT03593863|BEHAVIORAL|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
214703917|NCT02670330|DRUG|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
214555703|NCT03952091|DRUG|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
214555704|NCT03952091|DRUG|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
214703918|NCT01689376|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
215029771|NCT05562856|COMBINATION_PRODUCT|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
214555705|NCT05837377|OTHER|Control- standard medication education|"Common Procedure:~\- Student Information and Consent Form will be obtained from the students.~For the control group~* Theoretical training in drug administration skills is provided.~* Skill training: Skill training on intramuscular and subcutaneous injection and intravenous medication administration using task trainers in the simulation laboratory.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
214555706|NCT05837377|OTHER|Experiment- cognitive load theory based on medication education|"For the experiment group~* Theoretical training will be provided based on the results of both the knowledge test and the self-efficacy test, and will be designed according to the principles of cognitive load theory.~* Skills training: includes the necessary skill applications for students with task trainers and a virtual simulation designed according to the cognitive load theory for these skills.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
214555707|NCT00137969|DRUG|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
214555708|NCT00137969|DRUG|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
214555709|NCT00137969|DRUG|Prednisone|
214555710|NCT00137969|DRUG|Acetaminophen|
214555711|NCT00137969|DRUG|Diphenhydramine|
214555712|NCT02391142|DRUG|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
214555713|NCT01110408|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
214555714|NCT01110408|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
214703919|NCT01766882|BEHAVIORAL|Lower sodium intervention|"1\. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
214555715|NCT01110408|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
214555716|NCT01110408|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
214555717|NCT01110408|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
214555718|NCT03242902|DEVICE|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
214555719|NCT03242902|DEVICE|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
214703920|NCT01766882|OTHER|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
214703921|NCT04065087|BIOLOGICAL|GX-I7|Investigational drug
214703922|NCT04065087|OTHER|Placebo|Placebo drug
215162819|NCT04061720|BEHAVIORAL|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
214703923|NCT03359694|DRUG|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
214555720|NCT02534571|DEVICE|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once
214555721|NCT02534571|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
214555722|NCT02534571|DRUG|Epinephrine|epinephrine injection endoscopically \<20 mls
214555723|NCT02534571|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 4 pulses
214555724|NCT05733182|DEVICE|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
214555725|NCT05733182|DEVICE|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
214555726|NCT05733182|DEVICE|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
214555727|NCT03944590|OTHER|patient survey|patient survey on clinical outcome after screw osteosynthesis of radial head fractures
214555728|NCT03944590|OTHER|analysis of radiographs|analysis of radiographs on radiological outcome after screw osteosynthesis of radial head fractures
214555729|NCT04982770|OTHER|Survey|Reading of ethical guidelines.
214555730|NCT03364075|DRUG|Duloxetine|30 mg for seven days, then increased to 60 mg for seven days
214555731|NCT03364075|DRUG|Propranolol|40 mg for seven days, then increase to 60 mg for seven days
214555732|NCT03364075|GENETIC|Genotype for SNPs associated to Serotonin and COMT|DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
214555733|NCT03364075|DRUG|Placebo Treatment|1 capsule BID for two weeks
214703924|NCT03359694|DRUG|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
214555734|NCT01387191|DRUG|Epoprostenol|
214555735|NCT05433649|BEHAVIORAL|Therapeutic exercise|The therapeutic exercise intervention with the help of elastic bands was carried out for 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration.
214555736|NCT03872245|BIOLOGICAL|Probiotics|The patients will receive Adomelle 1caps/12h during 10 weeks
214555737|NCT03872245|PROCEDURE|PENS T6|The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
214555738|NCT00798291|OTHER|Ad lib diet and Control placebo|one packet with water two times a day
214555739|NCT00798291|OTHER|Ad lib diet and An 777|one packet with water two times a day
214555740|NCT00798291|OTHER|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
214555741|NCT00798291|OTHER|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
214555742|NCT02269423|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
214555743|NCT02269423|OTHER|Placebo|Normal saline placebo.
214555744|NCT02169570|DIETARY_SUPPLEMENT|Vitamin D|
214555745|NCT02169570|DIETARY_SUPPLEMENT|Calcium|
214555746|NCT02169570|DIETARY_SUPPLEMENT|Placebo Vit D|
214703925|NCT03359694|DRUG|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
214555747|NCT02169570|DIETARY_SUPPLEMENT|Placebo Calcium|
214555748|NCT00304759|PROCEDURE|7800 cGy/39 fractions in 8 weeks|see above
214703926|NCT00032994|BEHAVIORAL|Behavior Therapy|
214555749|NCT00304759|PROCEDURE|6000 cGy/20 fractions in 4 weeks|see above
214703927|NCT03111017|OTHER|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
215162820|NCT04061720|BEHAVIORAL|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
215162821|NCT00713492|DRUG|Alcohol|human laboratory alcohol consumption.
215162822|NCT05554406|DRUG|Azacitidine|Given SC or IV
214555750|NCT03399253|PROCEDURE|surgery|D2 gastrectomy + metastasectomy
214555751|NCT03399253|DRUG|chemotherapy|capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
214555752|NCT00002277|DRUG|Fluconazole|
214555753|NCT00002277|DRUG|Amphotericin B|
214703928|NCT04156828|DRUG|Copanlisib|Given IV
214703929|NCT04156828|DRUG|Gemcitabine|Given IV
214703930|NCT04156828|DRUG|Carboplatin|Given IV
215162823|NCT05554406|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215162824|NCT05554406|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215162825|NCT05554406|DRUG|Cytarabine|Given IV
214555754|NCT03452865|DRUG|Esomeprazole|"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."
214555755|NCT03452865|DRUG|Placebo|0.9% sodium chloride (same ml of the study drug)
214555756|NCT03774147|DEVICE|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
214555757|NCT03854357|PROCEDURE|Subscapularis Rehabilitation|Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.
214555758|NCT03854357|PROCEDURE|Standard Rehabilitation|Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
214555759|NCT02481570|OTHER|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
214555760|NCT05994638|DIETARY_SUPPLEMENT|Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)|Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
214555761|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
214555762|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
214555763|NCT05442684|BIOLOGICAL|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
214555764|NCT03530137|BEHAVIORAL|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
214555765|NCT03530137|BEHAVIORAL|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
214703931|NCT04156828|DRUG|Dexamethasone|Given PO
214703932|NCT04156828|BIOLOGICAL|Rituximab|Given IV
214703933|NCT04156828|BIOLOGICAL|Pegfilgrastim|Given SC
214703934|NCT04324918|DRUG|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
214703935|NCT04324918|DRUG|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
214703936|NCT03216083|DRUG|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
214703937|NCT03216083|OTHER|Placebo|67mL IV normal saline
214703938|NCT05152277|DRUG|HRS9531|Administered SC once
215162826|NCT05554406|DRUG|Daunorubicin Hydrochloride|Given IV
214555766|NCT03530137|BEHAVIORAL|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
214555767|NCT00839956|DRUG|Bortezomib|Given IV
214555768|NCT00839956|DRUG|Vorinostat|Given PO
214555769|NCT01509547|DRUG|Varenicline|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
214555770|NCT01509547|DRUG|placebo|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
214555771|NCT02544165|DIETARY_SUPPLEMENT|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214555772|NCT02544165|OTHER|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214555773|NCT02544165|OTHER|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214555774|NCT06022341|OTHER|Multiomic characterization|Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
214555775|NCT06022341|OTHER|In vitro drug screening|The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
214555776|NCT01686737|BEHAVIORAL|Iyengar Yoga|"* 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes"
214555777|NCT01686737|BEHAVIORAL|Walking|"* 12 weeks of walking~* 2 weekly sessions of 60 minutes"
214555778|NCT00277095|DEVICE|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
214555779|NCT03016351|OTHER|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
214555780|NCT03016351|OTHER|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
214555781|NCT04608838|BIOLOGICAL|JTR-161|JTR-161 (1 or 3 × 10\^8 cells/subject) will be suspended and administered in an intravenously infusion.
214555782|NCT04608838|BIOLOGICAL|Placebo|Placebo will be suspended and administered in an intravenously infusion.
214555783|NCT03432741|DRUG|Belinostat|Given intralesionally
214555784|NCT03432741|DRUG|Carfilzomib|Given intralesionally
214555785|NCT03432741|DRUG|Copanlisib Hydrochloride|Given intralesionally
214555786|NCT03432741|BIOLOGICAL|Daratumumab|Given intralesionally
214555787|NCT03432741|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET
214555788|NCT03432741|DRUG|Gemcitabine Hydrochloride|Given intralesionally
214555789|NCT03432741|OTHER|Laboratory Biomarker Analysis|Correlative studies
214555790|NCT03432741|BIOLOGICAL|Nivolumab|Given intralesionally
214555791|NCT03432741|BIOLOGICAL|Obinutuzumab|Given intralesionally
214555792|NCT03432741|BIOLOGICAL|Pembrolizumab|Given intralesionally
214555793|NCT03432741|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
214555794|NCT03432741|BIOLOGICAL|Rituximab|Given intralesionally
215162827|NCT05554406|PROCEDURE|Echocardiography Test|Undergo ECHO
215162828|NCT05554406|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215162829|NCT05554406|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214555795|NCT03432741|DRUG|Romidepsin|Given intralesionally
215162830|NCT05554406|DRUG|Venetoclax|Given PO
215162831|NCT05740540|DEVICE|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
214555796|NCT03432741|OTHER|Saline|Given intralesionally
214555797|NCT03432741|BIOLOGICAL|Trastuzumab|Given intralesionally
214555798|NCT04601636|DEVICE|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
214555799|NCT04601636|OTHER|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
214555800|NCT04925869|OTHER|Observational study|Observational study
214703939|NCT05152277|OTHER|placebo|Administered SC once
214703940|NCT05152277|DRUG|HRS9531|Administered SC for multiple dose
214703941|NCT05152277|OTHER|placebo|Administered SC for multiple dose
214703942|NCT05412537|OTHER|MI|How to motivate people
214703943|NCT05412537|OTHER|CAU|consult as usual
214555801|NCT06423651|BEHAVIORAL|Cognitive Remediation (REHACOP)|REHACOP is a structured neuropsychological rehabilitation program that covers most of the cognitive deficits present in psychotic disorder: attention, learning and memory, executive functions, language, social cognition, daily life activities, social skills and psychoeducation. The modules of language, social cognition and psychoeducation will not be used in the present clinical trial. Each module includes a hierarchy of exercises based on the cognitive subarea to be worked on and the grade of difficulty demanded for the performance of each task.The format of the sessions will be the same as MCT, that is, groups of 6-10 patients who will receive weekly sessions of 45-60 minutes in length. In this case, the duration of the intervention will be 12 sessions.
214555802|NCT06423651|BEHAVIORAL|Metacognitive Training (MCT)|The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.
214555803|NCT04036851|BEHAVIORAL|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
214555804|NCT03745547|OTHER|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
214555805|NCT03538782|PROCEDURE|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
214555806|NCT05586412|DEVICE|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
214555807|NCT03007797|BEHAVIORAL|vaccination rate for influenza|
214555808|NCT04147195|DRUG|LYS006|5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
214555809|NCT04147195|DRUG|Tropifexor|100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
214555810|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
214555811|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
214555812|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
214555813|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
214555814|NCT06421831|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
214703944|NCT00218790|PROCEDURE|Cool Dialysate|Decreased temperature of the dialysis bath
214703945|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|patient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
215162832|NCT05740540|DEVICE|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
215162833|NCT06049654|DEVICE|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
215162834|NCT06049654|DEVICE|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
215162835|NCT02509442|PROCEDURE|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
215162836|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
214555815|NCT06937255|DIAGNOSTIC_TEST|computerized Dynamic Assessment|The DA tests (with a duration of about 30 minutes) can be administered by accessing the digital platform MuLiMi, individually with the experimenter or examiner. The tests are in game form and require children to learn the names of characters presented in the context of stories (preschool version) or to learn new codes for reading and writing (primary school version). In both cases, the new materials (names or codes) are repeatedly presented to the child until (s)he reaches an accuracy threshold. The number of repetitions needed to reach the threshold constitutes the main measure of the child's learning capacity, together with the number of errors committed during the various cycles.
214555816|NCT05899413|DEVICE|Transcutaneous vagal nerve stimulation|The intervention consists of neurostimulation device that is programmed to a stimulus intensity at 0.5mA with a stimulation frequency of 25 Hz at the outer auditory canal.
214555817|NCT06939686|DEVICE|Miro3D Wound Matrix|Miro3D is a sterile, acellular, three-dimensional biologic wound matrix derived from porcine liver via perfusion decellularization and drying. It is trimmed to fit the wound and rehydrated with sterile saline or Lactated Ringer's solution before application. It provides a porous scaffold to support granulation and healing in chronic or post-surgical wounds.
214555818|NCT06939686|OTHER|Standard of Care (SOC)|SOC includes standard wound care practices such as wound cleansing, debridement, infection management (if applicable), use of protective dressings (e.g., Aquacel or foam covered with Adaptic), and offloading devices (e.g., Foot Defender boot) to relieve pressure on the wound.
214555819|NCT01555489|DRUG|Ascorbic Acid|3x per week
214555820|NCT01857375|DEVICE|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
214555821|NCT01824927|PROCEDURE|First eye (FE)|Phacoemulsification cataract extraction surgery
214555822|NCT01824927|PROCEDURE|Second eye (SE)|Phacoemulsification cataract extraction surgery
214555823|NCT01824927|DRUG|Steroids eye drops|Use steroids eye drops to decrease the pain.
214555824|NCT01006980|DRUG|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
214555825|NCT01006980|DRUG|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
214555826|NCT00527358|BEHAVIORAL|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
214555827|NCT05445453|OTHER|Museum visit|"The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient."
214555828|NCT00107094|DRUG|Abraxane|
214555829|NCT05193903|BEHAVIORAL|Simulation|The participants in the intervention group receive two interactive simulations in addition to a general text module that provides sequential, animated information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.
214555830|NCT05193903|BEHAVIORAL|Text|"The participants in the control group receive two text-based information in addition to a general text module that provides information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.~Both conditions ensure the provision of a level of knowledge that at least corresponds to standard care."
214555831|NCT02666144|DEVICE|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
214555832|NCT01287325|DRUG|DNK333 100 mg twice daily|
214555833|NCT01287325|DRUG|Placebo|
214555834|NCT05909826|DRUG|Carfilzomib|70 mg/m2 IV days 1, 8 and 15, every 4 weeks
214555835|NCT05909826|DRUG|Cyclophosphamide|50 mg PO days 1 to 21, every 4 weeks
214555836|NCT05909826|DRUG|Dexamethasone|40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
215162837|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
215162838|NCT05237401|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|participants will receive local anaesthesia, then thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes.
214555837|NCT03076073|OTHER|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
214555838|NCT04020315|PROCEDURE|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
214555839|NCT02566057|BIOLOGICAL|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
214555840|NCT03312023|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
214555841|NCT03312023|DRUG|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
214555842|NCT03312023|DRUG|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
214555843|NCT04263168|DIAGNOSTIC_TEST|Continuous Glucose monitoring in the perioperative period|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
214555844|NCT02706405|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
214555845|NCT02706405|DRUG|Cyclophosphamide|Given IV
214555846|NCT02706405|BIOLOGICAL|Durvalumab|Given IV
214555847|NCT02706405|DRUG|Fludarabine|Given IV
214555848|NCT04447105|DRUG|total intravenous anesthesia with propofol|In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
214555849|NCT04447105|DRUG|inhalation anesthesia with desflurane|In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
214555850|NCT01228318|DRUG|Zoledronic acid|"1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
214555851|NCT02886039|OTHER|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
214555852|NCT00225238|DRUG|esomeprazole (PPI)|
214555853|NCT03085823|DEVICE|Sirolimus Coated Balloon|
214555854|NCT03011567|DRUG|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
214555855|NCT03011567|DRUG|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
214555856|NCT00876824|DRUG|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
214555857|NCT00876824|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
214555858|NCT05753436|DIETARY_SUPPLEMENT|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
214555859|NCT01182441|DEVICE|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
214555860|NCT01182441|DRUG|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
214555861|NCT03473600|PROCEDURE|Cryotherapy|Liquid Nitrogen spray
214555862|NCT03473600|DRUG|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
214555863|NCT00362245|DRUG|Systemic and Intra-Thecal Amikacin Therapy|
214555864|NCT04329637|OTHER|Integrative healt care|Meditation and use of a care cordinator
214555865|NCT05931029|DRUG|Idebenone|The control group took Idebenone orally for 12 weeks.
214555866|NCT05931029|DRUG|Naohuan Dan and Idebenone|The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
214555867|NCT00146731|DRUG|SP|
214555868|NCT00146731|DRUG|SP + amodiaquine|
214555869|NCT00146731|DRUG|AQ + artesunate|
214555870|NCT00146731|DRUG|chlorproguanil-dapsone|
214555871|NCT06427421|BIOLOGICAL|Frequency of Treg and Teffs|additionnal blood sampling at inclusion
214555872|NCT06427421|BIOLOGICAL|Phenotype of Treg and Teffs|additionnal blood sampling at inclusion
214555873|NCT06427421|BIOLOGICAL|RNA seq analysis|additionnal blood sampling at inclusion
214555874|NCT06427421|BIOLOGICAL|HLA typing|additionnal blood sampling at inclusion
214555875|NCT06427421|BIOLOGICAL|beta-cell autoantibody dosage|additionnal blood sampling at inclusion
214703946|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|peripheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
214555876|NCT06427421|BIOLOGICAL|Glycated haemoglobin (HbA1C) dosage|additionnal blood sampling at inclusion
214555877|NCT06427421|BIOLOGICAL|blood glucose dosage|additionnal blood sampling at inclusion
214555878|NCT06427421|BIOLOGICAL|C-peptide dosage|additionnal blood sampling at inclusion
214555879|NCT03357419|DRUG|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
214555880|NCT03357419|DRUG|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
214555881|NCT05673031|DIAGNOSTIC_TEST|68Ga-HA-DOTATATE PET/CT imaging|"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."
215029772|NCT03283956|DEVICE|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
215029773|NCT05611164|DEVICE|Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection|Half of the oocytes will be injected with a sperm selected with SiD's assistance
215029774|NCT04221438|DRUG|Binimetinib|Given PO
215029775|NCT04221438|PROCEDURE|Conventional Surgery|Undergo surgery
215029776|NCT04221438|DRUG|Encorafenib|Given PO
215029777|NCT04221438|OTHER|Fluorothymidine F-18|Given IV
215029778|NCT06325410|PROCEDURE|resection of colorectal cancer|resection of bowel segment and re-anastmosis or stoma formation
215029779|NCT00855101|DRUG|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
214555882|NCT06446687|PROCEDURE|Dental implant with sinus lifting.|Surgery will be performed under local infiltration anaesthesia. Flap will be done. For maxillary sinus lifting by using Crestal approach with Membrane Control Technique by Wang (Wang, 2017) will be employed. After reflecting on the flap, Magic Split will be used to confirm bone quality clinically. This will be followed by site preparation using Magic Marking Drill. Bone drilling will then be performed by Magic Drill shorter by 2 mm from the sinus floor. This will be followed by sinus lifting by using Magic Sinus Lifter (MSL). The 3mm space of the apex of the Sinus Lifter instrument enables direct control of the bone-block and consequently the membrane, which is connected to the bone-block. the fixture will be installed in the conventional method. Then cover the fixture with the cover screw. The flap will be sutured. An immediate CBCT will be requested to ensure the implant is in its proper position.
214555883|NCT03459872|PROCEDURE|Acupuncture|Alternative medicine therapeutic intervention
214555884|NCT03459872|DEVICE|RU-Fit|FDA approved medical device for the measurement of fine motor control
214555885|NCT02672943|BEHAVIORAL|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
214555886|NCT02672943|OTHER|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
214555887|NCT04717453|OTHER|No Intervention|No Intervention
214555888|NCT03171662|OTHER|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
214555889|NCT02950597|DEVICE|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
214555890|NCT03950752|COMBINATION_PRODUCT|Optimized Bagel|Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
214555891|NCT03950752|COMBINATION_PRODUCT|Conventional Bagel|Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
214555892|NCT04508855|DRUG|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
214555893|NCT03568773|OTHER|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (\> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
214555894|NCT03568773|OTHER|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, \<threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
214555895|NCT03568773|OTHER|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
214555896|NCT04498637|OTHER|'Attitudes towards people with disability Scale'|The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
214703947|NCT05497895|BIOLOGICAL|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
214703948|NCT05497895|BIOLOGICAL|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
214703949|NCT05497895|PROCEDURE|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
214703950|NCT04031053|OTHER|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
215162839|NCT05237401|PROCEDURE|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|Patients will receive local anaesthesia and intrasulcular incisions will be made on the buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using diamond coated inserts, sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Osteoplasty (removal of non-supporting bone) may be carried out, as judged by the operator. The surgical site will be closed with resorbable or non-resorbable sutures.
215162840|NCT00434265|BEHAVIORAL|Physical training|
215162841|NCT05864807|DEVICE|UCon|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
215162842|NCT05002335|DEVICE|Medacta Shoulder System|Performance of Total Shoulder Arthroplasty (anatomic/reverse) with Medacta Shoulder System
215162843|NCT05920122|DRUG|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
214703951|NCT01226212|DIETARY_SUPPLEMENT|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
214703952|NCT01226212|DIETARY_SUPPLEMENT|Placebo|maltodextrose
214703953|NCT00959530|PROCEDURE|lingualized occlusion|occlusal surface arranged by lingualized occlusion
214703954|NCT00959530|PROCEDURE|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
214703955|NCT01868776|DRUG|buffered lidocaine|
214555897|NCT04361955|OTHER|EMG|recordings of muscle electrical activity during nerve stimulation using EMG
214555898|NCT04361955|OTHER|EEG|recordings of brain activity using EEG
214555899|NCT04462783|OTHER|Symptoms entered into the CovidX application|Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
214555900|NCT04782440|OTHER|Telerehabilitaton|Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
214555901|NCT04782440|OTHER|Home exercise|Patients will be given a home-based exercise program without telerehabilitation supervision
214703956|NCT01868776|DRUG|nonbuffered lidocaine|
214703957|NCT00160394|DRUG|Duac® Gel / Differin® Gel|
214703958|NCT01797991|DRUG|Dexamethasone per os|
214703959|NCT01797991|DRUG|Matching placebo for dexamethasone IV|
214703960|NCT01797991|DRUG|Dexamethasone IV|
214703961|NCT01797991|DRUG|Matching placebo for dexamethasone per os|
214703962|NCT00091936|DRUG|Didanosine|
214703963|NCT00091936|DRUG|Efavirenz|
214703964|NCT00091936|DRUG|Lamivudine|
214703965|NCT00091936|DRUG|Standard TB treatment|
214703966|NCT02615067|DRUG|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
214555902|NCT01395459|BEHAVIORAL|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
214555903|NCT01395459|BEHAVIORAL|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
214555904|NCT02124811|DRUG|Minocycline|
214555905|NCT04043143|OTHER|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
214555906|NCT04043143|OTHER|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
214555907|NCT03480932|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
214555908|NCT03480932|DRUG|Daclatasvir|Direct acting antiviral agent used for the treatment of hepatitis C
214555909|NCT03480932|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
214555910|NCT00254826|BIOLOGICAL|YF-VAX® plus saline|YF-VAX® plus saine
214555911|NCT00254826|BIOLOGICAL|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
214703967|NCT02615067|DIAGNOSTIC_TEST|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
214703968|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|DDD+/-R pacing
214703969|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|ODO pacing
214703970|NCT01481168|DEVICE|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
214703971|NCT05399550|DRUG|Balovaptan|Intravenous Solution
214703972|NCT05399550|DRUG|Placebo|Matching Intravenous Solution
214703973|NCT04278508|DRUG|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
214703974|NCT05534035|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
214703975|NCT05534035|BIOLOGICAL|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
214703976|NCT03805581|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
215029780|NCT05007704|BEHAVIORAL|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
215029781|NCT06459778|DEVICE|Piezo-ICSI|Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
215029782|NCT01441492|PROCEDURE|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
215029783|NCT01441492|PROCEDURE|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
215029784|NCT03510533|OTHER|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
215029785|NCT01019915|DEVICE|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
215029786|NCT06250257|DRUG|Bromocriptine mesylate plus standard GDMT|The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
215029787|NCT05049824|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
215029788|NCT06150742|DEVICE|Niyad (nafamostat mesylate)|Niyad (nafamostat mesylate) lyophilized
215029789|NCT06150742|DEVICE|Placebo (0.9% NaCl)|0.9% NaCl
214555912|NCT06134999|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
214555913|NCT06134999|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
214555914|NCT05757076|PROCEDURE|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
214555915|NCT03178149|DRUG|ASP7317|subretinal injection
214555916|NCT03178149|DRUG|tacrolimus|oral
214555917|NCT03178149|DRUG|trimethoprim-sulfamethoxazole|oral
214555918|NCT03178149|DRUG|Acyclovir|oral
214555919|NCT03178149|DRUG|Nystatin|oral
214555920|NCT05608668|DEVICE|Pro2 - 60% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
214555921|NCT05608668|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
214555922|NCT06484829|DRUG|Purinostat Mesylate 4 mg/m2|4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
214555923|NCT06484829|DRUG|Purinostat Mesylate 6 mg/m2|6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
214555924|NCT06484829|DRUG|Purinostat Mesylate 8.4 mg/m2|8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
214555925|NCT06840106|PROCEDURE|Nasal steam therapy|Nasal steam therapy is performed once a every other day for a total of 3three times. The steam inhalation stimulates the acupoints of bilateral LI20, EX-HN8, and EX-HN9
215029790|NCT05427201|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
214555926|NCT06840106|PROCEDURE|Routine management strategy|Depending on the patient's symptoms and degree of improvement, the clinician may utilize all drugs currently used in clinical practice to improve upper respiratory symptoms, if necessary. All drugs that fall under the Anatomical Therapeutic Chemical Classification System (ATC) codes of non-disease treatment (R01), throat disease treatment (R02), lung disease or expectorant (R03, R05), and other respiratory organ drugs (R06, R07) and other drugs. The usage and dosage should be within the range of the current clinical guidelines.
214555927|NCT06374849|OTHER|phone interview|Patient's phone interview 3 months after operating room discharge. The interview consisting of 3 questionnaires to detect the presence of CPSP, its intensity, its characteristics and its related analgesic consumption.
214555928|NCT05504954|BEHAVIORAL|IMARA-SA (intervention group)|The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
214555929|NCT05504954|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
214555930|NCT02601118|OTHER|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
214555931|NCT01896427|DRUG|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
215029791|NCT05427201|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
215029792|NCT04147286|DRUG|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
215029793|NCT04147286|DRUG|Placebo oral tablet|Identical placebo
215029794|NCT04275518|DRUG|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
215029795|NCT04275518|DRUG|Azacitidine|75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
215029796|NCT04275518|DRUG|Cytarabine|1g/m\^2 IV QD on Days 3-7 (28-day cycle)
214703977|NCT04894812|OTHER|Neurodevelopmental technique|"1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
214703978|NCT02268006|RADIATION|IMRT-SIB|
214703979|NCT02268006|DRUG|Capecitabine|
214703980|NCT02268006|PROCEDURE|Surgery|
214703981|NCT05242445|DRUG|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
214703982|NCT05242445|DRUG|Placebo|Placebo will be administered via SC injection or as an IV infusion.
214703983|NCT04404010|OTHER|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
214703984|NCT04404010|OTHER|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
214703985|NCT05414305|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
214703986|NCT00133835|PROCEDURE|Extracorporeal shock wave lithotripsy|
214703987|NCT00133835|PROCEDURE|Endoscopic drainage of the main pancreatic duct|
214555932|NCT03043703|DEVICE|AirSense 10 AutoSet for Her|Positive airway pressure
214555933|NCT01634386|DRUG|Torrent's Quetiapine Fumarate Tablets|
214555934|NCT02724852|BIOLOGICAL|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
214703988|NCT02120157|DRUG|Cyclophosphamide|Chemotherapy administration
214703989|NCT02120157|RADIATION|TBI|Radiation Therapy
214555935|NCT01796626|DEVICE|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
214703990|NCT02120157|DRUG|Busulfan|Chemotherapy Administered
214703991|NCT02120157|OTHER|Unmanipulated Bone Marrow|Bone Marrow Transplant
214703992|NCT02120157|DRUG|Tacrolimus|Immunosuppressive Drug Administered
214703993|NCT02120157|DRUG|Mycophenolate mofetil|Immunosuppressive Drug Administered
214703994|NCT05970744|BIOLOGICAL|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
214703995|NCT05970744|BIOLOGICAL|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
215162844|NCT05920122|DRUG|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
215162845|NCT03722303|OTHER|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
214555936|NCT06329258|DRUG|Enstilar|Add on Enstilar
214555937|NCT06329258|DRUG|Deucravacitinib|6mg QD
214555938|NCT05310422|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
214555939|NCT05310422|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
214555940|NCT02154880|PROCEDURE|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
214555941|NCT02154880|PROCEDURE|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
214555942|NCT02154880|PROCEDURE|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
214555943|NCT02154880|OTHER|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
214555944|NCT03405675|OTHER|SLAS 1|NA. Observational study, no interventions administered.
214703996|NCT05970744|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of Placebo
214555945|NCT03405675|OTHER|SLAS 2|NA. Observational study, no interventions administered.
214555946|NCT06245408|DRUG|Dazodalibep|IV infusion
214555947|NCT06245408|DRUG|Placebo|IV infusion
214555948|NCT00285701|DRUG|hexaminolevulinate|
214703997|NCT02195817|DRUG|Selincro® 18 mg with continuous psychosocial support: Cohort A|
214703998|NCT02195817|OTHER|Initial psychosocial support: Cohort B|
214703999|NCT04368455|BEHAVIORAL|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
215162846|NCT03722303|DRUG|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
214555949|NCT06317532|OTHER|Lifestyle modification advice|All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.
214555950|NCT06317532|OTHER|Functional exercises|Each female in group (B) will perform the exercise program three times a week for eight weeks at the University Women's Health Unit Exercise protocols mainly consist of relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga, and Pilates
214555951|NCT02911233|BIOLOGICAL|Thromboelastograpgy|
214555952|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
214555953|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
214555954|NCT02138786|DRUG|selinexor|"* 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~* 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0)."
214555955|NCT02308397|OTHER|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
214555956|NCT02308397|OTHER|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
214555957|NCT02308397|OTHER|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
214555958|NCT02308397|OTHER|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
214555959|NCT06460792|PROCEDURE|Ultrasound-guided peripheral nerve block|Ultrasound-guided peripheral nerve blocks. Registration of quality, complications and learning as detailed in the description
214555960|NCT01979406|BIOLOGICAL|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
214555961|NCT01979406|BIOLOGICAL|Ad4-PA-1|Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
214555962|NCT01979406|BIOLOGICAL|Ad4-PA-GPI-1|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
214555963|NCT02029963|DEVICE|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
214555964|NCT02029963|BEHAVIORAL|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
214555965|NCT04440020|OTHER|Beverage of Olive Oil Leaves|Beverage of Olive Oil Leaves,Oleuropein
214555966|NCT04440020|OTHER|Mediterranean Diet|Mediterranean Diet ,for a personal nutrition with the same dietary habits
214555967|NCT01523067|DRUG|Vasomera (PB1046)|Single dose of Vasomera
215162847|NCT05180448|BEHAVIORAL|Coach Share On|If an index participant is randomized to have Coach Share ON, the coach will have continuous access to objective, real-time, detailed device data, and address data directly in all individual interactions with index participants (groups, individual weigh-ins, phone calls, texts), conveying that they are closely monitoring progress.
214555968|NCT01523067|DRUG|0.9% Sodium Chloride|Placebo injection
214555969|NCT03078335|OTHER|Glove based care|Described in Experimental Arm: Glove based care
214555970|NCT03078335|OTHER|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
214555971|NCT03251053|DEVICE|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
214555972|NCT03251053|OTHER|Control regular cigarette smokers|
214555973|NCT04862442|OTHER|Qigong exercises|Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
214704000|NCT04368455|BEHAVIORAL|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
214555974|NCT04030871|DEVICE|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
214555975|NCT04030871|DEVICE|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
214555976|NCT06147297|BEHAVIORAL|Tuned In|The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
214704001|NCT00780702|DRUG|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
214555977|NCT06319742|DIAGNOSTIC_TEST|Extracellular vescicles (EV) analysis|"The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed."
214555978|NCT02570659|BEHAVIORAL|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
214555979|NCT01923662|DEVICE|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
214555980|NCT00322569|DEVICE|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
214555981|NCT00322569|DEVICE|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
214555982|NCT00322569|DEVICE|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
214555983|NCT00245908|DRUG|azithromycin|
214555984|NCT03943472|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
214555985|NCT03943472|DRUG|Fludarabine|30mg/m2/d
214555986|NCT03943472|DRUG|Cyclophosphamide|300mg/m2/d
214555987|NCT03943472|DRUG|Immune inhibitors|Immune inhibitors
214555988|NCT05759962|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
214555989|NCT05759962|OTHER|Placebo|Matching Placebo
214555990|NCT00659880|OTHER|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
214555991|NCT02963155|OTHER|Blood samples|
214555992|NCT04076787|DRUG|Sunitinib|patients who received sunitinib as first line therapy for mRCC
214555993|NCT04646291|DEVICE|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
214555994|NCT03699891|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
214704002|NCT00780702|DRUG|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
214704003|NCT05432102|DIAGNOSTIC_TEST|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
214704004|NCT05432102|DIAGNOSTIC_TEST|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
214704005|NCT04653142|DRUG|BI 765063|BI 765063
214555995|NCT02833324|BEHAVIORAL|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
214555996|NCT02833324|BEHAVIORAL|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
214555997|NCT02833324|OTHER|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
214555998|NCT01279928|PROCEDURE|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
214555999|NCT01279928|DEVICE|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
214556000|NCT01279928|PROCEDURE|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
214556001|NCT01279928|PROCEDURE|Laser Doppler Flowmetry|Examination of vascular flow
214556002|NCT00573742|DRUG|Candesartan Cilexeotil 16mg|
214556003|NCT05926778|OTHER|Liver allograft fibrosis|Observational studies without intervention
214556004|NCT03513705|OTHER|Best practices in pancreatic cancer care|All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
214556005|NCT06117228|OTHER|Data collection|Data collection
214556006|NCT05910905|PROCEDURE|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
214556007|NCT05910905|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
214556008|NCT04278170|OTHER|no attempt was made to patients|no attempt was made to patients
214556009|NCT04038164|BEHAVIORAL|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
214556010|NCT02092623|DEVICE|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
214556011|NCT02757677|DEVICE|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
214556012|NCT05780034|DRUG|AC676|AC676 will be given orally (PO) on a 28-day cycle.
214556013|NCT05316792|OTHER|walking|30 min walking on the treadmill and tartan floor
214704006|NCT04653142|DRUG|BI 754091|BI 754091
214704007|NCT01238406|DEVICE|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
214704008|NCT01238406|DEVICE|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
214704009|NCT05931185|OTHER|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
214704010|NCT05931185|OTHER|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
214704011|NCT05931185|OTHER|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
214556014|NCT00669877|DRUG|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
214556015|NCT00669877|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
214556016|NCT00669877|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
214556017|NCT00669877|DRUG|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
214556018|NCT00669877|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
214556019|NCT00669877|DRUG|G-CSF|10 mcg/kg
214556020|NCT00669877|DRUG|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
214556021|NCT00669877|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
214556022|NCT03113318|PROCEDURE|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
214704012|NCT03263156|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
214704013|NCT04509323|DRUG|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
214704014|NCT01372449|DRUG|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
214704015|NCT01372449|DRUG|Placebo|
214704016|NCT02491398|DRUG|Bendamustine + Rituximab|
214704017|NCT02623296|DRUG|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
215162848|NCT05180448|BEHAVIORAL|Group Share On|If Group Share is ON, participants in a given LM group will view and respond to aspects of each other's self-monitoring device data in their small-group text messages. Each small group participant's data will be highlighted one day of the month, and content from the Group Share Off message library also will be sent.
214556023|NCT03113318|PROCEDURE|Only pulmonary metastasectomy|
214556024|NCT05116826|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
214556025|NCT00749229|DEVICE|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
214556026|NCT01465763|DRUG|tofacitinib|10 mg oral BID
214556027|NCT01465763|DRUG|Placebo|Plabebo oral BID
214556028|NCT00286806|DRUG|AT-101|
214556029|NCT05261308|OTHER|new prosthesis|Operation to fix the new prosthesis
214556030|NCT01791504|DEVICE|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
214556031|NCT02920970|DEVICE|narafilcon A|contact lens
214556032|NCT02920970|DEVICE|stenfilcon A|contact lens
214556033|NCT00077389|DRUG|carboplatin|
214556034|NCT00077389|DRUG|cisplatin|
214556035|NCT00077389|DRUG|doxorubicin hydrochloride|
214556036|NCT00077389|PROCEDURE|adjuvant therapy|
214556037|NCT00077389|PROCEDURE|conventional surgery|
214556038|NCT00077389|PROCEDURE|neoadjuvant therapy|
214556039|NCT05584358|DIETARY_SUPPLEMENT|Dry protein blend ingestion|Ingestion of protein blend powders mixed in water
214556040|NCT05584358|DIETARY_SUPPLEMENT|Extruded protein blend ingestion|Ingestion of protein blend powders mixed in water
214704018|NCT02623296|DRUG|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
214704019|NCT02623296|DRUG|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
214704020|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
214704021|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (6 wk postpartum)|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
214704022|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
214704023|NCT02043223|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation, both at \<3-day and 6-wk postpartum.
214704024|NCT00269737|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
214556041|NCT02199158|PROCEDURE|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
214556042|NCT02690116|OTHER|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
214556043|NCT02690116|OTHER|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
215162849|NCT05180448|BEHAVIORAL|Friend/Family Share On|Index participants who are randomized to have Friend/Family Share ON will give their friend or family member access to their self-monitoring data. Text messages sent by the program bot, which includes the index participant and friend/family member, will use a similar format as described in Group Share ON. The friend or family member will be trained to respond to data in ways that enhance the participant's motivation and self-regulation.
215162850|NCT05180448|BEHAVIORAL|Coach Share Off|Among index participants who are randomized to have Coach Share OFF, the coach will have no access to their device data. Index participants will be explicitly told their coach does not have data access. During groups and phone calls, the participant will self-report progress, and goal setting will be based on that self-report. Text messages from the coach will be personalized in the OFF condition, as they are when coach data sharing is ON, though these messages will not be informed by device data. Instead, text messages will provide a reminder of key goals and strategies discussed in the previous phone call and provide encouragement for participant efforts.
215162851|NCT05180448|BEHAVIORAL|Group Share Off|Among index participants randomized to have Group Share OFF, supportive accountability will not be the target of participant interactions and no data will be shared with LM program peers. Instead, once weekly prompts for small group text exchanges will encourage index participants to provide social support (primarily of the informational type) to each other. Index participants will be explicitly told that they should not include information on goal progress such as weight change or minutes of PA.
215162852|NCT05180448|BEHAVIORAL|Friend/Family Share Off|If an index participant is randomized to Friend/Family Share OFF, the text messages from the bot will prompt the participant and friend/family member to communicate about the LM program; those messages will be standardized, except for names, and will not be tailored to index participant progress. Index participants will be instructed to refrain from sharing any device data with friends or family members.
214704025|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
214704026|NCT00441103|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
214704027|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
214704028|NCT03852121|BEHAVIORAL|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
214704029|NCT02098057|DIETARY_SUPPLEMENT|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
214704030|NCT02098057|DRUG|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
214556044|NCT02690116|OTHER|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
214556045|NCT00770744|DRUG|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
214704031|NCT04935047|OTHER|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
214704032|NCT04436874|DEVICE|endoscopy|transplant infusion of feces from healthy donors into affected subjects
214556046|NCT00770744|DRUG|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
214556047|NCT05449405|COMBINATION_PRODUCT|Chlorpheniramine Maleate 1% Nasal Spray|Chlorpheniramine Maleate 1% Nasal Spray
214556048|NCT05449405|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
214556049|NCT05306743|OTHER|CONQUEST Quality Improvement Program|"CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations."
214556050|NCT02378038|DRUG|PNT2258|
214556051|NCT05689775|PROCEDURE|Reconstruction with robot-assisted rectus abdominis muscle flap|Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
214556052|NCT01711853|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
214556053|NCT01229605|DRUG|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
214556054|NCT02885558|DRUG|Efonidipine|8 weeks treatment with either efonidipine
214556055|NCT02885558|DRUG|Nifedipine|8 weeks treatment with either nifedipine
214556056|NCT04745975|DRUG|Personalized treatment guided by mini-PDX and RNA sequencing|Personalized treatment guided by mini-PDX and RNA sequencing
214556057|NCT04745975|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w
214556058|NCT04745975|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1,8 q3w
214556059|NCT04745975|DRUG|Vinorelbine|Vinorelbine 25mg/m2 d1,8, q3w
214556060|NCT04745975|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, d1,8, q3w
214556061|NCT04745975|DRUG|Capecitabine|Capecitabine 1250 mg/m2 bid po
214556062|NCT04659122|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
214556063|NCT00218049|DRUG|GBR 12909|50mg GBR 12909 over 12 days
214556064|NCT00218049|DRUG|GBR 12909|GBR 12909 75 mg over 12 day period
214704033|NCT04612153|OTHER|Epidemiologic|Epidemiologic study. Observational, transverse study
214556065|NCT00218049|DRUG|GBR 12909|GBR 12909 100 mg over 12 day period
214556066|NCT05538026|DRUG|Mesalazine|daily dose of 3 g (2 g orally + 1 g rectally)
215029797|NCT04581083|DIAGNOSTIC_TEST|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
215029798|NCT04581083|DIAGNOSTIC_TEST|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
215029799|NCT04581083|DIAGNOSTIC_TEST|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
215029800|NCT04581083|DIAGNOSTIC_TEST|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
214556067|NCT05538026|BIOLOGICAL|Fecal transplantation|Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
214556068|NCT03434444|DRUG|Oxytocin|Oxytocin in solution, ranging from 10 -12M to 10 -5M
214556069|NCT03434444|DRUG|Propranolol|Propranolol in solution, 10-6M
214556070|NCT00003094|OTHER|preventative dietary intervention|
214556071|NCT01343758|OTHER|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
214556072|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
214556073|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
214556074|NCT03722225|OTHER|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
215029801|NCT05431556|OTHER|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
215029802|NCT05431556|OTHER|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
214556075|NCT02334475|BIOLOGICAL|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
214556076|NCT02334475|BIOLOGICAL|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
214556077|NCT04848818|PROCEDURE|Distal radial metaphyseal fracture fixation with percutaneous K-wires|Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..
214556078|NCT04848818|PROCEDURE|Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants|Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
214556079|NCT03261687|OTHER|water based exercise|
214556080|NCT03261687|OTHER|land based exercise|
214704034|NCT03529383|DEVICE|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
214556081|NCT03261687|BEHAVIORAL|advice|general advice given to all subjects
214556082|NCT02651025|OTHER|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
214556083|NCT02740725|OTHER|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
214556084|NCT02740725|DEVICE|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
214556085|NCT02261753|DIETARY_SUPPLEMENT|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
214556086|NCT01016847|DRUG|Montelukast|10 mg Q day
214556087|NCT01016847|OTHER|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
214704035|NCT03529383|BEHAVIORAL|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
214704036|NCT00400439|DRUG|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
214704037|NCT00400439|DRUG|placebo|po daily for 24 weeks
214704038|NCT00223288|DRUG|Lexapro|
214704039|NCT02584465|DRUG|Tamoxifen|Tamoxifen: 40 mg/day
214704040|NCT02584465|DRUG|Regorafenib|Stivarga; 120mg/day
214704041|NCT00835107|DRUG|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
214556088|NCT00476164|DRUG|Rituximab|2 doses of 1g 14 days apart
214556089|NCT00476164|OTHER|Control arm|Continue of optimised oral immunosuppression
214556090|NCT00807339|RADIATION|Stereotactic radiation|Dose escalation three consecutive treatments
214556091|NCT00807339|DEVICE|CyberKnife Robotic Radiosurgery System|
214556092|NCT00000683|BIOLOGICAL|HIVAC-1e|
214556093|NCT00000683|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214556094|NCT02795364|PROCEDURE|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
214556095|NCT02795364|PROCEDURE|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
214556096|NCT02879786|OTHER|Posturographic tests|
214556097|NCT02879786|OTHER|Questionnaire of motion sickness susceptibility|
214556098|NCT02079025|DEVICE|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
214556099|NCT02079025|DEVICE|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
214556100|NCT03566745|DIAGNOSTIC_TEST|Blood for protein activity|Blood for protein activity
214556101|NCT03265353|OTHER|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
214556102|NCT03265353|OTHER|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
214556103|NCT03265353|OTHER|High Potassium/High Sodium Diet|7 days of the prescribed diet
214704042|NCT00835107|DRUG|placebo|placebo comparator, oral capsules, BID, for one month
215029803|NCT05069740|DRUG|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
215029804|NCT05069740|DRUG|Placebo|Placebo for the salsalate intervention
215029805|NCT03206450|PROCEDURE|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
215029806|NCT03206450|OTHER|Laboratory Biomarker Analysis|Correlative studies
215029807|NCT03206450|OTHER|Questionnaire Administration|Ancillary studies
215029808|NCT04414930|DRUG|d-amphetamine|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
215029809|NCT04414930|DRUG|Placebo|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
215029810|NCT03865355|OTHER|Non- interventional|Translational, observational study
215029811|NCT05229705|BEHAVIORAL|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
215029812|NCT04869514|PROCEDURE|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
214556104|NCT02992691|DRUG|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
214556105|NCT02992691|DRUG|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
214556106|NCT02992691|DRUG|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
214556107|NCT02992691|DRUG|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
214556108|NCT02992691|DRUG|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
214556109|NCT02358434|RADIATION|Observational use of fluoroscopy|
214556110|NCT02906436|DEVICE|Xvivo Chamber|
214556111|NCT01427725|DRUG|Lipacreon|This study was an observational study and no intervention was specified
214556112|NCT04871399|PROCEDURE|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
214556113|NCT04871399|PROCEDURE|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~* The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~* The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
214556114|NCT04916951|DRUG|Amoxicillin|oral one-time dose of amoxicillin
214556115|NCT04916951|DRUG|Cephalexin|oral one-time dose of cephalexin
214556116|NCT05419622|BIOLOGICAL|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
214556117|NCT05071586|DEVICE|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
214556118|NCT01299051|BEHAVIORAL|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~* Face-to-face visit with counselor during Month 1 to set specific health goals.~* Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~* Monthly generic health education materials sent via e-mail.~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
214556119|NCT01299051|BEHAVIORAL|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~* Face-to-face visit with counselor at Month 1~* Meeting with exercise physiologist in Month 2~* Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~* Meeting with exercise physiologist during Month 5~* Quarterly biometric feedback (Months 3, 6, 9, and 12)~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
214556120|NCT04276051|DEVICE|Cryoablation of the Vagus Nerve|The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
214556121|NCT04276051|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
214556122|NCT02977767|PROCEDURE|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
214556123|NCT00517023|DEVICE|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
214556124|NCT00517023|OTHER|Other|Routine care and tests usually offered for syncope patients.
214556125|NCT04225481|OTHER|isolation of waste material and culturing with different supplement culture media|isolation of waste material and culturing with different supplement culture media
215162853|NCT05180448|BEHAVIORAL|Behavioral Weight Loss Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
215162854|NCT03650114|BIOLOGICAL|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
215162855|NCT03650114|BIOLOGICAL|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
215162856|NCT03650114|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
215162857|NCT03650114|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
215162858|NCT03650114|BIOLOGICAL|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
215162859|NCT03650114|BIOLOGICAL|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
214556126|NCT05661318|OTHER|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
214556127|NCT00392925|DRUG|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
214556128|NCT00392925|DRUG|metreleptin|subcutaneous injection, twice a day, 5mg
214556129|NCT00392925|DRUG|placebo-pramlintide 600 uL|twice a day
214556130|NCT00392925|DRUG|placebo-metreleptin 1 mL|twice a day
214556131|NCT00392925|DRUG|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
214556132|NCT01005082|BEHAVIORAL|Low salt diet|
214556133|NCT01005082|BEHAVIORAL|Water therapy alone|
214556134|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
214556135|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
214556136|NCT03176147|OTHER|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
214556137|NCT04081064|BEHAVIORAL|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
214556138|NCT04186104|OTHER|Routine diagnostic process|Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.
214556139|NCT04186104|OTHER|Artificial intelligence assisted diagnosis process|Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
214556140|NCT04441944|OTHER|Telemedicine|Use of provider-to-provider telemedicine
214556141|NCT03647761|DEVICE|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
214556142|NCT05693298|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
214556143|NCT05693298|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
214556144|NCT03764176|PROCEDURE|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
214556145|NCT03764176|PROCEDURE|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
214556146|NCT04863482|PROCEDURE|IOC|intra-operative cholangiography near-infrared fluorescence cholangiography
214556147|NCT05431764|DRUG|Camrelizumab, gemcitabin, cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.
215162860|NCT06584513|OTHER|Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements|The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
215162861|NCT04755387|DRUG|De-escalation strategy|De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).
215162862|NCT04755387|DRUG|Conventional strategy|Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.
215162863|NCT01871350|DIETARY_SUPPLEMENT|Daily intake for 10 weeks (+/- 2 weeks)|
215162864|NCT03173924|DRUG|18F-NaF|Baseline IV followed by PET/CT IMAGING
214556148|NCT05431764|RADIATION|Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy|"IMRT: 5 fractions per week for 6 weeks to a total dose of 70 Gy and 33 fractions to the primary tumor.~SBRT: 3 months after locoregional IMRT, patients receive SBRT for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.~Camrelizumab (200mg, iv drip for over 60min) every 2 weeks began on the first day of IMRT until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
214556149|NCT00522821|DRUG|intravenous immunoglobulins|"* Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week"
214556150|NCT00522821|DRUG|antibiotics|"* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
214556151|NCT05645601|BIOLOGICAL|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy.
214556152|NCT05761470|DRUG|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
214556153|NCT05761470|DRUG|Fluzoparib|Fluzoparib
214556154|NCT05761470|DRUG|Nab-paclitaxel|Nab-paclitaxel
214556155|NCT03799913|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
214556156|NCT03799913|DRUG|Fludarabine|30mg/m2/d
214556157|NCT03799913|DRUG|Cyclophosphamide|300mg/m2/d
214556158|NCT05576376|PROCEDURE|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
214556159|NCT05576376|PROCEDURE|plantar fascia open release|open partial release with or without baxter's nerve decompression
214556160|NCT05576376|PROCEDURE|plantar fascia endoscopic release|endoscopic partial plantar fascia release
214556161|NCT02221557|DEVICE|easy-graft (beta-Tricalcium Phosphate)|
214556162|NCT03846440|OTHER|No intervention|Cross-sectional
214556163|NCT02830477|BIOLOGICAL|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
214556164|NCT02102438|DRUG|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
214556165|NCT02102438|DRUG|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
214556166|NCT02102438|DRUG|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
214556167|NCT03219957|DRUG|AT-527|Ascending doses of AT-527 administered orally.
214556168|NCT03219957|OTHER|Placebo Comparator|Matching placebo
214556169|NCT04181372|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
214556170|NCT04181372|DRUG|platinum-based chemotherapy medicine|(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
214556171|NCT02228759|PROCEDURE|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
214556172|NCT01281839|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
214556173|NCT01281839|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
214556174|NCT01281839|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
214556175|NCT01281839|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
214556176|NCT01709175|BEHAVIORAL|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
214556177|NCT02892227|PROCEDURE|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
214556178|NCT03219047|OTHER|Best Practice|Receive standard of care
214556179|NCT03219047|DRUG|Ibrutinib|Given at standard dose and schedule
214556180|NCT03219047|OTHER|Patient Derived Xenograft|Xenograft developed
214556181|NCT03219047|OTHER|Personalized Medicine|Receive treatment based on the results of the PDX models
214556182|NCT02570919|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
214556183|NCT02570919|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
214556184|NCT04372862|PROCEDURE|Plane block|Two different plane blocks to control post-mastectomy pain
214556185|NCT01425619|BIOLOGICAL|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
214556186|NCT01425619|DRUG|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
214556187|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
214556188|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
214556189|NCT01516619|DRUG|Romiplostim|"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."
214556190|NCT01277887|BEHAVIORAL|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
214556191|NCT01277887|BEHAVIORAL|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
214556192|NCT00415051|BIOLOGICAL|RVF MP-12|Administer 1 ml SQ
214704043|NCT00239837|BEHAVIORAL|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
214704044|NCT04035265|PROCEDURE|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
214556193|NCT01987362|DRUG|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
214556194|NCT03532659|OTHER|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
214704045|NCT01153893|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
214704046|NCT01153893|BIOLOGICAL|InfanrixTM|Intramuscular injection, 1dose
214704047|NCT03056807|OTHER|25° head-up position|Angle person is positioned for procedure.
214704048|NCT03056807|OTHER|55° head-up position|Angle person is positioned for procedure.
214704049|NCT05939271|PROCEDURE|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
214704050|NCT01838590|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
214704051|NCT01838590|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214704052|NCT03162341|PROCEDURE|ultrasonography|The tophus volume will be assess using ultrasonography.
214704053|NCT03162341|PROCEDURE|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
214704054|NCT00219388|DRUG|Levosimendan|
214556195|NCT02200653|DRUG|High dose of MICARDIS®, once daily|
214556196|NCT02200653|DRUG|Low dose of MICARDIS®, once daily|
214556197|NCT02200653|DRUG|Low dose of COZAAR® / LORZAAR®, once daily|
214556198|NCT02200653|DRUG|High dose of COZAAR® / LORZAAR®, once daily|
214556199|NCT02200653|DRUG|Placebo|
214704055|NCT02469727|BEHAVIORAL|Fitbit|Participants will use the FitBit device to track their physical activity
214704056|NCT02469727|BEHAVIORAL|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
214704057|NCT02683304|BIOLOGICAL|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
214704058|NCT02683304|DEVICE|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
214704059|NCT01697904|PROCEDURE|Titration of oxygen during newborn resuscitation in delivery room|
214704060|NCT04467632|OTHER|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
214704061|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
215029813|NCT06096363|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
215029814|NCT05923099|DRUG|LEO 138559|LEO 138559 given by injection just under the skin
215029815|NCT05923099|DRUG|Placebo|Placebo given by injection just under the skin
215029816|NCT03947385|DRUG|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
215029817|NCT03947385|DRUG|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
215029818|NCT03947385|DRUG|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
215029819|NCT03340779|DRUG|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
215029820|NCT06484881|DIETARY_SUPPLEMENT|Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Probiotic
215029821|NCT06484881|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
215029822|NCT03213951|OTHER|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
214556200|NCT01424605|PROCEDURE|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
214556201|NCT00780559|BEHAVIORAL|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
214556202|NCT00780559|BEHAVIORAL|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
214556203|NCT03735797|DIAGNOSTIC_TEST|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
214556204|NCT02871505|DRUG|Benzathine Penicillin G|
214704062|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A."
214556205|NCT01495572|DRUG|Fludarabine|25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)
214556206|NCT01495572|DRUG|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
214556207|NCT01495572|DRUG|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
214556208|NCT01495572|DRUG|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
214556209|NCT02756533|OTHER|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
214556210|NCT02756533|OTHER|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
214556211|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire|A self-report questionnaire for assessing level of adaptive functioning
214556212|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire - adapted|A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
214556213|NCT00541177|DRUG|atropine|0.25% atropine
214556214|NCT00541177|DRUG|tropicamide|0.5% tropicamide
214556215|NCT04462289|BEHAVIORAL|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
214556216|NCT02104778|DRUG|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
214556217|NCT02104778|DRUG|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
214556218|NCT02506049|DEVICE|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
214556219|NCT01518153|DRUG|Fludarabine|40 mg/m\^2 by vein on Day -6 to -3.
214556220|NCT01518153|DRUG|Melphalan|140 mg/m\^2 by vein on Day -2.
214556221|NCT01518153|DRUG|Alemtuzumab|50 mg by vein on Day -1.
214556222|NCT01518153|PROCEDURE|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
214556223|NCT01518153|DRUG|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
214556224|NCT01518153|DRUG|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
214556225|NCT01518153|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
214704063|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
214556226|NCT01518153|PROCEDURE|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64.
214556227|NCT01518153|PROCEDURE|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64.
214556228|NCT02888236|DRUG|LEO 32731|
214556229|NCT02888236|DRUG|LEO 32731 Placebo|
214556230|NCT00856245|DRUG|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
214556231|NCT05167136|BEHAVIORAL|Awareness Level|"Demands and expectations about the green hospital were measured with a questionnaire applied to 287 people, consisting of health professionals and employees in a small private hospital that does not have a green hospital certificate in the province of Istanbul."
214556232|NCT01816347|PROCEDURE|Routine PCI|
214704064|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
214556233|NCT01046006|DRUG|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
214556234|NCT03044977|DRUG|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
214704065|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
214704066|NCT05190536|PROCEDURE|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
214704067|NCT05190536|PROCEDURE|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
214704068|NCT03530202|DRUG|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
214704069|NCT03530202|DRUG|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
214704070|NCT00753961|OTHER|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
214704071|NCT00753961|OTHER|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
214704072|NCT02399904|OTHER|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
214704073|NCT00694694|DRUG|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
214704074|NCT00694694|DRUG|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
214704075|NCT03666975|DEVICE|LIV 30 Hz|LivMD LIV platform
214704076|NCT03201887|BEHAVIORAL|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
214704077|NCT03201887|BEHAVIORAL|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
214704078|NCT03110198|DRUG|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
214704079|NCT03110198|DRUG|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
214704080|NCT03110198|DRUG|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
214704081|NCT04791033|PROCEDURE|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
214704082|NCT00671814|DRUG|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
214704083|NCT00671814|DRUG|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
214704084|NCT00671814|DRUG|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
214704085|NCT00160576|DRUG|Levetiracetam|
214704086|NCT01017809|DRUG|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
214704087|NCT04148599|DRUG|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
214704088|NCT04148599|DRUG|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
215162865|NCT03173924|DRUG|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
215162866|NCT03173924|DRUG|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
214556235|NCT03044977|DRUG|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
215162867|NCT02465060|DRUG|Adavosertib|Given PO
214556236|NCT01843725|DRUG|capecitabine|escalation dose of capecitabine continuously
214556237|NCT01843725|DRUG|aflibercept|Intravenous 6mg/kg every 3 weeks
214556238|NCT01843725|DRUG|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
215162868|NCT02465060|DRUG|Afatinib|Given PO
215162869|NCT02465060|DRUG|Afatinib Dimaleate|Given PO
214556239|NCT03168542|DEVICE|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
214704089|NCT04148599|DRUG|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
214704090|NCT06194981|DRUG|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
214704091|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
214704092|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
214704093|NCT02787993|BEHAVIORAL|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
214704094|NCT02403193|DRUG|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
214704095|NCT02403193|DRUG|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
214704096|NCT02403193|DRUG|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
214556240|NCT01064700|DEVICE|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
214556241|NCT01064700|DEVICE|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
214556242|NCT02919553|PROCEDURE|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
214556243|NCT02919553|PROCEDURE|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
214556244|NCT05338697|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
214556245|NCT06098053|OTHER|muscle energy technique|Muscle energy technique is used at a rate of three sessions per week for four and half weeks
214556246|NCT06098053|OTHER|Muscel energy technique along with interferential therapy|Muscle energy technique along with interferential therapy is used at a rate of three sessions per week for four and half weeks
214556247|NCT05131802|DEVICE|upper GIT endescopy|Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
214556248|NCT00438841|DRUG|bortezomib|
214556249|NCT00438841|DRUG|cyclophosphamide|
214556250|NCT00438841|DRUG|dexamethasone|
214556251|NCT00438841|DRUG|thalidomide|
214556252|NCT00450229|DRUG|diindolylmethane|Given PO
214556253|NCT00450229|DRUG|placebo|Given PO
214556254|NCT00450229|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214556255|NCT00450229|OTHER|laboratory biomarker analysis|Correlative studies
214556256|NCT00450229|OTHER|pharmacological study|Correlative studies
214704097|NCT02403193|DRUG|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
214704098|NCT02403193|DRUG|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
214704099|NCT02403193|DRUG|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
214704100|NCT02403193|DRUG|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
214704101|NCT02403193|DRUG|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
214704102|NCT02403193|DRUG|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
214704103|NCT03215394|BEHAVIORAL|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
215162870|NCT02465060|DRUG|Binimetinib|Given PO
215162871|NCT02465060|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215162872|NCT02465060|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215162873|NCT02465060|DRUG|Capivasertib|Given PO
215162874|NCT02465060|PROCEDURE|Computed Tomography|Undergo computed tomography (CT)
215162875|NCT02465060|DRUG|Copanlisib|Given IV
215162876|NCT02465060|DRUG|Copanlisib Hydrochloride|Given IV
214556257|NCT02091115|DIETARY_SUPPLEMENT|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
214556258|NCT02091115|DIETARY_SUPPLEMENT|Dairy drink|
214556259|NCT02514551|DRUG|Ramucirumab|Administered IV
214556260|NCT02514551|DRUG|Paclitaxel|Administered IV
214556261|NCT00003485|DRUG|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214704104|NCT03215394|BEHAVIORAL|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
214704105|NCT03215394|OTHER|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
214704106|NCT03215394|BEHAVIORAL|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
214704107|NCT01662297|DRUG|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
214704108|NCT01662297|DRUG|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
214704109|NCT00538980|DRUG|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
214704110|NCT03924791|DRUG|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
214704111|NCT03924791|DRUG|Methylprednisolone Acetate|In combination with lidocaine
214704112|NCT03924791|DRUG|Dexamethasone|In combination with lidocaine
215029823|NCT03213951|DIAGNOSTIC_TEST|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
215029824|NCT06674707|OTHER|Agility Training with Foot mobilization.|Agility training with foot mobilization with the frequency of 3 sets of 10 repetitions thrice per week for a total six weeks. Pre and post intervention values will be taken on 1st day and after six weeks. Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. TJM is a grade III Maitland technique and is applied with a high amplitude from the end range and 1s of vibration in the middle range of the joint through a linear motion to where tissue resistance is felt in the prone position, the patient is supported by a towel placed under the foot. Two sets of 5 min total were performed for 6weeks.
214556262|NCT00534170|DIETARY_SUPPLEMENT|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
214556263|NCT04148781|DRUG|Fampridine SR|Fampridine-SR 10 mg twice daily for 8 weeks
214556264|NCT06237088|OTHER|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
214556265|NCT06237088|OTHER|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
214556266|NCT05700968|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
214556267|NCT00021138|BEHAVIORAL|smoking cessation intervention|
214556268|NCT00021138|DRUG|nicotine|
214556269|NCT03911934|OTHER|Polypharmacy intervention|A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
214556270|NCT03911934|OTHER|Usual care|Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
214556271|NCT00672737|DRUG|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
214556272|NCT00672737|PROCEDURE|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
214556273|NCT00672737|DEVICE|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
214556274|NCT00672737|PROCEDURE|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
214556275|NCT00280722|BEHAVIORAL|patient information leaflet|
214556276|NCT02274155|DRUG|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
214556277|NCT02274155|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
214556278|NCT02908763|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
214556279|NCT02826382|DRUG|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
214556280|NCT02398253|BEHAVIORAL|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
214556281|NCT02398253|BEHAVIORAL|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
214556282|NCT01878396|DRUG|Anti-B-RAF|
214556283|NCT04837339|OTHER|Collection of biological samples|Blood sample, biopsies sample, hair sample.
214556284|NCT03066882|DIETARY_SUPPLEMENT|NCD|negative calorie diet
214556285|NCT03066882|DIETARY_SUPPLEMENT|LCD|low calorie diet
214556286|NCT05125926|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
214556287|NCT05125926|BIOLOGICAL|Placebo|Aluminum hydroxide
214556288|NCT05602753|BEHAVIORAL|Lifestyle Counseling|Referring to Stop smoking hotline, given pamphlets to encourage quitting smoking, pharmacy guidance, and possible referral to smoking cessation clinic.
214556289|NCT01460225|DRUG|lubiprostone|24 micrograms twice daily for 1 week
214556290|NCT00430833|DRUG|candesartan|
214556291|NCT01981226|DEVICE|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
214556292|NCT00426959|DEVICE|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
214556293|NCT05335746|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCT-A)|Optical coherence tomography angiography scanning will be done for all subjects in the study.
214556294|NCT05898100|DEVICE|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
214556295|NCT05898100|BEHAVIORAL|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
214556296|NCT03561571|OTHER|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
214556297|NCT03561571|OTHER|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
214556298|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
214556299|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
214704113|NCT05935904|OTHER|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
214556300|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
214556301|NCT06331624|DRUG|Tazarotene (GRI-0621)|Oral 4.5mg soft gel capsule
214556302|NCT06331624|DRUG|Placebo|Oral 4.5mg soft gel capsule
214556303|NCT02729142|PROCEDURE|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
214556304|NCT06120842|DRUG|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
214556305|NCT06120842|DRUG|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
214556306|NCT06120842|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
214556307|NCT06120842|DEVICE|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
214556308|NCT06120842|DEVICE|SpyGlass IOL|SpyGlass Intraocular Lens
214556309|NCT04430439|BEHAVIORAL|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
215162877|NCT02465060|DRUG|Crizotinib|Given PO
215162878|NCT02465060|OTHER|Cytology Specimen Collection Procedure|Optional correlative studies
215162879|NCT02465060|DRUG|Dabrafenib|Given PO
214556310|NCT04430439|BEHAVIORAL|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
214556311|NCT06444763|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
214556312|NCT06444763|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
214556313|NCT05935384|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
214556314|NCT02112617|RADIATION|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
214556315|NCT05589597|DRUG|EO4010|Sequential assignment
214556316|NCT06169137|BEHAVIORAL|Early Time-Restricted Eating|Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
214556317|NCT06169137|BEHAVIORAL|Conventional dietary regimen (12-hr, 9:30a-9:30p)|Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
214556318|NCT03356964|DRUG|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
214556319|NCT04906265|OTHER|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)
214556320|NCT04906265|OTHER|Control|Standard rehabiliation
214556321|NCT03564353|DEVICE|tDCS|tDCS
214556322|NCT02712489|OTHER|No intervention|
214556323|NCT02645123|DEVICE|TENS|Enraf-Nonius Sonopuls 692
214556324|NCT02645123|PROCEDURE|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
215162880|NCT02465060|DRUG|Dabrafenib Mesylate|Given PO
215162881|NCT02465060|DRUG|Dasatinib|Given PO
215162882|NCT02465060|DRUG|Defactinib|Given PO
214556325|NCT02645123|PROCEDURE|swedish type massage|petrissage, effleurage, tapotement
214556326|NCT02645123|PROCEDURE|static hamstring stretch|static hamstring stretching
214556327|NCT02645123|PROCEDURE|sham treatment|touching of the skin overlying the lumbar area
214556328|NCT01164111|OTHER|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
214556329|NCT02570997|DRUG|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
214556330|NCT02570997|DRUG|Placebo|Matching placebo administered.
215162883|NCT02465060|DRUG|Defactinib Hydrochloride|Given PO
215162884|NCT02465060|PROCEDURE|Echocardiography Test|Undergo echocardiography (ECHO)
215162885|NCT02465060|DRUG|Erdafitinib|Given PO
215162886|NCT02465060|DRUG|Fexagratinib|Given PO
215162887|NCT02465060|DRUG|Ipatasertib|Given PO
215162888|NCT02465060|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
214556331|NCT00388804|PROCEDURE|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
214556332|NCT00388804|DRUG|Bicalutamide|50 mg By Mouth (PO) Daily
214556333|NCT00388804|DRUG|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
214556334|NCT00388804|DRUG|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
214556335|NCT00388804|DRUG|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
214556336|NCT00388804|BEHAVIORAL|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
215162889|NCT02465060|DRUG|Larotrectinib|Given PO
215162890|NCT02465060|DRUG|Larotrectinib Sulfate|Given PO
215162891|NCT02465060|PROCEDURE|Magnetic Resonance Imaging|Undergo magnetic resonance imaging (MRI)
215162892|NCT02465060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162893|NCT02465060|BIOLOGICAL|Nivolumab|Given IV
215162894|NCT02465060|DRUG|Osimertinib|Given PO
215162895|NCT02465060|DRUG|Palbociclib|Given PO
215162896|NCT02465060|BIOLOGICAL|Pertuzumab|Given IV
215162897|NCT02465060|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
215162898|NCT02465060|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
215162899|NCT02465060|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
215162900|NCT02465060|BIOLOGICAL|Relatlimab|Given IV
215162901|NCT02465060|DRUG|Sapanisertib|Given PO
215162902|NCT02465060|DRUG|Sunitinib Malate|Given PO
215162903|NCT02465060|DRUG|Taselisib|Given PO
215162904|NCT02465060|DRUG|Trametinib|Given PO
215162905|NCT02465060|BIOLOGICAL|Trastuzumab|Given IV
215162906|NCT02465060|BIOLOGICAL|Trastuzumab Emtansine|Given IV
215162907|NCT02465060|DRUG|Ulixertinib|Give PO
215162908|NCT02465060|DRUG|Vismodegib|Given PO
215162909|NCT03985345|DEVICE|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
214556337|NCT00023998|DRUG|doxorubicin hydrochloride|Given IV
214704114|NCT05935904|OTHER|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
214704115|NCT04505696|OTHER|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
214704116|NCT06406686|PROCEDURE|Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter|Durable block across the cavotricuspid isthmus by radiofrequency ablation.
214704117|NCT03698513|DRUG|BMS-986177|BMS-986177 capsule
214704118|NCT03698513|OTHER|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
214704119|NCT03698513|DRUG|Clopidogrel|Clopidogrel tablet
214704120|NCT03698513|DRUG|Aspirin|Aspirin tablet
214704121|NCT01592890|DRUG|RO4917523|\[14C\]-labeled RO4917523, single oral dose
214704122|NCT01592890|DRUG|RO4917523|\[13C\]-labeled RO4917523, single intravenous tracer dose
214704123|NCT01076842|DRUG|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
214704124|NCT01076842|DRUG|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
214704125|NCT01076842|DRUG|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
214704126|NCT01076842|DEVICE|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
215162910|NCT05886049|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215162911|NCT05886049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214556338|NCT00023998|DRUG|cisplatin|Given IV
214556339|NCT00023998|DRUG|methotrexate|Given IV
214556340|NCT00023998|DRUG|leucovorin calcium|Given IV or orally
214556341|NCT00023998|BIOLOGICAL|filgrastim|Given IV
214556342|NCT00023998|PROCEDURE|therapeutic conventional surgery|Undergo resection
214556343|NCT00023998|RADIATION|radiation therapy|Undergo radiotherapy
214556344|NCT00023998|DRUG|etoposide|Given IV
214704127|NCT01076842|DEVICE|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
214704128|NCT03176797|DIAGNOSTIC_TEST|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
214704129|NCT02087384|BIOLOGICAL|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
214704130|NCT02087384|DRUG|Placebo|injection of 0.9% saline
214704131|NCT06011330|DRUG|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
214704132|NCT02055430|PROCEDURE|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
215162912|NCT05886049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
215162913|NCT05886049|DRUG|Cytarabine|Given IV
215162914|NCT05886049|DRUG|Daunorubicin|Given IV
215162915|NCT05886049|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215162916|NCT05886049|DRUG|Revumenib|Given PO
215162917|NCT05886049|PROCEDURE|Transthoracic Echocardiography Test|Undergo transthoracic ECHO
214556345|NCT00023998|DRUG|ifosfamide|Given IV
214556346|NCT00023998|BIOLOGICAL|trastuzumab|Given IV
214556347|NCT00023998|OTHER|laboratory biomarker analysis|Correlative studies
214556348|NCT02502747|DRUG|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
214556349|NCT02502747|DRUG|optimal standard of care|Optimal standard of care
214556350|NCT02502747|PROCEDURE|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
214556351|NCT02600312|DEVICE|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
214556352|NCT03006640|DRUG|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
214556353|NCT03006640|DRUG|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
214556354|NCT00205595|DEVICE|Positron Emission Tomography|
214556355|NCT06237166|BEHAVIORAL|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
214556356|NCT02437357|OTHER|Metacognitive Training|8 group sessions á 60 min
214556357|NCT02437357|OTHER|Positivity Training|8 group sessions á 60 min
214556358|NCT02605369|BEHAVIORAL|Intervention arm: An integrated package|See description in previous column
214556359|NCT04566913|PROCEDURE|Pontic Shield Technique|• Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
214556360|NCT01317329|OTHER|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
214556361|NCT00134355|DRUG|PTK787|
215162918|NCT05797168|DRUG|AZD5335|IV Antibody-drug conjugate
215162919|NCT05797168|DRUG|Saruparib (AZD5305)|Oral PARP inhibitor
215162920|NCT05797168|DRUG|Bevacizumab|IV Monoclonal antibody
215162921|NCT05797168|DRUG|Carboplatin|IV Alkylating agent
214556362|NCT00092092|DRUG|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
214556363|NCT00092092|DRUG|Budesonide inhaler|Budesonide 200 mcg inhalation powder
215162922|NCT05797168|DRUG|AZD9574|Oral PARP inhibitor
215162923|NCT06414993|BEHAVIORAL|Contingency Management for Emerging Adults (CM-EA)|After CM-EA is introduced, a contingency contract is developed between a parent and emerging adult (EA) that provides EAs with rewards for negative drug screens and completion of developmentally appropriate goals to build recovery capital, along with disincentives for positive screens or engaging in inappropriate behaviors. Concurrently, parents are taught to conduct random urine drug screens. Additionally, parents are trained to complete functional analyses in collaboration with their EA to identify the EA's triggers for poly-substance use and negative behaviors. Individualized triggers are targeted via self-management planning and drug refusal skills training. At the end of CM-EA, plans are made with the family for sustaining abstinence and improvements in other behaviors.
215162924|NCT06414993|BEHAVIORAL|Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services|Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation, employment). After needs are identified, a peer worker addresses needs through informational resources and community referrals and engages clients in positive recreational activities offering advice, hope and empowerment to encourage steps toward a reduction in substance use and eventual abstinence. When desired, peer workers also link clients to a broader recovery peer community. In addition, the peer worker will dedicate time to increasing recovery capital via improving skills related to V/E advancement using a workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health Providers, for which peer workers will be trained.
215162925|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
214556364|NCT00092092|DRUG|Placebo to montelukast chewable tablets|Placebo chewable tablets
214556365|NCT00092092|DRUG|Placebo to budesonide inhaler|Placebo inhalation powder
214556366|NCT00999999|PROCEDURE|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
214556367|NCT00925678|DRUG|DSP-3025|
214556368|NCT00925678|DRUG|Placebo|
214556369|NCT05223218|OTHER|Schirmer strip, a Class I Medical Device typically used to test for dry eye.|Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
214556370|NCT00777764|DRUG|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
214556371|NCT00777764|DRUG|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
214556372|NCT00433758|DEVICE|GlucoTrack|GT
214556373|NCT00852605|OTHER|Intermittent Non-Invasive Ventilation|
214556374|NCT01755377|DRUG|Benznidazole|
214556375|NCT05472740|DEVICE|TENS 7000|TENS device to be used in both the active and placebo groups
214556376|NCT05500170|DIETARY_SUPPLEMENT|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
214556377|NCT05500170|DIETARY_SUPPLEMENT|Placebo|The placebo pill will contain micro cellulose powder.
214556378|NCT02998476|DRUG|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
214556379|NCT03039413|DRUG|Copper Cu 64 TP3805|Given IV
214556380|NCT03039413|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
214556381|NCT03039413|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
214556382|NCT05987332|DRUG|IDE196|Dosed orally, twice daily
214556383|NCT05987332|DRUG|Crizotinib|Dosed orally, twice daily
214556384|NCT05987332|DRUG|Pembrolizumab|IV administration every 3 weeks
214556385|NCT05987332|DRUG|Ipilimumab|IV administration every 3 weeks for 4 Cycles
214556386|NCT05987332|DRUG|Nivolumab|IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
214556387|NCT05987332|DRUG|Dacarbazine|IV administration every 3 Weeks
214556388|NCT03567629|DRUG|Irinotecan|Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
214704133|NCT02055430|PROCEDURE|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
215162926|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
215162927|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23), Guselkumab (IL-23), or Ustekinumab (IL-12/23) as standard of care treatment.
215162928|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
215162929|NCT05980481|DRUG|RC48-ADC（2.5mg/kg）|2.5 mg/kg intravenous infusion every 2 weeks
215162930|NCT05980481|DRUG|Trastuzumab|First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks
215162931|NCT05980481|DRUG|Toripalimab|3.0 mg/kg intravenous infusion every 2 weeks
215162932|NCT05980481|DRUG|Oxaliplatin（130mg/m2 ）|130mg/m2 intravenous infusion Q3W
215162933|NCT05980481|DRUG|Capecitabine（1000mg/m2）|1000mg/m2 per os Q3W
215162934|NCT05980481|DRUG|RC48-ADC（2.0mg/kg）|2.0 mg/kg intravenous infusion every 2 weeks
215162935|NCT05980481|DRUG|Capecitabine（750mg/m2）|750mg/m2 per os Q3W
215162936|NCT05980481|DRUG|Oxaliplatin（100mg/m2 ）|100mg/m2 intravenous infusion Q3W
215162937|NCT05003414|DEVICE|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
215162938|NCT02472197|PROCEDURE|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
214556389|NCT03567629|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
214556390|NCT06027034|BEHAVIORAL|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
214556391|NCT03080337|OTHER|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
214556392|NCT06051331|BEHAVIORAL|simulation-based breast health education|The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
214556393|NCT03832595|OTHER|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
214556394|NCT03832595|OTHER|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
214556395|NCT05426863|BEHAVIORAL|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
214556396|NCT06417450|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
214556397|NCT06417450|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
214556398|NCT03729557|PROCEDURE|Nephrectomy|Unilateral nephrectomy
214556399|NCT05759832|DEVICE|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
214556400|NCT05759832|DEVICE|Non-rebreathing reservoir mask|In the non-rebreathing reservoir mask group, oxygen was delivered via a non-rebreathing reservoir mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen \> 90%.
214556401|NCT04157933|DRUG|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
214556402|NCT04157933|DRUG|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
214556403|NCT04157933|DRUG|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
214556404|NCT04157933|DRUG|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
214556405|NCT04157933|DRUG|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
214556406|NCT04157933|DRUG|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
214556407|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
214704134|NCT02055430|PROCEDURE|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
214704135|NCT04129606|DIAGNOSTIC_TEST|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
214704136|NCT02681952|DRUG|Renamezin capsule|
214704137|NCT02681952|DRUG|Kremezin granule|
214704138|NCT06017947|PROCEDURE|Music care|20 min music listening during transportation to hospital
214704139|NCT03586882|DEVICE|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
214704140|NCT05633134|PROCEDURE|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
214704141|NCT05633134|PROCEDURE|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
214704142|NCT00005612|BIOLOGICAL|filgrastim|
214704143|NCT00005612|DRUG|carboplatin|
215162939|NCT02472197|PROCEDURE|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
215162940|NCT06350591|OTHER|Immobilization|single-leg immobilization
214556408|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
214704144|NCT00005612|DRUG|cyclophosphamide|
214704145|NCT00005612|DRUG|etoposide|
214704146|NCT00005612|DRUG|paclitaxel|
214704147|NCT00005612|DRUG|topotecan hydrochloride|
214704148|NCT00005612|PROCEDURE|peripheral blood stem cell transplantation|
214704149|NCT04389580|DRUG|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
214704150|NCT04389580|DRUG|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
214704151|NCT00118027|DRUG|sulphadoxine-pyrimethamine intermittent preventive treatment|
214704152|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
214704153|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
214704154|NCT02738996|BEHAVIORAL|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
214704155|NCT04540081|OTHER|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
214704156|NCT03321214|OTHER|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
215162941|NCT06350591|OTHER|Resistance training|Leg extension and leg press; 3 sets of 8-12 reps
215162942|NCT05688982|BEHAVIORAL|General information provision|Patients will receive information with general oral health and aSDoH resources.
215162943|NCT05688982|BEHAVIORAL|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
215162944|NCT05688982|BEHAVIORAL|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
215162945|NCT06205537|OTHER|Control Liquid Supplement|Ready to drink supplement.
215162946|NCT06205537|OTHER|Experimental Liquid Supplement|Ready to drink supplement.
214556409|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
214556410|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
214704157|NCT01357304|BEHAVIORAL|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
214704158|NCT04338516|DEVICE|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
214704159|NCT04338516|DEVICE|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
214704160|NCT00539916|BEHAVIORAL|Regular orange juice consumption|600 mL /day.
214704161|NCT02730936|DEVICE|Antimicrobial Hernia Repair Device|hernia repair
214556411|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
214556412|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
214556413|NCT00119561|BEHAVIORAL|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
214556414|NCT03277352|DRUG|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
214556415|NCT03277352|DRUG|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
214704162|NCT00396149|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
214704163|NCT00396149|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
214704164|NCT05109819|RADIATION|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
214704165|NCT02235987|DRUG|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
214704166|NCT02235987|DRUG|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
214704167|NCT02745236|OTHER|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
215162947|NCT06311682|DRUG|Tralokinumab + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
215162948|NCT06311682|DRUG|Placebo + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
215162949|NCT05388214|BEHAVIORAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
215162950|NCT04638478|OTHER|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
214556416|NCT03277352|DRUG|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
214556417|NCT00707499|DRUG|BMS747158|Single dose administration.
214556418|NCT06546228|OTHER|No intervention. Only observational.|Only collection of data or parameters already required by the medical examination programmed.
214556419|NCT02923505|PROCEDURE|polygraphy or polysomnography|
214556420|NCT02760147|DEVICE|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
214556421|NCT02760147|DEVICE|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
214556422|NCT02760147|DEVICE|PEEP Over Level|PEEP Level upward by 50%, 2 hours
214556423|NCT02760147|DEVICE|PEEP Under Level|PEEP Level downward by 50%, 2 hours
214704168|NCT02745236|OTHER|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
214704169|NCT01364233|DEVICE|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
214704170|NCT00878215|DEVICE|Explorer Liver Image Guided System|
214704171|NCT00878215|DEVICE|Explorer Liver Passive Tracking|
214704172|NCT00878215|PROCEDURE|Liver surgery|-Standard of care
214704173|NCT00878215|PROCEDURE|Liver abalation|-Standard of care
214704174|NCT01911000|RADIATION|RT and hyperthermia after TACE|
214704175|NCT01961843|DRUG|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
214704176|NCT01961843|DRUG|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
214704177|NCT05522673|DRUG|11(R)-rolipram|Injected IV followed by PET scanning
214556424|NCT03140852|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
214556425|NCT02397447|DRUG|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
214556426|NCT02397447|DRUG|Placebo|Placebo: 2000 mg per day for three months
214704178|NCT03775772|PROCEDURE|Oral Health|"* test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
214704179|NCT03775772|PROCEDURE|Bite Force|"* test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training"
214704180|NCT04108013|DRUG|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
214704181|NCT04108013|DRUG|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
214704182|NCT00302718|BEHAVIORAL|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
214704183|NCT00302718|BEHAVIORAL|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
214704184|NCT00302718|BEHAVIORAL|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
214704185|NCT00819585|DRUG|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
214704186|NCT00819585|DRUG|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
214704187|NCT00819585|DRUG|Allopurinol|100-300 mg orally once daily for 24 weeks.
214704188|NCT00819585|DRUG|Placebo Matching Canakinumab|Subcutaneous injection.
214704189|NCT00819585|DRUG|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
214704190|NCT05228106|DIAGNOSTIC_TEST|[68Ga]-PSMA-617|The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
214704191|NCT03280342|DRUG|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
214704192|NCT03280342|DRUG|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
214704193|NCT04640207|DEVICE|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
214704194|NCT01108497|PROCEDURE|Bone Marrow Aspiration|
214704195|NCT06525545|PROCEDURE|early mobilizzation of the ankle|perform flexion-extension exercises of the operated ankle
214704196|NCT03370991|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
214556428|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
214556429|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
214556430|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
214704197|NCT03370991|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder for 12 weeks
214704198|NCT00738374|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
214704199|NCT00738374|DRUG|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
214556431|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
214556432|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
214556433|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
214704200|NCT00645294|DRUG|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
214704201|NCT00645294|DRUG|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
214704202|NCT00645294|DRUG|Adefovir Dipivoxil|ADV 10 mg on Day 1
214704203|NCT01665248|OTHER|18-F Sodium Fluoride Uptake in Positron emission tomography|
214704204|NCT04171648|OTHER|Roasted Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
214704205|NCT04171648|OTHER|Boiled Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
214704206|NCT05149248|BIOLOGICAL|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
214704207|NCT05149248|BIOLOGICAL|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
214704208|NCT05149248|OTHER|Control group|HPV vaccination at 12 months
214704209|NCT05149248|BIOLOGICAL|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
214704210|NCT01286948|DRUG|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
214704211|NCT06509724|RADIATION|Conventional Fractionated IMRT|"* Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions"
214704212|NCT06509724|RADIATION|Hypofractionated IMRT|"* Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions"
214704213|NCT01260363|PROCEDURE|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
214704214|NCT01260363|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
214704215|NCT00022971|BIOLOGICAL|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
214704216|NCT00022971|BIOLOGICAL|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
214556434|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
214556435|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
214556436|NCT06994286|DRUG|MT-7117|Oral
214556437|NCT06994286|DRUG|Placebo|Oral
214556438|NCT05398445|DRUG|Rocatinlimab|Participants will receive Rocatinlimab subcutaneously.
214556439|NCT05398445|DRUG|Placebo|Participants will receive a placebo subcutaneously.
214556440|NCT06502119|OTHER|Designed Questionnaire|Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
214556441|NCT03003585|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
214556442|NCT03003585|OTHER|Fiberoptic bronchoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
214556443|NCT00505310|BEHAVIORAL|Writing|20 minutes of writing on different topics at four different times.
214556444|NCT00505310|BEHAVIORAL|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
214704217|NCT01981278|DRUG|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
214556445|NCT05652803|BEHAVIORAL|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
214704218|NCT01981278|DRUG|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
214704219|NCT02822911|BEHAVIORAL|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
214704220|NCT02822911|PROCEDURE|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
215162951|NCT04261673|PROCEDURE|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
215162952|NCT04261673|PROCEDURE|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
215162953|NCT06447805|DEVICE|Double Sequential Defibrillation (DSD)|The second defibrillator will be applyed with electrodes placed in the A-P position
215162954|NCT06447805|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
215162955|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
215162956|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
214556446|NCT05652803|BEHAVIORAL|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
214556447|NCT05954572|DIAGNOSTIC_TEST|standardized skin surface biopsy (SSSB)|This technique is applied in four facial localizations, including the forehead, cheeks, and nose. The surface biopsy procedure is performed as follows: one cm² area was marked on a glass slide using a fine ruler. The designated skin area for sampling is gently swabbed with a dry gauze pad to create mild irritation. Subsequently, one drop of cyanoacrylate adhesive is applied to the marked area on the glass slide. The glass slide is carefully pressed onto the skin, allowing the adhesive to adhere. After approximately one minute, the glass slide is gently lifted. The sampled area on the glass slide is examined under x10 and x40 magnification. Immersion oil is applied to enhance visualization and determine the number of Demodex parasites within the marked area. An increased demodicosis is defined as the presence of five or more Demodex parasites per square centimeter of skin.
214556448|NCT00160797|DEVICE|MIS™ Minimally Invasive Solutions™ TKA System|
214556449|NCT00002154|DRUG|Thioctic acid|
214556450|NCT00002154|DRUG|Selegiline hydrochloride|
214556451|NCT07135791|DIAGNOSTIC_TEST|Real-time monitoring|Complete a brief 20-item survey 10 times a day for seven consecutive days, while wearing an accelerometer and completing daily sleep diaries.
214556452|NCT07135401|DIAGNOSTIC_TEST|Breath-hold conditions|Functional Residual Capacity/End-Expiration (breath-hold technique) with/without oxygen to optimize MRI image quality.
214556453|NCT01435772|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
214556454|NCT00402805|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|
214704221|NCT02822911|PROCEDURE|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
214704222|NCT02822911|PROCEDURE|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
214556455|NCT03238963|DRUG|BI 1467335|Once daily
214556456|NCT03238963|DRUG|Placebo|Once daily
214556457|NCT07041281|DRUG|spironolactone 25 mg orally once daily|Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
214704223|NCT02067091|DEVICE|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
214704224|NCT06399731|DEVICE|High-frequency (10Hz) rTMS|High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
214704225|NCT06399731|DEVICE|Anodal tDCS|Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
214704226|NCT05657782|BIOLOGICAL|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
214704227|NCT03046940|OTHER|Patient-centered style of communication|Different doctor-patient communication
214704228|NCT03046940|OTHER|Doctor-centered style of communication|Different doctor-patient communication
214704229|NCT01070524|DRUG|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
214556458|NCT07041281|DRUG|Placebo tablet to match spironolactone|Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
214556459|NCT07049562|DRUG|HRS-8427|\[14C\] HRS-8427 for injection
214556460|NCT07050290|PROCEDURE|Restoring segmental lordosis at the lumbar spine|All patients will undergo restoring segmental lordosis via one previous posterior approach after failed fusion at the same level.
214556461|NCT07045441|OTHER|Conservative Management for TMD|This intervention includes a standardized conservative treatment protocol for TMDs, comprising splint therapy and a structured counseling program. The counseling covers education on diagnosis, medication adherence, dietary modifications, posture and behavior correction, sleep hygiene, parafunctional habit avoidance, physiotherapy exercises, pain and stress management, and importance of follow-up visits. Patients receive individualized instructions and monitoring as part of their routine clinical care. Adherence to these components is measured after 6 months of treatment using a validated adherence questionnaire.
214704230|NCT01070524|DRUG|Budesonide extrafine pMDI|Budesonide extrafine pMDI
214704231|NCT01070524|DRUG|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
214704232|NCT05381012|OTHER|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
214704233|NCT05381012|OTHER|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
214704234|NCT01969799|DRUG|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
214704235|NCT01969799|DRUG|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
214704236|NCT05366270|DEVICE|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
214704237|NCT05366270|DEVICE|Sham|Sham (mild heating) using Heckel Hyperthermia Device
215162957|NCT04130269|OTHER|No intervention|Questionnaires, lab-run
214556462|NCT07046611|DRUG|Ketamine|Intravenous ketamine (5 mg/ml concentration) 2 mg/kg (max 90 mg) over 2 minutes
214556463|NCT07046611|DRUG|Levetiracetam|Intravenous levetiracetam (50 mg/ml concentration) 60 mg/kg (max 4500 mg) over 5 minutes
214556464|NCT07046611|DRUG|Placebo|Intravenous isotonic saline 0.4 mL/kg (maximum 18 mL) over 2 minutes
214556465|NCT07049289|OTHER|Telemonitoring|Patients randomized to intervention group will receive biweeky telephone calls and adaption of antiyhpertensive medication if needed
214556466|NCT07048912|DIETARY_SUPPLEMENT|Beetroot Juice (BJ)|This intervention involves a single 140 mL dose of a commercially available concentrated beetroot juice supplement (Beet-It Pro Elite Shot, James White Drinks Ltd., UK), containing approximately 12.8 mmol (800 mg) of dietary nitrate. Participants consume the juice 2.5 hours prior to performing a 30-second Wingate anaerobic test. The purpose of this intervention is to examine its acute effects on anaerobic performance, muscle oxygenation, and metabolic responses.
214556467|NCT07048912|DIETARY_SUPPLEMENT|Blackcurrant Juice (Placebo)|This intervention involves a single 140 mL dose of a low-calorie blackcurrant juice (Pfanner, Austria) with negligible nitrate content (\<0.1 mmol). The placebo is matched to beetroot juice in appearance, taste, and packaging to ensure double-blind conditions. It is consumed 2.5 hours before the Wingate test and serves as the control condition.
214556468|NCT07051044|DIAGNOSTIC_TEST|AIR-DS|AIR-DS is a supportive, non-diagnostic, risk-indicating software that assists healthcare providers in the early detection and risk assessment of lung cancer in high-risk populations, aiming to improve the cost-effectiveness and accessibility of lung cancer screening. It is imperative to note that the efficacy of the AIR-DS may be affected by the completeness and accuracy of the input data. Hence, any missing data fields should be identified, as they could impact the risk assessment's accuracy.
214556469|NCT07050927|BEHAVIORAL|Online occupational therapy group training|The intervention is a 4-week online parent training program based on occupational therapy principles, delivered via secure Zoom sessions once per week. Each session lasts approximately 60-75 minutes and focuses on topics such as feeding skill development, sensory-based feeding difficulties, responsive parenting strategies, and stress management techniques. The training includes interactive discussions and practical suggestions for daily feeding routines. Supporting materials, such as PDF slides and short demonstration videos, are shared with participants after each session. Attendance in at least three sessions is required to remain in the study.
214556470|NCT07048951|DIAGNOSTIC_TEST|The Near-Death Experience Content (NDE-C) scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 27/80
214556471|NCT07048951|OTHER|Threat perception measure|7 items scale investigating the participant's psychological vulnerability during their stay at the ICU
214556472|NCT07048951|OTHER|Interview about the participant's memories of the ICU|"Participants will be asked to describe any dream, hallucination, or any other unusual experience they can recall from their stay at the ICU.~Additionally, the participants will be asked to describe any memory they have of the environment of the ICU, such as the appearance of the room, medical staff, family visiting, noises, etc."
214704238|NCT05123651|BIOLOGICAL|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
214704239|NCT05044260|PROCEDURE|Direct sinus lift with titanium reinforced PTFE membrane|Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
214704240|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
214556473|NCT07050862|DEVICE|Transcranial Magnetic Stimulation|The first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex.
214556474|NCT07050862|DEVICE|personalized-image-guided and E-field-modeling dose rTMS (precision TMS)|with a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left DLPFC.
214556475|NCT05626452|BEHAVIORAL|PrEP Education|Education for participants regarding PrEP
214556476|NCT05626452|BEHAVIORAL|Provider training|Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
214556477|NCT05626452|OTHER|EMR Optimization|EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
214556478|NCT05626452|OTHER|PrEP Navigation|Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
214556479|NCT05626452|OTHER|Provider Audit and Feedback|Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
214556480|NCT07049107|DRUG|HRS-8427|HRS-8427
214556481|NCT07051005|BEHAVIORAL|Feasibility RCT of a tailored online self-compassion intervention|"This is a four-week online self-compassion course supplied by Balanced Minds. The researches of this study and an Expert by Experience have consulted with the owner of Balanced Minds to tailor this programme to people with diabetes.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~The Foundations of Self-Compassion Developing your Compassionate Self Deepening the Compassionate Relationship with Yourself Self-compassion in Everyday Life."
214556482|NCT07049380|DIAGNOSTIC_TEST|Comparative cross sectional|evaluating the efficacy of two analgesics, tramadol and nalbuphine. The primary objectives are to estimate pain severity in smokers versus nonsmokers and identify the effect of tramadol and nalbuphine between these groups
214704241|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
214556483|NCT07050576|DIAGNOSTIC_TEST|The prediction model of lymph node metastasis in early esophageal squamous cell carcinoma|The predictive performance of the model was validated in the test set. The optimal prediction model was determined based on the AUC and ACC. To assess the robustness of the chosen model, ROC analysis was conducted on the external validation set.
214556484|NCT07049991|PROCEDURE|surgical or percutaneous heart valve replacement.|para-prosthetic heart valve leakage after after surgical or percutaneous heart valve replacement
214556485|NCT07049445|BEHAVIORAL|Music Activity Program|Participants in the experimental group will receive the standard day care center activities plus a music activity intervention. The music activity consists of pre-recorded video sessions conducted twice a week, each lasting one hour, for a total duration of 8 weeks.
214704242|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
214704243|NCT02927873|DRUG|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
214704244|NCT05040789|BIOLOGICAL|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
214704245|NCT06250894|DRUG|PD-1inhibitor|Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
214704246|NCT01519284|DRUG|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
214704247|NCT01519284|DRUG|Entacapone|Entacapone 200 mg
214704248|NCT01519284|DRUG|Placebo|placebo (four times a day)
214704249|NCT01519284|DRUG|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
214704250|NCT01519284|DRUG|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
214704251|NCT01519284|DRUG|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
214704252|NCT00003817|DRUG|dolasetron mesylate|
214704253|NCT00003817|DRUG|granisetron hydrochloride|
214704254|NCT00003817|DRUG|ondansetron|
214704255|NCT00003817|DRUG|tropisetron|
214704256|NCT00003817|PROCEDURE|quality-of-life assessment|
214704257|NCT01262755|BEHAVIORAL|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
214704258|NCT06056349|DRUG|Midazolam oral solution|Buccal administration
214704259|NCT06056349|DRUG|ClonazePAM Oral Product|Orodispersable
214704260|NCT06056349|OTHER|Usual medication/ traditional|Medication that is usually used in the emergency department
214704261|NCT03107455|DEVICE|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
215162958|NCT04257448|DRUG|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
214556486|NCT07048847|OTHER|Exercise|The exercise program will be started with 25 Watt (W) for 5 minutes of warm-up. Then it is steadily increased automatically by 5W in 5 minutes apart for 25 minutes for the loading period. The last 5 minutes which will be started by lowering the load to 25 W for cooling will be implemented for cooling down. To prevent acommodation, the warm-up period will be modified by increasing nearly 10% of its previous rate three weeks apart.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.
214556487|NCT07050628|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
214704262|NCT01927419|DRUG|Nivolumab|
214704263|NCT01927419|DRUG|Ipilimumab|
215162959|NCT04257448|DRUG|Azacitidine|Powder for suspension for injection; Subcutaneous use
215162960|NCT04257448|DRUG|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
215162961|NCT04257448|DRUG|Gemcitabine|Powder for solution for infusion; Intravenous use
215162962|NCT04257448|DRUG|Durvalumab|Concentrate for solution for infusion; Intravenous use
215162963|NCT04257448|DRUG|Lenalidomide capsule|Hard capsule for oral use
214556488|NCT07050511|DRUG|GB-0669|Single IV infusion of GB-0669.
214704264|NCT01927419|DRUG|Placebo|Matching nivolumab
214704265|NCT00393913|DEVICE|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
214704266|NCT03991364|OTHER|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
214704267|NCT03991364|OTHER|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
214704268|NCT03488251|DRUG|MT-3724|MT-3724 will be administered.
214704269|NCT03488251|DRUG|Gemcitabine|Gemcitabine will be administered.
214704270|NCT03488251|DRUG|Oxaliplatin|Oxaliplatin will be administered.
214556489|NCT07050511|DRUG|Placebo|Single IV infusion of placebo. Sterile 0.9% (w/v) sodium chloride solution.
214556490|NCT01986088|DRUG|Placebo|matching placebo
214556491|NCT01986088|DRUG|Eletriptan 40 mg|40mg oral
214556492|NCT01986088|DRUG|Eletriptan 80 mg|80mg oral
214556493|NCT01986088|DRUG|Sumatriptan 50 mg|50mg oral
214556494|NCT01986088|DRUG|Sumatriptan 100 mg|100mg oral
214556495|NCT07049198|DEVICE|Real-time 2D motion capture and visual feedback system gait training|The difference between the VF group and the PT group lies in the use of real-time visual feedback during gait training; the VF group receives real-time visual feedback, while the PT group undergoes gait training without visual feedback.
214556496|NCT07049198|OTHER|Conventional physical therapy group|Ten minutes of strength training followed by thirty minutes of gait training, during which the 2DMV system is not used to provide visual feedback. During the gait training, the therapist provides gait correction feedback typically used in conventional physical therapy.
214556497|NCT07051070|DRUG|RTX treatment|This study used a drug dosage based on previous domestic and international literature as well as clinical experience from our center, set at 375mg/m2 per dose. During the course of the disease, TB lymphocyte subsets are monitored, and if the proportion of B lymphocytes is greater than or equal to 1%, a second dose will be administered.
214556498|NCT05840770|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214556499|NCT05840770|BIOLOGICAL|Cemiplimab|Given IV
214556500|NCT05840770|PROCEDURE|Computed Tomography|Undergo CT scan
214556501|NCT05840770|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214556502|NCT05840770|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214556503|NCT02506933|OTHER|Laboratory Biomarker Analysis|Correlative studies
214556504|NCT02506933|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214556505|NCT02506933|OTHER|Placebo|Given IM
214556506|NCT06832085|DRUG|Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)|Participants in this group will apply 1 NRT patch each morning for up to 26 weeks. Patches will be titrated based on cigarettes consumed. Short-acting NRT products (gum and lozenge) will be used as needed by the participants in this group.
214556507|NCT06832085|DRUG|Cytisine|Participants in this group will take 3mg of cytisine 3 times per day for 12 weeks.
214556508|NCT06832085|DRUG|Varenicline (Champix)|Participants in this group will take 1mg of varenicline 2 times per day for 12 weeks.
214556509|NCT06805786|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
214556510|NCT01424813|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
214556511|NCT01424813|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
214556512|NCT07057063|DEVICE|810 nm Light Therapy|Light therapy at 810 nm, 39 J/cm², delivered via wearable device.
214556513|NCT07057063|DEVICE|Sham Light Therapy|Identical device, no light output, delivered via wearable device.
214556514|NCT01395069|DRUG|Nepafenac 0.1%|1 drop QID for 1 month
214556515|NCT01395069|DRUG|Ketorolac 0.5%|1 drop QID for 1 month
214556516|NCT01395069|OTHER|Placebo (sterile saline drops)|1 drop QID for 1 month
214556517|NCT06771414|OTHER|data collection|data collection
214556518|NCT06641180|BIOLOGICAL|High-Dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
214556519|NCT06641180|BIOLOGICAL|Standard-dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
214556520|NCT05847868|DEVICE|Moment Tumour Hip Prothesis|"In the case of irreversible bone loss due to bone tumors, large and multi-part fractures, and pseudarthrosis in the proximal region of the femur bone, the defective bone area is removed and implants made of artificial materials are placed in order to replace the integrity of the bone. In addition, implant applications are made to the proximal femur region for the purpose of revision arthroplasty, which is typically replaced by total hip prosthesis depending on the wear condition.~In this way, the bone integrity will be preserved, long-term stabilization will be provided to the patient and existing pain will be eliminated.~Moment Tumor Hip Replacement Systems consist of proximal main body, extension pieces and intramedullary stems. Components are available in a variety of sizes to meet anatomical requirements and surgeon needs."
214556521|NCT05153330|DRUG|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
214556522|NCT06800651|DRUG|JMKX003142 will be administered orally|JMKX003142 will be administered orally
214556523|NCT06800651|DRUG|Plcacebo|matched to JMKX003142
214556524|NCT06744595|PROCEDURE|Biospecimen Collection|Undergo collection of blood or salvia samples
214556525|NCT06744595|OTHER|Educational Intervention|Receive personalized EPIC message
214556526|NCT06744595|OTHER|Electronic Health Record Review|Ancillary studies
214556527|NCT06744595|OTHER|Genetic Counseling|Receive pre-genetic test counseling
214556528|NCT06744595|OTHER|Genetic Counseling|Receive post-genetic test counseling
214556529|NCT06744595|GENETIC|Genetic Testing for Cancer Risk|Undergo SOC genetic testing
214556530|NCT06744595|OTHER|Survey Administration|Ancillary studies
214556531|NCT06774313|DRUG|ABBV-142|Intravenous (IV) Infusion
214556532|NCT06774313|DRUG|ABBV-142|Subcutaneous (SC) Injection
214556533|NCT06774313|DRUG|Placebo|IV Infusion
214556534|NCT06774313|DRUG|Placebo|SC Injection
214704271|NCT06303947|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214704272|NCT06303947|DEVICE|Nasogastric tube|The group is given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214704273|NCT06303947|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214704274|NCT04044092|OTHER|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
214704275|NCT04044092|OTHER|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
214704276|NCT03019744|DEVICE|MeCFES-assisted task-oriented upper limb rehabilitation|
214704277|NCT03019744|OTHER|Usual Care task-oriented upper limb rehabilitation|
214556535|NCT07136974|DRUG|TQB2102|TQB2102 is administered intravenously at 6 mg/kg every 3 weeks for 6 cycles.
214556536|NCT07136974|DRUG|Docetaxel + Carboplatin + Trastuzumab +Pertuzumab|Docetaxel 75 mg/m2(day 1) , Carboplatin (AUC=6) (day 1), Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Pertuzumab (840mg first dose, 420mg/kg sequential) are administered intravenously every 3 weeks for 6 cycles.
214556537|NCT00002198|DRUG|Abacavir sulfate|
214556538|NCT06841133|BEHAVIORAL|Chinese Art Activities|"This activity based on Recreation therapy, aims to heal the psychological symptom cluster and enhance the PWB of the old Chinese transit to the elderly center. The activity follows the usual care during the process with the addition of Chinese art activities. It employed the following two main activities:~(1) Traditional Chinese landscape painting; (2) Calligraphy. The activity will be conducted 50min by researchers. It can be conducted at hall, conference room, etc. in the elderly center (EC), and it is a group intervention"
214556539|NCT06841133|BEHAVIORAL|Chinese Art Activities combined with Peer Group Participation (PGP)|The activity follows the usual care during the process with the addition of Chinese art activities combined with Peer Group Participation. The activity will be conducted 80min by researchers. In groups of 5 people, after the painting and calligraphy activity, under the organization of peers, each group member will show their works and talk about their feelings and views on their works. They will also share the reasons why they chose these words or sentences. Everyone must say words of comfort and encouragement to others' work.
214556540|NCT06874283|PROCEDURE|Eye exam|Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. A standard of care exam will be performed to the reason for the visit. In addition to the standard of care exam, those in the Cancer Therapy arm will have certain biological samples (tear collection, impression cytology, and/or blood) collected, stored, and analyzed so we may obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.
214704278|NCT04448262|OTHER|data collection|collection of data about bronchial and systemic inflammation, quality of life, lung function
214704279|NCT00274157|BEHAVIORAL|Behavior|
214704280|NCT00274157|BEHAVIORAL|diet control, smoking cessation, exercize|
214704281|NCT04564430|DRUG|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
214704282|NCT04564430|OTHER|Saline|controlgroup receiving saline
215162964|NCT03545256|PROCEDURE|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~\- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
215162965|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
215162966|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
214556541|NCT06765499|OTHER|Chinese medicine - Silkworm pupa powder|Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable.
215162967|NCT05691478|DRUG|Cisplatin|Given IV
215162968|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
215162969|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
215162970|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214556542|NCT06765499|OTHER|Ultra-low dose silkworm pupa powder|0.5% of the effective components in the experimental group
214556543|NCT02614183|DRUG|Galcanezumab|Administered SC
214556544|NCT02614183|DRUG|Placebo|Administered SC
214556545|NCT02875197|OTHER|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
214556547|NCT04716751|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with tracheal malignant tumor received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
214556548|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
214556549|NCT05962034|OTHER|Placebo|placebo capsule
214556550|NCT07097285|BEHAVIORAL|sensory awareness training|Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program. protocol will be applied. Graded Sensory Discrimination protocol, localization training It includes level 1, localization training level 2 and graphesthesia training. Graded Engine Visualization (DMI) protocol includes right/left discrimination training and visual imagery training.
214556551|NCT05812092|DEVICE|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
214556552|NCT07138404|OTHER|self administration questioner|A self questionnaire will be distributed to evaluate the levels of stress experienced by dental students currently undertaking clinical training in 4th and 5th academic years at Cairo University during the performance of specific clinical procedures in conservative and endodontics treatment.The data obtained from the questionnaire will be statistically analyzed to identify and interpret the variations in the results.
214704283|NCT04153617|DIETARY_SUPPLEMENT|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
214704284|NCT04153617|DIETARY_SUPPLEMENT|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
214704285|NCT04280887|DEVICE|MyPad|Ultrasound bed wetting alarm
215162971|NCT05691478|DRUG|Methotrexate|Given IV
214556553|NCT07135817|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Hypofractionated SBRT delivered in 1-3 fractions within 10 days before surgery, using MRI-based planning and institutional immobilization standards according to ESTRO guidelines.
214556554|NCT07135817|PROCEDURE|Spinal Surgery for Decompression and/or Stabilization|Surgical intervention is performed following SBRT, based on clinical indication. It includes decompression of the spinal canal in cases of spinal cord or nerve compression (via laminectomy and/or foraminotomy), and/or dorsal instrumentation for unstable spines using pedicle screws guided by a neuronavigation system (Brainlab, Munich, Germany)
214704286|NCT05674500|OTHER|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
214704287|NCT05674500|OTHER|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
214704288|NCT02895256|DRUG|Any treatment for cluster headache|
214704289|NCT03215082|OTHER|Vestibular-Visual Intervention|vestibular-visual exercises
214704290|NCT03215082|BEHAVIORAL|standard care|standard care
214704291|NCT00822484|BIOLOGICAL|ILV-095|
214704292|NCT00822484|OTHER|Placebo|
214704293|NCT02518308|BEHAVIORAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
214704294|NCT00663455|DRUG|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
214704295|NCT06342323|RADIATION|SBRT|the fiducial marker was implanted with 3D template assistance under CT guidance
215162972|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
215162973|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
215162974|NCT06421675|DRUG|Elranatamab injection|Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
215162975|NCT04132362|BEHAVIORAL|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
214556555|NCT07137169|PROCEDURE|LIMA protocol|Cleft palate repair using Hybrid / One-flap technique
214556556|NCT07137169|PROCEDURE|RSCM Protocol|Cleft palate repair using Two-flap technique
214556557|NCT07138469|OTHER|Questionnaire|The questionnaire was offered on a voluntary basis and completed online by the participants. At the end of the inclusion period, the responses were analyzed. Participant indicated in the questionnaire whether or not they had already undergone oocyte cryopreservation. The responses were analyzed to assess demographic characteristics, the level of knowledge regarding the bioethics law on non-medical fertility preservation, and future perspectives in the event of use (desired parental model, likelihood of use) or non-use.
214556558|NCT04303117|DRUG|NHS-IL12|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
214556559|NCT04303117|DRUG|M7824|1200 mg administered IV every two weeks while on NHS-IL12.
214556560|NCT06747910|OTHER|Exercise Intervention - Ewing Battery Assessment|Undergo in-person Ewing battery assessment
214556561|NCT06747910|OTHER|Questionnaire Administration|Receive COMPASS31 questionnaire
214556562|NCT06747910|DEVICE|Medical Device Usage and Evaluation|Wear biosensensor heart monitor that remotely collects heart rate variability.
214556563|NCT06265324|DEVICE|Angioplasty|Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
214556564|NCT06927141|DEVICE|Bilateral Peripheral Intravenous Catheterisation|Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.
214556565|NCT05540730|DIAGNOSTIC_TEST|Gait Analysis|Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
214556566|NCT01469520|DRUG|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
214556567|NCT01469520|DRUG|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
214556568|NCT01469520|DRUG|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
214556569|NCT06155812|OTHER|Simultaneous administration of vasopressors|Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.
214556570|NCT06155812|OTHER|Successive administration of vasopressors|Administration and titration of norepinephrine and vasopressin. Administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II or dopamine) as per clinical team. Initiation of inotropes (dobutamin, levosimendan, milrinone) as per clinical team decision.
214556571|NCT06916845|DEVICE|Colon Capsule|All participants will swallow the CapsoCam® Colon (CV-3E) for this study.
214556572|NCT06922994|DRUG|Atorvastatin 80 mg/day|Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
214704296|NCT02999568|OTHER|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
214704297|NCT04453904|OTHER|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
214556573|NCT06922994|DRUG|Placebo atorvastatin|One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
214556574|NCT04340934|DEVICE|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
214556575|NCT06923384|BEHAVIORAL|F2F|After T1 assessment, students meet with a trained provider and receive prevention or brief intervention. Students then complete assessments at two additional times.
214556576|NCT06923384|BEHAVIORAL|eSBI|After T1 assessment, students watch and respond to a prevention or brief intervention video series. Students then complete assessments at two additional times.
214556577|NCT06923384|BEHAVIORAL|Control|Students complete the assessments at each time point, but do not receive any intervention or informational material.
214556578|NCT06927284|OTHER|Neurocognitive Therapy with Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy with soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object repositioned, and another object of a different shape or size offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object with soft robotic hand.
214704298|NCT00003466|DRUG|temozolomide|
214704299|NCT00328965|DRUG|Lacidipine|Lacidipine 2, 4, 6mg
214704300|NCT06131125|OTHER|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
214556579|NCT06927284|OTHER|Neurocognitive Therapy without Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy without soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object will be repositioned, and another object of a different shape or size will be offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object .
214556580|NCT06931418|OTHER|Early Strengthening Protocol|Patients in the ESP intervention arm will undergo active and passive exercises as well as strengthening exercises after their initial assessment by rehabilitation therapists within 2 weeks of their discharge. Early use of strength and passive stretching will be encouraged immediately after allocation.
214556581|NCT06931418|OTHER|Early Motion Protocol|Patients are instructed for active flexion, extension, supination, pronation and finger flexion of the operated wrist along with motion of the shoulder and elbow after operation. Active mobilization is continued for the initial post-operative 6 weeks with allied health therapists. Passive mobilization and strengthening is started at the post-operative 8-10-week period.
214556582|NCT06932536|DRUG|SR750 tablet|Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally
214556583|NCT06932536|DRUG|Placebo|Ascending single and multiple doses of placebo orally
214556584|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol \[10 mL. or 8 g of pure ethanol\]) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
214556585|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
214556586|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
214556587|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
214704301|NCT06131125|OTHER|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
214704302|NCT02612441|DEVICE|real Acupuncture Needles|Acupuncture needles
214704303|NCT02612441|DEVICE|sham Acupuncture Needles|sham Acupuncture Needles
214704304|NCT03111264|BEHAVIORAL|CHAMP|"The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
214704305|NCT03111264|BEHAVIORAL|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
214704306|NCT02719236|PROCEDURE|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
215162976|NCT04132362|BEHAVIORAL|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
214556588|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
214556589|NCT07126288|DRUG|GB08|"In Phase II trial, eligible PGHD patients will receive GB08 0.4mg/kg, 0.8mg/kg, or 1.2mg/kg subcutaneous injection, once a week for 24 weeks.~In Phase III trial, the individuals will receive GB08 subcutaneous injection, once a week for 52 weeks. The dose of GB08 at this stage will be determined by the outcomes of Phase II."
214556590|NCT07126288|DRUG|Norditropin NordiFlex|Norditropin NordiFlex 0.035 mg/kg subcutaneous injection, daily, for 24 weeks (Phase II) or 52 weeks (Phase III)
214556591|NCT05903261|RADIATION|SBRT|stereotactic body radiation therapy (SBRT)
214556592|NCT06934668|DEVICE|Extracorporeal Shock Wave Therapy|A single session of focused extracorporeal shock wave therapy (ESWT) applied to the upper trapezius muscle (2300 shocks). The treatment is applied to the muscle belly region with coupling gel, without local anesthesia. The protocol is designed to assess the acute effects of ESWT on muscle stiffness measured using shear-wave elastography.
214556593|NCT06933199|RADIATION|Neoadjuvant Stereotactic Radiotherapy (NaSRT)|Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
214556594|NCT06933199|RADIATION|Postoperative Stereotactic Radiotherapy (SRT)|Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
214704307|NCT02719236|PROCEDURE|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
214556595|NCT06934447|BIOLOGICAL|anti-BCMA/CD70-CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
214556596|NCT06936774|OTHER|Intensified follow-up program|The study intervention will be an intensified follow-up program which consists of different measures. Patients will attend follow-up visits 1, 4, 7 and 13 months after ileostomy repositioning, at which LARS symptoms, quality of life as well as sexual and urinary function will be recorded using various questionnaires. In case of LARS symptoms patients will receive medical treatment with loperamide and metamucil as well as pelvic floor muscle training (including biofeedback and home exercises). Regarding pelvic floor muscle training we are planning nine sessions instructed by physiotherapy staff. In case of therapy-resistant LARS symptoms after 6 months sacral neurostimulation is offered to the patients with a focus on incontinence symptoms and desire for surgery or transanal irrigation in patients with a focus on voiding disorders. In case of urinary and sexual complaints patients are referred to our urology or gynaecology department for further diagnostic and treatment.
214556597|NCT04198493|DEVICE|CPAP|CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling
214556598|NCT04198493|OTHER|CONSERVATIVE TREATMENT for OSA|Conservative treatment for OSA: sleep hygiene and dietary counseling
214556599|NCT06938282|DRUG|HRS-4642|HRS-4642 in Combination with Immunotherapy and Chemotherapy
214704308|NCT05429554|DRUG|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
214704309|NCT06441851|PROCEDURE|Videolaparoscopic Partial Nephrectomy|Videolaparoscopic partial nephrectomy
214704310|NCT06441851|PROCEDURE|Robot-assisted Partial Nephrectomy|Robot-assisted partial nephrectomy
214556600|NCT06937983|PROCEDURE|Optimised DeEP-guided ablation|Optimised decrement evoked potential (DeEP) mapping in VT ablation.
214704311|NCT03596658|DRUG|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
214704312|NCT00004929|BIOLOGICAL|MUC-2-KLH vaccine|
214704313|NCT00004929|BIOLOGICAL|QS21|
214704314|NCT02300896|OTHER|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
214704315|NCT04961918|PROCEDURE|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
214704316|NCT00609219|BIOLOGICAL|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"
214556601|NCT06942832|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has 3 phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
214556602|NCT06942832|OTHER|Control|Participants maintain their routine activities.
214704317|NCT06366295|DEVICE|subgingival mechanotherapy with perioscopy|Subgingival mechanotherapy using a machine scaler, curettes and a perioscope
214704318|NCT06366295|DEVICE|classical subgingival mechanotherapy|Subgingival mechanotherapy using a machine scaler and curettes
214556603|NCT06944080|OTHER|base material(Tetric® N-Flow,Beautifil-Flow PLUS,GC fuji II LC capsule)|subgingival restoration, deep marginal elevation procedure with different base materials will be applied then plaque index, gingival index, probing depth, clinical attachment level and biochemical marker will be measured at base line and after 3 months.
214556604|NCT06939777|BIOLOGICAL|SNA02-48|intramuscular injection
214556605|NCT06939777|BIOLOGICAL|Placebo|intramuscular injection
214556606|NCT06939777|BIOLOGICAL|HTIG|intramuscular injection
214556607|NCT06939777|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
214556608|NCT01531777|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
214556609|NCT01531777|DRUG|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
214556610|NCT00329212|DRUG|San Huang Xie Jin Tang|
214556611|NCT07136181|DRUG|NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.|NBM-BMX is a small molecule inhibitor of HDAC8. The majority of metastasizing uveal melanoma (UM) cases are characterized by the presence of BAP1 mutations. However, as BAP1 mutations lead to a loss of function, therapeutic strategies have primarily focused on exploiting vulnerabilities resulting from BAP1 loss or targeting downstream effectors affected by the BAP1-deficient phenotype. In uveal melanocytes, the absence of BAP1 disrupts their differentiated cell identity, potentially contributing to the metastatic behavior observed in BAP1-mutant UM cells. This differentiation block in the melanocytic lineage is thought to be influenced, at least in part, by the activation of HDAC8 downstream, which leads to the repression of differentiation genes through acetylation of the histone H3K27 at the promoter and enhancers associated with these genes. Consequently, inhibiting HDAC8 could potentially reverse the differentiation block caused by the loss of BAP1.
214556612|NCT07136558|DRUG|ICP-B794|Intravenous administration once every 3 weeks
214556613|NCT07138235|PROCEDURE|laparoscopic hiatal hernia repair|"Intraoperative endoscopic control and the use of calibration bougies allow for increasing the accuracy of cardiac sphincter reconstruction and reducing the risk of hyper- or hypocorrection. Endoscopic equipment. The Olympus EVIS EXERA III endoscopic video system (Olympus Medical Systems Corp., Tokyo, Japan), series 190, was used for diagnostic and therapeutic endoscopic examinations.~The complex included:~* CV-190 video processor with digital image magnification,~* CLV-190 light source (xenon/LED), providing high brightness and uniformity of illumination, a high definition (HD) video monitor,~* GIF-HQ190, GIF-H190 high-resolution series gastroscopes,~* CF-HQ190L/I series colonoscopes (if necessary). These functions made it possible to more accurately assess the condition of the mucous membrane of the esophagus and stomach, as well as to identify pathological changes.~Medications: omeprazole/esomeprazole, ondansetron, cephalosporins intravenously, metoclopramide."
214704319|NCT03079349|OTHER|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
214704320|NCT03079349|OTHER|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
214704321|NCT02085213|DRUG|Glyceryl Trinitrate|
214704322|NCT02085213|DRUG|Matched Placebo|Matched placebo
214704323|NCT00234728|DEVICE|Occlusive dressing|
214704324|NCT01079429|GENETIC|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
214704325|NCT02687750|DEVICE|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
214704326|NCT00004278|DRUG|ganciclovir|
214704327|NCT01244191|DRUG|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
215162977|NCT04132362|BEHAVIORAL|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
215162978|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
215162979|NCT04604275|DRUG|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
214704328|NCT01244191|DRUG|Placebo|Tivantinib Placebo tablets given twice a day
214704329|NCT01244191|DRUG|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
214704330|NCT01271387|DRUG|tasimelteon|20 mg tasimelteon capsules, PO single dose
215162980|NCT04604275|OTHER|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
215162981|NCT05710315|DEVICE|RELiZORB™|RELiZORB cartridges will be used with routine enteral feedings for 5 days for randomized participants
215162982|NCT05710315|OTHER|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants
214704331|NCT00251407|DRUG|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
214704332|NCT00251407|DRUG|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
214704333|NCT00251407|DRUG|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
214704334|NCT04068324|DIETARY_SUPPLEMENT|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
214556614|NCT07135739|DEVICE|funcional Electrical stimulation combined with mirror therapy|"* Subjects were treated with a combination therapy of task specific mirror therapy and functional electrical stimulation, consisting of two tasks, for a total duration of thirty minutes.~* The subject was positioned on a height adjustable table with the mirror placed in front of the mid line.~* The positive electrode and negative electrode of the muscle simulator were placed over the muscle belly of the wrist extensors on forearm over the motor (between one-third and half-way from the proximal end of the dorsal forearm) of the affected upper limb.~* The subject was then instructed to observe the mirror reflection for one to two minutes, trying to visualize the mirror image as the affected limb, asked to perform slow, easy to achieve simultaneous bilateral movements (perceived bilateral movements) while continuing to look at ,with the affected limb performing synchronously with the duty cycle of electrical stimulation."
214556615|NCT07135739|OTHER|Physical therapy program|"The program will be applied to all children in both groups (A and B). The exercise session for one hour for each child in both groups, conducted 3times/ week for 3 successive months.~1. Flexibility exercises for shorted muscles and spastic muscles.~2. Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles.~3. Postural control exercise in different positions and different surfaces~4. General endurance training (Sherief et al., 2020).~5. Exercises to facilitate hand function including basic reaching grasping, carrying, release and the more complex skills of in-hand manipulation and bilateral hand use were conducted."
214556616|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
214704335|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
214704336|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
214704337|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
214704338|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
214704339|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
214704340|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
215162983|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
215162984|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
215162985|NCT05874414|DRUG|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
215162986|NCT05191030|BEHAVIORAL|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
214704341|NCT00703755|DRUG|Placebo|Placebo
214704342|NCT01667393|DEVICE|IDEV SUPERA Stent|
214704343|NCT01667393|DEVICE|Percutaneous Transluminal Angioplasty|
214709029|NCT01182337|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
215162987|NCT04853251|DEVICE|PDS Implant With Ranibizumab 100 mg/ml|Ranibizumab 100 mg/mL will be delivered via PDS
215162988|NCT04853251|DRUG|LUCENTIS (Ranibizumab Injection)|Ranibizumab (0.5 mg intravitreal \[IVT\] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.
215162989|NCT05626478|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
215162990|NCT05626478|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
215162991|NCT05626478|DRUG|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
215162992|NCT05654532|DRUG|AC699|Participants will receive AC699 orally daily in 28-day cycles.
215162993|NCT06030037|BIOLOGICAL|Healthy Donor Fecal Microbiota Transplantation (hdFMT)|hdFMT (induction) via colonoscopy or oral capsule on C1D1 and C3D1. hdFMT (maintenance) via sigmoidoscopy or oral capsules will be repeated every 9 weeks.
214556617|NCT02994771|DRUG|Lymfactin® [1 x 10E10 vp]|Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
214704344|NCT02582580|OTHER|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
214704345|NCT02582580|DEVICE|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
214704346|NCT02582580|OTHER|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
215162994|NCT06030037|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
215162995|NCT06030037|DRUG|Lenvatinib|Lenvatinib will be administered at 20 mg daily
214556618|NCT02994771|DRUG|Lymfactin® [1 x 10E11 vp]|Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
214556619|NCT03313947|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
214556620|NCT03313947|OTHER|Questionnaire|"The following 6 questions will be asked during the preoperative visit:~1. While sleeping, does your child snore more than half the time?~2. While sleeping, does your child always snore?~3. Have you ever seen your child stop breathing during the night?~4. Does your child occasionally wet the bed?~5. Did your child stop growing at a normal rate at any time since birth?~6. Is your child overweight"
214556621|NCT06100913|BIOLOGICAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
214556622|NCT06100913|OTHER|Deuterium Labeled Water|An Emory Investigational Drug Service pharmacist will prepare sterile 50 ml aliquots of D2O with a tamper seal and stored at room temperature. Participants will be asked to drink a pre-measured volume of water three times a day and on days according to their assigned group schedule.
214556623|NCT05274204|DRUG|CA102N|
215162996|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
215162997|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
215162998|NCT05150015|DEVICE|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
214556624|NCT01165606|PROCEDURE|Chest physiotherapy|
214556625|NCT03763136|BIOLOGICAL|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
214556626|NCT04115657|OTHER|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
214556627|NCT04115657|OTHER|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
214556628|NCT04115657|OTHER|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
214556629|NCT04115657|OTHER|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
214556630|NCT04115657|OTHER|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
214556631|NCT04115657|OTHER|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
214556632|NCT04018274|DRUG|PF-06651600|50 mg by mouth (PO) once daily (QD)
214556633|NCT04018274|DRUG|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
214556634|NCT02097953|DRUG|Daptomycin|
214556635|NCT02097953|DRUG|Rifampin|
214556636|NCT01027052|OTHER|Hamburger meat patty with salt|hamburger meat cooked with salt
214556637|NCT01027052|OTHER|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
214556638|NCT03838731|DRUG|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
214556639|NCT03838731|DRUG|Placebo|Single subcutaneous (SC) dose of matching placebo
214556640|NCT02188680|OTHER|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
214556641|NCT03004001|DRUG|Alirocumab|150 mg biweekly
214556642|NCT03004001|DRUG|Alirocumab placebo|placebo
214556643|NCT03004001|DRUG|Atorvastatin|20 mg/day
214556644|NCT01997905|DEVICE|AtriClip LAA Exclusion Device|
214556645|NCT02775370|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
214556646|NCT03610711|DRUG|Nivolumab|240mg administered IV over 30 minutes every 2 weeks for one year
214556647|NCT03610711|DRUG|Relatlimab|every 2 weeks for one year
214704347|NCT00844064|DRUG|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
214704348|NCT04501198|DEVICE|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
214704349|NCT04501198|DEVICE|Moxibustion combined with lifestyle intervention.|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
214556648|NCT05689242|DRUG|Dexmedetomidine Injection [Precedex]|intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
214704350|NCT04501198|DEVICE|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
214704351|NCT00810719|DRUG|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
214704352|NCT00810719|DRUG|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
214704353|NCT04390568|DRUG|Spesolimap|Spesolimap
214704354|NCT04344379|DRUG|hydroxychloroquine|200 mg BID per day
214704355|NCT04344379|DRUG|azithromycin|250 mg per day
214704356|NCT04344379|DRUG|hydroxychloroquine placebo|200 mg BID per day
214704357|NCT00598715|DEVICE|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
214704358|NCT00598715|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
214704359|NCT00176670|DRUG|midazolam or GameBoy or parental presence|
214704360|NCT04614116|OTHER|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
215162999|NCT06154252|BIOLOGICAL|CABA-201 following preconditioning with fludarabine and cyclophosphamide|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
215163000|NCT03743935|OTHER|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
215163001|NCT05668988|DRUG|sunvozertinib|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
215163002|NCT05668988|DRUG|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
215163003|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
214556649|NCT05981742|DRUG|Metformin Hydrochloride 500 MG|Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
214556650|NCT05981742|DRUG|Cabergoline 0.5 MG|Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
214556651|NCT05981742|DRUG|Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG|"Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration"
214556652|NCT03937518|DRUG|Strontium Ranelate|"Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min ("
214556653|NCT03937518|OTHER|physiotherapy|"Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis"
214556654|NCT05817383|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
214556655|NCT05817383|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
214556656|NCT05483413|BEHAVIORAL|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
214556657|NCT03438357|OTHER|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
214556658|NCT00835744|DRUG|clomiphene citrate|ovulation induction
214556659|NCT00835744|DRUG|gonadotropins|ovulation induction
214704361|NCT04614116|DIAGNOSTIC_TEST|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
214704362|NCT04614116|DIAGNOSTIC_TEST|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
214704363|NCT04316663|BEHAVIORAL|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
215163004|NCT04995081|BIOLOGICAL|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
215163005|NCT04995081|OTHER|Placebo|Sterile Saline Solution 0.9%
215163006|NCT04572022|OTHER|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
215163007|NCT02392442|OTHER|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
215163008|NCT02392442|BIOLOGICAL|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
215163009|NCT04029896|BIOLOGICAL|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
215163010|NCT05296967|BEHAVIORAL|chewing|patients are asked to chew chewing gum X 3/ day
215163011|NCT05615935|OTHER|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
215163012|NCT05858034|OTHER|Customized activity plan|Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
215163013|NCT05858034|OTHER|Customized nutrition plan|Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
215163014|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
215163015|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
215163016|NCT06259851|BEHAVIORAL|Dialectical behavioral therapy program|Dialectical behavioral therapy (DBT) program with all the standard DBT modules (individual therapy 1 hour per week, skills group 3 hours per week, phone coaching, and therapist consultation team 1,5 hour per week). The program takes 24 weeks in total comprising two 12-week runs of skills training. The program will be precluded with 4 individual sessions of pretreatment before the start of the main program part.
214556660|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
214556661|NCT02239874|DIETARY_SUPPLEMENT|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214556662|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D placebo and fish oil placebo|placebo
214556663|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214556664|NCT05717894|DRUG|Vitex Agnus Castus Extract|The patient group received two pills containing 200mg of VAC daily for six months
214556665|NCT03416322|OTHER|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
214556666|NCT03412851|OTHER|A Direct Aspiration First Pass Technique|Distal aspiration technique
214556667|NCT03412851|OTHER|Stentriever Thrombectomy|Thrombectomy with stent retriever
214556668|NCT05723757|DIAGNOSTIC_TEST|blood sampling|Draw a 8.5mL blood sample for detection of SNPs of genomic origin
214556669|NCT02354820|OTHER|Evidence Based Constipation Reminders|
214556670|NCT02961439|BEHAVIORAL|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
214556671|NCT04442100|PROCEDURE|valve prosthetics|"prosthetics of heart valves with dentures MedEng-Bio"
214556672|NCT03637218|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214556673|NCT03637218|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214556674|NCT00603525|DRUG|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
214556675|NCT00603525|DRUG|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
214556676|NCT04394377|DRUG|Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Routine full anticoagulation strategy
214556677|NCT04394377|DRUG|Group 2: control group with enoxaparin 40mg/d|Usual standard of care and currently have no indication of full anticoagulation.
214556678|NCT02304705|DRUG|Sildenafil|20 mg three times daily by mouth for 90 days
214556679|NCT02304705|DRUG|Placebo|One capsule three times daily by mouth for 90 days
214556680|NCT04075877|BEHAVIORAL|FOCUS|See prior section.
214556681|NCT00032175|DRUG|capecitabine|
214556682|NCT00032175|DRUG|gemcitabine hydrochloride|
214556683|NCT01195948|DRUG|B27PD|
214556684|NCT01195948|DRUG|Placebo|Capsule with no active ingredients to mimic B27PD
214556685|NCT04263272|OTHER|Upper Body Circuit Training Program|16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
214556686|NCT00449267|DEVICE|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
214556687|NCT00770029|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
214556688|NCT00770029|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
214556689|NCT00736268|BEHAVIORAL|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
214556690|NCT00736268|OTHER|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
214709030|NCT01182337|DRUG|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
214556691|NCT01941173|BIOLOGICAL|ziv-aflibercept|Given IV
214556692|NCT01941173|DRUG|leucovorin calcium|Given IV
214556693|NCT01941173|DRUG|irinotecan hydrochloride|Given IV
214556694|NCT01941173|DRUG|fluorouracil|Given IV
214556695|NCT02535975|DRUG|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
214556696|NCT02535975|DRUG|Placebo|Tablets placebo PO three times a day for 24 weeks
214556697|NCT03480477|OTHER|ACE questionnaire|No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
214556698|NCT02092597|DRUG|Exenatide|
214556699|NCT02092597|DRUG|Linagliptin|
214556700|NCT02092597|DRUG|Gliclazide|
214556701|NCT03435445|BEHAVIORAL|Online platform group|The online platform has social network, gamification and short-text sessions.
214556702|NCT03435445|BEHAVIORAL|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
214556703|NCT03435445|BEHAVIORAL|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
214556704|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
215163017|NCT06259851|DEVICE|Prefrontal rTMS treatment|rTMS will be performed by DuoMag XT with 70BF cool coil. Patients will undergo 15 daily stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds. Gradual titration of the individual resting motor threshold (RMT) will apply, meaning probands will undergo first session with 90% RMT intensity, second session with 100% RMT intensity, third session with 110% RMT intensity. All the following sessions will use the final 120% RMT intensity. In case a session is left out because of any reason, the total duration of treatment will be prolonged by one day, so that the total number of sessions underwent is the same in all patients. Patients will receive 2000 pulses during one session (total 30000 pulses during the whole procedure) with 10 Hz frequency.
214704364|NCT04316663|BEHAVIORAL|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
214704365|NCT03082495|BEHAVIORAL|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
215163018|NCT06259851|DEVICE|Sham rTMS sessions|Sham TMS will be performed by sham coil that looks identical to DuoMag XT in the active group. Patients will undergo 15 daily sham stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds.
215163019|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
215163020|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
215163021|NCT02162849|DRUG|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
214556705|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
214556706|NCT02771821|OTHER|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
214556707|NCT04941599|DRUG|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
214556708|NCT04941599|OTHER|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
214556709|NCT05658003|DRUG|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
214556710|NCT05658003|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
214556711|NCT05658003|DRUG|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
214704366|NCT06692569|OTHER|Conventional Physical Therapy|The conventional Physical Therapy, the treatment will be based on the client's capabilities. It included functional reeducation, muscle strengthening and stretching, muscle tone regulation methods, and training for activities of daily living
214709031|NCT00033033|DRUG|Reserpine|
215163022|NCT02162849|DRUG|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
215163023|NCT02162849|DRUG|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
215163024|NCT02162849|DRUG|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
215163025|NCT02162849|BEHAVIORAL|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
214709032|NCT02810652|OTHER|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
214556712|NCT05658003|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
214556713|NCT05947955|DRUG|Rhu-pGSN|Intravenous administration based on actual body weight
214556714|NCT05947955|DRUG|normal saline|intravenous administration in the same volume as the active therapy
214556715|NCT03688165|DEVICE|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
214704367|NCT06692569|OTHER|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy (mCIMT) which involves trunk constraint along with conventional Physical Therapy treatment. Under the attentive guidance of a physiotherapist, the patient engages in specific hand activities aligned with personalized goals. These activities encompass tasks such as picking up marbles, flipping cards, stacking blocks, combing hair, writing, and other actions relevant to daily life. The difficulty level is dynamically adjusted according to the patient's abilities and progress during the training sessions.Tasks may vary from one patient to another, and each session introduces fresh, goal-oriented challenges to further enhance rehabilitation outcomes, along with the conventional physical therapy treatment. The patients were wearing a trunk west which had a Velcro strap on the non-effected side part of the west, and it was attached to the Velcro straps on the non-affected part on the back support of the treatment chair.
214704368|NCT06693323|DRUG|AHCC®capsules|Given PO
214704369|NCT06339333|BEHAVIORAL|ACT Now GAIN Later|ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.
214704370|NCT06339333|OTHER|Control Group|Waitlist Group
214704371|NCT01883323|DRUG|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
214704372|NCT01883323|DRUG|Fludarabine|i.v., 25mg/m2 per day for 5 days
214704373|NCT01883323|BIOLOGICAL|Tumor-Infiltrating Lymphocytes|i.v., 1x10\^10 - 1.6x10\^11 cells
215163026|NCT02162849|BEHAVIORAL|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
215163027|NCT02162849|OTHER|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
215163028|NCT02162849|OTHER|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
215163029|NCT01861106|PROCEDURE|Allogeneic HSCT|Stem cell transplant
214556716|NCT03688165|OTHER|Traditional Over-ground Gait Training|Traditional treatment for gait training consists in any conventional technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids.
214704374|NCT01883323|BIOLOGICAL|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
214704375|NCT00440427|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
214704376|NCT01511107|DRUG|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
214704377|NCT01511107|DRUG|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
214704378|NCT05824455|COMBINATION_PRODUCT|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
214704379|NCT05643157|DEVICE|Adaptive Optics - Optical Coherence Tomography (AO-OCT) retinal imaging|AO-OCT used in this study is an investigational OCT imaging system. . In this instrument, ocular aberration sensing and correction is achieved with a Shack-Hartmann wavefront sensor (SHWS) and deformable mirror, respectively. A pupil camera and fixation target are used to position the participant's head and eye for scanning a particular retinal region within 15 degrees of the fovea. Data collected generally includes AO-OCT volume videos and SHWS measurements of ocular aberrations.
215163030|NCT01861106|DRUG|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
215163031|NCT01861106|DRUG|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
215163032|NCT01861106|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
215163033|NCT01861106|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
214704380|NCT04224818|DRUG|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
214704381|NCT04224818|DRUG|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
215163034|NCT01861106|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
214709033|NCT02810652|OTHER|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
214709034|NCT00152074|BEHAVIORAL|Reduce salt intake|
215163035|NCT01861106|DRUG|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
214704382|NCT01146951|DRUG|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
214704383|NCT01146951|DRUG|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
214556717|NCT05751278|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
214556718|NCT05751278|DEVICE|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
214556719|NCT05846646|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
214556720|NCT05846646|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
214556721|NCT05846646|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
214556722|NCT04611009|BEHAVIORAL|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
214556723|NCT04611009|BEHAVIORAL|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
214556724|NCT00513188|BIOLOGICAL|denileukin diftitox|
214556725|NCT00513188|DRUG|cyclophosphamide|
214704384|NCT02269384|PROCEDURE|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
214704385|NCT02269384|BEHAVIORAL|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
214704386|NCT02269384|BEHAVIORAL|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
214704387|NCT02269384|PROCEDURE|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
214704388|NCT03563261|DIETARY_SUPPLEMENT|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
214709035|NCT03448224|OTHER|Questionnaire Administration|Questionnaire
215163036|NCT01861106|DRUG|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
215163037|NCT01861106|BIOLOGICAL|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
215163038|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 3T|Non-significant risk device used for brain imaging.
215163039|NCT02543983|DEVICE|NeurOptics PLRTM-3000 Pupillometer|The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
215163040|NCT02543983|DEVICE|Experimental Anxiety Devices|Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
215163041|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 7T|Non-significant risk device used for brain imaging.
215163042|NCT02543983|DRUG|Ketamine Hydrochloride|A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
214556726|NCT00513188|DRUG|cytarabine|
214556727|NCT00513188|DRUG|doxorubicin hydrochloride|
214556728|NCT00513188|DRUG|leucovorin calcium|
214556729|NCT00513188|DRUG|methotrexate|
214556730|NCT00513188|DRUG|prednisone|
214556731|NCT00513188|DRUG|vincristine sulfate|
214556732|NCT00513188|GENETIC|protein expression analysis|
214556733|NCT00513188|OTHER|flow cytometry|
214556734|NCT00513188|OTHER|laboratory biomarker analysis|
214556735|NCT03260478|PROCEDURE|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
214556736|NCT05352841|DIAGNOSTIC_TEST|Salivary sample analysis|The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
214556737|NCT05272943|OTHER|Oxgen saturation measurement with validated pulse oximetry|Oxgen saturation will be measured with validated pulse oximetry
214556738|NCT05272943|OTHER|Oxgen saturation measurement with smart electronics|Oxgen saturation will be measured with smart electronics
214556739|NCT04302688|OTHER||
214556740|NCT05162274|DRUG|Lazertinib(G001)|Current formulation
214556741|NCT05162274|DRUG|Lazertinib(G002)|New formulation
214709036|NCT03448224|OTHER|Internet-Based Intervention|Intervention
214709037|NCT02266758|OTHER|GDM Screening Methods|
214709038|NCT00325338|BIOLOGICAL|Ragweed MATAMPL|
214704389|NCT03563261|DIETARY_SUPPLEMENT|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
214556742|NCT04984005|BEHAVIORAL|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
214556743|NCT04984005|BEHAVIORAL|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
214556744|NCT04984005|BEHAVIORAL|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
214556745|NCT04200222|DIAGNOSTIC_TEST|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1\. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
214556746|NCT00150878|OTHER|Conditioning therapy|Preparation before allogeneic transplantation
214704390|NCT01160861|DRUG|MEMP1972A|Repeating ascending dose
214556747|NCT04200001|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ-BR23~* EORTC SHQ-C22~* CUPIDON 2 specific questionnaire"
214556748|NCT03674775|OTHER|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
214556749|NCT02523547|DRUG|Cavir|0.5mg/day
214556750|NCT02523547|DRUG|Baraclude|0.5mg/day
214556751|NCT01762969|OTHER|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
214704391|NCT01160861|DRUG|placebo|Repeating ascending dose
214556752|NCT03030313|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
214704392|NCT02311790|DIETARY_SUPPLEMENT|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
214704393|NCT02311790|DIETARY_SUPPLEMENT|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
214704394|NCT03345940|DRUG|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
214704395|NCT03345940|DRUG|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
214704396|NCT01232751|DIETARY_SUPPLEMENT|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
214704397|NCT03312868|RADIATION|SBRT|Stereotactic Body Radiotherapy
215029825|NCT06674707|OTHER|Agility Training without Foot mobilization|Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. Comprising of Hot pack and TENS for 10 minutes and Ultrasound for 5 minutes . Comprising of conventional exercises were given for 3 sessions per week for 6 weeks. It includes semi squat, quadriceps isometric, terminal knee extension with elastic band, terminal knee extension in supine position, and adductor squeeze in crook lying (squeeze the ball).
214556753|NCT05435950|DEVICE|Sono-Intruments|"Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~* The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~* The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley."
214556754|NCT06405763|PROCEDURE|Snodgrass repair|"A relaxing incision is made in the midline by using scalpel or scissors~A 6 F stent is passed into the bladder. The neourethra is closed"
214556755|NCT06405763|PROCEDURE|Snodgrass repair with graft|A relaxing incision is made in the midline by using scalpel or scissors In grafted Snodgrass repairA free graft was measured and harvested from the inner prepuce and was defatted and sutured onto the incised urethral plate The graft was sutured overlying the incision line A 6 F stent is passed into the bladder. The neourethra is closed
214556756|NCT01947569|BIOLOGICAL|Biological|
214556757|NCT00460395|PROCEDURE|Surgery|
214556758|NCT00460395|PROCEDURE|Stereotactic radiosurgery|
214556759|NCT04210427|DRUG|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
214556760|NCT04210427|DEVICE|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
214556761|NCT01482936|DRUG|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
214556762|NCT05422183|DRUG|Envafolimab|400mg，sc，d1，Q3W
214556763|NCT05422183|DRUG|Lenvatinib|8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
214556764|NCT05422183|DRUG|VP-16|50 mg/d, po,d1-14，Q3W
214556765|NCT01174446|BIOLOGICAL|BAX 326|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~* Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~* Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
214704398|NCT02915068|BEHAVIORAL|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
214704399|NCT05601908|OTHER|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
214704400|NCT05444010|BEHAVIORAL|mandala painting|nurse painted mandala for relaksing
214704401|NCT01141218|OTHER|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
214704402|NCT05281848|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
215163043|NCT03366116|DRUG|aza-TdC|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
214556766|NCT01174446|BIOLOGICAL|BeneFIX|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~* BeneFIX only used in Part 1 of this study.~* Study Part 2 and 3 only utilized BAX326"
214556767|NCT02845232|OTHER|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
214556768|NCT00743977|DRUG|Phenazopyridine HCl|100mg tablet in fasting state
214556769|NCT04706897|DRUG|Dexmedetomidine, ketamine and lidocaine|A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
214556770|NCT04706897|DRUG|Normal saline|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
214556771|NCT06287645|DIAGNOSTIC_TEST|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Participants will undergo retinal imaging by fundus camera. Three specialists will independently grade images for common retinal disorders like Diabetic Retinopathy. Final grading decisions will be unanimous among the specialists.
214556772|NCT05102318|PROCEDURE|Direct Pulp Capping|Direct Pulp Capping
214556773|NCT05102318|PROCEDURE|Partial Pulpotomy|Partial Pulpotomy
214556774|NCT05102318|PROCEDURE|Pulpotomy|Pulpotomy
214556775|NCT02815020|OTHER|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
214704403|NCT01329289|DRUG|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
214704404|NCT01329289|DRUG|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
214704405|NCT01329289|DRUG|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
214556776|NCT03676478|OTHER|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
214556777|NCT05736172|BEHAVIORAL|Pain neuroscience grupal education|The face to face education group will be carried out with a physiotherapist addressing various topics in the neurosciences of pain. In the active control group, information will only be provided in written form for the individual patient to read.
214556778|NCT06169462|PROCEDURE|PENG block|Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
214556779|NCT06169462|PROCEDURE|PENG block+ SIFCB|Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
214556780|NCT04964856|BEHAVIORAL|ERAS exercise|Take ERAS exercise twice a day from hospitalization to 30 days after surgery
214556781|NCT04964856|BEHAVIORAL|No ERAS exercise|Don't take ERAS exercise in perioperative period
214704406|NCT01299610|DRUG|GW870086 2.0%|White to slightly colored opaque cream
214704407|NCT01299610|DRUG|GW870086 0.2%|White to slightly colored opaque cream
214704408|NCT01299610|DRUG|FP 0.05%|White cream
214704409|NCT01299610|DRUG|Placebo|White to slightly colored opaque cream
214704410|NCT00804843|DRUG|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
214704411|NCT00804843|DRUG|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
215163044|NCT04909203|DEVICE|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
214704412|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
214704413|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
214704414|NCT00536848|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
214704415|NCT00536848|DIETARY_SUPPLEMENT|Placebo|
214704416|NCT00536848|DRUG|Metronidazole|
214704417|NCT00003129|DRUG|valrubicin|
214704418|NCT05979714|OTHER|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
214704419|NCT05979714|BEHAVIORAL|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
214704420|NCT05979714|OTHER|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
215163045|NCT04909203|DEVICE|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
215163046|NCT02579967|DRUG|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
215163047|NCT02579967|DRUG|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
214556782|NCT02039245|DRUG|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
214556783|NCT00480142|DRUG|Oxycodone 10 mg|
214556784|NCT05690997|OTHER|Intensive treatment|If the mean home SBP preceding clinic follow-up is \>130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
214556785|NCT05690997|OTHER|Standard treatment|If the mean home SBP preceding clinic follow-up is \>140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
214556786|NCT05171790|DRUG|QL1706 injection|5 mg/kg, IV, Q3w
214556787|NCT02901769|OTHER|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
214556788|NCT00929253|DRUG|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
214556789|NCT00929253|BEHAVIORAL|CRA|Computer-delivered Community Reinforcement Approach
214556790|NCT00929253|BEHAVIORAL|Therapy|Therapist-delivered therapy
214704421|NCT05979714|BEHAVIORAL|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
214704422|NCT02223429|DRUG|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
214704423|NCT02223429|DRUG|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
214704424|NCT02223429|DRUG|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
214704425|NCT04291924|DIAGNOSTIC_TEST|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
214704426|NCT04457570|OTHER|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
214704427|NCT01926470|PROCEDURE|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
214704428|NCT01926470|PROCEDURE|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
214704429|NCT04378257|BEHAVIORAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
214704430|NCT04378257|BEHAVIORAL|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
214704431|NCT02567357|BEHAVIORAL|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
214704432|NCT02567357|BEHAVIORAL|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
214704433|NCT04426994|DRUG|proton pump inhibitor use|Patients using long term proton pump inhibitor
214704434|NCT03978104|DIETARY_SUPPLEMENT|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
215163048|NCT02579967|DRUG|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
215163049|NCT02579967|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
214556791|NCT00929253|BEHAVIORAL|CM|Contingency management (vouchers) for providing a drug negative urine sample.
214556792|NCT02547272|PROCEDURE|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
214556793|NCT03826524|DRUG|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
214556794|NCT05518071|DRUG|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
214556795|NCT05518071|DEVICE|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
214556796|NCT03498469|BEHAVIORAL|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
214556797|NCT03498469|BEHAVIORAL|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
214556798|NCT03653767|DEVICE|Adjustable Furniture|The intervention will include adjustable school furniture.
214556799|NCT03959761|DRUG|Intraperitoneal (IP) nivolumab infusion|"Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~* Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~* Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions"
214556800|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
214556801|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
214556802|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
214556803|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
214556804|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
214556805|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
214556806|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
214556807|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
214556808|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
214556809|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
214556810|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
214556811|NCT06052527|OTHER|Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning|A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning
214556812|NCT03471546|BEHAVIORAL|Palliative Care|Initial consultation and follow-up with a palliative care provider
214556813|NCT05515354|OTHER|Timing of nicotine replacement therapy start date|Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
214556814|NCT05515354|DRUG|Nicotine Replacement Therapy Agent|Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
214556815|NCT03909490|OTHER|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
214556816|NCT03909490|OTHER|handout|handout with information about trigger fingers
214556817|NCT02497495|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
214556818|NCT03895047|OTHER|tomographic EEG Neurofeedback Training|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
214556819|NCT03057847|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
215163050|NCT02579967|PROCEDURE|Allo BMT|Allogeneic blood or marrow transplantation
214556820|NCT06221501|DRUG|Efgartigimod Alfa|Efgartigimod will be administered intravenously on Day (D)1, D8, D15, and D22 at a dose of 10 mg/kg according to the patient's weight (maximum infusion dose of 1200 mg) over approximately 1 hour for a total of 4 doses. Thymectomy will be performed on Day 9.
214556821|NCT03056651|OTHER|treatment in day-care heart failure unit|
214556822|NCT02769442|DEVICE|Terumo SurFlash Plus catheter|
214556823|NCT02769442|DEVICE|BD Insyte Autoguard catheter|
214556824|NCT06507423|DEVICE|Septicyte Lab Test pre operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
214556825|NCT06507423|DEVICE|Septicyte Lab Test post operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
214556826|NCT06337487|OTHER|QoL questionnaires|"The EORTC QLQ-C30 questionnaire is a specific cancer questionnaire. A score is calculated per dimension reflecting the patient's level for the corresponding QoL scale (dimension). These scores are calculated according to the EORTC recommendations.~Research work was recently developed by Giesinger et al. within the EORTC QoL group, with the aim of providing thresholds of clinical importance for the different dimensions of the QLQ-C30.~An item was added to complete the QLQ-C30. It comes from the EORTC bank library item based on the INCa organizational framework. This item was chosen because it addressed a theme not addressed in the QLQ-C30, sexual health. After consultation with a multidisciplinary team, the threshold was determined for this additional item. Has your illness or treatment had a negative effect on your sex life? , the threshold is reached when the answer is enough or a lot."
214556827|NCT06337487|OTHER|Qualitative Interview (for one part of nurses only)|At the end of the study, semi-directed qualitative interviews will be conducted with the nurses carrying out the TAS with the aim of understanding the obstacles and facilitators of the routine implementation of the QoL assessment to early identify the SOS needs of patients treated in medical oncology. The semi-structured interviews will be accompanied by an interview grid composed of main questions and follow-up questions. The main questions help introduce the theme. The follow-up questions make it possible to clarify the participants' comments without interrupting the fluidity of the exchanges. The themes discussed between the researcher and the participant during the interview will be as follows: Personal information and overall professional experiences, Knowledge of the study and experience of training with tools (questionnaire and software), Perception of tools (questionnaire and software) and their implementation, Definition and perception of key concepts.
214556828|NCT06337487|OTHER|ORIC questionnaire|Organisational readiness is a factor known to influence the predisposition of individuals to change within an organisation. Based on Weiner's organisational theory, Organizational Readiness for Implementing Change (ORIC) is a questionnaire that has been developed and validated, particularly in French, to measure the organisation's state of in the field of healthcare. It comprises ten items which measure two concepts: commitment to change and effectiveness of change.
214556829|NCT06337487|OTHER|Professionals satisfaction survey|"A satisfaction questionnaire will be offered to all professionals involved once the last patient has been included. This questionnaire has previously been developed by the UMQVC team to assess investigator satisfaction for other studies and adapted to the context of SOS-Deteqt.~This questionnaire evaluates in particular :~* the quality of training~* ease of use of the CHES~* the relevance of using the CHES and the PROs~* the relevance of maintaining the PRO evaluation approach in current clinical practice."
214704435|NCT03978104|DIETARY_SUPPLEMENT|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
214704436|NCT03978104|DIETARY_SUPPLEMENT|Control biscuits|Consumption of control biscuits together with habitual diet.
214704437|NCT02517853|DEVICE|Posterior tibial nerve stimulation|
214704438|NCT02517853|DEVICE|Sham posterior tibial nerve stimulation|
215163051|NCT06451965|OTHER|Timeline Intervention|"The proposed intervention consists of six sessions. In Session One, the focus is on building rapport, assessing individual difficulties, setting client-focused goals, and introducing the timeline. Participants complete timeline examples during the session and as homework.~In Session Two, psychoeducation is provided regarding the impact of stroke, addressing changes in identity and associated feelings of grievance.~Session Three onwards introduces active change methods, encouraging reflection on complex life events. The aim is to promote resilience, meaning, self-compassion, and self-acceptance by exploring past coping strategies and finding significance in events of regret. This framework aims to enhance research on complex interventions, considering efficacy, effectiveness, theory-based approaches, and systems perspectives."
214704439|NCT00978679|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
214704440|NCT00978679|DEVICE|Spectacles|Daily use of single vision lenses to correct refractive errors
214704441|NCT02097485|DRUG|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
214704442|NCT02097485|DRUG|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
214704443|NCT03607474|OTHER|Questionnaires of life quality for patients|"* the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale"
214704444|NCT03607474|OTHER|Questionnaires of life quality for caregivers|"* the WhoQoL~* The Beck II scale~* HAD scale"
214709039|NCT02679443|DIETARY_SUPPLEMENT|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
214556830|NCT06337487|OTHER|Patients satisfaction survey|"A patient satisfaction questionnaire was drawn up for the study. It includes items taken from :~* the EORTC's PATSAT33 satisfaction questionnaire, and in particular items relating to the quality of information provided by nurses and the time spent~* the EORTC COMU26 communication evaluation questionnaire, and in particular the items on being comfortable asking questions, professional responses to difficult difficult subjects, explanation of treatment objectives, etc.~* the questionnaire developed jointly by the UMQVC team and the psychology laboratory of the psychology laboratory at the University of Franche Comté as part of the REMOQOL-Poumon study and assessing in particular~* understanding of the purpose of using the QoL questionnaire~* ease of completion and use of the tablet~* satisfaction with the questionnaire and the tablet~* intention to use in the future"
214556831|NCT00398372|DRUG|Rituximab|
214556832|NCT00398372|DRUG|Epratuzumab|
214556833|NCT03577847|DIAGNOSTIC_TEST|Rural CT scanning|Rural computer tomography for acute stroke
214556834|NCT00381927|BEHAVIORAL|Physician Counseling|
214556835|NCT04190576|DEVICE|Low Level Laser Therapy|Hydroxyapatite bone graft with collagen
214556836|NCT06316518|OTHER|mindfulness group|In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.
214556837|NCT05889767|OTHER|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)"
214556838|NCT00967967|DRUG|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
214556839|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display can be seen|Pain scores are displayed on the screen when the participant presses the corresponding button
214704445|NCT05317702|OTHER|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
214704446|NCT02748122|OTHER|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
214704447|NCT05535101|DEVICE|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
215163052|NCT02581085|DRUG|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
215163053|NCT02581085|OTHER|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
215163054|NCT05490511|DRUG|Tacrolimus single dose|5 mg once
215163055|NCT05490511|DRUG|Epidiolex single dose|Epidiolex 5 mg/kg
215163056|NCT05490511|DRUG|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
215163057|NCT03858153|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
215163058|NCT03858153|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
215163059|NCT05672199|DRUG|Efavaleukin alfa|Subcutaneous (SC) injection
215163060|NCT05672199|DRUG|Placebo|SC injection
215163061|NCT04907188|BIOLOGICAL|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10\^8 cells) cells approximately every 28 days.
214556840|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display is hidden|Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
214556841|NCT01869504|DEVICE|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
214556842|NCT01738659|DIETARY_SUPPLEMENT|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
214556843|NCT00843505|BEHAVIORAL|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
214556844|NCT00843505|BEHAVIORAL|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
214556845|NCT03386825|DRUG|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
214556846|NCT01510080|BEHAVIORAL|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
215163062|NCT06424015|OTHER|Intralipid and heparin|Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
215163063|NCT06424015|OTHER|Saline|Saline will be infused
215163064|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Semestrial administration
215163065|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Annual administration
215163066|NCT05949619|DRUG|BL-M02D1|Administration by intravenous infusion
215163067|NCT04821284|DRUG|Gemcitabine Hydrochloride|Given IV
215163068|NCT04821284|DRUG|Nab-paclitaxel|Given IV
215163069|NCT04821284|DRUG|Fluorouracil|Given IV
215163070|NCT04821284|DRUG|Irinotecan Hydrochloride|Given IV
215163071|NCT04821284|DRUG|Leucovorin Calcium|Given IV
215163072|NCT04821284|DRUG|Oxaliplatin|Given IV
215163073|NCT04821284|OTHER|Perflubutane Microbubble|Oxaliplatin
215163074|NCT04821284|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214556847|NCT01510080|BEHAVIORAL|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
214556848|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS, a broadly neutralizing monoclonal antibody targeting the HIV-1 envelope CD4 binding site.
214556849|NCT03476759|PROCEDURE|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
214556850|NCT03476759|DRUG|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
214556851|NCT05853952|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
214556852|NCT05853952|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
214556853|NCT03236584|DRUG|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
214556854|NCT03236584|DRUG|Tenofovir Disoproxil Fumarate|switching to tenofovir
214556855|NCT04291053|DRUG|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
214556856|NCT04905576|BEHAVIORAL|Relaxation training|Muscle relaxation training
214556857|NCT04905576|BEHAVIORAL|Therapeutic touch|Healing Touch (HT) therapy
214556858|NCT04905576|OTHER|Questionnaire administration|
214556859|NCT04905576|OTHER|Ancillary studies|Subjects in all groups will give 4 blood samples during the study
214556860|NCT02360722|OTHER|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
214556861|NCT02360722|OTHER|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
214556862|NCT03329469|DEVICE|Toshiba CT-FFR|Patients receiving CCTA to diagnose acute chest pain or unstable angina will receive CT-FFR to estimate rate of blood flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
214556863|NCT02658877|DRUG|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
214556864|NCT02658877|DRUG|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
214556865|NCT02480192|OTHER|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
214556866|NCT01928238|DEVICE|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
214556867|NCT01928238|DEVICE|Noninvasive pressure support ventilation (NPSV)|
214704448|NCT05535101|DEVICE|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
215163075|NCT04821284|OTHER|Quality-of-Life Assessment|Ancillary studies
214556868|NCT02671188|DRUG|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
214556869|NCT02671188|DRUG|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
214556870|NCT06050616|OTHER|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
214556871|NCT06050616|OTHER|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
214556872|NCT06050616|OTHER|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
214556873|NCT06050616|BIOLOGICAL|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
214556874|NCT06050616|OTHER|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
214704449|NCT04172701|DRUG|Long-acting Muscarinic Antagonists (LAMA)|drug
214704450|NCT04172701|DRUG|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
214704451|NCT02472015|PROCEDURE|telemedicine|psycho-behavioural care by telemedicine
214704452|NCT04318379|BIOLOGICAL|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
214704453|NCT02126670|DRUG|ACT01|
214704454|NCT02126670|DRUG|Comp01|
214704455|NCT02126670|DRUG|Comp02|
214704456|NCT02126670|DRUG|Comp03|
214556875|NCT05249608|DEVICE|A prospective, open-label, multicenter, single-arm clinical study to evaluate the safety and performance of the Gastric Bypass Stent System as a weight loss treatment for obesity|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 9 months.
214704457|NCT02126670|DRUG|Comp04|
214704458|NCT03836352|OTHER|DPX-Survivac|SubQ injection (q9w)
214704459|NCT03836352|DRUG|Cyclophosphamide|PO (BID)
214704460|NCT03836352|DRUG|Pembrolizumab|IV Infusion (q3w)
214704461|NCT06048653|OTHER|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~* Patients will receive training for four weeks, two sessions per week.~* Each patient will assume a comfortable sitting position on a chair in front of the screen.~* A report will be generated at the end of the session. It will be used for follow up.~* Session duration will range from 45 to 60 min. including rest period."
214704462|NCT06048653|DEVICE|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
214704463|NCT02700139|DEVICE|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
214704464|NCT00313248|DRUG|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
214704465|NCT00313248|DRUG|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
214704466|NCT03437317|BEHAVIORAL|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
214704467|NCT03437317|BEHAVIORAL|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
214704468|NCT01286116|DEVICE|Parachute Implant|Mechanical ventricular partitioning
214704469|NCT03039920|OTHER|Electronic cigarette|Smoking of electronic cigarette
214704470|NCT03039920|OTHER|Conventional cigarette|Smoking tobacco cigarette
214704471|NCT02079051|BEHAVIORAL|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
214704472|NCT02079051|BEHAVIORAL|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
215163076|NCT04821284|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215163077|NCT04821284|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163078|NCT06481670|OTHER|Carbohydrate drink|The \>50 g carbohydrate drink will be consumed up to 2 hours prior to surgery.
215163079|NCT06311214|PROCEDURE|Biopsy Procedure|Undergo biopsy
215163080|NCT06311214|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214556876|NCT01294397|DRUG|Etanercept|Administered by subcutaneous injection once a week
214556877|NCT01294397|DRUG|Denosumab|Administered by subcutaneous injection
214704473|NCT00453856|DRUG|Sulfadoxine Pyrimethamine|
214709040|NCT01898364|DRUG|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
215163081|NCT06311214|PROCEDURE|Computed Tomography|Undergo CT
215163082|NCT06311214|PROCEDURE|Echocardiography Test|Undergo ECHO
215163083|NCT06311214|OTHER|Electronic Health Record Review|Undergo review of SOC RNA testing results
215163084|NCT06311214|DRUG|Enfortumab Vedotin|Given IV
215163085|NCT06311214|OTHER|Immunohistochemistry Staining Method|Undergo IHC assay
215163086|NCT06311214|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163087|NCT06311214|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215163088|NCT06311214|BIOLOGICAL|Sacituzumab Govitecan|Given IV
215163089|NCT06311214|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
215163090|NCT05082584|DRUG|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
215163091|NCT06459765|DEVICE|Mi2000 TICI|Cochlear Implantation
214556878|NCT01199068|DRUG|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
214556879|NCT01199068|DRUG|Erlotinib|Erlotinib 150 mg once daily
214556880|NCT05766527|BIOLOGICAL|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
214556881|NCT01541852|DRUG|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
214704474|NCT03842956|PROCEDURE|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
214704475|NCT00360048|DRUG|oxytocin|
214704476|NCT05862948|DEVICE|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
214704477|NCT04077229|BEHAVIORAL|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
214704478|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
214704479|NCT01975246|DRUG|hydrochlorothiazide|tablet
214704480|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
214704481|NCT01975246|DRUG|Placebo|placebo matching hydrochlorothiazide tablet
214704482|NCT01263093|DRUG|Clopidogrel|
214704483|NCT01263093|DRUG|LY2216684|
214704484|NCT02571608|DRUG|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
214704485|NCT02571608|DRUG|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
214704486|NCT00424346|DRUG|Canakinumab|
214704487|NCT00424346|DRUG|Placebo|
214704488|NCT04907864|COMBINATION_PRODUCT|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
214556882|NCT01541852|DRUG|Placebo|One tablet twice daily
214704489|NCT02855645|DRUG|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
214704490|NCT02855645|DRUG|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
214704491|NCT04464577|DRUG|Fluconazole|Specified Dose on Specified Days
215163092|NCT05125406|BEHAVIORAL|Exposure therapy with Virtual Reality.|Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
215163093|NCT06129539|DRUG|Debio 4326|Administered as an intramuscular (IM) injection
215163094|NCT06514794|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007
215163095|NCT04492410|OTHER|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
215163096|NCT05318729|DEVICE|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
215163097|NCT02505750|RADIATION|3D conformal EBRT|External Beam Radiation Therapy
215163098|NCT02505750|DEVICE|Contact X-ray brachytherapy 50 kV|
215163099|NCT02505750|DRUG|Capecitabine|
215163100|NCT03327597|OTHER|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
215163101|NCT03327597|OTHER|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
214556883|NCT04735848|DIETARY_SUPPLEMENT|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
214556884|NCT04866381|DRUG|SHR-6390|SHR-6390
214556885|NCT04866381|DRUG|SHR-6390 + Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
214556886|NCT04866381|DRUG|Camrelizumab (SHR-1210) + SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
214556887|NCT01815086|BIOLOGICAL|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
214704492|NCT04464577|DRUG|Bupropion|Specified Dose on Specified Days
214704493|NCT04464577|DRUG|Itraconazole|Specified Dose on Specified Days
214704494|NCT04464577|DRUG|BMS-986235|Specified Dose on Specified Days
214704495|NCT02653313|DRUG|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
214704496|NCT00571519|DRUG|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
214704497|NCT00571519|DRUG|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
214704498|NCT00571519|DRUG|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
215163102|NCT03327597|OTHER|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
214556888|NCT03245047|DIETARY_SUPPLEMENT|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
214556889|NCT03245047|OTHER|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
214556890|NCT00999739|BIOLOGICAL|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
214556891|NCT01250925|DRUG|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
214556892|NCT01250925|DRUG|OPTI-FREE® RepleniSH®|Contact Lens care regimen
214556893|NCT01250925|DRUG|Clear Care®|Contact lens care regimen
214556894|NCT06329323|DIAGNOSTIC_TEST|Blood test|Serum and plasma microRNA quantification
214556895|NCT06329323|DIAGNOSTIC_TEST|Pathology specimen miRNA expression|Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
214556896|NCT04000984|BEHAVIORAL|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
214556897|NCT04000984|BEHAVIORAL|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
214556898|NCT05465590|DRUG|MB1707|"MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism."
214556899|NCT00678301|BIOLOGICAL|GSK Biologicals' Synflorix™|3 IM doses.
214556900|NCT00678301|BIOLOGICAL|GSK Biologicals' Polio Sabin™|3 oral doses
214556901|NCT00678301|BIOLOGICAL|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
214556902|NCT03215862|DRUG|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
215163103|NCT03327597|OTHER|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
214556903|NCT03215862|DRUG|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
215163104|NCT03327597|OTHER|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
215163105|NCT03327597|OTHER|Clinical follow-up control|Control clinical visit
215163106|NCT02586857|DRUG|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
214556904|NCT05059444|DIAGNOSTIC_TEST|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
214556905|NCT03338296|DRUG|lorcaserin hydrochloride XR|oral tablet
214556906|NCT03338296|DRUG|Placebo|oral tablet
214556907|NCT01653600|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
214556908|NCT01653600|DEVICE|LifeStent|same to SMART STENT
214556909|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
214556910|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
214556911|NCT06215820|DRUG|MR-107A-02|tablet
214556912|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
214556913|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
214556914|NCT04421950|DIETARY_SUPPLEMENT|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
214556915|NCT04421950|DIETARY_SUPPLEMENT|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
214704499|NCT00571519|DRUG|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
214704500|NCT00571519|DRUG|pioglitazone HCl|15 mg capsules administered orally, once daily
215163107|NCT02976714|OTHER|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
214556916|NCT00966121|PROCEDURE|endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
214556917|NCT00966121|PROCEDURE|EBL+Propranolol|"* Start with 20 mg b.i.d~* Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
214556918|NCT01053767|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
214556919|NCT03993808|BEHAVIORAL|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
214556920|NCT03993808|BEHAVIORAL|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
214556921|NCT03993808|BEHAVIORAL|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
214556922|NCT03993808|BEHAVIORAL|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
214556923|NCT03993808|BEHAVIORAL|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
214556924|NCT00387244|DEVICE|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
214556925|NCT02791568|PROCEDURE|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
214556926|NCT02791568|PROCEDURE|MRI Scan|MR imaging will take approximately 30 minutes.
214556927|NCT02791568|DRUG|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
214556928|NCT03461770|OTHER|CPAP|Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
215163108|NCT01154374|DRUG|MEBO Wound Ointment|Topical application twice daily
215163109|NCT01154374|PROCEDURE|Standard of Care (sterile saline moistened gauze)|
215163110|NCT03712514|OTHER|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
215163111|NCT03747458|DRUG|OPN-375|OPN-375, BID
215163112|NCT06341712|DRUG|Cabozantinib|Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
215163113|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
215163114|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
215163115|NCT05459948|DEVICE|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
214556929|NCT01725126|DRUG|GSK2890457|Provided as powder and capsule.
214556930|NCT01725126|DRUG|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
214556931|NCT01725126|DRUG|Placebo|Provided as powder and Capsule.
214556932|NCT01725126|DRUG|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
214556933|NCT01849640|DRUG|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
214556934|NCT01022905|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
214556935|NCT01128270|DRUG|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
214556936|NCT01128270|DRUG|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
214704501|NCT00571519|DRUG|pioglitazone HCl|30 mg capsules administered orally, once daily
214704502|NCT00571519|DRUG|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
214704503|NCT00571519|DRUG|placebo|placebo capsules for pioglitazone administered orally, once daily
214704504|NCT00571519|DRUG|metformin|Oral tablets. Rescue medication.
214704505|NCT01924962|DEVICE|revascularisation|revascularisation of chronic occluded coronary artery
214704506|NCT03771690|BEHAVIORAL|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
214704507|NCT02522650|DRUG|Amiloride|5mg twice a day for 8 weeks
214704508|NCT02522650|DRUG|Triamterene|50mg twice a day for 8 weeks
214556937|NCT01128270|DRUG|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
214556938|NCT01128270|DRUG|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
214556939|NCT01269151|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
214704509|NCT06376929|OTHER|oral carbohydrate containing fluid|administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
214704510|NCT04740060|OTHER|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
214556940|NCT03296800|DRUG|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
214556941|NCT03296800|DRUG|Probenecid|Probenecid tablets, 500 mg; bid
214556942|NCT03296800|DRUG|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
214556943|NCT03296800|DRUG|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
214556944|NCT05082753|DRUG|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
214556945|NCT05082753|DRUG|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
214704511|NCT04740060|OTHER|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
215163116|NCT01173354|DIETARY_SUPPLEMENT|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
215163117|NCT01173354|DIETARY_SUPPLEMENT|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
215163118|NCT04232566|PROCEDURE|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
215163119|NCT06454864|BEHAVIORAL|Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
214556946|NCT03969368|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
214556947|NCT03969368|PROCEDURE|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
214556948|NCT03435913|OTHER|Standard PEEP ventilation|During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
214556949|NCT03435913|OTHER|Matched PEEP ventilation|During mechanical ventilation PEEP is matched to IAP level
214556950|NCT06349447|DEVICE|LED|308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. 830 nm LED and 590 nm LED were irradiated, respectively. For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.
214709041|NCT06483490|OTHER|This is a cross-sectional, non pharmacological study|Measurement of immune checkpoint levels, mitochondrial dysfunction, pollutant concentrations and G-quadruplex levels and their correlation in all enrolled subjects.
214556951|NCT06349447|OTHER|without any LED exposition|without any LED exposition
214556952|NCT05185505|DRUG|Atezolizumab|1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
214704512|NCT04740060|OTHER|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
214704513|NCT00005018|DRUG|Hydroxyurea|
215163120|NCT06454864|BEHAVIORAL|Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
215163121|NCT06454864|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
215163122|NCT06403280|DIETARY_SUPPLEMENT|Alcoholic drink|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
215163123|NCT06403280|DIETARY_SUPPLEMENT|Placebo drink|Participants will receive a non-alcoholic rum flavored orange juice.
215163124|NCT04731246|OTHER|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
215163125|NCT05809973|DIAGNOSTIC_TEST|VISA tool|Validation of VISA
215163126|NCT03288207|DEVICE|Step it Up mobile app|Step it Up mobile app
214556953|NCT05185505|DRUG|Bevacizumab|15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
214704514|NCT00005018|DRUG|Abacavir sulfate|
214704515|NCT00005018|DRUG|Efavirenz|
214704516|NCT00005018|DRUG|Didanosine|
214704517|NCT03549468|DEVICE|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
215163127|NCT03288207|DEVICE|Global Positioning System (GPS) Device|Global Positioning System (GPS) Device
215163128|NCT03288207|DEVICE|Bluetooth-enabled scale|Bluetooth-enabled scale
215163129|NCT03288207|DEVICE|Bluetooth-enabled glucometer|Bluetooth-enabled glucometer
215163130|NCT03288207|DEVICE|MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH)|Image Reconstruction and Analysis Software
215163131|NCT03288207|DEVICE|MRI: Research pulse sequences (Device Manufacturer: NIH)|pulse sequences
215163132|NCT03288207|DEVICE|MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.)|radiofrequency coils
215163133|NCT03288207|DEVICE|AMRA Researcher Image reconstruction software|Image reconstruction software
215163134|NCT03590652|DRUG|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
215163135|NCT03590652|DRUG|Pomalidomide|4mg days PO 1-21/28 days
215163136|NCT03590652|DRUG|Dexamethasone|"40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg"
214704518|NCT01902537|DRUG|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
214704519|NCT04539691|DEVICE|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
215163137|NCT03590652|DRUG|Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)|1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
215163138|NCT00862433|DRUG|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
214704520|NCT04919746|OTHER|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
214704521|NCT06338046|OTHER|Corthellus Shiitake(Mushroom) Extract|topical treatment with Corthellus Shiitake(Mushroom) Extract
214704522|NCT06338046|OTHER|Placebo|topical treatment with a placebo cosmetic formula
214704523|NCT02407314|PROCEDURE|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
215163139|NCT00862433|OTHER|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
215163140|NCT00862433|OTHER|Vitamin C|Oral vitamin C, one gram daily.
215163141|NCT04762498|BIOLOGICAL|Pegloticase|IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
215163142|NCT04762498|DRUG|Methotrexate (MTX)|15 mg oral dose methotrexate administered weekly
215163143|NCT06204549|OTHER|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
215163144|NCT03994510|OTHER|Clinical and biological assessments - a 5 Years follow-up|During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
214556958|NCT04962737|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
214556959|NCT05714280|BEHAVIORAL|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
214556960|NCT06000540|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
214556961|NCT02212353|OTHER|Observational study, not interventional|
214556962|NCT00677534|DRUG|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
214556963|NCT02136953|BEHAVIORAL|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
214556964|NCT02136953|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
214556965|NCT00690053|PROCEDURE|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
214556966|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
214556967|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
214556968|NCT05108441|OTHER|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
214556969|NCT02695875|PROCEDURE|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
214556970|NCT02695875|PROCEDURE|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
214556971|NCT04258332|DIETARY_SUPPLEMENT|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
214556972|NCT04258332|DIETARY_SUPPLEMENT|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
214556973|NCT01539369|OTHER|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
214556974|NCT03254043|BEHAVIORAL|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
214556975|NCT02687035|DEVICE|SAPIEN S3 valve|Transcatheter aortic valve replacement
214556976|NCT04419298|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to acute CO poisoned patients with elevated TnI \[during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)\]~2. TTE be taken to acute CO poisoned patients with elevated TnI \[At the ED and during admission (within 7 days after CO exposure)\]"
214556977|NCT02032082|OTHER|Carbone monoxide|
214556978|NCT01779570|DRUG|Macrolide treatment|
214556979|NCT00773331|DRUG|epoetin beta|As prescribed
214556980|NCT00773331|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
214556981|NCT05106205|DRUG|DA-5213 10mg|single dose administration (one tablet once a day)
214556982|NCT05106205|DRUG|DA-5213-R 10mg|single dose administration (one tablet once a day)
215163145|NCT06800066|BEHAVIORAL|Purchase Behavior - (Non-CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
214704524|NCT02407314|DEVICE|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
214704525|NCT02407314|OTHER|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
215163146|NCT06800066|BEHAVIORAL|Purchase Behavior - (CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
215163147|NCT06409455|BEHAVIORAL|Positive Dementia Caregiving in 30 Days|Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
215163148|NCT06494462|OTHER|virtual reality training|students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
214556983|NCT04615195|OTHER|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
214556984|NCT01102764|BEHAVIORAL|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
214556985|NCT01102764|BEHAVIORAL|In Person|PE therapy delivered in person at the VAMC
214556986|NCT02668276|OTHER|Standard NCCN counseling|
214556987|NCT02668276|OTHER|Standard NCCN counseling and Oncotype DX results|
214556988|NCT00200291|BEHAVIORAL|hypocaloric, low-fat diet|hypocaloric, low-fat diet
214556989|NCT04256863|BEHAVIORAL|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (\>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
214556990|NCT04256863|BEHAVIORAL|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume \>50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
214556991|NCT05110170|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
214556992|NCT05110170|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
214556993|NCT03214653|DRUG|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
214556994|NCT03214653|DRUG|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
214556995|NCT02506751|DRUG|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
214556996|NCT00089882|PROCEDURE|APOE Genetic susceptibility testing|
214556997|NCT03400111|RADIATION|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
214556998|NCT03400111|DRUG|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
214556999|NCT00333086|DRUG|Letrozole|
214557000|NCT05716724|DRUG|Semaglutide|Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
214557001|NCT03416660|DEVICE|Fractional Carbon Dioxide laser|
214557002|NCT00446888|BEHAVIORAL|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
214704526|NCT02407314|OTHER|Six minute walk distance|Assessment of the walking distance in 6 minutes.
214704527|NCT02407314|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
214557003|NCT00446888|DIETARY_SUPPLEMENT|Forticare|400 ml of commercially-available nutritional supplement.
214557004|NCT00446888|DIETARY_SUPPLEMENT|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
215163149|NCT06622161|DEVICE|automated oxygen vs manual oxygen|Patient characteristics, ventilator, and blood gas parameters at the time of study will be shown in Tabular form. At the start of the study, half of the babies will be randomly assigned to a manual 12-hour period where a bedside nurse will adjust the FiO2 of the baby according to SpO2 levels, and half of the babies to an automated 12-hour period where Oxygenie will adjust FiO2 according to target SpO2 levels. After 12 hours, they will be shifted to contralateral intervention. The ventilator parameters (peak inspiratory pressure, positive end expiratory pressure, and rate) will be compared between the automated and manual 12-hour periods. The amount of time spent within different ranges of SpO2 will also be measured and shown in tabular form.
215163150|NCT06121479|DRUG|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
215163151|NCT02694783|BIOLOGICAL|PyVST|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
214557005|NCT02797652|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
214557006|NCT02797652|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
214557007|NCT03408587|BIOLOGICAL|CVA21|Oncolytic virus
214557008|NCT03408587|BIOLOGICAL|Ipilimumab|Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
214557009|NCT04915274|OTHER|uses of an application|Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
214557010|NCT04830553|BEHAVIORAL|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
214557011|NCT04434326|DRUG|[14]CM082 suspension|Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
214557012|NCT05355740|DRUG|Corsodyl|Corsodyl (a chlorhexidine mouthwash) will be used to rinse the mouth for one minute with 10 ml twice daily during ten days after oral surgery
214557013|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
214557014|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
214557015|NCT03273842|BIOLOGICAL|PF-06881894|pre-filled syringe 6 mg
214557016|NCT03273842|BIOLOGICAL|US-approved Neulasta|pre-filled syringe 6 mg
214557017|NCT00960453|DRUG|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
214557018|NCT02160730|DRUG|R-roscovitine|See Arm Description
214557019|NCT01133223|DEVICE|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
214557020|NCT01133223|DRUG|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
214557021|NCT00250549|BEHAVIORAL|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
214557022|NCT01384162|DRUG|sNN0029|ICV infusion
214557023|NCT00223223|DRUG|Levetiracetam, Keppra|
214557024|NCT02081053|DEVICE|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
214557025|NCT03870009|OTHER|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
214557026|NCT05835609|DRUG|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
214557027|NCT05214378|DEVICE|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
214557028|NCT02999074|OTHER|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
214557029|NCT02999074|OTHER|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
214557030|NCT02999074|OTHER|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
214557031|NCT05224089|DRUG|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
214557032|NCT05224089|DRUG|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
214557033|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
214557034|NCT04028921|OTHER|No intervention|This is a cross-sectional study; no intervention
214557035|NCT05349227|BEHAVIORAL|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
214557036|NCT05349227|DEVICE|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
214557037|NCT04680195|DRUG|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
214557038|NCT04605640|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
214557039|NCT03085043|PROCEDURE|Bone Scan|Undergo bone scan
214557040|NCT03085043|PROCEDURE|Computed Tomography|Undergo CT of the abdomen and pelvis
214557041|NCT03085043|PROCEDURE|Magnetic Resonance Imaging|Undergo pelvic MRI
214557042|NCT03085043|PROCEDURE|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
214557043|NCT05758168|PROCEDURE|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
214557044|NCT06557707|OTHER|Childhood stress|Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
214557045|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
214557046|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
214557047|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
214557048|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
214557049|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
214557050|NCT04076943|DRUG|Roxadustat|Roxadustat will be administered per schedule specified in the arm description.
214557051|NCT06268197|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of twice weekly, in-person, gentle Hatha yoga classes delivered by a certified yoga instructor. Each class will last 60-75 minutes and will include an introduction to the day's topic, an opening breathing/meditation practice, yoga postures, a closing breathing/meditation practice, and end with a savasana pose and intention setting for a home practice.
214557052|NCT06157281|BEHAVIORAL|Connect|A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
214557053|NCT00572364|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214557054|NCT03873753|OTHER|Cleaning|Gauze and mineral water
214557055|NCT03873753|OTHER|No oral cleaning|Absence of cleaning
214557056|NCT02859129|DRUG|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
214557057|NCT02859129|DRUG|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
214557058|NCT02859129|DRUG|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
214557059|NCT02859129|DRUG|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
214704528|NCT02407314|DRUG|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
214704529|NCT02401802|DIETARY_SUPPLEMENT|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
214704530|NCT02401802|DIETARY_SUPPLEMENT|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
214704531|NCT01109069|DRUG|PCI-32765|Dose based on parent protocol
214704532|NCT01674816|DEVICE|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
214704533|NCT01674816|DEVICE|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
214704534|NCT05151224|DIAGNOSTIC_TEST|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
214704535|NCT04682678|PROCEDURE|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
214704536|NCT03246555|DRUG|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
214704537|NCT03246555|DRUG|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
214704538|NCT03457766|DEVICE|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
214704539|NCT02953613|DEVICE|NIRS/IVUS|Cardiac catheterization using infraredx
214704540|NCT05709314|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
214704541|NCT05369624|OTHER|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
215163152|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
215163153|NCT06148584|BEHAVIORAL|General, status-neutral HIV education|General, status-neutral HIV education
215163154|NCT06148584|DIAGNOSTIC_TEST|HIV self-test kits|HIV self-test kits
215163155|NCT06148584|OTHER|Information about where to receive HIV prevention services|Information about where to receive HIV prevention services
214704542|NCT00562640|BIOLOGICAL|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
214709042|NCT01654042|OTHER|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
215163156|NCT06148584|BEHAVIORAL|Barber-led peer support group education|Barber-led peer support group education
214557060|NCT04614701|PROCEDURE|Carotid Artery Ultrasound Measure|"Cardiac output will be assessed by measuring the LVOT diameter in parasternal long-axis window and the LVOT VTI in apical-four window. Carotid artery flow will be measured on the right neck 1-2cm from the bifurcation of the common carotid artery. All measurements will be taken with participants supine and the head of the bed elevated to 45°. measures all at 3 minute intervals.~1. One-leg compression test: Thigh-sized blood pressure cuff inflated to 60mmHg on middle part of one thigh for 60 seconds. LVOT and CCA measurements taken separately.~2. Two-leg compression test: Thigh-sized blood pressure cuff inflated on middle part of both thighs for 60 seconds. LVOT and CCA measurements taken separately.~3. Passive leg raise test: Bed adjusted to place participant at 0° and legs elevated at 45° by use of pillows. After 1 minute, measurements repeated. LVOT and CCA measurements taken separately."
214557061|NCT04331457|RADIATION|Brain magnetic resonance imaging (MRI) , computed tomography (CT)|imaging
214557062|NCT04447508|BEHAVIORAL|Participants receive one on one motivational interviewing and participate in a group exercise class virtually.|Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
215163157|NCT06148584|BEHAVIORAL|Facility-based HIV risk reduction counseling|Facility-based HIV risk reduction counseling
215163158|NCT06148584|DIAGNOSTIC_TEST|Facility-based HIV testing|Facility-based HIV testing
215163159|NCT06148584|OTHER|Information about facility distributed HIV self-test kits|Information about facility distributed HIV self-test kits
215163160|NCT06148584|DIAGNOSTIC_TEST|STI testing|STI testing
214557063|NCT03177239|DRUG|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
214557064|NCT03177239|DRUG|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
214557065|NCT00196157|PROCEDURE|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
214557066|NCT00196157|PROCEDURE|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
214557067|NCT04850664|DRUG|CBOT + TAU|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
214557068|NCT04850664|DRUG|Sham + TAU|Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
214557069|NCT02103517|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
214557070|NCT02103517|DIETARY_SUPPLEMENT|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
214557071|NCT04756102|OTHER|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
214557072|NCT06436768|DRUG|Sugammadex|"After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight."
214557073|NCT06436768|DRUG|Neostigmine|"After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight."
214557074|NCT04218032|DEVICE|sphygmomanometer, SpyghmoCor, CNAP500|blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
214557075|NCT05378477|DEVICE|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
214557076|NCT05378477|DEVICE|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
214557077|NCT05378477|DRUG|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
214557078|NCT05378477|DEVICE|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
214557079|NCT06314100|DEVICE|Tobacco heating systems|The study aims to explore the effect of tobacco heating system consumption on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
215163161|NCT04218331|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
215163162|NCT04218331|BEHAVIORAL|PROMPT|PROMPT is a multidimensional oral-motor approach to speech production disorders.
215163163|NCT06554223|BEHAVIORAL|SUSTAIN-DSD|"Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months."
214709043|NCT02297542|BIOLOGICAL|Flu Vaccine|
215163164|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|"As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate."
215163165|NCT06079671|BIOLOGICAL|Volrustomig|IV Infusion
215163166|NCT06079671|OTHER|Placebo|IV Infusion
215163167|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
215163168|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
215163169|NCT06467799|DRUG|Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1|Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
215163170|NCT05477524|BIOLOGICAL|VLA15|Shot in the deltoid muscle (preferable in the nondominant arm)
214557080|NCT06314100|BEHAVIORAL|cigarette smoking|The study aims to explore the effect of cigarette smoking on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
214557081|NCT06314100|BEHAVIORAL|non smoking|The non smoking group of subjects serve as control for the other two groups
214557082|NCT04483180|OTHER|Comparison of sweetener blends in liquid form (cross-over study)|The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
214557083|NCT00594698|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
215163171|NCT05477524|OTHER|Saline|Shot in the deltoid muscle (preferable in the nondominant arm)
214704543|NCT00562640|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
214704544|NCT00562640|DRUG|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
214704545|NCT00562640|OTHER|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
214704546|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
214704547|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
214704548|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
214704549|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
214557084|NCT06022445|OTHER|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
214557085|NCT01031628|DRUG|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
214709044|NCT03103906|OTHER|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
214709045|NCT03103906|OTHER|Cleanser (Reference Product)|Moisturizing facial cleanser
215163172|NCT06456190|BEHAVIORAL|Skills Training in Active Recovery (STAR) Video|a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
215163173|NCT06456190|BEHAVIORAL|Text Skills Training in Active Recovery (TextSTAR) program|a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
214557086|NCT01031628|DRUG|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
214557087|NCT01031628|DRUG|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
214557088|NCT02430753|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
214557089|NCT02430753|DEVICE|NanoKnife|
214557090|NCT01238536|PROCEDURE|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
214557091|NCT01238536|PROCEDURE|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
214557092|NCT01238536|DRUG|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
214557093|NCT01238536|DRUG|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
214557094|NCT00967005|DRUG|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
214709046|NCT03103906|OTHER|Sunscreen (Reference Product)|SPF 50 sunscreen
215163174|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
215163175|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
214557095|NCT00967005|OTHER|Sugar Pill|placebo control
214557096|NCT04771364|OTHER|ASAP care's protocol|Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
214709047|NCT03991559|DRUG|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
214709048|NCT03991559|DRUG|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
215163176|NCT06634277|BEHAVIORAL|NavSTAR (Philly adaptation)|Patient Navigation
214557097|NCT04374786|DEVICE|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
214557098|NCT05256615|BEHAVIORAL|30-minute walking intervention|Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
214557099|NCT05256615|BEHAVIORAL|10-minute|Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
214557100|NCT00758342|DRUG|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
214557101|NCT00758342|DRUG|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
214557102|NCT00900692|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
214557103|NCT04653233|DEVICE|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
214704550|NCT00848770|DRUG|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
214704551|NCT00848770|DRUG|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
215163177|NCT06038331|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
215163178|NCT03269422|RADIATION|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
215163179|NCT03190057|DEVICE|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
214557104|NCT05338385|BEHAVIORAL|Mental Skills Coaching|Participants will partake in a 1-hour pre-op initial intake, followed by five 30-min follow-up sessions at 2 weeks, 6 weeks, 3 months, 6 months and 9-months post-op. All sessions will be one-on-one with the same master's-level mental skills coach. At each session, the provider will allow time for participants to share their current injury experience to date (i.e. how they are doing, challenges they have encountered). Following this, participants will be introduced to a series of mental skills tools, including but not limited to mindset awareness, motivation, cognitive restructuring, goal setting, and objective performance assessment. Participants will be provided with handouts outlining the strategies addressed to help maintain consistency of mental skills engagement between sessions.
214557105|NCT01777165|DRUG|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
214557106|NCT01777165|DRUG|Placebo|Placebo infusion
214557107|NCT02780518|DEVICE|Airvo|Applying high flow nasal oxygen
214557108|NCT02650713|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
214557109|NCT02650713|DRUG|RO6958688|"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
214557110|NCT00423566|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
214557111|NCT05529888|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
214557112|NCT05129332|OTHER|Vaginal Moisturizer|Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
214557113|NCT05129332|DEVICE|Vaginal Dilator|Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
214704552|NCT00848770|DRUG|manipulation of SAP|Esmolol or NPS or NOR
214704553|NCT05193851|DRUG|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
215163180|NCT06133972|DRUG|Placebo|Placebo s.c. monthly
215163181|NCT06133972|DRUG|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
214557114|NCT01371825|DRUG|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
215163182|NCT02923206|DEVICE|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
215163183|NCT06177665|OTHER|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
215163184|NCT06177665|OTHER|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
215163185|NCT04773522|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
215163186|NCT05113641|DIETARY_SUPPLEMENT|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
214557115|NCT00891033|DRUG|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
214557116|NCT00891033|DRUG|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
214557117|NCT03428906|DRUG|Oxytocin|intranasally administrated
214557118|NCT03428906|DRUG|Placebo|intranasally administrated
214557119|NCT03362983|OTHER|CareHND|Multidisciplinary, integrated, person-centered care at the integrated HND-clinic
214557120|NCT00532207|DRUG|teriparatide|subcutaneous 20 micrograms
214557121|NCT02467439|OTHER|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
214557122|NCT00895895|DRUG|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
214557123|NCT00895895|DRUG|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
214557124|NCT00895895|DRUG|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
214557125|NCT00895895|DRUG|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
214557126|NCT00895895|DRUG|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
214557127|NCT00560144|DRUG|RG1507|3mg/kg iv weekly
214557128|NCT00560144|DRUG|RG1507|9mg/kg iv weekly
214557129|NCT00560144|DRUG|RG1507|Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
214557130|NCT02893189|GENETIC|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
214557131|NCT03338439|DEVICE|CSII|This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
215163187|NCT05113641|DRUG|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the dispensed by the clinic/hospital pharmacies.
214557132|NCT01261000|DRUG|Pegvisomant|Pegvisomant used as indicated
214557133|NCT06153992|DEVICE|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
214557134|NCT06153992|DEVICE|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
214557135|NCT06153992|OTHER|without test training|Treatment was performed without using any isokinetic muscle strength test training system
214557136|NCT00445835|OTHER|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
214557137|NCT00445835|OTHER|Conservative arm|Conservative medical approach
214557138|NCT06520150|PROCEDURE|Regional anaesthetic combined fascial plane block|Prior to the procedure, the anaesthetists will receive an envelope from a person not related to the project (a hospital administrative staff member). This envelope will contain a randomly indicated method of anaesthesia based on simple randomisation. This will determine the type of regional block used during the procedure. It is important to note that the patient will not know which study group they have been classified in. Furthermore, the operator performing the procedure will not be informed of the type of anaesthesia performed. This is to ensure double-blinding. In order to ensure the highest standards of objectivity, the operator performing the procedure will not be informed about the type of block performed. This will allow us to assess the extent and quality of anaesthesia after the procedure, We will use a proprietary scale of subjective operator comfort scale.
214557139|NCT06520150|DRUG|Ropivacaine 0.125% Injectable Solution +Lignocaine 0,25% Injectable Solution|administration under ultrasound guidance of a mixture of 2 local anaesthetics in a fixed total volume
214557140|NCT03101202|DEVICE|SSD tube|The SSD tube allows the suction of subglottic secretions that collect above the cuff of the endotracheal tube
214557141|NCT00708318|DRUG|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
214557142|NCT04417205|OTHER|Carbohydrate Rich Breakfast|Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
214557143|NCT04417205|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
214557144|NCT02944162|BIOLOGICAL|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
214557145|NCT05631704|DRUG|VH4524184|VH4524184 will be administered.
214557146|NCT05631704|DRUG|Midazolam|Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
214557147|NCT05631704|DRUG|Placebo|Placebo will be administered.
214557148|NCT02744248|DRUG|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
214557149|NCT02744248|DRUG|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
214557150|NCT00504777|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214557151|NCT00504777|DRUG|Methotrexate|10-25mg/week po or parenteral
214557152|NCT00990444|DRUG|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
215163188|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
214557153|NCT04413305|OTHER|screen of CRKP and infection control measure|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
214557154|NCT05517226|COMBINATION_PRODUCT|Cotadutide|Participants will receive cotadutide subcutaneously.
214557155|NCT05492851|DRUG|Zilretta|Intra-articular injection to treat knee osteoarthritis
214557156|NCT05492851|DRUG|Synvisc-One 48 MG in 6 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
214557157|NCT05492851|DRUG|Monovisc 88 MG Per 4 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
214557158|NCT03514277|DRUG|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
214557159|NCT03514277|DRUG|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
214557160|NCT03447301|DIETARY_SUPPLEMENT|Extra virgin olive oil (30mL daily)|Intervention arm will take 30 mL of Extra virgin olive oil daily.
214557161|NCT04480775|DRUG|Triamcinolone|transversus abdominis plane block with bupivacain and triamicinolone
214557162|NCT04480775|DRUG|Methylprednisolone|transversus abdominis plane block with bupivacaine and methylprednisolone
214557163|NCT04480775|DRUG|bupivacaine|transversus abdominis plane block with bupivacaine alone
214557164|NCT00239408|DEVICE|Pulmonary function Testing|
214704554|NCT06398093|BEHAVIORAL|Self-Compassion Tool Kit|Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
214704555|NCT02919735|DRUG|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
214704556|NCT02919735|DRUG|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
214557165|NCT00239408|DRUG|tiotropium bromide|
214557166|NCT05526469|PROCEDURE|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
214557167|NCT05526469|PROCEDURE|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
214557168|NCT05526469|DRUG|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
214557169|NCT01204411|DRUG|Artesunate-amodiaquine fixed-dose combination|"* artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~* artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~* artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
214557170|NCT03423576|BEHAVIORAL|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
214557171|NCT05842642|OTHER|Cervical|6 weeks of treatment
214557172|NCT05842642|OTHER|Oculomotor|6 weeks of treatment
214557173|NCT02993185|BEHAVIORAL|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
214557174|NCT02993185|BEHAVIORAL|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
214704557|NCT02787603|OTHER|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
214704558|NCT00272545|BEHAVIORAL|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
214704559|NCT00272545|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
214704560|NCT06136455|DRUG|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
214704561|NCT06136455|DRUG|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
214704562|NCT06136455|OTHER|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
214704563|NCT06136455|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
214704564|NCT03672669|GENETIC|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
214704565|NCT03672669|GENETIC|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
214704566|NCT01852630|DRUG|cefepime + Albumin|cefepime + Albumin will be given for 2 days
214704567|NCT01852630|DRUG|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
214704568|NCT02499575|DRUG|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
214704569|NCT02499575|DRUG|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
214704570|NCT03203590|DRUG|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
214704571|NCT03203590|DRUG|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
214704572|NCT01952704|BEHAVIORAL|Aerobic exercise|
214704573|NCT01952704|BEHAVIORAL|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
214704574|NCT06347965|BEHAVIORAL|Low load blood flow restriction training|Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
214557175|NCT03843697|DEVICE|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
214557176|NCT00318721|DEVICE|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
214557177|NCT04472884|BEHAVIORAL|mWACh-PrEP|Participants randomized to mWACh-PrEP will be registered into the system, in addition to receipt of SOC services. Women registered into the mWACh-PrEP platform will indicate their preferences for message delivery including a preferred name for messaging, language (English or Kiswahili or Dholuo), and day of the week and time for SMS delivery. Once registered, women will receive weekly automated push messages on the day/time of their choice from enrollment through 6-months postpartum. All automated push messages will include participant nickname, clinic and nurse name, an educational message or actionable advice targeting PrEP adherence and continuation and/or maternal and child health (MCH) topics, and a question related to the content. SMS topics will include adherence encouragement, PrEP efficacy and safety, self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications) and visit reminders.
214557178|NCT04472884|OTHER|Standard of Care|All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
214557179|NCT00924742|DRUG|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
214704575|NCT06347965|BEHAVIORAL|Progressive resistance training group|The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
214704576|NCT02658968|DRUG|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
214704577|NCT05118711|DIAGNOSTIC_TEST|Cardiorespiratory fitness|Cardiopulmonary exercise testing
214704578|NCT05118711|DIAGNOSTIC_TEST|Lung function|Body plethysmography
214557180|NCT01621776|DRUG|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
214557181|NCT01621776|DRUG|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
214704579|NCT05118711|DIAGNOSTIC_TEST|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
214704580|NCT05118711|DIAGNOSTIC_TEST|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
214704581|NCT05118711|DIAGNOSTIC_TEST|Blood sampling and analysis|Blood sampling by venepuncture
214704582|NCT05118711|DIAGNOSTIC_TEST|Physical activity|Physical activity surveillance using accelerometers
214704583|NCT05118711|DIAGNOSTIC_TEST|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
214704584|NCT05118711|DIAGNOSTIC_TEST|Body composition|Dual-energy x-ray absorptiometry (DXA)
214704585|NCT04644965|DIAGNOSTIC_TEST|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
214704586|NCT04644965|DIAGNOSTIC_TEST|Blood Taking|Sampling of blood of the finger pad to assess liver function
214704587|NCT04644965|DIAGNOSTIC_TEST|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
214557182|NCT01621776|DRUG|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
214704588|NCT04644965|DIAGNOSTIC_TEST|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
214704589|NCT04644965|DIAGNOSTIC_TEST|Ultrasound|Ultrasound for abdominal wall muscles
214704590|NCT04644965|DIAGNOSTIC_TEST|Stance and gait analyses|Stance and gait analyses for measuring the core stability
214557183|NCT06240338|DIAGNOSTIC_TEST|laboratory investigation and Imaging|laboratory parameters (white blood cell count,neutrophil count, lymphocyte count, hemoglobin level, platelet level, red cell distribution width (RDW) level, hematocrit (HCT), renal function, hepatic function, electrolytes, arterial blood gas, HOMA-IR) will be assessed and imaging: Abdominal ultrasonography, Abdominal CT or MRI if needed
214557184|NCT05251142|OTHER|Plyometric training|"Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~* Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~* Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~* Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~* Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting."
214557185|NCT05251142|OTHER|General exercises|Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
214557186|NCT04513067|BIOLOGICAL|YQ23|YQ23 as a single agent will be given in Stage 1.
214704591|NCT06440265|OTHER|AM-PAC inpatient short form (low function)|"The Activity Measure for Post-Acute Care(AM-PAC) 6-clicks instruments have advantages in that they are simple and quick to complete, easy to use within usual care and has been validated in the entire hospital population. It has gained broad adoption in acute care hospital and, although it includes items for people at lower levels of function, there is a concern of a floor effect in ICU measurement. So, new AM-PAC items are developed to measure physical function at the lowest level and added 2 new items to AM-PAC inpatient mobility short form. It lowered the floor effect and increased statistical power, measurement breath, and sensitivity.~2 new items~* Turning head~* Following simple instructions"
214704592|NCT02025803|DRUG|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
214557187|NCT04513067|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be given in combination with YQ23 in Stage 2
215163189|NCT05874375|DEVICE|Urge stimulation|Participants will receive stimulation for 60 seconds, when they feel an urgency.
215163190|NCT05874375|DEVICE|Time limited stimulation|Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
215163191|NCT01143558|DEVICE|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
214557188|NCT00195065|BEHAVIORAL|Semi-structured, open-ended interviews|
214557189|NCT03693976|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
214557190|NCT03693976|DEVICE|Ectoin Rhinosinusitis Nasal Spray|Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
214557191|NCT00666692|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
214704593|NCT00384826|DRUG|erlotinib|Erlotinib 150 mg/day (until progression)
214704594|NCT00384826|DRUG|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
214704595|NCT01635010|PROCEDURE|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
214704596|NCT01546844|OTHER|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
214709049|NCT03991559|COMBINATION_PRODUCT|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
215163192|NCT06534437|DRUG|MEN1703|MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
215163193|NCT06534437|DRUG|Glofitamab|Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
214557192|NCT06378736|OTHER|Electroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest.|The proposed study is to determine whether EEG signals, namely theta-gamma coupling (TGC); The investigators are testing whether TGC can be used as a non-invasive novel biomarker in diagnosis and monitoring of insidious and difficult to detect cognitive dysfunction in SLE patients.
214557193|NCT04449419|OTHER|There is not intervention.|There is not intervention
214557194|NCT01593605|DIETARY_SUPPLEMENT|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
214557195|NCT01593605|DIETARY_SUPPLEMENT|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
214704597|NCT05431049|PROCEDURE|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
214704598|NCT02134067|DRUG|TAS-119|
214704599|NCT02134067|DRUG|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
214709050|NCT01644942|OTHER|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
214709051|NCT03477071|PROCEDURE|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
215163194|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as standalone therapy and another minimum of approximately 15 patients will receive ECCO2R using PrismaLung+ in combination with CRRT.
215163195|NCT06223542|PROCEDURE|Biopsy Procedure|Undergo biopsy
215163196|NCT06223542|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215163197|NCT06223542|PROCEDURE|Computed Tomography|Undergo CT
215163198|NCT06223542|PROCEDURE|Echocardiography Test|Undergo ECHO
215163199|NCT06223542|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163200|NCT06223542|DRUG|UAE Inhibitor TAK-243|Given IV
215163201|NCT06027099|DRUG|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
215163202|NCT06027099|BEHAVIORAL|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
215163203|NCT06027099|DRUG|Placebo|1 tablet three times a day for 5 weeks after surgery
215163204|NCT06027099|BEHAVIORAL|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
215163205|NCT06962930|OTHER|8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions|The first session will lay the groundwork for the program, in which an orientation of the features of the online forum will be provided. In addition, goal setting, use of watches, and how to track progress will be discussed. During the remote sessions, the participant and coach will work through informational modules of how to overcome barriers to exercise engagement and how to manage PD symptoms. In addition, the coach will provide encouragement in relation to regular physical activity and exercise, and the participant will report on progress related to up to three realistic and individualized goals they developed. key elements: (1) participant-therapist interaction, (2) online forum featuring a physical activity guidebook and workbook, (3) an online platform with personal physical activity database, (4) a wearable smart watch for activity monitors, (5) a video exercise library, (6) online support group, and (7) incorporate adaptation to Arabic culture and available in Arabic
215163206|NCT06470048|DRUG|Placebo|Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
215163207|NCT06470048|DRUG|Ianalumab|subcutaneous (s.c.) injection as defined in the protocol
214709052|NCT03571256|DRUG|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
215163208|NCT06350903|OTHER|Fast + High-fat low-carbohydrate diet|Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
215163209|NCT06350903|COMBINATION_PRODUCT|Fast + Empagliflozin|Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
215163210|NCT03744156|BEHAVIORAL|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
215163211|NCT03744156|BEHAVIORAL|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
215163212|NCT06502353|DEVICE|BLOOM43|Heat preconditioning
215163213|NCT06119594|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
214709053|NCT03571256|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
214709054|NCT02266615|GENETIC|Biobanking of biomaterial for future genetic research.|
214704600|NCT03794752|DEVICE|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
214557196|NCT01593605|OTHER|Placebo treatment|Placebo - one tablet taken twice a day by mouth
214557197|NCT02924090|DRUG|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
214704601|NCT01621724|GENETIC|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
214704602|NCT01206452|DRUG|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
214704603|NCT01206452|OTHER|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
214704604|NCT01206452|PROCEDURE|Ablation Procedure|Atrial Fibrillation (AF) ablation
214704605|NCT00972842|DRUG|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
214704606|NCT03292952|DRUG|KP415 oral capsule|Daily dose
214704607|NCT03292952|DRUG|Placebo oral capsule|Daily dose
214704608|NCT01362946|BEHAVIORAL|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
214704609|NCT01362946|BEHAVIORAL|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
214704610|NCT00709358|OTHER|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
214557198|NCT02924090|DRUG|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
214557199|NCT02924090|PROCEDURE|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
214704611|NCT00709358|OTHER|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
214704612|NCT03302897|BIOLOGICAL|LEP-F1 + GLA-SE|Investigational vaccine
214704613|NCT04603040|DRUG|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
214704614|NCT00671216|DRUG|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
214557200|NCT02924090|PROCEDURE|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
214557201|NCT04654559|OTHER|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
214557202|NCT00691795|DRUG|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
214704615|NCT00671216|DRUG|GW642444|Subjects will receive 50 mcg once daily as a single dose
214704616|NCT00671216|DRUG|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
215163214|NCT06439420|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is a non-pharmacological approach to treating sleep disturbance consisting of educational, behavioral, and cognitive intervention components with evidence-based strategies including sleep efficiency, stimulus control, and sleep hygiene modification. CBT-I includes at least 6 group sessions, each approximately 90 minutes in length, delivered over 6 weeks via telehealth.
215163215|NCT05877963|BIOLOGICAL|Ublituximab|Administered as an intravenous (IV) infusion.
215163216|NCT05877963|DRUG|Placebo|IV infusion
215163217|NCT05686070|DRUG|Asundexian (BAY2433334)|Once daily, oral
215163218|NCT05686070|DRUG|Placebo|Placebo to asundexian, once daily, oral
214557203|NCT03552523|DEVICE|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
214557204|NCT03552523|OTHER|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
215163219|NCT05902013|DEVICE|laryngoscopy|laryngoscopy for nasotracheal intubation
215163220|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
215163221|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
214557205|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
214557206|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
214557207|NCT05331690|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
214557208|NCT03285555|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
214557209|NCT03285555|DEVICE|VICRYL|Vicryl #1
214557210|NCT05762562|OTHER|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
214557211|NCT04588129|DRUG|LB-102|(N-Methyl amisulpride)
214557212|NCT05153876|OTHER|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
214557213|NCT00267514|DRUG|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
214557214|NCT00267514|DRUG|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
214557215|NCT05057338|BEHAVIORAL|CoreDISTparticipation|CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
214557216|NCT05057338|BEHAVIORAL|Standard care|The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
214557217|NCT06336187|OTHER|active surveillance|Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter.
214557218|NCT06336187|GENETIC|molecular investigation|Transcriptomic analysis of tissues
214557219|NCT03995316|BEHAVIORAL|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
214557220|NCT03995316|BEHAVIORAL|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
214557221|NCT01792791|PROCEDURE|Tissue sample collection at the time of surgery|"Spanning surgery~* A blood sample (32.5 ml)~* joint aspirate (removal of synovial fluid) from both knees~* urine sample~ORIF surgery~* Joint aspirate (removal of synovial fluid) from both knees~* A blood sample (32.5 ml)~* Urine Sample~If patients only require one surgery, sample will be collected only once."
214557222|NCT00499967|DRUG|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
214557223|NCT00499967|DRUG|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
214557224|NCT00499967|DRUG|Placebo|Placebo matching GS-9191 ointment
214557225|NCT00896727|GENETIC|gene expression analysis|
214557226|NCT00896727|GENETIC|protein expression analysis|
214557227|NCT00896727|OTHER|fluorescent antibody technique|
214557228|NCT00896727|OTHER|laboratory biomarker analysis|
214557229|NCT03731897|OTHER|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
214557230|NCT03731897|OTHER|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
214557234|NCT00043433|DRUG|intravenous T900607-sodium|
214704617|NCT00671216|DRUG|Placebo|Placebo matching study medication will be inhaled by subjects
215163222|NCT03745313|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
215163223|NCT06168669|DIAGNOSTIC_TEST|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
215163224|NCT03863119|DRUG|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
214557235|NCT03202017|PROCEDURE|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
214557236|NCT03202017|PROCEDURE|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
214557237|NCT00001005|DRUG|Zidovudine|
214704618|NCT02131012|DRUG|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
214704619|NCT03634904|DRUG|Drug bood sampling|"Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
214704620|NCT01948895|DRUG|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
214704621|NCT05386121|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
214704622|NCT05386121|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
214704623|NCT05386121|DEVICE|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
214557238|NCT00001005|DRUG|Aldesleukin|
214557239|NCT00002687|BIOLOGICAL|aldesleukin|
214557240|NCT00469690|DRUG|Acular, Xibrom|"1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
214704624|NCT05386121|DEVICE|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
214704625|NCT05386121|DRUG|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
214557241|NCT01670253|BEHAVIORAL|Group 1|"* 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
214557242|NCT03697551|DRUG|Satoreotide trizoxetan|Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
214557243|NCT04409171|DIAGNOSTIC_TEST|oral glucose tolerance test|
214557244|NCT06165757|BEHAVIORAL|noise stimulation|Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
214557245|NCT00880204|BEHAVIORAL|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
214557246|NCT04654572|DIAGNOSTIC_TEST|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
214557247|NCT02985840|DRUG|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
214557248|NCT02985840|DRUG|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
214557249|NCT03985696|OTHER|blood sample|1 blood volume (5-7 ml EDTA)
214557250|NCT02152943|DRUG|Everolimus|Given PO
214557251|NCT02152943|OTHER|Laboratory Biomarker Analysis|Correlative studies
214557252|NCT02152943|DRUG|Letrozole|Given PO
214557253|NCT02152943|BIOLOGICAL|Trastuzumab|Given IV
214557254|NCT01546532|DRUG|RLX030|RLX030 as intravenous infusion for 24 hours.
214557255|NCT01546532|DRUG|Placebo|Intravenous infusion of Placebo over 24 hours
214557256|NCT04109781|PROCEDURE|Microscope assisted discectomy|Microdiscectomy
214557257|NCT00571467|DRUG|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg"
214704626|NCT05386121|DRUG|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
214704627|NCT00627835|DRUG|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
214704628|NCT00627835|DRUG|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
214704629|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
214704630|NCT00627835|DRUG|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
214704631|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
214704632|NCT03185104|DRUG|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
214704633|NCT03185104|DRUG|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
214704634|NCT00673686|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
214704635|NCT00673686|DRUG|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
214704636|NCT01353144|DRUG|aspirin|aspirin, 100 mg, qd x 8 weeks
214704637|NCT05244499|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
214704638|NCT05244499|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
214557258|NCT03793036|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
214704639|NCT00438789|DRUG|eculizumab|600mg IV every week and 900mg IV every 2 weeks
214704640|NCT01615796|DRUG|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
214704641|NCT01615796|DRUG|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
214704642|NCT02905942|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
214704643|NCT02905942|DRUG|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
214557259|NCT00705601|PROCEDURE|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
214557260|NCT01701336|BIOLOGICAL|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
214557261|NCT03838523|OTHER|Open Label Placebo|See group description
214557262|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + OTf|OTf (apo ovotransferrin) + FeSO4
214557263|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + Lf|Lf (lactoferrin) + FeSO4
214557264|NCT05233709|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate
214704644|NCT01128335|DRUG|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
214704645|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
214704646|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
214704647|NCT01128335|DRUG|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
214704648|NCT03786198|BEHAVIORAL|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
214704649|NCT03786198|BEHAVIORAL|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
214704650|NCT02770313|BEHAVIORAL|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
214704651|NCT01094951|BEHAVIORAL|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
214704652|NCT05795010|OTHER|MRD test|ctDNA detection based on tumor whole exon sequencing
214704653|NCT00604435|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
214709055|NCT05685888|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
215163225|NCT04764942|DRUG|Carfilzomib|Given IV
215163226|NCT04764942|DRUG|Dexamethasone|Given PO
215163227|NCT04764942|DRUG|Pomalidomide|Given PO
215163228|NCT04764942|OTHER|Quality-of-Life Assessment|Ancillary studies
215163229|NCT04764942|OTHER|Questionnaire Administration|Ancillary studies
215163230|NCT04764942|DRUG|Selinexor|Given PO
215163231|NCT04764942|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
215163232|NCT04764942|PROCEDURE|Computed Tomography|Undergo PET/CT
215163233|NCT04764942|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215163234|NCT04764942|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215163235|NCT04764942|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214704654|NCT00604435|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
214704655|NCT03582735|OTHER|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
214704656|NCT03355794|DRUG|ribociclib|Oral capsule or liquid formula
215163236|NCT04764942|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214557265|NCT00624247|OTHER|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
214557266|NCT04135612|OTHER|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
214557267|NCT06265519|PROCEDURE|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH
214557268|NCT01250509|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
214557269|NCT01766713|DRUG|Ezetimibe|10mg daily oral dose of ezetimibe
214557270|NCT02383251|DRUG|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
214557271|NCT02383251|DRUG|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
214557272|NCT02205034|DRUG|oxytocin|Intranasal administration
214557273|NCT00452231|DRUG|D-cycloserine|
214557274|NCT00452231|BEHAVIORAL|Cognitive-Behavioral Therapy|
214557275|NCT05031949|COMBINATION_PRODUCT|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
214704657|NCT03355794|DRUG|Everolimus|Oral tablets or dispersible tablets
214704658|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
214557276|NCT04540237|DIAGNOSTIC_TEST|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
214704659|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
214557277|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
214557278|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
214557279|NCT05424146|DIETARY_SUPPLEMENT|Prebiotic Bar +CPT|Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
214704660|NCT02592395|DRUG|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
214704661|NCT02592395|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
214704662|NCT04843826|PROCEDURE|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
215163237|NCT04567784|DRUG|Cannabidiol (CBD)|CBD 800 mg Cannabidiol - oral CBD solution
215163238|NCT04567784|DRUG|Placebo|inactive solution
215163239|NCT05574335|DRUG|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
215163240|NCT02748408|DEVICE|SMS femoral stem|
215163241|NCT06058650|PROCEDURE|Biopsy of Breast|Undergo biopsy of breast
215163242|NCT06058650|OTHER|Medical Device Usage and Evaluation|Utilization of the Stereo Navigator accessory
215163243|NCT06058650|RADIATION|Scintimammography|Undergo MBI
215163244|NCT06058650|OTHER|Technetium Tc-99m Sestamibi|Given IV
214704663|NCT04765748|DEVICE|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
214704664|NCT00004938|DRUG|fluconazole|
214704665|NCT01595165|PROCEDURE|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
214557280|NCT05424146|BEHAVIORAL|Non-Prebiotic Bar +CPT|Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
214704666|NCT01595165|PROCEDURE|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
214704667|NCT02267226|DRUG|Octafibrin|
214704668|NCT05467462|DRUG|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
214704669|NCT05467462|DRUG|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
214704670|NCT05467462|DRUG|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
214704671|NCT05467462|DRUG|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
214704672|NCT03939611|OTHER|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
214704673|NCT03939611|OTHER|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
214704674|NCT03882398|OTHER|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
214704675|NCT03882398|OTHER|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
214704676|NCT04781907|PROCEDURE|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
214704677|NCT00303615|DRUG|Fluoxymesterone 10 mg|
214704678|NCT00303615|DRUG|Anastrozole 1 mg|
214704679|NCT04693520|DRUG|ALZ-801|ALZ-801 265 mg twice daily (BID)
214557281|NCT04814498|DRUG|Geneva Cocktail|Fixed sequence use of drug cocktail
214557282|NCT04814498|DRUG|BLD-0409|Fixed sequence use of active product
214557283|NCT01377246|DRUG|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
214557284|NCT01377246|OTHER|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
214557285|NCT04535245|DIAGNOSTIC_TEST|LCI testing|all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
214557286|NCT01183247|DRUG|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
214557287|NCT01183247|DRUG|Everolimus|Add everolimus de novo to tacrolimus and MMF
214557288|NCT01183247|DRUG|Prednisone|Add prednisone de novo to tacrolimus and MMF
214557289|NCT00900263|GENETIC|cytogenetic analysis|
214557290|NCT00900263|GENETIC|microarray analysis|
214557291|NCT00900263|OTHER|biologic sample preservation procedure|
214557292|NCT00900263|OTHER|laboratory biomarker analysis|
214557293|NCT01722370|DRUG|Oxygen|
214557294|NCT01722370|DRUG|Medical air equivalent|
214557295|NCT04175314|OTHER|Clinical examination of gingival tissues|Measure of the periodontal recession
214557296|NCT00203268|DRUG|dihydroergotamine mesylate|1.0 mg. intramuscularly
214557297|NCT05136053|DRUG|Lu AG22515|sterile solution for infusion
214557298|NCT05136053|DRUG|Placebo|sterile solution for infusion
214704680|NCT02667457|RADIATION|99mTc-rhAnnexin V-128|
214704681|NCT05195268|PROCEDURE|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
214704682|NCT04811001|DRUG|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
214704683|NCT04811001|DRUG|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
214704684|NCT02475850|OTHER|Evidence-based tailored fall prevention|
214704685|NCT02475850|OTHER|Usual care|
214704686|NCT03701646|DEVICE|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
214704687|NCT01883869|DRUG|ticagrelor|
214704688|NCT01883869|DRUG|placebo|placebo
214704689|NCT01641757|PROCEDURE|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
214557299|NCT05136053|DRUG|Immune System Activator|sterile powder for injection
214557300|NCT02448329|DRUG|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
214704690|NCT03330041|DEVICE|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
215163245|NCT05153343|DRUG|flonoltinib 25mg|1 case,The starting dose.Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
215163246|NCT05153343|DRUG|flonoltinib 100mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
214557301|NCT02448329|DRUG|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
214557302|NCT01739023|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
215163247|NCT05153343|DRUG|flonoltinib 150mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
215163248|NCT05153343|DRUG|flonoltinib 225mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
214557303|NCT05231525|DEVICE|WiTOF|Data collection on the WiTOF monitor
214557304|NCT05231525|DEVICE|TOFscan|Data collection on the TOFscan monitor
214557305|NCT02071277|OTHER|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
214557306|NCT02348944|OTHER|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
214557307|NCT04797234|OTHER|Control|There will be no intervention to the control group.
214557308|NCT04797234|OTHER|Experiment|The experimental group will be trained for 6 weeks.
214557309|NCT00600613|RADIATION|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
214557310|NCT00847522|DRUG|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
214557311|NCT00388440|BIOLOGICAL|MMR vaccine (Priorix)|
214557312|NCT02807883|DRUG|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
214557313|NCT02807883|PROCEDURE|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
214557314|NCT03656250|DIAGNOSTIC_TEST|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
214557315|NCT03404544|DRUG|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
214557316|NCT03404544|DRUG|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
214557317|NCT01521247|OTHER|Asthma Transition Program|Asthma Education.
214557318|NCT04494204|COMBINATION_PRODUCT|Immunofree tablets and Reginmune capsule|2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
214557319|NCT04835792|OTHER|Stool and blood collection|One-time stool and blood collection
214557320|NCT02523690|DRUG|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
214557321|NCT02523690|DRUG|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
214557322|NCT02623660|DEVICE|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
214557323|NCT02623660|OTHER|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
215163249|NCT05153343|DRUG|flonoltinib 50mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
215163250|NCT05851586|PROCEDURE|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
214704691|NCT03058822|DRUG|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
215163251|NCT05851586|PROCEDURE|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
215163252|NCT05460676|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
214704692|NCT02839824|PROCEDURE|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
214704693|NCT03917225|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
214704694|NCT03917225|DRUG|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
214557324|NCT02623660|DEVICE|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
214557325|NCT00011934|BIOLOGICAL|recombinant interferon alfa|
214557326|NCT00011934|BIOLOGICAL|sargramostim|
214704695|NCT00525239|DRUG|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
214704696|NCT02017821|BEHAVIORAL|high intensity aerobic training|
214704697|NCT01746940|DRUG|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
214704698|NCT01746940|DRUG|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
214704699|NCT01746940|DRUG|Placebo Topical Solution|Placebo Topical Solution
214557327|NCT00011934|PROCEDURE|autologous bone marrow transplantation|
214557328|NCT04236687|DEVICE|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
214557329|NCT04236687|PROCEDURE|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
214557330|NCT00022737|BIOLOGICAL|filgrastim|Given SC
214557331|NCT00022737|DRUG|asparaginase|Given IM
214557332|NCT00022737|DRUG|cyclophosphamide|Given IV
214557333|NCT00022737|DRUG|cyclosporine|Given IV
214557334|NCT00022737|DRUG|cytarabine|Given IT and IV
214557335|NCT00022737|DRUG|daunorubicin hydrochloride|Given IV
214557336|NCT00022737|DRUG|dexamethasone|Given orally
214557337|NCT00022737|DRUG|etoposide|Given IV
214557338|NCT00022737|DRUG|ifosfamide|Given IV
214557339|NCT00022737|DRUG|imatinib mesylate|Given orally
214557340|NCT00022737|DRUG|leucovorin calcium|Given IV or orally
214557341|NCT00022737|DRUG|mercaptopurine tablet|Given orally
214557342|NCT00022737|DRUG|methotrexate|Given IT, IV, and orally
214704700|NCT01332604|DRUG|GDC-0980|Oral escalating dose
214704701|NCT01332604|DRUG|bevacizumab|Intravenous repeating dose
214704702|NCT01332604|DRUG|capecitabine|Oral repeating dose
214557343|NCT00022737|DRUG|pegaspargase|Given IM
214557344|NCT00022737|DRUG|vincristine sulfate|Given IV
214557345|NCT00022737|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
214557346|NCT00022737|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
214557347|NCT00022737|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
214557348|NCT00022737|RADIATION|radiation therapy|Undergo radiation therapy
214557349|NCT04041037|DEVICE|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
214557350|NCT01462006|DRUG|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
214557351|NCT01462006|OTHER|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
214557352|NCT02130323|DRUG|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
214557353|NCT02130323|PROCEDURE|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
214557354|NCT04693039|DRUG|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
214557355|NCT04693039|DRUG|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
214557356|NCT01871688|BEHAVIORAL|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
214557357|NCT01399918|DRUG|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
214557358|NCT06384105|RADIATION|frames per second|Other settings for frames per second
214704703|NCT01332604|DRUG|mFOLFOX6|Intravenous repeating dose
214704704|NCT05482035|DEVICE|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
214704705|NCT03261063|DEVICE|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
214704706|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
214704707|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet
214704708|NCT05295745|BEHAVIORAL|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
214704709|NCT02700919|DRUG|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
214557359|NCT03899831|BEHAVIORAL|Function-Based Elopement Treatment (FBET)|"The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~* to create a safer environment~* teach adaptive skills to replace elopement~* arrange the environment and rewards to reduce elopement~* and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding."
214557360|NCT03899831|BEHAVIORAL|Parent Education Program (PEP)|The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
214557361|NCT03501953|BEHAVIORAL|Physical Activity|Six weeks of instructor-led physical activity sessions.
214557362|NCT02893839|OTHER|Prick to prick test|
214557363|NCT06064071|DEVICE|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
214557364|NCT06064071|PROCEDURE|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
214557365|NCT06064071|DEVICE|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
214704710|NCT02700919|DRUG|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
214704711|NCT00003635|DRUG|nelarabine|
214704712|NCT06000436|OTHER|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
214704713|NCT06000436|OTHER|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
214704714|NCT06000436|OTHER|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases."
214704715|NCT06000436|OTHER|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
214704716|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
214557366|NCT03979508|DRUG|Abemaciclib|Given PO
214704717|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
214557367|NCT03979508|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
214557368|NCT06374875|PROCEDURE|Metabolic surgery|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure
214557369|NCT06374875|DRUG|Incretin-Based Therapy|Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.
214557370|NCT03598530|PROCEDURE|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
214557372|NCT05217940|DIAGNOSTIC_TEST|Diagnostic tests for anal cancer screening|The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
214557373|NCT05380362|OTHER|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
215163253|NCT05460676|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
215163254|NCT05460676|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
215163255|NCT04007276|DRUG|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
214557374|NCT05380362|OTHER|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
214557375|NCT05415748|DRUG|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
214557376|NCT05415748|DRUG|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
214557377|NCT05975099|BIOLOGICAL|mRNA-1975|Dispersion delivered IM
214557378|NCT05975099|BIOLOGICAL|mRNA-1982|Dispersion delivered IM
214557379|NCT05975099|BIOLOGICAL|Placebo|Solution delivered IM
214557380|NCT03312400|DRUG|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
214557381|NCT04970992|DRUG|DZ-002|DZ-002 Injection
214557382|NCT05410340|OTHER|Vojta Therapy|Minimal digital pressure at costal level to assess the activation and oxygenation occurring at the cerebral level
214557383|NCT05410340|OTHER|Massotherapy|Baby body massage with gliding
214557384|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
214557385|NCT04225117|DRUG|pembrolizumab|IV infusion
214557386|NCT04520659|BIOLOGICAL|RSV LID/ΔM2-2/1030s|10\^5 plaque-forming units (PFU); administered as nose drops
214557387|NCT04520659|BIOLOGICAL|Placebo|Administered as nose drops
214557388|NCT05194137|OTHER|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
214557389|NCT05194137|OTHER|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
214704718|NCT03973203|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
214704719|NCT02035579|BEHAVIORAL|Aerobic Training Intervention|
214704720|NCT02035579|BEHAVIORAL|Stretching Intervention|
214557390|NCT05459922|DEVICE|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
214557391|NCT05459922|DEVICE|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
214557392|NCT03990610|PROCEDURE|Mammoplasty|Undergo standard of care breast reconstructive surgery
214557393|NCT03990610|PROCEDURE|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
214557394|NCT05883878|GENETIC|PRS|genetic test for the evaluation of PRS cardiovascular risk
214557395|NCT05883878|DEVICE|Digital app and wearable device|a wearable device connected with its app
214557396|NCT05360719|BEHAVIORAL|Group tele-exercise|This tele-exercise class will be tailored to the physical and emotional needs of individuals with SCI based on results of our feasibility study, the initial emergent themes from qualitative data collection in this study, and input from our co-leader with lived experience (examples: seated exercise to accommodate wheelchair users, active co-leader with SCI).The research clinician will lead the instruction of each class while our co-leader will model movements alongside her and offer tailored modifications as needed. Each 45-minute class provides a comprehensive fitness experience to maximize functional independence and improve global physical activity engagement. Elements incorporated into each class session include a collective check-in and breathing meditation, postural control, trunk and shoulder strength, cardiovascular fitness, and body awareness.
214557397|NCT03156790|DRUG|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
214557398|NCT03629171|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214557399|NCT03629171|DRUG|Venetoclax|Given PO
214704721|NCT00605696|DRUG|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
215163256|NCT04007276|OTHER|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
215163257|NCT05495334|PROCEDURE|Treatment for Knee OA|Pain management treatment for knee OA.
215163258|NCT06736990|DRUG|CAL101|Intravenous infusions of CAL101 every 4 weeks over 24 weeks
215163259|NCT06736990|DRUG|Placebo|Intravenous infusions of placebo every 4 weeks over 24 weeks
214557400|NCT03852719|DRUG|Bulevirtide|Administered via SC injections
215163260|NCT06852664|BEHAVIORAL|Motivational Interviewing|The participants will meet with the research staff three times a week during the eight weeks of wearing the activity monitor via video or Webex call with a duration ideally not exceeding one hour. All staff involved in these coaching sessions have been MINT trained and certified and have mastered the skills of motivational interviewing. Their goal will be to discuss with the participant about how successful they have been or not been in increasing their daily step count and movement and discussing the barriers preventing them from achieving that goal. Open-ended questions, affirmations, reflections, summaries, balancing change and sustain talk, and eliciting change behavior will all be used accordingly during the sessions. Coaching is tied to the overall results in investigating if motivational interviewing and coaching are effective in increasing movement in populations with cerebral palsy.
214557401|NCT03588091|DRUG|Pyrotinib|pyrotinib: 400mg orally daily;
214557402|NCT03588091|DRUG|Placebo Oral Tablet|placebo: 400mg orally daily;
214557403|NCT03588091|DRUG|Trastuzumab|trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
214557404|NCT03588091|DRUG|Docetaxel|docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
214557405|NCT05499858|OTHER|Spiced|Vegetables provided to volunteers will be spiced.
214557406|NCT05499858|OTHER|Plain|Vegetables provided to volunteers will be plain.
214557407|NCT03562221|OTHER|Gluten free diet|Controlled gluten free diet
214557408|NCT03562221|DIETARY_SUPPLEMENT|Probiotics|Capsules
214557409|NCT03562221|DIETARY_SUPPLEMENT|Placebo|Capsules
214557410|NCT06406114|DRUG|Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing|Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
214704722|NCT02623387|PROCEDURE|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
214704723|NCT01842646|DRUG|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
214704724|NCT04771143|DRUG|AFQ056|oral administration
214704725|NCT04771143|DRUG|Placebo|matching placebo for oral administration
215163261|NCT03901755|DRUG|Alprolix|Extended half-life factor IX product
214557411|NCT06406114|DRUG|Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge|After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
214704726|NCT04374266|DIAGNOSTIC_TEST|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
214704727|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
214704728|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
214704729|NCT00730626|DIETARY_SUPPLEMENT|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
214704730|NCT02752724|DRUG|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
215163262|NCT02414789|PROCEDURE|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
215163263|NCT05713799|DRUG|Placebo|Placebo
215163264|NCT05713799|DRUG|Mirabegron|selective beta3-AR agonist approved
215163265|NCT05713799|DRUG|Alpha-lipoic acid|ALA is an antioxidant that is available over the counter
215163266|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
215163267|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
215163268|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
215163269|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
214704731|NCT02752724|DRUG|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
214704732|NCT01057134|DEVICE|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
214704733|NCT00067613|OTHER|Benchmarking Management Practices|"The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center"
214704734|NCT00067613|OTHER|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
214704735|NCT04197518|DIAGNOSTIC_TEST|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
214704736|NCT05343585|DEVICE|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
214704737|NCT06447571|OTHER|Trunk Rehabilitation|Activating and strengthening the trunk muscles.
214704738|NCT06447571|OTHER|Core Stability|Standard core stability fucus on lower trunk.
214704739|NCT00833807|DRUG|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
214704740|NCT00085488|BIOLOGICAL|autologous tumor cell vaccine|
215163270|NCT04530110|DRUG|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
214557412|NCT06406114|DRUG|Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
214704741|NCT00085488|BIOLOGICAL|therapeutic autologous dendritic cells|
214704742|NCT00944216|DRUG|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
214704743|NCT04089436|DIAGNOSTIC_TEST|CSF sampling|CSF sampling by lumbar puncture
214704744|NCT04089436|DIAGNOSTIC_TEST|Blood sampling|Blood sampling by blood test
214704745|NCT04089436|DIAGNOSTIC_TEST|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
214704746|NCT03320538|OTHER|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
214704747|NCT03320538|OTHER|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
214704748|NCT03320538|DRUG|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
214704749|NCT04226287|DEVICE|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
215163271|NCT05154851|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
214704750|NCT05399108|PROCEDURE|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
214704751|NCT05399108|PROCEDURE|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
214704752|NCT00104156|PROCEDURE|External Qigong therapy|
214704753|NCT00912340|DRUG|Everolimus|
214704754|NCT00912340|BIOLOGICAL|Trastuzumab|
215163272|NCT05625958|DEVICE|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
215163273|NCT04879628|DRUG|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
215163274|NCT04879628|DRUG|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
214557413|NCT06406114|DRUG|Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
214557414|NCT06406114|DRUG|Amoxicillin double-blind placebo-controlled drug challenge|Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well.
214557415|NCT05322577|DRUG|Bemarituzumab|Intravenous (IV) infusion
214557416|NCT05322577|DRUG|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
214557417|NCT05322577|DRUG|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
214557418|NCT05322577|DRUG|Nivolumab|IV infusion.
214704755|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
214704756|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
214704757|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
215163275|NCT04879628|DRUG|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
215163276|NCT04879628|DRUG|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
214557422|NCT02819024|DRUG|Dexamethasone|Given PO BID
214557423|NCT02819024|DEVICE|Device for PET|Undergo 18F-FLT PET scan
214557424|NCT02819024|OTHER|Laboratory Biomarker Analysis|Correlative studies
214557425|NCT02819024|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET scan
214557426|NCT06780878|OTHER|Progressive muscle relaxation technique|"PMR focuses on the relationship between muscle tension and relaxation. By deliberately tensing a muscle group for a few seconds and then releasing the tension, individuals become more aware of the sensation of relaxation.~Group A Participants will receive PMR for 10 minutes each session, 3 sessions per week for 2 weeks and outcome measures will be recorded pre and post for each session."
214557427|NCT06780878|OTHER|Stretching exercises|"Stretching exercises are physical activities designed to improve the flexibility of muscles and joints. These exercises involve elongating specific muscle groups to enhance their elasticity and improve the range of motion around a joint.~Participants will be given 15 second stretches for each large muscle group, 3 sessions per week, for 2 weeks. Outcome measures will be assessed pre and post intervention."
215163277|NCT04879628|DRUG|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
215163278|NCT05509608|DEVICE|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
215163279|NCT05509608|DEVICE|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
215163280|NCT06557850|DRUG|Lu AG22515|Solution for infusion
214704758|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
214704759|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
215163281|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
214557428|NCT06780878|OTHER|Control Group|This group will consist of 12 participants who will not be given any physical therapy interventions. Same measurements will be taken at same intervals as the experimental groups.
214557429|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator|Nerve stimulator that is traditionally used for nerve localization during block placements.
214557430|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator sham control|Stimulator will be placed and turned on, but the grounding electrode will not be connected to prevent nerve stimulation.
214557431|NCT00792948|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
214704760|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
214704761|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
214704762|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
214704763|NCT02755025|OTHER|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
215163282|NCT03591510|DRUG|Midostaurin|midostaurin 30mg/m2 bid
215163283|NCT03591510|DRUG|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
215163284|NCT03591510|DRUG|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
215163285|NCT03591510|DRUG|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
215163286|NCT03591510|DRUG|Mitoxantrone|10mg/m2/day D3 and D4
215163287|NCT03591510|DRUG|Etoposide|100mg/m2/day D1 to D5
214557432|NCT00792948|DRUG|Cyclophosphamide|Given IV
214557433|NCT00792948|DRUG|Cytarabine|Given IT
214557434|NCT00792948|DRUG|Dasatinib|Given PO
214557435|NCT00792948|DRUG|Dexamethasone|Given IV or PO
214557436|NCT00792948|DRUG|Doxorubicin Hydrochloride|Given IV
214557437|NCT00792948|DRUG|Etoposide|Given IV
214557438|NCT00792948|BIOLOGICAL|Filgrastim|Given SC
214557439|NCT00792948|OTHER|Laboratory Biomarker Analysis|Correlative studies
214557440|NCT00792948|DRUG|Leucovorin Calcium|Given IV
214557441|NCT00792948|DRUG|Methotrexate|Given IV or IT
214557442|NCT00792948|DRUG|Methylprednisolone|Given IV
214557443|NCT00792948|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
214557444|NCT00792948|DRUG|Prednisone|Given PO
214557445|NCT00792948|DRUG|Sirolimus|Given PO
214704764|NCT02938546|RADIATION|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
214704765|NCT03649516|DEVICE|iCKD APP|Use iCKD APP to upload home bio-information data
214704766|NCT00169910|DRUG|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
214704767|NCT01517412|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
214704768|NCT01517412|DEVICE|Self-injector pen device (OptiClik®)|
214704769|NCT01517412|DRUG|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
214704770|NCT04018703|DRUG|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
214704771|NCT04018703|DRUG|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
214704772|NCT01991405|DEVICE|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
214704773|NCT01566058|DEVICE|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
214704774|NCT01566058|OTHER|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
214704775|NCT03484351|OTHER|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
214704776|NCT01509872|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
214704777|NCT01509872|BEHAVIORAL|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
214704778|NCT06243822|DRUG|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
214704779|NCT06243822|DRUG|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
214704780|NCT02168894|PROCEDURE|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
214704781|NCT02168894|PROCEDURE|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
214704782|NCT02168894|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
214704783|NCT03252314|DEVICE|Second-generation hydrogel coils|Hydrogel coils 90% by length
214704784|NCT01836211|OTHER|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
214704785|NCT01836211|OTHER|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
214704786|NCT02321618|BEHAVIORAL|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
214704787|NCT02321618|BEHAVIORAL|BP educational materials|Exposure to hypertension educational materials
214557446|NCT00792948|DRUG|Tacrolimus|Given IV
214557447|NCT00792948|RADIATION|Total-Body Irradiation|Undergo TBI
214557448|NCT00792948|DRUG|Vincristine Sulfate|Given IV
214557449|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
214557450|NCT06094478|BEHAVIORAL|HI-SPEED Protocol|The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool. This protocol will be implemented at each participating health system in clusters of 2 health systems.
214557451|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
214557452|NCT00460902|DEVICE|Transcranial Magnetic Stimulation (TMS)|
214704788|NCT02705118|DEVICE|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
214557453|NCT04439045|BIOLOGICAL|VPM1002|VPM1002 is a recombinant BCG (rBCG)
214557454|NCT04439045|OTHER|Placebo|0.9% sodium chloride
214557455|NCT04944290|DRUG|Brinzolamide/brimonidine ophthalmic suspension|Test product
214557456|NCT04944290|DRUG|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
214704789|NCT02705118|DEVICE|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
214557458|NCT00378664|PROCEDURE|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
214557459|NCT05222594|OTHER|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
214557460|NCT02876289|DRUG|Perampanel|
214557461|NCT00003337|PROCEDURE|immunoscintigraphy|
214557462|NCT00003337|RADIATION|technetium Tc 99m epratuzumab|
214557463|NCT03809039|DRUG|MT-6345|MT-6345
214704790|NCT03329417|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
214704791|NCT03001336|OTHER|no intervention|This is a cross-sectional study
215029826|NCT06674187|PROCEDURE|Regular|"The stoma surgery will be performed using conventional non-molding suturing techniques. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Perform routine suturing around the stoma without additional mesentery shaping.~3. Form the stoma, ensuring a tight fit of the surrounding tissues."
214557464|NCT03809039|DRUG|MT-6345 Placebo|MT-6345 Placebo
214557465|NCT00988299|OTHER|exercise|exercise sessions at 45% and 60% of maximum effort
214557466|NCT02725021|BEHAVIORAL|Education Against Tobacco school-based intervention by medical students|
214557467|NCT03137043|OTHER|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
214557468|NCT03137043|OTHER|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
214557469|NCT01252355|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
214557470|NCT01252355|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
214557471|NCT01252355|DRUG|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
214557472|NCT03901716|DRUG|Sufentanil|Patients in Group S received sufentanil 0.1 mcg/kg.
214557473|NCT03901716|DRUG|Fentanyl|Patients in Group F received fentanyl 1 mcg/kg.
214557474|NCT03901716|DRUG|Remifentanil|Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
214557475|NCT03901716|DRUG|Midazolam|Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
214557476|NCT00002622|DRUG|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
214557477|NCT00002622|DRUG|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
214557478|NCT03451019|DRUG|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
214557479|NCT03451019|DRUG|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
214557480|NCT02420613|RADIATION|Radiation Therapy|Undergo radiation therapy
214557481|NCT02420613|DRUG|Temsirolimus|Given IV
214557482|NCT02420613|DRUG|Vorinostat|Given PO
214557483|NCT05575375|BEHAVIORAL|Values Affirmation + Usual Care|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. The participant's study medication monitoring devices will be labeled with the participants' most important core value(s). Participants will also continue with their usual care.
214557484|NCT05575375|OTHER|Usual Care|Participants will be asked to continue with their usual care (e.g., cardiac rehabilitation, ongoing medical management)
214557485|NCT05345990|DRUG|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
214557486|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)|25mg/kg SUL and 25mg/kg DUR
214557487|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)|20mg/kg SUL and 20mg/kg DUR
214557488|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)|25mg/kg SUL and 25mg/kg DUR
214557489|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)|20mg/kg SUL and 20mg/kg DUR
214704792|NCT05175209|DIAGNOSTIC_TEST|EMG|Electromyelography
214704793|NCT03256734|OTHER|Policy intervention|Incentive payment for physicians
214704794|NCT03555240|OTHER|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
214557490|NCT01734239|BIOLOGICAL|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
214557491|NCT04018677|BEHAVIORAL|Use of TOGETHERCare app|TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
214557492|NCT03882177|DRUG|Pravastatin|Tablets, administered orally
214557493|NCT03882177|DRUG|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
214557494|NCT03882177|DIETARY_SUPPLEMENT|Vitamin B6|Administered orally.
214557495|NCT05551325|OTHER|Chronobundle - light|"Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance."
214557496|NCT05551325|OTHER|chronobundle - feeding|For patients receiving enteral feeds, time-restricted (daytime) intermittent feeding will include 4 meals delivered at 08:00, 12:00, 16:00 and 20:00. Each meal will include one-fourth of the recommended daily tube feed volume.
214557497|NCT05551325|OTHER|chronobundle - mobility|While in the MICU, exercise/mobility sessions led by physical therapy or occupational therapy providers will occur twice daily between 09:00 and 16:00 (i.e., one additional session beyond usual care); intensity will be determined by clinical status and documented in the chart by our physical therapy service. Patients in other hospital locations (e.g., general medical ward post-MICU discharge) will receive one additional session beyond usual care via a study staff-led exercise/mobility session; intensity will be determined by clinical status.
214557498|NCT05551325|OTHER|chronobundle - sleep|Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
214557499|NCT02777892|OTHER|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
214557500|NCT03390959|OTHER|Proprioceptive Training|"Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints."
214704795|NCT04080869|DRUG|retinyl palmitate|topical retinyl palmitate loaded ethosomes
214704796|NCT04080869|DRUG|Tretinoin|topical tretinoin
214704797|NCT06375252|OTHER|Central Jugular Vein Catheter Lumen Holder Apparatus|Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
214704798|NCT02539355|OTHER|Diet A|12-week diet
214704799|NCT02539355|OTHER|Diet B|12-week Diet
214704800|NCT00511953|DRUG|Gabapentin Extended Release tablets|1800mg
214704801|NCT00511953|DRUG|Gabapentin|1800mg
214704802|NCT03054987|PROCEDURE|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
214704803|NCT03054987|PROCEDURE|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
214704804|NCT02384772|OTHER|Survey|
214704805|NCT02236741|DRUG|Mirapexin® (Sifrol®)|
214704806|NCT03053726|PROCEDURE|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
214704807|NCT04060810|OTHER|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
214704808|NCT03027388|DRUG|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
214704809|NCT02409056|BEHAVIORAL|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
214704810|NCT02409056|BEHAVIORAL|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
214704811|NCT03342456|DRUG|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
214704812|NCT03342456|DRUG|Amoxicillin Capsules|group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
214704813|NCT03342456|DRUG|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
214704814|NCT03342456|DRUG|Furazolidone Tablets|group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
214704815|NCT03342456|DRUG|Potassium Citrate Tablets|group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
214704816|NCT04169685|PROCEDURE|bronchoscopy|during flexible bronchoscopy
214704817|NCT00129792|DRUG|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
214704818|NCT00129792|BEHAVIORAL|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
214704819|NCT00382213|DRUG|Olmesartan medoxomil|
214704820|NCT00382213|DRUG|Placebo|
214557501|NCT03390959|OTHER|Control Group|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
214557502|NCT00509249|BIOLOGICAL|ziv-aflibercept|Given IV
214557503|NCT00509249|OTHER|laboratory biomarker analysis|Correlative studies
214557504|NCT00509249|OTHER|pharmacological study|Correlative studies
214557505|NCT03889353|DEVICE|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
214557506|NCT05765305|DRUG|Letrozole with chromium|Letrozole versus letrozole with chromium
214557507|NCT06331390|OTHER|niacinamide cosmetic product|immortella skincare product
214557508|NCT06331390|OTHER|placebo|nothing
214557509|NCT02224703|DRUG|GWP42003-P|
214557510|NCT02224703|DRUG|Placebo Control|
214557511|NCT06003842|OTHER|exercise|Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
214557512|NCT06003842|OTHER|taping|After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
214557513|NCT05248126|OTHER|Standard patient education|The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region \[Agence Régional de Santé Occitanie\].
214557514|NCT05248126|OTHER|Chatbot patient education|"The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention."
214557515|NCT06415123|DEVICE|MagnetOs Flex Matrix|MagnetOsTM Flex Matrix is a resorbable and osteoconductive bone graft for the repair of bony defects.
214557516|NCT01408420|PROCEDURE|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP \> 60 mmHg during extracorporeal circulation is used.
214557517|NCT04048902|DEVICE|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
214557518|NCT04048902|DEVICE|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
214557519|NCT01482689|DIETARY_SUPPLEMENT|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
214557520|NCT01482689|DIETARY_SUPPLEMENT|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
214557521|NCT00307762|BEHAVIORAL|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
214557522|NCT03572426|OTHER|genotyping all subjects|genotyping using SNaPshot genotyping method.
214557523|NCT00927134|GENETIC|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
214557524|NCT01627951|OTHER|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
214704821|NCT03028584|BEHAVIORAL|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
214704822|NCT03746808|BEHAVIORAL|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
214704823|NCT04234763|BEHAVIORAL|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
214704824|NCT04234763|BEHAVIORAL|Control group|Assess nutritional status and no active intervention is conducted.
214704825|NCT01861145|DEVICE|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
214704826|NCT01861145|DRUG|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
214704827|NCT05766293|DEVICE|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
214704828|NCT05766293|OTHER|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
214704829|NCT03946293|DIETARY_SUPPLEMENT|White Bread|White bread made with commercial white flour with bran/fibre removed
214704830|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
214704831|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
214704832|NCT01149343|BIOLOGICAL|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
214704833|NCT00502528|DRUG|Placebo|Peri-interventional
214704834|NCT00502528|DRUG|BQ-123|Peri-interventional
214704835|NCT01061736|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214704836|NCT01061736|DRUG|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214704837|NCT01061736|DRUG|Methotrexate|Same weekly dose as received prior to enrollment
214557525|NCT01627951|OTHER|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
214557526|NCT01627951|OTHER|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
214557527|NCT04956874|BEHAVIORAL|FL-REACH|The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
214557528|NCT03342274|BEHAVIORAL|Lifestyle Program|Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.
214557529|NCT03342274|OTHER|Usual Care|Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
214557530|NCT04403568|DRUG|Ursolic Acid|Ursolic Acid 150mg
214557531|NCT04403568|DRUG|Curcumin|Curcumin 600mg
214557532|NCT05909553|DRUG|Venetoclax|Oral; Tablet
214704838|NCT01061736|DRUG|Folic Acid|According to local standard
214704839|NCT05032417|OTHER|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
214704840|NCT03424317|BEHAVIORAL|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
214557533|NCT02932540|OTHER|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
214557534|NCT02922023|DEVICE|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
214704841|NCT03424317|BEHAVIORAL|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
214704842|NCT01768468|DRUG|LAYLA tablet|1 tablet twice a day
214704843|NCT01768468|DRUG|JOINS tablet|1 tablet at each time, 3 times a day
214704844|NCT01093755|DRUG|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
214704845|NCT01093755|DRUG|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
214704846|NCT03115112|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
214704847|NCT03115112|DRUG|Sitagliptin|tablets containing 100 mg sitagliptin
214704848|NCT03115112|DRUG|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
214704849|NCT03115112|DRUG|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
214704850|NCT00155454|PROCEDURE|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
214704851|NCT05027256|DEVICE|Entia Liberty|Home Monitoring solution
214557535|NCT02922023|OTHER|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
214557536|NCT00863681|DRUG|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
214557537|NCT04182295|DEVICE|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
214557538|NCT04182295|DEVICE|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. \& DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
214557539|NCT00233974|PROCEDURE|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
214557540|NCT03031496|DRUG|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
214557541|NCT03031496|DRUG|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
214704852|NCT03554070|PROCEDURE|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
214704853|NCT03554070|DEVICE|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
214709056|NCT00575094|DRUG|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
214557542|NCT00895557|DRUG|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
214557543|NCT01254552|DRUG|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
214557544|NCT01254552|DRUG|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
214557545|NCT06405100|DRUG|Supportive care+Prednisone|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Induction period: 1mg/kg/day. The maximum dose is not more than 60mg. The duration of adequate prednisone is a minimum of 4 weeks and a maximum of 16 weeks.~Maintenance period: A reduction of 5-10mg/wk was initiated after 2 weeks of complete remission and finally discontinued after 6 months of maintenance at 5mg/day."
214557546|NCT06405100|DRUG|Supportive care+Tacrolimus+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Tacrolimus：Induction period: 0.05mg/kg/d. It will be given in two doses 12 hours apart. The blood concentration should be up to 5-10ng/ml. Maintenance therapy was initiated two weeks after complete remission; Maintenance period: Reduced to a blood concentration of 3-8ng/ml, and stopped after 6 months of maintenance treatment.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
214557547|NCT06405100|DRUG|Supportive care+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
214557548|NCT05057871|DEVICE|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
214704854|NCT00624728|RADIATION|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
214557549|NCT05057871|DEVICE|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
214557550|NCT06256081|DEVICE|Hear Glue ear application|Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
214557551|NCT01533818|DRUG|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
214557552|NCT01533818|DRUG|Sugar Syrup|It will be given 2 times/day for 7 days
214704855|NCT04689672|DIAGNOSTIC_TEST|Lung ultrasound|Bedside lung ultrasound
214557553|NCT00175643|DRUG|imiquimod|
214704856|NCT04735965|DRUG|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
214704857|NCT04735965|DRUG|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
214704858|NCT04735965|DRUG|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
214704859|NCT05843071|DEVICE|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
214704860|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
214704861|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
214704862|NCT04019795|DEVICE|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
214704863|NCT04019795|DEVICE|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
214704864|NCT04019795|DEVICE|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
215163288|NCT05988645|DEVICE|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
215163289|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
215163290|NCT03167437|DRUG|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
214557554|NCT01224977|DRUG|azithromycin|azithromycin 500 mg 3/week for 3 months
214704865|NCT04019795|DEVICE|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
214704866|NCT05396313|DEVICE|CRT/ICD|The patients received implantation of CRT/ICD.
214704867|NCT06436729|PROCEDURE|Splinting|The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices
214704868|NCT06436729|PROCEDURE|MINST alone|Minimally invasive non surgical therapy alone
214704869|NCT02168803|DRUG|Evacetrapib|Administered orally
214704870|NCT05904184|DRUG|Epoxy resin-based sealers (ERS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
214704871|NCT05904184|DRUG|Calcium silicate-based sealers (CSS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
214704872|NCT02527122|DIAGNOSTIC_TEST|Allergen extracts|
214704873|NCT03016546|BEHAVIORAL|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
214704874|NCT03016546|BEHAVIORAL|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
214704875|NCT01933750|DEVICE|PresVIEW Device Implantation|
214557555|NCT05785403|OTHER|No intervention|No intervention
214557556|NCT01759524|DRUG|Bupivacaine|
214557557|NCT01759524|DRUG|Lidocaine|
214557558|NCT01312259|OTHER|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
214557559|NCT01720160|DEVICE|BAROSTIM NEO® System|Implant procedure
214557560|NCT01720160|OTHER|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
214557561|NCT02579135|BEHAVIORAL|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
214557562|NCT02579135|BEHAVIORAL|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
214557563|NCT00799032|DEVICE|PCI|coronary stent implantation
214557564|NCT01146600|DRUG|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
214557565|NCT01146600|DRUG|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
214557566|NCT04647838|DRUG|Tepotinib|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
214557567|NCT03600415|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214557568|NCT03600415|OTHER|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214557569|NCT02287298|PROCEDURE|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
214557570|NCT03507426|PROCEDURE|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% \& Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
214557571|NCT03507426|PROCEDURE|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
214557572|NCT02812940|DRUG|Everolimus|GvHD prophylaxis
214557573|NCT04870268|PROCEDURE|percutaneous drainage|
214557574|NCT04870268|PROCEDURE|endoscopic approach|
214557575|NCT04870268|PROCEDURE|surgical internal derivation of WON|
214557576|NCT04870268|PROCEDURE|surgical necrosectomy|
214704876|NCT02435550|GENETIC|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
214704877|NCT00980343|DRUG|vismodegib|Given orally
214704878|NCT00980343|PROCEDURE|therapeutic conventional surgery|undergo surgery
214704879|NCT00980343|OTHER|laboratory biomarker analysis|correlative studies
214557577|NCT02766777|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration.
214557578|NCT04004104|DIAGNOSTIC_TEST|Upright Exercise|Exercise is generally performed in the upright position.
214557579|NCT04004104|DIAGNOSTIC_TEST|Supine Exercise|Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.
214557580|NCT01518959|DRUG|Cholecalciferol|180.000 IU monthly
214557581|NCT01518959|DRUG|oleum neutralicum|Placebo comparator, 9 ml monthly
214557582|NCT00045526|DRUG|erlotinib hydrochloride|Given PO
214557583|NCT00045526|OTHER|laboratory biomarker analysis|Correlative studies
214557584|NCT01886287|DRUG|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
214557585|NCT04243551|DRUG|Latiglutenase|Administered orally (daily)
214557586|NCT04243551|OTHER|Placebo|Administered orally (daily)
214557587|NCT04996732|PROCEDURE|hospitalization|Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
214557588|NCT02182050|DRUG|BIBF 1120 ES low dose|
214557589|NCT02182050|DRUG|BIBF 1120 ES high dose|
214557590|NCT02182050|DRUG|Placebo to BIBF 1120 ES|
214557591|NCT02954978|DRUG|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
214557592|NCT02954978|DRUG|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
214557593|NCT02954978|DRUG|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
214557594|NCT03596762|DRUG|Elinzanetant (BAY3427080)|BAY3427080 capsules
214557595|NCT03596762|DRUG|Placebo|Placebo capsules
214704880|NCT00980343|OTHER|pharmacological study|correlative studies
214704881|NCT03060083|OTHER|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
214704882|NCT03060083|OTHER|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
214704883|NCT03783728|DRUG|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
214704884|NCT03783728|DRUG|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
214704885|NCT03783728|DRUG|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
214557596|NCT04995770|BEHAVIORAL|Praise Text Messages|Texting messages with praise content, to positive reinforce medication adherence
214557597|NCT05684549|OTHER|No intervention|Observational study, no intervention
214557598|NCT02157051|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
214557599|NCT02157051|OTHER|Laboratory Biomarker Analysis|Correlative studies
214557600|NCT06064019|DEVICE|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
214557601|NCT02231073|BEHAVIORAL|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
214557602|NCT06382662|DRUG|metaxalone m640|A single dose of micronize metaxalone 640 mg
214557603|NCT06382662|DRUG|tizanidine|A single dose of tizanidine 8 mg
214557604|NCT03099252|OTHER|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
214557605|NCT00612118|DRUG|GSK256066|200mcg bd
214557606|NCT00612118|DRUG|azelastine hydrochloride|140mcg
214557607|NCT06076317|BEHAVIORAL|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
214557608|NCT02358447|PROCEDURE|TKR|non-navigated versus computer-navigated total knee replacement
214557609|NCT06273813|DRUG|Ketorolac Tromethamine 15 MG/ML|Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
214557610|NCT06273813|DRUG|Ketorolac Tromethamine|Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
214557611|NCT05600426|DRUG|cyclosporine|cyclosporine
214557612|NCT05600426|PROCEDURE|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
214557613|NCT05600426|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
214557614|NCT05600426|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
214557615|NCT05600426|DRUG|Methotrexate|methotrexate
214557616|NCT05600426|DRUG|Fludarabine|fludarabine
214557617|NCT05600426|DRUG|Cyclophosphamide|cyclophosphamide
214557618|NCT05600426|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
214557619|NCT05600426|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
214557620|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
214557621|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
214557622|NCT05933681|DEVICE|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
214557623|NCT04554745|RADIATION|Ultrasound|ultrasound assessment of pregnant women
214557624|NCT05263674|DRUG|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
214557625|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
214557626|NCT00001197|DRUG|Hydroxyurea|
214557627|NCT05890053|DRUG|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
214557628|NCT02593123|DRUG|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
214557629|NCT02593123|BIOLOGICAL|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
214557630|NCT02593123|BIOLOGICAL|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
214557631|NCT05715749|OTHER|In-home body weight support harness system|A portable, adjustable body weight support harness system that occupies roughly 9 feet x 9 feet space in the home. The system allows 360 degrees of mobility anywhere within the footprint of the frame. The amount of body weight support is adjustable.
214557632|NCT05729308|PROCEDURE|caudal epidural block|"The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space"
215163291|NCT03167437|DRUG|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
215163292|NCT00702533|DEVICE|Pentagastrin Injection BP|
215163293|NCT00702533|DRUG|Pentagastrin|
215163294|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
215163295|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
214557633|NCT05729308|PROCEDURE|bilateral erector spinae plane block|The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
214704886|NCT01608490|DEVICE|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
214704887|NCT03581929|DIETARY_SUPPLEMENT|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
214704888|NCT03581929|OTHER|Placebo|Placebo comparator
214704889|NCT06461312|PROCEDURE|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
214704890|NCT03998917|DIAGNOSTIC_TEST|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
214557634|NCT05729308|PROCEDURE|general anesthesia with intravenous analgesia.|"* Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~* Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~* The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered."
214557635|NCT06515938|BIOLOGICAL|20μg Engerix-B hepatitis B vaccine|
214557636|NCT06515938|BIOLOGICAL|20μg Kangtai hepatitis B vaccine|
214557637|NCT06515938|BIOLOGICAL|60μg Kangtai hepatitis B vaccine|
214557638|NCT06515938|BIOLOGICAL|20μg CHO|
214557639|NCT04967898|OTHER|bowen technique|Bowen technique is a soft tissue mobilization technique. This medical care involves short mild rolling moves over the muscles, nerves, ligaments, and tendons of flesh utilizing the hands, fingers and thumb. Sequence of receiving bilateral rolling moves over segments of the erector spinae from the lumber toward cervical spine, latissimus dorsi, the gluteal, the hamstring muscles proximally and distally, tensor facia Lata and a medial hip striated muscle move.
214557640|NCT04967898|OTHER|sustained stretching|static stretching is one of the most common and safest technique used for hamstring tightness. A static stretch is performed by inserting muscles at their greatest attainable length and holding that position for an amount of your time.
214557641|NCT02633436|OTHER|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
214557642|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D2|Daily enteral dose of 100IU/kg
214557643|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D3|Daily enteral dose of 100IU/kg
214557644|NCT03193983|PROCEDURE|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
214557645|NCT03193983|PROCEDURE|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
214557646|NCT00065923|DRUG|Topiramate|
214557647|NCT02090010|PROCEDURE|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
214557648|NCT02090010|PROCEDURE|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
214557649|NCT05443113|DIAGNOSTIC_TEST|Genetic analysis|Genetic analysis by geneticists
214704891|NCT04498572|OTHER|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
214704892|NCT04498572|OTHER|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
214704893|NCT00326222|BEHAVIORAL|Lifestyle counseling|Self-management group education
214704894|NCT01969669|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
214704895|NCT01969669|DRUG|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
214557650|NCT03566004|DIAGNOSTIC_TEST|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
214704896|NCT01848639|DRUG|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
214704897|NCT01848639|DRUG|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
214704898|NCT04260919|PROCEDURE|Chest physiotherapy|
215163296|NCT04000152|DIAGNOSTIC_TEST|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
214557651|NCT05723445|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
214557652|NCT04366505|BEHAVIORAL|Treatment as usual (TAU) and neurofeedback (NFB)|This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.
214557653|NCT04366505|BEHAVIORAL|mindfulness-based relapse prevention (MBRP) and NFB|This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.
214557654|NCT04366505|BEHAVIORAL|TAU and sham NFB|This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
214557655|NCT04366505|BEHAVIORAL|MBT and sham NFB|This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
215163297|NCT04000152|OTHER|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
215163298|NCT01419561|DRUG|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
215163299|NCT01419561|DRUG|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
215163300|NCT01419561|DRUG|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
215163301|NCT01419561|DRUG|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
215163302|NCT01419561|OTHER|Standard Therapies|Standard of Care drugs
215163303|NCT01419561|OTHER|Cohort 1|Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
214557656|NCT05017077|DEVICE|DynaVision System|Telemonitoring for pediatric heart failure
214557657|NCT02223104|DEVICE|Flexima Active|
214557658|NCT02223104|DEVICE|Sensura|
215163304|NCT04235777|RADIATION|Stereotactic body radiation therapy (SBRT)|A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC
214557659|NCT03766776|DRUG|Anlotinib|Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
214557660|NCT00328289|DEVICE|transcutaneous muscle stimulation, treadmill|
214557661|NCT03333759|DEVICE|Alma - Harmony XL Laser|The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
214557662|NCT02440425|DRUG|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
214557663|NCT02440425|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
214557664|NCT06390384|OTHER|blinded-care counselling|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 2) weekly counselling over 6 weeks via videoconference for adolescents and their parents.~The counselling will be provided by experienced psychologists as employers of the Clinic of Child and Adolescent Psychiatry, RWTH Aachen University, the counselling will be supervised by the leading psychologist of the clinic. The counselling will include psychoeducative elements about psychological and psychosocial problems, behavioral interventions from cognitive-behavioral therapy, psychological techniques for better coping with stress, different therapeutic tasks such as fear exposure, activation exercises e.c. The students will be instructed to use the mobile treatment system STEPS in order to continue therapy at home."
214557665|NCT06390384|OTHER|App STEPS|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 3) blinded-care use of the mobile treatment system STEPS®.~This is transdiagnostic digital treatment system which consists of a students front-end as an App and a therapist front-end as an online platform. The App and the platform are connected to each other. In such a way, an effective data transter (for example, symptom evaluation by the student and tasks and requests by the therapist), direct communication between a student and a therapist, as well as registration of emergency situation, are possible."
215163305|NCT04235777|DRUG|PDS01ADC|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
215163306|NCT04235777|DRUG|M7824|1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
214704899|NCT04387318|DEVICE|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
214704900|NCT04387318|DEVICE|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
214704901|NCT04387318|DEVICE|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
214704902|NCT04387318|DEVICE|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
214704903|NCT05341570|DRUG|BPI-21668|Subjects will receive BPI-21668 until disease progression
214704904|NCT00004207|DRUG|liposomal daunorubicin citrate|
214704905|NCT02310906|DRUG|Placebo|SRP-4053 placebo-matching solution for IV infusion.
214704906|NCT02310906|DRUG|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
214557666|NCT06390384|OTHER|digital and mental literacy training|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®.~The intervention will include: 1) digital and mental literacy training for children, parents and teachers in the school.~This training program (4 weeks, 8 session a 2 lesson units, 2 sessions a week) includes information about rules and functions by using mobile applications, safety aspects of personal data, risks associated with data sharing, sexing and cybergrooming, managing social media, handling with fake news, influence of social media on mental health, forms of digital violence and strategies to cope with them."
214557667|NCT03432442|DRUG|Ivermectin|Ivermectin once every 24 hours for three administrations
214557668|NCT05910970|DRUG|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
214557669|NCT05910970|DRUG|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
214557670|NCT02807272|DRUG|Tipifarnib|Oral tablet
214557671|NCT01699113|DRUG|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
214557672|NCT01699113|DRUG|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
214557673|NCT02884284|OTHER|clinical biological database collection|
214557674|NCT00636935|DRUG|Antibiotics only|Antibiotic only for treatment for mild (pO2 \> 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
214557675|NCT00636935|DRUG|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
214557676|NCT00636935|DRUG|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.
214557677|NCT00218153|DRUG|Naltrexone|
214557678|NCT05963945|DEVICE|Carebot AI CXR|The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
214557679|NCT05840068|DRUG|MetFORMIN 500 Mg Oral Tablet|MetFORMIN 500 Mg Oral Tablet
214557680|NCT05840068|DRUG|Chemotherapy|The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
214704907|NCT05557669|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
214704908|NCT02667548|PROCEDURE|PCI|percutaneous coronary intervention
215163307|NCT06489873|DIETARY_SUPPLEMENT|Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)|Each participant will be assigned to t a LZF supplement daily for six months
214557681|NCT03117491|PROCEDURE|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
214557682|NCT03117491|PROCEDURE|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
214704909|NCT06248697|BIOLOGICAL|αPD1/CTLA4-MSLN-CAR T cells|BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
214704910|NCT05133544|DEVICE|Endocuff with AI|Use of endocuff with computer assisted polyp detection
214704911|NCT05133544|DEVICE|AI alone|Use of computer assisted polyp detection
214704912|NCT02567214|DRUG|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
215163308|NCT06489873|DIETARY_SUPPLEMENT|Placebo Comparator|Each participant will be assigned to take a placebo supplement daily for six months
215163309|NCT06014762|BIOLOGICAL|P-CD19CD20-ALLO1|Single weight-based IV administration
215163310|NCT06014762|DRUG|Rimiducid|Single weight-based IV administration
215163311|NCT06383403|DRUG|Elafibranor|Round and orange film coated tablet of 80 mg.
215163312|NCT06383403|OTHER|Placebo|Round and orange film coated tablet of placebo
214557683|NCT03117491|PROCEDURE|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
214557684|NCT00002653|DRUG|carmustine|
214557685|NCT00002653|DRUG|cyclophosphamide|
214557686|NCT00002653|DRUG|doxorubicin hydrochloride|
214557687|NCT00002653|DRUG|melphalan|
214557688|NCT00002653|DRUG|prednisone|
214557689|NCT00002653|RADIATION|radiation therapy|
214557690|NCT01038427|DRUG|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
214557691|NCT01038427|DRUG|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
214557692|NCT01038427|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
214557693|NCT04878315|DRUG|Capoten|Capoten will be administered per the treatment sequence
214557694|NCT04878315|DRUG|Captopril|Captopril will be administered per the treatment sequence
214557695|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
214557696|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
214557697|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
214557698|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
214557699|NCT05620277|DIAGNOSTIC_TEST|Digital Camera|Tooth color changes of 30 patients will be evaluated using a Digital Camera
214557700|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
214557701|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
214557702|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
214557703|NCT05620277|DIAGNOSTIC_TEST|Rayplicker|Tooth color changes of 30 patients will be evaluated using Rayplicker
214557704|NCT05620277|DIAGNOSTIC_TEST|Rayplicker with gray reference card|Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
214557705|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade|Tooth color changes of 30 patients will be evaluated using Vita Easyshade
214557706|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade with gray reference card|Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
214557707|NCT05260177|DEVICE|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
214557708|NCT05260177|DEVICE|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
214557709|NCT00101946|DRUG|683699|
214557710|NCT05802823|OTHER|Standardized Simülation Patient|There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
214557711|NCT04243746|BEHAVIORAL|Time Restricted Feeding|Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
214557712|NCT04243746|BEHAVIORAL|Standard Care|Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
214557713|NCT01162863|DRUG|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
214557714|NCT01162863|DRUG|Placebo|taken orally for 28 days
214557715|NCT01162863|OTHER|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
214557716|NCT03332043|DEVICE|HIRREM|HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
214557717|NCT03332043|OTHER|Ambient Nature Sounds|Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
214557718|NCT01063998|OTHER|Urine Marker|Urinary KIM-1 measurements
214557719|NCT05772182|DEVICE|ACORYS MAPPING SYSTEM|"Diagnostic Test: ECG-Imaging~Diagnostic Test: Standard 12-lead ECG~Diagnostic Test: Endocardial mapping and/or pacing"
214557720|NCT00588692|DEVICE|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
214557721|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg|will be administered 1 hour before arrival to operating room
214557722|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg|will be administered 1 hour before arrival to operating room
214557723|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg|will be administered 1 hour before arrival to operating room
214557724|NCT05223010|DRUG|Sevoflurane|for anaesthesia induction 3-8 MAC
215163313|NCT06319287|BIOLOGICAL|PEP (Purified Exosome Product) / TISSEEL|"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"
214557725|NCT03622970|DEVICE|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
214557726|NCT03622970|BEHAVIORAL|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
214557727|NCT02498782|DRUG|Fexinidazole|
214557728|NCT02498782|DRUG|Placebo|
214557729|NCT01374568|DRUG|sitagliptin|sitagliptin 100mg daily
214557730|NCT01374568|OTHER|Placebo|1 pill daily
214557731|NCT01274325|DRUG|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
214557732|NCT01274325|DRUG|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
214557733|NCT01364337|OTHER|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
214557734|NCT01364337|OTHER|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
214557735|NCT02867917|DRUG|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
214557736|NCT02867917|DRUG|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
214557737|NCT02867917|DRUG|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
214557738|NCT05497544|BEHAVIORAL|Exercise recommendation group|A verbal exercise recommendation will be provided. This recommendation will be reported also in the hospital resignation letter.
214557739|NCT05497544|BEHAVIORAL|Exercise recommendation plus guidebook group|This group will receive the exercise (verbal and written) recommendation. Additionally, the oncologist hand the patient a guidebook about exercise, specifically designed for cancer patients.
214557740|NCT01912404|DRUG|IDN-6556|25 mg BID for 28 days
214557741|NCT01912404|DRUG|Placebo|Placebo controlled
214557742|NCT03462862|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
214704913|NCT02567214|DRUG|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
214557743|NCT03462862|OTHER|Bre-Flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
214557744|NCT05142007|BEHAVIORAL|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
214557745|NCT05142007|BEHAVIORAL|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
214557746|NCT00006375|DRUG|LY293111|
214557747|NCT05259423|OTHER|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
214557748|NCT05259423|OTHER|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
214557749|NCT00000920|DRUG|Ritonavir|
214557750|NCT00000920|DRUG|Saquinavir|
214557751|NCT00000920|DRUG|Lamivudine|
214557752|NCT00000920|DRUG|Zidovudine|
214557753|NCT01138618|DEVICE|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
214557754|NCT01138618|DEVICE|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
214557755|NCT01228253|DEVICE|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
214557756|NCT01228253|DEVICE|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
214557757|NCT00455806|DRUG|esomeprazole|
214557758|NCT00455806|DRUG|moxifloxacin|
214557759|NCT00455806|DRUG|amoxicillin|
214557760|NCT03804177|PROCEDURE|immediate implant placement with melatonin hyaluronic acid vit C|immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
214557761|NCT03804177|PROCEDURE|immediate implant placement without melatonin hyaluronic acid vit C|immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
214557762|NCT04910139|DEVICE|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
214557763|NCT04789031|DIETARY_SUPPLEMENT|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
214557764|NCT00642408|DIETARY_SUPPLEMENT|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
214557765|NCT00642408|DIETARY_SUPPLEMENT|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
214557766|NCT01952067|PROCEDURE|line-to-line reaming and cementing technique|
214557767|NCT01952067|PROCEDURE|standard over-reaming with 2 broach sizes|
214557768|NCT00820170|DRUG|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
214557769|NCT02663531|DEVICE|DVA|
214557770|NCT02663531|DEVICE|FDOCT|
214557771|NCT02663531|DEVICE|Pattern ERG|
214557772|NCT02663531|DEVICE|Optical Coherence Tomography|
214557773|NCT06479369|BEHAVIORAL|Teaching training program|The investigators will try to carry out a training based on motivational strategies for physical education teachers of the experimental group, with the aim of improving their motivational teaching style during physical education classes, and finally, to obtain benefits in their students, such as a greater adherence to physical activity.
214557774|NCT04815980|OTHER|Exercise|Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
214557775|NCT02531555|DEVICE|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
214557776|NCT02531555|DEVICE|Gracey curettes|
214557777|NCT03538938|BEHAVIORAL|1-Call Quitline Counseling|The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
214557778|NCT03538938|BEHAVIORAL|4-Call Quitline Counseling|The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
214557779|NCT03538938|DRUG|Nicotine patch|Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
214557780|NCT03538938|DRUG|Nicotine Patch and Nicotine Lozenge|The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
214557781|NCT03538938|BEHAVIORAL|SmokefreeTXT|SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
214557782|NCT03538938|BEHAVIORAL|No SmokefreeTXT|Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
214557783|NCT03538938|BEHAVIORAL|Financial Incentives for Treatment Engagement|Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
214557784|NCT03538938|BEHAVIORAL|No Financial Incentives for Treatment Engagement|No Financial Incentives for Treatment Engagement are offered.
214557785|NCT00208559|DRUG|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
214557786|NCT01161238|OTHER|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
214557787|NCT00604708|BIOLOGICAL|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
214557788|NCT00604708|BIOLOGICAL|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
214557789|NCT01872559|OTHER|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
214557790|NCT03553108|DRUG|Olaparib Treatment A|Olaparib Tablet 25 mg
214557791|NCT03553108|DRUG|Olaparib Treatment B|Olaparib Tablet 100 mg
214557792|NCT03553108|DRUG|Olaparib Treatment C|Olaparib Tablet 150 mg
214557793|NCT03553108|DRUG|Olaparib Treatment D|Olaparib Tablet 250 mg
214557794|NCT02758275|BEHAVIORAL|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~1. Behavior Modification (4360) Promotion of a behavior change.~2. Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~3. Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~4. Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~5. Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~6. Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
214557795|NCT02765334|DEVICE|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
214704914|NCT01892449|OTHER|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
214704915|NCT01892449|OTHER|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
214704916|NCT05644379|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
214704917|NCT05644379|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
214704918|NCT01471860|DEVICE|BAROSTIM NEO System|
214704919|NCT01471860|DRUG|Medical Management|
214557796|NCT00072501|PROCEDURE|breast imaging study|
214704920|NCT04107558|DEVICE|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
214704921|NCT04532073|OTHER|Eurythmy Therapy|A mindfulness-oriented movement therapy
214704922|NCT04532073|OTHER|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
214704923|NCT04532073|OTHER|Standard Care|Treatment process that a clinician should follow for a certain type of patient
214704924|NCT06317922|DEVICE|Thealoz Duo;|THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
214557797|NCT00072501|PROCEDURE|comparison of screening methods|
214557798|NCT00072501|PROCEDURE|magnetic resonance imaging|
214557799|NCT00072501|PROCEDURE|radiomammography|
214557800|NCT00072501|PROCEDURE|ultrasound imaging|
214557801|NCT01361594|OTHER|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
214557802|NCT01361594|OTHER|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
214557803|NCT03340831|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
214557804|NCT00691587|BIOLOGICAL|KB001|Single low-dose, administered intravenously
214557805|NCT00691587|BIOLOGICAL|KB001|Single high-dose, administered intravenously
214557806|NCT00691587|BIOLOGICAL|Placebo|Placebo single-dose, administered intravenously
214557807|NCT03162198|OTHER|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
214557808|NCT03162198|OTHER|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
214557809|NCT04577053|DEVICE|Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device|Manufactured by QX World Ltd. in Budapest, Hungary
214557810|NCT03112460|DEVICE|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
214557811|NCT02421575|DRUG|Hydroxychloroquine|Given PO
214557812|NCT02421575|OTHER|Laboratory Biomarker Analysis|Correlative studies
214557813|NCT06306131|DRUG|Levonorgestrel 0.15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
214557814|NCT06306131|DRUG|Meloxicam 15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
214557815|NCT06306131|OTHER|calcium carbonate 750 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
214557816|NCT06125158|PROCEDURE|Conventional ankle training|The program included ankle elastic band resistance training and balance training, in which the elastic band resistance training required subjects to complete resistance training in ankle plantarflexion, dorsiflexion, inversion and eversion directions with the help of elastic bands; and the balance training required subjects to complete the movements of standing with eyes open, standing with eyes closed, and throwing and catching the ball on flat ground and BOSU ball.
214557817|NCT06125158|PROCEDURE|Hip strength training|Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
214557818|NCT06125158|PROCEDURE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
214704925|NCT06317922|DEVICE|sham (Hydrabak)|Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
214704926|NCT01790789|BEHAVIORAL|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
214704927|NCT01790789|OTHER|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
214704928|NCT06015412|DIAGNOSTIC_TEST|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
214704929|NCT02476357|DEVICE|Harmonic scalpel|
214704930|NCT01222572|RADIATION|Stereotactic boost|
214557819|NCT01754753|OTHER|Telephone Friendship groups|
214557820|NCT04526730|DRUG|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3
214557821|NCT04526730|DRUG|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
214704931|NCT01222572|RADIATION|Conventional RT|
214704932|NCT01222572|DRUG|Etoposide|
214704933|NCT01222572|DRUG|Cisplatin|
214704934|NCT00303758|DRUG|cisplatin|
214704935|NCT00303758|DRUG|fluorouracil|
214704936|NCT00303758|DRUG|gemcitabine hydrochloride|
214704937|NCT00303758|DRUG|leucovorin calcium|
214704938|NCT00432094|DRUG|carboplatin|Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
214704939|NCT00432094|DRUG|etoposide|600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
214704940|NCT00432094|DRUG|ifosfamide|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
214704941|NCT00432094|DRUG|paclitaxel|225 mg/m\^2 intravenous over 3 hours on Day -7.
214704942|NCT00432094|DRUG|thiotepa|150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
214704943|NCT00432094|PROCEDURE|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
214704944|NCT00432094|DRUG|Mesna|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
214704945|NCT00432094|BIOLOGICAL|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
214557822|NCT04526730|DEVICE|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
214557823|NCT00899977|DRUG|Placebo|Matching placebo
214557824|NCT00899977|DRUG|TC-5214|
214557825|NCT05936424|OTHER|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
214557826|NCT05936424|OTHER|Non-Exercise Control Leg|One leg will serve as a non-exercise control
214557827|NCT00047255|BIOLOGICAL|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
214557828|NCT00047255|DRUG|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
214557829|NCT00047255|DRUG|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
214557830|NCT00047255|BIOLOGICAL|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
214704946|NCT05374148|BEHAVIORAL|health education|health education to prevent respiratory diseases among workers
214704947|NCT04315480|DRUG|Tocilizumab|single intravenous administration 8mg/Kg
214704948|NCT00200018|DEVICE|Enterra Therapy System (H9900014)|
214704949|NCT00889993|DIETARY_SUPPLEMENT|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
214704950|NCT04591041|DEVICE|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
214704951|NCT04591041|OTHER|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
214704952|NCT05071352|DRUG|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
214704953|NCT05071352|DRUG|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
214704954|NCT05689138|OTHER|Oral and Fecal Sample Collection|No interventions
214704955|NCT04335604|DRUG|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
214704956|NCT04184115|DRUG|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
214557831|NCT00047255|DRUG|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
214557832|NCT05992857|PROCEDURE|Pancreaticoduodenectomy without retromesenteric omental flap|Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.
214557833|NCT05992857|PROCEDURE|Pancreaticoduodenectomy with retromesenteric omental flap|All exposed peripancratic arteries should be covered with a retromesentric omental flap
214557834|NCT03751670|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation programmes will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training, education and psychosocial support.
214557835|NCT03751670|DRUG|Daily medical treatment|Patients will be treated with daily medication prescribed by the physician.
214557836|NCT05173337|DRUG|Nefopam|"Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery."
214557837|NCT06554340|BEHAVIORAL|Home-based aerobic training|The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
214557838|NCT03745898|DRUG|Oxygen|Active nocturnal oxygen concentrator
214557839|NCT03745898|OTHER|Room Air|Sham nocturnal oxygen concentrator (room air)
214557840|NCT06144619|GENETIC|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
214557841|NCT00219011|DRUG|aliskiren|
214557842|NCT00208455|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
214557843|NCT03557671|DIETARY_SUPPLEMENT|rice formula|new rice based thickened formula
214557844|NCT03557671|DIETARY_SUPPLEMENT|placebo|formula previously tolerated by the subject - only for the 1st part of the study
214557845|NCT00040417|DRUG|FLUDARABINE|
214704957|NCT04184115|DRUG|Placebos|Placebo Nasal Gel and placebo patch
214704958|NCT00566449|DRUG|Placebo|one dose daily for 4 weeks
214704959|NCT00566449|DRUG|JNJ-31001074|10 mg daily for 4 weeks
214557846|NCT00040417|DRUG|CAMPATH-IH|
214557847|NCT00040417|PROCEDURE|Total Body Irradiation|
214704960|NCT00566449|DRUG|JNJ-31001074|30 mg daily for 4 weeks
214704961|NCT05739760|BEHAVIORAL|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
214704962|NCT05739760|BEHAVIORAL|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
214704963|NCT03084718|DRUG|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
214704964|NCT03084718|DRUG|Placebo pMDI|Placebo Control
214704965|NCT03084718|DRUG|Beclomethasone Dipropionate (BDP)|Active Control
214704966|NCT05825196|DIAGNOSTIC_TEST|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
214704967|NCT02978209|DEVICE|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
214704968|NCT06006910|BEHAVIORAL|Column-based nudge in the EHR|The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
214704969|NCT06006910|BEHAVIORAL|No column-based nudge in the EHR|No intervention control period prior to nudge deployment.
214704970|NCT04913441|OTHER|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
214704971|NCT04913441|OTHER|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
214704972|NCT04913441|OTHER|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
214704973|NCT02116816|DIETARY_SUPPLEMENT|Polyphenol|Polyphenol
214557848|NCT00040417|DRUG|FK506|
214557849|NCT00040417|DRUG|G-SCF (Granulocyte-colony stimulating factor)|
214557850|NCT02390453|BEHAVIORAL|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
214557851|NCT02390453|BEHAVIORAL|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
214557852|NCT02390453|BEHAVIORAL|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
214557853|NCT02390453|BEHAVIORAL|Active Control|Control modules provide social contact for group discussion of health and successful aging.
214557854|NCT03652441|DRUG|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
214557855|NCT03197766|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
214704974|NCT06509711|OTHER|PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)|First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
214704975|NCT06509711|OTHER|PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
214704976|NCT02767856|DEVICE|IO-therapy Glasses|
214704977|NCT04611178|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
214704978|NCT01398267|DRUG|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
214704979|NCT01398267|DRUG|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
214704980|NCT01398267|DRUG|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
214704981|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
214704982|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
214704983|NCT01327872|DRUG|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
214704984|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
214704985|NCT00091026|BIOLOGICAL|cetuximab|Given IV
214704986|NCT00091026|DRUG|gemcitabine hydrochloride|Given IV
214704987|NCT00091026|BIOLOGICAL|bevacizumab|Given IV
214704988|NCT00091026|DRUG|erlotinib hydrochloride|Given orally
214704989|NCT04286464|OTHER|No intervention|No intervention
214704990|NCT05239377|OTHER|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
214704991|NCT05398419|OTHER|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
214704992|NCT05398419|OTHER|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
214704993|NCT01475864|PROCEDURE|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
214704994|NCT00843843|DEVICE|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
214704995|NCT02763293|OTHER|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
214557856|NCT03197766|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
214557857|NCT02002377|DRUG|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
214557858|NCT06503081|PROCEDURE|Colonoscopy|Colonoscopy with video recording and biopsy collection
214557859|NCT05795803|OTHER|Forced isolation context|Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
214557860|NCT04033302|BIOLOGICAL|CD7-specific CAR gene-engineered T cells|Infusion of CD7-specific CAR-T cells
214557861|NCT00671177|PROCEDURE|water immersion colonoscopy|instillation of 300cc of water in the rectum
214704996|NCT05363670|DRUG|ARS-1|ARS-1
214704997|NCT05363670|DRUG|Albuterol MDI|180 mcg
214704998|NCT05363670|DRUG|Placebo|Placebo
214704999|NCT05678075|BEHAVIORAL|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
214705000|NCT02612389|OTHER|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
215029827|NCT06674187|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery will be shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Separate the mesentery around the stoma and shape it into a sturdy support structure.~3. Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~4. Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
215029828|NCT07011225|DIETARY_SUPPLEMENT|Verisol Collagen 2,5 g/day|Patients allocated to this group will consume Verisol Collagen 2,5 g/day for 90 days.
214557862|NCT00671177|PROCEDURE|standard air colonoscopy|air instillation in colon for visualization
214557863|NCT02214875|OTHER|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
214557864|NCT02214875|OTHER|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
214557865|NCT05327556|DRUG|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
214557866|NCT05327556|DRUG|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
214557867|NCT05141942|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
214557868|NCT00003768|DRUG|fosbretabulin disodium|
214557869|NCT05998408|DRUG|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
214557870|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
214557871|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
214557872|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
214557873|NCT06053333|OTHER|Non-Interventional Study|Non-interventional study
214557874|NCT04486352|DRUG|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
214557875|NCT04486352|DRUG|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
214557876|NCT04486352|DRUG|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
214557877|NCT04486352|DRUG|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
214557878|NCT04486352|DRUG|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
214557879|NCT04486352|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
214557880|NCT04486352|DRUG|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
214557881|NCT04486352|DRUG|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
214557882|NCT04486352|DRUG|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
214557883|NCT04486352|DRUG|Giredestrant|Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
215029829|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 2,5 g/day|Patients allocated to this group will consume Peptech Collagen 2,5 g/day for 90 days.
214557884|NCT04486352|DRUG|Abemaciclib|Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
214557885|NCT06303570|DRUG|CBL-514 injection|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL ; total of 5 mg CBL-514.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL ; total of 15 mg CBL-514.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL ; total of 25 mg CBL-514.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL ; total of 40 mg CBL-514.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL ; total of 60 mg CBL-514."
214557886|NCT06303570|DRUG|0.9% Sodium chloride|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL."
214557887|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
214557888|NCT05194293|BIOLOGICAL|Durvalumab|Given IV
214557889|NCT05194293|DRUG|Regorafenib|Given PO
214557890|NCT03361865|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
215029830|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 10 g/day|Patients allocated to this group will consume Peptech Collagen 10 g/day for 90 days.
214705001|NCT03743233|DEVICE|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
215029831|NCT07011225|OTHER|Pulmonary rehabilitation with aerobic and resistance training.|Patients enroled in this group will be submitted to Pulmonary rehabilitation with aerobic and resistance training.
214557891|NCT03361865|DRUG|Epacadostat|Epacadostat administered orally twice daily.
214557892|NCT03361865|DRUG|Placebo|Matching placebo administered orally twice daily.
214557893|NCT00469339|BEHAVIORAL|Family Health History|
214557894|NCT05698173|BIOLOGICAL|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
214557895|NCT05698173|BIOLOGICAL|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
214557896|NCT05543187|DRUG|TAK-625|TAK-625 orally, twice daily (BID)
214557897|NCT05930379|OTHER|LSVT-Loud delivered by telerehabilitation|LSVT-Loud treatment delivered by telerehabilitation
214557898|NCT05930379|OTHER|LSVT-Loud in the clinic|LSVT-Loud delivered face-to-face in the clinic
214557899|NCT04306536|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
215029832|NCT07011225|DIAGNOSTIC_TEST|Cardiorespiratory test|The patients allocated to this group will be submitted to initial and final evaluations only.
215029833|NCT07009808|DRUG|Nalbuphine 0.20mg/ml(total 30 mg)|In this group, participants will receive an intravenous infusion of Nalbuphine at a concentration of 0.20 mg/ml, which delivers a total of 30 mg over the course of 48 hours. Additionally, 10 mg of Metoclopramide will be administered to manage potential postoperative nausea. This intervention aims to assess the analgesic efficacy and its subsequent effect on psychological outcomes, specifically anxiety and depression, in patients undergoing surgery for ectopic pregnancy.
214557902|NCT05619575|DEVICE|CP1170 Sound Processor|The CP1170 Sound Processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
214557903|NCT05619575|DEVICE|CP1150 Sound Processor|Active comparator off-the-ear sound processor.
214557904|NCT05538806|DEVICE|TTFields|all patients will receive routine clinical care and TTFields
214557905|NCT01647542|DRUG|TAK-875|TAK-875 tablets
214557906|NCT01647542|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
214557907|NCT04045093|DRUG|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
214557908|NCT04045093|DRUG|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
214557909|NCT03086655|BEHAVIORAL|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
214557910|NCT03086655|BEHAVIORAL|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
215029834|NCT07009808|DRUG|Nalbuphine 0.27mg/ml(total 40 mg)|Participants assigned to this group will be treated with an intravenous infusion of Nalbuphine at a concentration of 0.27 mg/ml, resulting in a total dosage of 40 mg administered during the 48-hour postoperative period. They will also receive 10 mg of Metoclopramide to mitigate nausea and vomiting. This intervention is designed to evaluate the effectiveness of this dose in pain management and its influence on anxiety and depression levels post-surgery.
215029835|NCT07009808|DRUG|Nalbuphine 0.33mg/ml(total 50 mg)|In this group, subjects will receive Nalbuphine at a concentration of 0.33 mg/ml, totaling 50 mg, delivered through intravenous infusion for 48 hours. Along with this, 10 mg of Metoclopramide will be included to address potential postoperative discomfort. This intervention seeks to explore how this higher concentration impacts pain relief and subsequent psychological effects, specifically targeting anxiety and depression following ectopic pregnancy surgery.
215029836|NCT06675773|OTHER|Conscious Awareness Development Psychoeducation Program|The Conscious Awareness Development Psychoeducation Program consists of nine sessions. The sessions will be applied once a week and last 90 minutes. The psychoeducation program is prepared based on conscious awareness. Conscious awareness and self-compassion techniques will be used in the sessions. Homework will be given to the participants in each session.
215029837|NCT06673589|BEHAVIORAL|Transcendental Meditation|meditation practice
215029838|NCT06673485|PROCEDURE|Patients received vitamin D and calcium supplementation during the healing period|"The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill, maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paralling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement.~During the healing period, the patients recieved Vitamin D and Calcium Supplements."
214705002|NCT03743233|DEVICE|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
214705003|NCT05656898|DEVICE|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
214705004|NCT05656898|DEVICE|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
214705005|NCT05656898|DEVICE|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
214705006|NCT00749164|PROCEDURE|MSC transplantation|1-2X10\^6 MSC per kg
214705007|NCT00589979|DRUG|Lidoderm (Lidocaine 5% Patch)|Topical Patch
214705008|NCT00589979|DRUG|Placebo Patch|Topical Patch
214705009|NCT04771988|RADIATION|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
214705010|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
214705011|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
214705012|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
214705013|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
214705014|NCT00355849|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
214705015|NCT00355849|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
214705016|NCT01497535|DRUG|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
214557911|NCT03977896|PROCEDURE|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
214557912|NCT05269823|OTHER|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
214557913|NCT05269823|OTHER|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
214557914|NCT04153331|OTHER|Nasal swab|Patient included in emergency with a nasal swab
214557915|NCT04987203|DRUG|Tivozanib|Tivozanib will be administered orally.
214705017|NCT01497535|DRUG|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
214705018|NCT06103448|DEVICE|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
214705019|NCT04970394|BEHAVIORAL|Cervical Screening Reminder|Verbal reminder and if seen face-to-face, a written appointment booking slip.
214705020|NCT00217516|DRUG|selenium|Given orally
214705021|NCT00217516|OTHER|placebo|Given orally
214705022|NCT05731232|DIETARY_SUPPLEMENT|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
214557916|NCT04987203|DRUG|Nivolumab|Nivolumab will be administered via intravenous infusion.
214557918|NCT04900974|DRUG|Doravirine|100mg
214557919|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
214705023|NCT05605483|OTHER|Salad bar|Schools where the school district has installed salad bars
214705024|NCT05605483|OTHER|Waitlisted control|Schools where the school district has not yet installed salad bars
214705025|NCT05605483|OTHER|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
214705026|NCT01397448|DRUG|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
214705027|NCT01397448|DRUG|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
215163314|NCT01174121|DRUG|Pembrolizumab (Keytruda)|"Arm 3 or 5: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment~evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks)."
214557920|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
214557921|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
214557922|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
214557923|NCT02556099|DRUG|Hydroxyurea|drug to be administered
214557924|NCT03008005|DRUG|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
214557925|NCT03008005|DRUG|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
214557926|NCT03008005|DRUG|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
214557927|NCT06026410|DRUG|KO-2806|Oral administration
214557928|NCT06026410|DRUG|Cabozantinib|Oral administration
214557929|NCT06026410|DRUG|Adagrasib|Oral administration
214557930|NCT05929898|BEHAVIORAL|Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback|fMRI neurofeedback training of sustained midbrain/VTA activation via motivational imagery.
214557931|NCT06967818|DRUG|Potassium Nitrate Gel|Topical application of a 5% potassium nitrate gel (Emofrom Actisens) used to treat dentin hypersensitivity.
214557932|NCT06967818|DEVICE|Diode Laser (Active)|Application of a 980 nm diode laser at 1.5 W/cm² for 1 minute without contact and 1 minute with contact, using a sweeping motion perpendicular to the long axis of the tooth.
214705028|NCT01397448|DRUG|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
214705029|NCT00570531|DRUG|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
214705030|NCT00570531|DRUG|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
214705031|NCT00570531|DRUG|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
215163315|NCT01174121|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
215163316|NCT01174121|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
215163317|NCT01174121|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
214557933|NCT06967818|DEVICE|Diode Laser (Sham)|Inactive diode laser device used for 1 minute without contact and 1 minute with contact, mimicking the active laser procedure but without energy output.
215163318|NCT01174121|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
215163319|NCT06558643|DRUG|MMV371 LAI|Single intra-muscular dose
215163320|NCT06558643|DRUG|Placebo for MMV371|Single intramuscular dose
215163321|NCT06330064|DRUG|Ifinatamab deruxtecan|Intravenous administration
215163322|NCT03937830|DRUG|durvalumab|1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
215163323|NCT03937830|DRUG|Doxorubicin-Eluting Beads|used for TACE (only in patients with HCC BCLC stage B)
215163324|NCT03937830|PROCEDURE|TACE|TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.
215163325|NCT03937830|DRUG|bevacizumab|7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
215163326|NCT03937830|DRUG|Tremelimumab|300, 150 or 75 mg once on day 1 of cycle 1
215163327|NCT01810913|DRUG|Atezolizumab|Given IV
215163328|NCT01810913|PROCEDURE|Biopsy Procedure|Undergo biopsy
215163329|NCT01810913|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215163330|NCT01810913|BIOLOGICAL|Cetuximab|Given IV
215163331|NCT01810913|DRUG|Cisplatin|Given IV
215163332|NCT01810913|PROCEDURE|Computed Tomography|Undergo CT
215163333|NCT01810913|DRUG|Docetaxel|Given IV
215163334|NCT01810913|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215163335|NCT01810913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163336|NCT01810913|OTHER|Survey Administration|Ancillary studies
215163337|NCT03147885|DRUG|Selinexor|Given PO
215163338|NCT03642197|BEHAVIORAL|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
215163339|NCT04036331|BEHAVIORAL|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
215163340|NCT04036331|BEHAVIORAL|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories\*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories\*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
215163341|NCT04036331|BEHAVIORAL|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
215163342|NCT05322460|OTHER|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
215163343|NCT04604730|PROCEDURE|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
215163344|NCT04604730|PROCEDURE|Anastomosis with protective stoma|Anastomosis with protective stoma
214557934|NCT04569773|BEHAVIORAL|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
214557935|NCT04569773|BEHAVIORAL|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
214557936|NCT04569773|BEHAVIORAL|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
214557937|NCT02465151|OTHER|Protein-based beverage|protein-based beverage
214557938|NCT06413953|DRUG|TQB3107 Tablets|TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.
214557939|NCT04296968|DEVICE|Painful stimulation using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In the experimental paradigm, 160 painful stimuli of two intensities (3 J, 3.5 J) will be applied to the dorsum of the left hand using the laser device listed above.
214557940|NCT04296968|DEVICE|Visual cueing|Preceding to each painful stimulus, visual cues (e.g., blue dot and yellow square) will be presented on a screen indicating the intensity of the subsequent stimulus (low and high intensity) with an accuracy of 75%. The contingencies of the visual cues will be explicitly stated to the participants.
214557941|NCT05826145|BEHAVIORAL|Vocal Expression|There will be a total of 8 sessions. At baseline (week 0), only questionnaires will be completed. There will be 7 treatment sessions beginning at week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration where the vocal expression sessions will be provided.
214557942|NCT05826145|BEHAVIORAL|Cognitive Behavioral|There will be 8 treatment sessions where part of the baseline session of session 1 (week 0) will include some instruction, session 2 will occur in week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration. Sessions will include various cognitive-behavioral techniques including completing a grief monitoring diary, imaginal revisiting, cognitive restructuring, describing positive memories of the deceased, and identifying future goals.
215163345|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
214557943|NCT01744704|DRUG|rhNGF 0.5 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
214557944|NCT01744704|DRUG|rhNGF 5 µg/mL Sentinel|Part 0 represented a sentinel group.
214557945|NCT01744704|DRUG|rhNGF 20 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
214557946|NCT01744704|DRUG|rhNGF 20 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
214557947|NCT01744704|DRUG|rhNGF 60 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
214557948|NCT01744704|DRUG|rhNGF 180 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
214557949|NCT01744704|DRUG|rhNGF 20 µg/mL Part B|In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
214557950|NCT01744704|DRUG|rhNGF 60 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
214557951|NCT01744704|DRUG|rhNGF 180 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
214557952|NCT01744704|DRUG|Placebo Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
214557953|NCT01744704|DRUG|Placebo Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
214557954|NCT04522921|DIETARY_SUPPLEMENT|Diet with a higher amount of protein (25E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a higher protein (25E%/day) diet.
214557955|NCT04522921|BEHAVIORAL|Increased follow-up contact after the 10-week intervention|Both the control-group and the intervention-group were offered an increased follow-up contact after camp.
214557956|NCT04522921|DIETARY_SUPPLEMENT|Diet with a lower amount of protein (15E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a low-moderate protein (15E%/day) diet.
214557957|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
214557958|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
214557959|NCT01040169|DEVICE|Arginine/Calcium Carbonate|One application
214557960|NCT01040169|DEVICE|Mint Prophy paste - Fluoride free|one application
214557961|NCT04201587|OTHER|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
214557962|NCT00966147|OTHER|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
214557963|NCT05202054|OTHER|mindfulness stress reduction program|Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
214557964|NCT00558792|DRUG|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
214557965|NCT00558792|DRUG|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
214557966|NCT00558792|DRUG|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
214557967|NCT03243435|PROCEDURE|Native 1,5 Tesla breast MRI|
214705032|NCT00570531|DRUG|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
215163346|NCT05825287|OTHER|Management training|Management training
215163347|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
215163348|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
215163349|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
215163350|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
215163351|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
214705033|NCT00570531|RADIATION|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
214705034|NCT00570531|PROCEDURE|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
214557968|NCT05371665|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Prevention and Early Intervention (PEI) Program|The prevention and early intervention is originally an indicated cognitive-behavioral program for 8-13-year-old youth with higher anxiety. Our CAB adapted it as a universal prevention and early intervention for all American Indian youth in the tribal community. It was delivered across six weeks with 20-30 min weekly sessions. Youth engaged in games and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involved introductions, relaxation training, and discussing emotions. Session 2 taught youth about worries and how to handle them. Session 3 focused on having conversations with others. Session 4 taught youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 taught youth how to face their fears. Session 6 was a review session. Parents and teachers were sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
214557969|NCT03633799|DRUG|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
215163352|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
215163353|NCT03415828|DEVICE|Ethanol gel|Intradiscal injection of ethanol gel
214557970|NCT02373631|OTHER|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
214557971|NCT02373631|OTHER|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
214557972|NCT04694807|BEHAVIORAL|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
214557973|NCT04694807|BEHAVIORAL|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
214705035|NCT03528889|PROCEDURE|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
214705036|NCT06113497|DRUG|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
214705037|NCT06120309|DIAGNOSTIC_TEST|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
214705038|NCT06120309|DIAGNOSTIC_TEST|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
214705039|NCT01229241|DRUG|local anesthetic|"postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
214705040|NCT05218057|PROCEDURE|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
215163354|NCT03415828|DRUG|Prednisolone acetate|Intradiscal infiltration of steroids
215163355|NCT04956081|DEVICE|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
215163356|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
215163357|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
215163358|NCT06188910|OTHER|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
215163359|NCT06188910|OTHER|Health education|Health education on mobile phone addiction
215163360|NCT03516812|OTHER|Laboratory Biomarker Analysis|Correlative studies
215163361|NCT03516812|DRUG|Olaparib|Given PO
215163362|NCT03516812|OTHER|Quality-of-Life Assessment|Ancillary studies
215163363|NCT03516812|OTHER|Survey Administration|Ancillary studies
215163364|NCT03516812|DRUG|Testosterone Enanthate|Given IM
215163365|NCT03516812|DRUG|Testosterone Cypionate|Given IM
214557974|NCT06553391|DRUG|The tetralogy of medication regimen|"During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment."
214557975|NCT00631553|DRUG|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
214557976|NCT02082470|OTHER|follow-up care|Undergo survivorship care planning
214557977|NCT02082470|OTHER|active surveillance|Undergo cancer surveillance
214557978|NCT02082470|OTHER|questionnaire administration|Ancillary studies
214557979|NCT04993469|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament testing and questionnaires|Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
214557980|NCT06389292|DRUG|APG-2575(Lisaftoclax )|QD, oral administration, every 28 days for a dosing cycle.
214705041|NCT02492685|DEVICE|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
214705042|NCT02240745|OTHER|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
214705043|NCT06553846|DRUG|Lutetium [177Lu]-FAP-75|Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
214557981|NCT06389292|OTHER|Placebo|QD, oral administration, every 28 days for a dosing cycle.
214557982|NCT06389292|DRUG|Azacitidine Injection|QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.
214557983|NCT05676463|PROCEDURE|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
214557984|NCT05676463|DRUG|Antiandrogen Therapy|Receive SOC ADT
214557985|NCT05676463|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
214557986|NCT05676463|PROCEDURE|Computed Tomography|Undergo CT
214557987|NCT05676463|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214557988|NCT05676463|PROCEDURE|Bone Scan|Undergo bone scan
214557989|NCT05676463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214557990|NCT05676463|OTHER|Quality-of-Life Assessment|Ancillary studies
214557991|NCT04554641|OTHER|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
214557992|NCT04554641|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
214557993|NCT04554641|OTHER|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
214557994|NCT02370901|DEVICE|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
214557995|NCT02370901|BEHAVIORAL|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
214557996|NCT04200534|OTHER|Best Practice|Receive usual care counseling
214557997|NCT04200534|DRUG|Nicotine Patch|Given nicotine patches
214705044|NCT03365804|DEVICE|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
214705045|NCT04727606|DRUG|Ure-Na|"* Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month."
214705046|NCT05084794|PROCEDURE|Internal fixation|Fixation of posterior malleolus with either plate or screws.
214705047|NCT01811901|OTHER|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
214705048|NCT03537820|OTHER|questionnaire|questionnaire EVAN-G
214705049|NCT00736086|DEVICE|Vessel Closure (StarClose™)|
214705050|NCT02128620|BEHAVIORAL|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
214705051|NCT01680588|DRUG|[18F]NAV4694|
214705052|NCT01085305|BEHAVIORAL|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
214705053|NCT01085305|BEHAVIORAL|TAU|Usual treatment for behavioral disorders
214705054|NCT02782871|DEVICE|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
214557998|NCT04200534|OTHER|Quality-of-Life Assessment|Ancillary studies
214557999|NCT04200534|OTHER|Questionnaire Administration|Ancillary studies
214558000|NCT04200534|OTHER|Tobacco Cessation Counseling|Receive counseling over the phone
214558001|NCT00004068|DRUG|irinotecan hydrochloride|
214558002|NCT00004068|DRUG|temozolomide|
214558003|NCT00004068|PROCEDURE|conventional surgery|
214558004|NCT00004068|RADIATION|radiation therapy|
214558005|NCT01348334|PROCEDURE|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
214558006|NCT03551691|DRUG|Omeprazole 20mg Capsule|Omeprazole 20mg daily for 28 days
214558007|NCT03551691|DRUG|Placebo oral capsule|Identically-appearing capsule to omeprazole for 28 days
214558008|NCT04187859|BEHAVIORAL|Education Session|Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
214558009|NCT04187859|DEVICE|Prompting Cup|The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
214558010|NCT00022581|DRUG|thalidomide|Given orally
214558011|NCT00022581|OTHER|laboratory biomarker analysis|Correlative studies
214558012|NCT06202274|DEVICE|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
214558013|NCT06109467|DRUG|Neratinib|All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
214705055|NCT01694576|DRUG|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
214705056|NCT04200105|DEVICE|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
214558014|NCT06109467|DRUG|Trastuzumab|All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
214558015|NCT06109467|DRUG|Oxaliplatin|All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
214558016|NCT06109467|DRUG|5-Fluorouracil + leucovorin|All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
214558017|NCT06109467|DRUG|Pembrolizumab|All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
214705057|NCT04200105|DEVICE|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
214705058|NCT03039127|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
214705059|NCT04705324|PROCEDURE|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
214705060|NCT04705324|PROCEDURE|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
214705061|NCT04705324|PROCEDURE|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
214558018|NCT06493409|DRUG|Repotrectinib|Specified dose on specified days
214558019|NCT06493409|DRUG|Voriconazole|Specified dose on specified days
214558020|NCT06493409|DRUG|Quinidine|Specified dose on specified days
214558021|NCT03694483|DIAGNOSTIC_TEST|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
214558022|NCT05494918|DRUG|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
214558026|NCT05846698|DRUG|Luo-Bu-Fu-Ke-Bi-RI Pill|10 pills twice daily
214558027|NCT05846698|DRUG|tibolone|2.5 mg once daily
214558028|NCT03788811|DEVICE|ERG assessment (RSPA)|Processing and analysis of retinal signals
214558029|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
214705062|NCT05912855|DEVICE|qNOX|Non
214705063|NCT06156358|OTHER|No intervention|No intervention
214705064|NCT01376713|BIOLOGICAL|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
214705065|NCT01376713|BIOLOGICAL|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
214705066|NCT02938052|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
214705067|NCT00202111|PROCEDURE|Laparoscopic-assisted colectomy|
214705068|NCT00202111|PROCEDURE|Conventional open colectomy|
214705069|NCT00679731|DRUG|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
214705070|NCT00679731|DRUG|Methotrexate|5.0 to 25 mg weekly
214705071|NCT05642013|PROCEDURE|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
214705072|NCT05642013|OTHER|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
214705073|NCT04121312|BEHAVIORAL|Facilitation Intervention|"See arm description"
214705074|NCT00454155|DRUG|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
214705075|NCT00669916|BIOLOGICAL|AIN457|single infusion of 3 mg/kg
214705076|NCT00669916|DRUG|Placebo|single infusion of placebo
214705077|NCT04296526|BEHAVIORAL|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
214558030|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
214558031|NCT05436717|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
214705078|NCT04296526|BEHAVIORAL|Exercise Education|To organize sessions for how to proper exercise.
214705079|NCT04296526|BEHAVIORAL|Social Support|Supports such as peer influence or reminder phone messages
214558032|NCT06539390|OTHER|Transforaminal Epidural Injections?|Pain, lumbar disc herniation,Transforaminal Epidural Injections?
214558033|NCT05855967|DRUG|Ixekizumab|Administered SC
214558034|NCT07120919|OTHER|Peer Educatıon|The peer educators provided training on reproductive health and safe sexuality for young people and completed the intervention part by giving training brochures to the participants.
214558035|NCT02446821|DRUG|VeraCept|IUD placement of VeraCept
214705080|NCT02008838|DIETARY_SUPPLEMENT|Synbiotic|
214705081|NCT02008838|DIETARY_SUPPLEMENT|Placebo|
214705082|NCT04832919|BEHAVIORAL|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
214705083|NCT04359355|DEVICE|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
214705084|NCT01928043|DRUG|Curcumin|
214558036|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
214558037|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
214705085|NCT01175278|PROCEDURE|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
214705086|NCT01175278|OTHER|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
214558038|NCT01894997|DEVICE|Neuromuscular electrical stimulator|
214558039|NCT01894997|DEVICE|AV Impulse System Model 6000|
214558040|NCT06600854|DEVICE|BoneTape|"BoneTape is a craniofacial fracture repair device intended for use in the fixation of non-load-bearing bones of the craniofacial and midfacial skeleton. It can be used in skeletally mature individuals but is not intended for use in the mandible and/or full load bearing procedures. It is composed of: 1) BoneTape implant (device), and 2) BoneTape applicator (applicator)."
214558041|NCT04254133|BEHAVIORAL|Questionnaire|Complete questionnaire
214558042|NCT04254133|PROCEDURE|Biospecimen Collection|Provide saliva samples
215163366|NCT06472817|OTHER|Non-Interventional Study|Non-interventional study
215163367|NCT05244421|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
214558043|NCT04254133|DIAGNOSTIC_TEST|Genetic Testing|Undergo genetic testing
214558044|NCT04254133|OTHER|Genetic Counseling|Undergo counseling
214558045|NCT04254133|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214558046|NCT04647747|OTHER|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
214558047|NCT02638883|DEVICE|Hybrid SRW cochlear implant|Subjects will be implanted with the Hybrid SRW
214558048|NCT05743699|BEHAVIORAL|Bright Horizons|Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
214558049|NCT05743699|BEHAVIORAL|Case Management|Placebo condition
214558050|NCT02284009|BIOLOGICAL|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
214558051|NCT02284009|BIOLOGICAL|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
214558052|NCT02284009|BIOLOGICAL|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
214558053|NCT06666036|BEHAVIORAL|Connect|Community level enhancements
214558054|NCT06604832|DRUG|PrabotulinumtoxinA-Xvfs|Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
214558055|NCT06604832|DRUG|IncobotulinumtoxinA|Each vial of incobotulinumtoxinA contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the right side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
214558056|NCT06604832|DRUG|saline solution (placebo)|As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
214558057|NCT02902159|OTHER|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
214558058|NCT02902159|OTHER|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
214558059|NCT06026553|DRUG|Ketorolac (Toradol)|IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
214558060|NCT06026553|OTHER|Placebo (saline)|IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
214558061|NCT02967640|DRUG|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
214558062|NCT02967640|DRUG|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
214558063|NCT04281251|PROCEDURE|Endoscopic retrograde appendicitis therapy|"Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith."
214558064|NCT02469883|DRUG|Sinotecean|
214558065|NCT03652350|PROCEDURE|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
214558066|NCT03882086|OTHER|foot reflexology|Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
214558067|NCT03749304|DEVICE|ANI monitor|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
214558068|NCT03468790|DRUG|CMAB007|the study drug
214558069|NCT03468790|DRUG|Symbicort|asthma-controlled drug
214558070|NCT03468790|DRUG|Seretide|asthma-controlled drug
214558071|NCT03468790|DRUG|Ventolin|asthma rescue drug
214558072|NCT03468790|DRUG|placebo|No active components
214558073|NCT00075777|DRUG|valproic acid|250 mg by mouth twice a day
214558074|NCT01349153|BEHAVIORAL|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
214558075|NCT01349153|BEHAVIORAL|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
214558076|NCT06859957|DRUG|Melatonin 10 mg|10 mg melatonin daily for a period of 6 weeks
214558077|NCT06859957|DRUG|Placebo|Daily placebo for a period of 6 weeks
214558078|NCT06860022|BEHAVIORAL|Shape Coding|Intervention will include introducing and reviewing the relevant shapes from Shape Coding and the order in which the shapes go in a sentence. The researcher will then model how to put the word tiles in order according to the shapes. Next the researcher and student work together to construct sentences. The student is then given the opportunity to independently construct sentences using the word tiles and Shape Coding. At the end of instruction, the researcher and student review the shapes and the student has the opportunity to independently construct sentences without shape coding.
214558079|NCT05427084|DRUG|Canagliflozin|Canagliflozin tablet 300mg PO daily
214558080|NCT05427084|DRUG|Placebo|Placebo tablet
214558081|NCT06611930|DRUG|CK-0045|Interleukin-22 agonist
214558082|NCT06611930|DRUG|Placebo|Placebo (liquid for injection, which includes no active ingredient).
214558083|NCT06586190|OTHER|Floor Pedal Bike with Guided Instructions for Home|Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.
214558084|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 1|Medium dose, approximately 10\^4.5 TCID50/mL
214558085|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 2|High dose, approximately 10\^5.5 TCID50/mL
214558086|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 3|TBD, depending on outcome of Part A
214558087|NCT06995196|BEHAVIORAL|ReLiver-N App|"Intervention for intervention group: Patients will access all content of ReLiver-N App. The ReLiver-N App has comprehensive health education, patient activation practices, care algorithm, and clinical decision system, to provide and maintain the hepatic rehabilitation of patients with liver cirrhosis and to evaluate the effect of the use of ReLiver-N App on hepatic rehabilitation. Care algorithm and clinical decision system will be evaluated results of patient activation as normal, controllable, urgent. Feedbacks will be sent to patients based on the evaluations."
214558088|NCT06669728|DIAGNOSTIC_TEST|AI diagnostic algorithm|The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
214705087|NCT04680078|PROCEDURE|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
214705088|NCT04680078|PROCEDURE|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
214705089|NCT00195689|BIOLOGICAL|Human anti-TNF monoclonal antibody/adalimumab|
214705090|NCT01199250|OTHER|Laboratory Biomarker Analysis|Correlative studies
214705091|NCT05412472|DRUG|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
214705092|NCT02159469|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
214705093|NCT02475395|DEVICE|TRAK device|Use of TRAK to attain sperm concentration measurement
214558089|NCT06996249|BEHAVIORAL|Health-related quality of life and treatment outcome questionnaires|Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.
214705094|NCT03531333|PROCEDURE|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
214558090|NCT06996249|GENETIC|(Tumor) tissue and other biomaterials|Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.
214558091|NCT06996249|PROCEDURE|Blood samples|Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).
214558092|NCT06996769|OTHER|constraint induced therapy|Constraint induced movement therapy (CIMT) is a treatment approach that can be used with patients who have had a CVA. In order to be eligible for the therapy, the clients must have at least 10 degrees of active wrist and finger extension. During this treatment the unaffected limb is restrained (usually with a sling or a mitt) for 90% of their waking hours. This treatment forces the client to use the affected limb throughout their daily tasks in order to combat learned non-use of the affected limb.
214558093|NCT06996769|OTHER|Conventional therapy for stroke patient|general exercises
214558094|NCT05687188|OTHER|Blood Sample Collection|Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
214558095|NCT05687188|OTHER|Tissue Sample Collection|At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
214558096|NCT05687188|OTHER|Data Collection|Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
214558097|NCT05687188|OTHER|Medical Image Collection|Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
214558098|NCT06673056|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
214558099|NCT06673056|OTHER|Placebo|Matching Placebo Sachet
214705095|NCT04986020|DIAGNOSTIC_TEST|MRI|Identification of novel biomarkers from MRI
214705096|NCT02836860|OTHER|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
214705097|NCT03441568|DEVICE|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
214558100|NCT06324747|PROCEDURE|Vestibular socket therapy|Vestibular socket therapy will be used for the intervention.
214705098|NCT05237180|OTHER|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
214705099|NCT00995670|DRUG|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
214705100|NCT00995670|DRUG|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
214705101|NCT00995670|DRUG|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
214705102|NCT00995670|DRUG|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
214705103|NCT00503542|DRUG|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
214705104|NCT00503542|DRUG|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
214705105|NCT00503542|DRUG|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
214558101|NCT06324747|PROCEDURE|conventional full thickness flap|reflecting the mucoperiosteum to access the extraction socket
214558102|NCT05295433|DRUG|mRNA-3705|A sterile liquid for injection
214558103|NCT04897841|DRUG|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
214558104|NCT04897841|DRUG|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
214705106|NCT00503542|OTHER|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
214705107|NCT03771456|PROCEDURE|Colorectal resections|Colorectal resections
215163368|NCT05089370|COMBINATION_PRODUCT|Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab|Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells (MDSCs, Tregs) (1-4), increasing the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit mucosal melanoma patients.
214558105|NCT04897841|OTHER|saline|post-surgical saline
214558106|NCT07000240|OTHER|Midwife-led ultrasound-guided pushing training group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation.~Women randomized to the ultrasound-guided pushing training group will receive additional transperineal ultrasound (TPU) evaluations during practical exercises, performed by a midwife trained in ultrasound imaging. These assessments will ensure effective LAM relaxation during pushing practices and provide real-time visual feedback to optimize muscle coordination."
214558107|NCT07000240|OTHER|Midwife-led pushing training only group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation."
214705108|NCT04823767|OTHER|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
214705109|NCT03905629|OTHER|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
214705110|NCT01756066|BEHAVIORAL|Different levels of cost sharing|
214705111|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
214705112|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
214705113|NCT00383721|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
214705114|NCT00383721|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
214705115|NCT00383721|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
214705116|NCT01991938|DRUG|VS-5584|
214705117|NCT00607568|DRUG|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
215163369|NCT04064957|BIOLOGICAL|HB-adMSCs|
215163370|NCT06392074|DRUG|MB04|Subcutaneous injection
215163371|NCT06392074|DRUG|US License Enbrel|Subcutaneous injection
215163372|NCT06392074|DRUG|EU Source Enbrel|Subcutaneous injection
215163373|NCT05100004|DEVICE|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
214558108|NCT06999863|OTHER|Patients of a surgical intensive care unit|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of BP in 3 situations (thick sleeve, thin sleeve, bare arm) and with 2 algorithms (for bare arm measurement only).
214558109|NCT06670287|OTHER|Single-Sensor Tracking (In-Lab)|In-lab sleep tracking using only raw accelerometer data from a single sensor collected and processed with legacy actigraphy algorithms.
214558110|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (In-Lab)|In-lab sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
214558111|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (At-Home)|At-home sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
214558112|NCT02769845|DRUG|Hydroxyurea|drug to be administered
214558113|NCT02769845|PROCEDURE|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
214558114|NCT02603328|DRUG|Atorvastatin|40-80 mg OD
214558115|NCT02603328|OTHER|Placebo|inactive
214558116|NCT06920225|BEHAVIORAL|Maintain home-based schedule|The team will maintain their home-based time zone schedule despite being in a location that is three time zones away
214558117|NCT07126873|BIOLOGICAL|Allogeneic Human E-islet (E-islet 01)|Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein
214558118|NCT07005427|OTHER|dysphagia therapy|"This group will receive usual dysphagia care as provided in ICU settings~* Standard bedside swallowing evaluation~* Conventional compensatory strategies (postural changes, diet modifications)~* Traditional exercises focusing on oral motor control~* Therapy sessions 3 times per week for 30 minutes"
214558119|NCT07005427|BEHAVIORAL|Designed protocol for dysphagia|"* Innovative strengthening exercises adapted for ICU setting~* Early mobilization component~* ICU-specific compensatory strategies~* Therapy sessions 5 times per week for 30 minutes with additional brief daily reinforcement"
214558120|NCT05915234|DEVICE|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
214558121|NCT05915234|DEVICE|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
214705118|NCT05978687|DRUG|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
214705119|NCT05978687|DRUG|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
214705120|NCT06127706|DEVICE|twin vaginal delivery simulation|skill test after formal lecture and simulation in group 1 and after digital learning only
214705121|NCT05614713|PROCEDURE|Selected physical therapy program|Gait training and balance training
214705122|NCT05614713|PROCEDURE|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
214705123|NCT00338468|DRUG|epoetin alfa|
214705124|NCT00289562|DRUG|forodesine hydrochloride (BCX-1777)|
214705125|NCT03828149|COMBINATION_PRODUCT|Drug:OP0201|Drug: OP0201
214558122|NCT05915234|DEVICE|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
214558123|NCT06870201|DIETARY_SUPPLEMENT|Lipid-Based Nutrient Supplement|LNS labeled with a stable iron isotope
214558124|NCT06886139|DRUG|TRS005|Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.
214558125|NCT03898778|DEVICE|Minnesota Medical Technologies Anal Insert Device|Non-sterile soft, flexible, liquid-filled anal insert either 10 mm size or 13 mm size, meant for single use only
214705126|NCT03828149|COMBINATION_PRODUCT|Drug: Placebo|Drug: Placebo
214705127|NCT04568941|BEHAVIORAL|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
214705128|NCT04568941|BEHAVIORAL|Core Needle Biopsy|Core Needle Biopsy
214705129|NCT04568941|BEHAVIORAL|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
214705130|NCT00941616|BIOLOGICAL|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
214705131|NCT00941616|BIOLOGICAL|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
214705132|NCT02652507|DRUG|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
214705133|NCT02652507|DRUG|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
214558126|NCT07012525|PROCEDURE|Photobiomodulation Therapy + Hyaluronic Acid Gel Injection|This arm includes the test sites (e.g., left maxillary quadrant) in each participant. The same dose of hyaluronic acid (0.2 mL of 0.8% gel) will be injected in the same manner as in the control group. However, photobiomodulation therapy (PBMT) using a diode laser (wavelength 630-670 nm, 25 mW, 1.875 J/cm² for 20 seconds) will be applied before and after the injection. Laser application will be repeated at every follow-up appointment to promote tissue healing, angiogenesis, and papillary regeneration.
214705134|NCT04486924|DEVICE|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
214705135|NCT00016393|DRUG|ixabepilone|
214558127|NCT07012525|DRUG|Hyaluronic Acid Gel Injection|This arm includes the control sites (e.g., right maxillary quadrant) in each participant. The interdental papilla with Class I deficiency will be treated using 0.2 mL of 0.8% commercial hyaluronic acid gel, injected 2-3 mm apical to the papilla tip. This is a commonly used non-surgical soft tissue filler in periodontal and esthetic procedures. No photobiomodulation therapy will be applied in this arm.
214558128|NCT05739331|DEVICE|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
214558129|NCT05430815|BEHAVIORAL|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
214558130|NCT06632015|DRUG|Calcium Hydroxide (CH)|1 mL distilled water mixed with 1 g calcium hydroxide powder, placed into the root canals using a lentulo spiral.
214558131|NCT06632015|DRUG|Diclofenac Sodium (DCS)|1 mL distilled water mixed with 1 g diclofenac sodium powder, placed into the root canals using a lentulo spiral.
214558132|NCT06632015|DRUG|Calcium Hydroxide + Diclofenac Sodium (CH + DCS)|1 mL distilled water mixed with 950 mg calcium hydroxide powder and 50 mg diclofenac sodium powder, placed into the root canals using a lentulo spiral.
214558133|NCT06810765|OTHER|Hormone Replacement Therapy (HRT)|Hormone Replacement Therapy (HRT) is a medical treatment that involves restoring healthy endocrine functioning through supplementing or balancing hormones, such as testosterone or estrogen, to address deficiencies caused by injury, aging, or stress.
214558134|NCT06810765|OTHER|Magnetic Resonance Therapy (MeRT)|MeRT, an EEG (electroencephalography)-guided Repetitive Transcranial Magnetic Stimulation therapy, is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain, guided by an individual's brain patterns. MeRT is a neuromodulatory tool that has shown therapeutic efficacy in relation to a number of psychopathological targets including PTSD, depression, and TBI-related cognitive impairment through promoting cortical excitability, modulating neurotransmission, and restoring neuroplasticity.
214705136|NCT03784027|DEVICE|CamAPS FX|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
214705137|NCT03784027|OTHER|Sensor augmented therapy|Study insulin pump and study CGM.
214705138|NCT06898229|BEHAVIORAL|Education|The intervention program aimed to increase participation in breast cancer screenings and reduce fear among illiterate women. The three-month training was structured in three phases. In the first month, awareness was raised through visual-audio materials about breast cancer, risk factors, and the importance of early diagnosis. In the second month, practical training was provided on breast self-examination (BSE), and clinical breast examination (CBE) and mammography procedures were introduced. In the final month, group discussions and success stories supported behavioral change, reinforcing knowledge. The program's effectiveness was evaluated through pre-test and post-test comparisons.
214705139|NCT02632695|DEVICE|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
214705140|NCT06416059|BEHAVIORAL|Mobile Application|The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
214705141|NCT06898710|PROCEDURE|z mini plate with lingual extension|patient with class III mandible fracture will be treated with patient specific z mini plate with lingual extension
214558135|NCT06810765|DRUG|ibogaine with magnesium treatment|Ibogaine, an indole alkaloid that interacts with mu opioid, kappa opioid, N-methyl-D-aspartate receptor (NMDA), and nicotinic acetylcholine receptors, shows early signs of effectiveness as a rapid-acting treatment for a number of mental health disorders including addiction. It is believed to work by promoting neuroplasticity and modulating brain chemistry, which may help reset dysfunctional neural circuits. The treatment is unique in its psychoactive properties, offering a deeply introspective experience that may help individuals process emotional material from the individual's lives.
214558136|NCT06810765|DRUG|5-MeO-DMT|5-MeO-DMT, as described in the study, is a 5-HT 2A agonist compound used in previous clinical research to address depression. Unlike other treatments, 5-MeO-DMT acts rapidly and has a short duration of action, offering an intense but time-limited psychoactive state. Its potential to enhance neuroplasticity and recalibrate dysfunctional brain networks makes it a unique approach for addressing the complex interplay of psychological and neurological symptoms.
214558137|NCT06697301|DRUG|EIK1001|EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.
214558138|NCT06697301|DRUG|Pembrolizumab (KEYTRUDA® )|Pembrolizumab is a PD-1 inhibitor.
214558139|NCT07026084|OTHER|Bio feedback training|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~1\. BPU (Biofeedback Pressure Unit): performed at 5 pressure levels (22, 24, 26, 28, 30 mmHg).~Each level involves a 10-second hold, with 30 seconds rest between levels.~Targeted muscles:~* Deep Cervical Flexors (Capitus Longus, Capitus Colli).~* Rhomboids~* Trapezius Total duration (BPU): 20 minutes/session, performed 3 times/week."
214558140|NCT07026084|OTHER|conventional exercise program|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~EXERCISE PROGRAM:~* 1\. Supine: Neck curl with Chin Tucks (Deep Cervical Flexors Capitus Longus, Capitus Colli): 10 reps/session, holding each for 5 seconds.~* 2\. Sitting: Chin tuck with Head pushing against palm.~* 3\. Chin Up (Middle and Lower Trapezius): 10 reps/session, holding each for 5 seconds.~* 4\. Scapular Squeezes (Rhomboids): 2-3 sets of 10 reps/session, holding each for 5 seconds• 5. Doorway Pectoral Stretch (pect major) 2-3 reps, 30 sec hold (36)Total duration: 20 minutes/session, performed 3 times/week."
214558141|NCT06701032|OTHER|Cardiovascular rehabilitation program|The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)
214558142|NCT06626503|DRUG|Methadone based ERAS|Methadone intervention includes intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.05 mg/kg up to a maximum of 2.5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
214558143|NCT06626503|DRUG|Non-methadone based group|Non-methadone intervention includes standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards. Postoperative pain medication is recommended when reported pain level is considered moderate or higher (≥4 on NRS and FLACC).
214558144|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 1|Low dose, approximately 10\^4 TCID50/mL
214558145|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 2|Medium dose, approximately 10\^5 TCID50/mL
214558146|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 3|High dose, approximately 10\^6 TCID50/mL
214558147|NCT07135882|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.~Radiotherapy Techniques:~* Highly conformal techniques (IMRT/VMAT)~* High-precision techniques are allowed for non-centrally located primaries~Radiotherapy Dose:~\- Several fractionation schedules allowed; minimum biological effective dose approximating 50Gy (α/β ratio = 10); 50Gy in 20 fractions, 40Gy in 15 fractions, and 35Gy in 5 fractions"
214558148|NCT07135882|DRUG|Standard of Care (SOC)|Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.
214558149|NCT07137325|BEHAVIORAL|play therapy|"The intervention consisted of a structured play therapy program specifically designed for children residing in institutional care settings. What distinguishes this intervention from others is its targeted focus on reducing learned helplessness and improving social comparison tendencies, two psychological constructs particularly relevant to children in residential care.~The program was conducted over six weekly sessions, each lasting approximately 60 minutes, and implemented in a one-on-one format within a safe, quiet room in the child care facility. The content was developmentally appropriate and included modules on emotional expression, communication, realistic goal setting, resource awareness, problem-solving, and positive self-perception. The therapeutic techniques were based on principles of non-directive and humanistic play therapy, allowing children to express themselves freely while being guided through structured themes.~Unlike general play therapy programs, this intervention"
214558150|NCT07136519|DRUG|Toripalimab|240mg Q3W
214558151|NCT07136519|DIETARY_SUPPLEMENT|Omega-3|During radiotherapy, take 6 capsules once a day
214558152|NCT07136519|RADIATION|radiotherapy|radiotherapy
214558153|NCT07136519|DRUG|Paclitaxel (albumin bound)|260mg/m2 d1,Q3W
214558154|NCT07136519|DRUG|Cisplatin|80mg/m2 d2, Q3W
214558155|NCT07135336|PROCEDURE|surgery|Patients with preexisting cognitive impairment undergoing elective non-cardiac surgery under general anesthesia.
214705142|NCT06898710|PROCEDURE|conventional 2 mini plates|patient with class III mandible fracture will be treated with conventional 2 mini plates
214705143|NCT06898112|DRUG|PrEP|oral PrEP
214705144|NCT06899035|OTHER|Intervention Group (water-based and conventional exercise)|Patients in the study group will undergo individualized water-based exercises (including standing, balance, weight shifting, breathing exercises, range of motion, stretching, and strengthening exercises) under the supervision of an experienced physiotherapist, 2-3 times per week for six weeks. Additionally, routine conventional exercises will be continued daily for six weeks.
214705145|NCT06899035|OTHER|control group (conventional exercise)|Patients in the control group will continue passive, active, active-assisted, or resistance-based upper and lower extremity conventional exercises appropriate to their functional level and muscle strength. They will be instructed to perform these exercises 2-3 times per week, with each session lasting no more than 45 minutes, for six weeks.
214705146|NCT02541006|DRUG|Tiotropium 18 mcg|tiotropium 18 mcg once a day
214705147|NCT00825383|OTHER|High Fiber and Moderate Fiber Diets|Dietary
214705148|NCT06508320|BIOLOGICAL|mRNA-1083|IM injection in a deltoid muscle.
214705149|NCT04253041|BEHAVIORAL|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
214558156|NCT07135336|OTHER|norma|Cognitively normal individuals who do not undergo surgery but complete the same cognitive assessments at baseline, 3 months, and 12 months for normative reference.
214558157|NCT07137299|OTHER|Questionnaire and Physical Exam|"All study participants will be evaluated to assess:~* Healing of the vaginal stump in the case of a total hysterectomy (normal/abnormal),~* Symptoms of stress urinary incontinence (Ingelmann-Sundber scale, where 0 - no symptoms, Grade I - symptoms with coughing, pressure on the suprapubic area, laughing, or strenuous exertion, Grade II - loss of urine when levering, running, or climbing stairs, Grade III - loss of urine when lying down or standing without physical exertion)~* Symptoms of an overactive bladder - present, absent~* Symptoms of prolapse in the anterior and posterior compartments (assessed based on the POPQ scale) with an assessment of the defect site based on the de Lancey classification The examination will be performed by or with the assistance of a specialist in obstetrics and gynecology"
214558158|NCT07137507|PROCEDURE|Uniportal VATS|Decortication of pleural empyema is done using single-port VATS
214558159|NCT07137507|PROCEDURE|Multi-portal VATS|Decortication of pleural empyema is done using two or more ports with VATS
214558160|NCT07136142|DRUG|FH-006 for Injection|FH-006 for injection.
214558161|NCT07135570|DIAGNOSTIC_TEST|Multimodal Screening for Eye Disease|The eye disease screening process involved twelve distinct steps were that organized through a corresponding software platform (electronic health record). These steps included: (1) community awareness campaign, (2) participant registration, (3) blood pressure and finger-stick blood glucose measurement, (4) basic vision test, (5) on-site optometrist evaluation, (6) obtaining informed consent for imaging, (7) fundus imaging, (8) automated AI-based disease detection, (9) on-site ophthalmologist examination, (10) remote eye specialist review, (11) on-site counselor discussion, (12) referral for local surgery. This standardized protocol promoted the alignment of eye screening with data gathering and ongoing follow-up eye care interventions. All participants were offered steps 1 to 5. Those participants eligible for fundus imaging (Steps 6-8) included those with diabetes, hypertension, age 50+, or optometrist recommendation based on presenting symptoms.
214558162|NCT07135570|PROCEDURE|cataract surgery|Individuals diagnosed with high grade cataracts associated with moderate to sever visual impairment were offered cataract surgery, either through local surgery services or regional specialized vision services.
214558163|NCT07137949|BEHAVIORAL|Music therapy|Live music therapy (MT) sessions will occur 3 times/week, up to 5 sessions. Sessions will be responsive to patient preferences, culture, and identity using information gained from medical record review, intake assessment, and in the moment therapeutic assessments.
214558164|NCT07136649|DEVICE|Custom CAD/CAM Insoles|Custom insoles will be designed using 3D plantar scanning and pedobarographic analysis, produced with CAD/CAM technology. The insoles will be fitted into participants' regular footwear and worn daily for eight consecutive weeks. The design aims to optimize plantar pressure distribution and improve foot biomechanics in individuals with foot deformities.
214705150|NCT02497872|PROCEDURE|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
214705151|NCT04890574|DEVICE|CellMist™ System|Open Label, Safety and Feasibility
214705152|NCT02494739|OTHER|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
214705153|NCT02494739|OTHER|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
214705154|NCT00937794|BEHAVIORAL|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
214705155|NCT00937794|OTHER|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
214705156|NCT03629392|BEHAVIORAL|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
215163374|NCT05100004|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
215163375|NCT04870944|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215163376|NCT04870944|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
215163377|NCT04870944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215163378|NCT04870944|PROCEDURE|Echocardiography Test|Undergo ECHO
215163379|NCT04870944|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IV
215163380|NCT05873439|RADIATION|Genomically Guided Radiation Therapy (RT)|Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
214705157|NCT03629392|BEHAVIORAL|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
214705158|NCT03629392|BEHAVIORAL|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
214558165|NCT07137559|DRUG|CELZ-201-DDT|"CELZ-201-DDT is administered via intramuscular injection.~Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations."
214558166|NCT07136506|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214558167|NCT07136506|OTHER|Post-recording questionnaire|The post-recording questionnaire aims at describing as much as possible the subject activity and quality of life during the recording period while being as low a burden as possible for the subject. The question formats are, on one hand, inspired by Quality of life and Physical Activity questionnaires usually used in Clinical Research and, on the other hand, based on device-specific needs for an optimal analysis. It covers fatigue status, physical status, physical activity with the Syde®, event(s) or condition(s) that may have impacted the ability to wear the Syde® during the recording.
214558168|NCT07136363|DEVICE|DynamiCare|DynamiCare is a mobile contingency management (CM) platform. Participants randomized to this intervention receive access to the DynamiCare app, an FDA-approved mobile application that delivers CM through features such as at-home saliva drug testing, appointment check-ins, and incentives for healthy behaviors. The app is designed to promote substance use reduction and engagement in care by providing financial rewards for meeting health-related goals. The intervention aims to improve initiation and retention in HIV prevention or treatment (PrEP or ART), reduce stimulant use, and enhance overall health outcomes among justice-involved individuals.
214558169|NCT07136363|BEHAVIORAL|Patient Navigation (PN)|Participants work with a trained patient navigator (PN) who provides individualized support, assists with linkage to medical and social services, and helps address barriers to care. The PN meets with participants weekly during the first month and biweekly thereafter to conduct a comprehensive needs assessment and provide tailored support. This includes assistance with obtaining housing, identification, insurance, transportation, and linkage to health and social services such as HIV prevention or treatment (PrEP/ART), substance use disorder treatment, and other community-based care. The navigation protocol follows established procedures from prior studies (e.g., ACTION). All participants receive a smartphone to support communication and appointment coordination.
214558170|NCT07135622|DIAGNOSTIC_TEST|Xpert® MTB/RIF Ultra|Xpert® MTB/RIF Ultra test introduced for tuberculosis diagnosis at clinical trial sites randomized to interventional arm
214558171|NCT07135622|OTHER|Referral to the specialized TB clinics|No intervention introduced at clinical trial sites randomized to control arm, patients follow standard care: referral to specialized TB clinics
214558172|NCT07138170|PROCEDURE|Proximal Radial Artery Access|Using Proximal Radial Artery Access for Cardiac Catheterization
214558173|NCT07138170|PROCEDURE|Distal Radial Artery Access|Using Distal Radial Artery access for Cardiac Catheterization
214705159|NCT04782804|DRUG|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
214705160|NCT04782804|DRUG|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
214705161|NCT00597935|PROCEDURE|SSLF|sacrospinous ligament fixation (SSLF)
214705162|NCT00597935|PROCEDURE|ULS|uterosacral vaginal vault ligament suspension (ULS)
214705163|NCT00597935|BEHAVIORAL|PMT|Pelvic muscle training and exercises (PMT)
214705164|NCT02199301|PROCEDURE|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
214705165|NCT05524740|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
214705166|NCT04777214|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
214705167|NCT04777214|DEVICE|Sham TMS|Sham TMS will be administered
214705168|NCT00676936|DRUG|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
214705169|NCT00676936|DRUG|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
214705170|NCT01738737|DEVICE|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
214705171|NCT01738737|OTHER|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
214705172|NCT01738737|DEVICE|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
214705173|NCT05267613|DRUG|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
214705174|NCT05267613|DRUG|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
214705175|NCT00445250|DRUG|Calcipotriol|
214705176|NCT01930929|PROCEDURE|Bariatric surgery|
214705177|NCT05382988|DRUG|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
214705178|NCT01653002|OTHER|No intervention|
214705179|NCT00388323|OTHER|blood and biopsies|blood and biopsies
214705180|NCT03297216|DRUG|17P|Synthetic progestin
214705181|NCT03297216|OTHER|Placebo|Non-active placebo comparator
214705182|NCT05723458|COMBINATION_PRODUCT|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
215163381|NCT06261463|BEHAVIORAL|CAFES2|The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
215163382|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
215163383|NCT03417921|DRUG|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
214705183|NCT05723458|DRUG|Placebo|Placebo cream containing vaseline
214705184|NCT06279663|PROCEDURE|Revascularization|revascularization
214705185|NCT01383109|DRUG|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
214705186|NCT01798017|DRUG|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
214705187|NCT00397878|DRUG|saracatinib|Given orally
214705188|NCT00397878|OTHER|laboratory biomarker analysis|Correlative studies
214705189|NCT04241146|DEVICE|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
214705190|NCT04241146|DEVICE|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
214705191|NCT00915538|DRUG|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
214705192|NCT00915538|DEVICE|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
214705193|NCT02851368|DEVICE|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
214705194|NCT02851368|DRUG|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
214705195|NCT01646801|DEVICE|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
214705196|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
214705197|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
214705198|NCT01253187|DRUG|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
214705199|NCT04851002|PROCEDURE|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
214705200|NCT04851002|PROCEDURE|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
214705201|NCT04851002|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied
214705202|NCT04851002|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
215163384|NCT03417921|DRUG|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
214705203|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 1|
214705204|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 2|
214705205|NCT02317536|OTHER|Placebo|Placebo
214705206|NCT04195659|PROCEDURE|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
214705207|NCT00003194|BIOLOGICAL|filgrastim|
215163385|NCT03329313|DRUG|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
215163386|NCT03329313|DRUG|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
214705208|NCT00003194|DRUG|carboplatin|
214705209|NCT00003194|DRUG|cyclophosphamide|
214705210|NCT00003194|DRUG|etoposide|
214705211|NCT00003194|DRUG|thiotepa|
214705212|NCT00003194|DRUG|topotecan hydrochloride|
214705213|NCT00003194|PROCEDURE|peripheral blood stem cell transplantation|
214705214|NCT02679196|DRUG|KA2237|PI3 Kinase p110β/δ inhibitor
214705215|NCT03573440|OTHER|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
214705216|NCT04084249|DIAGNOSTIC_TEST|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
214705217|NCT04084249|OTHER|Intensified Follow-up Schedule|PET/CT-scans every 3. month
214705218|NCT00216541|DRUG|epoetin alfa|
214705219|NCT03336762|DIAGNOSTIC_TEST|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
214705220|NCT03336762|DIAGNOSTIC_TEST|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
214705221|NCT05969912|OTHER|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
214558177|NCT07136935|DRUG|Traditional Chinese Medicine treatment|"1. Oral Chinese herbal medicine or decoction: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them once a week.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint, the application time is 2 to 4 hours.~5. Nursing and health education and guidance.~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes.~7. Lifestyle health education and sports rehabilitation: Playing Baduanjin, ten skilled hand exercise, and health preservation videos, and providing personalized TCM exercise recommendations."
214558178|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 2hr wear|400mg progesterone Callavid, 2 hour wear, twice daily for 7 days
214558179|NCT07136922|DRUG|Cyclogest 400 mg|Cyclogest 400 mg pessary, twice daily for 7 days
214558180|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 3hr wear|400mg progesterone Callavid, 3 hour wear, twice daily for 7 days
214558181|NCT07138183|BEHAVIORAL|NP-led MDT|a nurse practitioner-led multidisciplinary team (MDT).
214558182|NCT07138183|BEHAVIORAL|Usual Care|Participants will receive usual inpatient care provided by the primary care team.
214558183|NCT07135661|RADIATION|moderate hypofractionated proton radiotherapy|moderate hypofractionated proton radiotherapy: Whole Breast Irradiation, at 40 Gy(RBE) in 15 fractions, tumor bed SIB to 48Gy(RBE)
214558184|NCT07135661|RADIATION|ultra-hypofractionated proton radiotherapy|Ultra-hypofractionated proton radiotherapy:Whole breast radiotherapy, 26 Gy(RBE) in 5 fractions，tumor bed boost with 10Gy(RBE) in 2 fractions.
214705222|NCT05969912|OTHER|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
214705223|NCT00292747|DRUG|Drotaverine|
214705224|NCT00292747|DRUG|Drotaverine Placebo|
214705225|NCT00292747|DRUG|Ibuprofen|
214705226|NCT00292747|DRUG|Ibuprofen Placebo|
214705227|NCT00002783|DRUG|cisplatin|
214705228|NCT00002783|DRUG|floxuridine|
214705229|NCT00002783|DRUG|fluorouracil|
214705230|NCT00002783|DRUG|leucovorin calcium|
214705231|NCT00002783|PROCEDURE|conventional surgery|
214705232|NCT01532713|PROCEDURE|oxygen administration|nasal O2 5L/min via nasal cannula
214705233|NCT04568317|BEHAVIORAL|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
214705234|NCT04568317|DEVICE|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
214705235|NCT03056976|DEVICE|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
214558185|NCT07137897|OTHER|Telerehabilitation|"Telerehabilitation involves a physiotherapy program delivered remotely using digital tools. Participants perform exercises independently with remote support from a physiotherapist, including:~Weekly scheduled phone consultations~Live virtual consultations via MS Teams, Zoom, or Skype~Text messages and emails for personalized guidance, motivation, and ongoing problem-solving~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
214558186|NCT07137897|OTHER|Control group|"Patients in the control group will receive written instructions for a home exercise program. They will independently perform the rehabilitation program at home without remote supervision.~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
214558187|NCT07136428|COMBINATION_PRODUCT|Asciminib and Trastuzumab|Each study treatment cycle will last 21 days. Asciminib will be taken orally every day during the treatment period at the dose determined as the MTD during the safety lead-in in combination with trastuzumab at a standard dose of 6mg/kg IV. Asciminib dose will begin at 80 mg daily (dose level 1), with a potential range from 40 mg daily (dose level -1A, with trastuzumab) to 200 mg bid (dose level 3, with trastuzumab) depending on the results of the safety lead-in. Trastuzumab will be given intravenously (IV) or subcutaneously (SQ) on Day 1 of each 21 day cycle.
214558188|NCT07136415|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-i)|This is a program called SHUT-i and is composed of six self-guided sessions on a website over 6-9 weeks. Each session will be about 45-60 minutes long. CBT-I involves changing behaviors that cause sleep problems to persist. However, it also includes teaching skills to teach the participant to identify thoughts and feelings that may contribute to sleep problems.
214558189|NCT07136415|DRUG|Trazodone|"Trazodone is a heterocyclic medication that is FDA-approved for depression (starting dose 150mg). An estimated 4 in 5 trazodone prescriptions are for insomnia. Low-dose trazodone's frequent off-label use stems from a long-standing perception that trazodone is an effective and safer sleep aid compared to other drugs despite potential risks documented in small studies.~A starting dosage of 25 mg will be used. After 1 week, patients will be instructed to increase the dose as needed to 50mg if tolerated. A second dose adjustment will be made at 4 weeks. At four weeks, study staff will contact participants and review medication adherence, and a standardized checklist will be used to assess ongoing symptoms and side effects and to consider an increase in dose to 100mg."
214558190|NCT07136415|DRUG|Daridorexant|"Daridorexant is a DORA drug. Dual orexin receptor antagonists (DORAs) are the newest class of FDA-approved medications for insomnia based on efficacy data from pivotal clinical trials demonstrating their efficacy for sleep onset and maintenance.~A single dose of 50 mg (1 pill each night within 30 minutes of bedtime) was selected based on better efficacy without evidence of higher risks than the 25mg dose."
214558191|NCT07136337|DIAGNOSTIC_TEST|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by flow cytometry
214558192|NCT07137715|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
214558193|NCT07137715|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
214558194|NCT07137715|OTHER|Usual Care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
214558195|NCT07135232|DIETARY_SUPPLEMENT|Sarmentosin - L- theanine|A capsule containing 275.184 mg of Sarmentosin and 400mg of L-theanine
214558196|NCT07135232|OTHER|Resistance Training|Home-based Resistance training. Exercises will target the lower and upper body and utilise body weight, resistance bands, dumbbells and push-up handles.
214558197|NCT07135232|DIETARY_SUPPLEMENT|Placebo Supplement|Capsule matched for taste and appearance, without any active ingredients.
214558198|NCT07138300|DEVICE|Low Level Laser Therapy by (Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy)|"(Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy) .~Patient lies in side lying on the non-affected side which is opposite to the side of radicular pain, hip and knee in flexion 90. Twenty points were established for treatment, 12 over the lumbar spine, at the same Side of the radicular pain, from l2 to s1 vertebra, distance between these points is 2 cm. In the thigh, eight points were marked at equal distances from each other, four in the path of l5 root and four in the path of s1 root from hip to knee. The leaser probe is held in 90 degree over the skin with complete skin contact"
214705236|NCT03056976|DEVICE|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
214705237|NCT03056976|DEVICE|Fixed mandibular denture|A fixed mandibular denture retained by four implants
214705238|NCT04899960|DRUG|Clinical Pharmacist Intervention|Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
214705239|NCT03817840|PROCEDURE|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
214705240|NCT05023850|PROCEDURE|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
214705241|NCT05023850|PROCEDURE|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
214705242|NCT05875389|OTHER|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
214705243|NCT05270642|PROCEDURE|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
214705244|NCT00284739|DRUG|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
214705245|NCT00284739|OTHER|saline|saline injection twice daily for three days
214705246|NCT04331990|OTHER|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
214558199|NCT07138300|PROCEDURE|neural mobilization|"Mobilization will be through using slump sitting maneuver (Both techniques slider and tensioner.~•The slider neurodynamic mobilization technique: The patient moves actively and conversely from a position of neck and trunk flexion, knee flexion, and ankle plantar flexion, to a position of neck and trunk extension, knee extension and ankle dorsiflexion~The tension neurodynamic mobilization technique:~The patient moves actively and conversely from a position of neck and trunk extension, knee flexion, and ankle plantar flexion, to a position of neck and trunk flexion, knee extension, and ankle dorsiflexion"
214558200|NCT07138300|OTHER|placebo laser therapy|patients receive the same treatment on the same area as experimental group for the same period without turning on the device.
214558201|NCT07137078|OTHER|pilates|"Pilates exercises, particularly those focusing on core stability, balance, and flexibility, are highly beneficial for individuals at risk of falls. These exercises enhance proprioception, which is the body's ability to sense movement, action, and location, thereby improving coordination and balance. For example, exercises like the Single Leg Stretch and Roll-Up target the abdominal muscles, which are crucial for maintaining stability. Additionally, Leg Circles and Side Planks help strengthen hip abductors and stabilizers, contributing to better postural alignment and reducing the likelihood of falls. By regularly incorporating Pilates into a fitness routine, individuals can build strength and confidence, ultimately helping to prevent falls and maintain independence."
214558202|NCT07137078|OTHER|gyrotonic expansion exercise|Exercise phase Training Time Warm-Up Gentle, dynamic stretches focusing on the spine, hips, and legs. Gently roll the head from side to side to release tension, Move shoulders in a circular motion to loosen muscles, While standing, rotate the torso gently from side to side, Rotate each ankle in both directions to improve mobility. 5 minutes Core Activation Using pulley rope system the Arch and Curl, to engage the abdominal muscles, Focus on maintaining proper alignment and breathing deeply. 13 minutes Balance and Coordination Using pulley rope system Standing Series, shifting weight, such as the Spiral Sequence, to improve coordination. 12 minutes Flexibility and Range of Motion Leg stretches using the Leg Extension Unit to improve hip and knee range of motion. 5 minutes
214558203|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples for ctDNA testing
214558204|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo possible collection of tissue
214558205|NCT07136493|OTHER|Electronic Health Record Review|Ancillary studies
214558206|NCT07136493|OTHER|Survey Administration|Ancillary studies
214558207|NCT07138378|DRUG|XS003 (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
214558208|NCT07138378|DRUG|Tasigna (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
214558209|NCT07137871|DRUG|Avasopasem|Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy
214558210|NCT07137104|DRUG|HeXell-2020|"Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose.~Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose.~Phase IIa: RP2D from phase I."
214558211|NCT07137689|DRUG|LY3537982|Administered orally
214558212|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
214558213|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
215163387|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|"For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis."
215163388|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers|For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
214558214|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
214558215|NCT07136389|DRUG|Divozilimab|Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously
214558216|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
215163389|NCT06447415|DRUG|HRS-7450|HRS-7450 Injection
215163390|NCT06447415|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection
215163391|NCT05675046|DEVICE|Carpal Tunnel Release with Ultrasound Guidance using the UltraGuideCTR device|Participants who were treated with the Carpal Tunnel Release with Ultrasound Guidance procedure using the UltraGuideCTR device in the ROBUST Study.
214558217|NCT07138092|OTHER|i jel LMA|Patients will be inserted i jel laryngeal mask under general anesthesia.
214558218|NCT07138092|OTHER|proseal LMA|Patients will be inserted proseal laryngeal mask under general anesthesia.
214558219|NCT07137780|DEVICE|Lokomat® V6 (GF < 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of less than 90%. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
214558220|NCT07137780|DEVICE|Lokomat® V6 (GF ≥ 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
214558221|NCT07137780|DEVICE|RoboGait®|Robotic-assisted gait training using the RoboGait® system (BAMA Teknoloji, Türkiye) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
214558222|NCT07135544|DRUG|Adebrelimab combined with the GC regimen and Apatinib|Adebrelimab 1200mg, intravenous infusion, on day 1, repeated every 3 weeks; Gemcitabine 1000mg/m2, on days 1 and 8, every 3 weeks Cisplatin 50mg/m2, on day 1, every 3 weeks Apatinib 250mg, once daily, orally
214558223|NCT07135492|DIAGNOSTIC_TEST|continuous noninvasive hemoglobin monitoring|noninvasive hemoglobin monitoring, Rainbow® Adult ReSposable™ sensors (Rev E) were placed on either the ring or middle fingertip of each participant and connected to a Radical-7 Pulse CO-Oximeter (SET version 7601; Masimo Corp., Irvine, CA).
214558224|NCT07135674|DRUG|placebo gel|local drug delivery of placebo gel
214558225|NCT07135674|DRUG|herbal drug|local drug delivery of herbal gel
214558226|NCT07135726|DEVICE|Patient Portal-Based Access to Clinical Notes|An intra-individual comparison of patient-reported outcomes is planned for the intervention group. For this purpose, the pre-intervention survey of the intervention group is conducted upon inclusion in the study, the post-intervention survey at the earliest after the intervention has been used once (accessing their open note). Due to potential selection bias of the intervention group, which occurs due to voluntary participation in the intervention, a control group is surveyed at t0, which does not participate in the intervention, so that an adjustment for the systematic differences, if any, between the intervention and control group is possible at t0. The survey of a post-intervention control group (t1) serves to adjust for any time-varying effects so that a general time effect can be ruled out.
214558227|NCT07138274|DRUG|Metyrapone 250 mg Oral Tablets|Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg
214558228|NCT07138274|DRUG|Placebo|Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding
214558229|NCT07137468|OTHER|Surveys|Electronic surveys will completed via REDCap.
214705247|NCT04331990|OTHER|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
215163392|NCT03159390|OTHER|phenylacetate salt of ornithine|
215163393|NCT03438747|DEVICE|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
215163394|NCT03438747|OTHER|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
215163395|NCT03584334|RADIATION|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
215163396|NCT05741060|DRUG|S-equol|Experimental drug
215163397|NCT05741060|DRUG|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
215163398|NCT04765059|DRUG|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
215163399|NCT04765059|DRUG|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
215163400|NCT06536426|BEHAVIORAL|Knee Isometric Program (KIP)|"The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes"
215163401|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
215163402|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
215163403|NCT03293667|OTHER|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
215163404|NCT02689505|DRUG|BI 836880|Solution for intravenous infusion
215163405|NCT05963984|DRUG|Samuraciclib|Samuraciclib tablet by mouth once a day
215163406|NCT05963984|DRUG|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
215163407|NCT04239989|DRUG|Itacitinib|Given PO
215163408|NCT04239989|DRUG|Itacitinib Adipate|Given PO
214558230|NCT07137468|OTHER|Video|Focus group sessions and community forums will be conducted via videoconference (Zoom)
214558231|NCT07136246|DEVICE|InBody S10|Bioelectrical Impedance Phase Angle Technology Measured via InBody S10 at six frequencies (1kHz-1000kHz) during each follow-up
214558232|NCT07027982|DRUG|Diluted Intravenous DA-5217|once a day
214558233|NCT07027982|DRUG|Undiluted Intravenous DA-5217|once a day
214558234|NCT07035379|DRUG|TRS005|TRS005 will be administered at a starting dose of 0.8mg/kg IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles (up to 8).
214558235|NCT07035379|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
214558236|NCT07035379|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
214558237|NCT07035379|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
214558238|NCT02169310|DEVICE|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
214558239|NCT02169310|DRUG|[11C] Raclopride|\[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
214558240|NCT07029360|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis®|Daily administration of Limosilactobacillus reuteri Prodentis® (1 oral tablet per day, taken after brushing in the evening), as an adjunct to non-surgical periodontal therapy and standard home care. Administered for 6 months only in the experimental arm.
214558241|NCT07029360|OTHER|Coenzyme Q10 Toothpaste|Twice-daily use of a commercially available toothpaste containing coenzyme Q10, used as part of a home oral hygiene regimen for 6 months. All participants in both study arms will use the same toothpaste, with or without adjunctive probiotic supplementation.
214558242|NCT07041216|OTHER|Squishy Toy Squeezing|In the intervention group, vein suitability was checked using the DIVA score. A tourniquet was applied, the area was cleaned with antiseptic, and the child squeezed a squishy toy 10 times. Afterward,
214558243|NCT07041216|OTHER|Palpation|In this group, once the vein was identified, the area was gently tapped 8 to 10 times using the inner surfaces of four fingers to stimulate blood flow and enhance vein visibility. This light palpation helped increase local circulation, making the vein easier to access. After the tapping procedure, the area was thoroughly cleaned with an antiseptic solution. Once the skin was completely dry, the catheter was inserted under sterile conditions.
214558244|NCT07041216|OTHER|Routine medical care|This group received standard IV insertion with no extra techniques applied.
214558245|NCT06732648|DRUG|HRS8179 injection|HRS8179 injection; high dose
214558246|NCT06732648|DRUG|HRS8179 blank preparation.|HRS8179 blank preparation.
214558247|NCT06745765|DEVICE|Virtual reality headset|Patients will use virtual reality before the procedure in addition to usual preoperative care.
214558248|NCT06889038|OTHER|Hyperbaric oxygen therapy combined with polarized light therapy|Optimum regime of therapy increase healing rate of neuropathic foot ulcer is a challenge for researchers to save patient normal life
214558249|NCT06889038|OTHER|traditional treatment|topical medication
215163409|NCT06413498|DRUG|Anitocabtagene Autoleucel|A single infusion of CAR+ transduced autologous T cells
215163410|NCT06413498|DRUG|Cyclophosphamide|Administered intravenously
214558250|NCT07051304|OTHER|numerical rating scale|"The Numerical Rating Scale (NRS) is a standardized, self-reported pain assessment tool in which patients are asked to rate their pain intensity on a scale from 0 to 10.~0 represents no pain~10 represents the worst pain imaginable"
214558251|NCT07051304|OTHER|Video-Based Pain Expression Scenarios|"This novel pain assessment method involves showing postoperative patients a set of pre-recorded video scenarios that visually represent different levels of pain intensity. The videos are 8 seconds long and were created using AI-generated scripts and VEO-3 software. Each scenario corresponds to a specific Numerical Rating Scale (NRS) range (1-2, 3-4, 5-6, 7-8, 9-10) and is portrayed by actors matched to the patient's age group and gender (18-44, 45-65, \>65 years; male and female versions available).~Participants are asked to watch the full video set and select the one that best represents their current postoperative pain experience. This intervention is designed to offer a visual and contextual method of pain expression, particularly beneficial for patients who have difficulty understanding or using abstract numerical scales."
214558252|NCT07052695|DRUG|Mosunetuzumab|Subcutaneous injection of a CD20xCD3 bispecific antibody
214558253|NCT07052695|DRUG|Ibrutinib|For participants who have been ibrutinib PO prior to enrollment
215163411|NCT06413498|DRUG|Fludarabine|Administered intravenously
215163412|NCT06413498|DRUG|Pomalidomide|Tablet administered orally
215163413|NCT06413498|DRUG|Bortezomib|Administered intravenously or subcutaneously
215163414|NCT06413498|DRUG|Dexamethasone|Tablet administered orally
215163415|NCT06413498|DRUG|Daratumumab|Administered intravenously or subcutaneously
215163416|NCT06413498|DRUG|Carfilzomib|Administered intravenously
214705248|NCT04331990|OTHER|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
214705249|NCT01902862|DRUG|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
214558254|NCT07052695|DRUG|Acalabrutinib|For participants who have been acalabrutinib PO prior to enrollment
214705250|NCT01902862|DRUG|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
214558255|NCT07052695|DRUG|Zanubrutinib|For participants who have been zanubrutinib PO prior to enrollment
214558256|NCT07052695|DRUG|Pirtobrutinib|For participants who have been pirtobrutinib PO prior to enrollment
214558257|NCT07052097|DRUG|TQC2938 injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
214558258|NCT07052097|DRUG|TQC2938 Placebo|TQC2938 placebo, 4 weeks as a treatment cycle.
214558259|NCT06015750|DRUG|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
214558260|NCT06015750|DRUG|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
214558261|NCT06015750|DRUG|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
214558262|NCT06015750|DRUG|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
214558263|NCT06015750|DRUG|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
214558264|NCT06794775|DRUG|Nivolumab|Adjuvant monotherapy with Nivolumab
214558265|NCT06794775|DRUG|Nivolumab + Ipilimumab|Adjuvant combination therapy with Nivolumab and Ipilimumab
214558266|NCT07056556|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
214558267|NCT07053683|DEVICE|Combined RME and Facemask Therapy|This intervention involves two components. First, a tooth-borne Hyrax-type rapid maxillary expander is banded to the maxillary first permanent and deciduous molars. The screw is activated twice daily until posterior crossbite is overcorrected. Second, immediately following expansion, a Petit-type facemask is used to apply orthopedic protraction forces to the maxilla.
214558268|NCT07053683|DEVICE|Facemask Therapy Alone|This intervention involves the use of a Petit-type facemask to apply orthopedic protraction forces (400-500g per side, 12-14 hours/day) to the maxilla. A removable mandibular occlusal splint (flat bite plane) is used concurrently to facilitate anterior crossbite correction.
214558269|NCT06722365|DEVICE|Backscatter Quantitative Ultrasound|The intervention consists of a regular abdominal ultrasound scan for fetal evaluation. The difference with a regular scan is that the scanner used to image the fetus provides access to raw/unprocessed ultrasound echo data that can be extracted from the scanner and processed offline (after acquisition) to extract compute backscatter quantitative ultrasound (bQUS) features. Thus, data acquisition does not represent a significant departure from conventional fetal imaging protocols. Other than the time needed to acquire the images, the participant will not perceive any difference from a regular fetal ultrasound scan.
214558270|NCT06805890|PROCEDURE|Colonoscopy - IBD inflamed tissue|Collection of 10 colonic biopsies in IBD inflamed tissue
214558271|NCT06805890|PROCEDURE|Surgical resection - IBD inflamed mucous membrane|Collection of a portion of IBD inflamed mucous membrane
214705251|NCT03629691|OTHER|lung cavitation|apatinib treated patients developed lung cavitation
215163417|NCT06569082|DEVICE|CD34+ Selected Donor Cell Boost|The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
215163418|NCT06569082|PROCEDURE|Blood Stem Cell Infusion|The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
215163419|NCT06568172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or plasma
215163420|NCT06568172|BIOLOGICAL|Cemiplimab|Given IV
215163421|NCT06568172|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
215163422|NCT06568172|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
215163423|NCT06568172|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215163424|NCT06568172|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163425|NCT06568172|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215163426|NCT06568172|OTHER|Questionnaire Administration|Ancillary studies
215163427|NCT06568172|PROCEDURE|Surgical Procedure|Undergo surgery per SOC
215163428|NCT06568172|PROCEDURE|Surgical Procedure|Undergo response-adaptive surgery
215163429|NCT05815160|DRUG|Debio 0123|Administered as capsules.
215163430|NCT05815160|DRUG|Etoposide|Administered as IV infusion.
215163431|NCT05815160|DRUG|Carboplatin|Administered as IV infusion.
215163432|NCT05692596|OTHER|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
215163433|NCT05513378|DEVICE|Needle guide|Please see the arm/group description
215163434|NCT06319807|BEHAVIORAL|Digital Health Intervention|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
214558272|NCT06805890|PROCEDURE|Colonoscopy - biopsies in healthy tissue|Collection of 10 colonic biopsies in healthy tissue
214558273|NCT06805890|PROCEDURE|Surgical resection - healthy mucous membrane|Collection of a portion of healthy mucous membrane
215163435|NCT06319807|BEHAVIORAL|Safety Control|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
215163436|NCT03388606|BEHAVIORAL|Growth Mindset|30 Minute interactive video
214558274|NCT07059377|DRUG|Semaglutide|Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
214558275|NCT07059377|DRUG|Nicotine replacement|Nicotine patch plus short-acting NRT gum or lozenge
214558276|NCT07054619|BEHAVIORAL|Experiential First Aid Training|A first aid training program based on Kolb's Experiential Learning Model conducted in four sessions using real-life scenarios and group exercises.
214558277|NCT07058194|PROCEDURE|Preoperative Erector Spinae Plane Block|This procedure involves bilateral ultrasound-guided erector spinae plane block at the T7 level using 20 mL of 0.25% bupivacaine per side (total 40 mL) before the induction of general anesthesia. The intervention aims to evaluate the effects of preoperative ESP block on changes in frontal QRS-T angle and other ECG-derived cardiac electrophysiological parameters.
214558278|NCT07058194|PROCEDURE|Postoperative Erector Spinae Plane Block|Patients in this group will undergo standard general anesthesia. At the end of the surgery, bilateral ESP block will be performed under ultrasound guidance at the T7 level using 0.25% bupivacaine (20 mL per side, total 40 mL). The aim is to evaluate the effect of postoperative ESP block on changes in frontal QRS-T angle and other cardiac electrophysiological parameters.
214558279|NCT07058194|PROCEDURE|Standard General Anesthesia|This group will receive standard general anesthesia without any additional regional block. ECG data will be collected preoperatively and 1 hour postoperatively to serve as a comparison for electrophysiological changes observed in the intervention groups.
214558280|NCT07058194|DRUG|Bupivacaine|0.25% bupivacaine, 20 mL per side (total 40 mL), administered bilaterally at T7 level under ultrasound guidance as part of ESP block.
214558281|NCT06792500|DRUG|Glycerol Tributyrate|Participants will be administered orally three times a day enteric hard capsules containing 500 mg of glycerol tributyrate with an 8-ounce glass of water on an empty stomach: morning, noon, and evening during the dose-escalation phase. Each MELAS participant will undergo a six-month dose escalation phase of glycerol tributyrate, starting at a dose of 1,000 mg (tid) per day during the first month followed by a monthly increase of 500 mg (tid) per dose of glycerol tributyrate with the maximal oral dose of glycerol tributyrate 3,500 mg (tid) per dose at the end of six-month-long dose escalation phase. Once the participant-specific fixed maximum tolerated dose (MTD) is determined, MELAS participants will take an oral administration of this MTD three times a day during the 12-month-long clinical phase.
214558282|NCT04731506|BEHAVIORAL|Family Connections|Parent participants will receive an activity workbook that promotes increased physical activity and consumption of fruits and vegetables and decreased screen time and intake of sugary drink consumption, two in-person support sessions to help parents to develop an action plan spaced one week apart \& Interactive Voice Response (IVR) automated telephone system calls of 5 to 10 minutes that provide health education messages over 6 months (4 weekly, 4 biweekly (4), and 2 monthly). During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
215163437|NCT05447598|OTHER|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
215163438|NCT05447598|OTHER|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
215163439|NCT06062628|DRUG|Ketamine Hydrochloride|Administration of ketamine with subsequent measurement of intracranial pressure and brain tissue oxygenation
215163440|NCT05237960|PROCEDURE|Biopsy|Undergo biopsy
215163441|NCT05237960|PROCEDURE|Biospecimen Collection|Correlative studies
215163442|NCT05237960|DRUG|Extended Release Metformin Hydrochloride|Given PO
215163443|NCT05237960|DRUG|Placebo Administration|Given PO
215163444|NCT04706429|DRUG|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
215163445|NCT04706429|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
215163446|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
215163447|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
215163448|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
215163449|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
215163450|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
215163451|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
215163452|NCT02867462|OTHER|Standard care|standard care
215163453|NCT02867462|OTHER|manipulator consultation radiotherapy added to standard care|
215163454|NCT05878717|BIOLOGICAL|Belimumab|Belimumab will be administered.
215163455|NCT05878717|OTHER|Placebo|.Placebo will be administered.
215163456|NCT05552469|DRUG|DFV890|DFV890 Single Agent
215163457|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
214705252|NCT06114394|PROCEDURE|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
214558283|NCT06693011|DEVICE|Contour Neurovascular System Treatment Attempt|The subject is brought into the procedure room, an angiogram on the day of the procedure indicates that the subject is anatomically eligible for the trial and any part of the investigational device comes in contact with the patient
214558284|NCT07064083|DRUG|intracanal nano-ketrolac|For the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
214558285|NCT07064083|DRUG|ketrolac gel|For the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
214558286|NCT07064083|DRUG|A placebo gel|a placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
214558287|NCT07069127|DEVICE|Biorepair Toothpaste and Mousse|Participants assigned to the experimental arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) and apply Biorepair® Plus Intensive Enamel Repair mousse once daily before bedtime, for a total of 6 months. The toothpaste contains microRepair® particles (zinc-substituted hydroxyapatite), designed to occlude dentinal tubules and promote enamel remineralization. The mousse, applied at night, enhances remineralization through higher concentrations of active hydroxyapatite. This combined regimen targets the reduction of dentin hypersensitivity and enamel demineralization in adult patients with celiac disease.
214558288|NCT07069127|DEVICE|Biorepair® Toothpaste|Participants assigned to the control arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) for 6 months. The toothpaste formulation contains microRepair® (zinc hydroxyapatite) to support daily enamel protection and tubule occlusion, without the adjunctive effect of the mousse. This arm is used to assess the baseline efficacy of the toothpaste alone compared to the combined regimen.
214558289|NCT07137260|DEVICE|Accelerometer (measurement of walking activity)|Wearing an accelerometer (size 23x32,5x8,9 mm, weight 11g) on the lower back consistently for one week at a time to measure walking activity. The sensor is fixed with waterproof plasters. No feedback is given to the participant while wearing the sensor and no data can be read directly from the sensor.
214705253|NCT06114394|PROCEDURE|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
214705254|NCT04182789|DRUG|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
214705255|NCT06517862|DRUG|Zinc sulfate|Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
214705256|NCT06517862|DRUG|Ursodeoxycholic acid|Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
214705257|NCT06257329|OTHER|register|Multicentre prospective observational register
214705258|NCT02680587|RADIATION|SBRT|SBRT (1-5 fractions) will be administered.
214705259|NCT00111930|DRUG|DHEA|
214705260|NCT03461432|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
214705261|NCT04759677|OTHER|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
214705262|NCT02899377|RADIATION|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
214705263|NCT02899377|RADIATION|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
214705264|NCT02899377|PROCEDURE|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
214558290|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
214558291|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
214558292|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
214558293|NCT07096011|OTHER|Meal Test - Human Milk|Infants will be fed a mixed meal test (meal challenge test) of human milk from his/her human milk donor (e.g., mother). Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents their standard meal, at a larger size. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of human milk that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for human milk is be estimated at 20 kcals/ounce.
214705265|NCT02899377|PROCEDURE|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
214705266|NCT05668676|DRUG|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
214705267|NCT05668676|OTHER|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
214705268|NCT05145712|DIAGNOSTIC_TEST|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
214705269|NCT02786108|PROCEDURE|left gastric artery embolization|
214705270|NCT02786108|BEHAVIORAL|healthy diet and exercise|
214705271|NCT02424006|DEVICE|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
214705272|NCT02424006|DEVICE|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
214705273|NCT05841108|DEVICE|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
214558294|NCT07096011|OTHER|Meal Test - Infant Formula|Infants will be fed a mixed meal test (meal challenge test) of ready-to-feed infant formula. Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents a meal different from their habitual food intake and is a standard meal that all participants receive. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of infant formula that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for the ready-to-feed infant formula is 20 kcals/ounce.
215163458|NCT03389802|BIOLOGICAL|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
215163459|NCT03389802|BIOLOGICAL|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
215163460|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
215163461|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
214558295|NCT07136727|OTHER|AI-assisted comprehensive management system|Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)
214558296|NCT07136688|DEVICE|Stamobil electric stimulator|The electric stimulation protocol will use stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode for 30 minutes daily. The goal is daily use of tTNS for 4 weeks , 5 days per week.
214558297|NCT07136688|DEVICE|sham tTNS device|The electric sham stimulation protocol will use sham stimulation (low intensity) for 30 minutes daily, for 4 weeks , 5 days per week
214558298|NCT07135362|DIETARY_SUPPLEMENT|TCI604 probiotics|TCI604 probiotics sachet
214558299|NCT07135362|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
214558300|NCT07136961|PROCEDURE|Robot-Assisted Bronchoscopy (RAB)|"1. Preoxygenation \& Navigation Registration~2. Robotic-Guided Navigation~3. Puncture Tunnel Establishment~4. Position Verification \& Adjustment~   Perform confirmatory CT scan to assess tool-nodule relationship:~   Tool-in-lesion (TIL) : Biopsy tool penetrates nodule Center Strike : Tool tip reaches central 1/3 of nodule (coronal/sagittal/horizontal planes) Tool-touch-lesion : Tool contacts but does not enter nodule~  * 4mm deviation : Proceed to biopsy \>4mm deviation : Adjust based on operator judgment~5. Biopsy \& Rapid Evaluation Obtain tissue samples Conduct ROSE (Rapid On-Site Evaluation) to guide next steps~6. Post-Procedure Safety Check Perform postoperative CT to exclude pneumothorax/hemorrhage Maintain identical ventilation settings during imaging and biopsy phases to prevent target shift"
214558301|NCT07138391|DRUG|chamomile gummy|The chamomile gummy used in this study was Zarbee's Gentle Bedtime Gummies for Kids (Zarbee's Inc., USA).
214558302|NCT07138391|DIETARY_SUPPLEMENT|a multivitamin gummy|multivitamins gummies for kids
214558303|NCT07137793|DRUG|Pentoxifylline 400mg plus chemotherapy|patient will receive standard chemotherapy for breast cancer plus pentoxifylline 400 mg orally 3 times per day with meals.
214558304|NCT07136571|DEVICE|bland particles|embolization with bland particles of appropriate size
214558305|NCT07137234|PROCEDURE|Modified Millard rotation advancement flap technique|the cleft is repaired by surgical intervention
214558306|NCT07137234|DRUG|botulinum toxin injection (BTX A) before surgical intervention|the patient will receive Botulinum toxin type A followed by surgical closure of cleft lip
214558307|NCT07135557|DEVICE|R-One vascular interventional navigation control system|"The interventional cardiologist sits at the cockpit and remotely performs the PCI using the console joysticks. The cassette, which is loaded with the interventional devices and connected to the guiding catheters, imposes axial and rotational forces on the intracoronary devices. Fluoroscopic, electrocardiographic, and hemodynamic images are slaved to the duplicate monitors inside the cockpit, enabling visualization from a closer distance. After completion of diagnostic angiography, the guiding catheter was positioned at the ostium of the coronary artery and connected to the disposable cassette on the robotic drive. The guidewire was loaded into the cassette. Treatment was administrated according to local site protocols. Pre and post dilation was done per operator discretion. All intracoronary devices were to be manipulated exclusively by the robotic system, with bailout to manual conversion when needed."
214558308|NCT07136311|DIAGNOSTIC_TEST|DPOAE with Contralateral Suppression|Participants will undergo distortion evoked otoacoustic emissions (DPOAE) testing with contralateral broadband noise stimulation. The test is performed to evaluate auditory efferent system function, specifically the presence and degree of contralateral suppression. No medication or treatment is administered as part of the study. The procedure is non-invasive and commonly used in auditory diagnostics.
214558309|NCT07137533|OTHER|Mandibular Four-Implant-Retained Overdenture (PEEK Framework); Mandibular All-on-4 Fixed Prosthesis (PEEK Framework)|"Group I: Four-implant-retained mandibular overdenture with a CAD/CAM-milled PEEK framework and acrylic denture teeth, retained via attachment mechanisms; implants placed in lateral incisor and first premolar sites; delayed loading protocol.~Group II: Mandibular All-on-4 fixed prosthesis with a CAD/CAM-milled PEEK framework and acrylic denture teeth; two anterior straight and two posterior tilted implants placed in lateral incisor and first premolar sites; delayed loading protocol."
214558310|NCT07136285|DRUG|Olvi-Vec|Olvi-Vec will be administered to patient for 3 days during C1
214705274|NCT05841108|OTHER|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
214705275|NCT04152148|BIOLOGICAL|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
214705276|NCT04152148|BIOLOGICAL|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
214705277|NCT04152148|BIOLOGICAL|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
214705278|NCT04152148|BIOLOGICAL|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
214705279|NCT01768312|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
214705280|NCT03084289|BIOLOGICAL|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
214705281|NCT03084289|BIOLOGICAL|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
214705282|NCT05955157|BIOLOGICAL|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
214705283|NCT05955157|DRUG|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
214705284|NCT01371448|DRUG|Paroxetine|
214558311|NCT07136285|DRUG|platinum (cisplatin or carboplatin)|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
214558312|NCT07136285|DRUG|Etoposide|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
214558313|NCT07135505|BEHAVIORAL|Early time-restricted eating|The participants will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-8:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.
214558314|NCT07135271|OTHER|Bespoke Decision Support tool|A newly-developed online patient decision aid offering comparative information of prostate cancer treatments (active surveillance, focal therapy, radical prostatectomy and external beam radiotherapy), personalised estimates of oncological and functional outcomes for each treatment and a value-clarification exercise.
214558315|NCT07135271|OTHER|Standard of Care (SOC) decision support material|"Standard of care information to inform the prostate cancer treatment decision. This includes the nationally approved Prostate Cancer UK information booklet Prostate Cancer - A guide if you have just been diagnosed in all sites. Further educational material may be provided as part of standard of care depending on local practice at each site."
214705285|NCT03600493|DRUG|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
214705286|NCT03600493|DRUG|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
214705287|NCT05572788|PROCEDURE|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
214705288|NCT03779633|DRUG|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
214705289|NCT03779633|OTHER|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
214705290|NCT03022513|OTHER|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
214705291|NCT02382783|OTHER|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
215163462|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
215163463|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
215163464|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
215163465|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
215163466|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
214558316|NCT07136792|DRUG|Pegmolesatide 2mg SC|All patients will receive pegmolesatide 2mg subcutaneously once every 4 weeks.
214558317|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
214558318|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
214558319|NCT07136792|DRUG|Pegmolesatide 6mg SC|All patients will receive pegmolesatide 6mg subcutaneously once every 4 weeks.
214558320|NCT07138144|DRUG|Standard Medical Therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet.
214558321|NCT07138144|DRUG|dual therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs
214558322|NCT07088679|DRUG|Sterify Gel (mucoadhesive bioactive gel)|Sterify Gel® is a sterile, ready-to-use mucoadhesive hydrogel formulated with polyvinyl polymers, hydroxytyrosol (a natural antioxidant), magnesium ascorbyl phosphate (a stable vitamin C derivative), and nisin (a naturally occurring antimicrobial peptide). In this study, it is applied into the peri-implant pocket using a 0.6 mm - 23GA sterile needle (Gerhò®) immediately after non-surgical debridement. Application is performed at baseline and at follow-up visits (1, 3, 6, and 9 months). Patients are instructed to avoid rinsing, eating, or using oral hygiene aids at the treated sites for at least 2 hours post-application, and to follow specific hygiene instructions for 48 hours.
214558323|NCT07088679|PROCEDURE|Standard Non-Surgical Peri-Implantitis Therapy|Standard therapy consists of supra- and subgingival professional mechanical debridement of peri-implant sites using ultrasonic inserts and manual curettes covered with biocompatible materials (PEEK, teflon, or titanium) to avoid damage to the implant surface. This is followed by air-polishing using erythritol powder (Air-Flow Plus®, EMS; 14 µm) for supragingival biofilm removal and glycine powder (Air-Flow Perio®, EMS; 25 µm) for subgingival polishing. This procedure is repeated at baseline and at 1, 3, 6, and 9 months without the adjunctive use of any topical gel.
214558324|NCT07125027|BEHAVIORAL|Move-MORE|Move-MORE is a multicomponent intervention which combines mindfulness training, physical activity, and motivational interviewing informed by the principles of self-determination theory. The version of Move-MORE being used in this study is specifically designed for use in patients with lumbosacral radiculopathy.
214558325|NCT07124130|DRUG|5% Dextrose (D5) in Normal Saline (NS)|A solution of 5% dextrose and lactate ringer will be given to one group of participants.
214558326|NCT07124130|DRUG|Lactate Ringer|A Lactate Ringer solution will be given to one group of participants.
214558327|NCT07124052|DEVICE|SleeperOne 5|A computerized local anesthetic delivery system (manufactured by Dental Hi-Tec, France) designed to minimize pain perception in children during dental procedures by controlling the pressure and flow rate of anesthetic injection. It will be used to deliver 3% mepivacaine (Mepecaine-L®, Alexandria Co. for Pharmaceuticals, Egypt) during maxillary primary molar extraction in pediatric patients.
214558328|NCT07124052|PROCEDURE|(Conventional Infiltration Anesthesia)|Local anesthetic solution (3% mepivacaine with no vasoconstrictor), manufactured by Alexandria Co. for Pharmaceuticals, Egypt. It will be administered using a 30-gauge short dental needle and standard dental syringe for conventional infiltration anesthesia during primary maxillary molar extraction in pediatric patients.
214558329|NCT07124078|DRUG|INCA034176|Axatilimab at the protocol-defined dose.
214558330|NCT07124078|DRUG|Best available Treatment (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
214558331|NCT07126418|OTHER|observation (cervical proprioception, neck pain and neck disability)|"1\) Assessment of cervical proprioception using CROM device: Head reposition accuracy tests: neutral head position (NHP) and target head position (THP) tests are common tests used to assess cervical proprioception. Repositioning to the NHP and repositioning into THP. The test procedures were the same as those described by Lee et al., 2006. The NHP test measures the subject's ability to actively reposition their head to their self-selected neutral position. The THP test measures the individual's ability to actively reposition the head to a previously demonstrated target position. A) Neutral head position: After explaining the testing procedure, the CROM device will securely fixed on the head of the subject. The participants will instructed to sit upright with their feet flat on the floor, their back against the chair backrest and facing straight ahead, this position will established as their self-selected NHP.~The magnetic part of the unit was then placed so that it was put"
214705292|NCT06177119|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
214705293|NCT06177119|DRUG|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
214705294|NCT06177119|DRUG|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
215163467|NCT06191640|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
215163468|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
215163469|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
215163470|NCT05190120|PROCEDURE|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
215163471|NCT05190120|PROCEDURE|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
215163472|NCT05190120|DRUG|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
214558332|NCT04959864|DIETARY_SUPPLEMENT|Isitol®|"1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
214558333|NCT04959864|OTHER|Placebo|"1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30."
214558334|NCT07137156|DIAGNOSTIC_TEST|cytobrush|buccal smear
214705295|NCT06177119|DRUG|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
214705296|NCT06177119|DRUG|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
214705297|NCT06177119|DRUG|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
214705298|NCT06177119|DRUG|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
214705299|NCT03222219|PROCEDURE|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
214705300|NCT05409768|PROCEDURE|Short axis out of plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
214705301|NCT05409768|PROCEDURE|Anteroposterior short axis in plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
214558335|NCT07137156|DEVICE|next-generation sequencing|next-generation sequencing
214558336|NCT07137039|DRUG|Adebrelimab+Albumin paclitaxel +Cisplatin|"1. Adebrelimab：1200mg, ivgtt, D1, Q3W;~2. Albumin paclitaxel :260mg/m2, ivgtt, D1, Q3W;~3. Cisplatin :60mg/m2, ivgtt, D1, Q3W."
214558337|NCT07137364|DRUG|spironolactone|The patients receive spironolactone treatment based on their conditions
214558338|NCT06551064|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
214558339|NCT06551064|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
214558340|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
214558341|NCT06409390|DRUG|Taxotere|75 mg/m2 once every 21 days for 4 cycles
214558342|NCT06409390|DRUG|Cytoxan|600 mg/m2 once every 21 days for 4 cycles
214558343|NCT06409390|DRUG|Trastuzumab deruxtecan|5.4 mg/kg once every 21 days for 5 cycles
214558344|NCT06409390|DRUG|Sacituzumab govitecan|10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
214558345|NCT06409390|DRUG|Xeloda|1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
214705302|NCT00363441|PROCEDURE|Intensity Modulated Radiotherapy|
214705303|NCT02818140|PROCEDURE|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
214705304|NCT02818140|PROCEDURE|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
214558346|NCT06409390|DRUG|Fulvestrant|500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
214558347|NCT06409390|DRUG|Ribociclib|600 mg orally daily 21 days on, 7 days off
214558348|NCT06409390|DRUG|Abemaciclib|150 mg by mouth twice daily
214558349|NCT06063850|GENETIC|AAV9-hSyn1-miGRIK2|AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
214558350|NCT04092530|BEHAVIORAL|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
214705305|NCT02818140|DRUG|Ropivacaine|
214705306|NCT02818140|DRUG|Saline|
214558351|NCT05261373|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
214558352|NCT05261373|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
214705307|NCT02818140|DEVICE|Ultrasound|
214705308|NCT00469209|DRUG|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
214705309|NCT00469209|DRUG|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
214705310|NCT00469209|DRUG|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
214705311|NCT00469209|DRUG|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
214558353|NCT05261373|OTHER|Behavioral: Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
214558354|NCT04494451|DRUG|Vit C|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
214558355|NCT04494451|DRUG|Standard medical Treatment|iv antibiotics alone
214558356|NCT05082168|DEVICE|Capnodynamic monitoring|"In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2."
214558357|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
214558358|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
214558359|NCT04942366|OTHER|High intensity interval training|HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
214558360|NCT04942366|OTHER|Strength training|Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
214558361|NCT04471831|OTHER|Rehabilitation exercise protocol|"The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions."
214558362|NCT03395977|DRUG|Placebos|Lactose placebo for pills and saline for perfusion.
214558363|NCT03395977|DRUG|Febuxostat|Febuxostat tablet.
214558364|NCT03395977|DRUG|Rasburicase|Rasburicase injectable solution.
214558365|NCT06791486|OTHER|AI-assisted predictive model|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.
214558366|NCT04829097|COMBINATION_PRODUCT|Temozolomide|The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
214705312|NCT01333306|PROCEDURE|Transcranial direct current stimulation (tDCS)|
214705313|NCT04995471|BEHAVIORAL|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
214705314|NCT04995471|BEHAVIORAL|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
214705315|NCT04995471|BEHAVIORAL|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
215163473|NCT05190120|DRUG|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
215163474|NCT06969430|DRUG|Debio 1562M|Administered as intravenous (IV) infusion
214705316|NCT04995471|BEHAVIORAL|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
214705317|NCT03668535|PROCEDURE|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
214705318|NCT03668535|PROCEDURE|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
214705319|NCT01115075|OTHER|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
214705320|NCT01115075|BEHAVIORAL|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
214558367|NCT05441709|BEHAVIORAL|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
214705321|NCT02943018|OTHER|anovaginal distance variation|Kappa calculation
214705322|NCT00041353|OTHER|cytology specimen collection procedure|
214705323|NCT00041353|PROCEDURE|comparison of screening methods|
214558368|NCT02143011|OTHER|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
214558369|NCT02143011|OTHER|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
214558370|NCT01134224|DRUG|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
214558371|NCT01134224|DRUG|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
214558372|NCT01134224|DRUG|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
214558373|NCT01134224|DRUG|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
214558374|NCT01134224|DRUG|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
214558375|NCT01134224|DRUG|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
214558376|NCT04317391|BEHAVIORAL|Pain management program|Mindfulness based stress reduction
214558377|NCT02243111|RADIATION|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
214558378|NCT00942864|DRUG|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
214558379|NCT02855736|BEHAVIORAL|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
214558380|NCT02855736|BEHAVIORAL|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
214705324|NCT00041353|PROCEDURE|study of high risk factors|
214705325|NCT00943488|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
214705326|NCT00386490|DRUG|larazotide acetate|capsule for oral administration
214705327|NCT05331456|DEVICE|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
214705328|NCT01560442|DRUG|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
214705329|NCT04668092|OTHER|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
214705330|NCT02336139|DRUG|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
214705331|NCT00712933|DRUG|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
214558381|NCT04209569|BEHAVIORAL|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
214558382|NCT05675462|DRUG|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
214558383|NCT05675462|DRUG|Tislelizumab|PD-1inhibitor
214558384|NCT05675462|DRUG|Lenvatinib|TKI
214558385|NCT06345469|OTHER|Patient blood management (PBM)|PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.
214558386|NCT06345469|BIOLOGICAL|Allogeneic transfusion|transfusion of donor red cells
214558387|NCT00450021|DRUG|[(11)C] MePPEP|
214558388|NCT01603888|OTHER|no intervention|
214558389|NCT03354936|BIOLOGICAL|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
214558390|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate bar|Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
214558391|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate mousse|Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
214558392|NCT03022955|DIETARY_SUPPLEMENT|White chocolate bar|White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
214705332|NCT01882777|BEHAVIORAL|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
214705333|NCT01015729|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
214705334|NCT01015729|DRUG|Esomeprazole|oral, single dose
214705335|NCT01015729|DRUG|ASA|Tablet, oral, single dose
214705336|NCT05126940|DIAGNOSTIC_TEST|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
214705337|NCT00085917|DRUG|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
214705338|NCT00085917|DRUG|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
214705339|NCT05424185|BEHAVIORAL|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
214558393|NCT03022955|DIETARY_SUPPLEMENT|White chocolate mousse|White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
214558394|NCT00597051|DRUG|ARD-0403|
214558395|NCT01416857|OTHER|RDDT|
214558396|NCT05281497|BEHAVIORAL|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
214558397|NCT05281497|BEHAVIORAL|Social media|We built a LINE group to inspire the intervention group.
214558398|NCT05281497|OTHER|Exercise training|exercise including walk and an 18-minutes calisthenics
214558399|NCT03301155|DRUG|Anaferon for children|Tablet for oral use.
214558400|NCT03301155|DRUG|Placebo|Tablet for oral use.
214558401|NCT00448201|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
214558402|NCT00448201|BIOLOGICAL|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) \< 1000/microliter (uL) past day 20
214558403|NCT00448201|BIOLOGICAL|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10\^6 cells/kg and a maximum 8 x 10\^6 cells/kg will be infused on day 0
214558404|NCT00448201|DRUG|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
214558405|NCT00448201|DRUG|fludarabine phosphate|fludarabine 30 mg/m\^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
214558406|NCT00448201|DRUG|methotrexate|Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
214558407|NCT00448201|DRUG|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
214558408|NCT00448201|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
214705340|NCT00397709|DRUG|I ( isoniazid), II (isoniazid + rifampin )|
214558409|NCT00448201|PROCEDURE|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
214558410|NCT04875442|DEVICE|Memowave emitting sounds|Memowave is worn during one night and emits sounds to increase slow brain waves
214558411|NCT04875442|DEVICE|Memowave not emitting sounds|Memowave is worn during one night and doesn't emit sounds
214705341|NCT00348413|DRUG|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
214705342|NCT01022151|DRUG|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
214705343|NCT01022151|DRUG|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
214705344|NCT01022151|DRUG|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
214705345|NCT01022151|DRUG|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
214705346|NCT01022151|DRUG|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
215163475|NCT06966778|DRUG|Oxybutynin chloride extended-release tablets 5mg/tab, 2 tab, PO, qd.|"The intervention being studied is oxybutynin chloride extended-release tablets (Oxbu), a muscarinic antagonist that is used to manage overactive bladder symptoms, including urinary incontinence. In this study, it is specifically evaluated for its potential to improve early continence recovery following robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.~This formulation is an extended-release version of oxybutynin, which allows for a slower, sustained release of the drug over time, ensuring more consistent therapeutic effects with reduced side effects compared to immediate-release formulations. The intervention involves a daily dose of 10 mg, administered as two 5 mg tablets, to assess its impact on postoperative continence recovery.~The key distinction of this intervention is its focus on improving continence recovery after prostate cancer surgery, specifically through its targeted use in early post-surgical recovery, making it different from othe"
215163476|NCT06966778|DRUG|Placebo (2 tab), PO, qd.|placebo, which is designed to look identical to the active drug but contains no therapeutic ingredient.
215163477|NCT02446600|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163478|NCT02446600|DRUG|Carboplatin|Given IV
214558412|NCT06084767|DIAGNOSTIC_TEST|68Ga-TCR-FAPI PET/CT|A dose of 3.7 MBq/kg 68Ga-TCR-FAPI will be intravenously injected and PET examination will be carried out within the specified time.
214558413|NCT04329377|DIAGNOSTIC_TEST|blood test|complete blood count and platelet function
214558414|NCT03270202|BEHAVIORAL|PAI group|"* physical activity defined as 100 weekly PAI during 1 year~* smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
214558415|NCT03270202|BEHAVIORAL|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
214558416|NCT03272906|DEVICE|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
214558417|NCT03272906|DEVICE|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
214558418|NCT03272906|BEHAVIORAL|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
214558419|NCT03950700|DRUG|Bupivacaine-epinephrine|BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
214558420|NCT03950700|DRUG|Saline Solution|Saline solution 0.9% (Baxter laboratories).
214558421|NCT05209516|BEHAVIORAL|Behavioral data|Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
214558422|NCT05209516|DIAGNOSTIC_TEST|Single-pulse transcranial magnetic stimulation (TMS)|While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
214558423|NCT05209516|OTHER|Questionnaires|Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
215163479|NCT02446600|DRUG|Cediranib Maleate|Given PO
215163480|NCT02446600|PROCEDURE|Computed Tomography|Undergo CT
215163481|NCT02446600|PROCEDURE|Echocardiography Test|Undergo ECHO
215163482|NCT02446600|DRUG|Gemcitabine|Given IV
215163483|NCT02446600|DRUG|Gemcitabine Hydrochloride|Given IV
215163484|NCT02446600|OTHER|Laboratory Biomarker Analysis|Correlative studies
215163485|NCT02446600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163486|NCT02446600|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215163487|NCT02446600|DRUG|Olaparib|Given PO
214558424|NCT05209516|OTHER|MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)|Specific Parkinson Questionnaire on Clinical motor status
214558425|NCT00384189|DRUG|Ciclesonide|inhaled Ciclesonide
214558426|NCT00384189|DRUG|Placebo|Ciclesonide placebo-matching inhaler
214558427|NCT00384189|DRUG|Salbutamol|Salbutamol inhalation powder
214558428|NCT00696943|DRUG|([18F]-ML-10)|\[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
215163488|NCT02446600|DRUG|Paclitaxel|Given IV
215163489|NCT02446600|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
215163490|NCT02446600|OTHER|Pharmacological Study|Correlative studies
215163491|NCT02446600|OTHER|Quality-of-Life Assessment|Ancillary studies
215163492|NCT06305247|DRUG|IPN01194|"IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision."
215163493|NCT06305247|DRUG|IPN01194|"All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision"
215163494|NCT04041778|OTHER|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
215163495|NCT05174351|OTHER|beta blocker discontinuation|beta blocker discontinuation
215163496|NCT04857684|DRUG|Atezolizumab|Intravenous Infusion
215163497|NCT04857684|DRUG|Bevacizumab|Intravenous Infusion
215163498|NCT04857684|RADIATION|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
214558429|NCT03912662|DEVICE|Mesh augmented reinforcement|Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
214558430|NCT05198102|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
214558431|NCT02316327|DRUG|gemcitabine, cisplatin and bevacizumab|Therapeutic
214558432|NCT05017090|PROCEDURE|M-TAPA block|After tracheal intubation, a high-frequency linear probe will placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
214558433|NCT05017090|OTHER|Standard perioperative and postoperative multimodal analgesia|The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
215163499|NCT06845358|BIOLOGICAL|BCG TICE strain|BCG TICE strain is an attenuated, live culture preparation of the BCG strain of Mycobacterium bovis.
215163500|NCT06845358|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
215163501|NCT06845358|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
215163502|NCT06317649|DRUG|Azacitidine|Given IV or SC
215163503|NCT06317649|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163504|NCT06317649|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
215163505|NCT06317649|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215163506|NCT06317649|DRUG|Gilteritinib|Given PO
215163507|NCT06317649|DRUG|Venetoclax|Given PO
215163508|NCT06128278|DRUG|S-equol|Oral supplementation of S-equol
215163509|NCT06128278|OTHER|Placebo|Oral supplementation of placebo
215163510|NCT06239064|DIAGNOSTIC_TEST|Genetic testing via blood collection|blood collection
215163511|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
214558434|NCT06408701|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
214558435|NCT00809367|OTHER|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
214558436|NCT01126645|PROCEDURE|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA."
214558437|NCT01126645|PROCEDURE|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
214558438|NCT00608868|DRUG|Gefitinib|Gefitinib tablet 250mg once daily orally
214558439|NCT05620407|DRUG|Deucravacitinib|Specified dose on specified days
214558440|NCT05620407|OTHER|Placebo|Specified dose on specified days
215163512|NCT05300724|OTHER|No intervention|No intervention will be administered in this study.
215163513|NCT06682429|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
214558441|NCT04924712|OTHER|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
214558442|NCT02630875|DRUG|A4250|A4250
214558443|NCT03507946|DEVICE|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
214558444|NCT06196775|BIOLOGICAL|AK104+AK112|Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.
214558445|NCT04727138|DRUG|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
214558446|NCT04727138|DRUG|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
214558447|NCT04727138|OTHER|Midazolam|Interaction
214558448|NCT04727138|OTHER|Food Effect|Fed/Fasted
214558449|NCT04727138|OTHER|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension
214558450|NCT00531336|DRUG|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
214558451|NCT00531336|DRUG|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
214558452|NCT05686798|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)|Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
214558453|NCT04427943|PROCEDURE|revision surgery|The intervention is the planned revision surgery according to local guidelines.
214558454|NCT02057211|BIOLOGICAL|autologous mesenchymal stem cell transplantation|
214558455|NCT02057211|PROCEDURE|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
214558456|NCT04517708|OTHER|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
214558457|NCT02566564|DRUG|Lopain|intra-articular injection
214558458|NCT03289351|DRUG|Piperacillin, Tazobactam Drug Combination|Single drug therapy
214558459|NCT06064968|OTHER|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
214558460|NCT00338143|DRUG|efalizumab|
214558461|NCT00335140|BIOLOGICAL|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
214558462|NCT00335140|DRUG|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
214558463|NCT00335140|DRUG|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
214558464|NCT00335140|DRUG|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
214558465|NCT00335140|DRUG|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
214558466|NCT00335140|DRUG|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
214558467|NCT00335140|DRUG|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
214558468|NCT05900414|BEHAVIORAL|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
214558469|NCT05900414|OTHER|Information|Link to website with information about atrial fibrillation treatments
214558470|NCT05090943|OTHER|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
214558471|NCT04390932|OTHER|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
214558472|NCT04390932|OTHER|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
214558473|NCT04390932|OTHER|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
214558474|NCT00431353|DRUG|Ganciclovir|5mg/kg iv bid for 21 days
214558475|NCT00431353|DRUG|valganciclovir [Valcyte]|900mg po bid for 21 days
214558476|NCT03934151|PROCEDURE|intracorporeal ileocolic anastomosis|laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
214558477|NCT03934151|PROCEDURE|extracorporeal ileocolic anastomosis|ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
214558478|NCT06441253|DIAGNOSTIC_TEST|Deep Friction massage|The calf muscles received a firm, deep-circulation massage with fingertip pressure
214558479|NCT06441253|COMBINATION_PRODUCT|Therapeutic exercises|Four stretching exercises were performed for twenty minutes, five minutes for each technique, and eight to ten repetitions of each exercise (calf wall stretch, back knee straight, bilateral calf stretches, knees straight, ankle plantarflexion/dorsiflexion)
214558480|NCT04773743|OTHER|Yoga|Remotely delivered yoga intervention
214558481|NCT04546425|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
214558482|NCT04546425|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
214558483|NCT02237677|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
214558484|NCT03582527|OTHER|all study participants|patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
215163514|NCT02664129|OTHER|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
215163515|NCT02664129|OTHER|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
215163516|NCT04108858|DRUG|Copanlisib|Given IV
215163517|NCT04108858|BIOLOGICAL|Pertuzumab|Given IV
215163518|NCT04108858|BIOLOGICAL|Trastuzumab|Given IV
215163519|NCT05861973|BEHAVIORAL|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless Bluetooth scale for 12 months.
215163520|NCT05861973|BEHAVIORAL|Diabetes Prevention Program (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
215163521|NCT05861973|BEHAVIORAL|Self-Guided Treatment (Self-Guided)|Provides paper and internet resources tailored to geographic area, educating on leading a healthier lifestyle, including information on wellness and physical activity. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
215163522|NCT06001801|BEHAVIORAL|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
215163523|NCT06001801|BEHAVIORAL|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
215163524|NCT05236439|DEVICE|Interposition supraciliary implant|Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
215163525|NCT05469568|OTHER|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
215163526|NCT05469568|OTHER|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
215163527|NCT04000529|DRUG|TNO155|Capsule
215163528|NCT04000529|DRUG|Spartalizumab|Concentrate for solution for infusion
215163529|NCT04000529|DRUG|Ribociclib|Capsule and tablet
215163530|NCT05036252|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
215163531|NCT05036252|DIAGNOSTIC_TEST|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
215163532|NCT05036252|DIAGNOSTIC_TEST|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
215163533|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
215163534|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
215163535|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
215163536|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
214558485|NCT05866042|DEVICE|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
215163537|NCT04628767|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
215163538|NCT04628767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163539|NCT04628767|DRUG|Cisplatin|Given IV
215163540|NCT04628767|PROCEDURE|Computed Tomography|Undergo CT
215163541|NCT04628767|DRUG|Doxorubicin Hydrochloride|Given Iv
215163542|NCT04628767|BIOLOGICAL|Durvalumab|Given IV
215163543|NCT04628767|DRUG|Gemcitabine Hydrochloride|Given IV
215163544|NCT04628767|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215163545|NCT04628767|DRUG|Methotrexate|Given IV
215163546|NCT04628767|BIOLOGICAL|Pegfilgrastim|Given via injection
215163547|NCT04628767|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214705347|NCT01022151|DRUG|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
214705348|NCT03770195|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
214705349|NCT00002434|DRUG|Trimetrexate glucuronate|
214705350|NCT00002434|DRUG|Leucovorin calcium|
214705351|NCT03905395|BEHAVIORAL|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
214705352|NCT04965129|DRUG|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
214705353|NCT04965129|DRUG|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
214705354|NCT03825263|DEVICE|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
214705355|NCT01295580|DEVICE|ARTZ|Hyaluronic acid (five 2.5 mL injections)
214705356|NCT01295580|DEVICE|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
214705357|NCT02071264|BEHAVIORAL|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
214705358|NCT05270850|PROCEDURE|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
214705359|NCT05270850|PROCEDURE|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
214705360|NCT04946799|BEHAVIORAL|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
214705361|NCT04946799|BEHAVIORAL|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
214705362|NCT04946799|BEHAVIORAL|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
214705363|NCT06483165|OTHER|BE FAST Educational video|A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
215163548|NCT04628767|DRUG|Vinblastine Sulfate|Given Iv
215163549|NCT06458075|BEHAVIORAL|CO-LEAD|The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
215163550|NCT03923270|DRUG|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
215163551|NCT03923270|DRUG|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
215163552|NCT03923270|DRUG|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
215163553|NCT03923270|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
215163554|NCT03923270|DRUG|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
214705364|NCT06483165|OTHER|F.A.S.T. Educational Video|A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
215163555|NCT06087276|DRUG|60 mg ulixacaltamide|Once daily oral treatment with titration
215163556|NCT06087276|DRUG|Placebo|Once daily oral treatment
214705365|NCT05142540|PROCEDURE|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
214705366|NCT01261546|DRUG|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
214558486|NCT05524090|OTHER|Implementation - International best-practice care|The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
214558487|NCT01753726|OTHER|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
214558488|NCT01753726|OTHER|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
214558489|NCT03982251|PROCEDURE|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
214558490|NCT03982251|PROCEDURE|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
214558491|NCT03266926|DRUG|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
214558492|NCT03266926|DRUG|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
214558493|NCT06539468|OTHER|Best Practice|Receive SOC treatment
214558494|NCT06539468|OTHER|Educational Activity|Watch an educational video on AS for LR-BCC
214558495|NCT06539468|OTHER|Patient Observation|Undergo active surveillance
214558496|NCT06539468|OTHER|Survey Administration|Ancillary studies
214558497|NCT05484414|DRUG|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
214558498|NCT05484414|DRUG|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
214558499|NCT04798170|OTHER|Utrasound|Ultrasound examination
214558500|NCT05788874|DIAGNOSTIC_TEST|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
214558501|NCT04468594|OTHER|rigid tapping|Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
214558502|NCT04468594|OTHER|scapular stabilizing excercise|"consisted of:~1. wall slides with squat,~2. wall push-ups plus ipsilateral leg extension,~3. lawnmower with diagonal squat,~4. resisted scapular retraction with contralateral leg squat and robbery with squat.~5. Robbery with squat~6. Resisted shoulder internal rotation with step~7. Resisted shoulder external rotation with step~8. Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly."
214558503|NCT04468594|OTHER|therapeutic exercises|"1. Pectoralis minor stretching~2. Posterior shoulder stretching~3. Levator scapula stretching~4. Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~5. Resisted shoulder internal rotation~6. Resisted shoulder external rotation~7. Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets."
214558504|NCT03165747|DRUG|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
214558505|NCT03165747|OTHER|Placebo|Two placebo sachets taken orally daily in a single administration.
214558508|NCT04320342|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
215163557|NCT03069352|DRUG|Placebo|tablet
215163558|NCT03069352|DRUG|Venetoclax|tablet
215163559|NCT03069352|DRUG|Cytarabine|Subcutaneous injection
214558509|NCT04320342|DRUG|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
214558510|NCT04320342|DRUG|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
214558511|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
214558512|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
214558513|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
214558514|NCT06557265|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
214558515|NCT06557265|DRUG|Fludarabine, Cyclophosphamide|Lymphodepletion
214558516|NCT00045201|DRUG|Erlotinib Hydrochloride|Given orally
214558517|NCT00045201|DRUG|Irinotecan Hydrochloride|Given IV
215163560|NCT02621424|DEVICE|RTMS|stimulation of the brain with magnetic pulses
215163561|NCT02621424|DEVICE|sham|sham noise to block the sound of stimulation
215163562|NCT06752694|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163563|NCT06752694|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
215163564|NCT06752694|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215163565|NCT06752694|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
215163566|NCT06752694|PROCEDURE|Computed Tomography|Undergo CT
215163567|NCT06752694|DRUG|Cyclosporine|Given PO
215163568|NCT06752694|DRUG|Fludarabine|Given IV
215163569|NCT06752694|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
215163570|NCT06752694|DRUG|Mycophenolate Mofetil|Given PO
215163571|NCT06752694|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
214558518|NCT06641362|DEVICE|Ultra High Frequency Electrocardiogram (UHF-ECG)|Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
214558519|NCT05461495|BEHAVIORAL|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
214558520|NCT04047251|DRUG|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
214558521|NCT05441462|PROCEDURE|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
214558522|NCT06795022|DRUG|AZD9793 Intravenous (IV) monotherapy|T cell-engaging antibody that targets GPC3 on tumour cells
214558523|NCT06795022|DRUG|AZD9793 Subcutaneous (SC) monotherapy)|T cell-engaging antibody that targets GPC3 on tumour cells
214558524|NCT01430234|DRUG|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
214558525|NCT04737876|BIOLOGICAL|BX002-A|bacteriophage cocktail
214558526|NCT04737876|OTHER|Placebo|Placebo
214558527|NCT00271310|DRUG|hypertonic saline|
214558528|NCT03809598|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
214558529|NCT05564000|OTHER|Dating Violence Prevention Program|We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
214558530|NCT03664440|DRUG|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
214558531|NCT03664440|DRUG|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
214558532|NCT02764268|DRUG|Apatinib|
214558533|NCT03478449|PROCEDURE|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
214558534|NCT02716636|PROCEDURE|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
214558535|NCT00130325|DRUG|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
214558536|NCT00130325|DRUG|Isoniazid|INH 900mg twice weekly for 6 months
214558537|NCT00130325|DRUG|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
214558538|NCT00821340|GENETIC|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
214558539|NCT03908151|DEVICE|CMK21 Hip system|Total hip arthroplasty
214558540|NCT04914598|DRUG|ENDOSTAR，cisplatin|After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
215163572|NCT06752694|DRUG|Ruxolitinib|Given PO
214558541|NCT04914598|DRUG|Placebo , cisplatin|Placebo , cisplatin
214558542|NCT04848324|OTHER|Corticosteroid Hydrodissection|The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
214558543|NCT04848324|OTHER|Corticosteroid Injection|1 mL of triamcinolone was delivered via the in-plane ulnar approach
214558544|NCT02979249|DRUG|Oral Iron|for one year
214705367|NCT01261546|DRUG|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
215163573|NCT06752694|DRUG|Sirolimus|Given PO
215163574|NCT06752694|RADIATION|Total-Body Irradiation|Undergo TBI
215163575|NCT06752694|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215163576|NCT06752694|PROCEDURE|Echocardiography|Undergo ECHO
215163577|NCT06659640|DRUG|ALN-6400|ALN-6400 will be administered subcutaneously (SC)
215163578|NCT06659640|DRUG|Placebo|Placebo will be administered subcutaneously (SC)
215163579|NCT05299125|DRUG|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
215163580|NCT05299125|DRUG|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
214558545|NCT01236638|DRUG|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
214558546|NCT01125046|BIOLOGICAL|bevacizumab|Given IV
214558547|NCT06799169|DRUG|Nortriptyline|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
214558548|NCT06799169|DRUG|Topiramate|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
214558549|NCT06799169|DRUG|Paroxetine|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
214558550|NCT06799169|DRUG|Verapamil|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
214558551|NCT00909129|DRUG|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
214558552|NCT00909129|DRUG|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
214558553|NCT02339545|DEVICE|Coronary Orbital Atherectomy plus Stenting|
214558554|NCT06365151|OTHER|Osteopathic manual therapy|osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.
214558555|NCT06365151|OTHER|Sham osteopathic manual therapy|a sham osteopathic manual treatment without therapeutic effect
214558556|NCT02620605|DRUG|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
214558557|NCT02620605|DRUG|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
214558558|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
214558559|NCT00443924|DRUG|Placebo|One drop of placebo in each eye every 12 hours for three days
214558560|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
214558561|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
214558562|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
214558563|NCT04074668|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214558564|NCT04074668|DRUG|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
214558565|NCT04074668|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
214558566|NCT04074668|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
214558567|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
214558568|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
214558569|NCT00425464|DEVICE|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
214558570|NCT00425464|DEVICE|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
214558571|NCT05078788|PROCEDURE|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
214558572|NCT05078788|PROCEDURE|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
214558573|NCT03705598|BEHAVIORAL|Light physical exercise|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/walking, upper and lower body strength exercise/walking, and stretching exercise/balance exercise/walking, respectively), each ending with a short break to record the Borg Rating of Perceived Exertion (RPE), followed by a 5-minute break time or cool-down/wrap-up session. The session will be taught by a certified exercise physiologist and a research assistant.
214558574|NCT03705598|BEHAVIORAL|Tai Chi|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/breathing exercise, Tai Chi walking drills, and Tai Chi 8-form, respectively), each ending with a short break to record the RPE, and followed by a 5-minute break or cool-down/wrap-up session. The session will be taught by an experienced Tai Chi instructor and a research assistant.
214558575|NCT03868787|DEVICE|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
214558576|NCT03868787|DEVICE|Sham TENS|Non-active TENS unit
214558577|NCT06267144|DRUG|Sintilimab plus chemotherapy|"Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly."
214558578|NCT05048498|DRUG|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
214558579|NCT05048498|DRUG|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
214558580|NCT02306551|OTHER|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
214558581|NCT01685229|DEVICE|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
214558582|NCT01685229|DRUG|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
214558583|NCT01635738|BIOLOGICAL|LP GMNL-133 capsule|One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO
214558584|NCT01635738|BIOLOGICAL|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO
214558585|NCT01635738|BIOLOGICAL|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10\^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
214558586|NCT01635738|BIOLOGICAL|Placebo|Placebo
214558587|NCT05937867|DRUG|HS-10353 Capsules 30 mg, Oral, QN for 14 days|HS-10353 Capsules 30 mg
214558588|NCT05937867|DRUG|HS-10353 Capsules 50 mg, Oral, QN for 14 days|HS-10353 Capsules 50 mg
214558589|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.|Placebo
214558590|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days|Placebo
214558591|NCT04684719|BIOLOGICAL|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
214558592|NCT04684719|BIOLOGICAL|Standard Care|crystalloid infusion or blood component transfusion resuscitation
214558593|NCT05648630|DIETARY_SUPPLEMENT|PB125|PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.
214558594|NCT05648630|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
214558595|NCT05648630|BEHAVIORAL|Exercise Rehabilitation|A 12-week treadmill based supervised rehabilitation
214558596|NCT05113108|DEVICE|CUS|All neonates undergoing CUS at nursery unit at assiut university hospital. Cranial ultrasound is performed with basic grayscale imaging. For optimal resolution and good overview, a multifrequency (5-10 MHz) linear or convex sector transducer is used. Imaging is obtained through the anterior fontanel in the coronal and sagittal planes.{12,13} Typically, six to eight coronal images are obtained beginning at the frontal lobes just anterior to the frontal horns and extending to the occipital lobes posterior to the lateral ventricle trigones.{14} The transducer is then rotated 90°, and approximately five images are obtained, including a midline sagittal view of the corpus callosum and cerebellar vermis in addition to bilateral parasagittal images beginning in the midline and progressing laterally through the peripheral cortex.Doppler ultrasound may be added to assess ischemic areas.{13-15}
214558597|NCT00241046|DRUG|Letrozole|
214558598|NCT04378673|OTHER|not interventional|This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
214558599|NCT00558844|DRUG|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
214705368|NCT05938777|BEHAVIORAL|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
215163581|NCT05299125|DRUG|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
214705369|NCT02022033|DRUG|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
214705370|NCT01429077|DRUG|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
214558600|NCT00558844|DRUG|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
214558601|NCT00558844|DRUG|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214558602|NCT00558844|DRUG|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214705371|NCT01429077|DRUG|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
214705372|NCT03838445|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
214705373|NCT00280241|DRUG|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
214705374|NCT00280241|DRUG|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
214705375|NCT00280241|DRUG|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
214705376|NCT00178048|DRUG|paroxetine|
214705377|NCT05669300|PROCEDURE|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
214705378|NCT02279121|DEVICE|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
215163582|NCT04594694|DRUG|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
215163583|NCT04594694|DRUG|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
215163584|NCT04594694|DRUG|OCA Placebo|One tablet daily for the remainder of the study
215163585|NCT04594694|DRUG|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
215163586|NCT04594694|DRUG|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
215163587|NCT04594694|DRUG|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
215163588|NCT04594694|DRUG|OCA|OCA one tablet will be administered.
215163589|NCT04594694|DRUG|Bezafibrate|Bezafibrate one tablet will be administered.
215163590|NCT00739362|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Active tDCS (anodal left DLPFC)
215163591|NCT00739362|OTHER|Sham/no-stimulation|Sham tDCS
215163592|NCT06560255|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
214705379|NCT02279121|DRUG|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
214705380|NCT02495740|BEHAVIORAL|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
214705381|NCT04991883|OTHER|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
215163593|NCT06560255|OTHER|Rape seed oil|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
215163594|NCT06118255|DRUG|fenfluramine|The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
215163595|NCT06481774|BEHAVIORAL|CONNECT platform|CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
215163596|NCT06646016|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
215163597|NCT06646016|DRUG|Infliximab|Infliximab will be administered intravenously.
215163598|NCT06646016|DRUG|Vedolizumab|Vedolizumab will be administered intravenously.
215163599|NCT05454956|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
215163600|NCT05454956|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
215163601|NCT05160636|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
214705382|NCT04357990|DEVICE|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
214705383|NCT04357990|OTHER|Placebo|The placebo will be a similar spray containing saline only.
214705384|NCT02556424|DRUG|Dexamethasone|Intravitreal implant at D0
214705385|NCT02556424|DRUG|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
214705386|NCT05129995|OTHER|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
214705387|NCT01164592|DEVICE|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
214705388|NCT04432844|PROCEDURE|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
214705389|NCT05688319|BEHAVIORAL|Problem-Solving Training|Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
214705390|NCT01103778|DRUG|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
214705391|NCT01839175|BIOLOGICAL|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
214705392|NCT01839175|BIOLOGICAL|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
214705393|NCT01839175|BIOLOGICAL|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
214705394|NCT01839175|BIOLOGICAL|RotaTeq|2 mL oral administration at 2, 3 and 4 months
214705395|NCT01839175|BIOLOGICAL|Nimenrix|0.5 mL intramuscular injection at 12 months
214705396|NCT01839175|BIOLOGICAL|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
214705397|NCT04740099|OTHER|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
214705398|NCT04740099|OTHER|Standard of Care|A handout including a map and list of locations offering this service.
214705399|NCT03562754|PROCEDURE|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
214705400|NCT03562754|PROCEDURE|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
214705401|NCT03067129|DRUG|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
214705402|NCT03067129|DRUG|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
214705403|NCT01193140|DRUG|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
214705404|NCT01193140|DRUG|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
214705405|NCT00943085|BEHAVIORAL|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
214705406|NCT00943085|BEHAVIORAL|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
214705407|NCT04266106|DRUG|SuperBio probiotic|One capsule po BID for 28 days
214705408|NCT04266106|DRUG|Placebo|One capsule po BID for 28 days
214558603|NCT00558844|DRUG|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
214558604|NCT01012362|DRUG|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
214558605|NCT01012362|DRUG|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
214558606|NCT01310608|OTHER|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
214558607|NCT01720277|BIOLOGICAL|HD Fluzone Vaccine|Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
214705409|NCT03330600|BEHAVIORAL|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
214705410|NCT03330600|BEHAVIORAL|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
214705411|NCT03963713|RADIATION|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
214705412|NCT03963713|RADIATION|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
214705413|NCT01809925|DIETARY_SUPPLEMENT|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
214705414|NCT01809925|DIETARY_SUPPLEMENT|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
214705415|NCT05108688|DRUG|Mirtazapine|Mirtazapine 30 mg tablet once daily for 3 successive days
214705416|NCT05108688|DRUG|Sumatriptan|Sumatriptan 50 mg tablet once daily for 3 successive days
214705417|NCT05108688|OTHER|Placebo|Placebo tablets once daily for 3 successive days.
214558608|NCT01720277|BIOLOGICAL|SD Fluzone Vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
214558609|NCT06136104|DIETARY_SUPPLEMENT|Mixhers HERTIME|A daily self-administered powder supplement packet mixed into water.
214558610|NCT06136104|DIETARY_SUPPLEMENT|Placebo|A daily self-administered powder placebo supplement packet mixed into water.
214558611|NCT03333213|OTHER|Gua Sha|
214558612|NCT01907867|DRUG|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
214558613|NCT06044038|BEHAVIORAL|Physical activity|Bi-weekly supervised physical activity intervention
214558614|NCT06044038|BEHAVIORAL|Cognitive rehabilitation program|weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
214558615|NCT02277184|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
214558616|NCT02277184|DRUG|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
215163602|NCT06471816|OTHER|Dialogue Based Early Detection|Before the biannual parent-teacher meeting, both the kindergarten teacher and the parents will complete the Early Worry Questionnaire containing 39 items related to development and well-being of the individual child. For each item the respondents are asked to indicate if they during the last three months have been concerned. In the parent-teacher meeting they will discuss their possible concerns and try to reach an agreement on how to evaluate the child. If necessary, possible supportive interventions or further assessments locally in the kindergarten or in the public services will be decided.
215163603|NCT06471816|OTHER|Traditional parent-teacher meeting|This is an annual or biannual meeting that is prepared by the kindergarten teacher where (s)he reports on the child's appearance / behaviour and possible challenges as to development and behaviour from an educationalist's view. There are no common templates for the agenda of such meetings, however, usually the kindergarten teacher's perspective and opinion will dominate.
215163604|NCT06121843|DRUG|BMS-986393|Specified dose on specified days
214558617|NCT02277184|RADIATION|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
214558618|NCT01399697|DRUG|methotrexate|orally, Week 1 - 16
214558619|NCT01399697|DRUG|methotrexate|orally, Week 17-28
214558620|NCT01399697|DRUG|placebo|methotrexate placebo orally, Week 17-28
214558621|NCT01399697|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
214558622|NCT06107868|DRUG|RP-6306|RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
214558623|NCT06107868|DRUG|Carboplatin|Carboplatin is an antineoplastic agent.
214558624|NCT06107868|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent.
214558625|NCT05085171|OTHER|Enhanced care package|The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections
214558626|NCT04324450|DEVICE|MRI|"The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging"
214558627|NCT04324450|BEHAVIORAL|Cognitive assessment|Battery of neuropsychological tests
214558628|NCT05143398|DIETARY_SUPPLEMENT|Diet + protein|Comparison of the efficacy
214558629|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA|Comparison of the efficacy
214558630|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA and TCA|Comparison of the efficacy
214558631|NCT05143398|OTHER|Diet|Comparison of the efficacy
214558632|NCT01796054|BEHAVIORAL|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
214705418|NCT03986190|BEHAVIORAL|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
214705419|NCT05057741|BEHAVIORAL|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
214705420|NCT00000384|BEHAVIORAL|Cognitive Behavior Therapy|
215163605|NCT06121843|DRUG|Alnuctamab|Specified dose on specified days
215163606|NCT06121843|DRUG|Mezigdomide|Specified dose on specified days
214705421|NCT00000384|BEHAVIORAL|Educational Support|
215163607|NCT06121843|DRUG|Iberdomide|Specified dose on specified days
215163608|NCT06121843|DRUG|Elranatamab|Specified dose on specified days
215163609|NCT05879887|BEHAVIORAL|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
215163610|NCT00302146|DRUG|15-0 H20|
214558633|NCT01796054|BEHAVIORAL|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
214558634|NCT01448629|DEVICE|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
214558635|NCT01448629|DEVICE|River|River is a new developed product with Coloplast as manufacturer
214558636|NCT01921153|OTHER|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
214558637|NCT00477503|DRUG|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
214558638|NCT00477503|DRUG|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
214558639|NCT01428375|DRUG|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
214558640|NCT01428375|OTHER|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
215163611|NCT05767034|DRUG|Secukinumab 300 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
215163612|NCT05767034|DRUG|Secukinumab 150 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
215163613|NCT05767034|OTHER|Placebo to secukinumab|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
215163614|NCT05766488|DEVICE|Continuous Glucose Monitor (CGM)|A Freestyle Libre 2 continuous glucose monitor (CGM) will be provided in the experimental arm of this study for 6 months.
215163615|NCT05766488|DEVICE|Self-monitoring Blood Glucose (SMBG)|A traditional glucometer device will be assigned in the active comparitor arm of this study for 6 months.
215163616|NCT04656054|PROCEDURE|liposuction|liposuction procedure and observation of the hematological changes on the patients
215163617|NCT05626673|BEHAVIORAL|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
214705422|NCT00000384|DRUG|Sertraline|
214705423|NCT00032617|PROCEDURE|Prolonged Exposure|trauma-focused exposure therapy
215163618|NCT03663725|DRUG|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
214558641|NCT04387500|DRUG|Sintilimab injection plus Inlyta treatment|Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
214705424|NCT00032617|PROCEDURE|Present Centered Therapy|therapy that focuses on current problems
214705425|NCT05194501|OTHER|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
215163619|NCT03663725|DRUG|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
215163620|NCT05350501|DRUG|EO2040|"EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC."
215163621|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
215163622|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)
214558642|NCT02627417|DRUG|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
214558643|NCT02627417|DRUG|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
214558644|NCT02627417|DRUG|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
215163623|NCT06346392|DRUG|Ramucirumab+ paclitaxel|Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
215163624|NCT06346392|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
215163625|NCT06346392|DRUG|Docetaxel|Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
215163626|NCT06346392|DRUG|Irinotecan|Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
215163627|NCT06346392|DRUG|TAS-102|TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
215163628|NCT06346392|DRUG|Apatinib|Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
215163629|NCT05433961|DRUG|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
215163630|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
214558645|NCT00990795|DRUG|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
214558646|NCT00990795|DRUG|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
215163631|NCT06580743|OTHER|No intervention|This is an observational study
215163632|NCT05746442|BEHAVIORAL|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
215163633|NCT05746442|DRUG|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
215163634|NCT05746442|BEHAVIORAL|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
215163635|NCT05746442|BEHAVIORAL|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
215163636|NCT04361708|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
215163637|NCT04361708|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
215163638|NCT04361708|DRUG|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
215163639|NCT04361708|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
215163640|NCT04361708|DRUG|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
215163641|NCT06399705|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
215163642|NCT06399705|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
215163643|NCT05889130|OTHER|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
215163644|NCT03216967|DRUG|everolimus|Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
215163645|NCT02911103|PROCEDURE|DBS surgery|Unilateral thalamic DBS therapy
215163646|NCT02911103|DEVICE|Medtronic Activa Rechargeable System|Used for diagnostic purposes.
215163647|NCT01935934|DRUG|Cabozantinib S-malate|Given PO
215163648|NCT01935934|OTHER|Laboratory Biomarker Analysis|Correlative studies
215163649|NCT01935934|OTHER|Pharmacological Study|Correlative studies
215163650|NCT05052099|DRUG|mFOLFOX6, Atezolizumab and Bevacizumab|"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"
215163651|NCT03327181|DIETARY_SUPPLEMENT|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
215163652|NCT05787808|DIETARY_SUPPLEMENT|Calsium, Vitamin D, Jarlsberg cheese|Oral
215163653|NCT05580458|BIOLOGICAL|Shingrix|Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
215163654|NCT06560398|BEHAVIORAL|Continuing Medical Education Events (CME)|An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.
215163655|NCT06560398|BEHAVIORAL|Trial Connect Portal|A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.
215163656|NCT06560398|BEHAVIORAL|Clinical Trial Newsletters|Electronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail.
215163657|NCT06560398|BEHAVIORAL|Implicit Bias Training|A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.
215163658|NCT06560398|BEHAVIORAL|Recruitment Dashboard|A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.
215163659|NCT06560398|BEHAVIORAL|Portfolio Profiler|An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment.
215163660|NCT06560398|BEHAVIORAL|Eligibility Calculator|A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.
215163661|NCT06560398|BEHAVIORAL|Clinical Trial Education Sessions (Community Residents Only)|An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.
215163662|NCT06560398|BEHAVIORAL|ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)|A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.
215163663|NCT06560398|BEHAVIORAL|New Patient Information (Moffitt Patients Only)|Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.
215163664|NCT06560398|OTHER|No Intervention|Control group with no intervention.
215163665|NCT06192160|DRUG|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
215163666|NCT06192160|DRUG|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
215163667|NCT06192160|DRUG|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
215163668|NCT06192160|DRUG|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
214558647|NCT04594044|BEHAVIORAL|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
214558648|NCT04715373|PROCEDURE|LISA|LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
214558649|NCT02649738|PROCEDURE|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
214558650|NCT02619903|PROCEDURE|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
214558651|NCT05380557|DIAGNOSTIC_TEST|Germline genetic testing|Germline genetic testing will be provided to each patient
214558652|NCT01624077|BIOLOGICAL|Regulatory T cells|Tregs will inject after liver transplantation
214558653|NCT06305052|OTHER|Milk|"Premature newborns allocated to the intervention group will receive olfactory and taste stimuli immediately before feeding through an oral/nasal gastric tube.~In the intervention group, the taste stimulus will be carried out through a drop of milk administered directly to the tongue of the premature baby if he is awake, if the newborn is sleeping the milk will be placed on his lips.~The olfactory stimulus will be offered through a drop of milk using a cotton swab, positioned close to the premature baby's nostrils as close as possible without touching them, immediately before the tube diet."
214558654|NCT06305052|OTHER|Water|In the control group, the taste stimulus will be done through a drop of double-distilled water on a cotton swab, then administered directly to the tongue of the premature baby if he is awake, however, when he is sleeping, the drop of water will be deposited on his lips. The olfactory stimulus in the control group will be carried out with a drop of double-distilled water using a cotton swab, positioned close to the nostrils as close as possible without touching them, immediately before carrying out the tube diet.
214558655|NCT01857089|DEVICE|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
214558656|NCT02179567|DRUG|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
214558657|NCT02179567|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
214558658|NCT03461159|OTHER|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
214558659|NCT03461159|OTHER|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
214558660|NCT01457898|DEVICE|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
214558661|NCT06027606|DRUG|Salbutamol 400mcg|Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma
214558662|NCT06027606|DRUG|Budesonide/formoterol|Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma
215163669|NCT06192160|DRUG|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
214558663|NCT06027606|DRUG|Placebo|Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
214558664|NCT02238418|DRUG|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
214558665|NCT04313608|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
214558666|NCT04313608|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
214558667|NCT04313608|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
214558668|NCT04313608|DRUG|Mosunetuzumab|Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
215163670|NCT06192160|DRUG|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
215163671|NCT06192160|DRUG|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
215163672|NCT06192160|DRUG|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
215163673|NCT06192160|DRUG|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
215163674|NCT06192160|DRUG|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
214705426|NCT00783172|DRUG|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
215163675|NCT06192160|DRUG|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
215163676|NCT04224493|DRUG|Tazemetostat|"Stage 1 (Phase 1b):~Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
215163677|NCT04224493|DRUG|Tazemetostat|"Stage 2:~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
215163678|NCT04224493|DRUG|Placebo oral tablet|"Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy."
214558669|NCT04313608|DRUG|Obinutuzumab|Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
215163679|NCT04224493|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
214558670|NCT04313608|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
214558671|NCT01162577|BEHAVIORAL|Weight Concerns|Standard Quitline plus weight coaching
214558672|NCT00504673|DRUG|insulin detemir|
214558673|NCT00504673|DRUG|insulin NPH|
214705427|NCT00783172|BIOLOGICAL|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
214705428|NCT03957356|DEVICE|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
214705429|NCT04929613|BEHAVIORAL|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
215163680|NCT04224493|COMBINATION_PRODUCT|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
215163681|NCT06562192|DRUG|[68Ga]Ga-NNS309|Radioligand imaging agent
215163682|NCT06562192|DRUG|[177Lu]Lu-NNS309|Radioligand therapy
215163683|NCT03053141|DEVICE|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
215163684|NCT06665646|BIOLOGICAL|CD40.HIVRI.Env (VRIPRO)|To be administered subcutaneously as 1 mg admixed with Hiltonol, Poly-ICLC as a single dose.
215163685|NCT06665646|BIOLOGICAL|Hiltonol Poly-ICLC-adjuvant|Vaccine adjuvant
215163686|NCT03075917|OTHER|Self Questionnaire|self questionnaire for allergic rhinitis control
215163687|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
215163688|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
215163689|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
214558674|NCT00504673|DRUG|insulin aspart|
214558675|NCT06160817|PROCEDURE|Conservative sharp debridement|The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
214558676|NCT03799744|GENETIC|VCN-01|Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient
214558677|NCT03799744|BIOLOGICAL|Durvalumab|Dose: 1500 mg Q4W
214558678|NCT05134987|DRUG|NNC0363-0845|Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
214558679|NCT05134987|DRUG|Insulin detemir|Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
214558680|NCT04099797|GENETIC|C7R-GD2.CART cells (IV and ICV infusion)|"Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion."
214558681|NCT04099797|GENETIC|C7R-GD2.CAR T cells (IV infusion)|Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.
214558682|NCT03079284|OTHER|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
214558683|NCT03966014|DRUG|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
214558684|NCT03966014|DRUG|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
214558685|NCT03966014|DRUG|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
214705430|NCT01924156|BIOLOGICAL|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
214705431|NCT00865189|DRUG|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
215163690|NCT06974201|DEVICE|Diabetes M bolus calculator|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
214705432|NCT00865189|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
214558686|NCT03966014|OTHER|Controls|No intervention.
214558687|NCT06435221|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
214558688|NCT06545812|DRUG|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
214558689|NCT06545812|DEVICE|Physical therapy for disc herniation|BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
214558690|NCT05827003|OTHER|Exercise|Supervised exercise program with a physiotherapist for 6 weeks, two days a week
214558691|NCT05827003|OTHER|Exercise&Topical Agent|Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
214558692|NCT05827003|OTHER|Topical Agent|Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
214558693|NCT02400216|DRUG|dual cholate|test for defining disease severity
214558694|NCT04430166|DRUG|PD-1 monoclonal antibody|200mg / intravenous drip, once every three weeks
214558695|NCT01857726|DRUG|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
214558696|NCT01857726|DRUG|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
214558697|NCT02323568|OTHER|Gynecological consultation|
214705433|NCT00865189|DRUG|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.
214558698|NCT03866369|DRUG|Moxifloxacin|Single oral dose at D-8
214558699|NCT03866369|DRUG|Placebo|Single oral dose at D-1
214558700|NCT03866369|DRUG|Lanifibranor|Single daily oral dose during 14 days
214558701|NCT03866369|DRUG|Placebo|Single daily oral dose during 14 days
214558702|NCT00656045|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
214558703|NCT00656045|BEHAVIORAL|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
214558704|NCT00656045|BEHAVIORAL|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
214558705|NCT04792476|OTHER|High Intensity Interval Training|Experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
214705434|NCT00865189|DRUG|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
214705435|NCT00865189|RADIATION|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
214558706|NCT05435053|DRUG|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
214705436|NCT00865189|PROCEDURE|Surgery|Radical rectal excision based on the TME technique.
214558707|NCT05435053|DEVICE|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
214558708|NCT03019640|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
214558709|NCT03019640|DRUG|Carmustine|Given IV
215163691|NCT06974201|DEVICE|Diabetes M app|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
214558710|NCT03019640|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
215163692|NCT03192007|DEVICE|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
215163693|NCT05086432|OTHER|Sputum-guided management|As previously described.
215163694|NCT05086432|OTHER|Standard of Care|As previously described.
215163695|NCT04789902|OTHER|SurgeCon|The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
215163696|NCT06178952|DEVICE|Transcranial pulse stimulation Verum|Participants are slated to undergo a total of five TPS sessions over a 10-day interval. Each stimulation session will endure approximately 30 minutes and will be administered once daily.
215163697|NCT06178952|DEVICE|Transcranial pulse stimulation Sham|Placebo treatment will be performed using the same medical device, handpiece and treatment paradigm as in the verum treatment with one difference: the standoff device at the end of the handpiece. This device is designed to replicate the appearance, feel, and sound of the verum system, while omitting the transmission of any pulses.
215163698|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app|"A smartphone app has been developed and is in keeping with guideline recommendations for the treatment of e-cigarette products. This app has a user-friendly Graphic User Interface (GUI) to allow users to build their own accounts and individualized contents conveniently, based on the input the users initially provide including e-cigarette use patterns, readiness to quit e-cigarette, beliefs about e-cigarette, nicotine addiction, self-efficacy, other substance use status, and parental or peer e-cigarette use status.~The proposed AI model in this app will learn information from the input data, including progress toward e-cigarette cessation (e,g, changes of readiness of quitting, quit attempts), and additional data including emotional status, stress level, feedback to the previous learning modules, and then predict the result on the fly. Based on the predicted result, the app will send in-time motivational messages and mindfulness training modules."
215163699|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app, but with delayed access|Participants in the control group will be placed on a three-month waitlist. After this period, they will receive access to the same app-based intervention as the immediate intervention group, allowing a comparison between immediate and delayed access.
215163700|NCT06078709|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163701|NCT06078709|PROCEDURE|Computed Tomography|Undergo CT and PET/CT scan
214558711|NCT03019640|DRUG|Cytarabine|Given IV
214558712|NCT03019640|DRUG|Etoposide|Given IV
214558713|NCT03019640|BIOLOGICAL|Filgrastim|Given SC
214558714|NCT03019640|DRUG|Lenalidomide|Given PO
214558715|NCT03019640|DRUG|Melphalan|Given IV
214705437|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
214705438|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
215163702|NCT06078709|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
215163703|NCT06078709|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
215163704|NCT06078709|DRUG|Fluorouracil|Given IV
215163705|NCT06078709|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215163706|NCT06078709|DRUG|Leucovorin Calcium|Given IV
215163707|NCT06078709|DRUG|Oxaliplatin|Given IV
215163708|NCT06078709|PROCEDURE|Positron Emission Tomography|Undergo PET and PET/CT scan
215163709|NCT06078709|OTHER|Survey Administration|Ancillary studies
215163710|NCT06078709|DRUG|Docetaxel|Given IV
215163711|NCT06078709|BIOLOGICAL|Durvalumab|Given IV
214558716|NCT03019640|BIOLOGICAL|Rituximab|Given IV
214558717|NCT00855647|PROCEDURE|Hypo-fractionated Radiotherapy|
214558718|NCT02977390|OTHER|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
214558719|NCT04630704|DEVICE|Pedra|Diffuse speckle contrast analysis perfusion system
214558720|NCT06579326|DIAGNOSTIC_TEST|Photoacoustic imaging|It could provide three-dimensional ultrasound images of vessels in the target area. It could also provides super-resolution and large-depth photoacoustic images. By effectively extracting photoacoustic spectral features and using spectral feature unmixing algorithm, blood oxygen saturation can be calculated.
214705439|NCT00602719|DRUG|Zolpidem|
214705440|NCT03428841|PROCEDURE|Audiometry|
214558721|NCT04300465|BEHAVIORAL|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
214558722|NCT05372107|DRUG|AG-80308|AG-80308 Eye Drop Solution
214558723|NCT03240653|OTHER|Stratified response to Enzyme Therapy|Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
214558724|NCT02741453|PROCEDURE|Standard Practice|
214558725|NCT02741453|PROCEDURE|Bilateral IJ Ultrasound Scanning|
214705441|NCT03641547|DRUG|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
214705442|NCT03641547|DRUG|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
214705443|NCT03641547|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
214705444|NCT03641547|RADIATION|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
214705445|NCT00988260|DRUG|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
214705446|NCT00988260|DRUG|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
214558726|NCT06292949|DIETARY_SUPPLEMENT|Resistant starch|Constipated patients take 1 pack of resistant starch (20g/pack) daily for 14 days
214558727|NCT01169012|DRUG|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
214558728|NCT05471531|BIOLOGICAL|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
214558729|NCT05471531|BIOLOGICAL|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
214558730|NCT02866513|OTHER|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
214558731|NCT01567631|PROCEDURE|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
214558732|NCT01567631|PROCEDURE|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
215163712|NCT06972381|BEHAVIORAL|Navigator|Participants in the navigator condition will meet with their counselor for sessions twice in month 1, once in month 2, once in month 4, and once in month 8. Three additional sessions may scheduled if desired by the participant. Navigators will assess treatment preferences, provide information about evidence-based treatment options for weight loss, aid in decision making, and facilitate action during the intervention initiation process. Following initiation of a weight loss treatment, navigators will also assess adherence to and acceptability of the selected weight loss intervention, and engage in problem solving and motivational enhancement to facilitate persistence with the original intervention or provide the support necessary for switching to an alternative intervention option. Additional intervention contact will include monthly emails over the 12 month period. Navigators will receive resource guides to help them tailor sessions to the individual participant.
214558733|NCT00668265|DRUG|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
214558734|NCT04261764|DEVICE|"Fastening-mimicking diet combined with a dispelling dampness meal replacement"|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
214558735|NCT04261764|OTHER|Normal diet|Carrying out normal diet under the guidance of a dietitian.
214558736|NCT03746587|DRUG|Arimoclomol|Arimoclomol in 3 different dosages
214558737|NCT03746587|DRUG|Placebo oral capsule|Matching placebo capsule
214558738|NCT03552952|OTHER|No intervention|No intervention
214558739|NCT04904198|BEHAVIORAL|Care Management Intervention for non-cardiac chest pain|Multicomponent eight-week care management intervention involving a consultation visit with a cardiologist and nurse. Recommendations from the consultation visit are conveyed to the primary care physician. Following the visit, the participant has eight weekly phone calls with a nurse to provide support, introduce therapeutic principals, and assess symptoms. The study nurse is supervised by a psychiatrist.
214558740|NCT04775706|DRUG|HM15912 Active|Randomized, double-blind, placebo-controlled
214558741|NCT04775706|DRUG|Placebo|Randomized, double-blind, placebo-controlled
214558742|NCT03824652|OTHER|walnuts|2 ounces of walnuts daily for 4-10 weeks
214705447|NCT00988260|DRUG|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
214705448|NCT03181074|OTHER|Non-Interventional|Non-Interventional
215163713|NCT06972355|PROCEDURE|Hiding the eyes|Patients will participate in walking rehabilitation sessions on a treadmill supported by a Lite Gait® harness. All treadmill sessions are consistent with regular rehabilitation sessions. A typical treadmill walking session will take place 3 times a week for 6 weeks, lasting 20 minutes. During the first minute, the speed of the treadmill is gradually increased until a comfortable speed is reached. From then on, the mask will be placed over the patient's eyes for 18 minutes at a constant, i.e. comfortable, speed. The last minute will be devoted to gradually decreasing the treadmill speed until it stops, and will also be performed without the mask.
214558743|NCT03824652|OTHER|usual diet|Subject continues usual diet
214558744|NCT03824652|OTHER|phone counseling with dietitian|Weekly calls with dietitian
214705449|NCT03537352|PROCEDURE|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
214705450|NCT03537352|DRUG|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
214705451|NCT01392053|OTHER|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
214705452|NCT01326117|DRUG|tadalafil|7 days of Cialis for Daily Use (5mg)
214705453|NCT05698121|DEVICE|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
214705454|NCT02368080|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
214558745|NCT05873829|OTHER|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
214558746|NCT06234514|DRUG|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
214558747|NCT06234514|DRUG|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
214558748|NCT01229878|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
214705455|NCT01464788|DRUG|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
215163714|NCT06973395|BEHAVIORAL|Nursing interventions, education, and follow-up will be provided to Type 2 diabetes patients for blood glucose variability.|Implementation of individual nursing interventions and provision of trainingIndividual nursing interventions will be applied to individuals with Type 2 diabetes regarding the risk of variability in blood glucose, and education and follow-up will be provided.
215163715|NCT05646251|DEVICE|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
215163716|NCT06366464|DRUG|Pitolisant tablet|Pitolisant tablet
215163717|NCT06366464|OTHER|Placebo tablet|Placebo tablet
214558749|NCT03329729|OTHER|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
214558750|NCT05780021|BEHAVIORAL|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
214558751|NCT05649969|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.
214558752|NCT05649969|BEHAVIORAL|Daily Food Intake Diary with Fitbit smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks
214558753|NCT05649969|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
214558754|NCT02744170|DEVICE|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
214705456|NCT01464788|DRUG|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
214705457|NCT01464788|DRUG|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
215163718|NCT06271668|OTHER|Naloxone Co-prescribing Clinical Decision Support (CDS)|Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
215163719|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
215163720|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
215163721|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
215163722|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
215163723|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
215163724|NCT05857137|DEVICE|Active TMS|Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.
215163725|NCT05857137|DEVICE|Placebo TMS|Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
215163726|NCT05317585|DEVICE|Continuous Glucose Monitor|Continuous Glucose Monitor
215163727|NCT05317585|DEVICE|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
215163728|NCT05809908|DRUG|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 2-4 weeks."
215163729|NCT05809908|DRUG|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of placebo; 80 ml total daily dose of placebo, over the course of 2-4 weeks."
215163730|NCT06136884|DRUG|AO-252|AO-252 will be administered oral tablets or capsules daily
215163731|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
215163732|NCT05250414|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
215163733|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
215163734|NCT05746520|OTHER|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
215163735|NCT04609826|DRUG|JNJ-74856665|JNJ-74856665 will be administered orally.
215163736|NCT04609826|DRUG|AZA|AZA will be administered IV infusion or SC injection.
215163737|NCT04609826|DRUG|VEN|VEN tablet will be administered orally.
215163738|NCT06481982|DIAGNOSTIC_TEST|MRI|MRI sequences
215163739|NCT04074746|BIOLOGICAL|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
215163740|NCT04074746|DRUG|Cyclophosphamide|Given IV
215163741|NCT04074746|DRUG|Fludarabine|Given IV
215163742|NCT04074746|DRUG|Fludarabine Phosphate|Given IV
214705458|NCT04394455|BEHAVIORAL|Brief cognitive behavioral therapy|9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
215163743|NCT04074746|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
215163744|NCT05956158|BEHAVIORAL|Behavioral Treatment|This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
214558755|NCT02744170|DEVICE|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
214558756|NCT02744170|DEVICE|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
215163745|NCT05956158|BEHAVIORAL|Sleep Education Treatment|This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
215163746|NCT05719441|BIOLOGICAL|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
215163747|NCT05719441|BIOLOGICAL|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
214558757|NCT05208177|DRUG|SHR-1802＋camrelizumab + famitinib|SHR-1802 for injection，q3w； Camrelizumab for injection, q3w; Famitinib malate capsules, qd.
214558758|NCT06240221|DEVICE|Elevation Spine Saber-C System|Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
214558759|NCT04539483|DRUG|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
214558760|NCT04539483|DRUG|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
214558761|NCT04539483|BEHAVIORAL|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
214558762|NCT04539483|BEHAVIORAL|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
214558763|NCT04539483|PROCEDURE|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
214558764|NCT04539483|PROCEDURE|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
214558765|NCT02265666|DRUG|BIIL 284 BS Tablet FF|
214558766|NCT02265666|DRUG|BIIL 284 BS tablet C|
214558767|NCT02265666|OTHER|standard breakfast|
214558768|NCT03617835|DRUG|R - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
214558769|NCT03617835|DRUG|T1 - Low dose of BI 655130|Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
214558770|NCT03617835|DRUG|T2 - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
214558771|NCT03617835|DRUG|T3 - High dose of BI 655130|Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
214558772|NCT06045715|OTHER|follow-up with different time intervals|After radical surgery, patients are followed up with different time intervals
214558773|NCT00753064|DRUG|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8"
214558774|NCT00753064|DRUG|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
214705459|NCT04394455|BEHAVIORAL|Crisis intervention therapy|3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
214705460|NCT01896388|DRUG|Ifenprodil Tartrate|
214705461|NCT01896388|DRUG|Placebo|
214705462|NCT00148421|DRUG|Darbepoetin alfa and Epoetin alfa|
215163748|NCT05719441|OTHER|Placebo|Sodium Chloride for Injection USP, 0.9%
215163749|NCT05719441|DRUG|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
215163750|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
215163751|NCT06545942|DRUG|Olaparib|Olaparib administered orally
215163752|NCT05189093|DRUG|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
215163753|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
215163754|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
215163755|NCT05148234|DRUG|BMS-986253|Intravenous (IV) infusion, 200 mg/Vial (20 mg/mL) or 1000 mg/vial (100mg/mL). Abbreviated Title: Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) in Myelodysplastic Syndromes 34 Version Date: 9/08/2021 outlined in Food and Drug Administration (FDA) product label.
214558775|NCT00753064|DRUG|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
214558776|NCT02831023|DRUG|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
214558777|NCT02831023|DRUG|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
214558778|NCT02831023|DRUG|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
214558779|NCT02831023|DRUG|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
214558780|NCT02831023|DRUG|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
214558781|NCT05367700|DRUG|HS-10382(Part 1: Dose escalation)|Single or multiple dose(s) of HS-10382 once daily.
214558782|NCT05367700|DRUG|HS-10382(Part 2: Dose expansion)|HS-10382 is administered orally once daily.
214558783|NCT00095953|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
214558784|NCT02817906|DRUG|ITI-007|
214558785|NCT02817906|DRUG|Placebo|
214558786|NCT05524662|DEVICE|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
214558787|NCT02305602|BIOLOGICAL|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
214558788|NCT01173432|DEVICE|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
214558789|NCT03363139|DRUG|Tirosin Kinase Inhibitors|Patients that received Tyrosin Kinase inhibitors and progressed
214558790|NCT03686423|PROCEDURE|Exercise Program|The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
214558791|NCT02833077|DEVICE|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
214558792|NCT04531020|DIAGNOSTIC_TEST|PAED measurement|The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
214558793|NCT04197375|BEHAVIORAL|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
214705463|NCT04083001|DEVICE|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
214705464|NCT02513784|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
215163756|NCT05148234|PROCEDURE|Bone Marrow Biopsy|"Bone marrow biopsy: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
214558794|NCT04197375|BIOLOGICAL|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
214558795|NCT00972322|DRUG|MK-8245|MK-8245 50 mg twice daily for 28 days
214558796|NCT00972322|DRUG|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
214558797|NCT01077518|DRUG|Ofatumumab|Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
214558798|NCT01077518|DRUG|Bendamustine infusion|Bendamustine 100 mg/vial, injection
214558799|NCT01077518|DRUG|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
214705465|NCT02943512|OTHER|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
214705466|NCT00680290|PROCEDURE|Exercise|Exercise x 8 weeks
214705467|NCT03345433|BEHAVIORAL|interactive group drumming sessions|interactive group drumming sessions
214705468|NCT05923450|PROCEDURE|Colorectal Resection|Radical resection of colorectal cancer
214705469|NCT00418379|DRUG|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
214705470|NCT00418379|DRUG|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
214705471|NCT00418379|DRUG|Placebo|Placebo tablet
215163757|NCT05148234|PROCEDURE|Bone Marrow Aspiration|"Bone marrow aspiration: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
215163758|NCT05148234|PROCEDURE|ECG|12-lead electrocardiogram (ECGs) will be performed at baseline only for safety.
215163759|NCT05437263|DRUG|Brepocitinib|Oral Brepocitinib
215163760|NCT05437263|DRUG|Placebo|Oral Placebo
214558800|NCT01077518|DRUG|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
215163761|NCT06486454|DEVICE|HistoSonics Edison System|Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors
215163762|NCT05339347|DEVICE|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
215163763|NCT05239754|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
215163764|NCT06425757|DRUG|ciprofol|Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
215163765|NCT01174108|DEVICE|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
214558801|NCT02625064|OTHER|Blood samples collection before treatment|
214558802|NCT02625064|OTHER|Blood samples collection after treatment|
214705472|NCT04240288|OTHER|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
214705473|NCT04240288|OTHER|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
214705474|NCT01790711|PROCEDURE|FMT through mid-gut|
215163766|NCT01174108|OTHER|Donor derived G-CSF mobilized PBC|Cell Therapy
215163767|NCT05400733|DIETARY_SUPPLEMENT|Total Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
214705475|NCT02834234|GENETIC|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
214705476|NCT06454851|BEHAVIORAL|Prosocial VR intervention|A four-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include four weekly sessions, each lasting between 15 to 20 minutes. Each session will depict a different daily life scenario-campus, lecture hall, canteen, and library, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
214705477|NCT06454851|OTHER|No intervention|The waitlist control group will not receive the intervention during the study.
214558803|NCT02625064|OTHER|laboratory biomarker proteomic analysis|
214558804|NCT02334579|RADIATION|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
214558805|NCT03991208|DRUG|Malarone|Malarone
214558806|NCT03439813|BEHAVIORAL|TASK-CBT|.Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
214558807|NCT03439813|BEHAVIORAL|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
215163768|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
214558808|NCT02614053|DEVICE|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI \& spHB
214558809|NCT02661191|DRUG|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
214558810|NCT04224402|DRUG|mFOLFORINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
214558811|NCT04004689|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|"Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry."
214558812|NCT05876390|PROCEDURE|Breast surgery|Breast surgery
214558813|NCT05876390|DRUG|analgesia|Multimodal analgesia
214558814|NCT05223075|DRUG|articaine local anethesia with vasoconstrictor|buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth
214558815|NCT05223075|DRUG|lidocaine local anethesia with vasoconstrictor|buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
214558816|NCT01495598|DRUG|Pomalidomide|5 mg by mouth (p.o.) for 21 of 28 days
214558817|NCT03599687|OTHER|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
214705478|NCT02786940|DEVICE|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
214708768|NCT03579225|DEVICE|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
215163769|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
214558818|NCT00121927|BEHAVIORAL|Atkins diet (15 grams/day carbohydrates)|
214558819|NCT00762775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
214558820|NCT03635372|DRUG|Alginate|10 cc of Alginate peroral
214558821|NCT03635372|DRUG|Sucralfate|10 cc of Sucralfate peroral
214558822|NCT03635372|DRUG|Hydrotalcite|10 cc of Hydrotalcite peroral
214558823|NCT05499273|PROCEDURE|scalpel-bougie tracheostomy|"1. The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~2. The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~3. Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~4. Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~5. An 8 FR Frova catheter is inserted through the orifice into trachea.~6. A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
215163770|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Leucine|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
214558824|NCT05499273|PROCEDURE|rapid sequence tracheotomy|"1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
214558825|NCT01836939|DRUG|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
214558826|NCT01836939|DRUG|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
214558827|NCT02479724|DEVICE|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
214558828|NCT01807000|DRUG|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
214558829|NCT04536129|DRUG|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
214558830|NCT05511038|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
214558831|NCT05543447|DEVICE|Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device|Flow diversion therapy fpr intracranial aneurysm treatment.
214558832|NCT01366144|DRUG|Carboplatin|Given IV
214558833|NCT01366144|OTHER|Laboratory Biomarker Analysis|Correlative studies
214558834|NCT01366144|DRUG|Paclitaxel|Given IV
214558835|NCT01366144|OTHER|Pharmacological Study|Correlative studies
214558836|NCT01366144|DRUG|Veliparib|Given PO
214558837|NCT05140915|BEHAVIORAL|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
214558838|NCT05140915|BEHAVIORAL|Peer Coaching via Text|Peer coaching, facilitated by texting
215163771|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids High|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
215163772|NCT05400733|DIETARY_SUPPLEMENT|Placebo Water|Water
215163773|NCT04557449|DRUG|PF-07220060|CDK4 inhibitor
215163774|NCT04557449|COMBINATION_PRODUCT|Letrozole|Endocrine Therapy
215163775|NCT04557449|COMBINATION_PRODUCT|Fulvestrant|Endocrine Therapy
215163776|NCT04557449|DRUG|Midazolam|Benzodiazepine used for DDI
214558839|NCT05140915|BEHAVIORAL|Gamification|Gamification, designed to motivate participation
214558840|NCT05140915|OTHER|E-Cigarette Cessation Materials|E-cigarette cessation materials by the Research Coordinator at the time of study enrollment.
215163777|NCT04557449|COMBINATION_PRODUCT|Enzalutamide|Androgen Receptor inhibitor
215163778|NCT05905575|BEHAVIORAL|Family dyad diabetes intervention|The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
215163779|NCT03061201|BIOLOGICAL|SB-525 (PF-07055480)|Single dose of investigational product SB-525 (PF-07055480)
215163780|NCT06047834|DRUG|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).
215163781|NCT06047834|OTHER|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
215163782|NCT06358209|PROCEDURE|Ventricular irrigation|Catheter ventricular irrigation can be employed by various forms. Lavage is performed with with each time at least 200ml of saline. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open.
215163783|NCT05703165|BEHAVIORAL|animal-assisted intervention|horse-assisted intervention
215163784|NCT05703165|BEHAVIORAL|watching the countryside|just watching the countryside
215163785|NCT05243797|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
215163786|NCT05243797|DRUG|Lenalidomide|Lenalidomide will be administered orally
215163787|NCT05797441|BEHAVIORAL|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
215163788|NCT05797441|OTHER|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
215163789|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
215163790|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
215163791|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
215163792|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
214558841|NCT05867407|DEVICE|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
214558842|NCT05867407|OTHER|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
214558843|NCT04078997|OTHER|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
214558844|NCT04879849|DRUG|Pembrolizumab|IV infusion.
214558845|NCT04879849|DRUG|TAK-676|IV infusion.
215163793|NCT06351579|OTHER|Control|This is an observational (registry) study for data collection only. No device or intervention will be used in this study.
215163794|NCT05827081|DRUG|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
215163795|NCT05827081|DRUG|Letrozole|Letrozole 2.5 mg orally once daily continuously
214558846|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
214558847|NCT06963957|OTHER|ChatGPT-4o Recommendations with Hallucinations|ChatGPT-4o's differential diagnoses of six clinical vignettes, three of which will contain deliberately introduced inaccurate information.
214558848|NCT05985122|DIAGNOSTIC_TEST|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
214558849|NCT02468765|OTHER|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
214558850|NCT03746392|BEHAVIORAL|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
214558851|NCT05699772|BEHAVIORAL|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
214558852|NCT05699772|BEHAVIORAL|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
214558853|NCT03810235|DRUG|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
214558854|NCT03810235|DRUG|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
214558855|NCT05593094|DRUG|ZN-A-1041|ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
214558856|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
214558857|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
214558858|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b|ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
214558859|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
214558860|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
214558861|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c|ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
214558862|NCT04777864|BEHAVIORAL|Decision Aid|In addition to usual care, participants (parents and adolescents) receive the newly developed decision aid prior to their clinic visit(s). Clinicians receive a summary to review and use to help facilitate the decision making process.
215163796|NCT05827081|DRUG|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
215163797|NCT05827081|DRUG|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
215163798|NCT05827081|DRUG|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
215163799|NCT05827081|DRUG|Exemestane|Exemestane 25 mg once daily continuously
215163800|NCT06373458|DRUG|Ritlecitinib|Ritlecitinib 50mg QD for 36 weeks starting at Day 1
215163801|NCT06432985|BEHAVIORAL|Focus Group|In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
215163802|NCT06432985|BEHAVIORAL|Contingency Management|Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
215163803|NCT06432985|BEHAVIORAL|Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
214558863|NCT05370651|DEVICE|BTL Emsella Chair|Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
214558864|NCT06457048|OTHER|Stroke Unit|The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
214558865|NCT03976414|OTHER|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
214558866|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
214558867|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
214558868|NCT04358575|DEVICE|Triathlon CS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
214558869|NCT04358575|DEVICE|Triathlon CS Knee System with metal-backed modular components|Primary Total Knee Replacement
214558870|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
214558871|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
214558872|NCT06967272|BIOLOGICAL|Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)|The controlled vaccine three doses administered orally
214558873|NCT05576662|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours
214558874|NCT05576662|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
214558875|NCT05576662|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours
214558876|NCT05323253|DEVICE|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
214558877|NCT05656807|BEHAVIORAL|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
215163804|NCT06432985|BEHAVIORAL|TUD Treatment as Usual (TAU)|Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
215163805|NCT05526313|DRUG|Purinostat Mesylate 1.2mg/m^2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
215163806|NCT05526313|DRUG|Purinostat Mesylate 2.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
215163807|NCT05526313|DRUG|Purinostat Mesylate 4.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
215163808|NCT05526313|DRUG|Purinostat Mesylate 6.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
215163809|NCT05526313|DRUG|Purinostat Mesylate 8.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
214558878|NCT05656807|BEHAVIORAL|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
214558879|NCT04929392|DRUG|Carboplatin|Given IV
214558880|NCT04929392|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
214558881|NCT04929392|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214558882|NCT04929392|DRUG|Lenvatinib Mesylate|Given PO
214558883|NCT04929392|DRUG|Paclitaxel|Given IV
214558884|NCT04929392|BIOLOGICAL|Pembrolizumab|Given IV
214558885|NCT04929392|PROCEDURE|Resection|Undergo surgical resection
214558886|NCT06019767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
214558887|NCT05534191|OTHER|Experimental, comparator and control|To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.
214558888|NCT05499832|DRUG|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
214558889|NCT06488378|DRUG|Axatilimab|Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
214558890|NCT06488378|DRUG|Olaparib|Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
214558891|NCT05841589|PROCEDURE|Green tea extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
214558892|NCT05841589|PROCEDURE|Garlic with lime extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
214558893|NCT05841589|PROCEDURE|Pomegranate extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
214558894|NCT05841589|PROCEDURE|Chlorhexidine mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
214558895|NCT01043003|OTHER|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
214558896|NCT01043003|PROCEDURE|quality-of-life assessment|Ancillary studies
214558897|NCT01043003|OTHER|Questionnaire Administration|Ancillary studies
214558898|NCT01043003|OTHER|psychosocial support for caregiver|Support for caregiver
214558899|NCT01043003|PROCEDURE|assessment of therapy complications|Ancillary study
214558900|NCT01043003|OTHER|informational intervention|Undergo evaluation sessions
214558901|NCT00281268|PROCEDURE|pulmonary artery catheter|
214558902|NCT00281268|PROCEDURE|central venous catheter|
214558903|NCT00281268|PROCEDURE|fluid management|
215163810|NCT05526313|DRUG|Purinostat Mesylate 11.2mg/m^2|Take the medicine once on D1, D8, D11, D15.
215163811|NCT05526313|DRUG|Purinostat Mesylate 15mg/m^2|Take the medicine once on D1, D8, D11, D15.
215163812|NCT06975059|DEVICE|NUSHU shoe|The NUSHU shoe, created by Magnes AG, can measure real-time detection of gait analysis while providing vibrotactile stimulus to the study participant through machine learning sensors. This may provide a feedback mechanism that acts as therapy for gait difficulties.
215163813|NCT05653349|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
215163814|NCT05653349|DRUG|Placebo|Intravenous infusion, prepared from matching placebo
215163815|NCT05653349|DRUG|Corticosteroids|Oral or parental (if clinically justified)
214558904|NCT03350399|DIAGNOSTIC_TEST|placenta growth factor|estimation level of derum placenta growth factor
214558905|NCT01217437|BIOLOGICAL|Bevacizumab|Given IV
214558906|NCT01217437|DRUG|Irinotecan Hydrochloride|Given IV
214558907|NCT01217437|DRUG|Temozolomide|Given PO
214558908|NCT00441922|DRUG|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
214558909|NCT00441922|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
214558910|NCT00871286|PROCEDURE|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
214558911|NCT00871286|PROCEDURE|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
214558912|NCT03682185|BEHAVIORAL|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
214558913|NCT03682185|BEHAVIORAL|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
214558914|NCT00350727|DRUG|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
214558915|NCT00350727|DRUG|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
215163816|NCT06098690|BEHAVIORAL|Culturally Tailored Multimedia Psychoeducational HPV Intervention|The culturally tailored multimedia psychoeducational intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
215163817|NCT06098690|BEHAVIORAL|General HPV Multimedia Psychoeducational Control Group|The general/publicly available multimedia intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
214558916|NCT04908631|DEVICE|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
214705479|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
214705480|NCT00565058|BIOLOGICAL|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
214705481|NCT03360045|DRUG|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
214705482|NCT03360045|DRUG|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
214705483|NCT03360045|DEVICE|Merocel|Merocel packing is applied.
214705484|NCT00869388|BIOLOGICAL|rBBX-01|
214705485|NCT05768425|DIAGNOSTIC_TEST|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
214705486|NCT05768425|DIAGNOSTIC_TEST|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
214705487|NCT05768425|DIAGNOSTIC_TEST|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
214705488|NCT01992848|OTHER|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
214705489|NCT01992848|OTHER|4-day food diary|
214705490|NCT01992848|OTHER|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
214705491|NCT01992848|RADIATION|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
214705492|NCT04861948|DRUG|IBI188|intravenous
214705493|NCT04861948|DRUG|GM-CSF|subcutaneous injection
214705494|NCT04861948|DRUG|Cisplatin/Carboplatin|intravenous
214705495|NCT04861948|DRUG|Bevacizumab|intravenous
214705496|NCT04861948|DRUG|Sintilimab|intravenous
214558917|NCT04908631|OTHER|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
214705497|NCT04861948|DRUG|Pemetrexed|intravenous
214558918|NCT06374095|DRUG|RATG|Thymoglobulin, Genzyme corporation, Italy.
214705498|NCT02776501|DRUG|Coppertone (BAY987521)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
214705499|NCT02879981|DRUG|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
214705500|NCT02879981|DRUG|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
214705501|NCT02879981|DRUG|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
214705502|NCT02072512|DRUG|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
214705503|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
214558919|NCT06374095|DRUG|Basiliximab|Simulect, Novartis, Italy.
214558920|NCT01760798|DRUG|Teriparatide|
214558921|NCT00518895|DRUG|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
214558922|NCT00518895|DRUG|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
214705504|NCT02072512|DRUG|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
215163818|NCT03412877|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
214705505|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
214705506|NCT06182540|DIETARY_SUPPLEMENT|Mango puree|Mango puree 300g
214705507|NCT00830804|DRUG|Raltegravir|400 mg tablet taken orally twice daily
214705508|NCT00830804|DRUG|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
215163819|NCT03412877|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
215163820|NCT03412877|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
214705509|NCT01794481|PROCEDURE|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
214705510|NCT01160341|DRUG|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
214705511|NCT01259635|DEVICE|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
214705512|NCT01319916|DRUG|ATX-101|ATX-101 2mg/cm2
214705513|NCT00510068|DRUG|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
215163821|NCT03412877|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
215163822|NCT03412877|DRUG|Pembrolizumab (KEYTRUDA(R))|Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
215163823|NCT05536804|DRUG|Tirzepatide|Administered SC
214705514|NCT00510068|DRUG|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
215163824|NCT05536804|DRUG|Placebo|Administered SC
215163825|NCT06389357|BEHAVIORAL|training and counselling|It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions. Separate educational modules have been developed for parents, teachers, and peers.
215163826|NCT06389357|OTHER|Interview|As part of the needs assessment in Phase 1, individual interviews with children with cancer and their parents lasting approximately 20-30 minutes were conducted.
215163827|NCT06335875|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 19 g (=12.5 g active C8-KE) of Juvenescence Cognitive Switch™ diluted in water, twice per day
214705515|NCT06423872|DRUG|ZT002|Participants will receive a single subcutaneous (SC) ZT002 injection.
214705516|NCT06423872|OTHER|Placebo|Participants will receive same volume as of the study drug.
214705517|NCT03220711|DEVICE|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
215163828|NCT06335875|BEHAVIORAL|Low Glycemic Index Diet|Participants will practice four dietary changes: 1. Not consuming sweets/candy, 2. Not consuming soda, 3. Replacing 'white' grains with complex carbohydrates such as brown rice or quinoa, and 4. Reserving any fruit consumption for the end of meals.
215163829|NCT05698316|DIAGNOSTIC_TEST|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
215163830|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
215163831|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
215163832|NCT06337318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163833|NCT06337318|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
215163834|NCT06337318|BIOLOGICAL|Mosunetuzumab|Given SC
215163835|NCT06337318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
215163836|NCT06337318|BIOLOGICAL|Rituximab|Given IV
215163837|NCT06337318|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
215163838|NCT03835429|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
215163839|NCT00018057|BEHAVIORAL|Attention Bias Modification Training|The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
215163840|NCT00018057|DRUG|Fluoxetine|Randomized assignment.
215163841|NCT06256562|DRUG|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
215163842|NCT06256562|OTHER|Placebo|Administered the same volume as GZR18
215163843|NCT03062358|BIOLOGICAL|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
215163844|NCT03062358|DRUG|placebo|Normal saline solution administered as an IV infusion Q3W
215163845|NCT03062358|OTHER|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
215163846|NCT06649045|DRUG|Orforglipron|Administered orally.
215163847|NCT06649045|DRUG|Placebo|Administered orally.
215163848|NCT06576076|BEHAVIORAL|Contingency management for cannabis abstinence|Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
215163849|NCT05259410|BEHAVIORAL|TRE|All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
215163850|NCT05259410|BEHAVIORAL|MedTRE|A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
215163851|NCT00968500|BEHAVIORAL|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
215163852|NCT01915212|BIOLOGICAL|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
215163853|NCT01915212|OTHER|Placebo|Sodium Chloride 0.9%
214705518|NCT03220711|DRUG|Fluorescein|Fluorescent dye used for imaging contrast only.
214705519|NCT00931476|DRUG|somatropin|
214705520|NCT00931476|DRUG|placebo|
214705521|NCT03809832|DIAGNOSTIC_TEST|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
214705522|NCT04198233|DRUG|Diazepam|Diazepam 10 mg compounded suppository
214705523|NCT04198233|DRUG|Placebos|Placebo suppository
214705524|NCT05688072|OTHER|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
214705525|NCT05688072|OTHER|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
214705526|NCT05928676|DIETARY_SUPPLEMENT|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
214558924|NCT05691608|BIOLOGICAL|Solid tumor and CT DNA|Biopsy and blood sample
214558925|NCT06975423|DEVICE|Active lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis provides real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
214558926|NCT06975423|DEVICE|Inactive lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis does not provide real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
214558927|NCT06398912|OTHER|Music Based Intervention|Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
214558928|NCT00178451|DRUG|Abciximab|
214558929|NCT05774288|DEVICE|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
214558930|NCT05774288|DEVICE|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
214558931|NCT00036348|DRUG|Aripiprazole|
214558932|NCT03732768|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
214705527|NCT04799067|OTHER|observational study|no study drug involved, observational study.
214705528|NCT04504435|DRUG|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
214705529|NCT04504435|DRUG|Placebo|Matching placebo capsules will be provided
214705530|NCT02180217|DRUG|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
214558933|NCT03520712|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
214558934|NCT07122180|DEVICE|CT3 Series Continuous Glucose Monitoring System:|The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated
214558935|NCT02478645|DRUG|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
214558936|NCT02478645|DRUG|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
214558937|NCT02478645|DRUG|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
214558938|NCT06812988|DRUG|SAR442970|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
214558939|NCT06812988|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
214558940|NCT05181787|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
214558941|NCT05181787|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
214558942|NCT06982963|BIOLOGICAL|FB102|FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.
214705531|NCT02180217|DRUG|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
214705532|NCT03472599|OTHER|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
214705533|NCT04753047|OTHER|No intervention|No intervention
215163854|NCT05347875|OTHER|Walking aid skills app|"The interventional app teaches users how to fit, walk with, and navigate stairs and chairs with a walking aid. It contains instructional videos with key components of these skills highlighted. The user can use their phone's video to record themselves performing the taught skills to enable them to review their usage of the walking aids."
214558943|NCT06982963|OTHER|Placebo|Placebo
214558944|NCT06983327|BEHAVIORAL|Trauma Focused Emotional Awareness and Expression Therapy (EAET)|The intervention is three-session program which includes pain neuroscience education, education on the relationship between trauma and chronic pain, and skills training to reduce pain- and stress-related symptoms.
214558945|NCT03198026|DRUG|Ibrutinib|Given PO
214558946|NCT03198026|BIOLOGICAL|Obinutuzumab|Given IV
214558947|NCT03198026|OTHER|Laboratory Biomarker Analysis|Correlative studies
214558948|NCT06522269|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
214705534|NCT03685526|DEVICE|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
214705535|NCT06081673|DRUG|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
214705536|NCT06081673|DRUG|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
214705537|NCT06081673|DRUG|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
214558949|NCT06522269|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
214558950|NCT06663163|OTHER|Observation|This study was an observational study without intervention
214558951|NCT04584476|PROCEDURE|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
214558952|NCT04584476|PROCEDURE|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
214558953|NCT03841526|DRUG|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
215163855|NCT05347875|OTHER|Breathing skills app|This app has the same interface as the ICanWALK app. Instead, it teaches deep breathing for stress relief and breathing to improve lung function.
215163856|NCT06572852|OTHER|No intervention|No intervention
215163857|NCT06083090|PROCEDURE|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
215163858|NCT06083090|PROCEDURE|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
215163859|NCT05536141|DRUG|casdatifan|Administered as specified in the treatment arm
214558954|NCT03841526|OTHER|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
214558955|NCT03841526|DRUG|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
214558956|NCT06824194|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214558957|NCT06824194|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214558958|NCT06824194|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214558959|NCT06824194|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
214558960|NCT06824194|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
214558961|NCT06824194|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214558962|NCT06824194|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214558963|NCT06824194|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
214558964|NCT06824194|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
214558965|NCT06824194|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
214558966|NCT00886353|BIOLOGICAL|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
214558967|NCT00886353|OTHER|Placebo|Physiological saline administrated i.v.
214558968|NCT03119883|OTHER|5-Carbon C 13-labeled Glutamine|Given IV
214558969|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214558970|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
214558971|NCT03119883|OTHER|Uniformly-labeled [13C]glucose|Given IV
214705538|NCT05005091|DIETARY_SUPPLEMENT|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
214705539|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
214705540|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
214705541|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
214705542|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
214705543|NCT05843305|DRUG|BPI-452080|Subjects will receive BPI-452080 until disease progression
215163860|NCT05536141|DRUG|Cabozantinib|Administered as specified in the treatment arm
215163861|NCT05536141|DRUG|Zimberelimab|Administered as specified in the treatment arm
215163862|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
215163863|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
214558972|NCT06004037|DRUG|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
214558973|NCT07006220|BEHAVIORAL|COPE Program|"The COPE Program (Coping Options for Parent Empowerment) is a brief, structured, transdiagnostic intervention designed to enhance parents' emotional regulation skills, improve parenting strategies, and foster a positive family environment. The program consists of four in-person group sessions, each lasting 90 minutes, conducted over four consecutive weeks.~Each session focuses on specific emotional regulation and parenting skills:~Session 1: Understanding emotional responses and parenting strategies based on positive reinforcement, selective attention, and empathy.~Session 2: Identifying family values, promoting healthy routines, and planning alternative parenting behaviors.~Session 3: Practicing mindfulness techniques and modeling emotional regulation in the presence of children.~Session 4: Addressing intolerance to uncertainty, cognitive distortions, and promoting healthy independence in adolescents."
214558974|NCT06389786|PROCEDURE|Bilateral Pelvic Lymph Node Dissection|Undergo bilateral pelvic lymph node dissection
214558975|NCT06389786|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
214558976|NCT06389786|PROCEDURE|Bone Scan|Undergo bone scan
214558977|NCT06389786|PROCEDURE|Computed Tomography|Undergo CT
214558978|NCT06389786|OTHER|Electronic Health Record Review|Ancillary studies
214558979|NCT06389786|OTHER|Flotufolastat F-18 Gallium|Given IV
214558980|NCT06389786|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic radical prostatectomy
214558981|NCT06389786|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
214558982|NCT06389786|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214558987|NCT07025148|DRUG|Prasugrel|Prasugrel 5 mg od for 30 ± 5 days
214558988|NCT07025148|DRUG|Clopidogrel|Clopidogrel 75 mg od for 30 ± 5 days
214705544|NCT05239312|DRUG|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
214705545|NCT04968340|PROCEDURE|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
214705546|NCT04968340|PROCEDURE|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
214705547|NCT02022696|GENETIC|Lentiviral Gene Transfer|
214705548|NCT00208312|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
214558990|NCT06699706|OTHER|Continuous theta-burst stimulation|"cTBS targets two regions: the dorsolateral prefrontal cortex (dlPFC) and the M1 area. Before the first treatment, each participant's resting motor threshold (RMT) will be determined using a five-step procedure for the primary motor cortex. RMT is defined as the minimum intensity required to elicit a motor response greater than 50 µV in at least 5 out of 10 consecutive trials in the right first dorsal interosseous muscle.~Participants will then undergo daily cTBS treatment three times a day for 7 consecutive days. Each stimulation session lasts 40 seconds, consisting of triplets of 50 Hz theta-burst stimulation repeated at 5 Hz, delivering a total of 600 pulses. Stimulation of the dlPFC target will be immediately followed by stimulation of the M1 target. To achieve cumulative aftereffects, the protocol will be repeated three times per day (a total of 3600 pulses/day) with two 15-minute breaks between sessions, timed with a stopwatch."
214705549|NCT00208312|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
214558991|NCT06699706|OTHER|sham continuous theta-burst stimulation|The treatment pattern for the sham continuous theta-burst stimulation was similar to that for real stimulation. The sham coil is identical in appearance to the active coil, but it only produces sounds and sensations similar to those of the active coil on the scalp without generating a current, preventing participants from identifying their group assignment.
214558992|NCT07138248|BIOLOGICAL|2D Transvaginal Ultrasound|Three-dimensional transvaginal ultrasound used to assess the same outcomes as 2D, providing volumetric imaging and coronal reconstruction to detect displacement or malposition of the IUD
214558993|NCT07135830|OTHER|Handball training|Athletes will perfrom their regular handball training
214558994|NCT07135466|OTHER|CD22 CAR-T cells|CD22 CAR-T cells
214558995|NCT07137130|DRUG|Concentrated secretome Injection 3 mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
214558996|NCT07137130|DRUG|Concentrated secretome Injection 3 mL with addition of TGF Beta 3|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
214558997|NCT07138157|OTHER|External Focus Exercises|The commands given during the exercises will encourage the participants to focus their attention on the effect of the movement/ external focus of attention
214558998|NCT07138157|OTHER|Internal Focus Exercises|The commands given in the second group will encourage the participants to focus their attention on the body part performing the movement/ Internal focus of attention
214558999|NCT07136948|BEHAVIORAL|Mindfulness Meditation|Participants will be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. The control group will not see the graph tracking their physiological responses or the predictive mindfulness skill scores based on the algorithm development.
214559000|NCT07136948|BEHAVIORAL|Mindfulness Meditation with Respiration Feedback Chart and Predictive Mindfulness Skill Scores|Participants will then be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. Following the guided meditation lessons, a subset of participants (the experimental group) will see a graph tracking their physiological responses from the guided meditation lesson and predictive mindfulness skill scores based on our algorithm development. The feedback chart is produced by the physiological measures tracked throughout the duration of the lesson, and is displayed within the Equa app, moments after the meditation lessons concludes.
214559001|NCT07137494|BIOLOGICAL|MB-CART19.1 Cellular Therapy|MB-CART19.1 will be infused as a single infusion during an inpatient admission.
214705550|NCT06048237|DIAGNOSTIC_TEST|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
214705551|NCT00535015|DRUG|Betamarc|2 tabs BID
215163864|NCT05883436|DEVICE|DEXA-C Cervical Interbody System|The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
214559002|NCT07136831|DEVICE|Primary Percutaneous Coronary Intervention (PPCI)|A catheter-based invasive procedure used to open blocked coronary arteries in patients presenting with ST-elevation myocardial infarction (STEMI).
214559003|NCT07033130|DEVICE|OMRP R2 + Percepolis Accessory Software|The Oticon Medical Research Platform Release 2 (OMRP R2) + Percepolis Accessory Software is an investigational or research tool that includes hardware, firmware and software elements, which can connect to an Oticon Medical Cochlear Implant (CI). It is intended to be used exclusively for research with Oticon Medical CI users participating in research experiments or clinical studies. The hardware components are referred to as 'OMRP R2' and the software components are called 'Percepolis Accessory Software'.
214559004|NCT07033130|DEVICE|Nuc8 Sound Path|Nuc8 is the sound path used in Cochlear Nucleus Sound Processors.
214559005|NCT07033130|DEVICE|Neu2 Sound Path|Neu2 is the sound path that is currently used in the Neuro 2 Sound Processor.
214559006|NCT07135518|BEHAVIORAL|Compassion Focused Staff Support|The Compassion Focused Staff Support (CFSS) intervention is designed to promote emotional resilience, compassion, and affect regulation. The intervention begins with a half-day introductory workshop covering the evolution-informed model of emotion regulation, the three-affect system framework, social mentalities, and the nature of compassion. This workshop provides psychoeducation and experiential exercises to introduce key concepts. Following the workshop, staff participate in six monthly 60-minute team sessions over a six-month period. These sessions involve reflective dialogue, experiential exercises, compassion-focused practices, and group-based exploration of emotionally challenging work situations.
214559007|NCT07135518|BEHAVIORAL|CFT Workshop|Participants attend a single half-day workshop providing psychoeducation and experiential exercises on compassion, affect regulation, and social mentalities based on Compassion Focused Therapy.
214559008|NCT07137663|OTHER|Educational and practical intervention on menstrual cup use|The intervention implemented in this study is a unique approach tailored to menstrual hygiene management among women who use wheelchairs. What distinguishes this intervention from others is the combination of both education and practical support for menstrual cup use. While menstrual hygiene management in the literature generally targets the general population, this study specifically addresses the unique needs and challenges faced by women with disabilities by providing individualized menstrual cup selection and usage guidance. Additionally, the intervention includes repeated follow-ups over six menstrual cycles, allowing continuous support and monitoring of the participants' experiences. This approach aims not only to improve hygiene practices but also to enhance user satisfaction and long-term adherence. The comprehensive and personalized nature of this intervention differentiates it from most existing studies and seeks to offer practical, sustainable solutions for menstrual hygiene
214559009|NCT07138313|OTHER|Low-fat dietary intervention|Low-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
214559010|NCT07138313|OTHER|High-fat dietary intervention|High-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
214559011|NCT07137819|DRUG|Topical treatment|Self-treatment of patients with ointment of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
214705552|NCT02289482|DRUG|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
214705553|NCT02289482|DRUG|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
214705554|NCT02289482|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
215163865|NCT04454528|RADIATION|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
215163866|NCT04454528|DRUG|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
215163867|NCT04454528|PROCEDURE|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
215163868|NCT06807983|DIAGNOSTIC_TEST|diagnostic strategy based on lung and cardiac ultrasonography|cardiopulmonary ultrasound performed by the emergency physician, immediately at patient's bed
215163869|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
215163870|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
214559012|NCT07135908|BEHAVIORAL|solution-oriented approach|"In this study, the solution-focused intervention was a structured psychosocial support program based on the principles of Solution-Focused Brief Therapy (SFBT). It consisted of six weekly sessions, each lasting 60 minutes, and was designed to help institutionalized children improve their hope levels and social participation skills.~The sessions included:~Enhancing communication and interpersonal skills~Identifying personal strengths and sources of hope~Developing social engagement strategies~Teaching simple problem-solving techniques~The approach focused on children's existing resources and future goals rather than their past problems. It encouraged positive thinking, goal setting, and active participation, promoting emotional resilience and social functioning."
214559013|NCT07136064|BEHAVIORAL|Emotion Regulation Skills Training|This arm will receive training in emotion regulation skills, including mindfulness skills to help redeploy their attention, cognitive reappraisal skills to analyze stimuli or emotion-eliciting events from a more comprehensive perspective, situation change skills to regulate emotions by exposing oneself to nature, and experiential acceptance skills through self-talk. This arm will also receive training in theories of the family emotion system.
214559014|NCT07136064|BEHAVIORAL|Moderation in Consumer Electronics Use Training|This arm will be trained to moderate their and their family members' use of commercial electronics. They will do so by learning mechanisms behind addictions, family communication skills, and various substitute activities for commercial electronics usage.
214559015|NCT07136779|DRUG|VBC101|VBC101
214559016|NCT07138079|OTHER|edentulous geriatric patients|Edentulous geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
214559017|NCT07138079|OTHER|dentate geriatric patients|Dentate geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
214559018|NCT07136532|DIAGNOSTIC_TEST|echocardiography|"Echocardiography will be performed using the ultrasound system echocardiographic equipment (Siemens Advanced Clinical Ultrasound Systems Optimized Navigation (ACUSON) P500), carotid doppler ultrasonography (Carotid blood flow and Corrected flow time) by using the ultrasound system echocardiographic equipment (Siemens ACUSON P500) .~Those measurements will be done at time zero and upon completion of fluid resuscitation .~• Statistical Analysis: All data will be collected, tabulated, and statistically analysed using International Business Machines\_Statistical Package for the Social Sciences (IBM SPSS) version 27."
214559019|NCT07135752|OTHER|Precision assessment|Digital tools, imaging markers and biological markers
214559020|NCT07137637|DRUG|HPB-092 tablet|HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles. This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays a crucial role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in acute myeloid leukemia (AML) and other malignancies.
214559021|NCT07137832|COMBINATION_PRODUCT|Intra-arterial thrombolysis as adjunct to endovascular treatment|Intra-arterial thrombolysis as adjunct to endovascular treatment, in addition to standard medical treatment
214559022|NCT07137832|OTHER|Standard medical treatment|Standard medical treatment
214559023|NCT07136987|DRUG|Metformin|Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment
214559024|NCT07136987|DIETARY_SUPPLEMENT|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment
214559025|NCT07136987|COMBINATION_PRODUCT|Standard TB treatment|Standard TB treatment
214705555|NCT02289482|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
214705556|NCT05692648|BEHAVIORAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
215163871|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
215163872|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
215163873|NCT06730256|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion chimeric antigen receptor T cells
215163874|NCT04628663|DRUG|Dexmedetomidine|Administration
215163875|NCT04628663|OTHER|Normal Saline|Administration
215163876|NCT06350760|BEHAVIORAL|Active control condition|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021.
215163877|NCT06350760|BEHAVIORAL|PROCARE-I+ 8-session|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021. In addition, PROCARE-I+ adds additional modules, which allow adolescents to be provided with tools to address the risk factors they present.
215163878|NCT05051527|DRUG|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
215163879|NCT05358808|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
215163880|NCT04745676|BEHAVIORAL|Telehealth|Telehealth ACP intervention advance care planning intervention
215163881|NCT04745676|BEHAVIORAL|Control|For the control arm, no telehealth visit will be scheduled.
215163882|NCT03396081|BEHAVIORAL|PRADO-IC|"1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
215163883|NCT03396081|BEHAVIORAL|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
215163884|NCT05133427|DEVICE|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
215163885|NCT04001777|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
215163886|NCT04001777|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
215163887|NCT06444867|DRUG|LEO 158968|SC injection
214559026|NCT07137975|OTHER|autogenous bone plug|"Preoperative assessment of the alveolar defect began with intraoral examination to check a proper transverse relationship between the maxillary segments and the presence of a normal upper arch form.~After the decision on alveolar bone grafting, Radiologic data from the cleft area will be required. Standard protocol is to take a high resolution CT scan of the patient's skull or at least the whole maxilla. Using the DICOM data acquired from the cleft area the bony defect will be segmented with specific software, in our daily routine blender for dental is used. The same program could be used to design the rough shape of the nasoalveolar graft, and this image could be exported in STL (standard tessellation language) format. and once the desired form is aquired, the final step is to construct a mold. For this purpose, the open-source software Blender (Blender Foundation, Amsterdam, and The Netherlands) will be used. After preoperative planning, the designed mold will be printed using polyam"
215163888|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
215163889|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
215163890|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
215163891|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
214559027|NCT07137975|OTHER|regular autogenous bone grafting|Gold standard grafting of alveolar cleft
214559028|NCT07135635|DIAGNOSTIC_TEST|Middle Cerebral Artery doppler|All cases of pregnant women diagnosed with anemia at 3rd trimester will have baseline assessment of history, clinical examination, HB level, obstetric ultrasonography done then they will have Middle Cerebral Artery Doppler done to assess correlation between MCA Doppler indices \& neonatal outcomes. Then appropriate treatment of anemia will be taken.
214559029|NCT07136025|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
214559030|NCT07136025|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
214559031|NCT07136662|OTHER|educational|see arm description
214559032|NCT07136844|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214559033|NCT07136844|DIAGNOSTIC_TEST|Dynamometric measurements of muscle strength|Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.
214559034|NCT07136844|DIAGNOSTIC_TEST|The 6-minute walk test (6MWT)|This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.
214559035|NCT07136844|DIAGNOSTIC_TEST|The 10-meter test (10MWT)|During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.
214559036|NCT07136844|DIAGNOSTIC_TEST|The 4 stair-climbing test (4SC)|This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.
214559037|NCT07136844|DIAGNOSTIC_TEST|Test of rising from the floor (TRF)|This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.
214559038|NCT07136844|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
215163892|NCT06210386|DEVICE|Noninvasive ventilation|noninvasive ventilation
215163893|NCT05831111|BIOLOGICAL|mRNA-1195.1|Sterile liquid for injection
215163894|NCT05831111|BIOLOGICAL|mRNA-1195.2|Sterile liquid for injection
215163895|NCT05831111|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
215163896|NCT05831111|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
215163897|NCT05831111|BIOLOGICAL|mRNA-1195|Sterile liquid for injection
214559039|NCT07136844|DIAGNOSTIC_TEST|The Progressive Supranuclear Palsy Rating Scale (PSP-RS)|This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.
214559040|NCT07136844|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment (MOCA)|The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.
214559041|NCT07136844|DIAGNOSTIC_TEST|The Charcot-Marie-Tooth examination score (CMTES)|The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.
214559042|NCT07136844|DIAGNOSTIC_TEST|9-Hole Peg Test (9-HPT)|The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.
214559043|NCT07136844|DIAGNOSTIC_TEST|The Unified Huntington's Disease Rating Scale (UHDRS)|This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.
214559044|NCT07136844|DIAGNOSTIC_TEST|Quantitative Myasthenia Gravis (QMG)|The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).
214705557|NCT05692648|BEHAVIORAL|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
214705558|NCT05692648|BEHAVIORAL|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
214705559|NCT05463042|BEHAVIORAL|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
214705560|NCT05463042|BEHAVIORAL|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
214705561|NCT01869062|DEVICE|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
214705562|NCT01869062|DEVICE|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
214705563|NCT02416362|OTHER|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
214705564|NCT02416362|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
214705565|NCT04534569|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
214705566|NCT03230344|PROCEDURE|open flap debridement|open flap debridement simultaneously with root canal treatment
214705567|NCT03230344|PROCEDURE|open flap debridement|open flap debridement and delayed root canal treatment
214705568|NCT02472925|BEHAVIORAL|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
214705569|NCT03487640|PROCEDURE|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
214705570|NCT03487640|PROCEDURE|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
214705571|NCT04958616|DIAGNOSTIC_TEST|Skin prick test.|Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
214705572|NCT02695706|DEVICE|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
214705573|NCT00645567|DEVICE|Unassisted Manual Transfer|No device assistance
214705574|NCT00645567|DEVICE|Standard Transfer Board|Flat surface board
214705575|NCT00645567|DEVICE|Glide n' Go|Flip down power lift chair
214705576|NCT00645567|DEVICE|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
214705577|NCT00645567|DEVICE|Ryno lift|Lift for the wheelchair
214559045|NCT07136844|DIAGNOSTIC_TEST|The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL)|This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.
214559046|NCT07136844|DIAGNOSTIC_TEST|The Scale for the Assessment and Rating of Ataxia (SARA)|This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.
214559047|NCT07136844|OTHER|Patient's Global Impression of Change (PGIC)|PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.
214559048|NCT07136480|DEVICE|Microwave Diathermy|Continuous mode microwave diathermy (2,450 MHz) will be applied to the lumbar region using a standard physiotherapy unit. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
214705578|NCT04664855|OTHER|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
214705579|NCT05602610|OTHER|No intervention|No intervention
214705580|NCT00353964|DRUG|rEV131|
214705581|NCT00353964|DRUG|Prenisolone sodium phosphate 1.0%|
214705582|NCT00353964|DRUG|rEV131 vehicle|
214705583|NCT02219087|DRUG|Liposomal bupivacaine|
214705584|NCT02219087|DRUG|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
214705585|NCT06429878|DIAGNOSTIC_TEST|Biparametric prostatic MRI|
214705586|NCT00156299|DRUG|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
215163898|NCT03513185|DRUG|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
214705587|NCT00156299|DRUG|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
214705588|NCT00153894|BEHAVIORAL|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
215163899|NCT04241835|DRUG|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
215163900|NCT03861273|BIOLOGICAL|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
214559049|NCT07136480|DEVICE|Shortwave Diathermy|Continuous mode shortwave diathermy (27.12 MHz) will be delivered to the lumbar region using capacitive or inductive electrodes according to manufacturer guidelines. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
214705589|NCT00153894|BEHAVIORAL|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
214705590|NCT04811469|DRUG|CBP-174|CBP-174 oral solution, given once
214705591|NCT04811469|DRUG|Placebo|Placebo oral solution, given once
214705592|NCT03093961|DEVICE|IASD implant|Single arm for implant
214705593|NCT02389673|DEVICE|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
214705594|NCT02760017|DRUG|B. forficata|
214705595|NCT02760017|DRUG|Placebo|
214705596|NCT01912716|DRUG|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
214705597|NCT01912716|DRUG|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
214705598|NCT01632735|BEHAVIORAL|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
214705599|NCT00900913|DRUG|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
214705600|NCT00118508|DRUG|risedronate (including placebo)|risedronate 35mg weekly
214705601|NCT03829865|DIAGNOSTIC_TEST|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
214705602|NCT04840706|DEVICE|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
214705603|NCT04840706|OTHER|Standard care|No HFNC treatment
214705604|NCT02352805|DEVICE|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
214705605|NCT04387994|OTHER|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
214705606|NCT05696262|BEHAVIORAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
214705607|NCT03435263|OTHER|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
214705608|NCT02300428|DIETARY_SUPPLEMENT|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
215163901|NCT05860699|DRUG|Placebo|Placebo made by the same manufacturer to look like the active pills
215163902|NCT05860699|DRUG|Half dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
215163903|NCT05860699|DRUG|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
215163904|NCT06366282|BEHAVIORAL|Caregiver Counseling for Childhood Traumatic Injury|Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
215163905|NCT06366282|BEHAVIORAL|Standard of Care for Childhood Traumatic Injury|Control group receives the current standard of care provided by the counseling team
215163906|NCT02963272|OTHER|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
215163907|NCT02963272|OTHER|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
215163908|NCT05012410|BEHAVIORAL|Immediate treatment group with High-Intensity Prompts|Caregivers in the immediate treatment group with high-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive telephone and email prompts to use the tool.
215163909|NCT05012410|BEHAVIORAL|Immediate treatment group with Low-Intensity Prompts|Caregivers in the immediate treatment group with low-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive email prompts to use the tool.
215163910|NCT05012410|BEHAVIORAL|Waitlist Control after three months with High-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive telephone and email prompts. Once the caregiver receives the WeCareAdvisor tool, they will receive a weekly automated email as well as a weekly telephone call from study staff to prompt them to use the tool.
215163911|NCT05012410|BEHAVIORAL|Waitlist Control after three months with Low-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive email prompts.
214559050|NCT07136480|DEVICE|Therapeutic Ultrasound|Continuous mode therapeutic ultrasound at 1 MHz frequency and 1.5 W/cm² intensity will be applied to the lumbar paraspinal muscles with slow circular movements using a coupling gel. Treatment will last 10 minutes per session, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
214559051|NCT07136480|BEHAVIORAL|Lumbar Stabilization and Flexibility Exercise|Participants will perform a home-based lumbar stabilization exercise program, including stretching, core strengthening, and posture correction exercises, supervised weekly by a physiotherapist. The program will be performed 3 sessions per week for 4 consecutive weeks.
214559052|NCT04571541|DEVICE|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
214559053|NCT06888557|BEHAVIORAL|Smartphone-based self-management support program ( 3S-C)|The 3S-C include: (1) two 30-minute individual sessions ; (2) a set of instant messages, 10-minute telephone-delivered health coaching ; (3) continuous personalized chat-based messaging, phone call support, and hotline service ; (4) an e-platform for goal setting and self-monitoring ; (5) A mutual support group session.
214559054|NCT07044401|DRUG|KAI-9531|SC Injection.
214559055|NCT04047862|DRUG|Ociperlimab|Administered as an intravenous (IV) injection
214559056|NCT04047862|DRUG|Tislelizumab|Administered as an IV injection
215163912|NCT05395390|BEHAVIORAL|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
215163913|NCT06730932|DRUG|JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)|"Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol"
215163914|NCT03677739|OTHER|Informational Intervention|Receive information focusing on skin cancer
214559057|NCT04047862|DRUG|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
214559058|NCT04047862|DRUG|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
214559059|NCT04047862|DRUG|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
215163915|NCT03677739|OTHER|Informational Intervention|Receive information on healthy lifestyle
215163916|NCT03677739|OTHER|Survey Administration|Ancillary studies
214559060|NCT04047862|DRUG|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
214559061|NCT04047862|DRUG|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
214559062|NCT04047862|DRUG|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
214559063|NCT04047862|DRUG|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
214559064|NCT04047862|DRUG|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
214705609|NCT01714752|PROCEDURE|measure of left ventricular and diastolic pressure at exercise|
214705610|NCT04742426|OTHER|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
214559065|NCT04047862|DRUG|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
214559066|NCT06737705|DRUG|Baritinib|Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
214559067|NCT06839248|OTHER|24-hour clear liquid diet|Participants randomly assigned to this arm will be instructed to follow a 24-hour clear liquid diet, defined as NPO for solids and last intake of clear liquids no less than 2 hours prior to the trial visit.
214559068|NCT06839248|OTHER|Standard fasting guidelines|Participants randomly assigned to this arm will be instructed to follow the ASA and ANZCA standards for preoperative fasting prior to presenting for their trial visit. This requires participants to only consume clear liquids up to 2 hours, a light or low calorific meal up to 6 hours, and fasting from fried foods, fatty foods, or meat for at least 8 hours prior to the trial visit.
214559069|NCT06898515|DEVICE|Reprieve System|The Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
214559070|NCT06898515|DRUG|furosemide infusion|Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy
214559071|NCT05468619|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
214559072|NCT07069166|DRUG|Para-probiotic oral care|This intervention includes the home use of a para-probiotic-based toothpaste (Biorepair Plus Parodontogel) and mouthwash (Biorepair Plus with para-probiotics), applied twice daily for 15 days after each recall visit, over a 6-month period. The products contain microRepair® (zinc hydroxyapatite), lactoferrin, zinc PCA, and para-probiotic extracts aimed at modulating the oral microbiota and improving periodontal health.
214559073|NCT07069166|DRUG|Chlorhexidine oral care|This intervention includes the home use of toothpaste and mouthwash containing 0.20% chlorhexidine digluconate, applied twice daily for 15 days after each recall visit, over a 6-month period. Chlorhexidine is used for its antimicrobial properties to control dental plaque and gingival inflammation.
214559074|NCT07069153|DEVICE|Laser Therapy|High-power diode laser therapy is applied to the oral mucosa using the Garda Laser LEO PLUS device with a flat-top handpiece at 660 nm wavelength. Treatment is delivered once daily over five consecutive days according to a standardized photobiomodulation protocol (energy density: 2-4 J/cm²).
214559075|NCT07069153|DEVICE|Ozone therapy|Medical ozone gas is delivered intraorally using the Sweden \& Martina DTA device. The treatment is administered once daily over five consecutive days. A flat-tipped probe is used to apply ozone directly to the mucosal lesions at a concentration of 30-40 µg/mL, following a standardized safety protocol.
214559076|NCT07066332|BEHAVIORAL|Cornell Note Taking education group|Students will be trained in the Cornell note-taking technique.
214559077|NCT07069140|DRUG|Lactoferrin-based Toothpaste and Mouthwash (Emoform Glic)|Participants in the experimental arm will receive professional supragingival and subgingival dental hygiene sessions every three months over a six-month period. In addition, they will follow a home oral care protocol consisting of twice-daily use of a lactoferrin-based toothpaste and a lactoferrin-based mouthwash, both commercially available as Emoform Glic (Polifarma Benessere S.r.l.). The toothpaste will be applied with a soft-bristle toothbrush for two minutes, and the mouthwash will be used at a dosage of 10 mL, rinsed for 60 seconds after toothbrushing, twice a day. The intervention aims to assess whether the combined use of lactoferrin-based toothpaste and mouthwash can enhance clinical outcomes related to plaque accumulation and periodontal inflammation in pregnant women between the fourth and eighth month of gestation.
214559078|NCT07069140|DRUG|Lactoferrin-Based Toothpaste Only (Emoform Glic)|Participants in the control arm will also undergo professional dental hygiene sessions every three months for a total duration of six months. At home, they will follow an oral hygiene protocol limited to the twice-daily use of a lactoferrin-based toothpaste (Emoform Glic, Polifarma Benessere S.r.l.), applied with a soft-bristle toothbrush for two minutes. No mouthwash will be used in this arm. The purpose of this intervention is to evaluate the effectiveness of lactoferrin toothpaste alone and to serve as an active comparator for assessing the additional benefit of the mouthwash in improving periodontal parameters.
214559079|NCT03041688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214559080|NCT03041688|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214559081|NCT03041688|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214559082|NCT03041688|DRUG|Decitabine|Given IV
214559083|NCT03041688|DRUG|Navtemadlin|Given PO
214559084|NCT03041688|DRUG|Venetoclax|Given PO
214559085|NCT07135934|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Gelatin capsules each containing 1g sodium bicarbonate (NaHCO₃)
214559086|NCT07135934|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules each containing 1g food-grade starch
214705611|NCT04742426|OTHER|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
214705612|NCT03097796|DRUG|PUL-042|PUL-042 Inhalation Solution
215163917|NCT06587386|DRUG|First patient Bupivacaine liposome and next patient Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome dose depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a dose of 66.5mg (15ml). Subsequently, if motor function was preserved, the next patient received a higher dose (increased by 6.65mg) with a probability of b=0.11; or the same dose with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower dose (decreased by 6.65mg).
215163918|NCT06304168|OTHER|Non-Interventional Study|Non-interventional study
215163919|NCT03952598|DRUG|HP 13C Pyruvate|Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)
215163920|NCT03952598|DEVICE|3T MRI scanner|Research proton MRS (1H-MRS) followed by DW-MRI
215163921|NCT05755620|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
215163922|NCT05755620|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
215163923|NCT05755620|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
215163924|NCT00001987|DEVICE|HR-pQCT scan|HR-pQCT is a non-invasive, low-dose three-dimensional imaging method used to evaluate volumetric bone mineral density and bone microarchitecture of peripheral skeletal sites, including distal radius and distal tibia. HR-pQCT has an ability to differentiate between cortical and trabecular bone compartments providing density and structure parameters.
214705613|NCT05685667|DEVICE|needless laser injector (Mirajet)|Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.
214705614|NCT05685667|DEVICE|needle injection|For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
215163925|NCT04222413|DRUG|Metarrestin|Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
214705615|NCT01013896|BEHAVIORAL|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
214705616|NCT01013896|OTHER|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
214559087|NCT07129135|PROCEDURE|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter before uterine incision or bladder dissection to help determine the borders better and enable dissection of the lower uterine segment without excessive bleeding or unintended Bladder kept distended during dissection.
214559088|NCT07138131|DRUG|Omega 3|Patients received omega-3 supplementation for 3 months.
214559089|NCT07138131|OTHER|Standard follow-up|Patients received standard follow-up without treatment.
214559090|NCT07138352|DRUG|XS003 under fed and fasted condition|XS003 under fed and fasted condition
214559091|NCT07137520|OTHER|Observation without intervention|Observation without intervention
214705617|NCT00601796|BIOLOGICAL|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
214705618|NCT00601796|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
214705619|NCT00601796|DRUG|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
214705620|NCT01414712|OTHER|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
214705621|NCT06518200|BEHAVIORAL|Individualised health recommentations|Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
215163926|NCT06827795|DEVICE|A burr used in spine surgery|A burr used in spine surgery
215163927|NCT04501328|BEHAVIORAL|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
214705622|NCT06518200|BEHAVIORAL|General health recommendations|Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
214705623|NCT06518200|BEHAVIORAL|Individualised physical exercise program|Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
214705624|NCT02449954|DRUG|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
214705625|NCT02449954|DRUG|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
214705626|NCT02449954|DRUG|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
214705627|NCT01464463|BEHAVIORAL|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
214705628|NCT01464463|BEHAVIORAL|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
214705629|NCT01464463|BEHAVIORAL|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
215163928|NCT04501328|BEHAVIORAL|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
214705630|NCT01230736|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
214705631|NCT00005060|DRUG|Taxotere-Cisplatin-5FU|Preoperatively
214705632|NCT00005060|DRUG|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
214705633|NCT00699101|DEVICE|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
214705634|NCT02499341|DRUG|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
214705635|NCT02499341|DRUG|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
214705636|NCT02075749|DRUG|Triamcinolone Acetonide|
214705637|NCT02075749|DRUG|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
214705638|NCT02387619|DRUG|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
214705639|NCT02387619|DRUG|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
215163929|NCT05523583|OTHER|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
215163930|NCT05859711|DRUG|thyme honey mouth rinse|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
214559092|NCT07138365|PROCEDURE|oral Cryotherapy|custom made plastic pack measuring 2.5 X5 cm containing ice gel will be placed intraorally in the mouth on the vestibular surface of the treated tooth.
214559093|NCT07138365|PROCEDURE|Intra radicular Cryotherapy|Final flush was done with cold (2-4 oC) Saline for 10 mins.
214559094|NCT07135804|DRUG|Iparomlimab and Tuvonralimab Injection|Patients will receive Iparomlimab and Tuvonralimab Injection on the basis of 3 cycles of induction chemotherapy, followed by standard concurrent chemoradiotherapy, and then 9 cycles of Iparomlimab and Tuvonralimab Injection as adjuvant therapy
214559095|NCT07138105|OTHER|National AI in Surgical Practice Survey - Sudan|An online, cross-sectional national survey targeting Sudanese doctors who provide surgical care in any capacity. The survey collects data on awareness, prior experience, perceived benefits, barriers, and training needs for adopting artificial intelligence in surgical practice. Participants include house officers, medical officers, registrars/residents, specialists, consultants, and general practitioners performing surgical procedures in public, private, NGO, or military hospitals. The study does not involve the implementation or testing of AI tools but aims to inform the design of future AI solutions tailored for low-resource and conflict-affected health systems.
214705640|NCT02387619|DRUG|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
214705641|NCT03360136|BEHAVIORAL|Multi-professional CBT-rehabilitation|"See Detailed description"
214705642|NCT01098838|DRUG|LCL161|
214705643|NCT04793854|OTHER|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…)."
214705644|NCT04507620|DEVICE|cervical neck collar|devices used for cervical immobilization
214705645|NCT02178176|BEHAVIORAL|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
214705646|NCT02178176|BEHAVIORAL|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
214705647|NCT03267992|BEHAVIORAL|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
215163931|NCT05859711|DRUG|saline mouth rinse|saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
214559096|NCT07084610|DRUG|Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)|Patients will receive neoadjuvant treatment with nivolumab (3 mg/kg, IV) combined with platinum-based chemotherapy (cisplatin 75 mg/m² or carboplatin AUC 5, plus pemetrexed 500 mg/m² for non-squamous or paclitaxel 175 mg/m² for squamous tumors) every 21 days for two cycles. All patients will undergo invasive mediastinal staging before treatment and will be treated with robotic-assisted anatomical lung resection and mediastinal lymphadenectomy after neoadjuvant therapy.
214559097|NCT07085026|BEHAVIORAL|Yoga Intervention|There are studies that have evaluated the effects of prenatal yoga on sleep. None of these studies have reported any negative effects of yoga on pregnancy. In all studies, yoga practice was applied with varying frequencies, durations, and techniques. However, no research has been found that evaluates the effects of a yoga program conducted in accordance with the World Health Organization (WHO) guideline recommendations on both sleep and stress. Therefore, the aim of this study is to evaluate the effects of yoga, practiced during the third trimester of pregnancy in line with WHO guideline recommendations, on sleep and stress.
214705648|NCT03730194|DIETARY_SUPPLEMENT|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
214705649|NCT03730194|BEHAVIORAL|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
214705650|NCT00111150|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily|
214705651|NCT06179030|DIAGNOSTIC_TEST|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
214705652|NCT06179030|DRUG|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
214705653|NCT06068322|OTHER|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
214705654|NCT05751057|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
214559098|NCT07084792|DEVICE|Direct cortical stimulation|Stimulation
214559099|NCT07085728|DRUG|Cyclophosphamide|Arm A
214559100|NCT07085728|DRUG|Bortezomib (VELCADE)|Arm A, Arm B
214559101|NCT07085728|DRUG|Dexamethasone|Arm A, Arm B
214705655|NCT00695240|DEVICE|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
214705656|NCT05606224|BEHAVIORAL|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
214705657|NCT06101524|PROCEDURE|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
214705658|NCT05985434|PROCEDURE|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
214559102|NCT07085728|DRUG|Daratumumab-hyaluronidase|Arm B
214559103|NCT06088004|DRUG|ABO2011 Injection|Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
214559104|NCT06088004|DRUG|Toripalimab|Anti-PD-1 antibody
214705659|NCT04521335|DRUG|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
215163932|NCT04038138|DIAGNOSTIC_TEST|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
214705660|NCT04521335|DRUG|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
214705661|NCT00546039|DRUG|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
215163933|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
215163934|NCT00004847|DRUG|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
215163935|NCT00004847|DRUG|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
215163936|NCT04659603|DRUG|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
215163937|NCT04659603|DRUG|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
215163938|NCT06300086|BEHAVIORAL|Electronically delivered nudging letters to patients with CKD|"Patients in the active arm will receive a digital nudge letter as part of the study. The nudge letter will be delivered at baseline. Letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD randomized to not receive digital nudge letters (usual care)."
214705662|NCT00546039|DRUG|Placebo|Capsule
214705663|NCT03204435|PROCEDURE|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
215163939|NCT06300086|BEHAVIORAL|Electronically delivered nudging letter to associated GPs of patients with CKD|"The associated GPs of the patients in the active arm will receive one digital nudge letter as part of the study. The nudge letter will be delivered at baseline. The letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD whose associated GP was randomized to not receive a digital nudge letter (usual care)."
215163940|NCT06528769|DRUG|all-trans retinoic acid|Given orally
215163941|NCT06528769|DRUG|Cemiplimab|Given intravenously (IV)
215163942|NCT06528769|PROCEDURE|Computed Tomography|Undergo CT
215163943|NCT06528769|PROCEDURE|Magnetic resonance imaging|Undergo MRI
215163944|NCT06528769|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215163945|NCT06284317|DRUG|Adjuvant durvalumab|Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
214705664|NCT03204435|PROCEDURE|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
214705665|NCT03204435|PROCEDURE|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
214705666|NCT03204435|PROCEDURE|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
214705667|NCT04427917|DRUG|PF-06835919|PF-06835919 300 mg repeated doses
214705668|NCT04427917|DRUG|Placebo|Placebo repeated doses
214705669|NCT01257919|DRUG|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
215163946|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
215163947|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
215163948|NCT01070433|DRUG|MEBO Wound Ointment (MEBO)|Topical application twice a day
215163949|NCT01070433|OTHER|Standard of Care|Topical application twice a day
215163950|NCT04604561|DEVICE|EnVisio SmartClip|The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
215163951|NCT04604561|DEVICE|EnVisio™ Navigation System|The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
215163952|NCT06498635|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215163953|NCT06498635|PROCEDURE|Computed Tomography|Undergo CT
215163954|NCT06498635|BIOLOGICAL|Durvalumab|Given IV
215163955|NCT06498635|OTHER|Patient Observation|Undergo active surveillance
215163956|NCT06498635|OTHER|Questionnaire Administration|Ancillary studies
215163957|NCT05353530|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
215163958|NCT05694689|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
215163959|NCT05694689|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
215163960|NCT05694689|OTHER|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
215163961|NCT05047263|DRUG|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
215163962|NCT05047263|DRUG|Placebo|Tablet, once daily, oral
215163963|NCT05357443|PROCEDURE|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
215163964|NCT05357443|PROCEDURE|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
215163965|NCT03254420|DEVICE|Calypso beacon implant|Calypso beacon implant before radiotherapy
215163966|NCT03254420|RADIATION|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
214705670|NCT01257919|DRUG|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
214705671|NCT00004095|DRUG|gemcitabine hydrochloride|
214705672|NCT00004095|DRUG|irinotecan hydrochloride|
214705673|NCT06441110|DRUG|Tislelizumab in Combination with Bacillus Calmette-Guérin|Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
214705674|NCT01240655|DRUG|LCL161|
214705675|NCT01240655|DRUG|Paclitaxel|
215163967|NCT05889117|DEVICE|Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)|3-10 minute sessions of brain stimulation applied to the left dorsolateral prefrontal cortex, up to 10 sessions a day, 30 sessions in total, planned within 2 weeks.
215163968|NCT06227091|DIETARY_SUPPLEMENT|Beetroot juice|acute dose of beetroot juice
215163969|NCT06227091|DIETARY_SUPPLEMENT|Placebo|depleted nitrate beetroot juice
214559105|NCT06789302|DRUG|DT2-SCT intravenous infusion|"DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects."
214559106|NCT06789302|OTHER|Placebo|Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
214559107|NCT05254834|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
214559108|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
214559109|NCT05564650|DRUG|Venetoclax|Given PO
214559110|NCT05564650|DRUG|Decitabine|Given IV
215163970|NCT03925649|BIOLOGICAL|HB-adMSCs|single infusion of HB-adMSCs
214559111|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214559112|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214705676|NCT04413643|DEVICE|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
214705677|NCT03085355|PROCEDURE|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
214705678|NCT03085355|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
214705679|NCT05202769|OTHER|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
214705680|NCT06446206|DRUG|Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib|Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
214705681|NCT00870818|DIAGNOSTIC_TEST|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
214705682|NCT00870818|BEHAVIORAL|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
214705683|NCT00870818|DIAGNOSTIC_TEST|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
214705684|NCT00178464|DRUG|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
214705685|NCT03503214|DIAGNOSTIC_TEST|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
214705686|NCT03503214|DIAGNOSTIC_TEST|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
215163971|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
215163972|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
214559113|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
214559114|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
214559115|NCT07138196|DRUG|Adrixetinib|Administered orally
214705687|NCT02723136|DEVICE|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
214559116|NCT07135973|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:Oral
214705688|NCT02227108|DRUG|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
214705689|NCT00243100|DRUG|vorinostat|Given orally
214705690|NCT00243100|DRUG|gemcitabine hydrochloride|Given IV
214705691|NCT04900038|DRUG|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
214705692|NCT04900038|DRUG|Dolutegravir|DTG was available as 50 mg tablets administered orally.
214705693|NCT04900038|DRUG|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
214705694|NCT04900038|DRUG|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
214705695|NCT04060264|BIOLOGICAL|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
215163973|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
215163974|NCT04863677|BEHAVIORAL|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
215163975|NCT04863677|BEHAVIORAL|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
215163976|NCT05765812|DRUG|Debio 0123|Administered as capsules.
215163977|NCT05765812|DRUG|Temozolomide|Administered as capsules.
214559117|NCT07137806|PROCEDURE|sacroiliac joint injection|Ultrasound-guided injection of the SI joints The patient is placed in a prone position to receive this injection treatment. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified. The cleft between the bony contours of the sacrum and ileum represents the posterior aspect of the SI joint. By tilting the transducer in a caudal direction, the lower one third of the SI joint is identified. Because of its synovial component, the lower one third of the SI joint is the portion of the entire SI joint in which the injection should be performed. The medial to lateral approach and intraarticular deposition is preferred for the ultrasound-guided SI joint
214559118|NCT07137806|PROCEDURE|combined sacroiliac joint injection and sub maltifidous plane block|patients will be positioned prone. A 6-13 MHz linear array ultrasound transducer was placed in the parasagittal orientation with the second sacral foramen (SF-2) in the field. A 21G short bevel needle is inserted in-plane approach from the cephalad to the caudad direction. After hitting the underlying bone, twenty millilitres of local anaesthetic solution (1:1 mixture of lidocaine 2% and bupivacaine 0.25%) will be injected. An anechoic LA spread in the plane between the multifidus muscle (MFM) and the hyperechoic bony area (between the median and intermediate sacral crests) will be confirmed. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified.
214705696|NCT04060264|BIOLOGICAL|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
214705697|NCT01843400|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
214705698|NCT02486952|DRUG|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
214559119|NCT06889584|COMBINATION_PRODUCT|All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin))|Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin.
214705699|NCT02486952|DRUG|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
214705700|NCT02486952|DRUG|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
214705701|NCT02486952|DRUG|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
214705702|NCT02486952|DRUG|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
214705703|NCT04450056|OTHER|No intervention|No intervention
214705704|NCT04764409|PROCEDURE|Chemoembolization|Transarterial Chemoembolization (TACE)
215163978|NCT05765812|RADIATION|Radiotherapy|Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
215163979|NCT02873533|OTHER|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
215163980|NCT04216472|DRUG|Alpelisib|Given PO
215163981|NCT04216472|DRUG|Nab-paclitaxel|Given IV
215163982|NCT04798066|BIOLOGICAL|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
214705705|NCT04764409|PROCEDURE|Chemoinfusion|Transarterial Infusion (TAI)
214705706|NCT06472388|DRUG|Everolimus 5 MG|oral everolimus 5 mg/daily
214705707|NCT04111107|DRUG|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
215163983|NCT06576856|OTHER|This is an observational study, no intervention is anticipated.|There is no intervention. This is an observational study.
215163984|NCT03225547|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
215163985|NCT03225547|DRUG|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
214705708|NCT04111107|OTHER|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
214705709|NCT04111107|DIAGNOSTIC_TEST|Next Gen Sequencing Report|1\) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
214705710|NCT02679209|BIOLOGICAL|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
214705711|NCT02679209|BIOLOGICAL|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
215163986|NCT04340531|OTHER|Best Practice|Receive usual care
215163987|NCT04340531|OTHER|Survey Administration|Ancillary studies
215163988|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive referred to counseling session
215163989|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive phone counseling
215163990|NCT04340531|OTHER|Training|Undergo training
215163991|NCT05311956|DEVICE|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
215163992|NCT05311956|DEVICE|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
214705712|NCT01928485|OTHER|active surveillance|Undergo active surveillance
214705713|NCT01928485|DRUG|Sunphenon|Given PO
214705714|NCT01928485|OTHER|laboratory biomarker analysis|Correlative studies
214705715|NCT01928485|OTHER|Questionnaire Administration|Ancillary studies
214705716|NCT04259385|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
214705717|NCT04259385|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
214705718|NCT03110419|OTHER|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
214705719|NCT00002903|DRUG|docetaxel|
214705720|NCT03512977|PROCEDURE|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
214559120|NCT06889584|COMBINATION_PRODUCT|AM Active Supplement Combination (Ashwagandha and Rhodiola rosea)|Ashwagandha and Rhodiola rosea
214559121|NCT06889584|COMBINATION_PRODUCT|PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin)|Magnesium threonate, L-theanine, and apigenin.
214559122|NCT06889584|OTHER|AM and PM Placebo|Placebo AM and PM
214705721|NCT03512977|DRUG|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
214705722|NCT01464242|DRUG|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
214705723|NCT01464242|DRUG|Placebo|Placebo 400mg orally 3 times a day for 20 days
214705724|NCT01464242|DRUG|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
214705725|NCT03132168|BEHAVIORAL|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
214705726|NCT03132168|PROCEDURE|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
214705727|NCT03132168|OTHER|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
214705728|NCT03637907|OTHER|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
214705729|NCT05225051|OTHER|skin biopsy|skin biopsy
214705730|NCT03011450|DRUG|K-877|
214705731|NCT03011450|DRUG|Fenofibrate|
214705732|NCT03011450|DRUG|Placebo (for K-877)|
214705733|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
214705734|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705735|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
214705736|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705737|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705738|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705739|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705740|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
214559123|NCT06927362|OTHER|Lee Silverman treatment big|"Half of the treatment sessions consist of standardized multidirectional whole-body movements performed with maximal amplitude of reaching and stepping. The second half is designed to address individual deficits in movement that occur in activities of daily living.~Dosage: 4 consecutive days a week for 12 weeks (16 sessions in one month) for 60 minutes Repetitions: minimum 8-16 repetitions/task"
214559124|NCT06927362|OTHER|Dual task training|Group B will receive cognitive motor dual task training for 60 minutes, 4 times a week for 12 weeks. The intervention include both motor and cognitive components.
214705741|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214705742|NCT03814590|DRUG|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
214559125|NCT06137287|DRUG|BOTOX|Intramuscular Injection
214559126|NCT06137287|DRUG|Placebo for BOTOX|Intramuscular Injection
214559127|NCT07105319|DRUG|Ropeginterferon|"1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24~2. Comparator arm (50 patients): Patients will be followed with no further CML treatment"
214559128|NCT07100990|DRUG|High-dose corticosteroids (HDCS)|"Subjects will receive initial treatment with high-dose corticosteroids (HDCS) in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~Subjects will be escalated to PLEX if there is an insufficient response to HDCS (decision point at 14±2 days for the ON sub-trial and 7±2 days for the TM sub-trial) PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
214559129|NCT07100990|DRUG|High-dose corticosteroids (HDCS) and PLEX|"Subjects will receive treatment with high-dose corticosteroids (HDCS) and PLEX initiated concurrently.~HDCS will be administered in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
214559130|NCT06918119|DEVICE|Transcutaneous stimulation|DS8R (Digitimer LLC) for transcutaneous neurostimulation.
214705743|NCT04385615|OTHER|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
214705744|NCT02329002|DEVICE|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
214705745|NCT04005950|DEVICE|Scalpel Bougie technique|ScalpelCric Set
214705746|NCT04005950|DEVICE|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
214705747|NCT03180827|PROCEDURE|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
214705748|NCT04209894|DIAGNOSTIC_TEST|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
214705749|NCT03623282|DRUG|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
214705750|NCT00679068|DRUG|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
215163993|NCT06307054|DRUG|anti-CLL-1 CAR NK cells|Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
215163994|NCT05818150|DEVICE|Embosphere Microspheres|Embolic Agent: Embosphere Microspheres
214559131|NCT07129122|OTHER|Transventricular access|Transventricular access will perform with LBBAP lead from left subclavian way.
214559132|NCT04746846|DEVICE|UG motion sensor with PDVibe3|UG motion sensor (which detects FoG) on worn each ankle. PDVibe3 (which provides vibration) on worn each ankle
214559133|NCT07135440|DEVICE|OCT angiography RTVue XR Avanti; Optovue, Inc, Fremont, California, USA|OCTA is a fast, non-invasive, and contactless imaging technique that enables detailed visualization of the retinal microvasculature by tracking erythrocyte movement within blood vessels in real time. It provides layer-by-layer analysis of the retina and choroid without the need for intravenous contrast, significantly reducing patient risk and improving accessibility. Increasing evidence suggests that neurodegenerative and vascular changes precede clinically visible signs of disease, making OCTA a valuable diagnostic tool for early detection of diabetic retinopathy before it can be confirmed through standard fundus examination. The MoCA test includes assessments of executive functions, high-level language abilities, and complex visuospatial tasks, making it suitable for detecting even mild cognitive dysfunction.
214559134|NCT07137195|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
214559135|NCT07137884|DRUG|Anlotinib+Cyclophosphamide+Vinorelbine|"Anlotinib hydrochloride capsules combined with Cyclophosphamide+Vinorelbine), Anlotinib hydrochloride capsules 8mg (weight ≤35kg) or 12mg (weight \> 35kg), po, qd, D1-D14;on an empty stomach ,Two weeks off for one week，with a cycle of 3 weeks.~Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60g/m2, po, qw, D1, 8,15, with a cycle of 4 weeks."
214559136|NCT07137884|DRUG|Cyclophosphamide+Vinorelbine|Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60mg/m2, po, qw, D1, 8,15, with a cycle of 4 weeks.
214559137|NCT07135414|PROCEDURE|iTBS|Intermittent theta burst stimulation (iTBS) targeting the left Dorsolateral Prefrontal Cortex (LDLPFC) will be delivered using a figure-of-eight coil at 50 Hz (3 pulses per burst, 5 Hz burst frequency), with 10 bursts over 2 seconds, followed by an 8-second pause, resulting in a 10-second cycle duration, repeated 60 times for a total of 1800 pulses.
215163995|NCT05818150|DRUG|Corticosteroid injection|Corticosteroid injection
215163996|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
215163997|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
215163998|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
215163999|NCT02960022|DRUG|Leuprolide acetate|Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily
215164000|NCT01161953|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
215164001|NCT01231906|DRUG|Cyclophosphamide|Given IV
215164002|NCT01231906|DRUG|Dexrazoxane|
215164003|NCT01231906|DRUG|Doxorubicin Hydrochloride|Given IV
214559138|NCT07135414|PROCEDURE|dTMS|Deep TMS (dTMS) targeting the medial prefrontal cortex (MPFC) will be delivered using an H7 coil at 20 Hz for 2 seconds per cycle, followed by a 20-second pause, resulting in a 22-second cycle duration, repeated 50 times for a total of 2000 pulses.
214705751|NCT04084340|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
215164004|NCT01231906|DRUG|Etoposide|Given IV
215164005|NCT01231906|DRUG|Ifosfamide|Given IV
215164006|NCT01231906|OTHER|Laboratory Biomarker Analysis|Correlative studies
215164007|NCT01231906|DRUG|Topotecan Hydrochloride|Given IV
215164008|NCT01231906|DRUG|Vincristine Sulfate|Given IV
215164009|NCT02747056|OTHER|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
215164010|NCT02747056|OTHER|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
215164011|NCT02747056|OTHER|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
215164012|NCT06192576|DRUG|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
215164013|NCT04927416|DRUG|68-Gallium-DOTATATE-PET/CT|68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.
215164014|NCT01116648|PROCEDURE|Biopsy Procedure|Undergo optional tissue biopsy
215164015|NCT01116648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164016|NCT01116648|DRUG|Cediranib Maleate|Given PO
215164017|NCT01116648|PROCEDURE|Computed Tomography|Undergo CT
215164018|NCT01116648|PROCEDURE|Echocardiography Test|Undergo ECHO
215164019|NCT01116648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164020|NCT01116648|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215164021|NCT01116648|DRUG|Olaparib|Given PO
215164022|NCT06777511|DRUG|5-aminolevulinic acid (5-ALA)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management.
215164023|NCT06777511|DEVICE|Photodynamic therapy (PDT)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device photodynamic therapy device as part of their standard stoma management.
215164024|NCT01172314|DIETARY_SUPPLEMENT|EAA+LEU vs total AA|15 g as a bolus
215164025|NCT01172314|DIETARY_SUPPLEMENT|Total AA vs EAA+LEU|15 g as a bolus
215164026|NCT04529252|OTHER|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
215164027|NCT00001595|PROCEDURE|MRI|
215164028|NCT00001595|PROCEDURE|Tissue specimen collection|
214559139|NCT07135414|BEHAVIORAL|ERP|Patients are admitted to a residential program that includes nonverbal therapies, cognitive behavioural therapy, and from week 3 onward, weekly Exposure Relapse Prevention (ERP) sessions (3 hours/week for 8 weeks; total admission = 10 weeks). ERP includes an inventory of OCD symptoms, psychoeducation on the difference between obsessions and compulsions using an OCD model, and the creation of a stepwise fear hierarchy with exposure and response prevention exercises. Patients practice both during and outside sessions, including at home on weekends. Family involvement is integrated: relatives are invited every three weeks to receive psychoeducation on OCD and ERP, are informed about accommodation behaviors, and may attend a session.
214559140|NCT05951985|BEHAVIORAL|HIFT|Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
214559141|NCT07137026|BEHAVIORAL|Personnel intervention and patients|The personnel intervention has three components. They are listed above. The patient intervention will include a brief assessment and intervention.
214559142|NCT07138014|DRUG|FHND1002 100mg|Investigational oral granules containing 100mg FHND1002 (chemical entity: 3-n-butylphthalide derivative). Administered once daily for 48 weeks. Granules are packaged in unit-dose sachets with identical appearance across all study arms. Participants dissolve contents in water prior to ingestion. Stability testing confirms compatibility with fasting or fed conditions.
214559143|NCT07138014|DRUG|FHND1002 200mg|Investigational oral granules containing 200mg FHND1002 (3-n-butylphthalide derivative). Delivered as two 100mg sachets or one 200mg sachet to maintain blinding. Daily dosing regimen for 48 weeks. Granule composition matches 100mg formulation in excipients and organoleptic properties.
214559144|NCT07138014|DRUG|Placebo|Placebo granules identical to active intervention in appearance, taste, packaging, and administration method. Contains inert excipients (microcrystalline cellulose, lactose monohydrate) without active
214705752|NCT04084340|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
214705753|NCT04065373|DEVICE|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
215164029|NCT06465966|DEVICE|iRAI|Ionizing-radiation photo acoustic imaging (iRAI) is a method of collecting images from inside the body using acoustic (sound) waves. Researchers will collect iRAI during a participant's radiation treatments. Researchers will use this imaging to examine the delivery and dose of the radiation to the participant's prostate. Researchers will also compare the delivery and dose calculated from iRAI to the expected doses that were calculated from CT images which are done as standard of care.
215164030|NCT06810505|DRUG|Atogepant|Oral tablet
215164031|NCT06810505|DRUG|Placebo for Atogepant|Oral tablet
215164032|NCT04133506|DRUG|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
215164033|NCT06197724|DEVICE|Magnetocardiography|Magnetocardiography
215164034|NCT04539938|DRUG|tucatinib|300 mg orally twice daily
215164035|NCT04539938|DRUG|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
215164036|NCT04870255|DEVICE|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
215164037|NCT04870255|DEVICE|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
215164038|NCT04870255|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
215164039|NCT00006421|DRUG|2-Fluorodeoxyglucose|
215164040|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
215164041|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
215164042|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
215164043|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
215164044|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
215164045|NCT06389149|OTHER|LEAP therapy|Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting
215164046|NCT06389149|OTHER|no LEAP therapy|2.5 hours of uninterrupted prolonged sitting (no movement)
215164047|NCT00942981|DRUG|PET|Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
215164048|NCT07119801|DEVICE|Radial Extracorporeal Shock Wave Therapy|rESWT will be administered to the FCU and FCR muscles two days per week over a period of four weeks (8 sessions in total). The point of application will be selected as the center of the muscle belly for both the FCU and FCR. Each muscle will receive 2000 shocks using a 15 mm applicator tip at a frequency of 5 Hz. The treatment will be conducted at an intensity of 60 mJ (1 bar), with an energy flux density of 0.340 mJ/mm².
215164049|NCT07119801|OTHER|Conventional rehabilitation|Conventional rehabilitation will be administered for 1-2 hours daily, 5 days a week, for 12 weeks. It will include range of motion exercises, stretching exercises, progressive resistive exercises, positioning, postural control, weight shifting, balance, gait training, occupational therapy, and speech-language therapy according to the patient's needs.
215164050|NCT05568095|DRUG|Domvanalimab|Intravenous (IV) Aqueous Solution
215164051|NCT05568095|DRUG|Zimberelimab|IV Aqueous Solution
215164052|NCT05568095|DRUG|Capecitabine|Oral Tablets
215164053|NCT05568095|DRUG|Fluorouracil|IV Aqueous Solution
215164054|NCT05568095|DRUG|Leucovorin|IV Aqueous Solution
215164055|NCT05568095|DRUG|Oxaliplatin|IV Aqueous Solution
214559145|NCT07136597|BEHAVIORAL|Narrative Medicine Workshop|participants will be asked to attend 3/6 monthly narrative medicine workshops through the study's duration following an initial workshop that will be used to introduce the concepts of narrative medicine and flash writing.
214559146|NCT07136233|BEHAVIORAL|Informational Flyer Insert on Enhanced Silver Plan Benefits|Alongside the standard eligibility notice informing participants about their upcoming coverage renewal, an informational flyer is also included. The flyer explains that everyone is eligible in 2025 for the Silver plan regardless of income and highlights its benefits, such as $0 deductibles, lower monthly premiums, free preventive visits, and reduced costs for primary care, emergency care, and medications.
214559147|NCT07135219|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
214559148|NCT07137702|PROCEDURE|Erector Spinae Plane Block|A standardized perioperative care management protocol is applied for all breast-conserving surgery procedures in our department. All patients are informed about ESPB and offered its application preoperatively. Patients who accept the procedure receive ESPB (preoperatively, in the sitting position, at the level of ipsilateral T4 vertebra, USG guided, out-of-plane approach) while those who refuse are subjected to routine intravenous analgesia protocols. All blocks were performed by an anesthesiologist experienced in the application of truncal blocks and 20 cc 0.5% bupivacaine (within the safe dose range for all patients to be used according to their weight) are injected and its spread is visualized under USG.
214705754|NCT06350565|DRUG|Dexamethasone|This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
214705755|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
214559149|NCT07136376|OTHER|Physical and social environmental interventions.|To be determined in the co-creation groups at the five sites (Denmark, Germany, Poland, Spain, the Netherlands)
214559150|NCT07135648|OTHER|VM16|VM16 contains a liquid with a nicotine concentration of 1.6%
214559151|NCT07135648|OTHER|VM32|VM32 contains a liquid with a nicotine concentration of 3.2%
214559152|NCT07135648|OTHER|Cigarette (CC)|Subjects will provide their own usual brand of commercially available cigarettes
214559153|NCT07135596|DEVICE|OviTex PRS|A multi-layer construct of extracellular matrix (ECM) derived from ovine forestomach and embroidered with polymer filament.
214559154|NCT07138326|DIAGNOSTIC_TEST|Monitoring|Monitoring
214559155|NCT07137676|BEHAVIORAL|AX-CPT|administration of the AX-CPT
214559156|NCT07137676|OTHER|No Interventions|Control group with no intervention treatment
214705756|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
214705757|NCT02204826|DRUG|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
214705758|NCT02204826|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
215164056|NCT05568095|DRUG|Nivolumab|IV Aqueous Solution
215164057|NCT07122973|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
215164058|NCT07122973|OTHER|Cowhage|The spicules will be manually inserted. Approximately 30-35 spicules are gently rubbed into a 1 cm diameter skin area on the forearm/face
215164059|NCT07122973|OTHER|Capsaicin 8% Patch|Capsaicin patches (dosage form: transdermal patch 8% Qutenza, Astellas) will be applied on 3 squared areas in the face.
215164060|NCT07122973|OTHER|Demo patch|Placebo patch (demo patch, containing the same formulation as the active treatment with the exception of capsaicin) will be applied on 3 squared areas in the face.
215164061|NCT06979076|DRUG|MS-553, DS1|Oral, Dose Schedule 1
214559157|NCT07136298|OTHER|Clinical Opinion|Staff participants will be asked to review video clips of events captured during EEGs performed on the ICU and asked to state whether they think the event was an epileptic seizure or not, and what aspects of each event led them to that decision
214559158|NCT04255810|PROCEDURE|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
215164062|NCT06979076|DRUG|MS-553, DS2|Oral, Dose Schedule 2
215164063|NCT02851706|OTHER|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
215164064|NCT06312579|BEHAVIORAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
215164065|NCT06312579|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
215164066|NCT05775848|DRUG|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
214559159|NCT06935344|GENETIC|Polygenic Risk Score|For the PRS analysis, SNPs for genotyping will be selected based on the latest findings from GWAS on EOC, particularly leveraging the results, as reported by Dareng et al. (doi:10.1038/s41431-021-00987-7). The PRS will be calculated as a weighted sum of risk alleles based on the selected SNPs.
214559160|NCT01835353|DRUG|Prasugrel 100mg loading dose|
215164067|NCT05775848|OTHER|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
215164068|NCT05049928|OTHER|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects"
215164069|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
215164070|NCT07124598|DEVICE|VR Headset Device - Meta Quest 3|The VR sessions will be conducted using hardware and software developed by AugMend Health Company. The AI-guided sessions will be administered using the commercially available Meta Quest 3 headset, which delivers high-resolution VR images and spatial audio through a standalone, wireless system.
215164071|NCT06608849|OTHER|Blood samples|Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
215164072|NCT06608849|OTHER|Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms|Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
215164073|NCT05147792|DEVICE|CLAAS|CLAAS
215164074|NCT05147792|DEVICE|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
215164075|NCT06445023|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
215164076|NCT06445023|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
215164077|NCT04825613|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
214559161|NCT01835353|DRUG|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
214559162|NCT06939153|OTHER|LBNP|Participants will be exposed to a lower body negative pressure chamber protocol consisting of 5-min stages in the order of 20, -30, -40 and -50 mmHg.
214559163|NCT06939153|OTHER|LBNP + Isometric handgrip exercise|Participants will undergo 5-minute stages of LBNP at -20, -30, -40, and -50 mmHg in sequence. During the -30, -40, and -50 mmHg stages, they will perform a 2-minute isometric handgrip exercise, starting at the third minute and sustaining it for the remaining duration.
214559164|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Weekly Feedback|A dual-axis management system categorizing participants into a 3x3 grid based on aerobic capacity (12-min run test) and total exercise volume (smart-device tracked). Includes weekly personalized feedback, tiered exercise prescriptions, and goal recalibration. Arm 1 receives updates every 7 days.
214559165|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Monthly Feedback|"Identical grid framework as Arm 1 (aerobic capacity + exercise volume assessment), but with monthly (30-day) feedback cycles. Participants receive delayed optimization strategies and tier adjustments once per calendar month, simulating conventional health programs."
214559166|NCT07136155|PROCEDURE|Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation in one side.
214559167|NCT07136155|PROCEDURE|Indirect pulp capping|Selective caries removal to hard dentin followed with G.I base material and subsequent preformed metal crown (PMC).
214559168|NCT07135258|DRUG|Ivabradine + Usual Care|For patients in the ivabradine arm targeting for strict rate control, ivabradine is started at 5mg BID, and titrated at follow-up visits if needed, up to 7.5mg BID to aim at the target heart rate \<80bpm. Uptitration of other existing or additional conventional rate control agents will considered after maximally tolerated dose of ivabradine. Conversely, if not tolerated, or if resting heart rate is persistently \<50bpm, ivabradine will be reduced to 2.5mg BID, followed by reassessment.
214559169|NCT07135258|DRUG|Placebo + usual care|For patients in the lenient rate control arm, medications will be adjusted, bidirectionally as appropriate, with a maximum heart rate that is tolerable by patient which is at \<110bpm. Routine heart rate control agents included betablockers, nondihydropyridine calcium channel blockers, or digoxin. All patients will be prescribed a matching placebo (morphologically identical to the comparison arm: ivabradine) that contains pharmacologically inactive cellulose.
214559170|NCT07138443|DIETARY_SUPPLEMENT|Melatonin 3 MG Oral Tablet|Participants will ingest an acute 3mg oral melatonin tablet
214559171|NCT07138443|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Participants will ingest a placebo tablet (sugar pill) of the same size, shape, and color of the active melatonin supplement
215164078|NCT04334889|OTHER|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
215164079|NCT03840447|BEHAVIORAL|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
215164080|NCT00068003|DRUG|Anti-CD19 CAR PBL|
214559172|NCT07135947|DEVICE|Point Powered partial hand prosthetic system|The Point Powered system includes 1-4 3-joint mechatronic digits, low-profile EMG electrodes, a low-profile controller, and flexible batteries. These components will be integrated into a waterproof and dustproof packaging
214559173|NCT07136740|DEVICE|Cerebri-TTH biofeedback|Cerebri-TTH biofeedback device is a therapist-independent home-based smartphone treatment application (app). Cerebri-TTH is a medical device in risk class IIa, according to MDR, and includes two non-invasive wireless sensors and a smartphone application. Both sensors shall be in contact with the skin: one sensor is applied on the index finger and measures heart rate (HR), heart rate variability (HRV) and peripheral skin temperature. The second sensor is applied on the trapezius muscle using adhesive electrodes and measures muscle tension. The sensors transmit the measurements to the user's smartphone where the user is instructed to perform a biofeedback session. The sensors are to be used for 10 minutes per session per day. The user can choose to use the device more frequently if desired - up to 6 sessions per day.
214559174|NCT07136740|OTHER|headache diary|"Participants randomized to the wait-list arm, are instructed to keep daily eDairy entries for 12 weeks.~The wait list control group will be offered active treatment for 12 weeks after the initial 12-week wait-list period is completed in an extension phase."
214705759|NCT04939025|PROCEDURE|Multi-interventional program|"1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
214559175|NCT07135284|DEVICE|Airway clearance system|The device is prescribed as part of each participant's regular medical care, independently of the study. The study does not assign the device or alter standard treatment. Participants are observed while using the device as part of their usual care.
214705760|NCT01951248|DEVICE|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
214559176|NCT07136714|DRUG|Semaglutide Injectable Product|Semaglutide (Wegovy) once-weekly injection s.c
214559177|NCT07136714|DRUG|Placebo|Placebo (BD Posiflush) once-weekly injection s.c
214559178|NCT07135609|DEVICE|Low-level laser therapy (LLLT)|Patients managed by Low-level laser therapy (LLLT).
214559179|NCT07135609|DRUG|Apitoxin|Patients managed with 0.3% Apitoxin Gel.
214559180|NCT07135323|GENETIC|Opioid Used Disorder Risk Assessment|Determine the likelihood of Opioid Used Disorder prior to prescribing opioids
214559181|NCT07137481|DRUG|C9/CD5CAR/IL-15 NK cells|Given PO or IV
214559182|NCT07137481|DRUG|Rituximab|Given by IV
214559183|NCT07137481|DRUG|Fludarabine|Given by IV
214559184|NCT07137481|DRUG|Cyclophosphamide|Given by IV
214559185|NCT07135297|DEVICE|Ultrathin bronchoscope (UTB)|A UTB will be used to perform white light bronchoscopy, then the rEBUS probe was inserted into the working channel and advanced to the PPL to obtain a rEBUS view per the navigation path created by VBN workstation. The probe will be withdrawn from the working channel when an optimal rEBUS view obtained. A 1.5-mm biopsy forceps and 1.4-mm cytology brush will be used to collect samples through the working channel.
214559186|NCT07135297|DEVICE|Thin bronchoscope (TB1)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 1.95-mm outer diameter guide sheath, 1.5-mm biopsy forceps, and 1.4-mm cytology brush, will be used to obtain samples with the guidance of VBN.
214559187|NCT07135297|DEVICE|Thin bronchoscope (TB2)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 2.55-mm outer diameter guide sheath, 1.9-mm biopsy forceps, and 1.8-mm cytology brush, will be used to obtain samples with the guidance of VBN.
214559188|NCT07137338|GENETIC|RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)|One-time treatment with a single ascending dose
214559189|NCT06942819|DEVICE|VersaWrap Nerve Protector|VersaWrap Nerve Protector is applied to the nerve root to protect the surrounding tissues
214705761|NCT02649530|DRUG|WNT974|
214705762|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
214705763|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
214705764|NCT00000639|DRUG|Itraconazole|
214705765|NCT00000639|DRUG|Flucytosine|
214705766|NCT00000639|DRUG|Fluconazole|
214705767|NCT00000639|DRUG|Amphotericin B|
214705768|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
214705769|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
214705770|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
214705771|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
214705772|NCT05298644|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
214559190|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
214559191|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
214559192|NCT06045975|DRUG|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"* Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions."
214559193|NCT01478997|DIETARY_SUPPLEMENT|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
214559194|NCT01478997|DIETARY_SUPPLEMENT|Placebo Capsules|Carboxy Methyl Cellulose
214559195|NCT05190783|DRUG|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
214559196|NCT05190783|DRUG|MTA|material used for pulp regeneration, direct and indirect pulp capping
214559197|NCT05190783|DRUG|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
214559198|NCT05190783|PROCEDURE|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
214559199|NCT05190783|PROCEDURE|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
215164081|NCT06531876|DEVICE|Dreem 3S recording|Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
215164082|NCT04440280|DRUG|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
215164083|NCT04440280|DRUG|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
215164084|NCT04440280|DRUG|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
214559200|NCT01605578|PROCEDURE|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
214559201|NCT04654637|BEHAVIORAL|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
214559202|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
214559203|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
214559204|NCT01097122|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
214559205|NCT02384187|DRUG|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
214559206|NCT02384187|DRUG|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
214559207|NCT04402931|PROCEDURE|Transcatheter Valve-in-Valve Intervention|Transcatheter mitral valve-in-valve implantation with SAPIEN 3
214559208|NCT04402931|PROCEDURE|Redo Mitral valve surgery|Transcatheter Valve-in-Valve Intervention
214559209|NCT04996004|DRUG|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
214559210|NCT04996004|DRUG|Doxorubicin|75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
214559211|NCT06547164|DRUG|Midazolam|Midazolam will be administered orally.
214559212|NCT06547164|DRUG|Camizestrant|Camizestrant will be administered orally.
214559213|NCT06547164|DRUG|Carbamazepine|Carbamazepine will be administered orally.
214705773|NCT05298644|DRUG|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
214705774|NCT04674839|DRUG|MS-20|fermented soymilk product
214705775|NCT04674839|OTHER|Placebo|No active ingredient
214705776|NCT01522625|DRUG|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
214705777|NCT01522625|DRUG|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
214705778|NCT03935165|DRUG|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~\- Indocyanine Green is administered Intravenously"
215164085|NCT04012073|DEVICE|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH\>7.30 and PaCO2\<50 mmHg and FiO2 will be set to achieve a SpO2\>88-95%.~In case of hypercapnia with Ph\<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
215164086|NCT04012073|DRUG|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
215164087|NCT04012073|PROCEDURE|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
215164088|NCT04012073|PROCEDURE|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2\<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but \<15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
215164089|NCT04012073|PROCEDURE|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
215164090|NCT04012073|PROCEDURE|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio\>150 mm Hg and FIO2\<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
215164091|NCT04012073|PROCEDURE|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
214559214|NCT04749251|PROCEDURE|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
214559215|NCT04749251|PROCEDURE|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
214559216|NCT06787586|DRUG|ATTO-1310|ATTO-1310 Attobody
214559217|NCT06787586|DRUG|ATTO-1310 Placebo|Placebo preparation to match ATTO-1310 Dose
214559218|NCT04656873|PROCEDURE|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
214559219|NCT04656873|OTHER|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
214559220|NCT04656873|OTHER|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
214559221|NCT02912546|PROCEDURE|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
214559222|NCT05914116|DRUG|DB-1311|Administered I.V.(intravenous infusion)
214559223|NCT05914116|DRUG|Lopinavir and Ritonavir Tablets|Lopinavir and Ritonavir Tablets
214559224|NCT05914116|DRUG|itraconazole|itraconazole
214559225|NCT05446727|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine bilaterally
214559226|NCT01272154|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
215164092|NCT04012073|PROCEDURE|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
215164093|NCT05023070|DRUG|Cannabidiol|Cannabidiol 200 mg
215164094|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
215164095|NCT05023070|DRUG|Cannabidiol|Epidiolex 400 mg
215164096|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
215164097|NCT06483984|DEVICE|Noninvasive ventilation|Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
215164098|NCT00092222|DRUG|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
214559227|NCT04439227|DRUG|Adavosertib|Given PO
214559228|NCT06540235|DEVICE|Otolith Device Active|The device will be providing different levels of stimulation hypothesized to affect the vestibular system
214559229|NCT06540235|DEVICE|Otolith Device Inactive|The device will be providing no stimulation to measure test-retest
214559230|NCT06334692|DIAGNOSTIC_TEST|"In-house ELISA, and ELISA kits from DBA Italy (Abbexa)."|"Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm."
214559231|NCT02942277|BIOLOGICAL|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
214559232|NCT02942277|BIOLOGICAL|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
214559233|NCT02942277|OTHER|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
214559234|NCT02942277|BIOLOGICAL|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
214559235|NCT02942277|BIOLOGICAL|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
214559236|NCT02942277|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
214559237|NCT02942277|DRUG|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
214559238|NCT05180864|PROCEDURE|Gastrectomy|Open or minimally invasive (sub)total gastrectomy
214559239|NCT06155435|BEHAVIORAL|solution focused approach training|To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
214559240|NCT05363267|DIETARY_SUPPLEMENT|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
214559241|NCT05577715|DRUG|MORAb-202|Specified dose on specified days
214559242|NCT04176198|DRUG|Nusivertib|Oral PIM Inhibitor
214559243|NCT04176198|DRUG|Ruxolitinib|Oral JAK inhibitor
214559244|NCT04176198|DRUG|Momelotinib|Oral JAK inhibitor
214559245|NCT05949814|DIAGNOSTIC_TEST|acceptability of a PrEP program among HIV-negative MSM and TG|STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
214559246|NCT05241834|DRUG|LOXO-260|Oral
214559247|NCT05608044|DRUG|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
214559248|NCT05608044|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
214559249|NCT05608044|DRUG|Standard of Care|Regorafenib or trifluridine and tipiracil.
214559250|NCT05641168|OTHER|Adhesive material|Newly developed adhesive material
214559251|NCT05641168|OTHER|Standard adhesive material|Standard adhesive material
214705779|NCT04237740|DRUG|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
214705780|NCT05078073|DEVICE|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
214705781|NCT01568424|DEVICE|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
214705782|NCT01506050|DRUG|Desloratadine|Desloratadine ODT 5 mg
215164099|NCT00092222|DRUG|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
215164100|NCT00092222|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
215164101|NCT00092222|DRUG|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
215164102|NCT00092222|DRUG|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
215164103|NCT00092222|DRUG|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
215164104|NCT00092222|DRUG|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
215164105|NCT00092222|DRUG|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
215164106|NCT00092222|DRUG|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
215164107|NCT00092222|DRUG|Cyclophosphamide|Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
215164108|NCT00092222|DRUG|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
215164109|NCT00092222|DRUG|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
215164110|NCT00092222|DRUG|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
215164111|NCT00092222|OTHER|Observation Only|Observation of symptoms
215164112|NCT06812494|BIOLOGICAL|VRC07-523LS 400mg|Intravenous infusion (IV)
215164113|NCT06812494|BIOLOGICAL|PGT121.414.LS 400mg|IV infusion
215164114|NCT06812494|BIOLOGICAL|PGDM1400LS 400mg|IV infusion
215164115|NCT06812494|BIOLOGICAL|VRC07-523LS 3200mg|IV infusion
215164116|NCT06812494|BIOLOGICAL|PGT121.414.LS 1600mg|IV infusion
214559252|NCT06444750|OTHER|Blood sample collection|Blood samples of 30 mL will be collected at admission. For the groups that receive a blood transfusion an extra 30 mL blood sample will be collected.
214705783|NCT00211250|DRUG|Valproic Acid and Depakote ER|
214705784|NCT00567541|DEVICE|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
214705785|NCT03348241|DRUG|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
214559256|NCT06316895|PROCEDURE|thyroid surgery|thyroid lobectomy
214559257|NCT06316895|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation; microwave ablation or laser ablation
214559258|NCT06609603|DIETARY_SUPPLEMENT|HTGT compound|oral administration of HTGT compound once daily
214559259|NCT06609603|DIETARY_SUPPLEMENT|Placebo|Oral administration of placebo once daily
214559260|NCT04872595|OTHER|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
214559261|NCT04872595|RADIATION|Hyper fractionated total body irradiation|"(1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
214559262|NCT04872595|DRUG|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
214705786|NCT03348241|DRUG|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
214705787|NCT03348241|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
214705788|NCT01825655|DRUG|Cetirizine|
214705789|NCT01825655|DRUG|Placebo or sugar pill|
214705790|NCT01147081|BIOLOGICAL|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
215164117|NCT06812494|BIOLOGICAL|PGDM1400LS 1600mg|IV infusion
214705791|NCT03519516|DRUG|PRO-174|"Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
214705792|NCT03519516|DRUG|Sophixín Ofteno®|"* Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
214559263|NCT04872595|DRUG|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
214559264|NCT04872595|DRUG|GCSF|Day +7
214559265|NCT04872595|DRUG|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
214559266|NCT04872595|DRUG|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
214559267|NCT04872595|DRUG|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
214559268|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
214559269|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
214559270|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
214559271|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
214559272|NCT05796505|BEHAVIORAL|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
214559273|NCT05889741|DRUG|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
214559274|NCT05889741|DRUG|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
214559275|NCT04087811|DEVICE|Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) (Superion® implant)
214559276|NCT06062888|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
214559277|NCT04933149|DRUG|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
214559278|NCT02552979|OTHER|atopic patch test|
214559279|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
214559280|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
214559281|NCT04407689|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
214559282|NCT04407689|DRUG|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
214559283|NCT05674396|RADIATION|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
214559284|NCT05674396|RADIATION|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
214559285|NCT01656252|DRUG|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
214559286|NCT01656252|DRUG|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
214705793|NCT02849314|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
214705794|NCT02849314|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214705795|NCT01935336|DRUG|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
214705796|NCT01529385|DEVICE|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
214705797|NCT01529385|DEVICE|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
214559287|NCT01656252|DRUG|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
214559288|NCT01969682|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
214559289|NCT01969682|DRUG|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
214559290|NCT04684823|DEVICE|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
214559291|NCT04684823|DEVICE|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
214559292|NCT04903392|OTHER|Backward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks"
214559293|NCT04903392|OTHER|Forward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks"
214559294|NCT04288518|DRUG|SPECT or SPECT-CT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
214559295|NCT04101253|PROCEDURE|new screening procedure with small variations in electrode positioning|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
214559296|NCT00876564|OTHER|Trauma patients|
214559297|NCT05794490|BEHAVIORAL|Learning from excellence|Health care professionals´ experiences of learning from excellence in a hospital unit
214559298|NCT05278819|OTHER|upper extremity elevation|5 repetitions of active upper extremity elevation in a sitting position
214559299|NCT05278819|OTHER|upper extremity elevation with deep breathing|5 repetitions of active upper extremity elevation with deep breathing in a sitting position
214559300|NCT02570204|BEHAVIORAL|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
214559301|NCT05471284|BEHAVIORAL|Proximal|The first factor tested framing of the near, proximal threat of continued smoking.
214559302|NCT05471284|BEHAVIORAL|Distal|The first factor tested framing of the long-term, distal threat of continued smoking.
214559303|NCT05471284|BEHAVIORAL|Cost|Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
214559304|NCT05471284|BEHAVIORAL|Benefit|Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
214559305|NCT05471284|BEHAVIORAL|Loss|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
214559306|NCT05471284|BEHAVIORAL|Gain|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
214559307|NCT05471284|BEHAVIORAL|Control|Does not include any of the three message factors.
214559308|NCT04200638|DIAGNOSTIC_TEST|ProTaper Next|The canal fluid sample before and after will evaluate after root canal instrumentation
214559309|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws ,The block was coated with a nonporous d-PTFE membrane
214559310|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws. The block was coated with a nonporous d-PTFE membrane
214559311|NCT04833127|BEHAVIORAL|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
214559312|NCT04833127|BEHAVIORAL|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
214559313|NCT04440839|OTHER|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
214559314|NCT04468945|OTHER|mirror box therapy|"* Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~* The patient is seated close to a table a mirror (33\*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~* The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~* During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously."
215164118|NCT05490433|PROCEDURE|Robot-assisted Nipple-Sparing Mastectomy (RNSM)|"Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision.~During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered."
214559315|NCT04468945|OTHER|Repetitive Facilitation Exercise|"* The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~* Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~* Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~* Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~* Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)"
214559316|NCT03605576|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
214559317|NCT03605576|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
214559318|NCT02022904|DEVICE|Near infrared (NIR) emissive nanotechnology|
214559319|NCT02021552|OTHER|blood sampling|5 ml blood sampling
214559320|NCT01450384|DRUG|sorafenib tosylate|Given PO
214559321|NCT01450384|DRUG|pemetrexed disodium|Given IV
214559322|NCT01450384|OTHER|laboratory biomarker analysis|Correlative studies
214559323|NCT01450384|PROCEDURE|biopsy|Optional correlative studies
214559324|NCT01071655|DRUG|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
214559325|NCT01071655|DRUG|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
214559326|NCT01194375|DRUG|Low Strength IDP-107|Once a day for 16 weeks
214559327|NCT01194375|DRUG|High Strength IDP-107|Once a day for 16 weeks
214559328|NCT01194375|DRUG|Placebo|Once a day for 16 weeks
214559329|NCT04552899|DRUG|PRM-151 (Zinpentraxin Alfa)|A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
214559330|NCT04552899|DRUG|Placebo|Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
214559331|NCT00288184|DRUG|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
214559332|NCT00288184|DRUG|Placebo|
214559333|NCT00001534|DRUG|Losartan|
214559334|NCT05120869|BEHAVIORAL|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
214559335|NCT05120869|BEHAVIORAL|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
214559336|NCT02894996|DRUG|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
214559337|NCT02296918|DRUG|acalabrutinib|Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.
214559338|NCT02296918|DRUG|Obinutuzumab|Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.
214559339|NCT02296918|DRUG|Venetoclax|Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.
214559340|NCT02296918|DRUG|Rituximab|Participants will receive intravenous rituximab in Cohort 3. The details are mentioned in the cohort description.
214559341|NCT06458127|OTHER|Tele-palliative care visit|Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
214705798|NCT05321485|OTHER|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
214705799|NCT00735085|DRUG|SLV334|1000mg SLV334 as a single dose
214705800|NCT00735085|DRUG|SLV334|1000mg SLV334 b.i.d. for one day
214705801|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for one day
214705802|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for three days
215164119|NCT05490433|PROCEDURE|Conventional nipple sparing mastectomy(CNSM)|"Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted.~During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered."
215164120|NCT03932370|PROCEDURE|Flexible ureteroscopy|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water.
215164121|NCT03932370|PROCEDURE|mini-Percutaneus nephrolithotomy|The procedure is done in the prone position under fluoroscopy guidance with a semi-rigid 12Fr. Nephroscope
215164122|NCT06980376|OTHER|a2 UHT milk|Pregnant women in this arm will drink a2 UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
215164123|NCT06980376|OTHER|Conventional UHT Milk|Pregnant women in this arm will drink conventional UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
215164124|NCT01730560|OTHER|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
215164125|NCT01730560|OTHER|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
215164126|NCT06980805|DRUG|IMVT-1402|Dose 1 or Dose 2 SC QW
215164127|NCT06980805|DRUG|Placebo|Matching Placebo SC QW
215164128|NCT04226248|DRUG|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
215164129|NCT04226248|OTHER|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
215164130|NCT06782451|PROCEDURE|Surgery or biopsy|A part of the tumor sample collected during the surgery or the biopsy performed as part of routine patient care will be used for the research.
215164131|NCT06782451|PROCEDURE|Blood sample|38 mL of blood will be taken for the study.
215164132|NCT06842823|DRUG|navenibart|Navenibart will be administered as a subcutaneous injection.
215164133|NCT06842823|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
215164134|NCT06159673|DRUG|ACP-204|ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
215164135|NCT06159673|DRUG|Placebo|ACP-204 matching placebo
214705803|NCT00735085|DRUG|Placebo|SLV334 Placebo arm
214705804|NCT01975233|DEVICE|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
214705805|NCT00450047|DEVICE|Speed-feedback therapy system with a bicycle ergometer|
214705806|NCT00450047|DEVICE|Ergometer at conventional settings|
214705807|NCT00321269|BEHAVIORAL|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
214705808|NCT00321269|BEHAVIORAL|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
214705809|NCT05496894|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
214705810|NCT06319001|OTHER|Low-volume high intensity exercise|This intervention will consist of 10 x 10-second interval sprints on a stationary bicycle interspersed with 50-second breaks between repetitions. The cycle resistance will be adjusted to the level equaling the highest power output, which will be determined during warm-up sprints.
214705811|NCT06319001|OTHER|Combined intermittent sauna and cold water bath (sauna+cold bath).|This intervention will consist of 3x10 min bouts in the dry sauna interspersed with 2x 60 seconds of cold water immersion up to the neck.
214559342|NCT04098146|PROCEDURE|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
214559343|NCT04835454|DIAGNOSTIC_TEST|piRNAs, miRNA-194, regucalcin and plasma aminoacids levels|PIWI-interacting RNAs (piRNAs), a class of small nuclear RNA molecules, are associated with the PIWI proteins. MicroRNAs (miRNAs) are conserved small non-coding RNAs (19-22 nucleotide-long) that mediate post-transcriptional regulation of gene expression, affecting mRNA stability and translation by binding complementary sites on target mRNAs. Regucalcin (RGN) is an inhibitory protein of calcium signaling with calcium-binding properties. It plays a multifunctional role in the regulation of cell functions, including maintenance of intracellular calcium homeostasis, inhibitions of protein kinases and protein phosphatases linked to cell signaling process, suppressions of protein production and nuclear DNA and RNA synthesis.Free amino acids, in biological fluids can be a reduced invasive method associated to a high diagnostic potential. It was found that free amino acid profiles vary depending on type of cancer and its stage.
214705812|NCT01213069|OTHER|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
214705813|NCT01773096|DRUG|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
214705814|NCT01773096|DRUG|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
215164136|NCT06598423|DEVICE|Specialized soft contact lens 1|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.
215164137|NCT06598423|DEVICE|Specialized soft contact lens 2|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
215164138|NCT06319248|DRUG|Midodrine|Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
215164139|NCT06319248|OTHER|Standard of Care|Subjects will receive standard of care for sepsis treatment.
215164140|NCT06079879|DRUG|Bomedemstat|Oral Capsule
215164141|NCT06079879|DRUG|Anagrelide|Oral Capsule
215164142|NCT06079879|DRUG|Busulfan|Oral Tablet
215164143|NCT06079879|DRUG|Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b|Subcutaneous Solution
215164144|NCT06079879|DRUG|Ruxolitinib|Oral Tablet
215164145|NCT06593717|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
215164146|NCT06593717|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
215164147|NCT06593717|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
215164148|NCT06593717|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
215164149|NCT06593717|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
215164150|NCT06593717|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
215164151|NCT06593717|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
215164152|NCT06593717|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
215164153|NCT06593717|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
215164154|NCT06587984|BEHAVIORAL|Text message reminder|One-time text message reminder with information about getting flu vaccine at CHOP
214705815|NCT05369026|OTHER|Single leg immobilization|2 weeks of single-leg immobilization
214559344|NCT05282121|DRUG|Avenciguat|one film-coated tablet orally twice a day, at least 10 hours apart. The starting dose (1 mg) was up-titrated up to 3 mg
214559345|NCT05282121|DRUG|Empagliflozin|one 10 mg film-coated tablet of orally once a day
214559346|NCT00429780|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
214705816|NCT00964158|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
214705817|NCT02961517|OTHER|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
214705818|NCT02137759|RADIATION|Standard Radiation Therapy|Radiation therapy to 60 Gy
214705819|NCT02137759|DRUG|Standard Temozolomide|Temozolomide given orally
214705820|NCT02137759|DRUG|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
214705821|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
214705822|NCT01666678|DRUG|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
214705823|NCT01666678|DRUG|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
214705824|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
214705825|NCT03658993|DRUG|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
214705826|NCT01077388|BEHAVIORAL|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
214705827|NCT03011580|DIETARY_SUPPLEMENT|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
214705828|NCT03011580|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
214705829|NCT04910763|BEHAVIORAL|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
214705830|NCT06006312|DIAGNOSTIC_TEST|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
214705831|NCT06006312|DIAGNOSTIC_TEST|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
214559347|NCT05198245|DRUG|Rimegepant|Rimegepant 75mg
214559348|NCT05198245|DRUG|Various|Various
214559349|NCT05198245|OTHER|No intervention|No intervention
214705832|NCT06006312|DIAGNOSTIC_TEST|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
214705833|NCT02389140|OTHER|Trigger point release|Trigger point therapy
214705834|NCT02389140|OTHER|Ultrasound|sham ultrasound
214705835|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
214705836|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
214705837|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
214705838|NCT03385382|DRUG|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
214705839|NCT03385382|DRUG|Ranibizumab Injection|Injection of ranibizumab
214705840|NCT03633565|DRUG|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
214705841|NCT03633565|DRUG|Prednisolone (Steroids)|tablet 20 mg
214705842|NCT03633565|PROCEDURE|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
214705843|NCT02491502|DEVICE|Echopulse|HIFU Under ultrasound guidance
214705844|NCT01623141|PROCEDURE|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
214705845|NCT02496481|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
214559350|NCT06220305|DIAGNOSTIC_TEST|DNA methylation joint AI imaging|DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
214559351|NCT01218347|DRUG|Rosuvastatin|20 mg once daily for 21 days
214559352|NCT04672811|DEVICE|Study App and Apple Watch|Study App and Apple Watch
214559353|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
214705846|NCT02496481|BEHAVIORAL|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
214705847|NCT02063919|OTHER|the mucosal microbiome in the biopsy specimen was analysed|
214559354|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
214559355|NCT06797609|OTHER|Sample analyses|Immunoturbidimetric assay for determination of serum Cys-C levels and the Chronic Kidney Disease Epidemiology (CKD-EPI) equation for GFR estimation
214559356|NCT01736189|DRUG|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
214705848|NCT00413335|DRUG|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
214705849|NCT00413335|DRUG|Placebo|Subject receives placebo.
214705850|NCT04752124|OTHER|Exercise Therapy|High intensity speed based interval treadmill training
214705851|NCT04752124|OTHER|conventional therapy|conventional physical therapy
214705852|NCT05529290|DRUG|Dexketoprofen Trometamol + Thiocolchicoside|Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
214705853|NCT05529290|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
214705854|NCT05529290|DRUG|Dexketoprofen Trometamol (25mg)|Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
214705855|NCT05529290|DRUG|Paracetamol|Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
214705856|NCT04009213|DEVICE|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
214705857|NCT04009213|DEVICE|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
214705858|NCT00545987|DEVICE|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
214705859|NCT00545987|DEVICE|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
214705860|NCT01252342|DRUG|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
214705861|NCT01252342|DRUG|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
214705862|NCT05414370|DRUG|Liquid oxygen|Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
214705863|NCT05414370|DRUG|medical air|Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.
214705864|NCT04944888|DRUG|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
214705865|NCT04944888|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
214705866|NCT04782193|BIOLOGICAL|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
214705867|NCT03450915|BIOLOGICAL|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
214705868|NCT03450915|BIOLOGICAL|Saline|0.9% sodium chloride (NaCl)
214705869|NCT02812446|OTHER|IAI infection|
214705870|NCT02812446|OTHER|Staphylococcus aureus nasal carriage infection|
214705871|NCT01709981|DRUG|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
214705872|NCT01709981|DRUG|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
214705873|NCT01763866|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214705874|NCT01763866|DRUG|Ezetimibe|Administered orally once a day
214705875|NCT01763866|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
214705876|NCT01763866|DRUG|Placebo to Ezetimibe|Administered orally once a day
214705877|NCT01763866|DRUG|Atorvastatin|Administered orally once a day
214705878|NCT01763866|DRUG|Rosuvastatin|Administered orally once a day
214705879|NCT01763866|DRUG|Simvastatin|Administered orally once a day
214705880|NCT05055570|OTHER|No intervention|No intervention
214705881|NCT00187629|BEHAVIORAL|dietary phosphorus|varying amts dietary phosphorus
214705882|NCT04275050|DRUG|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
215164155|NCT05639114|DRUG|Ianalumab|ianalumab s.c. monthly or quarterly
215164156|NCT05639114|DRUG|Placebo|placebo s.c. monthly
215164157|NCT06602453|DRUG|GDC-8264|GDC-8264 will be administered as per pre-defined regimen.
215164158|NCT06602453|DRUG|Placebo|Placebo will be administered as per pre-defined regimen.
215164159|NCT02733120|OTHER|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
215164160|NCT06806332|DEVICE|Nanodropper|The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.
215164161|NCT06669533|DRUG|Placebo|Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
215164162|NCT06669533|DRUG|Misoprostol|Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
214559357|NCT06799936|OTHER|"CKD Jumpstart- Tips priming intervention"|"The intervention includes 2 components:~1. Patient Priming: Patients will receive the Jumpstart CKD- Tips communication priming tool within 1 week before and on the day of a target clinic visit, which includes surveys on (i) Understanding of illness and possible treatment options, (ii) Readiness for treatment discussion and information preferences, (iii) Health priorities, goals, and preferences (iv) Preferred roles in decision-making. The Jumpstart CKD- Tips patient priming sheet includes (a) A summary of their survey responses that can be shared with their healthcare team, and (b) Tips on communication with clinician during upcoming visit.~2. Clinician Priming: Within 1 week before and on the day of the target clinic visit, clinicians will receive a Jumpstart CKD- Tips clinician priming sheet which contains (a) An abstracted version of the patients' survey responses and (b) Communication tips tailored to the patient's responses based on Vitaltalk curricula materials."
214559358|NCT03459222|BIOLOGICAL|Relatlimab|Specified dose on specified days
214559359|NCT03459222|BIOLOGICAL|Nivolumab|Specified dose on specified days
214559360|NCT03459222|DRUG|BMS-986205|Specified dose on specified days
214559361|NCT03459222|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214559362|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
214559363|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
214559364|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
214559365|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
214559366|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
214559367|NCT06552637|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
214559368|NCT04999618|DRUG|Haemoblock|Delivering with transdermal patches
214559369|NCT04999618|OTHER|Placebo|Delivering with transdermal patches
214559370|NCT05162573|DRUG|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)
214559371|NCT05162573|RADIATION|EBRT|External Beam Radiotherapy
214559372|NCT05846841|BEHAVIORAL|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
214559373|NCT05846841|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
214559374|NCT00561431|DEVICE|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
214559375|NCT00561431|DEVICE|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
214559376|NCT06357988|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214559377|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214559378|NCT06357988|PROCEDURE|Echocardiography Test|Undergo echocardiography
214559379|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
214559380|NCT06357988|DRUG|Vismodegib|Given PO
214705883|NCT02545491|BEHAVIORAL|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
215164163|NCT06811454|BEHAVIORAL|MINDSET|Participants randomized to MINDSET will receive a text message at their preferred time each day for 8 weeks containing a link to the 15-minute audio content. At the end of each week (on day 7), participants will receive a second link to the weekly survey in the text. Participants will be able to play the audio content on their device by clicking the first link and access the weekly survey by clicking the second.
215164164|NCT06811454|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants will receive a 1-page brochure summarizing publicly available information on depression self-care strategies via text each week for 8 weeks on the same day they receive the text message containing a link to the weekly survey (day 7). This information will come from the Facing Forward: Life After Cancer Treatment booklet from the National Cancer Institute.38 Weekly topics will include: 1) Reducing stress; 2) Coping with stress; 3) Coping with depression; 4) Feeling angry; 5) Feeling alone; 6) Finding meaning after treatment; 7) Social relationships; and 8) Seeking support. These materials do not include any content on mindfulness or cognitive therapy.
215164165|NCT05691465|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215164166|NCT05691465|PROCEDURE|Computed Tomography|Undergo CT scan
214559381|NCT02900547|OTHER|Patients with systolic heart failure|
214705884|NCT02545491|BEHAVIORAL|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
214705885|NCT03308565|BIOLOGICAL|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
215164167|NCT05691465|RADIATION|Gallium Ga 68-DOTATATE|Given IV
215164168|NCT05691465|DRUG|Lutetium Lu 177 Dotatate|Given IV
214559382|NCT05658653|OTHER|Educational Materials for Chronic Disease Management Test (CDMT)|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
214559383|NCT03512964|DRUG|Dolutegravir 50 MG|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
214559384|NCT03512964|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
215164169|NCT05691465|PROCEDURE|Positron Emission Tomography|Undergo PET
215164170|NCT06655896|BIOLOGICAL|rapcabtagene autoleucel|single infusion of rapcabtagene autoleucel
215164171|NCT06655896|BIOLOGICAL|rituximab|rituximab intravenous infusion (i.v.) as per protocol
215164172|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
215164173|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
215164174|NCT04209504|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
215164175|NCT04209504|DRUG|Ropivacaine|Local anesthetic (numbing drug)
215164176|NCT04209504|DRUG|Bupivacaine|Local anesthetic (numbing drug)
215164177|NCT04209504|DEVICE|MediPines AGM100 Advanced Respiratory Monitoring System|Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
215164178|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Volnewmer|Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
215164179|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Thermage CPT|Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
215164180|NCT04420624|DRUG|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
215164181|NCT06806293|DRUG|Atogepant|Oral Tablet
215164182|NCT06806293|DRUG|Placebo for Atogepant|Oral Tablet
215164183|NCT06672978|DRUG|Meropenem-Vaborbactam|Administered as specified in the treatment arm
215164184|NCT06672978|DRUG|Antibiotics|Administered as prescribed by the study physician in accordance with the local marketing authorizations
215164185|NCT02669251|DRUG|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
215164186|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
215164187|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
215164188|NCT04604288|BIOLOGICAL|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
215164189|NCT05524935|DRUG|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
215164190|NCT05524935|DRUG|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
215164191|NCT06194084|OTHER|Two-sequence of durian pulp doses (100 g and 200 g)|Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
215164192|NCT04201470|OTHER|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
215164193|NCT04201470|OTHER|MRI|Cervical and cerebral MRI without contrast injection
214559385|NCT00785811|DRUG|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
214559386|NCT00785811|DRUG|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
214705886|NCT01559064|DEVICE|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
215164194|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
215164195|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
215164196|NCT06522737|DRUG|Duvelisib|oral capsules
215164197|NCT06522737|DRUG|Gemcitabine|solution for intravenous infusion
215164198|NCT06522737|DRUG|Bendamustine|solution for intravenous infusion
215164199|NCT04234997|DRUG|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
215164200|NCT04234997|DRUG|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
214559387|NCT03780361|DRUG|Aflibercept Injection|Total 5 times of monthly intravitreal aflibercept injections will be done.
214705887|NCT03320291|DEVICE|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
214705888|NCT03128216|PROCEDURE|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
214705889|NCT03128216|PROCEDURE|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
214705890|NCT03128216|PROCEDURE|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
214705891|NCT03128216|DRUG|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
214705892|NCT03128216|DRUG|Bupivacaine|Local anesthetic used for Spinal Anesthesia
214705893|NCT02833116|DRUG|Betamethasone|
215164201|NCT06983158|DRUG|gene therapy|Intra-venous gene therapy
214705894|NCT02833116|DRUG|Dexamethasone|
215164202|NCT06982521|DRUG|RLY-2608|400 mg orally BID administered daily on a 28-day treatment cycle
215164203|NCT06982521|DRUG|Capivasertib|400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
215164204|NCT06982521|DRUG|Fulvestrant|500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)
215164205|NCT03294460|DRUG|Alcohol (Oral)|Oral Self-administration
215164206|NCT03294460|DRUG|Alcohol (IV)|IV Self-administration
215164207|NCT03294460|DRUG|Alcohol (Ethanol)|IV and Oral Self-administration
215164208|NCT06986226|BEHAVIORAL|Dose Calculations|Dose calculations either with or without performing ventilations during CPR (15:2)
214705895|NCT03850327|DEVICE|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
214705896|NCT02603185|DRUG|Hemay007|
214705897|NCT02603185|DRUG|placebo|
214559388|NCT04255953|BEHAVIORAL|behavioral telehealth|Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
214559389|NCT04255953|OTHER|Treatment as Usual|Treatment as Usual
214559390|NCT04703205|DRUG|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
214559391|NCT04703205|DRUG|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
214559392|NCT02849444|OTHER|Anti-myeloma treatment at physician discretion|non Interventional Study
214559393|NCT03657602|DRUG|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
214559394|NCT03657602|DRUG|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
214705898|NCT01146041|DRUG|Rivastigmine|Rivastigmine 1.5 mg Capsules
214705899|NCT03826355|PROCEDURE|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
214705900|NCT03826355|PROCEDURE|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
214705901|NCT04981574|OTHER|Massage and stretching on neck area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
214705902|NCT04981574|OTHER|Massage and stretching on low back area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
214559395|NCT01576380|DRUG|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
214559396|NCT05354414|DEVICE|Virtual reality|Administered as specified in the treatment arm.
214559397|NCT05354414|PROCEDURE|Standard of Care|Administered as specified in the treatment arm.
214559398|NCT02388126|DEVICE|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
214559399|NCT02388126|DEVICE|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
214559400|NCT01588964|PROCEDURE|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
214559401|NCT02597244|DEVICE|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
214559402|NCT02509832|DEVICE|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
214559403|NCT02509832|DEVICE|PCI only|Standard of Care for PCI
214559404|NCT02523703|BIOLOGICAL|glutamate and aspartate|
214559405|NCT05467293|DRUG|0.3% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
214559406|NCT05467293|DRUG|1% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
214559407|NCT05467293|DRUG|YP-P10 Placebo Ophthalmic Solution (vehicle)|Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
214559408|NCT05287997|DIAGNOSTIC_TEST|Neurolytixs Index|Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
214705903|NCT00101803|DRUG|vildagliptin|
214705904|NCT02723110|OTHER|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
214705905|NCT02723110|OTHER|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
214705906|NCT00313534|DRUG|masoprocol|
214559409|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
214559410|NCT00196469|DRUG|heparin|
214559411|NCT04393311|DRUG|Ulinastatin|Ulinastatin administered via IV infusion (200,000/infusion)
214559412|NCT04393311|DRUG|Placebo|Placebo to match ulinastatin administered via IV infusion
214559413|NCT04542967|BIOLOGICAL|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
214705907|NCT02730442|DRUG|F901318|Administration of F901318 intravenously
214705908|NCT02730442|DRUG|Fluconazole|Oral administration
214705909|NCT02663479|DIETARY_SUPPLEMENT|Cardiopressin|
214705910|NCT02663479|DIETARY_SUPPLEMENT|Placebo|
214705911|NCT02214316|OTHER|Hypertonic Saline|
214559414|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
215164209|NCT06986226|PROCEDURE|Ventilations|Performing ventilations during CPR in a 15:2 manner
215164210|NCT06605079|BEHAVIORAL|Complex intervention|"A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed."
214559415|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
214559416|NCT00731133|DRUG|Disulfiram|250 mg/day
214559417|NCT05643755|OTHER|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
214559418|NCT01052610|DRUG|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
214705912|NCT05864183|DIAGNOSTIC_TEST|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
214705913|NCT05864183|DIAGNOSTIC_TEST|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
214705914|NCT05864183|DIAGNOSTIC_TEST|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
214705915|NCT05864183|DIAGNOSTIC_TEST|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
215164211|NCT06605079|OTHER|Routine treatment|No complex intervention is established, just routine procedures.
214559419|NCT01052610|DRUG|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
214559420|NCT03510455|DRUG|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
214705916|NCT05864183|DIAGNOSTIC_TEST|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
214705917|NCT05864183|DIAGNOSTIC_TEST|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
214705918|NCT05864183|DIAGNOSTIC_TEST|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
214705919|NCT05864183|DIAGNOSTIC_TEST|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
214559421|NCT05408247|DRUG|N-acetyl cysteine|2400mg/day
215164212|NCT06605833|DIAGNOSTIC_TEST|12-Lead ECG|"Participants will undergo a standard 12-lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
215164213|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
215164214|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
214559422|NCT05408247|DRUG|Placebo|Matched placebo
214559423|NCT04396249|DEVICE|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
214559424|NCT04396249|DEVICE|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
214559425|NCT00004442|DRUG|chenodeoxycholic acid|
214705920|NCT05864183|DIAGNOSTIC_TEST|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
214705921|NCT06372054|OTHER|Biological sample collection|Collection of biological samples (blood, urine, saliva) and clinical data
214705922|NCT03245723|PROCEDURE|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
214559426|NCT00004442|DRUG|cholic acid|
214559427|NCT00004442|DRUG|ursodiol|
215164215|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
215164216|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
215164217|NCT06598150|OTHER|Shoulder Abduction|Individuals will be visually cued to perform short, unilateral, isometric shoulder abduction tasks. A visual display will provide real-time feedback of the shoulder abduction torque, to help the participant target a predetermined torque level.
215164218|NCT06600711|DRUG|Nitazoxanide|5 mL suspension (100 mg), 2x/day for 3 days
215164219|NCT06600711|DRUG|Placebo|identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
214559428|NCT04411329|DRUG|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
214559429|NCT04411329|DRUG|Dexamethasone|dexamethazone
214559430|NCT04411329|DRUG|Dexmedetomidine|dexmedetomidine
214559431|NCT04411329|DRUG|Hyalouridinase|hyalouridinase
214705923|NCT03245723|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
215164220|NCT06595953|BEHAVIORAL|Gaze-Contingent Music Reward Therapy|All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
214559432|NCT01534065|DEVICE|Barricaid|Implanted intra-operatively during discectomy
215164221|NCT06596005|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
214559433|NCT01046929|DIETARY_SUPPLEMENT|limonene|oral dosing at 2 gram QD
214559434|NCT02190903|OTHER|General endotracheal anesthesia|"General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol."
214705924|NCT03245723|PROCEDURE|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
215164222|NCT06596005|DRUG|Placebo|Capsule, Once Daily
214559435|NCT02190903|OTHER|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
214559436|NCT05179070|DRUG|Carvedilol|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
214559437|NCT00078351|PROCEDURE|High molecular weight hylan (Synvisc) injection|
214559438|NCT06131151|OTHER|Nerve block|Nerve block in percutaneous nephrolithotomy
214559439|NCT03414177|OTHER|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
214559440|NCT03336359|DIAGNOSTIC_TEST|Tandem colonoscopy|Different image enhanced endoscopy systems
214559441|NCT04498364|BEHAVIORAL|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics.
214559442|NCT02526966|BIOLOGICAL|blood sample|dosage of anti-hinge region antibodies
214705925|NCT03245723|PROCEDURE|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
214705926|NCT00519493|PROCEDURE|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
214559443|NCT03098563|DRUG|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
214559444|NCT00827476|PROCEDURE|ovarian transplantation|ovarian xenotransplantation or in vitro culture
214559445|NCT02218723|DRUG|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
215164223|NCT06588777|PROCEDURE|Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)|transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
214559446|NCT02218723|DRUG|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
214559447|NCT05539443|BEHAVIORAL|Intensive Clinic Management (ICM)|An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
214559448|NCT05539443|BEHAVIORAL|Intensive tailored telehealth management (ITTM)|A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
214559449|NCT01790841|DEVICE|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
214559450|NCT01209377|BEHAVIORAL|standard|EMDR treatment with bilateral stimulation via eye movement
214559451|NCT01209377|BEHAVIORAL|fixed|EMDR treatment with fixed eyes
214559452|NCT01209377|BEHAVIORAL|no focus|trauma exposure without external focus
214559453|NCT01209377|PROCEDURE|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
214559454|NCT03916406|DRUG|PF 06835919|300 mg
214559455|NCT03916406|DRUG|Midazolam|7.5 mg
214559456|NCT01246505|DEVICE|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
214559457|NCT06489860|DRUG|HIV|"Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5% Dosage Form:~Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date"
214559458|NCT06489860|DRUG|Malignant Neoplasms Safety Study for the Treatment of Neoplasms|Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.
214559459|NCT06230172|RADIATION|Weaning incubator (heat) at an lower postnatal weight|"Infants in the intervention group are weaned in the same manner as the infants in the control arm; however, the wean begins at a lower postnatal weight.~Our institutional guidelines for weaning infants from incubator to crib was unchanged for both groups."
214559460|NCT02397551|PROCEDURE|IVF/ICSI|
214559461|NCT02397551|DRUG|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
214559462|NCT06213818|DRUG|INCB160058|Oral; Immediate release solid tablet
214559463|NCT06213818|DRUG|Placebo|Oral; Tablet
214559464|NCT06213818|DRUG|Esomeprazole|Oral; Delayed-release capsule or tablet
214559465|NCT06213818|DRUG|Famotidine|Oral; Tablet
214559466|NCT05233475|BEHAVIORAL|Enhanced usual care (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
214559467|NCT05233475|BEHAVIORAL|Get Going after concussIoN Lite|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
214559468|NCT06082570|DRUG|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
214559469|NCT00007150|PROCEDURE|Phlebotomy|Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
214705927|NCT00519493|DEVICE|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
215164224|NCT06588777|PROCEDURE|Quadratus lumborum block|"using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle"
214705929|NCT06687122|DIETARY_SUPPLEMENT|3 whole eggs|Participants will be free-living and will not be supplied with any other food except for the eggs during the intervention period with no restrictions of energy intake.
214559470|NCT01495897|DEVICE|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
215164225|NCT06588153|DRUG|Prolia®|Subcutaneous (SC) injection in pre-filled syringe.
214705930|NCT00835419|DRUG|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
214705931|NCT03337139|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
214705932|NCT03337139|BEHAVIORAL|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
214705933|NCT03337139|BEHAVIORAL|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
214705934|NCT01754077|BEHAVIORAL|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
214705935|NCT01754077|BEHAVIORAL|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
214705936|NCT01754077|BEHAVIORAL|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
214705937|NCT02554253|DRUG|Ketamine|Ketamine used for induction
214705938|NCT02554253|DRUG|Propofol|Propofol for induction
214559471|NCT01495897|DEVICE|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
214559472|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
214559473|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
214559474|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214559475|NCT04549571|OTHER|Interview|Participate in interview
214559476|NCT04549571|OTHER|Training|Receive training
214559477|NCT04549571|OTHER|Media Intervention|Utilize the CDB
214559478|NCT04549571|OTHER|Best Practice|Utilize usual care
214559479|NCT04549571|OTHER|Survey Administration|Ancillary studies
214559480|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
214559481|NCT00560846|DIETARY_SUPPLEMENT|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
214559482|NCT00560846|DIETARY_SUPPLEMENT|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
214559483|NCT04548323|BEHAVIORAL|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
214559484|NCT04439292|DRUG|Dabrafenib Mesylate|Given PO
214559485|NCT04439292|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214559486|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
214559487|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
214559488|NCT05104203|PROCEDURE|Thoracolumbar Interfascial Plane block|Interfascial block done by injection between m. multifidus and m. longissimus
214559489|NCT05104203|PROCEDURE|Modified Thorcolumbar Interfascial Plane block|Injection of local anesthetics between m. longissimus and m. illiocostalis
214559490|NCT05854407|OTHER|skim milk|pasteurized or high-pasteurized skim milk
214559491|NCT00596882|OTHER|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
214559492|NCT00596882|OTHER|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
214559493|NCT00447746|PROCEDURE|D1 or D2 lymphadenectomy for gastric cancer patients|
214559494|NCT03290053|DRUG|SonoVue|SonoVue-infusion over 1 hour
214559495|NCT03290053|DRUG|Sodium chloride|Placebo
214559496|NCT03290053|PROCEDURE|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
214559497|NCT03290053|PROCEDURE|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
214559498|NCT02964325|DEVICE|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
214559499|NCT02964325|DEVICE|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
214559500|NCT04659330|BEHAVIORAL|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
214559501|NCT04659330|DEVICE|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
214559502|NCT04199559|DRUG|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
214559503|NCT00800553|DRUG|donepezil|5mg o.m. p.o. for approx. 2 weeks
214559504|NCT00800553|DRUG|Placebo|5mg of placebo for approx. 2 weeks
214559505|NCT06295198|OTHER|Single lep drop jump test|All evaluations will be repeated before and after the treatment.
214559506|NCT05552300|PROCEDURE|SAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
214559507|NCT05552300|DRUG|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
214559508|NCT01860326|DRUG|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
214559509|NCT02510040|DEVICE|Prism|Ground-in or Fresnel prism
214559510|NCT02510040|OTHER|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
214559511|NCT02510040|PROCEDURE|Eye Muscle Surgery|"* Bilateral medial rectus muscle resection surgery~* Single medial rectus muscle resection surgery~* Recess lateral rectus muscle resection medial rectus muscle surgery~* Bilateral lateral rectus muscle recession surgery~* Single lateral rectus muscle recession surgery~* Bilateral lateral rectus muscle resection surgery~* Single lateral rectus muscle resection surgery~* Recess medial rectus muscle resection lateral rectus muscle surgery~* Bilateral medial rectus muscle recession surgery~* Single medial rectus muscle recession surgery~* Vertical rectus muscle recession surgery~* Vertical rectus muscle mini-tenotomy (snip) surgery"
214559512|NCT02510040|PROCEDURE|Botox Injection|Botulinum toxin injection
214559513|NCT01133782|PROCEDURE|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
214705939|NCT03288493|BIOLOGICAL|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
214705940|NCT03288493|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
214705941|NCT00042250|DRUG|Chemotherapy for hematologic malignancy|
214705942|NCT04419324|DEVICE|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
214705943|NCT01238133|DRUG|Carboplatin|Given IV
214705944|NCT01238133|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214705945|NCT01238133|OTHER|Laboratory Biomarker Analysis|Correlative studies
214705946|NCT01238133|DRUG|Paclitaxel|Given IV
214705947|NCT01238133|OTHER|Pharmacological Study|Ancillary studies
214705948|NCT01238133|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214705949|NCT04260828|DRUG|Aspirin 100mg|Daily active drug administered orally for 3 months.
214705950|NCT04260828|OTHER|Placebo|Sugar pill administered orally for 3 months.
214705951|NCT03529123|DRUG|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
214705952|NCT03529123|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
214705953|NCT03529123|DRUG|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
214705954|NCT03529123|DRUG|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
214705955|NCT03190226|PROCEDURE|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
214705956|NCT03190226|PROCEDURE|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
214705957|NCT01671722|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
214705958|NCT01736254|DRUG|Evacetrapib|
214705959|NCT01736254|DRUG|Gemfibrozil|
214705960|NCT05847491|DIAGNOSTIC_TEST|IGRA/Tuberculin skin test|"All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible"
214705961|NCT00754728|DEVICE|JACTAX DES|Drug Eluting Stent
214705962|NCT04295200|OTHER|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
214705963|NCT01647659|DRUG|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
214705964|NCT01647659|DRUG|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
214705965|NCT02559206|DRUG|Linaclotide|Oral, once daily
214705966|NCT02559206|DRUG|Matching Placebo|Oral, once daily
214705967|NCT04480697|DRUG|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
214705968|NCT06011291|DRUG|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
214705969|NCT06011291|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
214705970|NCT01144078|BEHAVIORAL|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
214705971|NCT01144078|BEHAVIORAL|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
214705972|NCT00093678|DRUG|celecoxib|
214705973|NCT00093678|PROCEDURE|anticachectic therapy|
214705974|NCT00093678|PROCEDURE|nutritional support|
214705975|NCT00093678|PROCEDURE|pain therapy|
214705976|NCT00093678|PROCEDURE|supportive care/therapy|
214705977|NCT02755844|DRUG|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
214705978|NCT02755844|DRUG|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
214705979|NCT02755844|DRUG|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
214705980|NCT04061252|DRUG|KHK4827|brodalumab 210mg Q2W, SC
214705981|NCT04061252|DRUG|Placebo|Q2W, SC
214705982|NCT01561560|DEVICE|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
214705983|NCT01561560|DEVICE|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
214705984|NCT06754189|DEVICE|Time Limited stimulation|The participant self-administer 30 min. of electrical stimulation using Time Limited stimulation to the dorsal genital nerve (DGN) for 6 weeks using UCon with the UCon-Patch electrode.
214705985|NCT06754189|DEVICE|Sham stimulation|The participant self-administer 30 min. of sham stimulation to the dorsal genital nerve (DGN) for 6 weeks using a sham device with the UCon-Patch electrode.
214559514|NCT02338453|BEHAVIORAL|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
214559515|NCT02338453|BEHAVIORAL|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
214705986|NCT06890741|OTHER|exercise test|Participant perforemed 6000m ergometer test.
214559516|NCT00310557|DRUG|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
214559517|NCT01368471|DEVICE|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
214559518|NCT01368471|DEVICE|Control BMS or DES|Control BMS or DES
214559519|NCT04695184|DIAGNOSTIC_TEST|ICG-NIRF Imaging|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
214559520|NCT03225326|DRUG|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
214559521|NCT03225326|DRUG|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
214559522|NCT00198276|COMBINATION_PRODUCT|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
214559523|NCT03250793|DEVICE|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
214559524|NCT02145832|DRUG|Fluconazole|
214559525|NCT02145832|DRUG|Micafungin|
214559526|NCT03705897|OTHER|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
214559527|NCT03705897|OTHER|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
214559528|NCT03705897|OTHER|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
214559529|NCT06268457|PROCEDURE|Chemoembolization with Doxorubicin|"* Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
214705987|NCT06758518|OTHER|No Interventions|there will be no intervention
214705988|NCT06898671|BEHAVIORAL|Eye-Tracking in Visual World Paradigm|Participants complete six eye tracking tasks. They see images on a computer screen are tasked with finding a specific picture or saying a specific word (target). We track their eye movements to the visual representations of the target compared with their eye movements to visual representations of items that are similar to the target.
214559530|NCT06471075|BEHAVIORAL|Mindful Pain Management|The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
214559531|NCT06471075|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
214559532|NCT06372106|DEVICE|SaO2 Sampling|CO-Oximetry analysis of arterial blood samples
214559533|NCT00458276|DRUG|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
214559534|NCT00458276|DRUG|placebo|Placebo (i.e., normal saline) for i.v. use.
214559535|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Low Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate
214559536|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Intermediate Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
214559537|NCT02885415|PROCEDURE|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
214559538|NCT06472726|BEHAVIORAL|IONA Mind app|The IONA Mind app is a smartphone app that delivers mental health support.
214559539|NCT03250988|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
214559540|NCT03684278|DRUG|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
214559541|NCT03684278|DRUG|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
214559542|NCT03684278|OTHER|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
214559543|NCT03085225|DRUG|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
214559544|NCT05716048|BEHAVIORAL|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
214559545|NCT05716048|BEHAVIORAL|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
214559546|NCT06407024|PROCEDURE|laparoscopic transabdominal adrenalectomy|Adrenalectomy performed by laparoscopic approach
214559547|NCT06407024|PROCEDURE|robotic transabdominal adrenalectomy|Adrenalectomy performed by robotic approach
214559548|NCT05859880|BEHAVIORAL|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
214559549|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
214559550|NCT03877211|OTHER|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
214559551|NCT03877211|OTHER|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
214559552|NCT03877211|OTHER|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
214559553|NCT03877211|OTHER|Tonal audiometry|Tonal audiometry will be performed with headphones
214559554|NCT03877211|OTHER|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
214559555|NCT01264432|OTHER|Laboratory Biomarker Analysis|Correlative studies
214559556|NCT01264432|OTHER|Quality-of-Life Assessment|Ancillary studies
214559557|NCT01264432|RADIATION|Radiation Therapy|Undergo LDFWAR
214559558|NCT01264432|DRUG|Veliparib|Given PO
214559559|NCT00826332|PROCEDURE|transabdominal ultrasound|transabdominal ultrasound
214559560|NCT00826332|PROCEDURE|transvaginal ultrasound|transvaginal ultrasound
214559561|NCT05843292|DRUG|Taxane and Carboplatin|"Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles."
214559562|NCT05843292|DRUG|Short-term Sintilimab|Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
214559563|NCT05843292|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
214559564|NCT04977453|DRUG|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
214559565|NCT04977453|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
214559566|NCT04977453|DRUG|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
214559567|NCT04977453|RADIATION|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
214559568|NCT04977453|DRUG|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
214559569|NCT01423110|BIOLOGICAL|BYM338|
214705989|NCT00818285|DEVICE|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
214705990|NCT00004986|DRUG|Nitazoxanide|
214705991|NCT06897592|BEHAVIORAL|Enneagram|The training will be offered to students as 10 modules, 2 hours per week, for 8 weeks. The training content will consist of the Enneagram basic level and relationships.
214705992|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of esophageal pressure Peso (cmH2O)|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia.
214705993|NCT06899295|DIAGNOSTIC_TEST|Measurement of impedance variation with each respiratory cycle (EIT), Z in ohm|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
214705994|NCT06899295|DIAGNOSTIC_TEST|Measurement of regional respiratory compliance (EIT), Ohm/cmH2O|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
214705995|NCT06899295|DIAGNOSTIC_TEST|Measurement of lung volumes (EELV or CRF) mL, (ml/kg)|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
214705996|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of multiparametric monitoring data in place (hemodynamics, depth of sedation, respiratory data, temperature).|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
214705997|NCT06899295|DIAGNOSTIC_TEST|Quantification of delivered doses of hypnotics, morphine and paralytics|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
214705998|NCT06899295|DIAGNOSTIC_TEST|Demographic criteria: age, sex, height, weight, BMI, theoretical ideal weight, ASA. - Procedure-related criteria: type of surgery, technique (laparoscopic, endoscopic, laparoscopic), position, duratio|These parameters will be recorded during the perioperative hospitalization
214705999|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
214706000|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
214706001|NCT01806376|DRUG|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
214706002|NCT06088407|DRUG|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
214706003|NCT03630978|PROCEDURE|Liver resection|Major or minor, open or laparoscopic liver resection
214559570|NCT01423110|BIOLOGICAL|Placebo|
214706004|NCT01064076|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
214559571|NCT06176976|DIETARY_SUPPLEMENT|Lugol's iodine solution 5%|4 drops of LS every 8 hours for 10 days preoperatively will be given
214559572|NCT02860897|DRUG|Premarin|Vaginal estrogen cream
214559573|NCT02860897|DRUG|Vagifem|Vaginal estrogen tablet
214559574|NCT04606901|DRUG|neostigmine/glycopyrrolate|neuromuscular blockade reversal agents
214559575|NCT04606901|DRUG|sugammadex|neuromuscular blockade reversal agent
214559576|NCT00905320|PROCEDURE|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
214559577|NCT00905320|PROCEDURE|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
214559578|NCT03169400|DEVICE|Theranova dialyzer|Hemoadialysis
214559579|NCT04953962|DRUG|CBP501 (16)|16 mg/m2
214559580|NCT04953962|DRUG|CBP501 (25)|25 mg/m2
214559581|NCT04953962|DRUG|Cisplatin|60mg/m2
214559582|NCT04953962|DRUG|Nivolumab|240 mg
214559583|NCT05846958|DEVICE|laser acupuncture|"Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks ."
214559584|NCT05846958|DEVICE|night splint|wearing night splint for 4 weeks
214559585|NCT02551653|DRUG|[11C]-GSK2256098 500 MBq|\[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
214559586|NCT05355675|OTHER|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
214559587|NCT05355675|OTHER|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
214559588|NCT00403936|PROCEDURE|OA decompression manipulation|
214559589|NCT01049867|PROCEDURE|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
214559590|NCT02168348|OTHER|biological examination at consultations at 3 and 6 months|
214559591|NCT03435042|BEHAVIORAL|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
214559592|NCT06037304|OTHER|no intervention|no intervention
214559593|NCT03952052|OTHER|Determination of mutation|Recurrent mutation determination by digital PCR and next generation sequencing
214559594|NCT04990362|DIETARY_SUPPLEMENT|Pomegranate oil, Mediterranean Diet|Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
214559595|NCT04990362|DIETARY_SUPPLEMENT|Mediterranean Diet|Dietary Supplement: Mediterranean dietary protocol
214559596|NCT03132831|OTHER|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
214559597|NCT05752526|DRUG|Diclofenac 1%|vaginal hydrogel containing 1% Diclofenac
214559598|NCT05752526|DRUG|Diclofenac 3%|vaginal hydrogel containing 3% Diclofenac
214559599|NCT05752526|DRUG|Placebo|vaginal hydrogel, no active ingredient
214559600|NCT02927353|DRUG|DMB-3113|subcutaneously injected in a single dose of 40 mg.
214559601|NCT02927353|DRUG|Adalimumab|subcutaneously injected in a single dose of 40 mg.
214559602|NCT03574662|OTHER|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
214559603|NCT03574662|OTHER|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
214559604|NCT01373580|DEVICE|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
214559605|NCT00237536|DRUG|Lonidamine|
214559606|NCT00655525|DIETARY_SUPPLEMENT|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
214706005|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
214559607|NCT00655525|DIETARY_SUPPLEMENT|placebo|placebo administered orally every day for 3 months
214559608|NCT00770900|DRUG|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children \>15 years took 10mg tablet of montelukast"
214559609|NCT00770900|DRUG|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
214559610|NCT02690753|PROCEDURE|A protocol tailored to individual risk factors|
214559611|NCT02690753|DEVICE|The Prevalon® Turn and Position System 2.0|
214559612|NCT02690753|DEVICE|Comfort Shield® barrier cream cloths|
214559613|NCT05029713|DIAGNOSTIC_TEST|Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)|The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
214559614|NCT02202785|DRUG|MLN0264|MLN0264 IV infusion
214559615|NCT02180243|BEHAVIORAL|Mindfulness meditation/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
214706006|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
214706007|NCT06076148|DEVICE|Virtual reality games|three individual games (physical, cognitive and relaxation) and two multiplayer games will be tested.
214706008|NCT00860418|BEHAVIORAL|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
214559616|NCT02180243|OTHER|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
214559617|NCT06094946|DRUG|Ropivacaine Hydrocloride|1 mg/ml
214706009|NCT00860418|BEHAVIORAL|Standard asthma education|Standard asthma education during 2 home visits.
214559618|NCT06094946|DRUG|Fentanyl Citrate|2.5 micrograms/ml
214559619|NCT01137578|PROCEDURE|Ultrasound|Ultrasounds to be performed on children with central venous catheters
214559620|NCT01137578|DRUG|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
214706010|NCT00039468|DRUG|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
214706011|NCT00039468|DRUG|thalidomide|400mg/day oral
214706012|NCT01726283|DEVICE|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
214559621|NCT01137578|PROCEDURE|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
214559622|NCT00968071|DRUG|Decitabine|20 mg/m\^2 IV over an hour and half daily for 5 days.
214559623|NCT00968071|DRUG|Gemtuzumab Ozogamicin|3 mg/m\^2 IV on day 5.
214559624|NCT01409629|BEHAVIORAL|Computer game|Participants will play a computer game
214559625|NCT00353041|DRUG|lidocaine topical|
214559626|NCT02395731|BEHAVIORAL|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
214559627|NCT00158314|BEHAVIORAL|Referral to Gamblers Anonymous|
215164226|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
215164227|NCT06654778|OTHER|PEEP|Patients will be ventilated with PEEP of 8 cm H2O and fluid management: 500 ml of Ringer's lactate in the recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery.
215164228|NCT06654778|OTHER|PEEP/RM|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and fluid management: 500 ml of Ringer's lactate in recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery
215164229|NCT06654778|OTHER|PEEP/RM/RF|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and restrictive fluid management (RF). Ringer's lactate at a rate of 3 mL/kg/hour from the beginning to the end of the surgery
215164230|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
214559628|NCT00158314|BEHAVIORAL|Cognitive behavioral therapy|
214559629|NCT00158314|BEHAVIORAL|Cognitive behavioral self-help manual|
214559630|NCT00872755|PROCEDURE|Nissen|Laparoscopic Nissen Fundoplication
214559631|NCT00872755|PROCEDURE|Gastropexy|posterior gastropexy
214559632|NCT04145700|DRUG|Ramucirumab|Ramucirumab given IV
214559633|NCT04145700|DRUG|Gemcitabine|Gemcitabine given IV
214559634|NCT04145700|DRUG|Docetaxel|Docetaxel given IV
214559635|NCT02293577|DEVICE|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
214559636|NCT03598153|DRUG|Shujinjianyao Pill|According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
214559637|NCT05646576|BEHAVIORAL|Palliative Care|"* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.~* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.~* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot."
214559638|NCT05646576|BEHAVIORAL|Usual Care|Standard care for ACT per the treating team.
214559639|NCT00818779|DRUG|Aliskiren|150 - 300 mg once daily for 6 weeks
214559640|NCT00818779|DRUG|Amlodipine|5-10 mg once daily for 6 weeks
214559641|NCT02240953|DRUG|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
214559642|NCT02240953|DRUG|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
214559643|NCT02240953|DRUG|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
214559644|NCT02240953|DRUG|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
214559645|NCT03112824|DIETARY_SUPPLEMENT|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
214559646|NCT03112824|OTHER|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
214559647|NCT01343862|DRUG|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
214559648|NCT01343862|DRUG|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
214559649|NCT05009160|DEVICE|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
214559650|NCT04978493|DRUG|BI 706321|One dose of 8 mg as tablets orally once per day in the morning
214559651|NCT04978493|DRUG|Ustekinumab|A single intravenous infusion of 260 mg (body weight ≤55 kg), 390 mg (body weight 55-85 kg), or 520 mg (body weight \>85 kg) was administered on Day 0, followed by subcutaneous injection of 90 mg every 8 weeks.
214559652|NCT04978493|DRUG|Placebo|One dose of placebo matching BI 706321 as tablets orally once per day in the morning
214559653|NCT02712164|DEVICE|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
214559654|NCT02712164|DEVICE|Tegaderm|Standard of care for STSG donor sites.
214706013|NCT01726283|DRUG|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
214706014|NCT05594212|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
214706015|NCT03429322|BEHAVIORAL|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
214706016|NCT03429322|OTHER|Usual Care|Participants will receive and provide usual and customary care in their communities.
215164231|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
215164232|NCT01138436|DRUG|MEBO Wound Ointment (MEBO)|Topical application once a day
215164233|NCT01138436|PROCEDURE|Standard of Care|Application of Profore multilayer compression bandage system
214559655|NCT01808677|OTHER|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
214559656|NCT04312269|OTHER|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
214559657|NCT06319274|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
214559658|NCT06319274|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
214559659|NCT04311645|DRUG|Activated charcoal|Activated charcoal
214559660|NCT04311645|DIETARY_SUPPLEMENT|Dry seeds|Dry seeds
214559661|NCT00613743|DRUG|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
214559662|NCT00613743|DRUG|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
214559663|NCT06021626|DRUG|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"
214559664|NCT01342432|OTHER|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
214559665|NCT01342432|OTHER|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
214559666|NCT03326362|OTHER|Resistance training|Comparison between high and low intensities trainings described in arms
214559667|NCT04728139|DIAGNOSTIC_TEST|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
214706017|NCT03724617|DRUG|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
214706018|NCT04697602|DRUG|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
214706019|NCT04697602|DRUG|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
214706020|NCT00889811|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
215164234|NCT06819865|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).
215164235|NCT06641908|DRUG|M3554|M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
215164236|NCT05632380|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
215164237|NCT05632380|BIOLOGICAL|C-CAR088|C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
215164238|NCT06109857|OTHER|Non-Interventional Study|Non-interventional study
215164239|NCT06986863|OTHER|Always Uniquely Me mobile phone application|The app will allow the user to organize their healthcare information and personal needs which can help improve communication with doctors, clinicians and first responders.
215164240|NCT06098651|DRUG|DCR-STAT3|DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.
214559668|NCT06120868|OTHER|Surefil one®|For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
214559669|NCT06120868|OTHER|Filtek One|Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
214559670|NCT01327846|DRUG|Canakinumab|
214559671|NCT01327846|DRUG|Placebo|
214559672|NCT01327846|DRUG|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
215164241|NCT06987968|DRUG|VS-01 on top of SOC (Active Treatment Group)|Patients will received VS-01 intraperitoneally up to four consecutive days on top of SOC
215164242|NCT06987968|DRUG|SOC|Patients will received SOC
215164243|NCT06987643|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
215164244|NCT06987643|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
215164245|NCT06649812|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
215164246|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164247|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
215164248|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
215164249|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
215164250|NCT06649812|DRUG|Ibrutinib|Given PO
214559673|NCT04820998|OTHER|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
215164251|NCT06649812|DRUG|Lenalidomide|Given PO
215164252|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164253|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
215164254|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
215164255|NCT06649812|DRUG|Prednisone|Given PO
215164256|NCT06649812|DRUG|Venetoclax|Given PO
215164257|NCT06296056|BIOLOGICAL|Combi|Biological immune cell therapy
215164258|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
215164259|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
215164260|NCT06660355|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase inhibitor.
215164261|NCT06660355|DRUG|Prednisone|Prednisone is a glucocorticoid.
215164262|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
215164263|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
215164264|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
215164265|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
215164266|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
214706021|NCT05718661|BEHAVIORAL|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
215164267|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
214706022|NCT05718661|BEHAVIORAL|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
214706023|NCT00646113|DEVICE|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
214706024|NCT02109744|DRUG|Decitabine|
215164268|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
214706025|NCT05355935|DRUG|Brensocatib|Oral tablet.
214706026|NCT05355935|DRUG|Moxifloxacin|Oral tablet.
215164269|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
215164270|NCT06654037|DRUG|Abemaciclib|Given PO
215164271|NCT06654037|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
215164272|NCT06654037|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164273|NCT06654037|DRUG|Fluorouracil|Given IV
215164274|NCT06654037|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
215164275|NCT06660433|DEVICE|Point-of-care respiratory test platform|A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
215164276|NCT06660433|OTHER|Existing respiratory virus testing platform|Currently used respiratory virus testing platforms
215164277|NCT05867602|DRUG|Albumin|intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
215164278|NCT06824818|BEHAVIORAL|LHRH Agonist Therapy Discontinuation|The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
215164279|NCT04603014|COMBINATION_PRODUCT|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
215164280|NCT05202353|DRUG|BI 456906|BI 456906
215164281|NCT05202353|DRUG|Semaglutide|Semaglutide
215164282|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
215164283|NCT05592990|DRUG|NGI226|NGI226 MP
215164284|NCT05592990|DRUG|Placebo|Placebo MP
214559674|NCT04820998|OTHER|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
214559675|NCT04629456|OTHER|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
214706027|NCT05355935|DRUG|Placebo|Oral tablet.
214706028|NCT03099980|BIOLOGICAL|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
214706029|NCT03604068|DEVICE|RecoveryRx|A pulsed shortwave therapy medical device
215164285|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE001|P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
214706030|NCT03604068|DEVICE|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
215164286|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE002|P. vivax challenge agent derived from PvHMB-CCE002 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
215164287|NCT06608940|DRUG|BC3402|BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
215164288|NCT06608940|DRUG|Durvalumab|Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
215164289|NCT06608940|DRUG|Tremelimumab|Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
215164290|NCT06985862|OTHER|Voice recording 4 times a day|"* Morning (first recording): Text reading (article 25.1 of the Declaration of Human Rights).~* Noon (second recording): Counting from 1 to 20 at normal speed~* Evening (third recording): Prolonged phonation of the vowel 'a' without catching your breath.~* Bedtime (fourth recording): Free expression describing stressful moments of the day and their impact on diabetes management, for at least 30 seconds."
215164291|NCT06608927|DRUG|Quemliclustat|Administered as specified in the treatment arm
215164292|NCT06608927|DRUG|Placebo|Administered as specified in the treatment arm
215164293|NCT06608927|DRUG|Nab-paclitaxel|Administered as specified in the treatment arm
215164294|NCT06608927|DRUG|Gemcitabine|Administered as specified in the treatment arm
215164295|NCT06986200|PROCEDURE|Chest Compressions|Performing chest compressions in full firefighter's personal protcetion equipment
214706031|NCT06580730|PROCEDURE|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
214559676|NCT04629456|OTHER|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
214559677|NCT01523600|BEHAVIORAL|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
214706032|NCT06580730|OTHER|Standard medical treatment|Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
214706033|NCT01670175|DRUG|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
215164296|NCT06986200|PROCEDURE|One minute rotation intervall|Chest compressions using a one minute rotation intervall
215164297|NCT06986200|PROCEDURE|Two minute rotation intervall|Chest compressions using a two minute rotation intervall
215164298|NCT06985953|OTHER|TrialTalk™|TrialTalk™ is a communication tool that focuses on making the options visible and accessible while involving patients in the discussion.
215164299|NCT06498960|DEVICE|CereVasc eShunt System|"The eShunt System consists of the following components:~* eShunt Implant~* eShunt Delivery Catheter and Transfer Tool~* eShunt Anchor"
215164300|NCT06498960|DEVICE|VP Shunt|Control arm - VP shunt
215164301|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
215164302|NCT00001465|DEVICE|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
215164303|NCT06817889|DRUG|Remdesivir|Given IV
215164304|NCT06817889|OTHER|Survey Administration|Ancillary studies
215164305|NCT06817889|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164306|NCT06817889|PROCEDURE|Nasal Swab|Undergo nasal swabs
215164307|NCT06597396|DRUG|Abrocitinib|50 mg tablets
215164308|NCT06597396|DRUG|Placebo|Tablets
215164309|NCT06586437|BEHAVIORAL|Clinical Assessments|The participant will undergo a battery of clinical assessments to identify the upper extremity motor performance, sensory acuity, and ability to complete activities of daily living. Tests 1-5 will be completed separately for each hand. All participants will be video recorded while completing these assessments. The recordings will be used for grading tasks and data analysis: Box and Blocks, 9-hold peg board, Test of Arm Selective Control, Sensory Acuity Testing, KINARM End-Point Lab Sensory Test, Section GG of the inpatient Rehabilitaion Facility-Patient Assessment Instrument, NEURO-QOL Upper Extremity Function Scale, Edinburgh Handed Inventory
215164310|NCT06586437|BEHAVIORAL|Brain-Spinal Cord fMRI|Resting state, brain-spinal cord activity, spinal cord microstructure, magnetic resonance spectroscopy
215164311|NCT06586437|BEHAVIORAL|Hoffmann Reflex Assessments|Hmax 20-50 stimulations of increasing intensity. Next, the participant will sit quietly as 10 stimulations will be delivered at the participant's Hmax with an interstimulus interval of 15 seconds. Subsequently, stimulations at the participant's Hmax will be applied as the participants produce a contraction of 10-20% of their maximum voluntary contraction (MVC). The target contraction level will be shown in real-time based on the FCR EMG activity. The participant maintains their EMG activity at the target level for 6.5 seconds as 10 stimulations are delivered at the participants Hmax.
215164312|NCT06586437|BEHAVIORAL|MEG Imaging|Resting state, somatosensory, isometric force matching, entrainment
214706034|NCT02572011|OTHER|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
214706035|NCT05220241|BIOLOGICAL|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
214559678|NCT01523600|BEHAVIORAL|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
214559679|NCT06432673|DRUG|ATR-258 Oral solution|Oral solution
214559680|NCT06432673|DRUG|ATR-258 Oral capsule|Oral capsule
214559681|NCT05167422|BEHAVIORAL|Trusted Messenger|A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
214559682|NCT01509001|DRUG|Metformin|750 to 2500 mg/day, two times a day during 4 months
214706036|NCT04744610|DIAGNOSTIC_TEST|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
214706037|NCT05725330|OTHER|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
214706038|NCT04938271|DEVICE|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
214706039|NCT03019705|OTHER|Observation|
214706040|NCT04625985|DRUG|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
214706041|NCT04625985|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
214706042|NCT01141127|DRUG|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
215164313|NCT06586437|BEHAVIORAL|Transcutaneous Current Stimulation|Cortical stimulation, spinal cord stimulation - sham and stim
215164314|NCT06593756|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
215164315|NCT06593756|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
215164316|NCT06593756|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
215164317|NCT06593756|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
215164318|NCT06593756|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
214559683|NCT01509001|DRUG|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
214559684|NCT04515433|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
214559685|NCT04343976|DRUG|Pegylated interferon lambda|180 mcg subcutaneous injection of pegylated interferon lambda
214559686|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
214559687|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
214559688|NCT02217215|DEVICE|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
214706043|NCT05959304|OTHER|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
214706044|NCT00898404|OTHER|laboratory biomarker analysis|Correlative studies
215164319|NCT06593756|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
215164320|NCT06593756|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
214706045|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
214706046|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
214706047|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
215164321|NCT06593756|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
215164322|NCT06593756|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning
215164323|NCT06593405|COMBINATION_PRODUCT|occupational therapy interventions for low vision care|Occupational therapists utilize many different treatment strategies when caring for the client with low vision. Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Interventions include task lighting, organizational strategies, smart apps, contrast, enlarged print, typoscopes and electronic magnification devices.
215164324|NCT06246136|PROCEDURE|ELIOS|Following cataract surgery, surgeon will proceed to ELIOS treatment.
215164325|NCT06246136|PROCEDURE|Competitor Device|Following cataract surgery, surgeon will proceed to Competitor treatment.
215164326|NCT06840392|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
214706048|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
214706049|NCT04768699|DRUG|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
214706050|NCT04768699|DRUG|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
214706051|NCT04768699|DRUG|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
215164327|NCT06840392|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
214559689|NCT00661297|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
214559690|NCT00661297|DRUG|Placebo|Matching placebo
214559691|NCT01371708|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
214559692|NCT00694109|DRUG|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
214559693|NCT02012023|DEVICE|Low anterior resection|
214559694|NCT02012023|DEVICE|tube ileostomy|
214559695|NCT02012023|DEVICE|loop ileostomy|
214559696|NCT02012023|DEVICE|accept reversal operation|
215164328|NCT06840392|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
214559697|NCT02012023|DEVICE|remove the tube ileostomy|
214559698|NCT04134624|OTHER|Sepsis care bundle|Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
214559699|NCT05613777|DRUG|Microgynon®|ethinylestradiol (EE) and levonorgestrel (LNG)
214559700|NCT05613777|DRUG|BI 425809|BI 425809
215164329|NCT06840392|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
215164330|NCT06843239|BIOLOGICAL|Tibulizumab|Anti BAFF/IL-17 antibody
214559701|NCT03349151|BEHAVIORAL|Early feeding|Feeding on postoperative 2nd hour on return to the ward
214559702|NCT03349151|BEHAVIORAL|On- Demand feeding|Feeding whenever the patient asks for on return to the ward
214559703|NCT02487043|BEHAVIORAL|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
214559704|NCT03921853|OTHER|Behavioral|The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
214559705|NCT01254747|DEVICE|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
214559706|NCT01254747|DEVICE|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
214559707|NCT01254747|DEVICE|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
214559708|NCT01254747|DEVICE|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
214559709|NCT04954092|BIOLOGICAL|Gam-COVID-vac M|The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus
214559710|NCT04954092|BIOLOGICAL|Placebo|Composition without active ingredients
214559711|NCT00178555|DEVICE|DCI Video Intubation System-Macintosh Laryngoscope|
214559712|NCT00178555|DEVICE|Macintosh Laryngoscope|
214559713|NCT03759782|DRUG|Ribavirin|Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
214559714|NCT03759782|DRUG|Tenofovir|Tenofovir as per standard of care
214559715|NCT02532127|OTHER|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
214559716|NCT00613899|OTHER|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
214559717|NCT00930670|DRUG|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
214559718|NCT00930670|DRUG|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
214559719|NCT00930670|DRUG|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
214559720|NCT00930670|DRUG|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
214559721|NCT00930670|DRUG|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
214559722|NCT00930670|DRUG|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
214559723|NCT00930670|DRUG|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
214559724|NCT00930670|DRUG|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
214559725|NCT00245960|DRUG|etanercept|
214559726|NCT00245960|DRUG|etanercept|
214559727|NCT00245960|DRUG|Placebo|
214559728|NCT02097589|DRUG|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
214559729|NCT02097589|DRUG|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
215164331|NCT06843239|OTHER|Placebo|Placebo (inactive)
215164332|NCT06842355|DRUG|TYRA-300 0.125 mg/kg|Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
215164333|NCT06842355|DRUG|TYRA-300 0.25 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
215164334|NCT06842355|DRUG|TYRA-300 0.375 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
215164335|NCT06842355|DRUG|TYRA-300 0.50 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
215164336|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
215164337|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
215164338|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
215164339|NCT02841748|DRUG|Pembrolizumab|200mg, every three weeks, iv, x 1 year
215164340|NCT02841748|DRUG|Placebo|iv, every three weeks, x 1 year
215164341|NCT05450328|DRUG|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
215164342|NCT05450328|DRUG|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
214559730|NCT02097589|OTHER|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
214559731|NCT00147589|DRUG|Eplerenone|
214559732|NCT03924700|PROCEDURE|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
214559733|NCT03924700|PROCEDURE|Microdiscectomy|Using microscope for discectomy
214559734|NCT05395195|DRUG|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
214559735|NCT05395195|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
214559736|NCT06358248|DEVICE|Physician-modification of Valiant Captivia Endograft (Medtronic, Minneapolis, MN-USA).|"On a sterile back-table a Valiant Captivia thoracic graft is deployed. A dotted line is drawn to mark the graft anterior 0° degree, and fabric holes are performed with cautery in the desired position. The fenestrations need to be 6x6 mm for the renals and 8x8 mm for superior mesenteric artery (SMA) and celiac trunk (CT), and are reinforced with the tip of a 0.018 guidewire through a continuous 5-0 locking suture.~A posterior constraining wire is created to reduce the diameter of the graft by 20-30%, in order to allow rotation during the deployment phase. The four 8 markers on the top of the graft are carefully removed with a scalpel; one of these is modified as an S and re-sutured on the anterior aspect at 0 degree position, with a 5-0 prolene continuous suture. This S marker will allow anteroposterior graft orientation. Finally, the graft is re-sheathed and deployed."
214559737|NCT00737698|OTHER|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
214559738|NCT00737698|OTHER|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
214559739|NCT05141552|DRUG|Dapagliflozin 10Mg Tab|In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
214559740|NCT00912392|DRUG|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
214559741|NCT00912392|DRUG|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
214559742|NCT05316974|OTHER|Prevalence of lymphoedema|Measures of lymphoedema
214559743|NCT00004877|DRUG|BMS-214662|
214559744|NCT05650762|DEVICE|Cinesteam|Cinnamon-based Secondary dressing
214559745|NCT03444896|DEVICE|Acupuncture group|Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
214559746|NCT03444896|DEVICE|Sham acupuncture group|Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
214559747|NCT00126698|DRUG|trimethoprim-sulfamethoxazole|
214559748|NCT00126698|DRUG|ciprofloxacin|
214559749|NCT00034788|DRUG|Becaplermin|
214559750|NCT02360735|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
214559751|NCT02360735|OTHER|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
214559752|NCT00831662|DRUG|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
214559753|NCT00831662|DRUG|Placebo|One to two drops in each eye QID for 6 weeks
214559754|NCT05821920|DEVICE|MUST MINI system|cervical posterior fixation system
214559755|NCT01067846|DRUG|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
214559756|NCT01067846|DRUG|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
214559757|NCT01067846|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
214559758|NCT06366412|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
214559759|NCT06366412|OTHER|normal saline|normal saline will be administrated in placebo group
214559760|NCT01839942|PROCEDURE|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
214559761|NCT01839942|PROCEDURE|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
214559762|NCT01396772|BEHAVIORAL|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
214559763|NCT01396772|OTHER|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
214559764|NCT03299751|BIOLOGICAL|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
214559765|NCT01755572|DRUG|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
214706052|NCT04717076|BEHAVIORAL|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
215164343|NCT05053347|DIETARY_SUPPLEMENT|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 4.5 g/d (ALA 2.5g/d). The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
215164344|NCT05053347|DIETARY_SUPPLEMENT|Corn oil capsule|The participants were asked to take corn oil capsule 4.5 g/d. The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
215164345|NCT06858865|DRUG|AD-228A|AD-228A Oral Tablet
215164346|NCT06858865|DRUG|AD-2281 and AD-2282|AD-2281 Oral Tablet + AD-2282 Oral Tablet
215164347|NCT06858579|DRUG|DNTH103|IV Infusion
215164348|NCT06858579|DRUG|DNTH103|SC injection
215164349|NCT06858579|DRUG|Placebo|SC injection
215164350|NCT06854549|BEHAVIORAL|Parental Reading Picture-book|"In addition to receiving routine care, the experimental group will be given the Reading Picture Books from Scratch educational booklet once the preterm infant is removed from the incubator, the group assignment is confirmed, and participation in the study is verified. They will then undergo the Picture Book Reading Intervention. This intervention targets the preterm infant and one of the parents. It involves reading picture books from the second to the fourth day after the infant is removed from the incubator, during the visiting period from 14:10 to 14:20."
215164351|NCT04716231|BIOLOGICAL|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
215164352|NCT04716231|OTHER|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
215164353|NCT06654752|OTHER|Immediate Oral Antibiotics|Increase airway clearance and start 14 days of preselected oral antibiotics right away
215164354|NCT06654752|OTHER|Tailored Treatment: Oral Antibiotics only if Additional Treatment needed|Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
215164355|NCT06654193|DRUG|Allogeneic HB-adMSCs|Allogeneic HB-adMSCs
215164356|NCT06654193|DRUG|Normal Saline|Sterile Saline Solution
215164357|NCT06859099|DRUG|Riliprubart Prefilled Pen (PFP)|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
215164358|NCT03238976|OTHER|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
215164359|NCT04039464|DRUG|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
215164360|NCT04039464|DRUG|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
215164361|NCT06989957|DRUG|Psilocybin|Experimental Psilocybin (exact dosages not disclosed)
215164362|NCT06989957|DRUG|Psilocybin|Comparator Psilocybin (exact dosages not disclosed)
215164363|NCT06989957|DRUG|MDMA|Experimental MDMA (exact dosages not disclosed)
214706053|NCT04717076|BEHAVIORAL|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
214706054|NCT04717076|BEHAVIORAL|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
214706055|NCT03827668|DRUG|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
215164364|NCT06989957|DRUG|MDMA|Comparator MDMA (exact dosages not disclosed)
215164365|NCT06988527|DRUG|Honey in orabase 1: 1 paste|The experimental drug was manufactured and packed at the Faculty of Pharmacy, Price Sattam University, SA. Production of a mucoadhesive paste involves a step-by-step process. in the final step, honey, comprising 50% of the total composition was thoroughly blended with the prepared base to ensure homogeneity
214706056|NCT03827668|DRUG|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
214706057|NCT03827668|DRUG|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
214706058|NCT02282176|DRUG|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
214706059|NCT02282176|DRUG|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
214706060|NCT00700531|DEVICE|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
214706061|NCT00700531|PROCEDURE|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
214706062|NCT04656418|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
214706063|NCT04656418|DRUG|Placebo|Buffer without active ingredient
214706064|NCT03287245|DRUG|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
214706065|NCT02701192|OTHER|Coccygectomy|Patient receiving coccygectomy surgery.
214706066|NCT02779673|OTHER|Yoghurt drink containing plant stanol as esters|
214706067|NCT02779673|OTHER|Yoghurt drink without plant stanol as esters|
214706068|NCT05248555|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
214706069|NCT00989612|BIOLOGICAL|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
214706070|NCT00352313|DRUG|ATN-161|Given IV
214559766|NCT01755572|DRUG|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
214559767|NCT01167491|BIOLOGICAL|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
214559768|NCT00318539|DRUG|Quetiapine|
214559769|NCT04744753|DRUG|Calcium Ionophore A23187|"Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF."
214559770|NCT04652505|OTHER|Questionnaire Administration|Complete questionnaires
214559771|NCT00260377|PROCEDURE|Coronary artery bypass surgery|
214559772|NCT02654652|DIETARY_SUPPLEMENT|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
214559773|NCT02654652|DIETARY_SUPPLEMENT|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
214559774|NCT02458222|OTHER|language game therapy|participants will take part in game therapy
214559775|NCT02458222|OTHER|standard therapy|usual clinical care
214559776|NCT02578446|DEVICE|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
214559777|NCT02578446|DEVICE|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
214559778|NCT00201877|DRUG|Velcade|"Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 \& 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23."
214559779|NCT00201877|DRUG|Rituximab|"Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks."
214706071|NCT00352313|DRUG|carboplatin|Given IV
214706072|NCT05359809|BEHAVIORAL|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
214706073|NCT02854007|DEVICE|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
214706074|NCT01875913|BEHAVIORAL|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
214706075|NCT01875913|BEHAVIORAL|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
214706076|NCT02150213|PROCEDURE|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
214706077|NCT02150213|PROCEDURE|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
214706078|NCT02150213|PROCEDURE|Sonogram|Sonogram of the uterus (females only)
214706079|NCT02150213|PROCEDURE|Biopsy|Uterine endometrial biopsy (females only)
214706080|NCT02150213|DRUG|BGG492|No study-drug was administered in this study
215164366|NCT05975905|BIOLOGICAL|Dose A KER-012|Dose A KER-012 (Q4W);
215164367|NCT05975905|BIOLOGICAL|Dose B KER-012|Dose B KER-012 (Q4W);
214706081|NCT00751179|DRUG|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
214706082|NCT00751179|DRUG|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
215164368|NCT05975905|BIOLOGICAL|Dose C KER-012|Dose C KER-012 (Q4W);
214559780|NCT03508401|OTHER|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
214559781|NCT03508401|DEVICE|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
214559782|NCT03658759|PROCEDURE|Extracorporeal Cardiopulmonary Resuscitation|local ECPR clinical pathway, including transport with mechanical chest compression device and rapid response VA-ECMO
214559783|NCT04912427|DRUG|Isatuximab|Isatuximab is supplied by Sanofi.
214559784|NCT04912427|DRUG|Bortezomib|Bortezomib is commercially available.
214559785|NCT04912427|DRUG|Dexamethasone|Dexamethasone is commercially available.
214559786|NCT04332055|OTHER|ERVIN|ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
214559787|NCT03818126|DRUG|del Nido cardioplegia|"The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit."
214559788|NCT03818126|DRUG|cold blood cardioplegia|"The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius."
214559790|NCT00577057|PROCEDURE|Conventional Radiotherapy|
214559791|NCT00577057|PROCEDURE|Accelerated Radiotherapy|
214559792|NCT00577057|DRUG|Cisplatin|
214559793|NCT00577057|DRUG|5-fluorouracil|
214559794|NCT00577057|DRUG|Capecitabine|
214559795|NCT01943942|DRUG|Montelukast 10 mg|Reference product
214559796|NCT01943942|DRUG|Montelukast 10 mg|Test product
214559797|NCT06246695|DRUG|Jaktinib Hydrochloride Tablets|Oral Jaktinib 100 mg for 1 day
214559798|NCT06246695|DRUG|Itraconazole capsule|Oral Itraconazole 200 mg for 9 day
214559799|NCT06246695|DRUG|Rifampicin Capsules|Oral Rifampicin 600 mg for 11 day
214559800|NCT01361542|DRUG|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
214559801|NCT01361542|DRUG|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
214559802|NCT06035302|PROCEDURE|Madany Closure|Madany Closure is a new technique for the porte site closure
214559803|NCT06035302|PROCEDURE|Standard closure|Standard closure technique of the port site from ecternal
215164369|NCT05975905|BIOLOGICAL|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
214559804|NCT04608773|OTHER|Remineralizing Extreme Dry Mouth Spray with Xylitol|oral hydrating spray
214559805|NCT04608773|DEVICE|Alcohol-Free Moisturizing Dry Mouth Spray|oral hydrating spray
214559806|NCT04796077|OTHER|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
214559807|NCT02541370|BIOLOGICAL|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
214559808|NCT05444270|OTHER|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
214559809|NCT05444270|RADIATION|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
214559810|NCT04843267|DRUG|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
214559811|NCT02710175|OTHER|serum TSH level|
214559812|NCT01938053|OTHER|Call when test results are ready|Patients are called when the test results are ready
214559813|NCT01938053|OTHER|Text message when test results are ready|Patients receive a text message when results are ready
214559814|NCT01938053|OTHER|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
215164370|NCT04012411|PROCEDURE|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
215164371|NCT04012411|PROCEDURE|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
215164372|NCT04012411|GENETIC|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
215164373|NCT04012411|OTHER|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
215164374|NCT05089695|DEVICE|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
215164375|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
214559815|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
214559816|NCT03312413|DRUG|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
214559817|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
214559818|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
214706083|NCT00751179|DRUG|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
214706084|NCT03667508|PROCEDURE|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
214706085|NCT03667508|PROCEDURE|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
214706086|NCT02670018|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day
214706087|NCT02670018|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
214706088|NCT01666145|DEVICE|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
214706089|NCT01297309|DRUG|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
214706090|NCT00122421|BEHAVIORAL|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
214706091|NCT00122421|OTHER|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
214706092|NCT03039738|DEVICE|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
214706093|NCT03039738|DEVICE|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
214706094|NCT00324688|DRUG|Viread|
214706095|NCT00024193|BIOLOGICAL|filgrastim|
214706096|NCT00024193|DRUG|busulfan|
214706097|NCT00024193|DRUG|cisplatin|
214706098|NCT00024193|DRUG|cyclophosphamide|
214706099|NCT00024193|DRUG|doxorubicin hydrochloride|
215164376|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
215164377|NCT02901821|GENETIC|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
215164378|NCT06592001|DEVICE|Atala™ lead|Subjects will receive the Atala™ lead being evaluated in the study.
214706100|NCT00024193|DRUG|etoposide|
214706101|NCT00024193|DRUG|melphalan|
214706102|NCT00024193|DRUG|vincristine sulfate|
214706103|NCT00024193|PROCEDURE|conventional surgery|
214706104|NCT00024193|PROCEDURE|peripheral blood stem cell transplantation|
214706105|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
214706106|NCT02678312|DRUG|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
214706107|NCT02678312|DRUG|Placebo of LCZ696|
215164379|NCT06665906|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy (PainTrainer)|Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
215164380|NCT06665906|BEHAVIORAL|Social Intervention|At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
215164381|NCT06855732|BEHAVIORAL|Usual Care|"Usual care refers to the standard of care that patients receive at their primary care clinic.~The standard of care for patients is to discuss chronic pain with their providers at their discretion, and for providers to offer buprenorphine for OUD and/or provide referrals to specialty addiction treatment programs in the local community.~Participants will continue to have access to usual care for chronic pain, which could include pain clinic visits, physical therapy, medication (e.g., gabapentin), and/or seeing a counselor, psychiatrist, or psychologist.~The study protocol will not interfere with usual clinical care."
214559819|NCT04195802|OTHER|Salt and potassium Diet|Self-administration questionnary to evaluate the salt and potassium consumption
214559820|NCT02387970|PROCEDURE|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
214559821|NCT02387970|PROCEDURE|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
214559822|NCT02387970|DEVICE|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
214706108|NCT02678312|DRUG|Placebo of Enalapril|
214706109|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
214706110|NCT02527187|BIOLOGICAL|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
214706111|NCT02527187|BIOLOGICAL|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
214706112|NCT02527187|BIOLOGICAL|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
214706113|NCT02527187|BIOLOGICAL|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
214706114|NCT06506838|DRUG|Anlotinib|For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
215164382|NCT06855732|BEHAVIORAL|Pain Self-Management|"PSM is a manualized behavioral intervention tailored to patients in primary care with opioid misuse/OUD. The PSM intervention that consists of ten sessions/modules.~Participants will be offered a total of 10 PSM sessions, delivered weekly over a 12-week intervention period starting from the date of study enrollment.~A trained staff interventionist will lead the 60-minute sessions using a participant study manual that outlines the content for all 10 sessions.~The first two sessions, Introduction and Navigating Conversations About Opioids, are mandatory. Participants can choose the order of the remaining 8 sessions, prioritizing those they are most interested in. Additional session topics are: Stress Management and Your Pain, Relaxation Techniques to Help Your Pain, Thinking Differently About Your Pain, Sleeping Better to Help Your Pain, Physical Activity and Your Pain, Mood and Your Pain, and Communicating with Others."
215164383|NCT03942328|BIOLOGICAL|Atezolizumab|Given IV
215164384|NCT03942328|BIOLOGICAL|Bevacizumab|Given IV
215164385|NCT03942328|RADIATION|External Beam Radiation Therapy|Undergo high-dose EBRT
215164386|NCT03942328|PROCEDURE|Pheresis|Undergo apheresis
215164387|NCT03942328|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
215164388|NCT03942328|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given IT
215164389|NCT03942328|BIOLOGICAL|Tiragolumab|Given IV
215164390|NCT03942328|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
215164391|NCT03942328|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215164392|NCT03942328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215164393|NCT03942328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164394|NCT03942328|PROCEDURE|Biopsy Procedure|Undergo biopsy
215164395|NCT03942328|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
215164396|NCT06995521|DRUG|Vorinostat|"For Matched sibling and matched unrelated donor transplant recipients: Vorinostat will be given orally at a dose of 60 milligrams per square meter two times a day (BID) (120 mg/m2/day) from day -10 to day 30 post-transplant. The maximum dose will be 100 mg BID.~Haploidentical donor transplant recipients:~Vorinostat will be given orally at a dose of 60 mg/m2 BID (120 mg/m2/day) from day +5 (at least 24 hours after completion of the day +4 cyclophosphamide) through day 30 post-transplant. The maximum dose will be 100 mg BID.~Dosing may be rounded by +/- 10%. Patients that are able to take capsules and whose calculated dose is ≥91 mg may take 100 mg capsules."
215164397|NCT06993610|BIOLOGICAL|Tibulizumab Dose A|Anti BAFF/IL-17 antibody. ZB-106
214706115|NCT02335203|DRUG|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
215164398|NCT06993610|BIOLOGICAL|Tibulizumab Dose B|Anti BAFF/IL-17 antibody. ZB-106
215164399|NCT06993610|OTHER|Placebo|ZB-106 Placebo
215164400|NCT06668870|BEHAVIORAL|Supplemental Text Messaging|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. Supplemental text messages will be sent to engage patients and deliver personalized reminders to complete monitoring tasks.
215164401|NCT06668870|BEHAVIORAL|Education and Training for Patient-Generated Data|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information.
215164402|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via a PFS
215164403|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via an AI
215164404|NCT02850575|DEVICE|Mpact Double Mobility cup|
215164405|NCT05082571|DRUG|vadadustat|Vadadustat tablet orally once a day for 52 weeks
215164406|NCT06995872|DRUG|rhIL-15|rhIL-15 will be given at a dose of 0.13-2 mcg/kg/day (based on dose level) as a continuous IV infusion for 5 days each cycle.
215164407|NCT06995872|DRUG|Dinituximab|Dinituximab will be given at a dose of 17.5 mg/m\^2/dose by IV on days 2-5 of each cycle.
215164408|NCT06995872|DRUG|Temozolomide|Temozolomide will be given orally (PO) at a dose based on weight on days 1-5 of each cycle beginning with cycle 2.
215164409|NCT06995872|DRUG|Irinotecan Hydrochloride|Irinotecan will be given at a dose of 50 mg/m\^2/dose by IV on days 1-5 of each cycle beginning with cycle 2.
215164410|NCT06994923|BEHAVIORAL|BWLI-College|Behavioral modifications are based on empirically-supported principles for weight loss. Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention. Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant.
215164411|NCT06994923|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
214559823|NCT02387970|DEVICE|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
214559824|NCT02271360|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
214706116|NCT02335203|OTHER|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
214706117|NCT04445350|OTHER|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
214706118|NCT04445350|OTHER|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
215164412|NCT06056427|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
215164413|NCT06409130|DRUG|NNC0194-0499|Administered subcutaneously.
215164414|NCT06409130|DRUG|Semaglutide|Administered subcutaneously.
215164415|NCT06409130|DRUG|NNC0194-0499 placebo|Administered subcutaneously.
215164416|NCT06409130|DRUG|Semaglutide placebo (Group A)|Administered subcutaneously.
215164417|NCT06409130|DRUG|Cagrilintide + semaglutide|Administered subcutaneously.
215164418|NCT06409130|DRUG|Cagrilintide|Administered subcutaneously.
215164419|NCT06409130|DRUG|Cagrilintide placebo|Administered subcutaneously.
215164420|NCT06409130|DRUG|Semaglutide placebo (Group B)|Administered subcutaneously.
215164421|NCT00874458|PROCEDURE|magnetic resonance imaging|
215164422|NCT00874458|PROCEDURE|radiomammography|
215164423|NCT00874458|PROCEDURE|ultrasound imaging|
215164424|NCT06996678|BEHAVIORAL|virtual Reality|Virtual Reality: The virtual reality system consists of a camera, television, Eye Toy Play CD and Play Station 2. It is based on the principle of capturing movements represented in a virtual environment (Gatica and Méndez, 2014). In the Eye Toy system, individuals can see themselves on the screen through the camera. In this way, the person constantly interacts with the movements and challenges brought by video games. We can simply call the Eye Toy system a webcam with a motion sensor and microphone. The individual's position in the game is determined on the screen and can perceive the person according to the movements he/she exhibits. The main skills required by the games are; target-based movement, visuomotor skills, praxis and thinking process skills.
215164425|NCT06996678|BEHAVIORAL|occupational therapy|Occupational Therapy: The basis of OT intervention consisted of activities requiring increased attention, behavioral regulation, organizational skills, multiple cognitive skills, and motor skills
215164426|NCT05598931|DEVICE|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
215164427|NCT03771144|PROCEDURE|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
215164428|NCT06540521|OTHER|No intervention|No intervention
215164429|NCT06865105|DRUG|Lutikizumab|Subcutaneous (SC) Injection
215164430|NCT06865105|DRUG|Risankizumab|Subcutaneous (SC) Injection
215164431|NCT06672146|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164432|NCT06672146|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215164433|NCT06672146|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215164434|NCT06672146|DRUG|Decitabine and Cedazuridine|Given PO
215164435|NCT06672146|DRUG|Enasidenib|Given PO
214559825|NCT02271360|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
214559826|NCT04160377|DRUG|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
214559827|NCT00781105|DRUG|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
214559828|NCT03704168|DEVICE|CRYOABLATION|The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
214559829|NCT01310231|DRUG|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
215164436|NCT06672146|DRUG|Venetoclax|Given PO
215164437|NCT06671782|OTHER|Kegel exercises|Kegel exercises without any formal training
215164438|NCT06671782|OTHER|Pelvic Floor Muscle Exercise Program with biofeedback|Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
215164439|NCT06671782|OTHER|Questionnaires|All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
215164440|NCT06671782|OTHER|Interviews|A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
215164441|NCT06673017|DRUG|PTM-101|PTM-101, an absorbable drug product containing paclitaxel
215164442|NCT05668741|DRUG|VX-522 mRNA therapy|Oral inhalation using nebulizer.
215164443|NCT05668741|DRUG|IVA|Tablet for oral administration.
215164444|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
215164445|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
215164446|NCT03100149|DRUG|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
214559830|NCT01310231|DRUG|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
214559831|NCT04662060|DRUG|Acebilustat|100 mg capsule administered orally once daily
214559832|NCT04662060|DRUG|Placebo|Placebo to match acebilustat administered orally once daily
214559833|NCT03534895|DRUG|Midazolam Injectable Solution|intravenous
214559834|NCT03534895|OTHER|Normal saline|intravenous
214559835|NCT03534895|PROCEDURE|Spinal anesthesia|8mg of heavy bupivacaine 0.5% injected in the subarachnoid space, during lateral decubitus
214559836|NCT03534895|PROCEDURE|Surgery|Open inguinal hernia repair, varicose vein stripping, knee arthroscopy or hallux valgus surgery
214559837|NCT03534895|DRUG|Postoperative analgesia|IV acetaminophen 1g + IV ketorolac 30mg
214559838|NCT03534895|DRUG|Rescue analgesia|Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS\>3.
214559839|NCT03534895|DRUG|Wound infiltration|Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
214559840|NCT03534895|DRUG|Analgesia at home|Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
214559841|NCT02084199|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 10 days
214559842|NCT05266703|OTHER|Isotopically labelled iron sulfate 15mg|test drink: water containing isotopic iron solution with vitamin C
214706119|NCT00683813|BEHAVIORAL|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
214706120|NCT01207284|OTHER|Physical Therapy|strengthening passive and active stretching balance training gait training
214706121|NCT00271271|DRUG|oxaliplatine / gemcitabine / Vinorelbine|
215164447|NCT06991738|DIAGNOSTIC_TEST|68Ga-DOTA-TATE PET Scan|68Ga-DOTATATE is administered via intravenous injection of 5 1 mCi in a volume of 3 - 5 ml containing up to 50 micrograms \[68Ga\] DOTATATE.
215164448|NCT06991738|OTHER|Amino acid infusions|Appropriate amino acid solutions infused for this purpose should have a total lysine and arginine content between 18g and 25g and have an osmolality of \<= 1050 mOsmol. Concomitant administration of an amino acid infusion with the study drug 177Lu-DOTA-EB-TATE is for renal protection.
215164449|NCT06991738|DRUG|177Lu-DOTA-EB-TATE|Each single-dose vial contains sodium acetate (24.6 mg/mL), gentisic acid (3.7 mg/mL), L-ascorbate (0.445 mg/mL), DTPA (0.051 mg/mL). 177Lu-DOTA-EB-TATE, is a long-acting radiopharmaceutical for PRRT. It consists of a somatostatin analog peptide (TATE) conjugated with a truncated Evans blue (EB) molecule and the metal chelator 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) with the radioisotope 177Lu stably complexed.
214559843|NCT02172001|DRUG|Iron isomaltoside 1000|
214559844|NCT02172001|DRUG|Natrium Chloride 0,9%|100 ml or 5 ml
214559845|NCT00494520|PROCEDURE|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
215164450|NCT04751487|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
215164451|NCT04751487|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
215164452|NCT06666348|DRUG|Mirdametinib|Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
215164453|NCT06182072|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
215164454|NCT06182072|DRUG|Gemcitabine, nab paclitaxel|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
215164455|NCT06611748|DEVICE|Key Grip|KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing
215164456|NCT06611748|DEVICE|Implanted Key Grip Electrodes|"The KeyGrip System uses modified implanted wires (called electrodes) that deliver stimulation to the muscles. These electrodes are also investigational."
215164457|NCT06822790|DRUG|Plozasiran Injection|ARO-APOC3 injection
215164458|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
214706122|NCT05399849|BEHAVIORAL|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
214706123|NCT02591004|DRUG|Magesium sulphate|\*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
214706124|NCT02591004|DRUG|Nifedipine|\*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
214706125|NCT02591004|RADIATION|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
214706126|NCT04573205|DRUG|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
214706127|NCT04190212|BEHAVIORAL|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
214706128|NCT01028833|OTHER|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
214706129|NCT03989752|DEVICE|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
214706130|NCT02716194|BIOLOGICAL|BAX 826|
214706131|NCT02716194|BIOLOGICAL|Octocog alfa|
214706132|NCT00971425|BIOLOGICAL|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
214706133|NCT00971425|BIOLOGICAL|Fluarix™|1 dose intramuscular injection
214706134|NCT00971425|BIOLOGICAL|Placebo|1 dose intramuscular injection
214706135|NCT00966810|PROCEDURE|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
214706136|NCT01811381|DRUG|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
214706137|NCT01811381|BEHAVIORAL|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
214706138|NCT01811381|BEHAVIORAL|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
214706139|NCT01811381|DIETARY_SUPPLEMENT|Placebo|Subjects will take 4 capsules x BID of placebo
214706140|NCT04469803|BEHAVIORAL|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
214706141|NCT04101448|OTHER|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
214706142|NCT02297737|BEHAVIORAL|Tai Chi|
215164459|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
214706143|NCT02297737|OTHER|Health Education|
214706144|NCT03067194|DRUG|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
214706145|NCT03067194|DRUG|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
214706146|NCT05197140|OTHER|food: cooked 85% lean ground beef|see arm description
214706147|NCT05197140|OTHER|food: Impossible Burger (R)|see arm description
214706148|NCT02294422|DEVICE|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
214706149|NCT02294422|DEVICE|LOR|
214706150|NCT02294422|DEVICE|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
214706151|NCT06064903|BIOLOGICAL|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
214706152|NCT01753830|DEVICE|Durolane|4.5 mL
214706153|NCT01753830|DEVICE|PBS|4.5 mL
214706154|NCT03587584|DRUG|liposomal bupivacaine|Experimental
215164460|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
215164461|NCT05813327|DRUG|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
215164462|NCT05813327|DRUG|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
215164463|NCT05813327|RADIATION|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
214559846|NCT00494520|PROCEDURE|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
214559847|NCT02847286|DRUG|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
214559848|NCT02847286|DRUG|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
214559849|NCT02847286|DRUG|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
214559850|NCT03807895|BEHAVIORAL|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
214559851|NCT03807895|BEHAVIORAL|Regular Career Intervention|Eight sessions of regular career intervention.
214706155|NCT03587584|DRUG|Bupivacaine|Active Comparator
214706156|NCT04230798|OTHER|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
214706157|NCT03206112|OTHER|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
214706158|NCT03206112|OTHER|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
214706159|NCT03206112|OTHER|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
215164464|NCT05813327|DRUG|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
215164465|NCT06746753|DRUG|Angiotensin II|randomized to receive Angiotensin II continuous infusion for up to 48 hours
215164466|NCT06746753|DRUG|Norepinephrine|randomized to receive Norepinephrine continuous infusion for up to 48 hours
215164467|NCT06859346|DIETARY_SUPPLEMENT|Arm 1: TisinaTM complex|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
215164468|NCT06859346|DIETARY_SUPPLEMENT|Arm 2: Placebo (Microcrystalline Cellulose)|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
215164469|NCT06998134|DEVICE|Extension assist knee ankle foot orthosis (EA-KAFO)|A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion).
215164470|NCT06586905|DEVICE|Medical Device|Multiplo Complete Syphilis (TP/nTP) Antibody Test
215164471|NCT07000279|DEVICE|Assistive exoskeleton for activities of daily living (ADLs)|Portable assistive exoskeleton to support upper limb movement during activities of daily living
215164472|NCT07000279|DEVICE|Assistive exoskeleton for box and block|Portable assistive exoskeleton to support box and block test execution
215164473|NCT07000279|DEVICE|Assistive exoskeleton for maximum reaching height|Portable assistive exoskeleton to raise the upper limb at the maximum of its capability to reach objects at different heights
215164474|NCT07000591|OTHER|Experimental Group|"Patients will receive a neck massage based on Watson's Human Caring Model in addition to standard medical care. The massage will be performed three times a week for eight weeks, totaling 24 sessions. Sessions will last 30 minutes and follow evidence-based nursing interventions. Care will be individualized and delivered in a calming environment.~Pre- and post-intervention assessments will include the Epilepsy Self-Efficacy Scale and the Epilepsy Symptom Management Scale for patients, and the Zarit Burden Interview for caregivers. Caregivers will also complete an introductory form. All data will be collected at baseline and after eight weeks. The massage's impact on both patient outcomes and caregiver burden will be evaluated."
215164475|NCT06998329|OTHER|There will be no intervention|There will be no intervention
215164476|NCT07002203|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine|This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The intervention aims to induce T-cell responses against tumor-specific neoantigens. Vaccinations are given during priming and booster phases, with long-term follow-up and immune monitoring.
214559852|NCT01436253|BEHAVIORAL|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
214559853|NCT01436253|DRUG|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
214559854|NCT06307717|DRUG|volatile anaesthetic (sevoflurane, isoflurane, desflurane)|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
214559855|NCT01947699|DRUG|Glyburide|
214559856|NCT01947699|DEVICE|Continuous glucose monitor|
214559857|NCT00271206|DRUG|Progesterone|compared to placebo
214559858|NCT00271206|DRUG|sugar pill|Compared to progesterone
214559859|NCT03339232|DIETARY_SUPPLEMENT|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
214559860|NCT03339232|OTHER|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
214559861|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
214559862|NCT01390870|DRUG|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
214559863|NCT06418009|PROCEDURE|Cold needle application|Before use, the needle will be removed from the refrigerator and kept on the nurse's table. When the temperature of the needle reaches 0-2 °C, the patient will be cannulated.
214559864|NCT00316017|DRUG|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
214559865|NCT00316017|DRUG|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
214559866|NCT00316017|DRUG|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
214559867|NCT02445053|DRUG|ivacaftor|
214559868|NCT03394677|DRUG|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
214559869|NCT03394677|DRUG|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
214706160|NCT05525312|PROCEDURE|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
214706161|NCT05525312|PROCEDURE|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
214706162|NCT00225147|DRUG|Recombinant Human C1 Inhibitor|IV
214706163|NCT00225147|DRUG|placebo|saline solution
214559876|NCT01517100|OTHER|Nabilone|CB agonist
214559877|NCT01517100|DRUG|CP-945,598|Cannabinoid Receptor 1 antagonist
214559878|NCT01517100|OTHER|hyperglycemic clamp|assesses beta cell response
214559879|NCT01517100|OTHER|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
214559880|NCT01517100|OTHER|Nabilone|cannabinoid receptor agonist
214559881|NCT01198067|DRUG|Pomalidomide|Given PO
214559882|NCT05070858|DRUG|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
214559883|NCT05070858|DRUG|Cemdisiran|SC administration as described in the protocol
214559884|NCT05070858|OTHER|Placebo|SC administration as described in the protocol
214559885|NCT05070858|DRUG|Pozelimab|SC administration as described in the protocol
214559886|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
214559887|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
214559888|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
214559889|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
214706164|NCT03522883|DIETARY_SUPPLEMENT|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
214706165|NCT05060796|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
214706166|NCT01867645|DRUG|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
214706167|NCT01867645|DRUG|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
214706168|NCT00222742|PROCEDURE|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
214706169|NCT01121003|BEHAVIORAL|weight maintenance, low sugar diet|
214706170|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet|
214706171|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet+ exercise|
214706172|NCT03713216|DRUG|Naldebain|150 mg Nalbuphine sebacate
214706173|NCT03713216|DRUG|Morphine|Morphine
214706174|NCT01729572|OTHER|Tele-medicine monitoring of medication adherence|
214706175|NCT01285063|OTHER|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
215164477|NCT06527040|OTHER|Opioid Transitions Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
215164478|NCT03334669|BEHAVIORAL|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
214559890|NCT02101398|DEVICE|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
214559891|NCT02630407|BIOLOGICAL|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
214559892|NCT02630407|OTHER|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
214559893|NCT05826093|PROCEDURE|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
214559894|NCT05665543|BEHAVIORAL|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
214559895|NCT05485987|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
214559896|NCT04947254|DRUG|Abiraterone Acetate|Given PO
214559897|NCT04947254|DRUG|Antiandrogen Therapy|Given ADT
214559898|NCT04947254|DRUG|Apalutamide|Given PO
214559899|NCT04947254|PROCEDURE|Biopsy|Undergo biopsy
214559900|NCT04947254|DRUG|Niraparib|Given PO
214559901|NCT04947254|DRUG|Prednisone|Given PO
214559902|NCT04947254|RADIATION|Radiation Therapy|Undergo radiation therapy
214706176|NCT04169113|OTHER|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
214706177|NCT04169113|OTHER|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
214706178|NCT02685995|DEVICE|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
215164479|NCT03334669|BEHAVIORAL|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
214559903|NCT03641755|DRUG|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
214559904|NCT03641755|DRUG|Olaparib|Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
214559905|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)|625 mg/m2 IV over 30 minutes, q2weeks
214559906|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)|320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
214559907|NCT04150042|DRUG|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
214559908|NCT04150042|DRUG|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
214559909|NCT04150042|DRUG|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
214559910|NCT04150042|DRUG|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
214559911|NCT04150042|DRUG|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
214559912|NCT04150042|DEVICE|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
214559913|NCT03681210|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
214559914|NCT04531982|DRUG|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
214559915|NCT04531982|DRUG|Placebo|Placebo, taken as two blinded tablets once daily by mouth
214559916|NCT05922930|DRUG|TROP2-CAR-NK|Given by IP (intraperitoneal)
214559917|NCT05922930|DRUG|Cyclophosphamide|Given by IV (vein)
215164480|NCT03334669|BEHAVIORAL|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
215164481|NCT07001475|DRUG|BI 3031185|BI 3031185
214559918|NCT05922930|DRUG|Fludarabine|Given by IV (vein)
214559919|NCT06555263|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
215164482|NCT07001475|DRUG|Placebo|Placebo matching BI 3031185
215164483|NCT01697397|DEVICE|Recording of Myoelectric Signals|Obtain recordings of the electrical signals of the gut.
215164484|NCT04737720|DRUG|Recombinant LCAT|iv infusion
215164485|NCT06854692|OTHER|Cervical retraction exercise|Participants will perform end-range cervical retraction and cervical retraction with extension, holding the end-range of motion for 3 seconds and performing 10 repetitions of each exercise.
215164486|NCT06864104|DRUG|Tonlamarsen|Tonlamarsen will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
215164487|NCT06864104|DRUG|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
215164488|NCT01594047|DRUG|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
215164489|NCT01594047|DRUG|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
215164490|NCT06671496|DRUG|Zasocitinib|Zasocitinib tablets.
214559920|NCT07124585|DIETARY_SUPPLEMENT|Sucralose|Participants will consume one capsule containing sucralose 5mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
214559921|NCT07124585|DIETARY_SUPPLEMENT|Saccharin|Participants will consume one capsule containing saccharin 2mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
215164491|NCT06671496|DRUG|Placebo|Zasocitinib matching placebo.
215164492|NCT06545292|DIAGNOSTIC_TEST|Therapeutic drug monitoring with a dried blood spot and microatainer.|Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
215164493|NCT06678984|PROCEDURE|with treated umbilical vein allograft|Surgical treatment of female stress urinary incontinence using a treated allogeneic umbilical vein sling
215164494|NCT06678984|PROCEDURE|with autologous fascial pubovaginal sling|Surgical treatment of female stress urinary incontinence using a autologous fascial pubovaginal sling
215164495|NCT05588128|DRUG|18F-DCFpyL|Administered to Cohort.
215164496|NCT07005934|DEVICE|Theragun Prime|Percussion massager
215164497|NCT07109414|DRUG|NP-G2-044|NP-G2-044 will be provided as a tablet via oral route of administration in the study.
215164498|NCT07109414|DRUG|PLD|PLD will be provided as an infusion via intravenous route of administration in the study.
215164499|NCT07127874|DRUG|PHN-012|PHN-012 is an ADC
215164500|NCT06618118|DRUG|Fosigotifator|Oral Use
215164501|NCT06618118|DRUG|Placebo|Oral Use
215164502|NCT06865677|DRUG|Sacituzumab govitecan|10mg/kg administered IV infusion on days 1 and 8 of each 21-day cycle.
215164503|NCT06617962|DIAGNOSTIC_TEST|CBA method of live cells and fixed cells|"1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples."
215164504|NCT06868212|DRUG|Remibrutinib|Film-coated tablet, oral administration, 25 mg b.i.d.
215164505|NCT06868212|DRUG|Remibrutinib matching placebo|Film-coated tablet, oral administration, b.i.d.
215164506|NCT06868212|DRUG|Dupilumab|Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks
215164507|NCT06868212|DRUG|Placebo solution for injection|Solution for injection in pre-filled syringe every 2 weeks
215164508|NCT07008586|DIETARY_SUPPLEMENT|OliPhenolia®|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass.
215164509|NCT07008586|DIETARY_SUPPLEMENT|Taste and appearance matched placebo|Equal parts prune juice (Sunsweet California Prune Juice, Yuba City, CA, USA), diet cola (Tesco Cola, Tesco, UK) and tonic water (Tesco low calorie Indian tonic water, Tesco, UK).
215164510|NCT07007637|DRUG|Sonelokimab|Sonelokimab
215164511|NCT06615557|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
215164512|NCT06615557|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
215164513|NCT07006480|DEVICE|Real time CGM data monitoring|CGM data will be monitored in real time during daytime in the hospital. Alerts about high and low glucose levels will be communicated to patient's nurse and treating providers.
215164514|NCT07006480|DEVICE|Insulin dose adjustment based on glucometer and CGM glucose data trends|Insulin dose will be modulate based on glucometer values and previous day glucose trends as recorded on CGM.
215164515|NCT07006480|DEVICE|Share CGM data on admission and on discharge from the hospital|Record 14 days' worth of CGM data prior to admission and all CGM data recorded during the hospitalization at the time of discharge from the hospital
215164516|NCT05872295|DRUG|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
215164517|NCT06010355|PROCEDURE|Discussion|Participate in focus groups
215164518|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
215164519|NCT06010355|OTHER|Interview|Undergo interview
215164520|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
214559922|NCT07124585|OTHER|Placebo (Calcium Carbonate)|Participants will consume one capsule per day, containing a fixed dose of 500 mg. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
214559923|NCT06324461|DRUG|Dulaglutide 0.75mg subcutaneous injection|Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery
214559924|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
214559925|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
214559926|NCT01026129|DRUG|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
214559927|NCT04839185|DRUG|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
214559928|NCT04839185|PROCEDURE|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
214559929|NCT06509620|OTHER|Fatigue severity scale|fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.
214559930|NCT06984120|DIAGNOSTIC_TEST|Lung ultrasound|Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome.
214559931|NCT06984120|DIAGNOSTIC_TEST|Peripheral oxygen saturation|Peripheral oxygen saturation measured by non-invasive pulse oxymetry
214559932|NCT06984120|DIAGNOSTIC_TEST|Lung auscultation|Clinical auscultation of lungs
214559933|NCT06984120|DIAGNOSTIC_TEST|Body temperature|Body temperature measured by ear thermometer.
214559934|NCT03468478|DRUG|Sirolimus|sirolimus combined to reduced dose of tacrolimus
214559935|NCT03468478|DRUG|Everolimus|everolimus combined to reduced dose of tacrolimus
214559936|NCT03468478|DRUG|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
214559937|NCT00531089|DRUG|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
214559938|NCT06997029|DRUG|BMS-986500|Specified dose of specified days
215164521|NCT06010355|OTHER|Test|Complete test
215164522|NCT07133100|DEVICE|Upper limb rehabilitation wearable device|The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises. No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback.
215164523|NCT07129252|DRUG|CRN09682|Study drug CRN09682 intravenously
215164524|NCT00765440|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Given orally
215164525|NCT00765440|OTHER|placebo|Given orally
215164526|NCT05657548|RADIATION|spine and pelvis radiography|X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
215164527|NCT05959434|BEHAVIORAL|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
215164528|NCT05959434|BEHAVIORAL|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
215164529|NCT07009379|DEVICE|Intervention A|Intervention A means Pillow Brace
214559939|NCT06997029|DRUG|Palbociclib|Specified dose on specified days
214559940|NCT06997029|DRUG|Fulvestrant|Specified dose on specified days
214559941|NCT06673134|DRUG|enteral nutrition|exclusive enteral nutrition therapy or Partial enteral nutrition
214559942|NCT06673134|DRUG|Immunotherapy|Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
214559943|NCT06673134|DRUG|biological agents|Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
214559944|NCT06673134|DRUG|Glucocorticoids|Glucocorticoids treatments are given
214559945|NCT06673134|OTHER|fecal microbiota transplantation|Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc
214559946|NCT06672419|OTHER|AI-Guided Exercise and Pain Neuroscience Education|This intervention consists of a 12-week tele-rehabilitation program using AI and computer vision technology to guide personalized exercise sessions (three per week). Exercises are adjusted in real time by the AI system, and participants also attend weekly sessions of pain neuroscience education to develop improved pain management strategies. The program is delivered remotely via a digital platform that is visually identical for all participants. Supervising physiotherapists oversee progress and provide standardized support but remain blinded to group allocation.
215164530|NCT07009379|DEVICE|Intervention B|Intervention B means standard management
215164531|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
215164532|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
215164533|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
215164534|NCT06149481|DRUG|Retifanlimab|500 mg infused via IV over 30 minutes every 28 days
214706179|NCT02685995|DEVICE|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
214706180|NCT03823040|DRUG|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
214706181|NCT03823040|DRUG|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
214706182|NCT03625141|DRUG|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
215164535|NCT06149481|BIOLOGICAL|Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that
215164536|NCT06149481|DRUG|N-803|15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
215164537|NCT06149481|DRUG|SX-682|100 mg administered orally twice per day on days 6-26 of every cycle
215164538|NCT06869850|DIETARY_SUPPLEMENT|MFGM-RUTF (milk fat globule membrane ready-to-use therapeutic food)|MFGM whey protein/fat concentrate powder used in place of skim milk powder in peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications. There will be 10g of MFGM-containing whey protein/fat concentrate powder per 100g of MFGM-RUTF. Other ingredients and amounts per 100g: 9.5g rice flour, 5g whey permeate, 18.5g palm oil, 31g peanut paste, 22.1g sugar, 2.9g micronutrient mix, 1g fish oil.
215164539|NCT06869850|DIETARY_SUPPLEMENT|S-RUTF (standard ready-to-use therapeutic food)|Standard peanut paste-based ready-to-use therapeutic food made with skim milk powder meeting Codex Alimentarius specifications. This RUTF is modeled on the most widely used recipe worldwide, containing per 100g: 19.5g skim milk powder, 9.3g palm oil, 7g canola oil, 31.3g peanut paste, 28g sugar, 1g soy flakes, 1g hydrogenated vegetable oil, and 2.9g micronutrient mix.
215164540|NCT06869850|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
215164541|NCT06869850|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|Malaria chemoprophylaxis, dosed by weight, to be given every month during SAM treatment
215164542|NCT06866171|OTHER|Modular child restraint|The participant will be asked to install two different child safety seats into a vehicle, presented to the participant one at a time (random order). The researcher will explain that the participant should install each seat to the best of his/her ability and may take as long as needed. When each installation is completed, the participant will be led away from the vehicle while their work is evaluated by a study-team approved researcher who is a certified Child Passenger Safety Technician (CPST). A data collection form will be used to document any installation errors. Following the installations, participants will complete a short survey with open-ended queries to describe facilitators or barriers they experienced while installing the seats, as well as what they liked or did not like about each seat. They will use a Likert scale to rate their self-efficacy in installing the seats, if they believed they were installed correctly, general ease-of-use, and which seat they preferred.
215164543|NCT04807842|DEVICE|vaginal gel|The placebo gel is a non-buffered gel. The active device is an acidic gel.
215164544|NCT04827732|RADIATION|Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy|When feasible it is strongly recommended that radiotherapy begin on a Monday
215164545|NCT04827732|DEVICE|MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine|-The device that will administer the IMPT
215164546|NCT06678841|DEVICE|Personalized cardiac pacing|Personalized cardiac pacing treatment based each patient's height and baseline LVEF.
214559947|NCT06672419|OTHER|Usual Care for Fibromyalgia|"Standard care includes pharmacological management (pain relievers, antidepressants, anticonvulsants) and general recommendations on physical activity and disease management.~Drug: Pain Relievers - e.g., paracetamol, tramadol~Drug: Antidepressants - e.g., amitriptyline, duloxetine~Drug: Anticonvulsants - e.g., pregabalin, gabapentin~Other: General Physical Activity and Disease Education - recommendations consistent with current clinical guidelines"
214559948|NCT00786552|DRUG|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
214559949|NCT04192591|DEVICE|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
214559950|NCT07011004|BIOLOGICAL|Cytokine Induced Memory-Like Natural Killer Cells|Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.
214559951|NCT07011004|BIOLOGICAL|Atezolizumb|Single dose of Atezolizumab IV over 60 minutes IV.
214559952|NCT07011004|BIOLOGICAL|CIML-NK cell therapy|CIML-NK cell therapy as an intravenous (IV) infusion
214559953|NCT00545415|DIETARY_SUPPLEMENT|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
214559954|NCT00545415|DIETARY_SUPPLEMENT|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
214706183|NCT03625141|DRUG|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
215164547|NCT07011030|OTHER|Measure of skeletal muscle mass|Bioimpedance analysis with integrated electrodes and osteodensitometry examination
214559955|NCT00545415|DIETARY_SUPPLEMENT|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
215164548|NCT06604663|BEHAVIORAL|Activation of the CDSS system|Activation of the CDSS system, whereby outreach workers and clinicians have access to and ability to act upon lists of patients who are at highest risk of missing their upcoming clinical appointment.
215164549|NCT07010081|PROCEDURE|Surveys|Several questionnaires will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
214559956|NCT00545415|DIETARY_SUPPLEMENT|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
214559957|NCT00545415|DIETARY_SUPPLEMENT|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
214559958|NCT00545415|DIETARY_SUPPLEMENT|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
214559959|NCT06682039|OTHER|Internet-Based Intervention|Engage in ABM + text messaging prompts
214559960|NCT06682039|OTHER|Internet-Based Intervention|Engage in inert attention task sessions
214559961|NCT06682039|OTHER|Interview|Ancillary studies
214559962|NCT06682039|OTHER|Questionnaire Administration|Ancillary studies
214559963|NCT06682039|OTHER|Text Message-Based Navigation Intervention|Participants will respond to daily messaging prompts.
214559964|NCT06508775|BIOLOGICAL|MB-CART19.1|Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
214559965|NCT06508775|BIOLOGICAL|MB-CART20.1|Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
214559966|NCT06508775|BIOLOGICAL|MB-CART2019.1|Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
214559967|NCT06867809|DEVICE|Epidural spinal cord stimulation and paired spine and brain stimulation|The spinal cord and brain stimulator allows for stimulation of the spinal cord and brain. Spinal cord stimulation (SCS) is provided by temporarily implanted SCS catheter electrode leads (Medtronic) that are connected to an external stimulator (Digitimer); brain stimulation is provided by transcranial magnetic stimulation (TMS).
214559968|NCT04266795|DRUG|Pevonedistat|Pevonedistat IV infusion.
214559969|NCT04266795|DRUG|Venetoclax|Venetoclax tablets.
214559970|NCT04266795|DRUG|Azacitidine|Azacitidine IV or SC injection.
214559971|NCT00759122|DRUG|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
214559972|NCT00759122|DRUG|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
214559973|NCT06700811|DRUG|Ketogenic diet|The ketogenic diet formula will be KetoVie®, supplied by Ajinomoto Cambrooke. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 1.0mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1. Ratio will increase per standard clinical care for ketogenic diet initiation. For the trial we will aim to reach a maximum of 4:1 by the 6 week follow-up visit, but stopping at a lower ratio if BHB is ≥ 5mmol/L, CO2 ≤ 18 mmol/L, for tolerance, or to meet protein needs. A minimum 1:1 ratio is required to continue in the trial. Ratios higher than 1:1 are often required to obtain ketosis of ideally 2-5mmol/L in infants.
214559974|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
214559975|NCT07138482|OTHER|Survey using a questionnaire.|REDCap Survey
214559976|NCT07039253|BEHAVIORAL|Engaging Together for Health Relationships|Dating violence intervention for caregivers and adolescents to be delivered within pediatric primary care
214559977|NCT04643483|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
214559978|NCT04643483|DRUG|Adalimumab|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
214559979|NCT04643483|DRUG|Placebo|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
214706184|NCT03625141|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
214706185|NCT04429152|DRUG|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
214706186|NCT05558241|DEVICE|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
214706187|NCT03937193|DIAGNOSTIC_TEST|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
214706188|NCT00193219|DRUG|Bevacizumab|5 mg/kg IV
214706189|NCT00193219|DRUG|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
214706190|NCT00193219|DRUG|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
214706191|NCT00193219|DRUG|Leucovorin|350 mg IV
215164550|NCT07010107|DRUG|Anaprazole + Rabeprazole placebo|Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
214559980|NCT06717971|OTHER|Exergame-based multicomponent training program.|"The training program for the intervention group utilized the Nintendo Switch game WarioWare: Move It,. Participants engaged with the game through Joy-Con controllers, completing rapid micro-games designed to meet specific movement-oriented objectives. Each game session lasted approximately five seconds, requiring participants to quickly adapt to various physical actions and postures, such as waving, jumping, swinging arms, rotating, and mimicking object movements. The game's dynamic structure provides an engaging experience that promotes physical coordination, reaction speed, upper and lower limb strength, and hand-eye coordination through diverse movement patterns. Switching between tasks compels players to adjust to varying motion demands swiftly, enhancing physical agility while strengthening attention-shifting and quick decision-making skills."
214559981|NCT06717971|OTHER|Standard care|The standard care program for the control group is grounded in routine practices of long-term care facilities, aiming to sustain and enhance the physical and mental well-being of elderly residents through structured group activities. These activities encompass tailored fitness exercises, horticultural therapy, and sedentary group engagements for older adults. The fitness exercises are adapted to meet the varying physical conditions of participants, ensuring a safe and comfortable environment that promotes moderate physical activity. Horticultural therapy involves hands-on planting and tending to plants, stimulating the senses, and fostering emotional regulation, contributing to improved psychological health. Sedentary activities, such as tabletop games, emphasize social interaction and cognitive maintenance by promoting a relaxed social environment that helps participants remain cognitively engaged.
214559982|NCT06707103|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
214559983|NCT06707103|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
214559984|NCT07043595|PROCEDURE|Whole-Body Vibration (WBV)|Participants will stand quietly in an upright position while whole-body vibration (WBV) is applied through a vibration platform. The vibration stimulus is delivered while the participant's left foot remains on the vibration surface and the right foot is elevated or isolated. H-reflex recordings are taken from the soleus muscle during the procedure to assess spinal reflex modulation due to mechanical loading.
214559985|NCT02755870|OTHER|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
214706192|NCT00193219|DRUG|Oxaliplatin|85 mg/m2 IV
214706193|NCT02542436|OTHER|No intervention|No intervention administered in this study
214706194|NCT03151252|DIAGNOSTIC_TEST|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
214706195|NCT05167461|OTHER|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of \>95% compared to human assessment
214706196|NCT02580994|DRUG|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
214706197|NCT02580994|DRUG|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
214706198|NCT01900678|DEVICE|VytronUS Ablation System|Pulmonary vein isolation.
214706199|NCT00868166|DRUG|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
214706200|NCT00868166|DRUG|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
214706201|NCT00868166|DRUG|Riluzole|Riluzole given as add-on therapy 50mg bid
214706202|NCT03803592|BEHAVIORAL|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
215164551|NCT07010107|DRUG|Rabeprazole + Anaprazole placebo|Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
215164552|NCT07011615|BEHAVIORAL|Brief Motivational Mobile Health (mHealth) Intervention|Participants randomized to the mHealth intervention condition will receive a five-week online program that incorporates weekly text messages. The program will begin with prompting the young adult to reflect on their journey with cannabis and to reflect on their personal goals and how cannabis is reflected in these goals. Personalized feedback about their patterns of use, motivations, emotions, and social connections will be integrated throughout the program. Text messages will be sent throughout the week to prompt reflection and support any goals the participant indicates.
214559986|NCT02755870|OTHER|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
214559987|NCT07047976|DIETARY_SUPPLEMENT|Sulforaphane|This intervention involves the administration of Sulforaphane, a compound derived from glucoraphanin found in cruciferous vegetables. Participants will receive Avmacol® tablets, each containing 30 mg of glucoraphanin (approximately 68 μmol per tablet). They will take 3 tablets daily, resulting in a total daily dosage of approximately 90 μmol of Sulforaphane. The intervention will last for 8 weeks, during which participants will be monitored for clinical and biological outcomes.
214559988|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)
214559989|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - Control lunch (no fish) and omega 3 supplement
214559990|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Placebo comparator - Control lunch (no fish) and placebo supplement
214559991|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - 2 portions of fish (280g) per week and omega 3 supplement
214559992|NCT06717178|DRUG|Chemotherapy|Admission to the hospital for a new chemotherapy regimen (initial or change)
214559993|NCT07045402|OTHER|Kangaroo Care + Maternal Voice + Fetal Position Group|After ethical approval, all infants with a gestational age between 30-34 weeks in Neonatal Intensive Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. The infants will then be assigned to one of two groups: kangaroo care + mother's voice + fetal position (n=34) or fetal position only (n=34). In the first group, after tube feeding, infants will receive one hour of kangaroo care with the mother, including reading a story for the first 15 minutes. After finishing kangaroo care,they will then be placed in a fetal position in an incubator for 30 minutes. Comfort levels, weight, length, and head circumference will be measured daily until oral feeding begins, and the impact of kangaroo care and the mother's voice on the transition to full oral feeding will be assessed. All procedures will occur between 08:00 and 16:00.
214559994|NCT07045402|OTHER|control group|After ethical approval, all infants with a gestational age between 30-34 weeks in the Neonatal Intensıve Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. If infant is in the fetal position group, after being fed by a oral gastric tube, they will be placed in an incubator and positioned in a fetal position similar to that in the womb for one and a half hours. During all these procedures, infant's comfort levels will be assessed using a scale (form), and their weight, length, and head circumference will be measured every morning until they begin oral feeding. Additionally, the effect of the fetal position on infant's transition to full oral feeding will be evaluated.All procedures will take place between 08:00 and 16:00.
214559995|NCT05040347|OTHER|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
214559996|NCT07069218|DRUG|Biorepair® Total Protection Plus Toothpaste|Participants will use Biorepair® Total Protection Plus toothpaste twice daily for 6 months. The toothpaste contains biomimetic microRepair® particles based on zinc-substituted hydroxyapatite, intended to promote enamel remineralization, reduce sensitivity, and protect against erosion and plaque accumulation. Professional dental cleanings will also be performed every 3 months.
214559997|NCT07069218|DRUG|Bioniq® Toothpaste|Participants will use Bioniq® Repair toothpaste twice daily for 6 months. The toothpaste contains 20% conventional hydroxyapatite and is designed to restore enamel, reduce dentin hypersensitivity, and protect against erosion. Professional dental cleanings will also be performed every 3 months.
214559998|NCT07064564|DRUG|Naltrexone implant, 14.4 grams|Subcutaneous bioresorbable implant containing 14.4 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
214559999|NCT07064564|DRUG|Naltrexone implant, 9.6 grams|Subcutaneous bioresorbable implant containing 9.6 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
214560000|NCT07064564|DRUG|Extended-release naltrexone injection, 380 mg|Intramuscular injection of 380 mg extended-release naltrexone (Vivitrol), administered every 4 weeks for 12 months as the active comparator.
214560001|NCT06854731|BEHAVIORAL|Balance and Strength Training Exercises with Health Coaching|The OEP+ intervention integrates the OEP with health coaching by a physical therapists or kinesiologist. The OEP is an individualized home-based balance and strength exercise training program delivered by a PT or kinesiologist coach over 5 home visits.
215164553|NCT07011615|OTHER|Psychoeducational Attention Control (AC)|Participants randomized to the control group will receive a program to learn more about psychoeducational information about cannabis. They can opt in to receive psychoeducational material via text messages.
215164554|NCT06865742|BEHAVIORAL|Music intervention|This is the first study to evaluate the effects of music therapy on fatigue, sleep quality and mental well-being of individuals receiving HD treatment.
215164555|NCT05863702|BEHAVIORAL|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
215164556|NCT06871579|DIAGNOSTIC_TEST|EnteroTracker(R) EST|The device consists of a gelatin-coated capsule with a collection string wrapped inside.
215164557|NCT06873581|DEVICE|Voro Urologic Scaffold|The Voro Urologic Scaffold is placed during the prostatectomy procedure after prostate removal.
215164558|NCT06681740|DEVICE|Inspiratory muscle training|The control group will perform a standard cardiac rehabilitation program, consisting of 16 multicomponent exercise sessions, health education, and a weekly group of psychological therapy session. The intervention group will do the same program with the addition of Inspiratory Muscle Training (IMT). The following device will be used: Power Breath model: Medic Classic. The training will be performed by adjusting the device load to 70% of the Maximum Inspiratory Pressure value, performing 1 daily training session 4 days a week of 3 sets of 10 repetitions, with a rest of 3 minutes between sets, during 8 weeks. A physical therapist will teach participants how to use the device on the first day and they will be instructed to perform it at home. They will be given a diary to record their compliance. In addition, once a week the physiotherapist will supervise the execution of the IMT by the participants.
214560002|NCT06854731|OTHER|Education Session|All active comparator participants will be invited to join monthly interactive social and education sessions via Zoom or in-person (hybrid delivery).
214560003|NCT03570892|DRUG|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
214560004|NCT03570892|DRUG|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
214706203|NCT04121520|OTHER|Questionnaire|"1. Comprehensive perioperative assessment~2. Questionnaire administration"
214706204|NCT04191603|DEVICE|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
214706205|NCT04191603|DEVICE|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
215164559|NCT06681740|DEVICE|Sham Inspiratory muscle training|The control group will be given the same device as experimental group, but the load for all of the participants of the control group will be 5cm de H2O. This load is so low that it´s not able to induce improvement of the inspiratory musculature.
215164560|NCT06873152|PROCEDURE|Control preoperative program|Patients will undergo a control preoperative program with no enhances preparation when undergoing bilateral third molar extraction
215164561|NCT06873152|PROCEDURE|Advanced preoperative program|Patients will undergo an comprehensive program including enhanced preoperative preparation and a dedicated operating room team when undergoing bilateral third molar extraction
215164562|NCT06625411|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
215164563|NCT06625411|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
215164564|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
215164565|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
215164566|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
215164567|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
214560005|NCT06782347|BEHAVIORAL|Proactive Care|The proactive care intervention was designed to be similar to proactive care approaches used successfully in the tobacco control area. These proactive care procedures have not yet been adequately evaluated in the exercise promotion area.
214560006|NCT07138001|COMBINATION_PRODUCT|KH617+TMZ|use KH617 and TMZ(5/28) as Combination Product.
214560007|NCT07138001|DRUG|KH617|Single Clinical trial investigational drug
214706206|NCT06134791|OTHER|No intervention|No intervention
215164568|NCT06625060|BIOLOGICAL|IPN10200|Lyophilised powder
215164569|NCT06625060|OTHER|Placebo|Excipients without active substance, Lyophilised powder
215164570|NCT06625060|BIOLOGICAL|IPN10200 dose A|Lyophilised powder
215164571|NCT06625060|BIOLOGICAL|IPN10200 dose B|Lyophilised powder
214560008|NCT07138001|DRUG|TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16|"Comparator product, Two treatment options for physicians and subjects to choose from:~1. use TMZ(7/7)~2. Use Platinum (cisplatin or carboplatin)+VP-16"
214706207|NCT06014294|BEHAVIORAL|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
214706208|NCT06014294|BEHAVIORAL|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
214706209|NCT06014294|BEHAVIORAL|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
214706210|NCT00240539|PROCEDURE|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
214560009|NCT07136805|DRUG|VVN461 Ophthalmic Solution 1.0%|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
214706211|NCT05519618|PROCEDURE|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
214706212|NCT00031499|DRUG|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
214706213|NCT00031499|DRUG|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
214560010|NCT07136805|DRUG|1.0% prednisolone acetate|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
214560011|NCT04111172|BIOLOGICAL|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
214560012|NCT06840886|DRUG|PHST001|"* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~* Other Names:~* Dose Level 1~* Dose Level 2~* Dose Level 3~* Dose Level 4~* Dose Level 5~* Dose Level 6~* Dose Level 7~Drug: PHST001~* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~This study is an open label, Phase 1 dose escalation trial with three expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 40-80 in total will be in enrolled in part A, covering 7 dose level.~* Part B: Expansion cohorts will be added as an amendment as further preclinical data and clinical data from Part A become available."
214560013|NCT07084051|BEHAVIORAL|I-MAS|Participants will receive a one-to one session with the pharmacy technician that involves two parts; the first part include education on ischemic stroke and risk factors such as practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc., making healthier dietary choices, exercising regularly, smoking cessation, alcohol intake, and managing blood sugar. The second part involves an interview to collect information on socio-demographics, clinical factors, co-morbidities, medications, and medication adherence barriers. During the second part of the session, the pharmacy technician will identify barriers to medication adherence for secondary prevention of stroke medications including antihypertensives, antithrombotic agents, and statins. The pharmacist will collaborate with the pharmacy technician to develop an action plan to address medication adherence barriers
214560014|NCT07086664|DRUG|Placebo|Oral tablet
214560015|NCT07086664|DRUG|PF-07258669|Oral tablet
214560016|NCT06926075|DRUG|A novel hGIIA-Vimentin Inhibitor|Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.
214560017|NCT06926075|DRUG|Dose expansion|Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.
214560018|NCT06927505|OTHER|Bobath based trunk control training|Participants in the Bobath based trunk training group will undergo a comprehensive intervention encompassing strengthening exercises, stretching exercises, and motor training. This group will experience a 60-minute session, including 40 minutes of Bobath based exercises along with 20 minutes routine physical therapy. 1. Strengthening the oblique abdominals 2. Weight Shifting (Side-to-Side \& Forward-Backward) 3. Pelvic Tilts 4. Functional strengthening of trunk extensors 5. Reaching 6. Latissimus dorsi stretching exercise 7. Bridging 8. Trunk rotation (supine and standing position) 9. Sitting to Standing Transitions (with emphasis on trunk control) 10. Standing Weight Shifts There will be a rest of 1 minute between each set of exercise. Progression of exercises with increase in intensity and resistance.
214706214|NCT00031499|DRUG|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
214706215|NCT03108209|OTHER|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
214706216|NCT03108209|OTHER|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
214706217|NCT04173052|DEVICE|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
214706218|NCT03089970|DIAGNOSTIC_TEST|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
214706219|NCT05833685|OTHER|no intervention|no intervention
214706220|NCT02203669|OTHER|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
214706221|NCT02203669|OTHER|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
214706222|NCT01216449|DRUG|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
214706223|NCT01216449|DRUG|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
214706224|NCT04856956|OTHER|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
214706225|NCT03121118|OTHER|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
214706226|NCT03819218|DRUG|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
214706227|NCT00103571|DRUG|Olanzapine|
214706228|NCT00103571|DRUG|Aripiprazole|
214706229|NCT02267278|DRUG|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
214706230|NCT02267278|DRUG|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
214706231|NCT02267278|BEHAVIORAL|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
214706232|NCT00650091|DRUG|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
214706233|NCT00650091|DRUG|Placebo|Participants will receive placebo each day.
214560019|NCT06927505|OTHER|Unstable surface trunk training|"This group will receive 60-minute training session that consists of 40 minutes of unstable surfaces exercises and 20 minutes of routine physical therapy 3 days per week for a total of 12 weeks.~Hook-lying position: (1) Abdominal draw-in maneuver with ball under the buttocks.~(2) Abdominal muscles isometric contraction. (3) Bridging combining with abdominal draw-in maneuver. Each exercise will be performed with 5-8 repetitions. Sitting: (1) Seated balance (2) Weight shifting e.g. anterior, posterior, lateral (3) Pelvic tilts e.g. anterior and posterior tilt (4) Trunk flexion, extension and lateral flexion on both sides (5) trunk rotation on both sides (6) Reaching e.g. lateral, forward and upward reach (7) Marching while seated Each exercise will be performed with 5-8 repetitions."
214560020|NCT07077434|DRUG|BMS-986504|Specified dose on specified days
214560021|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
214560022|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
214560023|NCT06905275|BIOLOGICAL|3M-052-AF + Alum|Intramuscular (IM) injection
214560024|NCT06905275|BIOLOGICAL|UVAX-1107|IM injection
214560025|NCT06905275|BIOLOGICAL|UVAX-1197|IM injection
214706234|NCT05008068|DRUG|Simvastatin|Simvastatin with PRF at site of osteotome
214706235|NCT00329134|DRUG|Administration of quinine sulphate taste-masked pellets|
214706236|NCT04319419|DIETARY_SUPPLEMENT|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
214706237|NCT04319419|OTHER|Nutrition education|Group received nutrition education program during 6 months
214706238|NCT01784588|DEVICE|Solyx Single Incision Sling System|Solyx Single Incision Sling System
214706239|NCT01784588|DEVICE|Obtryx II Sling System|Standard outside-in transobturator sling
214706240|NCT04950205|DRUG|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
214706241|NCT03886441|DRUG|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
214706242|NCT01712217|DRUG|AT13387|HSP90 inhibitor
214706243|NCT01712217|DRUG|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
214706244|NCT04172311|OTHER|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
214706245|NCT04172311|DRUG|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
214706246|NCT03999541|OTHER|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
214560026|NCT06836739|DEVICE|Genital nerve stimulation|Genital nerve stimulation (GNS) will be administered via non-invasive surface skin electrodes. In men, two surface electrodes (1 cm diameter) will be placed on the dorsum of the penile shaft 2 cm apart. In women, one surface electrode will be placed near the clitoris and a second surface electrode will be placed on the labia majora or inner thigh. The electrodes will be connected to an electrical stimulator device.
214706247|NCT03086538|DRUG|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
214706248|NCT03086538|DRUG|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
214706249|NCT04372342|DRUG|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
214706250|NCT04372342|DRUG|remifentanil|remifentanil
214706251|NCT06256029|PROCEDURE|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
214706252|NCT01383642|OTHER|No intervention, observational study|
214706253|NCT03182465|DIAGNOSTIC_TEST|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
214560027|NCT06623097|BEHAVIORAL|Supervised Exercise and Diet Program|A home-based, virtually supervised, moderate-to-vigorous aerobic and resistance exercise intervention with a certified cancer exercise trainer. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch, and Wi-Fi enabled tablet (if needed) will be provided to participants. Dyads will receive remotely delivered nutrition coaching sessions (via telephone or video conferencing) with a health coach each week. Mediterranean eating pattern goals will be tracked using the journal feature of the My Wellness Research platform website.
214560028|NCT06623097|BEHAVIORAL|Unsupervised Exercise and Diet Program|A home-based, unsupervised moderate-to-vigorous aerobic and resistance exercise intervention. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch will be provided to participants. Dyads will receive Mediterranean eating pattern goals, with an introductory session conducted by research staff. Diet intake will be tracked using the journal feature My Wellness Research platform website.
214706254|NCT06071637|PROCEDURE|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
214706255|NCT02307838|OTHER|Assessments arm|Protocol required assessments not provided in standard of care
214706256|NCT05545904|BEHAVIORAL|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
214706257|NCT05545904|BEHAVIORAL|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
214706258|NCT01098825|OTHER|web-based survey|Anonymous web-based survey
214706259|NCT03605199|DRUG|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
214706260|NCT05200156|DIETARY_SUPPLEMENT|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
214706261|NCT06199622|OTHER|music|20 minutes of classical Turkish musicor classical western music
214706262|NCT06379438|COMBINATION_PRODUCT|Photodynamic therapy (indocyanine green+laser)|Photodynamic therapy with indocyanine green
215164572|NCT06625398|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
215164573|NCT06625398|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
215164574|NCT07011147|DEVICE|Bionic Pancreas|The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
215164575|NCT07011147|OTHER|Routine Care|Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.
215164576|NCT07010484|DIAGNOSTIC_TEST|PET/MRI|PET/MRI at baseline and week 8
215164577|NCT07010484|DIAGNOSTIC_TEST|PET/CT with 18-FDG|PET/CT in patients not receiving PET/MRI
215164578|NCT06399614|OTHER|Occupational Therapy-led Hand Therapy Service|Types of interventions provided by the therapist will include splinting, targeted exercises and activities, occupation-based intervention, edema management, scar management; desensitisation, functional tasks completion, and education. All interventions provided are within occupational therapists' scope of practice and are evidence based. Number of treatment sessions will be individualised to the patient and guided by stages of recovery.
215164579|NCT06399614|OTHER|Care as usual|Care as usual group: Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services\&#39; protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
214560029|NCT07089147|OTHER|questionnaire|Paris questionnaire, EuroQool (EQ-5D-3L) Questionnaire, Low Back Outcome Score
214706263|NCT03636568|OTHER|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
215164580|NCT07011888|DEVICE|SaeboStim GO with Saebo Glove Rehabilitation Program|The intervention consists of a comprehensive rehabilitation program for a chronic stroke patient, utilizing the SaeboStim GO device combined with the Saebo Glove orthosis to facilitate and strengthen hand and upper limb motor function. The program also includes therapeutic ultrasound to support tissue healing, and vestibular rehabilitation therapy (VRT) to enhance motor learning and engagement. This combined approach aims to improve motor skills, balance, gait, daily living activities, and cognitive functions over a treatment period of six months.
215164581|NCT07011745|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
215164582|NCT07011745|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
215164583|NCT07011745|DRUG|Placebo|Specified dose on specified days
215164584|NCT07011732|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
215164585|NCT07011732|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
215164586|NCT07011732|DRUG|Placebo|Specified dose on specified days
215164587|NCT06685757|DRUG|Felzartamab|Participants will receive felzartamab by intravenous infusion.
215164588|NCT06685757|DRUG|Placebo|Participants will receive 0.9% saline solution by intravenous infusion.
215164589|NCT07015424|DEVICE|TORe with OverStitch|Transoral Outlet Reduction with OverStitch Endoscopic Suturing System
215164590|NCT07015424|BEHAVIORAL|Intensive lifestyle modification|Intensive lifestyle modification program consists of the following: well-balanced calorie-restrictive diet, incorporation of exercise and coaching on lifestyle changes. The program should include personal discussions and goals designed and overseen by the treating physician, obesity management professional or dietician.
214560030|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TMAO Mesurement|Salivary and serum TMAO levels were measured by liquid chromatography-mass spectrometry (LC-MS/MS)
214560031|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TNF-α Mesurement|Salivary and serum TNF-α levels were measured by ELISA
214560032|NCT06907602|DRUG|Chemotherapy|carboplatin plus nab-paclitaxel
214560033|NCT06907602|DRUG|Immunotherapy (Pembrolizumab)|Pembrolizumab
214560034|NCT06907602|RADIATION|radiotherapy|40-45Gy/20fx，5 times a week
214560035|NCT07089745|BEHAVIORAL|Mindfulness-Based Intervention|MBI is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
214560036|NCT07089745|BEHAVIORAL|Organizational Skills Training|OST is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
214560037|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
214560038|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
214560039|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
214560040|NCT06912529|PROCEDURE|Leukapheresis|Axicabtagene ciloleucel is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure.
214560041|NCT06912529|DRUG|Bridging Therapy|Bridging therapy refers to treatment used to control a patient's disease or disease related inflammation prior to lymphodepletion.
214560042|NCT06912529|DRUG|Lymphodepletion|Patients will receive a non-myeloablative lymphodepleting regimen consisting of fludarabine and cyclophosphamide (FC) to induce lymphocyte depletion and create an optimal environment for expansion of axicabtagene ciloleucel in vivo.
214560043|NCT06912529|GENETIC|Axicabtagene Ciloleucel|Patient will receive the axicabtagene ciloleucel infusion in the hospital followed by daily monitoring in the hospital.
214560044|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
214560045|NCT07113626|BEHAVIORAL|Mobile app|The intervention will be a mobile app adapted from HealthMindr - an app based on Social Cognitive Theory - for young men who have sex with men in Vietnam. The app, which was developed and tested in the US, offers a range of testing and prevention services, including self-screening for HIV and sexually transmitted infection (STI) risk, a scheduling and reminder system for HIV/ STI testing, PrEP eligibility screener, an ordering platform for delivery of at-home test kits and condoms, and locators for HIV services. Additional features and contents might be revised and added depending on the needs of young men who have sex with men in Vietnam.
214560046|NCT07116096|DEVICE|Jamar Hand Dynamometer, Hand Dynamometer|Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests
214560047|NCT07138287|PROCEDURE|Concerned Growth factor in management of Mature permanent Molar with irreversible pulpitis|Concerned Growth factor in management of Mature permanent Molar of children with irreversible pulpitis
215164591|NCT07011576|DRUG|fruquintinib|Participants will receive oral fruquintinib, with or without food, for the first 21 days of each 28-day cycle.
215164592|NCT07011576|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|Participants will receive FOLFIRI once every 2 weeks on day 1 of every 28-day cycle (twice in each cycle). The FOLFIRI regimen consists of irinotecan given 180 mg/m2 intravenous infusion (IV), leucovorin 400 mg/m2 (or 200 mg/m2 levoleucovorin) IV, followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus injection and 5-FU continuous IV infusion of 2400 mg/m2 over 46 to 48 hours.
215164593|NCT03712527|OTHER|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
214706264|NCT01641965|DEVICE|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
214560048|NCT07136584|OTHER|Screening, Outcomes and Referral Pathways|"All participants complete baseline screening with follow up at 3 and 6 months. A key feature of the study is that a standardised information resource sheet (to community-based services) is provided to all caregivers, regardless of their screening scores. Primary outcomes focus on implementation feasibility and acceptability, while secondary outcomes examine service uptake and longitudinal measurement of caregiver wellbeing.~This differs from existing research by providing resources universally rather than only to those scoring above clinical thresholds. Our longitudinal follow-up addresses an evidence gap identified in our systematic review - limited published data on downstream effects on actual service uptake and mental health outcomes over time. The services in the resource sheet also link to routine clinical care that doesn't require specialist support programs with dedicated funding."
214560049|NCT07139925|OTHER|Self-care of COPD Inventory (SC-COPDI)|Self-care of COPD Inventory (SC-COPDI) - Assess the self-care of patients with IPF by adapting a tool designed for patients with COPD to those affected by IPF
214560050|NCT07139197|BEHAVIORAL|Cognitive Behavioral Approach-Based Psychoeducation Program|"Intervention Group: Cognitive Behavioral Approach-Based Psychoeducation Program Participants will receive a cognitive-behavioral psychoeducation program designed to improve cognitive flexibility and reduce rumination. The sessions include structured activities, discussions, and exercises based on cognitive-behavioral principles. Pre-test assessments will be conducted before group allocation.~Control Group: No intervention will be provided during the study period. Participants will complete pre-test assessments administered by an independent evaluator. After the study concludes, control group participants will be offered the opportunity to participate in the psychoeducation program if they wish."
214560051|NCT06927310|DRUG|Inpegsomatropin Injection|Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 consecutive weeks.
214560052|NCT06927310|DRUG|Recombinant Human Growth Hormone Injection|Recombinant Human Growth Hormone Injection, 350 μg/kg/week, s.c., divided into 7 doses, i.e., 50 μg/kg/day (0.15 IU/kg/day), once daily for 52 consecutive weeks.
214560053|NCT06948786|DRUG|Pirtobrutinib|Given PO
214560054|NCT06948786|BIOLOGICAL|Mosunetuzumab|Given IV
214560055|NCT06948786|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral swab and/or rectal swab collection
214560056|NCT06948786|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214560057|NCT06948786|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214560058|NCT06948786|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214560059|NCT06948786|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
215164594|NCT03712527|OTHER|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
214560060|NCT06948786|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214706265|NCT01930526|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
214706266|NCT00151749|DRUG|Colesevelam hydrochloride|
214560061|NCT06948786|OTHER|Questionnaire Administration|Ancillary studies
214560062|NCT05478759|BEHAVIORAL|Multimodal affect recognition training|8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.
214560063|NCT05478759|BEHAVIORAL|Attention Training|computerized attention drill training
214560064|NCT05478759|BEHAVIORAL|Brain Health Workshop|an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.
214560065|NCT05478759|BEHAVIORAL|National Geographic Movies|participant will watch movies and answer questions after
214560066|NCT05421741|DRUG|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
214560067|NCT05421741|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
214560068|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
214560069|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
214706267|NCT01413542|DRUG|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
214706268|NCT01413542|DRUG|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
214706269|NCT01413542|DRUG|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
214706270|NCT01413542|DRUG|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
214706271|NCT01413542|DRUG|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
214706272|NCT01413542|DRUG|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
214706273|NCT01894464|BEHAVIORAL|Teacher led intervention|
214706274|NCT05911464|DRUG|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
214706275|NCT03281447|OTHER|Nurse navigation|
214706276|NCT03281447|OTHER|Current care coordination|
215164595|NCT03396276|DRUG|Suboxone|8mg of buprenorphine/2mg of naloxone
215164596|NCT03396276|BEHAVIORAL|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
215164597|NCT03396276|BEHAVIORAL|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
215164598|NCT03396276|BEHAVIORAL|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
214560070|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
214560071|NCT01920698|OTHER|control|
214560072|NCT01876082|DRUG|PAZOPANIB treatment|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
214560073|NCT01876082|DRUG|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
214560074|NCT04854850|DEVICE|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
214560075|NCT01483456|OTHER|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases"
214560076|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
214560077|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5 millilitres (mL)) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
214560078|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
214560079|NCT02999685|BEHAVIORAL|Home-base Pulmonary Rehab with Health Coaching|
214560080|NCT04299243|DEVICE|Contact Lenses|Contact lenses for vision correction
214560081|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
214560082|NCT01230866|RADIATION|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
214560083|NCT01230866|RADIATION|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
214560084|NCT05043766|DRUG|PF614|PF614 is an oxycodone prodrug
214560085|NCT05043766|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
214560086|NCT05043766|DRUG|OxyContin|Bioequivalence single-dose comparison to OxyContin
214560087|NCT06199180|DEVICE|pulmonary vein isolation with RFA|Patients randomised to RFA will undergo PVI with point-by-point RFA.
214560088|NCT06199180|DEVICE|pulmonary vein isolation with PFA|Patients randomised to PFA will undergo PVI with PFA.
214560089|NCT04683627|DRUG|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
214560090|NCT04683627|DRUG|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
214560091|NCT03829501|DRUG|Alomfilimab|A human anti-ICOS monoclonal antibody
214560092|NCT03829501|DRUG|Atezolizumab|An anti-PD-L1 monoclonal antibody
214560093|NCT03625544|PROCEDURE|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
214560094|NCT03625544|DEVICE|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
214560095|NCT03625544|PROCEDURE|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
214560096|NCT03024463|PROCEDURE|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
214560097|NCT06276400|OTHER|Emotion valence|Positive vs. Negative (temporally extended sequence)
215164599|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
215164600|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
214560098|NCT06276400|OTHER|Time|∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)
214706277|NCT03685487|PROCEDURE|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
214560099|NCT06276400|DEVICE|TMS Stimulation|FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
214560100|NCT02446665|DEVICE|MR Elastography (MRE) and FibroScan|
214560101|NCT06280742|RADIATION|PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-DPA-714
214706278|NCT03685487|OTHER|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
214706279|NCT03795818|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
214706280|NCT04945213|DRUG|Biperiden|5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
214706281|NCT04945213|OTHER|Placebo|1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
214706282|NCT02806466|PROCEDURE|Fiberoptic bronchoscopy|
214706283|NCT02505542|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
214706284|NCT02505542|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
214706285|NCT03260972|DRUG|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
214706286|NCT03260972|DRUG|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
215164601|NCT06689956|OTHER|Non-Interventional Study|Non-Interventional Study
215164602|NCT05255601|DRUG|Relatlimab|Specified Dose on Specified Days
214560102|NCT05642611|PROCEDURE|Biospecimen Collection|Undergo collection of blood, plasma, and serum
214560103|NCT05642611|PROCEDURE|Cryocompression Therapy|Undergo cryocompression
214560104|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo continuous compression
214560105|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo low cyclic compression
214560106|NCT05642611|OTHER|Quality-of-Life Assessment|Ancillary studies
214706287|NCT02651792|DRUG|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
214706288|NCT02651792|DRUG|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
214706289|NCT01119157|BIOLOGICAL|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
215164603|NCT05255601|DRUG|Nivolumab|Specified Dose on Specified Days
214560107|NCT05642611|OTHER|Questionnaire Administration|Ancillary studies
214560108|NCT03642847|BIOLOGICAL|Prevnar 13|13 valent Pneumococcal Conjugate
214560109|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
214706290|NCT02783144|PROCEDURE|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
214706291|NCT02783144|OTHER|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
214560110|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
214560111|NCT01758445|RADIATION|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
214560112|NCT01123070|BIOLOGICAL|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
214560113|NCT01123070|BIOLOGICAL|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
214706292|NCT02783144|DRUG|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
214560114|NCT03270410|OTHER|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
214560115|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
214560116|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
214560117|NCT02891538|DRUG|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*
214560118|NCT00084344|DRUG|4-hydroxytamoxifen|
214560119|NCT00084344|PROCEDURE|breast imaging study|
214560120|NCT00084344|PROCEDURE|radiomammography|
214560121|NCT03663673|DRUG|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
214560122|NCT03663673|DRUG|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
214560123|NCT05873478|OTHER|High Intensity Interval Training|The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
214560124|NCT00660322|BEHAVIORAL|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~1. Using asthma controller medications as prescribed~2. Having and Asthma Action Plan available to all who may need it.~3. Using asthma rescue medications with the child's first symptoms.~4. Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
214560125|NCT00263172|BEHAVIORAL|behavior modification for weight loss|
214706293|NCT04980313|DEVICE|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
214706294|NCT04980313|DEVICE|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
214706295|NCT02645279|OTHER|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
215164604|NCT06623240|BIOLOGICAL|allogeneic Hope Biosciences adipose-derived mesenchymal stem cells|"Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)"
215164605|NCT06623240|OTHER|Normal Saline Solution 0.9%|Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)
215164606|NCT07012057|DRUG|Deucravacitinb|Participants will receive a 6mg pill taken 2 times per day over 24 weeks and an optional extension period
215164607|NCT07011771|DRUG|gene therapy|IV gene therapy
215164608|NCT07011771|DRUG|gene therapy|IV gene therapy
215164609|NCT05807074|DRUG|Tranexamic Acid|Applied intraoperatively
215164610|NCT05807074|OTHER|Saline|Applied intraoperatively
215164611|NCT04476563|DIAGNOSTIC_TEST|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
215164612|NCT06873516|DRUG|EVO756|Dose 1
215164613|NCT06873516|DRUG|EVO756|Dose 2
215164614|NCT06873516|DRUG|EVO756|Dose 3
214560126|NCT02207504|DRUG|Crizotinib|Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
214560127|NCT02207504|DRUG|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
214560128|NCT03520738|OTHER|Blood samples|Blood samples on an empty stomach
214560129|NCT03520738|OTHER|Urinary samples|first urinary in the morning
214560130|NCT01887704|DEVICE|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
214560131|NCT01887704|PROCEDURE|conventional angioplasty|Conventional angioplasty was used in both arms.
214560132|NCT01887704|PROCEDURE|stenting|Stenting was implanted in both arms.
214560133|NCT01887704|DEVICE|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
214560134|NCT01887704|DRUG|Aspirin|Aspirin will be administrated in participants in both arms.
214560135|NCT01887704|DRUG|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
214560136|NCT01887704|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
214560137|NCT01887704|DEVICE|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
214560138|NCT01887704|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
214560139|NCT01887704|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
215164615|NCT06873516|DRUG|Placebo control|Placebo control
215164616|NCT07020520|DEVICE|Optilume|Has pre-treatment (balloon dilation or ureterotomy) followed by paclitaxel-coated balloon (Optilume) treatment of the ureteric stricture.
215164617|NCT07019727|PROCEDURE|ESSKA/ESMA 'ACL Prevention for All' methodology|A workshop led by a trained physiotherapist/strength and conditioning coach and conducted under medical supervision. Based on the ESSKA/ESMA 'ACL Prevention for All' methodology, a total of 12 exercise units lasting 5 minutes each will be included.
215164618|NCT06312644|DRUG|Ultomiris|Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.
215164619|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
214560140|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
214560141|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
214560142|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
214560143|NCT01056705|BIOLOGICAL|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
214560144|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
214560145|NCT03264937|BEHAVIORAL|Social-software management|Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
214560146|NCT03284229|DEVICE|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
214560147|NCT01702324|DRUG|DD-25|A topical DD-25 cream at 0.025% concentration.
214560148|NCT05411133|DRUG|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
214706296|NCT02645279|DRUG|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
214706297|NCT03372603|DRUG|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
214706298|NCT03372603|DRUG|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
214706299|NCT04673487|DIAGNOSTIC_TEST|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
214706300|NCT01313481|BEHAVIORAL|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
214706301|NCT01313481|BEHAVIORAL|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
214706302|NCT04902898|DEVICE|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
215164620|NCT07020234|BEHAVIORAL|Epigenetics Video|Educational video about health and epigenetics.
215164621|NCT07020234|BEHAVIORAL|Nanotechnology Video|Educational video about nanotechnology
215164622|NCT06625242|DRUG|Filgotinib Maleate|Administered as oral tablets.
215164623|NCT06626074|DEVICE|Quantitative MRI sequences|additional sequences during MRI
214706303|NCT04902898|PROCEDURE|Circumcision in adults|Circumcision in adults
214706304|NCT04693923|PROCEDURE|Fluid challenge|Fluid challenge according to the assigned group
214706305|NCT03316677|PROCEDURE|Intraoperative testing of colorectal anastomoses|"1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
214706306|NCT03316677|PROCEDURE|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
214706307|NCT02014727|BIOLOGICAL|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
214706308|NCT02014727|BIOLOGICAL|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
214706309|NCT02014727|BIOLOGICAL|Group B2 : Placebo|
214706310|NCT04668794|PROCEDURE|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
214706311|NCT00049218|BIOLOGICAL|Autologous dendritic cell-adenovirus p53 vaccine|
214706312|NCT00049218|DRUG|Carboplatin|
214706313|NCT00049218|DRUG|Etoposide|
214706314|NCT03526315|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
214706315|NCT03526315|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
214706316|NCT03526315|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
214706317|NCT05816694|DRUG|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
214706318|NCT05816694|DRUG|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
214706319|NCT01608282|BEHAVIORAL|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
215164624|NCT07013149|OTHER|Switch from Ambrisentan to Bosentan|This intervention refers to a therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) in adult patients with pulmonary arterial hypertension (PAH), performed as part of routine clinical care. The switch was not assigned by the investigators but was made based on clinical indications prior to study enrollment. Patients are followed prospectively for up to 6 months to assess changes in risk stratification, functional status, laboratory parameters, and safety outcomes.
215164625|NCT07011706|DRUG|ATI-045|ATI-045 group
215164626|NCT07011706|DRUG|Placebo|Placebo group
215164627|NCT07011719|DRUG|Casdatifan|Administered as specified in the treatment arm
215164628|NCT07011719|DRUG|Cabozantinib|Administered as specified in the treatment arm
214706320|NCT04828356|OTHER|Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
214706321|NCT00870974|DRUG|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
214706322|NCT02422082|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
214706323|NCT02422082|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo twice daily for 12 months
214706324|NCT01889888|OTHER|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
214706325|NCT03109756|DRUG|OV101|Single-dose 5 mg OV101
214706326|NCT02806947|DRUG|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
214706327|NCT02806947|DRUG|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
214706328|NCT04635761|BEHAVIORAL|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
214706329|NCT04635761|BEHAVIORAL|Questionnaire Administration|Ancillary studies
214706330|NCT02750579|PROCEDURE|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
214706331|NCT00430963|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|
214706332|NCT00430963|DRUG|Placebo|
214560149|NCT02665767|DEVICE|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
214560150|NCT02908932|DIETARY_SUPPLEMENT|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
214560151|NCT02908932|DIETARY_SUPPLEMENT|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
214560152|NCT02833870|BEHAVIORAL|Musical intervention|
214560153|NCT02833870|BEHAVIORAL|Non-musical (cooking) intervention|
215164629|NCT07011719|DRUG|Placebo|Administered as specified in the treatment arm
214560154|NCT02833870|BEHAVIORAL|Control with no intervention|
214706333|NCT04291976|PROCEDURE|Back-to-back high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
215164630|NCT04616287|OTHER|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
214706334|NCT04291976|PROCEDURE|single-pass high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
214706335|NCT04291976|PROCEDURE|chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
214706336|NCT02080156|DEVICE|CPAP|
214706337|NCT00289744|BIOLOGICAL|TWINRIX™ ADULT|2 doses IM injection in primary study
214706338|NCT00289744|BIOLOGICAL|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
214706339|NCT02674165|BEHAVIORAL|HART|Skills based sexual education intervention plus PTSD awareness
214706340|NCT01708616|DRUG|RO5285119|multiple doses
215164631|NCT07014098|DEVICE|Robot-Aided Off-Axis Neuromuscular Training|A novel custom-designed elliptical trainer is developed, and its footplates are robot-controlled to be moved in four off-axis directions (sliding in/out, pivoting in/out; corresponding to knee valgus/varus, internal rotation/external rotation). Before the training, off-axis neuromechanical assessments will be conducted to determine which specific off-axis direction (valgus, varus, internal rotation, external rotation, or combination of the off-axis directions) has neuromechanical deficits. During the evaluation-based and subject-specific neuromuscular training, the different training modes will be conducted progressively from regular stepping, footplate position control, spring mode, perturbation, to slippery mode.
215164632|NCT07014098|DEVICE|Traditional elliptical regular stepping|traditional elliptical regular stepping
214560155|NCT03122132|DRUG|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
214560156|NCT03122132|DRUG|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
214706341|NCT01708616|DRUG|RO5285119 placebo|multiple doses
214706342|NCT01708616|DRUG|risperidone|single dose
214706343|NCT01708616|DRUG|risperidone placebo|single dose
214706344|NCT01978509|DRUG|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
214706345|NCT01978509|DRUG|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
214706346|NCT01978509|DRUG|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
214706347|NCT01444313|DEVICE|narafilcon A contact lens|Soft contact lenses with UV protection
215164633|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.
215164634|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.
215164635|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.
215164636|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
215164637|NCT05338944|BEHAVIORAL|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
214560157|NCT04318288|OTHER|Observational|Observational
214560158|NCT06446999|OTHER|Yoga-Based Breathing Exercise|"Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)"
214706348|NCT01444313|DEVICE|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
214706349|NCT03031548|DEVICE|Point-of-care ultrasound exam|No intervention
214706350|NCT03031548|RADIATION|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
214706351|NCT02359695|DRUG|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
214706352|NCT02293356|DRUG|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
214706353|NCT04744636|DRUG|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
214706354|NCT04744636|DRUG|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
214706355|NCT04324138|DRUG|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
214706356|NCT04324138|DRUG|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
214560159|NCT02165813|DRUG|Nitazoxanide|Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
214560160|NCT02165813|DRUG|placebo|An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
214560161|NCT03281161|BEHAVIORAL|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
214706357|NCT05508685|OTHER|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
214706358|NCT05508685|OTHER|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
214706359|NCT05508685|OTHER|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
214706360|NCT05508685|OTHER|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
214706361|NCT03141268|DIAGNOSTIC_TEST|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
215164638|NCT05338944|BEHAVIORAL|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
215164639|NCT05821426|DEVICE|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
215164640|NCT06868914|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|"TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.~Each subject will receive 3 active TBS (3-,4-, and 5-pulse TBS) and 1 sham TBS on 4 visits separated by at least 48 hours."
214706362|NCT02471911|DRUG|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
214706363|NCT02471911|DRUG|Rituximab|IV Rituximab 375 mg/m2 on D1
214706364|NCT02471911|DRUG|Etoposide|IV Etoposide 100 mg/m2 on D1-3
214706365|NCT02471911|DRUG|Carboplatin|IV Carboplatin AUC 5 on D2
214706366|NCT02471911|DRUG|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
214706367|NCT02471911|DRUG|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
214706368|NCT06391944|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
214706369|NCT06391944|DRUG|Osimertinib tablet|Osimertinib 80 or 160mg po everyday
214706370|NCT05399030|DRUG|ICP-332|ICP-332 will be administered as tablet
214706371|NCT05399030|OTHER|Placebo|Matching placebo will be administered as tablet
215164641|NCT06618157|DEVICE|Cerebellothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model
214560162|NCT03281161|BEHAVIORAL|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
214706372|NCT05217953|DEVICE|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
214706373|NCT00002392|DRUG|Thalidomide|
214706374|NCT01504048|PROCEDURE|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
214706375|NCT00664209|DRUG|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
215164642|NCT06618157|DEVICE|Pallidothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
215164643|NCT06618157|OTHER|No deep brain stimulation|Patients will also be tested without any deep brain stimulation
215164644|NCT06618157|DEVICE|Usual care deep brain stimulation|Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
215164645|NCT06691217|DRUG|CANAKINUMAB (ILARIS®)|Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
215164646|NCT06691217|DRUG|Saline (NaCl 0,9 %) (placebo)|Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
215164647|NCT05435976|DEVICE|CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)|Biological membranes used in dental surgery
215164648|NCT06328777|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
214560163|NCT03766477|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
214706376|NCT00664209|DRUG|placebo|placebo therapy
214706377|NCT01500928|DEVICE|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
214706378|NCT02097433|DRUG|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
214706379|NCT01078714|DRUG|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
214706380|NCT01847898|PROCEDURE|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
214706381|NCT01847898|PROCEDURE|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
215164649|NCT01754597|OTHER|Dosage of B-type natriuretic peptide (NT-proBNP)|"NT-proBNP concentration assessed at the following time points :~* T0: before induction of general anesthesia, NT-proBNP measurement~* T1: 30 minutes after induction of general anesthesia~* T2: at the end of the procedure~* T3: in the postoperative period, 6 hours after the end of the procedure~* T4: in the postoperative period, 24 hours after the end of the procedure"
215164650|NCT07021430|DRUG|Dihydroartemisinin Piperaquine|A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.
215164651|NCT07023029|DRUG|Etavopivat|Etavopivat will be administered orally.
215164652|NCT07023029|DRUG|Moxifloxacin|Moxifloxacin will be administered orally.
215164653|NCT07023029|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
215164654|NCT03564327|PROCEDURE|External electric cardioversion|Three attempts (200-250 joules)
214560164|NCT03766477|DIAGNOSTIC_TEST|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
214706382|NCT00065442|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
214706383|NCT00065442|BIOLOGICAL|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
214706384|NCT00082329|DRUG|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
214706385|NCT00082329|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
214560165|NCT03766477|DIAGNOSTIC_TEST|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
214560166|NCT04853446|DRUG|Dexamethasone 12 mg|Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
214560167|NCT04853446|DRUG|Placebo|Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
214560168|NCT04853446|DRUG|Dexamethasone 24 mg|Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
214560169|NCT00469105|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
214706386|NCT03594253|BEHAVIORAL|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
214706387|NCT01035008|PROCEDURE|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
214706388|NCT01866345|PROCEDURE|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
214706389|NCT01866345|PROCEDURE|Conventional orthodontic treatment|Conventional orthodontic Procedure
214706390|NCT04545398|OTHER|Food. Beef, Pasture-raised|Pasture-raised beef
214706391|NCT04545398|OTHER|Food. Beef, Grain-fed|Grain-fed beef
215164655|NCT06691854|OTHER|The group that applied the Intrapartum Care Model|"Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~A Personal Information form will be applied at the first clinic admission. All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations.~The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
215164656|NCT06686849|BEHAVIORAL|Low-touch: texting|Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.
215164657|NCT06686849|BEHAVIORAL|High-touch: Community health worker outreach|Community health worker (CHW) outreach: Within approximately one week of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
215164658|NCT07024745|BEHAVIORAL|Intervention Group|The Intervention is 1) interact with the Us\*Now mHealth app for 1 month; 2) participate in 4 weekly sessions with other group members and led by a Female Facilitator. Each week will cover a different topic - Week 1: Intersectional Stigma, Week 2: Sexual Health, Week 3: HIV Prevention, Week 4: Engagement in PrEP Care.
215164659|NCT07024745|BEHAVIORAL|Control (Standard treatment)|The Control group will be asked to interact with the Us\*Now mHealth app for 1 month.
215164660|NCT07020221|DRUG|VS-7375|VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
215164661|NCT07020221|DRUG|Cetuximab|Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
215164662|NCT07020221|DRUG|Carboplatin + Pemetrexed + Pembrolizumab|A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
215164663|NCT07020221|DRUG|Gemcitabine|A chemotherapy used for the treatment of several types of cancer including advanced or metastatic pancreatic ductal adenocarcinoma.
214560170|NCT00469105|BEHAVIORAL|Control Group|Receives standard diabetes disease management
214560171|NCT00954187|DRUG|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
214560172|NCT00954187|DRUG|pregabalin|50 mg PO TID
214560173|NCT04953598|DIAGNOSTIC_TEST|Ultrasonography|Patient undergoes diagnostic ultrasound examination
214560174|NCT06299800|OTHER|phenotyping of patients followed at a third-level diabetes centre with cancer|"Collection of the following data for each patient enrolled, where possible:~* Gender and age;~* Smoking habits and alcohol consumption (units per day);~* Weight and body mass index (BMI) at first (T0) and last visit (T1);~* Given by the diagnosis of type 2 diabetes mellitus;~* Treatment of type 2 diabetes at T0 and T1;~* Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar;~* Creatinine clearance at T0 and T1;~* Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST);~* T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG);~* Complications of type 2 diabetes;~* Treatment of cancer;~* Family history of cancer."
214560175|NCT03988244|DEVICE|HeartLight X3|Pulmonary vein isolation
214560176|NCT04315350|DRUG|Curcumin Liposome|Curcumin is given together with prednisolone
214560177|NCT04315350|DRUG|Prednisolone|Prednisolone is given together with curcumin-placebo
214560178|NCT04315350|DRUG|Placebos|Prednisolone-placebo is given together with curcumin-placebo
215164664|NCT07020221|DRUG|Gemcitabine + Nab-paclitaxel|A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.
215164665|NCT06874621|DRUG|VY7523|VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau
215164666|NCT06874621|DRUG|Placebo Comparator|Matching placebo to VY7523
215164667|NCT05561634|RADIATION|Radiotherapy|Irradiation of the tumoral bed.
215164668|NCT05561634|OTHER|Observation|Patients will be followed up in consultation every 3 months.
215164669|NCT05561634|DRUG|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
215164670|NCT06347718|DRUG|anti-CD19 CAR T cell therapy|Single-dose
215164671|NCT06697197|DRUG|BMS-986482|Specified dose on specified days
215164672|NCT06697197|DRUG|Nivolumab and rHuPH20|Specified dose on specified days
215164673|NCT06697197|DRUG|Nivolumab/relatlimab/rHuPH20|Specified dose on specified days
215164674|NCT06697197|DRUG|Bevacizumab|Specified dose on specified days
215164675|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin(high dose) and Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose.
215164676|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose), Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
214560179|NCT04192695|DEVICE|Cytosponge cell collection device|The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus. Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
214560180|NCT00489944|DRUG|cisplatin|
214560181|NCT00489944|DRUG|sunitinib malate|
214560182|NCT00489944|DRUG|tamoxifen citrate|
214560183|NCT00489944|PROCEDURE|adjuvant therapy|
214560184|NCT04546503|PROCEDURE|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~\+ General anaesthesia"
214560185|NCT04546503|PROCEDURE|Control Group|General anaesthesia without regional analgesia
214560186|NCT04490590|DRUG|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
215164677|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
215164678|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
215164679|NCT07026968|DRUG|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
215164680|NCT07024420|OTHER|Sigh Breaths|Sigh breaths were added by elevating PEEP, targeting a plateau pressure of 35 cmH2O (or 40 cmH2O for patients with a Body Mass Index \> 35 kg/m2). These sigh breaths were administered once every 6 minutes at predefined stages in the perioperative period from the time of anesthesia intubation until endotracheal extubation, postoperative day 7, or death, whichever occurred first, but not during transport. Each sigh consisted of the minimum number of respiratory cycles aimed to achieve a total duration of at least 5 seconds, based on the respiratory cycle duration preset on the ventilator.
215164681|NCT07024420|OTHER|Low Tidal Volume|6-8ml/kg predicted body weight
215164682|NCT07024420|OTHER|Moderate PEEP|PEEP set according to ARDSnet low PEEP- fraction of inspired oxygen table, FiO2 was set as the lowest fraction targeted to maintain SpO2 ≥ 96%
215164683|NCT06066203|DRUG|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
214706392|NCT04545398|OTHER|Food. Meat alternative|Meat alternative
214706393|NCT04545398|OTHER|Food, Lamb|Lamb
214706394|NCT01594333|DRUG|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
214706395|NCT01594333|DRUG|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
214706396|NCT04914078|DRUG|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
214706397|NCT01480557|PROCEDURE|liquefaction|Cataract extraction surgery type
214706398|NCT01480557|PROCEDURE|Torsional ip|A type cataract surgery using torsional ip technology
214560187|NCT04279132|BEHAVIORAL|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
214560188|NCT05784623|OTHER|User experience|User experience is assessed by validated scales
214560189|NCT00689585|DRUG|Placebo|250mg matching placebo capsules
214560190|NCT00689585|DRUG|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
214560191|NCT00472810|DEVICE|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
214560192|NCT00472810|DRUG|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
214560193|NCT05344664|BIOLOGICAL|GPC3-CAR-T cells|The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10\^6 to 1×10\^8 CAR-T+/kg.
214560194|NCT04774653|OTHER|No intervention|Associations and prevalence will be calculated
214560195|NCT02988050|DRUG|Remifentanil|Remifentanil used for conscious sedation.
214560196|NCT02988050|DRUG|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
214706399|NCT03335787|OTHER|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
214560197|NCT02988050|DRUG|Propofol|Used for conscious sedation.
214560198|NCT02988050|DRUG|Bupivacaine|Local anaesthetics
214560199|NCT02988050|DRUG|Lidocaine|Local anaesthetic
214560200|NCT02988050|DRUG|Epinephrine|With local anaesthetic for skin infiltration.
214560201|NCT00992043|DIETARY_SUPPLEMENT|creatine|
214560202|NCT00992043|OTHER|Exercise training|
214560203|NCT01977677|RADIATION|radiation therapy|Undergo radiation therapy
214560204|NCT01977677|DRUG|temozolomide|Given PO
214560205|NCT01977677|DRUG|plerixafor|Given IV
214560206|NCT01977677|OTHER|laboratory biomarker analysis|Correlative studies
214560207|NCT01977677|OTHER|pharmacological study|Correlative studies
214706400|NCT03335787|OTHER|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
214706401|NCT02085057|PROCEDURE|Functional Magnetic Resonance Imaging|
214706405|NCT05539586|OTHER|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
214706406|NCT05539586|OTHER|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
215164684|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
214560208|NCT01342289|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
214560209|NCT01342289|DRUG|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.
214560210|NCT01342289|RADIATION|Total body irradiation|Day -1: 200 centigray in one fraction.
214560211|NCT01342289|DRUG|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
214560212|NCT01342289|DRUG|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
214560213|NCT01342289|DRUG|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
214560214|NCT01342289|DRUG|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
214560215|NCT01342289|BIOLOGICAL|Bone marrow transplant|Donor stem cells infused IV on Day 0.
214560216|NCT04274205|OTHER|Intervention group|Brief supportive psychotherapy
214560217|NCT05990114|OTHER|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
214560218|NCT05683080|OTHER|Routine Clinical Care|Participants completing the research study will receive routine clinical care
214706407|NCT02985905|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
214706408|NCT02694211|BEHAVIORAL|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
214706409|NCT01764256|BIOLOGICAL|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
214706410|NCT01764256|OTHER|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
214706411|NCT02098694|OTHER|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
215164685|NCT06671483|DRUG|Zasocitinib|Zasocitinib over-encapsulated tablets.
214560219|NCT01514253|DRUG|Glucose 25%|1 ml glucose 25%, once
214560220|NCT01514253|DIETARY_SUPPLEMENT|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
214560221|NCT01514253|OTHER|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
214560222|NCT03237442|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
214560223|NCT03237442|BIOLOGICAL|placebo|Saline injection
214560224|NCT04065399|DRUG|revumenib|revumenib orally
214560225|NCT04065399|DRUG|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
214560226|NCT02986308|OTHER|No intervention|
214560227|NCT01953705|DRUG|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
215164686|NCT06671483|DRUG|Active Comparator|Active comparator capsule.
215164687|NCT06671483|DRUG|Placebo|Zasocitinib or active comparator matching placebo.
214560228|NCT01953705|DRUG|Placebo|
214560229|NCT02754063|DEVICE|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
214560230|NCT02754063|OTHER|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
214560231|NCT00974818|DRUG|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
214560232|NCT00974818|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
214560233|NCT00283751|DRUG|insulin detemir|
214560234|NCT00283751|DRUG|insulin glargine|
214560235|NCT03069703|BIOLOGICAL|PCV13|one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
214560236|NCT03069703|BIOLOGICAL|PPV23|one dose of PPV23 at M5
214560237|NCT03069703|DRUG|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
214560238|NCT00626197|DRUG|Corticosteroids|Intravenous and oral repeating dose
214560239|NCT00626197|DRUG|Cyclophosphamide|Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
214560240|NCT00626197|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
214560241|NCT00626197|DRUG|Ocrelizumab|Ocrelizumab was administed at a dose and as per schedule in arm description
214560242|NCT00626197|DRUG|Placebo|Placebo was administered as per schedule in arm description
214560243|NCT00626197|DRUG|Azathioprine|Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
214560244|NCT01460459|BEHAVIORAL|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
214560245|NCT05860582|DRUG|[14C]GB491|A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
214560246|NCT03297177|PROCEDURE|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
214560247|NCT03297177|DEVICE|Centricyte 1000|Closed System, Digestive Isolation \& Concentration of AD-cSVF
214560248|NCT03297177|PROCEDURE|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
214560249|NCT03750929|OTHER|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
214560250|NCT00497731|DRUG|AZD1152|2-hour continuous intravenous infusion
214560251|NCT02750449|DRUG|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
214560252|NCT02750449|OTHER|Untreated skin|This site is patched without treatment as control
214560253|NCT04051502|DRUG|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
214560254|NCT04051502|DRUG|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"
214560255|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
214560256|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
214560257|NCT05755906|DRUG|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
214560258|NCT05755906|DRUG|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
214560259|NCT05922982|DRUG|norepinephrine weaning protocol|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
214560260|NCT05922982|DRUG|norepinephrine weaning protocol and guided by the HPI|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
214560261|NCT00461981|BIOLOGICAL|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
214560262|NCT00461981|BIOLOGICAL|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
214560263|NCT03978039|DRUG|Chemotherapy|treatment as per standard of care
214560264|NCT03978039|DRUG|Immunotherapeutic Agent|treatment as per standard of care
214560265|NCT03978039|DRUG|target treatment|treatment as per standard of care
214560266|NCT03978039|PROCEDURE|Surgery|treatment as per standard of care
214560267|NCT03978039|RADIATION|Radiotherapy|treatment as per standard of care
214560268|NCT02542800|BEHAVIORAL|Episodic memory task|
214560269|NCT02542800|DEVICE|fMRI|
214560270|NCT03040934|DEVICE|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
214560271|NCT03040934|DEVICE|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
214560272|NCT03832218|DIAGNOSTIC_TEST|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~* Test : Wechsler Intelligence Scale for Children (WISC-V)~* Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~* Global Assessment of Functioning Scale~* Scale : Brief Psychiatric Rating Scale (BPRS)~* Test : Children Depression Inventory (CDI)~* Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~* Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~* Scale : Conners' scale (parents and teachers)"
214560273|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
214560274|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
214560275|NCT05336786|DRUG|Perflutren Lipid Microspheres|Given IV
214560276|NCT05336786|PROCEDURE|Ultrasound|Undergo ultrasound
214560277|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
214560278|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
214560279|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
214706412|NCT01874249|OTHER|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
214560280|NCT00455221|BIOLOGICAL|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
215164688|NCT07029412|DRUG|MBX 1416 (INN imapextide)|A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.
215164689|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
215164690|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
215164691|NCT07028281|DRUG|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
215164692|NCT07029828|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
214560281|NCT00455221|GENETIC|Cytokine gene adjuvant|Cytokine gene adjuvant
214706413|NCT01874249|OTHER|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
215164693|NCT07029828|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
215164694|NCT06395753|DRUG|Debio 4228|Administered as IM injection.
215164695|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
215164696|NCT02867475|OTHER|Physical activity motivation|Physical activity motivation
215164697|NCT07023341|DRUG|BAY3723113|Oral tablet
214560282|NCT04579783|DRUG|Triamcinolone Acetonide|Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline
214560283|NCT04579783|DRUG|Dextrose 5% in water|Group B: 5mL 5% dextrose
214560284|NCT02565524|OTHER|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
214706414|NCT01874249|OTHER|Transient elastography|Transient elastography values greater than 8 kPa
215164698|NCT01588236|DRUG|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
215164699|NCT01588236|DRUG|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
215164700|NCT01588236|DRUG|Placebo|3 capsules of placebo tid (morning, midday, and evening)
215164701|NCT07027839|DRUG|Intravenous Ethanol|Intravenous ethanol infusion before PET Scan
215164702|NCT07027839|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
215164703|NCT07030712|DRUG|MK-8294|30 µg via intravenous (IV) infusion
215164704|NCT07030712|DRUG|MK-8294|100 µg via intravenous (IV) infusion
215164705|NCT07030712|DRUG|MK-8294|300 µg via intravenous (IV) infusion
214560285|NCT05925231|DIAGNOSTIC_TEST|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
214560286|NCT02383940|DRUG|Sotagliflozin|Sotagliflozin 400 mg, once daily before the first meal of the day
214560287|NCT02383940|DRUG|Placebo|Placebo, once daily before the first meal of the day
214560288|NCT00201708|DRUG|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
214560289|NCT00201708|DRUG|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
214560290|NCT00201708|DRUG|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
214560291|NCT04150159|DIETARY_SUPPLEMENT|FMD Arm|ProLon Fasting Mimicking Diet Plan
214560292|NCT04059627|DEVICE|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
214560293|NCT02308787|DEVICE|Spectra Optia Apheresis System|Platelet Depletion
215164706|NCT07030712|DRUG|MK-8294|1 mg via intravenous (IV) infusion
215164707|NCT07030712|DRUG|MK-8294|3 mg via intravenous (IV) infusion
215164708|NCT07030712|DRUG|MK-8294|10 mg via intravenous (IV) infusion
215164709|NCT07030712|DRUG|MK-8294|30 mg via intravenous (IV) infusion
215164710|NCT07030712|DRUG|MK-8294|70 mg via intravenous (IV) infusion
215164711|NCT07027826|DEVICE|Esophageal string test|The esophageal string test consists of a gelatin or cellulose capsule containing a nylon string. The capsule dissolves allowing the nylon string to absorb esophageal secretions which can be analyzed for various inflammatory mediators.
215164712|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1|MP0533 is administered by intravenous infusion
215164713|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A|"* MP0533 is administered by intravenous infusion~* Obinutuzumab pretreatment administered"
215164714|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
215164715|NCT05673057|DRUG|MP0533 with Obinutuzumab pretreatment|"* MP0533 is administered by intravenous infusion at densified dosing schedule~* Obinutuzumab pretreatment administered"
215164716|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
214560294|NCT00040651|DRUG|Fludarabine|
214560295|NCT00040651|DRUG|Cyclophosphamide|
214560296|NCT00040651|DRUG|Thymoglobulin|
214560297|NCT00040651|PROCEDURE|Leukapheresis|
214560298|NCT00040651|PROCEDURE|Self bone marrow transplant|
214560299|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
215164717|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
214560300|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
214560301|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
214560302|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
214560303|NCT01509144|BIOLOGICAL|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
214560304|NCT01158287|DRUG|sorafenib tosylate|
214560305|NCT01158287|OTHER|laboratory biomarker analysis|
214560306|NCT02672852|DRUG|Risankizumab|Risankizumab administered by subcutaneous injection
214560307|NCT02672852|DRUG|Placebo|Placebo for risankizumab administered by subcutaneous injection
214560308|NCT04682743|DRUG|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
214560309|NCT04682743|DRUG|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
214706415|NCT02488525|DRUG|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
214706416|NCT04162535|DRUG|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
214706417|NCT04162535|BIOLOGICAL|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
214706418|NCT04162535|DRUG|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
214706419|NCT04162535|DRUG|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
214706420|NCT03061045|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
214706421|NCT02067741|DRUG|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
214706422|NCT06445894|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
214560310|NCT04682743|DRUG|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
214560311|NCT04797052|DEVICE|Prefrontal EEG (VEEGix by NeuroServo)|Prefrontal EEG reading
214560312|NCT04958642|DRUG|Adrabetadex|Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
214560313|NCT02086890|DEVICE|Electro-acupuncture|
214560314|NCT02086890|DEVICE|Laser Acupuncture|
214560315|NCT02086890|DEVICE|Transcorneal Electrical Stimulation|
214560316|NCT02086890|DEVICE|Sham Electro-acupuncture|
214560317|NCT02086890|DEVICE|Sham laser acupuncture|
214560318|NCT02086890|DEVICE|Sham transcorneal electrical stimulation|
214560319|NCT06037473|DRUG|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
214560320|NCT00445627|DRUG|Metformin|
214560321|NCT00445627|DRUG|Insulin|
214560322|NCT00445627|BEHAVIORAL|Nutrition counseling|
214560323|NCT00445627|BEHAVIORAL|Exercise counseling|
214560324|NCT04308590|DRUG|Relacorilant|Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
214560325|NCT04308590|OTHER|Placebo|Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
214560326|NCT01796015|OTHER|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
214560327|NCT05457751|PROCEDURE|Rocuronium injection pain|1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
214706423|NCT06445894|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
214706424|NCT04268095|OTHER|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
214706425|NCT02029638|BIOLOGICAL|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
214706426|NCT02029638|DRUG|Fludarabine|Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
214560329|NCT01541384|DEVICE|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
214560330|NCT06595459|DRUG|Nicotine Pouches|3mg or 6mg nicotine pouches
214560331|NCT06595459|DRUG|Mini Nicotine lozenges|2mg to 4mg mini lozenges
214560332|NCT06013631|OTHER|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
214560333|NCT06013631|OTHER|Phantom Exercises|The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
214560334|NCT04903418|DEVICE|CBCT software|"* Retrospective Data Analysis will be performed after the CBCT images are pooled from the computer database.~* All the CBCT examinations will be obtained for patients who were scanned using CBCT Software (Planmeca Romexis® Viewer software).~* CBCT images will be analysed in different planes."
214560335|NCT04808986|DIAGNOSTIC_TEST|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
214560336|NCT05258396|OTHER|MRI without injection of contrast product|MRI without injection of contrast product
214560337|NCT05856526|DRUG|Spesolimab - solution for infusion|Solution for infusion
214560338|NCT05856526|DRUG|Placebo matching to spesolimab - solution for infusion|Solution for infusion
214560339|NCT05856526|DRUG|Spesolimab - solution for injection|Solution for injection
214560340|NCT05856526|DRUG|Placebo matching to spesolimab - solution for injection|Solution for injection
215164718|NCT06876532|OTHER|Additional blood tests (CRP and serum albumin) and data collection.|"These blood tests will be carried out on several occasions (before, during and after treatment with Lu-177 oxodotreotide). No additional blood sampling is required.~In addition, patient clinical data and imaging data (standard examinations: thoraco-abdomino-pelvic CT +/- MRI and Ga-68 DOTA PET-CT) will be specifically collected for study purposes.~For IUCT-O patients only: blood samples may be taken (at cycles 1 and 2, then 12 months after inclusion) for bio-banking purposes."
215164719|NCT07030972|OTHER|Exercise|Individuals in the control and intervention groups will be included in a routine exercise program. For this exercise program; shoulder joint range of motion exercises, finger ladder, Codman and stick exercises will be given to protect functional range of motion in the early stages and to increase it in the later stages. Isometric exercises will be performed on the scapular muscles in the early stages to preserve muscle strength. In the later stages, rotator cuff, scapula stabilizers and deltoid strengthening exercises will be shown and applied, initially with low-resistance therabants for strengthening. In addition, neuromuscular control exercises and proprioceptive exercises will be included in the treatment to increase joint stabilization and coordination. Exercises will be performed for 6 weeks, 3 days a week, with 10-30 repetitions.
215164720|NCT07030972|OTHER|Deep friction massage|Individuals in the intervention group will receive a deep friction massage to the biceps tendon after the exercise program. The individual will be placed in a long sitting position with their back supported. While the patient's shoulder is next to the body and the elbow is flexed at 90 degrees, the therapist's thumb will be placed on the painful area on the extension of the biceps tendon fibers and a deep friction massage will be applied to the point where the tendonitis occurs in a transverse direction for 3-10 minutes.
215164721|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
215164722|NCT06873945|DRUG|Ritlecitinib 100 mg|100 mg Capsule
215164723|NCT06873945|DRUG|Ritlecitinib 50 mg|50 mg Capsule
215164724|NCT06873945|DRUG|Placebo - 100 mg|Capsule (to match Ritlecitinib 100 mg)
215164725|NCT06873945|DRUG|Placebo - 50 mg|Capsule (to match Ritlecitinib 50 mg)
215164726|NCT07034638|BEHAVIORAL|WNG|In addition to the hospital's standard care protocol, patients in this group will listen to white noise through headphones before and during the colonoscopy procedure, as directed by the researcher.
215164727|NCT07034638|BEHAVIORAL|PNG|In addition to the standard care protocol, patients included in this group will listen to pink noise through headphones as directed by the researcher.
215164728|NCT07032506|PROCEDURE|Intraoperative placement of an inflated intrauterine pediatric foley catheter|Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon to remain in place for 7-10 days following surgery.
215164729|NCT07032506|PROCEDURE|No Catheter placement|No Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon
215164730|NCT07032506|DRUG|Hormonal Therapy Agent|2 weeks of oral estradiol (2 mg daily) or transdermal (two 0.1 mg patches changed twice weekly) estradiol supplementation followed by 1 week of oral or transdermal estradiol (same dosing as above) with oral medroxyprogesterone acetate (10 mg daily)
215164731|NCT07032506|DRUG|Oral antibiotics|100 mg of oral doxycycline twice daily or other appropriate antibiotic in allergic patients to be given while the intrauterine stent is in place
215164732|NCT07030764|DEVICE|DOCT'UP|In addition to conventional physiotherapy sessions, DOCT'UP® is a mobile application which offers support programmes for patients following ACL reconstruction. This is digital therapy based on homebased physical exercises to be performed by patient.
215164733|NCT07030764|BEHAVIORAL|Physiotherapy|Physiotherapy includes sessions performed at physiotherapist office under physiotherapist overview
214560341|NCT02878447|RADIATION|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
214560342|NCT05487586|DRUG|ceftazidime avibactam group|Non-Interventional Study
214560343|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
214560344|NCT04798781|DRUG|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
214560345|NCT04798781|DRUG|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
214706427|NCT02029638|DRUG|Cyclophosphamide|"1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
214560346|NCT03214770|DRUG|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
214560347|NCT03214770|DRUG|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
214560348|NCT03853551|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
214560349|NCT06161207|PROCEDURE|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection|Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
214560350|NCT02511262|DEVICE|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
214560351|NCT02476175|DRUG|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
214560352|NCT03120468|DRUG|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
214560353|NCT03120468|DRUG|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
214560354|NCT03398304|OTHER|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
214560355|NCT03398304|OTHER|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
214560356|NCT06847204|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine is anti inflammatory drug which will be given to Covid pneumonia patients and their benefit will be observed in them
214560357|NCT05286125|PROCEDURE|erector spinae plane (ESP) block|Using the in plane technique, the needle will be advanced between the transverse process and erector spinae muscle. The correct location will be confirmed using 1ml of Local Anesthetic (LA) to view hydrodissection(12). 19ml of LA will be injected between the muscle and transverse process.
214560358|NCT05286125|PROCEDURE|oblique subcostal transverse abdominis plane (TAP) block|An echogenic needle will be inserted in-plane until the needle tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles. Once the needle enters the TAP plane, a dynamic injection can be performed by advancing the needle under ultrasound guidance laterally in the pocket created by the initial injection of 5 - 10 mL of local anesthetic; as the needle is advanced, the remaining local anesthetic will be injected. This allows for a more lateral spread of the local anesthetic
214560359|NCT00002320|DRUG|Lamivudine|
214560360|NCT00002320|DRUG|Zidovudine|
214560361|NCT04064996|OTHER|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
214560362|NCT04064996|OTHER|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
214560363|NCT01741805|OTHER|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
214560364|NCT04057027|PROCEDURE|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
214560365|NCT04057027|PROCEDURE|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
214560366|NCT05735171|PROCEDURE|GTR surgery|Gross total resection of the enhancing tumor volume
214560367|NCT05735171|PROCEDURE|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
214560368|NCT02219165|DRUG|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
214706428|NCT02029638|RADIATION|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
214706429|NCT02029638|DRUG|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
214706430|NCT02029638|DRUG|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
215164734|NCT07030998|DEVICE|Wearable Device|"Wearable device to collect the following health metrics directly from participants for the duration of the study (4 weeks). Health metrics are collected every 15 minutes, except for the ECG which will be collected once per week.~Data points:~* ECG data (Once per week)~* Exercise time~* Body Temperature~* Heart Rate~* Irregular Heart Rhythm~* Blood Oxygen Saturation~* Respiratory Rate"
215164735|NCT07137455|DEVICE|EDEN Intracardiac Electrogram Recording and Classifying System|EDEN will be used to record and classify intracardiac electrograms obtained in the practice of medicine.
215164736|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
215164737|NCT06711887|DRUG|Ianalumab|Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
215164738|NCT02587624|PROCEDURE|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
215164739|NCT07135986|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection
215164740|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Suspension-Route of administration:IM injection
215164741|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Lyophilized powder-Route of administration:IM injection
215164742|NCT06711588|DEVICE|As-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).
215164743|NCT06711588|DEVICE|Two categories stiffer than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories stiffer than the as-prescribed stiffness.
214560369|NCT02219165|DRUG|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
214560370|NCT05038124|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
214560371|NCT03417544|DRUG|ATEZOLIZUMAB|(IV) every 3 weeks
214560372|NCT03417544|DRUG|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
214560373|NCT03417544|DRUG|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
214560374|NCT03808142|OTHER|myBETAapp|Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
214560375|NCT03808142|OTHER|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
214560376|NCT03808142|DRUG|Betaferon, BAY86-5046|Injection
214560377|NCT03808142|DEVICE|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
214560378|NCT02175641|BEHAVIORAL|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
214560379|NCT02175641|BEHAVIORAL|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
214706431|NCT02029638|DRUG|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
214706432|NCT02029638|BIOLOGICAL|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
215164744|NCT06711588|DEVICE|Two categories less stiff than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories less stiff than the as-prescribed stiffness.
215164745|NCT06710483|BEHAVIORAL|Pre-Dental Telehealth (PDT)|The PDT will be a scripted telehealth interview 3-7 days before the scheduled dental visit to review medical and dental history, to evaluate the participants' needs for the dental visit, and to set an agreed goal for the dental visit using shared decision making. The goal wlll be one of the following: Goal 1: exam cleaning only, Goal 2: exam and cleaning, Goal 3: exam, radiographs, and cleaning.
214560380|NCT04417842|DIAGNOSTIC_TEST|Respimetrix flow-volume monitoring device|The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
214560381|NCT00821951|DRUG|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
214560382|NCT00821951|RADIATION|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
214706433|NCT02029638|DRUG|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
214560383|NCT03791554|PROCEDURE|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
214560384|NCT03791554|PROCEDURE|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
214560385|NCT03414385|OTHER|Exercise|Acute bout of aerobic exercise at moderate intensity for 2 hours
214560386|NCT00056875|DRUG|recombinant human keratinocyte growth factor|
214560387|NCT00897793|PROCEDURE|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
214560388|NCT00897793|RADIATION|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
214560389|NCT06223022|BEHAVIORAL|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
214560390|NCT04396288|DEVICE|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
214560391|NCT03921723|DRUG|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
214560392|NCT03921723|DRUG|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
214706434|NCT02029638|DRUG|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
214560393|NCT03921723|DRUG|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
214560394|NCT02518035|DRUG|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
214706435|NCT02029638|DRUG|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
214706436|NCT02029638|DRUG|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
214706437|NCT02570646|BEHAVIORAL|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
214706438|NCT04374812|OTHER|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
214706439|NCT04374812|OTHER|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
214706440|NCT05379894|PROCEDURE|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
214706441|NCT03427450|DIAGNOSTIC_TEST|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
214706442|NCT02992834|BIOLOGICAL|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
214706443|NCT02992834|BIOLOGICAL|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
214706444|NCT04562142|DEVICE|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
214706445|NCT06140277|PROCEDURE|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
214706446|NCT06140277|PROCEDURE|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
214706447|NCT06140277|PROCEDURE|tooth extraction only|hopeless tooth will be extracted without any intervention
214560395|NCT06224777|BIOLOGICAL|5% Albumin (human) Solution|Albumin is a biological product derived from human blood donors.
214560396|NCT06224777|DRUG|Paeds solution|Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
214560397|NCT05594134|OTHER|Automatic toothbrush with nylon bristle|The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch
214560398|NCT05594134|OTHER|Automatic toothbrush with silicone bristle|The automatic toothbrush with silicone bristles will be used for 10 seconds
214560399|NCT05594134|OTHER|Manual toothbrush used for 2 minutes|A conventional manual toothbrush will be used for 2 minutes
214560400|NCT05594134|OTHER|Manual toothbrush used for 45 seconds|A conventional manual toothbrush will be used for 45 seconds
214560401|NCT02410616|BEHAVIORAL|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
214706448|NCT01153841|BIOLOGICAL|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
214706449|NCT01153841|BIOLOGICAL|Infanrix hexa™|Intramuscular, 3 doses
214706450|NCT04134741|OTHER|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
214560402|NCT02410616|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
214560403|NCT04137328|DRUG|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
214706451|NCT03428256|DEVICE|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
214706452|NCT03428256|DEVICE|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
214706453|NCT00863980|DRUG|Micardis (Telmisartan)|40-80 mg/day oral administration
214560404|NCT04137328|DRUG|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
214706454|NCT00863980|DRUG|Blopress (Candesartan)|8-12 mg/day oral administration
214706455|NCT03948126|OTHER|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
214706456|NCT00391781|PROCEDURE|Temperature of contrast medium|
214706457|NCT02666508|OTHER|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
214560405|NCT06223919|BIOLOGICAL|LC16m8|"LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses"
214560406|NCT01162070|OTHER|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
214560407|NCT01162070|OTHER|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
214560408|NCT06412991|BEHAVIORAL|Cycle Therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
214706458|NCT02666508|OTHER|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
214706459|NCT04712357|DRUG|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
214706460|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
214706461|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
214706462|NCT06207695|BEHAVIORAL|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
214706463|NCT03248050|BEHAVIORAL|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
214706464|NCT00002707|DRUG|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
214706465|NCT00002707|DRUG|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
214706466|NCT00002707|DRUG|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
214706467|NCT00002707|DRUG|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
214706468|NCT03823807|DRUG|SH-1028|Oral,100mg or 200mg ,QD, fasted
214706469|NCT00018018|DRUG|CD34+ cells transduced with ADA retrovir|
214706470|NCT02792049|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
214706471|NCT02792049|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
214706472|NCT00779311|DRUG|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
214706473|NCT00779311|DRUG|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
214706474|NCT00779311|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
214706475|NCT03963934|OTHER|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
214706476|NCT00781872|BIOLOGICAL|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
214706477|NCT01867866|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214706478|NCT01867866|DRUG|Trifluridine|35 mg/m2, orally, single dose
214560409|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
214560410|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
214560411|NCT05945823|DRUG|Futibatinib|TAS-120 20 mg tablets, oral; once daily
214560412|NCT05945823|DRUG|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
214560413|NCT05945823|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy
214560414|NCT05945823|DRUG|5-FU|"4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy."
214560415|NCT05945823|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.
214560416|NCT05945823|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
214560417|NCT05945823|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
214560418|NCT05945823|DRUG|Irinotecan|150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
214560419|NCT03805776|OTHER|Fasting (diet restruction for specific period)|12-14 hours fasting
215164746|NCT07120789|OTHER|Application of Patient Knowledge Questionnaire on Pulmonary Hypertension|Participants will complete one version of the DICTA questionnaire, developed to assess patient knowledge about pulmonary arterial hypertension. Depending on the study phase, participants will contribute to content validation (expert judges), semantic validation (patients), or psychometric validation (patients). In the final phase, additional data including risk stratification (COMPERA 2.0), hospitalizations, and quality of life scores (CAMPHOR, SF-36, MBG) will be collected for correlational analysis.
215164747|NCT06712784|BEHAVIORAL|Treatment Package (for both simulation and procedure sessions|Treatment Package for both simulation and procedure sessions will include visit priming (contingency specifying stimuli in the form of social stories and YouTube videos) and differential reinforcement of alternative behavior (DRA).
214560420|NCT03689777|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
214706479|NCT00947843|DRUG|aspirin + pregrel (Clopidogrel resinate)|
214706480|NCT00947843|DRUG|aspirin + placebo|
214706481|NCT00947843|DRUG|aspirin + plavix (Clopidogrel bisulfate)|
214706482|NCT01127295|DRUG|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
215164748|NCT06714591|DRUG|BL-M11D1|"The study includes 2 parts:~Part 1 Dose escalation and Dose Finding"
215164749|NCT06713239|DEVICE|Cleerly Labs and Cleerly ISCHEMIA|Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
215164750|NCT07036159|BIOLOGICAL|RTS,S/AS01E vaccine|RTS,S/AS01E vaccine will be administered intramuscularly.
215164751|NCT07037277|DRUG|Bemnifosbuvir-Ruzasvir|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
214560421|NCT03689777|PROCEDURE|gastric bypass|gastric bypass
214560422|NCT01376492|OTHER|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
214560423|NCT01376492|OTHER|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
214560424|NCT02771379|DRUG|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
214560425|NCT03680352|DRUG|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
214706483|NCT02431130|OTHER|low-fidelity instructor driven simulation training|
214706484|NCT03428997|DEVICE|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
214706485|NCT03428997|OTHER|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
214706486|NCT00443235|DRUG|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
214706487|NCT00443235|DRUG|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
214706488|NCT02424812|BEHAVIORAL|Lifebuoy School of Five Handwashing Intervention|
215164752|NCT07037277|DRUG|Sofosbuvir-Velpatasvir|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
215164753|NCT07122687|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
215164754|NCT07122687|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
215164755|NCT07122687|DRUG|IBI363|1.5 mg/kg D1 IV Q3W
215164756|NCT07122687|DRUG|Carboplatin|AUC 5 mg/ml/min D1 IV Q3W
215164757|NCT07122687|DRUG|Keytruda|200mg D1 IV Q3W
215164758|NCT06880991|OTHER|Arm 1|Participant completion of questionnaires and participation in focus group(s) and/or interview sessions.
215164759|NCT06880744|DRUG|Risankizumab|Intravenous (IV) Infusion
215164760|NCT06880744|DRUG|Risankizumab|Subcutaneous (SC) injection
214560426|NCT02175953|BEHAVIORAL|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
214560427|NCT00269321|PROCEDURE|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
214560428|NCT00269321|PROCEDURE|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
214560429|NCT00269321|BEHAVIORAL|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
214706489|NCT03304327|BEHAVIORAL|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
214706490|NCT05506969|BIOLOGICAL|rF1V-1018|rF1V vaccine and CpG 1018® adjuvant
215164761|NCT06880744|DRUG|Vedolizumab|Intravenous (IV) infusion
215164762|NCT06876662|DRUG|Pirtobrutinib|Administered orally.
215164763|NCT06876064|BIOLOGICAL|Blood test|A total of 60 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.
215164764|NCT06876064|BIOLOGICAL|Urine test|Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.
215164765|NCT06876064|OTHER|stool collection|Stool samples will be collected either at the hospital or at home using a dedicated kit.
215164766|NCT06876064|OTHER|saliva collection|5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.
215164767|NCT06876064|OTHER|Induced expectoration|inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms
215164768|NCT06876064|OTHER|Hair and nails sampling|Hair and nails samples will be collected.
215164769|NCT06876064|OTHER|Schirmer test|To assess of tear secretion
215164770|NCT06876064|RADIATION|Ultrasound of hands and feet|To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.
214560430|NCT01724034|OTHER|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
214560431|NCT01724034|OTHER|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
214706491|NCT05506969|BIOLOGICAL|rF1V vaccine|rF1V vaccine
214706492|NCT04915326|PROCEDURE|rectal resection|every patients will undergo to the appropriate rectal resection
214706493|NCT01630759|DEVICE|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
214706494|NCT01630759|OTHER|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
215164771|NCT06876064|RADIATION|MRI Contrast|MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.
215164772|NCT06876064|OTHER|Patient questions|Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.
215164773|NCT06876064|DIAGNOSTIC_TEST|Dental panoramic X-ray|Performed as part of routine care to assess dental health
215164774|NCT06876064|OTHER|Consultation with a psychologist in certain centers|The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.
215164775|NCT06876064|OTHER|Measurement of heart rate variability.|The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).
215164776|NCT06487481|PROCEDURE|Surgical resection|Planned surgical resection (all participants) 4 weeks after completion of the preoperative RT
214560432|NCT01724034|OTHER|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
214560433|NCT01724034|OTHER|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
214560434|NCT01724034|OTHER|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
214560435|NCT01724034|OTHER|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
214560436|NCT00223847|BEHAVIORAL|Constraint Induced Language Therapy|
214560437|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214560438|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214560439|NCT05946603|DRUG|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
214560440|NCT05946603|DEVICE|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
214560441|NCT05946603|PROCEDURE|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
214560442|NCT05342805|PROCEDURE|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
214560443|NCT05634148|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
214560444|NCT03822429|DRUG|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
214560445|NCT01820884|PROCEDURE|TH|Total hysterectomy
214560446|NCT01820884|PROCEDURE|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
214560447|NCT01820884|PROCEDURE|BPLND|bilateral pelvic and para-aortic lymph node dissection
214560448|NCT03161613|OTHER|Non-Interventional|Non-Interventional
214560449|NCT02683785|DRUG|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
214560450|NCT02683785|DRUG|Placebo|Matching placebo will be administered as above.
214560451|NCT04921891|PROCEDURE|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
214560452|NCT04921891|PROCEDURE|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
214560453|NCT01823705|DEVICE|Exilis Implantable Gastric Electrical Stimulation (GES)|
214560454|NCT03671577|BEHAVIORAL|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
214560455|NCT04324723|BEHAVIORAL|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear \[First name\], Your BP reading during Beirut Marathon was \[reading\]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
214560456|NCT06068751|OTHER|Aerobic Exercise|The initial group will receive instructions to increase their moderate to high-intensity physical activity frequency to at least 60 minutes per day (in episodes exceeding 10 minutes) by 50%, with a minimum of three days per week. They will be encouraged to engage in enjoyable and age-appropriate activities, including jogging, brisk walking, swimming, dancing, cycling, as well as sports like basketball, football, and tennis.
214560457|NCT06068751|OTHER|Neck Exercises|The second group, focused on neck exercises, will receive guidance from an experienced physiotherapist and their families. The physiotherapist will demonstrate a series of stretching and isometric strengthening exercises for specific muscle groups: upper trapezius, levator scapula, sternocleidomastoid, cervical flexors, and extensors, which have been associated with migraines in prior studies. Each patient will perform 3 sets of 10-15 repetitions for both stretching and isometric strengthening exercises per muscle group, with a 1-minute break between sets. Patients will be advised to maintain a gentle stretch during stretching exercises, avoiding excessive force to prevent discomfort. Static stretching and isometric strengthening exercises will involve holding each position for 5-10 seconds. In the initial week, a reduced set of 5 repetitions will be allowed for adaptation. Throughout the intervention, participants will follow this exercise regimen for 3 days weekly.
214560458|NCT04457349|PROCEDURE|Therapeutic Plasma Exchange (TPE)|Treatment with Therapeutic Plasma Exchange (TPE)
214560459|NCT00534495|BIOLOGICAL|Rilonacept|2.2 mg/kg subcutaneously
214560460|NCT01870947|BEHAVIORAL|Exercise on stationary recumbent exercise cycle|
214560461|NCT01870947|BEHAVIORAL|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
214560462|NCT01870947|BEHAVIORAL|Questionnaires|
214560463|NCT01870947|PROCEDURE|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
214560464|NCT01870947|PROCEDURE|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
214560465|NCT02748551|PROCEDURE|Laparoscopic procedures|Laparoscopic surgery
214560466|NCT02748551|PROCEDURE|Open Surgery|Open surgery
214560467|NCT02459457|DRUG|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
214560468|NCT02459457|DRUG|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
214560469|NCT02459457|DRUG|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
214560470|NCT02459457|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
215164777|NCT06487481|RADIATION|Preoperative RT|Preoperative RT at escalating doses in daily fractions over approximately 2-3 weeks; 2 weeks (DL1), or 3 weeks (DL2 or DL3) based on assigned Cohort and Dose Level (DL). Cohorts are by mitotane status at enrollment: Cohort 1 (with detectable mitotane levels), Cohort 2 (never had or without detectable mitotane levels), Cohort 3 (either).
215164778|NCT06018415|BEHAVIORAL|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
215164779|NCT06018415|BEHAVIORAL|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
215164780|NCT07035431|DEVICE|Endo-SPONGE|The intervention involves the placement of an Endo-SPONGE in the leakage cavity, and applying suction to facilitate drainage.
215164781|NCT07039916|DRUG|IMVT-1402|• Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)
215164782|NCT07039916|DRUG|IMVT-1402|"* Dose 2 SC QW for 12 weeks (Period 1)~* Dose 2 SC QW for 14 weeks (Period 2)"
215164783|NCT07039916|DRUG|Placebo|• Placebo SC QW for 12 weeks (Period 1)
215164784|NCT07039916|DRUG|IMVT-1402|• Dose 1 SC QW for 14 weeks (Period 2)
215164785|NCT06716931|OTHER|Exercise|"A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated.~In person exercise supervised by physical therapist and then self-directed exercise in Group A"
215164786|NCT06716931|OTHER|Exercise|Exercise virtually supervised by physical therapist and then self-directed for group B
215164787|NCT06716931|OTHER|Exercise|Self-directed and virtually supervised exercise by physical therapist for Group C
215164788|NCT05148546|DRUG|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
215164789|NCT05148546|DRUG|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
215164790|NCT05148546|DRUG|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
215164791|NCT07042217|DEVICE|transcranial direct current stimulation (tDCS) and mindfulness instruction|tDCS together with audio providing mindfulness instruction and music
214560471|NCT03153553|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
214560472|NCT03153553|OTHER|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
214560473|NCT01809860|DRUG|isavuconazole|Oral
214560474|NCT01809860|DRUG|sirolimus|Oral
214560475|NCT00441259|BIOLOGICAL|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged \> 3 years and 0.5 ml to children and infants aged \< 3 years administered subcutaneously
214560476|NCT00441259|BIOLOGICAL|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged \> 3 years and 0.5 ml is given to children and infants aged \< 3 years administered subcutaneously
214560477|NCT02108002|DRUG|Vorinostat|
214560478|NCT03862677|OTHER|No intervention|Observational study, no intervention
214560479|NCT01839097|DRUG|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
214560480|NCT01839097|DRUG|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
214560481|NCT06046417|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
214560482|NCT06046417|DRUG|Lyumjev|Lyumjev delivered in a basal-bolus manner.
214560483|NCT06046417|DEVICE|Automated Insulin Delivery (AID) system|The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
215164792|NCT07042217|DEVICE|Sham tDCS and Mindfulness|Placebo electrical sitmulation and audio-guided mindfulness instruction
215164793|NCT06703593|DRUG|Alpha lipoic acid|ALA effectively inhibits nuclear factor-kappa B with subsequent decreasing proinflammatory cytokines production (TNF-α, IL-6) and increasing the release of anti- inflammatory cytokines such as interleukin-10 (Haghighatdoost and Hariri, 2019). Relying on the antioxidant and anti-inflammatory effect of Alpha lipoic acid confirmed by a variety of studies in vitro and in vivo, ALA is selected to be studied in Egyptian breast cancer patients who will be treated with doxorubicin including regimens.
214560484|NCT05494957|DRUG|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
214560485|NCT05809505|DIAGNOSTIC_TEST|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
214560486|NCT05809505|OTHER|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
214560487|NCT05809505|OTHER|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
214560488|NCT02562170|DEVICE|TiLoop Bra|
214560489|NCT02562170|DEVICE|Protexa|
214560490|NCT01346072|DRUG|tolvaptan|oral, 30 mg, single dose, one time administration
214560491|NCT00162916|DRUG|citalopram|20mg or 40mg, once daily, for 40 weeks
214560492|NCT00162916|DRUG|Placebo|Cornstarch
214560493|NCT01653977|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
214560494|NCT01653977|OTHER|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
214560495|NCT01682265|OTHER|Stretta procedure|
214560496|NCT01682265|OTHER|Sham procedure|No radiofrequency delivered
214560497|NCT02233803|DRUG|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
214560498|NCT02233803|DRUG|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
214560499|NCT02233803|DRUG|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
214560500|NCT02233803|DRUG|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
214560501|NCT01371292|BEHAVIORAL|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
215164794|NCT06881602|PROCEDURE|Remote clinical monitoring|Patients after a distal pancreatectomy will be discharged faster from the hospital and will be remote monitored
215164795|NCT05888623|DEVICE|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
215164796|NCT06686446|BEHAVIORAL|Enhanced Education Package|"Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~Education Toolkit - contains links to websites of key organisations including the National Allergy Council (NAC), Allergy \& Anaphylaxis Australia (A\&AA), Australasian Society of Clinical Immunology and Allergy (ASCIA), National Asthma Council Australia (NACA) and AusPollen which include educational videos and other resources."
215164797|NCT07038200|DRUG|AOC-1020|Placebo
215164798|NCT07038200|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
215164799|NCT06709339|DRUG|Faricimab Injection [Vabysmo]|The investigational medicinal product (IMP) for this study is faricimab (RO6867461), as per clinical practice. No control treatment will be used for this study
215164800|NCT07042165|DRUG|Atorvastatin|Participants will be orally administering one tablet daily of 40 mg Atorvastatin for two weeks followed by two tablets daily for two weeks (totalling 80 mg daily).
215164801|NCT07042165|DRUG|Placebo|Placebo tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the IMP except with the active ingredient (atorvastatin) omitted. Participants will be orally administering one tablet daily for two weeks followed by two tablets daily for two weeks.
215164802|NCT03520660|DRUG|Epclusa|sofosbuvir/velapatasvir combination (Epclusa)
215164803|NCT06887088|DRUG|Encorafenib + Binimetinib|Induction treatment with oral encorafenib 450 mg once daily (QD) + binimetinib 45 mg twice daily (BID)(combination: EB) for approximately two months (i.e. 8 weeks)
215164804|NCT06887088|DRUG|cemiplimab+fianlimab|cemiplimab 350 mg + fianlimab 1600 mg combination every 3 weeks (Q3W)(Combination: CF) administered to patients intravenously (IV) for up to two years.
214706495|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
214706496|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
214560502|NCT01371292|BEHAVIORAL|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
214560503|NCT04247477|OTHER|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
214560504|NCT05985226|DEVICE|intraoral scan|All the experimental groups will be developed with an intraoral scanner, a device that emits light and collects the image projected by that light, to build a 3-dimensional digital model. It is more comfortable than conventional impressions and it is a harmless, non-intrusive, and painless procedure.
214560505|NCT03197753|DEVICE|Laryngeal mask airway|Laryngeal mask airway
214560506|NCT03197753|DEVICE|Nasotracheal intubation|Nasotracheal intubation
214560507|NCT03635099|DRUG|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
214560508|NCT03635099|DRUG|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
214560509|NCT03635099|DRUG|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
214560510|NCT03635099|DRUG|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
214560511|NCT03635099|DRUG|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
214560512|NCT03635099|DRUG|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
214560513|NCT03635099|DRUG|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
214560514|NCT03635099|DRUG|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
214560515|NCT03259477|PROCEDURE|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
214560516|NCT03259477|PROCEDURE|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
214560517|NCT02457377|PROCEDURE|laparoscopic cerclage|The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
214560518|NCT05768165|BEHAVIORAL|High intensity exercise|"Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness."
214560519|NCT05715177|OTHER|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
214560520|NCT05715177|OTHER|Placebo kinesio-taping|Placebo kinesiotaping
214560521|NCT01068665|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214560522|NCT01068665|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214706497|NCT04655209|BEHAVIORAL|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
214706498|NCT06089954|OTHER|private web-portal eHealth disclosure of genetic results|The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
214706499|NCT06089954|OTHER|eHealth education intervention (web or chatbot)|The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
215164805|NCT06876142|DRUG|Mirdametinib|Capsules taken by mouth twice a day (2-12mg) for days 1-21 days of each 28 day cycle
214706500|NCT06517641|DRUG|Haploidentical donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant."
214706501|NCT06517641|DRUG|Unrelated donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant."
214706502|NCT01181440|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
214706503|NCT01181440|OTHER|Conventional care|Weekly application of conventional care
214706504|NCT01896739|BIOLOGICAL|Eutravac|
214560523|NCT05588050|DEVICE|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
214706505|NCT00255879|DRUG|Quetiapine|
214706506|NCT00255879|DRUG|Risperidone|
214706507|NCT00255879|DRUG|Olanzapine|
214706508|NCT05433636|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
214560524|NCT01546077|PROCEDURE|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
214560525|NCT01987492|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
214706509|NCT05433636|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
214706510|NCT05433636|BEHAVIORAL|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
215164806|NCT06876142|DRUG|Sirolimus|Tablets taken by mouth once a day for days 1-28 days of each 28 day cycle. Loading dose of 12 mg on Day 1 Cycle 1 with 4 mg being taken for the remaining doses.
215164807|NCT05785832|DEVICE|t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
214706511|NCT05433636|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
214706512|NCT05433636|BEHAVIORAL|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
214706513|NCT04763590|BEHAVIORAL|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
214706514|NCT04935970|DIAGNOSTIC_TEST|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
214706515|NCT04935970|DIAGNOSTIC_TEST|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
214706516|NCT02563925|RADIATION|Brain radiotherapy or Stereotactic Radiosurgery|
215164808|NCT05785832|DEVICE|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
215164809|NCT06709014|DRUG|buntanetap/posiphen|30mg capsule by mouth once daily for 18 months
215164810|NCT06709014|DRUG|Placebo|Placebo capsule by mouth once daily for 18 months
215164811|NCT04321954|DRUG|LENVATINIB|Orally
215164812|NCT07044648|PROCEDURE|Middle Meningeal Artery Embolization|Middle meningeal artery embolization using particles or coils
215164813|NCT06881784|DRUG|daraxonrasib|oral tablets
215164814|NCT06881784|DRUG|docetaxel|intravenous (IV) infusion
214560526|NCT01987492|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
214706517|NCT02563925|DRUG|Tremelimumab|
214706518|NCT02563925|DRUG|HER2 directed therapy|
214706519|NCT02563925|DRUG|Durvalumab|
214706520|NCT04395534|PROCEDURE|Complete mesocolic excision|
214706521|NCT05006339|DEVICE|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
214706522|NCT05006339|OTHER|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
215164815|NCT07046143|DEVICE|tSCS|The experimental group received noninvasive spinal cord electrical stimulation treatment, requiring patients to take the prone position or sitting position, the anode was placed in the patient's bilateral anterior superior iliac spines, the cathode was placed in the nerve root outlets corresponding to the upper and lower spinal segments of the spinous processes, the stimulation frequency was adjusted to 10,000 Hz, the treatment frequency was 30Hz, the pulse width was 1ms, the waveform was a square wave, and the length of a single session of the treatment was 20min, and the amplitude of current was adjusted to the sensory threshold below the threshold value for 20min twice a day for 2 weeks.The duration of a single treatment was 20 min, and the amplitude of the current was adjusted to below the sensory threshold, each time 20 min, twice a day for 2 weeks of noninvasive spinal cord electrical stimulation.
215164816|NCT07046078|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
215164817|NCT07046078|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164818|NCT07046078|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
214560527|NCT03983967|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
214560528|NCT03578653|BEHAVIORAL|Merging Yoga and Occupational Therapy for Parkinson disease|The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
214560529|NCT00569023|DIETARY_SUPPLEMENT|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
214560530|NCT00344864|DEVICE|LADARWave|
214560531|NCT00858689|DRUG|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
214706523|NCT05511025|DRUG|AZD6234|Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
214706524|NCT05511025|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC or IV injection
214706525|NCT05511025|COMBINATION_PRODUCT|Acetaminophen|Participants will receive a single dose of acetaminophen as part of a meal
214706526|NCT03771404|OTHER|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
214706527|NCT02257164|PROCEDURE|Femoral nerve block|2 mg/ml
214706528|NCT02257164|PROCEDURE|obturator nerve block|
214706529|NCT02257164|PROCEDURE|intraarticular injection|
214706530|NCT00400712|BEHAVIORAL|physical rehabilitation|two weeks intensive physical rehabilitation
214706531|NCT01996891|OTHER|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
214706532|NCT01619605|PROCEDURE|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
214706533|NCT03741296|PROCEDURE|Single stage revision|One-stage exchange hip joint replacement surgery
214706534|NCT03741296|PROCEDURE|Two-stage revision|Two-stage exchange hip joint replacement surgery
214706535|NCT00001735|PROCEDURE|Gene therapy|
214706536|NCT04729062|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214706537|NCT02335580|DRUG|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
214706538|NCT02335580|PROCEDURE|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
214706539|NCT00258388|DRUG|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
214706540|NCT00258388|DRUG|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
214560532|NCT05240326|OTHER|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
214560533|NCT05240326|OTHER|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
214560534|NCT04191616|DRUG|Carfilzomib|Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.
214560535|NCT04191616|DRUG|Dexamethasone|Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.
214560536|NCT04191616|DRUG|Pomalidomide|Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
214560537|NCT03276650|OTHER|data collection|biological, administrative, clinical, outcome date
214560538|NCT04230122|DRUG|LY3478006 - IV|Administered IV
214560539|NCT04230122|DRUG|LY3478006 - SC|Administered SC
214706541|NCT00258388|DRUG|prednisone|5mg PO BID
214706542|NCT05125107|DEVICE|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
214706543|NCT04172909|OTHER|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
214706544|NCT04172909|OTHER|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
214706545|NCT03624218|BEHAVIORAL|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
214706546|NCT04857749|OTHER|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
214706547|NCT04857749|OTHER|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
214706548|NCT04387526|DRUG|(SOF and DCV)|
214706549|NCT04387526|DRUG|(SOF, DCV, and RBV)|
214706550|NCT03176173|RADIATION|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
214560540|NCT04230122|DRUG|Placebo - IV|Administered IV
214560541|NCT04230122|DRUG|Placebo - SC|Administered SC
214706551|NCT03176173|DRUG|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
214560542|NCT03723018|BEHAVIORAL|Meditation|10 minutes a day of meditation, done on your own time.
214560543|NCT02951520|PROCEDURE|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
214560544|NCT05822739|DRUG|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
214560545|NCT04223986|DIAGNOSTIC_TEST|Ultrasound|decide between the need for intervention or not (Percutaneous coronary intervention)
214560546|NCT04223986|DIAGNOSTIC_TEST|Troponin- T quick test|Quick test for Troponin T blood assessment
214560547|NCT05568953|BIOLOGICAL|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
214560548|NCT05568953|BIOLOGICAL|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
214560549|NCT05568953|BIOLOGICAL|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
214560550|NCT04235517|OTHER|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
214706552|NCT05085431|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
214706553|NCT02466412|OTHER|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
214706554|NCT02466412|OTHER|mCC|Single use of subject's own menthol conventional cigarette (mCC)
214706555|NCT00237445|DRUG|telithromycin|
214706556|NCT00237445|DRUG|azithromycin|
214706557|NCT00425477|BIOLOGICAL|sargramostim|
214706558|NCT00425477|DRUG|bexarotene|
214706559|NCT00425477|GENETIC|cytogenetic analysis|
214560551|NCT06250959|DRUG|Blinatumomab Injection [Blincyto]|Reduced-intensity chemotherapy followed by Blinatumomab
214560552|NCT06250959|DRUG|Doxorubicin|HyperCVAD regimen
214560553|NCT06086899|PROCEDURE|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
214560554|NCT06086899|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
214560555|NCT00658905|DRUG|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
214560556|NCT00658905|DRUG|Placebo|One week treatment
214706560|NCT00425477|GENETIC|fluorescence in situ hybridization|
214706561|NCT00425477|OTHER|flow cytometry|
214706562|NCT00425477|OTHER|laboratory biomarker analysis|
214706563|NCT00425477|PROCEDURE|biopsy|
215164819|NCT07046078|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
214560557|NCT02798042|OTHER|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
214560558|NCT03170687|DEVICE|short foot cast|metatarsal foot cast
214560559|NCT03170687|DEVICE|short leg cast|full short leg cast
214560560|NCT05028114|DRUG|AC-1202|Tricaprilin formulated as AC-1202
214560561|NCT05028114|DRUG|AC-OLE-01|Tricaprilin Formulation
214560562|NCT05028114|DRUG|AC-OLE-02|Tricaprilin Formulation
214560563|NCT05028114|DRUG|AC-OLE-03|Tricaprilin Formulation
214560564|NCT05028114|DRUG|AC-OLE-04|Tricaprilin Formulation
214560565|NCT05028114|DRUG|AC-OLE-05|Tricaprilin Formulation
214560566|NCT05028114|DRUG|AC-OLE-06|Tricaprilin Formulation
214560567|NCT05028114|DRUG|AC-OLE-07|Tricaprilin Formulation
214560568|NCT05028114|DRUG|AC-OLE-08|Tricaprilin Formulation
214706564|NCT05058898|OTHER|blood samples|5 mL
214706565|NCT05058898|OTHER|Scabs and pus samples|if available
214706566|NCT04207268|BEHAVIORAL|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
214706567|NCT04207268|BEHAVIORAL|Nutrition Advice|Participate in only nutrition advice
214706568|NCT02709772|BEHAVIORAL|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
214706569|NCT00960258|DRUG|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
214706570|NCT00044486|DRUG|Posaconazole oral suspension|
214706571|NCT03509987|DEVICE|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
214706572|NCT00672360|DIETARY_SUPPLEMENT|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
214706573|NCT00672360|DIETARY_SUPPLEMENT|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
214706574|NCT03620812|DIETARY_SUPPLEMENT|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
215164820|NCT07046078|DRUG|Cytarabine|Given IV
215164821|NCT07046078|PROCEDURE|Echocardiography Test|Undergo ECHO
215164822|NCT07046078|DRUG|Fludarabine|Given IV
214560569|NCT05028114|DRUG|AC-OLE-09|Tricaprilin Formulation
214560570|NCT05028114|DRUG|AC-OLE-010|Tricaprilin Formulation
214560571|NCT05028114|DRUG|AC-OLE-P|Placebo to tricaprilin formulation
214560572|NCT02473731|BIOLOGICAL|KTN3379|
214560573|NCT03398902|BEHAVIORAL|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
214560574|NCT03398902|OTHER|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
214560575|NCT05090566|DRUG|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
214560576|NCT05090566|DRUG|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
214560577|NCT06172192|PROCEDURE|Core Strengthening|"1. Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~2. Core Strengthening:~   Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~3. Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise."
214560578|NCT06172192|PROCEDURE|Self-Diaphragm breathing exercises|"Participants will place one hand on the chest and other on the abdomen, feeling the swelling of the stomach and the movement of the chest. It will be performed in supine position.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
214560579|NCT06172192|PROCEDURE|Resistive-Diaphragm breathing exercises|"Participants will place one hand on the chest and another on the sand bag placed over abdomen. This sand bag weighing 3-5 Kgs will provide resistance to breathing. These exercises will be performed in supine position. We will adjust the weight of the sandbag as per individual's level of 11-13 of 'Rating of Perceived Exercise (RPE)'.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
214560580|NCT00667316|BEHAVIORAL|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
214560581|NCT00107939|DRUG|Licarbazepine|
214560582|NCT03741920|DEVICE|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~* A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.~* A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
214560583|NCT06228209|BEHAVIORAL|Tier - Palliative Care|TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
214560584|NCT03575195|DRUG|Rifaximin|Rifaximin 550mg orally
214560585|NCT03575195|OTHER|Placebo|Placebo control
214560586|NCT06492772|OTHER|experimental group|The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
214560587|NCT06436638|DEVICE|Non-invasive ventilation support equipment|Non-invasive ventilation support is provided by nasal airway and nasal CPAP mask to avoid respiratory complications such as hypoxia, desaturation, hypercarbia, respiratory depression etc. during extraction of impacted molars under deep sedation.
214560588|NCT01853189|OTHER|OMT + Usual Care|patients from this group received 6 sessions of OMT
215164823|NCT07046078|DRUG|Idarubicin|Given IV
215164824|NCT07046078|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215164825|NCT07046078|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
215164826|NCT07046078|OTHER|Questionnaire Administration|Ancillary studies
215164827|NCT07046078|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
215164828|NCT07046078|RADIATION|Total-Body Irradiation|Undergo TBI
215164829|NCT07044336|DRUG|Puxitatug Samrotecan|2.4 mg/kg on Day 1 Q3W Route of administration: IV infusion
215164830|NCT07044336|DRUG|Doxorubicin|60 mg/m2 on Day 1 Q3W Route of administration: IV
215164831|NCT07044336|DRUG|Paclitaxel|80 mg/m2 on Days 1, 8, and 15 in 28-day cycles Route of Administration: IV
215164832|NCT06889844|DIAGNOSTIC_TEST|blood sampling|Patients will donate a blood sample for molecular analysis of molecular biomarkers in plasma, which being the only procedure in the study.
215164833|NCT07042594|DRUG|RBD1119|Subcutaneously Administered RBD1119 in Healthy Subjects.
215164834|NCT07042594|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subject.
215164835|NCT07041359|DRUG|Compound Danshen Dripping Pills|The experimental group used compound Danshen dripping pills as an intervention on the basis of conventional western medicine treatment.
215164836|NCT07041359|DRUG|Qishen Yiqi Drop Pills|The experimental group used Qishen Yiqi dripping pills as an intervention on the basis of conventional western medicine treatment.
215164837|NCT07041359|DRUG|Placebo|Intervention with placebo on the Basis of optimal medical treatment
215164838|NCT06723795|OTHER|Cardiologist evaluation|The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.
215164839|NCT06723795|OTHER|Pulmonologist evaluation|optimize basic treatment, and recommend continued follow-up as needed.
214560589|NCT01853189|OTHER|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
214560590|NCT01840410|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
214560591|NCT01840410|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
214560592|NCT00000300|DRUG|LAAM|
214560593|NCT03360448|DRUG|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
214560594|NCT03360448|DRUG|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
214560595|NCT01275742|BEHAVIORAL|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
214560596|NCT01868425|DRUG|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
214560597|NCT01868425|DRUG|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
214560598|NCT04538612|DEVICE|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~* Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~* Veinous vascular occlusion test (30mmHg),~* Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
214560599|NCT05025592|DRUG|Regorafenib|patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
214560600|NCT05025592|DEVICE|cTACE/DEB-TACE-HAIC|conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
214560601|NCT00443170|DRUG|GSK626616, placebo, midazolam|
214560602|NCT00443170|DRUG|omeprazole, caffeine, flurbiprofen, rosiglitazone|
214560603|NCT05988944|OTHER|TT+CIMT+VR|TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
214560604|NCT05988944|OTHER|TT+CIMT|TT: Traditional Techniques CIMT: constraint-induced movement therapy
214560605|NCT05988944|OTHER|TT|TT: Traditional Techniques
214560606|NCT05559151|PROCEDURE|Remimazolam Benzenesulfonate|"In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation."
214560607|NCT02843451|DRUG|Milk Thistle|
214560608|NCT02843451|DRUG|Placebo|
214560609|NCT04127500|DRUG|dexmedetomidine|dexmedetomidine
214560610|NCT03725527|PROCEDURE|Rectus Sheath Block|Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
214560611|NCT01800890|DEVICE|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
214560612|NCT01800890|DEVICE|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
214560613|NCT01800890|DEVICE|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
214560614|NCT01800890|DEVICE|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
214560615|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.
214560616|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
214560617|NCT04014595|PROCEDURE|Rotational atherectomy in combination with cutting balloon|Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
214560618|NCT01743391|PROCEDURE|Office-hysteroscopy with biopsy|
214560619|NCT01012297|BIOLOGICAL|Bevacizumab|Given IV
214560620|NCT01012297|DRUG|Docetaxel|Given IV
214560621|NCT01012297|BIOLOGICAL|Filgrastim|Given SC
214560622|NCT01012297|DRUG|Gemcitabine Hydrochloride|Given IV
214560623|NCT01012297|BIOLOGICAL|Pegfilgrastim|Given SC
214560624|NCT01012297|OTHER|Placebo|Given IV
214706575|NCT05220761|DIAGNOSTIC_TEST|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
214706576|NCT00553137|DRUG|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
214706577|NCT00553137|DRUG|fluconazole|150 mg fluconazole tablets once daily for 14 days
214706578|NCT02553317|BIOLOGICAL|Caplacizumab|"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
214706579|NCT02553317|BIOLOGICAL|Placebo|"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
214706580|NCT01965912|DRUG|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
214706581|NCT03092349|DEVICE|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
215164840|NCT07043647|OTHER|Shamba Maisha|"The Shamba Maisha Intervention has three key parts: A. Agricultural Commodities: KickStart Starter Pump (\~$60 USD, 2.5 Kg), hosing, fertilizer, and seeds. B. Training: We developed model farms near each health facility where didactic and hands on training will be conducted. Our weekly didactic and practical skills training will rotate topics to ensure all participants receive full coverage. Women will be encouraged to invite a key farming support person to trainings. C. Model farm harvest: Participants will harvest vegetables at the model farms for their own consumption until their individual farms start producing in 6-8 weeks to ensure access to a nutritious diet from the time of enrollment."
214560625|NCT02671500|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
214560626|NCT04323540|PROCEDURE|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
214560627|NCT03410498|OTHER|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
214560628|NCT00059189|DEVICE|Magstim Rapid Magnetic Stimulator|
214560629|NCT02215525|DEVICE|UVA|device uses UVA
214560630|NCT02215525|DIETARY_SUPPLEMENT|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
214560631|NCT01297153|DEVICE|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
214560632|NCT01297153|DEVICE|No IOL|No IOL will be implanted in these eyes
214560633|NCT04749680|DEVICE|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
214560634|NCT01169922|BEHAVIORAL|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
214560635|NCT01169922|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
214560636|NCT02870049|BEHAVIORAL|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
214560637|NCT02870049|BEHAVIORAL|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
214560638|NCT02870049|BEHAVIORAL|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
214560639|NCT02870049|BEHAVIORAL|Usual care|Usual care: FIT kit delivery as part of usual care
214560640|NCT04078698|DEVICE|Immunoadsorber GLOBAFFIN®|Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
214560641|NCT06803446|OTHER|physical test|continuous and intermittent exercise on cycloergometer
214560642|NCT06802276|OTHER|High Cysteine Diet|A healthy diet pattern which contains high levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. No additional supplementation of cysteine will be used. Examples of high cysteine foods: chicken, eggs, lentils, yogurt, garlic, cheese, soybeans
214560643|NCT06802276|OTHER|Low Cysteine Diet|A healthy diet pattern which contains low levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. The low cysteine diet includes lower-protein food sources. Examples of low cysteine foods: rice, bread, oranges, bananas, lettuce, snow peas, peppers
214560644|NCT05032976|BIOLOGICAL|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
214560645|NCT05032976|BIOLOGICAL|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
214560646|NCT05032976|BIOLOGICAL|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
214560647|NCT05032976|BIOLOGICAL|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
214560648|NCT05032976|BIOLOGICAL|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
214560649|NCT05032976|BIOLOGICAL|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
214560650|NCT05032976|BIOLOGICAL|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
214560651|NCT05032976|BIOLOGICAL|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
215164841|NCT07045467|DRUG|Remimazolam Besylate|"This is the first clinical trial evaluating Remimazolam's pharmacokinetics (PK), pharmacodynamics (PD), and safety in renal transplant recipients-a population with unique physiological alterations due to end-stage renal disease and graft reperfusion. Key differentiators include:~Population-Specific Dosing Protocol:~Induction: 6 mg/kg/h until MOAA/S ≤1 (vs. 5-12 mg/kg/h in general surgery).~Maintenance: Titrated (0.5-2 mg/kg/h) to Narcotrend Index 27-60 (lower than typical BIS 40-60 targets), accounting for altered drug metabolism post-transplant.~Transplant-Specific Context:~Administered alongside standard immunosuppressants (methylprednisolone 750 mg + furosemide 60 mg at reperfusion) but prohibits common sedatives (midazolam/propofol) to isolate Remimazolam's effects.~PK/PD sampling accounts for graft function dynamics (e.g., blood draws during reperfusion and post-op days 1-6).~Exploratory Genetic Analysis:~First study linking VDR/"
215164842|NCT06888193|DRUG|Bimekizumab|Bimekizumab under the care of their treating physician.
215164843|NCT07045181|DIAGNOSTIC_TEST|XGBoost machine learning|XGBoost is a powerful machine learning algorithm known for its efficiency and performance. It is an optimized gradient boosting library designed to be highly efficient, flexible, and portable. XGBoost works by combining multiple weak prediction models, typically decision trees, to produce a strong predictive model. It supports various objective functions and evaluation metrics, making it suitable for a wide range of tasks, including classification and regression. XGBoost also includes features like regularization to prevent overfitting and can handle missing data effectively.
215164844|NCT06730061|DRUG|Elafibranor|Tablet of 80 mg
214706582|NCT05521100|PROCEDURE|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
214706583|NCT05521100|PROCEDURE|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
214706584|NCT00406991|DRUG|aspirin|
214560652|NCT05686122|BEHAVIORAL|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
214560653|NCT06365788|DRUG|Abemaciclib|150 mg tablet orally twice daily
214560654|NCT06365788|DRUG|Bicalutamide|150 mg tablet orally once daily
214560655|NCT03835741|DEVICE|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
214706585|NCT00406991|DRUG|clopidogrel|
214706586|NCT01492699|DRUG|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
214706587|NCT02830035|PROCEDURE|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
214706588|NCT02830035|PROCEDURE|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
214706589|NCT00188266|DRUG|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
214706590|NCT04511442|OTHER|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
214706591|NCT02292992|DEVICE|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
214706592|NCT03125876|DRUG|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
214706593|NCT03070561|BIOLOGICAL|sublingual film with peanut extract|
215164845|NCT06730919|DIAGNOSTIC_TEST|Estimated Blood Loss after cesarean delivery within 24 h|The total estimated blood loss was calculated by equation: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2
215164846|NCT06926660|DRUG|Vicadrostat|Vicadrostat
215164847|NCT06926660|DRUG|Empagliflozin|Empagliflozin
214560656|NCT03835741|OTHER|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
214560657|NCT05235269|DRUG|124I-AT-01|All participants received 1 mCi 124I-AT-01 on Day 1 and at Week 6 via IV infusion over 2-5 minutes or slow IV bolus at 1 mL/5 seconds.
214560658|NCT00720785|DRUG|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
214560659|NCT00720785|BIOLOGICAL|NK cells|NK Cell Infusion
214560660|NCT05660122|DRUG|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
214560661|NCT06354829|DIAGNOSTIC_TEST|Medical imaging procedures|The following medical imaging procedure will b applied: Magnetic resonance images (MRI), computerized tomography images (CT), and ultrasound images (US).
214706594|NCT01478399|DRUG|PB1023 Injection|90 mg Dose
214706595|NCT01747785|OTHER|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
214706596|NCT01747785|OTHER|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
214706597|NCT01747785|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
214706598|NCT01158729|DRUG|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
214706599|NCT01158729|OTHER|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
214706600|NCT02204514|PROCEDURE|Surgery for external snapping hip|
214706601|NCT02439944|DRUG|Nicotine patch|
214706602|NCT02439944|DRUG|Nicotine mouthspray|
214706603|NCT00216177|DRUG|Infliximab|Remicade
214706604|NCT00216177|DRUG|Adalimumab|Humira
214706605|NCT04700852|DEVICE|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
214706606|NCT00225056|DRUG|docetaxel and capecitabine|
214706607|NCT05015738|OTHER|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
214706608|NCT05015738|DEVICE|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
214706609|NCT01769703|DRUG|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
214706610|NCT03271788|OTHER|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
214706611|NCT03700632|OTHER|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
214706612|NCT00364325|OTHER|Acute Decompensated Heart Failure|Standard of Care
214706613|NCT05830188|BEHAVIORAL|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
214706614|NCT05830188|OTHER|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
214706615|NCT04095754|PROCEDURE|Head-Up Position|Anti-Trendelenburg Position
214706616|NCT04095754|DRUG|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
214560667|NCT01492972|RADIATION|Radiation|"Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
214560668|NCT01492972|DRUG|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
214560669|NCT02585544|PROCEDURE|day-care surgery|day-care surgery
214560670|NCT06302621|DRUG|Afatinib|Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
214560671|NCT06302621|DRUG|Pemigatinib|Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
214706617|NCT04095754|DRUG|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
214706618|NCT04305886|OTHER|Discussion Guide|Written list of prompts to facilitate discussion
214706619|NCT03130712|DRUG|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
214706620|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
214706621|NCT03691610|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
214560672|NCT06121180|DRUG|ZIV-Aflibercept|Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
214560673|NCT06121180|DRUG|Cemiplimab|"Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells."
214706622|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
214706623|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
214706624|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
214706625|NCT03691610|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
214706626|NCT03691610|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
214706627|NCT03691610|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
214706628|NCT03691610|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
214706629|NCT03691610|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
214706630|NCT03691610|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
214706631|NCT03661827|DIAGNOSTIC_TEST|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
215164848|NCT06926660|DRUG|Placebo matching vicadrostat|Placebo matching vicadrostat
215164849|NCT06925503|BEHAVIORAL|Mind-Body Conditioning Course|Evidence-based mindfulness intervention curated to the physical and emotional needs of University Dance students
215164850|NCT06732427|DRUG|fospropofol Disodium for injection|Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)
215164851|NCT06732427|DRUG|Propofol|Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
215164852|NCT06722235|DRUG|Mezagitamab|Mezagitamab injection administered SC.
215164853|NCT06722235|DRUG|Placebo|Mezagitamab placebo-matching injection administered SC.
214560674|NCT03050736|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
214560675|NCT02858310|BIOLOGICAL|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
215164854|NCT07046819|DRUG|Tirzepatide|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
214560676|NCT02858310|DRUG|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
214560677|NCT02858310|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214560678|NCT02858310|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
215164855|NCT07046819|OTHER|Placebo|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
214560679|NCT03110861|DEVICE|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
215164856|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 52 weeks
215164857|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
214560680|NCT06442475|PROCEDURE|Biospecimen Collection|Undergo blood, oral, and/or rectal sample collection
215164858|NCT06727604|DRUG|Placebo|SC QW for 52 weeks
215164859|NCT04544410|DRUG|Tildacerfont/Placebo|Tablet, administered daily
215164860|NCT05142241|PROCEDURE|Biopsy Procedure|Undergo biopsy
215164861|NCT05142241|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164862|NCT05142241|PROCEDURE|Computed Tomography|Undergo CT
215164863|NCT05142241|DRUG|Talazoparib|Given PO
215164864|NCT05142241|DRUG|Temozolomide|Given PO
215164865|NCT06263647|BEHAVIORAL|Houston-HVIP treatment|Participants will be assigned a case manager to provide a brief assessment of , psychological and social needs and a risk assessment and create individualized discharge planning. Participants will be referred to tailored social service programs based on the needs, including assessments of social determinants of health, educational and financial needs, and subsequent referral for programs such as job training, educational support, housing assistance, or financial assistance programs for identified needs. Participants identified at risk for violence perpetration via a risk assessment screener will be referred to the violence interrupter services. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged.Participants will receive a structured curriculum that will include regular check-in with an assigned case manager over 6 months to promote successful community-based program integration and completion.
215164866|NCT06263647|BEHAVIORAL|Standard of Care|Participants will be assigned a case manager to meet with the injured patients to briefly assess (a) psychological and social needs and (b) a risk assessment and create individualized discharge planning. Resources for the patient to connect with social service programs will be provided by the case manager. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged. Follow-up contacts and services from an assigned case manager over two weeks following discharge from the hospital to ensure that the patient has contacted the community-level violence outreach organizations.
215164867|NCT06726265|BIOLOGICAL|eftilagimod alfa|30 mg of efti every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
215164868|NCT06726265|DRUG|carboplatin plus paclitaxel|For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2
215164869|NCT06726265|DRUG|cisplatin or carboplatin + pemetrexed|For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks
215164870|NCT06726265|BIOLOGICAL|Pembrolizumab (KEYTRUDA®)|200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months
215164871|NCT06726265|OTHER|Placebo|efti-matching placebo every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
214560681|NCT06442475|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214560682|NCT06442475|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214560683|NCT06442475|BIOLOGICAL|Mosunetuzumab|Given IV
214560684|NCT06442475|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215164872|NCT07040397|DEVICE|EMMA massage therapy|Expert Manipulative Massage Automation (EMMA) is equipped with sensors to measure muscle stiffness and uses 3D vision technology to measure muscle stiffness and identify pressure points while delivering a massage to patients. Following that, the electronic massager will determine the best course of action for our patients based on the information stored by our Artificial Intelligence and EMMA's robotic arm will perform the massage. EMMA executes massages through soft treatment modules that are warmed to a temperature of between 38℃ and 40℃ to mimic human touch.
215164873|NCT07040397|OTHER|Clinical massage treatment|The direct person clinical massage treatment will be delivered by a clinical licensed massage therapist. The type of massage will follow the EMMA massage in that it will be a deep tissue massage (to mimic the Tuina massage) and generally will be for about 30 minutes to once again mimic the duration of massage therapy of the EMMA.
215164874|NCT07041164|DIAGNOSTIC_TEST|Bitewing radiograph|Digital radiograph, proximal caries, initial caries
214560685|NCT06442475|OTHER|Questionnaire Administration|Ancillary studies
214560686|NCT06383351|OTHER|Questionnaire|"Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire."
214560687|NCT03789240|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
214560688|NCT03789240|DRUG|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
214560689|NCT06581159|BIOLOGICAL|HS135|Subcutaneous Injection
214560690|NCT06581159|OTHER|Placebo|Subcutaneous Injection
214560691|NCT03904862|DRUG|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
214560692|NCT06966024|DRUG|DCC-2812|Administered orally
214706632|NCT04597255|DEVICE|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
214706633|NCT00122356|DRUG|Alendronate sodium|70mg tablets, once weekly
215164875|NCT07041164|DIAGNOSTIC_TEST|Near-infrared light transillumination|DIAGNOcam, proximal caries, initial caries
215164876|NCT06732102|BEHAVIORAL|DECIDE|Decision-making Education for Choices In Diabetes Everyday (DECIDE) is a self-management program in which education and problem-solving training are utilized to promote behavior change for optimal clinical outcomes.
215164877|NCT06732102|BEHAVIORAL|Community Health Worker Support|CHWs are expected to actively equip individuals and communities by enhancing health knowledge and promoting self-sufficiency through various activities such as outreach, community education, informal counseling, social support, and advocacy. They act as a crucial link between communities and healthcare providers, helping residents navigate the healthcare system. By offering guidance and social assistance, they improve community members' ability to communicate effectively with healthcare professionals. They also deliver health education that is culturally and linguistically appropriate, advocate for the health of individuals and communities, coordinate care through referrals and follow-up services, and assist eligible individuals in enrolling in federal, state, local, or nonprofit health and human services programs.
215164878|NCT06592261|DRUG|Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)|Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
215164879|NCT06592261|DRUG|Insulin regular, 32 mU/m2/min (hyperinsulinemia)|Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
215164880|NCT06592261|DRUG|Octreotide Acetate, 6-45 ng/kg/min|Suppression of endogenous insulin secretion
215164881|NCT06592261|DRUG|Dextrose 20 % in Water|Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
215164882|NCT06592261|DRUG|Glucagon, 0-0.5 ng/kg/min|Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
214560693|NCT04557709|OTHER|Medical Chart Review|Review of medical charts
214560694|NCT02470897|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
214560695|NCT02470897|RADIATION|SBRT|Undergo moderate dose SBRT with SIB
214560696|NCT02470897|RADIATION|SBRT|Undergo uniform dose SBRT
214560697|NCT06271707|DRUG|0.5% bupivacaine|an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
214560698|NCT06271707|OTHER|Saline|an ultrasound guided left stellate ganglion block with 5 mL of saline
214560699|NCT06542250|DRUG|AZD5492|CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
214560700|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
214560701|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
214560702|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
214560703|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
214560704|NCT00798434|DRUG|Placebo|placebo administered orally in the morning or evening.
214706634|NCT04183699|DIAGNOSTIC_TEST|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
214560705|NCT00798434|DRUG|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
214560706|NCT05811299|OTHER|Kinesio taping|Total of 8 sessions for 4 weeks 2 sessions in a week.
214560707|NCT05811299|OTHER|Abominal exercises|Total of 8 sessions for 4 weeks 2 sessions in a week.
214706635|NCT00764400|BEHAVIORAL|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
214706636|NCT03146052|DRUG|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
214706637|NCT00756496|DEVICE|Mammography screening and diagnosis|Mammography screening and diagnosis
214706638|NCT02438995|DRUG|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
214706639|NCT05338957|DRUG|MRG002+HX008|Administrated intravenously
214706640|NCT05349058|DRUG|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
214706641|NCT05833321|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
214706642|NCT00622869|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
215164883|NCT07050186|PROCEDURE|Biopsy Procedure|Undergo optional biopsy
215164884|NCT07050186|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214560708|NCT04256317|DRUG|Azacitidine|Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for SC administration.
214560709|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|FDC Capsules for oral administration.
214560710|NCT04256317|DRUG|Azacitidine|Powder for reconstitution to aqueous suspension for SC administration.
214560711|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|Tablets/Capsules for oral administration.
214560712|NCT04256317|DRUG|Cedazuridine|Tablets for oral administration.
214560713|NCT04256317|DRUG|Venetoclax|Oral tablets.
214560714|NCT06853132|BEHAVIORAL|Baduanjin with Resistance Training Program|Baduanjin with Resistance Training Program
214560715|NCT02236832|DEVICE|transcranial magnetic stimulation|
214560716|NCT02236832|OTHER|MRI imaging|
214560717|NCT02236832|OTHER|EEG recording|
214560718|NCT02236832|BEHAVIORAL|Neuropsychological examination|
214560719|NCT06415266|OTHER|Quality of life questionnaire (QLQ)|Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
214560720|NCT06415266|OTHER|Satisfaction survey|The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
214706643|NCT00622869|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
214706644|NCT00622869|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
214706645|NCT00622869|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
214706646|NCT00622869|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
214706647|NCT00622869|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
214706648|NCT02678663|PROCEDURE|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
214706649|NCT02678663|PROCEDURE|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
214706650|NCT03378154|PROCEDURE|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
214560721|NCT06415266|OTHER|Assessment of patient needs in the field of oncosexology|Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
215164885|NCT07050186|BIOLOGICAL|Cemiplimab|Given IV
215164886|NCT07050186|PROCEDURE|Computed Tomography|Undergo CT
215164887|NCT07050186|OTHER|Digital Photography|Undergo digital photography
215164888|NCT07050186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164889|NCT07050186|OTHER|Questionnaire Administration|Ancillary studies
215164890|NCT07051148|BEHAVIORAL|UJI Online Transdiagnostic Protocol|Is a manualized treatment for emotional disorders delivered through an interactive multimedia platform. The self applied format consists of 12 self applied modules (psychoeducation, emotional processing, cognitive flexibility training, exposure, coping strategies, maladaptive behaviors, avoidance, etc)
214560722|NCT03490682|OTHER|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
214706651|NCT03378154|PROCEDURE|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
214706652|NCT01592669|PROCEDURE|passive leg raising|bilateral PLR was achieved by raising the legs of patient
214706653|NCT00057590|BEHAVIORAL|Care manager outreach and monitoring|
214706654|NCT00422708|PROCEDURE|Local anesthesia|
214560723|NCT06969573|DRUG|Placebo|Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
214560724|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 36 mcg|Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
214560725|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 78 mcg|Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
214560726|NCT03180034|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
214560727|NCT03180034|OTHER|Questionnaire Administration|Ancillary studies
214560728|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
214560729|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214560730|NCT04265144|BIOLOGICAL|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
214560731|NCT04265144|OTHER|Biopsy|Skin biopsies only for volunteers among patients
214560732|NCT04265144|OTHER|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
214560733|NCT04265144|OTHER|Biopsy|Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
214706655|NCT00103467|BIOLOGICAL|rPA102 Vaccine|
214706656|NCT00282789|DEVICE|bilevel positive airway pressure|
214706657|NCT00282789|DEVICE|bilevel positive airway pressure (Device)|
214706658|NCT00999219|DRUG|FK199B|oral
214706659|NCT00999219|DRUG|Zolpidem|oral
214706660|NCT00001906|BIOLOGICAL|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
214706661|NCT05679973|DEVICE|Polybutester suture|After third molar surgery this suture used for primary closure.
214706662|NCT05679973|DEVICE|Polypropylene suture|After third molar surgery this suture used for primary closure.
214706663|NCT04803968|OTHER|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
215164891|NCT07051148|BEHAVIORAL|UJI On Line Transdiagnostic Hibrid Protocol|Hybrid format: 12 self applied modules with two synchronous sessions with a trained therapist
215164892|NCT07050563|DRUG|Compound Ciwujia Granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, Compound Ciwujia Granules were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
215164893|NCT07050563|DRUG|Placebo granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, placebo granules which containing 10% of Compound Ciwujia Granules drug were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
215164894|NCT07050563|COMBINATION_PRODUCT|Standard treatment protocol for ovarian cancer combined with psychological intervention.|Standard treatment protocol for ovarian cancer: In accordance with the 2024 NCCN International Guidelines, patients opt for chemotherapy regimens containing platinum-based drugs and/or targeted therapy, anti-angiogenic therapy, hormonal therapy, etc. Psychological intervention is conducted once a week in the form of online and offline patient education sessions for psychological intervention, continuing until the end of the study period. Both the intervention group and the control group use this as the baseline treatment plan.
215164895|NCT07049172|DRUG|Rituximab|"* Dosage: 375 mg/m²~* Route: Intravenous infusion~* Frequency: Once a week~* Duration: 12 consecutive weeks~* Details: Diluted in 5% glucose solution. Infusion started at 25 ml/h, increased by 25 ml/h every 30 minutes if no adverse reactions, up to 100-150 ml/h."
215164896|NCT07049172|BEHAVIORAL|Targeted Nursing Care|A structured, individualized nursing approach involving joint goal-setting. Included health education, psychological support, relaxation techniques, dietary care, lifestyle guidance, complication management, and medication guidance. Delivered throughout hospital stay and reinforced during monthly follow-ups.
215164897|NCT07049172|DRUG|Baseline Glucocorticoid Therapy|Patients already on maintenance glucocorticoids continued their regimen. For relapse at admission, IV methylprednisolone (2 mg/kg/day), then oral prednisone (2 mg/kg/day, max 60mg/day) tapered according to standard protocols.
215164898|NCT07049172|DRUG|Tacrolimus|"* Dosage: Initial dose 0.05-0.1 mg/kg/day, adjusted to maintain target trough levels of 5-10 ng/mL.~* Route: Oral~* Frequency: Divided into two doses (morning and evening)~* Duration: Throughout the 6-month study period."
215164899|NCT01624792|DIETARY_SUPPLEMENT|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
215164900|NCT01624792|DIETARY_SUPPLEMENT|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
215164901|NCT01624792|DIETARY_SUPPLEMENT|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
214560734|NCT04557748|OTHER|Observational|"Treatment:~Up to five interactions: In-person visits at Baseline, 3 months, and 12 months after initial visit, and phone/online interaction at 6 months and 9 months after initial visit.~Each in-person follow up visit is expected to last up to 2 hours and each phone/online interaction is expected to last up to 1½ hours.~Answering questions about your general health and urinary symptoms - may be done remotely Physical exam Completing Self- Reported Measures questionnaires - may be done remotely Completing voiding/intake and food diaries, either online or on paper Weekly text message survey regarding symptom and treatment changes~Biosample collection:~At baseline: Up to 4 tablespoons of whole blood, dried blood spots, and urine At baseline: Whole blood will be collected with other biospecimens At 3 months: Up to 4 tablespoons of blood, dried blood spots and urine At 12 months: Dried blood spots"
214560735|NCT04557748|OTHER|Observational Controls|One in-person visit that is expected to last up to 2 hours Answering questions about your general health and urinary history Physical exam Completing Self- Reported Measures questionnaires Completing voiding/intake and food diaries, either online or on paper Biosample collection of up to 4 tablespoons of whole blood, dried blood spots, and urine
214560736|NCT04557748|OTHER|Central Sensitization|"One in-person visit expected to take up to 30 minutes, that include:~Segmental Mechanical Hyperalgesia - a hand-held device with a small flat rubber surface will be placed above the pubic bone and forearm, and will apply pressure. Participant will be asked about the intensity and unpleasantness that they experience.~Pinprick Temporal Summation - participant will receive tactile stimulation by a pointed skin probe (pinprick stimulator) being placed above the pubic bone and forearm. Participant will be asked to rate the sensation they are feeling.~Current treatment information including prior surgery or procedures, medication use, other current treatment/therapy used at the time of the visit.~Self-reported measures questionnaires"
215164902|NCT07049640|OTHER|Acupressure Group|Effects of Acupressure Interventions
215164903|NCT07049640|OTHER|Cold Application to Acupressure Points Group|Effects of Cold Application to Acupressure Points Interventions
215164904|NCT06712810|DRUG|Axl/Mer/CSF1R Inhibitor Q702|Given PO
215164905|NCT06712810|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215164906|NCT06712810|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214560737|NCT04557748|OTHER|Physical Activity and Sleep Tracker|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period starting at baseline prior to treatment and again at 3 months. During each 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
214560738|NCT04557748|OTHER|Physical Activity and Sleep Tracker Controls|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period at baseline prior to treatment. During the 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
214560739|NCT04557748|OTHER|Organ-Based|"One in-person visit involving:~Urethral vibratory sensation threshold Urethral Pressure Profilometry Cystometry Uroflowmetry Lidocaine Pre-Treatment Cystometry"
215164907|NCT06712810|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
215164908|NCT06712810|PROCEDURE|Computed Tomography|Undergo CT scan
215164909|NCT06712810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164910|NCT06712810|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214560740|NCT04557748|OTHER|Qualitative Assessment of Patients with Urinary Urgency|"Participation will include two interviews with a research assistant over the phone and are expected to take up to 60 minutes for each interview. The first interview will be done within four weeks from enrollment, before the start of treatment. The interview will include questions about participant's urinary urgency, including symptoms experienced, the onset of symptoms and other factors that affect urgency.~Approximately three months after the start treatment the participant will be interviewed again. This interview will cover changes in symptoms and experience with treatment, such as side effects and satisfaction with treatment."
215164911|NCT06712810|OTHER|Survey Administration|Ancillary study
215164912|NCT06733675|DRUG|Ledaborbactam etzadroxil|capsules
215164913|NCT06733675|DRUG|Ceftibuten|capsules
215164914|NCT06733675|DRUG|Ceftibuten-ledaborbactam etzadroxil|Fixed Dose Combination (FDC)
215164915|NCT06733675|DRUG|Esomeprazole|40 mg capsule
215164916|NCT06732596|OTHER|Embodied conversational agent (ECA)|The app with the ECA will be provided.
215164917|NCT06732596|OTHER|Technical support|Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.
215164918|NCT06732596|OTHER|Additional ECA messages|Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.
215164919|NCT06732596|OTHER|Additional incentives|Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
215164920|NCT06733649|OTHER|substance abuse treatment education|Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
214560741|NCT06136481|OTHER|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT). CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. Prior to engaging in therapy, one session will be devoted to gathering information regarding psychosocial history, trauma, and current functioning. The following sessions will follow the standard outpatient CPT protocol. The standard outpatient CPT consists of 12 one-hour sessions conducted over a 6- to 12-week period. An additional 3 weeks will be provided in case of participant and therapist vacation and/or sick days. CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
214560742|NCT05773586|DRUG|APG-5918|oral tablets 10mg, 50mg, 200mg.
214560743|NCT05773586|DRUG|Placebo|Matching placebo
214560744|NCT01370798|DRUG|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
214560745|NCT01370798|DRUG|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
214560746|NCT01370798|PROCEDURE|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
215164921|NCT06734039|DEVICE|Programming of cochlear implant audio processor frequency settings|Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software
215164922|NCT07046936|DIAGNOSTIC_TEST|muscle sample|"For participants undergoing standard of care interval cytoreductive surgery via laparotomy, a skeletal muscle biopsy from the rectus abdominis muscle (1 cm x 1 cm x 1 cm, \~300 mg) will be collected.~For participants who undergo standard of care interval cytoreductive surgery with a laparoscopic approach, a skeletal muscle biopsy will be taken from either the rectus abdominis (1 cm x 1 cm x 1 cm, \~300 mg) or the psoas (1 cm x 0.5 cm x 0.5 cm, \~200 mg) muscle."
215164923|NCT07046936|OTHER|blood draw|A total of approximately 60mL or 4 tablespoons of blood will be collected throughout the study
215164924|NCT03273023|DEVICE|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
215164925|NCT06745284|DRUG|Survodutide|Survodutide
215164926|NCT06745284|DRUG|Semaglutide|Semaglutide
215164927|NCT07045311|DRUG|JS207 in combination with 9MW2821|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)
215164928|NCT07045311|DRUG|JS207 in combination with Albumin paclitaxel|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).
215164929|NCT06745180|BEHAVIORAL|Short Message System (SMS)|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors.
215164930|NCT06745180|BEHAVIORAL|Peer Coach|The peer coach will deliver an intervention that will help participants maintain physical activity.
215164931|NCT06745180|BEHAVIORAL|Usual Care|Participants will be given written materials providing advice on maintaining their physical activity.
215164932|NCT06745180|BEHAVIORAL|Peer Coach and SMS|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors. The peer coach will deliver an intervention that will help participants maintain physical activity.
215164933|NCT02583672|DRUG|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
215164934|NCT06892275|BEHAVIORAL|Enhanced Usual Care|Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC)
215164935|NCT06892275|BEHAVIORAL|Decision Support|The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits.
215164936|NCT06891352|BEHAVIORAL|Dietary Monitoring|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and continue their habitual eating patterns.
215164937|NCT06891352|BEHAVIORAL|Time-Restricted Eating (TRE)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window.
215164938|NCT06891352|BEHAVIORAL|Time-Restricted Eating with a Low-Glycemic Snack (TRE-LGS)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window. On nights that participants work night shifts, they will consume a low-glycemic snack provided by the research team.
215164939|NCT05371964|DRUG|Imetelstat sodium|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
215164940|NCT05371964|DRUG|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) in cohort B as the standard of care per local prescribing guidelines.
215164941|NCT05371964|DRUG|Pacritinib|Pacritinib will be administered once daily (QD) or BID in cohort B as the standard of care per local prescribing guidelines.
215164942|NCT05371964|DRUG|Momelotinib|Momelotinib will be administered once daily QD in cohort B as the standard of care per local prescribing guidelines.
215164943|NCT05371964|DRUG|Fedratinib|Fedratinib will be administered QD in cohort B as the standard of care per local prescribing guidelines.
215164944|NCT06880510|DEVICE|t-VNS transcutaneous auricular vagus nerve stimulator|An investigator will clip the the transcutaneous auricular vagus nerve stimulator (taVNS) to the outer ear, and apply electrical current to modulate the activity of the vagus nerve. During this process, the investigator will monitor pupil size and heart rate to determine whether either of these variables is affected by vagus nerve stimulation.
215164945|NCT06742307|DRUG|Faricimab Injection [Vabysmo]|A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.
215164946|NCT06727214|DRUG|Chemotherapy with platine|medical records that patients received neoadjuvant systemic chemotherapy platine based
215164947|NCT06727305|DRUG|Sirolimus 0.5 Mg Oral Tablet|Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
214706664|NCT04803968|OTHER|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
214706665|NCT01833104|BEHAVIORAL|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
214706666|NCT01833104|BEHAVIORAL|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
214706667|NCT01833104|BEHAVIORAL|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
214706668|NCT03064958|OTHER|Herbs and spices|Mix of commonly used herbs and spices
214706669|NCT03064958|OTHER|High fat meal|Meal containing 1000kcal and 45g fat
214560747|NCT01370798|RADIATION|Wrist X ray|Wrist X ray to follow the degree of bone maturation
214560748|NCT01370798|PROCEDURE|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
214560749|NCT06274801|DRUG|Seralutinib|Capsule containing seralutinib
214706674|NCT02292316|BEHAVIORAL|gait and cognitive assessments|several tests are given in each domain
214706675|NCT02292316|BIOLOGICAL|blood sample|routine analyses in rheumatology such blood count and 25OH-D
214706676|NCT02292316|OTHER|osteodensitometry|Looking for osteoporosis
215164948|NCT06727305|DRUG|Sirolimus 1Mg Oral Tablet|Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
214560750|NCT06274801|DEVICE|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
214560751|NCT04726618|DRUG|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
214560752|NCT06592508|OTHER|Remote Virtual Cardiology Program|Ventricle Health Program, which is a remote, virtual, cardiology program that provides heart failure education to patients, monitors for worsening heart failure, and rapidly titrates heart failure medical therapy.
214560753|NCT06533748|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
214560754|NCT06533748|DRUG|Vincristine|Given IV.
214560755|NCT06533748|DRUG|Inotuzumab|Given IV.
214560756|NCT06533748|DRUG|Blinatumomab|Given IV.
214560757|NCT06533748|DRUG|Dasatinib|Given PO.
214560758|NCT06533748|PROCEDURE|IT MHA|Given Intrathecal (IT), Age adjusted.
214560759|NCT06533748|DRUG|Cyclophosphamide|Given IV.
214560760|NCT06533748|DRUG|Cytarabine|Given IV or IT.
214560761|NCT06533748|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
214560762|NCT06533748|DRUG|6-Mercaptopurine|Given PO.
214706677|NCT00935519|DEVICE|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
214706678|NCT03454412|PROCEDURE|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
214706679|NCT01461512|DRUG|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
214706680|NCT01461512|DRUG|Placebo administration|NaCl isotonic
214706681|NCT00490659|DRUG|gemcitabine|
214706682|NCT00490659|DRUG|cisplatin|
214706683|NCT00490659|PROCEDURE|radical surgery|
214706684|NCT00490659|PROCEDURE|chemoradiotherapy|
214706685|NCT05762874|DRUG|Ruxolitinib|JAK inhibitor
215164949|NCT06727305|DRUG|Sirolimus 2 MG Oral Tablet|Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
215164950|NCT06727305|DRUG|Everolimus 0.5 MG Oral Tablet|Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
215164951|NCT06727305|DRUG|Everolimus 1 MG Oral Tablet|Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
214706686|NCT05675891|OTHER|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
214560763|NCT06533748|DRUG|Calaspargase|Given IV.
214560764|NCT06533748|DRUG|Daunorubicin|Given IV.
214560765|NCT06533748|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
214560766|NCT05639647|DRUG|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
214560767|NCT05639647|DRUG|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
214560768|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
214560769|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
214560770|NCT05062044|DRUG|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
214560771|NCT05062044|DIETARY_SUPPLEMENT|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
214560772|NCT05292586|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
214706687|NCT03074994|DRUG|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
214706688|NCT03074994|DRUG|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
214706689|NCT03074994|PROCEDURE|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
214706690|NCT03074994|PROCEDURE|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
215164952|NCT06727305|DRUG|Everolimus 2 MG Oral Tablet|Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
215164953|NCT06734208|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective cohort.
215164954|NCT06742853|DRUG|AZD0780|AZD0780 tablet will be administered orally.
215164955|NCT06742853|DRUG|Ezetimibe|Ezetimibe tablet will be administered orally.
215164956|NCT06742853|DRUG|Rosuvastatin|Rosuvastatin tablet will be administered orally.
215164957|NCT06742853|DRUG|Bempedoic Acid|Bempedoic Acid tablet will be administered orally.
215164958|NCT06742853|DRUG|Placebo|Placebo will be administered orally.
215164959|NCT06894771|BIOLOGICAL|MK-4700|Administered via subcutaneous (SC) injection
215164960|NCT06894771|BIOLOGICAL|Pembrolizumab|Administered via intravenous infusion
215164961|NCT06893471|OTHER|GAS for SAM|"This study adapts Goal Attainment Scaling (GAS) for group-level goal setting within systematic work environment management. Developed collaboratively with organizational stakeholders, the method is:~Tailormade - Allows flexibility in defining and scaling goals. Co-created - Encourages ownership and employee involvement. Standardized - Uses a five-level scale (-2 to +2) for tracking progress and enabling comparisons.~Data-driven - Includes a Progress Graph for systematic follow-up and documentation of goals and initiatives.~Managers in the experiment group will receive training before implementation begins"
215164962|NCT03359954|RADIATION|Radiation Therapy|Undergo radiation therapy
215164963|NCT03359954|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast surgery
214560773|NCT05292586|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
214560774|NCT04949646|OTHER|Pelvic Intraoperative Neuromonitoring|Pelvic Intraoperative Neuromonitoring (pIONM) allows mapping of the pelvic autonomous plexus during total mesorectal excision (TME).
214560775|NCT06398418|DRUG|R-5780|Probiotic
214560776|NCT03502668|DRUG|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
214560777|NCT03502668|DRUG|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
214560778|NCT05093959|DRUG|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
214560779|NCT05093959|DRUG|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
214560780|NCT01681615|DRUG|Acetylsalicylate|1-2 drops
214560781|NCT01681615|DRUG|Isotonic NaCl|1 drop
214560782|NCT03777852|DIAGNOSTIC_TEST|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
214560783|NCT03777852|DIAGNOSTIC_TEST|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
214560784|NCT02579395|BEHAVIORAL|Collaborative implementation Intentions|With spouse/romantic partner
214560785|NCT02579395|BEHAVIORAL|Individual implementation Intentions|Without spouse/romantic partner
214560786|NCT02579395|BEHAVIORAL|Control|
214560787|NCT02265809|DRUG|Aldesleukin|
214560788|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
214560789|NCT03653000|PROCEDURE|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
214560790|NCT03653000|DRUG|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
214706691|NCT00845494|BEHAVIORAL|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
214560791|NCT06415604|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving."
214560792|NCT06415604|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
214560793|NCT01072708|OTHER|Prospective cohort with an annual follow-up|"Annualfollow-up including :~* oral glucose tolerance test~* dietary survey~* biological evaluation~* bacteriological and respiratory measures~* dual-energy x-ray absorptiometry~* physical activity survey"
214560794|NCT06396078|DRUG|Ceftriaxone 1000 MG|Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
214560795|NCT06396078|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
214560796|NCT06396078|DRUG|Metronidazole 500 mg|Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
214560797|NCT06396078|DRUG|Ampicillin 2 GM Injection|Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
214560798|NCT06396078|DRUG|Amoxicillin 250 MG|Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
214560799|NCT06396078|DRUG|Azithromycin|Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
214706692|NCT00115765|DRUG|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
214706693|NCT00115765|DRUG|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
214706694|NCT00115765|DRUG|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
214706695|NCT00115765|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
214560800|NCT06396078|DRUG|Erythromycin|Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
214560801|NCT04154982|DRUG|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
214560802|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
214560803|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
214560804|NCT06990087|DRUG|Application of T-lymphocytes|Dosage form: Infusion; Route of administration: Intravenous; Cell dose: 1-2 x 10.000 viable CD3+ T-lymphocytes per kg bodyweight; Application at three timepoints: baseline, after two weeks, after 6 weeks
214560805|NCT06597656|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
214706696|NCT01578057|DRUG|tasimelteon|20mg, once
214706697|NCT01578057|DRUG|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
214560806|NCT06597656|PROCEDURE|Plasmapheresis|Therapeutic plasma exchange procedure
214560807|NCT06672237|BIOLOGICAL|nexiguran ziclumeran|nexiguran ziclumeran 55 mg by single IV infusion
214560808|NCT06672237|DRUG|Normal Saline as Placebo|Normal saline (0.9% NaCl) by single IV infusion
214560809|NCT06858137|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in four weeks using a single Polydioxaone thread. Needles have a gauge size of 30G, a shaft length of 26mm, folded in half, and are applied to nine acupoints, including Yintang (EX-HN3), Yingxiang (LI20) on both sides of the body. Needles with a gauge size of 29G, a shaft length of 30mm, and a thread length of 50mm, folded in half, are used for three acupoints, which included Hegu (LI4), Zusanli (ST36), Feishu (BL13), on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
214560810|NCT06858137|OTHER|Standal treatment|Inhaled corticosteroid spray - fluticasone propionate patients were permitted to use Fluticasone propionate 1 or 2 sprays (50 mcg/spray) in each nostril once a day as needed in four weeks and participants must change life style attaches including smoke and traffic pollution avoidant, preventing pets going into the bedroom, washing clothes.
214560811|NCT07127692|DIAGNOSTIC_TEST|Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire|Self-administered screening tool for sarcopenia
214560812|NCT07127692|DIAGNOSTIC_TEST|Hand grip strength|Used to assess sarcopenia
214560813|NCT07127692|DIAGNOSTIC_TEST|Timed Up and Go test|Screening test for falls in elderly
214560814|NCT07127692|DIAGNOSTIC_TEST|Gait speed|Assessment to check for functional mobility and risk of falls.
214706698|NCT01578057|OTHER|Placebo tasimelteon|once
214706699|NCT01578057|DRUG|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
214560815|NCT07127692|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|Used to assess level of frailty.
214560816|NCT05582499|DRUG|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
214560817|NCT05582499|DRUG|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
214706700|NCT00781248|DEVICE|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
214706701|NCT04084626|DRUG|PD1 antibody|2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
214706702|NCT04084626|DRUG|lenalidomide|5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
214706703|NCT03014440|DRUG|Cannabidiol|
214706704|NCT01839201|OTHER|control|No psychological intervention
214706705|NCT01839201|OTHER|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
214706706|NCT01839201|OTHER|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
214706707|NCT03543358|DRUG|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
214706708|NCT03543358|DRUG|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
214706709|NCT01144234|BEHAVIORAL|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
214706710|NCT01144234|BEHAVIORAL|Information letter|In this arm the pregnant women got an information letter
214706711|NCT02281903|DEVICE|The TrueCPR feedback device|feedback devices
214706712|NCT02281903|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
214560818|NCT05582499|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
215164964|NCT07127016|BEHAVIORAL|Mindfulness Sessions|8 sessions of mindfulness prior to completing their physical therapy session. Each mindfulness session will take 5-10 minutes and will be completed once weekly, immediately prior to their physical therapy sessions. Mindfulness prompts will focus on self-reflection, relaxation, body scanning and being present.
214560819|NCT05582499|DRUG|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
214706713|NCT04810299|OTHER|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
214706714|NCT04810299|OTHER|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
214706715|NCT00530556|DRUG|zolpidem|
214706716|NCT03126331|DRUG|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
215164965|NCT07127016|BEHAVIORAL|No Mindfulness Sessions|Standard of care physical therapy without mindfulness sessions.
215164966|NCT07052032|BIOLOGICAL|CND261|CND261 will be dosed according to the assigned cohort
215164967|NCT06896188|DRUG|Retifanlimab|(PD-1)-blocking monoclonal antibody
215164968|NCT06896188|DRUG|Chemotherapy|oxaliplatin - Antineoplastic - Platinum Complexes Chemotherapy agent; leucovorin - a form of Folic acid helps the body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer; irinotecan - anti-cancer medication used to treat colon cancer in combination with other chemotherapeutic agents; 5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents
214560820|NCT05582499|DRUG|Camrelizumab|an anti-programmed death-1 (PD1) antibody
214560821|NCT05582499|DRUG|SHR-A1921|Trophoblast cell-surface antigen 2 (TROP2) ADC
214560822|NCT05582499|DRUG|Pertuzumab|Pertuzumab
214560823|NCT05582499|DRUG|Trastuzumab|Trastuzumab
214560824|NCT05582499|DRUG|Goserelin|goserelin
214560825|NCT05582499|DRUG|Letrozole|letrozole
214560826|NCT05582499|DRUG|Nab paclitaxel|Albumin paclitaxel
214560827|NCT05582499|DRUG|Carboplatin|Carboplatin
214560828|NCT05582499|DRUG|Epirubicin|Epirubicin
214560829|NCT05582499|DRUG|Cyclophosphamide|Cyclophosphamide
214560830|NCT05582499|DRUG|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
214560831|NCT05582499|DRUG|Apatinib|tyrosine kinase inhibitors
214560832|NCT05582499|DRUG|Famitinib|tyrosine kinase inhibitors
214560833|NCT05582499|DRUG|HB1801|Albumin docetaxel
214560834|NCT05582499|DRUG|LEM|liposome-entrapped mitoxantrone
214560835|NCT05582499|DRUG|TQB2102|an anti-HER2 ADC
214560836|NCT05582499|DRUG|Benmelstobart|an anti-PDL1 antibody
214560837|NCT05582499|DRUG|Anlotinib|an tyrosine kinase inhibitor
214560838|NCT05582499|DRUG|TQB2868|anti-PD-1/TGF-βRII
214560839|NCT05582499|DRUG|Ivonescimab|an anti-PD-1/VEGF bispecific antibody
214560840|NCT05582499|DRUG|JS207|an anti-PD-1/VEGF bispecific antibody
214560841|NCT05582499|DRUG|JSKN003|an anti-HER2 ADC
214560842|NCT05582499|DRUG|HRS-4508|an HER2 inhibitor
214706717|NCT03126331|DRUG|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
214706718|NCT03956225|DEVICE|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
214706719|NCT03956225|DEVICE|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
214706720|NCT04093258|DEVICE|Dailies Total 1® Multifocal Contact Lenses|TEST
214706721|NCT04093258|DEVICE|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
214706722|NCT00594204|DRUG|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
214706723|NCT00594204|DRUG|Placebo|matching placebo 1 tablet twice a day for 12 weeks
214706724|NCT01477372|BEHAVIORAL|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
214706725|NCT00176241|DRUG|gemcitabine|2000-3000mg/m2 IV on days 1 \& 15
214706726|NCT00176241|DRUG|paclitaxel|150 mg/m2 IV on days 1 \& 15
214706727|NCT00176241|RADIATION|radiation|50-80 cGy on days 1,2,15,16
214706728|NCT01213095|DRUG|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
214560843|NCT05582499|DRUG|SHR-4602|an anti-HER2 ADC
214560844|NCT05582499|DRUG|paclitaxel|paclitaxel
214560845|NCT07016165|DRUG|Ceftazidime|Ceftazidime 150 mg/kgBW/24 hours divided into 3 doses.
214560846|NCT07016165|DRUG|Ciprofloxacin|Ciprofloxacin 10 mg/kgBW/12 hours
214560847|NCT06691464|DIAGNOSTIC_TEST|PET|FAPI - PET/CT
214560848|NCT01796600|DEVICE|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
214560849|NCT06626516|DRUG|Tebentafusp-Tebn|Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
214560850|NCT06626516|DRUG|GM-CSF (Sargramostim)|Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.
214560851|NCT06626516|DRUG|BCNU|Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
214560852|NCT07014007|DEVICE|RV4421B- EV0407|Medical device. Product application on studied areas, 5 to 15 minutes after corticosteroids application, if applicable. The maximum duration of application of medical device is 87 days.
214560853|NCT03649178|OTHER|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
214560854|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
214560855|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
214560856|NCT07030179|OTHER|Frailty status|This was an observational study with no intervention measures. The exposure factor was the frailty status of the patients.
214560857|NCT06876259|DIAGNOSTIC_TEST|Standard Clinical Ear Exam|The clinician will examine the child's ear with a standard otoscope and give a clinical diagnosis and decision to treat with antibiotics.
214706729|NCT01830296|DRUG|Remifentanil+morphine|Morphine, Remifentanil+Morphine
214706730|NCT03785795|DEVICE|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
214706731|NCT00986427|DRUG|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
214706732|NCT00986427|DRUG|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
214706733|NCT03314714|PROCEDURE|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
214706734|NCT02247674|PROCEDURE|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
214706735|NCT01363557|OTHER|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
214706736|NCT01363557|DRUG|Gefitinib (IRESSA)|250 mg/day
214706737|NCT04564326|PROCEDURE|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
214706738|NCT04564326|PROCEDURE|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
214706739|NCT04564326|DRUG|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
214706740|NCT04597892|DIAGNOSTIC_TEST|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
214560858|NCT06876259|DIAGNOSTIC_TEST|AI app ear exam and diagnosis|Using a standard otoscope with a cell phone mounted to it, research personnel will record a video image of the tympanic membrane and send it to the cloud for analysis using AI enhanced classification software to render a diagnosis and treatment recommendation
214706741|NCT01115738|DRUG|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
214706742|NCT01115738|DRUG|Clopidogrel|Loading dose administered once orally.
214706743|NCT01115738|DRUG|Placebo|Loading dose administered once orally
214706744|NCT00261326|DRUG|simvastatin|80 mg once daily
214706745|NCT00261326|DRUG|placebo|calcium tablets once daily
214706746|NCT05155657|BIOLOGICAL|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)
214706747|NCT05155657|BIOLOGICAL|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)
214706748|NCT05155657|BIOLOGICAL|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
214706749|NCT00295217|DEVICE|ExAblate 2000|
214706750|NCT04758858|OTHER|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
214706751|NCT04758858|DEVICE|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
214560859|NCT07137988|DIETARY_SUPPLEMENT|600 mg grape seed extract|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
214560860|NCT07137988|DIETARY_SUPPLEMENT|600 mg Starch|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
214560861|NCT01734733|OTHER|NTCELL|
214706752|NCT04758858|OTHER|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
214706753|NCT04758858|OTHER|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
214706754|NCT04758858|OTHER|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
214706755|NCT04758858|OTHER|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
214706756|NCT04758858|OTHER|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
214706757|NCT04758858|OTHER|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
214706758|NCT04758858|OTHER|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
214706759|NCT04758858|DEVICE|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
214706760|NCT04758858|OTHER|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
214706761|NCT04758858|OTHER|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
214706762|NCT04758858|OTHER|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
214706763|NCT04758858|OTHER|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
214706764|NCT04758858|OTHER|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
214560862|NCT06256328|DRUG|ONO-4578|Specified dose, once daily
214560863|NCT06256328|DRUG|Oxaliplatin|Specified dose on specified days
214560864|NCT06256328|DRUG|Capecitabine|Specified dose on specified days
214560865|NCT06256328|DRUG|S-1|Specified dose on specified days
214706765|NCT04758858|OTHER|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
214706766|NCT04758858|OTHER|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
214706767|NCT04758858|OTHER|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
214706768|NCT01606735|DRUG|IBI-10090|dexamethasone
214706769|NCT02160886|BEHAVIORAL|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
214706770|NCT02160886|BEHAVIORAL|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
214706771|NCT03077763|DRUG|Sodium Nitrite|
214706772|NCT04395963|DEVICE|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
214706773|NCT02290886|OTHER|Intravenous administration of placebo|
214706774|NCT02290886|DRUG|Intravenous administration of 1 million of MSC|
214706775|NCT02290886|DRUG|Intravenous administration of 2 million of MSC|
214706776|NCT02290886|DRUG|Intravenous administration of 4 million of MSC|
214706777|NCT04908917|DEVICE|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
214706778|NCT04908917|DEVICE|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
214706779|NCT00922350|OTHER|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
214560866|NCT06256328|DRUG|Nivolumab|Specified dose on specified days
214560867|NCT06256328|DRUG|Placebo|Specified dose, once daily
214560868|NCT06728605|DEVICE|Enhanced External Counterpulsation (EECP)|Patients randomly assigned to EECP received 3 1/2-h sessions of EECP for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 300 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
214560869|NCT06728605|DEVICE|Sham Comparator|Patients randomly assigned to sham group received 3 1/2-h sessions of sham treatment for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 70 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
214560870|NCT07050173|DRUG|Gamma-glutamylcysteine (GGC)|400mg tablet orally (two times) per day.
214560871|NCT06728046|OTHER|ESPB|Participants will receive ultrasound-guided ESPB preoperatively, using 40 ml of 0.3% ropivacaine.
214560872|NCT06728046|DEVICE|PCA|Participants will receive postoperative PCA with a formulation of 200 µg sufentanil diluted to 100 ml. The PCA settings will include a background dose of 3 ml/hour, a lockout time of 15 minutes, and a bolus dose of 2 ml.
214560873|NCT06029907|OTHER|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
214560874|NCT06029907|DRUG|Varenicline|Patients will receive varenicline prescribed by their oncologist
214560875|NCT00896935|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
214560876|NCT06514339|DRUG|shenhuang granule|"Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification."
214560877|NCT06514339|DRUG|placebo|Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
214560878|NCT07075406|DRUG|Luspatercept|According to product label
214560879|NCT07136454|DRUG|Rugonersen|Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).
214560880|NCT07136766|DRUG|Facial Toner|Brightening Toner
214706780|NCT00922350|OTHER|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
214706781|NCT00922350|OTHER|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
214560881|NCT07136766|OTHER|Placebo Toner|Placebo Control Toner
214560882|NCT07137065|BEHAVIORAL|PRImary care MultilEvel intervention for low back pain (PRIME)|"The multilevel intervention includes four main components:~1\. GP training. GPs will receive training to improve their confidence in LBP guidelines, diagnostic triage and best practice. Furthermore, they will be trained to provide both general and cognitive reassurance to patients, use a stratified care strategy and improve interprofessional communication. 2. Reminders. GPs will receive regular reminders by email to reinforce the integration of high-value care into practice. 3. Patient education. GPs will reassure patients, help them understand their LBP in the initial consultation and target unhelpful beliefs about LBP. 4. Clinical pathway. The clinical pathway includes a gradual stratified care pathway based on risk factors for chronicity. The core interventions of this 3-step clinical pathway are education and self-management, individual sessions with a trained physiotherapist, and multidisciplinary group management. GPs remain free to make all clinical decisions."
214560883|NCT07137065|OTHER|Usual Care|In this arm, general practitioners will treat their patients as usual. They can prescribed any treatment or diagnostic tests to their patients.
214560884|NCT07136220|OTHER|Consumption of soy protein bar|The participants will be provided one soy protein bar to consume after dinner on day 1.
214560885|NCT07135765|PROCEDURE|Additional 5 minutes of lying down position during MRI|During axial MRI for scoliosis assessment, additional 5 minutes of lying down position in order to performing a specific sequence for the study of the vertebral muscles (Diffusion Tensor Imaging).
214560886|NCT02627443|DRUG|Berzosertib|Given IV
214560887|NCT02627443|DRUG|Carboplatin|Given IV
214560888|NCT02627443|DRUG|Gemcitabine Hydrochloride|Given IV
214560889|NCT02627443|OTHER|Laboratory Biomarker Analysis|Correlative studies
214560890|NCT02627443|OTHER|Pharmacological Study|Correlative studies
214560891|NCT07076615|DRUG|Dapagliflozin (DAPA)|Receives dapagliflozin 10 mg once daily + standard intravenous diuretic therapy
214560892|NCT07076615|DRUG|Diuretic|Arm B (Control Group): Receives standard intravenous diuretic therapy alone
214560893|NCT06767111|DEVICE|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm in vitro diagnostic (IVD) device|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm to be used for AI-assisted review
214560894|NCT06755827|BEHAVIORAL|Emotion regulation and self-monitoring to treat pediatric obesity|Participants will attend telehealth group sessions once weekly and be asked to self-monitor their mood and health behaviors daily between sessions.
214560895|NCT06755827|OTHER|Psychoeducation|Participants who are randomized to the control group will receive an online, one-time, self-led psychoeducation program with information about current daily sleep, diet, and physical activity recommendations (e.g., information about sleep hygiene, the food pyramid, and recommendations for 60 minutes of moderate-to-vigorous physical activity daily).
214560896|NCT06122870|BIOLOGICAL|CampETEC HBC product|Immunoglobulin from bovine milk/colostrum and challenge strain
214560897|NCT06122870|BIOLOGICAL|ProMilk 85|Placebo ProMilk 85
214560898|NCT06122870|BIOLOGICAL|C. jejuni CG8421 Challenge strain|Challenge strain C. jejuni CG8421
214560899|NCT02726711|DRUG|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
214560900|NCT02726711|DRUG|Placebo|0.5 - 4.0 mg IV to be infused
214706782|NCT00922350|OTHER|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
214706783|NCT00966303|OTHER|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
214706784|NCT03716518|DRUG|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
214706785|NCT03716518|DRUG|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
214560901|NCT05511467|BEHAVIORAL|Visuomotor learning task|Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
214560902|NCT07081633|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214560903|NCT07081633|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
214560904|NCT07081633|COMBINATION_PRODUCT|Lenvatinib|Lenvatinib Oral
214560905|NCT07083271|OTHER|Administration of validated questionnaires with established Turkish versions|Participants will complete validated Turkish versions of three self-administered instruments: the Zarit Caregiver Burden Scale (ZCBS), the EORTC QLQ-C30, and the Hospital Anxiety and Depression Scale (HADS). Financial toxicity will be assessed via self-reported socioeconomic data. No clinical, behavioral, or pharmaceutical intervention will be applied.
214560906|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
214560907|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
214560908|NCT07089862|DRUG|Indobufen treatment|Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
214706786|NCT02545842|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214706787|NCT00997178|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
214706788|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
214706789|NCT04973215|OTHER|no intervention|this is not an intervention study
214706790|NCT02793323|OTHER|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
214706791|NCT02793323|OTHER|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
214706792|NCT02793323|OTHER|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
214706793|NCT02793323|OTHER|IV placebo|100 ml IV saline
214706794|NCT02793323|OTHER|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
214706795|NCT01106742|DIETARY_SUPPLEMENT|AndoSan|AndoSan, 20mlx3, 12 days
214706796|NCT05157399|DEVICE|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
214706797|NCT05157399|DEVICE|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
214706798|NCT00847756|OTHER|questionnaire|Identification of risk factors
214706799|NCT00847756|PROCEDURE|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
214706800|NCT00847756|PROCEDURE|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
214560909|NCT07089862|DRUG|Aspirin treatment|Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
214560910|NCT06902883|DEVICE|Serum holder connected to the wheelchair|Serum holder connected to the wheelchair
214560911|NCT06902883|DEVICE|wheelchair seat|wheelchair seat
214560912|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
214560913|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
214560914|NCT07090876|DIETARY_SUPPLEMENT|Standardized Grape Seed Extract|Grape seed dry extract standardized to provide: ≥95.0% of proanthocyanidins by spectrophotometry, ≥5.0% ≤15.0% of catechin and epicatechin by High-Performance Liquid Chromatography (HPLC)
214706801|NCT00847756|PROCEDURE|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
215164969|NCT06896188|DRUG|9-ING-41|a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells
214560915|NCT07090876|OTHER|Placebo|Placebo
214560916|NCT06908447|BEHAVIORAL|Cold-water immersion|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 10-16°C on the experimental day
214560917|NCT06908447|BEHAVIORAL|Warm-water immersion (Control)|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 30-36°C on the experimental day
214706802|NCT02825433|OTHER|No intervention, only ventilation monitoring|
215164970|NCT04782258|DRUG|Tolvaptan Suspension|Syrup
215164971|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
214706803|NCT03556748|OTHER|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
214706804|NCT02993913|DRUG|Simmiparib|Simmiparib Tablets, oral administration
214706805|NCT01669811|DRUG|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
214706806|NCT01669811|DRUG|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
214706807|NCT02571751|DEVICE|UNIGEL Silicone Gel-Filled Breast Implant|
214706808|NCT04627142|DRUG|BI 1701963|Tablet
214706809|NCT04627142|DRUG|Camptosar®|Solution for infusion
214706810|NCT04794556|DEVICE|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
214706811|NCT06366828|OTHER|retrospective|follow up
214706812|NCT01524367|DRUG|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
214706813|NCT01524367|DRUG|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
214706814|NCT03201172|DEVICE|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
214706815|NCT03758430|OTHER|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
214706816|NCT03758430|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
214706817|NCT05507060|DEVICE|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
214706818|NCT05507060|DEVICE|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
214706819|NCT03558191|DRUG|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
214706820|NCT05657704|DRUG|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
214706821|NCT04748406|DEVICE|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
214706822|NCT04748406|OTHER|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
214706823|NCT04748406|OTHER|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
214706824|NCT04748406|OTHER|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
214706825|NCT04699214|DRUG|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
214706826|NCT04699214|DRUG|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
214706827|NCT05049447|DRUG|Pascoflair|1 x 2 tablets (single-dose)
214706828|NCT05049447|OTHER|Placebo|1 x 2 tablets (single-dose)
214706829|NCT05556551|OTHER|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
214706830|NCT05556551|OTHER|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
214706831|NCT06460636|OTHER|progressive muscle relaxation therapy|Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
214706832|NCT06460636|OTHER|aquatic therapy|participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
214706833|NCT01478152|OTHER|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
214706834|NCT00165581|DEVICE|High Dose Intracavitary Brachytherapy|
214706835|NCT01046383|DIETARY_SUPPLEMENT|IMN1207|20 grams of IMN1207 per day for 40 weeks.
214706836|NCT01046383|DIETARY_SUPPLEMENT|Casein|20 grams of Casein per day for 40 weeks
215164972|NCT07054411|DEVICE|Radical-7 Pulse CO-Oximeter|Rainbow sensors will be placed on the 4th fingertips of the non-dominant hand of the patients and connected to the Radical-7 Pulse CO-Oximeter device and the initial Hb value will be recorded routinely and recorded hourly during the operation. Hemogram samples will be studied in the laboratory. During the operation, every hour and at the end of the operation, SpHb value, Hb, Hct levels in hemogram will be recorded.
215164973|NCT06785415|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215164974|NCT06785415|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215164975|NCT06785415|PROCEDURE|Bone Scan|Undergo bone scan
215164976|NCT06785415|PROCEDURE|Chest Radiography|Undergo chest x-ray
215164977|NCT06785415|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
215164978|NCT06785415|BIOLOGICAL|Daratumumab|Given SC
214706837|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
214560918|NCT06907524|BEHAVIORAL|Longitudinal, Individualized Health Coaching|During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.
214560919|NCT05590949|OTHER|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
214560920|NCT05590949|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
214560921|NCT05590949|DIAGNOSTIC_TEST|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
214560922|NCT07126795|DRUG|magnesium sulfate|IV Magnesium Sulfate 50 mg/kg (max 2 grams) over 20 minutes given immediately prior to initiation of daily sedated dressing change
214560923|NCT07126795|DRUG|Normal Saline (0.9% NaCl)|Normal Saline given in equivalent volume as study drug over 20 minutes, immediately prior to initiation of sedated dressing change
214560924|NCT07127536|BEHAVIORAL|CO-OP (Cognitive Orientation to daily Occupational Performance)|"The CO-OP approach is a client-centered, performance-based intervention that uses cognitive strategies to help individuals improve performance in meaningful daily activities. In this study, CO-OP sessions will be delivered in addition to standard occupational therapy, 5 days per week for 4 weeks, with each session lasting 45 minutes. The intervention group will receive standard occupational therapy intervention in addition to CO-OP.~Standard Occupational Therapy Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site."
214560925|NCT07127536|BEHAVIORAL|Standard Occupational Therapy|Participants in this group will receive standard occupational therapy only, without the additional CO-OP intervention. Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site.
214560926|NCT07129460|DRUG|Berberine hydrochloride|Subjects will be instructed to take three tablets (300mg) of Berberine hydrochloride two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214560927|NCT07129460|DRUG|Placebo|Subjects will be instructed to take three tablets (300mg) of placebo two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214560928|NCT07137221|OTHER|Post menopausal breast cancer patients|"All selected patients will undergo peripheral blood samplingfor the evaluation of inflammatory biomarkers and must have agreed to store and use part of their sample for research purposes.~A panel of inflammatory cytokines (IFNγ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, TNFα) will be detected by ELISA assay. Other biomarkers such as RANKL, OPG, Vitamin D levels, CTX, PTH will be evaluated by immunoenzymatic assays. In addition, mirNAs as mir-16 and mir-378 will be evaluated by RT-PCR. Glucose metabolic markers such as fasting glucose and insulin, HbA1c and other parameters such as calcemia, PTH, c-telopeptide etc. will be collected.~In particular, the evaluation of the biomarkers will be done on plasma samples at different time points (previously the administration of 10 course of weekly acupuncture; at the end and 6 months after the end of acupuncture and at the time of symptoms recurrence."
214560929|NCT07137390|DRUG|Regorafenib|Given Orally
214560930|NCT07137390|DRUG|Lorigerlimab|Given Orally
214560931|NCT06927492|OTHER|Cognitive Sensorimotor training along with whole body vibration|This group will receive sensorimotor training with cognitive dual-task training in addition to whole body vibration. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes, The whole-body vibration will be administered using a vibration machine. This includes asking the patient to stand barefoot on the vibrator platform evenly distributing their body weight on both feet with knees bent at 20 degrees as flexing of knees is a common postural adaptation used to minimize transmission of vibration to the head. The patients will receive the whole body vibration at 30Hz consisting of three sessions per week with at least one day between sessions for 12 weeks. The time for each session will be 15 minutes (five bouts of 2 min) . There will be a rest of 1 minute between each bout of vibration therapy.
214560932|NCT06927492|OTHER|Cognitive Sensorimotor training|This group will receive sensorimotor training with cognitive dual task training simultaneously. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes,
214560933|NCT06929598|BEHAVIORAL|Shiatsu Therapy|Participants will receive one 30-minute session of Shiatsu therapy per week for 6 weeks. Therapy will be provided by trained Shiatsu practitioners under a standardized protocol developed for this study.
215164979|NCT06785415|DRUG|Dexamethasone|Given PO
215164980|NCT06785415|BIOLOGICAL|Elotuzumab|Given IV
215164981|NCT06785415|DRUG|Iberdomide|Given PO
215164982|NCT06785415|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215164983|NCT06785415|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214706838|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
214706839|NCT04020055|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
214560934|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
214560935|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
214560936|NCT06935084|OTHER|ASTHMAXcel Voice platform|ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.
214560937|NCT07136896|OTHER|Nutritional Assessment Protocol|Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements (weight, height, BMI, skinfold thickness), dietary intake evaluation through 24-hour recall, and bioelectrical impedance analysis to assess body composition. Relevant biochemical parameters will also be measured to evaluate nutritional status
214560938|NCT07137962|PROCEDURE|PENG Block|"The curvilinear low-frequency (2-5 MHz) ultrasound probe was placed over the line parallel to the inguinal ligament. It was subsequently rotated 45° to identify the anterior inferior iliac spine, the ilio-pubic eminence, and the psoas tendon.~A 22-gauge echogenic needle was inserted in plain to place the tip in musculo-fascial plain between pubic ramus posteriorly and psoas tendon anteriorly, using hydro-dissection technique. Following negative aspiration, a total volume of 0.5 ml/kg of 0.25% bupivacaine was injected."
214560939|NCT07137962|PROCEDURE|FICB Block|"The linear ultrasound probe was placed over the inguinal ligament in the sagittal plane, inferomedial to the anterior superior iliac spine. Upon identifying the bow-tie sign formed by the sartorius muscle and the internal oblique muscle by sliding medially and rotating the probe. 22-gauge echogenic needle was introduced 1 cm cephalad to the inguinal ligament to place the needle tip in the space between the internal oblique and iliacus muscles, using the hydro-dissection technique. A total volume of 0.5 mL/kg of bupivacaine 0.25% was injected following negative aspiration."
214560940|NCT07137962|PROCEDURE|Caudal Block|"After induction of general anesthesia, the patient was placed in the left lateral position with the upper hip flexed at 90° and the lower hip flexed at 45°. The region was then swabbed in a craniocaudal direction with a 70% alcohol solution.~After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture was performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, a needle was inserted immediately below the spinous process S4. After perforating the membrane, which occludes the sacral hiatus, the needle was advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection. Bupivacaine 0.25% at a dose of 1 ml/kg was injected."
214560941|NCT07139327|DEVICE|Cochlear Implant|TICI G2 Clinical Investigation System
214560942|NCT07136324|DEVICE|EUS-guided RFA treatment|A 19-gauge EUS-RFA catheter will be inserted into pancreatic lesions under EUS guidance. RFA energy is then applied in 2-10 cycles with each cycle lasting about 10-30 seconds and the power setting ranging from 10-30 Watts.
214560943|NCT07137858|DRUG|Preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adalimumab 1200mg are administered intravenously. According to the allocation to the short-course group or long-course group, two or three cycles are carried out respectively, and surgery is performed 21 days after the end of the last cycle of medication. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive maintenance therapy with PD-L1 inhibitor (adalimumab) alone. Patients who require radiotherapy and chemotherapy receive maintenance therapy with the drug alone at the same time. The duration of medication for all patients is one year (calculated from the time of the first medication at the initial diagnosis to the last medication after the surgery).
214560944|NCT07137858|DRUG|Two courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously. Two treatment courses were carried out in total, and surgery was performed 21 days after the end of the second course of medication. Postoperative radiotherapy and chemotherapy were administered based on the pathological stage. Patients who did not require radiotherapy received adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who required radiotherapy and chemotherapy received monotherapy maintenance during the same period. The duration of medication for all patients was one year (from the first medication time at the initial diagnosis to the last medication time after surgery).
214706840|NCT00653913|DRUG|SCH 58235|SCH 58235 10 mg (once daily)
214706841|NCT00653913|DRUG|pitavastatin|Pitavastatin 2 mg (once daily)
214706842|NCT00412906|DRUG|Escherichia Coli Endotoxin|
214706843|NCT04923698|OTHER|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
214706844|NCT02801422|OTHER|fMRI|
214706845|NCT01645865|BEHAVIORAL|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
214706846|NCT01645865|BEHAVIORAL|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
214706847|NCT04675736|PROCEDURE|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
214706848|NCT05294341|DRUG|Norethindrone Acetate 5 MG|As specified in arm design
214706849|NCT05294341|DRUG|Norethindrone 0.35 MG|As specified in arm design
215164984|NCT04111718|BIOLOGICAL|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
214560945|NCT07137858|DRUG|Three courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg are administered intravenously. This treatment is carried out for a total of three cycles, and surgery is performed 21 days after the end of the third cycle. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who require radiotherapy and chemotherapy receive monotherapy maintenance simultaneously. The duration of medication for all patients is one year (from the first administration after diagnosis to the last administration after surgery).
214560946|NCT07137416|PROCEDURE|Biopsy Procedure|Undergo biopsy
214560947|NCT07137416|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214560948|NCT07137416|PROCEDURE|Echocardiography Test|Undergo ECHO
214706850|NCT01773798|DRUG|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
214706851|NCT01773798|DRUG|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
214706852|NCT01773798|DRUG|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
214560949|NCT07137416|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214560950|NCT07137416|DRUG|Pidnarulex|Given IV
214706853|NCT01773798|DRUG|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
214706854|NCT01773798|DRUG|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
215164985|NCT04111718|BEHAVIORAL|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
215164986|NCT06702696|DIETARY_SUPPLEMENT|Black chokeberry (Aronia melanocarpa)|The aronia group, who will consume 30 g of freeze-dried aronia powder (n=25)
215164987|NCT06702696|OTHER|Placebo powder|The placebo group, who will consume placebo powder (n=25).
214560951|NCT07137416|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
214560952|NCT07137416|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214560953|NCT07135245|DRUG|Semaglutide (Rybelsus®) combined with other interventions|The full intervention includes treatment with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®)
215164988|NCT04555161|DEVICE|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
215164989|NCT06805539|OTHER|No treatment given|No treatment given
215164990|NCT06861855|OTHER|Observation|observation of METTL-14 prognosis
215164991|NCT06861855|BEHAVIORAL|IHC|IHC of METTL-14
215164992|NCT06860607|BEHAVIORAL|Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption|This study investigates how different environments and activities affect alcohol consumption and related outcomes.
215164993|NCT06743347|OTHER|MRI Contrast|Pass a Phase Contrast MRI. No injection required.
215164994|NCT06732401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215164995|NCT06732401|DRUG|Ceralasertib|Given PO
215164996|NCT06732401|PROCEDURE|Computed Tomography|Undergo CT scan
215164997|NCT06732401|BIOLOGICAL|Durvalumab|Given IV
215164998|NCT06732401|PROCEDURE|Echocardiography Test|Undergo echocardiography
215164999|NCT03414684|DRUG|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
215165000|NCT03414684|DRUG|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
214706855|NCT04638868|DEVICE|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
214560954|NCT07135245|OTHER|Placebo|A control group treated with placebo and no further intervention
214560955|NCT07135245|DRUG|Semaglutide (Rybelsus®)|An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo
214560956|NCT07141914|OTHER|No treatment given|No treatment given
214560957|NCT07141914|OTHER|No treatment given|No treatment given
214560958|NCT06939023|PROCEDURE|Laparoscopic minimally invasive left-sided pancreatecomy|Laparoscopic minimally invasive left-sided pancreatecomy
214560959|NCT06939023|PROCEDURE|Robot-assisted minimally invasive left-sided pancreatecomy|Robot-assisted minimally invasive left-sided pancreatecomy
214560960|NCT06938438|PROCEDURE|single locking miniplate|Ten patients in whom anterior mandibular fractures will be fixed with titanium single locking miniplate
214706856|NCT04638868|DEVICE|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
214706857|NCT04095442|DEVICE|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
214706858|NCT04095442|DEVICE|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
214706859|NCT00083343|DRUG|MK0991, caspofungin acetate/Duration of Treatment: variable|
214706860|NCT04374201|OTHER|2 zirconia FDPs|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
214706861|NCT04374201|OTHER|1 zirconia FDP|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
214706862|NCT05340101|BEHAVIORAL|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
214706863|NCT01374672|OTHER|laboratory biomarker analysis|Correlative studies
214560961|NCT06938438|PROCEDURE|double conventional miniplates.|Ten patients in whom, anterior mandibular fractures will be fixed with double conventional titanium miniplates.
214560962|NCT07143006|DEVICE|BestShape Go Intelligent Generation Transformable Electric Vehicle|The specific applications of artificial intelligence in intelligent electric vehicles mainly include gait monitoring and analysis, real-time feedback and guidance, autonomous adaptive assistance, safety prevention and warnings, data collection and long-term tracking, as well as adding interactive and entertainment elements.
214560963|NCT02533024|OTHER|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
214560964|NCT05323123|DRUG|Pre-Exposure Prophylaxis (PrEP)|FDA-approved oral medication to reduce the risk of HIV infection
214560965|NCT05323123|BEHAVIORAL|SPARK|SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).
214560966|NCT05323123|BEHAVIORAL|HealthMpowerment|PrEP adherence support app that utilizes engaging social networking and game-based elements, with an in-app portal for individualized live adherence counseling.
214560967|NCT07146490|BEHAVIORAL|Low Exercise|Low-Intensity Continuous Training (LICT): Participants ran continuously for 24 minutes at 50-60% of their MAS without breaks.
214560968|NCT07146490|BEHAVIORAL|Long Interval Exercise|Long-interval high-Intensity Interval Training (LI-HIIT): Participants ran at a speed corresponding to 80-90% of their MAS. The protocol consisted of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants ran at 50% of their MAS. This pattern totaled 24 minutes of exercise.
214560969|NCT07146490|BEHAVIORAL|Short Intevral Exercise|Short-interval high-Intensity Interval Training (SI-HIIT): Participants ran at 110-120% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets were completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
214560970|NCT07145164|DRUG|N-803|This is the active drug.
214560971|NCT07145164|DRUG|Saline placebo|This is the placebo.
214560972|NCT07144072|DRUG|HeXell-2020|Cohort 1: 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 3 doses Cohort 2 : 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 6 doses
214560973|NCT07143474|DRUG|RhizomK|RhizomK 50 mg once daily
214560974|NCT07143474|OTHER|Plcebo|Placebo matching to RhizomK
214560975|NCT00466154|DRUG|Aspirin|
214560976|NCT06947447|DEVICE|No intervention|Device
214560977|NCT07137377|BEHAVIORAL|On line teaching CESARCOM teaching programe (immersive podcasts, digital flashcards)|"A short e-learning program (immersive podcasts, digital flashcards) will be carried out for the medical and paramedical staff of the cesarean section operating room, by a specialized team. It will will consist of :~* the presentation of the basic principles of therapeutic communication (listening, empathy, verbal, non-verbal, paraverbal language)~* the distribution of the HUG communication lexicon/wordbook .~* educational scenes illustrating the impact of therapeutic communication in the operating room (good versus bad words)."
214560978|NCT06954441|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"The investigational product is V-IMMUNE®, a 5% human normal immunoglobulin I.P. (5 g/100 mL) manufactured from qualified human plasma for intravenous use. Each vial contains human immunoglobulin at 50 g/L, maltose at 100 g/L, and water for injection. The 5% Human Immunoglobulin Solution for Intravenous Administration (I.P.) is a sterile and pyrogen-free preparation of human normal immunoglobulin in a single-dose form for intravenous administration. Each 10 mL, 50 mL, or 100 mL vial contains 0.5 g, 2.5 g, or 5 g of human normal immunoglobulin, respectively, and is produced from qualified human plasma using membrane filtration and a combination of chromatographic steps and viral inactivation procedures. The IgA content does not exceed 2 mg/mL.~This manufacturing process uses plasma collected from donors who undergo screening according to guidelines set by regulatory authorities. Blood is tested for all mandatory infectious diseases."
214560979|NCT07143643|OTHER|Excape room game|"Application of Research:The escape room game scenario prepared by the researchers was designed according to the steps of the Nursing Process. The game consists of five stages, each conducted at different stations, and each stage includes various clues and activities. The stages were organized to cover the steps of the Nursing Process: Assessment, Nursing Diagnosis, Planning, Implementation, and Evaluation. Before starting the game, the students who will participate will be informed about the expected objectives, the game rules, and the duration. In addition, it will be stated that each group must select a group leader. The students will be given a total of 60 minutes to answer the questions in each stage, assemble puzzle pieces, unlock locked boxes, follow the clues, and find the exit key in order to leave the room. The students will be expected to complete the tasks at the stations prepared in accordance with the Nursing Process stages and to exit the room within the allotted time."
214560980|NCT07141459|DEVICE|810 nm diode laser disinfection|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each. A 200 μm fiber optic tip (Lite medics, Italy) will be inserted 1 mm from the working length, activated and moved in slow helical motion from the apex to the cervical third with alternating between clockwise and counterclockwise direction at speed of about 2 mm/s
214706864|NCT02726126|DRUG|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
215165001|NCT06887647|OTHER|Physical Therapy Using Hippotherapy and the Equine Environment|"Subjects will be mounted on a horse for 15-30 minutes. Therapeutic activities will include movements like reaching, throwing, and bilateral coordination tasks in addition to assuming various positions on the horse during equine movement, per the tolerance of individual participants. Remaining treatment time will involve participation-based functional motor activities in the equine environment, such as feeding and grooming horses.~Treatment will include the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities with equines to guide practice of functional motor skills.~3. Design therapeutic activities with the equines to practice participation (ie. activities involved in life situations).~4. Utilize the presence of the equines to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use the equines as positive reinforcement)"
214560981|NCT07141459|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
214560982|NCT07147192|DEVICE|AAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.
214560983|NCT07147192|DEVICE|BAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
214560984|NCT07147192|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.
214560985|NCT07136909|OTHER|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.
214560986|NCT07137910|DRUG|AHB-137|AHB-137 will be injected
214560987|NCT07138053|OTHER|OFA group|OFA group Premedication with Midazolame and Paracetamol 30 minutes before surgery on ward, Dexamethasona and infusion of Dexmedetomidin and 2% Lidocaine 10 min before intubation( 50mcg Dexmedetomidin and 500mg 2% Lidocaine add up to 50ml normal saline) 1ml/10kg in 10 min after intubation 1ml/10kg/h discontinued after last surgical sutures. TAP bloc ultrasound guided performed after intubation. Ketamine given 60 sec before incision in doses 0.5 mg/kg, and after if it is necessary according to ER and qNOX. Provided value range between 40-60 during surgery.
214560988|NCT07155694|DRUG|Finerenone 10 MG|Take Finerenone 10 mg orally daily
214560989|NCT07155694|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
214560990|NCT07155850|DEVICE|Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas|YntraDose™ is a locoregional therapy device used for percutaneous radio-ablation of solid tumours
214560991|NCT01562223|OTHER|motexafin gadolinium|
214706865|NCT04087408|DRUG|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
214706866|NCT05986825|OTHER|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
214706867|NCT00567060|DRUG|Piracetam|
214560992|NCT06316310|OTHER|acupoint thread embedding|Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
214560993|NCT02548286|DRUG|Candesartan 8mg|PO, 1day or 22day
214560994|NCT02548286|DRUG|Amlodipine 5mg|PO, 1day or 22day
214560995|NCT02548286|DRUG|CKD-330 8/5mg|PO, 1day or 22day
214706868|NCT03508544|PROCEDURE|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
214706869|NCT03508544|PROCEDURE|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
214560996|NCT01099215|BIOLOGICAL|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
214706870|NCT03508544|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214560997|NCT02896075|OTHER|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
214560998|NCT02896075|OTHER|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
214560999|NCT03408405|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
214561000|NCT03435679|PROCEDURE|one-stage|one-stage surgery
214561001|NCT03435679|PROCEDURE|two-stage|two-stage surgery
214561002|NCT04358601|DEVICE|Triathlon PS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
214561003|NCT04358601|DEVICE|Triathlon PS Knee System with metal-backed modular components|Primary Total Knee Replacement
214561004|NCT03680339|PROCEDURE|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
214561005|NCT03680339|DRUG|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
214561006|NCT03680339|DRUG|Oxytocin|10 IU of oxytocin with fetal delivery
214561007|NCT00211068|DRUG|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
214561008|NCT00747227|DEVICE|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
214561009|NCT00747227|DEVICE|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
214561010|NCT02558127|GENETIC|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
214561011|NCT01715662|DEVICE|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
214561012|NCT01715662|DEVICE|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
214561013|NCT02777476|DEVICE|B-Lite- Light Weight Breast Implants|
214561014|NCT06426212|DRUG|Use of teicoplanin three times a week|retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
214561015|NCT02816775|DEVICE|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
214561016|NCT02816775|DEVICE|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
214561017|NCT01612598|OTHER|counseling intervention|Undergo PCI
215165002|NCT06887647|OTHER|Standard Play-Based Physical Therapy|"The treatment will focus on encouragement of functional play activities, such as reaching, throwing, and catching games. Treatment will incorporate the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities using play and games to guide practice of functional motor skills.~3. Design therapeutic activities with play and games to practice participation (ie. activities involved in life situations).~4. Utilize play and games to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use play and games as positive reinforcement)"
215165003|NCT06894511|DRUG|AAA617|"Dose formulation: open-label vial~Dose level: 7.4 GBq (200 mCi) ± 10% Once, every 6 weeks for 6 cycles, intravenous administration"
215165004|NCT06894511|DRUG|ARPI: Abiraterone|"Dose formulation: tablet/capsule~Dose level: 160 mg (four 40 mg or two 80 mg soft capsules) as a single daily dose, oral administration"
215165005|NCT06894511|DRUG|ARPI: Enzalutamide|"Dose formulation: tablet~Dose level: 1000 mg daily (two 500 mg tablets or four 250 mg tablets as a single daily dose together with 5 mg oral prednisone 2 times a day, oral administration"
215165006|NCT04711811|BIOLOGICAL|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
215165007|NCT06895057|OTHER|Exercise|Individuals who voluntarily accept to participate in the study will be divided into two groups as telerehabilitation and clinical practice groups by randomization. Exercises will be applied face to face to the clinical practice group and online to the telerehabilitation group via tablet. Individuals who will participate in the study will be applied twice a week for 8 weeks, each session lasting 50 minutes. Pain, quality of life, endurance, functionality, and flexibility assessments will be taken face to face for both groups before and after the application. Treatment satisfaction scale (PGIC) will be taken from both groups in the 4th and 8th weeks. All assessments will be evaluated twice before and after the training by the same therapist in the clinic, face to face.
215165008|NCT06753838|BIOLOGICAL|Sampling of 3 additional BAPA tubes|the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test
215165009|NCT04887935|DRUG|Dapagliflozin|-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
215165010|NCT06739811|DEVICE|Implantable Insulin Pump System|Medtronic Implantable Insulin Pump System (MIIPS 2020)
215165011|NCT06759376|OTHER|Vibration massage|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Performing vibration massage with a vibration massage device for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
214561018|NCT01612598|PROCEDURE|quality-of-life assessment|Ancillary studies
214561019|NCT01612598|OTHER|questionnaire administration|Ancillary studies
214561020|NCT01612598|OTHER|educational intervention|Undergo PCI
214561021|NCT03917862|COMBINATION_PRODUCT|TDM-621|The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
214561022|NCT05169398|DEVICE|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
214561023|NCT02309931|PROCEDURE|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
214561024|NCT02309931|PROCEDURE|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
214561025|NCT03440957|OTHER|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
214561026|NCT03554629|DEVICE|Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2|Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
214561027|NCT00523861|DIETARY_SUPPLEMENT|Moderate alcohol consumption|
214561028|NCT04164121|DRUG|Phenlarmide Tablets|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
214561029|NCT04164121|DRUG|Placebos|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
214706871|NCT01620697|PROCEDURE|Colorectal surgery|Colorectal surgery
214561030|NCT05400577|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
215165012|NCT06759376|OTHER|Static stretching exercise|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Perform static stretching exercise for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
215165013|NCT06759376|OTHER|Usual Care|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Usual care,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
215165014|NCT04569591|DRUG|Acthrel|Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
215165015|NCT03570801|OTHER|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
215165016|NCT06741618|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence
215165017|NCT06741618|BEHAVIORAL|Electronic PrEP peer navigation|Electronic peer navigation to PreP services
215165018|NCT07060365|DRUG|Saruparib|Participants will receive saruparib via oral administration.
215165019|NCT06747351|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
215165020|NCT06747351|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
215165021|NCT06747351|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881/HYQVIA to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
215165022|NCT07061288|DRUG|KarXT|Specified dose on specified days
215165023|NCT06752096|PROCEDURE|cerebral angiography, arterial embolization, thrombectomy|This intervention will be conducted using robotic navigation.
215165024|NCT06752096|DEVICE|Cerebral angiogram using robotic device|Diagnostic cerebral angiogram will be performed using a robot to navigate guidewires and catheters to target vessels.
215165025|NCT06752096|DEVICE|Meningioma embolization using robotic device.|Meningioma tumors will be embolized using a robot to navigate catheters and wires to the target vessels to the tumor.
214561031|NCT03311477|DRUG|ABBV-399|Intravenous infusion
214561032|NCT02567760|DIETARY_SUPPLEMENT|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
214561033|NCT02567760|OTHER|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
214561034|NCT01695941|DRUG|Alisertib|Given PO
214561035|NCT01695941|DRUG|Bortezomib|Given SC
214561036|NCT01695941|OTHER|Laboratory Biomarker Analysis|Correlative studies
214561037|NCT01695941|BIOLOGICAL|Rituximab|Given IV
214561038|NCT04318106|DEVICE|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
214561039|NCT06429098|DRUG|Venetoclax|Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
214561040|NCT06429098|DRUG|azacitidine|Given SC
214561041|NCT06429098|DRUG|decitabine|Given IV
214561042|NCT06429098|DRUG|Cytarabine|Given IV
214561043|NCT03304197|DIETARY_SUPPLEMENT|Hypotonic|N/A: see arm description
214561044|NCT03304197|DIETARY_SUPPLEMENT|Isotonic|N/A: see arm description
214561045|NCT03304197|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
214561046|NCT03304197|OTHER|Dehydrated|N/A: see arm description
214561047|NCT01399385|DEVICE|MR Imaging Techniques - 1|Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
214561048|NCT01399385|DEVICE|MR Imaging Techniques - 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
214561049|NCT01399385|DEVICE|MR Imaging Techniques - 3|Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
214561050|NCT01399385|DEVICE|MR Imaging Techniques - 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
214561051|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
214561052|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
214561053|NCT03619447|DRUG|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
214561054|NCT03619447|DRUG|serratus block group|USG guided serratus plane block will perform bilaterally
214561055|NCT04223804|DRUG|ABBV-181|Intravenous (IV) Infusion
214561056|NCT04223804|DRUG|Placebo|Intravenous (IV) infusion
214561057|NCT05824598|BEHAVIORAL|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
214561058|NCT03149809|DRUG|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
214561059|NCT03149809|BEHAVIORAL|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
214561060|NCT03486860|BEHAVIORAL|Parent Psychoeducation|6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.
214561061|NCT03486860|BEHAVIORAL|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
215165026|NCT06752096|DEVICE|Mechanical thrombectomy for stroke using a robotic device.|Mechanical thrombectomy procedure will use a robot to navigate catheters, guidewires, and thrombectomy devices to the target vessel.
215165027|NCT07061678|DRUG|perineural dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg perineural dexamethasone
215165028|NCT07061678|DRUG|intravenous dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg intravenous dexamethasone
215165029|NCT07061678|DRUG|control|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine
215165030|NCT07060807|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
215165031|NCT07060807|DRUG|Paclitaxel|Administered via IV infusion
215165032|NCT07060807|DRUG|Nab-paclitaxel|Administered via IV infusion
215165033|NCT07060807|DRUG|Capecitabine|Administered via oral tablets
215165034|NCT07060807|DRUG|Liposomal doxorubicin|Administered via IV infusion
214561062|NCT05591014|DEVICE|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
214561063|NCT03787056|OTHER|Blood draws|"Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort"
214561064|NCT05701527|DRUG|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
214561065|NCT05701527|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
214561066|NCT01608126|PROCEDURE|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
214561067|NCT01692951|OTHER|serum sample|Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
214561068|NCT06043258|OTHER|Bond Apatite|composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
214561069|NCT06043258|OTHER|Bio-Oss|xenograft bone substitute
214561070|NCT02867215|OTHER|Barley bread|120g barley bread per day for 3 weeks.
214561071|NCT02867215|OTHER|Wheat bread|120g wheat bread per day for 3 weeks.
214561072|NCT01174576|OTHER|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
214561073|NCT01108926|DRUG|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
214561074|NCT01365936|DRUG|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
215165035|NCT07060807|BIOLOGICAL|Trastuzumab deruxtecan|Administered via IV infusion
215165036|NCT07059429|DRUG|Ketamine|Ketamine administered intravenously at 0.15 mg/kg/h via PCA with 1 mg boluses, 5-minute lockout, maximum 500 mg per 24 hours after knee arthroplasty.
215165037|NCT07059429|DRUG|Standard Analgesia|Standard analgesia includes ketoprofen 100 mg twice daily and paracetamol 1000 mg every 8 hours for 24 hours after knee arthroplasty; morphine 10 mg IM as needed for rescue therapy.
214561075|NCT01365936|DRUG|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
214561076|NCT06395025|DEVICE|Insoles|Insoles At Day 0, the patient received the insoles and adapted them to his shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled a usability's questionnaire at Day14.
214561077|NCT04616872|DRUG|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
214561078|NCT04616872|DRUG|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
214561079|NCT00237731|DRUG|morphine|morphine 0.05
214706872|NCT04489537|BIOLOGICAL|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
214706873|NCT03159013|OTHER|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
214561080|NCT00237731|DRUG|morphine|morphine 0.10
214706874|NCT01343355|DRUG|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
214706875|NCT01304472|DRUG|Prasugrel|Prasugrel 10mg per day
214561081|NCT03789175|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
214561082|NCT04035902|DRUG|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
214561083|NCT04035902|DRUG|control|Ferric carboxymaltose is not administered
214706876|NCT01304472|DRUG|Clopidogrel|Clopidogrel 150mg per day
214706877|NCT00369746|DRUG|citalopram|tablets, 60 mg maximum, daily, 12 weeks
214706878|NCT06330974|OTHER|No intervention|No intervention
214706879|NCT03947255|DRUG|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
214561084|NCT00515671|BEHAVIORAL|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
215165038|NCT07060963|BEHAVIORAL|Motivational interviews within the context of a health promotion-based diabetes self-management program|The researcher provided counseling services to pregnant women to provide Diabetes Self-Management Group training based on Pender's Health Promotion Model. A group was formed consisting of at least 10 people. The training was completed face-to-face and practically, in 1 day (160 minutes), in 4 sessions, each session being 40 minutes. Motivational interviews were conducted by the researcher within the scope of the health promotion-based diabetes self-management program. A second motivational interview was planned according to the determined need and the interviews were provided. Each interview lasted approximately 40 minutes. In order to ensure continuity for the pregnant women who obtained positive behavioral outcomes, reinforcement was provided by telephone interviews and the counseling process was completed.
215165039|NCT04038580|DEVICE|Laminated Socket|This is the currently prescribed socket the participant normally wears.
214561085|NCT00515671|BEHAVIORAL|Problem Solving|Weekly problem-solving support group
215165040|NCT04038580|DEVICE|Quatro|The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
215165041|NCT04038580|DEVICE|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
214561086|NCT06479031|OTHER|Occupational Therapy|Occupational Therapy intervention, once a day, for 5 days, for 40 minutes each session.
214561087|NCT00678613|DRUG|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
214561088|NCT00678613|DRUG|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
214561089|NCT00814177|DRUG|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
214561090|NCT00814177|DRUG|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
214561091|NCT03955562|OTHER|Footbridge|Access to a pedestrian footbridge.
214561092|NCT03955562|OTHER|Comparison villages|Villages that do not receive a footbridge.
214561093|NCT03790553|RADIATION|Radiotherapy|Different total radiotherapy dose between two arms.
214561094|NCT04530097|PROCEDURE|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
214561095|NCT00288639|DRUG|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
214561096|NCT02894970|DEVICE|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
214561097|NCT02952534|DRUG|Rucaparib|Rucaparib will be administered daily
215165042|NCT04038580|DEVICE|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
215165043|NCT05616338|OTHER|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
214561098|NCT02698943|PROCEDURE|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
214561099|NCT02686177|DRUG|Liraglutide|
214561100|NCT02686177|DRUG|Metformin or sulfonylurea|
214561101|NCT02779114|DRUG|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
214561102|NCT02779114|OTHER|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
215165044|NCT07055477|DRUG|Cyclophosphamide|Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days
215165045|NCT07055477|DRUG|Fludarabine|Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days
215165046|NCT07055477|BIOLOGICAL|Autologous CCR4 CAR T cells|Day 0: Cells will be infused intravenously (IV) over 10-30 minutes
214561103|NCT02779114|OTHER|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
214561104|NCT03245853|DRUG|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
214561105|NCT04284605|OTHER|Aerobic exercise combined with strength training|30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
214561106|NCT04284605|OTHER|Yoga|60 minute yoga intervention including different asanas, breath control and meditation
214561107|NCT03691272|DEVICE|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
214561108|NCT03691272|DEVICE|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
214561109|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
214561110|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Reference)|
214706880|NCT02774044|DRUG|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
214561111|NCT02385240|DRUG|Placebo gel|
214561112|NCT03341325|OTHER|animal-assisted activity|a live animal (small dog and/or rabbit)
214706881|NCT02774044|DRUG|Survanta|
214706882|NCT06362395|RADIATION|Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)|Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
214706883|NCT00949910|DRUG|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
214706884|NCT01611766|PROCEDURE|Secondary Cytoreductive Surgery|Complete Cytoreduction
214706885|NCT01611766|DRUG|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
214706886|NCT03097614|DEVICE|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
215165047|NCT07053111|BEHAVIORAL|Wellness Intervention|Licensed counselors will provide evidence based curricula on the following: work/life balance, resilience building, stress management, self- care practices, imposter syndrome, psychological effects, compassion fatigue, peer support, and mindfulness practices.
214561113|NCT03341325|OTHER|control activity|a stuffed toy animal
214561117|NCT01014208|DRUG|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
214561118|NCT01014208|DRUG|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
214706887|NCT00444470|DRUG|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
214706888|NCT00444470|DRUG|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
214706889|NCT04197024|DEVICE|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
214706890|NCT04197024|DEVICE|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
214706891|NCT00556335|PROCEDURE|manual aspiration|air aspiration
215165048|NCT07054242|DRUG|Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab|SKB264 will be administered intravenously (IV) at a dose of 4 mg/kg every two weeks (Q2W); Pembrolizumab will be administered intravenously at a dose of 200mg every three weeks (Q3W)
215165049|NCT06685718|DRUG|BG-60366|Administered orally
215165050|NCT01922440|OTHER|No intervention|This is a non-interventional study.
214561119|NCT04651478|BEHAVIORAL|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
214561120|NCT04651478|BEHAVIORAL|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
214561121|NCT03730129|DRUG|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
214561122|NCT00133562|DRUG|Alanyl-glutamine|
214561123|NCT00133562|DRUG|Glycine|
214561124|NCT06274931|PROCEDURE|Bronchoscopy|Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
214561125|NCT04961177|OTHER|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
214706892|NCT00556335|PROCEDURE|conventional drainage|drainage, pneumocath
214706893|NCT02474823|OTHER|polysomnogram|all participants will undergo PSG for assessment of OSA
214706894|NCT02474823|OTHER|home sleep test|all participants will undergo HST for assessment of OSA
214706895|NCT02474823|OTHER|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
214706896|NCT03029949|BEHAVIORAL|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
214706897|NCT03029949|BEHAVIORAL|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
214706898|NCT03029949|OTHER|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
214706899|NCT04521309|BIOLOGICAL|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
214706900|NCT02482012|OTHER|Survey|This was a survey
214706901|NCT04048538|OTHER|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
214706902|NCT04048538|OTHER|usual standard of care|individuals will receive treatment as per the usual standard of care
214706903|NCT00606853|BEHAVIORAL|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
214706904|NCT01345370|DRUG|Temozolomide|According to sites procedures
214706905|NCT01345370|RADIATION|Radiation Therapy|According to sites procedures
214706906|NCT02406053|GENETIC|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
214706907|NCT00833677|BEHAVIORAL|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
214706908|NCT01993056|BEHAVIORAL|"FIFA 11+"|
214706909|NCT01993056|BEHAVIORAL|"no FIFA 11+"|
215165051|NCT04350138|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
215165052|NCT04350138|OTHER|Placebo|150mM sodium chloride (0.9% saline solution).
215165053|NCT06750562|BEHAVIORAL|interactive game|Interactive game supported sleep hygiene will be prepared by researchers. The game will be shared after each sleep hygiene training. The intervention is planned as 4 trainings and 4 games in total.
215165054|NCT06750666|DIAGNOSTIC_TEST|De-implementation of Urinary Dipsticks|In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
214561126|NCT04961177|OTHER|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
214561127|NCT04961177|OTHER|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
214561128|NCT05474495|OTHER|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
214706910|NCT03025893|DRUG|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
214706911|NCT03025893|DRUG|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
214561129|NCT05474495|OTHER|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
214561130|NCT03081910|GENETIC|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
214561131|NCT03081910|GENETIC|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
214706912|NCT05158179|DEVICE|Sensation testing|Sensation testing tactile aesthesiometer.
214706913|NCT04059471|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
214706914|NCT03081598|DRUG|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
214706915|NCT03081598|OTHER|Placebo|Placebo soft gelatine capsule
215165055|NCT06750666|OTHER|Usual practice with no intervention|In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
215165056|NCT05727020|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
215165057|NCT05727020|DIAGNOSTIC_TEST|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
215165058|NCT06784726|BIOLOGICAL|Odronextamab|Given IV
215165059|NCT06784726|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral or rectal swab samples
215165060|NCT06784726|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215165061|NCT06784726|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215165062|NCT06784726|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo CAR-T cell therapy
215165063|NCT06784726|PROCEDURE|Computed Tomography|Undergo PET/CT
215165064|NCT06784726|PROCEDURE|Leukapheresis|Undergo leukapheresis
215165065|NCT06784726|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214706916|NCT06380764|PROCEDURE|Greater Occipital Nerve Block|"The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance."
214561132|NCT02795403|OTHER|blood draw of 150ml, twice|
214561133|NCT02940600|DEVICE|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
214561134|NCT02940600|PROCEDURE|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
214561135|NCT04165031|DRUG|LY3499446|Administered orally
214561136|NCT04165031|DRUG|Abemaciclib|Administered orally
214561137|NCT04165031|DRUG|Cetuximab|Administered IV
214561138|NCT04165031|DRUG|Erlotinib|Administered orally
214561139|NCT04165031|DRUG|Docetaxel|Administered IV
214561140|NCT01367288|DRUG|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
214561141|NCT01367288|DRUG|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
214561142|NCT03691675|DEVICE|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
214561143|NCT04683068|BEHAVIORAL|Message comparison|Message comparison
214561144|NCT00113945|DRUG|Cinacalcet|
214561145|NCT00615875|DRUG|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
214561146|NCT00615875|DRUG|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
214706917|NCT06380764|PROCEDURE|Bilateral suboccipital intramuscular injection|Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
215165066|NCT06784726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215165067|NCT06784726|OTHER|Questionnaire Administration|Ancillary studies
215165068|NCT06784726|PROCEDURE|Biopsy|Undergo tissue biopsy
214561147|NCT03237572|DRUG|Pembrolizumab|Pembrolizumab (200 mg)
214561148|NCT03237572|DEVICE|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
214561149|NCT00621075|OTHER|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
214561150|NCT00225017|DRUG|Atazanavir|atazanavir 400 mg once daily
214561151|NCT00225017|DRUG|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs
214561152|NCT00140335|BEHAVIORAL|handwashing|
214561153|NCT01956253|DRUG|Neratinib|240 mg orally once daily
214561154|NCT04519905|DRUG|Paclitaxel plus carboplatin|Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw
214561155|NCT04519905|RADIATION|radiotherapy|Different radiotherapy dose in different groups.
214561156|NCT05877911|DRUG|Sodium Sulfate|Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.
215165069|NCT07055516|DRUG|NT-0796|Orally administered capsules
215165070|NCT07055516|DRUG|Placebo|Orally administered capsules
215165071|NCT06424522|DIETARY_SUPPLEMENT|Dietary Fiber|Receive dietary fiber
215165072|NCT06424522|PROCEDURE|Enema Administration|Undergo RRE
215165073|NCT06424522|DRUG|Loperamide Hydrochloride|Receive loperamide hydrochloride
215165074|NCT06424522|PROCEDURE|Physical Therapy|Undergo pelvic floor physical therapy
215165075|NCT06424522|OTHER|Questionnaire Administration|Ancillary studies
215165076|NCT06424522|PROCEDURE|X-Ray Imaging|Undergo abdominal film x-ray
215165077|NCT04548752|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215165078|NCT04548752|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214706918|NCT06380764|PROCEDURE|Epidural Blood Patch|Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
215165079|NCT04548752|PROCEDURE|Computed Tomography|Undergo CT scan
215165080|NCT04548752|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165081|NCT04548752|DRUG|Olaparib|Given PO
215165082|NCT04548752|BIOLOGICAL|Pembrolizumab|Given IV
215165083|NCT06428409|BIOLOGICAL|Sacituzumab tirumotecan|Given by IV infusion.
215165084|NCT06428409|DRUG|Fluorouracil (5-FU)|5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks.
215165085|NCT06428409|DRUG|Leucovorin (LV) or levoleucovorin|LV or levoleucovorin is administered by IV infusion every 2 weeks.
215165086|NCT06428409|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
214561157|NCT05877911|OTHER|Hydration|On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
214561158|NCT05877911|DRUG|Cisplatin|Infuse cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
214706919|NCT06380764|DRUG|Normal Saline 10 mL Injection|Placebo drug
215165087|NCT06428409|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
215165088|NCT06428409|DRUG|Cisplatin|Given by IV infusion.
214561159|NCT04569201|PROCEDURE|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
214561160|NCT01332630|DRUG|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
214561161|NCT01332630|DRUG|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
214561162|NCT01332630|DRUG|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
214561163|NCT01332630|DRUG|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
214706920|NCT06380764|DRUG|Lidocaine 2% Injectable Solution|Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
214706921|NCT04154657|PROCEDURE|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
214706922|NCT05739357|DEVICE|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
215165089|NCT06428409|BIOLOGICAL|Pembrolizumab|Given by IV infusion.
215165090|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
215165091|NCT06570889|DIETARY_SUPPLEMENT|Cholecalciferol D3|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
215165092|NCT06570889|OTHER|Olive oil|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
214561164|NCT03140280|DRUG|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
214561165|NCT01125631|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
214561166|NCT01125631|DRUG|Placebo|Placebo every 8 weeks (4 doses total)
214561167|NCT02981108|DRUG|HS-10296|HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
215165093|NCT06578390|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
215165094|NCT04370795|DRUG|Sirolimus|Post transplant immunosuppressant drug
215165095|NCT04370795|DRUG|Busulfan|Conditioning drug
214561168|NCT00949000|DEVICE|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
214561169|NCT04896424|PROCEDURE|cryoballoon-based pulmonary veins isolation|A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases \< -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation\<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
214561170|NCT00073268|BEHAVIORAL|Exercise|
214706923|NCT02057367|DRUG|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
214706924|NCT02057367|DRUG|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
215165096|NCT04370795|DRUG|Horse -Anti-thymocyte|Immune suppression conditioning drug
215165097|NCT04370795|DRUG|G-CSF|Used to prevent infection and neutropenic fevers caused by chemotherapy
215165098|NCT04370795|RADIATION|Total Body Irradiation (TBI)|Conditioning (only patients in Group 1 will receive TBI)
215165099|NCT02483429|DEVICE|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
215165100|NCT06826105|DRUG|Zenpep|two capsules (each containing 15000 USP units of lipase) together with nutritional supplements
215165101|NCT06826105|DRUG|Placebo|two capsules (containing placebo) together with nutritional supplements
215165102|NCT06740305|OTHER|Altitude|"Subjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA (space walks)."
214706925|NCT06418568|DEVICE|Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
214706926|NCT00278941|DRUG|Quetiapine Fumarate Sustained Release|
214706927|NCT03392441|OTHER|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
215165103|NCT06740305|DRUG|100% Oxygen|Oxygen pre-breathing prior to altitude or simulated high altitude exposure is routinely used by the Air Force, NASA and organizations such as Duke Medical Center to prevent and treat decompression sickness as well as for treatment of patients. Oxygen used for this study is medical grade.
214706928|NCT05143567|OTHER|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
214706929|NCT05143567|OTHER|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
215165104|NCT06892288|DRUG|GLM101 (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A
215165105|NCT06892288|DRUG|Placebo (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A
214706930|NCT05143567|OTHER|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
214706931|NCT02281968|DRUG|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
214706932|NCT02281968|DRUG|Placebo|
214706933|NCT04807101|DRUG|midazolam alone|elimination of fentanyl from conscious sedation
214706934|NCT02254551|DRUG|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
214706935|NCT02254551|DRUG|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
214706936|NCT02539719|DRUG|SC-003|
214706937|NCT02539719|DRUG|SC-003 in combination with ABBV-181|
215165106|NCT06892288|DRUG|GLM101 (Part B, Open-label)|IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants
215165107|NCT06896916|DRUG|Etentamig|Intravenous (IV) Infusion
215165108|NCT06896916|DRUG|Iberdomide|Oral Capsule
214706938|NCT01598207|DRUG|Marinol|5mg BID, orally for 1 month
214706939|NCT01598207|DRUG|Placebo|5mg BID, orally for 1 month
214561171|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage|The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.
214706940|NCT04678297|BEHAVIORAL|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
215165109|NCT06897267|BEHAVIORAL|The Grow to Recovery program-Short Version|"The program is based on Pathways to Recovery:A Strengths Recovery Self-help Workbook. After completing the leader training program, one peer and one professional will conduct a 10-week Grow to Recovery program-Short Version for people with mental illness. This program covers recovery concepts, strengths, and goal setting, which will be helpful for people in recovery."
214706941|NCT04678297|BEHAVIORAL|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
214706942|NCT05451472|DIAGNOSTIC_TEST|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
214706943|NCT05451472|DIAGNOSTIC_TEST|complete blood count|complete blood count
214706944|NCT05451472|DIAGNOSTIC_TEST|serum creatinine|serum creatinine
214706945|NCT05451472|DIAGNOSTIC_TEST|blood urea|blood urea
214706946|NCT05451472|DIAGNOSTIC_TEST|serum electrolyte|serum electrolyte
214706947|NCT05451472|DIAGNOSTIC_TEST|serum calcium|serum calcium
215165110|NCT07062094|DEVICE|Intragastric Balloon|The Orbera365™ IGB System is to be used in conjunction with a long-term supervised diet and behavior modification program designed to increase the possibility of long-term weight loss maintenance. The IGB is placed in the stomach and filled with sterile saline, causing it to expand into a spherical shape. The filled IGB is designed to occupy space and move freely within the stomach, potentially altering appetite and satiety to achieve weight loss.
215165111|NCT06762795|GENETIC|Genome sequencing|Neonates enrolled in this study will undergo genome sequencing with parental controls as applicable.
215165112|NCT07058519|DRUG|Osimertinib-based adaptive treatment|Participants in Cohort 1 will receive Osimertinib-based adaptive treatment (either Osimertinib monotherapy or Osimertinib plus chemotherapy) depending on ctDNA EGFRm clearance or relapse by ctDNA EGFRm dynamic monitoring, until radiological disease progression (PD) as per RECIST v1.1 or other withdrawal criteria are met.
215165113|NCT07058519|DRUG|Osimertinib 80 MG|Participants in Cohort 2 will receive Osimertinib 80 mg once daily (QD) plus pemetrexed maintenance every 3 weeks (Q3W) until radiological PD as per RECIST v1.1 or other withdrawal criteria are met.
215165114|NCT07063654|BEHAVIORAL|Heart2Heart|Heart2Heart is a mobile health program for teens with congenital heart disease. It includes information and interactive features to help teens learn about staying healthy with congenital heart disease.
215165115|NCT06172296|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214706948|NCT05451472|DIAGNOSTIC_TEST|serum phosphorus|serum phosphorus
214706949|NCT05451472|DIAGNOSTIC_TEST|parathyroid hormone level|parathyroid hormone level
214706950|NCT05451472|DIAGNOSTIC_TEST|liver function test|ALT\_AST\_Total biliruin\_total protein \_serum albumin
214706951|NCT05451472|DIAGNOSTIC_TEST|arterial blood gases|PH\_PCO2\_PO2\_HCO3\_base deficit
214706952|NCT05451472|DIAGNOSTIC_TEST|complete urine analysis|complete urine analysis
215165116|NCT06172296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215165117|NCT06172296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215165118|NCT06172296|DRUG|Carboplatin|Given IV
215165119|NCT06172296|DRUG|Cisplatin|Given IV
215165120|NCT06172296|PROCEDURE|Computed Tomography|Undergo CT scan
215165121|NCT06172296|DRUG|Cyclophosphamide|Given IV
215165122|NCT06172296|BIOLOGICAL|Dinutuximab|Given IV
215165123|NCT06172296|DRUG|Doxorubicin|Given IV
215165124|NCT06172296|PROCEDURE|Echocardiography Test|Undergo ECHO
215165125|NCT06172296|DRUG|Etoposide|Given IV
215165126|NCT06172296|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG PET
215165127|NCT06172296|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell infusion
215165128|NCT06172296|DRUG|Irinotecan|Given IV
215165129|NCT06172296|DRUG|Isotretinoin|Given PO
215165130|NCT06172296|PROCEDURE|Leukapheresis|Undergo apheresis
215165131|NCT06172296|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165132|NCT06172296|DRUG|Melphalan|Given IV
215165133|NCT06172296|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214561172|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage|The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)
214561173|NCT06028243|BEHAVIORAL|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage|The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
214561174|NCT00193232|DRUG|Docetaxel|
214561175|NCT00193232|DRUG|Bortezomib|
214561176|NCT05444582|DRUG|Levonorgestrel 52 MG Intrauterine System|"Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days."
214561177|NCT05474339|OTHER|Cardiac rehabilitation|Using Cardiac rehabilitation for patients after coronary artery bypass graft
214561178|NCT02754349|DEVICE|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
214561179|NCT05415670|DIAGNOSTIC_TEST|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
214561180|NCT01132443|DRUG|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
214561181|NCT00250445|DRUG|MK0663, etoricoxib|
214561182|NCT00250445|DRUG|Comparator: Diclofenac sodium|
214561183|NCT04571840|DIAGNOSTIC_TEST|Multiparametric MRI +/- prostate biopsy|MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
214561184|NCT04571840|DIAGNOSTIC_TEST|Biparametric MRI +/- prostate biopsy|MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
214561185|NCT02914418|DEVICE|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
214561186|NCT00003236|BIOLOGICAL|ISIS 3521|
214561187|NCT00003236|DRUG|ISIS 5132|
214561188|NCT00019552|DRUG|irofulven|
214561189|NCT03189940|BEHAVIORAL|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
214561190|NCT03189940|BEHAVIORAL|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
214561191|NCT05104359|OTHER|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
214561192|NCT04078295|DRUG|E7389-LF|E7389-LF Intravenous infusion.
214561193|NCT04078295|DRUG|Nivolumab|Nivolumab Intravenous infusion.
214561194|NCT04898959|OTHER|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
214561195|NCT03329755|OTHER|Dedicated and coordinated e-follow-up during the treatment period|"* Completion of questionnaires using an electronic tool~* Telephone follow-up between the nurse and the patient~* Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)"
214561196|NCT03329755|OTHER|Standard follow-up during the treatment period|\- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
214561197|NCT00192868|PROCEDURE|Distal protection and drug eluting stent|
214561198|NCT02937467|DEVICE|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
214561199|NCT05305729|OTHER|No intervention|No intervention
214561200|NCT01282502|DRUG|Midostaurin|50 mg BID for 8 cycles
214561201|NCT06804551|DEVICE|iovera system|Reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study.
214561202|NCT06804551|DEVICE|Radiofrequency ablation alone|An electrode at the tip of the needle sends radio waves that lesion the nerve bundles.
214561203|NCT04021979|DIETARY_SUPPLEMENT|Enteral Nutrition Powder Ensure|Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.
214561204|NCT04021979|DRUG|1.5L PEG|Low volume PEG
214561205|NCT04021979|OTHER|Self-controlled diet|Self-controlled low residue diet.
214561206|NCT04021979|DRUG|2L PEG|Normal volume of PEG
214561207|NCT02629653|DEVICE|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
214561208|NCT00663702|DRUG|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
214561209|NCT02627703|OTHER|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
214561210|NCT04940975|BEHAVIORAL|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
214706953|NCT06482580|OTHER|PNF exercise|Ankle and foot exercises practiced for 6 weeks.
214706954|NCT06482580|OTHER|Clam exercise|Hip exercise practiced for 6 weeks.
214706955|NCT06482580|OTHER|Short-foot exercise|Foot exercise practiced together for 6 weeks.
214706956|NCT02771652|BEHAVIORAL|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
214706957|NCT02771652|OTHER|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
214561211|NCT04940975|BEHAVIORAL|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
214561212|NCT00905385|BIOLOGICAL|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
214706958|NCT04157868|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
214706959|NCT04157868|DRUG|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
214706960|NCT04865185|DIAGNOSTIC_TEST|Xylocaine spray 100mg/ml|Topical application
214706961|NCT04865185|DIAGNOSTIC_TEST|Ethanol|Topical application
214706962|NCT04404023|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
214561213|NCT03354585|BEHAVIORAL|mindfulness training|A well-validated brief mindfulness-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
214561214|NCT03354585|BEHAVIORAL|non-mindfulness training|A well-validated brief meditation-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice deep breathing. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
214561215|NCT03354585|BEHAVIORAL|book-listening|Study volunteers will listen to The Natural History and Antiquities of Selborne throughout the intervention.
214561216|NCT01733173|PROCEDURE|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
214561217|NCT00579800|PROCEDURE|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
214561218|NCT06175377|PROCEDURE|Percutaneous coronary intervention|A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
214561219|NCT06175377|DRUG|Short dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
214706963|NCT04641819|DRUG|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
214706964|NCT04641819|OTHER|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
214706965|NCT02325687|PROCEDURE|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
214706966|NCT00648661|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
214706967|NCT00648661|DRUG|Lexapro® Tablets 20 mg|20mg, single dose fed
214706968|NCT01053702|DRUG|R475|IV
214706969|NCT01053702|DRUG|Placebo|Placebo
214706970|NCT03585673|DRUG|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
214706971|NCT03585673|DRUG|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
214706972|NCT01684683|DRUG|Theophylline|Theophylline 0.1 bid
214706973|NCT01684683|DRUG|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
215165134|NCT06172296|RADIATION|Radiation Therapy|Undergo radiation therapy
215165135|NCT06172296|PROCEDURE|Radionuclide Imaging|Undergo I-MIBG scan
214706974|NCT05414149|PROCEDURE|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
214561220|NCT06175377|OTHER|Long dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
214561221|NCT06175377|OTHER|Follow-up visit at 1 month|At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
214561222|NCT06175377|OTHER|Follow-up visit at 6 months|At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
214561223|NCT06175377|OTHER|Follow-up visit at 12 months|At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
214561224|NCT02767284|DEVICE|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
214561225|NCT02767284|DEVICE|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
214561226|NCT02767284|DEVICE|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
214561227|NCT02767284|DEVICE|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
214561228|NCT02767284|DEVICE|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
214561229|NCT02767284|DEVICE|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
214561230|NCT04596943|DIAGNOSTIC_TEST|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), \[68Ga\]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
214561231|NCT01498887|DRUG|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
214561232|NCT00538148|DRUG|Telithromycin|
214561233|NCT00064233|DRUG|dasatinib|
214561234|NCT01215487|PROCEDURE|Stem Cell and Mutational Assay|Laboratory blood testing
214561235|NCT01520805|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
214561236|NCT03079297|DRUG|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
214561237|NCT03079297|OTHER|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
214561238|NCT03252717|BIOLOGICAL|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
214561239|NCT00667225|DRUG|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
214561240|NCT00667225|DRUG|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
214561241|NCT05737615|DIAGNOSTIC_TEST|PET Scan|Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination
214561242|NCT05737615|DRUG|hu5B1-TCO|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
214561243|NCT05737615|DRUG|64Cu-Tz-SarAr|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
214561244|NCT05737615|DIAGNOSTIC_TEST|Pharmacokinetics|All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
214561245|NCT01502774|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
214561246|NCT01502774|DRUG|Placebo|One single intravenous bolus injection of Placebo
214561247|NCT01502774|PROCEDURE|Echocardiography|1 year after AMI
214561248|NCT03551964|DRUG|Cangrelor|"Cangrelor: IV bolus 30 µg/kg (application \< 1 minute) followed immediately by continuous infusion at 4 µg/kg. Tables to calculate bolus dose in ml and infusion (in ml per hour) rate for each body weight group will be prepared in advance and will be included in the study medication kit to accelerate treatment start.~* Cangrelor treatment will be discontinued after circulatory stabilization (but no earlier than 2 hours after infusion initiation) i.e. after systolic Blood Pressure (sBP) is maintained at the level \> 100 mmHg for one hour after the end of IABK and/or vasoactive treatment is discontinued, but no later than 4 hours after PCI,~* 30 minutes before the end of Cangrelor infusion, administration of Ticagrelor 180 mg (crushed tablets) and then dose 90 mg every 12 hours."
214561249|NCT03551964|DRUG|Ticagrelor|Ticagrelor: 180 mg loading dose - crushed tablets, 2 x 90 mg maintenance dose
214706975|NCT06068179|DRUG|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
214706976|NCT06068179|DRUG|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
214706977|NCT00171106|DRUG|valsartan|
214706978|NCT06418126|BIOLOGICAL|blood sampling before radiotherapy|A blood sample (20 ml) will be taken prior to radiotherapy
214706979|NCT06418126|BIOLOGICAL|blood sampling after the fourth radiotherapy session|A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
214706980|NCT06418126|OTHER|collection of acute toxicity (radiodermatitis)|for the entire duration of radiotherapy
214706981|NCT06418126|OTHER|collection of late toxicity|every year for 5 years
214706982|NCT06418126|OTHER|collection of disease status|throughout the study
214706983|NCT06418126|RADIATION|Radiotherapy - Breast +/- lymph node areas|40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
214706984|NCT06418126|RADIATION|Radiotherapy - Boost operating bed|10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
214706985|NCT05510609|DEVICE|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
214706986|NCT00425568|DRUG|AndroGel (Transdermal Testosterone Gel)|
214706987|NCT00407173|DRUG|HCV-796|HCV-796 1000mg single dose
214706988|NCT05066633|DRUG|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
214706989|NCT05066633|DRUG|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
214706990|NCT02030587|PROCEDURE|Radiofrequency Ablation|
214706991|NCT02030587|PROCEDURE|Laparoscopic Adrenalectomy|
214561260|NCT06776289|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be used to fill an osteotomy after endodontic microsurgery is completed.
214561261|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the Micro Hand S robot group.
214561262|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the da Vinci robot group
214561263|NCT00894205|BEHAVIORAL|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
214561264|NCT01325753|PROCEDURE|cryotherapy|Undergo CT-guided CA
214561265|NCT01325753|PROCEDURE|quality-of-life assessment|Ancillary studies
214706992|NCT01705964|DRUG|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
214706993|NCT01705964|OTHER|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
214706994|NCT04255017|DRUG|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
214706995|NCT04255017|DRUG|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
214706996|NCT04255017|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
214561266|NCT00124787|DRUG|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
214561267|NCT00124787|DRUG|Placebo|Placebo PO q 6 hours x 4 doses
215165136|NCT06172296|OTHER|Survey Administration|Ancillary studies
214561268|NCT02993406|DRUG|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
214561269|NCT02993406|DRUG|Matching placebo tablet|Patients take matching placebo tablet orally once daily
214561270|NCT03891771|DEVICE|Telemonitoring sensors|This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
214561271|NCT02295943|OTHER|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
214561272|NCT05776043|DRUG|Empagliflozin 10 MG|once daily for 6 or 9 months
214561273|NCT05776043|DRUG|Dapagliflozin 10 MG|once daily for 6 or 9 months
214561274|NCT05776043|DRUG|Placebo|once daily for 3 months
214561275|NCT02248818|DRUG|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
214561276|NCT02248818|DRUG|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
214561277|NCT04959539|PROCEDURE|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
214561278|NCT04959539|PROCEDURE|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
214561279|NCT00400998|DRUG|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~\- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
214706997|NCT04944381|BIOLOGICAL|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
214706998|NCT04944381|BIOLOGICAL|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
214706999|NCT00627770|DEVICE|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
214707000|NCT02759562|DRUG|Andecaliximab|Administered via subcutaneous injection
214707001|NCT02759562|DRUG|Placebo|Administered via subcutaneous injection
214707002|NCT02045251|DRUG|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
215165137|NCT06172296|DRUG|Temozolomide|Given PO or via NG or G tube
215165138|NCT06172296|DRUG|Thiotepa|Given IV
215165139|NCT06172296|DRUG|Topotecan|Given IV
215165140|NCT06172296|PROCEDURE|Tumor Resection|Undergo tumor resection surgery
214561280|NCT00400998|OTHER|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
214561281|NCT02953405|DRUG|Clopidogrel|
214561282|NCT06788314|DRUG|Enalapril|"Each participant will receive a dose of enalapril 5 mg once daily. If the participant doesn't have effect of the intervention after 3 months, the dose of enalapril will be increased to 10 mg daily, if the tolerance of enalapril is good. Lack of effect will be defined as unchanged or increased NRS score.~Treatment duration will be 12 months."
214561283|NCT04537013|PROCEDURE|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
214561284|NCT04537013|DEVICE|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
214561285|NCT01825928|DRUG|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
214561286|NCT01825928|DRUG|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
214561287|NCT05262517|DRUG|Rimegepant|75 mg ODT
214561288|NCT05262517|DRUG|Placebo|matching placebo
215165141|NCT06172296|DRUG|Vincristine|Given IV
215165142|NCT07055451|DRUG|B/F/TAF|Tablet for oral suspension administered
215165143|NCT04907175|BIOLOGICAL|HB-adMSCs|Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.
214707003|NCT04698109|OTHER|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
214707004|NCT04698109|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
215165144|NCT05621291|DIAGNOSTIC_TEST|NGS testing|antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
215165145|NCT06827990|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
215165146|NCT01306019|BIOLOGICAL|Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector|Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
215165147|NCT01306019|DRUG|Busulfan|3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day
214707005|NCT04698109|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214707006|NCT01697852|OTHER|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
214561289|NCT04993105|OTHER|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
214561290|NCT04993105|OTHER|exercise only|gastrocnemius and plantarstretching
214561291|NCT05163769|DEVICE|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
214561292|NCT05163769|DEVICE|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
214561293|NCT06003946|BEHAVIORAL|BreLax: Antenatal education class|An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.
214561294|NCT06003946|BEHAVIORAL|Standard care (control)|An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.
214561295|NCT02222298|PROCEDURE|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
214561296|NCT02222298|PROCEDURE|Bascom Cleft lift procedure|
214561297|NCT01708343|PROCEDURE|DIMMST|
214561298|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
214561299|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
214561300|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
214561301|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
214561302|NCT00003253|DRUG|paclitaxel|
214561303|NCT00003253|OTHER|antitumor drug screening assay|
214561304|NCT03430947|DRUG|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
214561305|NCT03430947|DRUG|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
214561306|NCT02185222|DRUG|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
214561307|NCT02185222|DRUG|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
214561308|NCT03203187|OTHER|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
214561309|NCT03203187|OTHER|No intervention|No mango intake for two weeks.
214561310|NCT01666587|DIETARY_SUPPLEMENT|Antioxidant|
214561311|NCT01666587|DRUG|Prostaglandin inhibitor (Ibuprophen)|
214561312|NCT04211597|OTHER|Control|No scar prevention or treatment.
214561313|NCT04211597|OTHER|Silicone gel|Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
214561314|NCT04211597|OTHER|microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg|4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
214707007|NCT01697852|OTHER|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
214707008|NCT01322451|DRUG|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
214707009|NCT01322451|DRUG|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
214707010|NCT00502632|DRUG|Urokinase and Dornase alfa|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
214707011|NCT00502632|DRUG|Urokinase|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
215165148|NCT01306019|DRUG|Palifermin|Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
215165149|NCT07065409|BIOLOGICAL|iPSC-EVs|iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.
214561315|NCT06190964|OTHER|Integrative medicine|Acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) and/or mind-body medicine (for example, relaxation and breathing exercises)
214561316|NCT05996432|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants will undergo Magnetic Resonance Imaging
214561317|NCT05996432|PROCEDURE|Positron Emission Tomography (PET)|Participants will undergo Positron Emission Tomography
214561318|NCT05996432|DRUG|18F-fluoromisonidazole|Given by IV
214561319|NCT03972085|OTHER|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
214561320|NCT03972085|OTHER|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
214561321|NCT04347759|BEHAVIORAL|Coaching Messages|Participants receive real-time self-management coaching messages based on the severity of their symptoms. When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad.
214561322|NCT04347759|BEHAVIORAL|Automated Daily Monitoring|Participants report daily symptoms and symptom severity. There are three categories of severity based on a numeric scale of 1 to 3 for mild symptoms, 4 to 7 for moderate symptoms, and 8 to 10 for severe symptoms.
214561323|NCT00098072|PROCEDURE|Heart Catheterization|Heart Catheterization and collection of samples
214561324|NCT04325282|DEVICE|Active rTMS|1Hz rTMS delivered for 15-20 minutes
214561325|NCT04325282|DEVICE|Sham rTMS|sham rTMS delivered for 15-20 minutes
214561326|NCT06411353|DIAGNOSTIC_TEST|MRI acquisition|Non-contrast enhanced acquisitions will be performed using a whole-body MRI scanner operating at 1.5 Tesla or greater.
214561327|NCT06411353|DIAGNOSTIC_TEST|US examination|A complete assessment of the AVF vessels is performed using advanced 3D US procedures.
214561328|NCT02662452|DRUG|GLPG2222 single dose|single ascending doses, oral suspension
214561329|NCT02662452|DRUG|Placebo single dose|single doses, oral suspension, matching placebo
214561330|NCT02662452|DRUG|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
214561331|NCT02662452|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
214561332|NCT03806881|DEVICE|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
214561333|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
214561334|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
214561335|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
214561336|NCT00545194|DRUG|Prostaglandin E2|
214561337|NCT01628562|DRUG|Esmolol|Esmolol 50 mcg/kg/min
214561338|NCT01628562|DRUG|Remifentanil|Remifentanil 0.5 mcg/kg/min
215165150|NCT06770855|PROCEDURE|Total consolidative MPDT|After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and/or radiotherapy (SAbR or other definitive radiotherapy).
214707012|NCT03015025|GENETIC|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
214707013|NCT03487328|PROCEDURE|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
214707014|NCT02401087|PROCEDURE|Anaesthesiological procedure|
214707015|NCT04142749|DRUG|Oltipraz|Total 90mg, By mouth, TID
214707016|NCT04142749|DRUG|Placebos|Total 90mg, By mouth, TID
214707017|NCT02152358|DRUG|Aciclovir|Intravenous 15 mg/kg/d during 14 days
214707018|NCT02152358|DRUG|Ganciclovir|intravenous 10 mg/kg/d for 14 days
215165151|NCT07065929|DIETARY_SUPPLEMENT|Early nutritional management|"The food ingested by patients is collected until the day 7 of the stroke so that dieticians can calculate their needs and provide a suitable diet. If this is not sufficient, a reinforced nutrition strategy (meal enrichment) is implemented.~On day 5 of the stroke, if energy intake is less than 2/3 of the energy objectives, the strategy is switched to level 2, unless it is possible to increase intake within 48 hours."
215165152|NCT07062419|DEVICE|endoactivator|activation of irrigant during root canal treatment
215165153|NCT07062406|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|8 weekly sessions delivered by federally qualified health center behavioral health provider focusing on stimulus control, sleep restriction, and cognitive therapy
215165154|NCT07062406|OTHER|Usual care for diabetes management|Usual clinical care for management of diabetes (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
215165155|NCT07062406|OTHER|Usual care for treatment of insomnia|Usual clinical care for treatment of insomnia (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
215165156|NCT07062198|DRUG|Combined metabolic activators|A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.
214707019|NCT02152358|DRUG|Placebo|
214707020|NCT01001858|OTHER|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
214707021|NCT00387348|DRUG|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
215165157|NCT07062198|OTHER|Collagen and maltodextrin|As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.
215165158|NCT07063498|BEHAVIORAL|Coughing Maneuver|1\. Voluntary Coughing Maneuver (Hileli Öksürük): Patients in this group were instructed to perform a voluntary coughing maneuver immediately prior to the percutaneous biopsy procedure. The maneuver was demonstrated by the clinician, and patients were asked to perform 2-3 forceful coughs while in the biopsy position, 30 seconds before needle insertion, to reduce anxiety and procedural pain perception.
215165159|NCT07063498|BEHAVIORAL|Stress ball|2\. Stress Ball Intervention: Patients were given a standard-sized rubber stress ball to hold and repeatedly squeeze during the entire percutaneous biopsy procedure. The intervention began 1 minute before needle insertion and continued until the procedure was completed. The aim was to provide a behavioral distraction to alleviate anxiety and pain.
215165160|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
215165161|NCT02954432|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
215165162|NCT02954432|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
215165163|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).
215165164|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.
215165165|NCT05417594|DRUG|AZD9574|Participants will receive AZD9574 orally.
215165166|NCT05417594|DRUG|Temozolomide (TMZ)|Participants will receive temozolomide orally.
215165167|NCT05417594|DRUG|[11C]AZ1419 3391|Participants will receive \[11C\]AZ1419 3391 intravenously.
215165168|NCT05417594|DRUG|Trastuzumab Deruxtecan (T-DXd)|Participants will receive T-DXd intravenously.
215165169|NCT05417594|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Participants will receive Dato-DXd intravenously.
214561339|NCT06509373|BEHAVIORAL|Advance Care Planning Tool - ACPVoice|Eligible patients will be sent a secure MyChart message with a motivational message asking them to complete the advance care planning tool (ACPVoice) with their care partner/surrogate decision-maker or loved one before their upcoming primary care visit. The ACPVoice tool will be attached electronically to the mychart message. A reminder message will be sent to an non-responders with a different motivational message.
214561340|NCT06509373|BEHAVIORAL|Standard of Care for Advance Care Planning|Patients will have access to the standardized advance care planning questionnaires readily available already within their mychart account which is part of standard of care.
214561341|NCT00144352|DRUG|sulfadoxine-pyrimethamine|
214561342|NCT06534983|DRUG|Autogene Cevumeran|Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
214561343|NCT06534983|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
214561344|NCT06534983|DRUG|Saline|Saline solution for IV infusion
214561345|NCT03901599|OTHER|Alveolar ventilation monitoring estimated by the capnographic ventilation|Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
214561346|NCT06569303|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
214561347|NCT06569303|BEHAVIORAL|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
214561348|NCT04586231|DRUG|Belzutifan|Immediate-release 40 mg tablet
214561349|NCT04586231|DRUG|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
214707022|NCT00387348|DRUG|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
214707023|NCT05094895|PROCEDURE|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
215165170|NCT06769165|OTHER|EMDR therapy|In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.
214561350|NCT04586231|DRUG|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
215165171|NCT06886126|DRUG|HDM1005 injection or placebo|HDM1005 injection subcutaneous injection QW for 22weeks
215165172|NCT07068776|DEVICE|Shockwave treatment|The shockwave device will be set to an energy flux density of 0.1 mJ/mm² at 5 Hz, with approximately 25 impulses per centimeter of wound length. This means that one centimeter of the wound will be treated for 5 seconds. The shockwave treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
215165173|NCT07068776|DEVICE|Sham treatment|The applicator will not be connected to the shockwave device. The applicator treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
215165174|NCT05302908|BEHAVIORAL|NuestraSaludSegura|It blends peer navigation and mHealth
215165175|NCT06208735|BIOLOGICAL|CLIC-2201|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.
215165176|NCT07065227|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
215165177|NCT07065227|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
214561351|NCT01012401|OTHER|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
214561352|NCT00527787|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
214561353|NCT00527787|DRUG|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
214561354|NCT05017662|OTHER|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
214561355|NCT02562443|DRUG|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
214561356|NCT02562443|DRUG|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
214561357|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
214561358|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC).
214561359|NCT04406415|DRUG|Nafamostat Mesilate|Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days
214561360|NCT04406415|DRUG|Placebo|Oral placebo administered three times daily for up to 5 days
214561361|NCT01831947|BIOLOGICAL|Ranibizumab|
214561362|NCT05189210|DRUG|GV1001 Placebo|0.9% normal saline
214561363|NCT05189210|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
214561364|NCT05189210|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
214561365|NCT03330405|DRUG|Avelumab Phase 1b|Avelumab
214561366|NCT03330405|DRUG|Talazoparib Phase 1b|Talazoparib
214561367|NCT03330405|DRUG|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
214561368|NCT03330405|DRUG|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
214561369|NCT05026762|OTHER|Treatment|Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
214561370|NCT01228331|DRUG|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
214707024|NCT05094895|PROCEDURE|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
214707025|NCT04579796|OTHER|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
214707026|NCT04579796|PROCEDURE|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
214707027|NCT03010722|DRUG|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
214707028|NCT05905757|PROCEDURE|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
214707029|NCT05905757|DRUG|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
214707030|NCT06180668|PROCEDURE|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
214707031|NCT03515018|DRUG|hydroxyurea|pulse therapy
214707032|NCT03515018|DRUG|Imatinib|400mg qd PO per day
214707033|NCT00944788|OTHER|qi-gong|Physical activity similar to tai-chi
214707034|NCT02501837|DRUG|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
215165178|NCT04622150|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
214561371|NCT01228331|DRUG|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
214561372|NCT01228331|DRUG|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
214561373|NCT01228331|DRUG|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
214561374|NCT01228331|DRUG|Daunorubicin hydrochloride|part of induction and reinduction therapy
214561375|NCT01228331|DRUG|Dexamethasone|part of reinduction therapy
214561376|NCT01228331|DRUG|Doxorubicin hydrochloride|part of reinduction therapy
215165179|NCT04622150|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
214561377|NCT01228331|DRUG|Etoposide phosphate|part of different chemotherapy blocks
214561378|NCT01228331|DRUG|Mercaptopurine|part of different chemotherapy blocks
214561379|NCT01228331|DRUG|Methotrexate|part of different chemotherapy blocks
214561380|NCT01228331|DRUG|Methylprednisolone|part of different chemotherapy blocks
214561381|NCT01228331|DRUG|Pegaspargase|part of different chemotherapy blocks
214561382|NCT01228331|DRUG|Thioguanine|part of different chemotherapy blocks
214561383|NCT01228331|DRUG|Vincristine sulfate|part of intravenous chemotherapy
214561384|NCT01228331|RADIATION|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
214707035|NCT05304572|DIAGNOSTIC_TEST|Multi-Detector CT angiography|Multiphasic CT within 4 weeks interval prior to TACE will be done including non-enhanced, arterial, portal and venous phases using IV bolus injection of a 75-100-mLiodinated contrast material iopamidol at a rate of 3.0 mL/s. The images of arterial phase will be transferred to workstation to produce 3D angiographic reconstruction images .
214707036|NCT05304572|PROCEDURE|Trans-arterial chemoembolization and DSA|Percutaneous arterial access is achieved through the common femoral artery (19 G needle) under local anesthesia with placement of a 5-Fr sheath. A 5-Fr Cobra (C2) or sidewinder (SIM1) catheter was used for catheterizing the coeliac trunk and SMA. Then celiac and superior mesenteric angiography was done by injecting 24 mL of iopamidol using forced manual injection method or using a pump at a rate of 6 mL/s according to the operator preferences.Then a microcatheter was used for selective and super-selective access of the hepatic arteries. The micro-catheter was placed in the feeding artery as close as possible to the tumor.The chemotherapeutic drugs (Doxorubicin 50 mg) solved within 5 ml of iodinated non-ionic contrast media and then mixed with 10 ml of iodized oil (lipiodol) will be delivered through the feeding hepatic artery and then embolized using Poly-vinyl Alcohol (PVA) particles.
214707037|NCT05138341|DEVICE|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
214561385|NCT02643303|DRUG|Durvalumab|
214561386|NCT02643303|DRUG|Tremelimumab|
214561387|NCT02643303|DRUG|Poly-ICLC|
214561388|NCT06321601|DRUG|Avacopan|Oral administration
214561389|NCT00767390|DEVICE|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
214561390|NCT02783027|BEHAVIORAL|SleepTrackTXT2|Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
215165180|NCT06894498|OTHER|No Intervention: Observational Cohort|No Intervention, Observational Cohort
214707038|NCT01755741|COMBINATION_PRODUCT|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
215165181|NCT05463289|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
214561391|NCT06799247|BIOLOGICAL|Decartes-08|Autologous mRNA CAR T-cell therapy
214561392|NCT06799247|OTHER|Placebo Drug|infusion without Decartes-08
214707039|NCT01755741|DEVICE|Condom|Male condom
214707040|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
214707041|NCT04645823|DRUG|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
214707042|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
214707043|NCT00278863|DRUG|S-1|
214707044|NCT00278863|DRUG|Capecitabine|
214707045|NCT01351311|OTHER|Exercise|Resistance Training exercise with swiss ball
214707046|NCT01351311|OTHER|Drug treatment|Drug treatment
215165182|NCT07067138|DEVICE|Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT)|This is a computational algorithm that takes RNA-seq data from tumor FFPE blocks and, given a list of pre-specified treatments, generates as output the predicted responses to those treatments.
215165183|NCT07067138|DEVICE|TruSight(R) Oncology 500|TSO500 uses formalin-fixed, paraffin-embedded (FFPE) tumor blocks to generate a 523-gene DNA panel (with tumor mutational burden and microsatellite instability) to assess for biomarkers linked to FDA-approved, on-label therapies as well as whole-exome RNA-seq that can be used with the ENLIGHT algorithm.
214561393|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
214561394|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
214561395|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
214561396|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
214561397|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
214561398|NCT02762643|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
214561399|NCT02762643|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
214561400|NCT02762643|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
214561401|NCT03389373|DEVICE|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
214561402|NCT03916796|OTHER|Exercise|-The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
214561403|NCT03916796|OTHER|Enhanced Recovery after surgery|-The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
214561404|NCT03916796|OTHER|Psychological screening with counselling services as needed|-The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
214561405|NCT03916796|OTHER|Dietary Counseling Services|-Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
214561406|NCT01485497|DEVICE|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
214561407|NCT06159699|OTHER|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
214707047|NCT03421509|OTHER|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
214707048|NCT05066867|OTHER|Smart sharps bin - collects data on compliance|collects compliance data
214707049|NCT04145869|PROCEDURE|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
214707050|NCT00505752|DRUG|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
214707051|NCT00505752|DRUG|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
214707052|NCT00505752|DRUG|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
214707053|NCT00505752|DRUG|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
214707054|NCT00505752|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
214707055|NCT02349737|OTHER|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
214707056|NCT03288740|DRUG|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
214707057|NCT03288740|DRUG|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
214561408|NCT06159699|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
214561409|NCT05532514|OTHER|MICRONUCLEI COUNT|MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
214561410|NCT06834594|DRUG|Micronized progesterone 200 MG|Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle
214561411|NCT06834594|DRUG|Micronized Progesterone 100 MG|Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
214561412|NCT02474719|OTHER|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
214561413|NCT00210145|BEHAVIORAL|Aesthetic care|
214561414|NCT03151070|OTHER|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants"
214561415|NCT03282825|DRUG|Decitabine|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
214707058|NCT03288740|DRUG|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
214707059|NCT03288740|DRUG|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
214561416|NCT03282825|DRUG|Paclitaxel|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
214561417|NCT02184975|PROCEDURE|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
214561418|NCT02184975|PROCEDURE|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
214561419|NCT01598662|DEVICE|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
214561420|NCT00002107|DRUG|Aldesleukin|
214561421|NCT01093677|DRUG|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
214561422|NCT01093677|DRUG|Placebo|Oral solution placebo BID for 14 days.
214561423|NCT04941053|DIAGNOSTIC_TEST|laboratory test|seroprevalnce
214561424|NCT06503302|DIAGNOSTIC_TEST|ultrasound Doppler function detection|Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
214561425|NCT04689945|DRUG|Morphine|"PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol"
214707060|NCT04662411|DIETARY_SUPPLEMENT|Placebo|acute intake of 0 mg butyrate and hexanoate
214707061|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
214561426|NCT04689945|PROCEDURE|Erector Spinae Block|"PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
214561427|NCT04689945|DRUG|Control|"PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
214561428|NCT03898167|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
214561429|NCT03898167|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
214561430|NCT03898167|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
214561431|NCT02203526|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
214561432|NCT02203526|DRUG|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
214707062|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
214561433|NCT02203526|BIOLOGICAL|Rituximab|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
214707063|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
214707064|NCT03989856|DEVICE|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
214707065|NCT03989856|DEVICE|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
214707066|NCT00933192|DEVICE|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
214707067|NCT03046017|DEVICE|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
214707068|NCT03046017|OTHER|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
214561434|NCT02203526|DRUG|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
214707069|NCT03046017|OTHER|Control cream|A neutral cream will be applied as a control.
214707070|NCT04163107|DRUG|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
214707071|NCT04163107|DRUG|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
214707072|NCT04163107|DRUG|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
214707073|NCT00232505|BIOLOGICAL|cetuximab|Given IV
214707074|NCT00232505|DRUG|carboplatin|Given IV
214707075|NCT01646463|BEHAVIORAL|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
214707076|NCT01646463|BEHAVIORAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
214561435|NCT02203526|DRUG|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
214561436|NCT02203526|DRUG|Ibrutinib (Arms 2, 3 and 4)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
214561437|NCT02203526|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
214561438|NCT02203526|DRUG|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
214561439|NCT02203526|DRUG|Ibrutinib (Arm 4)|Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
214561440|NCT05245591|DRUG|Pentosan Polysulfate Sodium 100 MG Oral Capsule|Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
214561441|NCT05245591|DRUG|Placebo|Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
214707077|NCT02051738|DRUG|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
214707078|NCT02051738|DRUG|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
214707079|NCT00022958|DRUG|Iodine-131 Anti-B1 Antibody|
214707080|NCT04618926|DEVICE|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
214707081|NCT03457480|OTHER|Computer-Assisted Intervention|Read computer messages
214707082|NCT03457480|BEHAVIORAL|Focus Group|Attend focus group
214707083|NCT03457480|OTHER|Informational Intervention|Receive text messages
214707084|NCT03457480|OTHER|Survey Administration|Complete surveys about experience
214707085|NCT05129761|DRUG|Syrup Hydryllin|( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
214707086|NCT06308146|DIETARY_SUPPLEMENT|Bacillus subtilis ATCC 122264|One capsule (5 billion CFU) per day for 8 weeks.
214707087|NCT06308146|DIETARY_SUPPLEMENT|Placebo|One capsule per day for 8 weeks.
214707088|NCT05987345|DEVICE|PEF|PEF device treated in the trial.
214707089|NCT05987345|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
214707090|NCT01925612|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
214707091|NCT01925612|DRUG|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
214707092|NCT01925612|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214707093|NCT01925612|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
214707094|NCT01925612|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214707095|NCT01925612|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
214707096|NCT01925612|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214707097|NCT02591888|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
214561442|NCT02593799|PROCEDURE|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
214561443|NCT00455897|DRUG|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
214561444|NCT00455897|DRUG|CHOP|Administered as part of standard care
214561445|NCT00455897|DRUG|Rituximab|Administered as part of standard treatment
214561446|NCT01607151|OTHER|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
214561447|NCT01607151|OTHER|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
214561448|NCT02646956|OTHER|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
214561449|NCT04478253|DEVICE|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
214561450|NCT00998842|DEVICE|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
214561451|NCT00998842|DEVICE|GE 5000 ECG Monitor System|Wired ECG system
214561452|NCT00343551|DRUG|Aliskiren|
214561453|NCT00004449|BEHAVIORAL|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
214561454|NCT00004449|BEHAVIORAL|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
214561455|NCT05164380|OTHER|Picture naming tasks|PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
214561456|NCT06177392|PROCEDURE|Secondary TAVI access|The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
214561457|NCT06052358|DEVICE|LAAC with Watchman FLX device|LAAC with Watchman FLX device
214561458|NCT04259827|OTHER|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
214561459|NCT04259827|OTHER|Aspecific online games|Online gaming without cognitive training
214561460|NCT05048212|DRUG|Nivolumab|Given by IV
214561461|NCT05048212|DRUG|Ipilimumab|Given by IV
214561462|NCT05048212|DRUG|Cabozantinib|Given by IV
214561463|NCT05177354|DEVICE|Inceptiv|Implantable Neurostimulator with Neuro Sense
214561464|NCT05817240|DRUG|taladegib|100 mg per tablet, dosed once daily
214561465|NCT05817240|DRUG|nintedanib|100 mg per capsule, dosed once daily
214561466|NCT05318859|OTHER|Pharmacopuncture|Registry (observational study)
214561467|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (10G-A)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
214561468|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (20G-A)|Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
214561469|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-A)|Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
214561470|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-B)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth three times per day (30 total grams of R-1,3-Butanediol) for 12 weeks, with a possible additional 12 week extension
214561471|NCT05141643|DIAGNOSTIC_TEST|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
214561472|NCT03469401|OTHER|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
214561473|NCT05444205|BEHAVIORAL|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
214561474|NCT05444205|BEHAVIORAL|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
214561475|NCT05444205|BEHAVIORAL|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
214561476|NCT05444205|BEHAVIORAL|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
214561477|NCT05444205|BEHAVIORAL|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
214561478|NCT05444205|BEHAVIORAL|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
214561479|NCT05444205|BEHAVIORAL|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
214561480|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
214561481|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
214561482|NCT02342938|PROCEDURE|MEG or fMRI And INtracranial EEG|
214561483|NCT02342938|PROCEDURE|fMRI|
214561484|NCT04542733|DRUG|Everolimus|Everolimus will be given with tacrolimus.
214561485|NCT04542733|DRUG|reduced dose tacrolimus and Leflunomide|Reduced dose tacrolimus will be given with leflunomide
214561486|NCT00462605|DRUG|entinostat|Given PO
214561487|NCT00462605|DRUG|sargramostim|Given SC
214561488|NCT00002539|BIOLOGICAL|filgrastim|
214561489|NCT00002539|DRUG|cisplatin|
214561490|NCT00002539|DRUG|doxorubicin hydrochloride|
214561491|NCT00002539|PROCEDURE|conventional surgery|
214561492|NCT04439188|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
214561493|NCT06360354|DRUG|AMG 193|Administered Orally
214561494|NCT06360354|DRUG|Gemcitabine|Administered IV
214561495|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
214561496|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
214561497|NCT06360354|DRUG|RMC-6236|Administered orally
214561498|NCT03548220|DRUG|Placebo|Placebo matching AG-348 tablets, administered to maintain the blind.
214561499|NCT03548220|DRUG|AG-348|AG-348 tablets.
214561500|NCT00501657|DRUG|Sitagliptin|100mg mane for 2 days
214561501|NCT00501657|DRUG|Placebo|100mg mane for 2 days
214561502|NCT05418634|OTHER|point of care EEG|For pocEEG, scalp electrodes are applied in five locations.
214561503|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
214561504|NCT06534502|DRUG|Zonisamide Oral Product|Zonisamide oral suspension
214561505|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
214561506|NCT02906007|DRUG|Bedaquiline|Participants received bedaquiline (BDQ) once per day through intensive PK sampling visit, then 3 times per week on Monday, Wednesday and Friday through the week 24 visit.
214561507|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
214561508|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
214561509|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
214561510|NCT05703607|BIOLOGICAL|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
214561511|NCT05703607|BIOLOGICAL|Shingrix|Intramuscular injection
214561512|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
214561513|NCT03560375|BEHAVIORAL|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
214561514|NCT03560375|BEHAVIORAL|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
214561515|NCT03560375|DRUG|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
214707098|NCT02591888|DRUG|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
215165184|NCT07067138|DEVICE|TruSeq Matched Tumor Normal Whole Exome Sequencing Assay|The TruSeq Matched Tumor-Normal Whole Exome Sequencing assay is a next-generation sequencing assay that uses tumor DNA from formalin-fixed, paraffin-embedded (FFPE) tumor blocks and germline DNA drawn from blood to provide extended sequencing information on the tumor as well as any pathogenic variants, likely pathogenic variants, and variants of uncertain significance in 156 genes from the normal blood sample.
214561516|NCT04669496|DRUG|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
214561517|NCT05795855|BEHAVIORAL|ADEPT|Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
214561518|NCT05593302|BEHAVIORAL|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
214561519|NCT05764954|DEVICE|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
214561520|NCT02082171|OTHER|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
214561521|NCT05550662|DRUG|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
214561522|NCT06467175|BIOLOGICAL|blood sampling for high molecular weight DNA extraction|2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
214561523|NCT01712620|DRUG|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
214561524|NCT01712620|DRUG|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
214561525|NCT05486416|DRUG|HSK3486|HSK3486 for induction of general anesthesia
214561526|NCT05486416|DRUG|Propofol|Propofol for induction of general anesthesia
214561527|NCT06400225|PROCEDURE|Biopsy Procedure|Undergo biopsy
214561528|NCT06400225|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214561529|NCT06400225|PROCEDURE|Computed Tomography|Undergo CT scan
214561530|NCT06400225|PROCEDURE|Echocardiography Test|Undergo ECHO
214561531|NCT06400225|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214561532|NCT06400225|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
214561533|NCT06400225|DRUG|Ulixertinib|Given PO
214561534|NCT06500429|DRUG|NG101|NG101 20 mg BID
214561535|NCT06500429|DRUG|Placebo|Placebo BID
214561536|NCT06500429|DRUG|Semaglutide Injectable Product|Semaglutide 0.5 or 1 mg
214561537|NCT03993262|DRUG|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
214561538|NCT03993262|DRUG|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
214561539|NCT05572021|DEVICE|Propspective VHR with Fortiva|Ventral hernia repair using Fortiva biologic mesh
214561540|NCT05572021|DEVICE|RetroSpective VHR with Strattice|Retrospective cohort of ventral hernia repair patients using Strattice mesh
215165185|NCT05559892|BEHAVIORAL|DM-CCT|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions).
214561541|NCT01946529|DRUG|vincristine|Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
214561542|NCT01946529|DRUG|doxorubicin|Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
214707099|NCT02778945|DRUG|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
214561543|NCT01946529|DRUG|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
214561544|NCT01946529|DRUG|ifosfamide|Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
214561545|NCT01946529|DRUG|etoposide|Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
214561546|NCT01946529|DRUG|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
214561547|NCT01946529|DRUG|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
214561548|NCT01946529|DRUG|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
214561549|NCT01946529|DRUG|sorafenib|Dosage and route of administration: 90 mg/m\^2/dose PO BID
214561550|NCT01946529|PROCEDURE|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
214561551|NCT01946529|RADIATION|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
214561552|NCT06385496|PROCEDURE|Biopsy Procedure|Undergo biopsy
214561553|NCT06385496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214561554|NCT06385496|PROCEDURE|Computed Tomography|Undergo CT scan
214561555|NCT06385496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214561556|NCT06385496|DRUG|Sapanisertib|Given PO
214561557|NCT05820204|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
214561558|NCT05820204|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
214561559|NCT05820204|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain
214561560|NCT06493162|PROCEDURE|Intubation|Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery
214561561|NCT06493162|DEVICE|Flow Controlled Ventilation|Patients in FCV group will be ventilated with flow controlled ventilation mode
214561562|NCT06493162|DEVICE|Volume Controlled Ventilation|Patients in VCV group will be ventilated with volume controlled ventilation mode
214561563|NCT04759976|BEHAVIORAL|Robotic motor training|The experiments consist in performing motor tasks with upper-limb robotic devices.
214561564|NCT05534425|BEHAVIORAL|GenX intergenerational mentoring program|GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
214561565|NCT03960047|BEHAVIORAL|Virtual Reality Training|This group gets trained to cross streets using virtual reality
214561566|NCT03960047|BEHAVIORAL|Streetside Training|This group is trained to cross streets based on streetside experiences
214561567|NCT02919631|DRUG|Triheptanoin|Anaplerotic dietary oil
214561568|NCT02919631|DRUG|Placebo oil|Safflower oil
214561569|NCT06511310|OTHER|Exercise|High Intensity Exercise
214561570|NCT04915820|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
214561571|NCT05177835|DRUG|ABX464|All subjects will receive ABX464 given at 25 mg QD.
214561572|NCT04218773|DRUG|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
214561573|NCT04218773|DRUG|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
214561574|NCT06507293|PROCEDURE|Paravertebral block|Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
214561575|NCT06507293|PROCEDURE|Erector spiane plane block|Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
214561576|NCT06408142|DIAGNOSTIC_TEST|HIV testing|Point of Care HIV testing universally regardless of risk factors
214561577|NCT06408142|OTHER|In-depth interview|In-depth interviews of providers using Normalization Process Theory semi-structured interview guide to assess provider perspectives of PrEP delivery in the ED
214561578|NCT07134010|OTHER|perineural injection|"Intervention The procedure will be performed by a rehabilitation physician who has obtained hospital-level credentialing and privileging to practice Perineural Injection Therapy (PIT). The physician has undergone hands-on training with Dr. Lyftogt-certified trainers in Malaysia.~PIT will be administered weekly for six week (Total 6 sessions). In addition to this intervention, patient will also receive conventional therapy which is monthly outpatient physiotherapy with supplementary home-based exercise program, and oral analgesia (except NSAIDs).~Solution: Buffered 5% dextrose.~Pre injection: Chronic constriction injury points will be identified by palpation along the shoulder's cutaneous nerves - the suprascapular, supraclavicular, axillary, musculocutaneous, and radial nerves. These points will be marked to ensure precise targeting. Taking into account these nerve pathways, the maximum injection area for this research is set at 10 sites per session."
214707100|NCT02778945|DRUG|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
214707101|NCT03331224|DEVICE|OTSC|OTSC placement
214707102|NCT03331224|DEVICE|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
215165186|NCT05559892|BEHAVIORAL|DM-UCT|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
215165187|NCT06161545|BIOLOGICAL|PD-L1 t-haNK cells|Irradiated PD-L1 t-haNK cells at a dose of 2 x 10\^9 administered via IV infusion over 30 minutes on Days 1, 5, 8, 12, and 15
215165188|NCT06161545|DRUG|pembrolizumab|400 mg administered as a 30 minute IV infusion on Day 1
215165189|NCT06161545|DRUG|N-803|15 ug/kg via subcutaneous injection on Day 1
215165190|NCT05642195|BIOLOGICAL|Montanide (Registered Trademark) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
215165191|NCT05642195|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
215165192|NCT05642195|DRUG|N-803|N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.
215165193|NCT05642195|DEVICE|Ventana PD-L1 (SP263 or SP142) assay|FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.
215165194|NCT06899802|BIOLOGICAL|MVA-BN-WEV|MVA-mBN396 (common name MVA-BN-WEV vaccine), is a highly attenuated, live recombinant virus based on the licensed viral vector MVA-BN, provided as a liquid frozen formulation. It is administered as an intramuscular injection.
215165195|NCT06899802|OTHER|Placebo|Tris-Buffered Saline (TBS) (placebo) is a clear liquid, free from visible extraneous particles. TBS is acceptable for use as a diluent and for intramuscular injection.
215165196|NCT00001168|BEHAVIORAL|Balanced diet|Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
214707103|NCT01009918|DRUG|Coreg CR®|Given orally
214707104|NCT01009918|DRUG|lisinopril|Given orally
214561579|NCT07134010|OTHER|Physiotherapy|Patients will be receiving a structured home-based exercise program and will be instructed on how to perform these exercises at home. The exercise regime will be 30 minutes, 3 times a day to enhance shoulder mobility and strength in addition to the regular monthly outpatient physiotherapy session. Oral analgesics exclude NSAIDs will be prescribed as needed to manage pain.
214707105|NCT01009918|OTHER|placebo|Given orally
214707106|NCT01271413|BEHAVIORAL|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
214707107|NCT05848180|OTHER|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
214707108|NCT05848180|OTHER|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
214707109|NCT06020573|DEVICE|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
214707110|NCT04229069|DIETARY_SUPPLEMENT|alkaline salt mixture|blood and tissue alkalinisation
214707111|NCT04229069|DIETARY_SUPPLEMENT|placebo|no blood and tissue alkalinisation
214707112|NCT01537094|DIETARY_SUPPLEMENT|Placebo|
214707113|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 250 mg once daily|
214707114|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 1,000 mg once daily|
215165197|NCT03948529|DRUG|eltrombopag|eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
215165198|NCT07057258|PROCEDURE|Endoscopic suture repair|Children receiving endoscopic suture repair of laryngeal cleft
215165199|NCT07057258|PROCEDURE|Injection laryngoplasty|Children receiving injection of the interarytenoid space for laryngeal cleft treatment
214561580|NCT02726984|DRUG|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
214561581|NCT02920112|BEHAVIORAL|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
214561582|NCT06373068|OTHER|Resuscitation orders|Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
214561583|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
214561584|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks (56 days).
214561585|NCT06603324|DEVICE|CVVHD treatment in paediatric mode with multiFiltratePRO|Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
214561586|NCT00393497|DRUG|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
214561587|NCT04482933|BIOLOGICAL|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
214561588|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
214561589|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
214561590|NCT06591221|PROCEDURE|Chuna Maintenance Therapy|"it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner."
214561591|NCT06606210|DEVICE|InnovaMatrix® AC|Weekly dressing applications
214561592|NCT04866004|BEHAVIORAL|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
214561593|NCT06817902|DEVICE|Intermittent theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
214561594|NCT06817902|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
214707115|NCT02547519|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
214707116|NCT02547519|DRUG|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
215165200|NCT07072975|OTHER|Normobaric hypoxia|Normobaric hypoxia (inspired oxygen fraction of 12.9%) applied between-sets recovery periods
214561595|NCT06986772|DRUG|[14C]TGRX-678|Healthy subjects will be given TGRX-678 240 mg orally on day 1.
214707117|NCT00634465|DEVICE|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
214707118|NCT04624672|DRUG|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
214707119|NCT04624672|DRUG|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
215165201|NCT07072975|OTHER|normoxic condition|Between-sets recovery periods under normoxic condition
215165202|NCT06829368|OTHER|Transcranial Focused Ultrasound Stimulation|Using MRI neuronavigation, the investigators will implement theta-burst tFUS in one of the four targets.
215165203|NCT05223036|PROCEDURE|Biopsy Procedure|Undergo biopsy
215165204|NCT05223036|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215165205|NCT05223036|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
215165206|NCT05223036|BIOLOGICAL|Obeticholic Acid|Given PO
215165207|NCT05223036|DRUG|Placebo Administration|Given PO
215165208|NCT05223036|OTHER|Questionnaire Administration|Ancillary studies
215165209|NCT05995353|DRUG|Risankizumab|Intravenous (IV) Infusion
215165210|NCT05995353|DRUG|Risankizumab|Subcutaneous (SC) Injection
214707120|NCT02791867|DRUG|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
214707121|NCT01216904|DRUG|nicotine patch|7 mg patches to be worn for 16 hours per day
214707122|NCT01216904|DRUG|placebo|placebo patch to be worn 16 hours per day
214707123|NCT01489761|DEVICE|percutaneous coronary intervention|drug eluting stent implantation
214707124|NCT03472040|DRUG|BCX7353|BCX7353 mg oral capsules administered once daily
215165211|NCT06025747|DRUG|Abemaciclib|Given PO
215165212|NCT06025747|PROCEDURE|Computed Tomography|Undergo CT
215165213|NCT06025747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165214|NCT06025747|RADIATION|Radiation Therapy|Undergo radiation therapy
215165215|NCT06025747|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
215165216|NCT06559891|DEVICE|TIVUS™ Renal Denervation System|Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
215165217|NCT06559891|OTHER|Sham|For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
215165218|NCT06854159|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR T-cell therapy
215165219|NCT06854159|BIOLOGICAL|Odronextamab|Given IV
215165220|NCT06561828|DEVICE|continuous Theta Burst Stimulation (cTBS)|Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).
214561596|NCT06664034|BEHAVIORAL|Multi-component reproductive health care intervention|"The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
214561597|NCT06825364|OTHER|auricular stimulation|Different points on both ears will be repeatedly stimulated with a plastic filament. This will be felt, but not be painful and should not result in lasting irritation.
214561598|NCT06293794|OTHER|Personalized Clinical Decision Support (CDS)|The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.
214561599|NCT06293794|OTHER|Traditional Clinical Decision Support (CDS)|The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
214561600|NCT02525601|DEVICE|Triathlon CR cemented|Implantation of Knee Prosthesis
214561601|NCT02525601|DEVICE|Triathlon CR uncemented|Implantation of Knee Prosthesis
214561602|NCT06200272|COMBINATION_PRODUCT|Germ and Carob Molasses Pulp added standard whole wheat breads|Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
214561603|NCT06597279|BEHAVIORAL|Web-based dialysis decision support tool|"The intervention in this study is the Kidney Care Roadmap, a web-based dialysis decision support tool designed to assist patients with advanced chronic kidney disease and their caregivers."
214561604|NCT06106542|OTHER|assessment|assessment of motor imagery on muscle oxygenation
214561605|NCT06611371|BIOLOGICAL|IVT GBS-06|Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.
214561606|NCT06611371|BIOLOGICAL|Placebo|0.9% sodium chloride
214561607|NCT06858280|DRUG|Patiromer 8400 MG [Veltassa]|Randomized patients will receive one 8.4 g packet of patiromer per day or one identical packet containing a placebo. To minimize the possibility of interference with gastrointestinal absorption of other orally administered medications, administration of patiromer will be separated by at least 3 hours from other oral medicinal products. Throughout the whole study period, the study drug will be administered every day in the morning.
214561608|NCT06858280|DRUG|Placebo|Randomized patients will receive one packet of placebo identical to that of patiromer. Following the same treatment sequence of patiromer, administration of the placebo will be separated by at least 3 hours from any other oral medicinal products. As for patiromer, the placebo will be administered every day in the morning.
214561609|NCT06297213|DRUG|R-2487|R-2487 DP
215165221|NCT06561828|DEVICE|intermittent Theta Burst Stimulation (iTBS)|Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).
215165222|NCT06561828|DEVICE|sham Theta Burst Stimulation (sham TBS)|iTBS or cTBS delivered with placebo side of A/P coil.
215165223|NCT06056024|DRUG|BI 3706674|BI 3706674
215165224|NCT06856226|OTHER|Arm 1|Short tandem repeat (STR) analysis from genomic DNA extracted from biospecimens.
215165225|NCT04972162|DEVICE|Web App Strategy Fitting|Web App Strategy fitting of hearing aids
215165226|NCT04972162|DEVICE|Standard-of-care Fitting|Standard-of-care fitting of hearing aids
215165227|NCT07071519|DRUG|Risankizumab|Risankizumab intravenous (IV) infusion
215165228|NCT07071519|DRUG|Risankizumab|Risankizumab subcutaneous (SC) injection
215165229|NCT05644951|DEVICE|Hot AXIOS system used for EPASS|EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
214561610|NCT06612710|DRUG|extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）
214561611|NCT06612710|DRUG|a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles placebo (4×10\^9 particles/kg)
214707125|NCT02072694|OTHER|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
214707126|NCT02072694|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
214707127|NCT04669145|DRUG|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
214707128|NCT02932150|DRUG|TAF|Administered orally once daily
214707129|NCT02932150|DRUG|Placebo|Administered orally once daily
214707130|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
214707131|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
214707132|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
214707133|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
214707134|NCT03064568|DRUG|Misoprostol 200Mcg Tab|4 tablets will be inserted rectally
214707135|NCT03064568|DRUG|Placebo|
215165230|NCT06356129|DRUG|Golcadomide|Specified dose on specified days
214707136|NCT04473781|PROCEDURE|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
214707137|NCT06226103|OTHER|Aerobic Exercise and Computerized Cognitive Training|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function."
214707138|NCT06226103|OTHER|Conventional Exercises and Brain health lectures|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
215165231|NCT06356129|DRUG|Placebo|Specified dose on specified days
215165232|NCT06356129|DRUG|Rituximab|Specified dose on specified days
214707139|NCT04874480|DRUG|Decitabine|Given IV
214707140|NCT04874480|DRUG|Tegavivint|Given IV
214707141|NCT04658199|DRUG|UCB0107 (bepranemab)|UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
214707142|NCT05810844|DIAGNOSTIC_TEST|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
214707143|NCT05810844|DIAGNOSTIC_TEST|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
214707144|NCT04308473|OTHER|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
215165233|NCT06356129|DRUG|Cyclophosphamide|Specified dose on specified days
215165234|NCT06356129|DRUG|Doxorubicin|Specified dose on specified days
214561612|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
214561613|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
215165235|NCT06356129|DRUG|Vincristine|Specified dose on specified days
215165236|NCT06356129|DRUG|Prednisone|Specified dose on specified days
215165237|NCT04665739|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
215165238|NCT04665739|PROCEDURE|Computed Tomography|Undergo CT
215165239|NCT04665739|DRUG|Everolimus|Given PO
215165240|NCT04665739|OTHER|Fludeoxyglucose F-18|Given FDG
215165241|NCT04665739|DRUG|Lutetium Lu 177 Dotatate|Given IV
215165242|NCT04665739|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214561614|NCT04089358|OTHER|Educational Intervention|Receive educational materials
214561615|NCT04089358|DEVICE|FitBit|Wear a Fitbit
214561616|NCT04089358|OTHER|Goal Setting|Set goals
215165243|NCT04665739|PROCEDURE|Positron Emission Tomography|Undergo PET
215165244|NCT04665739|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
215165245|NCT04665739|OTHER|Survey Administration|Ancillary studies
214707145|NCT04308473|OTHER|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
214707146|NCT00834886|DIETARY_SUPPLEMENT|Melatonin|Capsules, 3 mg, once every night
214707147|NCT00834886|OTHER|Bright light|Bright light therapy 10.000 lux by Miljølys AS
215165246|NCT05554328|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214561617|NCT04089358|OTHER|Health Promotion and Education|Receive text message about goal setting
214561618|NCT04089358|OTHER|Media Intervention|Follow Instagram group
214561619|NCT04089358|BEHAVIORAL|Telephone-Based Intervention|Receive phone call about goal setting
214561620|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
215165247|NCT05554328|PROCEDURE|Biospecimen Collection|Undergo blood collection
215165248|NCT05554328|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
215165249|NCT05554328|PROCEDURE|Computed Tomography|Undergo CT scan
215165250|NCT05554328|PROCEDURE|Echocardiography Test|Undergo ECHO
215165251|NCT05554328|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214561621|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
214561622|NCT06591091|DRUG|Clemastine Fumarate|Listed in arm/group description
214561623|NCT06591091|DRUG|Placebo|Listed in arm/group description
214707148|NCT00834886|OTHER|Placebo red light|Red light 400 lux as placebo light
214707149|NCT00834886|OTHER|Placebo capsule|Capsules containing 3 mng rice flour, once every night
214707150|NCT01596530|DRUG|Drug-AZD8931|Active drug for biological activity
214561624|NCT06604234|DIETARY_SUPPLEMENT|Probiotic|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule
214561625|NCT06604234|OTHER|Placebo|Placebo comparator containing maltodextrin
214561626|NCT06994468|DIAGNOSTIC_TEST|Flow-cytometry tetramer-based antigen-bait assay|"For tetramer assembly, recombinant biotinylated PLA2R will be incubated with either streptavidin-PE (Agilent) or streptavidin-APC (Agilent) conjugates according to the NIH protocol (https://tetramer.yerkes.emory.edu/support/protocols#10).~PBMCs will be thawed and resuspended in antibody cocktail medium containing 7.5ug APC- and PE- PLA2R tetramers. Multicolor flow cytometry will be used to identify B-cell subsets with standard technique and equipment (FACS FortessaX20, BD Biosciences and FlowJo software). PLA2R-specific B cells will be determined as Tetramer double (PE/APC) positive B cells that bind with proportional fluorescent intensities to each tetramer. Each sample will be incubated with only streptavidin-PE/APC conjugates to exclude B cells binding to the fluorochrome portion of the tetramers. T cell- and NK/NKT cell phenotyping will be assessed by FACS using ad-hoc antibody panels."
214561627|NCT00739115|OTHER|Heliox gas|Heliox gas used in conjunction with nasal CPAP
214561628|NCT00542542|PROCEDURE|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
214561629|NCT00542542|DRUG|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
214707151|NCT01596530|DRUG|Drug-Placebo|Placebo comparator for biological activity comparison
214707152|NCT06042530|DIAGNOSTIC_TEST|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
214707153|NCT06042530|DIAGNOSTIC_TEST|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
215165252|NCT05554328|DRUG|Olaparib|Given PO
215165253|NCT05554328|DRUG|Selumetinib Sulfate|Given PO
215165254|NCT00001452|DRUG|oCRH|
215165255|NCT06335979|DRUG|PIT565|In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
215165256|NCT03996005|PROCEDURE|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
215165257|NCT00044304|DRUG|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
214561630|NCT00542542|DRUG|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
214561631|NCT00542542|DRUG|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
214561632|NCT00542542|DRUG|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
214561633|NCT05702684|OTHER|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
214561634|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 1，IVI
214561635|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 2，IVI
214561636|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 3，IVI
214561637|NCT06672536|DRUG|EYLEA 2 MG|EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period
214561638|NCT06674616|OTHER|Replicating Effective Programs|Replicating Effective Programs (REP), based on Social Learning Theory and Rogers' Diffusion of Innovations, incorporates program packaging, training, and technical support
214707154|NCT06042530|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
214707155|NCT06042530|DIAGNOSTIC_TEST|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
214707156|NCT04568187|DEVICE|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
214707157|NCT04568187|DEVICE|placebo|radiofrequency with 3000 Hz
215165258|NCT00044304|DRUG|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
215165259|NCT05840159|DRUG|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
215165260|NCT05840159|OTHER|Placebo|Placebo
215165261|NCT05189925|BIOLOGICAL|gp91 Grans|Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
214561639|NCT06674616|OTHER|Coaching|Coaching is based on the Positive Behavior Interventions and Supports model, addresses staff barriers by building implementers' evidence-based practice (EBP) knowledge, self-efficacy, and skills through clinical support and feedback.
214561640|NCT06674616|OTHER|Facilitation|Facilitation addresses potential organizational barriers to delivery, including leadership support and acceptance among other staff.
214561641|NCT06997718|OTHER|RV5075A MF6793|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
215165262|NCT06780150|DRUG|Ocrelizumab|Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
215165263|NCT07076121|DRUG|BMS-986504|Specified dose on specified days
215165264|NCT07076121|DRUG|Gemcitabine|Specified dose on specified days
214561642|NCT06997718|OTHER|CO5075A|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
214561643|NCT04446728|BEHAVIORAL|Training Webinar|The training webinar is a three hour training. The purpose of the study is to implement the Psychosocial Assessment Tool (PAT) in their center.
214561644|NCT04446728|BEHAVIORAL|Training Webinar Plus Implementation Enhanced Resources (TIER)|In addition the Training Webinar, sites randomized to Strategy II will identify a Champion and will participate in monthly consultation calls in support of implementation of the PAT
214561645|NCT03004716|OTHER|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
214561646|NCT03549858|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
214561647|NCT06603363|DRUG|Rosuvastatin 40mg|Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.
214561648|NCT06603363|DRUG|Placebo|Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.
214561649|NCT06603363|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (Coronary CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.
214707158|NCT02204813|DRUG|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
214707159|NCT02204813|DRUG|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
214707160|NCT02204813|DRUG|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
214561650|NCT06603363|DIAGNOSTIC_TEST|Blood test|Blood test at baseline, 3-month, and 24-month visits.
214561651|NCT06369298|DRUG|JK07|JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
215165265|NCT07076121|DRUG|Nab-paclitaxel|Specified dose on specified days
215165266|NCT07076121|DRUG|Placebo|Specified dose on specified days
215165267|NCT06750289|COMBINATION_PRODUCT|ICS-LABA|ICS-LABA inhalation
215165268|NCT06750289|COMBINATION_PRODUCT|benralizumab|Benralizumab. SC injection.
215165269|NCT06750289|COMBINATION_PRODUCT|Placebo for Benralizumab|"Placebo for Benralizumab (aka, placebo). SC injection."
215165270|NCT01747213|DRUG|BNC|
215165271|NCT01747213|OTHER|Placebo|Microcrystalline cellulose fiber
215165272|NCT07129226|OTHER|Smart Watch|Participants will be asked to wear the smartwatch daily, for at least 12 hours per day during the 12-week study period, with breaks to recharge the watch as needed.
215165273|NCT07134231|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
215165274|NCT07134231|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
215165275|NCT07134231|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
215165276|NCT07134231|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
215165277|NCT06359041|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
214561652|NCT06369298|DRUG|Placebo|0.9% sodium chloride
214561653|NCT07015385|DEVICE|Lip Bumper with Integrated Distal Shoe|This novel appliance integrates a traditional lip bumper with a distal shoe extension designed to engage the mesial surface of the unerupted second permanent molar. The goal is to prevent mesial movement of the first molars and guide proper eruption of the second molars while simultaneously addressing anterior deep bite by eliminating lip pressure and promoting vertical incisor development. The device will be custom-fabricated for each participant and will be worn for 12 months, with clinical and radiographic evaluations conducted every 6 weeks.
214561654|NCT07015385|DEVICE|Conventional Lip Bumper|The conventional lip bumper is an interceptive orthodontic appliance used to alleviate lower anterior crowding, eliminate perioral muscle pressure, and promote dental arch expansion. It does not include a distal shoe component and therefore offers no guidance for second molar eruption. This device will also be custom-fabricated and worn for 12 months, with scheduled monitoring every 6 weeks to assess treatment progress and compare outcomes with the experimental device.
214561655|NCT03446001|DRUG|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
214561656|NCT03446001|DRUG|Control|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
215165278|NCT06121297|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
215165279|NCT07076394|BEHAVIORAL|Forgiveness Education|"The curriculum will apply the textbook of Forgiveness is a Choice: A Step-by-Step Process for Resolving Anger and Restoring Hope written by Dr. Robert Enright."
215165280|NCT04086485|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
215165281|NCT04086485|DRUG|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
215165282|NCT04086485|DIAGNOSTIC_TEST|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
214707161|NCT02204813|DRUG|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
215165283|NCT04086485|DIAGNOSTIC_TEST|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
214561657|NCT03446001|DRUG|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
214561658|NCT03987295|DRUG|AL001|60 mg/kg of AL001 every 4 weeks
214561659|NCT04432571|BEHAVIORAL|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
214561660|NCT04432571|BEHAVIORAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
214561661|NCT04432571|BEHAVIORAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
214561662|NCT04432571|BEHAVIORAL|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
214561663|NCT04432571|BEHAVIORAL|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
214707162|NCT05521464|OTHER|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
215165284|NCT04086485|DRUG|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
215165285|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
215165286|NCT07077070|DEVICE|Standard Electrical Categorical Loudness Scaling task (Standard-ELS)|The Standard-ELS task is conducted using the Mobile Research Application within the Nexus Research system. It is completed in two phases: the first phase identifies the lower and upper bounds of the loudness range based on participant ratings, while the second phase collects data from stimulations delivered within the established range.
215165287|NCT07077070|DEVICE|Fast Electrical Categorical Loudness Scaling task (Fast-ELS)|The Fast-ELS task employs an algorithm to estimate the lower and upper bounds of the loudness range using a limited number of samples. This range is then refined by collecting additional samples across various loudness categories for comprehensive coverage.
215165288|NCT05340582|DRUG|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
215165289|NCT05340582|DRUG|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
215165290|NCT05340582|OTHER|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
215165291|NCT03761173|DEVICE|FlowTriever System|Thrombectomy
215165292|NCT03761173|DRUG|Anticoagulation Agents|Anticoagulation medication
215165293|NCT05904080|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215165294|NCT05904080|DRUG|Cabozantinib S-malate|Given PO
215165295|NCT05904080|PROCEDURE|Computed Tomography|Undergo CT scan
215165296|NCT05904080|BIOLOGICAL|Ipilimumab|Given IV
215165297|NCT05904080|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165298|NCT05904080|BIOLOGICAL|Nivolumab|Given IV
215165299|NCT05849298|DRUG|AAA617|Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
215165300|NCT05849298|DRUG|AAA517|Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
214707163|NCT05521464|OTHER|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
214561664|NCT04432571|BEHAVIORAL|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
214707164|NCT02765503|RADIATION|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
214707165|NCT03874351|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
214561665|NCT06693752|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]|Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
214561666|NCT06596135|DRUG|Setmelanotide|Open-label daily injections of setmelanotide
214561667|NCT06533657|DRUG|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)|Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
214707166|NCT01510223|DIETARY_SUPPLEMENT|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
214707167|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
214707168|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
214707169|NCT01510223|DIETARY_SUPPLEMENT|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
214707170|NCT00004696|DRUG|morphine|
215165301|NCT05849298|DRUG|Piflufolastat F 18|Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
215165302|NCT05849298|DRUG|ARPI|Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
215165303|NCT05849298|DRUG|ADT|as prescribed by the local investigator
215165304|NCT05849298|OTHER|Best supportive care|as prescribed by the local investigator
215165305|NCT06896045|BEHAVIORAL|Assess stress levels 4 times a day before meals (morning, noon and evening and at bedtime) using a visual analogue scale|In addition to stress assessment with the stress meter, patients will be fitted with a Continious Glucose Monitoring
215165306|NCT07076186|DRUG|Trabectedin|Given by IV Infusion
215165307|NCT07076186|DRUG|Doxorubicin Hydrochloride|Given by IV Infusion
215165308|NCT07080320|DEVICE|MoCap|"For each subject, the displacement of markers, the deformation of regions between markers, and the evolution of angles formed by the markers during facial expressions and vertical movements will be analyzed with MoCap. These will be compared between the two age groups (18-33 years vs. 50-65 years) using a MANOVA model. The reference values for marker displacement will be defined by the interval between the 2.5% and 97.5% percentiles of the values for each marker. If the distribution is Gaussian, the percentiles will be derived from the standard normal distribution; otherwise, the non-parametric method will be used.~The intervention will be Interventions :~* Recruitment of healthy and pathological subjects.~* Full-face and macro images of the periorbital region~* Measurement of periorbital skin properties using MoCap and standard reference tools.~* Application of a tightening product (aloe vera) and periorbital massage.~* Measurement of skin response to a vertical jump."
215165309|NCT07081243|DEVICE|Symplicity Spyral Renal Denervation System|Symplicity Renal Denervation
214561668|NCT06696079|DRUG|Early Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.
214561669|NCT06696079|DRUG|Late Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.
214561670|NCT06689267|DIAGNOSTIC_TEST|computed tomography myocardial perfusion|The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.
214707171|NCT02147496|OTHER|Dietary Intervention|
214707172|NCT00074802|DRUG|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
214707173|NCT00074802|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
214707174|NCT00225680|DEVICE|drug eluting coronary stent|
214707175|NCT02846805|PROCEDURE|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
214707176|NCT05082298|BEHAVIORAL|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
214707177|NCT05082298|BEHAVIORAL|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
214707178|NCT05852730|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
214707179|NCT05852730|DRUG|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
214707180|NCT04016688|PROCEDURE|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
214707181|NCT01877785|DRUG|MHAA4549A|Single-ascending dose of MHAA4549A
214707182|NCT01877785|DRUG|Placebo|Placebo to MHAA4549A
214707183|NCT00561613|OTHER|SILCS and lubricant|
214707184|NCT00561613|OTHER|SILCS and spermicide|
214707185|NCT03007719|DRUG|Fluorine F 18 Ara-G|Given IV
214707186|NCT03007719|PROCEDURE|Positron Emission Tomography|Undergo PET/MR imaging
214707187|NCT03007719|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR imaging
214707188|NCT04547998|DEVICE|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
215165310|NCT07075237|DRUG|Paliperidone Palmitate Injection (PP1M)|"Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment).~To avoid missed doses, administration is permitted ±7 days around the scheduled monthly date."
215165311|NCT06783647|DRUG|LBL-024 for Injection|intravenous infusion.
215165312|NCT06783647|DRUG|Docetaxel Injection|intravenous infusion.
215165313|NCT06783647|DRUG|Bevacizumab Injection|intravenous infusion.
215165314|NCT06783647|DRUG|Pemetrexed Disodium for Injection|intravenous infusion.
215165315|NCT06783647|DRUG|Paclitaxel Injection|intravenous infusion.
215165316|NCT06783647|DRUG|Carboplatin Injection|intravenous infusion.
215165317|NCT07078604|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
215165318|NCT07078604|DRUG|Cisplatin|Given cisplatin
215165319|NCT07078604|PROCEDURE|Computed Tomography|Undergo CT scans
215165320|NCT07078604|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT-guided biopsy
215165321|NCT07078604|DRUG|Docetaxel|Given docetaxel
215165322|NCT07078604|DRUG|Doxorubicin|Given doxorubicin
215165323|NCT07078604|DRUG|Eribulin|Given eribulin
215165324|NCT07078604|DRUG|Paclitaxel|Given paclitaxel
215165325|NCT07078604|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given liposomal doxorubicin
215165326|NCT07078604|BIOLOGICAL|Sargramostim|Given ID
215165327|NCT07078604|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided biopsy
215165328|NCT07078604|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215165329|NCT07078604|DRUG|Carboplatin|Given carboplatin
215165330|NCT07078604|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
215165331|NCT07080762|DEVICE|antimicrobial photodynamic therapy (aPDT) after non-surgical therapy|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-non-surgical site for 60 seconds to promote disinfection Other Name: antimicrobial photodynamic therapy (aPDT) after non surgical therapy
215165332|NCT06834347|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
215165333|NCT06834347|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
214561671|NCT06689267|PROCEDURE|Invasive Coronary Angiography|Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.
214561672|NCT02030613|GENETIC|Blood test|
214561673|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
214561674|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
214561675|NCT07025811|DRUG|Vevye®|Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.
214561676|NCT07025811|DRUG|Xiidra®|Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.
214561677|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
214561678|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
214561679|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
214561680|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
214561681|NCT07030166|OTHER|No intervention measures were used.|The exposure factors were the perioperative related operations experienced by the patients and their individual conditions
214561682|NCT06877793|DIAGNOSTIC_TEST|Administration of indocyanine green (ICG) and fluorescence imaging|Patients with clinical and lab findings consistent with a diagnosis of NSTI who consent to this study will receive a one-time, weight-appropriate dose of ICG (0.2 mg/kg, in accordance with FDA-approved recommendations). Each patient will undergo fluorescence imaging immediately before and after administration of ICG.
215165334|NCT06834347|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
215165335|NCT07080632|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 300mg CBS per day from day 1 to day 7
215165336|NCT07080632|DRUG|Natural Calculus Bovis(NCB)|Subjects will orally receive 300mg NCB per day from day 1 to day 7
215165337|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
215165338|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
215165339|NCT06801587|DRUG|Triamcinolone acetonide plus ropivacaine|The local infiltration solution in the triamcinolone acetonide plus ropivacaine group will consist of ropivacaine and triamcinolone acetonide. For local infiltration, a total of 30mL solution will be prepared for each group, 1 ml of triamcinolone acetonide (40mg per 1ml) plus 15 ml of 1% ropivacaine diluted to 30 ml with saline as the test drug in the triamcinolone acetonide group. The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
215165340|NCT06801587|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 15ml of ropivacaine added to 15mL of saline for ropivacaine group . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
215165341|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
215165342|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
215165343|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
214561683|NCT07135479|OTHER|Youth Mental Health First Aid|This Youth Mental Health First Aid training has been adapted for South Asian American adults working with South Asian American youth. This training is a full-day, 5.25 hour blended course (some self-paced work and some live, virtual participation).
214561684|NCT07137000|OTHER|Art therapy|Five different art therapy methods (making bead jewelry, pencil drawing, painting, mandala, making clay figures) be used for people in this group.
214561685|NCT06721585|DRUG|Tecovirimat Oral Capsule [Tpoxx]|"Tecovirimat Oral Capsule 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
214561686|NCT06721585|OTHER|Standard of Care (SOC)|Participants are provided SOC for mpox
214561687|NCT07041736|DEVICE|diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
214561688|NCT07041736|OTHER|conventional irrigation|After each file use, the root canal will be irrigated with 5ml of freshly prepared 2.5% sodium hypochlorite (NaOCl) solution (Alex. Deteregents and Chemical Co., Egypt) for 1 minute using a 31-gauge Navi-Tip flexible irrigating needle (Navi-Tip, Ultradent product, South Jourdan, UT). 5 ml of 17% EDTA (Colgate Oral Care Company, Waverly, Australia) for 1 min will be used for smear layer removal. 5 ml of saline solutio
214561689|NCT07041736|DEVICE|Diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
214561690|NCT07041736|DEVICE|Ultrasonic|The needle will be operated using Satelec P5 Piezoelectric Ultrasonic Unit (Acteon, Mount Laurel, NJ, USA.) at power setting of 5. The stopper on the PiezoFlow needle will be set 1 mm short of binding in the canals, but not more than 75% of the WL. A syringe containing 5 mL of 2.5% NaOCl will be attached to the Piezoflow activation needle and the inactive needle will be inserted in the canal, and irrigant flow will be started before activation. During activation, the needle will be moved up and down passively in the canal
214561691|NCT07031388|COMBINATION_PRODUCT|1-Hydrogen peroxide and hyaluronic acid|"Hydrogen Peroxide (1.80%): Acts as an antiseptic agent, releasing oxygen that helps in reducing bacterial load and disrupting biofilms associated with gingivitis.~* Hyaluronic Acid (0.10%): A naturally occurring polysaccharide known for its anti-inflammatory and tissue-regenerative properties, aiding in the healing of gingival tissues Clinical studies have demonstrated the efficacy of Perhyal in managing gingivitis. In a randomized controlled trial, Perhyal showed a significant reduction in gingival inflammation compared to placebo, with no reported adverse effects over 21 days."
214561692|NCT07031388|COMBINATION_PRODUCT|2- Hyaluronic acid|This intervention involves the use of a mouthwash containing hyaluronic acid (0.12%) of high molecular weight, without any additional active agents. Hyaluronic acid is a naturally occurring substance known for its anti-inflammatory and wound-healing properties. It supports gingival tissue regeneration and hydration, which may contribute to reducing signs of gingivitis such as redness, swelling, and bleeding. Participants assigned to this arm will rinse with 10 mL of the solution twice daily for three weeks, following standardized oral hygiene instructions. This arm serves to evaluate the independent therapeutic effect of hyaluronic acid in managing gingival inflammation.
214707189|NCT04547998|DEVICE|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
214707190|NCT05306184|PROCEDURE|Electroconvulsive therapy (ECT)|ECT
215165344|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
215165345|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
215165346|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
215165347|NCT06139328|DRUG|BI 765845|BI 765845
215165348|NCT06139328|DRUG|Placebo matching BI 765845|Placebo matching BI 765845
215165349|NCT05800964|DRUG|AMG 305|Short-term intravenous (IV) infusion
215165350|NCT06793358|DRUG|fentanyl and Remimazolam|This is the first dental study that will combine these two sedation drugs
215165351|NCT06750913|PROCEDURE|Comparison between PCNL without Catheterization in the Split-leg Prone Position and Traditional PCNL|Before the start of PCNL, one group of patients was placed in the lithotomy position and then converted to the prone position, and one group of patients directly separated from the leg prone position without an external brace
215165352|NCT06077500|DRUG|BI 764532|BI 764532
215165353|NCT06077500|DRUG|Carboplatin|Carboplatin
215165354|NCT06077500|DRUG|Etoposide|Etoposide
215165355|NCT06077500|DRUG|Atezolizumab|Atezolizumab
215165356|NCT06077500|DRUG|Durvalumab|Durvalumab
215165357|NCT06077500|DRUG|Cisplatin|Cisplatin
215165358|NCT07084090|BEHAVIORAL|Implementation intention planning|Implementation intention planning to promote patient safety concerns
215165359|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
215165360|NCT07082803|DRUG|TLN-254|Specified dose on specified days.
215165361|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
215165362|NCT07074483|DEVICE|Upper limb rehabilitation wearable device|"The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises.~No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback."
214561693|NCT07031388|COMBINATION_PRODUCT|Chlorhexidine|This intervention uses a commercially available chlorhexidine gluconate 0.12% mouthwash, widely recognized for its strong antimicrobial properties. Chlorhexidine is considered a gold-standard agent for chemical plaque control and is effective in reducing bacterial load, gingival inflammation, and bleeding. Participants in this group will rinse with 10 mL of the solution twice daily for three weeks, in addition to maintaining regular oral hygiene practices.
214561694|NCT07031388|COMBINATION_PRODUCT|Placebo mouthwash|This placebo mouthwash was specially formulated to visually and sensorially resemble the active mouthwash products without containing any active therapeutic ingredients. It was prepared in the AwaMedica laboratory using 1 liter of distilled water, 98.5% distilled water, 2 mL of glycerin for mild viscosity, 5 mL of vanilla flavoring for taste masking, and 8 mL of brown food coloring to match the appearance of chlorhexidine. The solution was stored in 120 mL opaque brown bottles, each labeled only with the participant number to ensure blinding. Participants will use 10 mL of the placebo rinse twice daily for three weeks, following the same oral hygiene protocol as other groups.
214561695|NCT06719609|OTHER|Ankle tape|The influence of ankle tape on gait biomechanics
214561696|NCT06719609|OTHER|Standard lace-up ankle brace|The influence of lace-up ankle brace on gait biomechanics
214561697|NCT06719609|OTHER|Standard high ankle-sprain (HAS) brace|The influence of standard HAS brace on gait biomechanics
214561698|NCT06719609|OTHER|Low-profile HAS brace|The influence of low-profile HAS brace on gait biomechanics
214561699|NCT06719609|OTHER|No ankle brace or tape|The influence of no ankle tape or brace on gait biomechanics
214561700|NCT00365170|DRUG|human insulin|
214561701|NCT00365170|DRUG|insulin aspart|
214561702|NCT06724003|OTHER|Computer-based virtual reality simulation|The computer-based virtual practice simulation was created as a single scenario for oral care practice in the unconscious patient. The scenario software was created and designed by the researcher who is an IT specialist. In the formation phase of the scenario, the software was realized by working together with the researcher, the expert faculty member, the nurse and the informatics specialist for the photographs required for the virtual reality application and the steps of the scenario software.
215165363|NCT05907746|DRUG|Mycophenolate Mofetil|15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)
215165364|NCT05907746|DRUG|Tacrolimus|0.02 mg/kg IV daily starting on day +5
215165365|NCT05907746|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg IV daily on days +3 and +4
215165366|NCT05907746|RADIATION|Total Body Irradiation|200cGy on day -1
215165367|NCT05907746|PROCEDURE|Hematopoietic Cell Transplant|stem cell transplant on day 0
215165368|NCT05907746|DRUG|Briquilimab|Single 0.6 mg/kg IV infusion administered between days -13 and day -10
215165369|NCT05907746|DRUG|Cyclophosphamide|14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
215165370|NCT05907746|DRUG|Fludarabine|30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
215165371|NCT06744647|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously (SC).
215165372|NCT06744647|DRUG|Placebo|Placebo will be administered SC.
215165373|NCT07084012|DRUG|hUC-MSCs treatment (high dose)|2.0×10\^8 cells per infusion, single administration on D0. Infusion of cell medium placebo on Day 7 (±2 days), and Day 14 (±2 days).
215165374|NCT07084012|DRUG|hUC-MSCs treatment (low dose)|1.0×10\^8 cells per infusion, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
214561703|NCT06390865|PROCEDURE|Biopsy Procedure|Undergo biopsy
214561704|NCT06390865|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214561705|NCT06390865|PROCEDURE|Computed Tomography|Undergo CT scan
214561706|NCT06390865|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214561707|NCT06390865|DRUG|Sapanisertib|Given PO
214561708|NCT06726928|DEVICE|Sinus Stenting|Stenting of symptomatic sinus stenosis
214561709|NCT03004053|DEVICE|Reflectance Confocal Microscopy (RCM) endoscope device|
214561710|NCT02995759|OTHER|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
214561711|NCT06379542|DRUG|XC8|40 mg/day or 80 mg/day for 7-14 days
214561712|NCT06379542|DRUG|Placebo|2 tablets/day for 7-14 days
214561713|NCT06729632|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
214561714|NCT06729879|OTHER|Yoga eye exercises group:|Yoga eye exercises
214707191|NCT01960426|OTHER|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
214707192|NCT01960426|OTHER|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
214707193|NCT01452724|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
214707194|NCT01452724|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
214707195|NCT01452724|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
214707196|NCT01452724|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
214707197|NCT05167188|OTHER|no intervention|no intervention
214707198|NCT05133206|OTHER|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
214707199|NCT04925518|DEVICE|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
214707200|NCT04925518|DEVICE|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
214707201|NCT02252575|DEVICE|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
214707202|NCT03128385|OTHER|Intensive CIT Model Program|"Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
214707203|NCT03128385|OTHER|Distributed CIT Model Program|"Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
214707204|NCT04072172|DEVICE|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
214707205|NCT01147406|DRUG|N6022|This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
214707206|NCT01147406|DRUG|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
214707207|NCT04689841|OTHER|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
214707208|NCT04689841|OTHER|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
214707209|NCT00797485|BIOLOGICAL|bevacizumab|Given IV
214707210|NCT00797485|DRUG|capecitabine|Given orally
214707211|NCT00797485|DRUG|fluorouracil|Given IV
214707212|NCT00797485|DRUG|irinotecan hydrochloride|Given IV
214707213|NCT00797485|DRUG|leucovorin calcium|Given IV
214707214|NCT04403529|DRUG|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
214707215|NCT04403529|DRUG|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
215165375|NCT07084012|DRUG|Placebo|Cell medium, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
214561715|NCT06729879|OTHER|Myofascial release-postural correction exercises group|Myofascial release-postural correction exercises
214561716|NCT06729879|OTHER|Yoga eye exercises, myofascial release-postural correction exercises group|Yoga eye exercises, myofascial release-postural correction exercises group
214561717|NCT06729879|OTHER|control group|no intervention
214707216|NCT06145152|PROCEDURE|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
214707217|NCT06145152|PROCEDURE|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
214707218|NCT01691287|BEHAVIORAL|Michael Method|
214707219|NCT01280266|DRUG|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
214707220|NCT01913860|BEHAVIORAL|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
215165376|NCT06366750|BIOLOGICAL|barzolvolimab|subcutaneous administration
215165377|NCT06366750|OTHER|Matching Placebo|subcutaneous administration
215165378|NCT07087054|DRUG|Paltusotine|Experimental Drug: Randomized
215165379|NCT07087054|DRUG|Placebo|Matching Placebo Drug: Randomized
215165380|NCT07080866|DIAGNOSTIC_TEST|MRI|Participants will undergo a 60-minute MRI
215165381|NCT07080866|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
215165382|NCT07079098|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and the first (of five) fractions. Subsequent fractions will be delivered using standard image-guided radiotherapy (IGRT) or ART; this will be decided by the treating physician and institutional guidelines.
214561718|NCT07046260|OTHER|Blood sample collection|The study will collect up to 40 mL of whole peripheral blood in Streck Cell-Free DNA BCT® tubes from each Subject.
215165383|NCT07079098|RADIATION|SBRT|Participants will receive SBRT per standard of care in up to five fractions. Fractions will be delivered once daily or once every other day over a total period of one to two weeks.
215165384|NCT06664814|DRUG|ManNAc|2 grams twice daily by mouth
215165385|NCT07086521|BIOLOGICAL|ULSC|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1 x 10\^8 ULSC will be added to into 250 sterile saline for infusion (total volume of 260 mL volume).
215165386|NCT07086521|BIOLOGICAL|Placebo|The Placebo will be 250 ml of sterile saline for IV administration.
215165387|NCT00295113|PROCEDURE|EFR|
215165388|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
215165389|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
215165390|NCT06270875|BEHAVIORAL|ADAPT HF|ADAPT is a multicomponent, lay palliative care coach-led or self-led supportive care intervention designed to improve pain of life in individuals with advanced heart failure. Participants will complete weekly sessions of the educational programs. This program includes the following modules: pain psychoeducation, self-care and relaxation tips, social support and communication, and spirituality and meaning coping. The sessions will either be self-guided or completed with a lay coach navigator.
215165391|NCT06930625|DRUG|Debio 4126|IM injection, a 12-week extended-release formulation of octreotide
215165392|NCT06930625|DRUG|Placebo|IM injection of mannitol suspension
215165393|NCT06928051|DRUG|S-892216|S-892216 will be administered orally as a tablet.
215165394|NCT06928051|DRUG|Placebo|Placebo will be administered orally as a tablet.
215165395|NCT06930157|DRUG|Shenling Baizhu granules (TCM patent medicine)|Shenling Baizhu granules is a traditional Chinese medicine preparation in granular form. Participants in the experimental group will take 6 grams orally three times daily, before or with meals, for 6 months each year over a 2-year period. The granules contain multiple Chinese herbs including Ginseng, Poria, Atractylodes macrocephala, and other traditional ingredients. This formulation is standardized according to Chinese pharmacopoeia standards and is manufactured under GMP conditions. This intervention is being tested for its ability to prevent the recurrence of low-risk colorectal adenomas after endoscopic resection.
215165396|NCT06624930|OTHER|Behavioural Counselling|"The PA+BC group will receive a behavioural counselling support session with a QEP every two weeks during the intervention period (12 total). Of the 12 video-conferencing calls, one session will target reflective processes (instrumental/affective attitudes), five sessions will target behavioural regulation (action planning, coping planning, social support, goal setting), and four sessions will target reflexive processing (self-regulation, habit). The remaining two sessions are booster sessions to revisit topics discussed. The importance of sustaining PA for clinical outcomes (e.g., fatigue) and PA logs will be stressed. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up."
215165397|NCT06624930|OTHER|Exercise Counselling|The PA+EC group will receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. However, the focus will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines.
215165398|NCT06929221|OTHER|use of whiteboard|"Patients will be followed up for 7 days. Routine nursing care will be applied to the control group. The following information will be included on the whiteboard fixed in the patient room for the intervention group.~* Nurse's name~* Doctor's name~* Treatment times during the day~* Nursing interventions and hours for the diagnoses considered for the patient's major problems~* Timing of diagnostic and imaging techniques to be performed on the patient~* Content of appropriate discharge education for the patient~* Points to be considered by the patient before and after treatment~* Dietary considerations for the patient~* Nurse and patient's private note As a result of the data obtained, statistical analyses will be performed and interpreted to determine the effect of whiteboard use on anxiety, depression and satisfaction with nursing care in COPD patients."
215165399|NCT07083960|DRUG|OM336|OM336 is an engineered bispecific antibody directed against BCMA and CD3
215165400|NCT07085767|DRUG|Palazestrant|Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.
215165401|NCT07085767|DRUG|Letrozole-matching placebo|Participants will be treated with letrozole-matching placebo once daily on a 4-week (28 day) cycle
215165402|NCT07085767|DRUG|Ribociclib|Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.
215165403|NCT07085767|DRUG|Letrozole|Participants will be treated with letrozole 2.5 mg once daily on a 4-week (28-day) cycle
215165404|NCT07085767|DRUG|Palazestrant matching-placebo|Participants will be treated with palazestrant-matching placebo once daily on a 4-week (28-day) cycle
215165405|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
215165406|NCT03725436|DRUG|Paclitaxel|Given IV
215165407|NCT06905509|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHCT
215165408|NCT06905509|DRUG|Carboplatin|Given carboplatin
215165409|NCT06905509|DRUG|Cytarabine|Given cytarabine
215165410|NCT06905509|DRUG|Dexamethasone|Given dexamethasone
215165411|NCT06905509|BIOLOGICAL|Epcoritamab|Given SC
215165412|NCT06905509|DRUG|Etoposide Phosphate|Given etoposide phosphate
215165413|NCT06905509|DRUG|Gemcitabine|Given gemcitabine
215165414|NCT06905509|DRUG|Ifosfamide|Given ifosfamide
215165415|NCT06905509|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214561719|NCT07046494|DRUG|RAP-219|RAP-219 tablets administered orally, once daily for 21 days
214561720|NCT07046494|OTHER|Placebo|Matching placebo tablets administered orally, once daily for 21 days
214561721|NCT06889324|OTHER|Vibration therapy|Its therapy uses mechanical vibrations delivered via a specialized device called Thrive vibrator device model 717 to stimulate the calf muscles, which can help reduce the severity of restless legs syndrome and sleep disturbances among patients undergoing hemodialysis.
215165416|NCT06905509|DRUG|Oxaliplatin|Given oxaliplatin
215165417|NCT06905509|BIOLOGICAL|Rituximab|Given rituximab
215165418|NCT06904274|COMBINATION_PRODUCT|BAY865028|Intrauterine delivery system
215165419|NCT06904274|DRUG|Medroxyprogesterone acetate|Oral tablet
214561726|NCT06132256|DRUG|Axatilimab|Administered as intravenous (IV) infusion
214561727|NCT06132256|OTHER|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
214561728|NCT07103512|OTHER|Scalene Hold Relax Technique|Scalene Hold Relax Technique Scalene Hold for 10 Second 10 Repetition. Hold your arms behind your back to keep them from rising then slowly tilt your head trying to touch your ear to your shoulder. Bend your neck only as far as it is comfortable, and hold for 5 to 10 seconds. Relax your neck and repeat 2-3 times on each side. The treatment will be provided for 1-4 weeks as per need
214561729|NCT07103512|OTHER|Conventional Physical Therapy|"Diaphragmatic Breathing Exercise Inhale through nose about 4 Seconds, hold Breath for 2 Seconds, repeat 5 times, exercise repeated for 2-3 days per week followed up to 4 weeks.~\+ Buteyko Breathing Exercise Exhale slowly and then hold that breath. Use index figure and thumb to plug nose hold that breath until there is an urge to breathe and then inhale Breathe normally at least 10 second repeat several. Frequency 2-3 days per week with Moderate Intensity follow-up to 4weeks"
214561730|NCT07118527|DRUG|SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection|SHR-A1811: intravenous infusion; Adebrelimab Injection: intravenous infusion; Capecitabine Tablets: oral administration Fluorouracil Injection: intravenous infusion
214561731|NCT07118527|DRUG|Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)|Trastuzumab : intravenous infusion; Pembrolizumab: intravenous infusion; Capecitabine Tablets: oral administration; Oxaliplatin: intravenous infusion; Fluorouracil Injection: intravenous infusion; Cisplatin: intravenous infusion;
214561732|NCT00371098|BIOLOGICAL|Influenza vaccination: Influvac (SolvayPharma)|
214561733|NCT00371098|BIOLOGICAL|placebo influenza vaccine|
214561734|NCT06920251|DRUG|Letermovir|"Elranatamab: Participants will receive SC administration of elranatamab QW, Q2W or Q4W. The initial doses of elranatamab will be 12 mg (C1D1) and 32 mg (C1D4) and will serve as the 2 step-up priming regimen.~Dexamethasone: Dexamethasone is administered at the dose of 20 mg/day on C1D1, C1D4 and C1D8 as a premedication for elranatamab~Letermovir: Letermovir is administered at the dose of 480mg/day PO from C1D15 (W3) to C4 (W16) (total of 98 days)."
214561735|NCT06923748|DEVICE|Superfloss|Use of Superfloss daily as the interproximal cleaning device, combined with an electronic toothbrush, as part of a tailored oral hygiene protocol in patients with peri-implant disease.
214561736|NCT06923748|DEVICE|Interdental brush|Use of interdental brush once daily as the interproximal cleaning device, combined with an electronic toothbrush, within a professional oral hygiene maintenance program for peri-implant disease
214561737|NCT07129772|DRUG|Gemcitabine (GEM)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
215165420|NCT06888921|DRUG|COM701|COM701 will be administered via intravenous (IV) infusion once every 3 weeks.
215165421|NCT06888921|DRUG|Normal Saline|Saline will be administered via intravenous (IV) infusion once every 3 weeks
214561738|NCT07129772|DRUG|Cisplatin|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
214561739|NCT07129772|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
214561740|NCT07126327|DEVICE|Peristeen Light - trans anal irrigation system|Subjects naive to TAI will use Peristeen Light trans anal irrigation
215165422|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 1|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1
214561741|NCT07131007|BEHAVIORAL|Immunotherapy Monitoring and Sample Collection|For cancer patients receiving immune checkpoint inhibitors (ICIs), we conduct behavioral monitoring: collect blood, urine, and feces samples before medication and 7 days after medication for multi - omics analysis. Monitor organ function indicators at 24 hours, 72 hours, and 1 week post - medication. No interference with standard ICI treatment; focus on observational data collection to construct an organ damage early - warning system.
215165423|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.
215165424|NCT06788002|OTHER|Low-dose radiotherapy combine with chemoimmunotherapy|Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)
215165425|NCT07083947|DIETARY_SUPPLEMENT|CL19183|One capsule taken orally each morning after breakfast with water for 16 weeks
215165426|NCT07083947|DIETARY_SUPPLEMENT|CL24212|One capsule taken orally each morning after breakfast with water for 16 weeks
215165427|NCT07083947|OTHER|Placebo|One capsule taken orally each morning after breakfast with water for 16 weeks
215165428|NCT06527690|DRUG|Niraparib/Abirate rone acetate fixed-dose combination|Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.
214561742|NCT07139938|PROCEDURE|Isolated lumbar decomression|"All patients will undergo microsurgical decompression of stenosed neural structures of the lumbar canal at all clinically significant levels with saving the posterior spinal column (type of decompression may be as unilateral, bilateral, or bilateral from a unilateral approach (over-the-top)).~Degenerative lumbar stenosis may be caused by thickened yellow and posterior longitudinal ligaments, facet joints hypertrophy, vertebral body osteophytes posteriorly, synovial (facet joints cysts) and disc cysts."
214561743|NCT06939933|OTHER|aquatic exercise in addition to physical exercise|"Aquatic exercise refers to the use of water that facilitates the application of established therapeutic interventions, including stretching, strengthening, joint mobilization, balance and gait training and endurance training. Water has been throughout history for a variety of purposes including ; physical therapy, rehabilitation and sport. There activities are made possible by water's special qualities and the influence of these attributes on humans.~Hydrotherapy is one of the most popular forms of complementary therapies that help in the treatment of children with disabilities. It is known to provide an opportunity to the children to do easier exercise. It also improves .~Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life."
214561744|NCT06939933|GENETIC|designed physical exercises only|"Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life (Ballas et al., 2010).~benefit from anaerobic activity patterns (Dougherty et al., 2018). A study to examine maximal muscle strength and peak power in children with sickle cell anemia found that maximal muscle strength and peak power are significantly less in children with sickle cell anemia compared to the control group"
214561745|NCT07144696|BEHAVIORAL|structured education and regular follow-up|Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\&amp;#39;s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting
215165429|NCT06527690|DRUG|Prednisone|Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.
215165430|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
215165431|NCT06620380|DEVICE|Pharmacoscopy 1.0|Pharmacoscopy is currently an academically developed platform. The study is designed to investigate the clinical performance of this academic platform. In the interventional arm, the best candidate agent defined by pharmascopy will be considered to guide the therapeutic decision for each patient.
214561746|NCT07135310|BEHAVIORAL|STROKE 120 multifaceted intervention campaign|"Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period).~The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows:~1. Training medical workers in stroke center;~2. Training emergency center staff and primary care physicians;~3. Conducting public education;"
214561747|NCT01963637|DEVICE|gastric tomodensitometry with gas at 3 months and 12 months|
215165432|NCT06620380|OTHER|Control|The next systemic treatment after surgery will be discussed, with the investigator and at the tumor board, considering also standard histopathological and molecular analysis, including next generation sequencing, molecular profiling analysis and previous treatments received
215165433|NCT00336024|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
215165434|NCT00336024|DRUG|Carboplatin|Given IV
215165435|NCT00336024|DRUG|Cisplatin|Given IV
215165436|NCT00336024|DRUG|Cyclophosphamide|Given IV
215165437|NCT00336024|DRUG|Etoposide|Given IV
215165438|NCT00336024|BIOLOGICAL|Filgrastim|Given IV or SC
215165439|NCT00336024|OTHER|Laboratory Biomarker Analysis|Correlative studies
215165440|NCT00336024|DRUG|Leucovorin Calcium|Given IV or orally
215165441|NCT00336024|DRUG|Methotrexate|Given IV
215165442|NCT00336024|OTHER|Quality-of-Life Assessment|Ancillary studies
215165443|NCT00336024|DRUG|Thiotepa|Given IV
215165444|NCT00336024|DRUG|Vincristine Sulfate|Given IV
215165445|NCT06473597|DRUG|Rimegepant|NURTEC ODT 75 mg orally disintegrating tablets
215165446|NCT06473597|DRUG|Rizatriptan Benzoate|Rizatriptan ODT 10mg orally disintegrating tablets
215165447|NCT07088458|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.
215165448|NCT07088406|BEHAVIORAL|Physical Activity Promotion|The Conmigo Physical Activity intervention involves the delivery of ten weekly sessions led by YMCA Facilitators supported by Drs. Arredondo and Ayala, Project Manager and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in ten in-person 2-hour sessions on topics such as PA parenting, communication, goal setting, etc. Mothers and daughters participate together in most activities, with small group breakouts where just mothers or just daughters have separate activities during some sessions. Each session includes didactic teaching, skill building (e.g. role plays), interactive discussions, 30 minutes of group PA, and goal-setting/review of previous goals. Overall, the activities are designed to promote increased physical activity and mediators to PA (family communication, parenting strategies, etc.). Each cohort will include 12-15 mother-daughter dyads.
214561748|NCT07145983|BEHAVIORAL|Structured Diabetes Education on medication Adherence and self care|Lived-experience facilitation, goal setting, real-world problem solving, and ongoing peer accountability not provided in standard clinician-led education. Peer-led, group-based sessions emphasizing lived experiences, problem-solving, and mutual support. Participants meet regularly in small groups facilitated by trained peers with diabetes. Includes structured booster follow-ups and SMS reminders to reinforce adherence and self-care.
214561749|NCT07146620|OTHER|Forearm massage|A general massage of the forearm will be performed. The physical therapist perform deep, longitudinal strokes. Pressure will be maintained at a level the patient finds comfortable for 3 minutes.
214561750|NCT07146620|OTHER|Pressure release for forearm trigger points|Pressure will be applied to trigger points in the forearm. This will be done in three sets of 30-second applications, with 30 seconds of rest between each.
214561751|NCT07146620|OTHER|Mulligan mobilization with movement technique|A lateromedial glide will be performed. The technique will be applied for three sets of 10 repetitions, with 30 seconds of rest between each set.
214561752|NCT07146620|OTHER|Radial Nerve Neurodynamic Mobilization|Three sets of 30 nerve glides will be performed at a rhythm of one second of tension followed by one second of rest. There will be 30 seconds of rest between sets.
214561753|NCT07146620|OTHER|Diacutaneous fibrolysis (Real)|A real technique of Diacutaneous fibrolysis will be applied to the forearm region for 5 minutes.
214561754|NCT07146620|OTHER|Diacutaneous Fibrolysis (Sham)|A sham Diacutaneous Fibrolysis technique (skin pinch) will be applied to the forearm region for 5 minutes.
214561755|NCT07139743|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Obecabtagene autoleucel (obe-cel) given as a single infusion.
214561756|NCT06748729|DEVICE|Navii Knee|Microprocessor controlled prosthetic knee (MPK)
214561757|NCT07155629|DRUG|mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine|The benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.
214561758|NCT07154264|DRUG|DZD8586|DZD8586 will be taken orally once daily on days 1-28 of each cycle.
214561759|NCT07154264|DRUG|Venetoclax|Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
214561760|NCT07155902|OTHER|The community-to-facility integrated strategy|The community-to-facility integrated strategy will focus on a joined-up T2D care delivery across the primary, secondary, and healthcare facilities, and urban communities.
214561761|NCT07154212|DIAGNOSTIC_TEST|Hepatitis B virus infection|anti-hepatitis B virus core antigen positive serologic status
214561762|NCT07154745|DRUG|Pozelimab|Administered per the protocol
214561763|NCT07154745|DRUG|Cemdisiran|Administered per the protocol
214561764|NCT07155954|DIAGNOSTIC_TEST|SRUS imaging of the lymph nodes before surgery or biopsy|Ultrasound contrast agent (Sonovue/Sonazoid) is administered to the patients through a peripheral vein. When the micro-bubbles enter the lymph nodes, super-resolution ultrasonography imaging will initiate immediately, to capture the trajectory of the micro-bubbles, thus construct a map of the microvascular distribution.
214561765|NCT07155603|BEHAVIORAL|Animated Video Group 1|The animated video intervention provides a clear and engaging multimedia explanation of the colonoscopy procedure in multiple languages. It includes visual aids to help explain the process, preparation instructions, risks, and expected outcomes, aiming to improve patient comprehension and adherence.
214561766|NCT07153757|DRUG|Endocrine Therapy of Physician's Choice|This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.
214561767|NCT07155681|DEVICE|Virtual Reality intervention|Virtual Realtiy intervention with biofeedback for 10 minutes during a shift on the ward for healthcare professionals
214561768|NCT07155837|DEVICE|TENS group|The intervention group received TENS twice a day.
214561769|NCT07154251|OTHER|Community Health Worker|Community Health Worker will meet with families monthly (and more often as needed) in the role of a diabetes technology coach
214707221|NCT04818528|OTHER|Constraint Induced Movement Therapy and Routine Physical Therapy|"Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization."
214707222|NCT04818528|OTHER|Routine Physical Therapy|As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
214707223|NCT01274117|PROCEDURE|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
215165449|NCT07088406|BEHAVIORAL|Healthy Eating|The Healthy Eating intervention involves the delivery of 10 sessions by YMCA facilitators supported by Drs. Arredondo and Ayala, the Project Manager, and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in 10 2-hour in-person sessions that include both large and small group activities. Overall, the activities are designed to promote engagement in dietary behavioral strategies and parenting strategies across contexts and settings to promote fruit, vegetable and fiber consumption. Large and small groups activities include goal setting, implementation planning, homework activities, and focused discussion on mediators (e.g., family communication, parenting strategies) and moderators (e.g. acculturation). Each cohort will include 12-15 mother-daughter dyads.
215165450|NCT07088120|DEVICE|Precision-Controlled Ventilation with Real-Time Feedback|Manual ventilation during CPR using a real-time feedback device (EOlife, Archeon Medical) to guide the delivery of tidal volumes (6-8 mL/kg predicted body weight) and ventilation rate (10 breaths per minute). The device measures and displays ventilation parameters in real time, helping providers achieve guideline-recommended targets during resuscitation.
215165451|NCT07088120|OTHER|Standard Manual Ventilation During CPR|Manual ventilation during CPR without real-time feedback, using clinician judgment to guide tidal volume (visible chest rise) and ventilation rate, consistent with American Heart Association guidelines.
215165452|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
215165453|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
215165454|NCT06907914|OTHER|Schroth|The Schroth intervention consists of a structured, three-dimensional exercise program based on scoliosis-specific principles. It incorporates corrective postural alignment, rotational breathing techniques, and targeted activation of spinal and scapular stabilizing muscles. The exercises are designed to improve postural control, enhance muscle endurance, and promote neuromuscular re-education for better functional alignment during daily activities.
215165455|NCT06907199|PROCEDURE|Electrofulguration (EF)|Nitrofurantoin (NF) daily antibiotic prophylaxis for 6 months plus Electrofulguration.
215165456|NCT06907199|DRUG|Nitrofurantoin (NF)|Nitrofurantoin (NF) daily antibiotic prophylaxis given daily for 6 months.
215165457|NCT06902558|DRUG|ABBV-CLS-628|IntraVenous Infusion
215165458|NCT06902558|DRUG|Placebo|IntraVenous Infusion
215165459|NCT05350072|BIOLOGICAL|VAY736|ianalumab s.c.
215165460|NCT05350072|OTHER|Placebo|placebo s.c.
214561770|NCT07153523|OTHER|High intensity interval training|High intensity interval training provides time efficient benefits for strength and endurance training. It comprises of high burst training with rest periods. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
214707224|NCT05843812|DRUG|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
214707225|NCT02505815|PROCEDURE|Surgery|
214707226|NCT02505815|PROCEDURE|Cortisol Level Measurement|
214707227|NCT02505815|PROCEDURE|Neurocognitive Testing|
215165461|NCT06904287|DRUG|Magnesium|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
215165462|NCT06904287|DRUG|Placebo|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)
215165463|NCT02629120|DRUG|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
215165464|NCT02629120|DRUG|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
215165465|NCT02629120|DRUG|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
215165466|NCT02629120|DRUG|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
215165467|NCT02629120|RADIATION|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
214561771|NCT07153523|OTHER|Routine physical therapy|For control group routine physical therapy will be applied for strength training using weights and running drills for endurance training. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
214561772|NCT07155941|BEHAVIORAL|Training of reward processing/sensitivity|"Participants in the experimental group complete a two-week ecological momentary intervention (EMI) consisting of three brief training units per day, each delivered via a smartphone. The exercises target different aspects of reward processing and are scheduled at specific times throughout the day.~The morning unit (to be completed between 10:00 and 12:00 a.m.) involves a positive mental imagery task guided by audio recording. Participants are guided to vividly imagine a future situation with the most pleasurable and meaningful outcome possible. They are encouraged to mentally activate all senses, thoughts, and emotions associated with this scenario.~The afternoon unit (to be completed between 3:00 and 5:00 p.m.) consists of a savoring exercise guided by audio recording. Participants recall a positive experience from the past and are instructed to re-experience and savor it mentally by focusing on its sensory details, emotional quality, and personal significance.~The evening unit (to be"
214707228|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
214707229|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
214707230|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
214707231|NCT04655703|DEVICE|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
214707232|NCT02452112|DRUG|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
214707233|NCT02452112|DRUG|Placebo|Placebo patch to be placed on the site of pain
214707234|NCT04499846|OTHER|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
214707235|NCT00215241|DRUG|sertraline and risperidone|
214707236|NCT01422512|BIOLOGICAL|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
214707237|NCT02268136|DRUG|BIII 890 CL|
214707238|NCT02268136|DRUG|Placebo|
215165468|NCT02629120|BIOLOGICAL|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
215165469|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
214707239|NCT02103036|PROCEDURE|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
215165470|NCT06906562|DRUG|Pemigatinib|Pemigatinib will be taken orally with a targeted starting does of 13.5 mg
215165471|NCT06906562|PROCEDURE|Computed Tomography (CT)|Undergo CT scan
215165472|NCT06906562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165473|NCT06906562|PROCEDURE|Optical Coherence Tomography|Undergo OCT
215165474|NCT06906562|PROCEDURE|Bone Scan|Undergo whole body bone scan
215165475|NCT06906562|PROCEDURE|Ophthalmoscopy|Undergo dilated ophthalmoscopy
215165476|NCT06907901|BEHAVIORAL|PHAS Assessment|Participants will complete the Postural Habits and Awareness Scale (PHAS) to assess postural awareness and habits. The scale will be administered twice, two weeks apart, to evaluate reliability.
215165477|NCT07089043|DRUG|CST-3056|Administered as an oral solution
215165478|NCT07089043|DRUG|Placebo|Administered as an oral solution
215165479|NCT07090226|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
215165480|NCT05940493|DRUG|Abemaciclib|Tablet
215165481|NCT05940493|DRUG|Placebo|Tablet
215165482|NCT04709705|BIOLOGICAL|Human platelets|Platelets given to control bleeding
215165483|NCT06766864|DRUG|DR-01|DR-01 is a monoclonal antibody
215165484|NCT06766864|OTHER|Placebo|Placebo
214561773|NCT07155941|BEHAVIORAL|Relaxation Training (PMR)|"Participants in the control group complete a two-week progressive muscle relaxation (PMR) program designed to match the reward training in both frequency and duration. The intervention consists of three daily units, each delivered via a smartphone app and guided by audio recordings.~The first and second units of each day consist of short audio-guided PMR sessions (approximately 5 minutes each). These exercises systematically guide participants through alternating tension and relaxation of different muscle groups to promote physical and mental relaxation.~The third unit of the day focuses on reflection. Participants are asked to evaluate their experiences with the relaxation exercises over the course of the day. They reflect on their ability to engage with the exercises, the perceived effects (e.g., feelings of relaxation), any difficulties they encountered, and strategies to enhance the effectiveness of relaxation in their daily life beyond the intervention."
214561774|NCT07155941|OTHER|Psychoeducation|All participants receive a psychoeducation session on the day before the respective intervention starts. In this session, a graduate-level study team member introduces the rationale behind the training (PMR or reward-training), and demonstrates each exercise. Participants also practice each task.
214561775|NCT07154069|RADIATION|Radical radiotherapy of nasopharynx and neck|Radical radiotherapy of nasopharynx and neck
214561776|NCT07154069|DRUG|Capecitabine|Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year
214561777|NCT07154069|DRUG|Concurrent chemoradiotherapy (cCRT)|Concurrent chemoradiotherapy
214561778|NCT07154069|DRUG|Toripalimab|Adjuvant Toripalimab (240mg day1, Q3W )
214561779|NCT07154563|DIAGNOSTIC_TEST|NIR-II probe (i.e ICG-CK) incubation solution|After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.
214561780|NCT07153809|PROCEDURE|FMT|FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days.
214561781|NCT07153809|PROCEDURE|Placebo|Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.
214561782|NCT07154407|OTHER|AI-assisted Mastisting Training App|An artificial intelligence (AI) recognition system for the 'AI-assisted Masticatory Muscle Training,' tailored to train masticatory muscles in patients with schizophrenia. By finishing certain exercise per day, expecting the experimental oral hygience, masticating and swallowing fuction could be advanced,
214561783|NCT07154199|DEVICE|sham transcranial ultrasound stimulation|In the sham group, the transducer power was turned off, pre-recorded pulse repetition sounds were played to control for auditory confounds. The equipment appearance is consistent with the test device. Single stimulation, 60 seconds.
214707240|NCT02103036|PROCEDURE|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
214707241|NCT02103036|DEVICE|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
214707242|NCT02103036|DEVICE|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
214707243|NCT04041908|OTHER|Experimental Product|2 sachets per day
214707244|NCT05625828|BEHAVIORAL|Cognitive-motor Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of cognitive-motor exercises where participants have to perform two tasks consequently (for example, walking while answering math questions or throwing a ball while reverse walking) and 5 minutes of stretching exercises.
214707245|NCT05625828|BEHAVIORAL|Multifactorial Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of multifactorial exercises that consists of high speed walking, resistance training and balance training in single task condition and 5 minutes of stretching exercises.
214561784|NCT07154199|DEVICE|real transcranial ultrasound stimulation|Ultrasound stimulation was delivered using TPO-203 and H-104MR\_4AA-4CH transducer (Sonic Concepts, Woodinville, WA, USA). In the real stimulation group, theta-burst TUS (Yaakub et al., 2024; Yaakub et al., 2023) was performed with the following parameters: pulse duration = 20 ms; pulse repetition interval = 200 ms; total duration = 80 s. The target free-field spatial peak pulse-average intensity was maintained at 33.85 W/cm². The stimulation target was defined as the overlapping region between the source localisation results and the right inferior insula in the Destrieux atlas
214707246|NCT05256082|DIAGNOSTIC_TEST|six-minutes-walking test|Patients conducting a six-minutes-walking test
214707247|NCT00881361|DRUG|systemic chemotherapy|
214707248|NCT00881361|PROCEDURE|axillary lymph node dissection|
214707249|NCT00881361|PROCEDURE|neoadjuvant therapy|
214707250|NCT00881361|PROCEDURE|sentinel lymph node biopsy|
214707251|NCT00881361|PROCEDURE|therapeutic conventional surgery|
214707252|NCT00881361|PROCEDURE|ultrasound imaging|
214707253|NCT00012883|BEHAVIORAL|Homewalking exercise program|
214707254|NCT00957255|DEVICE|OrthoADAPT|soft tissue augmentation device
214707255|NCT00957255|PROCEDURE|Standard of care|Standard of care rotator cuff repair
215165485|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
215165486|NCT05867927|DEVICE|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
215165487|NCT05867927|DEVICE|Non-da Vinci Surgery|Non-da Vinci Surgery
215165488|NCT07092579|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
214561785|NCT07155824|DIETARY_SUPPLEMENT|Whey and plant protein blend|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
214561786|NCT07153640|OTHER|1 ) Wim Hof Breathing Exercise|"1. Subjects will be asked to breathe deeply for an average of 20-30 breaths then exhale, (deep rapid inhalations and relaxed expirations)~2. Hold their breath in an unforced manner for one minute or longer until they feel the urge to breathe (retention phase).~   (For safety, they were instructed not to hold their breath longer than 3.5 min).~3. Take deep inhalation breath and hold again for 15 seconds (recovery breath).~4. This procedure was repeated a total of three times.~5. After the last cycle, subjects were instructed to return to their natural rhythm of breathing and remain lying down without moving to relax for five minutes.~6. Done every day in the morning or at least three hours postprandial for four weeks.~(Marko et al., 2022)"
214561787|NCT07153640|OTHER|2) Aerobic exercises|Aerobic exercises were performed by walking on the treadmill for 30 minutes a day (5 days/week) and at least 150 minutes per week of moderate-intensity aerobic activity at 60-75% of the maximum heart rate (HR) for four weeks. Maximum heart rate is taken from 220 - to age. Both the warm-up and cool-down were performed for five minutes. Each session concluded with stretching the calf, hamstring, quadriceps, gluteus, back, neck, and shoulder muscles (Acar et al., 2024; Shandu et al., 2023a)
214561788|NCT07155044|DRUG|NAC|Participants in NAC+RNU cohort will receive 3-4 cycles of neoadjuvant chemotherapy (NAC) with the gemcitabine and cisplatin (GC) regimen prior to undergoing definitive surgery. Gemcitabine (1000 mg/m²) will be administered on Day 1 and Day 8, and cisplatin (70 mg/m²) will be administered on Day 2 of each 21-day cycle.
214561789|NCT07154537|BIOLOGICAL|2-dose PCV13|2 doses PCV13 with one month apart
214707256|NCT02234557|BEHAVIORAL|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
214707257|NCT00365768|DRUG|Glutamine|Administered orally twice daily for 21 days
214707258|NCT00365768|OTHER|Placebo|Administered orally twice daily for 21 days
214707259|NCT02467829|DEVICE|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
214707260|NCT02764983|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
214707261|NCT02764983|BEHAVIORAL|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
214707262|NCT02764983|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
214707263|NCT02764983|BEHAVIORAL|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
214707264|NCT02764983|BEHAVIORAL|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
214707265|NCT02764983|BEHAVIORAL|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
214561790|NCT07154537|BIOLOGICAL|1-dose PCV13|1 dose PCV13
215165489|NCT07092579|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and optionally at 16 weeks if healing isn't confirmed. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
215165490|NCT07092579|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
215165491|NCT07092579|PROCEDURE|Lower Limb Rehabilitation Exercise Program|A structured exercise program prescribed postoperatively to promote functional recovery after tibial shaft fracture surgery. Exercises target quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent stiffness, and improve circulation. The program includes isometric and dynamic exercises such as: static quadriceps and hamstring contractions, straight leg raises, hip abduction, knee extension, hamstring curls, heel slides, ankle dorsiflexion/plantarflexion, ankle inversion/eversion, ankle circles, toe spreading, and passive ankle stretching using a strap or towel. Exercises are performed in pain-free ranges with gradual progression in repetitions and sets according to the rehabilitation plan. Certain ankle and foot mobility exercises (dorsiflexion/plantarflexion) are also performed hourly during the day to prevent swelling and thrombosis.
215165492|NCT07093398|DRUG|D3S-001|"The investigational product dose: 600 mg D3S-001 capsules.~A 600-mg oral dose of D3S-001 will be given to potential participants on Day 1 and Day 4."
215165493|NCT06797544|DRUG|Levofloxacin 0.5%|"Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously."
214561791|NCT07154095|DRUG|Sustained-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
214561792|NCT07154095|DRUG|Immediate-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
214561793|NCT07155499|BIOLOGICAL|GNR-127, 20 mcg|GNR-127, 20 mcg in 0.5 ml administered 5 times every 4 weeks
214561794|NCT07155499|BIOLOGICAL|GNR-127, 40 mcg|GNR-127, 40 mcg in 0.5 ml administered 5 times every 4 weeks
214561795|NCT07155499|BIOLOGICAL|GNR-127, 80 mcg|GNR-127, 80 mcg in 0.5 ml administered 5 times every 4 weeks
214707266|NCT02764983|PROCEDURE|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
214707267|NCT02764983|OTHER|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
214707268|NCT06528899|BEHAVIORAL|Physical Therapy|Assessment and/or treatment by physitoherapist during the visit
214707269|NCT01428999|DIETARY_SUPPLEMENT|probiotics|probiotics 1 pack (2g) bid for three weeks
214707270|NCT03634917|DRUG|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
214707271|NCT03634917|DRUG|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
214707272|NCT03634917|DRUG|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
214561796|NCT07155499|BIOLOGICAL|GNR-127 placebo|GNR-127 placebo 0.5 ml administered 5 times every 4 weeks
214561797|NCT07154238|OTHER|No treatment given|No treatment given
214561798|NCT07153393|DEVICE|Type I Bovine Collagen (HTIC)|HTIC is a sterile collagen powder (100 mg) contained in a glass vial, which is diluted by adding 5 ml of saline solution (0.9% sodium chloride solution) to obtain a suspension. This suspension will be prepared immediately before treatment. The procedure consists of performing a few microinjections of the product (0.1 ml per injection) into the dermis at intervals of approximately 2 cm, using a very fine needle (30G/32G, 4 mm) in the areas to be treated (face, neck, décolleté, and hands).
214561799|NCT07154043|PROCEDURE|Complete Decongestive Therapy (CDT)|Manual lymph drainage, multilayer bandaging, skin care, and exercise. 75 minutes per session, 5 sessions per week, for 3 weeks.
214707273|NCT03634917|DRUG|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
214707274|NCT01701219|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
214707275|NCT02988219|DRUG|Bupivacaine-fentanyl|Local anesthetic
214707276|NCT02988219|DEVICE|Holter ECG monitor|3-chanel, CM5 leads
214707277|NCT02988219|PROCEDURE|Open kidney cancer surgery|Lateral position
214707278|NCT02988219|PROCEDURE|General anesthesia|
214707279|NCT02988219|PROCEDURE|Epidural Anaesthesia|
214707280|NCT06365476|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
214707281|NCT05420194|OTHER|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
214561800|NCT07154043|PROCEDURE|CDT + Intermittent Pneumatic Compression (IPC)|Complete decongestive therapy program including manual lymph drainage, multilayer bandaging, skin care, and exercise, plus intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 115 minutes per session, 5 sessions per week, for 3 weeks.
214561801|NCT07154043|PROCEDURE|CDT without Manual Lymph Drainage plus Intermittent Pneumatic Compression|Complete decongestive therapy consisting of multilayer bandaging, skin care, and exercise, with manual lymph drainage replaced by intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 75 minutes per session, 5 sessions per week, for 3 weeks.
214561802|NCT07155109|OTHER|Low pressure group|In laparoscopic gyneco-oncological surgeries, low pressure group will receive below 12 mmHg intraperitoneal pressure.
214561803|NCT07155109|OTHER|Normal pressure group|In laparoscopic gyneco-oncological surgeries, normal pressure group will receive 12 and abowe 12 mmHg intraperitoneal pressure.
214561804|NCT07156019|DRUG|Sintilimab+Temozolomide+Surufatinib|After fully informed and signed informed consent, subjects will receive Sintilimab (200mg each fixed dose, once every 21 days) combined with Temozolomide (BSA≤1.7m2; BSA \&amp;amp;gt; 1.7m2 was administered with 300mg, QD, d1-d5, and with Surufatinib (250mg, QD, continuous administration). A treatment cycle of 21 days until disease progression, death, toxicity intolerance or withdrawal of informed consent, with a maximum treatment period of 24 months.
214561805|NCT07154914|DRUG|Abiraterone + ADT|Patients receiving androgen deprivation therapy (ADT) combined with abiraterone. Abiraterone is a CYP17A1 inhibitor used in combination with prednisone and ADT for metastatic hormone-sensitive prostate cancer (mHSPC). This combination is given in real-world practice according to clinical guidelines.
214561806|NCT07153718|PROCEDURE|Electrogram-guided ablation|pulmonary vein ioslation; target electrograms ablation, including (1) Spatial-temporal Dispersion Activation, (2) Locally Short Cycle Length Activity, (3) High-Frequency Potentials, (4) Focal Activity.
214707282|NCT05420194|OTHER|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
214707283|NCT02538367|DRUG|YH12852 IR 0.05mg|
214707284|NCT02538367|DRUG|YH12852 IR 0.1mg|
214707285|NCT02538367|DRUG|YH12852 IR 0.3mg|
214707286|NCT02538367|DRUG|YH12852 IR 0.5mg|
214707287|NCT02538367|DRUG|YH12852 IR 1mg|
214707288|NCT02538367|DRUG|YH12852 IR 2mg|
214707289|NCT02538367|DRUG|YH12852 IR 3mg|
214707290|NCT02538367|DRUG|YH12852 DR1 0.5mg|
214707291|NCT02538367|DRUG|YH12852 DR1 1mg|
214707292|NCT02538367|DRUG|YH12852 DR1 2mg|
214707293|NCT02538367|DRUG|YH12852 DR1 4mg|
214707294|NCT02538367|DRUG|YH12852 DR2 8mg|
214707295|NCT02538367|DRUG|Prucalopride 2mg|
215165494|NCT07090174|BIOLOGICAL|PDS0101|PDS0101 is an HPV 16-targeted immunotherapy administered as two subcutaneous injections of 0.5 mL each (total 1.0 mL). Each dose contains 3.0 mg of Versamune®, a proprietary cationic lipid nanoparticle adjuvant, and 2.7 mg of HPVmix, a blend of HPV16 E6 and E7 proteins. Versamune® enhances antigen uptake and dendritic cell activation, promoting T-cell priming and memory formation. In preclinical studies, subcutaneous administration resulted in low systemic bioavailability (\<6%) and efficient dendritic cell uptake, consistent with a favorable safety profile. PDS0101 has been studied in a completed Phase I trial in HIV-uninfected women with high-risk HPV and cervical intraepithelial neoplasia (CIN) I. Each participant in this study will receive three doses, spaced 21 days apart (± 7 days) unless there has been Grade 3 or greater toxicity at least possibly related to the study agent.
215165495|NCT07090746|DEVICE|Clear aligner|Clear aligner
215165496|NCT07090746|DEVICE|Fixed orthodontic appliance|Fixed orthodontic appliance
214707296|NCT02538367|DRUG|Placebo|
214707297|NCT01057914|DIETARY_SUPPLEMENT|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
214707298|NCT01057914|OTHER|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
214707299|NCT01057914|OTHER|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
214707300|NCT01522443|DRUG|cabozantinib|Tablets taken orally once daily.
214707301|NCT01522443|DRUG|mitoxantrone|Given by IV once every 3 weeks.
214707302|NCT01522443|DRUG|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
214707303|NCT02995213|BEHAVIORAL|Accelerometer based feedback about paretic arm use|
214707304|NCT05590767|PROCEDURE|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
214707305|NCT00228930|DRUG|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
214707306|NCT04131985|PROCEDURE|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
214707307|NCT00305812|DRUG|dexamethasone|
214561807|NCT07153718|PROCEDURE|Anatomical-guided Ablation|pulmonary vein isolation; LA roof, posterior inferior wall and mitral isthmus linear lesion; Vein of Marshall (VOM) ethanol infusion.
214561808|NCT07153718|PROCEDURE|Extensive electrogram-anatomical guided ablation|pulmonary vein isolation; target electrogram ablation; linear ablation
214561809|NCT07156110|PROCEDURE|Traditional prosthetic procedure|Three months later, after an impression, haling abutment will be removed and a screw-retained restoration will be seated using a Ti-Base abutment.
214561810|NCT07156110|PROCEDURE|one abutment-one time|Three months later, after an impression, a screw-retained restoration will be seated directly on the connect healing
214561811|NCT07153627|OTHER|Rectal ozone sessions|Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
214561812|NCT07153627|OTHER|Conventional rehabilitation program|Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
214561813|NCT07154277|PROCEDURE|Small bite closure|Small bite suturing is small tissue bite of 0.5cm depth x 0.5cm travel x 0.5cm apart, on the aponeurosis away from midline using Prolene 2/0
214561814|NCT07154277|PROCEDURE|Large bite closure|Large bite closure is defined as tissue bite of 1cm depth x 1 cm travel x 1cm apart, on the aponeurosis away from midline using Prolene 0
214561815|NCT07153796|DRUG|Blinatumomab|Given by IV
214561816|NCT07153796|DRUG|Mini-CVD|Given by IV
214561817|NCT07153796|DRUG|MTX/ARA-C|Given by IV
214707308|NCT00305812|DRUG|lenalidomide|
214707309|NCT00305812|DRUG|melphalan|
214561818|NCT07153549|DIETARY_SUPPLEMENT|Biolizin|Oral zinc-containing syrup taken per age-based dosing specified in the protocol, once or twice daily for 42 consecutive days. Product is dispensed at baseline (with refill if needed); batch and expiry are recorded. Caregivers receive instructions for use and complete dosing diaries; adherence is checked by diary review and returned bottle counts. Concomitant zinc products or pharmacologic appetite stimulants are not allowed. Safety is monitored through adverse event review and routine laboratory tests at baseline and Day 42.
214561819|NCT07153549|BEHAVIORAL|Standardized caregiver counseling on responsive feeding|Structured counseling delivered to caregivers at each clinic visit (Day 0, Day 7, Day 21, Day 42). Content includes mealtime routines, recognizing hunger/satiety cues, age-appropriate portions and textures, repeated exposure to diverse foods, and strategies to manage refusal or prolonged meals. A brief checklist guides delivery to ensure consistency across visits. No dietary supplement is provided in this intervention.
214561820|NCT07154316|RADIATION|LCRT|50Gy/25Fx
214561821|NCT07154316|RADIATION|SCRT|25Gy/5Fx
214561822|NCT07154316|DRUG|CAPOX|1000mg/m2 bid d1-14
214561823|NCT07154316|DRUG|PD-1|300mg d1，q3w
214561824|NCT07154316|DRUG|Celecoxib|200mg, bid
214561825|NCT07155772|PROCEDURE|Extracorporeal CardioPulmonary Resuscitation (eCPR)|The intervention of this study consists of moving the current eCPR program out of the hospital to reduce the time from collapse to ECMO flow (low-flow time).
214561826|NCT07154511|DRUG|Tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
214561827|NCT07154511|DRUG|Placebo|Participants will take 500mg TID placebo for 90 days +/- 7 days.
214707310|NCT05185648|BEHAVIORAL|standard trauma care taining|trauma care training
214707311|NCT01827241|OTHER|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
214561828|NCT07155135|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) is a vital diagnostic tool in modern medicine due to its ability to produce detailed images of the body's internal structures without using ionizing radiation.
214561829|NCT07155447|DIETARY_SUPPLEMENT|CEAA supplementation|(including calcium beta-hydroxy-beta- methylbutyrate monohydrate, L-Arginine, L-Glutamine and Ciltruline) Supplementation will be started within 72 hours of presentation and continued for a period of 28 days.
214561830|NCT07155447|OTHER|Placebo|a neutral powder containing the non- essential amino acid Alanine which will be indistinguishable from the CEAA supplement powder in in regards to packaging and supplement appearance.
214707312|NCT02199613|DRUG|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
214707313|NCT05265130|DRUG|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
214707314|NCT05265130|DRUG|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
214707315|NCT00776555|DRUG|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
214561831|NCT07154797|COMBINATION_PRODUCT|Bimatoprost Implant System / IOL Combination|Bimatoprost Implant System used in combination with the SpyGlass intraocular lens
214561832|NCT07153926|DIAGNOSTIC_TEST|Serum ferritin|Serum ferritin is a protein that stores iron, and high serum ferritin levels can suggest iron overload, but are also a common indicator of other conditions like inflammation, liver disease, or metabolic syndrome.
214561833|NCT07153926|DIAGNOSTIC_TEST|Serum hepcidin|"Hepcidin hormone has been found to be a key regulator of iron homeostasis. It controls plasma iron levels by regulating two key steps in iron metabolism, namely digestive iron absorption in enterocytes and iron recycling in macrophages.~Hepcidin is synthesized predominantly in the hepatocytes, which is physiologically increased by elevated serum iron level and decreased by erythropoietic activity. Recently, hepcidin has been used as a new marker for evaluation of liver fibrosis in patients with thalassemia major."
214561834|NCT07155733|DEVICE|Transcutaneous Vagus Nerve Stimulation|Participants receive 10 sessions of transcutaneous vagus nerve stimulation over 3 weeks using a TENS device. stimulation is applied to the auricular branch of the vagus nerve (cymba conchae/tragus) for 30 minutes per session. Participants continue usual medical care. Parameters (frequency, pulse width, intencity) are standartized according to safety guidelines. This intervention specifically targets the auricular branch of the vagus nerve, distinguishing it from other device-based intervention such as conventional TENS for pain management or non-auricular vagus stimulation used in other studies.
214561835|NCT07155733|BEHAVIORAL|Myofascial Release Exercises|Participants receive 10 supervised session over 3 weeks focusing on myofascial release of cervical muscles. in addition to their usual medical management for tinnitus. Exercises are designed to reduse muscle tensionpotentially contributing to tinnitus. This intervention is distinct from general physical therapy or standart relaxation exercises beacause it specifically targets myofascial structures implicated in tinnitus pathophysiology.
214561836|NCT07155733|OTHER|Standard medical treatment|Participants continue their usual medical management for tinnitus without additional interventions. This group serves as a control to compare the effects of tVNS and myofascial exercises. It differs from sham or placebo interventions used in oter studies because no active or stimalated treatment is provided.
214561837|NCT07154342|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
214561838|NCT07154342|BIOLOGICAL|Placebo|Placebo
214707316|NCT00776555|DRUG|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
215165497|NCT06648460|OTHER|Effort-based Decision-Making Task|"Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive."
215165498|NCT07091253|OTHER|HIV+|Participants living with HIV will use a triaxial accelerometer for a week in order to measure the physical activity and sedentary behaviors
215165499|NCT07093814|DRUG|VRT106|VRT106,intravenous
215165500|NCT04625946|DRUG|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
215165501|NCT04625946|BEHAVIORAL|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
215165502|NCT04625946|DEVICE|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
215165503|NCT06902480|DIETARY_SUPPLEMENT|WPPC|A chocolate-flavored drink with WPPC added
215165504|NCT06902480|DIETARY_SUPPLEMENT|Whole egg powder|A chocolate-flavored drink with whole egg powder added
215165505|NCT06904833|DEVICE|locomotion formats|two different types of popular locomotion methods in golf (i.e., walking 18 holes and using a buggy)
215165506|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
215165507|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
215165508|NCT06908824|PROCEDURE|Conventional surgery|Pars plana vitrectomy (PPV) with temporal internal limiting membrane (ILM) flap would be performed. Perfluorocarbon liquid (PFCL) or viscoelastic may be used as an adjunct. Air/Fluid exchange would be performed at the end of surgery, further exchange of air with 8-14% octafluoropropane (C3F8) would be performed based on operating surgeon's discretion. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Patients with visually significant cataract may undergo concomitant phacoemulsification and intraocular lens implantation or deferred to post-operative month 6-12. Patients would be instructed to adopt a face-down posturing in the first 5 days following operation.
215165509|NCT06908824|PROCEDURE|ILM flap with no gas tamponade|Pars plana vitrectomy with temporal internal limiting membrane (ILM) flap would be performed. The ILM flap would be stabilised over the macular hole using perfluorocarbon liquid (PFCL) followed by sub-PFCL dispersive viscoelastic injection. The PFCL would be removed towards the end of surgery. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Concomitant phacoemulsification and intraocular lens implantation would be performed in patients with visually significant cataract or deferred to post-operative month 6-12. Patients will be instructed to avoid excessive movement and adopt a face forward/ supine position for first 24 hours. Afterwards, there would be no restriction on post-operative posturing.
214707317|NCT05341635|DIAGNOSTIC_TEST|Swab sampling|Collection of three nose-pharyngeal and oral swabs
214707318|NCT00936117|DRUG|Posaconazole|200 mg (liquid) by mouth 3 times per day.
214707319|NCT00866515|DRUG|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
214707320|NCT00866515|DRUG|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
214561839|NCT07155642|OTHER|yoga|"Participants in the yoga group received a total of 8 weeks of intervention, conducted 3 days a week, for 60 minutes per day. The program components were: • 8 minutes of meditation practice. • 40 minutes of Yin and Yang yoga postures. (It's highly recommended to briefly explain what Yin and Yang yoga postures specifically entail in the full paper's methodology section, e.g., Yin yoga focuses on holding passive poses for longer durations to target deep connective tissues, while Yang yoga incorporates more active, flowing sequences to build strength and flexibility.) • 2 minutes of breathing exercises (pranayama). • 10 minutes of deep relaxation (savasana)."
214561840|NCT07155642|OTHER|conventional physiotheraphy|"Participants in the conventional physiotherapy group also underwent an 8-week program, 3 days a week, for 60 minutes per day. This program included:~* Aerobic exercises.~* Stretching exercises.~* Strengthening exercises.~* Spinal stabilization exercises.~* Balance exercises."
214561841|NCT07156045|BIOLOGICAL|anti-PSMA CAR-NK|Targeting PSMA CAR-NK cells
214561842|NCT07153367|DRUG|REKOVELLE (Follitropin Delta)|"Each patient will start the ovarian stimulation with a fixed dose of 3,66 mcg of Rekovelle ® on day 4 of the natural cycle (Stimulation day 1-S1). The stimulation period will last a maximum of 13 days.~Patients will be regularly evaluated to monitor the response to stimulation with ultrasound scan and blood sampling"
214561843|NCT07154667|PROCEDURE|Use of AuryzoN™ EAR 2.0 device|AuryzoN™ EAR 2.0 is an investigational non-significant risk device developed to improve cartilage construct shape and stability prior to use in ear reconstructive surgery.
214561844|NCT07154667|PROCEDURE|Hand carving|Standard hand carving using standard surgical blades will be performed in this intervention arm of the study.
214561845|NCT07155018|PROCEDURE|Micro-osteoperforations (MOPs)|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations.
214561846|NCT07155018|PROCEDURE|Conventional Canine Retraction|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations
214561847|NCT07155200|DRUG|Cirtuvivint|Cirtuvivint will be supplied by Biosplice.
214561848|NCT07155200|DRUG|Irinotecan|Irinotecan is commercially available.
214561849|NCT07155759|DIAGNOSTIC_TEST|PSA/Stockholm3/MRI|Stockholm3+PSA followed by MRI of the prostate
214707321|NCT04369755|OTHER|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
214707322|NCT03119818|DEVICE|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
214707323|NCT03119818|OTHER|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
214707324|NCT06086756|BEHAVIORAL|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
214707325|NCT06086756|BEHAVIORAL|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
214707326|NCT04846894|DIAGNOSTIC_TEST|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
214707327|NCT00000361|DRUG|Corticosteroids|
214707328|NCT00000361|DRUG|Methotrexate|
214561850|NCT07155759|DIAGNOSTIC_TEST|PSA|PSA followed by standard biopsies
214707329|NCT02356640|PROCEDURE|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
214707330|NCT02356640|PROCEDURE|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
214707331|NCT02356640|DEVICE|Olympus UM 2000|
214707332|NCT02356640|DEVICE|B-D Quincke Type Point|
214707333|NCT02356640|DRUG|Levobupivacaine|
214707334|NCT05831527|DRUG|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
214707335|NCT03945903|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
214707336|NCT03743207|OTHER|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
214707337|NCT03743207|OTHER|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
214561851|NCT07155811|DIAGNOSTIC_TEST|test immunitaire fonctionnel automatisé VIDAS® STIMM™ T RUO|"The functional assessment of T lymphocytes is based on the use of the VIDAS® STIMM™ T RUO test, which will be performed on freshly collected whole blood in lithium heparin tubes without gel separators. Blood samples will be sent to the Immunology Laboratory at E. Herriot Hospital (Prof. Guillaume Monneret). T lymphocytes will be stimulated ex vivo for 3.5 hours (non-antigen-dependent stimulation by PHA) on the VIDAS®3 automated system (bioMérieux).~The automated system then performs a assay (immunofluorescence technique) to quantify the concentrations of IFN-γ in the supernatant of each sample. The entire process is automated, and results are obtained within 4 hours."
214707338|NCT05459766|BEHAVIORAL|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
215165510|NCT06909136|DRUG|Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)|5-20mg BID (dosage per investigator judgement,JAKi intolerable pts will receive recuded dose of RUX(≥ 5mg BID),and suboptimal JAKi response pts will receive RUX of 15-20 mg BID）
214561852|NCT04009733|BIOLOGICAL|Blood sample|A study specific blood sample will be collected.
214561853|NCT04009733|BIOLOGICAL|Blood sample|Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.
215165511|NCT07096297|DRUG|Luspatercept|Luspatercept will be administered every 3 weeks (21 days) at a starting dose of 1.0 mg/kg (Dose Level 0). Luspatercept will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Participants must have Hgb, blood pressure and weight assessed (changes of body weight of ≤ ± 5% do not require a dose adjustment) prior to each luspatercept dose administration. Subcutaneous injections will be given in the upper arm, thigh, and/or abdomen. Volume for subcutaneous injection will be per institutional standard/guidelines.
215165512|NCT07096297|DRUG|Darbeopoetin|Darbepoetin alfa will be administered every 3 weeks (21 days), at a starting dose of 300 ug (Dose Level 0). Darbepoetin alfa will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Darbepoetin alfa will be administered as a subcutaneous injection by the site staff in the upper arm, thigh, and/or abdomen per institutional standard/guidelines.
215165513|NCT07092566|DRUG|Ropivacaine HCL|123 mg, intramuscular
214561854|NCT00910377|BEHAVIORAL|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
214561855|NCT00282672|DEVICE|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
214561856|NCT00282672|DEVICE|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
214561857|NCT04403087|DRUG|Trimebutine 100 MG|Trimebutine 100mg three times a day
214561858|NCT01852318|DRUG|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
214561859|NCT01852318|DRUG|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
214561860|NCT01852318|DRUG|placebo|
214561861|NCT02525718|DRUG|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
214561862|NCT02525718|DRUG|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
214561863|NCT01621308|OTHER|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
214561864|NCT01253135|BIOLOGICAL|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
214561865|NCT01253135|OTHER|White Petrolatum|Topical application
214561866|NCT02712073|OTHER|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
214561867|NCT02285296|OTHER|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
214561868|NCT04532229|DRUG|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
214561869|NCT06422000|DRUG|Pentoxifylline|Pentoxifylline 30 mg/kg given over 6 hours daily
214561870|NCT06422000|DRUG|Probiotic Formula|probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
214561871|NCT06455735|DRUG|68Ga-JH04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
214561872|NCT06455735|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
214561873|NCT00075842|DIETARY_SUPPLEMENT|Valeriana officinalis extract|Given orally
214561874|NCT00075842|OTHER|placebo|Given orally
214561875|NCT03915847|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.
214707339|NCT05459766|BEHAVIORAL|Usual care|Participants will be educated about the postoperative rehabilitation program
214707340|NCT04819581|DRUG|SP-103|lidocaine topical system 5.4%
214707341|NCT04819581|DRUG|ZTlido|lidocaine topical system 1.8%
214561876|NCT03915847|PROCEDURE|Double layer closure|The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
214561877|NCT03915847|PROCEDURE|Doble layer closure with trimming|Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
214561878|NCT03186053|DRUG|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
214561879|NCT03186053|DRUG|saline|.Loading dose followed by continuous infusion in operation
214707342|NCT04226963|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
214707343|NCT05840341|DRUG|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
214707344|NCT01153308|OTHER|Observational Study|This is an Observational study
214707345|NCT04685499|DRUG|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
214707346|NCT04685499|DRUG|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
214707347|NCT03176277|DRUG|ONO-7475 3mg once daily|Part A initial dose level
214707348|NCT03176277|DRUG|ONO-7475 6mg once daily|Part A 2nd dose level
214707349|NCT03176277|DRUG|ONO-7475 10mg once daily|Part A 3rd dose level
214707350|NCT03176277|DRUG|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax Combination
214707351|NCT04508062|PROCEDURE|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
215165514|NCT07092566|DRUG|Exparel|100 mL total dose - Intramuscular (IM), intraoperatively
215165515|NCT07092566|DRUG|Epinephrine|0.25 mg, intramuscular
215165516|NCT07092566|DRUG|Clonidine HCL|0.04 mg, intramuscular
214561880|NCT05702697|DEVICE|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
214561881|NCT05702697|BEHAVIORAL|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
214707352|NCT04508062|PROCEDURE|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
214707353|NCT04565600|DRUG|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
214707354|NCT00634114|DRUG|Esomeprazole|10mg once daily oral administration
214707355|NCT00634114|DRUG|Esomeprazole|20mg once daily oral administration
214707356|NCT00634114|DRUG|Omeprazole|10mg once daily oral administration
214707357|NCT02598505|DRUG|Indacaterol|
214707358|NCT02598505|DRUG|Placebo|
214707359|NCT04895098|DRUG|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
214707360|NCT04895098|DRUG|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
214707361|NCT01442532|DRUG|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
214707362|NCT01442532|DRUG|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
214707363|NCT01442532|DRUG|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
214707364|NCT01442532|DRUG|Placebo|Form=tablet, route=oral use, for 14 days
214707365|NCT01442532|DRUG|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
215165517|NCT07092566|DRUG|Ketorolac|15 mg, intramuscular
215165518|NCT06731855|PROCEDURE|Abdominal Surgery for congenital gut malformation in the first 5 days of life.|Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.
215165519|NCT06905158|DEVICE|White noise device|"* Product name: TinniSoothe white noise-non-invasive tinnitus device~* Usage: Worn around the neck during the daytime and docked to a stand at night~* Duration: At least one-month of use"
215165520|NCT06908954|DRUG|Palovarotene|A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function
215165521|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)
215165522|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).
215165523|NCT07098663|DRUG|MKP10241|Oral liquid suspension of unit dose strength 6.6 mg/mL
215165524|NCT07098663|DRUG|Placebo|Oral liquid suspension matched in appearance to MKP10241 at dosage strengths
215165525|NCT06911502|DRUG|Golcadomide|Specified dose on specified days
215165526|NCT06911502|DRUG|Rituximab|Specified dose on specified days
215165527|NCT06911502|DRUG|Lenalidomide|Specified dose on specified days
215165528|NCT06911502|DRUG|Cyclophosphamide|Specified dose on specified days
214707366|NCT03315728|OTHER|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
214707367|NCT04742049|OTHER|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
214707368|NCT04742049|OTHER|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
214707369|NCT06999993|DRUG|Sodium hyaluronate jell|sodium hyaluronate gel was used to decrease or prevent tissue lyres adhesion after surgery
214707370|NCT06999993|DRUG|Sodium Bicarbonate|sodium bicarbonate decreases tissue acidosis and so it decreases fibrosis
214707371|NCT06999993|DRUG|Saline|saline 0.9% is a placebo
214707372|NCT00344149|DRUG|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
214561882|NCT05290753|DRUG|Prokinetic Motility Agents as primpiram and gastreg|Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
214561883|NCT01886859|DRUG|Ibrutinib|Given PO
214561884|NCT01886859|DRUG|Lenalidomide|Given PO
214561885|NCT05726240|DRUG|Ghrelin|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
214707373|NCT03699631|DRUG|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
214707374|NCT03699631|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
214561886|NCT02880787|DRUG|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
214561887|NCT02880787|DEVICE|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
214561888|NCT01802151|DIETARY_SUPPLEMENT|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
214561889|NCT01802151|DIETARY_SUPPLEMENT|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
214707375|NCT03699631|DRUG|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
215165529|NCT06911502|DRUG|Doxorubicin|Specified dose on specified days
214561890|NCT03663543|DRUG|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
215165530|NCT06911502|DRUG|Vincristine|Specified dose on specified days
215165531|NCT06911502|DRUG|Prednisone/Prednisolone|Specified dose on specified days
215165532|NCT06911502|DRUG|Bendamustine|Specified dose on specified days
215165533|NCT07090785|DRUG|LY4088044|Administered IV
215165534|NCT07090785|DRUG|LY4088044|Administered SC
215165535|NCT07090785|DRUG|Placebo|Administered IV
215165536|NCT07090785|DRUG|Placebo|Administered SC
214707376|NCT06440369|OTHER|Training group|"The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR."
214707377|NCT06440369|OTHER|Physical activity orientation group|Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
214561891|NCT03663543|DRUG|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
214561892|NCT01901432|DRUG|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
214561893|NCT05859516|DIAGNOSTIC_TEST|Ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
214707378|NCT03292679|PROCEDURE|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
214707379|NCT02940626|DRUG|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
214707380|NCT02940626|DRUG|Placebo|Placebo
214561894|NCT00129480|BEHAVIORAL|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
214561895|NCT00379288|DRUG|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
214561896|NCT00379288|DRUG|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
214561897|NCT00379288|DRUG|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
214561898|NCT00379288|DRUG|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
214561899|NCT06144021|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
214561900|NCT06144021|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
214561901|NCT03898232|RADIATION|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
214561902|NCT02297659|PROCEDURE|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
214561903|NCT02297659|DEVICE|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
214561904|NCT05457075|DIAGNOSTIC_TEST|Immune checkpoint measure|The measurement of soluble immune checkpoints of stage II-III rectal cancer before neoadjuvant treatment
214561905|NCT06298240|OTHER|nursing procedure for acute health problems of low complexity|An agreed nursing procedure is applied for users of a primary care emergency center who spontaneously consult for 5 acute health problems of low complexity: gastroenteritis, cystitis in women, dental pain, upper respiratory tract affections and acute wounds
214561906|NCT06390852|PROCEDURE|Biopsy Procedure|Undergo biopsy
214561907|NCT06390852|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214561908|NCT06390852|PROCEDURE|Computed Tomography|Undergo CT scan
214561909|NCT06390852|DRUG|Larotrectinib|Given PO
214561910|NCT06390852|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214561911|NCT03997175|OTHER|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
214561912|NCT03997175|OTHER|Placebo|Sand that looks like intervention sand but does not have high biodiversity
214561913|NCT03468062|DRUG|Dexmedetomidine|Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
214561914|NCT00918879|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
214561915|NCT00918879|DRUG|Placebo|Oral tablet, once daily for 24 weeks
214707381|NCT01364350|OTHER|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
214707382|NCT05737173|DRUG|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
214707383|NCT05737173|DRUG|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
214707384|NCT05737173|DRUG|Corticosteroid|Intra-articular knee injection
214707385|NCT01996904|PROCEDURE|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
214707386|NCT01996904|PROCEDURE|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
214707387|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
214707388|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
214707389|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
214707390|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
214707391|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
214561916|NCT00491166|DRUG|Bromfenac ophthalmic solution|
214561917|NCT04606186|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
214561918|NCT04606186|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
214561919|NCT00003397|BIOLOGICAL|filgrastim|
214561920|NCT00003397|BIOLOGICAL|rituximab|
214561921|NCT00003397|BIOLOGICAL|sargramostim|
214561922|NCT00003397|DRUG|carmustine|
214707392|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
215165537|NCT07087340|DEVICE|UBLoop System|"Participants (people living with Type-1-Diabetes) will attend a study visit where the UBLoop system will manage insulin delivery via an insulin pump, using blood glucose values from a continuous glucose meter (CGM). Specialized staff and a remote monitoring system, which is integrated into the UBLoop system, will oversee the participants. The investigational product comprises (1) the BernSHELL App, communicating with the CGM and the insulin pump, (2) the UBLoop algorithm receiving CGM data, processing the control algorithm, calculating insulin dosing, checking the safety of the calculated insulin injections, and transmitting instructions to the insulin pump via BernSHELL, (3) the UBLoop Cloud providing secure storage, analytics support, and data backup, (4) DigiCare, monitoring the safety of the study participants and the system's execution flow in real time.~During the intervention, participants will use the Ypsomed myLife YpsoPump (insulin pump) and the Dexcom G6 or G7 CGM."
214561923|NCT00003397|DRUG|cisplatin|
214561924|NCT00003397|DRUG|cyclophosphamide|
214561925|NCT00003397|DRUG|dexamethasone|
214561926|NCT00003397|DRUG|etoposide|
214561927|NCT00003397|DRUG|gemcitabine hydrochloride|
214561928|NCT00003397|DRUG|melphalan|
214561929|NCT00003397|DRUG|paclitaxel|
214561930|NCT00003397|PROCEDURE|bone marrow ablation with stem cell support|
214561931|NCT00003397|PROCEDURE|peripheral blood stem cell transplantation|
214561932|NCT05321277|DIETARY_SUPPLEMENT|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
214561933|NCT05321277|DIETARY_SUPPLEMENT|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
214561934|NCT00685139|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
214561935|NCT00685139|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
214561936|NCT00833261|DRUG|cetuximab|cetuximab
214561937|NCT00833261|DRUG|cisplatin|cisplatin
214561938|NCT00833261|RADIATION|intensity-modulated radiation therapy|IMRT
214561939|NCT00833261|DRUG|Nab-Paclitaxel|Nab-Paclitaxel
214561940|NCT00259623|DEVICE|Radiofrequency ablation|
214561941|NCT00127686|DRUG|Dextromethorphan|
214561942|NCT00127686|DRUG|Buckwheat Honey|
214561943|NCT00031642|BIOLOGICAL|rituximab|
214561944|NCT00031642|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214561945|NCT04716777|BEHAVIORAL|Brief Transdiagnostic group-based Cognitive-Behavioral Treatment|Weekly group-based transdiagnostic CBT sessions for eight weeks.
214707393|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
214707394|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
214707395|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
214707396|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
214707397|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
214707398|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
214707399|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
214707400|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
214707401|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
214707402|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
214707403|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
214707404|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
214707405|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
214707406|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
214707407|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
214707408|NCT02430662|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
214561946|NCT04151589|BEHAVIORAL|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
214561947|NCT01805453|DRUG|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg\*2/day until the halting for any reason
214561948|NCT01805453|DRUG|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
214561949|NCT01532804|DRUG|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
214561950|NCT01532804|DRUG|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
214561951|NCT03149575|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
214561952|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
214561953|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
214561954|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
214561955|NCT03544853|DEVICE|Prosthetic socket for transtibial amputee|To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
214561956|NCT03753698|DEVICE|eCoin|"Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient."
214561957|NCT02930395|PROCEDURE|serum S100B assay|
214561958|NCT05500677|DRUG|Lidocaine topical|Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
214561959|NCT00357110|DRUG|Fulvestrant|intramuscular injection
214561960|NCT00357110|DRUG|Anastrozole|1 mg oral tablet
214561961|NCT00688129|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
214561962|NCT04496245|DRUG|Broncho-Vaxom®|Broncho-Vaxom adult capsules® (OM85)
214561963|NCT06126458|OTHER|shooting performance|collecting total points after 72 target shootings done
214561964|NCT04850872|BEHAVIORAL|PLAYwithHEART Programme for adolescent athletes|PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
214561965|NCT00301678|BEHAVIORAL|behavioral dietary intervention|
214561966|NCT00301678|OTHER|educational intervention|
214561967|NCT00301678|OTHER|preventative dietary intervention|
214561968|NCT01303653|PROCEDURE|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
214561969|NCT06138613|DRUG|Tradipitant|Oral Capsule
214561970|NCT02863770|OTHER|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
214561971|NCT01244932|DRUG|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
214561972|NCT00962377|PROCEDURE|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
214707409|NCT02430662|DEVICE|NanoKnife|
214707410|NCT00648193|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
214707411|NCT00648193|DRUG|Paxil® 40 mg Table|40mg, single dose fasting
214707412|NCT00198445|DRUG|Bromfenac|One drop in study eye every 12 hours for 14 days
214707413|NCT00198445|DRUG|Placebo|One drop in study eye every 12 hours for 14 days
214707414|NCT01047761|OTHER|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
214707415|NCT02205606|DRUG|HGP0816 5mg|P.O.
214707416|NCT02205606|DRUG|HGP0816 10mg|P.O.
214707417|NCT02205606|DRUG|HGP0816 20mg|P.O.
214707418|NCT02205606|DRUG|HCP1306 5/10mg|P.O.
214707419|NCT02205606|DRUG|HCP1306 10/10mg|P.O.
214707420|NCT02205606|DRUG|HCP1306 20/10mg|P.O.
214707421|NCT00382980|BIOLOGICAL|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
214707422|NCT00382980|BIOLOGICAL|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
214707423|NCT00382980|DRUG|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
214561973|NCT00962377|PROCEDURE|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
214561974|NCT05912829|DEVICE|IOL Master 700|Biometry using the IOL Master 700
214561975|NCT05912829|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
214561976|NCT05912829|DEVICE|MS-39|Corneal Topography using the MS-39
214707424|NCT00585923|DEVICE|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
214707425|NCT00585923|DEVICE|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
214707426|NCT02840890|PROCEDURE|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
214707427|NCT02840890|PROCEDURE|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
214707428|NCT05322057|DRUG|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
214707429|NCT04345406|DRUG|ACEIs|Captopril or enalapril
214707430|NCT04345406|DRUG|Conventional treatment|alexoquine
214707431|NCT00923819|PROCEDURE|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
214707432|NCT00923819|BEHAVIORAL|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
214707433|NCT03447613|PROCEDURE|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
214561977|NCT05912829|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
214561978|NCT05912829|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
214561979|NCT05912829|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
214561980|NCT05912829|DIAGNOSTIC_TEST|Biomicroscopy|Slit Lamp Examination
214561981|NCT02116790|DRUG|Naproxen|Subjects will take one 250mg Naproxen capsule
214561982|NCT02116790|DRUG|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
214561983|NCT02116790|DRUG|Sinemet|Subjects will take one 25mg/100mg Sinemet.
214561984|NCT02116790|DRUG|Placebo|Subjects will take two placebos.
214561985|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
214707434|NCT02051894|DRUG|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
214707435|NCT00000944|DRUG|Indinavir sulfate|
214707436|NCT00000944|DRUG|Lamivudine|
214707437|NCT00000944|DRUG|Zidovudine|
214707438|NCT01791114|OTHER|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
214561986|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
214561987|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
214561988|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
214707439|NCT01791114|OTHER|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
214707440|NCT01791114|OTHER|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
214707441|NCT01791114|OTHER|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
214707442|NCT01791114|OTHER|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
214707443|NCT01791114|OTHER|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
214707444|NCT01791114|OTHER|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
214707445|NCT03016299|PROCEDURE|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
214561989|NCT01290289|OTHER|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia \& a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl \& a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
214561990|NCT01985451|DRUG|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
214561991|NCT01985451|DRUG|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
214561992|NCT06335485|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend 4 CBT sessions prior to surgery and 2 optional sessions after surgery.
214561993|NCT03675373|BEHAVIORAL|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
214707446|NCT06391957|DIETARY_SUPPLEMENT|Spirulina supplement|Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
215165538|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
215165539|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
215165540|NCT07098338|DRUG|Rilvegostomig|Rilvegostomig will be administered as IV infusion.
215165541|NCT07098338|DRUG|Ramucirumab|Ramucirumab will be administered as IV infusion.
215165542|NCT07098338|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
215165543|NCT07099651|OTHER|tests|neuropsychological tests + Neuroimaging
215165544|NCT07099482|DEVICE|Sham ultrasound (placebo)|Participants will receive conventional wound care including debridement, cleaning, and dressing. A sham ultrasound device that emits no therapeutic waves will be applied to simulate the intervention procedure.
215165545|NCT07099482|DRUG|Propolis gel (10%)|Participants will receive topical application of 10% propolis gel on the diabetic foot ulcer followed by therapeutic ultrasound (phonophoresis) using 1 MHz frequency, 0.5-1.5 W/cm² intensity, pulsed mode (20%), for 5 minutes per session, 3 sessions/week for 4 weeks.
214707447|NCT06391957|PROCEDURE|Eccentric exercise|On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
214707448|NCT06391957|DIETARY_SUPPLEMENT|Placebo supplement|Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
214707449|NCT00972829|DRUG|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
214707450|NCT00972829|DRUG|Ezetimibe|Ezetimibe 5 or 10 milligrams
214707451|NCT00054249|DRUG|T900607|
214707452|NCT02541474|OTHER|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
214707453|NCT05625854|BEHAVIORAL|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
214707454|NCT05625854|BEHAVIORAL|Blow a fan to the face|Blow a fan to the face
215165546|NCT00310180|DRUG|Anastrozole|Given PO
215165547|NCT00310180|DRUG|Exemestane|Given PO
214561994|NCT03675373|BEHAVIORAL|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
214561995|NCT05070585|DIETARY_SUPPLEMENT|Isothiocyanate rich sprouts|Isothiocyanate rich sprout juice consumption for 1 week
214561996|NCT05070585|DIETARY_SUPPLEMENT|Placebo Juice|Sprout juice devoid of isothiocyanates for 1 week
214561997|NCT00559312|DRUG|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
214561998|NCT00559312|DRUG|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
214561999|NCT03942484|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the device.
214562000|NCT03075696|DRUG|Glofitamab|Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
214562001|NCT03075696|DRUG|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
214562002|NCT03075696|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
214562003|NCT05540106|BEHAVIORAL|Nature Coloring Packet|Coloring packet containing nature scenes
214562004|NCT05540106|BEHAVIORAL|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
214562005|NCT05540106|BEHAVIORAL|Activity Book|Pages containing word searches, connect the dots, etc.
214562006|NCT05540106|BEHAVIORAL|Blank Paper and Pencil|Blank sheets of paper and a pencil.
214707455|NCT05625854|BEHAVIORAL|Blow a fan to the feet|Blow a fan to the feet
214707456|NCT03800862|DEVICE|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
214707457|NCT02399592|DRUG|Bevacizumab|10 mg/kg q3w
214707458|NCT02399592|DRUG|Tocotrinol|300 mg tid
214707459|NCT01457001|DRUG|25-OH-D vitamin|
214707460|NCT01324622|DEVICE|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
214707461|NCT01324622|PROCEDURE|laminectomy|standard procedure
214707462|NCT00041769|PROCEDURE|Therapeutic Drug Monitoring (TDM)|
214707463|NCT00618449|DRUG|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
214707464|NCT00618449|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
215165548|NCT00310180|OTHER|Laboratory Biomarker Analysis|Correlative studies
214562007|NCT02860494|DRUG|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
214562008|NCT02860494|DRUG|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
214562009|NCT05039216|BIOLOGICAL|Blood sampling|4 tubes of 7 mL will be sampled
214562010|NCT04045964|DRUG|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
214562011|NCT04045964|BEHAVIORAL|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
214562012|NCT04045964|BEHAVIORAL|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
214707465|NCT05127421|DRUG|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
214707466|NCT05127421|DRUG|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
214707467|NCT01441115|PROCEDURE|Radiation Therapy|
215165549|NCT00310180|DRUG|Letrozole|Given PO
215165550|NCT00310180|OTHER|Quality-of-Life Assessment|Ancillary studies
214707468|NCT01441115|DRUG|ECI301|
214707469|NCT02709473|DRUG|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
214562013|NCT04521569|DRUG|Regadenoson|If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
214562014|NCT04521569|DRUG|Placebo|If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
214562015|NCT06011018|OTHER|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
214562016|NCT06011018|OTHER|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
214562017|NCT06011018|OTHER|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (pink noise), with 14Hz binaural beat stimulation
214562018|NCT06218823|DRUG|Transdermal Nicotine Patch|a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
214562019|NCT06218823|BEHAVIORAL|Standard Telephone Counseling|3 brief telephone-based smoking cessation counseling sessions
214562020|NCT06218823|DRUG|Varenicline|12 weeks of an oral smoking cessation medication
214562021|NCT06218823|BEHAVIORAL|Cancer-Targeted Telephone Counseling|7 telephone-based smoking cessation counseling sessions adapted for cancer patients
214562022|NCT06218823|OTHER|Mailed Information about Standard Care Resources|Publicly funded treatment resources including the SmokefreeTXT program sponsored by the National Cancer Institute and the Wisconsin Tobacco Quit Line.
215165551|NCT00310180|RADIATION|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
215165552|NCT00310180|DRUG|Tamoxifen Citrate|Given PO
215165553|NCT06779890|DRUG|Sevoflurane|Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
215165554|NCT06779890|DRUG|Desflurane|Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
215165555|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
215165556|NCT02625480|DRUG|Fludarabine|Administered intravenously
215165557|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
215165558|NCT06058455|BEHAVIORAL|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
215165559|NCT06058455|BEHAVIORAL|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
215165560|NCT07095140|OTHER|Ecological Momentary Assessment|Complete EMAs
215165561|NCT07095140|OTHER|Monitoring|Wear alcohol monitoring wristband
215165562|NCT07095140|DRUG|Nicotine Oral Pouch|Receive ONPs
215165563|NCT07095140|OTHER|Survey Administration|Ancillary studies
215165564|NCT07098312|BEHAVIORAL|creative drama|It is aimed to develop cultural competence in nursing students through creative drama workshops.
215165565|NCT06926881|DEVICE|BiWaze Clear System|"The BiWaze Clear device includes several components as follows:~1. BiWaze Clear System.~2. BiWaze Clear Dual Lumen Breathing Circuit.~   * Dual Lumen bacterial/viral filter.~  * Dual Lumen breathing tube.~  * Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter).~3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System"
215165566|NCT06904066|DRUG|aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
215165567|NCT06904066|DRUG|cyclophosphamide|300 mg/m\^2 IV infusion over 30 minutes. Daily x 3 doses on days -5, -4, -3.
215165568|NCT06904066|DRUG|fludarabine phosphate|30 mg/m\^2 IV infusion over 30 minutes administered immediately following cyclophosphamide on day -5, -4, -3. Participants with renal dysfunction receive a lower dose of fludarabine.
215165569|NCT06904066|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Up to 1.5x10\^11 total cells for non-transplant subjects. 1x10\^10 total cells for post-alloHSCT subjects.
215165570|NCT06904066|DEVICE|TruSight Oncology (TSO) 500|TSO500 sequencing panel performed in the NCI Laboratory of Pathology to detect TP53 or RAS mutations
214707470|NCT02709473|DRUG|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
214707471|NCT02709473|DRUG|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
214707472|NCT00234416|DRUG|Gefitinib|
214707473|NCT00234416|DRUG|Gemcitabine|
214707474|NCT01589055|DRUG|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
214707475|NCT06019910|OTHER|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
214707476|NCT02503631|DEVICE|Stool Sample Collection Kit|Stool sample collection kit
214707477|NCT01798940|DRUG|Torrent's Pioglitazone|
214707478|NCT00208741|DRUG|Gabitril|
214707479|NCT00138424|DRUG|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
214707480|NCT00138424|DRUG|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
214707481|NCT01498081|DRUG|AZD2115|AZD2115 administered via inhalation
214707482|NCT01498081|DRUG|Placebo|Placebo administered via inhalation
214707483|NCT01498081|DRUG|Indacaterol|Indacaterol administered via inhalation
214707484|NCT01498081|DRUG|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
214707485|NCT02477228|PROCEDURE|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
214707486|NCT02477228|PROCEDURE|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
214707487|NCT01802554|BEHAVIORAL|Pleasant Events Program (PEP)|Behavioral Activation Therapy
214707488|NCT01802554|BEHAVIORAL|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
214707489|NCT06271447|OTHER|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
214707490|NCT04813939|DEVICE|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
214707491|NCT05310513|OTHER|Whether the patient needs to be admitted to the ICU|According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
214707492|NCT00912899|DRUG|Noscapine HCl|Escalating doses given twice per day
214707493|NCT00062699|DRUG|Zemplar (paricalcitol injection)|
214707494|NCT00062699|DRUG|Calcijex|
214707495|NCT04156932|PROCEDURE|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
214707496|NCT00574496|DRUG|cyclophosphamide|
214707497|NCT00574496|DRUG|cyclosporine|
214707498|NCT00574496|DRUG|fludarabine phosphate|
214707499|NCT00574496|DRUG|gemcitabine hydrochloride|
214707500|NCT00574496|DRUG|ifosfamide|
214707501|NCT00574496|DRUG|mechlorethamine hydrochloride|
214707502|NCT00574496|DRUG|melphalan|
214707503|NCT00574496|DRUG|methotrexate|
214707504|NCT00574496|DRUG|mycophenolate mofetil|
214707505|NCT00574496|DRUG|prednisone|
214707506|NCT00574496|DRUG|procarbazine hydrochloride|
214707507|NCT00574496|DRUG|vincristine sulfate|
214707508|NCT00574496|DRUG|vinorelbine tartrate|
214707509|NCT00574496|PROCEDURE|allogeneic bone marrow transplantation|
214707510|NCT00574496|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214562023|NCT00700700|DEVICE|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1\. Ovatio CRT 6750"
214562024|NCT02683551|PROCEDURE|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
214562025|NCT06797336|DRUG|PT0253|PT0253 injection.
214562026|NCT05574699|OTHER|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
214562027|NCT05574699|OTHER|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
214562028|NCT05143697|BEHAVIORAL|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
214562031|NCT03711032|BIOLOGICAL|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
214562032|NCT03711032|BIOLOGICAL|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
214562033|NCT06833372|DEVICE|ESWT group|During each session, participants will receive 2000 pulses at a frequency of 4 Hz and an EDF between 0.02 and 0.2 mJ/mm2.
214562034|NCT06833372|OTHER|exercise group|daily exercise program
214562035|NCT06375629|DEVICE|FocalOne|The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device. This study is a non-interventional study. All the data will be collected from routine care. Data as indicated in the table below will be systematically recorded on the e-CRF to coincide with the scheduled follow-up visits at 3, 6 and 12 months.
214562036|NCT06223269|DRUG|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
214562037|NCT06223269|PROCEDURE|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
214562038|NCT05905419|OTHER|Opioid Phase|"Opioid-taking patients are assigned to take their prescribed opioid medication before (peak opioid phase) during 1 scan and after (trough opioid phase) during the other MRI scan"
214562039|NCT06457451|OTHER|DIAPASOM program|A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized dietetic care by a dietician for one year.
214562040|NCT04881383|DIAGNOSTIC_TEST|OGTT and HbA1c|An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
214562041|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
214562042|NCT06460259|BEHAVIORAL|Breathing Exercise|He individual will be seated in a quiet environment in a semi-fowler or fowler position with their feet pointing forward. Then, they will be asked to join their hands on their abdomen and breathe normally while focusing on their breath. They will ensure their shoulders are relaxed, their body is loose, and they will inhale and exhale slowly and deeply through the nose without rushing.Next, while sitting upright with relaxed muscles, they will close their eyes, block their right nostril with their thumb or ring finger, inhale as much air as possible through the left nostril, and hold their breath. Then, they will block the left nostril with their ring finger or thumb and exhale slowly through the right nostril. The same process will be repeated for the left nostril. They will continue this process for approximately 2 minutes.
214562043|NCT05046613|OTHER|Rimegepant|75mg
214562044|NCT05046613|OTHER|Not taking Rimegepant|No rimegepant
214562045|NCT00537589|PROCEDURE|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
214707511|NCT00574496|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214707512|NCT00574496|PROCEDURE|peripheral blood stem cell transplantation|
214707513|NCT00574496|PROCEDURE|umbilical cord blood transplantation|
214707514|NCT00574496|RADIATION|total-body irradiation|
214707515|NCT04935125|PROCEDURE|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
214707516|NCT04935125|PROCEDURE|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
214707517|NCT02176291|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
214707518|NCT02176291|DRUG|Placebo|matched placebo
214707519|NCT02946541|DRUG|evogliptin 5mg|evogliptin 5mg, QD
214707520|NCT02946541|DRUG|Placebo|Placebo, QD
214707521|NCT01005511|DEVICE|Grindcare|Active treatment
214707522|NCT01005511|DEVICE|Grindcare - inactive|Placebo treatment
214707523|NCT01881971|DRUG|Placebo|suger pill manufactured to mimic crestor pills
214707524|NCT01881971|DRUG|Rouvastatin calcium|
214707525|NCT00740883|DRUG|warfarin|18 months of warfarin therapy, once daily
214707526|NCT00740883|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
214707527|NCT04284020|BEHAVIORAL|Therapeutic educational program|See arm/group descriptions
214707528|NCT04284020|OTHER|PFMT|See arm/group descriptions
214707529|NCT04284020|OTHER|TTNS|See arm/group descriptions
215165571|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
215165572|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
215165573|NCT06911320|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination|A single dose of BEM/RZR will be administered
215165574|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
215165575|NCT06319872|DRUG|Oral disulfiram|250 mg/day
215165576|NCT06118333|DRUG|BL-B01D1|Administration by intravenous infusion
215165577|NCT06118333|DRUG|capecitabine|Oral administration
215165578|NCT06118333|DRUG|gemcitabine|Administration by intravenous infusion
215165579|NCT06118333|DRUG|docetaxel|Administration by intravenous infusion
215165580|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
215165581|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
215165582|NCT06752330|DIETARY_SUPPLEMENT|Use of probiotics during oral hygiene at home|The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
215165583|NCT07099430|DRUG|LBL-024 for Injection|LBL-024 , Intravenous infusion.
215165584|NCT07099430|DRUG|LBL-007 Injection|LBL-007 , intravenous infusion.
215165585|NCT07099430|DRUG|Toripalimab Injection|Toripalimab , intravenous infusion.
214562046|NCT05854472|OTHER|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
214707530|NCT03506022|OTHER|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
214707531|NCT01318772|DEVICE|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
214707532|NCT01018719|DEVICE|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
214707533|NCT05127070|DEVICE|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
214707534|NCT01881841|BEHAVIORAL|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
214707535|NCT00901147|DRUG|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
214707536|NCT02247284|DEVICE|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
214707537|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
214707538|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
214707539|NCT01167582|BIOLOGICAL|Red blood cell transfusion|Liberal versus restrictive transfusion
214707540|NCT02303873|DRUG|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
214707541|NCT05685576|DEVICE|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
214707542|NCT02231294|DRUG|Sifrol®|
214707543|NCT04060576|PROCEDURE|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
214562047|NCT05602727|DRUG|MK-1942|MK-1942 oral capsule
214707544|NCT04060576|PROCEDURE|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
214562048|NCT05602727|DRUG|Placebo|Placebo oral capsule
214562049|NCT02087449|DEVICE|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
214562050|NCT00309205|DRUG|dapivirine (TMC120) vaginal gel|
214562051|NCT03729401|DRUG|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
214562052|NCT03729401|DRUG|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
214562053|NCT03729401|DRUG|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
214562054|NCT00319462|DEVICE|hemoclip|
214707545|NCT04060576|PROCEDURE|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
214707546|NCT00004992|BEHAVIORAL|Intensive lifestyle|
214707547|NCT00004992|DRUG|Metformin|
214707548|NCT00004992|DRUG|Placebo|
214707549|NCT02723292|BEHAVIORAL|TOP|
214562055|NCT03896126|OTHER|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
214562056|NCT05777655|OTHER|Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)|Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
214562057|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
214707550|NCT02723292|BEHAVIORAL|Control intervention|
214707551|NCT04493294|RADIATION|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
214707552|NCT02557360|DIETARY_SUPPLEMENT|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
215165586|NCT06603246|DRUG|GDC-6988|GDC-6988 will be administered using a dry powder inhalation
214707553|NCT01431729|OTHER|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
214562058|NCT05314686|OTHER|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
214707554|NCT02172092|DRUG|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
214562059|NCT05314686|OTHER|Telerehabilitation|"An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
214562060|NCT04912453|PROCEDURE|Primary anastomosis|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
214562061|NCT04912453|PROCEDURE|Enterostomy|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
214562062|NCT02204332|DRUG|Cabazitaxel|
214562063|NCT02204332|OTHER|Best Supportive Care|
214562064|NCT00569101|DRUG|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg \~0.02 mg/kg + prednisolone tapering
214562065|NCT04287595|OTHER|Inhalation aromatherapy with orange essential oil|
214562066|NCT06000345|OTHER|AOT + MI|During the AOT session, the patients were shown a video containing motor contents. In particular, the video demonstrated quadriceps concentric and isometric contractions, presented in the third person perspective. At the conclusion of each video, the patients were asked to spend 1 minute imagining what they had just seen.
214562067|NCT06000345|OTHER|Control AOT + MI|The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
214562068|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
214562069|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
214562070|NCT00703066|BIOLOGICAL|Rabies vaccine|3 doses of Rabies vaccine
214562071|NCT00369252|DRUG|Nimotuzumab (TheraCIM h-R3)|
214562072|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
214562073|NCT05520775|DRUG|Semaglutide|Semaglutide (subcutaneous)
214562074|NCT05520775|DRUG|Sham/placebo|Sham subcutaneous injection
214562075|NCT03213717|OTHER|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
214562076|NCT03213717|BEHAVIORAL|Standing|Study subjects will be standing for at least 50 minutes every hour
214562077|NCT03213717|DIETARY_SUPPLEMENT|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
214562078|NCT03213717|BEHAVIORAL|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
214562079|NCT03213717|OTHER|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
214562080|NCT06500468|DEVICE|PillSense System|"The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected."
214562081|NCT05906251|GENETIC|SRP-6004|Single IV infusion of SRP-6004
214707555|NCT05368129|PROCEDURE|Balloon dilation|Balloon dilation was performed after DES implantation.
214562082|NCT06573801|DEVICE|Aktiia Bracelet|Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.
214562083|NCT06573801|DEVICE|Healthstats BPro Evo|Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.
214562084|NCT06573801|DEVICE|Spacelabs OnTrak Ambulatory Blood Pressure monitor|Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
214707556|NCT02225574|DRUG|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
214707557|NCT02225574|DRUG|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
214707558|NCT02225574|BEHAVIORAL|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
214707559|NCT03386331|BEHAVIORAL|diet and exercise|Diet and lifestyle intervention
214707560|NCT00574431|OTHER|Data Collection|Collection of patient data before implementation of a nutritional management protocol
214707561|NCT00574431|OTHER|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
214707562|NCT01518244|DRUG|Brinzolamide/timolol maleate fixed combination|
214707563|NCT00955292|DRUG|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
214707564|NCT02289404|DRUG|NVP-1203|Oral
214707565|NCT02289404|DRUG|NVP-1203|Oral
214707566|NCT01766817|DRUG|BMS-986020|
214707567|NCT01766817|DRUG|Placebo matching with BMS-986020|
214562085|NCT02013921|OTHER|Physical activity|
214562086|NCT00822653|DEVICE|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
214562087|NCT01283152|DRUG|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
214562088|NCT01283152|DRUG|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
214562089|NCT02961803|DRUG|MD1003 100 mg capsule|
214562090|NCT02961803|DRUG|Placebo|
214707568|NCT02902913|OTHER|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
214707569|NCT02902913|OTHER|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
214707570|NCT02902913|OTHER|D2i0|No oleocanthal and no oleacein
214707571|NCT02902913|DRUG|Ibuprofen|400 mg of Ibuprofen
214707572|NCT00674518|BEHAVIORAL|One on one counseling|Motivational Interviewing
214707573|NCT00674518|BEHAVIORAL|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
214707574|NCT00674518|BEHAVIORAL|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
214707575|NCT00094887|DRUG|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
214707576|NCT00094887|DRUG|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
214707577|NCT05166759|DEVICE|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
214707578|NCT02099942|DEVICE|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~* as stand-alone intervention~* as a bridge to transcatheter aortic valve replacement (TAVR)~* as a bridge to surgical aortic valve replacement (SAVR)~* as an intraprocedural predilatation prior to TAVR"
214707579|NCT02878733|DRUG|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
214707580|NCT00258206|BIOLOGICAL|rituximab|
214707581|NCT00258206|DRUG|cyclophosphamide|
214707582|NCT00004799|BIOLOGICAL|whole-cell pertussis vaccine|
214707583|NCT00004799|BIOLOGICAL|diphtheria-tetanus vaccine|
214707584|NCT04675359|PROCEDURE|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
214562091|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
214562092|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
214562093|NCT02441985|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
214562094|NCT02441985|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
214562095|NCT02441985|OTHER|Fullerton Advanced Balance (FAB) Scale|All participants will receive a clinical assessment of balance ability and fall risk.
214562096|NCT02441985|OTHER|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
214562097|NCT02441985|OTHER|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
214562098|NCT02441985|OTHER|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
214562099|NCT02441985|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition (CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
214562100|NCT05722353|OTHER|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
214562101|NCT06241547|DEVICE|electrical stimualtion via EmeTerm bracelet|We planned to exert electrical stimulation via the bracelet.
214562102|NCT06241547|DRUG|antimetic drugs（ dexamethasone，ondansetron）|Antimetic drugs (dexamethasone ondansetron) are used to prevent postoperative nausea and vomiting.
214562103|NCT05241314|BEHAVIORAL|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
214562104|NCT05241314|BEHAVIORAL|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
214562105|NCT03475654|BEHAVIORAL|Technology-assisted rehabilitation|The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
214562106|NCT03475654|BEHAVIORAL|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
214562107|NCT04020185|DRUG|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
214562108|NCT04020185|DRUG|Immune checkpoint inhibitor (ICI)|Administered according to product label
214562109|NCT04020185|DRUG|Immuno-oncology (IO) therapy|Administered according to product label
214562110|NCT02247453|OTHER|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
214562111|NCT01868932|OTHER|hypertonic saline|inhaled nebulized 3%NaCl
214562112|NCT01868932|OTHER|saline|inhaled nebulized 0.9% NaCl
215165587|NCT06821022|OTHER|Pain Neuroscience Education|The intervention group will receive a lecture of 70min duration on pain neuroscience. The objective of this educational session is to educate students that pain can be overprotective, and that nociceptive transmission can be heavily influenced by central sensitisation (sensitivity of the central nervous system) as well as the thoughts and beliefs of the individual. The session used drawings, stories and metaphors to depict the underlying neuroscience of pain, and current pain theory.
215165588|NCT06821022|OTHER|Red Flags Education|The control group received an education session of red flags. Red flags form part of routine subjective practice for therapists as a process of screening serious or potentially sinister pathologies. Sign and symptoms for such pathologies include history of cancer, systemic symptoms such as fever or unexplained weight loss, and saddle analgesia. The red flag session will not include the neuroscience of pain.
215165589|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
214562113|NCT00330252|DRUG|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
214562114|NCT00330252|DRUG|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
214707585|NCT03179007|BIOLOGICAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
214707586|NCT03215524|BIOLOGICAL|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
214707587|NCT03215524|BIOLOGICAL|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
214707588|NCT04287101|OTHER|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
214707589|NCT06252857|DRUG|Imiquimod Topical|Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
214707590|NCT00946569|DRUG|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
214707591|NCT00946569|DRUG|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
214707592|NCT04039191|BEHAVIORAL|SMS education|Patients will receive additional educational SMS messages post-operatively
214707593|NCT04039191|BEHAVIORAL|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
214707594|NCT01417065|DRUG|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
214707595|NCT02834091|PROCEDURE|Hypnoanalgesia|
214707596|NCT03714282|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
214707597|NCT03714282|DEVICE|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
214707598|NCT03714282|OTHER|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
214562115|NCT06380296|OTHER|Primary molars pulpotomies with NeoMTA|Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
214562116|NCT06380296|OTHER|Primary molar pulpotomies with NeoPUTTY|Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
214707599|NCT02089620|DRUG|Yasmin|will be used every 21 days for three months by the patient
214707600|NCT02089620|DIETARY_SUPPLEMENT|Calver|Calver will be given daily for 3 months
214707601|NCT02089620|DRUG|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
214707602|NCT02089620|DRUG|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
214707603|NCT03975374|DRUG|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
214707604|NCT03975374|DRUG|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
215165590|NCT07081555|DRUG|[177Lu]Lu-ABY-271|A single infusion of \[177Lu\]Lu-ABY-271
215165591|NCT07105020|BEHAVIORAL|Interviews|Interviews will be conducted in person, over the phone, or via Zoom.
215165592|NCT05296070|DRUG|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
215165593|NCT05296070|DRUG|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
215165594|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
215165595|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
215165596|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
215165597|NCT06618144|OTHER|Texting platform|Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
215165598|NCT07072234|DRUG|Lymphodepleting chemotherapy|Given by IV
215165599|NCT07072234|DRUG|Dexamethasone|Given PO
215165600|NCT07072234|DRUG|Fludarabine|Given by IV
215165601|NCT07072234|DRUG|Cyclophosphamate|Given by IV
214707605|NCT05760820|BEHAVIORAL|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini \& SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
214707606|NCT01240148|DRUG|AZD3161|Single dose, intradermal injection
214707607|NCT01240148|DRUG|Lidocaine|Single dose, intradermal injection
214707608|NCT01240148|DRUG|AZD3161 Placebo|
214707609|NCT05331430|OTHER|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
214707610|NCT02260648|DRUG|Evacetrapib|Administered orally
214707611|NCT02260648|DRUG|Ezetimibe|Administered orally
214707612|NCT02260648|DRUG|Atorvastatin|Administered orally
214707613|NCT02260648|DRUG|Placebo|Administered orally
214707614|NCT04755465|DEVICE|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
214562117|NCT04414202|PROCEDURE|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
214562118|NCT04414202|RADIATION|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
214562119|NCT06075186|OTHER|A survey to assess anesthesiologists' secondary victim experience and quality of support resources.|cross-sectional descriptive questionnaire
214562120|NCT00618176|DRUG|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid
214562121|NCT00618176|DRUG|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
214707615|NCT04755465|OTHER|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
214707616|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
214707617|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
214707618|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
214707619|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
214707620|NCT05454722|DEVICE|ADEX Gel|Emollient Gel with added anti-inflammatory
214707621|NCT05091892|OTHER|Hydrotherapy programm|Treatment
214562122|NCT00618176|DRUG|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
214562123|NCT06563999|DRUG|Sunvozertinib|300 mg orally once a day, 28 days as one cycle.
214562124|NCT06563999|DRUG|Crizotinib|300 mg orally once a day, 28 days as one cycle.
214562125|NCT06563999|DRUG|Pralsetinib|400 mg orally once a day, 28 days as one cycle.
214562126|NCT06563999|DRUG|Larotrectinib|100 mg orally twice daily, 28 days as one cycle.
214562127|NCT06563999|DRUG|Savolitinib|600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
214562128|NCT06563999|DRUG|Pyrotinib|400 mg orally once a day, 28 days as one cycle.
214562129|NCT06563999|DRUG|Dabrafenib+Trametinib|Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
214562130|NCT06563999|DRUG|Glecirasib|800 mg daily orally, 28 days as one cycle.
214562131|NCT06563999|DRUG|Ensartinib|225 mg daily orally, 28 days as one cycle.
214562132|NCT00717431|PROCEDURE|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
214707622|NCT02335112|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
214707623|NCT02335112|DEVICE|NanoKnife|
214707624|NCT02757781|BEHAVIORAL|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
214707625|NCT03691753|DEVICE|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
215165602|NCT07072234|DRUG|TGFBR-2 KO CD70 CAR NK|Given by IV
215165603|NCT06914908|DRUG|lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214707626|NCT03691753|DEVICE|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
214707627|NCT01401465|DRUG|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
214707628|NCT01401465|DRUG|mometasone|200 mcg mometasone aqueous nasal spray once daily
214707629|NCT02819895|OTHER|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
214562133|NCT05022901|COMBINATION_PRODUCT|Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)|Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
214562134|NCT03914001|DEVICE|mpMRI|all eligible patients will undergo mpMRI 4 weks after initial TURBT
214562135|NCT03914001|PROCEDURE|Second look TURBT|after mpMRI all patients will subjected to second look TURBT
214562136|NCT05829798|DEVICE|SYNOLIS VA 80/160|Single 4mL intra-articular injection of SYNOLIS VA 80/160
214562137|NCT05829798|DEVICE|SYNOLIS VA 40/80|Single 2mL intra-articular injection of SYNOLIS VA 40/80
214707630|NCT03497260|DIETARY_SUPPLEMENT|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
214707631|NCT03497260|OTHER|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
214707632|NCT04105569|PROCEDURE|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
214707633|NCT04545788|DRUG|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
214707634|NCT03001583|BEHAVIORAL|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
214707635|NCT03001583|BEHAVIORAL|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
214707636|NCT04944329|PROCEDURE|Hip fracture surgery|Hip fracture surgery
214707637|NCT01259973|DRUG|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
214707638|NCT01259973|DRUG|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
214707639|NCT01259973|DRUG|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
214707640|NCT04005196|DIAGNOSTIC_TEST|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
214707641|NCT06069011|OTHER|Interdisciplinary management|assessment and treatment in an interdisciplinary model
214707642|NCT06069011|OTHER|usual care|assessment and treatment in usual care model
214707643|NCT02916095|DRUG|Kanitinib|Oral administration of Kanitinib tablets.
214562138|NCT04035278|BIOLOGICAL|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
214562139|NCT04035278|BIOLOGICAL|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
214707644|NCT01011452|DRUG|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
214707645|NCT01011452|DRUG|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
214707646|NCT03565848|PROCEDURE|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
214707647|NCT05454930|OTHER|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
214707648|NCT00684125|DEVICE|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
214707649|NCT00684125|DEVICE|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
214707650|NCT04142216|DIETARY_SUPPLEMENT|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
214707651|NCT02615795|DEVICE|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
214707652|NCT00778986|DEVICE|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
214707653|NCT01737658|OTHER|Exercise Program|Exercise Program for Obese Adolescents
214707654|NCT03299855|OTHER|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
214707655|NCT02766790|DIETARY_SUPPLEMENT|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
214707656|NCT02766790|OTHER|Placebo|Placebo, an inactive formulation
214562140|NCT02811406|PROCEDURE|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
214707657|NCT05536193|DRUG|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
214707658|NCT05536193|DIAGNOSTIC_TEST|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
214707659|NCT03307954|DEVICE|Ekso Therapy (Exoskeleton Suit)|
214707660|NCT03307954|OTHER|Usual Physiotherapy|
214707661|NCT02746354|OTHER|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
214707662|NCT04901533|PROCEDURE|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
214707663|NCT04901533|PROCEDURE|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
214707664|NCT03558451|OTHER|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
214707665|NCT03558451|OTHER|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
214707666|NCT03095053|PROCEDURE|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
214707667|NCT04090047|DRUG|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
214707668|NCT04090047|DRUG|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
214707669|NCT04249505|DEVICE|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
214707670|NCT04249505|DEVICE|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
214707671|NCT04249505|DEVICE|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
214707672|NCT04965376|PROCEDURE|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
214707673|NCT04965376|PROCEDURE|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
214707674|NCT04870827|DRUG|13N Amonia|Administered during PET/CT scans
214707675|NCT01054976|DRUG|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
214707676|NCT01195363|DRUG|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
215165604|NCT06914908|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Intranasal spray Route of administration: intranasal
215165605|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used overnight for 14 days post-SRP
215165606|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used 2x/day for 30 minutes use
215165607|NCT06914609|DRUG|ION582|ION582 will be administered by IT injection.
215165608|NCT06914609|DRUG|Placebo|ION582 matching placebo will be administered by IT injection.
215165609|NCT03072927|DEVICE|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
214707677|NCT01195363|DRUG|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
214707678|NCT00744016|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
214707679|NCT00744016|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
214707680|NCT00000341|DRUG|Buprenorphine|
214707681|NCT02661841|OTHER|LI-Guided Therapy|Preemptive treatment according to LI monitoring
214707682|NCT02661841|OTHER|Heart Failure Guidelines|Treatment according to clinical signs
215165610|NCT03072927|DEVICE|Interspinous Process Decompression|Interspinous Process Decompression
214707683|NCT03665012|OTHER|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
214707684|NCT01178736|PROCEDURE|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
215165611|NCT00065676|OTHER|Quercetin|1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
215165612|NCT00065676|OTHER|Placebo|
214562141|NCT02811406|BIOLOGICAL|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
214707685|NCT01178736|PROCEDURE|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
214707686|NCT01178736|PROCEDURE|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
214707687|NCT01178736|PROCEDURE|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
214707688|NCT00514436|BEHAVIORAL|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
214707689|NCT02058485|DRUG|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
214562142|NCT02960737|DEVICE|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
214707690|NCT02058485|DRUG|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
214707691|NCT00750165|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
214707692|NCT02612961|OTHER|3mL of normal saline from the pink sodium chloride bullet|
214707693|NCT02612961|OTHER|Sham Comparator of 3mL normal saline|
214707694|NCT02240537|DRUG|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
214707695|NCT02240537|DRUG|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
214707696|NCT02240537|DRUG|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
214562143|NCT06147349|PROCEDURE|Radical or partial nephrectomy|Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
214707697|NCT00154141|DRUG|Fibrin sealant (FS2)|
214707698|NCT00538824|DRUG|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
214707699|NCT00538824|DRUG|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
214707700|NCT00538824|DRUG|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*"
214562144|NCT05087251|BEHAVIORAL|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
214562145|NCT05087251|BEHAVIORAL|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
214707701|NCT05580861|DRUG|Sulfasalazine|Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
214707702|NCT06885125|DIETARY_SUPPLEMENT|anti-inflammatory diet|The anti-inflammatory diet consists of a 12-week plant-based diet, followed by guidance and monitoring from a nutritionist.
214707703|NCT00077376|BIOLOGICAL|trastuzumab|Given IV
214707704|NCT00077376|DRUG|ixabepilone|Given IV
214707705|NCT00077376|DRUG|carboplatin|Given IV
214707706|NCT00077376|OTHER|laboratory biomarker analysis|Correlative studies
214707707|NCT02664532|OTHER|Miller group|Miller blade was used for laryngoscopy
214707708|NCT02664532|OTHER|Macintosh group|Macintosh blade was used for laryngoscopy
214707709|NCT04767919|PROCEDURE|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
214562146|NCT02847429|DRUG|Crenolanib|
214562147|NCT02847429|DRUG|Placebo|
214562148|NCT03433677|DRUG|LY900014|Administered by CSII
214707710|NCT04767919|PROCEDURE|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
214707711|NCT06812520|BEHAVIORAL|Educational intervention in adherence|An educational intervention of 4 face-to-face sessions will be carried out as a complement to the care provided by professionals to users with venous ulcers, which consists of the advanced healing procedure that includes compressive bandaging of the venous ulcer.
214707712|NCT00184782|PROCEDURE|FDG-PET|
214707713|NCT02024204|DRUG|Fluticasone propionate 230mcg for 3 Months|
215165613|NCT05939414|DRUG|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
215165614|NCT03899155|DRUG|Nivolumab|Specified dose on specified days
215165615|NCT03899155|DRUG|Ipilimumab|Specified dose on specified days
215165616|NCT03899155|DRUG|Cabozantinib|Specified dose on specified days
215165617|NCT03899155|DRUG|Trametinib|Specified dose on specified days
214562149|NCT03433677|DRUG|Insulin lispro|Administered by CSII
214562150|NCT00377442|DRUG|GK Activator (2)|100mg po
214562151|NCT00377442|DRUG|Simvastatin|80mg po
214562152|NCT06209853|DEVICE|PSMA PET/CT|Patients need no specific preparation. F-18 PSMA dose will be 3-4 MBq/kg and injected via IV route scan will be performed 90-120 min after injection
214562153|NCT04744272|DEVICE|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
214562154|NCT04339959|OTHER|Remote Assessment of Physical Function with Direct Observation|An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
214707714|NCT02024204|DRUG|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
214707715|NCT02024204|DRUG|Salmeterol 21mcg for 3 Months|
214707718|NCT07091162|OTHER|CTCA results|Participants who are assigned to CTCA group will receive their CTCA results
214707719|NCT07091162|OTHER|PRS results|Participants who are assigned to PRS group will receive their PRS results
214707720|NCT00717262|DRUG|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
214707721|NCT00717262|DRUG|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
214707722|NCT05506553|DEVICE|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
214707723|NCT05506553|DEVICE|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
214707724|NCT04643223|OTHER|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
215165618|NCT03899155|DRUG|Relatlimab|Specified dose on specified days
215165619|NCT03899155|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
215165620|NCT03899155|DRUG|Capecitabine|Specified dose on specified days
215165621|NCT03899155|DRUG|Bevacizumab|Specified dose on specified days
215165622|NCT03899155|DRUG|Temozolomide|Specified dose on specified days
215165623|NCT03899155|DRUG|Rucaparib|Specified dose on specified days
215165624|NCT03899155|DRUG|Daratumumab|Specified dose on specified days
215165625|NCT03899155|DRUG|Regorafinib|Specified dose on specified days
215165626|NCT03899155|DRUG|Leucovorin|Specified dose on specified days
215165627|NCT03899155|DRUG|Fluorouracil|Specified dose on specified days
214562155|NCT04339959|OTHER|Remote Assessment of Physical Function|An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
214562156|NCT03189342|BEHAVIORAL|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
214562157|NCT03189342|BEHAVIORAL|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
214562158|NCT03189342|BEHAVIORAL|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
214562159|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
214562160|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
214562161|NCT03304678|DRUG|Sirolimus 2mg|Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.
214562162|NCT03786991|OTHER|No intervention|No intervention
214562163|NCT01499303|DRUG|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
214562164|NCT01682772|DRUG|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
214562165|NCT06264128|DEVICE|TPAP|"TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase."
214562166|NCT06264128|DEVICE|CPAP|CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
215165628|NCT03899155|DRUG|Oxaliplatin|Specified dose on specified days
215165629|NCT03899155|DRUG|Enzalutamide|Specified dose on specified days
215165630|NCT03899155|DRUG|Sunitinib|Specified dose on specified days
215165631|NCT03899155|DRUG|Pemetrexed|Specified dose on specified days
215165632|NCT03899155|DRUG|Pembrolizumab|Specified dose on specified days
215165633|NCT06806592|DRUG|Nerandomilast|Nerandomilast
215165634|NCT06806592|DRUG|Placebo matching nerandomilast|Placebo matching nerandomilast
215165635|NCT07107256|DRUG|TQC2731 injection|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
215165636|NCT07107256|DRUG|Placebo of TQC2731|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
215165637|NCT07107685|OTHER|Global cohort|All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.
215165638|NCT06779773|DRUG|Avacincaptad pegol (ACP)|intravitreal injection
215165639|NCT07107945|DRUG|Empagliflozin|Empagliflozin
215165640|NCT07107945|DRUG|Placebo|Placebo
215165641|NCT06096844|DRUG|Carboplatin|Given IV
215165642|NCT06096844|PROCEDURE|Computed Tomography|Undergo CT scan
215165643|NCT06096844|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165644|NCT06096844|DRUG|Nab-paclitaxel|Given IV
215165645|NCT06096844|DRUG|Paclitaxel|Given IV
215165646|NCT06096844|BIOLOGICAL|Pembrolizumab|Given IV
215165647|NCT06096844|DRUG|Pemetrexed|Given IV
215165648|NCT06096844|PROCEDURE|Positron Emission Tomography|Undergo PET
215165649|NCT06096844|OTHER|Questionnaire Administration|Ancillary studies
215165650|NCT07020936|DEVICE|Normal Glycemia Goal|Participants will use the normal AIDANET system aggressivity adjustment to achieve target glucose for both the hotel and AIDANET at home periods.
214707725|NCT04643223|OTHER|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
214707726|NCT03170557|OTHER|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
214562167|NCT05302180|OTHER|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
214562168|NCT05302180|OTHER|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
214562169|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned hamstring autograft|After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.
214562170|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft|After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
214562171|NCT02038712|DIETARY_SUPPLEMENT|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
214562172|NCT02038712|DIETARY_SUPPLEMENT|Fasted condition|Subjects will consume 600mL plain water.
214562173|NCT02038712|PROCEDURE|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
214562174|NCT02038712|BEHAVIORAL|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
214562175|NCT02038712|PROCEDURE|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
214562176|NCT01684189|OTHER|Patient registry|Patient registry without study intervention
214562177|NCT04939701|DRUG|ASP0739|Intravenous (IV)
214562178|NCT05510427|DRUG|Infigratinib|Given by PO
214562179|NCT05510427|DRUG|Atezolizumab|Given by (IV) vein
214562180|NCT05510427|DRUG|Bevacizumab|Given by (IV) vein
214562181|NCT06487130|OTHER|N/A Observational Registry|Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.
214562182|NCT03523611|PROCEDURE|Lung Resection|Lung resection surgery
214562183|NCT04183036|PROCEDURE|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
214707727|NCT03170557|OTHER|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
214707728|NCT05174130|DEVICE|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
214707729|NCT04829955|OTHER|Eccentric manual resistance training|Eccentric bodyweight resistance training
214707730|NCT04829955|OTHER|Concentric manual resistance resistance training|Concentric bodyweight resistance training
214707731|NCT01017822|BIOLOGICAL|conatumumab|
214562184|NCT02839525|DIETARY_SUPPLEMENT|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
214562185|NCT02839525|DIETARY_SUPPLEMENT|Isolate whey protein|23g of protein of whey protein
214562186|NCT02839525|DIETARY_SUPPLEMENT|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
214562187|NCT02839525|OTHER|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
214562188|NCT05364372|BEHAVIORAL|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
214562189|NCT05364372|BEHAVIORAL|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
214562190|NCT02142868|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
214562191|NCT02142868|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
214562192|NCT04011488|OTHER|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
214707732|NCT01017822|DRUG|capecitabine|
214562193|NCT02157389|OTHER|Administration of a pharmacological placebo|
214562194|NCT00565773|DRUG|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
214562195|NCT00565773|DRUG|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
214562196|NCT00565773|DRUG|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
214562197|NCT01390662|DIETARY_SUPPLEMENT|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
214562198|NCT01390662|DIETARY_SUPPLEMENT|placebo|one tablet of sugar pill pr. day, for 24 weeks.
214562199|NCT05061368|DRUG|Sildenafil Citrate|Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
214562200|NCT05061368|OTHER|Placebo|Placebo
214562201|NCT01601522|PROCEDURE|Peanut protein|500 mg
214562202|NCT01601522|PROCEDURE|Oat flour|500 mg Oat flour
214707733|NCT01017822|DRUG|gemcitabine hydrochloride|
214707734|NCT01017822|RADIATION|3-dimensional conformal radiation therapy|
214707735|NCT05603039|DRUG|QL1706|5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
214707736|NCT05603039|DRUG|QL1604|200mg#D1#Q3W IV
214707737|NCT05603039|DRUG|Bevacizumab|15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
214707738|NCT05466266|DEVICE|ICE|All patients received ICE examination.
214707739|NCT05466266|DEVICE|TEE|All patients received TEE examination.
214707740|NCT01248494|DRUG|BEZ235|"* Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID"
214707741|NCT01248494|DRUG|BKM 120|"* Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily"
214707742|NCT01248494|DRUG|Letrozole|All levels: 2.5mg/day PO
214562203|NCT01601522|DRUG|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
214562204|NCT04555785|DRUG|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
214562205|NCT04555785|OTHER|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
214707743|NCT01248494|DRUG|BKM120|"* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
215165651|NCT07020936|DEVICE|Tight Glycemia Goal|Participants will have the AIDANET system controller target set to have higher aggressivity adjustment to maintain target glucose for both the hotel and AIDANET at home periods.
215165652|NCT06869590|OTHER|blood sampling|When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).
215165653|NCT06869590|OTHER|blood sampling after 3-4 months|In the event of AAHIF positivity, a second sample will be taken between 12 and 16 weeks later to verify the persistence of autoantibodies: Visit 2.
214562206|NCT00702962|DRUG|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
214562207|NCT04153422|DRUG|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
214562208|NCT04153422|DRUG|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
214562209|NCT06518785|DEVICE|Low Intensity Focused Ultrasound|An inhibitory LIFU protocol that allows suppression of neuronal activity in the basal ganglia and thalamus will be used.
214562210|NCT00919191|DRUG|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
214562211|NCT00919191|DRUG|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
214562212|NCT02475512|OTHER|Wash wipes (3M)|
214562213|NCT02475512|OTHER|water and pH neutral soap|
214562214|NCT03894072|DEVICE|CPAP|Conventional CPAP
214562215|NCT03894072|DEVICE|HFHO|A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
214562216|NCT05908851|DRUG|100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml)|Ultrasound guided brachial plexus blockade
214562217|NCT00019175|BIOLOGICAL|aldesleukin|
214562218|NCT00019175|BIOLOGICAL|fowlpox virus vaccine vector|
214562219|NCT00019175|BIOLOGICAL|gp100 antigen|
214562220|NCT05049577|DEVICE|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
214562221|NCT02251769|DRUG|Tipranavir|
214562222|NCT02251769|DRUG|Ritonavir|
214562223|NCT02251769|DRUG|Clarithromycin|
214562224|NCT02251769|OTHER|High-Fat Test Meal|
214562225|NCT00564746|DRUG|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"\[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed."
215165654|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
215165655|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.
215165656|NCT05434234|DRUG|YL201 and atezolizumab|Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle
214562226|NCT05324670|OTHER|Didactic model for suicidal behavior in the framework of impulsivity and ideations|It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
214562227|NCT06039020|DRUG|Anti-human thymocyte immunoglobulin, equine|Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
214562228|NCT05701267|DEVICE|MRI research|3T MRI protocol of \~1 hour
214562229|NCT02960698|OTHER|IRM and comportemental tasks|
214562230|NCT05481476|DRUG|Surufatinib|250mg, qd, po, 21 days for a cycle
214562231|NCT05481476|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
214562232|NCT05481476|DRUG|AG|nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
214562233|NCT01727284|PROCEDURE|MR-guided cryoablation|
214562234|NCT03870360|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
214562235|NCT03870360|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
214562236|NCT03870360|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
214562237|NCT03870360|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
214562238|NCT03870360|BEHAVIORAL|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
215165657|NCT05859334|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215165658|NCT05859334|DRUG|Erdafitinib|Given PO
214562239|NCT05964647|DRUG|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
214562240|NCT05964647|DRUG|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
214562241|NCT05964647|DRUG|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
214562242|NCT05964647|DRUG|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
214562243|NCT05964647|DRUG|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
214707744|NCT05894070|OTHER|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~* Standardized, phonetically balanced text~* Sustained, modulated production of five vowels~* Picture description~* Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~* Health barometer~* Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
214707745|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over 12 weeks. Eight core modules discussing essential elements (such as main problems of solid waste management, health effects of exposure to burning plastic, sustainable alternatives to plastic litter) and four periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize one task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as:~* engaging in a community clean-up~* starting an organic compost pile free of plastic waste~* training on community recycling, focusing on plastics recycling~* making organic soaps, to use for personal grooming or washing clothes, eliminating plastic packaging~* creating materials out of plastic, like bottle planters"
214707746|NCT05456256|DRUG|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
214707747|NCT05456256|DRUG|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
214707748|NCT05456256|DRUG|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
215165659|NCT05859334|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214562244|NCT06309290|OTHER|Prehabilitation with resistance-exercise training|The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
214562245|NCT06309290|OTHER|Usual care program|The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
215165660|NCT05859334|PROCEDURE|Optical Coherence Tomography|Undergo OCT
215165661|NCT06479824|DEVICE|TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)|In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.
215165662|NCT04579224|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215165663|NCT04579224|PROCEDURE|Bone Scan|Undergo bone scan
215165664|NCT04579224|PROCEDURE|Computed Tomography|Undergo CT
215165665|NCT04579224|DRUG|Docetaxel|Given IV
215165666|NCT04579224|DRUG|Eribulin Mesylate|Given IV
215165667|NCT04579224|DRUG|Gemcitabine Hydrochloride|Given IV
215165668|NCT04579224|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165669|NCT04579224|DRUG|Paclitaxel|Given IV
214562246|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
214562247|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
214562248|NCT06435494|OTHER|Systematic use of patient reported outcome measures in clinical work with the patients|Se description of the arms
214562249|NCT01923467|BEHAVIORAL|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
214562250|NCT01923467|DRUG|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
214562251|NCT04721613|OTHER|Assessment of Melatonin level|Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
214562252|NCT03015129|DRUG|Durvalumab|
214562253|NCT03015129|DRUG|Tremelimumab|
215165670|NCT04579224|BIOLOGICAL|Sacituzumab Govitecan|Receive IV
215165671|NCT05653219|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
215165672|NCT05653219|DRUG|Eltrombopag|Film-coated tablet for oral use
215165673|NCT05653219|DRUG|Placebo|Concentrate for solution for infusion for intravenous use.
215165674|NCT05603104|DRUG|Clozapine|See arm description
215165675|NCT05603104|DRUG|Esketamine Nasal Product|See arm description
215165676|NCT05603104|DRUG|Escitalopram|See arm description
215165677|NCT05603104|DRUG|Sertraline|See arm description
215165678|NCT05603104|DRUG|Venlafaxine|See arm description
215165679|NCT05603104|DRUG|Lithium|See arm description
214707749|NCT06234059|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
214707750|NCT06234059|BEHAVIORAL|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
214707751|NCT05691829|DRUG|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
214707752|NCT05691829|RADIATION|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
214707753|NCT05691829|DRUG|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
214707754|NCT05876208|OTHER|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
214707755|NCT05876208|OTHER|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
214707756|NCT05821556|DRUG|Valproic acid|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
214707757|NCT05821556|DRUG|Simvastatin 20mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
214707758|NCT05821556|DRUG|Gemcitabine 1000 mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
215165680|NCT05603104|DRUG|Valproate acid|See arm description
214562254|NCT04090177|BEHAVIORAL|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
214562255|NCT05917847|OTHER|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
214562256|NCT00963612|PROCEDURE|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
214562257|NCT00967902|DEVICE|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
215165681|NCT05603104|DRUG|Quetiapine|See arm description
215165682|NCT05603104|DRUG|Second-line Antidepressants|See arm description
215165683|NCT05603104|DRUG|Second-line Antipsychotics|See arm description
215165684|NCT05603104|DRUG|Ketamine Hydrochloride|See arm description
215165685|NCT05603104|DRUG|Esketamine hydrochloride|See arm description
215165686|NCT05603104|DRUG|Bupropion|See arm description
215165687|NCT01036581|DEVICE|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
214562258|NCT00974194|PROCEDURE|Single Trocar CCK|CCK using Triport
214562259|NCT00974194|PROCEDURE|Standard CCK|CCK using three or four ports
214562260|NCT02145338|DRUG|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
214562261|NCT02145338|OTHER|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
214562262|NCT04454931|DEVICE|Root® with O3® Regional Oximetry|"May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device."
214562263|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
214562264|NCT00527462|PROCEDURE|Bronchoscopy|bronchoscopy with segmental allergen challenge
214562265|NCT00527462|OTHER|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
214562266|NCT06114303|OTHER|Stool sampling|1 stool sample is taken during the study with a stool sample kit
214562267|NCT05781412|DEVICE|tDCS|Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
214562268|NCT05318573|DRUG|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
214562269|NCT05318573|DRUG|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
214562270|NCT06343298|DRUG|MANP|MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
214707759|NCT05821556|DRUG|Nab paclitaxel|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
214707760|NCT05821556|DRUG|Cisplatin|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
214707761|NCT05821556|DRUG|Capecitabine|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
214707762|NCT06588660|BIOLOGICAL|Vevoctadekin|Given SC
214707763|NCT06588660|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214707764|NCT06588660|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214707765|NCT06588660|OTHER|Medical Chart Review|Ancillary studies
214707766|NCT06588660|DRUG|Teclistamab|Given SC
214707767|NCT06588660|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214707768|NCT05867212|DRUG|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
214707769|NCT06028750|PROCEDURE|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
214707770|NCT06028750|PROCEDURE|Freehand|Freehand implant placement
214707771|NCT05524597|BEHAVIORAL|Writing Intervention|Participants will be asked to write about different kinds of experiences.
214707772|NCT04469764|DRUG|Abemaciclib|Given PO
214562271|NCT06343298|OTHER|Placebo Matched control|This is a placebo matched vehicle - Vehicle minus the active ingredient
214562272|NCT06146205|PROCEDURE|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
214562273|NCT06146205|PROCEDURE|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
214707773|NCT04469764|DRUG|Anastrozole|Given PO
214707774|NCT04469764|DRUG|Letrozole|Given PO
214707775|NCT04690205|OTHER|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
214707776|NCT04756388|OTHER|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
214707777|NCT04756388|OTHER|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
214707778|NCT06147713|DEVICE|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
214562274|NCT03660644|BEHAVIORAL|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
214562275|NCT05805709|OTHER|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
214562276|NCT05805709|OTHER|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
214562277|NCT05805709|OTHER|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
214562278|NCT05805709|OTHER|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
214562279|NCT05047068|DEVICE|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
214562280|NCT03783416|DRUG|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
214562281|NCT04439149|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
214562282|NCT04559373|OTHER|Virtual Reality and Field Training (VRFT)|The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
214707779|NCT04421963|DRUG|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
214707780|NCT06109519|PROCEDURE|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
214707781|NCT03452202|DEVICE|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
214707782|NCT03452202|DEVICE|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
214707783|NCT02762799|BIOLOGICAL|Leucostim®|Leucostim® is filgrastim biosimilar.
214707784|NCT02762799|BIOLOGICAL|Neupogen®|
214707785|NCT00453180|DRUG|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
214707786|NCT00453180|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
214707787|NCT04183387|DRUG|Simvastatin 40mg|
214707788|NCT03722472|BIOLOGICAL|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
214707789|NCT00547898|DRUG|Crofelemer 125 mg|Crofelemer 125 mg
214707790|NCT00547898|DRUG|Crofelemer 250 mg|Crofelemer 250 mg
214562283|NCT00376077|DRUG|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
214562284|NCT00376077|DRUG|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
214562285|NCT02954744|PROCEDURE|HIFU treatment|High intensity focused ultrasound
214562286|NCT03788759|DRUG|Alpha-lipoic acid|Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
214562287|NCT03788759|DRUG|Placebo Oral Tablet|Administration of placebo, as an adjunct to antipsychotic medication.
214562288|NCT02242097|DRUG|ibrutinib|Given PO
214562289|NCT02242097|OTHER|laboratory biomarker analysis|Correlative studies
214562290|NCT05714124|PROCEDURE|Embolization|Endovascular treatment for patients with primary and secondary liver tumors
214562291|NCT04688697|PROCEDURE|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
214562292|NCT04688697|PROCEDURE|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
214562293|NCT01562041|DRUG|Ranolazine 500 mg|Ranolazine 500 mg, oral tablet, b.i.d.
214562294|NCT02997826|OTHER|Infantil formula|
214562295|NCT01616004|DRUG|N2O|
214562296|NCT01616004|DRUG|Air|sham comparator
214562297|NCT00188942|DRUG|Fluoxetine+Olanzapine|
214562298|NCT00188942|DRUG|Olanzapine|
214562299|NCT00188942|PROCEDURE|Functional Magnetic Resonance Imaging|
214562300|NCT00002477|DRUG|carboplatin|
214562301|NCT00002477|DRUG|cisplatin|
214562302|NCT00002477|DRUG|cyclophosphamide|
214562303|NCT00002477|DRUG|doxorubicin hydrochloride|
214707791|NCT00547898|DRUG|Crofelemer 500 mg|Crofelemer 500 mg
214562304|NCT04296266|DRUG|Alda-341|Dietary supplement d-limonene orally administered as a drug.
214562305|NCT00304304|BEHAVIORAL|Asthma education|Research assistant worked with CCC staff on asthma prevention
214707792|NCT00547898|DRUG|Placebo|Placebo
214707793|NCT03406364|DRUG|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
214707794|NCT01082978|DEVICE|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
214562306|NCT03808701|DRUG|SCT200|Recombinant Anti-EGFR Monoclonal Antibody
214562307|NCT02793271|BEHAVIORAL|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
214562308|NCT02793271|BEHAVIORAL|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
214562309|NCT00292422|DRUG|BG9924|
214562310|NCT02073240|BEHAVIORAL|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~1. Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~2. Audits and Feedback of performance~3. A TB IC collaborative membership~4. A standardized unit-level daily checklist of critical IC activities"
214562311|NCT06065982|OTHER|Questionnaires|Health-related quality of life will be measured using the 12-item Short Form (SF-12) and EQ5D-5L questionnaires. The SF-12 is summarized into two component scores, the Physical Component Score (PCS) and Mental Composite Score (MCS).
214562312|NCT05025670|BEHAVIORAL|Supportive psychotherapy|Participants will receive monthly 30-45 minute supportive psychotherapy sessions. Supportive psychotherapy is an integrative and eclectic psychotherapeutic approach, based upon the individual's needs and symptoms. It draws from elements of a variety of psychotherapeutic disciplines, including cognitive-behavior, psychodynamic, and interpersonal therapies.
214562313|NCT04651790|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
214707795|NCT01082978|DEVICE|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
214707796|NCT04833868|OTHER|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
214707797|NCT04833868|OTHER|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
214707798|NCT03457740|DIETARY_SUPPLEMENT|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
214707799|NCT03457740|DIETARY_SUPPLEMENT|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
214707800|NCT03457740|DIETARY_SUPPLEMENT|Placebo|Placebo comparison
214562314|NCT05049057|DRUG|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
214562315|NCT05049057|DRUG|Placebo|Placebo delivered via subcutaneous injection.
214562316|NCT03553199|DEVICE|TRS, Tissue Retraction System|Tissue Retraction System
214562317|NCT06135740|DEVICE|Fitbit wearing, with notification for sleep, activity and nutrition based fitbit data|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data, and Nutritional supplementation and Promotion of Exercise
214562318|NCT06135740|DEVICE|Routine care|Regular Care on sleep, activity and nutrition
214562319|NCT03733314|DRUG|E6011|E6011, infusion, intravenously.
214562320|NCT03733314|DRUG|Placebo|Placebo, infusion, intravenously.
214562321|NCT02594657|PROCEDURE|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
214562322|NCT02594657|PROCEDURE|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
214562323|NCT00064740|BEHAVIORAL|relaxation response|
214562324|NCT05304455|DRUG|Apixaban 2.5 MG|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
214562325|NCT05304455|DRUG|Dipyridamole 25Mg Tab|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
214562326|NCT05304455|DRUG|subcutaneous Low Molecular Weight Heparin|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
214562327|NCT00770887|PROCEDURE|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
214562328|NCT05955508|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
214562329|NCT02791997|OTHER|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
214707801|NCT02318069|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 5 arms
214707802|NCT02671955|DRUG|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
214707803|NCT06203483|DRUG|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
214562330|NCT02791997|OTHER|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
214562331|NCT01240915|DRUG|placebo|once every 7 days for 1- 3 doses
214562332|NCT01240915|DRUG|MultiStem low dose|1-3 doses
214562333|NCT01240915|DRUG|placebo|Single dose at week 8
214562334|NCT01240915|DRUG|MultiStem low dose|Single dose at week 8
214562335|NCT01240915|DRUG|placebo|Single dose Day 1
214562336|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
214562337|NCT01240915|DRUG|placebo|Single dose at week 8
214562338|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
214562339|NCT01240915|DRUG|placebo|Single dose Day 1
214562340|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
214562341|NCT01240915|DRUG|placebo|Single dose at week 8
214562342|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
214562343|NCT02982551|DRUG|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
214562344|NCT02982551|OTHER|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
214562345|NCT02982551|OTHER|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
214562346|NCT02982551|DRUG|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
214562347|NCT02441478|RADIATION|functional magnetic resonance imaging exam|
214562348|NCT04297631|DRUG|Tobramycin Powder|Everyone gets tobramycin powder.
214562349|NCT04297631|DEVICE|Vancomyscin|Everyone gets the vancomyscin powder.
214562350|NCT00322075|DRUG|insulin glargine|
214562351|NCT03847792|DRUG|Group DB/Dexamethasone-Bupivacaine|The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
214562352|NCT03847792|DRUG|Group FB /Fentanyl-Bupivacaine|The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
214562353|NCT03847792|DRUG|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
214562354|NCT00002950|BIOLOGICAL|sargramostim|
214562355|NCT00002950|DRUG|topotecan hydrochloride|
214562356|NCT02702323|DRUG|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
214562357|NCT02702323|PROCEDURE|TACE|one times every 4-6 weeks.
214562358|NCT02234505|PROCEDURE|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
214562359|NCT01575600|OTHER|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
214562360|NCT04193540|OTHER|ACE questionnaire|Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
214562361|NCT02574845|DRUG|Rosuvastatin|
214562362|NCT02574845|DRUG|Metformin HCl|
214562363|NCT02574845|DRUG|Furosemide|
214562364|NCT01164618|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
214562365|NCT01164618|OTHER|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
214562366|NCT01538641|DRUG|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
214562367|NCT00845962|DRUG|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
214562368|NCT00845962|DRUG|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
214562369|NCT01581502|OTHER|This is an observational study.|This is an observational, not intervention, study.
214562370|NCT06381544|OTHER|Aromatherapy application|Applying lemon, orange and frankincense oils via inhalation
214562371|NCT00682981|DRUG|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
214562372|NCT00682981|DRUG|Carboplatin/etoposide|Carboplatin/etoposide combination
214562373|NCT02374723|DEVICE|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
214562374|NCT02374723|DEVICE|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
214562375|NCT04246021|DRUG|Ferric carboxymaltose (FCM)|intravenous iron formulation
214562376|NCT01035359|PROCEDURE|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
214562377|NCT01035359|PROCEDURE|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
214562378|NCT00350038|DRUG|Irbesartan|
214562379|NCT00350038|DRUG|Ciprofibrate|
214562380|NCT06317467|OTHER|Blood sampling|Four blood samples will be collected, in conjunction with the collection of samples already programmed for assistance during pregnancy: blood sampling for the B-test (within the 13th week of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo; blood sampling for toxoplasmosis or blood sugar level, upon execution of the morphological ultrasound scanning (around the 20th and 34th weeks of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo, as well. Finally, 40 days after delivery, during routine gynaecological control after the puerperium.
214562381|NCT06317467|OTHER|Blood sampling|For patient of group 2, the blood sample will be collected at the time of the diagnosis of PE and 40-50 days after delivery in Obstetrics and Gynaecology Department of the institute or in Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
214562382|NCT04974762|PROCEDURE|Wound infiltration|Surgical wound infiltration by proceduralist
214562383|NCT04974762|PROCEDURE|Truncal blocks|Truncal blocks provided by anesthesiology team for device placement
214562384|NCT04412928|PROCEDURE|mid-urethral sling procedure|mid-urethral sling procedure
214562385|NCT03435692|PROCEDURE|Lumbar Plexus Catheter|lumbar plexus catheter placed intraoperatively for perioperative pain control
214562386|NCT03435692|PROCEDURE|Lumbar Epidural Catheter|lumbar epidural catheter placed intraoperatively for perioperative pain control
214562387|NCT03435692|PROCEDURE|Patient Controlled Analgesia|Patient Controlled Analgesia (PCA) was started post operatively for perioperative pain control
214562388|NCT03435692|DRUG|Fentanyl|Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and occurring more than 30 minutes after the block if applicable.
214562389|NCT03435692|DRUG|Morphine|In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
214562390|NCT03435692|DRUG|Lorazepam|Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
214562391|NCT03435692|DRUG|Ondansetron|Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
214562392|NCT03435692|DRUG|Diphenhydramine|Intravenous Diphenhydramine was administered as needed for itching postoperatively.
214562393|NCT03435692|DRUG|Acetaminophen|Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
214562394|NCT03435692|DRUG|Oxycodone|Oral Oxycodone was administered as needed for breakthrough pain post operatively.
214562395|NCT03435692|DRUG|Ropivacaine|Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
214562396|NCT02291939|PROCEDURE|Parotidectomy|Surgical Intervention with the FMwand Surgical System
214562397|NCT03999801|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
214707804|NCT06203483|DRUG|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
214707805|NCT04401397|PROCEDURE|Intensive early mobilization techniques|"Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques."
214707806|NCT05750238|OTHER|no intervention|no intervention, survey was applied to the participants
214707807|NCT01238913|PROCEDURE|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
214707808|NCT04568811|BIOLOGICAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
214707809|NCT06229483|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
214707810|NCT06229483|OTHER|Placebo|0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
214707811|NCT01002742|DRUG|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
214707812|NCT01002742|DRUG|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
214707813|NCT00154219|DRUG|Lumiracoxib (drug)|
214707814|NCT01001728|RADIATION|Imaging investigations (with radiation)|
214707815|NCT03532724|DEVICE|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
214707816|NCT05241938|PROCEDURE|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
214707817|NCT05241938|DRUG|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
214707818|NCT00271791|DRUG|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
214707819|NCT00271791|DRUG|Prednisone|PO, Placebo, 17 days
214707820|NCT03064165|DRUG|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
214707821|NCT03064165|PROCEDURE|Sham block|Injection as for obturator nerve block, but with placebo
214707822|NCT03064165|PROCEDURE|Obturator nerve block|Postoperative obturator nerve block
214707823|NCT03064165|DRUG|Sodium Chloride 9mg/mL|Placebo
214707824|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
214707825|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
214707826|NCT04306900|COMBINATION_PRODUCT|TTX-030 and mFOLFOX6|Dose and schedule per protocol
214707827|NCT04306900|COMBINATION_PRODUCT|TTX-030 and budigalimab|Dose and schedule per protocol
214707828|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
214707829|NCT04306900|COMBINATION_PRODUCT|TTX-030 and pembrolizumab|Dose and schedule per protocol
214707830|NCT04306900|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
214707831|NCT04306900|COMBINATION_PRODUCT|Budigalimab and mFOLFOX6|Dose and schedule per protocol
214707832|NCT04175301|DRUG|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
214707833|NCT04175301|DRUG|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
214707834|NCT02862548|DRUG|TAF|Tablet administered orally
214707835|NCT02862548|DRUG|TDF|Tablet administered orally
214707836|NCT02862548|DRUG|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
214707837|NCT00880763|DRUG|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
214707838|NCT00880763|DRUG|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
214707839|NCT00880763|DRUG|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
214707840|NCT00880763|DRUG|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
214562398|NCT02687438|DEVICE|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
214562399|NCT02687438|OTHER|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
214707841|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
214707842|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
214707843|NCT05307445|DEVICE|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
214707844|NCT01223326|DRUG|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
214707845|NCT01223326|DRUG|Saline|Na Cl 0.9% infusion
214562400|NCT04091061|DRUG|PF-06865571 100 mg|PF-06865571 in 100 mg oral tablet will be administered on Day 1
214562401|NCT01620918|PROCEDURE|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
214562402|NCT01620918|PROCEDURE|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
214562403|NCT00969826|DRUG|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
214562404|NCT02361268|BEHAVIORAL|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
214562405|NCT02361268|BEHAVIORAL|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
214562406|NCT05811962|OTHER|No intervention|No intervention, only comparison
215165688|NCT01036581|DEVICE|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
215165689|NCT01036581|DEVICE|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
215165690|NCT06455202|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
214562407|NCT04885985|DEVICE|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
214562408|NCT05905627|BEHAVIORAL|exercise|intervention group
214562409|NCT06010927|DRUG|ketamine/midazolam|premedication
214562410|NCT06010927|DRUG|Ketofol|Pre-extubation
214562411|NCT00821587|DRUG|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
214562412|NCT00821587|DRUG|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
214562413|NCT01693900|PROCEDURE|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
214562414|NCT01693900|PROCEDURE|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
214562415|NCT03846180|DRUG|Terlipressin|Continuous or intermittent intravenous infusion of terlipressin was given.
214562416|NCT03846180|DRUG|Somatostatin|Continuous or intermittent intravenous infusion of somatostatin was given.
214562417|NCT03846180|DRUG|Octreotide|Continuous or intermittent intravenous infusion of octreotide was given.
214562418|NCT02941900|GENETIC|MC1R genotyping|
214562419|NCT02941900|BEHAVIORAL|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
214562420|NCT02941900|BEHAVIORAL|Baseline Survey|
214562421|NCT03856983|OTHER|Point light display|Experimental group who will do usual rehabilitation and visualization of point-light human actions
214562422|NCT05590442|OTHER|Tests|Cognitive assessments and olfactory tests
214562423|NCT04694170|OTHER|additional therapy|Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
214562424|NCT04694170|OTHER|conventional physiotherapy|Using conventional physiotherapy only.
214562425|NCT01378689|OTHER|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
214562426|NCT00693940|BEHAVIORAL|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
214562427|NCT00693940|OTHER|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
214562428|NCT06629181|OTHER|Education|"The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training"
214562429|NCT04712136|OTHER|MRI|MRI cardiac
214562430|NCT03045965|PROCEDURE|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
214562431|NCT06063434|BEHAVIORAL|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
214562432|NCT06063434|BEHAVIORAL|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
214562433|NCT02138708|OTHER|Pharmacological test of pulmonary endothelial|
214562434|NCT03871582|OTHER|No intervention|Cross-sectional
214562435|NCT06240923|DEVICE|Maxillary molars distalization|Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
214707846|NCT04387929|DIAGNOSTIC_TEST|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
214707847|NCT06315244|PROCEDURE|US Guided Perineural Injection and Neuroprolotherapy|Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
214562436|NCT03506659|DEVICE|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
214562437|NCT01712061|DRUG|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
214562438|NCT01712061|DRUG|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
214562439|NCT06202963|DRUG|Triamcinolone Acetonide|"1. group will receive ultrasound-guided hydrodilatation~2. group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
214562440|NCT02313389|DRUG|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
214562441|NCT05092074|DRUG|Vosevi 400/100/100 Oral Tablet|Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
214707848|NCT03620435|DRUG|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
214707849|NCT02675725|DEVICE|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
214707850|NCT04501835|OTHER|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
214707851|NCT01984736|DRUG|Experimental: EVP-6124|
214707852|NCT04868136|BEHAVIORAL|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
214707853|NCT05561712|OTHER|Laboratory method validation|Test several sampling conditions
214707854|NCT04229108|DEVICE|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
215165691|NCT06455202|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
215165692|NCT04071223|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215165693|NCT04071223|PROCEDURE|Bone Scan|Undergo bone scan
215165694|NCT04071223|DRUG|Cabozantinib S-malate|Given PO
215165695|NCT04071223|PROCEDURE|Computed Tomography|Undergo CT
214562442|NCT04470947|DIAGNOSTIC_TEST|Next generation functional drug screening|High-throughput image based in-vitro drug screening on primary patient tumor cells
214562443|NCT04470947|DIAGNOSTIC_TEST|Comprehensive genomic profiling|Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
214562444|NCT04481568|BEHAVIORAL|PES-4-BPSD Model|We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
214707855|NCT06085287|DEVICE|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
214707856|NCT06210438|DRUG|SHR-A1921 + Bevacizumab|SHR-A1921 + Bevacizumab
214707857|NCT03524911|BEHAVIORAL|CHFFF nutrition education|
214707858|NCT02670928|BEHAVIORAL|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
214707859|NCT00443937|DRUG|enteric-coated mycophenolate sodium|oral
214707860|NCT00443937|DRUG|everolimus|oral
214707861|NCT00950976|OTHER|citrulline|TID for 5 days
214707862|NCT00950976|OTHER|Lemonade|TID for 5 days
215165696|NCT04071223|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165697|NCT04071223|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET or NaF-PET
215165698|NCT04071223|OTHER|Questionnaire Administration|Ancillary studies
215165699|NCT04071223|RADIATION|Radium Ra 223 Dichloride|Given IV
215165700|NCT06765109|DRUG|Neladalkib (NVL-655)|Oral tablet of Neladalkib (NVL-655)
215165701|NCT06765109|DRUG|Alectinib|Oral capsule of alectinib
215165702|NCT06638307|DRUG|MEN2312|MEN2312 administered as oral tablets.
215165703|NCT06638307|DRUG|Elacestrant|Elacestrant administered as oral tablets.
215165704|NCT06515002|GENETIC|BI 3720931|BI 3720931
215165705|NCT06515002|DRUG|Placebo|Placebo
215165706|NCT06515002|DEVICE|Inhaler|Inhaler for application of BI 3720931 and placebo
214562445|NCT04481568|BEHAVIORAL|The attention control condition|On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
214562446|NCT05312281|DEVICE|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Wear for 6 weeks post-surgery
215165707|NCT05125302|DRUG|Ubrogepant|Oral Tablet
215165708|NCT05125302|DRUG|Placebo-Matching Ubrogepant|Oral Tablet
215165709|NCT02535702|OTHER|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
215165710|NCT02535702|OTHER|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
214562447|NCT02108769|BEHAVIORAL|Yogic Breathing|"1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a)."
214562448|NCT02108769|BEHAVIORAL|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
214562449|NCT00345098|DRUG|SR58611A|
214562450|NCT00879775|DRUG|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
214562451|NCT00879775|DRUG|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
214562452|NCT04791098|OTHER|Specific infectious diseases consultation|"Specific infectious diseases consultation at Clermont Ferrand Hospital with a specialist doctor :~* Update vaccinations~* Advice to travelers~* Diagnostic and treatment of latent tuberculosis infection"
214562453|NCT04162379|DRUG|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
214562454|NCT02282553|DEVICE|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
214562455|NCT02282553|DEVICE|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
214562456|NCT03026959|BEHAVIORAL|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, \& Bédard, (2015).
214562457|NCT00000219|DRUG|Buprenorphine|
214562458|NCT03610347|DEVICE|Bare metal Stent plus Paclitaxel Balloon|
214562459|NCT03610347|DEVICE|Drug Eluting Stent|
214562460|NCT04806204|OTHER|music therapy|Music therapy will be applied to one group before angiography and to the other group during angiography. Patients who will listen to music before angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes. Patients who will listen to music during angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the angiography hall during the angiography procedure.
214707863|NCT06527508|OTHER|Non-Interventional|This study has a observational design
214707864|NCT01494987|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
215165711|NCT02535702|OTHER|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
215165712|NCT02535702|OTHER|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
215165713|NCT02535702|OTHER|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
215165714|NCT02535702|OTHER|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
215165715|NCT06564038|DRUG|AZD0486|AZD0486 will be administered as either SC injection or IV infusion.
215165716|NCT06564038|DRUG|Prednisone (or equivalent)|Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.
215165717|NCT06564038|DRUG|Rituximab|Rituximab will be administered as IV infusion as per standard of care.
215165718|NCT06564038|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as IV infusion as per standard of care.
215165719|NCT06564038|DRUG|Vincristine|Vincristine will be administered as IV infusion as per standard of care.
215165720|NCT06564038|DRUG|Doxorubicin|Doxorubicin will be administered as IV infusion as per standard of care.
214562461|NCT05941247|DRUG|Hemay005 60 mg|"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
214562462|NCT00000331|DRUG|Test Drug|
214562463|NCT00000331|DRUG|Placebo Drug|
214562464|NCT00418548|DRUG|Etanercept|
214562465|NCT01195623|PROCEDURE|preoperative duplex examination|
214562466|NCT01195623|PROCEDURE|Preoperative duplex|
214562467|NCT00867295|DRUG|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
214562468|NCT00867295|DRUG|placebo|placebo
214562469|NCT06016218|DRUG|Simvastatin|Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
214562470|NCT06017739|DEVICE|Bronchial Clearance A|EFA technology: the patient has to breathe at tidal volume by a mouthpiece at level 5 for half an hour twice a day.
214562471|NCT06017739|DEVICE|Bronchial Clearance B|High Flow Technology: patient has to wear nasal cannula and breathe his nose for one hour twice a day. After he has to use EFA technology level 5 for half an hour twice a day.
214562472|NCT03285698|DEVICE|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
214562473|NCT03285698|DEVICE|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
214562474|NCT02373579|DRUG|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
214562475|NCT02373579|DRUG|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
214562476|NCT01293942|DRUG|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
214562477|NCT05862428|DRUG|Rectal misoprostol|This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
214562478|NCT02517762|BEHAVIORAL|Physical activity|
214562479|NCT02212652|DIETARY_SUPPLEMENT|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
214562480|NCT02212652|OTHER|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
214562481|NCT02212652|OTHER|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
214562482|NCT05303389|PROCEDURE|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
214562483|NCT01940432|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
214562484|NCT01940432|BEHAVIORAL|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
214562485|NCT05003024|DEVICE|TOF SCAN|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~Once 2 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 2 mg/kg sugammadex will be injected. Train of four ratio (delivered every minute) will be recorded.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
214707865|NCT01494987|DRUG|Placebo|Placebo to match ranolazine for the duration of the study
214707866|NCT01494987|DRUG|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
214707867|NCT01494987|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
214707868|NCT01494987|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
214707869|NCT01250652|DRUG|Levocetirizine|20 mg levocetirizine for 5 days
214707870|NCT01250652|DRUG|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
214707871|NCT03350971|OTHER|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
214707872|NCT03350971|OTHER|Control|chest physical therapy exercises
214707873|NCT00425074|DRUG|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
214707874|NCT00425074|DRUG|ASA|normal release acetylsalicylic acid
214707875|NCT00425074|DRUG|SR-ASA|slow release acetylsalicylic acid 150 mg
214707876|NCT00436982|DEVICE|Cemented Triathlon total knee system|Orthopaedic implant
214707877|NCT00436982|DEVICE|Duracon total knee system|Orthopaedic implant
214562486|NCT05003024|DEVICE|ITF|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~On the ITF device side, 3 minutes after sugammadex administration, a tetanus 100 Hz stimulation will be done followed 2 minutes later by a tetanus 50 Hz stimulation.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
214562487|NCT00430729|DRUG|Roflumilast|
214562488|NCT04207580|OTHER|Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,|"The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients.~A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment)."
214562489|NCT03156972|PROCEDURE|Replacment of mitral valve|Mitral valve replacment by prothsis
214562490|NCT04314141|PROCEDURE|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes"
214562491|NCT05727189|DRUG|TR-01-XRR (1)|Extended-release form
214562492|NCT05727189|DRUG|TR-01-XRR (2)|Extended-release form
214562493|NCT05727189|DRUG|TR-01-XRR (3)|Extended-release form
214562494|NCT05727189|DRUG|TR-01-XRS|Extended-release form
214562495|NCT05727189|DRUG|TR-01-XR|Extended-release form
214562496|NCT05727189|DRUG|TR-01-IR|Active comparator
214707878|NCT05730374|BEHAVIORAL|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
214707879|NCT05730374|BEHAVIORAL|Music therapy|"* The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~* This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
214562497|NCT05727189|DRUG|Placebo|Placebo comparator
214562498|NCT04870008|PROCEDURE|Suture|The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.
214562499|NCT03427151|DRUG|IPP-201101|200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
214562500|NCT04596839|DRUG|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
214562501|NCT04596839|OTHER|Standard of Care|Standard of Care Treatment for COVID-19 Infection
214562502|NCT05049135|DEVICE|Somnofy® sleep monitor|Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
214562503|NCT03586934|DRUG|Acetaminophen|Acetaminophen Tablet
214562504|NCT03586934|DRUG|Celecoxib 200mg|Celecoxib Tablet
214562505|NCT03586934|DRUG|Celecoxib 400 mg|Celecoxib Tablet
214562506|NCT03586934|DRUG|Ropivacaine|Ropivicaine nerve block (injection)
214562507|NCT03586934|DRUG|Ketorolac|ketorolac injection
214562508|NCT03586934|DRUG|Acetaminophen Injectable Product|Acetaminophen injection
214562509|NCT03586934|DRUG|Oxycodone|oxycodone tablet
214562510|NCT03586934|DRUG|Tramadol|Tramadol tablet
214562511|NCT03586934|DRUG|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
214562512|NCT03586934|DRUG|hydrocodone bitartrate and acetaminophen|Norco tablet
214562513|NCT03586934|DRUG|Morphine|morphine injection
214562514|NCT03586934|DRUG|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
214562515|NCT03586934|DRUG|Meloxicam|meloxicam tablet
214562516|NCT01261117|DRUG|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
214562517|NCT05385380|BEHAVIORAL|Safe motherhood Promotion|Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
214562518|NCT02642692|PROCEDURE|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
215165721|NCT06564038|DRUG|Acalabrutinib|Acalabrutinib will be administered orally
215165722|NCT06564142|DRUG|Povetacicept|Subcutaneous injection administration.
215165723|NCT06564142|DRUG|Placebo (matched to Povetacicept)|Placebo matched to Povetacicept subcutaneous injection administration.
215165724|NCT06118515|DRUG|Letermovir|Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
215165725|NCT06389136|DRUG|Upadacitinib 15mg Dose|Oral tablet
215165726|NCT06389136|DRUG|Dupilumab 300mg Dose|Subcutaneous (SC) injection
215165727|NCT06389136|DRUG|Upadacitinib 30mg Dose|Oral tablet
215165728|NCT06814509|BEHAVIORAL|Enhanced Standard of Care (ESoC)|Standard recommended nutrition and gestational weight gain counseling; WIC and SNAP enrollment assistance; emergency food referrals
215165729|NCT06814509|BEHAVIORAL|Delivering HOPE|ESoC plus healthy food provision
215165730|NCT01568671|OTHER|Room temperatures|Room temperature of metabolic chamber set between 16C and 31C
215165731|NCT02339571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215165732|NCT02339571|PROCEDURE|Computed Tomography|Undergo CT scan
215165733|NCT02339571|PROCEDURE|Echocardiography Test|Undergo ECHO
215165734|NCT02339571|BIOLOGICAL|Ipilimumab|Given IV
215165735|NCT02339571|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
215165736|NCT02339571|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214562519|NCT02642692|PROCEDURE|Hamstring Graft|Acl reconstruction with hamstring graft
214562520|NCT03163927|OTHER|Simulation-based training|See arm description
214562521|NCT00077831|BEHAVIORAL|neurobehavioral development|observational study of infant and child development
214562522|NCT02303600|DRUG|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
214562523|NCT02303600|OTHER|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
214562524|NCT03846453|BIOLOGICAL|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
214562525|NCT03846453|BIOLOGICAL|Placebo|Placebo vehicle solution
214562526|NCT01173965|DEVICE|MEA|Microwave endometrial ablation device
214562527|NCT01173965|DEVICE|Novasure|Bipolar impedence control system
214562528|NCT02888574|DRUG|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
214562529|NCT02888574|DRUG|Placebo|Placebo nasal spray
214562530|NCT02341742|DEVICE|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
214562531|NCT04210921|DEVICE|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
214562532|NCT04210921|DEVICE|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
214562533|NCT00468143|DRUG|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
214707880|NCT04310865|DRUG|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
214562534|NCT00468143|DRUG|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
214562535|NCT04313257|OTHER|Monocular Active Occlusion|Occlusion treatment of one hour daily with action video game.
214562536|NCT04313257|OTHER|Monocular Passive Occlusion|Occlusion treatment of two hour daily.
214562537|NCT00472849|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
214562538|NCT00472849|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
214562539|NCT00472849|DRUG|Cytarabine|Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
214562540|NCT00472849|DRUG|Rituximab|Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).
214562541|NCT00472849|DRUG|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
215165737|NCT02339571|BIOLOGICAL|Nivolumab|Given IV
215165738|NCT02339571|BIOLOGICAL|Sargramostim|Given SC
215165739|NCT06552754|BEHAVIORAL|Motion Reset|virtual reality-based experiential, sensory intervention
215165740|NCT06552754|BEHAVIORAL|Placebo|virtual reality-based experiential, sensory experience without intervention
215165741|NCT06577454|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.
215165742|NCT07110532|BIOLOGICAL|A/Arkansas/08/2020 (pH1N1)|GMP-grade, cell-based influenza A (pH1N1) virus (Lot #24-005), derived via reverse genetics for use in controlled human infection studies.
215165743|NCT07110532|OTHER|Sham/Diluent (1X SPG+Arg+Gel)|Sterile diluent containing 1X Sucrose Phosphate Glutamate (SPG), 1% arginine, and 1% hydrolyzed gelatin, used as a sham comparator in the human challenge trial.
215165744|NCT03816345|PROCEDURE|Biospecimen Collection|Undergo collection of blood, CSF, tissue, stool and urine samples
215165745|NCT03816345|BIOLOGICAL|Nivolumab|Given IV
215165746|NCT07099092|DEVICE|TUS PirC|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting piriform cortex
215165747|NCT07099092|DEVICE|TUS Amy|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting amygdala
214562542|NCT01384799|DRUG|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
214562543|NCT01384799|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
214562544|NCT01384799|RADIATION|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
214562545|NCT04664075|BIOLOGICAL|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
214562546|NCT01667094|DRUG|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
214562547|NCT01667094|DRUG|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
214562548|NCT01667094|DRUG|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
214562549|NCT01667094|DRUG|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
214562550|NCT01667094|DRUG|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
214562551|NCT01667094|DRUG|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
214562552|NCT01667094|DRUG|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
214562553|NCT01667094|DRUG|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
214562554|NCT01667094|DRUG|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
214562555|NCT01667094|DRUG|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
214562556|NCT02636725|DRUG|Axitinib|5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
214562557|NCT02636725|DRUG|Pembrolizumab|200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
214562558|NCT02915419|BIOLOGICAL|PRP|platelet rich plasma
214562559|NCT02915419|BIOLOGICAL|PRF|PLATELET RICH FIBRIN
214562560|NCT04210167|BEHAVIORAL|web-based training and telephone monitoring|web-based training and telephone monitoring and short message
214562561|NCT03659864|OTHER|diesel exhaust particulate|aerosolised diesel exhaust particulate
214562562|NCT03659864|OTHER|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
214562563|NCT03659864|OTHER|small graphene oxide|aerosolised 'small' graphene oxide
214562564|NCT03659864|OTHER|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
214562565|NCT03659864|OTHER|filtered air|control: filtered air
214562566|NCT01344772|PROCEDURE|Internal fixation|Two cannulated screws are placed under x-ray guidance
214707881|NCT04310865|DRUG|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
214562567|NCT01344772|PROCEDURE|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
214562568|NCT02466464|DEVICE|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
214562569|NCT02466464|DEVICE|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
214562570|NCT06225505|DIAGNOSTIC_TEST|ctDNA monitoring|For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
215165748|NCT07099092|DEVICE|TUS Sham|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting white matter
215165749|NCT07106762|DRUG|Iza-bren|Specified dose on specified days
215165750|NCT07106762|DRUG|Cisplatin|Specified dose on specified days
215165751|NCT07106762|DRUG|Gemcitabine|Specified dose on specified days
215165752|NCT07106762|DRUG|Carboplatin|Specified dose on specified days
215165753|NCT06917781|OTHER|Patients with 18F-PET-PSMA indication|"Blood samples taken on several occasions:~* before the 18F-PSMA PET scan for extension assessment, for all patients.~* at 2nd and 4th treatment cycles (prior to treatment administration), only for patients receiving PLUVICTO® therapy.~During the 1st treatment cycle, samples (optional for the patient) may also be taken at 5 different post-perfusion times.~In addition, all imaging examinations performed during the study (standard 18F-PSMA PET scans) will be collected and centralized by the Sponsor for analysis."
215165754|NCT06910033|DEVICE|Craniomaxillofacial (CMF) porous titanium implant|All patients were treated, between 2016 and 2023, with patient-specific CMF Porous Titanium Implants for facial and/or cranial reconstruction or restoration of bone defects.
215165755|NCT07106632|DRUG|test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone|In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
214562571|NCT06225505|DIAGNOSTIC_TEST|68Ga-FAPI-46-PET-CT|). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
214562572|NCT05821582|OTHER|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
214562573|NCT06330012|DIAGNOSTIC_TEST|GeoMx data analysis with clinical outcome|"1. List of HER2 positive breast cancer~   * Stage IV disease~  * Treated with T-Dxd~  * Available FFPE samples~2. Prepare tissue for digital spatial proteomics~   * FFPE/H\&E slide~  * Region of Interest(ROI) check~  * Make a Tissue microarray~  * Prepare special slide for GeoMx~3. GeoMx data analysis with clinical outcome"
214562574|NCT03370744|DIAGNOSTIC_TEST|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
214562575|NCT05078593|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
214562576|NCT04508127|DEVICE|Spinal cord stimulation|
214562577|NCT02145468|DRUG|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
214562578|NCT02145468|DRUG|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
214562579|NCT02145468|DRUG|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
214562580|NCT02352519|PROCEDURE|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
214562581|NCT02352519|PROCEDURE|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
214562582|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
214562583|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
214562584|NCT06052709|OTHER|Occupational balance assessment|There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
214562585|NCT01241825|OTHER|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
214562586|NCT01241825|OTHER|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
214562587|NCT03055429|OTHER|Full Scale Unit|Pre-test, usability, post-test
214562588|NCT00623805|DRUG|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
214562589|NCT00623805|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
214562590|NCT00623805|DRUG|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
214562591|NCT00713505|OTHER|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
214562592|NCT00713505|PROCEDURE|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
214562593|NCT00635128|BIOLOGICAL|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
214562594|NCT02169544|DRUG|Abatacept|
214562595|NCT04032184|OTHER|Fluoride toothpaste|regimen using fluoride toothpaste
214562596|NCT04032184|OTHER|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
214562597|NCT04032184|OTHER|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
214562598|NCT04818008|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
214562599|NCT01949389|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
214562600|NCT04655027|DRUG|Roxadustat|The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
214562601|NCT04655027|DRUG|rHuEPO|The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of \>6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.
214562602|NCT03698110|BEHAVIORAL|Intervention Group|PUEDES program included eight hours in groups and activities to practice at home.
214562603|NCT03350932|BEHAVIORAL|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
214562604|NCT02860689|OTHER|using questionnaires - International Index Erectile Function|using questionnaires
214562605|NCT04781413|DRUG|Nab-PTX, Sintilimab, S-1|This is a single-arm study with all patients receiving these three drugs.
214562606|NCT05298059|RADIATION|Laser of low frequncy|Apply the laser at three points on each tooth.
214562607|NCT05298059|DRUG|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
214562608|NCT05504252|DRUG|Nivolumab|"Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks"
214562609|NCT05504252|DRUG|Oxaliplatin|FLOX, Q2W
214562610|NCT02245022|DRUG|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
214562611|NCT02245022|DRUG|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
214562612|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
214562613|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
214562614|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
214562615|NCT06405360|DIETARY_SUPPLEMENT|Egg consumption|Participants in the intervention group will be provided two eggs to consume daily.
214562616|NCT05887115|BEHAVIORAL|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
214562617|NCT02753179|OTHER|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
214562618|NCT02753179|OTHER|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
214562619|NCT02753179|OTHER|VEMPs & VEMPo|VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
214562620|NCT02753179|OTHER|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
214562621|NCT02753179|OTHER|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
214562622|NCT03519997|DRUG|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
214562623|NCT03519997|DRUG|Bavituximab|Bavituximab 3mg/kg IV weekly
214562624|NCT03820947|DEVICE|VenaSeal™ System|The VenaSeal™ System is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
214562625|NCT03820947|DEVICE|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
214562626|NCT03820947|PROCEDURE|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
214562627|NCT07101419|OTHER|Long PRT|PRT (in seconds) set at 75% of inspiratory time (in seconds)
214562628|NCT07101419|OTHER|Short PRT|PRT (in seconds) set at 33% of inspiratory time (in seconds).
214562629|NCT07107568|DIAGNOSTIC_TEST|Standard Invasive Coronary Angiography|Standard invasive coronary angiography performed routinely for all participants in this arm to assess coronary artery disease before TAVR.
214562630|NCT07107568|DIAGNOSTIC_TEST|PCD-CT-Guided Diagnostic Strategy|Participants randomized to this arm will undergo coronary artery disease (CAD) assessment using photon-counting detector computed tomography (PCD-CT). Invasive coronary angiography (ICA) will only be performed if PCD-CT shows significant CAD, defined as ≥70% diameter stenosis in vessels ≥2.5 mm or ≥50% in the left main artery.
214562631|NCT07110584|DRUG|MDX2004|MDX2004 intravenous infusion
214562632|NCT07111481|BEHAVIORAL|Mozart music|Participants will be played Mozart's Sonata for Two Pianos in D Major, K. 448 during their surgical simulation training session with an AI tutor.
214562633|NCT07112378|DRUG|dupilumab|Administered as defined in the protocol
214562634|NCT06626035|DRUG|Methadone based ERAS|Children randomized to the methadone arm will include standardized perioperative care and analgesia, including intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.1 mg/kg up to a maximum of 5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral or IV doses of methadone (0.1 mg/kg up to a maximum of 5 mg) every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
214707882|NCT04310865|OTHER|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
214707883|NCT02821091|OTHER|Interactive Dynamic Balance Training|
214562635|NCT06626035|DRUG|Non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
214562636|NCT06738121|PROCEDURE|Infra-umbilical incision|Traditional curvilinear infra-umbilical incision is used to repair the umbilical hernia
214562637|NCT06738121|PROCEDURE|Transumbilical incision|The incision for the repair of the umbilical hernia will be carried through the umbilicus itself.
214562638|NCT06915220|BEHAVIORAL|mobile health app|HeartSteps is an innovative mobile health (mHealth) app designed for cardiac rehabilitation patients. The app features dynamic push notifications, daily and weekly surveys to capture psychosocial data, and an in-app dashboard that provides feedback on activity levels, goal progress, and reminders. Integrated with a Fitbit Charge tracker, HeartSteps emphasizes behavioral changes through engaging features. The intervention is personalized to meet individual needs and preferences, enhancing patient engagement and promoting sustained physical activity.
214562639|NCT07107841|OTHER|Autologous Hair Follicle-Derived Secretome|Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.
214562640|NCT07107841|OTHER|Placebo Control|The same saline used for diluting the active treatment in will be used as a control.
214562641|NCT07109505|DIETARY_SUPPLEMENT|Nutritional Shake|The shake mixes will be dry shelf -stable powders prepared with ingredients readily available in the US food supply and contain a minimum of 990 mg total cocoa flavanols, with a profile to support general nutritional health including 10 g protein. Accordingly, each shake contains approximately 95 mg of caffeine, equivalent to a medium-sized cup of coffee. Based on prior studies of cognition, additional composition specifications are: 1600 mg DHA and up to 400 mg EPA and 550 mg choline; \>250 mg epicatechin and epigallocatechin (plant polyphenols); multivitamin/mineral fortification to ensure 50-100% of all essential micronutrients except calcium (to prevent competitive absorption with other divalent cations). Participants will be given a supply of pre-portioned daily servings upon discharge from the hospital, for 30 days after surgery.
214562642|NCT07109505|OTHER|Nutritional Instructions Only|The control arm receives the Nutrition After Surgery instructions, which provide guidelines for healthy eating after surgery but not the nutritional shake. The intervention arm receives the same instructions along with the nutrition shake mix and accompanying postoperative supplementation
214562643|NCT07115953|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
214562644|NCT06905964|BEHAVIORAL|Eccentric cycling exercise (ECC)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, rest in sitting position for 20 min. Exercise intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
215165756|NCT07106632|DRUG|In the control arm, the treatment will be as standard of care : chemo-endocrine therapy|Standard treatment: Chemotherapy followed by endocrine therapy
215165757|NCT07111559|DRUG|rt-PA|Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.
215165758|NCT07111559|DRUG|DAPT|Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.
215165759|NCT07101926|BIOLOGICAL|blood sampling|One-time peripheral blood draw (10.8 mL total, 4 citrated tubes) collected during a routine clinical visit for thrombin generation testing on platelet-rich and platelet-poor plasma. No additional medical procedures or treatments are involved in the study.
215165760|NCT05809856|DEVICE|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
215165761|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
215165762|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
215165763|NCT06919016|BIOLOGICAL|DV700P-RNA|Intramuscular (IM) injection
215165764|NCT06919016|BIOLOGICAL|DV701B1.1-RNA|IM injection
215165765|NCT06920199|BIOLOGICAL|Donor-derived Treg cell injection combined with interleukin 2|Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.
215165766|NCT05063565|DEVICE|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
215165767|NCT05063565|DRUG|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
215165768|NCT05063565|DRUG|Tremelimumab immunotherapy|300 mg, single administration
215165769|NCT07112651|DIETARY_SUPPLEMENT|CL25216|250mg to take one capsule a day after breakfast for 105 days
215165770|NCT07112651|DIETARY_SUPPLEMENT|Placebo|One capsule a day after breakfast for 105 days
215165771|NCT07113483|DRUG|Midazolam|"Midazolam:~A commonly used benzodiazepine for sedation, administered intravenously at 0.025-0.05 mg/kg with supplemental doses as required. Known for effective anxiolysis and sedation but with a longer recovery profile compared to remimazolam."
215165772|NCT07113483|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|"Remimazolam:~A novel, ultra-short-acting benzodiazepine used for procedural sedation. Administered intravenously at 5 mg over 1 minute with supplemental dosing as needed. Characterized by rapid onset and quick recovery, with minimal residual sedation."
214562645|NCT06905964|BEHAVIORAL|Eccentric cycling exercise with assistive devices (ECA)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, receive NMES in sitting position for 20 min.~Intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
214562646|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
214562647|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
214562648|NCT01217788|DRUG|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
214562649|NCT07119268|DEVICE|SPARK Healthy Sleep|SPARK-Healthy Sleep is a single-session digital intervention delivered via smartphone that combines stigma reduction with evidence-based sleep improvement strategies.
214707884|NCT01804257|OTHER|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
214707885|NCT02661620|DEVICE|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
214707886|NCT05446974|OTHER|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
214562652|NCT07156058|OTHER|MiniPDX group|Personalized treatment for guided by mini-PDX. The MiniPDX test can provide drug sensitivity results in as little as 7 days. Drugs including but not limited to the following agents: capecitabine, gemcitabine + cis-platinum, gemcitabine + capecitabine, 5-FU + oxaliplatin, gemcitabine, 5-FU, capecitabine + cis-platinum, 5-FU + cis-platinum.
214562653|NCT07156058|DRUG|Capecitabine|Drug: Capecitabine
214562654|NCT07155928|BEHAVIORAL|Cardiac Rehabilitation|"* The cardiac rehabilitation program include supervised exercise training, patient education, and risk factor modification.~* CR starts 1-3 weeks after PCI (based on the patient's general condition) and lasting 12 weeks thereafter.~* Patients will undergo a supervised CR program based on published guidelines (FITT principle). The core will be a moderate-intensity aerobic exercise regimen (e.g. treadmill or cycle ergometer) 2-3 times per week for 12 weeks. Each session will last \~20-60 minutes of exercise followed by cool-down, with intensity gradually increased to High intensity interval training (HIIT) in low-moderate risk individuals. Resistance exercises (e.g. light weights or band exercises) will also be included twice weekly. Exercise dose (frequency, intensity, time) will be tracked. Physical therapists will supervise all sessions in an outpatient CR facility or affiliated gym. Patients' vitals and ECG will be monitored during initial sessions for safety."
215165773|NCT07109297|BIOLOGICAL|Nirsevimab|Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
215165774|NCT06921590|DRUG|AL001|Crystalized Lithium
215165775|NCT06921590|DRUG|Lithium Carbonate Capsule|Lithium Carbonate
215165776|NCT07115745|GENETIC|BMS-986515|Specified dose on specified days
215165777|NCT07115745|DRUG|Fludarabine|Specified dose on specified days
215165778|NCT07115745|DRUG|Cyclophosphamide|Specified dose on specified days
215165779|NCT07115745|DRUG|Tocilizumab|Specified dose on specified days
215165780|NCT07110688|BEHAVIORAL|Virtual human social interaction|The participants will perform a social interaction with the virtual human agent platform to assess mental states.
215165781|NCT07110688|BEHAVIORAL|Cold pressor test|Healthy participants will immerse one hand in cold water for less than 3 minutes, while physiological data will be collected by the new wearable sensor from the other hand.
215165782|NCT07115875|OTHER|Digital Outreach|Digital outreach interventions through focus groups. The study is based on narrative interventions that highlights culturally sensitive and values among Native American communities.
214562655|NCT07155928|PROCEDURE|Primary Percutaneous Coronary Intervention|Patients will undergo Primary Percutaneous Coronary Intervention (PPCI) within 24 hours of symptom onset for urgent revascularization of the occluded coronary artery.
214562656|NCT07155512|BEHAVIORAL|Mindfulness based intervention|A mindfulness intervention was designed especially for this study and delivered by a RD also qualified as a mindfulness teacher. The intervention was delivered synchronously online and consisted of 4 x 50 minute sessions delivered across 4 weeks.
214562657|NCT07154459|OTHER|Breastfeeding Education|Breastfeeding Education
214562658|NCT07153510|OTHER|Post-Isometric Relaxation|Participants will undergo Post-Isometric Relaxation technique targeting the hamstring muscles. The technique involves an isometric contraction of the hamstring followed by a passive stretch. Participant will be in supine position; hip at 90° flexion, Isometric contraction of hamstrings for 7 seconds, Followed by 15 seconds of passive stretch, 10 repetitions, 3 times/week for 4 weeks
214562659|NCT07153510|OTHER|Active Static Stretching|Participants will perform Active Static Stretching exercises for the hamstrings, where the stretch is held actively without assistance.Seated long sitting position. Participant actively stretches hamstrings for 30 seconds. 10 repetitions, 3 times/week for 4 week
215165783|NCT07115875|OTHER|In Person consultation|In-Person Consultation will receive standard of care at IHS Lawton Hospital. Consultation includes a colonoscopy risk assessment (i.e., current medication use, risk of perforation and bleeding, ability to complete bowel prep).
215165784|NCT05554393|DRUG|Azacitidine|Given IV or SC
215165785|NCT05554393|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215165786|NCT05554393|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215165787|NCT05554393|DRUG|Cytarabine|Given IV
215165788|NCT05554393|DRUG|Daunorubicin Hydrochloride|Given IV
215165789|NCT05554393|DRUG|Venetoclax|Given PO
215165790|NCT06907719|OTHER|Primary Services|Participants receive 40 hours of the Blueprint and 24/7 Dad curricula over the course of ten weeks.
214562660|NCT07155291|BEHAVIORAL|Abdominal Self-Massage|Daily self-administered visceral abdominal massage consisting of circular motions and pressure point techniques, performed for 5-20 minutes in total based on participant preference. The massage includes two parts: belly exercises (10 exercises) and pelvic exercises (3 exercises), with each exercise repeated 5-10 times or until the area feels relaxed. The app provides instructional videos and written step-by-step guides with drawings in English and German. Participants are recommended to use oil/cream, find a comfortable position, and integrate the massage into a daily routine.
214562661|NCT07153406|DRUG|Experimental regimen|Esketamine intranasal spray at flexible doses (28, 56 and 84 mg) once or twice a week
214562662|NCT07153406|DRUG|Control regimen|Oral aripiprazole 5-30 mg daily, once or twice daily for the duration of the study
214562663|NCT07153965|DRUG|Sacituzumab Tirumotecan plus Tagitanlimab|Sacituzumab Tirumotecan 5mg/kg intravenously (IV) infusion every 2 weeks on Day 1, Tagitanlimab 900mg IV every 2 weeks on Day 1, until disease progression, unacceptable toxic effects, withdrawal from the trial, or death, whichever occurred first.
214562664|NCT07154355|BEHAVIORAL|community-based exercise training|The patients will engage in 40-60 minutes of exercise training, either at home or in the community, five times a week, for eight weeks. Brisk walking, jogging, swimming, cycling, and trekking were among the exercise modalities that were chosen mostly based on the patient's individual preferences and habits. To guarantee safe and efficient exercise, exercise intensity was modified based on each person's subjective effort level and the results of their individual cardiorespiratory exercise tests.
214562665|NCT07155785|DRUG|Lidocain spray|Lidocaine spray as a local anaesthetic agent was applied to the cervix before intrauterine device application.
214562666|NCT07154680|DIAGNOSTIC_TEST|GPT-4o mini;Claude 3 Haiku;Gemini 1.5 Flash;Llama 3.1 7OB;GPT-4o;Claude 3.5 Sonnet;Gemini 1.5 Pro;Llama 3.1 4O5B|Input all the patient's information into the large language model and process it using a pre-defined prompt.
214562667|NCT07153575|PROCEDURE|suprainguinal fascia iliaca block|The ultrasound-guided suprainguinal fascia iliaca block (SFIB) procedure was first described by Hebbard et al. in 2011. It is a prevalent regional anesthesia technique employed in surgical procedures involving the hip joint and femur. Local anesthetics are administered in close proximity to the fascia iliaca. The primary objective is to obstruct the femoral, obturator and lateral femoral cutaneous nerve in a simultaneous manner. In clinical practice, it is a safe and simple alternative to lumbar plexus blocks and femoral blocks. A 30-ml solution of 0.25% bupivacaine was injected between the iliac muscle and the iliac fascia. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
214562668|NCT07153575|PROCEDURE|Pericapsular nerve group (PENG) block|In pericapsular nerve group (PENG) block the local anesthetic agent is injected into the musculofascial plane between the psoas muscle tendon and the pubic ramus. The primary objective of this technique is to obstruct the genicular branches of the femoral, obturator, and accessory obturator which innervate the hip capsule. Therefore, a comparison with the SFIB was undertaken. A 30-ml block of 0.25% bupivacaine solution was injected between the pubic ramus and the iliopsoas muscle tendon. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
214562669|NCT07154836|OTHER|Telephone calls|Regular telephone reminders and health information will be sent to help mothers or caregivers of children 0-23 months to remind them to go vaccine their children
214562670|NCT03578887|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
214562671|NCT03578887|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
214562672|NCT05464615|DRUG|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
214562673|NCT06118957|DRUG|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
214562674|NCT04388163|DRUG|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
214562675|NCT00036127|DRUG|aripiprazole|
214562676|NCT05212727|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214562677|NCT00252109|BEHAVIORAL|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
214562678|NCT04255199|BEHAVIORAL|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
214562679|NCT04255199|BEHAVIORAL|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
214562680|NCT02695342|BEHAVIORAL|Home balance exercise program|
214562681|NCT02801695|DRUG|Citrulline|Citrulline supplementation
214562682|NCT02801695|DRUG|Placebo|Placebo
214562683|NCT01077453|DRUG|letrozole|Given orally
214562684|NCT01077453|OTHER|quality-of-life assessment|Ancillary studies
214562685|NCT01077453|OTHER|laboratory biomarker analysis|Correlative studies
215165791|NCT06062238|BIOLOGICAL|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
214562686|NCT01736943|DRUG|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
214707887|NCT00609804|DRUG|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
214562687|NCT01736943|DRUG|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
214562688|NCT00387426|DRUG|sunitinib malate|Given PO
214562689|NCT01038375|BEHAVIORAL|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
214562690|NCT02218606|DRUG|Abiraterone acetate 1000 mg po daily|
214562691|NCT02218606|DRUG|Cabazitaxel 25 mg/m2 IV|
214707888|NCT00609804|DRUG|Erlotinib|Erlotinib 150 mg once daily by mouth
214707889|NCT04992637|BEHAVIORAL|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
214707890|NCT04992637|OTHER|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
214562692|NCT02218606|DRUG|prednisone 5 mg po BID|
214562693|NCT01844024|OTHER|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
214562694|NCT03046108|DEVICE|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
214562695|NCT03046108|DRUG|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
214562696|NCT03046108|DRUG|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
214562697|NCT03046108|DEVICE|ultrasound guided injection|Introduction of a needle based guided by ultrasound
214562698|NCT03046108|DRUG|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
214562699|NCT03046108|DRUG|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
214707891|NCT05168852|OTHER|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
214562700|NCT02537210|DRUG|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
214562701|NCT02537210|DRUG|Placebo oral capsule|Patients will be prescribed placebo 5 capsules daily for 12 months
214562702|NCT03222713|OTHER|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
214707892|NCT05808023|OTHER|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
215165792|NCT06062238|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent \[%\] sodium chloride \[NaCl\]), on Day 1 and Day 29.
215165793|NCT07118241|DRUG|Recombinant Human Proteoglycan 4|rhPRG4 450ug/ml
215165794|NCT07118241|DRUG|Vehicle Control|PBS based Vehicle Conrtol
215165795|NCT07118254|DRUG|rhPRG4 450ug/ml|Treatment
215165796|NCT07118254|DRUG|Vehicle Control|PBS Based Vehicle Control
215165797|NCT06924606|DRUG|JS207 injection +docetaxel|Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
215165798|NCT06924606|DRUG|JS207 injection +JS004 injection|Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
214562703|NCT00004853|BIOLOGICAL|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC \>=10,000/microliter
214562704|NCT00004853|BIOLOGICAL|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
214562705|NCT00890695|DIETARY_SUPPLEMENT|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
214562706|NCT04542213|DRUG|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
214562707|NCT04542213|DRUG|Insulin|Basal-bolus insulin scheme
214562708|NCT05758948|DIAGNOSTIC_TEST|NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue|In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
214562709|NCT03561662|DIETARY_SUPPLEMENT|Alpro soya drinks|12 weeks
214562710|NCT02290808|BEHAVIORAL|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
214562711|NCT01531673|DRUG|VX-661|
214562712|NCT01531673|DRUG|Ivacaftor|
214562713|NCT01531673|DRUG|Placebo matched to VX-661|
214562714|NCT01531673|DRUG|Placebo matched to ivacaftor|
214562715|NCT01508624|OTHER|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
214562716|NCT01508624|OTHER|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
215165799|NCT06924606|DRUG|JS207 injection|Patients receive JS207 10mg/kg or other dosage.
214562717|NCT01508624|BEHAVIORAL|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
214562718|NCT01508624|BEHAVIORAL|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
214562719|NCT02490033|DEVICE|Ablation Catheter|
214562720|NCT00954889|DRUG|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
214562721|NCT00954889|DRUG|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
214562722|NCT04945889|DIAGNOSTIC_TEST|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score \<15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
214562723|NCT04945889|DIAGNOSTIC_TEST|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
214562724|NCT04945889|DIAGNOSTIC_TEST|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
214562725|NCT00801762|DEVICE|Fibered confocal microscope|
214562726|NCT05691803|BEHAVIORAL|Exercise intervention|"The 6 month intervention consists of usual care (PaP) plus an initial 12 weeks of instructor led exercise (described below) followed by a 12 week period in where the participant will have to conduct their physical activity on their own.~Exercise intervention:~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks in where a physiotherapist contact the participant and discuss how they will adhere to their Physical activity on prescription."
214562727|NCT04218149|DRUG|Bupivacaine Injection|Block with bupivacaine
214562728|NCT04662723|DRUG|Corticosteroid|To reduce the progression of renal damage in IgAN Patients
214562729|NCT04662723|DRUG|Renin-angiotensin sytem blockers|To reduce the progression of renal damage in IgAN Patients
214562730|NCT04662723|DRUG|Sodium-glucose cotransporter 2 inhibitor|To reduce the progression of renal damage in IgAN Patients
214562731|NCT04795765|PROCEDURE|SpineJack system|For use in the reduction of painful osteoporotic vertebral compression fractures.
214562732|NCT04795765|PROCEDURE|Balloon kyphoplasty|Treatment of osteoporotic vertebral compression fractures.
214562733|NCT04795765|PROCEDURE|Vertebroplasty|Treatment of osteoporotic vertebral compression fractures.
214562734|NCT03495843|DIAGNOSTIC_TEST|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
214562735|NCT02187159|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
214562736|NCT02187159|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
214562737|NCT02187159|DRUG|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
214562738|NCT02187159|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
214562739|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM who can access and existing registry of patients with possible or confirmed AUD to examine quality metrics for patients with an AUD on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide performance metric data that indicates the proportion of patients on their primary care panel who are initiating and engaging in AUD treatment. Additionally, the PHM will circulate a weekly report of higher risk patients on the clinician's panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. PHM does not directly help clinicians with implementation of care with individual patients, and has no direct patient contact.
214562740|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). The clinician will be supported by a CCM who will assist in identifying patients who need further assessment on the clinician patient panel. The CCM will conduct outreach to patients regarding alcohol use care, and will communicate with the clinician to help decide potential care plans, and then assist in implementing those plans for patients. The CCM has expertise on how to provide appropriate care to patients and can help patients navigate the complex care system. Further assistance by the CCM may include facilitating prescriptions for clinician sign-off, assuring refills, finding, selecting and coordinating specialty AUD care, and contacting patients to make appointments.
214707893|NCT02215616|DRUG|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
214707894|NCT02215616|DRUG|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
214707895|NCT00080184|PROCEDURE|Low Energy Neurofeedback System|
214707896|NCT01052831|DRUG|Naltrexone|50-100 mg qd for 8 weeks
214707897|NCT01052831|DRUG|Placebo|50-100 mg qd for 8 weeks
214707898|NCT01594346|DRUG|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
214562741|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM and clinical care manager CCM. The PHM can access and existing registry of patients with possible or confirmed alcohol use disorder to examine quality metrics for patients with an alcohol use disorder on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide summaries of data of those who have initiated or engaged in treatment for alcohol use, as well as a weekly report of higher risk patients on their panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. The CCM will assist in identifying patients who need further assessment, and will assist in conducting outreach and implementing care to those patients regarding alcohol use care.
214562742|NCT03930862|DEVICE|Locator Attachment (positioner)|intra oral attachment
214562743|NCT02776839|DEVICE|Mobile sensing|
214562744|NCT00652769|PROCEDURE|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
214562745|NCT00652769|PROCEDURE|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
214562746|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1\&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
214562747|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1\&2 LNs) and para-aortic lymph nodes must be removed during the operation."
214562748|NCT02423278|DRUG|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
214562749|NCT04212637|OTHER|MRI|Examine BOLD activity in relation to eye movements measures
214562750|NCT00567567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214562751|NCT00567567|DRUG|Carboplatin|Given IV
214562752|NCT00567567|DRUG|Cisplatin|Given IV
214562753|NCT00567567|DRUG|Cyclophosphamide|Given IV
214562754|NCT00567567|DRUG|Doxorubicin Hydrochloride|Given IV
214562755|NCT00567567|DRUG|Etoposide|Given IV
214562756|NCT00567567|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214562757|NCT00567567|BIOLOGICAL|Filgrastim|Given IV or SC
214562758|NCT00567567|DRUG|Isotretinoin|Given orally
214562759|NCT00567567|OTHER|Laboratory Biomarker Analysis|Correlative studies
214562760|NCT00567567|DRUG|Melphalan|Given IV
214562761|NCT00567567|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214562762|NCT00567567|OTHER|Pharmacological Study|Correlative studies
214562763|NCT00567567|DRUG|Thiotepa|Given IV
214562764|NCT00567567|DRUG|Topotecan Hydrochloride|Given IV
214562765|NCT00567567|DRUG|Vincristine Sulfate Liposome|Given IV
214562766|NCT04216563|DRUG|Asciminib|Given PO
214562767|NCT06244576|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a trans diagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
214562768|NCT02209493|BEHAVIORAL|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
214562769|NCT02209493|BEHAVIORAL|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
214562770|NCT04825405|PROCEDURE|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
214562771|NCT05852665|DEVICE|Ultrasound-guided resection|Ultrasound-guided resection of buccal squamous cell carcinomas
214562772|NCT02075281|BIOLOGICAL|HM11260C|Glucagon-like peptide-1 analogue
214562773|NCT02075281|BIOLOGICAL|Placebo|
214562774|NCT06153342|DRUG|TL-925|TL-925 is an eye drop.
214562775|NCT06153342|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
214562776|NCT03126669|DEVICE|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
214562777|NCT03126669|DEVICE|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
214562778|NCT04609488|DIAGNOSTIC_TEST|Surfactant assessment|To determine surfactant levels in lung fluid
214562779|NCT03570567|DEVICE|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
214562780|NCT06184126|DEVICE|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
214707899|NCT01594346|DRUG|Sugar Pill|
214707900|NCT01352845|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
214562781|NCT06184126|OTHER|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
215165800|NCT06918067|DEVICE|Coloplast Micro Zone Luja Female Catheter|clean self-catheterization with 14 Fr Coloplast micro zone Luja female urinary catheter
215165801|NCT06918067|DEVICE|Coloplast SpeediCath Female Catheter|clean self-catheterization with 14 Fr two eyelet Coloplast SpeediCath female urinary catheter
215165802|NCT06923072|DRUG|Baricitinib|Participants will be instructed to take baricitinib 4mg oral daily for 24 weeks (with or without food)
215165803|NCT06863974|OTHER|Blood test|Drawing blood to realize biomarkers of disease course of MOGAD-ADEM and pathophysiology of ADEM (and MOGAD) : cellular and molecular signatures, inflammatory signaling.
215165804|NCT07114614|OTHER|Specimen #1|Specimen 1 will be collected in a 10 ml SST (serum separator tube).
214562782|NCT01786226|DRUG|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
214562783|NCT01786226|DRUG|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
214562784|NCT00003933|OTHER|laboratory biomarker analysis|
214562785|NCT03845231|BIOLOGICAL|Flucelvax(R)|Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
214562786|NCT03845231|OTHER|Human Challenge virus|A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
214562787|NCT00281060|PROCEDURE|primary stenting|
214562788|NCT00399464|DRUG|alfuzosin|
214562789|NCT00508053|PROCEDURE|Small stitches|
214562790|NCT00508053|PROCEDURE|Mass closure|
214562791|NCT05594381|DRUG|Sintilimab|"Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles)."
214562792|NCT05645341|DIAGNOSTIC_TEST|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
214562793|NCT04609202|BEHAVIORAL|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
214562794|NCT04609202|OTHER|Usual care|Usual care provided by doctors
214562795|NCT03585010|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
214562796|NCT03585010|BEHAVIORAL|Parent Educational Support|12 sessions with parents
214707901|NCT01352845|OTHER|Placebo|0.5 mL dose, given at 0, 2 and 6 months
215165805|NCT07114614|OTHER|Specimen #2|Specimen #2 will be collected in a 10 ml SST (serum separator tube)
215165806|NCT06824103|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.
214562797|NCT03585010|BEHAVIORAL|Cognitive-Behavioral Therapy|12 sessions with child
214562798|NCT04137744|PROCEDURE|AXILLARY REVERSE MAPPING|subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
214562799|NCT00531219|PROCEDURE|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
214562800|NCT00531219|PROCEDURE|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
214562801|NCT01582841|PROCEDURE|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
214562802|NCT06458270|BEHAVIORAL|Salt warning label|A salt warning label will feature on the restaurant menu next to menu items that are high in salt (\>3g, more than 50% of guideline daily amount \[GDA\] in the UK).
214562803|NCT00198770|DIETARY_SUPPLEMENT|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
215165807|NCT07118371|OTHER|Clamshell exercise|The clamshell starts with lying on the side, with legs stacked and knees bent at a 45-degree angle. Rest the head on the lower arm and use the top arm to steady the frame. Hipbones are stacked on top of one another, as there is a tendency for the top hip to rock backward. Engage the abdominals by pulling your belly button in, as this will help to stabilize the spine and pelvis. Keeping the feet touching, raise the upper knee as high as they can without shifting the hips or pelvis. They don't move their lower leg off the floor. Pause, and then return the upper leg to the starting position on the ground. 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set.
214562804|NCT04772859|BEHAVIORAL|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
214562805|NCT04772859|OTHER|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
214562806|NCT03390764|PROCEDURE|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
214562807|NCT03390764|PROCEDURE|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
214562808|NCT03889704|DEVICE|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
214562809|NCT02330705|DRUG|HCG|Women will be given HCG before IUI
214562810|NCT03482466|BEHAVIORAL|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
214562811|NCT03241108|DRUG|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
214562812|NCT03241108|OTHER|Placebo|Placebo
214562813|NCT00006405|BEHAVIORAL|Exercise|
214562814|NCT00900224|GENETIC|DNA analysis|
214562815|NCT00900224|GENETIC|DNA methylation analysis|
214562816|NCT00900224|GENETIC|gene expression analysis|
214562817|NCT00900224|GENETIC|mutation analysis|
214562818|NCT00900224|GENETIC|polymerase chain reaction|
214562819|NCT00900224|GENETIC|reverse transcriptase-polymerase chain reaction|
214562820|NCT00900224|OTHER|high performance liquid chromatography|
214562821|NCT00900224|OTHER|laboratory biomarker analysis|
214562822|NCT00508313|PROCEDURE|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
214562823|NCT02060370|DRUG|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
214562824|NCT02060370|BEHAVIORAL|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
214562825|NCT04685746|BEHAVIORAL|Balanced Growth Protocol|Assessment of the Balanced Growth Protocol, consisting of audiovestibular testing, motor and cognitive tasks
214562826|NCT00017368|BIOLOGICAL|filgrastim|
214562827|NCT00017368|BIOLOGICAL|sargramostim|
214562828|NCT00017368|DRUG|carboplatin|
214562829|NCT00017368|DRUG|cisplatin|
214562830|NCT00017368|DRUG|cyclophosphamide|
214562831|NCT00017368|DRUG|doxorubicin hydrochloride|
215165808|NCT07118371|OTHER|Frog pump exercises|"The Frog pump exercise will start with lying on your back, arms by sides, palms facing down. Alternatively, make fists with your hands, rest the elbows on the floor, and lift the fists so that your forearms are perpendicular to the floor. Then bend the knees and press the soles of the feet together so that the legs create a frog legs or butterfly shape. Pressing the outer edges of the feet against the floor, engage the core, and use the glutes to lift the hips. Make sure the shoulders and upper back remain anchored to the floor. Pause, then slowly lower the hips to the floor. . 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set."
215165809|NCT07119489|BEHAVIORAL|Dialectical Behavior Therapy -Skill Training brief intervention|A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness
215165810|NCT07121478|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
215165811|NCT06916143|DRUG|LY4100511|Administered orally.
215165812|NCT06916143|DRUG|Rabeprazole|Administered orally.
215165813|NCT07122401|DRUG|MT1013|MT1013 + dummy cinacalcet
215165814|NCT07122401|DRUG|Cinacalcet|Cinacalcet + dummy MT1013
215165815|NCT06925555|DRUG|BV+R-CHP|Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5
215165816|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Open Label Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Adaptations targeting those in JHOME will be made on a per-client basis as part of the open-label pilot. The investigators will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain those perspectives of the acceptability and feasibility of implementing the CAPABLE Care + Connect intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
214562832|NCT00017368|DRUG|etoposide|
214562833|NCT00017368|DRUG|etoposide phosphate|
214562834|NCT00017368|DRUG|ifosfamide|
214562835|NCT00017368|DRUG|isotretinoin|
214562836|NCT00017368|DRUG|melphalan|
214562837|NCT00017368|DRUG|thiotepa|
214562838|NCT00017368|DRUG|vincristine sulfate|
214562839|NCT00017368|PROCEDURE|conventional surgery|
214562840|NCT00017368|PROCEDURE|peripheral blood stem cell transplantation|
214562841|NCT00017368|RADIATION|radiation therapy|
214562842|NCT03971383|DRUG|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
214562843|NCT03971383|DRUG|Placebo|3 tablets one time, 3 times a day(tid)
214562844|NCT02625051|PROCEDURE|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
214562845|NCT02625051|PROCEDURE|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
214562846|NCT05762913|OTHER|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
214562847|NCT03177499|PROCEDURE|Invasive PPG|Invasive PPG obtained by means of catheterization.
214562848|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
214562849|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
214562850|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
214562851|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
214562852|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
214562853|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
214562854|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
214562855|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
214562856|NCT05880537|OTHER|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
214562857|NCT04896073|DRUG|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
214562858|NCT05215964|PROCEDURE|Renal artery embolization|After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
214562859|NCT03203330|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
214562860|NCT03203330|BIOLOGICAL|Placebo Control|2 mL normal saline injection
214562861|NCT05959759|DRUG|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
214562862|NCT05959759|DRUG|Placebo|placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
214562863|NCT04180033|DIAGNOSTIC_TEST|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
214562864|NCT01493427|DRUG|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
214562865|NCT01461811|DEVICE|Nelfilcon A toric contact lenses (with comfort additives)|
214562866|NCT01461811|DEVICE|Nelfilcon A toric contact lenses|
214562867|NCT03330145|BEHAVIORAL|Scales, questionnaires and inventory|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
214562868|NCT04495075|OTHER|Visuomotor Therapy|"The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback."
214562869|NCT04495075|OTHER|Passive Motion|The knee is passively moved through a range of motion.
214562870|NCT05892705|DRUG|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
214562871|NCT00031668|RADIATION|radiation therapy|
214562872|NCT00662142|DIETARY_SUPPLEMENT|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
214562873|NCT02958046|DRUG|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
214562874|NCT04393870|OTHER|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
214562875|NCT02781090|BEHAVIORAL|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
214562876|NCT02781090|BEHAVIORAL|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
214562877|NCT02781090|DRUG|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
214562878|NCT05027035|OTHER|"surgical plication or nocturnal non-invasive ventilation"|10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
214562879|NCT02876822|DIETARY_SUPPLEMENT|Vitamin D|
214562880|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
214562881|NCT05994469|BEHAVIORAL|Copenhagen Adduction Exercise|The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
214562882|NCT04547647|RADIATION|X- Ray|X-Ray with A-P and lateral view of the whole spine.
214562883|NCT02461004|DRUG|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
214562884|NCT02461004|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
214562885|NCT03117764|DEVICE|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
214562886|NCT03117764|BEHAVIORAL|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
214562887|NCT03117764|DEVICE|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
214562888|NCT03878329|BEHAVIORAL|remote home monitoring|Will use telemedicine to guide behavior changes in outcomes
214562889|NCT03842540|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~1. Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~2. Digital materials for recipients to keep and/or share with friends.~3. Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~4. Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut."
214562890|NCT03842540|BEHAVIORAL|PartyWise|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
214562891|NCT05447234|BIOLOGICAL|Tcrx T cell|Sequential IV infusion
214562892|NCT02278484|DEVICE|XprESS device and PathAssist confirmation tools|
214562893|NCT01401153|OTHER|Skipping lunch|Just water.
214562894|NCT02964533|OTHER|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
214562895|NCT02964533|OTHER|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
214562896|NCT03474926|PROCEDURE|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
214562897|NCT03474926|PROCEDURE|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
214562898|NCT00757627|DRUG|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
214562899|NCT00031070|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
214562900|NCT00031070|DRUG|Cyclosporine|
214562901|NCT00031070|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
214562902|NCT00031070|DRUG|Efavirenz|
214562903|NCT00031070|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
214562904|NCT00031070|BIOLOGICAL|Rabies Vaccine|
214562905|NCT05717491|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
214562906|NCT05717491|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
214562907|NCT05247905|DRUG|Lutetium Lu 177 Dotatate|Given IV
214562908|NCT05247905|DRUG|Capecitabine|Given PO
214562909|NCT05247905|DRUG|Temozolomide|Given PO
214562910|NCT05247905|OTHER|Quality-of-Life Assessment|Ancillary studies
214562911|NCT05247905|OTHER|Questionnaire Administration|Ancillary studies
214562912|NCT00709267|DRUG|Folic acid|
214562913|NCT00003124|DRUG|flutamide|
214562914|NCT00003124|DRUG|leuprolide acetate|
214562915|NCT00003124|RADIATION|radiation therapy|
214562916|NCT00403767|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
214562917|NCT00403767|DRUG|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
214562918|NCT00403767|DRUG|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
214562919|NCT00403767|DRUG|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
214562920|NCT01585077|BIOLOGICAL|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
214562921|NCT04860362|BEHAVIORAL|PEERS|Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
214562922|NCT03968380|OTHER|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
214562923|NCT01383655|DRUG|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
214562924|NCT01383655|DRUG|Placebo|NaCl
214562925|NCT00261976|DRUG|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
214562926|NCT05010343|RADIATION|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
214562927|NCT05010343|RADIATION|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
214562928|NCT04767100|DEVICE|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
214562929|NCT05330676|PROCEDURE|coronary artery bypass grafting, valve repair/replacement|cardiovascular surgery with cardiopulmonary bypass
214562930|NCT00920322|DEVICE|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
214562931|NCT00920322|DEVICE|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
214562932|NCT01529320|DRUG|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
214562933|NCT00436605|DRUG|dasatinib|
214562934|NCT03878277|DRUG|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
214562935|NCT06185231|OTHER|Percussion Massage Group|In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
214562936|NCT06185231|OTHER|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes."
214562937|NCT00355303|DRUG|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
214562938|NCT00355303|DRUG|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
214562939|NCT04058275|OTHER|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
214562940|NCT06345651|DEVICE|Transcranial Magnetic Stimulation|Individually MR-neuronavigated TMS, 600 pulses, 120% RMT
214562941|NCT01013038|PROCEDURE|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
214562942|NCT01013038|PROCEDURE|conventional PCI|balloon angioplasty and/or stent implantation
215165817|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
215165818|NCT07125378|BEHAVIORAL|Task-oriented resistance exercise|The intervention program includes progressive resistance exercise and daily activity exercise, delivered over a six-week period with an ideal frequency of three sessions per week. Progressive resistance exercise will be provided through a combination of in-person and online sessions, while daily activity exercise will be delivered exclusively in person.
215165819|NCT07125209|OTHER|Patient Reported Outcomes Assessment|Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes.
215165820|NCT07125209|OTHER|Cognitive and General Health Assessments|"* Rey Verbal Learning Test~* Trail Making Test~* Patient Health Questionnaire (PHQ-2)~* Mini Mental State Exam (MMSE)~* Controlled Oral Word Association Test of the Multilingual Aphasia Examination"
214562943|NCT03417570|PROCEDURE|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
214562944|NCT03417570|DEVICE|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
214562945|NCT01638143|DIETARY_SUPPLEMENT|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
215165821|NCT07127835|DIAGNOSTIC_TEST|Nurse-led penicillin allergy delabelling service|Patients in this group undergo risk assessment and categorization by nurses to identify low-risk individuals for delabeling. For these patients, nurses will collaborate with allergists in the delabeling process.
215165822|NCT07127835|DIAGNOSTIC_TEST|Allergist-led penicillin allergy delabelling service|Patients assigned to this group will undergo risk assessment and delabeling led by allergists for both low-risk and high-risk cases.
215165823|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
215165824|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
215165825|NCT07129694|DEVICE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
215165826|NCT07129694|PROCEDURE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
215165827|NCT06926868|DRUG|Iza-bren|Specified dose on specified days
215165828|NCT06926868|DRUG|Nab-paclitaxel|Specified dose on specified days
215165829|NCT06926868|DRUG|Paclitaxel|Specified dose on specified days
215165830|NCT06926868|DRUG|Capecitabine|Specified dose on specified days
215165831|NCT06926868|DRUG|Carboplatin|Specified dose on specified days
215165832|NCT06926868|DRUG|Gemcitabine|Specified dose on specified days
215165833|NCT06753916|PROCEDURE|Corneal Donor Tissue with Cross Linking|Participants are transplanted with corneal donor tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) with UV light treatment.
214562946|NCT01638143|DIETARY_SUPPLEMENT|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
214562947|NCT01638143|DIETARY_SUPPLEMENT|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
214562948|NCT01184040|BEHAVIORAL|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
214562949|NCT04337671|OTHER|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
214562950|NCT00091559|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
214562951|NCT00193752|OTHER|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
214562952|NCT03265171|BIOLOGICAL|Plasminogen (Human)|
214562953|NCT02736240|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
214562954|NCT02736240|BIOLOGICAL|13-valent pneumococcal polysaccharide conjugate vaccine|
214562955|NCT00484484|DRUG|Ketamine|Ketamine
214562956|NCT01432587|DRUG|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
214562957|NCT01559129|DRUG|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
214562958|NCT01559129|DRUG|Placebo|Matching placebo capsules taken orally once a day
214562959|NCT04703998|PROCEDURE|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
214562960|NCT04703998|BIOLOGICAL|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
214562961|NCT00368927|DRUG|sulindac|Given orally
214562962|NCT00368927|OTHER|placebo|Given orally
214562963|NCT03017898|PROCEDURE|Laser Coagulation|Laser coagulation of anal fistula
214562964|NCT02392052|BEHAVIORAL|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
214562965|NCT02392052|BEHAVIORAL|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
214707902|NCT06295601|OTHER|Traditional rehabilitation|The program consists of a joint treatment in which lower extremity strengthening and balance exercises are carried out synchronously. The program will include a total of 5 minutes of warm-up, 5 minutes of cool-down and 30 minutes of exercises related to the program. The difficulty of the program will increase by changing the number of exercises and increasing the weight in strengthening exercises. Progress in balance and coordination exercises will vary by changing the ground, increasing the standing time, and keeping the eyes open and closed.
214562966|NCT00009659|DRUG|CDB 2914|
214562967|NCT03260777|DEVICE|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
214562968|NCT00878683|DEVICE|silicone catheter boot|silicone device using Dermabond
214562969|NCT00881062|DRUG|Proellex|A single oral dose administered after at least a 10 hour fast
214562970|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (lower dose)
214562971|NCT01521936|OTHER|pharmacological study|Correlative studies
214562972|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (higher dose)
214562973|NCT01521936|OTHER|laboratory biomarker analysis|Correlative studies
214562974|NCT04606108|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
214562975|NCT04445740|BEHAVIORAL|i♥rhythm project|behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
214562976|NCT03525392|DRUG|177Lu-3BP-227 (also called 177Lu-IPN01087)|The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
214562977|NCT03750786|DRUG|Arfolitixorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
214562978|NCT03750786|DRUG|Leucovorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
214562979|NCT01802177|PROCEDURE|UVB excimer light|
214562980|NCT01922388|DEVICE|Bilateral deep brain stimulation of the subthalamic nucleus|
214562981|NCT03284203|DEVICE|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
214562982|NCT03454126|DRUG|BIIB095|Administered as specified in the treatment arm.
214562983|NCT03454126|DRUG|Placebo|Administered as specified in the treatment arm.
215165834|NCT06753916|PROCEDURE|Corneal Donor Tissue without Cross Linking|Participants are transplanted with corneal donor tissue that has not been treated with the UV light and the 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) without UV light treatment, this is the control group.
214562984|NCT04395300|OTHER|Web Based Survey|On line survey distributed electronically
214562985|NCT05151900|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
214562986|NCT02229851|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
215165835|NCT07137247|PROCEDURE|Venipuncture|"For adults (including those who are 18 years old): During the routine follow-up visits, an extra 30 milliliters of peripheral blood will be drawn.~For minors (under 18 years old): During the routine follow-up visits, an extra 6 milliliters of peripheral blood will be drawn.~Follow-ups will be conducted every six months, with a minimum of six visit points."
214562987|NCT02229851|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
214562988|NCT02229851|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
214562989|NCT06403189|OTHER|Biologic samples and MRI|"* blood sample~* lumbar punction~* MRI"
214562990|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
214562991|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
214562992|NCT04078763|BEHAVIORAL|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
214562993|NCT04078763|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
214562994|NCT04078763|BEHAVIORAL|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
214562995|NCT05414344|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
214562996|NCT05414344|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
214562997|NCT05414344|BEHAVIORAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
214562998|NCT05538130|DRUG|PF-07799544|Tablet
214562999|NCT05538130|DRUG|PF-07799933|Tablet
214563000|NCT05538130|DRUG|encorafenib|Capsule
214563001|NCT02623751|DRUG|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
214563002|NCT02623751|DRUG|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
214563003|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
215165836|NCT06933524|DRUG|ATB-320|IV infusion
215165837|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
215165838|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215165839|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215165840|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
215165841|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215165842|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
215165843|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215165844|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
214563004|NCT02441868|BEHAVIORAL|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
214563005|NCT02206061|BEHAVIORAL|School-Based Asthma Care for Teens (SB-ACT)|
214563006|NCT02206061|BEHAVIORAL|Directly Observed Therapy|
214563007|NCT02206061|BEHAVIORAL|Asthma Education|
214563008|NCT03873168|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
214563009|NCT06437951|DRUG|Fexuprazan Injection|20/40/80 mg
214563010|NCT06437951|DRUG|Fexuprazan Injection placebo|20/40/80 mg
214563011|NCT06437951|DRUG|Fexuprazan Injection_part 2|20mg
214563012|NCT06437951|DRUG|Fexuprazan Injection_part 3|40mg
214563013|NCT06437951|DRUG|Fexuprazan tablet|40mg
214563014|NCT04187326|BEHAVIORAL|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
214563015|NCT06042413|OTHER|Personalized CPC Prehabilitation|Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
214563016|NCT06042413|BEHAVIORAL|Cognitive Training|Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
215165845|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
215165846|NCT06172478|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
215165847|NCT06939361|OTHER|Smaller endotracheal tube|"* Inner diameter 7.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 6.5 mm (for patients with a height \< 64 inches)"
215165848|NCT06939361|OTHER|Larger endotracheal tube|"* Inner diameter 8.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 7.5 mm (for patients with a height \< 64 inches)"
215165849|NCT06938412|DEVICE|Physical Activity Intervention Using FitBit Wearable Device|The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device.
215165850|NCT06940427|DRUG|FAPI tracer|"radioactive substance called a tracer injected into the arm"
215165851|NCT06940427|DEVICE|PET/MRI|positron emission tomography (PET) takes pictures of inside of the body
215165852|NCT06937931|BIOLOGICAL|IPN10200|Study intervention will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
214563017|NCT06042413|BEHAVIORAL|Meditation|A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
215165853|NCT06937931|OTHER|Placebo|Excipients without active substance will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
215165854|NCT06941272|BIOLOGICAL|Patritumab Deruxtecan|IV Infusion
215165855|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
215165856|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
215165857|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
215165858|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
214563018|NCT06042413|BEHAVIORAL|Daily Exercise|Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
214563019|NCT06042413|BEHAVIORAL|Enhanced Social Support|"Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program."
214563020|NCT06042413|OTHER|Proactive Bundle Interventions|Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit \>30, MAP \>70, and anesthetic BIS \>50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
214563021|NCT06042413|PROCEDURE|Pre-operative Standard of Care|Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
215165859|NCT06942949|DEVICE|ELS (Enhanced Lithotripsy System)|ELS (Enhanced Lithotripsy System) utilizes low pressure ultrasound to actuate proprietary microbubbles administered into the urine to pit and fragment urinary stones.
215165860|NCT06941129|BIOLOGICAL|UCAR T-cell|universal allogeneic anti-CD19/BCMA CAR T-cells
215165861|NCT06935890|OTHER|Jack Jumper Ant Venom Immunotherapy|Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-\<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial.
215165862|NCT06940050|PROCEDURE|Coronally advanced flap with a connective tissue graft|The gum at the recession site is detached and reattached higher (combined with a connective tissue graft).
215165863|NCT06940050|PROCEDURE|Tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined with a connective tissue graft).
215165864|NCT06940752|DEVICE|VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms)|Non-surgical catheter approach called VINTAGE will be used to treat ventricular arrhythmias arising from difficult-to-reach portions of the heart.
215165865|NCT07144267|DRUG|Epinephrine|Normal saline bolus over 10 min followed by Epinephrine intravenous infusion of 0.05-0.1 mcg/kg/min.of epinephrine 5-10 minutes before aortic unclamping
215165866|NCT07144267|DRUG|Milrinone Injection|Milrinone initial bolus doses of 50 µg/kg, followed by 0.40 - 0.80 µg/kg/min of milrinone 5-10 minutes before aortic unclamping
215165867|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
215165868|NCT06945406|DRUG|LY4057996 SC|Administered SC
215165869|NCT06945406|DRUG|LY4057996 IV|Administered IV
215165870|NCT06945406|DRUG|Placebo SC|Administered SC
215165871|NCT06945406|DRUG|Placebo IV|Administered IV
215165872|NCT06945406|DRUG|Degludec SC|Administered SC
215165873|NCT06945406|DRUG|Lispro SC|Administered SC
215165874|NCT06945406|DRUG|Degludec IV|Administered IV
215165875|NCT06945406|DRUG|Pre-study basal insulin SC|Administered SC
215165876|NCT06945198|PROCEDURE|Anatomical reconstruction|Anatomical ligamentoplasty or anatomical reconstruction is performed under arthroscopy. The principle of this method, which lasts around 40 minutes under spinal anaesthetic or general anaesthetic, is to reconstruct the LTFA and sometimes also the LCF, if it has been damaged, using a fragment of the tendon gracilis, located in the thigh, removed through an incision under the knee
215165877|NCT06945198|PROCEDURE|Broström anatomical repair|Broström's anatomical repair is performed under arthroscopy. The principle of this method is to tighten and reattach the LTFA using very small anchors, when it is detached from the fibula but not too retracted and still of good quality. If necessary, this may also be accompanied by ligament reinforcement ('gould'), using a fragment of a fibrous structure in the ankle, the extensor retinaculum
215165878|NCT06943833|BIOLOGICAL|Volrustomig|IV infusion
215165879|NCT04801589|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
215165880|NCT04801589|DRUG|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
215165881|NCT03778307|BEHAVIORAL|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
214563022|NCT06042413|PROCEDURE|Intra-operative Standard of Care|This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
214563023|NCT01607476|DRUG|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
214563024|NCT01607476|DRUG|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
215165882|NCT03778307|BEHAVIORAL|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
215165883|NCT06945172|PROCEDURE|Total prostatectomy|Total prostatectomy is a surgical procedure performed to treat prostate cancer.
215165884|NCT06945172|PROCEDURE|Focal HIFU|Focal HIFU treatment is an innovative technique that consists of destroying prostate tumour cells using high-intensity ultrasound focused exclusively on the affected area of the gland.
215165885|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
214563025|NCT04706299|OTHER|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
215165886|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
214563026|NCT04964349|DRUG|Corticosteroids Acting Locally|topical application of jessener solution
214563027|NCT05703906|BEHAVIORAL|Telerehabilitation - VRRS Khymeia|Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
215165887|NCT07145996|OTHER|AI Based Exercises|This intervention combines structured exercise therapy with artificial intelligence-powered movement analysis using Google MediaPipe Pose technology. Participants perform prescribed exercises (flexibility, core stability, functional strength) while a computer vision system analyzes their movements through standard webcam or smartphone cameras. The AI provides real-time feedback on exercise form, automatically counts repetitions, measures hold times, and flags technique errors. Physiotherapists review AI-generated performance data and provide personalized corrective guidance through scheduled video consultations. The platform delivers 8-week progressive exercise programs specifically designed for chronic non-specific low back pain, integrating objective movement monitoring with human therapeutic oversight to optimize adherence and clinical outcomes.
214563028|NCT01675453|DRUG|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
214563029|NCT01675453|DRUG|0.9% NaCl|
214563030|NCT00002775|DRUG|docetaxel|
214563031|NCT00002775|DRUG|estramustine phosphate sodium|
214563032|NCT06003322|PROCEDURE|non - Incised Papilla surgical approach NIPSA for intrabony defect|"As described by Rodríguez and Caffesse in 2018, a single incision apical to the defect ,on the buccal aspect, only one apical horizontal or oblique incision will be made in the alveolar mucosa, as far removed as possible from the interdental papillae and marginal keratinized tis- sues.~Following flap reflection, the bony defect will be examined carefully. Root planing is performed,. Flap closure will be performed by horizontal mattress sutures, placed 3 mm away from the borders, will be used as the first line of closure, promoting connective tissue contact between both edges of the incision, and single interrupted sutures will then be placed as a second line of closure. Using 5/0 polypropylene monofilament suture, Assut, Swiss"
214563033|NCT06003322|PROCEDURE|single-flap approach SFA|"As described by Trombelli et al 2010, A horizontal, butt-joint incision will be performed at the interdental papilla 1-2 mm coronal to the bone crest (as detected through pre-operative bone sounding).~-A buccal mucoperiosteal envelope flap will be elevated by using a microsurgical periosteal elevator, leaving the residual portion of the interdental supracrestal soft tissues undetached.Flap closure will be performed by a horizontal internal mattress suture,will be performed at the base of the papilla, and a second internal mattress suture (vertical or horizontal) was performed between the most coronal portion of the flap and the most coronal portion of the palatal/lingual papilla. Using a resorbable suture"
214563034|NCT02193490|DRUG|DNase|DNase 0.1% eye drops four times a day for 8 weeks
214563035|NCT02193490|DRUG|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
214563036|NCT05407181|OTHER|Blood and Liver Function test|Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
214563037|NCT02299414|DRUG|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
214563038|NCT02299414|OTHER|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
214563039|NCT04913467|OTHER|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.
214563040|NCT04913467|DIETARY_SUPPLEMENT|ColoVit capsule|Vitamin B2/B3/C supplement in a ColoPulse-coated capsule
215165888|NCT07145996|OTHER|Standard Telerehabilitation|This intervention delivers structured exercise therapy through pre-recorded video instructions without AI monitoring or automated feedback. Participants receive the same exercise components as the AI-enhanced group (flexibility, core stability, functional strength) but rely on video demonstrations and written instructions for proper technique. Physiotherapists conduct periodic consultations via video conferencing to monitor progress, provide guidance, and adjust exercise programs based on visual observation and participant self-reports. The 8-week progressive program represents current standard telerehabilitation practice for chronic non-specific low back pain, serving as an active comparator to isolate the specific effects of AI-enhanced movement analysis and real-time feedback systems.
214563041|NCT04913467|OTHER|ColoPulse-placebo capsule|A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
214563042|NCT01869023|DRUG|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
214563043|NCT01869023|DRUG|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
214563044|NCT03349502|DRUG|MG4101|Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
214563045|NCT02273258|DRUG|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
214563046|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
214563047|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
214563048|NCT00299442|BEHAVIORAL|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
214563049|NCT04098562|DRUG|LL37|cream
214563050|NCT04098562|PROCEDURE|Standard Wound Care|Standard wound debridement
214563051|NCT04958200|BEHAVIORAL|mhealth-pc for alcohol and pain|Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.
214563052|NCT04958200|BEHAVIORAL|Treatment As Usual|psychoeducation on pain and alcohol use and treatment resource information
214563053|NCT00397670|DRUG|Drug: BufferGel® with diaphragm|
214563054|NCT01260818|DRUG|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
214563055|NCT01260818|DRUG|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
214563056|NCT00543231|DRUG|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
214563057|NCT05871320|DRUG|[99mTc]Tc-TECANT1|only one arm - the administration of \[99mTC\]-Tc-TECANT1 in all patients included
214563058|NCT02539459|DRUG|Everolimus|10 mg tablets
214563059|NCT03000205|DEVICE|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
214563060|NCT03000205|DEVICE|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
214563061|NCT02773173|PROCEDURE|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
214563062|NCT02773173|PROCEDURE|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
214563063|NCT00749957|BIOLOGICAL|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
214563064|NCT01533753|DRUG|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
214563065|NCT01533753|DRUG|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
214563066|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot B|Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml
214563067|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot A|Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml
214563068|NCT04531098|BIOLOGICAL|Engerix-B|Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
214563069|NCT05038605|DRUG|Topical metronidazole|Topical application of metronidazole cream on the anal verge every 8 hours after surgery
214563070|NCT05038605|DRUG|oral metronidazole|Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
214563071|NCT00543023|DRUG|teriparatide 20 micrograms/day subcutaneous|
214563072|NCT00543023|DRUG|salmon calcitonin 100 IU/day subcutaneous|
214563073|NCT02628028|DRUG|LY3337641|Administered orally
214563074|NCT02628028|DRUG|Placebo|Administered orally
214563075|NCT05639712|DRUG|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
214563076|NCT05639712|DRUG|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
214563077|NCT05639712|DRUG|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
214563078|NCT05639712|DRUG|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
214563079|NCT05639712|DRUG|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
214563080|NCT05639712|DRUG|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
214563081|NCT05639712|DRUG|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
214563082|NCT05639712|DRUG|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
214563083|NCT05639712|DRUG|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
214563084|NCT05639712|DRUG|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
214563085|NCT01073644|DRUG|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
214707903|NCT06295601|OTHER|Action observation therapy and motor imagery|In the experimental group, in addition to traditional telerehabilitation, action observation and motor imagery of 4 exercises will be performed in each session. A video will be prepared for 4 exercises. Then, the participant will perform 2 minutes of action observation of each movement, followed by 1 minute of motor imagery. In addition to the traditional telerehabilitation program, a 12-minute combination of action observation and motor imagery will be performed in each session. Exercises will be changed every two weeks, gradually increasing the difficulty.
214707904|NCT00357149|DRUG|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
214707905|NCT00357149|DRUG|Concomitant cisplatin, 5-FU and radiotherapy|
215165889|NCT07141238|OTHER|Environmental microplastic exposure|Exposure to environmental microplastics measured by their presence in intestinal tissue, blood, urine, and stool using Raman spectroscopy. This study does not assign any exposure or treatment; it investigates the existing presence of microplastics as an environmental factor of interest.
215165890|NCT07143461|BEHAVIORAL|Faith Healing|In the prayer condition, the participants will engage and vocalize in prayers they are already familiar with and commonly practice at least once, then continue silently for 10 minutes, focusing on the content. If distracted, participants should refocus on the prayer and reflect on its meaning.
215165891|NCT07143461|BEHAVIORAL|Control|In the control condition, participants will read a neutral text with no spiritual or religious content for 10 minutes. If distracted, they should refocus on the text.
215165892|NCT07070089|DEVICE|BosSTENT implantation|BosSTENT implantation in the transverse venous sinus
215165893|NCT06954675|DIETARY_SUPPLEMENT|Exogenous ketone ester|25g Bis-octanoyl-(R)-1,3-butanediol (C8)
215165894|NCT06953375|PROCEDURE|NMES|The NMES intervention protocol in this study ensures patients receive NMES intervention that is adequately dosed (dose = treatment minutes x intensity), delivered using evidence-based parameters, and feasible. The investigators will deliver NMES using a portable two-channel stimulator that the investigators have found to produce stronger muscle contractions than other portable NMES units and has been used in previous clinical studies. It also has a built-in compliance meter to monitor patient treatment minutes (adherence) to NMES application. NMES sites will perform routine collection of outcomes as part of standard practice.
214563086|NCT03796377|DRUG|St Johns Wort Extract|20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
214563087|NCT03796377|DRUG|Rivaroxaban|20 mg rivaroxaban.
214563088|NCT02512731|DEVICE|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
214563089|NCT00673621|DRUG|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
214563090|NCT00673621|DRUG|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
214563091|NCT00673621|DRUG|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
214563092|NCT00218270|DRUG|Tobacco free snuff|Tobacco free snuff
214563093|NCT00135473|DRUG|10% Hemohes® (10% Hydroxyethyl starch)|
214563094|NCT00135473|DRUG|Sterofundin® (Ringer lactate solution)|
214563095|NCT00135473|DRUG|Actrapid® (Insulin)|
214563096|NCT00573053|OTHER|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
214563097|NCT00573053|OTHER|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
214707906|NCT02769078|DRUG|dabigatran|
214707907|NCT02769078|DRUG|rivaroxaban|
214707908|NCT02769078|DRUG|apixaban|
214707909|NCT02769078|DRUG|warfarin|
214707910|NCT02427750|BIOLOGICAL|Aggripal®|TIV
214707911|NCT02319213|OTHER|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
214707912|NCT02319213|OTHER|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
214707913|NCT02319213|OTHER|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
214707914|NCT04121572|DEVICE|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
214707915|NCT03373318|DRUG|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
214707916|NCT03373318|DRUG|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
214563098|NCT04157400|DEVICE|Intraoperative Parameter Testing|"Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals."
214707917|NCT01309490|DRUG|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
215165895|NCT06953375|OTHER|Usual Care|Usual Care clinics will continue with routine collection and documentation of physical performance outcomes as standard practice. A combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Usual Care clinics including the facility, rehabilitation clinicians, and patients will not have access to NMES materials developed for this study.
215165896|NCT06948097|DRUG|fostamatinib|The study intervention is fostamatinib, administered orally starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for 28 additional days and randomized to receive either fostamatinib or placebo, along with standard of care.
214707918|NCT00453843|DEVICE|rehabilitation robotics|sequence of intervention
214707919|NCT00453843|PROCEDURE|Movement therapy|sequence of intervention
214707920|NCT02739256|PROCEDURE|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
214707921|NCT03465176|OTHER|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214707922|NCT03465176|OTHER|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
214563099|NCT04157400|DEVICE|Proprioception Testing During Stimulation|"Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task."
214563100|NCT04157400|DEVICE|Gait Analysis During Stimulation|"Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM."
214563101|NCT04917640|RADIATION|Radiation Therapy|Either SBRT or IMRT radiation therapy
214563102|NCT01809834|DEVICE|Etafilcon A|
214563103|NCT01809834|DEVICE|Stenfilcon A|
214563104|NCT05834062|DRUG|Qsymia and lifestyle management therapy|Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
214563105|NCT05834062|BEHAVIORAL|Placebo and lifestyle management therapy|Placebo will be used in lieu of Qsymia to maintain the blind. Participants will be offered lifestyle management therapy.
214563106|NCT02296736|RADIATION|Computerised tomography (CT) scan|Retrospective review of CT scans
214563107|NCT04920942|DRUG|Ivermectin 0.4mg/kg/day for 5 days|Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
214563108|NCT05684718|DRUG|BV100 (300 mg)|Intravenous solution
214563109|NCT05684718|DRUG|Itraconazole 200 mg|Oral solution
214563110|NCT05249738|DIAGNOSTIC_TEST|Measuring tongue cross-sectional area by submental ultrasonography|The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
214563111|NCT01500811|BIOLOGICAL|cell injection|Intra articular injection of chondrocyte
214563112|NCT00232453|PROCEDURE|Combined Radiation and Chemotherapy|
214563113|NCT05697263|OTHER|Periodization of training|Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
214563114|NCT05082961|OTHER|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
214563115|NCT04204252|DRUG|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
214563116|NCT04204252|DRUG|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
214563117|NCT00186888|PROCEDURE|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
215165897|NCT06948097|DRUG|Placebo|Placebo tablets will match fostamatinib, starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, and then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for an additional 28 days.
215165898|NCT07147634|BEHAVIORAL|Outdoor science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks in an outdoor setting
215165899|NCT07147634|BEHAVIORAL|Indoor classroom-based science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks inside the classroom
215165900|NCT07148999|COMBINATION_PRODUCT|Opt-IVF|Opt-IVF provides optimized dosage profile for each patient
215165901|NCT07148999|OTHER|Control|Physicians will decide the dosage for each day for patients
215165902|NCT06954402|BEHAVIORAL|Acute Stress Intervention (MAST-based)|This intervention uses the Maastricht Acute Stress Test (MAST) to induce an acute stress response. Participants are exposed to standardized stress tasks while performing laboratory-based assessments of cognitive, emotional, and control aspects of resilience.
215165903|NCT06954402|BEHAVIORAL|Non-Stress Intervention (NST-based)|In this control intervention, participants complete the same battery of laboratory tasks without exposure to the acute stressor.
215165904|NCT06955741|DRUG|BMS-986446 IV|Specified dose on specified days was administered intravenously (IV).
215165905|NCT06955741|DRUG|BMS-986446 SC|Specified dose on specified days was administered subcutaneously (SC).
215165906|NCT06955741|DRUG|Acetaminophen|Specified dose on specified days
215165907|NCT06955741|DRUG|Loratadine|Specified dose on specified days
215165908|NCT06954909|BEHAVIORAL|Hydration education and self-assessment|Hydration education is a 25-minute session based on the theory of planned behavior, including the instructions how to use a worksheet for hydration self-assessment and materials.
215165909|NCT06951217|COMBINATION_PRODUCT|AP01|AP01 will be administered open-label via the eFlow Nebulizer System
215165910|NCT06948214|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
215165911|NCT06948214|OTHER|Matched Placebo (Capsules)|Administered orally once daily
215165912|NCT06954597|DRUG|TOP-N53|TOP-N53 solution (IMP) containing 80 µg/ml TOP-N53 is applied topically directly to the digital ulcer of patients with systemic sclerosis. The dose if defined by volume and exposure time of the IMP.
215165913|NCT06954597|DRUG|Sildenafil|Parallel treatment with Sildenafil 20 mg 3-times per day is permitted if patient has been on a stable dose for 2 weeks prior to screening.
215165914|NCT06954597|DRUG|TOP-N53 vehicle|TOP-N53 vehicle solution will be topically applied to digital ulcers of systemic sclerosis patients.
215165915|NCT06953960|DRUG|ABBV-453|Oral Tablet
214563118|NCT00186888|DRUG|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage\< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
214563119|NCT00186888|PROCEDURE|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
214563120|NCT00186888|RADIATION|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
214563121|NCT00186888|DRUG|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.
215165916|NCT06953960|DRUG|Daratumumab|Subcutaneous (SC) Injection
214563122|NCT00186888|DRUG|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
215165917|NCT06953960|DRUG|Dexamethasone|Oral Tablet
215165918|NCT06953960|DRUG|Pomalidomide|Oral Capsule
215165919|NCT06951711|DRUG|KarXT|Specified dose on specified days
215165920|NCT06951711|OTHER|Placebo|Specified dose on specified days
215165921|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-poor, plant sterol-poor shake|The first arm is the cholesterol-poor arm, where participants will be given a mixed meal in the form of a cholesterol-poor, plant-sterol-poor shake which provides the lowest cholesterol absorption rate.
215165922|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-poor shake|The second arm is the high-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-poor shake, which provides the highest cholesterol absorption rate.
214563123|NCT00186888|DRUG|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
214563124|NCT00186888|DRUG|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
214563125|NCT00186888|PROCEDURE|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
214563126|NCT00186888|OTHER|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
214563127|NCT04752722|DRUG|EG-70 (phase 1)|Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
214563128|NCT04752722|DRUG|EG-70 (phase 2)|Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
214563129|NCT02108964|DRUG|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
214563130|NCT04711837|DRUG|HSK3486|HSK3486 for induction of general anesthesia.
215165923|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-rich shake|The third arm is the moderate-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-rich shake, which provides the moderate cholesterol absorption rate.
214563131|NCT04711837|DRUG|Propofol|Propofol for induction of general anesthesia.
215165924|NCT07142512|BEHAVIORAL|Step Count tracking and goals|We will provide participants and partners with Fitbits for the duration of the trial. After one week of step counting, the next week target will be to increase by 500 steps/day if baseline \< 5000 steps/day; increase by 750 steps/day if baseline 5000 to 7,500 steps/day; and increase by 1,000 steps/day if baseline \> 7,500 steps/day). Each week thereafter, study staff will pull the step data and apply an algorithm to generate new targets for the next week. In our algorithm, subsequent targets are higher if the participant exceeds prior week targets, and lower/unchanged if below target. This is similar to the algorithm we used in our trial ACTIVE PATIENT GDM (Dasgupta K, Chan D, Bond R, Garfield N, Coolen J, Halperin IJ, Peters TM, et al. Step and weight tracking with targets and coaching interventions in gestational diabetes: A randomized factorial feasibility trial. Diabetes Res Clin Pract. 2025 Jun;224:112241. doi: 10.1016/j.diabres.2025.112241. Epub 2025 May 9. PMID: 40349846.)
215165925|NCT07142512|BEHAVIORAL|Dyadic coping intervention|"Couples will participate in 8 one-hour coaching sessions over 12 weeks (virtual, in-person, or a combination, as preferred). The sessions aim to enhance the couple's understanding of how they influence each other. Both couple members will explore their preferences in terms of ways of communicating and supporting one another's goals. We will use changes in steps as a context to explore how partners can effectively support and coach each other without without eliciting behavioural reactance. We will use are goal setting, action planning, self-monitoring, graded tasks, social environment restructuring, and social support. The coaches will be psychology students. They will receive structured training on the coaching strategy from a licensed mental health professional. We will record the sessions for fidelity and quality assurance purposes. All coaches will meet weekly with the supervising licensed mental health professional."
215165926|NCT07140783|DRUG|0.75% Phentolamine Ophthalmic Solution|Once daily dosing
214707923|NCT02467023|DEVICE|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
215165927|NCT07140783|DRUG|Placebo|Once daily dosing
215165928|NCT07147348|BIOLOGICAL|BNT3212|Intravenous infusion
215165929|NCT07147348|BIOLOGICAL|BNT327|Intravenous infusion
214563135|NCT04694534|DIAGNOSTIC_TEST|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
214563136|NCT04694534|DIAGNOSTIC_TEST|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
214563137|NCT04231760|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
214563138|NCT04231760|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
214563139|NCT04712591|DIAGNOSTIC_TEST|Auditory stimuli|Auditory stimuli (passive, active perturbations)
214563140|NCT03037437|DRUG|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
214563141|NCT03037437|DRUG|Hydroxychloroquine (HCQ)|400mg by mouth daily
214563142|NCT06963658|OTHER|Multiple repetition isometric wall squat|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold.
214563143|NCT06963658|OTHER|Multiple Isometric wall squat exercise + Double Leg Lower with Isometric Hold|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold. Immediately post 60 second rest, Determine the participant's maximum angle using the double leg lowering test from supine position let the participant with both legs straightened before lifting the posterior hip, lowering the legs to a specific angle. Turn on the stopwatch. Hold the position near--maximally, try to achieve on (IES=9/10) and hold for the longest duration. They should reach 4 minutes for 3 repetition with 30 seconds rest between repetition
214563144|NCT06963658|OTHER|Control quiet seated rest|The control group served as the control group and did not perform any exercise. Participants were instructed to sit quietly in a standard height stationary clinical room patient chair for the entire eight minutes.
214563145|NCT06964685|DEVICE|Impella|US commercially approved Impella CP is the device that study inclusion will be based on. Only patients with AMICS who receive Impella CP as the first Impella device after cardiogenic shock onset will be included in the study.
214563148|NCT06418295|OTHER|Unilateral thoracotomy|Unilateral thoracotomy to proceed as per standard of care guidelines. Thoracic epidural analgesia, or patient controlled analgesia (PCA) pumps will be offered to each study participant as per standard of care. Pre- and post-operative (post-operative day 1 and 3 months) pain scores and blood samples will be collected. Blood samples will be analyzed to determine the concentration of cytokines, chemokines, and growth factors that are potentially associated with CPSP (epidermal growth factor, eotaxin, fibroblast growth factor basic, G-CSF, GM-CSF, human growth factor, IFN-α, IFN-γ, IL-1ra, IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF). DNA promotor methylation for these targets will also be investigated.
214563149|NCT01602029|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
214563150|NCT01602029|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
214563151|NCT01602029|DRUG|Placebo|Placebo added to TAU
214563152|NCT01602029|DRUG|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
214563153|NCT04836169|DEVICE|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
214563154|NCT00131105|BEHAVIORAL|The Stanford Active Choices program|
214563155|NCT06415097|DEVICE|Insulin Smart Pen|Retrospective analysis of electronic health records for individuals with type 1 diabetes receiving multiple daily doses of insulin, combined with glucose monitoring devices and who have used or are currently using insulin smart pens.
214563156|NCT03628547|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
214707924|NCT02467023|DEVICE|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
215165930|NCT03857529|DEVICE|transcranial direct current stimulation and electrical stimulator|"Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration."
214707925|NCT02467023|PROCEDURE|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
214563157|NCT06266208|PROCEDURE|Exostectomy|Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.
214707926|NCT02467023|DRUG|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
215165931|NCT07149376|DEVICE|TOMs of Maine Sensitive SLS Free Xtra Fresh|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for one (1) minute each time.~For investigational use only by the study participant. Not for Sale."
214563158|NCT06266208|PROCEDURE|Cut fingernail|Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
214563159|NCT04956705|DIETARY_SUPPLEMENT|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
214563160|NCT03322839|BEHAVIORAL|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
214563161|NCT03322839|BEHAVIORAL|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
214563162|NCT04058834|DRUG|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
214563163|NCT04058834|DRUG|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
214563164|NCT03297502|DRUG|pimecrolimus cream 1%|
214563165|NCT03297502|DRUG|Elidel (pimecrolimus) cream 1%|
214563166|NCT03297502|DRUG|placebo|
214563167|NCT00587691|BIOLOGICAL|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
214563168|NCT03095469|DRUG|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
214563169|NCT03095469|DRUG|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
214563170|NCT06341140|OTHER|Breastfeeding support and Booklet containing information about breastfeeding|Pregnant women in the intervention group were given individual counseling with a wearable breastfeeding model. During postnatal home visits, mothers were given support on breastfeeding, breast problems were addressed, and information was given to support the mother's self-efficacy.
214563171|NCT06341140|OTHER|Booklet containing information about breastfeeding|Pregnant women in the control group were given only a breastfeeding booklet, breastfeeding status, breast problems and breastfeeding self-efficacy were evaluated during postnatal home visits and telephone interviews, and risky situations were referred to health professionals.
214563172|NCT05891951|OTHER|Fluid therapy under the guide of Carotid ultrasound|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
214563173|NCT05570630|BEHAVIORAL|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
214563174|NCT05570630|OTHER|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
214563175|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
214563178|NCT06595251|OTHER|Fit2Play curriculum|Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
214563179|NCT06605807|OTHER|Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.|All clinicians will attend an educational session where they will be provided a clinical decision framework for management of chronic conditions in hospitalized older adults, reviewing guiding principles for managing chronic disease in the hospital, and working through case-based hypothetical examples.
214563180|NCT06604650|BEHAVIORAL|Active older Adults|The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
214563181|NCT02172677|BEHAVIORAL|Episodic memory task|
214707927|NCT02467023|DRUG|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
215165932|NCT07149376|DRUG|Colgate Cavity protection toothpaste|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for (2) two minutes each time.~For investigational use only by the study participant."
214563182|NCT02172677|DEVICE|fMRI|
214563183|NCT06593093|OTHER|a bundled intervention|a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.
214563184|NCT06593093|OTHER|control group|participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.
214563185|NCT05811598|DEVICE|repeated ultra low lever red light|Myopia indoor lighting therapy
214563186|NCT06987981|DEVICE|Chitosan-based dressing|Chitosan-based dressing for wound and scar treatment will be used (e.g. ChitoCare® medical Wound Healing Gel)
215165933|NCT07148232|DRUG|Nicotine Replacement Therapy (NRT)|NRT will be administered as patch (transdermal), gum, or lozenge
214563187|NCT06987981|DEVICE|Silver-based dressing|Silver-based dressing (e.g. AQUACEL® Ag), followed by a cosmetic lotion (e.g.: Bepanthol® DERMA) will be used
214563188|NCT06853431|DRUG|dexmedetomidine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
214563189|NCT06853431|DRUG|Esketamine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
214563190|NCT05615766|DEVICE|Experimental: Device Intervention|The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
214563191|NCT06470360|OTHER|Surgycal procedure|surgical technique
214707928|NCT02467023|DRUG|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
215165934|NCT07148232|BEHAVIORAL|Wellness Coaching|Delivered via phone call
215165935|NCT07152327|DRUG|Terbinafine Hydrochloride Cream|Topical antifungal treatment. Terbinafine hydrochloride 1% cream will be applied on an ear pack, inserted into the external auditory canal, and changed every 2 days. Treatment continues for 14 days.
214563192|NCT06987903|PROCEDURE|Pre- and post-operative physical exercise programme|"Pre- and post-operative physical exercise programme during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~A program will be designed according to the needs and preferences of the individual and will include:~Aerobic exercise: Activities that mobilize large muscle groups for prolonged periods of time.Walking, running at a slow or moderate pace (especially on a treadmill), cycling, cycloergometer, etc. In addition, due to the characteristics of the patients, the recommended exercises will be of low impact.~Strength exercise: Exercises of large muscle groups with intensities adapted to patients using body weight or elastic bands of different resistances.~Flexibility exercise: Stretching exercises will be included during the warm-up and cool-down of each exercise session of the program."
214563193|NCT06987903|PROCEDURE|Pre- and post-operative respiratory physiotherapy|"Pre- and post-operative respiratory physiotherapy during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~Breathing exercises:~Abdomino-diaphragmatic respiratory control exercises, costo-diaphragmatic respiratory control exercises, costo-diaphragmatic breathing control exercises, exercises with costal expansion and arm elevation and breathing exercises with pursed lips in different positions.~Incentive spirometry:~Incentive spirometry with the performance of slow, deep breaths in a volumetric incentive device."
214563194|NCT06824168|DRUG|Quizartinib High Dose|Participants in Arm 1 will receive oral daily higher dose of quizartinib,
214563195|NCT06824168|DRUG|Quizartinib Low Dose|Participants in Arm 2 will receive oral daily lower dose of quizartinib
214563196|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
214563197|NCT05820295|BEHAVIORAL|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
214563198|NCT05820295|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
214563199|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
214563200|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
214563201|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
214563202|NCT06658093|DRUG|Everolimus|mTOR inhibitor
214563203|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
214563204|NCT06613984|BIOLOGICAL|Bretovameran|Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
214563205|NCT06994767|OTHER|The Canary Application|The CANARY application will use clinically validated survey instruments and voice recordings to measure user MCI status /Alzheimer's data. These tests are designed to evaluate a user's voice characteristics and potentially identify disease-specific patterns.
214563206|NCT05874401|DRUG|Trilaciclib|Participants will receive intravenous trilaciclib infusion
214563207|NCT05874401|DRUG|Placebo|Participants will receive intravenous placebo infusion
214563208|NCT05874401|DRUG|Topotecan|Participants will receive intravenous topotecan infusion
214563209|NCT06121336|DIAGNOSTIC_TEST|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
214563210|NCT06999772|DEVICE|Active rTMS|A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). Stimulation parameters will be obtained by measuring the motor threshold of the first right interosseous muscle, then the rTMS intensity will be set at 110% of this motor threshold. High frequency (HF) rTMS consisting of 60 trains of 5 s at 10 Hz with 15 s intertrain intervals, for a total of 3000 pulses per session, will be used. The coil will be positioned over the left dorsolateral PFC using the BeamF3 methods.
214563211|NCT06999772|DEVICE|Sham rTMS|A sham coil will be used (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS and will be located over the same area (dorso-lateral prefrontal cortex).
214563212|NCT06999772|OTHER|Psychologically-informed physiotherapy (PiP)|Participants will receive 6 intervention sessions (45 min) over 6 weeks by a physiotherapist. The objective of this intervention is to identify biopsychosocial factors that may impede recovery and to address these factors within the physiotherapist's scope of practice. Physiotherapists will use strategies such as the establishment of common goals and therapeutic alliance, the use of behavior change model, motivational interview, education on pain neurophysiology, gradual exposure to movement and stress management strategies (e.g. breathing techniques). Participants allocated to PiP groups will have access to a website offering support information related to understanding their pain (e.g. pain neuroscience education), myths and false beliefs related to back pain, understanding the impact of psychological factors on their pain, self-management strategies, and healthy lifestyle habits. This site will be freely available to participants during the course of the study.
214563213|NCT06999772|OTHER|Usual physiotherapy|Participants will receive 6 intervention sessions (45 min) over 8 weeks by a physiotherapist. This is a pragmatic group that aims to represent real-word clinical practice i.e. interventions commonly used in physiotherapy to manage CLBP. All interventions that a physiotherapist can deliver in the province of Quebec will be allowed (e.g. manual therapy, exercises). No training will be provided to better reflect usual clinical practice in physiotherapy.
214563214|NCT05043454|OTHER|High Intensity Interval Training (HIIT) Exercise|Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
215030339|NCT05612945|OTHER|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
215030340|NCT00157261|DRUG|tenecteplase|
215165936|NCT07151248|DEVICE|Cranial electrical/electrotherapy stimulation (CES)|"Cranial electrical/electrotherapy stimulation (CES) is a non-pharmacological, portable, non-invasive intervention.~Active research units will be locked at the specified amplitude and administer that amplitude of stimulation for 60 minutes therapy."
215165937|NCT07151248|DEVICE|Sham Cranial electrical/electrotherapy stimulation (CES)|Sham research units will be locked into active sham mode which provides stimulation designed to provide the sensation of stimulation for only 5 minutes while continuing to count down for the remaining 55 minutes.
215165938|NCT07152652|BEHAVIORAL|Groups 4 health|Groups 4 Health (G4H) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology master's students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 European Credit Transfer and Accumulation System (ECTS) credits for completing the intervention.
215165939|NCT07153250|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered program for parents that takes about 20 minutes to complete.
215165940|NCT07153250|BEHAVIORAL|Being Brave Parent Education|Being Brave Parent Education is an online, self-guided program which consists of three brief video-recorded lessons (approximately 20 minutes each) with accompanying knowledge checks and workbook on implementing parent-directed cognitive-behavioral therapy.
215165941|NCT07153250|BEHAVIORAL|Sharing Feelings|A self-guided 20-minute educational control, that teaches parents about the importance of sharing feelings and about helpful versus unhelpful expression of emotion.
215165942|NCT07153341|BEHAVIORAL|STEP Decision Support Toolkit|The STEP toolkit includes (1) an educational booklet provided upon admission and annually, (2) condition-specific decision aids addressing common clinical scenarios, and (3) structured phone scripts for staff. STEP empowers residents and care partners to actively engage in decision-making, promotes care aligned with personal values, and supports staff in facilitating advance care planning to reduce unnecessary or complex transitions.
215165943|NCT07148414|DRUG|SPY002-072|Experimental
214563215|NCT02344290|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
214563216|NCT02344290|DRUG|Placebo|One tablet taken once daily, orally with or without food
215030341|NCT02304185|BIOLOGICAL|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
214563218|NCT07135089|DRUG|Intravenous tirofiban before endovascular thrombectomy|The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
214563219|NCT07135089|DRUG|Intravenous placebo before endovascular thrombectomy|The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
214563220|NCT07126470|PROCEDURE|CTR implantation|Device: CTR (275001G, OPHTEC BV, Netherlands) All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL (J\&J Tecnis DCB00) is implanted.
214563221|NCT07008963|OTHER|non-interventional|This is a non-interventional, observational study
214563222|NCT05765487|DRUG|Sildenafil|Sildenafil Cream, 3.6%
215165944|NCT07148414|DRUG|Placebo|Matching Placebo
215165945|NCT07152821|OTHER|Best Supportive Care|Measures designed to provide palliation of symptoms and improve quality of life as much as possible
215165946|NCT07152821|DRUG|Balstilimab|450mg IV every 3 weeks
215165947|NCT07152821|DRUG|Botensilimab|75mg IV every 6 weeks x 4 doses
214563223|NCT05765487|DRUG|Vehicle|No Active or experimental ingredients
214563224|NCT05765487|DRUG|Placebo|Cream with only L-arginine
214563225|NCT06676488|DEVICE|Re-Timer glasses|Morning bright light therapy (BLT) will be administered through a safe wearable glasses device called a Re-Timer, purchased from the manufacturer Re-Timer.
214563226|NCT06676488|DEVICE|Placebo Device|Placebo glasses not providing Bright Light Therapy
214563227|NCT04998812|DRUG|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
214563228|NCT06619236|DRUG|Rina-S|Intravenous (IV) infusion
214563229|NCT06619236|DRUG|Paclitaxel|IV infusion
214563230|NCT06619236|DRUG|Topotecan|IV infusion
214563231|NCT06619236|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
215165948|NCT07150494|DEVICE|Phototherapy|Phototherapy used to decrease high billirubin level in neonatal jaundice
214563232|NCT06619236|DRUG|Gemcitabine|IV infusion
214563233|NCT06867848|PROCEDURE|laminar bone membrane for labial bone augmentation|adding laminar bone membrane in one group and pericardium membrane in another group with sticky bone by using vestibular incision in both groups to augment the labial bone over dental implant
214563234|NCT04545736|DRUG|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
214563235|NCT05303792|DRUG|Cyclophosphamide|Given IV
214563236|NCT05303792|DRUG|Vincristine|Given IV
214563237|NCT05303792|DRUG|Dexamethasone|Given IV or PO
214563238|NCT05303792|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
215030342|NCT02304185|BIOLOGICAL|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
215030343|NCT02304185|BIOLOGICAL|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
214563239|NCT05303792|DRUG|Methotrexate|Given IV or PO
214563240|NCT05303792|DRUG|Cytarabine|Given IV
214563241|NCT05303792|DRUG|Methylprednisolone|Given IV
214563242|NCT05303792|BIOLOGICAL|Rituximab|Given IV
214563243|NCT05303792|DRUG|Prednisone|Given PO
214563244|NCT05303792|DRUG|Mercaptopurine|Given PO
214563245|NCT05303792|DRUG|Doxorubicin|Given IV
214563246|NCT06892418|BEHAVIORAL|Ketoflex 12/3 Diet|A plant-based ketogenic diet combined with intermittent fasting (12/3)
214563247|NCT06894537|OTHER|Experimental (percutaneous echo-guided electrical nerve stimulation)|The protocol applied in this study will consist of: 10 stimulations of 10 seconds at 10Hz with a rest of 10 seconds between one stimulation and the next one. The intensity of the current (mA) will be adapted to each of the subjects until the greatest possible muscle contraction is achieved without reaching the painful threshold.
215030344|NCT02304185|BIOLOGICAL|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
215030345|NCT02304185|DRUG|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
215030346|NCT01842347|OTHER|Fecal microbiota|
215030347|NCT03757494|DEVICE|Alpha Stim|Use of Alpha Stim Device
215030348|NCT04492384|OTHER|non-interventional|Interview on health conditions
215030349|NCT04875533|BIOLOGICAL|20vPnC|20vPnC
215030350|NCT04875533|OTHER|Saline|Saline
215030351|NCT04875533|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
215030352|NCT04875533|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
215030353|NCT02033941|DRUG|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
215030354|NCT02033941|DRUG|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
215165949|NCT07157982|BEHAVIORAL|COORDINATE Program|"The COORDINATE Program is a nurse-led, multicomponent intervention designed to support older adults with multiple chronic conditions during their transition from hospital to home. The intervention is delivered over a 6-week period and includes the following components:~1. Discharge Planning Visit: Conducted in person or via video, this session includes a needs assessment and shared decision-making conversation to identify participants' values and preferences.~2. Question Prompt List: A tailored list of questions is provided to help participants engage more effectively with their care team.~3. Goal Setting: Participants work with a nurse to identify short-term goals and action steps related to their health and care needs.~4. Symptom Monitoring: Participants track symptoms weekly using a symptom checklist to support ongoing management and communication with providers."
215165950|NCT07157982|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive enhanced usual care, which includes standard discharge instructions, scheduled check-ins, and a resource toolkit with educational materials. The content includes guidance on symptom management, advance care planning, and available community resources. Participants will receive follow-up reminders and wellness checks but will not receive the structured, nurse-led intervention provided in the COORDINATE Program.
215165951|NCT07156201|DRUG|ABS-1230|ABS-1230
215165952|NCT07156201|DRUG|Placebo|Placebo
215165953|NCT07154823|OTHER|None - Observational Study|There are no interventions in this observational study.
215165954|NCT04172532|PROCEDURE|Biopsy Procedure|Undergo tissue collection
215165955|NCT04172532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215165956|NCT04172532|PROCEDURE|Computed Tomography|Undergo CT
215165957|NCT04172532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
215165958|NCT04172532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165959|NCT04172532|DRUG|Peposertib|Given PO
215165960|NCT04172532|OTHER|Placebo Administration|Given PO
215165961|NCT06839079|BEHAVIORAL|A Trauma-informed, Paraprofessional Delivered Virtual Cognitive Rehabilitation Program|The intervention will involve 8 proposed individual sessions conducted virtually by a trained bilingual paraprofessional. The intervention will be provided in English or Spanish depending on the participant's preference. The sessions cover psychoeducation about TBI and related symptoms like depression and anxiety, and cognitive activities to address cognitive symptoms (e.g., relaxation strategies and exercises around improving attention, concentration, learning, and memory). Each session covers the topic, real-life examples and practice, and exercises to do outside of the sessions.
215165962|NCT02211768|PROCEDURE|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
215165963|NCT02211768|DRUG|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
215165964|NCT07156084|BIOLOGICAL|HPV nonavalent vaccine (Gardasil-9)|One dose HPV nonavalent vaccine
214563248|NCT06894537|OTHER|Control (placebo) group|For the subjects in the control group, the same process shall be carried out without increasing the intensity of the current. It shall be explained to the subjects that the current will reach a non-perceptible stimulus.
214563249|NCT07051655|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will undergo two test days separated by 3-7 days. On both test days, participants will arrive fasted and consume a single dose of ketone monoester or placebo (357 mg/kg of body weight) in random order. Drinks will be prepared by non-study personnel and matched in taste, texture, and appearance to maintain blinding. Thirty minutes after consuming the ketone monoester or placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
214563250|NCT07051655|DIETARY_SUPPLEMENT|Placebo|Participants will undergo two test days separated by 3-7 days. On one test day, participants will consume a single dose of placebo (357 mg/kg of body weight). Thirty minutes after consuming the placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
214563251|NCT07052929|GENETIC|ASP2957|Intravenous infusion
214563252|NCT07052929|DRUG|Methylprednisolone|Intravenous infusion
214563253|NCT07052929|DRUG|Prednisolone|Route of administration based on locally sourced product
214563254|NCT07052929|DRUG|Sirolimus|Route of administration based on locally sourced product
214563255|NCT07049328|DRUG|HCW9302, an IL-2 fusion protein|Injection
214563256|NCT05204290|DRUG|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
214563257|NCT05204290|RADIATION|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
214563258|NCT05204290|OTHER|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
214563259|NCT05822583|DRUG|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
214563260|NCT05822583|DRUG|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
215165965|NCT07156188|OTHER|Permanent Suture|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed in a standardized manner. In the control group, a permanent 0-0 polypropylene suture will be used to close the hernia defect in a transverse or vertical interrupted fashion using either the simple interrupted or the figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
214563261|NCT07055945|OTHER|Experimental group|Individuals in both groups will receive a physiotherapy program for 3 sessions per week, 60 minutes per day, for a total of 8 weeks.The study consists of two groups: the experimental group and the control group. Both groups will receive a physiotherapy program of 3 sessions per week, each lasting 60 minutes, for a total of 8 weeks. Within the 60-minute physiotherapy session, patients from both groups will undergo 30 minutes of exercises based on the Neurodevelopmental Treatment (NDT) method. In addition, a 12-minute training session will be conducted using a light-based trainer system (Light Trainer® Exercise System).
214563262|NCT07055945|OTHER|Control group|"In addition to the full-body exercises mentioned, individuals in the control group will also receive upper extremity exercises based on the Neurodevelopmental Treatment approach. These exercises are as follows:~* Functional reaching activities at the table in a sitting position (e.g., pushing objects, wiping the table, touching various points)~* Ball sliding on the wall in a standing position~* Touching different targets on the wall in a standing position~* Drawing shapes on the wall in a standing position~These exercises will be performed bilaterally and on the hemiparetic side. The exercises will be given for approximately 12 minutes, in line with the exercises given to the experimental group. The difficulty level will not be increased during the training."
214563263|NCT06567925|BEHAVIORAL|Customized Sleep Coaching|Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.
214563264|NCT06567925|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
214563265|NCT06750432|DRUG|PMN310|A humanized immunoglobulin G1 (IgG1) monoclonal antibody
214563266|NCT06750432|DRUG|Placebo|0.9% NaCl 100 mL
214563267|NCT01934751|OTHER|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
214563268|NCT01934751|OTHER|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
214563269|NCT06747273|DRUG|SRP-9004|Intravenous (IV) infusion.
214563270|NCT04990713|PROCEDURE|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
214563271|NCT04990713|PROCEDURE|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
214563272|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
214563273|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
214563274|NCT07059312|DRUG|JADE101|JADE101 is supplied as sterile solution to be administered by SC injection.
214563275|NCT07059312|DRUG|Placebo|Placebo solution to be administered at a matching volume by SC injection.
214563276|NCT07055542|DIAGNOSTIC_TEST|Observational|Prospective observational study
214563277|NCT07053865|DEVICE|Surface Electromyography (dia-BRUXO)|Participants will undergo 24-hour surface electromyographic recording of the left masseter muscle using the dia-BRUXO portable device to quantify sleep bruxism activity through Bruxism Work Index (BWI) and Bruxism Time Index (BTI).
214563278|NCT06313710|OTHER|head down position|-10° Trendelenburg
214563279|NCT07062133|PROCEDURE|Electrical pudendal nerve stimulation|Electrical Pudendal Nerve Stimulation (EPNS) delivered by four deep acupuncture needles targeting bilateral sacrococcygeal points near the pudendal nerve. Connected to G6805-2 electrical stimulator, 2 Hz, 60 minutes/session, three times per week for 4 weeks.
214563280|NCT07062133|OTHER|Conventional conservative treatment|Conventional conservative treatment including medications (e.g., oxybutynin), clean intermittent catheterization, and diaper use as needed
214563281|NCT06897930|BIOLOGICAL|AZD0120|Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
215165966|NCT07156188|OTHER|Absorbable|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed. An 0-0 polydioxanone suture (PDS) will be used to close the hernia defect in either a transverse or vertical interrupted fashion using either simple interrupted or figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
215165967|NCT07151235|OTHER|Simulated wildfire smoke exposure|1 hour exposure to simulated wildfire smoke (300 ug/m3 PM)
214563282|NCT06897930|DRUG|Cyclophosphamide|Lymphodepletion - specified dose prior to receiving AZD0120
214563283|NCT06897930|DRUG|Fludarabine|Lymphodepletion - specified dose prior to receiving AZD0120
214563284|NCT00001230|DRUG|Diethylcarbamazine|Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
214563285|NCT06770270|DRUG|Pucotenlimab|"Pucotenlimab combined with long-course concurrent chemoradiotherapy, followed by two cycles of pucotenlimab combined with chemotherapy, and then based on tumor response, TME surgery or a watch and wait strategy will be adopted."
214563286|NCT02049853|DEVICE|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
214563287|NCT06770660|BEHAVIORAL|Telemedicine|"A 10-week telemedicine-based exercise programme consisting of 90-minute sessions conducted weekly via a video conferencing platform.~All participants will also be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form."
214563288|NCT06770660|BEHAVIORAL|Lifestyle|All participants will be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form.
215165968|NCT07151235|OTHER|Clean Air exposure|1 hour exposure to clean (HEPA-filtered) air (0 ug/m3 PM)
215165969|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
214563289|NCT07067684|OTHER|Low Tidal Volume Ventilation During CPB|"Group Low: Patients in this group will receive low tidal volume mechanical ventilation during cardiopulmonary bypass (CPB).~Ventilation settings will be:~Tidal Volume: 3-4 mL/kg (ideal body weight)~PEEP: 5-8 cmH₂O~Respiratory Rate: adjusted to maintain normocapnia (PaCO₂ 35-45 mmHg)"
215165970|NCT06092333|DRUG|VIR-2218 and peginterferon alfa-2a|(VIR-2218) administered as a lead-in followed by combination with peginterferon alfa-2a
215165971|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
215165972|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
215165973|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
215165974|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
215165975|NCT07157254|OTHER|No intervention|During the no treatment period participants do not receive any study drug
215165976|NCT07157254|DRUG|GTX-102|antisense oligonucleotide
215165977|NCT07153887|DRUG|Vebreltinib|"Vebreltinib： Oral capsule formulation, specification: 100 mg/capsule. Subjects will start medication after enrollment, 200 mg bid po, until disease progression, intolerable toxicity, or death.~If disease progression is observed in the first evaluation (2 months after the first administration), if the investigator deems it possible to continue benefiting from targeted therapy, targeted therapy combined with best supportive care can be continued until the second evaluation (4 months)."
215165978|NCT07153887|OTHER|Standard medical treatment|standard treatment like chemotherapy, PD1, Anlotinib……
215165979|NCT07160829|OTHER|No treatment given|No treatment given
215165980|NCT07160972|OTHER|Lifestyle Management|Participants will use the X Life model via AR glasses or mobile terminal (smartphone/tablet) for 7 days. The system provides personalized dietary and exercise recommendations at dynamic trigger points (before/after meals, before/after exercise, before bedtime) using baseline clinical data, real-time CGM readings, dietary images, activity data, and wearable monitoring (activity, sleep, heart rate). Standard care guidance will also be provided in accordance with national dietary and physical activity guidelines.
215165981|NCT05773274|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214563290|NCT06789406|DEVICE|Axonics SNM System INS Model 5101 (R20)|Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
214563291|NCT06053164|DRUG|Exertional Oxygen|Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes
214563292|NCT06053164|BEHAVIORAL|Education and Support|Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
214563293|NCT06804109|DEVICE|Active nVNS|2-min transcutaneous nVNS stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
214563294|NCT06804109|DEVICE|Control nVNS|2-min control stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
214563295|NCT07066293|PROCEDURE|Unilateral alveolar cleft repair|10 patients in whom unilateral alveolar cleft will be repaired using sticky bone grafting combined with concentrated growth factor membrane
215165982|NCT05773274|DRUG|Cabozantinib|Given PO
214563296|NCT07070336|OTHER|Neuroathletic exercise|After warm-up and resetting exercises, it will start with eye muscle training with a star chart. It then consists of exercises that regulate the accommodation reflex, balance the right and left lobes, regulate the vestibular system and rhythm exercises.
214563297|NCT06269627|DRUG|Acamprosate calcium|Two oral capsules (packaged as one) containing 666 mg of acamprosate calcium will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
214563298|NCT06269627|OTHER|Placebo|Two oral capsules (packaged as one) containing 666 mg of inactive substance (e.g., sugar) will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
214563299|NCT04666792|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
214563300|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
215165983|NCT05773274|PROCEDURE|Computed Tomography|Undergo CT scan
215165984|NCT05773274|DRUG|Everolimus|Given PO
215165985|NCT05773274|DRUG|Lutetium Lu 177 Dotatate|Given IV
215165986|NCT05773274|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215165987|NCT05773274|OTHER|Quality-of-Life Assessment|Ancillary studies
215165988|NCT05773274|OTHER|Questionnaire Administration|Ancillary studies
215165989|NCT05773274|DRUG|Sunitinib|Given PO
215165990|NCT07158242|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
215165991|NCT07162948|DEVICE|The ICU-Recover Box: using smart technology for monitoring health status after ICU admission Pilot 2.0|The Corsano CardioWatch 287-2 measures blood pressure, heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature and their daily activity.This devices is used for personal management, never to directly base a diagnosis or treatment on. The patient has to download the Corsano App on his/her mobile phone.
214563301|NCT06756074|DRUG|Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)|pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.
214563302|NCT06756074|PROCEDURE|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
214707929|NCT02467023|OTHER|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
214563303|NCT07073885|OTHER|Ultra-Low Tidal Volume Ventilation|Ventilation continued during CPB using volume-controlled mode with ultra-low tidal volume (3-4 mL/kg IBW(Ideal Body Weight)), 12-14 breaths/min, 5 cm H₂O PEEP, and 50% FiO₂.
214563304|NCT07073885|OTHER|Apnea Group|In this group, mechanical ventilation will be discontinued after aortic cross-clamping during CPB, and apnea will be maintained throughout the bypass period.
214563305|NCT06547151|DRUG|AMOR-1|Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
214563306|NCT06547151|DRUG|Crystalline Calcium Carbonate|Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
214563307|NCT06900647|DRUG|Bortezomib (B)|1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
214563308|NCT06900647|DRUG|Cisplatin (CDDP)|50mg/m2, IV, D1-3, every 3 weeks
214563309|NCT06900647|DRUG|Bortezomib (B)|1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
214563310|NCT06900647|DRUG|Bortezomib (B)|1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
214563311|NCT06900647|DRUG|Cisplatin (CDDP)|70mg/m2, IV, D1-3, every 3 weeks
214563312|NCT06878365|DRUG|BI 3000202_low dose|BI 3000202\_low dose
214563313|NCT06878365|DRUG|BI 3000202_high dose|BI 3000202\_high dose
214563314|NCT07074288|DEVICE|MAD|MAD intervention involves the use of a mandibular advancement device, which is designed to reposition the lower jaw and tongue to keep the airway open during sleep.
214563315|NCT07074288|DEVICE|HGNS|HGNS intervention involves a surgical procedure to implant a device that stimulates the hypoglossal nerve to prevent airway collapse during sleep.
214563316|NCT07076030|DRUG|Petrelintide|Solution administered with a syringe
214707930|NCT02467023|DEVICE|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
214707931|NCT01778400|PROCEDURE|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
214707932|NCT01778400|PROCEDURE|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
214707933|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
214707934|NCT03532776|DRUG|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
214707935|NCT03532776|DRUG|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
214707936|NCT03532776|DRUG|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
214707937|NCT06314997|DRUG|panitumumab (EGFR inhibitors)|Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
215165992|NCT07163806|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Patients will fast for at least four hours before imaging with blood glucose level \<200 mg /dL before intravenous administration of about 3.7 MBq/kg (0.1 mCi/kg). Imaging will be performed approximately 45 to 60 min after 18F-FDG injection , an imaging field of view from the base of skull to mid thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body.~The semiquantitative analysis will be done using standardized uptake values (SUV). The SUV calculation will be done via the default method by body weight \[(SUV = mean ROI activity (MBq/g)/injected activity (MBq)/body weight (g)\]. For measurement of SUVs of lesion, multiple circular ROIs will be drawn covering the lesion over its entire length. For healthy organs, a circular ROI of 10 mm diameter will be drawn"
215165993|NCT07157774|DRUG|Muvalaplin|Administered orally
215165994|NCT07157774|DRUG|Placebo|Administered orally
214563319|NCT07135531|DEVICE|Continuous Glucose Monitoring (CGM)|Continuous glucose monitors will be placed subcutaneously every 14 days.
214563320|NCT07128576|DRUG|Romiplostim N01|Romiplostim N01: 3-10 μg/kg(Initial dose 3 μ g/kg), qw, H.
214563321|NCT05170399|BIOLOGICAL|Fluzone|Annual Influenza Vaccine
214563322|NCT05170399|BIOLOGICAL|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
214563323|NCT05170399|BIOLOGICAL|Flucelvax|Annual Influenza Vaccine
214563324|NCT05170399|BIOLOGICAL|Afluria|Annual Influenza Vaccine
214563325|NCT05170399|BIOLOGICAL|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
214563326|NCT05170399|BIOLOGICAL|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
214563327|NCT05170399|BIOLOGICAL|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
214563328|NCT05170399|BIOLOGICAL|FluLaval|Annual Influenza Vaccine
214563329|NCT05170399|BIOLOGICAL|Fluarix|Annual Influenza Vaccine
214563330|NCT05170399|BIOLOGICAL|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
214563331|NCT05170399|DRUG|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
214563332|NCT05170399|DRUG|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
214563333|NCT00900198|PROCEDURE|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
214563334|NCT07077122|PROCEDURE|Scaling and Root Planing|Mechanical debridement of tooth surfaces using hand and ultrasonic instruments
214563335|NCT07077122|DRUG|antibiotic prophylaxis|2g Amoxicillin given 1 hour prior to instrumentation
214563336|NCT07077122|DEVICE|810nm Diode Laser|Laser applied at base of gingival pockets prior to mechanical debridement.
214563337|NCT07077122|PROCEDURE|Air Polishing|air flow-based mechanical debridement with erythritol powder
214563338|NCT03826030|DEVICE|Sham|Sham group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject.
214563339|NCT03826030|DEVICE|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
214563340|NCT03826030|DEVICE|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
214563341|NCT03826030|BEHAVIORAL|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
214563342|NCT07076862|DRUG|A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.
214563343|NCT07076862|DRUG|A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
214563344|NCT07076862|DRUG|B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.
214563345|NCT07076862|DRUG|B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive 5 mCi (±20%) of \[¹⁸F\]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
214563346|NCT07086768|DRUG|BSI-082|BSI-082 is a sterile solution for injection which contains the active ingredient at the nominal concentration of 50.0 mg/mL. T
214563347|NCT07086768|OTHER|Trastuzumab deruxtecan|T-DXd: Administrate as per the drug package insert and Investigator's guidance, and T-DXd can be continued after the patients been taken off from the study.
214563348|NCT02745353|DRUG|naloxegol|
214563349|NCT06903897|OTHER|WE CARE SDOH System|The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.
214563350|NCT06903897|OTHER|Standard Pediatric Care|Standard pediatric care includes any existing screening practices, which can vary at each clinic.
214563351|NCT06805994|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
214563352|NCT06805994|BIOLOGICAL|Placebo|Placebo sterile swab
214563353|NCT06852209|PROCEDURE|Cognitive remediation therapy|Cognitive remediation therapy as treatment as usual
214563354|NCT06852209|PROCEDURE|Neuropsychological assessment|Neuropsychological assessment to measure cognitive performances
214563355|NCT06852209|PROCEDURE|Real-time functional MRI neurofeedack (rt-fMRI NF)|Real-time functional MRI neurofeedack (rt-fMRI NF) is a procedure of brain-machine interface supporting self-regulation of brain activity, with promising results in the treatment of mental disorders. The main objective of the study is to evaluate in a pilot study, the ability of stroke patients to learn to self-regulate their brain activity in a priviledged direction.
214563356|NCT06852209|PROCEDURE|fMRI sessions|fMRI sessions but without receiving feedback
214563357|NCT06906731|DRUG|SHR-9803|SHR-9803
214563358|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
215165995|NCT07146568|OTHER|Pink and Pearl Campaign|This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening.
214563359|NCT07137351|DIAGNOSTIC_TEST|The Biosensor Using the Target Urine Volatile Organic Compounds|"The authors opted to utilize five distinct commercially available semiconductors (metal oxide sensors) to detect all the targeted VOCs which were manufactured by Figaro company.~Urine samples from patients were placed in a urine container, which was then placed into the VOCs detection device. The lid was closed, and the system was set to operate in a closed-loop mode at a room temperature of 25 degrees Celsius. The device then vacuumed VOCs from the urine samples of the patients through a gas tube into the biosensor chamber located on top, where analysis was performed."
214563360|NCT07091955|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CRL1505|Probiotic product containing Lacticaseibacillus rhamnosus CRL1505 formulated in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
214563361|NCT07091955|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo product containing cornstarch, in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
214563362|NCT04074057|OTHER|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
214563363|NCT04074057|DEVICE|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
214563364|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
214563365|NCT05014568|DRUG|Vehicle cream|applied topically once daily
214563366|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
214563367|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
214563368|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
214563369|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
214563370|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
214563371|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
214563372|NCT06904222|BIOLOGICAL|Placebo|0.5 mL 0.9% sodium chloride (normal saline) injection per dose
214563373|NCT04893460|BEHAVIORAL|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
214563374|NCT07088900|PROCEDURE|caudal block using dexmedetomidine with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 µg/kg of dexmedetomidine (diluted in 1 mL of normal saline).
214563375|NCT07088900|PROCEDURE|caudal block with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 mL of normal saline
214563376|NCT07104370|PROCEDURE|Bone augmentation using an autologous bone block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the control group, an autologous bone block graft is harvested from the retromolar donor area using rotary instruments and piezoelectric surgery.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In the case of an amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
214563377|NCT07104370|PROCEDURE|Bone augmentation using freeze-dried allograft block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the test group, a freeze-dried allograft bone block is prepared to the required size using rotary instruments.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In case of amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
214563378|NCT07104370|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|• Preoperatively, a CBCT scan is performed to assess inflammatory and other pathological changes and anatomical variations in the dentomaxillofacial region.
214563379|NCT07104370|DIAGNOSTIC_TEST|post-operative cone beam computed tomography (CBCT)|Postoperatively, a CBCT scan is performed to assess bone quantity and quality before implantation.
214563380|NCT07104370|PROCEDURE|Dental implant placement|Following the 3-month-long healing period following bone augmentation, dental implants are placed non-submerged in the augmented bone under local anaesthesia.
214563381|NCT07104370|DIAGNOSTIC_TEST|Bone core biopsy|At the time of dental implant placement, a rotary instrument is used to harvest a bone core biopsy sample from the augmented bone. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
215165996|NCT07155057|DEVICE|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|Prospective, single-site, single-arm study enrolling 60 patients who have elected advanced IOL implantation at the time of cataract surgery and have a diagnosis of dry eye disease. The study will consist of 5 study visits, over a 3-5 month time period. Patients will receive bilateral lacrimal occlusion of crosslinked hyaluronate canalicular gel pre-operatively
214563382|NCT07104370|PROCEDURE|Fixed dental prosthesis (FDP) fabrication|After 3 months of dental implant placement, fixed dental prosthesis are delivered on the dental implants.
214563383|NCT07104370|DEVICE|Bone grafting|Freeze-dried bone allograft block
214563384|NCT07105371|BIOLOGICAL|AlloEx exosomes|This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
215165997|NCT07164053|DEVICE|MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su|"MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes (ARveo 8/ARveo 8x) and other medical imaging systems. It is a digital accessory to an operating surgical microscope that enables the visualization of the surgical field through a visualization headset including:~* Display of surgical field illuminated and magnified by the surgical microscope (White Light).~* Display of fluorescence of fluorophores within the indicated excitation and emission ranges, as defined by the respective filters (accessories to the compatible surgical microscopes ARveo 8x such as GLOW400 and GLOW800)."
215165998|NCT07162454|DRUG|Group 1. Complete formula|After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.
215165999|NCT07162454|DRUG|Group 2. Cannabidiol and Urea 10% formula.|After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.
215166000|NCT07162454|DRUG|Group 3. Placebo formula.|Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.
215166001|NCT07166861|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
215166002|NCT07166861|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
215166003|NCT07166380|DRUG|RK-4 injection|patients with LHI will take drug RK-4 (1 mg or 2 mg or 4 mg) by transcranial bone marrow injection once daily for consecutive 3 days.
215166004|NCT07164859|DRUG|short dual antiplatelet therapy (DAPT) duration|patients will receive DAPT for 7 days (after randomization) followed by P2Y12 inhibitor alone
215166005|NCT07164859|DRUG|Standard DAPT duration|patients will receive DAPT for at least 3 months after randomization or longer and followed by single antiplatelet therapy
214563385|NCT07099404|OTHER|PET/CT imaging with rubidium-82|PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
214563386|NCT07102407|OTHER|Contructivist|Implementation of constructivist training on VAP in small groups
214563387|NCT07102407|OTHER|Routine training|Implementation of routine training on VAP in large groups
214563388|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
214563389|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
214707938|NCT03967756|DEVICE|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
214707939|NCT05779800|DEVICE|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
214707940|NCT05779800|DEVICE|periodontal pack|Non eugenol containing dressing supplied in two tubes
215166006|NCT07162038|BIOLOGICAL|mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)|CAR-T cell infusion given at four escalating dose levels (DL1: 3 x 10\^4 cells/kg, DL2: 1 x 10\^5 cells/kg, DL3: 3 x 10\^5 cells/kg, DL4: 1 x 10\^6 cells/kg) with a dose de-escalation dose (DL-1: 1 x 10\^4 cells/kg), if needed.
214707941|NCT04560673|DRUG|Duloxetine|Given PO
214707942|NCT04560673|BEHAVIORAL|Neurofeedback|Receive neurofeedback training
215166007|NCT07162038|DRUG|Fludarabine|Pre-transplant: 30 mg/m\^2 IV infusion over 30-60 minutes once daily for 5 days from day -6 through day -2
214707943|NCT04560673|OTHER|Quality-of-Life Assessment|Ancillary studies
215166008|NCT07162038|DRUG|Cyclophosphamide|"Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant on day -6 and day -5.~Post-transplant: 25 mg/kg/day on day +3 and day +4."
215166009|NCT07162038|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35 post-transplant.
215166010|NCT07162038|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 post-transplant.
215166011|NCT07162038|DEVICE|CD19 Flow Cytometry Assay|Assay used to determine CD19+ status
215166012|NCT07162038|DEVICE|CD19 Immunohistochemical Assay|Assay used to determine CD19+ status
215166013|NCT07162038|RADIATION|Total Body Irradiation|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice a day on Day -1 pre-transplant.
215166014|NCT07161700|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
215166015|NCT07166601|BIOLOGICAL|M0324|M0324 will be tested at increasing doses as monotherapy to determine dose-toxicity relationship and MTD (if reached) in order to support selection of recommended dose(s) for expansion (RDE).
214707944|NCT04560673|OTHER|Questionnaire Administration|Ancillary studies
215166016|NCT07166601|BIOLOGICAL|M0324|M0324 will be further investigated in part 2 and part 3 of the study as combination regimen, in order to determine dose-toxicity relationship in combination and MTD (if reached) in order to support selection of RDE(s) in combination.
215166017|NCT07166601|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously as per standard of care.
215166018|NCT07166601|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered intravenously as per standard of care.
215166019|NCT07169318|OTHER|Placebo for VNT-101|Capsules will be size 00 and filled with microcrystalline cellulose
215166020|NCT07169318|DRUG|VNT-101|VNT-101 is an orally bioavailable, direct-acting antiviral with a novel mechanism of action - inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.
215166021|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage RSV vaccine uptake.
215166022|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the RSV vaccine to encourage vaccine uptake, but do not receive the counseling intervention
214563390|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
214563391|NCT04015869|DRUG|Allopregnanolone|neurosteroid
214563392|NCT04015869|DRUG|Placebos|placebo
214563393|NCT06826794|OTHER|Clinicians|Clinicians will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
214563394|NCT06826794|DEVICE|VenitlO|VentilO application (or web platerform) will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
214563395|NCT06381492|DEVICE|MRI|MRI using DTI technology
215166023|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage discussion of RSV vaccine uptake among older adults in their social networks
215166024|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the vaccine to encourage discussion of RSV vaccine uptake among older adults in their social networks, but do not receive the counseling intervention
214563396|NCT06381492|DEVICE|Ultrasound (US)|Standard US
214563397|NCT06381492|DEVICE|Neuromuscular electric stimulation (NMES)|Standard NMES
214563398|NCT07105670|OTHER|Controlled dietary intervention|Participants will complete a 2-week baseline period consuming their standard diet without any food or beverages provided followed by a randomized, crossover-controlled feeding study of a lacto-ovo vegetarian diet versus the same diet with 20% of the protein replaced by red meat. In between the two diets, there will be a five-week washout where participants will consume their standard diet without any food or beverages provided.
215166025|NCT07170878|DIETARY_SUPPLEMENT|Blueberry Supplementation|The research group (Control Group (CG) (n:12): soccer training group; Supplementation Group (EG) (n:12): group given blueberry supplement in addition to soccer training; Reinforcement+Exercise (SEG) (n:12): the group who was given additional blueberry supplement in soccer training and 20 minutes of resistance band exercise) consisted of 36 male athletes in the football branch and regularly participating.
215166026|NCT07170878|DIETARY_SUPPLEMENT|Supplementation Group|Supplementation + Exercise
215166027|NCT07161037|DRUG|VX-407|Tablets for oral administration.
215166028|NCT07164105|DEVICE|Low intensity focused ultrasound|Low intensity focused ultrasound neuromodulation of the ventral anterior cingulate cortex
214563401|NCT06953089|DRUG|DB-1311/BNT324|Administered I.V.
214563402|NCT06953089|DRUG|BNT327|Administered I.V.
214563403|NCT06953089|DRUG|DB-1305/BNT325|Administered I.V.
214563404|NCT07140939|DRUG|CBL-514 Injection|Provided as a ready for use injectable CBL-514 solution
214563405|NCT07140939|OTHER|0.9% Sodium Chloride|Injectable 0.9% Sodium Chloride solution as placebo
214563406|NCT07153731|DRUG|Shenkangling|Chinese herbal tonics taken orally: Shenkangling, one dose, 2 times a day, 1 time before breakfast and 1 time 30 minutes after dinner.
214707945|NCT01274455|GENETIC|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
215166029|NCT07164105|DEVICE|Sham modulation|Low intensity focused ultrasound with a Sorbothane membrane cover to prevent acoustic energy transmission
214563407|NCT07153952|RADIATION|radiotherapy|The surgical method is determined by the gynecological oncologist, including total hysterectomy, pelvic exenteration, or radical total hysterectomy. The specific surgical choice needs to be comprehensively judged based on the patient's residual tumor location, size, and other complications. Supplementary radiotherapy is mainly image-guided brachytherapy ± external irradiation. The irradiation range and dose must be comprehensively considered based on the location and size of the residual lesions. The best local treatment plan is jointly determined by gynecological oncologists and radiotherapists.
214563408|NCT07153952|DRUG|Systemic treatment|Systemic treatment regimens include chemotherapy ± targeted therapy ± immunotherapy. According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel and cisplatin/paclitaxel. The addition of immunotherapy can be determined based on the PD-L1 expression level. The specific chemotherapy regimen will be determined by the gynecological oncologist based on the residual tumor site, the number of lesions, and other complications. In addition, if the patient's pathological results indicate HER2 positivity or the genetic test results show PIK3CA mutation, targeted therapy, such as neratinib or apelisimab, can be considered as a second-line regimen after the first-line chemotherapy regimen progresses.
214563409|NCT07153614|PROCEDURE|Intrathecal Morphine Block|Morphine 150 mcg
214563410|NCT07153614|PROCEDURE|Bilateral Quadratus Lumborum Block|30 mL of 0.25% bupivacaine and 4mg of dexamethasone
214563411|NCT07153614|PROCEDURE|Bilateral Transverse Abdominis Plane Block|Exparel-based solution mixed with 50mL of saline
214563412|NCT07155174|DRUG|ABBV-706|Intravenous (IV) Infusion
214563413|NCT07155174|DRUG|Atezolizumab|IV Infusion
214563414|NCT07155174|DRUG|Etoposide|IV Infusion
214563415|NCT07155174|DRUG|Carboplatin|IV Injection
214563416|NCT07155174|DRUG|Carboplatin|IV Infusion
214563417|NCT07155174|DRUG|Lurbinectedin|IV Infusion
214563418|NCT07154693|DEVICE|Combination 70% FDBA and 30% DFDBA|A combination freeze-dried bone allograft consisting of 70% mineralized FDBA and 30% demineralized FDBA
214563419|NCT07154693|DEVICE|OsteoGen Plug|A synthetic calcium apatite material combined with Type 1 bovine collagen (in a sponge-like product)
214563420|NCT07154147|DRUG|Alprazolam|Participants will take oral alprazolam 0.5 mg 15 to 90 minutes before surgery to promote relaxation and reduce anxiety. An IV placebo (normal saline) will be administered to maintain blinding.
214563421|NCT07154147|DRUG|Midazolam|Participants will receive IV midazolam 1 mg immediately before surgery to promote relaxation and reduce anxiety. An oral placebo pill will be used to maintain blinding.
214563422|NCT07153744|DRUG|Aspirin|Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
214563423|NCT07153744|DRUG|Shexiang Baoxin Pill|Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
214563424|NCT07156136|DRUG|IMC-P115C|IV infusion
214563425|NCT07154849|DRUG|Hydrocortisone|received 2mg/kg.
214563426|NCT07154849|DRUG|Dexmedetomidine|received 1 µg/kg
214563427|NCT07154732|DEVICE|Transcranial photobiomodulation (active)|During the active stimulation session, participants completed 11 sessions of active stimulation within 16 days. The stimulation duration was 9-12 minutes per session, administered once daily.
214563428|NCT07154732|DEVICE|Transcranial photobiomodulation (sham)|During the sham stimulation session, participants completed 11 sessions of sham stimulation within 16 days, with the same stimulation frequency and duration as the active stimulation group. The intervention was delivered at the same target area and wavelength, with intensity matched to the active stimulation for the first 30 seconds and the last 30 seconds of each session, while no intervention was applied during the intermediate period.
214563429|NCT07153666|DRUG|Ruxolitinib 1.5% Cream BID|ruxolitinib twice per day
214563430|NCT07154030|PROCEDURE|Micro needle injection|"* Disinfection: the affected area by alcohol 70 %.~* Topical anaesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with tretinoin 0.025% of the affected area will be done by dermapen that will be applied on the affected area as follows: inserting the sterilized needle into the dermapen tip, turning on using speed setting and adjusting speed on 5, needle depth of dermapen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with dermapen in a stamping pattern until pin point bleeding appear."
214707946|NCT04219969|DRUG|Fludeoxyglucose F-18|Given IV
214707947|NCT04219969|DEVICE|Magnetic Resonance Imaging|Undergo PET-MRI
214707948|NCT04219969|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
214707949|NCT02322268|DIETARY_SUPPLEMENT|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
215166030|NCT07162012|DRUG|EBV TCR-T|"After signing the informed consent form and completing screening according to the inclusion/exclusion criteria, eligible subjects will be sequentially assigned to the following dose cohorts of TCR-T cells (single administration): 1×10⁶ TCR-T cells/kg, 2.5×10⁶ TCR-T cells/kg, 5×10⁶ TCR-T cells/kg, and 10×10⁶ TCR-T cells/kg.~The first dose cohort (1×10⁶ TCR-T cells/kg) will use a rapid titration approach. If no significant safety issues occur within 28 days after infusion-defined as ≥Grade 3 non-hematologic toxicity, Grade 4 hematologic toxicity lasting more than 28 days (excluding disease- or chemotherapy-related causes), ≥Grade 2 neurotoxicity, or ≥Grade 3 cytokine release syndrome (CRS)-the next dose cohort will be initiated. If a dose-limiting toxicity (DLT) occurs, evaluation will be performed after 6 subjects have been treated.~The subsequent three dose cohorts will follow a 3+3 dose-escalation design, with 3-6 subjects per cohort receiving a single infusion. For subjects in th"
215166031|NCT07170709|DEVICE|Whole-Body Vibration|Participants will receive whole-body vibration (WBV) at 30-36 Hz under different mechanical loading conditions (e.g., standing on one foot, both feet,). Vibration-induced reflex responses will be recorded from the soleus muscle using surface electromyography. The intervention is designed to evaluate latency differences between tonic vibration reflex (TVR) and bone myoregulation reflex (BMR) under controlled biomechanical scenarios.
215166032|NCT07151573|OTHER|Big Five|"The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Things you do action and how it promotes mental health. The final section presents the five core actions: 1) healthy thinking, 2) meaningful activities, 3) goals and plans, 4) healthy habits, and 5) social connections. Participants are advised to engage in the five daily actions throughout the intervention period. They are also encouraged to fill out a weekly planner and monitor their progress by keeping an overview of the number of daily activities in My Week.The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions."
215166033|NCT07151573|OTHER|Gratitude|The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Gratitude and how it promotes mental health, followed by a short summary on the benefits of gratitude. The final section introduces practical strategies for cultivating gratitude by focusing on five key gratitude activities: 1) keeping a gratitude journal, 2) expressing gratitude to others, 3) finding gratitude in misfortune or difficult situations, 4) appreciating good things and 5) another perspective. The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
215166034|NCT07168161|DRUG|BDB-001 injection|Intravenously administered
214563431|NCT07154030|PROCEDURE|Micro needle injection only|"* Disinfection: the affected area by alcohol 70 %.~* Topical anesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with timolol 0.5% of the affected area will be done by derma pen that will be applied on the affected area as follows: inserting the sterilized needle into the derma pen tip, turning on using speed setting and adjusting speed on 5, needle depth of derma pen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with derma pen in a stamping pattern until pin point bleeding appear."
214563432|NCT07154771|OTHER|First with the arm circumference measurement tool, then with the traditional tape measure|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the newly developed arm circumference measurement device, followed by the traditional tape measure.
214563433|NCT07154771|OTHER|First with the traditional tape measure , then with the arm circumference measurement tool|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the traditional tape measure, and then using the newly developed arm circumference measurement device.
214563434|NCT07155343|COMBINATION_PRODUCT|Bulk Fill Composite|Orthodontic brackets will be bonded using a bulk fill composite resin, which is formulated for faster application and reduced polymerization shrinkage compared to conventional composites. This material will be used to assess its bond strength, failure rate, and overall clinical performance.
214563435|NCT07155343|COMBINATION_PRODUCT|Conventional Composite|Orthodontic brackets will be bonded using a conventional light-cured orthodontic composite resin that requires careful incremental application and standard curing time. This material is commonly used in routine clinical practice and serves as the benchmark for comparison.
214563436|NCT07155720|OTHER|Intervention (Kinesio Taping) group|No studies have been found in the literature examining whether kinesio taping increases happiness in women with PMS.
214563437|NCT07155187|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214563438|NCT07155187|DRUG|Standard of Care|Standard of Care
214707950|NCT05273658|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
214707951|NCT05273658|DRUG|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
214707952|NCT02625675|OTHER|Ultrasound scan|
214707953|NCT05093998|DRUG|AV5080|oral hard gelatin capsules
215166035|NCT07168161|DRUG|Cyclophosphamide|Intravenously administered
215166036|NCT07168161|BIOLOGICAL|Rituximab|Intravenously administered
215166037|NCT07168161|DRUG|Azathioprine|Intravenously administered
215166038|NCT07168161|DRUG|Prednisone|Intravenously administered
215166039|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 3 cycles, IT
215166040|NCT07170592|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
215166041|NCT07170592|DRUG|Atezolizumab|1,200 mg, once q3 weeks, 2 cycles, IV
215166042|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 2 cycles, IT
215166043|NCT07170592|DRUG|OTS-412|1×10E8 pfu, once q3 weeks, 2 cycles, IT
215166044|NCT07170592|DRUG|Hydroxyurea (HU)|20 mg/kg/day, 14 days, 1 cycle, PO
215166045|NCT07170592|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
215166046|NCT07170592|DRUG|Hydroxyurea (HU)|30 mg/kg/day, 14 days, 1 cycle, PO
214707954|NCT05093998|OTHER|Placebo|Hard gelatin capsules with a white body
215166047|NCT07170592|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days q3 weeks, 2 cycles, PO
215166048|NCT07170592|DRUG|OTS-412|optimal dose, once q3 weeks, 2 cycles, IT
215166049|NCT07170592|DRUG|Hydroxyurea (HU)|optimal dose, 14 days q3 weeks, 2 cycles, PO
215166050|NCT07165028|DRUG|Tirzepatide|Administered SC
215166051|NCT07165028|DRUG|Retatrutide|Administered SC
215166052|NCT07165028|DRUG|Placebo|Administered SC
215166053|NCT07169630|DRUG|18F-PF974|Injected IV followed by PET scanning
215166054|NCT07169630|DRUG|18F-florbetaben|Injected IV followed by PET scanning
215166055|NCT07161999|DRUG|COYA 302|Administered as specified in the treatment arm.
215166056|NCT07161999|DRUG|Placebo|Administered as specified in the treatment arm.
215166057|NCT07172412|DRUG|Selinexor|Selinexor 60 mg biw q21d
215166058|NCT07172412|DRUG|Anlotinib|Anlotinib 12mg d1-14 qd PO
215166059|NCT07172412|BIOLOGICAL|DLL3 CAR-NK cells|1.0×10\^9 DLL3-CAR-NK+ cells d5 q6w
215166060|NCT07172412|DRUG|Etoposide + Cisplatin/Carboplatin|Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5
215166061|NCT07172412|DRUG|Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab|Use immunotherapy according to the standard immunotherapy-combined-chemotherapy protocol.
215166062|NCT07170150|DRUG|Trontinemab|Participants will receive IV trontinemab
215166063|NCT07170150|OTHER|Placebo|Participants will receive IV placebo
215166064|NCT07171970|PROCEDURE|IVM-Fresh (No gonadotropin + Fresh embryo transfer)|Patients randomized to this arm will receive estradiol valerate 8 mg/day. IVM will be performed after ≥10 days of estrogen and ET ≥8 mm. From the day of ICSI, they will continue estradiol and start vaginal progesterone 800 mg/day + dydrogesterone (20mg/day). A fresh embryo transfer will subsequently be performed.
215166065|NCT07171970|PROCEDURE|IVF-FET (GnRH-Antagonist - Agonist Trigger - Frozen embryo transfer)|Patients randomized into this group will receive FSH at a dose of 150 IU/day. Oocyte retrieval will be performed once the criteria for triggering are fulfilled, followed by embryo cryopreservation and frozen embryo transfer in the subsequent cycle. Endometrial preparation for frozen embryo transfer will be conducted using an exogenous steroids regimen. Patients will receive estradiol 8 mg/day starting from cycle days 2-3 for 10 days. When the endometrial thickness reaches ≥8 mm, luteal phase support will be initiated with vaginal progesterone 800 mg/day plus dydrogesterone 20 mg/day.
215166066|NCT07160985|OTHER|AI-based Lifestyle Management|Participants will use the X Life model via smartphone/tablet for 28 days, receiving real-time, personalized dietary and exercise recommendations triggered by CGM and activity tracker data. Participants can interact with the system by uploading meal images, physical activity data, and wearable-derived metrics.
215166067|NCT07160985|OTHER|Lifestyle Management|Participants will receive guideline-based lifestyle counseling according to national prediabetes prevention guidelines, delivered via mobile terminal, without AI-generated recommendations.
215166068|NCT07179484|DRUG|CT041 autologous CAR T-cell injection|The planned dose of CT041 is 2.5×108 cells. The participants are recommended to receive only a single infusion or multiple infusions (up to 3 infusions) according to the safety and efficacy data of the participants per the investigator. The dose and method of re-infusion are the same as the first infusion. Lymphodepletion pretreatment should be given before re-infusion, and the requirements before lymphodepletion pretreatment and cell infusion should also be met before re-lymphodepletion pretreatment or re-infusion.
215166069|NCT07175987|OTHER|RDTH002581|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
215166070|NCT07175987|OTHER|RDTH002580|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
215166071|NCT07175987|OTHER|RDTH002582|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
215166072|NCT07175987|OTHER|RDTH002578|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
215166073|NCT07175987|OTHER|RDTH002577|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
214563439|NCT07153692|DEVICE|tDCS|The IS200 intelligent electrical stimulator, manufactured in Chengdu, Sichuan, will be used. The electrode pads are 4cm × 6cm in size. The anode of the electrode pad will be placed on the swallowing sensorimotor cortex (S1/M1). The specific positioning will follow the international 10-20 electroencephalographic system: the left S1/M1 area is located at the midpoint of the line connecting C3 and T3 in the left hemisphere; the right S1/M1 area is located at the midpoint of the line connecting C4 and T4 in the right hemisphere. The cathode will be placed on the contralateral supraorbital margin. The S1/M1 areas of the left and right hemispheres will be stimulated alternately, with a current intensity of 1.6mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere).
214563440|NCT07153692|BEHAVIORAL|Conventional Dysphagia Treatment|"1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.;~2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;"
214563441|NCT07153692|DEVICE|sham tDCS|According to previous literature, the electrode positions and treatment frequency of sham tDCS will be the same as those of real tDCS. The current will be adjusted to 0.05mA.
215166074|NCT07175987|OTHER|RDTH002579|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
215166075|NCT07179016|BEHAVIORAL|Auricular Point Acupressure (APA) - Self Management (SM)|APA is a noninvasive and needle-free pain management therapy based on the principles of acupuncture. The APA-SM intervention program is aimed to manage chronic musculoskeletal pain leveraging a mobile app containing APA videos and remote vs in-person guidance or coaching to practice APA based on APA study assignment.
215166076|NCT07179016|BEHAVIORAL|Education Control|Education Control group receive an app but the content will be specific to pain and self-management (no APA content) and they practice pain self-management skills (no APA practice).
215166077|NCT07179276|PROCEDURE|CO2gap-guided resuscitation strategy|"For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas:~* Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients.~* The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice)."
215166078|NCT07181408|OTHER|Wheat flour-based control snack|Consumption of a single 50-gram portion of a wheat flour-based control snack.
214563442|NCT07155278|DRUG|Elravie Re2O|Elravie Re2O is a particulated human Acellular Dermal Matrix (phADM), with each 5 mL syringe containing 150 mg of phADM. This product is classified as a human tissue product and received its approval via a tissue bank establishment permit from the Ministry of Food and Drug Safety.
214563443|NCT07155278|DRUG|Elravie Balance|Elravie Balance is a gel-type hyaluronic acid (HA) skin booster. It contains HA at a concentration of 20mg/ml in a 2.5 cc syringe with a volume of 1.5 mL.
214563444|NCT07154108|BIOLOGICAL|recombinant human endostatin adenovirus|Recombinant Human Endostatin Adenovirus: Administered via intratumoral injection twice every 3 weeks for a total of eight doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first.
214563445|NCT07154108|DRUG|PD-1 Inhibitor|PD-1 inhibitor: Administered via intravenous infusion once every 3 weeks.
214707955|NCT05605977|BEHAVIORAL|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
215166079|NCT07181408|OTHER|Snack enriched with 15% cricket flour|Consumption of a single 50-gram portion of a snack enriched with 15% cricket flour (Acheta domesticus).
215166080|NCT07181408|OTHER|Snack enriched with 15% pea flour.|Consumption of a single 50-gram portion of a snack enriched with 15% pea flour.
215166081|NCT07175506|DRUG|Placebo|Placebo injection administered IV, once.
215166082|NCT07175506|BIOLOGICAL|CM559|CM559 injection administered IV, once.
215166083|NCT07167121|DIAGNOSTIC_TEST|CPAx|"Evaluation of :~Respiratory function Cough Moving within the bed Supine to sitting on the edge of the bed Dynamic sitting Standing balance Sit to stand (starting position ≥ 90°) Transfering from bed to chair Stepping Grip strength (predicted mean for age and gender on the strongest hand)"
215166084|NCT07183592|PROCEDURE|7-day Infusion set replacement|7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.
215166085|NCT07183592|PROCEDURE|4-day infusion set replacement|4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.
215166086|NCT07173491|OTHER|classical music group|classical music therapy with standard restorative treatment
215166087|NCT07173491|OTHER|turkish music group|Turkish music therapy with standard restorative treatment
215166088|NCT07173491|OTHER|control|no music therapy with standard restorative treatment
215166089|NCT07179614|BEHAVIORAL|Overdose Prevention Intervention Package (OPIP)|WJCOIN-II's multi-level 2 X 2 randomized factorial design will examine the effectiveness of OPIP components across four study conditions randomly assigned after baseline data collection (n=75 per condition, 100 per jail site), summarized in Table 7 and described below. In addition to group assignment, outcomes will be assessed as a function of engagement in each intervention component defined as the number of sessions attended (RC and CM conditions) and perceived support, which is a count of the number of types of support provided by the RC and SP (e.g., emotional, financial, etc.).
215166090|NCT07183657|OTHER|Education in inhalation technique|Education in inhalation technique
215166091|NCT07184151|DRUG|well root putty ( premixed bioceramic putty) retrograde filling|well root putty ( premixed bioceramic putty) retrograde filling
215166092|NCT07184151|DRUG|MTA retrograde filling|MTA retrograde filling
215166093|NCT07160608|DRUG|Placebo|Participants will receive placebo.
215166094|NCT07160608|DRUG|Tarperprumig|Participants will receive tarperprumig.
215166095|NCT07181902|PROCEDURE|Erector Spinae Plane Block (ESP)|Ultrasound-guided ESP block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
215166096|NCT07181902|PROCEDURE|Retrolaminar Block (RLB)|Ultrasound-guided Retrolaminar Block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
215166097|NCT07183709|BIOLOGICAL|PepGNP-COVID19|A synthetic T cell priming setpoint-modifying SARS-CoV-2 vaccine composed of ultrasmall carbohydrate-coated gold nanoparticles carrying covalently bound MHC class I-binding SARS-CoV-2 peptides.
215166098|NCT07183709|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
215166099|NCT07176104|DIETARY_SUPPLEMENT|Functional Bovine Milk|Functional milk product enriched with standardised bioactive peptides, provided daily for 12 months.
215166100|NCT07176104|DIETARY_SUPPLEMENT|Non-Functional Bovine Milk|Standard bovine milk with identical caloric and macronutrient profile to the functionalized milk, without enrichment, provided daily for 12 months.
215166101|NCT07177287|BEHAVIORAL|IMB navigator app|Mobile application developed based on the IMB model, supported by a navigator nurse. Includes educational content, reminders and behavioral support. Patients will be followed for 6 months.
215166102|NCT07175155|DEVICE|COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO endoscopy oropharyngeal airway with High-Flow Nasal Cannula Oxygenation in sedated gastrointestinal endoscopy for morbidly obese patients
215166103|NCT07175155|DEVICE|High-Flow Nasal Cannula Oxygenation|In this group, patients use high-flow nasal cannula oxygenation
215166104|NCT07180680|PROCEDURE|laparoscopic assisted transanal proximal rectosigmoidectomy|using laparoscopy for such procedure in children is unique for this study
215166105|NCT07181499|DRUG|Befotertinib|Befotertinib was administered orally at a starting dose of 75 mg per day for 21 days, which could be increased to 100 mg per day if grade 2 or higher thrombocytopenia or headache did not occur within 21 days, or maintained at the original dose (75 mg per day) if grade 2 or higher thrombocytopenia or headache occurred within 21 days.
215166106|NCT07181499|DRUG|Pemetrexed + Carboplatin|pemetrexed (500 mg/m²) and carboplatin (AUC 5), administered every 3 weeks, for a total of 2\~4 cycles.
215166107|NCT07182383|DRUG|Bempedoic acid|"180 mg film coated tablet administered individually or as FDC~Component of FDC"
215166108|NCT07182383|DRUG|Ezetimibe|"10 mg tablet administered individually or as FDC~Component of FDC"
215166109|NCT07182383|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
215166110|NCT07181837|GENETIC|MVX-220|AAVhu68 viral vector
214707956|NCT05605977|BEHAVIORAL|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
215166111|NCT07187310|PROCEDURE|EXORA block|in a supine position, a linear Ultrasound probe (L6-12 RS linear array transducer (6-12 MHz) on GE Healthcare Logiq P7, made in Korea) will be sagittally applied at the parasternal line, lateral to the sternum and xiphoid process. The probe will be manipulated craniocaudally to identify the 6th, 7th, and 8th costal cartilages. At the level of the 8th costal cartilage, a transverse orientation will be used to visualize the rectus abdominis muscle and the costal cartilage beneath. An 88-mm, 22-gauge needle will be directed in-plane from medial to lateral. After confirming the needle position below the rectus abdominis muscle using 4 ml isotonic saline as a hydro-dissection, 25 ml of plain bupivacaine 0.25% concentration will be injected. the spread of the local anesthetic is to be observed to advance laterally under the external oblique muscle and medially under the rectus muscle. The same procedure will be repeated on the other side.
215166112|NCT07187310|PROCEDURE|Erector Spinae Plane block|in a right lateral position, the linear Ultrasound probe will be placed vertically 3 cm lateral to the midline at the level of the 7th thoracic spinal process, identifying the T7 transverse process, and the overlying erector spinae (ES) muscle. An 88-mm, 22-gauge needle will be advanced craniocaudally in-plane until hitting the T7 transverse process. After using hydro-dissection with 4 ml of isotonic saline to confirm the correct needle position, 25 ml of 0.25% bupivacaine will be administered below the erector spinae muscle. The same procedure will be repeated on the other side.
215166113|NCT07187297|DEVICE|Thermage FLX|The Thermage FLX System ('System') is a monopolar, capacitively coupled radiofrequency System designed for use in non-invasive dermatological procedures
215166114|NCT07189052|OTHER|Virtual Reality Rehabilitation|A virtual reality-based rehabilitation program including breathing, stretching, cervical range-of-motion, and posture-strengthening tasks delivered in a gamified seaside environment using a head-mounted VR display. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
215166115|NCT07189052|OTHER|Conventional Rehabilitation|Standard physiotherapy including diaphragmatic breathing, trapezius stretching, cervical range-of-motion, and posture-strengthening with proprioceptive neuromuscular facilitation. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
215166116|NCT04586660|DRUG|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
215166117|NCT07184619|DRUG|Evenamide 15 mg bid|Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment
215166118|NCT07184619|DRUG|Placebo|Matching placebo capsules bid for a total of 12 weeks of add-on treatment
215166119|NCT07190911|OTHER|Olfactory rehabilitation consists of smelling a series of spices every day for 2 months|"Olfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin.~This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8~Allergies to certain spices will be noted at the start of the study:~* in known allergy: change by another spice which belongs to the same chemical category.~* in case of allergies to several scents: patient is not included in the study.~* in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category.~* in case of allergies to several scents occuring during participation: patient is excluded from the study."
215166120|NCT07190105|OTHER|Sonocea Sonic Augmentation Technology (SAT)|The Sonocea Sonic Augmentation Technology (SAT) is a sound-based approach delivered via headphones through a smartphone application. The approach uses music soundscapes that have been standardized in format, intensity and duration.
215166121|NCT07190105|OTHER|Truvaga Electrical Vagus Nerve Stimulator|The Truvaga Electrical Vagus Nerve Stimulator is a general wellness product that sends gentle electrical signals through the skin to stimulate the vagus nerve on the neck.
215166122|NCT07190534|DRUG|Hydroxychloroquine (HCQ)|400 mg orally once daily
215166123|NCT07190534|DRUG|Methotrexate (MTX)|15 mg weekly, orally or subcutaneously (+ concomitant medication: Folic acid 10 mg once weekly, taken 24 hours after MTX)
215166124|NCT07190625|DRUG|fentanyl intravenous|giving intravenous fentanyl
215166125|NCT07190625|DRUG|Fentanyl intranasal using atomizer|giving intranasal fentanyl using nasal atomizer
215166126|NCT07190625|DRUG|fentanyl intranasal direct|giving intranasal fentanyl directly into nostrils
215166127|NCT07189572|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a medium-potency synthetic corticosteroid. This intervention is administered via a commercially available, metered-dose nasal spray that delivers 55 μg of the active drug per spray. It exerts potent local anti-inflammatory and immunomodulatory effects in the nasal mucosa and Eustachian tube orifice. In this study, it is investigated for the prevention of radiotherapy-induced otitis media with effusion in patients with nasopharyngeal carcinoma.
215166128|NCT07189572|DRUG|Placebo|The placebo nasal spray is specifically formulated to be indistinguishable from the active triamcinolone acetonide nasal spray. It is identical in all physical properties including appearance, scent, taste, packaging, and administration procedure. It contains the same inactive excipients (e.g., preservatives, suspending agents) but does not contain any triamcinolone acetonide or other active pharmaceutical ingredient.
215166129|NCT07189130|OTHER|Exercise: 80% 1 RM with 2 minutes break|Participant will do resistance exercise at 80% 1RM with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
215166130|NCT07189130|OTHER|Exercise: 80% 1RM with1 minute break|Participant will do resistance exercise at 80% 1RM with 1 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
214563446|NCT07153536|DEVICE|Spinal Cord Stimulator (Medtronic Inceptiv™ System)|The Medtronic Inceptiv™ spinal cord neurostimulation system is a rechargeable implantable pulse generator (IPG) designed to deliver electrical pulses to the spinal cord via implanted leads. The system is intended for use in patients with chronic pain.
214707957|NCT02819505|DIETARY_SUPPLEMENT|beta-alanine|
214707958|NCT02819505|DIETARY_SUPPLEMENT|Placebo|
215166131|NCT07189130|OTHER|Exercise: accenuated eccentric exercise|Participant will do accenuated eccentric resistance exercise at 80% 1RM in concetric part of movement and 110% 1RM in eccentric part of movement with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
215166132|NCT07189130|OTHER|Control|Timeline of events will be same as in exercise protocol (blood withdrawal and Stroop test), except participants will not do any kind of exercise protocol, instead they will be seating.
215166133|NCT07187518|DEVICE|Measurements with the POROUS R4C ultrasound device at the midshaft tibia|The POROUS R4C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
215166134|NCT07187518|DEVICE|DXA measurement of the hip and lumbar spine|The following DXA measurements are to be performed: • Spine L1-4 • Hip left • Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R4C ultrasound scan.
215166135|NCT07188506|DIAGNOSTIC_TEST|Clinical and blood parameters|Clinical data and MRI measurements
215166136|NCT07188506|GENETIC|Illumina Infinium Global Screening Array 4.0 (GSA 4.0)|Genomic analyses
215166137|NCT07188506|DEVICE|dTMS treatment|high-intensity deep transcranial magnetic stimulation (dTMS) device recognized for clinical application in mood disorders
215166138|NCT07191353|DRUG|Everolimus|Everolimus 5 mg administered once weekly for 24 weeks
214563447|NCT07153536|OTHER|Physical Therapy|The physical therapy intervention consists of two components: the Mind-Pod Dolphin system (targeting arm function) and the Hummingbird Hunt system (targeting hand function). Both systems use interactive gaming software that enables participants to engage in remote, game-based therapy. Each system offers multiple difficulty levels, allowing participants to progress as their skills improve.
214563448|NCT07155252|DIAGNOSTIC_TEST|GTT@Home|self-administered fingerstick based glucose tolerance test
215166139|NCT07191353|DRUG|Placebo|Placebo administered once weekly for 24 weeks
214563449|NCT07153653|BEHAVIORAL|Prenatal Baduanjin Exercise Program|A structured 12-week program featuring Baduanjin, a traditional Chinese mind-body exercise involving gentle, flowing movements. Participants receive 24 online instructional sessions (approximately 2 s
215166140|NCT07191353|OTHER|Resistance training|Resistance training 3 times a week for 24 weeks
215166141|NCT07190066|OTHER|Data Collection campaign|Participants will be asked to download the MELIROA app, compatible with iOS and Android, to their smartphones and test it for 14 days. The app will prompt the user to set a weekly goal on physical activity and support daily self-monitoring and step count tracking. Τhe app will also offer culturally adapted educational material through mini-courses, motivational and practical tips and an embedded library of materials relevant to physical activity, healthy diet and alcohol consumption. To boost motivation, it will also include reminders and gamification features like badges and points.
214563450|NCT07154550|DEVICE|Mastisol|a liquid adhesive used to secure dressings for extended periods of time
215166142|NCT07189936|DRUG|To Measure levels of circulating monocyte/ T cell doublets at Baseline|To determine the levels of circulating monocyte/ T cell doublets on all the LCPOTS subjects
214563451|NCT07155083|OTHER|Survey using a questionnaire.|REDCap Survey
214563452|NCT07154485|DRUG|NS101 IV infusion|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
214563453|NCT07154485|DRUG|Placebo IV Infusion|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
215166143|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment|Subjects will be randomized 1:1 to 2-HOBA or matching placebo. The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment
215166144|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment|The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment and compare it to the placebo arms
215166145|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA|We will Measure changes in Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and compare it with baseline during 30 Mins head up tilt . All the LCPOTS subjects will be randomized 1:1 to 2-HOBA or matching placebo
214563454|NCT07154082|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|Patients in the neoadjuvant treatment group will receive TACE treatment within one week after enrollment. One week after the resolution of the TACE treatment syndrome, they will be given Camrelizumab (200 mg, once every two weeks, for a total of 4 cycles) and oral Apatinib mesylate tablets (250 mg, once a day, for a total of 2 months).To ensure surgical safety, Camrelizumab should be discontinued at least two weeks before surgery, while Apatinib should be discontinued at least one week before surgery.
215166146|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo|We will Measure changes in splanchnic venous capacitance during 30 mins head up tilt ,after 28 days of Treatment with Placebo, we will compare it to the subjects who received 2 HOBA for 28 days
215166147|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with 2HOBA at 30 minutes of head up Tilt
215166148|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with Placebo at 30 minutes of head up Tilt and compare it with the subjects who received 28 days of 2HOBA
215166149|NCT07191288|DEVICE|VR (VR-Breathing+Mystical)|The VR-based slow-paced breathing application is designed to provide rewarding biofeedback for a specific breathing pattern characterized by prolonged exhales. As users extend their exhales, a veil of fog gradually lifts, introducing a mystical type experience. Over time, users are rewarded with a full 360-degree panoramic view of the beautiful nature scene, accompanied by relaxing music. After approximately 5 minutes of prolonged exhales, the nature scene responds to the user's breathing by slowing down, with falling snowflakes moving more slowly, further enhancing the mystical atmosphere. This intervention was designed to be visually captivating, mystically evocative, and emotionally engaging. Duration: 10 minutes.
215166150|NCT07191288|DEVICE|VR (VR-Mystical)|Users will experience the gradual unveiling of a beautiful natural landscape as the fog lifts, and eventually, the scene slows down similar to the VR Breathing+Mystical condition. However, this application does not provide any biofeedback or breathing instructions. Users are invited to passively observe the unfolding experience, immersing themselves in the environment for 10 minutes. Relaxing music accompanies the scene. This condition relies solely on the immersive and aesthetic qualities of the virtual environment to potentially induce relaxation.
215166151|NCT07191288|DEVICE|Computer (Non-VR-Breathing)|In this conventional breathing intervention, participants will be instructed to follow a slow-paced breathing pattern guided by a simple visual cue (an expanding and contracting circle) displayed on a computer screen for 10 minutes. This condition is designed to guide slow-paced breathing without incorporating any rewarding elements.
215166152|NCT07191288|DRUG|VR (VR-Control)|In the control condition, participants will watch a neutral documentary for 10 minutes in VR. This condition is used to control for the effects of the immersive VR experience. It does not include any components related to guided breathing or mystical-type content, or any form of rewarding elements.
215166153|NCT07190443|DRUG|Endocrine therapy + Abemaciclib|"This intervention consists of adjuvant endocrine therapy in combination with abemaciclib, a CDK4/6 inhibitor, administered to patients with HR-positive, HER2-negative breast cancer who have undergone curative-intent local treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~Abemaciclib is given orally at a dose of 150 mg twice daily for a maximum of 2 years, in accordance with the approved dosing regimen in the adjuvant setting. The choice of endocrine therapy-aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression-is determined based on menopausal status and prior treatment history."
214563455|NCT07154888|OTHER|Fast Track to Fertility Algorithmic Text Messaging Platform|"The Fast Track to Fertility algorithmic text messaging platform uses branching logic based on our standard workup protocol to text patients to schedule blood tests and an ultrasound timed to their menstrual cycle, as well as remind male partners to schedule blood and semen analyses.~The platform will use an algorithmic approach to facilitate two-way communication, and any queries with no available responses will be escalated to the clinical team. Patients are not dependent on structured messages to progress through their journey; they can ask relevant questions in real time, and they are supported with fewer reminders. Response categories include clinical guidance and FAQs (e.g., how to determine cycle start or uterine cavity evaluation pre-appointment instructions), administrative guidance and FAQs (when to schedule test/appointment or clinic locations or phone numbers), and conversational pleasantries."
214563456|NCT07153419|DEVICE|Laparoscopic and robotic (DaVinci) RYGB|Laparoscopic and robotic (DaVinci) Roux-en-Y Gastric Bypass
214563457|NCT07155356|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
214563458|NCT07155356|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care。
214563459|NCT07156006|DIAGNOSTIC_TEST|Mammography|Participants will undergo mammographic imaging using a digital full-field mammography system, following standard clinical practices and blood sampling.
214563460|NCT07155655|BEHAVIORAL|Motor Imagery (MI)|Participants followed an audio-guided motor imagery protocol describing the lumbopelvic dynamometer movement. The audio was played three times per session, with pauses for visualization. Training was delivered online via Microsoft Teams, twice weekly for four weeks, in a quiet and focused environment.
214707959|NCT02375269|DEVICE|RIPC with a tourniquet|
214707960|NCT01030380|DEVICE|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
214563461|NCT07155655|BEHAVIORAL|Action Observation (AO)|Participants viewed three videos of the lumbopelvic dynamometer movement (two third-person, one first-person perspective). Each video was watched three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks, with participants instructed to remain silent and focused.
215166154|NCT07190443|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|"This intervention consists of adjuvant endocrine therapy alone in patients with HR-positive, HER2-negative breast cancer who have undergone curative treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~The choice of endocrine therapy (aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression) is determined based on the patient's menopausal status and prior treatment history, as specified in the protocol. Treatment is continued for five years or until disease recurrence, unacceptable toxicity, or withdrawal of consent.~This intervention does not include CDK4/6 inhibitors."
215166155|NCT07184281|BEHAVIORAL|12-hour time-restricted eating|Based on the current health education model, the subjects in the experimental group were administered for 12 hours of TRE. Carry out the propaganda and education of the 12-hour TRE feeding mode, the core content is that the eating time window is limited to 12 hours/day, the last meal is no later than 19:00, the study subjects can freely choose the eating time window, do not restrict energy intake during eating, and during the fasting period, they are allowed to drink non-calorie, sugar-free drinks (water, tea, coffee). Record the time of eating every day.
215166156|NCT07184281|BEHAVIORAL|health education|"The current health education model is adopted, that is, health education is carried out in accordance with the Guiding Outline for Health Education in Primary and Secondary Schools."
215166157|NCT07189104|BEHAVIORAL|SAGA for Toddlers|SAGA for Toddlers includes training sessions and workshops for the ECEC personnel on the mentalization-based shared reading intervention following the SAGA model. During the intervention shared reading sessions (5-10-minutes each) are held for groups of 2 to 3 children for 10 weeks (at least 3 sessions per week) at the ECEC by the personnel. Caregivers are involved in the intervention via caregiver meetings held at the ECEC by the investigators.
215166158|NCT07186647|PROCEDURE|laparoscopic-assisted Swenson-like (LASwL)|Following port placement, laparoscopic exploration was performed to evaluate the spastic colonic segment and transitional zone. An aperture was created in the sigmoid mesentery, and the sigmoid colon was mobilized. The proximal ganglionic bowel was mobilized while preserving the marginal arcades. The peritoneal reflection was sharply incised to facilitate dissection and mobilization of the aganglionic rectum. The procedure diverged between the two groups at this juncture: LASwl group: The rectum below the peritoneal reflection was dissected circumferentially up to a level 2 cm above the anal verge . LASo group: The rectum below the peritoneal reflection was minimally mobilized (within 1 cm of the peritoneal reflection). Following laparoscopic dissection, the ports were left in situ, and the position was adjusted for transanal dissection of the remaining rectum.
215166159|NCT07186647|PROCEDURE|laparoscopic-assisted Soave (LASo)|Transanal endorectal procedure was conducted according to the standard technique described by De la Torre-Mondragon and Ortega-Salgado \[12\]. A circular incision was made in the mucosa, and mucosectomy was performed. The muscle sleeve was cut, connecting the two dissection planes circularly . After keeping the muscular cuff as short as possible, a longitudinal incision was made posteriorly. Then, the bowel was extracted, and the anastomosis was performed as described above.
215166160|NCT07189416|PROCEDURE|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"
215166161|NCT07190469|DRUG|PQ203|PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.
215166162|NCT07188467|BEHAVIORAL|Digitized SH+|Digitized SH+ is a group-based, stress management program (adapted from the original Self-Help Plus intervention developed by the World Health Organization), that utilizes animated videos and group discussions to teach participants skills such as Grounding, Unhooking (from difficult thoughts), Being Kind (to self and others), Identifying Values, and Making Room for Difficult Thoughts and Feelings.
215166163|NCT07185776|DRUG|HRS-5632 Injection|HRS-5632 injection.
215166164|NCT07185776|DRUG|HRS-5632 Injection Placebo|HRS-5632 injection placebo.
215166165|NCT07185555|DIETARY_SUPPLEMENT|VLEKT|Participants will follow a Very Low-Energy Ketogenic Therapy (VLEKT) providing 600-800 kcal/day for 4 weeks. The intervention consists of meal replacements (solid or liquid, ready-to-use or reconstituted) with very low carbohydrate content, high-quality proteins (milk, whey, pea, soy), and fiber (inulin, FOS). Gluten-free, lactose-free, and vegan options are available. Meal replacements are provided by Therascience or Penta at discounted prices. Participants will self-monitor capillary ketonemia daily, maintain adequate hydration, and avoid intense physical exercise. The Advanced Hybrid Closed Loop (AHCL) insulin delivery system will be used throughout the study with periodic adjustments based on device downloads. At the end of the 4-week intervention, a structured reintroduction of conventional meals will be initiated.
215166166|NCT07188623|BEHAVIORAL|VR-Enhanced BA|"Participants will choose at least one activity per day to complete in the loaned HTC VIVE Flow Immersive Glasses extended reality over the course of the week. These activities are chosen from the headset and include video 360."
215166167|NCT07191821|DRUG|XBD173|Small molecule experimental medication binding to mitochondrial protein TSPO
215166168|NCT07191561|DIAGNOSTIC_TEST|Liver biopsy|Biopsy of the liver
214563462|NCT07155655|BEHAVIORAL|Motor Imagery with Motivation (MIm)|Participants followed the MI protocol, combined with a motivational strategy. Intrinsic motivation was provided through self-talk statements, and extrinsic motivation through an audio simulating a weightlifting competition. Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
214563463|NCT07155655|BEHAVIORAL|Action Observation with Motivation (AOm)|Participants followed the AO protocol, combined with the same motivational strategy described for the MIm group (self-talk + extrinsic audio simulation). Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
215166169|NCT07194954|DIETARY_SUPPLEMENT|Combined Dietary Fiber and Probiotics.|The intervention consisted of a daily oral administration of 20g of a mixed dietary fiber powder (FibroBalance®, containing inulin, pectin, and β-glucan) and one multi-strain probiotic capsule (ProbioCare Forte®, delivering 10\^9 CFU of Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bi-07, and Streptococcus thermophilus St-21).
215166170|NCT07194954|OTHER|Standard Nutritional Support|This included dietary counseling from a registered dietitian and, if necessary, a standard oral nutritional supplement (Ensure®) to meet estimated energy and protein requirements.
215166171|NCT07187466|DRUG|mirabegron|Mirabegron is a beta-3-agonist, which acts upon the noradrenergic system and avoids the cognitive and gastrointestinal side effects of anticholinergic bladder relaxants.
215166172|NCT07187466|BEHAVIORAL|Exercise-based behavioral therapy|The exercise-based behavioral therapy is a comprehensive training program administered individually by a trained nurse practitioner interventionist to address urinary incontinence and other lower urinary tract symptoms.
215166173|NCT07193030|BEHAVIORAL|Peer-led Alcohol Brief Intervention (identification + advice)|"The intervention consists of a peer-led ABI for university students. This intervention aligns with the ABI approach recommended by the WHO as a cost-effective strategy to reduce harmful alcohol use, particularly in primary care and community settings. The brief advice component of the intervention will incorporate Motivational Interviewing (MI) techniques, a client-centred, evidence-based counselling style intervention effective for reducing risky drinking behaviours. The brief advice will be tailored based on behavioural insights identified through formative research, such as individual perceived facilitators and barriers.~The Alcohol Use Disorders Identification Test- Consumption (AUDIT-C) will be used as the screening tool for identification.~A one-on-one Brief Advice sessions of 15-20 minutes will be delivered by trained peer educators, i.e., university students who are not healthcare professionals but have been specifically trained in delivering brief advice."
215166174|NCT07194720|DIETARY_SUPPLEMENT|Cornus mas lyophilisate|Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.
215166175|NCT07194720|DIETARY_SUPPLEMENT|Placebo|Participants receiving a starch- and sugar-based placebo for 4 weeks.
215166176|NCT07194733|OTHER|VET FAM Product Box and Nutrition Education|Food boxes and nutrition education
215166177|NCT07186049|BEHAVIORAL|Thesis Sessions|Thesis Sessions
215166178|NCT07186049|BEHAVIORAL|General Health Guidelines|General Health Guidelines
215166179|NCT07186049|BEHAVIORAL|Thesis and Exercises|Thesis and Exercises
215166180|NCT07187648|DIETARY_SUPPLEMENT|Golden Rice Cookies With Piper crocatum|Golden Rice cookies enriched with Piper crocatum were formulated as a functional food containing β-carotene and bioactive compounds (polyphenols, flavonoids, tannins). Participants in the experimental arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are iso-caloric with control cookies but differ by inclusion of Golden Rice and Piper crocatum.
215166181|NCT07187648|OTHER|Iso-Caloric Control Cookies (Placebo)|Iso-caloric cookies made from standard flour without Golden Rice and without Piper crocatum. Participants in the control arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are designed to match the intervention cookies in calories and appearance but do not contain the active ingredients.
215166182|NCT07185256|GENETIC|OPGx-BEST1|Experimental Genetic Therapy
215166183|NCT07192432|GENETIC|Dose Level 1, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
215166184|NCT07192432|GENETIC|Dose Level 2, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
215166185|NCT07192432|GENETIC|Dose Level 3, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
215166186|NCT07192432|GENETIC|Dose Level 4, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
215166187|NCT07192419|BEHAVIORAL|Promoting Aging and Thriving with HIV (PATH)-Implementation of a Tailored Geriatric Assessment and Management Strategy for HIV Care Settings|"For the intervention arm, participants will be sent geriatric assessment questions through the patient portal in advance of a routine HIV appointment. If the participant is unable to complete the questions in advance, they will be done with the help of a research coordinator to go through on the day of appointment. Every attempt will be made to ensure the assessment can be done in advance of the appointment, however the study team will allow for visits after the regular appointment as in which case the provider will receive results after the patient has left clinic.~The provider will receive the PATH assessment responses and a discussion guide with suggested initial management steps. The provider ultimately determines with the participant when and if they will address concerns identified (that visit or future visit) based on participant priorities. The patient participant will also receive a copy of their screening results."
214563464|NCT07154901|DRUG|Opemalirsen (AZD2373)|Single, subcutaneous injection of AZD2373
214563465|NCT07153601|DRUG|Norepinephrine 4mcg|Norepinephrine 4 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
214563466|NCT07153601|DRUG|Phenylephrine 50 mcg|Phenylephrine 50 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
214563467|NCT07155980|DRUG|GSM-779690T|Opaque capsules for oral consumption.
214563468|NCT07155980|OTHER|Placebo|Opaque capsules for oral consumption.
214563469|NCT07153588|OTHER|Level of awareness|"This study uses a structured, interviewer-assisted questionnaire as the main intervention. The questionnaire is designed to assess patients' awareness and perception of glaucoma. It includes four sections:~Sociodemographic information (age, gender, education, occupation, residence, family history)~Ocular history (diagnosis of glaucoma, history of eye disease, surgery, or previous eye checkups)~Awareness of glaucoma (understanding of risk factors, symptoms, prevention, and treatment options)~Perceptions and attitudes (beliefs about curability, reversibility of vision loss, and willingness for screening and education).~For illiterate participants, trained research staff will administer the questionnaire verbally without influencing responses. The data collection method distinguishes this intervention from treatment-based studies, as it focuses on knowledge assessment and perception analysis rather than a medical or surgical procedure."
214563470|NCT07154290|DRUG|Ubamatamab|Administered per the protocol
214563471|NCT07154290|DRUG|REGN7075|Administered per the protocol
214563472|NCT07154290|DRUG|Sarilumab|Administered per the protocol
214563473|NCT07155551|DEVICE|Lens A|Lens A of Study P/883/24/MO
214563474|NCT07155551|DEVICE|Lens B|Lens B of Study P/883/24/MO
214563475|NCT07155551|DEVICE|Lens C|Lens C of Study P/883/24/MO
214563477|NCT07155369|BIOLOGICAL|UCAR-T cells|UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.
214563478|NCT07155369|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
214563479|NCT07155369|DRUG|Fludarabine|Fludarabine will be administered intravenously.
214563480|NCT07155915|DIETARY_SUPPLEMENT|Sweet cherries, 280 g daily for 42 days|Participants will consume 280 grams of fresh sweet cherries daily for 42 consecutive days. Cherries are provided in pre-weighed portions to be consumed in the morning on an empty stomach
214563481|NCT07155668|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
214563482|NCT07155668|DEVICE|Autoinjector|The autoinjector is a single-dose, disposable, ready-to-use delivery device
214563483|NCT07154498|BEHAVIORAL|Conventional physiotherapy with Cognitive Behavior Therapy|Gentle exercises include stretching and strengthening exercises. Cognitive-behavioral therapy (CBT) sessions.
214707961|NCT00433446|BIOLOGICAL|CNTO 328|
214563484|NCT07154498|COMBINATION_PRODUCT|Conventional physiotherapy|Gentle exercises include stretching and strengthening exercises mobilisation, soft tissue mobilisation Interventions was applied at two sessions per week, each session is about an hour total of 24 sessions. Assessment was done at baseline in the 6th week and 12th week.
214563485|NCT07154017|OTHER|Combination of Movement Representation Techniques with neural mobilization exercises|The experimental intervention will be an exposition of movement representation techniques in an established sequential order, consisting of action observation, implicit/explicit motor imagery and visual feedback with a mirror in combination with neural mobilization exercises.
214707962|NCT02999880|PROCEDURE|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
214707963|NCT00221429|DRUG|Lithium|lithium
214707964|NCT00221429|DRUG|sodium divalproex|Depakote
214707965|NCT00221429|OTHER|Placebo|Placebo
215166188|NCT07193264|OTHER|Caffeine (200 mg)|Participants receive a single oral dose of 200 mg caffeine under fasting conditions. Blood samples are collected before and three hours after intake to evaluate effects on hematopoietic stem and progenitor cells, including mobilization, function, gene expression, and metabolism.
215166189|NCT07194837|DEVICE|diode laser|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each.
214563486|NCT07154017|OTHER|Neural mobilization exercises|The control intervention will consist in three series of active neural mobilization exercises
214563487|NCT07155226|DRUG|AZD3632|AZD3632 will be administered orally.
214563488|NCT07155226|DRUG|Posaconazole|Posaconazole will be administered orally.
214563489|NCT07155330|DEVICE|High-flow nasal cannula|Using high-flow nasal cannula oxygenation
214563490|NCT07153861|PROCEDURE|Oral mucosal graft|Patients will be admitted for the surgical management by the oral mucosal graft urethroplasty with the anterior onlay technique.
214563491|NCT07153861|PROCEDURE|Labial graft|Patients will be admitted for the surgical management by the labial graft urethroplasty with the anterior onlay technique.
214563492|NCT07154602|OTHER|3D printed hybrid resin ceramic crowns|3D printed hybrid resin ceramic crowns in anterior and premolar maxillary teeth
214563493|NCT07154602|OTHER|milled hybrid resin ceramic crown|milled hybrid resin ceramic crown on implants in anterior and premolar maxillary teeth
214563494|NCT07154173|PROCEDURE|Biospecimen Collection Procedure|Collection of fecal samples from healthy volunteers, non-metastatic (M0) and metastatic (M1) colorectal cancer patients. Additionally, collection of tissue samples during surgery from operable patients (M0 and M1) for subsequent research analysis.
214563495|NCT07153978|DEVICE|Effectivity of TFL on large renal stone|While literature studies on TFL have focused on the effect of stone size on laser efficacy parameters, the present study is important as it is a prospective study examining the effects of TFL lithotripsy on SFRs in stones \>1000 mm3.
214563496|NCT07155005|DEVICE|CVAC® SYSTEM|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
214563497|NCT07155005|DEVICE|FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)|Group/Cohort Description: FANS is designed to incorporate suction to facilitate stone fragment removal through its lumen and is used with a separate ureteroscope. FANS is fitted with a Y connector with a pressure control vent and connects to a standard vacuum device. A separate ureteroscope provides direct visualization and irrigation and a separate specimen collector captures stone debris.
214707966|NCT04164329|DRUG|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
214707967|NCT05996380|DRUG|SHR-3167|SHR-3167, Single administration
214707968|NCT05996380|DRUG|SHR-3167 Placebo|SHR-3167 Placebo Single administration
214707969|NCT00456794|DRUG|Istradefylline (KW-6002)|
214707970|NCT01108562|DRUG|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
214707971|NCT01108562|OTHER|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
214707972|NCT04801394|PROCEDURE|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
215166190|NCT07194837|OTHER|Calcium Hydroxide (Ca(OH)2)|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
214707973|NCT00110578|PROCEDURE|Adoptive transfer of HIV-specific CD8+ T cells|
215166191|NCT07192341|DRUG|Sacubitril/Valsartan|Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].
215166192|NCT07192341|DRUG|Conventional anti-heart failure therapy|Patients will be treated only with conventional anti-heart failure therapy as a control group.
215166193|NCT07193199|DEVICE|Revanesse Sculpt+|Revanesse Sculpt+ is approved and commercially available for use in Canada and is manufactured by Prollenium Technologies Inc. All study participants will receive Revanesse Sculpt+ for the treatment of mild to severe chin retrusion.
215166194|NCT07190885|DRUG|YN001|YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).
215166195|NCT07190339|PROCEDURE|ultrasound-guided femoral and obturator nerve articular branches pulsed radiofrequency|"Hemodynamic monitoring is provided. The hip joint where the procedure will be performed is cleaned with povidone-iodine. Sterile draping is performed. For PRF application to the articular branches of the femoral nerve, a convex ultrasound probe is first used to locate the articular branches of the femoral nerve in the groin area, followed by the articular branches of the obturator nerve. The radiofrequency cannula is inserted sequentially into the target points and sensory feedback is obtained. Then, a pulsed radiofrequency current, which has therapeutic properties for chronic pain and does not damage tissues by exceeding a temperature of 42 degrees, is applied to the relevant nerve root for 240 seconds. Subsequently, an injectate consisting of 2 cc of 5% bupivacaine, 4 mg of dexamethasone, and 2 cc of physiological saline is administered to the same nerve.~Translated with DeepL.com (free version)"
215166196|NCT07193004|BEHAVIORAL|Quality of Life|"Measures - We will use the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to assess QoL, Mini-Montreal Cognitive Assessment (Mini-MoCA) to assess cognitive function, the Clinical Frailty Scale (CFS) to assess frailty status, and life expectancy estimation by the heart team to categorize patients as having: 1-2 years expected survival or more than 2 years expected survival (This will allow for an analysis of how life expectancy correlates with QoL improvements after TAVI).~Assessment Timeline - Patients will be assessed at four key time points: at time of referral (baseline assessment), pre-procedure (to assess impact of delay on the patient), 30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVI (longer-term follow-up to evaluate sustained QoL changes). At each time point, the KCCQ-12, Mini-MoCA, and Clinical Frailty Scale (CFS) will be administered."
215166197|NCT07194642|OTHER|Dexcom G7 CGM|The Dexcom G7 is a continuous glucose monitor, FDA 510K cleared (K213919) for people with diabetes. Worn for 10 days at a time, the device monitors the glucose levels of interstitial fluid and, via bluetooth, transmits data every 5 minutes to a receiver.
215166198|NCT07196267|DEVICE|Extracorporeal Shockwave Therapy|Delivered using Shock Master (Master Plus MP200, STORZ Medical AG, Switzerland). Applied at 7 Hz frequency, 2.5-3 bar pressure, for 15 minutes per session, 3 times per week for 8 weeks. Target: supraspinatus tendon region. Applied after Cryoflow therapy in experimental group.
215166199|NCT07196267|DEVICE|Cryoflow Therapy|Delivered using Cryoflow 1000IR (Model ICE-CT, EC). Applied at 14°C for 15 minutes per session, 3 times per week for 8 weeks. Applied directly over rotator cuff tendon region before ESWT in experimental group.
215166200|NCT07196267|BEHAVIORAL|Traditional Physical Therapy Program|tretching of shoulder flexors/adductors/internal rotators Strengthening of shoulder extensors/external rotators Weight-bearing exercises (sitting \& quadruped) Neuromuscular Facilitation (PNF) for upper limb Hand dexterity training using Purdue Pegboard
215166201|NCT07196267|DEVICE|Placebo ESWT and Cryoflow|Identical device setup as active ESWT and Cryoflow, but with energy delivery disabled (no acoustic pulses, no cold air output). Applied for 15 min each, mimicking active treatment to maintain blinding where possible. Used in control group alongside traditional PT.
215166202|NCT07192874|OTHER|MyMedDiary|myMedDiary is a HIPAA-compliant, researcher-configurable mobile and web-based application designed for real-time dietary, symptom and lifestyle data collection. It was utilized to collect dietary data in an IRB-approved study at Seattle Children's Hospital evaluating the dietary cost burden of gluten-free foods in pediatric patients with celiac disease (submitted for publication). The application enables participants to log meals using barcode scanning, keyword search, and manual entry, including recipe-level data. The backend system stores encrypted data securely in Microsoft Azure, and dietary entries are automatically converted to nutrient data using a standardized reference system. Researchers access de-identified participant data and analytics through a secure online dashboard. The system supports multicenter trials.
215166203|NCT07192874|OTHER|Feedback on Gluten Exposure|The MyMedDiary Application will provide feedback on potential gluten exposure when participants input dietary record information into the application.
215166204|NCT07193719|PROCEDURE|End-expiratory lung volume optimization maneuver with PEEP titration|PEEP titration (incremental/decremental) will be performed to optimize lung volume after surgery and find levels of PEEP corresponding to the best lung compliance. Typically PEEP levels between 10-20cmH2O will be applied based on individual response of patients' lung mechanics. Tidal volume will be kept constant at 6ml/kg in both arms. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate.
215166205|NCT07193719|PROCEDURE|Standard Care (in control arm)|Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O.
215166206|NCT07193472|PROCEDURE|serratus intercostal plane block as analgesic technique|the SIPB will be applied after starting surgery and before general anaesthesia
214707974|NCT00110578|DRUG|Aldesleukin|
214707975|NCT01823770|DRUG|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
214563498|NCT07155005|DEVICE|DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)|DISS is a system that integrates controlled suction into the working channel of a standard flexible ureteroscope during ureteroscopic lithotripsy. A suction adapter is attached externally to the ureteroscope's working port, which connects to a standard hospital suction source.
215166207|NCT07193173|OTHER|2 minute step test|The 2-Minute Step Test (2MST) is a simple, validated field test used to assess aerobic endurance and functional fitness, especially in older adults or people with chronic conditions (e.g., cardiopulmonary disease, neurological disorders).
214563499|NCT07155005|PROCEDURE|URETEROSCOPY (URS) WITHOUT SUCTION|URS allows the surgeon to visualize the stone by inserting the ureteroscope into the ureter, most often a flexible scope that allows them to accommodate to the shape of the ureter and renal collecting system. A laser fiber is advanced through the working channel of the ureteroscope to perform stone fragmentation (dusting or breaking up the calculi). Once the stones are dusted or fragmented, the pieces can be removed by active extraction of individual stone fragments using a retrieval basket or using the concept of stone dusting where the fragments are small enough to be passed after the procedure.
214563500|NCT07155005|PROCEDURE|PERCUTANEOUS NEPHROLITHOTOMY (PCNL)|This is a surgical procedure under general anesthesia, where a rigid probe is placed through the flank, creating a percutaneous tract into the renal collecting system under fluoroscopy. Via nephoscopy, stones are fragmented, pulverized, and extracted.
214563501|NCT07153679|DEVICE|1064-nm Nd:YAG Picosecond Laser|Treatment was performed using 1064 nm Nd:YAG microlens array picosecond laser (Picocare 450, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
214563502|NCT07153679|DEVICE|1927-nm Fractional Thulium Laser|Treatment was performed using 1927-nm thulium fractional laser (Lavieen, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
214707976|NCT01823770|DRUG|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
215166208|NCT07195747|DIAGNOSTIC_TEST|Creatinine|Renal Function Follow-Up for 5 years
215166209|NCT07196540|COMBINATION_PRODUCT|Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab|radiotherapy + rmhTNF-NC + tislelizumab
215166210|NCT07195708|DEVICE|Treatment group|The treatment group was the group with the placement of Orbera 365 plus lifestyle management
215166211|NCT07197190|PROCEDURE|Autologous augmentation mastopexy with subpectoral lipofilling and upper and medial pole fat grafting.|"The term 'internal bra' refers to a range of techniques that aim to stabilise the position of the breast and improve longevity of surgical results. In this study, we address one of them which is dermal flap technique. Dermal flaps have two key advantages, the first of which is that they are low cost due to their autologous nature. The fact that they utilise the patient's own tissue also means they are not associated with an increased risk of infection or immunological reaction, which is their second main advantage, But it has some drawbacks on the long term, such as upper pole hollowness and lack of breast parenchymal tissue to give a good breast volume.~In this research, we used the autogenous internal BRA mastopexy technique for correction of breast ptosis and sub pectoral lipofilling to help increase the breast volume and subcutaneous fat grafting to give the breast upper pole fullness."
215166212|NCT07196150|BEHAVIORAL|Exercise Program|Participants will complete an 8-week supervised exercise program, delivered twice per week. The program includes lumbopelvic stabilization, stretching, and endurance training exercises designed to reduce menstrual pain and improve physical function.
215166213|NCT07196150|BEHAVIORAL|Exercise plus Motor Imagery Training|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will practice kinesthetic motor imagery of the prescribed movements prior to performing them, aiming to enhance motor control and pain modulation.
215166214|NCT07196150|BEHAVIORAL|Exercise plus Pain Neuroscience Education|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will receive weekly face-to-face pain neuroscience education sessions focused on pain neurophysiology, supported with home assignments to reinforce learning.
215166215|NCT07196943|DEVICE|Fully guided static computer-assisted implant surgery (CAIS) for mandibular overdentures using Equator® attachments|Mandibular edentulism will be rehabilitated with implant-supported overdentures using a fully guided static computer-assisted implant surgery (CAIS) protocol. Each patient will receive four implants placed in a quadrilateral configuration (lateral incisor and first premolar regions) under a stereolithographically manufactured surgical guide. Following 3-4 months of osseointegration, definitive mandibular overdentures will be fabricated and retained exclusively with Equator® attachment systems (Rhein 83, Bologna, Italy). Patients will be followed for 3 years to assess implant survival, peri-implant soft tissue health, and marginal bone changes.
215166216|NCT07196527|DEVICE|Puressentiel Allergy Protection Nasal Spray|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
214563503|NCT07154056|DEVICE|Lead(s) and Implantable Pulse Generator implantation|8-contact lead(s) will be radiologically positioned within the spinal foramen under awake anesthesia in order to optimize paresthesia coverage. Awake anesthesia will allow patients to be tested during the surgery in order to determine the sweet spot and the optimal paresthesia coverage using the PREDI-P platform for a single lead. A trial phase will be performed for a period of 7 days in order to assess the benefits of stimulation according to the HAS (French Health Authority) guidelines. Subjects who succeed the lead trial will receive a permanent implant depending on the patient electrical consumption during the lead trial period or according to the implanter decision.
214563504|NCT07153770|DRUG|Bozitinib|Participants will receive bozitinib in combination with standard platinum-based doublet chemotherapy for 8 weeks. Following investigator-assessed operability, surgical resection will be performed approximately 4 weeks after completion of neoadjuvant therapy. The first MRD assessment will be conducted after completion of neoadjuvant therapy and before surgery.A second MRD assessment will be performed within 7 days to 1 month after surgery. Based on a comprehensive evaluation of MRD status, tumor markers, and imaging results, if molecular abnormalities are detected., patients will receive bozitinib within 3 months after surgery. If CEA remains within the normal range and blood cfDNA-MRD is negative, patients will enter a regular follow-up program, with MRD assessments every 3 months during the first 2 years and every 6 months from years 3 to 5. If MRD conversion to positive, abnormal CEA, or abnormal CT findings occur within 5 within 5 years, bozitinib will be administered.
214563505|NCT07153445|DRUG|Atezolizumab|Patients will receive atezolizumab administered by intravenous infusion in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
214563506|NCT07153445|DRUG|Paclitaxel|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Paclitaxel: Intravenous infusion.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
214563507|NCT07153445|DRUG|Carboplatin|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin\*~\*Infusion according to the standard of each center~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Carboplatin: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
214563508|NCT07153835|DRUG|Paliperidone extended-release (ER)|Paliperidone extended-release (ER) tablets will be administered orally once daily at flexible doses ranging from 6 mg to 12 mg, based on the clinical judgment of the treating psychiatrist. The treatment duration is 12 weeks. Dose adjustments may be made throughout the study period depending on patient response and tolerability.
214563509|NCT07153939|DEVICE|Velocity Percutaneous Arteriovenous Fistula|The Velocity pAVF is a catheter-based device used to create an arteriovenous fistula for hemodialysis access through a minimally invasive, percutaneous procedure. Unlike surgical AVF creation or other pAVF systems, Velocity is designed to simplify the procedure and improve consistency of maturation and long-term function. All participants in this study will undergo AVF creation using the Velocity pAVF.
214563510|NCT07154758|OTHER|Screening for need of HFrEF GDMT implementation through SwedeHF|Screening for need of HFrEF GDMT implementation through SwedeHF
214563511|NCT07154615|OTHER|Observational Only|No intervention is included in this study
214707977|NCT05100433|PROCEDURE|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
214707978|NCT05812937|PROCEDURE|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
214707979|NCT01188538|DRUG|Epiduo gel|Once daily application on the face in the evening for 12 weeks
214707980|NCT01188538|DRUG|BPO|Once daily application on the face in the evening for 12 weeks
214563512|NCT07154641|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer is a surgical procedure that aims to restore active range of motion and stability of the shoulder in patients with massive rotator cuff tears. The tendon of the latissimus dorsi muscle is dettached from its insertion in the midbicipital groove of the humerus and reattached to the greater tubetosity. Therefore, the muscle acts as an external rotator, while the forces created pull the humeral head down and stabilize it in the glenoid.
214563513|NCT07154641|PROCEDURE|Superior capsular reconstruction|Superior capsular reconstruction is a surgical procedure that aims to restore shoulder stability in patients with massive rotator cuff tears. The superior capsule of the shoulder joint is attached to the greater tuberosity and is therefore often torn in cases of supraspinatus or infraspinatus tears. A fascia lata autograft is used to reconstruct the torn capsule, between the greater tuberosity and the glenoid. Thus, superior migration of the humeral head is prevented, and pain and functionality are improved.
214563514|NCT07154719|DRUG|Tirzepatide|GLP-1 based treatment for obesity
214563515|NCT07154719|BEHAVIORAL|Lifestyle toolkit|2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
214563516|NCT07155486|OTHER|Interview|Interview
214563517|NCT07154134|DIAGNOSTIC_TEST|Serum endocan|Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
214563518|NCT07154134|DIAGNOSTIC_TEST|Serum copeptin|Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
214563519|NCT07154004|OTHER|Test Serum 897222 210|Repeated application
214563520|NCT07154004|OTHER|Test Serum 897222 212|Repeated application
214563521|NCT07154004|OTHER|Test Serum 897250 39|Repeated application
214563522|NCT07154004|OTHER|Test Serum 897250 102D|Repeated application
214563523|NCT07154004|OTHER|Test Serum 774569 67|Repeated application
214563524|NCT07155616|OTHER|Blood flow measurement|Intraoperative blood flow measurement
214563525|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Diagnostic Test: Periodontal Examination
214563526|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Periodontal Examination
214563527|NCT07156097|OTHER|Mediterranean-style Diet (SAFF)|Participants followed a 4-week Mediterranean-style dietary pattern (SAFF), characterized by high intake of vegetables, fruits, whole grains, olive oil, and lean protein sources. This arm served as a comparator for the boron-rich diet.
214563528|NCT07156097|OTHER|Boron-rich Diet|Participants assigned to this arm will follow a boron-rich dietary pattern for 4 weeks. The diet includes foods naturally high in boron (e.g., dried fruits, nuts, legumes, and boron-rich water). Daily dietary intake will be monitored and adjusted to ensure consistent boron exposure.
214563529|NCT06180642|OTHER|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
214563530|NCT06180642|OTHER|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
214563531|NCT04193826|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
214563532|NCT05718466|DRUG|Bevacizumab|
214563533|NCT05718466|DRUG|Chemotherapy|
214563534|NCT05718466|RADIATION|Fractionated radiosurgery|
214563535|NCT02159508|BEHAVIORAL|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
214563536|NCT00386282|DRUG|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
214563537|NCT04203095|DIAGNOSTIC_TEST|the level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs.
214563538|NCT06009484|PROCEDURE|Colon resection|Colon cancer resection
214563539|NCT03065257|PROCEDURE|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
214563540|NCT01109641|DEVICE|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
215166217|NCT07196527|DEVICE|Saline spray (0.65%)|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
215166218|NCT07197528|BEHAVIORAL|Experimental Arm：Smart-assisted rehabilitation exercise system Control Arm：Usual care or routine physical activity|"Interventions~Behavioral: Smart-assisted rehabilitation exercise system (KNEESUP) A wearable smart-assisted rehabilitation system providing personalized, progressive lower limb resistance training for elderly residents with sarcopenia in long-term care institutions. The system includes real-time monitoring, feedback, and remote adjustment by rehabilitation specialists. Unlike traditional programs, it integrates sensor technology to track knee joint angles and exercise performance, enabling precise and adaptive training.~Other: Usual care / routine physical activity Participants follow standard daily activities and rehabilitation provided by the long-term care facility, without the smart-assisted rehabilitation system."
215166219|NCT07196449|DRUG|Methotrexate|Methotrexate Tab. 2.5 mg (Korea United Pharm)
215166220|NCT07196449|DRUG|Rifampicin|Rifampin Cap. 150 mg (Yuhan Corporation)
215166221|NCT07196449|DRUG|Cyclosporine|Cypol-N Cap. 100 mg (Chong Kun Dang)
215166222|NCT07197762|BIOLOGICAL|Trumenba|"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains two lipidated factor H binding protein (fHbp) variants-A05 from subfamily A and B01 from subfamily B-delivered in a 0.5 mL prefilled syringe. Each dose includes 120 µg of protein (60 µg per variant), 0.018 mg polysorbate 80, and 0.25 mg aluminum as AlPO₄, formulated in histidine-buffered saline at pH 6.0.~A single intramuscular dose will be administered in the deltoid."
215166223|NCT07197762|BIOLOGICAL|PENBRAYA|"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. It consists of two components:~* A lyophilized MenACWY portion (polysaccharides conjugated to tetanus toxoid)~* A liquid MenB portion (two recombinant fHbp variants: A05 and B01) Each 0.5 mL dose contains 20 µg of polysaccharides (5 µg per serogroup), 44 µg tetanus toxoid, 120 µg of MenB protein (60 µg per variant), plus stabilizers and aluminum phosphate.~This will be administered intramuscularly in the deltoid."
215166224|NCT07196241|OTHER|Survey using a questionnaire.|Questionnaires regarding cancer treatment and follow-up care, fertility preservation, clinical trial participation, general information (education on health- related topics, gender, and sexual orientation, perceived needs for resources, support areas, programs and activities.), emotional health and interpersonal relationships, financial burden and mental health status.
215166225|NCT07196384|DEVICE|Spectroscopy system|System that measures the fluorescence intensity in tissue in vivo.
215166226|NCT07196384|DRUG|Nivolumab-800CW|Fluorescent tracer
215166227|NCT07196384|DRUG|Durvalumab-680LT|Fluorescent tracer
215166228|NCT07197541|DRUG|Bleomycin Injection|Bleomycin injection treatment group: local injection treatment, once every 4 weeks.
215166229|NCT07197541|DRUG|Pingyangmycin Injection|Pingyangmycin injection treatment group: local injection treatment, once every 4 weeks.
215166230|NCT07196280|DRUG|5-Alpha Reductase Inhibitors|Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.
215166231|NCT07196761|OTHER|Bowel care advice|"It includes: - Encourage adequate fiber intake (20 to 35 grams) each day.~* Avoid caffeine - containing foods and beverages~* Drink at least 1.5 to 2 liters of water/day~* Proper defecation position such as, sitting with knees higher than hips (use a foot stool or other flat, stable object if necessary) , lean forward and put elbows on knees, relax and bulge out the stomach and straighten the spine"
215166232|NCT07196761|DEVICE|Whole-body vibration|Crazy fit massager (made in China ) with platform surface size (65 cm X 35 cm ) base height 20 cm, heavy-duty motor wattage: 200 - 500 watts, will be used to provide whole body vibration for the participants in the experimental group, for 25 minutes, 3 times per week for 6 weeks.
214563541|NCT03203473|DRUG|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
214563542|NCT03203473|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
214563543|NCT06013553|OTHER|Control Group|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
214707981|NCT00654953|DRUG|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
214707982|NCT00654953|DRUG|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
215166233|NCT07197034|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 50 weeks
215166234|NCT07196072|BEHAVIORAL|MiPAL|MiPAL participants meet with a coach to co-develop a self-directed yoga practice based on individual preferences and limitations.
215166235|NCT07197502|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
215166236|NCT07196709|DEVICE|high-power laser acupuncture and the exercise program|The experimental group will receive high-power lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises
215166237|NCT07196709|DEVICE|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
215166238|NCT07196969|DEVICE|Electric toothbrush|Two minutes; twice a day; 3-months.
215166239|NCT07196969|DEVICE|Manual toothbrush|Two minutes; twice a day; 3-months.
215166240|NCT07196462|DEVICE|3 Minute iTBS to the L DLPFC|Five daily sessions of TMS (iTBS) to the L DLPFC target.
215166241|NCT07196462|DEVICE|One-Minute, Personalized, DMN Targeted CTBS|Personalized, DMN Targeted CTBS to the DMN for one minute, five daily sessions.
214563544|NCT06013553|OTHER|Aerobic Exercises group|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given"
214563545|NCT04666623|DRUG|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
214563546|NCT04666623|DRUG|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
214563547|NCT04492449|OTHER|congenital malformation|congenital malformation
214563548|NCT03247387|DEVICE|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
214563549|NCT03247387|DEVICE|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
214563550|NCT03247387|DEVICE|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
214563551|NCT02226861|DEVICE|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
214563552|NCT02226861|BIOLOGICAL|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
214563553|NCT05462158|BEHAVIORAL|Impact of Nudges on CKD Testing|The investigators will examine the impact of different messages on different dimensions of testing for CKD
214707983|NCT00654953|DRUG|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
215166242|NCT07196592|BEHAVIORAL|Olfactory stimulation|"Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
214707984|NCT00489372|DRUG|Se-methyl-seleno-L-cysteine|Given orally
214707985|NCT00489372|OTHER|placebo|Given orally
214707986|NCT00489372|OTHER|pharmacological study|Correlative studies
214707987|NCT00489372|OTHER|laboratory biomarker analysis|Correlative studies
215166243|NCT07196592|BIOLOGICAL|Temporal Interference,TI|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region."
214563554|NCT04420949|BEHAVIORAL|Sensory re-weighting|During training, sensory re-weighting is driven by priming upregulation of somatosensory cues. Two rounds of training, each lasting 15 minutes and block-randomized in sets of 10 trials, are conducted per training visit. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity. Immediate auditory and non-orienting, visual feedback is provided after each trial. A staircase method is used to adapt the level of difficulty based on response accuracy. After two consecutive correct responses, the difficulty increases. After each incorrect response, the difficulty decreases. This process is repeated in each round.
214563555|NCT01718808|DRUG|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
215166244|NCT07196592|COMBINATION_PRODUCT|Olfactory-TI Stimulation|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region.~Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
215166245|NCT07196592|COMBINATION_PRODUCT|Sham Control|"During stimulation, the parameters were set as follows:~Δf=0Hz (2000Hz vs. 2000Hz) 2mA Stimulation duration: 20min.~Olfactory stimulation were set as follows:~Essential oil types: air. lasting 20 minutes."
215166246|NCT07196956|DEVICE|Low-Frequency Electromagnetic Field Therapy (0.5 Hz)|Active electromagnetic field therapy delivered via a PMT Quattro PRO device (Italy, 2002). Settings: 0.5 Hz frequency, 30 mA intensity, applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with a standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training).
215166247|NCT07196956|DEVICE|Placebo Electromagnetic Field Therapy|identical-appearing electromagnetic therapy device with no active field output (placebo/sham). Applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with the identical standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training) as the active EMT group.
215166248|NCT07197749|DRUG|Vitamin C (Ascorbic Acid)|"All patients enrolled on this trial will receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Patients will be treated with intravenous (IV) or oral (PO) vitamin C depending on the severity of symptoms, ability to tolerate PO intake, and location of treatment (inpatient versus outpatient setting): IV dosing:~50 mg/kg/day divided TID (max 4 grams total/day) PO dosing: 500 mg BID or 1000 mg daily (depending on the prescribed formulation)~Vitamin C will be administered through day 56 from start of vitamin C treatment. Patients initially receiving IV administration may be transitioned to PO formulation once tolerating PO intake; per treating physician discretion."
215166249|NCT07196332|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
214563556|NCT01718808|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
214563557|NCT03788603|DRUG|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
214563558|NCT01325311|DRUG|Cholecalciferol|Given PO
214563559|NCT01325311|DRUG|Genistein|Given PO
214563560|NCT01325311|OTHER|Laboratory Biomarker Analysis|Correlative studies
214563561|NCT01325311|OTHER|Pharmacological Study|Correlative studies
214563562|NCT01325311|OTHER|Placebo|Given PO
214563563|NCT06188897|OTHER|Self-stretching of the masticatory musculature|"If the subject belonged to the Treatment group, he was instructed to self-stretch the masticatory muscle.~This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting."
214563564|NCT06188897|OTHER|Control group intervention|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
214563565|NCT04270591|DRUG|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
214563566|NCT01980680|DRUG|hCG|
214563567|NCT01980680|DRUG|Progesterone and Estradiol|
214563568|NCT01788553|OTHER|remission prevalence of generalized anxiety disorder|
214563569|NCT01696552|PROCEDURE|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
214563570|NCT01696552|PROCEDURE|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
214563571|NCT00023296|DRUG|Nitric Oxide|
214563572|NCT00023296|DEVICE|INO Pulse - NO Delivery System|
214563573|NCT00568178|DRUG|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
214563574|NCT00568178|OTHER|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
214563575|NCT00568178|DRUG|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
214563576|NCT00568178|OTHER|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
215166250|NCT07196332|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. Treatment begins with learning how to alternately tense and relax 14 major muscle groups, and then to use progressively more efficient tensing-relaxing and passive relaxation exercises, with sessions used to teach techniques and problem-solve barriers to its daily use.
215166251|NCT07195929|OTHER|Allergenic Extract|In each subject, a drop of each of the 3 concentrations of the allergenic extract, in addition to the positive control (histamine) and the negative control, will be applied. The application will be duplicated on the subject's anterior forearm, with a distance of approximately 4 cm between each application to avoid overlapping reactions and false-positives results.
215166252|NCT07195838|BEHAVIORAL|Hybrid Mindfulness-Based Group Sessions|Eight 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. The sessions cover topics such as the eight yoga's ethical guidelines (yamas and niyamas) for positive lifestyle behaviors, breathing mechanisms, dysfunctional breathing styles, voluntary control of breathing (pranayama), relaxation and sense withdrawal (pratyahara), concentration (dharana), meditation (dhyana), and enlightenment (samadhi). Subsequent sessions will be delivered via videoconferencing using Zoom and will include guided breathing-focused practices.
215166253|NCT07195838|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Personalised mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period. The intervention protocol will cover message content library, regular message delivery and personalised chat-based support.
215166254|NCT07195838|BEHAVIORAL|Single General Education on Pulmonary Rehabilitation and Lifestyle Modification Group|The control group participants will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification based on the GOLD 2024 teaching set and HEARTS technical package for NCD prevention as recommended by the WHO.
215166255|NCT07195838|DEVICE|Activity Monitoring|All participants will wear a wristband activity tracker to monitor their physical activity in daily life.
215166256|NCT07196371|BEHAVIORAL|Aerobic Training with Blood Flow Restriction|"Participants will undergo a 6-week aerobic training intervention with blood flow restriction applied to the lower limbs.~Blood flow restriction will be applied using a blood pressure cuff set between 60-80% of limb arterial occlusion pressure.~Training will consist of treadmill walking at 40-50% of heart rate reserve (HRR) for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
215166257|NCT07196371|BEHAVIORAL|Standard Aerobic Training|"Participants will follow the same aerobic training protocol as the AT+BFR group but without blood flow restriction.~Training will consist of treadmill walking at 40-50% of HRR for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
215166258|NCT07197112|DRUG|Gecacitinib|Administer 50 mg twice daily for a minimum of 28 days.
215166259|NCT07196826|PROCEDURE|Active Aquatic Therapy|Active Aquatic Therapy involves structured, therapist-guided exercises in a heated hydrotherapy pool (32-34°C). Water buoyancy and resistance reduce spinal load, facilitate movement, and enhance muscle activation. Sessions last 45-60 minutes, 3 times per week for 4 weeks, supervised by licensed physiotherapists. Each session includes warm-up (water marching, arm swings, trunk rotations), main exercises (lumbar spine function, core strengthening, balance, hip abduction, back extensions, aqua walking, arm/leg strengthening), and cool-down (floating, deep breathing, passive stretches). Intensity is monitored using the Borg RPE scale (60-80% max HR). This intervention uniquely uses active engagement in water to reduce pain and improve strength, flexibility, and function, distinguishing it from passive aquatic therapy and land-based physiotherapy.
214563577|NCT00568178|OTHER|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
214563578|NCT00568178|DRUG|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
214563579|NCT00350597|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
214707988|NCT02174783|OTHER|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
215166260|NCT07196826|PROCEDURE|Passive Aquatic Therapy|Passive Aquatic Therapy (Watsu) is a therapist-guided, passive aquatic technique performed in a warm hydrotherapy pool (35°C). The patient floats while the therapist gently moves their body in rhythmic, synchronized patterns, providing massage, stretching, joint mobilization, and acupressure. Sessions last 45-60 minutes, 3 times per week for 4 weeks, and include preparation/floating, cradling with passive movements, passive stretching and mobilization, acupressure, and final relaxation. Neck and knee supports are used for comfort. This intervention uniquely emphasizes passive relaxation and gentle mobilization, making it suitable for patients with severe movement limitations, distinguishing it from active aquatic therapy and conventional land-based physiotherapy.
215166261|NCT07196826|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy is a land-based intervention for chronic low back pain, delivered in an outpatient physiotherapy clinic. Sessions last 45 minutes, 3 times per week for 4 weeks, and include hot pack application (10-12 min) to reduce stiffness, electrotherapy (TENS/Interferential, 15 min) for pain modulation, and supervised therapeutic exercises (15-20 min) focusing on lumbar mobility, core stability, and spinal strengthening. Exercises include William's flexion, prone press-ups, cat-cow mobilization, hamstring stretches, pelvic tilts, and abdominal bracing. This intervention emphasizes pain reduction, postural control, and strengthening deep abdominal and paraspinal muscles, distinguishing it from passive and active aquatic therapies, and serves as the standard comparator in this crossover study.
215166262|NCT07196358|OTHER|Standard dressing|Intervention Description: Donor site of STSG treated with standard dressing. Wound is cleaned, paraffin gauze applied, covered with gauze pieces and bandaged. Dressing is removed on the 10th post-operative day, or earlier if excessive exudate is present. Pain and wound healing monitored per standard care protoco
215166263|NCT07196358|OTHER|Topical Heparin Dressing|Intervention Description: Donor site of STSG treated with heparin dressing. 5 ml of 5000 IU/ml heparin is diluted in 50 ml normal saline to produce 500 IU/ml concentration. Gauze is soaked in this solution and applied to donor site immediately after graft harvest. Dressing remains in place until 10th post-operative day unless clinical indication requires earlier change. Pain, wound healing, and hypertrophic scarring assessed during follow-up.
214563580|NCT01355861|BEHAVIORAL|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
214563581|NCT01364792|DRUG|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
215166264|NCT07197671|DRUG|90Y-NM600|NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity
215166265|NCT07196098|OTHER|Slow tempo music|Slow tempo music will be played 15 minutes before and during intravitreal injection.
215166266|NCT07197710|OTHER|video-guided acupuncture imagery treatment (VGAIT)|Unlike traditional acupuncture, VGAIT can be self-administered and does not require physical needle insertion, making it a practical alternative for patients seeking non-invasive pain management.
215166267|NCT07197710|OTHER|Education video|Education video about postoperative precautions
215166268|NCT07196774|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
215166269|NCT07196774|DRUG|Docetaxel injection|Docetaxel injection.
215166270|NCT07196774|DRUG|Trastuzumab Injection|Trastuzumab injection.
215166271|NCT07196774|DRUG|Carboplatin for Injection|Carboplatin for injection.
215166272|NCT07196774|DRUG|Pertuzumab Injection|Pertuzumab injection.
215166273|NCT07196202|OTHER|Laid-Back position training|This intervention is a structured training session for pregnant woman on the use of the laid-back breastfeeding position after birth. The training is designed to be delivered in a single, standardized session by the researcher during the last trimester of pregnancy to be applied within the first 24 hours post-cesarean delivery.
215166274|NCT07196202|OTHER|Standard Postpartum Care|Postpartum mothers who receive structured training and support on the laid-back breastfeeding position
215166275|NCT07195786|PROCEDURE|Expansion-floating Craniotomy|Following craniotomy with bone flap removal, cerebral edema is assessed. The bone flap is then elevated using 2-3 titanium connectors. The elevation height must be sufficient to at least prevent contact between the bone flap and the underlying brain tissue. If cerebral swelling proves less severe than anticipated or begins to subside, the connectors can be loosened minimally invasively after a maximum scalp expansion period of 7-10 days. The elevated bone flap gradually repositions itself. Mild compression is applied using an elastic bandage for fixation, thereby restoring cranial integrity.
215166276|NCT07195786|PROCEDURE|decompressive craniectomy|The patient is placed supine with the head rotated contralaterally. A large retroauricular question-mark incision is made in the scalp. Alternatively, a Kempe incision or preauricular incision may be used according to surgeon preference. Meticulous preservation of the superficial temporal artery (STA) is essential during the procedure to prevent ischemic complications in the flap. After elevating the myocutaneous flap to expose the operative field, a fronto-temporo-parietal craniectomy is performed. For unilateral decompressive craniectomy, the bone window should measure at least 15 × 12 cm, extending inferiorly to the floor of the temporal fossa to ensure adequate decompression.
215166277|NCT07195786|DRUG|drug conservative therapeutic|Pharmacotherapy for malignant cerebral edema has been implemented according to current guidelines.
215166278|NCT07196553|DEVICE|Ultrasound|ultrasound examination
215166279|NCT07196059|DIETARY_SUPPLEMENT|Delphinol|Contains maqui berry powder
215166280|NCT07196059|DIETARY_SUPPLEMENT|Placebo|Contains cellulose
215166281|NCT07195812|DRUG|Dual Antiplatelet (DAPT) Therapy|aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days
214563582|NCT00080353|DRUG|IL-2|
214563583|NCT00080353|DRUG|gp100:209-217|
214563584|NCT00080353|DRUG|OKT3|
214563585|NCT00080353|DRUG|rF-go 100P209|
214563586|NCT00080353|DRUG|Montanide ISA 51|
214563587|NCT04601675|DRUG|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
214563588|NCT04601675|DRUG|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
214563589|NCT02808078|DEVICE|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
215166282|NCT07195812|DRUG|Rivaroxaban|Rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily plus clopidogrel 75 mg daily for 30 days
214563590|NCT02808078|DEVICE|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
214563591|NCT02201615|OTHER|Perineal massage in childbirth|
214563592|NCT03919604|PROCEDURE|Extracorporeal Life Support|Any extracorporeal blood treatment technique for respiratory and/or cardiac support
215166283|NCT07197645|DRUG|153Sm-DOTMP|TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.
215166284|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+®|Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
215166285|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+® with semaglutide|Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.
215166286|NCT07197840|DEVICE|Numen SILK coil embolization system|The Numen SILK coil embolization system is designed to be used in conjunction with the NumenFR detachment system. It consists of two main parts: • Introducer Sheath: The purpose of this sheath is to facilitate the introduction of the coil into the microcatheter. • Coil System: Composed of the pusher and coil implant. The coil is a permanent implant intended to occlude blood flow in vascular abnormalities. The pusher is used to deliver the coil implant to the target lesion. The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries
215166287|NCT07195669|DRUG|Suzetrigine (SUZ)|Used in the course of acute post-operative pain following oral and maxillofacial surgeries
215166288|NCT07195669|DRUG|Norco|Its standard of care
215166289|NCT07196722|DRUG|Icotrokinra|Icotrokinra will be administered orally, daily.
215166290|NCT07196722|DRUG|Placebo|Matching placebo will be administered orally, daily.
215166291|NCT07195903|DEVICE|Angioplasty or stenting|Jugular Vein Stenting
215166292|NCT07197567|DRUG|Sevoflurane + Remifentanil|Combination of an inhalational anesthetic (sevoflurane) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
214563593|NCT04292353|OTHER|Cognitive tests and Patient Reported Outcome|
214563594|NCT06097351|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
214563595|NCT01695252|OTHER|MEMOS|Patient informed clinical outcomes supervision
214563596|NCT01914601|DEVICE|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
214563597|NCT01914601|DEVICE|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
214563598|NCT00008359|DRUG|caspofungin acetate|
214563599|NCT00008359|DRUG|liposomal amphotericin B|
214563600|NCT06088459|BIOLOGICAL|1mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
214563601|NCT06088459|BIOLOGICAL|4mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
214563602|NCT06088459|BIOLOGICAL|8mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
214707989|NCT02174783|OTHER|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
215166293|NCT07197567|DRUG|Propofol + Remifentanil|Combination of an intravenous anesthetic (propofol) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for induction and maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
215166294|NCT07197567|DRUG|Sevoflurane + Propofol + Remifentanil|Combination of an inhalational anesthetic (sevoflurane), an intravenous anesthetic (propofol), and an intravenous opioid analgesic (remifentanil). These agents are routinely used together in clinical practice for combined intravenous-inhalational anesthesia (CIVIA). All drugs are administered according to standard of care, not as experimental interventions.
215166295|NCT07196410|BIOLOGICAL|KAN-004|Each dose of KAN-004 contains a consortium of bacteria isolated from the stool of healthy donors formulated as a powder in a capsule intended for oral administration
215166296|NCT07198919|DRUG|Chlorhexidine gel|0.12% Chlorhexidine gel (Consepsis Ultradent)
215166297|NCT07198919|DRUG|Nitrofurantoin 100 MG|Nitrofurantoin Tablets 100mg
215166298|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Placebo Product (PP)|1 capsule (placebo)
215166299|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Active Control (AC)|1 capusle (melatonin)
215166300|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Test Product (TP)|1 capsule (valerian root extract)
215166301|NCT07200063|OTHER|nano silver mouthwash|nano silver mouthwash will reduce the side effect of chlorhexidine and increase acceptance of the mouthwash to patients
215166302|NCT07200063|OTHER|Chlorhexidine mouthwash (0.12%)|the concentration of chlorhexidine
215166303|NCT07200063|OTHER|Chlorhexidine mouthwash (0.2%)|chlorhexidine mouthwash 0.2% (orovex )
215166304|NCT07200154|DRUG|Adebrelimab with concurrent chemoradiotherapy|Adebrelimab combined with chemotherapy and concurrent radiotherapy, followed by maintenance therapy with Adebrelimab until disease progression or intolerable toxicity, for up to 2 years.
214563603|NCT04334200|BEHAVIORAL|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
214563604|NCT04422327|DIETARY_SUPPLEMENT|Probiotic capsule|"Each probiotic capsule contains 5 x 10\^8 CFU B. longum 35624® and 5 x 10\^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
214563605|NCT01695031|BEHAVIORAL|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
214563606|NCT01695031|BEHAVIORAL|Generic web-based education|Generic, web-based asthma education
214563607|NCT03745911|COMBINATION_PRODUCT|Paclitaxel and TAK-228|Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
214563608|NCT03240705|BEHAVIORAL|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
214563609|NCT03103984|OTHER|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
214563610|NCT00678431|DIETARY_SUPPLEMENT|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
214563611|NCT00678431|DIETARY_SUPPLEMENT|Placebo|Liquid placebo
215166305|NCT07200141|RADIATION|GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant long course radiotherapy using VMAT or IMAT with daily image guided.~Gross tumor volume (GTV): A total dose of 58.75Gy delivered in 25 fractions using a simultaneous integrated boost approach; CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f ; Lateral lymph node（GTVnd2）：60Gy/25f;"
215166306|NCT07200141|RADIATION|GTV 50 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant radiotherapy with GTV 50 Gy in 25 fractions , delivered with IMRT or VMAT technique.~CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f; Lateral lymph node（GTVnd2）"
215166307|NCT07200141|DRUG|Concurrent Chemotherapy|Concurrent administration of capecitabine (825 mg/m² twice daily, 5 days per week) or XELOX regimen during radiotherapy.
215166308|NCT07200141|PROCEDURE|Total mesorectal excision (TME) surgery or non-operative management|"After treatment, patients will undergo restaging and proceed to total mesorectal excision (TME) or non-operative management (watch-and-wait) depending on response and clinical assessment."
215166309|NCT07198269|DEVICE|Intelligent emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
214563612|NCT01813877|RADIATION|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
214563613|NCT00902928|DRUG|YM150|oral
214563614|NCT00902928|DRUG|enoxaparin|SC injection
214563615|NCT04799743|DRUG|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
214563616|NCT04799743|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
214563617|NCT06151028|OTHER|No intervention|This is an observational study and did not involve interventions.
214563618|NCT06126003|OTHER|Observation|No Intervention
214563619|NCT01242579|DRUG|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
214707990|NCT02174783|OTHER|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
214563620|NCT01242579|DRUG|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
214563621|NCT01242579|DRUG|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
214563622|NCT01242579|DRUG|Matching Placebo Gel|Matching placebo gel containing 2.5g
214563623|NCT04523389|BIOLOGICAL|analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
214707991|NCT01231607|DRUG|1mg Finasteride active|1mg finasteride active, by mouth once daily
214707992|NCT01231607|DRUG|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
214707993|NCT01231607|DRUG|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
214563624|NCT04523389|OTHER|Gathering additional information about the patient's cancer|Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
214563625|NCT04523389|DIAGNOSTIC_TEST|Diagnostic test|Diagnostic test
214563626|NCT01010347|PROCEDURE|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
214563627|NCT01010347|PROCEDURE|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
214563628|NCT00220051|DRUG|Oxaliplatin, Capecitabine|
214563629|NCT00220051|PROCEDURE|Pre operative radiotherapy|
214563630|NCT00220051|PROCEDURE|Surgical Resection|
214563631|NCT01008553|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
214563632|NCT01008553|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
214563633|NCT05894395|BIOLOGICAL|MMR booster vaccination (as M-M-R-VaxPro)|a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine
214563634|NCT00130260|BIOLOGICAL|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
214563635|NCT00130260|BIOLOGICAL|placebo|placebo to match StaphVAX
214563636|NCT01681901|PROCEDURE|ultrasound imaging|Undergo ultrasound
214707994|NCT01231607|DRUG|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
214707995|NCT01231607|DRUG|Finasteride placebo|finasteride placebo, by mouth once daily
214707996|NCT01231607|DRUG|Dutasteride placebo|dutasteride placebo, by mouth once daily
214563637|NCT04998760|DRUG|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
214563638|NCT04998760|DRUG|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
214563639|NCT05671627|DRUG|DMARDs|Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
214563640|NCT02807935|DEVICE|Optical coherence tomography imaging|
214707997|NCT05460650|BEHAVIORAL|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
214707998|NCT03213483|PROCEDURE|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
214707999|NCT03213483|PROCEDURE|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
214708000|NCT04320277|DRUG|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
214563641|NCT00847925|DRUG|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
214563642|NCT03823157|BEHAVIORAL|Tai Chi|mind-body exercise
214563643|NCT03733990|BIOLOGICAL|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
214563644|NCT01571401|BEHAVIORAL|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
214563645|NCT05870839|BIOLOGICAL|VXCO-100|Sterile liquid for injection
214563646|NCT05339412|BEHAVIORAL|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
214563647|NCT05670353|DRUG|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
214708001|NCT00370877|DRUG|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
214563648|NCT05670353|DRUG|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
214563649|NCT05670353|DRUG|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
214563650|NCT03563157|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
214563651|NCT03563157|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]
214563652|NCT03563157|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214708002|NCT00370877|PROCEDURE|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
214563653|NCT03563157|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-\[HER2\]
214563654|NCT03563157|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214563655|NCT03563157|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
214563656|NCT03563157|BIOLOGICAL|GI-4000|RAS yeast
214708003|NCT01917708|DRUG|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
214708004|NCT04943666|OTHER|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
214708005|NCT02501902|DRUG|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
214563657|NCT03563157|BIOLOGICAL|GI-6207|CEA yeast
214708006|NCT02501902|DRUG|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
214708007|NCT04771026|DRUG|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
214708008|NCT01261598|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
215030355|NCT04813120|BEHAVIORAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
214563658|NCT03563157|BIOLOGICAL|GI-6301|Brachyury yeast
214563659|NCT03563157|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
214563660|NCT03563157|DRUG|Avelumab|BAVENCIO® injection
214563661|NCT03563157|DRUG|Capecitabine|XELODA® tablets
214563662|NCT03563157|DRUG|Cetuximab|ERBITUX® injection
214563663|NCT03563157|DRUG|Cyclophosphamide|Cyclophosphamide Capsules
214563664|NCT03563157|DRUG|5-Fluorouracil|5-FU; Fluorouracil Injection
214563665|NCT03563157|DRUG|Leucovorin|Leucovorin Calcium
214563666|NCT03563157|DRUG|Nab-paclitaxel|ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
214563667|NCT03563157|DRUG|Oxaliplatin|ELOXATIN® injection
214563668|NCT03563157|DRUG|Regorafenib|STIVARGA® tablets
214563669|NCT03563157|PROCEDURE|SBRT|Stereotactic body radiation therapy
214563670|NCT06632756|BEHAVIORAL|Individual and Group Treatment for Smoking Cessation|Positive psychology-based individual treatment and groups
214708009|NCT02513771|DRUG|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
214708010|NCT02513771|DRUG|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
214708011|NCT01972854|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
214708012|NCT01972854|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
214708013|NCT01972854|DEVICE|KXL System|30mW/cm2
215166310|NCT07198269|DEVICE|high-performance emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
215166311|NCT07199049|OTHER|Neuro-Mimic Observation Protocol|Observation of eyelid reflex, eye movements, and pupil responses at three standardized intraoperative time points (after induction, during skin incision, and mid-surgery). Parameters will be recorded alongside BIS values without any intervention, device application, or additional risk to patients.
215166312|NCT07200011|OTHER|Observational: Serum Vitamin D Levels|Participants' serum vitamin D levels will be measured from existing laboratory records, and radiographic images of mandibular implant overdentures will be analyzed to assess marginal bone loss. No active treatment or experimental intervention will be administered
215166313|NCT07198464|DRUG|Relmacabtagene autoleucel and transplantation|This study enrolled patients with primary central nervous system lymphoma, from whom mononuclear cells and hematopoietic stem cells were collected. Participants receive infusions of hematopoietic stem cells and CAR-T cells, followed by maintenance therapy with orelabrutinib and sintilimab starting on day 15 post-transplantation, for a median duration of up to 6 months and 1 year, respectively.
215166314|NCT07199504|DRUG|dipyridamole 50mg tid|restless legs syndrome in patients with uremia will take dipyridamole daily (50mg each time, three times a day) for 12 weeks
214563671|NCT06409234|OTHER|Transthoracic Echocardiography Recieved|Transthoracic Echocardiography Recieved
214563672|NCT04847206|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
215166315|NCT07199192|DRUG|Corticosteroid|systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge
215166316|NCT07199465|DRUG|Letermovir|Administered orally (as tablets/pellets) or via gastrostomy or nasogastric tube (as pellets) for 7 consecutive days.
215166317|NCT07199036|DEVICE|TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation)|Per session 20 min, twice daily; 5 days/week; up to 28 days or until successful weaning.
215166318|NCT07199036|DEVICE|abFES (Functional Electrical Stimulation of Abdominal Muscles)|Per session 20 min, twice daily
215166319|NCT07199036|DEVICE|Sham TEDS|Position/time matched; 2 Hz low-intensity sensation only; no visible contraction.
215166320|NCT07199036|DEVICE|Sham abFES|Position/time matched; sensation only; no visible contraction.
215166321|NCT07189390|DRUG|Probiotic|Probiotic capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. Probiotic Infloran® Hard capsules (Bifidobacterium bifidum \& Lactobacillus acidophilus) are a listed medicine on the Australian Register of Therapeutic Goods (ARTG). Infloran® has been previously used in infants including pre-term infants for other indications including supporting healthy digestion or improving digestive system flora. Infloran® is manufactured by Laboratorio Farmaceutico SIT S.r.l., Via Cavour 70 - 27035 Mede (PV) Italy.
215166322|NCT07189390|DRUG|Matching placebo|Placebo contains the same excipients as Infloran, it is also made from the same capsule, but it does not contain any bacterial strains. Placebo capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. The placebo is manufactured by Syntro Health, 558-562 Swan St, Richmond, VIC 3121.
215166323|NCT07195955|OTHER|Cold Spray Application|A cold spray is applied to the skin at the planned injection site immediately before LMWH administration to reduce pain and ecchymosis.
215166324|NCT07197684|DRUG|Ketamine|"Before skin incision, a bolus 0.35 mg/kg ketamine will be given followed by a continuous infusion 0.25 mg/kg/hr.~Ketamine infusion will be stopped 30 minutes before the end of the surgery"
214563673|NCT04847206|DRUG|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
214563674|NCT04847206|DRUG|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
214563675|NCT04847206|DRUG|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
214563676|NCT04847206|OTHER|Placebo|Placebo (Mannitol)
214563677|NCT00847067|PROCEDURE|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
214563678|NCT00847067|PROCEDURE|Sham injections|Sham injections with Normal Saline
214563679|NCT05672901|DEVICE|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
214563680|NCT05672901|DRUG|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
214563681|NCT04335591|DRUG|75 mg linzagolix tablet|For oral administration once daily
215166325|NCT07197684|PROCEDURE|Pecs block|Pecs block will be performed before surgical incision with the help of an ultrasound (US) by experienced anesthesiologist. The drug used for the pecs block will be two syringes of 10ml and 20 ml containing bupivacaine 0.25% (total 30 ml).
215166326|NCT07197684|DRUG|Nalbuphine|Intravenous Nalbuphine 0.1 mg/kg
215166327|NCT07197684|DRUG|Paracetamol|Intravenous Paracetamol 1g or 15mg/kg (if weight is \< 50kg).
215166328|NCT07200102|DRUG|Selinexor|Selinexor will be provided by Karyopharm Therapeutics, Inc.
215166329|NCT07197359|OTHER|Looksmaxxing AI Facial Analysis|Participants' standardized frontal facial photographs will be analyzed using the Looksmaxxing AI application (versions 4o and 5) to determine the presence or absence of chin deviation relative to the facial midline.
214563682|NCT04335591|DRUG|200 mg linzagolix tablet|For oral administration once daily
214563683|NCT04335591|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
214563684|NCT04335591|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
215166330|NCT07196163|DRUG|Golidocitinib|Golidocitinib will be administered orally as capsules in a 28-day cycle.
214563685|NCT04335591|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
214563686|NCT04335591|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
214563687|NCT00239551|DRUG|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
214563688|NCT05721547|OTHER|Assessment|Assessment
214563689|NCT05816304|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
214563690|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
214563691|NCT05270369|BEHAVIORAL|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
214563692|NCT05270369|BEHAVIORAL|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
214563693|NCT03240822|PROCEDURE|Penile Transplant|Penile Allotransplantation
214563694|NCT03240822|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
214563695|NCT03240822|DRUG|Tacrolimus|
214563696|NCT05503199|DEVICE|Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).|Combined suture- and plug-based VCD strategy after TF-TAVI.
214563697|NCT05503199|DEVICE|Combination of two ProGlides or ProStyles (Abbott Vascular).|Pure suture-based VCD strategy after TF-TAVI.
214563698|NCT02507453|OTHER|parabolic flight|
214563699|NCT02507453|OTHER|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
214563700|NCT02507453|DEVICE|ESA short-arm human centrifuge (SAHC)|
214563701|NCT04893252|DRUG|durvalumab and vactosertib|durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
214563702|NCT01575301|DRUG|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
214563703|NCT03412201|OTHER|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
214563704|NCT03412201|OTHER|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
214563705|NCT03028727|PROCEDURE|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
214563706|NCT03028727|PROCEDURE|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
214563707|NCT00356408|BIOLOGICAL|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
214563708|NCT00405366|DRUG|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
214563709|NCT00069173|BEHAVIORAL|Project FAB (Fitness and Bone)|
214563710|NCT05045651|PROCEDURE|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
214563711|NCT03864198|DIETARY_SUPPLEMENT|Genante|A dietary supplement for male infertility
214563712|NCT01219907|BIOLOGICAL|HER-2/neu peptide vaccine|Given intradermally
214563713|NCT01219907|DRUG|cyclophosphamide|Given IV
214563714|NCT01219907|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
215166331|NCT07196163|DRUG|Placebo|Placebo will be administered orally as capsules in a 28-day cycle.
214563715|NCT01219907|OTHER|laboratory biomarker analysis|Correlative studies
214563716|NCT01219907|OTHER|flow cytometry|Correlative studies
214563717|NCT01219907|OTHER|immunoenzyme technique|Correlative studies
214563718|NCT00868153|DRUG|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
214563719|NCT04558398|OTHER|Resistance exercise training|"Each session will be performed at home, with resistance bands used to provide resistance. Participants will be guided to increase the resistance if over 15 repetitions can be performed prior to fatigue. Weekly contact will be made with participants to encourage participation and to guide the exercise.~Each session will include:~2 min warm-up jogging on the spot~2 sets of 12-15 repetitions of:~Squats~Hip flexion~Hip extension~Hip abduction~Seated row~Bench press~Lateral raises~2 min jogging on the spot cooldown."
214563720|NCT04558398|OTHER|High-intensity interval training|"Each session will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot~Participants will be contacted weekly to encourage participation and to guide the exercise"
214563721|NCT01217853|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
214563722|NCT05762393|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
214563723|NCT05653063|OTHER|A web-based artificial intelligence (AI) auto-planning tool|"The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.~In this study patients will not be treated with the AI tool but the manual plan created by the local teams."
214563724|NCT02252770|DIETARY_SUPPLEMENT|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
214563725|NCT02252770|DIETARY_SUPPLEMENT|Placebo|Placebo will not contain nitric oxide supplement.
214563726|NCT00645268|DRUG|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
214563727|NCT00645268|DRUG|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
214563728|NCT00645268|DRUG|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
214563729|NCT01852461|DRUG|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
214563730|NCT01852461|DRUG|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
214708014|NCT02770118|BEHAVIORAL|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
215166332|NCT07197827|DRUG|YL242|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.
215166333|NCT07197827|DRUG|YL242; Pembrolizumab|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. Pembrolizumab will be administered subsequent to YL242.
215166334|NCT07197827|DRUG|YL242; 5-FU; LV|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.~LV and 5-FU will be sequentially administered following YL242."
215166335|NCT07197827|DRUG|YL242; Pembrolizumab; 5-FU|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. YL242 will be administered via Intravenous (IV) Infusion.~Pembrolizumab and 5-FU will be administered in sequence after YL242."
215166336|NCT07197853|DRUG|Huaier Granule|Patients in this arm will undergo CT-guided percutaneous microwave ablation using a standard protocol (2450 MHz, 30-50 W, 5-10 minutes per lesion, multi-probe as needed based on tumor size). Seven days post-ablation, patients will start oral administration of Huaier granules at a dose of 10g, three times daily (TID), for 72 consecutive weeks. The combined therapy aims to improve local tumor control and modulate anti-tumor immunity.
215166337|NCT07197268|DRUG|nL-ASXL3-001|Personalized antisense oligonucleotide
215166338|NCT07195864|DRUG|PHMB 0.08%|The study population for this study is patients diagnosed with AK treated with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program.
215166339|NCT07196254|PROCEDURE|sandwich mesh technique|the hernia repair include using double mesh onlay and sublay
215166340|NCT07197788|DEVICE|Endogenex System|The Endogenex System procedure utilizes a catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum.
215166341|NCT07195916|DRUG|INCA036873|Intravenously (IV)
215166342|NCT07196189|OTHER|Patients|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the patients eligibility criteria to be verified. If the patient is included, the self-questionnaire will be completed on site and stool collection will be carried out.
215166343|NCT07196189|OTHER|healthy volunteer|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the volunteer's eligibility criteria to be verified. If the volunteer is included, the self-questionnaire will be completed on site and stool collection will be carried out.
215166344|NCT07197177|PROCEDURE|regional block|We will infiltrate local anesthesia (Bupivicaine 0.25 %), in pectoral plane vs Erecter spine plane, will observe intraoperative morphine consumption, pain scores and Pacu stay.
215166345|NCT07197346|DEVICE|rTMS - cTBS (Continuous Theta-Burst Stimulation)|Continuous theta-burst stimulation (cTBS) is a patterned form of rTMS consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz), administered continuously without breaks. In this study, cTBS is delivered over the target cortical area according to established safety guidelines (e.g., a continuous 40s train for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure is used to induce a transient reduction in cortical excitability as a priming intervention prior to motor practice.
214563731|NCT05844670|DRUG|Vincristine|"The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient."
214563732|NCT00953186|DEVICE|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
214563733|NCT00953186|DEVICE|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
214563734|NCT03858829|OTHER|Psychometric analysis|Psychometric analysis
214563735|NCT01986270|DRUG|Placebo|Matching Placebo
214563736|NCT01986270|DRUG|Eletriptan 40 mg|40mg oral
214563737|NCT01986270|DRUG|Eletriptan 80 mg|80mg oral
214563738|NCT01986270|DRUG|Sumatriptan 25 mg|25mg oral
214563739|NCT01986270|DRUG|Sumatriptan 50 mg|50mg oral
214563740|NCT00968825|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
214563741|NCT00968825|DRUG|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
214563742|NCT02005575|DRUG|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
214563743|NCT02005575|DRUG|Placebo|
214563744|NCT04037176|DRUG|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
214563745|NCT04037176|OTHER|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
214563746|NCT04204746|OTHER|We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.|
214563747|NCT01694316|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
214563748|NCT05850728|DRUG|TLC-ART|TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
214563749|NCT03500991|BIOLOGICAL|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
214563750|NCT00981877|DRUG|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
214563751|NCT00981877|DRUG|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
214563752|NCT00981877|DRUG|GC (placebo)|Placebo 1 gram twice daily for 5 days.
214563753|NCT04571788|PROCEDURE|Foldable Capsular Buckle|Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera \>10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
214563754|NCT04571788|PROCEDURE|Silicone scleral padding|Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
214563755|NCT04514510|DRUG|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
214563756|NCT04514510|DRUG|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
214563757|NCT01250561|DRUG|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
214563758|NCT01250561|DRUG|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
214563759|NCT01068275|PROCEDURE|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
214563760|NCT01068275|PROCEDURE|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
214563761|NCT01068275|PROCEDURE|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
214563762|NCT00406692|DRUG|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
214563763|NCT03838120|OTHER|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
214563764|NCT00069537|DEVICE|The GlucoWatch® G2™ Biographer (GW2B)|
214563765|NCT00069537|DEVICE|The Continuous Glucose Monitoring System (CGMS™)|
214563766|NCT03524196|OTHER|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
214563767|NCT01597609|DRUG|sibutramine|10 mg, taken orally once per day for 12 weeks
214563768|NCT01597609|OTHER|sibutramine placebo|taken orally once per day for 12 weeks
214563769|NCT03217695|BEHAVIORAL|Mindfulness-based Yoga Arm|
214563770|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
214563771|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
214563772|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
214563773|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
214563774|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.004%|
214563775|NCT01298687|DRUG|Travoprost Vehicle|Inactive ingredients used as an active comparator
214563776|NCT03174431|DEVICE|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
214563777|NCT03174431|DEVICE|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
214563778|NCT00181870|DRUG|carbamazepine ER (Equetro)|
214708015|NCT02770118|BEHAVIORAL|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
214563779|NCT06629740|DEVICE|Measurements with a eHealth system|The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
214563780|NCT04746885|DIETARY_SUPPLEMENT|DHA|Oral supplement
214563781|NCT05000840|BEHAVIORAL|Enrollment in existing SDRI diabetes education programs|Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
214563782|NCT03264911|DRUG|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
214563783|NCT00573638|DEVICE|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
214563784|NCT00776217|DRUG|loratadine 10 mg orally disintegrating tablets|
214563785|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
214708016|NCT02770118|BEHAVIORAL|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
214708017|NCT00511849|DRUG|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
214563786|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
214563787|NCT01867333|BIOLOGICAL|Enzalutamide|An androgen receptor inhibitor.
214563788|NCT03390582|DRUG|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
214563789|NCT02137889|DRUG|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
214563790|NCT01708304|BEHAVIORAL|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
214563791|NCT04473898|OTHER|Aerobic Exercise Training|Aerobic exercises using all body muscles and that one can do on their own after being shown online
214563792|NCT04473898|BEHAVIORAL|Patient Education|Patient education about covid-19 and hygiene education
214563793|NCT04473898|OTHER|Respiratory Exercise Training|Respiratory exercises that one can do on their own after being shown online
214563794|NCT04253873|DRUG|Apatinib|Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
214563795|NCT00000689|DRUG|Bleomycin sulfate|
214708018|NCT01797445|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
214563796|NCT00000689|DRUG|Vincristine sulfate|
214563797|NCT00000689|DRUG|Doxorubicin hydrochloride|
214563798|NCT00000689|DRUG|Cyclophosphamide|
214563799|NCT00000689|DRUG|Methotrexate|
214563800|NCT00000689|DRUG|Cytarabine|
214563801|NCT00000689|DRUG|Leucovorin calcium|
214563802|NCT00000689|DRUG|Sargramostim|
214563803|NCT00000689|DRUG|Dexamethasone|
214563804|NCT06235437|BIOLOGICAL|ASD141|Subjects will receive one of 4 dose levels of ASD141.
214563805|NCT06808022|BEHAVIORAL|Preoperative Resistance Exercise|Participants will have been deemed to be medically safe to participate in exercise-based physical therapy based on their physician recommendation and may also undergo an in-person evaluation by a licensed physical therapist to evaluate their physical capacity. This will inform the frequency and intensity of exercise prescription according to a participant's identified physical impairments and activity tolerance levels. Based on this information, an exercise program will be implemented either via web-based HIPAA compliant platforms (e.g. Zoom or WebEx) or in the clinic(e.g if the participant does not have internet access) on a 1-2x/week basis for the 4-6 week pre-operative duration. Each exercise session will be approximately 30 minutes. During these sessions, exercises including gravity-assisted, body-weighted, or body-weight-augmented resistance exercises targeting the paraspinal extensor muscles (multifidus, erector spinae, latissimus dorsi, lower trapezius) will be performed at a mo
214563806|NCT05817552|DIAGNOSTIC_TEST|Geomagic Control X|3D Surface matching and compare
214708019|NCT01797445|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
214708020|NCT01797445|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
214708021|NCT01797445|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
214708022|NCT03140683|DEVICE|non-stress test|antepartum fetal monitoring
215166346|NCT07197346|BEHAVIORAL|Self-controlled (autonomy)|Self-controlled practice is a motor learning intervention in which participants are granted autonomy to make choices about key aspects of their practice sessions (e.g., when to receive feedback, the sequence/timing of trials, or selection of specific practice parameters). This design allows participants to actively control elements of the training experience according to their preference, thereby fostering intrinsic motivation and engagement. The intervention is grounded in the OPTIMAL theory of motor learning, which highlights the role of autonomy support in enhancing learning outcomes and motivation. In this study, participants in the self-controlled practice group make their own decisions regarding practice conditions, in contrast to yoked controls who follow externally assigned parameters.
215166347|NCT07197346|DEVICE|Sham|Sham TBS involves the application of a sham theta-burst stimulation protocol designed to mimic the sensory experience of active TBS without delivering effective magnetic pulses to the brain. This is typically achieved by angling the coil to prevent cortical stimulation. The procedure controls for placebo effects and participant expectations while ensuring blinding. The sham stimulation session matches the timing and setup of active TBS interventions but does not induce cortical excitability changes.
215166348|NCT07197346|BEHAVIORAL|Yoked Practice|Yoked practice refers to a motor learning protocol in which participants perform tasks under externally controlled practice conditions, matched to the parameters (e.g., feedback) of a paired participant from a self-controlled practice group. This design removes participant autonomy over practice choices, allowing comparison between self-controlled and externally controlled practice to evaluate the effects of autonomy on motor learning and motivation.
215166349|NCT07197346|DEVICE|rTMS- iTBS (Intermittent Theta-Burst Stimulation)|Intermittent theta-burst stimulation (iTBS) is a patterned form of repetitive transcranial magnetic stimulation (rTMS) consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz). In this study, iTBS is delivered over the target cortical area using standard protocols (e.g., 2s trains of TBS repeated every 10s for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure aims to facilitate cortical excitability as a priming intervention prior to motor practice.
215166350|NCT07197593|OTHER|Calf Raise Test|The study participants perform three single-leg CRTs (tracked by the CRT App) in a fixed sequence: concentric power, eccentric-concentric power and endurance. ATRC/LAS Individuals start with the affected leg, healthy participants with the dominant leg.
215166351|NCT07196800|RADIATION|High intensity laser therapy (low dose) combined with conventional physiotherapy program|840 joules delivered during each session combined with conventional physiotherapy program Participants
215166352|NCT07196800|PROCEDURE|High intensity laser therapy (High dose) combined with conventional physiotherapy program|2632 joules delivered during each session combined with conventional physiotherapy program
214563807|NCT01157767|OTHER|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
214708023|NCT03908905|DIAGNOSTIC_TEST|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
214708024|NCT04606368|DEVICE|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
214563808|NCT02472990|OTHER|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
214708025|NCT06306326|DIAGNOSTIC_TEST|3dMD technology|By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
214563809|NCT02162797|DIETARY_SUPPLEMENT|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
214563810|NCT02162797|DIETARY_SUPPLEMENT|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
214563811|NCT05439382|PROCEDURE|Gingival recession regenerative surgery|Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
214563812|NCT02280369|DEVICE|Automated abdominal binder|Inflatable abdominal binder
215166353|NCT07197073|OTHER|Ozonated olive oil|Ozonated olive oil mouthwash will be prepared by Smart Ozone Marvel using by company's ozone. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
214563813|NCT01145898|DRUG|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
214563814|NCT00023894|DRUG|alvocidib|
214563815|NCT03956693|BEHAVIORAL|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
214563816|NCT06803745|RADIATION|200 cGy or 400 cGy total body irradiation (TBI)|Either 200 or 400cGy will be given as part of reduced-intensity conditioning prior to consolidative allogeneic bone marrow transplant (alloBMT)
214563817|NCT00521066|DEVICE|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
214563818|NCT05527262|BEHAVIORAL|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
214563819|NCT05527262|DEVICE|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
214563820|NCT00211302|DRUG|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
214563821|NCT05431374|OTHER|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (10-40mg/day) or open-label mirtazapine (7.5-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
214563822|NCT05431374|OTHER|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
214563823|NCT00768170|DRUG|MK0633|MK0633 (50 mg) Oral, single dose
214563824|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
214563825|NCT02443831|PROCEDURE|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19+CD22 CAR T-cells
214563826|NCT02443831|RADIATION|Total Body Irradiation (TBI)|Participants will receive total body irradiation delivered as a single fraction (2Gy) on day -7 prior to CD19+CD22CAR T-cell infusion.
214563827|NCT02443831|DRUG|Lymphodepletion with Fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -6 to -3 prior to CD19+CD22CAR T-cell infusion.
214563828|NCT02443831|DRUG|Lymphodepletion with Cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -6 to -5 prior to CD19+CD22CAR T-cell infusion.
214563829|NCT02443831|BIOLOGICAL|CD19+CD22 CAR T-cells|Dose level 1: 2 doses of 4 x 10\^5 CD19+CD22 CAR T-cells/kg Dose level 2: 2 doses of 1 x 10\^6 CD19+CD22 CAR T-cells/kg given as a split dose as an intravenous injection through a Hickman line or PICC line (peripherally inserted central catheter) on day 0 and day 14.
215166354|NCT07197073|OTHER|Propolis|Propolis mouthwash will be prepared by using 2% raw propolis, 40 ml flavouring and 0.1 gm coloring agents, 150 ml propylene glycol, and 60 gm sorbitol. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
215166355|NCT07197073|OTHER|Chlorhexidine|The patients were given 0.12% Chlorhexidine. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
215166356|NCT07197463|OTHER|drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）|The experimental group received Phase I cardiac rehabilitation intervention + medication treatment + general treatment, while the control group only received medication treatment + general treatment.
214563830|NCT06225440|DIETARY_SUPPLEMENT|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
214563831|NCT06225440|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
215166357|NCT07197801|BEHAVIORAL|Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment|The intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and aﬃliational support to participants.
214563832|NCT00448942|BEHAVIORAL|Daily bathing with Chlorhexidine based product|
214563833|NCT02638597|DRUG|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
214563834|NCT02638597|BEHAVIORAL|smoking cessation counseling|smoking cessation counseling
214563835|NCT00493740|PROCEDURE|chocolate cake|
214563836|NCT00951015|DRUG|GSK1349572|investigational HIV-1 integrase inhibitor
214563837|NCT00951015|DRUG|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
214563838|NCT04408352|DEVICE|selective bladder denervation using RF energy|RF ablation of the trigone for the treatment of UUI
214708026|NCT01157546|PROCEDURE|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
215166358|NCT07193771|OTHER|Geographic Altitude|Participants are grouped according to the altitude of the pediatric intensive care unit (PICU) where they are admitted: low altitude (0-1500 m), intermediate altitude (1501-2500 m), high altitude (2501-3500 m), and very high altitude (\>3500 m). Altitude is treated as the primary exposure variable. No therapeutic intervention is administered as part of this study.
215166359|NCT07195877|DEVICE|Insertion/placement of tension threads|"* Standard preoperative anti-staphylococcal antibiotic prophylaxis by intramuscular injection.~* Disinfection of the surgical area.~* Marking of the paths of the threads to be implanted according to the physician's choice.~* Placement of sterile surgical drapes.~* Local anesthesia of the paths.~* Implantation of a needle (manufactured by Thread \& Lift) and pulling of the threads into the subcutaneous tissue. Adjustment of the tension of all the implanted threads. Cutting of the ends of the threads."
215166360|NCT07197632|PROCEDURE|Surgery with intraoperative MRI|In this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically
215166361|NCT07195851|OTHER|1.Bare Anatomy Expert Advanced Hair Growth Serum 2.Bare Anatomy Expert Ultra-Smoothing Shampoo 3.Bare Anatomy Expert Ultra-Smoothing Hair Serum 4.Bare Anatomy Expert Ultra-Smoothing Hair Mask|Dose: 0.1 ml of sample solution Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 48 hours.
215166362|NCT07197476|BEHAVIORAL|ASSIST Video Intervention|Video intervention for participants: adolescent trauma patient-parent dyads.
215166363|NCT07197021|DEVICE|TEER|TEER
215166364|NCT07197021|DRUG|GDMT|GDMT
214563839|NCT02180750|OTHER|Memory Work Therapy|
214563840|NCT02180750|OTHER|Standard care|Pediatric clinic, ART
214563841|NCT02635893|DRUG|D-Cycloserine|100 mg of Seromycin by mouth will be administered
214563842|NCT02635893|DRUG|Placebo|placebo pill will be administered instead of medication by mouth
214563843|NCT02635893|OTHER|Training|walking around a designated track at different speeds both forward and backward
214563844|NCT02635893|OTHER|Stimulation|magnetic stimulation and electrical stimulation may be applied
214563845|NCT02635893|OTHER|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
214563846|NCT01167452|DRUG|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
214563847|NCT00081575|DRUG|Tigecycline|
214563848|NCT00081575|DRUG|Levofloxacin|
214563849|NCT02398669|DRUG|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
214563850|NCT06541496|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle regions.
214563851|NCT01766115|DRUG|Telaprevir|HCV Protease Inhibitor
214563852|NCT03819634|DEVICE|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
214563853|NCT01208103|BIOLOGICAL|Bevacizumab|Given IV
214563854|NCT01208103|DRUG|Capecitabine|Given PO
214563855|NCT01208103|DRUG|Oxaliplatin|Given CVC
214563856|NCT03315013|PROCEDURE|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
214563857|NCT00305838|DRUG|tamoxifen citrate|
214563858|NCT00305838|OTHER|diagnostic laboratory biomarker analysis|
214563859|NCT01804868|OTHER|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
214563860|NCT01804868|OTHER|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
214563861|NCT00368342|DRUG|Erythromycin, Azithromycin , Clarithromycin|
214563862|NCT05440253|DEVICE|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
214708027|NCT01157546|PROCEDURE|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
215166365|NCT07196696|DEVICE|GMA-Tulip|Under general anesthesia, GMA-Tulip laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
215166366|NCT07196696|DEVICE|I-gel|Under general anesthesia, I-gel laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
215166367|NCT07196696|DEVICE|LMA-Supreme insertion|Under general anesthesia, LMA Supreme laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
215166368|NCT07199153|DEVICE|D Printed Custom Registration Marker for Dynamic Navigation|A patient-specific, 3D printed registration marker designed for use with the Mininavident dynamic navigation system. The marker is fabricated based on CBCT and intraoral scans, enabling accurate registration between virtual planning and clinical implant placement in the esthetic zone. Accuracy of placement is assessed through postoperative CBCT superimposition.
215166369|NCT07197385|PROCEDURE|Laparoscopic Ureterolithotomy|Keyhole laparoscopic approach to remove proximal ureteral stones by direct ureteral incision and closure.
215166370|NCT07197385|PROCEDURE|Ureteroscopic Lithotripsy|Semirigid ureteroscopic fragmentation of upper ureteral stones using pneumatic lithotripsy.
214563863|NCT05440253|PROCEDURE|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
214563864|NCT03128281|BEHAVIORAL|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
214563865|NCT03128281|DEVICE|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
214563866|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
214563867|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
214563868|NCT00771992|PROCEDURE|Bronchoscopy|Bronchoscopy with segmental allergen challenge
214563869|NCT04601025|DIETARY_SUPPLEMENT|Yoghurt|200 ml plain full-fat yoghurt
215166371|NCT07190560|BIOLOGICAL|plasma transfusion : PC-CHIK-V|plasma transfusion , from donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection
215166372|NCT07197814|OTHER|Rice formula (New formula based on hydrolysed rice proteins)|Infant formula based on hydrolysed rice proteins.
214563870|NCT04601025|DIETARY_SUPPLEMENT|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
214563871|NCT04601025|DIETARY_SUPPLEMENT|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
214563872|NCT00867984|OTHER|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
214563873|NCT00867984|OTHER|Usual Care|AV optimization (VTI) only
214563874|NCT04441177|DEVICE|PlayStation®VR training|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
214563875|NCT05905107|OTHER|Neurodynamic Slider Technique from Proximal to Distal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
214563876|NCT05905107|OTHER|Neurodynamic Slider Technique from Distal to Proximal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
214563877|NCT04016012|DIETARY_SUPPLEMENT|Local Zambian Foods|Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
214563878|NCT05769946|DRUG|Hemay005|A PDE-4 inhibitor
214563879|NCT04481698|OTHER|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
214563880|NCT02299947|DRUG|Haemocomplettan P|
214563881|NCT02299947|DRUG|Placebo|
214563882|NCT01169376|GENETIC|DNA analysis|
214563883|NCT01169376|GENETIC|DNA methylation analysis|
214563884|NCT01169376|GENETIC|RNA analysis|
214563885|NCT01169376|GENETIC|comparative genomic hybridization|
214563886|NCT01169376|GENETIC|mutation analysis|
214563887|NCT01169376|GENETIC|polymorphism analysis|
214563888|NCT03787342|PROCEDURE|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
214708028|NCT02397590|DRUG|Fimasartan|
214708029|NCT02397590|DRUG|Atorvastatin|
214708030|NCT06200285|OTHER|Registry of patients with accidental hypothermia|
214563889|NCT03787342|PROCEDURE|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
214708031|NCT05621590|DRUG|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
214708032|NCT05621590|DRUG|Placebo|placebo capsules filled with stevia sweetened powder
214708033|NCT01022385|DIETARY_SUPPLEMENT|24-hour low-residual diet|
214708034|NCT01595438|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
214708035|NCT01595438|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
215166373|NCT07197814|OTHER|Placebo formula|The placebo formula will be the formula the subject is currently successfully fed with as part of his/her diet to eliminate cow's milk proteins.
214563890|NCT03787342|PROCEDURE|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
214563891|NCT03787342|PROCEDURE|Periosteal releasing incision|
214563892|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
214563893|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
214563894|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
214563895|NCT00299494|DRUG|Rituximab|rituximab 375 mg/m\^2 via IV infusion on Day 1
214563896|NCT02764047|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
214563897|NCT05109767|DEVICE|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
214708036|NCT01595438|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
214563898|NCT05109767|DEVICE|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
214708037|NCT01595438|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
214708038|NCT04745312|DEVICE|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
214708039|NCT00930709|DRUG|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
214708040|NCT00930709|BEHAVIORAL|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
215166374|NCT07197398|OTHER|Spinal block level analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the whole study group will be assessed. Only cases with 12.5mg of hyperbaric bupivacaine will be included.
215166375|NCT07197398|OTHER|Data collection|Intervention is to retrieve and analyse anonymous perioperative data. After identification of eligible cases, statistical analysis will be performed
215166376|NCT07197398|OTHER|Sub-group analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the sub-groups of different height (\<165cm and \>165cm) will also be performed.
215166377|NCT07196514|DIETARY_SUPPLEMENT|Raw turmeric shots|This group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks.
215166378|NCT07196514|OTHER|Placebo|This group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks.
215166379|NCT07199400|BEHAVIORAL|physical activity program|Received eight sessions of technology-assisted exercise courses, covering 26 movements in the shoulders, neck, chest, upper limbs and lower limbs, with demonstrations and real-time feedback on movement performance through high-end monitors
214563899|NCT00416195|DRUG|E2007|
214563900|NCT00416195|DRUG|Placebo|
214563901|NCT00033618|DRUG|ixabepilone|Given IV
214563902|NCT00033618|OTHER|laboratory biomarker analysis|Correlative studies
214563903|NCT01882764|DRUG|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
214563904|NCT01882764|DRUG|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
214563905|NCT04347057|OTHER|Bed bathing with 2% CHG solution|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with CHG solution for each period. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions.
214563906|NCT04347057|OTHER|Bed bathing with soap and water|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with soap and water. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions. During control period, patients were washed with soap and then rinsed with water, and dried with disposable towels
214563907|NCT02121964|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
214563908|NCT02121964|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
214563909|NCT00414167|DRUG|bupropion|300 mg per day for 8 weeks
214563910|NCT00414167|OTHER|Placebo|Placebo
214563911|NCT02489240|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
214563912|NCT02489240|DRUG|placebo|2000 IU placebo tablets were taken daily for 6 days
214563913|NCT02372838|PROCEDURE|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
214563914|NCT02604082|OTHER|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
214563915|NCT02604082|OTHER|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
214563916|NCT02604082|OTHER|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
214563917|NCT02089568|DRUG|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
214563918|NCT02089568|DRUG|Normal Saline|Placebo - 0.9% saline
214563919|NCT00733252|PROCEDURE|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
214563920|NCT00733252|PROCEDURE|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
214563921|NCT00733252|PROCEDURE|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
214563922|NCT00733252|PROCEDURE|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
214563923|NCT01417104|DRUG|Aliskiren|150 mg/300mg
214563924|NCT01417104|DRUG|Placebo|150mg/300mg
214563925|NCT00451724|DRUG|Intranasal ketamine|
214563926|NCT02283476|DRUG|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
214563927|NCT02283476|DRUG|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
214563928|NCT02283476|DRUG|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
214563929|NCT02283476|DRUG|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
214563930|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
214563931|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
214563932|NCT00526253|PROCEDURE|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
214563933|NCT04149431|DRUG|Derinat|desoxyribonucleate sodium
214563934|NCT02713477|DRUG|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214563935|NCT02713477|DRUG|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214563936|NCT02713477|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214563937|NCT02727855|BIOLOGICAL|Shanchol|Oral Cholera Vaccine
214563938|NCT05775172|PROCEDURE|Sleeve gastrectomy|laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.
214563939|NCT05775172|DIETARY_SUPPLEMENT|Lifestyle intervention|balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification
214563940|NCT05775172|OTHER|Control|No interventions were applied
214563941|NCT04823676|DIETARY_SUPPLEMENT|Probiotic composition|Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)
214563942|NCT04823676|OTHER|Placebo|Maltodextrin (E1400, qs)
214563943|NCT03225690|DRUG|Morphine|Prevention of remifentanil induced hyperalgesia
214563944|NCT03225690|DRUG|Serum physiologic|For placebo, serum physiologic will use
214563945|NCT04477395|DIETARY_SUPPLEMENT|fish oil|SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.
214563946|NCT04477395|PROCEDURE|SRP only|Scaling and root planing will be the only method of treatment.
214563947|NCT00227942|DRUG|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
214563948|NCT00227942|DRUG|Zolpidem|10 mg/day, po qhs
214563949|NCT00227942|DRUG|placebo|placebo
214563950|NCT00909831|DRUG|hydroxychloroquine|
214563951|NCT00909831|DRUG|temsirolimus|
214563952|NCT00909831|OTHER|electron microscopy|
214563953|NCT00909831|OTHER|high performance liquid chromatography|
214563954|NCT00909831|OTHER|immunologic technique|
214563955|NCT00909831|OTHER|laboratory biomarker analysis|
215166380|NCT07196436|DEVICE|Energy Recovery Ventilator|A mechanical ventilation system that exchanges stale indoor air with fresh outdoor air while transferring heat and moisture between the incoming and outgoing air streams
215166381|NCT07196436|DEVICE|Portable Air Cleaner|A standalone home device that filters indoor air to remove particulate matter, allergens, and other pollutants
214563956|NCT00909831|OTHER|mass spectrometry|
215166382|NCT07196436|DEVICE|Energy Recovery Ventilator (Sham)|A home-installed ERV unit that operates in recirculation mode only, providing no fresh air exchange or heat/moisture transfer, serving as a placebo for study purposes.
215166383|NCT07196436|DEVICE|Portable Air Cleaner (Sham)|A portable air cleaner that appears to operate like an active unit but does not contain a HEPA filter and does not clean the air, serving as a placebo for study purposes
214563957|NCT00909831|OTHER|pharmacological study|
215166384|NCT07196007|BEHAVIORAL|Community-Clinical Intervention|The intervention involves enhancing usual care for screening patients with diabetes for unmet social needs and referring those who screen positive to a Community Health Worker. Patients who screen positive for unmet social needs will work with CHWs to be connected to community organizations.
215166385|NCT07196670|DRUG|intralesional vitamin D3 versus intralesional acyclovir|injecting intralesional vitamin D in group A versus injecting intralesional acyclovir in group B in treatment of plantar warts
214563958|NCT00909831|PROCEDURE|autophagy inhibition therapy|
214563959|NCT02760095|DRUG|3 mg zinc sulfate supplement|
214563960|NCT02760095|DRUG|0.5 mg of 13C10-retinyl-acetate|
214563961|NCT01589159|DRUG|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
214563962|NCT01589159|DRUG|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
214563963|NCT01075295|BEHAVIORAL|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:~* STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~* STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake \& physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~* STEP 3 (Nutrition \& Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~* STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
215166386|NCT07196085|BEHAVIORAL|Imagery Rescripting|"Four ImRs sessions over 2 weeks, targeting autobiographical criticism memory. Therapist-guided rescripting involved modifying the hotspot scene (critical interaction) with protective interventions addressing unmet needs."
215166387|NCT07196085|BEHAVIORAL|Sham Neutral Imagery|Four neutral imagery sessions over 2 weeks. Participants imagined neutral interpersonal interactions matched in structure and duration to ImRs but with rescription of neutral instead of criticism memories.
214563964|NCT01075295|OTHER|TAU|Treatment as provided by individuals' existing healthcare providers
215166388|NCT07197294|DRUG|nL-MAPK8-001|Personalized antisense oligonucleotide
215166389|NCT07197580|RADIATION|177Lu-TLX250|3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals
215166390|NCT07196046|DIETARY_SUPPLEMENT|Supplement 2|A dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
215166391|NCT07196046|DIETARY_SUPPLEMENT|Supplement 3|A third dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
215166392|NCT07196046|DIETARY_SUPPLEMENT|Supplement 1|A dietary supplement administered daily for 14 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
215166393|NCT07195656|DEVICE|Device Group|non-implanted, vaginal electrical stimulation device
215166394|NCT07195656|DRUG|Medication Group|OAB Medication
215166395|NCT07196501|DRUG|NBI-1065845|Oral tablet
215166396|NCT07196501|DRUG|Placebo|Oral tablet
215166397|NCT07195734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215166398|NCT07195734|DRUG|Carboplatin|Given IV
215166399|NCT07195734|BIOLOGICAL|Cemiplimab|Given IV
215166400|NCT07195734|DRUG|Cisplatin|Given IV
214563965|NCT03101462|BIOLOGICAL|Inactivated Influenza Vaccine|
214563966|NCT03101462|BIOLOGICAL|Live Attenuated Influenza Vaccine|
214563967|NCT04081870|DIAGNOSTIC_TEST|3D power doppler US|Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
214563968|NCT03711292|BEHAVIORAL|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
214563969|NCT03556904|RADIATION|Ablative Radiation Therapy|Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.
214563970|NCT03556904|DRUG|Hormone therapy or chemotherapy|Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
214563971|NCT02799394|OTHER|Activity modification, exercises and gradual return to sport|
214563972|NCT00795275|DRUG|Sitagliptin Phosphate|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
214563973|NCT05963477|PROCEDURE|laparatomy|all abdominal procedures which are approached by different incisions
214563974|NCT00214019|DRUG|salmeterol|salmeterol diskus 50 mcg twice per day
214563975|NCT00214019|DRUG|Fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
214563976|NCT00214019|DRUG|Placebo|placebo diskus
214563977|NCT00953277|OTHER|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
214563978|NCT02243670|DEVICE|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
214563979|NCT03921099|DRUG|Ascorbic Acid|ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
214563980|NCT04654767|OTHER|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
214563981|NCT01055847|DRUG|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
214563982|NCT01055847|DRUG|Placebo|Saline Placebo
214563983|NCT00513877|DRUG|bortezomib|
214563984|NCT00513877|PROCEDURE|quality-of-life assessment|
215166401|NCT07195734|PROCEDURE|Computed Tomography|Undergo CT scan
215166402|NCT07195734|DRUG|Paclitaxel|Given IV
215166403|NCT07195734|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215166404|NCT07195734|RADIATION|Radiation Therapy|Undergo radiation therapy
215166405|NCT07195734|PROCEDURE|Salvage Surgery|Undergo standard of care salvage surgery
215166406|NCT07195968|DIAGNOSTIC_TEST|NTG-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Intracoronary NTG dosage will follow the protocol based on blood pressure.
215166407|NCT07195968|DIAGNOSTIC_TEST|Saline-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Ten millilitres of intracoronary saline will be given over five seconds.
215166408|NCT07197879|DEVICE|Dynamic office chair (saddle chair with standard pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
215166409|NCT07197879|DEVICE|Dynamic Office Chair (office swivel chair with integrated newly developed pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
214563985|NCT00842244|DRUG|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
214563986|NCT00842244|DRUG|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
214563987|NCT00842244|DRUG|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
214563988|NCT00827099|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin
214563989|NCT00827099|DRUG|fludarabine phosphate|fludarabine phosphate
214563990|NCT00827099|DRUG|Melphalan|melphalan
214563991|NCT00827099|DRUG|mycophenolate mofetil|mycophenolate mofetil
214563992|NCT00827099|DRUG|tacrolimus|tacrolimus
214563993|NCT00827099|PROCEDURE|umbilical cord blood transplantation|umbilical cord blood transplantation
214563994|NCT01701102|PROCEDURE|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
214563995|NCT01701102|PROCEDURE|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
214563996|NCT01701102|PROCEDURE|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
214563997|NCT01701102|PROCEDURE|Mepivacaine|Mepivacaine 37.5 mg
214563998|NCT05899803|DIAGNOSTIC_TEST|Posture Analysis|This analysis consists of 13 different body parts and evaluates the body in terms of current posture changes. Our study evaluated children from two angles: posterior (head, shoulders, back, hips, feet, and arches) and lateral (neck, chest, shoulders, upper back, trunk, abdomen, and waist). In the scoring system, correct posture was recorded as five points, a moderate amount of deformity posture as three points, and severe deformity posture as one point. The total score calculated at the end of the questionnaire was a maximum of 65 points and a minimum of 13 points. The results of the analysis were evaluated as follows: ≥ 45 points, very good, 40-44 points good, 30-39 points moderate, 20-29 points poor, and a total score of ≤ 19 points.
214563999|NCT05899803|DIAGNOSTIC_TEST|Physical activity level|This questionnaire, administered to children aged 4-14, evaluates the activities performed during a week. The questionnaire consisted of nine questions, each of which was evaluated on a 5 points. One point indicated a low physical activity level and five points indicated a high physical activity level. Dividing the total score of the selected items by the number of items gives a summary score for the PAQ-C questionnaire. In our study, we used the Turkish version of the questionnaire, which was found to be reliable and valid.
214564000|NCT05899803|DIAGNOSTIC_TEST|Muscle strength|"Our study objectively measured muscle strength using the JTech Commander PowerTrack Muscle Dynamometer.~Right and left muscle tests: Hip flexors/hyperextensors/adductors/abductors/internal rotators/external retractors, knee flexors/extensors, and foot plantar flexors/dorsiflexors were evaluated. The measurement results were recorded in Newtons, the measurements were repeated three times, and the average of these three repetitions was recorded."
214564001|NCT02876042|DEVICE|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
214564002|NCT06507280|PROCEDURE|Periodontal theraphy|periodontal therapy
214564003|NCT01404364|DRUG|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
214564004|NCT01404364|DRUG|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
214564005|NCT01745575|DRUG|Alprazolam 2mg tablets|Reference product
214564006|NCT01745575|DRUG|Alprazolam 2 mg tablets|Test product
214564007|NCT03789331|OTHER|Anogenital distance measurement|"The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used."
214564008|NCT02297490|DRUG|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
215166410|NCT07196124|BIOLOGICAL|BCMA/GPRC5D CAR-T|A single infusion of BCMA/GPRC5D CAR-T Injection administered intravenously.
215166411|NCT07197047|OTHER|Neck static stretching|"The static stretching intervention targeted the right posterolateral region of the neck. The stretching protocol consisted of four sets of 45 seconds each, separated by 45-second rest intervals, for a total intervention time of 3 minutes. Seated in a chair, participants performed the stretch by gently flexing their head forward and to the left in an anterolateral direction, using their contralateral (left) hand to assist the movement and ensure selective stretching of the right posterolateral region of the neck. Participants were asked to achieve a subjective discomfort intensity of at least 8 out of 10 on the Numerical Rating Scale (NRS), where 0 represents no pain and 10 indicates the strongest pain imaginable"
214564009|NCT02297490|BIOLOGICAL|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
214564010|NCT04085484|DIETARY_SUPPLEMENT|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight \< 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
214564011|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 3 hour.
214564012|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 3 hour.
214564013|NCT06191055|OTHER|Control group|4 intakes of 2.5 g of wheat semolina every 3 hour.
215166412|NCT07196787|OTHER|Exercise|"The 18-Week Program Structure This program is divided into three 6-week phases. Each week consists of 5 sessions, mixing different focuses to ensure balanced development.~Day 1: Foundational Strength \& Stability~Day 2: Low-Impact Cardio \& Active Recovery~Day 3: Core Focus \& Hip Stability~Day 4: Low-Impact Cardio \& Mobility~Day 5: Full Body Integration \& Strength"
215166413|NCT07196904|DEVICE|Ultrasonic Device (Piezosurgery)|Mandibular impacted third molar extraction performed with an ultrasonic surgical device. The piezosurgery device was used exclusively for the osteotomy (bone removal) stage, while conventional rotary instruments were still used for tooth sectioning when required. This selective approach aimed to evaluate whether piezosurgery could reduce surgical trauma compared to full rotary techniques.
214564014|NCT03271853|DEVICE|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
214564015|NCT00003705|DRUG|BMS-184476|
214564016|NCT00241553|DRUG|Esomeprazole|
214564017|NCT01240421|DRUG|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
214564018|NCT03719417|PROCEDURE|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
214564019|NCT03719417|PROCEDURE|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
214564020|NCT01353118|BIOLOGICAL|gastric bypass|Optimise glucose control within 3 months before operation
214564021|NCT05287490|DEVICE|FormaV and VTone|Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
214564022|NCT05202392|OTHER|Myofascial release with isometric exercises|Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.
214564023|NCT05202392|OTHER|Myofascial release with scapular stabilization exercise|Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
214564024|NCT05114486|COMBINATION_PRODUCT|Pilocarpine Ophthalmic administered with the Optejet dispenser|Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
214564025|NCT05114486|COMBINATION_PRODUCT|Placebo administered with the Optejet dispenser|Vehicle ophthalmic solution administered with the Optejet dispenser
214564026|NCT05297006|DIETARY_SUPPLEMENT|The infants who drank milk powder were given a dietary intervention four months before|The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
214564027|NCT01696955|BIOLOGICAL|Cetuximab|Given IV
214564028|NCT01696955|OTHER|Laboratory Biomarker Analysis|Correlative studies
214564029|NCT01696955|DRUG|Tivantinib|Given PO
215030356|NCT04813120|BEHAVIORAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
214564030|NCT03192475|BEHAVIORAL|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
214564031|NCT03192475|BEHAVIORAL|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
214564032|NCT06310408|DEVICE|nasal mask|Give interface nasal mask
215166414|NCT07196904|DEVICE|Conventional rotary instruments|Mandibular impacted third molar extraction performed entirely with conventional rotary instruments. Both bone removal and tooth sectioning were conducted using high-speed rotary instruments under continuous irrigation. This served as the control arm to compare with the ultrasonic-assisted technique.
214564033|NCT06310408|DEVICE|nasal prong|give interface nasal prong
214564034|NCT03556956|DRUG|Masitinib|Tyrosine kinase inhibitor
214564035|NCT01681121|DRUG|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
214564036|NCT01681121|DRUG|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
214564037|NCT05133349|DRUG|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
214564038|NCT01696045|BIOLOGICAL|Ipilimumab|
214564039|NCT00573859|DRUG|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
214564040|NCT00573859|DRUG|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
214564041|NCT04398823|DRUG|Sclerosing foam of Lauromacrogol|Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
214564042|NCT04398823|DRUG|Sclersing liqiud of Lauromacrogol|Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
214564043|NCT00144495|DRUG|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
214564044|NCT00144495|DRUG|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
214564045|NCT05741138|OTHER|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
214564046|NCT05741138|OTHER|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
214564047|NCT02294526|OTHER|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
214564048|NCT05319912|DRUG|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
214564049|NCT05319912|DRUG|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
214564050|NCT05319912|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
214564051|NCT04488523|BEHAVIORAL|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
214564052|NCT01148329|DEVICE|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
214564053|NCT03541200|DRUG|MT-8554|MT-8554 Oral
214564054|NCT02519140|DRUG|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
214564055|NCT02297100|DRUG|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
214564056|NCT02297100|PROCEDURE|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
214564057|NCT02297100|PROCEDURE|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
214564058|NCT04215445|DRUG|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
214564059|NCT04215445|DEVICE|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
214564060|NCT04198064|PROCEDURE|Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/\~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy."
214564061|NCT04198064|PROCEDURE|No Bag Squeeze|Participants will receive a standard cystocopy procedure as per standard of care.
214564062|NCT03377478|DRUG|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
214564063|NCT04349839|DEVICE|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
214564064|NCT01120730|DRUG|fluid resuscitation|fluid resuscitation with HES
214564065|NCT01120730|DRUG|Fluid resuscitation|Fluid resuscitation in standardized fashion
214564066|NCT00876577|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
215166415|NCT07196397|PROCEDURE|cardioneuroablation|Cardioneuroablation and related autonomic interventions aim to modulate parasympathetic and/or sympathetic inputs to the heart in order to treat functional bradycardia, inappropriate sinus tachycardia, vasovagal syncope, and other reflex arrhythmias. Techniques include catheter-based ablation of ganglionated plexi, thoracoscopic sinus node-sparing ablation, cardiac sympathetic denervation, and percutaneous stellate ganglion blockade. These procedures are tailored to each patient's autonomic profile and diagnosis.
214564067|NCT02972268|DRUG|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
214564068|NCT02972268|DRUG|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
214564069|NCT05984836|BEHAVIORAL|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
214564070|NCT03738644|OTHER|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
214564071|NCT02632604|BEHAVIORAL|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
214564072|NCT02632604|BEHAVIORAL|Computer games|
214564073|NCT05526131|OTHER|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
214564074|NCT01913834|DRUG|Forsteo|Subcutaneous administration 20 micrograms
214564075|NCT01913834|DRUG|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
214564076|NCT03818360|BEHAVIORAL|an evidence-based smoking cessation intervention comprising brief advice plus active referrals|The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
214564077|NCT04374214|PROCEDURE|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
214564078|NCT04374214|PROCEDURE|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
214564079|NCT01333813|BIOLOGICAL|Engerix-B™ Kinder|Intramuscular, single dose
214564080|NCT03198468|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
214564081|NCT03947307|DEVICE|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
214564082|NCT03947307|PROCEDURE|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
214564083|NCT03947307|DEVICE|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
214564084|NCT00619749|DIETARY_SUPPLEMENT|juice rich in polyphenols|juice during 2 weeks
214564085|NCT00619749|DIETARY_SUPPLEMENT|juice poor in polyphenols|juice during 2 weeks
214564086|NCT01303679|DRUG|Paclitaxel|IV, 80mg/m² at d1, d8, d15
214564087|NCT01303679|DRUG|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
214564088|NCT01303679|DRUG|Exemestane|daily 25 mg (1 pill) oral intake
214564089|NCT01689571|DRUG|CHF6001|
214564090|NCT01689571|DRUG|Placebo|
214564091|NCT05838378|OTHER|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
214564092|NCT05838378|OTHER|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
214564093|NCT05838378|OTHER|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
214564094|NCT00509431|DRUG|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
214564095|NCT01276379|DRUG|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
214564096|NCT01276379|DRUG|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
214564097|NCT01276379|DRUG|Cetuximab|\- 500 mg/m2 i.v. Every 2 weeks.
214564098|NCT01376232|DRUG|GSK1278863|GSk1278863 100mg
214564099|NCT01376232|DRUG|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
214564100|NCT01376232|DRUG|Gemfibrozil|600 mg Gemfibrozil
214564101|NCT00864253|DRUG|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
214564102|NCT00864253|DRUG|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
214708041|NCT06962631|BIOLOGICAL|5% (5g/100 ml) intravenous immunoglobin|"A 5% human normal immunoglobulin I.P. (5 g/100 mL) V-IMMUNE® will be administered at a dose of 1 g/kg, intravenously, once daily for 2 consecutive days (Day 1 and Day 2). The infusion rate starts at 0.01 mL/kg/min during the first 30 minutes and is gradually increased up to 0.06 mL/kg/min if no adverse events occur. This will constitute the first cycle of V-IMMUNE® treatment. The dose of 1 g/kg/day on 2 consecutive days is consistent with recommendations for the use of other IVIG products in Immune Thrombocytopenia.~If the platelet count is not maintained for the desired duration after the first V-IMMUNE® cycle, and at the discretion of the investigator and the patient/legal representative, participants may receive up to one additional cycle of V-IMMUNE®-at the same dosing regimen used in Cycle 1-between Day 15 and Day 30"
214564103|NCT06459700|DIETARY_SUPPLEMENT|Probiotic supplements|See arm/group description
214708042|NCT04707378|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
214564104|NCT06459700|DIETARY_SUPPLEMENT|Placebo supplements|See arm/group description
214564105|NCT01896726|DRUG|Baricitinib|Administered orally
214564106|NCT01896726|DRUG|Microgynon|Administered orally
214564107|NCT01128114|DRUG|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
214564108|NCT01632540|DRUG|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
214708043|NCT03625297|OTHER|shelter cat|families will adopt a shelter cat
214708044|NCT01620008|PROCEDURE|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
214708045|NCT01444872|DRUG|TRV120027|IV infusion
214708046|NCT01444872|DRUG|Normal Saline|IV infusion
214708047|NCT04790539|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
214708048|NCT03932019|DRUG|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
214708049|NCT03932019|DRUG|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
214708050|NCT03932019|DRUG|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
214708051|NCT01000519|OTHER|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
214708052|NCT01000519|OTHER|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
214708053|NCT01113788|DEVICE|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
214708054|NCT01003353|BEHAVIORAL|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
214564109|NCT06078228|DRUG|Propofol - Fentanyl- Atracurium|investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
214564110|NCT04532567|DRUG|GLPG1205|GLPG1205 film-coated tablets
214564111|NCT04532567|DRUG|Placebo|placebo film-coated tablets
214564112|NCT00208325|DEVICE|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
214564113|NCT00208325|DEVICE|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
214564114|NCT04258683|DRUG|Pembrolizumab|Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
214708055|NCT04374279|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily for 7 days
214708056|NCT01817647|PROCEDURE|Colorectal surgery|
214708057|NCT04105413|DIAGNOSTIC_TEST|Blood culturs|CBC, Blood culture and CRP
214708058|NCT00408759|BEHAVIORAL|hypnosis|
214708059|NCT05931133|OTHER|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
214708060|NCT01734707|DIETARY_SUPPLEMENT|Allicor|
214708061|NCT01734707|DRUG|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
214708062|NCT05244538|DEVICE|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
214708063|NCT05244538|DRUG|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
214708064|NCT00175162|DEVICE|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
214708065|NCT00778726|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
214708066|NCT04263779|BEHAVIORAL|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
214708067|NCT04263779|BEHAVIORAL|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
214708068|NCT02084069|DRUG|Atorvastatin|
214708069|NCT00861588|DRUG|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
214708070|NCT00861588|DRUG|placebo|starch placebo
214708071|NCT03273231|DRUG|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
214708072|NCT03273231|DRUG|Saline|0.9% saline solution
214708073|NCT00515580|PROCEDURE|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
214708074|NCT01933321|BIOLOGICAL|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
214708075|NCT02178072|DRUG|5-Azacitadine|
214708076|NCT01661309|DIETARY_SUPPLEMENT|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
214564115|NCT04419922|BEHAVIORAL|Smartphone Contingency Management Intervention|Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
214564116|NCT02574962|DRUG|H.P. Acthar® Gel|
214564117|NCT01913262|BEHAVIORAL|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
214564118|NCT03877861|DEVICE|Readiband Sleep Tracking|Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
214564119|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
214564120|NCT00636740|DRUG|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
214564121|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
214564122|NCT01070446|DIETARY_SUPPLEMENT|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
214564123|NCT04650399|BIOLOGICAL|Active|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
214708077|NCT01661309|DIETARY_SUPPLEMENT|Methylcobalamin|Aimed at reducing plasma tHcy.
214708078|NCT00280605|DRUG|Alfuzosin|
214708079|NCT06279637|BEHAVIORAL|Joint Home-DM-BAT Intervention|8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.
214708080|NCT06279637|BEHAVIORAL|Usual Care|Diabetes education materials will be mailed weekly and monthly according to the booster schedule
214708081|NCT04062370|DRUG|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
214708082|NCT04062370|DEVICE|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
214708083|NCT04116073|DRUG|INCMGA00012 (PD-1 antibody)|INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days)
214708084|NCT03200795|OTHER|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017)."
214564124|NCT04650399|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
214564125|NCT04606498|OTHER|Observational|Observational study only - no intervention
214564126|NCT00249964|DRUG|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."
214564127|NCT00249964|DRUG|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."
214564128|NCT00249964|DRUG|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."
214564129|NCT00249964|DRUG|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."
214564130|NCT03460808|DRUG|atorvastatin|Atorvastatin was used in combination with acetylcysteine and danazol.
214564131|NCT03460808|DRUG|Acetylcysteine|Acetylcysteine was used in combination with atorvastatin and danazol.
214564132|NCT03460808|DRUG|Danazol|Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
214564133|NCT04332159|PROCEDURE|Closed nasal fracture reduction|Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
214708085|NCT03200795|OTHER|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
214708086|NCT05041491|BEHAVIORAL|BREAK|The BREAK intervention is a physical activity regimen.
214708087|NCT05041491|BEHAVIORAL|ONE|The ONE intervention is a physical activity regimen.
215166416|NCT07196397|PROCEDURE|SN sparing hybrid ablation|Sinus node-sparing hybrid ablation is a minimally invasive surgical procedure that modulates autonomic inputs to the sinoatrial node while preserving its intrinsic function. The intervention is performed via video-assisted thoracoscopic surgery (VATS) and targets the epicardial autonomic ganglia and neural connections responsible for inappropriate sinus tachycardia or autonomic dysfunction. Unlike traditional sinus node modification, this approach avoids direct ablation of the sinus node and focuses on surrounding autonomic structures. The goal is to reduce pathologic chronotropic activity and improve symptom control without inducing iatrogenic bradycardia.
214564134|NCT04562740|DEVICE|ABLUMINUS DES drug eluting stent|Following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
214564135|NCT04052295|PROCEDURE|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
214564136|NCT03617900|DRUG|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
214564137|NCT03617900|DRUG|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
214564138|NCT03617900|DRUG|Paracetamol|500 mg paracetamol. use in need
214564139|NCT04351035|PROCEDURE|Tumour resection|It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.
214564140|NCT01883102|DRUG|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
214564141|NCT01883102|DRUG|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
214564142|NCT02879526|DRUG|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
214564143|NCT04445987|DRUG|ARQ-154|ARQ-154 foam 0.3% applied once daily for 52 weeks
214564144|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
214564145|NCT03807960|OTHER|written form|The written form which include PCA usage information.
214564146|NCT03807960|OTHER|video|The video about PCA usage
214564147|NCT03807960|OTHER|routine care|The routine description about PCA usage
214564148|NCT02654353|PROCEDURE|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
214564149|NCT01728311|DRUG|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
214564150|NCT06528847|DRUG|Benmelstobart|The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.
214564151|NCT02005042|BEHAVIORAL|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
214564152|NCT04218786|DRUG|Colchicine|The tablet will be given once daily for the span of the study
214564153|NCT04218786|DRUG|Placebo oral tablet|The tablet will be given once daily for the span of the study
214564154|NCT03582787|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
214564155|NCT03582787|DEVICE|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
214564156|NCT05413239|BEHAVIORAL|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting \~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
214564157|NCT02865239|PROCEDURE|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
214564158|NCT01940133|DRUG|PQR309|Dosing will be orally, once a day for the duration of the trial.
214564159|NCT06020183|DEVICE|Hybrid hyrax|these patents will be treated using Four mini-screws supported hybrid hyrax
214564160|NCT01008800|BEHAVIORAL|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey \& Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
214564161|NCT01008800|BEHAVIORAL|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy \& Grusec, 2001).
214564162|NCT00072137|BIOLOGICAL|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
214564163|NCT00072137|BIOLOGICAL|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
214564164|NCT00072137|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy
214564165|NCT00072137|OTHER|Pharmacological Study|Correlative studies
214564166|NCT00072137|OTHER|Laboratory Biomarker Analysis|Correlative studies
214564167|NCT02893787|OTHER|Speckle Tracking Echocardiography|Echocardiography analyses
214564168|NCT01803282|DRUG|Andecaliximab|Administered intravenous infusion
214564169|NCT01803282|DRUG|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
214564170|NCT01803282|DRUG|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
214564171|NCT01803282|DRUG|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
214564172|NCT01803282|DRUG|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
214564173|NCT01803282|DRUG|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214564174|NCT01803282|DRUG|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214564175|NCT01803282|DRUG|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214564176|NCT01803282|DRUG|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214564177|NCT01803282|DRUG|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214564178|NCT01803282|DRUG|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
214564179|NCT04502017|DRUG|ASA plus Clopidogrel|OAC (6 weeks) + DAPT (until 6 months) + ASA
214564180|NCT04502017|DRUG|Genetic-Tailored AntiThrombotic Strategy|Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype
214564181|NCT04502017|DRUG|Half-Dose of novel OAC|Half Dose of novel OAC post-device Implantation
214564182|NCT01743989|DRUG|Nilotinib|Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
214564183|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
214564184|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
214564185|NCT01941147|DEVICE|pulsed ELF-MF|(75 Hz, 1,8 mT)
214564186|NCT00311987|DRUG|3,5-Diiodothyropropionic acid (DITPA) therapy|
214564187|NCT03568643|DRUG|Azithromycin|Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
214564188|NCT03568643|DRUG|Amoxicillin|Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
214564189|NCT03193775|BIOLOGICAL|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
214564190|NCT02235311|DRUG|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
214564191|NCT00566605|PROCEDURE|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty \[IEK\])
214564192|NCT00566605|PROCEDURE|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
214564193|NCT00701649|BIOLOGICAL|CYT006-AngQb|s.c.
214564194|NCT00701649|BIOLOGICAL|Placebo|s.c.
214564195|NCT04684017|DRUG|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
214564196|NCT04684017|DRUG|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
214564197|NCT04684017|DRUG|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
214564198|NCT01741103|DRUG|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
214564199|NCT01741103|DRUG|Placebo|Take one by mouth daily for 12 weeks
214564200|NCT05293665|BIOLOGICAL|UB-612|UB-612 (100µg), 0.5mL suspension, intramuscular injection
214564201|NCT05293665|BIOLOGICAL|BNT162b2 vaccine|BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
214564202|NCT05293665|BIOLOGICAL|ChAdOx1-S vaccine|ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
214564203|NCT05293665|BIOLOGICAL|Sinopharm BIBP|Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
214564204|NCT01060839|BEHAVIORAL|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
214564205|NCT03018522|OTHER|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
214708088|NCT01110772|DEVICE|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
214708089|NCT01110772|DEVICE|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
214708090|NCT06281574|PROCEDURE|Questionnaires|"To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)"
214708091|NCT02919137|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
214708092|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
214708093|NCT06701188|BEHAVIORAL|Virtual Coaching and social support|The investigators propose a randomized clinical trial (RCT) of a virtual coaching and social support intervention that integrates evidence- and theory-based approaches to build self-efficacy, self-regulation, and perceived social support after cardiac rehabilitation (CR) to improve physical activity, psychosocial, social cognitive, and clinical outcomes, delivered via a social networking platform (Trainerize). Our intervention will also include goal setting for exercise and tailored feedback by our qualified intervention team.
214564206|NCT04969068|DRUG|Remimazolam|Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
214564207|NCT05095207|DRUG|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
214564208|NCT05095207|DRUG|Bicalutamide|150 mg orally daily, day 1 to 28.
214564209|NCT05543707|DRUG|PBI-0451 (Pomotrelvir)|2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
214564210|NCT05543707|DRUG|Placebo|2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
214564211|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
214564212|NCT05691205|OTHER|PEEP|After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
214564213|NCT00804154|DRUG|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
214564214|NCT05020535|DRUG|MW189|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
214564215|NCT05020535|OTHER|Saline|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
214564216|NCT06453811|OTHER|Self-efficacy Theory-based Childbirth Preparation Program|According to the block randomisation method, the couples who are included in the experimental group by applying the pre-test will be included in the programme in groups of 3-4 couples by planning the day and time they can participate in the programme. At the end of the sessions, the training guide reflecting the training content will be given to the couples and they will be asked to read it at home and do their homework by using the relevant parts of the guide. At the same time, these couples will continue their routine pregnancy controls in the hospital. It is planned to complete the trainings once a week, twice in total and for two weeks. After the trainings are completed, it is planned to send at least three reminders by text message until the calculated delivery date. Brochures and text message content related to the training content will be used in the reminder.
214564217|NCT06073002|OTHER|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
214564218|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
214564219|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
214564220|NCT01622062|BIOLOGICAL|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
214564221|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
214564222|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
214564223|NCT01187381|DRUG|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
214564224|NCT01735227|DRUG|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
214564225|NCT01735227|DRUG|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
214708094|NCT05929352|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
214708096|NCT06799234|BIOLOGICAL|ChAdOx1 RVF|One 0.36mL dose contains 5x10\^10vp ChAdOx1 RVF.
214708097|NCT06799234|BIOLOGICAL|Rabies Vaccine|1mL per dose
214708098|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
214708099|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
214708100|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
214564226|NCT04685837|OTHER|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
214564227|NCT03812042|DIAGNOSTIC_TEST|Enzyme assay and molecular sequencing|Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
214564228|NCT06417710|OTHER|Neurological Assessment|Clinical neurological assessment performed by 2 raters
214564229|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214564230|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214564231|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214564232|NCT03197168|BEHAVIORAL|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
214564233|NCT03197168|BEHAVIORAL|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
214564234|NCT02630680|DRUG|Eziclen®/Izinova®|
214564235|NCT01853267|PROCEDURE|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
214564236|NCT01853267|PROCEDURE|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
214564237|NCT03455244|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
214564238|NCT03749317|DRUG|IVIEW-1201|IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
214564239|NCT03749317|DRUG|Placebo|Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
214564240|NCT05036980|DRUG|Trans Sodium Crocetinate|Single IV bolus
214564241|NCT04080037|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
214564242|NCT02336451|DRUG|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
214564243|NCT01214642|DRUG|pegfilgrastim|Administered subcutaneously
214564244|NCT01214642|DRUG|LY2523355|Administered intravenously
214708101|NCT04871139|OTHER|Radioactive Iodine|Given IV
214708102|NCT00695214|DRUG|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
215166417|NCT07196397|PROCEDURE|Cardiac sympathetic denervation|Cardiac sympathetic denervation is an interventional procedure aimed at reducing excessive sympathetic drive to the heart by ablating or removing components of the sympathetic nervous system. It is typically performed via a thoracoscopic approach and involves bilateral or left-sided denervation of the stellate ganglion and thoracic sympathetic chain (usually T2-T4). CSD is used in patients with arrhythmias associated with sympathetic overactivity, such as long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), or autonomic dysfunction-related tachyarrhythmias. The procedure helps reduce arrhythmic burden, modulate autonomic tone, and improve symptom control.
215166418|NCT07196397|BEHAVIORAL|Hybrid Cardiac Rehabilitation Program|A two-phase program combining supervised inpatient exercise, respiratory training, psychological support, and education with a home-based telerehabilitation phase (Nordic walking, remote ECG and vital sign monitoring). The aim is to restore functional capacity, reduce symptoms, and improve autonomic balance.
214564245|NCT00720031|BIOLOGICAL|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.~After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
214564246|NCT00482157|DRUG|Vitamin D (Calcitriol)|
215166419|NCT07196397|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique in which the vagus nerve is stimulated via surface electrodes placed on the skin, most commonly in the auricular region (e.g., tragus or cymba conchae). The intervention is performed using a certified external stimulation device that delivers mild electrical impulses to activate afferent vagal fibers. tVNS is used in the treatment of various conditions, including depression, epilepsy, migraine, chronic pain, and disorders of the autonomic nervous system such as postural orthostatic tachycardia syndrome (POTS) and inappropriate sinus tachycardia (IST). In this study, tVNS is applied as a supportive neuromodulatory therapy with individualized stimulation parameters and session duration based on clinical response and patient tolerance.
215166420|NCT07198152|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
215166421|NCT07198685|DRUG|bedaquiline|Administer 400 mg orally once daily for 2 weeks, followed by 200 mg orally three times a week for 22 weeks
215166422|NCT07198685|DRUG|Delamanid (DLM)|Administer 100 mg orally, twice daily for 24 weeks.
215166423|NCT07198685|DRUG|Linezolid (LZD)|Administer 600 mg orally, once daily for 24 weeks.
215166424|NCT07198685|DRUG|Levofloxacin|test group:Administer 800 mg orally, once daily for 24 weeks;control group:Administer 800 mg orally, once daily for 72 weeks
215166425|NCT07198685|DRUG|Cycloserine|Administer 250mg orally, twice daily for 72 weeks.
215166426|NCT07198685|DRUG|Clofazimine|Administer 100 mg orally, once daily for 72 weeks
215166427|NCT07196891|OTHER|frontal-QRST angle|The frontal QRS/T angle represents the angle between the ventricular depolarization (QRS) and repolarization (T) vectors on the ECG and serves as a parameter for assessing cardiac electrical heterogeneity. In this study, the frontal QRS/T angle was calculated using data obtained from standard 12-lead surface ECGs. The QRS and T axes in the frontal plane were derived from the automated ECG device reports.
215166428|NCT07196891|OTHER|Hunt-Hess scale|The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5: - Grade 1: Asymptomatic or minimal headache, slight neck stiffness. - Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy. - Grade 3: Drowsiness, confusion, or a mild focal deficit. - Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance. - Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance.
215166429|NCT07196891|OTHER|modified Fisher scale|The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed: - Grade 0: No hemorrhage apparent in CT. - Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH). - Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH. - Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH. - Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH.
214564247|NCT02353364|OTHER|PGS|Embryos screened by the validated NGS technology CNV-Seq
214564248|NCT05764135|BEHAVIORAL|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
214564249|NCT04045847|BIOLOGICAL|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
214564250|NCT00896597|DRUG|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
214564251|NCT00007670|DRUG|Carbamazepine|
214564252|NCT00007670|DRUG|Gabapentin|
214564253|NCT00007670|DRUG|Lamotrigine|
214564254|NCT00099749|DRUG|FTY 720|
214564255|NCT04554719|DRUG|68Ga-DOTA-FAPI|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
214564256|NCT04554719|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
214564257|NCT04554719|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
214564258|NCT04822077|RADIATION|Proton radiation|"* Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
214564259|NCT06142110|OTHER|Funcional movement screen|FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
214564260|NCT06142110|DIAGNOSTIC_TEST|Respiratory muscle strength|Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
214564261|NCT00724165|BEHAVIORAL|Intervention|Culturally-modified, individually tailored physical activity print materials
214564262|NCT00724165|BEHAVIORAL|Control|Bilingual health education booklets
215166430|NCT07196475|PROCEDURE|FOCAL LASER ABLATION OF PROSTATE|All monopolar TURP procedures were performed under spinal anaesthesia, whereas all TU-FLAP procedures were conducted under local anaesthesia with intravenous sedation. A single experienced surgical team performed all operations, with each surgeon having completed over 100 similar procedures prior to the study's initiation. Prophylactic antibiotic coverage with a third-generation cephalosporin has been administered at the time of anaesthesia induction. Cases were placed in the lithotomy position, followed by diagnostic urethrocystoscopy. In the TU-FLAP group, a 980 nm diode laser fig(1) by applying end-firing fiber fig(2) was introduced via the side working channel of a 22 Fr cystoscope under local anesthesia. Laser energy was applied at 15 watts for two minutes at multiple sites within the right and left prostatic lobes, approximately 1.5 cm distal to the bladder neck, with 1 cm spacing between punctures. In cases with an enlarged median lobe, one or two additional laser punctures were
215166431|NCT07196878|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|An ultrasound-guided puncture is performed to place one needle near the sciatic nerve and another near the peroneal nerve. Then, an electrical stimulus at 10 Hz is applied for 10 seconds, repeated 10 times.
215166432|NCT07199933|DRUG|Diacerein 50 mg Capsule|Drug:Diacerein 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
215166433|NCT07199933|DRUG|Placebo 50 mg|Drug:Placebo 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
215166434|NCT07196579|DRUG|KXV01 TCR Lentinvivo Injection|KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.
215166435|NCT07196111|BIOLOGICAL|BAFFR CAR-T|A single infusion of BAFFR CAR-T Injection administered intravenously.
215166436|NCT07198945|PROCEDURE|6-month follow-up|Eligible patients randomized to the 6-month follow-up arm will undergo their first surveillance procedure 6 months after the removal of their large polyp to check for recurrent polyp tissue.
215166437|NCT07198945|PROCEDURE|12-month follow-up|Eligible patients randomized to the 12-month follow-up arm will undergo their first surveillance procedure 12 months after the removal of their large polyp to check for recurrent polyp tissue.
215166438|NCT07198711|DRUG|Propofol - Emergence-from-LOR Protocol|Intravenous propofol infusion that meets the criteria: (1) maintenance of spontaneous ventilation, (2) sedation level corresponding to a Patient State Index (PSI) no lower than 25; and (3) loss of responsiveness (LOR) defined by the Richmond Agitation Sedation Scale (RASS) = -5 \[unarousable\]. Anesthesia is then maintained at that level for 30 minutes, followed by spontaneous emergence.
215166439|NCT07198711|DRUG|Propofol - Light Sedation Protocol|Intravenous propofol infusion titrated stepwise to reach a state where participants are sedated but have behavioral responsiveness. Sedation is maintained at this level for 30 minutes.
214564263|NCT00380302|DRUG|AVE1625|
214564264|NCT01293253|BEHAVIORAL|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
214564265|NCT03435302|DRUG|Temozolomide Plus Cisplatin|"Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide."
214564266|NCT03435302|DRUG|High-Dose IFN-a2b|Interferon belongs to the large class of glycoproteins known as cytokines.
214564267|NCT06203353|DIAGNOSTIC_TEST|diaphragm ultrasound monitoring|Ultrasound measure the diaphragm excursion, thickening fraction and maximal contraction and relaxation velocities
214708103|NCT06263699|PROCEDURE|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
214708104|NCT05799079|DRUG|Venetoclax|Given by mouth
214708105|NCT05799079|DRUG|Decitabine|Given by mouth
214708106|NCT05799079|DRUG|Cedazuridine|Given by mouth
215166440|NCT07199842|OTHER|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment
215166441|NCT07195695|DRUG|Zongertinib|Zongertinib
215166442|NCT07195695|DRUG|Pembrolizumab|Pembrolizumab
215166443|NCT07195695|DRUG|Atezolizumab|Atezolizumab
215166444|NCT07195695|DRUG|Durvalumab|Durvalumab
215166445|NCT07195695|DRUG|Nivolumab|Nivolumab
214564268|NCT03942692|OTHER|Phone call questionnaire|"Questionnaire for parents of subject about :~* the frequency of consultations with an allergist~* the information of the general practitioner or pediatrician~* the prescription of epinephrin auto-injector~* the frequency of renewal of epinephrin auto-injector~* the specialty of doctor who prescribed the renewal~* the implementation of specific measures in schools~* the frequency of renewal of specific measures in schools~* the number of recurrence of anaphylactic reaction~* the use of medical advice in case of recurrence of anaphylactic reaction"
214564269|NCT03008798|DRUG|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
214564270|NCT03008798|DRUG|The Placebo of Herbal Medicine C-117|
214564271|NCT04287699|OTHER|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
215166446|NCT07197216|BEHAVIORAL|Tap Trust|Home-based intervention includes tap water testing kits (instructions provided with videos or phone/Zoom), filtration devices if water quality concerns are identified, reusable water bottles and educational materials (handouts and videos), and phone/Zoom sessions with the research team using motivational interviewing.
215166447|NCT07197606|DRUG|Placebo|Intravenous injection of placebo
215166448|NCT07197606|DRUG|IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)|Intravenous injection of IxCell hUC-MSC-S
215166449|NCT07196657|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
215166450|NCT07196657|DRUG|Crisugabalin|For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.
215166451|NCT07199959|PROCEDURE|venipuncyure|venipuncture as clinical practical setting
215166452|NCT07199959|DRUG|Entrectinib|600mg, oral, once daily
215166453|NCT07197424|DIAGNOSTIC_TEST|Robot assisted magnetically controlled capsule endoscopy|Examination of the upper GI tract (oesophagus and stomach) with robot assisted magnetically controlled capsule endoscopy. Examination of the small bowel will be completed using the same capsule, however it will not be robot assisted.
215166454|NCT07198802|OTHER|No Intervention|This project involves no therapeutic intervention for the subjects.
215166455|NCT07197658|PROCEDURE|endodontic microsurgery / rotary bur osteotomy|Endodontic microsurgery will be executed by use of a rotary bur
215166456|NCT07197658|PROCEDURE|Endodontic microsurgery / piezo osteotomy|Endodontic microsurgery will be performed by use of a piezosurgery unit
215166457|NCT07197658|PROCEDURE|Endodontic microsurgery / bone window|'Bone window' technique will be performed by use of piezoelectric surgery
215166458|NCT07199634|OTHER|"Undetectable & You HIV treatment literacy app"|The app delivers information on the transmission prevention benefits of HIV treatment through the Undetectable Equals Untransmutable (U=U) message, alongside real-life video testimonials of patients living with HIV (PLHIV) and their partners. It underscores the key behavioral skills required for U=U, namely, ART adherence and viral load monitoring.
215166459|NCT07200115|DEVICE|Cervical Ripening Double Balloon (CRDB) Catheter|The physician will place a CRDB catheter for overnight cervical preparation. The CRDB catheter is comprised of two balloons that can be inflated with up to 80 mL of sterile water.
215166460|NCT07200115|DEVICE|Osmotic Dilators|Osmotic dilators (e.g., laminaria and Dilapan-S) are mechanical dilators that are placed in the cervix prior to gynecologic procedures and facilitate dilation through the slow absorption of moisture. The physician will place osmotic dilators in the standard fashion.
215166461|NCT07195773|DEVICE|rTMS|investigate the effects of repetitive transcranial magnetic stimulation on corticomotor excitability, balance performance, and mobility in patients with Parkinson's disease, and to further explore the effects on corticomotor excitability by single low-frequency and high-frequency repetitive transcranial magnetic stimulation. Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, corticomotor excitability, balance, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
215166462|NCT07196605|DRUG|Sodium Sivelestat|For enrolled patients, administer intravenous sodium sivelestat as soon as possible (recommended within 2 hours). The daily dosage is 4.8 mg/kg, delivered via continuous infusion with a microinfusion pump or intravenous drip, for a total duration of 5 days
215166463|NCT07199764|DRUG|Odetiglucan|Odetiglucan 4 mg/kg IV every 3 weeks
215166464|NCT07199764|DRUG|Mitazalimab|Mitazalimab 0.9 mg/kg IV every 3 weeks
215166465|NCT07196566|PROCEDURE|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.
215166466|NCT07199309|DRUG|MAR001|Subcutaneous Injection
215166467|NCT07199309|DRUG|Placebo|Subcutaneous Injection
215166468|NCT07195890|OTHER|A course of teen Mental Health First Aid to be provided to participants|The teen Mental Health First Aid course consists of three sessions developed in Mental Health First Aid in Australia. It has been translated and attuned to the Chinese in Hong Kong.
214564272|NCT03255005|DEVICE|Endomina|Endoscopic sleeve reduction
214564273|NCT03255005|BEHAVIORAL|Diet|Multidisciplinary follow-up
214564274|NCT00157027|PROCEDURE|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy \[ECP\]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
214564275|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
214564276|NCT06573749|DIETARY_SUPPLEMENT|Whey protein isolate supplement|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
214564277|NCT02868606|OTHER|Physiologic Insulin Therapy|
214564278|NCT02868606|OTHER|Sliding-Scale Insulin Therapy|
214564279|NCT05355857|DIAGNOSTIC_TEST|brain PET-MRI with 18F-FDG|Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
214564280|NCT00994175|DRUG|Pioglitazone|
214564281|NCT00994175|DRUG|Placebo|
214564282|NCT05157243|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
215166469|NCT07197515|BEHAVIORAL|Legal Navigation|• Participants will receive monthly outreach from a trained legal navigator over a 6-month period. The legal navigator is a lawyer (Juris Doctor, or JD) who will proactively address specific legal barriers the patient may encounter during treatment. Communication will include phone calls (and if requested, virtual consultations) tailored to patient needs. In between legal outreach periods, patients may call the legal navigator team themselves for legal needs that may arise.
215166470|NCT07197203|PROCEDURE|Sacral ESP Block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
215166471|NCT07197203|PROCEDURE|Caudal epidural block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
215166472|NCT07196488|OTHER|Dyadic Co-learning Intervention|Participants in the experimental group will receive routine care plus an 8-week Dyadic Co-learning Intervention, which will consist of three components: (1) a co-learning handbook, (2) a co-learning mobile app, and (3) professional support.
215166473|NCT07199452|DRUG|MK-4646|Oral Capsule
215166474|NCT07199452|DRUG|Rifabutin|Oral Capsule
215166475|NCT07196228|DEVICE|Intervention Name (Arm 1): Narrow tie-base abutment Intervention Name (Arm 2): Regular tie-base abutment|"Arm 1 - Narrow tie-base abutment~Intervention Name: Narrow tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a narrow-diameter tie-base abutment.~Arm 2 - Regular tie-base abutment~Intervention Name: Regular tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a regular-diameter tie-base abutment."
215166476|NCT07198048|BEHAVIORAL|Music-Based Therapy for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to randomized selections from the playlist that meets their needs that day (i.e., energizing or relaxing). Participants will listen to their music selections on shuffle for 30 minutes per day for 8 weeks using the strategies provided by the music therapist. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after music listening. The music therapist will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the music therapist will update the music playlists and help submit their logs.
214564283|NCT05157243|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
214564284|NCT05157243|DRUG|Placebo|Two matching placebo tablets administered orally with food twice daily for 5 days
214564285|NCT05157243|OTHER|Standard of Care|Local standard of care for COVID-19
214564286|NCT00003072|DRUG|amifostine trihydrate|
214564287|NCT00003072|DRUG|carboplatin|
214564288|NCT00003072|DRUG|paclitaxel|
214564289|NCT05802316|DEVICE|tracheal intubation using videolaryngoscope with a hyperangulated blade or standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)|In the awake group tracheal intubation performed by an videolaryngoscope with a hyperangulated blade. In the asleep group the standard intubation were performed by videolaryngoscopy (VL) and direct laryngoscopy (DL)
214564290|NCT02954198|DRUG|Tacrolimus|goal trough level 5-12ng/mL
214564291|NCT02954198|DRUG|Prednisone|goal dose 5mg QD
214564292|NCT02954198|DRUG|Mycophenolate mofetil|goal dose 1g BID
214564293|NCT02954198|DRUG|Everolimus|goal trough level 3-8ng/mL
214564294|NCT01220245|PROCEDURE|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
214564295|NCT01220245|PROCEDURE|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
215166477|NCT07198048|BEHAVIORAL|Audiobook Intervention for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to an audiobook selected with a speech-language pathologist (SLP). Participants will listen to their audiobook for 30 minutes per day for 8 weeks using the strategies provided by the SLP. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after audiobook listening. The SLP will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the SLP will update the audiobook library and help submit their logs.
215166478|NCT07195825|GENETIC|Injecting BBM-P002 into the bilateral putamen|BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's Disease
214564296|NCT05774197|BEHAVIORAL|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
214564297|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
214564298|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
214564299|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
215166479|NCT07200024|OTHER|Virtual functional- based treadmill training|rehabilitation technique that combines virtual reality (VR) with treadmill training to improve gait, balance, and functional mobility for individuals with conditions like stroke
215166480|NCT07200024|OTHER|gait training|a specialized form of physical therapy focused on improving a person's walking ability, balance, and coordination after an injury, stroke, neurological condition, or other illness.
215166481|NCT07199725|COMBINATION_PRODUCT|immediate dental implant|control group: 8 teeth were extracted then 8 immediate implants were placed without bone grafting
215166482|NCT07199725|COMBINATION_PRODUCT|immediate dental implant, natural bovine bone substitute material|study group: 8 teeth were extracted then received 8 immediate implants followed by grafting with natural bovine bone substitute material with hyaluronic acid
215166483|NCT07196306|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution|At the time of enrollment, the intervention arm subjects are administered single or double dose of study drug while the placebo arm subjects are administered the placebo drug (normal saline). Subjects will be assigned to the intervention or placebo arm in random order.
215166484|NCT07196306|DRUG|Placebo|Normal saline 0.9% 1.14 mL Subcutaneous x 1 or 2 dose(s)
215166485|NCT07199023|DIETARY_SUPPLEMENT|Amino Acid Formula (AAF)|A formula composed of 100% free amino acids with no intact cow's milk protein. Participants will be fed AAF ad libitum according to their nutritional needs. Daily intake and symptoms will be recorded through an electronic diary (eCOA).
214564300|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
214564301|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
214564302|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
214564303|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
214564304|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
214564305|NCT06703229|DRUG|The Transversus Abdominis Plane (TAP) block|or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.
214564306|NCT06703229|DRUG|The transverse abdominis plane (TAP) block|Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
214564307|NCT06715878|PROCEDURE|Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation|Under the visualization of ultrasound contrast imaging through the operative channel, a microwave ablation probe was inserted into the tumor (at the interface between the tumor and kidney, close to the tumor base). The microwave ablation device was used, with a power setting of 70 W for initiating microwave ablation. Depending on the tumor volume and depth, 1-3 ablation cycles were performed, with each cycle lasting 1-3 minutes. After reaching the pseudocapsule of the tumor, a combination of blunt dissection, sharp cutting, and blunt dissection was employed to separate the tumor from the renal parenchyma . The renal artery was not occluded during the procedure.If intraoperative injury to the collecting system is suspected, the collecting system should be sutured normally, while simultaneously suturing the outer layer of renal parenchyma to prevent urine leakage.
214564308|NCT06715878|PROCEDURE|robotic-assisted laparoscopic partial nephrectomy|robotic-assisted laparoscopic partial nephrectomy
214564309|NCT06725069|OTHER|Neuromuscular Electrical Stimulation|NMES was performed using the Enraf Nonius Myomed 632X device. Both applications were performed 5 days/week for 4 weeks. NMES was performed with the patients in a sitting position and the affected arm resting on a table with the forearm supinated (Agonist group) / forearm pronated (Antagonist group). Surface electrodes (50x50 mm self-adhesive) were placed on the wrist and finger flexor/extensor muscle group. NMES parameters; Symmetric biphasic, pulse width 200 μs, on time 6 seconds (ramp up 1 second, ramp down 2 seconds), off time 12 seconds, stimulation intensity according to the patient's tolerance (not exceeding 90 mA), frequency 50 Hz and was adjusted to elicit contraction in the flexor and extensor muscles of the wrist and fingers.
214564310|NCT06725069|OTHER|Control (Standard treatment)|In addition to conventional treatment, participants were included in an occupational rehabilitation program for 20 minutes to improve upper extremity functions.
214564311|NCT06729398|DEVICE|NIRS|NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours
214564312|NCT06729398|OTHER|SafeboosC|SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
214564313|NCT06729008|DIETARY_SUPPLEMENT|Diabetes-specific nutrition formula (DSNF)|The diabetes-specific nutrition formula to be used in this study will be Glucerna (Abbott Laboratories). It features an advanced blend of low-glycemic carbohydrates for steady energy release, a dual fiber blend to support digestive health, and a unique lipid blend free from trans fats, cholesterol, and low in saturated fat. Additionally, Glucerna is enriched with 4x more inositol and high levels of trivalent chromium, which contribute to maintaining normal blood glucose levels. It provides 28 essential vitamins and minerals, is low in lactose, and gluten-free, making it a suitable option for various dietary needs. 5 scoops will be mixed in 200 mL of water, and this amounts to 228 calories, with 30.01g of carbohydrates, 10.16g of protein, and 8.70g of fat. This will be given twice, as a breakfast replacement and an afternoon snack replacement.
214564314|NCT06729008|OTHER|Medical Nutrition Therapy|Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
214564315|NCT06731803|DRUG|Trastuzumab deruxtecan + 5FU/LV|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
215166486|NCT07199023|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Formula (eHF)|A formula in which cow's milk proteins are broken down into small peptides through enzymatic hydrolysis, reducing allergenicity. Participants will be fed eHF ad libitum based on their nutritional needs. Intake and symptoms will be tracked through an electronic diary (eCOA).
215166487|NCT07200037|BEHAVIORAL|inspiratory muscle training|This intervention will include a long term program of 8 weeks IMT in PMV patients who these patients who have required at least 6h of mechanical ventilation for 21 consecutive days.
214564316|NCT06731803|DRUG|Trastuzumab deruxtecan + FLO|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles FLO: oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
214564317|NCT06729047|DRUG|normal Saline|patients will receive placebo (normal saline)
215166488|NCT07197138|DEVICE|Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS|iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.
215166489|NCT07198061|DEVICE|Cold Atmospheric Plasma (CAP)|CAP-activated gas treatment developed by Xi'an Jiaotong University (Chinese patent No. ZL202110209052.X); administered once daily for 10 days, 25 minutes per session.
215166490|NCT07198061|DEVICE|Sham CAP Therapy|Identical equipment without plasma activation; simulates treatment environment (sound, airflow) for participant blinding.
215166491|NCT07198061|PROCEDURE|Infrapopliteal Endovascular Revascularisation|Balloon angioplasty is performed on infrapopliteal arteries with significant stenosis or occlusion. Technical success is defined as \<30% residual stenosis, confirmed intraoperatively by digital subtraction angiography (DSA). Only patients with successful revascularisation are eligible for randomisation.
214564318|NCT06729047|DRUG|Neostigmine|patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
214564319|NCT06729047|DRUG|Ketorolac|patients will receive ketorolac (0.5 mg/kg)
214564320|NCT06727968|PROCEDURE|Compression Stocking|Wear the compression stockin at least 6-8 hours/day
214564321|NCT06727968|PROCEDURE|Therapeutic exercise|Home-based exercise programm based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting, and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day.
214564322|NCT06727968|PROCEDURE|Self-massage|Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.
214708107|NCT05799079|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy
214708108|NCT05799079|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215166492|NCT07198061|OTHER|Guideline-Based Standard DFU Care|All participants will receive diabetic foot ulcer (DFU) care according to current international and Chinese clinical guidelines
215166493|NCT07196618|DRUG|dimethyl sulfoxide|dentin pretreated using dimethyl sulfoxide and follow up of patients at 2 weeks, 3 months and 6 months
215166494|NCT07196618|DRUG|Cholorhexidine|dentin pretreated using chlorhexidine and follow up of patients at 2 weeks, 3months and 6 months
215166495|NCT07199998|OTHER|Samples collection (whole blood, urine, vaginal and cervical cells)|During the clinical visit, samples will be collected from participants, including blood, urine, and vaginal and cervical cells. These samples will be used for a range of analyses, including determination of the vaginal microbiota composition and sequencing, cytokine profiling, and assessment of local immunity through flow cytometry using CyTOF technology. Urine samples will be analyzed for pollutants such as phthalates and bisphenol, while blood samples will be used for blood cell counts.
214564323|NCT06727968|PROCEDURE|Prevention measures|"General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC."
214564324|NCT06728514|PROCEDURE|Erector spinae plane block group.|In ESPB technique the linear transducer will be placed over the spinous process of the vertebra and a point 3 cm lateral to it are marked at the T10-T11 level before performing the block. Under aseptic precautions, the 23G spinal needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra. The transverse process of the thoracic vertebra lies at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, local anesthetic is injected in 3-5 ml aliquots. A volume of 20-25 ml of 0.25% bupivacaine will be used for analgesia on each side depending upon the surgery and requirements. The number of attempts will be noted.Time taken to perform block in minutes will be noted from placing transducer to taking out needle after injecting drug in plane.
214564325|NCT06728514|PROCEDURE|Paravertebral Nerve Block|In PVB technique the patient will be placed in the lateral position, and the superior aspect of the T9,T10 and T11 spinous processes will be identified. Under complete aseptic precautions and after skin infiltration with LA, 23G spinal needle will be inserted perpendicular to the skin, with the goal of contacting the tranverse process. Once the TP is contacted, generally at a depth of 2 to 5 cm in adults, the needle is withdrawn into the subcutaneous tissue, redirected in a caudal direction, and then slowly advanced with the purpose of entering the PVS at an approximate depth of 1.0 to 1.5 cm past the initial contact with the TP. After perforating the costotransverse ligament and negative aspiration for blood, air, or spinal fluid,10 mL of 0.25% bupivacaine will be injected at each level superficial to to the pleural line. Displacement of the pleura line anteriorly will be confirmed proper injection of the local anaesthetic solution. The number of attempts will be noted.
214564326|NCT06728514|DRUG|Inj Bupivacaine|Inj Bupivacaine 0.25% (10ml) in both groups
214564327|NCT06727474|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL) with EQ-5D-3L|The EQ-5D-3L and EQ-VAS questionnaires, administered at all visits, evaluated five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Responses generated a Health Status sequence and calculated the EQ-5D-3L Index. A visual analogue scale (VAS) rated health from 0 (worst) to 100 (best). Functional capacity was assessed using the Katz Index (IK) and Timed Up and Go (TUG), which measured the time to rise from a chair, walk 3 meters, and return. Anthropometric variables, measured by the same researcher (LP) at 1 month and 1 year, included limb circumferences using specific techniques. Muscle strength, evaluated with the EF-MRC scale, involved verbal commands for movement tests. Calf circumference was measured on the largest circumference area. Living conditions and work reintegration were recorded. Health issues detected during follow-up were referred to the clinic's coordinating physician for appropriate care.
214564328|NCT06891560|DRUG|Enfortumab Vedotin|intravenously on Days 1, 8 and 15 of a 28-day cycle
214564329|NCT04962997|OTHER|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient."
214564330|NCT06906380|OTHER|Non interventional study|Non Intervention, an observation LTFU study
214564331|NCT03553511|PROCEDURE|Vaginal vault suspension to the uterosacral ligaments|Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments
214564332|NCT03553511|PROCEDURE|McCall culdoplasty|Vaginal hysterectomy with McCall culdoplasty
214564333|NCT01477580|BIOLOGICAL|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564334|NCT01477580|BIOLOGICAL|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564335|NCT01477580|BIOLOGICAL|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
214564336|NCT01477580|BIOLOGICAL|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564337|NCT01477580|BIOLOGICAL|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564338|NCT01477580|BIOLOGICAL|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
214564339|NCT01477580|BIOLOGICAL|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
214564340|NCT01477580|BIOLOGICAL|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564341|NCT01477580|BIOLOGICAL|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564342|NCT01477580|BIOLOGICAL|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564343|NCT01477580|BIOLOGICAL|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564344|NCT01477580|BIOLOGICAL|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
214564345|NCT01477580|BIOLOGICAL|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
214564346|NCT03345576|DEVICE|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
214564347|NCT03345576|DRUG|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
214564348|NCT07153991|DRUG|Donepezil group|Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months
214564349|NCT07153991|DRUG|Placebo group|35 Pacients with tinnitus received for 3 months placebo medication
214564350|NCT07154966|OTHER|Standard Chemotherapy (Carboplatin-Paclitaxel)|Standard-of-care chemotherapy with carboplatin (AUC 5, every 21 days) and paclitaxel (175-200 mg/m², every 21 days) for six cycles. No additional drugs, dose modifications, or alternative regimens introduced.
214564351|NCT07155798|DEVICE|bamboo toothbrush|recent toothbrush
214564352|NCT07155798|DEVICE|conventional toothbrush|conventional toothbrush
214564353|NCT07153874|OTHER|Physical exercise rehabilitation intervention|12 weeks of physical exercise intervention, including aerobic snd anaerobic exercise at home. 36 sessions of monitorized training with distance supervision.
214564354|NCT07155408|DRUG|Povidone-Iodine 10%|Preoperative skin antisepsis performed with 10% povidone-iodine solution according to standard surgical preparation guidelines before hair transplantation.
214564355|NCT07155408|DRUG|Povidone-Iodine + Rifampicin|Preoperative skin antisepsis performed with a combination of 10% povidone-iodine and rifampicin solution according to study-specific preparation guidelines before hair transplantation.
214564356|NCT07155473|DIAGNOSTIC_TEST|C-peptide dosage|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT)
214564357|NCT07155265|DRUG|Remimazolam Besylate|Continuous IV infusion; start 0.10 mg/kg/h and titrate every 15-30 minutes in 0.025-0.05 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5 for clinical safety). Maximum typical rate 0.20 mg/kg/h; temporary higher rates permitted per protocol for breakthrough agitation.
214564358|NCT07155265|DRUG|Midazolam|Continuous IV infusion; start 0.04 mg/kg/h and titrate every 15-30 minutes in 0.01-0.03 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5). Maximum typical rate 0.20 mg/kg/h per protocol.
214564359|NCT07155304|PROCEDURE|percutaneous sigmoid colon fixation|after endoscopic sigmoid colon untwisting , percutaneous colon fixation using anchor device
214564360|NCT06272500|OTHER|oral administration of receives only oral administration of placebo|receives oral administration of placebo, with two capsules before each meal.
214564361|NCT06272500|DIETARY_SUPPLEMENT|oral administration of Betaine hydrochloride|receives oral administration of Betaine hydrochloride(BHCL), with two capsules before each meal.
214564362|NCT05576753|PROCEDURE|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
214708109|NCT03894098|PROCEDURE|Nerve block|High ankle nerve block
215166496|NCT07196683|PROCEDURE|Regenerative pulpotomy|Regenerative pulpotomy combines the use of hydraulic calcium silicate based cements; MTA, together with biodegradable scaffolds such as PRF.
215166497|NCT07199426|OTHER|Physical-Cognitive Training|Participants will receive an 8-week physical-cognitive training program using the Blazepod device, consisting of exercises targeting both balance and cognitive skills. Sessions will be conducted three times per week, each lasting one hour.
214708110|NCT02330913|PROCEDURE|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
214708111|NCT01927393|OTHER|palliative care|Receive PCPI
214708112|NCT01927393|BEHAVIORAL|educational intervention|Receive education sessions
214708113|NCT01927393|PROCEDURE|quality-of-life assessment|Ancillary studies
214708114|NCT01927393|OTHER|questionnaire administration|Ancillary studies
214708115|NCT01927393|BEHAVIORAL|telephone-based intervention|Receive telephone contacts
214708116|NCT01241123|PROCEDURE|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
214708117|NCT01241123|DRUG|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
214708118|NCT01241123|RADIATION|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
214708119|NCT01241123|DEVICE|pedometers|to record the amount of ambulation
214708120|NCT04365894|OTHER|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
214708121|NCT05236036|DRUG|Mycophenolate Mofetil|Given PO
214708122|NCT05236036|OTHER|Quality-of-Life Assessment|Ancillary studies
214708123|NCT05236036|RADIATION|Radiation Therapy|Receive radiation therapy
214708124|NCT05236036|DRUG|Temozolomide|Given Orally (PO)
214708125|NCT00954057|DRUG|LIPO-102|intraorbital injection
214708126|NCT00954057|DRUG|Placebo|intraorbital injection
214708127|NCT05814471|DEVICE|Cable fastening system and 3d printed straps(14 days)|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
214708128|NCT05814471|DEVICE|Velcro straps system(14 days)|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
214708129|NCT05814471|DEVICE|Adjustment period(Velcro-14 days)|The participants will wear a new Odra knee brace held in place with by a velcro straps system for 2 weeks.
214564363|NCT05947032|OTHER|Supervised endurance exercise training + Patient Education|"ENDURANCE TRAINING:~Treadmill Walking:~Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training~Recumbent Bike:~Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training~\+ Patient Education"
214564364|NCT05947032|OTHER|Home exercises + Patient Education|"HOME EXERCISES:~CONVENTIONAL Treatment:~Walking:~Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training~Stair climbing:~Frequency: 1 flight/ day Type: aerobic training~\+ Patient Education"
214564365|NCT04695912|DEVICE|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
214564366|NCT03861026|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
215030357|NCT04813120|BEHAVIORAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
214564367|NCT04593953|PROCEDURE|TLIP|Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
214564368|NCT06475963|OTHER|surveys|telephone survey
214564369|NCT03953924|OTHER|Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)|The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
214564370|NCT01431495|DRUG|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
214564371|NCT01431495|DRUG|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
214564372|NCT02081430|PROCEDURE|CT Manipulation|
214564373|NCT02081430|PROCEDURE|Upper trapezius stretch|
214564374|NCT01732822|DRUG|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
214564375|NCT01732822|DRUG|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
215030358|NCT04813120|BEHAVIORAL|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
215030359|NCT04855890|PROCEDURE|Ablation|The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
215030360|NCT03648892|DRUG|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
215030361|NCT03648892|DRUG|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
215030362|NCT01889446|DIETARY_SUPPLEMENT|Calcium propionate|
215030363|NCT03391791|GENETIC|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
215030364|NCT03338920|DRUG|sumatriptan nasal powder|nasal powder administered via nosepiece
215030365|NCT03338920|DRUG|Placebo|lactose monohydrate powder administered via nosepiece
214564376|NCT02912923|OTHER|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
214564377|NCT02912923|OTHER|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
214564378|NCT01620268|DRUG|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
214564379|NCT02315300|DEVICE|medilog® DARWIN FD12|
214564380|NCT02315300|DEVICE|Continuous Glucose Monitoring|
214564381|NCT02314780|DRUG|Heme arginate 3mg/kg|
214564382|NCT02314780|DRUG|Heme arginate 1mg/kg|
214564383|NCT02314780|DRUG|Placebo|
214564384|NCT00109330|BIOLOGICAL|Combined diphtheria, tetanus, acellular pertussis vaccine|
214564385|NCT04396652|PROCEDURE|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
214564386|NCT04396652|PROCEDURE|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
214564387|NCT04396652|PROCEDURE|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
214564388|NCT04579718|OTHER|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
214564389|NCT04579718|OTHER|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
214564390|NCT06224127|DEVICE|active heat|Users receive an active Soovu heating pod(s).
214564391|NCT06224127|DRUG|Active c tactile fiber stimulation|Hair brushes that activate c tactile fibers
214564392|NCT06224127|DEVICE|sham heat|A Soovu heating pod(s) in the subtherapeutic temperature range
214564393|NCT06224127|DEVICE|Sham c tactile fiber stimulation|Hair brushes that do not activate c tactile fibers
214564394|NCT02413853|DRUG|CBP/beta-catenin Antagonist PRI-724|Given IV
214564395|NCT02413853|BIOLOGICAL|Bevacizumab|Given IV
214564396|NCT02413853|DRUG|Leucovorin Calcium|Given IV
214708130|NCT03646760|BEHAVIORAL|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
215166498|NCT07199426|OTHER|Conventional Balance Training|Participants will receive an 8-week conventional balance training program. Sessions will be conducted three times per week, each lasting one hour.
215166499|NCT07199777|DRUG|SNP318|Once daily, oral administration
215166500|NCT07199777|DRUG|Placebo|Once daily, oral administration
215166501|NCT07198204|OTHER|isometric exercises|Isometric quadriceps exercise: Patients lie in a supine position. A rolled-up towel was put beneath the knee. They were instructed to maximally activate their thigh muscles to straighten their knee and hold the contraction for 5 seconds (Group A), 10 seconds (Group B), or 20 seconds (Group C).
215166502|NCT07198204|OTHER|therapeutic ultrasound|all patients will reciece ultrasound for 5 minutes using 1MHz frequency, 0.8 wc2, 5cm2 head with adequate gel as a coupling medium
215166503|NCT07198204|OTHER|Transcutanous electrical nerve stimulation|all participants will recieve TENS for 30 minutes per session. the parameters will be Burst TENS, with main frequency of 100Hz, burst frequency of 4 Hz, intensity to the comfortable muscle twitch, electrodes size according to the size of the patients knee.
215166504|NCT07198607|OTHER|Pistacia lentiscus Oil Nasal Drops (Bactorinol®)|Bactorinol® nasal drops (medical device containing ultra-fractioned and winterized Pistacia lentiscus oil). Participants will receive isotonic saline nasal wash plus 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
215166505|NCT07198607|OTHER|Placebo Nasal Drops (matched to Bactorinol®)|Placebo nasal drops identical in appearance and administration to Bactorinol®. Participants will receive isotonic saline nasal wash plus placebo drops, 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
215166506|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 1|Subject receives dietary supplement for 90 days
215166507|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 2|Subject receives dietary supplement for 90 days
214564397|NCT02413853|DRUG|Oxaliplatin|Given IV
214564398|NCT02413853|DRUG|Fluorouracil|Given IV
214564399|NCT02413853|OTHER|Laboratory Biomarker Analysis|Correlative studies
215166508|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 3|Subject receives dietary supplement for 90 days
215166509|NCT07199829|OTHER|Placebo|Subject receives placebo for 90 days
215166510|NCT07197970|DEVICE|NxiDIME™ Intracranial Drug-Eluting Stent System|The experimental group will receive the NxiDIME™ Intracranial Drug-Eluting self-expanding Stent System (RICOTON Technology Co., Ltd.)
215166511|NCT07197970|DEVICE|NOVA DES Intracranial Drug-Eluting Stent|The experimental group will receive the NOVA DES Intracranial Drug-Eluting balloon-expandable stent System
215166512|NCT07198360|OTHER|No intervention|Not found
214564400|NCT04998929|OTHER|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
214708131|NCT03646760|BEHAVIORAL|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
214708132|NCT04904614|DRUG|Letermovir|Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
214708133|NCT02816879|PROCEDURE|Cytology Specimen Collection Procedure|Undergo anal cytology collection
215166513|NCT07198997|OTHER|digital anesthesia|mandibular anestezi ile digital intrsosseoz anesteziyi kıyasslayan calısma yok.
214708134|NCT02816879|OTHER|Laboratory Biomarker Analysis|Correlative studies
214708135|NCT03241732|OTHER|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
214708136|NCT03241732|DIETARY_SUPPLEMENT|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
215166514|NCT07199075|BEHAVIORAL|Questionnaires|"Questionnaires~* Oswestry Disability Index (ODI)~* Pain NRS lower back and (wors side) leg~* EQ-5D-3L"
215166515|NCT07199075|RADIATION|Computer Tomography|One additional CT scan is performed for some patients
215166516|NCT07198425|OTHER|Successful decannulation group|Patients who successfully completed the decannulation process and had their tubes removed, with no reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours after decannulbation.
215166517|NCT07198425|OTHER|Successful decannulation group|Patients who did not pass the decannulation process, and the multidisciplinary team advised against removal of the tracheostomy tube; or patients who passed the decannulation process and had the tracheostomy tube removed but required reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours due to medical conditions.
215166518|NCT07198035|DRUG|PF-07248144|Participants will receive a single dose of PF-07248144 by mouth in Period 1 on Day 1 and Period 2 on Day 14, with a washout period of at least 14 days between two doses of PF-07248144
215166519|NCT07198035|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for Day 1 through 3, then twice a day for Day 4 through 7, and then three times daily for Day 8 through 20 in Period 2.
215166520|NCT07199647|OTHER|Questionnaire Administration|Participants completed a sociodemographic questionnaire, the Hospital Anxiety and Depression Scale, the Pain Beliefs Questionnaire, the Complementary, Alternative, and Conventional Medicine Attitude Scale, the Complementary and Alternative Medicine Health Belief Scale, and the Three-Factor Spiritual Well-Being Scale.
215166521|NCT07198451|DRUG|Gemcitabine Submucosal Injection|A chemotherapeutic agent. Administered via submucosal injection into the bladder wall using a specialized injection gun. Dosage: 1000mg per injection. Regimen: One injection immediately post-TURBT, followed by one injection every three months for a total of four injections.
215166522|NCT07198451|DRUG|Gemcitabine Intravesical Instillation|Standard therapy. Administered by instilling a solution into the bladder via a catheter. Dosage: 2000mg dissolved in 50mL normal saline per instillation. Regimen: One instillation immediately post-TURBT, followed by an induction phase (once weekly for 8 weeks) and a maintenance phase (once monthly for 10 months). The solution is retained for 30-60 minutes.
215166523|NCT07199621|PROCEDURE|uterine incision by scissors versus scalpel|procedure in uterotomy in cs
215166524|NCT07199114|BEHAVIORAL|Adapted CrossFit Program (12 weeks)|Supervised sessions focused on functional, multi-joint movements adapted for older adults; emphasis on safety and progressive overload.
215166525|NCT07197944|DRUG|Glepaglutide|Subcutaneous (SC) injections twice weekly
215166526|NCT07197944|OTHER|Placebo|SC injections twice weekly
215166527|NCT07199218|DRUG|Terpenes-Enriched CBD-Predominant Oil|Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD/THC: 280/10 mg per g) produced by Bazelet Group, Israel.
215166528|NCT07199218|DRUG|Placebo|Oral olive oil with added flavors to mimic the appearance, texture, and taste of the study drug, administered in two daily doses.
215166529|NCT07199218|DRUG|Terpenes-Enriched CBD Oil (THC-Free)|Oral cannabidiol (CBD; 7.2 mg/kg/day) and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD- 280 mg per g) produced by Bazelet Group, Israel.
215166530|NCT07199374|BEHAVIORAL|PARCA|PARCA is an s an app to facilitate goal management, resource allocation, and managing progress.
215166531|NCT07199738|DEVICE|Cemented CoCr|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (CoCr) Femoral component
215166532|NCT07199738|DEVICE|Cemented Oxinium|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (Ox) Femoral component
215166533|NCT07199738|DEVICE|Cementless|Primary TKA performed using the LEGION MS with CONCELOC Tibia with LEGION CR porous (without HA) Femoral component
214708137|NCT03241732|BEHAVIORAL|Neuro Emotive Technique|Neuro Emotive Technique sessions
214708138|NCT04906135|OTHER|Experimental manipulation of stimulation parameters|This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
214708139|NCT04702165|DEVICE|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
214708140|NCT05380453|BIOLOGICAL|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
214708141|NCT05380453|DRUG|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
215166534|NCT07199140|BEHAVIORAL|Haptonomy|Pregnant participants will receive a four-session haptonomy intervention, each lasting approximately 45 minutes. The sessions aim to enhance body awareness, reduce childbirth-related anxiety, and support birth self-efficacy. The intervention includes breathing exercises, relaxation techniques, and activities promoting maternal-fetal interaction.
215166535|NCT07200076|PROCEDURE|Quadratus Lumborum (QL) Block|"In the QLB-2 approach, a needle will be inserted in-plane from anterior to posterior, directed towards the posterior QL muscle border, and a 20 ml solution of 0.25% ropivacaine will be injected.~For the QLB-3 approach, the needle will be inserted in-plane from anterior to posterior, traversing the QL muscle's proper fascia to target the plane between the QL and PM muscles, and a 20 ml solution of 0.25% ropivacaine will be injected."
215166536|NCT07198568|DIAGNOSTIC_TEST|Surface electromyography|A previous other study has examined the suprahyoid muscle activity patterns in sarcopenic dysphagia patients using surface electromyography (sEMG). However, there was a lack of research analyzing the swallowing dynamics of sarcopenic dysphagia alongside Videofluoroscopic Swallowing Study (VFSS). VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. Therefore, the present study aims to investigate the characteristics of sarcopenic dysphagia across phases using sEMG and VFSS. Additionally, the investigators aim to analyze the relationship between suprahyoid muscle activity patterns and swallowing dynamics utilizing these modalities.
215166537|NCT07198568|DIAGNOSTIC_TEST|Videofluoroscopic swallowing study (VFSS)|VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. The investigators will utilize Videofluoroscopic Dysphagia Scale (VDS), that composed of fourteen categories, which can be divided into oral and pharyngeal phases to assess scores based on VFSS results. The oral phase composed of 7 items (lip closure, bolus formation, mastication, apraxia, tongue-to-palate contact, premature bolus loss, and oral transit time). The pharyngeal phase also included 7 items (triggering of pharyngeal swallowing, vallecular residues, pyriform sinus residues, laryngeal elevation, coating of pharyngeal wall, pharyngeal transit time, and aspiration). VDS can assess the components of dysphagia in such detail. Therefore, investigators can evaluate the etiology of dysphagia more precisely.
215166538|NCT07197229|BEHAVIORAL|Pulmonary Rehabilitation|A tailored pulmonary rehabilitation program combining hospital-based and home-based components over 12 weeksParticipants undergo a 12-week structured PR program including both hospital-based sessions (education, structured exercise, nutrition counseling, smoking cessation) and home-based exercises (daily walking, strength training progression
215166539|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ia)~Low dose group， Middle dose group； High dose group； Control group ：Placebo"
215166540|NCT07198555|DRUG|Placebo|Placebo(phase Ia)
215166541|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group~Control group ：Placebo"
215166542|NCT07198555|DRUG|Placebo|Placebo（phase Ib）
215166543|NCT07199491|BEHAVIORAL|Healthy Liver/Hígado Sano program|Participants will attend weekly classes over the 6-month period. This consists of 16 core sessions delivered in the first 6 months (weekly, but with flexibility to skip weeks as necessary due to holidays, etc). The sessions are 30-60 minutes long, conducted in a group setting, with a CDC-certified Lifestyle Coach facilitating the sessions.
214564401|NCT04659577|BEHAVIORAL|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
215166544|NCT07199491|BEHAVIORAL|Usual Care|participants will first complete a 30- to 45-minute questionnaire that will cover topics such as physical activity, diet, alcohol use, and stress.Participants will then be asked to wear an accelerometer for 7 days and complete a log to identify when it was worn and removed each day.Height and weight will also be measured and a Fibroscan® assessment (to measure amount of fat and scar tissue in the liver), as well as blood work to monitor the liver enzymes will be done
214564402|NCT05205187|PROCEDURE|Healthy control specimen collection|Collecting blood and feces from healthy population.
215166545|NCT07198334|OTHER|Heat acclimation|Passive heat acclimation was designed to induce adaptation in participants through 14 consecutive days of controlled 5-minute whole-body immersion in water at 45°C.
215166546|NCT07199296|DRUG|Orelabrutinib|orelabrutinib 150mg/day PO once daily
215166547|NCT07199296|DRUG|Rituximab (R)|rituximab 375 mg/m² IV on day 1, 8, 15, 22 in Cycle 1, then day 1/cycle
215166548|NCT07199296|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|the reference doses are as follows (each center may adjust them as appropriate based on actual conditions): carmustine 300mg/m² IV d-1; etoposide 200mg/m² IV d-6-(-3); cytarabine 200mg/m² IV d-6-(-3); melphalan 140mg/m² IV d-2.
215166549|NCT07199296|DRUG|orelabrutinib maintenance|orelabrutinib 150mg/day PO once daily
215166550|NCT07197892|OTHER|CIRCA Texting Platform|Two-way texting platform that uses artificial intelligence to match patient texts to clinician-vetted responses and send educational content
215166551|NCT07199348|DEVICE|Embobio|Embolization with the device Embobio
214564403|NCT05205187|PROCEDURE|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
214564404|NCT05205187|PROCEDURE|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
214564405|NCT02083107|DRUG|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
214564406|NCT02083107|OTHER|Placebo|
214564407|NCT01056900|PROCEDURE|Autologous Chondrocyte Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
214564408|NCT01115127|DIETARY_SUPPLEMENT|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
214564409|NCT01115127|DIETARY_SUPPLEMENT|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
215166552|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke with AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the AI-based decision support system (CO-AIDER). Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
215166553|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke without AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the clinical team based on their expertise. Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
214564410|NCT01115127|DIETARY_SUPPLEMENT|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
214564411|NCT00310934|DRUG|methadone|
214564412|NCT00310934|DRUG|buprenorphine / methadone sequence|
215166554|NCT07198672|DRUG|Herombopag|Each T-DM1 treatment cycle typically lasts 3 weeks, with prophylactic administration of eltrombopag continuing until 21 days after the end of that T-DM1 treatment cycle. Oral administration of eltrombopag ethanolamine tablets begins on the evening of the first day of each T-DM1 treatment cycle, starting at a dose of 7.5 mg once daily.
215166555|NCT07198633|DRUG|QLC5508|B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol.
215166556|NCT07198633|DRUG|abiraterone acetate|An oral CYP17 inhibitor; abiraterone acetate will be administered orally at the dose and dosing frequency specified in the protocol
215166557|NCT07198633|DRUG|enzalutamide|An oral androgen receptor inhibitor; enzalutamide will be administered orally at the dose and dosing frequency specified in the protocol.
214564413|NCT00310934|BEHAVIORAL|Relapse prevention|
214564414|NCT00310934|BEHAVIORAL|Contingency management|
214564415|NCT04023773|DEVICE|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
214564416|NCT02468219|BEHAVIORAL|cardiovascular rehabilitation program|"Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training."
214564417|NCT05922059|DEVICE|Transcutaneous vagus nerve stimulation|Auricular transcutaneous vagus nerve stimulation will be used in the left cavity of the external ear with a stimulation frequency of 20-30 Hz for half hour. Monophasic rectangular waveforms will be used, and the intensity will be adjusted below the patient's pain threshold.
214564418|NCT05922059|DEVICE|Heart rate variability biofeedback|The patient will receive visual HRV feedback during resonance frequency breathing. Finally, the patient will be instructed to maximize their peak-to-peak HRV and attain the phase between respiration and HRV changes as closely as possible
214564419|NCT05922059|OTHER|Standard-care physiotherapy|consists of cervical mobilization on the painful segment, isometric exercise for neck flexors, and a combination of strengthening and stretching exercises from sitting position; cervical extensors strengthening exercise using red color Thera-band and stretching exercises upper trapezius of the painful side.
214564420|NCT00215137|DRUG|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
214564421|NCT00215137|DRUG|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
214564422|NCT00082875|DRUG|cilengitide|Given IV
215166558|NCT07198633|DRUG|QLH12016|An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol
215166559|NCT07198828|BEHAVIORAL|mHealth Smoking Cessation Application|"Participants receive the mHealth smoking cessation application with:~* Educational content about smoking risks and cessation benefits~* Motivational messages and progress tracking~* Social support features~* Interactive elements and quizzes~* Monthly monitoring and support"
214564423|NCT00082875|OTHER|pharmacological study|Correlative studies
214564424|NCT00082875|OTHER|laboratory biomarker analysis|Correlative studies
214564425|NCT03154853|OTHER|Behavioral: short foot exercise|Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
214564426|NCT03392259|BEHAVIORAL|Smartphone app|Installment and use of smartphone app
214564427|NCT01948700|BEHAVIORAL|Motivational Interviewing|
214564428|NCT01948700|OTHER|Education|
215166560|NCT07198828|BEHAVIORAL|Paper-based Control Materials|"Participants receive paper-based smoking cessation module containing equivalent content:~* Motivational content and cessation benefits~* Ex-smoker success stories~* Trigger identification and coping strategies~* Weekly quizzes with prizes (online access)~* Monthly check-ins"
215166561|NCT07199673|DRUG|Injection Sclerotherapy|identifying the hemorrhoidal pedicle, 3-5 ml of 5% phenol in almond oil is injected into the submucosal plane of the hemorrhoid pedicle
215166562|NCT07199673|DEVICE|Rubber Band Ligation|knee-elbow position is used. After identifying the hemorrhoids with a proctoscope, a rubber band is applied at the base of each hemorrhoid using Barron's Gun and Elise's tissue forceps.
215166563|NCT07196982|OTHER|No intervention (observational study)|This is an observational retrospective case-control study. No experimental intervention is administered. All participants received standard surgical management for intertrochanteric femoral fractures according to clinical practice, including proximal femoral nail antirotation (PFNA) with or without additional lateral wall plate fixation. The study only compares clinical and radiological data between patients with isolated intertrochanteric fractures and those with concomitant lateral wall involvement.
215166564|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166565|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166566|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166567|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166568|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166569|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
215166570|NCT07200180|DRUG|Аrgon-oxygen breathing mixture|Patients receive a course of inhalations with an argon-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
215166571|NCT07200180|DRUG|Nitrogen-oxygen breathing mixture|Patients receive a course of inhalations with an nitrogen-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
214564429|NCT01241487|DRUG|valsartan/amlodipine|160/10 mg
214564430|NCT02754739|DRUG|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
214564431|NCT02754739|DRUG|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
214564432|NCT02754739|BEHAVIORAL|Nutritional education only|Only nutritional education by a nutritionist
215166572|NCT07198906|OTHER|Determination of VEXUS score and onset of chronic renal failure|The aim is to prospectively evaluate the association between the ultrasound score (VEXUS) and the occurrence of acute renal failure post-operatively following cardiac surgery. The VEXUS (Venous Excess UltraSound) score is an ultrasound tool used in medicine to assess systemic venous congestion, i.e. excess pressure in the venous system linked to volume overload or right heart failure. The VEXUS score relies on ultrasound of the inferior vena cava (IVC) to assess the extent of congestion in this vein. score 0 : Normal IVC + Normal Dopplers; score 1 : Dilated IVC + altered hepatic venous Doppler, but normal portal vein; score 2 : Portal vein shows significant pulsatility; score 3 : Severe pulsatility + marked alteration of hepatic and portal flow
215166573|NCT07199816|PROCEDURE|Fluoroscopy-Guided Caudal Epidural Block|Under fluoroscopic guidance, the patient in the prone position will receive a caudal epidural injection through the sacral hiatus. A 22-gauge, 3.5-inch spinal needle (Spinocan®, BRAUN) is used to inject 1 mL of contrast media (Omnipaque 300) to confirm correct needle placement. Then, 10 mL of treatment solution (8 mL of 0.5% lidocaine and 2 mL of 8 mg dexamethasone) is administered.
215166574|NCT07199816|PROCEDURE|Combined Lumbar Sympathetic Ganglion Block and Caudal Epidural Block|Patients will receive both a caudal epidural block and a lumbar sympathetic ganglion block (LSGB) under fluoroscopic guidance. The LSGB is performed at the L2 or L3 vertebral body on the affected side using a 21-gauge Chiba needle. After confirming needle position with contrast imaging, 10 mL of solution (2 mL of 8 mg dexamethasone + 8 mL of 1% lidocaine) is injected. A caudal block is then performed as described above.
215166575|NCT07199517|OTHER|HRP Sampling period|During a 28-day sampling period, participants randomized to HRP are instructed to try their selected HRP (ECIGS, IQOS, or ONPs) and will complete daily e-diaries of cigarette smoking behavior and product uptake.
215166576|NCT07199517|OTHER|NPL Sampling period|During a 28-day sampling period, participants randomized to NPL are instructed to try nicotine patches and nicotine lozenges and will complete daily e-diaries of cigarette smoking behavior and product uptake.
215166577|NCT07197918|DEVICE|portable MRI scanner|Participants will receive 2-3 portable MRI scans: \<6 hours, 6-24 hours, and within 12 (+/- 12) hours of conventional MRI
215166578|NCT07198412|PROCEDURE|Ultrasound-guided spinal anesthesia|Spinal anesthesia performed under real-time ultrasound guidance using a curvilinear ultrasound probe and 25-27G pencil-point spinal needle. Intrathecal injection of bupivacaine 0.5% hyperbaric (12-15 mg) following local infiltration with lidocaine 1% (2-3 mL).
215166579|NCT07198412|DRUG|Midazolam plus ultrasound-guided spinal anesthesia|Patients will receive midazolam (0.02-0.05 mg/kg IV; max 5 mg) 5-10 minutes prior to spinal anesthesia. Ultrasound guidance used for spinal needle placement. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration. Oxygen supplementation at 2 L/min and standard monitoring.
215166580|NCT07198412|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia performed using the traditional landmark palpation technique without ultrasound guidance or sedation. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration, using a 25-27G pencil-point spinal needle.
215166581|NCT07199530|OTHER|Blood Product|blood sample for d dimer
215166582|NCT07197905|DRUG|Intravenous iron|The Intravenous iron infusion will be administered according to standard clinical care. The provider will choose the dosage and formulation of IV iron.
214564433|NCT05180331|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
214564434|NCT00296985|DEVICE|Fresenius Cellsaver|
215166583|NCT07199712|OTHER|Ozone Therapy (In-Office and Home-Based Treatment)|The intervention consists of professional in-office ozone therapy delivered with the Ozono DTA device (Sweden-Martina) applied to oral mucosal lesions. The first treatment is administered at baseline and additional sessions are performed at 48 hours, day 5, day 8, day 12, and day 15, if clinically required. Alongside in-office therapy, participants perform a 15-day domiciliary regimen with ozonated oral care products, including toothpaste with 2% ozonated sunflower oil, a mouthrinse with 4% ozonated sunflower oil solution, and a topical gel with 15% ozonated sunflower oil, each used twice daily. Clinical outcomes are assessed at each visit from baseline to day 15 with the WHO oral mucositis scale and the Visual Analogue Scale for pain.
214564435|NCT00336700|DRUG|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
214564436|NCT00336700|DRUG|Erlotinib|150 mg/d Daily, oral 12 months
214564437|NCT02644395|DRUG|Chlorthalidone|Drug
214564438|NCT02644395|DRUG|Amlodipine|Drug
214564439|NCT02655068|OTHER|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
214564440|NCT02655068|OTHER|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
215166584|NCT07199166|BEHAVIORAL|Autobiographical Rewriting Workshops|10 two-hour autobiographical rewriting workshop sessions, held weekly. This program encourages participants to explore their own history in a way that fosters narrative resilience, highlighting their ability to overcome challenges, transform failures into learning opportunities, express themselves creatively, reexamine their memories, and rebuild a more positive sense of identity that better aligns with the needs of accurate self-recognition of their potential. This program is particularly inspired by the concepts of resilience (Boris Cyrulnik), identification (Karine Gros), the Hero's Journey (Joseph Campbell), narrative therapy (David Denborough), and works on various types of story structures (Blake Snyder).
214564441|NCT00244998|DRUG|fulvestrant|IM
214564442|NCT05684263|OTHER|Weight Science Educational Video|Educational videos on the topic of weight science created by a registered clinical psychologist.
215166585|NCT07199166|BEHAVIORAL|Non-specific writing workshops|10 sessions of 2 hours of non-specific writing, held weekly. To increase the active role of the participants, they will be encouraged to write on the theme of the session during the time between sessions. The writing themes are non-specific, unlike the intervention group, and include topics such as poetry, historical events, nature reports, imaginary interviews, children's stories, etc.
215166586|NCT07200128|DRUG|Ritlecitinib|As provided in real world practice
215166587|NCT07199946|DRUG|Verapamil (Part A)|Verapamil 3-6mg/kg body weight and 24 hrs
215166588|NCT07199946|DRUG|Placebo|Placebo given in part B, the comparator arm of the double blind randomized trial
215166589|NCT07198386|DRUG|CS060380|Oral QD
214564443|NCT05684263|OTHER|Healthy Eating Educational Video|Educational videos on the topic of healthy eating created by a registered clinical psychologist.
214564444|NCT05684263|OTHER|Healthy Sleep Educational Video|Educational videos on the topic of healthy sleep created by a registered clinical psychologist.
214564445|NCT01320059|DRUG|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
214564446|NCT01320059|PROCEDURE|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
214564447|NCT02777138|OTHER|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
214564448|NCT02844218|OTHER|Age of patient|"* Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
214564449|NCT03581604|DIAGNOSTIC_TEST|Allergy work-up|Allergy work-up
214564450|NCT03581604|OTHER|Blood samples|Blood samples
214564451|NCT06253078|DRUG|Ciprofol dose 0.4mg/Kg|The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
214564452|NCT06253078|DRUG|Ciprofol dose 0.3mg/Kg|The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
215166590|NCT07198386|DRUG|Placebo|Oral QD
215166591|NCT07198854|OTHER|Not applicable- observational study|This is a retrospective cohort study and intervention is not applicable.
215166592|NCT07198724|DRUG|Elacestrant|Selective estrogen receptor degrader (SERD), film-coated tablet, taken orally per protocol.
215166593|NCT07198724|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody-drug conjugate, vial, via intravenous (into the vein) infusion per standard of care
215166594|NCT07199244|DIETARY_SUPPLEMENT|marine-based heme iron|Participants will consume 9mg of SalmoFer on day 1, followed by 6mg each day for 56 days.
215166595|NCT07198516|DRUG|Addition of Hengge Liejing treatment for 48 weeks|Treatment with Hengge Liejing for 48 weeks, drug formulation: tablets. Dosage: 10mg qd, taken orally in the morning, before or after breakfast, for 48 consecutive weeks
215166596|NCT07199790|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
215166597|NCT07199790|OTHER|Therapeutic exercise|The therapeutic exercise program aimed at improving balance and preventing falls will be carried out three times per week (Monday, Wednesday, and Friday), with each session lasting 30-45 minutes. Each session will be structured into three blocks: a warm-up of 5-10 minutes, a main block focused on balance and strength lasting 20-25 minutes, and a cool-down of 5-10 minutes.
215166598|NCT07199283|OTHER|Bundle Intervention|Bundle intervention
214564453|NCT06253078|DRUG|Ciprofol dose 0.2mg/Kg|The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
214564454|NCT05530759|PROCEDURE|Biopsy Specimen|Undergo collection of tissue samples
214564455|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal swab samples
214564456|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of archived tissue and blood samples
214564457|NCT05530759|OTHER|Medical Chart Review|Review of medical record
214564458|NCT04871854|DRUG|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
214564459|NCT04871854|DRUG|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
214564460|NCT05720845|PROCEDURE|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
214564461|NCT05720845|PROCEDURE|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
215166599|NCT07199335|DRUG|APRETUDE (cabotegravir)|All participants will be prescribed APRETUDE based on APRETUDE's FDA approved indication, which is sexual risk of HIV transmission.
214564462|NCT03082404|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
214564463|NCT04523428|DRUG|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
214564464|NCT04497064|OTHER|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
214564465|NCT04201054|DRUG|Fluconazole|50 mg of fluconazole administered orally in a single dose.
214564466|NCT00371189|DRUG|Placebo|Normal saline.
214564467|NCT00371189|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.
214564468|NCT06208449|PROCEDURE|Robotic repair for EA|The paitents with EA were repaired by Da Vinci robot
214564469|NCT06208449|PROCEDURE|Thoracoscopic repair for EA|The patients with EA were repaired by thoracoscopy
214564470|NCT06208449|PROCEDURE|Thoracotomy repair for EA|The patients with EA were repaired by traditional open thoracotomy.
214564471|NCT02812693|DRUG|Imatinib Mesylate|Given PO
214564472|NCT02812693|OTHER|Laboratory Biomarker Analysis|Correlative studies
215166600|NCT07199920|DEVICE|Achieva 3.0T dStream Philips|Classic and MRF sequences will be carried out on the clinical machine (Achieva 3.0T dStream Philips) of the IRMaGe platform (CHUGA, Université Grenoble Alpes, Inserm, CNRS).
215166601|NCT03147287|DRUG|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
215166602|NCT03147287|DRUG|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
215166603|NCT03147287|DRUG|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
215166604|NCT07198750|DEVICE|HI-PEMF - Knee (Chronic Pain Protocol)|"High-intensity pulsed electromagnetic field (HI-PEMF) therapy applied to the symptomatic knee using the Chronic Pain protocol of the BTL-6000 Super Inductive System, 10-minute duration per session, applied twice per week over 5 weeks (total of 9 sessions). The applicator is positioned 2-3 cm above the patella, without skin contact, with the patient seated or in supine position."
215166605|NCT07198750|DEVICE|HI-PEMF - Quadriceps (Muscle Strengthening Protocol)|"HI-PEMF therapy will be applied to both the symptomatic knee and the quadriceps muscle (rectus femoris). The knee application will follow the same procedure as in Group A, using the Chronic Pain protocol of the BTL-6000 Super Inductive System. In addition, the quadriceps will be treated using the Muscle Strengthening protocol. Each site will receive 10 minutes of therapy per session, twice per week over 5 weeks (total of 9 sessions). The applicator for the quadriceps will be positioned perpendicular to the muscle belly, without skin contact, with the patient lying supine and a cushion under the knee for slight flexion."
215166606|NCT07198750|BEHAVIORAL|Home-Based Exercise Program|Standardized home-based exercise program prescribed to both groups. It includes five exercises: isometric quadriceps contractions, straight leg raises, seated knee extensions, sit-to-stand from chair, and stationary marching. Participants are instructed to perform the exercises three times per week during the 5-week intervention. Printed instructions and a video guide are provided. Adherence is reinforced via weekly follow-up.
215166607|NCT07198295|DEVICE|TEAVR with false lumen embolization|The procedure involves two key steps: first, deploying a stent-graft in the true lumen to seal the proximal entry tear; second, selectively catheterizing the false lumen to place 1-3 vascular plugs at critical locations-below the distal end of the stent-graft, at the celiac trunk level, and at the distal re-entry tear in the infrarenal aorta-to occlude distal outflow and induce complete false lumen thrombosis.
215166608|NCT07199127|DIAGNOSTIC_TEST|DRACO|A novel endoscopic classification to predict the risk of duodenal and ampullary high-grade dysplasia and cancer from baseline esophagogastroduodenoscopy (EGD)
215166609|NCT07197008|DRUG|Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab|Eligible patients will receive Sacituzumab tirumotecan at a dose of 4 mg/kg in combination with bevacizumab 5mg/kg by intravenous infusion on day 1 and day 15 of each 28-day cycle.
215166610|NCT07199088|OTHER|Acetazolamide|A carbonic anhydrase inhibitor, 500 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
215166611|NCT07199088|OTHER|Metolazone|A thiazide-like diuretic, 5 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
215166612|NCT07198789|OTHER|Altograno® Bakery Foods|Altograno® Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
214564473|NCT02812693|BIOLOGICAL|Pembrolizumab|Given IV
214564474|NCT04630392|OTHER|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
214564475|NCT04630392|OTHER|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
214564476|NCT03107338|DRUG|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
214564477|NCT03107338|OTHER|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
214564478|NCT00433212|DEVICE|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
214564479|NCT00433212|DEVICE|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
214564480|NCT03029221|OTHER|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
215166613|NCT07198789|OTHER|Standard Whole-Grain Bakery Foods|Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
215166614|NCT07198698|OTHER|Paloma Sahid Method, a patented technique (PCT/CL2023/050061)|The participants will receive treatment that integrates manual and mechanical lymphatic drainage through linear sliding movements directed toward relevant lymph nodes. Each session lasts approximately one hour. This intervention was complemented by compression therapy, applying 30-40 mmHg at the ankle, 70% compression at the calf, and 30% compression at the thigh.
215166615|NCT07198022|DRUG|Cryotherapy|Using crytotherapy as topical anesthetic
214564481|NCT03029221|OTHER|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
215166616|NCT07198022|DRUG|topical anesthetic|Comparing the two versions (the room temperature and + 4°C) of the gold standard of local anesthetics, the solution, which contains lidocaine.
215166617|NCT07198022|DRUG|Topical anesthetic gel|Tolerable taste, containing benzocaine at gel formula.
214564482|NCT03029221|OTHER|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
215166618|NCT07198022|DRUG|Placebo|The placebo participants will be informed to have the standard topical anesthetic spray.
214564483|NCT05505240|OTHER|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
214564484|NCT05505240|OTHER|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
214564485|NCT05505240|OTHER|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
214564486|NCT05505240|OTHER|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
214564487|NCT02294903|PROCEDURE|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
214564488|NCT05709340|OTHER|proprioceptive neuromuscular facilitation exercises|PNF exercises will be done for Masseter, Temporalis, Lateral pterygoid and medial pterygoid muscles. Each contraction will be held for 10 seconds, and each stretch (relaxation phase) will be allowed to continue as long as the muscle tension continued to give away.
214564489|NCT05709340|OTHER|traditional physical therapy treatment|"* Ultrasound: Continuous ultrasound at 1MHZ to temporomandibular joint at 1.0-1.25 W/CM2 for 5 min over each affected TMJ and masseter area, with the mouth in a slightly open position.~* Forward head posture correction exercises including: chin tuck exercise, Strengthening shoulder retractors, stretching of sternocleidomastoid muscle, and Stretching of pectoralis muscle."
214564490|NCT00207610|BEHAVIORAL|Daily iron supplements of 65 mg a day for 3 months|
214564491|NCT00207610|BEHAVIORAL|Universal anemia screening and treatment|
214564492|NCT00207610|BEHAVIORAL|Selective anemia screening and treatment|
214564493|NCT05680038|DRUG|Penpulimab|Penpulimab is a modified PD1 inhibitor, which innovated the use of IgG1 subtype. On the basis of ensuring the stability of the antibody, it eliminated ADCC, ADCP, CDC and other effects that were not conducive to the efficacy of T cells and reduced the effect of ADCR by modifying the Fc segment
214564494|NCT04252443|OTHER|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
214564495|NCT04712695|OTHER|Exercise Based Interventions|Proprioception Training Interventions
214564496|NCT01183260|DEVICE|Trabecular Metal Revision Cup|Revision of the acetabular cup
214564497|NCT01183260|DEVICE|Trabecular Metal Modular Cup|Revision of the acetabular cup
214564498|NCT05403112|PROCEDURE|Bone ring with open sinus lifting|All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
214564499|NCT05055505|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
214564500|NCT06446986|OTHER|Single and Dual-Task Timed Up and Go Test|Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.
214564501|NCT06446986|OTHER|Single and Dual-Task Tandem Walking Test|"The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards"
215166619|NCT07199608|PROCEDURE|subcision|patients will undergo subcision procedure alone using 18 gauge blunt cannula to release fibrous bands under atrophic acne scars.this group will serve as control comparator
215166620|NCT07199608|PROCEDURE|subcision+fractional co2 laser|patients will undergo subcision procedure followed by fractional co2 laser applied to right side of face, the left side will receive subcision alone
214564502|NCT06446986|OTHER|Simple Shoulder Test|Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
214564503|NCT06025760|OTHER|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
214564504|NCT03667430|DIETARY_SUPPLEMENT|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
215166621|NCT07199608|BIOLOGICAL|subcision+PRP|patients will undergo subcision procedure followed by intradermal injection of autologous PRP prepared from patients blood on right side.left side will receive subcision alone
214564505|NCT03667430|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
214564506|NCT06079619|OTHER|Analysis of photos of pigmented tumours by the three groups|Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
214564507|NCT02470156|BEHAVIORAL|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
214564508|NCT02470156|BEHAVIORAL|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
214564509|NCT06013696|OTHER|Adding household bleach to urine sample|Adding household bleach to urine sample
214564510|NCT06132542|BIOLOGICAL|stem cell therapy|The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.
214564511|NCT03599258|DEVICE|Skylife|Newly FDA approved device
214564512|NCT03599258|DEVICE|Standard Therapy|Both devices are considered standard therapy
214564513|NCT02869529|OTHER|Data collection|
214564514|NCT01581177|DRUG|Albuterol DPI 25 mcg/inh|Albuterol DPI with 25 mcg Albuterol/inhalation
214564515|NCT01581177|DRUG|Albuterol DPI 90 mcg/inh|Albuterol DPI with 90 mcg Albuterol/inhalation
214564516|NCT01581177|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
214564517|NCT01581177|DRUG|Albuterol MDI 90 mcg/inh|Albuterol MDI with 90 mcg Albtuerol/inhalation
214564518|NCT02144792|DRUG|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
214708142|NCT05840614|BEHAVIORAL|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
214708143|NCT04459052|DIETARY_SUPPLEMENT|N acetyl cysteine|Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
214708144|NCT04459052|DRUG|[F-18] Fluorodopa Positron Emission Tomography|FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
215166622|NCT07198347|DRUG|AG2001|Oral administration, three times daily for 7 days.
215166623|NCT07198347|DRUG|AG20011|Oral administration, three times daily for 7 days.
215166624|NCT07198347|DRUG|AG20012|Oral administration, three times daily for 7 days.
215166625|NCT07198594|OTHER|rTMS|individualized rTMS target the IFC with symptom provocation
215166626|NCT07199413|BIOLOGICAL|SV-BR-1-GM Vaccine|\~20 X 10\^6 cells across 4 injection sites
215166627|NCT07199413|DRUG|Cyclophosphamide|300 mg/m\^2 Intravenous
215166628|NCT07199413|DRUG|Pembrolizumab|200 mg/m\^2 Intravenous
215166629|NCT07199413|DRUG|Interferon|0.18 mcg subcutaneous
215166630|NCT07199699|PROCEDURE|Subxiphoid Minimally Invasive Resection of Giant Mediastinal Teratoma Assisted by Double Sternal Elevation|All patients underwent minimally invasive mediastinal tumor resection using a double hook technique via the subxiphoid approach. The procedure was as follows: A 3-4 cm longitudinal incision was made below the xiphoid, and subcutaneous tissue was dissected to reach the anterior rectus sheath. The retroxiphoid space was bluntly dissected, and a thoracoscopic lens was inserted. A double-retractor system was placed in the subxiphoid and suprasternal regions, and retractor height was adjusted to aid in separating tumor adhesions from residual thymic tissue. Blunt dissection was used to separate the tumor from the innominate vein and phrenic nerve. After full tumor mobilization, it was placed into a sterile specimen bag and removed through the incision. The surgical area was rinsed and a mediastinal drainage tube was inserted, and the incision was closed layer by layer.
215166631|NCT07197697|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy|The dosage of Iparomlimab and Tuvonralimab Injection is 5mg/kg, administered intravenously, with each treatment cycle lasting every 3 weeks. The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles. A total of 8 cycles of neoadjuvant chemotherapy combined with immunotherapy were performed before the surgery. It is recommended that the surgery be conducted within 4 weeks after the completion of neoadjuvant treatment. The postoperative adjuvant treatment can be continued with postoperative adjuvant chemotherapy and the treatment of the etolo combination antibody according to the decision of the researcher and/or the willingness of the subject.
214564519|NCT01255631|DEVICE|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
214564520|NCT01255631|DEVICE|Sham PEMF Device|Inactive PEMF device, delivers no PMF
214564521|NCT04393194|DRUG|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
214564522|NCT00313092|DEVICE|nCPAP treatment|treatment with positive air pressure during night
214564523|NCT00384774|DRUG|Lasmiditan|Administered as intravenous infusion
214564524|NCT00384774|DRUG|Placebo|Administered as intravenous infusion
214564525|NCT04921475|DEVICE|Regional oxygen saturation monitoring|Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
214564526|NCT04631159|BEHAVIORAL|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
214564527|NCT04631159|OTHER|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
214564528|NCT04695522|BIOLOGICAL|ADR-002K administration|ADR-002K administration
214564529|NCT04604574|OTHER|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
214564530|NCT04215484|DIAGNOSTIC_TEST|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
214564531|NCT02420951|DRUG|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
214564532|NCT02420951|OTHER|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
214564533|NCT01674829|BIOLOGICAL|MA09-hRPE|Transplantation of MA09-hRPE cells accoding to the assigned dose group
214564534|NCT02760875|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
214564535|NCT05698576|DEVICE|TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)|A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
214564536|NCT02880410|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
214564537|NCT02880410|DRUG|Radiation therapy and temozolomide|Radiation therapy and temozolomide
214564538|NCT02032589|BEHAVIORAL|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
214564539|NCT01618253|DRUG|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
214564540|NCT01618253|RADIATION|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or \>10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If \>1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions \>10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
214564541|NCT04819659|DEVICE|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
214564542|NCT02823197|OTHER|Active transport lesson|
214564543|NCT02823197|OTHER|Active transport lesson and Facebook group|
215166632|NCT07198815|DRUG|Investigational Eye Drops (NPDR-01)|NPDR-01 is an investigational ophthalmic solution administered as one drop (50 μL) to the affected eye(s) once daily for a period of 6 months. It is designed to reduce retinal microaneurysms and slow the progression of non-proliferative diabetic retinopathy.
215166633|NCT07198971|OTHER|Music therapy|"Music therapy sessions in addition to nursing consultations:~creation of a soundtrack to listen to in order to help quit smoking"
214564544|NCT02255253|DRUG|Telmisartan|capsule,40mg per day,2 months
214564545|NCT02255253|DRUG|Hydrochlorothiazide|tablet, 25mg per day, 2 months
214564546|NCT00264303|DRUG|Levocetirizine|5mg oral capsules, once daily, 4 week duration
215166634|NCT07199855|DRUG|blinatumomab combined with venetoclax as maintenance therapy|blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation
215166635|NCT07198581|BEHAVIORAL|LLM-assisted chemotherapy side effect management|Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.
215166636|NCT07199361|DEVICE|Peripheral Transcutaneous Magnetic Stimulation from MagVenture|"MagVenture Pain Therapy System: It is an FDA-cleared magnetic stimulator system that provides brief and focused magnetic pulses to non-invasively stimulate peripheral nerves and provide relief of chronic intractable, post-traumatic, and post-surgical pain for patients 18 years or older. It is a relatively new technique in the US for pain relief in the clinical setting and thus not very widespread yet. Evidence shows Magnetic Peripheral Nerve Stimulation to have a promising average pain relief of up to 87%\*. Using magnetic pulses, MagVenture Pain Therapy engages sensory, pain, and motor fibers mechanistically to recondition the central nervous system by eliminating noxious pain signals to the brain, reducing chronic neuropathic pain for responsive patients.~\*Bedder M, Parker L.: Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain, 2023"
214564547|NCT00264303|DRUG|Desloratadine|5mg oral capsules, once daily, 4 week duration
214564548|NCT02815579|OTHER|Shamba Maisha Intervention|A) A loan (\~$175) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
214564549|NCT02389452|DRUG|Synvisc-One|intraarticular injection
214564550|NCT02311673|DRUG|Setmelanotide|subcutaneous injection
214564551|NCT02311673|DRUG|Placebo|Subcutaneous injection
214564552|NCT01855971|DIETARY_SUPPLEMENT|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
214564553|NCT01855971|DIETARY_SUPPLEMENT|Placebo|Same capsules containing rice flour. No active treatment is given.
214564554|NCT01855971|OTHER|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
214564555|NCT05003518|BEHAVIORAL|ParentText|ParentText delivers content, aligning with children's developmental stages (0-23 months, 2-9 years, 10-17 years). ParentText content is delivered through text messages, images, audio and video for parents/ caregivers and their children. Parents receive parenting content surrounding three themes: 1) relationship building by spending time together, 2) positive reinforcement, 3) stress reduction for parents and caregivers. Further supportive content is available for parents of children living with disabilities, child development, online child safety, talking about COVID-19 with children, family budgeting, family harmony, helping with schoolwork and sexual violence prevention.
214564556|NCT04136821|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
214564557|NCT04136821|OTHER|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
214564558|NCT04595851|OTHER|Patient Reported Outcome Measure (PROM)|Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
214564559|NCT04595851|OTHER|Comprehensive Medication Review (CMR)|Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
214564560|NCT04595851|OTHER|Communications between oncology and primary care pharmacists|Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
214564561|NCT02566044|OTHER|Placebo|Placebo
214564562|NCT02566044|DRUG|QBW276|0.3 mg and 1.5 mg strengths
214564563|NCT03156881|OTHER|Global Osteopathic Treatment|"The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance."
214708145|NCT06145464|BEHAVIORAL|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
214708146|NCT06145464|BEHAVIORAL|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
214564564|NCT06114316|BEHAVIORAL|individualized nursing interventions based on the Roy Adaptation Model /experimental|"The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
214564565|NCT01077427|DEVICE|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3\* and 16, 17\* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3\*, and 16, 17\* of each course~\* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
214564566|NCT01077427|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
214564567|NCT02380924|DRUG|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
214564568|NCT02380924|DRUG|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
214564569|NCT00769652|BEHAVIORAL|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
214708147|NCT06145464|BEHAVIORAL|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
214564570|NCT00769652|BEHAVIORAL|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during \& after treatment."
215166637|NCT07197411|DIAGNOSTIC_TEST|Evaluating the Consistency and Accuracy of Two Devices in Monitoring Hemodynamic Parameters|This portable patch-type carotid ultrasound has not yet been used in clinical settings.
215166638|NCT07197411|DEVICE|Hemodynamic monitoring|Whether the parameters monitored by portable patch-based ultrasound devices agree with the gold standard has not yet been thoroughly validated
215166639|NCT07199010|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
215166640|NCT07198542|DEVICE|gammaCore Sapphire|This intervention utilizes transcutaneous cervical Vagus Nerve Stimulation (tcVNS). A conductive gel is applied to the device's stimulation surfaces. The device is then placed on the neck over the vagus nerve. The daily treatment protocol consists of three consecutive 2-minute stimulations on the left side of the neck, with a 30-60 second interval between each stimulation. After a brief rest of approximately one minute, the same procedure is repeated on the right side of the neck. The total daily session duration is approximately 20 minutes. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
214564571|NCT00271726|PROCEDURE|Osteosynthesis with palmar locking plate|
214564572|NCT00271726|PROCEDURE|Osteosynthesis with external fixator|
214564573|NCT00271726|PROCEDURE|Osteosynthesis with Kirschner wires|
214564574|NCT00414908|DRUG|Pancrelipase delayed release capsule|24,000 unit capsule
214564575|NCT00414908|DRUG|Placebo Comparator|Placebo
214564576|NCT01367925|DEVICE|Stryker Triathlon® CS Tibial Insert|
214564577|NCT01367925|DEVICE|Stryker Triathlon® PS Tibial Insert|
214564578|NCT04245059|DEVICE|Multi-channel Transcranial direct current stimulation|A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
214564579|NCT03679715|OTHER|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops."
214564580|NCT00204321|DRUG|sirolimus (drug), mmf (drug)|
214564581|NCT02069652|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling
214564582|NCT06010277|DRUG|Folinic acid|Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
214708148|NCT06145464|BEHAVIORAL|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
214708149|NCT04130828|DRUG|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
214708150|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
214708151|NCT02079558|DRUG|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
214708152|NCT02079558|DRUG|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
215166641|NCT07198542|DEVICE|Nurosym|This intervention utilizes transcutaneous auricular Vagus Nerve Stimulation (taVNS). The device consists of an earpiece electrode that is clipped onto the left tragus. A small amount of water is applied to the skin for conductivity. The daily treatment protocol consists of one continuous 30-minute stimulation session. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
214564583|NCT03780218|OTHER|Respiratory function|Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
215166642|NCT07198321|DRUG|GFH276|GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
215166643|NCT07198841|DRUG|IBI351 combined with cetuximab β|Subjects will receive treatment with IBI351 plus cetuximab β, consisting of oral IBI351 administered at 600 mg twice daily (BID) either in a fasting or fed state, combined with intravenous infusion of cetuximab β injection dosed at 500 mg/m² (body surface area) every two weeks. Each treatment cycle spans two weeks. Therapy will continue until disease progression, unacceptable toxicity, or meeting other protocol-defined criteria for treatment discontinuation-whichever occurs first. Dose adjustments may be implemented throughout the study based on drug-related toxicities.
215166644|NCT07196215|PROCEDURE|passive ultrasonic activation|passive ultrasonic irrigant activation will be performed by using a stainless steel ultrasonic Irrisafe file of size 20 (IRRI S 21/25; VDW, Germany) mounted on ultrasonic unit (Woodpecker Ultrasonic Scaler UDS-J). The file will be kept 2 mm short of working length loosely without binding to the canal. 2.5% NaOCl will be activated for 30 seconds by using a power setting of five
214564584|NCT04069481|OTHER|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
214564585|NCT04069481|OTHER|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
214564586|NCT06272552|OTHER|PROMs and PREMs|"Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient\&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
214564587|NCT06272552|OTHER|PREMs|"Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
214564588|NCT06272552|OTHER|Control|At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
214564589|NCT06272552|OTHER|Healthcare professionals|Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
214564590|NCT04633525|PROCEDURE|Optimum Cup Orientation|Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
214564591|NCT05138354|OTHER|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
214564592|NCT05138354|OTHER|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
214708153|NCT03101046|DRUG|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
214708154|NCT03101046|DRUG|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
214708155|NCT02445599|DRUG|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
215166645|NCT07196215|PROCEDURE|sonic activation|root canals will be filled with 2.5% sodium hypochlorite and medium size tip (red, 25/04) of EndoAcivator (YAHOPE A3, China) will be used keeping it 2 mm short of working length. The activation of irrigant will be done in 2-3 mm vertical strokes for 30 seconds in between each instrumentation
215166646|NCT07200089|DRUG|NT-I7|NT-I7 will be supplied by NeoImmuneTech Inc
214564593|NCT05138354|OTHER|Standard care|"1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles."
214564594|NCT04411693|DRUG|Dexamethasone implant|A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.
214564595|NCT04411693|DRUG|Aflibercept|A single dose, 2mg, drug administered by intravitreal injection.
214564596|NCT00039390|DRUG|capecitabine|Given orally (PO)
214564597|NCT00039390|DRUG|gefitinib|Given PO
214564598|NCT00039390|OTHER|pharmacological study|Correlative studies
214564599|NCT00039390|OTHER|laboratory biomarker analysis|Correlative studies
214564600|NCT00818168|BIOLOGICAL|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
214564601|NCT01015040|DRUG|solifenacin succinate suspension|Oral
214564602|NCT01015040|DRUG|solifenacin succinate tablet|Oral
214564603|NCT00846729|PROCEDURE|CT angiogram of the remaining kidney.|
214708156|NCT02445599|DRUG|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
215166647|NCT07200089|DRUG|Placebo|Placebo will be supplied by NeoImmuneTech Inc
215166648|NCT07200089|BIOLOGICAL|B-cell Maturation Antigen (BCMA) CART-T therapy|Standard of care
215166649|NCT07198867|BIOLOGICAL|A-CAR028|A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens
215166650|NCT07199660|BEHAVIORAL|Human-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed by humans without using artificial intelligence.
215166651|NCT07199660|BEHAVIORAL|Voluntary warning|Participants will view a message suggesting user take a break from scrolling on social media. The message was developed by humans without using artificial intelligence.
215166652|NCT07199660|BEHAVIORAL|Human-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed by humans without using artificial intelligence.
215166653|NCT07199660|BEHAVIORAL|Human-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed by humans without using artificial intelligence.
215166654|NCT07199660|BEHAVIORAL|Human-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed by humans without using artificial intelligence.
215166655|NCT07199660|BEHAVIORAL|Human-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed by humans without using artificial intelligence.
215166656|NCT07199660|BEHAVIORAL|Human-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed by humans without using artificial intelligence.
215166657|NCT07199660|BEHAVIORAL|Control message|Participants will view a message about encouraging seatbelt use while traveling in a vehicle.
215166658|NCT07199660|BEHAVIORAL|California's proposed social media warning|Participants will view a message warning about the harms of social media use that mirrors the language the state of California has proposed for mandatory social media warnings.
215166659|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed using artificial intelligence.
215166660|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed using artificial intelligence
214564604|NCT00846729|PROCEDURE|Kidney Function study using Iothalamate & PAH as clearance markers|
214564605|NCT06415539|OTHER|classical physical therapy program|Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.
214564606|NCT06415539|OTHER|exercises|Children in this group will be given vestibular and proprioceptive exercise training in addition to the classical physiotherapy program. Skateboard, swing, hammock, bowl, ball, sensory pads, ball pool, slide, climbing bar, trampoline and balance board will be used as materials in vestibular and proprioceptive exercise training. In addition, at the end of the training sessions, parents will be informed about the application of exercise training to daily activities.
214564607|NCT05586477|DRUG|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
214564608|NCT05586477|DRUG|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
214564609|NCT04476251|BIOLOGICAL|E7 T-Cell Receptor (TCR)|Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).
214564610|NCT02334982|DRUG|TAK-137|TAK-137 tablets
214564611|NCT02334982|DRUG|Placebo|TAK-137 placebo-matching tablets
214564612|NCT00480402|DRUG|200 mg of Progesterone|Administration of 200 mg of Progesterone
214564613|NCT00480402|DRUG|400 mg Progesterone|Administration of 400 mg Progesterone
215166661|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed using artificial intelligence.
215166662|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed using artificial intelligence.
214564614|NCT00480402|DRUG|Placebo|Administration of a Placebo
214564615|NCT00921687|BEHAVIORAL|Education only|The education will consist of a lecture and distribution of a CKD reference card.
214564616|NCT00921687|BEHAVIORAL|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
214564617|NCT00316602|BIOLOGICAL|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
214564618|NCT02710318|BEHAVIORAL|Electronic immunization alert|Immunization alert in the electronic health record
214564619|NCT04807673|BIOLOGICAL|Pembrolizumab|"Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.~Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery."
214564620|NCT04807673|DRUG|Paclitaxel|Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
214564621|NCT04807673|DRUG|Cisplatin|Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
214564622|NCT04807673|RADIATION|neoadjuvant chemoradiotherapy|neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week
214564623|NCT00626990|DRUG|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
214564624|NCT00626990|GENETIC|DNA methylation analysis|O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
214564625|NCT00626990|OTHER|laboratory biomarker analysis|Prognostic factor analyses
214564626|NCT00626990|PROCEDURE|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
214564627|NCT00626990|PROCEDURE|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
214564628|NCT00626990|RADIATION|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
214564629|NCT05983380|OTHER|Hand Mobility and Grip Strengthening Exercises|Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
214564630|NCT05983380|OTHER|Usual Care|Manual lymphatic drainage, compression, exercise, skin hygiene.
214564631|NCT01507987|DEVICE|Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads|"Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies"
214564632|NCT02270541|OTHER|Telemedicine|In-ambulance telemedicine
214564633|NCT04357054|DIAGNOSTIC_TEST|Darwish test|Infertile women planned for combined laparoscopy and hysteroscopy as an integral part of infertility wok-up.
215166663|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed using artificial intelligence.
215166664|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed using artificial intelligence.
214564634|NCT00484081|PROCEDURE|Microdissection Testicular Sperm Extraction|
215166665|NCT07199894|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis
214564635|NCT00484081|PROCEDURE|ICSI|
214564636|NCT01534143|OTHER|pharmacological study|Correlative studies
214564637|NCT01534143|DRUG|tacrolimus|Given IV
214564638|NCT01534143|DRUG|sirolimus|Given PO
214564639|NCT01534143|BIOLOGICAL|anti-thymocyte globulin|Given IV
214564640|NCT01534143|DRUG|fludarabine phosphate|Given IV
214564641|NCT01534143|DRUG|busulfan|Given IV
214564642|NCT01534143|DRUG|bortezomib|Given IV
214564643|NCT01534143|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
214564644|NCT01534143|OTHER|laboratory biomarker analysis|Correlative studies
214564645|NCT04449328|DEVICE|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
214564646|NCT04449328|DEVICE|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
214564647|NCT01008410|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
214708157|NCT02445599|DRUG|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
215166666|NCT07199894|DRUG|Desmopressin (DDAVP)|ADH analogue in treatment of mono-symptomatic nocturnal enuresis
215166667|NCT07198009|DIETARY_SUPPLEMENT|2-HOBA (Hobamine)|Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.
215166668|NCT07199543|DRUG|benzydamine HCl|The investigational medicinal products were tasted during two study ambulatory visits, separated by a wash-out of at least 3 days
215166669|NCT07199101|RADIATION|Low dose CT|Participants will undergo a low dose CT adopting the pediatric low-dose CT protocol established based on low dose simulation technique.
215166670|NCT07195682|DRUG|BMS-986506|Specified dose on specified days
215166671|NCT07199595|DRUG|Dexamedomedine|"Group A (the Dexmedetomidine group):~Dexmedetomidine: loading dose 1 µg/kg IV over 10 min after induction and then maintenance dose 0.2- 0.7 µg/kg/hr based on hemodynamic response."
215166672|NCT07199595|DRUG|MgSO4|Magnesium Sulfate: Used as an IV loading dose at 20 mg/kg IV over 17 minutes as an induction agent, followed by maintenance of 10 mg/kg/h
215166673|NCT07198659|COMBINATION_PRODUCT|Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents|Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.
215166674|NCT07198932|DRUG|Cofrogliptin add to insulin|Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.
215166675|NCT07198932|DRUG|Linagliptin add to insulin|Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.
215166676|NCT07196423|DEVICE|Transcranial direct current stimulation (tDCS)|2mA anodal stimulation to be delivered for 20 minutes using a Neuroconn DC stimulator PLUS which will be repeated once after a 20-minute break.
215166677|NCT07196423|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Using a 7T Philips scanner with total scanning session lasting no more than 1 hour.
215166678|NCT07198880|DEVICE|BiPAP device (non invasive ventilation)|"BiPAP initiated 2-4 weeks post-discharge; IPAP 16 cmH₂O (titrate), EPAP 4 cmH₂O; supplemental O₂ as needed monitor SpO₂, ABG, vitals; target ≥20% PaCO₂ reduction, improved pH, reduced work of breathing; adherence ≥4 hrs/nigh~Scheduled monitoring of SpO₂, symptoms, and adherence; outpatient follow-up at 2-4 weeks and after 1, 3, 6 ,12 month intervals"
215166679|NCT07198880|DRUG|Optimal Medical Management ( long acting beta agonist , long acting muscarinic antagonist and inhaled corticosteroids)|Patients will continue on standard COPD management: inhaled bronchodilators, inhaled corticosteroids, LTOT when required, but without NIV
215166680|NCT07200193|GENETIC|CRMA-1001|Epigenetic gene silencing therapy delivered by intravenous (IV) infusion
215166681|NCT07197307|DRUG|Loncastuximab Tesirine and Epcoritamab|Combination therapy of loncastuximab tesirine and epcoritamab
215166682|NCT07198191|DRUG|SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)|Exposure to SGLT2 inhibitors following AMI in patients with T2DM
215166683|NCT07198191|DRUG|DPP4 inhibitors|Exposure to DPP4 inhibitors following AMI in patients with T2DM
215166684|NCT07199387|DEVICE|Mobile App|All participating organizations will receive access to PeerOnCall, a mobile mental health and peer support platform co-designed by and for Canadian public safety providers (PSP) that includes: a) an app for frontline workers, b) an app for peer support providers, and c) an administrative portal for organizational leaders. The goal of the technology is to promote early intervention and support through culturally relevant information to promote mental health literacy, and by reducing barriers to reaching out for support. The frontline worker app provides access to customized resources for first responders and links to local supports. It also includes self-management tools and an option to connect with a range of trained peer supporters via text or phone. The peer support provider app is linked to the frontline worker app and facilitates anonymous, private peer support connections, while also providing resources and crisis management tools to support peer supporters in their role.
215166685|NCT07198438|DEVICE|Deep Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a double-cone coil (90BFVT-LQC) to target the anterior cingulate cortex (ACC). The resting motor threshold (rMT) is determined from the tibialis anterior muscle. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
215166686|NCT07198438|DEVICE|Standard Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a planar coil (70BF-LQC) to target the left dorsolateral prefrontal cortex (DLPFC). The resting motor threshold (rMT) is determined from the abductor pollicis brevis muscle. The DLPFC is localized 5.5 cm anterior to the motor hotspot. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
215166687|NCT07199881|PROCEDURE|Stepwise PSV adjustment protocol|Patients will undergo standardized stepwise PSV changes (baseline, ±3 cmH₂O, ±6 cmH₂O, return to baseline), with 2-minute stabilization and repeated measurements of ventilatory parameters.
214564648|NCT01008410|DRUG|Placebo|Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
214564649|NCT01477164|BEHAVIORAL|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at \~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
214564650|NCT01477164|BEHAVIORAL|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
214564651|NCT01477164|BEHAVIORAL|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
214564652|NCT02154464|DRUG|Paracetamol|
214564653|NCT02154464|DRUG|Placebo|
214564654|NCT01151852|DRUG|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
214564655|NCT01151852|DRUG|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
214564656|NCT00297427|PROCEDURE|Acupuncture|Acupuncture twice weekly for 6 weeks.
214564657|NCT00297427|OTHER|Sham acupuncture|Twice a week for 6 weeks
215166688|NCT07198243|DRUG|STW 5-II|"STW 5-II is an herbal medicinal product for the symptomatic treatment of functional dyspepsia with main symptoms such as epigastric pain, epigastric burning, postprandial fullness and early satiation, but often also loss of appetite, excessive belching and heartburn. STW5-II consists of six herbal extracts: bitter candy tuft, camomile flower, caraway fruit, melissa leaf, peppermint leaf, and licorice root.~STW 5-II will be a solution for oral intake, for the treatment of FD, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention"
214564658|NCT01951352|OTHER|Soap|
214564659|NCT02022787|OTHER|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
214564660|NCT03056300|DEVICE|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
214564661|NCT02888210|DEVICE|MD-15 Intraocular Lens|
214564662|NCT05042908|DRUG|LBL-003 Injection|LBL-003 was given every two weeks for treatment
214564663|NCT00475124|DEVICE|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
214564664|NCT00475124|DEVICE|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
214564665|NCT01808937|OTHER|Morphea|
214564666|NCT05440916|RADIATION|Palliative Radiotherapy: 5 x 4Gy|Palliative irradiation of 2 to 5 sites (metastatic sites or/and primary lung tumour) in one week before systemic therapy. Systemic therapy should be given as soon as possible after irradiation.
214564667|NCT05440916|DRUG|chemotherapy + immune checkpoint inhibitors|Systemic therapy according to national/European recommendations.
214564668|NCT04973501|BEHAVIORAL|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
214564669|NCT04973501|BEHAVIORAL|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
214564670|NCT04806438|OTHER|Group A|Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
214564671|NCT04806438|OTHER|Group B|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice
214564672|NCT01227837|DIETARY_SUPPLEMENT|placebo|placebo given to patients
214564673|NCT01227837|DIETARY_SUPPLEMENT|omga3|use of omega 3
214564674|NCT02048475|OTHER|desflurane|changing concentration
214564675|NCT03248882|DRUG|Placebo|Placebo
214564676|NCT03248882|DRUG|PF-05221304|PF-05221304, Experimental Drug
214564677|NCT01656200|BIOLOGICAL|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
214564678|NCT03872024|DEVICE|For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
214564679|NCT03872024|DEVICE|From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe)."
214564680|NCT04627779|DRUG|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
214564681|NCT03546400|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
214708158|NCT02445599|DRUG|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
215166689|NCT07198243|DRUG|Placebo|Matching placebo will be a solution for oral intake, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention.
214564682|NCT01457482|OTHER|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
214564683|NCT01457482|OTHER|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
214564684|NCT03625180|BIOLOGICAL|NAMIC: nanofractured autologous matrix-induced chondrogenesis|the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
214564685|NCT01449500|DIETARY_SUPPLEMENT|L. reuteri|Chewable tablet, one tablet/day for 28 days
214564686|NCT01449500|DIETARY_SUPPLEMENT|Placebo|Chewable tablet, one tablet per day for 28 days
214564687|NCT00269438|DRUG|5 ASA, enemas, suppositories, corticosteroids|
214564688|NCT03570489|BEHAVIORAL|Exercise|Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
214564689|NCT03570489|BEHAVIORAL|Relaxation|Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
214564690|NCT03813277|DRUG|Dexmedetomidine|infusion
214564691|NCT02557529|BEHAVIORAL|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
214564692|NCT02557529|BEHAVIORAL|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
214564693|NCT02557529|BEHAVIORAL|Diet diary|Weekly diet diary during the 12-weeks intervention
214564694|NCT02734576|DEVICE|Venous Sinus Stenting with the Precise Pro Stent|Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
214564695|NCT04887779|BEHAVIORAL|Pathologist intervention|viewing explanted organ and microscopy
214564696|NCT00011752|DRUG|FCWAY|
214564697|NCT05368792|DIETARY_SUPPLEMENT|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
214564698|NCT00961480|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
214564699|NCT00961480|DRUG|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
214564700|NCT00961480|DRUG|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
214564701|NCT00961480|DRUG|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
214564702|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
214564703|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
214564704|NCT00961480|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
214564705|NCT00961480|DRUG|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
214564706|NCT01156376|DEVICE|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
214564707|NCT01156376|DEVICE|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
214564708|NCT01156376|DEVICE|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
214564709|NCT00512655|BEHAVIORAL|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
215166690|NCT07199270|BIOLOGICAL|GR2303 injection|single dose
215166691|NCT07199270|BIOLOGICAL|Placebo|single dose
215166692|NCT07199270|BIOLOGICAL|GR2303 injection|multiple dose
215166693|NCT07199270|BIOLOGICAL|Placebo|multiple dose
215166694|NCT07198737|DEVICE|VR and VNS|Participants will have Vagus nerve stimulation at the same time as a relaxing VR experience
214708159|NCT02445599|DRUG|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
214708160|NCT02445599|DRUG|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
214708161|NCT02445599|DRUG|Metamizole-sodium|Additional rescue analgetic 2g intravenously
214708162|NCT02445599|DRUG|Tramadol|Additional rescue analgetic 100mg intravenously
215166695|NCT07198178|OTHER|Peer Training|"Peer Selection Fourth-year nursing students who have completed the Clinical Practice-I course and are currently attending the Clinical Practice-II course and are in clinical practice four days a week will be invited to volunteer to become peer tutors after being informed about the purpose of the study. These volunteer peer tutors will be selected from among students with strong academic achievement (grade point average of 3.50 or above) and good communication skills, taking into account their clinical experience.~Peer Training Fourth-year students selected as peers will receive a training program consisting of four 40-minute sections, each lasting 160 minutes, prepared by the faculty members and aligned with the Fundamentals of Nursing course curriculum. This training aims to equip peers with the knowledge and skills to guide, provide feedback, and support to first-year students during clinical practice. The training will utilize active learning methods such as role-playing and case st"
215166696|NCT07198776|PROCEDURE|Percutaneous Vertebroplasty|Injection of PMMA cement into fractured vertebra under fluoroscopic guidance.
215166697|NCT07197983|DEVICE|Automated Vitrification|The PRESERVE-CR system performs automated vitrification (ultra-rapid freezing) of human oocytes and embryos using robotic manipulation and computer-controlled timing.
215166698|NCT07197983|DEVICE|Manual Vitrification|Control specimens are vitrified by standard vitrification protocol.
215166699|NCT07197723|GENETIC|cheek (buccal) swab|swab sample in person or at home with a mailed test kit and will fill out a survey
215166700|NCT07197723|OTHER|Assessments|about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.
215166701|NCT07197723|OTHER|optional collection of blood|for research testing
215166702|NCT07197996|DEVICE|Intermittent Pneumatic Compression|The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.
214564710|NCT05293977|BEHAVIORAL|Routine care by the dispensing pharmacist|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
214708163|NCT02585726|DEVICE|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
215166703|NCT07197996|DEVICE|geko® T3|The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.
215166704|NCT07199569|BIOLOGICAL|Jynneos|MVA-BN manufactured in primary CEF cells. MVA-BN (CEF) vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U and is an LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
215166705|NCT07199569|BIOLOGICAL|MVA-BN (Quail)|MVA-BN manufactured in CCX.E10 quail cell line. Vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U. and is a LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
215166706|NCT07198126|PROCEDURE|Pterygium Excision with Conjunctival Autograft|Excision of primary Grade II or Grade III pterygium Conjunctival autograft harvested and transplanted at the excision site Graft secured with sutures
214564711|NCT05293977|BEHAVIORAL|Pharmaceutical education/counseling about prescribed antibiotic|Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
214564712|NCT00146367|BEHAVIORAL|Active Living Every Day|
214564713|NCT03395262|DIETARY_SUPPLEMENT|Active with caffeine|Novel formula with caffeine
214564714|NCT03395262|DIETARY_SUPPLEMENT|Active without caffeine|Novel formula without caffeine
214564715|NCT03395262|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
214564716|NCT05511064|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701
214564717|NCT03988738|OTHER|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
214564718|NCT00510640|DRUG|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
214564719|NCT04073446|DEVICE|Spinal Cord Stimulation|Patients eligible for SCS
214564720|NCT02797080|DRUG|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
214564721|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
214564722|NCT05842499|PROCEDURE|Line Set Strategy|Substrate-guided ablation procedure of atypical atrial flutter
214564723|NCT05842499|PROCEDURE|Conventional strategy|Electrical activation-guided ablation
214564724|NCT01428427|DRUG|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
214564725|NCT01428427|DRUG|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
214564726|NCT01875029|DEVICE|sham-tDCS + back school|sham tDCS + back school
214564727|NCT01875029|DEVICE|real-tDCS + back school|real tDCS + back school
214564728|NCT03042923|DRUG|lactulose:mannitol (L:M) oral challenge|
214564729|NCT05150977|OTHER|Polysomnography|Reviewing collected data
214564730|NCT04708951|DEVICE|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
214564731|NCT04708951|DEVICE|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
214564732|NCT05090670|OTHER|Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy|Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy
214564733|NCT05090670|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
214564734|NCT00377689|BEHAVIORAL|high intensity functional exercise|high intensity functional exercise
214564735|NCT01305408|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
214564736|NCT01305408|DRUG|Placebo|Matching placebo tablets, taken orally, once daily in the morning
214564737|NCT02899351|DEVICE|Respiratory Volume Monitor|
214564738|NCT04523753|PROCEDURE|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
214564739|NCT02864277|PROCEDURE|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
214708164|NCT04765618|PROCEDURE|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
214708165|NCT04015440|BEHAVIORAL|HBMT|Individual is presented with words with some letters missing and told to complete the word.
214708166|NCT04015440|BEHAVIORAL|Other Training|Alternative to HBMT training
214708167|NCT02453009|DRUG|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
214708168|NCT02453009|DRUG|Prednisone|Pharmaceutical form:tablet Route of administration: oral
214708169|NCT02453009|DRUG|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
214564740|NCT02864277|PROCEDURE|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
214564741|NCT01315470|DRUG|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
214708170|NCT00993395|BEHAVIORAL|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
214564742|NCT05017428|DIETARY_SUPPLEMENT|Spermidine|Spermidine in the form of a 0.1% spermidine wheat germ extract
214564743|NCT05017428|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide given as niacinamide
214564744|NCT05017428|DIETARY_SUPPLEMENT|PEA|Palmitoylethanolamide given at 98% purity
214564745|NCT05017428|DIETARY_SUPPLEMENT|OEA|Oleoylehtanolamide given at 90% purity
214564746|NCT05017428|DIETARY_SUPPLEMENT|Wheat Flour|Wheat flour given as a placebo control
214564747|NCT05269953|DEVICE|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
215166707|NCT07199868|PROCEDURE|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.
214564748|NCT05269953|DEVICE|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
214564749|NCT02699138|DRUG|Trazodone|100mg of trazodone to be administered orally once.
214564750|NCT02699138|DRUG|Placebo|Compounded sugar pill
214564751|NCT02699138|DEVICE|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
214564752|NCT04391998|DRUG|Iron Supplement|oral tablet twice daily after meals
214564753|NCT04391998|DRUG|Metronidazole Oral|500 mg oral twice daily
215166708|NCT07199556|DIETARY_SUPPLEMENT|Food supplement|Tenflex® is an authorized food supplement.
215166709|NCT07199257|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
215166710|NCT07199257|BIOLOGICAL|Placebo|Placebo
215166711|NCT07197931|PROCEDURE|Additional extra-pulmonary vein trigger ablation group|"1. Circumferential PVI is performed in all patients.~2. After PVI, isoproterenol is infused starting at 5 μg/min, increased every 3-5 min to 10 and 20 μg/min (max 30 μg/min) to reach 85% of predicted heart rate for ≥10 min.~   2-1) If AF persists, internal cardioversion (5-30 J) is performed using catheters in the right atrium and coronary sinus.~   2-2) If sinus rhythm is present, a 15-beat drive train (10 mA, 2 ms) is delivered at 250 ms, shortened by 10 ms to 180 ms or until capture fails, up to three times, to induce AF or AT. Isoproterenol continues for 2 min. If arrhythmia occurs, cardioversion is repeated.~3. After cardioversion, isoproterenol is stopped and the patient is observed for 10 min.~4. Sustained or reproducible arrhythmias are defined as non-PV triggers.~5. These are localized with activation mapping, P-wave analysis, and high-density mapping.~6. Ablation is performed with the same catheter.~7. Reassessment is done with the same protocol."
214564754|NCT04391998|DRUG|Albendazole|200 mg oral single dose
214564755|NCT03156192|BEHAVIORAL|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
214564756|NCT02119442|DEVICE|Transcather Valve Implantation|Transcather Valve Implantation
214564757|NCT00582413|BEHAVIORAL|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
214564758|NCT04875299|OTHER|The study is observational|The study is observational
214564759|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting
214564760|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
214564761|NCT01367470|DIETARY_SUPPLEMENT|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
214564762|NCT01367470|OTHER|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
214564763|NCT05816772|DRUG|Endosequence Bio ceramic Sealer|Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
214564764|NCT05816772|DRUG|Sealapex Calcium hydroxide Based Sealer|KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
214564765|NCT04213742|OTHER|Thanksgiving diary intervention|Record gratitude.
214708171|NCT04782986|DIAGNOSTIC_TEST|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
214708172|NCT03748277|PROCEDURE|Decompression|Bilateral decompression
214708173|NCT03748277|PROCEDURE|PLIF|Traditional open surgery
214708174|NCT03748277|PROCEDURE|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
214708175|NCT03748277|PROCEDURE|Screw Fixation|Transpedicular Screw Fixation
214708176|NCT00000450|DRUG|Naltrexone Tablet|
214708177|NCT00000450|DRUG|Matched Placebo Tablet|
214708178|NCT01403467|DEVICE|Continuous positive airway pressure|CPAP 8 cmH2O
214564766|NCT04365231|DRUG|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~\- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
214564767|NCT04365231|OTHER|conventional management of patients|conventional management of patients
215166712|NCT07197931|PROCEDURE|Empirical pulmonary vein isolation group|"1. Circumferential pulmonary vein isolation (PVI) is performed in all patients.~2. After PVI, a waiting period of at least 20 minutes is observed, followed by reassessment of pulmonary vein isolation before concluding the procedure.~3. Additional linear ablation or CFAE ablation not specified in the study protocol should be avoided whenever possible.~4. In cases where typical atrial flutter has been documented prior to the procedure or is induced during the procedure, cavo-tricuspid isthmus (CTI) ablation is performed. At the operator's discretion, CTI ablation may also be permitted even in patients without a prior history or inducibility.~5. If atypical atrial flutter involving these pathways is induced during the procedure, additional linear ablation (e.g., roof line, posterior-inferior line, left lateral isthmus, or anterior line) may be performed."
215166713|NCT07198373|DRUG|Maintenance Therapy Group|Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.
215166714|NCT04833114|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
215166715|NCT04833114|DRUG|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
215166716|NCT04833114|DRUG|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
215166717|NCT04833114|DRUG|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
215166718|NCT04833114|DRUG|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
215166719|NCT07201844|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
214564768|NCT02060877|OTHER|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
214564769|NCT03599102|BEHAVIORAL|LOVED Intervention|
215166720|NCT07201844|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
214564770|NCT00417742|BEHAVIORAL|Service delivery through a Headache Management Program|
214564771|NCT01492153|DRUG|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
214564772|NCT01492153|DRUG|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
214564773|NCT01492153|DRUG|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
214564774|NCT04646863|RADIATION|laser therapy|performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
214564775|NCT04646863|OTHER|exercise|"The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~1. Modified Hundred~2. Modified Single Leg Stretch~3. One Leg Circle~4. Modified Scissors"
214564776|NCT04646863|OTHER|combination|laser therapy + Pilates exercises
214564777|NCT04678505|DRUG|MK-3402|"MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2"
214564778|NCT04080453|OTHER|Septic shock|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
214564779|NCT04080453|OTHER|Systemic Inflammatory Response Syndrome|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
214564780|NCT05716295|DRUG|MDK-703|MDK-703 will be administered as specified under Arm description.
214564781|NCT05716295|DRUG|Checkpoint Inhibitor, Immune|Checkpoint inhibitor will be administered as specified under Arm description.
214564782|NCT06399562|DIAGNOSTIC_TEST|carbon-13 urea breath test (13C-UBT)|The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.
215029839|NCT06673485|PROCEDURE|Patients have not received any nutritional supplementation during the healing period.|The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill while maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paraling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement. During the healing period, the patients did not receive vitamin or calcium supplements.
214564783|NCT06399562|BEHAVIORAL|questionnaires|The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.
214564784|NCT01005069|DRUG|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
214564785|NCT01005069|DRUG|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
214564786|NCT01005069|DRUG|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
214564787|NCT01005069|DRUG|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
214564788|NCT01005069|DRUG|Placebo capsule|Placebo capsules once daily and lifestyle modification
215166721|NCT07202351|OTHER|Screening and management of sleep disorders|Patients in the intervention group will undergo a systematic and standardised screening of sleep disorders. If any trouble is identified, a specific treatment plan is offered at the Chronos centre, including for instance, cognitive behavioural therapy for insomnia, or nightmares will be treated with Image Rehearsal Therapy (IRT).
215166722|NCT07196631|DRUG|Liposomal Bupivicaine|patients randomized to the intervention arm received 133mg of liposomal bupivacaine
214564789|NCT01655953|DIETARY_SUPPLEMENT|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
214564790|NCT01655953|OTHER|Control: high NaCl|7.7 mmol Na/kgBW/d
214564791|NCT01613482|RADIATION|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
214564792|NCT01613482|DRUG|Trastuzumab|Weekly, 2mg/kg of corporal weight
214564793|NCT01613482|DRUG|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
214564794|NCT00056277|DRUG|lamotrigine|
214564795|NCT02015364|PROCEDURE|Controlled early mobilization|1\. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
214564796|NCT02712268|OTHER|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
214564797|NCT04940338|DRUG|Bromfenac Ophthalmic 0.09% Ophthalmic Solution|topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
214564798|NCT04940338|DRUG|Dexamethasone Ophthalmic|topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
214564799|NCT04940338|DRUG|Placebo|topical placebo (artificial tears substitute) 2x daily before the surgery
214564800|NCT04940338|PROCEDURE|Phacoemulsification surgery (PHACO)|About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
214564801|NCT03202953|PROCEDURE|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~* Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
214564802|NCT03202953|PROCEDURE|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.~\- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
214564803|NCT03586011|BEHAVIORAL|Predicting factors for increased physical activity|
214564804|NCT01365481|DRUG|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
214564805|NCT01365481|DRUG|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
214564806|NCT01365481|DRUG|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
214564807|NCT05097196|OTHER|Moderate-intensity aerobic activities|The exercise intensity of the individual is planned at 50-60% heart rate reserve using the Karvonen method.
214564808|NCT03221166|DRUG|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
214564809|NCT03221166|DRUG|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
214564810|NCT00047697|DRUG|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
214564811|NCT00047697|DRUG|Placebo|Placebo used in placed of Donepezil HCL
214564812|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
214564813|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
214564814|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
214564815|NCT05315505|OTHER|Maintenance programme|"Continuous educational support, exercise training, behaviour change intervention, and self-management.~Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision"
214564816|NCT05315505|OTHER|Usual Care|No maintenance programme, and the patient has the usual follow-up and medical appointments
214564817|NCT01745692|DEVICE|Mechanical thrombectomy|
214564818|NCT01745692|DRUG|Intravenous rtPA|All patients receive IV alteplase
214564819|NCT00260286|BEHAVIORAL|Energy availability|
214564820|NCT05871684|DRUG|BTK inhibitor|Intervention were given during bridging therapy and maintanance treament of CAR-T cell therpay.
214564821|NCT05871684|DRUG|PD-1 inhibitor|Intervention were given during maintanance treament of CAR-T cell therpay.
215166723|NCT07196631|DRUG|ropivacaine|those in the control group received 80mg of ropivacaine
214564822|NCT05732753|OTHER|Mindfulness + Education in Neurophysiology of pain|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
214564823|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
214564824|NCT04160026|DRUG|Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
214564825|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer|Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
214564826|NCT05254080|DEVICE|Active taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).
214564827|NCT05254080|DEVICE|Sham taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.
215029840|NCT07010666|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate|25 grams of BHB
214564828|NCT02915484|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
214564829|NCT04646967|DRUG|Bupivacain|See active comparator description
214564830|NCT04646967|DRUG|Sevoflurane|See active comparator description
214564831|NCT04646967|DRUG|Acetaminophen|See active comparator description
214564832|NCT04646967|DRUG|Ibuprofen|See active comparator description
214564833|NCT04646967|DRUG|Ketorolac|See experimental arm description
214564834|NCT00002305|DRUG|Flucytosine|
214564835|NCT00002305|DRUG|Fluconazole|
214564836|NCT00002305|DRUG|Amphotericin B|
214564837|NCT02803008|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - SR15-46-Z13-072)
215029841|NCT07010666|DIETARY_SUPPLEMENT|Carbohydrate|25 grams of carbohydrate
215029842|NCT07010666|DIETARY_SUPPLEMENT|Caffeine|4 mg/kg of caffeine
215029843|NCT07010900|PROCEDURE|Injection|patients randomized in intervention group will use also penile extender
215029844|NCT06685770|OTHER|Mini mental state assessment test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
215029845|NCT06685770|OTHER|Mini-cog test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
214564838|NCT00484029|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
214564839|NCT00484029|OTHER|Air|Air (Medical Grade)
214564840|NCT04148664|PROCEDURE|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard."
214564841|NCT04148664|PROCEDURE|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard."
214564842|NCT04224857|DRUG|AMT-101|Single or daily dosing at doses A, B, C, D, E, F
214564843|NCT04224857|DRUG|Placebos|Single or daily dosing at doses A, B, C, D, E, F
214564844|NCT02909218|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
214564845|NCT04792619|OTHER|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
214564846|NCT04792619|OTHER|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
214564847|NCT00483990|DRUG|PSD502|
214564848|NCT00799981|DEVICE|A=SpeediCath Compact 7 cm and B=POBE 10 cm|Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
214564849|NCT03296670|DRUG|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
214564850|NCT03296670|DRUG|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
214564851|NCT04680806|DEVICE|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
214564852|NCT04680806|DEVICE|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
214564853|NCT02436434|DEVICE|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
214564854|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
214564855|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
214564856|NCT03041974|PROCEDURE|Red Blood Cell transfusion|
214564857|NCT03041974|PROCEDURE|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
215029846|NCT07009743|DIAGNOSTIC_TEST|MRI contrast-enhancing agents|All patients underwent standard pelvic MRI examinations (1.5T or 3T) with the following sequences: T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) with and without fat suppression; axial, sagittal, and coronal post-contrast T1WI following intravenous administration of gadolinium-based contrast agents (GBCA); functional sequences including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging MRI (DWI-MRI). Enhancement sequences may be omitted if no adnexal masses were identified on T2WI, T1WI, or DWI sequences.
215029847|NCT06691438|DEVICE|prostate biopsy|prostate biopsies with virtual reality hypnosis headset
214564858|NCT01641159|DRUG|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
214564859|NCT01641159|DRUG|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
214564860|NCT04484116|DIAGNOSTIC_TEST|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
214564861|NCT00632489|DRUG|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
214564862|NCT00632489|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
214564863|NCT00632489|DRUG|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
214564864|NCT02826928|BIOLOGICAL|blood sample withdrawn|
214564865|NCT00883064|DRUG|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
214564866|NCT00883064|DRUG|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
214564867|NCT05563350|DIAGNOSTIC_TEST|Blood samples|p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping
214564868|NCT03653208|DRUG|hzVSF-v13|Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
214564869|NCT03653208|DRUG|Placebo|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
214564870|NCT01249027|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
214564871|NCT01939444|DRUG|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
214564872|NCT01939444|DRUG|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
214564873|NCT00805805|DRUG|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
214564874|NCT00805805|OTHER|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
214564875|NCT03778268|PROCEDURE|sentinel lymph node biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
214564876|NCT03545477|OTHER|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
214564877|NCT03545477|OTHER|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
214564878|NCT03545477|OTHER|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
214564879|NCT03752970|DRUG|Spesolimab|Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
215029848|NCT06690840|DRUG|Atezolizumab in combination with Cyclophosphamide and Vinorelbine|Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
215029849|NCT06686641|DRUG|Local and systemical treatment|Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.
215029850|NCT06689761|DIETARY_SUPPLEMENT|ColCT|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
215029851|NCT06689761|DIETARY_SUPPLEMENT|ColET|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
215029852|NCT06689761|DIETARY_SUPPLEMENT|PlaCT|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
215029853|NCT06689761|DIETARY_SUPPLEMENT|PlaET|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
215029854|NCT04857528|RADIATION|Radiation Treatment With or Without Chemotherapy|Standard care radiation treatment.
215029855|NCT04857528|OTHER|Blood Sample Collection|Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.
215029856|NCT04857528|DIAGNOSTIC_TEST|HPV Genotyping (HPV DNA Test)|A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.
214564880|NCT03752970|DRUG|Placebo|Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
214564881|NCT00556465|DRUG|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
214564882|NCT02690259|PROCEDURE|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
214564883|NCT00354575|DRUG|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
214564884|NCT04625699|DRUG|Durvalumab|4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
214564885|NCT04625699|DRUG|Tremelimumab|2 doses of Tremelimumab 300 mg IV Day 1, q56 days
214564886|NCT04344080|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
214564887|NCT02984722|DRUG|Metformin|
214564888|NCT03117829|BEHAVIORAL|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
214564889|NCT05215028|DEVICE|web-application|web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
214564890|NCT02605551|PROCEDURE|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~1. OM Occipitomastoid release technique~2. Sub-Occipital Release Technique~3. Rib Raising Technique~4. Rotatory stimulation of posterior Chapman's Reflexes~5. Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
214564891|NCT02605551|BEHAVIORAL|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
214564892|NCT04479228|DEVICE|Endosonography guided transmural drainage|The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
214564893|NCT00685451|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214564894|NCT04179916|DIAGNOSTIC_TEST|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
214564895|NCT02158923|PROCEDURE|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
214564896|NCT02158923|PROCEDURE|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
214564897|NCT02158923|PROCEDURE|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
214564898|NCT03478904|DRUG|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
214564899|NCT03478904|DRUG|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
214564900|NCT02630589|DEVICE|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
214564901|NCT03385590|DIETARY_SUPPLEMENT|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
214564902|NCT03385590|DIETARY_SUPPLEMENT|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
215029857|NCT04857528|DIAGNOSTIC_TEST|Testing Archival Tumor Tissue|Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.
215029858|NCT04857528|OTHER|Physical Exam|A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).
215029859|NCT04857528|DIAGNOSTIC_TEST|Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)|Tests that use computers and/or rotating x-rays to scan/create images of the body.
215166724|NCT07201090|BEHAVIORAL|Brief Parent-Child Interaction Therapy with videos and virtual reality (360-degree VR)-films|"10 sessions of PCIT delivered by trained psychologists, supplemented with videos and 360-degree VR-films~Sessions follow the standard PCIT structure, with an initial phase focused on child-directed interaction, followed by a second, modified phase, focused on parent-directed interaction.~To support skill learning, families are provided with digital materials including conventional video modules at home and 360-degree virtual reality (VR) films. The VR films are shown during two sessions at the clinic. Additional videos are available online through a platform for parents to view and practice between sessions. These tools allow parents to rehearse skills flexibly in their home environment and reinforce the in-session training."
215166725|NCT07201415|PROCEDURE|minimally invasive suprachoroidal drainage|minimally invasive suprachoroidal drainage
215166726|NCT07198087|DRUG|Tirabrutinib|Administered orally
215166727|NCT07198100|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
215166728|NCT07198100|DEVICE|Sham stimulation|The control intervention consists of a sham stimulation. The electrode will be placed at the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.
215166729|NCT07198100|DIAGNOSTIC_TEST|Oral glucose tolerance test (oGTT)|"The oGTT will be conducted as a standardized metabolic challenge to assess glucose metabolism and insulin sensitivity. After an overnight fast, participants ingest a 75 g glucose solution. Venous blood samples are collected at five time points (0, 30, 60, 90, and 120 minutes) to measure plasma glucose and insulin concentrations. The primary variable of interest will be the peripheral insulin sensitivity index (ISI) according to Matsuda and DeFronzo as 10,000/(G0 × I0 × Gmean × Imean)1/2 with G = glucose and I = insulin.~Additionally we will investigate the correspondence of ISI with other measures of insulin sensitivity (HOMA-IR), and Insulin secretion indices (Insulinogenic index (IGI), Corrected insulin response (CIR), Areas under the curve (AUC)), and HbA1c."
215166730|NCT07196865|PROCEDURE|Open Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after external stripping and internal ligation, the surgical wound is left entirely open without sutures to heal by secondary intention. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
214564903|NCT04839822|OTHER|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time."
214564904|NCT04839822|OTHER|Health tips|Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.
214564905|NCT04839822|DIAGNOSTIC_TEST|Surveys|Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.
214564906|NCT04839822|OTHER|Popular psychological interventions|Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
214564907|NCT00193167|DRUG|Topotecan|
214564908|NCT01152814|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
214564909|NCT04314635|BEHAVIORAL|Brief family engagement intervention for CHR|The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
214564910|NCT04314635|BEHAVIORAL|Treatment as usual (TAU)|The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
214564911|NCT03560024|OTHER|PACAP27|PACAP27 is vasodilator of cerebral vessels
214564912|NCT03560024|OTHER|Placebo|Saline
214564913|NCT02893384|DRUG|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
214564914|NCT02818725|DRUG|Chemotherapy|METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
214564915|NCT02818725|DRUG|Panitumumab|PANITUMUMAB: 6 mg/kg on day 2
214564916|NCT03235752|DRUG|TJ301 300mg|TJ301 300mg IV infusion
214564917|NCT03235752|DRUG|TJ301 600mg|TJ301 600mg IV infusion
214564918|NCT03235752|DRUG|Placebo|Placebo IV infusion
214564919|NCT00285025|DRUG|SR57667B|
214564920|NCT04716062|PROCEDURE|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
214564921|NCT02237729|BIOLOGICAL|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
214564922|NCT02237729|BIOLOGICAL|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
215166731|NCT07196865|PROCEDURE|Closed Hemorrhoidectomy (Ferguson Technique)|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the entire surgical wound is closed primarily using interrupted non-absorbable sutures. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
215166732|NCT07196865|PROCEDURE|Semi-Closed Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the distal half of the incision (away from the anal canal) is closed with interrupted sutures, while the proximal half remains open. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
215166733|NCT07198282|PROCEDURE|Conventional Suturing|Wound edges are approximated using 3/0 braided, non-absorbable silk sutures (Doğsan®, Turkey). Standard oral surgery closure technique.
215166734|NCT07198282|PROCEDURE|Sutureless Technique|The wound is left to heal by secondary intention without using any suturing material.
215166735|NCT07198282|PROCEDURE|Surgical Drain|A biocompatible sterile plastic drain is placed in the surgical site to facilitate drainage of blood and fluids, helping to reduce edema and hematoma formation.
215166736|NCT07198282|PROCEDURE|Cyanoacrylate Tissue Adhesive|Cyanoacrylate-based medical tissue adhesive (PeriAcryl®90 High Viscosity) is applied to the wound edges, providing rapid polymerization and effective closure.
215166737|NCT07200492|OTHER|Facial serum application|The trained technician will apply the 0.3g-0.4g investigational products on the subject's half face.
215166738|NCT07200492|OTHER|Forearm serum application|The trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm.
215166739|NCT07200583|PROCEDURE|Protein A immunoadsorption|Extracorporeal therapy performed prior to haploidentical HSCT to remove donor-specific anti-HLA antibodies (DSA)
215166740|NCT07200583|DRUG|Rituximab (optional, in some patients)|Anti-CD20 monoclonal antibody occasionally combined with immunoadsorption as part of desensitization strategy
215166741|NCT07200583|DRUG|Bortezomib (optional, in some patients)|Proteasome inhibitor occasionally used in combination with desensitization therapy.
215166742|NCT07200700|DIAGNOSTIC_TEST|Knee laxity arthrometer|Inter-reliability analysis of the GNRB arthrometer between two examinors compared to standard KT 1000 arthrometer
214564923|NCT02237729|BIOLOGICAL|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
214564924|NCT00464984|BEHAVIORAL|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
214564925|NCT04278014|PROCEDURE|ultrasound-guided continuous sciatic block with longitudinal approach|ultrasound-guided continuous sciatic block with longitudinal approach
214564926|NCT01353651|DEVICE|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
214564927|NCT01353651|DEVICE|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
214564928|NCT00306267|DRUG|epoetin alfa|
214564929|NCT02429453|DRUG|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
214564930|NCT02429453|BIOLOGICAL|Fresh Frozen Plasma|A pooled collection of plasma from donors
214564931|NCT04368364|DRUG|Intrathecal morphine sulfate (ITM)|Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
214564932|NCT04368364|DRUG|Bupivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
214564933|NCT04368364|DRUG|ropivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
214564934|NCT01669577|PROCEDURE|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
214564935|NCT04068233|OTHER|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
214564936|NCT00183157|BEHAVIORAL|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
214564937|NCT00183157|BEHAVIORAL|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
215166743|NCT07201779|BEHAVIORAL|REDCHiP|REDCHIP comprises 10 telehealth group sessions for parents of young children with T1D, is grounded in Cognitive Behavioral Therapy (CBT) principles, and is designed to address parents FH, and their avoidant coping behaviors related to FH. Sessions also focus on strengthening parents' coping strategies associated with T1D management and helping them to reduce feelings of diabetes distress.
215166744|NCT07201779|OTHER|Treatment As Usual Control Group|Participants will receive their treatment as usual in medical appointments
215166745|NCT07202507|OTHER|self-report questionnaires, research interviews|self-report questionnaires and research interviews
215166746|NCT07198139|DRUG|CDI-988|Antiviral to treat norovirus
215166747|NCT07198139|DRUG|Placebo|Matching placebo
215166748|NCT07198139|OTHER|Snow Mountain Virus|Challenge with Snow Mountain Virus
214564938|NCT00183157|BEHAVIORAL|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
214564939|NCT04404127|DRUG|Basiliximab 20 milligram [Simulect]|Basiliximab
214564940|NCT04404127|OTHER|Normal Saline|No-Induction
214564941|NCT03339739|OTHER|Isometric mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
214564942|NCT03339739|OTHER|Isotonic mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
214564943|NCT03339739|BEHAVIORAL|Counseling group|subjects included in this group get an education brochure about the disorder and receive no further interventions
214564944|NCT03212495|DRUG|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
214564945|NCT03212495|DRUG|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
214564946|NCT04647552|DRUG|Drug Steroid|hydrocortisone injection
214564947|NCT06502886|PROCEDURE|combined protocol of retention (bonded lingual retainer and vacuum formed retainers)|Combined bonded retainer and vacuum formed retainer
214564948|NCT06502886|PROCEDURE|Bonded lingual retainer|Bonded retainer
214564949|NCT04094441|OTHER|chest physiotherapy|chest physiotherapy
214564950|NCT01283516|DRUG|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
215166749|NCT07201194|OTHER|Holistic acupuncture and acupressure|"The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding.~Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure.~A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes."
215166750|NCT07201194|OTHER|Standard medical treatment|Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.
215166751|NCT07202494|OTHER|Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)|Functional MRI (fMRI) Diffusion Tensor Imaging (DTI) Sodium Imaging (23Na-MRI) Phosphorus Imaging (31P-MRI)
215166752|NCT07197151|OTHER|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
215166753|NCT07199803|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
215166754|NCT07197554|DRUG|ST-01156|ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer
215166755|NCT07202013|OTHER|Kinesio taping|Kinesio taping was applied in a fan-shaped pattern once weekly for four consecutive weeks. Elastic therapeutic tape was applied with 0-15% tension to the buttocks and thighs at standardized anatomical points, including the gluteus maximus (above the sacroiliac joint), posterior thigh (gluteal fold), and anterior thigh (above the anterior inferior iliac crest). This protocol was designed to promote lymphatic drainage, improve microcirculation, and enhance dermal density and structure in women with stage II cellulite.
215166756|NCT07201272|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 3.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
215166757|NCT07201272|DRUG|Morphine|Patients will receive spinal anesthesia (using 3 mL of hyperbaric bupivacaine 0.5%) + (75 µg morphine diluted in 0.5ml saline) with sham block at the end of surgery.
215166758|NCT07200245|OTHER|adrenalectomy|adrenalectomy for pheochromocytoma and non-secreting tumor (incidentaloma)
215166759|NCT07196345|DRUG|TAS-102|Administered orally at 35 mg/m²/dose twice daily (morning and evening), in a bi-weekly regimen on Days 1-5.
215166760|NCT07196345|RADIATION|Radiotherapy|Total dose of 50-60 Gy, delivered in 25-28 fractions, administered Monday through Friday (daily) until the full prescribed dose is achieved.
215166761|NCT07197866|DRUG|TEV-56286|administered orally
215166762|NCT07198399|DIETARY_SUPPLEMENT|Auri Super Mushroom Daily Gummies|Each gummy contains a blend of 12 functional mushroom extracts (300 mg equivalent each).
214564951|NCT04369781|DIAGNOSTIC_TEST|transcutaneous oxygen pressure recording at rest|Recording of limb and chest transcutaneous oxygen pressure
214564952|NCT00599573|DRUG|ondansetron|Ondansetron 4mg BID for six weeks
214564953|NCT03593551|COMBINATION_PRODUCT|five relaxation treatments and one control|Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
214564954|NCT04076189|PROCEDURE|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
214564955|NCT04076189|PROCEDURE|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
214564956|NCT05833100|DEVICE|CareSens PRO GK Blood Glucose/b-Ketone Monitoring system|"All BG results were compared to YSI 2300 reference method results obtained from subjects' capillary blood.~All Ketone results were compared to Randox Imola D-3-Hydroxybutyrate analyzer."
214564957|NCT03369327|DRUG|sofosbuvir and daclatasvir|"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg"
215166763|NCT07200817|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes and Platelets ratio (N/LP)|The Neutrophils to Lymphocytes and Platelets ratio (N/LP) will be measured
215166764|NCT07199907|BEHAVIORAL|Associative Inference|Objects, faces, and scenes will be arranged into 12 ABC triads presented as overlapping AB and BC pairs. AB pairs will comprise objects; BC pairs will consist of the same B object paired with a face or scene (C). Twelve non-overlapping (NO) pairs will serve as controls. Participants will study overlapping (AB, BC) and NO pairs (4s) across two 5-minute fMRI runs. Each pair will be presented three times within a run. Following learning, participants will complete a self-paced 3-alternative forced choice (AFC) inference task during which they will select the C item that shares a common relationship with an A cue. Foils for inference trials will be C items from other ABC triads, of the same face/scene subcategory. Participants will then complete a final, self-paced 3-AFC memory test of premise associations (AB, BC) and NO pairs. To quantify memory retrieval and how overlapping events are organized, before and after learning, participants will view the A and C items during fMRI scanning.
215166765|NCT07199907|BEHAVIORAL|Probabilistic Inference|"Participants will visit a virtual zoo, which is divided into three zones, each containing the same five monsters, but with different likelihoods of occurrence. Participants learn the underlying likelihood distributions by virtually navigating each zone. On each trial, two monsters appear; participants select the monster that they predict will next appear (6s). After making their choice, the correct monster appears and feedback is provided (2s). Participants tour each zone four times across 9 runs. Following learning, participants are tested on probabilistic inference. Here, participants see a series of monster photographs and are asked to infer in which zone they were taken. On each trial, a sequence of individual monster images (3.5s each) will then appear (1-6 monsters) prior to a decision screen, in which participants choose which of the two zones most likely produced the photos (4s) and are given feedback (1.5s). Participants will perform nine fMRI runs of the inference task."
215166766|NCT07200518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Hetox multistrain probiotic|OMNi-BiOTiC® Hetox multistrain probiotic
215166767|NCT07200518|DIETARY_SUPPLEMENT|Placebo|Placebo
215166768|NCT07198763|OTHER|Conventional pulmonary rehabilitation|After completing the assessments, participants will be randomly divided into two groups: Group 1, which will perform PR exercises and the Group 2, which will perform PR through dance. Both groups will have the interventions of pulmonary rehabilitation during approximately 50 minutes, for 8 weeks. The group 1 will perform five different exercises with resistance bands, with 3 sets of 1 minute each. Exercises will always begin with the lightest resistance band, and if more than 30 repetitions are observed in 1 minute, the resistance band will be replaced with one of the next highest resistance. The Group 2 will perform rehabilitation through dance using 2 different playlists. The music will be from nationally and internationally known artists. The steps will be based on the exercises performed in group 1 and will be incremented throughout each song and playlist. At the end of 8 weeks of intervention, the evaluative tests will be applied again.
215166769|NCT07201129|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
215166770|NCT07201129|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
215166771|NCT07200648|OTHER|Unconditional cash transfer|$1,000 unconditional cash transfer per month for 12 months
215166772|NCT07200713|OTHER|Treatment as usual (TAU)|Best practice ordinary psychological treatment
215166773|NCT07200713|OTHER|Sensory motor arousal regulation treatment (SMART)|Psychological treatment using SMART room and associated techniques
215166774|NCT07201545|DRUG|Bempedoic acid|"180 mg film coated tablet administered as FDC or co-administered with ezetimibe~Component of FDC"
215166775|NCT07201545|DRUG|Ezetimibe|"10 mg tablet administered as FDC or co-administered with bempedoic acid~Component of FDC"
215166776|NCT07201545|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
214564958|NCT00132873|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
214564959|NCT02045875|DRUG|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
214564960|NCT00444275|DRUG|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
214564961|NCT00444275|DRUG|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
214564962|NCT03001375|PROCEDURE|Laparoscopic high anterior resection splenic flexure mobilization|
214564963|NCT03001375|PROCEDURE|Laparoscopic high anterior resection without splenic flexure mobilization|
214564964|NCT03798041|BEHAVIORAL|Debridement Within 24 Hours After Surgery|Debrided within 24 hours after surgery
214564965|NCT03775928|DRUG|Apatinib|apatinib 425mg qd po
214564966|NCT03775928|DRUG|capecitabine|capecitabine 1000mg/m2 bid d1-d14
214564967|NCT01048801|DEVICE|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
214564968|NCT01048801|OTHER|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
214564969|NCT03030859|OTHER|Usual Care|Undergo usual care only
214564970|NCT03030859|OTHER|Usual Care plus LEF-SCP|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
214564971|NCT03030859|OTHER|Usual Care plus LEF-SCP plus Follow-up|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
214564972|NCT05313659|DRUG|Ketamine Hydrochloride|intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
214564973|NCT04224376|DEVICE|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
214564974|NCT04690894|PROCEDURE|erector spinae block - caudal block|the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
214564975|NCT01675245|DRUG|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
214564976|NCT00513487|DRUG|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
215029860|NCT07010549|DEVICE|Hyaluronic Acid injections|Among treatments today available, bio-revitalization is a process which triggers the skin's own, natural collagen production and cell rejuvenation through the injection of hyaluronic acid serums. This substance is hydrophilic, drawing many times its weight in water. As we age, we have less naturally produced HA in our tissues and skin dehydration becomes a telltale sign of aging. The HA owns a great hydrating power, due to this property is widely used in the biorevitalization treatments. Its use results in supple, younger-looking skin with reduced wrinkles and improved elasticity.In bio-revitalization procedures that involve intradermal micro-injections of natural HA, with a molecular weight close to the endogenous one, carried out in correspondence with the imperfections, the viscoelastic properties of HA allow to rehydrate the tissues, allowing to prevent and contrast the aging process skin and promote their remodeling.
215166777|NCT07201662|OTHER|Condensed and Revised Multifaceted Empathy Test|Experimental emotional decoding task that measures the cognitive and affective dimensions of empathy based on performance (Edele et al., 2013; Grynberg et al., 2017).Participants view 40 photos of faces expressing either a positive or negative emotion and must identify the emotion (decoding) and then rate on a 1-9 scale the extent to which they share it (emotional sharing). The task lasts approximately 10 minutes on average.
215166778|NCT07201662|OTHER|Hospital Anxiety and Depression Scale|"A self-administered scale with 14 items, divided into two subscales of seven items, used to detect the presence of depression and anxiety. Non-cases or asymptomatic individuals (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11).~The administration time is approximately 5 minutes."
215166779|NCT07201662|OTHER|Interpersonal Reactivity Index|The Interpersonal Reactivity Index (Davis, 1980; Guttman \& Laporte, 2002) is a 28-item self-report questionnaire measuring four dimensions of empathy: fantasy, perspective taking, empathic concern, and personal distress. Each item is rated on a 1-to-5 scale and provides a subscore for each dimension, with no overall total score. Administration takes approximately 5 minutes.
215166780|NCT07201662|OTHER|Vicarious Distress Questionnaire|The Vicarious Distress Questionnaire (Grynberg et al., 2012) is an 18-item self-report scale assessing distress experienced in response to others' suffering and its impact on prosocial behaviors. It includes three dimensions-distress, support, and avoidance-each yielding a specific subscore. Administration takes approximately 5 minutes.
214564977|NCT02878707|DRUG|Dexmedetomidine|Intraoperative dexmedetomidine infusion
214564978|NCT01204710|BIOLOGICAL|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
214564979|NCT01204710|DRUG|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
214564980|NCT01204710|DRUG|Prednisone|5 mg orally (PO) twice daily (BID) on each day
214564981|NCT04698759|OTHER|No Intervention|no Intervention
214564982|NCT02538159|DEVICE|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
214564983|NCT02538159|DEVICE|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
215166781|NCT07201662|OTHER|Binge Eating Scale|The Binge Eating Scale (Gormally et al., 1982; Brunault et al., 2016) is a 16-item self-report questionnaire assessing the behavioral, emotional, and cognitive manifestations of binge eating disorder (BED) according to DSM-V criteria. The total score (0-46) reflects symptom severity and can be interpreted dimensionally or categorically (≥ 18 indicating significant symptomatology). Administration takes approximately 5 minutes.
214564984|NCT03039101|PROCEDURE|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
214564985|NCT03039101|PROCEDURE|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
214564986|NCT03039101|PROCEDURE|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
214564987|NCT03039101|PROCEDURE|Peripheral blood|Peripheral blood draw
214564988|NCT03039101|DRUG|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
214564989|NCT03039101|DRUG|Placebo Oral Tablet|one pill orally, daily, for 1 week
214564990|NCT00002001|DRUG|Zidovudine|
214564991|NCT00002001|DRUG|Zalcitabine|
214564992|NCT00002001|DRUG|Didanosine|
214564993|NCT05129228|DEVICE|OCT-guided saphenous vein CABG|OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
214564994|NCT05901909|BEHAVIORAL|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
214564995|NCT04270396|BEHAVIORAL|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
214564996|NCT03186573|DIETARY_SUPPLEMENT|Grape juice|400ml diary of grape juice
214564997|NCT03186573|DIETARY_SUPPLEMENT|Maltodextrin|400ml diary of maltodextrin
214564998|NCT06188429|DIAGNOSTIC_TEST|DSM-5|Using DSM-5 for diagnostic testing of the children in the study group.
214564999|NCT05865132|DRUG|Palbociclib|120mg/125mg po qd on day 1 to 21, every 28 days
214565000|NCT05865132|DRUG|Afatinib|30mg/40mg po qd on day 1 to 28, every 28 days
214565001|NCT00476073|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
214565002|NCT02639832|DEVICE|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
214565003|NCT02824354|DRUG|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
214565004|NCT02824354|DRUG|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
214565005|NCT02080559|BIOLOGICAL|4CMenB|0.5ml IM
214565006|NCT03537547|OTHER|GeneSight Psychotropic test|GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
214565007|NCT03537547|DRUG|FDA-approved antidepressant or antipsychotic treatment|Participant is treated with medications included in the GeneSight Psychotropic product.
214565008|NCT06147908|DRUG|DW5221|megestrol acetate
214565009|NCT06147908|DRUG|DW5221-R|megestrol acetate
214565010|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.006mg|ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
214565011|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.012mg|ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
214565012|NCT04228926|DRUG|ZKY001 simulated eye drops|ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
214565013|NCT03089138|DRUG|Regan Tangjiang|The treatment duration is 3 consecutive days.
214565014|NCT01780259|DRUG|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
214565015|NCT01780259|DRUG|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
214565016|NCT01780259|DRUG|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
214565017|NCT02870829|DRUG|menaquinone-7|Oral supplement given post dialysis 3x/week
214565018|NCT00055588|PROCEDURE|Locomotor training|
214565019|NCT03178370|DEVICE|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
214565020|NCT00447564|DRUG|Probuphine|4 implants
214565021|NCT00447564|DRUG|placebo|4 implants
214565022|NCT05381545|BEHAVIORAL|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.
214565023|NCT05381545|BEHAVIORAL|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
214565024|NCT03613025|DIAGNOSTIC_TEST|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
214565025|NCT02397382|DRUG|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.
214565026|NCT02397382|DRUG|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
214565027|NCT02397382|DRUG|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
214565028|NCT02397382|DRUG|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
214565029|NCT02397382|DRUG|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
214565030|NCT02397382|DRUG|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
214565031|NCT00450541|BEHAVIORAL|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
214565032|NCT00450541|BEHAVIORAL|Interview|Interview lasting about 30 minutes.
214565033|NCT00586612|BIOLOGICAL|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
214565034|NCT00586612|BIOLOGICAL|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
214565035|NCT00586612|BIOLOGICAL|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
214565036|NCT00586612|BIOLOGICAL|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
214565037|NCT00222872|DRUG|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
214565038|NCT00222872|DRUG|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
215029861|NCT07010198|DIAGNOSTIC_TEST|Quantitative HBeAg Testing|Quantitative HBeAg Testing in Population-Based Primary Screening
215029862|NCT07010198|BIOLOGICAL|Measurement Indicators Required for Risk Scoring in HCC Screening Strategies|REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.
215029863|NCT07010198|BIOLOGICAL|Follow-Up Monitoring Parameters|AFP, Liver Ultrasound
214565039|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
214565040|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
214565041|NCT00330148|DRUG|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
214565042|NCT02903563|OTHER|observational|
214565043|NCT02302170|BIOLOGICAL|H. pylori vaccine|
214565044|NCT02302170|BIOLOGICAL|placebo|
214565045|NCT04890548|DRUG|AZD3427|Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
214565046|NCT02839889|DRUG|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
214565047|NCT02839889|DRUG|Placebo|Placebo once daily for two weeks, followed by two week open-label period
214565048|NCT05812742|BEHAVIORAL|Early intervention programme|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
214565049|NCT05812742|BEHAVIORAL|Enhanced usual care|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
214565050|NCT02001064|BEHAVIORAL|Care4Today v2.0 mobile application + electronic monitoring of adherence|Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
215029864|NCT06690229|DRUG|glass ionomer cement|A cement used for crown cementation
215029865|NCT06690229|DRUG|self-adhesive resin cement|A cement used for crown cementation
214565051|NCT00315991|BEHAVIORAL|Blood Glucose Awareness Training for Parents|
215029866|NCT06690229|DRUG|resin modified glass ionomer cement|A cement used for crown cementation
214565052|NCT03892252|OTHER|No intervention|No intervention
214565053|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
214565054|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
214565055|NCT00409721|DRUG|Memantine|
215029867|NCT01647256|DRUG|Nikkomycin Z|Capsule, 500 mg, single-dose
215029868|NCT04732468|BIOLOGICAL|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
215029869|NCT04732468|DRUG|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
215029870|NCT04657068|DRUG|ART0380|Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
215029871|NCT04657068|DRUG|Gemcitabine|Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
215029872|NCT04657068|DRUG|Irinotecan|Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
215029873|NCT06694051|PROCEDURE|marking|axis marking
215029874|NCT06694077|DRUG|Bupivacaine with Dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
215029875|NCT06694077|DRUG|Bupivacaine only|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
215029876|NCT06695585|DRUG|Lidocaine 2% without vessel constrictor|different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
215029877|NCT06689774|BEHAVIORAL|Cognitive-Motivational Feedback|Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.
215029878|NCT06689774|BEHAVIORAL|Staff Tobacco Quit Line Referral Implementation Support|Salvation Army personnel will receive training and will be engaged in efforts to plan, evaluate, adapt, and sustain tobacco treatment referral as part of the social services they provide to adult Salvation Army service consumers who use tobacco. Implementation support will take the form of ongoing engagement of an outreach specialist with a team of Salvation Army personnel and consumers who lead Quit Line referral efforts in the Salvation Army.
215029879|NCT06689774|BEHAVIORAL|Consumer Incentives for Immediate Referral to a Tobacco Quit Line|Salvation Army personnel will offer an incentive to adult consumers who use tobacco to encourage immediate acceptance of a live call with the Wisconsin Tobacco Quit Line. The incentive will be designed by Salvation Army personnel to fit the local context and to be sustainable over time, such as extra access to existing support or resources.
215029880|NCT06688188|DRUG|68Ga-JH12|The dose will be 148-222 MBq given intravenously.
215029881|NCT06690125|DIAGNOSTIC_TEST|Classical and computerized assessment|"Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)"
215029882|NCT06686628|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
215029883|NCT06686628|DRUG|Midazolam|Pharmaceutical form: Solution Route of administration: Oral
215029884|NCT06686628|DRUG|Caffeine|Pharmaceutical form: Tablet Route of administration: Oral
215029885|NCT06686628|DRUG|Metoprolol|Pharmaceutical form: Tablet Route of administration: Oral
215029886|NCT06686628|DRUG|Omeprazole|Pharmaceutical form: Capsule Route of administration: Oral
215029887|NCT06686628|DRUG|Warfarin|Pharmaceutical form: Tablet Route of administration: Oral
215029888|NCT05868655|OTHER|Exercise with Video-Based|A program of stability and balance exercises will be provided
215029889|NCT05868655|OTHER|Standart exercise-Home-Based|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
215029890|NCT06695611|OTHER|Increase systolic blood pressure|"To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic"
215166782|NCT07202195|DEVICE|electro-stimulation suit|"In EXOPULSE Mollii Suit is a multi-channel full-body suit with a low energy electrical stimulation - 20 Volt and 20 Hz. It generates 2 milliamp pulses (into 0-10,000 Ohms) with the following parameters:~* Pulse width: variable between 25 and 170 μs.~* Length of period: 50 ms.~* Maximum amplitude: 20 V. It is composed of a control unit, a jacket and pants, with 58 embed-ded electrodes, in direct contact with the skin, and pre-positioned to stimulate 40 key muscle groups.~The suit comes in different sizes. A trained medical staff pre-programs which nerves/muscles to be stimulated based on a clinical assessment of the user and the outcome is evaluated through standardized methods. The stimulation program is thus specific to each user."
215166783|NCT07202195|OTHER|Usual Care|The rehabilitation therapy that is being offered at the National MS Center Melsbroek, but somewhat reduced/adjusted to make time for initiation and follow-up of using the neuromodulation suit and potentially also during the weeks at home (i.e., rehabilitation being offered by municipalities).
215166784|NCT07202091|DRUG|Trimethoprim Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
215166785|NCT07202091|DRUG|Amoxycillin/clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.
215166786|NCT07202091|BIOLOGICAL|Immune Globulin Intravenous|Participants will continue treatment with their current Ig replacement schedule. Participants will receive monthly (every 4 weeks ± 1 week) intravenous immunoglobulin at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range. For patients who have already had their Ig dose titrated to IgG trough level, they may continue on their current monthly dose of Ig replacement. SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.
215166787|NCT07200219|BEHAVIORAL|Psychological Performance Strategies Training|A structured 4-week program of psychological performance strategies training delivered to licensed athletes. The program consisted of 8 sessions (twice per week, 60 minutes each) including modules on goal setting, self-talk, emotional control, imagery, automaticity, action orientation, attention control/negative thinking management, and relaxation techniques. Training was conducted in a supervised group format by qualified instructors.
215166788|NCT07201883|DRUG|Ondansetron (Zofran)|4 mg IV push
215166789|NCT07201883|OTHER|chewing gum|Peppermint sugar free chewing gum
214565056|NCT01406470|DRUG|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
214565057|NCT02738853|DEVICE|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
214565058|NCT05624905|PROCEDURE|Percutaneous coronary intervention|Percutaneous Coronary Intervention Procedure
214565059|NCT02602639|DEVICE|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
214565060|NCT05034159|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Same as is described previously.
214565061|NCT04936477|OTHER|Calculation of ventilation-perfusion ratio|"Three to five paired measurements of fraction of inspired oxygen and peripheral oxygen saturations.~Insertion of mainstream capnograph with combined pressure and flow sensor to perform end-tidal capnography measurement.~Echocardiogram to assess intra-cardiac shunting."
214565062|NCT00413205|DRUG|Placebo|po daily
214565063|NCT00413205|DRUG|RAR Gamma|5mg po daily
214565064|NCT02387190|OTHER|Telenursing monitoring|"The telenursing program protocol is based on:~1. Contact the patient by telephone, weekly;~2. Distribution and explanation of the educational booklet;~3. Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
214565065|NCT05512351|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
214565066|NCT05276908|PROCEDURE|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
214565067|NCT05276908|PROCEDURE|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
215166790|NCT07201883|COMBINATION_PRODUCT|Ondansetron + Chewing gum|Ondansetron 4 mg IV push Peppermint sugar free chewing gum
214565068|NCT05276908|DRUG|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
214565069|NCT05276908|DRUG|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
214565070|NCT00644163|BEHAVIORAL|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
214565071|NCT00644163|BEHAVIORAL|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
214565072|NCT00565487|DRUG|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
214565073|NCT04321421|OTHER|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
215166791|NCT07200934|DEVICE|Transcutaneous electrical stimulation (TENS)|"The negative/active pad surface electrode will be applied at the T6 dermatome on the abdomen (is located at the left upper quadrant of the abdomen, 2 cm below the ribcage at the left midclavicular line) for stimulation and the passive/positive electrode will be applied on the left T6 costovertebral junction to complete the circuit.~* The specific parameters of TENS will be burst mode, 2.0 Hz frequency, and 300 micro-seconds width~* The patients will receive 3 times 30 min session each week for a period of consecutive 12 weeks.~* The intensity of TENS will be gradually increased from 0 mA till the subject felt a comfortable tingling sensation beneath the electrode without any muscle contraction and pain."
215166792|NCT07200934|OTHER|Mediterranean Diet|The recommended composition of Mediterranean diet regimen: is characterized by a high intake of plant foods, fruits, vegetables, breads and other cereals (traditionally minimally refined), potatoes, beans, nuts and seeds; minimally processed, fresh fruits as a typical dessert, with sweets containing sugars or honey a few times per week; .a high intake of olive oil (especially virgin and extra-virgin olive oil) as the main source of fat; a moderate intake of dairy products (mostly as cheese and yoghurt); zero to four eggs per week; low to moderate amounts of fish and poultry; low amounts of red meat. The diet plan included generally 50% carbohydrates (from vegetables, fruits, legumes, and whole grains), 35% fats (from healthy oils, nuts, seeds, and fish), and 15% protein (from legumes, fish, nuts, dairy, poultry, and eggs).
215166793|NCT07200414|BEHAVIORAL|Integrated Adolescent Health Package|Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
215166794|NCT07200414|OTHER|Routine Government Health Services|Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
215166795|NCT07201493|BEHAVIORAL|color temperature change mode|Subjects are asked to read a terminal display device for 50 minutes, featuring texts with different color temperature mode treatments. Specifically, they will read the same text content for 50 minutes with different color temperature mode. The participants will complete a total of 2 sets of tests in a random order.
215166796|NCT07200804|DIAGNOSTIC_TEST|Measurement of Serum Vitamin D Level|Vitamin D is made of two types, named ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). Vitamin D2 is produced by converting ergosterol, a fungi and plants sterol, when it is exposed to light from the sun. Vitamin D3 is made differently, as it is formed in animal skin such as human skin with the help of 7-dehydrocholesterol when the skin is exposed to sunlight (UVB radiation).
214565074|NCT01109680|DRUG|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
214565075|NCT02789644|DRUG|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
214565076|NCT00081822|DRUG|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
214565077|NCT00081822|DRUG|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.
214565078|NCT03953755|PROCEDURE|Tricuspid valve repair|Tricuspid valve repair
214565079|NCT00659555|DRUG|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
214565080|NCT00659555|DRUG|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
214565081|NCT04866953|OTHER|Blood transfusion|Number of units of blood received within 24 hours of admission
214708179|NCT02681185|OTHER|Virtual Care|"Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
214565082|NCT02944201|DRUG|Carvedilol|Carvedilol will give twice daily until prostatectomy
214565083|NCT01891942|PROCEDURE|twitch by magstim|
214565084|NCT02922504|BEHAVIORAL|Music intervention group|
215166797|NCT07200804|OTHER|Measurement of Carotid Intima-Media Thickness|Samples were collected by measuring the carotid intima-media thickness (CIMT) with a Mind ray Real time ultrasound scanner DC-6 doppler machine that has a probe at a frequency of 7.5 MHz. The measurement was done from three different sites each 1 cm proximal to the carotid bulb. The average of three values was taken to determine the final value. If CIMT \> 0.8 mm, it was defined as thickened. The measurements adhered to the Mannheim CIMT Consensus (2004-2006)
214565085|NCT02922504|BEHAVIORAL|Controlled group|
214565086|NCT03330626|DEVICE|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
214565087|NCT03330626|OTHER|IO group|Fluid removal are guided by intake-output balance.
214565088|NCT04061460|PROCEDURE|mechanical plaque control|supra and sub gingival debridment ( plaque control)
214565089|NCT00515723|DRUG|risperidone|randomized to 12 week trial of risperidone.
214565090|NCT00515723|DRUG|olanzapine|randomized to 12 week trial of olanzapine.
214565091|NCT00515723|DRUG|quetiapine|randomized to 12 week trial of quetiapine.
214565092|NCT00515723|DRUG|ziprasidone|randomized to 12 week trial of ziprasidone.
214565093|NCT01368029|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
214565094|NCT01368029|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
214565095|NCT00152984|DRUG|Tiotropium inhalation capsules|
214565096|NCT00152984|DRUG|Placebo inhalation capsules|
214565097|NCT04496934|BEHAVIORAL|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
214565098|NCT06336252|BEHAVIORAL|Digital nudging intervention target to change behavior|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
214565099|NCT05540613|BEHAVIORAL|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
214565100|NCT05540613|BEHAVIORAL|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
214565101|NCT05540613|BEHAVIORAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
214565102|NCT06620848|DRUG|HRS-4642 monotherapy|HRS-4642 will be administrated per dose level in which the patients are assigned.
214565103|NCT06620848|DRUG|HRS-4642 and adebrelimab combination therapy|HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
214565104|NCT04092010|BEHAVIORAL|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
214565105|NCT04092010|BEHAVIORAL|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
214565106|NCT04092010|BEHAVIORAL|Usual care|Normal services provided children and their mothers in Head Start
214565107|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
214565108|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
214565109|NCT02626455|DRUG|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
214708180|NCT02681185|OTHER|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
214708181|NCT00645918|DRUG|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
215030366|NCT04981912|DRUG|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"* Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
214565110|NCT02626455|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
214565111|NCT02626455|DRUG|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
214565112|NCT02626455|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
214565113|NCT02626455|DRUG|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
215166798|NCT07202208|PROCEDURE|"Delirium Zero protocol"|The protocol consists of: i) a patient orientation poster placed in the room in a visible location for the patient, with information updated daily by the family member/caregiver; ii) a clock hung on the wall next to the orientation poster; and iii) a verification sheet of the preventive measures taken by the caregiver/family member, where the caregiver/family member must indicate daily the frequency with which preventive activities have been performed. The caregiver/family member will have this document in the patient's room all day and will need to complete it at the end of the day, when the nurse will collect it for safekeeping. From that day until the patient is discharged, the nurse responsible for the patient's care will be responsible for providing a new verification sheet of the preventive measures taken by the family member/caregiver and collecting it at the end of the day once it has been completed by the family member/caregiver.
214565114|NCT02626455|DRUG|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
214565115|NCT02626455|DRUG|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
214565116|NCT02626455|DRUG|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
214565117|NCT00043953|DRUG|Lopinavir/ritonavir|
214565118|NCT00043953|DRUG|Saquinavir mesylate|
214565119|NCT00043953|DRUG|Lamivudine/zidovudine|
214565120|NCT01224470|DRUG|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
214565121|NCT01744470|DRUG|Tacrolimus targeted half-dose|
214565122|NCT01744470|DRUG|Tacrolimus targeted plain dose|
214565123|NCT04237311|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
214565124|NCT04237311|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb\> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).
214565125|NCT01344551|DIETARY_SUPPLEMENT|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
214565126|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete expressive disclosure writing
214565127|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete benefit finding writing
214565128|NCT02339870|OTHER|Questionnaire Administration|Ancillary studies
214565129|NCT02339870|OTHER|Sham Intervention|Complete writing on an emotionally neutral topic
214565130|NCT02127138|DEVICE|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
214565131|NCT01937026|DRUG|Baricitinib|Administered orally
214565132|NCT01937026|DRUG|Probenecid|Administered orally
214565133|NCT04902183|DRUG|CovenD24|The drug will be administrated once daily for 5 days
214565134|NCT06546722|PROCEDURE|Transversus Thoracic Plane Block|The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
214565135|NCT02447653|DEVICE|G7 HA Acetabular Component|G7 HA Acetabular Component
214565136|NCT02447653|DEVICE|G7 PPS Acetabular Component|G7 PPS Acetabular Component
214565137|NCT04168281|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|instead of PCI patients will be followed-up with MRI
214565138|NCT05550753|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
214565139|NCT05550753|BEHAVIORAL|No intervention - placebo control|No intervention - placebo control
214565140|NCT06195462|OTHER|Laying on of hands with intention health (LHHI)|The participants will receive systemic acupuncture. The no healers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
214565141|NCT06195462|OTHER|Laying on of hands by spiritist passe|The participants will receive systemic acupuncture. The healers will prepare before the start with prayer for connection with Good Spirits and will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
214565142|NCT06195462|OTHER|Control|The participants will receive systemic acupuncture and they not receive the laying on of hands.
214565143|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
214565144|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
214565145|NCT05569213|DIAGNOSTIC_TEST|motor evoked potentials|see previous descriptions
214565146|NCT04232267|DEVICE|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
214565147|NCT05333874|DRUG|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
214565148|NCT05333874|OTHER|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
214565149|NCT03228147|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given PO
214565150|NCT03228147|OTHER|Questionnaire Administration|Ancillary studies
214565151|NCT04126252|DRUG|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
214708182|NCT00645918|DRUG|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
214708183|NCT00645918|DRUG|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
214565152|NCT04126252|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
214565153|NCT04126252|COMBINATION_PRODUCT|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
214565154|NCT04126252|OTHER|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
214565155|NCT03166995|OTHER|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
214565156|NCT03166995|OTHER|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
214565157|NCT04455503|DRUG|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
214708184|NCT02570282|DRUG|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
214708185|NCT02570282|DRUG|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
214708186|NCT03895112|DRUG|AVID200|dose cohorts of 21-day cycles
215030367|NCT04573738|PROCEDURE|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
214708187|NCT01668030|DRUG|Enzymatic agent|Enzymatic agent
214708188|NCT01668030|DRUG|Bacitracin|
214708189|NCT01058733|OTHER|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
214708190|NCT04766151|DRUG|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
214708191|NCT04766151|DRUG|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
214565158|NCT04455503|DRUG|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
214565159|NCT04455503|DRUG|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
214565160|NCT00000367|DRUG|Treatment of depression|
214565161|NCT00000367|BEHAVIORAL|Suicide prevention intervention|
214565162|NCT00000367|DRUG|Suicide prevention treatment|
214565163|NCT04816123|DRUG|[14C]Donafenib|Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
214565164|NCT04911478|GENETIC|ADI-001|No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
214565165|NCT03381677|DEVICE|Pedicle Lengthening Osteotomy with Altum® Device|Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
214565166|NCT03381677|DEVICE|Control|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
214565167|NCT05250427|OTHER|No treatment given|No treatment given
214565168|NCT04165044|PROCEDURE|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
214565169|NCT04165044|PROCEDURE|Connective tissue graft plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
214565170|NCT00407862|DRUG|Telmisartan 80 mg|
214565171|NCT00407862|DRUG|Losartan 50 mg|
214565172|NCT03758547|DEVICE|in-exufflator technique|application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
214565173|NCT03758547|DEVICE|percussion technique|sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
214565174|NCT06225908|PROCEDURE|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
214565175|NCT01882543|DRUG|AQX-1125|Synthetic SHIP1 activator
214565176|NCT01882543|DRUG|Placebo|Double blind placebo capsule
214565177|NCT05189600|DEVICE|Mechnical Insufflation:Exsufflation|Cough Augmentation device
214565178|NCT04222764|DIAGNOSTIC_TEST|Real-time three-dimensional echocardiography|"The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers."
214565179|NCT02070939|DRUG|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
214565180|NCT02070939|DRUG|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
214565181|NCT02070939|DRUG|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
214565182|NCT02070939|DRUG|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
214565183|NCT02070939|DRUG|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
214565184|NCT02070939|DRUG|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
214565185|NCT04725877|BIOLOGICAL|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
214565186|NCT04725877|DRUG|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
214565187|NCT02504983|DRUG|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
214565188|NCT02504983|PROCEDURE|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
214565189|NCT04505423|PROCEDURE|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
214565190|NCT04505423|PROCEDURE|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
214565191|NCT06090188|OTHER|A Culture-Based Multicomponent Cognitive Training Program|Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
214565192|NCT05799651|BIOLOGICAL|Glycovax-002|Intramuscular injection of vaccine against SARS-CoV-2
214565193|NCT00223639|DRUG|Topiramate|200mg twice a day
214565194|NCT05550545|OTHER|cohort study|Please note that this is an observational study; not applicable
214565195|NCT04458805|DRUG|NX-13 250 mg|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
214565196|NCT04458805|DRUG|Placebo|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
214565197|NCT00979550|DRUG|Imiquimod|commercially available topical antiviral drug
214565198|NCT00979550|DRUG|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
214565199|NCT04963452|OTHER|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
214565200|NCT04963790|BEHAVIORAL|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
214565201|NCT04963790|OTHER|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
214565202|NCT03164694|DRUG|Apatinib|Apatinib was given 850 mg per day orally.
214565203|NCT03164694|DRUG|Pemetrexed|pemetrexed (500 mg/m2)
214565204|NCT03164694|DRUG|Carboplatin|carboplatin (AUC =5)
214565205|NCT02432508|DEVICE|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
214565206|NCT02432508|DEVICE|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
214565207|NCT05630820|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214565208|NCT05630820|OTHER|Placebo|Matching placebo will be administered.
214565209|NCT03002220|DRUG|radium-223|Radium-223 at a dose of 55 kBq
214565210|NCT02420197|BEHAVIORAL|High-intensity resistance training|
214565211|NCT02420197|BEHAVIORAL|General physical activity|
214565212|NCT02420197|BEHAVIORAL|Multidisciplinary rehabilitation program|
214565213|NCT01425905|OTHER|The Blues Program|
214565214|NCT01425905|OTHER|Hey Durham|
214565215|NCT05113745|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
214565216|NCT05113745|DRUG|Placebo|Placebo tablets, taken twice daily
214565217|NCT01015560|DRUG|anti-CCR2 monoclonal antibody MLN1202|
214565218|NCT01015560|GENETIC|polymorphism analysis|
214565219|NCT01015560|OTHER|laboratory biomarker analysis|
214565220|NCT00926497|OTHER|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
214565221|NCT00640133|DEVICE|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
214565222|NCT00640133|DEVICE|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
214565223|NCT02717221|OTHER|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
214565224|NCT01847677|DRUG|Bevacizumab|
214565225|NCT01847677|DRUG|Paclitaxel|
214565226|NCT01847677|DRUG|Carboplatin|
214708192|NCT00895648|DRUG|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
214708193|NCT00895648|DRUG|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
214708194|NCT00526461|DRUG|HPPH|IV
215166799|NCT07202208|PROCEDURE|Standard of Care to prevent Delirium.|All participants in the study, regardless of the assigned group, receive information on strategies to prevent delirium, which is provided in the participant information sheet and includes an infographic and a guide for patients and their families. Participants are advised to keep this document accessible throughout their stay for reference.
215166800|NCT07202117|DEVICE|Sculptra Aesthetic|"Sculptra® Aesthetic is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%).~For this study, commercial products will be used. The study products are for single use only."
214565227|NCT04110704|PROCEDURE|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
214565228|NCT03143647|OTHER|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
214565229|NCT01096654|OTHER|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
214565230|NCT03704623|DRUG|Paracetamol|Paracetamol 1g IV
214565231|NCT03704623|DRUG|Parecoxib|Parecoxib 40 mg IV
214565232|NCT04854876|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA+SFC)|The food supplement 5-Aminolevulinic acid phosphate and Sodium ferrous citrate (5-ALA-Phosphate + SFC) will be administered orally daily for 28 days. The dose will be in total 3 capsules of 50 mg 5-ALA-Phosphate and 28.68 mg SFC (3.04 mg as Fe) per day, 2 capsules in the morning and 1 capsule in the evening resulting in 150 mg 5-ALA-Phosphate and 86.04 mg SFC ( 9.12 mg as Fe).
214565233|NCT05213897|DEVICE|SARS-CoV-2 Antigen Assay|To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
214565234|NCT05926440|BIOLOGICAL|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
214565235|NCT05926440|BIOLOGICAL|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
214565236|NCT00589589|DEVICE|Endo Tool|Computer tool to help achieve glucose control
214565237|NCT06342414|DIAGNOSTIC_TEST|ELUCIDATE|ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
214565238|NCT00128102|DRUG|Vorinostat|Vorinostat 100 mg oral capsules
214565239|NCT00128102|DRUG|Placebo|Vorinostat-matching placebo oral capsules
214565240|NCT00693667|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
214565241|NCT04929275|PROCEDURE|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
214565242|NCT02225132|DRUG|Hydroxyurea|"The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium."
214565243|NCT01202903|DRUG|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
214565244|NCT01202903|DRUG|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
214565245|NCT05331313|GENETIC|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
214565246|NCT04586764|DEVICE|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
214708195|NCT03645889|OTHER|PLTG|A combination of 13 herbal granules
214708196|NCT03645889|OTHER|Placebo|90% starch filler and 10% PLTG
214708197|NCT00618995|DRUG|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
214708198|NCT00618995|DRUG|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
214708199|NCT00618995|DRUG|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
214708200|NCT00618995|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
214708201|NCT02420301|OTHER|Tuina exercises|
214708202|NCT02420301|OTHER|Placebo Tuina exercises|
215166801|NCT07202117|DEVICE|Radiesse|"Radiesse® is manufactured by Merz Aesthetics. It is a sterile, non-pyrogenic, semi-solid injectable implant composed of synthetic CaHA suspended in a gel carrier of sterile water, glycerin, and sodium carboxymethylcellulose. Each pre-filled syringe contains 1.5 mL of product. The product includes 0.3% lidocaine for pain reduction during injection.~For this study, commercial products will be used. The study products are for single use only."
215166802|NCT07200297|OTHER|Active Comparator: Control|Patients who were given only a standard chlorhexidine oral care set
215166803|NCT07200297|OTHER|Experimental: Electric Toothbrush|Patients who were given an electric toothbrush and toothpaste along with a chlorhexidine set
214565247|NCT05814588|OTHER|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
214565248|NCT05814588|OTHER|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
214565249|NCT01302080|DRUG|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
214565250|NCT01302080|BEHAVIORAL|psychotherapy|Non-interventional study- as above
214565251|NCT02117453|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day
214565252|NCT02117453|DRUG|Placebo|Placebo
214565253|NCT03729375|DRUG|10cc injection of bupivacaine|10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
214565254|NCT03729375|DRUG|20cc injection of bupivacaine|20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
214565255|NCT03282669|DRUG|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
214565256|NCT03282669|DRUG|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
214565257|NCT03425097|DRUG|Fexofenadine|Fexofenadine 180 mg in the morning
214565258|NCT03425097|DRUG|Placebo - Cap|Placebo cap in the morning
214565259|NCT05781191|BIOLOGICAL|COMIRNATY|Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
214565260|NCT00633646|DIETARY_SUPPLEMENT|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
214565261|NCT05473559|PROCEDURE|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
214565262|NCT05651152|DRUG|JZP441|Nighttime oral dose
214565263|NCT05651152|DRUG|Placebo|Nighttime oral dose
214565264|NCT00943839|DRUG|sunitinib malate|
214565265|NCT00943839|OTHER|laboratory biomarker analysis|
214565266|NCT00943839|OTHER|pharmacological study|
214565267|NCT03995862|OTHER|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
215166804|NCT07200297|OTHER|Experimental: Manual Toothbrush|Patients who were given a manual toothbrush and toothpaste along with a chlorhexidine set.
215166805|NCT07200596|DRUG|SHR-3045 Injection|SHR-3045 injection.
215166806|NCT07200596|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
215166807|NCT07201974|OTHER|Virtual Reality Training|The VR intervention involves the intensive practice of community ambulation skills. The training sessions will be performed in a virtual environment. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
214565268|NCT01006252|DRUG|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
214565269|NCT01006252|DRUG|Paclitaxel|80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
214565270|NCT02878226|PROCEDURE|repair of rupture|
214565271|NCT05907525|DRUG|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
214565272|NCT05907525|DRUG|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
214565273|NCT05064527|DEVICE|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
215166808|NCT07201246|OTHER|Necrotizing Pancreatitis patients' organdysfunction progression|Study the dynamic nature of organ dysfunction
214565274|NCT05064527|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
214565275|NCT05064527|BEHAVIORAL|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
215166809|NCT07201103|BEHAVIORAL|Conventional PSSE-Schroth|Participants performed conventional Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) for 4 weeks. The program consisted of one 45-minute supervised session per week complemented by home-based exercises. The exercises focused on posture correction, spinal alignment, and corrective breathing techniques according to standard scoliosis rehabilitation protocols.
214565276|NCT04425759|DIAGNOSTIC_TEST|Blood sample|Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.
214565277|NCT00285662|DRUG|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
214565278|NCT02683772|DEVICE|Astral|Astral ventilator
214565279|NCT05396534|PROCEDURE|Atrial Fibrillation transcatheter ablation|We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
215166810|NCT07201103|BEHAVIORAL|AR-Assisted PSSE-Schroth|Participants performed Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) enhanced with augmented reality (AR) support for 4 weeks. The intervention included one 45-minute supervised session per week, plus home-based exercises. The AR system provided real-time visual and kinesthetic feedback during exercise sessions to improve body awareness, trunk appearance perception, and adherence.
215166811|NCT07201077|DEVICE|Articulating lymph-node grasper (SurgeoFlex Grasp)|Arm 1 - SurgeoFlex Grasp A single-use, low-profile articulating grasper with a 5-millimetre (mm) shaft and a 360-degree (360°) steerable distal tip. During uniportal video-assisted thoracoscopic surgery (UVATS), the device is introduced through the same 3-4-centimetre (cm) utility incision used for the camera and stapler. The flexible neck allows the jaws to approach hilar and mediastinal lymph nodes from multiple angles without repositioning the instrument shaft, thereby reducing instrument collision and chest-wall torque.
215166812|NCT07201077|DEVICE|Arm 2 Intervention Name Traditional rigid endograsper|Arm 2 - Traditional Rigid EndoGrasper A reusable, straight-shafted 5 mm grasper with fixed-angle jaws identical to those used in conventional multi-port video-assisted thoracoscopic surgery (VATS). The instrument is passed through the single 3-4 cm incision in the same fashion as the SurgeoFlex Grasp, but its rigid shaft limits the working angle and often requires external repositioning of the entire instrument to reach deep lymph-node stations.
215166813|NCT07201701|BIOLOGICAL|Supplementary blood samples for PBMC analysis at V2|Supplementary blood (serum and plasma) and urines samples for bio collection at V3
214565280|NCT00106210|BEHAVIORAL|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
214565281|NCT00106210|BEHAVIORAL|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
214565282|NCT01076153|DRUG|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
214565283|NCT03695939|BIOLOGICAL|realSKIN (skin xenotransplant)|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
214565284|NCT03695939|BIOLOGICAL|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
214565285|NCT00817713|DRUG|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
214565286|NCT02823990|BIOLOGICAL|TG4010|Given SC
214565287|NCT02823990|BIOLOGICAL|Nivolumab|Given IV
214565288|NCT00399191|DRUG|stable isotope of iron, dysprosium|
214565289|NCT05383144|OTHER|Complete Positioning scans|Entire treatment zone imaging at mi-treatment and at end of treatment
214565290|NCT00173992|BEHAVIORAL|Balance and Exercise|
214565291|NCT02966327|DEVICE|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
214565292|NCT02966327|BEHAVIORAL|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
214565293|NCT02966327|BEHAVIORAL|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
214565294|NCT01133795|DRUG|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
214565295|NCT02652325|DRUG|Saline|
214565296|NCT02652325|DRUG|Povidone-Iodine|
214565297|NCT02652325|DRUG|5% Povidone-Iodine USP swabs|
214565298|NCT01142232|DRUG|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
214565299|NCT01142232|DRUG|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
214565300|NCT05350280|DEVICE|electric current|Electric current will be applied in this group of patients using removable device.
214565301|NCT05350280|DEVICE|Traditional treatment|No acceleration method will be performed in this group.
214565302|NCT01663922|DRUG|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
214565303|NCT01663922|DRUG|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
214565304|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
214565305|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
214565306|NCT00219700|DRUG|Ibuprofen-PC|
214565307|NCT01249716|DIETARY_SUPPLEMENT|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
214565308|NCT01129544|BIOLOGICAL|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
214565309|NCT01069653|BIOLOGICAL|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
214565310|NCT04377685|OTHER|CT-Scan|Chest CT scan on admission to the hospital
215166814|NCT07200895|DEVICE|Inspiratory Muscle Training (30% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 30% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following a standardized diaphragmatic-breathing warm-up.
215166815|NCT07200895|DEVICE|Inspiratory Muscle Training (60% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 60% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following the same standardized warm-up.
215166816|NCT07201324|OTHER|cranial helmet therapy - observational|"This observational study involves children undergoing cranial helmet therapy. The intervention is not assigned by the investigator. Repeated measurements are performed within participants to evaluate therapy effects. Stage 1 assesses head shape changes to analyze therapy effectiveness. Stage 2 examines factors influencing effectiveness, considering age, deformity type, and sex.~Stage 3 measures body surface temperature using thermal imaging before, during, and after helmet use, with participants analyzed in three age groups: 4-6, 7-9, and 10-12 months. Stage 4 evaluates cervical spine rotation before therapy and after completion, with participants analyzed in the same three age groups."
215166817|NCT07202104|DEVICE|Eko digital stethoscopes|Use of the Eko CORE 500 digital stethoscope and 3M Littmann CORE Digital Stethoscope to auscultate and record cardiac phonocardiogram and (when available) electrocardiogram waveforms, as well as heart sounds.
214565311|NCT02928276|OTHER|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
214565312|NCT00574873|DRUG|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
214565313|NCT00574873|DRUG|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
214565314|NCT00285428|DRUG|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
214565315|NCT05537168|PROCEDURE|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
214565316|NCT00597246|DRUG|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
215166818|NCT07200791|BEHAVIORAL|Mobile Application|Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.
215166819|NCT07200791|BEHAVIORAL|Usual Care Only|Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.
215166820|NCT07198074|BIOLOGICAL|Bevacizumab|Given IV
215166821|NCT07198074|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214565317|NCT00597246|OTHER|PET Scan|GE Advance PET scanner for sequential body imaging
214565318|NCT04410601|PROCEDURE|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
214565319|NCT03674359|DIAGNOSTIC_TEST|BDG analysis|BDG analysis
214565320|NCT00449618|DRUG|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
214565321|NCT00449618|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
214565322|NCT00449618|PROCEDURE|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
214565323|NCT00449618|DRUG|Placebo|Use of placebo on awakening versus bedtime
214565324|NCT04481308|DRUG|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
214565325|NCT00092287|DRUG|lanreotide Autogel (somatostatin analogue)|
215166822|NCT07198074|DRUG|Carboplatin|Given IV
215166823|NCT07198074|PROCEDURE|Computed Tomography|Undergo CT
214565326|NCT00092287|DRUG|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
214565327|NCT03581383|BEHAVIORAL|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
214565328|NCT03581383|BEHAVIORAL|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
215166824|NCT07198074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215166825|NCT07198074|DRUG|Paclitaxel|Given IV
215166826|NCT07198074|BIOLOGICAL|Pembrolizumab|Given IV
215166827|NCT07201207|DEVICE|Robotic-assisted total knee arthroplasty|In robotic-assisted total knee arthroplasty, the procedure is performed with the guidance of the robot according to CT-based plan.
215166828|NCT07201207|PROCEDURE|Manual total knee arthroplasty|In manual total knee arthroplasty, the procedure is performed with jig guides according to whole leg weight bearing x-ray planning.
215166829|NCT07199478|PROCEDURE|Integrated mHealth and ERAS Digital Rehabilitation via WeChat Mini-Program|"This intervention arm is distinguished by the following key features:~Theory-Driven Design: Uniquely integrates three established behavioral theories into its core functionality: Bandura's Self-Efficacy Theory, the Health Belief Model, and Illeris's Learning Model. This theoretical foundation directly informs the app's features to target psychological and behavioral barriers to recovery.~Multi-Functional Platform: Combines several evidence-based components into a single, cohesive platform within the ubiquitous WeChat ecosystem. Key features include:~Visual Goal and Progress Tracking: Provides patients with mastery experiences.~Peer Community (Modeling Community): Features patient stories and videos to provide vicarious experiences and social support.~AI-Powered Persuasion System: Delivers automated, personalized feedback and remote encouragement from healthcare providers.~Built-in Emotional Management Tools: Includes an emotion diary"
215166830|NCT07199478|PROCEDURE|Standardized ERAS Protocol|Participants received only the standardized Enhanced Recovery After Surgery (ERAS) protocol, representing the conventional care model.
215166831|NCT07200232|DEVICE|Phase 1 Test Device Sensor and Adhesive and Reference Device|Test Device Sensor and Adhesive and Reference Device ECG Data Collection for 1 hour
215166832|NCT07200232|DEVICE|Phase 2 Test Device ECG Signal quality over a 10-day simulated use period|Evaluation of the ECG-signal quality of the Test Device sensor and adhesive applied to a single site on a subject's chest to collect ECG readings for a 10-day period.
215166833|NCT07200232|DEVICE|Test Device Sensor and Adhesive Variable Placement|Comparison of nine incorrect locations of Test Device Sensor and Adhesive to the ideal location
215166834|NCT07202377|DIAGNOSTIC_TEST|SPECIFIC REVEAL® Rapid AST system|The SPECIFIC REVEAL™ system uses biosensors capable of detecting volatile substances released by microorganisms during their growth. The detection of these volatile compounds by ultra-high-performance biosensors enables very early detection of bacterial growth compared with standard technologies based on visual systems (e.g. diffusion antibiogram or MICs determined by microdilution in liquid media) or optical density measurement systems (e.g. Vitek2)
215166835|NCT07202377|DIAGNOSTIC_TEST|antibiotic susceptibility testing on agar medium|Performance of an antibiotic susceptibility test on agar medium, with results expected between H18 and H24
215166836|NCT07201831|OTHER|No treatment given|No treatment given
215166837|NCT07202520|DEVICE|IVR : H'Ability Home|H'Ability Home is a Dtx (Digital therapeutics) designed for the neurological rehabilitation of patients who have suffered a stroke, via a wireless virtual reality headset, with a simplified control interface on a tablet or PC
215166838|NCT07202520|DEVICE|Control: paper-based exercise guide|self-rehabilitation booklet used in current practice in centers
215166839|NCT07201064|DRUG|SZ1003 injection|once every two weeks at a dose of SZ1003 injection per infusion.
215166840|NCT07202468|DEVICE|Virtual Reality|"1. Aquarium VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Aquarium video. The video included underwater scenes with fish, sharks, and marine mammals. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to provide distraction.~2. Kaleidoscope VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Kaleidoscope video consisting of colorful, shifting geometric patterns. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to distract the child and reduce procedural pain and fear.~3. Routine Care (Control Group)~Children in this group received standard peripheral intravenous catheterization procedure in the pediatric surgery unit without any additional distraction intervention."
215166841|NCT07200687|OTHER|Music therapy|this research hopes to offer new insights into the benefits of combining music therapy with occupational therapy.
214565329|NCT03581383|BEHAVIORAL|Patient Telemedicine Questionnaire|The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
214565330|NCT01385852|PROCEDURE|microcoaxial phacoemulsification|conventional longitudinal ultrasound
215166842|NCT07200687|OTHER|occupational therapy|standard treatment
215166843|NCT07200752|BEHAVIORAL|telerehabilitaion based neck exercise training|Participants received a 6-week telerehabilitation exercise program delivered via video calls and digital platforms, 3 sessions per week. Exercises included stretching, active range of motion, isometric strengthening, and postural correction with progressive intensity.
214565331|NCT05611112|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
215166844|NCT07200752|BEHAVIORAL|supervised physiotherapy exercise training|Participants received the same 6-week exercise program as the telerehabilitation group, but delivered in a face-to-face supervised setting by a physiotherapist, 3 sessions per week.
215166845|NCT07201532|OTHER|eDelphi method|A Delphi consensus study will be undertaken to establish a core outcome set for disease modification in type 2 diabetes.
215166846|NCT07200726|OTHER|Observational study design - no intervention|Observational study design - no intervention
215166847|NCT07201935|BEHAVIORAL|Cold Water Immersion|Participants will complete 14 daily sessions of cold-water immersion exposure.
215166848|NCT07201935|BEHAVIORAL|High Heat Sauna|Participants will complete 14 evening sessions in the high heat sauna
214565332|NCT04195139|DRUG|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
214565333|NCT04195139|DRUG|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
214565334|NCT04300751|DRUG|Alcohol|Active alcohol or placebo, administered orally
214565335|NCT04300751|DRUG|Opioid Agonist|Active opioid agonist or placebo, administered orally
214565336|NCT03831126|DRUG|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
214565337|NCT02246153|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
214565338|NCT02246153|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
214565339|NCT03932305|DIETARY_SUPPLEMENT|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
214565340|NCT03932305|DIETARY_SUPPLEMENT|Placebo|Inactive placebo tablet
214565341|NCT06195540|DRUG|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
214708203|NCT01503580|DRUG|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
214708204|NCT00367029|BEHAVIORAL|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
214708205|NCT05825599|DEVICE|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
214708206|NCT01256983|BEHAVIORAL|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
214708207|NCT01256983|BEHAVIORAL|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
214708208|NCT00403819|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
214708209|NCT00233818|DEVICE|Sirolimus-coated Bx VELOCITY Stent|
215030368|NCT04573738|PROCEDURE|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
215030369|NCT05368935|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
215030370|NCT04751357|DIAGNOSTIC_TEST|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
215030371|NCT02657343|DRUG|Ribociclib|
215030372|NCT02657343|DRUG|T-DM1|
215030373|NCT02657343|DRUG|Trastuzumab|
215030374|NCT02657343|DRUG|Fulvestrant|
215030375|NCT00811850|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
214565342|NCT06195540|DRUG|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
214565343|NCT00736905|DRUG|TMC278|
214565344|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
214565345|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
214565346|NCT00201643|DRUG|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
214565347|NCT00201643|DRUG|Placebo|Course of Placebo (NS)
214565348|NCT00242905|BEHAVIORAL|Study of memory using MRI|Study of memory using MRI
214565349|NCT05519098|DEVICE|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
214565350|NCT06797258|DEVICE|FlexHD® Pliable|Acellular Dermal Matrix
214565351|NCT06797258|OTHER|No intervention|Historical Control Arm
214565352|NCT03866798|BIOLOGICAL|Panzyga|Immune Globulin, intravenous, human-ifas
214565353|NCT04142359|BIOLOGICAL|BCG in Combination with N-803|BCG in Combination with N-803
214565354|NCT04142359|DRUG|N-803 alone|N-803 alone
214565355|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.
214565356|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 225 IU fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose could be adjusted by 75 IU based on the participant's response. The minimum GONAL-F dose was 75 IU and the maximum GONAL-F dose was 300 IU. Participants could be treated for a maximum of 20 days.
214565357|NCT05789056|DRUG|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
214565358|NCT05656235|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)
214565359|NCT05656235|DRUG|Pembrolizumab|Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)
214565360|NCT05293756|BEHAVIORAL|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
214565361|NCT05946187|BEHAVIORAL|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
214565362|NCT05946187|OTHER|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
215166849|NCT07202338|BEHAVIORAL|CHRONOS therapy|Description: Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
215166850|NCT07202234|DRUG|Phage cocktail administered via nebulization|Phage cocktail administered via nebulization，BID
215166851|NCT07202234|DRUG|Nebulized normal saline inhalation therapy|Nebulized normal saline inhalation therapy, BID
215166852|NCT07202182|BEHAVIORAL|Creative Drama-Based Stress Management Program|A creative drama-based stress management program is an intervention that aims to reduce nursing students' stress levels and increase their coping and emotional intelligence skills.
215166853|NCT07202182|BEHAVIORAL|Training|In the study, the control group will receive training on a topic different from the experimental intervention for three weeks. This method aims to prevent any loss of motivation that might result from the control group not receiving any training. It also helps determine whether the effects observed in the experimental group are due solely to the creative drama-based stress management program or to the overall training process.
215166854|NCT07201233|BIOLOGICAL|Umbilical cord blood|Umbilical cord blood transfusion should be performed 24 hours to 2 weeks after chemotherapy. One to multiple units of cord blood can be applied, and the minimum interval between two cord blood transfusions should be 2 weeks.
215166855|NCT07200440|PROCEDURE|Intervention 1|Digital scans using conventional scan bodies scanned with an intra-oral scanner.
215166856|NCT07200440|PROCEDURE|Intervention 2|Digital scans using intra-oral photogrammetry scanned with an intra-oral scanner.
215166857|NCT07200440|PROCEDURE|Intervention 3|Digital scans using calibrated scan flags scanned with an intra-oral scanner.
215166858|NCT07200440|PROCEDURE|Control|Digital scans using conventional scan bodies scanned with a desktop scanner.
215166859|NCT07198529|DRUG|Short DAPT|Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.
215166860|NCT07198529|DRUG|Standard DAPT|Patients with high bleeding risk will receive aspirin and clopidogrel for 6 months after PCI (unoptimization confirmed in OCT), followed by single antiplatelet therapy thereafter.
215166861|NCT07198529|DRUG|Extended DAPT|Patients (with stet unoptimazation results in OCT imaging) receive aspirin and clopidogrel for 12 months after PCI.
215166862|NCT07198529|DEVICE|OCT-guided PCI|All patients undergo percutaneous coronary intervention with mandatory intravascular imaging using optical coherence tomography to assess stent optimization (expansion, apposition, dissection).
215166863|NCT07202455|DEVICE|Active tDCS|Patients will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on/off ramp of 0.1 mA/s) delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
215166864|NCT07202455|DEVICE|Sham tDCS|Patients will receive 10 sessions of sham tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up, stimulation stopped after the current ramp), delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
215166865|NCT07202481|DIETARY_SUPPLEMENT|Psyllium powder|Psyllium powder: soluble fiber gel forming, provided at 20 g per day (two doses of 10 g each)
215166866|NCT07202481|DIETARY_SUPPLEMENT|Fructooligosaccharide|Fructooligosaccharide: prebiotic, provided at 20 g per day (two doses of 10 g each)
214565363|NCT06609824|BEHAVIORAL|Leer te Durven!|'Leer te Durven!' is an eight-week preventative group training for children between the ages of 8 and 12. This training is evidence-based and is based on the principles of Cognitive Behavioral Therapy. With this program children learn to stand up for themselves in a safe environment, to face the situations that they find exciting and to be more confident in their own abilities. The training consists, among other things, of psychoeducation, exposure, and relaxation.
214565364|NCT05434052|OTHER|Turkish Validity and Reliability of The CIQ-R Scale|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
214708210|NCT02451202|PROCEDURE|Deep Neuromuscular Blockade|"* During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
214565365|NCT02393300|DRUG|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
214565366|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
215166867|NCT07201155|DEVICE|Continuous Glucose Monitoring Systems|"A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.~Patients monitored their blood glucose using fingerstick point-of-care (POC) measurements every 1-6 hours as needed and had routine arterial blood gas analysis 4-6 times a day. After 24 hours of patient wear, the arterial blood gas glucose (aBG) was used to calibrate the CGMS device at least twice a day. Nurses recorded CGMS data paired with POC values and aBG values in a 1:1 format."
214708211|NCT02451202|PROCEDURE|Moderate Neuromuscular Blockade|\- During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
214708212|NCT02451202|DRUG|Sugammadex|
214708213|NCT02451202|DRUG|Rocuronium|
214708214|NCT04717778|DIETARY_SUPPLEMENT|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
214708215|NCT05096494|DRUG|SP-103|SP-103 topical system is worn daily for 12 hours per day for 28 days
214565367|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
215166868|NCT07201155|DEVICE|Continuous Glucose Monitoring|This study is a single-center, prospective, observational study conducted in the Intensive Care Unit (ICU) of Nanfang Hospital, Southern Medical University, from May 2024 to August 2024. Patients with elevated blood glucose levels (BG\>180 mg/dL) undergoing intravenous insulin therapy were included. Simultaneous blood glucose monitoring was performed using fingerstick blood samples and arterial blood gas analysis, along with the installation of CGMS for concurrent monitoring. CGMS data (CGM values) were recorded in a 1:1 paired format with fingerstick point-of-care (POC) values and arterial blood gas (aBG) values. The correlation of paired blood glucose data was examined using Pearson's correlation coefficient. The accuracy of CGMS was assessed using metrics such as Mean Absolute Relative Difference (MARD), ISO 15197-2013, CLSI POCT12-A3, and Clarke Error Grid Analysis, analyzed with R v.4.4.1 software.
214565368|NCT06133153|DEVICE|THIODERM ELATE|Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
214565369|NCT06133153|DEVICE|Juvéderm Ultra 3|BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
214565370|NCT04907565|BIOLOGICAL|Blood sampling|4 tubes of 7 mL of blood will be collected
214565371|NCT04907565|BIOLOGICAL|white adipose tissue sampling|At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.
214565372|NCT02787044|BIOLOGICAL|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
214565373|NCT02787044|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
214565374|NCT04900571|DRUG|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
214565375|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
214565376|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
214565377|NCT01528553|DEVICE|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
214565378|NCT01528553|DEVICE|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
214565379|NCT01056952|PROCEDURE|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
214565380|NCT01056952|PROCEDURE|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher \& Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
214565381|NCT01056952|PROCEDURE|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%
215166869|NCT07201155|DEVICE|Continuous Glucose Monitoring|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
214708216|NCT05096494|DRUG|Placebo|Placebo topical system is worn daily for 12 hours per day, for 28 days
214565382|NCT03819790|DRUG|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
214565383|NCT03819790|DRUG|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
214565384|NCT03819790|DRUG|Metformin|Patients can be administered with most tolerant dose of metformin
214565385|NCT04160910|DRUG|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
214565386|NCT04160910|DRUG|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
214565387|NCT00542776|OTHER|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
214565388|NCT06078345|OTHER|Carbohydrate|400 Kcal glucose (100g oGTT)
214565389|NCT06078345|OTHER|Fat|400 Kcal glucose rapeseed oil.
214565390|NCT06078345|OTHER|Protein|400 Kcal Moltein PURE (111g)
214565391|NCT05594797|DRUG|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
214708217|NCT03373110|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy|see arm description
214708218|NCT03373110|BEHAVIORAL|Online Cognitive Behavioral Therapy|see arm description
214708219|NCT03373110|BEHAVIORAL|Fitbit Alone|see arm description
214708220|NCT04871230|DIAGNOSTIC_TEST|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
214708221|NCT04871230|DIAGNOSTIC_TEST|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
215166870|NCT07201155|DEVICE|CGMS|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
214565392|NCT03093376|BEHAVIORAL|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
214565393|NCT05401006|DRUG|Acitretin 25Mg Cap|Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
214565394|NCT05401006|RADIATION|Narrowband ultraviolet B|Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
215166871|NCT07202390|OTHER|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
215166872|NCT07202390|OTHER|Intervention|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
214565395|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
214565396|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
214708222|NCT04871230|DIAGNOSTIC_TEST|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
214708223|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
214708224|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
215166873|NCT07201454|BEHAVIORAL|nursing care|The first stage is the collection of quantitative data. Only quantitative data were collected from patients and caregivers in the experimental and control groups before the implementation of curative care practices based on human caring theory. The second stage includes curative care practices within the scope of the study for the experimental group. Patients and their relatives in the control group will receive routine care services provided at the clinics where the study was conducted, but no interventions will be implemented by the researchers. The third stage is the stage where patient satisfaction, caregiver burden, feelings of entrapment, and satisfaction with caregiving are assessed after the curative care practices. This stage is the final test of quantitative data and the collection of qualitative data. The fourth stage is the evaluation stage. In the final stage, data obtained from all stages will be compared, evaluated, and interpreted.
214565397|NCT00490490|DRUG|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
214708225|NCT03407508|DIETARY_SUPPLEMENT|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
215166874|NCT07201298|DEVICE|Ray-Tracing Guided LASIK|A form of LASIK where Ray-Tracing technology is used to create the surgical profile for treating the cornea.
215166875|NCT07201298|DEVICE|Keratorefractive Lenticule Extraction (KLEx)|A form of corneal refractive surgery utilizing a femtosecond laser to create a lens shaped lenticule of corneal tissue that is removed through a small corneal incision.
214708226|NCT03329599|DRUG|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
215166876|NCT07201298|DEVICE|WaveFront Optimized LASIK|A form of LASIK where the corneal treatment profile is modified to decrease induced Spherical Aberration.
215166877|NCT07201298|DEVICE|Topography Guided LASIK|A form of LASIK where a corneal topography of the cornea is used to create the surgical profile for treating the cornea.
215166878|NCT07201376|DRUG|Ameluz 10% Topical Gel|One-time topical application of 10% Ameluz gel for up to 1 hour
215166879|NCT07201376|DEVICE|Protoporphyrin IX|Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.
215166880|NCT07201363|DIAGNOSTIC_TEST|Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples|In all patients, peripheral venous blood samples will be collected before the TAVI procedure for analysis and calculation of prespecified inflammatory and fibrosis biomarkers. In a subpopulation of 40 individuals, four specific microRNAs (miR-21, miR-29b, miR-155, and miR-146b) will be additionally analysed. The level of each biomarker will be correlated with rates of new-onset TAVI-related CDs and compared between patients with detected and patients without detected new-onset CDs.
215166881|NCT07201363|DIAGNOSTIC_TEST|Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS|The echocardiographic stage of extravalvular cardiac damage related to AS and myocardial deformation parameters will be analysed in each patient before TAVI procedure and compared between the group with detected new-onset CDs and the group without new-onset CDs with a goal to examine their predictive value for the development of TAVI-related CDs.
214708227|NCT03917082|DRUG|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
214565398|NCT00490490|PROCEDURE|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
214708228|NCT05976932|DRUG|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
215030376|NCT00811850|DRUG|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
215030377|NCT03416387|DEVICE|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
215030378|NCT00044733|DRUG|Mylotarg (gemtuzumab ozogamicin) Injection|
215030379|NCT01333787|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
215030380|NCT02011542|DRUG|VSL#3|This is a probiotic mixture
215030381|NCT02011542|DRUG|Placebo|This is a pill with inactive ingredients.
215030382|NCT05713292|DRUG|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
215030383|NCT05713292|DRUG|Pirfenidone placebo|Pirfenidone placebo
215030384|NCT06312059|OTHER|Advance Infant Formula Powder|Sole source infant nutrition for the control arm.
215030385|NCT06312059|OTHER|"Kendamil Cow milk test product"|Sole source infant nutrition for the cow milk test arm.
215030386|NCT06312059|OTHER|"Kendamil goat milk test product"|Sole source infant nutrition for the goat milk test arm.
214565399|NCT00490490|DRUG|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
214565400|NCT06364787|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
214565401|NCT06364787|DRUG|Targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
214565402|NCT06364787|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
214565403|NCT04063475|DRUG|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
214565404|NCT02324608|BIOLOGICAL|cetuximab|Given IV
215030387|NCT03988205|BEHAVIORAL|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
215030388|NCT03988205|DRUG|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
214565405|NCT02324608|OTHER|laboratory biomarker analysis|Correlative studies
214565406|NCT03483259|DRUG|Sulfatinib T capsule|Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
214565407|NCT03483259|DRUG|Sulfatinib R capsule|Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
215030389|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
215030390|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
215030391|NCT05338736|DIAGNOSTIC_TEST|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
215030392|NCT00330733|DRUG|Salsalate|Participants were randomized to 12-week treatment with up to 4 g/day.
215030393|NCT00330733|DRUG|Placebo|Participants were randomized to 12-week treatment matching the active salsalate arm.
215030394|NCT03358173|PROCEDURE|Conservative Treatment|Conservative Treatment
215030395|NCT03358173|PROCEDURE|Operative Plate Fixation|Operative Plate Fixation
215030396|NCT00072995|BEHAVIORAL|Four Diets Differing in Macronutrient Composition|
215030397|NCT00072995|BEHAVIORAL|Diets Low in Saturated Fat|
215030398|NCT01836354|BEHAVIORAL|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
215030399|NCT03531541|DEVICE|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
214565408|NCT04116580|OTHER|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
214565409|NCT04333251|BIOLOGICAL|high-titer anti-Sars-CoV-2 plasma|Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer \>1:64 vs best supportive care
214565410|NCT04333251|OTHER|oxygen therapy|oxygen therapy
214565411|NCT03823573|BEHAVIORAL|Walk within 24 hours|Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
214565412|NCT03207451|DRUG|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
214565413|NCT03207451|DRUG|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
214565414|NCT03207451|DRUG|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
214565415|NCT03207451|DRUG|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
215029891|NCT06695611|OTHER|Decrease systolic blood pressure|"To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight"
214565416|NCT03434990|OTHER|Spinal manipulation/myofascial release|The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
215029892|NCT06695338|PROCEDURE|Guided Bone Regeneration (Submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (submerged approach)
215029893|NCT06695338|PROCEDURE|Guided Bone Regeneration (Non-submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (Non submerged Approach)
215029894|NCT06695741|DRUG|Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
215166882|NCT07200310|OTHER|Non-invasive audiologic and vestibular assessments|standardized, single-session test battery performed in a sound-treated clinical laboratory. Procedures include tympanometry, tympanometry with simple maneuvers (Valsalva/Toynbee) for Eustachian tube function, pure-tone audiometry, otoacoustic emission (OAE) testing, acoustic reflex thresholds, and cervical vestibular evoked myogenic potentials (cVEMP) with EMG monitoring for adequate sternocleidomastoid activation. Testing is non-invasive, takes \~60 minutes, and is conducted under routine clinical practice conditions. No investigational drugs, devices, or biospecimens are used.
215166883|NCT07201441|BEHAVIORAL|Smart Nursing Based on the Health Cloud Platform|On the day of surgery, ensure that the patient or their family members have followed the hospital's official account and bound the patient's information. Through the intelligent cloud platform on the mobile device, they can query the patient's inpatient information, such as examination reports and details of inpatient expenses, and also consult and communicate about the patient's condition.
215166884|NCT07202429|DEVICE|MRI|"Multiparametric MRI of adnexal lesions, including conventional sequences, diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) measurement, and dynamic contrast-enhanced (DCE) MRI. Imaging findings were evaluated using the O-RADS MRI scoring system."
215166885|NCT07201519|DEVICE|Hepatic Artery Infusion Pump (HAIP)|HAIP will be filled with mixture of FUDR + Dexamethasone, Heparin \& Saline for a 14 day infusion of drugs, followed by a 14 day infusion of Heparin+Saline.
215166886|NCT07201519|PROCEDURE|Standard Treatment|systemic therapy per standard-of-care and institutional standards; visits every two weeks and standard manual HAI dose calculation
215029895|NCT02434614|DRUG|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
215029896|NCT02434614|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
215166887|NCT07201519|PROCEDURE|Community Treatment|systemic therapy fill by home infusion based on TO orders. In person visit with CO for systemic chemotherapy with dose recommendations from TO. Locally obtained testing with telehealth visits with TO team.
215166888|NCT07201519|DRUG|Systemic Chemotherapy Standard of Care|"Dosing of systemic therapy will be according to established routine practice guidelines. Patients with colon cancer will receive systemic chemotherapy that will consist of either FOLFIRI, FOLFOX, or Irinotecan/oxaliplatin at the discretion of the oncologist.~Patients with intrahepatic cholangiocarcinoma will receive Gemcitabine/Oxaliplatin or Gemcitabine alone, at the discretion of the oncologist."
215166889|NCT07201519|DRUG|Standard Of Care targeting driver mutations|Per current SOC guidelines, EGFR inhibitors targeting driver mutations (e.g., RAS wild-type) will be administered as appropriate (FDA-approved agents such as Panitumumab for EGFR)
215166890|NCT07201792|OTHER|Early Physiotherapy|The early physiotherapy program will begin when the infant is stable and continue until discharge. Depending on the infant's gestational age and respiratory needs, chest physiotherapy, developmental physiotherapy, or both will be administered, if necessary. The early family collaborative physiotherapy program will begin from the first day the infant is stable and parental contact is established, and will consist of routine-based care and family education programs that include therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will be based on a model of goal-oriented active motor learning and sensory strategy development in an enriched environment, and will include family education programs that integrate holding, carrying, and positioning training into daily routines. All parents will participate in the training.
215166891|NCT07200349|DRUG|Calcitriol Delivery|Local delivery of Calcitriol (active form of vitamin D3) to one side of the maxillary canine area during orthodontic treatment. The aim is to assess its effect on dental and skeletal changes during canine retraction in a split-mouth design.
215166892|NCT07201987|DRUG|Vancomycin (local, via calcium sulfate beads)|Patients undergoing spine surgery will receive intraoperative placement of calcium sulfate beads impregnated with vancomycin. The beads are intended to provide local infection prophylaxis.
215166893|NCT07201987|DRUG|Morphine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with morphine. The beads are intended to provide sustained local analgesia.
215166894|NCT07201987|DRUG|Bupivacaine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with bupivacaine. The beads are intended to provide sustained local analgesia.
215166895|NCT07201922|DRUG|Nerandomilast|Nerandomilast
215166896|NCT07201922|DRUG|Placebo|Placebo
215166897|NCT07200531|BEHAVIORAL|Psychotherapy|6-week psychotherapy group intervention
215029897|NCT02434614|DRUG|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
214565417|NCT03434990|OTHER|Spinal manipulation|The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
214565418|NCT02240459|DRUG|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
214565419|NCT02240459|DRUG|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
214565420|NCT02240459|DRUG|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
214565421|NCT02240459|DRUG|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
214565422|NCT00841217|DRUG|GW501516|2.5mg/day
214565423|NCT00841217|DRUG|placebo pill|
214565424|NCT02040584|DRUG|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
214565425|NCT02040584|DRUG|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
214565426|NCT00628576|DRUG|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
214565427|NCT00628576|DRUG|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
214565428|NCT05094024|DIETARY_SUPPLEMENT|Central kitchen-prepared version of MDCF-2|Kitchen-prepared MDCF-2 containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be freshly prepared in central kitchens on a daily basis and provided to participants on the same day. Every child in this arm will be offered 25g of the MDCF-2 formulation twice daily.
214565429|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with green banana powder|This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 21.77g of the formulation twice daily.
214565430|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with sweet potato|This shelf-stable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 23.34g of the MDCF formulation twice daily.
214565431|NCT05094024|DIETARY_SUPPLEMENT|Freshly reconstituted MDCF-2 ingredients|This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding session. Every child in this arm will be offered 21.72g of the formulation twice daily.
215029898|NCT02471677|DRUG|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
215029899|NCT02471677|DRUG|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
215029900|NCT05952323|OTHER|Teach-back|According to the prepared educational materials for medical devices, students will be trained using the teach-back method.
215029901|NCT05952323|OTHER|Video-assisted teaching|Students will be sent educational videos related to medical devices and asked to watch them.
214565432|NCT05094024|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF) arm|Locally-produced ready-to-use supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean flour, sugar, and micronutrient mix. Every child in this arm will be offered 25g of the formulation twice daily.
214565433|NCT01507519|DEVICE|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
214565434|NCT02415673|DEVICE|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
215166898|NCT07202442|PROCEDURE|Emergency General surgery patients with robotic approach for the surgery|vPrimary Endpoint: The proportion of procedures performed robotically versus laparoscopically or via laparotomy for selected indications. Secondary Endpoints: A 5% change in perioperative morbidity, laparotomy rate, LOS, critical care admission rate, and operative time. Included Pathologies (for patients eligible for laparoscopy) : Acute cholecystitis with predictors of intraoperative difficulty. Bowel obstruction requiring bowel resection (in presence of CT signs of visceral compromise: poor enhancement of bowel loops, pneumoperitoneum). Complicated acute diverticulitis with perforation and peritonitis. Penetrating abdominal trauma with hemodynamic stability requiring surgery (e.g., bowel resection-anastomosis). Right or left colectomy for other etiologies. Splenectomy in hemodynamically stable or embolized patients.
215166899|NCT07201948|BEHAVIORAL|Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:|"1. : Two distinct groups will be enrolled:~   * Those diagnosed with hypertension: BP \>=140/90, within the last 2 years.~  * Those with BP \>=130/80. Not yet diagnosed with hypertension.~2. . Intervention: Comprehensive and integrated intervention components~   * Implemented by 3 certified experts (Dietician, Fitness Trainer, Cardiologist)~  * Modules: Education, Demonstration, Practical skill development sessions.~3. . Intervention is based on American Hearts Association Life's Simple 7. The nutrition aspect will follow the DASH Diet plan."
215166900|NCT07202065|BIOLOGICAL|Immune Globulin Intravenous|Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week).
215166901|NCT07200609|OTHER|Virtual Reality Intervention|"The virtual reality training group will have sessions lasting 40 minutes, 3 days a week for 8 weeks.~* A 30-minute VR-based training session using Kinect Xbox (5 min warm-up, 30 min VR, 5 min cool-down)~* The device has an infrared camera sensor (Kinect sensor) that detects the participant's movement in real time~* Even if the user's movement is not performed correctly in the game settings, the user receives visual and auditory sensory feedback about movement errors.~* All games are provided to engage participants' interest in the topics and require the use of the person's lower extremities.~* Each game will be played for 10 minutes during the 30-minute training session. (A total of 3 games will be played)~* Participants in VR programs typically perform active hip flexion, hip abduction, hip external and internal rotation, knee flexion and extension, ankle dorsiflexion, and plantar flexion while standing.~* Game content: Kinect Sports, Kinect Adventures and Kinect Sports Rivals."
214565435|NCT01410123|OTHER|Integrated Stepped Care (ISC)|"1. At risk drinking:~   Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~2. Alcohol abuse/dependence:~   Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~3. Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
214565436|NCT01410123|OTHER|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
214565437|NCT05540717|BIOLOGICAL|PQ Grass|Suspension for Injection
214565438|NCT05540717|BIOLOGICAL|Placebo|Solution for injection
214565439|NCT01322802|BIOLOGICAL|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
214565440|NCT01322802|OTHER|laboratory biomarker analysis|Correlative studies
214565441|NCT06436443|OTHER|SMS Counseling|In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
214565442|NCT05527652|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
214565443|NCT06040593|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
215029902|NCT04340258|DEVICE|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
215029903|NCT04340258|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
215029904|NCT06742762|DRUG|AZD5004|Dose 1
215029905|NCT05995665|DEVICE|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
215029906|NCT05995665|OTHER|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
215029907|NCT00177632|BEHAVIORAL|behavioral weight loss|
215029908|NCT05345314|PROCEDURE|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
215029909|NCT03094273|PROCEDURE|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
215029910|NCT01423890|GENETIC|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
215029911|NCT03780322|DEVICE|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
215029912|NCT03780322|OTHER|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
215029913|NCT02541201|DIETARY_SUPPLEMENT|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
215029914|NCT02541201|DIETARY_SUPPLEMENT|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
215029915|NCT04279093|OTHER|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
215029916|NCT06905340|PROCEDURE|NOL (Nociception Level Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by NOL during general anesthesia in the experimental arm.
215029917|NCT06905340|OTHER|Control (Standard treatment)|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist
214565444|NCT02626988|BEHAVIORAL|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
214565445|NCT05612503|OTHER|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
214565446|NCT05612503|OTHER|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
214565447|NCT01828489|DRUG|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
214565448|NCT01828489|DRUG|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
214565449|NCT01940939|DEVICE|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
214565450|NCT01470001|DRUG|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
214565451|NCT01001182|OTHER|non interventional|non interventional
215029918|NCT05845580|OTHER|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
215029919|NCT05845580|OTHER|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
215029920|NCT06319053|DEVICE|Turbine-based insufflator|The use of a turbine-based insufflator instead of a conventional insufflator
215029921|NCT06209372|PROCEDURE|Group PENG|Pericapsular Nerve Group Block (PENG)
215029922|NCT06209372|DRUG|Group C|Tramadol infusion
215029923|NCT06534723|DRUG|Wujia Yizhi granules|Drug: Wujia Yizhi granuless
215029924|NCT06534723|DRUG|Placebo|Placebo
215029925|NCT03296982|OTHER|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
215029926|NCT03296982|DRUG|edoxaban|
215029927|NCT03296982|DRUG|Enoxaparin|
215029928|NCT03296982|DRUG|Saline sham|
215029929|NCT01888016|OTHER|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
215029930|NCT01888016|OTHER|standard physiotherapies treatment|"10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror"
215029931|NCT01990690|DRUG|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
215029932|NCT05697640|DRUG|Vericiguat Oral Tablet|The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
215029933|NCT05544695|DEVICE|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
215029934|NCT05937243|BEHAVIORAL|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
215029935|NCT05937243|BEHAVIORAL|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
215166902|NCT07200609|OTHER|Home-Based Exercise Intervention|"* Home-based exercise training group will also be given online exercises 3 days a week for 8 weeks.~* Active/passive stretching exercises within pain limits~* Patients will perform exercises at home under a supervised exercise program~* They will perform exercises matching the virtual reality group in terms of exercise sequence, intensity, duration, and mode, incorporating open and closed kinetic chain movements~* A 20-second stretch followed by a 20-second relaxation performed five times per session for each muscle~* Light resistance exercises targeting muscle groups in the lower extremities, with a 5-second contraction followed by a 5-second relaxation, performed five times per session~* Bodyweight exercises~* Balance exercises~* Posture exercises"
215166903|NCT07200284|PROCEDURE|Airpolishing device|The authors will assess biochemical and clinical variables
215166904|NCT07200284|PROCEDURE|Manual SRP|Gold standard
215166905|NCT07197450|DRUG|intravenous administration of PTH1-84 mRNA|intravenous administration of PTH1-84 mRNA
215166906|NCT07201402|DRUG|Scapular-site insertion of etonogestrel contraceptive implant|Participants will undergo insertion of the etonogestrel contraceptive implant subdermally over the inferior edge of their non-dominant scapula
215166907|NCT07200622|DRUG|Semaglutide (Rybelsus®)|All subjects will receive oral semaglutide once daily (4-weekly dose escalation from 3 mg to 7 mg and finally 14 mg). This dose escalation schedule is specified in the IMP (Rybelsus) SmPC.
214565452|NCT00717327|OTHER|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
214565453|NCT02077101|OTHER|Questionnaire|
215166908|NCT07200622|DRUG|Placebo|Matched oral Placebo to be taken once daily.
215166909|NCT07199231|OTHER|AI clinical reference tool|Residents will use OpenEvidence clinical reference tool in the course of routine clinical care. They must also use a Gold Standard clinical reference tool (e.g. PubMed, UpToDate) to mitigate risk.
215166910|NCT07195981|DEVICE|virtual reality|The virtual reality (VR) technology is defined as a system that allows users to interact with images and sounds in a virtual environment, which can stimulate responses and provide real-time feedback concerning their performance.
215166911|NCT07195981|OTHER|selected physical therapy|selected physical therapy program only included: (Therapeutic Ultrasound device, Transcutaneous Electrical Nerve Stimulation (TENS) and Hot packs)
214565454|NCT02077101|OTHER|Interview|
214565455|NCT04635969|BEHAVIORAL|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
214565456|NCT05826470|DEVICE|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
215166912|NCT07198165|DRUG|PD-1 inhibitor based immunotherapy|Short-course radiotherapy (25Gy/5Fx) followed by 4 cycles of CAPOX regimen (Oxaliplatin 130mg/m² IV infusion, Capecitabine 1000mg/m² orally for 14 days, Q3w) combined with Bevacizumab (7.5mg/kg IV infusion, D1, Q3w) + PD-1 inhibitor (Toripalimab 240mg IV infusion, D1, Q3w).
215166913|NCT07197437|DEVICE|Hybrid Coat desensitizer|Dental desensitization treatment
215166914|NCT07197437|DEVICE|Single Bond Universal as desensitizer|Dental desensitization treatment
215166915|NCT07196852|DIETARY_SUPPLEMENT|N Acetyl L Cysteine|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ).
215166916|NCT07196852|DIETARY_SUPPLEMENT|Placebo|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day.
215166917|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin|(IVIg) intravenous immunoglobulin every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an (IgG) immunoglobulin G trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
215166918|NCT07202052|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
215166919|NCT07202052|DRUG|Amoxicillin clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical. Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin. Ciprofloxacin is omitted for participants with hypersensitivity.
215166920|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"Arm A: Low dose (IgRT) immunoglobulin replacement therapy: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.25g/kg. No dose adjustment for trough serum IgG levels is required.~Arm B: Usual dose: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range."
215166921|NCT07201805|OTHER|Early Physiotherapy Program|The physiotherapy program provided upon discharge will consist of family education programs that include parental contact and therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapist will provide training to integrate these programs into daily routines. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will consist of family education programs based on a goal-oriented model of active motor learning and sensory strategy development for the baby in an enriched environment, incorporating holding, carrying, and positioning into daily routines. If possible, the entire family will participate in these programs.
215166922|NCT07201805|OTHER|Control group|The control group will be shown one-time positioning and holding and carrying principles in addition to routine developmental NICU care at the time of discharge.
215166923|NCT07200570|BEHAVIORAL|LLM-Powered HPV Vaccine Chatbot|A vaccine chatbot delivered via WeChat or a web browser, designed to provide information and health education about the HPV vaccine. The chatbot is powered by large language models and is trained on an expert-validated knowledge base derived from authoritative sources such as the WHO and China CDC to ensure accuracy. The knowledge base is validated by experts. The chatbot engages users in interactive, conversational dialogue to answer questions and address concerns regarding HPV and HPV vaccines.
215166924|NCT07201766|DRUG|intralesional bleomycin|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
215166925|NCT07201766|DRUG|5-flourouracil and triamcinolone acetonide|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
214565457|NCT03085173|BIOLOGICAL|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
214565458|NCT04786964|DRUG|Cosibelimab|IV infusion
214565459|NCT04786964|DRUG|Cisplatin|IV infusion
214565460|NCT04786964|DRUG|Carboplatin|IV infusion
214565461|NCT04786964|DRUG|Pemetrexed|IV infusion
214565462|NCT04786964|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
214565463|NCT04786964|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
214565464|NCT04786964|DRUG|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
214565465|NCT06788600|DRUG|EBV mRNA vaccine (WGc-043)|"Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.~The specific dose of mRNA vaccine will be determined according to the experimental group."
214565466|NCT02728739|PROCEDURE|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (\>30 pg/ ml) for grading of MR severity within 7 days.
215029936|NCT05937243|BEHAVIORAL|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
215029937|NCT05521178|DIAGNOSTIC_TEST|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
215029938|NCT05521178|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 6 months
215029939|NCT05521178|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
215029940|NCT05521178|DEVICE|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
215029941|NCT05521178|DIAGNOSTIC_TEST|Blood pressure monitoring|Home blood pressure monitoring three times per week
215029942|NCT05521178|DIAGNOSTIC_TEST|Blood draw|Blood draw at baseline, 3 and 6 months
215029943|NCT06389123|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
215029944|NCT02615288|DIETARY_SUPPLEMENT|Vitamin D3|
215029945|NCT00233246|PROCEDURE|FFP Infusion|
215029946|NCT00568009|DRUG|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
215029947|NCT05786326|DEVICE|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
215029948|NCT05786326|DEVICE|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
215029949|NCT05786326|DEVICE|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
215029950|NCT04707209|DRUG|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."
215029951|NCT05425121|PROCEDURE|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
215029952|NCT05425121|DEVICE|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
215029953|NCT06254833|OTHER|micro dosing of ICG|smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
215029954|NCT05334797|OTHER|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
215029955|NCT04904302|BIOLOGICAL|Nivolumab|Given IV
215029956|NCT04904302|OTHER|Quality-of-Life Assessment|Ancillary studies
215029957|NCT04904302|OTHER|Questionnaire Administration|Ancillary studies
215029958|NCT04904302|DRUG|Sitravatinib|Given PO
215029959|NCT06563921|BEHAVIORAL|physical exercise programme|resistance/hypertrophy-oriented resistance programme
215029960|NCT06563921|DIETARY_SUPPLEMENT|probiotics supplementation|probiotics supplementation
215029961|NCT06563921|DIETARY_SUPPLEMENT|placebo|placebo
215029962|NCT06560190|OTHER|Orthopaedic Manual Physical Therapy|Individualized Treatment
215029963|NCT06564090|OTHER|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
215029964|NCT06564090|OTHER|conventional gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
215166926|NCT07197164|DRUG|Remdesivir (RDV)|Participants will receive their first dose of remdesivir also within the 24 (+/-12) hours prior to going to the operating room. Remdesivir doses will be 200 mg on day 1, followed by 100 mg daily from days 2 to 10, for a total of 10 days.
215166927|NCT07196293|PROCEDURE|Customized Healing Abutment - bulk fill composite|instead of standard healing abutments , customization was done using bulk fill composite
215166928|NCT07196293|PROCEDURE|customized healing abutments - Bis acryl composite materials|customized healing abutments with bis acryl composite material was used instead of standard healing abutments
215166929|NCT07196644|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
215166930|NCT07202299|OTHER|HFOV weaning protocol 1|weaning preterm neonates with RDS from HFOV directly to CPAP
215166931|NCT07202299|OTHER|HFOV weaning protocol 2|weaning of preterm neonates with RDS to CMV then to CPAP
215166932|NCT07200206|BIOLOGICAL|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
215166933|NCT07201727|BIOLOGICAL|CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic|For patients with refractory and relapsed AML, CD123+CLL-1 dual-target CAR-T cells (JY017) are used for treatment. Then, for patients who cannot achieve the minimum residual negative, CD7-targeted CAR-T cells (JY008) are sequentially infused. Finally, allogeneic hematopoietic stem cell transplantation is performed based on patient conditions.
214565467|NCT04254822|PROCEDURE|Transjugular intrahepatic portosystemic shunt|The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
214565468|NCT04254822|DRUG|Carvedilol|Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
214565469|NCT04254822|PROCEDURE|Endoscopic variceal ligation|For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
215029965|NCT02811887|BEHAVIORAL|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
215029966|NCT02811887|OTHER|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
215029967|NCT02811887|BEHAVIORAL|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
215029968|NCT06396559|BEHAVIORAL|pre test-post test|The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
215166934|NCT07201870|OTHER|Acces to Precare online platform|Precare is an online educational platform for patients on the waiting list for bariatric surgery. Precare offers personalized educational content as well as a calendar and appointment management system. It has been accredited by the Quebec Ministry of Health and Social Services.
215166935|NCT07202273|RADIATION|simulation-free, single-fraction palliative radiation therapy|Radiation will be delivered in a single fraction. The recommended prescription dose is 8 Gy with external beam radiation therapy.
215166936|NCT07202364|DRUG|YL202|YL202 will be intravenously infused over 60±10 min
215166937|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
215166938|NCT07202533|OTHER|Pain Neuroscience Education|A 6-week educational program with weekly sessions using slide presentations and interactive discussions, covering pain neurophysiology, central sensitization, and pain coping strategies, delivered by a certified physiotherapist.
215166939|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
215029969|NCT02485886|DRUG|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
215029970|NCT01688804|BEHAVIORAL|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
215029971|NCT04921267|BEHAVIORAL|training|training with filtered speech
215029972|NCT03412955|DRUG|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
215029973|NCT04057157|DEVICE|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
215166940|NCT07200336|DRUG|Mepolizumab|Subcutaneous injection of mepolizumab is administered every 4 weeks for a total treatment duration of 24 weeks.
215166941|NCT07200336|PROCEDURE|Simple Polypectomy|Removal of nasal polyps in the middle meatus and superior turbinate region via the middle meatus and olfactory cleft, without opening the involved sinuses and without resection of diseased bone.
214565470|NCT04836403|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
214565471|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
214565472|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
214708229|NCT03876145|OTHER|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
214708230|NCT02755142|BIOLOGICAL|Gliolan|
215029974|NCT04978415|PROCEDURE|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
215029975|NCT04085250|OTHER|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
215029976|NCT04085250|OTHER|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
215029977|NCT04085250|RADIATION|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
215029978|NCT04085250|DRUG|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
215029979|NCT04085250|OTHER|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
215029980|NCT03796104|OTHER|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
215029981|NCT05370092|OTHER|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
215166942|NCT07200336|PROCEDURE|Extended Endoscopic Sinus Surgery|"1. Complete opening of all sinuses~2. Resection of diseased mucosa and hyperplastic bone~3. Ethmoid skeletonization with middle turbinectomy~4. Draf IIb/III frontal dissection when indicated by CT severity."
215166943|NCT07200830|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
215166944|NCT07200830|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215166945|NCT07200830|PROCEDURE|Patient Monitoring|Undergo PSA monitoring
215166946|NCT07200830|PROCEDURE|Computed Tomography|Undergo CT
215166947|NCT07200830|PROCEDURE|Bone Scan|Undergo Bone Scan
215166948|NCT07200830|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
215166949|NCT07200830|PROCEDURE|MRI|Undergo MRI
215166950|NCT07200830|OTHER|Questionnaire Administration|Ancillary studies
215166951|NCT07200869|OTHER|No intervention|retrospective observational study. No intervention will be administered; data will be collected from existing medical records of pediatric sickle cell patients at Assiut University Hospital.
215166952|NCT07202156|DEVICE|10%TXA+2%Reduced Glutathione applied via ultrasound at 5W/cm² in10min|5w/cm² Ultrasound-assisted topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
215166953|NCT07202156|OTHER|10%TXA+2%Reduced Glutathione applied via ultrasound at 0W/cm² 10min|topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
215166954|NCT07200427|BEHAVIORAL|MELIORA Virtual Coach Intervention|Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.
215166955|NCT07200427|OTHER|Control (generic advice)|The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.
214708231|NCT04161612|OTHER|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
214708232|NCT03063853|OTHER|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
214708233|NCT03063853|PROCEDURE|Elective cesarean delivery|non emergent elective cesarean delivery
215029982|NCT05370092|OTHER|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
215029983|NCT05370092|OTHER|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
215029984|NCT00392574|DRUG|Prulifloxacin|Tablet
215029985|NCT00392574|DRUG|Placebo|Tablet
215029986|NCT04746755|DEVICE|Orthotic Insole: Lower Back|This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
215029987|NCT04746755|DEVICE|Orthotic Insole: Heel|This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
215029988|NCT04746755|DEVICE|Orthotic Insole: Knee to Heel|This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
215029989|NCT04746755|DEVICE|Orthotic Insole: Arch|"This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes."
215029990|NCT01434940|OTHER|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
215029991|NCT02415114|DIETARY_SUPPLEMENT|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
215029992|NCT03409809|BEHAVIORAL|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
215029993|NCT03409809|BEHAVIORAL|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
215029994|NCT03409809|BEHAVIORAL|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
215029995|NCT01502527|DIETARY_SUPPLEMENT|Femarelle|Twice daily oral treatment with Femarelle
215029996|NCT03673176|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
215029997|NCT02015130|OTHER|Individual treatment|See detailed description
215029998|NCT02518529|BIOLOGICAL|G17DT|
215029999|NCT02407119|DRUG|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
215030000|NCT02407119|DRUG|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
215030001|NCT01353729|DRUG|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
215030002|NCT01353729|DRUG|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
215030003|NCT01353729|DRUG|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
215030004|NCT01353729|DRUG|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
215030005|NCT05903703|DRUG|Canagliflozin and Gemcitabine|"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"
215030006|NCT05903703|DRUG|Gemcitabine|on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
215030007|NCT02439957|DRUG|Brincidofovir|
215030008|NCT02439957|DRUG|Valganciclovir|
215030009|NCT00666263|BIOLOGICAL|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
215030010|NCT00666263|BIOLOGICAL|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
215030011|NCT03091855|OTHER|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
215030012|NCT03091855|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
215030013|NCT04908644|DRUG|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
215030014|NCT04908644|OTHER|Placebo|Placebo
215030015|NCT00273884|DRUG|Amonafide L-Malate|
215030016|NCT00273884|DRUG|Cytarabine|
215030017|NCT02691156|DIAGNOSTIC_TEST|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
215030018|NCT02691156|DIAGNOSTIC_TEST|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
215030019|NCT02691156|DIAGNOSTIC_TEST|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
214565473|NCT04371120|DIAGNOSTIC_TEST|BICS Q|assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
214565474|NCT02591953|PROCEDURE|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
214565475|NCT02591953|PROCEDURE|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
214565476|NCT02591953|DRUG|Methylprednisolone|Corticosteroid used in injection (40 mg)
214565477|NCT02591953|DRUG|Lidocaine 1%|Anesthesic used in injection
214565478|NCT05304234|DIAGNOSTIC_TEST|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
214565479|NCT04293003|OTHER|fasting|6-hour fasting
214565480|NCT04293003|OTHER|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
214565481|NCT04293003|OTHER|Mediterranean|Consumption of a Mediterranean-type breakfast
214565482|NCT01603901|DEVICE|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
214565483|NCT06138652|BEHAVIORAL|App|Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
214565484|NCT03732742|PROCEDURE|TOF repair with trans-annular patch VS preservation of PV|One group study
215030020|NCT00212004|DRUG|pioglitazone|
215030021|NCT00212004|OTHER|control|
215030022|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
215030023|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
215030024|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
215030025|NCT01067807|DRUG|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
215030026|NCT05149729|PROCEDURE|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
215030027|NCT02288130|DRUG|GnRHa|
215030028|NCT02288130|DRUG|Ulipristal|
215030029|NCT00062764|DRUG|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
215030030|NCT01225952|DEVICE|Crystalens AO|Bausch \& Lomb model silicone multi-piece accommodating IOL.
215030031|NCT01225952|DEVICE|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
215030032|NCT01225952|DEVICE|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
215030033|NCT01183351|BEHAVIORAL|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
215030034|NCT00286286|DEVICE|Intraperitoneal Aerosolization System, IntraMyst|
215030035|NCT02378480|DRUG|Omadacycline|Injection for IV dosing; Tablets for oral dosing
215030036|NCT02378480|DRUG|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
215030037|NCT01916031|BEHAVIORAL|Education|
215030038|NCT02573064|DRUG|Colistin|
215030039|NCT02573064|DRUG|Tigecycline|
215030040|NCT02573064|DRUG|Vancomycin|
215030041|NCT05825040|BEHAVIORAL|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
215030042|NCT05825040|BEHAVIORAL|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
215030043|NCT05825040|BEHAVIORAL|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
215030044|NCT02302287|DIETARY_SUPPLEMENT|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
215030045|NCT02302287|OTHER|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
215030046|NCT02302287|OTHER|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
214565485|NCT02753153|PROCEDURE|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
214565486|NCT02753153|PROCEDURE|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
214565487|NCT02753153|PROCEDURE|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
214565488|NCT05870605|OTHER|No Intervention|This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.
214708234|NCT03419936|DIAGNOSTIC_TEST|Endoscopic biopsy|"1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
215030047|NCT00916487|DIETARY_SUPPLEMENT|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
215030048|NCT05006248|DEVICE|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
215166956|NCT07201051|DRUG|GSK3862995B|Participants will be administered with dose level 1 of GSK3862995B.
215166957|NCT07201051|DRUG|Placebo|Participants will be administered with matching placebo.
215166958|NCT07201714|DRUG|Levocarnitine|Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
215166959|NCT07201259|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
215166960|NCT07200505|OTHER|TR Mixed CORE Exercices|The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalise the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously. he intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance.
215166961|NCT07200505|OTHER|TR Asyncronous CORE Exercices|"The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalize the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously.~The intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance."
215166962|NCT07200258|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|"Remote incisions will be performed in the test group. The VISTA technique will be performed as described by Zadeh (Zadeh, 2011).~After administration of local anaesthesia, an access incision will be made in the vestibulum to permit elevation of a broad subperiosteal tunnel. A specialized periosteal elevator will be used to create the tunnel by dissecting beneath the periosteum, extending at least one tooth beyond the recession defects and under each papilla, without surface incisions at the gingival margin. The connective tissue graft will be inserted and positioned beneath the tunnel through the incision. A coronally anchored suturing technique will be used. This technique mean placing a horizontal mattress suture using a 6.0 suture with at approximately 2 to 3 mm apical to the gingival margin of each tooth, covering the width of the tooth. If keratinized gingiva is present, the suture will be placed within the band of keratinized gingiva."
215166963|NCT07200258|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)|In the MCAT group, the surgical approach will follow the technique described by Aroca et al. (2010). After sulcular incisions made without releasing incisions, a full-thickness muco-periosteal tunnel will be carefully elevated beyond the mucogingival junction and under adjacent papillae using tunneling instruments. The root surfaces will be planed, and a subepithelial connective tissue graft will be harvested from the palatal donor site and inserted into the tunnel. Suspended horizontal mattress sutures will be placed around the contact points to advance and stabilize the flap in a position coronal to the cemento-enamel junction (CEJ) (previous composite at the contact point if necessary). Postoperative care will be identical to that described for the VISTA group.
215166964|NCT07202221|OTHER|Participant views Epidural animation before reading gold standard written information|Addition of introductory animation to written OAA epidural information card about labour epidural
215166965|NCT07202221|OTHER|Participant receives current gold standard written information alone|Gold standard OAA (Obstetric Anaesthetists' Association) epidural information card
215166966|NCT07202000|DRUG|Activin ligand-trap biological therapy|Investigational therapy
215166967|NCT07202000|DRUG|Placebo, Normal Saline|Inactive drug
215166968|NCT07202325|BEHAVIORAL|Resilience Training for Veterans (REST-V)|A 6-week self-help intervention tailored for post-9/11 Veterans offering guidance on cognitive-behavioral self-management coping strategies plus when and how to access recovery support services including mental health treatment. Materials are sent once a week for 6 weeks, and participants can opt to receive weekly reminder text messages or up to 3 brief telephone support calls.
215166969|NCT07202325|OTHER|Usual resources|Standard printed resource/treatment information provided in VHA usual care to post-9/11 Veterans. Covers similar domains as the intervention materials and provides information on a variety of VA and community resources for Veterans. Materials are sent once.
214565489|NCT00673959|OTHER|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
214565490|NCT00673959|OTHER|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
215166970|NCT07200544|DRUG|Meloxicam 7.5 mg|This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.
215166971|NCT07200544|DRUG|Meloxicam 15 mg|This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.
215166972|NCT07200544|DRUG|Acetaminophen 500mg|This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.
215166973|NCT07201311|DRUG|Combination of activated charcoal with polyethylene glycol for digestive decontamination|"A dose of 25-100g of activated charcoal via the nasogastric tube will be administered, followed by polyethylene glycol1L/15-20 kg ideal body weight at a flow rate of 1L/hour.~polyethylene glycol will be continued until clear stools are obtained, a maximum of 24h of treatment of until the maximum dose of 1L per 15 kg of ideal body weight are administered.~Serial activated charcoal 50g 6 times/day will be administered if prolonged-release forms or drugs with enterohepatic circulation were ingested."
215166974|NCT07201311|DRUG|Standard Treatment (Guideline-Based)|Patients receive activated charcoal according to French guidelines - activated charcoal 25-100g and serial activated charcoal 50g 6 times/day if sustained-release forms or drugs with enterohepatic circulation as routine treatment.
215166975|NCT07200375|DRUG|Glofitamab|Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
215166976|NCT07202143|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ vial) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
215166977|NCT07202143|DRUG|Normal Saline|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
215166978|NCT07200908|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
215166979|NCT07200908|DRUG|Bulevirtide 2 mg and Brelovitug - 300 mg|Route of Administration- Subcutaneous Injection
214565491|NCT04157725|DRUG|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
214708235|NCT06318221|DIETARY_SUPPLEMENT|Experimental (Immunonutrition) Group|"Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group."
215166980|NCT07198217|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|The enrolled population consists of patients with stage IIIB/C-IV non-small cell lung cancer who are driver gene negative or unknown, as well as those with driver gene positive targeted drug resistance. The patients reaching SD, PR, or CR after 4 cycles of platinum based dual drug chemotherapy. The patient will receive SBRT radiotherapy combined with Tislelizumab treatment, followed by Tislelizumab maintenance therapy.
215166981|NCT07201350|OTHER|distraciton technices|UTETC is a distraction method used during ECG procedures.
215166982|NCT07201636|DIAGNOSTIC_TEST|Motor Function Assessments|The planned functional motor assessments are specific to age and degree of motor impairment. Participants are expected to have varying degrees of motor impairment, for example some will be non-ambulant. There is also a wide range of ages of participants. Therefore, some assessments will not be applicable. Some participants may gain or lose these abilities during the study and the assessments they complete shall be tailored accordingly aiming to reflect their most typical abilities on the day assessed.
215166983|NCT07201636|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
215166984|NCT07201636|DIAGNOSTIC_TEST|Respiratory Assessments|The planned respiratory assessments are tailored to the participant's age and respiratory capacity. Participants are expected to have varying degrees of respiratory impairment, and some assessments may not be applicable to all. As participants may gain or lose respiratory function over the course of the study, the assessments completed will be adapted accordingly to reflect their most typical respiratory abilities on the day of assessment.
215166985|NCT07201636|DIAGNOSTIC_TEST|Bulbar Function Questionnaires|The planned bulbar function assessments are age-specific and designed to reflect the participant's typical oral intake abilities. For participants aged 1-17 years, the Children's Eating and Drinking Activity Scale (CEDAS), will be used. For those aged 18 years and older, the Functional Oral Intake Scale (FOIS) will be applied. Both tools are part of a unified 7-item scale validated across paediatric and adult populations, ensuring continuity across age groups.
215166986|NCT07201636|DIAGNOSTIC_TEST|Clinical Global Impression (CGI)|The Clinical Global Impression (CGI) tool will be used to assess overall disease severity and improvement across three functional domains: Physical Motor Function, Respiratory Function, and Bulbar Function. Assessments are based on clinician judgment using all available clinical data and are conducted by clinicians experienced with the disease under study.
215166987|NCT07201636|OTHER|Quality of Life Questionnaires|The planned quality of life and functional status assessments are designed to capture the participant's overall well-being and daily functioning, taking into account the wide range of ages and disease severities in the study population. Validated questionnaires appropriate to age and functional level will be used to evaluate aspects such as health-related quality of life, fatigue, and daily activity limitations.
215166988|NCT07201636|PROCEDURE|Blood Sample Collection|Blood sample collection is usually done annually for NM patients as part of their standard of care. This is usually done by a nurse or a medical doctor according to standard guidelines for blood sampling. During routine blood sampling, additional blood will be collected and up to 20 ml of blood will be taken.
215166989|NCT07200960|PROCEDURE|ESPB|Patient receiving ESPB for major oncological breast surgery Patient receiving Retrolaminar Block for major oncological breast surgery
215166990|NCT07202416|PROCEDURE|Erector spinae plane block|Ultrasound-guided Erector Spinae Plane Block performed at the T9 level with 0,375%, ropivacaine 20 mL administered bilaterally at the end of surgery for postoperative analgesia following cesarean section.
215166991|NCT07202416|PROCEDURE|Intrathecal morphine|Intrathecal administration of 100 mcg of morphine in combination with a local anesthetic was performed at the time of spinal anesthesia for cesarean section.
215166992|NCT07196748|DRUG|Icotrokinra|Icotrokinra tablet will be administered orally.
215166993|NCT07196748|DRUG|Placebo|Placebo tablet will be administered orally.
215166994|NCT07201168|OTHER|Structured Multimodal Educational Program for Critical Limb Ischemia|A comprehensive 12-month educational program combining face-to-face and digital learning modalities. Components include: weekly interactive group sessions (4 weeks) led by vascular specialists covering disease pathophysiology, risk factor modification, and treatment options; digital platform access with multimedia educational materials, printed educational materials for home reference; peer support group participation; medical hotline access for patient-initiated consultations and urgent questions; smoking cessation counseling; supervised exercise program recommendations; wound care training. The program emphasizes patient self-management skills, early recognition of complications, and adherence to medical therapy alongside standard clinical care.
214565492|NCT04157725|DRUG|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
215166995|NCT07201168|OTHER|Standard medical care|Routine clinical management for critical limb ischemia according to current standard of care guidelines. Includes vascular surgery consultation, standard medical therapy (antiplatelet agents, statins, antihypertensive medications as indicated), routine wound care instructions, general lifestyle counseling typically provided during clinical encounters, and scheduled follow-up appointments as clinically indicated. No structured educational materials, formal patient education sessions, or additional follow-up contacts beyond routine clinical care are provided. Patients receive standard verbal and written discharge instructions and have access to the same medical and surgical treatments as the intervention group when clinically warranted.
215166996|NCT07200739|DIAGNOSTIC_TEST|Mini-mental State Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
215166997|NCT07200739|DIAGNOSTIC_TEST|Addenbrooke's Cognitive Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
215166998|NCT07200739|OTHER|Speech task - Picture Description|Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
215166999|NCT07200739|OTHER|Speech task - Story Retellling|"Participants will be asked to retell the fairy-tale Cinderella, based on pictures that summarize the fairy-tale. In case Cinderella is not known, participants are asked to tell a story with a start, a middle and an end based on the provided pictures. The task will take 4 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns."
215167000|NCT07200739|OTHER|Fluency tasks|"Two fluency tasks from the Addenbrooke's Cognitive Examination. First, the participant is asked to name as many animals as possible within 1 minutes. Next the participant is asked to name as many words starting with S as possible within 1 minute.~Participants will be recorded during the tasks in order to allow the AI to learn and analyze speech patterns."
215167001|NCT07200739|DIAGNOSTIC_TEST|MRI|"For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions).~For participants in the follow-up or new referral cohorts, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
214565493|NCT04028089|BEHAVIORAL|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
214565494|NCT04028089|OTHER|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
214565495|NCT03969381|RADIATION|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
214565496|NCT00615745|DRUG|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
214565497|NCT03167359|RADIATION|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
214565498|NCT00162448|DRUG|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
214565499|NCT00162448|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
214565500|NCT03735589|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
214565501|NCT03735589|BIOLOGICAL|Autologous Natural Killer Cell-like CTLs|Given IP
214565502|NCT03649438|DRUG|131 I-Metaiodobenzylguanidine|"* Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
214565503|NCT03649438|DRUG|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
215030049|NCT05006248|DEVICE|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
215030050|NCT05006248|DEVICE|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
214565504|NCT03649438|DRUG|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
214565505|NCT05820165|RADIATION|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
215167002|NCT07200739|DIAGNOSTIC_TEST|blood sampling|"Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment.~For participants in the follow-up or new referral cohorts, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
214565506|NCT05820165|RADIATION|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
214565507|NCT05820165|RADIATION|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
214565508|NCT05820165|RADIATION|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
214565509|NCT05820165|RADIATION|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
215167003|NCT07200739|DIAGNOSTIC_TEST|Depression screening|"Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients \> 65 year of age or the Major Depression Index (MDI) for patiens \<65 year of age.~For participants in the follow-up or new referral cohorts, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
214565510|NCT03805542|COMBINATION_PRODUCT|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
214708236|NCT06318221|DIETARY_SUPPLEMENT|Active Comparator Group ( Standard enteral nutrition)|"Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group."
215167004|NCT07200739|OTHER|Somatic- and neurological examination|"Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status.~For participants in the follow-up or new referral cohorts, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal"
215167005|NCT07201857|DIETARY_SUPPLEMENT|nutrition education plus active supplement|Nutrition Group (NUT) Participants will receive standard clinical care combined with nutrition education and protein-enriched soy milk supplementation for approximately 2 weeks before surgery and about 3 weeks after hospital discharge.
214565511|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
214565512|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
214565513|NCT01896557|DRUG|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
214565514|NCT01896557|DRUG|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
214565515|NCT01896557|DRUG|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
214565516|NCT02811718|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
214565517|NCT02811718|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
214565518|NCT03635203|DEVICE|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
214565519|NCT00013247|BEHAVIORAL|Prostate Cancer Screening Education|
214565520|NCT01221636|DRUG|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
214708237|NCT01056419|PROCEDURE|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
214708238|NCT01056419|DRUG|Propylthiouracil|150-600 mg in two-three divided doses
214565521|NCT01205854|DEVICE|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
214565522|NCT01230346|OTHER|questionnaire administration|Ancillary studies
214565523|NCT01230346|OTHER|survey administration|Ancillary studies
214708239|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
215167006|NCT07201857|BEHAVIORAL|Exercise|"Exercise and Nutrition~Participants will receive peri-habilitation exercise training together with nutritional intervention, including carbohydrate plus protein-enriched soy milk supplementation twice daily (before and after exercise), for approximately 2 weeks before surgery and about 3 weeks after hospital discharge."
215167007|NCT05192434|BEHAVIORAL|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
215167008|NCT05192434|BEHAVIORAL|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
215167009|NCT07200947|DRUG|QL1706, nab-paclitaxel, carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1) in combination with nab-paclitaxel (260 mg/m², IV, day 1) and carboplatin (AUC=4-5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) every 21 days. Treatment will continue until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or meeting other protocol-defined criteria for discontinuation. The maximum duration of QL1706 treatment is 24 months, after which continuation will be at the investigator's discretion based on individual benefit-risk assessment.
215167010|NCT07200973|BEHAVIORAL|Adapted LINK LA Peer Navigator|Our study will adapt the LINK LA peer navigation intervention (NCT01406626) for the current context (e.g., HIV care provision, substance use risk environments, etc.) and measure its effects on participants' HIV and substance care engagement.
215167011|NCT07200986|BIOLOGICAL|Ixekizumab|80 mg (single dose), SC injection via PFS
215167012|NCT07200479|DRUG|CAR T cells chimeric antigen receptor cells|CT1194D cells infusion
215167013|NCT07200362|DRUG|Compound Nanying zhitong Ointment|Use Compound Nanying Pain Relief Ointment alone, or use it in conjunction with conventional Western medicine treatment, without using any other similar Chinese patent medicines or traditional Chinese medicines.
215167014|NCT07200362|OTHER|Do not use any other similar proprietary medicines or traditional Chinese medicines.|Do not use any other similar proprietary medicines or traditional Chinese medicines.
215167015|NCT07201285|OTHER|Edge of laminar block|Patients will receive edge of laminar block using 20ml of bupivacaine 0.25%.
215167016|NCT07201285|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block using 20ml of bupivacaine 0.25%.
215167017|NCT07200843|OTHER|Heel rise test and postural/tibial sway measurement|Participants undergo a heel rise test to assess plantar flexor muscle endurance. Postural and tibial sway are measured during single-leg stance using a wearable sensor under eyes-open and eyes-closed conditions. No therapeutic intervention is applied.
215167018|NCT07201558|BIOLOGICAL|Surovatamig|"Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Surovatamig in adult participants with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study consists of up to three parts:~Part 1 (SAD): Single ascending dose - participants receive one dose of Surovatamig.~Part 2 (sSUD): Single step-up dosing - participants receive two doses. Part 3 (dSUD): Double step-up dosing - participants receive three doses. Participants are assigned to a study part based on protocol-defined criteria. The study includes follow-up for a minimum of 179 days post-first dose, with extended monitoring up to 12 months for certain participants."
215167019|NCT07202247|DRUG|Antiandrogen Therapy|Given ADT
214565524|NCT01230346|OTHER|counseling intervention|Telephone intervention
214565525|NCT01230346|OTHER|educational intervention|Telephone intervention
214565526|NCT05597813|PROCEDURE|microneedling|15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
214565527|NCT05597813|PROCEDURE|microneedling with topical timolol 0.5%|15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
214565528|NCT04449380|DRUG|Interferon-ß-1a|IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
215167020|NCT07202247|BEHAVIORAL|Behavioral Intervention|Receive fasting reminders via Oncpatient Companion Mobile Application
215167021|NCT07202247|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215167022|NCT07202247|PROCEDURE|Cardiac Computerized Tomographic Angiography|Undergo a coronary computerized tomography angiography
215167023|NCT07202247|PROCEDURE|Computed Tomography|Undergo CT
215167024|NCT07202247|OTHER|Electronic Health Record Review|Ancillary studies
215167025|NCT07202247|OTHER|Internet-Based Intervention|Complete survey and food diary collection via Oncpatient Companion Mobile Application
215167026|NCT07202247|BEHAVIORAL|Lifestyle Counseling|Receive diet and lifestyle counseling
215167027|NCT07202247|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
215167028|NCT07202247|OTHER|Nutritional Intervention|Receive AHA HHD guidelines
215167029|NCT07202247|OTHER|Nutritional Intervention|Receive AHA Life Essential 8 recommendations with personalized caloric intake
215167030|NCT07202247|OTHER|Questionnaire Administration|Ancillary studies
215167031|NCT07202247|RADIATION|Radiation Therapy|Undergo RT
215167032|NCT07202247|OTHER|Referral|Receive a referral to an endocrinologist
215167033|NCT07202247|DRUG|Semaglutide|Given SC
214565529|NCT04449380|COMBINATION_PRODUCT|Standard of Care (SOC)|Any pharmacological (e.g. antibiotics, etc.) and non-pharmacological (e.g. oxygen, ventilation, etc.) treatments prescribed on clinical grounds
214565530|NCT00681148|DRUG|Botox injection|Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
214565531|NCT00681148|DRUG|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
215167034|NCT07202247|OTHER|Short-Term Fasting|Participate in an overnight fast
215167035|NCT07202247|DRUG|Tirzepatide|Given SC
215167036|NCT07200778|PROCEDURE|temporary internal iliac artery occlusion|participants will undergo temporary internal iliac artery occlusion during laparoscopic myomectomy
215167037|NCT07200778|PROCEDURE|local epinephrine infiltration|participants will undergo local injections of epinephrine into the serosal and/or myometrium, covering the myoma before the uterine incision during laparoscopic myomectomy
215167038|NCT07201623|BEHAVIORAL|web-based childbirth preparation education|group providing web-based childbirth preparation training
215167039|NCT07200271|PROCEDURE|Arthroscopic reconstruction surgery|Arthroscopic reconstruction with allograft, in which a tendon (generally from a tissue bank) is used to reconstruct the ligaments. This technique is performed through small incisions using arthroscopy.
215167040|NCT07200271|PROCEDURE|Open surgery|Open surgery consists of the modified Broström-Gould technique, which allows for the reconstruction of damaged ligaments using the patient's own tissues through an incision on the lateral side of the fibula. This technique has shown satisfactory functional results.
215167041|NCT07201909|DIETARY_SUPPLEMENT|Prebiotic fibre blend|A blend of prebiotic fibres in a powdered supplement form.
215167042|NCT07201909|DIETARY_SUPPLEMENT|Maltodextrin powder|Maltodextrin powder
215167043|NCT07201467|DRUG|KN060|pharmacokinetic and pharmacodynamic characteristics of KN060 in ESRD on Hemodialysis
215167044|NCT07202078|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
215167045|NCT07202078|BIOLOGICAL|Immune Globulin Intravenous|IVIg every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
215167046|NCT07202026|BEHAVIORAL|Patient-centered Decision Aid to support long-term opioid therapy tapering|Earlier aims of this study developed a patient-centered Decision Aid (DA) that uses stories of people who benefited from discontinuing and clear explanations of evidence for key choices to decrease stigma; empower patients; increase engagement and productive interaction with providers in decision making; and reduce fear, anger and anxiety about tapering. The DA will be designed to support conversations that providers often find challenging and help providers maintain patient trust and satisfaction. Participants in the pilot test will be asked to: 1) complete a pre-DA survey, 2) review the DA, 3) have a guided conversation with a trained study interventionist with a behavioral health background who is trained on how to use the DA, and 4) complete a post-DA survey.
215167047|NCT07201584|DRUG|Torasemide tablet 10 mg|Tablets by Berlin-Chemie AG (Germany)
215167048|NCT07201584|DRUG|Unat® 10 tablets (Torasemide 10 mg)|Tablets by Viatris Healthcare GmbH (Germany)
215167049|NCT07200921|DRUG|Naoxuekang Dropping Pills|A traditional Chinese medicine. Each pill weighs 35mg. Dosage: 20 pills, three times daily, orally for 90 days.
215167050|NCT07200921|DRUG|Naoxuekang Matching Placebo|A placebo pill matched to Naoxuekang Dropping Pills in appearance, taste , size, and packaging. Dosage: 20 pills, three times daily, orally for 90 days.
214565532|NCT02564380|DRUG|Pembrolizumab|
214565533|NCT02564380|DRUG|Placebo|
214565534|NCT03021980|BEHAVIORAL|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
214565535|NCT04371523|DRUG|Apo-Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
214565536|NCT04371523|DRUG|Matched Placebo|Matching Placebo
214565537|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (250 mg)|Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
214565538|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (500 mg)|Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
214565539|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (1000 mg)|Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
215167051|NCT07201649|OTHER|a blood test and urine sample collection.|The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.
215167052|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：42Gy/26Fr.
215167053|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：54Gy/33Fr.
215167054|NCT07201389|DEVICE|Scalp Cooling by DigniCap|Scalp cooling with the DigniCap Delta will occur with each chemotherapy dose. The cooling wrap is primed, fitted, and checked for proper contact before a standardized pre-cool phase of 20-30 minutes. Cooling continues during chemotherapy, followed by a post-cool phase of 90-180 minutes based on regimen. The system circulates temperature-controlled coolant through channels in the wrap, with sensors monitoring flow and scalp temperature; a safety sensor ensures scalp temperature never falls below 32°F (0°C). Alerts notify staff of low flow or temperature issues. After cooling, the cap is loosened for 5 minutes to warm before removal, and subjects are given 5 minutes to acclimate before standing.
215167055|NCT07200661|DEVICE|Experimental A tDCS: Transcranial direct current stimulation.|Group 1: Active tDCS combined with dual-task stepping (Experimental A) Participants in this group will receive anodal tDCS applied over the ipsilesional primary motor cortex (M1) at C3 or C4 (based on the 10-20 EEG system), with the reference electrode positioned over the contralesional supraorbital area. Stimulation will be delivered at an intensity of 2 mA for 20 minutes, During the stimulation period, participants will perform dual-task stepping exercises on unstable surfaces. The stepping program stepping on a foam pad (5 cm thick, 20 cm wide, 12 cm long). Each stepping session lasts 10 minutes and is immediately followed by overground walking at a comfortable speed for 10 meters, while simultaneously performing a cognitive task of counting backwards from 99 to 0. Participants are instructed not to pause or stop while performing the dual task. If they stop for more than 5 seconds, it is considered an error, which will be recorded.
215167056|NCT07200661|DEVICE|Experimental B tDCS: Transcranial direct current stimulation.|Group 2:This group follows the same stepping and dual-task walking program as Group 1 (stepping on foam pad for 10 minutes, followed by overground walking with backward counting for 10 minutes). However, instead of active stimulation, participants receive sham tDCS.
215167057|NCT07200661|DEVICE|Experimental C tDCS: Transcranial direct current stimulation.|Group 3:Participants in this group will receive anodal tDCS only, without any dual-task or stepping training.
215167058|NCT07201818|DEVICE|Lymphatic Enhancement Technology (LET)|Lymphatic Enhancement Technology (LET) is an FDA-approved electrotherapeutic modality, with indications for addressing local lymphatic and vascular circulation as well as muscle pain and spasm. The Aria LET Elite Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the intervention group.
215167059|NCT07201818|DEVICE|Sham Lymphatic Enhancement Technology (LET)|A separate modified Aria Elite LET Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the sham group. The sham LET device used for the control group will emit a light and sound similar to the true LET device, but will not emit energy waves.
215167060|NCT07202039|BEHAVIORAL|Brief individual counseling sessions|Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
215167061|NCT07200401|PROCEDURE|Self-swabbing of surgical wound|Participants will perform self-swabbing of their surgical wound under observation by a research nurse via secure video call.
215167062|NCT07200453|BEHAVIORAL|intervention group 1.1 - e-learning|"The e-learning environment will include text, images, and short videos created using Articulate Rise 360, an easy-to-use e-learning authoring tool, with the following content to improve the different skills of digital health literacy:~1. Evaluating reliability skills: Participants will get to know criteria and indicators for evaluating the content of the information they find and for assessing the trustworthiness of website providers.~2. Improving information skills: Participants will learn simple rules on how to optimize their Google searches.~3. Improving navigation skills: Participants will learn simple rules for navigation; using the back button; using more than one tab; drop-down lists and anchor links are introduced.~4. Additional goals are to raise awareness about various aspects related to online searches, including the exploration of alternative and complementary therapies, and the importance of data protection."
215167063|NCT07200453|BEHAVIORAL|intervention-group 1.2 - e-learning|Participants are also given access to the e-learning environment. However, they will not be taken step-by-step through the content (tunneling). They can choose the order of the content.
215167064|NCT07200453|BEHAVIORAL|intervention-group 1.3 - e-learning|Participants are also given access to the e-learning environment, but all rehearsal elements such as quizzes will be removed from the e-learning environment.
215167065|NCT07200453|BEHAVIORAL|intervention-group 2 - PDF|Participants in IG2 will receive the same content as participants in the IG1.1, but not within the interactive learning environment, but in a non-interactive PDF format.
215167066|NCT07202312|DEVICE|Ozone-therapy after non-surgical therapy|The test group received ozone therapy immediately after non-surgical treatment, at a fixed concentration of 2100 ppm and 80% oxygen, applied three times at the site. Ozone was delivered into the periodontal pocket using a sterile syringe with a flat tip. Ozone was generated with the Ozone DTA Ozone Generator (Denta Tec Dental AS, Norway), which was operated for 20 seconds in accordance with the manufacturer's instructions.
215167067|NCT07201688|DRUG|rhTNK-tPA|Each vial should be dissolved in 3mL of sterile water for injection to prepare a drug solution with a concentration of 5.33mg/mL. Calculate the total drug amount based on the participant's actual body weight, measure the required volume of the drug solution, and ensure the maximum dose does not exceed 25mg. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
215030051|NCT03981510|DIAGNOSTIC_TEST|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
214565540|NCT05611827|DIETARY_SUPPLEMENT|Regular/standard Quercetin (500 mg)|Total dose of 500 mg of quercetin
214565541|NCT00013260|PROCEDURE|Integrated model of primary care|
214565542|NCT01514708|BIOLOGICAL|AdimFlu-S Influenza Vaccine|Suspension for injection
214708240|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
214708241|NCT06263231|DRUG|INT230-6|INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
214708242|NCT06263231|DRUG|Eribulin|Eribulin IV
214565543|NCT03183219|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
214565544|NCT03183219|BIOLOGICAL|γδ T cell|γδ T cells will be used against Liver Cancer
214565545|NCT03183219|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
214565546|NCT05353205|DRUG|Flumatinib mesylate tablets (400mg)|Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
214565547|NCT05353205|DRUG|Flumatinib mesylate tablets (600mg)|Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
214565548|NCT01517295|DRUG|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
214565549|NCT02819427|DEVICE|Near Infra Red Spectroscopy (NIRS)|
214708243|NCT06263231|DRUG|Trabectedin|Trabectedin infusion
214708244|NCT06263231|DRUG|Pazopanib|Pazopanib pill
214708245|NCT01274312|PROCEDURE|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
215030052|NCT01217892|DRUG|dapagliflozin|2.5 mg tablet, taken orally, twice daily
214565550|NCT02819427|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
214565551|NCT00281515|DRUG|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
214565552|NCT06031103|PROCEDURE|mini-PCNL procedure|"Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age"
214565553|NCT06031103|PROCEDURE|RIRS procedure|RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
214565554|NCT03966768|DEVICE|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
214565555|NCT03966768|DEVICE|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
214565556|NCT01749111|DRUG|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
214565557|NCT01749111|DRUG|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
214565558|NCT00958503|DRUG|Thiamphenicol|750 and 1500 mg/day;tablets
214708246|NCT06642610|DEVICE|CGM Dynamic Index (CDI)|Participants will undergo one-time oral glucose tolerance test (OGTT) and a one-time use of a CGM device, which will be worn for up to 10 days.
214708247|NCT04062266|DRUG|Azacitidine|Given SC or IV
214708248|NCT04062266|DRUG|Venetoclax|Given PO
214708249|NCT03745300|DRUG|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
214708250|NCT03745300|DRUG|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
214708251|NCT03745300|DRUG|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
214708252|NCT00335998|DRUG|triapine|Given IV
214708253|NCT00335998|OTHER|laboratory biomarker analysis|Correlative studies
214708254|NCT00335998|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
215030053|NCT01217892|DRUG|dapagliflozin|5 mg tablet taken orally, twice daily
215030054|NCT01217892|DRUG|dapagliflozin|10 mg tablet taken orally, once daily
215030055|NCT01217892|DRUG|metformin|\>/= 1500 mg total daily dose, tablets taken orally, twice daily
215030056|NCT01217892|DRUG|placebo|placebo
215030057|NCT03594708|DIETARY_SUPPLEMENT|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
215030058|NCT03594708|DIETARY_SUPPLEMENT|Placebo supplement|rice starch, light olive oil, vegetable oil
215030059|NCT05385107|DIAGNOSTIC_TEST|Serum procalcitonin concentration|
215030060|NCT01205516|DRUG|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
215030061|NCT01205516|DRUG|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
215030062|NCT03532347|DEVICE|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
215030063|NCT01401673|DRUG|Indantadol|Titration
215030064|NCT04125602|OTHER|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
215030065|NCT04125602|OTHER|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
214565559|NCT00958503|DRUG|Placebo|Matched tablets without active ingredient
215167068|NCT07201688|DRUG|Placebo|One vial is dissolved in 3mL of sterile water for injection. Calculate the total drug amount based on the participant's actual body weight, then measure the required volume of the drug solution. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
215167069|NCT07201506|DEVICE|PVC and VT ablation with ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation with intracardiac echocardiography (ICE)
215167070|NCT07201506|DEVICE|PVC and VT ablation without ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation without intracardiac echocardiography (ICE)
215167071|NCT07201012|DIAGNOSTIC_TEST|Sampling of suspected skin lesions (in accordance with good care practices).|Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.
215167072|NCT07201012|GENETIC|Constitution of a biobank|Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients
215167073|NCT07201116|DEVICE|Health-GIS Rehabilitation Coordination Platform|Participants receive access to a specialized mobile application with integrated Geographic Information System (GIS) components for rehabilitation service coordination. While hospitalized, patients submit rehabilitation requests through the platform, indicating their location, desired time, and specific rehabilitation needs. Registered rehabilitation centers within the platform receive these requests and can submit counter-proposals with available slots, services offered, and estimated costs. The platform provides real-time visualization of available rehabilitation facilities on an interactive map, displays facility ratings, services offered, current capacity, and waiting times. Patients receive automated notifications about new proposals and can compare options based on location proximity, service quality ratings, and availability. Technical support is available through in-app messaging and a dedicated helpline during business hours.
215167074|NCT07201116|OTHER|Standard Rehabilitation Referral|Upon discharge, patients receive written recommendations stating that rehabilitation is advised as part of their post-operative care plan. No specific rehabilitation facilities are recommended or contacts provided by the surgical team. Patients are instructed to contact their assigned primary care physician (general practitioner) at their local polyclinic for further referral coordination. The primary care physician is responsible for identifying available rehabilitation facilities, making referrals, and coordinating the rehabilitation timeline based on their knowledge of local resources and current availability. This intervention represents routine clinical practice typically provided to patients after total hip arthroplasty.
215167075|NCT07200466|DIAGNOSTIC_TEST|ENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.|The intervention group are patients receiving a personalized risk on lymph node metastases as predicted by the ENDORISK model, they also receive a treatment plan (hysterectomy + bilateral salpingo-oophorectomy with or without lymph node surgery) based on this personalized risk.
215167076|NCT07200856|OTHER|Nocturnal Blood Pressure Dipping|Patients will be classified as dippers (≥10% nocturnal BP fall) or non-dippers (\<10% nocturnal BP fall) based on 24-hour ambulatory blood pressure monitoring.
215167077|NCT07200635|OTHER|HA injection|Using vacuum negative pressure technology, hyaluronic acid and other moisturizing nutrients are directly injected into the deep skin, effectively improving dermal dehydration and dryness from the muscle base, so that the skin can quickly replenish water.
214565560|NCT02840344|BEHAVIORAL|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
214565561|NCT02840344|BEHAVIORAL|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
215167078|NCT07200635|OTHER|Facial serum application|Dosage on face: About 0.5g/face for serum.
215167079|NCT07201220|BEHAVIORAL|meditation|The study is planned to include 60 pregnant women (30 in the experimental group and 30 in the control group) in the first stage of labor. After informing the participants about the study and obtaining informed consent, pre-test scales will be administered. Relaxation meditation will be applied during labor for the experimental group, followed by post-test scales.
215167080|NCT07201740|DEVICE|Leap Motion-based Virtual Reality Therapy|"Arm 1 - Experimental (Leap Motion + Routine Hand Rehabilitation)~Intervention Description: Participants will receive standard postoperative hand rehabilitation plus Leap Motion-based virtual reality training. The VR training will be performed for 20 minutes per day, 5 days per week, for 4 weeks, in addition to routine rehabilitation. The Leap Motion Controller tracks hand and finger movements without physical contact and allows participants to practice functional tasks and grasp patterns in a virtual environment.~Arm 2 - Active Comparator (Routine Hand Rehabilitation Only)~Intervention Description: Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist."
215167081|NCT07201740|OTHER|Active Comparator - Routine Rehabilitation Only|Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist.
215167082|NCT07201675|DRUG|RC48-ADC combined with toripalimab for bladder-sparing therapy|RC48-ADC combined with toripalimab for bladder-sparing therapy
214565562|NCT03798782|PROCEDURE|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
214565563|NCT03798782|PROCEDURE|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
214565564|NCT01511783|DRUG|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
214565565|NCT01511783|DRUG|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
214565566|NCT04110353|OTHER|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
214565567|NCT04110353|OTHER|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
214565568|NCT04110353|OTHER|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
214565569|NCT01955967|DRUG|Lidocaine|
214565570|NCT04237168|DIAGNOSTIC_TEST|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
214565571|NCT05622916|DRUG|Topical Ethanol Extract (Piper crocatum)|Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
214565572|NCT05622916|DRUG|Trichloroacetic Acid Topical|Trichloroacetic acid topical 90%
214565573|NCT06092424|BEHAVIORAL|Relocation from HA to LA|Patients will be relocated by bus from Quito (2840m) to Pedernales (sea level) and have investigations at both altitudes
214565574|NCT05451823|DEVICE|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
214708255|NCT00335998|RADIATION|brachytherapy|Undergo intracavitary or interstitial brachytherapy
215167083|NCT07201480|BEHAVIORAL|Mortality Salience Prompts|"This intervention implies giving two prompts to participants, in a written format, while asking them to write out answers to the given prompts. The first prompt is: Please briefly describe the emotions that the thought of your death arouses in you. The second prompt is Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead."
214565575|NCT00639782|DEVICE|On-X Heart valve replacement|On-X Heart valve replacement
214565576|NCT00639782|DEVICE|SJM Heart valve replacement|SJM Heart valve replacement
214565577|NCT05410639|OTHER|online education program|The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.
214565578|NCT05410639|OTHER|no online education program|Parents and their infants in the control group did not receive any online education program
214708256|NCT00335998|DRUG|cisplatin|Given IV
215167084|NCT07201480|BEHAVIORAL|Dental Pain Prompts|"This intervention implies giving two prompts to participants, and requesting that participants write out their answers to these prompts. The first prompt is: Please briefly describe the emotions that the thought of dental pain arouses in you. The second prompt is: Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."
215167085|NCT07202403|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. While it's found in various foods, the highest concentrations are in wheat germ, soy, and fermented foods like cheese and miso (Madeo et al. 2018). Spermidine is known for its role in promoting autophagy, a cellular process that helps to clear damaged cells and improve overall cellular function (Eisenberg et al. 2009; Gabandé-Rodríguez, Gómez de Las Heras, and Mittelbrunn 2019). As a result, spermidine has recently attracted significant scientific interest for its potential to enhance lifespan and overall health in laboratory studies.
215167086|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
215167087|NCT06035068|DRUG|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
215167088|NCT06526338|DRUG|1.0% IP-001 for injection|Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation
215167089|NCT06526338|PROCEDURE|Surgical Resection and Local Ablation|Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
215167090|NCT06526338|PROCEDURE|Local Ablation Alone|Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
215167091|NCT05319587|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
214708257|NCT00335998|OTHER|pharmacological study|Correlative studies
214708258|NCT04875403|OTHER|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
214565579|NCT05110027|DRUG|Enpatoran|Participants will receive single oral dose of enpatoran tablet on Day 1
214565580|NCT05110027|DRUG|[14C]enpatoran microtracer|Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.
214565581|NCT05110027|DRUG|[14C]enpatoran microdose|Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
214565582|NCT01644448|OTHER|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
214565583|NCT01644448|OTHER|Standard Therapy|Topical Applications as directed by the investigator
214565584|NCT05076084|PROCEDURE|QUICK questionnaire and 6 additional questions|QUICK questionnaire and 6 additional questions
214565585|NCT05076084|OTHER|Retrospective collection of clinical data from the patients' medical records|Retrospective collection of clinical data from the patients' medical records
214565586|NCT03818724|DEVICE|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
214565587|NCT02156726|DRUG|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
214565588|NCT01800734|OTHER|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
214565589|NCT02182947|DEVICE|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
214565590|NCT03024905|BEHAVIORAL|Village meeting and travel vouchers|"The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery."
214565591|NCT03024905|DEVICE|Birth kit with misoprostol|Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
214708259|NCT04875403|OTHER|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
214708260|NCT03630484|OTHER|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
214708261|NCT03630484|OTHER|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
214708262|NCT01804036|DRUG|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
214565592|NCT01940068|DIETARY_SUPPLEMENT|Amino acid based formula|
214708263|NCT01804036|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
215167092|NCT05319587|DRUG|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
215167093|NCT03688503|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
215167094|NCT03688503|DIETARY_SUPPLEMENT|placebo|placebo
215167095|NCT02478528|DEVICE|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
215167096|NCT02478528|DEVICE|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
215167097|NCT02478528|OTHER|control condition|No exposure of the subject to any light sources (control condition)
215167098|NCT03049462|DRUG|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
215167099|NCT03049462|OTHER|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
214708264|NCT00164736|DRUG|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
215167100|NCT06348628|BEHAVIORAL|Motivational Interview|4 Motivational interviews within first 6 months
215167101|NCT06348628|BEHAVIORAL|Placebo|Advices on standard of care treatment of NAFLD within first 6 months
215167102|NCT02632994|DRUG|LY2503029|Administered orally.
214708265|NCT00164736|DRUG|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
215167103|NCT02632994|DRUG|LY3023414|Administered orally.
214565593|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
215167104|NCT02632994|DRUG|LY3838915|Administered orally.
215167105|NCT02632994|DRUG|LY3847429|Administered orally.
215167106|NCT05328752|DRUG|XXB750|XXB750
215167107|NCT05328752|DRUG|Placebo|Placebo
215167108|NCT05322226|BEHAVIORAL|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
215167109|NCT04823624|DRUG|MBG453|intravenous infusion
214565594|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
214565595|NCT05847673|OTHER|Questionnaire Administration|Ancillary studies
214565596|NCT05847673|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
214565597|NCT04669015|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
214565598|NCT04669015|BIOLOGICAL|Placebo|Formulation vehicle
214565599|NCT05444023|PROCEDURE|Pubocervical fascia reconstruction|Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
214708266|NCT00164736|DIETARY_SUPPLEMENT|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
215030066|NCT01468064|GENETIC|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
215030067|NCT01468064|GENETIC|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
215030068|NCT01468064|GENETIC|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
215030069|NCT01459120|OTHER|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
215030070|NCT01459120|OTHER|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
215030071|NCT03694028|OTHER|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
215030072|NCT03694028|OTHER|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
214565600|NCT04427059|PROCEDURE|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
214708267|NCT03962556|OTHER|bimanual palpation|bimanual palpation....i..
214565601|NCT04427059|PROCEDURE|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
214565602|NCT01609244|DEVICE|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
214565603|NCT01609244|DEVICE|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
214565604|NCT02236988|DRUG|Apremilast Immediate Release|30 mg immediate release tablets
214565605|NCT02236988|DRUG|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
214565606|NCT02236988|DRUG|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
214565607|NCT02236988|DRUG|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
214565608|NCT02236988|DRUG|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
214565609|NCT02236988|DRUG|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
214565610|NCT02236988|DRUG|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
214565611|NCT02236988|DRUG|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
214565612|NCT02236988|DRUG|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
214565613|NCT02236988|DRUG|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
214565614|NCT02236988|DRUG|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
214565615|NCT02236988|DRUG|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
214565616|NCT02236988|DRUG|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
214565617|NCT00730275|DRUG|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
214565618|NCT00730275|DRUG|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
214565619|NCT00735631|DEVICE|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
214565620|NCT02448433|DEVICE|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m\^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
214565621|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for reducing risk behaviors|Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD \& SZ it is alcohol use.
214565622|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for increasing non-risk behaviors|Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.
214565623|NCT00251901|DRUG|Esomeprazole|
214565624|NCT01917721|DRUG|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
214708268|NCT05708937|BEHAVIORAL|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body \& Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
214565625|NCT01917721|DRUG|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
214565626|NCT04032613|OTHER|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
214708269|NCT01833325|RADIATION|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
214565627|NCT02067559|BEHAVIORAL|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
214565628|NCT02067559|BEHAVIORAL|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
214565629|NCT00626626|DRUG|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
214565630|NCT00626626|DRUG|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
214565631|NCT02920489|DRUG|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
214565632|NCT02920489|DRUG|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
214565633|NCT04334187|BEHAVIORAL|Mindfulness Based addition treatment|The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
214565634|NCT02404727|PROCEDURE|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
214565635|NCT02404727|DEVICE|Avantage® Cup|
214565636|NCT02625688|OTHER|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
214565637|NCT02625688|OTHER|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
214708270|NCT03297437|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
214708271|NCT02677220|DEVICE|CI532 cochlear implant|
214708272|NCT05902429|DRUG|Cladribine 10 mg oral tablet|Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
214708273|NCT00965146|DEVICE|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
214565638|NCT02625688|OTHER|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
214565639|NCT01652495|DRUG|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
214565640|NCT01652495|DRUG|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
214565641|NCT04235829|PROCEDURE|Laparoscopic sleeve gastrectomy|Form of obesity surgery
214565642|NCT02553967|DEVICE|Functional MRI|Functional MRI
214565643|NCT00480935|DRUG|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
214565644|NCT04556903|COMBINATION_PRODUCT|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
214565645|NCT04556903|COMBINATION_PRODUCT|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~* Block placement- 10minutes~* Peg targeting- 10 minutes~* Peg inversion-10miutes~* Transferring objects- 10minutes"
214565646|NCT01382368|DRUG|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
214565647|NCT03053518|DEVICE|Abbott Freestyle Libre Pro|A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
214565648|NCT03053518|BEHAVIORAL|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
214565649|NCT06198348|OTHER|Aerobic Exercise|"Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase."
214708274|NCT00553553|DRUG|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
214708275|NCT00553553|DRUG|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
215030073|NCT02648360|BEHAVIORAL|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
215030074|NCT06467188|OTHER|Validity and reliability|"In order to evaluate the content validity of the Turkish version of the scale, 12 expert researchers in the field of gynecology and obstetrics were consulted. The experts were asked to evaluate the items as 1-Not Appropriate, 2-Somewhat Appropriate, 3-Reasonably Appropriate, and 4-Very Appropriate. Experts were asked to suggest items not evaluated as very appropriate. In the Davis technique, the content validity index which is calculated by dividing the number of experts who marked the options a (The item is appropriate) and b (The item needs minor revision) for each item by the total number of experts providing opinions is expected to be over 0.80 \[30\]. Based on expert opinions, the content validity index (CVI) value of the scale was calculated to be 96%, meaning that content validity was ensured. The items were reorganized by considering the experts' suggestions. The scale was administered to 252 women over 18 who were included in the study sample after scoring."
215030075|NCT04628806|DIAGNOSTIC_TEST|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
215030076|NCT01285102|COMBINATION_PRODUCT|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
215030077|NCT01285102|PROCEDURE|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
215030078|NCT04143776|PROCEDURE|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
215030079|NCT05879029|DRUG|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
215030080|NCT05879029|DRUG|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
214565650|NCT06198348|OTHER|Aerobic Exercises with Resistance training|"These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~1. Leg press (dual leg press):~   Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~2. Crunches:~   Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~3. Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set"
214565651|NCT06518031|OTHER|meditation|meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
214565652|NCT05358041|DEVICE|Robotic Bronchoscopy|Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
214565653|NCT02071290|DEVICE|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
214565654|NCT04938167|OTHER|95% - 99% SpO2 target|If the infant is randomized to the intervention arm, the oxygen saturation goal will be changed from the standard goal of 91% - 95% to the experimental goal of 95%-99%. The treating medical team will then adjust the oxygen and respiratory support to maintain these goals (SpO2 alarm levels will be set at 93% and 100%).
214565655|NCT00656708|OTHER|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
214565656|NCT01843153|DRUG|Ropivacaine|
214565657|NCT06502730|BEHAVIORAL|Creating Opportunities for Parent Empowerment (COPE) Program|It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
214565658|NCT04578353|DEVICE|The AquaPass System|The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
214565659|NCT04374539|BIOLOGICAL|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick \<50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
214565660|NCT04374539|DRUG|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
214565661|NCT04472416|DEVICE|VRD in addition to standardized analgesic protocol|Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
214565662|NCT03374449|PROCEDURE|continuation of the RAS-inhibitors|drug intake
214565663|NCT03374449|PROCEDURE|discontinuation of the RAS-inhibitors|no drug intake
214565664|NCT05435482|BEHAVIORAL|Education|Participants will receive two small group meetings and two follow-up calls
214565665|NCT05435482|OTHER|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
214565666|NCT05435482|OTHER|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
214565667|NCT02410460|DRUG|clonidine|
214565668|NCT02410460|DRUG|glycopyrrolate|
214565669|NCT02410460|DRUG|propofol|
214565670|NCT02410460|DRUG|ketamine|
214565671|NCT02410460|DRUG|marcaine|
214565672|NCT02410460|DRUG|scopolamine|
214565673|NCT02410460|DRUG|midazolam|
214565674|NCT02410460|DEVICE|ondansetron|
214565675|NCT02410460|DRUG|metoclopramide|
214565676|NCT02410460|DRUG|glycopyrrolate|
214565677|NCT02410460|DRUG|lidocaine|
214565678|NCT02410460|DRUG|famotidine|
214565679|NCT02410460|DRUG|desflurane|
214565680|NCT02410460|DRUG|sevoflurane|
214565681|NCT03674580|BEHAVIORAL|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
214565682|NCT00683683|BEHAVIORAL|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
214565683|NCT02005770|DRUG|Sevoflurane|
214565684|NCT02005770|DRUG|Propofol|
214565685|NCT00004426|DRUG|gonadotropin releasing hormone|
214565686|NCT00004426|DRUG|leuprolide|
214565687|NCT06151093|OTHER|Video-based games intervention|"These games are applied via using Nintendo Wii~1st - 2nd Week Applications~* Basic Step~* Penguin slide (right-left weight transfer)~* Snowball flight (right-left weight transfer)~* Tilt city (right-left weight transfer)~  3rd-4th Week Applications~* Advanced Step~* Snowball flight (right-left weight transfer)~* Penguin slide (right-left weight transfer)~* Table tilt (weight transfer in 4 directions)~  5th-6th Week Applications~* Advanced Step~* Table tilt (weight transfer in 4 directions)~* Balance bubble (weight transfer to 4 directions)~* Ski slalom (weight transfer in 4 directions)"
214565688|NCT06151093|OTHER|Balance exercises|"1st-2nd Week Applications On a flat-hard surface;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Taking a step back towards the step~* Stepping on the stability ball~  3rd-4th Week Applications All exercises which applied in 1st and 2nd week are applied on mat.~  5th-6th Week Applications On the balance board;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Catching balls thrown by the enforcer"
214565689|NCT02146404|OTHER|hypoglycemia|Blood glucose levels will be kept at \~3.0 mmol/l
214565690|NCT02146404|OTHER|euglycemia|Blood glucose levels will be kept at \~5.0 mmol/l
214565691|NCT04590157|DEVICE|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
214565692|NCT04590157|OTHER|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
214565693|NCT06396351|PROCEDURE|Laparoscopic surgery|effect of carbondioxide insufflation on abdominal compliance was evaluated
214565694|NCT00591539|PROCEDURE|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
214565695|NCT04871880|BEHAVIORAL|Dietitian led life style modification intervention|All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.
214565696|NCT04871880|BEHAVIORAL|Conventional care (control)|Receive routine care
214565697|NCT06130670|OTHER|nerve block|Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.
214565698|NCT05719740|DIAGNOSTIC_TEST|osteocrin|laboratory routine test
214565699|NCT00003187|BIOLOGICAL|filgrastim|
214565700|NCT00003187|DRUG|cyclophosphamide|
214565701|NCT00003187|DRUG|cyclosporine|
214565702|NCT00003187|DRUG|cytarabine|
214565703|NCT00003187|DRUG|methotrexate|
214565704|NCT00003187|DRUG|methylprednisolone|
214565705|NCT00003187|PROCEDURE|allogeneic bone marrow transplantation|
214565706|NCT00003187|PROCEDURE|in vitro-treated bone marrow transplantation|
214565707|NCT00003187|RADIATION|radiation therapy|
214565708|NCT05565495|DRUG|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
214565709|NCT04488770|DRUG|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
214565710|NCT04488770|DRUG|Placebo|Matching strength placebo capsules will be provided
214565711|NCT00913848|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
214565712|NCT00913848|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
214565713|NCT00564577|BIOLOGICAL|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
215030081|NCT03377751|PROCEDURE|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
215030082|NCT03377751|PROCEDURE|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
215030083|NCT03377751|PROCEDURE|PVI only group|PVI will be performed in this arm.
215030084|NCT01040247|OTHER|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
215030085|NCT06495606|DIAGNOSTIC_TEST|Voice sample; Recording with microphone + Questionnaire|Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
215030086|NCT05241366|DEVICE|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
215030087|NCT05241366|DEVICE|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
215030088|NCT02169596|DRUG|Ticagrelor|Blood tests taken for flow cytometry
215030089|NCT02169596|OTHER|EndoPAT - endothelial assessment|
215030090|NCT02119273|DRUG|Prednisone|See arm description
215030091|NCT02119273|DRUG|Placebo|See arm description
215030092|NCT01066845|DRUG|tadalafil|prescribed in accordance with usual clinical practice
215030093|NCT04020640|OTHER|no intervention|Measure human intake using stable isotope technique
215030094|NCT00659022|PROCEDURE|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
215030095|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
215030096|NCT00659022|DRUG|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
215030097|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
215030098|NCT02348021|PROCEDURE|Percutaneous coronary intervention (PCI)|
215030099|NCT02348021|DRUG|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
215030100|NCT01101776|DRUG|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
215030101|NCT03984279|OTHER|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
215030102|NCT00744614|PROCEDURE|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
215030103|NCT06488833|BEHAVIORAL|Komtü Programme (Komtü)|"Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully."
215030104|NCT06488833|BEHAVIORAL|Komtü Training and Reflective Practice|"This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group."
215030105|NCT04999410|BEHAVIORAL|High Intensity Interval Training|Interventions will contrast alternative training protocols
215030106|NCT01668680|DRUG|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
215030107|NCT06489366|DEVICE|Thulium Fiber laser (TFL) lithotripsy|Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
215030108|NCT06489366|DEVICE|Ho: YAG lithotripsy|Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
215030109|NCT01905540|DRUG|SSP-004184AQ|Magnesium salt
215030110|NCT01905540|DRUG|SSP-004184SS|Disodium salt
215030111|NCT00000395|DRUG|Methotrexate|
215030112|NCT00000395|DIETARY_SUPPLEMENT|Folinic acid|
215030113|NCT00000395|DIETARY_SUPPLEMENT|Folic acid|
215030114|NCT00498628|DRUG|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
215030115|NCT00498628|OTHER|Placebo|Placebo
215030116|NCT01322152|DRUG|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
215030117|NCT00850330|OTHER|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
215030118|NCT02137343|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
215030119|NCT02137343|DRUG|Placebo|Placebo
215030120|NCT02137343|DRUG|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
215030121|NCT02137343|DRUG|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
215030122|NCT06230146|DRUG|Insulin group|"Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas."
215030123|NCT06230146|DRUG|Botulinum toxin group|Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
215030124|NCT06230146|DRUG|Triamcinolone acetonide group|Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
215030125|NCT01224314|OTHER|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
215030126|NCT02743962|DEVICE|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
215030127|NCT02743962|OTHER|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
215030128|NCT03526666|OTHER|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
215030129|NCT04993196|DIAGNOSTIC_TEST|T1rho imaging|Magnetic Resonance Imaging using T1rho
215030130|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
215030131|NCT06563934|DRUG|Lenvatinib + PD-1 monoclonal antibody|"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."
215030132|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules placebo|Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
215030133|NCT01980264|DEVICE|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
215030134|NCT06034340|DEVICE|LET Gel after STAR Particle Application (Right or Left Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.
215030135|NCT06034340|OTHER|LET Gel Application without STAR Particle Application (Contralateral Arm)|Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
215030136|NCT04692922|DIAGNOSTIC_TEST|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
215030137|NCT04692922|DIAGNOSTIC_TEST|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
215030138|NCT06639178|OTHER|DECLARAN cream|Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
215030139|NCT06642597|OTHER|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
215030140|NCT06642597|OTHER|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
215030141|NCT06564363|DIAGNOSTIC_TEST|IUrisure test|Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
215030142|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy with use of Emdogain|Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
215030143|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy without the use of Emdogain|Scaling of root with assisted use of the Videoscope.
215030144|NCT04998513|DRUG|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
215030145|NCT04998513|PROCEDURE|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
215030146|NCT04198428|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
214565714|NCT06418945|COMBINATION_PRODUCT|Tinidazole oral microneedle patch|Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.
214565715|NCT06124469|DIAGNOSTIC_TEST|US-guided fine needle aspiration (FNA)|This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
214565716|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under popliteal sciatic nerve
214565717|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under an ankle block
214565718|NCT04650139|PROCEDURE|PCI - percutaneous coronary intervention|percutaneous coronary intervention
214565719|NCT02075073|BIOLOGICAL|SB3|
214565720|NCT02075073|BIOLOGICAL|EU sourced Herceptin®|
214565721|NCT02075073|BIOLOGICAL|US sourced Herceptin®|
214565722|NCT05923515|DRUG|JMKX000197|for injection
214708276|NCT02913742|PROCEDURE|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
214708277|NCT01244958|BIOLOGICAL|Rituximab|1000 mg Rituximab infusion
214708278|NCT01244958|DRUG|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
214708279|NCT02853981|DEVICE|Harmonic scalpel|a method for liver parenchymal transection
214708280|NCT02853981|DEVICE|Kelly clamp crush technique|a method for liver parenchymal transection
214708281|NCT03285906|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
214565723|NCT05731999|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
214565724|NCT05718063|BEHAVIORAL|MAP for Coaches - Complete Course|The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.
214565725|NCT05718063|BEHAVIORAL|Map for Coaches - Overview|This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
214565726|NCT00785993|OTHER|Vitrification of oocytes for IVF treatment|
214565727|NCT00785993|OTHER|Protocolary IVF treatment with fresh donor oocytes|
214565728|NCT00629733|DRUG|RO-14|
214565729|NCT02786550|DRUG|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
214565730|NCT02786550|OTHER|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
214565731|NCT02686684|DRUG|Dimethyl fumarate|
214565732|NCT00540865|BEHAVIORAL|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
214708282|NCT05161182|OTHER|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
214708283|NCT05161182|OTHER|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
214565733|NCT00540865|BEHAVIORAL|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
214565734|NCT02592993|DEVICE|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
214565735|NCT04458129|DRUG|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
214565736|NCT05922384|DRUG|KL-7SHRNA injection solution|Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
214565737|NCT02491515|DRUG|Denosumab|every 6 month injection
214565738|NCT02586428|OTHER|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
214565739|NCT06349356|DEVICE|Intense pulsed light with C.STIM device|4 flashes per treatment session
214565740|NCT05145543|DRUG|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
214565741|NCT05145543|DRUG|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
214565742|NCT05145543|DRUG|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
214565743|NCT05145543|DRUG|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
214565744|NCT01611597|OTHER|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
214565745|NCT03912051|DEVICE|asymmetric balloon|Asymmetric balloon for treatment of intranasal bleeding
214565746|NCT05976373|DRUG|Dupilumab (SAR231893)|injection solution subcutaneous
214565747|NCT03247868|COMBINATION_PRODUCT|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
214565748|NCT04957147|OTHER|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
214565749|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
214565750|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
214565751|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
214565752|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Control Vaccine
214565753|NCT01538966|DRUG|Pegvisomant|
214565754|NCT01538966|DRUG|Octreotide LAR|
214565755|NCT01538966|DRUG|Lanreotide|
214565756|NCT05418751|OTHER|Manual therapy|Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
214565757|NCT05418751|OTHER|Placebo treatment|Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
214565758|NCT03361605|DRUG|Propofol|Propofol administration
214565759|NCT02770612|OTHER|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
214565760|NCT04853641|PROCEDURE|Cadaveric|Cadaveric Organ Transplant
214565761|NCT04853641|PROCEDURE|Living Donor|Living Donor Organ Transplant
214565762|NCT02822430|OTHER|Pain scales|"* Visual analogic scale of pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Clinical Global impression~* Mini International Neuropsychiatric Interview (MINI)"
214565763|NCT05702385|OTHER|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
214565764|NCT03834324|DEVICE|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
214565765|NCT03698253|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
214565766|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
214565767|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
214565768|NCT03698253|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
214565769|NCT02369068|DRUG|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
214565770|NCT02369068|DRUG|Kenalog|Intravaginal pelvic floor injection one series
214565771|NCT06401070|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
214565772|NCT06401070|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
214565773|NCT01291030|DIETARY_SUPPLEMENT|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of \> 1,9 mg/dl.
214565774|NCT05416944|OTHER|Personalized blood pressure management|Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
214565775|NCT00958841|DRUG|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
214565776|NCT05648929|OTHER|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
214565777|NCT05648929|DIAGNOSTIC_TEST|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
214565778|NCT05648929|PROCEDURE|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
214565779|NCT05648929|PROCEDURE|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
214565780|NCT05648929|PROCEDURE|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
214565781|NCT05648929|OTHER|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
214565782|NCT05219994|OTHER|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
214565783|NCT05219994|OTHER|Normoxia Exposure|2 hours of normoxia exposure during OGTT
214565784|NCT05252442|OTHER|Pre-COVID-19|Pre-COVID-19 period
214565785|NCT05252442|OTHER|COVID-19|COVID-19 period
214565786|NCT05252442|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
214565787|NCT02402153|DEVICE|Hyposafe device|Subcutaneous EEG recorder for EEG measurements
214565788|NCT03908957|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
214565789|NCT00355290|BEHAVIORAL|Changes on Oral Vitamin K Intake|
214565790|NCT00932542|DRUG|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
214565791|NCT00932542|DRUG|placebo|placebo
214565792|NCT00932542|DRUG|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
214565793|NCT01962532|DRUG|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
214565794|NCT01962532|DRUG|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
214565795|NCT03466905|OTHER|Ambulant assessment|
214565796|NCT05591261|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
214565797|NCT03325491|DIETARY_SUPPLEMENT|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
214565798|NCT03325491|DIETARY_SUPPLEMENT|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
214565799|NCT04641676|DIAGNOSTIC_TEST|NGS testing|NGS test will be performed
214565800|NCT03183505|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
214565801|NCT03183505|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
214565802|NCT06186921|DRUG|Dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
214565803|NCT04716270|PROCEDURE|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
214565804|NCT05045274|DRUG|Dapagliflozin 10Mg Tab|"1. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.~2. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~3. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~4. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
214565805|NCT05045274|DRUG|Placebo|"1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
214565806|NCT02449551|DRUG|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
214565807|NCT01158079|DRUG|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
214565808|NCT06415149|PROCEDURE|High power short duration ablation with 50 W|Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
214565809|NCT06415149|PROCEDURE|High power short duration ablation with 45 W|Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
214565810|NCT00452777|DRUG|BVT.115959|
214565811|NCT00452777|DRUG|Placebo|
214565812|NCT03014011|OTHER|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
214565813|NCT03014011|OTHER|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
214565814|NCT03551327|BEHAVIORAL|Experimental: Intervention plus information|The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
214565815|NCT03551327|OTHER|Active Comparator: Information only|Participants in this arm will be provided with information about fatigue.
214565816|NCT02276144|OTHER|Liver ultrasound|For evaluate whether fatty liver is exist or not
214565817|NCT00956176|DRUG|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
214565818|NCT02416453|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.
214565819|NCT02416453|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
214565820|NCT02416453|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
214565821|NCT04573088|BEHAVIORAL|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
214565822|NCT00599703|OTHER|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
214565823|NCT03882580|DRUG|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
214565824|NCT01986764|DRUG|Lisdexamfetamine|
214565825|NCT01986764|DRUG|Estradiol|
214565826|NCT01986764|DRUG|Placebo|Placebo capsules will be filled with lactose powder.
214565827|NCT00418769|DRUG|Nilotinib|
214565828|NCT01955408|OTHER|Questionnaires, anticholinergic treatment, urodynamic study|
214565829|NCT04521751|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
214565830|NCT04521751|DRUG|EMP16-02 150 mg orlistat/50 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
214565831|NCT04521751|DRUG|Placebo|Matching oral placebo capsules
214565832|NCT04682860|DRUG|Hyoscine N Butylbromide|Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
214565833|NCT04682860|OTHER|Placebo|2 ml of normal saline injection as placebo
215030147|NCT06455033|OTHER|Manual Diaphragm Release Technique|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.
215030148|NCT06455033|OTHER|Breathing Exercise|"Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards."
215030149|NCT03544463|DEVICE|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
215030150|NCT06033560|DEVICE|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
215030151|NCT03003663|DEVICE|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
215030152|NCT03592355|OTHER|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
215030153|NCT01656122|DRUG|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
215030154|NCT01656122|DRUG|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
215030155|NCT01661283|DRUG|everolimus|10 mg tablet once daily
215030156|NCT01661283|DRUG|bevacizumab|10 mg/kg dose every 14 days
215030157|NCT02327169|DRUG|MLN2480|MLN2480 tablets.
215030158|NCT02327169|DRUG|MLN0128|MLN0128 capsules.
215030159|NCT02327169|DRUG|Alisertib|Alisertib tablets.
215030160|NCT02327169|DRUG|Paclitaxel|Paclitaxel IV infusion.
215030161|NCT02327169|DRUG|Cetuximab|Cetuximab IV infusion.
215030162|NCT02327169|DRUG|Irinotecan|Irinotecan IV infusion.
215030163|NCT02626884|DRUG|Ibrutinib|
214565834|NCT04525794|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
214565835|NCT01593475|RADIATION|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~\- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
214565836|NCT01143181|DRUG|Brincidofovir|Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
214565837|NCT01266551|DEVICE|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
214565838|NCT00359983|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
214565839|NCT00359983|BIOLOGICAL|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
214565840|NCT01486290|BEHAVIORAL|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
214565841|NCT03720951|RADIATION|pudendal nerve|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
214565842|NCT03720951|RADIATION|sacral n roots|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
214565843|NCT04025489|DIETARY_SUPPLEMENT|Randomized control trial of vitamin D supplementation|This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
214565844|NCT02320981|DIAGNOSTIC_TEST|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
214565845|NCT04408703|DIAGNOSTIC_TEST|Red Density|Image analysis of endoscopic images in patients with ulcerative colitis
214565846|NCT05512689|DEVICE|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
214565847|NCT02167009|DEVICE|Embosphere Microspheres|Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
214565848|NCT03101839|DRUG|AZD4785|KRAS Antisense Oligonucleotide
214565849|NCT05945589|BEHAVIORAL|Singapore A-Health Intervention|The Singapore A-Health Intervention spanned 12 weeks, with each weekly session lasting for two hours. The program is structured around three thematic domains of the past, present, and future. In each thematic domain consisting of four weeks, participants were tasked with creating an artwork related to the theme and incorporating the learned art techniques. The structure of each thematic domain follows the same structure: the first week involved a 45-minute docent-led gallery tour on three selected pieces of artworks, followed by a 75-minute artist-led brainstorming session where participants were introduced to the techniques and discuss ideas on the artwork to be created. The subsequent three sessions involved further guidance from the artist and a scaffolded delivery of art techniques for participants to incorporate their learning to their artwork. At the end of each domain, there was a showcase where participants present their artwork.
214565850|NCT00728897|DRUG|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
214565851|NCT00728897|DRUG|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
214565852|NCT02145559|DRUG|Metformin XR|
214565853|NCT02145559|DRUG|Delayed Metformin|
214565854|NCT02145559|DRUG|Sirolimus|
214565855|NCT03162562|BIOLOGICAL|Oregovomab|Monoclonal antibody against CA 125
214565856|NCT03162562|DRUG|Poly ICLC|Immune adjuvant
214565857|NCT00111410|DRUG|Anakinra (r-metHuIL-1ra)|
214565858|NCT00831129|DRUG|Rosiglitazone|4 mg daily
214565859|NCT00831129|DRUG|Placebo Rosiglitazone|1 tab daily
214565860|NCT00831129|DRUG|Simvastatin|40 mg daily
214565861|NCT02513303|DRUG|Sirolimus|A single dose of sirolimus delivered locally
214565862|NCT02513303|PROCEDURE|AV Fistula Surgery|AV Fistula Surgery
214565863|NCT02513303|DEVICE|Sirolimus-eluting Collagen Implant (SeCI)|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
214565864|NCT01877239|OTHER|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
214565865|NCT01992601|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
214565866|NCT01098318|DIETARY_SUPPLEMENT|Herbal extract|340-1,360 mg daily
214565867|NCT01098318|DRUG|Sertraline|50-200 mg daily
214565868|NCT01098318|OTHER|Lactose monohydrate|1-4 capsules daily
214565869|NCT00874692|OTHER|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
214565870|NCT02328859|OTHER|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
214565871|NCT02328859|OTHER|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
214565872|NCT04184232|BIOLOGICAL|Dendritic cells|Autologous dendritic cells primed with muc-1/wt-1 peptides
214565873|NCT04184232|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder cancer according to the Clinical protocols
214565874|NCT01038739|DRUG|Mesalazine|3 g per day
214565875|NCT01038739|DRUG|Mesalazine|1.5 g per day
214565876|NCT01038739|DRUG|Placebo|0 g per day
215030164|NCT05575102|OTHER|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
215030165|NCT02947971|DEVICE|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
215030166|NCT05206370|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
215030167|NCT05206370|DRUG|Placebo|film-coated oral tablets containing matched placebo
215030168|NCT05206370|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
215030169|NCT03132142|DRUG|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
215030170|NCT03132142|DRUG|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
215030171|NCT03132142|DRUG|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
214565877|NCT05880901|BEHAVIORAL|After school program|The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.
214565878|NCT05880901|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
214565879|NCT00743431|DRUG|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
214565880|NCT05978206|DRUG|Nandrolone Decanoate|Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
215030172|NCT03132142|DRUG|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
215030173|NCT05910346|BEHAVIORAL|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
214565881|NCT05978206|BEHAVIORAL|Physiotherapy Intervention|"The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate."
214565882|NCT05978206|BEHAVIORAL|Nutritional Intervention|An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
214565883|NCT05978206|DRUG|Placebo|Placebo
214565884|NCT03291288|DRUG|Tolbutamide|Commercially available tolbutamide
214565885|NCT03291288|DRUG|Midazolam|Commercially available midazolam
214565886|NCT03291288|DRUG|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
214565887|NCT04276415|DRUG|DS-6157a|Administered as a single agent intravenously (IV) every 3 weeks
214565888|NCT04385550|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214565889|NCT04385550|DRUG|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
214565890|NCT04385550|DRUG|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
214565891|NCT04385550|DRUG|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
214565892|NCT06137326|DEVICE|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
214565893|NCT06137326|DEVICE|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
214565894|NCT04434573|OTHER|Observation study|French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
214565895|NCT04173351|BEHAVIORAL|Education and Counseling|Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
214565896|NCT03091231|DIAGNOSTIC_TEST|mpUS multiparametric Ultrasound|compare the mpUS to other methods
214565897|NCT00074477|DRUG|R092670|
214565898|NCT03981328|DEVICE|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
214565899|NCT03981328|DEVICE|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
214565900|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
214565901|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions
214565902|NCT04561778|DEVICE|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
214565903|NCT04561778|DEVICE|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
214565904|NCT06266624|DIAGNOSTIC_TEST|Tourniquet Test|Tourniquet Test was performed in patients with HHT
214565905|NCT00312598|DRUG|Aripiprazole|
214565906|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
214565907|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
214565908|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
214565909|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
214565910|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
214565911|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
214565912|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
214565913|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
214565914|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
214565915|NCT02686619|DRUG|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
214565916|NCT02686619|DRUG|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
214565917|NCT02686619|DRUG|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
214565918|NCT02686619|DRUG|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
214565919|NCT02686619|DRUG|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
214565920|NCT03752086|PROCEDURE|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
214565921|NCT03752086|PROCEDURE|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
214565922|NCT00251706|DRUG|amiodarone|
214565923|NCT05914051|OTHER|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
214565924|NCT01989169|DRUG|Midazolam|
214565925|NCT01989169|DRUG|SSP-004184SS|
214565926|NCT01580553|DRUG|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
214565927|NCT01580553|DRUG|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
214565928|NCT00936572|PROCEDURE|Probiotics (La1, BB536)|
214565929|NCT00936572|BIOLOGICAL|probiotics (La1, BB536)|
214565930|NCT00936572|BIOLOGICAL|placebo|Maltodoxtrin
214565931|NCT00106301|DRUG|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
214565932|NCT02749110|DEVICE|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
214565933|NCT04761432|DEVICE|neoGuard|NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
214565934|NCT00139880|DRUG|Parcopa|
214565935|NCT05099432|PROCEDURE|CARMA technique|Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
214565936|NCT00948649|DRUG|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
214565937|NCT00948649|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
214565938|NCT02406677|OTHER|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
214565939|NCT01114880|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
214565940|NCT01114880|OTHER|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
214565941|NCT03656224|OTHER|Survey Administration|Ancillary studies
214565942|NCT00288002|BIOLOGICAL|trastuzumab|
214565943|NCT00288002|DRUG|capecitabine|
214565944|NCT00288002|DRUG|cyclophosphamide|
214565945|NCT00288002|DRUG|docetaxel|
214565946|NCT00288002|DRUG|epirubicin hydrochloride|
214565947|NCT00288002|PROCEDURE|adjuvant therapy|
214565948|NCT00288002|PROCEDURE|conventional surgery|
214565949|NCT00288002|PROCEDURE|neoadjuvant therapy|
214565950|NCT04672785|BEHAVIORAL|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
214565951|NCT05508204|DRUG|BION-1301|A solution for SC injection administered as a single dose
214565952|NCT01623193|OTHER|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
214565953|NCT01623193|PROCEDURE|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
214565954|NCT02613234|DEVICE|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
214565955|NCT02613234|DEVICE|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
214565956|NCT04531904|DEVICE|EMBOVAC Aspiration Catheter|The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.
214565957|NCT02251249|DRUG|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
214565958|NCT03585803|DRUG|KMRC011 5μg or Placebo|Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
214565959|NCT03585803|DRUG|KMRC011 10μg or Placebo|Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
214565960|NCT03585803|DRUG|KMRC011 15μg or Placebo|Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
214565961|NCT03585803|DRUG|KMRC011 20μg or Placebo|Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
214565962|NCT03585803|DRUG|KMRC011 25μg or Placebo|Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
214565963|NCT04997772|DEVICE|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
214565964|NCT00566189|PROCEDURE|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
214565965|NCT04461444|GENETIC|Skin biopsy|"COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~* risk of pain due to the procedure performed under local anaesthesia~* can leave a visible scar (about 2 x 1 cm)"
214565966|NCT03655457|DEVICE|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
214565967|NCT03655457|DEVICE|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
214565968|NCT02260323|OTHER|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
214565969|NCT02260323|OTHER|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
214565970|NCT06272396|DEVICE|Smart watch|ECG 1D/6D
214565971|NCT00283244|DRUG|erlotinib hydrochloride|given orally
214565972|NCT00283244|DRUG|gemcitabine hydrochloride|given IV
214565973|NCT05670015|DRUG|Low dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
214565974|NCT05670015|DRUG|High dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
214565975|NCT01934348|BEHAVIORAL|Psychological First Aid|
214565976|NCT01934348|BEHAVIORAL|Usual victim advocacy Services|
214565977|NCT06900218|DRUG|Sintilimab|Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles
214565978|NCT06900218|DRUG|Capecitabine|Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.
214565979|NCT06900257|PROCEDURE|Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.|All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
214565980|NCT06907927|BEHAVIORAL|Control group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
214565981|NCT06907927|BEHAVIORAL|Experimental group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
214565982|NCT06906757|DRUG|Erythromycin 250mg + placebo|Antibiotic.
214565983|NCT06906757|DRUG|Azithromycin 500mg + placebo|Antibiotic.
214565984|NCT06906757|DRUG|Erythromycin 250mg and Amoxicillin 500mg|Antibiotics.
214565985|NCT06906692|DIAGNOSTIC_TEST|Serum Bactericidal Assay|The Serum Bactericidal Assay (SBA) will be used for the analysis of the antibody titer, which represents a valid surrogate for the efficacy of the tetravalent vaccine. Subjects' sera will be serially diluted and incubated with a solution containing a certain strain of meningococcus. At this point, an exogenous source of rabbit complement will be added. Bactericidal activity will be assessed against controls. Neutralizing antibody titers will be defined as the highest dilution of sera at which at least 50% of bacteria death occurs. Antibody titers will be considered protective with a cut-off greater than or equal to 1:8.
214565987|NCT07155460|DEVICE|HDC-GCog|Surface electromyography records
214565988|NCT07156032|DEVICE|Starpen automatic injection device|Starpen device will be used on high speed 45-150s with the conventional carpule of articaine HCL 4% with 1:100,000 epinephrine and short needle
214565989|NCT07156032|PROCEDURE|conventional syringe|injection will be done using conventional metal syringe with articaine HCL 4% with 1:100,000 epinephrine and short needle
214565990|NCT07154303|DIAGNOSTIC_TEST|Computer algorithms|Computer algorithms that are designed to perform heart sound, ECG, and/or facial photoplethysmography analysis on data collected from smartphone's internal hardware and/or external accessories.
214565991|NCT05655273|DRUG|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
214565992|NCT05655273|DRUG|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
214565993|NCT04500769|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
214565994|NCT05812820|COMBINATION_PRODUCT|LiveSpo DIA30|LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
214565995|NCT05812820|COMBINATION_PRODUCT|LiveSpo CLAUSY|LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
214565996|NCT05812820|OTHER|RO|"Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle"
214565997|NCT04642807|PROCEDURE|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
214565998|NCT04642807|PROCEDURE|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
214565999|NCT01967147|DRUG|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
214566000|NCT01967147|DRUG|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
214566001|NCT03986164|DEVICE|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
214566002|NCT03986164|DEVICE|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
214566003|NCT04852341|DEVICE|Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth|observation
214566004|NCT05253157|OTHER|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
214566005|NCT00012324|DRUG|doxorubicin hydrochloride|
214566006|NCT00012324|DRUG|nolatrexed dihydrochloride|
214566007|NCT01774877|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
214566008|NCT01774877|DRUG|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
215030174|NCT00952692|BIOLOGICAL|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~* One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~* One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
215030175|NCT00952692|DRUG|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
214566009|NCT05199987|BEHAVIORAL|Standard Occupational Therapy|Standard occupational therapy sessions include patient therapeutic education (implementation of strategies and/or technical aids promoting autonomy and independence), walking and stair exercises in real-life conditions (weighted shopping bag, unstable ground, ...), as well as work on activities of daily living aiming to improve toileting skills (includes individual assessment, the use of technical aids depending of this assessment, and personalised strategies to conserve energy).
214566010|NCT05199987|BEHAVIORAL|Occupational Therapy with Breathing Control Exercises|Includes the same treatment than the one described in standard occupation therapy but with the addition of 30-minute sessions per day on breathing control exercises. These exercises included the reproduction of gestures reproducing daily activities and simultaneous explanations of breathing techniques that the patient can perform in order to set up strategies for saving breath during exercise.
214566012|NCT04777370|OTHER|posterior glide mobilization|The participant will be positioned supine on a plinth, with their scapula stabilized against a firm wedge on the table, and the shoulder joint in the resting position (approx. 55 degrees abduction, 30 degrees horizontal adduction, and slight external rotation). With the extremity held in the same position, the researcher will then apply a grade III (into tissue stretch) PG mobilization. This will consist of five 30-second bouts of sustained gr III posterior glide mobilizations.
214566013|NCT04777370|OTHER|Sleeper stretch|All participants randomized to the stretching group will perform five 30-second holds of the sleeper stretch. This is performed by lying on the side to be stretched, elevating the upper arm to 90° on the support surface with the elbow bent 90°, then passively internally rotating the shoulder with force provided by with the opposite arm.
214566014|NCT04777370|OTHER|thoracic manipulation|"Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed."
214566015|NCT03505177|DIETARY_SUPPLEMENT|Chitin-glucan fiber|4.5g per day of chitin-glucan during 3 weeks
214566016|NCT01788462|DRUG|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
214566017|NCT02523859|DRUG|Propofol|Hypnotic drug used for anesthesia
214566018|NCT02523859|DRUG|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
214566019|NCT00389701|DRUG|bortezomib|
214566020|NCT00389701|DRUG|dexamethasone|
214566021|NCT00001629|DRUG|Angiotensin II type 1 receptor antagonists|
214566022|NCT00329147|DRUG|desvenlafaxine SR|
214566023|NCT00329147|DRUG|desipramine|
214566024|NCT00329147|DRUG|paroxetine|
214566025|NCT01502683|PROCEDURE|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
214566026|NCT01502683|PROCEDURE|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
214566027|NCT01502683|PROCEDURE|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
214566028|NCT01502683|PROCEDURE|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
214566029|NCT00898209|GENETIC|protein expression analysis|Blood and exhaled breath condensate will be collected.
214566030|NCT00898209|GENETIC|proteomic profiling|Blood and exhaled breath condensate will be collected.
214566031|NCT00898209|OTHER|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
214566032|NCT00898209|OTHER|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
214566033|NCT00898209|OTHER|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
214566034|NCT00898209|OTHER|questionnaire administration|Questionnaire will be completed.
214566035|NCT03455803|DEVICE|CPAP|Continuous positive airway pressure
214566036|NCT05302492|DEVICE|CPAP|CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.
214566037|NCT05302492|DEVICE|Light box|Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
214566038|NCT00544310|BIOLOGICAL|Anti adhesion agent|Adhesions prevention
214566039|NCT02885844|PROCEDURE|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
214566040|NCT02885844|PROCEDURE|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
214708284|NCT05930990|BEHAVIORAL|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
214708285|NCT03452891|OTHER|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
214566041|NCT04147520|BEHAVIORAL|Brief Motivational Interview|Single (60 min) session discussion of alcohol use and associated experiences.
214566042|NCT02862587|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
214566043|NCT02862587|BIOLOGICAL|precision cells|precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
214566044|NCT05301647|DIAGNOSTIC_TEST|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
214566045|NCT05301647|OTHER|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
214708286|NCT03452891|DRUG|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
214708287|NCT00002212|DRUG|Bexarotene|
214708288|NCT00002247|DRUG|Ganciclovir|
214708289|NCT05836363|PROCEDURE|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
214708290|NCT04744701|DIAGNOSTIC_TEST|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
214708291|NCT04776421|PROCEDURE|Diverting ileostomy|Diverting ileostomy
215030176|NCT02878863|DRUG|Paeoniflorin + phosphatidylcholine or silymarin|
215030177|NCT02878863|DRUG|Phosphatidylcholine or silymarin|
215030178|NCT04548960|OTHER|cancer patients|Blood sample RNA\_seq at time of diagnostic, best response and relapse ; Biopsy Exom\_seq and RNA\_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
215030179|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
214566046|NCT05301647|OTHER|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
214566047|NCT05301647|OTHER|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
214566048|NCT06146127|OTHER|phenotyping|Large scale molecular phenotyping
214566049|NCT04997681|BEHAVIORAL|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
214566050|NCT04997681|BEHAVIORAL|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
214566051|NCT04997681|BEHAVIORAL|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
214566052|NCT04997681|BEHAVIORAL|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
214566053|NCT01293045|DIETARY_SUPPLEMENT|hydrolyzed collagen|10g/day at breakfast during 90 days
214566054|NCT01293045|DIETARY_SUPPLEMENT|wheat protein|10g/day at breakfast during 90 days
214566055|NCT01350284|DIETARY_SUPPLEMENT|Cinnamon|acute oral administration of 3 g cinnamon
214566056|NCT01350284|DIETARY_SUPPLEMENT|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
214566057|NCT01733537|OTHER|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
214566058|NCT01733537|BEHAVIORAL|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
214566059|NCT03976492|DIAGNOSTIC_TEST|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
214566060|NCT04237025|OTHER|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
214708292|NCT02711904|DRUG|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h."
214566061|NCT04752410|PROCEDURE|Selective Brachial Plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
214566062|NCT01497353|PROCEDURE|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
214566063|NCT01497353|PROCEDURE|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
214566064|NCT00550589|DRUG|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
214566065|NCT00550589|GENETIC|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
214566066|NCT00550589|GENETIC|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
214566067|NCT00550589|GENETIC|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
214566068|NCT00550589|PROCEDURE|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
214566069|NCT00550589|PROCEDURE|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
214566070|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
214566071|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
214566072|NCT05470647|BIOLOGICAL|Placebo|Placebo was injected subcutaneously.
214566073|NCT02333305|DIETARY_SUPPLEMENT|CoQ10|• 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
214566074|NCT02333305|OTHER|Sanomit Placebo|• according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
214566075|NCT00166712|DRUG|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
214566076|NCT00166712|DRUG|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
214566077|NCT00166712|DRUG|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
214566078|NCT00166712|DRUG|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
214566079|NCT00350350|DEVICE|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
214566080|NCT00350350|DEVICE|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :~* 94.4% of oxygenated oil~* Silicium dioxide~* aspartame artificial flavoring"
214566081|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
214566082|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
214566083|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
214566084|NCT04764461|OTHER|Use of customised GROW Charts|Intervention group will follow the same antenatal visit plan and two ultrasounds will be offered (NT 11-13+6 weeks \& anomaly scan 19-22 weeks of gestation) in routine. A third trimester scan will not be offered in routine to Intervention group. Serial SFH measurements will be plotted against estimated date of delivery at each review from 26 weeks of gestation on the customized GROW chart already attached in the maternity notes. On each visit patient will be examined after emptying bladder in a semi-recumbent position, using non-elastic tape with cm side hidden; measurement will be taken from the fundus to upper margin of pubic symphysis. Abnormal SFH measurements, when plotted below the 10th or does not follow its trajectory on customized growth charts will be referred for growth scan suspecting SGA. SFH plotted above 90th centile will also be referred for growth scan, as a part of antenatal care.
214566085|NCT06115629|OTHER|Surveillance protocol|Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
214566086|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
214566087|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
214566088|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
214566089|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
214566090|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
214566091|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
214566092|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
214566093|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
214566094|NCT04771754|DRUG|Dolutegravir|50 mg once daily orally
214566095|NCT00245921|DRUG|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
214566096|NCT02409069|DEVICE|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
214566097|NCT02409069|DEVICE|Sham stimulation (Nemos®, Cerbomed GmbH)|
214566098|NCT03866291|OTHER|No intervention, observational|See above
214566099|NCT05298722|DIAGNOSTIC_TEST|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"* The images from CT scans and MRI with DWI will be processed using specialized software to determine the direction of diffusion tensors. This will indicate the diffusion direction using color coding (red, green, and blue for the x, y, and z components of the vector) and the intensity using anisotropy (brightness of voxels). Further analysis will be performed using fiber tracking, which provides a clear representation of the functional connectivity of adjacent tissues.~* Genetic profiling of liquid biopsies: Multi-omics profiling of liquid biopsies (blood samples) will be conducted, followed by cell phenotyping, longitudinal analysis of driver mutations and epigenetic changes in cfDNA, and genotyping of germline variations.~* Questionnaires for patient-reported outcomes and health economic analysis:~EQ-5D-5L PAN 26 HADS"
214566100|NCT03795753|DEVICE|F2S Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
214566101|NCT03795753|OTHER|Non-functioning Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
214566102|NCT00924690|OTHER|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
214566103|NCT00924690|OTHER|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
214566104|NCT04808752|DRUG|Almonertinib|Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
214566105|NCT00352326|DEVICE|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
214566106|NCT05229276|OTHER|Sternum Guard|"The intervention being assessed is a surgical drape used as a cover of sternal bones and the neighboring structures exposed during median sternotomy named Sternum Guard.~Sternum guard® is a single use, sterile surgical drape with modified cellulose designed specifically to reduce the risk of surgical site infection (SSI).~It is made of 4 parts, the main part is in contact with the retractors and the sternum edge. It is made of carboxymethylated cellulose (CMC) spunlace which makes direct contact with the sternum edges. It contributes to blood absorption, to decreasing of pH environment, and to haemostatic action through a physical effect (compression); another part was made from hydrophilic spunbond (swabs) allowing blood absorption, comfort and protection"
214566107|NCT05229276|OTHER|Bone Wax|patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
214566108|NCT03081364|OTHER|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
214566109|NCT00085553|DRUG|Erlotinib Hydrochloride|Given PO
214566110|NCT00085553|OTHER|Laboratory Biomarker Analysis|Correlative studies
214566111|NCT00085553|OTHER|Pharmacological Study|Correlative studies
214566112|NCT00085553|DRUG|Tipifarnib|Given PO
214708293|NCT02711904|DRUG|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h."
214566113|NCT02768532|DRUG|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
214566114|NCT03339245|OTHER|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
214566115|NCT03339245|OTHER|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
214566116|NCT02897050|DRUG|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
214566117|NCT02897050|DRUG|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
214566118|NCT02897050|DRUG|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
214566119|NCT02897050|DRUG|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
214566120|NCT02897050|DRUG|Epirubicin|Epirubicin 100mg/m2, iv, d1
214566121|NCT02897050|DRUG|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
214566122|NCT00964275|PROCEDURE|diagnostic procedure|Standard diagnostic procedures followed
214566123|NCT00964275|RADIATION|fludeoxyglucose F 18|PET with flueoxyglucose F 18
214566124|NCT03916679|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
214566125|NCT06182553|OTHER|Expiratory Rib Cage Compression|Expiratory rib cage compression (ERCC) In this study, ERCC is a technique consisting of bilateral manual compression of the lower rib cage (anterolateral region of the chest at the level of the six last ribs) gradually during the expiratory phase of the ventilatory cycle and release from the compression at the end of the expiration.
214708294|NCT05405907|OTHER|PuraBond haemostatic agent|Application of Purabond to surgical field
214708295|NCT02878512|PROCEDURE|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
214708296|NCT02878512|PROCEDURE|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
214566126|NCT06182553|OTHER|PEEP-ZEEP Maneuver|PEEP-ZEEP maneuver In this study, PEEP-ZEEP maneuver refers to PEEP which stands for positive end-expiratory pressure, and ZEEP which stands for zero end-expiratory pressure. In this maneuver PEEP will be incremented to 15 cmH2O throughout five consecutive respiratory cycles, then immediately after the inspiratory phase of the fifth cycle has been ended ZEEP should be done by abruptly reducing PEEP value to 0 cmH2O. The PEEP-ZEEP maneuver should be performed in two sets, consisting of a total of 10 consecutive breathing cycles. Subsequently, the patient is ventilated according to his/her baseline ventilator parameters.
214566127|NCT06182553|OTHER|ERCC + PEEP-ZEEP maneuver|\- The ERCC technique will be applied as mentioned above, then followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before.
214566128|NCT01570959|DRUG|Quetiapine Fumarate|300 mg tablet
214566129|NCT04389151|DRUG|Toripalimab|Toripalimab union CAPEOX scheme： Toripalimab 240mg, ivgtt, Q3w Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w
214566130|NCT05154877|DEVICE|OMNI PET/CT Scan|The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.
214566131|NCT02166996|PROCEDURE|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
214566132|NCT02166996|PROCEDURE|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
214566133|NCT00000444|DRUG|nicotine replacement patch|
214566134|NCT04630041|BEHAVIORAL|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
214566135|NCT05557175|DEVICE|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
214566136|NCT05557175|DEVICE|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
214708297|NCT02330107|OTHER|MAT & LAT|"For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
214566137|NCT04143945|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
214566138|NCT04143945|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
214566139|NCT04370548|DRUG|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
214566140|NCT04850677|OTHER|Observational Cohort|Observational study
214708298|NCT06275243|DIAGNOSTIC_TEST|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
214708299|NCT06275243|OTHER|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
214566141|NCT00306670|DRUG|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
214566142|NCT00306670|DRUG|prednisone|\<30 mg/day
214566143|NCT00159939|PROCEDURE|prone positioning|prone positioning
214566144|NCT05775081|OTHER|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
214566145|NCT03450837|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
214566146|NCT03450837|DIAGNOSTIC_TEST|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
214566147|NCT02776722|OTHER|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
214566148|NCT00072228|DRUG|gemcitabine|
214566149|NCT00072228|DRUG|soblidotin|
214708300|NCT06275243|OTHER|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
214566150|NCT00072228|PROCEDURE|chemotherapy|
214566151|NCT02735655|OTHER|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
214566152|NCT02169362|DEVICE|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
214566153|NCT06229652|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
214566154|NCT06229652|OTHER|Body-oriented Yoga|"Body-oriented Yoga following the Ashtanga style will be held by certified yoga teacher parallel to the experimental one hour per week 10 times.~Each yoga session will start with the proper warming up of the whole body with some stretching exercises (20 min). The main part will last about 30 minutes and consist of dynamic and active yoga sequencing containing sun salutation with a mix of exercises. A relaxation phase with controlled breathing and meditation-elements will finish the class (10 min). Each exercise has different complexity levels of implementation and will be adapted to the performance abilities of each participant."
214566155|NCT01178697|DRUG|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
214566156|NCT01178697|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
214566157|NCT03275597|DRUG|Durvalumab|Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
214708301|NCT06016140|OTHER|Medication plan|Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
214708302|NCT00899210|OTHER|laboratory biomarker analysis|
214566158|NCT03275597|DRUG|Tremelimumab|Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
214566159|NCT03275597|RADIATION|Stereotactic Body Radiotherapy|SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
214566160|NCT03690583|DRUG|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
214566161|NCT03690583|OTHER|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
214566162|NCT00503139|DRUG|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
214566163|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL of\[ 5\]µg dexmedetomidine. The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
214566164|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL normal saline . The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
214708303|NCT00899210|PROCEDURE|cryosurgery|
214708304|NCT00899210|PROCEDURE|radiofrequency ablation|
214708305|NCT00899210|PROCEDURE|therapeutic conventional surgery|
214708306|NCT05767710|BEHAVIORAL|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
214566165|NCT02735577|DRUG|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
214566166|NCT01640470|DEVICE|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
214566167|NCT01640470|DEVICE|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
214566168|NCT01800682|DRUG|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
214566169|NCT02731690|DRUG|Aceneuramic Acid Extended-Release|oral tablets
214566170|NCT04723914|BIOLOGICAL|dual target CAR-T cell therapy|CD19/CD20 dual target CAR-T cell therapy
214566171|NCT04340791|BEHAVIORAL|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
214566172|NCT04340791|BEHAVIORAL|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
214566173|NCT05253300|OTHER|Positioning the patient|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
214566174|NCT00833833|DRUG|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
214566175|NCT00833833|DRUG|Dexamethasone|oral dexamethasone
214566176|NCT00833833|DRUG|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
214566177|NCT01291823|DRUG|gefitinib|gefitinib 250mg/day
214566178|NCT01291823|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
214566179|NCT02365727|DRUG|Liposomal bupivacaine|
214566180|NCT02365727|DRUG|Ropivacaine|
214566181|NCT02365727|DRUG|Epinephrine|
214566182|NCT02365727|DRUG|Clonidine|
214566183|NCT02365727|DRUG|Saline|
214566184|NCT02814084|DEVICE|Bilateral Internal Mammary Artery grafts|Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
214566185|NCT02814084|DEVICE|Prevena|The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
214566186|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
214566187|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
214566188|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
214566189|NCT01994837|DRUG|ABT-199|Tablet
214566190|NCT04135690|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
214566191|NCT04135690|DRUG|Toripalimab|240mg intravenously every 3 weeks
214566192|NCT04135690|DRUG|Sorafenib|400mg bid po
214566193|NCT04135690|DRUG|systemic treatment|atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on
214566194|NCT00518544|DRUG|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
214566195|NCT02630108|PROCEDURE|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
214566196|NCT02630108|DRUG|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
214566197|NCT02630108|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
214566198|NCT02630108|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
214566199|NCT03206892|DEVICE|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
214566200|NCT06363071|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
214566201|NCT06363071|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
214566202|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
214566203|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
214566204|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
214566205|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
214566206|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
214566207|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
214566208|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
214566209|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
214566210|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
214566211|NCT01262677|DRUG|placebo|matched to the active drug
214566212|NCT02913053|BEHAVIORAL|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
214566213|NCT02913053|BEHAVIORAL|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
214566214|NCT03356782|BIOLOGICAL|Sarcoma-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
214566215|NCT02905071|OTHER|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
214566216|NCT02905071|OTHER|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
214566217|NCT02905071|OTHER|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
214566218|NCT05180929|DEVICE|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
214566219|NCT05180929|DEVICE|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
214566220|NCT05180929|DEVICE|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
214566221|NCT04512703|DEVICE|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
214566222|NCT05416073|DRUG|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
214566223|NCT05416073|DRUG|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
214566224|NCT05316272|BEHAVIORAL|Exercise|Supervised bone-loading exercise on 3 days per week for 36 weeks
214566225|NCT05316272|DIETARY_SUPPLEMENT|DHEA|DHEA in pill form 50 milligrams taken daily for 36 weeks
214566226|NCT05621577|DEVICE|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
214566227|NCT02043964|PROCEDURE|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
214566228|NCT01440998|DRUG|Carboplatin|Given IV
214566229|NCT01440998|DRUG|Dasatinib|Given PO
214566230|NCT01440998|OTHER|Laboratory Biomarker Analysis|Correlative studies
214566231|NCT01440998|DRUG|Paclitaxel|Given IV
214566232|NCT02541955|DRUG|Acthar|Injections will be self administered
214566233|NCT02055781|DRUG|Pacritinib|
214566234|NCT02055781|DRUG|Best Available Therapy|
214566235|NCT03623945|OTHER|Collection of blood|Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
214566236|NCT03017573|PROCEDURE|Tumor biopsies / Tumor surgery|"Tumoral tissues samples must be collected at different times points :~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)~OR~* before neoadjuvant therapy~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)"
215030180|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
214566237|NCT03017573|PROCEDURE|Blood withdrawal|"Blood samples must be collected at different times points :~* at the time of surgery or before the beginning of chemoradiotherapy~* after surgery or after chemoradiotherapy~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression~OR~* before neoadjuvant therapy~* during neoadjuvant therapy (post cycle 1)~* at the time of surgery~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression"
214566238|NCT06204445|DIETARY_SUPPLEMENT|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
214566239|NCT06204445|DIETARY_SUPPLEMENT|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
214566240|NCT06233890|DEVICE|Motion watch|Actigraphy watch to be worn for 14 days
214566241|NCT05769556|OTHER|Brain Gym Exercises|Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.
214566242|NCT05769556|OTHER|Traditional physiotherapy|A Group of exercises
214566243|NCT01791387|DRUG|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
214566244|NCT04330001|DEVICE|Alcon Fluid Accommodating Intraocular Lens|Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.
214566245|NCT04330001|OTHER|Top Con Autorefractor|Device intended to automatically determine the focusing characteristics of the eye
214566246|NCT01355900|PROCEDURE|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
214708307|NCT05767710|BEHAVIORAL|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
214566247|NCT01231009|DRUG|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
214566248|NCT01231009|OTHER|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
214566249|NCT03837210|DRUG|Pylorin|Poly Herbal formulation
214566250|NCT01671254|DIETARY_SUPPLEMENT|FishOil|
214566251|NCT01671254|DIETARY_SUPPLEMENT|CBE75|
214566252|NCT01671254|DIETARY_SUPPLEMENT|CBE150|
214566253|NCT01671254|DIETARY_SUPPLEMENT|placebo|
214566254|NCT04199832|DIETARY_SUPPLEMENT|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
214566255|NCT04681599|DEVICE|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
214566256|NCT04681599|DEVICE|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
214566257|NCT06080243|BIOLOGICAL|R21/Matrix-M1|10 µg of R21 and 50 µg of Matrix-M1
214566258|NCT06080243|BIOLOGICAL|Saline and R21/Matrix-M1|Saline and 10 µg of R21 and 50 µg of Matrix-M1
214566259|NCT06080243|OTHER|Sterile isotonic (0.9%) normal saline|Saline
214566260|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
214566261|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
214566262|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
214566263|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
214566264|NCT03387748|BEHAVIORAL|Gesture elicitation|"* Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~* Participants retell a cartoon to the researcher~* The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
214566265|NCT03446781|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
214566266|NCT03446781|BIOLOGICAL|Placebo|Placebo
214566267|NCT00056992|DRUG|ADI-PEG 20|
214566268|NCT05550090|DRUG|Chemotherapy|All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
214566269|NCT01899898|OTHER|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~1. Pictorial representation of various food items and exchange lists will be provided.~2. Instead of weights, we will provide standardized measures~3. We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~4. We will formulate recipes and diets based on locally available and culturally acceptable foods.~5. We will develop a parent instruction manual.~6. We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~7. We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
214566270|NCT01899898|DRUG|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
214566271|NCT02508220|DRUG|Syntocinon|Oxytocin nasal spray
214566272|NCT02508220|DRUG|Placebo|distilled water in nasal spray
214566273|NCT02093949|PROCEDURE|Routine substrate ablation without pulmonary vein Isolation|
214566274|NCT02093949|PROCEDURE|Routine conventional ablation with pulmonary vein Isolation|
214566275|NCT02551718|OTHER|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
214566276|NCT02551718|OTHER|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
214566277|NCT02551718|GENETIC|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
214566278|NCT02551718|GENETIC|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
214566279|NCT02551718|DRUG|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
214566280|NCT00858377|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
214566281|NCT00858377|DRUG|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
214566282|NCT02450045|PROCEDURE|Continuous femoral nerve block|
214566283|NCT02450045|DRUG|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
214566284|NCT05331573|DEVICE|apomorphine pump|observationnal
214566285|NCT02796300|DEVICE|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
214566286|NCT02796300|DEVICE|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
214566287|NCT05490238|PROCEDURE|Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)|Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
214566288|NCT02078843|DRUG|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
214566289|NCT02078843|DRUG|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
214566290|NCT05141500|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~* 1859 \& 2329~* MAX-A \& MAX-N"
214566291|NCT02590900|DRUG|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
214566292|NCT00957177|DRUG|Pregabalin|300mg pregabalin orally 1 hour before operation
214566293|NCT00957177|DRUG|Placebo|Placebo
214566294|NCT00449605|DRUG|Rimonabant|Tablet, oral administration
214566295|NCT00449605|DRUG|Glimepiride|Tablet, oral administration
214566296|NCT00449605|DRUG|Metformin|Metformin continued at stable dose as background therapy
214566297|NCT00044265|DRUG|ramipril|
214566298|NCT05246527|BEHAVIORAL|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
214566299|NCT05246527|BEHAVIORAL|Control Intervention|30 min of watching a movie
214566300|NCT01638429|DRUG|Neomycin|Neomycin: 500mg po bid for 10 days
214566301|NCT01638429|DRUG|Rifaximin|Rifaximin: 550mg po tid for 10 days
214566302|NCT04909398|BEHAVIORAL|Dynamic pupillometry sessions|"The evaluation protocol will include the following steps:~* Installation of the subject, adaptation of the chin rest for the best comfort of the participant~* Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen~* Final validation of the eligibility of the subject in the study according to the success or not of the calibration."
214708308|NCT05767710|BEHAVIORAL|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
214566303|NCT01281059|DEVICE|BreathID - Breath Test - 13C Octanoate|
214566304|NCT06426420|DIAGNOSTIC_TEST|FTIR spectroscopy analysis|ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.
214566305|NCT02703181|DRUG|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
214566306|NCT02703181|DRUG|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
214566307|NCT04610541|DRUG|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
214566308|NCT02486276|DRUG|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214566309|NCT02486276|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214566310|NCT02486276|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214566311|NCT05589805|DEVICE|Extracorporeal shock wave therapy|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
214566312|NCT05589805|DEVICE|Laser therapy|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
214566313|NCT05589805|OTHER|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
214566314|NCT04761900|DIAGNOSTIC_TEST|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
214566315|NCT06308887|DRUG|Triamcinolone Hexacetonide|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 0.5 mg/5 ml of triamcinolone acetonide was injected.
214566316|NCT06308887|DRUG|Dextrose 5% in water|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 5 ml of 5% dextrose was injected.
214566317|NCT01205334|BIOLOGICAL|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
214566318|NCT04338659|BIOLOGICAL|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
214566319|NCT06475430|BIOLOGICAL|fecal microbiota transplantation|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration.
214566320|NCT06475430|DIETARY_SUPPLEMENT|Formulated probiotic supplements|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the control group receiving a standardized probiotic formula.
214566321|NCT05635201|DRUG|Anesthesia induction with propofol|After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
214566322|NCT05635201|DRUG|Anesthesia induction with remimazolam|After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
214566323|NCT03257943|DRUG|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
214566324|NCT03257943|DRUG|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
214566325|NCT03257943|DRUG|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
214566326|NCT04398290|DRUG|Inhaled nitric oxide (iNO)|iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
214566327|NCT04398290|DRUG|Nitrogen gas|250 mcg/kg ideal body weight (IBW)/hour
214566328|NCT04398290|DRUG|Oxygen gas|Supplemental oxygen administered via nasal cannula
214566329|NCT00859729|BIOLOGICAL|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
214566330|NCT00859729|DEVICE|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
214566331|NCT04439162|PROCEDURE|retrograde cardioplegia protection|antegrade-retrograde cardioplegia
214566332|NCT04421443|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
215030181|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
215030182|NCT05389072|DEVICE|control contact lens|control CRT lens
215030183|NCT02002325|DRUG|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
215030184|NCT02002325|OTHER|Standard care|Standard treatment for acute stroke without intravenous alteplase.
215030185|NCT05106556|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
215030186|NCT05106556|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
215030187|NCT03715907|BEHAVIORAL|Financial Incentives|Incentives for gap closure.
215030188|NCT03715907|BEHAVIORAL|Information|Information on care gap and closure process.
215030189|NCT00849992|DRUG|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
215030190|NCT00849992|PROCEDURE|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
215030191|NCT03470025|OTHER|Psychological Intervention|"1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
215030192|NCT04879407|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
215030193|NCT04879407|DRUG|Warfarin|Any warfarin dispensing claim is used as the reference group
215030194|NCT02294864|DEVICE|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
215030195|NCT02294864|PROCEDURE|Physical Therapy|
215030196|NCT05399173|DEVICE|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
215030197|NCT05399173|DRUG|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
215030198|NCT03755193|DRUG|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
215030199|NCT03755193|DRUG|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
215030200|NCT03755193|DRUG|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
215030201|NCT00187109|DRUG|Recombinant Human Thrombopoietin|
215030202|NCT02094235|DRUG|E6005 0.05%|
215030203|NCT02094235|DRUG|Placebo|0.5 g placebo ointment
215030204|NCT02094235|DRUG|E6005 0.2%|
215030205|NCT06365463|BEHAVIORAL|Telerehabilitation|The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
215030206|NCT04330859|OTHER|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
215030207|NCT04330859|OTHER|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
214566333|NCT05374200|OTHER|Mind-body intervention with 1-1 support from study personnel|"The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (\~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered."
214566334|NCT05838560|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
214566335|NCT05838560|DRUG|quercetin|The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
214566336|NCT02885324|DRUG|Cabozantinib|Subjects will receive Cabozantinib
214566337|NCT03457870|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
214566338|NCT03457870|BEHAVIORAL|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
214566339|NCT03457870|BEHAVIORAL|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
214566340|NCT00996476|DRUG|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
214566341|NCT00996476|DRUG|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
214566342|NCT00996476|DRUG|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
214566343|NCT06466720|BEHAVIORAL|Neurocognitive testing|The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
214566344|NCT06466720|BEHAVIORAL|Quality of Life questionnaire|The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
214566345|NCT06466720|RADIATION|Stereotactic radiosurgery|This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
214566346|NCT04285138|OTHER|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
214708309|NCT05767710|BEHAVIORAL|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
215030208|NCT05480007|DRUG|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
215030209|NCT05480007|DRUG|Sitagliptin|sitagliptin treatment (100mg per day)
215030210|NCT05480007|DRUG|Metformin|metformin group who received metformin (500mg three times per day)
215030211|NCT03982810|DRUG|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
215030212|NCT01381679|DRUG|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
215030213|NCT02106806|DIETARY_SUPPLEMENT|Zinc|35 mg of elemental zinc twice daily for 16 weeks
215030214|NCT02106806|OTHER|Placebo|One capsule, twice daily for 16 weeks
215030215|NCT03129906|DIETARY_SUPPLEMENT|Gluten|
215030216|NCT03129906|DIETARY_SUPPLEMENT|Rice protein|
215030217|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 100 and 150
215030218|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
215030219|NCT00420537|DRUG|Mycophenolate mofetil|mycophenolate with low doses
214566347|NCT04285138|OTHER|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror \[Figure 1\]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
214566348|NCT04290559|PROCEDURE|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
214566349|NCT01851499|DIETARY_SUPPLEMENT|Ultramicronized PEA (Normast)|600 mg
214566350|NCT00473265|DRUG|PTH|
214566351|NCT02488538|DRUG|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
214566352|NCT02488538|DRUG|Fluoxetine|women will receive oral fluoxetine 20 mg daily
214566353|NCT02488538|DRUG|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
214566354|NCT02488538|DRUG|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
214566355|NCT02488538|PROCEDURE|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
214566356|NCT00519519|DRUG|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
214566357|NCT01802567|DEVICE|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
214566358|NCT00588978|BEHAVIORAL|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
214566359|NCT04513652|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
214566360|NCT04513652|DRUG|Placebo|Placebo Topical Ophthalmic Solution
214566361|NCT00692276|DEVICE|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
214566362|NCT00692276|DEVICE|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
214566363|NCT04538911|DRUG|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
214566364|NCT03825731|BIOLOGICAL|GC022|GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
214566365|NCT00363688|DRUG|Penicillin test and challenge|
214566366|NCT01895101|DRUG|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
214566367|NCT01895101|DRUG|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
214566368|NCT04546490|OTHER|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
214566369|NCT04546490|OTHER|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
214566370|NCT02126761|BIOLOGICAL|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
214566371|NCT02126761|BIOLOGICAL|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
214566372|NCT02126761|BIOLOGICAL|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
214566373|NCT02126761|BIOLOGICAL|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
214566374|NCT04500795|PROCEDURE|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
214566375|NCT03246776|DRUG|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
214566376|NCT03879369|DIAGNOSTIC_TEST|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
214566377|NCT04435678|DIAGNOSTIC_TEST|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
214566378|NCT00823576|DRUG|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
214566379|NCT02632435|DEVICE|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
214566380|NCT02632435|DEVICE|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
214566381|NCT01885520|DIETARY_SUPPLEMENT|fasting condition|eperisone SR tablet 75mg administrated under fasting
214566382|NCT01885520|DIETARY_SUPPLEMENT|fed condition|eperisone SR tablet 75mg administrated fed condition
214566383|NCT03339583|BEHAVIORAL|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
214566384|NCT03339583|DRUG|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
214566385|NCT00734591|DRUG|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
214566386|NCT00734591|OTHER|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
214566387|NCT03526276|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
214566388|NCT03526276|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily
214566389|NCT03526276|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
214566390|NCT01659853|DRUG|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
214566391|NCT01659853|DRUG|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
214566392|NCT01085968|BEHAVIORAL|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
214566393|NCT03592810|OTHER|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
214566394|NCT04891705|DEVICE|Lung Ultrasound Scan|Ultrasound scan of subjects in up to 14 lung zones
214566395|NCT02545829|DRUG|HIP1302|Tenofovir 292mg
214566396|NCT02545829|DRUG|HGP1406|Tenofovir 300mg
214566397|NCT06190210|DIAGNOSTIC_TEST|electroencephalography|Pre-, per- and postoperative electroencephalography
214566398|NCT06190210|DIAGNOSTIC_TEST|Near-Infrared Spectroscopy|Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
214566399|NCT06190210|DIAGNOSTIC_TEST|neuronal cell-free DNA|CfDNA which is characterized based on methylation patterns to determine the tissue of origin
215030220|NCT00420537|DRUG|Everolimus|
215030221|NCT04023487|BEHAVIORAL|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
215030222|NCT06564987|DRUG|4% Articaine with 1:200,000 epinephrine|Inferior Alveolar Nerve Block with 4% articaine
214566400|NCT04907019|DRUG|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
214566401|NCT05926453|OTHER|Maximal cardiorespiratory exercise test|previously described
214566402|NCT05156151|OTHER|Relex-Smile|
214566403|NCT05268536|OTHER|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
214566404|NCT05268536|OTHER|resistance exercise|resistance exercise
214566405|NCT05951270|DIETARY_SUPPLEMENT|Apple Polyphenols|ApplePhenon® is prepared from unripe green apples (malus domestica) and contains a large amounts of polyphenols. The supplement contains 63.8% procyanidins, 12.4% flavon-3-ols, 6.5% chalcones and 10.8% phenolcarboxylic acids
214566406|NCT05951270|OTHER|Control|The placebo used in this study is 1100 mg maltodextrin (Avebe, Veendam, the Netherlands). This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
215030223|NCT06564987|DRUG|2% lidocaine with 1:100,000 epinephrine|Inferior Alveolar Nerve Block with 2% lidocaine
215030224|NCT00361712|PROCEDURE|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
215030225|NCT00361712|DRUG|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
215030226|NCT06641024|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
215030227|NCT06638515|OTHER|Walking apnea at Low Lung Volume|Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
215030228|NCT06638515|OTHER|Walking at normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
215030229|NCT02003313|BIOLOGICAL|Group T|0.5ml, Intramuscular
215030230|NCT02003313|BIOLOGICAL|Group C|0.5ml, Intramuscular
215030231|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
215030232|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
215030233|NCT06505395|DRUG|SYHX2008 injection|The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
215030234|NCT06505395|DRUG|Sandostatin LAR@|The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
215030235|NCT05176665|DRUG|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
215030236|NCT04904913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
215030237|NCT04904913|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
215030238|NCT00803855|DRUG|AZD1446|oral, single dose
215030239|NCT00979758|DRUG|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
215030240|NCT02014376|DRUG|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
215030241|NCT02014376|DRUG|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
215030242|NCT02014376|DRUG|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
215030243|NCT04017312|DEVICE|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
214566407|NCT06341686|DRUG|Letermovir 480 MG|Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
214566408|NCT06341686|DRUG|Ganciclovir|The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
214566409|NCT01996462|DRUG|Escitalopram Oxalate Tablets|
214566410|NCT04489953|OTHER|Viral Load|For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time
214566411|NCT02950610|DEVICE|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
214566412|NCT04326322|DIETARY_SUPPLEMENT|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
214566413|NCT04702321|OTHER|Procedure: Biospecimen Collection|Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction
214566414|NCT04702321|OTHER|Procedure: Medical Chart Review|Collection of clinical data
214566415|NCT06161727|OTHER|HPV exposure|According to group descriptions
214566416|NCT06224062|BIOLOGICAL|SARS-CoV-2|Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
214566417|NCT06224062|BIOLOGICAL|Adenovirus (AdV)|Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
214566418|NCT06224062|BIOLOGICAL|Rhinovirus|RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
214566419|NCT06224062|BIOLOGICAL|No Intervention|no infection
214566420|NCT05187364|BEHAVIORAL|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
214566421|NCT05560243|BEHAVIORAL|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
214566422|NCT04903262|PROCEDURE|Ultraprotective ventilation with Extracorporeal CO2 removal|HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.
214566423|NCT04903262|PROCEDURE|Conventional protective ventilation|"Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)"
214566424|NCT04116892|PROCEDURE|the Cover group|The internal limiting membrane around the MH was left to cover the hole
214566425|NCT04116892|PROCEDURE|the Fill group|The internal limiting membrane around the MH was left to fill the hole
214566426|NCT04116892|PROCEDURE|the peeling group|the internal limiting membrane was discarded
214566427|NCT06612645|BIOLOGICAL|B7H3-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
214566428|NCT03147703|BEHAVIORAL|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
214566429|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.25%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
214566430|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.125%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
214566431|NCT01417624|OTHER|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
214566432|NCT05228743|PROCEDURE|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
214566433|NCT05228743|DRUG|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
214566434|NCT05228743|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
214566435|NCT06801756|OTHER|Questionnaire|The patients will respond to a questionnaire about their parental project, the occurence or not of complications during the pregnancy, and the impact of pregnancy on craniopharyngioma.
214566436|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
214566437|NCT02757872|DRUG|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214566438|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
214566439|NCT02757872|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214566440|NCT05915949|DRUG|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
214566441|NCT05915949|DRUG|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
214566442|NCT05915949|DRUG|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
214566443|NCT06150859|DRUG|Ayahausca-Assisted psychotherapy|"Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions."
214566444|NCT06150859|BEHAVIORAL|Constructivist Psychotherapy|Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions
214566445|NCT06150859|OTHER|No treatment|No treatment during the control period
214566446|NCT00939822|DRUG|Simvastatin|40 mg Simvastatin/day
214566447|NCT00939822|DRUG|Placebo|Matching Placebo
214708310|NCT05767710|BEHAVIORAL|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
214566448|NCT03652727|DEVICE|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) \[CE marked device, C. R. Bard, Inc.\].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
214566449|NCT03652727|DEVICE|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
214566450|NCT01021618|DRUG|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
214708311|NCT05767710|BEHAVIORAL|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
214566451|NCT01021618|OTHER|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
214566452|NCT00318162|DRUG|low dose naltrexone|
214566453|NCT05183789|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
214566454|NCT00327262|DRUG|Imatinib|
214566455|NCT01783964|DRUG|[14C]-Elacytarabine|Single intravenous administration
214566456|NCT00263016|DRUG|Docetaxel|
214566457|NCT03415373|DEVICE|Microneedle Adapter (Model UAR-2S)|Investigational device
214566458|NCT03415373|DEVICE|Hypodermic needle + syringe|Control device
214566459|NCT03301441|OTHER|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
214566460|NCT01072630|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
214566461|NCT01072630|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
214566462|NCT05183529|DEVICE|Vitals Monitoring Pill System|The Celero Vitals Monitoring Pill (VM Pill) uses 3 axis accelerometry to measure physiological signals from within the GI tract.
214566463|NCT02653612|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
214566464|NCT01232738|DRUG|rasagiline|rasagiline 2 mg daily for 12 months
214566465|NCT01341054|OTHER|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
214566466|NCT01341054|OTHER|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
214566467|NCT00338962|DRUG|paroxetine|paroxetine (40mg/day)
214566468|NCT00338962|DRUG|desipramine|200 mg per day
214566469|NCT00338962|DRUG|Naltrexone|50 mg per day
214566470|NCT00338962|DRUG|Placebo|placebo
214566471|NCT02974777|DRUG|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
214566472|NCT02974777|DRUG|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
214566473|NCT02974777|DRUG|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
214566474|NCT03046121|BEHAVIORAL|Family-centered Function-focused Care (Fam-FFC)|"An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period."
214566475|NCT03214640|DEVICE|Rivanna Accuro US Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
214566476|NCT03214640|OTHER|Palpation|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method using conventional landmarks (spinous process and iliac crest). For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
214566477|NCT03214640|PROCEDURE|Neuraxial Analgesia|Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
214566478|NCT03214640|PROCEDURE|Spinal Block|Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
214566479|NCT03099564|DRUG|Pembrolizumab|pembrolizumab 200mg IV every three weeks
214566480|NCT03099564|DEVICE|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
214566481|NCT00910039|DRUG|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
214566482|NCT00910039|OTHER|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
214566483|NCT03415737|OTHER|Questionnaire|Profile Fitness Mapping Neck Questionnaire
214566484|NCT03151993|DRUG|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
214566485|NCT03151993|DRUG|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
214566486|NCT00385177|DRUG|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
214566487|NCT04221672|DRUG|Terlipressin plus standard care|All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.
214566488|NCT04221672|OTHER|Standard care|All the participants received routine care after surgery only.
214566489|NCT04565275|DRUG|Drug ICP-192|"1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase."
214566490|NCT06340477|OTHER|Thoracic SNAGs with conventional therapy|"Thoracic (T1- T5) SNAGs 3 repetitions x 1 set, 2 days/week Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
214566491|NCT06340477|OTHER|conventional therapy|"Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
214566492|NCT02147899|DRUG|SYM-1219|Oral
214566493|NCT02147899|DRUG|Placebo|Oral
214566494|NCT04155047|COMBINATION_PRODUCT|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
214566495|NCT04155047|DRUG|Placebo administered by Magnair|Placebo Inhalation Solution
214566496|NCT04329468|DEVICE|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
214566497|NCT00078000|DRUG|SU011248|
214566498|NCT01143870|OTHER|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
214566499|NCT01770977|DEVICE|Light-emitting diode therapy|
214566500|NCT01770977|DEVICE|Placebo light-emitting diode therapy|
214566501|NCT03303768|DIAGNOSTIC_TEST|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
214566502|NCT00131729|BEHAVIORAL|Educational programme|
214566503|NCT02689843|DRUG|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
214566504|NCT02689843|DRUG|Metformin|Metformin 500mg three times daily
214566505|NCT02689843|DRUG|Pioglitazone|Pioglitazone 30mg once daily
214566506|NCT00528619|DRUG|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
214566507|NCT00202917|DRUG|Fludarabine|
214566508|NCT00202917|DRUG|Thiotepa|
214566509|NCT00202917|DRUG|Melphalan|
214566510|NCT00202917|DRUG|OKT-3|
214566511|NCT00202917|PROCEDURE|CD3/CD19 depletion on CliniMACS|
214708312|NCT05767710|BEHAVIORAL|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
214566512|NCT05893368|OTHER|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~* a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~* report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~* digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
214566513|NCT05341401|DRUG|Budesonide MMX|Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
214566514|NCT05341401|DRUG|Prednisolone|It is a corticosteroid used as a standard therapy for management of ulcerative colitis
214566515|NCT01454687|PROCEDURE|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
214566516|NCT03342989|BEHAVIORAL|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
214566517|NCT03342989|BEHAVIORAL|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
214566518|NCT05041010|DRUG|Neu2000KWL group|1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
214708313|NCT05767710|BEHAVIORAL|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
215030244|NCT04017312|DEVICE|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
214566519|NCT05041010|DRUG|Placebo group|1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
214566520|NCT06487117|DRUG|Huafu Shengji Ointment|"Huafu Shengji Ointment~1. The experimental group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The experimental group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks."
214566521|NCT06487117|DRUG|ethacridine lactate solution|"ethacridine lactate solution~1. The control group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The control group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks."
214566522|NCT03727542|DEVICE|adjustment of atrioventricular delay in DDD packers|Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
214566523|NCT05308706|DEVICE|8 weeks of home based use.|Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
214566524|NCT01911390|DIETARY_SUPPLEMENT|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
214566525|NCT01911390|DIETARY_SUPPLEMENT|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
214566526|NCT01911390|DIETARY_SUPPLEMENT|Control arm|No bean or rice bran additive in smoothie or muffin.
215030245|NCT01531335|DIETARY_SUPPLEMENT|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
215030246|NCT01531335|DIETARY_SUPPLEMENT|Standard care|25 kcal per kg of body weight
215030247|NCT06563869|DRUG|PEG-rhG-GSF|Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
215030248|NCT04656561|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT
215030249|NCT04656561|OTHER|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
215030250|NCT06195007|BEHAVIORAL|Motivational Interview|"The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior."
214566527|NCT01911390|DIETARY_SUPPLEMENT|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
214566528|NCT06012227|DIETARY_SUPPLEMENT|kent'erbas cheese study|"Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming"
214566529|NCT01066429|DRUG|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
214566530|NCT04620343|PROCEDURE|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
214566531|NCT04620343|PROCEDURE|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
214566532|NCT04620343|PROCEDURE|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
214566533|NCT04620343|PROCEDURE|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
214566534|NCT04620343|PROCEDURE|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
214566535|NCT04620343|PROCEDURE|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
215030251|NCT05727501|OTHER|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
215030252|NCT05727501|OTHER|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
215030253|NCT06172023|DRUG|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
215030254|NCT06172023|DRUG|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
215030255|NCT01929694|DIETARY_SUPPLEMENT|Berocca Boost|
215030256|NCT01929694|DIETARY_SUPPLEMENT|Placebo|
215030257|NCT03000881|OTHER|standard adhesive|This is a standard adhesive (hydrocolloid)
215030258|NCT03000881|OTHER|New adhesive strip|This is a newly developed adhesive strip
215030259|NCT00718185|PROCEDURE|Obtain blood specimens|Obtain blood samples at multiple timepoints.
215030260|NCT04873557|OTHER|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
215030261|NCT00001854|DRUG|Ribavirin|
215030262|NCT05623605|DRUG|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
215030263|NCT05623605|DRUG|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
215030264|NCT05623605|DRUG|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
215030265|NCT01833078|DRUG|ghrelin|ghrelin administration subcutaneously for 7 days
215030266|NCT05532800|DRUG|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
215030267|NCT05532800|DRUG|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
214566536|NCT04620343|PROCEDURE|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
214566537|NCT04969315|DRUG|TT-10|TT-10 orally administered BID
214566538|NCT04969315|DRUG|TT-4|TT-4 is orally administered QD
214566539|NCT00558038|DRUG|AST-120|AST-120
214566540|NCT00558038|DRUG|lactulose|lactulose
214566541|NCT01280357|DEVICE|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
214566542|NCT01280357|DEVICE|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
214566543|NCT00886795|DRUG|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
214566544|NCT02818244|DEVICE|Fit Bit Blaze Heart Rate Monitoring Device|
214566545|NCT02818244|DEVICE|Garmin Forerunner 235 Heart Rate Monitoring Device|
214566546|NCT02818244|DEVICE|Tom Tom Spark Cardio Heart Rate Monitoring Device|
214566547|NCT02818244|DEVICE|Apple Watch Heart Rate Monitoring Device|
214566548|NCT02818244|DEVICE|Scosche Rhythm + Heart Rate Monitor|
214566549|NCT01259089|DRUG|erlotinib hydrochloride|Given orally
214566550|NCT01259089|DRUG|Hsp90 inhibitor AUY922|Given IV
214566551|NCT01259089|OTHER|laboratory biomarker analysis|Correlative studies
214566552|NCT01259089|PROCEDURE|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
214566553|NCT01259089|GENETIC|mutation analysis|Correlative studies
214566554|NCT01259089|OTHER|pharmacological study|Correlative studies
214566555|NCT02837003|DRUG|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
214566556|NCT02837003|DRUG|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
214566557|NCT02310100|DEVICE|TactiCath Quartz treatment|
214566558|NCT02580721|DEVICE|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
214566559|NCT01828762|BIOLOGICAL|DC-TC+GM-CSF|
214566560|NCT00688870|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
214566561|NCT00688870|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
214566562|NCT02905448|OTHER|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
214566563|NCT00937677|DRUG|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
215030268|NCT02531256|DEVICE|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
215030269|NCT02951481|BEHAVIORAL|Systematic evaluation by an ID expert.|"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
215030270|NCT01459627|OTHER|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
215030271|NCT01459627|OTHER|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
215030272|NCT00854737|DIETARY_SUPPLEMENT|cytidine|cytidine (2g po daily for 4 months)
215030273|NCT00854737|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
215030274|NCT00854737|DRUG|placebo|sugar pill
215030275|NCT02162173|PROCEDURE|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
214566564|NCT00625547|DRUG|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
214566565|NCT00625547|DRUG|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
214566566|NCT03537495|DRUG|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
214566567|NCT02878005|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
214566568|NCT02878005|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
214566569|NCT00477659|DRUG|Donepezil hydrochloride|Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
214566570|NCT00329173|DRUG|Rosuvastatin|
214566571|NCT00329173|DRUG|Atorvastatin|
214566572|NCT03924440|DIAGNOSTIC_TEST|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
214566573|NCT05833477|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin treatment three times per week for three weeks
214566574|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
214566575|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention"
214566576|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
214566577|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
214566578|NCT06194552|DRUG|NTRX-07|Investigational orally administered CB2 agonist
214566579|NCT06194552|DRUG|Placebo|Matched placebo administered orally
214566580|NCT04059302|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy for Insomnia|The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
214566581|NCT02324400|DEVICE|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
214566582|NCT02324400|DEVICE|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
214566583|NCT02571153|DRUG|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
214566584|NCT02571153|DRUG|Normal saline|Intravenous normal saline 0.9% 5 mL
214566585|NCT02571153|DRUG|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
215030276|NCT06486220|DRUG|Intestinal bacteria freeze-dried powder capsules|Oral healthy intestinal bacteria freeze-dried powder capsules, tid
215030277|NCT03256487|DRUG|Buprenorphine|buprenorphine 0.3mg IV
215030278|NCT03256487|DRUG|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
215030279|NCT04831229|OTHER|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
215030280|NCT04831229|OTHER|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
215030281|NCT02786329|DRUG|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
215030282|NCT02786329|DRUG|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
215030283|NCT02786329|DRUG|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
215030284|NCT02786329|DRUG|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
215030285|NCT04962516|DEVICE|single-use precision filtered infusion sets|single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
215030286|NCT04962516|DEVICE|single-use precision filter infusion set with needle|single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
215030287|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
214566586|NCT05723159|DEVICE|Clinical Validation of the Hyfe Cough Monitoring System|The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.
214566587|NCT05751954|RADIATION|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
214566588|NCT05751954|DEVICE|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
214566589|NCT06270043|PROCEDURE|Focal Therapy|"Focal ablation of prostate cancer using different modalities. These modalities include:~* Cryoablation or Cryotherapy~* Irreversible Electroporation - Nanoknife~* High Intensity Frequency Ultrasound - FocalOne~* Transurethral Ultrasound Ablation - TULSA - PRO"
215030288|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
215030289|NCT01051661|BIOLOGICAL|Placebo|Intramuscular injection, one dose
215030290|NCT05929313|DEVICE|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
215030291|NCT05929313|DEVICE|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
215030292|NCT04642079|BIOLOGICAL|20vPnC|20-valent pneumococcal conjugate vaccine
215030293|NCT05272280|OTHER|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
215030294|NCT05272280|OTHER|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
215030295|NCT03097978|DEVICE|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
215030296|NCT03097978|DEVICE|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
215030297|NCT03097978|OTHER|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
215030298|NCT03097978|OTHER|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
215030299|NCT02412982|DRUG|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
215030300|NCT02412982|DRUG|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
215030301|NCT01172392|DRUG|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
215030302|NCT01172392|DRUG|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
215030303|NCT01832194|DRUG|Botox|
215030304|NCT03032809|OTHER|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
215030305|NCT06341335|DRUG|cadonilimab|iv, q3w
215030306|NCT06341335|DRUG|pulocimab|iv, q3w
215030307|NCT06341335|DRUG|paclitaxel|iv, q3w
215030308|NCT06341335|DRUG|placebo|iv, q3w
215030309|NCT03030534|COMBINATION_PRODUCT|Educational package and software package|Using Information and communication technology to deliver health promoting activities
215030310|NCT03030534|OTHER|Health promotion tips|Give general information on health promotion
215030311|NCT02668757|BEHAVIORAL|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
215030312|NCT04270019|DRUG|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
214566590|NCT01140295|DRUG|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age \>12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
214566591|NCT02094287|DRUG|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
214566592|NCT02094287|BEHAVIORAL|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
214566593|NCT02094287|OTHER|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
214566594|NCT01821352|DEVICE|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
214566595|NCT01821352|DEVICE|Placebo Laser|Emits light that has no therapeutic effect
214566596|NCT04953897|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
215030313|NCT04270019|DRUG|Normal Saline|Standard solution of sterile normal saline.
215030314|NCT06116097|BEHAVIORAL|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
215030315|NCT04913116|DIAGNOSTIC_TEST|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
215030316|NCT00386581|DRUG|atomoxetine|
215030317|NCT00386581|DRUG|placebo|
215030318|NCT03038620|DRUG|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
215030319|NCT03038620|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
214566597|NCT00163280|DRUG|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
214566598|NCT04419376|DEVICE|driving pressure|Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
214566599|NCT01966172|DRUG|Ibuprofen|oral ibuprofen 400mg 4 times daily
214566600|NCT01966172|DRUG|Gabapentin|Oral Gabapentin 300mg twice daily
214566601|NCT01966172|DRUG|Morphine|10 mg morphine orally 4 times daily
214566602|NCT01966172|DRUG|Paracetamol|oral paracetamol 1000mg four times daily
214566603|NCT02753569|OTHER|Imaging - DW-MRI|
214566604|NCT02753569|RADIATION|FDG PET-CT|
214566605|NCT02604303|OTHER|No Intervention|No intervention; prospective observational study
214566606|NCT05180643|BEHAVIORAL|Mindfulness-Based Stress Reduction-based program (MBSR).|The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
214566607|NCT01791075|DEVICE|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
214566608|NCT01791075|DEVICE|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
214566609|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
214566610|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
214566611|NCT04538560|PROCEDURE|polar body biopsy|Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
214566612|NCT05684744|DRUG|Roflumilast|The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks
214566613|NCT05684744|DRUG|Methotrexate|The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
214566614|NCT06198322|OTHER|Platelet-rich Fibrin|Platelet-rich Fibrin will be injected distal to the canine on the experimental side
214566615|NCT06198322|OTHER|Vitamin D3|Vitamin D3 will be injected distal to the canine on the experimental side
214566616|NCT00036387|DRUG|Infliximab|
214566617|NCT03401008|OTHER|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
214566618|NCT02982824|DIETARY_SUPPLEMENT|Magnesium|Oral magnesium
214566619|NCT02982824|DRUG|Placebo - Concentrate|Placebo will be given
214566620|NCT03472716|PROCEDURE|Biological Samples|"5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)"
214566621|NCT01129700|RADIATION|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
214566622|NCT02427945|BEHAVIORAL|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
215030320|NCT01711099|DEVICE|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
215030321|NCT03653819|OTHER|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
215030322|NCT03653819|OTHER|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
215030323|NCT01156350|DRUG|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
215030324|NCT04011241|DRUG|BI 1323495|Tablet
215030325|NCT04011241|DRUG|Itraconazole|Oral solution
215030326|NCT01871922|DRUG|Placebo|Saline
215030327|NCT01871922|DRUG|Atropine|Atropine
214566623|NCT02427945|BEHAVIORAL|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
214566624|NCT01941433|BEHAVIORAL|Arthritis Health Journal|
214566625|NCT01580891|DRUG|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
214708314|NCT05767710|BEHAVIORAL|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
214566626|NCT01580891|DRUG|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
214566627|NCT01580891|DRUG|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
214566628|NCT04734054|DEVICE|Modified Hyrax Palatal Expander|The rapid maxillary expansion will be performed. The expansion should be accomplished between 10 to 15 days at most. The screw is going to be turned in a rapid manner.
214566629|NCT04734054|DEVICE|Removable Palatal Expander|The slow maxillary expansion will be performed. The expansion will be performed in a slow manner. Patients may need between 6 to 8 months to achieve the required expansion.
214566630|NCT03479853|PROCEDURE|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
214566631|NCT01998074|DIETARY_SUPPLEMENT|extensively hydrolyzed rice protein formula|
214566632|NCT02917603|BEHAVIORAL|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
214566633|NCT05619757|BEHAVIORAL|Compliance with medical treatment for endometriosis|"During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.~Patients will be included once they log in and complete the questionnaire."
214566634|NCT03714087|DEVICE|T1 before aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
214708315|NCT04402853|DIAGNOSTIC_TEST|Tears swab|rtPCR on tears swabs samples
214566635|NCT03714087|OTHER|T2 after the aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
214566636|NCT03714087|OTHER|Historic control group|
214566637|NCT04906629|BIOLOGICAL|INO-4201|One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
214566638|NCT04906629|BIOLOGICAL|Placebo|One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
214566639|NCT06363682|PROCEDURE|ERCP|ERCP of the biliary duct ou the pancreatic duct, with or without the use of a stent, in a context of gallstone or tumor or other
214566640|NCT06363682|PROCEDURE|endoscopic ultrasound|The use of endoscopic ultrasound in diverse situation with the necessity of using X rays
214566641|NCT06363682|PROCEDURE|gastroscopy|"The diverse procedure in witch scopy is use in orders to place or switch or remove an oesophageal or gastroduodenal stent during a gastroscopy.~Or for oesophageal or gastroduodenal dilatation."
214566642|NCT06363682|PROCEDURE|Colonoscopy|The diverse procedure in witch scopy is use during a colonoscopy
214708316|NCT00285103|DRUG|SPC2996|
214708317|NCT04206527|BEHAVIORAL|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
214566643|NCT06363682|PROCEDURE|placement of a nasojejunal tube|placement of a nasojejunal tube for enteral nutritional support
214566644|NCT02006524|DEVICE|'MyDiagnostick|
214566645|NCT03520101|PROCEDURE|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is \>18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
214566646|NCT03520101|PROCEDURE|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
214566647|NCT03331913|DRUG|Botulinum Toxin type A (intradermal / submucosal injection at pain area)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
214566648|NCT03331913|DRUG|Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
214566649|NCT01253018|BEHAVIORAL|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
214708318|NCT04206527|BEHAVIORAL|Enhanced FP training|Participation in an enhanced FP training including PCC
214708319|NCT03000387|DRUG|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
214566650|NCT01253018|BEHAVIORAL|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
214566651|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
214566652|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
214566653|NCT06000033|DRUG|Disitamab Vedotin+Anlotinib|Disitamab Vedotin:2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
214566654|NCT00002248|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
214708320|NCT03000387|DRUG|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
215030328|NCT04150445|BEHAVIORAL|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
215030329|NCT01648322|DRUG|F-627|subcutaneous injection given 1 per chemotherapy.
215030330|NCT01648322|DRUG|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
215030331|NCT03983239|DRUG|Fedratinib|Fedratinib
215030332|NCT03983239|DRUG|Rifampin|Rifampin
215030333|NCT03983239|DRUG|Efavirenz|Efavirenz
215030334|NCT00165607|DRUG|MENATETRANONE|
215030335|NCT03063645|DRUG|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
215030336|NCT03063645|DRUG|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
215030337|NCT03063645|DRUG|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
214566655|NCT03449901|DRUG|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
214566656|NCT03449901|DRUG|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
214566657|NCT03449901|DRUG|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
214566658|NCT03449901|PROCEDURE|Tumor biopsy|"* Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort"
214566659|NCT03449901|PROCEDURE|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
214566660|NCT06424431|PROCEDURE|stapler combined with electrocautery|Closure with a closure device combined with electrocoagulation for pancreatic stump closure in distal pancreatectomy
214708321|NCT03671382|BEHAVIORAL|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
215030400|NCT03531541|DEVICE|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
215030401|NCT03531541|DEVICE|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
215030402|NCT03531541|DEVICE|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
215030403|NCT00751985|OTHER|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
215030404|NCT00751985|OTHER|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
215030405|NCT00751985|OTHER|Control|The participant is being informed about their allocation to the control group.
214566661|NCT06424431|PROCEDURE|simple closure with a closure device|Simple closure with a closure device for pancreatic stump closure in distal pancreatectomy
214566662|NCT02185001|PROCEDURE|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
214566663|NCT02185001|PROCEDURE|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
215030406|NCT00660231|DRUG|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
214566664|NCT06046105|DRUG|Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
215030407|NCT00660231|DRUG|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
215030408|NCT00982280|DRUG|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
215030409|NCT01979185|DRUG|Simvastatin|
215030410|NCT01979185|DRUG|SSP-004184SS|
215030411|NCT00980798|DRUG|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
215030412|NCT00980798|DRUG|Placebo|placebo tablet once daily for 16 weeks
215030413|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
215030414|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
215030415|NCT03749239|DIETARY_SUPPLEMENT|Collagen protein|Collagen protein
215030416|NCT04724837|DRUG|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
215030417|NCT04724837|DRUG|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
215030418|NCT04724837|DRUG|Placebo|Participants will receive placebo as per the arms they are randomized to.
215030419|NCT05962736|DEVICE|Mirror therapy|The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
215030420|NCT05018728|DRUG|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
214566665|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
215030421|NCT04375358|BIOLOGICAL|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
215030422|NCT00522379|DRUG|Rotigotine|2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
215030423|NCT00522379|DRUG|Rotigotine|4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
215030424|NCT00522379|OTHER|Placebo|Placebo transdermal patch applied daily
215030425|NCT00522379|DRUG|Rotigotine|6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
214708322|NCT05816967|PROCEDURE|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
214708323|NCT02308176|BEHAVIORAL|APP + health advice|health advice and reinforcement to it
214708324|NCT02308176|BEHAVIORAL|health advice|health advice
214566666|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
214566667|NCT03269682|DEVICE|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
214566668|NCT03466073|DRUG|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
214566669|NCT03466073|OTHER|Normal Saline Placebo|Normal saline in volume equivalent to drug
214566670|NCT00744757|DRUG|Decitabine|Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
214566671|NCT01600248|BEHAVIORAL|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
214566672|NCT02249598|BIOLOGICAL|lactamica|
214566673|NCT02249598|BIOLOGICAL|Placebo|
214566674|NCT03682302|DRUG|Exparel|EXPAREL 4mg/kg (maximum 266 mg)
214566675|NCT03682302|DRUG|0.5% Bupivacaine HCl|Bupivacaine HCl 2mg/kg
214708325|NCT02262234|OTHER|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
214708326|NCT02262234|OTHER|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
214708327|NCT03223493|OTHER|No treatment given|Completion of a questionnaire
214708328|NCT03120728|DRUG|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
214708329|NCT01181102|DRUG|edoxaban|
214566676|NCT02832401|DRUG|Caffeine|
214566677|NCT02832401|DRUG|Placebo|
214566678|NCT02707549|DRUG|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
214566679|NCT02707549|DRUG|0.9% sodium chloride|
214566680|NCT00495105|BEHAVIORAL|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
214566681|NCT04473599|BEHAVIORAL|Uniform random message delivery|In this arm, the categories and timings of text-messages will be delivered to participants using a random schedule
214708330|NCT01181102|DRUG|enoxaparin sodium|
214708331|NCT04776564|OTHER|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
214708332|NCT04979949|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
215030426|NCT00522379|DRUG|Rotigotine|8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
215030427|NCT03901365|OTHER|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
215030428|NCT03901365|OTHER|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
214566682|NCT04473599|BEHAVIORAL|Reinforcement learning message delivery|In this arm, the categories and timings of text-messages will be chosen by a reinforcement learning algorithm
214566683|NCT04473599|BEHAVIORAL|Mood ratings only|In this arm, participants will monitor their mood daily and receive feedback on that mood randomly
214566684|NCT04095559|DIAGNOSTIC_TEST|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
214566685|NCT04095559|DIAGNOSTIC_TEST|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
214566686|NCT04095559|DIAGNOSTIC_TEST|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
214708333|NCT04979949|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
214566687|NCT05052788|DEVICE|Optical coherence tomography angiography|"OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine ."
214708334|NCT01142453|DRUG|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
214566688|NCT03749018|DRUG|Cyclophosphamide|Given IV
214566689|NCT03749018|DRUG|Doxorubicin Hydrochloride|Given IV
214566690|NCT03749018|DRUG|Etoposide|Given IV
214566691|NCT03749018|BIOLOGICAL|Nivolumab|Given IV
214708335|NCT01577784|DRUG|Pazopanib|800 mg / day of pazopanib in monotherapy.
214566692|NCT03749018|DRUG|Prednisone|Given PO
214566693|NCT03749018|BIOLOGICAL|Rituximab|Given IV
214566694|NCT03749018|DRUG|Vincristine Sulfate|Give IV
214708336|NCT06144242|BEHAVIORAL|Feedback on RTD metric|Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
214708337|NCT01315002|DRUG|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
214708338|NCT01315002|DRUG|Placebo patch|Placebo patch
214566695|NCT05845281|PROCEDURE|Bupivakain + deksametazon Adjuvant|In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
214566696|NCT00856440|DRUG|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
214566697|NCT00856440|DRUG|Colyte|Lavage preparation for colonoscopy
214566698|NCT00856440|DRUG|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
214566699|NCT06444204|DRUG|Rilzabrutinib|Rilzabrutinib tablet administered orally
214708339|NCT04576247|BEHAVIORAL|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
214708340|NCT05053126|DRUG|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
214708341|NCT05053126|DRUG|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
214566700|NCT03083418|DEVICE|control group|No EDP treatment
214566701|NCT03083418|DEVICE|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
214566702|NCT00860847|DIETARY_SUPPLEMENT|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
214566703|NCT00697645|DEVICE|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
214566704|NCT00697645|DEVICE|Brainsway Deep TMS|Deep TMS applied over the motor strip
214566705|NCT04445727|COMBINATION_PRODUCT|Vitamin C|Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
214708342|NCT05053126|DRUG|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
214708343|NCT05053126|DRUG|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
214708344|NCT05053126|DRUG|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
214566706|NCT04445727|COMBINATION_PRODUCT|spinal manipulation|Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.
214566707|NCT04445727|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation (TENS)|Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
214566708|NCT02009098|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
214566709|NCT05614193|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
214566710|NCT02054559|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
214566711|NCT02054559|RADIATION|Radiotherapy|
214566712|NCT00195468|DRUG|CYCLOSPORINE|
214708345|NCT05053126|DRUG|Placebo|Participant will receive an oral dose of placebo
214708346|NCT04334915|DRUG|Cenicriviroc Mesylate (CVC)|Administered orally
214708347|NCT04334915|DRUG|Placebo|Administered orally
214708348|NCT00057395|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
214708349|NCT03442348|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
214566713|NCT06474819|DEVICE|Pacemaker implant|All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.
214566714|NCT01124331|PROCEDURE|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
214566715|NCT01124331|PROCEDURE|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
214566716|NCT04531501|DIAGNOSTIC_TEST|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
214566717|NCT00105599|BEHAVIORAL|End of life care coordination|
214566718|NCT00105599|PROCEDURE|FairCare System|
214566719|NCT02160236|DRUG|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
214566720|NCT02160236|DRUG|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
214566721|NCT02160236|DRUG|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
214566722|NCT01671397|BEHAVIORAL|Diet and exercise counseling|Not needed
214566723|NCT01671397|BEHAVIORAL|Diet, exercise, sleep hygiene counseling|None needed
214566724|NCT04104828|BIOLOGICAL|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
214566725|NCT04104828|BIOLOGICAL|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
214566726|NCT04104828|BIOLOGICAL|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
214566727|NCT03887949|DEVICE|Group VCV|Volume controlled ventilation
214566728|NCT03887949|DEVICE|Group PCV|Pressure controlled ventilation
214566729|NCT03887949|DEVICE|Group PCV-VG|Pressure controlled ventilation with volume guarantee
214566730|NCT01353768|OTHER|retrospective chart review|retrospective chart review
214566731|NCT02461784|PROCEDURE|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
214566732|NCT03309813|DEVICE|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
214566733|NCT03309813|DEVICE|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
214566734|NCT03309813|DEVICE|Crossover Transcranial Exablate|Subjects randomized to the Sham Exablate could opt for the Crossovover Transcranial Exablate Arm (Exablate Thalamotomy) after completing the Month 3 visit in the Sham Arm.
214566735|NCT05912205|DRUG|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
214566736|NCT05912205|RADIATION|radiotherapy|radiotherapy
214566737|NCT05754164|BEHAVIORAL|Attention Control Training|Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
214566738|NCT02766101|BEHAVIORAL|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
214566739|NCT02766101|BEHAVIORAL|Standard PE|Non-aerobic skill building.
214566740|NCT02929277|OTHER|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
214566741|NCT06143592|OTHER|Inspiratory Muscle Training|Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.
214566742|NCT00515684|DRUG|bevacizumab (Avastin)|
214566743|NCT04944745|OTHER|Myofascial Release|Moderate pressure manual treatment to the pectoral fascia.
214566744|NCT04944745|OTHER|Soft-touch Control|No pressure manual treatment to the pectoral fascia.
214566745|NCT04190836|BEHAVIORAL|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
214566746|NCT05827913|DEVICE|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
214566747|NCT05827913|DEVICE|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
214566748|NCT05827913|DEVICE|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
214566749|NCT03636191|DIETARY_SUPPLEMENT|Probiotic strain|Lactobacillus
214566750|NCT03636191|DIETARY_SUPPLEMENT|Placebo|Placebo
214566751|NCT00449722|DRUG|mesalazine|
214566752|NCT00658788|DRUG|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
214566753|NCT00658788|DRUG|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
214566754|NCT05181059|DIAGNOSTIC_TEST|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
214566755|NCT01891201|DRUG|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
214708350|NCT03442348|DIETARY_SUPPLEMENT|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
214566756|NCT00653523|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
214566757|NCT00653523|DRUG|Simvastatin|Simvastatin 20 mg daily
214566758|NCT03909438|PROCEDURE|Endovascular Thrombectomy|Endovascular therapy includes direct mechanical thrombectomy or intravenous thrombolysis with mechanical thrombectomy. Endovascular Thrombectomy Device: Trepo trevor Retriever Device: SolitaireTM FR Revascularization Device
214566759|NCT05286827|DRUG|Olaparib|Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
214566760|NCT05439590|BEHAVIORAL|High dose CSO|Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
214708351|NCT01309841|DRUG|NKTR-118|12.5 mg oral tablet once daily
214708352|NCT01309841|DRUG|NKTR-118|25 mg oral tablet once daily
214708353|NCT01309841|DRUG|Placebo|Oral tablet once daily
214566761|NCT05439590|BEHAVIORAL|Low dose CSO|Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
214566762|NCT05439590|BEHAVIORAL|Low dose OO|Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
214566763|NCT05439590|BEHAVIORAL|High dose OO|Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
214566764|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
214566765|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
214566766|NCT00854893|DEVICE|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
214566767|NCT04251507|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
214566768|NCT04958031|DRUG|CVL-871 1.0 mg|CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)
214566769|NCT04958031|DRUG|CVL-871 3.0 mg|CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
214566770|NCT04958031|DRUG|Placebo|Placebo QD, oral (tablet), once per day for 12 weeks
214566771|NCT06511453|DEVICE|Acupressure (using AcuWand or pencil eraser)|"The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure."
214566772|NCT02603653|DEVICE|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
214566773|NCT04713891|DRUG|KF-0210 tablets, 120 mg|KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
214566774|NCT04713891|DRUG|KF-0210 tablets, 240 mg|KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
214566775|NCT04713891|DRUG|KF-0210 tablets, 450 mg|KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
214566776|NCT04713891|DRUG|KF-0210 tablets, 600 mg|KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
214566777|NCT04713891|DRUG|KF-0210 (dosage RP2D-2) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
214566778|NCT04713891|DRUG|KF-0210 (dosage RP2D-1) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
214566779|NCT04713891|DRUG|KF-0210 (dosage RP2D) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
214566780|NCT04711109|DRUG|Denosumab|Given SC
214566781|NCT04711109|DRUG|Placebo|Given SC
214566782|NCT04711109|OTHER|Quality-of-Life Assessment|Ancillary studies
214566783|NCT05384938|BIOLOGICAL|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
214566784|NCT06295536|DEVICE|Comparator device, Closed-field autorefractometer|"* Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia"
214566785|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
214566786|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
214566787|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
214566788|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
214566789|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
214566790|NCT06451133|OTHER|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
214566791|NCT01470053|DRUG|mometasone furoate plus azelastine HCl|
214566792|NCT01470053|DRUG|mometasone furoate|
214566793|NCT01470053|DRUG|azelastine HCl|
214566794|NCT03442153|DIETARY_SUPPLEMENT|Solgar No7 Complex|Solgar No7 Capsules
214566795|NCT03442153|DIETARY_SUPPLEMENT|placebo|Placebo tablets Cellulose
214566796|NCT01663051|DEVICE|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
214566797|NCT03800953|DRUG|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
214566798|NCT02906163|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
214566799|NCT02906163|DRUG|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
214566800|NCT06402565|DRUG|NOX1416 and SOC|Topical Nitric Oxide
214708354|NCT02745132|OTHER|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
214566801|NCT06402565|PROCEDURE|SOC (Standard of care)|SOC as provided in the Arm/Group description.
214566802|NCT06686758|DIETARY_SUPPLEMENT|Sugar cane polysaccharide|Sugar cane polysaccharide
214566803|NCT06686758|DIETARY_SUPPLEMENT|Control|placebo
214566804|NCT06688799|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
214566805|NCT04537533|DRUG|Tranexamic acid|Intraoperative infusion
214708355|NCT01459770|OTHER|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
214708356|NCT01459770|OTHER|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
214708357|NCT00050960|DRUG|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
214566806|NCT04537533|OTHER|Normal saline|intravenous infusion
214708358|NCT00050960|DRUG|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
214708359|NCT01330641|PROCEDURE|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
214708360|NCT05184127|DRUG|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
214566807|NCT02304692|DEVICE|Bone anchored hearing aid|
214708361|NCT05184127|COMBINATION_PRODUCT|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
214566808|NCT06728111|OTHER|High sensitive Troponin T|The baseline population will consist of all patients who underwent a form of non-cardiac surgery. Baseline variables, medication use, type of surgery and perioperative hemodynamic and laboratory variables will be extracted from the hospital information system. One year mortality is registered, as well as major vascular events. This is in line with previous publications from our group. The adjudication strategy used for patients with myocardial injury. For the adjudication process minimal two senior anesthesiologists will be invited. Two members with at least one senior anesthesiologist will receive a sample of patients to adjudicate. Together the entire panel will adjudicate all patients. The goal to investigate the differences between the raters.
214708362|NCT03530618|DEVICE|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
214708363|NCT03530618|DEVICE|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
214708364|NCT02448004|DRUG|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
214708365|NCT03379480|BEHAVIORAL|Yoga arm|Yoga module developed for patients with Schizophrenia
214708366|NCT05445011|DRUG|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
214708367|NCT02843295|OTHER|blood samples|
214708368|NCT04566822|BEHAVIORAL|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
214708369|NCT04566822|BEHAVIORAL|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
214566809|NCT06727942|DEVICE|V-TARGET intervention|V-TARGET intervention will be delivered through a 360 degree self-paced treadmill in a university clinical laboratory for 5-weeks (2 days/week, 30 minutes/session) with total 10 sessions. The treadmill is the first-of-kind motion platform that an individual can walk and run at self-paced speed in 360 degree (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. During the V-TARGET intervention, participants will self-pace their locomotor action (walking/running) while they wear the HTC vivo headset and experience daily exercises/games augmented by the VR Therapy System. Therapy System is a library of VR exercises/games targeted on neurological rehabilitation, balance improvement training as well as cognitive therapy suited for variety of conditions, and includes various daily living simulation activities such as Retail Shopping, Gait Training, Cafeteria Experience, and Nature Walk.
214566810|NCT06897033|BEHAVIORAL|Health education followed by AI-generated Whatsapp reminders|Participants will receive dental health education in a one to one personal session followed by Text messages generated by AI large language model (ChatGPT free version) about oral hygiene practices for three month in a tapering frequency. These messages will be designed based on Fogg's Behavior Model, focusing on enhancing motivation, ability, and providing clear triggers for action.
214566811|NCT06897033|BEHAVIORAL|Oral Health Education|Oral health education in a one to one session explaining the importance of oral hygiene measures and demonstrating teeth brushing techniques and healthy dietary guidelines and recommendations.
214566812|NCT06897813|DRUG|WD-910 tablet|Administered P.O.
214566813|NCT06897813|DRUG|WD-910 Tablets Placebo|Administered P.O.
214566814|NCT06898242|OTHER|Manual myofascial treatment direct to upper and lower limb|Manual treatment direct specifically on fascia connective tissue
214566815|NCT06898242|OTHER|Rehabilitative treatment following rehabilitation project|Intensive multidisciplinary rehabilitation program for at least 180 minutes/day, 6 days a week, following rehabilitation project
214708370|NCT04566822|BEHAVIORAL|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
214708371|NCT04566822|BEHAVIORAL|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
214566816|NCT06876766|DEVICE|Lung Ultrasound|Lung ultrasound (LUS) is a non-invasive, radiation-free imaging technique that uses sound waves to visualize the lungs. It will be used in the experimental arm to help guide decisions regarding antibiotic therapy in hospitalized children and adolescents with lower respiratory tract infections (LRTIs). The LUS will be performed within 24 hours of enrollment.
214566817|NCT06876766|DEVICE|Sham|In the sham group, participants will undergo a mock or placebo version of the lung ultrasound. This involves performing the procedure in a way that mimics the real ultrasound process but does not provide any diagnostic results or influence clinical decision-making regarding antibiotic therapy.
214566818|NCT06897150|DRUG|Carotegrast methyl|a dosage of 960 mg three times daily
214566819|NCT06822569|OTHER|Cue reactivity paradigm|Participants will be exposed to cues in a fixed sequence while they answer questions about their emotions and thoughts. The cues will include everyday items (e.g., an ink pen) and substance-related items (e.g., a vape pen).
214566820|NCT06900725|DRUG|edoxaban|edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.
214566821|NCT06900725|DRUG|Edoxaban 30 mg|edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.
214708372|NCT00424333|DRUG|Inhaled human insulin|
214708373|NCT00702585|DRUG|Org 36286|Org 36286 single-dose subcutaneous injection
214708374|NCT00702585|DRUG|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
214708375|NCT04223700|PROCEDURE|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
214708376|NCT02787642|DRUG|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
214708377|NCT02787642|RADIATION|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
214708378|NCT02530957|DEVICE|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
214708379|NCT02530957|DEVICE|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
214708380|NCT06310096|OTHER|TLF fascial stretching exercise|"Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF"
214708381|NCT06310096|OTHER|conventional physiotherapy program.|hotpack, ultrasound ,Tens
214708382|NCT03488914|BEHAVIORAL|YMHP Intervention|
214708383|NCT03488914|BEHAVIORAL|Enhanced Treatment as Usual|
214708384|NCT05619562|DIAGNOSTIC_TEST|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
214708385|NCT00000524|DRUG|cyclosporine|
214708386|NCT00000524|DRUG|prednisone|
214708387|NCT03811717|OTHER|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
214708388|NCT03811717|OTHER|FAST|Participants will complete an 8-hour fast.
214708389|NCT02843581|DEVICE|Cryosurgery|Argon-helium cryosurgical system
214708390|NCT02843581|BIOLOGICAL|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
214566846|NCT05020457|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
214566847|NCT05020457|DRUG|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
214566848|NCT05020457|DRUG|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
214708391|NCT01743014|DRUG|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
214708392|NCT01743014|DRUG|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
214708393|NCT00258102|DRUG|Levofloxacin|
214708394|NCT01492283|OTHER|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
214566860|NCT00146094|PROCEDURE|BMD Measurement|
214566861|NCT00146094|DRUG|antiretrovirals|Treated with antiretrovirals
214708395|NCT01492283|OTHER|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
214708396|NCT02521961|OTHER|Informational Intervention|Watch a Chair-robics DVD
214708397|NCT02521961|OTHER|Informational Intervention|Receive community resource booklet
214708398|NCT02521961|OTHER|Quality-of-Life Assessment|Ancillary studies
214708399|NCT02521961|OTHER|Questionnaire Administration|Ancillary studies
214708400|NCT02521961|PROCEDURE|Support Group Therapy|Attend support group sessions
214708401|NCT03901261|PROCEDURE|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
214708402|NCT04311177|DRUG|Losartan|Losartan; 25 mg daily; oral administration
214708403|NCT04311177|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
214566889|NCT06477250|BEHAVIORAL|Empathy-based socio-emotional mental training|The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
214566893|NCT06398457|DRUG|Darzalex Faspro (Daratumumab and hyaluronidase-fihj)|Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.
214566894|NCT06398457|DEVICE|JH-DSA Semi-Quant Screen and Response Score|Serum based semi-quantifiable investigational testing regimen used to screen for high DSA level or assess response to desensitization. It is based on results from cross-matched flow cytometric assessment cellular-based and solid phase immunoassays (SPI) that estimates antibody level.
214708404|NCT02517151|DRUG|Ferric carboxymaltose|
214708405|NCT02517151|DRUG|Placebo|
214708406|NCT01911234|BIOLOGICAL|TNF-Kinoid|IM administration
214708407|NCT01911234|OTHER|Placebo|IM administration
214566908|NCT04917107|BEHAVIORAL|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
214566914|NCT05501769|DRUG|ARV-471 in combination with Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
214566943|NCT06834724|OTHER|Standard OSA care|All people will undergo standard care.
214566944|NCT04965675|DRUG|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
214566945|NCT04965675|DRUG|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
214566946|NCT06632483|DRUG|Vericiguat (Verquvo, BAY1021189)|Prescibed as per local label
214566964|NCT04693546|DIAGNOSTIC_TEST|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
214566965|NCT04693546|DIAGNOSTIC_TEST|FIT Test|Procedure: Colonoscopy
214566977|NCT05038735|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
214566978|NCT05038735|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
214566979|NCT05038735|DRUG|Alpelisib-matching placebo|"Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~After Protocol Amendment 5 is implemented, alpelisib matching-placebo will no longer be supplied or administered once participants have been unblinded."
214566980|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
214566981|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
214566982|NCT05977491|OTHER|addressing psycholsocial problems|"1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics"
214708408|NCT04370717|OTHER|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
214708409|NCT01172834|BEHAVIORAL|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
214708410|NCT05378516|OTHER|no intervention|no intervention
214708411|NCT02391350|BEHAVIORAL|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
214566987|NCT05245513|BEHAVIORAL|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
214566988|NCT05245513|BEHAVIORAL|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
214708412|NCT02391350|PROCEDURE|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
214708413|NCT04045717|RADIATION|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
214708414|NCT02893527|BEHAVIORAL|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
214708415|NCT00413062|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
214708416|NCT00413062|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
214708417|NCT04621669|DRUG|SHR3680|240 mg
214708418|NCT04621669|DRUG|digoxin|0.25 mg
214708419|NCT04621669|DRUG|Rosuvastatin calcium|10 mg
214708420|NCT04621669|DRUG|metformin hydrochloride|500 mg
214708421|NCT01669941|DRUG|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
214708422|NCT01669941|DRUG|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
214566999|NCT05385692|DRUG|BL-M02D1|Administration by intravenous infusion
214567000|NCT05630703|BEHAVIORAL|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
214567001|NCT05630703|OTHER|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
214567004|NCT03843554|OTHER|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
214567005|NCT03843554|PROCEDURE|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
214708423|NCT01669941|DRUG|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
214708424|NCT04237324|PROCEDURE|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
214708425|NCT04237324|PROCEDURE|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
214708426|NCT04658381|GENETIC|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
214708427|NCT04658381|PROCEDURE|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
214708428|NCT04473144|DRUG|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
214708429|NCT02713763|DRUG|Sunitinib|Sunitinib 37.5 mg/day
214708430|NCT00360919|BEHAVIORAL|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
214708431|NCT06552806|DIETARY_SUPPLEMENT|SLAB51|One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
214708432|NCT01848899|DRUG|Iodixanol|contrast media used during coronary angiography
214567014|NCT05944978|DRUG|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
214567017|NCT06003231|DRUG|disitamab vedotin|Given into the vein (IV, intravenous) every 2 weeks
214708433|NCT01848899|DRUG|Ioxaglate|contrast media used during coronary angiography
214708434|NCT01848899|DRUG|Bivalirudin|A direct thrombin inhibitor
214708435|NCT02699242|DEVICE|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
214708436|NCT05947747|DRUG|EXO-CD24|Twice a day for 5 days, dose 10\^10
214708437|NCT05947747|OTHER|Placebo|Twice a day for 5 days
214708438|NCT02815293|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
214708439|NCT02815293|DRUG|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
214708440|NCT00628953|DRUG|Esomeprazole|40mg twice a day
214708441|NCT00628953|DRUG|Placebo|40mg twice a day
214708442|NCT01129180|DRUG|azacitidine|Given SC
214567021|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
214567022|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
214567023|NCT00988767|BIOLOGICAL|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
214708443|NCT01129180|DRUG|bortezomib|Given IV
214708444|NCT01129180|PROCEDURE|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
214708445|NCT00006604|DRUG|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
214708446|NCT00006604|DRUG|Ritonavir|Administered as 100 mg capsules or oral solution.
214708447|NCT02752568|PROCEDURE|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
214708448|NCT02752568|PROCEDURE|assisted hatching|using Octax laser 20120644-laser 5452
214708449|NCT02752568|PROCEDURE|controlled ovarian hyperstimulation|using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
214708450|NCT00118729|DRUG|GW685698X Aqueous Nasal Spray|
214708451|NCT03180489|DRUG|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
214708452|NCT03180489|DRUG|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
214708453|NCT03414762|DEVICE|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
214708454|NCT03414762|DEVICE|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
214708455|NCT01056341|DRUG|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
214708456|NCT01056341|DRUG|Placebo|Treatment with placebo for 6 months
214708457|NCT05062941|OTHER|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
214708458|NCT05062941|DEVICE|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
214708459|NCT01476384|DIETARY_SUPPLEMENT|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
214708460|NCT01476384|DIETARY_SUPPLEMENT|Placebo|250 ml water
214708461|NCT00987012|DIETARY_SUPPLEMENT|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
214708462|NCT00987012|DIETARY_SUPPLEMENT|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
214708463|NCT05316090|PROCEDURE|Core stability exercises program|Strengthening to the trunk muscles
214708464|NCT05316090|PROCEDURE|Traditional physical therapy program|Neurodevelopmental training excercises
214708465|NCT03766802|BEHAVIORAL|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
214708466|NCT03766802|BEHAVIORAL|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
214567042|NCT06429059|DRUG|Astaxanthin|Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).
214567043|NCT06429059|DRUG|Protandim|Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
214567044|NCT06429059|DRUG|Melatonin|Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
214567045|NCT06429059|DRUG|MitoQ|The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.
214708467|NCT03766802|BEHAVIORAL|Supervised exercise training group|3/week training supervised by a physical therapist
214567048|NCT06791109|DIAGNOSTIC_TEST|Primary care physicians|For participants in Group A, a nonblinded independent staff member will first collect medical history, followed by sequential auscultation and CHD assessment by a specialist physician and a primary care physician, with an echocardiogram performed last.
214567049|NCT06791109|DIAGNOSTIC_TEST|AI + Primary care physicians|For participants in Group B, after medical history collection, both a specialist physician and a primary care physician will perform auscultation and CHD assessment. Subsequently, the primary care physician will use an electronic stethoscope to collect heart sound data according to the protocol and upload the recordings to a cloud platform. The AI model will analyze the data on the cloud platform and provide a diagnostic result within 5-10 seconds for the primary care physician's reference. The primary care physician may reassess the findings based on the AI model's feedback, and the participant will then undergo an echocardiogram.
214567050|NCT04122976|DRUG|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
214567054|NCT05958875|DRUG|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
214567055|NCT05958875|DRUG|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
214567056|NCT06957327|DRUG|ERAS-601|ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy
214567057|NCT05626114|BIOLOGICAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
214567058|NCT04396366|DRUG|QBW251|QBW251, 300 mg, oral use, one capsule, twice daily.
214567059|NCT04396366|DRUG|Placebo|Matching placebo, 300 mg, oral use, one capsule, twice daily.
214567061|NCT06029894|DIETARY_SUPPLEMENT|Citicoline Supplement|Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
214567062|NCT06029894|OTHER|Placebo|Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
214708468|NCT05819736|OTHER|Monitoring|Monitoring
214708469|NCT00661349|DRUG|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
214708470|NCT00661349|DRUG|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
214567077|NCT06835972|DRUG|Abemaciclib|twice a day, orally
214567078|NCT06835972|DRUG|Cabozantinib|once daily, orally
214567079|NCT05973786|DRUG|Escitalopram|See arm description
214567080|NCT05973786|DRUG|Sertraline|See arm description
214567081|NCT05973786|DRUG|Venlafaxine|See arm description
214567082|NCT05973786|DRUG|Lithium|See arm description
214567083|NCT05973786|DRUG|Valproate acid|See arm description
214567084|NCT05973786|DRUG|Quetiapine|See arm description
214567085|NCT05973786|DRUG|Bupropion|See arm description
214708471|NCT01086150|PROCEDURE|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
214708472|NCT01086150|DRUG|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
214567101|NCT05134480|PROCEDURE|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
214567102|NCT06150482|OTHER|No intervention|No intervention
214567103|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC tablet for oral administration.
214567104|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration.
214708473|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
214567117|NCT03990116|PROCEDURE|Lateral|Posture lateral kangaroo care
214567118|NCT03990116|PROCEDURE|Prone|Posture prone kangaroo care
214567119|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
214567120|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
214567123|NCT06964776|DRUG|LY4268989|Administered orally
214567124|NCT06964776|DRUG|Placebo|Administered placebo
214567125|NCT06964776|DRUG|Midazolam|Administered orally
214567126|NCT06964776|DRUG|Midazolam|Administered intravenously (IV)
214708474|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
214708475|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
214708476|NCT04790552|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
214708477|NCT04790552|OTHER|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
214708478|NCT04790552|OTHER|Fast Bar|Subjects will be asked to consume a Fast Bar.
214708479|NCT04790552|OTHER|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
214708480|NCT04790552|OTHER|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
214708481|NCT02033772|PROCEDURE|Thoracoscopic surgery|
214708482|NCT00736580|OTHER|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
214708483|NCT00736580|OTHER|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
214567129|NCT06956235|DRUG|Tulisokibart|Solution in autoinjector for subcutaneous (SC) injection
214567130|NCT06956235|DRUG|Placebo|Solution in autoinjector for SC injection
214567146|NCT06019624|BEHAVIORAL|Fresh Takes!|Receipt of a fresh produce box, nutritional education and support in a 6 month program
214567151|NCT06056791|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
214567152|NCT05715021|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
214567156|NCT06463665|BIOLOGICAL|Olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
214567157|NCT06463665|DRUG|Platinum chemotherapy: carboplatin or cisplatin|Administered according to local practice.
214567158|NCT06463665|DRUG|Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|Administered according to local practice.
214567159|NCT06463665|DRUG|Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|Administered according to local practice.
214708484|NCT01681576|DRUG|Valsartan|Valsartan 320mg tablet once daily
214708485|NCT01681576|DRUG|LCZ696|LCZ696 400mg tablet once daily
214708486|NCT00693680|DIETARY_SUPPLEMENT|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
214567160|NCT06463665|DRUG|Docetaxel|Administered according to local practice.
214567196|NCT04603287|DRUG|SI-B001|Administration by intravenous infusion.
214567200|NCT05628805|DEVICE|iTBS|intermittent theta burst stimulation with TMS
214708487|NCT00693680|DIETARY_SUPPLEMENT|Placebo|placebo + imipramine (100-200mg/day)
214708488|NCT05072665|DEVICE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
214708489|NCT04119817|DIETARY_SUPPLEMENT|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
214708490|NCT04119817|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
214567201|NCT06504160|DRUG|ShA9 Topical Gel|The ShA9 topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose containing lyophilized ShA9 bacteria. The ShA9 bacteria is derived from a healthy donor-derived (allogeneic) commensal Staph species. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
214567202|NCT06504160|DRUG|Hydrocortisone Ointment|All participants will apply hydrocortisone ointment 2.5% alongside the study product in sensitive body areas (e.g., face, neck, intertriginous regions) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
214567203|NCT06504160|DRUG|Clobetasol Ointment|All participants will apply clobetasol ointment 0.05% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It will be applied twice daily to lesional skin and selected sampling areas from Baseline to Week 2. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
214567204|NCT06504160|DRUG|Fluocinonide Ointment|Participants with a past intolerance to clobetasol or who become too sensitive to clobetasol in the initial two-week cotreatment period will apply fluocinonide ointment 0.05% as an alternative. In these cases, fluocinonide ointment 0.05% will be applied alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
214567205|NCT06504160|DRUG|Placebo (Vehicle) Topical Gel|The placebo (vehicle) topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
214708491|NCT01236313|PROCEDURE|TEE report|Information will be collected during cardiac surgery.
214708492|NCT01333852|DRUG|metformin up to 2500mg/d|metformin up to 2500mg/d
214708493|NCT01333852|DRUG|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
214567213|NCT06370520|BEHAVIORAL|Validated Questionnaires|Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), The Rivermead Post Concussion Symptom Questionnaire (Rivermead), Pediatric Quality of Life Inventory (PedsQL), Strengths and Difficulties Questionnaire (SDQ)
214567214|NCT06370520|BEHAVIORAL|Questionnaires|Early Physical Activity/Return to School Questionnaire, Mental Health Utilization Questionnaire
214567215|NCT06370520|OTHER|Clinician / Medical Record Variables|Medical History, Emergency Department Clinical Variables
214567216|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
214567217|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
214567218|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
214567221|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
214567222|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
214567223|NCT05571579|BIOLOGICAL|blood and/or csf collection|"blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
214708494|NCT01333852|DRUG|placebo|placebo
214708495|NCT01393756|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
214708496|NCT05907993|DRUG|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
214708497|NCT03107676|OTHER|trunk extensors endurance training|endurance training
214567238|NCT03283254|BEHAVIORAL|Practical Resources for Effective Postpartum Parenting (PREPP)|A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
214567239|NCT03283254|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|"Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate."
214567241|NCT05689710|DIETARY_SUPPLEMENT|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
214567246|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
214567247|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
214567248|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
214567249|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
214567253|NCT05286684|PROCEDURE|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
214567254|NCT05286684|PROCEDURE|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
214567255|NCT05286684|BIOLOGICAL|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
214567256|NCT05745922|BEHAVIORAL|Moderate intensity exercise|Treadmill walking/running with moderate intensity
214567257|NCT05745922|BEHAVIORAL|High intensity exercise|Treadmill walking/running with high intensity
214567258|NCT03486873|DRUG|Pembrolizumab|200 or 400 mg IV infusion
214567259|NCT03486873|DRUG|Standard of Care (SOC)|IV infusion or oral tablets
214567260|NCT03486873|DRUG|Lenvatinib|Oral capsules
214567261|NCT03486873|DRUG|Olaparib|300mg or 250mg or 100mg oral tablers
214567262|NCT03486873|DRUG|MK-4280|IV Infusion
214567263|NCT03486873|BIOLOGICAL|MK-4280A|800mg favezelimab + 200mg pembrolizumab IV Infusion
214567275|NCT04344652|DEVICE|Photoscreening -|external picture taken with a an phone based app
214567276|NCT03883139|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
214567277|NCT03883139|BEHAVIORAL|DTT (Discrete Trial Training)|"DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction."
214567282|NCT05137132|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
214567283|NCT05137132|DIETARY_SUPPLEMENT|Placebo|MCT oil
214567288|NCT05830864|DRUG|Isoflurane|no other intervention
214567318|NCT05225428|BEHAVIORAL|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
214567319|NCT05225428|BEHAVIORAL|Genetic Counseling|Standard genetic counseling
214567321|NCT06203600|PROCEDURE|Biospecimen Collection|Undergo optional blood sample collection
214567322|NCT06203600|PROCEDURE|Computed Tomography|Undergo CT scan
214567323|NCT06203600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214567324|NCT06203600|BIOLOGICAL|Nivolumab|Given IV
214567325|NCT06203600|DRUG|Paclitaxel|Given IV
214567326|NCT06203600|OTHER|Questionnaire Administration|Ancillary studies
214567327|NCT06203600|BIOLOGICAL|Ramucirumab|Given IV
214567363|NCT06629649|OTHER|Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.|Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
214567369|NCT05663970|BEHAVIORAL|VG Social ABCs|The Social ABCs is an evidence-based caregiver-mediated early intervention. This trial examines the 6-week Virtual Group Social ABCs; an adapted model of the existing evidence-based Social ABCs. The targets are functional directed vocalizations and positive emotion sharing with a caregiver. It is provided to small groups of parents (4-8 per group) who meet virtually for a series of 6 didactic learning sessions led by two trained Coaches, supported by the programs Parent Manual, PowerPoint slides, facilitated discussion, reflection, and idea generation. Each family is assigned a Coach, and one parent per family receives 9 individualized, 1:1 live coaching sessions over a 6-week period via the virtual platform with the goal of learning to implement the Social ABCs strategies with their child. 10-min video recordings of caregiver and child are taken at baseline(time 0), post intervention (time 1),and follow up (time 2) as a measurement of fidelity of implementation and child responsivity.
214567370|NCT03786042|BEHAVIORAL|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
214567371|NCT03786042|OTHER|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
214567372|NCT05924841|DRUG|BL-B01D1|Administration by intravenous infusion
214567373|NCT05924841|DRUG|SI-B003|Administration by intravenous infusion
214567379|NCT05720156|OTHER|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
214567380|NCT06845852|DRUG|varegacestat|Single oral dose of varegacestat
214567392|NCT06034509|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
214567396|NCT06385249|DEVICE|Navina Mini|Trans-anal irrigation (TAI) with a new CE-marked device, Navina Mini
214567404|NCT05147558|DRUG|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
214567405|NCT05147558|DRUG|Lenvatinib|Lenvatinib (20mg once daily orally)
214567406|NCT06440291|PROCEDURE|Cardioneuroablation|Cardioneuroablation procedure performed according to the protocol
214567424|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
214567425|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
214567426|NCT05262491|DRUG|BL-B01D1|Administration by intravenous infusion
214567439|NCT06169722|DRUG|TDI01 suspension|200mg or 400mg oral once a day
214567440|NCT04712461|OTHER|SUPPORTS|The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
214567441|NCT01158482|PROCEDURE|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
214567445|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
214567452|NCT06241898|DRUG|BB-1709|Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
214567467|NCT06184581|DRUG|Lithium Carbonate|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
214567468|NCT06184581|DRUG|Lamotrigine|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
214567469|NCT05879133|BEHAVIORAL|Questionnaires|Survey
214567470|NCT05879133|OTHER|Fit Bit|measures physical activity
214567471|NCT05177991|DRUG|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
214567472|NCT05177991|DRUG|Bupivacaine|20cc of Bupivacaine for TAP block
214567497|NCT05875805|BEHAVIORAL|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
214567498|NCT05875805|OTHER|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
214567508|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
214567517|NCT06420518|OTHER|Ketogenic diets|During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.
214567518|NCT06420518|OTHER|8-hour insulin-suspension period|Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.
214567530|NCT02140255|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
214567531|NCT02140255|DRUG|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
214567532|NCT02140255|DRUG|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
214567533|NCT02140255|DRUG|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
214567534|NCT02140255|DRUG|VRC01|40 mg/kg administered subcutaneously.
214567535|NCT02140255|DRUG|DTG|Administered orally. Dosed according to participant's weight.
214567536|NCT02140255|DRUG|VRC07-523LS|40 mg/kg administered subcutaneously.
214567540|NCT04790370|DRUG|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
214567541|NCT04790370|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
214567547|NCT03568318|DRUG|Placebo|Tablets taken orally once a day
214567548|NCT03568318|DRUG|Upadacitinib|Tablets taken orally once a day
214567549|NCT03568318|DRUG|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
214567575|NCT00897117|GENETIC|gene expression analysis|Blood and lung tissue collection
214567576|NCT00897117|GENETIC|microarray analysis|Blood and lung tissue collection
214567577|NCT00897117|GENETIC|protein expression analysis|Blood and lung tissue collection
214567578|NCT00897117|OTHER|biologic sample preservation procedure|Blood and lung tissue collection
214567579|NCT00897117|OTHER|laboratory biomarker analysis|Blood and lung tissue collection
214567580|NCT00897117|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
214567581|NCT02625961|BIOLOGICAL|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
214567582|NCT02625961|BIOLOGICAL|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
214567583|NCT02625961|BIOLOGICAL|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
214567584|NCT01881555|PROCEDURE|invasive coronary angiography|
214567585|NCT01881555|PROCEDURE|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
214567596|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
214567597|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
214567598|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
214567609|NCT05987800|DIAGNOSTIC_TEST|Titration procedure|"The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV."
214567610|NCT05987800|DIAGNOSTIC_TEST|Electrical impedance tomography|This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.
214567611|NCT05987800|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|"Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure."
214567612|NCT05010590|DRUG|Romosozumab|Monthly romosozumab
214567613|NCT05010590|DRUG|Denosumab|Every 6 months denosumab
214567617|NCT00249262|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.
214567627|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
214567628|NCT05511363|DRUG|Placebo|Placebo Capsules
214567629|NCT05396833|DRUG|Tuvusertib|Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
214567630|NCT05396833|DRUG|Lartesertib|Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
214567631|NCT05396833|DRUG|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
214567634|NCT04681768|DRUG|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
214567635|NCT05880602|DIETARY_SUPPLEMENT|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
214567636|NCT05880602|DIETARY_SUPPLEMENT|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
214567644|NCT06233344|DRUG|Psilocybin plus mindfulness training|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists. The psilocybin dosing session will take place approximately halfway through an 8-week mindfulness training course. The mindfulness training course will consist of weekly 2-hour classes with experienced mindfulness teachers; participants will be encouraged to practice mindfulness for 45 minutes per day between classes.
214567645|NCT06233344|DRUG|Psilocybin|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists.
214567646|NCT05044897|DRUG|SI-B001|administration weekly by intravenous infusion（QW）.
214567650|NCT01261065|DRUG|carvedilol|Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
214567652|NCT06306716|DEVICE|RENASYS Film with AIRLOCK Technology|RENASYS Film with AIRLOCK Technology intended for use with Smith+Nephew RENASYS NPWT Systems
214567657|NCT04763317|GENETIC|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
214567658|NCT06281821|BEHAVIORAL|mhealth-pc|Participants meet with an interventionist who explains the rationale for the mobile app. They complete video and survey-based intervention content each week for 8 weeks. App-based sessions are supplemented with brief chat-based coaching weekly.
214567661|NCT06291675|DRUG|gender-affirming hormone therapy|We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
214567669|NCT02881320|DRUG|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food.
214567670|NCT02881320|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food.
214567671|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.
214567672|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
214567673|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
214567674|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
214567703|NCT06358638|DRUG|Daratumumab|Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
214567704|NCT06358638|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
214567705|NCT06358638|DRUG|Sirolimus|Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
214567706|NCT06358638|RADIATION|Total Body Irradiation|Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
214567707|NCT05871606|DRUG|iNO|Inhaled Nitrous Oxide
214567708|NCT06472102|PROCEDURE|Cardioneuroablation|Endocardial radio-frequency ablation of areas of ganglionated plexi in the left and the right atrium
214708498|NCT01552824|PROCEDURE|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
214708499|NCT01552824|PROCEDURE|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
214708500|NCT00011479|DRUG|Abacavir sulfate|
214708501|NCT01022346|DRUG|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
214708502|NCT01022346|DRUG|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
214708503|NCT02721251|BEHAVIORAL|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
214708504|NCT02721251|BEHAVIORAL|Weight Loss|16 week. the goal is 10% weight loss.
214708505|NCT02721251|BEHAVIORAL|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
214567719|NCT03619551|DRUG|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
214567720|NCT03619551|DEVICE|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
214567731|NCT06639464|DRUG|Semaglutide|This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
214567732|NCT06639464|OTHER|Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
214708506|NCT00599261|PROCEDURE|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
214708507|NCT06314529|OTHER|Assessments|Safety and efficacy assessments
214567743|NCT05501873|DEVICE|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
214708508|NCT05022745|OTHER|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
214708509|NCT06050967|COMBINATION_PRODUCT|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
214708510|NCT01714817|BIOLOGICAL|BMS-188667|
214708511|NCT01714817|DRUG|Mycophenolate mofetil|
214708512|NCT01714817|DRUG|Prednisone|
214708513|NCT01714817|BIOLOGICAL|Placebo matching with BMS-188667|
214708514|NCT00131820|BIOLOGICAL|Typhoid Vi vaccine|
214567780|NCT06008054|DRUG|SI-B003|Administered by intravenous infusion every 3 weeks (Q3W).
214567781|NCT06008054|DRUG|BL-B01D1|Administered by intravenous infusion for a cycle of 3 weeks.
214567782|NCT06008054|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
214567783|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
214567784|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
214567802|NCT06325644|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
214567803|NCT06325644|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
214567804|NCT06325644|BIOLOGICAL|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
214567805|NCT06325644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
214567806|NCT06325644|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
214567807|NCT06325644|OTHER|Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .|Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
214567816|NCT04974125|PROCEDURE|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
214567817|NCT04974125|PROCEDURE|Manual exsufflation|Exsufflation through the trocar opening.
214567827|NCT03293875|BEHAVIORAL|Community Events|The coalitions in collaboration with CABs and peer leaders in their respective cities convened community meetings and events and invited PWID who had participated in other intervention components, who were receiving services at the partner organizations, and members at-large to participate. Events and meetings were advertised at the partner organizations offices, by staff during delivery of harm reductions supplies at places where PWID congregated to use drugs, and through social media. Events and meetings took place at community venues including parks, neighborhood gathering spaces, and at organizations. Events covered topics about HIV, sexual health, and human rights and included health fairs.
214567828|NCT03293875|BEHAVIORAL|Social Network HIV Testing|The social network HIV testing intervention consisted of offering rapid HIV tests to PWID using a social network referral methodology.
214567829|NCT03293875|BEHAVIORAL|Peer Network Intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 PWID.
214567830|NCT03585491|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
214567831|NCT03585491|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
214708515|NCT00131820|BIOLOGICAL|Hepatitis A (control)|
214708516|NCT02921763|DRUG|Dydrogesterone|
214708517|NCT02527655|BEHAVIORAL|Choice-Based Physical Activity and Active Transportation|
214708518|NCT06051851|DRUG|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
214708519|NCT06051851|DRUG|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
214708520|NCT06051851|DRUG|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
214567843|NCT05990803|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
214708521|NCT06051851|DRUG|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
214567844|NCT05990803|DRUG|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
214708522|NCT00005848|DRUG|chemotherapy|
214708523|NCT00005848|DRUG|tipifarnib|
214708524|NCT01582971|OTHER|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
214567849|NCT05649722|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
214567850|NCT05649722|DRUG|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
214567854|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
214567855|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
214567860|NCT05881993|DRUG|CBP-4888|siRNA therapeutic
214567861|NCT05881993|OTHER|Placebo|Normal Saline
214708525|NCT01338883|DRUG|Cenicriviroc 100 mg|100 mg CVC plus Truvada
214708526|NCT01338883|DRUG|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
214708527|NCT01338883|DRUG|Sustiva + Truvada|Sustiva plus Truvada
214567866|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
214567867|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
214567868|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
214567869|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
214567883|NCT05526066|BIOLOGICAL|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).
214567884|NCT05526066|OTHER|Placebo|Normal Saline
214567888|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
214567889|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
214567916|NCT05949866|BEHAVIORAL|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
214567917|NCT05949866|BEHAVIORAL|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
214567987|NCT06830798|DRUG|Ravulizumab|Participants will receive ravulizumab via intravenous (IV) infusion.
214567988|NCT06830798|DRUG|Placebo|Participants will receive placebo via intravenous (IV) infusion.
215030429|NCT03901365|OTHER|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
214568010|NCT06287775|BIOLOGICAL|Atezolizumab|Given IV
214568011|NCT06287775|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
214568012|NCT06287775|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214568013|NCT06287775|PROCEDURE|Computed Tomography|Undergo CT scan
214568014|NCT06287775|BIOLOGICAL|Durvalumab|Given IV
214568015|NCT06287775|PROCEDURE|Echocardiography Test|Undergo ECHO
214568016|NCT06287775|DRUG|Iadademstat|Given PO
214568017|NCT06287775|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214568018|NCT06287775|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214568028|NCT02194738|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214568029|NCT02194738|DRUG|Carboplatin|Given IV
214568030|NCT02194738|DRUG|Cisplatin|Given IV
214568031|NCT02194738|OTHER|Clinical Observation|Undergo observation
214568032|NCT02194738|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214568033|NCT02194738|DRUG|Crizotinib|Given PO
214568034|NCT02194738|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
214568035|NCT02194738|PROCEDURE|Echocardiography Test|Undergo ECHO
214568036|NCT02194738|DRUG|Erlotinib|Given PO
214568037|NCT02194738|DRUG|Gemcitabine Hydrochloride|Given IV
214568038|NCT02194738|BIOLOGICAL|Nivolumab|Given IV
214568039|NCT02194738|DRUG|Paclitaxel|Given IV
214568040|NCT02194738|BIOLOGICAL|Pembrolizumab|Given IV
214568041|NCT02194738|DRUG|Pemetrexed|Given IV
214568042|NCT02194738|DRUG|Pemetrexed Disodium|Given IV
214568043|NCT02194738|OTHER|Placebo Administration|Given PO
214568044|NCT02194738|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214568062|NCT06745921|BIOLOGICAL|HydroVax-001B WNV|A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells. The vaccine contains 10 mcg of inactivated purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.10% aluminum hydroxide, 10% D-sorbitol, 0.001% Polysorbate 80 (Tween80) in 10 mM phosphate-buffer with 350 mM NaCl.
214568063|NCT06745921|OTHER|Placebo|Placebo
214568064|NCT06745921|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
214568069|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
214568070|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
214568079|NCT03535506|DRUG|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
214568080|NCT05126563|BIOLOGICAL|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
214568081|NCT05126563|OTHER|Placebo|Placebo comarator
214568082|NCT05081882|DRUG|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
214568083|NCT05081882|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
214708528|NCT02007954|DEVICE|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
214708529|NCT02659605|PROCEDURE|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
214568086|NCT04284267|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
214568087|NCT06612255|DRUG|Delafloxacin|Delafloxacin tablet
214568088|NCT06612255|DRUG|Delafloxacin Powder|Delafloxacin powder for oral suspension formulation
214568096|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.
214568097|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant
214568098|NCT06190509|BIOLOGICAL|Vaccine|The placebo is administered twice, 2 months apart
214708530|NCT02659605|PROCEDURE|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
214708531|NCT00460447|DRUG|Gemtuzumab Ozogamicin|
214568108|NCT06121206|OTHER|Altitude-like hypoxia (12% O2)|Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
214568109|NCT06121206|OTHER|Normoxia (20% O2)|Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
214568110|NCT06121206|BEHAVIORAL|Cognitive training|The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
214568111|NCT06121206|BEHAVIORAL|Sham training|Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
214568127|NCT05458297|BIOLOGICAL|Zilovertamab vedotin|IV infusion
214568128|NCT05458297|DRUG|Nemtabrutinib|Oral tablet
214568129|NCT05254743|DRUG|Pirtobrutinib|Administered orally.
214568130|NCT05254743|DRUG|Ibrutinib|Administered orally.
214568136|NCT06527937|DRUG|DESF|DESF administered in the sublingual space.
214568137|NCT06527937|DRUG|Epinephrine Injection|Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
214568141|NCT04202640|PROCEDURE|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
214568142|NCT04202640|PROCEDURE|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~* One part muscle exercise~* One part skin work (drainage)"
214568143|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
214568146|NCT06029348|BEHAVIORAL|Paced Auditory Serial Addition Task|Study volunteers will be asked to complete a 4-minute Paced Auditory Serial Addition Task, which is a standardized task that is widely used to study cardiovascular responses to acute psychological challenges (or stressors) in a laboratory setting.
214568147|NCT06042894|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
214568148|NCT06042894|DRUG|SI-B003|SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
214568149|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
214568150|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
214568155|NCT05020769|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
214568156|NCT05020769|DRUG|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
214708532|NCT06101082|BIOLOGICAL|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
214708533|NCT06079866|DEVICE|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
214708534|NCT06079866|DEVICE|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
214708535|NCT00218920|BEHAVIORAL|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
214568170|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
214568182|NCT06962280|DRUG|Tirzepatide|Administered SC
214568183|NCT06962280|DRUG|Placebo|Administered SC
214568186|NCT06431048|OTHER|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).
214568187|NCT06431048|OTHER|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
214568188|NCT04482309|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
214568189|NCT06960902|OTHER|Coronary CT scan with CAC score measurement|Coronary CT scan with CAC score measurement (on the same day or within 6 months after the inclusion visit).
214568201|NCT06145854|DRUG|Cabotegravir Injection [Apretude]|Apretude for PrEP
214568212|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
214568213|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
214568218|NCT05870774|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
214568219|NCT05870774|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
214708536|NCT00218920|BEHAVIORAL|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
214568230|NCT06120985|DEVICE|Countertop pitcher water filter|Point-of-use drinking water filter
214708537|NCT00218920|BEHAVIORAL|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
214708538|NCT04928495|DRUG|Vitamin C|Vitamin C 500 mg / day for ten days
214708539|NCT04928495|DRUG|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
214708540|NCT04928495|DRUG|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
214708541|NCT01589510|DRUG|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
214568239|NCT05803018|DRUG|BL-B01D1|Administration by intravenous infusion
214568244|NCT06504394|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|SC injection
214568262|NCT04004468|BEHAVIORAL|Resistance Training|Standard barbell resistance training programs
214568263|NCT06010433|DEVICE|CERAMENT G|"* Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~* Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
214568264|NCT05945485|BIOLOGICAL|DCVC H1 HA mRNA vaccine|A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
214568265|NCT05945485|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
214568266|NCT05945485|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
214568271|NCT03335839|DRUG|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
214568272|NCT03335839|OTHER|Saline|Placebo
214568273|NCT06643728|DRUG|Bimagrumab|Administered SC
214568274|NCT06643728|DRUG|Tirzepatide|Administered SC
214568275|NCT06643728|DRUG|Bimagrumab Placebo|Administered SC
214568276|NCT06643728|DRUG|Tirzepatide Placebo|Administered SC
214568293|NCT05868954|BEHAVIORAL|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
214568294|NCT05868954|BEHAVIORAL|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
214568295|NCT02631759|DRUG|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
214568296|NCT02631759|DRUG|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
214568297|NCT05485753|DRUG|GNC-038|Administration by intravenous infusion
214568299|NCT06576089|OTHER|Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)|"Participants randomized into ORDER will be approached by the Site Coordinator for interest in the host trial. The Coordinator will introduce the trial and share a brief, women-centred, aphasia-friendly, close-captioned video that further describes the trial procedures and an accompanying leaflet.~ORDER recruitment materials will be saved to a mobile tablet. The Coordinator will watch the video together with the potential participant, engage in discussion about the host trial and answer any questions they may have. The Coordinator will offer to leave the tablet with the potential participant, along with printed copies of the leaflet and participant information letter. The Coordinator will encourage them to share these materials with their family members, friends or member of their healthcare team who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial."
214568300|NCT06576089|OTHER|Traditional recruitment and enrollment processes (TRAD)|Participants randomized into the traditional recruitment process (TRAD) will be approached by the Site Coordinator for interest in the CAMAROS trial and presented with the standard participant information letter and full informed consent form. The information letter and consent form will be left with the potential participant to view again; the Coordinator will encourage them to share these materials with their family members or friends who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.
214708542|NCT03782636|DRUG|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
214708543|NCT03782636|OTHER|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
214568305|NCT06152627|BEHAVIORAL|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
214568306|NCT06152627|BEHAVIORAL|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
214568313|NCT06131450|DRUG|BL-M07D1|Administration by intravenous infusion
214568348|NCT06393387|DRUG|DTG/3TC versus BIC/F/TAF|A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
214568349|NCT05130294|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
214568350|NCT05130294|DIETARY_SUPPLEMENT|Placebo|MCT oil
214568352|NCT05178069|DRUG|: Placebo for Probiotic|Capsule manufactured without active ingredients.
214568353|NCT05178069|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
214568354|NCT03121209|PROCEDURE|Revascularization|Patients in this arm are randomized to CEA/CAS plus IMM
214568355|NCT03121209|OTHER|Intensive Medical Management (IMM) alone|Patients in this arm are randomized to intensive medical management (IMM) alone
214568359|NCT05870228|BEHAVIORAL|Strathclyde Sleep Intervention|Manual-based CBT-I
214568371|NCT04529772|DRUG|acalabrutinib|Investigational Product
214568372|NCT04529772|DRUG|placebo|Placebo comparator
214568373|NCT04529772|DRUG|Prednisone|Investigational Product
214568374|NCT04529772|DRUG|Rituximab|Investigational Product
214568375|NCT04529772|DRUG|Cyclophosphamide|Investigational Product
214568376|NCT04529772|DRUG|Vincristine|Investigational Product
214568377|NCT04529772|DRUG|Doxorubicin|Investigational Product
214568378|NCT01842386|DRUG|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
214568379|NCT04394546|DEVICE|WATCHMAN FLX LAAC Device|WATCHMAN FLX LAAC Device Implantation
214568380|NCT04394546|DRUG|Non-Vitamin K Oral Anticoagulant|Initiation or continuation of a NOAC drug
214568385|NCT06431815|DEVICE|FARAPULSE™ Pulsed Field Ablation System|De-novo pulmonary vein isolation (PVI) will be performed with the FARAPULSE Pulsed Field Ablation (PFA) System.
214568391|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
214568392|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
214568393|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
214568394|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
214568395|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
214568396|NCT05705323|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
214568397|NCT05705323|BEHAVIORAL|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
214568403|NCT06636110|DEVICE|Jun mHealth app|The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
214568406|NCT05192486|DRUG|GNC-038|Administration by intravenous infusion
214568407|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
214568594|NCT06196320|DRUG|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
214568595|NCT06196320|DRUG|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
214568599|NCT05890001|DRUG|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
214568602|NCT05020587|BEHAVIORAL|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
214568603|NCT03262662|DRUG|Varenicline|oral varenicline tablets
214568604|NCT03262662|BEHAVIORAL|Brief smoking cessation counseling|\~10-minute individual counseling at each of 6 clinic visits
214634077|NCT02751840|OTHER|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
214634078|NCT02751840|OTHER|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
214634079|NCT04947670|PROCEDURE|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
214634080|NCT04947670|PROCEDURE|Sham Renal arteriography|Renal arteriography only
214568614|NCT04582136|DRUG|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
214568615|NCT04582136|DRUG|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
214568633|NCT06283966|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
214568634|NCT06283966|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and formoterol fumarate pressurized inhalation suspension
214568653|NCT06305754|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg via IV infusion
214568654|NCT06305754|DRUG|Pemetrexed|500 mg/m\^2 via IV infusion
214568655|NCT06305754|DRUG|Carboplatin|AUC 5 mg/mL\*min via IV infusion
214568656|NCT06305754|DRUG|H1 Receptor Antagonist|Administered as rescue medication per approved product label
214568657|NCT06305754|DRUG|H2 Receptor Antagonist|Administered as rescue medication per approved product label
214568658|NCT06305754|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication per approved product label
214568659|NCT06305754|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication per approved product label
214568660|NCT06305754|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered as rescue medication per approved product label
214568671|NCT06393374|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg intravenous (IV) infusion q6w
214568672|NCT06393374|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
214568673|NCT06393374|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
214568678|NCT05010018|BEHAVIORAL|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
214568684|NCT04662931|DRUG|crizanlizumab|Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
214568685|NCT05271604|BIOLOGICAL|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
214568686|NCT05271604|BIOLOGICAL|Pembrolizumab|PD-1 inhibitor
214568687|NCT05271604|BIOLOGICAL|Evalstotug (BA3071)|Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody
214568688|NCT05271604|BIOLOGICAL|Cetuximab|Epidermal growth factor receptor (EGFR) antagonist
214634081|NCT00371865|BEHAVIORAL|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
214568692|NCT03736226|DEVICE|SYNERGYTM Stent System|no intervention design in the study
214568702|NCT06485635|DRUG|Nintedanib|Nintedanib
214568703|NCT06485635|DRUG|Pirfenidone|Pirfenidone
214568709|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
214568711|NCT05893186|OTHER|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
214568712|NCT05893186|OTHER|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
214568715|NCT06616025|COMBINATION_PRODUCT|NTX-001 (PEG-Fusion)|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
214634082|NCT00371865|BEHAVIORAL|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
214634083|NCT01088581|DRUG|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
214634084|NCT04817111|DRUG|MIB-626|Two (2) 500 mg Tablets, By Mouth, Daily
214634085|NCT00710073|DEVICE|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
214634086|NCT05307029|PROCEDURE|rehabilitation with fixed full-arch prosthesis|
214634087|NCT01328951|DRUG|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
214634088|NCT01328951|DRUG|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
214568719|NCT06053450|OTHER|Oil Inhalation Patch|Each participant will wear a patch for a work week (3 worked shifts) and then no patch is worn for a week. This alternates for a total of a month.
214568722|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
214568723|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
214568724|NCT05399537|DRUG|Prismocitrate 18|Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
214568725|NCT05399537|DEVICE|PrisMax System Version 3.x with calcium line accessory|The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
214568733|NCT04366531|BEHAVIORAL|START-VET|prison reentry program
214568734|NCT04366531|OTHER|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
214568735|NCT05660291|BEHAVIORAL|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
214568736|NCT05660291|BEHAVIORAL|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
214568763|NCT05355948|DEVICE|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
214568764|NCT05355948|DEVICE|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
214568765|NCT05576246|DIAGNOSTIC_TEST|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
214568781|NCT03691909|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
214568784|NCT05510687|DEVICE|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
214568792|NCT05631964|DRUG|BL-M07D1|Administration by intravenous infusion
214568802|NCT03075423|DRUG|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
214568803|NCT03075423|DRUG|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
214568809|NCT05238376|BEHAVIORAL|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
214568810|NCT04967989|PROCEDURE|Low Energy SLT|SLT performed at low energy
214568811|NCT04967989|PROCEDURE|Standard Energy SLT|SLT performed at standard energy
214568824|NCT05958342|DRUG|Calcium Gluconate|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
214568825|NCT05958342|DRUG|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
214568826|NCT05958342|DRUG|saline placebo|saline placebo volume matched to prehospital or in hospital phase
214568829|NCT06356311|BIOLOGICAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
214568830|NCT06356311|DRUG|Trifluridine-Tipiracil|Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
214568831|NCT06356311|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
214568832|NCT06356311|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
214568833|NCT06356311|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
214568834|NCT06356311|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
214568835|NCT06356311|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
214568838|NCT05051462|BEHAVIORAL|Family / systemic constellation therapy|Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
214568840|NCT04655976|BIOLOGICAL|Cobolimab|Cobolimab will be administered.
214568841|NCT04655976|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214568842|NCT04655976|DRUG|Docetaxel|Docetaxel will be administered.
214568847|NCT02425904|DRUG|Clofarabine|second-generation purine nucleoside analog
214634089|NCT01328951|DRUG|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
214634090|NCT00472433|DRUG|Alemtuzumab|
214568851|NCT05461768|DRUG|BL-M07D1|Administration by intravenous infusion
214568852|NCT05452278|OTHER|Product A|Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
214568853|NCT05452278|OTHER|Product B|Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
214568854|NCT05452278|OTHER|Product C|Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
214568855|NCT05452278|OTHER|Product D|Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
214568856|NCT06616363|BEHAVIORAL|Questionnaires to be competed|"* The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)"
214568857|NCT06616363|BEHAVIORAL|Provide list of medication and lifetime events|Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
214568858|NCT06616363|BEHAVIORAL|Use phone App to record new life events|Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
214568859|NCT06616363|DEVICE|Will wear an activity monitor|Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
214568860|NCT06616363|OTHER|Periodic 24-hour urine sodium check|POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
214568861|NCT06616363|DIAGNOSTIC_TEST|A fMRI scan|• Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
214568862|NCT06616363|DIAGNOSTIC_TEST|A bedside tilt test will be performed|A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
214568863|NCT06616363|OTHER|IV placed to collect blood samples|• An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
214568864|NCT06616363|OTHER|Stool Sample|• Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
214568865|NCT06463587|OTHER|Placebo|Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
214568866|NCT06463587|DRUG|Cladribine Low Dose|Participants will receive cladribine low dose in two courses separated by 4 weeks.
214568867|NCT06463587|DRUG|Cladribine High Dose|Participants will receive cladribine high dose in two courses separated by 4 weeks.
214568891|NCT05260021|DRUG|Tirzepatide Dose 1|Administered SC
214568892|NCT05260021|DRUG|Tirzepatide Dose 2|Administered SC
214568893|NCT05260021|DRUG|Placebo|Administered SC
214568903|NCT05393427|DRUG|BL-B01D1|Administration by intravenous infusion
214568931|NCT03663257|DEVICE|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
214568952|NCT05705479|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
214568953|NCT05705479|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
214568954|NCT06291922|BEHAVIORAL|Exercise Intervention|See arm description.
214568955|NCT06291922|BEHAVIORAL|Usual Care|See arm description.
214709057|NCT01461408|BEHAVIORAL|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
214709058|NCT02899117|OTHER|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
214709059|NCT01788982|DRUG|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
214568958|NCT06556407|DEVICE|renal denervation|ultrasound based renal denervation
214709060|NCT01788982|DRUG|Placebo|
214568971|NCT05139017|BIOLOGICAL|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
214568972|NCT05139017|BIOLOGICAL|Rituximab|IV Infusion 375 mg/m\^2
214568973|NCT05139017|DRUG|Gemcitabine|IV Infusion 1000 mg/m\^2
214568974|NCT05139017|DRUG|Oxaliplatin|IV Infusion 100 mg/m\^2
214568975|NCT05139017|DRUG|Bendamustine|IV Infusion 90 mg/m\^2
214568976|NCT05139017|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.
214568978|NCT05804747|DRUG|Edoxaban|This is observational, non-interventional study. No study drug will be administered during this study.
214568981|NCT06690996|DRUG|LY4005130|Administered IV
214568982|NCT06690996|DRUG|LY4005130|Administered SC
214568983|NCT06690996|DRUG|Placebo|Administered IV
214568984|NCT06690996|DRUG|Placebo|Administered SC
214568985|NCT05608499|DRUG|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
214568986|NCT05608499|DRUG|Placebo|Topical does not contain active properties of study drug
214568987|NCT05608499|DRUG|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
214634091|NCT05502575|BEHAVIORAL|Self-monitoring and personalized stress management|Self-monitoring and personalized stress management education and materials.
214634092|NCT05502575|BEHAVIORAL|Self-monitoring and general stress management|Self-monitoring and general stress management education and materials.
214634093|NCT01631136|DRUG|Cisplatin|75 mg/m²
214634094|NCT01631136|DRUG|Pemetrexed|500 mg/m²
214634095|NCT01631136|DRUG|Cisplatin|80 mg/m²
214634096|NCT01631136|DRUG|Gemcitabine|1250 mg/m²
214568992|NCT06143345|BEHAVIORAL|High-intensity interval training and eucaloric diet|Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants\&amp;#39; tolerance and instructor recommendations. Intensity will start at 75% of estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.
214568993|NCT06143345|BEHAVIORAL|No intense physical activity and eucaloric diet|Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.
214568994|NCT06143345|DEVICE|Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)|The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
214709061|NCT06410079|PROCEDURE|total hip replacement|Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
214709062|NCT00868452|DRUG|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
214568997|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
214568998|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
214569003|NCT05535881|BEHAVIORAL|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
214569004|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
214569006|NCT03730649|DRUG|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
214569007|NCT03730649|RADIATION|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
214569008|NCT03688126|BEHAVIORAL|Self-Guided Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
214569009|NCT03688126|BEHAVIORAL|Structured Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
214634097|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
214634098|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
214634099|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
214634100|NCT04042103|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
214635022|NCT02626507|DRUG|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
214569010|NCT02332447|DRUG|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
214569011|NCT02332447|DRUG|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
214569012|NCT03842358|DEVICE|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
214569022|NCT06034262|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
214569029|NCT05905328|DRUG|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
214569030|NCT05905328|DRUG|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
214569031|NCT05905328|DRUG|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
214569032|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
214569046|NCT06456346|DRUG|Bomedemstat|Oral capsule
214569047|NCT06456346|DRUG|Hydroxyurea|Oral capsule
214569048|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
214709063|NCT00868452|DRUG|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
214709064|NCT02290964|PROCEDURE|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
214569049|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
214709065|NCT03390712|DRUG|Paliperidone Palmitate|Monthly injections
214709066|NCT03390712|DRUG|Risperidal Consta|Bi-weekly injection
214709067|NCT03390712|DRUG|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
214569053|NCT04606472|DRUG|SI-B003|Administration by intravenous infusion.
214569070|NCT03269669|DRUG|Bendamustine Hydrochloride|Given IV
214569071|NCT03269669|PROCEDURE|Biopsy Procedure|Undergo biopsy
214569072|NCT03269669|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214569073|NCT03269669|PROCEDURE|Computed Tomography|Undergo PET/CT scans
214569074|NCT03269669|DRUG|Cyclophosphamide|Given IV
214569075|NCT03269669|DRUG|Doxorubicin Hydrochloride|Given IV
214569076|NCT03269669|PROCEDURE|Echocardiography Test|Undergo ECHO
214569077|NCT03269669|DRUG|Lenalidomide|Given PO
214569078|NCT03269669|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214569079|NCT03269669|BIOLOGICAL|Obinutuzumab|Given IV
214569080|NCT03269669|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
214569081|NCT03269669|DRUG|Prednisone|Given PO
214569082|NCT03269669|DRUG|Umbralisib|Given PO
214569083|NCT03269669|DRUG|Vincristine Sulfate|Given IV
214569089|NCT06387355|DIAGNOSTIC_TEST|Coronary computed topography (CT) angiography with FFR-CT|The investigational treatment strategy will have a coronary CT angiography diagnostic imaging with computational analysis FFR-CT (Fractional Flow Reserve from the coronary CTA)
214569091|NCT04505566|DRUG|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
214569092|NCT04505566|DRUG|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
214569093|NCT04505566|OTHER|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
214634101|NCT06108895|OTHER|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
214634102|NCT06108895|OTHER|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
214635023|NCT02626507|DRUG|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
214635024|NCT02626507|DRUG|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
214635025|NCT02626507|DRUG|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
214635026|NCT05590286|DRUG|Vonoprazan Tablets|Vonoprazan 20 mg, tablets, orally，QD
214635027|NCT05590286|DRUG|Amoxicillin Capsules|Amoxicillin 750mg, Capsules ,orally，QID
214569094|NCT06404879|OTHER|determining scores with tests|"Parents of children preparing for the operation will be given a child and family information form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will be asked to fill them out themselves.~An anesthesia technician blind to the content of the study will calculate and take notes on the children\&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative Anxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation mask is shown (T4).~FLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and complications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th minutes of all children taken to the recovery unit in the postoperative period will be recorded by the recovery unit nurse. . Children who are thought to have pain according to the FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be taken."
214569096|NCT05785039|DRUG|BL-B01D1|Administration by intravenous infusion
214569097|NCT05143554|DEVICE|Auricular percutaneous neurostimulation|Percutaneous neurostimulation
214569098|NCT05143554|DEVICE|Sham percutaneous neurostimulation|Sham percutaneous neurostimulation
214569099|NCT03158922|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
214569100|NCT03158922|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
214569101|NCT03158922|PROCEDURE|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
214569113|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
214569114|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
214569117|NCT05983588|DRUG|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
214569118|NCT05983588|DRUG|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
214569141|NCT05574439|BEHAVIORAL|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
214569142|NCT05574439|DRUG|Semaglutide 3 mg/ml|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
214569143|NCT05574439|DRUG|Placebo (Semaglutide 3 mg/ml)|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
214635028|NCT05590286|DRUG|Esomeprazole|Esomeprazole 20mg, Capsules ,orally，BID
214569174|NCT06326697|DRUG|Azacitidine|Azacitidine 300 mg Film coated tablets
214569175|NCT06326697|DRUG|Onureg|Azacitidine 300 mg Film coated tablets
214569179|NCT05160545|DRUG|GNC-035|Administration by intravenous infusion
214709068|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
214709069|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214569198|NCT06176001|OTHER|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
214569199|NCT05097274|OTHER|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
214569200|NCT05097274|OTHER|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
214569201|NCT05097274|OTHER|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
214569203|NCT05696496|DEVICE|night recording|"The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera."
214569212|NCT05913479|DEVICE|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
214569214|NCT06069375|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day
214569217|NCT04458207|PROCEDURE|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
214569218|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
214569219|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
214569227|NCT06312137|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
214569228|NCT06312137|BIOLOGICAL|Pembrolizumab|Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
214569229|NCT06312137|DRUG|Cisplatin|Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
214569230|NCT06312137|DRUG|Pemetrexed|Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
214569231|NCT06312137|DRUG|Gemcitabine|Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
214709070|NCT05128682|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
214709071|NCT04223401|OTHER|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention"
214709072|NCT01673191|DRUG|Dexamethasone intravitreal implant|
214709073|NCT01673191|DRUG|Steroid plus NSAID eye drop combination therapy|
214569232|NCT06312137|DRUG|Carboplatin|Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
214569233|NCT06312137|DRUG|Paclitaxel|Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
214569234|NCT06312137|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
214569235|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
214569236|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
214709074|NCT00772382|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
214569259|NCT06965582|DEVICE|ALPFA BPH PFA System|PFA system for treatment of Benign Prostatic Hyperplasia
214569260|NCT00261456|DIAGNOSTIC_TEST|PSA test|Patients tested for their level of Prostate Specific Antigen.
214569261|NCT00261456|PROCEDURE|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
214709075|NCT04186468|OTHER|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
214709076|NCT02833220|DEVICE|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
214569276|NCT05906381|DIETARY_SUPPLEMENT|Probiotics|A specific probiotics capsule product, containing Streptococcus thermophilus will be given to participants for oral intake for 35 days.
214569277|NCT05906381|DIETARY_SUPPLEMENT|Placebo|A specific capsule product, containing microcrystalline cellulose will be given to participants for oral intake for 35 days.
214569280|NCT05457283|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
214569283|NCT04905069|DEVICE|SpaceOAR Vue System|"The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
214569296|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
214569297|NCT06966700|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
214569298|NCT06966700|BIOLOGICAL|Pembrolizumab|IV infusion
214569299|NCT06966700|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
214569300|NCT06966700|DRUG|Carboplatin|IV infusion
214569301|NCT06966700|DRUG|Paclitaxel|IV infusion
214569302|NCT06966700|DRUG|Doxorubicin|IV infusion
214569303|NCT06966700|DRUG|Epirubicin|IV infusion
214569304|NCT06966700|DRUG|Cyclophosphamide|IV infusion
214569305|NCT06966700|DRUG|Capecitabine|Oral tablet
214569306|NCT06966700|DRUG|Olaparib|Oral tablet
214569311|NCT06540391|BIOLOGICAL|MB097|Live bacterial therapeutic for oral administration
214569312|NCT06540391|BIOLOGICAL|Pembrolizumab|IV infusion
214709077|NCT00906867|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
214709078|NCT00906867|PROCEDURE|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
214569313|NCT06540391|DRUG|Vancomycin|Antibiotic
214569329|NCT03964090|DRUG|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
214569330|NCT03964090|DRUG|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
214569331|NCT03964090|DRUG|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
214569332|NCT03964090|DRUG|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
214569333|NCT03964090|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
214709079|NCT05796804|PROCEDURE|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
214709080|NCT05796804|PROCEDURE|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
214569334|NCT03964090|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
214569335|NCT06067802|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin
214569338|NCT04906395|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
214569339|NCT04906395|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet or solution
214569340|NCT04906395|DRUG|Letrozole Tablets|One 2.5 mg tablet taken orally once daily
214569341|NCT04906395|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
214569342|NCT04906395|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
214569351|NCT05437575|DRUG|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
214569352|NCT05437575|DRUG|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
214709081|NCT05796804|PROCEDURE|spinal anesthesia|bupivacaine 0.5% 2.2 ml
214569409|NCT04937062|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/203284s005lbl.pdf)."
214569412|NCT04435288|DRUG|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~1. In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~2. In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~3. In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
214569413|NCT04435288|DRUG|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
214634103|NCT06122480|PROCEDURE|Surgery|All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
214634104|NCT04539210|DEVICE|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
214569414|NCT04435288|DRUG|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~1. If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~2. If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~3. If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
214569415|NCT04435288|DRUG|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
214569422|NCT06252493|DRUG|Radiotracer Injection|"Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall."
214569423|NCT06252493|DRUG|Contrast Media, Magnetic Resonance|Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
214569424|NCT06252493|DIAGNOSTIC_TEST|Blood Draw|All subjects will undergo placement of an intravenous catheter (IV). Through the same catheter, 10 mL of venous blood will be collected to evaluate blood markers for fibrostenosis.
214569425|NCT06252493|DRUG|Glucagon|Glucagon will be injected into the subject's indwelling i.v. catheter (0.3-0.5 mg) before imaging acquisition; or intramuscularly (1-2 mg) prior to imaging the abdomen and pelvis. A second administration of IV glucagon (0.3-0.5mg) may take place during image acquisition.
214569426|NCT06252493|DIAGNOSTIC_TEST|Imaging|MR and PET images of the abdomen and pelvis will be acquired using the Siemens 3 Tesla Biograph mMR scanner. Multiple anatomical and functional imaging sequences may be run to assess specific image quality measures in addition to those used for anatomical diagnosis. Among the sequences, patients will undergo a full set of standard of care MR enterography sequences to ensure they get at least same quality of study and of clinical information they would gain from a clinical study. Certain MR sequences scans may be repeated after varying a limited range of pulse sequence parameters to assess their effect on the image contrast, image artifacts and signal to noise ratio.
214569427|NCT06252493|DRUG|Oral contrast media application|Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
214569428|NCT05924750|DRUG|BL-M11D1|Administration by intravenous infusion
214569430|NCT05421728|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
214569431|NCT05421728|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
214569432|NCT02963025|PROCEDURE|PEEP level|
214569433|NCT02963025|PROCEDURE|Use of recruitment maneuvers|
214569434|NCT05565378|DRUG|Pembrolizumab|Pembrolizumab will be administered.
214569435|NCT05565378|DRUG|Dostarlimab|Dostarlimab will be administered
214569436|NCT05565378|DRUG|Belrestotug|Belrestotug will be administered.
214569437|NCT05565378|DRUG|Nelistotug|Nelistotug will be administered.
214569438|NCT03065062|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
214569439|NCT03065062|DRUG|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
214569440|NCT04557150|DRUG|Forimtamig|Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
214569442|NCT04824859|BEHAVIORAL|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
214569447|NCT04876456|DRUG|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
214634105|NCT01483781|DRUG|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
214569465|NCT05745038|BEHAVIORAL|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
214569466|NCT06972472|DRUG|Orforglipron|Administered orally
214569467|NCT06972472|DRUG|Placebo|Administered orally
214569468|NCT02966665|OTHER|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
214569469|NCT02966665|DRUG|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
214569470|NCT02966665|DRUG|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
214569471|NCT02966665|DRUG|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
214569472|NCT02966665|OTHER|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
214634106|NCT01483781|DRUG|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
214634107|NCT00325026|DRUG|Misoprostol|
214634108|NCT00325026|DEVICE|Foley bulb|
214634109|NCT01762852|DRUG|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
214569473|NCT02966665|DRUG|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
214569474|NCT02966665|DRUG|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
214569478|NCT06665919|OTHER|CYP2C19 Genotype-Guided Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
214569479|NCT06665919|OTHER|CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel|An antiplatelet drug alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor, or prasugrel).
214569480|NCT06665919|OTHER|The Conventional Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or clopidogrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
214569481|NCT06972446|DRUG|Lutikizumab|Subcutaneous (SC) injection
214569482|NCT06972446|DRUG|Placebo|Subcutaneous (SC) injection
214569483|NCT06972446|DRUG|Ravagalimab|Subcutaneous (SC) injection
214569484|NCT05433090|BEHAVIORAL|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
214569485|NCT05425641|BEHAVIORAL|Goal Setting|"Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?."
214569486|NCT05425641|BEHAVIORAL|Action Planning|"Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?"
214569487|NCT05425641|BEHAVIORAL|Self-Monitoring of Behavior|"Individuals will receive daily text messages that include the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Self-Monitoring BCT is Check your fitbit for yesterday. Type in the number of steps you did yesterday."
214569488|NCT05425641|BEHAVIORAL|Feedback on Behavior|"Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm. "
214709082|NCT03141372|DEVICE|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
214709083|NCT00760604|PROCEDURE|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
214709084|NCT00643604|DRUG|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
214709085|NCT03608904|OTHER|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
214569491|NCT06564506|DEVICE|Disposable acupuncture needles (0.30 × 75 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
214569492|NCT06564506|DEVICE|Placebo needles (0.30 × 25 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.
214569493|NCT06564506|DEVICE|SDZ-V electroacupuncture devices|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
214634110|NCT01762852|DRUG|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
214634111|NCT04449055|DEVICE|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
214634112|NCT02244502|DEVICE|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
214634113|NCT02244502|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
214634114|NCT01003210|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
214634115|NCT02256514|BIOLOGICAL|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
214634116|NCT03754075|PROCEDURE|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
214634117|NCT03754075|PROCEDURE|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
214709086|NCT03608904|OTHER|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
214709087|NCT02763072|DEVICE|Enlighten Laser|
214709088|NCT02763072|DEVICE|Excel V Laser|
214709089|NCT05594108|DIAGNOSTIC_TEST|ultrasonography|transabdominal ultrasonography
214569512|NCT06972459|DRUG|Orforglipron|Administered orally
214569513|NCT06972459|DRUG|Placebo|Administered orally
214569514|NCT06320067|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
214569515|NCT06320067|OTHER|177Lu-PSMA-617|177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
214569516|NCT06320067|DRUG|Androgen Deprivation Therapy (ADT)|Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
214634118|NCT00542256|DEVICE|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
214569517|NCT06320067|DRUG|Androgen Receptor Signalling Inhibitor (ARPI)|"Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles."
214569518|NCT06320067|RADIATION|Radiotherapy to Prostate ± Pelvic Nodes|Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
214569519|NCT06320067|DRUG|Docetaxel|Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
214569523|NCT05377996|DRUG|XMT-1660|XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
214569528|NCT05965856|DRUG|BL-B01D1|Administration by intravenous infusion
214569529|NCT05965856|DRUG|SI-B003|Administration by intravenous infusion
214569531|NCT06481891|DRUG|Sotagliflozin|Sotagliflozin will be administered as a tablet(s), orally once daily.
214569532|NCT06481891|DRUG|Placebo|Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
214569533|NCT05858281|BEHAVIORAL|Survey|Black adolescent girls (aged 12-17) will participate in an online survey and will be asked questions regarding their strengths, family, school and community experiences, sexual education knowledge, physical health and mental wellbeing, etc.
214569534|NCT05858281|BEHAVIORAL|Interviews|Parents/guardians of Black girls (aged 12-17) and Black emerging adult women aged 18-22 will participate in individual interviews and will be asked questions about their understanding of Black girls' strengths and resources.
214569535|NCT05858281|BEHAVIORAL|Focus group|Black adolescent girls (aged 12-17) will participate in a focus group and will be asked questions regarding their strengths, family, school and community resources, etc.
214569551|NCT05929183|DEVICE|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
214569552|NCT05929183|DEVICE|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
214569561|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
214709090|NCT03843736|BEHAVIORAL|Lifestyle intervention|"1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation."
214569566|NCT06046014|OTHER|BI Focused writing|BI Focused writing program
214569567|NCT06046014|OTHER|Control|Attention Control Writing
214709091|NCT03843736|DRUG|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
214569579|NCT03883646|BEHAVIORAL|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
214569580|NCT03883646|BEHAVIORAL|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
214569582|NCT05194982|DRUG|BL-B01D1|Administration by intravenous infusion.
214569598|NCT06575699|PROCEDURE|Rectus sheath block|bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
214569599|NCT06575699|PROCEDURE|Thoracic Epidural Analgesia|Low thoracic Epidural Analgesia.
214569600|NCT06575699|DRUG|Liposomal bupivacaine|133 mg liposomal bupivacaine per side for rectus sheath block
214569601|NCT06575699|DRUG|Bupivacaine Hydrochloride|20 mL bupivacaine 0.25% per side for rectus sheath block
214569602|NCT06575699|DRUG|Bupivacaine-Hydromorphone Cassette|Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
214569605|NCT04095923|BEHAVIORAL|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
214569606|NCT04095923|BEHAVIORAL|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
214709092|NCT03843736|DRUG|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
214569614|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
214569615|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
214569616|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
214634119|NCT00542256|DEVICE|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
214634120|NCT02037932|DEVICE|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
214634121|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
214709093|NCT05931055|DIAGNOSTIC_TEST|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
214569635|NCT06419374|BIOLOGICAL|Pegozafermin|Subcutaneous injection
214569636|NCT06419374|DRUG|Placebo|Subcutaneous injection
214569637|NCT06651281|DRUG|Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
214569638|NCT06651281|DRUG|Placebo to tulisokibart|Placebo matching SC tulisokibart
214569641|NCT05223608|OTHER|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
214569644|NCT05666921|OTHER|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
214569646|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
214709094|NCT01225471|BIOLOGICAL|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
214569654|NCT06464549|DIAGNOSTIC_TEST|EEG-EOG recording at rest and during an auditory oddball paradigm|Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
214569655|NCT04150068|DRUG|Oral Lenacapavir|Tablets administered without regard to food
214569656|NCT04150068|DRUG|Oral Lenacapavir Placebo|Tablets administered without regard to food
214569657|NCT04150068|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
214569658|NCT04150068|DRUG|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
214569659|NCT04150068|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
214569660|NCT06455787|DEVICE|J-Valve Transfemoral (TF) System|Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.
214569661|NCT05316701|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
214569662|NCT05316701|BIOLOGICAL|Standard-of-Care|unmanipulated donor allograft
214569664|NCT04696653|OTHER|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
214569672|NCT06265272|DRUG|Injection of a gadolinium contrast agen|"All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;"
214569673|NCT06265272|DRUG|Radiotracer Injection|"All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan"
214569674|NCT06265272|DIAGNOSTIC_TEST|Imaging|PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
214569676|NCT04615130|OTHER|Rehabilitation|Rehabilitation, exercise training
214569677|NCT05013632|DRUG|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
214569678|NCT05013632|DRUG|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
214569681|NCT05054439|DRUG|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
214569682|NCT05054439|DRUG|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
214569683|NCT04141735|DIAGNOSTIC_TEST|ultrasound|no intervention
214569684|NCT05890898|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
214569685|NCT05890898|DRUG|Nitrous Oxide|Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
214569686|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
214569687|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
214634122|NCT00271817|DRUG|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
214634123|NCT00271817|DRUG|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
214634124|NCT00271817|DRUG|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
214634125|NCT00271817|DRUG|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
214709095|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 48 weeks
214709096|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 24 weeks
214569694|NCT04625413|BEHAVIORAL|Behavioral: UR-GOAL communication tool|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
214569696|NCT06318390|DIETARY_SUPPLEMENT|XO Genius|This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health
214569710|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
214569721|NCT04679935|BIOLOGICAL|Brolucizumab|Intravitreal injection
214569722|NCT04112667|OTHER|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
214569723|NCT04112667|OTHER|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
214569724|NCT04112667|OTHER|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
214709097|NCT03591055|OTHER|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
214709098|NCT04426838|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
214709099|NCT01644955|DRUG|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
214709100|NCT01644955|PROCEDURE|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
214569747|NCT05760001|OTHER|Assigned Interventions|"Financial well-being interventions:~• Tax preparation; access to public benefits; financial counseling and microgrants~Place-based interventions:~• Vacant lot greening; abandoned house remediation; trash cleanup; tree planting"
214569748|NCT02577120|DEVICE|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
214569749|NCT02577120|BIOLOGICAL|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
214709101|NCT03550638|DEVICE|Coil system(Ton-bridgeMT)|1\. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
214709102|NCT03550638|DEVICE|Axium Detachable Coil(Medtronic)|2\. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
214709103|NCT04678011|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
214709104|NCT03539861|DEVICE|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
214709105|NCT02702011|DRUG|empagliflozin medium dose|
214709106|NCT02702011|DRUG|empagliflozin low dose|
214709107|NCT02702011|DRUG|empagliflozin high dose|
214709108|NCT02702011|DRUG|placebo|
214569751|NCT06973577|DRUG|Centanafadine|Centanafadine QD XR fixed dose 328.8mg
214569752|NCT06973577|OTHER|Placebo|Placebo
214569753|NCT06312176|DRUG|Sacituzumab tirumotecan|IV infusion
214569754|NCT06312176|BIOLOGICAL|Pembrolizumab|IV infusion
214569755|NCT06312176|DRUG|Paclitaxel|IV infusion
214569756|NCT06312176|DRUG|Nab-paclitaxel|IV infusion
214569757|NCT06312176|DRUG|Capecitabine|oral tablet
214569758|NCT06312176|DRUG|Liposomal doxorubicin|IV infusion
214569762|NCT06575426|COMBINATION_PRODUCT|OPF-310|"Dose(Part1): 6,000 islet equivalents (IEQ)/kg or 12,000 islet equivalents (IEQ)/kg~Dose(Part2): Recommended Phase II Dose(RP2D), which will be determined based on the data of Part1~* In Part1, three subjects will be enrolled into the first dosing cohort (Cohort 1: 6,000 IEQ/kg) and they will undergo safety monitoring. Three subjects in Cohort 2 will be dosed with 12,000 IEQ/kg and will undergo safety monitoring.~* In Part2, 7 subjects will be enrolled into the Part 2 dose-expansion part."
214569771|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
214569772|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
214569783|NCT05085210|DEVICE|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
214569784|NCT05085210|BEHAVIORAL|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
214569785|NCT05085210|DEVICE|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
214569786|NCT05085210|BEHAVIORAL|Virtual Reality Based Visual Training|• Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center point within the VR headset during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
214709109|NCT02000453|DRUG|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
214709110|NCT00466583|DRUG|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
214709111|NCT02165033|DRUG|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
214709112|NCT03203954|BEHAVIORAL|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
214569813|NCT06979336|DRUG|RO7837195|RO7837195 will be administered as per the schedule specified in the protocol.
214569814|NCT06979336|DRUG|RO7837195 Matched Placebo|RO7837195 matched placebo will be administered as per the schedule specified in the protocol.
214569818|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System|Standard of Care Surgery + Embolization
214569819|NCT04816591|OTHER|Standard of Care Surgery|Standard of Care Surgery Only
214569820|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System|Standard of Care Medical Management + Embolization
214569821|NCT04816591|OTHER|Standard of Care Medical Management|Standard of Care Medical Management Only
214634126|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
214634127|NCT00271817|DRUG|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
214634128|NCT00271817|DRUG|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
214634129|NCT06368713|BEHAVIORAL|Exercise|"* Frequency: Exercise sessions will occur no less than three times per week.~* Intensity: The intensity will be based on a rating of perceived exertion score ranging from 12 to 16 on a scale of 6 to 20.~* Exercise duration: Each exercise session will last approximately 30 minutes.~* Exercise Type:The exercise regimen will include aerobic exercise, resistance exercise, and flexibility training."
214569830|NCT04901195|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214634130|NCT02954497|DEVICE|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
214709113|NCT03203954|BEHAVIORAL|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
214709114|NCT03203954|BEHAVIORAL|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
214709115|NCT00006454|DRUG|carboplatin|
214709116|NCT00006454|DRUG|paclitaxel|
214709117|NCT00006454|DRUG|topotecan hydrochloride|
214709118|NCT03017365|OTHER|Stable Resistance Training|traditional machine-based resistance training
214709119|NCT03017365|OTHER|Unstable Resistance Training|free weight resistance training using unstable devices
214569861|NCT06853665|DRUG|Adderall XR (mixed salts amphetamine)|Capsule
214569862|NCT06853665|DRUG|Placebo|Capsule
214569865|NCT06979596|DRUG|MK-5684|Tablet for oral administration.
214709120|NCT03017365|OTHER|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
214569866|NCT06979596|DRUG|Fludrocortisone/ Fludrocortisone acetate|Tablet for oral administration.
214569867|NCT06979596|DRUG|Dexamethasone/Dexamethasone acetate|Tablet for oral administration.
214569868|NCT06979596|DRUG|Rescue Medications|Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.
214569869|NCT06979596|DRUG|Fulvestrant|Administered via intramuscular injection.
214569870|NCT06979596|DRUG|Exemestane|Tablet for oral administration.
214569871|NCT06979596|DRUG|Megestrol acetate/Medroxyprogesterone acetate|Tablet for oral administration.
214569872|NCT06979596|DRUG|Tamoxifen|Tablet for oral administration.
214569873|NCT06979596|DRUG|Letrozole|Tablet for oral administration.
214709121|NCT02930616|DEVICE|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
214709122|NCT02930616|DEVICE|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
214569884|NCT06841354|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
214569885|NCT06841354|BIOLOGICAL|Pembrolizumab|IV Infusion
214569886|NCT06841354|DRUG|Rescue Medication|Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
214569887|NCT06841354|DRUG|Paclitaxel|IV Infusion
214569888|NCT06841354|DRUG|Nab-paclitaxel|IV Infusion
214569889|NCT06841354|DRUG|Gemcitabine|IV Infusion
214569890|NCT06841354|DRUG|Carboplatin|IV Infusion
214634131|NCT02954497|PROCEDURE|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
214634132|NCT01049685|DRUG|First-line Antiretroviral Therapy|"* Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background"
214709123|NCT04143763|OTHER|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
214709124|NCT04208334|DIETARY_SUPPLEMENT|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
214709125|NCT04208334|OTHER|Placebo|We give a control arm to consume placebo for 60 consecutive days.
214709126|NCT06251219|DIAGNOSTIC_TEST|PCR|PCR test for EV71, CA16, CA10, or CA6
214709127|NCT03546790|DRUG|Marijuana|Marijuana smoked via blunts with different cigar wrappers
214709128|NCT00874679|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
214709129|NCT02407041|DRUG|GR-MD-02|IV infusion
214569904|NCT06357533|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
214569905|NCT06357533|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
214569906|NCT06357533|DRUG|Pembrolizumab|Pembrolizumab IV (intravenous)
214569907|NCT06597773|OTHER|Online patient navigation and supportive care referrals|In the online patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to web-based, systematic supportive care resources consisting of pre-recorded videos led by specialists and which will be available on a study-specific website, allowing each participant to access the resources as soon as they receive a referral. Additionally, online support groups will be held monthly to complement the supportive care programs.
214569908|NCT06597773|OTHER|In-person patient navigation and supportive care referrals|In the in-person patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to supportive care services available at their healthcare institution.
214569913|NCT03598595|DRUG|Docetaxel|Given IV
214569914|NCT03598595|DRUG|Gemcitabine|Given IV
214709130|NCT05052528|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
214569915|NCT03598595|DRUG|Hydroxychloroquine|Given PO
214569922|NCT02683980|DEVICE|Lumenis Pulse P120H and Xpeeda side firing fiber|
214709131|NCT05052528|DRUG|Cyclophosphamide|Given IV
214709132|NCT05052528|DRUG|Fludarabine Phosphate|Given IV
214709133|NCT05052528|BIOLOGICAL|Rituximab|Given IV
214569932|NCT06814028|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During the Second and Third Menstruations, participants will self-administer daily active tAN sessions Volta System Device beginning Day 1 of menstruation through the final day of menstruation.
214569933|NCT06138067|BEHAVIORAL|High intensity approach|PEM, cancer center support services material, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the participants appointment with the medical oncologist. If enrolled in a clinical trial, the patient navigator will call the participant biweekly, or more often if they are working to resolve any needs identified in the needs assessment) until the participant is successfully enrolled in the therapeutic clinical trial. The patient navigator will call the participant once weekly for 4 weeks, or less than 4 weeks in other cases including withdrawal from the clinical trial or this navigation study, disease progression, or death. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
214569934|NCT06138067|BEHAVIORAL|Low intensity approach|The participant will receive PEM, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the appointment with the medical oncologist. The patient navigator will call the participant 4 weeks after enrollment on the trial. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
214569942|NCT05022654|DRUG|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
214569943|NCT05022654|DRUG|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
214569949|NCT06985940|OTHER|Visual stimulation|Participants will watch a 10-minute snow- or fire-themed video
214569950|NCT06985940|OTHER|Acoustic stimulation|Participants will listen to a natural sound from fire burning or snow falling
214569951|NCT06985940|OTHER|Combination|Participants will undergo both visual and acoustic stimulation
214569954|NCT04171440|PROCEDURE|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
214709134|NCT05184309|OTHER|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
214569968|NCT06818643|BIOLOGICAL|MK-3120|IV infusion
214569970|NCT06817668|RADIATION|ePURT 5Gy x 5 fractions with single HDR boost of 15Gy|ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.
214709135|NCT05184309|OTHER|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
214709136|NCT01703611|OTHER|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
214709137|NCT01703611|OTHER|Usual Nutrition Care|Usual nutrition care in India
214709138|NCT00213161|DRUG|iron supplement, iron drops|
214569972|NCT06170788|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
214569973|NCT06170788|BIOLOGICAL|Pembrolizumab|IV infusion
214709139|NCT03648307|DIAGNOSTIC_TEST|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
214569974|NCT06170788|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
214569994|NCT06820463|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214569995|NCT06820463|DRUG|Fluorouracil|IV Infusion; IV Injection
214569996|NCT06820463|DRUG|Oxaliplatin|IV Infusion
214569997|NCT06820463|DRUG|Leucovorin|IV Infusion; IV Injection
214569998|NCT06820463|DRUG|Bevacizumab|IV Infusion
214569999|NCT06820463|DRUG|Panitumumab|IV Infusion
214570000|NCT05552976|DRUG|Mezigdomide|Specified dose on specified days
214570001|NCT05552976|DRUG|Carfilzomib|Specified dose on specified days
214570002|NCT05552976|DRUG|Dexamethasone|Specified dose on specified days
214709140|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
214570009|NCT04504019|DEVICE|USCTR|Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR
214570010|NCT04504019|PROCEDURE|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
214570011|NCT02993146|OTHER|Laboratory Biomarker Analysis|Correlative studies
214570012|NCT02993146|OTHER|Pharmacological Study|Correlative studies
214570013|NCT02993146|OTHER|Quality-of-Life Assessment|Ancillary studies
214570014|NCT02993146|DRUG|Ropidoxuridine|Given PO
214570015|NCT02993146|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214570016|NCT06824662|DRUG|Quisinostat|a highly potent and orally active HDAC inhibitor
214570020|NCT06658405|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.
214570021|NCT06817356|DRUG|Mazdutide|Administered SC
214570022|NCT06817356|DRUG|Placebo|Administered SC
214570026|NCT05281471|BIOLOGICAL|olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
214570027|NCT05281471|DRUG|Platinum chemotherapy: carboplatin (preferred) or cisplatin|Administered according to local practice
214570028|NCT05281471|DRUG|Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|Administered according to local practice
214570029|NCT05281471|DRUG|Bevacizumab (or biosimilar)|Administered according to local practice
214570032|NCT05470348|DRUG|BL-B01D1|Administration by intravenous infusion
214570038|NCT04362189|BIOLOGICAL|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
214709141|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
214709142|NCT01422590|DRUG|Sitagliptin|Single oral administration of sitagliptin 100 mg
214709143|NCT01422590|DRUG|Mitiglinide|Single oral administration of mitiglinide 10 mg
214709144|NCT01422590|DRUG|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
214709145|NCT05557734|PROCEDURE|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
214709146|NCT05557734|PROCEDURE|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
214570039|NCT04362189|OTHER|Placebo|Saline
214570050|NCT02111681|DEVICE|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
214570052|NCT06597474|BEHAVIORAL|Food-Body-Mind|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
214570057|NCT05500391|OTHER|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
214709147|NCT04462757|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
214709148|NCT04985331|DEVICE|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
214709149|NCT00883220|BEHAVIORAL|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
214709150|NCT02058758|DEVICE|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
214709151|NCT01374217|DRUG|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
214709152|NCT01374217|DRUG|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
214709153|NCT01374217|DRUG|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
214570063|NCT06603571|DRUG|LY3841136|Administered SC
214570064|NCT06603571|DRUG|Tirzepatide|Administered SC
214570065|NCT06603571|DRUG|Placebo|Administered SC
214709154|NCT01374217|DRUG|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
214709155|NCT02450734|PROCEDURE|Ultrasound-guided intermediate cervical plexus block|
214709156|NCT01740388|DRUG|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
214709157|NCT01740388|DRUG|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
214709158|NCT05344625|DRUG|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
214709159|NCT01025258|BEHAVIORAL|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
214570084|NCT04258449|DEVICE|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
214709160|NCT01025258|BEHAVIORAL|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
214570088|NCT06809400|DRUG|LY4006896|Administered intravenously (IV)
214570089|NCT06809400|DRUG|Placebo|Administered IV
214570092|NCT06859294|DRUG|LY3541860|Administered IV
214570093|NCT06824675|OTHER|Teledidactic Training|Participants will take part in a tele-didactic training session, matching the duration of the control group's training. This workshop will cover the same content as the control group's session, but instead of in-person instruction, teaching experts will deliver the training remotely using telemedicine software.
214570094|NCT06824675|OTHER|In-Person Hands-on Training|Participants will attend a face-to-face, hands-on workshop led by experts to learn the eFAST protocol.
214570095|NCT06825000|BEHAVIORAL|neuro-education|30 minutes of videos about the neuroscience of stress, fear, emotion-regulation, and therapy.
214570096|NCT06825000|BEHAVIORAL|psycho-education|30 minutes of videos about the psychological science of stress, fear, emotion-regulation, and therapy.
214570097|NCT06859177|DEVICE|Remote eCTG|"Device: Remote eCTG monitoring~A remote self-administered electrophysiological cardiotocography (eCTG) monitoring (using Nemo Remote®), daily in a Home@Hospital setting, or at least twice weekly at the outpatient clinic, between 32 and 37 weeks of pregnancy."
214570103|NCT06859970|DEVICE|PAS-C System|All patients will undergo catheterization with the PAS-C System to create an interatrial shunt to reduce left atrial pressure in the heart.
214570106|NCT04728204|BEHAVIORAL|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
214570117|NCT05753501|DRUG|ABBV-101|Oral:Tablet
214570118|NCT06595602|DEVICE|Artificial intelligence based decision support system (AI-DSS); software|"The device is intended for monitoring and recommending ventilator settings, ventilation mode to qualified Intensive Care Unit (ICU) health care professionals (HCP). This is for medical indications that require invasive mechanical ventilation of the respiratory system in the ICU under international / EU guidelines.~The device receives clinical data via the ICU's data integration platform that includes patient physical and demographic data as well as current vital signs, ventilation parameters, blood gas analysis, general blood laboratory reports, fluid balance and medication. Prediction models based on artificial intelligence algorithms are used to deduce therapy suggestions from received data. The algorithm is carried out on a secured cloud platform."
214570119|NCT06596694|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
214709161|NCT04490317|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients"
214709162|NCT04490317|PROCEDURE|Hyperbaric oxygen therapy|"1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients"
214709163|NCT01369212|DRUG|Tenofovir|300 mg daily for 192 weeks (4 years)
214709164|NCT01369212|DRUG|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
214709165|NCT01309438|DRUG|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
214709166|NCT01309438|DRUG|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
214709167|NCT01309438|DRUG|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
214709168|NCT01309438|DRUG|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
214709169|NCT00862121|DRUG|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
214709170|NCT00862121|DRUG|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
214709171|NCT02943005|PROCEDURE|Rotator cuff repair|
214709172|NCT04007601|DEVICE|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
214570163|NCT06864026|DRUG|Tirzepatide|Administered SC
214709173|NCT04007601|DEVICE|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
214570179|NCT06863272|DRUG|Docetaxel|Administered via Intravenous (IV) infusion at a specified dose on specified days
214570180|NCT06863272|DRUG|Ifinatamab Deruxtecan|Administered via IV infusion at a specified dose on specified days
214570181|NCT06863272|DRUG|MK-5684|Administered orally at a specified dose on specified days
214570182|NCT06863272|DRUG|Abiraterone|Administered orally at a specified dose on specified days
214570183|NCT06863272|DRUG|Enzalutamide|Administered orally at a specified dose on specified days
214709174|NCT04358198|DIAGNOSTIC_TEST|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
214570196|NCT00809172|DRUG|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
214570197|NCT00809172|DRUG|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
214570206|NCT06677060|DRUG|Baxdrostat and dapagliflozin|baxdrostat tablet and dapagliflozin tablet
214570207|NCT06677060|OTHER|Placebo and dapagliflozin|placebo tablet and dapagliflozin tablet
214570214|NCT07001293|BEHAVIORAL|MomMA Intervention|The MomMA program is a CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings.
214570215|NCT07001293|OTHER|Treatment as Usual (TAU)|Participants will receive treatment as usual, including but not limited to medication and behavioral therapy. No participation in treatment is required.
214570217|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
214570218|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
214570219|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
214570220|NCT05116540|BIOLOGICAL|HB-adMSCs|Autologous product
214570221|NCT05116540|DRUG|Placebo|Normal Saline
214570223|NCT07003919|COMBINATION_PRODUCT|DBV712 250 mcg|DBV712 250 mcg epicutaneous system.
214570224|NCT07003919|COMBINATION_PRODUCT|Placebo|DBV712 matching placebo epicutaneous system.
214570225|NCT06857942|DRUG|Tirzepatide|Administered SC
214570226|NCT06858878|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be adminstered SC.
214570227|NCT06858878|DRUG|Placebo|Placebo will be adminstered SC.
214570228|NCT04684563|BIOLOGICAL|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
214570233|NCT05949606|DRUG|SI-B001|Administration by intravenous infusion
214570234|NCT05949606|DRUG|SI-B003|Administration by intravenous infusion
214570240|NCT06478017|DRUG|Belatacept|"Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter"
214570241|NCT06478017|DRUG|Tacrolimus|Prograf (tacrolimus) or tacrolimus generic
214570242|NCT06478017|DRUG|Mycophenolate Mofetil/Sodium|CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)
214570243|NCT06478017|DRUG|Prednisone|Prednisone
214709175|NCT04345497|OTHER|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
214570258|NCT06679985|DRUG|Casdozokitug|Solution for infusion
214570259|NCT06679985|DRUG|Toripalimab|Solution for infusion
214570260|NCT06679985|DRUG|Bevacizumab|Solution for infusion
214570261|NCT06680232|BIOLOGICAL|PBGENE-HBV|PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.
214570274|NCT06869018|DRUG|LY3549492|Administered orally
214570275|NCT06869018|DRUG|Placebo|Administered orally
214709176|NCT04345497|OTHER|Standard Of Care|Standard of Care
214709177|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
214570280|NCT05627856|DRUG|GNC-038|Administration by intravenous infusion
214570281|NCT06869889|PROCEDURE|Retrolaminar plane block|Retrolaminar plane infiltration with the local anesthetic mixture.
214570282|NCT06869889|PROCEDURE|Local wound infiltration|Local infiltration along the surgical incision.
214570288|NCT06674460|DRUG|Edaravone Dexborneol Sublingual Tablets|One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
214570289|NCT06674460|DRUG|Placebo|One placebo tablet, to be taken sublingually, twice daily
214570291|NCT07010978|BEHAVIORAL|Recovery Community Center Participation|Recovery community centers are brick and mortar buildings that house recovery-oriented organizations, located in the heart of their communities. They act as recovery hubs, offering a variety of recovery support services in house as well as connecting participants to resources in their area. They are peer-led organizations that are open to anyone in early or long-term recovery from substance use and that recognize that there are multiple pathways to recovery. Study participants will be provided with information about their local RCC (including a video link, contact information, a monthly calendar of events, a list of services and activities offered by the RCC, transportation options, etc.) and will be asked to visit the RCC on two different occasions within one month of enrollment.
214570292|NCT07010978|BEHAVIORAL|Enhance Treatment as Usual|In this study, the enhanced treatment as usual intervention will encompass providing participants with information about diverse recovery activities (e.g., mutual help group meetings, exercise, job search, recovery coach meetings, etc.) and then to assign participants to complete a recovery activity of their choosing one two different days within one month after enrollment. Participants can do the same activity twice, or different activities on each of the two days assigned.
214570295|NCT05145400|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab:10 mg/kg intravenous or 1400 mg subcutaneous (SC) via on-body delivery system (OBDS) will be administered in cycles 1-24.
214570296|NCT05145400|DRUG|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
214570297|NCT05145400|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
214570298|NCT07009522|BEHAVIORAL|Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents - HEART|The group program for adolescents with ASD takes place weekly. Each session lasts 100 minutes (including a break), and the training includes a total of 12 sessions. The intervention is manualized and is based on the theoretical foundations of Cognitive Behavioral Therapy, Mindfulness-Based Therapy, and the TEACCH approach (Mesibov et al., 2005). Parallel to the adolescents, their parents will participate in a separate group training, which will be conducted in five sessions of 100 minutes each and is closely linked in content to the adolescent group training.
214634133|NCT01319409|PROCEDURE|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
214634134|NCT01319409|PROCEDURE|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
214634135|NCT04563494|DRUG|dexamethasone|Prevention of post op nausea and vomiting
214570307|NCT05319730|DRUG|Paclitaxel|80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
214570308|NCT05319730|DRUG|Irinotecan|180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.
214570309|NCT05319730|BIOLOGICAL|Pembrolizumab|200 mg IV infusion, administered every Q3W up to 35 infusions.
214570310|NCT05319730|BIOLOGICAL|MK-4830|800 mg IV infusion, administered Q3W up to 35 infusions.
214570311|NCT05319730|DRUG|Lenvatinib|20 mg oral administration every day.
214570312|NCT05319730|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
214570313|NCT05319730|DRUG|Antihistamine|Administered per product label.
214570314|NCT05319730|DRUG|H2 Receptor Antagonist|Administered per product label.
214709178|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
214709179|NCT03051841|DRUG|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
214570315|NCT05319730|DRUG|Acetaminophen (or equivalent)|Administered per product label.
214570316|NCT05319730|DRUG|Dexamethasone (or equivalent)|Administered per product label.
214570317|NCT05319730|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered per product label.
214570318|NCT05319730|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.
214709180|NCT03780036|DEVICE|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
214570321|NCT06624982|OTHER|observational study|Observational study; alveolar ridge preservation
214709181|NCT05717959|BEHAVIORAL|Oropharyngeal Exercises|Oropharyngeal Exercises
214709182|NCT00895193|OTHER|Apple pectin|Apple pectin 2000mg
214709183|NCT00895193|DRUG|Aspirin 325 mg|Aspirin 325 mg
214709184|NCT00895193|OTHER|Placebo|Placebo
214709185|NCT01578785|DRUG|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
214709186|NCT01578785|DRUG|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
214709187|NCT03517306|OTHER|No Interventions|No Interventions
214709188|NCT02637726|DRUG|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
214570340|NCT06672939|DRUG|Orforglipron|Administered orally
214570341|NCT06672939|DRUG|Placebo|Administered orally
214570344|NCT04348435|BIOLOGICAL|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
214570345|NCT04348435|OTHER|Placebos|Saline
214709189|NCT02637726|DRUG|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
214709190|NCT02637726|DRUG|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
214709191|NCT02637726|DEVICE|EEG Monitoring|Maintaining a bispectral index between 45 and 55
214709192|NCT02637726|DRUG|Remifentanil|Remifentanil at discretion of the anesthesiologist
214709193|NCT03977350|DEVICE|EEG monitoring|EEG monitoring under general anesthesia
214570348|NCT07013487|BIOLOGICAL|V181|Participants will receive a single 0.5 mL SC dose of V181 on Day 1.
214570349|NCT07013487|BIOLOGICAL|Placebo|Participants will receive a single 0.5 mL SC dose of placebo on Day 1.
214570354|NCT05668637|OTHER|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
214570357|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
214570358|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
214570359|NCT07012135|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response will be tested.
214570362|NCT07014111|BEHAVIORAL|Fight Fatigue|Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
214570363|NCT07014111|OTHER|Attention Control|End-stage kidney disease education
214634136|NCT05687461|OTHER|Build a national diagnosis and treatment quality control platform for major respiratory diseases|"1. Build a national diagnosis and treatment quality control platform for major respiratory diseases~2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases~3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases"
214634137|NCT00700271|DRUG|Amlodipine|5 mg or 10 mg tablets.
214634138|NCT00700271|DRUG|Valsartan|160 mg capsules.
214634139|NCT04943991|DIAGNOSTIC_TEST|blood sampling (alpha-Galactosidase & LysoGb3)|"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"
214634140|NCT02004080|OTHER|Intensive Care treatment|intensive care treatment
214634141|NCT06162910|DIAGNOSTIC_TEST|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
214634142|NCT06162910|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
214634143|NCT05138835|DRUG|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
214634144|NCT00861744|BIOLOGICAL|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
214634145|NCT00861744|BIOLOGICAL|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
214634146|NCT00861744|BIOLOGICAL|Varivax®|Subcutaneous injection, one dose
214634147|NCT00861744|BIOLOGICAL|Havrix®|Intramuscular injection, one dose
214570369|NCT06170606|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
214570371|NCT06875206|DEVICE|Low-intensity focused ultrasound|Low-intensity focused Ultrasound (LIFU) is a noninvasive brain stimulation technique that uses low-intensity ultrasound to stimulate specific parts of the brain.
214570372|NCT06875206|DEVICE|Immersive virtual reality|IVR is a noninvasive, computer-based audiovisual therapy designed to enhance visual function. Using a VR headset, the system delivers targeted visual stimulation through an interactive game that the participant engages with during each session.
214570373|NCT06875206|DEVICE|Inactive Low-intensity focused ultrasound|High acoustic impedance disk placed between LIFU and scalp that mimics the audible sensation of a slight buzzing but attenuates more than 95% of the energy into the brain.
214570400|NCT06686394|BIOLOGICAL|Patritumab deruxtecan|Patritumab deruxtecan administered via IV infusion
214570401|NCT06686394|BIOLOGICAL|Trastuzumab|Trastuzumab administered via IV infusion
214570402|NCT06686394|BIOLOGICAL|Trastuzumab Biosimilar|Trastuzumab biosimilar administered via IV infusion
214570403|NCT06686394|BIOLOGICAL|Pertuzumab|Pertuzumab administered via IV infusion
214570404|NCT06686394|BIOLOGICAL|Tucatinib|Tucatinib administered as oral tablets
214570407|NCT07019883|BIOLOGICAL|H5 AC-Anhui RNA Vaccine|A nucleoside-modified mRNA vaccine encoding a stabilized, antigenically central hemagglutinin (HA) from influenza A(H5), based on A/Anhui/1/2005 (clade 2.3.4) with substitutions 222QL, 224GS, 156TA, and 134TA. The 2119-nt mRNA is encapsulated in lipid nanoparticles (LNPs) for intramuscular delivery.
214570408|NCT07019883|BIOLOGICAL|H5 Astrakhan RNA Vaccine|The vaccine product consists of a monovalent nucleoside-modified mRNA that encodes a traditionally selected avian influenza HA. The H5 Astrakhan RNA encodes the HA from the clade 2.3.4.4b A/Astrakhan/3212/2020 virus.
214570409|NCT07019883|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
214570410|NCT07025291|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated salivav was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214709194|NCT05652413|BEHAVIORAL|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
214570413|NCT07017179|DRUG|AZD6234|Participants will receive a subcutaneous injection weekly
214570414|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly.
214570415|NCT07017179|DRUG|AZD9550|Participants will receive a subcutaneous injection weekly
214570416|NCT07017179|DRUG|Plocebo|Participants will receive a subcutaneous injection weekly
214570417|NCT07017179|DRUG|AZD6234 in combination with AZD9550|Participants will receive a subcutaneous injection weekly
214570418|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly
214570419|NCT05085782|DRUG|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
214709195|NCT03283618|BEHAVIORAL|Video Conferencing Group|
214570420|NCT05085782|DRUG|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
214570421|NCT05085782|BEHAVIORAL|Reactivation procedure|Description/visualization of painful movements/activities
214570422|NCT05085782|BEHAVIORAL|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
214570427|NCT06697600|BEHAVIORAL|UR-GOAL|Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.
214570428|NCT06698042|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered subcutaneously on Day 1 of each cycle
214570429|NCT06698042|BIOLOGICAL|Pembrolizumab|Administered intravenously on Day 1 of each cycle
214570442|NCT05335369|BEHAVIORAL|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
214570443|NCT05513547|OTHER|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
214570444|NCT05513547|OTHER|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
214570445|NCT05513547|OTHER|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
214570450|NCT07028905|PROCEDURE|Total caries removal|Total caries removal and application of bioactive material
214570451|NCT07028905|PROCEDURE|Partial caries removal|Partial caries removal then application of biodentin
214570456|NCT07029711|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in high-density polyethylene (HDPE) bottles.
214570457|NCT07029711|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
214570458|NCT07029711|DRUG|Placebo|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
214570459|NCT06697314|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 for the treatment of acute pulmonary embolism
214570460|NCT06698770|OTHER|Anticipated long-term use of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.
214570461|NCT06698770|OTHER|Period re-evaluation of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.
214634148|NCT00861744|BIOLOGICAL|Prevnar®|Intramuscular injection, one dose
214634149|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
214634150|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
214634151|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent totally covers the deep femoral artery
214570470|NCT07030530|DEVICE|Virtual Glasses Group|Virtual Glasses Group; Pregnant women in the virtual reality group will be shown a virtual reality video in VR mode via smartphone during the NST procedure (with the pregnant woman lying on her left side). It will be watched with virtual reality glasses containing nature sounds (streams, birds, etc.). Pregnant women will be informed about the use of virtual reality goggles before being shown the virtual reality video and will be asked to stop watching the video if they feel any discomfort. It is recommended to watch virtual reality videos for 5-20 minutes because they may cause nausea and vomiting (23). Since this study includes pregnant women, it is planned to play the virtual reality videos for 5-10 minutes.
214570471|NCT07030530|OTHER|Mandala Coloring activity group;|Mandala Coloring activity group; In studies examining the effect of art therapy on the reduction of psychological symptoms, it has been shown that the use of round patterns is more effective in symptom management. In line with these studies, ready-made mandala coloring templates with round shapes will be used in our study. Each participant will be asked to choose one of the mandala coloring templates. Each participant will be given colored pencils and asked to color the mandala template of their choice during the NST
214570472|NCT07029555|BIOLOGICAL|PIT565|Study treatment will be provided in vials as open-label participant specific supply.
214634152|NCT03042208|OTHER|Self guided handout|Written handout with basic weight management strategies
214570493|NCT06710132|DRUG|M9140|All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
214570494|NCT06710197|DRUG|Anakinra (Kineret®)|100 mg/daily subcutaneously
214570496|NCT06715241|COMBINATION_PRODUCT|combination of relatlimab and nivolumab wich are two immunotherapy treatments|Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks
214570497|NCT06715241|OTHER|Nivolumab alone|Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
214634153|NCT03042208|BEHAVIORAL|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
214634154|NCT05832281|DRUG|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
214634155|NCT05832281|DRUG|Placebo|Placebo for Purysis
214634156|NCT06129266|OTHER|oral care with breastmilk|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
214634157|NCT05107765|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
214570510|NCT06876649|DRUG|Pirtobrutinib|Administered orally.
214570529|NCT06875427|DRUG|Ropivacaine 2-2.5mg/kg + dexmedetomidine 1 mcg/kg delivered via a single-shot adductor canal block under ultrasound guidance|The local anesthetic (ropivacaine) + dexmedetomidine will be administered via single-shot adductor canal block under ultrasound guidance
214570530|NCT06721013|DRUG|Pirtobrutinib|Administered orally
214570531|NCT06721013|DRUG|Placebo|Administered orally
214634158|NCT05107765|DRUG|Placebo|Pill capsules will look same as that of active drug.
214634159|NCT02542709|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
214570534|NCT07033117|OTHER|Performance Feedback Reports on Referral and Evaluation Closures|Performance feedback reports will reflect each transplant center's performance related to kidney transplant evaluation initiation and referral closure. These reports aim to help centers understand common reasons why patients do not initiate the evaluation process or failed to proceed beyond the evaluation process, and to identify patterns in referral and evaluation closure practices. Reports will be individualized and distributed quarterly to the transplant center champion by the intervention lead.
214570535|NCT07033117|OTHER|Dialysis Facility Awareness Campaign|As part of the intervention, dialysis centers will participate in an Awareness Campaign designed to educate staff about transplant center quality improvement efforts and how they may be contacted as part of the project. This campaign may include brief webinars or informative documents distributed via platforms such as IPRO Learn.
214570536|NCT07033117|OTHER|Patient Contact via Preferred Method|Transplant centers will contact patients using their preferred method of communication.
214570537|NCT07033117|OTHER|Phone Call to Dialysis Facility During the Patient's Dialysis Session|Facilities will enhance their patient communication procedures by making a phone call to the dialysis facility during the patient's dialysis session if the patient has not responded to initial outreach attempts. This additional step increases the likelihood of reaching the patient during a time when they are accessible and can engage in scheduling or follow-up.
214570538|NCT07033117|OTHER|Phone Call to Provider|"Transplant centers will enhance their outreach procedures by making a phone call to the referring provider (e.g., nephrologist, medical assistant) or another provider involved in the patient's care (e.g., primary care provider) in the event of self-referral if the patient has not responded to initial outreach attempts or no-shows an initial evaluation appointment. This additional step ensures that the referring provider is informed of the patient's progress and can assist in re-engagement or decision-making prior to referral closure."
214570539|NCT07033117|OTHER|Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show|Transplant center staff will utilize transplant referral communication platforms and/or email to communicate updates to dialysis staff regarding patient status (e.g., unable to contact the patient or no-show) before referral closure.
214570540|NCT07033117|OTHER|Audit and Tracking of Patient Contact Attempts Prior to Referral Closure|Transplant center staff will continue internally tracking the frequency that a patient is contacted before closure and the date of closure, in alignment with center standard practice. This intervention introduces an audit process to be conducted before closure to ensure that all contact attempts (including one or more attempts to contact the patient directly, one or more phone calls to the alternate preferred contact, or one or more attempted contacts to the dialysis unit to connect with the patient), in alignment with center communication procedures, are appropriately executed.
214709196|NCT03371732|BEHAVIORAL|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
214709197|NCT03371732|BEHAVIORAL|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
214709198|NCT05424887|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
214709199|NCT05424887|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
214709200|NCT01237561|OTHER|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
214709201|NCT04217083|DIAGNOSTIC_TEST|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
214709202|NCT05551091|DIETARY_SUPPLEMENT|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
214709203|NCT02084784|DRUG|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
214709204|NCT02084784|DRUG|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
214570544|NCT07036835|PROCEDURE|LASIK Surgery|Laser assisted in situ keratomileusis (LASIK) surgery conducted for the purpose of correcting refractive error
214570545|NCT07036835|DEVICE|UV fs-Laser|WaveLight Ultraviolet Femtosecond Laser used for creating a corneal flap during LASIK surgery
214570546|NCT07036835|DEVICE|IR fs-Laser|WaveLight FS200 Infrared Femtosecond Laser used for creating a corneal flap during LASIK surgery
214570547|NCT07036835|DEVICE|Anesthetic 1 eye drops|Topical anesthetic used to numb the surface of the eye
214570548|NCT07036835|DEVICE|Anesthetic 2 eye drops|Topical anesthetic used to numb the surface of the eye
214570549|NCT07032038|DRUG|Otic neural progenitors|Advanced Cell Therapy - tissue engineered product
214570550|NCT07032038|DEVICE|cochlear implantation|cochlear implant
214570558|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
214570559|NCT05931913|BEHAVIORAL|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
214570560|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
214570561|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
214570565|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
214570566|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
214570567|NCT06885658|BEHAVIORAL|Visual Storytelling Intervention for Antibiotic Adherence|The intervention involves the use of a visual storytelling approach designed to improve antibiotic adherence in patients diagnosed with urinary tract infections (UTIs). The intervention consists of a sticker featuring simple, visually appealing illustrations and a narrative highlighting the importance of completing the full course of prescribed antibiotics. The story contrasts the positive outcomes of adhering to the treatment with the negative consequences of stopping early, such as increased bacterial resistance. Key messages are reinforced through bold text and visual cues. This intervention aims to engage patients emotionally and cognitively, promoting behavior change by making the concept of antibiotic adherence more relatable and memorable.
214709205|NCT03860350|DIETARY_SUPPLEMENT|Aged Garlic Extract|
214709206|NCT03860350|DIETARY_SUPPLEMENT|Placebo|
214709207|NCT00171314|DRUG|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
214709208|NCT00171314|DRUG|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
214570591|NCT07044297|DRUG|MK-8527|Oral tablet
214570592|NCT07044297|DRUG|FTC/TDF|Oral tablet
214570593|NCT07044297|DRUG|Placebo to MK-8527|Placebo tablet matched to MK-8527
214570594|NCT07044297|DRUG|Placebo to FTC/TDF|Placebo tablet matched to FTC/TDF
214570599|NCT06709820|DRUG|LY4060874|Administered SC
214570600|NCT06709820|DRUG|LY4060874|Administered IV
214570601|NCT06709820|DRUG|Placebo|Administered SC
214570602|NCT06709820|DRUG|Placebo|Administered IV
214570619|NCT06451055|BEHAVIORAL|Low-calorie diet|The low-calorie diet consists of approximately 1,300 kcal/day (37% carbohydrates, 25% protein, 39% fat, and 7 g of fiber per meal) over an eight-week period. Participants receive weekly pre-prepared meals from Trifecta Nutrition (Trifecta Inc. California, USA) with options for breakfast, lunch, and dinner, meticulously crafted by certified dieticians and expert chefs. Participants are encouraged to consume 1-2 liters of water daily and maintain their habitual physical activity levels.
214570620|NCT06451055|BEHAVIORAL|Routine dietary and physical activity habits|Participants are asked to maintain their habitual dietary and physical activity habits for the 8-week study period.
214634160|NCT02542709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
214634161|NCT06092073|PROCEDURE|recto-intercostal fascial plane block|Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.
214634162|NCT06092073|DRUG|bupivacaine|bupivacaine 0.25%
214634163|NCT04391699|DEVICE|heated humidification|heated humidification system
214570623|NCT06725329|BEHAVIORAL|A tailored psychosocial education intervention|"Participants will get ten 60-minute psychoeducational group sessions about chronic pain and its management. The group sessions will be conducted by the PI and a bilingual project director at Korean churches or daycare centers in Baltimore-Washington Metropolitan area.~The psychoeducational group session will be adapted from LAMP intervention that has been previously developed. The intervention provides biopsychosocial education sessions about chronic pain and its management. For example, sessions focus on providing information regarding: (1) pain and the biological stress response and the gate control theory of pain, (2) the psychological impact of thoughts and emotions on pain and (3) facilitated group discussions to help participants develop a new understanding of pain through shared social experiences, all of which have been shown to improve pain outcomes."
214570643|NCT07048197|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of Rapcabtagene autoleucel
214570658|NCT04806347|BIOLOGICAL|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
214570659|NCT04806347|DEVICE|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
214570660|NCT05973851|DRUG|Esketamine Nasal Product|See arm description
214570661|NCT05973851|DRUG|Ketamine Hydrochloride|See arm description
214570662|NCT05973851|DRUG|Esketamine hydrochloride|See arm description
214570663|NCT05973851|DRUG|Second-line Antidepressants|See arm description
214570666|NCT07049900|DEVICE|NeoBelly Band|The DandleLion NeoBellyBand (NBB) is an FDA listed Class 1 medical device that is 510k exempt and is categorized under therapeutic medical binders. This device is indicated to be used while the infant is receiving CPAP support in order to reduce CBS. The NBB is made of a medical-grade blend of fabric and foam that is latex and neoprene-free and is reported as safe to use on premature infant skin. There are two sizes available and the outer fabric is attached with adjustable Velcro. It is a single baby use and may be hand washed and reused. This device is currently in use in multiple NICUs around the country, and as it has already been FDA-approved for the purpose of our investigation.
214570670|NCT06745843|OTHER|Questionnaire|The patient information, informed consent form and questionnaire will collectively be distributed digitally or by mail to all patients.
214570671|NCT07044817|BEHAVIORAL|Stroke Rehabilitation Guideline Adherence Survey|"This intervention consists of a structured online survey, the Stroke Rehabilitation Guideline Adherence Survey, designed to assess physiotherapists' and physiotherapy internship students' adherence to stroke rehabilitation clinical practice guidelines, their attitudes toward implementing evidence-based post-stroke care, and the perceived barriers-such as time constraints, limited resources, or insufficient training-that influence their compliance. No clinical treatments or procedures are administered; the sole intervention is the delivery of this comprehensive questionnaire."
214570674|NCT06890884|BIOLOGICAL|Zilovertamab vedotin|IV infusion
214570675|NCT06890884|BIOLOGICAL|Rituximab|IV infusion
214570676|NCT06890884|DRUG|Cyclophosphamide|IV infusion
214570677|NCT06890884|DRUG|Doxorubicin|IV infusion
214570678|NCT06890884|BIOLOGICAL|Rituximab Biosimilar|IV infusion
214570679|NCT06890884|DRUG|Prednisone|Oral administration or IV infusion
214570680|NCT06890884|DRUG|Prednisolone|Oral administration or IV infusion
214570681|NCT06890884|BIOLOGICAL|Polatuzumab vedotin|IV infusion
214570682|NCT06890884|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).
214709209|NCT02797639|OTHER|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
214709210|NCT02797639|OTHER|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
214570693|NCT06739122|DRUG|Dulaglutide|Administered SC
214570695|NCT06784466|DEVICE|Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Ablation using the Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
214570704|NCT02407405|DRUG|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
214570710|NCT05956587|DRUG|BL-B01D1|Administration by intravenous infusion
214570711|NCT05956587|DRUG|SI-B003|Administration by intravenous infusion
214570712|NCT06744712|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
214570713|NCT06893705|OTHER|Conventional Therapy|Conventional Therapy Group: Group A will be control group which will receive conventional physical therapy program for the affected neck like stretching exercises, active range of motion exercise, and neck isometrics for 6 weeks (3 sessions per week).
214570714|NCT06893705|OTHER|Pilates+Conventional Therapy|Group B will be experimental group, which will receive Pilate's exercises like cat stretch, swan dive/roll up along with conventional therapy for 6 weeks(3 sessions per week). In each session there will be 25 minutes of conventional therapy and 25 minutes of Pilate's exercises program.
214570715|NCT06482073|OTHER|Non-Interventional Study|Non-interventional study
214570718|NCT07051330|OTHER|Healthy Minds Program (HMP) app|"All participants will complete baseline surveys, weekly questionnaires (for 4 weeks) through the HMP app intervention, and will be surveyed again at 3-months post-intervention. Participants are randomized to each of the following binary conditions.~1. Introduction video for the app (yes / no)~2. Introduction video for the training modules (yes / no)~3. Module order based on ACIP score (highest-first / lowest-first)~4. Practice-nudging text messages (yes / no)~5. Microsupport messages during the intervention period (yes / no)~6. Microsupport messages during the follow-up period (yes / no"
214709211|NCT04945824|DRUG|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
214570727|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
214570728|NCT07056309|DRUG|Remternetug (Test)|Administered SC
214570729|NCT07056309|DRUG|Remternetug (Reference)|Administered SC
214709212|NCT04945824|DEVICE|Dilator|Intracanalicular Dilator Device
214709213|NCT02034604|DRUG|Naftofidil|
214709214|NCT02034604|DRUG|Tamsulosin|
214709215|NCT05508672|OTHER|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
214709216|NCT05508672|OTHER|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
214709217|NCT04284904|DIAGNOSTIC_TEST|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
214709218|NCT04949724|OTHER|translation and adaptation study|translation and adaptation study
214570744|NCT06090669|DRUG|imatinib|Imatinib at 300-400 mg PO QD based on arm assignment/dose level
214570745|NCT06090669|DEVICE|TruSight Oncology|Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
214570746|NCT06813274|DRUG|hypoglycemic treatment|"The diabetes management adheres to the The 2025 Guidelines for Standards of Diabetes Care issued by the American Diabetes Association (ADA)."
214570747|NCT06813274|DRUG|Tangshen'an Granules|Tangshen'an Granules comprises a meticulously blended mix of Astragalus, Prepared Rehmannia Root, Dodder Seed, Kudzu Root, Millettia Speciosa Champ, Salviae Miltiorrhizae Radix et Rhizoma, Poria Cocos, and Polygala Tenuifolia. Tangshen'an Granules is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
214570748|NCT06813274|DRUG|Ginkgo Leaf Tablets|The primary active ingredients of Ginkgo Leaf Tablets are ginkgo flavonoid glycosides and terpene lactones. The prescribed oral dosage is one tablet each time, administered three times a day.
214570749|NCT06813274|DRUG|Mecobalamin Tablets|Mecobalamin Tablets primarily contain mecobalamin, which is a coenzyme-active form of vitamin B12. The prescribed oral dosage is 0.5mg, administered three times a day.
214570750|NCT06813274|DRUG|placebo|The placebo contains 10% of the active ingredients in Tangshen'an Granules, formulated by controlling the concentration to mimic Tangshen'an Granules. The placebo is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
214570754|NCT06717347|BIOLOGICAL|Zilovertamab vedotin|IV infusion
214570755|NCT06717347|BIOLOGICAL|Rituximab|IV infusion
214570756|NCT06717347|DRUG|Cyclophosphamide|IV infusion
214570757|NCT06717347|DRUG|Doxorubicin|IV infusion
214570758|NCT06717347|BIOLOGICAL|Rituximab Biosimilar|IV infusion
214570759|NCT06717347|DRUG|Prednisone|Per Approved Product Label
214570760|NCT06717347|DRUG|Prednisolone|Oral administration
214570761|NCT06717347|DRUG|Vincristine|IV infusion
214570762|NCT06717347|DRUG|Rescue medication|Participants receive rescue medication at the investigator's discretion, per approved product label. The recommended rescue medication is granulocyte colony-stimulating factor (G-CSF).
214570771|NCT06741228|OTHER|Placebo|A substance that is designed to have no therapeutic value
214570772|NCT06741228|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
214634164|NCT04726878|PROCEDURE|Erector spinae plane block|Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
214634165|NCT04726878|PROCEDURE|Sham block|Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
214709219|NCT05638906|DEVICE|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
214709220|NCT02978664|PROCEDURE|Air insufflation|Air insufflation during colonoscopy including insertion phase
214709221|NCT02978664|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
214570779|NCT05897320|DRUG|Eptinezumab|Solution for infusion
214570780|NCT05897320|DRUG|Placebo|Solution for infusion
214709222|NCT02978664|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
214709223|NCT01156207|DRUG|Aliskiren|300mg Aliskiren qd for 6 month
214709224|NCT02307656|DRUG|Atazanavir|
214709225|NCT02307656|DRUG|Cobicistat|
214709226|NCT02307656|DRUG|Active Pharmaceutical Ingredient|
214709227|NCT06205394|OTHER|Non-Interventional Study|Non-interventional study
214709228|NCT00475540|DEVICE|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
214709229|NCT01718626|DRUG|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
214570796|NCT05668858|DRUG|SI-B001|Administration by intravenous infusion
214709230|NCT01718626|DRUG|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
214570797|NCT05668858|DRUG|SI-B003|Administration by intravenous infusion
214570810|NCT06550388|BEHAVIORAL|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
214570811|NCT06550388|BEHAVIORAL|Physical Activity|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
214570812|NCT03598257|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214570813|NCT03598257|DRUG|Olaparib|Given PO
214570814|NCT03598257|RADIATION|Radiation Therapy|Undergo radiation therapy
214570815|NCT03598257|OTHER|Survey Administration|Ancillary study
214570824|NCT05563220|DRUG|Elacestrant|Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
214570825|NCT05563220|DRUG|Alpelisib|Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
214570826|NCT05563220|DRUG|Everolimus|Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
214570827|NCT05563220|DRUG|Ribociclib|Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
214570828|NCT05563220|DRUG|Palbociclib|Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
214570829|NCT05563220|DRUG|Capivasertib|Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
214570830|NCT05563220|DRUG|Abemaciclib|Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
214570853|NCT07053774|DRUG|Intravenous oxytocin|Oxytocin, 10 International Units (IU) will be administered by IV infusion over 30 minutes and, 30 minutes later, a second 10 IU will be administered over 30 min, for a total dose of 20 IU. The first infusion will be at a rate of 0.125 IU/min for the first 5 min, then at 0.375 IU/min for the remaining 25 min. The second 30-min infusion will be at a fixed rate of 0.333 IU/min.
214570854|NCT07053774|DRUG|Intravenous placebo|Saline will be administered as two 30-min IV infusions separated by 30-min, using the same volume of infusion solution and rates of administration as in the intravenous oxytocin intervention.
214570855|NCT07053774|DRUG|Intranasal oxytocin|Oxytocin will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray (20 IU) in each nostril followed in 5 min by another spray in each nostril. The total dose of oxytocin is 80 IU.
214570856|NCT07053774|DRUG|Intranasal placebo|Placebo (solution containing the excipients in the oxytocin solution but without oxytocin) will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray in each nostril followed in 5 min by another spray in each nostril.
214570867|NCT06896669|DIETARY_SUPPLEMENT|vitamin D3|600IU of vitamin D3 and 1.5 to 2g of calcium will be provided for time period of 6 weeks once daily. In addition, Participants dietary intake will be assessed through 24 hours dietary recall.
214570869|NCT06768827|OTHER|Lactulose Oral Product|Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
214570899|NCT07063095|DRUG|Ceftazidime± avibactam with fosfomycin|"The intervention will last 72h (±6h). Ceftazidime will be administered intravenously in 5% glucose serum (per hospital standard), either intermittently (divided into three doses daily) or as continuous infusion; doses will be adapted to renal function. The decision to administer CAZ by continuous infusion and to add AVI will be left to the attending physician. CAZ±AVI will be adjusted for renal insufficiency per internal guidelines of dosing and international recommendations.~The use of CAZ with its paired beta-lactamase inhibitor avibactam, i.e., the use of ceftazidime-avibactam (Zavicefta®) instead of CAZ will occur in case of suspicion of infection by either extended-spectrum-beta-lactamase-producing Enterobacterales (ESBL-E), cephalosporinase-carrying Enterobacterales (ampC-E) or carbapenem-resistant Enterobacterales (CRE), as determined by treating physician and/or the infectious diseases consultant."
214570900|NCT07063095|DRUG|Ceftazidime± avibactam with placebo|Participants randomized to the control arm will receive placebo infusion. Placebo will be 5% glucose serum and will be administered IV with the same frequency as FOS would be for the participant's renal function.
214570914|NCT06777368|DEVICE|Medtronic TAV|Medtronic TAV where commercially available
214570915|NCT06777368|DEVICE|Edwards TAV|Edwards TAV where commercially available.
214570924|NCT06808217|DEVICE|FARAPULSE Pulsed Field Ablation System|Subjects who have provided written informed consent are considered enrolled. Subjects who have received ablation treatment with the FARAPULSE™ System are assigned to the 'TREATMENT' group.
214570926|NCT06834932|DRUG|Placebo|Administered orally as tablets
214570927|NCT06834932|DRUG|Rosuvastatin Dose 1|Administered orally as tablets
214570928|NCT06834932|DRUG|Rosuvastatin dose 2|Administered orally as tablets
214709231|NCT01692223|BEHAVIORAL|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
214570929|NCT06834932|DRUG|AZD0780|Administered orally as tablets
214570933|NCT07061964|PROCEDURE|Biospecimen Collection|Undergo tissue, urine, and blood sample collection
214570934|NCT07061964|PROCEDURE|Computed Tomography|Undergo CT
214570935|NCT07061964|PROCEDURE|Cystoscopy|Undergo cystoscopy
214570936|NCT07061964|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214570937|NCT07061964|BIOLOGICAL|Pembrolizumab|Given IV
214570938|NCT07061964|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam RT
214570939|NCT07061964|PROCEDURE|Positron Emission Tomography|Undergo PET
214570940|NCT07061964|OTHER|Questionnaire Administration|Ancillary studies
214570941|NCT07061964|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
214570942|NCT07069725|DRUG|AZD2389|Doses of AZD2389 will be administrated orally
214570943|NCT07069725|DIAGNOSTIC_TEST|PET scan and radioligand|PET scan and radioligand
214570944|NCT04536584|OTHER|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
214570945|NCT04536584|OTHER|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
214570950|NCT07062614|OTHER|Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment|at inclusion, 3 months and 6 months of follow-up, patients must answer the Girerd compliance questionnaire. After 6 months of follow-up, two strands of hair will be taken from the base of the skull using scissors
214570952|NCT07071948|DEVICE|Multifunctional Integrated Flexible Ureteroscope|"Investigational ureteroscope with three integrated functions:~1. Real-time pressure control: Continuous renal pelvic pressure monitoring with auto-adjustment of irrigation/aspiration flow to maintain pressure \<30 mmHg (safety threshold)~2. Simultaneous lithotripsy \& fragment removal: Holmium laser lithotripsy (200-365 μm fiber) coordinated with suction through working channel~3. Single-pass stone clearance: Designed to reduce residual fragments requiring secondary procedures~Distinguishing features vs conventional ureteroscopes:~1. Eliminates need for separate suction devices~2. Prevents intraoperative washout failure causing obscured vision~3. Patent-pending pressure sensor"
214570956|NCT06900374|DEVICE|GynWave-360|"For patients randomized to the experimental group:~3 sessions of 20 minutes each, spaced 4 to 6 weeks apart (M0, M1, M2) ideally, with +/- 1 maintenance session between 8 and 12 months after the first session (M8-12)."
214570957|NCT06900374|OTHER|Local hydratation|Reference treatment combining local hydration (hyaluronic acid-based treatment, 3 times a week), with the possibility of using associated measures at the investigator's discretion (physiotherapy, vaginal dilators, etc.).
214570965|NCT07069569|DRUG|AHB-137|AHB-137 will be injected.
214570966|NCT07069569|DRUG|Peg-IFN|Peg-IFN will be administered .
214570967|NCT07069569|DRUG|Hepatitis B Vaccine|Hepatitis B vaccine will be administered.
214570975|NCT06816329|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
214570996|NCT02363296|DEVICE|TMS|Paired associative stimulation and single pulse TMS
214571006|NCT06634719|DEVICE|Juveena Hydrogel System|The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
214571007|NCT05310448|DEVICE|Optune device|Wear Optune device
214571009|NCT06215066|DEVICE|Virtual reality|The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.
214571010|NCT06215066|OTHER|Modified Progressive Muscle Relaxation|The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.
214709232|NCT03114566|OTHER|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
214571013|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
214571014|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
214709233|NCT00377429|DRUG|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
214709234|NCT01403831|OTHER|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
214709235|NCT02013089|DRUG|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
214709236|NCT02013089|DRUG|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
214571015|NCT06533826|DRUG|Trastuzumab Deruxtecan|A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
214571016|NCT06533826|DRUG|Datopotamab Deruxtecan|A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
214571017|NCT06585787|DRUG|KarXT|Specified dose on specified days
214709237|NCT02013089|DRUG|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
214571018|NCT06585787|DRUG|Placebo|Specified dose on specified days
214571024|NCT06780111|BIOLOGICAL|Pembrolizumab|IV infusion
214571025|NCT06780111|BIOLOGICAL|I-DXd|IV infusion
214571026|NCT06780111|DRUG|Leucovorin|IV infusion
214571027|NCT06780111|DRUG|Levoleucovorin|IV infusion
214571028|NCT06780111|DRUG|5-Fluorouracil (5-FU)|IV Infusion
214571029|NCT06780111|DRUG|Oxaliplatin|IV infusion
214571031|NCT06040086|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
214571032|NCT06040086|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study.
214571054|NCT06621524|DEVICE|EucaLimus coronary stent system|The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
214634166|NCT04726878|PROCEDURE|General anesthesia|"Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl."
214634167|NCT04726878|PROCEDURE|Patient-controlled analgesia|All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
214634168|NCT04726878|DRUG|Oxycodone|Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
214634169|NCT04726878|DRUG|paracetamol|intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
214571060|NCT06890598|DRUG|Olomorasib|Administered orally.
214571061|NCT06890598|DRUG|Pembrolizumab|Administered intravenously (IV).
214571062|NCT06890598|DRUG|Durvalumab|Administered IV.
214571063|NCT06890598|DRUG|Placebo|Administered orally.
214709238|NCT02013089|DRUG|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
214571097|NCT07122193|DRUG|NT 201|Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
214571098|NCT07122193|DRUG|NT 201 Placebo|NT 201 matching-placebo
214571099|NCT02379377|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative 18F-FSPG|Undergo 18F-FSPG PET scan
214709239|NCT02013089|DRUG|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
214709240|NCT05589480|OTHER|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
214709241|NCT03729934|DIETARY_SUPPLEMENT|Ketone Ester|This arm receives 25 g ketone ester.
214571100|NCT02379377|BIOLOGICAL|Carbon C 11 Acetate|Undergo 11C-acetate PET scan
214571101|NCT02379377|PROCEDURE|Positron Emission Tomography|Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
214709242|NCT03729934|DIETARY_SUPPLEMENT|Ketone Salt|This arm receives 25 g ketone salt.
214571102|NCT02379377|OTHER|Laboratory Biomarker Analysis|Correlative studies
214571103|NCT02379377|BIOLOGICAL|Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose|Undergo 18F-FDG PET scan
214571111|NCT04993508|DIAGNOSTIC_TEST|PSA test|testing for blood levels of PSA
214571112|NCT04993508|DEVICE|multiparametric prostate Magnetic Resonance Imaging (mpMRI)|mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD \> 0.15 will considered suspicious for csPCa.
214571113|NCT04993508|PROCEDURE|targeted MRI/US fusion-guided biopsy|Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
214709243|NCT00904995|DRUG|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
214709244|NCT00904995|DRUG|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
214709245|NCT01584258|PROCEDURE|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
214709246|NCT01584258|RADIATION|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
214709247|NCT01584258|RADIATION|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
214709248|NCT04485234|DIAGNOSTIC_TEST|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
214709249|NCT05291416|DIAGNOSTIC_TEST|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
214709250|NCT05741086|DRUG|Evolocumab|evolocumab (140 mg every 2 weeks)
214709251|NCT05741086|DRUG|Atorvastatin|Atorvastatin 20-40mg
214571114|NCT04993508|PROCEDURE|combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)|The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
214571115|NCT04993508|PROCEDURE|MRI inbore biopsy|MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
214571119|NCT06930651|DRUG|Dexamethasone|Given Orally
214571120|NCT06930651|DRUG|Cyclophosphamide|Given by IV
214571121|NCT06930651|DRUG|Fludarabine|Given by IV
214571122|NCT06930651|DRUG|Decitabine|Given by IV
214571123|NCT06930651|BIOLOGICAL|TGFBR2 KO CAR27/IL-15 NK cells|Given by Infusion
214571124|NCT05886621|BEHAVIORAL|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
214634170|NCT01295216|BEHAVIORAL|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
214634171|NCT00002827|BIOLOGICAL|bleomycin sulfate|Given IV
214634172|NCT00002827|BIOLOGICAL|filgrastim|Given IV
214709252|NCT04718324|OTHER|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
214634173|NCT00002827|DRUG|dexrazoxane hydrochloride|Given IV
214634174|NCT00002827|DRUG|doxorubicin hydrochloride|Given IV
214634175|NCT00002827|DRUG|etoposide|Given IV
214634176|NCT00002827|DRUG|vincristine sulfate|Given IV
214634177|NCT00002827|RADIATION|low-LET cobalt-60 gamma ray therapy|
214634178|NCT00002827|RADIATION|low-LET electron therapy|
214634179|NCT00002827|RADIATION|low-LET photon therapy|
214634180|NCT00128544|DRUG|telbivudine|
214634181|NCT00128544|DRUG|valtorcitabine|
214571125|NCT05886621|BEHAVIORAL|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
214571126|NCT06926920|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
214571149|NCT06623136|DRUG|ES102|ES102 is administered via intravenous infusion, once every 21 days.
214571150|NCT06623136|DRUG|Toripalimab|Toripalimab is administered via intravenous infusion, once every 21 days.
214709253|NCT04718324|OTHER|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
214709254|NCT02067416|DRUG|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
214709255|NCT02067416|DRUG|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
214571191|NCT07093281|BIOLOGICAL|Live Attenuated Influenza Vaccine|Nasal spray
214709256|NCT02827279|OTHER|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
214709257|NCT00675558|PROCEDURE|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) \& fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
214709258|NCT00675558|PROCEDURE|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
214571196|NCT07094685|PROCEDURE|Biopsy Procedure|Undergo biopsy
214571197|NCT07094685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214709259|NCT01033487|DRUG|placebo|oral inhaled formulation, single dose
214571198|NCT07094685|PROCEDURE|Computed Tomography|Undergo PET-CT and CT scan
214709260|NCT01033487|DRUG|active comparator|oral inhaled formulation, single dose
214709261|NCT01033487|DRUG|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
214709262|NCT01033487|DRUG|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
214709263|NCT01033487|DRUG|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
214709264|NCT05948852|PROCEDURE|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
214571199|NCT07094685|BIOLOGICAL|Ivonescimab|Given IV
214571200|NCT07094685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214571201|NCT07094685|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
214571202|NCT07094685|PROCEDURE|Surgical Procedure|Undergo surgical dissection
214709265|NCT00255099|DRUG|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
214709266|NCT00255099|DRUG|Placebo|2 tablets b.i.d. / 96 weeks
214709267|NCT06123910|DIETARY_SUPPLEMENT|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
214709268|NCT06123910|OTHER|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
214709269|NCT05341674|OTHER|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
214709270|NCT03807115|OTHER|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
214709271|NCT04830228|DEVICE|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
214709272|NCT04090437|PROCEDURE|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
214571211|NCT07095231|BIOLOGICAL|STX-S|A proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express spike proteins on the surface
214571217|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
214571218|NCT07095933|DRUG|Everolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 2.5 mg per dose for BSA \<1.2 m², 5 mg per dose for BSA 1.3-2.1 m², and 7.5 mg per dose for BSA \>2.2 m².
214571220|NCT07136857|DRUG|EPTACOG BETA|"Eptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously.~SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity."
214571222|NCT07136077|DRUG|Tislelizumab|Given by IV
214571223|NCT07136077|DRUG|Fruquintinib|Give by PO
214571224|NCT06904391|OTHER|Educational Intervention|Receive access to SWOG APP Clinical Research workshop. Receive The Advanced Practice Provider Clinical Trials Research Manual
214571225|NCT06904391|OTHER|Behavioral Intervention|Complete mentorship intervention
214571226|NCT06904391|OTHER|Survey Administration|Ancillary studies
214571227|NCT06904391|OTHER|Interview|Ancillary studies
214571230|NCT06910566|PROCEDURE|Chemoradiotherapy or radiotherapy alone|Patients included in the study receive standard treatment with chemoradiotherapy or radiotherapy alone for their head and neck cancer or lung cancer. These treatments are part of their routine care and are not part of the observational study.
214571248|NCT07099898|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
214571249|NCT07099898|DRUG|Topotecan|Topotecan will be administered
214571250|NCT07134972|DRUG|Ozone treatment|Ozone treatment was administered to study group only. 90 ml of blood was collected into a vacuum sterile glass bottle (Ozonosan). To prevent clotting, 10 ml of 3.8% Na Citrate solution was added to the glass vial. The blood to citrate volume ratio is 9:1. After blood collection, the O3 concentration is ozonized to 20-50 mcg/ml. After at least 5 minutes of mixing, ozonized blood was infused over 20 minutes. Ozone/oxygen mixture was administered intravenously. Ozone therapy was administered twice a week for a total of 16 sessions.
214571251|NCT06762717|DEVICE|FARAPULSE™ Pulsed Field Ablation system|no intervention design in the study
214571270|NCT04349631|BIOLOGICAL|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
214709273|NCT05984797|OTHER|Integrated Short-term Palliative Rehabilitation|"Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians."
214709274|NCT02939599|DRUG|QCC374|0.015mg and 0.06mg
214709275|NCT04011748|COMBINATION_PRODUCT|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
214571281|NCT07092865|BIOLOGICAL|Adjuvanted RSVPreF3 vaccine|1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).
214571288|NCT06706284|DRUG|Semaglutide Injectable Product|A GLP-1 inhibitor used to control T2DM
214571289|NCT06706284|OTHER|Placebo|Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
214571299|NCT06914895|DRUG|Tirzepatide|Administered SC
214571300|NCT06914895|DRUG|Placebo|Administered SC
214571328|NCT01621594|DEVICE|Cannon Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
214571329|NCT06832631|DEVICE|Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon|Balloon angioplasty for the treatment of symptomatic peripheral arterial disease with a paclitaxel drug-coated balloon
214571330|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
214709276|NCT03104998|DRUG|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
214709277|NCT05820620|PROCEDURE|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
214709278|NCT05820620|PROCEDURE|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
214709279|NCT05820620|OTHER|Control Group|Control Group + Patient Control Analgesia (PCA)
214709280|NCT05796882|BEHAVIORAL|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
214709281|NCT05796882|BEHAVIORAL|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
214709282|NCT04260659|DRUG|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
214709283|NCT04260659|DRUG|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
214709284|NCT04260659|DRUG|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
214571375|NCT05949684|BIOLOGICAL|Luspatercept|Specified dose on specified days
214571376|NCT05949684|BIOLOGICAL|Epoetin Alfa|Specified dose on specified days
214571403|NCT04009499|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214709285|NCT04260659|DRUG|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
214709286|NCT04260659|DRUG|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
214709287|NCT04260659|DRUG|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
214709288|NCT01762306|DRUG|Diclofenac Potassium|
214709289|NCT01762306|DRUG|Folic Acid|
214709290|NCT05596786|DRUG|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
214709291|NCT05596786|OTHER|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
214571420|NCT06624228|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
214571421|NCT06624228|DRUG|Risankizumab|Study participants will receive risankizumab at pre-specified time points.
214571422|NCT06624228|DRUG|Placebo|Study participants will receive placebo at pre-specified time points.
214571434|NCT06223568|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
214571435|NCT06223568|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
214571436|NCT06223568|DRUG|PRGN-2009|PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
214571443|NCT06918990|BIOLOGICAL|Carfilzomib|Administered by intravenous infusion over 60 minutes.
214709292|NCT02839941|DRUG|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
214571444|NCT06918990|BIOLOGICAL|Belatacept|Administered by intravenous infusion over 30 minutes.
214571449|NCT06916065|DRUG|Eloralintide and Tirzepatide|Administered SC
214571450|NCT06916065|DRUG|Eloralintide|Administered SC
214571451|NCT06916078|DRUG|Lepodisiran|Lepodisiran administered SC
214571452|NCT07104578|DIAGNOSTIC_TEST|Pleuropulmonary ultra sound|pleuropulmonary ultrasound performed as part of the treatment
214709293|NCT02839941|DRUG|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
214709294|NCT02839941|DRUG|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
214709295|NCT02839941|DRUG|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
214709296|NCT04007913|BEHAVIORAL|teleCBIT|Eight sessions of individual behavior therapy
214709297|NCT04965506|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
214709298|NCT04965506|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
214571453|NCT07115576|PROCEDURE|Radiofrequency ablation alone|Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat benign thyroid nodules without surgery. It involves inserting a thin, needle-like electrode into the nodule under ultrasound guidance. Using high-frequency alternating current, the electrode generates heat to destroy targeted thyroid tissue, causing the nodule to shrink over time.
214571460|NCT06921928|DRUG|AZD4360|Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
214709299|NCT04965506|OTHER|Dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
214709300|NCT02209649|DRUG|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
214709301|NCT02209649|DRUG|Lacidipine|
214709302|NCT02209649|DRUG|Telmisartan|
214709303|NCT05918588|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
214709304|NCT05918588|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
214709305|NCT02148211|OTHER|Data collection|Initial and follow-up data was collected using questionnaires.
214709306|NCT05227482|RADIATION|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
214709307|NCT05227482|RADIATION|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
214571463|NCT07115368|DRUG|GS-1219|Administered orally
214571464|NCT07115368|DRUG|BVY|Administered orally
214571465|NCT07115368|DRUG|Standard of Care|Antiretroviral therapy, administered orally non nonnucleoside reverse transcriptase inhibitor (NNRTIs), examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
214571466|NCT06921759|DRUG|Lebrikizumab|Administered SC
214709308|NCT04673604|DIAGNOSTIC_TEST|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
214709309|NCT04673604|DRUG|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
214571467|NCT06921759|DRUG|Placebo|Administered SC
214571474|NCT06921850|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
214571481|NCT06919003|BIOLOGICAL|Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
214571482|NCT06919003|OTHER|Placebo for Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
214571493|NCT07119593|OTHER|Intradialytic Cycling|Intradialytic exercise has emerged as a safe and effective non-drug therapeutic approach to improve cardiovascular health and is now recommended for people undergoing hemodialysis treatment. Administration of a higher intensity exercise could offer better cardio-protective mechanisms and if the efficacy of cardiovascular protection is proven, it could be developed as a therapeutic option in the dialysis population.
214571494|NCT07122102|DRUG|Cofrogliptin|10mg administered once every two weeks
214571495|NCT07122102|DRUG|Acarbose|50mg administered 3 times daily
214571499|NCT07124650|DRUG|Hydrocortisone Acetate 1% Ointment|Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.
214571500|NCT07124650|DRUG|Lidocaine hydrochloride 0,05% with chlorhexidine|Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.
214571505|NCT06919497|BEHAVIORAL|Spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
214571506|NCT06919497|BEHAVIORAL|No spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
214571513|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (2 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 2 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
214571514|NCT06933732|DEVICE|Device: Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (4 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 4 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
214571515|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (6 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 6 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
214571518|NCT06931093|BEHAVIORAL|Group Guided Written Exposure Therapy for CPTSD (GWE-C)|"Group Guided Written Exposure Therapy for CPTSD (GWE-C) is a manualized, exposure-based therapeutic program consisting of 7 to 10 sequential sessions. The intervention follows a structured sequence of trauma processing that addresses trauma details, associated emotions, cognitions, and impacts. Writing tasks incorporate imagery dialogues, self-compassion exercises, and resource identification to help participants alleviate C-PTSD symptoms.~The interval between two consecutive sessions ranges from 0 to 2 days, with participants expected to complete all sessions within 1 to 2 weeks. The first and last sessions are scheduled to last 1.5 hours each, while the intermediate sessions are 60 minutes in duration. Each group will consist of 6 to 10 participants and will be facilitated by one counselor and one assistant."
214571519|NCT06931093|BEHAVIORAL|Supportive counselling|Supportive counselling, the comparator intervention, is a non-trauma-focused treatment based on the Rogerian psychotherapy model and has been used as an active comparator in previous trials of trauma-focused therapies. The program comprises seven sessions: the first two employ group activities such as card games and interactive drawing to build a sense of belonging; sessions three to six focus on stress management and emotion regulation skills through methods including expressive drawing, relaxation training, and resource identification; the final session emphasizes reflection and sharing. Throughout, counsellors provide supportive guidance to encourage emotional expression, mutual listening, and peer support, while discussions deliberately exclude participants' individual traumatic experiences.
214571521|NCT06929559|OTHER|Pain expectation conditioning|Participants receive application of a neutral cream (MEDICAFARM) with verbal and behavioral suggestions that it may cause localized pain. Researchers wear gloves during application and emphasize potential discomfort, stating effects may intensify with movement.
214571522|NCT06929559|OTHER|Comparator (Control Group)|Participants receive identical application of the neutral cream but are informed it is inert and harmless. Researchers apply the cream without gloves and provide neutral instructions.
214571523|NCT06929559|OTHER|Intervention: Gait|"Participants undergo assessment procedures including:~* Pre- and post-application gait analysis (GAITRite mat, Zebris treadmill)~* Physiological monitoring (EMG, HRV, EDA)~* Identical questionnaires (BPI, TSK, FACS, PCS, VAS)"
214571524|NCT06931405|DRUG|BLU-808|Oral administration
214571525|NCT06931405|DRUG|Placebo|Oral administration
214571526|NCT06935357|DRUG|Felzartamab|Administered IV
214571527|NCT06935357|DRUG|Placebo|Administered IV
214571528|NCT06935604|BEHAVIORAL|VR with a trained facilitator|"Intervention Group 1 - VR with a facilitator:~Each participant in the intervention group will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Facilitator training: The facilitator group will include trained healthcare professionals skilled in VR technology, C-I-CARE, and empathetic patient engagement. All facilitators also complete the Creative \& Healing Arts Heart-to-Heart training which includes observation, empathy training, and reflection to support complex communication, and companionship needs of adult patients ."
214709310|NCT03036449|BEHAVIORAL|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~\- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
214571529|NCT06935604|BEHAVIORAL|VR without a trained facilitator.|"Intervention Group 2 - VR without an inperson facilitator:~Each participant in the intervention groups will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Instructional video: A research assistant will use C-I-CARE to give the patient an instructional video and the headset to engage in the VR technology.~Patients will take a surveys before and after the intervention"
214571541|NCT06937086|DRUG|Mirikizumab|Administered IV
214571542|NCT06937086|DRUG|Mirikizumab|Administered SC
214571543|NCT06937086|DRUG|Tirzepatide|Administered SC
214571544|NCT06937086|DRUG|Placebo|Administered SC
214571545|NCT06937099|DRUG|Mirikizumab|Administered IV
214571546|NCT06937099|DRUG|Mirikizumab|Administered SC
214571547|NCT06937099|DRUG|Tirzepatide|Administered SC
214571548|NCT06937099|DRUG|Placebo|Administered SC
214571549|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
214571550|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
214571551|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
214571552|NCT06938074|DIAGNOSTIC_TEST|CT and MRI|All participants will undergo both CT imaging and MRI imaging to identify areas of ischemic scar. Treatment plans will be created based on CT scans, for all participants using various treatment delivery and motion management techniques.
214571558|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
214571559|NCT06937229|DRUG|KarXT|Specified dose on specified days
214571560|NCT06937229|DRUG|KarX-EC|Specified dose on specified days
214571561|NCT06943755|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
214571562|NCT06943755|DRUG|Everolimus|Administered as specified in the treatment arm.
214709311|NCT02436733|PROCEDURE|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
214571568|NCT06944379|DRUG|ORKA-002|ORKA-002 is supplied as sterile solution to be administered by SC injection
214571569|NCT06944379|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
214571572|NCT06939478|DEVICE|Arrhythmia Mapping|vMap is indicated for analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.
214571574|NCT06945419|DRUG|LY4086940|Administered orally
214571575|NCT06945419|DRUG|Placebo|Administered orally
214571578|NCT07136350|OTHER|Communication Coaching|Nurses in this group will receive caring communication coaching (2 CEUs).
214571579|NCT07136350|BEHAVIORAL|Implement S.M.A.R.T. Discharge Tool|Implement the S.M.A.R.T. discharge tool.
214709312|NCT02436733|DRUG|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
214709313|NCT02726113|DRUG|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
214571587|NCT07142551|DRUG|Testosterone cypionate|Intermittent intramuscular testosterone cypionate (T) at a dose of 400 mg every 4 weeks.
214571588|NCT07142551|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Eligible patients will initiate combined androgen deprivation therapy (ADT) with an LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx) in combination with standard dose darolutamide (600 mg twice daily) for a total of 6 months.
214571589|NCT07142551|DRUG|Darolutamide|600 mg twice daily during the lead-in phase and on darolutamide cycle.
214571592|NCT06948422|DRUG|Orforglipron|Administered orally.
214571593|NCT06948422|DRUG|Placebo|Administered orally.
214571597|NCT06948435|DRUG|Orforglipron|Administered orally
214571598|NCT06948435|DRUG|Placebo|placebo administered.
214709314|NCT02726113|OTHER|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
214571601|NCT07144306|DIAGNOSTIC_TEST|Smartphone-based AI skin lesion analysis (NuvanaDx platform).|Smartphone-based AI skin lesion analysis (NuvanaDx platform).
214571602|NCT07140900|DRUG|Xaluritamig|Participants will receive xaluritamig intravenously.
214571603|NCT07140900|DRUG|Darolutamide|Participants will receive darolutamide orally.
214709315|NCT01305213|BIOLOGICAL|Bevacizumab|Given IV
214571604|NCT07140900|DRUG|Abiraterone|Participants will receive abiraterone orally.
214571605|NCT06952530|DRUG|Orforglipron|Administered orally
214571606|NCT06952530|DRUG|Placebo|placebo administered
214709316|NCT01305213|DRUG|Fosbretabulin Tromethamine|Given IV
214709317|NCT01305213|OTHER|Laboratory Biomarker Analysis|Correlative studies
214709318|NCT05588180|PROCEDURE|FVD/FAD ratio guided|Ultrasound-guided ratio
214709319|NCT05588180|PROCEDURE|PPV|PPV
214709320|NCT00250406|DEVICE|Ureteral Stent|triclosan-eluting ureteral stent
214709321|NCT00250406|DEVICE|Ureteral Stent|Percuflex Plus Stent as the control
214571609|NCT07148765|DEVICE|Fitbit Sense 2|Continuous biometric monitoring (e.g., heart rate, pulse oximetry, respiratory rate, etc.) that will trigger alerts based on predefined threshold criteria for health care providers to respond to by contacting patients within 24 hours of alert.
214571610|NCT07148765|OTHER|Smartphone application survey|Daily questionnaire to record PROs will be administered via patient smartphones. Concerning PROs will trigger alerts which health care providers will respond to by contacting patients within 24 hours of alert.
214571622|NCT06952504|BIOLOGICAL|Pembrolizumab|Intravenous (IV) Infusion
214571623|NCT06952504|DRUG|Carboplatin|During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
214571624|NCT06952504|DRUG|Paclitaxel|During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
214571625|NCT06952504|DRUG|Docetaxel|During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
214571626|NCT06952504|BIOLOGICAL|Sacituzumab Tirumotecan|IV Infusion
214571638|NCT07152002|DRUG|LY4064912|Administered SC
214571639|NCT07152002|DRUG|LY4064912|Administered IV
214571640|NCT07152002|DRUG|Placebo|Administered SC
214571641|NCT07152002|DRUG|Placebo|Administered IV
214709322|NCT01376362|DRUG|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
214571652|NCT07155876|OTHER|Aromatherapy plus standard of care|"The participant is offered an aromatherapy scented tab that is attached to their gown based on symptoms (anxiety, pain, and/or nausea/vomiting):~1. Pain or anxiety: lavender or lavender sandalwood,~2. Nausea/vomiting: orange ginger, or~3. Despite the type of discomfort, the participant may request the alternate scent if the scent offered is not to their liking.~Plus, the patient receives SoC for treatment based on symptoms (anxiety, pain, and/or nausea/vomiting) as prescribed by the physician."
214709323|NCT01690104|DRUG|Rifampicin|
214709324|NCT01690104|DRUG|Placebo|
214571653|NCT07155876|OTHER|Standard of Care Only|Participant receives symptom management medications for pain, nausea/vomiting, and/or anxiety as prescribed by the physician.
214571654|NCT07150247|DRUG|Iparomlimab and Tuvonralimab|3mg/kg，ivdrip
214571655|NCT07150247|DRUG|Bevacizumab|5mg/kg，ivdrip
214571656|NCT07150247|DRUG|5-Fluorouracil|400mg/m2 iv followed by 2.4g/m2 civ 48h
214571657|NCT07150247|DRUG|Irinotecan (drug)|180mg/m2
214571658|NCT07155213|BEHAVIORAL|Virtual reality exergaming|High-intensity active video gaming using head-mounted display.
214571661|NCT05095415|OTHER|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
214571662|NCT05095415|OTHER|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
214571679|NCT07153900|DEVICE|Treatment with BACK4 System|Use of combined RF and EMS therapy with BACK4 Device
214571686|NCT07153471|DRUG|Orforglipron|Administered orally
214571687|NCT07153471|DRUG|Placebo|Administered orally
214571688|NCT07158593|OTHER|Claudia carraro prevention program|"The Claudia Carraro prevention program is grounded in a cognitive-behavioral conceptualization of the development of eating disorders or disordered eating. The program was designed to address specific and non-specific risk factors that appear relevant: body dissatisfaction and unhealthy weight control behaviors. Its dual objective is to help participants reduce the importance they place on body weight and shape in self-evaluation while simultaneously promoting healthy weight regulation through adherence to Mediterranean dietary guidelines and an active lifestyle.~The strategies and procedures used are derived from cognitive behavioral therapy protocols for eating disorders (Dalle Grave \& Calugi, 2020). The intervention is delivered by psychologists specialized in eating and weight disorders using an interactive, rather than didactic, format, involving small group activities and assigned homework tasks between sessions."
214571705|NCT07162363|DRUG|Alteplase|Up to nine doses of 1.0 mg alteplase will be administered via the catheter placed directly into the intracerebral hemorrhage using minimally invasive surgery.
214571706|NCT07162363|DRUG|Deferoxamine|Deferoxamine will be administered as a continuous intravenous infusion at a dose of 32 mg/kg/day over 24 hours for a total of 3 consecutive days.
214571707|NCT07162363|OTHER|Standard Medical Care (SMD)|We will follow the American Heart Association and European Stroke Organization guidelines for the management of non-traumatic spontaneous intracerebral hemorrhage, ensuring a standardized approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacologic management of intracranial mass effect.
214571710|NCT07162181|DRUG|Pirtobrutinib|Administered orally.
214571711|NCT07165015|DRUG|LY3537031|Administered SC
214721920|NCT01174940|DRUG|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
214571721|NCT07167706|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|BBTI is a multi-component intervention consisting of techniques from sleep restriction and stimulus control therapy. It targets behavioral elements of insomnia using four techniques: 1) reduce time in bed, 2) get up at the same time every day, 3) do not go to bed unless sleepy, and 4) do not stay in bed unless asleep.
214721921|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
214721922|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
214571722|NCT07167706|BEHAVIORAL|Sleep Hygiene Therapy|SHE consists of education on lifestyle factors (diet, exercise, substance use) and enviromental variables (noise, light, temperature) affecting sleep quality.
214571733|NCT07169747|DRUG|Psilocybin|The intervention consists of two oral doses of 25 mg synthetic psilocybin administered in a controlled clinical setting, combined with psychological support. The psychological support includes preparatory sessions prior to psilocybin administration, support during the drug experience and integration sessions following each dosing session.
214571734|NCT07165002|DRUG|LY3537031|Administered SC
214721923|NCT00959894|DRUG|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
214571753|NCT07167225|BEHAVIORAL|Effectiveness of different recruitment approaches|Subjects will asked which type of recruitment material they've seen when completing the screening survey
214571754|NCT07167225|OTHER|Choice of study completion locations|subjects will choose location when coordinator calls to schedule appointment
214571755|NCT07167225|BEHAVIORAL|Cannabis Engagement Assessment|Self reported measure of current cannabis use that contains 30 questions assessing quantity, frequency of use and method of consumption in the past 30 days.
214571756|NCT07167225|BEHAVIORAL|E-cigarette dependence Scale|A 22-item questionnaire measuring e-cigarette dependence. Higher scores indicate greater dependence.
214571767|NCT07169851|DRUG|LY3537021|Administered SC
214571768|NCT07169851|DRUG|Placebo|Administered SC
214571769|NCT07169851|DRUG|Standard of Care Antiemetic Therapies|5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally
214571770|NCT07169851|DRUG|Background Chemotherapy|Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV
214571771|NCT07167966|DRUG|AADvac1|Subcutaneous injection of AADvac1
214571772|NCT07167966|DRUG|Anti-amyloid Monoclonal Antibody (mAb)|Active comparator: intravenous infusion of an anti-amyloid mAb
214571773|NCT07167862|DIAGNOSTIC_TEST|Butterfly iQ3 ultrasound system for determination of postpartum volume status|"A trained study staff member will perform point-of-care ultrasound (POCUS) of the lungs and the inferior vena cava (IVC). All POCUS assessments will be performed using either the curvilinear or phased array settings on a portable Butterfly iQ3 ultrasound system. Images obtained via the Butterfly iQ3 ultrasound system will be labeled according to the subject's unique identification number and transmitted directly to a digital study archive. The lead investigator or physician of record will review all captured ultrasound images to ensure that an appropriate therapy is selected moving forward.~Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider."
214571774|NCT07167862|DRUG|Oral furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The first cohort of 48 patients will be treated with oral furosemide 20mg daily and oral potassium chloride 40mEq daily for a total of 5-days. As patients delivered vaginally are typically discharged 2-3 days after birth and delivered via cesarean are typically discharged 4-5 days after birth, patients who have not yet completed the medication course by the time of planned discharge will be prescribed the remainder of their medications before departing the hospital.
214571775|NCT07167862|DRUG|Intravenous furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The second cohort of 48 patients will be treated with a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq on postpartum day 1.
214571776|NCT07171840|DRUG|10 cc of oxygen-ozone plus thumb splint|Oxygene-Ozone therapy plus splint therapy
214571777|NCT07171840|DEVICE|thumb splint|thermoplastic splint
214571778|NCT07172672|DIETARY_SUPPLEMENT|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer
214571779|NCT07174583|DRUG|IDE849|IV administration
214721924|NCT00959894|DRUG|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
214571782|NCT07174986|DEVICE|Double sequential defibirllation|A second defibrillator will be applyed with electrodes placed in the A-P position and defibrillation will be performed with two defibrllators in a sequential manner
214571783|NCT07174986|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
214571790|NCT07174336|DRUG|LY4064809|Administered orally
214571791|NCT07174336|DRUG|Placebo|Administered orally
214571792|NCT07174336|DRUG|Ribociclib|Administered orally
214571793|NCT07174336|DRUG|Palbociclib|Administered orally
214571794|NCT07174336|DRUG|Abemaciclib|Administered orally
214571795|NCT07174336|DRUG|Anastrozole|Administered orally
214571796|NCT07174336|DRUG|Letrozole|Administered orally
214571797|NCT07174336|DRUG|Exemestane|Administered orally
214571798|NCT07174336|DRUG|Fulvestrant|Administered intramuscular
214571799|NCT07177339|DRUG|Depemokimab|Depemokimab will be administered.
214571800|NCT07177339|DRUG|Placebo|Matching placebo will be administered.
214571801|NCT07178288|OTHER|Physiological/measurement-validation study|"Protocols PPT Reliability The assessor measured Pressure Pain Threshold; PPT, using an electronic digital algometer. Measurements will be taken at two test sites wrist at baseline, at 1, 3 and 5 minutes. Three PPT measurements were taken at each time point with a 15-20 seconds interval between each. Mean values will then be used in analysis.~Conditioned Pain Modulation In order to assess CPM, PPT was used as a tested stimulus on the painful arm (elbow and wrist). Baseline PPTs will assessed three times with an interval of 30 seconds between the repetitions. A Cold Pressure Task (CPT) will be used as the conditioning stimulus. Participants will be instructed to immerse their uninvolved hand in the ice water for 2 minutes. PPT will be measured at baseline pre and 1 minute during immersion to calculate CPM response, and then at various time points post immersion (minutes: 1, 5, 15, 30, 45, and 60) to determine the time point at which PPT returns to baseline."
214571802|NCT07179250|DEVICE|Volume-Oriented Incentive Spirometer|Participants in the experimental group will perform volume-oriented incentive spirometry training twice daily (morning and evening) for 6 weeks. Each session consists of 10 deep inspirations using the spirometer, with the target volume initially set according to the participant's predicted maximum inspiratory capacity and increased by approximately 5% each week starting from week 2. For each breath, participants inhale to reach the target volume, hold their breath for 3-5 seconds, and then exhale. A rest period of 30-60 seconds is allowed between maneuvers, and the pace is adjusted according to individual tolerance. Training is performed in a seated or semi-recumbent position.
214571803|NCT07179250|BEHAVIORAL|Diaphragmatic Breathing Exercise (DBE)|Participants in the control group will perform diaphragmatic breathing exercises twice daily (morning and evening) for 6 weeks. During weeks 1-2, each session consists of 10 breaths per set; from week 3 to week 6, each session consists of 15 breaths per set. The exercise is performed without devices and includes the following sequence: slow inspiration through the nose with abdominal expansion, holding the breath for 5 seconds, followed by exhalation through the mouth with visible abdominal contraction. After each set, participants rest with natural breathing for 1-2 minutes to prevent hyperventilation or diaphragmatic fatigue. Training is conducted in a semi-recumbent position with both hands placed behind the head, focusing on abdominal movement control and breathing rhythm.
214571804|NCT07179250|BEHAVIORAL|Usual Care and Education|Participants in the control group will receive usual clinical care for gastroesophageal reflux disease (GERD) without structured breathing training. At study entry, participants are provided with standardized patient education regarding GERD and lifestyle modification strategies, along with an educational leaflet. No specific posture or breathing exercises are required during the study period.
214721925|NCT02744053|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
214721926|NCT02744053|OTHER|Laboratory Biomarker Analysis|Correlative studies
214721927|NCT02744053|RADIATION|Scintimammography|Undergo MBI
214721928|NCT02744053|DRUG|Technetium Tc-99m Sestamibi|Given via injection
214721929|NCT05406245|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
214571805|NCT07178977|BEHAVIORAL|Psychoeducation group|"A structured, group-based psychoeducation program designed for parents of adolescents with anorexia nervosa. The intervention consists of four weekly sessions, each lasting 90 minutes, delivered in small groups (up to 7 families) at the Child Psychiatry Department, University Medical Centre Ljubljana. Each session follows a standardized structure. The session topics are: Understanding eating disorders; Maintaining factors in anorexia nervosa and strategies to address them; Establishing and supporting normal eating patterns, Promoting and sustaining change.~The program is adapted from evidence-based approaches, including family-based treatment (FBT) and enhanced cognitive-behavioral therapy (CBT-E), and is tailored to a psychoeducational group format for parents. The aim is to reduce parental distress, improve coping, and enhance adolescent treatment outcomes (BMI, eating disorder symptoms, anxiety, depression)."
214571813|NCT07181941|BIOLOGICAL|Linvoseltamab|Given IV
214709325|NCT04924010|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
214709326|NCT04924010|BEHAVIORAL|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
214571814|NCT07181941|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214571815|NCT07181941|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214709327|NCT01692912|OTHER|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
214709328|NCT02905916|DRUG|PEG-rhG-CSF|
214571816|NCT07181941|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214571817|NCT07181941|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214571818|NCT07181941|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214571825|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.
214571826|NCT07183319|DRUG|Pembrolizumab|Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.
214571827|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.
214709329|NCT06092632|OTHER|Pigmented rice|Cooked black rice
214709330|NCT06092632|OTHER|White Rice|Cooked white rice
214709331|NCT04982835|DEVICE|M6-C Artificial Cervical Disc|An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.
214709332|NCT04982835|DEVICE|ACDF|One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.
214709333|NCT07011901|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD. It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).
214709334|NCT00638924|OTHER|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
214709335|NCT01325324|DEVICE|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
214571846|NCT07184983|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (19 minutes), and then ramp down (for 30 seconds) at the end.
214571847|NCT07184983|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 18 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end.
214571848|NCT07184983|BEHAVIORAL|Mindfulness meditation|Participants will follow an audio track for guided mindfulness during the stimulation.
214721930|NCT01654393|OTHER|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
214571861|NCT07186660|DRUG|CIR-0602K|mitochondrial pyruvate carrier inhibitor
214571862|NCT07186660|DRUG|Placebo|Placebo tablet
214571867|NCT07187765|DRUG|Oliceridine|Oliceridine will be administered intravenously at a dose of 1 mg for gastroscopy or 1.5 mg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
214571868|NCT07187765|DRUG|Sufentanil|Sufentanil will be administered intravenously at a dose of 5 μg for gastroscopy or 7.5 μg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
214571888|NCT07184190|OTHER|Trancutaneous Auriculotemporal Nerve Stimulation|Trancutaneous Auriculotemporal Nerve Stimulation
214571895|NCT07185022|PROCEDURE|Intra-arterial Thrombolysis|rhTNK-tPA（Tenecteplase）dose: 0.4 - 0.8 mg/min, maximum dose: 16mg.
214571896|NCT07185022|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
214571897|NCT07190131|DIAGNOSTIC_TEST|Investigational Flu A/B And Covid-19 Diagnostic Test|A diagnostic test in lateral flow cassette format designed to detect Influenza A, Influenza B and SARS-CoV-2 from anterior nasal swab specimens.
214709336|NCT04896190|OTHER|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
214709337|NCT01809678|BEHAVIORAL|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
214709338|NCT01809678|BEHAVIORAL|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
214709339|NCT01809678|OTHER|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
214571899|NCT07188896|DRUG|Fianlimab|Fianlimab will be co-administered by IV.
214571900|NCT07188896|DRUG|Ipilimumab|Ipilimumab will be administered by IV.
214571901|NCT07188896|DRUG|Nivolumab|Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
214571902|NCT07188896|DRUG|Cemiplimab|Cemiplimab will co-administered by IV.
214571909|NCT07194421|OTHER|Sunscreen RV4620A RP2552|Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon.
214571910|NCT07194174|OTHER|Strength exercise|3 weekly supervised trainings with specific strengt exercises
214571911|NCT07194746|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
214571912|NCT07194746|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
214571913|NCT07194941|BIOLOGICAL|Freeze-dried product made of fresh feces|"FMT represents an ecological alternative for restoring the damaged intestinal ecosystem in this infection, increasing ecological diversity and thus limiting the spread of the pathogen. Recurrence of C. difficile is its only approved indication.~The impact of FMT on the intestinal ecosystem is attributable to intraspecific bacterial competition: commensal microorganisms (sensitive and non-virulent) have more effective growth rates than pathogenic bacteria (resistant and virulent), so FMT produces an ecological replacement in favor of grafting the donor microbiota and eliminating antibiotic-resistant clones."
214571914|NCT07194070|OTHER|Standard of Care|No study treatment will be administered as part of this study. Participants will receive standard of care therapy as per local clinical practice.
214571915|NCT07195032|DRUG|Commercial measles, mumps, and rubella (MMR) vaccine|Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
214571916|NCT07194226|OTHER|No intervention (observational study)|This is an observational survey; participants complete an anonymous questionnaire and no medical or behavioral intervention is applied.
214571917|NCT07195422|DEVICE|Japet.W+|Current care of low back pain and wearing the Japet.W+
214571918|NCT07195422|DEVICE|Control (Standard treatment)|Current care of low back pain
214571919|NCT07195513|BEHAVIORAL|ePRO-Directed Referral and Navigation to Palliative/Supportive Care|This intervention combines routine electronic patient-reported outcome (ePRO) symptom monitoring with additional components designed to connect patients more directly to palliative/supportive care. In addition to weekly ePRO symptom surveys, participants complete a monthly palliative care-focused ePRO survey, receive structured palliative care education from a trained study coordinator, and are offered navigation support to facilitate access to palliative/supportive care services. Severe or persistent symptoms or unmet needs reported on ePROs generate an alert to the oncology team along with a recommendation for palliative care referral. This multicomponent approach is intended to address gaps in timely referral and access to palliative/supportive care that are not addressed through symptom monitoring alone.
214571920|NCT07195513|OTHER|ePRO Symptom Monitoring with Usual Palliative Care Referral|Participants complete weekly electronic patient-reported outcome (ePRO) symptom monitoring surveys. Survey results are shared with the oncology team to support routine care. Referral to palliative/supportive care is made according to usual clinical practice at the discretion of the oncology team. Unlike the intervention arm, participants do not receive structured palliative care education, a monthly palliative care-focused ePRO survey, navigation support, or referral alerts generated from persistent or severe symptoms and unmet care needs.
214571921|NCT07194187|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound (HIFU) works with an image-guided transrectal probe that utilizes 3-10 MHz ultrasound waves at very high powers (200W). These waves can be very precisely directed at target tissue. Through both thermal and mechanical forces (shearing motion and mechanical energy leading to hyperthermia) the focal point core temperature can be raised significantly (\> 80°C) leading to coagulative necrosis to the target tissue while sparing surrounding tissue. The degree of tissue injury is based on the temperature and the duration of exposure, with the cooling off time allowing for the heat to dissipate to prevent the damage to surrounding tissues. The most common device involves a transrectal transducer with ultrasound guidance that can be performed under either general or spinal anesthesia. The device has been FDA approved to be used in ablation of prostatic tissue since 2018.
214571922|NCT07194629|DRUG|Silver diamine Fluoride 38%|SDF 38%, applied on tooth surface for arrestation of active carious lesions and prevention of development of new carious lesions
214571923|NCT07194629|DRUG|placebo solution|bluish liquid designed to mimic the appearance of SDF 38%
214571924|NCT07193563|DRUG|ENX-102|oral capsule
214571925|NCT07193563|OTHER|Placebo|oral capsule
214571926|NCT07193511|DRUG|AVZO-103|Specific dose in protocol specified schedule
214571927|NCT07193511|DRUG|Combination Agent|Per label based on combination agent used
214571928|NCT07194694|DRUG|Dexmedetomidine & Bupivacaine.|Group D (Dexmedetomidine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine + 1mcg/kg dexmedetomidine +normal saline.
214571929|NCT07194694|DRUG|ketamine and bupivacaine injection|Group K (ketamine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine+0.5 mg/kg ketamine + normal saline.
214571930|NCT07194694|DRUG|Bupivacaine|Group C (Control Group): Patients will receive 20 ml solution containing 1 mg/kg bupivacaine + normal saline.
214571933|NCT07187479|OTHER|Physiologic Insulin Resensitization (PIR)|PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.
214571934|NCT07195617|DRUG|BCMA-GPRC5D CART|The entire study process was as follows: Screening period (V1) : Informed consent was signed, screening was checked, criteria were evaluated, and baseline demographic information and subject status were recorded. Blood collection period (V2) : For subjects who meet the inclusion and exclusion criteria, the blood required for CAR-T preparation will be obtained by leukocyte isolation monopexy or intravenous collection according to the conditions of the subjects. Preconditioning phase (V3) : cytokine and cell changes. Pre-transfusion assessment (V4) : The investigator assessed that the test results met the cell transfusion criteria, and D0 CAR T cell infusion could be performed with investigator permission. Infusion phase (V5) : CAR-T cells were transfused according to the dosage and method specified in the protocol. Safety and efficacy were followed up on D1, D4, D7, D10, D14, D21, D28, M3, M6, M9, M12, and M24.
214571935|NCT07193654|DRUG|Intrathecal injection of thiotepa|Intrathecal injection of thiotepa: Administered via lumbar puncture or OMMAYA reservoir according to the study protocol.
214571936|NCT07193654|DRUG|Stupp regimen (oral temozolomide)|Stupp regimen (oral temozolomide)::75 mg/m² daily during radiotherapy; 150-200 mg/m² daily for 5 days every 28 days for 6 cycles after radiotherapy;
214571937|NCT07193654|RADIATION|Radical radiotherapy|Radical radiotherapy: Delivery of 60 Gy of radiation, typically divided into 30 fractions of 2 Gy each;
214571938|NCT07193654|PROCEDURE|Maximal surgical resection|Maximal surgical resection: Removal of as much tumor as possible while preserving neurological function;
214571939|NCT07194707|OTHER|Intraoperative Noise Monitoring|Noise levels will be passively measured during surgery using a calibrated sound level meter (CEM DT-8850) placed near the patient's head. Measurements will be taken every 10 minutes without physical contact or interference with clinical care. The procedure is purely observational and does not modify anesthesia or surgical practice.
214571940|NCT07194590|DRUG|Equol|This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
214571941|NCT07194590|DRUG|Placebo|This group will receive 2 placebo capsules per day.
214571942|NCT07194278|DEVICE|Blue-blocking glasses|The intervention will last for 7 days, during which patients are required to wear the glasses from 6 p.m. to 8 a.m. and whenever a light is turned on during this interval. Additionally, patients will be asked to wear an actimeter and fill out a sleep diary each day. Doctors will conduct daily interviews to assess manic symptoms, with more in-depth assessments scheduled on days 0, 3, and 7 to evaluate other clinical characteristics.
214571943|NCT07195149|DRUG|High-Dose Aspirin 300 mg|High-dose Aspirin 300 mg once daily taken orally for three months
214571944|NCT07195149|DRUG|DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)|"Drug: Prasugrel 10 mg~Prasugrel 10 mg once daily taken orally for 3 months~Drug: Low-Dose Aspirin~75 mg once daily taken orally"
214571945|NCT07195149|DRUG|Low-Dose Aspirin 75 mg|Low-Dose Aspirin 75 mg once daily taken orally
214571946|NCT07193589|DRUG|The high-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.
214571947|NCT07193589|DRUG|The low-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.
214571948|NCT07193589|DRUG|The placebo group|The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.
214571949|NCT07194577|DIETARY_SUPPLEMENT|Moringa oleifera|5.6 grams of Moringa oleifera Lam dried leaf powder administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
214571950|NCT07194577|DIETARY_SUPPLEMENT|Placebo|Starch placebo administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
214571951|NCT07194902|BEHAVIORAL|"HIVST for Partners and PrEP uptake for HIV-uninfected Postpartum Women (H4P)."|"For female participants, the intervention includes a 30-45 minute counseling session that will cover (1) SOC PrEP information, (2) communications skills training for HIVST kit distribution, (3) Motivational interviewing strategies (e.g., PrEP/HIVST pros/cons), (4) problem-solving barriers to PrEP uptake or HIVST distribution, (5) linkage enablers (e.g., care sites, transportation, asking questions of providers). For their male partners, an informative video will cover geographically diverse HIV treatment resources, as well as on why linkage to HIV care is needed in the context of the relationship with his female partner and gender norms. The video will also demonstrate a brief motivational exercise whereby men are asked to consider the pros and cons of linking to HIV care versus not (with examples), as well as a step-by-step guide to generate a concrete plan for linkage to care based on linkage enablers."
214571954|NCT07194343|PROCEDURE|Laparoscopic colposacropexy with levator ani muscle mesh fixation|The standard technique includes dissection of the rectovaginal space and bilateral mesh fixation to the levator ani muscle at the deep limit of the pararectal fossae dissection.
214709340|NCT03395756|DRUG|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
214571955|NCT07194343|PROCEDURE|Simplified modification of laparoscopic colposacropexy|Rectovaginal dissection is avoided, and the mesh is anchored to the posterior aspect of the cervix or vaginal vault rather than to the levator ani muscle, representing the specific modification from the standard technique.
214571956|NCT07195357|OTHER|epidemiological|collection of data from all participating subjects involving tooth erosion examinations, tooth sensitivity and questionnaire data collection
214571957|NCT07195370|OTHER|peripheral iridotomy|This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.
214709341|NCT02178501|DIETARY_SUPPLEMENT|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
214709342|NCT01005446|DEVICE|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
214571958|NCT07195123|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional psychoeducational content regarding self-management skills will be provided in-app.
214571959|NCT07193550|DRUG|Zanzalintinib|Participants will take zanzalintinib 100mg daily by mouth
214571960|NCT07194655|OTHER|Acupuncture at the Yanglingquan point|Acupuncture at the Yanglingquan point
214721931|NCT05935813|OTHER|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
214721932|NCT03275519|OTHER|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
214721933|NCT03275519|OTHER|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
214721934|NCT06287658|BEHAVIORAL|Training on Kegel exercise and Ba Duan Jin applications online|Kegel exercises and Ba Duan Jin applications online
214571961|NCT07194655|OTHER|Acupuncture at the Xiabai Point|Acupuncture at the Xiabai Point
214571962|NCT07194655|OTHER|Acupuncture at non-meridian points|Acupuncture at non-meridian points
214571963|NCT07195097|DRUG|Oral intake of sildosin|Oral intake of sildosin in male non hormonal contraception
214571964|NCT07195097|OTHER|Oral intake of placebo|Intake of placebo to compare effecacy of other group
214571965|NCT07195279|OTHER|Experimental Group|The VR intervention consisted of a simulated driving experience delivered over nine sessions, three times per week, each lasting 20 minutes, over a three-week period. The virtual reality (VR) therapy employed a full immersion approach, delivering intense multisensory visual-auditory stimulation. Patients were exposed to diverse driving scenarios, specifically: urban streets (featuring intersections, traffic lights, and pedestrians to simulate complex urban environments), ring roads (designed for practicing smooth and confident high-speed driving in dense traffic), and tunnels (sections aimed at gradually desensitizing users to claustrophobic responses during driving).
214571966|NCT07195279|OTHER|Control Group|Conventional cardiac rehabilitation protocol consisted of 1.5-hour group calisthenics sessions with a 10-minute break, held six times per week. This was accompanied by aerobic reconditioning exercises on a stationary bike or treadmill, depending on medical prescription and the patient's health status.
214571967|NCT07194304|DRUG|alpha-Tocopherol|patients in the intervention group received parenteral alpha-tocopherol at a dose of 4 mg/kg body weight
214571968|NCT07194304|DRUG|Sterile Water for Injection|the control group received a placebo (sterile water for injection/aquabidest)
214571969|NCT07194980|DRUG|Nemtabrutinib|Given PO
214571970|NCT07194980|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214721935|NCT06287658|BEHAVIORAL|training on Kegel exercises and Ba Duan Jin applications after the research is completed|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
214721936|NCT00653068|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214571971|NCT07195201|DEVICE|3D Printed Onlay Restoration|Onlay restorations will be fabricated using a 3D printer and a biocompatible permanent resin (Bego VarseoSmile TriniQ). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
214571972|NCT07195201|DEVICE|CAD/CAM Onlay Restoration|Onlay restorations will be fabricated using a CAD/CAM milling unit and hybrid ceramic blocks (GC Cerasmart 270). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
214571973|NCT07193940|PROCEDURE|Flexible Ureterorenoscopy|Flexible Ureterorenoscopy
214721937|NCT00653068|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
214571974|NCT07193940|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|extracorporeal shock wave lithotripsy (ESWL)
214571975|NCT07195305|PROCEDURE|Radiofrequency endometrial ablation|Radiofrequency endometrial ablation
214571976|NCT07195305|PROCEDURE|Uterine artery embolization|Uterine artery embolization
214571977|NCT07195305|PROCEDURE|Hysterectomy|Hysterectomy
214721938|NCT00653068|DRUG|Carboplatin|Given IV
214721939|NCT00653068|DRUG|Cisplatin|Given IV
214721940|NCT00653068|DRUG|Cyclophosphamide|Given IV
214571978|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)|2.5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
214571979|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2)|5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
214571980|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)|10 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
214571981|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4)|20 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
214571982|NCT07195071|DEVICE|Natera empower comprehensive hereditary cancer panel|Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers
214571983|NCT07195071|DEVICE|Obstetrical carrier screening|Obstetrical carrier screening for genetic conditions
214571984|NCT07195578|OTHER|Three Dimensional Puzzle Game (3D puzzle)|Individuals in the intervention group were exposed to the 3D puzzle game three days a week for a total of 10 weeks. Three-dimensional puzzle figures, ranging in size from 20 to 50 pieces, were used in 30 sessions, each with a different figure.
214571987|NCT07194148|BEHAVIORAL|Gamified Digital Education (ORNurse: Steril Setup 1.0)|A behavioral intervention utilizing a custom-developed 3D digital game designed to teach perioperative nurses or students the correct layout of surgical instrument tables in total hip arthroplasty. The game includes interactive modules, feedback mechanisms, and simulated scenarios based on a validated protocol.
214721941|NCT00653068|DRUG|Etoposide|Given IV
214721942|NCT00653068|BIOLOGICAL|Filgrastim|Given IV or SC
214571988|NCT07194018|DRUG|Use of cannabis oil|Use of cannabis oil on pain relief in patients suffering from fibromyalgia syndrome
214571989|NCT07195266|BEHAVIORAL|Strategic Psychoterapy|Strategic psychotherapy as described in scientific literature
214571990|NCT07195019|BEHAVIORAL|Integrative Yoga & Mindful Self-Compassion training|Group Integrative Yoga \& Mindful Self-Compassion training for women with a history of interpersonal violence exposure and distress
214571991|NCT07195019|BEHAVIORAL|Women's Wellbeing Education|Group women's wellbeing education for women with a history of interpersonal violence exposure and distress
214571992|NCT07193888|DEVICE|Navitor Transcatheter Aortic Valve Implantation|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System.
214571993|NCT07193953|DEVICE|Next Generation Dome Helmet Focused Ultrasound|Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.
214721943|NCT00653068|OTHER|Laboratory Biomarker Analysis|Correlative studies
214721944|NCT00653068|DRUG|Leucovorin Calcium|Given IV or PO
214721945|NCT00653068|DRUG|Methotrexate|Given IV
214721946|NCT00653068|DRUG|Thiotepa|Given IV
214721947|NCT00653068|DRUG|Vincristine Sulfate|Given IV
214571994|NCT07193953|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|"Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose.~Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight."
214571995|NCT07193953|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.
214571996|NCT07195344|BIOLOGICAL|Pharmacokinetics blood samples|Blood samples will be collected at different time points during the first four treatment cycles and at the end of T-DXd treatment or at 24 months after inclusion in case of T-DXd continuation beyond this time period.
214571997|NCT07193862|COMBINATION_PRODUCT|Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373|"Patients with diagnosed liver metastasis from a colorectal primary deemed resectable. The study intervention will be limited to the percutaneous placement of up to 2 IMDs per lesion with a maximum of 4 devices total, with the subsequent en bloc resection of the tumor plus IMD within 3 (+2) days after placement. The microdevices will remain in the tumor for a minimum of a 2-day incubation period, although ideally for 3 days.~The IMD is a small cylindrical device approximately 750 um in diameter and 5 mm in length (Figure 2), housing up to 21 reservoirs. It is made of PEEK, biocompatible material used in other implantable constructs, including joint replacements. 11-13 Drugs are solubilized with poly-ethylene glycol (PEG) and loaded into the individual reservoirs. The drug diffusion has been mapped extensively to ensure that the weight of PEG is selected such that drug diffusion is limited and will not mix or interfere with another drug."
214571998|NCT07193810|BIOLOGICAL|CC312|CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.
214571999|NCT07195045|DIAGNOSTIC_TEST|Thai PainPREDICT Questionnaire and Mobile Application|The Thai PainPREDICT Questionnaire is a culturally adapted and validated version of an internationally recognized neuropathic pain assessment tool. In this study, it is administered via both paper form and a secure mobile application designed for Thai patients with diabetes. The app automates scoring, provides real-time feedback, and securely stores data in REDCap in compliance with Thai Personal Data Protection Act (PDPA). The intervention is used to screen for painful diabetic neuropathy and compare results against clinical diagnosis and neurophysiological testing, including DN4, nerve conduction studies, and quantitative sensory testing.
214572000|NCT07195136|BEHAVIORAL|Essential Oil|essential oil
214572001|NCT07195058|BEHAVIORAL|Trauma Informed Obstetric Care (TIOC)|"TIOC providers will receive a training that was developed for this study. Elements of trauma-informed care described in the literature -combined with the experience of the study team, with deep expertise in trauma-informed obstetric care, were used to create three training modules, each of which includes didactics and role-plays to help participants practice and embody skills they learn. The three modules are:~1. Effects of trauma on physiological and psychological process relevant to pregnancy and childbirth.~2. Body language and verbal language for safety, respect, and patient agency~3. Recognizing and responding to distress and dissociation"
214721948|NCT01017692|PROCEDURE|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
214721949|NCT03908086|OTHER|Risk factors in RA cohort|
214721950|NCT03908086|OTHER|Risk factors in general population|
214721951|NCT01305941|DRUG|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
214721952|NCT01305941|DRUG|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
214721953|NCT01305941|DRUG|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
214572002|NCT07193706|BEHAVIORAL|Traditional group training program|This intervention consists of two supervised plyometric training sessions per week, each lasting about 40 minutes. It represents the traditional approach with fewer but longer sessions. The total weekly training volume is equivalent to the micro-dosed group but distributed differently.
214572003|NCT07193706|BEHAVIORAL|Micro-dosed group training program|This intervention consists of three to four shorter supervised plyometric sessions per week, each lasting about 20 minutes. It represents a micro-dosed approach, with higher frequency but shorter duration per session. The total weekly training volume is equivalent to the traditional group but distributed across more frequent sessions.
214635029|NCT05073107|OTHER|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
214721954|NCT01326676|DRUG|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
214635030|NCT00931359|DEVICE|DTS-G2 System|Treatment with microwave energy
214635031|NCT00931359|DEVICE|DTS System (Sham treatment)|Sham treatment - no energy is delivered
214635032|NCT04153188|DEVICE|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
214635033|NCT04153188|DRUG|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
214635034|NCT02613962|PROCEDURE|biopsy or surgical resection of tumor and blood sampling|
214635035|NCT01480336|DRUG|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
214635036|NCT01480336|DRUG|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
214635037|NCT00185978|BEHAVIORAL|diet, physical activity, reduced sedentary behavior|
214635038|NCT00716755|DRUG|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
214635039|NCT03258658|BIOLOGICAL|Autologous Engineered Urethral Construct|urethral construct
214572004|NCT07195435|BEHAVIORAL|Genital Hygiene Education|Genital Hygiene Training: Young girls who agree to participate will receive two sessions of two hours of genital hygiene training on a predetermined date, as appropriate. Genital hygiene training will be delivered via PowerPoint presentation, and at the end of the training, a training booklet and brochure, developed in accordance with the relevant literature, will be distributed to the participating girls to ensure retention. The training booklet and brochure will be prepared by the researcher based on current literature sources. Expert opinions will be sought from obstetrics and gynecology nursing experts regarding the training content and will be revised as necessary. The content of the training booklet will cover the female internal and external genital organs, the importance of genital infections for women's health, factors affecting genital hygiene, characteristics of normal and abnormal genital discharge, common genital infections, signs and symptoms of genital infection, and pro
214572005|NCT07194772|OTHER|Low-calorie sweeteners (LCS)|"Consumption of sucralose-sweetened beverages (LCS) using doses and formulations reflecting real-world conditions.~Individualized dose equivalent volume (mL) to SSB group. Average dose received of 150 mg (±30 mg) of pure sucralose per day (2.00 ± 0.23 mg/Kg BW) among participants, which is below Acceptable Daily Intake for sucralose (5 mg/Kg BW/day). LCS matched for sweetness to SSB based on the manufacturer's information."
214572006|NCT07194772|OTHER|Refined sugars (SSB)|"Consumption of sugar-sweetened beverages (SSB) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada. SSB matched total free sugar concentration of 100% natural orange juice (FJ)."
214572007|NCT07194772|OTHER|Natural sugars (FJ)|"Consumption of natural fruit juice (100% natural orange juice) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada."
214572008|NCT07194408|OTHER|Sunscreen RV4620A RP2552|"Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product.~Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon."
214572009|NCT07194928|OTHER|We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.|We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
214572010|NCT07195643|OTHER|Drain|We want to put a assess the predictive factors for prophylactic drain after cholecystectomy.
214572012|NCT07193836|DRUG|Normal Saline (0.9% NaCl)|Participants in the control group received a single intravenous injection of 0.9% normal saline at induction of anesthesia.
214572013|NCT07193836|DRUG|Lidocaine|Participants in this group received a single intravenous bolus of lidocaine (1.5 mg/kg) at anesthesia induction. No additional lidocaine was administered thereafter.
214572014|NCT07193836|DRUG|Lidocaine Bolus + Infusion|Participants in this group received a bolus of lidocaine (1.5 mg/kg) at induction followed by continuous intravenous infusion of lidocaine (2 mg/kg/h) until the end of surgery.
214572015|NCT07195383|OTHER|Nutrion plan based on GUSS-ICU scale|To ensure a rapid and accurate transition to post-extubation nutrition, patients will be assessed using the GUSS-ICU scale at 4 hours after extubation. A nutrition plan will be created based on the patient's GUSS-ICU score and will be maintained for 4 days.
214572016|NCT07194031|OTHER|Ankle Exercise|In the literature, studies have evaluated ankle proprioception following interventions applied to the knee. However, no studies report the effects of ankle exercises on knee proprioception
214721955|NCT01326676|DRUG|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
214721956|NCT01507441|GENETIC|gene mapping|
214572017|NCT07194031|OTHER|Knee Exercise|The literature emphasizes that long-term and multidirectional exercise programs provide proprioceptive improvements
214572018|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (1 per day)|Children consume one yogurt smoothie per day for 4 weeks (93 mL and \~70 kcal).
214572019|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (2 per day)|Children consume two yogurt smoothies per day for 4 weeks (186 mL and \~140 kcal).
214572020|NCT07195474|DIETARY_SUPPLEMENT|Fruit Juice Control|Children consume one fruit juice per day for 4 weeks (\~140 kcal, isocaloric with 2 yogurt smoothie).
214572021|NCT07195539|OTHER|Tranexamic Acid sprinkle with CO2 LASER|tranexamin acid will be sprayed after CO2 LASER
214572022|NCT07194083|BEHAVIORAL|Function-Based Elopement Treatment|"FBET is a structured, caregiver-implemented behavioral intervention targeting elopement in children. It includes:~* Psychoeducation and Behavioral Assessment-caregivers receive training on elopement, behavioral principles, and assessment strategies~* Functional Analysis Coaching-therapists guide caregivers through a latency-based functional analysis to identify the function of elopement~* Individualized Treatment Implementation-caregivers apply a function-based plan using differential reinforcement, providing preferred items/activities contingent on safe behavior~* Treatment Modification-therapists support caregivers in adjusting the plan based on child's response.~There will be 12 2-hour, caregiver-mediated sessions across 20 weeks Caregivers also learn safety and prevention strategies, including the use of resources like the Big Red Safety Toolkit."
214572023|NCT07194083|BEHAVIORAL|Treatment as Usual|TAU consists of ongoing Applied Behavior Analysis (ABA) services, including caregiver training as it normally exists, provided by the family's Board Certified Behavior Analyst (BCBA), independent of the study protocol. The BCBA determines session frequency, content, and focus based on clinical judgment and the child's individual needs. Topics may include skill acquisition, behavior reduction (including elopement), or other areas deemed relevant to the child's care. The research team does not influence or standardize the TAU content, but will monitor and document the services delivered for descriptive and comparative purposes
214721957|NCT01507441|GENETIC|microarray analysis|
214721958|NCT01507441|GENETIC|mutation analysis|
214721959|NCT01507441|GENETIC|nucleic acid sequencing|
214721960|NCT01507441|OTHER|laboratory biomarker analysis|
214572024|NCT07193667|DRUG|CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases|"This is a prospective, single-center, open, single-arm, dose-escalation clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory autoimmune diseases. Intravenous infusion will be used, and the trial procedure will be divided as follows:~1. Screening period (D-28 to D-6):~   After subjects voluntarily sign an informed consent form, a screening period will be conducted to determine whether subjects are eligible for the trial based on inclusion and exclusion criteria.~2. Lymphocyte depletion pretreatment (Study D-5 to Study D-3):~   Subjects will be pre-treated with Lymphocyte depletion starting 5 days prior to CAR-T cell infusion (FC regimen)~3. Rest and Observation (Study D-2 to Study D-1):~   Follow the study procedures and perform the relevant examinations during the rest and observation period.~4. Cell Infusion and Primary Study Endpoint Observation Period (Study D0 to W12 post-infusion):Subjects will undergo CAR-T cell infusion at 2-da"
214572025|NCT07195240|DIETARY_SUPPLEMENT|Active: Lemongrass|200mg of lemongrass extract
214709343|NCT04093687|OTHER|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
214709344|NCT01635634|OTHER|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
214572026|NCT07195240|DIETARY_SUPPLEMENT|Control: Placebo|microcrystalline cellulose
214572030|NCT07188675|OTHER|Functional Inspiratory Muscle Training (FIMT)|Participants will begin with Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks. Training will be performed once a week face-to-face, while adherence will be monitored on other days via WhatsApp. During each face-to-face session, MIP will be reassessed and training loads adjusted. Participants will perform 30 dynamic inspiratory efforts twice daily. In the following 4 weeks, Functional Inspiratory Muscle Training (FIMT) will be applied: once face-to-face, twice online under physiotherapist supervision, and twice unsupervised IMT. FIMT exercises will be performed with the POWERbreathe Classic Light Resistance device, consisting of 10 breaths lasting 15-30 seconds in 2 sets. Each session will include warm-up (diaphragmatic breathing and trunk stretches), loading (core stabilization exercises), and cool-down (trunk stretches). IMT intensity will be adjusted weekly using MIP measurement
214572031|NCT07188675|OTHER|Inspiratory Muscle Training (IMT)|Participants will perform IMT daily for 8 weeks. Training will be conducted once a week face-to-face, while on other days adherence will be monitored via WhatsApp. The group will complete 30 dynamic inspiratory efforts twice daily. The POWERbreathe Classic Light Resistance device (PowerBreathe, IMT Technologies Ltd, Birmingham, UK) will be used to strengthen the diaphragm and chest wall muscles by breathing against a set pressure load. Training intensity will be set at 50% of maximal inspiratory pressure (MIP). After 10-15 consecutive breaths, participants will perform 3-4 recovery breaths before continuing. IMT intensity will be re-adjusted weekly during face-to-face sessions using MIP measurements to maintain 50% loading.
214572034|NCT07188922|OTHER|Non-invasive intraocular pressure measurement during ventilator weaning Description: Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from|Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from mechanical ventilation to spontaneous breathing. Measurements will be performed as part of routine clinical care and will not involve any experimental intervention.
214572035|NCT07195461|DEVICE|Magnetic Bead Tracking System|The Magnetic Beads will be implanted in a subject during either an already required revision of an existing unilateral or bilateral transtibial amputation or during the performance of a unilateral or bilateral transtibial amputation.
214572036|NCT07194824|OTHER|Pragmatic allergy management according to risk stratification|"Intervention based on allergy risk stratification. Tipus A) Patients in this group can undergo direct delabeling without the need for exposure, with this being documented in the EMR. If the patient refuses, an exposure to penicillin and/or cephalosporin will be performed. Once completed, de-labeling can proceed without the need for re-exposure.~Tipus B) Indication for use of a penicillin: Oral exposure to 250 mg of amoxicillin.~\- Indication for cephalosporin : administration of a cephalosporin that exhibits the lowest level of cross-reactivity with penicillin.~Re-exposure to penicillin/ cephalosporin or both is performed at least 2 weeks after the first tolerated exposure. De-labeling is performed when tolerance to re-exposure is verified.~Tipus C) These high-risk patients are managed following the protocol for the treatment of patients with beta-lactam allergy, referring them to allergy consultation for further specific test."
214709345|NCT05266794|DRUG|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
214709346|NCT05266794|DRUG|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
214572037|NCT07193602|DEVICE|VR-based dexterity training in MS|Training of limited manual dexterity in people with multiple sclerosis through a specially developed home-based dexterity training programm using a virtual headset
214572038|NCT07193602|OTHER|mediation program|Sham Training is the comparator. The Sham group is performing a commercially available mediation programm TRIPP:
214572039|NCT07194603|PROCEDURE|Spinal mobilization (SM) of the neck|This cohort intervention study has only one arm and this arm has only one intervention, the one described above. Both SM and JM mean the same thing and are synonymous.
214572040|NCT07193797|OTHER|Phenotypes of ICU delirium|The included delirium patients will be divided into different phenotypes, according to delirium risk factors such as age, history of cerebrovascular accident, blood transfusion, surgery duration etc.
214572041|NCT07193784|BEHAVIORAL|Reiki|Reiki therapy applied by trained practitioner for 30 minutes.
214572042|NCT07193784|BEHAVIORAL|Sham reiki|Sham Reiki applied by same practitioner, mimicking Reiki without actual energy technique.
214572043|NCT07194044|DRUG|Vincristine|IV Push
214572044|NCT07194044|DRUG|Doxorubicin|IV
214572045|NCT07194044|DRUG|Cyclophosphamide|IV and Maintenance PO
214572046|NCT07194044|DRUG|Ifosfamide|IV
214572047|NCT07194044|DRUG|Actinomycin|IV
214572048|NCT07194044|DRUG|Irinotecan|IV
214572049|NCT07194044|DRUG|Cabozantinib|PO
214572050|NCT07194044|DRUG|Topotecan|IV
214572051|NCT07194044|DRUG|Temozolomide|IV
214572052|NCT07194044|DRUG|Etoposide|PO
214709347|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
214721961|NCT04901390|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
214572053|NCT07194044|DRUG|Liposomal doxorubicin|IV
214572058|NCT07194967|DEVICE|Virtual Reality Hypnosis for Labor Pain and Anxiety Management|"For patients randomized to the intervention arm, the investigator will provide a clear explanation of the procedure and the use of the HypnoVR virtual reality headset. The investigator will remain present throughout the session to supervise the experience, using the companion tablet to monitor the visualization in real time.~Participants will be invited to select one of eight immersive visual environments designed to promote relaxation and analgesia during labor. Available options include: Tropical Beach, Underwood, Underwater Dive, Zen Garden, Astral Travel, Winter Landscape, Aurora Borealis, and Oasis.~Patients will be informed that they may discontinue the use of the headset at any time and for any reason, without any consequences for their standard medical care."
214572059|NCT07194109|DRUG|Remimazolam based total intravenous anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with remimazolam in a dose of 0.4 - 0.5 mg/kg anesthesia maintenance was administered with remimazolam at a rate of 1.0 - 3.0 mg/kg/h.
214572060|NCT07194109|DRUG|Propofol based general anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with propofol in a dose of 2.0 - 3.5 mg/kg , anesthesia maintenance was administered with propofol at a rate of 4 - 12 mg/kg/h.
214572063|NCT07194850|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
214572064|NCT07194850|OTHER|Placebo IV|Intravenous infusion of placebo
214572065|NCT07193524|DEVICE|3D Fracture Analysis Tool|"Based on a pre-operative computed tomography (CT) scan, fractured bone fragments of a proximal tibia are segmented and aligned to achieve adequate fracture reduction.~Bone material properties for each fragment are derived from Hounsfield Units (HU) of the CT scan, based on internal density calibration with air, fat, muscle, and cortical bone. Screws and implants are then modelled based on the manufacturer's design and material properties Placement of off-the-shelf plate and screws can be analyzed and support a personalized plan on how to individually treat a patient with a specific fracture pattern and anatomical biometric data.~Surgeons can define up to three approaches (different placement of implants and screws) to be visualized and analyzed for construct stability.~The surgeons will receive a visualization of the fracture, fracture-reduction, implant and screw placement in 3D as well as a comparison of construct stabilites of the submitted approaches"
214572066|NCT07194395|DEVICE|PatenSee System|Contactless AV access monitoring device
214572067|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 1|10g single oral dose dissolved in water
214572068|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 2|10g single oral dose dissolved in water
214572069|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 3|10g single oral dose dissolved in water
214572070|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 4|10g single oral dose dissolved in water
214572071|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 5|10g single oral dose dissolved in water
214572073|NCT07194551|COMBINATION_PRODUCT|Vaginal DNA swab, microbiome swab and pH test|Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.
214572074|NCT07195331|DRUG|Intravenous injection of indocianine green at least three hours before surgery at a dose of 2.5 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 10 mL of water for injectable solutions, yielding a concentration of 2.5 mg/mL. Once the solution is prepared, 1 mL will be administered directly via a peripheral venous line in the patient's upper limb.
214572075|NCT07195331|DRUG|Intravenous injection of indocianine green 15 to 30 minutes before surgery at a dose of 0.25 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 25 mL of water for injectable solutions, yielding a concentration of 1 mg/mL. Subsequently, 0.25 mL will be administered as a direct intravenous injection via a peripheral venous line in the patient's upper limb.
214572076|NCT07194668|BIOLOGICAL|10μg R21/50μg Matrix-M|Adults and adolescents receiving the standard adult vaccine dose: 10μg R21/50μg Matrix-M (n=125)
214572077|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with adaptor preservative free|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with adaptor Preservative Free (n=125)
214572078|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with 2PE preservative|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with 2PE Preservative (n=125)
214572079|NCT07194252|OTHER|Guided imagery technique application|Intervention is a guided imagery technique designed for patients undergoing total joint arthroplasty. It will be administered in a total of 4 sessions: once daily on the day before surgery, twice daily on the day of surgery, and once daily on the 2nd and 3rd days after surgery, accompanied by imagery scenarios developed in accordance with the Compact Disc (CD) and literature developed by the Turkish Psychological Association. The study aims to examine its effects on surgical anxiety levels, postoperative pain intensity, and analgesic consumption. This approach is structured as a non-pharmacological method specific to surgical nursing practice and differs from previous similar studies in that it is applied in both the preoperative and postoperative periods using the same sample in the literature.
214572080|NCT07194434|OTHER|No.intervrntion|No intervention
214572081|NCT07195318|DIETARY_SUPPLEMENT|Fisetin|One capsule (100 mg) daily
214572082|NCT07195318|DIETARY_SUPPLEMENT|Placebo|One capsule daily
214709348|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
214709349|NCT07080021|DRUG|Standard Reagents, Pancreatic Cancer|This is a non-interventional study. Neoadjuvant therapy regimens and surgical approaches are determined solely by attending physicians according to clinical treatment standards.
214572084|NCT07194876|OTHER|No Intervention (subjects were previously treated with Onglyza®)|no intervention
214572085|NCT07195175|DRUG|MAR002|subcutaneous injection
214572086|NCT07195175|DRUG|Placebo|Subcutaneous injection
214572088|NCT07195006|OTHER|Malnutrition in pregnancy as exposure|MUAC ≤23 cm in pregnancy at least 20 weeks gestational age
214572089|NCT07195006|OTHER|Poor WASH living conditions as exposure|"Poor water (source, quality, access, reliability), sanitation (toilet type, cleanliness, number of people using toilet) and personal (hand wash practices) and household hygiene (dumpster availability and emptying frequency) index scores.~WASH Index score ranges; 1.Basic services (76-100%), 2.Semi-basic services (51-75%) 3.Poor services (26-50%) 4.No services (0-25%)"
214572090|NCT07193875|DRUG|Efavirenz 600mg|Take One pill daily for 6 months in addition to baseline combination antiretroviral therapy regimen
214572091|NCT07195409|BEHAVIORAL|Out of School Time Coach (OST-Coach)|Four data coaching session (investigate, design, practice, reflect) will be conducted over an academic year. Each session will involve: a customized site level data report, goal setting and implementing strategies to address child physical activity, motor competence, and staff physical activity promoting behaviors.
214572092|NCT07193966|BIOLOGICAL|NG2 and DLL3 CAR-T cells|Infusion of NG2 and DLL3-specific CAR-T via intravenous route
214572093|NCT07194473|BEHAVIORAL|ZeroOCD|"The ZeroOCD app contains the following components:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
214572094|NCT07194473|BEHAVIORAL|Videoconferencing CBT|"Videoconferencing CBT contains the following chapters:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
214572095|NCT07195188|BEHAVIORAL|"Let's Learn Diabetes Game-Based Education"|"Participants in the experimental group will receive diabetes education using the Let's Learn Diabetes board game. The program consists of four weekly sessions, each lasting two hours, over one month. The intervention is designed to improve diabetes knowledge, reduce anxiety, and enhance treatment adherence among patients with Type 2 Diabetes Mellitus on insulin therapy."
214572096|NCT07195188|BEHAVIORAL|Traditional Diabetes Education|Participants in the control group will receive standard diabetes education through traditional lecture-based presentations. The education schedule matches the experimental group with four weekly sessions, each lasting two hours, over one month.
214572097|NCT07194616|PROCEDURE|Primary Surgery|Patients undergo radical surgical resection with TME without preceding neoadjuvant therapy
214572098|NCT07194616|PROCEDURE|Neoadjuvant radiochemotherapy and surgery|Neoadjuvant treatment: long-course pelvic radiotherapy (conventional fractionation) with concurrent chemotherapy (standard fluoropyrimidine-based regimen)
214572101|NCT07194499|OTHER|No interventions|No intervention
214572102|NCT07195552|DIETARY_SUPPLEMENT|Agaricus blazei|Agaricus blazei mushroom capsules. 2000 mg per serving
214572103|NCT07195552|DIETARY_SUPPLEMENT|Reishi|Reishi mushroom capsules. 2000 mg per serving.
214572104|NCT07195552|DIETARY_SUPPLEMENT|Turkey Tail|Turkey tail mushroom capsules. 2000 mg per serving.
214572105|NCT07195552|OTHER|Placebo|Placebo
214572110|NCT07193849|DRUG|MEBO Wound Ointment|both are used for second pressure ulcer
214572111|NCT07193849|DRUG|zinc oxide|both are used to treat second degree pressure ulcer but with no superiority
214572112|NCT07194447|DRUG|Simvastatin Gel|A single local application of 1.2% simvastatin incorporated into 4% methylcellulose gel, placed around the implant site immediately after implant placement and before flap closure.
214572113|NCT07194447|DRUG|Methylcellulose Gel|A single local application of 4% methylcellulose gel without simvastatin, placed around the implant site immediately after implant placement and before flap closure.
214709350|NCT07084870|OTHER|High flow nasal oxygen|Patients in group I then received HFNO. The initial flow rate was adjusted to 50L/min and gradually reduced as tolerated by the patient. The humidification chamber temperature was set at 37°C and gradually reduced to the patient comfort. FiO2 was 100% and then gradually reduced over time according to improvement in oxygenation.
214572114|NCT07194317|DEVICE|Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)|55 participants will be recruited (target to complete the study n=50). The acceptability trial will be conducted remotely. A baseline questionnaire will capture demographic data. Over three weeks participants will be asked to record three random consecutive days of dietary intake each week using a different tool. Participants will be randomised to the order they complete the tools. To minimise potential biases. Participants will be randomly assigned to one of the six possible tool completion sequences (Table 1) using a relevant participant randomization package (e.g., rempsyc) in R (v4.4.2), which is a free, open-source statistical software used for data analysis and randomisation.
214572115|NCT07195487|OTHER|Fermented Extract Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
214572116|NCT07195487|OTHER|Placebo Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
214572117|NCT07195084|RADIATION|Hypervision proton surgery|Proton radiaotherapy (34GyE or 39GyE)
214572118|NCT07195604|DRUG|HRS-2162|HRS-2162
214572119|NCT07195604|DRUG|Placebo|Placebo
214572120|NCT07194291|OTHER|Follow up of female sexual function|We follow up menstrual changes in diabetic adolescent girls to improve the outcome
214572121|NCT07194356|PROCEDURE|Pericapsular nerve group (PENG) block|A single-shot PENG block was administered preoperatively using ultrasound guidance. The block was performed with the patient in the supine position, and 20 mL of local anesthetic (0.25% bupivacaine) was injected between the psoas tendon and the superior pubic ramus to achieve analgesia of the anterior hip capsule.
214572122|NCT07194356|PROCEDURE|Standard Spinal Anesthesia (Control)|Patients in this arm were managed according to standard care protocols for spinal anesthesia in hip fracture surgery. No preoperative regional block was performed. Pain scores and postoperative tramadol use were measured for comparison with the experimental arm.
214572123|NCT07195526|BEHAVIORAL|Bicycle balance control training|The intervention involves three components: (1) training on an exercise bicycle, (2) a balance control training on a bicycle simulator, and (3) cycling on the public roads with a safe start-and-stop technique that was practiced on the bicycle simulator. In the bicycle simulator training, the difficulty of the balance control will be increased gradually, slowly approaching the difficulty of bicycle balance control on the public roads.
214572124|NCT07193615|DRUG|YOLT-202|The IP is administered intravenously at the predetermined dose; Administration frequency: Once
214572125|NCT07193901|DRUG|Low Dose PRT042 nasal spray|two times a week, for 4 weeks
214572126|NCT07193901|DRUG|median Dose PRT042 nasal spray|two times a week, for 4 weeks
214572127|NCT07193901|DRUG|high dose PRT042 nasal spray|two times a week, for 4 weeks
214572128|NCT07193901|DRUG|placebo|two times a week, for 4 weeks
214572129|NCT07194785|DIAGNOSTIC_TEST|AI-Assisted Cardiac Auscultation using the HearTech Smart Stethoscope|This intervention utilizes the HearTech smart stethoscope, where trained research personnel perform standardized examinations of four cardiac auscultation areas on subjects. The integrated AI algorithm analyzes heart sounds in real time and automatically generates reports. An initial positive detection triggers a repeat testing process, with the algorithm ultimately determining a positive screening result based on three detection outcomes (any two positive). This AI-assisted auscultation system is designed to achieve large-scale, standardized, and highly efficient preliminary heart murmur screening.
214572132|NCT07193576|DRUG|flunotinib|100mg
214572133|NCT07194200|BIOLOGICAL|Lactobacillus plantarum|Intervention measures for the experimental group: Apply 5ml of Lactobacillus plantarum solution extracted from the skin surface of healthy individuals to the psoriatic lesions daily, for a duration of 2 months.
214572134|NCT07194200|BIOLOGICAL|inactivated Lactobacillus plantarum|Intervention measures for the control group: Apply 5ml of inactivated Lactobacillus plantarum solution to the psoriatic lesions daily, for a duration of 2 months.
214572135|NCT07195630|OTHER|Moderate-Intensity Continuous Exercise|15 recreationally active males completed the \~21 min of exercise at 55% of VO2max, consisting of a 3-minute warm-up and 3-minute cool-down at 60 W.
214572136|NCT07195630|OTHER|High-Intensity Interval Exercise|15 recreationally active males performed 10 x 1-minute intervals at 90% of VO2max, separated by 75 s of active recovery at 60 W, and a final 3-minute cool-down period at 60 W.
214572137|NCT07194239|BEHAVIORAL|Lifestyle medicine Health coaching|Participants assigned to this group will have 4 face-to-face sessions with the health coach. Lifestyle modifications with the aim of pain reduction will be determined in a shared decision-making approach. Lifestyle modifications will be based on the 6 pillars of lifestyle medicine: Physical activity, Healthy eating, Stress reduction, Sleep restoration, Social Support, and Avoiding risky substances. The health coach will make use of motivational techniques such as motivational interviewing to guide and assist participants in realizing the lifestyle modifications.
214572138|NCT07194993|OTHER|Nonradioactive stable oral isotope|"NaH13CO3 \[99% atom percent excess (APE) and L-\[1-13C\]Leu (99% APE) will be given orally.~Isotope administration will begin with the fifth meal on each study day with each remaining meal.~The nonradioactive stable oral isotope is being administered to study the physiological process of amino acid oxidation."
214572139|NCT07194993|OTHER|Test diet|"Test diets will be provided on study days in 8 hourly isocaloric and isonitrogenous meals to maintain a metabolic steady state.~Each meal will provide one-twelfth of the participant's daily needs to model a 12-hour fasted and 12-hour fed feeding pattern.~The diet will be composed of PFD2 (Mead Johnson), Tang and Kool-Aid (Kraft), corn oil, and protein-free wheat starch cookies. Each participant will receive 1 of 7 test protein intakes (0.2-3.2 g ⋅ kg-1 ⋅ d-1) on each study day. Protein will be provided as a crystalline L-amino acid mixture based on an egg protein pattern. Phe will be provided separately based on the Phe tolerance for each patient established by the metabolic dietitian listed on the IRB protocol. Leucine will be provided at a constant amount of 82.6 mg/kg/day as it is used as the indicator amino acid. The medical food used in this study is being fed to subjects for nutritional purposes to study the oxidation of the nonradioactive oral isotope."
214572140|NCT07193914|OTHER|ECCCLORE program|2-hour sessions in groups of up to 10 people, once a week for 12 weeks plus 30-minute individual sessions after each group session At the beginning of each session, there will be a discussion about the past week and home practices. This will be followed by an alternation between presentations/explanations of key concepts and associated practices. In the individual sessions the previous session and any difficulties encountered during the group session will be reviewed, as well as to address the implementation of home practices.
214572141|NCT07195227|DRUG|Camizestrant|Next-generation oral SERD molecule that is intended for the treatment of women and men with ER+ breast cancer. In addition to degradation of ERα, camizestrant also acts as a pure ER antagonist
214572142|NCT07195227|DRUG|Ribociclib|Selective inhibitor of CDK 4 and 6, with 50% inhibition (IC50) values of 0.01 μM (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated by binding to D-cyclins and are crucial to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates the cell cycle by phosphorylating the retinoblastoma protein (pRb).
214572143|NCT07195253|DIAGNOSTIC_TEST|Polysomnography (PSG) to explore OSA|"Patients will undergo full-night PSG (including electrocardiogram to monitor heart rate and the JAWAC system to record mandibular movements) in the sleep unit of Hôpital Femme-Mère-Enfant (Bron, France) to explore OSA, included in the routine care of children with DS.~OSA diagnosis will be made based on the obstructive apnea-hypopnea index (OAHI) resulting from the PSG. OSA will be diagnosed when OAHI ≥1.5/hour."
214572144|NCT07195253|BEHAVIORAL|Oro-myo-functional clinical evaluation|Orofacial myofunctional evaluation will be conducted by a physiotherapist according to the OMES-E (Orofacial Myofunctional Evaluation with Scores for Nursing Infants).
214572145|NCT07195253|OTHER|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children is a short questionnaire answered by parents about their child's sleep disorders.~Total score and scores for each sleep disorder will be calculated, according to the classical procedures during hospitalization of all children in our sleep unit."
214572146|NCT07195253|OTHER|Non-nutritive sucking recording|Non-nutritive sucking performance will be recorded through an experimental method using a classical pacifier, equipped with pressure sensors. Recording will last about 10 minutes. Variables related to sucking performance (maximum amplitude, frequency of sucking bursts, etc.) will be recorded.
214572147|NCT07195253|OTHER|Neurocognitive evaluation|The Brunet-Lézine test will be administered by a neuropsychologist. Global score will be calculated along with its four subscores (posture, hand-eye coordination, language, sociability).
214572148|NCT07195253|OTHER|PedsQL-Infants|The PedsQL-Infants questionnaire is designed to evaluate quality of life in infants. It will be given to parents during their child's hospitalization.
214572149|NCT07195591|DEVICE|GammaTile®|GammaTiles are a U.S. FDA-cleared, surgically targeted radiation therapy for patients with certain brain tumors. GammaTile consists of bioresorbable collagen tiles embedded with Cesium-131 (Cs-131) radioactive seeds
214572150|NCT07195591|RADIATION|External Beam Radiation Therapy|External beam radiation therapy (EBRT) is a type of radiation therapy that is standard of care. EBRT uses a machine outside the body to deliver high-energy beams of radiation to cancerous areas within the body
214572151|NCT07195591|DRUG|Temozolomide|TMZ (Chemotherapy) is used as a first-line treatment, often in combination with radiation therapy after surgical resection of the tumor
214572152|NCT07194382|DRUG|AP02|Oral inhalation solution
214572153|NCT07194382|DRUG|Placebo|Placebo oral inhalation solution
214572154|NCT07194005|DRUG|Disitamab vedotin(RC48)|2.5 mg/kg, administered intravenously every 3 weeks (Q3W) on Day 1 of each cycle.
214572155|NCT07194005|DRUG|Sintilimab|200 mg, administered intravenously, d1, every 3 weeks.
214572156|NCT07194005|DRUG|S-1|Oral, 40-60 mg, twice daily (bid), d1-14, every 3 weeks.
214572157|NCT07194005|DRUG|Oxaliplatin|130 mg/m², administered intravenously on Day 1 (d1), every 3 weeks.
214572158|NCT07193537|OTHER|Virtual reality exercises|Thirty one subjects will receive virtual reality exercises by VR Training using Xbox Kinect. The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor. Before the start of the training session, the research assistant adjusted the position of the sensor while the patient is sitting to ensure optimal position and motion capture, and loaded games into the system. After the setup is completed, the research assistant demonstrated games included in the Kinect adventure
214572159|NCT07193537|OTHER|Motor control training|Thirty one subjects will receive motor control training two times a week for eight weeks in form of deep cervical flexors strengthening using pressure biofeedback unit (craniocervical flexor exercise) :Pressure biofeedback unit will be used to perform Cranio-cervical flexor muscle training. Through which an endurance and isometric exercise for DNFs in progressive range positions will be performed each session, the PBU's air bag will be positioned below the occiput, and the inflatable cuff pressure sensor will be inflated to a baseline of 20 mmHg. Participants will instruct to target five pressure levels between 22 and 30 mmHg by nodding. scapular exercises .With patient in prone position, pillow under the chest and upper limb in varying degree of shoulder abduction, the participant lifts the hand toward the ceiling while retracting the scapula
214572160|NCT07193537|OTHER|conventional treatment|"Thirty one subjects will receive conventional treatment for 3 times per week for 4 weeks. Conventional treatment will include the following:~1-Posture correction (chin tuck exercise) Stand with the upper back against the wall, with the feet shoulder-width apart. Tuck the chin in and hold for 5 seconds 10 repetitions .Return to the starting position and repeat a number of times. This can help stretch the muscles in the upper neck 2. Stretching exercise: Self-stretching exercise for most common tight muscles. These muscles include upper trapezius (by contralateral side bending), levator scapulae (flexion, contralateral side bending and rotation) and sternocleidomastoid muscle (slight flexion with ipsilateral side bending and rotation). Each position should be maintained for 30 seconds and repeated for 3 times."
214709351|NCT07084870|OTHER|non invasive BIPAP|Patients in group II received oxygen therapy via intermittent non- invasive positive pressure ventilation, BiPAP mode ventilator using a face mask. BiPAP settings were adjusted as follows: P (low) of 5cm H2O to 10cm H2O and an inspiratory pressure P (high) of 10-20cm H2O . FiO2 was adjusted to 100% and then gradually reduced over time according to improvement in oxygen saturation and PaO2/Fio2 ratio. Respiratory rate was adjusted from 10-12 at then changed according to patient´s respiratory effort and according to ABG.
214572161|NCT07194265|DEVICE|TAVR with DurAVR THV|Transcatheter aortic valve replacement (TAVR)
214572162|NCT07194265|DEVICE|TAVR with SAPIEN THV series or the Evolut THV series|Transcatheter aortic valve replacement (TAVR)
214709352|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
214709353|NCT07088380|DRUG|Ketamine Hydrochloride|Ketamine will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
214572166|NCT07193680|OTHER|Intervention arm: expectant management if sFlt-1/PlGF<38|If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.
214572167|NCT07193680|OTHER|Standard care: elective delivery at 37 weeks of gestation|In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.
214572168|NCT07194057|GENETIC|Whole genome sequencing|Whole genome sequencing (WGS) is an advanced genomic technique that allows for the comprehensive analysis of an individual's entire DNA sequence, including both coding and non-coding regions. In the context of pediatric transplantation, WGS offers a powerful tool for uncovering underlying genetic disorders that may influence transplant eligibility, donor-recipient compatibility, immune response, or risk of post-transplant complications. It enables the identification of rare monogenic diseases, pharmacogenomic markers relevant to immunosuppressive therapy, and potential genetic predispositions to graft rejection or infection. Integrating WGS into transplant evaluation process enhances personalized medicine approaches, contributing to improved long-term outcomes in pediatric transplant recipients.
214572169|NCT07194057|GENETIC|Polygenic Risk Score Calculation|A polygenic risk score (PRS) calculation will be performed to quantitatively estimate the an individual's genetic predisposition to the original disease that led to transplantation. These scores are calculated by aggregating the weighted sum of risk alleles-most commonly single nucleotide polymorphisms (SNPs)-each of which contributes a small effect size as determined by genome-wide association studies (GWAS).
214572170|NCT07194057|DIAGNOSTIC_TEST|Methylome and episignatures|"Methylomic analysis in paediatric transplantation refers to the comprehensive profiling and study of DNA methylation patterns across the genome to understand epigenetic modifications associated with transplant-related outcomes.~This epigenetic approach enables the identification of differentially methylated regions (DMRs) that may correlate with clinical phenotypes, such as graft acceptance or rejection, infectious complications, or immune dysregulation.~The studies withjin the Protect\_Child\_101 project will be aimed at: 1) Refinement of episignatures, to increase specificity, sensitivity and robustness of those episignatures that already exist and 2) Discovery and validation of new disease, gene or variant specific mDNA signatures."
214572171|NCT07194330|DIAGNOSTIC_TEST|None-placebo|Not be displayed, only retrospective data will be required
214572172|NCT07193641|RADIATION|Spatially Fractionated Radiotherapy (SFRT)+Stereotactic Body Radiation Therapy (SBRT)|"The intervention includes SFRT for larger oligoprogressive lesions (≥4.5 cm in diameter), utilizing image-guided CT, including 4D-CT, with Lattice technique planning. The dose fractionation will be determined by the radiation oncologist based on clinical parameters, with peak doses ranging from 6-15 Gy/Fx and valley doses from 1.8-4 Gy/Fx, typically in 1-5 fractions.~For smaller oligoprogressive lesions, stereotactic body radiotherapy (SBRT) or intensity-modulated radiotherapy (IMRT) will be selected based on clinical parameters."
214572173|NCT07193641|DRUG|The systemic therapy|Continuation or switch of prior standard regimen (chemotherapy, targeted TKI, or PD-1/PD-L1 inhibitor) at investigator discretion until further progression or intolerable toxicity.
214572174|NCT07194525|OTHER|A standardized treatment algorithm for postoperative ileus after abdominal surgery, based on nasogastric tube output and including stepwise use of water-soluble contrast, imaging, and prokinetic medic|"The Ileus Management Protocol (I-MAP) is a standardized algorithm for the treatment of postoperative ileus (POI) after abdominal surgery. Management decisions are based on nasogastric tube (NGT) output measured every 12 hours. Depending on output and tolerance, patients may receive:~Water-soluble contrast (Telebrix® gastro, ioxitalamic acid 300 mg/mL) administered via NGT, followed by a clamp test at 4 hours.~Diagnostic imaging (CT-scan or X-ray) if ileus persists or small bowel obstruction is suspected.~Intravenous Neostigmine® (2.5 mg diluted in 500 mL NaCl 0.9%, infused over 5 hours) as a prokinetic, only after small bowel obstruction is excluded.~The protocol is applied until resolution of POI or requirement of further intervention."
214709354|NCT07088380|DRUG|Placebo|Placebo will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
214709355|NCT06906367|DRUG|migalastat HCl|Non-interventional study of participants receiving migalastat HCl 150 mg
214709356|NCT06906367|DRUG|ERT|Non-interventional study of participants receiving enzyme replacement therapy
214572175|NCT07193927|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum Probiotic Mixture|A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.
214572176|NCT07193927|DIETARY_SUPPLEMENT|Placebo comparator containing maltodextrin|Placebo comparator containing maltodextrin
214572178|NCT07194564|BEHAVIORAL|Control Exercise|A standard exercise without self-correction, performed by all participants as the control condition.
214572179|NCT07194564|BEHAVIORAL|Self-corrective Exercise|A self-corrective exercise intervention targeting improved postural alignment and muscle activation.
214572183|NCT07194096|OTHER|no intervention|no intervention
214572184|NCT07194460|DEVICE|Peripheral Magnetic Stimulation (PMS)|Treatment will be administered using a Peripheral Magnetic Stimulation (PMS) device. The intervention involves directing magnetic fields to stimulate specific peripheral nerve regions to regulate neural activity and improve symptoms.
214572185|NCT07194460|DEVICE|ham control group receiving PMS intervention|Identical to the experimental group in all procedures, except that no electrical stimulation is delivered.
214572186|NCT07194460|OTHER|Exercise|See previous sections
214709359|NCT07091890|DEVICE|Fluoride gel|After non-surgical therapy, 6-8 g of a gel containing 12,500 ppm of fluoride was applied for 4 min using a disposable tray appropriately sized for the patient's mouth. As per the guidelines, the patient was asked to briefly rinse their mouth with water. The aim was to remineralize the dental enamel to make it less susceptible to acid attacks caused by low salivary pH and the byproducts of bacterial metabolism
214572187|NCT07194460|OTHER|PMS＋Exercise|See previous sections
214709360|NCT07091890|DEVICE|Fluoride varnish|After non-surgical therapy, a fluoride varnish containing 7,700 ppm of fluoride in a homogeneous solution was evenly distributed over the dental surfaces using a micro-brush. Patients were instructed to spit out excess saliva but not to rinse their mouth with water, and to refrain from eating or drinking for at least 60 min afterward. After drying, the varnish formed a fluoride-rich layer on the enamel, increasing the concentration by up to four times. Despite the high concentration of fluoride, the resin component of the varnish allowed for a slow, controlled release of fluoride over time, thus preventing its immediate loss and minimizing the amount ingested by the patient. The purpose was to prevent mineral loss from the enamel and promote its restoration, making the dental tissue more resistant to the acidic pH of saliva caused by the production of organic acids through bacterial metabolism.
214572221|NCT07193732|BEHAVIORAL|Psychotherapy-Empathic Attunement Phase|The initial focus of our therapeutic intervention is on establishing empathic attunement to aid individuals in processing the inherent pain of grief in a constructive manner. For this phase, therapists will focus solely on adhering to the relationship formation and introspective exploration. Practitioners aimed at empathetically tuning into the patient's emotional experience, validating and reassuring the patient's emotional state, and adhering to the fundamental principles of empathy, sincerity, and positive regard for establishing and upholding a strong therapeutic alliance. Also, accompanying the patients to uncover and process the natural pain to gain self-awareness about their emotions.
214572222|NCT07193732|BEHAVIORAL|Psychotherapy - Chair-work intervention phase|During this phase, bereavement person will conduct imaginal conversation with a deceased. Practitioners utilized the resolution model including 5 components: (1) emotional reaction of the bereavement (blame, hurt, regret etc.) and enactment of the deceased; (2) differentiation of the bereavement's feelings and deceased's specific negative aspects accessed; (3) intense expression of the bereavement's specific emotions; (4) expression of the bereavement's previously unmet interpersonal needs from the deceased and the deceased validates bereavement's feelings; (5) understanding and forgiveness of the deceased or shift in view of the deceased.
214709361|NCT07090408|BEHAVIORAL|Artificial intelligence support|Each student in the intervention group will be asked to solve a given case example using ChatGPT support. However, students in the control group will be asked to analyze the case using their own academic knowledge without ChatGPT support.
214709362|NCT07090993|BEHAVIORAL|sustainable nutrition education|"The educational intervention applied to the experimental group was carried out in 12 sessions. The knowledge-attitude-behavior education model was adopted in the education sessions. The education program, which was created by obtaining expert opinions, consists of five basic topics and was carried out with the interactive education method.~Sessions;~1. Environmental effects during the production of animal and plant foods~2. Production and environmental effects of processed foods~3. Foods with low environmental impact and nutrition models~4. What are food losses and wastes?~5. Workshops~6. Processing and storage of foods~7. Consumption of local, regional and seasonal fruits, vegetables and fish~8. The importance of sustainable nutrition and alternative protein sources~9. Mediterranean diet model~10. Preparing a shopping list~11. Reading labels and nutritional content~12. Watching a documentary on the harms of packaged foods on living beings and the environment"
214709363|NCT07091188|BEHAVIORAL|Health education, capacity building and economic incentives|"1. Social media platform-based for health education. Pregnant women in the same gestational month will be invited to join specific WeChat group chats tailored to their similar health education and management needs.~2. Capacity building. ANC providers at township hospitals will participate in short-term, small-class training courses designed to cover essential aspects of antenatal care prior to the intervention with the pregnant women.~3. Economic incentives. To encourage ANC attendance, a monetary reward system will be implemented for village doctors every time they successfully identify and invite a newly pregnant woman to initiate her ANC visit."
214572223|NCT07193732|BEHAVIORAL|Psychotherapy - Cognitive consolidation and spiritually behavioral activation phase|Cognitive consolidation and spiritually behavioral activation complement the emotional interventions implemented in earlier stages. This cognitive process aids in the transformation and integration of adaptive growth, enabling patients to assimilate the knowledge and insights acquired during therapy. Therapists take a directive and co-constructivist approach, guiding patients to discover emotionally adaptive reconciliations and meanings that challenge and reshape their emotional and cognitive frameworks in the cognitive consolidation and spiritually behavioral activation phase. Aligned with this cognitive shift, spiritual behavioral activations involve creating plans to address unmet needs.
214709364|NCT07091968|BEHAVIORAL|Technology-Enabled Tailored Referral|Participants in the intervention arm will receive a technology-enabled, text-based referral platform designed to improve depression referral uptake. The platform includes an initial text with a brief video explaining common barriers, tailored text messages based on participant-identified barriers, and an automated referral link. Messages are mapped to stages of readiness using the Transtheoretical Model and sent every two days over a two-week period to non-responders or decliners. This approach aims to engage survivors with depression through personalized, accessible, and stage-matched communication.
214709365|NCT07091175|BIOLOGICAL|Dupilumab|Subcutaneous injection of Dupilumab for 24 weeks (weight based dosing)
214709366|NCT07091175|DRUG|Placebo|Subcutaneous injection of normal saline placebo (matching dupilumab subcutaneous injection dosing) for 24 weeks
214721962|NCT03869216|BEHAVIORAL|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
214721963|NCT04945304|PROCEDURE|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
214709367|NCT07091175|DRUG|Co-intervention of Prednisolone wean during randomised controlled phase|"The Prednisolone wean will commence 2 weeks after receiving the loading dose of Dupilumab/placebo, with each weaning step 2 weeks apart. Prednisolone will be first weaned to the same dose every other day, if the current dosing is daily (or more frequent). The dose will subsequently weaned to 4 pre-determined levels of 30mg/m2, 15mg/m2, 10mg/m2 and 5mg/m2 every other day, rounding up to the nearest 5mg. For instance, if the current dose of prednisolone is 12mg/m2 every other day, the patient will decrease the dose to 10mg/m2 every other day for 2 weeks, followed by 5mg/m2 every other day for 2 weeks, before discontinuing the drug.~If patients enter the trial on Mycophenolate or Levamisole, this will be continued for the duration of the trial at the same dose."
214709368|NCT07091175|BIOLOGICAL|Dupilumab open label extension phase|Upon nephrotic relapse, participants will be unmasked. If they were given placebo, they will be invited to enrol in an open label extension phase to receive dupilumab for 24 weeks (with dosing identical to the experimental arm).
214709369|NCT07091175|DRUG|Co-intervention of Prednisolone wean during open label extension phase|Patients will also receive prednisolone 60mg/m2/day as a single daily dose (max 80mg OD) until in remission for 3 days, before prednisolone is weaned to 40mg/m2 every other day for 2 weeks. Doses should be rounded up to nearest 5mg where possible. Prednisolone will then be weaned in steps as per the randomised controlled phase. If patients do not enter full remission after 2 weeks from enrolment into the extension phase, they will be removed from the study. Additional agents, e.g. Mycophenolate, Levamisole, Calcineurin inhibitors should not be started during this time unless there is strong clinical indication.
214709370|NCT03143972|DRUG|Dexmedetomidine|Single drug administration
214709371|NCT03143972|DRUG|Remifentanil|Single drug administration
214709372|NCT00805922|OTHER|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
214709373|NCT04407455|DIAGNOSTIC_TEST|Karaduman Chewing Performance Scale|For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
214709374|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for pretest genetic education
214709375|NCT07091617|OTHER|Genetic Testing|Complete standard of care genetic testing
214709376|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for disclosure of results
214709377|NCT07091617|OTHER|Internet-Based Intervention|Receive access to Genetic Journey Chatbot
214709378|NCT07091617|OTHER|Educational Intervention|Complete digital pre-test genetic education
214709379|NCT07091617|BEHAVIORAL|Patient Navigation|Utilize chatbot to answer questions, assess barriers, and provide reminders for next steps during the testing period
214709380|NCT07091617|OTHER|Interview|Complete interview
214709381|NCT07091617|OTHER|Survey Administration|Ancillary studies
214709382|NCT07092085|DIAGNOSTIC_TEST|AI model|An AI model provides an objective and rapid assessment of potential mental health risks in students by holistically analyzing their facial expressions, vocal characteristics, and linguistic content from data.
214709383|NCT01987349|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
214709384|NCT01987349|BIOLOGICAL|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
214709385|NCT03861195|PROCEDURE|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
214709386|NCT02769806|PROCEDURE|MRI|
214709387|NCT04707872|DIAGNOSTIC_TEST|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
214709388|NCT04707872|DIAGNOSTIC_TEST|Prospera|Donor derived cell-free DNA in patient blood
214709389|NCT04707872|DIAGNOSTIC_TEST|HLA antibody|Centralized measurement of HLA antibodies in patient blood
214709390|NCT05481203|BEHAVIORAL|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
214709391|NCT05481203|BEHAVIORAL|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
214709392|NCT05018117|DRUG|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
214709393|NCT05018117|OTHER|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
214709394|NCT03897868|DRUG|HCP1803|HCP1803
214709395|NCT03897868|DRUG|Amlodipine|Amlodipine
214709396|NCT03897868|DRUG|Losartan|Losartan
214709397|NCT03897868|DRUG|Placebo|Placebo
214709398|NCT04151095|OTHER|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
214709399|NCT04151095|OTHER|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
214709400|NCT00961922|OTHER|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
214709401|NCT00961922|OTHER|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
214709402|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
214709403|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
214709404|NCT01234857|DRUG|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
214709405|NCT01234857|DRUG|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
214709406|NCT01234857|DRUG|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
214709407|NCT01234857|DRUG|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
214709408|NCT00397176|DRUG|desvenlafaxine succinate sustained release (DVS SR)|
214721964|NCT04945304|PROCEDURE|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
214709409|NCT04417504|OTHER|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood\_PPS4.
214709410|NCT04417504|OTHER|Control isocaloric breakfast|White bread, butter and milk.
214721965|NCT02892734|BIOLOGICAL|Ipilimumab|Given IV
214721966|NCT02892734|OTHER|Laboratory Biomarker Analysis|Correlative studies
214721967|NCT02892734|BIOLOGICAL|Nivolumab|Given IV
214721968|NCT02043509|BEHAVIORAL|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
214709411|NCT05108480|OTHER|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
214709412|NCT06026007|OTHER|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
214709413|NCT06026007|OTHER|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
214709414|NCT06026007|OTHER|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
214709415|NCT02452801|DRUG|ALKS 5461|Single dose, given orally
214721969|NCT03672552|OTHER|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
214721970|NCT06398665|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
214721971|NCT01940549|DEVICE|Trauma Focused Therapy + tDCS|
214721972|NCT02659137|OTHER|HV measurement|Electrophysiology (EP) study during the TAVI procedure
214709416|NCT03728712|DIAGNOSTIC_TEST|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
214709417|NCT04644016|DRUG|Clofarabine|Clofarabine
214709418|NCT04644016|DRUG|Fludarabine|Fludarabine
214709419|NCT04644016|DRUG|Busulfan|Busulfan per PK
214709420|NCT04644016|DRUG|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
214709421|NCT04644016|DRUG|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
214709422|NCT04644016|BIOLOGICAL|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
214721973|NCT03930277|DIAGNOSTIC_TEST|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
214709423|NCT02306174|BEHAVIORAL|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
214709424|NCT06375967|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
214709425|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm."
214572418|NCT07193407|DEVICE|Sacral Neuromodulation System|INOPASE Sacral Neuromodulation System (INO-SNM-01) for treatment of overactive bladder.
214572436|NCT07194512|OTHER|Taekwondo-Specific Agility Test (TSAT), Frequency Speed of Kick Test (FSKT), Frequency Speed of Kick Test (FSKT10s), Multiple Frequency Speed of Kick Test (FSKTmult), Kick Decrement Index (KDI)|After pre-test measurements, the experimental group performed an eight-week high-intensity interval training (HIIT) program three times per week (Monday, Wednesday, Friday) alongside their regular taekwondo training. The control group continued with their regular taekwondo training only. After the eight-week intervention, post-tests were administered to both groups, and the results were recorded by the researchers.
214634182|NCT03343496|PROCEDURE|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I\~II, aged 18\~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
214709426|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
214709427|NCT01512108|DRUG|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
214709428|NCT01512108|DRUG|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
214709429|NCT03488628|OTHER|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours
214709430|NCT03488628|OTHER|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.
214709431|NCT05984199|BIOLOGICAL|VCAR33|Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
214634183|NCT07132970|DEVICE|Monoplus Suture Material|Ileocolic Anastomosis Construction using Monoplus Suture Material after open or laparoscopic surgery
214635040|NCT06094257|DIAGNOSTIC_TEST|Sensory testing|Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
214635041|NCT00147524|DRUG|quinapril|
214635042|NCT00147524|PROCEDURE|Laser Doppler imaging|
214635043|NCT07131982|OTHER|Informative Animated Video to be Viewed with Virtual Reality Glasses|No study has been found in the literature evaluating the effect of animated videos shown to children through virtual reality glasses on mothers and children. The aim of this study was to determine the effect of animated videos shown through virtual reality glasses before surgery on perioperative anxiety and fear in children and their mothers.
214635044|NCT07132840|PROCEDURE|Kinesio tape application followed by single session of balance training on various unstable surfaces.|Participants with functional ankle instability received balance training on various unstable surfaces after kinesio tape application.
214635045|NCT02200185|DRUG|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~* SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
214635046|NCT02200185|DRUG|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
214635047|NCT02200185|DRUG|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
214635048|NCT06809179|DRUG|Fasedienol Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.
214635049|NCT06809179|DRUG|Fasedienol Nasal Spray - Fasedienol Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.
214635050|NCT06809179|DRUG|Placebo Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.
214635051|NCT03809611|DRUG|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
214635052|NCT03809611|DRUG|Placebo|placebo
214721974|NCT04724291|DEVICE|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
214721975|NCT02300506|OTHER|No intervention|
214572603|NCT07194135|DRUG|Tenoxicam|Intra-articular administration of tenoxicam, 20 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
214572604|NCT07194135|DRUG|Triamcinolone Acetonide|Intra-articular administration of triamcinolone acetonide, 40 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
214635053|NCT06817499|OTHER|Nasal Insert + VNS|Participants will complete olfactory training with scented nose plugs along with VNS
214635054|NCT06817499|OTHER|Nasal Insert|Participants will complete olfactory training with scented nose plugs
214635055|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
214635056|NCT04319107|OTHER|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
214721976|NCT04093206|DIETARY_SUPPLEMENT|EpiCor and Vitamin C|One daily dose
214721977|NCT04093206|DIETARY_SUPPLEMENT|Vitamin C|One daily dose
214721978|NCT03189563|DRUG|DA-9805 45mg|DA-9805 15mg tid
214721979|NCT03189563|DRUG|DA-9805 90mg|DA-9805 30mg tid
214721980|NCT03189563|OTHER|Placebo|Placebo, tid
214635057|NCT01493934|DRUG|injection of 6-DIG|Unique injection dose of 92.5 MBq
214635058|NCT06299293|OTHER|Facial Emotion Recognition Test|In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
214635059|NCT02926950|DRUG|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
214635060|NCT02926950|DRUG|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
214635061|NCT02926950|DRUG|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
214635062|NCT06801015|DRUG|Semaglutide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
214635063|NCT06801015|DRUG|Tirzepatide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
214635064|NCT06801015|DRUG|Placebo|Placebo administered by subcutaneous injection once per week.
214635065|NCT02905578|DRUG|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
214721981|NCT01200563|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
214721982|NCT01200563|DEVICE|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
214572741|NCT01982448|DRUG|Cisplatin|
214572742|NCT01982448|DRUG|Paclitaxel|
214721983|NCT01200563|DEVICE|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
214572758|NCT06332963|BEHAVIORAL|Floatation-REST|Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
214572759|NCT06332963|BEHAVIORAL|IFT|Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
214572760|NCT06332963|BEHAVIORAL|EFT|Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
214572764|NCT04840225|OTHER|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
214709432|NCT03135886|OTHER|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
214572770|NCT06440967|DRUG|Fezolinetant|oral
214572771|NCT06440967|DRUG|Placebo|oral
214572772|NCT06440967|DRUG|Tamoxifen|oral
214572773|NCT06440967|DRUG|Aromatase inhibitor|oral
214634184|NCT06855251|BEHAVIORAL|The crossmodal dual-task|"Two main sensory tasks performed together:~1\. the visual task, in which participants are requested to monitor visual stimuli presented on a computer screen and to detect the deviant target as soon as possible. The target changes across blocks: in half of the trials, participants will have to respond to food stimuli presented together with irrelevant non-food stimuli (food target condition); in the other half conditions, participants will have to respond to non-food stimuli presented together with irrelevant food stimuli (non-food target condition). For each participant, we will collect the Reaction Time in milliseconds only for the valid responses, and the level of Accuracy in percentage.~2\) The interoceptive task, in which participants are requested to monitor their heartbeat presented through headphones and registered through pulse oximetry. Participants will judge the level of asynchrony between their heartbeat and the auditory cue."
214634185|NCT02093013|OTHER|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
214634186|NCT00387400|DRUG|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
214634187|NCT00387400|DRUG|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
214634188|NCT00387400|GENETIC|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
214634189|NCT00387400|OTHER|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
214634190|NCT03116932|BEHAVIORAL|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
214721984|NCT03185091|OTHER|rapid ventricular pacing|
214721985|NCT03185091|PROCEDURE|Surgery|
214721986|NCT04535258|DEVICE|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
214572786|NCT01015859|DEVICE|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
214572787|NCT01242735|BEHAVIORAL|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
214572788|NCT01242735|BEHAVIORAL|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
214572789|NCT04539080|PROCEDURE|transversus abdominis plane block|transversus abdominis plane block group
214572790|NCT01827475|DRUG|Ibuprofen|single dose
214572791|NCT01827475|DRUG|Acetaminophen|single dose
214572792|NCT01827475|DRUG|Ibuprofen-acetaminophen combination|single dose
214572793|NCT03293160|OTHER|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
214572794|NCT00687687|DRUG|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
214572795|NCT00687687|DRUG|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
214572796|NCT00687687|DRUG|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
214572797|NCT00522405|PROCEDURE|TACE|"* Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization"
214572798|NCT03472053|DRUG|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
214709433|NCT03135886|OTHER|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
214709434|NCT03135886|OTHER|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
214572799|NCT03472053|DRUG|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
214572800|NCT00082940|BIOLOGICAL|denileukin diftitox|
214572801|NCT04844619|DRUG|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
214572802|NCT04844619|DRUG|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
214572803|NCT05183126|DRUG|Paclitaxel|Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
214572804|NCT05183126|DRUG|Paclitaxel|"Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time."
214572805|NCT00588991|DRUG|Carboplatin|Given IV
214572806|NCT00588991|OTHER|Laboratory Biomarker Analysis|Correlative study
214572807|NCT00588991|DRUG|Topotecan Hydrochloride|Given IV
214572808|NCT00588991|DRUG|Veliparib|Given orally
214572809|NCT05414994|OTHER|Eye swab|This is a simple swab under the eyelids of both eyes
214572810|NCT06520826|DRUG|Vadadustat|A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
214572811|NCT06520826|DRUG|Erythropoiesis Stimulating Agent|Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
214572812|NCT04534972|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \> 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
214572813|NCT04967807|DIAGNOSTIC_TEST|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
214572814|NCT04967807|DIAGNOSTIC_TEST|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
214572815|NCT04981795|DRUG|Tafasitamab|Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
214572816|NCT01330849|BEHAVIORAL|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
214572817|NCT01330849|OTHER|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
214572818|NCT05185934|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with COVID-19 infection will be randomized to receive food supplement Endocalyx for 4 months.
214572819|NCT05185934|DIETARY_SUPPLEMENT|Placebo|Patients with COVID-19 infection will be randomized to receive placebo for 4 months.
214572820|NCT02133222|PROCEDURE|blood sample|
214572821|NCT02898077|DRUG|Ramucirumab|Administered IV
214572822|NCT02898077|DRUG|Paclitaxel|Administered IV
214572823|NCT02898077|DRUG|Placebo|Administered IV
214572824|NCT04845204|OTHER|Relaxation Treatment|Relaxation Group recieve progressive muscle relaxation exercises additional to the standard exercises. The relaxation exercises are applied two times a day till the discharge day starting on the postoperative day one. Progressive muscle relaxation included the relaxing of different muscle groups along with deep breathing. The maximal contraction period consist of the contraction of muscle groups around ankle, calf, knee, hip, lumbar, thoracic and cervical regions, shoulder, arm, forearm for 5 s and continued with a relaxation period for 30 s while focusing on breathing. These two periods ware repeated for each muscle groups and lasted approximately 30 min
214572825|NCT04845204|OTHER|Standard Exercises|The physiotherapy protocol is applied under the supervision of the same physiotherapist within a progressive manner immediately after surgery. Continued passive range of motion is applied twice a day starting with 45º of knee flexion range of motion and increased gradually as tolerated. All patients performed same isometric, isotonic and active exercises. Patients were instructed to bear weight as tolerated on the postoperative day 1
214721987|NCT00505544|BEHAVIORAL|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
214572826|NCT03584542|OTHER|No interventional study|No Interventional study - Only one questionnaire will be done for patients and for general practitioners
214572827|NCT00621777|DRUG|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
214572828|NCT00621777|DRUG|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
214572829|NCT04410523|DRUG|CSJ117|"CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment"
214572830|NCT04410523|DRUG|Placebo|"Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device."
214572831|NCT06363760|OTHER|Safety and efficacy assessments|Assessed throughout the duration of the study.
214572832|NCT04905459|DIAGNOSTIC_TEST|ARDA software application|Subject images will be sent to the investigational ARDA software
214572833|NCT03492749|DIAGNOSTIC_TEST|Saliva monitoring|The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
214572834|NCT02138955|DRUG|Liposomeal curcumin|
214572835|NCT01239043|BIOLOGICAL|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
214572836|NCT01239043|BIOLOGICAL|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214709435|NCT06794125|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy
214709436|NCT06794125|RADIATION|Radiation Therapy|standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy
214721988|NCT00505544|DEVICE|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
214721989|NCT03254849|DRUG|Empagliflozin|1 tablet
214721990|NCT03254849|DRUG|Hydrochlorothiazide 25 mg|1 tablet
214634191|NCT05442307|BEHAVIORAL|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
214634192|NCT05442307|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
214572837|NCT05953649|DEVICE|Extracorporeal Diaphragm Pacing|In the EDP group, a pacer using the extracorporeal diaphragm pacemaker provided by Guangzhou Xueliang Biotechnology Developing Co., Ltd., the pacing electrode is pasted on the body surface closest to the phrenic nerve at the outer edge of the lower end of the sternocleidomastoid muscle under ultrasound guidance, and the auxiliary electrode is placed between the second intercostal of the midline of the clavicle. The intensity of treatment parameters was set from low to high, and the intensity of treatment was increased when the patient could tolerate it, pacing 12-18 times/min at a frequency of 40 hertz (Hz)/30min/time, and performed every 12 hours for a week.
214572838|NCT05953649|DEVICE|Tilt Table Verticalization|VitalGo bed (VitalGo Systems Ltd., Fort Lauderdale） is used for verticalization. Verticalization was set to minimum 30°, depending on cardiopulmonary parameters (respiratory rate, heart rate, blood pressure, oxygen saturation), vertical position was gradually increased (in 5° steps) to a maximum of 90°, as long as the above-named cardiopulmonary parameters of the patient remained stable and remain this position for 30 minutes simultaneously with extracorporeal diaphragm pacing for a week.
214572839|NCT05953649|OTHER|Conventional Physiotherapy|Patients receive early mobilization, which refers to a series of clinical intervention protocols (such as passive movement or active exercises, etc.) that confers physical benefits at an early period in collaboration with a multidisciplinary team (intensive care physicians, rehabilitation physicians, physical therapists, occupational therapists, respiratory therapists, and nurses). The study intervention take place during working time between 8 a.m. and 17 p.m. Patients of all three study groups receive this rehabilitation program until they transfer out of ICU.
214572840|NCT05109572|OTHER|Hospitalized|It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.
214572841|NCT05109572|OTHER|Non-hospitalized with emergency care|It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
214572842|NCT05109572|OTHER|Non-hospitalized and non-emergency care|"Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always."
214572843|NCT02548975|DRUG|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
214572844|NCT02548975|OTHER|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
214709437|NCT05536713|DEVICE|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
214572845|NCT05461833|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
214572846|NCT05461833|DRUG|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
214572847|NCT05461833|DIETARY_SUPPLEMENT|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
214572848|NCT01062802|DRUG|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
214572849|NCT01062802|OTHER|Placebo|Placebo given once daily for 4 weeks.
214572850|NCT03223831|OTHER|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 \& 12cm.
214572851|NCT03223831|OTHER|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
214572852|NCT01519089|DRUG|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
214572853|NCT01519089|DRUG|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
214572854|NCT00165204|DRUG|Tibolone|
214572855|NCT00127205|DRUG|clodronate disodium|Given orally
214572856|NCT00127205|DRUG|ibandronate sodium|Given orally
214572857|NCT00127205|DRUG|zoledronic acid|Given IV
214572858|NCT00734357|PROCEDURE|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
214572859|NCT00673036|OTHER|Blood sample|60 ml of whole blood
214572860|NCT00126802|PROCEDURE|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
214572861|NCT04777877|OTHER|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
214572862|NCT02051959|DEVICE|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
214572863|NCT02051959|DEVICE|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
214572864|NCT02051959|DEVICE|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
214572865|NCT02051959|DEVICE|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
214572866|NCT06546917|BEHAVIORAL|bWell Cognitive Remediation|"Patients will take part in the bWell cognitive remediation protocol, consisting of 40-minute sessions of bWell, administered 2 times a week for 8 weeks. These sessions consist of tasks that target various cognitive domains and increase in complexity and difficulty as training progresses. The tasks are as follows:~1. Lab Exercise: participant alternates between two different, increasingly complex 'recipes', targeting executive functioning and divided attention.~2. Egg Exercise: In an office environment, participants must seek out and maintain their gaze on certain objects in order to collect them in the presence of visual distractors, targeting sustained attention.~3. Mole Exercise: participants must strike moles with the matching coloured hammer as fast as possible, targeting selective attention.~4. Theatre Exercise: participants must remember objects presented on stage and recreate the sequence after the curtains close, targeting working memory."
214572867|NCT06546917|BEHAVIORAL|VR Experience|Patients will take part in the viewing of VR scenes which contain no instructed cognitive tasks. This consists of 40-minute sessions of viewing VR scenes, administered 2 times a week for 8 weeks.
214572868|NCT02757040|DRUG|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
214572869|NCT02757040|DRUG|ibrutinib|ibrutinib
214572870|NCT04459117|DRUG|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
214572871|NCT04459117|DRUG|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
214572872|NCT02940587|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
214572873|NCT04239469|DRUG|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
214572874|NCT04239469|DRUG|Placebo|Placebo
214572875|NCT03856190|OTHER|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
214572876|NCT03856190|OTHER|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
214572877|NCT03784001|BEHAVIORAL|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
214572878|NCT03784001|BEHAVIORAL|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
214572879|NCT03784001|BEHAVIORAL|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
214572880|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
214572881|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
214572882|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
214572883|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
214572884|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
214572885|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
214572886|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
214634193|NCT00603759|DRUG|celecoxib|100 mg qid
214572887|NCT01189175|DRUG|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
214572888|NCT01189175|DRUG|BI 113823|single oral dose
214572889|NCT00004487|DRUG|chondrocyte-alginate gel suspension|
214572890|NCT04068961|OTHER|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
214572891|NCT00224887|BEHAVIORAL|In home nutrition counseling|In home family-based behavioral counseling
214572892|NCT00224887|OTHER|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
214572893|NCT03525067|OTHER|Bile sampling for bacterial examination|At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
214572894|NCT03199118|PROCEDURE|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
214572895|NCT03199118|OTHER|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
214572896|NCT02309151|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
214572897|NCT00348530|DRUG|Verapamil|
214572898|NCT02277353|OTHER|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
214572899|NCT00754364|DRUG|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
214572900|NCT00754364|DRUG|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
214572901|NCT02874417|BEHAVIORAL|CAST psychoeducation|
214572902|NCT02874417|BEHAVIORAL|PHET|
214572903|NCT06373523|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.
214572904|NCT06373523|DRUG|Placebo|The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).
214572905|NCT06373523|DRUG|Levothyroxine Replacement daily|Levothyroxine Replacement daily for 28 weeka
214572906|NCT03114787|OTHER|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
214572907|NCT04343287|DRUG|BRM421|The active control with BRM421 solution
214572908|NCT04343287|DRUG|Placebo|The vehicle solution
214572909|NCT03582943|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
214572910|NCT03582943|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
214572911|NCT03582943|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
214572912|NCT02708563|PROCEDURE|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
214572913|NCT02708563|PROCEDURE|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
214572914|NCT01134068|OTHER|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
214572915|NCT05861700|OTHER|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|A change Dbic in a middle of hemodialysis
214709438|NCT00873145|PROCEDURE|HMRS|Modular prosthetic replacement of the humerus and elbow.
214572916|NCT05861700|OTHER|Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L|A change Dbic in a middle of hemodialysis
214572917|NCT03916939|OTHER|osteopathy|osteopathy treatment
214572918|NCT03916939|OTHER|simulated osteopathy|simulated osteopathic sessions
214634194|NCT00603759|DRUG|placebo|1 cap qid
214634195|NCT02727283|DRUG|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
214634196|NCT02727283|DRUG|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
214572919|NCT03942900|OTHER|Additional biological samples|"* Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~  * at baseline,~ * at first tumor assessment (phase 2 in OPTIMANAL study),~ * at second tumor assessment (phase 4 in OPTIMANAL study),~ * at end-point visit.~* A tumor biopsy or archived tumor sample will be mandatory at baseline."
214572920|NCT05310305|COMBINATION_PRODUCT|Radiotherapy for targeted lesions and PD-1 antibody|Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
214572921|NCT00620295|DRUG|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
214572922|NCT00620295|DRUG|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.
214572923|NCT01373073|OTHER|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
214572924|NCT01373073|OTHER|Control human milk fortifier|Control human milk fortifier to be added to human milk
214572925|NCT04656496|BEHAVIORAL|NOURISH-T+|NOURISH-T+ (Nourishing Our Understanding of Role Modeling to Improve Support and Healthy - Transitions) is a 6 session, psychoeducational program designed to teach parents of childhood cancer survivors with overweight/obesity knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
214572926|NCT04656496|BEHAVIORAL|Brief NOURISH-T+|Enhanced Usual Care (or Brief NOURISH-T+) is an abbreviated version of the full NOURISH-T+ intervention in which parents are engaged in a one-time information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
214572927|NCT04747327|BEHAVIORAL|mandate public|mandate by airlines, bars, restaurants
214572928|NCT04747327|BEHAVIORAL|employer mandate|your employer requires vaccination
214572929|NCT04747327|BEHAVIORAL|incentive reward|$1,000 tax credit
214572930|NCT04747327|BEHAVIORAL|penalty|$1000 tax penalty
214572931|NCT04747327|BEHAVIORAL|incentive lottery small|100,000 smaller monetary amount
214572932|NCT04747327|BEHAVIORAL|incentive lottery medium|200,000 mid monetary amount
214572933|NCT04747327|BEHAVIORAL|incentive lottery large|1 million dollar lottery
214572934|NCT04747327|BEHAVIORAL|cash small|smaller guaranteed cash amount
214572935|NCT04747327|BEHAVIORAL|cash medium|mid sized quarenteed cash amount
214572936|NCT04747327|BEHAVIORAL|cash large|large quarenteed cash amount
214572937|NCT04747327|BEHAVIORAL|invitation for exercise financial incentive study|financial incentives earned when increasing exercise behaviors
214572938|NCT04747327|BEHAVIORAL|invitation for exercise social incentive study|social incentives earned when increasing exercise behaviors
214572939|NCT04747327|BEHAVIORAL|invitation for sleep social incentive study|social incentives earned when increasing sleep
214572940|NCT04747327|BEHAVIORAL|invitation for sleep financial incentive|Financial incentives earned when increasing sleep
214572941|NCT00171717|DRUG|Cyclosporine - cyclosporine microemulsion|
214572942|NCT06088654|DRUG|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
214572943|NCT03907644|DEVICE|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
214572944|NCT04797143|DEVICE|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
214572945|NCT06420752|DEVICE|Calf Plantar flexion|Daily passive calf stretching
214572946|NCT06420752|DIETARY_SUPPLEMENT|Dietary nitrate|Weekday 140 ml dietary nitrate consumption two hours prior to passive stretching
214572947|NCT01172470|DRUG|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
214572948|NCT01172470|DRUG|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
214572949|NCT01172470|DRUG|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
214572950|NCT00873028|OTHER|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
214572951|NCT00004572|PROCEDURE|Sustacal challenge|
214572952|NCT04848389|PROCEDURE|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
214572953|NCT04848389|PROCEDURE|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
214572954|NCT00870077|DIETARY_SUPPLEMENT|ProWHEY 94 CFM, SponserR|3 times 20g per day
214572955|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
214572956|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
214572957|NCT04399759|BEHAVIORAL|Approach-Instrumental Activities of Daily Living|Individualized instrumental activities of daily living training
214572958|NCT04399759|BEHAVIORAL|Home health education|Individualized home health education
214572959|NCT03231280|DEVICE|SB-061|delivered via intra-articular injection
214572960|NCT03231280|OTHER|Placebo|Placebo delivered via intra-articular injection
214572961|NCT05032872|BEHAVIORAL|Social Exergame Treatment Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~* Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~* In-app rewards (unlock new flowers to grow each week) if participants post stories"
214572962|NCT05032872|BEHAVIORAL|Control Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit and use the app"
214572963|NCT06233227|DRUG|Dutasteride-Test product|Dutasteride soft capsule 0.5 mg Test product Manufactured by: Phil Inter Pharma Co., Ltd., Vietnam
214572964|NCT06233227|DRUG|Dutasteride-Reference product|Dutasteride soft capsule 0.5 mg Reference product Manufactured by: DELPHARM POZNAN S.A., Poland
214572965|NCT01155089|DRUG|Anastrozole|1 mg tablet
214572966|NCT00956553|BIOLOGICAL|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
214572967|NCT00956553|BIOLOGICAL|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
214572968|NCT06249958|OTHER|Rehabilitation|Specific rehabilitation exercises
214572969|NCT06249958|OTHER|Verticalisation|Day of patient verticalisation after surgery
214572970|NCT01481987|PROCEDURE|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
214572971|NCT04522622|DRUG|Teriparatide|20 micrograms
214572972|NCT04522622|DIAGNOSTIC_TEST|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
214572973|NCT04522622|PROCEDURE|Bone biopsy|All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.
214572974|NCT04522622|DIAGNOSTIC_TEST|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
214572975|NCT04522622|OTHER|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
214572976|NCT00730873|DEVICE|Continuous positive airway pressure|
214634197|NCT04486755|RADIATION|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
214572977|NCT04585867|DRUG|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
214572978|NCT04585867|DRUG|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
214572979|NCT00488475|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
214572980|NCT00351208|DEVICE|Medtronic Manufactured Spinal Cord Stimulators|
214572981|NCT04940819|BEHAVIORAL|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
214572982|NCT03583567|DRUG|Chlorpheniramine and ranitidine|Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
214572983|NCT03583567|DRUG|0.9% Normal Saline|Patient will receive normal saline as placebo.
214572984|NCT04436575|DEVICE|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
214572985|NCT04025541|BIOLOGICAL|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
214572986|NCT04025541|BIOLOGICAL|Blood sampling C3|"Blood samples will be collected at four key time points:~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
214572987|NCT04025541|BIOLOGICAL|Blood sampling C4/7/10/13|Blood samples will be collected before any treatment
214572988|NCT04025541|BIOLOGICAL|Blood sampling C5|"Blood samples will be collected at four key time points:~* At the inclusion (T1)~* Before the beginning of the treatment (cycle 1 day 1) (T2)~* After the first cycle of T-DXd (cycle 2 day 1) (T3)~* At progression or at the end of the follow-up (after 3 years) (T4)"
214572989|NCT04025541|BIOLOGICAL|Blood sampling C6|"Blood samples will be collected at three key time points:~* At the inclusion (T1)~* For patients starting treatment at the time of inclusion (T2):~* Chemotherapy: 3 months after inclusion,~* Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy,~* For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3)."
214572990|NCT04025541|BIOLOGICAL|Blood sampling C8|"Blood samples will be collected at five key time points:~* At the inclusion~* At follow-up visit 2 to 6, every 3 months"
214572991|NCT04025541|BIOLOGICAL|Blood sampling C9|"Blood samples will be collected at four key time points:~* At the inclusion before the beginning of the treatment (Cycle 1 Day 1)~* After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1)~* After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1)~* After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery"
214572992|NCT04025541|BIOLOGICAL|Blood sampling C11 + FFPE|"Blood samples will be collected at five key time points:~* At the inclusion (T1)~* At first clinical evaluation (T2): 4th week after start of treatment~* At first scan evaluation (T3a): 8th week after start of treatment~* At the Nth scan evaluation (T3b, c, ...)~* At progression (T4)~Tumor sampling :~* At the inclusion~* At tumor progression"
214572993|NCT04025541|BIOLOGICAL|Blood sampling C12|"Blood samples will be collected at several points :~* Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment,~* Every 4 weeks until meningeal progression, or for a maximum of 4 months,~* Then every 3 months beyond 4 months until meningeal progression."
214572994|NCT00263341|COMBINATION_PRODUCT|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
214572995|NCT01984138|DRUG|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
214572996|NCT01984138|DRUG|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
214572997|NCT00267085|BIOLOGICAL|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
214572998|NCT04775199|BEHAVIORAL|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
214572999|NCT00461513|BEHAVIORAL|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
214573000|NCT03894618|DRUG|SL-279252|The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
214573001|NCT06344546|DIAGNOSTIC_TEST|Metabolomics|Analysis of the metabolome in plasma samples.
214573002|NCT05530317|BEHAVIORAL|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols with special attention to post-exertional malaise. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Most participants will participate in a hybrid approach (12-16 sessions in person), but participants will be allowed to select a fully in-person approach (36 sessions).
214573003|NCT03250442|DEVICE|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
214573004|NCT03250442|OTHER|Standard Dry Dressing|These are customary dry dressings.
214573005|NCT02074189|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
214573006|NCT04242043|DIAGNOSTIC_TEST|intel@med-feasibility|"Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care."
214573007|NCT04515290|DRUG|TSG-01|Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
214573008|NCT04515290|DRUG|TSG-01 and Placebo|One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
214573009|NCT04515290|DRUG|Placebo|Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
214573010|NCT04493775|DEVICE|Brainwave Entrainment|Alpha frequency visual and auditory stimulation delivered through a smartphone application, with the use of a virtual reality headset and earphones respectively.
214573011|NCT01584960|BEHAVIORAL|endurance training|2 years of home-based endurance training
214573012|NCT02946853|PROCEDURE|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
214573013|NCT02946853|DEVICE|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
214573014|NCT04073992|BEHAVIORAL|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
214573015|NCT05441644|DEVICE|Bispectral index|A new placemewnt to monitor intraoperative BIS
214573016|NCT02854878|DEVICE|The Lucy ultrasonic comb models A and B combined with the LucyGel|
214573017|NCT00798590|DRUG|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
214573018|NCT00798590|DRUG|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
214573019|NCT03913923|BIOLOGICAL|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
214573020|NCT03913923|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
214573021|NCT03913923|OTHER|Placebo|Placebo
214573022|NCT01404429|DRUG|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
214634198|NCT02540486|OTHER|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
214634199|NCT02540486|OTHER|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
214573023|NCT02794415|OTHER|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for \~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
214573024|NCT03934177|DIETARY_SUPPLEMENT|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
214573025|NCT03934177|DIETARY_SUPPLEMENT|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
214573026|NCT00001145|DRUG|Bacteriophage|
214573027|NCT00001145|DRUG|rhuCD40L|
214573028|NCT00001145|DRUG|KLH|
214573029|NCT03693859|BEHAVIORAL|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
214573030|NCT03693859|BEHAVIORAL|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
214573031|NCT00972660|BIOLOGICAL|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
214573032|NCT00972660|DRUG|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
214573033|NCT03573076|COMBINATION_PRODUCT|Photodynamic therapy|Photodynamic therapy with Methyl Aminolevulinate creme and red light.
214573034|NCT03573076|DEVICE|Non-ablative Thulium laser (NAFL)|Non-ablative Thulium laser (NAFL).
214573035|NCT03573076|DEVICE|Radio-frequency microneedles (RF-MN)|Radio-frequency microneedles (RF-MN).
214573036|NCT04618562|OTHER|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
214573037|NCT05850559|DIAGNOSTIC_TEST|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer by Enzyme-linked immunosorbent assay (ELISA
214573038|NCT01170676|BEHAVIORAL|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
214573039|NCT01170676|BEHAVIORAL|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
214573040|NCT03297424|DRUG|PLX2853|tablets
214573041|NCT05155176|BEHAVIORAL|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.
214573042|NCT02716259|PROCEDURE|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
214573043|NCT02716259|PROCEDURE|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
214573044|NCT03794700|OTHER|Hospice Decision Aids|Paper and video hospice decision aid
214573045|NCT06182891|DRUG|Dulaglutide Injection|Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
214573046|NCT00293501|DRUG|tinzaparin sodium|
214573047|NCT04097353|BEHAVIORAL|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
214573048|NCT04097353|BEHAVIORAL|Surviving Strong for Kids (SS4K)|Enhanced usual care
214573049|NCT00744562|DRUG|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
214573050|NCT02120287|DRUG|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
214573051|NCT02120287|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
214573052|NCT02120287|PROCEDURE|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
214573053|NCT03905343|DRUG|Ribociclib|Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
214573054|NCT03905343|OTHER|Mono-chemotherapy|mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
214573055|NCT03905343|OTHER|Endocrine-Therapy|The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
214573056|NCT04127851|DRUG|TJO-018 (HA 0.15%)|TJO-018 / one drop / 6 times daily in both eyes
214573057|NCT04127851|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)|Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes
214573058|NCT04127851|DRUG|TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%|TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
214573059|NCT04549649|OTHER|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
214573060|NCT01579500|DRUG|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
214573061|NCT01579500|DRUG|normal saline|Subcutaneous injection of normal saline
214573062|NCT00517400|DEVICE|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
214573063|NCT00311389|DRUG|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214573064|NCT00311389|DRUG|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214573065|NCT01555840|DEVICE|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
214573066|NCT01482923|BEHAVIORAL|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
214573067|NCT01482923|BEHAVIORAL|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
214573068|NCT06065254|OTHER|Efficacy of free gingival grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Two vertical incisions will be made in the previously elevated flap against the placed implant , where these two incisions will be 10 mm apart from each other, and the free graft to will be placed in this distance (10 x 10 mm). The graft will be obtained from the donor site (the hard palate), and will be thinned to obtain a regular graft with the required thickness. After that, the graft will be moved to its correct place accurately, while avoiding leaving a distance between the graft and the tissue underneath, and the graft will be sutured well to ensure its stability and correct placement.
214573069|NCT06065254|OTHER|Efficacy of connective tissue grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Vertical incisions will not be made in the previously elevated flap against the placed implant, where there is no need to suture the flap apically of the grafting place because the graft will be covered with it after fixing it in place. The area will be washed with the serum to remove the clot before fixing the graft.The graft will be obtained from the donor site according to the previously mentioned method. Then the epithelium will be removed to leave the connective tissue underneath, and then the graft will be moved to its place (buccally dental implant site) and the flap will be sutured over it.
214573070|NCT06065254|OTHER|No types of grafts will be made to improve the quality of the peri-implant mucosa|The simple suturing of the two surgical incisions will be done after the completion of the dental implant process, with no procedure will be made to improve the quality of the peri-implant mucosa.
214573071|NCT04179942|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide and CRP levels|measurement of FeNO and Hs-CRP after 3months of CPAP
214573072|NCT06347328|PROCEDURE|echo-guided infiltration|the subjects will receive their injection in the ultrasound room. a glucocorticoid injection is given at the time of consultation, using anatomical ultrasound scan to guide needle placement
214573073|NCT06347328|PROCEDURE|non-echo-guided infiltration|"the subjects will receive their injection in the ultrasound room.~a glucocorticoid injection is given at the time of consultation, using anatomical landmarks to guide needle placement.~The investigator simulate an ultrasound scan with a film shown on the screen."
214573074|NCT05841992|DRUG|Al18F-PSMA-617|Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617. Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
214573075|NCT05841992|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
214573076|NCT00004242|DRUG|fluorouracil|
214573077|NCT00004242|DRUG|gemcitabine hydrochloride|
214573078|NCT00004242|DRUG|oxaliplatin|
214573079|NCT03223662|OTHER|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
214573080|NCT03223662|PROCEDURE|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
214573081|NCT02217475|DRUG|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
214573082|NCT02217475|DRUG|Placebo|Placebo administered orally once daily and taken every morning with food.
214573083|NCT04276753|OTHER|Terminalia Chebula Fruit Extract|Standardized fruit extract
214573084|NCT04276753|OTHER|Placebo|Placebo
214573085|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
214573086|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
214573087|NCT06024434|OTHER|Exercises|Experimental Group Exercises for Core: Crunches, Glute bridges Crunches Glute bridge Week 1-2 (set/rep/sec) Week 3-4 (set/rep/sec) Week 5-6 (set/rep/sec) Exercises for upper body: Push up (4), Bicep curls Exercises Weeks Reps/sets Push up walk out Bicep curls 1-3 16-20\*3 Push up Bicep curl with Dumbbell 4-6 12-15\*3 Exercises for Lower body: Lunges and Squats Exercises Weeks Reps/set Split Squat with body weight Body weight Squat 1-3 16-20\*3 Split Squat with Dumbbell Squat with Dumbbell 4-6 12-15\*
214573088|NCT06024434|OTHER|Walking|Walking for 30min, 5 days a week
214573089|NCT02643472|BEHAVIORAL|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
214573090|NCT02643472|BEHAVIORAL|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
214573091|NCT05955300|OTHER|Training program|The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.
214573092|NCT05955300|OTHER|Nutrition therapy|Nutrition therapy based on the New Nordic Diet
214573093|NCT02830126|OTHER|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
214573094|NCT00506441|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
214573095|NCT00506441|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
214573096|NCT01215188|BIOLOGICAL|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
214573097|NCT01215188|BIOLOGICAL|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
214573098|NCT01215188|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
214573099|NCT01012414|DRUG|paricalcitol|2 mcg oral paricalcitol daily
214573100|NCT01012414|DRUG|placebo|placebo
214573101|NCT02601300|DRUG|GED-0301|
214573102|NCT03656172|BIOLOGICAL|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
214573103|NCT02506075|DEVICE|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
214573104|NCT02506075|BEHAVIORAL|Visual inattention training|
214573105|NCT04177043|DIAGNOSTIC_TEST|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
214573106|NCT04177043|DRUG|DAAs|Treatment with different regiments with DAAs
214573107|NCT00673400|PROCEDURE|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
214573108|NCT05787327|DRUG|Chinese Herb|Yinqiaosan-Maxingganshitang granules
214573109|NCT05787327|DIAGNOSTIC_TEST|Placebo|Placebo
214573110|NCT00335933|DRUG|Gabapentin extended-release tablets|
214573111|NCT04955782|BEHAVIORAL|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability|"The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer"
214573112|NCT05072028|DRUG|[14C]DBPR108|\[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
214573113|NCT01217177|DRUG|everolimus|
214573114|NCT01018238|DRUG|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
214573115|NCT01018238|DRUG|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
214573116|NCT05447572|OTHER|FIT + FC|FIT + FC
214573117|NCT01258842|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
214573118|NCT01258842|DIETARY_SUPPLEMENT|Placebo|Placebo sachet, consumed once per day for 12 weeks
214573119|NCT00853944|DRUG|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
214573120|NCT01680640|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic to be used is fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
214573121|NCT01680640|DIETARY_SUPPLEMENT|Maltodextrin|
214573122|NCT01249950|OTHER|feasibility|feasibility
214573123|NCT01691170|OTHER|Stretching Hamstring|
214573124|NCT01691170|OTHER|Quadriceps Strengthening|
214573125|NCT00528931|BIOLOGICAL|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
214573126|NCT03262142|DRUG|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam four times daily
214573127|NCT03262142|DRUG|Ciprofloxacin|Oral Ciprofloxacin twice daily
214573128|NCT06132438|DRUG|PEP-CMV vaccine|The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
214573129|NCT00480480|BEHAVIORAL|Trauma and Grief Component Therapy for Adolescents (Group Version)|
214573130|NCT02605655|DRUG|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
214573131|NCT02605655|OTHER|Placebo|Instant noodles without drug
214573132|NCT02471105|DRUG|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
214573133|NCT02471105|DRUG|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
214573134|NCT02920437|BEHAVIORAL|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
214573135|NCT02920437|OTHER|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
214573136|NCT00992225|DRUG|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
214573137|NCT02459002|BEHAVIORAL|QOL Questionnaire|Participant outcomes assessed with survey
214573138|NCT02459002|BEHAVIORAL|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
214573139|NCT03835351|DEVICE|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
214573140|NCT01208649|DRUG|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
214573141|NCT02756221|DIETARY_SUPPLEMENT|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
214573142|NCT02756221|OTHER|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
214573143|NCT05945004|OTHER|ChatGPT-4|Subjects' clinical records will be read by ChatGPT-4 to write preoperative visit sheets.
214709439|NCT03453970|BEHAVIORAL|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
214709440|NCT03513289|OTHER|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
214709441|NCT04300790|DRUG|Alpelisib|Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
214709442|NCT04300790|DRUG|Metformin|500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
214573144|NCT05945004|OTHER|Clinician|Subjects' clinical records will be read by clinicians to write preoperative visit sheets.
214573145|NCT05841329|DEVICE|tDCS|High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001\&4×1-C3A). The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex). The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig. 3). Participants were randomized to receive 20 minutes of active(1.5mA) or sham (0 mA) tDCS in a single-blind design. In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation. For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
214573146|NCT05841329|BEHAVIORAL|virtual reality exposure therapy|The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
214573147|NCT03644303|RADIATION|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
214573148|NCT02943239|DRUG|REGN1033|REGN1033
214573149|NCT02943239|DRUG|REGN2477|REGN2477
214573150|NCT02943239|OTHER|Placebo|Placebo
214573151|NCT05216159|BEHAVIORAL|HAPA behavioural counselling + weekly HAPA worksheets|Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
214709443|NCT04300790|DRUG|Fulvestrant|"fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)"
214573152|NCT02064348|DRUG|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
214573153|NCT02064348|DRUG|placebo|Solution for s.c. injection or tablets for oral administration
214573154|NCT02064348|DRUG|moxifloxacin|Tablets for oral administration
214573155|NCT03764527|DRUG|Artemether-lumefantrine|Two doses a day for 3 days, under supervision
214709444|NCT04300790|DRUG|Letrozole|Letrozole 2.5 mg tablets, once daily, orally
214709445|NCT04300790|DRUG|Exemestane|Exemestane 25 mg tablets, once daily, orally
214709446|NCT04300790|DRUG|Vildagliptin|Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
214709447|NCT04300790|DRUG|Tamoxifen|Tamoxifen 20 mg tablets, once daily, orally
214709448|NCT02269150|BIOLOGICAL|fecal microbiota transplantation (FMT)|
214709449|NCT02269150|OTHER|No fecal microbiota transplantation (FMT), routine management|
214573156|NCT03764527|DRUG|Coadministered Artesunate plus Amodiaquine|One dose a day for 3 days, under supervision
214573157|NCT00291642|DRUG|Placebo drops|"* Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use"
214573158|NCT00291642|DRUG|Placebo tablets matching to levocetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
214573159|NCT00291642|DRUG|Placebo tablets matching to cetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
214573160|NCT00291642|DRUG|Levocetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use"
214573161|NCT00291642|DRUG|Levocetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use"
214573162|NCT00291642|DRUG|Cetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use"
214573163|NCT00291642|DRUG|Cetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use"
214573164|NCT06400940|DRUG|ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).|Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
214573165|NCT06400940|DRUG|combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).|Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
214573166|NCT02341729|DRUG|ticagrelor|crushed tablets and non-crushed tablets
214573167|NCT01875289|PROCEDURE|obturator nerve block|
214573168|NCT00684723|DRUG|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
214573169|NCT00684723|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
214573170|NCT00924118|DRUG|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
214573171|NCT03013075|PROCEDURE|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
214573172|NCT03013075|DRUG|Bupivacaine heavy and Morphine|
214573173|NCT03013075|DRUG|General Anesthetics|
214573174|NCT03540563|OTHER|Blood draw|Blood will be drawn to assess ctDNA
214709450|NCT01025687|DIETARY_SUPPLEMENT|water with noncalorie sweetener|
214709451|NCT01025687|DIETARY_SUPPLEMENT|water with glucose|
214709452|NCT01025687|BEHAVIORAL|TV program showed while feeding|
214709453|NCT01025687|BEHAVIORAL|TV program showed while feeding|
214573175|NCT05770518|BEHAVIORAL|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
214573176|NCT05770518|BEHAVIORAL|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
214573177|NCT03055052|OTHER|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
214573178|NCT03055052|OTHER|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
214573179|NCT02576587|OTHER|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI \>=15) will be place on CPAP therapy.
214573180|NCT00341432|BEHAVIORAL|Nicotine Replacement Therapy|
214709454|NCT01824693|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
214709455|NCT01824693|DRUG|Busulfan|Given IV
214709456|NCT01824693|DRUG|Cyclophosphamide|Given IV
214709457|NCT01824693|DRUG|Fludarabine Phosphate|Given IV
214709458|NCT01824693|OTHER|Laboratory Biomarker Analysis|Correlative studies
214709459|NCT01824693|DRUG|Melphalan|Given IV
214709460|NCT01824693|DRUG|Mycophenolate Mofetil|Given IV or PO
214709461|NCT01824693|OTHER|Pharmacological Study|Correlative studies
214709462|NCT01824693|DRUG|Tacrolimus|Given IV or PO
214573181|NCT00532493|DRUG|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
214573182|NCT00532493|OTHER|placebo|"sugar pill"
214573183|NCT02157701|DIETARY_SUPPLEMENT|Polyherbal capsule|
214573184|NCT02157701|DIETARY_SUPPLEMENT|Placebo capsule|
214573185|NCT00375440|DRUG|Tranexamic Acid|
214573186|NCT02405143|DEVICE|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
214573187|NCT02405143|DEVICE|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
214573188|NCT04981171|PROCEDURE|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
214573189|NCT04981171|PROCEDURE|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
214573190|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
214573191|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
214573192|NCT01579331|DEVICE|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
214573193|NCT02713087|DRUG|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
214573194|NCT02713087|DRUG|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
214573195|NCT00224679|DRUG|Aspirin|
214573196|NCT05131269|DRUG|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
214709463|NCT05203627|OTHER|Best Practice|Receive standard nutritional support
214573197|NCT05131269|DRUG|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
214573198|NCT03018431|OTHER|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
214573199|NCT00738894|DEVICE|Septal Occluder Device|PFO closure with study septal occluder device
214573200|NCT00738894|DRUG|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
214573201|NCT05106413|OTHER|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.
214573202|NCT05106413|OTHER|Monaural fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.~Monaural hearing aid fitting acts as control intervention."
214573203|NCT05106413|OTHER|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
214573204|NCT05106413|OTHER|CROS baseline|"Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.~This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention."
214573205|NCT02297321|DEVICE|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
214573206|NCT04064073|DRUG|DWP16001|Tablets, Oral, once daily single dose
214573207|NCT04064073|DRUG|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
214573208|NCT04064073|DRUG|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
214573209|NCT03085654|DRUG|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
214573210|NCT03085654|DRUG|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
214573211|NCT05745701|DRUG|PF-07081532|Oral Tablet
214573212|NCT05745701|DEVICE|Cyclosporine|Oral Solution
214573213|NCT05745701|DRUG|Itraconazole|Oral Capsule
214573214|NCT04501913|PROCEDURE|Patient Monitoring|Undergo remote perioperative telemonitoring
214573215|NCT04501913|OTHER|Questionnaire Administration|Complete questionnaires
214573216|NCT00046969|BIOLOGICAL|epoetin beta|
214573217|NCT00046969|DRUG|cisplatin|
214573218|NCT00046969|RADIATION|brachytherapy|
214573219|NCT00046969|RADIATION|radiation therapy|
214573220|NCT01275781|DRUG|[14C]-AZD9742|1000 mg intravenous over 2 hours
214573221|NCT00719329|DRUG|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
214573222|NCT00719329|BEHAVIORAL|Dry Cord Care|Educational messages regarding clean cord care
214573223|NCT03211117|DRUG|Docetaxel|Given IV
214573224|NCT03211117|DRUG|Doxorubicin Hydrochloride|Given IV
214573225|NCT03211117|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214573226|NCT03211117|OTHER|Laboratory Biomarker Analysis|Correlative studies
214573227|NCT03211117|BIOLOGICAL|Pembrolizumab|Given IV
214573228|NCT03211117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214573229|NCT05351320|DRUG|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
214573230|NCT05351320|DRUG|chemotherapy|Platinum-based chemotherapy
214573231|NCT05351320|RADIATION|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
214573232|NCT05232747|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test
214573233|NCT01186822|DEVICE|Lung Flute|Used twice daily
214573234|NCT02649504|DRUG|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
214573235|NCT02649504|DRUG|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
214709464|NCT05203627|OTHER|Questionnaire Administration|Ancillary studies
214573236|NCT02649504|DRUG|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
214573237|NCT02649504|DRUG|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
214573238|NCT02870374|BEHAVIORAL|Answering specific quality of life questionnaire in kidneys transplantation population|
214573239|NCT02936882|PROCEDURE|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
214573240|NCT05009784|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
214573241|NCT05009784|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
214573242|NCT05009784|OTHER|Traffic Sound|Active Comparator: Traffic Sound (Played through speakers)
214573243|NCT05009784|OTHER|Traffic and Masking Sound|Experimental: Traffic and Masking Sound (Played through speakers)
214573244|NCT05009784|OTHER|Silence|No Intervention: No sound (Played through speakers)
214573245|NCT03328104|DRUG|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
214573246|NCT03328104|DRUG|Nelarabine|650 mg/m2 IV daily x Day 1-5
214573247|NCT03328104|DRUG|Cyclophosphamide|440 mg/m2 IV x Day 1-5
214573248|NCT03328104|DRUG|Etoposide|100 mg/m2 IV x Day 1-5
214573249|NCT02773004|OTHER|EPClin genomic test|
214573250|NCT05475275|PROCEDURE|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
214573251|NCT04589481|OTHER|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
214573252|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Tandem Stance Test (ATST) and Physical Therapist's Measurements of Tandem Stance Test (PTST)|For the Tandem Stance Test comparisons, the Azure Kinect-based Tandem Stance Test system quantified the distance traveled by the pelvic point to X, Y, and Z coordinates over a 30-second duration while the physical therapist measured the time elapsed until the participant lost balance was measured with a maximum of 30 seconds. Participants remained a tandem stance, positioning their preferred leg in front such that the heel of the front foot touched the toes of the back foot, ensuring both feet were aligned as straight as possible. They stood with holding on to two chairs each placed on their sides for stability and safety. Upon the cue to 'start', the participants let their hands go and both the Azure Kinect-based system and the physical therapist's stopwatch initiated their measurements. Participants tried to maintain their stance for 30 seconds. The participants had to reposition themselves when they stepped, used hands or lose balance for 30 seconds
214709465|NCT05203627|OTHER|Telemedicine Visit|Receive telehealth sessions
214709466|NCT01966263|PROCEDURE|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
214573253|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Five Times Sit-to-Stand Test (AFTSS) and Physical Therapist's Measurements of Five Times Sit-to-Stand Test (PFTSS)|The Five Times Sit-to-Stand Test (FTSS), standardized by Csuka and McCarty, has been designed to assessing lower limb strength as well as balance and postural control among elder population with high level of reliability. A previous study reported excellent intra-rater reliability (ICC=.914-.933) and inter-rater reliability (ICC=.988-.995) among healthy older adults. In addition, Five Times Sit-to-Stand Test more than 11.50 seconds had been reported to represent risk of falls among elders over 65-year-old. To assess Five Times Sit-to-Stand Test , a chair, 45cm in height and fixed to the ground, was placed three meters from the camera. Participants began seated, and on start cue, repeatedly stood up and sat down five times. The Azure Kinect-based system automatically ended its measurement as the participant completed the fifth stand, whereas the physical therapist manually measured time using the stopwatch. The time measures from the system and therapist were compared.
214573254|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Timed Up and Go Test (ATUG) and Physical Therapist's Measurements of Timed Up and Go Test (PTUG)|The Timed Up and Go test (TUG) has been employed as a straightforward assessment of an individual's mobility, necessitating both static and dynamic balance. A Timed Up and Go test duration exceeding 9.50 seconds has been identified as indicative of a heightened fall risk in individuals aged 65 and older. A previous study reported excellent intra-rater reliability (ICC=.97) and inter-rater reliability (ICC=.96). Initiating in a seated position, participants stood upon commencement of the test. Simultaneously, the Azure Kinect-based system and stopwatch began the time measurements. Participants then walked a distance of three meters, turned around, retraced their steps, and resumed their seated position. The Azure Kinect-based system automatically terminated its timing once the participant was seated, while the physical therapist manually stopped the stopwatch. The time measures from the system and therapist were compared.
214573255|NCT06519864|DIAGNOSTIC_TEST|Short Physical Performance Battery (SPPB)|The assessment includes three tests: a Timed Up and Go test test where participants walked a distance of 3 meters at their comfortable pace; a Five Times Sit-to-Stand Test which the duration is also measured; and the standing balance test which determines a participant's capacity to maintain three different stances of side-by-side, semi-tandem, and full tandem, each for 10 seconds.
214573256|NCT06519864|DIAGNOSTIC_TEST|Berg Balance Scale (BBS)|Participants are scored on a 5-point scale for each task, where a score of 0 signifies an inability to perform, while a 4 denotes independence in execution. A perfect score of 56 is a marker of excellent balance. Administering the Berg Balance Scale is efficient, taking between 10 to 20 minutes, and requires only basic equipment such as a chair, stopwatch, ruler, and step within a small space.
214573257|NCT06519864|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|Participants, standing barefoot, aligned the side of their body with a wall, ensuring no contact. Their stance was parallel with feet comfortably spaced. With their shoulders flexed at a 90° angle adjacent to the wall, they kept their elbows straight and hands clenched. The starting point on a horizontally affixed measuring tape, level with the floor, was determined by where the third metacarpal touched. This tape was aligned with each participant's acromion height. Without taking a step, lifting heels or losing balance, participants leaned forward to their maximum extent. The difference between the initial and final third metacarpal positions on the tape denoted the reach distance.
214573258|NCT06519864|DIAGNOSTIC_TEST|Four-Square Step Test (FSST)|During the Four-Square Step Test, participants were instructed to step over four straight tapes, each 90 cm in length, laid out in a cross-shape configuration on the floor. Beginning in square 1 and facing square 2, participants followed a specific sequence: they stepped forward into the next quadrant, then to the right, backward, and finally to the left, moving in a clockwise direction. This sequence was then retraced in a counterclockwise manner. It was essential for both feet to touch down in each quadrant. Participants aimed to complete this pattern as fast as they could, avoiding stepping the tapes. The duration taken to finish the sequence was recorded.
214573259|NCT06519864|DIAGNOSTIC_TEST|Grip Strength (GS)|The strength of the dominant hand's maximal grip force, indicative of upper extremity muscle strength, was gauged using a digital isometric hand dynamometer.
214573260|NCT02102607|OTHER|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
214573261|NCT05624671|OTHER|bupivacaine,fentanyl|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
214573262|NCT00213889|OTHER|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
214573263|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
214573264|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
214709467|NCT01966263|PROCEDURE|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
214709468|NCT01966263|PROCEDURE|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
214573265|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
214573266|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
214709469|NCT01966263|PROCEDURE|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
214573267|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
214573268|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
214573269|NCT02546921|DRUG|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
214709470|NCT05259930|OTHER|Amino MP9|Name used by Nualtra for their product of BCAA
214573270|NCT00495443|DEVICE|Peterio|
214573271|NCT04255472|BEHAVIORAL|WHO Caregiver skills training (CST) program|Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
214709471|NCT03287869|DRUG|Brexpiprazole|Brexpiprazole tablets
214709472|NCT03488238|DEVICE|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
214709473|NCT05860998|DIAGNOSTIC_TEST|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
214709474|NCT02884518|DEVICE|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
214709475|NCT02884518|BEHAVIORAL|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
214573272|NCT04255472|BEHAVIORAL|Treatment as usual|WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
214573273|NCT05054803|DRUG|WJ-MSC (XCEL-UMC-BETA)|Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
214573274|NCT05054803|DRUG|Placebo|Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
214573275|NCT04950595|OTHER|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
214573276|NCT04950595|OTHER|Beef mince|Spaghetti bolognaise meal made with beef mince
214573277|NCT05271968|PROCEDURE|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
214573278|NCT05843422|DRUG|0.1% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
214573279|NCT05843422|DRUG|0.3% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
214573280|NCT05843422|DRUG|0.8% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
214709476|NCT04435561|OTHER|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
214573281|NCT05843422|DRUG|1.5% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
214573282|NCT04779762|OTHER|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
214573283|NCT04779762|DRUG|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
214573284|NCT00301938|DRUG|7-hydroxystaurosporine|Given IV
214573285|NCT00301938|DRUG|perifosine|Given orally
214573286|NCT00301938|OTHER|pharmacological study|Correlative studies
214573287|NCT00929942|DEVICE|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
214573288|NCT01647555|DRUG|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
214573289|NCT01647555|RADIATION|Radiotherapy|Curative dose: 66 to 70 Gy
214573290|NCT01504477|DRUG|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
214573291|NCT03154970|DEVICE|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
214573292|NCT03420248|DEVICE|Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere|One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
214573293|NCT00677105|DRUG|JNJ-26481585|
214709477|NCT04435561|OTHER|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
214709478|NCT01376401|DRUG|Bendamustine|
214573294|NCT02573389|DEVICE|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
214573295|NCT01546675|OTHER|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
214573296|NCT03863015|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
214573297|NCT03863015|DRUG|isotonic saline|A one hour infusion of 100mL isotonic saline
214573298|NCT05478889|PROCEDURE|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
214573299|NCT04730817|DEVICE|Virtual Reality Motor-Cognitive Training System|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong. The VR training system is designed as a game with 16 progressive levels (anticipating intervention group participants to complete 2 levels per week for 8 weeks) which aim to train their motor and cognitive functions.
214573300|NCT03064399|PROCEDURE|without lateral ligament repairment|microfracture without repairment of the lateral ligament
214573301|NCT03064399|PROCEDURE|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
214573302|NCT05679089|DEVICE|early detection test|Blood collection and early detection testing
214573303|NCT05474053|DRUG|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
214573304|NCT05474053|DRUG|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
214573305|NCT05675813|DRUG|CHOP+selinexor+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
214573306|NCT05675813|DRUG|CHOP+duvelisib+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
214709479|NCT01376401|DRUG|Velcade|
214709480|NCT01376401|DRUG|Prednisone|
214709481|NCT05671315|DRUG|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
214721991|NCT02392676|DRUG|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
214573307|NCT05675813|DRUG|CHOP+chidamide+tislelizumab|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
214573308|NCT05675813|DRUG|standard CHOP|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
214573309|NCT03242967|DRUG|Vadadustat|Oral tablet
214573310|NCT03242967|DRUG|Darbepoetin alfa|subcutaneous or intravenous
214573311|NCT02731144|OTHER|Peptamen intense|
214573312|NCT02731144|OTHER|Novasource senior|
214573313|NCT05155670|DEVICE|WRL HX MCP|WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
214573314|NCT05781126|DIAGNOSTIC_TEST|The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires|a) medical history record, b) ENT examination, c) pure tone audiogram and speech audiometry (with and without the hearing amplification) d) listening effort evaluation (with and without the hearing amplification) Self-report and behavioral methods will be used: Evaluation of subjective performance (Spatial Hearing Questionnaire (SHQ) Evaluation of time response in auditory message Evaluation of speech comprehension with background noise or a competitive speaker e) cognitive function evaluation by using the Greek version of Mini-Mental State Examination, f) evaluation of hearing-aid satisfaction, by using the Glasgow Hearing Aid Benefit Profile (GHABP), and International Outcome Inventory - Hearing Aid (IOI-HA), questionnaires and g) evaluation of stress level and depression by using BECK-II and STAI questionnaires.
214573315|NCT01640639|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
214573316|NCT01640639|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
214573317|NCT04812197|PROCEDURE|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
214573318|NCT03058575|DIETARY_SUPPLEMENT|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement"
214573319|NCT03058575|OTHER|Control|No Intervention for 8 weeks
214573320|NCT01721928|DEVICE|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
214573321|NCT00680992|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
214573322|NCT04322903|BEHAVIORAL|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
214573323|NCT04469049|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
214573324|NCT02753543|DRUG|Chidamide|
214573325|NCT02275429|PROCEDURE|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
214573326|NCT00175201|PROCEDURE|Proactive care and rehabilitation|
214573327|NCT04812002|DRUG|PD-1 inhibitor， bevacizumab|Both drugs are given intravenously
214573328|NCT01585155|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
214573329|NCT00422812|DRUG|Inhaled Placebo|Inhaled Staccato Placebo
214573330|NCT00422812|DRUG|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
214573331|NCT00422812|DRUG|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
214573332|NCT00422812|DRUG|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
214573333|NCT02318459|OTHER|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
214573334|NCT02318459|OTHER|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
214573335|NCT04197362|OTHER|Evaluation|Subjects will be asked to walk across the gait laboratory floor at their self-selected walking speed. They will complete a 3-5 minute warm up period, as it was found to produce stable estimates of kinetic parameter mean values during treadmill activity. The positions of each marker will be recorded through the motion capture system. Ground reaction force will be obtained in real time from the gait laboratory force plates as marker dimensions are recorded. For walking data, two trials of 15 seconds each will be recorded. The second trial will be a redundancy in the setting of potential significant marker dropout.
214573336|NCT04690153|OTHER|Patients with three vertical Hayman Sutures|Patients who are referred to our clinic due to postpartum hemorrhage between the ages of 18-45 and who need to undergo a surgical procedure (not responding to medical treatment) due to abnormal uterine bleeding in our clinic will be included. Patients with a previously known diagnosis of bleeding and coagulation disorders will not be included in the study. Considering that we are one of the primary referral centers in Istanbul in terms of deliveries and post-partum bleeding in our hospital, it is aimed to terminate the study with approximately 50 participants.
214573337|NCT03660423|OTHER|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
214573338|NCT01397422|DRUG|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
214573339|NCT02627053|DRUG|rivaroxaban|
214573340|NCT03921385|DEVICE|Augmented Reality Headset|Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
214573341|NCT04337853|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
214573342|NCT04337853|OTHER|No intraoral stent|Radiotherapy without intraoral stent
214573343|NCT05039294|BEHAVIORAL|School-Based Physical Activity Educational Program|The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
214573344|NCT04730193|DRUG|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
214573345|NCT04730193|DRUG|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
214573346|NCT02140840|DRUG|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
214573347|NCT03772587|DRUG|M281|M281 administered as IV infusion
214573348|NCT03772587|OTHER|Placebo|Placebo administered as intravenous (IV) infusion
214709482|NCT05671315|DRUG|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
214573349|NCT06005545|DEVICE|Passive Ultrasonic Irrigation (PUI) group|Passive ultrasonic irrigation is the current golden standard in root canal cleaning and irrigation devices. It is used after root canal shaping using manual or rotary instruments. It uses sodium hypochlorite which is mobilized in the canal using ultrasonic non-cutting tips to clean, debride, disinfect, and prepare the root canal for obturation.
214573350|NCT06005545|DEVICE|Endoclean (EC) group|Endoclean is a novel device that uses hydraulic inertial cavitation with the help of pressure and saline solution to debride the root canal after minimal shaping using manual or rotary shaping instruments. It is used to effectively clean, debride and prepare the root canal before obturation in the root canal treatment procedure.
214573351|NCT06005545|DEVICE|Conventional group|Conventional root canal preparation uses manual or rotary files along with manual irrigation using syringes and irrigant solutions like sodium hypochlorite or EDTA to clean, debride and prepare the root canal for obturation.
214573352|NCT01456572|DIETARY_SUPPLEMENT|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
214573353|NCT01456572|DIETARY_SUPPLEMENT|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
214573354|NCT04851353|BEHAVIORAL|GT+VC|Gentle touch and verbal comfort,
214573355|NCT04851353|BEHAVIORAL|Smell|Smell breast milk
214573356|NCT04851353|BEHAVIORAL|Taste|Taste breast milk
214709483|NCT05906992|BIOLOGICAL|CT-P53|Intravenous(IV) infusion
214573357|NCT06226272|DEVICE|Spinal Fusion|Cervical Spinal Fusion
214573358|NCT06226272|DEVICE|Spinal Fusion|Thoracic / Lumbar Spinal Fusion
214573359|NCT06226272|DEVICE|Spinal Deformities Correction|Spinal Deformities Correction
214573360|NCT05637359|DEVICE|Tracked ultrasound measurement|"Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself."
214573361|NCT03311464|DRUG|adalimumab|Study drug will be administered subcutaneously.
214573362|NCT02086305|BEHAVIORAL|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
214573363|NCT02086305|BEHAVIORAL|Usual care|Usual care is the routine practice in the hospital
214573364|NCT04293458|DEVICE|EsoGuard|EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
214709484|NCT05906992|BIOLOGICAL|US-Ocrevus|Intravenous(IV) infusion
214709485|NCT05906992|BIOLOGICAL|EU-Ocrevus|Intravenous(IV) infusion
214709486|NCT00334646|DRUG|Oral GW679769|150mg oral, once daily on days 1-3
214709487|NCT00334646|DRUG|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
214573365|NCT06150274|DEVICE|Percutaneous Balloon Mitral Valvulotomy|Stenotic mitral valve will be dilated to open the commissures
214573366|NCT06131606|BEHAVIORAL|experimental group|Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
214573367|NCT00513305|DRUG|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
214573368|NCT00513305|DRUG|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
214573369|NCT01827644|DRUG|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
214573370|NCT01827644|DRUG|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
214573371|NCT01827644|DRUG|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
214573372|NCT01827644|DRUG|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
214573373|NCT01827644|DRUG|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
214573374|NCT01827644|DRUG|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
214573375|NCT04613544|DEVICE|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
214573376|NCT03464851|DIAGNOSTIC_TEST|Carotid Stenotic Scan (CSS)|"Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart."
214573377|NCT06259578|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
214573378|NCT00636805|DRUG|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
214573379|NCT03613376|OTHER|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
214573380|NCT05539144|RADIATION|"Oropharyngeal mucosa"|"Oropharyngeal mucosa was delineated as OARs and limiting its dose"
214573381|NCT05539144|RADIATION|oropharynx|oropharynx was delineated as OARs and limiting its dose
214573382|NCT05539144|RADIATION|"oropharynx and oropharyngeal mucosa"|"oropharynx and oropharyngeal mucosawere delineated as OARs and limiting its dose"
214573383|NCT04389203|PROCEDURE|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
214573384|NCT04389203|PROCEDURE|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
214573385|NCT04642248|OTHER|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
214573386|NCT02367547|DRUG|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
214573387|NCT02367547|DRUG|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
214573388|NCT02367547|DRUG|Methylaminolevulinate cream|In the study we use Metvix.
214573389|NCT02856100|DRUG|18F DCFPyL- Radiopharmaceutical|
214573390|NCT05640271|DRUG|Tocilizumab|Tocilizumab 80 mg IV dose (one time per patient)
214573391|NCT03787836|BEHAVIORAL|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
214709488|NCT02660866|DRUG|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
214709489|NCT02660866|DRUG|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
214573392|NCT03787836|BEHAVIORAL|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
214573393|NCT05008939|DRUG|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
214573394|NCT05008939|DRUG|Placebo|Patients received 30% oxygen for 1 hour.
214573395|NCT00830505|DRUG|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
214573396|NCT00830505|DRUG|fluticasone|2 puffs twice a day for 2 weeks
214573397|NCT00596700|DEVICE|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
214573398|NCT01065142|PROCEDURE|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
214573399|NCT00929747|DEVICE|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
214573400|NCT00929747|PROCEDURE|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
214573401|NCT02918305|DEVICE|PRDS-001 Renal Denervation Ultrasound System|
214573402|NCT02918305|PROCEDURE|Sham Procedure|
214573403|NCT05930613|DRUG|Certolizumab (CIMZIA® ; TNF-α antagonist)|400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
214573404|NCT05930613|DRUG|Placebo (NaCl 0.9 % solution)|NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
214573405|NCT00710905|DEVICE|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
214573406|NCT02461953|DEVICE|hemoperfusion apparatus|
214573407|NCT02461953|DEVICE|low flux dialyzer|
214573408|NCT02461953|DEVICE|high flux dialyzer|
214573409|NCT02888652|DRUG|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
214573410|NCT00052000|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
214573411|NCT03776539|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
214573412|NCT05901064|PROCEDURE|Axillary clearance|Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
214573413|NCT04765332|OTHER|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
214573414|NCT04904939|PROCEDURE|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
214573415|NCT00102739|DRUG|SB497115|
214573416|NCT00685906|DRUG|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
214573417|NCT00685906|DRUG|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
214573418|NCT02297139|DRUG|Dasatinib|
214709490|NCT05610657|DRUG|Mitapivat|Mitapivat tablets
214573419|NCT05476302|OTHER|Cognitive digital treatment|The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
214573420|NCT03007446|DRUG|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
214573421|NCT03007446|DRUG|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
214573422|NCT03007446|DRUG|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
214573423|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
214573424|NCT04425304|BEHAVIORAL|Group counseling|4 times
214573425|NCT04425304|BEHAVIORAL|Intensive group counseling|14 times
214573426|NCT04425304|BEHAVIORAL|Persuasive ICT support|Weekly reminders for 12 months
214573427|NCT00760968|DRUG|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
214573428|NCT00760968|DRUG|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
214573429|NCT03994354|PROCEDURE|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
214573430|NCT03446833|DEVICE|The LFP Beta aDBS System|The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
214573431|NCT00867204|PROCEDURE|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
214573432|NCT06058975|OTHER|Observational|Review the management of duodenal trauma in France
214573433|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
214573434|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
214573435|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
214573436|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
214573437|NCT06168539|OTHER|Emboless|Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
214573438|NCT06168539|OTHER|Standard|Standard dialysis set is used as comparative
214573439|NCT05336630|DEVICE|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
214573440|NCT05170633|DEVICE|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
214573441|NCT06260683|DRUG|Nicotine Replacement|Given nicotine patches and nicotine lozenges
214573442|NCT06260683|OTHER|Questionnaire Administration|Ancillary studies
214709491|NCT02889757|DRUG|Acteylcysteine|randomized into three arms
214709492|NCT04394143|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
214709493|NCT04394143|DRUG|Mannitol|Oral administration of two capsules before sleep for 7 days.
214709494|NCT02591238|OTHER|non-smoker oral placebo|Participants oral placebo last 2 weeks.
214573443|NCT06260683|DEVICE|Vaping|Given Preferred Flavor e-liquid
214573444|NCT06260683|DEVICE|Vaping|Given Tobacco flavored e-liquid
214573445|NCT05003856|OTHER|Quality-of-Life Assessment|Ancillary studies
214573446|NCT05003856|PROCEDURE|Radiofrequency Ablation|Undergo RFA
214709495|NCT02591238|DRUG|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
214573447|NCT04375072|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
214573448|NCT04375072|DEVICE|sham tDCS paired with active MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
214573449|NCT04375072|DEVICE|active tDCS paired with sham MBM|Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
214573450|NCT04375072|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
214573451|NCT06520124|DEVICE|Essilor® Stellest® spectacle lens|Spectacle lens with highly aspherical lenslets.
214573452|NCT06520124|DEVICE|Single-vision spectacle lens|Standard single-vision distance spectacle lens.
214573453|NCT05598281|DRUG|AMG 510|Oral tablet
214573454|NCT05598281|DRUG|Digoxin|Oral tablet
214573455|NCT04924166|DRUG|Placebo|Inactive dose of capsules that appear identical to active dose
214573456|NCT04924166|DRUG|Hydrocortisone|Hydrocortisone 180 mg in capsule form
214573457|NCT03329859|PROCEDURE|High resolution standardized laparoscopic cholecystectomy|High resolution standardized laparoscopic cholecystectomy
214573458|NCT01519505|BEHAVIORAL|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
214573459|NCT02365090|OTHER|patching|covering the sound eye with a patch to force use of the amblyopic eye
214573460|NCT02365090|OTHER|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
214573461|NCT05766384|DRUG|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
214709496|NCT02591238|OTHER|smoker oral placebo|Participants oral placebo last 2 weeks.
214573462|NCT06340360|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
214573463|NCT06340360|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
214573464|NCT04688320|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
214573465|NCT04688320|DRUG|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
214573466|NCT05742438|DRUG|Lidocaine IV|Continuous intravenous infusion of lidocaine
214573467|NCT05742438|DRUG|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
214573468|NCT05742438|DRUG|intrathecal morphine|intrathecal morphine injection
214635066|NCT02905578|DRUG|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
214635067|NCT02905578|DRUG|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
214635068|NCT07001748|DRUG|Standard of Care Chemotherapy|The most common regimens are FOLFOX, CAPOX, FLOT, CF, and CX. Other local institutional standard of care regimens as well as targeted agents for gastric/GEJ adenocarcinoma are allowed.
214635069|NCT07001748|PROCEDURE|Biospecimen Collection|Plasma is to be submitted at baseline and every three months for the first year or until progression, whichever comes first. For patients who have progression, their last plasma sample should be at time of progression.
214573469|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
214573470|NCT05148962|BIOLOGICAL|GRT-R910|Injection administered intramuscularly
214573471|NCT06050759|DIAGNOSTIC_TEST|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
214573472|NCT05806151|DIAGNOSTIC_TEST|Genetic and immunologic assessments|Definitive Local Therapies including surgery, radiotherapy, radio-frequency ablation of metastases.
214573473|NCT05881135|DRUG|Citicoline|i.v. bolus administration every 12 hours for 5 days.
214573474|NCT05881135|DRUG|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
214573475|NCT01372839|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
214573476|NCT01372839|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
214573477|NCT02595580|DEVICE|Glucopred|
214573478|NCT00181142|DRUG|Zenapax|
214573479|NCT01115179|DRUG|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
214573480|NCT01115179|DRUG|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
214573481|NCT01115179|DRUG|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
214573482|NCT06292442|OTHER|traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
214573483|NCT06292442|OTHER|High intensity interval training|This group received High Intensity interval training along with conventional treatment for lower limb muscles, performed 3 times per week fr 4 weeks.
214573484|NCT04419727|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
214573485|NCT05722639|DEVICE|X-Trodes acquisition system|No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
214573486|NCT03889145|DRUG|Telmisartan 80mg|Telmisartan 80mg
214573487|NCT03889145|DRUG|Amlodipine10mg|Amlodipine 10mg
214573488|NCT03889145|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
214573489|NCT04478136|DIAGNOSTIC_TEST|Blood test of factor levels|Blood draw from central line to check coagulation factors
214573490|NCT06450847|OTHER|Soleus Muscle Push Up Exercise|"Members will be asked to do the SPUs for 270 minutes/day for most days of the week (minimum 5 days) for 3 months:~1. Begin seated on a bench or chair so knees form a 90-degree angle with feet flat on the floor and toes pointed forward. Keep spine straight and shoulders back (not hunched or rounded forward).~2. Using a slow and controlled tempo, push toes into the floor and lift heels off the ground.~3. Hold for one to two seconds, pushing down on the balls of feet. Keep your thigh muscles relaxed.~4. Slowly lower heels and return to start. That's 1 rep. Without shoes Educational session will be given before the intervention time WhatsApp messages will be sent 1-2 times/day to remind the participants to continue doing the exercise and ascertain compliance. Also, the participants are required to daily fill logbook about the duration (in minutes) of the SPU that they did."
214573491|NCT06450847|OTHER|Other Exercise|Participants will be asked to continue their regular lifestyle
214573492|NCT03549390|BEHAVIORAL|Physical activity|Light-moderate intensity physical activities
214573493|NCT02368457|DRUG|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
214573494|NCT05867277|OTHER|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
214573495|NCT05623696|DEVICE|Sham or actual non-invasive (Magnetic) brain stimulation|5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
214573496|NCT05847907|DEVICE|Implant placement|Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
214573497|NCT03410004|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
214709497|NCT02591238|DRUG|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
214709498|NCT04721938|BEHAVIORAL|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
214709499|NCT01268033|DRUG|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
214573498|NCT04747197|DRUG|EYP-1901|Intravitreal injection
214573499|NCT05216822|DRUG|Racecadotril|racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
214573500|NCT00246220|DRUG|methylphenidate hydrochloride|
214573501|NCT03636529|DIETARY_SUPPLEMENT|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
214573502|NCT03636529|OTHER|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
214573503|NCT05173389|OTHER|TechnoBody|"1\. Group-TechnoBody balance training (15 min / 5 days a week, 4 weeks) In the study, the first group will be included in the balance program with the TechnoBody device Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
214573504|NCT05173389|OTHER|Thera-Trainer|"2\. Group-Thera-Trainer balance training (15 min / 5 days a week, 4 weeks) the second group will be taken into the balance program with the Thera-Trainer device and the results of both groups will be compared after 4 weeks.~Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
214573505|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
214573506|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
214573507|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
214573508|NCT02932098|BEHAVIORAL|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
214573509|NCT02932098|BEHAVIORAL|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
214573510|NCT02932098|BEHAVIORAL|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
214573511|NCT02651532|DEVICE|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
214573512|NCT06415526|PROCEDURE|OPERA|Robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction
214573513|NCT03890003|DEVICE|AID System|AID system
214573514|NCT03890003|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
214573515|NCT06269094|OTHER|CGM|CGM use for 6 weeks during virtual focus groups
214573516|NCT00607724|DRUG|GDC-0449|
214573517|NCT01419327|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
214709500|NCT01268033|DRUG|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
214573518|NCT00555529|PROCEDURE|radial artery applanation tonometry (RAAP)|non-invasive tonometry
214573519|NCT03738423|DRUG|REGN3500|Administered subcutaneous (SC)
214573520|NCT03738423|DRUG|REGN3500-Matching Placebo|Administered subcutaneous (SC)
214573521|NCT04311710|DRUG|ipilimumab|Specified Dose on Specified Days
214573522|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
214573523|NCT04311710|DRUG|ENHANZE (rHuPH20)|Specified Dose on Specified Days
214573524|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
214573525|NCT06519084|OTHER|Home based exercise training|"Intervention: home based physical exercise performed 4 times a week, each session lasting 40 minutes each. Aerobic and muscular resistance exercises, using body weight and elastic bands.~The sessions were proposed through video classes, in total 12 video classes during the 12 weeks of physical training. Patients monitored their heart rate during exercise and wrote it down on spreadsheets that were monitored weekly."
214573526|NCT00360217|DRUG|docosahexanoic acid (DHA)|
214573527|NCT01241604|DEVICE|BiPAP S/T|Mechanical Non-invasive Ventilation
214573528|NCT01241604|DEVICE|BiPAP Auto SV3|Auto Servo Ventilation Device
214634200|NCT07009353|DRUG|PF-07054894|"Cohort 1 Period 1 - Oral \[cyclobutenyl-14C\]PF-07054894 under fasted state. Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose.~Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose."
214634201|NCT07009353|DRUG|PF-07054894|Cohort 2 Period 1 - Oral \[Methyl-14C\]PF-07054894 under fasted state.
214573529|NCT03093623|BEHAVIORAL|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points \* time of each exercise (hours) \* Number of times per week + moderate level 5 points \* time per activity (hours) \* number of times per week + low level 3 points \* time per activity (hours) \* number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (\>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
214573530|NCT05148910|DEVICE|Silver and copper IUD (TCu380Ag)|An intrauterine device containing 380mm² of copper with a silver core.
214573531|NCT05148910|DEVICE|Copper IUD (TCu380A)|An intrauterine device containing 380mm² of copper.
214573532|NCT06578741|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)|Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
214573533|NCT02642562|DRUG|Ferric Derisomaltose|
214573534|NCT03771794|DEVICE|ReguRate neurostimulation|"Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode"
214573535|NCT05359887|OTHER|standardized liquid mixed meal Nutridrink®|Administration of food in controlled situation
214573536|NCT04668040|OTHER|Muscle energy technique|Muscle energy technique for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
214573537|NCT04668040|OTHER|Stretching|Stretching exercises for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
214573538|NCT03539588|DEVICE|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
214573539|NCT03539588|DEVICE|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
214573540|NCT00558077|DRUG|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
214709501|NCT00656084|DRUG|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
214709502|NCT00656084|DRUG|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
214573541|NCT00558077|PROCEDURE|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
214573542|NCT00631839|RADIATION|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies \>=6MV.
214573543|NCT02844634|DRUG|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
214573544|NCT02844634|DRUG|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
214573545|NCT02844634|DRUG|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
214573546|NCT01593787|DRUG|LCZ696|100 mg, 200 mg, 400 mg tablets.
214573547|NCT04224012|OTHER|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
214573548|NCT05785377|DRUG|Bupivacaine-Neostigmine|20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
214573549|NCT05785377|DRUG|Bupivacaine|20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
214573550|NCT01974778|DIETARY_SUPPLEMENT|Meal|Meal
214573551|NCT00151281|DRUG|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
214573552|NCT00151281|DRUG|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
214573553|NCT00151281|DRUG|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
214573554|NCT01279213|DRUG|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
214573555|NCT04353505|DRUG|Ketorolac|Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
214573556|NCT04353505|DRUG|Dexamethasone|Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
214573557|NCT01865747|DRUG|Cabozantinib tablets|
214573558|NCT01865747|DRUG|Everolimus (Afinitor) tablets|
214573559|NCT02592876|DRUG|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
214573560|NCT02592876|DRUG|rituximab|375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
214573561|NCT02592876|DRUG|ifosfamide|5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
214573562|NCT02592876|DRUG|carboplatin|AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
214573563|NCT02592876|DRUG|etoposide|100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
214573564|NCT04196127|OTHER|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
214573565|NCT04527432|OTHER|Survey|Survey at baseline, 6 and 12 months
214573566|NCT04527432|DIAGNOSTIC_TEST|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
214573567|NCT01464775|OTHER|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
214573568|NCT01464775|OTHER|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
214634202|NCT02071407|DRUG|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
214634203|NCT02071407|DRUG|Placebo|
214634204|NCT06877221|PROCEDURE|ultrasound renal denervation|Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device
214573569|NCT01133418|OTHER|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
214573570|NCT01133418|OTHER|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
214573571|NCT02859740|OTHER|SIGAM Questionnaire|
214573572|NCT00611975|DRUG|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
214573573|NCT00611975|DRUG|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
214573574|NCT04192253|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
214573575|NCT04299022|OTHER|Vivigen Cellular Bone Matrix|Allograft bone matrix
214573576|NCT03899402|DRUG|Insulin|Standard of care insulin for pump or injection and serves as a control
214573577|NCT03899402|DRUG|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
214709503|NCT00656084|DRUG|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
214709504|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
214573578|NCT03899402|DRUG|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
214573579|NCT03899402|DRUG|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
214573580|NCT06414603|DIAGNOSTIC_TEST|The Prospera™ Test|"The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory."
214573581|NCT05997199|DIETARY_SUPPLEMENT|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
214709505|NCT05054179|OTHER|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
214709506|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
214709507|NCT06360471|OTHER|fertility preservation|If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
214573582|NCT05924438|DRUG|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
214573583|NCT05924438|DRUG|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
214573584|NCT04423523|DIAGNOSTIC_TEST|Blood drop sampling|For each patient included, 1 additional EDTA blood tube (2 ml) will be collected for research purposes at different times (4 visits), and 1 PAXgene-type tube adapted for pediatric collection of only 500 μl (2 visits).
214573585|NCT05087758|OTHER|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
214573586|NCT05087758|OTHER|Conventional Care Wound Management|Advanced wound care with debridement and dressings
214573587|NCT03342833|DEVICE|Blood flow restriction|Occlusion of venous flow between bouts of HIIT training exercise
214573588|NCT03621787|DEVICE|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
214573589|NCT06342479|BEHAVIORAL|Discharge Education|Discharge education will be provided.
214573590|NCT00317733|DRUG|Ketoprofen in Transfersome|
214573591|NCT01828905|DEVICE|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
214709508|NCT04147507|OTHER|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
214709509|NCT04147507|BEHAVIORAL|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
214709510|NCT04549415|DRUG|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
214709511|NCT04549415|OTHER|lifestyle modification|Lifestyle modification Standard Principles
214709512|NCT04639843|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.
214709513|NCT04639843|DRUG|Duvelisib|Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).
214709514|NCT04639843|DRUG|Romidepsin|Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.
214709515|NCT04639843|DRUG|Doxorubicin|Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
214709516|NCT04329000|DRUG|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
214709517|NCT04329000|DRUG|Esomeprazole|Continuous Esomeprazole 40 mg QD
214573592|NCT01828905|PROCEDURE|Autologous cancellous bone graft|autologous cancellous bone graft
214573593|NCT06609109|DRUG|THC High Dose|Low dose of THC (30 mg)
214573594|NCT06609109|DRUG|THC Low Dose|Low dose of THC (5 mg)
214573595|NCT06609109|DRUG|THC 0mg|Placebo dose of THC (0 mg)
214573596|NCT06609109|DRUG|E-Cigarette Full Nicotine|E-Cigarette with Nicotine
214573597|NCT06609109|DRUG|E-Cigarette Placebo Nicotine|E-Cigarette with No Nicotine
214573598|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
214573599|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
214573600|NCT06857253|DRUG|HRS-1301|HRS-1301.
214573601|NCT06857253|DRUG|HRS-1301 placebo|HRS-1301 placebo.
214573602|NCT05713955|DEVICE|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
214573603|NCT05406622|DEVICE|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
214573604|NCT05406622|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
214573605|NCT06274190|DIAGNOSTIC_TEST|bowel e-diary|This bowel diary will be available on the smartphone in the form of an application.
214573606|NCT05917028|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
214573607|NCT05498987|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant Achilles Tendon
214573608|NCT06357325|OTHER|a qualitative study.|"Before the interview process began, an interview form was created in accordance with the study design. In the study, care was taken to use open-ended general questions that would allow the participant to provide detailed information on the subject and did not require short answers such as short and clear questions, multiple choice questions, and yes-no questions.~For the analysis and reporting phase, an introduction was made in the form of a conversation with the participant before starting the interview, and then the interview was started if the participant was available. During the transcription phase, the questions were asked during the interview in such a way as to allow the participant to express themselves in detail without any direction or comment. The interview was conducted individually by calling each woman by telephone. During the interview, the researcher transcribed the interviewee's sentences exactly as she expressed them."
214573609|NCT02261987|OTHER|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
214573610|NCT02261987|OTHER|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
214573611|NCT02261987|OTHER|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
214573612|NCT03333876|DEVICE|Nasal Dilator|Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.
214709518|NCT04099706|PROCEDURE|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
214573613|NCT03333876|DEVICE|Mandibular Advancement|"For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States."
214573614|NCT03333876|DEVICE|Positional Therapy|Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
214573615|NCT01587859|PROCEDURE|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
214573616|NCT00095498|DRUG|placebo|placebo subcutaneous injection
214573617|NCT00095498|DRUG|denosumab|For subcutaneous injection
214573618|NCT05020327|DRUG|Graded Oral Amoxicillin Challenge|Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
214573619|NCT05020327|OTHER|De-labelling in electronic medical record|Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
214573620|NCT05020327|OTHER|Referral to Allergy Immunology/Retention of Allergy Label|Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
214573621|NCT04684394|BIOLOGICAL|GEM103|GEM103 500 mcg/50 mcL intravitreal injection
214573622|NCT04684394|DRUG|Aflibercept|"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
214573623|NCT04684394|DRUG|Sham|Sham intravitreal injection
214573624|NCT05749484|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
214573625|NCT01094210|DRUG|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
214573626|NCT01558401|OTHER|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
214573627|NCT05199415|BEHAVIORAL|Health and Well-being Committee|Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
214573628|NCT05599503|BEHAVIORAL|Behavioral Interventions|Traditional SimpleC Wellness
214573629|NCT05599503|BEHAVIORAL|Robot Interventions|Robot interventions
214573630|NCT03407937|BEHAVIORAL|Hypnosis|Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.
214573631|NCT03407937|BEHAVIORAL|Meditation|Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
214709519|NCT02490943|OTHER|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
214709520|NCT02490943|OTHER|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
214709521|NCT00105209|DRUG|Aspirin|
214709522|NCT00105209|DRUG|clopidogrel|
214709523|NCT00004226|RADIATION|radiation therapy|
214709524|NCT02181036|OTHER|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
214709525|NCT05004519|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
214573632|NCT03407937|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.
214573633|NCT03407937|DRUG|Placebo Oral Tablet|A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
214573634|NCT05808881|DRUG|Nalmefene Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
214573635|NCT05808881|DRUG|Naloxone Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
214573636|NCT03143621|DIETARY_SUPPLEMENT|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
214573637|NCT03143621|OTHER|Water|Tap water heated to same temperature as coffee
214573638|NCT04874285|DIETARY_SUPPLEMENT|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
214573639|NCT00482690|DRUG|nicotine polacrilex|
214573640|NCT00482690|DRUG|nicotine transdermal system|
214573641|NCT00482690|DRUG|nicotine inhaler|
214573642|NCT02037633|DRUG|Fentanyl|Fentanyl IV
214573643|NCT02037633|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
214573644|NCT02037633|DRUG|ropivacaine|
214573645|NCT02932566|DRUG|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
214573646|NCT02932566|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
214573647|NCT05747300|OTHER|Premixed bioceramic paste wellroot PT|Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
214573648|NCT00591370|DRUG|Temozolomide (TMZ)|One group treatment study
214573649|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.
214573650|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.
214709526|NCT05004519|DRUG|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
214573651|NCT05952687|DRUG|Selinexor|Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
214573652|NCT04101214|OTHER|Dry needling|Dry needling into spastic muscle
214573653|NCT04101214|OTHER|Sham dry Needling|Sham dry needling into spastic muscle
214573654|NCT03439254|DRUG|Obeticholic acid (10 mg)|Tablets administered orally once daily.
214573655|NCT03439254|DRUG|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
214573656|NCT03439254|DRUG|Placebo|Tablets administered orally once daily.
214573657|NCT02442492|DRUG|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
214573658|NCT02442492|DRUG|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
214573659|NCT00080457|DRUG|sitaxsentan sodium|
214573660|NCT04556292|DRUG|SC10914|SC10914 400mg tid
214573661|NCT06531993|DRUG|Pectin|Using pectin as tablets 600 mg per day for 6 months
214709527|NCT00953225|DRUG|vitamin D3|4,000 IU daily for one year
214709528|NCT00953225|DRUG|Placebo daily for one year|Placebo
214709529|NCT04225390|DRUG|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
214573662|NCT02780154|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
214573663|NCT02780154|BIOLOGICAL|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
214573664|NCT02952118|DEVICE|Forrest Snoring device|
214573665|NCT00770705|DRUG|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
214573666|NCT00770705|OTHER|Standard surgical approach|Historical controls
214573667|NCT04399070|DRUG|S-ketamine|The depression patients received propofol and S-ketamine before ECT
214573668|NCT04399070|DRUG|ketamine|The depression patients received propofol and ketamine before ECT
214573669|NCT04399070|DRUG|saline|The depression patients received propofol and saline before ECT
214573670|NCT00271960|BEHAVIORAL|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
214573671|NCT00271960|BEHAVIORAL|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
214573672|NCT00271960|BEHAVIORAL|Usual care|Participants will receive usual prenatal care.
214573673|NCT03232580|DRUG|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
214573674|NCT04362943|DRUG|Baricitinib or Anakinra|Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
214573675|NCT02851888|DRUG|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
214573676|NCT02851888|OTHER|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
214573677|NCT02851888|PROCEDURE|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
214573678|NCT02265289|DRUG|Lefradafiban|
214573679|NCT02265289|DRUG|Clopidogrel|
214573680|NCT06281106|DRUG|Deucravacitinib|Daily drug intake for 4 weeks.
214573681|NCT02392520|DRUG|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
214573682|NCT02392520|DRUG|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
214573683|NCT06254937|OTHER|Reproductive Life Plan training|Reproductive Life Plan trainings; It will be done in the form of group training, which is considered an advantageous health education method in terms of low cost, wide scope and practicality. During the training, after the power point presentation to the initiative group, question-answer, discussion, brainstorming and visualizations will be made with the Pecha Kucha Technique. Presentations prepared in line with the Reproductive Life Plan Training Booklet will be used as training tools. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in booklet.
214573684|NCT04506645|DRUG|REGN5381|Single dose REGN5381 administered via IV infusion
214573685|NCT04506645|OTHER|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
214709530|NCT03864536|BEHAVIORAL|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
214573686|NCT05490901|DIAGNOSTIC_TEST|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
214573687|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
214573688|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
214573689|NCT02492022|OTHER|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
214634205|NCT03124563|BEHAVIORAL|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
214709531|NCT01855113|DEVICE|Invisalign|
214573690|NCT05139251|OTHER|Recovering from Intimate partner violence through Strengths and Empowerment (RISE)|RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician
214573691|NCT05139251|OTHER|ePALS|"Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently."
214573692|NCT04379362|PROCEDURE|Focal laser ablation|Focal laser ablation
214573693|NCT02084563|DRUG|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
214573694|NCT02084563|DRUG|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
214573695|NCT02084563|DRUG|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
214573696|NCT02084563|DRUG|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
214573697|NCT02084563|DRUG|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
214573698|NCT02084563|DRUG|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
214573699|NCT02371291|BEHAVIORAL|Memory Flexibility Training|As in experimental arm description.
214573700|NCT02371291|BEHAVIORAL|Psychoeducation|As in experimental arm description.
214573701|NCT01051934|DRUG|SS1 (dsFv) PE38|
214573702|NCT01051934|DRUG|Paclitaxel|
214573703|NCT01051934|DRUG|Carboplatin|
214573704|NCT01051934|DRUG|Bevacizumab|
214573705|NCT02075476|PROCEDURE|Hemiarthroplasty|
214573706|NCT02075476|PROCEDURE|reverse arthroplasty|
214573707|NCT00301587|DRUG|Norgestimate-ethinyl estradiol, with or without folic acid|
214573708|NCT06042322|OTHER|Educational intervention|Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
214573709|NCT00567203|DRUG|PF-3463275|PF-3463275 10mg
214573710|NCT00567203|DRUG|PF-3463275|PF-3463275 25mg
214573711|NCT00567203|DRUG|Placebo|Placebo
214573712|NCT05882409|BEHAVIORAL|Education|Education covers women's education on violence, conflict and awareness.
214573713|NCT05894902|DRUG|SM-001|The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
214573714|NCT05201391|BEHAVIORAL|"Eat Right Now (ERN) mobile application"|"Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete."
214573715|NCT05617664|DRUG|desmopressin 120 mcg oral tablets|treatment for three months then will stop
214573716|NCT05617664|DRUG|Mirabegron 25 MG Oral Tablet, Extended Release|treatment for three months then will stop
214573717|NCT05617664|BEHAVIORAL|behavioral therapy alone|no medications will be given to the patient
214573718|NCT06191822|OTHER|Nutrition|Interact with mobile app and work toward personalized nutrition goals
214573719|NCT06191822|OTHER|Fitness|Interact with mobile app and work toward personalized fitness goals
214573720|NCT06191822|OTHER|Sleep|Interact with mobile app and work toward personalized sleep goals
214573721|NCT02780908|OTHER|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
214573722|NCT02780908|OTHER|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
214573723|NCT00530140|BIOLOGICAL|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
214573724|NCT05452200|BEHAVIORAL|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
214573725|NCT05452200|OTHER|added exams to the usual lung cancer screening|"* spirometry examination~* Questionnaires~* Blood samples and breath samples to find biomarkers"
214573726|NCT00095056|DRUG|sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
214573727|NCT00095056|DRUG|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
214573728|NCT00095056|DRUG|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
214573729|NCT00095056|DRUG|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
214573730|NCT06245148|OTHER|Observation|Observation
214573731|NCT03918499|DRUG|Cyclophosphamide|Given IV
214573732|NCT03918499|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
214573733|NCT03918499|BIOLOGICAL|Pembrolizumab|Given IV
214573734|NCT04019990|OTHER|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
214573735|NCT01882205|DEVICE|Virtual chromoendoscopy|
214573736|NCT01882205|PROCEDURE|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
214573737|NCT03498859|OTHER|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
214573738|NCT03498859|OTHER|Home-based training|The intervention is home-based training during 10 weeks
214573739|NCT02321202|DRUG|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
214573740|NCT02321202|DRUG|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
214573741|NCT01169740|PROCEDURE|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
214573742|NCT02999802|BEHAVIORAL|Exercise|Progressive resistance exercise training
214573743|NCT06162962|OTHER|Retrospective analysis|Retrospective analysis
214709532|NCT04991064|OTHER|Complete denture base modified by Titanium dioxide nanoparticles.|Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
214573744|NCT00363350|DRUG|rituximab (anti-CD20)|2 infusions of 1000 mg
214709533|NCT03609489|DRUG|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
214709534|NCT03609489|DRUG|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
214709535|NCT01727557|PROCEDURE|regional anesthesia|Regional anesthesia will be compared to local anesthesia
214709536|NCT01727557|PROCEDURE|local anesthesia|Regional anesthesia will be compared to local anesthesia
214709537|NCT04600843|OTHER|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
214573745|NCT02209662|DEVICE|APIC-PRP|APIC-PRP
214709538|NCT04600843|OTHER|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
214709539|NCT03437291|PROCEDURE|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
214573746|NCT02209662|OTHER|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
214573747|NCT00682851|DEVICE|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
214573748|NCT00682851|DEVICE|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
214573749|NCT02746432|DRUG|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
214573750|NCT03114839|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of LcS.
214573751|NCT03700112|OTHER|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
214573752|NCT03700112|OTHER|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
214573753|NCT03700112|OTHER|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
214573754|NCT03700112|OTHER|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
214573755|NCT03700112|OTHER|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
214573756|NCT03700112|OTHER|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
214573757|NCT03700112|OTHER|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
214573758|NCT03700112|OTHER|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
214573759|NCT03601377|BEHAVIORAL|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
214573760|NCT03601377|BEHAVIORAL|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
214709540|NCT03437291|DEVICE|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
214573761|NCT03601377|BEHAVIORAL|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
214573762|NCT00535756|DRUG|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
214573763|NCT00535756|DRUG|Placebo|Placebo
214573764|NCT04734743|OTHER|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
214573765|NCT06316453|OTHER|Evaluating ASCVD risk over 10 and 30 year and lifetime|Utilizing validated tools such as the Pooled Cohort Equations (PCE) for 10-year ASCVD risk, the 30-year ASCVD risk prediction tool, and lifetime ASCVD risk categories, participants will undergo a thorough risk assessment. This multi-dimensional approach ensures a nuanced understanding of short and long-term cardiovascular risks. Further, The genetic risk for ApoB will be meticulously assessed by genotyping the APOB rs1042031 variant. Subsequently, the calculation of the genetic risk score (GRS) based on risk alleles will provide personalized insight into genetic predispositions related to ASCVD risk. Moreover, Participants will receive personalized management recommendations derived from the ACC/AHA Cardiovascular Risk Assessment Guidelines. These tailored suggestions may encompass dietary programs, lifestyle modifications, and, when indicated, pharmaceutical therapies like statins, aiming to mitigate identified risks effectively
214573766|NCT02886273|OTHER|Group 1|Observation
214573767|NCT02886273|OTHER|Group 2|Observation
214573768|NCT02886273|OTHER|Group 3|Observation
214573769|NCT02886273|OTHER|Group 4|Observation
214573770|NCT00396760|DRUG|aprotinin or tranexamic acid|
214573771|NCT02914340|DEVICE|Spiration Valve System|
214709541|NCT03437291|DEVICE|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
214709542|NCT03219801|BIOLOGICAL|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
214709543|NCT00640146|DRUG|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
214573772|NCT00923260|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
214573773|NCT00923260|PROCEDURE|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
214573774|NCT06213259|DRUG|KD6005|Biological: KD6005, SQ
214573775|NCT06213259|DRUG|Placebo|Placebo, SQ
214573776|NCT03704675|DRUG|TEW-7197|Administered orally
214573777|NCT03100643|OTHER|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
214573778|NCT04565093|PROCEDURE|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
214573779|NCT04565093|PROCEDURE|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
214573780|NCT04997447|BEHAVIORAL|Step-reduction/Exercise Rehab|2-week limited daily steps (\<2000), and then 4 weeks of typical strength+endurance exercise for older adults
214573781|NCT05617729|OTHER|Saline applied via swab|sterile saline applied via swab
214573782|NCT05617729|OTHER|Povidone-iodine based gel|gel applied via swab
214573783|NCT03260257|OTHER|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
214573784|NCT00660543|DRUG|Gadolinium|Given IV
214573785|NCT00660543|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
214573786|NCT00660543|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
214573787|NCT00660543|OTHER|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
214573788|NCT00660543|OTHER|Diffusion Weighted Imaging|Undergo DWI
214709544|NCT00640146|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
214573789|NCT00660543|OTHER|MRI-Based Angiogram|Undergo TOF MR angiography
214573790|NCT03388697|DIAGNOSTIC_TEST|Quantose IR and Quantose IGT analysis|Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
214709545|NCT05308160|DRUG|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
214709546|NCT05308160|DRUG|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
214709547|NCT02967770|OTHER|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
214709548|NCT02967770|DRUG|Standard of Care Second Line Therapy|
214573791|NCT03388697|DIAGNOSTIC_TEST|HOMA IR the standard testing for insulin resistance|Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.
214573792|NCT02116673|OTHER|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
214573793|NCT02116673|OTHER|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
214573794|NCT03429829|DEVICE|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
214573795|NCT04242836|DIAGNOSTIC_TEST|MNREAD testing|One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
214573796|NCT05999695|OTHER|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
214573797|NCT05999695|OTHER|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
214573798|NCT00689975|BEHAVIORAL|behavioral dietary intervention|
214573799|NCT00689975|BEHAVIORAL|exercise intervention|
214573800|NCT00689975|OTHER|counseling intervention|
214573801|NCT00689975|OTHER|flow cytometry|
214573802|NCT00689975|OTHER|immunoenzyme technique|
214573803|NCT00689975|OTHER|laboratory biomarker analysis|
214573804|NCT00689975|PROCEDURE|complementary or alternative medicine procedure|
214573805|NCT00689975|PROCEDURE|standard follow-up care|
214573806|NCT03930290|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation by vaginal tactile imaging analysis.
214573807|NCT05261919|PROCEDURE|Acupuncture manipulation|The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
214721992|NCT02392676|DRUG|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
214573808|NCT03646591|DRUG|Chemotherapy|Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
214573809|NCT00197587|DRUG|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
214573810|NCT00197587|DRUG|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
214573811|NCT03022253|BIOLOGICAL|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~1. PDA closes or~2. A maximum of 120 hours after the point of randomisation"
214573812|NCT03022253|BIOLOGICAL|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is \< 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count \< 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count \< 1, 00,000 per microliter and requires a neurosurgical procedure"
214573813|NCT03022253|DRUG|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
214573814|NCT03022253|DRUG|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
214573815|NCT02717351|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
214573816|NCT04585854|OTHER|Caffeine|Consumption of 3 shots of espresso
214573817|NCT01451892|OTHER|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
214573818|NCT01451892|OTHER|patient education|overweight individuals participating in a patient education program
214573819|NCT02480959|PROCEDURE|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
214573820|NCT04838951|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
214573821|NCT01276938|RADIATION|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
214721993|NCT00093158|DRUG|Angiomax (bivalirudin) anticoagulant|
214573822|NCT01276938|RADIATION|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
214573823|NCT00886496|BIOLOGICAL|recombinant human mannose-binding lectin|
214573824|NCT04576403|DEVICE|activated mittens|activated mittens (with electronic heat)
214573825|NCT04576403|DEVICE|deactivated mittens|deactivated mittens (without electronic heat)
214573826|NCT05442905|DRUG|propofol|Anesthesia will be induced with propofol 2-3mg/kg
214573827|NCT05442905|DRUG|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
214573828|NCT05442905|DRUG|sevoflurane|sevoflurane(1%-2%) used during anesthesia
214573829|NCT06431100|BIOLOGICAL|TCR T-cells|The strengthened T cells are re-infused into the patient to achieve the killing effect
214573830|NCT01316406|DRUG|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
214573831|NCT03603249|DRUG|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
214573832|NCT00039312|OTHER|Papanicolaou test|
214573833|NCT00039312|OTHER|cytology specimen collection procedure|
214573834|NCT00039312|PROCEDURE|annual screening|
214573835|NCT00039312|PROCEDURE|colposcopic biopsy|
214573836|NCT00039312|PROCEDURE|comparison of screening methods|
214573837|NCT03829475|DRUG|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
214573838|NCT03829475|DRUG|Placebo|placebo is an infusion of normal saline.
214573839|NCT03829475|DRUG|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
214573840|NCT04978272|DRUG|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
214573841|NCT04978272|OTHER|DP Placebo|Placebos will be identical appearance to DP.
214573842|NCT04500249|DRUG|infiltration rescue intraoperative analgesia|in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
214721994|NCT03059511|DRUG|Nalbuphine|Opioid Pain Medicine
214721995|NCT00307944|DRUG|Pantoprazole|
214721996|NCT00608244|DRUG|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
214573843|NCT04500249|DRUG|rescue IA|in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
214573844|NCT04500249|DRUG|rescue antyhypertensive medication|in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
214573845|NCT04500249|DRUG|rescue antyemetic medication|in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
214573846|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
214573847|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
214573848|NCT00836745|OTHER|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
214573849|NCT02060539|DEVICE|Biofinity XR|
214573850|NCT04835337|BEHAVIORAL|Air Purifiers|Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.
214573851|NCT04835337|BEHAVIORAL|Sham Air Purifiers|The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
214573852|NCT05459376|OTHER|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
214573853|NCT05299814|BEHAVIORAL|Behavioral Parenting Intervention|8 session evidence based parenting intervention
214573854|NCT04488393|DEVICE|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
214573855|NCT04709289|OTHER|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
214573856|NCT06051136|BEHAVIORAL|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
214573857|NCT04288102|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
214709549|NCT04142710|DEVICE|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
214709550|NCT01634113|DRUG|tiotropium-bromide|IMP
214573858|NCT04288102|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
214573859|NCT00752947|DRUG|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
214573860|NCT00752947|DRUG|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
214573861|NCT00752947|DRUG|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
214573862|NCT04394208|DRUG|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
214573863|NCT04394208|DRUG|Placebo|Placebo comparator
214573864|NCT01952353|PROCEDURE|Preoprative TACE|
214573865|NCT01952353|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
214709551|NCT01634113|DRUG|tiotropium-bromide|IMP
214709552|NCT01634113|DRUG|placebo|placebo matching tiotropium
214709553|NCT05255341|PROCEDURE|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
214573866|NCT05961787|DEVICE|SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)|"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"
214573867|NCT01756768|RADIATION|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
214573868|NCT01475279|DRUG|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
214573869|NCT04307771|BEHAVIORAL|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
214573870|NCT02121301|DRUG|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
214573871|NCT02121301|DRUG|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
214573872|NCT02121301|DRUG|Placebo (Vehicle) opthalmic solution|eyedrops
214573873|NCT01769768|DRUG|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
214573874|NCT01769768|DRUG|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
214573875|NCT01769768|DRUG|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
214573876|NCT04721535|DRUG|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
214573877|NCT04721535|DRUG|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
214573878|NCT04158232|OTHER|Method|treatment of mature teeth with apical periodontitis
214573879|NCT04129697|DRUG|Dexamethasone or Methylprednisolone|steroids
214573880|NCT00353522|DRUG|Placebo|po daily for 24 weeks
214573881|NCT00353522|DRUG|dalcetrapib|900mg po daily for 24 weeks
214573882|NCT02469103|DEVICE|C2|C2 and colonoscopy will be performed one after another on the same day
214573883|NCT02469103|PROCEDURE|colonoscopy|
214573884|NCT01658332|OTHER|blood samples|3 tubes (15 ml)
214573885|NCT01066520|DRUG|Traumeel S ointment|2 g, 3 times daily topical during 14 days
214573886|NCT01066520|DRUG|Traumeel S gel|2 g, 3 times daily topical during 14 days
214573887|NCT01066520|DRUG|Diclofenac gel|2 g, 3 times daily topical during 14 days
214573888|NCT00553072|DRUG|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
214573889|NCT00553072|DRUG|Normal saline|1 ml/kg/dose
214573890|NCT00436852|DRUG|ABT-751|Given orally
214573891|NCT00436852|PROCEDURE|quality-of-life assessment|Ancillary studies
214573892|NCT04135768|PROCEDURE|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
214573893|NCT04135768|PROCEDURE|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
214573894|NCT00370682|BIOLOGICAL|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
214573895|NCT00370682|BIOLOGICAL|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
214573896|NCT00370682|OTHER|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
214573897|NCT00167167|PROCEDURE|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
214573898|NCT04218045|PROCEDURE|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
214573899|NCT04218045|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
214573900|NCT02883998|OTHER|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
214573901|NCT02883998|OTHER|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
214573902|NCT02934256|DRUG|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
214573903|NCT02938026|PROCEDURE|Bariatric surgery|
214573904|NCT02938026|BEHAVIORAL|Telephone Intensive Lifestyle Counselling|
214573905|NCT05195502|DIAGNOSTIC_TEST|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
214573906|NCT06091293|BEHAVIORAL|Narrative Intervention for Long COVID-19 (NICO)|The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
214573907|NCT00943852|DRUG|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
214573908|NCT00943852|DRUG|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
214573909|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
214573910|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
214573911|NCT00943852|DRUG|Comparator: Placebo|Single dose placebo only in one of five treatment periods
214573912|NCT04640831|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
214573913|NCT00733876|BIOLOGICAL|Multipotent Stromal Cells|Post-operative administration of MSC
214573914|NCT00733876|BIOLOGICAL|Administration of MSC|Dose escalation protocol
214573915|NCT00002870|BIOLOGICAL|filgrastim|
214573916|NCT00002870|DRUG|cyclophosphamide|
214573917|NCT00002870|DRUG|epirubicin hydrochloride|
214573918|NCT00002870|DRUG|fluorouracil|
214573919|NCT00002870|DRUG|thiotepa|
214573920|NCT00002870|PROCEDURE|peripheral blood stem cell transplantation|
214573921|NCT02141620|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
214573922|NCT02141620|DRUG|n-Acetylcysteine|
214573923|NCT02141620|DRUG|Placebo|
214573924|NCT03651622|BEHAVIORAL|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
214573925|NCT03651622|BEHAVIORAL|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
214573926|NCT03651622|BEHAVIORAL|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
214573927|NCT03096080|DRUG|Tesevatinib|One dose of the study drug in liquid form
214573928|NCT00822211|DRUG|Vildagliptin 50 mg bid|
214573929|NCT00822211|DRUG|Vildagliptin 50 mg qd|
214573930|NCT00822211|DRUG|Placebo|
214573931|NCT02718430|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
214573932|NCT03377699|DRUG|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
214573933|NCT03377699|DRUG|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
214573934|NCT03377699|DRUG|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
214573935|NCT03517813|DEVICE|Contrast-enhanced Spectral Mammography (CESM)|Dual energy mammography images obtained after the administration of an intravenous contrast agent
214573936|NCT00307684|DRUG|double blind placebo|matching placebo tablets once daily for 4 weeks
214573937|NCT00307684|DRUG|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
214573938|NCT00307684|DRUG|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
214573939|NCT02580305|DRUG|SUVN-502|Once-daily, tablets, orally
214573940|NCT02580305|DRUG|Placebo|Once-daily, tablets, orally
214573941|NCT02580305|DRUG|Donepezil|Donepezil HCl (10 mg, once a day)
214573942|NCT02580305|DRUG|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
214573943|NCT02370927|OTHER|Control|Non pulse extruded cereal
214573944|NCT02370927|OTHER|Pea protein|Pulse extruded cereal
214573945|NCT02370927|OTHER|Pea Starch|Pulse extruded cereal
214573946|NCT02370927|OTHER|Pea fibre + pea starch|Pulse extruded cereal
214573947|NCT02370927|OTHER|Pea protein + pea starch|Pulse extruded cereal
214573948|NCT02370927|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
214573949|NCT05831722|PROCEDURE|Rapid Maxillary Expansion|Rapid Maxillary Expansion consists in the mid palatal suture opening through temporary anchorage mini implants placed in the palatal area.
214573950|NCT05625451|DEVICE|Elastic Tension Digital Neoprene Orthosis|The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
214573951|NCT01422551|BEHAVIORAL|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
214573952|NCT01422551|BEHAVIORAL|a psycho-educational control|a single-day psycho-educational seminar
214573953|NCT00270140|DRUG|epoetin alfa|
214573954|NCT00419978|PROCEDURE|Colectomy|
214573955|NCT00720772|DRUG|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
214573956|NCT04134988|OTHER|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
214573957|NCT04134988|OTHER|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
214573958|NCT00575120|OTHER|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
214573959|NCT04916093|DRUG|Vildagliptin 50 MG|Galvus 50 mg oral tablets
214573960|NCT04916093|DRUG|Sitagliptin 100mg|Januvia 100mg oral tablets
214573961|NCT04916093|DRUG|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
214573962|NCT01744938|PROCEDURE|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
214573963|NCT01253109|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
214573964|NCT05880745|DIAGNOSTIC_TEST|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
214573965|NCT01493843|DRUG|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
214573966|NCT01493843|DRUG|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
214573967|NCT01493843|DRUG|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
214573968|NCT01493843|DRUG|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
214573969|NCT01493843|DRUG|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
214573970|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ less than 10 minutes|lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
214573971|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
214573972|NCT05949073|DRUG|impregnated gingival retraction cord - less than 10 minutes|lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
214573973|NCT05949073|DRUG|impregnated gingival retraction cord - more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
214573974|NCT05784831|DEVICE|Reappraisal training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
214573975|NCT05784831|DEVICE|Ecological Momentary Assessment|The EMA tested here collects data on participants' mood and behavior.
214573976|NCT06129578|DIETARY_SUPPLEMENT|Mediterranean diet supplement with 20 g / day of hemp protein.|"All participants followed a low-energy diet (1315 kcal/daily) based on Mediterranean diet for 12 weeks, supplement with 20 g / day of hemp protein. The specific menu was designed by a trainee nutritionist. The program prescribed five meals a day, with the time customized to fit the lifestyle of each patient. Based on the baseline metabolism, the energy and nutritional parameters of every patient were computed. Patients reported the dietary intake data daily.~The intervention included face to face visit every two weeks, individual nutrition counseling and education sessions."
214573977|NCT06268548|OTHER|Manual diaphragmatic activation|Manual diaphragm release on diaphragm
214573978|NCT02797431|DRUG|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000
214573979|NCT02797431|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
214573980|NCT03502031|DRUG|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
214573981|NCT03502031|DRUG|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
214573982|NCT00579267|OTHER|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
214573983|NCT00457860|DRUG|Immunotoxin therapy|
214573984|NCT00457860|DRUG|CAT-8015 immunotoxin|
214573985|NCT00457860|PROCEDURE|Biological therapy|
214573986|NCT02384265|BEHAVIORAL|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
214573987|NCT05816226|DRUG|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
214573988|NCT05816226|DRUG|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
214573989|NCT01244529|DEVICE|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
214573990|NCT01244529|DEVICE|seno A|senofilcon A, BC:8.4 or 8.8
214573991|NCT01244529|DEVICE|galy A|galyfilcon A , BC: 8.3 or 8.7
214573992|NCT03746782|DIAGNOSTIC_TEST|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
214573993|NCT03974139|DRUG|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
214573994|NCT00941070|DRUG|triapine|Given IV
214573995|NCT00941070|DRUG|cisplatin|Given IV
214573996|NCT00941070|RADIATION|external beam radiation therapy|Undergo pelvic external beam radiation therapy
214573997|NCT00941070|PROCEDURE|quality-of-life assessment|Ancillary studies
214573998|NCT00941070|OTHER|questionnaire administration|Ancillary studies
214573999|NCT00941070|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET/CT
214574000|NCT00941070|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
214574001|NCT00941070|PROCEDURE|computed tomography|Undergo FDG-PET/CT
214574002|NCT03428529|DRUG|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
214574003|NCT03428529|DRUG|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
214574004|NCT01247285|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
214574005|NCT01247285|DRUG|PROZAC WEEKLY®|90 mg Capsules
214574006|NCT02645227|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
214574007|NCT02645227|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
214574008|NCT02645227|PROCEDURE|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
214574009|NCT03316820|DRUG|K0706|Study treatment with water after an overnight fast
214574010|NCT03316820|DRUG|K0706|Study treatment with water after food
214574011|NCT02811731|DRUG|CKD-330 16/5mg - B|
214574012|NCT02811731|DRUG|Candesartan 16mg and Amlodipine 5mg|
214574013|NCT01075802|DRUG|Tamoxifen|Dose escalation
214574014|NCT04160065|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
214574015|NCT00243048|DIETARY_SUPPLEMENT|soy protein isolate|
214574016|NCT00243048|RADIATION|radiation therapy|
214574017|NCT06371638|DRUG|Dexmedetomidine|General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml
214574018|NCT06371638|DRUG|Sevoflurane|General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.
214574019|NCT01416389|DRUG|LY2523355|Administered intravenously as a one hour infusion
214574020|NCT01416389|DRUG|ixabepilone|Administered intravenously
214574021|NCT01416389|DRUG|pegfilgrastim|Administered intravenously
214574022|NCT01416389|DRUG|filgrastim|Administered intravenously
214574023|NCT03711422|DRUG|Afatinib|40mg daily
214574024|NCT03711422|DRUG|Afatinib|160mg for 3 days every 3 weeks
214574025|NCT02927197|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
214574026|NCT00538694|DRUG|daptomycin|
214574027|NCT04306016|OTHER|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
214574028|NCT01125514|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
214574029|NCT01125514|DRUG|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
214574030|NCT01125514|DRUG|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
214574031|NCT01125514|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet
214574032|NCT02033083|DEVICE|Laminaria|
214574033|NCT02033083|DEVICE|Dilapan-S|
214574034|NCT03684668|BEHAVIORAL|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
214574035|NCT04716335|DRUG|DMT|DMT
214574036|NCT04716335|DRUG|Harmine|Harmine
214574037|NCT04716335|DRUG|Placebo (Harmine)|Placebo for Harmine
214574038|NCT04716335|DRUG|Placebo (DMT)|Placebo for DMT
214574039|NCT04061044|DRUG|Ophthalmic Insert|Travoprost, 0.32 mg
214574040|NCT02755818|DRUG|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
214574041|NCT03369171|DEVICE|Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)|"MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2)."
214574042|NCT05271721|DRUG|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
214574043|NCT05271721|DRUG|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
214574044|NCT05271721|DRUG|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
214574045|NCT04419272|DRUG|Methylphenidate|10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.
214574046|NCT04419272|OTHER|Placebo|When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
214574047|NCT04419272|DRUG|Methylphenidate|During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
214574048|NCT02015208|DRUG|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
214574049|NCT04197739|DRUG|Amikacin|"Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram"
214574050|NCT00031798|DRUG|methylphenidate hydrochloride|
214574051|NCT00031798|PROCEDURE|quality-of-life assessment|
214574052|NCT00031798|RADIATION|radiation therapy|
214574053|NCT04990011|PROCEDURE|BioXclude amnion chorion membrane|The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
214574054|NCT05857189|DEVICE|Digitalized printed paper|Patients will receive a newly formed digitalized printed paper inserted into eyeglasses
214574055|NCT05857189|DEVICE|Traditional drawing image|Patients will receive eyeglasses that hold a traditional drawing image of the eye
214574056|NCT05857189|OTHER|Healthy controls|Patients will include volunteering participants with un defected eye
214574057|NCT02535091|DRUG|YKP3089|see above
214574058|NCT03045835|DEVICE|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
214574059|NCT03045835|DEVICE|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
214574060|NCT05617430|DRUG|HAIC|"Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W"
214574061|NCT05617430|DRUG|Sintilimab|200mg IV d1, Q3W
214574062|NCT05617430|DRUG|Bevacizumab Biosimilar IBI305|7.5mg/kg IV d1, Q3W
214574063|NCT05956275|DRUG|Tramadol|ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
214574064|NCT05956275|DRUG|Morfin|No block was applied to the patients in control
214574065|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with limited application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.
214574066|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with full application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
214574067|NCT03581903|BIOLOGICAL|H7N3 pLAIV|Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
214574068|NCT03581903|BIOLOGICAL|H7N9 pIIV|30 micrograms administered by intramuscular (IM) injection
214574069|NCT04235153|OTHER|Evaluation of the 9 dimensions of the CANUT-QVA questionnaire|"Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~1. Making food~2. Place where the meals are eaten~3. Eating and drinking: Nutrition~4. Eating and drinking: The pleasure of tasting, chewing~5. Eating and drinking: Satiated, well being~6. Food preparation: Supply, choice, presentation~7. Eating and drinking: Feelings~8. After eating: heaviness, discomfort, hunger~9. Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions."
214574070|NCT04909827|PROCEDURE|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
214574071|NCT04909827|PROCEDURE|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
214574072|NCT01127763|DRUG|RAD001|
214574073|NCT01127763|DRUG|Carboplatin|
214574074|NCT01823939|DRUG|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
214574075|NCT03032432|DEVICE|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
214574076|NCT03032432|DRUG|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
214574077|NCT06065683|PROCEDURE|surgery|Surgical procedures performed in the study period
214574078|NCT00230880|BEHAVIORAL|follow-up phone counseling|9 calls over 12 months
214574079|NCT03904225|DRUG|Tegafur-Gimeracil-Oteracil|oral administration for 12 months
214574080|NCT02028078|DRUG|Insulin human|Induces hypoglycaemia
214574081|NCT02881346|DRUG|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
214574082|NCT04440852|BEHAVIORAL|TEACCH|The Treatment and Education of Autistic and Communication Handicapped Children
214574083|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
214574084|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
214574085|NCT00399243|DRUG|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
214574086|NCT01769326|OTHER|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
214574087|NCT01769326|DEVICE|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
214574088|NCT01769326|OTHER|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
214574089|NCT01769326|DEVICE|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
214574090|NCT01036438|DEVICE|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
214574091|NCT01036438|DEVICE|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
214574092|NCT00659659|DRUG|MEDI-563|1.0 mg/kg IV: MEDI-563
214574093|NCT00659659|DRUG|MEDI-563|100 mg, 200 mg SC
214574094|NCT00659659|OTHER|Placebo Comp.|Placebo SC
214574095|NCT00659659|OTHER|Placebo|Placebo as a single IV infusion (Certain number of subjects)
214574096|NCT02977273|OTHER|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
214574097|NCT02977273|OTHER|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
214574098|NCT02977273|OTHER|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
214574099|NCT02977273|OTHER|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
214574100|NCT02153073|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
214574101|NCT05333692|DIETARY_SUPPLEMENT|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
214574102|NCT05333692|DIETARY_SUPPLEMENT|NEPRO® , Abbott|2-4 cans NEPRO® per day
214574103|NCT03702231|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
214574104|NCT02076438|DIETARY_SUPPLEMENT|Probiotics|Randomized to receive probiotics or placebo
214574105|NCT02039232|DEVICE|Pedicle screw system|
214574106|NCT02443454|DEVICE|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
214574107|NCT02443454|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
214574108|NCT03134794|BEHAVIORAL|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
214574109|NCT01657786|DIETARY_SUPPLEMENT|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100\_-102delAAG).
214574110|NCT01278173|DRUG|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
214574111|NCT00857129|PROCEDURE|Normal Unit|low-risk patients randomised to Normal Unit
214574112|NCT00857129|PROCEDURE|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
214574113|NCT03301129|BEHAVIORAL|Smoke|See arm/group descriptions.
214574114|NCT01549938|DIETARY_SUPPLEMENT|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
214574115|NCT01549938|DIETARY_SUPPLEMENT|Placebo|Microcellulose capsule identical in appearance to treatment
214574116|NCT02505386|DRUG|Ertapenem|
214574117|NCT03090828|BEHAVIORAL|app-based therapeutic education|Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
214574118|NCT03090828|BEHAVIORAL|enhanced app-based therapeutic education|Patients in the enhanced app group will also have access to a social network. (forum, chat room)
214574119|NCT01367639|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
214574120|NCT03590366|BIOLOGICAL|B244|B244 Suspension
214574121|NCT03590366|BIOLOGICAL|Vehicle|Vehicle suspension
214574122|NCT00879073|DRUG|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
214574123|NCT06377046|DEVICE|Accelerated pacing|The lower rate of the pacemaker will be programmed to 80 bpm in DDDR mode with mode switch to DDIR mode.
214574124|NCT06377046|DEVICE|Current standard of care|The lower rate of the pacemaker will be programmed to the current standard of care which is 60 bpm in DDDR mode with mode switch to DDIR mode.
214574125|NCT04326166|DRUG|Evogliptin|Evogliptin
214574126|NCT04326166|DRUG|Evogliptin|Evogliptin
214574127|NCT04326166|DRUG|Metformin and Evogliptin|Metformin and Evogliptin
214574128|NCT04570215|OTHER|Gotcha! Therapy application|"Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item."
214574129|NCT04570215|OTHER|Gotcha Therapy application: Maintenance|Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
214574130|NCT04449120|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
214574131|NCT04449120|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
214574132|NCT02137317|DEVICE|LAPPE (locally adapted personal protective equipment)|"* Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
214574133|NCT01373151|DRUG|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
214574134|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
214574135|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
214574136|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
214574137|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
214574138|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
214574139|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
214574140|NCT01373151|DRUG|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
214574141|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
214574142|NCT01373151|DRUG|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
214574143|NCT01373151|DRUG|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
214574144|NCT00128531|DRUG|leuprolide acetate|
214574145|NCT03026075|DEVICE|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
214574146|NCT01714661|DRUG|EVP-6124|Arms 1, 2
214574147|NCT01714661|DRUG|Placebo|Arm 3
214574148|NCT00625651|DRUG|Placebo|Inactive dummy AMG 655 (to maintain blind)
214574149|NCT00625651|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
214574150|NCT00625651|DRUG|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
214574151|NCT00625651|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
214574152|NCT03970538|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
214574153|NCT04548102|OTHER|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
214574154|NCT02408991|DRUG|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
214574155|NCT02408991|DEVICE|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
214709554|NCT05535309|DRUG|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
214574156|NCT05596253|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
214574157|NCT03583775|OTHER|Cardiovascular Magnetic Resonance Imaging|Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
214574158|NCT00612872|DRUG|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
214574159|NCT00704899|PROCEDURE|Physiotherapy|Structured exercise regimen
214574160|NCT00704899|DRUG|Amitryptiline|Amitryptiline 25mg once daily
214574161|NCT03506074|DIAGNOSTIC_TEST|Flavor test|The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
214574162|NCT02290080|DRUG|Oxygen|see arm description
214574163|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
214574164|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
214574165|NCT04188275|DIAGNOSTIC_TEST|Periodic ARV7 and miRNA evaluation|Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
214574166|NCT03408977|OTHER|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
214574167|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
214574168|NCT01035567|PROCEDURE|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
214574169|NCT01035567|PROCEDURE|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
214574170|NCT02657044|PROCEDURE|EMR|
214574171|NCT02657044|PROCEDURE|ESD|
214574172|NCT04270253|PROCEDURE|Conservative therapy|Conservative therapy including aquatic exercises, land-based exercises, balneotherapy, TENS therapy
214574173|NCT04270253|PROCEDURE|Manual therapy|End-range mobilization
214574174|NCT00501280|BEHAVIORAL|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
214574175|NCT04327297|DIETARY_SUPPLEMENT|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
214574176|NCT03399851|DEVICE|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
214574177|NCT03399851|DEVICE|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
214574178|NCT02790827|BEHAVIORAL|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
214574179|NCT02790827|BEHAVIORAL|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
214574180|NCT04827472|DRUG|Normal saline|100ml
214709555|NCT01593579|BEHAVIORAL|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
214574181|NCT04827472|DRUG|DWJ1521|Single dose
214574182|NCT04827472|DRUG|DWP14012 Tablet|Single dose, Tablet
214574183|NCT04152057|DRUG|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
214574184|NCT04152057|DRUG|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
214574185|NCT04152057|DRUG|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
214574186|NCT01447940|DEVICE|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
214574187|NCT00419081|DRUG|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
214574188|NCT00419081|DRUG|Forodesine Hydrochloride Capsules (100 mg)|
214574189|NCT02712905|DRUG|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
214574190|NCT02712905|DRUG|all-trans retinoic acid (ATRA)|
214574191|NCT02712905|DRUG|azacitidine|
214574192|NCT02712905|DRUG|nivolumab|
214574193|NCT01468181|DRUG|LY2189265|
214574194|NCT01468181|DRUG|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
214574195|NCT01468181|DRUG|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
214574196|NCT01468181|DRUG|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
214574197|NCT01468181|DRUG|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
214574198|NCT01468181|DRUG|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
214709556|NCT01593579|OTHER|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
214709557|NCT06796985|DRUG|Botulinum neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm). Participants will receive this drug twice throughout the duration of the study. Approximately 200 units of botulinum neurotoxin will be administered per injection.
214574199|NCT04888962|OTHER|OUD|History of opioid use disorder.
214574200|NCT00143208|DRUG|Xalacom|
214574201|NCT00878826|DRUG|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
214574202|NCT04337541|OTHER|Surgical facial mask|Participants will follow normal Authority recommendations AND wear mask outside their homes, or when receiving visits in their home.
214574203|NCT05353075|OTHER|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
214574204|NCT05353075|OTHER|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
214574205|NCT03391817|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation administered in gastroscopy
214574206|NCT00002324|DRUG|Nevirapine|
214574207|NCT00002324|DRUG|Zidovudine|
214574208|NCT03529682|OTHER|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
214574209|NCT03529682|OTHER|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
214574210|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
214574211|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
214574212|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
214574213|NCT01453400|DRUG|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
214574214|NCT01453400|DRUG|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
214574215|NCT01453400|DRUG|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
214574216|NCT03676491|OTHER|Music Intervention|Music intervention
214574217|NCT01986452|DEVICE|CPAP therapy|
214574218|NCT01986452|OTHER|Support|
214574219|NCT03588559|DIAGNOSTIC_TEST|Blood Pressure Measurement|Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
214574220|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
214574221|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
214574222|NCT04174898|BIOLOGICAL|human Mesenchymal Stem Cell (MSC) infusion therapy|Subjects will be infused with 100million human MSCs
214574223|NCT00000686|DRUG|Stavudine|
214574224|NCT04281459|OTHER|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
214574225|NCT01423227|BEHAVIORAL|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
214574226|NCT01423227|BEHAVIORAL|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
214574227|NCT02025959|BEHAVIORAL|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
214574228|NCT00031876|DRUG|capecitabine|
214574229|NCT00031876|DRUG|paclitaxel|
214574230|NCT04044898|DRUG|ALA 5%|prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose
214574231|NCT04044898|DRUG|ALA 10%|prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
214574232|NCT00021736|DRUG|EYE001 anti-VEGF aptamer|
214574233|NCT01651221|OTHER|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
214574234|NCT00606060|DRUG|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
214574235|NCT04451967|PROCEDURE|thrombolysis|transfer after thrombolysis for STEMI patients within 6h since onset
214574236|NCT05213494|OTHER|Inulin|Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
214574237|NCT05213494|OTHER|soluble corn fiber|soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
214574238|NCT05171478|DIAGNOSTIC_TEST|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
214574239|NCT03403582|OTHER|Raspberries|250g frozen whole red raspberries
214574240|NCT00066313|DRUG|vandetanib|
214574241|NCT00066313|PROCEDURE|adjuvant therapy|
214574242|NCT03367429|DRUG|Botox|THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
214574243|NCT01921010|DRUG|Niaspan|See Arm Description
214574244|NCT01921010|DRUG|Placebo|See Arm Description
214574245|NCT01942785|DRUG|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
214574246|NCT05657652|DRUG|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
214574247|NCT06374017|DRUG|Normal saline, Lidocaine, dexmetomidine|The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.
214574248|NCT04788043|DRUG|Magrolimab|45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
214574249|NCT04788043|DRUG|Pembrolizumab|200 mg IV infusion
214574250|NCT04788043|PROCEDURE|PET/CT|Scan
214574251|NCT04730154|BEHAVIORAL|Pain Neuroscience Education (PNE)|PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.
214574252|NCT04730154|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.
214574253|NCT04730154|BEHAVIORAL|Biomedically-focused education|The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
214574254|NCT06251284|OTHER|Saline nasal spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
214574255|NCT06089096|DIAGNOSTIC_TEST|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
214574256|NCT05417958|OTHER|Extremely thick blenderized tube feed|Commercial blenderized tube feed, not diluted
214574257|NCT05417958|OTHER|Mildly thick blenderized tube feed|Commercial blenderized tube feed, diluted with ingredients contained in blend
214574258|NCT06211322|DEVICE|"Urika, a self-management application for patients with gout"|The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
214574259|NCT06027671|BEHAVIORAL|Group SPARCS Intervention|Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
214574260|NCT06027671|BEHAVIORAL|ART-SPARCS Intervention|"ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
214574261|NCT06417697|DRUG|XEN-101|capsule formulation
214574262|NCT06417697|DRUG|Placebo|capsule formulation
214574263|NCT02227199|DRUG|Brentuximab Vedotin|Given IV
214574264|NCT02227199|DRUG|Carboplatin|Given IV
214574265|NCT02227199|DRUG|Etoposide|Given IV
214574266|NCT02227199|DRUG|Ifosfamide|Given IV
214574267|NCT02227199|OTHER|Laboratory Biomarker Analysis|Correlative studies
214574268|NCT06414720|DRUG|Dienogest 2 MG|The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
214574269|NCT05183152|DEVICE|NMES Feedback|Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
214574270|NCT05183152|DEVICE|Visual Feedback|Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
214574271|NCT05183152|DEVICE|TESS|Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
214574272|NCT04613583|OTHER|SAFeR fetuses|NO active intervention performed.
214574273|NCT06784999|DRUG|sufentanil|1\. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
214574274|NCT06784999|DRUG|methadone|2\. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
214574275|NCT06260397|PROCEDURE|serratus anterior plane block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
214574276|NCT06260397|PROCEDURE|costotransverse block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
214574277|NCT06260397|PROCEDURE|patient controlled analgesia|PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
214574278|NCT05676034|DRUG|AMX0035|AMX0035
214574279|NCT05717101|OTHER|Electronic Health Record Review|Review of medical records
214574280|NCT06202612|DRUG|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
214574281|NCT06202612|DRUG|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
214574282|NCT05866822|OTHER|APA|24 APA sessions
214574283|NCT05866822|OTHER|PAE|8 individuals sessions of PAE
214574284|NCT04903197|DRUG|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
214574285|NCT04903197|DRUG|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
214574286|NCT05597787|BEHAVIORAL|HIV Connect|online education and clinical skills
214574287|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention|education and clinical skills
214574288|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
214574289|NCT06222580|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214574290|NCT06222580|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214574291|NCT06222580|DRUG|Gilteritinib|Given PO
214574292|NCT06222580|DRUG|Revumenib|Given PO
214574293|NCT04827901|DRUG|XEN1101|two 10 mg capsules
214574294|NCT04827901|DRUG|Placebo|matching placebo
214574295|NCT04874818|DIAGNOSTIC_TEST|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
214574296|NCT05646888|BIOLOGICAL|Blood sampling|the blood sample will be taken during a planned blood sampling
214574297|NCT06006780|DEVICE|Porcine acellular dermal matrix|Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage
214574298|NCT06006780|OTHER|Coronally advanced flap (CAF)|Coronally advanced flap for root coverage
214574299|NCT05695846|DEVICE|externally applied cricoid cartilage pressure|
214574300|NCT04758065|OTHER|Radial pressure waves Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Experimental Group: Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves."
214574301|NCT04758065|OTHER|Therapeutic Exercise and Manual Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy."
214574302|NCT05169593|DRUG|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
214574303|NCT04512430|DRUG|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles \> 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
214574304|NCT04512430|DRUG|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
214574305|NCT04512430|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
214574306|NCT04512430|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
214574307|NCT06199336|BIOLOGICAL|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
214574308|NCT06199336|BIOLOGICAL|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
214574309|NCT06199336|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
214574310|NCT05920720|BEHAVIORAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
214574311|NCT05937373|DEVICE|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
214574312|NCT05937373|OTHER|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
214574313|NCT04242069|BEHAVIORAL|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
214574314|NCT04242069|OTHER|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
214574315|NCT04040218|PROCEDURE|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
214574316|NCT04168970|PROCEDURE|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
214574317|NCT01934790|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
214574318|NCT05308030|DRUG|Rivaroxaban and Aspirin|After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
214574319|NCT02284217|DEVICE|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
214574320|NCT05479032|DRUG|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
214574321|NCT03453853|DEVICE|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
214574322|NCT04534959|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
214574323|NCT01363570|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
214574324|NCT04265352|OTHER|No intervension|There is intervention at all.
214574325|NCT04073004|BEHAVIORAL|Rapid Resolution Therapy|psychotherapy that includes trance states
214574326|NCT04777201|DRUG|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
214574327|NCT04777201|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
214721997|NCT00608244|DRUG|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
214574328|NCT00552929|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered."
214574329|NCT05456906|OTHER|No intervention|No interventions
214574330|NCT03437395|DEVICE|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
214574331|NCT03437395|RADIATION|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
214574332|NCT05701774|DRUG|DCCR|Once daily oral administration
214574333|NCT04809506|BIOLOGICAL|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
214574334|NCT05241353|BEHAVIORAL|Reduced Frequency Self-Monitoring|Participants will be asked to record only a subset of daily eating throughout the intervention, with the prescription for self-monitoring individually tailored at baseline dependent on participants' self-reported eating patterns.
214574335|NCT05241353|BEHAVIORAL|Full-Frequency Self-Monitoring|Participants will be asked to record all contents of their diet throughout the intervention.
214574336|NCT05241353|BEHAVIORAL|Standard Behavioral Treatment|Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
214574337|NCT01200290|DRUG|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
214574338|NCT03725111|DEVICE|venous compression|venous compression
214574339|NCT03532503|DEVICE|Foley catheter|Transcervical foley catheter will be applied
214574340|NCT05555147|DRUG|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
214574341|NCT05555147|OTHER|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
214574342|NCT05375097|OTHER|Erenumab|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
214574343|NCT02944812|DRUG|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
214574344|NCT03092817|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
214574345|NCT03092817|OTHER|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
214574346|NCT05371106|OTHER|exposure to mycotoxins|self-report eating questionnaire
214574347|NCT05845541|BEHAVIORAL|Technology Supported Meditation and Biofeedback|"Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed."
214574348|NCT05845541|OTHER|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
214574349|NCT00728910|DRUG|Atorvastatin|10 mg QD for 4 weeks
214574350|NCT00728910|DRUG|ABT335|135 mg QD added to atorvastatin for 8 weeks
214574351|NCT00728910|DRUG|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
214574352|NCT00769262|OTHER|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
214574353|NCT00769262|OTHER|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
214574354|NCT06248437|OTHER|innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage|All participants completed a survey on sociodemographic data (age, sex, respiratory problems, smoking, among others). Weight, height, skin folds, and a blood sample were taken to quantify the Oxygen Radical Absorption Capacity (ORAC) units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and lipid profile. At that time, they were explained how they should eat the nutraceutical food, starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant
214574355|NCT04155203|DRUG|Mupirocin Calcium|mupirocin cream
214574356|NCT04155203|DRUG|Mupirocin Calcium|Reference mupirocin cream
214574357|NCT04155203|DRUG|Vehicle|vehicle control cream
214574358|NCT04199845|DIETARY_SUPPLEMENT|PS128|PS128 or placebo will be given twice daily for 8 weeks.
214574359|NCT05756270|DIAGNOSTIC_TEST|pCASL|Brain 3 Tesla MRI with pCASL sequence
214574360|NCT06240013|OTHER|Foam Rolling|Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.
214574361|NCT06240013|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
214574362|NCT01144377|DRUG|LY2541546|Administered subcutaneously
214574363|NCT01144377|DRUG|Placebo|Administered subcutaneously
214574364|NCT04168983|OTHER|sophrology|Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
214574365|NCT00116597|GENETIC|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
214574366|NCT00116597|BIOLOGICAL|Intranodal booster immunizations with synthetic melanoma associated epitopes|
214574367|NCT05974670|DEVICE|Consumer wearable device|The subjects are required to wear the consumer wearable devices continuously during the whole study period. The device can provided several physiological parameters, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep.
214574368|NCT05963347|DRUG|Golidocitinib|Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
214574369|NCT05963347|DRUG|CHOP Regimen|CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
214574370|NCT04914429|DRUG|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
214574371|NCT04914429|DRUG|Placebo|Matching placebo will be administered as a SC injection.
214574372|NCT00576563|DRUG|FDG|contrast medium
214574373|NCT06104813|OTHER|Interviews|Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
214574374|NCT03776708|OTHER|Spinal manipulation|Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
214574375|NCT03776708|OTHER|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires"
214574376|NCT01728337|DRUG|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
214574377|NCT01728337|DRUG|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
214574378|NCT02489968|DRUG|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
214574379|NCT02489968|DRUG|empagliflozin 10 mg|empagliflozin low dose once daily
214574380|NCT02489968|DRUG|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
214574381|NCT02489968|DRUG|empagliflozin 25 mg|empagliflozin high dose once daily
214574382|NCT02489968|DRUG|Placebo|
214574383|NCT06045052|DRUG|Eltrombopag|Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
214574384|NCT04637269|BIOLOGICAL|anti-BCMA CAR-T|5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
214574385|NCT02371590|DRUG|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
214574386|NCT02371590|DRUG|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
214574387|NCT00263367|OTHER|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
214574388|NCT01640405|DRUG|modified FOLFOX6 + bevacizumab|"* Bevacizumab 5 mg/kg iv, day 1, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~  * LV 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
214574389|NCT01640405|DRUG|FOLFOXIRI + Bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~* LV 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
214574390|NCT02156323|DRUG|CMS|Multiple doses of CMS over 2.5 days
214574391|NCT02156323|DRUG|RO7033877|Multiple doses of RO7033877 over 2.5 days
214574392|NCT02156323|DRUG|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
214574393|NCT05986500|OTHER|Galactose|The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)
214574394|NCT05986500|OTHER|No intervention|The participants will receive a saline infusion
214574395|NCT01970722|DRUG|Carboplatin|Given IP or IV
214574396|NCT01970722|DRUG|Cisplatin|Given IP
214574397|NCT01970722|DRUG|Gemcitabine Hydrochloride|Given IP or IV
214574398|NCT01970722|OTHER|Laboratory Biomarker Analysis|Correlative studies
214574399|NCT01970722|DRUG|Paclitaxel|Given IP or IV
214574400|NCT01970722|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
214574401|NCT01970722|OTHER|Quality-of-Life Assessment|Ancillary studies
214574402|NCT01970722|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214574403|NCT06430476|OTHER|EMI|A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path
214574404|NCT06430476|OTHER|EMA|A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
214574405|NCT05962554|BEHAVIORAL|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
214574406|NCT05167669|DEVICE|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
214574407|NCT06472336|PROCEDURE|Intracranial stenting|Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.
214574408|NCT06472336|PROCEDURE|Continuation of conventional endovascular therapy (EVT)|Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
214574409|NCT03696797|PROCEDURE|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
214574410|NCT03696797|PROCEDURE|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
214574411|NCT05397691|OTHER|Modified Family Talk|The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
214721998|NCT05223686|DRUG|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
214574412|NCT05397691|OTHER|Control-like parameter estimation|Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
214574413|NCT03877497|BEHAVIORAL|Adapted SBIRT-T for transgender women|Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
214574414|NCT05436990|DRUG|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
214574415|NCT05119179|DRUG|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
214574416|NCT06405568|BEHAVIORAL|Physical activity intervention|Participants will receive a copy of physical activity (PA) recommendations plus a PA motivation package - namely three 20-minute online webinars (explaining PA benefits and how to get started), digitized PA materials (integrating evidence-based behaviour change tools, and a digitized logbook (to track PA).
214574417|NCT05594706|OTHER|Measurement of blood levels of 1,5-anhydroglucitol|Measurement of blood levels of 1,5-anhydroglucitol
214574418|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
214574419|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at HCG|Ultrasound
214574420|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
214574421|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
214574422|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at HCG|Ultrasound
214574423|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at TVOR|Ultrasound
214574424|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at ET|Ultrasound scan
214574425|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at coordination scan|Ultrasound scan
214574426|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at HCG|Ultrasound scan
214574427|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at TVOR|Ultrasound scan
214574428|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at ET|Ultrasound scan
214574429|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at coordination scan|Ultrasound scan
214574430|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at HCG|Blood test
214574431|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at TVOR|Blood test
214574432|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at ET|Blood test
214574433|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at coordination scan|Blood test
214574434|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between TVOR and ET|Ultrasound scan
214574435|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at HCG|Blood test
214574436|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at TVOR|Blood test
214574437|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at ET|Blood test
214574438|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at coordination scan|Blood test
214574439|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at HCG|Ultrasound scan
214574440|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
214574441|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at ET|Ultrasound scan
214574442|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
214574443|NCT03860636|DIAGNOSTIC_TEST|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
214574444|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
214574445|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between HCG and ET|Ultrasound scan
214574446|NCT06115603|DRUG|Cannabigerol|1 mL of 80mg Cannabigerol once during experimental session
214574447|NCT06115603|OTHER|Placebo|1 mL of placebo once during experimental session
214721999|NCT00492895|DRUG|Discontinuation of Azathioprin|Discontinuation of Azathioprin
214722000|NCT00251849|DRUG|Rifalazil|
214722001|NCT04350918|DEVICE|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
214574448|NCT00673010|RADIATION|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
214574449|NCT05284695|PROCEDURE|Bariatric surgery|Patients undergoing elective bariatric surgery
214574450|NCT06649331|DRUG|SHR-A1811|A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
214574451|NCT06649331|DRUG|SHR-A1921|A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
214574452|NCT06649331|DRUG|SHR-A2009|A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
214574453|NCT06649331|DRUG|SHR-A2102|A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
214574454|NCT05339386|DRUG|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
214574455|NCT01305200|DRUG|supersaturated calcium phosphate rinse|Mouth rinse
214574456|NCT01305200|OTHER|placebo|Mouth rinse
214574457|NCT01305200|OTHER|questionnaire administration|Ancillary studies
214574458|NCT01305200|PROCEDURE|quality-of-life assessment|Ancillary studies
214574459|NCT06605846|OTHER|otago excercises|"Otago training is helpful, and one of the most powerful interventions where the original randomized controlled trials reported improvements in functional outcomes and a 35% reduction in falls for frail, high-risk older adults (Shubert et al., 2018). In Egypt, there are little researches about Otago Exercise Program.~Exercise is well-known as an economic and key adjuvant treatment in clinical oncology that improves QOL of cancer survivors. Many studies focused on investigating the benefits of exercise interventions on preventing falls and improving physical performance of older adults. Combination of strength and functional balance exercise has been demonstrated as an effective method to improve balance performance, rather than strength training alone"
214574460|NCT06605846|OTHER|Medical ADT treatment|Medical ADT treatment according to patient age, prostatic cancer stage
214574461|NCT04210440|PROCEDURE|Core decompression procedure|Core Decompression with Bone Chips Allograft adjuvanted by Fibrin Platelet Rich-plasma (PRP) and Concentrated Autologous Mesenchymal Stromal Cells (MSCS), isolated from Bone Marrow
214574462|NCT04639297|DEVICE|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
214574463|NCT04639297|DEVICE|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
214574464|NCT04536870|DIAGNOSTIC_TEST|Echocardiography|Ultrasound of heart
214574465|NCT04536870|DIAGNOSTIC_TEST|ECG screening|Single lead ECG screening twice daily for two weeks
214574466|NCT04536870|DIAGNOSTIC_TEST|ECG Screening|12-lead ECG screening
214634206|NCT03124563|BEHAVIORAL|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
214634207|NCT07029009|DRUG|Liraglutide|Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.
214634208|NCT07132632|BEHAVIORAL|12-week multicomponent therapeutic exercise program including supervised and home-based sessions focused on strength, balance, mobility, and aerobic capacity|This intervention consists of a 12-week multicomponent therapeutic exercise program for older adults with mild to moderate frailty. Participants will complete 12 sessions (8 supervised in primary care and 4 home-based), each lasting approximately 60 minutes. Sessions include warm-up, strength exercises (using body weight or elastic bands), moderate aerobic activity (e.g., walking or pedaling), balance and coordination training (including dual tasks), and a cool-down phase. The program follows FITT-VP principles and is tailored to functional capacity. Intensity is monitored using the Borg scale (CR10 and RPE), estimated 1RM (20-80%), and 64-76% HRmax. Exercises are progressively adjusted in volume, intensity, and complexity. Home sessions are guided by an illustrated manual and reinforced by biweekly follow-up phone calls to promote adherence and safety. The intervention is aligned with international guidelines and aims to improve physical performance, reduce frailty and sarcopenia.
214574467|NCT05422404|PROCEDURE|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
214574468|NCT05422404|PROCEDURE|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
214574469|NCT04487704|OTHER|camrelizumab|camrelizumab 200 mg, intravenous infusion (no need for prophylactic administration), no less than 30 min ，No more than 60 min, one cycle every 2 weeks (14 days) or one cycle every 3 weeks (21 days). Try to complete the administration before the ECG
214574470|NCT00574756|DRUG|ranolazine|extended release 500 mg twice a day for two weeks
214574471|NCT02261259|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
214574472|NCT01107821|DEVICE|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
214574473|NCT03663491|PROCEDURE|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
214574474|NCT03663491|PROCEDURE|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
214574475|NCT03663491|PROCEDURE|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
214574476|NCT03663491|PROCEDURE|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
214574477|NCT00417105|PROCEDURE|hemodialysis|group 1: twice weekly, four hours
214574478|NCT00417105|PROCEDURE|hemodialysis|group 2: twice weekly, eight hours
214709558|NCT06796985|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management. The device will be used five times during the study. Each use will last approximately ten minutes.
214709559|NCT03201848|DRUG|Placebo|Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
214709560|NCT03201848|DRUG|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
214709561|NCT00003828|DRUG|vinorelbine|
214709562|NCT04578015|DRUG|Metronidazole|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
214709563|NCT04578015|DRUG|Placebo|Participants in this arm will receive placebo
214574479|NCT00417105|PROCEDURE|hemodialysis|group 3: every other day, eight hours
214709564|NCT01357980|BIOLOGICAL|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
214709565|NCT01357980|DRUG|Placebo|Intra detrusor injection on Day 1 (single dose)
214574480|NCT00417105|PROCEDURE|hemodialysis|group 4: six days a week, eight hours
214574481|NCT03871673|DIETARY_SUPPLEMENT|Sweet manioc starch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
214709566|NCT02528253|BIOLOGICAL|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
214709567|NCT02528253|BIOLOGICAL|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
214709568|NCT02528253|BIOLOGICAL|Tanezumab 5 mg SC|Tanezumab 5 mg SC
214709569|NCT02528253|BIOLOGICAL|Tanezumab 10 mg SC|Tanezumab 10 mg SC
214709570|NCT02528253|BIOLOGICAL|Tramadol PR oral|Tramadol PR oral
214709571|NCT03078023|DEVICE|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
214709572|NCT00523653|OTHER|blood test|looking at DNA
214709573|NCT05953571|PROCEDURE|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
214709574|NCT05220371|DIETARY_SUPPLEMENT|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
214574482|NCT03871673|DIETARY_SUPPLEMENT|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
214574483|NCT00094289|DRUG|Disulfiram|
214574484|NCT05499845|DIAGNOSTIC_TEST|butanol threshold test and smell identification tests|no additional intervention
214574485|NCT02321332|PROCEDURE|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
214574486|NCT02321332|PROCEDURE|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
214574487|NCT04573829|PROCEDURE|Home visit|Psychologist come once a week for the carer and three times a week for the patient
214574488|NCT06419400|BEHAVIORAL|Supportive text messages|The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency.
214574489|NCT00484133|DRUG|Dopamine|
214574490|NCT00484133|DRUG|dobutamine|
214574491|NCT00484133|DRUG|enoximone|
214574492|NCT00484133|DRUG|nitroglycerine|
214574493|NCT00484133|DRUG|noradrenaline|
214574494|NCT05269745|OTHER|Stretching through immobilisation (IG)|The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
214574495|NCT05269745|OTHER|Stretching through immobilisation and activity (IAG)|The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
214574496|NCT05269745|OTHER|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
214574497|NCT03093103|DRUG|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
214574498|NCT03093103|DRUG|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
214709575|NCT05220371|OTHER|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
214709576|NCT00406211|BIOLOGICAL|MMRV|
214574499|NCT01828632|PROCEDURE|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
214574500|NCT04041674|BIOLOGICAL|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
214574501|NCT04041674|BIOLOGICAL|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
214574502|NCT04041674|BIOLOGICAL|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
214574503|NCT04041674|BIOLOGICAL|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
214574504|NCT04041674|BIOLOGICAL|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
214574505|NCT03026699|BEHAVIORAL|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
214574506|NCT03026699|BEHAVIORAL|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
214574507|NCT00150865|DRUG|ropivacaine|
214574508|NCT06121167|DIAGNOSTIC_TEST|urinary partial oxygen pressure|arterial blood gas
214574509|NCT04075994|BEHAVIORAL|Relational Agent and heart rate and rhythm monitor|Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.
214574510|NCT04075994|BEHAVIORAL|Usual Care|Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
214574511|NCT06218160|DRUG|Hydromorphone combined with ropivacaine|1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
214574512|NCT06218160|DRUG|Ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
214574513|NCT05422664|DRUG|Lacosamide|Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
214574514|NCT04143958|DRUG|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
214574515|NCT04143958|DRUG|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
214574516|NCT02721667|DEVICE|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
214574517|NCT02721667|OTHER|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
214574518|NCT05518617|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,"
214574519|NCT05158816|PROCEDURE|ECMO|Patients undergoing extracorporeal membrane oxygenation
214574520|NCT01998503|DRUG|Bortezomib|
214574521|NCT01998503|DRUG|dexamethasone|Given orally
214574522|NCT01998503|BIOLOGICAL|filgrastim|Given subcutaneous
214574523|NCT01998503|PROCEDURE|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
214574524|NCT01998503|DRUG|Melphalan|
214574525|NCT04668430|OTHER|imaging and motion analysis|performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
214574526|NCT03510494|BEHAVIORAL|Augmented physical education program|Augmented physical education program
214574527|NCT03182192|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
214574528|NCT03803124|DRUG|Tolvaptan|1 tablet before renography
214574529|NCT03803124|DRUG|Placebo|1 tablet before renography
214574530|NCT01452373|DRUG|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
214574531|NCT01452373|DRUG|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
214574532|NCT01896323|DRUG|CC-223|CC-223 20 mg tablets
214574533|NCT01896323|DRUG|Ketoconazole|Ketoconazole 400 mg tablets
214574534|NCT02722642|BIOLOGICAL|Bronchial basal cells|Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
214574535|NCT04677829|BIOLOGICAL|PNT001|30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg
214574536|NCT04677829|BIOLOGICAL|%5 dextrose for infusion|30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg
214574537|NCT01141647|BEHAVIORAL|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
214574538|NCT05551533|OTHER|Kampung Care App|Please refer to the previous session
214574539|NCT02750982|OTHER|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
214574540|NCT04727892|PROCEDURE|epilepsy surgery|Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
214574541|NCT05416190|DIAGNOSTIC_TEST|Lupus anticoagulant testing|The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
214574542|NCT00371332|DRUG|Minocycline HCL Microspheres|
214574543|NCT04850794|BEHAVIORAL|Decision Support Tool|The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
214634209|NCT07132632|BEHAVIORAL|Placebo Pre-Treat|The pre-intervention period (Month 0 to Month 3) will serve as the control phase, during which participants will receive no specific exercise program. From Month 3 to Month 6, the intervention phase will begin. Participants act as their own control.
214574544|NCT04625387|OTHER|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
214574545|NCT02436473|DRUG|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
214574546|NCT02436473|OTHER|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
214574547|NCT02436473|DRUG|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
214574548|NCT02436473|DRUG|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
214709577|NCT00406211|BIOLOGICAL|MMR (Priorix®)|
214709578|NCT00406211|BIOLOGICAL|Varicella (Varilrix®)|
214709579|NCT02781350|OTHER|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
214574549|NCT00577876|PROCEDURE|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
214574550|NCT00816478|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
214574551|NCT04416373|DIAGNOSTIC_TEST|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
214574552|NCT01009151|BEHAVIORAL|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
214574553|NCT01009151|BEHAVIORAL|Heart Care Self Tracker|Web-based Home Tele-monitoring System
214574554|NCT06204874|PROCEDURE|Pulsed radiofrequency ablation|See left.
214574555|NCT06204874|PROCEDURE|Sham ablation|See left.
214574556|NCT03435354|BEHAVIORAL|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
214574557|NCT06419426|OTHER|Battery incidence|Incidence of batteries from negative Gram germs; Incidence of batteries from gram positive germs; Incidence of fungemie; Incidence of septic shock; Incidence of batteries from colonising germs; Incidence of resistance to the main classes of antibiotics
214574558|NCT05151705|DRUG|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
214574559|NCT05151705|DRUG|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
214574560|NCT05151705|DRUG|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
214709580|NCT02781350|DIETARY_SUPPLEMENT|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
214709581|NCT03994393|DRUG|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
214574561|NCT01941719|BEHAVIORAL|Enhanced foot care education|In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
214574562|NCT01941719|BEHAVIORAL|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
214574563|NCT02138084|DRUG|BMS-663068|BMS-663068
214574564|NCT02138084|DRUG|Rifabutin|Rifabutin
214574565|NCT02138084|DRUG|Ritonavir|Ritonavir
214574566|NCT01480219|DRUG|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
214574567|NCT01480219|OTHER|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
214574568|NCT01744392|BEHAVIORAL|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
214574569|NCT00851838|DRUG|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
214574570|NCT04024774|BIOLOGICAL|Biological samples|blood samples, urine samples, tissue samples
214574571|NCT04024774|GENETIC|Genetic test|anamnesis and NGS sequencing
214574572|NCT05631301|OTHER|Exercise Circuits|Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination
214574573|NCT05631301|BEHAVIORAL|Goal Setting|Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities
214574574|NCT05631301|BEHAVIORAL|Psychoeducation-Youth|Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.
214574575|NCT05631301|BEHAVIORAL|Psychoeducation-Caregiver|Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms
214574576|NCT05631301|OTHER|Waitlist Control Surveys|Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
214574577|NCT00334672|BIOLOGICAL|anti-thymocyte globulin|
214574578|NCT00334672|DRUG|busulfan|
214574579|NCT00334672|DRUG|cyclophosphamide|
214574580|NCT00334672|DRUG|cyclosporine|
214574581|NCT00334672|DRUG|dexamethasone|
214574582|NCT00334672|DRUG|etoposide|
214574583|NCT00334672|DRUG|methotrexate|
214574584|NCT00334672|DRUG|mycophenolate mofetil|
214574585|NCT00334672|DRUG|therapeutic hydrocortisone|
214574586|NCT00334672|OTHER|laboratory biomarker analysis|
214574587|NCT00334672|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214574588|NCT00334672|PROCEDURE|biopsy|
214634210|NCT06877234|PROCEDURE|Ultrasonic Nerve Ablation System|Treatment of patients with essential hypertension using the ultrasonic nerve ablation system
214574589|NCT03253445|BEHAVIORAL|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
214574590|NCT03253445|OTHER|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
214574591|NCT04406506|DEVICE|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
214574592|NCT04406506|DEVICE|nasojejunal|"* The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~* Patients were placed in right lateral position"
214574593|NCT04406506|DRUG|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
214574594|NCT04037657|DRUG|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
214574595|NCT04037657|DRUG|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
214574596|NCT04650542|DRUG|HBI-3000|small molecule, multi-ion channel blocker
214574597|NCT04650542|DRUG|Paroxetine|serotonin uptake inhibitor, CYP2D6 inhibitor
214574598|NCT00254046|DRUG|TMC125|2 X100 mg tablets b.i.d.96 weeks
214574599|NCT00254046|DRUG|Placebo|2 tablets b.i.d.96 weeks
214574600|NCT00151580|DRUG|Ribavirin|18 months of oral ribavirin maintenance treatment
214574601|NCT00151580|DRUG|Placebo|18 months oral placebo treatment
214574602|NCT03992131|DRUG|Rucaparib|Rucaparib will be administered per schedule specified in the arm description.
214574603|NCT03992131|DRUG|Lucitanib|Lucitanib will be administered per schedule specified in the arm description.
214574604|NCT03992131|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered per schedule specified in the arm description.
214574605|NCT05653102|DEVICE|Truliant Total Knee System|Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
214574606|NCT04864262|OTHER|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
214574607|NCT02512640|PROCEDURE|Volume-controlled ventilation|a tidal volume of 8 ml/kg
214574608|NCT02512640|PROCEDURE|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
214574609|NCT00858364|DRUG|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
214574610|NCT00858364|DRUG|Placebo|Administered subcutaneously once every 3 weeks
214574611|NCT05833490|OTHER|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at \~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
214574612|NCT05833490|OTHER|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
214574613|NCT00418340|DRUG|probiotic (bacterial/dietary supplement)|
214574614|NCT01729442|OTHER|Shear-wave ultrasound elastography (SWUE)|
214574615|NCT01971801|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Capsule given by mouth once a week
214574616|NCT01971801|OTHER|Placebo|One capsule given by mouth weekly
214574617|NCT02850289|DRUG|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
214574618|NCT02850289|DRUG|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
214574619|NCT00214552|DRUG|rabeprazole|
214574620|NCT02680990|BEHAVIORAL|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
214574621|NCT02680990|OTHER|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
214574622|NCT05485545|OTHER|Electrophysiological exploration of the right ventricle|"* CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI"
214574623|NCT00157508|DRUG|nitroaspirin|
214574624|NCT03980808|BEHAVIORAL|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
214574625|NCT03980808|BEHAVIORAL|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
214574626|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
214574627|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
214574628|NCT01655693|DRUG|Doxorubicin 20 mg/m2|
214574629|NCT01655693|DRUG|Doxorubicin 30 mg/m2|
214574630|NCT01655693|DRUG|Best Standard of Care|
214574631|NCT05521815|OTHER|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
214574632|NCT05521815|OTHER|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
214574633|NCT02741323|DRUG|Maraviroc|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
214574634|NCT02741323|DRUG|Placebo|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
214574635|NCT04602559|DEVICE|MOBIDERM Panty group|"In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance)."
214574636|NCT01637948|DRUG|Listerine mouthrinse|For six months
214709582|NCT03994393|DRUG|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
214709583|NCT00838721|OTHER|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
214574637|NCT01637948|DRUG|Chinese Medicine mouthrinse|six months
214574638|NCT00357331|DRUG|potassium citrate|20 meq by mouth in capsule form twice daily
214574639|NCT04348253|PROCEDURE|Berger|Treatment 1
214574640|NCT04348253|PROCEDURE|3LT|Treatment 2
214574641|NCT02904070|DEVICE|Vaginal swabbing|
214574642|NCT02604888|OTHER|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
214574643|NCT03189459|BEHAVIORAL|Home Visit Program|RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
214574644|NCT03189459|BEHAVIORAL|Caregiver Mentorship Program|"Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor"
214574645|NCT06263127|BEHAVIORAL|oral stimulation|Prefeeding OS is a 5-minute oral sensorimotor intervention, containing peri- and intra-oral stimulation for 3 minutes and pacifier sucking for 2 minutes.
214574646|NCT06263127|BEHAVIORAL|infants massage|IM is a 15-minute intervention, involving 5-min manual stroking on the infant's head, neck, back, upper limbs, and lower limbs twice and 5-min gentle flexion and extension exercises on the infant's arms and legs.
214574647|NCT00225823|DRUG|GW685698X|
214709584|NCT00393068|DRUG|Erlotinib|Erlotinib
214574648|NCT04220619|DIAGNOSTIC_TEST|Tranesophageal Echocardiography|RescueTEE during ACLS versus Conventional ACLS
214709585|NCT00393068|DRUG|Bevacizumab|Bevacizumab
214709586|NCT00393068|DRUG|Paclitaxel|Paclitaxel
214709587|NCT00393068|DRUG|Carboplatin|Carboplatin
214709588|NCT00393068|DRUG|5-FU|5-FU
214574649|NCT01756378|PROCEDURE|joint mobilization with movement|
214574650|NCT01756378|PROCEDURE|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
214574651|NCT01240187|DRUG|perampanel|Single dose of 6 tablets 2 mg orally
214574652|NCT01240187|DRUG|perampanel|Single dose of 1 tablet 12 mg orally
214574653|NCT03993600|DIAGNOSTIC_TEST|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects"
214709589|NCT00393068|PROCEDURE|Radiation therapy|Radiation therapy
214709590|NCT00393068|PROCEDURE|Surgery|Surgery
214709591|NCT02293993|DRUG|SGI-110|
214722002|NCT04350918|DEVICE|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
214722003|NCT03474237|OTHER|Hormone study and Imaging study|"1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging"
214722004|NCT02748785|DRUG|Methotrexate|Methotrexate will be continued
214722005|NCT02748785|BIOLOGICAL|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
214722006|NCT02572089|DRUG|Naloxone|
214574654|NCT00929110|DRUG|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214574655|NCT00929110|DRUG|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214574656|NCT00929110|DRUG|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
214574657|NCT02416960|OTHER|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
214574658|NCT02416960|OTHER|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
214574659|NCT00236379|DRUG|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
214574660|NCT00236379|DRUG|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
214574661|NCT06525714|DRUG|cisplatin oxaliplatin tegafur|Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg/m2 cisplatin at 43°C, with an infusion rate of 600 ml/min for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg/m2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \<1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \>1.5m2, 60 mg bid) from day 1 to 14.
214574662|NCT02757690|DEVICE|3-dimensional distal pancreatectomy|3D laparoscopy
214574663|NCT02757690|DEVICE|2-dimensional distal pancreatectomy|2D laparoscopy
214574664|NCT04385381|DEVICE|URECA CTO device|facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
214574665|NCT04642313|OTHER|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
214574666|NCT00701857|DRUG|cisplatin|Standard weekly dose
214574667|NCT00701857|DRUG|Pemetrexed|Biweekly pemetrexed dose escalation
214574668|NCT00701857|RADIATION|radiation therapy|Weekly standard dose radiation therapy
214574669|NCT00647933|DRUG|Org 36286|Subcutaneous Org 36286
214574670|NCT00647933|DRUG|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
214574671|NCT02199223|DRUG|regorafenib + panitumumab|
214574672|NCT03501602|DEVICE|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
214574673|NCT03501602|DEVICE|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
214574674|NCT02942524|OTHER|Communication Intervention|Complete TEPID
214574675|NCT02942524|OTHER|Questionnaire Administration|Ancillary studies
214574676|NCT02942524|OTHER|Survey Administration|Ancillary studies
214574677|NCT01226342|DEVICE|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
214574678|NCT04671966|DRUG|Estradiol patch|Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
214634211|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7, 14 and 28, total 5 doses"
214722007|NCT00269295|BIOLOGICAL|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
214574679|NCT04671966|DRUG|Cetrotide|Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
214574680|NCT04671966|OTHER|Fasting|Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
214574681|NCT04671966|OTHER|Lower Body Negative Pressure|This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
214574682|NCT03975751|DIAGNOSTIC_TEST|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
214574683|NCT00412152|DRUG|Oxycodone nalaxone prolonged release tablets (OXN)|
214574684|NCT05084170|PROCEDURE|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
214574685|NCT02703259|DRUG|Gabapentin|
214574686|NCT02703259|DRUG|Acetaminophen|
214574687|NCT02703259|DRUG|Celecoxib|
214722008|NCT00269295|DRUG|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
214574688|NCT06270706|DRUG|PLN-101095|PLN-101095
214574689|NCT06270706|DRUG|Pembrolizumab|Pembrolizumab
214574690|NCT02682277|DEVICE|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
214574691|NCT02682277|OTHER|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
214722009|NCT00726492|OTHER|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
214722010|NCT00726492|OTHER|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
214574692|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Lumenless leads|Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
214574693|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Stylet-driven leads|Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE \& Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
214574694|NCT03451682|DIETARY_SUPPLEMENT|procyanidine|Natural antioxidant
214574695|NCT04573348|DIAGNOSTIC_TEST|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
214574696|NCT00002003|DRUG|Mitoxantrone hydrochloride|
214574697|NCT00002003|DRUG|Etoposide|
214574698|NCT03863873|PROCEDURE|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
214574699|NCT03090139|DRUG|Anti-TNF Therapy|Anti-TNF therapy.
214574700|NCT02666859|DEVICE|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
214574701|NCT04206202|DEVICE|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
214574702|NCT02311231|DRUG|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
214574703|NCT02311231|DRUG|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
214574704|NCT04138264|OTHER|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
214574705|NCT02615002|DRUG|Piromelatine|
214574706|NCT02615002|DRUG|Placebo|
214574707|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
214574708|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
214574709|NCT06352684|DEVICE|CadAI-B for Breast|CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.
214574710|NCT03678428|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
214574711|NCT03678428|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
214574712|NCT03678428|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
214574713|NCT03678428|DRUG|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
214574714|NCT03678428|DRUG|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
214574715|NCT03678428|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
214574716|NCT05769712|DIAGNOSTIC_TEST|Shear wave ultrasonic imaging|Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.
214574717|NCT05176041|OTHER|Naser Al-Husban|observation
214574718|NCT05308797|PROCEDURE|ESP block|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
214574719|NCT05308797|PROCEDURE|CASP block|Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
214574720|NCT04670289|DRUG|TenoMiR (Low Dose)|Mimic of miR29a
214574721|NCT04670289|DRUG|TenoMiR (Medium Dose)|Mimic of miR29a
214574722|NCT04670289|DRUG|TenoMiR (High Dose)|Mimic of miR29a
214574723|NCT04670289|DRUG|Placebo|0.9% saline
214574724|NCT02920580|PROCEDURE|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
214574725|NCT02920580|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
214574726|NCT04835350|DEVICE|Pancreas4ALL - meal announcement or full closed loop|Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
214574727|NCT05465447|DEVICE|subjective refraction|Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
214574728|NCT01834872|DEVICE|Amigo|
214574729|NCT01834872|DEVICE|Manual ablation|
214574730|NCT02408601|OTHER|Helioseal - F|"Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepeted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion"
214574731|NCT02408601|OTHER|ART sealant|"Fuji IX extra strength~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes."
214574732|NCT00918892|GENETIC|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
214574733|NCT00918892|OTHER|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
214574734|NCT00918892|OTHER|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
214574735|NCT00817700|OTHER|Sleep restriction|Sleep restriction.
214574736|NCT04559763|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
214574737|NCT04559763|OTHER|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
214574738|NCT01182883|DRUG|IMC-A12|
214574739|NCT01182883|DRUG|Temsirolimus|
214574740|NCT02935660|DEVICE|enLighten Laser|Laser tattoo removal treatment
214574741|NCT02642263|DRUG|Carbetocin|Postpartum uterotonic drug
214574742|NCT00400127|DEVICE|Silesian suspension belt|
214574743|NCT04714749|PROCEDURE|Endovenous treatment|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
214574744|NCT04714749|DEVICE|Cyanoacrylate glue|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
214574745|NCT00935727|OTHER|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
214574746|NCT03277092|DEVICE|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
214574747|NCT03277092|PROCEDURE|Usual care|The blood drawing is performed traditionally
214574748|NCT04305717|DEVICE|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
214574749|NCT01109927|DRUG|Insulin|Insulin treatment in accordance to glucose values
214574750|NCT04012476|DRUG|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
214574751|NCT05842772|OTHER|Shared decision making intervention for patients with kidney failure when planning end-of-life care|Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
214574752|NCT05517187|OTHER|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
214574753|NCT05517187|BIOLOGICAL|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
214574754|NCT06218862|DRUG|Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.
214574755|NCT06218862|DRUG|Control|Not use Sivelestat sodium
214722011|NCT02410746|OTHER|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
214574756|NCT02802189|OTHER|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles"
214574757|NCT02802189|OTHER|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~* Upper border of the trapezius muscle~* sternocleidomastoid~* levator scapulae muscle~* splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~* Ischemic compression~* Muscle energy technique~* Strain-counterstrain technique"
214574758|NCT02296723|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
214634212|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 14, total 4 doses"
214634213|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 28, total 4 doses"
214634214|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 2 dose on day 0, 1 dose on day 7 and 21, total 4 doses"
214574759|NCT01827995|OTHER|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
214574760|NCT01827995|OTHER|Routine assessment|Follow up in the clinic
214574761|NCT02293213|BEHAVIORAL|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
214574762|NCT02293213|BEHAVIORAL|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
214574763|NCT02293213|BEHAVIORAL|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
214574764|NCT02293213|BEHAVIORAL|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
214574765|NCT02293213|BEHAVIORAL|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
214574766|NCT02293213|BEHAVIORAL|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
214574767|NCT03111459|DEVICE|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
214574768|NCT01462032|BEHAVIORAL|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
214574769|NCT01462032|BEHAVIORAL|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
214574770|NCT02807818|BEHAVIORAL|Home visiting Program for Young Pregnant Women|
214574771|NCT00182559|DRUG|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
214574772|NCT00182559|DRUG|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
214574773|NCT02925598|DEVICE|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
214574774|NCT02925598|DEVICE|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
214574775|NCT02925598|DEVICE|ETT insertion|'ETT insertion' was done following anesthesia induction.
214574776|NCT00294606|DRUG|Comparison of Effects of Phenylephrine and Norepinephrine|
214574777|NCT02285153|DRUG|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
214574778|NCT02285153|DRUG|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
214574779|NCT02155751|BEHAVIORAL|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
214574780|NCT02155751|BEHAVIORAL|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
214574781|NCT00939159|DRUG|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
214574782|NCT02544451|DRUG|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
214574783|NCT02544451|DRUG|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
214574784|NCT03815682|BIOLOGICAL|Arm A: RPTR-147:1|Escalating doses of RPTR-147:1 as a monotherapy
214574785|NCT03815682|BIOLOGICAL|Arm B: RPTR-147:1 and Pembrolizumab|Escalating doses of RPTR-147:1 in combination with Pembrolizumab
214574786|NCT03815682|BIOLOGICAL|Arm C: RPTR-147:2|Escalating doses of RPTR-147:2 in patients with HPV positive tumors
214574787|NCT04549896|PROCEDURE|CT scan|Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.
214722012|NCT02410746|OTHER|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
214574788|NCT04549896|PROCEDURE|No CT scan|The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
214574789|NCT04306406|OTHER|Raspberries|Red raspberry smoothies drink
214574790|NCT00085462|BIOLOGICAL|aldesleukin|
214574791|NCT00085462|BIOLOGICAL|filgrastim|
214574792|NCT00085462|BIOLOGICAL|gp100-fowlpox vaccine|
214574793|NCT00085462|BIOLOGICAL|therapeutic autologous lymphocytes|
214574794|NCT00085462|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214574795|NCT00085462|DRUG|cyclophosphamide|
214574796|NCT00085462|DRUG|fludarabine phosphate|
214574797|NCT04363034|BIOLOGICAL|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
214574798|NCT02888873|OTHER|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
214574799|NCT02888873|OTHER|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
214574800|NCT04642300|PROCEDURE|Holmich Protocol|"Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board"
214574801|NCT04642300|PROCEDURE|Myofascial Release Technique|"1. Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~2. Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique"
214574802|NCT00526500|BEHAVIORAL|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
214574803|NCT05068141|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
214574804|NCT05068141|DRUG|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
214574805|NCT01472549|DRUG|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
214574806|NCT01472549|DRUG|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
214722013|NCT02410746|OTHER|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
214722014|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of multiple IVT injection
214574807|NCT00998790|DEVICE|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
214574808|NCT01979627|PROCEDURE|transulnar approach interventional procedure|
214574809|NCT01979627|PROCEDURE|transradial approach interventional procedure|
214574810|NCT01303029|DRUG|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
214574811|NCT01303029|DRUG|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
214574812|NCT02554227|OTHER|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
214574813|NCT02417519|OTHER|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
214574814|NCT02417519|OTHER|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
214722015|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of single IVT injection
214722016|NCT05489718|BIOLOGICAL|IBI324|Dose 1 IBI324 of single IVT injection
214574815|NCT02417519|OTHER|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
214574816|NCT02555852|DRUG|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
214574817|NCT02555852|DRUG|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
214574818|NCT02555852|DRUG|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
214574819|NCT02555852|DRUG|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
214709592|NCT06046547|OTHER|Pulmonary rehabilitation integrating education about palliative care|"PR will include exercise training twice a week, and education and psychosocial support once per week during 12 weeks.~The intervention will include an education session on palliative care, a Peer-to-peer session, a Get-apart session and online sessions.~The education session on palliative care will be facilitated by two specialist healthcare professionals. The main topics that will be discussed are: concept of palliative care, symptom control, disease impact, psychosocial support and planning for the future.~Participants will be the primary communicators in the Peer-to-peer session, and the dialogue will be based on their suggestions. Those who feel more reluctant to reveal private thoughts in front of their loved ones will have the opportunity to discuss their issues in a Get-apart environment.~Individual cases will be referred to a specialist palliative care team or to any other health/social care professional according to the unmet needs identified."
214709593|NCT06046547|OTHER|Pulmonary rehabilitation|"Participants will receive the same PR program as the experimental group besides the education session on palliative care, the Peer-to-peer session, the Get-apart session and the online sessions (i.e. traditional pulmonary rehabilitation)."
214574820|NCT02555852|DRUG|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
214574821|NCT02555852|DRUG|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
214574822|NCT02555852|DRUG|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
214574823|NCT02555852|DRUG|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
214574824|NCT02555852|DRUG|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
214574825|NCT02555852|DRUG|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
214574826|NCT02555852|DRUG|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
214574827|NCT02555852|DRUG|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
214574828|NCT02555852|DRUG|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
214574829|NCT02555852|DRUG|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
214709594|NCT04849910|BIOLOGICAL|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
214709595|NCT04849910|DRUG|Mylotarg|Infusion of Mylotarg
214709596|NCT06641765|DEVICE|Continous Glucose Monitoring|10 days of real time open access to Continous Glucose Monitoring - either at defined time intervals (Group 2) or continuously for 9 months (Group 3).
214709597|NCT00094835|BIOLOGICAL|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
214709598|NCT00094835|DRUG|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
214709599|NCT00094835|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
214574830|NCT02555852|DRUG|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
214574831|NCT01489891|DRUG|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
214574832|NCT01489891|DRUG|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
214574833|NCT02316951|DEVICE|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
214574834|NCT02976571|DRUG|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
214574835|NCT01369771|DRUG|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
214574836|NCT06113887|OTHER|psychoeducation based on acceptance and commitment therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
214574837|NCT02148640|DRUG|Innovator infliximab|
214574838|NCT02148640|DRUG|Biosimilar infliximab|
214574839|NCT03581760|OTHER|Cycling Exercise|Cycling exercise will be performed in the patients once a day.
214574840|NCT03581760|OTHER|Conventional Physiotherapy|Conventional physiotherapy will be performed in the patients twice a day.
214574841|NCT04662853|DIAGNOSTIC_TEST|Gut microbiota determination from feces samples.|Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
214574842|NCT03001076|DRUG|Bempedoic acid|bempedoic acid 180 mg tablet
214574843|NCT03001076|DRUG|Ezetimibe|ezetimibe 10 mg tablet
214574844|NCT03001076|OTHER|Placebo|matching placebo tablet
214574845|NCT02823405|DRUG|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
214574846|NCT02823405|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
214574847|NCT06200129|DIAGNOSTIC_TEST|sws grade 1|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 1.
214574848|NCT06200129|DIAGNOSTIC_TEST|sws grade 2|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 2
214574849|NCT06200129|DIAGNOSTIC_TEST|control|Group of patients without scattered white lesions in the dueodenum on endoscopy.
214574850|NCT00095420|BEHAVIORAL|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
214574851|NCT00095420|BEHAVIORAL|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
214574852|NCT00095420|BEHAVIORAL|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
214574853|NCT00095420|BEHAVIORAL|Usual training|Participants will receive the usual training offered in their local school districts.
214574854|NCT01712945|DRUG|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
214574855|NCT01712945|DRUG|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
214574856|NCT04072692|OTHER|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
214574857|NCT04072692|OTHER|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
214574858|NCT04072692|OTHER|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
214574859|NCT04802616|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
214574860|NCT04802616|DRUG|Placebo|Matched tablets without any active substance.
214574861|NCT05599841|PROCEDURE|PI solution|3,000 cc of \<2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
214574862|NCT05599841|PROCEDURE|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
214574863|NCT00156689|DRUG|levetiracetam|
214574864|NCT00601159|DRUG|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
214574865|NCT05253287|DRUG|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
214574866|NCT00100087|DEVICE|Ocular Brachytherapy|
214574867|NCT03374527|OTHER|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
214574868|NCT03374527|PROCEDURE|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
214634215|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Chengdu Kanghua Biological Products Co., LTD Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection~Receive 1 dose on day 0, 3, 7, 14and 28, total 5 doses"
214574869|NCT06058312|OTHER|Self-questionnaire|The self-administered questionnaires to be completed at the time of inclusion will be presented to the patient on a tablet during the inclusion visit and will be completed on the same day in the Day Hospital using the Compusense software. Online self-questionnaires and sensory tests at the 9th week of treatment will also be conducted using the Compusense software in small groups at a designated location within the center.
214574870|NCT06058312|OTHER|Self-questionnaire|The MediLite questionnaire consists of nine items that assess daily consumption of fruits, vegetables, grains, meats and meat products, dairy products, alcohol, and olive oil, as well as weekly consumption of legumes and fish.
214574871|NCT06058312|OTHER|Self-questionnaire|"The CITAS is a self-administered questionnaire consisting of 18 items evaluated on a five-point Likert scale and divided into three dimensions: 1) quantitative changes in taste perception (hypogeusia and ageusia), 2) qualitative changes in taste perception (heterogeusia, cacogeusia), and 3) nutrition-related problems (difficulty eating hot or fatty foods).~Using a Likert scale ranging from 1 to 5 (where 1 = no difficulty or absence of disturbance and 5 = maximum difficulty or disturbance), CITAS assesses the four dimensions of taste disturbances: taste intensity, discomfort, phantogeusia, and parageusia, as well as overall taste alterations.~For the original version by Kano and Kanda (2013), five items assessing changes in smell from the modified CITAS version by Drareni et al. 2021 will be added in this study."
214574872|NCT06058312|OTHER|Self-questionnaire|"Food neophobia will be assessed using the Food Neophobia Scale (FNS) developed by Pliner \& Hobden (1992). The FNS consists of ten statements evaluated on a 7-point agreement scale ranging from 1 = I strongly disagree to 7 = I strongly agree. Individual FNS scores are calculated as the sum of the ratings given to the ten statements after reversing the neophilic items; thus, scores theoretically range from 10 to 70, with higher scores reflecting higher levels of food neophobia."
214574873|NCT06058312|OTHER|Self-questionnaire|The quality of life related to food in cancer patients is composed of 46 items with a 4-point scale (never, almost never, almost always, always). The questionnaire is divided into different subdomains: Cooking, where one eats and conviviality, Eating and drinking, After eating.
214574874|NCT06058312|OTHER|Self-questionnaire|Individual baseline disgust sensitivity is assessed using the Disgust Sensitivity-Short Form (DS-SF) questionnaire; this questionnaire is a shortened version of the disgust scale aimed at measuring disgust of animal origin, based on contamination and revulsion (Haidt, 2004; Haidt et al., 1994; Inbar, Pizarro, and Bloom, 2009; Olatunji et al., 2007). This measure consists of 8 items divided into 2 parts. In the first part, statements were rated on a scale from 1 (not at all agree-very false about me) to 5 (completely agree-very true about me); for the second part, additional statements were rated from 1 (not at all disgusting) to 5 (extremely disgusting). The total disgust sensitivity score is obtained by summing the scores after two items have been reversed and ranges from 8 to 40.
214574875|NCT06058312|OTHER|Self-questionnaire|The subscale of reward sensitivity from the short version of reward and punishment sensitivity has been selected (17 items). Each item will be assessed on a 4-point Likert scale, ranging from 1 (completely no) to 4 (completely yes).
214574876|NCT06058312|OTHER|Self-questionnaire|"The EmoPrefMed questionnaire was developed to measure declared appreciation and emotional responses to selected Mediterranean diet (RM) products and changes in appreciation before and after chemotherapy.~The assessment of the acceptability of a series of RM foods (listed in the questionnaire appendix) will be evaluated using a nine-point hedonic scale ranging from a minimum of 1 = I don't like it at all to a maximum of 9 = I like it a lot (Peryam \& Pilgrim, 1957).~Emotions will be assessed using a check-all-that-apply (CATA) list of emotions, including 4 negative and 4 positive emotions with low, moderate, and high arousal levels (It brings me joy, It intrigues me, It relaxes me, It annoys me, It leaves me indifferent, It makes me sad, It's monotonous, It disgusts me). Patients will be asked to select all the emotions they deem appropriate to describe the food product."
214634216|NCT02447588|OTHER|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
214634217|NCT02447588|OTHER|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
214709600|NCT00094835|DRUG|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
214634218|NCT07039396|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214634219|NCT06926621|DRUG|VX-670|Solution for intravenous administration.
214634220|NCT07049692|OTHER|Hyperbaric Oxygen Therapy|1.6 atmosphere absolute (1.6 ATA), HBO treatment administrated via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
214574877|NCT06058312|OTHER|Self-questionnaire|"Food-related attitudes will be measured using the HTAS (Health and Taste Attitude Scale) proposed by Roininen et al. (1999), consisting of six subscales focusing on perceived health and taste aspects of foods. The two scales selected in this study are general interest in health (eight items, measuring overall interest in a healthy diet) and the use of food as a reward (six items, measuring attitudes towards using food as a reward). Each subscale consists of an equal number of statements phrased positively and negatively (Roininen et al., 1999). All items were rated on a seven-point category scale, ranging from strongly disagree to strongly agree. As suggested by Roininen et al. (1999), negative statements were reversed and recoded for the calculation of final scores."
214574878|NCT06058312|OTHER|Self-questionnaire|"The response to PROP (6-n-propyl-2-thiouracil) is measured using 1.5 cm diameter paper disks previously soaked in a solution of deionized water with a concentration of 3.2 mM PROP, dissolving 0.5477 g/L of PROP. Each paper disk will contain approximately 0.280 mg of PROP. Participants are asked to place the paper disk on the tip of their tongue for 20 seconds, then remove it and assess the perceived bitter intensity on a Labelled Magnitude Scale (LMS).~The LMS scale consists of a vertical line of 100 units with labels placed at no sensation, 0; barely detectable, 1.4; weak, 6; moderate, 17; strong, 34.7; very strong, 52.5; and the strongest imaginable sensation of any kind, 100. Numeric labels are not reported on the scale. Participants are instructed to think of the strongest imaginable sensation as the most intense sensation they can imagine in the realm of taste. Participants are encouraged to ask questions about the use of the scale if they need more clarification."
214574879|NCT06058312|OTHER|Self-questionnaire|The odors (Mint, Anise, Banana, Pine, Garlic, Cinnamon, Lemon) are trapped in tightly packed microcapsules (aminoplast type, diameter: 4-8 μm). Microcapsule-based ink is printed on cardboard paper (SILK-250 g; Size: 11 cm × 21 cm). Each odorant has been printed in a defined area (2 cm in diameter). The odor is released by simply rubbing the printed microcapsule reserve (scratch-and-sniff method).Patients receive a disposable single-use sample and are asked to identify the odors and evaluate on a visual analog scale the perceived intensity, perceived irritation, and appreciation of each odor.
214574880|NCT06058312|OTHER|Self-questionnaire|"Two model foods were developed to investigate responses to variations in sweetness, acidity, and freshness. The first range consists of Apple-Mint Juice, composed of four samples containing different concentrations of mint syrup (0, 15, 60, 240 g/kg). The second range is a chickpea mousse made up of four samples containing different quantities of citric acid and glucose-fructose syrup (glucose-fructose syrup: 0, 50, 100, 200 g/kg; citric acid: 8, 6, 4, 4 g/kg). Participants are asked to evaluate the samples using the Labelled Affective Magnitude Scale. Regarding the LAM scale, subjects are instructed to consider the extremes of appreciation, the best I can imagine and the worst I can imagine. After a break, they are asked to taste the samples again and rate the intensity of sweetness, acidity, apple flavor, mint flavor, and freshness on the Labeled Magnitude Scale: from 'not detectable' to 'the strongest imaginable'."
214709601|NCT06565325|BEHAVIORAL|Exercise + Audible Cues|Combined Terminal Knee Extension Exercise with Audible Cues
214709602|NCT06565325|BEHAVIORAL|Exercise|Terminal Knee Extension Exercise
214574881|NCT05187143|DEVICE|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
214574882|NCT04831918|DEVICE|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
214709603|NCT00734812|PROCEDURE|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
214574883|NCT04463966|DRUG|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
214574884|NCT00229138|DRUG|EC-MPS, Tacrolimus|
214574885|NCT05087901|DIAGNOSTIC_TEST|Multifocal electroretinogram|A device that records electric potentials generated by the retinal photoreceptors and neural elements in a multifocal fashion
214574886|NCT01327443|BEHAVIORAL|Weight loss|Nutritional counseling
214574887|NCT01327443|BEHAVIORAL|Exercise|Under direct supervision
214574888|NCT00948766|DRUG|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.
214574889|NCT00948766|DRUG|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.
214574890|NCT00948766|DRUG|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.
214574891|NCT00948766|DRUG|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
214574892|NCT02505438|BEHAVIORAL|Exercise|
214574893|NCT04394468|DEVICE|PlasmaJet|Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
214574894|NCT02810587|DRUG|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
214709604|NCT00734812|PROCEDURE|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
214574895|NCT04469127|DRUG|Lutetium-177-DOTAGA-IAC|Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.
214574896|NCT00841555|DRUG|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
214574897|NCT00841555|RADIATION|Hypofractionated radiation therapy|Patients will undergo HIMRT
214709605|NCT04019210|PROCEDURE|MODIFIED TRABECULECTOMY|Rectangular scleral flap
214709606|NCT01573403|DRUG|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
214709607|NCT01573403|DRUG|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
214709608|NCT01573403|DRUG|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
214709609|NCT04048629|DEVICE|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
214709610|NCT04048629|OTHER|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
214709611|NCT05461183|OTHER|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
214709612|NCT03690947|DRUG|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
214709613|NCT03690947|PROCEDURE|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
214574898|NCT00841555|RADIATION|Intensity-modulated radiation therapy|Patients undergo HIMRT
214574899|NCT02235389|DRUG|Alteplase (Actilyse)|
214574900|NCT02235389|DRUG|Standard therapy|
214574901|NCT04937972|DRUG|SHR-1701 Combined With Fluazopalil|SHR-1701 +fluzoparib
214574902|NCT03803839|DRUG|Clodronate|
214574903|NCT03803839|DRUG|Saline|
214709614|NCT03690947|DRUG|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
214709615|NCT00445731|BEHAVIORAL|exercise intervention|
214709616|NCT00445731|PROCEDURE|management of therapy complications|
214709617|NCT00445731|PROCEDURE|observation|
214709618|NCT02514772|BIOLOGICAL|GP2013 - A Proposed biosimilar rituximab|
214574904|NCT01843790|DRUG|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
214574905|NCT01843790|DRUG|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
214574906|NCT00351663|DRUG|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day"
214574907|NCT05460403|RADIATION|Adjuvant Radiotherapy|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
214574908|NCT02773563|OTHER|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
214574909|NCT02773563|OTHER|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
214574910|NCT05613387|DRUG|ZP8396|"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
214574911|NCT05613387|DRUG|Drug: Placebo (ZP8396)|"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
214574912|NCT02878889|DRUG|S-1|
214574913|NCT03235102|OTHER|No treatment given|Completion of a survey
214574914|NCT00655018|DIETARY_SUPPLEMENT|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
214574915|NCT00655018|DIETARY_SUPPLEMENT|Placebo|placebo and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
214574916|NCT02842801|OTHER|Hip manipulation|High-amplitude and low-velocity thrust mobilization
214574917|NCT05714345|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214709619|NCT02514772|BIOLOGICAL|Originator rituximab - Rituxan ® or MabThera ®|
214574918|NCT05714345|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214574919|NCT05714345|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214574920|NCT05714345|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
214574921|NCT05419973|OTHER|Anthropometric measurement for pregnant women|Weight, length, upper arm circumference
214574922|NCT05419973|OTHER|Anthropometric measurement for infants|birth weight, length, head circumference, nutritional status
214709620|NCT00004916|DRUG|ifosfamide|
214709621|NCT00004916|DRUG|paclitaxel|
214709622|NCT00004916|DRUG|teniposide|
214574923|NCT05419973|OTHER|Blood sampling|3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.
214574924|NCT00003827|DRUG|amifostine trihydrate|
214574925|NCT00003827|DRUG|cytarabine|
214574926|NCT00003827|DRUG|topotecan hydrochloride|
214574927|NCT03350373|DRUG|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
214574928|NCT01291459|DRUG|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
214709623|NCT00004916|PROCEDURE|peripheral blood stem cell transplantation|
214709624|NCT01526681|OTHER|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
214574929|NCT00888927|BIOLOGICAL|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
214574930|NCT03459443|DRUG|Danicopan|Danicopan was to be administered as an oral tablet.
214574931|NCT03222388|OTHER|Questionnaire - IIEF 5/15|International Index of Erectile Function
214574932|NCT06249659|PROCEDURE|Extubation in operative room|Extubation takes place in operative room
214574933|NCT06249659|PROCEDURE|Extubation in post anesthesia care unit|Extubation takes place in post anesthesia care unit
214574934|NCT02440945|DEVICE|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
214709625|NCT01526681|OTHER|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
214574935|NCT00566592|OTHER|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
214574936|NCT00566592|OTHER|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
214574937|NCT00566592|OTHER|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
214574938|NCT00566592|OTHER|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
214574939|NCT04247763|OTHER|Saturated Fat Meal|
214574940|NCT04247763|OTHER|Oleic Sunflower Oil Meal|
214574941|NCT04592120|BEHAVIORAL|Coalition Check-Up|The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
214574942|NCT04141059|DIETARY_SUPPLEMENT|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
214574943|NCT04141059|DIETARY_SUPPLEMENT|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
214574944|NCT05438628|DIAGNOSTIC_TEST|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
214574945|NCT00537654|DRUG|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
214709626|NCT01526681|OTHER|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
214709627|NCT01526681|DEVICE|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
214709628|NCT01526681|PROCEDURE|Autologous Breast Reconstruction with Neurotization|
214709629|NCT01526681|PROCEDURE|Autologous Breast Reconstruction without Neurotization|
214722017|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of single IVT injection
214574946|NCT00537654|DRUG|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
214574947|NCT00537654|DRUG|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
214574948|NCT00537654|DRUG|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
214574949|NCT05958550|BEHAVIORAL|The tympanic membrane temperature of patients was measured.|After the patient entered the anesthesia recovery room ( PACU ) at the end of the operation, the ear canal was cleaned with cotton swabs by nurses trained in the use of ear temperature guns to avoid the impact of earwax. The patient was in a supine position, the patient 's head was fixed, the patient 's auricle was gently pulled back and up, the ear canal was straight, the ear temperature gun was put into the ear canal, the temperature of the patient 's left and right ears was measured uniformly, and the average value was taken as the final body temperature value. Thereafter, the same measurement was performed every 20 minutes until the patient left the resuscitation room.
214574950|NCT02806648|DRUG|Palbociclib|Palbociclib
214574951|NCT01080716|BIOLOGICAL|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
214574952|NCT01080716|BIOLOGICAL|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
214574953|NCT01080716|BIOLOGICAL|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
214574954|NCT01080716|BIOLOGICAL|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
214574955|NCT05812417|DRUG|DA-8010|DA-8010 5mg single dose administration
214574956|NCT00502463|DRUG|Docetaxel|75mg/m² day 1
214574957|NCT00502463|DRUG|Cisplatin|75mg/m² day 1
214574958|NCT00502463|DRUG|5-FU|750mg/m²/day day 1-5
214574959|NCT00502463|RADIATION|Radiotherapy|standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks
214574960|NCT00502463|DRUG|Cetuximab|250mg/m²/week after an initial loading dose of 400mg/m²
214574961|NCT03812302|DIAGNOSTIC_TEST|68-Ga HA-DOTATATE PET/CT|See arm description.
214574962|NCT03592550|DEVICE|Ultrasound imaging|Abdominal ultrasound imaging of the liver
214574963|NCT00160602|DRUG|Certolizumab Pegol|
214574964|NCT02022189|PROCEDURE|Renal Biopsy|
214574965|NCT02293564|DRUG|gevokizumab|Solution for subcutaneous injection
214709630|NCT00817206|DRUG|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
214574966|NCT04192903|DRUG|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
214574967|NCT05924308|OTHER|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
214574968|NCT05924308|OTHER|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
214574969|NCT00287690|DRUG|Genistein|Drink taken once daily
214574970|NCT00287690|DRUG|Placebo|Drink taken once daily
214574971|NCT02063373|OTHER|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
214574972|NCT03592745|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
214574973|NCT03592745|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
214722018|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of multiple IVT injection
214722019|NCT01957215|DRUG|Indomethacin|Topical indomethacin
214574974|NCT02712710|DEVICE|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
214574975|NCT00151632|DRUG|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
214574976|NCT00151632|DRUG|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
214574977|NCT06108011|OTHER|Lollipop|sucking of lollipop after operation
214574978|NCT00460226|DRUG|lamotrigine|lamotrigine treatment for 12weeks
214574979|NCT05017103|BIOLOGICAL|Sintilimab|Given IV
214574980|NCT05194332|DEVICE|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
214709631|NCT00817206|DRUG|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
214574981|NCT05305924|DRUG|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
214709632|NCT02570529|DRUG|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
214722020|NCT01957215|DRUG|Placebo|Placebo patch
214722021|NCT04376736|OTHER|Home visit|Home visit by medical provider
214574982|NCT03206762|DEVICE|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
214574983|NCT02597647|BIOLOGICAL|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
214574984|NCT02597647|OTHER|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
214574985|NCT00004815|DRUG|growth hormone|
214574986|NCT03796962|DRUG|XEN1101|Oral dose
214574987|NCT05321459|OTHER|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
214574988|NCT04265326|OTHER|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
214709633|NCT02570529|DRUG|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
214709634|NCT02700295|DEVICE|Orthokeratology lens|
214709635|NCT00793182|DRUG|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
214574989|NCT03878992|DRUG|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
214709636|NCT00793182|DRUG|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
214709637|NCT05069285|OTHER|self-help book|information and advice given in the self-help book
214709638|NCT05069285|OTHER|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
214709639|NCT02278991|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
214709640|NCT06377722|DRUG|Cabozantinib|This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
214574990|NCT05473611|PROCEDURE|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
214709641|NCT03396978|OTHER|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
214709642|NCT00003810|DRUG|docetaxel|
214709643|NCT00003810|DRUG|gemcitabine hydrochloride|
214709644|NCT03628521|DRUG|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
214574991|NCT03406078|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214574992|NCT03406078|OTHER|Placebo|Placebo subcutaneous injection
214574993|NCT01413503|RADIATION|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
214574994|NCT03378453|DEVICE|PET-scan18F-AV-45|The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
214574995|NCT03378453|DEVICE|PET-scan18F-AV-45|PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
214634221|NCT07049692|OTHER|High-flow oxygen therapy|1 atmosphere absolute (1 ATA), high-flow oxygen delieved at 10L/min (100%) via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
214634222|NCT06742957|DRUG|Tapinarof Cream 1%|Cream
214634223|NCT06742957|DRUG|VTAMA®|Cream
214634224|NCT06742957|DRUG|Placebo|Cream
214634225|NCT07058376|PROCEDURE|Herbal Medicine Strategy|A pragmatic intervention involving tailored herbal prescriptions created by Korean medicine doctors. The specific composition, dose, and duration of herbal medicine vary per patient, and prescriptions are adjusted according to clinical response.
214574996|NCT05096520|PROCEDURE|radiofrequency|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
214574997|NCT05096520|PROCEDURE|control|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
214574998|NCT05096520|DRUG|2% lidocaine|2% lidocaine
214574999|NCT04519866|OTHER|Electroacupuncture|"Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms."
214575000|NCT04519866|OTHER|Manual acupuncture|"After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above)."
214575001|NCT01363544|OTHER|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
214575002|NCT01363544|BEHAVIORAL|Exercise|30 sessions of individual sports training during 10 weeks.
214575003|NCT01363544|DRUG|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
214575004|NCT02527863|DRUG|Tolvaptan|60 mg Tolvaptan pr day for 1 day
214575005|NCT02527863|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
214575006|NCT04821024|DIAGNOSTIC_TEST|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
214575007|NCT02708407|PROCEDURE|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
214575008|NCT06233604|DRUG|0.9%sodium chloride|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
214575009|NCT06233604|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
214575010|NCT06233604|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
214575011|NCT02186600|DRUG|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
214575012|NCT02186600|DRUG|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
214575013|NCT02186600|DRUG|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
214575014|NCT02186600|BEHAVIORAL|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
214575015|NCT05458570|OTHER|Breast Cancer positive patients|
214575016|NCT02776995|OTHER|Thermography imaging|Thermography imaging of the treated - irradiated body area.
214575017|NCT06311344|DIAGNOSTIC_TEST|Molecular biology analyses|Samples of M. perstans microfilariae will be processed by PCR to investigate the presence (or absence) of Wolbachia using a set of primers targeting the genes ftsZ and 16S and optimized using reference material during the first year of the study. Samples of Schistosoma eggs from urine and feces will be processed for DNA extraction. Each sample will be genetically characterised by multi locus analysis of the mitochondrial cox1 region and the nuclear ITS and 18S rRNA regions. PCR products will be analysed by agarose gel electrophoresis and selected amplicons will be purified and Sanger sequenced. For the individuation of Schistosoma hybrids, the nuclear DNA for each sample will be confirmed by analysis of the species-specific polymorphic positions of the ITS1+2 and 18S. The mitochondrial and nuclear DNA genetic profiles for each individual sample will be recorded to determine the species involved in the infections and also any hybrid schistosomes
214575018|NCT00587626|DEVICE|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
214575019|NCT00587626|DEVICE|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
214575020|NCT04022512|RADIATION|computed tomography|thoracic CT examinations for pre-treatment staging and/or subsequent post-treatment follow-up.
214575021|NCT02387268|DEVICE|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
214575022|NCT00644670|DRUG|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
214575023|NCT00644670|DRUG|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
214575024|NCT03117998|BIOLOGICAL|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
214575025|NCT03117998|BIOLOGICAL|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
214575026|NCT04624087|BEHAVIORAL|food-specific go/no-go computerized training|Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
214575027|NCT04624087|BEHAVIORAL|nonfood-specific go/no-go computerized training|Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
214575028|NCT04846777|DEVICE|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
214575029|NCT04846777|DEVICE|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
214575030|NCT00293059|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
214575031|NCT00293059|DRUG|Placebo|Matching placebo to be taken orally daily.
214575032|NCT05630534|DRUG|Minocycline|Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
214575033|NCT05630534|OTHER|starch|Use starch capsules as placebo
214575034|NCT01485146|DRUG|ETC-1002|escalating doses
214575035|NCT00970762|DRUG|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
214575036|NCT00970762|DRUG|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
214575037|NCT00970762|DRUG|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
214575038|NCT00970762|DRUG|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
214575039|NCT00970762|DRUG|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
214575040|NCT00970762|DRUG|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
214575041|NCT00970762|DRUG|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
214575042|NCT01983189|PROCEDURE|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
214575043|NCT00350103|DRUG|SPM 929|"* Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use"
214575044|NCT00350103|DRUG|Placebo|"* Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use"
214575045|NCT04295967|OTHER|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
214575046|NCT00438672|DRUG|Placebo Injection|Injection without steroid
214575047|NCT00438672|DRUG|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
214575048|NCT04744493|DEVICE|ExaBlate 4000|The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
214575049|NCT00045773|DRUG|Sertraline|50 - 200mg, once per day for 12 weeks.
214575050|NCT05155215|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level: 100×10\^6 CAR-T cells or 200×10\^6 CAR-T cells
214575051|NCT05155215|DRUG|Cyclophosphamide|300 mg/m\^2 per day for 3 days (IV)
214575052|NCT05155215|DRUG|Fludarabine|30 mg/m\^2 per day for 3 days (IV)
214575053|NCT04828837|DEVICE|bubble PEP|Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
214575054|NCT00320528|DRUG|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
214575055|NCT03591653|DRUG|LXI-15028|The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.
214575056|NCT03591653|DRUG|Placebo|Placebo
214575057|NCT02729064|DRUG|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
214575058|NCT02729064|DRUG|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
214575059|NCT06150170|OTHER|Proprioceptive training|Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.
214575060|NCT02815943|PROCEDURE|biliopancreatic diversion with duodenal switch|
214575061|NCT02815943|PROCEDURE|sleeve gastrectomy|
214575062|NCT02815943|OTHER|liquid meal|will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
214575063|NCT02815943|RADIATION|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
214575064|NCT02815943|OTHER|[7,7,8,8-2H]-palmitate|i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.
214575065|NCT02815943|DEVICE|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
214575066|NCT02209870|BEHAVIORAL|E-checklist Group|The patient group after E-checklist system deployed
214575067|NCT04953559|DEVICE|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
214575068|NCT04953559|DEVICE|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
214575069|NCT00297505|DRUG|citalopram|
214575070|NCT00545753|DRUG|Spinosad|10 minute topical application product, following by a complete rinse off.
214575071|NCT00545753|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
214575072|NCT00545753|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
214575073|NCT01383564|PROCEDURE|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
214575074|NCT01383564|PROCEDURE|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
214575075|NCT04593043|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
214575076|NCT04593043|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure
214575077|NCT05031715|DIETARY_SUPPLEMENT|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
214575078|NCT05119062|OTHER|Usual care|Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
214575079|NCT05119062|OTHER|an online intergenerational co-parenting programme+usual care|The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
214575080|NCT04616729|DRUG|Triptorelin 3.75 MG Injection|Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
214575081|NCT04616729|PROCEDURE|Transvaginal oocyte retrieval|Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
214575082|NCT04616729|DRUG|Triptorelin Injection|Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
214575083|NCT01696903|PROCEDURE|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
214575084|NCT00821717|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
214575085|NCT00821717|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
214575086|NCT03883100|DRUG|HQP1351|40 mg tablet, taken orally once every other day
214575087|NCT03545802|BEHAVIORAL|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
214575088|NCT00003489|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214575089|NCT00000739|DRUG|Dapsone|
214575090|NCT00015899|DRUG|lonafarnib|
214575091|NCT05453201|BEHAVIORAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
214575092|NCT01511341|BEHAVIORAL|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
214575093|NCT05625178|DEVICE|Transcutaneous vagus nerve stimulation|tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
214575094|NCT00002745|DRUG|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
214575095|NCT00669279|DRUG|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
214575096|NCT00669279|DRUG|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
214575097|NCT03223051|OTHER|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
214575098|NCT04408053|DEVICE|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
214709645|NCT01916707|DRUG|Dosing of enoxaparin for VTE prophylaxis|
214709646|NCT02197897|DRUG|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
214709647|NCT04188002|BEHAVIORAL|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
214722022|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - weekly
214575099|NCT03011762|DEVICE|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
214575100|NCT04558892|DRUG|Enoxaparin|
214575101|NCT04577001|DRUG|Letrozole|2.5 mg orally daily for 6 months
214575102|NCT04577001|DRUG|Placebo|No active ingredient taken orally daily for 6 months
214575103|NCT00507403|DRUG|infliximab|
214575104|NCT03984981|OTHER|Assessment of process required to diagnose brain death in adult patients|Assessment of process required to diagnose brain death in adult patients (demographics, clinical, laboratory, imaging, and treatment data). No questionnaires or study visits will be used.
214575105|NCT04902677|OTHER|Cross-sectional|No intervention
214575106|NCT06170177|PROCEDURE|Radical Cystectomy|A radical cystectomy is an operation to remove the whole bladder
214575107|NCT05918276|DRUG|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
214575108|NCT02960243|DEVICE|Deep Brain Stimulation|"* DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well"
214575109|NCT06194487|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50mL) per day
214575110|NCT06194487|DIETARY_SUPPLEMENT|MAXI Collagen drink|consume 1 bottle (50mL) per day
214575111|NCT06194487|DIETARY_SUPPLEMENT|Normal fish collagen drink|consume 1 bottle (50mL) per day
214575112|NCT04436770|OTHER|Non-immersive virtual reality therapy|"Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used."
214575113|NCT04436770|OTHER|Standard Physiotherapy|"Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used."
214575114|NCT00004094|DRUG|carboplatin|
214575115|NCT00004094|DRUG|fluorouracil|
214575116|NCT00004094|DRUG|hydroxyurea|
214575117|NCT00004094|DRUG|paclitaxel|
214575118|NCT00004094|PROCEDURE|conventional surgery|
214575119|NCT00004094|RADIATION|radiation therapy|
214575120|NCT04206657|DRUG|1mg KHK7580|Single oral dose administration of 1mg KHK7580
214575121|NCT04206657|DRUG|3mg KHK7580|Single oral dose administration of 3mg KHK7580
214575122|NCT04206657|DRUG|6mg KHK7580|Single oral dose administration of 6mg KHK7580
214709648|NCT04188002|OTHER|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
214575123|NCT04206657|DRUG|12mg KHK7580|Single oral dose administration of 12mg KHK7580
214575124|NCT04206657|DRUG|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
214575125|NCT00588900|DRUG|cediranib maleate|
214575126|NCT00588900|DRUG|irinotecan hydrochloride|
214575127|NCT02828787|OTHER|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
214575128|NCT02451852|DRUG|AZD9291|AZD9291 80mg tablet once daily, open label
214575129|NCT05526651|OTHER|true electroacupuncture|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
214709649|NCT03553550|OTHER|biospecimen collection|Peripheral blood collection Archival tissue collection
214709650|NCT06304519|DEVICE|Dynamic ankle-foot orthosis|customized, carbon fiber, passive ankle-foot orthosis
214722023|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - fortnightly
214722024|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - weekly
214575130|NCT05526651|OTHER|sham electroacupuncture|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
214575131|NCT05241600|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
214575132|NCT05241600|BEHAVIORAL|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
214575133|NCT00816790|DRUG|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
214575134|NCT00816790|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
214575135|NCT01717742|DRUG|TPA (Tissue Plasminogen Activator)|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
214575136|NCT01717742|DRUG|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
214575137|NCT01717742|OTHER|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (\>10 kg)
214575138|NCT02491476|DEVICE|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
214575139|NCT04996446|DRUG|Tislelizumab|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
214575140|NCT04996446|PROCEDURE|ALPPS surgery|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
214575141|NCT06215885|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics|Detecting genomic and proteomic information
214575142|NCT00722280|PROCEDURE|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
214575143|NCT04346459|PROCEDURE|"Tracheal intubation through Fastrach - Group A"|"Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device"
214575144|NCT04346459|PROCEDURE|"Tracheal intubation through I-gel - Group B"|"Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope"
214575145|NCT04346459|PROCEDURE|"Tracheal intubation through Protector - Group C"|"Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope"
214575146|NCT03397875|PROCEDURE|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
214575147|NCT03397875|PROCEDURE|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
214575148|NCT03397875|PROCEDURE|Bioactive silicone based sealer|
214575149|NCT05609903|DRUG|Atezolizumab in combination with nab-paclitaxel|Treatment of patients with stage IV triple negative breast cancer with Atezolizumab in combination with nab-paclitaxel
214575150|NCT05922501|DRUG|Isatuximab|An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
214575151|NCT05922501|DRUG|Belantamab mafodotin|An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
214575152|NCT05922501|DRUG|Pomalidomide|An immunomodulatory agent, capsule taken orally.
214575153|NCT05922501|DRUG|Dexamethasone|A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
214722025|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - fortnightly
214722026|NCT00854685|DRUG|Placebo|Placebo s.c. - weekly
214575154|NCT05748223|OTHER|Mindfulness Meditation|Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
214575155|NCT03066349|OTHER|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
214575156|NCT05454332|DRUG|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
214575157|NCT05454332|OTHER|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
214575158|NCT03465904|DEVICE|Verum Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
214575159|NCT03465904|DEVICE|Sham Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
214575160|NCT01916148|DRUG|18F-DOPA|18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.
214575161|NCT05642832|DEVICE|Throughflow titration phase|"Ventilation will be applied in the TF mode with TF set to 0 LPM for 10 minutes. Patients will receive assist through the NAVA line of the tri-piece (NAVA set to similar settings as Servo period, \~60-80 LPM flow). Ventilation with Throughflow will be started at a TF flow of 5 LPM, and the NAVA flow will be reduced by 5 LPM. After 10 minutes measurements will be collected. If Edi is greater than or equal to 4 µV, TF flow will be increased to 10 LPM and NAVA flow will be adjusted to keep total flow constant. Measurements will be collected again after 10 minutes. TF flow will be increased in steps of 5 LPM and measurements collected every 10 minutes until Edi is below 3 µV or TF flow reaches the total flow observed during the NAVA period.~After either the Edi target has been met or TF flow has reached the total flow, ventilation with TF will be reduced in steps of 5 LPM every 10 minutes (the reverse of the above), while NAVA flow is accordingly adjusted to keep total flow constant."
214575162|NCT05543382|DEVICE|Axonics System|The Axonics System will be implanted as standard care
214575163|NCT06303258|OTHER|Core Stabalization Exercises|Low Intensity Warm Up Exercises Core Stabilization Exercises Cool Down Stretching Exercises
214575164|NCT06303258|OTHER|Generalized Antenatal Exercises|Low Intensity WarmUp Exercise Aerobic Training Endurance Training Pelvic Floor Muscle Training Cool Down Stretching Exercises
214575165|NCT06598410|OTHER|Digital gaming|Children in this group will be allowed to play digital games 5 minutes before the procedure starts. They will continue to play the game during the procedure.
214575166|NCT06598410|OTHER|watching cartoon|Children in this group will be shown a cartoon film 5 minutes before the procedure. They will continue to play the game during the procedure.
214575167|NCT06856460|DIETARY_SUPPLEMENT|powder shake with very low glycemic index|2 weeks of cereal and standard process glucose assist shake as part of breakfast. The diet for the remainder of the day will remain unchanged.
214575168|NCT06856460|DIETARY_SUPPLEMENT|Ceral Breakfast|consume of 400kcal of oat-based cereal with honey for breakfast
214575169|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
214575170|NCT06660069|DRUG|CPC Mouthwash (Parodontax Active Gum Health Mouthwash)|Mouthwash containing 0.07% w/w CPC.
214575171|NCT06660069|DRUG|Regular Fluoride Toothpaste (Crest Cavity Protection)|Toothpaste containing 0.243% w/w sodium fluoride.
214575172|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454% w/w SnF2.
214575173|NCT06862401|PROCEDURE|Glass ceramic onlay preparation|The participants engaged in two practice sessions, each lasting two hours. They either started with their dominant hand followed by non-dominant hand or practiced solely with their non-dominant hand. Each participant prepared a mandibular left first molar resin typodont fixed to the table for a glass ceramic onlay restoration. Preparation was conducted extraorally.
214575174|NCT06588491|BIOLOGICAL|Standard lymphodepletion regimen|Standard lymphodepletion regimen
214575175|NCT06589700|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder.
214575176|NCT06610604|PROCEDURE|thermal ablation|thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
214575177|NCT06610604|PROCEDURE|thyroidectomy|surgical resection of thyroid nodules
214722027|NCT00854685|DRUG|Placebo|Placebo s.c. - fortnightly
214575178|NCT05618912|DEVICE|Hydrocolloid dressing|A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
214575179|NCT05618912|OTHER|Petrolatum jelly dressing|The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
214575180|NCT06678880|BEHAVIORAL|Phase Advanced Intervention (PAI)|Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
214575181|NCT06678880|BEHAVIORAL|Phase Delay Intervention (PDI)|Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
214575182|NCT06243354|DRUG|Test product: HYP-2090PTSA|"Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest)."
214575183|NCT03079453|DRUG|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
214575184|NCT06682481|OTHER|Measurement of biomarker|Measurement of blood levels of 1,5-anhydroglucitol
214575185|NCT03797690|PROCEDURE|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
214709651|NCT05506917|PROCEDURE|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
214709652|NCT02384395|DRUG|Dolutegravir 50 mg|Initial therapy for AHI
214709653|NCT02384395|DRUG|Lamivudine 300 mg|Initial therapy for AHI
214709654|NCT02384395|DRUG|Abacavir 600 mg|Initial therapy for AHI
214709655|NCT02904525|DEVICE|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
214575186|NCT03797690|PROCEDURE|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
214575187|NCT05110690|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
214575188|NCT05110690|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
214575189|NCT02522559|OTHER|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
214575190|NCT06870214|OTHER|relaxation|Women in the 3rd trimester will receive routine care only.
214575191|NCT05967169|DEVICE|Nasal Septal Strap implantation|Correction of NSD with Nasal Septal Strap implant
214575192|NCT06619756|BEHAVIORAL|Phonomotor Treatment (PMT)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
214575193|NCT06619756|BEHAVIORAL|Phonological Components Analysis (PCA)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
214575194|NCT03091660|BIOLOGICAL|BCG Solution|Given intravesically
214575195|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Solution|Given intravesically
214575196|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Vaccine|Given ID
214575197|NCT03091660|OTHER|Laboratory Biomarker Analysis|Correlative studies
214575198|NCT06872723|BEHAVIORAL|Lung Cancer Screening|Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening
214575199|NCT06708832|DEVICE|SIMBA ingestion|Ingestion of 2 SIMBA capsules at the same time and their excretion.
214575200|NCT04939363|COMBINATION_PRODUCT|Obinutuzumab with Ibrutinib and Venetoclax|"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
214575201|NCT06715150|DRUG|Azithromcyin|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
214575202|NCT06715150|OTHER|Placebo|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
214575203|NCT06718335|DRUG|Pyrotinib|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.
214575204|NCT02328235|OTHER|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
214575205|NCT02928159|DEVICE|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
214575206|NCT01209234|BEHAVIORAL|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
214575207|NCT01209234|DRUG|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
214709656|NCT03202745|OTHER|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
214722028|NCT01221662|DRUG|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
214575208|NCT06723184|BEHAVIORAL|The training|"Behavioral: Antenatal Education Education Hours: The training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be in a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Grandmothers in both the control and intervention groups will be asked to fill out the Introductory Information Form, Pharis Self-Confidence Scale, State-Trait Anxiety Scale and Knowledge Measurement Questionnaire for Grandchild Care measurement tools. The data of the intervention group will be filled in before and after the training. The data of the control group will be filled in parallel with the intervention group. At the end of the study, the same training will be applied to the control group.~Group to receive training: Grandmothers who are expecting a grandchild and have a grandchild will be included in the training."
214575209|NCT06723886|DIETARY_SUPPLEMENT|Experimental arm: Olive pomace oil|Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
214575210|NCT06723886|DIETARY_SUPPLEMENT|High-oleic acid sunflower oil|Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
214575211|NCT06718712|OTHER|Lower body resistance training|The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.
214575212|NCT06727708|DEVICE|Tone Your Body BioCircuit Program|Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.
214575213|NCT06727708|DEVICE|Boost Performance BioCircuit Program|Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
214575214|NCT06727695|DEVICE|BioStrength Intervention|Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week
214575215|NCT06727695|DEVICE|Conventional training|Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
214575216|NCT06727630|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day
214575217|NCT06728124|DRUG|GZR18|Used as specified in the protocol
214575218|NCT06728124|OTHER|Placebo|Administered the same volume as GZR18
214575219|NCT06727786|OTHER|Serious game training|A serious game featuring a dramatic/realistic film, pauses with questions for active learning, and practice administration of naloxone and performing CPR
214575220|NCT06729840|DRUG|Injection|Vitamin D , botox , tramcinolone intralesionally injected in keloid
214575221|NCT06729684|DEVICE|digital health (application and smartwatch)|The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
214575222|NCT06729372|BEHAVIORAL|Deliberate Flawed Performance|Deliberate Flawed Performance during simulation-based training
214575223|NCT06729372|BEHAVIORAL|Error Avoidance Training|Error Avoidance during simulation-based training
214575224|NCT06886529|OTHER|ML-based intervention|ML model predicting a serious cardiac event in cardiac patients, defined as VAD procedure, being wait listed for heart transplant or death within the next three months.
214575225|NCT06732960|BIOLOGICAL|Efsubaglutide Alfa|Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.
214575226|NCT06732960|OTHER|Placebo|Placebo subcutaneous injection weekly
214575227|NCT06007222|DRUG|Aspirin group|Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
214575228|NCT06007222|DRUG|Non-antithrombotic group|No antithrombotic agents will be administered after randomization until the end of the study period.
214709657|NCT03202745|OTHER|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
214709658|NCT01254578|OTHER|Laboratory Biomarker Analysis|Correlative studies
214575229|NCT06735625|BIOLOGICAL|Measurement of AHSP concentration|"Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory."
214575230|NCT06726707|COMBINATION_PRODUCT|Diaper with a copper-based product + usual care|The intervention is an incontinence aid product and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
214575231|NCT06726707|COMBINATION_PRODUCT|Barrier product with common diaper|The common diaper is an incontinence aid and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
214575232|NCT06743100|DIAGNOSTIC_TEST|18F-Floretyrosine|Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine.
214575233|NCT06743685|BEHAVIORAL|HEALthy Beginnings|HEALthy Beginnings, an innovative, enhanced, trauma-informed, chronic disease self-care program and nurse-driven intervention, developed and tailored for middle-aged, and older, homeless women (MAO-HW).
214575234|NCT06845826|DEVICE|Point-of-Care high-sensitivity troponin testing|To establish in a randomized interventional controlled trial whether a novel POC test-guided strategy in acute chest pain patients in the ED results in a reduced length of stay compared to the usual central laboratory testing strategy when managing patients with a suspicion of NSTEMI
214575235|NCT03414541|DRUG|DS102|DS102
214575236|NCT03414541|OTHER|Placebo|Placebo
214575237|NCT06896344|OTHER|In vitro culture|In vitro culture of bone marrow MNCs to obtain mesenchymal stromal cells
214575238|NCT06898853|DRUG|0.1% Ciclosporin A eye drops|The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
214575239|NCT06898853|DRUG|Mineral oils eye drops|This arm is the comparator arm has mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
214575241|NCT06836856|DRUG|control|Patients will receive standard care with no interventions until end of treatment.
214575242|NCT06836856|DRUG|propranolol|starting at 20mg propranolol three times daily by mouth or per feeding tube. The dose was increased daily in 20mg three times daily increments (60mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 640mg/day in addition to standard care until end of treatment.
214575243|NCT06836856|DRUG|Carvedilol|starting at 6.25mg carvedilol three times daily by mouth or per feeding tube. The dose was increased daily in 6.25 mg three times daily increments (18.75 mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 100 mg/day in addition to standard care until end of treatment.
214709659|NCT01254578|DRUG|Lenalidomide|Given orally
214709660|NCT01254578|OTHER|Pharmacological Study|Correlative studies
214709661|NCT00606528|OTHER|No intervention|None. This is an observational study.
214575244|NCT06816875|DEVICE|NozeBot Electric Nasal Aspirator|The NozeBot is a rechargeable, battery-operated baby nasal aspirator with a nosepiece that loops directly onto the caregivers fingers for ease of use, and is intended to be held so it sits just inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
214575245|NCT06816875|DEVICE|NoseFrida the SnotSucker|The NoseFrida is nose-to-mouth nasal suctioning device with a disposable hygienic filter. The nosepiece is a larger tube that is to be held so it sits against and not inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
214575246|NCT06816875|DEVICE|hydraSense Baby Nasal Care Nasal Aspirator Starter Kit|The hydraSense Baby Nasal Aspirator Starter Kit is a nose-to-mouth nasal suctioning device with a disposable hygienic filter. The kit contains pre-proportioned saline solution vials to liquify mucus prior to suctioning. The nosepiece is intended to be held so it sits inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
214575247|NCT06816875|DEVICE|Braun Nasal Aspirator|The Braun nasal aspirator is a battery-operated nasal suctioning device with a washable collection chamber for mucus. There are two nosepiece sizes to accommodate a best fit in the nose. It will be used according to its manufacturer's instructions for use in this study.
214709662|NCT00430898|DRUG|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
214709663|NCT03351010|BEHAVIORAL|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
214575248|NCT06895720|OTHER|Myofascial Self-Release|Athletes will be asked to use the myofascial release roller for 2 minutes before training on each of the three muscle groups: anterior and posterior thigh and posterior leg. They will be instructed to roll while applying as much pressure as possible on the roller. For the anterior thigh, the roller will be moved along the entire front part of the thigh; for the posterior thigh, it will be rolled from just below the gluteal region to just above the knee; and for the posterior leg, it will be rolled from just below the knee to just above the heel.
214575249|NCT06907316|DRUG|Cefixime 400mg|cefixime 400 mg taken orally two times a day for 14 consecutive days
214575250|NCT06907316|DRUG|Benzathine penicillin 2.4 million units|single dose of benzathine penicillin G 2.4 MIU intramuscularly
214575251|NCT06906289|OTHER|resumption of enteral feeding within 24 hours of surgery|Patients will be subjected to resumption of enteral feeding within 24 hours of surgery
214575252|NCT06906289|OTHER|resumption of enteral feeding after 24-48 hours|Patients will be subjected to late resumption of enteral feeding after 24 to 48 hours of surgery
214575253|NCT06907810|OTHER|Blood sample + questionnaire|"* blood sample before tumor surgery and at every follow-up visit~* questionnaire before tumor surgery and at every follow-up visit"
214575254|NCT06906224|DRUG|Control group (clozapine, placebo)|Patients received oral clozapine (Jiangsu Pharmaceutical Co., Ltd., Approval No. H32022963) in combination with a placebo. Each dose of the placebo was 1 mg, taken three times a day.
214575255|NCT06906224|DRUG|Low-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Approval No. H19991024) in combination with clozapine. The total daily dose of buspirone was 15 mg, divided into three administrations. The dose remained unchanged throughout the entire study period.
214575256|NCT06906224|DRUG|High-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets in combination with clozapine. The initial total daily dose of buspirone was 15 mg, divided into three administrations. One week later, the dose was increased to a total daily dose of 30 mg, also divided into three administrations.
214575257|NCT06907641|DRUG|64Cu-SAR-bisPSMA|All participants will receive a single administration of 200 MBq of 64Cu-SAR-bisPSMA
214575258|NCT06906211|DEVICE|low intensity focused ultrasound (LIFU)|Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
214575259|NCT06907251|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10mg orally once a day for 12 months
214575260|NCT06907251|DRUG|Placebo|Participants will receive a matching placebo taken once daily by mouth for 12 months.
214575261|NCT05762055|DEVICE|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
214575262|NCT05762055|DEVICE|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
214575263|NCT06906354|PROCEDURE|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
214575264|NCT06621576|DRUG|HM2002 injection|Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
214575265|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
214575266|NCT01185275|DEVICE|Alair system|Bronchial thermoplasty
214575267|NCT06906913|DIAGNOSTIC_TEST|HPV testing|Oropharyngeal and anal swab samples are evaluated in the Microbiology laboratory for the existence of HPV.
214709664|NCT03351010|DEVICE|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
214575268|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
214709665|NCT03669406|PROCEDURE|Autograft fat|autograft fat
214709666|NCT00550277|DRUG|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
214709667|NCT05448989|DRUG|1% atropine 5+3|A method for myopia control using high-concentration atropine
214709668|NCT02473224|BIOLOGICAL|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
214709669|NCT02473224|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
214575269|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
214575270|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
214575271|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
214575272|NCT06094387|DIAGNOSTIC_TEST|Thrombin generation assay|Thrombin generation parameters in patients receiving central catheter insertion
214709670|NCT06531226|OTHER|Fill in personality questionnaires|For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
214575273|NCT01022112|DRUG|TA-7284-Low|TA-7284-Low
214575274|NCT01022112|DRUG|TA-7284-Low-middle|TA-7284-Low-middle
214575275|NCT01022112|DRUG|TA-7284-High-middle|TA-7284-High-middle
214575276|NCT01022112|DRUG|TA-7284-High|TA-7284-High
214575277|NCT01022112|DRUG|Placebo|Placebo
214575278|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
214575279|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
214575280|NCT05521438|DRUG|Vehicle|Vehicle Lotion
214575281|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
214575282|NCT00550303|DRUG|bazedoxifene/conjugated estrogens combination|
214575283|NCT00006353|DRUG|temozolomide|
214575284|NCT00006353|RADIATION|radiation therapy|
214575285|NCT00925353|DRUG|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
214575286|NCT01153867|BEHAVIORAL|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
214575287|NCT00905515|DRUG|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
214575288|NCT00905515|DRUG|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
214709674|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
214722029|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
214575289|NCT05183776|DEVICE|Fractional administration device|The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
214575290|NCT00358176|DRUG|Risedronate (HMR4003)|
214575291|NCT06069817|DEVICE|High flow nasal cannula|home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
214575292|NCT06069817|DEVICE|nebulized normal saline|home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
214575293|NCT01464372|DEVICE|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
214575294|NCT01464372|DEVICE|Sham Nerve Stimulation Device|Use of the sham device
214575295|NCT00563888|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
214575296|NCT00248482|DRUG|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
214575297|NCT00248482|DRUG|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
214575298|NCT00248482|DRUG|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
214575299|NCT04013048|DRUG|[14C]-Fluzoparib|Patients will receive single dose of orally \[14C\]- Fluzoparib on Day 1.
214575300|NCT01455389|DRUG|DOTAP:Chol-TUSC2|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
214575301|NCT01455389|DRUG|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
214575302|NCT01455389|DRUG|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
214575303|NCT01455389|DRUG|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
214575304|NCT04554524|DRUG|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
214575305|NCT02227979|BEHAVIORAL|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
214575306|NCT02227979|BEHAVIORAL|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
214575307|NCT05161221|DRUG|OxyCODONE 5 mg Oral Tablet|Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
214575308|NCT05161221|DRUG|Naproxen 500 Mg|Participant will receive Naproxen 500 Mg post surgery for pain control
214575309|NCT05161221|DRUG|Tylenol Pill|Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
214575310|NCT05161221|DRUG|Liposomal bupivacaine|Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
214575311|NCT05161221|PROCEDURE|Femoral Nerve Catheter|Participants will receive pre-operative femoral nerve catheter
214575312|NCT04187807|DRUG|Melatonin 5 mg|Placebo
214575313|NCT05103787|PROCEDURE|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
214575314|NCT05103787|PROCEDURE|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
214575315|NCT03057522|BEHAVIORAL|Change in running cadence|The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
214575316|NCT02736461|PROCEDURE|Floor repair surgery|
214575317|NCT02628639|DEVICE|high-density electroencephalography|
214575318|NCT04312334|OTHER|Control|Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
214575319|NCT04312334|OTHER|Treatment|The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
214575320|NCT01843127|DRUG|Ranolazine|
214575321|NCT01843127|DRUG|Placebo|
214575322|NCT01843127|DRUG|Exenatide|
214575323|NCT05762289|OTHER|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
214575324|NCT03394001|PROCEDURE|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
214575325|NCT03394001|DRUG|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
214575326|NCT03394001|DRUG|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
214575327|NCT05401825|BIOLOGICAL|pfizer, astrazeneca,moderna,sinofac|effect of COVID 19 vaccination on pregnancy outcomes
214575328|NCT05162989|DEVICE|iCare HOME2 vs iCare IC200|Measurement of IOP with iCare HOME2 compared with iCare IC200.
214575329|NCT04140019|DIAGNOSTIC_TEST|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
214575330|NCT06145477|BEHAVIORAL|Chicago Parent Program - individualized for families (CPPi)|CPPi is a 8-12 session individual- based parenting skills program
214575331|NCT04790656|OTHER|Conventional Therapy|Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
214575332|NCT04790656|OTHER|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
214575333|NCT04196491|BIOLOGICAL|bb2121|CAR-T Cell Therapy
214575334|NCT04196491|DRUG|Fludarabine|Lymphodepleting Chemotherapy
214575335|NCT04196491|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
214575336|NCT04196491|DRUG|Lenalidomide|Maintenance Therapy
214575337|NCT01787149|DRUG|DMARDs|
214575338|NCT02474485|DEVICE|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
214575339|NCT02474485|DEVICE|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
214575340|NCT02474485|PROCEDURE|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
214575341|NCT02474485|PROCEDURE|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
214575342|NCT02474485|OTHER|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
214575343|NCT02081443|DRUG|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
214575344|NCT02081443|DRUG|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
214575345|NCT02016040|PROCEDURE|High Intensity Focused Ultrasound|
214575346|NCT00658255|DRUG|budesonide/formoterol|
214575347|NCT00658255|DRUG|formoterol|
214575348|NCT02121951|PROCEDURE|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
214575349|NCT02121951|PROCEDURE|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
214575350|NCT02121951|DRUG|MAC|Incremental doses are given to the targed sedation and analgesia
214575351|NCT02968316|OTHER|BIA measurement|observation only
214575352|NCT03134105|OTHER|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
214575353|NCT03134105|OTHER|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
214575354|NCT06138314|OTHER|Physical Exercise Program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
214575355|NCT06138314|OTHER|Neural Mobilization|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
214575356|NCT05396768|OTHER|Assessment using the ACTION-tool.|Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
214709675|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
214709676|NCT00992004|DIETARY_SUPPLEMENT|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
214709677|NCT02850497|DEVICE|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
214575357|NCT01275950|BEHAVIORAL|Health Education|"1. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~2. Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~3. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
214575358|NCT03074890|DEVICE|Application Protocol|Application lMassive Transfusion Protocol
214709678|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
214575359|NCT05322993|DEVICE|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
214575360|NCT05322993|DEVICE|Standard white light colonoscope|Standard colonoscopy.
214575361|NCT03470246|BEHAVIORAL|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
214575362|NCT03470246|BEHAVIORAL|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
214575363|NCT03470246|BEHAVIORAL|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
214575364|NCT04393337|OTHER|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
214575365|NCT04393337|OTHER|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
214575366|NCT04341402|DRUG|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
214575367|NCT02766192|DRUG|Ketamine|
214575368|NCT02766192|BEHAVIORAL|TIMBER Psychotherapy|
214575369|NCT02766192|DRUG|Placebo (normal saline)|
214575370|NCT05497973|BEHAVIORAL|E-health ecosystem of stepped psychosocial care|"1. Screening and monitoring: weekly administration of an emotional state thermometer. If the score is \>5, participants are asked to complete the HADS. If HADS' score \>10, step 2 is assigned. The same procedure is followed for steps 3 \& 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~2. Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~3. Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q\&As.~4. Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
214709679|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
214709680|NCT01929213|DRUG|Udenafil|Udenafil is administered
214709681|NCT01929213|DRUG|Bosentan|Bosentan is administered
214575371|NCT05497973|BEHAVIORAL|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
214575372|NCT00551590|DRUG|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
214575373|NCT00551590|DRUG|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
214575374|NCT00551590|DRUG|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
214575375|NCT00551590|DRUG|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
214575376|NCT03090243|DEVICE|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
214575377|NCT02259647|DRUG|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
214575378|NCT02259647|DRUG|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
214575379|NCT04465253|OTHER|Best Practice|Undergo standard of care occupational therapy
214575380|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in discussions via videoconferencing
214575381|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in interview via videoconferencing
214575382|NCT04465253|OTHER|Quality-of-Life Assessment|Ancillary studies
214575383|NCT04465253|OTHER|Questionnaire Administration|Ancillary studies
214575384|NCT01302067|DRUG|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
214575385|NCT01302067|DRUG|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
214575386|NCT01302067|DRUG|Placebo|Oral, 1 tablet per day, 12 weeks duration
214575387|NCT04864288|DEVICE|Shear Wave Elastography|is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
214709682|NCT01929213|DRUG|Udenafil/Bosentan|Udenafil and Bosentan are administered
214575388|NCT00834626|PROCEDURE|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
214575389|NCT04359043|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
214575390|NCT04359043|BEHAVIORAL|Treatment as Usual|Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
214575391|NCT02738203|DRUG|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
214575392|NCT02738203|DRUG|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
214575393|NCT04330924|OTHER|Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)|3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
214575394|NCT05022160|DRUG|pudendal nerve block|All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
214575395|NCT01572168|OTHER|Acupuncture|Eight session of weekly acupuncture
214575396|NCT04675190|PROCEDURE|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
214575397|NCT05589324|BEHAVIORAL|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
214575398|NCT03934138|OTHER|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
214575399|NCT03934138|OTHER|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
214575400|NCT03241927|BIOLOGICAL|Pembrolizumab|Day 1 of each 3 week cycle
214575401|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
214575402|NCT01198756|BIOLOGICAL|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
214575403|NCT01198756|BIOLOGICAL|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
214575404|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
214575405|NCT05887154|DEVICE|Microwave ablation|microwave ablation
214575406|NCT03559231|PROCEDURE|dFTRD|Duodenal Full-Thickness Resection
214575407|NCT03559231|PROCEDURE|EMR|Endoscopic Mucosal Resection
214575408|NCT02992821|PROCEDURE|Bed-side pocket size ultrasound imaging|
214575409|NCT02992821|PROCEDURE|High frame rate tracking doppler|
214575410|NCT04031807|PROCEDURE|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
214575411|NCT00004444|DRUG|paromomycin|
214575412|NCT00004444|DRUG|streptomycin|
214575413|NCT05676853|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
214575414|NCT02402673|OTHER|Temporary activity modification and graded exercises|
214575415|NCT03462173|DRUG|yimitasvir|Capsule administered orally once daily
214709683|NCT03842215|DEVICE|smart physical exam|Use smart physical exam to collect functional performance
214575416|NCT03462173|DRUG|placebo|Matching Placebo Capsule
214575417|NCT00670631|COMBINATION_PRODUCT|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 \& 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
214575418|NCT02124447|DRUG|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
214575419|NCT02124447|DRUG|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
214709684|NCT03103880|DEVICE|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
214709685|NCT01136863|DRUG|Felodipine|
214709686|NCT01136863|DRUG|Placebo|
214709687|NCT00438919|DEVICE|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
214709688|NCT04373018|PROCEDURE|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
214575420|NCT02124447|DRUG|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
214575421|NCT02124447|DRUG|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
214575422|NCT04822493|OTHER|Counseling Aid|Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
214575423|NCT01290315|DRUG|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
214575424|NCT01290315|DRUG|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
214575425|NCT05837962|BEHAVIORAL|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|"The nursing professional will perform 1 session weekly, for 4 weeks, lasting 90 minutes each. The contents that make up each of the sessions are:~Session 1. Knowledge about the risk factors, signs and symptoms, maternal and fetal complications of HDP.~Session 2. Control over behaviour, positive attitude and family and social support: essential components for conducting self-care behaviour.~Session 3. Nutritional recommendations: eating healthy helps prevent or reduce the risk of developing HDP.~Recommendations to improve sleep, rest and physical exercise: key routines in my health to prevent or reduce the risk of developing HDP.~Session 4. Mental health promotion: managing my stress, anxiety and depression levels help prevent or decrease the risk of HDP"
214575426|NCT03866499|DRUG|BPI-7711|180 mg, oral, QD
214575427|NCT03866499|DRUG|Gefitinib|250 mg, oral, QD
214575428|NCT03866499|DRUG|Placebo Tablet|250 mg gefitinib placebo tablet, QD
214575429|NCT03866499|DRUG|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
214575430|NCT02724059|PROCEDURE|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
214575431|NCT00591721|BEHAVIORAL|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
214575432|NCT00599911|DRUG|Lu AA24530|per oral, once daily for 6 weeks
214575433|NCT00599911|DRUG|Duloxetine|per oral, once daily for 6 weeks
214575434|NCT00599911|DRUG|Placebo|per oral, once daily for 6 weeks
214575435|NCT06433973|PROCEDURE|Test group 1 - CM+LLLT+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. LLLT will be applied on the site for 10 sec.
214575436|NCT06433973|PROCEDURE|Test group 2 - CM+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts. Adequate size of CM will be trimmed and applied over the recession defect using minimally invasive technique and secured with sutures.
214575437|NCT06433973|PROCEDURE|Control group - SCTG+VISTA|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
214575438|NCT00269360|PROCEDURE|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
214709689|NCT04373018|PROCEDURE|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
214722030|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
214575439|NCT00269360|PROCEDURE|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
214575440|NCT00269360|BEHAVIORAL|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
214575441|NCT01900197|DRUG|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
214575442|NCT00423943|DRUG|modafinil|200 milligrams daily dose
214575443|NCT00423943|DRUG|Placebos|capsule containing placebo
214575444|NCT04032587|BEHAVIORAL|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
214575445|NCT04032587|BEHAVIORAL|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
214575446|NCT01953653|BEHAVIORAL|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
214575447|NCT04669353|DRUG|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
214575448|NCT01386762|OTHER|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
214575449|NCT02909530|DEVICE|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
214575450|NCT02909530|DEVICE|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
214575451|NCT02699086|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
214575452|NCT05035784|DRUG|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
214575453|NCT05035784|DRUG|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
214575454|NCT06206187|OTHER|Automated detection of the intracardiac thrombus through deep learning|A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.
214575455|NCT06206187|OTHER|Electrophysiologist judgment of the intracardiac thrombus|Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
214722031|NCT02089178|DRUG|propofol-remifentanil|
214575456|NCT01837784|OTHER|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
214575457|NCT03636282|BEHAVIORAL|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
214575458|NCT01670955|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
214575459|NCT01670955|DRUG|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
214575460|NCT05577884|DIAGNOSTIC_TEST|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
214575461|NCT02050711|BEHAVIORAL|Pulmonary rehabilitation|
214575462|NCT02050711|OTHER|Usual care|
214575463|NCT02896049|DEVICE|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
214575464|NCT04447664|DEVICE|Inclouded telespirometry system|Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
214575465|NCT02716818|DRUG|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
214575466|NCT02716818|DRUG|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
214575467|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
214575468|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
214575469|NCT05872360|DIETARY_SUPPLEMENT|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
214575470|NCT05872360|DIETARY_SUPPLEMENT|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
214575471|NCT04407871|OTHER|Acupuncture and Chinese Herbal Medicine|1\) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
214575472|NCT03464799|OTHER|immunohistochemical staining|immunohistochemical staining
214575473|NCT04103060|DRUG|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
214575474|NCT04103060|DRUG|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
214575475|NCT00901186|DRUG|RFB002|0.5 mg
214575476|NCT00901186|PROCEDURE|Laser photocoagulation|
214709690|NCT04373018|PROCEDURE|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
214709691|NCT01106391|DEVICE|"Cordis AAA stent graft system INCRAFT TM"|
214709692|NCT06470555|OTHER|A figure-of-eight suture secured with a three-way tap|Femoral haemostasis using a figure-of-eight suture technique
214575477|NCT01016743|DEVICE|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
214575478|NCT00541060|GENETIC|mutation|a mutation of a gene coding
214575479|NCT03842722|DEVICE|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
214575480|NCT01543984|OTHER|Tailored Physical Activity|Tailored Physical Activity (3\*50 min/week in 10 weeks)
214575481|NCT01543984|BEHAVIORAL|Health Counselling|Health guidance (1,5h)
214575482|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
214575483|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
214575484|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
214709693|NCT06470555|OTHER|Shortened bed rest duration of 2-hours|Bed rest duration of 2-hours after initial haemostasis
214575485|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
214575486|NCT03980600|DEVICE|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
214575487|NCT03980600|DEVICE|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
214575488|NCT03980600|DEVICE|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
214575489|NCT00987246|DRUG|Placebo Gel|Topical
214575490|NCT00987246|DRUG|LAS41005|Topical
214575491|NCT00987246|DRUG|LAS106521|Topical
214575492|NCT01327859|DRUG|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
214575493|NCT01327859|DRUG|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
214575494|NCT01327859|DRUG|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
214575495|NCT05222724|DRUG|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
214575496|NCT05222724|DRUG|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
214709694|NCT06470555|OTHER|Manual compression|Femoral haemostasis using manual compression
214575497|NCT01597141|BEHAVIORAL|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
214575498|NCT01597141|BEHAVIORAL|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
214575499|NCT01329692|BEHAVIORAL|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
214575500|NCT02299154|BEHAVIORAL|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
214575501|NCT02383056|DEVICE|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
214575502|NCT02383056|DEVICE|Omnilux Sham|Sham light instead of phototherapy from the same light device
214575503|NCT01762319|DRUG|Misoprostol|
214575504|NCT01762319|DRUG|Vitamin B6|
214709695|NCT06470555|OTHER|Conventional bed rest duration of 4-hours|Bed rest duration of 4-hours after initial haemostasis
214709696|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
214575505|NCT00294203|DRUG|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
214709697|NCT04655755|DRUG|Venetoclax|Given PO
214722032|NCT02089178|DRUG|sevoflurane-remifentanil|
214722033|NCT01670825|PROCEDURE|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
214575506|NCT00294203|OTHER|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
214575507|NCT00581555|DRUG|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
214575508|NCT00581555|OTHER|Placebo|Randomized to placebo during taper of ciclosporin
214575509|NCT03336567|OTHER|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
214575510|NCT05807529|DRUG|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
214575511|NCT05807529|DRUG|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
214575512|NCT05303220|DRUG|Branebrutinib|Specified dose on specified days
214575513|NCT05303220|DRUG|Placebo|Specified Dose on specified days
214575514|NCT05225727|BEHAVIORAL|Me & You - Tech|The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
214575515|NCT06799481|OTHER|Aerobic Exercise|Participate in personalized, progressive aerobic training
214575516|NCT06799481|BEHAVIORAL|Behavioral Intervention|Receive active lifestyle behavior coaching
214575517|NCT06799481|PROCEDURE|Follow-Up|Receive calls from the trainer
214575518|NCT06799481|OTHER|Internet-Based Intervention|Receive access to Physitrack
214575519|NCT06799481|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit monitor
214575520|NCT06799481|OTHER|Questionnaire Administration|Ancillary studies
214575521|NCT06799481|OTHER|Resistance Training|Participating in strength training exercises
214575522|NCT03828747|DRUG|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
214575523|NCT03828747|DRUG|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
214575524|NCT03828747|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
214575525|NCT04007380|OTHER|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
214575526|NCT00964587|BEHAVIORAL|Education + Problem-Solving Training Self-Study|"* Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
214575527|NCT00964587|BEHAVIORAL|Education + Group Problem-Solving Training|"* Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions"
214575528|NCT00964587|BEHAVIORAL|Education + Individual Problem-Solving Training|"* Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)"
214575529|NCT00964587|BEHAVIORAL|Usual Care|"* Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
214575530|NCT05816330|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
214575531|NCT05816330|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
214575532|NCT03245151|DRUG|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
214575533|NCT03245151|DRUG|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
214575534|NCT02571595|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
214575535|NCT04465500|RADIATION|External Beam Radiation|EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
214575536|NCT04465500|RADIATION|HDR Brachytherapy|HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
214575537|NCT04465500|DRUG|Androgen Deprivation Therapy|The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
214575538|NCT03900416|BEHAVIORAL|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
214575539|NCT03534128|OTHER|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
214575540|NCT05009953|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
214575541|NCT05009953|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
214575542|NCT05009953|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
214575543|NCT05009953|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
214575544|NCT03069755|OTHER|No intervention|No intervention
214575545|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises|In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks
214575546|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises with dual task|In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
214575547|NCT01354184|DRUG|CRD007|
214575548|NCT01354184|DRUG|CRD007 matching placebo|
214575549|NCT06631950|OTHER|Educational intervention|The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
214575550|NCT04321668|DEVICE|Synvisc-One|SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication
214575551|NCT06492915|DRUG|Chiauranib|Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
214575552|NCT06492915|DRUG|Albumin-paclitaxel Injection|Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
214575553|NCT06492915|DRUG|Gemcitabine Injection|Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
214575554|NCT04445532|OTHER|Gene expression analysis|Gene expression analysis
214575555|NCT04445532|OTHER|Genomic analysis|Genomic analysis
214575556|NCT04445532|OTHER|Protein expression analysis|Protein expression analysis
214575557|NCT04445532|OTHER|Proteomic profiling|Proteomic profiling
214575558|NCT04445532|OTHER|Polymerase chain reaction|Polymerase chain reaction
214575559|NCT04445532|OTHER|Mass spectrometry|Mass spectrometry
214575560|NCT04445532|OTHER|Immunohistochemistry|Immunohistochemistry
214575561|NCT04445532|OTHER|Metabolomics profiling|Metabolomics profiling
214575562|NCT04445532|OTHER|Methylation and epigenetic analysis|Methylation and epigenetic analysis
214575563|NCT04445532|OTHER|Liquid biopsy analysis|Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
214575564|NCT04445532|OTHER|Laboratory biomarker analysis|Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
214575565|NCT01699659|OTHER|allergen immunotherapy|allergy shots
214575566|NCT00899782|OTHER|cytology specimen collection procedure|correlative studies
214575567|NCT04837651|DEVICE|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
214575568|NCT04837651|DEVICE|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
214575569|NCT05920460|BEHAVIORAL|Cognitive Behavioral Therapy Program|"Brief description of the Cognitive Behavioral Therapy program is given below:~* Session 1: Mutual understanding and rapprochement~* Session 2: Sleep hygiene education~* Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~* Session 4: Training on relaxation techniques~* Session 5: Psycho education about depression~* Session 6: Cognitive restructuring~* Session 7: The terminating session"
214575570|NCT01375400|DRUG|Aspirin|Administration of 300 mg of aspirin, per os.
214575571|NCT01375400|BIOLOGICAL|blood sample|2 blood samples will be performed
214575572|NCT04553289|OTHER|exercising into pain|the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
214575573|NCT04553289|OTHER|exercising with no/slight pain|the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
214575574|NCT05458947|PROCEDURE|pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
214575575|NCT05458947|PROCEDURE|electrical stimulation (ES)|high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
214575576|NCT05458947|PROCEDURE|electrical stimulation (ES) and pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
214575577|NCT04744545|BEHAVIORAL|Meru Health Program|12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
214575578|NCT04744545|DIETARY_SUPPLEMENT|Curcumin|1500mg/day curcumin plus black pepper to aid absorption
214575579|NCT05016362|PROCEDURE|medial fat preservation upper blepharoplasty|medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
214575580|NCT02533817|DIETARY_SUPPLEMENT|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
214575581|NCT04687059|BIOLOGICAL|PQ Grass|Suspension for injection
214575582|NCT04687059|DRUG|Placebo Option 1|Suspension for injection
214575583|NCT04687059|DRUG|Placebo Option 2|Solution for injection
214575584|NCT04155736|BEHAVIORAL|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
214575585|NCT00359216|DRUG|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
214575586|NCT00359216|DRUG|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
214575587|NCT05436197|BEHAVIORAL|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
214575588|NCT00641329|DRUG|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
214575589|NCT00641329|DRUG|Placebo|Matching placebo tablets
214575590|NCT00703937|DRUG|Ferric Carboxymaltose (FCM)|
214575591|NCT00703937|DRUG|Standard Medical Care (SMC) for the treatment of IDA|
214575592|NCT03698500|OTHER|Removal of blood|10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
214575593|NCT01473446|PROCEDURE|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV\> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding \>1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
214575594|NCT05323760|DEVICE|Cardiopulmonary exercise test (CPET)|A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
214575595|NCT05142852|DEVICE|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
214575596|NCT05142852|OTHER|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
214575597|NCT00334464|DRUG|Standard of care or genotyping dosing of warfarin dosing|
214575598|NCT00180063|DRUG|L-NMMA(drug)|
214575599|NCT00476970|BEHAVIORAL|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
214575600|NCT03041051|BIOLOGICAL|PCV13|
214575601|NCT03041051|BIOLOGICAL|PPV23|
214575602|NCT04311528|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV vaccine
214575603|NCT01033422|DRUG|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
214575604|NCT01033422|DRUG|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
214575605|NCT02663518|DRUG|PF-0791800 (TTI-621)|Monotherapy
214575606|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Rituximab|Combination therapy
214575607|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Nivolumab|Combination therapy
214575608|NCT03805620|OTHER|Combined physical-cognitive training|combined physical-cognitive training
214575609|NCT03805620|OTHER|Physical training|Multi-component physical exercise
214575610|NCT03805620|OTHER|Cognitive training|cognitive training
214575611|NCT04392661|PROCEDURE|Laparoscopic Sleeve Gastrectomy|bariatric surgeries and data collection
214575612|NCT04174794|DEVICE|Lung ultrasound|The two different lung ultrasound protocols are performed initially within 48 hours of internal medicine ward admission by a pair of expert-beginner echographers. In case of admission during non-working days, the first scan can be done within 72 hours from admission. Follow-up scans are repeated 4 to 6 days later or on the day of discharge if it occurs before de fourth day. Experts and beginners execute the lund ultrasound protocols in sequence, reciprocally blinded, without accessing to clinical data files.
214575613|NCT02935725|DRUG|Low dose AUT00206 800mg|
214575614|NCT02935725|DRUG|High dose AUT00206 2000 mg|
214575615|NCT02935725|DRUG|Placebo|
214575616|NCT02935725|DRUG|Ketamine|
214575617|NCT02935725|OTHER|Saline|
214575618|NCT04713800|DEVICE|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR-TiB)|In group ZR-TiB the implant impressions will be taken using an intra-oral scanner and the respective scanbody. The restorations will be manufactured by means of CAD/CAM procedures using monolithic zirconia. For sufficient aesthetics, the zirconia restorations can be manually veneered with veneering ceramic only at the buccal surface, while the occlusal surface will remain monolithic and will be high-gloss polished. The zirconia restorations will be extra-orally cemented onto titanium base abutments (Straumann® Variobase® for crown, Straumann AG), correctly polished and delivered to the patient, by screw-retention onto the implant.
214575619|NCT04713800|DEVICE|porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM-GA)|In group PFM-GA implant impression will be taken using a polyvinyl siloxane or polyether impression material in a conventional manner with the use of stock trays and corresponding impression copings. The framework will be manufactured by the lost wax-technique using a gold-abutment (Straumann® Gold abutment for crown, Straumann AG) and a gold-alloy. All metal frameworks will be manually veneered with veneering ceramic, polished and glazed, and delivered to the patient, by screw-retention onto the implant.
214575620|NCT02289092|BEHAVIORAL|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
214575621|NCT04167527|DEVICE|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
214575622|NCT04167527|COMBINATION_PRODUCT|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
214575623|NCT06002633|OTHER|Alcohol|Participants will consume beverages containing alcohol.
214575624|NCT06002633|OTHER|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
214575625|NCT02569593|DIETARY_SUPPLEMENT|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
214575626|NCT04820218|DEVICE|With Try-on glasses|Subjects will be asked to measure their visual acuity with their try-on glasses
214575627|NCT03896152|DRUG|LNP023|approximately 2 year of Treatment with LNP023
214575628|NCT02163005|DRUG|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
214575629|NCT05210751|OTHER|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
214575630|NCT05483738|DIAGNOSTIC_TEST|Clinical assessment, blood samples, bone marrow and bone biopsy|Assessment of blood samples, bone marrow and bone biopsy
214575631|NCT01296802|DRUG|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
214575632|NCT01698190|PROCEDURE|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
214575633|NCT03141697|DEVICE|Carbon Dioxide|Insufflation of Carbon Dioxide
214575634|NCT03141697|DEVICE|Room air|Insufflation of room air
214575635|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
214575636|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
214575637|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
214575638|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
214575639|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
214575640|NCT01629732|DRUG|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
214575641|NCT01629732|DRUG|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
214709698|NCT06172127|DRUG|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
214575642|NCT06371859|BEHAVIORAL|"XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions"|"This study includes 1840 ultrasound images, split into UA and MCA flow and spectrum images, each duplicated for a total of 3680 images to compare explainable AI (XAI) feedback vs. no feedback. The investigators will provide matched sets of 40 images (one for the XAI group and one for the non-XAI group) to participants. Participants are matched based on their level of experience within each hospital (Resident physicians, obstetricians, and gynecologists with obstetric ultrasound experience).~All participants are instructed to place gates on the flow images of the umbilical artery and the middle cerebral artery and to assess the quality of the resulting flow curves. Specifically, for flow images, participants must identify the most appropriate gate placement. For spectral flow curves, they are to decide if the curves are of sufficient quality to guide medical management decisions."
214575643|NCT00978523|DRUG|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
214575644|NCT00699049|DRUG|Alpha blocker|oral
214575645|NCT00699049|DRUG|placebo|oral
214575646|NCT00699049|DRUG|solifenacin|oral
214575647|NCT02527642|OTHER|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
214575648|NCT02984293|DRUG|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
214575649|NCT02984293|DRUG|Placebo|Placebo once daily for 28 days.
214575650|NCT04403464|BEHAVIORAL|HABIT-ILE with REAtouch®|65h HABIT-ILE including 30h REAtouch®
214575651|NCT04403464|BEHAVIORAL|HABIT-ILE without REAtouch®|65h HABIT-ILE
214575652|NCT01854853|BEHAVIORAL|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
214575653|NCT01854853|BEHAVIORAL|Health Promotion|Health promotion intervention
214575654|NCT05865015|OTHER||
214575655|NCT01959997|PROCEDURE|Redo PVI|
214575656|NCT01959997|PROCEDURE|PVI + RDN|
214575657|NCT01883232|DEVICE|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
214575658|NCT01883232|DEVICE|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
214575659|NCT06261632|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
214575660|NCT00772330|DEVICE|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
214722034|NCT01670825|DRUG|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
214709699|NCT06172127|DRUG|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
214709700|NCT06172127|DRUG|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
214709701|NCT06295107|DIAGNOSTIC_TEST|Ankle Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
214709702|NCT06295107|DIAGNOSTIC_TEST|Knee Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
214575661|NCT01056497|DRUG|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
214575662|NCT01269723|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
214575663|NCT01269723|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
214575664|NCT02742402|OTHER|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
214575665|NCT02742402|OTHER|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
214575666|NCT02654301|DIETARY_SUPPLEMENT|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
214575667|NCT02654301|DIETARY_SUPPLEMENT|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
214575668|NCT02654301|DIETARY_SUPPLEMENT|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
214575669|NCT02654301|DIETARY_SUPPLEMENT|Control|sucrose 50 g + deionized water 100 g
214575670|NCT06009757|DEVICE|GUIDEX® guiding catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
214575671|NCT06009757|DEVICE|Launcher™ coronary guide catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
214575672|NCT01291940|OTHER|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
214575673|NCT01291940|OTHER|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
214575674|NCT00063427|DRUG|MAC-321|
214575675|NCT01786759|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
214575676|NCT01786759|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
214575677|NCT01353859|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
214575678|NCT01353859|DRUG|methotrexate|10-25 mg orally weekly
214575679|NCT04893343|OTHER|Antibiotic treatment|Antibiotic treatment
214575680|NCT04893343|OTHER|No antibiotic treatment|No antibiotic treatment
214575681|NCT02541877|DEVICE|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
214575682|NCT02541877|DEVICE|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
214575683|NCT02541877|DEVICE|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
214575684|NCT05366101|DRUG|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
214575685|NCT05366101|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
214575686|NCT00003601|DRUG|fenretinide|
214575687|NCT00003601|DRUG|tretinoin|
214575688|NCT01001338|DRUG|RDEA594|Uricosuric agent for the treatment of gout.
214575689|NCT01001338|DRUG|Placebo|Matching Placebo
214575690|NCT01001338|DRUG|Allopurinol|Allopurinol
214575691|NCT02347423|BIOLOGICAL|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
214575692|NCT02347423|BIOLOGICAL|IPV Vaccine SSI|
214575693|NCT05115643|BEHAVIORAL|Immobilization|Immobilization of left arm using a brace and sling.
214575694|NCT02015455|OTHER|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
214575695|NCT03082118|DEVICE|Vesair Bladder Control System|Intravesical balloon
214575696|NCT01242826|DRUG|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
214575697|NCT04033666|OTHER|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
214575698|NCT04033666|OTHER|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
214575699|NCT04073251|DIETARY_SUPPLEMENT|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
214575700|NCT04073251|DIETARY_SUPPLEMENT|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
214575701|NCT01181323|OTHER|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
214575702|NCT01181323|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
214575703|NCT01181323|OTHER|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
214575704|NCT01181323|BIOLOGICAL|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
214575705|NCT00766363|DRUG|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
214575706|NCT00766363|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
214575707|NCT00766363|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
214575708|NCT00766363|DRUG|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
214575709|NCT00766363|DRUG|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
214575710|NCT00766363|DRUG|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
214709703|NCT05879250|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214575711|NCT02890212|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
214575712|NCT02890212|DIETARY_SUPPLEMENT|placebo|administration of placebo pills for randomized subjects
214575713|NCT00469573|DRUG|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
214575714|NCT01153321|DRUG|AZD2423|100mg Oral dose od
214575715|NCT01153321|DRUG|AZD2423 Placebo|Oral dose od
214575716|NCT02751541|DRUG|Sunscreen Sport Spray (BAY987519)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
214575717|NCT02751541|OTHER|Untreated Skin|This site is patched without treatment as irradiated control.
214709704|NCT05879250|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214709705|NCT05879250|RADIATION|Radiation Therapy|Undergo routine radiation therapy
214709706|NCT05879250|DRUG|STAT3 Inhibitor WP1066|Given PO
214709707|NCT05879250|PROCEDURE|Surgical Procedure|Undergo removal or biopsy of tumor
214722035|NCT01670825|DRUG|Local anethestic injection|
214722036|NCT04287205|DRUG|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
214575718|NCT04461093|OTHER|Acupressure wristband and Palanosetron|"Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction."
214575719|NCT04393753|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
214575720|NCT03596333|OTHER|Retrospective chart review|We conducted a retrospective chart review to evaluate the stored ultrasound images used during labor epidural placement, as well as demographic and anesthetic variables.
214575721|NCT03811262|PROCEDURE|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
214575722|NCT03811262|PROCEDURE|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
214575723|NCT05330689|BIOLOGICAL|PRP injection dose (<5 billion platelets)|PRP injection with a dose of platelets that is less than 5 billion platelets
214575724|NCT05330689|BIOLOGICAL|PRP injection dose (between 5 and <10 billion platelets)|PRP injection with a dose of platelets that is between 5 and \<10 billion platelets
214575725|NCT05330689|BIOLOGICAL|PRP injection dose (between 10 and <20 billion platelets)|PRP injection with a dose of platelets that is between 10 and \<20 billion platelets
214575726|NCT05330689|BIOLOGICAL|PRP injection dose (20 billion or greater platelets)|PRP injection with a dose of platelets that is 20 billion platelets or greater
214575727|NCT05330689|OTHER|Saline injection control|Saline control
214575728|NCT05182281|DEVICE|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
214575729|NCT05182281|DEVICE|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
214575730|NCT05182281|OTHER|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
214575731|NCT02083120|DEVICE|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
214575732|NCT02083120|OTHER|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
214575733|NCT06448273|DRUG|TQB3702 tablets|TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
214575734|NCT06448273|DRUG|TQB3702 placebo|TQB3702 placebo contains no active substance.
214575735|NCT04848701|OTHER|latent phase duration|latent phase duration in post term pregnancies
214575736|NCT04848701|OTHER|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
214575737|NCT05526079|OTHER|Watchfuf waiting|Careful review of patient response with the hope of avoiding radical surgery.
214575738|NCT04325360|PROCEDURE|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
214575739|NCT04325360|PROCEDURE|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
214575740|NCT06281899|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg once daily
214722037|NCT00003282|DRUG|EF5|Given IV
214722038|NCT00003282|PROCEDURE|therapeutic conventional surgery|Undergo resection
214575741|NCT06281899|BEHAVIORAL|Low protein diet|Plant based low protein diet (0.6 g/kg IBW)
214575742|NCT01010334|OTHER|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
214575743|NCT04896151|DIAGNOSTIC_TEST|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath \& Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
214575744|NCT00911937|DRUG|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
214575745|NCT00911937|DRUG|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
214575746|NCT05161728|DIAGNOSTIC_TEST|PSMA-PET/CT|PSMA-PET/CT
214575747|NCT01841931|DRUG|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
214575748|NCT03898037|BEHAVIORAL|weight loss intervention|weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.
214575749|NCT03898037|DRUG|metformin intervention|metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
214722039|NCT00003282|PROCEDURE|biopsy|Undergo biopsy
214722040|NCT00003282|OTHER|pharmacological study|Correlative studies
214722041|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
214575750|NCT05573867|OTHER|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
214575751|NCT04617977|BEHAVIORAL|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
214575752|NCT04617977|BEHAVIORAL|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
214575753|NCT04428268|DRUG|Chloroquine Phosphate Tablets|Orally administered
214575754|NCT01315210|DRUG|D-Ribose Powder|5 g TID for 12 Weeks
214575755|NCT01315210|DIETARY_SUPPLEMENT|Placebo Powder|5 g TID for 12 Weeks
214575756|NCT03398213|OTHER|Acupuncture|Acupuncture
214575757|NCT03398213|OTHER|Sham procedure|Ear stimulation with plaster
214575758|NCT00700427|DRUG|atomoxetine hydrochloride|Oral 40-100 mg/day
214575759|NCT00700427|DRUG|Placebo|Oral delivery of matching placebo
214575760|NCT05033951|OTHER|Standard care|Both groups: standard care+ questionnaires
214575761|NCT04940403|DEVICE|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
214575762|NCT04940403|DEVICE|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
214575763|NCT03025685|PROCEDURE|TRUST technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
214575764|NCT03025685|PROCEDURE|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
214575765|NCT03025685|PROCEDURE|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
214575766|NCT05962801|DEVICE|Lumoral device, Lumorinse|Regular use of dual-light photodynamic therapy at home
214575767|NCT03887078|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
214575768|NCT03482401|DIETARY_SUPPLEMENT|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
214575769|NCT02849522|PROCEDURE|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
214575770|NCT02849522|PROCEDURE|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
214575771|NCT02849522|PROCEDURE|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
214575772|NCT02849522|PROCEDURE|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
214575773|NCT01870908|DRUG|tacrolimus|
214575774|NCT01870908|DRUG|biological agents|
214575775|NCT02232607|DRUG|Lacidipine, low dose|
214575776|NCT02232607|DRUG|Lacidipine, medium dose|
214575777|NCT02232607|DRUG|Lacidipine, high dose|
214575778|NCT02232607|DRUG|Placebo|
214575779|NCT01581359|DRUG|Triptorelin acetate|"* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
214575780|NCT00901433|DEVICE|Personal WheezoMeter|pulmonary sounds analyzer
214575781|NCT04539535|OTHER|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
214575782|NCT02935985|OTHER|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
214575783|NCT01805401|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
214575784|NCT01792050|DRUG|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
214575785|NCT01792050|OTHER|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
214575786|NCT01792050|DRUG|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
214575787|NCT01792050|DRUG|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
214575788|NCT00625261|OTHER|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
214575789|NCT01348568|DIETARY_SUPPLEMENT|low glycemic index diet with canola oil bread|
214575790|NCT01348568|DIETARY_SUPPLEMENT|High fiber diet|
214575791|NCT04938700|DRUG|probiotics|Probiotics as granules can be used for infants and adolescents
214575792|NCT04938700|DRUG|conventional medical treatment|Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
214575793|NCT00424385|DRUG|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
214575794|NCT05564416|BIOLOGICAL|Atezolizumab|Given IV
214575795|NCT05564416|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214575796|NCT05564416|PROCEDURE|Biospecimen Collection|Correlative studies
214575797|NCT05564416|PROCEDURE|Computed Tomography|Undergo CT
214575798|NCT05564416|PROCEDURE|Cystoscopy|Undergo cystoscopy
214575799|NCT05564416|DRUG|Erdafitinib|Given PO
214575800|NCT05564416|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214575801|NCT00373477|PROCEDURE|Generalist Care Manager vs Usual Care|
214575802|NCT05907109|BEHAVIORAL|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"* Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic."
214575803|NCT00355199|DRUG|Rituximab-HDS|Rituximab-HDS
214575804|NCT00355199|DRUG|Rituximab-CHOP|Rituximab-CHOP
214575805|NCT02104050|DRUG|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
214575806|NCT02104050|DRUG|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
214575807|NCT00582686|PROCEDURE|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
214575808|NCT00582686|PROCEDURE|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
214575809|NCT02503189|DRUG|KCT-0809 ophthalmic solution|
214575810|NCT02503189|DRUG|Placebo|
214575811|NCT06250244|DRUG|177Lu-LNC1011|\[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.
214575812|NCT02302378|PROCEDURE|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
214575813|NCT02302378|PROCEDURE|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
214575814|NCT06130280|RADIATION|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
214575815|NCT00319410|PROCEDURE|vaginoscopic hysteroscopy|
214575816|NCT01308138|BEHAVIORAL|Exercise training|exercise training
214575817|NCT01308138|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning
214575818|NCT00085787|DRUG|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
214575819|NCT02405728|DEVICE|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
214575820|NCT02405728|DEVICE|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
214575821|NCT01978327|DRUG|GSK2647544|repeat dose
214575822|NCT01978327|DRUG|drug-drug interaction|drug-drug interaction
214575823|NCT04120571|OTHER|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
214575824|NCT04120571|OTHER|sham control|no noise
214575825|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
214575826|NCT02503852|DEVICE|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
214575827|NCT02503852|DEVICE|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
214575828|NCT02503852|PROCEDURE|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
214575829|NCT02503852|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
214575830|NCT03231800|DRUG|dasotraline|dasotraline 2mg capsule once daily
214575831|NCT03231800|DRUG|Placebo|Placebo capsule once daily
214575832|NCT00110877|DRUG|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
214575833|NCT00110877|DRUG|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
214575834|NCT00859222|DRUG|LBH589|
214575835|NCT00859222|DRUG|bevacizumab|
214575836|NCT00034060|DRUG|Etanercept|
214575837|NCT00701831|DRUG|Insulin glargine|The dose is titrated according to patient needs
214575838|NCT03670095|DRUG|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
214722251|NCT06257615|BEHAVIORAL|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
214575839|NCT03670095|DRUG|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
214575840|NCT05715385|PROCEDURE|laser photocoagulation|"Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500"
214575841|NCT05715385|DRUG|eye drop bromfenac 0.09%|twice daily e/d bromfenac 0.09% for 6 weeks
214575842|NCT05715385|DRUG|Placebo|Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
214575843|NCT04984447|DEVICE|TNIB Catheter|Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
214575844|NCT00942305|DRUG|Brincidofovir|Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
214575845|NCT00942305|DRUG|Placebo|"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
214575846|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
214575847|NCT00400725|DRUG|Clobex® Vehicle Shampoo|Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
214575848|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
214575849|NCT02668549|OTHER|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
214575850|NCT02342470|DRUG|Placebo|Drug : Placebo
214575851|NCT02342470|DRUG|PMK-S005 1|Drug : PMK-S005 1 (50mg)
214575852|NCT02342470|DRUG|PMK-S005 2|Drug : PMK-S005 2 (100mg)
214575853|NCT02342470|DRUG|PMK-S005 3|Drug : PMK-S005 3 (150mg)
214575854|NCT01081600|OTHER|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
214575855|NCT00018239|PROCEDURE|Exercise|
214575856|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
214575857|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
214575858|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
214575859|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
214575860|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
214575861|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
214575862|NCT03233139|DRUG|Fianlimab|To be administered per protocol
214575863|NCT05303259|DRUG|Bevacizumab|Bevacizumab 2.5mg/kg, q2w, 4 cycles.
214575864|NCT04220840|PROCEDURE|Damage control strategy|"The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~1. definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~2. lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery"
214575865|NCT01593956|BEHAVIORAL|tDCS|
214575866|NCT04081623|DEVICE|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
214575867|NCT02545023|OTHER|Quality-of-Life Assessment|Complete an in-person one-on-one interview
214575868|NCT02545023|OTHER|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
214575869|NCT01375231|PROCEDURE|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
214575870|NCT01375231|PROCEDURE|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
214575871|NCT00142181|DRUG|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
214575872|NCT03929172|BIOLOGICAL|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
214575873|NCT03929172|DRUG|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
214575874|NCT04700020|DIAGNOSTIC_TEST|ITT|In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
214575875|NCT01670760|DEVICE|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
214575876|NCT01971710|BEHAVIORAL|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
214575877|NCT01971710|BEHAVIORAL|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
214575878|NCT01971710|BEHAVIORAL|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
214575879|NCT01748877|DRUG|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
214575880|NCT01748877|DRUG|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
214575881|NCT05033171|DIAGNOSTIC_TEST|3D Scanning|3D scanning of the rod using Artec Eva Spider type manual 3D scanner
214575882|NCT05033171|DIAGNOSTIC_TEST|EOS 2D/3D scanning|EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
214575883|NCT05884177|OTHER|Short-term cold exposure|Short-term cold exposure
214575884|NCT03697317|BEHAVIORAL|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
214575885|NCT03697317|BEHAVIORAL|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
214575886|NCT00324558|DRUG|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
214575887|NCT04718779|OTHER|Digital Engagement Application (GD App)|This is a chart review (prospective) data analysis study to describe the effect of the treatment change on the clinical parameters and patient reported outcomes (PROs) with the use of a digital engagement application (GD app) (to evaluate participants clinical engagement, shared decision making, emotional wellbeing, activities of daily living, goal attainment and Gaucher Disease specific measures).
214722252|NCT03247218|DRUG|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
214575888|NCT04718779|OTHER|No Intervention|This is a chart review (retrospective) data analysis study to describe the effect of the treatment change on the clinical parameters.
214575889|NCT00741390|DEVICE|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
214575890|NCT00741390|DEVICE|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
214575891|NCT00741390|DEVICE|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
214575892|NCT00741390|DEVICE|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
214575893|NCT00741390|DEVICE|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
214575894|NCT05901623|OTHER|'Ages and Stages Questionnaries' (ASQ)|''ASQ' is a screening tool for assessing the development of infants and preschoolers in the areas of communication, fine motor, gross motor, problem-solving and personal-social development, and 'ASQ:SE' is a screening tool for social-emotional development
214575895|NCT03718351|PROCEDURE|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
214575896|NCT03718351|PROCEDURE|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
214575897|NCT01044017|DRUG|Placebo|single oral dose
214575898|NCT01044017|DRUG|RO4998452|single oral doses
214575899|NCT02141022|OTHER|plasticity-based computerized cognitive remediation program|
214575900|NCT02141022|DRUG|Gileyna|
214575901|NCT01170104|DRUG|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
214575902|NCT01170104|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
214575903|NCT04738292|DRUG|Onapristone|Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
214575904|NCT04738292|DRUG|Fulvestrant|Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
214575905|NCT00965367|DEVICE|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
214575906|NCT06110390|DEVICE|High flow nasal oxygen|An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0
214575907|NCT05198895|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)
214575908|NCT04192019|DRUG|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
214575909|NCT04192019|DRUG|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
214575910|NCT05869578|PROCEDURE|Anesthesia Intervention|Patients exposed to any anesthesia intervention will be assessed to whether the exposure to anesthesia confers a risk for perioperative outcomes
214575911|NCT03573687|DIETARY_SUPPLEMENT|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
214575912|NCT03573687|OTHER|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
214575913|NCT04259944|DRUG|CAPOX|"DAY 1~* OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~* CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting."
214575914|NCT04259944|DRUG|Capecitabine|"DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting."
214722253|NCT02255955|DRUG|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
214575915|NCT04259944|DRUG|FOLFIRI|"Day 1:~* IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~* LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~* 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest."
214575916|NCT00484822|DRUG|Bemiparina Sodica|3.500 UI/día.
214575917|NCT00484822|DRUG|Heparina Cálcica|10.000 UI/día.
214575918|NCT01757431|DRUG|Eculizumab|
214575919|NCT01056718|DRUG|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
214575920|NCT05086276|DRUG|FX-322|Active Comparator
214575921|NCT05086276|DRUG|Placebo|Placebo
214575922|NCT00777088|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
214575923|NCT04495101|BIOLOGICAL|Prolastin|Intravenous infusion 120 mg/kg
214575924|NCT04495101|DRUG|Standard Medical Treatment|Standard medical treatment per local policies or guidelines
214575925|NCT05240079|DEVICE|Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).|Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
214575926|NCT03300973|PROCEDURE|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
214575927|NCT04018573|BEHAVIORAL|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
214575928|NCT04018573|BEHAVIORAL|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
214575929|NCT04648722|PROCEDURE|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
214575930|NCT06380673|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
214575931|NCT06380673|OTHER|Implementation of heated cow's milk|Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
214575932|NCT06380673|OTHER|No intervention|Healthy subjects undergo no intervention.
214575933|NCT00672945|DRUG|PRX-03140|
214575934|NCT00672945|DRUG|Placebo|
214575935|NCT04428073|BIOLOGICAL|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
214575936|NCT04670939|PROCEDURE|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
214575937|NCT02819830|BEHAVIORAL|Exercise Intervention|Combined strength and aerobic exercise
214575938|NCT04065945|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
214575939|NCT00421954|DRUG|Ziprasidone|subjects will use ziprasidone
214575940|NCT01636323|OTHER|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
214575941|NCT01170390|DRUG|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
214575942|NCT01170390|DRUG|Portia|30 mcg EE/0.15 mg LNG cyclically
214575943|NCT01170390|DRUG|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
214575944|NCT04847791|DIETARY_SUPPLEMENT|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
214575945|NCT04847791|DIETARY_SUPPLEMENT|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
214575946|NCT00349362|DRUG|Testosterone|Sustanon- 200mg intramuscular testosterone
214575947|NCT00349362|DRUG|0.9% saline|Saline intramuscular injection every two weeks
214575948|NCT00760474|DRUG|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
214575949|NCT00760474|DRUG|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
214575950|NCT01026506|DIETARY_SUPPLEMENT|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
214575951|NCT00515853|BEHAVIORAL|Biofeedback|Biofeedback sessions or biofeedback exercises
214575952|NCT01472458|BEHAVIORAL|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
214575953|NCT00119457|DRUG|TTP889|
214575954|NCT02801032|DRUG|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
214575955|NCT02801032|DRUG|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
214575956|NCT01810458|DEVICE|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
214575957|NCT01810458|PROCEDURE|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
214575958|NCT01810458|PROCEDURE|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
214575959|NCT01810458|PROCEDURE|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
214722254|NCT02255955|DRUG|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
214575960|NCT01810458|OTHER|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
214575961|NCT01810458|PROCEDURE|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
214575962|NCT01810458|DRUG|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575963|NCT01810458|DRUG|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575964|NCT01810458|DRUG|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214722255|NCT02255955|DRUG|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
214722256|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
214575965|NCT01810458|DRUG|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575966|NCT01810458|DRUG|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575967|NCT01810458|DRUG|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575968|NCT01810458|DRUG|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
214575969|NCT03957824|DIAGNOSTIC_TEST|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
214575970|NCT01334424|DRUG|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
214575971|NCT01394978|OTHER|Control|Standard surgical techniques including staples and sutures.
214575972|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant with standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
214575973|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant without standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
214575974|NCT01044225|DRUG|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
214575975|NCT01044225|DRUG|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
214575976|NCT02350985|DRUG|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
214575977|NCT02350985|DRUG|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
214575978|NCT01081132|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
214575979|NCT01081132|OTHER|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
214575980|NCT03825549|BEHAVIORAL|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
214575981|NCT03825549|BEHAVIORAL|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
214575982|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
214575983|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
214575984|NCT00964964|DRUG|placebo|Placebo injected s.c. (under the skin) four times weekly
214575985|NCT02577822|DEVICE|Taperloc standard length stem|
214575986|NCT02577822|DEVICE|Taperloc short length stem|
214575987|NCT03763890|DEVICE|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
214575988|NCT06404801|BEHAVIORAL|Stance Control|Instead of stability coming from a locked knee joint, the brace is able to lock and unlock at just the right time while walking
214575989|NCT00128089|BEHAVIORAL|Dietary treatment|
214575990|NCT02101385|DRUG|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
214575991|NCT02101385|OTHER|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
214575992|NCT02432196|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
214575993|NCT00287807|BEHAVIORAL|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
214575994|NCT01557114|DRUG|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
214575995|NCT01557114|RADIATION|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
214575996|NCT05607537|DRUG|E7386 Tablet|E7386 40 mg tablet.
214575997|NCT05607537|DRUG|(14C)E7386 Capsule|(14C)E7386 40 mg capsule.
214575998|NCT05607537|DRUG|(14C)E7386|(14C)E7386 administered intravenously.
214575999|NCT05375032|OTHER|Cycling combined with cognitive tasks|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
214576000|NCT05375032|OTHER|Cycling|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
214576001|NCT06296979|DEVICE|Phrenic nerve neuromodulation|The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
214576002|NCT06296979|PROCEDURE|common Physical therapy|the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
214576003|NCT05038163|OTHER|Nutrition Facts|The nutritional information label for each beverage is enlarged.
214576004|NCT05038163|OTHER|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
214576005|NCT05038163|OTHER|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
214576006|NCT06642896|DEVICE|pupillometer|describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children in intensive care and the operating room
214576007|NCT06642896|DEVICE|pupillometer|Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
214576008|NCT01905150|DRUG|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
214576009|NCT01905150|DRUG|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
214576010|NCT01905150|DIETARY_SUPPLEMENT|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
214576011|NCT00981136|PROCEDURE|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
214576012|NCT00981136|PROCEDURE|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
214576013|NCT02409524|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
214576014|NCT02409524|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
214576015|NCT02409524|BIOLOGICAL|CRCL|Autologous tumor-derived chaperone protein mixture
214576016|NCT05153720|PROCEDURE|Erector spinae plane block|Ultrasound guided erector spinae plane block
214576017|NCT05153720|PROCEDURE|Caudal block|Ultrasound guided caudal block
214576018|NCT05423652|DEVICE|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
214576019|NCT05423652|OTHER|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
214576020|NCT06478342|PROCEDURE|ablation|Pulsed field ablation, MRI and TEE examinations (LA strain)
214576021|NCT05620797|OTHER|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
214576022|NCT05620797|OTHER|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
214576023|NCT05572593|GENETIC|Pharmacogenomics (PGx) genetic testing|A buccal swab to collect cells from the inside the cheek
214576024|NCT06052670|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)
214576025|NCT01147536|BIOLOGICAL|HSPPC-96|
214576026|NCT04785105|OTHER|No intervention|No intervention
214576027|NCT03916640|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
214576028|NCT03916640|DRUG|Placebo|Subcutaneous injection of 0.9% NaCl
214576029|NCT03916640|DRUG|Symlin®|Subcutaneous injection of pramlintide
214576030|NCT03916640|DRUG|Humulin®|Subcutaneous injection of human insulin
214576031|NCT03916640|DRUG|Humalog®|Subcutaneous injection of insulin lispro
214576032|NCT06092567|PROCEDURE|Group A ( Oblique Incremental Placement Technique)|In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
214576033|NCT06092567|PROCEDURE|Group B (Bulk-fill Placement technique)|In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm
214576034|NCT04715438|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
214576035|NCT04116801|PROCEDURE|microsurgical resection|resection of cerebral metastases by microsurgery
214576036|NCT02085395|DRUG|SR-T100 ® Gel|
214709708|NCT04268004|BEHAVIORAL|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
214576037|NCT03762200|DEVICE|SURGICEL Powder|SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
214576038|NCT02631577|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
214576039|NCT02631577|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
214576040|NCT02631577|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
214576041|NCT02417077|OTHER|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
214576042|NCT02241590|DRUG|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
214576043|NCT02241590|DRUG|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
214576044|NCT02296333|DRUG|ondansetron|8 mg intravenous in the skin closure
214576045|NCT02296333|DRUG|isotonic|8 mg intravenous in the skin closure
214576046|NCT04002843|OTHER|paraclinical evaluation of single fibre|ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
214576047|NCT02299089|DRUG|octreotide FluidCrystal® injection depot|
214576048|NCT00071461|DRUG|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
214576049|NCT00071461|DRUG|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
214576050|NCT04949243|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionaires
214576051|NCT06645080|OTHER|Focus group or interview participation|90 minute focus group or 60 minute interview participation
214576052|NCT06645080|OTHER|Delphi survey participation|Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
214576053|NCT03222804|DIETARY_SUPPLEMENT|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
214576054|NCT05816538|PROCEDURE|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
214576055|NCT05816538|PROCEDURE|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
214576056|NCT05816538|DEVICE|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
214576057|NCT05816538|DEVICE|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)\], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
214576058|NCT05816538|DRUG|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
214576059|NCT05816538|PROCEDURE|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium \[Zemuron®, Schering - Plow\] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium \[Zemuron®, Schering - Plow\] 0.01 mg / kg / min per perfusor.
214576060|NCT03430180|DRUG|Naloxone hydrochloride|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
214576061|NCT03430180|DRUG|Placebo|One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
214576062|NCT06336356|DRUG|Baxdrostat|Baxdrostat will be administered orally once daily.
214576063|NCT06336356|DRUG|Placebo|Placebo will be administered orally once daily.
214576064|NCT04613414|OTHER|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
214576065|NCT06610487|DRUG|FT1|Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.
214576066|NCT06610487|DRUG|Placebo|Placebo will be administered.
214576067|NCT06871488|DRUG|CNS Stimulant|The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo for a total of 14 days of data collection.
214576068|NCT06871488|DRUG|Placebo|Placebo is only used during the second of two treatment phases. The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo.
214576069|NCT06871488|OTHER|CNS Stimulant open label first phase|The first treatment phase will optimize CNS stimulant dose under open label conditions using any approved FDA medication for pediatric ADHD at the FDA approved doses.
214576070|NCT06901024|OTHER|Tendon Gliding Exercise|Tendon gliding exercises were performed for both hands in a sequential manner, with 20 repetitions in 3 sets. The exercises started with fingers and wrist positioned in extension. Subsequent positions included the hook position, full fist position, MCP joint at 90° flexion with finger extension, and MCP and proximal interphalangeal (PIP) joints at 90° flexion positions, with a 5-second hold at each position. During the TG exercises, the hand and fingers are brought to five different positions
214576071|NCT06901024|OTHER|Neuromobilization Exercise|The neuromobilization exercises included median, radial and ulnar nerve mobilizations. For median nerve mobilization, the patient's wrist was placed in extension, the shoulder in 90° abduction, the forearm in supination, the elbow extended, and the head positioned in lateral flexion toward the same side. For radial nerve mobilization, the wrist was initially placed in flexion and ulnar deviation, the forearm in pronation, with the elbow extended, and the head positioned in lateral flexion toward the same side. For ulnar nerve mobilization, the wrist was positioned in extension and radial deviation, the elbow fully flexed, the forearm in pronation, the shoulder in 90°abduction, and the head in lateral flexion toward the same side. The head was then moved into lateral flexion toward the opposite side while extending the elbow. The neuromobilization protocol was performed in 4 sets of 10 repetitions, with a 5-second hold for each movement.
214576072|NCT06901024|OTHER|Robotic Assitive Exercise|The robotic glove set used in this study weighs 497 grams, powered by a battery weighing 170 grams that provides a 5 V voltage and 1 A current. Made from elastic fabric, the glove wraps around all fingers on both the dorsal and palmar sides. The palm section of the glove is hollow. The device features four Velcro straps: one at the wrist, one across the web space between the thumb and index finger, one between the second and third fingers, and one between the fourth and fifth fingers, securing the inner side of the wrist. The robotic glove facilitates passive joint movements through pneumatic air pressure. The device offers several benefits, including proprioceptive stimulation, visual input, increased functional independence, pain and edema reduction, enhanced lymphatic and blood circulation, improved coordination and hand dexterity, as well as increased grasp and compression strength.
214709709|NCT05558696|DRUG|Bomedemstat|Oral tablet
214709710|NCT03995108|DRUG|Mavorixafor|Mavorixafor provided as 100 mg capsules.
214709711|NCT03995108|DRUG|Placebo|Placebo matching to mavorixafor capsules
214709712|NCT06394804|DRUG|Avutometinib|Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks
214709713|NCT06394804|DRUG|Defactinib|Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks
214709714|NCT06394804|DRUG|Letrozole|2.5 mg PO daily
214709715|NCT05818865|DEVICE|CLG|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
214709716|NCT03519672|OTHER|No intervention|This is a non-interventional study.
214576073|NCT06901024|OTHER|Conventional Exercises|Wrist extensor exercise, wrist radial deviation exercise, and wrist flexor exercise were perfomed using a 1-kg dumbbell. Holding the 1-kg dumbbell against gravity for 10 seconds, with the shoulder flexed at 90°, elbow extended, and forearm in pronation position. Squeezing exercise with a green soft ball (Thera-Band; diameter: 5 cm); the ball was squeezed for 10 seconds, followed by relaxing. Pushing a blue Pilates ball (Thera-Band; diameter: 20 cm) against the wall with fingers in extension position. Squeezing a black Pilates ring (Thera-Band; diameter: 38 cm) with the fingers, while the MCP joints are in extension and the wrist in a neutral position.
214576074|NCT06898411|DEVICE|Single tooth restoration with IPS e.max|Examination of single tooth restorations with IPS e.max after a wearing time of more than 15 years. Intraoral situation will be examined similar to a standard dental examination while single tooth restorations will be documneted by photos.
214576075|NCT05963100|BIOLOGICAL|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
214576076|NCT06896617|DRUG|Estradiol + Progesterone|Pregnancies with absence of corpus luteum(PC-FET)
214576077|NCT06896617|DRUG|Ovitrelle ( Hcg 250 mcg)|NC-FET(natural cycle FET, endometrial preparation with presence of CL)
214576078|NCT06900803|DEVICE|interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)|The dashboard serves as an interactive communication tool during education sessions, promoting real-time dialogue between patients and pharmacists. By collaboratively entering patient-specific data, patients gain insight into personalized visual representations of actionable risk factors. Initially, data specific to the patient are inputted to generate a baseline assessment, presenting hazard ratios that indicate the current condition and pinpoint areas needing improvement. To simulate potential changes, an alternative dataset is deliberately entered, portraying either improvement or deterioration in the patient's status, thereby acting as a motivational tool. Throughout the education session, the dashboard continuously updates hazard ratios, enabling direct comparisons of patient outcomes under varying conditions or treatment scenarios. This dynamic process clearly demonstrates individualized risk-benefit trade-offs in diverse treatment contexts.
214576079|NCT06900049|DRUG|LE051|LE051 dose escalation : dose 1 and dose 2.
214576080|NCT06735001|PROCEDURE|FA ablation|Ablation of the FA
214576081|NCT06735001|BIOLOGICAL|Lab test|Blood collection
214576082|NCT06115499|DRUG|Nab paclitaxel|Given IV
214576083|NCT06115499|DRUG|Gemcitabine|Given IV
214576084|NCT06115499|DRUG|Cisplatin|Given IV
214576085|NCT06115499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214576086|NCT06115499|PROCEDURE|Computed Tomography|Undergo CT
214576087|NCT06115499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214576088|NCT06895174|DEVICE|Titanium miniplates|Titanium miniplates are used for open reduction and internal fixation in mandible fractures according to Champy's principle of osteosynthesis
214576089|NCT06895174|OTHER|Arch Bar|Arch bars are used for intermaxillary fixation in facial fractures as a mean of closed reduction.In this study arch bars placed in tension zone will be combined with single miniplate placed at inferior border of mandible and this modality efficacy will be compared with two miniplate group.
214576090|NCT05342090|OTHER|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
214576091|NCT06546020|DIETARY_SUPPLEMENT|Haskap berry smoothie|A smoothie blend of berries and water
214576092|NCT06546020|DIETARY_SUPPLEMENT|Placebo comparator|A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
214576093|NCT03973931|BEHAVIORAL|Nudge|Interventions will include a variety of text messages aimed at improving medication adherence.
214576094|NCT06898424|BEHAVIORAL|Ketoflex 12/3 Diet|plant-based ketogenic diet combined with intermittent fasting (12/3)
214709717|NCT01381718|DRUG|modafinil|Given PO
214576095|NCT04807712|OTHER|non interventional study|
214709718|NCT01381718|OTHER|placebo|Given PO
214709719|NCT01027572|DEVICE|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
214576096|NCT06907082|DRUG|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.
214576097|NCT06905860|DRUG|Platelet-rich fibrin (PRF)|"The Intervention Group consists of the intra-articular application of PRF in the knee. The applications will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. A total of 3 applications of PRF will be conducted, with intervals of 14 to 28 days between them.~10ml of PRF will be applied intra-articularly, on an outpatient basis, with patients being instructed to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
214576098|NCT06905860|DRUG|Corticosteroid|"The procedures will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. In this group, 40ml of peripheral blood will also be collected and placed for centrifugation. During the preparation for the application, a nurse (who will not participate in the study) will have a list of the randomization and will prepare the material in an opaque syringe (blinding both the applicator and the patient).~In this group of patients, a solution of 10ml containing 40mg of Triamcinolone will be administered in the first application and 10ml of saline in the second and third applications, with intervals of 14 to 28 days between the applications. The applications will be performed on an outpatient basis, with patients being advised to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
214576099|NCT06907862|OTHER|Reference Treatment|≥4 servings/day of soy products categorized as non-ultra processed according to the NOVA classification system (NOVA non-Group 4): ≥2 servings/day of a Group 1 soy milk and ≥1 serving/day of another Group 1 food, such as edamame or roasted soy nuts, and ≥1 serving/day of a Group 3 food, such as tofu or tempeh) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
214576100|NCT06907862|OTHER|Control|Usual care provided by their primary care physician and/or specialist.
214576101|NCT06907862|OTHER|Active Treatment|≥4 servings/day of soy products categorized as ultra processed according to the NOVA classification system (NOVA Group 4): ≥2 servings/day of soy milk and ≥2 servings/day of other soy-based products such as soy yogurt, soy burgers, or soy ground round) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
214576102|NCT06907225|OTHER|None-placebo|None - observational study
214576103|NCT06906991|BEHAVIORAL|FIBROWALK|"FIBROWALK is a structured, multicomponent therapeutic program designed specifically for patients with fibromyalgia, combining evidence-based interventions that target both physical and emotional symptoms of the condition. Unlike traditional standalone interventions (e.g., exercise-only or CBT-only), FIBROWALK integrates multiple therapeutic modalities in a holistic, group-based format to address the broad symptom profile of fibromyalgia, including chronic pain, fatigue, and impaired functionality. Sessions are delivered in groups of up to 20 participants, fostering peer support and shared learning.~Key Components of FIBROWALK:~* Therapeutic Exercise~* Pain Neuroscience Education~* Cognitive-Behavioral Therapy~* Mindfulness-Based Stress Reduction~* Psychoeducation"
214576104|NCT06906991|BEHAVIORAL|Unified Protocol|"The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy (CBT) intervention designed to address emotional dysregulation across a range of mental health conditions. Unlike traditional disorder-specific CBT interventions (e.g., CBT for anxiety or depression), the UP targets core emotional processes common to multiple disorders, making it particularly suitable for fibromyalgia patients who often experience comorbid anxiety, depression, and emotional distress. Unlike condition-specific therapies, the UP addresses the shared emotional mechanisms underlying anxiety, depression, and chronic pain, making it well-suited for fibromyalgia patients with complex emotional and physical symptomatology. UP emphasizes increasing tolerance to emotional and physical discomfort, a critical area for fibromyalgia patients who often experience heightened emotional reactivity and pain sensitivity.~The UP is delivered individually and consists of 12 structured, manualized modules."
214576105|NCT06907108|DEVICE|Systemic vibratory therapy|The interventions were performed on a vibratory platform with side-alternating displacement of the base (Novaplate Fitness Evolution model, DAF Produtos Hospitalares Ltda, São Paulo). The individual was positioned barefoot, with knees flexed at 130º on the base of the vibratory platform. The protocol was performed over a 6-week period with 2 weekly sessions, totaling 12 sessions. The frequency was 5-16Hz according the protocol, and the peak-to-peak displacement was 2.5, 5.0, and 7.5 mm in all sessions. During the protocol, the individuals performed static and dynamic squats, with one static and one dynamic session (interleaved). The variables were evaluated before and after the interventions.
214576106|NCT06907121|DRUG|Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma|Intervention will be an intra-articular injection of 10 units of HGH and 10 mL PRP conjunct. Three total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.
214576107|NCT06906003|OTHER|visual rehabilitation program|"I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of table activities V. meeting: meeting with caregivers."
214576108|NCT06906484|DEVICE|echocardiography|analyse echocardiographic reports on cardiac abnomalies
214576109|NCT06901947|DIETARY_SUPPLEMENT|Glucose drink|Intervention group will receive maltodextrin glucose drinks 2 hours prior to the operation
214576110|NCT04574856|RADIATION|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
214576111|NCT04574856|DRUG|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
214576112|NCT04574856|DRUG|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
214576113|NCT06907589|DEVICE|Motor Data Analysis|The SensMode System includes wearable devices for upper and lower limb motion analysis. The upper limb device, SensHand, consists of 3 sensorized elements: 2 sensorized rings to be placed at the level of the distal phalanx of the thumb and forefinger of the hand and 1 sensorized wristband to be placed at the level of the distal portion of the forearm near the wrist. Each element of SensHand allows the acquisition of inertial data with respect to the biomechanics of the arm-forearm-wrist and the first three fingers of the hand, measuring the 3 components in space of linear acceleration, angular velocity, and magnetic field. The lower limb device, SensFoot, is a device that integrates the same electronic components as the bracelet and is placed in a plastic housing shaped like a small rectangular parallelepiped that is placed over the shoe.
214576114|NCT06907368|OTHER|Quantitative Gait Analysis|"The following explorations will be carried out pre-operatively (pre-OP), then post-operatively at 3 months (post-OP3) and 12 months (post-OP12) :~* Quantified gait analysis (QGA)~* Functional tests (mechanical analysis of everyday tasks):~  * SIT-TO-STAND test (test consisting of standing up and sitting down on a chair)~ * STEP INITIATION test (test consisting of walking up a step and then down)~* Proprioceptive tests :~  * Joint Position Sense (JPS) (angle memorization and reproduction test at the knee joint)~ * OBSTACLE CLEARANCE test (test consisting in simulating the clearance of an obstacle)~* Questionnaires :~  * Functional questionnaires :~ * KSS (Knee Society Score)~ * SKV (Simple knee value)~ * KOOS (Knee Injury and Osteoarthritis Outcome Score)~ * Quality of life (EQ5D-5L) The total duration of each exploration session is estimated at 1 hour ."
214576115|NCT06906172|BEHAVIORAL|Plant-based intensive lifestyle intervention|The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.
214576116|NCT06906172|OTHER|Standard of Care|Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.
214576117|NCT06906939|DEVICE|repetetive transcranial magnetic stimulation|rTMS treatments will be performed with the MagVenture MagPro X100 stimulator equipped with the Cool-B70 A/P for sham-controlled stimulation. The coil has two sides, one of which is shielded so that no energy is imparted to the brain when the shielded side is applied to the subject's head. Small skin electrodes are applied to the scalp under the coil that impart a small microcurrent to the scalp simulating the sensation of active treatment. The operator receives a code from the device instructing them which side of the coil to use for each subject, ensuring complete treatment blinding.
214576118|NCT06906575|BEHAVIORAL|A Comprehensive Intervention to Improve Sexual and Relationship Well-being for Cancer Patients and Their Partners|"This intervention targets three core areas:~Body Image Improvement - Supports patients in understanding and accepting physical changes resulting from cancer treatments, fostering positive attitudes toward body image and self-esteem.~Psychological Flexibility Enhancement - Utilizes ACT-based strategies to help participants acknowledge and adaptively manage difficult emotions, thoughts, and experiences related to cancer diagnosis and treatment.~Dyadic Coping Skill Training - Provides structured skill-building exercises to strengthen mutual support mechanisms, enhance effective partner communication, and promote collaborative problem-solving when facing cancer-related stressors.~The intervention consists of six weekly sessions (90-120 minutes each), delivered in a hybrid format (virtual and in-person) to maximize accessibility. Each session integrates psychoeducational presentations, facilitated discussions, guided experiential exercises."
214722257|NCT05737667|BEHAVIORAL|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
214722258|NCT01851525|DEVICE|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
214576119|NCT06907069|DRUG|Intravenously atomized polycolistin E sodium mesylate|To explore the therapeutic effect of CMS combined with intravenous atomization in patients with carbapenem resistant gram-negative bacteria in lung infection.
214576120|NCT06906055|DEVICE|Multicath|Use of a multifunctional catheter for revascularization of blocked arteries below the knee
214576121|NCT06906055|DEVICE|Standard of Care (SOC)|Use of single function crossing catheters, diagnostic catheters, angioplasty balloon catheters
214576122|NCT06907303|DIAGNOSTIC_TEST|EndoDx|PCR assay for Endometriosis diagnosis
214576123|NCT06906393|BEHAVIORAL|Preventive treatment|4-second Sprint Interval Training (SIT) over 8 weeks to improve cardiovascular health.
214576124|NCT06906718|DEVICE|Implantation of an intraocular lens|Successful bilateral IOL implantation into the capsular bag with at least 12 months follow-up.
214576125|NCT00743301|OTHER|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
214576126|NCT03258684|DRUG|Hydrocortisone, Vitamin C, and Thiamine|Intervention
214576127|NCT03258684|OTHER|Normal saline|Placebo
214576128|NCT01234077|DEVICE|CPC M1|CPC M1
214576129|NCT05389085|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids|In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
214576130|NCT02516332|DRUG|Lexapro|
214576131|NCT02516332|DRUG|Placebo|
214576132|NCT02516332|BEHAVIORAL|Supervised Aerobic Exercise|
214576133|NCT03838887|DEVICE|ultrasound machine|Ultrasound machine with a vocal software
214576134|NCT00214578|DRUG|Seroquel (quetiapine)|
214576135|NCT00134745|DRUG|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
214576136|NCT02139293|DEVICE|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
214709720|NCT01906957|OTHER|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
214576137|NCT00661479|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
214576138|NCT00661479|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
214576139|NCT00661479|DRUG|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
214576140|NCT00661479|OTHER|Sham (no implant)|Sham in the fellow eye on Day 1.
214576141|NCT04613232|DEVICE|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
214576142|NCT02275832|DRUG|3 % Minoxidil lotion|
214576143|NCT02275832|DRUG|Placebo|
214576144|NCT00828477|DRUG|Xibrom|Xibrom: two times a day for seven days in the first eye.
214576145|NCT00828477|DRUG|Nevanac|Nevanac: three times a day for seven days in the second eye.
214576146|NCT02704754|DRUG|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
214576147|NCT02704754|OTHER|placebo|Pill with inactive ingredients
214576148|NCT01048554|DRUG|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
214576149|NCT01048554|DRUG|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
214576150|NCT05216497|DRUG|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
214576151|NCT05216497|DRUG|Placebo|1-2 capsules for 7 days on top of standard therapy
214576152|NCT05999643|DIAGNOSTIC_TEST|Drug: 68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image SpA lesions in SI joints, spine, musculoskeletal and the extra-articular involvement by PET/CT.
214576153|NCT03042897|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo DASH diet
214576154|NCT03042897|BEHAVIORAL|Exercise Intervention|Undergo in aerobic exercise
214576155|NCT03042897|OTHER|Laboratory Biomarker Analysis|Correlative studies
214576156|NCT03042897|OTHER|Quality-of-Life Assessment|Ancillary studies
214576157|NCT05611008|DEVICE|CDSS|A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.
214576158|NCT05611008|DEVICE|Patient Portal|A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
214576159|NCT03809429|DRUG|FE 999049 + GnRH agonist (GONAPEPTYL)|Pre-filled injection pen
214576160|NCT03809429|DRUG|FE 999049 + GnRH antagonist (CETROTIDE)|Powder and solvent for solution for injection
214576161|NCT00840151|BEHAVIORAL|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
214576162|NCT02596438|OTHER|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
214576163|NCT00538915|BIOLOGICAL|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
214576164|NCT04639271|DRUG|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
214576165|NCT04639271|DRUG|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
214576166|NCT04639271|DRUG|Abraxane|Abraxane 125mg/M2, qw iv
214709721|NCT01906957|OTHER|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
214709722|NCT03025152|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
214709723|NCT03025152|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
214709724|NCT00630708|DRUG|Benazepril|20 mg per day
214576167|NCT01251185|DEVICE|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
214576168|NCT02323282|DRUG|ropivacaine|
214576169|NCT05273697|PROCEDURE|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
214576170|NCT05273697|PROCEDURE|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
214576171|NCT02943486|OTHER|dac-MSCs|Cell-free therapy
214576172|NCT02943486|OTHER|MSCs|Cell-based therapy
214576173|NCT02943486|DRUG|Fitostimoline|Triticum vulgare
214576174|NCT03611413|PROCEDURE|ERAS care|ERAS PROTOCOL
214576175|NCT04214600|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills"
214576176|NCT02978378|OTHER|biomarker levels|The level of the biomarker hyaluronic acid will be measured
214576177|NCT02501798|DRUG|Methylphenidate|Drug: Methylphenidate
214576178|NCT02501798|DRUG|Placebo|Drug: Placebo
214576179|NCT01968993|DEVICE|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
214576180|NCT06002893|DIETARY_SUPPLEMENT|Cholesfytol NG®) supplement|General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement
214576181|NCT04079751|PROCEDURE|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
214576182|NCT04079751|PROCEDURE|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
214576183|NCT03507777|DEVICE|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
214576184|NCT03507777|DEVICE|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
214576185|NCT04719975|OTHER|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
214709725|NCT00630708|DRUG|Losartan|100 mg per day
214709726|NCT00630708|DRUG|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
214709727|NCT00703170|DRUG|Temsirolimus|
214709728|NCT00703170|DRUG|Pegylated liposomal doxorubicin|
214709729|NCT04503850|DRUG|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
214709730|NCT04503850|DRUG|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
214709731|NCT04309669|DRUG|TOT'HEMA|three ampoules per day during 12 weeks
214722259|NCT03487315|DIAGNOSTIC_TEST|immunoblot|immunoblot
214576186|NCT04719975|OTHER|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
214576187|NCT02611336|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
214576188|NCT02233452|DRUG|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
214576189|NCT02233452|DRUG|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
214576190|NCT02233452|DRUG|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
214576191|NCT04064593|DIAGNOSTIC_TEST|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
214576192|NCT03009552|PROCEDURE|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
214576193|NCT04268290|COMBINATION_PRODUCT|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
214576194|NCT04397991|OTHER|Furosemide|Patients will receive nebulised furosemide solution 1 mg/kg
214576195|NCT04397991|OTHER|Placebo|Patients will receive nebulised 0.9% saline
214576196|NCT04620304|BIOLOGICAL|UB-421 SC(dB4C7C22-6 mAb)|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
214576197|NCT00875498|PROCEDURE|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
214576198|NCT00875498|PROCEDURE|sham iTBS|iTBS placebo (placebo coil)
214576199|NCT00442273|DRUG|Umbilical cord serum eyedrops|
214576200|NCT00442273|DRUG|Autologous serum eyedrops|
214576201|NCT00229437|DRUG|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
214576202|NCT00229437|DRUG|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
214709732|NCT03935607|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
214709733|NCT05326217|OTHER|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
214709734|NCT05326217|OTHER|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
214709735|NCT04922697|OTHER|Educational Intervention|Watch educational videos and use wearable air pollution sensor
214709736|NCT04922697|OTHER|Questionnaire Administration|Complete questionnaires
214709737|NCT02662413|OTHER|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
214709738|NCT04285944|OTHER|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
214709739|NCT04563819|GENETIC|Genom-wide association study (GWAS) and biological pathway analyses|
214709740|NCT02976727|DRUG|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
214576203|NCT00229437|DRUG|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
214576204|NCT00229437|DRUG|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
214576205|NCT06226675|PROCEDURE|PENG Block|To apply local anesthetic under psoas tendon
214576206|NCT06226675|PROCEDURE|LFCN block|to apply local anesthetic around lateral femoral cutaneous nerve
214576207|NCT03299998|PROCEDURE|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
214576208|NCT03299998|PROCEDURE|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
214576209|NCT02241005|OTHER|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
214576210|NCT02241005|OTHER|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
214576211|NCT00873431|BIOLOGICAL|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
214576212|NCT01552603|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
214576213|NCT04285203|OTHER|Educational Video Intervention|Educational videos
214576214|NCT01587027|DRUG|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
214576215|NCT01587027|DRUG|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
214576216|NCT01587027|DRUG|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
214576217|NCT01164644|DRUG|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
214709741|NCT02976727|DRUG|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
214576218|NCT01164644|DRUG|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
214576219|NCT03051789|DEVICE|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect \~30 ml of menstrual blood when inserted into the vaginal canal
214576220|NCT03051789|OTHER|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
214576221|NCT03051789|OTHER|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
214576222|NCT01004055|DEVICE|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
214576223|NCT01004055|DRUG|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
214576224|NCT01004055|DRUG|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
214576225|NCT04797650|DRUG|CTP-543 matching placebo|Administered as tablets.
214576226|NCT04797650|DRUG|CTP-543|Administered as tablets.
214576227|NCT00465920|BEHAVIORAL|modified cognitive behavioural therapy (mCBT)|
214576228|NCT04100876|GENETIC|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
214576229|NCT00657020|DRUG|Nicotine|Nicotine lozenge containing 4 mg of nicotine
214576230|NCT00657020|DRUG|Placebo|Placebo lozenge
214576231|NCT03789448|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
214576232|NCT03084341|PROCEDURE|Neuromuscular Electrical Elongation|Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
214576233|NCT03084341|PROCEDURE|Proprioceptive Neuromuscular Facilitation|Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
214576234|NCT03862001|BEHAVIORAL|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
214576235|NCT06245993|OTHER|EOS imaging|EOS imaging 3 years after skin traction treatment for femoral shaft fracture.
214576236|NCT04925687|BIOLOGICAL|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
214576237|NCT00244816|DRUG|Taxoprexin|
214576238|NCT04365023|DRUG|platinum chemotherapy|First line platinum chemotherapy
214576239|NCT04661800|OTHER|Sniffin's stick test|The sniffin's stick test is a three-part test consisting of smelling odor pens: 1) determining a detection threshold, 2) discriminating ability, 3) ability to identify odors. It lasts about 30 minutes, is achievable in the room.
214576240|NCT04484103|OTHER|Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.|"The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used."
214576241|NCT06524206|BEHAVIORAL|The Awareness, Courage and Love Intervention|Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
214576242|NCT00092352|DRUG|MK0966, rofecoxib|
214576243|NCT00092352|DRUG|Comparator: celecoxib, placebo|
214576244|NCT03848013|DEVICE|Q switched Nd YAG laser|Laser device emitting Q switched Nd YAG aiming for skin toning
214576245|NCT03848013|DEVICE|Fractional CO2 laser|Laser device emitting fractionated ablative laser aiming for skin resurfacing
214576246|NCT02651857|DEVICE|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
214576247|NCT02651857|DEVICE|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
214576248|NCT00279643|PROCEDURE|Laser Hair Removal|
214576249|NCT03623854|BIOLOGICAL|Nivolumab|Given IV
214576250|NCT03623854|BIOLOGICAL|Relatlimab|Given via infusion
214576251|NCT06148363|DEVICE|High-Definition transcranial Direct Current Stimulation (HD-tDCS)|tDCS, or Transcranial Direct Current Stimulation, is a non-invasive brain stimulation technique that involves applying a small, constant direct current through electrodes placed on the scalp to modulate neuronal activity in specific brain regions.
214576252|NCT06148363|DEVICE|sham High-Definition transcranial Direct Current Stimulation (HD-tDCS)|In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
214576253|NCT01144052|DRUG|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units \[MIU\])
214576254|NCT01144052|DRUG|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
214576255|NCT02530164|DEVICE|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
214576256|NCT05070442|BEHAVIORAL|Norm-based messaging and peer comparison features|"Participants are shown a version of NUSMart which includes Nutri-Score labels that are enabled and displayed besides all the products in the store. Additionally, they are shown a video that gives them background information about Nutri-Score labels and describes the following features enabled in this intervention:~* Norm-based messaging will be displayed in the form of a happy or sad emoticon based on whether the participant's current basket average Nutri-Score (weighted by number of servings) is above or below other shoppers (Nutri-Score=3.98).~* Peer comparison will be implemented as a vertical ruler display of the participant's current basket average Nutri-Score (weighted by number of servings) as well as that of their peers.~Nutri-Score=3.98 was chosen as it is 10% better than the mean Nutri-Score of baskets purchased by participants in the Nutri-Score labelled intervention arm of a prior study."
214576257|NCT05070442|BEHAVIORAL|Financial Incentives leveraging on loss aversion|"Participants are informed that they have received an additional $5 towards their participant reimbursement. However, this amount will be forfeited if they check-out with a basket average Nutri-Score (weighted by the number of servings) that falls below the average Nutri-Score of other shoppers i.e. 3.98. An indicator on the screen that informs the participants of this potential forfeiting will be included."
214576258|NCT02206477|DRUG|Dimethyl Sulfoxide|
214576259|NCT02206477|DRUG|Saline 0.9%|
214576260|NCT05014711|DRUG|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
214576261|NCT05014711|DRUG|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
214576262|NCT03448770|DRUG|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
214576263|NCT03448770|DRUG|Lactulose : 20-30gm|Lactulose : 20-30gm
214576264|NCT06226324|OTHER|neuropsychological test|The subjects were evaluated for memory, cognition, mood and sleep
214576265|NCT05514041|DRUG|Varenicline solution|OC-01 nasal spray 0.03 mg
214576266|NCT05514041|DRUG|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
214576267|NCT00253084|DRUG|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
214576268|NCT00253084|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
214576269|NCT00253084|DRUG|IPX054 Placebo|Placebo to match IPX054 200 mg
214576270|NCT00253084|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
214576271|NCT05839392|BIOLOGICAL|Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal
214576272|NCT04488627|DIAGNOSTIC_TEST|Conventional transthoracic echocardiographic examination at the intensive care unit.|Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
214576273|NCT05243238|DIETARY_SUPPLEMENT|dietary supplement flavonoids|patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention
214576274|NCT03178643|DRUG|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
214576275|NCT03178643|DRUG|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
214576276|NCT03178643|DRUG|Dihydroartemisinin-Piperaquine (DP)|"3\) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
214709742|NCT02976727|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
214576277|NCT04361851|DRUG|Pembrolizumab|Experimental
214576278|NCT06429644|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
214576279|NCT02415517|BEHAVIORAL|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken \& Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
214576280|NCT02415517|BEHAVIORAL|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
214576281|NCT00774930|DRUG|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
214576282|NCT00774930|DRUG|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
214576283|NCT01104597|PROCEDURE|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
214576284|NCT01104597|DRUG|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
214576285|NCT06017843|OTHER|Camps site selection for active case finding for TB using MATCH-AI|The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
214576286|NCT01631227|DRUG|Eprosartan|Eprosartan 450 mg
214576287|NCT01631227|DRUG|Eprosartan Mesylate|Eprosartan mesylate 600 mg
214576288|NCT01631227|DRUG|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
214576289|NCT01631227|DRUG|Placebo Eprosartan|Placebo Eprosartan
214576290|NCT05294601|OTHER|High-Intensity Interval Training|high intensity exercise with games
214576291|NCT05294601|OTHER|Medium-Intensity Interval Training|medium intensity exercise with games
214576292|NCT02548598|PROCEDURE|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
214576293|NCT03020576|DEVICE|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
214576294|NCT03020576|OTHER|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
214576295|NCT03385343|DIAGNOSTIC_TEST|VLE imaging for staging EAC|Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
214576296|NCT05108129|PROCEDURE|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
214576297|NCT05108129|PROCEDURE|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
214709743|NCT02976727|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
214709744|NCT02976727|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
214709745|NCT02976727|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
214576298|NCT00002987|BIOLOGICAL|bleomycin sulfate|
214576299|NCT00002987|DRUG|cyclophosphamide|
214576300|NCT00002987|DRUG|doxorubicin hydrochloride|
214576301|NCT00002987|DRUG|etoposide|
214576302|NCT00002987|DRUG|prednisolone|
214576303|NCT00002987|DRUG|vincristine sulfate|
214576304|NCT00002987|RADIATION|radiation therapy|
214576305|NCT01994759|OTHER|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
214576306|NCT01994759|DRUG|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
214576307|NCT01994759|BEHAVIORAL|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
214576308|NCT01471496|PROCEDURE|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
214576309|NCT01177800|DRUG|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
214576310|NCT01177800|DRUG|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
214576311|NCT04472559|BEHAVIORAL|Self-acupressure|Self-acupressure
214576312|NCT06332937|PROCEDURE|postmastectomy breast reconstruction|postmastectomy immediate breast reconstruction
214576313|NCT03527550|OTHER|Cognitive Control Training|Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
214576314|NCT03460691|PROCEDURE|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
214709746|NCT02976727|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
214709747|NCT01388868|OTHER|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
214709748|NCT01388868|OTHER|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
214709749|NCT01388868|OTHER|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
214576315|NCT00940732|OTHER|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
214576316|NCT00940732|OTHER|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
214576317|NCT00940732|OTHER|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
214576318|NCT01097707|DRUG|LY500307|Administered orally, daily for 24 weeks
214709750|NCT04809272|BEHAVIORAL|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
214576319|NCT01097707|DRUG|Placebo|Administered orally, daily for 24 weeks
214576320|NCT06279026|BIOLOGICAL|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
214576321|NCT04678999|BEHAVIORAL|Mind-body exercise and education|The intervention will delivered via a secure Zoom video platform.
214576322|NCT01912560|DRUG|CAT-2003|
214576323|NCT01912560|DRUG|Placebo|
214576324|NCT01912560|DRUG|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
214576325|NCT02729662|DRUG|Tolvaptan|"* Before administration of tolvaptan~  * TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~ * 24-hour urine collection・Hematology/urinalysis: Once/year~ * Physical findings: Blood pressure and medical interview at ambulatory visit~* Hospitalization for education and examination at the start of tolvaptan administration~  * 24-hour urine collection・Hematology/urinalysis・Inulin clearance~ * Physical findings: Body weight, blood pressure~ * Adverse Events~* After administration of tolvaptan~  * TKV・Liver capacity・inulin clearance: Once/year~ * 24-hour urine collection: Once/6 months~ * Hematology/urinalysis: Once/month in principle~ * Physical findings: Blood pressure and medical interview at ambulatory visit~ * Adverse Events"
214576326|NCT05336851|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)
214576327|NCT04849494|OTHER|ATS-DLD-78-C and ISAAC questionnaires|Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history
214576328|NCT04781400|BEHAVIORAL|Mobile phone support|Mobile phone support (SMS)
214576329|NCT04781400|BEHAVIORAL|Remote service delivery model|ART treatment delivery via a courier service
214576330|NCT04284215|DRUG|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
214576331|NCT01498679|DRUG|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
214576332|NCT01498679|DRUG|Placebo|Placebo administered once daily in the evening via a NDPI
214576333|NCT02369146|DRUG|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
214576334|NCT02861547|OTHER|death|
214576335|NCT05882552|DIAGNOSTIC_TEST|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
214576336|NCT05882552|DIAGNOSTIC_TEST|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
214576337|NCT02635568|OTHER|Cannabis Use|Observational Study
214576338|NCT02114710|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
214576339|NCT00157560|DRUG|Chemotherapy, multiple agents|
214576340|NCT05201118|DRUG|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
214576341|NCT05201118|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
214576342|NCT01767701|DRUG|Raltegravir|400mg twice daily for 3 months
214576343|NCT00583193|DRUG|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
214709751|NCT04372043|OTHER|Questionnaire|"Sleep Hygiene Index and demographic questions."
214709752|NCT04225884|OTHER|DTx for pain software|Software with active intervention
214709753|NCT04225884|OTHER|Control software|Software without active intervention
214709754|NCT04225884|OTHER|Standard care|Pain medication
214576344|NCT04619940|DIAGNOSTIC_TEST|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
214576345|NCT04619940|DIAGNOSTIC_TEST|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
214576346|NCT00626301|DRUG|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
214576347|NCT00566878|BIOLOGICAL|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
214576348|NCT01424449|RADIATION|[11C]PHNO|examine the effects of \[11C\]PHNO mass carry-over and displaceable binding
214576349|NCT01424449|DRUG|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
214576350|NCT02608723|DEVICE|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
214576351|NCT02608723|DEVICE|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
214576352|NCT02608723|DEVICE|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
214576353|NCT05152420|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
214576354|NCT05152420|DRUG|Placebo|VMX-C001 matched placebo
214576355|NCT05152420|DRUG|Apixaban|FXa Inhibitor
214576356|NCT05152420|DRUG|Rivaroxaban|FXa Inhibitor
214576357|NCT05152420|DRUG|Edoxaban|FXa Inhibitor
214576358|NCT02775773|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
214576359|NCT02775773|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
214576360|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
214576361|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
214576362|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
214576363|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
214576364|NCT00613665|BIOLOGICAL|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
214576365|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
214576366|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
214576367|NCT04005573|DIETARY_SUPPLEMENT|VD3|VD3 50000 IU/ week for 8 weeks
214576368|NCT04005573|DIETARY_SUPPLEMENT|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
214576369|NCT04005573|DIETARY_SUPPLEMENT|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
214576370|NCT04005573|OTHER|no intervention|no intervention is given
214576371|NCT03273361|BEHAVIORAL|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
214576372|NCT03002831|BIOLOGICAL|Cytokine-induced Killer Cells|
214576373|NCT03002831|DRUG|Tegafur-Gimeracil-Oteracil Potassium|
214709755|NCT02759861|DRUG|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
214709756|NCT06382337|OTHER|Group A : ice cream cone technique|collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
214709757|NCT06382337|OTHER|Group B : the vestibular socket therapy|cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
214709758|NCT00570440|DRUG|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
214709759|NCT04150562|DRUG|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
214709760|NCT04150562|BIOLOGICAL|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
214722260|NCT05305625|PROCEDURE|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
214722261|NCT05305625|DRUG|standard therapy|received standardized treatment
214576374|NCT03212989|DRUG|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
214576375|NCT03212989|BIOLOGICAL|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
214576376|NCT02988518|BEHAVIORAL|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
214576377|NCT00003773|DRUG|oglufanide disodium|
214576378|NCT04357444|DRUG|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
214576379|NCT04357444|DRUG|2: Placebo Comparator|placebo in Subcutaneous route
214576380|NCT04241107|PROCEDURE|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
214576381|NCT04241107|PROCEDURE|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
214576382|NCT02225210|DRUG|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
214576383|NCT02225210|DRUG|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
214576384|NCT02225210|DRUG|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
214576385|NCT04379505|DEVICE|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
214576386|NCT04379505|RADIATION|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
214576387|NCT05854095|DEVICE|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
214576388|NCT04798859|OTHER|Family centered in-home rehabilitation|Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
214576389|NCT04798859|OTHER|Control|Usual follow-up in the municipality
214576390|NCT00650884|DEVICE|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
214576391|NCT05672420|BIOLOGICAL|umbilical cord derived mesenchymal stem cells|umbilical cord derived mesenchymal stem cells, intravenous infusion
214576392|NCT04480138|DRUG|Pegylated Interferon-α2b|1 mcg/kg on day 1 and day 8 after safety evaluations.
214576393|NCT04480138|OTHER|Standard of Care|Standard of care as per local authority
214576394|NCT04704583|BEHAVIORAL|SPACE parental-guidance|The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
214576395|NCT05271370|DRUG|PRO 140 350|Pro140 SC injection 350 mg
214576396|NCT05271370|DRUG|PRO 140 525|525 mg
214576397|NCT05271370|DRUG|PRO 140 700|700 mg
214722262|NCT04628338|DRUG|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
214722263|NCT02298075|DRUG|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
214576398|NCT01035645|DRUG|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
214576399|NCT04550338|DRUG|Tranexamic acid|Oral administration of blinded medications
214576400|NCT04550338|DRUG|Placebo|Oral administration of blinded medications
214576401|NCT06339853|DEVICE|WELT-IP with wearable devices (Apple/galaxy watch. Oura ring)|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot. By using WELT-IP simultaneously with wearing an Apple Watch/Galaxy Watch and Oura Ring, sleep and environmental data can be collected.
214576402|NCT03446326|DEVICE|Pacing|Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
214576403|NCT00703209|PROCEDURE|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
214576404|NCT04972305|OTHER|Exercise and ergonomics|12 week exercise and fit bike
214576405|NCT04972305|OTHER|Ergonomics|Fit bike
214576406|NCT04611308|OTHER|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
214576407|NCT06283368|PROCEDURE|Thyroidectomy, Bilaterally Total|Thyroidectomy, Bilaterally Total
214576408|NCT06283368|PROCEDURE|Thyroidectomy, Unilaterally Total|Thyroidectomy, Unilaterally Total
214576409|NCT06283368|PROCEDURE|Thyroidectomy, Complementary|Thyroidectomy, Complementary
214576410|NCT06283368|PROCEDURE|Thyroidectomy, Near Total|Thyroidectomy, Near Total
214576411|NCT02111187|DRUG|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
214576412|NCT02644291|DRUG|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
214576413|NCT05229042|DRUG|Ricolinostat|Oral
214576414|NCT03620916|PROCEDURE|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days
214576415|NCT03620916|PROCEDURE|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days in the postoperative period
214722264|NCT02298075|DRUG|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
214576416|NCT05367154|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
214576417|NCT04496531|DEVICE|Portable Neuromodulation Stimulator|
214576418|NCT04870684|OTHER|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
214576419|NCT01383460|DRUG|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
214576420|NCT01383460|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
214576421|NCT03108456|DEVICE|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
214576422|NCT03108456|DEVICE|Balloon|Vessel preparation with conventional and/or specialty balloons
214576423|NCT00252577|DRUG|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
214576424|NCT03099746|BEHAVIORAL|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
214576425|NCT03099746|BEHAVIORAL|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
214576426|NCT03099746|BEHAVIORAL|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
214576427|NCT01788787|BEHAVIORAL|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
214576428|NCT01788787|BEHAVIORAL|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
214576429|NCT01788787|BEHAVIORAL|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
214576430|NCT01788787|BEHAVIORAL|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
214576431|NCT06096454|DRUG|Metformin|effect of life style modification and metformin on hypothyroidism with insulin resistance
214576432|NCT03751046|BEHAVIORAL|Trial-Based Cognitive Therapy|Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.
214576433|NCT03751046|OTHER|Control group. Standard healthcare.|"Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV"
214576434|NCT04550533|OTHER|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
214576435|NCT04916080|DRUG|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
214576436|NCT04715243|DEVICE|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
214576437|NCT04715243|DEVICE|Helmet NIV|NIV interface
214576438|NCT04715243|DEVICE|Face-mask NIV|NIV interface
214576439|NCT05551312|OTHER|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
214576440|NCT05675787|DRUG|Medroxyprogesterone acetate + Atorvastatin|MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
214576441|NCT04230603|PROCEDURE|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
214576442|NCT04230603|DIAGNOSTIC_TEST|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
214576443|NCT04230603|DIAGNOSTIC_TEST|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
214576444|NCT02046889|BEHAVIORAL|Bicycle Training Intervention|
214576445|NCT05774743|OTHER|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
214576446|NCT00251823|DRUG|Eptifibatide facilitated PCI|
214576447|NCT03606434|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia
214576448|NCT01949038|DRUG|Oral alprazolam|
214576449|NCT01949038|DRUG|Sublingual alprazolam|
214576450|NCT01949038|DRUG|Oral placebo|
214576451|NCT01949038|DRUG|Sublingual placebo|
214576452|NCT04773197|BEHAVIORAL|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
214576453|NCT04773197|BEHAVIORAL|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
214576454|NCT04773197|BEHAVIORAL|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
214709761|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
214709762|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
214576455|NCT01627977|OTHER|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
214576456|NCT03203395|BEHAVIORAL|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
214576457|NCT02496689|BIOLOGICAL|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
214576458|NCT02335710|DEVICE|Journey II BCS TKA|
214576459|NCT01801735|DRUG|Meloxicam Test Capsules|
214576460|NCT00560066|BIOLOGICAL|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
214576461|NCT00560066|BIOLOGICAL|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
214576462|NCT03686631|BEHAVIORAL|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
214576463|NCT05145959|DEVICE|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
214576464|NCT00620282|DRUG|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
214576465|NCT00620282|DRUG|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
214576466|NCT00620282|DRUG|glimepiride|Tablets, 1 - 4 mg daily
214576467|NCT01258595|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
214576468|NCT01258595|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
214576469|NCT05423990|DIAGNOSTIC_TEST|Video-Electroencephalography|Three types of video EEG monitoring equipment produced by Nicolet, Bio-logic and Nihon Kohden were used to collect data in the multi-center. The 19-lead recording electrode was placed according to the international 10-20 system, and the average lead was used. The recording time was 24h. All patients underwent eyes open and closed test, intermittent photic stimulation and hyperventilation induction test.
214576470|NCT06441370|PROCEDURE|waterbirth|waterbirth: laboured for all or part of the first stage of labour and remained in the water for birth of newborn
214576471|NCT02843061|DRUG|Rituximab|
214576472|NCT02843061|BIOLOGICAL|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
214576473|NCT02751268|DRUG|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
214576474|NCT02751268|DRUG|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
214576475|NCT02643043|OTHER|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
214576476|NCT02338180|OTHER|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
214576477|NCT02338180|OTHER|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
214576478|NCT04224207|BIOLOGICAL|Wharton's jelly derived mesenchymal stem cell|The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
214576479|NCT01565278|DRUG|Soybean oil (Standard treatment)|1\. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
214576480|NCT01565278|DRUG|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
214576481|NCT04701359|DEVICE|TiN-alloy based total knee arthroplasty|TiN-alloy based TKA implanted for knee osteoarthritis.
214576482|NCT04701359|DEVICE|CoCr-coating based total knee arthroplasty|CoCr-coating based TKA implanted for knee osteoarthritis.
214576483|NCT00240799|DRUG|acetaminophen extended release|
214576484|NCT00240799|DRUG|placebo|
214576485|NCT05794308|BEHAVIORAL|Non-Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.
214576486|NCT05794308|BEHAVIORAL|Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
214576487|NCT02948673|DIETARY_SUPPLEMENT|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
214576488|NCT02948673|OTHER|Placebo|4 oral placebo tablets for 4 weeks
214576489|NCT00440440|DRUG|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
214576490|NCT00440440|DRUG|placebo|placebo gel apply daily
214576491|NCT03293004|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
214576492|NCT03293004|DIETARY_SUPPLEMENT|Vitamin C|Escalating dose of Vitamin C
214576493|NCT03293004|DIETARY_SUPPLEMENT|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
214576494|NCT03293004|DIETARY_SUPPLEMENT|Gummy Placebo|Gummy placebo
214576495|NCT04542889|DIAGNOSTIC_TEST|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
214576496|NCT04542889|DIAGNOSTIC_TEST|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
214576497|NCT02850510|BEHAVIORAL|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
214576498|NCT03097081|OTHER|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
214576499|NCT03097081|DEVICE|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
214576500|NCT01556191|DRUG|Gefitinib|250 mg per day (oral)
214576501|NCT01556191|DRUG|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
214576502|NCT01556191|DRUG|Erlotinib|150 mg per day (oral)
214576503|NCT00236600|DRUG|topiramate|
214576504|NCT02848287|DRUG|normal saline|1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
214576505|NCT02848287|DRUG|ropivacaine|1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
214576506|NCT01967589|DRUG|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
214576507|NCT01967589|DRUG|placebo|Once-daily doses for oral administration
214576508|NCT03618043|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
214576509|NCT03950843|DRUG|CKD-825|"* Dosage Form: capsule~* Dosage: 3 types(low/medium/high dose)~* Frequency: QD(once daily) administration"
214576510|NCT03950843|DRUG|Placebo oral capsule|"Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration"
214576511|NCT02910050|DRUG|Bicalutamide|50mg once a day orally
214576512|NCT02910050|DRUG|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
214576513|NCT03280589|OTHER|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
214709763|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
214576514|NCT03280589|OTHER|Sitting Quietly|Participant breaths in their natural way with out instruction
214576515|NCT03280589|OTHER|Deep breathing|Participant is required to pay attention to each breath
214576516|NCT00503100|DEVICE|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
214576517|NCT00464867|BIOLOGICAL|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
214576518|NCT04512794|DEVICE|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
214576519|NCT01820585|DRUG|Placebo|Tablets
214576520|NCT01820585|DRUG|ESL 400 mg|tablets
214576521|NCT01820585|DRUG|ESL 800 mg|tablets
214576522|NCT01820585|DRUG|ESL 1200 mg|tablets
214576523|NCT04142229|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
214576524|NCT04142229|OTHER|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
214576525|NCT04385589|DRUG|Dapagliflozin|Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
214576526|NCT04385589|DRUG|insulin|insulin
214576527|NCT06396364|DEVICE|Cryotherapy|Treatment group: the ankle was immobilized in a walking boot, then a third-generation cryotherapy device (Z- One®, Zamar) was applied daily for 2 hours two times a day up to the day of surgery. The walking boot was removed when the cryotherapy device was applied.
214576528|NCT03814148|DRUG|LENINGRADO 5 association|1 coated sustained-release tablet, oral, once a day.
214576529|NCT03814148|DRUG|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
214576530|NCT03814148|OTHER|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
214576531|NCT03814148|OTHER|Leningrado 5 association Placebo|1 coated sustained-release tablet, oral, once a day.
214576532|NCT04648644|OTHER|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
214576533|NCT00313625|DRUG|busulfan|
214576534|NCT00313625|DRUG|melphalan|
214576535|NCT00313625|DRUG|methotrexate|
214576536|NCT00313625|DRUG|tacrolimus|
214576537|NCT00313625|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214576538|NCT00313625|PROCEDURE|peripheral blood stem cell transplantation|
214576539|NCT00548262|DRUG|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
214576540|NCT00548262|DRUG|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).
214576541|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
214576542|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
214576543|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
214576544|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
214576545|NCT06263764|OTHER|Listening to Qur'an Recital|Listening to Surah Ar Rahman twice a day for minimum 15 minutes each for 40 days
214576546|NCT04535310|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
214576547|NCT01769651|OTHER|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
214576548|NCT05746364|BEHAVIORAL|Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating|The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
214576549|NCT02184364|DRUG|Low dose of Klimadynon®|
214576550|NCT02184364|DRUG|Medium dose of Klimadynon®|
214576551|NCT02184364|DRUG|High dose of Klimadynon®|
214576552|NCT02184364|DRUG|Oestrofeminal®|
214576553|NCT02184364|DRUG|Placebo|
214576554|NCT04258202|OTHER|Alveolar recruitment maneuver|The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
214576555|NCT05661422|DEVICE|RESP™ Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
214576556|NCT01390077|DRUG|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
214576557|NCT03095131|DEVICE|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
214576558|NCT02442336|BEHAVIORAL|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
214576559|NCT02534506|DRUG|Urelumab|
214576560|NCT02534506|DRUG|Nivolumab|
214576561|NCT02338973|DRUG|Interferon gamma-1b|
214576562|NCT04995939|PROCEDURE|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
214576563|NCT02884310|DRUG|Remifentanil adapted to SPI|
214576564|NCT02884310|DRUG|Remifentanil fixed|
214576565|NCT01302860|DRUG|ACZ885|
214576566|NCT00844532|DEVICE|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
214576567|NCT00574613|DRUG|P144|Cream 0,3 ml once a day (3 months)
214576568|NCT00574613|DRUG|placebo|Cream 0,3 ml once a day (3 months)
214576569|NCT01026532|BIOLOGICAL|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
214576570|NCT02769767|GENETIC|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
214576571|NCT04736901|DRUG|Enoxaparin|0.5 mg/kg every 12 hours
214576572|NCT04736901|DRUG|Enoxaparin|40 mg/day
214576573|NCT04736901|DRUG|Rivaroxaban|10 mg once daily
214576574|NCT04736901|DRUG|Rivaroxaban|20 mg once daily
214576575|NCT04736901|DRUG|Apixaban|2.5 mg twice daily
214576576|NCT04736901|DRUG|Apixaban|5 mg twice daily
214576577|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
214576578|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
214576579|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
214576580|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
214576581|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
214576582|NCT00439803|BIOLOGICAL|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
214576583|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
214576584|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
214576585|NCT03182218|DRUG|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
214709764|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
214709765|NCT04392869|BEHAVIORAL|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
214634226|NCT07058376|PROCEDURE|Standard Korean Medicine Treatment|"This includes the application of Korean medical procedures widely used for chronic low back pain:~Acupuncture: Insertion of needles at 10-20 selected acupoints for 10-15 minutes.~Electroacupuncture: Electrical stimulation at 3 Hz to 4 acupoints for 10-15 minutes.~Infrared Therapy: Application of infrared rays from 30 cm for 10-15 minutes.~Cupping: Wet or dry cupping at 2-4 points on the lower back.~Moxibustion: Applied to two points near the painful area at 43±1°C for 10-15 minutes.~Physical Therapy (ICT or TENS): Applied for 10-15 minutes focusing on the quadratus lumborum.~Treatment frequency is 2 times/week for 5 weeks, but may be adjusted to 1-3 times/week depending on symptoms. Total number of sessions is limited to 10."
214576586|NCT05421507|RADIATION|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
214576587|NCT04656704|DRUG|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
214576588|NCT00318071|DEVICE|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
214576589|NCT02744911|DEVICE|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
214576590|NCT02744911|BEHAVIORAL|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
214576591|NCT02744911|BEHAVIORAL|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
214576592|NCT03189745|BIOLOGICAL|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
214576593|NCT04600492|DRUG|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
214576594|NCT01466101|DRUG|Placebo administration|Administration of placebo
214576595|NCT01466101|DRUG|Pregabalin administration|Administration of pregabalin
214576596|NCT04836689|DEVICE|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen\&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate\<100 bpm), saturation\<90% and\>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
214576597|NCT00727701|BEHAVIORAL|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
214576598|NCT01993927|DRUG|Voglibose|Voglibose Tablets / Voglibose OD Tablets
214576599|NCT04976504|DEVICE|Oxygen reserve index|This is an observational study of the routine clinical practice with no specific additional interventions required. The investigators enrolled the ASA physical status I to III patients scheduled for elective surgery with planned arterial catheter placement before induction. ORi and standard monitors were placed. The patients were preoxygenated and received anesthesia induction as routine clinical practice. Intubation was done by video-laryngoscope. The endotracheal tube was not connected to the breathing circuit to avoid apneic oxygenation. Ventilation was resumed when SpO2 fell to 90%. ORi and SpO2 were recorded every ten seconds.
214576600|NCT06018727|DRUG|Hydrocortisone|Hydrocortisone 20 mg capsule will be administered orally.
214576601|NCT06018727|DIETARY_SUPPLEMENT|Yohimbine|Yohimbine 20 mg capsule will be administered orally.
214576602|NCT06018727|DRUG|Placebo|Two placebos will be administered orally.
214576603|NCT00895154|BEHAVIORAL|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
214576604|NCT00895154|BEHAVIORAL|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
214576605|NCT06571565|COMBINATION_PRODUCT|conservative treatment|Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
214576606|NCT05084469|PROCEDURE|PET-MRI in pain-free remission period|Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic \[18F\]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
214576607|NCT05286320|DRUG|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
214576608|NCT05609110|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
214576609|NCT05609110|DEVICE|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
214576610|NCT02955732|DEVICE|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
214576611|NCT02247973|BIOLOGICAL|mesenchymal stem cells|Intravenous administration of up to 1\~2x10\^6 MSCs per kg,for 2 times,d0 and d14
214576612|NCT02247973|BIOLOGICAL|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
214576613|NCT04715165|DRUG|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
214576614|NCT04715165|DRUG|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
214576615|NCT00488332|PROCEDURE|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
214576616|NCT00488332|PROCEDURE|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
214576617|NCT00488332|BEHAVIORAL|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
214576618|NCT02497248|PROCEDURE|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
214576619|NCT03286101|DRUG|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
214576620|NCT03286101|DRUG|Vehicle|The intervention is composed of a single application of the vehicle control.
214576621|NCT05591885|DIETARY_SUPPLEMENT|Study product group (Nutrilite Memory Builder)|During study intervention, subjects are required to take the randomly assigned study product following the instructions.Take one tablet twice daily with meals.
214576622|NCT05591885|DIETARY_SUPPLEMENT|Placebo group|During study intervention, subjects are required to take the randomly assigned placebo following the instructions.Take one tablet twice daily with meals.
214576623|NCT03948165|PROCEDURE|Distal Transradial Access|The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
214576624|NCT02850484|DRUG|Budesonide|Inhaled corticosteroid
214576625|NCT02850484|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
214576626|NCT06155994|DRUG|68Ga-DOTA-MGS5|intravenous administration
214576627|NCT06306339|DRUG|Burfiralimab|Humanized monoclonal antibody.
214576628|NCT06306339|DRUG|SOC (Standard of care)|"The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)"
214576629|NCT06306339|DRUG|Placebo|The placebo for Burfiralimab (hzVSF-v13)
214576630|NCT01018147|PROCEDURE|4-dimensional computed tomography|Undergo 4-D CT imaging
214576631|NCT04289831|PROCEDURE|Preoperative Biliary Drainage (PBD)|Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
214576632|NCT04289831|PROCEDURE|Surgery|The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
214576633|NCT00138567|DRUG|vildagliptin|
214576634|NCT02047331|PROCEDURE|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
214576635|NCT02047331|PROCEDURE|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
214576636|NCT04328883|DRUG|Aspirin|Oral and inhaled ASA formulations
214576637|NCT06378385|BEHAVIORAL|Childhood Early Oral Aging Syndrome index|Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
214576638|NCT03517033|DRUG|Torrent's Nebivolol Tablets|
214576639|NCT03517033|DRUG|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
214576640|NCT01850277|DRUG|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
214576641|NCT01850277|PROCEDURE|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
214576642|NCT01850277|DRUG|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% \>95%
214634227|NCT06282159|DRUG|DNTH103|Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks
214634228|NCT06282159|DRUG|Placebo|Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
214634229|NCT06858787|DEVICE|Continuous glucose monitor|Device is a remote sensor applied to the upper extremity that continuously samples glucose of interstitial fluid and uploading results to a mobile application.
214576643|NCT01850277|PROCEDURE|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
214576644|NCT05156684|DRUG|Placebo|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
214576645|NCT05156684|DRUG|Pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
214576646|NCT05156684|DRUG|zinc|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
214576647|NCT05156684|DRUG|zinc + pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
214576648|NCT02729831|BEHAVIORAL|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
214576649|NCT02729831|BEHAVIORAL|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
214576650|NCT02729831|BEHAVIORAL|Provider Report|A short report that includes the patients' goals and treatment preferences
214576651|NCT04261426|DRUG|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
214576652|NCT04261426|OTHER|Standard care|Standard care
214576653|NCT02996331|OTHER|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
214576654|NCT02996331|OTHER|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
214576655|NCT02996331|OTHER|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
214576656|NCT00294918|DRUG|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
214576657|NCT02305836|PROCEDURE|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
214576658|NCT02305836|DRUG|donepezil|cholinesterase inhibitors (ChE-Is)
214576659|NCT04869293|DEVICE|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
214576660|NCT01996189|DEVICE|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
214576661|NCT01996189|DEVICE|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
214576662|NCT00475397|DRUG|Duloxetine|
214576663|NCT00475397|DRUG|Placebo|
214576664|NCT06290674|OTHER|Extracorporeal Shockwave therapy|2000 shots, 120mJ pulse energy setting, 3 bar pressure, and 15 Hz for 15 minute per session.
214576665|NCT06290674|OTHER|Balanced low-calorie diet|1500 k/cal for 6 weeks
214576666|NCT00994084|BEHAVIORAL|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
214576667|NCT00994084|BEHAVIORAL|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
214576668|NCT01719354|OTHER|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
214576669|NCT01719354|OTHER|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
214576670|NCT05089253|OTHER|Dry Needling|"The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks."
214576671|NCT05089253|OTHER|Kinesio tapping|"The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks."
214576672|NCT00927030|DRUG|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
214576673|NCT00927030|DRUG|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
214576674|NCT03482830|PROCEDURE|Major emergency gastrointestinal surgery|"* Open, laparoscopic, or laparoscopically-assisted procedures~* Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction"
214576675|NCT03046654|DIAGNOSTIC_TEST|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
214576676|NCT03046654|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
214576677|NCT03046654|DIAGNOSTIC_TEST|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
214576678|NCT00614965|DRUG|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
214576679|NCT00614965|DRUG|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
214576680|NCT00614965|DRUG|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
214576681|NCT01747551|DRUG|Oxaliplatin|
214576682|NCT01747551|DRUG|Leucovorin|
214576683|NCT01747551|DRUG|Fluorouracil|
214576684|NCT01747551|DRUG|Ziv-aflibercept|
214576685|NCT01382277|DRUG|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
214576686|NCT01142115|DEVICE|Intermittent catheter CP063CC|intermittent catheterisation
214576687|NCT01142115|DEVICE|SpeediCath|intermittent catheterisation
214576688|NCT05953168|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression
214576689|NCT04556487|OTHER|evaluation|we will evaluate the home environment of the children asking by parents
214576690|NCT03208036|DEVICE|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
214576691|NCT03208036|DEVICE|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
214576692|NCT03208036|BEHAVIORAL|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
214576693|NCT03208036|BEHAVIORAL|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
214576694|NCT02720120|DRUG|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
214576695|NCT02720120|DRUG|Placebo|Participants will receive single IV infusion of placebo.
214576696|NCT00599443|BIOLOGICAL|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
214576697|NCT00599443|BIOLOGICAL|Placebo Comparator|0.5 mL im, single dose
214576698|NCT00211211|DEVICE|Balloon Kyphoplasty|
214576699|NCT03321877|DRUG|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
214576700|NCT00453791|DRUG|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
214576701|NCT00453791|DRUG|Placebo|Placebo MDI will be given to the subjects.
214576702|NCT02091206|DRUG|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
214576703|NCT02091206|DRUG|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
214576704|NCT02091206|DRUG|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
214576705|NCT02091206|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
214576706|NCT00700778|BIOLOGICAL|recombinant human chorionic gonadotropin|
214576707|NCT00700778|GENETIC|microarray analysis|
214576708|NCT00700778|OTHER|immunohistochemistry staining method|
214576709|NCT00700778|OTHER|laboratory biomarker analysis|
214576710|NCT00700778|PROCEDURE|needle biopsy|
214576711|NCT00759005|DRUG|propranolol and cortisol|
214576712|NCT00544986|DRUG|Anastrozole|
214576713|NCT06172153|OTHER|No interventions|No intervention
214576714|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
214576715|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
214576716|NCT03440060|DIAGNOSTIC_TEST|procalcitonin|procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
214576717|NCT05404724|DRUG|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
214576718|NCT05412251|RADIATION|health promotion program|Multi-domain intervention 120 minutes cognitive training, 120 \~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
214576719|NCT02341443|PROCEDURE|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
214576720|NCT02835118|DRUG|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
214576721|NCT02835118|DRUG|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
214576722|NCT03243682|PROCEDURE|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
214576723|NCT03243682|PROCEDURE|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
214576724|NCT04482959|DRUG|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
214576725|NCT04482959|DRUG|Sodium chloride 0.9%|Physiological solution will be used as placebo
214576726|NCT05557500|DEVICE|Repitetive transcranial magnetic stimulation|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
214576727|NCT01865175|DRUG|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
214576728|NCT01865175|DRUG|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
214576729|NCT00763776|DEVICE|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
214576730|NCT00763776|DEVICE|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
214576731|NCT04557553|DIETARY_SUPPLEMENT|Lagenbone|Traditional Chinese medicine herbal formula
214576732|NCT00329810|DRUG|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
214576733|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
214576734|NCT03767829|DRUG|Placebo|Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
214576735|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
214634230|NCT05865301|OTHER|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
214576736|NCT02193126|OTHER|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
214576737|NCT05195021|DEVICE|EDDY|EDDY (VDW) sonic irrigation activation system
214576738|NCT05195021|DEVICE|Diode Laser device|980-nm diode laser device
214576739|NCT05195021|DEVICE|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
214576740|NCT06274229|OTHER|Air pollution and noise reducing installations|A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
214576741|NCT05630729|OTHER|My Kidney Guru|My Kidney Guru is a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.
214576742|NCT03381339|DEVICE|Oscillating rotating power toothbrush|a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
214576743|NCT04278196|OTHER|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
214576744|NCT02627404|OTHER|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
214576745|NCT02627404|DEVICE|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
214576746|NCT02097173|DRUG|Methotrexate|
214576747|NCT00004583|DRUG|Lopinavir/Ritonavir|
214576748|NCT00004583|DRUG|Nelfinavir mesylate|
214576749|NCT00004583|DRUG|Lamivudine|
214576750|NCT00004583|DRUG|Stavudine|
214576751|NCT03230877|DEVICE|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
214576752|NCT03230877|DEVICE|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
214576753|NCT00157313|BEHAVIORAL|Integrated treatment, family involvement|
214576754|NCT00157313|BEHAVIORAL|Social skills training|
214576755|NCT01422642|DEVICE|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
214576756|NCT01422642|DEVICE|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
214576757|NCT04927247|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
214576758|NCT04927247|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
214576759|NCT01796379|BEHAVIORAL|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
214576760|NCT01796379|BEHAVIORAL|Moderate Training|
214576761|NCT00478387|BIOLOGICAL|The current season's trivalent killed influenza vaccine|
214576762|NCT02862522|OTHER|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
214576763|NCT00591851|DRUG|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
214576764|NCT02995642|DRUG|18F-FPPRGD2|One single intravenous injection.
214576765|NCT02995642|DEVICE|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
214576766|NCT02995642|PROCEDURE|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
214576767|NCT02995642|DEVICE|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
214576768|NCT04050657|OTHER|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
214576769|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
214576770|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
214576771|NCT02767336|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
214634231|NCT06909201|DRUG|HP 129Xe MRI|Gas delivery will be from a Tedlar bag
214576772|NCT01161875|DEVICE|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~* facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~* helmet use with non-invasive pressure support ventilation mode to define adequate settings~* helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
214576773|NCT06220136|DEVICE|TOFscan monitoring|observation and data recording
214576774|NCT02622529|OTHER|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
214576775|NCT04664400|BEHAVIORAL|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
214576776|NCT04664400|BEHAVIORAL|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
214576777|NCT04664400|BEHAVIORAL|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
214576778|NCT04664400|BEHAVIORAL|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
214576779|NCT01227200|DRUG|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
214576780|NCT00656097|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
214576781|NCT00656097|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
214576782|NCT00656097|BIOLOGICAL|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
214576783|NCT03609892|DRUG|Berberine|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.
214576784|NCT03609892|DRUG|Amoxicillin|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID
214576785|NCT03609892|DRUG|Esomeprazole|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID
214576786|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
214576787|NCT03609892|DRUG|Tetracycline|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
214576788|NCT03609892|DRUG|Furazolidone|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
214576789|NCT03609892|DRUG|Esomeprazole|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID
214576790|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
214576791|NCT03695653|BEHAVIORAL|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
214576792|NCT03695653|BEHAVIORAL|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
214576793|NCT03695653|BEHAVIORAL|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
214576794|NCT03049553|DEVICE|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
214576795|NCT04041453|DRUG|Ivermectin|Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
214576796|NCT04041453|DRUG|Albendazole|Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
214576797|NCT05196490|DEVICE|Micro-CT|Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.
214576798|NCT05196490|DEVICE|CAD/CAM|CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
214576799|NCT01307683|BEHAVIORAL|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
214576800|NCT04870229|DRUG|Carnosine|
214576801|NCT04870229|DRUG|Placebo|Placebo
214576802|NCT04768855|DRUG|LY3540378|Administered IV or SC.
214576803|NCT04768855|DRUG|Placebo|Administered IV or SC.
214576804|NCT04768855|DRUG|LY3540378|Administered SC.
214576805|NCT04662177|DRUG|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
214576806|NCT02310867|DRUG|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
214576807|NCT02310867|PROCEDURE|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
214576808|NCT06462703|DEVICE|Tablet-based neurorehabilitation with myReha|The myReha therapy software provides cognitive therapy in the domains attention, executive functions, perception, language, speech, arithmetics, and memory. It automatically creates weekly plans that are individually tailored to a patient's abilities and provides real-time feedback when completing tasks. Intelligent algorithms ensure that the exercises always remain at the optimum level of difficulty.
214576809|NCT01526239|OTHER|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
214576810|NCT02861235|OTHER|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
214576811|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
214576812|NCT02861235|OTHER|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
214576813|NCT02861235|OTHER|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
214576814|NCT02861235|OTHER|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
214576815|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
214576816|NCT05424497|OTHER|Vignettes|Presenting vignettes with fictive cases
214576817|NCT01318395|DRUG|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
214576818|NCT01318395|DRUG|Placebo|orally once per day
214576819|NCT04225689|OTHER|CD-TREAT diet|Dietary intervention
214576820|NCT01998100|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
214576821|NCT01998100|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
214576822|NCT05606510|OTHER|Mindful exercise|In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.
214576823|NCT05606510|OTHER|usual care|Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
214576824|NCT00002229|DRUG|Saquinavir|
214576825|NCT02923791|BIOLOGICAL|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
214576826|NCT02923791|BIOLOGICAL|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
214576827|NCT06486792|DRUG|Apixaban|Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.
214576828|NCT06486792|DRUG|Aspirin|Aspirin is used as the standard of care
214576829|NCT01307657|OTHER|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
214576830|NCT01856452|DEVICE|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
214576831|NCT01856452|DEVICE|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
214576832|NCT04670718|DEVICE|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
214576833|NCT04259151|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
214576834|NCT04259151|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
214576835|NCT01860378|OTHER|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
214576836|NCT01860378|OTHER|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
214576837|NCT05197283|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214576838|NCT05197283|OTHER|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214576839|NCT05197283|OTHER|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214576840|NCT05197283|OTHER|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214576841|NCT05197283|OTHER|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214576842|NCT03638167|BIOLOGICAL|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
214576843|NCT00733187|DRUG|ABT-869|0.25 mg/kg
214576844|NCT00476866|DEVICE|intermittent positive-pressure breathing (IPPB)|
214576845|NCT03014479|DRUG|Trelagliptin|Trelagliptin 100 mg or 50 mg
214576846|NCT03014479|DRUG|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
214576847|NCT04520503|DRUG|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
214576848|NCT04520503|DEVICE|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
214576849|NCT00955175|RADIATION|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
214576850|NCT04705701|PROCEDURE|Hemodialysis|Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
214576851|NCT02688218|BEHAVIORAL|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
214576852|NCT02688218|BEHAVIORAL|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
214576853|NCT03457051|PROCEDURE|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
214576854|NCT03457051|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
214576855|NCT04793789|OTHER|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
214576856|NCT01781078|RADIATION|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
214576857|NCT01781078|DEVICE|ImageReady System implant|Pacemaker and lead(s) implant
214576858|NCT05570097|DEVICE|intercostal nerves cryoanalgesia|Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
214576859|NCT04887064|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
214576860|NCT04201340|DEVICE|DRI OCT Triton with SS-OCT Angio software|The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
214576861|NCT04201340|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
214576862|NCT04201340|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
214576863|NCT04668404|DIAGNOSTIC_TEST|Sonoclot|Sonoclot machine
214576864|NCT02957032|DRUG|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
214576865|NCT02957032|DRUG|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
214576866|NCT00652470|PROCEDURE|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
214576867|NCT00652470|PROCEDURE|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
214576868|NCT01420887|PROCEDURE|Continuous Passive Motion|Continuous passive motion.
214576869|NCT01420887|PROCEDURE|Physical Therapy|Physical therapy.
214576870|NCT05523843|OTHER|Tulsa Life Chart (TLC)|The TLC is a self-administered, interactive assessment of patient history. Participants are asked to provide information from birth to their current age in developmental epochs (i.e., ages 0 to 5; 6 to 10; 11 to 14; 15 to 18; 19 to 25; 26 to 35; and so on in 10-year increments). Participants are first asked to rate their average mood during the epoch. They are then asked about locations lived, schools attended, people they were close to, hobbies, medical conditions, medications, hospitalizations, direct and indirect substance use exposure, mental health symptoms, mental health treatment, and important life events. The information is then displayed in an interactive, graphic of the individual's life that is reviewable by the patient and the healthcare providers enrolled in the study that the patient consents to having access.
214576871|NCT04839952|BEHAVIORAL|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
214576872|NCT04839952|BEHAVIORAL|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
214576873|NCT01805752|OTHER|Task-shifting to lower-cadre providers at PMTCT sites|
214576874|NCT01805752|OTHER|POC CD4+ cell count testing|
214576875|NCT01805752|OTHER|integrated mother-infant care|
214576876|NCT01805752|OTHER|Prominent role for influential family members (male partners) in collaboration with CHWs|
214634232|NCT05149573|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
214634233|NCT05149573|DEVICE|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
214576877|NCT05599659|BEHAVIORAL|Palliative care|"It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant."
214576878|NCT05600686|DRUG|Cyclophosphamide|Given IV
214576879|NCT05600686|DRUG|Doxorubicin|Given IV
214576880|NCT05600686|DRUG|Etoposide|Given IV
214576881|NCT05600686|BIOLOGICAL|Loncastuximab Tesirine|Given IV
214576882|NCT05600686|DRUG|Prednisone|Given PO
214576883|NCT05600686|BIOLOGICAL|Rituximab|Given IV
214576884|NCT05600686|DRUG|Vincristine|Given IV
214576885|NCT02217501|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
214576886|NCT02217501|DRUG|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
214576887|NCT00675675|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
214576888|NCT00675675|BEHAVIORAL|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
214576889|NCT04636736|DIAGNOSTIC_TEST|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
214576890|NCT00337259|DRUG|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
214576891|NCT04787887|DRUG|Abcertin|60IU/kg Single Intravenous Administration
214576892|NCT04787887|DRUG|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
214576893|NCT05069675|PROCEDURE|vitrectomy|vitrectomy with gas tamponade
214576894|NCT04600830|PROCEDURE|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
214576895|NCT00018278|DRUG|Aricept|
214576896|NCT00018278|DRUG|Exelon|
214576897|NCT00018278|DRUG|Nicoderm Patch|
214576898|NCT00649636|DRUG|Fluoxetine Capsules 40 mg|40mg, single dose fasting
214576899|NCT00649636|DRUG|Prozac Pulvules 40 mg|40mg, single dose fasting
214576900|NCT06158932|DIETARY_SUPPLEMENT|Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement|This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
214576901|NCT02062853|OTHER|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
214576902|NCT02062853|OTHER|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
214576903|NCT02007915|DRUG|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
214576904|NCT02800018|OTHER|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
214576905|NCT02019667|DRUG|SGS-742|
214576906|NCT02019667|DRUG|Placebo|
214576907|NCT03104946|DIAGNOSTIC_TEST|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
214576908|NCT04011943|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
214576909|NCT05321654|BEHAVIORAL|Education for Behavior Modification|Please see arm description for a detailed description of the intervention
214576910|NCT05321654|BEHAVIORAL|Corrective Exercise Program|Please see arm description for a detailed description of the intervention
214576911|NCT02461043|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
214576912|NCT02461043|RADIATION|radiation|radiation
214576913|NCT03935802|RADIATION|radiation|
214576914|NCT02286986|DRUG|Cannabidiol|
214576915|NCT05398991|DEVICE|the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.|the Coronary Covered Stents System contains a covered stent and a delivery system
214576916|NCT01410968|DRUG|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
214576917|NCT05121246|DRUG|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
214576918|NCT05121246|DRUG|EU-Synagis®|Single IM dose of 3 mg/kg
214576919|NCT05121246|DRUG|US-Synagis®|Single IM dose of 3 mg/kg
214576920|NCT04154059|OTHER|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
214576921|NCT05759481|DRUG|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
214576922|NCT05759481|OTHER|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
214576923|NCT06619067|DIETARY_SUPPLEMENT|PROBAFLOR|PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.
214576924|NCT06619067|OTHER|Placebo|Placebo
214576925|NCT04917445|BEHAVIORAL|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
214576926|NCT00427570|BIOLOGICAL|BCG vaccine|
214576927|NCT00427570|BIOLOGICAL|biological therapy|
214576928|NCT00427570|DRUG|fluorouracil|
214576929|NCT00427570|DRUG|semustine|
214576930|NCT00427570|DRUG|vincristine sulfate|
214576931|NCT02428062|PROCEDURE|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~1. vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~2. intravenous fluids~3. patient's positioning~4. reduction of depth of anesthesia"
214576932|NCT02428062|DRUG|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
214576933|NCT02428062|DRUG|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
214576934|NCT02428062|PROCEDURE|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
214576935|NCT02428062|PROCEDURE|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
214576936|NCT02428062|DRUG|Ephedrine|Ephedrine 5-25 mg intravenous bolus
214576937|NCT02428062|DRUG|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
214576938|NCT02428062|DRUG|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
214576939|NCT02428062|DRUG|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
214576940|NCT03313375|OTHER|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
214576941|NCT03313375|OTHER|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
214576942|NCT00045227|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
214576943|NCT00045227|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
214576944|NCT00045227|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
214576945|NCT00045227|BIOLOGICAL|sargramostim|
214576946|NCT00045227|DRUG|docetaxel|
214576947|NCT06610656|OTHER|Pacifier and White Noise Therapy|Infants will receive both pacifier and white noise therapy to enhance sleep quality and reduce restlessness
214576948|NCT06610656|OTHER|pacifier therapy|Infants will receive pacifier therapy to enhance sleep quality and reduce restlessness
214576949|NCT03981861|DRUG|Metformin and Spironolactone|Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
214576950|NCT05524753|BEHAVIORAL|AquOTic|group-based aquatic occupational therapy sessions with 1:1 support
214576951|NCT03063801|OTHER|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
214576952|NCT00330265|DEVICE|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
214576953|NCT00330265|OTHER|Conventional Wound Therapy|Normal Saline Dressings
214576954|NCT00432666|DRUG|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
214576955|NCT00432666|DRUG|Placebo|Placebo
214576956|NCT00978627|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
214576957|NCT00978627|DRUG|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
214576958|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
214576959|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
214576960|NCT02247557|DRUG|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
214576961|NCT02247557|DRUG|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
214576962|NCT02247557|DRUG|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
214576963|NCT02130921|BEHAVIORAL|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
214576964|NCT02345187|DIETARY_SUPPLEMENT|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
214576965|NCT02345187|DIETARY_SUPPLEMENT|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
214576966|NCT00004404|DRUG|clotrimazole|
214576967|NCT00004404|DRUG|hydroxyurea|
214576968|NCT06209333|OTHER|Standard Patient Education|Standard Patient Education will take approximately 20 minutes. Within the scope of standard patient education, some recommendations will be made to the patient to lose weight, drink sufficient water, avoid consuming caffeinated foods and beverages, acidic/carbonated or alcoholic beverages, spicy/acidic foods, and quit smoking. Patients will be evaluated on the day they receive standard patient training (before receiving this training) and 10 weeks after the training.
214576969|NCT06209333|OTHER|bladder training|Interval urination in bladder training in bladder training will be determined according to the bladder diaries filled in by the patients. If the patient is able to do it, bladder education will be improved by increasing the interval urination in bladder training. A total of 5 sessions of bladder training will be applied to patients, the first session of which will be face-to-face. Within the scope of Bladder Training, the patient will be given information about bladder, pelvic floor, incontinence and relaxation techniques. The patient will be asked to fill out a 3-day bladder diary before starting bladder training, and an appropriate progressive timed voiding program will be drawn according to the bladder diaries, and the patient will be given a training brochure to implement this program.
214576970|NCT06209333|OTHER|pelvic floor exercise|This training will take between 45 and 60 minutes.Within the scope of exercise training, patients will be taught 3 types of contractions: maximal (fast), slow and submaximal contractions. The patient will be asked to continue the maximum and submaximal contraction for 1-2 seconds, and to continue the Deceleration contraction for 3-10 seconds. These contractions will be performed in different positions such as supine, lying on the side, sitting, crawling, squatting and standing, specifically for the pelvic floor November muscle strength of the patient. These exercises will be performed every day and each type of contraction (maximal, slow and submaximal contraction) will be performed 8-12 repetitions, 3 sets per day. Progress will be achieved with follow-ups.
214576971|NCT00976872|DRUG|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
214576972|NCT00976872|DRUG|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
214576973|NCT04674787|OTHER|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
214576974|NCT02500810|DRUG|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
214576975|NCT02799264|DRUG|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
214576976|NCT05405439|DRUG|TQB3823 tablets|TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
214576977|NCT05405439|DRUG|Abiraterone acetate tablets|Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
214576978|NCT05405439|DRUG|prednisone acetate tablets|Prednisone acetate tablet is a kind of glucocorticoids
214576979|NCT04101552|PROCEDURE|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
214576980|NCT02237443|DRUG|Rocuronium|Administration of a NMBD
214576981|NCT02237443|DRUG|Vecuronium Bromide|Administration of a NMBD
214576982|NCT02237443|DRUG|Succinylcholine|Administration of a NMBD
214576983|NCT05838144|DEVICE|Acapella device|Group A. Will use Acapella device.
214576984|NCT05838144|OTHER|Only routine chest physical therapy program|Group B. Will take medications and perform routine chest physical therapy program.
214576985|NCT02113345|BEHAVIORAL|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
214576986|NCT02158052|DRUG|Tacrolimus|Tacrolimus starting on Day -1
214576987|NCT02158052|DRUG|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
214576988|NCT02158052|PROCEDURE|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
214576989|NCT02158052|DRUG|Bone marrow transplant from a related donor|Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
214576990|NCT02158052|RADIATION|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
214576991|NCT06246266|PROCEDURE|Helfer Skin Tap Technique group|During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
214576992|NCT06246266|PROCEDURE|ShotBlocker Technique group|"The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain."
214576993|NCT05016518|DRUG|Arm I (Propofol group)|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
214576994|NCT05016518|DRUG|Arm II (Remimazolam group)|Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
214576995|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
214576996|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
214576997|NCT05470049|DRUG|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
214576998|NCT00081627|DRUG|CoFactor and 5FU|
214576999|NCT04984434|DRUG|F182112|Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
214577000|NCT05144126|OTHER|CT radioraphic assessment|CT radioraphic assessment
214577001|NCT05616520|DEVICE|drug-coated balloon|The intervention relates to a drug-coated balloon catheter includes a balloon and cover the drug-coated balloon surface.
214577002|NCT00014807|BEHAVIORAL|Reducing Pesticide Exposure in Minority Families|
214577003|NCT00155974|BIOLOGICAL|Community-based vaccine outreach intervention|
214577004|NCT01835938|DRUG|1- Erlotinib|"* Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,"
214577005|NCT01835938|DRUG|placebo|"* Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,"
214577006|NCT03123601|DEVICE|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~* Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~* Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
214577007|NCT05900362|DEVICE|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
214577008|NCT04490967|COMBINATION_PRODUCT|Silymarin|Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
214577009|NCT04490967|PROCEDURE|Salicylic acid|Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
214577010|NCT04694209|PROCEDURE|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
214577011|NCT04694209|PROCEDURE|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
214577012|NCT02482168|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
214577013|NCT00543712|DRUG|PRO95780|Intravenous repeating dose
214577014|NCT04068766|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214577015|NCT04068766|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214577016|NCT04068766|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214577017|NCT04095481|DEVICE|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
214577018|NCT03037931|DRUG|Ferric Carboxymaltose|Intravenous Iron
214577019|NCT03037931|DRUG|Placebo|Normal Saline Solution
214577020|NCT00605215|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
214577021|NCT00605215|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
214577022|NCT00605215|DRUG|Avonex®|Avonex® will be administered per dose and schedule specified in the arm description.
214577023|NCT00233870|DRUG|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
214577024|NCT05432726|OTHER|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
214577025|NCT01405326|BIOLOGICAL|adalimumab|40mg sc. every two weeks for six months
214577026|NCT02837224|DEVICE|The Situate Detection System|The Situate Detection System for locating surgical sponges
214577027|NCT01716897|DRUG|E2609|
214577028|NCT03975777|OTHER|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)
214577029|NCT03975777|OTHER|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)
214577030|NCT03053687|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
214577031|NCT03053687|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
214577032|NCT02914275|BIOLOGICAL|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
214577033|NCT02914275|BIOLOGICAL|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
214577034|NCT03191500|DEVICE|steerable catheter|peripheral vascular disease
214577035|NCT04049734|DRUG|oral losatan|50 mg of oral losartan one hour before the ERCP once
214577036|NCT04869228|DRUG|GT0918 tablets or placebo|GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
214577037|NCT03635528|DEVICE|Test Lens 1|EMO-114
214577038|NCT03635528|DEVICE|Test Lens 2|EMO-116
214577039|NCT03635528|DEVICE|Test Lens 3|EMO-118
214577040|NCT03635528|DEVICE|Test Lens 4|RMY-100
214577041|NCT03635528|DEVICE|Test Lens 5|Biofinity multifocal D Lens
214577042|NCT03635528|DEVICE|Control Lens 1|EMO-117
214577043|NCT03635528|DEVICE|Control Lens 2|Proclear 1 day
214577044|NCT04464954|DEVICE|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
214577045|NCT04464954|DEVICE|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
214577046|NCT04464954|DEVICE|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
214709766|NCT04392869|BEHAVIORAL|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
214577047|NCT05972031|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
214577048|NCT02273817|DRUG|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
214709767|NCT03409029|DIAGNOSTIC_TEST|MRI Scan|Additional imaging using MRI scan
214577049|NCT05351359|BEHAVIORAL|mHealth|A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
214577050|NCT05351359|BEHAVIORAL|phone counselling|Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.
214577051|NCT05351359|BEHAVIORAL|Fitbit tracker|Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
214577052|NCT05351359|BEHAVIORAL|brief advice|A brief advice will be provided by the general practitioner at the start of the study.
214577053|NCT02485782|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
214577054|NCT02485782|DEVICE|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
214577055|NCT02485782|DEVICE|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
214577056|NCT00601770|BIOLOGICAL|IC41|injection
214577057|NCT00169078|DRUG|Chloroquine|
214577058|NCT04288609|OTHER|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
214577059|NCT04288609|OTHER|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
214577060|NCT00542243|DRUG|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
214577061|NCT00542243|DRUG|Placebo|Placebo will be given once a day for 6 months.
214577062|NCT06308003|PROCEDURE|Anterior hip arthroplasty|Anterior hip arthroplasty
214577063|NCT05954507|DIAGNOSTIC_TEST|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
214577064|NCT02535429|OTHER|massage|
214577065|NCT06610721|DIAGNOSTIC_TEST|Urine Biomarkers|At baseline midstream urine will be collected in a sterile urine container.
214577066|NCT05444218|PROCEDURE|Open flap debridement|After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
214709768|NCT00992186|DRUG|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
214709769|NCT00333697|OTHER|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
214709770|NCT01178346|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
214709771|NCT01178346|BIOLOGICAL|Placebo|Placebo vaccine given 6 times over 6 months
214709772|NCT03002103|DRUG|EndoTAG-1|
214709773|NCT03002103|DRUG|Paclitaxel|
214709774|NCT03002103|DRUG|Gemcitabine Hydrochloride|
214577067|NCT05444218|OTHER|Er: YAG irradiation|An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
214577068|NCT05444218|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
214577069|NCT05444218|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
214577070|NCT05444218|DRUG|Placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
214577071|NCT05689203|DRUG|QLS1128|dose 1
214577072|NCT05689203|DRUG|QLS1128|dose 2
214577073|NCT05689203|DRUG|Placebo|Placebo
214577074|NCT03250923|DRUG|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
214577075|NCT02593721|PROCEDURE|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
214577076|NCT02593721|DRUG|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
214577077|NCT00171041|DRUG|valsartan|
214577078|NCT01534377|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
214577079|NCT01534377|BEHAVIORAL|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
214577080|NCT00509691|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
214577081|NCT00509691|GENETIC|polymerase chain reaction|
214577082|NCT00509691|OTHER|diagnostic laboratory biomarker analysis|
214577083|NCT00509691|OTHER|flow cytometry|
214577084|NCT00509691|OTHER|immunologic technique|
214577085|NCT04107168|DRUG|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
214577086|NCT04107168|DRUG|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
214577087|NCT04107168|DRUG|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
214577088|NCT04107168|DRUG|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
214577089|NCT04107168|DRUG|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
214577090|NCT04107168|DRUG|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
214577091|NCT04107168|DRUG|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
214577092|NCT00688883|DRUG|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
214577093|NCT00670839|BIOLOGICAL|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
214577094|NCT00670839|BIOLOGICAL|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
214577095|NCT02905955|DEVICE|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
214577096|NCT02366468|DRUG|ranibizumab 0.5 mg|intravitreal injection
214577097|NCT03882541|OTHER|Music therapy|To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
214577098|NCT03882541|DRUG|Sedation with midazolam|To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
214577099|NCT04293692|BIOLOGICAL|UC-MSCs|0.5\*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
214577100|NCT04293692|OTHER|Placebo|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
214577101|NCT02699723|DRUG|Arsenic Trioxide|Given PO
214577102|NCT02699723|DRUG|Itraconazole|Given PO
214577103|NCT02699723|OTHER|Laboratory Biomarker Analysis|Correlative studies
214577104|NCT01417143|DRUG|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
214577105|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214709775|NCT05961800|BEHAVIORAL|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
214577106|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214577107|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214577108|NCT00504998|GENETIC|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
214709776|NCT05961800|BEHAVIORAL|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
214577109|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214577110|NCT00446043|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
214577111|NCT02018939|OTHER|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
214577112|NCT04950829|DEVICE|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
214577113|NCT04950829|DEVICE|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
214577114|NCT04950829|PROCEDURE|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
214709777|NCT05961800|BEHAVIORAL|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
214709778|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
214709779|NCT04713787|DRUG|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
214709780|NCT04713787|DRUG|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
214709781|NCT04929418|OTHER|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
214709782|NCT04929418|OTHER|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
214709783|NCT02751021|OTHER|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
214709784|NCT02751021|OTHER|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
214709785|NCT00684112|DRUG|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
214709786|NCT00684112|DRUG|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
214709787|NCT02726529|BEHAVIORAL|Brighter Bites|
214709788|NCT02726529|BEHAVIORAL|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
214577115|NCT03666377|OTHER|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
214577116|NCT01473004|DEVICE|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
214577117|NCT06338930|OTHER|Remote monitoring|The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
214577118|NCT04744168|OTHER|Acupuncture|Puncture of 5 points 4GI, 6RP, 34VB, 36E, 3F
214577119|NCT04744168|OTHER|Placebo Acupuncture|Puncture of point HM
214577120|NCT00408239|DRUG|YM150|Oral
214577121|NCT00408239|DRUG|enoxaparin|Sub cutaneous
214577122|NCT04220697|OTHER|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
214577123|NCT04220697|OTHER|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
214577124|NCT04220697|OTHER|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
214577125|NCT04220697|OTHER|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
214577126|NCT04772898|BEHAVIORAL|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
214577127|NCT00336089|BEHAVIORAL|exercise intervention|
214577128|NCT00336089|OTHER|educational intervention|
214577129|NCT00336089|PROCEDURE|complementary or alternative medicine procedure|
214577130|NCT00336089|PROCEDURE|fatigue assessment and management|
214577131|NCT00336089|PROCEDURE|management of therapy complications|
214577132|NCT00336089|PROCEDURE|pain therapy|
214577133|NCT00336089|PROCEDURE|quality-of-life assessment|
214577134|NCT02436590|DEVICE|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
214577135|NCT04725786|OTHER|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
214577136|NCT05297669|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
214577137|NCT05297669|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
214577138|NCT02389582|DRUG|Dabigatran|Use for 5 days
214577139|NCT02389582|DRUG|Enoxaparin|Use for 5 days
214577140|NCT02947087|DRUG|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
214577141|NCT02947087|DRUG|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
214577142|NCT04444973|PROCEDURE|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
214577143|NCT01057329|DRUG|Atomoxetine|mg according to body weight
214577144|NCT01057329|DRUG|Duloxetine|30 mg / die
214577145|NCT01057329|DRUG|Olanzapine|5mg 1 wwek and 10 mg from second week
214577146|NCT01057329|DRUG|Aripiprazole|5 mg from week 1, 10 mg from week 2
214577147|NCT05109182|DEVICE|Innersight3D|Innersight3D generates a virtual interactive 3D model of the CT scan.
214577148|NCT01736800|DRUG|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
214577149|NCT01736800|DRUG|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
214709789|NCT06458257|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
214577150|NCT04357600|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell|All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
214577151|NCT00105001|DRUG|Fludarabine Phosphate|Given IV
214577152|NCT00105001|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
214577153|NCT00105001|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214577154|NCT00105001|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214577155|NCT00105001|DRUG|Tacrolimus|Given IV or PO
214577156|NCT00105001|DRUG|Mycophenolate Mofetil|Given PO
214577157|NCT00105001|DRUG|Sirolimus|Given PO
214577158|NCT02869516|OTHER|Clinical data collection|
214577159|NCT02143752|BEHAVIORAL|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
214577160|NCT02143752|BEHAVIORAL|Quit Line|see arm
214577161|NCT01579279|DRUG|ABT-652 6 mg|6 mg capsules
214577162|NCT01579279|DRUG|ABT-652 12 mg|12 mg capsules
214577163|NCT01579279|DRUG|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
214577164|NCT01579279|DRUG|Placebo|Placebo capsules
214577165|NCT01579279|DRUG|Duloxetine|Duloxetine capsules
214709790|NCT06458257|DRUG|Chemotherapy|Chemotherapy
214709791|NCT06311110|OTHER|Vancouver symptom score for dysfunctional elimination symptoms Questionnaire|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
214577166|NCT02355054|DRUG|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
214577167|NCT02230098|OTHER|Remote Ischemic Conditioning|
214577168|NCT05978973|DIETARY_SUPPLEMENT|Elemental Diet|. Elemental diets contain all daily required vitamins, micronutrients and macronutrients. The ingredients are readily digestible (carbohydrates, amino acids and medium chain fatty acids) and are absorbed within the proximal small bowel. One main disadvantage of elemental diets such as Vivonex is their unpalatability3 which has limited their use.
214577169|NCT00234845|DRUG|adalimumab|
214577170|NCT00234845|DRUG|methotrexate|
214709792|NCT06311110|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.
214577171|NCT02877329|BEHAVIORAL|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
214577172|NCT01102010|BIOLOGICAL|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
214577173|NCT01879722|DRUG|TAK-063|TAK-063 tablets
214577174|NCT01879722|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
214577175|NCT05909852|DRUG|ABP 501-HCF|Participants will receive a single-dose SC injection of ABP 501-HCF.
214577176|NCT05909852|DRUG|ABP 501-LCF|Participants will receive a single-dose SC injection of ABP 501-LCF
214577177|NCT04591431|DRUG|Erlotinib|TT arm
214577178|NCT04591431|DRUG|Trastuzumab|TT arm
214577179|NCT04591431|DRUG|Trastuzumab emtansine|TT arm
214577180|NCT04591431|DRUG|Pertuzumab|TT arm
214577181|NCT04591431|DRUG|Lapatinib|TT arm
214577182|NCT04591431|DRUG|Everolimus|TT arm
214577183|NCT04591431|DRUG|Vemurafenib|TT arm
214577184|NCT04591431|DRUG|Cobimetinib|TT arm
214577185|NCT04591431|DRUG|Alectinib|TT arm
214577186|NCT04591431|DRUG|Brigatinib|TT arm
214577187|NCT04591431|DRUG|Palbociclib|TT arm
214577188|NCT04591431|DRUG|Ponatinib|TT arm
214577189|NCT04591431|DRUG|Vismogedib|TT arm
214577190|NCT04591431|DRUG|Itacitinib|TT arm
214577191|NCT04591431|DRUG|Ipatasertib|TT arm
214577192|NCT04591431|DRUG|Entrectinib|TT arm
214577193|NCT04591431|DRUG|Atezolizumab|TT arm
214577194|NCT04591431|DRUG|Nivolumab|TT arm
214577195|NCT04591431|DRUG|Ipilimumab|TT arm
214577196|NCT04591431|DRUG|Pemigatinib|TT arm
214577197|NCT04591431|DRUG|Oncology Drugs|Standard of Care Arm
214577198|NCT04591431|DRUG|Pralsetinib|TT arm
214577199|NCT04591431|DRUG|Selpercatinib|TT arm
214577200|NCT04591431|DRUG|Talazoparib|TT arm
214577201|NCT04591431|DRUG|Tepotinib|TT arm
214577202|NCT04591431|DRUG|Alpelisib|TT arm
214577203|NCT00697697|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
214577204|NCT00697697|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
214577205|NCT01559753|DRUG|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
214577206|NCT01559753|DRUG|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
214577207|NCT03454841|DRUG|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
214577208|NCT03454841|DRUG|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
214577209|NCT02892695|BIOLOGICAL|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
214577210|NCT05141240|DRUG|Ribiciclib|Participants who initiated CDK4/6i therapy
214577211|NCT05141240|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
214577212|NCT05141240|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
214577213|NCT02951689|DIETARY_SUPPLEMENT|Probiotic|
214577214|NCT02951689|DIETARY_SUPPLEMENT|Placebo|
214577215|NCT01253304|DRUG|LY2189265|Subcutaneous (SC) injection
214577216|NCT00741559|DEVICE|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
214577217|NCT00741559|DEVICE|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
214577218|NCT00741559|DEVICE|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
214577219|NCT05379036|DRUG|prescribing anapproved drug, examination|"* Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months."
214577220|NCT02407158|DEVICE|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
214577221|NCT01327495|OTHER|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
214577222|NCT01327495|OTHER|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
214577223|NCT01327495|DRUG|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
214577224|NCT01327495|DRUG|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
214577225|NCT01327495|DRUG|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
214577226|NCT01327495|DRUG|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
214577227|NCT01327495|DRUG|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
214577228|NCT01327495|DRUG|Acyline|300 ug/kg subcutaneous injection every 2 weeks
214577229|NCT02442089|BEHAVIORAL|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
214577230|NCT01503385|DRUG|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
214577231|NCT00741364|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
214577232|NCT04096833|OTHER|Virtual Reality Group|Participants are from 3 to 14 years old who attend a pediatric primarey health care of the Fuensanta Health Center (Valencia) for immunization by vaccine.
214577233|NCT00481624|DRUG|Epoetin Alfa plus Iron|"1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
214577234|NCT01534689|DEVICE|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
214577235|NCT03384160|DIAGNOSTIC_TEST|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
214577236|NCT03384160|DIAGNOSTIC_TEST|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
214577237|NCT05565027|DEVICE|Dynamic digital radiography|The use of advanced dynamic X-ray photography and acquisition technology can obtain high-definition dynamic lung images of patients throughout the respiratory cycle for analysis.
214577238|NCT05565027|DEVICE|Pneumotachograph|The pneumotachograph monitors the flow rate, and the lung volume is calculated by integrating.
214577239|NCT00006011|DRUG|Doxorubicin Hydrochloride|Given IV
214577240|NCT00006011|DRUG|Cisplatin|Given IV
214577241|NCT00006011|BIOLOGICAL|Filgrastim|Given SC
214577242|NCT00006011|BIOLOGICAL|Pegfilgrastim|Given SC
214577243|NCT00006011|DRUG|Paclitaxel|Given IV
214577244|NCT00345527|BEHAVIORAL|Emotion and Behaviour Regulation Treatment (EBRT)|
214577245|NCT00345527|BEHAVIORAL|Cognitive Behavioural Therapy|
214577246|NCT00831753|BIOLOGICAL|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
214577247|NCT00831753|BIOLOGICAL|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
214577248|NCT02109315|DRUG|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
214577249|NCT02109315|DRUG|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
214577250|NCT00116883|DRUG|GW685698X aqueous nasal spray|
214577251|NCT00146120|DRUG|Idarubicin|
214577252|NCT00146120|DRUG|Cytosin-Arabinosid|
214577253|NCT00146120|DRUG|Etoposide|
214577254|NCT00146120|DRUG|All-trans Retinoid acid|
214577255|NCT00201227|OTHER|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
214577256|NCT06186661|OTHER|neurophysiological exercise|The content of the treatment program consisted of neurophysiological exercises based on Bobath.
214577257|NCT06186661|OTHER|cognitive rehabilitation|Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
214577258|NCT00795366|DRUG|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
214577259|NCT00795366|DRUG|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
214577260|NCT03410368|BIOLOGICAL|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
214577261|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via Cowhorn forcep technique|Cowhorn forceps technique used to extract the tooth results in less post operative pain and swelling also it makes the extraction easier.
214577262|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via conventional technique|Conventional method of extraction uses dental elevator and forceps resulting in post operative pain and swellig.
214577263|NCT00187564|DRUG|controlled-release oral alpha-lipoic acid|
214577264|NCT01833845|DRUG|Ribavirin|weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
214577265|NCT01833845|DRUG|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
214577266|NCT02207569|DEVICE|CoreValve Evolut R TAVR system|
214577267|NCT04948281|OTHER|no intervention|no intervention
214577268|NCT01844687|DRUG|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
214577269|NCT01465529|DRUG|OligoG CF-5/20|6% OligoG CF-5/20 in water
214577270|NCT01465529|DRUG|Saline|0.9% NaCl in water
214577271|NCT00933855|BEHAVIORAL|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
214577272|NCT03196154|DIAGNOSTIC_TEST|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
214577273|NCT03196154|DIAGNOSTIC_TEST|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
214577274|NCT00669370|DRUG|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
214577275|NCT04539782|OTHER|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
214577276|NCT01283204|DRUG|SP|"\<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest."
214577277|NCT01283204|DRUG|FL/Tax|"\<Every q 3 weeks\>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
214577278|NCT01283204|DRUG|FL/Doc|"\<Every q 3 weeks\>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
214577279|NCT01283204|DRUG|FOLFOX|\<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
214577280|NCT00002323|DRUG|Nevirapine|
214577281|NCT00002323|DRUG|Zidovudine|
214577282|NCT00640081|BIOLOGICAL|cetuximab|
214577283|NCT00640081|DRUG|capecitabine|
214577284|NCT00640081|DRUG|fluorouracil|
214577285|NCT00640081|DRUG|leucovorin calcium|
214577286|NCT00640081|DRUG|oxaliplatin|
214709793|NCT06311110|OTHER|Questionnaire concerning impaired toilettraining and comorbities|Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
214709794|NCT03933280|DRUG|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
214709795|NCT03933280|DRUG|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
214577287|NCT00640081|OTHER|immunohistochemistry staining method|
214577288|NCT00640081|OTHER|laboratory biomarker analysis|
214577289|NCT05333952|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
214709796|NCT03933280|DRUG|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
214709797|NCT03933280|DRUG|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
214709798|NCT04965168|PROCEDURE|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
214709799|NCT04166656|BIOLOGICAL|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
214709800|NCT04166656|BIOLOGICAL|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
214577290|NCT05333952|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
214577291|NCT06445829|DRUG|Magnesium sulfate|adding 300mg magnesium sulfate into cocktail injection
214577292|NCT05567354|DRUG|PF614|PF614 100 mg capsules
214577293|NCT05567354|DRUG|Oxycodone|Oxycodone HCl IR 40mg
214577294|NCT05567354|OTHER|Placebo|placebo powder
214577295|NCT02015182|OTHER|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
214577296|NCT05626790|OTHER|Exercise|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
214577297|NCT05626790|OTHER|PNF Stretching|"In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~1. Biceps: Flex-Add-ER repositioned half pattern~2. Brachioradialis: Flex-Abd-ER repositioned half pattern~3. Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches."
214709801|NCT00612989|DRUG|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose."
214577298|NCT05626790|OTHER|Prolonged Stretching|"In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~1. In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~2. In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched."
214577299|NCT03751579|PROCEDURE|coelioscopic surgery|observational study based on the computation of respiratory quotient in patient cohort treated by routine coelioscopic surgery
214577300|NCT01170793|BEHAVIORAL|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
214577301|NCT04245228|BEHAVIORAL|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
214577302|NCT05383508|OTHER|CA35|Nicotine concentration: 3.5 % e-liquid flavor: Tobacco
214577303|NCT05383508|OTHER|CM35|Nicotine concentration: 3.5 % e-liquid flavor: Menthol
214577304|NCT05383508|OTHER|Cig|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
214577305|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
214577306|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2mg/L) without lactoferrin|
214577307|NCT02103205|DIETARY_SUPPLEMENT|Formula with normal iron concentration (8 mg/L) without lactoferrin|
214577308|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo"
214577309|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
214577310|NCT01994967|DRUG|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
214577311|NCT01994967|DRUG|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
214577312|NCT01419470|DRUG|dapoxetine|"1. multiple dosing~2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
214577313|NCT03865927|OTHER|Placebo Oral Tablet|see Arm/Group description
214577314|NCT03865927|DRUG|GKT137831|GKT137831 is a NOX enzyme inhibitor
214577315|NCT03499470|OTHER|Protocol for structured discharge and follow-up|
214577316|NCT03047395|BIOLOGICAL|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
214577317|NCT01859988|DRUG|Dupilumab|
214577318|NCT01859988|DRUG|Placebo|
214577319|NCT00941967|DRUG|gemcitabine hydrochloride|Given IV
214577320|NCT00941967|DRUG|oxaliplatin|Given IV
214577321|NCT00941967|DRUG|sorafenib tosylate|Given orally.
214577322|NCT05912101|PROCEDURE|Pericapsular Nerve Group Block|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
214577323|NCT05912101|PROCEDURE|Suprainguinal Fascia Compartment Block|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
214577324|NCT05912101|PROCEDURE|3-1 Block|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
214577325|NCT04719546|OTHER|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
214577326|NCT05659498|BEHAVIORAL|Cardiac Rehabilitation Program|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
214577327|NCT04702698|DRUG|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
214577328|NCT04702698|DRUG|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
214577329|NCT01145209|DRUG|Fludarabine Phosphate|Given IV
214577330|NCT01145209|BIOLOGICAL|Ofatumumab|Given IV
214577331|NCT01145209|DRUG|Cyclophosphamide|Given IV
214577332|NCT00407108|PROCEDURE|Vitrectomy|
214577333|NCT06256237|DRUG|JS004|Specified dose on specified days.
214577334|NCT06256237|DRUG|Toripalimab|Specified dose on specified days.
214577335|NCT06256237|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
214577336|NCT06256237|DRUG|Etoposide|Specified dose on specified days.
214577337|NCT06256237|DRUG|Platinum|Specified dose on specified days.
214577338|NCT00124683|DRUG|Bupropion|
214577339|NCT00124683|DRUG|nicotine transdermal patch|
214577340|NCT05979415|DRUG|Apomorphine Cartridge|Staccato Cartridge
214577341|NCT05890859|DIAGNOSTIC_TEST|DXA scan|The patients will undergo 5 DXA scans fro pre- to post treatment
214577342|NCT05890859|BEHAVIORAL|Physical testing|The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
214577343|NCT05138744|OTHER|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
214577344|NCT00005645|DRUG|ILX-295501|
214577345|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: POCT|measurement of blood glucose concentration using 5 different POCT glucometer
214577346|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: reference|measurement of blood glucose concentration using 2 different laboratory analyzer
214577347|NCT04694261|BEHAVIORAL|SM-ART|Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
214577348|NCT06069310|DRUG|Mepolizumab 100 MG|Monthly administartion of mepolizumab 100mg
214577349|NCT00020735|DRUG|toremifene|
214577350|NCT00020735|PROCEDURE|conventional surgery|
214577351|NCT00020735|PROCEDURE|neoadjuvant therapy|
214577352|NCT02550353|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
214577353|NCT02550353|PROCEDURE|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
214577354|NCT04331678|BEHAVIORAL|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
214577355|NCT02396329|DRUG|Chlorhexidine|
214577356|NCT02396329|DRUG|Povidone-Iodine|
214577357|NCT03100877|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214577358|NCT03100877|DRUG|Cyclophosphamide|Given IV
214577359|NCT03100877|BIOLOGICAL|Filgrastim|Given SC or IV
214577360|NCT03100877|OTHER|Laboratory Biomarker Analysis|Correlative studies
214577361|NCT03100877|DRUG|Lenalidomide|Given PO
214577362|NCT03100877|PROCEDURE|pheresis|Undergo apheresis
214577363|NCT03100877|DRUG|Melphalan|Given IV
214577364|NCT03100877|BIOLOGICAL|Palifermin|Given IV
214577365|NCT03100877|RADIATION|Total Marrow Irradiation|Undergo TMI
214577366|NCT04560010|DRUG|Tranexamic Acid Injection (TXA)|Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
214577367|NCT02234648|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
214577368|NCT02234648|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
214577369|NCT01737424|DRUG|LC28-0126|LC28-0126
214577370|NCT01737424|DRUG|Placebo|Placebo
214577371|NCT01563159|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
214577372|NCT03804489|OTHER|Decision aids|Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
214577373|NCT03859245|BEHAVIORAL|Photobiomodulation|Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
214577374|NCT03859245|BEHAVIORAL|Ketogenic diet|Experimental group will follow a clinically prescribed ketogenic diet.
214577375|NCT00635427|BIOLOGICAL|VPRIV®|Intravenous infusion, every other week (EOW)
214577376|NCT03307005|DRUG|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
214577377|NCT03307005|DRUG|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
214577378|NCT00298259|PROCEDURE|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
214577379|NCT06228391|DRUG|IV ketamine|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.
214577380|NCT06228391|DRUG|Midazolam|Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.
214577381|NCT04654026|DRUG|Aspirin/Clopidogrel|No intervention, only observational studies
214577382|NCT06292052|DRUG|Immunotherapy|Received neoadjuvant chemotherapy plus immunotherapy
214577383|NCT00562055|DRUG|Atomoxetine|
214577384|NCT00562055|DRUG|PNU-165442G; [S,S]-reboxetine|
214577385|NCT06100081|DIAGNOSTIC_TEST|Detection of lesions using fluorescence molecular imaging|Using a fluorescence camera, lesions will be detected and biopsies will be taken to try and find cancer of unknown primary
214577386|NCT01566877|DRUG|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
214577387|NCT01566877|OTHER|Placebo|Normal Saline Solution (NSS)
214577388|NCT05299294|OTHER|Data collection|Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain
214577389|NCT02213341|PROCEDURE|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
214709802|NCT05703698|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
214709803|NCT06853496|DRUG|RK-582|"Dosing Frequency:~Do single dose of RK-582 at the dose level specified for the cohort. Seven days after the first dose, Start repeated daily dose and continue until discontinuation criteria were met.~Dose level per dose:~Dose Level 1: 5 mg BID Dose level 2: 10 mg QD Dose level 3: 20 mg QD Dose level 4: 40 mg QD Dose Level 5: 60 mg QD Dose Level 6: 80 mg QD Dose Level 7: 100 mg QD Dose Level 8: 200 mg QD"
214709804|NCT06813014|PROCEDURE|Oral Glucose Tolerance Test|Three hour glucose tolerance test
214577390|NCT02213341|PROCEDURE|Blood draw|
214577391|NCT02054611|OTHER|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
214577392|NCT02054611|OTHER|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
214577393|NCT06086600|OTHER|Instrument Assisted Soft Tissue Mobilization|"give gentle strokes from proximal to distal to check for trigger point or taut band. After knowing the exact location, give gentle strokes with minimal pressure in all directions by keeping the instrument in 30 to 60 degree angle. Application time will be between 40- 120 seconds.~Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles)"
214577394|NCT06086600|OTHER|Dynamic oscillatory stretch technique|"Passively dorsiflexe the ankle to a point of the first stretch sensation. The next component to DOS, 2- second, passive stretch with slow oscillations at end range was applied. This procedure is repeated 10 times in each set with total of 3 sets .Therefore,10reps x2 second hold oscillation x 3 sets are given.Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles"
214577395|NCT00366002|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
214577396|NCT05343520|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
214577397|NCT06461702|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
214577398|NCT02854969|BEHAVIORAL|Device: Anapphylaxis|
214709807|NCT02193672|DRUG|[18F] Fluciclatide|\[18F\] Fluciclatide given by vein before PET/CT scan.
214709808|NCT02193672|PROCEDURE|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
214709809|NCT02193672|BEHAVIORAL|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
214709810|NCT03334474|OTHER||no intervention
214709811|NCT01847261|DIETARY_SUPPLEMENT|Soy Dairy Protein Blend|
214709812|NCT01847261|DIETARY_SUPPLEMENT|Positive Control (Dairy Whey Protein)|
214577399|NCT02720302|BEHAVIORAL|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
214577400|NCT02720302|BEHAVIORAL|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
214577401|NCT03484273|DEVICE|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
214709813|NCT00543621|OTHER|daily enteral nutritional product and/or behavioral changes|
214577402|NCT06243692|DRUG|Lacosamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214577403|NCT06243692|DRUG|Topiramate 50Mg Tab|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214577404|NCT02081417|BEHAVIORAL|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
214577405|NCT01405833|DRUG|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
214577406|NCT01405833|DRUG|Placebo|Single dose IV matched placebo
214577407|NCT02197559|PROCEDURE|DES group|all the participants in this group will be performed with drug -eluting stents
214577408|NCT02197559|PROCEDURE|BMS group|all the participants in this group will be performed with bare-metal stents
214577409|NCT03121248|RADIATION|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
214709814|NCT06371664|DRUG|Conventional Tray (1 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
214577410|NCT03121248|RADIATION|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
214709815|NCT06371664|DRUG|Extended Tray (3 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
214577411|NCT03121248|RADIATION|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
214577412|NCT03121248|RADIATION|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
214577413|NCT03121248|RADIATION|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
214577414|NCT03121248|RADIATION|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
214577415|NCT03121248|RADIATION|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
214577416|NCT03121248|RADIATION|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
214577417|NCT00525382|DRUG|levocetirizine dihydrochloride|
214577418|NCT03469531|DRUG|Nimotuzumab|Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
214577419|NCT03469531|DRUG|Cisplatin|Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
214577420|NCT03469531|RADIATION|external-beam radiation|Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
214577421|NCT03469531|RADIATION|brachytherapy|high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
214577422|NCT04144101|DRUG|Etoricoxib|Etoricoxib 60 mg QD Oral
214577423|NCT04144101|DRUG|Aceclofenac|Aceclofenac 100 mg BID Oral
214577424|NCT03097484|DRUG|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
214577425|NCT01157676|PROCEDURE|Open radical cystectomy|Standard of care removal of urinary bladder.
214577426|NCT01157676|PROCEDURE|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
214577427|NCT01157676|DEVICE|DaVinci robot|DaVinci robotic surgical system.
214577428|NCT00501839|DRUG|clomiphene citrate|
214577429|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214577430|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance|Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.
214577431|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance|Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
214577432|NCT01170559|DEVICE|Implantable Loop Recorder|
214709816|NCT06013267|OTHER|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
214577433|NCT02437071|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
214577434|NCT02437071|RADIATION|Radiotherapy|
214577435|NCT02437071|PROCEDURE|Radiofrequency ablation|
214577436|NCT03268525|DRUG|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
214577437|NCT03268525|DRUG|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
214577438|NCT02856854|DRUG|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
214577439|NCT02856854|DRUG|Placebo|EMB-001 matched placebo
214577440|NCT02856854|DRUG|Cocaine IV|Cocaine administered at doses of 20 and 40mg
214709817|NCT04213937|DRUG|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
214709818|NCT04213937|DRUG|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
214577441|NCT02856854|DRUG|Saline IV|Cocaine matched placebo
214577442|NCT00555594|DRUG|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
214577443|NCT06086366|OTHER|[11C]DTBZ PET scan|One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
214577444|NCT06086366|OTHER|[18F]SDM8 PET scan|One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
214577445|NCT06086366|OTHER|MRI scan|One MRI scan
214577446|NCT06258226|DRUG|Conventional dosage reduction|The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
214577447|NCT06258226|PROCEDURE|Auricular acupressure|Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.
214577448|NCT06258226|PROCEDURE|Sham auricular acupressure|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
214577449|NCT06415565|OTHER|conventional physiotherapy|Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.
214709819|NCT02448316|PROCEDURE|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
214709820|NCT02448316|DRUG|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
214709821|NCT02448316|DRUG|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
214709822|NCT02448316|BEHAVIORAL|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
214709823|NCT00830960|DRUG|Prasugrel|Oral, daily, 90 days
214709824|NCT00830960|DRUG|Clopidogrel|Oral, daily, 90 days
214709825|NCT02855450|DRUG|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
214709826|NCT02855450|DRUG|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
214709827|NCT03383978|BIOLOGICAL|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
214709828|NCT03383978|DRUG|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
214577450|NCT06415565|OTHER|thoracic mobilization methods|Methods applied as conventional physiotherapy methods: hotpack, Transcutaneous electrical nerve stimulation and ultrasound applications will be applied. Also within the scope of thoracic mobilization: thoracic region extension stretching in the kneeling position, thoracic flexion in the crawling position, halo exercise, thoracic rotation exercises in the crawling position, thoracic rotation in the side lying position. , quadruped extension and rotation exercises will be applied. Patients will be informed that these exercises can also be done as home exercises and they will be asked to practice for 8 weeks.
214577451|NCT03568396|DEVICE|Pupillometer|Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
214577452|NCT05462301|OTHER||Neonatal bedside echocardiography was performed by a trained neonatologist or sonographer
214577453|NCT02021097|DRUG|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
214577454|NCT02021097|DRUG|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
214577455|NCT01096485|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
214577456|NCT01096485|DRUG|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
214577457|NCT01426867|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
214577458|NCT01426867|DRUG|Brinzolamide ophthalmic suspension, 1%|
214577459|NCT01426867|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
214577460|NCT03231631|BEHAVIORAL|Education plan and adherence to exercise|"* Send text messages with motivational sense at any time of the day, every 3 or 4 days.~* They will be given the option of performing directed exercise at the cardiac rehabilitation center.~* It will be recorded in an Excel table every time that text is sent to the patient.~* At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
214577461|NCT01812551|DRUG|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
214577462|NCT01812551|DRUG|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
214577463|NCT02293304|OTHER|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
214577464|NCT02293304|OTHER|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
214577465|NCT05697952|DRUG|E1K 1,200 ㎍/joint|Injection of E1K 1,200 ㎍/joint/ml on target lesion
214577466|NCT05697952|DRUG|E1K 2,400 ㎍/joint|Injection of E1K 2,400 ㎍/joint/ml on target lesion
214577467|NCT05697952|DRUG|placebo|Injection of 3ml saline on target lesion
214709829|NCT02604615|DRUG|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
214577468|NCT00142077|DEVICE|Electronic health record and messaging system|
214577469|NCT01683656|DRUG|niacin/laropiprant|
214577470|NCT01683656|DRUG|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
214577471|NCT01263665|DEVICE|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
214709830|NCT02604615|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
214709831|NCT02604615|RADIATION|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
214709832|NCT00769808|DEVICE|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
214577472|NCT05164029|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
214577473|NCT05469750|DRUG|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
214709833|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg|
214577474|NCT03518827|OTHER|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
214577475|NCT00636311|DRUG|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
214577476|NCT00636311|DRUG|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
214709834|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg X 2|
214709835|NCT01785108|DRUG|Vitamin D|
214709836|NCT01785108|DRUG|Ibuprofen|
214709837|NCT05159362|OTHER|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
214709838|NCT01376245|DRUG|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
214709839|NCT01376245|DRUG|Placebo|matching placebo
214577477|NCT04580082|BEHAVIORAL|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
214577478|NCT02960750|BEHAVIORAL|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
214577479|NCT02960750|BEHAVIORAL|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
214577480|NCT01681173|DIETARY_SUPPLEMENT|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
214577481|NCT01681173|DIETARY_SUPPLEMENT|Placebo|200ml Placebo, BID, over 24 months
214577482|NCT00913315|DRUG|tolterodine|4 mg of tolterodine ER
214577483|NCT00913315|DRUG|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
214577484|NCT00913315|DRUG|placebo|placebo once a day for 8 weeks
214577485|NCT06414707|DRUG|Vonoprazan, Amoxicillin and Levofloxacin|Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
214577486|NCT06414707|DRUG|Pantoprazole 40mg, Amoxicillin and Levofloxacin|Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
214577487|NCT01254240|DEVICE|UVA / UVB phototherapy|UVA / UVB phototherapy
214577488|NCT01254240|DEVICE|UVB phototherapy|UVB phototherapy
214577489|NCT00445354|DRUG|cinnamon|
214577490|NCT03983629|OTHER|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
214577491|NCT01227382|PROCEDURE|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
214577492|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 100 days
214577493|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 200 days
214709840|NCT04149847|PROCEDURE|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
214577494|NCT02706899|DRUG|vadastuximab talirine|Intravenous (IV) push every 4 weeks
214577495|NCT02706899|DRUG|Azacitidine|75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks
214577496|NCT02706899|DRUG|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
214577497|NCT00324675|DRUG|Rosiglitazone|4 mg tablets, bid, 12 months
214577498|NCT00324675|DRUG|Placebo|2 tablets per day
214709841|NCT01335698|DRUG|Atazanavir Sulphate|
214709842|NCT01335698|DRUG|Ritonavir|
214709843|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
214709844|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
214577499|NCT05703997|DIETARY_SUPPLEMENT|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
214577500|NCT05703997|DRUG|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
214577501|NCT04206930|OTHER|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
214577502|NCT04483505|DRUG|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
214577503|NCT01435616|DRUG|Glargine|
214577504|NCT01435616|DRUG|LY2605541|
214577505|NCT05923671|DIAGNOSTIC_TEST|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
214577506|NCT05923671|DIAGNOSTIC_TEST|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
214577507|NCT02947269|DRUG|Prucalopride|Prucalopride 2mg capsule
214577508|NCT02947269|DRUG|Placebo Oral Capsule|Placebo capsule
214577509|NCT01763515|PROCEDURE|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
214577510|NCT00371683|DRUG|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
214577511|NCT00371683|DRUG|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
214577512|NCT03122223|BIOLOGICAL|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
214709845|NCT00473044|BEHAVIORAL|Sisters in Motion|
214709846|NCT01879254|DEVICE|Deep Brain Stimulation|
214577513|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
214577514|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
214577515|NCT03122223|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
214577516|NCT04717245|DRUG|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
214577517|NCT04717245|OTHER|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
214577518|NCT04717245|OTHER|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
214577519|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents and active parents"|"Prevention program: Millie, with the participation of adolescents and parents"
214577520|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents only"|"Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program"
214577521|NCT04563208|DRUG|Placebo|Placebo administered on Days 1-5
214577522|NCT04563208|DRUG|DuACT|Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
214577523|NCT03181789|BIOLOGICAL|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
214577524|NCT03181789|BIOLOGICAL|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
214577525|NCT03181789|BIOLOGICAL|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
214577526|NCT03181789|BIOLOGICAL|Placebo|Administered bilaterally using the TDS-IM EP device
214577527|NCT03181789|DEVICE|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
214709847|NCT05564442|DRUG|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
214709848|NCT05564442|DEVICE|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
214577528|NCT01569672|BEHAVIORAL|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
214577529|NCT01569672|BEHAVIORAL|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
214577530|NCT01119872|OTHER|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
214577531|NCT01151410|DRUG|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
214577532|NCT01151410|DRUG|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
214577533|NCT04012801|DIAGNOSTIC_TEST|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
214577534|NCT00200629|PROCEDURE|Adenosine SPECT myocardial perfusion imaging|
214577535|NCT00200629|PROCEDURE|Combined adenosine / exercise SPECT myocardial perfusion imaging|
214577536|NCT04642716|OTHER|Saliva collection of patients and salivary free amino acids analysis|
214577537|NCT02008851|BIOLOGICAL|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
214709849|NCT05564442|DRUG|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
214709850|NCT05564442|OTHER|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
214709851|NCT03970824|BIOLOGICAL|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
214709852|NCT03970824|BIOLOGICAL|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
214709853|NCT03970824|BIOLOGICAL|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
214709854|NCT00054236|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
214709855|NCT00054236|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
214709856|NCT00054236|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
214709857|NCT00054236|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
214709858|NCT00054236|PROCEDURE|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
214709859|NCT00054236|DRUG|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
214577538|NCT02755051|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~1. Sleep education~2. Sleep scheduling, limit setting, and stimulus control~3. Teaching relaxation strategies and other adaptive coping skills~4. Parenting strategies (differential attention, rewards, consequences)~5. Identification of maladaptive \& adaptive cognitions~6. Problem solving \& communication skills~7. Sleep restriction; bright light to change circadian rhythms~8. Review gains and plan for long-term maintenance"
214577539|NCT04294927|PROCEDURE|Risk-reducing salpingectomy with delayed oophorectomy|"* BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~* BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~* BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)"
214577540|NCT04294927|PROCEDURE|Risk-reducing salpingo-oophorectomy|"* BRCA1 at a maximum age of 40 (advised between age 35 and 40)~* BRCA2 at a maximum age of 45 (advised between age 40 and 45)~* BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)"
214577541|NCT01350739|PROCEDURE|intraumbilical incision|vertical, intraumbilical incision
214577542|NCT01350739|PROCEDURE|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
214577543|NCT03626987|DIAGNOSTIC_TEST|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
214577544|NCT06095687|BEHAVIORAL|Mindfulness Meditation|Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.
214577545|NCT06095687|BEHAVIORAL|Clinical Hypnosis|Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
214577546|NCT01917539|DEVICE|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
214577547|NCT01917539|DEVICE|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
214577548|NCT04602221|DRUG|Lamotrigine|Tablet
214577549|NCT04602221|DRUG|BI 409306|Film-coated tablet
214577550|NCT04602221|DRUG|Placebo|Tablet, Film-coated tablet
214577551|NCT04602221|DRUG|BI 425809|Film-coated tablet
214577552|NCT02327351|OTHER|Biological: TCR alfa beta T cell depletion|
214577553|NCT04802798|DIETARY_SUPPLEMENT|Fibre 1|Food derived fibre presented as a white powder
214577554|NCT04802798|DIETARY_SUPPLEMENT|Fibre 2|Food derived fibre presented as a white powder
214577555|NCT04802798|DIETARY_SUPPLEMENT|Placebo|Simple sugar, presented as a white powder
214577556|NCT03619304|DIETARY_SUPPLEMENT|coffee|coffee beverage
214577557|NCT00723541|PROCEDURE|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
214709860|NCT04066946|DEVICE|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
214709861|NCT04066946|OTHER|Standard of care|"Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
214577558|NCT05737368|RADIATION|fractionated radiotherapy|fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume)
214577559|NCT05737368|DRUG|cadonilimab|Cardunizumab (10mg/kg, Q3W, d1)
214577560|NCT03111511|DRUG|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
214709862|NCT00416312|DEVICE|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7."
214709863|NCT00416312|DEVICE|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
214577561|NCT03111511|DRUG|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
214577562|NCT03111511|DRUG|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
214577563|NCT04621513|DEVICE|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
214577564|NCT04621513|DRUG|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
214577565|NCT05805228|OTHER|Sexual Counseling|Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
214577566|NCT02586571|BEHAVIORAL|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
214577567|NCT06326593|OTHER|Wii aerobic training|Nintendo Wii Fit Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character
214577568|NCT06326593|OTHER|conservative chest care|Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
214577569|NCT04490200|DEVICE|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
214577570|NCT04490200|DEVICE|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
214577571|NCT00688558|DRUG|JTT-705 600 mg and simvastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
214577572|NCT00688558|DRUG|Placebo and simvastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
214577573|NCT03922516|DIAGNOSTIC_TEST|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
214577574|NCT03988920|DRUG|Tenapanor|NHE3 Inhibitor
214577575|NCT03988920|DRUG|Sevelamer Carbonate|Phosphate binder
214577576|NCT04933773|OTHER|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
214577577|NCT04933773|OTHER|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
214577578|NCT04933773|OTHER|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
214577579|NCT04933773|OTHER|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
214577580|NCT04933773|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
214577581|NCT06306547|OTHER|no interventions were involved|no interventions were involved
214577582|NCT05873764|DRUG|200 mg RV521/78 µCi [ 14C]-RV521.|200 mg RV521/78 µCi \[ 14C\]-RV521
214577583|NCT02478710|DRUG|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
214577584|NCT02478710|DRUG|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
214577585|NCT02880891|PROCEDURE|prothetic procedure|splinted crown
214577586|NCT06292962|DEVICE|non-invasive transcutaneous vagal nerve stimulation (tVNS)|The device is used stimulate the vagus nerve
214577587|NCT06292962|DEVICE|Sham device|Sham device that does not stimulate the vagus nerve
214577588|NCT05029232|DIAGNOSTIC_TEST|MLPA for duchenne|MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
214577589|NCT03741452|OTHER|transversalis fascia plane block|patient controlled analgesia devices with tramadol
214577590|NCT01533480|DRUG|Zirgan|0.15% ganciclovir gel(Zirgan)
214577591|NCT01533480|DRUG|genteal gel|0.3% Hypromellose gel
214577592|NCT01237587|DRUG|Duloxetine|Administered orally
214577593|NCT01237587|DRUG|Placebo|Administered orally
214577594|NCT05307211|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
214577595|NCT05307211|OTHER|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
214577596|NCT05307211|OTHER|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
214577597|NCT02216045|DRUG|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
214577598|NCT02216045|DRUG|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
214709864|NCT05587634|BEHAVIORAL|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
214709865|NCT05764460|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
214709866|NCT02593968|DRUG|Recombinant Human Interferon a-2b Gel|
214709867|NCT02593968|DRUG|Placebo|
214709868|NCT00004014|DRUG|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
214577599|NCT04114864|BEHAVIORAL|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
214577600|NCT02318173|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
214577601|NCT04080921|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
214577602|NCT03053154|OTHER|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
214577603|NCT03636425|OTHER|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
214577604|NCT06151223|OTHER|Bio-specimen Collection: Blood|At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.
214577605|NCT06151223|OTHER|Bio-specimen Collection: Pancreatic Juice|This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.
214709869|NCT03797508|DIAGNOSTIC_TEST|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
214577606|NCT06151223|DIAGNOSTIC_TEST|MRI|"A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia/anxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.~Clinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.~If a clinical MRI/MRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI/MRCP could be used to obtain baseline imaging data."
214577607|NCT03693885|OTHER|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
214577608|NCT02799901|BIOLOGICAL|Nivolumab|Injection of nivolumab
214577609|NCT02799901|RADIATION|hypofractionned radiotherapy|radiation
214577610|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
214577611|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
214577612|NCT02656329|DRUG|Thyroid blocking|Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
214577613|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
214577614|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|All participants allocated to the SoC (control) group underwent ICD implantation.
214577615|NCT00465075|DRUG|Bazedoxifene/conjugated estrogens combination|
214577616|NCT01139580|DRUG|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
214577617|NCT01139580|DRUG|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
214577618|NCT01520220|DRUG|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
214577619|NCT05654142|BEHAVIORAL|Base intervention|12 Group Lifestyle Balance videos and digital motivational messages
214577620|NCT05654142|BEHAVIORAL|Augmented Intervention|12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
214577621|NCT05067153|DRUG|Fragmin 5000 UNT in 0.2 ML Prefilled Syringe|30 days postoperative prophylactic treatment.
214577622|NCT00293514|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|
214577623|NCT02546622|BIOLOGICAL|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
214577624|NCT02546622|BIOLOGICAL|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
214577625|NCT00740987|DEVICE|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
214577626|NCT03699826|DEVICE|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
214577627|NCT05774132|PROCEDURE|ultrasound guided Subgluteal sciatic nerve block|Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .
214577628|NCT05774132|PROCEDURE|ultrasound guided Caudal block|Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
214577630|NCT00672334|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
214577631|NCT00672334|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
214577632|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
214577633|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
214577634|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
214577635|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
214577636|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
214577637|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
214577638|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
214577639|NCT02784249|PROCEDURE|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
214577640|NCT02784249|DEVICE|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
214577641|NCT02784249|PROCEDURE|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
214577642|NCT04713449|OTHER|Empowered Survivor Online|Informational online intervention for head and neck cancer survivors
214577643|NCT04713449|OTHER|Springboard Beyond Cancer|Informational online intervention for all cancer survivors
214577644|NCT04713449|OTHER|Survey Administration|Survey measures administered at BL, two and 6 months post-baseline
214577645|NCT06502431|OTHER|phase contrast sequences|patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.
214577646|NCT01135303|DEVICE|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
214577647|NCT00667147|DRUG|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
214577648|NCT00667147|DRUG|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
214577649|NCT01118013|BIOLOGICAL|anti-thymocyte globulin|
214577650|NCT01118013|BIOLOGICAL|donor lymphocytes|
214577651|NCT01118013|BIOLOGICAL|filgrastim|
214577652|NCT01118013|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214709870|NCT02715999|PROCEDURE|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
214577653|NCT01118013|DRUG|busulfan|
214577654|NCT01118013|DRUG|fludarabine phosphate|
214577655|NCT01118013|DRUG|methotrexate|
214577656|NCT01118013|DRUG|mycophenolate mofetil|
214577657|NCT01118013|DRUG|tacrolimus|
214577658|NCT01118013|OTHER|reduced-intensity transplant conditioning procedure|
214577659|NCT01118013|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214577660|NCT01118013|PROCEDURE|peripheral blood stem cell transplantation|
214577661|NCT03814551|BEHAVIORAL|Signage|Placement of signage discouraging consumption of beverages with added sugar
214577662|NCT00633880|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214577663|NCT00633880|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214577664|NCT02734953|DRUG|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
214577665|NCT02729883|OTHER|Quality-of-Life Assessment|Ancillary studies
214577666|NCT02729883|OTHER|Questionnaire Administration|Complete interviews
214577667|NCT02729883|PROCEDURE|Supportive Care|Receive patient navigation via the Take the Fight strategists
214577668|NCT03849677|OTHER|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
214577669|NCT03857997|BIOLOGICAL|Patient blood sampling|sequencing by WGS and RNA-seq
214577670|NCT03857997|BIOLOGICAL|Parents blood sampling|sequencing by WGS
214577671|NCT04512131|PROCEDURE|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
214577672|NCT02906189|RADIATION|MRI|
214577673|NCT01666964|OTHER|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
214577674|NCT04571450|BEHAVIORAL|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
214577675|NCT00259402|DRUG|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
214577676|NCT00847080|DRUG|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
214577677|NCT00847080|DRUG|Placebo|Placebo 1 tablet per day per 2 weeks
214577678|NCT02078908|DRUG|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
214577679|NCT02078908|DRUG|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
214709871|NCT02715999|PROCEDURE|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
214577680|NCT02078908|DRUG|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
214577681|NCT02078908|DRUG|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
214709872|NCT02907671|PROCEDURE|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
214709873|NCT00086736|DRUG|bicalutamide|
214709874|NCT00086736|DRUG|eflornithine|
214709875|NCT00086736|DRUG|oral eflornithine placebo|
214577682|NCT02158988|PROCEDURE|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
214577683|NCT01099475|PROCEDURE|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
214577684|NCT01099475|PROCEDURE|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
214577685|NCT04164342|OTHER|surveys|Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
214577686|NCT01511094|PROCEDURE|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
214577687|NCT04237870|DEVICE|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
214577688|NCT04237870|DEVICE|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
214577689|NCT04554017|OTHER|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
214577690|NCT06294405|DEVICE|Intraocular lens Implantation|Intraocular lenses are implanted during cataract surgery to replace the human crystalline lens.
214577691|NCT02919930|DEVICE|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
214577692|NCT02919930|DEVICE|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
214577693|NCT05010239|OTHER|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
214709876|NCT00086736|DRUG|oral bicalutamide placebo|
214709877|NCT03498976|PROCEDURE|pulsed radiofrequency|Echoguided technic
214709878|NCT00198458|DRUG|Vitrase|
214577694|NCT05010239|OTHER|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
214577695|NCT00165100|PROCEDURE|Dynamic Area Telethermometry (DAT)|
214577696|NCT05564260|BEHAVIORAL|Kaleidescope|watching kaleidescope
214577697|NCT05564260|BEHAVIORAL|Virtual Reality|wearing virtual reality glasses
214577698|NCT02323178|DRUG|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
214577699|NCT00262145|DRUG|tea extracts|
214577700|NCT02204501|DRUG|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
214577701|NCT02204501|DRUG|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
214577702|NCT02204501|DRUG|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
214577703|NCT05299593|DRUG|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
214577704|NCT04831151|DRUG|Yasmin|Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
214577705|NCT04831151|DRUG|Diane-35|Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
214577706|NCT05834205|OTHER|Plyometric Training|"Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1\&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3\&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5\&6"
214577707|NCT05834205|OTHER|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
214577708|NCT03419832|OTHER|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
214577709|NCT03419832|OTHER|Standard Form|The regular IRB approved version.
214577710|NCT02079480|DRUG|BMS-986090|
214577711|NCT02079480|DRUG|Placebo matching with BMS-986090|
214577712|NCT02079480|DRUG|Keyhole limpet hemocyanin|
214577713|NCT03653325|DEVICE|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
214577714|NCT03653325|DEVICE|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
214577715|NCT03656952|DRUG|PF-06700841|a single oral dose of 200 mg PF-06700841
214577716|NCT03656952|DRUG|Placebo|Placebo matching PF-06700841
214577717|NCT03656952|DRUG|moxifloxacin|a single oral dose of 400 mg moxifloxacin
214577718|NCT00000998|DRUG|Trimetrexate glucuronate|
214577719|NCT00000998|DRUG|Leucovorin calcium|
214577720|NCT02654951|OTHER|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
214577721|NCT02654951|OTHER|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
214577722|NCT04580927|BEHAVIORAL|Breastfeeding self-efficacy (BSE)|Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
214577723|NCT01844960|PROCEDURE|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
214577724|NCT01844960|PROCEDURE|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
214577725|NCT04997980|DRUG|Amiodarone Injection|
214577726|NCT05362500|DRUG|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
214577727|NCT05362500|DRUG|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
214577728|NCT02866630|BIOLOGICAL|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
214577729|NCT02457988|DEVICE|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
214577730|NCT04817943|OTHER|Non applicable|When the patient enters the operating room, oxygen saturation, blood pressure, and electrocardiogram are monitored, and general anesthesia is induced using 1-2 mg/kg of 1% propofol. 0.8 mg/kg of rocuronium, a neuromuscular blocker, is injected intravenously, and a human endotracheal tube is intubated. A thermometer is attached to the inside of the double-layered endotracheal tube cuff, which measures the temperature in the trachea. After the endotracheal intubation is performed, the esophageal thermometer is inserted, and from this point, the temperature measured by the esophageal thermometer and the thermometer of the endotracheal tube are recorded. The temperature immediately after insertion of the esophageal thermometer is set as Tbaseline, and the temperature of the esophagus and trachea, the temperature of the operating room, and the temperature of breathing circuit with heated wire humidifier are recorded every 5 minutes from thereafter until the end of the operation.
214577731|NCT00057031|DRUG|DN-101 (calcitriol)|
214577732|NCT01619397|DEVICE|Test condom with new Xanthan gum condom coating|
214577733|NCT02627092|OTHER|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
214577734|NCT03063333|OTHER|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
214577735|NCT03063333|OTHER|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
214577736|NCT01503593|DEVICE|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
214577737|NCT06417580|OTHER|Placebo Treatment|Desensitizing protocol with none active ingredient to evaluate the control of cervical dentin hypersensitivity
214577738|NCT06417580|OTHER|Nitrate Potassium Treatment|Desensitizing protocol with potassium nitrate gel to analyze and compare with other groups the effects of controlling cervical dentin hypersensitivity
214577739|NCT06417580|OTHER|Pregabalin Treatment|Desensitizing protocol with experimental 10% pregabalin gel to evaluate the control of cervical dentin hypersensitivity
214577740|NCT00490230|DRUG|WR 279396|
214577741|NCT03748992|DRUG|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
214709879|NCT02309814|DEVICE|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
214709880|NCT02147509|DRUG|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
214577742|NCT00847808|DRUG|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
214577743|NCT03893669|BIOLOGICAL|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
214577744|NCT03893669|BIOLOGICAL|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
214577745|NCT04204603|DRUG|CKD-506|Tablets for oral administration
214709881|NCT02147509|DRUG|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
214709882|NCT02147509|OTHER|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
214709883|NCT02147509|DRUG|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
214709884|NCT06233214|DEVICE|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
214577746|NCT04204603|DRUG|Placebo|Tablets for oral administration
214577747|NCT00007449|DRUG|DPC 083|
214577748|NCT03404453|DIAGNOSTIC_TEST|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
214709885|NCT06249009|DEVICE|Non invasive ventilation|CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
214709886|NCT05987189|DIAGNOSTIC_TEST|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
214577749|NCT01134536|DRUG|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight \<20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight \>=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
214577750|NCT01681888|DEVICE|Sanger EMG Biofeedback Device|
214577751|NCT04224337|DRUG|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
214577752|NCT04708730|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
214577753|NCT03924765|DEVICE|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
214577754|NCT05410431|OTHER|clinical and radiologic manifestations of rare presentations of Dermoid cyst|
214577755|NCT05702814|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
214577756|NCT04336787|OTHER|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
214709887|NCT03005041|OTHER|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
214709888|NCT03005041|OTHER|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
214709889|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
214709890|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
214577757|NCT03480308|DRUG|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
214577758|NCT03480308|DRUG|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
214577759|NCT03480308|DRUG|Bupivacaine|Bupivacaine
214709891|NCT00162708|DRUG|CDDP, 5 Fu|
214577760|NCT02593266|BEHAVIORAL|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up"
214577761|NCT03814096|DIAGNOSTIC_TEST|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
214709892|NCT02670850|OTHER|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
214577762|NCT03417895|DRUG|SHR-1210|A humanized anti-PD-1 monoclonal antibody
214577763|NCT03417895|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
214709893|NCT05297799|DEVICE|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
214709894|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
214709895|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
214577764|NCT02824081|BIOLOGICAL|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
214577765|NCT06212882|DIAGNOSTIC_TEST|Lower concentration and lower volume contrast agent group|CT images using lower concentration and lower volume contrast material
214577766|NCT03821753|OTHER|Case|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
214709896|NCT04749576|DIETARY_SUPPLEMENT|saffron supplement for IBD|anti inflammatory effect
214709897|NCT05702970|DRUG|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
214577767|NCT03821753|OTHER|Control|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
214577768|NCT04059172|DRUG|Ibuprofen 200 mg and acetaminphen 650 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
214577769|NCT04059172|DRUG|Ibuprofen 200 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
214709898|NCT05702970|DRUG|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
214709899|NCT05702970|DRUG|Ferric Carboxymaltose 50 MG/ML|Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
214709900|NCT03601793|BEHAVIORAL|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
214709901|NCT03601793|BEHAVIORAL|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
214709902|NCT06218199|DRUG|Furosemide|oral administration
214709903|NCT06218199|DRUG|Torsemide|oral administration
214709904|NCT06218199|DRUG|Bumetanide|oral administration
214709905|NCT06218199|DRUG|sacubitril/valsartan|oral administration
214709906|NCT06218199|DRUG|Hydralazine|oral administration
214709907|NCT06218199|DRUG|Isosorbide Dinitrate|oral administration
214709908|NCT04273009|DEVICE|Renew VS PTNS|These will be prescribed and applied as described above.
214709909|NCT02727660|DRUG|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
214709910|NCT02727660|DRUG|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
214709911|NCT02727660|DRUG|FF MDI (PT005) 9.6 μg|Blinded Treatment
214709912|NCT01812122|DRUG|Glimepiride|
214709913|NCT01812122|DRUG|Vildagliptin|
214709914|NCT02327156|DRUG|dexmedetomidine|adding dexmedetomidine to the local anesthetic
214709915|NCT00305604|DRUG|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
214709916|NCT00305604|DRUG|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
214709917|NCT00105560|RADIATION|radiation therapy|Radiation therapy with proton beam to standard doses
214709918|NCT04020406|BIOLOGICAL|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
214709919|NCT00006234|PROCEDURE|peripheral blood stem cell transplantation|
214709920|NCT00006234|RADIATION|holmium Ho 166 DOTMP|
214709921|NCT03460925|RADIATION|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
214577770|NCT04059172|DRUG|Placebo oral tablet|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
214577771|NCT04865133|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214577772|NCT04865133|OTHER|Electronic Health Record Review|Medical record reviewed
214577773|NCT04972565|BEHAVIORAL|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
214577774|NCT02391753|DEVICE|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
214577775|NCT04595565|DRUG|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
214577776|NCT04595565|DRUG|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
214577777|NCT04595565|DRUG|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
214577778|NCT04595565|DRUG|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
214577779|NCT03642626|DRUG|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
214577780|NCT03642626|DRUG|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
214577781|NCT03642626|DRUG|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
214577782|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
214577783|NCT03642626|DRUG|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
214577784|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
214577785|NCT03642626|DRUG|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
214577786|NCT03642626|DRUG|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
214577787|NCT03642626|DRUG|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
214709922|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
214577788|NCT03642626|DRUG|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
214577789|NCT03642626|DRUG|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
214577790|NCT03642626|DRUG|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
214577791|NCT05929209|DIAGNOSTIC_TEST|Assessment of disease biomarkers|Assessment of serum, histological and radiological biomarkers
214577792|NCT06145438|DRUG|Dienogest|Drug is administered orally at the same time every day
214577793|NCT06145438|DRUG|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
214577794|NCT06145438|DRUG|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
214577795|NCT06145438|DRUG|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
214577796|NCT05003609|OTHER|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
214577797|NCT06348082|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|MBTI will be administered in 6 weekly sessions. Session 1 consists of introductions and an overview. Subsequent sessions consist of mindfulness concepts/practice and behavioral strategies for sleep. Each session will begin with guided formal meditation followed by discussion. Mindfulness practice (at home) expectations are 30-45 minutes of meditation/day at least 5 days during the period of the intervention, followed by 20 minutes/day until the final follow-up assessment (at 12 weeks). Mindfulness concepts: Overview of Mindfulness, Mindfulness of the Body, Obstacles to Mindfulness, Working with Difficult Emotions, Cultivating Positive Emotions, Working with Difficult Thoughts, Mindful Interactions.
214577798|NCT06420661|BEHAVIORAL|SPACE for T1D|school-partnered collaborative care model
214577799|NCT06420661|BEHAVIORAL|Enhanced usual care|routine diabetes care with optional monthly insulin dose adjustment
214577800|NCT05858528|DIAGNOSTIC_TEST|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
214577801|NCT04524377|PROCEDURE|Deep Brain Stimulation|"Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain."
214577802|NCT04988555|DRUG|Enzomenib|DSP-5336 orally
214577803|NCT04988555|DRUG|azoles|Posaconazole, Voriconazole, or Fluconazole
214709923|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
214709924|NCT02171819|OTHER|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
214709925|NCT03684941|DEVICE|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
214577804|NCT04988555|DRUG|Venetoclax|Venetoclax orally
214577805|NCT04988555|DRUG|Gilteritinib|Gilteritinib orally
214577806|NCT04988555|DRUG|Azacitidine (AZA)|Azacitidine orally
214577807|NCT05734638|BEHAVIORAL|MIM-DASH|Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.
214709926|NCT03684941|DEVICE|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
214709927|NCT04814472|DRUG|BLD-0409|Randomized to active product.
214577808|NCT05734638|BEHAVIORAL|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice."
214577809|NCT05734638|BEHAVIORAL|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
214577810|NCT00391859|PROCEDURE|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
214709928|NCT02428972|DRUG|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
214709929|NCT02428972|DRUG|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
214709930|NCT01248364|DRUG|BI 10773|BI 10773 tablets once daily high dose
214577811|NCT05394753|BEHAVIORAL|Unified Protocol for mood disorders|The group-based UP is structured and manualized and consists of 9 1.5 hours weekly sessions (90-min, 18 participants in each group). The group-based UP is a course consisting of components of psycho-education about mood disorders, cognitive and behavioural skills, and relapse prevention and is adapted for the non-clinical population in the current study. The UP will be led and delivered by trained therapists.
214577812|NCT02880345|DRUG|PEMBROLIZUMAB|
214577813|NCT02880345|RADIATION|hypofractionated radiation|
214577814|NCT05638698|BIOLOGICAL|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
214577815|NCT05638698|DRUG|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
214577816|NCT05638698|DRUG|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
214577817|NCT00153270|DRUG|Sodium Valproate|
214577818|NCT05204355|DIAGNOSTIC_TEST|MRI|Patients will be imaged using MRI
214577819|NCT05204355|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
214577820|NCT05204355|DIAGNOSTIC_TEST|HRCT|High Resolution Computer Tomography
214577821|NCT04844814|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
214577822|NCT04844814|DRUG|Prednisone|Prednisone 30 mg/d
214577823|NCT04844814|DRUG|Placebo of Prednisone|Placebo of Prednisone
214577824|NCT04844814|DRUG|Placebo of Anakinra|Placebo of Anakinra
214577825|NCT06412354|DEVICE|EasyCross™ first-in human|"At T0 the patient will undergo the TAVR procedure including the investigational procedure with the VIVHEART EasyCross™ catheter.~The interventional cardiologist will introduce the VIVHEART EasyCross™ catheter through the femoral artery with a percutaneous access according to the clinical practice through a vascular introducer on an already positioned guidewire. An operator in the procedure room will start a chronometer at this point to measure the investigational device crossing procedure duration.~The VIVHEART EasyCross™ catheter will be progressed into the aorta and up to the aortic valve.~At that time the external part of the VIVHEART EasyCross™ catheter will be opened to allow the self-centering of the catheter on the aortic valve. The guidewire will be introduced and once having crossed the valve the VIVHEART EasyCross™ catheter will be retracted by the physician and removed from the patient's body."
214577826|NCT05695586|BEHAVIORAL|Mindful Self-Compassion (MSC) training|8-week Mindful Self-Compassion (MSC) intervention protocol, developed by Germer and Neff (2013, 2019). After the training, participants will enter a 12-month phase of regular MSC-based supervised practice.
214577827|NCT05695586|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) training|8-week Mindfulness Based Stress Reduction (MBSR) intervention protocol, as developed by Stahl \& Goldstein (2010). After the training, participants will enter a 12-month phase of regular MBSR-based supervised practice.
214577828|NCT04039971|PROCEDURE|ACL Reconstruction|Surgical techniques
214577829|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
214577830|NCT05367271|DRUG|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
214577831|NCT05367271|DRUG|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
214577832|NCT04834635|PROCEDURE|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
214577833|NCT04834635|PROCEDURE|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
214577834|NCT04548544|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
214577835|NCT06545500|DRUG|Glycopyrrolate (85 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
214577836|NCT06545500|DRUG|Glycopyrrolate (42.5 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
214709931|NCT01567891|BIOLOGICAL|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
214577837|NCT06545500|DRUG|Glycopyrrolate (14 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
214577838|NCT06545500|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
214577839|NCT05618106|OTHER|Low FODMAP DIET = Diet with Low polyol, FOS and GOS|Low Polyol diet
214577840|NCT04367285|OTHER|Sensor-based Training|Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
214577841|NCT04367285|OTHER|Upper limb motor training|Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
214709932|NCT01200160|DRUG|Niacin|
214709933|NCT04140604|OTHER|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
214577842|NCT06478511|PROCEDURE|Classic Immediate implant|The teeth will be extracted gently using periotomes to preserve facial and lingual bone plates. All walls of the socket will be inspected and checked for the presence of fenestration or dehiscence defects in bone. The length and width of extracted roots will be measured to determine the length and diameter of implants placed. The osteotomy sites will be prepared and the drills will be used in proper sequence according to manufacturer's instructions, with maximum use of bone apical to the extraction sockets. The drills will extend 3 to 5 mm beyond the apex of the socket to ensure primary stability after placement, taking care of the anatomical boundaries. The implants will be placed.
214577843|NCT06478511|PROCEDURE|Immediate implant combined with subepithelial connective tissue graft|Connective tissue graft was harvested from palate using trap door technique utilizing a horizontal incision 3-4 mm away from the gingival margin with two vertical incisions on the either end of the first incision, the door is then undermined and opened using a sharp dissection, the underlying connective tissue is then harvested using a periosteal elevator, and the door was then sutured using 4 0 silk sutures Finally, the connective tissue graft was immediately placed into the recipient site after a tunneling procedure and sutured with 6-0 nonresorbable monofilament sutures.
214577844|NCT06478511|PROCEDURE|Immediate dental implant placement using socket shield technique|The crown of the involved tooth will be removed and the root will be then sectioned in a mesiodistal direction along its long axis as far apical as was possible using a long shank fissure bur. Preserving the facial root section unmanipulated and attached to the tooth socket. Periotomes will be then inserted between the palatal root removed gentelly.The remaining root section will be then reduced coronally to 1 mm above the alveolar crest.The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants and the root section will be checked for immobility with a sharp probe. With the preparation steps complete, the tooth root hereafter will be known as the socket-shield. An osteotomy will be then sequentially prepared and internal conical connection implant was inserted palatal to the shield with the implant 2 mm below the facial crest.
214577845|NCT05785923|DIAGNOSTIC_TEST|Point-of-Care Echocardiogram|Four view ultrasound of the heart performed at the bedside by trained emergency medicine physicians.
214577846|NCT01499563|DRUG|ITI-007|Capsules containing ITI-007 for 28 days
214577847|NCT01499563|DRUG|Placebo|Capsules containing inactive placebo for 28 days
214577848|NCT01499563|DRUG|Risperidone|Capsules containing risperidone for 28 days
214577849|NCT05172050|DRUG|Raloxifene|Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
214577850|NCT05172050|OTHER|Placebo|Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
214577851|NCT04910451|OTHER|No Intervention|
214577852|NCT03974477|DEVICE|SALT CONTROL H equipment to control and monitor salt during cooking process|Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
214577853|NCT02576119|DRUG|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
214577854|NCT02576119|DRUG|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
214577855|NCT04419129|DEVICE|Oxford UKA|knee arthroplasty
214577856|NCT04419129|DEVICE|Vanguard TKA|knee arthroplasty
214577857|NCT01853202|BEHAVIORAL|Supervised aerobic exercise training|
214577858|NCT06675825|DEVICE|BougieCap|The BougieCap is attached to the tip of the endoscope, offers direct visual and tactile control and the endoscope acts as a carrier of the radial and longitudinal force vectors for the dilation.
214577859|NCT06675825|DEVICE|Savary-Bougie (A) or balloon dilation (B)|"A: In the Savary- Bougie treatment, dilators of different sizes are advanced to dilate the stenosis. The same procedure is then repeated with the next larger dilator, with the position of the dilator being checked radiologically each time.~B: In the case of balloon dilation, a balloon is inserted and inflated at the level of the stenosis. Depending on the age of the child and possibly also the etiology of the stenosis, different balloons sizes are applied, which are then maintained inflated for about one until three minutes and the respective pressure. This procedure could take place under endoscopic or radiological control."
214577860|NCT06619951|DRUG|VC004 and Itraconazole|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.
214577861|NCT06619951|DRUG|VC004 and rifampicin|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.
214577862|NCT00283088|PROCEDURE|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
214577863|NCT00283088|DRUG|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
214577864|NCT02368028|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
214577865|NCT06422468|DEVICE|FibriCheck recordings|PPG, ACC, GYR, ECG and sound measurements
214709934|NCT04140604|OTHER|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
214709935|NCT04140604|OTHER|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
214577866|NCT03750045|DIAGNOSTIC_TEST|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
214577867|NCT03750045|DIAGNOSTIC_TEST|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
214577868|NCT03750045|OTHER|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
214577869|NCT05919862|PROCEDURE|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
214577870|NCT05919862|PROCEDURE|Freehand surgery|Freehand implant placement by experienced surgeon.
214577871|NCT04633798|PROCEDURE|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
214577872|NCT04633798|PROCEDURE|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
214577873|NCT02173847|PROCEDURE|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
214709936|NCT02227472|OTHER|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
214709937|NCT02227472|OTHER|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
214577874|NCT02173847|DEVICE|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
214577875|NCT02173847|DEVICE|Diode laser|Low power, near infrared diode laser for welding the surgical wound
214577876|NCT02648490|DRUG|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
214577877|NCT02648490|DRUG|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
214577878|NCT02648490|DRUG|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
214577879|NCT02648490|DRUG|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
214577880|NCT02648490|DRUG|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
214577881|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
214577882|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
214577883|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
214577884|NCT00969709|DRUG|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
214577885|NCT02980731|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
214577886|NCT02140281|DRUG|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
214577887|NCT02140281|DRUG|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
214577888|NCT03639831|DIETARY_SUPPLEMENT|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
214577889|NCT03639831|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|2 capsules/ day providing no active component
214577890|NCT01140698|OTHER|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
214577891|NCT02907307|DEVICE|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
214709938|NCT05733260|BEHAVIORAL|Exercise|10 weeks of resistance training.
214709939|NCT06294041|BEHAVIORAL|Sleep Restriction Therapy (SRT)|SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
214577892|NCT02907307|DEVICE|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
214577893|NCT02907307|DRUG|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
214577894|NCT01495832|OTHER|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
214577895|NCT01495832|OTHER|Control Group|The control group will consume comparator foods for 12 weeks.
214577896|NCT03552432|DRUG|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
214577897|NCT00061984|BIOLOGICAL|pegfilgrastim|
214577898|NCT00061984|DRUG|doxorubicin hydrochloride|
214577899|NCT00061984|DRUG|ifosfamide|
214577900|NCT00061984|PROCEDURE|multimodality therapy|
214577901|NCT06019741|DRUG|Rivaroxaban and aspirin 80|rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
214577902|NCT06019741|DRUG|Aspirin 80|aspirin 80 mg orally post coronary bypass surgery
214577903|NCT01149109|DRUG|Temozolomide and lomustine|
214577904|NCT01149109|DRUG|Temozolomide|
214577905|NCT04725474|BIOLOGICAL|visugromab (CTL-002)|monoclonal antibody
214577906|NCT05732051|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
214577907|NCT05732051|DIETARY_SUPPLEMENT|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
214577908|NCT03086525|OTHER|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
214577909|NCT04123574|DRUG|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
214577910|NCT06198205|OTHER|Fundamental motor skills|This will receive fundamental motor skills(FMS) program include 12 basic motor skills(running,hopping,galloping,leaping,jumping,sliding,strinking,dribbling,catching overhand throwing and underhand rolling)
214709940|NCT06294041|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
214577911|NCT06198205|OTHER|Regular after school program|This group will receive regular afterschool programs unstructured child's free play which include sliding, hide and seek, sea-saw, and running along with reading, drawing. Each intervention session lasted 60 minutes. The study will be conducted in the duration of 8 weeks with 3 sessions per week (total 24 sessions) will be given to the students.
214709941|NCT04514588|DIETARY_SUPPLEMENT|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
214577912|NCT02770456|DIETARY_SUPPLEMENT|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
214577913|NCT02770456|DIETARY_SUPPLEMENT|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
214577914|NCT02770456|DIETARY_SUPPLEMENT|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
214709942|NCT02920281|OTHER|Polysomnography|
214709943|NCT02418767|DRUG|MOD-4023|
214577915|NCT01342341|DRUG|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
214577916|NCT01635205|PROCEDURE|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
214577917|NCT01635205|PROCEDURE|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
214577918|NCT00016601|DRUG|Indinavir sulfate|
214577919|NCT00016601|DRUG|Ritonavir|
214709944|NCT02418767|DRUG|Placebo|
214709945|NCT03801811|PROCEDURE|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
214577920|NCT00016601|DRUG|Nelfinavir mesylate|
214577921|NCT00016601|DRUG|Efavirenz|
214577922|NCT00016601|DRUG|Nevirapine|
214577923|NCT00016601|DRUG|Medroxyprogesterone acetate|
214577924|NCT02747641|PROCEDURE|Pixel CO2 Laser System|
214577925|NCT06301425|OTHER|Intervention group|"Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7."
214577926|NCT06301425|OTHER|Control group|Receive allo-HSCT directly without the second consolidation chemotherapy.
214577927|NCT01084837|DRUG|velcade|"INDUCTIoN (Cycles 1-4)~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~* Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~* Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
214577928|NCT01238900|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
214577929|NCT06083779|GENETIC|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
214577930|NCT00508703|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
214577931|NCT00508703|PROCEDURE|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
214577932|NCT04619979|PROCEDURE|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
214577933|NCT01015339|DRUG|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
214577934|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
214577935|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
214577936|NCT01015339|DRUG|cisplatin|80mg/m2, day 1 of every 3 weeks
214577937|NCT03208777|GENETIC|taking blood samples|taking blood samples and measure telomeric abnormalities
214709946|NCT06305221|DRUG|Opioid-free Analgesics (esketamine, dexmedetomidine)|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
214577938|NCT05342506|DRUG|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
214577939|NCT00616902|DRUG|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
214577940|NCT00616902|DRUG|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
214577941|NCT04107987|DIETARY_SUPPLEMENT|Reglicem|Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
214577942|NCT04107987|OTHER|Placebo|Placebo
214577943|NCT03927339|DIAGNOSTIC_TEST|pre and post excercise group|"Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C)."
214577944|NCT01593332|DRUG|Rituximab|two 500 mg rituximab infusions 2 weeks apart
214577945|NCT01593332|DRUG|Rituximab|500mg,two times with two weeks interval
214577946|NCT02708329|PROCEDURE|T-provisional stenting|Standard endovascular T-provisional stenting technique
214577947|NCT02708329|PROCEDURE|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
214577948|NCT02708329|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
214709947|NCT06305221|DRUG|Opioid Anesthetics (sufentanil and remifentanil)|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
214709948|NCT00764946|DRUG|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
214709949|NCT03388086|DRUG|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
214709950|NCT04569799|DRUG|Lumason|2.4 mL per lesion
214709951|NCT03590704|DEVICE|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
214709952|NCT03552627|DRUG|Oxygen|Medical Oxygen
214709953|NCT00206011|PROCEDURE|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
214709954|NCT00903253|DRUG|LNK-754|
214577949|NCT01869387|DEVICE|Non-invasive ventilation|
214577950|NCT02940405|DRUG|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
214577951|NCT02940405|DRUG|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
214577952|NCT00153881|DRUG|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
214577953|NCT05589168|BEHAVIORAL|Triage nurse|Triage nurse joins 911 call
214577954|NCT05589168|BEHAVIORAL|No triage nurse|Triage nurse does not join 911 call (business as usual)
214577955|NCT03725085|DRUG|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
214577956|NCT02194673|OTHER|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
214577957|NCT02194673|OTHER|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
214577958|NCT02194673|OTHER|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
214577959|NCT03471351|DRUG|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
214577960|NCT03471351|BIOLOGICAL|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
214577961|NCT06399133|OTHER|Warm water intake|Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.
214577962|NCT06399133|OTHER|High-fiber diet|After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
214577963|NCT06399133|OTHER|Abdominal massage|Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
214577964|NCT04775771|BEHAVIORAL|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
214577965|NCT06417528|PROCEDURE|Chronic Post Surgery Pain (CPSP)|"The outcome variable is the presence of CPSP assessed 3 months after surgery and defined as an average pain intensity of at least 3 on the NRS scale (11-point one-dimensional pain scale) in the last three days, and pain localized to the surgical field (or in the lesion area) projected into the innervation territory of a nerve located in this area or referred to a dermatome.~Separate prediction models will be developed using data derived from surveys conducted at the relevant time points for the development of the risk index."
214577966|NCT00090129|DRUG|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
214577967|NCT00090129|DRUG|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
214577968|NCT00002332|DRUG|Thymopentin|
214577969|NCT04698642|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
214577970|NCT01458431|DRUG|Levobupivacaine|continuous levobupivacaine subfascial infusion
214577971|NCT01458431|DRUG|NaCl|continuous NaCl subfascial infusion
214577972|NCT05443646|DRUG|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
214577973|NCT05443646|RADIATION|hypofractionated radiotherapy|45Gy/3Gy/3week
214577974|NCT05443646|RADIATION|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
214577975|NCT04338087|OTHER|Questionnaire and personal interviews.|Questionnaire and personal interviews.
214577976|NCT04898439|OTHER|greening of the school environment|The school will be greened and biodiversity will be increased. This will be done on the playground and area around the school. Special needs corners for playing, relaxing or gardening will be installed.
214577977|NCT04369482|DEVICE|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
214577978|NCT04369482|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
214577979|NCT04021550|DEVICE|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
214577980|NCT04021550|DRUG|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
214577981|NCT04021550|DIETARY_SUPPLEMENT|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
214577982|NCT04021550|OTHER|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
214577983|NCT01313247|DRUG|paracetamol|1000 mg 4 times daily
214577984|NCT01313247|DRUG|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
214577985|NCT05452174|DRUG|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
214577986|NCT01823692|OTHER|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
214577987|NCT02879474|BEHAVIORAL|Melanoma scale questionnair|
214577988|NCT03856489|OTHER|Richards-Campbell Sleeping Questionnaire (RCSQ)|This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
214577989|NCT02853838|OTHER|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
214577990|NCT02853838|OTHER|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
214577991|NCT02853838|OTHER|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
214577992|NCT01119105|DRUG|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
214577993|NCT01119105|DRUG|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
214577994|NCT01119105|DRUG|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
214577995|NCT00421044|DRUG|Patupilone/EPO906|
214577996|NCT05102604|OTHER|Avocado|Subjects will eat one avocado in addition to their usual diet
214577997|NCT05102604|OTHER|Habitual diet|Subjects will eat their usual diet
214577998|NCT03701529|DRUG|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
214577999|NCT03701529|DRUG|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
214709955|NCT03903744|PROCEDURE|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
214578000|NCT01775475|DRUG|cyclophosphamide|Given IV
214578001|NCT01775475|DRUG|doxorubicin hydrochloride|Given IV
214578002|NCT01775475|DRUG|vincristine sulfate|Given IV
214578003|NCT01775475|DRUG|prednisone|Given PO
214578004|NCT01775475|DRUG|lomustine|Given PO
214578005|NCT01775475|DRUG|etoposide|Given PO
214578006|NCT01775475|DRUG|cyclophosphamide|Given PO
214578007|NCT01775475|DRUG|procarbazine hydrochloride|Given PO
214578008|NCT01775475|OTHER|laboratory biomarker analysis|Correlative studies
214578009|NCT01181388|PROCEDURE|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
214578010|NCT01181388|PROCEDURE|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
214578011|NCT05351684|DRUG|Dolutegravir 50 MG|already included in arm/group descriptions.
214578012|NCT02590705|DRUG|Lidocaine|surface anesthesia with lidocaine
214578013|NCT00416832|DRUG|cyclophosphamide|
214578014|NCT00416832|DRUG|dacarbazine|
214578015|NCT00416832|DRUG|doxorubicin hydrochloride|
214578016|NCT00416832|DRUG|etoposide|
214578017|NCT00416832|DRUG|prednisone|
214578018|NCT00416832|DRUG|procarbazine hydrochloride|
214578019|NCT00416832|DRUG|vincristine sulfate|
214578020|NCT00416832|RADIATION|radiation therapy|
214578021|NCT04479345|OTHER|Questionnaire|Online questionnaire
214578022|NCT00435591|DRUG|Conivaptan|ampoule or premix bag
214578023|NCT00435591|DRUG|placebo|ampoule or premix bag
214578024|NCT00210470|BIOLOGICAL|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
214578025|NCT00210470|DRUG|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
214578026|NCT00210470|DRUG|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
214578027|NCT00210470|DRUG|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
214578028|NCT00210470|DRUG|Omeprazole|21 days of 20 mg. orally
214578029|NCT00995969|DRUG|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
214578030|NCT00995969|DRUG|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
214578031|NCT01299870|DRUG|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
214578032|NCT01299870|DRUG|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
214578033|NCT05384405|DEVICE|Active iTBS|MagPro X100
214578034|NCT05384405|DEVICE|Sham iTBS|MagPro X100
214578035|NCT05438017|DEVICE|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
214578036|NCT04661956|PROCEDURE|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
214578037|NCT03111251|BEHAVIORAL|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
214578038|NCT03111251|BEHAVIORAL|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
214578039|NCT03111251|BEHAVIORAL|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
214578040|NCT03111251|BEHAVIORAL|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
214578041|NCT03111251|BEHAVIORAL|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
214578042|NCT02838927|OTHER|No intervention|No intervention
214578043|NCT00936741|DRUG|mifepristone|Mifepristone 300 mg to 1200 mg once daily
214709956|NCT03086317|DEVICE|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
214578044|NCT02245737|DRUG|Lanabecestat|Administered orally
214578045|NCT02245737|DRUG|Placebo|Administered orally
214578046|NCT02926599|BEHAVIORAL|Personal Optimization Training|
214578047|NCT06062290|DEVICE|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
214578048|NCT06062290|DEVICE|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
214578049|NCT06106932|DRUG|Leuprolide Acetate|Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
214578050|NCT06274372|DEVICE|flow controlled ventilation|effects of flow controlled ventilation
214578051|NCT06274372|DEVICE|volume controlled ventilation|effects of volume controlled ventilation
214578052|NCT02830360|DRUG|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
214578053|NCT02830360|PROCEDURE|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
214578054|NCT04410640|OTHER|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
214578055|NCT02622776|OTHER|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
214578056|NCT00618618|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214578057|NCT00618618|DRUG|Placebo|
214578058|NCT00002459|RADIATION|radiation therapy|
214578059|NCT05295420|PROCEDURE|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
214578060|NCT03711344|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
214578061|NCT00431080|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
214578062|NCT00431080|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
214578063|NCT00431080|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
214578064|NCT00431080|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
214578065|NCT00431080|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
214578066|NCT00431080|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
214578067|NCT04974242|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
214578068|NCT04083677|DEVICE|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
214578069|NCT05710159|DEVICE|iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes|Development and implementation of a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study.
214578070|NCT04547868|OTHER|Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
214578071|NCT04547868|OTHER|Decaffeinated Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
214578072|NCT04547868|OTHER|Warm water|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
214709957|NCT03086317|DEVICE|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
214578073|NCT02819362|DEVICE|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
214578074|NCT04096053|OTHER|TEACHH|See arm/group description.
214578075|NCT02708264|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
214578076|NCT01800552|PROCEDURE|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
214578077|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
214578078|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
214578079|NCT03271567|DIAGNOSTIC_TEST|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
214578080|NCT00944398|DIETARY_SUPPLEMENT|Zinc fortified food|Daily consumption
214578081|NCT00944398|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement containing zinc sulfate
214578082|NCT00944398|OTHER|Placebo supplement|Liquid placebo supplement
214578083|NCT00944398|DIETARY_SUPPLEMENT|Non-fortified food|Non-fortified complementary food.
214578084|NCT03787927|DRUG|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
214578085|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
214578086|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
214578087|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
214578088|NCT03787927|DRUG|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
214578089|NCT03787927|DRUG|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
214578090|NCT02929329|DRUG|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
214578091|NCT02929329|DRUG|Placebo|Matching placebo tablets
214578092|NCT02929329|DRUG|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
214578093|NCT01531010|DEVICE|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
214578094|NCT05925361|PROCEDURE|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
214578095|NCT01423032|DRUG|bendamustine|100 mg/m² iv, day 1+2, q4w
214578096|NCT01423032|DRUG|Fludarabine|25 mg/m² iv, days 1-5, q4w
214709958|NCT02575573|OTHER|Factors influencing resuscitation decisions of patients|
214709959|NCT02575573|OTHER|Factors leading to not asking patients about resuscitation preference|
214578097|NCT05837715|DEVICE|Chattanooga Stabilizer pressure biofeedback|"Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error."
214709960|NCT05699317|OTHER|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
214578098|NCT05837715|DEVICE|VibraSens - Focal Vibration Therapy (TechnoConcept - France)|"Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation."
214578099|NCT05837715|OTHER|Telerehabilitation|Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
214578100|NCT03095690|OTHER|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
214578101|NCT04401501|OTHER|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
214578102|NCT04401501|OTHER|Exercise|Exercises for cervicogenic headache
214578103|NCT00377494|BIOLOGICAL|MVA-CSO Vaccine|
214578104|NCT00377494|BIOLOGICAL|PfCSP DNA (VCL-2510) Vaccine|
214578105|NCT00370305|DRUG|rosiglitazone|89 mg BID for 8 weeks, orally
214578106|NCT00964093|DEVICE|Silver Alginate|(Algidex ™)
214578107|NCT01431222|DEVICE|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
214578108|NCT03840915|DRUG|Cisplatin|Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
214578109|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
214578110|NCT03840915|DRUG|Pemetrexed|Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
214578111|NCT03840915|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
214578112|NCT03840915|DRUG|Gemcitabine|Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
214578113|NCT03840915|DRUG|Docetaxel|Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
214578114|NCT03840915|DRUG|M7824|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
214578115|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
214578116|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
214578117|NCT03840915|DRUG|Bintrafusp alfa|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
214578118|NCT03840915|DRUG|Paclitaxel|Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
214578119|NCT06074965|DEVICE|Medtronic Extended Infusion Set|Each subject will be given 2 types of infusion sets to wear and change sets per label use (3 days for Medtronic Quick-set™ and 7 days for Medtronic Extended).
214578120|NCT03787082|DRUG|Nitrates|1,000 mg/11.18 mmol, oral
214578121|NCT03787082|DRUG|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
214578122|NCT03787082|DRUG|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
214578123|NCT03250234|OTHER|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
214578124|NCT03250234|OTHER|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
214578125|NCT00309959|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214578126|NCT00309959|OTHER|Laboratory Biomarker Analysis|Correlative studies
214709961|NCT06138561|BEHAVIORAL|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
214578127|NCT01819259|DRUG|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
214578128|NCT01819259|DRUG|Placebo|
214578129|NCT00962403|BEHAVIORAL|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
214578130|NCT03368339|DRUG|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
214578131|NCT03368339|DRUG|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
214578132|NCT03368339|DRUG|Vehicle|Vehicle
214578133|NCT05325801|BIOLOGICAL|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
214578134|NCT04301531|OTHER|Mass testing using RDTs|To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
214578135|NCT04301531|DRUG|Treatment for all cases confirmed positive malaria cases with ACTs|During each mass testing, all confirmed positive cases are treated in both arms.
214578136|NCT04301531|OTHER|Determination of Hb|Hb of all children in the subgroup study are measured using a haemocure photometer.
214578137|NCT04301531|OTHER|Household survey|Determine the prevalence of febrile illnesses among children in the subgroup study
214578138|NCT04301531|OTHER|Community-base management of malaria|Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
214578139|NCT02470910|DEVICE|Magnetic Resonance Imaging|
214578140|NCT04212520|OTHER|No intervention|No intervention
214578141|NCT04401852|DRUG|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
214578142|NCT04401852|DRUG|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
214578143|NCT02516020|DRUG|Global|Embryos are cultured in single step culture from day 1 to day 5
214709962|NCT06138561|BEHAVIORAL|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
214709963|NCT06138561|BEHAVIORAL|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
214709964|NCT00194272|DRUG|Methotrexate|Two dose methotrexate
214709965|NCT00945802|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
214578144|NCT02516020|DRUG|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
214578145|NCT01075828|DRUG|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
214578146|NCT02056353|DEVICE|LOGIC-Insulin algorithm|
214578147|NCT02056353|DEVICE|Paper protocol|
214578148|NCT03167372|OTHER|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
214578149|NCT03167372|OTHER|Fitbit Flex2 TM|Standard system activity and sleep tracker
214578150|NCT03268447|DIETARY_SUPPLEMENT|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
214709966|NCT00945802|DRUG|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
214578151|NCT03268447|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
214709967|NCT00186654|PROCEDURE|Acupuncture|
214578152|NCT02856477|BIOLOGICAL|urine analysis|a sample of urine is collected during 8 hours.
214578153|NCT04782336|OTHER|Sample Collection|"Sample Collection - Adult Population:~* Two (2) Nasal AND/OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample~Sample Collection - Paediatric Population:~* Two (2) Nasal OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample"
214578154|NCT03497416|OTHER|No intervention|No intervention
214578155|NCT06048679|DEVICE|Endovascular pulmonary artery flow-limiting covered stent implantation|selective reduction of flow in the pulmonary arteries affected by anomalous pulmonary venous drainage using a modified flow-limiting covered stent
214578156|NCT02381600|DRUG|Vitamin D|"Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
214578157|NCT05557513|DEVICE|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
214578158|NCT00560560|BIOLOGICAL|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
214578159|NCT00140985|DRUG|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
214578160|NCT00140985|DRUG|Comparator: amlodipine / Duration of Treatment: 20 weeks|
214578161|NCT05560438|DEVICE|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
214578162|NCT00322543|DEVICE|Corio™ Pimecrolimus-eluting stent|
214578163|NCT03475277|DRUG|Ketamine|Acute administration
214578164|NCT00272675|DRUG|Chlorhexidine gluconate (drug) vs placebo|
214578165|NCT03323073|OTHER|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
214578166|NCT02134418|BEHAVIORAL|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
214578167|NCT00184665|DRUG|insulin detemir|
214578168|NCT00184665|DRUG|insulin NPH|
214578169|NCT00184665|DRUG|insulin aspart|
214578170|NCT03836716|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
214578171|NCT01165853|OTHER|Glucose|25% dose at 8-week intervention assigned to subjects.
214578172|NCT01165853|OTHER|Fructose|25% dose at 8-week intervention assigned to subjects.
214578173|NCT05898347|OTHER|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
214578174|NCT05734352|OTHER|Questionnaire|Completion of the patient reported experience measurements (PREMs) questionnaire
214578175|NCT03347097|DRUG|TIL|
214578176|NCT03347097|DRUG|PD1-TIL|
214578177|NCT05377437|OTHER|Natural Language Processing|Natural Language Processing: classification and regression tasks.
214578178|NCT03870347|DIAGNOSTIC_TEST|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
214578179|NCT04571359|OTHER|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
214578180|NCT02630602|DIETARY_SUPPLEMENT|Functional goat cheese|60 g per day during 12 weeks
214709968|NCT00186654|PROCEDURE|Perinatal massage|
214709969|NCT02431468|DRUG|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
214578181|NCT02630602|DIETARY_SUPPLEMENT|Control cheese|60 g per day during 12 weeks
214578182|NCT01983254|BEHAVIORAL|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
214578183|NCT01983254|OTHER|education program|web-based, ICU-specific education program
214578184|NCT05149053|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
214578185|NCT05149053|OTHER|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
214578186|NCT06169683|DEVICE|Lyric4|Lyric4 Hearing instrument use
214578187|NCT03211754|DIETARY_SUPPLEMENT|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
214578188|NCT05180188|BEHAVIORAL|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
214578189|NCT00434213|DRUG|Daytrana|Methylphenidate Transdermal System (MTS)
214578190|NCT04322838|DIAGNOSTIC_TEST|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
214578191|NCT04322838|DIAGNOSTIC_TEST|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
214578192|NCT04322838|DIAGNOSTIC_TEST|Skin Prick Test|Diagnostic skin test for sensitization to allergens
214578193|NCT04322838|DIAGNOSTIC_TEST|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
214578194|NCT04322838|DIAGNOSTIC_TEST|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
214578195|NCT04322838|DIAGNOSTIC_TEST|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
214578196|NCT06039631|PROCEDURE|Surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended.
214578197|NCT06039631|RADIATION|Radiation|"In the surgical group, depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended.~In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin at a dosage of 30 mg/m²."
214578198|NCT06039631|DRUG|Toripalimab|In the both groups, starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
214578199|NCT00000632|BIOLOGICAL|Env 2-3|
214578200|NCT04208945|DRUG|Colistin|500000 units of inhaled colistin three times daily for 10 days
214578201|NCT02478268|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
214578202|NCT02478268|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
214578203|NCT04278222|DRUG|Anlotinib Plus Toripalimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
214578204|NCT01990729|DIETARY_SUPPLEMENT|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
214578205|NCT02828540|DRUG|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
214578206|NCT02828540|DRUG|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
214578207|NCT02828540|DRUG|Placebo|placebo having the same appearance as HT047 Tab. 250mg
214578208|NCT02587988|DRUG|HCP1302|
214578209|NCT02587988|DRUG|HGP0904|
214578210|NCT02587988|DRUG|Placebo (for HCP1302)|
214578211|NCT02587988|DRUG|Placebo (for HGP0904)|
214578212|NCT02857569|DRUG|Ipilimumab IT|
214578213|NCT02857569|DRUG|Ipilimumab IV|
214578214|NCT02857569|DRUG|Nivolumab IV|
214578215|NCT00167089|BEHAVIORAL|Treadmill Training|Partian body weight support treadmill training, 30 min/day \* 3 days /week
214578216|NCT05332353|DRUG|Bacillus Calmette-Guerin|Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
214578217|NCT00768079|OTHER|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
214578218|NCT00768079|BIOLOGICAL|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
214578219|NCT00666601|DRUG|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
214578220|NCT00666601|DRUG|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
214578221|NCT04399811|DIAGNOSTIC_TEST|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
214578222|NCT01015547|DRUG|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
214578223|NCT01015547|DRUG|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
214578224|NCT01015547|DRUG|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
214578225|NCT02704793|OTHER|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
214578226|NCT02704793|OTHER|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
214578227|NCT02393027|DRUG|[18F] LBT-999 PET|
214578228|NCT04568694|PROCEDURE|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
214578229|NCT04568694|PROCEDURE|Conventional Lung Transplantation|Reference Therapy
214578230|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Single dose
214578231|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Multiple dose
214578232|NCT04531644|PROCEDURE|double stimulation|the patients will be treated with two consecutive ovarian stimulations in one cycle
214578233|NCT04531644|PROCEDURE|conventional ovarian stimulation|the patients will be treated with one conventional ovarian stimulation in one cycle
214578234|NCT02796625|OTHER|Painful Stimuli|warm or painful heat administration
214578235|NCT00106587|DEVICE|PTCA|
214578236|NCT00106587|COMBINATION_PRODUCT|paclitaxel coated balloon catheter (device with drug)|
214578237|NCT01611805|DRUG|GSK1605786|Opaque Swedish orange body and cap.
214578238|NCT01611805|DRUG|GSK1605786 Placebo|Opaque Swedish orange body and cap.
214578239|NCT06410768|BEHAVIORAL|multistage shared decision-making program|The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
214578240|NCT02235831|DEVICE|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
214578241|NCT02235831|DEVICE|Nelfilcon A single vision contact lenses (DACP)|
214578242|NCT04949061|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
214578243|NCT04949061|OTHER|Enhanced Treatment as Usual (ETA-U)|Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
214578244|NCT01721460|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
214709970|NCT02431468|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
214578245|NCT00014651|DRUG|vapreotide|
214578246|NCT00014651|PROCEDURE|conventional surgery|
214709971|NCT01361919|PROCEDURE|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
214578247|NCT05137015|OTHER|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~1. Balance~2. Core stability~3. Hamstring eccentrics~4. Glute activation~5. Plyometrics~6. Running~7. Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
214578248|NCT02534454|BEHAVIORAL|Active Retraining|
214578249|NCT02534454|BEHAVIORAL|Sham Retraining|
214578250|NCT02534454|DEVICE|Active transcranial direct current stimulation (TDCS)|
214578251|NCT02534454|DEVICE|Sham transcranial direct current stimulation (TDCS)|
214578252|NCT02534454|DRUG|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
214578253|NCT06072508|BIOLOGICAL|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
214578254|NCT05366790|BEHAVIORAL|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
214578255|NCT03152097|DIETARY_SUPPLEMENT|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
214578256|NCT03152097|OTHER|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
214578257|NCT04860297|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214578258|NCT00396019|DRUG|PEG-Intron|
214578259|NCT04811131|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
214578260|NCT04811131|DRUG|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
214578261|NCT04811131|DEVICE|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
214578262|NCT04811131|DEVICE|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
214578263|NCT02782312|DRUG|ICS+LABA|Seretide is inhaled for one year
214578264|NCT02782312|OTHER|routine therapy|routine therapy for one year
214578265|NCT02631824|PROCEDURE|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
214578266|NCT02631824|DEVICE|TFNA|Trochanteric Femoral Nail Advance
214578267|NCT02631824|DEVICE|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
214578268|NCT00003453|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214578269|NCT06251362|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
214578270|NCT00133510|BIOLOGICAL|Trivalent Subviron Influenza vaccine (Fluzone)|
214578271|NCT02072785|DRUG|Vincristine Sulfate Liposome|
214578272|NCT02072785|DRUG|Vincristine Sulfate|
214578273|NCT02223676|PROCEDURE|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
214578274|NCT03955523|OTHER|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation \>5% VO2peak for at least 3 minutes of exercise.
214578275|NCT03955523|DIETARY_SUPPLEMENT|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
214578276|NCT05251194|DEVICE|video laryngoscope at thyroid surgical position|After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.
214578277|NCT03664934|OTHER|Exercises|Neck-specific exercises for chronic whiplash associated disorders
214578278|NCT02129270|DRUG|Lidocaine HCl 2% .|comparison of different dosages of drug
214578279|NCT02129270|DRUG|Lidocaine HCl 1%|comparison of different dosages of drug
214578280|NCT00148070|DRUG|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
214578281|NCT00148070|PROCEDURE|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
214578282|NCT03100487|DEVICE|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
214709972|NCT01361919|PROCEDURE|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
214709973|NCT01361919|PROCEDURE|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
214709974|NCT04385914|OTHER|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
214709975|NCT00212303|BEHAVIORAL|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
214578283|NCT06280040|DIAGNOSTIC_TEST|Clinical examination and multimodal ocular imaging|Imaging consists of sonography, fundus photography, oximeter, optical coherence tomography angiography, and Microperimetry.
214578284|NCT00564694|PROCEDURE|psychosocial assessment and care|
214578285|NCT00564694|PROCEDURE|quality-of-life assessment|
214578286|NCT00133406|DRUG|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
214578287|NCT00133406|DRUG|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
214578288|NCT00133406|DRUG|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
214578289|NCT00133406|DRUG|zinc|40 mg twice weekly for 12 months
214578290|NCT04323176|OTHER|Village Model implementation|Participate in the Village Model using a website
214578291|NCT02528526|DRUG|OXY111A|OXY111A intravenous infusion
214578292|NCT01528345|DRUG|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
214578293|NCT01528345|DRUG|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
214578294|NCT01528345|DRUG|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
214578295|NCT03014076|DRUG|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
214578296|NCT03014076|DRUG|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
214709976|NCT03001843|DRUG|Ketamine|Anesthesia of only Ketamine
214709977|NCT03001843|DRUG|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
214578297|NCT00473148|PROCEDURE|BNP-guided weaning|BNP-guided weaning
214578298|NCT00473148|PROCEDURE|Standard physician-directed weaning|Standard physician-directed weaning
214578299|NCT05918718|DRUG|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
214578300|NCT05918718|DRUG|methotrexate|methotrexate
214578301|NCT05938140|DRUG|Nirmatrelvir/ritonavir|Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
214578302|NCT03698903|BEHAVIORAL|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
214578303|NCT01010659|DEVICE|Lacrimal Tube|Lacrimal Tube
214578304|NCT02601976|DRUG|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
214578305|NCT02601976|DRUG|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214578306|NCT05885087|DEVICE|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
214578307|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
214578308|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
214578309|NCT02624791|OTHER|No contact lenses|simulated driving tests
214578310|NCT02423148|DRUG|Indocyanine green (ICG)|
214578311|NCT02423148|DEVICE|FluoSCOPE|
214578312|NCT00700492|DRUG|progesterone|vaginal capsules 3X200mg daily
214578313|NCT01131182|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
214578314|NCT01131182|DRUG|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
214578315|NCT01131182|DRUG|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
214578316|NCT04831541|DRUG|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
214578317|NCT02483026|DIETARY_SUPPLEMENT|Multi vitamin|Multi vitamin
214578318|NCT02483026|DIETARY_SUPPLEMENT|vitamin D|Vitamin D
214709978|NCT03001843|BEHAVIORAL|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
214578319|NCT03182361|DEVICE|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
214578320|NCT03343327|DRUG|Chronocort®|Single dose of 20mg Chronocort® administered in one treatment period
214578321|NCT03343327|DRUG|Cortef®|Single dose of 20mg Cortef® administered in one treatment period
214578322|NCT00735475|BIOLOGICAL|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
214578323|NCT00735475|BIOLOGICAL|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
214578324|NCT01763801|DEVICE|P-Max|tip placement in correspondence to the P-Max on the ECG
214578325|NCT01763801|DEVICE|P-Submax|tip placement in correspondence to the P-Submax on the ECG
214578326|NCT04339530|OTHER|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
214578327|NCT04405349|BIOLOGICAL|VB10.16|Vaccination
214578328|NCT04405349|BIOLOGICAL|Atezolizumab|Intravenously infusion
214578329|NCT00526838|DRUG|XL228|1-hour IV infusion
214578330|NCT00662818|DRUG|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
214578331|NCT00662818|DRUG|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
214578332|NCT00662818|DRUG|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
214578333|NCT00662818|DRUG|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
214578334|NCT06387628|DRUG|LM-108|LM-108, 10mg/kg, d1, q6w
214578335|NCT06387628|DRUG|Toripalimab|Toripalimab, 240 mg, d1, q3w
214578336|NCT06387628|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1, 8 , q3w
214578337|NCT06387628|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m2, d1, 8 , q3w
214578338|NCT02055391|BEHAVIORAL|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
214578339|NCT02055391|BEHAVIORAL|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
214578340|NCT00659178|DRUG|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
214578341|NCT06204952|DRUG|Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)|In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
214578342|NCT06204952|DRUG|Placebo|In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
214578343|NCT03780075|DRUG|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
214578344|NCT03780075|DRUG|2.00 GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
214578345|NCT03780075|DRUG|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
214578346|NCT06298929|PROCEDURE|medial rectus fenestration|Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.
214578347|NCT06298929|PROCEDURE|medial rectus recession|recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.
214578348|NCT01146782|DEVICE|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
214578349|NCT03390647|DRUG|E6130|Oral dose
214578350|NCT03390647|DRUG|Placebo|E6130-matched placebo
214578351|NCT05963373|DIAGNOSTIC_TEST|Urine analysis|Diagnostic test
214578352|NCT02685345|DRUG|DS-8500a 25 mg|
214578353|NCT02685345|DRUG|DS-8500a 75 mg|
214578354|NCT02685345|DRUG|placebo|
214709979|NCT03155295|OTHER|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
214578355|NCT00008073|DRUG|doxorubicin hydrochloride|
214578356|NCT00008073|DRUG|octreotide acetate|
214578357|NCT03384901|PROCEDURE|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
214578358|NCT03392285|DEVICE|Internal fixation or hip arthroplasty|Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
214578359|NCT00710359|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
214578360|NCT02270515|OTHER|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
214578361|NCT04684407|PROCEDURE|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
214578362|NCT06077253|PROCEDURE|Iridotomy|Peripheral iridotomy (size \>200µm)
214578363|NCT01912677|DRUG|Nifedipine|
214578364|NCT01912677|DRUG|Labetalol|
214578365|NCT01912677|DRUG|Methyldopa|
214578366|NCT02930031|DIETARY_SUPPLEMENT|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
214578367|NCT02930031|DIETARY_SUPPLEMENT|Placebo|500 mL orally, daily for eight days following exercise
214578368|NCT02220231|PROCEDURE|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
214578369|NCT02341131|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
214578370|NCT02341131|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
214578371|NCT03309462|DEVICE|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
214578372|NCT00130624|PROCEDURE|Multidisciplinary intervention: primary or secondary care|
214578373|NCT02135354|DRUG|Azithromycin|"* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
214578374|NCT02135354|DRUG|Placebo|"* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
214578375|NCT03806101|DRUG|PF-04965842|200 mg dose of PF-04965842 once daily (QD) for 3 days
214578376|NCT03806101|DRUG|Rosuvastatin|Single 10 mg dose of rosuvastatin
214578377|NCT00719147|PROCEDURE|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
214578378|NCT00719147|OTHER|Functional Status and Symptom Questionnaire|Questionnaire
214578379|NCT00447889|DRUG|gadoteric acid|
214578380|NCT04973904|DRUG|Toripalimab|IV infusion
214578381|NCT04973904|DRUG|Paclitaxel|IV infusion
214578382|NCT04973904|DRUG|Cisplatin|IV infusion
214578383|NCT04973904|DRUG|Bevacizumab|IV infusion
214578384|NCT05406076|BEHAVIORAL|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
214578385|NCT05406076|BEHAVIORAL|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
214578386|NCT01164904|DRUG|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
214578387|NCT01089738|DRUG|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
214578388|NCT01089738|DRUG|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
214578389|NCT01089738|DRUG|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
214578390|NCT01089738|DRUG|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
214578391|NCT04739943|BEHAVIORAL|Mobile Monitoring|Participants use a smartphone app for self monitoring of respiratory symptoms
214578392|NCT05540067|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
214578393|NCT05540067|OTHER|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
214578394|NCT00911768|DIETARY_SUPPLEMENT|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
214709980|NCT03155295|OTHER|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
214709981|NCT06379867|DRUG|HSK3486|0.4 mg/kg, IV bolus administration
214578395|NCT00911768|DIETARY_SUPPLEMENT|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
214578396|NCT06457789|DRUG|[18F]F-AraG PET imaging|Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
214578397|NCT06457789|DRUG|[89Zr]Zr-Df-Crefmirlimab PET imaging|Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
214709982|NCT06379867|DRUG|Placebo|IV bolus administration
214709983|NCT06379867|DRUG|Moxifloxacin|0.4 g, Oral administration with 240 mL
214709984|NCT01770691|DEVICE|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
214709985|NCT05233982|DRUG|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
214709986|NCT02907320|DRUG|CYCLO 3 ® FORT|
214709987|NCT02907320|DRUG|MPFF|
214709988|NCT02907320|DRUG|placebo CYCLO 3 ® FORT|
214709989|NCT02907320|DRUG|placebo MPFF|
214709990|NCT03472274|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
214709991|NCT03472274|DRUG|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
214578398|NCT05982795|OTHER|Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge|"A CultureSwab MaxV(+) (BD, Franklin Lakes, NJ) will be placed under endoscopic visualization to the middle meatus through a sterile sheath (red rubber urinary catheter) and gently rotated 5 full turns or until the tip is saturated with mucus (no more than 20 seconds).~Under direct visualization, a sterile Leukosorb sponge (Leukosorb; Pall Scientific, Port Washington, NY) will be placed in the middle meatus. A piece of Leukosorb filter paper will additionally be placed in the olfactory cleft. The sponge and paper will be left for 5 minutes and will then be removed under direct visualization and collected for analysis."
214578399|NCT05982795|OTHER|Olfactory Function Testing|"Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Odors will be delivered using felt-tip pens (Sniffin' Sticks, MediSense, NL). The pen cap will be removed from the pen for approximately 3 seconds, and the pen's tip will be brought in front of the subject's nose and carefully moved from left to right nostril. Threshold testing will be obtained by asking the subject to identify the pen containing the odor from two pens containing only solvent. This will be conducted starting with the lowest concentration of odor and moving stepwise until patient is no longer able to identify the odor from the solvent.~Subjects may also be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT can be self-administered and uses microencapsulated odorants which are released by scratching standardized odor-impregnated test booklets."
214709992|NCT03472274|DRUG|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"
214709993|NCT04149639|DIETARY_SUPPLEMENT|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
214709994|NCT02263495|DRUG|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
214578400|NCT05982795|OTHER|Survey Completion|"Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised (CFQ-R) survey. This survey evaluates Cystic Fibrosis-specific and general quality of life metrics.~Participants will also be asked to complete the validated Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with chronic rhinosinusitis.~Participants will also be asked to complete the validated Sinus Control Test (SCT) - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis.~Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a 25-question validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease."
214578401|NCT06576258|DIAGNOSTIC_TEST|cobas eplex multiplex PCR|Positive blood culture samples from the intervention group are subjected to cobas eplex multiplex PCR in addition to the SOC culture methods.
214578402|NCT05253794|DRUG|Colchicine 0.6 mg|oral tablet daily for 6 months
214578403|NCT05253794|DRUG|Placebo|oral tablet daily for 6 months
214578404|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
214578405|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
214578406|NCT04517214|DRUG|Toripalimab|PD-1 inhibitor
214578407|NCT04517214|RADIATION|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
214578408|NCT04517214|DRUG|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
214578409|NCT04517214|DRUG|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
214578410|NCT05677490|DRUG|Fluorouracil|Given IV
214578411|NCT05677490|DRUG|Leucovorin Calcium|Given IV
214578412|NCT05677490|DRUG|Oxaliplatin|Given IV
214578413|NCT05677490|DRUG|Irinotecan|Given IV
214709995|NCT02263495|DRUG|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
214578414|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
214578415|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214578416|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
214578417|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214578418|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
214578419|NCT01361191|DRUG|R-MEGACHOP|"* If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
214578420|NCT05520372|COMBINATION_PRODUCT|Autologous immune enhancement therapy (AIET) for cancer patients|Autologous NK cell and CD8 T cell therapy for cancer patients
214578421|NCT02817802|DEVICE|Magmaris|PCI (Magmaris)
214578422|NCT01758900|DEVICE|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
214578423|NCT01758900|DEVICE|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
214578424|NCT04631900|BEHAVIORAL|Christianity approach as framework for spiritual intervention|Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
214578425|NCT03122691|DRUG|cannabis|Cannabis will be self-administered by study participants
214578426|NCT05624151|DRUG|Dexmedetomidine +Bupivacaine|infraorbital nerve block by dexmedetomidine plus bupivacaine
214578427|NCT05624151|DRUG|Magnesium Sulfate + Bupivacaine|infraorbital nerve block by magnesium sulphate plus bupivacaine
214578428|NCT05624151|DRUG|Bupivacaine|infraorbital nerve block by bupivacaine only
214578429|NCT03397043|OTHER|Protein intake (dose)|Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
214578430|NCT00935818|DRUG|Varenicline|varenicline - 1 mg bid for 12 weeks
214578431|NCT00935818|DRUG|placebo|placebo for 12 weeks
214578432|NCT00935818|DRUG|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
214578433|NCT02437201|BEHAVIORAL|Liberty Program|
214578434|NCT01707745|PROCEDURE|Intravitreal Bevacizumab|
214578435|NCT00435175|DRUG|estradiol|
214578436|NCT00086255|DRUG|Tiagabine|
214578437|NCT05060640|PROCEDURE|Detection of anal HSIL in a routine colonoscopy.|Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
214578438|NCT05121558|OTHER|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants will be provided with a home-based guided program for days classes are not held. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
214578439|NCT05121558|OTHER|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN), how yoga may help with CIPN, and how different therapies may help with CIPN. To encourage participation and adherence, patients in the EC group will receive sixteen free yoga sessions after completing the study. Patients in the EC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
214578440|NCT05121558|OTHER|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
214709996|NCT02263495|DRUG|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
214578441|NCT06149325|PROCEDURE|Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes
214578442|NCT06149325|PROCEDURE|Sham Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
214578443|NCT02538952|DEVICE|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
214578444|NCT02538952|OTHER|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
214578445|NCT02846272|PROCEDURE|Observation|Observation of MRI changes in subjects
214578446|NCT04893577|DRUG|EDTA|Patients will treat their cold sore with EDTA eye drops based upon their randomization.
214578447|NCT04893577|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
214578448|NCT06804616|DRUG|20% benzocaine Gel|Participants in this group received 20% Benzocaine Gel applied to the injection site for 5 minutes prior to local anesthesia administration. The gel acts as a topical anesthetic to numb the area and reduce pain perception during the injection procedure.
214578449|NCT06804616|DEVICE|Powered Toothbrush|Participants in this group received vibration stimulation using a powered toothbrush applied to the injection site for 1 minute before the local anesthesia injection. The vibration works on the principle of gate control theory, aiming to disrupt pain signals and reduce discomfort during the injection procedure.
214578450|NCT03140839|BEHAVIORAL|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
214578451|NCT03140839|BEHAVIORAL|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
214578452|NCT03140839|OTHER|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
214578453|NCT01739439|DRUG|gemcitabine hydrochloride|Given IV
214578454|NCT01739439|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
214578455|NCT01739439|RADIATION|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
214578456|NCT01739439|RADIATION|radiosurgery|Undergo radiosurgery boost
214578457|NCT01739439|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
214578458|NCT01370590|DRUG|Atorvastatin|20 mg tablet administered orally once daily
214578459|NCT01370590|DRUG|Ezetimibe|10 mg tablet administered orally once daily
214578460|NCT01370590|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
214578461|NCT01370590|DRUG|Placebo to atorvastatin|Administered orally once daily
214578462|NCT01370590|DRUG|Placebo to ezetimibe|Administered orally once daily
214578463|NCT01370590|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
214578464|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
214578465|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
214578466|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
214578467|NCT03106168|PROCEDURE|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
214578468|NCT04252274|DRUG|Darunavir and Cobicistat|Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
214709997|NCT00790101|DRUG|Risedronate|
214709998|NCT00790101|DRUG|Raloxifene|
214709999|NCT00790101|OTHER|Placebo|
214578469|NCT04083820|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
214710000|NCT03029481|DRUG|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
214578470|NCT06239389|DRUG|Thalidomide 100mg|Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
214578471|NCT06239389|DRUG|Hydroxyurea|Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
214578472|NCT06487429|DRUG|Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab|"Short range radiotherapy, PCTV (clinical planned target area) DT 25Gy/5F, once a day, for a total of 5 days, continuous irradiation, and IMRT (intensity modulated radiation therapy) technology; After a week of rest, radiotherapy and chemotherapy combined with immunotherapy will be performed~* Disitamab Vedotin: 2.5 mg/kg, intravenous infusion, d1, Q3W;~* Sintilimab: 200mg, iv;~* S-1: 40 mg/dose, oral, bid, d1-14; Q3W Whether to undergo adjuvant therapy after surgery is determined by the researcher"
214578473|NCT04229264|DRUG|Apixaban|Oral Apixaban 2.5 mg twice daily for one year
214578474|NCT04229264|DRUG|ASA|Acetil Salicilic Acid 100mg once daily for one year
214710001|NCT01767519|BIOLOGICAL|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
214578475|NCT04229264|DRUG|Clopidogrel 75mg|Clopidogrel 75mg once daily for 3 months
214578476|NCT02726100|BEHAVIORAL|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
214578477|NCT00349934|BIOLOGICAL|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
214578478|NCT00353288|BIOLOGICAL|MeMuRu-OKA (study vacc)|
214578479|NCT00353288|BIOLOGICAL|MMR, Varicella vacc (control)|
214578480|NCT04245943|BEHAVIORAL|Exercise training|18 weeks supervised strength and aerobic exercise training.
214578481|NCT00539435|PROCEDURE|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
214578482|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
214578483|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
214578484|NCT00684619|DRUG|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
214578485|NCT02125045|DIETARY_SUPPLEMENT|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
214578486|NCT02125045|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
214578487|NCT02056990|OTHER|Advice|
214578488|NCT03280147|DRUG|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
214710002|NCT01767519|DRUG|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
214710003|NCT01767519|DRUG|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
214578489|NCT03280147|DRUG|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
214578490|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
214578491|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
214578492|NCT04720248|DRUG|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
214578493|NCT06575790|BEHAVIORAL|Simple Meal Bolusing|Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting
214710004|NCT01767519|DRUG|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
214710005|NCT00039741|DRUG|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
214710006|NCT00039741|DRUG|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
214578494|NCT06575790|BEHAVIORAL|Carbohydrate counting|Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks
214578495|NCT06572449|DRUG|KarXT|Specified dose on specified days
214578496|NCT06643039|BIOLOGICAL|Nasopharyngeal swab|Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
214578497|NCT06643039|OTHER|Questionnaire|questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
214578498|NCT01028313|DRUG|LBH589|20 mg PO three times weekly
214710007|NCT00039741|DRUG|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
214710008|NCT02898519|OTHER|cohort|Blood sampling
214578499|NCT01028313|DRUG|Methylprednisolone|1 mg/kg/day PO continuously
214578500|NCT00440921|DRUG|Single donor Allogenous Fibrin Sealant|
214578501|NCT00604825|DRUG|Other: Placebo|
214578502|NCT00604825|DRUG|GSK232802|
214578503|NCT00604825|DRUG|PREMARIN|
214578504|NCT06076395|DEVICE|LMA (Laryngeal Mask Airway)|Pressure controlled versus Volume controlled ventilation using LMA
214578505|NCT04617275|DRUG|PF-06882961|PF-68882961 will be provided as tablets twice a day (BID)
214578506|NCT04617275|OTHER|Placebo|Placebo comparator will be provided as tablets twice daily for 12 weeks
214578507|NCT05853380|DEVICE|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
214578508|NCT02604875|OTHER|observation|blood sampling during 24 hours
214578509|NCT02822105|BIOLOGICAL|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
214578510|NCT02822105|OTHER|Placebo|saline
214578511|NCT02549105|DRUG|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
214578512|NCT02549105|DRUG|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
214578513|NCT05177887|DEVICE|Traumacel PULVIS, Traumacel ENDO Applicator|Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
214578514|NCT06509815|DEVICE|MIRA|The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
214578515|NCT00695032|DRUG|cisplatin|
214578516|NCT00695032|DRUG|ifosfamide|
214578517|NCT00695032|OTHER|laboratory biomarker analysis|
214578518|NCT05772273|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
214578519|NCT05772273|BIOLOGICAL|Donor lymphocyte infusion|The 4 DLI doses (dose range: ±10%) of sib-matched donor HSCT patients were 1×10\^6/kg, 5×10\^6/kg, 1×10\^7/kg, 5×10\^7/kg; The 4 DLI doses (dose range: ±10%) of haploidentical or unrelated donor HSCT patients were 1×10\^5/kg, 5×10\^5/kg, 1×10\^6/kg, 5×10\^6/kg.
214578520|NCT05772273|DRUG|Camrelizumab|Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
214578521|NCT00231803|OTHER|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
214578522|NCT00231803|OTHER|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
214578523|NCT00231803|OTHER|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
214578524|NCT00231803|OTHER|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
214578525|NCT05708807|OTHER|Observational - all|All stroke patients are included.
214578526|NCT05586802|DRUG|Anastrozole|This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D
214578527|NCT05586802|DRUG|Semaglutide|This will be an experimental treatment for 26 weeks in Group 2 Arm E
214578528|NCT05586802|DRUG|human chorionic gonadotropin|This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B
214578529|NCT05586802|DRUG|Testosterone gel|This will be an active comparator for 26 weeks in Group 2 - Arm C
214578530|NCT03691480|PROCEDURE|simple exsufflation|simple exsufflation
214578531|NCT03691480|PROCEDURE|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
214578532|NCT04906252|DIAGNOSTIC_TEST|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
214578533|NCT04906252|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
214578534|NCT04101188|OTHER|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
214578535|NCT04101188|OTHER|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
214578536|NCT04101188|OTHER|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
214578537|NCT04502732|OTHER|NSSM and GEBT|The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
214578538|NCT05604001|DEVICE|hysteroscopic ablation of submucous uterine fibroid using diode laser|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
214578539|NCT03387137|BIOLOGICAL|RSV 6120/∆NS2/1030s|Delivered as nose drops
214578540|NCT03387137|BIOLOGICAL|Placebo|Delivered as nose drops
214578541|NCT02437253|DRUG|Adalimumab|Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
214578542|NCT02437253|OTHER|Placebo|Saline placebo
214578543|NCT05574517|PROCEDURE|Without reverse insertion of a ureteral catheter|Traditional tubeless percutaneous nephrolithotomy usually need retrograde ureteral catheter insertion. Our intervention is that the tubeless percutaneous nephrolithotomy is executed without reverse insertion of a ureteral catheter.
214578544|NCT06273982|BEHAVIORAL|STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)|STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
214578545|NCT06273982|BEHAVIORAL|ARC (assisted referral to community care)|ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
214578546|NCT05535218|DRUG|Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi|"Neoadjuvant treatment: 7,5mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
214578547|NCT05248906|DIAGNOSTIC_TEST|Giant cell arteritis|Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy
214578548|NCT05578274|RADIATION|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
214578549|NCT05578274|RADIATION|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
214578550|NCT05482334|DRUG|Sargramostim for Injection|Recombinant human GM-CSF
214578551|NCT05482334|DRUG|Saline Placebo|Bacteriostatic Saline
214578552|NCT02979405|DRUG|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
214578553|NCT04153838|OTHER|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
214578554|NCT04953910|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
214578555|NCT05444894|GENETIC|EDIT-301|Administered by intravenous infusion after myeloablative conditioning with busulfan.
214578556|NCT06082947|DEVICE|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
214578557|NCT04381897|DRUG|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
214578558|NCT04381897|OTHER|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
214578559|NCT06423690|DEVICE|EAS1 System|tumor ablation system in IRE method
214710009|NCT00946881|DRUG|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
214710010|NCT06134713|DRUG|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
214710011|NCT06134713|DRUG|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
214578560|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
214710012|NCT00293423|BIOLOGICAL|HSPPC-96|25 mcg
214710013|NCT00293423|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
214710014|NCT00411736|DRUG|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
214710015|NCT00411736|DRUG|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
214710016|NCT04427436|OTHER|No Intervention|No Intervention
214578561|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
214578562|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
214578563|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
214578564|NCT03959826|BEHAVIORAL|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
214578565|NCT03959826|BEHAVIORAL|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
214578566|NCT05859451|DEVICE|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
214578567|NCT05859451|OTHER|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
214578568|NCT06640634|DEVICE|active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
214710017|NCT00123149|DRUG|Epoetin alfa|
214578569|NCT06640634|DEVICE|sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
214578570|NCT06640634|DEVICE|active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
214578571|NCT06640634|DEVICE|sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
214578572|NCT00133809|DRUG|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
214578573|NCT04927884|BIOLOGICAL|N-803|"Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)"
214710018|NCT05005988|BEHAVIORAL|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
214722042|NCT04513106|BEHAVIORAL|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
214578574|NCT04927884|BIOLOGICAL|PD-L1 t-haNK|"Dose: \~2 × 10\^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
214578575|NCT04927884|DRUG|Sacituzumab Govitecan-Hziy|"Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
214578576|NCT04927884|DRUG|Cyclophosphamide|"Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)"
214578577|NCT00002888|DRUG|cisplatin|
214578578|NCT00002888|DRUG|fluorouracil|
214578579|NCT00002888|DRUG|paclitaxel|
214578580|NCT05145140|DRUG|Standardized Western Medicine Treatment|Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
214578581|NCT05145140|DRUG|Tangningtongluo tablet and cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
214578582|NCT05145140|DRUG|Tangningtongluo tablet|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
214578583|NCT05145140|DRUG|Tangningtongluo cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
214578584|NCT00766545|DRUG|cilostazol|oral tablet 100 mg, twice daily, over 1 year
214578585|NCT00766545|DRUG|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
214578586|NCT01511705|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
214578587|NCT01511705|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
214578588|NCT06500676|DRUG|GFH375|GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
214578589|NCT06600776|DRUG|Ultra Rapid Lispro (URLi)|"Dosage Form:~Subcutaneous insulin infusion~Dosage:~Based on individual carbohydrate counting, adjusted using the MiniMed 780G hybrid closed-loop system.~Frequency:~Administered at mealtime (premeal) during one phase and immediately after meals (postmeal) during the other phase.~Duration:~Each intervention phase lasts up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~Both interventions (mealtime and postmeal dosing) are applied to the single arm of the study."
214578590|NCT06600776|DEVICE|Insulin pump with continuous glucose monitoring (CGM)|"The insulin pump with continuous glucose monitoring (CGM) system is used by patients with Type 1 Diabetes Mellitus (T1DM) as part of their regular treatment regimen. This system combines an insulin pump with real-time glucose monitoring, adjusting basal insulin delivery every 5 minutes based on continuous glucose data. In this study, participants are already using the system before the trial begins. The research does not examine the effect of the CGM itself but rather focuses on the timing of insulin bolus delivery (mealtime vs. postmeal) using their existing treatment system.~Frequency:~The system delivers basal insulin continuously and requires the patient to manually deliver bolus doses at mealtime (premeal) or postmeal, depending on the study phase.~Duration:~The device is used continuously throughout the entire study period, with each intervention phase (premeal vs. postmeal dosing) lasting up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~This device will be us"
214578591|NCT02713061|DRUG|TAK-850|TAK-850 injection
214578592|NCT04260178|OTHER|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
214578593|NCT04260178|OTHER|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
214578594|NCT04441853|OTHER|YouTube video|Tutoral session on using YouTube personal stories on older people
214578595|NCT04441853|OTHER|Control|Tutorial session with same content without Youtube video
214578596|NCT05101824|RADIATION|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
214578597|NCT04302974|PROCEDURE|Different structures and processes of primary care management strategies|Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
214722043|NCT04513106|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
214722044|NCT04532281|DRUG|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
214578598|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
214578599|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
214578600|NCT04302974|PROCEDURE|Patient Support Call Centre (PSCC)|RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
214578601|NCT02549456|PROCEDURE|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
214578602|NCT02549456|PROCEDURE|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
214710019|NCT05978856|OTHER|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~* All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~* Through the use of software, the initial cephalogram and the initial photograph will be linked.~* Then, the final values of some angles will be tracted from the post-treatment cephalogram.~* These values will be inserted in the treatment simulationsection of the software.~* A post-treatment projected image of the patient will be simulated by the software.~* Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~* From the pupil , real horizontal and vertical reference lines will be drawn.~* Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
214710020|NCT01597037|BEHAVIORAL|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
214578603|NCT06727747|OTHER|Cervical traction|Cervical traction procedure was performed using Saunders device. During the procedure, the patient lies in installed in a supine position with 20 degrees of cervical flexion and the physiotherapist gradually increases (5 minutes) the load to the defined kilograms which is maintained for 10 minutes then progressively decreases (5 minutes) the load to zero kilograms. The procedure is performed twice with a rest interval of 5 minutes.
214578604|NCT06727747|OTHER|Rehabilitation|The rehabilitation program compiled cervical spine mobilization, stretching of neck muscles and isometric strengthening exercises. Passive stretching of neck muscles groups was carried-out in a seated position with 3 repetition of 30 seconds each. Isometric strengthening exercises of neck extensors were performed in a seated position, against the resistance of the physiotherapist hand for 3 repetitions of 10 seconds each
214578605|NCT05361564|DRUG|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
214578606|NCT02031549|OTHER|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
214578607|NCT01149577|DRUG|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
214578608|NCT00967031|DRUG|capecitabine|
214578609|NCT00967031|DRUG|lapatinib ditosylate|
214578610|NCT00967031|OTHER|circulating tumor cell analysis|
214578611|NCT00967031|OTHER|laboratory biomarker analysis|
214578612|NCT06658574|DRUG|Acetaminophen|Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
214578613|NCT01533597|DRUG|Solifenacin|Solifenacin (5mg, qd, oral)
214578614|NCT01533597|DRUG|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
214578615|NCT05165888|BEHAVIORAL|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
214578616|NCT05165888|BEHAVIORAL|Communication skills training|Training to improve communication skills between physicians and caregivers.
214578617|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in low dose.
214578618|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in high dose.
214578619|NCT06825416|DRUG|Enoxaparin sodium injection|Enoxaparin sodium injection.
214578620|NCT06825416|DRUG|Enoxaparin sodium injection placebo|Enoxaparin sodium injection placebo.
214578621|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in low dose.
214578622|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in high dose.
214578623|NCT06056804|DRUG|capecitabine|825-1000mg/m2,po,bid
214578624|NCT06056804|DRUG|tislelizumab|200mg,iv.gtt,q3w
214578625|NCT06056804|DRUG|thymalfasin|4.8mg,sc,biw
214578626|NCT06056804|RADIATION|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
214578627|NCT03507751|DRUG|Meropenem|1.0 gram of meropenem given intravenously every 8 hours
214578628|NCT03507751|DEVICE|CRRT|Continuous renal replacement therapy for three days
214578629|NCT06607757|DRUG|Capivasertib|find arm A description
214578630|NCT06607757|DRUG|Fulvestrant injection|find arm B description
214578631|NCT06608147|OTHER|Sampling|sternal bone marrow aspiration
214578632|NCT05593445|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214578633|NCT05593445|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
214578634|NCT06604520|DRUG|Vortioxetine|Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
214578635|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
214710021|NCT03659370|OTHER|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
214710022|NCT03659370|OTHER|Acupuncture|Acupuncture
214578636|NCT06610591|PROCEDURE|Achilles Lengthening Surgery|The procedure is undertaken under general anaesthetic and involves horizontal hemi-section of the Achilles tendon via small 'stab' incisions at three levels to effect a lengthening of the tendon. The patient is then placed in a walking cast for four weeks thereafter. This surgery is usual care for most children with symptomatic ITW with plantarflexion contractures who have failed non-operative management.
214578637|NCT06611332|OTHER|Electroacupuncture|The main acupoints selected for the electroacupuncture group are bilateral BL23, bilateral BL25, bilateral GB30, bilateral LR11, bilateral LR8, GV4, GV3, and the affected BL40, and the secondary acupoints selected are bilateral BL54, the affected side BL57 and the affected side BL60.The treatment will be administered once every other day for 30 minutes each time, lasting for 8 consecutive weeks, totaling 24 sessions.
214578638|NCT06611332|OTHER|Sham electroacupuncture|In the sham electroacupuncture group, the acupoints will be at a position 2 cm lateral to the correct acupoints horizontally. The dosage and treatment course are the same as those in the electroacupuncture group.
214578639|NCT01577459|DRUG|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
214710023|NCT03870256|DRUG|misoprostol|Patient receive 600mic gm sublingual misoprostol
214578640|NCT01577459|OTHER|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
214578641|NCT04631692|BEHAVIORAL|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
214578642|NCT05559476|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
214578643|NCT05559476|BIOLOGICAL|FLU HD vaccine|FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
214710024|NCT03870256|DRUG|Carbetocin|Patient receive 100 mic gm carbetocin IV
214710025|NCT03870256|DRUG|TA|The patient receives 1gm oral tranexamic acid
214710026|NCT04180800|OTHER|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
214710027|NCT02632500|OTHER|Quality of chest compressions|
214578644|NCT06403709|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
214578645|NCT06611202|OTHER|Exercise|"A multidisciplinary six-minute walking group intervention-spearheaded by physiotherapists, occupational therapists, and psychologists-in enhancing physical activity, mobility, cognitive function, and functional independence among patients with dementia.~Physiotherapy Component: A six-minute walking group will be conducted twice a week for 8 weeks, targeting improvements in mobility, endurance, and balance. Occupational Therapy Intervention: Occupational therapists will integrate functional tasks (Games and throwing of balls to court, bean bag target game to enhance exercise relevance to daily activities. A psychologist will provide mental health support during the sessions, utilising techniques like time focus reminiscence therapy to engage patients and reduce anxiety."
214578646|NCT06611202|DRUG|Clonazepam|Medication on our dementia wards are being review during ward round and when needs arise. The medication management in drugs will be fully documented and accounted for in the course of the study.
214578647|NCT02791178|PROCEDURE|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
214710028|NCT04697433|DEVICE|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
214578648|NCT02791178|PROCEDURE|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
214578649|NCT02791178|OTHER|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
214710029|NCT01415856|DEVICE|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
214710030|NCT01415856|DEVICE|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
214710031|NCT05735509|DEVICE|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
214710032|NCT00354497|OTHER|physiologic testing|
214710033|NCT00354497|OTHER|study of socioeconomic and demographic variables|
214710034|NCT00354497|PROCEDURE|evaluation of cancer risk factors|
214710035|NCT00354497|PROCEDURE|mutation carrier screening|
214710036|NCT00354497|PROCEDURE|study of high risk factors|
214710037|NCT02491697|BIOLOGICAL|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
214578650|NCT06611189|OTHER|surgery|In order to preserve kidney from warm ischemia during graft implantation, on the back table, graft were prepared for implantation with standard techniques. The kidney was introduced into the bag which was filled with a small amount of ice and preservation fluid (Figure 1). After inplacement of the graft, a small hole was made near the hilum and the renal artery and vein were passed through the hole. A Kocher clamp was used to maintain the fluid and ice in place and as a handle. Also, a Hartman Mosquito Clamp was used to mark urether-side, and to maintain orientation.
214578651|NCT06611189|OTHER|Ray-Tech sponge technique|On the back table, graft were prepared for implantation with standard techniques. A Raytech sponge is soaked in ice-cold preservative solution, and wrapped around the kidney and held with a clamp (Figure 2). Position and oriantation of the graft was done by direct vision of urether.
214578652|NCT05157269|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
214578653|NCT05157269|DRUG|Placebo|Two matching placebo tablets administered orally twice daily for 5 days
214578654|NCT05157269|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
214578655|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
214578656|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
214578657|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
214578658|NCT05587790|BEHAVIORAL|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
214710038|NCT02491697|DRUG|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
214710039|NCT01191905|DRUG|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
214710040|NCT01191905|DRUG|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
214710041|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
214710042|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
214710043|NCT03242005|DEVICE|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
214710044|NCT03242005|DEVICE|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
214710045|NCT05096702|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
214710046|NCT05096702|DRUG|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
214578659|NCT06611878|BEHAVIORAL|Music training - intensive|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered twice a week for 5 months.
214578660|NCT06611878|BEHAVIORAL|Music training - minimal|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered once a month for 5 months.
214578661|NCT06611878|OTHER|Treatment as Usual (TAU)|Medications, behavioural interventions and other treatments that participants may receive outside the study during the period of participation.
214578662|NCT05242419|DRUG|Sodium Chloride Injection|0.9% Sodium Chloride Injection
214578663|NCT05242419|DRUG|Huperzine A Injection|Huperzine A Injection
214578664|NCT05202210|BIOLOGICAL|blood and urine sampling|extra sample of blood and urine will be collected
214578665|NCT06609980|DRUG|autologous fecal matter transplant|Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
214578666|NCT02305654|PROCEDURE|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
214578667|NCT02305654|DRUG|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
214578668|NCT02305654|DRUG|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
214578669|NCT02305654|DRUG|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
214578670|NCT02305654|RADIATION|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
214578671|NCT02305654|PROCEDURE|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
214578672|NCT06485986|OTHER|DBS on/off|DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
214578673|NCT04891562|OTHER|interlimb coordination of the lower limbs and synchronization|4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
214578674|NCT00727311|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
214578675|NCT00727311|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
214578676|NCT06688422|DEVICE|incentive spirometry|The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment.
214710047|NCT05096702|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
214578677|NCT04491396|BEHAVIORAL|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
214578678|NCT04877353|DEVICE|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
214578679|NCT06716658|DRUG|JAK1 Inhibitor|Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
214578680|NCT06715618|OTHER|FMS test|Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
214578681|NCT06723197|DRUG|vonoprazan+amoxicillin|Drug combinations for dual regimens：vonoprazan+amoxicillin
214578682|NCT06723197|OTHER|Duration of eradication regimen: 7-day|Duration of eradication regimen: 7-day
214578683|NCT06723197|DRUG|vonoprazan+amoxicillin+tetracycline+bismuth|Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
214578684|NCT06723197|OTHER|Duration of eradication regimen: 10-day|Duration of eradication regimen: 10-day
214578685|NCT06723197|OTHER|Duration of eradication regimen: 14-day|Duration of eradication regimen: 14-day
214578686|NCT06887751|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"The self-guided Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos.~The intervention is expected to have the following overall structure: Session 1: Introduction to the intervention and promotion of creative hopelessness, Awareness of bodily sensations, Values clarification Session 2: Committed action, Acceptance, Cognitive defusion Session 3: Self as context, Conclusions Session 4-8: personalised content (in-depth material and tasks based on individual difficulties assessed with diary)"
214710048|NCT05243394|OTHER|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
214710049|NCT05243394|OTHER|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
214710050|NCT05243394|OTHER|Treadmill gait training|Progressive treadmill gait training
214710051|NCT06213129|DEVICE|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
214710052|NCT02288065|DRUG|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
214710053|NCT02066194|PROCEDURE|Electroacupuncture|
214578687|NCT06887751|OTHER|Psychoeducation|"Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company.~The content of the education course will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS, such as disease pathophysiological me"
214578688|NCT06728956|OTHER|READY for MS UK digital programme|Online self-directed programme supported by HCPs
214578689|NCT06727994|OTHER|Providing Genital Hygiene training|"After the informed consent of all participants in the study is obtained, pre-test data, Self-Care Power Scale and Genital Hygiene Behavior Scale will be collected face-to-face.~Genital Hygiene training will be given. Reminder training will be given 15 days, 1 month and 2 months after the training, and 1 month after the reminder training, the Self-Care Power Scale and Genital Hygiene Behavior Scale will be re-administered to women as a final test."
214578690|NCT06729580|BEHAVIORAL|Behavioural Activation|10-week standardized behavioural activation program.
214578691|NCT06729151|DRUG|Onabotulinum toxin A|Cystoscopic injection of Onabotulinum toxin A per standard clinic protocol.
214578692|NCT06729151|BEHAVIORAL|Conservative management (dietary and behavioral)|Dietary and behavioral modifications consistent with recommendations from the American Urogynecological Society
214578693|NCT06729671|DIETARY_SUPPLEMENT|Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule|Bifidobacterium longum APC1472 capsule
214578694|NCT06729671|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
214578695|NCT05798793|DRUG|Camrelizumab plus TP|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
214578696|NCT05798793|DRUG|TP|The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
214578697|NCT06727838|DRUG|HRS-7535 tablets|HRS-7535 tablets.
214578698|NCT06727838|DRUG|Metformin Hydrochloride Extended-release Tablets|Metformin Hydrochloride Extended-release Tablets.
214578699|NCT06727838|DRUG|Metformin Hydrochloride Tablets|Metformin Hydrochloride Tablets.
214578700|NCT06729515|DEVICE|PCA|Immediately post-surgery, patients in the PCA group received a programmed PCA infusion (YG-B-3; Jiangsu Yaguang Medical Device Co., Ltd., China) containing either ketorolac (180 mg) or sufentanil (200 µg) in 100 mL, delivered as a 2 mL/h basal infusion with 0.5 mL boluses; lockout interval: 15 min.
214578701|NCT06729515|DEVICE|CEA|Following epidural catheter placement in the operating room, the CEA group received an initial bolus of 2% lidocaine (3 mL). Once sensory blockade was confirmed, continuous epidural infusion of 0.1% ropivacaine (8 mL/h) commenced.
214578702|NCT06729515|DEVICE|RISS|RISS blocks were performed at the T4-T10 level under ultrasound guidance (EPIQ5 with L12-4 linear 7.5 MHz transducer; Philips Healthcare, Best, Netherlands). A 19-gauge, 40-cm catheter was advanced 3-5 cm beyond the needle tip into the subserratus plane, its position confirmed by injecting 5 mL of 0.2% ropivacaine. A further 15 mL of 0.2% ropivacaine was then administered. The catheter was connected to a PCA pump programmed to deliver a 7 mL/h basal infusion with 2 mL boluses; lockout interval: 30 min.
214578703|NCT06729034|DRUG|Apixaban (Eliquis)|5 mg twice daily
214578704|NCT06729034|DRUG|Placebo|placebo twice daily
214710054|NCT04907591|DEVICE|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
214710055|NCT00507416|DRUG|Bortezomib|Bortezomib bolus intravenous (IV) injection
214710056|NCT00507416|DRUG|Dexamethasone|Dexamethasone for oral administration
214578705|NCT06729749|OTHER|Bioptron Pro 1 Class II|Bioptron Pro 1 Class II: Made by Bioptron AG, Wollerau, Switzerland, a device with a floor stand emits a polarized light lamp. The device has an ergonomic table stand that can be combined with a functional floor stand, allowing flexible use in domestic and professional environments. easily adjustable height and head inclination and the ability to rotate the device head up to 360 allow a convenient usage of nearly any position. Treatments can easily be timed by a control panel down to 30 seconds, an integrated distance rod ensures the recommended distance from the skin surface It will be used for the treatment procedures for all participants in group B only with the following parameters, Wavelengths ranging from 480-3400 nm, Degree of polarization \>95% (590 - 1550 nm), Specific power density Av. 40 mW/cm2 Light energy per minute av.2.4 J/cm2, Light Intensity per min. 10.000 lux, Weight without stand 3.4 kg and Weight with stand7.8 kg ,Energy consumption in sleep mode0.5
214578706|NCT06729749|OTHER|Vitamin D|All participants in both groups will take this supplements daily for 3 months
214578707|NCT06729086|DRUG|sedation using propofol|The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.
214578708|NCT06729086|DRUG|sedation using sevoflurane|The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
214710057|NCT00507416|DRUG|Melphalan|Melphalan for oral administration
214710058|NCT00507416|DRUG|Prednisone|Prednisone for oral administration
214710059|NCT00507416|DRUG|Thalidomide|Thalidomide for oral administration
214710060|NCT04047758|DRUG|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
214710061|NCT04047758|DRUG|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
214578709|NCT01551459|DRUG|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
214578710|NCT01551459|DRUG|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
214578711|NCT02818959|DEVICE|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
214578712|NCT06905912|DEVICE|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses
214578713|NCT06906146|DEVICE|CRET therapy|Capacitive Resistive Electric Transfer (CRET) therapy is a treatment modality that applies high-frequency electrical currents to stimulate tissue regeneration, enhance blood circulation, and reduce muscle pain. It operates through two modes: the capacitive mode, which targets superficial tissues such as skin and muscle, and the resistive mode, which penetrates deeper structures like tendons, ligaments, and joints. This technique is widely used in rehabilitation, sports physiotherapy, and pain management to accelerate muscle recovery and optimize neuromuscular function.
214710062|NCT04810234|DEVICE|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
214710063|NCT00773565|DIETARY_SUPPLEMENT|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
214710064|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood"
214578714|NCT06906146|DEVICE|Sham CRET Therapy|Same as CRET therapy but in a aham form.
214578715|NCT06905977|DEVICE|pentacam|we will follow up on cases of thick cornea with high back elevation
214578716|NCT06906159|DIETARY_SUPPLEMENT|Cricket protein|Muffins made with cricket-derived protein from house crickets (Acheta domesticus )
214578717|NCT06906159|DIETARY_SUPPLEMENT|Whey protein|Muffins made with whey protein
214578718|NCT06907277|DRUG|Dexmedetomidine|Dexmedetomidine (DXM) loading dose of 0.6 µg/kg followed by DXM infusion given at a rate of 0.4 ml/kg/h and was provided as 0.15 µg/kg/h for 24-h PO.
214578719|NCT06907277|DRUG|Fentanyl|A bolus of fentanyl 5 µg/kg followed by an intraoperative (IO) fentanyl infusion of 3-5 µg/kg/h that was continued as PO analgesia for 24 hours in a dose of 0.3 µg/kg/h.
214578720|NCT06907277|DRUG|Lidocain|Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.
214578721|NCT06906445|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
214578722|NCT06906445|OTHER|Anti-Inflammatory Diet|The modified diet plan will be given to each study participant
214578723|NCT06906445|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
214578724|NCT06906445|OTHER|Sham Diet|Dietary counselling alone
214578725|NCT06906445|OTHER|Advanced Therapy|Advanced therapy as standard dose and schedule
214578726|NCT06906666|OTHER|Athletes sample|Elite athletes in whom the risk of injury will be calculated and the influence of confounding factors will be assessed through a personal interview.
214578727|NCT06907394|OTHER|Osteopathic Manipulations|Osteopathic Manipulations (a. Myofascial release technique: Direct scar release+ Indirect scar release 'Fascial unwinding'; b. Grand Maneuver; Visceral manipulations of uterus
214578728|NCT06907394|OTHER|Control Group|Paracetamol tablets
214578729|NCT06907264|DEVICE|Wearable ECG Garment for Continuous Atrial Fibrillation Screening and Stroke Risk Assessment|This intervention utilizes a wearable ECG garment, a non-invasive, textile-based device for continuous 24-hour ECG monitoring. The garment features embedded electrodes to capture heart rate, rhythm, HRV parameters (e.g., SDNN, RMSSD, LF/HF), and P-wave indices (e.g., P-wave duration, PtfV1), enabling comprehensive assessment of atrial fibrillation (AF) and stroke risk. The device is lightweight, comfortable, and supports wireless data transmission to the cloud for real-time analysis. The study incorporates machine learning algorithms to identify AF patterns and explore stroke risk predictors, targeting individuals aged 40+ at high stroke risk. It also evaluates device acceptability and usability, aiming to improve AF detection rates, enable early intervention, and reduce stroke risk.
214578730|NCT02199743|DRUG|Lurasidone|Compare to haloperidol and perphenazine
214578731|NCT02199743|DRUG|Haloperidol|Compare to lurasidone
214578732|NCT02199743|DRUG|Perphenazine|Compare to lurasidone
214578733|NCT05939973|DEVICE|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
214578734|NCT00266227|DRUG|placebo|Intravenous repeating dose
214578735|NCT00266227|DRUG|rituximab|Intravenous repeating dose
214578736|NCT00266227|DRUG|methotrexate|Oral or parenteral repeating dose
214578737|NCT00266227|DRUG|folate|Intravenous repeating dose
214578738|NCT05851703|OTHER|Manual therapy application|"In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, instrument-assisted pushing technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present."
214578739|NCT05851703|OTHER|Proprioceptive Neuromuscular Facilitation|With the rhythmic initiation technique, it is to teach the movement to the person, to improve the feeling of movement, coordination and to help relaxation. With rhythmic initiation, we want the patient's initial passive and then active participation to understand the movement, the direction and rhythm of the movement. After people actively participate, they can use active joint movement.
214578740|NCT04033185|OTHER|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
214578741|NCT04033185|OTHER|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
214578742|NCT02295553|DRUG|Ketamine|
214578743|NCT02295553|DRUG|Propofol|
214578744|NCT05184023|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
214710065|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample"
214578745|NCT05184023|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
214578746|NCT03597074|DIAGNOSTIC_TEST|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
214578747|NCT02790944|GENETIC|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
214578748|NCT04822974|OTHER|blood collection|longitudinally collection of blood samples for each patient included.
214578749|NCT05513924|DRUG|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
214710066|NCT04883658|DRUG|CKD-348(2)|QD, PO
214710067|NCT04883658|DRUG|CKD-828, D097, D337|QD, PO
214710068|NCT00150059|DRUG|Pimecrolimus Cream 1%|
214722045|NCT04493489|DRUG|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
214578750|NCT05513924|DRUG|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
214578751|NCT02323451|DEVICE|Medical Chitosan|intra-articular injection
214578752|NCT02323451|DRUG|Sodium Hyaluronate Injection|intra-articular injection
214578753|NCT00446628|BEHAVIORAL|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
214578754|NCT05331677|PROCEDURE|correction of deformities around the knee with external fixator|minimally invasive surgery
214578755|NCT05778669|OTHER|Monitoring of medical, health and psychosocial conditions|"Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system."
214578756|NCT05104281|DRUG|osimertinib oral and bevazizumab intravenously|osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
214578757|NCT02731183|PROCEDURE|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
214578758|NCT03012698|DEVICE|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
214578759|NCT02099045|DEVICE|Point of Care Ultrasonography|
214578760|NCT03037853|OTHER|Healthy volunteers|MRI scanner
214578761|NCT02539147|BIOLOGICAL|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
214578762|NCT05442996|DRUG|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
214578763|NCT05442996|DRUG|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
214578764|NCT00335647|DRUG|fluphenazine hydrochloride|
214578765|NCT00191178|DRUG|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
214578766|NCT00191178|DRUG|insulin glargine|
214578767|NCT04337892|DEVICE|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
214578768|NCT05466409|OTHER|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
214578769|NCT05466409|OTHER|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
214578770|NCT05466409|OTHER|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
214578771|NCT05466409|OTHER|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
214578772|NCT05466409|OTHER|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
214578773|NCT05466409|OTHER|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
214578774|NCT05466409|OTHER|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
214578775|NCT05466409|OTHER|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
214578776|NCT05466409|OTHER|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
214578777|NCT05466409|OTHER|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
214578778|NCT06502912|OTHER|no intervention|no intervention
214578779|NCT06081504|OTHER|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
214578780|NCT06081504|OTHER|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
214578781|NCT06081504|OTHER|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
214578782|NCT01954966|DRUG|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
214578783|NCT01954966|DRUG|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
214578784|NCT01939665|DEVICE|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
214710069|NCT02719470|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
214578785|NCT04641377|OTHER|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
214578786|NCT04641377|OTHER|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
214578787|NCT02610907|OTHER|Buffer|The sleeve contains phosphate buffered saline buffer
214578788|NCT02610907|OTHER|Own output|The sleeve contains the subject own ileal effluent
214578789|NCT02610907|OTHER|simulated output|The sleeve contains simulated output
214578790|NCT06417567|DRUG|NEPA|NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
214578791|NCT05396469|DIAGNOSTIC_TEST|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
214578792|NCT02034370|DEVICE|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
214578793|NCT02034370|DEVICE|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
214710070|NCT04742270|DEVICE|SIMEOX+ respiratory physiotherapy telecare|"Every 10 days, the patient's expert physiotherapist will contact the patient by video-transmission or telephone call for motivational reinforcement and technical support in the use of the device.~During these phone calls, a quick 3-question questionnaire will be administered to the patient to monitor events of hemoptysis, chest pain and clinical symptoms of gastroesophageal reflux disease: pyrosis.If patients report this type of event, the physiotherapist will inform the patient's physician for management at his/her discretion.~The expert physiotherapist will also conduct this sessions in order to increase the patient's motivation and compliance to the device. In order to do this, he will identify (in collaboration with the patient), the patient's difficulties and obstacles and he will try to find solutions with him."
214578794|NCT06191497|PROCEDURE|non surgical periodontal therapy|NSPT based on Guided biofilm therapy principle (EMS Dental, Switzerland)
214578795|NCT06191497|DRUG|Chlorhexidine mouthwash|0.12% chlorhexidine based mouthwash used twice a day for 15 days after therapy
214578796|NCT03743285|DEVICE|AID System|AID system
214578797|NCT03743285|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
214578798|NCT05464797|PROCEDURE|Pulp therapy|partial or complete removal of inflamed pulp tissue
214578799|NCT05464797|DIAGNOSTIC_TEST|Cytokines level in pulpal blood.|Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
214578800|NCT04988867|DRUG|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
214578801|NCT02414737|DRUG|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
214578802|NCT06337604|DRUG|TNP-2092 capsules|TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
214578803|NCT06337604|DRUG|TNP-2092 capsules placebo|TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
214578804|NCT06337604|DRUG|Rabeprazole sodium enteric-coated tablets|Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
214578805|NCT00037830|DRUG|GM1 ganglioside|100 mg twice per day by subcutaneous injection
214578806|NCT00037830|DRUG|Placebo|Twice per day subcutaneous injection, equal volume as active drug
214578807|NCT02435121|DRUG|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
214578808|NCT04492800|DEVICE|Paxman Scalp Cooling Device|Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
214578809|NCT05486962|BEHAVIORAL|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
214578810|NCT01854138|DEVICE|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
214578811|NCT00912262|DRUG|Capsaicin Topical Liquid|
214578812|NCT01699503|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
214578813|NCT01432184|PROCEDURE|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
214578814|NCT01879059|BEHAVIORAL|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
214578815|NCT00951002|PROCEDURE|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
214578816|NCT03420170|OTHER|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
214578817|NCT03420170|OTHER|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
214578818|NCT01778257|DIETARY_SUPPLEMENT|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
214578819|NCT01778257|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Mate extracts.
214578820|NCT05335551|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
214578821|NCT01004848|BEHAVIORAL|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
214578822|NCT01767571|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
214578823|NCT01767571|DRUG|Cephalexin 250mg/5ml|Test product 10 ml
214578824|NCT01160289|DRUG|LY2452473|Administered orally, once daily for 12 weeks
214578825|NCT01160289|DRUG|tadalafil|Administered orally, once daily for 12 weeks
214578826|NCT01160289|DRUG|placebo (tadalafil)|Administered orally, once daily for 12 weeks
214578827|NCT01160289|DRUG|placebo (LY2452473)|Administered orally, once daily for 12 weeks
214578828|NCT03026192|DEVICE|near infrared spectroscopy|Near infrared spectroscopy will be placed on infants both with and without hsPDA
214578829|NCT02842762|DEVICE|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
214578830|NCT02842762|PROCEDURE|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
214578831|NCT02842762|DEVICE|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
214578832|NCT02842762|DEVICE|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
214578833|NCT05108545|DRUG|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
214578834|NCT02855697|DRUG|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
214578835|NCT02855697|DRUG|Cediranib|20mg dose of cediranib was selected for this study
214578836|NCT02855697|DRUG|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
214578837|NCT01090479|DRUG|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
214578838|NCT04193436|DRUG|PF-06835919 25 mg|PF-06835919 in 25 mg oral tablet will be administered on Day 1
214578839|NCT02822859|DEVICE|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
214578840|NCT02822859|DEVICE|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
214578841|NCT02822859|DEVICE|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
214578842|NCT03292432|BEHAVIORAL|TERA Intervention (TERA)|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
214578843|NCT03292432|BEHAVIORAL|Standard of Care (SOC)|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
214578844|NCT03193359|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
214578845|NCT03724773|DEVICE|Long-Arm Cast|A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.
214578846|NCT03724773|DEVICE|Sugar-Tong Splint|A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
214578847|NCT05364892|OTHER|Blood samples (80 mL)|Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
214578848|NCT05364892|OTHER|Fecal samples|Fecal samples at inclusion
214578849|NCT05364892|OTHER|Urinary sample (20-40 mL)|Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
214578850|NCT05364892|OTHER|Questionnaires|Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
214578851|NCT05847959|DRUG|Traditional Chinese medicine prescription：XinKang-I|XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
214578852|NCT00146627|DRUG|Eflornithine|
214578853|NCT00146627|DRUG|Nifurtimox|
214578854|NCT04223739|DRUG|Landiolol|"Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate \< 90 bpm. Doses are modified every 10 minutes if necessary.~Once heart rate goal is obtained, switch to an oral dose of Bisoprolol."
214578855|NCT04223739|DRUG|Amiodarone|Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day
214578856|NCT00152932|DRUG|Dorzolamide 2% drops|
214578857|NCT00152932|DEVICE|HRF and CLBF|
214578858|NCT05347043|OTHER|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
214578859|NCT01530451|DRUG|Desmopressin|120mg OD
214578860|NCT01530451|DRUG|Placebo|one tab OD
214578861|NCT01560468|DRUG|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
214578862|NCT04470232|OTHER|Self-assessment questionnaires|"120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
214578863|NCT01236534|DRUG|Lubiprostone|24 mcg twice daily for 21 days.
214578864|NCT01236534|DRUG|Placebo|matching placebo twice daily for 21 days.
214578865|NCT03138772|OTHER|This is an observational study, no intervention used.|No intervention is being used in this study.
214578866|NCT01915472|DRUG|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
214578867|NCT02502903|DRUG|BIV009|
214578868|NCT02502903|OTHER|Placebo|
214578869|NCT01014143|DRUG|Fluoride|Half mouth toothbrushing twice a day for four days.
214578870|NCT01014143|DRUG|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
214578871|NCT01014143|DRUG|Fluoride, triclosan|Half mouth Brushing twice daily
214578872|NCT05918237|OTHER|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
214578873|NCT03902925|PROCEDURE|Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
214722046|NCT04493489|DRUG|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
214578874|NCT03902925|PROCEDURE|Peribulbar injection|Peribulbar injection of 4-6 ml of ropivacaine 10%
214578875|NCT06172387|DRUG|intra-arterial infusion albumin|The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.
214578876|NCT06172387|OTHER|mechanical thrombectomy and a standard clinical therapy|mechanical thrombectomy and a standard clinical therapy
214578877|NCT04921787|OTHER|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
214578878|NCT04921787|OTHER|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
214578879|NCT02405403|DRUG|[18F]DPA-714 PET|\[18F\]DPA-714 Positron Emission Tomography
214578880|NCT02029872|DRUG|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
214578881|NCT02029872|DRUG|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
214578882|NCT02029872|DRUG|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
214578883|NCT03932669|DRUG|Nilotinib|150-300mg daily dose of nilotinib
214578884|NCT06301984|DEVICE|Insight GS|"The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.~The Andromeda Insight Growing System consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. The implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. The components are implanted from a posterior approach and are made from Titanium alloy (Ti6AL-4V-ELI), and High Density Polyethylene (HDPE)."
214710071|NCT04428359|DRUG|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
214710072|NCT04428359|DRUG|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
214710073|NCT03304470|DRUG|ATx201 2% Cream|Anhydrous Cream
214710074|NCT03304470|DRUG|ATx201 Cream Vehicle|Anhydrous Cream
214710075|NCT02350933|PROCEDURE|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
214710076|NCT02157506|DRUG|CXL-1427|
214710077|NCT02157506|DRUG|Placebo|
214578885|NCT05613374|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
214578886|NCT05613374|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~* Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~* Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
214578887|NCT00665158|BEHAVIORAL|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
214578888|NCT00665158|BEHAVIORAL|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
214710078|NCT03101514|DRUG|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
214578889|NCT02719587|PROCEDURE|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
214578890|NCT02719587|PROCEDURE|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
214578891|NCT02719587|PROCEDURE|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
214578892|NCT03450512|OTHER|prospective study on digestive affections in an homogeneous cohort of hematological patients|"Systematic realization during the induction and/or every consolidation of a CTscan with injection, at the same time as the thoracic CTscan (to research an invasive fungal bronchopulmonary infection), in front of a febrile neutropenia with persistent fever after 5 days of antibiotics and presence of digestive signs.~Statement of the information characterizing the digestive affection: clinical symptoms, microbiological, characteristic, realized additional explorations, infectious complications and specific therapeutics.~The abdominal scanner will be repeated in case of suspicion of complication or clinical worsening. In case of EC, the abdominal scanner will be realized before beginning the next cycle of AML treatment to evaluate digestive remission. Finally, a CT scan, will be performed when digestive disease, digestive neoplasia or digestive symptoms are noted at AML diagnosis."
214578893|NCT03224754|BEHAVIORAL|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
214578894|NCT00447811|DRUG|MOA-728|
214578895|NCT03234985|BIOLOGICAL|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
214578896|NCT01963923|BEHAVIORAL|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
214578897|NCT04855838|DEVICE|Oral neuromuscular training|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
214578898|NCT04637178|BEHAVIORAL|Resistance training|Resistance training sessions twice a week for ten weeks
214578899|NCT04637178|BEHAVIORAL|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
214578900|NCT03699085|BEHAVIORAL|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
214578901|NCT02164123|OTHER|Spinal mobilization|Experimental group
214578902|NCT02164123|OTHER|Spinal Mobilization II|Active comparator group
214578903|NCT02164123|OTHER|Placebo|Placebo group
214578904|NCT00168623|DRUG|Vitamin A|
214710079|NCT03101514|DRUG|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
214578905|NCT02789046|PROCEDURE|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
214578906|NCT02952807|DRUG|Misoprostol|vaginal Misoprostol Plus Foley Catheter
214578907|NCT02952807|DEVICE|Foley Catheter|
214578908|NCT04814641|BIOLOGICAL|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
214710080|NCT02680886|DEVICE|Novosyn® Quick|Skin closure
214710081|NCT02252692|DRUG|Enalapril|oral administration
214710082|NCT03273517|PROCEDURE|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
214710083|NCT04314596|OTHER|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
214578909|NCT02038543|DRUG|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
214578910|NCT02216305|PROCEDURE|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
214578911|NCT02216305|PROCEDURE|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
214578912|NCT00875654|GENETIC|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke
214578913|NCT03248154|DEVICE|Procellera|burn dressing
214578914|NCT04646538|OTHER|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
214578915|NCT01436851|BIOLOGICAL|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
214578916|NCT04553250|PROCEDURE|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
214578917|NCT05525884|OTHER|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
214578918|NCT03407664|OTHER|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
214578919|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with intracorporeal anastomosis.|Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector
214578920|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with extracorporeal anastomosis.|Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
214578921|NCT02001298|DRUG|remifentanil|
214578922|NCT02001298|DRUG|nitroprusside|
214578923|NCT04638920|OTHER|No intervention|No intervention
214578924|NCT04865341|BEHAVIORAL|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
214578925|NCT04865341|BEHAVIORAL|Information-Only Control|Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
214578926|NCT02449369|DRUG|Preop acetaminophen IV|
214578927|NCT02449369|DRUG|Preop orphenadrine IV|
214578928|NCT02449369|DRUG|Postop oral oxycodone & acetaminophen|
214578929|NCT02449369|DRUG|Postop hydromorphone IV|
214578930|NCT02449369|DRUG|Postop oral orphenadrine|
214578931|NCT02449369|DRUG|Postop oral oxycodone|
214578932|NCT02449369|DRUG|Postop acetaminophen IV|
214578933|NCT02449369|DRUG|Postop orphenadrine IV|
214578934|NCT03629379|DRUG|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
214578935|NCT03629379|DRUG|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
214578936|NCT05301491|OTHER|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
214578937|NCT05301491|OTHER|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~1. Unilateral hip-knee flexion (self-assisted exercise)~2. Bilateral hip-knee flexion (self-assisted exercise)~3. Straight leg lifting with the aid of a sheet/rigid band~4. Posterior pelvic tilt~5. Bridge building exercise~6. Cat-camel exercise~7. Half shuttle in sagittal plane~8. Right and left rotational shuttle~9. Trunk hyperextension in prone position~10. Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
214578938|NCT05301491|OTHER|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
214578939|NCT05084859|DRUG|SM08502|SM08502 to be administered orally.
214578940|NCT05084859|DRUG|Abiraterone|Abiraterone to be administered orally.
214578941|NCT05084859|DRUG|Prednisone|Prednisone to be administered orally.
214578942|NCT05084859|DRUG|Docetaxel|Docetaxel to be administered intravenously.
214578943|NCT05084859|DRUG|FOLFIRI Protocol|FOLFIRI Protocol to be administered intravenously.
214578944|NCT05084859|DRUG|Panitumumab|Panitumumab to be administered intravenously.
214578945|NCT03775434|DRUG|Experimental: B244|B244 suspension in 30ml/bottle
214578946|NCT04531826|OTHER|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
214578947|NCT04723238|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
214578948|NCT04723238|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
214578949|NCT04185129|DRUG|Foster|a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation
214578950|NCT03130881|DRUG|PLB1003|PLB1003 is a capsule and is administered orally.
214710084|NCT04314596|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
214710085|NCT04662216|PROCEDURE|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
214578951|NCT01662375|OTHER|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
214710086|NCT04662216|PROCEDURE|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
214578952|NCT04100278|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
214578953|NCT06442007|BEHAVIORAL|Behavioral Activation - single session intervention (BA-SSI)|Single session intervention
214578954|NCT06442007|BEHAVIORAL|4-session Mindset intervention|This is comprised of 4 sessions.
214578955|NCT05687357|DRUG|Tislelizumab|IV infusion
214578956|NCT05687357|DRUG|S-1|Oral tablets
214578957|NCT05687357|DRUG|Oxaliplatin|IV infusion
214578958|NCT05687357|DRUG|Nab paclitaxel|IV infusion
214578959|NCT05687357|RADIATION|Radiation|TOMO/VMAT
214578960|NCT05399914|OTHER|S-NIPPV|Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
214578961|NCT02842177|PROCEDURE|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
214578962|NCT02842177|PROCEDURE|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
214578963|NCT02842177|RADIATION|Transvaginal ultrasound|
214578964|NCT02842177|DEVICE|Cu-IUD|
214578965|NCT05057780|OTHER|Communication Skills Curriculum|Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
214578966|NCT02334423|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
214578967|NCT02334423|OTHER|0.9% sterile, unpreserved saline|Placebo
214578968|NCT00712140|BIOLOGICAL|trastuzumab|Given IV
214578969|NCT00712140|DRUG|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
214578970|NCT04040790|DEVICE|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
214578971|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
214578972|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
214578973|NCT04040790|DRUG|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
214578974|NCT03693326|DRUG|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
214578975|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 12 weeks
214578976|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 8 weeks
214578977|NCT03232853|OTHER|Elearning|Elearning
214578978|NCT02930226|BIOLOGICAL|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
214578979|NCT02930226|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
214578980|NCT01846377|BEHAVIORAL|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
214578981|NCT02065687|DRUG|Carboplatin|Given IV
214578982|NCT02065687|OTHER|Laboratory Biomarker Analysis|Correlative studies
214578983|NCT02065687|DRUG|Metformin Hydrochloride|Given PO
214578984|NCT02065687|DRUG|Paclitaxel|Given IV
214578985|NCT02065687|OTHER|Placebo Administration|Given PO
214578986|NCT02065687|OTHER|Quality-of-Life Assessment|Ancillary studies
214578987|NCT02065687|OTHER|Questionnaire Administration|Ancillary studies
214578988|NCT01569477|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
214578989|NCT01569477|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
214578990|NCT01854398|DEVICE|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
214578991|NCT01854398|DEVICE|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
214578992|NCT01903824|DRUG|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
214578993|NCT01903824|DRUG|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
214578994|NCT01903824|DRUG|modafinil|modafinil 200 mg tablet, over-encapsulated
214578995|NCT01903824|DRUG|Placebo|Placebos formulated to match each active drug
214578996|NCT01665131|DEVICE|Cameron Health S-ICD SQ-RX|
214578997|NCT00706290|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
214578998|NCT03228628|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
214578999|NCT03228628|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
214579000|NCT05019404|PROCEDURE|Functional anterior temporal lobectomy (FATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. The 3D model of incision and bone flap is printed prior to surgery by the slicer software based on the MRI data. Slightly curve incision with the length of about 6 cm in the temporal region is marked according to the 3D model. Temporal craniotomy via small bone window with the diameter of about 3 cm is performed. From the temporal pole along T1 about 5 cm posteriorly, temporal horn is opened by dissecting the middle temporal gyrus. The head of temporal horn is exposed. The amygdala is resected. Then, the parahippocampal gyrus and hippocampus are en bloc resected. The lateral temporal lobotomy is easy due to large view following the removal of mesial structures. The lateral posterior temporal lobotomy is no more than 5 cm from the temporal pole.
214722047|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
214579001|NCT05019404|PROCEDURE|Anterior temporal lobectomy (ATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. Large frontotemporal craniotomy is performed. Question mark-shaped incision with the length of 20- 25 cm in the frontotemporal region is marked. The size of the bone flap is approximately 5×7 cm for the exposure of lateral temporal lobe. ATL consists of en bloc resection of the anterior 5 cm of lateral temporal lobe, followed by the removal of mesial structures including the amygdala, parahippocampal gyrus, and hippocampus.
214710087|NCT04578106|BIOLOGICAL|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
214579002|NCT04138108|OTHER|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
214579003|NCT03758859|OTHER|sodium hyaluronate eyedrops|sodium hyaluronate eyedrops administered - route ocular -topical
214710088|NCT01021813|DRUG|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
214579004|NCT00652327|DRUG|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
214579005|NCT00652327|DRUG|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
214710089|NCT01021813|DRUG|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
214722048|NCT02613338|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
214722049|NCT02616328|OTHER|No intervention|No intervention administered in this study
214722050|NCT01018251|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Given IV
214579006|NCT00778960|BEHAVIORAL|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
214579007|NCT00778960|BEHAVIORAL|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
214579008|NCT00778960|BEHAVIORAL|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
214579009|NCT00778960|BEHAVIORAL|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
214579010|NCT00089921|DRUG|SCIO-469|60 mg capsule three times daily for 12 weeks
214579011|NCT00089921|DRUG|SCIO-469|30 mg capsule three times daily for 12 weeks
214579012|NCT00089921|DRUG|Placebo|2 capsules three times daily and one tablet daily
214579013|NCT00089921|DRUG|SCIO-469|100 mg tablet once daily for 12 weeks
214579014|NCT04767243|PROCEDURE|open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
214579015|NCT04767243|PROCEDURE|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
214579016|NCT04767243|DRUG|open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
214579017|NCT00848731|DRUG|nitric oxide|nitric oxide gas is delivered by facemask
214579018|NCT01076647|DRUG|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
214579019|NCT01076647|DRUG|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
214579020|NCT02360033|BEHAVIORAL|Systemic Therapy for Social Anxiety Disorder|
214579021|NCT02360033|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|
214579022|NCT01234051|DRUG|Docetaxel, Oxaliplatin|"1\. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
214579023|NCT04677634|DIETARY_SUPPLEMENT|ISOThrive Prebiotic Nectar|The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
214579024|NCT03699553|BEHAVIORAL|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
214579025|NCT03699553|BEHAVIORAL|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
214579026|NCT00920075|DRUG|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
214579027|NCT03210922|DEVICE|Miami cervical collar|Collar group is put on the Miami cervical collar.
214579028|NCT02880267|DEVICE|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
214579029|NCT01599494|DRUG|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
214722051|NCT01018251|PROCEDURE|Positron Emission Tomography/computed tomography|
214722052|NCT01018251|RADIATION|FLT-PET/CT|
214722053|NCT05077280|RADIATION|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
214579030|NCT01599494|DRUG|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
214579031|NCT01599494|DRUG|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
214579032|NCT01599494|DRUG|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
214579033|NCT01599494|DRUG|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
214579034|NCT01167764|DRUG|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
214579035|NCT03188913|DIAGNOSTIC_TEST|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
214579036|NCT00254618|DRUG|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
214579037|NCT00254618|DRUG|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
214579038|NCT00254618|DRUG|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
214579039|NCT02133209|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
214722054|NCT05077280|DRUG|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
214579040|NCT02133209|BEHAVIORAL|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
214579041|NCT02926898|DRUG|ZX008 (Fenfluramine Hydrochloride)|"ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base."
214579042|NCT02926898|DRUG|Matching Placebo|Matching Placebo
214579043|NCT05928351|OTHER|Pain Neuroscience Education|"The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience."
214579044|NCT05928351|OTHER|Standard Physiotherapy Program (SPP)|The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
214710090|NCT03771599|OTHER|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
214722055|NCT05841069|PROCEDURE|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
214579045|NCT06397300|PROCEDURE|bilateral Ultrasound guided erector spinae plane (ESP) block|To perform ESP block in the lateral position bilaterally ,the skin will be disinfected with 70% alchol bilaterally and a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle (rhomboid major muscle is absent below T6 level) and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.
214579046|NCT06397300|PROCEDURE|quadratus lumborum block|In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
214579047|NCT06397300|PROCEDURE|lumbar epidural|"under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia."
214579048|NCT03481543|PROCEDURE|In-line nebulization through NIV mask|In-line nebulization will be given through NIV circuit.
214579049|NCT03481543|PROCEDURE|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
214722056|NCT05841069|RADIATION|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
214579050|NCT03827083|OTHER|cerebral pulse oximetry|Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
214579051|NCT01871805|DRUG|Alectinib|Participants will receive alectinib as described in the arm descriptions.
214579052|NCT06533358|DRUG|MT1002 Injection|MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI
214579053|NCT02006251|DEVICE|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
214579054|NCT02006251|PROCEDURE|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
214579055|NCT06292468|OTHER|Traditional physical therapy|This group received 30 minutes of muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training and foot care guidelines, 3 times a week for a duration of six weeks.
214579056|NCT06292468|OTHER|Plantar cutaneous sensory stimulation|This group received 45 minutes of plantar cutaneous sensory stimulation, TENS, muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training, and foot care guidelines, 3 times a week for a duration of six weeks.
214579057|NCT02752698|PROCEDURE|Micro Hand S robotic surgery|20-70 patients undergo Micro Hand S robotic surgeries
214579058|NCT02752698|PROCEDURE|laparoscopic surgery|20-70 patients undergo laparoscopic surgeries
214579059|NCT02752698|PROCEDURE|da Vinci robotic surgery|20-70 patients undergo da Vinci robotic surgeries
214579060|NCT03477773|OTHER|High-intensity exergaming|Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (\~70% HRmax). Periods of exercise were performed at an intensity \>85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
214579061|NCT02570087|PROCEDURE|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
214579062|NCT04491552|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
214579063|NCT03028753|DEVICE|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
214579064|NCT03028753|PROCEDURE|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
214579065|NCT03028753|PROCEDURE|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
214579066|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test with walker|to walk during 6 minutes with walker
214579067|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test|to walk during 6 minutes with walker
214579068|NCT04373824|DRUG|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
214579069|NCT06218654|DIAGNOSTIC_TEST|biomarkers|"Serum tests for specific cardiac troponin (cTPI), neuron-specific enolase (NSE), natriuretic peptides (NT-ProBNP), S100 protein (S100B), Soluble Suppressor of Tumorigenesis-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR) tests will be performed, as well as urinary tests for epinephrine and norepinephrine. On these samples, conducted according to clinical practice, additional measurements will also be taken for glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH-L1) as specific study biomarkers on blood samples.~All samples will be collected within 24 hours of admission to the Emergency Department (T0) and after 72 hours (T1). A sample at day 7 (T2) will be taken."
214579070|NCT01973244|DRUG|somapacitan|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
214579071|NCT01973244|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
214579072|NCT00398268|PROCEDURE|Kirschner-wire fixation|
214579073|NCT03412747|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
214579074|NCT03412747|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
214579075|NCT03412747|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
214579076|NCT01039792|DRUG|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
214579077|NCT01039792|DIETARY_SUPPLEMENT|Placebo|placebo
214579078|NCT05296018|OTHER|Mandala coloring page|Mandala program will be applied three days a week (30 minutes) for 8 weeks.
214579079|NCT00950586|DRUG|GSK1043702|Oral dose in liquid or tablet formulation
214579080|NCT00950586|DRUG|Dextromethorphan|30mg Oral dose
214579081|NCT00950586|DRUG|Placebo|To match GSK1034702
214579082|NCT01476098|DRUG|Placebo|SB-705498 placebo
214579083|NCT01476098|DRUG|SB-705498|400 or 600mg oral SB-705498
214579084|NCT00727779|BEHAVIORAL|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
214579085|NCT02218294|DRUG|BCX4161|
214579086|NCT05197725|DEVICE|Face mask|Individuals in intervention communities will be given surgical or KF94 face masks.
214579087|NCT05197725|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
214579088|NCT05197725|BEHAVIORAL|Face mask promotion through community values or individual information|"In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)"
214579089|NCT03773315|DIETARY_SUPPLEMENT|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
214579090|NCT03773315|DIETARY_SUPPLEMENT|Placebo|Starch placebo 500 mg/day for 12 weeks
214579091|NCT02139761|DRUG|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
214710091|NCT03771599|OTHER|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
214710092|NCT04905875|PROCEDURE|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
214710093|NCT02103452|PROCEDURE|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
214710094|NCT00977015|DRUG|Treatment A|Inhaled, 750/150, single dose
214710095|NCT00977015|DRUG|Treatment B|Inhaled, 750/150, single dose
214710096|NCT05580471|DEVICE|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
214710097|NCT02790671|DRUG|DS-8500a|DS-8500a 25mg tablet
214710098|NCT02790671|DRUG|Itraconazole|200mg itraconazole
214710099|NCT05101460|DEVICE|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
214710100|NCT00764478|DRUG|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
214579092|NCT02139761|DRUG|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
214579093|NCT00468104|DRUG|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
214579094|NCT00468104|DRUG|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
214579095|NCT01351831|OTHER|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
214579096|NCT01351831|OTHER|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
214579097|NCT06179784|BEHAVIORAL|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
214579098|NCT00141219|DRUG|pregabalin|150-600mg/day, BID
214579099|NCT00141219|DRUG|Placebo|Placebo
214579100|NCT02224690|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
214579101|NCT02224690|DRUG|Placebo|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
214579102|NCT04679480|DRUG|Cemiplimab Injection [Libtayo]|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
214579103|NCT05949294|DRUG|ARO-SOD1 Injection|single doses of ARO-SOD1 Injection by IT infusion
214579104|NCT00086333|DRUG|SGN-15, Docetaxel|
214579105|NCT05325580|DRUG|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
214579106|NCT00297596|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
214579107|NCT00297596|DRUG|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
214579108|NCT02723526|OTHER|Blood drawing|
214579109|NCT02615080|DRUG|CRD007|
214579110|NCT02615080|DRUG|Placebo|
214579111|NCT02244021|DRUG|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
214579112|NCT05179382|OTHER|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
214579113|NCT05179382|OTHER|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
214710101|NCT00764478|DRUG|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
214710102|NCT00764478|DRUG|Placebo|placebo sublingual tablet, administered BID for 21 days
214579114|NCT03191773|COMBINATION_PRODUCT|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
214579115|NCT02580643|BIOLOGICAL|APS|intra-articular injection
214579116|NCT06265064|DIAGNOSTIC_TEST|STOP-Bang score >= 3 with factors predicting difficult intubation|patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm
214579117|NCT04292184|DRUG|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
214579118|NCT02646007|BIOLOGICAL|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
214579119|NCT02518737|OTHER|Meal Test|
214579120|NCT02314845|OTHER|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
214579121|NCT02314845|OTHER|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
214579122|NCT00645866|DRUG|capecitabine|
214579123|NCT00645866|DRUG|docetaxel|
214579124|NCT00645866|DRUG|epirubicin hydrochloride|
214579125|NCT00645866|OTHER|laboratory biomarker analysis|
214579126|NCT00645866|OTHER|pharmacogenomic studies|
214579127|NCT00645866|PROCEDURE|biopsy|
214579128|NCT00645866|PROCEDURE|neoadjuvant therapy|
214579129|NCT00645866|PROCEDURE|therapeutic surgical procedure|
214579130|NCT02730637|OTHER|Early nephrologist consultation|
214579131|NCT02274532|DEVICE|SoftHand|Biomechanical, ADL, and functional testing.
214579132|NCT02510209|BEHAVIORAL|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
214722057|NCT05841069|PROCEDURE|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
214579133|NCT00002768|BIOLOGICAL|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
214579134|NCT00002768|DRUG|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
214579135|NCT00002768|DRUG|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
214579136|NCT00002768|DRUG|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
214579137|NCT00002768|DRUG|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
214579138|NCT00002768|PROCEDURE|peripheral blood stem cell transplantation|Infusion on Day 0
214579139|NCT01667211|DRUG|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
214579140|NCT00122460|DRUG|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
214579141|NCT00122460|DRUG|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
214579142|NCT01506609|DRUG|Placebo|
214579143|NCT01506609|DRUG|Veliparib|
214579144|NCT01506609|DRUG|Carboplatin|
214579145|NCT01506609|DRUG|Temozolomide|
214579146|NCT01506609|DRUG|Paclitaxel|
214579147|NCT01710891|PROCEDURE|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
214579148|NCT01710891|PROCEDURE|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
214579149|NCT06294054|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
214579150|NCT05128461|OTHER|Exercise|M-CIMT-based telerehabilitation will be implemented.
214579151|NCT05128461|OTHER|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
214579152|NCT05253820|PROCEDURE|distal radial approach|coronary diagnosis and intervention via distal vs conventional radial approach
214710103|NCT03624764|PROCEDURE|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
214579153|NCT05253820|PROCEDURE|conventional radial access|conventional radial access
214579154|NCT03922646|BEHAVIORAL|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
214710104|NCT03624764|PROCEDURE|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
214722058|NCT05659004|BEHAVIORAL|Qualitative interview|No intervention
214579155|NCT03922646|BEHAVIORAL|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
214579156|NCT00381615|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
214579157|NCT00381615|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
214579158|NCT00381615|BIOLOGICAL|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
214579159|NCT00381615|BIOLOGICAL|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
214579160|NCT00381615|BIOLOGICAL|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
214579161|NCT00381615|BIOLOGICAL|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
214579162|NCT00381615|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
214579163|NCT03254446|DRUG|TRC150094|TRC150094 Tablet 45 mg
214579164|NCT03254446|DRUG|Placebo|Matching Placebo Tablet
214579165|NCT05413109|RADIATION|Coronary CT angiography|"A coronary CT angiography will be used to study the relationship between the PA and the LMCA and 4 radiological patterns will be considered:~1. Normal: minimum distance between the two vessels\> 1 mm;~2. Proximity: distance between the two vessels ≤1 mm without displacement or stenosis of the LMCA;~3. Dislocation: dislocation of the LMCA by the main branch of the PA with a take-off angle \<60 ° (the take-off angle is defined by the angle formed by the perpendicular to the aortic valve ring and the longitudinal axis of the LMCA);~4. Compression: stenosis of the LMCA ≥50% due to extrinsic compression by the PA."
214579166|NCT03990493|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
214579167|NCT03990493|BIOLOGICAL|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
214722059|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
214579168|NCT02518321|DEVICE|Technology-Assisted Toileting|
214579169|NCT02428361|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
214579170|NCT02595073|DRUG|DSXS|Active treatment
214579171|NCT02595073|DRUG|Placebo|Placebo treatment
214579172|NCT02962960|DRUG|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
214579173|NCT02962960|DRUG|Placebo|subcutaneous administration every two weeks from week 0 to week 50
214579174|NCT02276183|DIETARY_SUPPLEMENT|Nutrition intervention, test formula|
214579175|NCT02276183|BEHAVIORAL|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
214579176|NCT04418570|BEHAVIORAL|cognitive remediation|
214579177|NCT04418570|OTHER|attendance to an Early Intervention Service for Psychosis|
214579178|NCT00568035|DRUG|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
214579179|NCT00002996|DRUG|flecainide acetate|
214579180|NCT02031692|DRUG|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
214579181|NCT04696380|DRUG|Nicotine|Participants will sample high vs low nicotine.
214579182|NCT04696380|DEVICE|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
214579183|NCT04161625|BEHAVIORAL|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)"
214579184|NCT02261597|BEHAVIORAL|Cold Pressor Test|Repeated immersion of hand in ice-cold water
214579185|NCT05071196|OTHER|Facilitated Vegan Diet|Vegan boxed meal kits
214579186|NCT05071196|OTHER|Omnivorous Diet|Non-vegan boxed meal kits
214579187|NCT05915650|BEHAVIORAL|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
214579188|NCT05915650|BEHAVIORAL|Routine Education|Carry out routine education intervention for TKA patients
214579189|NCT06572098|OTHER|Complex decongestive therapy|Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
214579190|NCT05635942|DRUG|optimized quadruple therapy|Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
214579191|NCT05635942|DRUG|standard quadruple therapy|Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
214579192|NCT05501977|PROCEDURE|thoracotomy|thoracic surgery for pulmonary diseases
214579193|NCT02942992|BEHAVIORAL|Resistance exercise|resistance exercise
214579194|NCT01464840|DRUG|Azithromycin|500 mg intravenous infused over 1 hour
214579195|NCT00421031|DRUG|DVS-233 SR|
214579196|NCT05667103|DEVICE|Embotrap stent retriever|Embotrap has a novel design of an open outer cage for clot capture and a closed inner channel for clot stabilization, with great thrombus fixation and anti-escape ability, to improve the successful recanalization rate and good prognosis of patients.
214579197|NCT05667103|DEVICE|Solitaire FR, Trevo stent retriever without inner channel|Other stent retriever without inner channel, such as Solitaire FR, Trevo, and other stent retrievers approved by FDA or NMPA.
214579198|NCT00944515|DRUG|placebo|placebo tablet or syrup 3 days/week
214579199|NCT00944515|DRUG|azithromycin|azithromycin 3 days/week
214579200|NCT00468559|DRUG|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
214579201|NCT00468559|DRUG|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
214579202|NCT00468559|DRUG|Double Blind Placebo|Double Blind Placebo
214579203|NCT05012553|OTHER|education of self and peer assesment|Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
214579204|NCT05705843|DRUG|Intraosseous Vancomycin Injection|• IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
214579205|NCT05705843|DRUG|Intravenous Vancomycin|IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
214579206|NCT02910284|BIOLOGICAL|Observational|
214579207|NCT02536820|BEHAVIORAL|psychoneuroimmune therapy|
214579208|NCT02536820|DRUG|Conventional treatment|Actual diabetes treatment in each participant
214579209|NCT04986839|DRUG|Paracetamol injection|Intravenous Paracetamol
214579210|NCT04986839|DRUG|Ibuprofen injection|Intravenous Ibuprofen
214579211|NCT02703064|DIETARY_SUPPLEMENT|Furocyst|Furocyst caps BD
214579212|NCT03914638|DRUG|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
214579213|NCT03914638|DRUG|Placebo oral capsule|Placebo, three times daily
214579214|NCT03236038|DIAGNOSTIC_TEST|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
214579215|NCT02647775|PROCEDURE|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
214579216|NCT02647775|PROCEDURE|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
214579217|NCT01923090|DRUG|Finasteride|Finasteride 5mg once daily for 3 weeks
214579218|NCT01923090|DRUG|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
214579219|NCT03888157|DRUG|Liraglutide|Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
214579220|NCT00044798|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
214579221|NCT00044798|DRUG|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
214579222|NCT00044798|PROCEDURE|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
214579223|NCT01594775|DRUG|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
214579224|NCT01594775|DRUG|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
214579225|NCT04417738|DEVICE|unilateral transcranial photobiomodulation, near infrared mode|The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.
214579226|NCT04417738|DEVICE|Sham treatment|The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
214579227|NCT06488989|DEVICE|left bundle branch area pacing|Cardiac resynchronization therapy obtained by conduction system pacing
214579228|NCT06003140|DEVICE|Celsi Warmer|A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
214579229|NCT05110352|DIAGNOSTIC_TEST|Polysomnography|A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).
214579230|NCT05110352|DIAGNOSTIC_TEST|Pharyngeal ph-metry Restech|Pharyngeal ph-metry Restech over 24 hours (night and day)
214579231|NCT05110352|PROCEDURE|Peptest|Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome
214579232|NCT05110352|BEHAVIORAL|Questionnaire RSS-12|Questionnaire with 12 items about quality of life. Score between 0 and 5.
214579233|NCT05110352|PROCEDURE|Reflux Sign Assessment|RSA score about anatomy and morphology of the mouth
214579234|NCT00749034|BIOLOGICAL|VPM1002|live vaccine
214579235|NCT00749034|BIOLOGICAL|BCG|commercially available live vaccine BCG
214579236|NCT01386073|DRUG|FreshKote|Three times a day for three months
214579237|NCT01386073|DRUG|Systane|three times a day for three months
214579238|NCT00029133|PROCEDURE|mild intraoperative hypothermia (33 degrees Celsius)|
214579239|NCT02211885|DRUG|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
214579240|NCT00936546|DRUG|Rituximab|Mabthera, Rituximab 1000 mg I.V.
214579241|NCT00538200|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
214579242|NCT00538200|OTHER|Dietary Advice|Standard dietary advice
214579243|NCT02037464|DIETARY_SUPPLEMENT|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
214579244|NCT02729285|DRUG|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
214579245|NCT02729285|DRUG|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
214579246|NCT02729285|PROCEDURE|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
214579247|NCT01174290|DRUG|Haloperidol decanoate|"IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
214579248|NCT01174290|DRUG|Placebo|"D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
214710105|NCT00879606|DRUG|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
214579249|NCT00956059|DRUG|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
214579250|NCT00956059|DRUG|prednisone|In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
214579251|NCT00173654|PROCEDURE|blood drawing|
214579252|NCT00677716|DRUG|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
214579253|NCT03358251|DEVICE|Pocket-X Gel|Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
214579254|NCT03358251|PROCEDURE|Scaling and root planing|Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
214579255|NCT03941951|BEHAVIORAL|Non-impositive Program for Optimizing the Use of Antimicrobials|Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
214579256|NCT01487447|OTHER|Customized sound|treatment with customized sound therapy
214579257|NCT01487447|OTHER|Regular Masker|treatment with white noise
214579258|NCT02149953|DIETARY_SUPPLEMENT|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
214579259|NCT04630288|DRUG|Clopidogrel|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
214579260|NCT04630288|DRUG|Ticagrelor|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
214579261|NCT00258557|DRUG|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
214579262|NCT00258557|DRUG|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
214710106|NCT00879606|DRUG|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
214710107|NCT05239364|PROCEDURE|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
214710108|NCT02270684|DEVICE|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
214710109|NCT02322684|DEVICE|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
214579263|NCT06090006|OTHER|Screening package|Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).
214579264|NCT06090006|DIAGNOSTIC_TEST|Psychosocial and mental health disorder screening|HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
214579265|NCT06090006|DIAGNOSTIC_TEST|Alcohol, tobacco and substance use screening|World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated
214579266|NCT06090006|BEHAVIORAL|Diet and physical activity screening|HEEADSSS (Klein et al., 2014) and counselling and advice
214579267|NCT06090006|DIAGNOSTIC_TEST|Underweight and overweight screening|MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated
214579268|NCT06090006|DIAGNOSTIC_TEST|Anemia|Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (\<8g/dl) refer to health facility.
214579269|NCT06090006|BEHAVIORAL|Oral health screening|Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
214710110|NCT06197542|OTHER|Active Release Technique|active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
214710111|NCT06197542|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
214579270|NCT06090006|BEHAVIORAL|Circumcision screening|Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)
214579271|NCT06090006|BEHAVIORAL|Risky behaviours|Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)
214579272|NCT06090006|DIAGNOSTIC_TEST|HIV testing|HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated
214579273|NCT06090006|DIAGNOSTIC_TEST|STI (CT, NG, TV) testing|Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
214579274|NCT06090006|BEHAVIORAL|Immunization screening|Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization
214579275|NCT06090006|DIAGNOSTIC_TEST|Visual impairment screening|Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated
214579276|NCT06090006|DIAGNOSTIC_TEST|Hearing screening|"HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated"
214579277|NCT06090006|DIAGNOSTIC_TEST|Physical impairment screening|Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated
214579278|NCT06090006|DIAGNOSTIC_TEST|Uncontrolled epilepsy screening|Questions on experience of convulsions followed by referral to specialist if indicated
214579279|NCT06090006|DIAGNOSTIC_TEST|Pre-hypertension screening|Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
214579280|NCT00866970|BIOLOGICAL|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
214579281|NCT00866970|BIOLOGICAL|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
214579282|NCT00866970|BIOLOGICAL|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
214579283|NCT00866970|BIOLOGICAL|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
214579284|NCT00467350|DRUG|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
214579285|NCT00467350|DRUG|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
214579286|NCT00534898|DRUG|Bexarotene|
214579287|NCT00534898|DRUG|Fenretinide|
214579288|NCT00534898|DRUG|Placebo|
214579289|NCT03192657|DRUG|Basiliximab|The first administration should be within 8 weeks after disease onset.
214579290|NCT03192657|DRUG|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
214579291|NCT03192657|DRUG|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
214579292|NCT02231801|BEHAVIORAL|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
214579293|NCT04554043|DRUG|SHR7280|treatment
214579294|NCT04554043|DRUG|Placebo oral tablet|blank control
214579295|NCT03851718|DEVICE|Acupuncture Procedure|Each session will run about 30\~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
214579296|NCT03851718|BEHAVIORAL|Power pumping|It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
214579297|NCT03538301|DRUG|ND-L02-s0201 (Low Dose)|Intravenous administration every 2 weeks
214579298|NCT03538301|DRUG|ND-L02-s0201 (High Dose)|Intravenous administration every 2 weeks
214579299|NCT03538301|OTHER|Other: Placebo|Saline
214710112|NCT01555905|DEVICE|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
214710113|NCT05753098|DRUG|estrogen therapy|oral estradiol valerate
214710114|NCT05753098|DRUG|Sildenafil|PDE5 inhibitor
214579300|NCT02893007|OTHER|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
214579301|NCT00453193|DRUG|Pentostatin|4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks
214579302|NCT00453193|DRUG|Alemtuzumab|30 mg IV three times weekly
214579303|NCT01357291|BEHAVIORAL|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
214579304|NCT01357291|BEHAVIORAL|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
214579305|NCT05843825|PROCEDURE|Surgical placement of dental implants|Three dental implants were placed (one anterior in midline area and two posterior at first molar area).
214579306|NCT05843825|DEVICE|Overdenture supported by locator attachment system|"Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer"
214710115|NCT05753098|DRUG|Clomiphene Citrate 50mg|used for ovulation induction
214710116|NCT00380276|DRUG|MPC-7869|800 mg BID Oral dosing
214710117|NCT05293574|DRUG|norethisterone acetate|Norethindrone, a progesterone agonist
214710118|NCT04904965|DRUG|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
214579307|NCT04136743|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
214579308|NCT04136743|DRUG|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
214579309|NCT04801277|PROCEDURE|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
214579310|NCT03795129|BEHAVIORAL|SleepLife Application w/FitBit|"Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application."
214579311|NCT03795129|BEHAVIORAL|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
214710119|NCT04904965|DRUG|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
214710120|NCT04904965|DRUG|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
214579312|NCT00546026|OTHER|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
214579313|NCT01312636|DRUG|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
214579314|NCT04825561|DRUG|AD-208|PO, Once daily(QD), 24weeks
214579315|NCT04825561|DRUG|AD-2081|PO, Once daily(QD), 24weeks
214579316|NCT04825561|DRUG|placebo of AD-208|PO, Once daily(QD), 24weeks
214579317|NCT04825561|DRUG|placebo of AD-2081|PO, Once daily(QD), 24weeks
214710121|NCT04904965|DRUG|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
214710122|NCT04065191|OTHER|High-intensity interval training|Heart rate based high-intensity interval training
214710123|NCT03866148|DEVICE|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
214710124|NCT02682030|DEVICE|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
214710125|NCT02682030|DEVICE|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
214710126|NCT04257084|DIAGNOSTIC_TEST|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
214579318|NCT01887886|DRUG|erlotinib|150 mg orally daily
214579319|NCT01887886|DRUG|onartuzumab|15 mg/kg IV every 3 weeks
214579320|NCT01887886|DRUG|placebo|IV every 3 weeks
214579321|NCT03685851|PROCEDURE|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
214579322|NCT03661762|DEVICE|CAVA|prototype device for monitoring dizziness
214579323|NCT03732404|DRUG|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
214579324|NCT03732404|DRUG|Placebo|The control group will receive plain water with the same volume and timing of treatment.
214579325|NCT03745261|DRUG|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
214579326|NCT03745261|DRUG|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
214579327|NCT03745261|DRUG|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
214579328|NCT03745261|DRUG|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
214579329|NCT03745261|DRUG|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
214579330|NCT00557180|DRUG|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
214579331|NCT00557180|DRUG|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
214579332|NCT00557180|DRUG|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
214579333|NCT02158351|PROCEDURE|liver and white adipose tissue biopsies|
214579334|NCT04184843|OTHER|iWalk Toolkit|"Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone"
214579335|NCT02842151|PROCEDURE|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
214710127|NCT04441879|BEHAVIORAL|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
214579336|NCT02842151|DEVICE|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
214579337|NCT02842151|DEVICE|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
214579338|NCT01879553|BIOLOGICAL|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
214579339|NCT05863728|PROCEDURE|Piezosurgery assisted group|apicectomy will be done using the Piezosurgery device
214579340|NCT05863728|PROCEDURE|Trephine Bur assisted group|apicectomy will be done using the trephine burs
214579341|NCT05218070|DRUG|EgyVax Vaccine Candidate|EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
214579342|NCT05218070|DRUG|Placebo|0.5ml Saline (0.9%)
214579343|NCT02739555|DEVICE|Thermal destruction with radiofrequency or laser|
214579344|NCT02739555|DRUG|Acide Zoledronique|
214579345|NCT01253070|PROCEDURE|Biopsy|Undergo biopsy
214579346|NCT01253070|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
214579347|NCT01253070|DRUG|Cytarabine|Given IV
214579348|NCT01253070|DRUG|Daunorubicin Hydrochloride|Given IV
214579349|NCT01253070|OTHER|Laboratory Biomarker Analysis|Correlative studies
214579350|NCT01253070|OTHER|Quality-of-Life Assessment|Ancillary studies
214579351|NCT01253070|OTHER|Questionnaire Administration|Ancillary studies
214579352|NCT01253070|DRUG|Sorafenib Tosylate|Given PO
214579353|NCT04898491|OTHER|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
214579354|NCT05381415|OTHER|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
214579355|NCT05381415|OTHER|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
214579356|NCT05734898|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
214579357|NCT04433546|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
214579358|NCT04433546|DRUG|Low Dose (10 mg) Control|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
214579359|NCT01398995|OTHER|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
214579360|NCT05573880|DEVICE|Galileo Med35|whole-body vibration training on the platform
214579361|NCT02758067|DRUG|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
214710128|NCT04441879|BEHAVIORAL|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
214579362|NCT02758067|DRUG|risperidone|4-6 mg/day, tablets, oral, 28-weeks
214579363|NCT03654521|DIAGNOSTIC_TEST|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
214579364|NCT03598010|DEVICE|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
214710129|NCT04609995|BEHAVIORAL|Incentives|No financial incentive
214579365|NCT03598010|DEVICE|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
214579366|NCT02544477|DEVICE|High-flow Nasal Cannula Oxygen (HFNCO)|
214579367|NCT02544477|DEVICE|Conventional oxygen treatment|
214710130|NCT02029495|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
214710131|NCT02029495|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
214579368|NCT04834544|COMBINATION_PRODUCT|DCVAC/OvCa|An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines
214579369|NCT04834544|COMBINATION_PRODUCT|Placebo|Placebo
214579370|NCT03767140|PROCEDURE|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
214579371|NCT01580254|DRUG|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
214579372|NCT01580254|DRUG|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
214579373|NCT01580254|DRUG|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
214579374|NCT00387946|DRUG|SSR591813L (dianicline)|
214579375|NCT01974401|DEVICE|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
214579376|NCT04107298|DEVICE|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
214579377|NCT00577967|DRUG|Gabapentin|
214579378|NCT04247334|DEVICE|Transcranial direct current stimulation|20 minutes of 2 milliamp transcranial direct current stimulation
214579379|NCT03318224|OTHER|none (observational study)|only assessments via questionnaires, no interventions
214710132|NCT02029495|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
214710133|NCT00019721|BIOLOGICAL|MART-1 antigen|
214710134|NCT00019721|BIOLOGICAL|aldesleukin|
214710135|NCT00019721|BIOLOGICAL|gp100 antigen|
214710136|NCT00019721|BIOLOGICAL|incomplete Freund's adjuvant|
214579380|NCT03802461|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Feces from healthy donor
214579381|NCT02355990|PROCEDURE|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
214710137|NCT02986685|DRUG|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
214710138|NCT02986685|DRUG|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
214579382|NCT05902949|PROCEDURE|Streching Group|The Streching group will perform a conventional stretching exercise.
214579383|NCT05902949|PROCEDURE|Heel group|The heel pad group will be applied a plantar support during the months of the study.
214579384|NCT04360343|DRUG|Film-coated tablet|uncoated tablet
214579385|NCT02559895|DRUG|ALD403|
214579386|NCT02559895|DRUG|Placebo|
214579387|NCT04693195|DRUG|BLU-5937|Oral administration of BLU-5937 tablets
214579388|NCT04693195|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 tablets
214579389|NCT02352168|DRUG|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
214579390|NCT02352168|DRUG|Placebo|1 putt/nostril,b.i.d
214579391|NCT02046629|DRUG|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
214710139|NCT03498287|DEVICE|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
214579392|NCT02046629|DRUG|cholestyramine|Pharmaceutical form:power Route of administration: oral
214579393|NCT06268067|DEVICE|PET/CT|F-18 FDG PET/CT studies
214579394|NCT05808777|OTHER|Phone interview|A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
214579395|NCT03666572|OTHER|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
214579396|NCT03666572|OTHER|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
214579397|NCT03666572|OTHER|Placebo (Lactose)|Placebo (Lactose)
214579398|NCT01030406|DRUG|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
214579399|NCT01030406|DRUG|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
214579400|NCT01030406|DRUG|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
214579401|NCT01030406|DRUG|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
214579402|NCT01030406|DRUG|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
214579403|NCT01852253|PROCEDURE|2% chlorhexidine|
214579404|NCT01852253|PROCEDURE|0.12% chlorhexidine|
214579405|NCT00588653|DEVICE|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
214579406|NCT02573194|DIETARY_SUPPLEMENT|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
214579407|NCT04824690|DEVICE|Virtual reality|Immersive virtual reality tour of the operating theatre before surgery and distraction methods both using VR headset
214579408|NCT05484362|OTHER|D-Glucose beverage as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
214579409|NCT05484362|OTHER|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
214579410|NCT05484362|OTHER|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
214579411|NCT05366036|OTHER|No Intervention|This is a non-interventional study.
214579412|NCT04263753|PROCEDURE|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~\* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~\* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
214579413|NCT05972928|DRUG|Sitagliptin 100mg|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
214579414|NCT01445600|DRUG|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214579415|NCT01216800|PROCEDURE|adjuvant therapy|
214579416|NCT01216800|PROCEDURE|assessment of therapy complications|
214579417|NCT01216800|PROCEDURE|quality-of-life assessment|
214579418|NCT01216800|RADIATION|3-dimensional conformal radiation therapy|
214579419|NCT01216800|RADIATION|intensity-modulated radiation therapy|
214579420|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
214579421|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
214579422|NCT05960253|PROCEDURE|Pericapsular Nerve Group Block|1st group to be applied PENG block
214579423|NCT05960253|PROCEDURE|Lumber Erector Spinae Plane Block|2nd group to be applied Lumber ESP block
214579424|NCT01929629|DRUG|Part A|Single ascending doses
214579425|NCT01929629|DRUG|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
214579426|NCT01685723|BEHAVIORAL|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
214579427|NCT01685723|BEHAVIORAL|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
214579428|NCT04220762|DRUG|WIN-1001X|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
214579429|NCT04220762|DRUG|Placebo|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
214579430|NCT03598959|DRUG|tofacitinib|orally 10 mg daily
214579431|NCT03598959|DRUG|chidamide|orally 20 mg twice weekly
214579432|NCT04540887|DEVICE|Pulsed Electromagnetic Field (PEMF) Therapy|PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
214579433|NCT02700347|DRUG|Pyrazinamide|
214579434|NCT02700347|DRUG|Allopurinol|
214579435|NCT00899873|GENETIC|cytogenetic analysis|
214579436|NCT00899873|OTHER|flow cytometry|
214579437|NCT00899873|OTHER|fluorescence activated cell sorting|
214579438|NCT00899873|OTHER|immunoenzyme technique|
214579439|NCT00899873|OTHER|laboratory biomarker analysis|
214579440|NCT02794922|DRUG|Neurovit Forte|
214579441|NCT02794922|DRUG|Corn Starch|
214579442|NCT02186249|DRUG|Nivolumab|
214579443|NCT02186249|DRUG|Ipilimumab|
214579444|NCT02733055|OTHER|posturographic evaluation|subjects will undergo CDP testing using one of the ext\_mCTSIB tests without (baseline) and with oculomotor task
214579445|NCT05255887|OTHER|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
214579446|NCT00278837|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
214579447|NCT01262027|DRUG|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
214579448|NCT03856385|BEHAVIORAL|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
214579449|NCT02469272|DRUG|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
214579450|NCT04435210|DRUG|Hydralazine|Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
214579451|NCT04435210|DRUG|Nifedipine|Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
214579452|NCT02998580|DEVICE|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
214579453|NCT02998580|DEVICE|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
214579454|NCT01453543|OTHER|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
214579455|NCT01980927|PROCEDURE|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
214579456|NCT00765453|OTHER|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
214579457|NCT00765453|OTHER|Placebo infusion|Placebo infusion
214579458|NCT03688451|DRUG|Rituximab|Intrathecal administration over 3-5 minutes
214579459|NCT03782675|DEVICE|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
214579460|NCT03782675|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
214579461|NCT00610740|DRUG|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
214579462|NCT00610740|PROCEDURE|therapeutic conventional surgery|hysterectomy
214579463|NCT06397326|BEHAVIORAL|Return to work coordinator + PRATICAdr 2.0|The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).
214579464|NCT06397326|BEHAVIORAL|Return to work coordinator only|The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual
214579465|NCT00035191|DRUG|galantamine|
214579466|NCT02819557|DRUG|Ataluren|White to off-white powder for oral suspension.
214579467|NCT06550089|DRUG|Oxytocin|Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
214579468|NCT00531453|DRUG|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
214579469|NCT00531453|DRUG|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
214579470|NCT02665338|DEVICE|Transcranial Magnetic Stimulation|
214579471|NCT00942760|DEVICE|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
214579472|NCT03007043|OTHER|blood sample|
214579473|NCT00589121|DRUG|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
214579474|NCT00589121|RADIATION|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
214579475|NCT00589121|PROCEDURE|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
214579476|NCT01239459|DRUG|Teriflunomide HMR1726|"Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition"
214579477|NCT01239459|DRUG|Cholestyramine|"Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55"
214579478|NCT04355247|DRUG|MethylPREDNISolone 80 Mg/mL Injectable Suspension|"* Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
214579479|NCT01315691|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
214579480|NCT01315691|DRUG|Placebo for liposomal amikacin for inhalation|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days."
214579481|NCT05252104|DIAGNOSTIC_TEST|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
214579482|NCT02661919|DEVICE|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
214579483|NCT05447091|BEHAVIORAL|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
214579484|NCT05447091|BEHAVIORAL|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
214579485|NCT05447091|BEHAVIORAL|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
214579486|NCT02793388|DRUG|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
214579487|NCT02793388|DRUG|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
214579488|NCT01173497|DRUG|INIPARIB + irinotecan|21 day cycle
214579489|NCT05789368|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
214579490|NCT05789368|DIETARY_SUPPLEMENT|VeCollal sachet|consume 1 sachet per day
214579491|NCT05789368|DIETARY_SUPPLEMENT|Collagen sachet|consume 1 sachet per day
214579492|NCT01856777|DEVICE|Semi-quantitative panel test|
214579493|NCT01856777|DEVICE|High sensitivity urine pregnancy test|
214579494|NCT06089850|OTHER|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
214579495|NCT01831479|DRUG|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
214579496|NCT01831479|DRUG|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
214579497|NCT01831479|DRUG|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
214579498|NCT06533085|PROCEDURE|Adductor canal block by surgeon|"Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)"
214579499|NCT01892540|DIAGNOSTIC_TEST|positron emission tomography/computed tomography|Undergo PET/CT
214579500|NCT01892540|DIAGNOSTIC_TEST|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
214579501|NCT01892540|DEVICE|Position Device|
214579502|NCT05937893|OTHER|Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans|Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
214579503|NCT04723966|DIETARY_SUPPLEMENT|TPN|Total parenteral nutrition
214579504|NCT04352998|DIETARY_SUPPLEMENT|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
214579505|NCT04352998|DIETARY_SUPPLEMENT|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
214579506|NCT04352998|DIETARY_SUPPLEMENT|Placebo condition|one dose of a placebo
214579507|NCT03337659|OTHER|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
214579508|NCT03831386|PROCEDURE|Vacuum-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
214579509|NCT03831386|PROCEDURE|Gravity-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
214579510|NCT03171779|OTHER|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
214579511|NCT05259592|BEHAVIORAL|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
214579512|NCT03152058|DRUG|Certolizumab Pegol|"Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
214579513|NCT00706953|DRUG|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
214579514|NCT04781257|DIAGNOSTIC_TEST|New test candidates|"The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial"
214579515|NCT04854824|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
214579516|NCT04854824|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family physician personal practice
214579517|NCT02317432|BEHAVIORAL|Comparison of a combined CBT + exercise intervention and enhanced usual care|
214579518|NCT06609135|DEVICE|Sentec LuMon Device (EIT system)|Sentec EIT belts will be placed on infants up to once daily from consent through NICU discharge.
214579519|NCT06609135|DEVICE|Sentec Digital Monitoring System (transcutaneous CO2 monitor)|Sentec transcutaneous CO2 monitors will be placed on infants concurrently with EIT belts.
214579520|NCT04807582|OTHER|[18F]FPIA PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
214579521|NCT06611046|OTHER|organ donor|"Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group."
214579522|NCT03005353|DRUG|Cumin seed extract|patients will receive the drug in suppository form
214579523|NCT03005353|DRUG|clotrimazole|patients will receive the drug in suppository form
214579524|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 12-18 months, or earlier if they develop symptoms. While 12-18 months is the preferred window for repeat imaging, if imaging during this time frame is not achievable, the patient may return anytime throughout the remainder of the study.
214579525|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
214579526|NCT06870331|DIETARY_SUPPLEMENT|Probiotic|Participants will take one sachet BIOTICS-G (Burgerstein, Switzerland, 2.5 g) daily for eight weeks. The supplement contains 14 bacterial strains with a total viable cell count of 2.5 billion colony-forming units per sachet.
214579527|NCT06870331|DIETARY_SUPPLEMENT|Prebiotic|Participants will take 5 g of oat bran (Naturaplan Bio Haferkleie, Coop, Switzerland) daily for eight weeks.
214579528|NCT04489134|DRUG|Treatment A|Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
214579529|NCT04489134|DRUG|Treatment B|Administration of a 2 mg dose of LCP-tacro (Envarsus®)
214579530|NCT04489134|DRUG|Treament C|Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
214579531|NCT04489134|DRUG|Treatment D|Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
214579532|NCT04489134|BIOLOGICAL|Pharmacocinetik|Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.
214579533|NCT04489134|GENETIC|Genetic|A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.
214579534|NCT04489134|OTHER|Selection visit:|"During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal."
214579535|NCT06685848|DEVICE|Hemanext ONE system|Hypoxic red blood cells
214579536|NCT06685848|DEVICE|Conventional RBCs|Conventional manufactured Red blood cells
214579537|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
214579538|NCT06728033|OTHER|supra-inguinal fascia iliaca compartment block|Supra-inguinal fascia iliaca compartment block with 40 ml of 0.25% ropivacaine
214579539|NCT06728033|DRUG|Tramadol|intravenous tramadol at a dose of 2 mg/kg
214579540|NCT06728865|DRUG|The treatment regimen is Furmonertinib combined with Bevacizumab.|The treatment regimen is Furmonertinib combined with Bevacizumab.
214579541|NCT00484107|DRUG|Conjugated Estrogen Cream (Premarin®)|
214579542|NCT03449251|DRUG|Apelin|Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
214579543|NCT03449251|DRUG|Relaxin|Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
214579544|NCT03449251|DRUG|Normal saline|Vehicle
214579545|NCT03449251|DIAGNOSTIC_TEST|Verapamil|NO independent challenge agent
214579546|NCT03449251|DIAGNOSTIC_TEST|LN Monomethyl arginine|Basal NO synthase inhibitor
214579547|NCT06524765|OTHER|Living conditions|There are many patients with multi-resistant bacterial infections in intensive care units (ICU), making it possible for a great deal of these pathogens to exist in the ICU environment. The exposure factors in this study were ICU environment or daily living environment.
214579548|NCT05767060|DRUG|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
214579549|NCT03236987|DRUG|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
214579550|NCT03236987|DRUG|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
214579551|NCT03236987|DRUG|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
214579552|NCT03236987|DRUG|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
214579553|NCT04381650|DRUG|TAK-981|TAK-981 IV infusion.
214579554|NCT04381650|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
214579555|NCT03992846|DRUG|75 mg linzagolix tablet|For oral administration once daily
214579556|NCT03992846|DRUG|200 mg linzagolix tablet|For oral administration once daily
214579557|NCT03992846|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
214579558|NCT03992846|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
214579559|NCT03992846|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
214579560|NCT03992846|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
214579561|NCT02439047|PROCEDURE|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~\- Adipose tissue samples : will be collected during surgery for breast reconstruction"
214579562|NCT03647488|DRUG|Capmatinib|Capmatinib 400 mg (tablets) orally taken twice daily
214579563|NCT03647488|DRUG|Spartalizumab|Spartalizumab 400 mg via intravenous infusion once every 28 days
214579564|NCT03647488|DRUG|Docetaxel|Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
214579565|NCT02697994|OTHER|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
214579566|NCT02697994|OTHER|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
214579567|NCT06374173|DRUG|TGI-6 Injection|TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
214579568|NCT00565851|BIOLOGICAL|Bevacizumab|Given IV
214579569|NCT00565851|DRUG|Carboplatin|Given IV
214579570|NCT00565851|DRUG|Docetaxel|Given IV
214579571|NCT00565851|DRUG|Gemcitabine Hydrochloride|Given IV
214579572|NCT00565851|OTHER|Laboratory Biomarker Analysis|Correlative studies
214579573|NCT00565851|DRUG|Paclitaxel|Given IV
214579574|NCT00565851|OTHER|Quality-of-Life Assessment|Ancillary studies
214579575|NCT00150423|DRUG|Pregabalin|
214579576|NCT02214056|OTHER|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
214579577|NCT02214056|PROCEDURE|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
214579578|NCT02588105|DRUG|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
214579579|NCT02588105|DRUG|Olaparib|Module 1 combination with olaparib
214579580|NCT02588105|DRUG|irinotecan|Module 2 combination with irinotecan/FOLFIRI
214579581|NCT02588105|DRUG|Fluorouracil|Module 2 combination with irinotecan/FOLFIRI
214579582|NCT02588105|DRUG|Folinic Acid|Module 2 combination with irinotecan/FOLFIRI
214579583|NCT00950222|DRUG|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
214579584|NCT00544375|DEVICE|Optical measurement|Optical measurement neonatal tissues
214579585|NCT00775463|DRUG|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
214579586|NCT00775463|DRUG|placebo|
214579587|NCT03274167|DRUG|Gabapentin 300mg|
214579588|NCT03274167|DRUG|Placebo oral capsule|
214579589|NCT04310384|DEVICE|ShuttleScope|Alternative intervention
214579590|NCT04310384|DEVICE|MacIntosh Laryngoscope|Gold Standart
214579591|NCT05331092|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
214579592|NCT00346671|OTHER|Rest|30 min supine rest
214579593|NCT00346671|OTHER|Sham|30 min session with Sham practitioner
214579594|NCT00346671|OTHER|Reiki|30 min session with Reiki practitioner
214579595|NCT00555724|DRUG|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
214579596|NCT05163782|DEVICE|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
214579597|NCT05163782|DEVICE|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
214579598|NCT05163782|DEVICE|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
214579599|NCT05163782|DEVICE|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
214579600|NCT00003424|DRUG|tamoxifen citrate|
214579601|NCT02666469|OTHER|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
214579602|NCT02666469|OTHER|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
214579603|NCT02666469|DEVICE|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
214579604|NCT04541784|OTHER|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
214579605|NCT04541784|OTHER|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
214579606|NCT03289429|DRUG|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
214579607|NCT03289429|DRUG|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
214579608|NCT03289429|OTHER|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
214579609|NCT03289429|OTHER|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
214579610|NCT02142140|BEHAVIORAL|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
214579611|NCT02142140|BEHAVIORAL|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
214579612|NCT02142140|BEHAVIORAL|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
214579613|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
214579614|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
214579615|NCT01319630|DEVICE|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
214579616|NCT01319630|DEVICE|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
214579617|NCT05146180|DEVICE|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
214579618|NCT04601701|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
214579619|NCT04601701|DRUG|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
214579620|NCT03695237|DRUG|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
214579621|NCT05444569|DRUG|LY3537021|Administered SC.
214579622|NCT05444569|DRUG|Liraglutide|Administered SC.
214579623|NCT05444569|DRUG|Placebo|Administered SC.
214579624|NCT04772482|DIAGNOSTIC_TEST|Sensitivity Patch Testing|Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
214579625|NCT02807662|BEHAVIORAL|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
214579626|NCT00305240|PROCEDURE|T Wave Alternans Test|
214579627|NCT02110719|DRUG|Celebrex|
214579628|NCT02110719|DRUG|Gabapentin|
214579629|NCT02110719|DRUG|IV acetaminophen|
214579630|NCT02110719|DRUG|oral acetaminophen|
214579631|NCT02110719|DRUG|oral ibuprofen|
214579632|NCT02110719|DRUG|percocet|
214579633|NCT02110719|DRUG|vicodin|
214579634|NCT02110719|DRUG|Oxycodone|
214579635|NCT02110719|DRUG|dilaudid|
214579636|NCT02110719|DRUG|Dexamethasone|
214579637|NCT02110719|DRUG|zofran|
214579638|NCT00452426|DEVICE|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
214579639|NCT00452426|OTHER|benzodiazepines and opioid sedation|per site's current standard of care
214579640|NCT04752982|BEHAVIORAL|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
214579641|NCT04752982|BEHAVIORAL|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
214579642|NCT03224923|DRUG|Ticagrelor 60mg|twice daily
214579643|NCT03224923|DRUG|Clopidogrel 75mg|once daily
214579644|NCT03224923|DRUG|Aspirin 81 mg|once daily
214579645|NCT03890718|PROCEDURE|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
214579646|NCT00418626|DRUG|Nilotinib|
214579647|NCT00839904|BEHAVIORAL|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
214579648|NCT01444833|DRUG|Candesartan|32 mg per day duration 6 months
214579649|NCT02466750|BIOLOGICAL|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
214579650|NCT05560334|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
214579651|NCT01789567|DEVICE|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
214579652|NCT05268445|PROCEDURE|Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis|Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
214579653|NCT00091169|DIETARY_SUPPLEMENT|levocarnitine|Given orally
214579654|NCT00091169|OTHER|placebo|Given orally
214579655|NCT00872989|DRUG|docetaxel|Given IV
214579656|NCT00872989|DRUG|vandetanib|Given orally
214579657|NCT00734383|DRUG|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
214579658|NCT00734383|DRUG|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
214579659|NCT01608763|BEHAVIORAL|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
214579660|NCT02407990|BIOLOGICAL|BGB-A317|In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
214579661|NCT02407990|BIOLOGICAL|BGB-A317|Participants were assigned to different groups based on their tumor types
214579662|NCT06236659|DIETARY_SUPPLEMENT|Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
214579663|NCT06236659|DIETARY_SUPPLEMENT|Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
214579664|NCT00606125|DRUG|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
214579665|NCT06014840|OTHER|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
214579666|NCT03505034|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
214579667|NCT00000500|DRUG|aspirin|
214579668|NCT00000500|DRUG|carotene|
214579669|NCT03284801|OTHER|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
214579670|NCT00607347|OTHER|Glucose|Oral Glucose Tolerance Test
214579671|NCT00734097|DRUG|Esomeprazole 40 mg|Once a day
214579672|NCT00734097|PROCEDURE|Physical Exam|every visit
214579673|NCT00734097|OTHER|Quality of Life Questionnaires|every visit
214579674|NCT00734097|PROCEDURE|pregnancy test, if applicable|as needed
214579675|NCT00919347|OTHER|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~1. RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~2. LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~3. SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~* Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa \< 0.1 bpm2.~* Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa \< 0.5 bpm2 or 0.1 \< RFa \< 0.5 bpm2.~* Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
214579676|NCT05478850|PROCEDURE|radiotherapy under anesthesia|Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
214579677|NCT01550445|DRUG|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
214579678|NCT04037267|PROCEDURE|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
214579679|NCT03147404|DRUG|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
214579680|NCT01946763|BEHAVIORAL|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
214579681|NCT01946763|BEHAVIORAL|pre operative education|
214579682|NCT03484845|DRUG|Lactoferrin and ferrous fumarate|"* Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
214579683|NCT03723616|BEHAVIORAL|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
214579684|NCT03723616|BEHAVIORAL|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
214579685|NCT03723616|BEHAVIORAL|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
214579686|NCT01745731|OTHER|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
214579687|NCT02540928|DRUG|AMG 319 hydrate|
214579688|NCT02540928|DRUG|Placebo|
214579689|NCT02784054|DRUG|Carboplatin|
214579690|NCT02784054|DRUG|Etoposide|
214579691|NCT02784054|DRUG|Cyclophosphamide|
214579692|NCT02784054|DRUG|Bleomycin|
214579693|NCT02784054|DRUG|Thiotepa|
214579694|NCT02784054|DRUG|Melphalan|
214579695|NCT02784054|RADIATION|Reduced dose radiotherapy|
214579696|NCT06135428|OTHER|Education Group|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
214579697|NCT02792673|OTHER|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
214579698|NCT02792673|OTHER|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
214579699|NCT02792673|OTHER|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
214579700|NCT02792673|DEVICE|Labotect embryo transfer catheter|
214579701|NCT01553773|DRUG|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
214579702|NCT01553773|DRUG|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
214579703|NCT06408480|DIAGNOSTIC_TEST|Neonatologist-performed lung ultrasound|lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants
214579704|NCT02609347|OTHER|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
214579705|NCT02609347|OTHER|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
214579706|NCT03566446|BIOLOGICAL|CALRLong36 peptide|200 ug CALRLong36 peptide in water mixed with 500ul montanide
214579707|NCT05198011|PROCEDURE|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
214579708|NCT05198011|PROCEDURE|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
214579709|NCT01877772|PROCEDURE|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
214579710|NCT01877772|PROCEDURE|Control|The control group will undergo standard rotator cuff repair.
214579711|NCT03955796|DEVICE|Hydrophobic IOL|RayOne Hydrophobic Aspheric, hydrophobic IOL
214579712|NCT03955796|DEVICE|Non-hydrophobic IOL|RayOne Aspheric, non-hydrophobic IOL
214579713|NCT05130047|DRUG|Aldafermin|1 mg solution
214579714|NCT05130047|DRUG|Placebo|Aldafermin placebo solution
214579715|NCT01764685|DRUG|Topiramate|Max therapeutic dose of 150mg/day
214579716|NCT01764685|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
214579717|NCT01764685|DRUG|Placebo|Placebo
214579718|NCT06015828|DIETARY_SUPPLEMENT|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
214579719|NCT01546636|OTHER|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
214579720|NCT01546636|OTHER|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
214579721|NCT01750203|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
214579722|NCT03013153|PROCEDURE|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
214579723|NCT03013153|PROCEDURE|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
214579724|NCT02233543|DRUG|QVA149|Delivered once daily via single-dose dry powder inhaler
214579725|NCT02233543|DRUG|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
214579726|NCT00447655|BEHAVIORAL|Self-management and peer support|
214579727|NCT00561366|DRUG|Placebo|Placebo t.i.d.
214579728|NCT00561366|DRUG|Arimoclomol|capsule, 400 mg t.i.d.
214710140|NCT03498287|DEVICE|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
214579729|NCT06034418|DEVICE|Pulse radiofrequency treatment|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.
214579730|NCT06034418|DRUG|Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
214579731|NCT03573583|BEHAVIORAL|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
214710141|NCT01545609|OTHER|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
214579732|NCT03573583|BEHAVIORAL|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
214579733|NCT04682444|DRUG|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
214579734|NCT04682444|DRUG|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
214579735|NCT02107183|DEVICE|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
214579736|NCT02107183|DEVICE|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
214579737|NCT04004936|OTHER|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
214579738|NCT04004936|OTHER|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
214579739|NCT00619333|DRUG|follitropin and lutropin|follitropin and lutropin
214579740|NCT01800084|DEVICE|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
214579741|NCT04865198|DIAGNOSTIC_TEST|Neurl1 gene expression|This observational case control study. The gene expression was examined.
214579742|NCT04865198|DIAGNOSTIC_TEST|RGS14 gene expression|This observational case control study. The gene expression was examined.
214579743|NCT05612152|OTHER|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
214579744|NCT05612152|OTHER|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
214579745|NCT00808054|DRUG|EMLA|0.5g topical EMLA
214710142|NCT03136952|DEVICE|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
214710143|NCT03823092|DIAGNOSTIC_TEST|polarization sensitivity|test of polarization vision as described in Study Description
214710144|NCT05515952|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
214710145|NCT05515952|DEVICE|Transcranial Magnetic Stimulation (Sham)|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used.
214710146|NCT04605536|OTHER|animation videos|watch animation videos about capsule endoscopy
214579746|NCT05189873|DRUG|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
214579747|NCT05189873|DRUG|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
214579748|NCT06419478|OTHER|postoperative symptoms|Observational study, focusing solely on symptom surveys of patients.
214579749|NCT06335602|DEVICE|LASER acupuncture|Low level LASER therapy
214579750|NCT02062593|PROCEDURE|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
214579751|NCT04666402|OTHER|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
214579752|NCT04666402|DIAGNOSTIC_TEST|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
214579753|NCT04666402|DIAGNOSTIC_TEST|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
214710147|NCT04605536|OTHER|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
214710148|NCT00531245|DRUG|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
214710149|NCT04240171|DRUG|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
214710150|NCT04240171|DRUG|Glimepiride 4Mg Tab|Glimepiride Tablets daily
214710151|NCT02555657|BIOLOGICAL|pembrolizumab|
214710152|NCT02555657|DRUG|capecitabine|
214710153|NCT02555657|DRUG|eribulin|
214710154|NCT02555657|DRUG|gemcitabine|
214710155|NCT02555657|DRUG|vinorelbine|
214579754|NCT03531385|DIAGNOSTIC_TEST|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
214579755|NCT03531385|DIAGNOSTIC_TEST|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
214579756|NCT03531385|OTHER|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
214579757|NCT03531385|OTHER|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
214579758|NCT01378780|BEHAVIORAL|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
214579759|NCT01378780|BEHAVIORAL|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
214579760|NCT00417261|DRUG|ATF936|
214579761|NCT00417261|DRUG|AXT914|
214579762|NCT02279628|DRUG|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
214579763|NCT02279628|DRUG|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
214579764|NCT01493011|DEVICE|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
214579765|NCT03284047|DRUG|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
214579766|NCT03730480|DEVICE|Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes|Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
214579767|NCT01227577|DRUG|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
214579768|NCT05251467|OTHER|Focus group|Focus group to confirm PROM conceptual framework
214579769|NCT05251467|OTHER|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
214579770|NCT05251467|OTHER|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
214579771|NCT05251467|DEVICE|Testing of the pilot PROM in a smartphone app (n = 150)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
214579772|NCT05566977|OTHER|autologous adoptive T regulatory cell transfer.|Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
214579773|NCT02970331|DRUG|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
214579774|NCT00737971|DRUG|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
214579775|NCT00737971|DRUG|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
214579776|NCT00737971|DRUG|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
214579777|NCT00669994|DRUG|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
214579778|NCT04236505|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
214579779|NCT04236505|BEHAVIORAL|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
214710156|NCT01214941|DRUG|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
214579780|NCT04236505|BEHAVIORAL|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
214579781|NCT00852540|DRUG|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
214579782|NCT00852540|DRUG|Linezolid|Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
214579783|NCT01639495|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
214579784|NCT04168333|BIOLOGICAL|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
214579785|NCT04168333|BIOLOGICAL|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
214579786|NCT01556477|DRUG|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
214579787|NCT01556477|DRUG|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
214579788|NCT05166187|OTHER|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
214579789|NCT02888704|DRUG|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
214579790|NCT04708210|DRUG|IBI319|Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
214579791|NCT01415362|DEVICE|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
214579792|NCT03867032|BEHAVIORAL|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
214579793|NCT01593345|OTHER|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
214579794|NCT01593345|OTHER|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
214579795|NCT03756987|DRUG|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
214579796|NCT03756987|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane.
214579797|NCT01694173|OTHER|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
214579798|NCT01694173|OTHER|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
214579799|NCT01694173|OTHER|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
214710157|NCT01214941|DRUG|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
214710158|NCT01214941|DRUG|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
214710159|NCT00001449|DRUG|gemcitabine|
214710160|NCT00001449|DRUG|fluorodeoxyuridine|
214710161|NCT00001449|DRUG|leucovorin|
214710162|NCT03077113|DIAGNOSTIC_TEST|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
214579800|NCT01694173|OTHER|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
214579801|NCT05631470|DIAGNOSTIC_TEST|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
214579802|NCT02197403|DRUG|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion
214579803|NCT02197403|DRUG|Propofol|25\~75mcg/kg/min continuous infusion
214579804|NCT02371213|OTHER|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
214579805|NCT03433508|BIOLOGICAL|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
214579806|NCT03433508|OTHER|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
214579807|NCT04960189|PROCEDURE|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
214579808|NCT01183234|DRUG|SPD544|two 30mg capsules, single oral dose
214579809|NCT01183234|DRUG|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
214579810|NCT04735328|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
214579811|NCT04735328|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
214579812|NCT04735328|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
214579813|NCT00363909|DRUG|citalopram hydrobromide|
214579814|NCT00363909|OTHER|placebo|
214579815|NCT00704379|DRUG|Placebo|an inactive substance
214579816|NCT00704379|DRUG|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
214579817|NCT04535024|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
214579818|NCT04535024|DRUG|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
214579819|NCT00821574|DRUG|Fluvastatin|Fluvastatin: daily 80 mg, oral
214579820|NCT00821574|DRUG|Valsartan|Valsartan: daily 160 mg, oral
214579821|NCT00821574|DRUG|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
214579822|NCT03925545|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
214579823|NCT03925545|DEVICE|AcrySof IQ monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
214579824|NCT03925545|PROCEDURE|Cataract surgery|Standard cataract extraction with phacoemulsification
214579825|NCT00884494|DRUG|Ghrelin infusion to assess effects on insulin sensitivity|
214579826|NCT04009915|PROCEDURE|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
214579827|NCT04009915|PROCEDURE|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
214710163|NCT03077113|DIAGNOSTIC_TEST|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
214710164|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
214710165|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
214710166|NCT00966693|DRUG|Dexamethasone|Given PO
214710167|NCT00966693|DRUG|Lenalidomide|Given PO
214710168|NCT00966693|DRUG|Thalidomide|Given PO
214579828|NCT01264822|DRUG|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
214579829|NCT06327581|DRUG|Lactic Acid|patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
214579830|NCT06327581|DRUG|vit D|patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
214579831|NCT06327581|DRUG|Triamcinolone Acetonide|patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
214579832|NCT06327581|DRUG|Saline|patients will be treated with MN combined with normal saline 0.9%
214579833|NCT01940224|DRUG|Pregabalin|Preoperative administration of pregabalin 300mg
214579834|NCT01940224|DRUG|Placebo|Preoperative administration of placebo
214579835|NCT01940224|DRUG|Morphine|Postoperative administration of morphine via PCA pump for 48h
214579836|NCT00406159|DEVICE|Hyperbaric Oxygen Therapy|
214579837|NCT00171808|DRUG|Letrozole|
214579838|NCT04580342|DRUG|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
214579839|NCT04580342|DRUG|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
214579840|NCT05304052|BEHAVIORAL|Mindfulness Meditation classes|The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
214579841|NCT03472248|BEHAVIORAL|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
214579842|NCT05377775|DEVICE|Iliac Stenting|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
214579843|NCT00316628|BIOLOGICAL|influenza vaccine|
214579844|NCT03114800|DEVICE|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
214579845|NCT04844645|OTHER|mini program|To design, construct, and test the mini program in patients managing cancer pain
214579846|NCT04844645|OTHER|conventional pharmaceutical care|conventional pharmaceutical care
214579847|NCT00833768|DRUG|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
214579848|NCT00833768|DRUG|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
214579849|NCT01639560|DRUG|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
214579850|NCT01639560|DRUG|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
214579851|NCT05059743|DRUG|[14C]-Larotinib|Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.
214579852|NCT04266600|PROCEDURE|Extensive mesentery resection|Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
214579853|NCT03251391|OTHER|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
214579854|NCT03251391|OTHER|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
214579855|NCT03759314|OTHER|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
214579856|NCT00099827|BEHAVIORAL|Education|Individuals will receive information about depression
214710169|NCT00347412|DRUG|Paclitaxel|"Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first."
214579857|NCT03461536|BEHAVIORAL|Ultrasound-first Clinical Decision Support tool|"Intervention: The intervention is the CDS tool, which consists of 4 components:~1. Four questions which assess the appropriateness of ultrasound for this patient~2. A link to the evidence~3. Buttons to remove CT scan and order ultrasound~4. If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~1. Adults aged \>18 and \< 76~2. Non-obese (men \< 285lbs, women \< 250lbs)~3. Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~4. Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided."
214579858|NCT03959410|DIAGNOSTIC_TEST|Cervical biopsy|in office Cervical biopsy
214579859|NCT03909529|DRUG|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
214579860|NCT03909529|DRUG|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
214579861|NCT02016859|OTHER|Immature Platelet Fraction|
214579862|NCT05696587|OTHER|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~* Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~* Mechanical desensitization;~* Transcutaneous electric nerve stimulation (TENS) electrotherapy;~* Aquatherapy (arm or leg whirlpool bath of the affected extremity);~* Graded Motor Imagery, including the Recognise™ app and mirror therapy;~* Psychoeducation on relaxation and coping with chronic pain."
214579863|NCT01141556|DRUG|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
214579864|NCT01467882|DRUG|Triptorelin|Powder and solution for solution for injection
214579865|NCT04875559|OTHER|Standardised multimodal pain treatment regimen|"Preoperatively:~* Paracetamol 1000 mg p.o.~* Celecoxib 400 mg p.o.~* Dexamethasone 12 mg p.o.~Perioperatively:~* Ondansetron 4 mg IV~* Bupivacaine 2.5 mg/mL, 20 mL LIA~* Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~* Paracetamol 1000 mg p.o. every 6h PRN~* Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~* Oxycodone 5 mg IV or 10 mg p.o. PRN~* Ondansetron 4 mg IV or p.o. PRN"
214579866|NCT04545229|OTHER|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
214579867|NCT04325243|DRUG|Sildenafil 50 mg|50 mg oral Sildenafil tablet
214579868|NCT04325243|DRUG|Placebo oral tablet|placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
214579869|NCT03712059|DIAGNOSTIC_TEST|FIT test and colonoscopy|All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
214579870|NCT03712059|DIAGNOSTIC_TEST|Polypectomy and biopsy|All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
214579871|NCT03712059|DIAGNOSTIC_TEST|Classification|Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
214579872|NCT03161600|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
214579873|NCT01156792|DRUG|FP 100|FP 100mcg BID
214579874|NCT01156792|DRUG|GSK2190915 100|GSK2190915 100mg QD (AM)
214579875|NCT01156792|DRUG|GSK2190915 300|GSK2190915 300mg QD (AM)
214579876|NCT01156792|DRUG|montelukast|montelukast 10mg QD (PM)
214579877|NCT01156792|DRUG|placebo|placebo BID
214579878|NCT01156792|DRUG|FP/SAL 100/50|FP/SAL 100/50mcg BID
214579879|NCT02878577|DEVICE|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
214579880|NCT01474434|DRUG|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
214579881|NCT01474434|DRUG|Placebo|matching placebo tablets
214579882|NCT00343447|BIOLOGICAL|autologous tumor cell vaccine|
214579883|NCT00343447|BIOLOGICAL|rituximab|
214579884|NCT00343447|DRUG|cyclophosphamide|
214579885|NCT01045343|OTHER|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
214579886|NCT01045343|OTHER|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
214579887|NCT05271552|DRUG|BXCL501|Sublingual Film
214579888|NCT05271552|DRUG|Matching Placebo|Sublingual Placebo Film
214579889|NCT02289573|DEVICE|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
214579890|NCT02698085|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
214579891|NCT02698085|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
214579892|NCT04859569|DRUG|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
214579893|NCT04859569|DRUG|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
214579894|NCT02483000|BIOLOGICAL|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
214579895|NCT02483000|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
214579896|NCT02483000|DRUG|Carmustine|Given IV
214579897|NCT02483000|DRUG|Clearing Agent|Given IV
214579898|NCT02483000|DRUG|Cytarabine|Given IV
214579899|NCT02483000|DRUG|Etoposide|Given IV
214579900|NCT02483000|RADIATION|Indium In 111-DOTA-Biotin|Given IV
214579901|NCT02483000|OTHER|Laboratory Biomarker Analysis|Correlative studies
214579902|NCT02483000|DRUG|Melphalan|Given IV
214579903|NCT02483000|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
214579904|NCT02483000|OTHER|Pharmacological Study|Correlative studies
214579905|NCT02483000|RADIATION|Yttrium Y 90-DOTA-Biotin|Given IV
214579906|NCT03403218|BEHAVIORAL|Case group|assessment of quality on posture, transfers and displacement
214579907|NCT02876159|BIOLOGICAL|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
214579908|NCT06540534|PROCEDURE|Dexamethasone|In the adjuvan group (dexamethasone)group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of dexamethasone(8mg).
214579909|NCT06540534|PROCEDURE|kontrol group|In the control group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of 0.9% saline.
214579910|NCT00497185|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
214579911|NCT01076426|DRUG|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
214579912|NCT01076426|DIETARY_SUPPLEMENT|Oligosaccharide|oligosaccharide one pack per day
214579913|NCT04592042|BEHAVIORAL|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
214579914|NCT06271460|OTHER|Traditional physiotherapy|All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.
214579915|NCT06084091|DEVICE|Myocardial spectrometric measurement|Myocardial spectrometric measurement during open-heart Surgery
214579916|NCT00662935|PROCEDURE|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
214579917|NCT04603638|DRUG|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
214579918|NCT04603638|DRUG|Isotonic|100 ml
214579919|NCT03234101|BEHAVIORAL|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1\) Healthy body weight (Minimum: BMI \<30kg/m2 or WC of \<88 in females or \<92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits \& vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation \>12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (\>6 hours)"
214579920|NCT00495586|DRUG|Placebo|One pill to be taken every eight hours for 8 days
214710170|NCT00347412|DRUG|NOV-002|"* Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
214579921|NCT00495586|DRUG|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
214579922|NCT02641600|DEVICE|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
214579923|NCT02641600|DEVICE|Placebo stockings|Placebo stocking with pressure applied to the legs
214579924|NCT01955889|BEHAVIORAL|Mobile Health Technology|
214579925|NCT01955889|BEHAVIORAL|Stretching & Strengthening Exercises|
214579926|NCT01955889|BEHAVIORAL|Walking with Pedometer|
214579927|NCT01795573|BIOLOGICAL|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
214579928|NCT03487354|DRUG|Misoprostol|Misoprostol
214579929|NCT02301260|BEHAVIORAL|Speed of Processing Training (SPT)|
214579930|NCT02301260|BEHAVIORAL|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
214579931|NCT04451174|DRUG|Prednisone|Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
214579932|NCT00827866|OTHER|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
214579933|NCT00827866|OTHER|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
214579934|NCT00158860|DRUG|Valaciclovir|1g once daily
214579935|NCT00158860|DRUG|Placebo|placebo
214579936|NCT02117947|BEHAVIORAL|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
214579937|NCT02117947|BEHAVIORAL|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
214710171|NCT00347412|DRUG|Carboplatin|"Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
214710172|NCT00410449|DRUG|Alpha tocopherol|
214710173|NCT01873443|DRUG|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
214579938|NCT00563485|DRUG|Doxazosin GITS (Cardura XL)|
214579939|NCT00563485|DRUG|Terazosin (Hytrin)|
214579940|NCT06434454|BEHAVIORAL|EFT Group:Emotional Free Technıcal|The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
214579941|NCT05333770|DEVICE|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
214579942|NCT02372656|DRUG|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
214579943|NCT02372656|DRUG|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
214579944|NCT02372656|DRUG|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
214579945|NCT01029652|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
214579946|NCT01029652|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
214579947|NCT01029652|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
214579948|NCT01029652|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
214579949|NCT06378489|DRUG|Etonogestrel implant|The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management
214579950|NCT06327750|DEVICE|Hemodialysis (DNa = PNa)|High-flux hemodialysis with an expected zero diffusive sodium balance (DNa = PNa)
214579951|NCT06327750|DEVICE|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
214579952|NCT06327750|DEVICE|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with an expected zero diffusive sodium balance (DNa=PNa)
214579953|NCT06327750|DEVICE|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with an expected zero diffusive sodium balance (DNa=PNa) Convection volume: ≥23L/session
214579954|NCT06327750|DEVICE|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L) Convection volume: ≥23L/session
214579955|NCT06301282|BEHAVIORAL|assessment during the transition between OFF-levodopa (i.e. withdrawal of levodopa phase) and ON-levodopa (i.e. effect of Levodopa phase)states|Electroencephalographic measurements are taken during both motor and non-motor assessments while the transition between the OFF-levodopa and ON-levodopa states occurs
214579956|NCT02095951|DRUG|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
214579957|NCT00454389|DEVICE|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
214579958|NCT00454389|DRUG|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
214579959|NCT03618823|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214710174|NCT05886179|OTHER|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
214710175|NCT00608452|OTHER|Symptom Assessment Scale|"* Memorial Symptom Assessment Scale~* History and neurologic examination"
214710176|NCT02312583|BEHAVIORAL|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
214579960|NCT03618823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214579961|NCT03618823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214579962|NCT01319214|DRUG|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
214579963|NCT02631512|DEVICE|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
214579964|NCT02631512|DEVICE|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
214579965|NCT02503033|DRUG|HMPL-523|Oral administration, once daily
214579966|NCT01498159|BEHAVIORAL|Pharmacist disease/medication management|
214579967|NCT01498159|BEHAVIORAL|Pharmacist-patient encounters|
214579968|NCT01498159|BEHAVIORAL|Pharmacist medication intensification and adherence support|
214579969|NCT01498159|BEHAVIORAL|Pharmacist communication with primary care physicians|
214579970|NCT01498159|BEHAVIORAL|Pharmacist documentation in electronic medical record|
214579971|NCT01498159|BEHAVIORAL|Health promoter-patient encounters in-person or by phone|
214579972|NCT01498159|BEHAVIORAL|Health promoter medication and lifestyle support|
214579973|NCT01498159|BEHAVIORAL|Health promoter communication with pharmacists|
214579974|NCT03392545|COMBINATION_PRODUCT|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
214579975|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
214579976|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
214579977|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
214579978|NCT00964886|DRUG|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
214579979|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
214579980|NCT02758847|DEVICE|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
214579981|NCT02758847|DEVICE|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
214579982|NCT05071820|OTHER|Health U mobile application|Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
214579983|NCT05071820|OTHER|National Diabetes Prevention Program|CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
214710177|NCT02312583|BEHAVIORAL|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
214579984|NCT06203366|PROCEDURE|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
214579985|NCT00523640|DRUG|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
214579986|NCT05184712|DRUG|Ivonescimab (SMT112 or AK112) Injection|Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
214579987|NCT05184712|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
214579988|NCT03139669|DEVICE|Viba collection brush|HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
214579989|NCT00366080|DRUG|GSK189254|
214579990|NCT05305612|OTHER|early anticoagulation|Anticoagulation prior to transseptal puncture
214579991|NCT05305612|OTHER|late anticoagulation|Anticoagulation after transseptal puncture
214579992|NCT04367259|PROCEDURE|TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
214579993|NCT05192148|OTHER|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
214579994|NCT04708353|DRUG|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
214579995|NCT04708353|DRUG|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
214579996|NCT04708353|DRUG|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
214579997|NCT05052177|DEVICE|Edge to edge repair in systemic tricuspid valve regurgitation|Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
214579998|NCT01071343|DEVICE|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
214579999|NCT04587752|BEHAVIORAL|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
214580000|NCT01621568|DRUG|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
214580001|NCT01621568|DRUG|Sunitinib|50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
214580002|NCT00670345|DRUG|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
214580003|NCT00670345|DRUG|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
214580004|NCT00201890|PROCEDURE|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
214580005|NCT01051830|OTHER|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
214580006|NCT01379378|DEVICE|Artificial urinary sphincter|Standard of care
214580007|NCT01379378|DEVICE|InVance Sling|Standard of care
214580008|NCT01379378|DEVICE|AdVance Sling|Standard of care
214580009|NCT01379378|DEVICE|Virtue Sling|Standard of care
214580010|NCT01379378|DRUG|Contigen|2.5-10 cc
214580011|NCT05845034|PROCEDURE|PVI + SPEs ablation|electrophysiology substrate mapping is the critical difference between both groups.
214580012|NCT05845034|PROCEDURE|PVI ablation|electrophysiology substrate mapping is the critical difference between both groups.
214580013|NCT00042718|DRUG|levofloxacin, azithromycin, amoxicillin/clavulanate|
214580014|NCT04211662|BEHAVIORAL|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
214580015|NCT05502549|DRUG|CB03-154|CB03-154 tablet once daily.
214580016|NCT05502549|DRUG|Placebo|Placebo tablet once daily.
214580017|NCT02765802|DRUG|Peginterferon Lambda-1A|
214580018|NCT02582112|OTHER|Active Comparator: Warming group|Placebo Comparator: Control group
214580019|NCT04538001|DEVICE|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
214580020|NCT04538001|PROCEDURE|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
214580021|NCT04984538|OTHER|Pharmacogenomic Testing|Cheek swab as a part of routine care
214580022|NCT03500159|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
214580023|NCT03500159|DRUG|Placebo|Appearance and weight matched tablets without the active product ingredient
214580024|NCT01710644|DRUG|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
214580025|NCT01710644|DRUG|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
214580026|NCT03535597|DEVICE|Quikclot Radial (QC) Pad|The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.
214580027|NCT00603252|BIOLOGICAL|Twinrix|
214580028|NCT00603252|BIOLOGICAL|Engerix-B|
214580029|NCT00603252|BIOLOGICAL|Havrix|
214580030|NCT00603252|BIOLOGICAL|HBVAXPRO|
214580031|NCT00603252|BIOLOGICAL|Vaqta|
214580032|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
214580033|NCT03942185|DRUG|Oral Chinese Herbal Medicine according with syndrome differentiation therapy|Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
214580034|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
214580035|NCT04565847|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
214580036|NCT04565847|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
214580037|NCT00407576|DRUG|[11C]MeS-IMPY|
214580038|NCT00653445|DRUG|Rosuvastatin|40mg
214580039|NCT00653445|DRUG|Ezetimibe|10mg
214580040|NCT02292927|BEHAVIORAL|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
214580041|NCT03262324|OTHER|VAS-FA Turkish version|Self-reported outcome questionnaires
214580042|NCT00568802|DRUG|Hydroxyurea|
214580043|NCT00568802|DRUG|Placebo to match hydroxyurea|
214580044|NCT01277900|PROCEDURE|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
214580045|NCT03394729|DRUG|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
214580046|NCT03394729|DRUG|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
214580047|NCT05823831|DIAGNOSTIC_TEST|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
214580048|NCT05823831|DIAGNOSTIC_TEST|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
214580049|NCT05823831|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
214580050|NCT05823831|DIAGNOSTIC_TEST|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
214580051|NCT03117322|BIOLOGICAL|agave inulin|Duration: four weeks Dosage: powder 4 g/d
214580052|NCT03117322|BIOLOGICAL|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
214580053|NCT03117322|OTHER|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
214580054|NCT03117322|OTHER|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
214580055|NCT04280341|BIOLOGICAL|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
214580056|NCT04067648|DRUG|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
214580057|NCT00725933|DRUG|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
214580058|NCT05721404|DRUG|Icodextrin Peritoneal Dialysis Solution|Icodextrin (Extraneal) for long night dwell
214580059|NCT05721404|DRUG|Hypertonic Dextrose solution|Hypertonic Dextrose solution for long night dwell
214580060|NCT05786430|DRUG|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
214580061|NCT05300347|DIAGNOSTIC_TEST|adenosine deaminase enzyme deficiency test|adenosine deaminase enzyme deficiency
214580062|NCT04361682|PROCEDURE|Surgical Drain Management|
214580063|NCT03117231|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
214580064|NCT03117231|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
214580065|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
214580066|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
214580067|NCT02090036|DRUG|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
214580068|NCT02090036|DRUG|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
214580069|NCT05842239|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
214580070|NCT03302078|DRUG|BI 1015550|Fed state
214580071|NCT03302078|DRUG|BI 1015550|Fasted state
214580072|NCT02971761|DRUG|Enobosarm|Given PO
214580073|NCT02971761|OTHER|Laboratory Biomarker Analysis|Correlative studies
214580074|NCT02971761|BIOLOGICAL|Pembrolizumab|Given IV
214580075|NCT02166294|OTHER|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
214580076|NCT02166294|PROCEDURE|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
214580077|NCT01605916|DRUG|AZD6244|Tablet Oral bid
214580078|NCT05012501|DIAGNOSTIC_TEST|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
214580079|NCT01587391|DRUG|Placebo to BI 163538 XX|1 single dose per subject as oral solution
214580080|NCT01587391|DRUG|BI 163538 XX|1 single dose per subject as oral solution
214580081|NCT03744104|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
214580082|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
214580083|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
214580084|NCT02073747|DRUG|Normal Saline|One hour inhaled normal saline
214580085|NCT02073747|DRUG|Albuterol|One hour inhaled ten milligrams of albuterol
214580086|NCT05064683|OTHER|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
214580087|NCT03983603|DIETARY_SUPPLEMENT|Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)|Soft chews containing 0.5g plant stanols delivered as plant stanol esters
214580088|NCT03983603|DIETARY_SUPPLEMENT|Placebo soft chew|Soft chew that does not contain plant stanols
214580089|NCT03594201|OTHER|semen pretreatment|semen pretreatment
214580090|NCT05849831|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
214580091|NCT05515380|OTHER|8-stage model based exercise program|The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.
214580092|NCT05515380|OTHER|Conventional exercise program|The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
214580093|NCT04491565|OTHER|educational video|an interactive educational video was viewed by participants in the intervention arm.
214580094|NCT03639467|DRUG|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
214580095|NCT04881981|RADIATION|SCART radiation therapy|We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
214580096|NCT01588431|DRUG|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
214580097|NCT06470061|DRUG|Resveratrol, Quercetin, and Curcumin (RQC)|"2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)"
214580098|NCT06470061|DRUG|Curcumin|2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
214580099|NCT02632526|DRUG|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
214580100|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
214580101|NCT02632526|DRUG|AZD5718 placebo oral suspension|Single and multiple doses
214580102|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
214580103|NCT01976117|DEVICE|enose|
214580104|NCT01060579|DRUG|AR-12286 0.5% ophthalmic solution|q.d. PM
214580105|NCT01060579|DRUG|AR-12286 0.25% Ophthalmic solution|q.d. PM
214580106|NCT01060579|DRUG|Latanoprost ophthalmic solution|q.d. PM
214580107|NCT06315504|OTHER|Observation|Observation
214580108|NCT04659941|BIOLOGICAL|BCG vaccine|Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.
214580109|NCT04659941|BIOLOGICAL|0.9% sodium chloride (NaCl) saline solution|A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
214580110|NCT03500601|OTHER|Nut components|nut components consumed daily for a period of 28 days
214580111|NCT03500601|OTHER|Placebo|Placebo consumed daily for a period of 28 days
214580112|NCT01986673|DRUG|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
214580113|NCT01986673|DRUG|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
214580114|NCT01994655|OTHER|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
214580115|NCT01994655|OTHER|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
214580116|NCT02120742|BEHAVIORAL|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
214580117|NCT04110639|DEVICE|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
214580118|NCT04110639|OTHER|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
214580119|NCT04867928|DRUG|Venetoclax+azacitidine|subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
214580120|NCT02549196|DRUG|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
214580121|NCT02549196|DRUG|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
214580122|NCT06375447|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for insomnia.
214580123|NCT03096704|DIAGNOSTIC_TEST|vitamine d dosage|dosage of vitamine D in slow transit time constipation
214580124|NCT00410943|DRUG|OROS Hydromorphone HCI SR (slow release)|
214580125|NCT02679027|OTHER|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
214580126|NCT02679027|OTHER|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
214580127|NCT04579289|OTHER|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~* morbidity and mortality linked with COVID-19~* structural features of the facility (location, architecture, residents characteristics)~* human resources~* crisis management (visits and circulation restrictions, personal protective equipment)"
214580128|NCT03896412|OTHER|Detecton of circulating tumor DNA|7 blood samples to design a molecular probe
214580129|NCT06211881|DRUG|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
214580130|NCT03505541|BIOLOGICAL|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
214580131|NCT03994289|BEHAVIORAL|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
214710178|NCT01841528|OTHER|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
214580132|NCT03994289|BEHAVIORAL|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
214580133|NCT01010191|OTHER|Sugar pill|
214580134|NCT04496492|DRUG|Tocotrienol|Tocotrienol 200 mg orally twice a day
214580135|NCT03954392|BEHAVIORAL|Cognitive behavior therapy with social cognitive training (CBT+SCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.
214580136|NCT03954392|BEHAVIORAL|CBT-only|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
214580137|NCT00648154|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
214580138|NCT00648154|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fed
214580139|NCT04611321|DRUG|IBI318|IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
214580140|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
214580141|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
214580142|NCT01103362|DRUG|flibanserin|all patients will receive open-label flibanserin 100mg
214580143|NCT00254631|DRUG|Oxycodone hydrochloride|
214580144|NCT02002793|OTHER|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
214580145|NCT02002793|OTHER|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
214580146|NCT02567773|DRUG|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
214580147|NCT02567773|DRUG|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
214580148|NCT02567773|DRUG|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
214580149|NCT00376831|DRUG|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
214580150|NCT00376831|DRUG|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
214580151|NCT00543374|DRUG|Placebo|Placebo
214580152|NCT00543374|DRUG|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
214580153|NCT00669682|OTHER|Congestive heart failure|Spontaneous occurrence of fluid overload.
214580154|NCT02097082|DEVICE|STANZA Drug-eluting resorbable Scaffold|
214580155|NCT01321320|OTHER|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
214580156|NCT03800615|PROCEDURE|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
214580157|NCT00939666|PROCEDURE|Wait&see or TEM with intensive follow-up|Wait\&see or TEM with intensive follow-up
214580158|NCT01892826|DRUG|hCG|5000IU
214580159|NCT01526031|PROCEDURE|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
214580160|NCT01526031|PROCEDURE|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
214580161|NCT01526031|PROCEDURE|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
214580162|NCT01526031|PROCEDURE|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program"
214580163|NCT00065377|DRUG|Glucosamine Hydrochloride|
214580164|NCT01178554|BEHAVIORAL|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
214580165|NCT01178554|BEHAVIORAL|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
214580166|NCT01178554|BEHAVIORAL|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita \& Weisz, 2004)
214580167|NCT00225966|DEVICE|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
214580168|NCT04708925|OTHER|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
214580169|NCT03265938|DEVICE|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
214580170|NCT05636956|OTHER|Education and Counseling Program|Researches created an education and counseling program. In this context, patients receive an one hour education. Education program consist of face-to-face informing and teach-back method. At the end of the face-to-face informing, researchers give a comicbook about instructions of living with CIEDs as a written material. After discharge, researches follow-up patients with phone calls. In the context of phone calls researches continue to informing patients, remind related instructions for that time and answer questions of patients. Patients are allowed to reach reserarches any time if they have any concern or question. This program lasts for six months.
214580171|NCT01543529|DRUG|RO4917838|Single dose of RO4917838
214580172|NCT01543529|DRUG|Placebo to RO4917838|Single dose of placebo to RO4917838
214580173|NCT01543529|OTHER|Alcohol|Standard alcoholic drink
214580174|NCT02202382|DRUG|Korean Red Ginseng, Varicocelectomy|
214580175|NCT02202382|DRUG|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
214580176|NCT02202382|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
214580177|NCT00002570|DRUG|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
214580178|NCT00002570|DRUG|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
214580179|NCT03871842|DEVICE|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
214580180|NCT03871842|DEVICE|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
214580181|NCT02617849|DRUG|Pembrolizumab|200 mg IV every 3 weeks
214580182|NCT02617849|DRUG|Carboplatin|AUC=6, every 3 weeks x 4
214580183|NCT02617849|DRUG|Paclitaxel|175 mg/m2, every 3 weeks x 4
214580184|NCT05598671|PROCEDURE|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
214580185|NCT02679508|DRUG|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
214580186|NCT02679508|DRUG|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
214580187|NCT01285271|DRUG|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
214580188|NCT01285271|DRUG|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
214580189|NCT06485362|DIAGNOSTIC_TEST|Termography|Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).
214580190|NCT01513980|PROCEDURE|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
214580191|NCT01513980|PROCEDURE|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
214580192|NCT01854723|DRUG|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
214580193|NCT01854723|DRUG|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
214580194|NCT03143166|DRUG|Dabigatran Etexilate|Tablet, film coated
214580195|NCT03143166|DRUG|Rabeprazol sodium|Tablet
214580196|NCT00573495|BIOLOGICAL|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
214580197|NCT01574196|OTHER|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
214580198|NCT01906970|DEVICE|ClampArt|
214580199|NCT01453426|DRUG|BG00012 Dose 1|
214580200|NCT01453426|DRUG|BG00012 Dose 2|
214580201|NCT00002197|DRUG|Abacavir sulfate|
214580202|NCT04360486|BIOLOGICAL|Anti-Sars-CoV-2 Convalescent Plasma|Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
214580203|NCT04341467|DRUG|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
214580204|NCT04341467|DRUG|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
214580205|NCT01702272|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
214580206|NCT05249491|DIAGNOSTIC_TEST|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
214580207|NCT04842370|DRUG|PHI-101|PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
214580208|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
214580209|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
214580210|NCT00094042|DRUG|Iron Supplement, 120mg|
214580211|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
214580212|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
214580213|NCT04013087|DIETARY_SUPPLEMENT|Breast feeding|Breast feeding of human milk for 16 weeks
214580214|NCT06262074|OTHER|Structured Exercise Program|30 minutes of structured exercise programs
214580215|NCT06262074|OTHER|Non structured exercise program|Non structured exercises
214580216|NCT04013568|OTHER|Exercise|"First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students~Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes"
214580217|NCT06248970|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
214580218|NCT06248970|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
214580219|NCT06248970|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
214580220|NCT02651597|OTHER|Oatmeal|
214580221|NCT03580005|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
214580222|NCT03580005|DRUG|Placebo|Placebo to Match Quillichew ERCT
214580223|NCT06486207|COMBINATION_PRODUCT|Gong's mobilization|increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula
214580224|NCT06486207|OTHER|Kendall Exercise|The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
214580225|NCT01028027|DRUG|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
214580226|NCT01028027|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
214580227|NCT02811952|OTHER|without intervention|without intervention
214580228|NCT04208282|DEVICE|7 day infusion set|7 days survival of the sets
214580229|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control bread|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination
214580230|NCT05955131|OTHER|Nutritional acute postprandial intervention: bread suppelmented with Chilean beans|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.
214580231|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control glucose|Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.
214580232|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
214580233|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
214580234|NCT01116102|DRUG|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
214580235|NCT03438877|PROCEDURE|Intensive dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
214580236|NCT03438877|PROCEDURE|Regular dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
214710179|NCT01841528|OTHER|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
214634234|NCT06534827|BEHAVIORAL|Great Life Mentoring|The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
214710180|NCT00095511|DRUG|aripiprazole|
214710181|NCT02521623|DEVICE|SurgiMend® Acellular Dermal Matrix|See arm description.
214710182|NCT02521623|DEVICE|Strattice™ Acellular Dermal Matrix|See arm description.
214580237|NCT04048421|PROCEDURE|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
214580238|NCT06429007|DRUG|Metformin|"Metformin will be initiated at 25% of the target dose (4 mg/kg administered twice daily, total daily dose 8 mg/kg) for three weeks. In the absence of adverse effects, metformin dose will be escalated to 50% of the target dose (8 mg/kg administered twice daily for a total daily dose of 16mg/kg) for remaining 3 weeks to minimize potential gastrointestinal upset at higher doses. Parents will be documenting adverse events and performing glucometer checks twice a day for 3 days post dose escalation.~Parents will then receive a 6-week supply of metformin at the target dose (16 mg/kg administered twice daily, total daily dose 32 mg/kg). Adverse events will be documented and glucometer checks will be performed twice a day for 3 days following dose escalation."
214580239|NCT04662034|DEVICE|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
214580240|NCT04662034|DRUG|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
214580241|NCT05591989|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
214580242|NCT03848676|DIAGNOSTIC_TEST|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
214580243|NCT04743791|DRUG|Dupilumab|Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
214580244|NCT04743791|OTHER|Placebo|Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
214634235|NCT06922539|DRUG|Fenretinide|Intravenous administration
214634236|NCT06922539|DRUG|Fenretinide|Intravenous administration
214580245|NCT05000931|DEVICE|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
214580246|NCT04168528|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
214580247|NCT03562975|DRUG|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
214580248|NCT05709600|DIETARY_SUPPLEMENT|Fasting mimicking diet|"Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.~The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet."
214580249|NCT05709600|DIETARY_SUPPLEMENT|Ketogenic diet|"Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.~The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption"
214580250|NCT05709600|DIETARY_SUPPLEMENT|Dietary restriction of sulfur containing amino acids|"Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.~A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption."
214580251|NCT05709600|DIETARY_SUPPLEMENT|Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)|Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.
214580252|NCT02539745|OTHER|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
214580253|NCT02539745|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
214580254|NCT00351312|DEVICE|special socks|
214580255|NCT05490342|DIAGNOSTIC_TEST|Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.|Blood test to value the antibody response to vaccination
214580256|NCT04055532|OTHER|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
214580257|NCT04133051|DRUG|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
214580258|NCT04133051|DRUG|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
214580259|NCT00901654|BIOLOGICAL|ACE527 vaccine|"First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21"
214580260|NCT00901654|BIOLOGICAL|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
214580261|NCT05571345|DRUG|PF614|PF614 capsules (50 mg or 100 mg)
214580262|NCT05571345|DRUG|Oxycodone Hydrochloride 40 mg|Oral 20 mg tablets (two each)
214580263|NCT05571345|DRUG|Placebo|Placebo to match PF614 capsules will be provided by the sponsor.
214580264|NCT05488145|OTHER|Best Practice|Receive standard of care
214580265|NCT05488145|OTHER|Internet-Based Intervention|Receive application intervention
214580266|NCT05488145|OTHER|Questionnaire Administration|PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.
214580267|NCT05488145|OTHER|Survey Administration|Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
214580268|NCT05118828|BEHAVIORAL|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
214580269|NCT05118828|BEHAVIORAL|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
214580270|NCT06374108|BEHAVIORAL|Progressive resistance training|The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
214580271|NCT06081153|DRUG|Evolocumab|See arm description.
214580272|NCT06081153|DRUG|Placebo|See arm description.
214580273|NCT05390021|COMBINATION_PRODUCT|PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent|The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.
214580274|NCT00732589|DRUG|1% xylocaine|10 cc. of 1%xylocaine, once a week
214580275|NCT00732589|OTHER|ultrasound|ultrasound at shoulder area about 10 mins.
214580276|NCT02527824|DRUG|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7"
214580277|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
214580278|NCT00979134|DRUG|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
214580279|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
214580280|NCT00000747|DRUG|Nevirapine|
214710183|NCT05314361|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
214710184|NCT02581982|OTHER|Laboratory Biomarker Analysis|Correlative studies
214710185|NCT02581982|DRUG|Paclitaxel|Given IV
214710186|NCT02581982|BIOLOGICAL|Pembrolizumab|Given IV
214710187|NCT01928992|DEVICE|3D|subjects that underwent 3D mammography
214710188|NCT01928992|DEVICE|2D|those subjects that underwent 2D mammography
214710189|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
214580281|NCT06458413|DRUG|Utidelone Capsule Plus Capecitabine|"Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle ."
214580282|NCT04083105|DRUG|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
214580283|NCT04083105|DRUG|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
214580284|NCT00352638|OTHER|counseling intervention|
214580285|NCT00352638|OTHER|educational intervention|
214580286|NCT00352638|OTHER|study of socioeconomic and demographic variables|
214580287|NCT04676061|DRUG|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
214580288|NCT04676061|DRUG|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
214580289|NCT00933790|DRUG|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
214580290|NCT02271438|DRUG|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.
214580291|NCT02271438|DRUG|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
214580292|NCT02271438|DRUG|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
214580293|NCT02271438|DRUG|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
214580294|NCT00963053|DRUG|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
214580295|NCT01719705|DRUG|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
214580296|NCT01719705|DRUG|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
214580297|NCT01719705|DRUG|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
214580298|NCT06084923|OTHER|Observation|Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
214580299|NCT06012422|OTHER|evaluation group|Elderly individuals will be evaluated once, by face-to-face interview method.
214580300|NCT00380224|DRUG|bifeprunox, olanzapine|
214580301|NCT02272673|DIETARY_SUPPLEMENT|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
214580302|NCT05180500|DRUG|Q-Griffithsin|Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
214580303|NCT05180500|DRUG|Placebo|A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
214634237|NCT07143955|BEHAVIORAL|Structured Dietary Intervention|A comprehensive dietary program consisting of dietary modification (high-fiber, lean protein), daily probiotic supplementation capsule (Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus), and encouraged intake of prebiotics and unsaturated fatty acids.
214634238|NCT07143955|BEHAVIORAL|Routine Dietary Care|Standard institutional dietary counseling for patients with HCC, providing general advice on nutrition.
214634239|NCT07143331|DRUG|Part 1 KS101|Six doses of oral KS101 will be administered to participants.
214580304|NCT04605289|DRUG|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
214634240|NCT07143331|DRUG|Part 1 Placebo|Six doses of oral matching placebo will be administered to participants.
214634241|NCT07143331|DRUG|Part 2 with Food|KS101 administered with food
214634242|NCT07143331|DRUG|Part 2 without food|KS101 administered without food
214634243|NCT07143331|DRUG|Part 3 KS101|3 multiple doses of KS101
214580305|NCT04605289|DRUG|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
214580306|NCT04605289|PROCEDURE|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
214580307|NCT00867308|DRUG|Lenalidomide 50 mg|
214580308|NCT00867308|DRUG|Lenalidomide 15 mg|
214580309|NCT00002851|PROCEDURE|adjuvant therapy|
214580310|NCT00002851|RADIATION|low-LET electron therapy|
214580311|NCT00002851|RADIATION|low-LET photon therapy|
214580312|NCT00067262|DRUG|Divalproex Sodium Extended-Release Tablets|
214580313|NCT00452023|DRUG|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
214634244|NCT07142798|DRUG|Bismuth amoxilillin potassium|vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days
214634245|NCT07144046|OTHER|Micropore covering of the medial half of the scar|3 months of micropore covering of the medial half of the scar
214580314|NCT05917470|DRUG|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
214580315|NCT06663592|OTHER|Conventional treatment|hot pack, stretching of the neck muscles, cervical isometrics exercise
214580316|NCT06663592|OTHER|Tensioner Neuro Dynamic Mobilization|Median nerve tensioner neural mobilization with addition to conventional treatment
214580317|NCT06663592|OTHER|Slider Neuro Dynamic Mobilization|Median nerve neural sliding mobilization with addition to conventional treatment
214580318|NCT02248181|DRUG|Pramipexole|
214580319|NCT06607354|OTHER|Grass fed lamb|This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.
214580320|NCT06598436|OTHER|Digital Health Coaching (Patient-Level Intervention)|The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.
214580321|NCT06598436|OTHER|Practice Facilitation (Clinic-Level Intervention)|The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).
214580322|NCT06610877|DEVICE|Focused Ultrasound Neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
214580323|NCT06610877|DEVICE|Focused ultrasound neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
214580324|NCT05595252|BIOLOGICAL|cervical biopsy|cervical biopsy made during and after pregancy
214580325|NCT00231452|DRUG|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
214580326|NCT05599555|BIOLOGICAL|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
214580327|NCT05599555|BIOLOGICAL|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
214580328|NCT06728670|BEHAVIORAL|Tranexamic acid Intravenous Infusion|A slow intravenous infusion of 1g TXA was administered at a rate of about 1ml/min.
214580329|NCT06728670|BEHAVIORAL|TXA intramuscular injection|5ml intramuscular injections of TXA with twice, each injection time no more than 30 seconds, the injection site was selected as triangle
214580330|NCT06729359|DIAGNOSTIC_TEST|Ultrasonography of the abdomen and pelvis|ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe
214580331|NCT06728306|BEHAVIORAL|Immersive Virtual Reality-Based Relaxation|"Participants experienced a 20-minute immersive relaxation session using the virtual reality headset and the Nature Treks application, while seated comfortably. Participants were instructed to select the natural environment they found most relaxing from options such as Blue Ocean, Orange Sunset, Violet Down, White Winter, and Green Meadows, and spent 20 minutes immersed in their chosen virtual environment."
214580332|NCT06728306|BEHAVIORAL|Non-immersive VR-Based Exergaming|"Participants engaged in a 20-minute calisthenic exercise session guided by the Kinect Adventures game on the Xbox Kinect 360 system. The exercise session consisted of playing two rounds each of the game segments 20,000 Leaks, Reflex Ridge, and River Rush, each lasting approximately 3 minutes"
214580333|NCT06728306|BEHAVIORAL|Jacobson's Relaxation|Participants underwent 20 minutes of progressive relaxation training as developed by Dr. Jacobson. The training involves a series of deep diaphragmatic breaths followed by the systematic tensing and relaxing of 16 major muscle groups throughout the body. Participants were guided through the exercise by an approximately 20-minute audio recording prepared by a psychologist and available online
214580334|NCT04207177|DRUG|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
214580335|NCT04207177|DRUG|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
214580336|NCT06867718|DRUG|RGT001-075|RGT001-075 is a small molecule GLP-1 agonist
214580337|NCT06867718|DRUG|Placebo Comparator|Placebo comparator
214580338|NCT06897605|DRUG|Dapagliflozin (DAPA)|Dapagliflizin 10 mg tablets once daily for 12 weeks
214580339|NCT06897605|DRUG|Erythropoiesis Stimulating Agent|Erythropoiesis stimulating agent (ESA) therapy
214580340|NCT06774001|PROCEDURE|Appendicectomy|Both open and minimally invasive (laparoscopic and robotic) interventions are eligible for inclusion. Laparoscopic and robotic converted to open cases are also eligible.
214580341|NCT06900894|BIOLOGICAL|Platelet-Rich Fibrin (PRF)|PRF was prepared using a centrifugation protocol and applied to the extraction socket.
214580342|NCT06900894|DEVICE|Kinesio Taping|Kinesio Tape was applied postoperatively to the masseter and submandibular region.
214580343|NCT06900894|OTHER|Standard Postoperative Care|Patients in the control group received standard postoperative care.
214580344|NCT03227406|BEHAVIORAL|Sleep deprivation|Subjects are kept awake all night.
214580345|NCT03227406|BEHAVIORAL|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
214580346|NCT02390700|BIOLOGICAL|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
214580347|NCT02691533|DRUG|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
214580348|NCT02691533|DRUG|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
214580349|NCT02691533|DRUG|No Lipid Emulsion/Placebo|
214580350|NCT05939856|OTHER|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
214580351|NCT05939856|OTHER|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
214580352|NCT06906068|DIETARY_SUPPLEMENT|Three strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®|A probiotic beverage (98 g) at dose of 50.10\^9 CFU, taken once daily for 14 weeks.
214580353|NCT06906068|OTHER|Placebo|Non fermented beverage (98 g) with no probiotic strains, taken once daily for 14 weeks.
214580354|NCT06907459|OTHER|upper Track of Deep Front Facial Line realese|The MFR techniques were applied to the designated regions, with soft, steady pressure lasting 90 to 120 seconds postural correction exercises The upper track of deep front facial line release procedures were applied. Hyoid mobilization; Larynx mobilization; Sternal oscillations; and Barral's Transversus Thoracis mobilization. The thoracic inlet releasing ; intrathoracic fascia elongation; scalene releasing and diaphragm relaxation
214580355|NCT06907459|OTHER|Myofascial Release With IASTM|The instrument is designed to mobilize soft tissues. Facilitation approaches were employed to break apart adhesions. Emollient Gel/Lubrication Gel (Hawk Grips product) was also used to lubricate the skin and allow the instrument to move more easily. The tool has two sides: one for therapy and the other for holding plus postural correction exercises
214580356|NCT06907459|OTHER|supervised corrective exercises|The exercise program included cervical stabilization exercises performed in 3 sets of 10 repetitions with a 10-second maintenance, scapular stabilization exercises plus stretching of cervical muscles.
214634246|NCT07143526|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCT-A)|Two Optical Coherence Tomography Angiography swept source devices are compared for the detection of large pigment epithelium detachments in age related macular degeneration. The sensitivity of the devices is compared in both the automatic segmentation done by the device and the manual segmentation done by a retina specialist.
214634247|NCT07144735|DRUG|Allogeneic γδ T (ABOUT) cells|Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.
214634248|NCT07143071|PROCEDURE|Acute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in acute phase (2-14days)
214580357|NCT06906328|BEHAVIORAL|Cognitive remediation program, with the PRESCO® software|"The program runs for 12 weeks, with two sessions per week, one with a neuropsychologist. In the first 4 weeks, the patient will have weekly sessions at the center and complete the other session at home using the app provided for the study. For the next 8 weeks, sessions with the neuropsychologist will be every other week, with the other session at home. The neuropsychologist will track progress through the software history and follow up by phone if needed.~The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron)."
214580358|NCT06906328|BEHAVIORAL|Control program, with the AUDITICO® software|"Control program, with the same functional characteristics but without the targeted cognitive functions.~For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users."
214580359|NCT06906952|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
214580360|NCT06906952|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
214580361|NCT04198753|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
214580362|NCT04198753|DEVICE|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
214580363|NCT04198753|DIAGNOSTIC_TEST|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
214580364|NCT06905899|OTHER|audiobook app|audio book listening
214580365|NCT06906653|BEHAVIORAL|Augmented Initial Type 2 Diabetes Care|"The intervention will include 4 components: 1) Making primary care providers (PCPs) aware that the patient has been selected to receive Augmented Initial Type 2 Diabetes (T2D) Care, 2) encouraging early care manager outreach to establish care, ensure prescribing of appropriate medications, and support medication adherence, 3) a one-on-one virtual health educator visit to reinforce self-management education and ensure set-up of remote glucose monitoring or continuous glucose monitoring (if eligible), and 4) a one-on-one virtual nutrition visit to provide individualized counseling."
214580366|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
214580367|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
214580368|NCT03754114|OTHER|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
214634249|NCT07143071|PROCEDURE|Subacute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in subacute phase (≥14days)
214634250|NCT07143669|OTHER|Screening|After providing informed consent and relevant medical history data, samples will be collected from participants with suspected clonal mast cell disease.
214580369|NCT03754114|OTHER|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
214580370|NCT06017934|BEHAVIORAL|Volunteer-led physical activity|Participants will be assessed by the therapy team who will prescribe tailored activity and then liaise with the mobility volunteers, who will deliver the intervention. Participants who can mobilise independently will be encouraged to perform walking exercises, progressing their walking distance over set markers in the hospital (e.g., to the end of the bed and back; to the doorway and back; to the toilet and back). Participants who require assistance in mobility will perform bed (e.g., hip abduction, static quads), or chair exercises (e.g., ankle pumps, knee extension, arm raise), and will be progressed to performing walking exercises when their physical function improves. Volunteers will check with nursing staff that participants are safe to exercise before each activity session. Participants will receive the mobility sessions twice daily, starting upon recruitment and continuing until the day of discharge from hospital.
214580371|NCT04954404|DEVICE|transcatheter mitral valve repair/transcatheter mitral valve replacement|transcatheter mitral valve repair/transcatheter mitral valve replacement
214580372|NCT03694275|DRUG|Soticlestat|TAK-935 tablets
214580373|NCT01274845|OTHER|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
214580374|NCT05077085|DRUG|Bezlotoxumab|single intravenous infusion of bezlotoxumab 10 mg/kg
214580375|NCT05077085|PROCEDURE|Fecal Microbiota Transplantation (FMT)|single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
214580376|NCT05077085|DRUG|Vancomycin oral|14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
214580377|NCT06444412|PROCEDURE|Computed Tomography|Undergo PET/CT
214580378|NCT06444412|OTHER|Electronic Health Record Review|Ancillary studies
214580379|NCT06444412|DRUG|Ga 68 PSMA-11|Contrast dye given IV
214580380|NCT06444412|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214580381|NCT02498431|PROCEDURE|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
214580382|NCT02498431|PROCEDURE|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
214580383|NCT02498431|DEVICE|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
214580384|NCT02708654|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
214580385|NCT02708654|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
214580386|NCT02708654|BEHAVIORAL|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
214580387|NCT02708654|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
214580388|NCT05353946|DEVICE|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
214580389|NCT02417402|OTHER|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
214580390|NCT02417402|OTHER|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
214580391|NCT02772419|DRUG|benralizumab|SC administration
214580392|NCT02772419|DRUG|benralizumab|SC administration
214580393|NCT02772419|DRUG|Placebo|SC administration
214580394|NCT02956785|DRUG|10 mg Dinoprostone; CTS, UK|
214580395|NCT02956785|DRUG|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
214580396|NCT02956785|DRUG|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
214580397|NCT04714931|DIAGNOSTIC_TEST|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
214580398|NCT01924728|DEVICE|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
214580399|NCT01924728|DEVICE|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
214580400|NCT03963531|OTHER|chemotherapy, surgery, radiotherapy, interventional radiology.|
214580401|NCT03542370|OTHER|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
214580402|NCT00136539|DRUG|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
214580403|NCT00136539|DRUG|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
214580404|NCT00136539|DRUG|Adriamycin|Given every three weeks for 12 weeks after surgery.
214580405|NCT00136539|DRUG|Cytoxan|Given every three weeks for 12 weeks after surgery.
214580406|NCT03541174|DRUG|Aprocitentan 12.5 mg|Tablet, oral use
214580407|NCT03541174|DRUG|Aprocitentan 25 mg|Tablet, oral use
214580408|NCT03541174|DRUG|Placebo|Matching placebo tablet
214580409|NCT03618121|DEVICE|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
214580410|NCT03618121|DEVICE|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax \& Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
214580411|NCT03618121|BEHAVIORAL|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
214580412|NCT03618121|BEHAVIORAL|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
214580413|NCT01574391|DEVICE|Epidrum|Epidrum is used
214580414|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
214580415|NCT00000145|DIETARY_SUPPLEMENT|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
214580416|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
214580417|NCT04183309|OTHER|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
214580418|NCT00472160|PROCEDURE|Non Invasive Ventilation|Non Invasive Ventilation
214580419|NCT04928430|DRUG|XAV-19|150 mg of XAV-19 single IV perfusion
214580420|NCT04928430|DRUG|Placebo|Single IV infusion
214580421|NCT02775825|OTHER|survey|
214580422|NCT05559008|DRUG|Azacitidine Injection|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
214580423|NCT05559008|DRUG|Dasatinib|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
214580424|NCT05559008|DRUG|Linperlisib|Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
214580425|NCT05559008|DRUG|Tucidinostat|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
214580426|NCT05559008|DRUG|SHR2554|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
214580427|NCT05559008|DRUG|Camrelizumab|Camrelizumab and Apatinib will be administered in T3.2 subtypes
214580428|NCT05559008|DRUG|Apatinib|Camrelizumab and Apatinib will be administered in T3.2 subtypes
214580429|NCT02002650|DRUG|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
214580430|NCT02002650|DRUG|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
214580431|NCT01978522|OTHER|Randomisation of questionnaire receipt.|"1. The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~2. Self-completion questionnaire handed to participants immediately after completing the CAPI."
214580432|NCT02217332|DRUG|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
214580433|NCT04719325|OTHER|Herbert screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
214580434|NCT04719325|OTHER|Lag screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
214580435|NCT04058366|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
214580436|NCT04058366|DRUG|IVA|Tablet for oral administration.
214580437|NCT00330486|DRUG|Acamprosate|
214580438|NCT03769662|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
214580439|NCT05971459|BEHAVIORAL|Improvised Active Music Therapy|During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
214580440|NCT04764643|DRUG|N-acetylcysteine solution|use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
214580441|NCT04764643|DRUG|sodium thiosulfate solution|use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
214580442|NCT05916339|DRUG|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
214580443|NCT05916339|DRUG|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
214580444|NCT03437681|BEHAVIORAL|Insufficient sleep|Four days of insufficient sleep
214580445|NCT01029951|PROCEDURE|manipulation|
214580446|NCT01029951|PROCEDURE|Mobilisation|
214580447|NCT01029951|DEVICE|Activator instrument|
214580448|NCT02706613|BEHAVIORAL|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
214580449|NCT02706613|BEHAVIORAL|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
214580450|NCT00817973|DIETARY_SUPPLEMENT|Casein|
214580451|NCT00817973|DIETARY_SUPPLEMENT|Whey|
214580452|NCT00817973|DIETARY_SUPPLEMENT|Cod|
214580453|NCT00817973|DIETARY_SUPPLEMENT|Gluten|
214580454|NCT05079451|DRUG|3BNC117-LS|3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
214580455|NCT05079451|DRUG|10-1074-LS|10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
214580456|NCT02751411|DEVICE|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
214580457|NCT02751411|DRUG|Macrogol 4000|Stool softener
214580458|NCT05596058|OTHER|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
214580459|NCT05596058|OTHER|active exercise|Physical activity and motor task only
214580460|NCT05596058|OTHER|cognitive task only|cognitive exercise in executive functions
214580461|NCT00534144|DRUG|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
214580462|NCT00534144|DRUG|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
214580463|NCT05834439|OTHER|flower printing activities for the elderly|Experimental group
214580464|NCT05834439|OTHER|Routine activities in nursing home|Control group
214580465|NCT04929405|BEHAVIORAL|ADAPT|ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
214580466|NCT04476368|OTHER|weekly yoga classes|Weekly 90 min pregnancy-adapted yoga classes lead by certified yoga instructors.
214580467|NCT04476368|OTHER|walk|20-30 min easy walking
214580468|NCT03056027|DIAGNOSTIC_TEST|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
214580469|NCT00641901|BEHAVIORAL|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
214580470|NCT01074918|DRUG|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
214580471|NCT01074918|DRUG|Potassium Chloride|Potassium Chloride
214580472|NCT04782401|OTHER|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
214580473|NCT04782401|DEVICE|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
214580474|NCT02512367|OTHER|Dental care education program|Dental care education program
214580475|NCT02512367|OTHER|Surveillance|Surveillance
214580476|NCT00098332|DRUG|forodesine hydrochloride|
214634251|NCT07142928|OTHER|light-blocking lenses|The eye with higher hyperopia will be fitted with light-blocking lenses for full-time wear, while the fellow eye with lower hyperopia will be fitted with conventional single-vision lenses for full-time wear, over 12 months
214634252|NCT07142928|OTHER|single-vision lenses|Both eyes of the subjects will be fitted with conventional single-vision lenses for full-time wear over 12 months.
214634253|NCT07143279|DRUG|Sustanon 250|Sustanon 250® (1 ml, IM) every 10 days
214634254|NCT07144189|DIAGNOSTIC_TEST|AI diagnostic test for severe low-gradient aortic stenosis|All participants will undergo standard transthoracic echocardiography performed for clinical indications. Echocardiographic images will be analyzed both by experienced physicians and by the investigational AI model. Additional diagnostic tests (such as cardiac CT, low-dose dobutamine stress echocardiography or transesophageal echocardiography) may be performed if clinically indicated, according to current guideline recommendations. The AI-derived results will not influence clinical decision-making.
214580477|NCT01446757|PROCEDURE|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
214580478|NCT01446757|PROCEDURE|control group|No intervention
214580479|NCT00347607|BEHAVIORAL|community surveillance and re-treatment|
214580480|NCT05233332|DRUG|HL-085|12mg BID HL-085
214580481|NCT05233332|DRUG|Vemurafenib|720mg BID Vemurafenib
214580482|NCT00006230|DRUG|rubitecan|
214580483|NCT02984202|DEVICE|auditory midbrain implant (AMI)|
214580484|NCT05077644|DEVICE|Stella (TM) Mobile Application|Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
214580485|NCT00603304|DRUG|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
214580486|NCT00603304|DRUG|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
214580487|NCT00603304|DRUG|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
214580488|NCT00603304|DRUG|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
214580489|NCT00603304|DRUG|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
214580490|NCT00603304|DRUG|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
214580491|NCT06248099|DRUG|Nebivolol-Test product|Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India
214580492|NCT06248099|DRUG|Nebivolol-Reference product|Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
214580493|NCT00682747|DRUG|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
214580494|NCT06471777|PROCEDURE|Fluid removal|Fluid removal during kidney replacement therapy
214580495|NCT01483547|DEVICE|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
214580496|NCT02253901|DRUG|BILR 355 BS|
214580497|NCT02253901|DRUG|Ritonavir|
214580498|NCT02253901|DRUG|TRUVADA|
214580499|NCT01859273|BEHAVIORAL|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
214580500|NCT03805347|DRUG|Helminthostachys zeylanica(L.)Hook|Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
214580501|NCT03805347|DRUG|Starch|Starch in capsule, 1gm/time, 3 times daily
214580502|NCT01295762|OTHER|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
214580503|NCT00667771|DRUG|Naltrexone|
214580504|NCT03361280|DRUG|Beta blocker|Beta blockers are administered as described in arms.
214580505|NCT01085266|DRUG|Dimebon (latrepirdine)|
214580506|NCT03546322|OTHER|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
214580507|NCT01886612|DEVICE|Duo-STIM neuromuscular electrical stimulator|
214580508|NCT01886612|DEVICE|AV Impulse System Model 6000|
214580509|NCT03138928|DEVICE|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
214580510|NCT00633724|BIOLOGICAL|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
214580511|NCT02480153|BIOLOGICAL|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
214580512|NCT02480153|BIOLOGICAL|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
214580513|NCT05272956|PROCEDURE|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
214580514|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
214580515|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
214580516|NCT01435330|DRUG|BVS857|
214580517|NCT01435330|DRUG|Placebo|
214580518|NCT00512317|DRUG|ganaxolone|liquid suspension dosed tid
214580519|NCT04729413|BEHAVIORAL|Couples Counseling|Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
214580520|NCT04729413|OTHER|Enhanced Standard of Care|Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
214580521|NCT02619149|DRUG|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
214580522|NCT02619149|DRUG|Saline solution|Saline iv as placebo control
214580523|NCT05149911|BEHAVIORAL|Life Coaching|Sessions with a professional life coach.
214580524|NCT01717690|DRUG|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
214580525|NCT00159133|DRUG|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
214580526|NCT01864057|DRUG|thiamine hydrochloride 100 mg|
214580527|NCT05406830|DEVICE|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
214580528|NCT05406830|BEHAVIORAL|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
214580529|NCT05406830|DEVICE|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
214580530|NCT04647045|DIETARY_SUPPLEMENT|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
214580531|NCT00239343|DRUG|gefitinib|
214580532|NCT04433585|DRUG|LY3471851|Administered SC
214580533|NCT04433585|DRUG|Placebo|Administered SC
214580534|NCT01633918|BEHAVIORAL|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
214580535|NCT01633918|BEHAVIORAL|Usual health education|Usual health education lessons
214580536|NCT01039623|BIOLOGICAL|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
214634255|NCT07144761|DEVICE|Ziplyft|Ziplyft™ is a Class 1, 510(k) Exempt device for removing excess unwanted eyelid skin using a novel surgical device called Ziplyft™.
214634256|NCT07144280|DRUG|PF-08046054|"Antibody Drug Conjugate~Participants will receive PF-08046054, administered as an IV infusion."
214634257|NCT07144280|DRUG|Docetaxel monotherapy|Participants will receive Docetaxel, administered as an IV infusion.
214634258|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
214580537|NCT00852033|BEHAVIORAL|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
214580538|NCT00852033|BEHAVIORAL|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
214580539|NCT00852033|BEHAVIORAL|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
214580540|NCT00852033|OTHER|Assessment only|No intervention, assessment only.
214580541|NCT00409266|DEVICE|Computer assisted navigation|
214580542|NCT05680623|DIAGNOSTIC_TEST|PPAP diagnosis|"Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.~A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications."
214580543|NCT00531739|OTHER|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
214580544|NCT04962932|BEHAVIORAL|Internet-deliviered exposure-based CBT|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
214580545|NCT04962932|BEHAVIORAL|Internet-delivered stress management treatment|The intervention last for 10 weeks and include: Internet-SMT include life-style advice (e.g., exercise, sleep advice), relaxation and problem-solving skills to reduce stress. Patients are offered regular online contact with a psychologist with the same frequency and intensity as in the CBT arm.
214580546|NCT01739842|DIETARY_SUPPLEMENT|Kudzu extract|
214580547|NCT02265627|DRUG|BIIL 284 BS|
214580548|NCT03927573|DRUG|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
214580549|NCT04413487|OTHER|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
214580550|NCT03455621|PROCEDURE|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
214580551|NCT03266705|DRUG|tafamidis|bioequivalence study
214580552|NCT00252837|DRUG|Tesaglitazar|
214580553|NCT00252837|BEHAVIORAL|Dietary and Lifestyle counseling|
214580554|NCT02510898|BEHAVIORAL|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
214580555|NCT00626132|DIETARY_SUPPLEMENT|Eucommia|two capsules three times a day orally for 2 weeks
214580556|NCT00875927|OTHER|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
214580557|NCT00875927|OTHER|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
214580558|NCT00875927|OTHER|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
214580559|NCT00875927|OTHER|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
214580560|NCT00875927|OTHER|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
214580561|NCT00975767|DRUG|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
214580562|NCT00975767|DRUG|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
214580563|NCT02163564|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
214580564|NCT02630693|DRUG|Palbociclib 100mg|100mg PO daily
214580565|NCT02630693|DRUG|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
214580566|NCT02630693|DRUG|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
214580567|NCT01175447|DRUG|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
214580568|NCT02004470|PROCEDURE|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
214580569|NCT06352476|BEHAVIORAL|Sleep Hygiene Training|The effect of sleep hygiene education in a pre-test quasi-experimental study.
214580570|NCT02487732|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
214580571|NCT02487732|DRUG|Prasugrel|Prasugrel 10mg once daily for 5 weeks
214580572|NCT03312283|DRUG|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
214580573|NCT03312283|DRUG|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
214580574|NCT03711331|OTHER|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
214580575|NCT03711331|OTHER|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
214580576|NCT00057629|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
214710190|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
214580577|NCT00057629|BEHAVIORAL|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
214580578|NCT00057629|BEHAVIORAL|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
214580579|NCT02871531|PROCEDURE|Pneumatic retinopexy|
214580580|NCT02871531|PROCEDURE|Vitrectomy|
214580581|NCT00901706|OTHER|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
214580582|NCT00901706|OTHER|APS usual care|APS usual care consists of social, medical, and legal assistance.
214580583|NCT04719624|DEVICE|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
214580584|NCT04719624|DEVICE|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
214710191|NCT01152489|DEVICE|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
214580585|NCT04719624|DEVICE|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
214580586|NCT04719624|PROCEDURE|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
214580587|NCT04719624|DEVICE|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
214580588|NCT03753659|DRUG|Pembrolizumab|IV infusion
214580589|NCT03753659|PROCEDURE|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
214580590|NCT03753659|PROCEDURE|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
214580591|NCT03753659|RADIATION|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
214580592|NCT03753659|DRUG|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
214580593|NCT04579822|BIOLOGICAL|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
214580594|NCT00993668|OTHER|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
214580595|NCT00993668|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
214580596|NCT06196632|DRUG|Peginterferon-α; Nucleoside analogs|Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
214580597|NCT04955444|OTHER|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
214710192|NCT01152489|DEVICE|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
214580598|NCT00208780|DRUG|Tetrahydrobiopterin|
214580599|NCT00208780|DRUG|Tetrahydrobiopterin|
214580600|NCT00999674|OTHER|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
214580601|NCT04894760|DIAGNOSTIC_TEST|Rapid Antigen Test (PanBio Ag test)|Rapid Antigen Test (PanBio Ag test)
214580602|NCT06526013|OTHER|Cholesterol self-measurement|Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
214580603|NCT02351518|OTHER|No intervention|There will be no interventions in this study
214580604|NCT02136160|BEHAVIORAL|attitude change, behavioral change|
214580605|NCT02136160|BEHAVIORAL|prevention program|
214580606|NCT03606668|DEVICE|HTC Vive Virtual Reality (VR) system|VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
214580607|NCT01452321|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
214580608|NCT00160043|DRUG|SH T00268C|1250 mg experimental drug od
214580609|NCT00160043|DRUG|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
214580610|NCT00952120|DEVICE|GSUC|Gauze-based wall suction negative pressure wound therapy
214580611|NCT00952120|DEVICE|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
214580612|NCT01639781|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
214580613|NCT01639781|DIETARY_SUPPLEMENT|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
214580614|NCT06261580|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, and FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
214580615|NCT06261580|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
214580616|NCT02238353|DRUG|azelastine + fluticasone|
214580617|NCT02238353|DRUG|Placebo|
214580618|NCT03710031|OTHER|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
214580619|NCT00730457|BIOLOGICAL|VAX125|Single intramuscular dose
214580620|NCT01770106|DRUG|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
214580621|NCT01770106|DRUG|Alendronate|Alendronate 70mg once weekly
214580622|NCT00080132|DRUG|implitapide|
214580623|NCT01944813|BEHAVIORAL|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
214580624|NCT04641494|DIETARY_SUPPLEMENT|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
214580625|NCT04641494|DIETARY_SUPPLEMENT|High oleic acid safflower oil capsules|
214580626|NCT02677454|DEVICE|Flash Glucose Monitor|
214580627|NCT02541123|OTHER|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
214580628|NCT04227964|DEVICE|Enamel matrix derivative, bone replacement graft, barrier membrane|
214580629|NCT04227964|PROCEDURE|Tooth extraction and replacement|
214580630|NCT03422523|DRUG|Atezolizumab|Intravenous drip
214580631|NCT03422523|DRUG|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
214580632|NCT03422523|DRUG|Gemcitabine 1000 mg|intravenous drip
214580633|NCT03422523|DRUG|Oxaliplatin 100 MG|intravenous drip
214580634|NCT04943367|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
214580635|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
214580636|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
214580637|NCT01444573|DEVICE|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
214580638|NCT00470340|DRUG|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
214580639|NCT00002448|DRUG|Ritonavir|
214580640|NCT00002448|DRUG|Efavirenz|
214580641|NCT00002448|DRUG|Saquinavir|
214710193|NCT06159348|DIAGNOSTIC_TEST|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
214710194|NCT06159348|DIAGNOSTIC_TEST|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
214580642|NCT02426346|BEHAVIORAL|Behavioral weight control|Prescription of diet \& physical activity and behavioral strategies for weight control
214580643|NCT02426346|BEHAVIORAL|Group-based physical activity|Teens exercise for 60 minutes with their group
214580644|NCT02426346|BEHAVIORAL|Group-based incentives|Adolescents earn reinforcements within group
214580645|NCT02426346|BEHAVIORAL|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
214580646|NCT03660800|DRUG|CTAP101 Capsules|Calcifediol Extended-Release Capsules
214580647|NCT01942265|DRUG|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
214580648|NCT01942265|DRUG|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
214580649|NCT01942265|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
214580650|NCT02057523|DRUG|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
214580651|NCT03098420|DRUG|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
214580652|NCT03098420|DRUG|4mg Dexamethasone|1 mL (4mg) of dexamethasone
214580653|NCT03098420|DRUG|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
214580654|NCT03098420|DRUG|Morphine|
214580655|NCT03098420|DRUG|Bupivacaine Hydrochloride|
214580656|NCT03098420|DRUG|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
214580657|NCT03098420|DRUG|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
214580658|NCT05253677|DEVICE|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
214580659|NCT05253677|DEVICE|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
214580660|NCT02630888|DRUG|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
214580661|NCT02630888|DRUG|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
214580662|NCT04355910|BEHAVIORAL|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
214580663|NCT05621603|BEHAVIORAL|Training|"The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session"
214580664|NCT02835833|DRUG|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
214580665|NCT02835833|DRUG|Bevacizumab|Bevacizumab will be given at 15 mg/kg
214580666|NCT00558337|DRUG|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
214580667|NCT00064610|DRUG|VELCADE TM (bortezomib) for Injection|
214580668|NCT02313233|DIETARY_SUPPLEMENT|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
214580669|NCT02313233|DIETARY_SUPPLEMENT|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
214580670|NCT03445923|OTHER|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
214580671|NCT03018054|DRUG|E6007|once daily administration
214580672|NCT03018054|DRUG|Placebo|once daily administration
214710195|NCT05511831|DRUG|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
214710196|NCT05511831|DRUG|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
214710197|NCT00603213|PROCEDURE|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
214634259|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
214634260|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
214580673|NCT01859286|OTHER|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
214580674|NCT06032936|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
214580675|NCT06032936|DRUG|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
214710198|NCT05566821|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
214710199|NCT05485259|DIETARY_SUPPLEMENT|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
214710200|NCT05485259|OTHER|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
214580676|NCT00944073|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
214710201|NCT00003091|BIOLOGICAL|aldesleukin|
214710202|NCT00003091|BIOLOGICAL|recombinant interferon alfa|
214710203|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
214710204|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
214710205|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
214710206|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
214710207|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
214710208|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
214710209|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection
214580677|NCT05345808|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
214710210|NCT04929756|BEHAVIORAL|Visual Feedback|Gaze-contingent visual feedback
214580678|NCT04316351|DRUG|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
214580679|NCT01965353|DRUG|Panobinostat|\- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
214580680|NCT01965353|DRUG|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
214580681|NCT01965353|DRUG|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
214580682|NCT01965353|DRUG|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
214580683|NCT02318953|DEVICE|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
214580684|NCT02318953|OTHER|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
214580685|NCT04130763|BIOLOGICAL|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
214580686|NCT02275975|DRUG|K-877|
214580687|NCT02275975|DRUG|Fluconazole|
214580688|NCT00809744|DRUG|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
214580689|NCT00830089|DRUG|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
214580690|NCT04976244|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata
214580691|NCT02712086|OTHER|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
214580692|NCT01073787|DRUG|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
214580693|NCT03078777|DRUG|Fexofenadine|Fexofenadine will be administered to patients.
214580694|NCT00810433|PROCEDURE|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
214580695|NCT05347251|OTHER|Cervicothoracic mobility program|"Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed"
214580696|NCT05347251|OTHER|Conventional Treatment|"It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed."
214580697|NCT01180205|DRUG|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
214580698|NCT01180205|DRUG|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
214580699|NCT01180205|DRUG|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
214580700|NCT01180205|DRUG|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
214580701|NCT00219102|DRUG|aliskiren|
214580702|NCT02441231|DRUG|Visbiome|Visbiome probiotic
214580703|NCT02441231|OTHER|Placebo|Placebo
214580704|NCT02774239|DRUG|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
214580705|NCT00564889|DRUG|cyclophosphamide|300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
214580706|NCT00564889|DRUG|dexamethasone|40 mg weekly taken orally
214580707|NCT00564889|DRUG|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
214580708|NCT05365360|DEVICE|LaserCap SD|LaserCap SD
214580709|NCT05365360|DEVICE|Sham LaserCap|Sham LaserCap
214580710|NCT05365360|DEVICE|LaserCap HD+|LaserCap HD+
214580711|NCT01290653|OTHER|Dry needling|Deep dry needling until achieving twitch response of the muscle
214580712|NCT01290653|OTHER|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
214580713|NCT01290653|OTHER|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
214580714|NCT04595318|DRUG|Standard clinical care first, followed by standard clinical care and varenicline|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
214580715|NCT04595318|DRUG|Standard clinical care and varenicline first, followed by standard clinical care|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
214580716|NCT02907515|DEVICE|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
214580717|NCT02907515|DEVICE|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
214580718|NCT01632982|BEHAVIORAL|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
214580719|NCT01632982|BEHAVIORAL|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
214580720|NCT01632982|BEHAVIORAL|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
214580721|NCT00054054|DRUG|cisplatin|
214580722|NCT00054054|DRUG|docetaxel|
214580723|NCT00054054|DRUG|fluorouracil|
214580724|NCT00054054|RADIATION|radiation therapy|
214580725|NCT02183844|BEHAVIORAL|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
214580726|NCT05688345|DRUG|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
214580727|NCT05688345|DRUG|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
214580728|NCT05688345|DRUG|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
214580729|NCT04660591|DEVICE|femoral stem in hip arthroplasty|using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
214580730|NCT02684448|PROCEDURE|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
214580731|NCT01288521|DRUG|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
214580732|NCT01288521|DRUG|Tacrolimus alone, Then Tacrolimus + Ketoconazole|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
214580733|NCT02825173|DEVICE|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
214580734|NCT02084173|BEHAVIORAL|MET + CRA|
214580735|NCT00580645|DRUG|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
214580736|NCT00580645|DRUG|placebo|placebo
214580737|NCT04374851|DEVICE|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
214580738|NCT04374851|DEVICE|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
214580739|NCT03390218|BEHAVIORAL|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
214580740|NCT03390218|BEHAVIORAL|Treatment as usual|Individual and group therapy, generic in nature
214580741|NCT03180177|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.
214580742|NCT03180177|PROCEDURE|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
214580743|NCT03180177|DRUG|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
214580744|NCT03180177|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
214634261|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
214634262|NCT04306588|OTHER|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
214634263|NCT01777802|RADIATION|SBRT|
214634264|NCT01777802|RADIATION|IMRT|
214580745|NCT04326595|PROCEDURE|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
214580746|NCT04738227|RADIATION|Low-Level Laser Therapy|Low level laser will be applied and post laser results will be seen to assess any improvements.
214580747|NCT00682890|DRUG|placebo|placebo birth control pill daily
214580748|NCT00682890|DRUG|metformin|2000 mg per day for 3 months daily birth control pill
214580749|NCT03545503|DRUG|Etomidate|Etomidate will be administered as the sedative for RSI on even days
214580750|NCT03545503|DRUG|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
214580751|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
214580752|NCT01344954|DRUG|Rivaroxaban|Administered orally as a capsule once a day for 35 days
214580753|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
214580754|NCT01046773|DRUG|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
214580755|NCT01046773|DRUG|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
214580756|NCT03801122|DRUG|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
214634265|NCT01777802|RADIATION|Brachytherapy|
214634266|NCT06829459|DRUG|Glumetinib|Patients will be administered glumetinib 300 mg/dose once daily once daily under fasting conditions in each 21-day treatment cycle.
214634267|NCT06829459|DRUG|Osimertinib mesylate|Patients will be administered osimertinib mesylate 80 mg/dose once daily under fasting conditions in each 21-day treatment cycle.
214634268|NCT06829459|DRUG|Pemetrexed|Patients will be administered pemetrexed 500 mg/m\^2 via intravenous infusion on the first day of each 3-week cycle.
214634269|NCT06829459|DRUG|Cisplatin or carboplatin|Patients will be administered cisplatin 75 mg/m\^2 or carboplatin AUC=5 via intravenous infusion on the first day of each 3-week cycle
214634270|NCT04909125|RADIATION|Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy|The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes
214634271|NCT03983850|DRUG|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
214580757|NCT05347368|OTHER|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
214580758|NCT05347368|OTHER|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
214580759|NCT06154109|DRUG|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
214580760|NCT06154109|DRUG|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
214580761|NCT06154109|DRUG|Placebo|The placebo does not contain any active pharmaceutical ingredients .
214710211|NCT00676793|DRUG|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
214710212|NCT07007780|DRUG|Sacituzumab Tirumotecan|Sacituzumab Tirumotecan monotherapy before surgery at a dose of 5mg/kg, with a dosing schedule of once every 2 weeks for a total of 12 weeks
214580762|NCT00212420|PROCEDURE|parenteral nutrition; enteral nutrition|
214580763|NCT03786523|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
214580764|NCT03786523|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
214580765|NCT03028220|DEVICE|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
214580766|NCT03028220|DEVICE|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
214580767|NCT01214265|DEVICE|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
214710213|NCT05092880|DEVICE|radioembolization|holmium-166 microspheres
214580768|NCT04156854|DIAGNOSTIC_TEST|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
214580769|NCT05636423|OTHER|Survey|Online survey via a questionnaire composed of 28 questions.
214580770|NCT05619029|RADIATION|X-ray|Chest radiographs
214580771|NCT00802698|DEVICE|Transcorneal electric stimulation|central artery occlusion
214580772|NCT00802698|DEVICE|Transcorneal stimulation|new waveform
214580773|NCT00802698|DEVICE|transcorneal electric stimulation|Novel waveform central artery occlusion
214580774|NCT00836420|PROCEDURE|no intervention|the value of the clinical use of microdialysis monitoring of the brain
214580775|NCT02317133|BIOLOGICAL|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
214580776|NCT02317133|BIOLOGICAL|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
214580777|NCT03561831|DRUG|Propofol|propofol based anesthesia
214580778|NCT03561831|DRUG|Sevoflurane|sevoflurane based anesthesia
214710214|NCT05092880|DRUG|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
214710215|NCT03479216|DRUG|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
214710216|NCT03479216|DRUG|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
214580779|NCT03896204|BEHAVIORAL|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
214580780|NCT03896204|BEHAVIORAL|joint protection technique training|Training will be given to individuals about joint protection technique
214580781|NCT00950794|DRUG|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
214580782|NCT00950794|DRUG|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
214710217|NCT00124241|DRUG|telbivudine|
214710218|NCT00124241|DRUG|lamivudine|
214710219|NCT03276013|DRUG|Pembrolizumab|pembrolizumab in combination with doxorubicin
214580783|NCT01777451|OTHER|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
214580784|NCT02389920|DRUG|Nilotinib|
214580785|NCT05319301|DIETARY_SUPPLEMENT|Melatonin|A single dose of melatonin (1.9 mg)
214580786|NCT01478529|DRUG|mirabegron OCAS|oral administration
214710220|NCT06868290|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
214710221|NCT06868290|OTHER|Active Comparator|Active comparator option as per protocol
214580787|NCT01478529|DRUG|mirabegron|iv administration
214580788|NCT00090077|DRUG|GW695634|
214580789|NCT02192125|DEVICE|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database"
214580790|NCT02884908|DRUG|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
214580791|NCT02884908|OTHER|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
214580792|NCT05252650|BEHAVIORAL|pain|postoperative pain
214580793|NCT04612959|OTHER|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
214710222|NCT06868290|DRUG|Glucocorticoids|Concomitant glucocorticoids as per protocol
214710223|NCT02800720|BEHAVIORAL|Meditation Awareness Training|8 Week Meditation Intervention
214710224|NCT02800720|BEHAVIORAL|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
214580794|NCT03704246|DRUG|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
214580795|NCT01873066|DEVICE|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
214580796|NCT01873066|DEVICE|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
214580797|NCT05114239|DRUG|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
214580798|NCT05114239|OTHER|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
214580799|NCT05839015|BEHAVIORAL|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
214580800|NCT02850120|PROCEDURE|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
214580801|NCT02850120|PROCEDURE|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
214580802|NCT02850120|PROCEDURE|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
214580803|NCT05352568|BEHAVIORAL|Cognitive Training|Computer-Based Cognitive Training from BrainHQ (Posit Science)
214580804|NCT02684851|DRUG|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
214580805|NCT02684851|DRUG|Placebo|Placebo
214580806|NCT00003025|BIOLOGICAL|vitespen|
214580807|NCT00174512|DRUG|GTN|
214580808|NCT00174512|DRUG|Moxifloxacin|
214634272|NCT03983850|DRUG|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
214580809|NCT04705636|DEVICE|"Connected device named Leo from Ludocare society"|"Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device."
214580810|NCT04709315|DRUG|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
214580811|NCT04709315|DRUG|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
214580812|NCT01605019|DEVICE|CoSeal|3 - 8mls of Coseal
214580813|NCT01605019|DEVICE|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
214580814|NCT02395029|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
214580815|NCT04629573|PROCEDURE|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
214634273|NCT03983850|DRUG|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
214580816|NCT04629573|PROCEDURE|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
214710225|NCT06526806|OTHER|Kahoot game strategy|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course."
214580817|NCT00862719|DRUG|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
214580818|NCT05885243|DEVICE|ESWT|will be given once a week, total 5 sessions ofESWT+ home exercises program
214580819|NCT05885243|DEVICE|customized insoles|Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
214580820|NCT05885243|COMBINATION_PRODUCT|combined ESWT and custtomized insoles|Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
214580821|NCT00457652|DRUG|Rosuvastatin|7 day treatment rosuvastatin 20mg
214580822|NCT05766085|DIAGNOSTIC_TEST|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
214580823|NCT00423631|BEHAVIORAL|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
214580824|NCT00423631|BEHAVIORAL|Standard Care|Standard care delivered by the primary care provider.
214710226|NCT00798577|DRUG|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
214710227|NCT00798577|DRUG|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
214710228|NCT00082043|DRUG|Dutasteride|
214710229|NCT00082043|DRUG|Placebo oral capsule|
214580825|NCT04805229|OTHER|Retrospective analysis of opioid use after surgery|Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
214580826|NCT00470366|BIOLOGICAL|pegfilgrastim|
214580827|NCT00470366|DRUG|cisplatin|
214580828|NCT00470366|DRUG|ifosfamide|
214580829|NCT00470366|DRUG|paclitaxel|
214580830|NCT00602563|BEHAVIORAL|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
214580831|NCT00602563|BEHAVIORAL|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
214580832|NCT00602563|BEHAVIORAL|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
214580833|NCT00602563|BEHAVIORAL|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
214580834|NCT04493502|DRUG|Placebo|Administered IV
214580835|NCT04493502|DRUG|LY3041658|Administered IV
214580836|NCT02379104|DEVICE|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
214580837|NCT00377923|DRUG|Progesterone|
214580838|NCT02108990|DRUG|Acetaminophen|
214580839|NCT00493298|DRUG|Tysabri|According to the local prescribing information
214580840|NCT04184739|OTHER|My Braces App|An App designed to support patients undertaking orthodontic treatment.
214580841|NCT02816944|PROCEDURE|EUS-guided laser ablation for refractory neoplasms|
214580842|NCT04498338|OTHER|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
214580843|NCT04498338|OTHER|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
214580844|NCT01021215|DRUG|Zileuton|1200 mg twice daily given orally (PO) for 6 days
214580845|NCT01021215|DRUG|Celecoxib|200 mg twice daily given orally for 6 days
214580846|NCT01021215|OTHER|laboratory biomarker analysis|Correlative studies
214580847|NCT02751320|DRUG|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580848|NCT02751320|DRUG|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580849|NCT02751320|DRUG|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580850|NCT02751320|OTHER|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580851|NCT02751320|DRUG|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580852|NCT02751320|DRUG|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
214580853|NCT03860701|PROCEDURE|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
214580854|NCT01244854|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
214580855|NCT00283127|PROCEDURE|Home sampling (urine test) for uro-genital C.trachomatis.|
214580856|NCT04132531|PROCEDURE|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
214580857|NCT02195154|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
214580858|NCT01014533|DRUG|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
214580859|NCT01014533|DRUG|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
214580860|NCT00559611|PROCEDURE|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
214580861|NCT00559611|PROCEDURE|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
214580862|NCT02588300|PROCEDURE|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
214580863|NCT00296400|DRUG|Rosuvastatin|
214580864|NCT00296400|DRUG|Atorvastatin|
214580865|NCT02810574|BEHAVIORAL|Cognitive training|
214580866|NCT02810574|DEVICE|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
214580867|NCT02810574|DEVICE|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
214580868|NCT04291222|DEVICE|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
214710230|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
214580869|NCT00412061|DRUG|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
214580870|NCT00412061|DRUG|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
214710231|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
214710232|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
214710233|NCT00685841|DRUG|Salmeterol MDI|Salmeterol MDI 42 mcg BID
214580871|NCT00412061|DRUG|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
214580872|NCT04881604|DEVICE|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
214710234|NCT00685841|DRUG|Placebo|Placebo BID MDI
214710235|NCT03870685|PROCEDURE|TAP Block|Transversus Plane block
214710236|NCT03870685|PROCEDURE|Surgical Site Infiltration|Surgical Site Infiltration
214710237|NCT03870685|DRUG|Exparel|liposomal bupivacaine
214710238|NCT05010525|DRUG|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
214710239|NCT07017933|DEVICE|Renal assist device|The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.
214710240|NCT02259127|DRUG|Dolutegravir|
214580873|NCT04881604|DEVICE|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
214580874|NCT00578461|DRUG|Ara C|3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
214580875|NCT00578461|DRUG|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
214710241|NCT02259127|DRUG|Standard of Care|PI or non nucleoside transcriptase inhibitors
214710242|NCT06695026|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
214580876|NCT00578461|DRUG|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
214580877|NCT00578461|RADIATION|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
214580878|NCT01739491|DRUG|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
214580879|NCT00410982|DRUG|Busulfan|Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous
214580880|NCT00410982|DRUG|Gemcitabine|Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.
214580881|NCT00410982|DRUG|Melphalan|Day -3 and Day -2 = 60 mg/m\^2 Intravenous.
214580882|NCT00410982|OTHER|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
214580883|NCT00410982|DRUG|Rituximab for Patients with B-Cell Malignancies|375 mg/m\^2 Intravenous on Days 1 and 8.
214580884|NCT00410982|DRUG|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
214710243|NCT06695026|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
214580885|NCT03451617|DEVICE|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
214580886|NCT03451617|DEVICE|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
214580887|NCT02307461|DRUG|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
214580888|NCT02307461|DRUG|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
214580889|NCT02307461|DRUG|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
214580890|NCT00221026|DRUG|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
214580891|NCT00221026|PROCEDURE|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
214580892|NCT04157374|OTHER|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
214580893|NCT04157374|OTHER|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
214580894|NCT00289497|DEVICE|TempTouch®|
214580895|NCT01942590|DRUG|Clenbuterol|
214710244|NCT06695026|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
214710245|NCT02336412|OTHER|SMS reminder|Daily SMS medication reminder
214580896|NCT01942590|DRUG|Placebo|
214580897|NCT05332145|BEHAVIORAL|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
214580898|NCT00111215|DRUG|Tranexamic Acid|
214580899|NCT00111215|DRUG|Desmopressin Acetate|
214710246|NCT07047365|DRUG|TQB2930+ chemotherapy|TQB2930 injection is a HER2 bispecific antibody drug； Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
214710247|NCT07047365|DRUG|Trastuzumab+ chemotherapy|Trastuzumab is a HER2-specific targeted drug； Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
214710248|NCT07053423|DRUG|Dupilumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
214580900|NCT05101031|DEVICE|Starling SV|The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
214580901|NCT00312923|DRUG|Policosanol|20 mg of policosanol in capsular form daily
214580902|NCT00312923|DIETARY_SUPPLEMENT|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
214710249|NCT07053423|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
214710250|NCT06016790|GENETIC|cfDNA sequencing|Multi-omics sequencing of cfDNA in peripheral venous blood.
214580903|NCT02880384|OTHER|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
214710251|NCT06466928|PROCEDURE|Total pancreatectomy|Surgical removal of the entire pancreas
214580904|NCT04307420|PROCEDURE|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
214580905|NCT04307420|PROCEDURE|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
214580906|NCT01011387|PROCEDURE|NPWT System|Dressing change 3 times per week
214580907|NCT01011387|DEVICE|NPWT system|3 dressing changes/week for maximum 4 weeks.
214710252|NCT05945329|DEVICE|GalaFLEX LITE™ Scaffold|Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue
214710253|NCT05945329|OTHER|Standard surgery|Surgery performed without the use of a scaffold
214710254|NCT06762275|DIAGNOSTIC_TEST|Diagnostic strategy|GPs' use of an externally validated cPR followed by CRP-POCT in the medium risk group. See for details: Detailed description - Intervention.
214710255|NCT07065305|DRUG|Curodont Repair Fluoride Plus (Self-assembling peptide remineralization agent)P11-4 peptide, fluoride, mild acidic buffer (pH ~4.5) , Credentis AG, Switzerland|Pretreatment with Curodont Repair Fluoride Plus (P11-4 + fluoride)
214710256|NCT07065305|DRUG|Beautifil II LS|Application of Giomer restorative material following standard adhesive procedures without pretreatment.
214710257|NCT07072195|DRUG|AMC6156 0.1mg|Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
214710258|NCT07072195|DRUG|AMC6156 0.3mg|Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
214710259|NCT07072195|DRUG|AMC6156 1.0mg|Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
214580908|NCT00653666|OTHER|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is \< 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
214580909|NCT01097382|DRUG|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
214580910|NCT02518789|DRUG|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
214580911|NCT02518789|DRUG|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
214580912|NCT02518789|DRUG|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
214580913|NCT02518789|DRUG|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate."
214580914|NCT02518789|DRUG|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg
214580915|NCT02518789|DRUG|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
214580916|NCT02708914|BIOLOGICAL|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
214580917|NCT02708914|BIOLOGICAL|Eprex|Eprex® is chosen as the comparator.
214580918|NCT06327932|PROCEDURE|TURBT|Transurethral Resection of Bladder Tumors
214580919|NCT06327932|PROCEDURE|HIVEC|Hyperthermic Intravesical Chemotherapy with Gemcitabine (3g/150ml NS) at 45 °C for 60 minutes. Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
214580920|NCT06327932|PROCEDURE|Intravesical Chemotherapy|Intravesical Chemotherapy with Gemcitabine (3g/150ml NS). Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
214580921|NCT06327932|DRUG|Gemcitabine|Gemcitabine (3g/150ml NS).
214580922|NCT01022060|DIETARY_SUPPLEMENT|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
214580923|NCT01022060|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
214580924|NCT01182467|RADIATION|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
214580925|NCT06414187|DEVICE|Intra-Aortic Balloon Pump|Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
214580926|NCT04557943|DRUG|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
214580927|NCT04557943|DRUG|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
214580928|NCT02433340|DRUG|ABT-122|
214580929|NCT02794753|BEHAVIORAL|Working memory training|
214580930|NCT02794753|BEHAVIORAL|Game|
214580931|NCT03655821|DRUG|Pemetrexed|Dosing is either based on BSA or renal function
214580932|NCT01422421|OTHER|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
214580933|NCT01422421|OTHER|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
214580934|NCT00622258|DRUG|Everolmus|
214580935|NCT00386139|DRUG|Aliskiren/HCTZ|
214580936|NCT04428372|DRUG|Mannitol|Hypertonic mannitol infusion
214580937|NCT04428372|DRUG|0.9% saline|Normal saline 'placebo' arm
214580938|NCT04182945|OTHER|Data collection for algorithm development|50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
214580939|NCT00000731|DRUG|Zidovudine|
214580940|NCT00000731|DRUG|Acetaminophen|
214580941|NCT03971630|OTHER|Telemedicine|Patients will be followed up using the MyVENT System and APP
214580942|NCT00806572|DRUG|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
214580943|NCT02291081|OTHER|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~* Anamnesis with the participants~* File recherche,Physical examination~* Documentation of the cardiovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Exercise Montreal Cognitive Assessment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
214580944|NCT05285930|COMBINATION_PRODUCT|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
214580945|NCT05285930|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
214580946|NCT02325427|DEVICE|tDCS|tDCS could deliver either real or sham stimulation.
214580947|NCT00611429|BEHAVIORAL|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
214580948|NCT00611429|BEHAVIORAL|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
214580949|NCT01618604|PROCEDURE|Quantitative Sensory Testing|following the standardized protocol of DFNS
214580950|NCT01618604|PROCEDURE|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
214580951|NCT01618604|PROCEDURE|Repetition of four QST parameters|"* warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)"
214580952|NCT00350116|DRUG|topical vitamin B12|
214580953|NCT03368638|OTHER|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
214580954|NCT03589508|BEHAVIORAL|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
214580955|NCT03589508|BEHAVIORAL|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
214580956|NCT02810548|PROCEDURE|OFD alone|Periodontal surgical cleaning procedure
214580957|NCT02810548|DRUG|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
214580958|NCT02810548|DRUG|Nanohydroxyapatite|Synthetic bone graft
214580959|NCT02501915|DEVICE|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
214580960|NCT06132243|DRUG|Jaktinib Hydrochloride Tablets|Orally, one tablet at a time
214580961|NCT01178385|BEHAVIORAL|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
214580962|NCT01178385|BEHAVIORAL|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
214580963|NCT02516475|DIETARY_SUPPLEMENT|zinc sulfate|1 zinc sulfate capsule for 15 weeks
214580964|NCT02516475|OTHER|corn starch|1 corn starch capsule for 15 weeks
214580965|NCT06253091|PROCEDURE|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist laparoscopic radical cystectomy was performed extraperitoneal
214580966|NCT03802084|DRUG|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
214580967|NCT00058760|BEHAVIORAL|NIA intervention (after school health promotion didactic program)|
214580968|NCT01786733|BEHAVIORAL|Behavioral Activation|
214580969|NCT01786733|BEHAVIORAL|Supportive Therapy|
214580970|NCT00297687|BIOLOGICAL|MnB rLP2086|
214580971|NCT06341348|OTHER|Case management|Case Management (CM) is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone. All interventions were delivered by a nursing case manager who had over 5 years of nursing experience and received more than 20 hours of CM training.
214580972|NCT05132192|PROCEDURE|living donor liver transplantation|Living donor liver transplantation
214580973|NCT05132192|PROCEDURE|Thrombectomy or interposition graft|Portal flow restoration due to PVT in any manner
214580974|NCT03868072|DRUG|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
214580975|NCT03868072|DRUG|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
214580976|NCT03774485|DEVICE|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
214580977|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
214580978|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
214580979|NCT05639660|OTHER|non-interventional|The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
214580980|NCT02876276|PROCEDURE|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
214580981|NCT06112561|DEVICE|CO/CI/SVR|fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
214580982|NCT02395874|PROCEDURE|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
214580983|NCT02238665|DEVICE|Endomicroscopy|
214580984|NCT00485901|DRUG|Olanzapine Hydrochloride|
214580985|NCT00485901|DRUG|Haloperidol|
214580986|NCT04650308|DIAGNOSTIC_TEST|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
214580987|NCT02039453|DRUG|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
214580988|NCT02039453|DRUG|pethidine dose|pethidine dose 50mg, IV bolus (25mg if \< 50kg or \>70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
214580989|NCT05511792|PROCEDURE|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
214580990|NCT05511792|PROCEDURE|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
214580991|NCT01688830|DRUG|Dabigatran|
214580992|NCT01688830|DRUG|BI 655075|
214580993|NCT01688830|DRUG|Placebo|
214580994|NCT04822597|DRUG|Lidocaine patch|Lidocaine is a local anesthetic.
214580995|NCT04822597|DEVICE|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
214580996|NCT04822597|OTHER|Ice pack|Ice cools the skin and can provide some numbing for pain.
214580997|NCT01285609|DRUG|Ipilimumab|
214580998|NCT01285609|DRUG|Placebo|
214580999|NCT01285609|DRUG|Paclitaxel|
214581000|NCT01285609|DRUG|Carboplatin|
214581001|NCT03283072|DEVICE|Intervention 1|15 bouts of 2mins:1min hypoxia:hyperoxia
214581002|NCT03283072|DEVICE|Intervention 2|15 bouts of 1mins:1min hypoxia:hyperoxia
214581003|NCT03283072|DEVICE|Intervention 3|8 bouts of 2mins:1min hypoxia:hyperoxia
214581004|NCT03283072|DEVICE|Intervention 4 (sham)|15 bouts of 1min:1min normoxia
214581005|NCT05880615|OTHER|collection of datas|"collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery"
214581006|NCT00209716|DRUG|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
214581007|NCT00209716|DRUG|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.
214581008|NCT00209716|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.
214581009|NCT03797677|DEVICE|MN 4000|Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
214581010|NCT06181565|OTHER|Datas of Medistim machine|Datas will be collected by Medistim machine before and after pericardial closure: Flow through the grafts, Resistance on grafts, Pulsatility of the grafts, Systolic and diastolic curves before and after pericardial closure
214581011|NCT00015041|DRUG|Buprenorphine|
214581012|NCT04563286|OTHER|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
214710260|NCT07072195|DRUG|Placebo|Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
214581013|NCT03219515|DRUG|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
214581014|NCT03219515|DRUG|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
214581015|NCT02279225|RADIATION|Group Phototherapy|
214581016|NCT02279225|RADIATION|Phototherapy + Physical activity|
214581017|NCT02279225|OTHER|Physical activity|
214581018|NCT02279225|OTHER|Placebo|
214581019|NCT06074029|DRUG|Immune Checkpoint Inhibitors|Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
214581020|NCT00100581|DRUG|Efavirenz|
214581021|NCT00100581|DRUG|Lamivudine|
214581022|NCT00100581|DRUG|Lopinavir/ritonavir|
214581023|NCT00100581|DRUG|Pegylated interferon alfa-2a|
214581024|NCT00100581|DRUG|Ribavirin|
214581025|NCT00100581|DRUG|Tenofovir disoproxil fumarate|
214581026|NCT02552368|DEVICE|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
214581027|NCT00414245|DRUG|metformin|
214581028|NCT03002753|BEHAVIORAL|detached mindfulness|Please see detailed study description.
214581029|NCT03002753|BEHAVIORAL|cognitive restructuring|Please see detailed study description.
214581030|NCT05354180|OTHER|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
214581031|NCT05354180|OTHER|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
214581032|NCT05354180|OTHER|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
214581033|NCT05302349|OTHER|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * Active pelvic floor exercise (supine position)~  * Bridge exercise (supine position)~  * Back Extension and Ball Back Extension exercises (prone position)~  * Abdominal and Oblique Crunch exercises (supin position)~  * Leg lift exercise (prone position)~  * Plank and Side Plank exercise~  * Superman exercise~Weeks 5-8 (Three days a week)~1. Stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * The same exercises as for Weeks 1-4 will perform."
214710261|NCT04007666|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
214710262|NCT04007666|BEHAVIORAL|Control Group|Coping-focused treatment.
214710263|NCT07084597|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D ,50000 IU/week will be given for 8 consecutive weeks
214581034|NCT05302349|OTHER|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1\. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
214581035|NCT02704468|OTHER|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
214581036|NCT01645293|GENETIC|Genetically modified T cells # 1138|
214581037|NCT06425874|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery
214581038|NCT06425874|PROCEDURE|Mastectomy|Mastectomy without reconstruction
214710264|NCT03196427|DRUG|Vedolizumab|Vedolizumab intravenous infusion
214710265|NCT07092293|OTHER|occupational therapy|N/A as there is no intervention for this study
214581039|NCT06425874|PROCEDURE|Mastectomy with reconstruction|Any type of reconstruction(include implant and autologous)
214581040|NCT00349674|DRUG|Azathioprine: 2 mg/kg/day|
214581041|NCT00349674|DRUG|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
214710266|NCT07090304|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
214581042|NCT02911415|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
214581043|NCT00882154|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
214581044|NCT00882154|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
214581045|NCT06485453|DRUG|Botox 200 UNT Injection|Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
214581046|NCT00201994|DRUG|Tolvaptan|
214710267|NCT07090304|DIAGNOSTIC_TEST|FIT-sDNA|FIT-sDNA test combines Fecal Immunochemical Test (FIT) and stool DNA (sDNA) analysis. It detects hemoglobin in stool through FIT to identify occult blood in the gastrointestinal tract and simultaneously analyzes specific DNA mutations or epigenetic alterations (such as methylation changes) in stool DNA to assess the risk of colorectal neoplasms.
214710268|NCT07090486|DRUG|nirmatrelvir-ritonavir|Paxlovid standard of treatment care
214581047|NCT05682703|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
214581048|NCT03499145|DEVICE|Ophthalmology diagnostic system.|An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
214581049|NCT03539887|DRUG|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
214581050|NCT03539887|DRUG|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
214581051|NCT06127823|BEHAVIORAL|Dietary treatment|Dietary counselling
214581052|NCT05922254|OTHER|Active cycle of breathing technique|The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
214581053|NCT05922254|OTHER|Autogenic drainage|Huffing or blowing the nose helped to get rid of any secretions in the upper airways. The therapist was placed close enough to hear the subject's breathing while sitting to the side and slightly behind the patient. Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency.
214581054|NCT02769403|DEVICE|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
214581055|NCT02769403|OTHER|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
214581056|NCT02769403|OTHER|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
214581057|NCT02769403|OTHER|Sick Days|Sick days during the 12 week study period will be collected
214581058|NCT02769403|OTHER|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
214581059|NCT01159210|BIOLOGICAL|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
214581060|NCT00998998|BEHAVIORAL|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
214581061|NCT00998998|BEHAVIORAL|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
214581062|NCT00998998|DIETARY_SUPPLEMENT|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
214581063|NCT01755208|PROCEDURE|light-scattering spectroscopy|Undergo light-scattering spectroscopy
214581064|NCT01100827|OTHER|EGFR mutation status in patients|
214581065|NCT05570773|OTHER|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
214581066|NCT00856037|DRUG|Doxorubicin Hydrochloride|Given IV
214581067|NCT00856037|OTHER|Laboratory Biomarker Analysis|Correlative studies
214581068|NCT00856037|OTHER|Quality-of-Life Assessment|Ancillary studies
214581069|NCT00856037|DRUG|Topotecan Hydrochloride|Given PO
214581070|NCT04664803|DRUG|Cefecin Tab.|
214581071|NCT04664803|DRUG|Omnicef Cap.|
214581072|NCT04463316|DIAGNOSTIC_TEST|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
214581073|NCT02923492|BEHAVIORAL|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
214581074|NCT05120726|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Dehydrated human amnion/chorion membrane (dHACM) has been commercially available for nearly 15 years. dHACM has been shown to elute growth factors including platelet-derived growth factors, fibroblast growth factors (PDGF), fibroblast growth factors (FGF), transforming growth factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Additionally, dHACM exerts immunomodulatory effects by releasing anti-inflammatory interleukins and factors which help regulate the matrix metalloproteinase (MMP) activity. Furthermore, dHACM has also been shown to stimulate mesenchymal stem cell migration and recruitment. dHACM is routinely utilized in the management of chronic wounds including diabetic ulcer and venous ulcers.
214581075|NCT04422444|DIAGNOSTIC_TEST|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
214581076|NCT00480129|BEHAVIORAL|Probiotic or placebo yogurt consumed daily|
214581077|NCT00480129|DEVICE|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
214581078|NCT00480129|PROCEDURE|Blood sample|
214581079|NCT00480129|PROCEDURE|Nasal lavage|
214581080|NCT02412371|DRUG|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
214581081|NCT02412371|DRUG|Placebo for Veliparib|Capsule for oral administration
214581082|NCT02412371|DRUG|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
214581083|NCT02412371|DRUG|Veliparib|Capsule for oral administration
214581084|NCT02412371|RADIATION|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
214581085|NCT03383822|DRUG|Intranasal insulin|Humalog lispro 40 IU intranasally
214581086|NCT03383822|DRUG|Intranasal placebo|Diluent intranasally
214581087|NCT00040027|DRUG|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
214581088|NCT00040027|DRUG|placebo + PEGinterferon alfa-2a|
214581089|NCT05568732|PROCEDURE|Root coverage procedure will be done with VCMX|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
214581090|NCT05568732|PROCEDURE|Root coverage procedure will be done with CTG|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
214581091|NCT05096585|BEHAVIORAL|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
214581092|NCT05096585|BEHAVIORAL|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
214581093|NCT00682773|OTHER|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
214581094|NCT05470192|OTHER|Qigong exercise training|"Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~1. Raising arms with palms up,~2. Shooting arrows left and right like an archer in a semi-crouching position~3. Keeping one arm up~4. Looking back with trunk rotations in a semi-crouching position~5. Nodding the head and lowering the body to relieve stress,~6. Fisting and staring~7. Touching feet with hands touching back and legs~8. Raising and lowering heels"
214581095|NCT01270074|DRUG|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
214581096|NCT01270074|DRUG|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
214581097|NCT02217124|OTHER|dried apples|120 calories
214581098|NCT02217124|OTHER|muffin|120 calories
214581099|NCT01935973|OTHER|Laboratory Biomarker Analysis|Correlative studies
214581100|NCT01935973|DRUG|Trametinib|Given PO
214581101|NCT01935973|DRUG|Uprosertib|Given PO
214581102|NCT06444230|OTHER|Routine Physical therapy with Neurodevelopmental technique|participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks
214581103|NCT06444230|OTHER|Routine Physical therapy|participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo
214581104|NCT00000167|PROCEDURE|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
214581105|NCT03796702|PROCEDURE|Deileostomy|Deileostomy
214581106|NCT04654975|PROCEDURE|Esophagectomy for esophageal cancer|Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
214581107|NCT01449136|OTHER|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
214581108|NCT01375088|DRUG|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
214581109|NCT03671694|PROCEDURE|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
214581110|NCT02053792|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
214581111|NCT05800418|DRUG|Ramucirumab Injection|Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
214581112|NCT05800418|DRUG|Ramucirumab Injection [Cyramza]|Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
214581113|NCT00391131|DRUG|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
214581114|NCT00701532|DRUG|Modafinil and PET (brain imaging)|duration 90 days
214581115|NCT00701532|DRUG|placebo|duration 90 days
214581116|NCT00124293|DRUG|activated recombinant human factor VII|
214581117|NCT01666938|OTHER|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
214581118|NCT01666938|OTHER|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
214581119|NCT02170818|OTHER|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
214581120|NCT02170818|OTHER|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
214581121|NCT03638973|PROCEDURE|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
214581122|NCT04062487|DEVICE|Mixed Reality technology|combine image with real body
214581123|NCT02167737|BEHAVIORAL|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
214722060|NCT00698139|DEVICE|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
214581124|NCT02167737|BEHAVIORAL|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
214581125|NCT01027182|DRUG|Raltegravir|One 400mg tablet on day 1.
214722061|NCT02937090|OTHER|Blood Draw|Blood sample will be drawn from participants at study entry.
214581126|NCT03732599|PROCEDURE|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
214581127|NCT03732599|PROCEDURE|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
214722062|NCT02937090|OTHER|Stool collection|Stool will be collected from participants at study entry.
214722063|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
214722064|NCT00547989|DRUG|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
214722065|NCT00547989|DRUG|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
214581128|NCT04687280|OTHER|non interventional|non interventional, study on data
214722066|NCT00547989|DRUG|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
214581129|NCT02336295|OTHER|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
214581130|NCT06540625|DEVICE|the use of CP device application on human subjects.|"Trained providers will be asked to apply CP at 10N of force to the marked location using the cricoid applicator for one minute. Data relating to applied force across the whole one minute will be measured continuously and will be captured and stored. The CP device will have a microdisc port for internal memory and then the wifi on the board will transfer the information to a cloud server for backup and storage for redundancy.~A threshold of 10 ± 2 N applied force will be set to define successful CP attempts. Participants must remain in this range for 95% of the trial time after the first five seconds have passed.~At any point during the CP application, if the volunteer experiences pain, they can request that the pressure be stopped. However, we do not expect any pain with 10N, except for minor discomfort."
214581131|NCT04108143|DEVICE|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
214581132|NCT05174936|BEHAVIORAL|PLWH intervention|The intervention curriculum will consist of five interactive training sessions (2 hours each) with four specific areas of resilience-building: individual assets (self-esteem, emotion regulation, positive future orientation), coping with infection/illness (medical adherence, stress reduction, healthy lifestyle, self-care), relationship building (family relationship, provider-patient relationship), and social support (identifying and seeking social support at various socioecological levels).
214581133|NCT05174936|BEHAVIORAL|Family member intervention|The intervention will consist of five sessions of group activities (2 hours each), with each session addressing one or more of the following areas: 1) HIV and ART knowledge; 2) support to strengthen the capacity of PLWH and their family members to adapt to living with HIV; 3) relationship building (family relationships, intimate relationships); 4) emotional and behavioral support for PLWH's adherence to care and treatment, including tailored coping or support strategies to address unique needs of some participants who may be more prone to HIV stigma (e.g., MSM and their family members); and 5) self-care.
214581134|NCT05174936|BEHAVIORAL|Healthcare provider intervention|The HCP intervention will adapt Popular Opinion Leaders (POL) principles by teaching participants skills for initiating/disseminating stigma reduction messages/practices to colleagues in the workplace. The HCP intervention will consist of four 1.5-hour sessions addressing the following topics: 1) universal HIV precautions and occupational safety (e.g., correctly knowing and practicing universal precautions and decreasing fear of PLWH); 2) intersecting stigma against PLWH (e.g., manifestations of intersecting stigma in clinical settings); 3) provider-patient relationship (e.g., reducing stigmatizing attitudes and behaviors toward PLWH, respecting patients' rights for privacy related to care and disclosure); 4) improving quality of patient care (e.g., increasing skills and comfort in working with PLWH); 5) building a supportive medical environment for better care of PLWH; and 6) skills and confidence in delivering stigma reduction messages to coworkers.
214581135|NCT03906422|DEVICE|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
214581136|NCT03906422|DEVICE|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
214581137|NCT03906422|DEVICE|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
214581138|NCT05215665|DRUG|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
214581139|NCT05215665|DRUG|Lenvatinib|8/12mg PO QD continuously
214581140|NCT05215665|DRUG|Toripalimab|240mg IV d1 Q3W
214581141|NCT05652647|DRUG|Oral [14C]PF-07081532|A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
214581142|NCT05652647|DRUG|Oral PF-07081532 and IV [14C]PF-07081532|In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
214581143|NCT05465083|DEVICE|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
214581144|NCT05326815|DIAGNOSTIC_TEST|N-Telopeptide, Bone Marker|"This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest (N-Telopeptide), and their association with baseline DEXA scan measures and fracture risk within 6 months.~Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn."
214581145|NCT06498011|OTHER|Home Graded Repetitive Arm Supplementary Program (GRASP)|The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
214581146|NCT06498011|OTHER|integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)|The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
214581147|NCT01296789|OTHER|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
214581148|NCT01296789|OTHER|Usual Care|Usual Care
214581149|NCT00925132|DRUG|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
214581150|NCT02545933|DRUG|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
214581151|NCT02545933|DRUG|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
214581152|NCT02545933|DRUG|Aspirin|Aspirin will be administered at the dose of 81mg once daily
214581153|NCT02545933|DRUG|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
214581154|NCT03149549|DRUG|CX-2009|CX-2009 Monotherapy
214710269|NCT07091240|BEHAVIORAL|Behavioral Parent Training|Family Check-Up® Online is delivered through a secure website that can be accessed via computer or phone at participating caregivers' convenience. Caregivers will complete the Developmental Early Childhood Instrument for Deciding Effectively about Mental Health (DECIDE) tool, a risk calculator that screens for early signs of future mental health challenges, at their child's 24- or 30-month well-check visit with their pediatrician. Clinicians will use the DECIDE tool risk calculator score to refer caregivers of at-risk children to FCU-O. Caregivers may use FCU-O independently, or they may work with a trained coach who will facilitate their use of the program. Participation is open to caregivers who are referred to FCU-O based on their DECIDE risk calculator score by their child's pediatrician and is available in English or Spanish. Participants will also complete assessments via survey and direct observation before beginning FCU-O, and 6- and 12-months after their referral to FCU-O.
214581155|NCT00835900|DRUG|varenicline|variable dosing schedule
214581156|NCT00835900|DRUG|placebo|placebo
214581157|NCT03373942|OTHER|Choroidal thickness measurements with SD-OCT device|
214581158|NCT02396628|DRUG|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
214581159|NCT02396628|DRUG|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
214581160|NCT05822830|DRUG|Tirzepatide|Administered SC
214581161|NCT05822830|DRUG|Semaglutide|Administered SC
214581162|NCT06180031|DRUG|Pericapsular nerve group block using bupivicaine and magnesium sulphate|This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
214722067|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
214722068|NCT04006704|DRUG|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
214722069|NCT03132441|OTHER|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
214722070|NCT03597503|DRUG|SPN-810|Flexible dose
214581163|NCT06071897|DRUG|monoclonal antibodies GD2|"Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy"
214581164|NCT00427310|DRUG|fluorouracil|
214581165|NCT00427310|OTHER|Observation|
214722071|NCT03597503|DRUG|Placebo|Placebo
214722072|NCT04023136|PROCEDURE|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
214722073|NCT01399255|BIOLOGICAL|Insulin lispro|Dosage form- Subcutaneous Injection
214722074|NCT05932381|OTHER|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
214581166|NCT00427310|DRUG|sodium heparin|
214581167|NCT06610812|BEHAVIORAL|KETOGENIC MEDITERRANEAN diet|"each patient in group A was instructed briefly about the nature of the treatment regimen to gain the patient's confidence and cooperation. the patient will receive ketogenic Mediterranean diet with aerobic training program. The diet will contain approximately 9300 kJ accordingly, 37% as total fat, 18% as monounsaturated and 9% as saturated, and 33 g of fiber per day for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.~This procedure performed by using the components of ketogenic Mediterranean diet:~* Protein source: fatty fish, seafood, poultry, and eggs.~* Fats and oils: olive oil, avocado oil, and MCT oil (medium-chain triglycerides oil).~* Low carb vegetables: leafy greens, cruciferous vegetables, and other low carb veggies.~* Low carb fruits: avocados, olives, and tomato.~* Flavourings: paprika, cumin, cinnamon, coriander, anise, lemon or lime juice , mint , parsley and garlic ."
214581168|NCT06610812|BEHAVIORAL|hypo-caloric diet:|"Group (b) received low caloric balanced diet regimen with aerobic exercise for 3 months in the form of moderate aerobic exercises in the form of walking for 30 to 45 minutes a day, 3 times per week for 3 months. This group received a diet of 1800 calories or lower accordingly including a combination of two or more of the following in each meal: Non starchy vegetable: spinach, broccoli, cauliflower, peppers, mushrooms, tomatoes, etc.~Fruits: berries, apples bears, citrus fruits, melon, grapes bananas, etc. Starchy vegetables: potatoes peas, sweet potatoes etc. Fish and shellfish: salmon, clams, Trouts, oysters, etc. Eggs: whole eggs are more nutrient dense than white eggs. Poultry and meat: chicken turkey, beef, lamb, etc. Whole grains: oats, brown rice, farro etc. Legumes: chickpeas, kidney beans, lentils etc. Healthy fats: avocados, olive oil, unsweetened coconut, avocado oil. Dairy products: full-fat or reduced fat plain yogurt kefir and full-fat cheese."
214581169|NCT06610812|BEHAVIORAL|moderate aerobic exercises|moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
214581170|NCT06609629|PROCEDURE|Selective lung recruitment|A bronchial blocker with a lumen is inserted in one inferior pulmonary lobe using a fibroscope. The baloon of the blocker is expended to isolate the lobe. A second ventilator is used to apply a pressure of 45cmH2o through the lumen of the blocker. The recruiting pressure is maintained 30 to 60 second. After the procedure, the blocker is removed and the procedure is repeated in the controlateral inferior lobe.
214581171|NCT06610331|PROCEDURE|FREE GİNGİVAL GRAFT|Free Gingival Graft removal from the palate donor area for the treatment of gingival recession
214581172|NCT06610331|DEVICE|polyvinylpyrrolidone sodium hyaluronate gel|Patients are told to gargle with a mouthwash containing polyvinyl pyrrolidone sodium hyaluronate twice a day for 2 weeks. 15 ml (1 tablespoon) of mouthwash containing polyvinyl pyrrolidone sodium hyaluronate is poured into a glass and approximately 40 ml (3 tablespoons) of water is added and mixed well, then it is shaken for at least 1 minute, making contact with the entire mouth.
214581173|NCT06885970|DRUG|Cytisinicline administration|Participants will receive in the smoki
214581174|NCT06896981|DRUG|Metformin with Semaglutide|One arm: Metformin 500 mg bd, Other arm: Metformin 500 mg bd + Semaglutide 0.5 mg once weekly
214581175|NCT06907472|DRUG|Protocol-based treatment|"PROTOCOL:~Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5: Metformin 1000 mg twice daily + glibenclamide 5 mg twice daily"
214581176|NCT00903604|DRUG|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
214581177|NCT00903604|DRUG|Placebo|Three 10-minutes infusions of isotonic saline solution
214581178|NCT04452968|BEHAVIORAL|intermittent fasting|Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.
214581179|NCT04452968|BEHAVIORAL|Caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
214581180|NCT06074276|OTHER|Food: whole almonds|60 grams or (\~2 oz) will be consumed 5 times per week.
214581181|NCT06074276|OTHER|Food: non-nut snack|Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
214581182|NCT03029351|DRUG|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
214581183|NCT03029351|DRUG|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
214581184|NCT01572103|DIETARY_SUPPLEMENT|Coffee|Administration of 4 cups of coffee per day for 1 month
214581185|NCT01572103|DIETARY_SUPPLEMENT|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
214581186|NCT05420376|PROCEDURE|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
214581187|NCT00491569|DRUG|Sarcosine and D-serine|
214581188|NCT03062579|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
214581189|NCT01034176|DRUG|levofloxacin|500 mg tablet, daily, 30 days
214581190|NCT01034176|DRUG|placebo|no dose, tablet, daily, 30 days
214581191|NCT02892786|OTHER|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
214581192|NCT00715962|BEHAVIORAL|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
214581193|NCT00715962|OTHER|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
214581194|NCT00715962|OTHER|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
214581195|NCT02567747|OTHER|Data collection|Data will be collected retrospectively for cases identified through RIPS\*/ DANE\*\* from 2008 until 2014 and through PAI\*\*\* from 2009 until 2014. \*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. \*\*Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. \*\*\*Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
214722075|NCT05932381|OTHER|Medical treatment|the patients will receive routine medical treatment
214722076|NCT01318525|DRUG|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
214722077|NCT01318525|DRUG|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
214581196|NCT05415943|DEVICE|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
214581197|NCT00698945|DRUG|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
214581198|NCT00698945|DRUG|Alphagan|Alphagan: two drops a day for 28 days
214581199|NCT03207009|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
214581200|NCT04558879|BEHAVIORAL|CT|12 weeks of exercise Cardiovascular Training
214581201|NCT04558879|BEHAVIORAL|RT|12 weeks of exercise Resistance Training
214581202|NCT03797261|DRUG|Venetoclax|tablet, oral
214581203|NCT03797261|DRUG|AMG 176|solution, intravenous
214581204|NCT00183001|DRUG|Vitamin K|
214710270|NCT07091305|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|"Induction: QL1706 5 mg/kg IV on Day 1, Etoposide: 100 mg/m² IV on Days 1-3, Cisplatin or Carboplatin: Cisplatin 75 mg/m² IV on Day 1 or Cisplatin 25 mg/m² IV on Days 1-3, Or Carboplatin AUC = 5 IV on Day 1, Q3W, for a total of 2 cycles.~Chemoradiotherapy：Thoracic Radiotherapy（60 Gy in 30 fractions, once daily (2 Gy/fraction), or 45 Gy in 30 fractions, twice daily (1.5 Gy/fraction)），Etoposide 100 mg/m² IV on Days 1-3, Cisplatin either 75 mg/m² IV on Day 1, or 25 mg/m² IV on Days 1-3, Or Carboplatin AUC=5 IV on Day 1 PCI: Patients achieving or approaching complete response, per investigator assessment, 25Gy in 10 fractions.~Consolidation: QL1706 5 mg/kg IV on Day 1, Q3W"
214581205|NCT04343872|BEHAVIORAL|Receive lifestyle modification alone|Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
214581206|NCT04343872|BEHAVIORAL|Metformin therapy|The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
214581207|NCT01869582|DEVICE|Fetoscope, Fetal heart rate|
214581208|NCT01869582|DEVICE|Upright Resuscitator, Resuscitation|
214581209|NCT01869582|DEVICE|Doppler, Fetal heart rate|
214581210|NCT01869582|DEVICE|Standard Resuscitator, Resuscitation|
214581211|NCT01347801|DRUG|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
214581212|NCT01347801|DRUG|Placebo (Saline)|Normal saline (NaCl 0,9%)
214581213|NCT01347801|DRUG|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
214581214|NCT01347801|OTHER|OGTT|Oral glucose tolerance test with 75 g glucose
214581215|NCT01347801|OTHER|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
214581216|NCT06153225|DIETARY_SUPPLEMENT|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
214581217|NCT03820674|OTHER|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
214581218|NCT03820674|OTHER|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
214581219|NCT04452565|DRUG|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
214581220|NCT04452565|COMBINATION_PRODUCT|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
214581221|NCT04452565|COMBINATION_PRODUCT|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
214581222|NCT04452565|COMBINATION_PRODUCT|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
214581223|NCT04843553|DRUG|Oral Nicotinamide|
214581224|NCT04330885|OTHER|Supervised abdominal exercises and stationary biking|Explain pain to the patients in order to minimize fear of movement
214581225|NCT03898401|COMBINATION_PRODUCT|Platelet rich plasma|After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
214581226|NCT04487912|DRUG|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
214581227|NCT04487912|DRUG|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
214581228|NCT04390022|DRUG|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
214581229|NCT04390022|DRUG|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
214581230|NCT03241225|BEHAVIORAL|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
214581231|NCT03241225|BEHAVIORAL|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
214581232|NCT04420715|OTHER|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
214581233|NCT05228041|DRUG|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
214581234|NCT03290209|PROCEDURE|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
214581235|NCT03290209|PROCEDURE|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
214581236|NCT05174455|DRUG|Niraparib Tosylate Monohydrate|Given PO
214581237|NCT03720054|BEHAVIORAL|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
214581238|NCT03720054|BEHAVIORAL|Fitbit|Fitbit Only
214581239|NCT02618915|GENETIC|DTX101|solution for IV infusion
214581240|NCT01635920|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
214581241|NCT01635920|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
214581242|NCT01893125|DRUG|CNV2197944|
214581243|NCT01893125|DRUG|Placebo|
214581244|NCT01738425|DRUG|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
214581245|NCT01738425|DRUG|GIC-1001 matching placebo|"Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]"
214581246|NCT02844426|DRUG|bifid triple viable capsule and pectin|
214581247|NCT02844426|DRUG|maltodextrin|
214581248|NCT04568460|OTHER|Intervention Group Sessions|Participants will undergo a multi-session group intervention over the course of six months.
214581249|NCT05788393|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
214581250|NCT05788393|DRUG|Lidocaine IV|lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
214581251|NCT05674331|PROCEDURE|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
214581252|NCT05674331|DEVICE|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
214581253|NCT05674331|PROCEDURE|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
214581254|NCT04644562|OTHER|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
214581255|NCT01470313|DRUG|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
214581256|NCT01470313|DRUG|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
214581257|NCT04217733|DRUG|pentoxyifylline|Pentoxyifylline two times daily for 3 months
214581258|NCT04217733|DRUG|Mebeverine|Mebeverine 3 times for 3 months
214581259|NCT04217733|DRUG|ethosuximide|ethosuximide 3 times for 3 months
214581260|NCT00007345|DRUG|Romidepsin|
214581261|NCT02436785|OTHER|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
214581262|NCT02436785|OTHER|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
214634274|NCT03983850|DRUG|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
214634275|NCT03983850|DRUG|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
214581263|NCT02800577|DEVICE|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
214581264|NCT04095741|DIAGNOSTIC_TEST|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
214581265|NCT00824356|DRUG|GSK1004723 (200mg)|Intranasal antihistamine.
214581266|NCT00824356|OTHER|Placebo|Equivalent to GSK1004723 in presentation etc.
214581267|NCT00824356|DRUG|GSK1004723 (1000mg)|Intranasal antihistamine.
214581268|NCT05977504|OTHER|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
214581269|NCT03975738|OTHER|To be part of a blog|To be part of a blog - to respond to questions and free to comment on other participants comments
214581270|NCT00988520|DRUG|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
214581271|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
214581272|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
214581273|NCT00988520|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
214581274|NCT00988520|DRUG|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
214581275|NCT02709915|OTHER|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
214581276|NCT02709915|OTHER|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
214710271|NCT07090837|OTHER|Caregiver Support Model|"1. CarePal: A one-stop resource library for caregivers of older adults~2. Nasogastric tube (NGT) webapp: An electronic training platform to learn NGT feeding and management~3. Carer OnBoard programme~4. Caregiver resources in NHG Health App (NHA): Relevant healthcare professionals or TTSH staff will introduce caregivers to the resources they may need in the NHA app.~5. Carer guide, a resource booklet providing information and community resources for caregivers.~6. Group Caregiver Training, for caregivers who are able to attend group caregiver training (instead of learning at the bedside);~7. NHG Care Telephonic team to provide telephonic support to caregivers post-discharge.~8. Nurses or other healthcare professionals providing relevant information on community programmes"
214710272|NCT07090837|OTHER|Standard caregiver support|Participants are provided standard bedside caregiver education as appropriate and information reinforcement through leaflets and booklets
214581277|NCT02074553|DRUG|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
214581278|NCT02074553|DRUG|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
214581279|NCT02074553|DRUG|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
214581280|NCT02074553|DRUG|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
214581281|NCT04278040|DRUG|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
214581282|NCT01600521|DRUG|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
214581283|NCT00194987|DRUG|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
214581284|NCT00194987|DRUG|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
214581285|NCT03085030|DRUG|Antioxidant Formula|Antioxidant tablet will be taken by the patients
214581286|NCT03085030|DRUG|Placebo|The placebo will be taken by the patients
214581287|NCT01664598|DRUG|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
214581288|NCT01487408|DRUG|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
214581289|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
214581290|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
214581291|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
214581292|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
214581293|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
214581294|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
214581295|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
214581296|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
214581297|NCT00118833|DRUG|Hypericum perforatum (St. John's wort)|
214581298|NCT01465204|BEHAVIORAL|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
214581299|NCT01465204|BEHAVIORAL|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
214581300|NCT01658150|DRUG|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
214581301|NCT04508231|OTHER|Gender-affirming hormone therapy|Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
214581302|NCT03325920|DEVICE|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
214710273|NCT07091682|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
214581303|NCT04123834|PROCEDURE|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
214710274|NCT02578823|DEVICE|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
214710275|NCT02578823|DEVICE|Arcticgel™|
214581304|NCT04123834|PROCEDURE|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
214581305|NCT04123834|DEVICE|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
214581306|NCT05787028|DRUG|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
214581307|NCT05787028|DRUG|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
214581308|NCT05172141|BIOLOGICAL|IBI314(low dose)|intravenously, once, on Day 1
214581309|NCT05172141|BIOLOGICAL|IBI314(high dose)|intravenously, once, on Day 1
214581310|NCT05172141|BIOLOGICAL|IBI314(medium dose)|intravenously, once, on Day 1
214581311|NCT05172141|OTHER|Placebo|intravenously, once, on Day 1
214581312|NCT02898844|BEHAVIORAL|Mixed Diet Condition|One roommate dieted and the other ate normally.
214581313|NCT02898844|BEHAVIORAL|Both Diet Condition|Both roommates dieted.
214581314|NCT02057120|PROCEDURE|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
214581315|NCT02057120|DEVICE|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
214581316|NCT02342743|DEVICE|CEFALY|
214581317|NCT02486133|DRUG|Prezista|once daily
214581318|NCT02486133|DRUG|Norvir|once daily
214581319|NCT02486133|DRUG|Tivicay|once daily
214581320|NCT02486133|DRUG|Truvada|once daily
214581321|NCT02486133|DRUG|Kivexa|once daily
214581322|NCT02486133|DRUG|Descovy|once daily
214581323|NCT00321113|DRUG|tacrolimus|immunosuppression
214581324|NCT00321113|DRUG|mycophenolate mofetil|oral
214581325|NCT00321113|DRUG|steroids|oral
214581326|NCT04875676|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
214581327|NCT04187989|BEHAVIORAL|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
214581328|NCT06445426|DEVICE|Cystometry|The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure. The investigational device is inserted into a 12F single-use hydrophilic catheter. After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter. The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder. The investigational device is connected to a data logger. In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate. The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder. The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
214581329|NCT03646656|BEHAVIORAL|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
214581330|NCT03305354|BEHAVIORAL|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
214581331|NCT03305354|BEHAVIORAL|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
214581332|NCT03602066|DRUG|Chlorine Dioxide Sterilization|Given via oral rinse
214581333|NCT03602066|OTHER|Laboratory Biomarker Analysis|Correlative studies
214581334|NCT03602066|OTHER|Placebo|Given via oral rinse
214581335|NCT00092495|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
214581336|NCT01793311|OTHER|decaffeinated coffee|contains caffeine 0.5-2 mg
214581337|NCT01793311|OTHER|regular dose coffee|contains 91.8 mg of caffeine
214581338|NCT01793311|OTHER|high dose coffee|contains 144 mg of caffeine
214581339|NCT02454179|DRUG|pembrolizumab|
214581340|NCT02454179|DRUG|Acalabrutinib|
214581341|NCT00460200|GENETIC|polymorphism analysis|
214581342|NCT00460200|OTHER|laboratory biomarker analysis|
214581343|NCT00460200|OTHER|physiologic testing|
214581344|NCT00460200|OTHER|questionnaire administration|
214581345|NCT00460200|PROCEDURE|conventional surgery|
214581346|NCT00460200|PROCEDURE|fatigue assessment and management|
214581347|NCT00460200|PROCEDURE|psychosocial assessment and care|
214581348|NCT02859532|RADIATION|elastography SWIRE|
214581349|NCT03182725|DRUG|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
214581350|NCT03182725|DRUG|Placebo|A substance that has no therapeutic effect and will act as a control.
214581351|NCT04697771|OTHER|Fine Motor Skills Training|The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani \& Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith \& O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
214581352|NCT02558686|OTHER|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
214581353|NCT02558686|OTHER|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
214581354|NCT02558686|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
214581355|NCT00938470|DRUG|capecitabine|Given PO
214581356|NCT00938470|DRUG|docetaxel|Given IV
214581357|NCT00938470|DRUG|fluorouracil|Given IV
214581358|NCT00938470|DRUG|oxaliplatin|Given IV
214581359|NCT00938470|RADIATION|radiation therapy|Undergo radiation therapy
214710276|NCT02578823|PROCEDURE|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
214581360|NCT00938470|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214581361|NCT01412463|DEVICE|stent placement|"* pre-dilation of the study lesion is mandatory~* stent placement with 1 Protégé Everflex+ stent~* only 1 stent is allowed within the study protocol~* post-dilation may be performed but is not mandatory"
214581362|NCT04851925|OTHER|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
214581363|NCT02808637|OTHER|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
214581364|NCT02808637|OTHER|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
214581365|NCT02808637|OTHER|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
214581366|NCT02808637|OTHER|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
214581367|NCT00712309|DEVICE|Lifestent|Stent for endovascular treatment of popliteal artery lesions
214581368|NCT00712309|DEVICE|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
214581369|NCT00267839|BEHAVIORAL|physical exercise, wellness|
214581370|NCT05105451|OTHER|Collecting clinical data, EGG，arterial blood gas data and venous blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），arterial blood gas data(before induction of anesthesia and first day after surgery) and venous blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
214710277|NCT07091149|BEHAVIORAL|CBT-I|Cognitive behavioral therapy for insomnia
214634276|NCT02355288|PROCEDURE|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
214634277|NCT02355288|PROCEDURE|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
214710278|NCT05009030|DRUG|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
214634278|NCT04780269|DEVICE|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
214634279|NCT04780269|DRUG|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
214710279|NCT07090057|PROCEDURE|Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy|Participants undergo Tendoachilles (TA) lengthening or gastrocnemius (GN) recession surgery before Plantaris tenotomy.
214710280|NCT07090057|PROCEDURE|Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession|Participants undergo plantaris tenotomy surgery before Tendoachilles (TA) lengthening or gastrocnemius (GN) recession.
214581371|NCT02853253|DIETARY_SUPPLEMENT|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
214581372|NCT02853253|DIETARY_SUPPLEMENT|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
214581373|NCT03356626|DEVICE|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
214710281|NCT00369395|DRUG|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
214581374|NCT03356626|DEVICE|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
214581375|NCT03356626|DEVICE|Thunderbeat|to use Thunderbeat when performing gastrectomy
214581376|NCT03760731|BEHAVIORAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
214581377|NCT03760731|BEHAVIORAL|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
214581378|NCT00551265|DRUG|Cyclophosphamide|Given IV
214581379|NCT00551265|PROCEDURE|Laboratory Biomarker Analysis|Correlative studies
214581380|NCT00551265|BIOLOGICAL|Oregovomab|Given IV
214581381|NCT00070824|PROCEDURE|acupuncture|
214581382|NCT01505218|DRUG|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
214581383|NCT01505218|DRUG|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
214581384|NCT06101043|PROCEDURE|Pectoral nerve block|An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).
214634280|NCT03012373|PROCEDURE|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
214710285|NCT06065202|DIETARY_SUPPLEMENT|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
214710286|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214581385|NCT06312228|OTHER|Helfer Skin Tap|Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
214581386|NCT06312228|OTHER|Buzzy|The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
214581387|NCT02982395|DRUG|Nanoxel®M|Intravesical
214581388|NCT02982395|DRUG|Mitomycin-C|Intravesical
214581389|NCT05643352|PROCEDURE|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
214581390|NCT04680338|DIAGNOSTIC_TEST|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
214581391|NCT02982460|OTHER|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
214581392|NCT02982460|OTHER|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
214581393|NCT05564780|DRUG|RASI and/or a single pill combination based RASI|The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
214581394|NCT05389917|PROCEDURE|Pancreaticoduodenectomy|"In Pre Operative phase~64 Slice MD CT scan will be taken in all patients undergoing PD in pre op period 3D reconstruction of Peripancreatic vascular system using MDCT images Measure longitudinal distance between Root of Left renal vein, origin of IPDA Measure distance between origin of SMA , MCA and the IPDA~In Intraoperative period~Distance will be measured using standard disposable ruler from Root of Left renal vein to IPDA after Transection of Pancreas followed by specimen removal and to measure the distance between MCA, SMA and IPDA using standard disposable ruler ."
214581395|NCT00434005|DRUG|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
214581396|NCT00434005|DRUG|Placebo|matched appearance to acetylcysteine and ascorbate intervention
214581397|NCT03870217|BEHAVIORAL|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
214581398|NCT04020627|OTHER|BiPAP Group|"BIPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
214581399|NCT04020627|OTHER|CPAP Group|"CPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
214581400|NCT04207151|BEHAVIORAL|SNAPS intervention|"The intervention is multi-level yet, targets the weakest chains in the link of PrEP initiation at safety-net hospitals designed for scalability, sustainability, and implementability across a wide range of settings. It consists of Surveillance by STI testing, Navigation by unannounced patient navigators to the Sexual Health Clinic (SHC), Accelerated follow-up with providers with PrEP expertise, Point-of-care PrEP counseling and laboratory testing, and Seamless, consistent, longitudinal, comprehensive care (SNAPS). SNAPS will selectively target those care settings where PrEP prescribing is particularly rare or absent (eg, OB/GYN). Study team will utilize a quasi- experimental design to compare rates of PrEP uptake overall, PrEP initiation in disproportionately-impacted groups, and PrEP retention pre-versus post-initiation of SNAPS, controlling for secular trends."
214581401|NCT04279392|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zoledronic acid infusion
214581402|NCT04279392|DRUG|Placebos|Saline infusion
214581403|NCT06155227|OTHER|aerobic exercise combined with blood flow restriction|aerobic exercise combined with blood flow restriction for 18 sessions
214581404|NCT06155227|OTHER|aerobic exercise|aerobic exercise for 18 sessions
214581405|NCT03017534|PROCEDURE|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
214581406|NCT04019223|DIAGNOSTIC_TEST|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
214581407|NCT04019223|DIAGNOSTIC_TEST|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
214710287|NCT04550481|DRUG|Lisinopril|Given PO
214710288|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
214710289|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
214581408|NCT02961543|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
214581409|NCT02961543|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
214581410|NCT01171807|DRUG|Dex 21-P|At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.
214581411|NCT01171807|DRUG|Placebo|Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
214581412|NCT00136942|DRUG|Atorvastatin|
214581413|NCT01488877|DRUG|PF-03882845|3 mg tablet once daily
214581414|NCT01488877|DRUG|PF-03882845|up to 10 mg tablet once daily
214581415|NCT01488877|DRUG|PF-03882845|up to 30 mg once daily
214581416|NCT01488877|DRUG|Spironolactone|spironolactone 25 mg once daily
214581417|NCT01488877|OTHER|placebo|placebo once daily
214581418|NCT04294953|DRUG|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
214581419|NCT04294953|DRUG|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
214581420|NCT01035073|DRUG|Duloxetine|30-60 mg daily for 8 weeks
214581421|NCT03318042|OTHER|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
214581422|NCT03318042|OTHER|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
214581423|NCT00602940|PROCEDURE|Acupuncture|12 treatments over 8 weeks
214581424|NCT00602940|PROCEDURE|Sham Acupuncture|12 treatments over 8 weeks
214581425|NCT01693705|PROCEDURE|Tracheostomy|
214581426|NCT05145153|PROCEDURE|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
214581427|NCT02957851|DRUG|Medical Air|
214581428|NCT02957851|DRUG|EMONO|
214710290|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
214710291|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
214581429|NCT04209959|DRUG|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
214581430|NCT04277351|DEVICE|Transcranial alternating current stimulation|Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
214581431|NCT02443090|DRUG|fispemifene|
214581432|NCT02443090|OTHER|Placebo|
214581433|NCT02969239|DRUG|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
214581434|NCT02969239|DRUG|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
214581435|NCT04229875|OTHER|CAG Bipolar|See description of CAG Bipolar
214581436|NCT04289051|DEVICE|HYDRAL Oral Rinse|Application 4 times a day for two weeks
214581437|NCT04289051|DEVICE|BIOTENE® Oral Rinse|Application 4 times a day for two weeks
214581438|NCT04289051|DEVICE|Placebo Oral Rinse|Application 4 times a day for two weeks
214581439|NCT05356299|OTHER|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
214581440|NCT01901341|DRUG|CB-5945|
214581441|NCT01901341|DRUG|Placebo|
214710292|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
214710293|NCT05452772|DRUG|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
214581442|NCT02093000|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
214581443|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"* 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment"
214581444|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
214581445|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
214581446|NCT05927662|PROCEDURE|lumbar discectomy|mini-open discectomy
214581447|NCT01806103|BEHAVIORAL|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
214710294|NCT05452772|DRUG|Niacin|Participants will received two niacin sessions, 1 week apart
214581448|NCT00864201|DRUG|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
214581449|NCT02093559|BEHAVIORAL|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
214581450|NCT04991532|OTHER||
214581451|NCT02977637|PROCEDURE|Feraheme MRI/MRA|
214581452|NCT01152632|OTHER|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
214710295|NCT03521661|PROCEDURE|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
214581453|NCT04950504|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
214581454|NCT04950504|DRUG|Placebo|CNP-201 Placebo
214710296|NCT06554717|DRUG|Tesamorelin|Tesamorelin WR 1.28 mg given subcutaneously daily
214710297|NCT06554717|DRUG|Placebo|Identical placebo injection given subcutaneously daily
214710298|NCT06554717|BEHAVIORAL|Exercise|Home-based semi-supervised exercise program
214710299|NCT06120465|OTHER|Yoga|Yoga classes
214710300|NCT03326869|DEVICE|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
214581455|NCT02944591|DEVICE|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
214581456|NCT03306459|DIAGNOSTIC_TEST|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
214581457|NCT06063018|DRUG|RC48 + Tislelizumab|RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
214581458|NCT02787889|OTHER|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.
214581459|NCT02787889|OTHER|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
214581460|NCT01630746|DRUG|TAK-438|
214581461|NCT01630746|DRUG|TAK-438|
214581462|NCT01182701|BEHAVIORAL|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
214581463|NCT00920049|BEHAVIORAL|Persuasion|
214581464|NCT03450187|DRUG|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
214581465|NCT02561754|DIETARY_SUPPLEMENT|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
214581466|NCT02561754|DIETARY_SUPPLEMENT|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
214581467|NCT02561754|BEHAVIORAL|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
214581468|NCT02561754|BEHAVIORAL|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
214581469|NCT02561754|OTHER|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
214581470|NCT06155448|OTHER|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
214581471|NCT04219579|DRUG|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
214581472|NCT04219579|DRUG|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
214581473|NCT02579499|DRUG|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
214581474|NCT02579499|DRUG|targeted LDL-C goal statin|"1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
214581475|NCT00677326|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214581476|NCT00169052|BEHAVIORAL|Health Care Management and Supported Rehabilitation|
214581477|NCT00822172|DIETARY_SUPPLEMENT|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
214581478|NCT00822172|DRUG|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
214581479|NCT02749435|OTHER|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
214581480|NCT02156128|BEHAVIORAL|Cogmed working memory training|
214581481|NCT02156128|BEHAVIORAL|Control group|
214581482|NCT06284720|DEVICE|Gamma tACS (40 Hz) over the precuneus|5 sessions of gamma tACS (40 Hz) over the precuneus
214581483|NCT06284720|DEVICE|Sham tACS over the precuneus|5 sessions of sham tACS over the precuneus
214581484|NCT02479048|DIETARY_SUPPLEMENT|Test meal 1|High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
214581485|NCT02479048|DIETARY_SUPPLEMENT|Test meal 2|High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.
214581486|NCT02479048|DIETARY_SUPPLEMENT|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
214581487|NCT03809559|DEVICE|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
214581488|NCT00003493|DRUG|dexamethasone|
214581489|NCT00003493|DRUG|pegylated liposomal doxorubicin hydrochloride|
214581490|NCT00003493|DRUG|vincristine sulfate|
214581491|NCT06277544|PROCEDURE|lateral ankle ligament repair or reconstruction|repair or reconstruction procedure for lateral ankle ligament
214581492|NCT01072760|PROCEDURE|K wire|Mallet finger treatment
214581493|NCT01528176|DRUG|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
214581494|NCT05741359|DRUG|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
214581495|NCT03061071|DEVICE|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
214581496|NCT03061071|DEVICE|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
214581497|NCT05515003|OTHER|Individualized patient education|"In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes."
214710301|NCT01630798|DRUG|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
214581498|NCT00768794|DIETARY_SUPPLEMENT|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
214581499|NCT00768794|DIETARY_SUPPLEMENT|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
214581500|NCT01376427|DRUG|Dexamethasone|Dexamethasone
214581501|NCT01376427|DRUG|Methotrexate|Methotrexate
214581502|NCT01376427|DRUG|Vincristine|Vincristine
214581503|NCT04374344|OTHER|Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements|Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
214581504|NCT01981473|OTHER|no intervention|
214581505|NCT01981473|OTHER|no intervention|
214581506|NCT01981473|OTHER|no intervention|
214710302|NCT03788967|DRUG|TBPM-PI-HBr|TBPM-PI-HBr tablets administered orally.
214710303|NCT03788967|DRUG|Ertapenem|Antibiotic Therapy for cUTI.
214710304|NCT03788967|DRUG|Dummy Infusion|Dummy intravenous infusion.
214710305|NCT03788967|DRUG|Dummy tablets|Dummy tablets orally.
214581507|NCT01336803|DRUG|Feraheme|5 mg/kg by intravenous (IV) administration
214581508|NCT01336803|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
214581509|NCT00452062|DRUG|Dexamethasone|
214581510|NCT05251662|DRUG|Sintilimab|200mg IV d1 Q3W
214581511|NCT05251662|DRUG|IBI305|7.5mg/kg IV d1 Q3W
214581512|NCT05251662|DRUG|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
214581513|NCT03235960|DEVICE|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
214581514|NCT00600678|DIETARY_SUPPLEMENT|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
214710306|NCT03927911|DRUG|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
214581515|NCT01283477|DEVICE|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
214581516|NCT01283477|DEVICE|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
214581517|NCT01119599|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
214581518|NCT01119599|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214581519|NCT01119599|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214581520|NCT01119599|OTHER|Laboratory Biomarker Analysis|Correlative studies
214581521|NCT01119599|OTHER|Pharmacological Study|Correlative studies
214710307|NCT03927911|DRUG|Standard of Care|Standard of Care
214710308|NCT04432376|DRUG|miconazole 2% oil|Drug treatment of otomycosis for 14 days
214710309|NCT04432376|DRUG|vehicle oil|Placebo treatment of otomycosis for 14 days
214581522|NCT01119599|DRUG|Temozolomide|Given PO
214581523|NCT01119599|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214581524|NCT00406055|DEVICE|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
214581525|NCT00514891|BIOLOGICAL|Vitamin A|The effect of vitamin A given with different vaccines will be studied
214581526|NCT03354091|DEVICE|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
214710310|NCT03122249|BEHAVIORAL|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
214710311|NCT05038852|DEVICE|smartphone applications|app is designed to help you learn relaxation skills.
214581527|NCT06020053|PROCEDURE|saline irrigation at various temperatures (4°C, 25°C)|cold serum application
214581528|NCT02937454|DRUG|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
214581529|NCT02937454|OTHER|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
214581530|NCT05755360|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
214581531|NCT01600820|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
214710312|NCT05038852|DEVICE|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
214581532|NCT01600820|OTHER|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
214581533|NCT01600820|OTHER|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
214581534|NCT03276325|DRUG|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
214581535|NCT03276325|DRUG|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
214581536|NCT04643522|OTHER|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
214581537|NCT04417296|DIAGNOSTIC_TEST|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
214581538|NCT02313376|BIOLOGICAL|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
214581539|NCT02703051|DRUG|GMI-1271|
214581540|NCT02703051|DRUG|Filgrastim|
214581541|NCT02703051|DRUG|Placebo Injection|
214581542|NCT02703051|DRUG|Placebo Infusion|
214581543|NCT01147601|DRUG|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
214581544|NCT01147601|DRUG|Control (placebo) group|Control (placebo) group
214581545|NCT04152304|OTHER|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
214581546|NCT00113100|DRUG|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
214581547|NCT04897750|COMBINATION_PRODUCT|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
214581548|NCT03534401|BEHAVIORAL|ARCHES Kenya|ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
214581549|NCT01711723|DRUG|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
214581550|NCT02335528|BEHAVIORAL|SimCoach|
214581551|NCT05900687|BEHAVIORAL|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
214581552|NCT06463561|DEVICE|Continuous positive airway pressure|Treatment will start with an empirical pressure of 8 cmH2O and, within a maximum of 3 weeks, the pressure will be adjusted by means of automatic titration, establishing the pressure corresponding to the 95th percentile.
214581553|NCT06463561|OTHER|Hygienic-dietary recommendations and daily physical activity promotion|Hygienic-dietary recommendations on sleep and intervention for the promotion of daily physical activity, establishing walking as a goal 10,000 steps per day. To do this, they will be provided with a pedometer and asked to fill out a form with the steps walked each day. At each visit, the distance walked will be reviewed and the goal set will be reiterated.
214581554|NCT03404687|RADIATION|ultrasound|for assessment of adnexal masses size and pattern
214581555|NCT03404687|DIAGNOSTIC_TEST|cancer antigen 125 level|for prediction of malignancy
214581556|NCT03404687|RADIATION|Doppler|for detection of blood flow
214581557|NCT04601870|OTHER|No Financial Incentive|No monetary incentive to participate in quit planning and quit counseling with a tobacco cessation specialist.
214581558|NCT04601870|OTHER|Financial Incentive (100 dollars)|Financial incentive (100 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
214581559|NCT04601870|OTHER|Financial Incentive (50 dollars)|Financial incentive (50 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
214581560|NCT05963139|DRUG|Bupivacaine|US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
214581561|NCT05963139|DRUG|Morphine Sulfate|In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
214581562|NCT01888900|DRUG|DUAL|Asunaprevir and Daclatsvir
214581563|NCT01888900|DRUG|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
214581564|NCT03932812|BEHAVIORAL|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
214581565|NCT05686538|OTHER|iDLI|TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: \>10e7 NK cells/kg and \>10e6 TCRgd cells/kg
214581566|NCT05467189|DRUG|Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)|As part of routine treatment.
214581567|NCT04645667|DRUG|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
214581568|NCT01548378|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
214581569|NCT01548378|GENETIC|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
214581570|NCT01548378|GENETIC|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
214581571|NCT01548378|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
214581572|NCT02192879|DEVICE|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
214710313|NCT00211874|BEHAVIORAL|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
214710314|NCT00498849|DEVICE|CPAP|
214581573|NCT02192879|DEVICE|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
214581574|NCT02192879|DRUG|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
214581575|NCT06078865|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
214581576|NCT05117164|OTHER|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
214581577|NCT03034538|DRUG|Zonegran|100mg
214581578|NCT03034538|DRUG|Zonegran|200mg
214581579|NCT00154765|DEVICE|sling suspension exercises|
214581580|NCT02585232|BEHAVIORAL|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
214581581|NCT02585232|BEHAVIORAL|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
214581582|NCT04303767|DRUG|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
214581583|NCT04303767|PROCEDURE|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
214581584|NCT04318067|DRUG|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
214581585|NCT03912246|BIOLOGICAL|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
214581586|NCT03912246|PROCEDURE|lumbar puncture|collection of cerebrospinal fluid
214581587|NCT02734927|OTHER|realization of computerized exercises|
214581588|NCT02257567|DRUG|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
214581589|NCT02257567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
214581590|NCT02257567|DRUG|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
214581591|NCT02257567|DRUG|Rituximab|Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
214581592|NCT02257567|DRUG|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
214581593|NCT03215810|PROCEDURE|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
214581594|NCT03215810|DRUG|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
214581595|NCT03215810|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
214581596|NCT03215810|DRUG|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
214581597|NCT03215810|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
214581598|NCT03215810|DRUG|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
214581599|NCT03814031|OTHER|NO internvention|NO internvention
214581600|NCT01466933|BEHAVIORAL|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
214581601|NCT01466933|BEHAVIORAL|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
214581602|NCT01354561|PROCEDURE|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
214710315|NCT02979366|DRUG|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
214710316|NCT02979366|DRUG|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
214581603|NCT04762121|PROCEDURE|Peripheral IV|Insertion of peripheral intravenous catheter
214581604|NCT04006054|DRUG|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
214581605|NCT04006054|DRUG|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
214581606|NCT02479321|OTHER|GDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
214581607|NCT02479321|DEVICE|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
214710317|NCT00672295|DRUG|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
214581608|NCT03106597|DRUG|Manidipine 20mg|"After a 1\~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
214581609|NCT03106597|DRUG|Amlodipine 10mg|"After a 1\~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
214581610|NCT01927926|DIETARY_SUPPLEMENT|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
214581611|NCT01927926|DIETARY_SUPPLEMENT|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
214581612|NCT02679573|DRUG|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
214581613|NCT02679573|DRUG|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
214581614|NCT02679573|DRUG|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
214581615|NCT00004204|DRUG|temozolomide|
214581616|NCT03996343|DEVICE|Endotracheal intubation|COMPLETE
214581617|NCT03996343|DEVICE|Laryngeal mask airway|COMPLETE
214710318|NCT06269718|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
214710319|NCT06269718|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
214710320|NCT01261260|DRUG|Uridine|1 gram tablets BID for 7 days
214581618|NCT03170999|OTHER|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
214581619|NCT03170999|OTHER|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
214581620|NCT03170999|OTHER|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
214581621|NCT01143779|DRUG|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
214581622|NCT05023083|OTHER|Functional Status Questionnaire Urdu version|The FSQ instrument translated into Urdu consists of only 34 items, main sections addressed physical function in the activities of daily living, psychological function, role function, social function and variety of performance measures.(8) Scores range from a 0 - 4, 1 - 4, and 1 - 6 scale per question depending on section. It increases reliability and patients ease and comfort. Total score range from 0 to 100 higher score represents the more severe condition.
214581623|NCT05023083|OTHER|Original Functional Status Questionnaire|FSQ was developed to allow the comprehensive and efficient assessment of physical, psychosocial, social, and role functioning in ambulatory patients. It is a self-administered survey that takes approximately 15 min to complete. The results can be scored to produce a one-page report for clinicians to use in their practices. The responses to items within a scale are averaged and transformed to a scale with a potential range of 0 to 100.Higher score represents the more severe condition.
214581624|NCT04080908|DRUG|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
214581625|NCT04654845|PROCEDURE|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
214581626|NCT04654845|PROCEDURE|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
214581627|NCT00324116|DRUG|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
214581628|NCT05786703|DIAGNOSTIC_TEST|Biochemical, weight measurements, Blood pressure and blood sugar level|At first visit short interview using the STEPwise approach of the STEPS surveillance tool for NCDs from the WHO will be conducted. On subsequent visits, hypertension and blood sugar level and cholesterol levels will be measured and adherence to medication will be assessed. The patient's registry will be developed following recommendation from the HEARTS technical package of World Health Organization (WHO) with some modification if needed.
214581629|NCT01806623|DRUG|Fluconazole|Single oral dose of 150mg Fluconazole
214581630|NCT00751361|DEVICE|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
214581631|NCT00153153|DRUG|polyethyleneglycol3350|
214581632|NCT03635723|DEVICE|Activity monitor|Technology allowing measurement of physical activity
214581633|NCT00568412|DEVICE|Zarzenda|Topical cream, applied twice daily for three weeks
214581634|NCT00568412|DRUG|Elidel|1% cream, applied topically twice daily for three weeks
214581635|NCT01215201|PROCEDURE|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
214581636|NCT01215201|PROCEDURE|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
214581637|NCT01908192|DRUG|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
214581638|NCT01908192|DRUG|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
214581639|NCT01266681|DRUG|amiodarone|"Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
214710321|NCT01410162|DRUG|Tacrolimus|tacrolimus extended release capsules vs Prograf
214581640|NCT01266681|DRUG|Dronedarone|"Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
214581641|NCT01737827|DRUG|INC280|INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.
214581642|NCT04411160|DRUG|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
214581643|NCT04411160|DRUG|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
214581644|NCT04411160|DEVICE|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
214581645|NCT02521987|PROCEDURE|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
214581646|NCT02521987|PROCEDURE|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
214581647|NCT01451827|DRUG|Tolvaptan MR|50/80 mg capsules
214581648|NCT01451827|DRUG|Tolvaptan IR|60/30 mg capsules
214581649|NCT01451827|DRUG|Placebo|tablet
214581650|NCT04454775|DIAGNOSTIC_TEST|coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.|
214581651|NCT03003455|PROCEDURE|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
214581652|NCT03003455|PROCEDURE|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
214581653|NCT02458703|OTHER|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
214581654|NCT03819998|DIAGNOSTIC_TEST|measurement of Fetuin-A level in serum|Fetuin A level will be measured in blood of the PCOS women
214581655|NCT01034605|DIETARY_SUPPLEMENT|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
214581656|NCT00473005|DRUG|Capecitabine|825 mg/m2 bid, Oral
214581657|NCT00473005|DRUG|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
214581658|NCT00968227|BIOLOGICAL|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
214581659|NCT06180018|OTHER|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
214581660|NCT01856868|DRUG|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
214581661|NCT02103244|DRUG|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
214581662|NCT00876681|PROCEDURE|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
214581663|NCT02854787|DRUG|Phenylephrine|A bolus of 100 mcg
214581664|NCT02854787|DRUG|Norepinephrine|A bolus of 0,2 mcg/kg
214581665|NCT01865968|BIOLOGICAL|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
214581666|NCT01865968|BIOLOGICAL|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
214581667|NCT03971903|BEHAVIORAL|Attention bias modification|The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
214581668|NCT02133118|DRUG|individual SUs, insulin, pioglitazone|
214581669|NCT01034163|DRUG|Panobinostat|
214581670|NCT01034163|DRUG|Placebo|Placebo
214581671|NCT05382143|DRUG|Atosiban|Pilot study
214581672|NCT03281655|DRUG|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
214581673|NCT01462123|OTHER|endoscopic assessment of colonic polyps|
214581674|NCT03677765|PROCEDURE|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
214581675|NCT05412797|BEHAVIORAL|Cycling/Using a DeskCycle|The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2
214581676|NCT05412797|BEHAVIORAL|Regular activities|The active comparator performed normal daily activities
214581677|NCT00379028|DRUG|Budesonide/Formoterol Turbuhaler|
214581678|NCT00379028|DRUG|Salmeterol/Fluticasone Diskus|
214581679|NCT01757444|DEVICE|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
214581680|NCT01757444|DEVICE|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
214581681|NCT00492102|DRUG|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing \>1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
214581682|NCT06507995|DRUG|thoracic interlaminar epidural injection|. Injections were administered under sedation and sterile conditions, with all patients positioned prone and monitored. A single physician performed all injections using an 18 gauge Tuohy needle, employing the loss of resistance technique and confirming the epidural space placement with 5 mL of nonionic contrast.
214581683|NCT04051736|BIOLOGICAL|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
214581684|NCT03891693|DEVICE|Passeo-18 Lux and SUPERA® stent|Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
214581685|NCT05786105|OTHER|Bone Marrow samples collection|Bone Marrow samples collection - one ethylenediaminetetraacetic acid (EDTA) tube - for Optical Genome Mapping
214581686|NCT03950050|DRUG|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
214581687|NCT03515343|DIAGNOSTIC_TEST|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
214581688|NCT01876459|OTHER|MRI|
214581689|NCT01876459|PROCEDURE|lumbar puncture|
214581690|NCT01876459|BEHAVIORAL|neuropsychological tests|
214581691|NCT04328116|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
214581692|NCT01566253|DRUG|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
214581693|NCT01566253|DRUG|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
214581694|NCT02086604|DRUG|Brentuximab vedotin|
214581695|NCT02086604|DRUG|Lenalidomide|
214581696|NCT03026751|PROCEDURE|Bone Marrow Aspirate|Bone marrow aspirate
214581697|NCT04673253|OTHER|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
214581698|NCT04673253|OTHER|control|The controlled group was positioned in the normal supine position.
214581699|NCT04159623|DEVICE|Belk Device|Knee exoskeleton with electrostimulation
214581700|NCT04159623|OTHER|Standard Rehabilitative treatment|Use the standard rehabilitative treatment
214581701|NCT01857128|DEVICE|Drawtex dressing|
214581702|NCT01857128|DEVICE|Negative Pressure Wound Therapy|
214581703|NCT04315259|DEVICE|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
214581704|NCT01960777|PROCEDURE|Onstep|
214581705|NCT01960777|PROCEDURE|Laparoscopic repair|
214581706|NCT00989534|BEHAVIORAL|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
214581707|NCT00989534|BEHAVIORAL|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
214581708|NCT01795482|DEVICE|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
214581709|NCT02884895|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
214581710|NCT02884895|DEVICE|Direct Laryngoscopy|Direct Laryngoscopy
214581711|NCT02424734|DRUG|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
214581712|NCT02424734|DRUG|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
214581713|NCT02424734|DRUG|Aminoglycoside|Optional, will be given as per local standard of care.
214581714|NCT01240473|DRUG|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
214581715|NCT02849717|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
214581716|NCT00528645|DRUG|saracatinib|Given orally
214581717|NCT00223873|PROCEDURE|Penile Vibratory Stimulation|
214581718|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
214581719|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
214581720|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
214581721|NCT04600154|DRUG|MS-20|Specific fraction from fermented soy milk
214581722|NCT04600154|OTHER|Placebo|Fermented soy milk without active component
214581723|NCT01460173|OTHER|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
214581724|NCT00313131|DRUG|tinidazole+fluconazole vs metronidazole+clotrimazole|
214581725|NCT02641860|BIOLOGICAL|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
214581726|NCT01058031|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
214581727|NCT02627170|DEVICE|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
214581728|NCT02627729|DEVICE|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
214581729|NCT02627729|DEVICE|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
214581730|NCT04431700|OTHER|Anti-inflammatory diet|Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.
214581731|NCT04431700|OTHER|Regular diet|Focus on food journal and recording all food intake.
214581732|NCT01578200|DRUG|Lanthanum Carbonate|
214581733|NCT01578200|DRUG|Calcium Carbonate|
214581734|NCT01642251|DRUG|Cisplatin|Given IV
214581735|NCT01642251|DRUG|Etoposide|Given IV
214581736|NCT01642251|DRUG|Veliparib|Given PO
214581737|NCT01642251|DRUG|Placebo|placebo of Veliparib
214581738|NCT04054700|DEVICE|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
214581739|NCT04054700|DEVICE|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
214581740|NCT01445301|DRUG|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
214581741|NCT01445301|DRUG|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
214581742|NCT02614417|OTHER|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
214581743|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
214581744|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
214581745|NCT00752557|DRUG|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
214581746|NCT06226740|OTHER|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
214581747|NCT05372952|DEVICE|Dynetic-35 Peripheral Balloon-Expandable Stent System|Stenotic iliac lesions will be treated with the Dynetic 35 stent via a radial access
214581748|NCT00296673|DEVICE|Rehabilitation device|
214710322|NCT01092026|OTHER|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
214710323|NCT06252246|DEVICE|Phacoemulsification machine|type of phacoemulsification machine is different
214710324|NCT04836507|BIOLOGICAL|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
214710325|NCT04836507|DRUG|Fludarabine|Administered according to package insert
214710326|NCT04836507|DRUG|Cyclophosphamide|Administered according to package insert
214710327|NCT03926637|OTHER|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
214581749|NCT06171581|OTHER|stress ball|In the study, the experimental group was given a round, compressible ball for stress ball application and it was planned to squeeze this ball in their hands as often as they wanted during anaesthesia and endometrial biopsy application. The endometrial biopsy procedure is a procedure that usually takes between 8-10 minutes. The results will be evaluated considering these average times. As it is foreseen that individuals may experience the most intense anxiety and stress during anaesthesia and biopsy, it was preferred to cover this time period.
214581750|NCT06171581|OTHER|control|In the study, the no intervention group ( control group) will receive no intervention and blood pressure and stress measurements will be made with routine care and nursing interventions.
214581751|NCT02413333|DEVICE|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
214581752|NCT02413333|DEVICE|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
214581753|NCT02413333|DEVICE|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
214581754|NCT06275139|OTHER|Integrated Assessment of Cervicocerebral Vessels|Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.
214581755|NCT06520254|OTHER|Massage therapy|"A 30-minute massage session will be applied in the following structures:~* Flexor hallucis longus muscle,~* Flexor digitorum longus muscle,~* Tibialis posterior muscle,~* Semitendinosus muscle,~* Semimembranosus muscle,~* Gluteus maximus muscle,~* Longissimus muscle,~* Levator costarum muscles 1-5 During the massage session basic Swedish massage techniques were used."
214581756|NCT01984073|DRUG|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
214581757|NCT01984073|DRUG|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
214581758|NCT01984073|OTHER|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
214710328|NCT02448017|DEVICE|The Herbst appliance|Orthodontic functional appliance
214581759|NCT06193304|DRUG|Eliglustat|Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
214581760|NCT02996474|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
214581761|NCT02996474|DRUG|Decitabine|Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
214581762|NCT04100577|OTHER|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
214581763|NCT04277182|BIOLOGICAL|burn wound dressing|"1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."
214581764|NCT01269515|DRUG|Etoricoxib|90 mg QD
214581765|NCT00540046|DEVICE|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
214581766|NCT05310851|OTHER|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
214581767|NCT02891837|DRUG|L-citrulline|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
214581768|NCT02891837|OTHER|Placebo|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
214581769|NCT04971278|BEHAVIORAL|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
214581770|NCT02598024|BEHAVIORAL|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
214581771|NCT02598024|BEHAVIORAL|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
214581772|NCT04662099|BIOLOGICAL|Conditioning chemotherapy followed by CAR T cell infusion|Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10\^6-3.0X10\^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 3.0X10\^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.
214581773|NCT03037073|DRUG|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
214581774|NCT03037073|DRUG|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
214581775|NCT04318847|DRUG|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
214581776|NCT00185965|DRUG|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
214581777|NCT02533531|DEVICE|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
214581778|NCT01423721|DRUG|Bromihexine hydrochloride syrup|syrup
214581779|NCT01423721|DRUG|Bromihexine hydrochloride granules|granules
214581780|NCT02032979|BEHAVIORAL|Psychiatric test|
214581781|NCT02047903|DRUG|Afatinib|50, 40, 30 or 20 mg
214581782|NCT05769647|DEVICE|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
214581783|NCT05769647|DEVICE|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
214581784|NCT00057174|DRUG|Disease management of gastroesophageal reflux disease|
214581785|NCT03901482|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
214581786|NCT03901482|DRUG|Placebos|Placebo for STS101
214581787|NCT03496831|DRUG|Biologic Agents|
214581788|NCT01140711|PROCEDURE|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
214581789|NCT06439459|PROCEDURE|Stromal vascular fraction transplantation|"Stromal vascular fraction was extracted from subcutaneous fat harvested from either the abdomen or the posterior inner thigh region. The SVF cell-pellet was washed and was adjusted to 2×10\^6 cells/mL. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares.~The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg. This procedure was repeated until adequate skin area was achieved for subsequent facial restoration surgery."
214581790|NCT03481192|BEHAVIORAL|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
214581791|NCT02647216|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
214581792|NCT02647216|BEHAVIORAL|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
214581793|NCT01957449|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
214581794|NCT01957449|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
214581795|NCT02772406|DEVICE|Linked Color Imaging|
214581796|NCT02772406|DEVICE|white light imaging|
214581797|NCT05094505|OTHER|Exercise in normoxia|Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
214581798|NCT05094505|OTHER|Control diet|Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
214581799|NCT05094505|OTHER|Exercise in hypoxia|Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
214581800|NCT05094505|OTHER|Low carbohydrate diet|Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
214581801|NCT06058754|BEHAVIORAL|The ADAPT Program|The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0
214710329|NCT02448017|DEVICE|Twin block appliance|Orthodontic functional appliance
214710330|NCT00371813|DRUG|Varenicline tartrate|
214710331|NCT00371813|DRUG|Placebo|
214710332|NCT02485613|DRUG|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
214581802|NCT06058754|BEHAVIORAL|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
214581803|NCT03616977|DRUG|LY900014 U-200|Administered SC
214581804|NCT03616977|DRUG|LY900014 U-100|Administered SC
214581805|NCT04879953|DRUG|PIPAC with systemic chemotherapy|PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
214581806|NCT04879953|DRUG|Systemic chemotherapy alone|Intravenous chemotherapy
214581807|NCT04395872|BEHAVIORAL|Psychiatric counseling|Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
214581808|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
214581809|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
214581810|NCT06452498|DRUG|Metformin Hydrochloride|Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
214581811|NCT06452498|DRUG|Placebo|Capsule filled with cellulose.
214581812|NCT03456427|DEVICE|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) \& Mediolateral Oblique (MLO).
214581813|NCT03456427|DEVICE|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
214581814|NCT01323972|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
214581815|NCT03804970|BEHAVIORAL|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
214581816|NCT03804970|BEHAVIORAL|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
214581817|NCT03804970|BEHAVIORAL|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
214581818|NCT03804970|BEHAVIORAL|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
214581819|NCT03804970|BEHAVIORAL|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
214581820|NCT01540864|DRUG|HPP404|Administered orally once daily for 26 weeks
214581821|NCT01540864|DRUG|Placebo|Administered orally once daily for 26 weeks
214581822|NCT00060762|BEHAVIORAL|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
214581823|NCT00060762|BEHAVIORAL|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
214581824|NCT00060762|BEHAVIORAL|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
214581825|NCT04268927|DRUG|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
214581826|NCT04268927|DRUG|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
214581827|NCT04072068|DRUG|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
214581828|NCT05728320|DEVICE|Glucose monitoring with flash glucose monitor|All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.
214581829|NCT05316623|DEVICE|TENS|TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
214581830|NCT04129827|OTHER|Clinical, self-reported psychological and biomechanical assessments|"1. medical check up~   * active and passive Range Of Motion (ROM)~  * anterior drawer test~  * knee's alignment~  * modified cincinnati rating system questionnaire (mCRSQ)~  * tegner lysholm knee scoring scale (TLKS)~  * Tegner Activity Level Score (TALS)~2. self-reported psychological questionnaires~   * Tampa Scale of Kinesiophobia (TSK)~  * ACL Return to Sport after Injury (ACL-RSI) score~3. biomechanical tests~   * Stability test: to balance on one/two legs on a free to move disc for 30s~  * Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~  * Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~  * fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
214581831|NCT03993951|DEVICE|ICT System|Update the Information and Communications Technology System in Family Service Agencies
214581832|NCT05189392|DEVICE|PICO|after hip arthroplasty application of visible opsite plaster on the surgical wound
214581833|NCT00051259|DRUG|Extended-Release Bupropion Hydrochloride|
214710333|NCT05645653|BEHAVIORAL|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
214710334|NCT01894334|DRUG|Ulinastatin|
214710335|NCT01894334|DRUG|Tranexamic acid|
214710336|NCT01894334|DRUG|Edaravone|
214710337|NCT04058158|DRUG|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
214710338|NCT04058158|DRUG|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
214581834|NCT04007250|DEVICE|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~* FENIX™ System Implant~* FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
214581835|NCT02008877|DRUG|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
214581836|NCT02008877|DRUG|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
214581837|NCT01992952|DRUG|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
214581838|NCT01992952|DRUG|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
214581839|NCT01992952|DRUG|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
214581840|NCT01740141|PROCEDURE|Plexus brachialis block|
214581841|NCT05352659|BEHAVIORAL|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
214581842|NCT05352659|BEHAVIORAL|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
214581843|NCT03760445|DRUG|HDM201|2.5 mg and 10mg capsules, given orally
214581844|NCT03760445|DRUG|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
214581845|NCT03760445|DRUG|anthracycline|20mg or other strength as locally available given intravenously
214581846|NCT03760445|DRUG|midostaurin|25mg capsules given orally
214710339|NCT04847141|BIOLOGICAL|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
214581847|NCT03760445|DRUG|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
214581848|NCT03760445|DRUG|posaconazole|100mg delayed release tablet or other strength as locally available given orally
214581849|NCT03760445|DRUG|midazolam|2mg/mL oral solution or in other strength as locally available
214581850|NCT01049217|DRUG|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
214581851|NCT01049217|DRUG|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
214581852|NCT02111317|DRUG|ASP015K|oral
214581853|NCT02111317|DRUG|verapamil|oral
214581854|NCT03341689|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
214581855|NCT03341689|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
214581856|NCT03341689|DRUG|Placebo|microcrystalline cellulose capsule
214581857|NCT00834327|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
214581858|NCT01038622|DRUG|L-arginine|5-day L-arginine treatment
214581859|NCT01038622|DRUG|placebo|5-day placebo treatment
214581860|NCT05134077|PROCEDURE|CT scan with contrast|CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
214581861|NCT05134077|RADIATION|Nephroscintigraphy|Nephroscintigraphy is necessary to determine the renal function
214581862|NCT03495947|BEHAVIORAL|high flow nasal cannula|24 hours of continuous use in the immediate post-extubation period.
214581863|NCT00903682|DRUG|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
214581864|NCT00903682|DRUG|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
214581865|NCT02495792|DEVICE|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
214581866|NCT00359125|DRUG|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
214581867|NCT00359125|OTHER|Placebo|Placebo, 600 mg/day for 1 week.
214581868|NCT02589561|DEVICE|Remote fitting|remote fitting of hearing aids
214581869|NCT02589561|DEVICE|Face to face fitting|face to face fitting of hearing aids
214581870|NCT04351568|OTHER|quesionnair|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
214581871|NCT06502223|PROCEDURE|Pain Perception in Patients Undergoing Lumbar Disc Herniation Surgery|Analyze tryptophan metabolites (picolinic acid, 3- Hydroxykynurenine, anthranilic acid, kynurenine, quinolinic acid, kynurenic acid, xanthurenic acid). Concurrent VAS pain assessments were conducted, and correlations between tryptophan metabolites and VAS were evaluated.
214581872|NCT04783831|DEVICE|Biodegradable stent|Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.
214581873|NCT06171347|OTHER|Oral cold spray (tap water)|Oral cold spray (tap water)
214710340|NCT04847141|DRUG|0.9% Sodium chloride|C19-IG 20% matching placebo
214581874|NCT02813629|DEVICE|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
214581875|NCT03228745|BEHAVIORAL|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
214581876|NCT03629639|DRUG|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
214581877|NCT02374892|BEHAVIORAL|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
214581878|NCT04213950|OTHER|Rabies PEP quality improvement bundle|The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
214581879|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
214581880|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
214581881|NCT03643393|PROCEDURE|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
214581882|NCT05977036|DEVICE|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
214581883|NCT05977036|DRUG|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
214581884|NCT00784940|DRUG|Anastrozole|1mg, orally, once daily
214581885|NCT00784940|DRUG|Tamoxifen|20mg, orally, once daily
214581886|NCT03799835|DRUG|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
214581887|NCT03799835|DRUG|Atezolizumab|IV perfusion
214581888|NCT02909764|OTHER|Low Sodium Group|Breakfast Cereal
214581889|NCT02686827|DRUG|Paricalcitol|Vitamin D3 analogue
214581890|NCT02686827|DRUG|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
214581891|NCT03183726|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."
214581892|NCT03141905|OTHER|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
214581893|NCT03141905|OTHER|Usual Care|Standard clinical care
214581894|NCT04638634|BIOLOGICAL|CSL760|An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
214581895|NCT01002300|DRUG|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
214581896|NCT05987202|OTHER|DA closure in a population of premature infants|Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
214581897|NCT06654102|OTHER|Deep UVA Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 1 and 2 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
214581898|NCT06654102|OTHER|Deep UVA+HEV Blue Light Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 3 and 4 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
214581899|NCT06247059|DEVICE|Box Fan|Classrooms assigned to this arm will be equipped with 2 - 8 box fans each with a single minimum efficiency reporting value-14 (MERV-14) filter sufficient to increase effective air changes per hour to 12 based on the clean air delivery rate measured in cubic feet per minute of the box fan + filter \* 60 divided by the room volume.
214581900|NCT06247059|DEVICE|UV Germicidal Irradiation Lamp Unit|Classrooms assigned to this arm will be equipped with one or two 222nm wavelength light ultraviolet germicidal irradiation lamp units (number of units per classroom based on room volume).
214581901|NCT06247059|DEVICE|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms assigned to this arm will be equipped with both box fans and UV germicidal irradiation lamp units.
214581902|NCT04706559|DRUG|Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii|Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
214581903|NCT04706559|DRUG|Conventional treatment|topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
214581904|NCT06863324|DIAGNOSTIC_TEST|Radiation induced Lymphocyte Apoptosis diagnostic test|Diagnostic test for estimation of individual radiosensitivity, based on blood test, whose clinical value has been demonstrated in predicting complications in patients irradiated for breast or prostate cancer. These tests are based on the rate of radiation-induced lymphocyte apoptosis, known as the RILA (Radiation Induced Lymphocyte Apoptosis) score
214581905|NCT06729320|BIOLOGICAL|Umbilical cord blood mononuclear cells|Intravenous infusion of UCB-MNCs (3×10\^8/ time, once a week, four times in total)
214581906|NCT06729320|COMBINATION_PRODUCT|Conventional hematopoietic recovery therapy|Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
214581907|NCT06728501|BEHAVIORAL|Diabetes education|Patients receive 5 hours of diabetes education
214581908|NCT06728618|DRUG|Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel|"Neoadjuvant treatment: the participants will receive Tislelizumab 200 mg, Cisplatin 75 mg/m2, Nab-paclitaxel 260 mg/m2 (each 3-week cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles.~Adjuvant treatment: the participants will receive Tislelizumab 200 mg (each 3-week cycle, a total of 8 cycle) and Cetuximab (250 mg/m2, each 2-week, a total of 12 cycle) for a total of half a year."
214581909|NCT06728150|RADIATION|computerized tomography|The patients will have 3 monthly CT scans of the brain for 2 years and 6 monthly CT scans for 2 years for total of 4 years.
214581910|NCT06729593|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
214581911|NCT06729593|BIOLOGICAL|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
214581912|NCT06729593|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
214581913|NCT06729736|PROCEDURE|ERAS protocol|"The ERAS protocol includes:~* Pre-admission education, counselling and nutritional support~* Pre-induction oral analgesics~* Minimal fasting and carbohydrate loading~* Omission of nasogastric intubation~* Intra-operative abdominal nerve block~* Early mobilization~* Early oral nutrition and minimal IV fluids~* Multimodal opioid sparing analgesia~* Postoperative nausea and vomiting prophylaxis~* Early removal of urinary catheters"
214581914|NCT06729476|DEVICE|Uroshield vibrator device|UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
214581915|NCT06745934|BEHAVIORAL|Healthy Minds Program|Participants in this arm engage with the Healthy Minds Program app/
214581916|NCT01732159|OTHER|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
214581917|NCT06906016|BIOLOGICAL|Collection of blood samples for the study of HBV biomarkers|The intervention involves the additional and minimal collection of two blood samples during routine care procedures (9mL in a dry tube and 9mL in a Paxgene tube). These samples are specifically collected for research purposes and will be stored in the laboratory at the Henri Mondor Biobank Platform under the responsibility of Pr Bijan Ghaleh-Marzban for 15 years. The samples will be preserved under strict conditions and may be used for future analyses related to the pathology of HBV infection or other scientific advancements, with the patient's informed consent.
214581918|NCT06907420|DEVICE|Visual stimulation|40 Hz visual stimulation will be delivered at the same time of day over 5 consecutive days. Participants will lay down while wearing the customized sleep mask with inbuilt red LEDs flickering at 40 Hz linked to a microcontroller. Participants will be asked to keep their eyes closed and encouraged to fall asleep for the full stimulation duration of 60 minutes.
214581919|NCT06907433|OTHER|Kinesiotaping|The lymphatic correction technique described by Kase for use in sacroiliac sprains or inflammations was used in KT of the dysfunctional sacroiliac joint. While the patient is standing with the spine in a neutral position, the base part of the fan-shaped cut Kinesio tape will be attached approximately 2-3 inches (approximately 5-8 cm) above the dysfunctional sacroiliac joint. Then, the patient is asked to lean forward and rotate in the opposite direction to the dysfunctional side. The tail parts of the fan-shaped tape are passed downward and inward at a 45-degree angle over the sacroiliac joint and attached to the superior edge of the gluteus maximus. The base of another kinesio tape was attached approximately 2-3 inches (approximately 5-8 cm) below the dysfunctional sacroiliac joint, the tails of the fan-shaped tape were passed upward and inward at a 45-degree angle over the sacroiliac joint and attached approximately to the upper edge of the PSIS.
214581920|NCT06907433|OTHER|Rigid taping|The technique specified in the study by Allah et al. was taken as a reference for RT of the dysfunctional sacroiliac joint. Patients were placed in a lateral position on their healthy side, with the affected side uppermost, hip flexed to 45 degrees, and the femur in a neutral position. The rigid tape was attached to the anterior superior iliac spine of the upper hip and pulled tight, and attached linearly to the posterior superior iliac spine. Another piece was attached between the same points, but in a curved shape with the opening facing downward.
214581921|NCT06907433|OTHER|Exercise|Patients in all 3 groups were shown an exercise program by a physiotherapist that included lumbopelvic stabilization, flexibility and strengthening exercises for the low back and hip, and were asked to apply the exercise program for 15 days by providing visual material showing the exercises.
214581922|NCT06906198|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461, 1.0%
214581923|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461, 0.5%
214581924|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.25%|VVN461, 0.25%
214581925|NCT06906198|DRUG|VVN461 Ophthalmic Solution Placebo|Vehicle
214581926|NCT06907498|DRUG|Paromomycin|Paromomycin 500mg X3 / day
214581927|NCT06905847|DRUG|HSK39004 in healthy|1.5-12mg
214581928|NCT06905847|DRUG|HSK39004|Placebo
214581929|NCT06905847|DRUG|HSK39004 in COPD|1.5-6mg
214581930|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
214581931|NCT06056544|BEHAVIORAL|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
214581932|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
214581933|NCT05565352|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
214581934|NCT06907706|BEHAVIORAL|Physical Activity/Physical Functioning|"The physical activity portion of the program sessions focuses on teaching cognitive and behavioral skills to increase physical activity, including goalsetting, self-monitoring, overcoming barriers to physical activity, enlisting social support, and how to handle high risk situations that may result in relapses to a sedentary lifestyle. The health educator teaches participants about various forms of moderate intensity activity and has them practice brief bouts of activity of various types to ensure that they are doing the activities safely and correctly. Each week participants receive a handout to provide information about the behavioral skill taught that week. The program also provides activity trackers (week 1) and resistance bands (week 5). The pedometer assists participants in self-monitoring their activity, and the resistance bands provide a form of home-based exercise that participants can do even with limited space."
214581935|NCT06907706|BEHAVIORAL|Quality of Life|The survivorship portion of the program features a guided discussion on a different topic each session. The goals of the discussion are to present information about the topic, answer participants' questions about the topic, encourage participants to share solutions and ideas relevant to the topic with each other, and provide information on community resources participants can access if they require additional help. The health educator makes a brief presentation about the topic, answers questions, and then asks a series of 2-3 open-ended questions to facilitate discussion about the topic. At the end of the session, the health educator navigates participants who need additional information or service related to the topic to resources in the community.
214581936|NCT06329700|PROCEDURE|Hepatectomy|Surgical removal of a part of the liver
214581937|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
214581938|NCT05404581|DEVICE|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
214581939|NCT05176483|DRUG|Zanzalintinib|Zanzalintinib orally once daily (qd)
214581940|NCT05176483|DRUG|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
214581941|NCT05176483|DRUG|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
214581942|NCT05176483|DRUG|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
214581943|NCT05176483|DRUG|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
214581944|NCT05176483|DRUG|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
214581945|NCT05992350|OTHER|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
214581946|NCT04538443|OTHER|functional capacity|impact of hemodialysis on functional capacity in children with CKD
214581947|NCT04538443|OTHER|muscle strength|impact of hemodialysis on muscle strength in children with CKD
214581948|NCT04538443|OTHER|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
214581949|NCT04538443|OTHER|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
214581950|NCT00763737|PROCEDURE|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
214581951|NCT00589238|DRUG|carboplatin|
214581952|NCT00589238|DRUG|cyclophosphamide|
214581953|NCT00589238|DRUG|doxorubicin hydrochloride|
214581954|NCT00589238|DRUG|paclitaxel|
214581955|NCT05125705|BIOLOGICAL|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
214581956|NCT05125705|OTHER|Saline injection|Saline injection
214581957|NCT02502799|BEHAVIORAL|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
214581958|NCT02502799|BEHAVIORAL|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
214581959|NCT02502799|DRUG|Methylphenidate|Adolescents will receive methylphenidate.
214581960|NCT04199897|DIETARY_SUPPLEMENT|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
214581961|NCT04199897|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
214581962|NCT04199897|OTHER|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
214581963|NCT04199897|OTHER|Placebo tablets|Placebo lozenges 2 times a day for 35 days
214581964|NCT02301715|DRUG|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
214581965|NCT02301715|DRUG|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
214581966|NCT00593294|BEHAVIORAL|Physical exercise|45 minutes each day for three times/week for 6 months
214581967|NCT00593294|DRUG|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
214581968|NCT00593294|DIETARY_SUPPLEMENT|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
214581969|NCT03605173|DIAGNOSTIC_TEST|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
214581970|NCT03605173|DIAGNOSTIC_TEST|total vitamin d|routinely measured from serum
214581971|NCT02946190|BIOLOGICAL|Pertagen® aP + Td-pur®|see arm/group descriptions
214581972|NCT02946190|BIOLOGICAL|Boostrix® dTpa|see arm/group descriptions
214581973|NCT01710332|DRUG|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
214581974|NCT01851954|DRUG|Clarithromycin|IV clarithromycin infusion
214581975|NCT04694430|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
214581976|NCT04694430|OTHER|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool."
214581977|NCT04694430|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
214581978|NCT02637973|DRUG|Empagliflozin|25 mg once daily
214581979|NCT02637973|DRUG|Placebo|once daily
214581980|NCT06432608|DIETARY_SUPPLEMENT|fermented milk, Yakult|Study subjects will be provided with a product based on fermented milk, Yakult (80mL) daily for four weeks in order to know the effects of clinical manifestation of functional constipation and short-fatty acids in the Mexican population
214581981|NCT04324203|OTHER|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
214581982|NCT02166125|PROCEDURE|Endosuturing|Endoscopic suturing
214581983|NCT01304238|DRUG|lepirudin|lepirudin
214581984|NCT01304238|DRUG|danaparoid|danaparoid
214581985|NCT01304238|DRUG|argatroban|argatroban
214581986|NCT01304238|DRUG|fondaparinux|fondaparinux
214581987|NCT03532087|DRUG|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
214581988|NCT03532087|DRUG|Denosumab 60 mg|Denosumab 60 mg every 6 months.
214581989|NCT05834426|DIAGNOSTIC_TEST|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
214581990|NCT02851641|PROCEDURE|"pushed mono-canaliculonasal intubation"|
214581991|NCT01621737|DRUG|Oxytocin|42 IU BID for six weeks
214581992|NCT01621737|DRUG|Oxytocin|84 IU BID for six weeks
214581993|NCT01621737|DRUG|Placebo|Vehicle placebo
214581994|NCT05610202|DRUG|TQB3702 tablets|TQB3702 tablets are selective BTK inhibitors.
214581995|NCT02112032|DRUG|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
214581996|NCT02112032|DRUG|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
214581997|NCT00477360|DEVICE|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
214581998|NCT06372873|OTHER|re-evaluate by two senior radiologists in our medical center|The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
214581999|NCT00201786|DRUG|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
214582000|NCT02511912|PROCEDURE|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
214582001|NCT04027192|DRUG|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
214582002|NCT04027192|DRUG|BAY2328065 tablet|50 mg tablet, orally
214582003|NCT04027192|DRUG|Placebo LSF|Matching Placebo LSF, orally
214582004|NCT04027192|DRUG|Placebo tablet|Matching Placebo tablet, orally
214582005|NCT04027192|DRUG|Midazolam|1 mg per day, orally
214582006|NCT06334484|DEVICE|Advanced hybrid closed loop systems|Collect data from advanced hybrid closed loop users
214582007|NCT05259254|OTHER|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
214582008|NCT05259254|OTHER|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
214582009|NCT01345773|PROCEDURE|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
214582010|NCT00119210|DRUG|Bupropion SR|
214582011|NCT00119210|OTHER|placebo|
214582012|NCT01092741|DRUG|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
214582013|NCT04362384|DRUG|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
214582014|NCT04362384|DRUG|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
214582015|NCT04165876|DEVICE|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
214582016|NCT04165876|DEVICE|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
214582017|NCT04165876|DEVICE|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
214582018|NCT04165876|DEVICE|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
214582019|NCT05087979|DEVICE|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
214582020|NCT05715918|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
214582021|NCT05715918|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
214582022|NCT02632162|OTHER|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
214582023|NCT00339456|DRUG|HAART|
214582024|NCT05480579|BIOLOGICAL|placebo|Dose4 placebo of single IV injection
214582025|NCT05480579|BIOLOGICAL|IBI311|Dose2 IBI311 of single IV injection
214582026|NCT05480579|BIOLOGICAL|IBI311|Dose4 IBI311 of single IV injection
214582027|NCT05480579|BIOLOGICAL|placebo|Dose3 placebo of single IV injection
214582028|NCT05480579|BIOLOGICAL|placebo|Dose1 placebo of single IV injection
214582029|NCT05480579|BIOLOGICAL|IBI311|Dose1 IBI311 of single IV injection
214582030|NCT05480579|BIOLOGICAL|IBI311|Dose 3 IBI311 of single IV injection
214582031|NCT05480579|BIOLOGICAL|placebo|Dose2 placebo of single IV injection
214582032|NCT05037877|DIETARY_SUPPLEMENT|HUM supplement|HUM supplement - 1 capsule per day
214582033|NCT05037877|DIETARY_SUPPLEMENT|Placebo|Placebo supplement - 1 capsule per day
214582034|NCT05074927|DIAGNOSTIC_TEST|diaphragm ultrasonography|For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
214582035|NCT04290936|DRUG|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
214582036|NCT04290936|DRUG|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
214582037|NCT00625248|DRUG|Antithrombotics|With or without or discontinuted use of Antithrombotics
214582038|NCT04026880|DRUG|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
214582039|NCT04026880|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
214582040|NCT03429231|DIETARY_SUPPLEMENT|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
214582041|NCT00001396|DEVICE|Paragon Pacemaker|
214582042|NCT02863497|BEHAVIORAL|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
214582043|NCT03251781|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
214582044|NCT00040677|DRUG|Low Dose ICA-17043|Low dose arm
214582045|NCT00040677|DRUG|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
214582046|NCT00040677|DRUG|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
214582047|NCT00607685|DRUG|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
214582048|NCT00607685|DRUG|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
214582049|NCT03468231|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
214582050|NCT03468231|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214582051|NCT03468231|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
214582052|NCT04837898|DIETARY_SUPPLEMENT|Haskapa|Haskapa Ltd, Oxford, UK
214582053|NCT04837898|DIETARY_SUPPLEMENT|Placebo|isocaloric to the haskap powder
214582054|NCT02924428|DEVICE|Venus Versa|
214582055|NCT06054282|BEHAVIORAL|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
214582056|NCT02687893|BEHAVIORAL|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
214582057|NCT02687893|BEHAVIORAL|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
214582058|NCT01850446|DRUG|Ergoferon|Safety and Efficacy
214582059|NCT01850446|DRUG|Oseltamivir|Safety and Efficacy
214582060|NCT05060978|BEHAVIORAL|Watch your Weight During the Holidays Program|Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
214582061|NCT05060978|OTHER|Relative 5:2 Fasting|Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
214582062|NCT05060978|OTHER|Control Group|Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
214582063|NCT06271629|DIAGNOSTIC_TEST|Insomnia severity index|"The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties."
214582064|NCT02680002|BIOLOGICAL|7.5 mcg H5N1 (stored as monobulk)|
214582065|NCT02680002|BIOLOGICAL|15 mcg H5N1 (stored as monobulk)|
214582066|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored as monobulk)|
214582067|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored in vials)|
214582068|NCT02680002|OTHER|MF59|
214582069|NCT02680002|OTHER|MF59 (stored as monobulk)|
214582070|NCT01451125|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
214582071|NCT04200885|DRUG|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
214582072|NCT04200885|DRUG|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
214582073|NCT04200885|DEVICE|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
214582074|NCT04889547|DRUG|Dexamethasone|Intraoperative intravenous dexamethasone
214582075|NCT04889547|OTHER|No dexamethasone|No intraoperative intravenous dexamethasone
214582076|NCT02442154|PROCEDURE|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
214582077|NCT03508037|OTHER|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
214582078|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Single dose of theobromine
214582079|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Multiple doses of theobromine
214582080|NCT01544829|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
214582081|NCT04499820|DIETARY_SUPPLEMENT|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
214582082|NCT04499820|DIETARY_SUPPLEMENT|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
214582083|NCT00759915|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
214582084|NCT00759915|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
214582085|NCT04088487|BEHAVIORAL|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
214582086|NCT06016673|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
214582087|NCT03173573|DRUG|FDL176|CFTR modulator
214582088|NCT03173573|DRUG|Placebo|Placebo for FDL176
214582089|NCT02272296|DEVICE|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
214582090|NCT02272296|DEVICE|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
214582091|NCT04259645|DRUG|Drug: Bupivacaine 0.375% 20 mL|20 mL 0.375% Bupivacaine
214582092|NCT04259645|DRUG|Drug: Bupivacaine 0.375% diluted to 0.1875%|Each block of 0.375% Bupivacaine x 20 ml mixed (diluted) with Normal Saline Solution 20 mL (total 40 mL)
214582093|NCT03527173|BIOLOGICAL|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
214582094|NCT03527173|DRUG|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
214582095|NCT03527173|BIOLOGICAL|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
214582096|NCT03790319|BEHAVIORAL|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
214582097|NCT03790319|BEHAVIORAL|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
214582098|NCT02856828|DEVICE|DIE|digital image enhancement
214582099|NCT00284687|DRUG|Artesunate|PO Artesunate
214582100|NCT02977585|DEVICE|10 cmH2O peep|positive end expiratory pressure
214582101|NCT04312893|OTHER|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
214582102|NCT04312893|OTHER|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
214582103|NCT00504660|DRUG|Capecitabine|Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
214582104|NCT00504660|DRUG|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
214582105|NCT00504660|DRUG|Temozolomide|Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.
214582106|NCT00504660|DRUG|Lomustine|Arms 2,3 = 100 mg/m\^2 PO on Day 4.
214582107|NCT00504660|DRUG|6-Thioguanine|Arms 1,2,3 = 80 mg/m\^2 PO Every 6 Hours on Day 1-3.
214582108|NCT01662726|DRUG|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
214582109|NCT05974215|DEVICE|assessment of change in bone height by cone beam computed tomography|bone height was measured at 1 ,30 ,90 days after denture insertion
214582110|NCT01248780|DRUG|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
214582111|NCT01248780|DRUG|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
214582112|NCT01248780|DRUG|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
214582113|NCT01481220|DRUG|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
214582114|NCT00798915|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
214582115|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
214582116|NCT00798915|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
214582117|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
214582118|NCT02148549|DRUG|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
214582119|NCT04097301|DRUG|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
214582120|NCT02198079|BIOLOGICAL|Sputum|
214582121|NCT02522351|OTHER|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582122|NCT02522351|OTHER|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582123|NCT02522351|OTHER|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582124|NCT02522351|OTHER|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582125|NCT02522351|OTHER|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582126|NCT02522351|OTHER|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
214582127|NCT05986747|BEHAVIORAL|Video-based CBT guided self-help Interventions|"Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments."
214582128|NCT00006342|GENETIC|chromosomal translocation analysis|
214582129|NCT00006342|GENETIC|gene rearrangement analysis|
214582130|NCT00006342|GENETIC|mutation analysis|
214582131|NCT05160792|DEVICE|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
214582132|NCT06460584|OTHER|Pursed Lip Breathing|In each set, 10 times will be included. Reading will be taken from 1st POD and comparison will be done on each 4rth POD. Ask the patient to sit in a comfortable position and relax. Then, instruct the patient to take deep breath 12 through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
214582133|NCT06460584|OTHER|Incentive Spirometer|For the use of flow based IS, the Patient will be sited in a comfortable Position (Semi-Recumbent Position Of 45 Degrees), With a Pillow under the knees or Semi-Fowler Position on bed, and then asked to perform this technique with the same order to ensure that she / he understands the process. The patient will be instructed to inhale with a slow continuous and deep breathing, and hold for a period of not less than 5 seconds and exhale passively. And is instructed to hold the spirometry upright to perform slowly inhalation, thus lifting the ball. At the end of the evaluation of respiratory measures for patients with lung function, and then compare the results with the previous results. IS will be recommended to be performed by patient every 10 breaths hourly and 5 times per day.
214582134|NCT03821441|BIOLOGICAL|bOPV(Candy)|"A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
214582135|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
214582136|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
214582137|NCT03068533|OTHER|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
214582138|NCT03068533|OTHER|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
214582139|NCT00203476|DRUG|Niacin|
214582140|NCT00203476|DRUG|Colestipol|
214582141|NCT00203476|DRUG|Ezetimibe|
214582142|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
214582143|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
214582144|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
214582145|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
214582146|NCT04314804|COMBINATION_PRODUCT|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
214582147|NCT04314804|COMBINATION_PRODUCT|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
214582148|NCT00897312|BIOLOGICAL|infliximab|
214582149|NCT00897312|BIOLOGICAL|pegylated interferon alfa|
214582150|NCT00897312|BIOLOGICAL|ticilimumab|
214582151|NCT00897312|DRUG|ribavirin|
214582152|NCT00897312|OTHER|high performance liquid chromatography|
214582153|NCT00897312|OTHER|laboratory biomarker analysis|
214582154|NCT06064175|DRUG|Ibuprofen 400 mg|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
214582155|NCT06064175|DRUG|Ibuprofen 800 mg|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
214582156|NCT03620370|DRUG|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
214582157|NCT05997368|OTHER|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
214582158|NCT05997368|OTHER|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
214582159|NCT05997368|OTHER|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
214582160|NCT02377115|OTHER|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
214582161|NCT02774031|DEVICE|Aisys with Et control|
214582162|NCT02774031|DEVICE|Aisys conventional|
214582163|NCT02774031|DEVICE|Flow-i with ACG|
214582164|NCT02774031|DEVICE|Flow-i conventional|
214582165|NCT00414037|DRUG|Eszopiclone|
214582166|NCT00414037|DRUG|Placebo|Placebo-treatment
214582167|NCT00947739|DRUG|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
214582168|NCT02055196|BIOLOGICAL|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
214582169|NCT02055196|DRUG|irinotecan hydrochloride|Given IV
214582170|NCT02055196|OTHER|laboratory biomarker analysis|Correlative studies
214582171|NCT04574752|DIAGNOSTIC_TEST|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
214582172|NCT00005829|DRUG|gemcitabine hydrochloride|
214582173|NCT02032277|DRUG|Cyclophosphamide|Cyclophosphamide
214582174|NCT02032277|DRUG|Placebo|Placebo for Carboplatin
214582175|NCT02032277|DRUG|Doxorubicin|Doxorubicin
214582176|NCT02032277|DRUG|Paclitaxel|Paclitaxel
214582177|NCT02032277|DRUG|Carboplatin|Carboplatin
214582178|NCT02032277|DRUG|Veliparib|Veliparib
214582179|NCT02032277|DRUG|Placebo|Placebo for Veliparib
214582180|NCT00610103|DRUG|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
214582181|NCT03650517|PROCEDURE|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
214582182|NCT03650517|PROCEDURE|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
214582183|NCT03650517|PROCEDURE|Robotic Surgery|Procedure is performed using robotic instruments
214582184|NCT03650517|PROCEDURE|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
214582185|NCT00559858|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|
214582186|NCT00559858|OTHER|placebo|
214582187|NCT00559858|PROCEDURE|quality-of-life assessment|
214582188|NCT02907164|BEHAVIORAL|Email invitation|Receive emails encouraging them to sign up
214582189|NCT02907164|BEHAVIORAL|Social norm|Receive information about how many people have signed up
214582190|NCT02907164|BEHAVIORAL|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
214582191|NCT02907164|BEHAVIORAL|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
214582192|NCT00420433|PROCEDURE|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
214582193|NCT00420433|PROCEDURE|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
214582194|NCT00420433|PROCEDURE|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
214582195|NCT01813929|DRUG|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
214582196|NCT01813929|DRUG|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
214582197|NCT05999097|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
214582198|NCT05999097|DIETARY_SUPPLEMENT|Placebo Group|This group will receive 12 g of corn starch as a control group.
214582199|NCT06164080|OTHER|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
214582200|NCT04012138|DRUG|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
214582201|NCT04012138|DRUG|Insulin Aspart|"Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
214582202|NCT03130803|BEHAVIORAL|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
214582203|NCT04171323|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
214582204|NCT04171323|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
214582205|NCT04952454|PROCEDURE|External Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.
214582206|NCT04952454|PROCEDURE|Endonasal Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.
214582207|NCT04952454|PROCEDURE|Transcanalicular Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.
214582208|NCT04821687|DRUG|Ongentys 50mg|Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
214582209|NCT04821687|DRUG|Madopar Tab. 125 or Perkin Tab. 25-100mg|Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
214710341|NCT00565019|DRUG|Triamcinolone Acetonide|"* Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg"
214582210|NCT01246557|DRUG|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
214582211|NCT01246557|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
214710342|NCT00324740|DRUG|vorinostat|Given orally
214582212|NCT01413776|DIETARY_SUPPLEMENT|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
214582213|NCT01814852|DEVICE|Shockwave system|
214582214|NCT01814852|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
214710343|NCT00324740|DRUG|isotretinoin|Given orally
214710344|NCT04463238|COMBINATION_PRODUCT|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
214710345|NCT04463238|PROCEDURE|Microfracture|Operate in accordance with the clinical microfracture surgery method.
214582215|NCT06118203|DRUG|Semaglutide|Semaglutide in addition to standard of care
214582216|NCT04722939|DIAGNOSTIC_TEST|Cerebral oxygenation|Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
214582217|NCT00030498|DRUG|erlotinib hydrochloride|Given orally
214582218|NCT00030498|OTHER|laboratory biomarker analysis|Correlative studies
214582219|NCT01567904|DRUG|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
214582220|NCT04101318|DEVICE|Non-Conformité Européene marked product|New Baseplate is not named at this point
214710346|NCT02271009|DRUG|AllerT|Ultrafast immunotherapy
214710347|NCT02271009|DRUG|Placebo|placebo control
214582221|NCT04101318|DEVICE|Conformité Européene marked competitor products|The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
214582222|NCT03170895|DRUG|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
214582223|NCT03170895|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
214710348|NCT03143556|DEVICE|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
214582224|NCT00148512|DRUG|1. Tesofensine (NS 2330)|
214582225|NCT01244178|DRUG|Insulin|Intravenous Hyperinsulinemic therapy
214582226|NCT01244178|DRUG|Insulin|Standard Intravenous Insulin Therapy
214582227|NCT06055348|DRUG|SC0191|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
214582228|NCT06055348|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
214582229|NCT06055348|DRUG|Paclitaxel|Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
214582230|NCT01874431|DRUG|Finerenone (BAY94-8862)|
214582231|NCT01874431|DRUG|Placebo|
214582232|NCT01703351|DRUG|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
214582233|NCT01703351|DRUG|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
214582234|NCT00642772|OTHER|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
214582235|NCT04540393|BIOLOGICAL|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
214582236|NCT05901662|OTHER|Competence training program|A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
214582237|NCT05901662|OTHER|Control|This group provided their routine services at senior activity centers.
214582238|NCT00757588|DRUG|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
214582239|NCT00757588|DRUG|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
214582240|NCT00220467|BEHAVIORAL|Aerobic exercise|
214582241|NCT04223427|PROCEDURE|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
214582242|NCT04073459|BIOLOGICAL|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
214582243|NCT04073459|BIOLOGICAL|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
214582244|NCT03023761|DEVICE|low level laser|low level laser irradiation
214582245|NCT03023761|DEVICE|laser sham|laser without irradiation
214582246|NCT01827618|DRUG|Rapamycin|
214582247|NCT04280302|BEHAVIORAL|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
214582248|NCT04280302|BEHAVIORAL|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
214582249|NCT00480376|DRUG|ofloxacin|
214582250|NCT00480376|DRUG|gentamicin|
214582251|NCT02778854|GENETIC|detection of driver mutation|participants are received gene detection via the liquid biopsy
214582252|NCT05398237|OTHER|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
214582253|NCT05936294|DIAGNOSTIC_TEST|Optimization of CRT Device|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
214582254|NCT04023500|BEHAVIORAL|Motivational interview vs. prevailing education|"In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care."
214582255|NCT00200993|BEHAVIORAL|physical activity|
214582256|NCT00691327|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
214582257|NCT04317365|OTHER|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
214582258|NCT01220518|DRUG|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
214582259|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
214582260|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
214582261|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
214582262|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
214582263|NCT01174732|DRUG|Placebo|placebo, lactose inhalation carrier
214582264|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
214582265|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
214582266|NCT02234973|BEHAVIORAL|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
214582267|NCT01237275|DRUG|SSRI treated group|characterize in arm of a study (SSRI treated group)
214582268|NCT01812434|DRUG|Sildenafil|20mg three time daily for 28 days
214582269|NCT01812434|DRUG|Placebo|20 mg three times daily for 28 days
214582270|NCT01123876|DRUG|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
214582271|NCT04137159|OTHER|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
214582272|NCT00990977|BEHAVIORAL|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
214582273|NCT05956639|DRUG|6-month course of antiandrogen drugs|6-month course of Rezvilutamide and ADT + chemotherapy
214582274|NCT05956639|DRUG|Long-term course of antiandrogen drugs|Long-term course of Rezvilutamide and ADT + chemotherapy
214582275|NCT02875886|DRUG|Amiloride|Combined with hydrochlorothiazide
214582276|NCT02875886|DRUG|Hydrochlorothiazide|Combined with amiloride
214582277|NCT02875886|OTHER|Low-sodium diet|
214582278|NCT02234687|DRUG|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
214582279|NCT02234687|DRUG|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
214582280|NCT02234687|DRUG|Placebo|Placebo, one dose, one time
214582281|NCT03271021|DRUG|FMX101|FMX101, 4% minocycline foam
214582282|NCT03271021|DRUG|Vehicle Foam|Vehicle Foam
214582283|NCT02903264|OTHER|Gestational diabetes mellitus|
214582284|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
214582285|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
214582286|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
214582287|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
214582288|NCT01452659|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
214582289|NCT01452659|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
214582290|NCT01452659|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
214582291|NCT01452659|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
214582292|NCT04275089|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
214582293|NCT05416541|BEHAVIORAL|social media|ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
214582294|NCT03657654|OTHER|No intervention: observational only|No intervention: observational only
214582295|NCT03421626|DEVICE|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
214582296|NCT04125732|BIOLOGICAL|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
214582297|NCT03831373|OTHER|Physical exercise|Three physical exercise programs, two of resistance training with elastic bands and one of stretching exercises, all performed in a sitting position.
214582298|NCT01478139|PROCEDURE|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
214582299|NCT01478139|PROCEDURE|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
214582300|NCT03131583|DRUG|Colchicine|Day-14\~Day16 qd
214582301|NCT03131583|DRUG|Febuxostat|Day1 and Day8 qd
214582302|NCT03131583|DRUG|SHR4640|Day3\~Day8 qd
214582303|NCT00287495|DRUG|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
214582304|NCT04367012|OTHER|Abdominal Ultrasound|patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
214582305|NCT00180323|DEVICE|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
214582306|NCT01739816|BEHAVIORAL|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
214582307|NCT00297232|DRUG|Natalizumab|
214582308|NCT04635592|DIAGNOSTIC_TEST|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
214582309|NCT00596479|DRUG|Filgrastim (rG-CSF)|
214582310|NCT02717403|BEHAVIORAL|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
214582311|NCT02717403|BEHAVIORAL|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
214582312|NCT02717403|BEHAVIORAL|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
214582313|NCT02717403|BEHAVIORAL|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
214582314|NCT03562650|BEHAVIORAL|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
214582315|NCT03562650|BEHAVIORAL|Present Centered|Participants are asked to try to increase their focus on the present.
214582316|NCT02443974|DEVICE|Brace (Fisiotensor®)|
214582317|NCT02443974|DEVICE|Sleeve (Fisiotensor®)|
214582318|NCT02350777|PROCEDURE|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
214582319|NCT02350777|DEVICE|CliniMACS Cell Selection System|
214582320|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
214582321|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Test product 20 ml
214582322|NCT05074485|DRUG|anakinra|intravenous injection of 100 milligrams anakinra
214582323|NCT05074485|DRUG|Placebo|intravenous injection of 1 milliliter normal saline
214582324|NCT05074485|OTHER|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
214582325|NCT04016467|OTHER|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
214582326|NCT04016467|OTHER|Sham thoracic treatment|Hand placement on thorax without thrust.
214582327|NCT03038438|DEVICE|Abre venous self-expanding stent system|venous stent
214582328|NCT00992433|BIOLOGICAL|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
214582329|NCT00504608|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
214582330|NCT01656733|DRUG|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
214582331|NCT01656733|DRUG|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
214582332|NCT01847300|BEHAVIORAL|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
214582333|NCT03141723|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
214582334|NCT03141723|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
214582335|NCT03141723|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
214582336|NCT03141723|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\]
214582337|NCT05788211|OTHER|standard of care|retrospective study: standard of care
214582338|NCT01065844|DRUG|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
214582339|NCT02822313|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76\_V27-006)
214582340|NCT04617561|DRUG|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
214582341|NCT04617561|DRUG|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
214582342|NCT02845206|PROCEDURE|Patient specific cutting blocks|'MyKnee' Instrumentation
214582343|NCT02845206|PROCEDURE|Conventional cutting blocks|Standard Instrumentation
214582344|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
214710349|NCT06291506|OTHER|Radiofrequency ablation of heart atrial tissue.|Ablation with radiofrequency, advances techniques: contact force-guided, improved tissue temperature sensors, automark algorithms.
214582345|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
214582346|NCT05729971|PROCEDURE|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
214582347|NCT00900744|DRUG|Tamoxifen|20 mg daily
214582348|NCT00954486|DRUG|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
214582349|NCT04703738|PROCEDURE|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
214582350|NCT04703738|DEVICE|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
214582351|NCT01948726|RADIATION|Hypofractionation with simultaneous integrated boost|
214710350|NCT04507776|DRUG|Etanercept|Patients with spondyloarthrosis as provided in real world practice
214710351|NCT06527677|DRUG|ANT3310|ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
214710352|NCT06527677|DRUG|Meropenem|meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
214710353|NCT06638541|RADIATION|Prostate radical radiotherapy|Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
214582352|NCT02206594|PROCEDURE|Descemetorhexis|
214582353|NCT01360710|DRUG|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
214582354|NCT01360710|DRUG|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
214582355|NCT02819154|BEHAVIORAL|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~* Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~* Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~* ADL: Assessment of independence in activities of daily life"
214582356|NCT02440009|DRUG|Itraconazole|Oral itraconazole 200 mg BD for 6 months
214582357|NCT02440009|DRUG|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
214582358|NCT03864822|DEVICE|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
214582359|NCT04985968|DRUG|Cobitolimod 250 mg|Rectal administration
214582360|NCT04985968|DRUG|Cobitolimod 500 mg|Rectal administration
214582361|NCT04985968|DRUG|Placebo|Rectal administration
214582362|NCT04961658|BIOLOGICAL|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
214582363|NCT01863576|DIETARY_SUPPLEMENT|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
214582364|NCT01863576|DIETARY_SUPPLEMENT|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
214710354|NCT05189132|DIAGNOSTIC_TEST|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
214582365|NCT01096823|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
214582366|NCT03614637|OTHER|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
214582367|NCT00327496|BIOLOGICAL|DC vaccine|
214582368|NCT04789772|DEVICE|Laser acupuncture|The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
214582369|NCT04001231|DRUG|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
214582370|NCT00577473|DRUG|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
214582371|NCT00577473|DRUG|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
214582372|NCT01580423|DRUG|aprepitant|125 mg capsule
214582373|NCT01580423|DRUG|placebo|capsule identical to aprepitant
214582374|NCT02013518|BEHAVIORAL|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
214582375|NCT05564728|OTHER|Conversational Agent/Chatbot App|Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
214582376|NCT04312217|BEHAVIORAL|Medical clowning|Medical clowning
214582377|NCT05780320|OTHER|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
214582378|NCT03830749|DRUG|Eltrombopag|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
214582379|NCT01775280|RADIATION|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
214582380|NCT01240226|DRUG|GDC-0941|Oral repeating dose
214582381|NCT01240226|DRUG|GDC-0941|Oral repeating dose
214582382|NCT01240226|DRUG|ketoconazole|Oral repeating dose
214582383|NCT05663879|DRUG|ID120040002|Drug: ID120040002
214582384|NCT05663879|DRUG|Compound-X|Drug: Compound-X
214582385|NCT05663879|DRUG|Placebo comparator|Placebo comparator
214582386|NCT04913454|OTHER|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
214582387|NCT04913454|OTHER|Cognitive training|Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
214582388|NCT00950274|DRUG|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
214582389|NCT00950274|DRUG|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
214582390|NCT01485081|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
214582391|NCT03213860|OTHER|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
214582392|NCT05050994|PROCEDURE|Microwave ablation|Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
214582393|NCT03326453|DEVICE|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
214582394|NCT00164931|DRUG|Intravenous omeprazole infusion|
214582395|NCT00164931|PROCEDURE|Scheduled second endoscopy|
214582396|NCT02238574|PROCEDURE|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
214582397|NCT02238574|OTHER|follow up|Intensified outpatient follow up (16 visits in 5 years)
214582398|NCT00681330|BIOLOGICAL|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214582399|NCT04618328|DRUG|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
214582400|NCT00313001|DRUG|biphasic insulin aspart|
214582401|NCT00313001|DRUG|exenatide|
214582402|NCT01502631|DRUG|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
214582403|NCT01502631|DRUG|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
214582404|NCT00419133|BIOLOGICAL|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
214582405|NCT00419133|BIOLOGICAL|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
214634281|NCT03012373|PROCEDURE|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
214710355|NCT05189132|DIAGNOSTIC_TEST|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
214582406|NCT05078320|BEHAVIORAL|Exposure and response prevention (ERP)|"The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).~Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns."
214582407|NCT05660239|OTHER|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
214582408|NCT01798121|BIOLOGICAL|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
214582409|NCT01798121|BIOLOGICAL|Reference standard|Response of reference standard material compared to Aplisol@.
214582410|NCT05309915|DRUG|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
214582411|NCT04923074|OTHER|diffusion tensor imaging(DTI) evaluation|DTI is a new kind of MRI technique to evaluate peripheral neuropathy
214582412|NCT06109025|COMBINATION_PRODUCT|FESIA GRASP|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
214582413|NCT06109025|COMBINATION_PRODUCT|VIRTUAL REHAB|VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.
214582414|NCT06109025|COMBINATION_PRODUCT|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
214582415|NCT01115296|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
214582416|NCT01115296|OTHER|Placebo|Placebo
214582417|NCT05506657|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
214710356|NCT05189132|DIAGNOSTIC_TEST|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
214710357|NCT02533687|PROCEDURE|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
214710358|NCT02533687|PROCEDURE|Bipolar TURP-2|Bipolar TURP
214710359|NCT02533687|PROCEDURE|Monopolar TURP|Monopolar TURP
214582418|NCT05506657|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
214582419|NCT02084056|DRUG|Linagliptin|Linagliptin
214582420|NCT02084056|DRUG|Metformin|Metformin
214582421|NCT02084056|DRUG|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
214582422|NCT01293487|BIOLOGICAL|RN564|Intravenous, single dose with experimental dose
214582423|NCT04643288|PROCEDURE|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
214582424|NCT04643288|PROCEDURE|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
214582425|NCT03936582|BEHAVIORAL|Treatment|information already included in arm/group descriptions
214582426|NCT00395460|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
214582427|NCT00395460|DRUG|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
214582428|NCT01975974|DEVICE|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
214582429|NCT04984733|DRUG|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
214582430|NCT04984733|DRUG|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
214582431|NCT04984733|DRUG|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
214582432|NCT04984733|DRUG|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
214582433|NCT04399590|OTHER|Interficial Intelligence|Interficial Intelligence
214582434|NCT01679574|DRUG|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
214582435|NCT01679574|DRUG|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
214582436|NCT01679574|DRUG|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
214582437|NCT01124409|RADIATION|EPID Verification|Set up error verification and correction by EPID
214582438|NCT01124409|RADIATION|CBCT verification|Setup error verification and correction by CBCT
214582439|NCT05715866|DEVICE|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
214582440|NCT05715866|PROCEDURE|therapeutic exercise|patients receive adapted therapeutic exercise
214582441|NCT05715866|BEHAVIORAL|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
214710360|NCT02760160|OTHER|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
214710361|NCT06553365|DRUG|FCN-159|FCN-159 8mg qd po
214582442|NCT00580346|DEVICE|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
214582443|NCT05849948|BEHAVIORAL|choronobiological nutrition|Providing infant nutrition in accordance with crinobiological nutrition
214582444|NCT01164124|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
214582445|NCT01164124|OTHER|Placebo|routine feedings
214582446|NCT04452396|DEVICE|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
214582447|NCT02489123|DRUG|Enzalutamide|Given PO
214582448|NCT02489123|OTHER|Laboratory Biomarker Analysis|Correlative studies
214634282|NCT04077658|BEHAVIORAL|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
214634283|NCT04077658|BEHAVIORAL|Waitlist Control|Standard of Care Migraine Treatment
214634284|NCT03939507|OTHER|AEP score available to the treating physician|the treating physician knew the AEP score results
214634285|NCT04046679|DRUG|Bleomycin|Skin bleomycin infusion through tattoo machine
214582449|NCT04841356|PROCEDURE|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
214582450|NCT02974439|DRUG|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
214582451|NCT02974439|DRUG|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
214582452|NCT04299438|DRUG|Propranolol Hydrochloride|2mg/mL vials
214582453|NCT04299438|OTHER|Saline|0.9% saline in vials matching the vials of the active drug
214582454|NCT04771611|DRUG|Fisetin|\~20mg/kg /day oral for four days (days 0,1 and days 8,9)
214582455|NCT04771611|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
214582456|NCT04223830|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
214634286|NCT04046679|OTHER|Saline Solution|Saline solution infusion through tattoo machine
214710362|NCT03628599|DEVICE|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
214710363|NCT03628599|DEVICE|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
214710364|NCT04745078|OTHER|Caboxy30|carboxy30 to periorbital dark halos
214582457|NCT05468892|DRUG|Trifluridine Tipiracil|"Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest"
214582458|NCT05468892|DRUG|Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]|Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
214582459|NCT05690724|DIETARY_SUPPLEMENT|Mitocholine™ or Placebo|Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
214582460|NCT05417022|DEVICE|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
214582461|NCT02388243|BEHAVIORAL|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
214582462|NCT02388243|BEHAVIORAL|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
214582463|NCT02388243|BEHAVIORAL|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
214582464|NCT02388243|BEHAVIORAL|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
214582465|NCT04303715|PROCEDURE|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
214582466|NCT04303715|PROCEDURE|SLNB|BCS with SLNB(+/-ALND)
214582467|NCT01818583|DRUG|Potassium chloride|
214582468|NCT01818583|DRUG|Glucose 50 MG/ML|
214582469|NCT06532786|OTHER|Fractal Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
214582470|NCT06532786|OTHER|Isochronous Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) single in leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
214710365|NCT04745078|OTHER|Caboxy60|carboxy60 to periorbital dark halos
214582471|NCT06532786|OTHER|Self Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at their own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
214582472|NCT00680446|DRUG|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
214582473|NCT05965804|DIAGNOSTIC_TEST|McMurray knee examination test|The McMurray test will be performed in different knee flexion and rotation angles.
214582474|NCT01964924|DRUG|Akt Inhibitor GSK2141795|Given PO
214582475|NCT01964924|OTHER|Laboratory Biomarker Analysis|Correlative studies
214582476|NCT01964924|DRUG|Trametinib|Given PO
214582477|NCT06142266|OTHER|Exercise rehabilitation program|This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs for 12-week
214582478|NCT04572308|BIOLOGICAL|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
214582479|NCT01808326|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
214582480|NCT03695458|DEVICE|Phototherapy|The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
214582481|NCT00922753|OTHER|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
214582482|NCT00922753|OTHER|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
214582483|NCT00922753|OTHER|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
214582484|NCT06131489|OTHER|Segmental bowel resection combined with the DEP regimen|Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
214582485|NCT03524053|OTHER|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
214582486|NCT03524053|OTHER|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
214582487|NCT00577577|DRUG|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
214582488|NCT00577577|DRUG|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
214582489|NCT01153958|DRUG|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
214582490|NCT01153958|DRUG|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
214582491|NCT01127152|PROCEDURE|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
214582492|NCT01340677|DRUG|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
214582493|NCT01340677|DRUG|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
214582494|NCT01340677|DRUG|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
214582495|NCT03299972|DIETARY_SUPPLEMENT|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
214582496|NCT03299972|DIETARY_SUPPLEMENT|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
214582497|NCT03299972|OTHER|Resistance Exercise|60 minutes of resistance exercise twice a week
214582498|NCT02670759|DRUG|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
214582499|NCT02670759|DRUG|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
214710366|NCT04101669|DEVICE|RESET Liner|The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
214710367|NCT04101669|OTHER|Sham|Patient receives upper endoscopy but no treatment
214710368|NCT00908622|PROCEDURE|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
214582500|NCT02299180|BEHAVIORAL|ACP|
214710369|NCT00908622|PROCEDURE|Cardiac revascularization|Cardiac revascularization
214582501|NCT03572387|DRUG|5-Azacitidine|subcutaneously on days 1-5 at a dose of 40 mg/m\^2
214582502|NCT03572387|DRUG|all trans retinoic acid|45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses
214582503|NCT03572387|DRUG|Lupron|7.5 mg x 1
214710370|NCT02931526|DRUG|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
214582504|NCT01780181|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
214582505|NCT01780181|DRUG|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
214582506|NCT02881905|DEVICE|ball attachment|it is attachment part that connects the overdenture to the implant
214582507|NCT02881905|DEVICE|cm loc attachment|It is a new attachment made of peek material
214582508|NCT04223817|DEVICE|7.0 T RMI|Single 7.0 Tesla MRI of both hands in the same time
214582509|NCT02141451|DRUG|Rituximab|Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
214582510|NCT02141451|DRUG|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
214582511|NCT03755375|DEVICE|TENS|transcutaneous electrostimulation to improve the pain.
214582512|NCT03755375|BEHAVIORAL|Postural exercises|breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position
214582513|NCT03755375|DEVICE|Biofeedback|pelvic floor muscle coordination and relaxation exercises using intravaginal probes
214582514|NCT03755375|BEHAVIORAL|Manual therapy|myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
214582515|NCT05083000|DRUG|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
214582516|NCT05571371|OTHER|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
214582517|NCT06093776|DEVICE|ioveraº system|the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold
214582518|NCT02407301|OTHER|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
214582519|NCT02407301|OTHER|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
214582520|NCT02407301|OTHER|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
214582521|NCT02407301|OTHER|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
214710371|NCT01248403|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
214582522|NCT02407301|OTHER|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
214582523|NCT05644860|COMBINATION_PRODUCT|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
214582524|NCT05644860|COMBINATION_PRODUCT|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
214582525|NCT03575988|OTHER|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
214582526|NCT05239637|OTHER|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
214582527|NCT05239637|OTHER|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
214582528|NCT05792358|PROCEDURE|wet cupping therapy|wet cupping therapy will be applied to participants in this arm for three sessions once a month
214582529|NCT02262091|DIETARY_SUPPLEMENT|Food fibers|
214582530|NCT02262091|DIETARY_SUPPLEMENT|Maltodextrin|
214582531|NCT02262091|BIOLOGICAL|Influenza vaccine (incl. criterion)|
214582532|NCT04441060|OTHER|Distress intervention (CBT & Mindfulness-based program)|Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
214582533|NCT01147276|DRUG|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
214582534|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
214582535|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
214582536|NCT04742127|DIAGNOSTIC_TEST|Single surgical debridement|To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
214582537|NCT03710668|RADIATION|MRI if indicated|MRI brain if indicated
214582538|NCT02150343|DRUG|HDM-SPIRE|1 dose every 4 weeks
214582539|NCT02150343|DRUG|Placebo|1 dose every 4 weeks
214710372|NCT01248403|DRUG|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
214722078|NCT01506219|PROCEDURE|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
214582540|NCT05192668|OTHER|Quiet time care|This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected
214582541|NCT02862834|GENETIC|High-throughput exome sequencing|
214582542|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
214582543|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
214582544|NCT06021171|DIETARY_SUPPLEMENT|Maltodextrin|5 g Maltodextrin
214582545|NCT00350480|DRUG|Provera|
214582546|NCT00350480|DRUG|Combination Birth Control pills|
214722079|NCT01337518|DRUG|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
214582547|NCT04572113|DEVICE|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
214582548|NCT02187627|DRUG|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
214722080|NCT05058118|DRUG|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
214582549|NCT02187627|DRUG|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi).
214582550|NCT02187627|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
214582551|NCT06238518|PROCEDURE|Intravascular Lithotripsy|The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.
214582552|NCT06238518|PROCEDURE|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
214582553|NCT03946579|OTHER|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
214582554|NCT02729753|DEVICE|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
214582555|NCT02729753|DEVICE|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
214582556|NCT00190749|DRUG|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
214582557|NCT00190749|DRUG|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
214582558|NCT05660343|DRUG|Ozonized Olive Oil Solutions|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.
214582559|NCT05660343|DEVICE|Low Level Laser LLL Therapy|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
214582560|NCT05941728|OTHER|Avocado|The intervention treatment will contain avocado
214582561|NCT05941728|OTHER|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
214582562|NCT05941728|OTHER|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
214582563|NCT05420844|OTHER|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
214582564|NCT04127708|BIOLOGICAL|acupuncture|acupuncture group and control group
214582565|NCT00036023|DRUG|darbepoetin alfa|
214582566|NCT02865837|OTHER|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
214582567|NCT01200589|BIOLOGICAL|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
214582568|NCT01200589|BIOLOGICAL|Rituximab|sourced locally from commercial stock
214582569|NCT01200589|BIOLOGICAL|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
214582570|NCT01200589|BIOLOGICAL|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
214582571|NCT01090427|DRUG|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
214582572|NCT01090427|DRUG|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
214582573|NCT01090427|OTHER|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
214582574|NCT01154010|DEVICE|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
214582575|NCT01154010|DEVICE|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
214582576|NCT04235179|RADIATION|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
214582577|NCT04085185|DRUG|IBI110|Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
214582578|NCT04085185|DRUG|IBI110|IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
214582579|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
214582580|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
214582581|NCT02558504|PROCEDURE|Oesophagectomy|
214582582|NCT02558504|DEVICE|Radiofrequency ablation|
214582583|NCT04232059|DEVICE|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
214582584|NCT05045508|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
214582585|NCT05045508|DRUG|Placebo (vehicle) Nasal Spray|Placebo (vehicle) nasal spray \[control\]
214582586|NCT01025401|DEVICE|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
214582587|NCT02000193|DRUG|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."
214582588|NCT01660581|BIOLOGICAL|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
214582589|NCT01660581|BIOLOGICAL|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
214582590|NCT00439231|DRUG|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
214582591|NCT00837798|DEVICE|CRM Device|Pacemaker, ICD, or CRT device
214582592|NCT03566654|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
214582593|NCT03566654|DEVICE|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
214582594|NCT03566654|DEVICE|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
214582595|NCT00513513|DRUG|TMC114 (darunavir) / ritonavir|
214582596|NCT04602273|DRUG|Azacitidine Injection [Vidaza]|
214582597|NCT00287066|DRUG|Inhaled Human Insulin|
214582598|NCT00287066|DRUG|Regular Human Insulin|
214582599|NCT03541031|DIETARY_SUPPLEMENT|Micronutrient & Fish oil|Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
214582600|NCT03541031|DIETARY_SUPPLEMENT|Olive oil & Safflower oil|Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
214582601|NCT03060668|OTHER|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
214582602|NCT03060668|OTHER|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
214582603|NCT02388854|GENETIC|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
214582604|NCT01714531|BEHAVIORAL|Telephone-Based Goal Management Training|
214582605|NCT01714531|BEHAVIORAL|Telephone-Based Attention-Control|
214582606|NCT01598623|DRUG|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
214582607|NCT01598623|BEHAVIORAL|Social Skills Training|three times a week for three weeks.
214582608|NCT01598623|BEHAVIORAL|Placebo + Non Specific Counselling|
214582609|NCT03402815|DRUG|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
214582610|NCT00163397|DRUG|Ciclesonide|
214582611|NCT04160520|DRUG|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
214582612|NCT04160520|DRUG|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
214582613|NCT04160520|DRUG|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
214582614|NCT00804089|PROCEDURE|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
214582615|NCT00804089|PROCEDURE|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
214582616|NCT00804089|PROCEDURE|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
214582617|NCT04044274|DEVICE|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
214582618|NCT04044274|DEVICE|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
214582619|NCT00901823|DRUG|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
214582620|NCT00901823|DRUG|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
214722081|NCT05058118|DRUG|Placebo|empty bottle
214582621|NCT00585416|DRUG|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
214582622|NCT05880394|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
214582623|NCT05880394|DRUG|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
214582624|NCT03035968|OTHER|Vojta therapy|
214582625|NCT03035968|OTHER|conventional physiotherapy|
214582626|NCT01538329|DRUG|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
214582627|NCT01538329|DRUG|placebo|200mg / day once daily in the morning and at noon - oral administration -
214582628|NCT05584969|BEHAVIORAL|Peer-led integrated nutrition education intervention delivered through Care Groups|The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
214582629|NCT04143074|BEHAVIORAL|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
214582630|NCT01986075|BEHAVIORAL|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
214582631|NCT01986075|DRUG|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
214582632|NCT01986075|DRUG|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
214582633|NCT04242251|OTHER|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
214582634|NCT02105623|BEHAVIORAL|Standard Therapy|Risk factor control Diet Exercise for 24months
214582635|NCT02105623|DRUG|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
214582636|NCT03789838|OTHER|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
214582637|NCT02894567|DEVICE|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
214582638|NCT05790577|DRUG|Metformin and Nicotinamide vs Kligman Formula|Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
214582639|NCT02531945|DEVICE|Use of Biomod device|
214582640|NCT05939531|BEHAVIORAL|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
214582641|NCT05939531|BEHAVIORAL|Standard Care|Standard post-stroke care
214582642|NCT03664362|BEHAVIORAL|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
214582643|NCT06424405|PROCEDURE|titration procedure for MAD treatment|The OSAHS patients referred for MAD treatment will experience either the objective titration procedure or the subjective titration procedure.
214582644|NCT02842450|DEVICE|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
214582645|NCT02842450|OTHER|definitions only|
214582646|NCT05128994|DEVICE|User-controlled FES system|Wearable FES sleeve with non-invasive user controls
214582647|NCT02104297|DRUG|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
214582648|NCT02104297|DRUG|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
214582649|NCT02104297|DRUG|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
214582650|NCT03972150|DRUG|BI 836880|Solution for infusion
214582651|NCT03972150|DRUG|BI 754091|Solution for infusion
214582652|NCT05851053|DIAGNOSTIC_TEST|Echocardiography|"During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality"
214582653|NCT00223717|DRUG|Clonidine|0.1-0.2mg po. Single dose.
214582654|NCT00223717|DRUG|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
214582655|NCT00223717|DRUG|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
214582656|NCT00223717|DRUG|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
214582657|NCT00223717|DRUG|Sildenafil|25- 100 mg po. Single dose.
214582658|NCT00223717|DRUG|Nifedipine|10-30 mg po. Single dose.
214582659|NCT00223717|DRUG|Hydralazine|10-50 mg po. Single dose
214582660|NCT00223717|DRUG|Hydrochlorothiazide|12.5-100 mg po. Single dose.
214582661|NCT00223717|DRUG|Placebo|Po or patch. Single dose.
214582662|NCT00223717|DRUG|Bosentan|62.5 -125 mg po. Single dose.
214582663|NCT00223717|DRUG|Diltiazem|30-60 mg po. Single dose.
214582664|NCT00223717|DRUG|Eplerenone|50-100 mg po. Single dose.
214582665|NCT00223717|DRUG|guanfacine|1-3 mg po. Single dose.
214582666|NCT00223717|DIETARY_SUPPLEMENT|L-arginine|6-17 g po. Single dose
214582667|NCT00223717|DRUG|captopril|25-50 mg PO. Single dose.
214582668|NCT00223717|DRUG|carbidopa|25-200 mg PO. Single dose.
214582669|NCT00223717|DRUG|losartan|25-200 mg PO. Single dose.
214582670|NCT00223717|DRUG|metoprolol tartrate|25-100 mg PO. Single dose.
214582671|NCT00223717|DRUG|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
214582672|NCT00223717|DRUG|prazosin hydrochloride|0.5-1 mg PO. Single dose.
214582673|NCT00223717|DRUG|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
214582674|NCT00223717|OTHER|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
214582675|NCT00223717|DRUG|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
214582676|NCT00223717|OTHER|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
214582677|NCT03148444|DRUG|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
214582678|NCT01815762|OTHER|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
214582679|NCT01725789|DRUG|Ferinject®|"Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .~Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight \<50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value \<15ng/mL and Hb\<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)"
214582680|NCT01725789|DRUG|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
214582681|NCT03103490|DRUG|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
214582682|NCT03683823|BEHAVIORAL|Attention guidance|Explicitly guiding attention towards faces during public speaking exposures
214582683|NCT03683823|BEHAVIORAL|Control intervention|Public speaking exposures
214582684|NCT02271776|DIETARY_SUPPLEMENT|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
214582685|NCT02271776|DIETARY_SUPPLEMENT|maltodextrin|
214582686|NCT06049576|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
214582687|NCT06049576|PROCEDURE|Bone Scan|Undergo bone scan
214582688|NCT06049576|PROCEDURE|Computed Tomography|Undergo CT
214582689|NCT06049576|BIOLOGICAL|Ipilimumab|Given IV
214582690|NCT06049576|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214582691|NCT06049576|DRUG|Myrciaria dubia Prebiotic Supplement|Given PO
214582692|NCT06049576|BIOLOGICAL|Nivolumab|Given IV
214582693|NCT06529055|OTHER|Oral Pouch - Nicotine|Ingestion of a randomized oral nicotine pouch
214582694|NCT06529055|OTHER|Oral Pouch - Caffeine|Ingestion of a randomized oral caffeine pouch
214582695|NCT06529055|OTHER|Oral Pouch - Placebo|Ingestion of a randomized oral placebo pouch
214582696|NCT03965351|DRUG|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
214582697|NCT03965351|OTHER|Placebo|placebo
214582698|NCT02774967|PROCEDURE|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
214582699|NCT03479762|DRUG|Liraglutide|No treatment given
214582700|NCT04322877|PROCEDURE|Temporary pacing Study|Temporary delivery of CRT
214582701|NCT04322877|RADIATION|Thoracic CT|As part of non-invasive mapping protocol
214582702|NCT04322877|DIAGNOSTIC_TEST|Acute hemodynamic study|Measurement of invasive dP/dTmax
214582703|NCT04322877|DIAGNOSTIC_TEST|Non-invasive body surface mapping|Cardioinsight body surface mapping
214582704|NCT04322877|DIAGNOSTIC_TEST|Invasive catheter-based mapping|Invasive electroanatomical mapping
214582705|NCT05221359|DEVICE|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
214582706|NCT05221359|DRUG|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
214582707|NCT05832697|DRUG|Ursodeoxycholic Acid 250 Mg Oral Tablet|Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
214582708|NCT05299697|DRUG|TG103 15 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
214582709|NCT05299697|DRUG|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
214582710|NCT05299697|DRUG|Placebo|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
214582711|NCT02813876|OTHER|Enhanced recovery protocol|
214582712|NCT04892914|DEVICE|Embr thermal device|Participants use the Embr thermal device for 4 weeks
214582713|NCT00169377|PROCEDURE|deep brain stimulation|Stimulator on followed by off
214582714|NCT00169377|PROCEDURE|No stimulation|Stimulator off followed by on
214582715|NCT01638351|BEHAVIORAL|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
214582716|NCT01638351|BEHAVIORAL|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
214582717|NCT04021329|BEHAVIORAL|CBT Therapy|information added previously
214582718|NCT03397732|PROCEDURE|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
214582719|NCT02770417|DIETARY_SUPPLEMENT|beta-alanine|Patients receive beta-alanine
214582720|NCT02770417|DIETARY_SUPPLEMENT|placebo|Patients receive placebo
214582721|NCT02770417|OTHER|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
214582722|NCT00490724|DRUG|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
214582723|NCT00490724|DRUG|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
214582724|NCT00490724|DRUG|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
214634287|NCT00679952|PROCEDURE|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
214582725|NCT05793008|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) analysis|18F-FDG-PET/CT imaging will be performed 3 months after the acute event at the Department of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS using an integrated scanner. Intravenous 18F-FDG (370 MBq) will be given following an overnight fast. Three-dimensional PET imaging will be performed after 1 h of quiet waiting. A non-gated, non-contrast CT will be acquired for attenuation correction. Brain structures analyzed will include the neocortex, limbic system (insula, amygdala, cingulate cortex, and hippocampus), reticular formation, brainstem, and spinal cord.
214582726|NCT05793008|DIAGNOSTIC_TEST|Blood samples collection|"At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis."
214582727|NCT05793008|OTHER|Clinical follow up visit|Participation in this study requires for patients with primary vs secondary TTS, a follow-up visit at 3 months (90 +/- 5 gg) after enrollment to assess a Positron Emission Tomography (PET) analysis, and during the same visit, venous blood sampling as described above will be further performed.
214582728|NCT05179213|DRUG|Azacitidine|75 mg/m2 subcutaneously on days 1-7
214582729|NCT05179213|DRUG|Chidamide|20mg orally per week continuously
214582730|NCT00924261|OTHER|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
214582731|NCT00924261|OTHER|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
214582732|NCT05731453|GENETIC|Polygenetic risk score|Polygenetic risk score assessment for breast cancer
214582733|NCT04524026|DRUG|Letrozole 5 mg|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
214582734|NCT03765008|OTHER|Water intake manipulation|for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
214582735|NCT04709952|DEVICE|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
214582736|NCT04709952|DEVICE|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
214582737|NCT04709952|DEVICE|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
214582738|NCT05616000|DRUG|Acetyl-l-carnitine, folic acid|Acetyl-l-carnitine 2gm once a day\& folic acid will be given to 43 primary infertile men
214582739|NCT02877888|DRUG|fluoride varnish 22600ppm|topical application on teeth every 6months
214582740|NCT03384277|DRUG|Steroid|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
214582741|NCT03384277|DRUG|Rituximab|375mg/m2 for one dose
214582742|NCT03384277|DRUG|Cyclophosphamide|cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
214582743|NCT02697370|DRUG|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
214582744|NCT00994682|DRUG|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
214582745|NCT00994682|DRUG|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
214634288|NCT00679952|PROCEDURE|natural drainage of pancreatic duct|Natural drainage group
214634289|NCT05135715|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
214634290|NCT01989000|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
214582746|NCT00994682|DRUG|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
214582747|NCT00083213|BIOLOGICAL|ziv-aflibercept|
214582748|NCT04727268|OTHER|No intervention|No interventions present in this study.
214582749|NCT01409304|DEVICE|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
214582750|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
214582751|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
214582752|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
214582753|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
214582754|NCT03427853|DRUG|LY06006|LY06006 18mg, 60mg, 120mg subcutaneous injection
214582755|NCT03427853|DRUG|Placebos|Placebo subcutaneous injection
214582756|NCT02677428|BEHAVIORAL|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
214582757|NCT02677428|BEHAVIORAL|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation \& Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C\&P office where issues pertaining to an individual Veteran's specific application are addressed.
214582758|NCT03795259|DRUG|Rocuronium|After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
214582759|NCT03795259|DRUG|Sugammadex|Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
214582760|NCT03211767|DIETARY_SUPPLEMENT|Aged garlic extract|Each capsule contains 600mg of aged garlic extract powder
214582761|NCT03211767|DIETARY_SUPPLEMENT|Placebo|Each capsule contains cellulose as a filler.
214582762|NCT03069001|DRUG|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
214582763|NCT03069001|DRUG|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
214582764|NCT02859324|DRUG|CC-122|
214582765|NCT02859324|DRUG|Nivolumab|
214582766|NCT04512859|PROCEDURE|Stellate Ganglion Block|Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL
214582767|NCT04512859|PROCEDURE|Placebo|Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL
214582768|NCT04890119|DIAGNOSTIC_TEST|tenosynovial tissue biopsy|Biopsy of tenosynovial tissue during surgery for amyloid aggregate search
214582769|NCT03170791|DEVICE|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
214582770|NCT03580668|DRUG|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
214582771|NCT04556721|DRUG|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
214582772|NCT04876235|PROCEDURE|endoscopic ultrasound|All patients were implanted with stents（DPPS or LAMS）under the EUS
214582773|NCT04876235|DEVICE|lumen-apposing metal stent|In the LAMS group, patients were stented with LAMS
214582774|NCT04876235|DEVICE|double-pigtail plastic stents|In the DPPS group, patients were stented with DPPS
214582775|NCT01052129|DRUG|Naproxen sodium|Naproxen Sodium Tablets 550 mg
214582776|NCT03567824|DRUG|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
214582777|NCT03567824|DRUG|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
214582778|NCT01272128|DRUG|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
214582779|NCT03229590|PROCEDURE|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
214582780|NCT04006353|DRUG|ABT|320 mg, Intravenous infusion
214582781|NCT04006353|DRUG|RIF|600mg q.d.
214582782|NCT01322997|DEVICE|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
214634291|NCT01989000|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
214582783|NCT01322997|BEHAVIORAL|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
214582784|NCT01322997|DEVICE|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
214582785|NCT00335439|DRUG|ketorolac tromethamine 0.5% (Acular®)|
214582786|NCT06445413|OTHER|Tai Chi|Ten weekly 60-minute Tai Chi classes
214582787|NCT02940184|DRUG|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
214582788|NCT02940184|OTHER|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
214582789|NCT03753737|OTHER|Questionnaires and semi-structured interview|"* Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
214582790|NCT00001689|DRUG|Vincristine|
214582791|NCT01810601|DRUG|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
214582792|NCT00547768|DRUG|Fexofenadine HCI|
214582793|NCT01541098|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
214582794|NCT01541098|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
214582795|NCT03720743|OTHER|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
214582796|NCT02239900|DRUG|Ipilimumab|"Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4"
214582797|NCT02239900|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1."
214582798|NCT03187691|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
214634292|NCT01989000|DRUG|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
214634293|NCT01989000|RADIATION|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
214634294|NCT01989000|PROCEDURE|Pancreaticoduodenectomy|
214634295|NCT03573453|OTHER|enteral nutrition|administration of enteral nutrition
214582799|NCT03029312|DEVICE|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
214582800|NCT05601947|OTHER|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
214582801|NCT05601947|OTHER|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
214582802|NCT03701815|BEHAVIORAL|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
214582803|NCT00001267|DRUG|zidovudine|
214582804|NCT00001267|DRUG|2',3'-dideoxyinosine|
214582805|NCT06050187|PROCEDURE|implant casts fabrication|four implant casts fabricated
214582806|NCT00672893|OTHER|Vibration Response Imaging|12 seconds of recording lung sounds
214582807|NCT02134977|DRUG|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
214582808|NCT04975477|PROCEDURE|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
214582809|NCT04975477|PROCEDURE|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
214582810|NCT03383120|DEVICE|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
214582811|NCT03383120|PROCEDURE|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
214582812|NCT02010008|BEHAVIORAL|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
214582813|NCT01773291|OTHER|acupuncture|acupuncture on GV26 and 12 Well points
214582814|NCT01773291|OTHER|laser acupuncture|laser acupuncture on GV26 and 12 Well points
214582815|NCT01773291|OTHER|control|sham laser acupuncture
214582816|NCT04004247|DEVICE|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
214582817|NCT00827320|DRUG|Levetiracetam|1000 mg tablet
214582818|NCT04628819|DIETARY_SUPPLEMENT|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
214582819|NCT04685057|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo for 6 months
214582820|NCT04685057|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic for 6 months
214582821|NCT04685057|DIETARY_SUPPLEMENT|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
214582822|NCT02207348|DRUG|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
214582823|NCT02054988|OTHER|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake."
214582824|NCT02054988|OTHER|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
214582825|NCT00892931|DRUG|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
214582826|NCT05029180|OTHER|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
214582827|NCT02839759|OTHER|TELLYHealth|Educational videos and questions.
214582828|NCT02080312|DRUG|Magnevist (gadopentetate dimeglumine)|
214582829|NCT06384638|BIOLOGICAL|topical application of coconut oil|topical application of coconut oil
214582830|NCT06384638|OTHER|scaling and debridement|scaling and debridement
214582831|NCT04257591|OTHER|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
214582832|NCT06101849|BEHAVIORAL|I-Can-Manage-Pain after cancer (Pain Management Program)|6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
214582833|NCT00107120|DRUG|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
214582834|NCT00107120|DRUG|Placebo|Placebo once daily for up to 8 weeks
214582835|NCT02088307|DIETARY_SUPPLEMENT|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
214582836|NCT06093854|RADIATION|Intraoperative radiotherapy (IORT)|Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)
214582837|NCT06093854|RADIATION|Stereotactic body radiotherapy (SBRT)|postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
214582838|NCT01013454|DRUG|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
214582839|NCT00294853|PROCEDURE|MDCT calcium score|
214582840|NCT06258460|OTHER|psychotherapy training program intervention|The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
214582841|NCT06258460|OTHER|the wail-list control intervention|The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
214582842|NCT01281150|DRUG|Carboplatin|Given IV
214582843|NCT01281150|OTHER|Laboratory Biomarker Analysis|Correlative studies
214582844|NCT01281150|DRUG|Paclitaxel|Given IV
214582845|NCT01281150|OTHER|Pharmacological Study|Correlative studies
214582846|NCT01281150|DRUG|Veliparib|Given PO
214582847|NCT02068209|DRUG|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
214582848|NCT02068209|DRUG|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
214582849|NCT04660630|DIAGNOSTIC_TEST|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
214582850|NCT04660630|BEHAVIORAL|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
214582851|NCT03296033|DRUG|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
214582852|NCT03296033|DRUG|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
214582853|NCT04178044|BIOLOGICAL|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
214634296|NCT05618743|PROCEDURE|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
214634297|NCT06565156|OTHER|BR-AM|BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
214634298|NCT06565156|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
214634299|NCT00870337|DRUG|everolimus|
214634300|NCT00925015|BIOLOGICAL|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
214634301|NCT00925015|BIOLOGICAL|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
214582854|NCT04178044|BIOLOGICAL|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
214582855|NCT04178044|BIOLOGICAL|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
214582856|NCT04178044|BIOLOGICAL|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
214582857|NCT04178044|BIOLOGICAL|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
214582858|NCT00842270|DRUG|AB1010|3 mg/kg/day
214582859|NCT00842270|DRUG|AB1010|4,5 mg/kg/day
214582860|NCT00842270|DRUG|AB1010|6 mg/kg/day
214582861|NCT00842270|DRUG|placebo|matching placebo to AB1010 dosages
214582862|NCT00718354|DRUG|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
214582863|NCT00718354|DRUG|Standard Chemotherapy|Investigator's discretion
214634302|NCT00925015|DRUG|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
214634303|NCT00925015|BIOLOGICAL|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
214634304|NCT03261622|DEVICE|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
214634305|NCT01617837|DEVICE|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
214634306|NCT01617837|OTHER|Placebo band|Comparison between groups 0-48 hours postoperatively
214634307|NCT06134232|DRUG|Sipuleucel-T Injection|Single Infusion
214634308|NCT04539730|DRUG|Liposomal bupivacaine|266 mg or 20 ml Liposomal Bupivacaine injectable solution
214634309|NCT04539730|PROCEDURE|Drug: SoC Ropivacaine|0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
214582864|NCT03076333|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
214582865|NCT01706887|OTHER|Diet Amiloride|only arm of the trial
214582866|NCT00896051|DRUG|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
214582867|NCT00896051|DRUG|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
214582868|NCT00896051|DRUG|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
214582869|NCT00896051|DRUG|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
214582870|NCT00896051|DRUG|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
214582871|NCT00896051|DRUG|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
214582872|NCT03173677|DIETARY_SUPPLEMENT|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
214582873|NCT03173677|DIETARY_SUPPLEMENT|Glucose intake|300 calories of glucose
214582874|NCT03173677|DIETARY_SUPPLEMENT|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
214582875|NCT00944177|DRUG|Metformin HCl|
214582876|NCT02935452|BEHAVIORAL|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
214582877|NCT05080816|DIETARY_SUPPLEMENT|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
214582878|NCT05080816|DIETARY_SUPPLEMENT|Enteral nutrition|Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.
214582879|NCT05080816|OTHER|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
214582880|NCT05316415|OTHER|Acemaşiran Music Group|Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
214582881|NCT04616703|RADIATION|CT imaging|CT of abdomen
214582882|NCT03133754|PROCEDURE|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
214582883|NCT03133754|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
214582884|NCT05384353|OTHER|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
214582885|NCT03217643|DRUG|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
214582886|NCT00876928|DRUG|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
214582887|NCT00876928|DRUG|placebo|medium chain triglyceride given once per week
214582888|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
214582889|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
214582890|NCT00044538|DRUG|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
214582891|NCT03719170|BEHAVIORAL|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
214582892|NCT00451880|DRUG|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
214582893|NCT00451880|DRUG|famotidine|single dose, supplied as 20-mg or 40-mg tablets
214582894|NCT05052866|BEHAVIORAL|Social Robot|Participants will interact with a social robot companionbot for a period of 8-10 weeks. The robot will stay in participants' apartments.
214582895|NCT02838433|OTHER|biological samples|blood and tissue samples
214582896|NCT00978796|DRUG|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
214582897|NCT00978796|DRUG|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
214582898|NCT03970460|DEVICE|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
214582899|NCT03970460|DEVICE|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
214582900|NCT05165797|BIOLOGICAL|platelet activation factors|platelet activation factors of subject blood
214582901|NCT04937803|DEVICE|Drug-coated balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
214582902|NCT04937803|DEVICE|Zotarolimus-Eluting Coronary Stent|Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
214582903|NCT00947557|DRUG|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
214582904|NCT00947557|DRUG|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
214582905|NCT01617304|OTHER|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
214582906|NCT02708719|PROCEDURE|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
214582907|NCT05025202|OTHER|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
214582908|NCT05412849|RADIATION|Radiotherapy|Radiotherapy site, time perspective and dose
214582909|NCT00383136|DRUG|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
214582910|NCT00383136|DRUG|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
214582911|NCT02091648|BEHAVIORAL|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
214582912|NCT02091648|BEHAVIORAL|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
214582913|NCT00534573|DRUG|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
214582914|NCT04716491|DEVICE|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
214582915|NCT00273767|DRUG|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
214582916|NCT00273767|DRUG|placebo|60ml of NaCl IV slow
214582917|NCT06071260|DRUG|0.01% atropine eye drop|One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.
214582918|NCT04956172|DEVICE|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
214582919|NCT02833532|DEVICE|Volus/Powerfill|Maximum: 22ml
214582920|NCT04014725|DEVICE|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
214582921|NCT01203280|OTHER|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
214582922|NCT04593316|OTHER|Saliva collection|A saliva sample will be collected before physical exercise.
214582923|NCT04593316|BEHAVIORAL|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
214582924|NCT04593316|OTHER|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
214582925|NCT04593316|OTHER|Physical exercise|The participant will perform a walk/run test.
214582926|NCT04593316|OTHER|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
214582927|NCT04593316|OTHER|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
214582928|NCT00553423|DRUG|Lactulose|Lactulose 30 ml q6h for 48 hrs
214582929|NCT00553423|DRUG|Placebo|Placebo 30 ml q6hrly for 48 hrs
214582930|NCT03103763|DRUG|Warfarin|Patients on warfarin for atrial fibrillation
214582931|NCT04482686|DRUG|Ivermectin|Treatment days 1, 4, and 8
214582932|NCT04482686|DRUG|Doxycycline Hcl|10 day treatment
214582933|NCT04482686|DIETARY_SUPPLEMENT|Zinc|10 Day treatment
214582934|NCT04482686|DIETARY_SUPPLEMENT|Vitamin D3|10 day treatment
214582935|NCT04482686|DIETARY_SUPPLEMENT|Vitamin C|10 day treatment
214582936|NCT03011502|OTHER|Biological samples collection of blood and feces|
214582937|NCT04162340|BIOLOGICAL|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214582938|NCT03168789|BEHAVIORAL|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
214582939|NCT03168789|BEHAVIORAL|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
214582940|NCT04511182|BEHAVIORAL|Exercise-based cardiac rehabilitation|"Exercise program is based on aerobic exercise and supplemented by strength training following the principle of gradual improvement. The type of exercise, such as walking, jogging, cycling, and the intensity of exercise which is recommended to use a cardiotach or pedometer to detect, are both defined by the results of CPET, such as METs value. Participators must be prepared for about 5-10 minutes to warm up and recover before and after exercise. 30-50 minutes a day, 5 days a week, with a total exercise time of not less than 150 minutes per week. It can be carried out in different stages according to the physical condition. After 1-3 months, the exercise prescription will be re-adjusted according to the results of reexamination.~All patients will undergo Cardiopulmonary Exercise Test, SF-36, echocardiography and laboratory examination prior to initiation of the trial, and which will be checked again after 3 months, and 6 months."
214582941|NCT03592901|DRUG|brachial plexus anesthesia|Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
214582942|NCT01970631|BEHAVIORAL|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
214582943|NCT01970631|OTHER|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
214582944|NCT01970345|DRUG|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
214582945|NCT01970345|DRUG|Placebo/saline|Placebo
214582946|NCT00536302|DIETARY_SUPPLEMENT|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
214582947|NCT00536302|DIETARY_SUPPLEMENT|Placebo|Matching placebo solution per day by mouth for 48 weeks.
214582948|NCT00413998|PROCEDURE|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
214582949|NCT00413998|PROCEDURE|CABG|Patients will undergo coronary artery bypass grafting alone.
214582950|NCT00714545|RADIATION|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
214582951|NCT06414837|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
214582952|NCT06414837|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
214582953|NCT00767416|BIOLOGICAL|MEDI-559|Cohort 1 (5 to \<24 months): N=80 MEDI-559 at 10\^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10\^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
214582954|NCT00767416|OTHER|Placebo|Cohort 1 (5 to \< 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
214582955|NCT02277041|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
214582956|NCT02277041|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
214582957|NCT00400348|DRUG|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
214582958|NCT00650351|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
214582959|NCT00650351|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
214582960|NCT03344653|DEVICE|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
214582961|NCT03344653|DEVICE|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
214582962|NCT04826861|BEHAVIORAL|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
214582963|NCT00005951|DRUG|irinotecan hydrochloride|
214582964|NCT00005951|DRUG|temozolomide|
214582965|NCT02617303|PROCEDURE|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
214582966|NCT02617303|PROCEDURE|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
214582967|NCT03346161|OTHER|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
214634310|NCT05942092|PROCEDURE|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
214634311|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
214634312|NCT01368835|DEVICE|Ulthera treatment|treatment of cheeks and upper neck area of face
214582968|NCT03346161|OTHER|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
214582969|NCT03346161|OTHER|Usual Care Group - Outcome Measures|"* Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
214582970|NCT03346161|OTHER|Decision Group - Outcome Measures|"* Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
214582971|NCT03346161|OTHER|Demographic and Background Questions|"* Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
214582972|NCT00562133|DRUG|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
214582973|NCT00562133|DRUG|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
214582974|NCT00465556|BEHAVIORAL|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
214582975|NCT00465556|BEHAVIORAL|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
214582976|NCT00433940|DRUG|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
214582977|NCT00892073|DRUG|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
214582978|NCT00892073|DRUG|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
214582979|NCT02272088|BEHAVIORAL|physical activity-moderate|cross -over of moderate and intense physical activity
214582980|NCT02272088|BEHAVIORAL|Intense physical activity|cross -over of moderate and intense physical activity
214582981|NCT01346475|DRUG|valacyclovir|1000 mg orally three times daily for 5 weeks
214582982|NCT01346475|DRUG|Valacyclovir|500 mg orally once daily for 5 weeks
214582983|NCT01678105|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
214582984|NCT05813639|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
214582985|NCT05813639|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
214582986|NCT05813639|PROCEDURE|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
214582987|NCT05324397|DEVICE|NEUROMARK System|The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
214582988|NCT03629327|DRUG|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
214582989|NCT03629327|OTHER|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
214582990|NCT03629327|DRUG|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
214582991|NCT06242860|DEVICE|ELM|Treatment of dry eye with ELM device
214582992|NCT06043583|PROCEDURE|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
214582993|NCT06043583|PROCEDURE|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
214582994|NCT04860076|DRUG|Pembrolizumab|Standard of care
214582995|NCT02342431|DEVICE|Forced air warming compressible|Warming with a compressible forced air mattress
214582996|NCT02342431|DEVICE|Forced air non-compressible|Warming with a non-compressible forced air mattress
214582997|NCT04955340|DRUG|[14C]-resminostat|1 single dose of 400 mg \[14C\]-resminostat
214582998|NCT00955253|DRUG|Guanfacine|2mg oral guanfacine (encapsulated)
214582999|NCT00955253|DRUG|Placebo|placebo
214583000|NCT05212805|BEHAVIORAL|Aerobic exercise|Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
214583001|NCT05212805|BEHAVIORAL|Task-oriented upper-limb training|The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
214583002|NCT05212805|BEHAVIORAL|Sport events participation|A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
214583003|NCT03689959|PROCEDURE|Eight plate hemiepiphysiodesis|Patient is positioned in a classic supine position. Under fluoroscopic guidance and tourniquet hemostasis, the distal femoral physis is identified. Two 3-cm incisions are made, one on either side of the patella, centred at the level of the physis. The capsule and synovium are opened to visualize the sulcus and place the plates just outside the articular portion of the joint surface, medially and laterally. Care is taken not to damage the periosteum and a needle is inserted into the physis. The 8-plate, which has a central hole, is slipped over the needle and screws inserted. After wound closure, a soft dressing is used, and the patient is allowed to ambulate as tolerated.
214583004|NCT00355459|DRUG|Tetracycline: Doxycycline analog|
214583005|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 3|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves
214583006|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 4|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
214583007|NCT04109105|OTHER|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
214583008|NCT01128816|DEVICE|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
214583009|NCT00537953|DRUG|Miltefosine , meglumine antimoniate|
214583010|NCT03057990|DRUG|Pyrimethamine|Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
214583011|NCT00702351|DRUG|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
214583012|NCT00217308|DRUG|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
214583013|NCT00558259|DRUG|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
214583014|NCT00558259|DRUG|matching placebo twice daily (BID)|Matching placebo BID
214583015|NCT06181487|OTHER|High Intensity Functional Training|12 weeks of high-intensity functional training, 3 times/week. Each class lasts 60 minutes, including warm-up, physical training, and cool down.
214583016|NCT04391634|OTHER|volume guarantee|volume guarantee assist-control mechanical ventilation
214583017|NCT04391634|OTHER|pressure-controlled|pressure-controlled assist-control mechanical ventilation
214583018|NCT02415452|PROCEDURE|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
214583019|NCT02874924|DRUG|Rapamycin|treatment
214583020|NCT02874924|DRUG|Placebo|control
214583021|NCT02874924|DRUG|Rapamycin|No placebo control in this substudy group
214583022|NCT02529631|DRUG|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
214583023|NCT02529631|DEVICE|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
214583024|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
214583025|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
214583026|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
214583027|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
214583028|NCT04871022|PROCEDURE|Double layer closure of the hysterotomy|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
214583029|NCT04871022|PROCEDURE|Purse closure of the hysterotomy|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
214583030|NCT02728869|BIOLOGICAL|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
214583031|NCT02728869|BIOLOGICAL|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
214583032|NCT02728869|BIOLOGICAL|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
214583033|NCT02732977|OTHER|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
214583034|NCT02771080|PROCEDURE|Cardiac surgery|
214583035|NCT00459615|DRUG|Artesunate for Injection|
214583036|NCT02190045|OTHER|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
214583037|NCT02190045|OTHER|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
214583038|NCT02029846|DRUG|Standard Treatment|traditional drugs only
214583039|NCT02029846|DRUG|Incretin-Based Treatment|incretin-based drugs
214583040|NCT04762823|DEVICE|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214583041|NCT04762823|DEVICE|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
214583042|NCT02966301|DRUG|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
214583043|NCT02389608|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
214583044|NCT02389608|DEVICE|Functional electrical stimulation (FES)|
214583045|NCT02389608|DEVICE|Sham stimulation|
214583046|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
214583047|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
214583048|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
214583049|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
214583050|NCT00700258|DRUG|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
214583051|NCT05057299|OTHER|retrospective data analysis|chart review, analysis and reporting outcomes
214583052|NCT01666379|DRUG|Fentanyl|
214583053|NCT00832637|DRUG|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
214583054|NCT00832637|DRUG|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
214583055|NCT00832637|DRUG|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
214583056|NCT03782077|PROCEDURE|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
214583057|NCT00370331|DRUG|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
214583058|NCT00370331|DRUG|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
214583059|NCT02367820|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
214583060|NCT03507465|DRUG|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
214583061|NCT03507465|DRUG|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
214583062|NCT01638832|DEVICE|Transient Elastography (FibroScan), Echosens, Paris, France|
214583063|NCT01638832|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
214583064|NCT00889668|DEVICE|GlucoTrack|comparison of different glucose monitoring devices
214583065|NCT04261998|OTHER|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
214583066|NCT03834051|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Rectal Administration Open Label
214583067|NCT00710853|OTHER|YiRen Qi gong|One hour weekly class for 8 week duration
214583068|NCT00710853|OTHER|Tai Chi|One hour weekly class for 8 week duration
214583069|NCT00710853|OTHER|Hatha yoga|One hour weekly class for 8 week duration
214583070|NCT00677001|DRUG|R306465|
214583071|NCT06476756|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUE|Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.
214583072|NCT06476756|OTHER|Buteyko techniques|Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1.
214583073|NCT01610141|OTHER|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
214583074|NCT01610141|OTHER|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
214583075|NCT05423626|DEVICE|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
214583076|NCT05423626|DEVICE|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers."
214583077|NCT00738582|DRUG|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
214583078|NCT00738582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
214583079|NCT00738582|DRUG|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
214583080|NCT05344820|BEHAVIORAL|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
214583081|NCT02416817|OTHER|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
214583082|NCT02416817|OTHER|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
214583083|NCT01873820|DIETARY_SUPPLEMENT|Calcium ascorbate|
214583084|NCT01873820|DIETARY_SUPPLEMENT|Ascorbic acid|
214583085|NCT04665999|DEVICE|Continuous Glucose Monitor|Data collection only
214583086|NCT06394232|DRUG|Eyecyte-RPE™|Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
214583087|NCT05352243|BEHAVIORAL|Expressive Disclosure|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write about their deepest thoughts and feelings surrounding their bereavement experience.
214634313|NCT01049841|DRUG|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
214583088|NCT05352243|BEHAVIORAL|Expressive Helping|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their first two writing will remain confidential, and their final essay will be de-identified before being provided to newly bereaved young adults. Three writing sessions will be spaced 1-2 weeks apart. In the first two writing sessions, participants will receive a writing prompt that will instruct them to write about their deepest thoughts and feelings surrounding their bereavement experience. For the final writing session, participants will receive a writing prompt instructing them to provide advice and support for a newly bereaved young adult.
214583089|NCT05352243|BEHAVIORAL|Fact-Writing|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
214583090|NCT01052103|DRUG|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
214583091|NCT01052103|DRUG|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
214583092|NCT01052103|DRUG|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
214583093|NCT02947893|DRUG|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
214583094|NCT02947893|DRUG|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
214583095|NCT04800432|BEHAVIORAL|ADAPT+|ADAPT+ is designed as an 6-week intervention. For each session, children and parents participate in separate 1.5-hour group meetings, followed by a joint goal setting session. Practical strategies related to improving diet and physical activity as well as the role of dealing with parent stress-related factors related to making long-lasting behavioral changes in the family are addressed.
214583096|NCT04800432|BEHAVIORAL|EUC|Enhanced Usual Care is an abbreviated version of the full ADAPT+ intervention in which parents are engaged in a one-time, two hour information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
214583097|NCT03929445|DEVICE|Endotracheal tube introducers|"Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie."
214583098|NCT00888628|BIOLOGICAL|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
214583099|NCT00888628|DRUG|Etanercept|Given as induction for islet cell transplant
214583100|NCT00545051|DRUG|Placebo|po monthly for 12 months
214583101|NCT00545051|DRUG|ibandronate|150mg po monthly for 12 months
214583102|NCT05196568|DIETARY_SUPPLEMENT|Fasting mimicking diet|Women will be given three administrations of fasting mimicking diet once a month
214583103|NCT05505331|RADIATION|three-Dimensional ultrasonography|transadominal and transvaginal examination
214583104|NCT05505331|RADIATION|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
214583105|NCT05505331|PROCEDURE|myomectomy|myoma excision
214583106|NCT02468180|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
214583107|NCT02468180|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
214583108|NCT02468180|DRUG|N-butyl-2-cyanoacrylate|
214583109|NCT02468180|DRUG|Lauromacrogol|
214583110|NCT04261491|PROCEDURE|scaling and root planing|scaling and root planing
214583111|NCT01241175|DRUG|Magnesium Sulfate|
214583112|NCT01241175|DRUG|normal saline|
214634314|NCT04644809|DRUG|LY3561774|Administered SC.
214634315|NCT04644809|DRUG|Placebo|Administered SC.
214583113|NCT00903006|DRUG|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
214583114|NCT00903006|DRUG|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
214583115|NCT00903006|DRUG|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
214583116|NCT04331145|DRUG|Ticagrelor 60mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
214583117|NCT05277103|BEHAVIORAL|Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD|The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
214583118|NCT01159002|DEVICE|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
214583119|NCT02469389|BEHAVIORAL|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
214583120|NCT02469389|BEHAVIORAL|Health & Wellness (H&W)|"Health \& Wellness (H\&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
214583121|NCT01079663|DRUG|Chlorhexidine 2.5 mg|
214583122|NCT01079663|DRUG|Placebo chip|
214583123|NCT02372500|DIETARY_SUPPLEMENT|Chewing gum|Sugar free chewing gum
214583124|NCT01847469|BEHAVIORAL|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
214583125|NCT01847469|DRUG|Zonisamide|
214583126|NCT01847469|DRUG|Placebo|
214583127|NCT02768311|PROCEDURE|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
214583128|NCT02768311|PROCEDURE|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
214583129|NCT02768311|PROCEDURE|hand files k-files|Procedure: hand files k-files
214583130|NCT02115516|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
214583131|NCT02115516|BIOLOGICAL|0.9% Sodium Chloride (Placebo)|
214583132|NCT03018951|OTHER|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
214583133|NCT03018951|OTHER|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
214583134|NCT03018951|OTHER|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
214583135|NCT04460274|OTHER|Model Building|Model building
214583136|NCT04460274|OTHER|Model validation|Model validation
214583137|NCT03781999|DIETARY_SUPPLEMENT|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
214583138|NCT03781999|OTHER|Placebo|Maltodextrin
214583139|NCT02898415|PROCEDURE|Liver transplantation|
214583140|NCT02851927|PROCEDURE|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
214583141|NCT02851927|PROCEDURE|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
214583142|NCT06476613|OTHER|Permissive Hypotension|Patients will be randomized in 1:1 fashion to either a) Permissive Hypotension (MAP target \> 60mmHg) or b) Usual Care. The duration of the intervention will extend until the patient no longer needs vasopressors to maintain prespecified MAP.
214583143|NCT02412410|BEHAVIORAL|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
214583144|NCT06421610|DRUG|PITAC|Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
214583145|NCT04083573|OTHER|application of medical augmented reality glasses|Endoscopic images from medical monitor and medical augmented reality glasses will be collected and reviewed. Outcomes from both series of images will be compared
214583146|NCT06243861|BEHAVIORAL|Mother-child bond|assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
214583147|NCT02674815|OTHER|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
214583148|NCT04304521|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
214583149|NCT05494177|DIAGNOSTIC_TEST|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART)."
214583150|NCT05494177|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
214583151|NCT03375216|BEHAVIORAL|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
214583152|NCT03375216|BEHAVIORAL|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
214710373|NCT03228706|BEHAVIORAL|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
214710374|NCT05072756|OTHER|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
214710375|NCT03771807|DIETARY_SUPPLEMENT|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
214710376|NCT03771807|OTHER|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
214710377|NCT03771807|OTHER|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
214710378|NCT06014957|DRUG|spinal anesthesia|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
214583153|NCT05396482|DIAGNOSTIC_TEST|Pure tone audiometer|Pure tone audiometer
214583154|NCT04226885|DRUG|fentanyl|nebulized fentanyl 2μg/kg body weigh
214583155|NCT04226885|DRUG|midazolam|nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
214583156|NCT04226885|DRUG|dexmedetomidine|nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
214583157|NCT01935180|DEVICE|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
214583158|NCT05069103|DEVICE|Intervention|"Similar to the original TWIST trial , patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s)."
214583159|NCT00662506|DRUG|Cediranib Maleate|Given PO
214583160|NCT00662506|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
214583161|NCT00662506|PROCEDURE|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
214583162|NCT00662506|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
214583163|NCT00662506|RADIATION|Fludeoxyglucose F-18|Undergo 18 FDG PET
214583164|NCT00662506|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214583165|NCT00662506|OTHER|Laboratory Biomarker Analysis|Correlative studies
214583166|NCT00662506|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo PWI
214710379|NCT06014957|DRUG|saddle block|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
214710380|NCT05779345|PROCEDURE|surgery|short implant placement
214583167|NCT00662506|PROCEDURE|Positron Emission Tomography|Undergo 18 F FDG-PET
214583168|NCT00662506|DRUG|Temozolomide|Given PO
214583169|NCT05827432|DEVICE|Field-cycling imaging (FCI)|FCI scan
214583170|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
214583171|NCT01236339|PROCEDURE|LVP|Large Volume Paracentesis
214583172|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
214583173|NCT02042222|DRUG|Hydroxyurea|
214583174|NCT01810120|BIOLOGICAL|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
214583175|NCT02054741|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
214583176|NCT02054741|OTHER|Quality-of-Life Assessment|Ancillary studies
214583177|NCT02054741|OTHER|Survey Administration|Ancillary studies
214583178|NCT02450799|DEVICE|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
214583179|NCT02450799|DEVICE|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
214583180|NCT02450799|DEVICE|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
214583181|NCT00159276|PROCEDURE|Induced Sputum|
214583182|NCT03418831|DRUG|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
214583183|NCT03418831|OTHER|Placebo|1 tablet daily for 12 weeks
214583184|NCT03468738|OTHER|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
214583185|NCT02610127|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
214583186|NCT03390374|DRUG|Nystatin Oral|Nystatin oral suspension
214634316|NCT05911906|DRUG|Remdesivir|"Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.~Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes."
214634317|NCT05474300|OTHER|mechanical ventilation|Pressure controlled ventilation mode on mechanical ventilation
214634318|NCT00963898|DEVICE|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
214634319|NCT02870231|DRUG|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
214634320|NCT02870231|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
214634321|NCT02870231|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration
214583187|NCT05024227|BEHAVIORAL|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
214583188|NCT00369720|PROCEDURE|Titration of oxygen in delivery room|
214583189|NCT01501760|DRUG|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
214583190|NCT01501760|DRUG|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
214583191|NCT04896112|DRUG|LNK01002|LNK01002 will be administrated orally.
214583192|NCT01130584|OTHER|Pyruvate kinase isoform M2|
214710381|NCT05246488|DIAGNOSTIC_TEST|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
214710382|NCT02468206|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
214583193|NCT04778423|OTHER|Avatar Therapy|In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
214583194|NCT00163306|DRUG|Pantoprazole|
214710383|NCT02468206|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
214710384|NCT02468206|DRUG|N-butyl-2-cyanoacrylate|
214710385|NCT02468206|DRUG|Lauromacrogol|
214583195|NCT01945060|DEVICE|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server."
214583196|NCT01945060|OTHER|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
214583197|NCT00866853|DRUG|TMC435|
214583198|NCT04002193|OTHER|volume expansion|To assess fluid responsiveness
214583199|NCT02925026|DIETARY_SUPPLEMENT|Lactoferrin|
214583200|NCT02925026|DIETARY_SUPPLEMENT|Lysozyme|
214583201|NCT02925026|DIETARY_SUPPLEMENT|Placebo|
214583202|NCT02777385|DRUG|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
214583203|NCT02777385|DRUG|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
214583204|NCT02777385|RADIATION|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
214583205|NCT03174912|PROCEDURE|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
214583206|NCT02754817|DRUG|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
214583207|NCT00402597|DRUG|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
214583208|NCT00402597|DRUG|Placebo|1 placebo tablet twice daily for 6 months.
214583209|NCT00402597|DRUG|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
214583210|NCT03129139|DRUG|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
214583211|NCT04705129|DRUG|Zanubrutinib|160mg Bid, D1-21, po
214583212|NCT04705129|DRUG|Tislelizumab|200mg, D1, ivgtt
214583213|NCT00366808|PROCEDURE|LASIK surgery|
214583214|NCT02731053|BEHAVIORAL|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
214583215|NCT00518492|PROCEDURE|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
214583216|NCT02619981|PROCEDURE|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
214583217|NCT02619981|DRUG|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
214583218|NCT03294148|OTHER|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
214583219|NCT03294148|BEHAVIORAL|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
214583220|NCT02300441|OTHER|ECG, blood pressure and oximetry|
214583221|NCT01581138|DRUG|VX-222|400 mg tablets twice daily for oral administration
214583222|NCT01581138|DRUG|telaprevir|1125 mg tablets twice daily for oral administration
214583223|NCT01581138|DRUG|ribavirin|1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
214583224|NCT04120636|DRUG|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
214583225|NCT01869127|DEVICE|Shoes|A unisex canvas slip-on with a sturdy sole.
214583226|NCT04032054|DEVICE|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
214710386|NCT04246125|PROCEDURE|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
214710387|NCT06094972|BEHAVIORAL|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
214583227|NCT02013960|DRUG|Cytotec|Cytotec medication compared with cytotec and laminaria
214583228|NCT06454994|DEVICE|Eyebrow lift|Upper face lifting
214583229|NCT06454994|DEVICE|Jaw lift|Mid-face and low-face lifting
214583230|NCT01424904|DIETARY_SUPPLEMENT|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
214583231|NCT05712473|DIAGNOSTIC_TEST|PYLARIFY|PYLARIFY PET
214583232|NCT04987736|DIAGNOSTIC_TEST|RT-PCR|COVID 19 diagonostic test
214710388|NCT06094972|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
214583233|NCT02575001|BEHAVIORAL|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~1. Child Attachment Interview (CAI)~2. General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~3. Parenting Stress Index with the 19-item Life Stress Scale (PSI)~4. Achenbach System of Empirically Based Assessment (CBCL, YSR)~5. Holmes and Rahe Social readjustment rating scale~6. Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~7. Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
214583234|NCT02575001|GENETIC|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
214583235|NCT02575001|PROCEDURE|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
214583236|NCT02575001|PROCEDURE|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
214583237|NCT00986973|DRUG|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
214583238|NCT03854773|OTHER|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214583239|NCT03854773|OTHER|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214583240|NCT03854773|OTHER|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214583241|NCT03776227|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214583242|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
214583243|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214583244|NCT00598273|DRUG|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214583245|NCT01332773|PROCEDURE|Artery first procedure|early identification of SMA to evaluate infiltration
214583246|NCT01332773|PROCEDURE|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
214583247|NCT00174343|DRUG|exemestane (Aromasin®)|
214583248|NCT03446820|OTHER|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
214583249|NCT01940185|DEVICE|LINX device|
214583250|NCT06520800|BEHAVIORAL|Treatment and handling obesity-related comorbidities in adolescents through exercise|Tailor-made, one-to-one, physical exercise program
214583251|NCT04667832|DIAGNOSTIC_TEST|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
214583252|NCT03770910|OTHER|GIP receptor antagonist|GIP receptor antagonist
214583253|NCT03770910|OTHER|GIP receptor agonist|GIP(1-42)
214583254|NCT03770910|OTHER|Saline|Placebo (vehicle for infusions)
214583255|NCT01607632|BEHAVIORAL|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
214583256|NCT05550701|OTHER|lymph node yield|We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer
214710389|NCT05450744|DRUG|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
214710390|NCT04798846|PROCEDURE|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
214710391|NCT06415162|OTHER|Cooling Pillowcases|No intervention will be given to the patients in the control group.
214710392|NCT00962754|PROCEDURE|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
214583257|NCT05010837|OTHER|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
214583258|NCT05010837|OTHER|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
214583259|NCT00577837|DRUG|risedronate|tablet, 5 mg risedronate daily for 6 months
214583260|NCT00577837|DRUG|risedronate|tablet, 100 mg risedronate monthly for 6 months
214583261|NCT00577837|DRUG|risedronate|tablet, 150 mg risedronate monthly for 6 months
214583262|NCT00577837|DRUG|experimental|tablet, 200 mg risedronate monthly for 6 months
214583263|NCT03989518|BEHAVIORAL|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
214583264|NCT03989518|BEHAVIORAL|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
214583265|NCT03989518|BEHAVIORAL|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
214583266|NCT02097901|PROCEDURE|Microfracture|Rotator Cuff Repair AND Microfracture
214583267|NCT02097901|PROCEDURE|NO microfracture|Rotator Cuff Repair without microfracture
214583268|NCT06143969|PROCEDURE|ultrasound-assisted, catheter-directed thrombolysis|After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
214583269|NCT05002829|OTHER|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
214583270|NCT05002829|OTHER|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
214583271|NCT04569643|DIAGNOSTIC_TEST|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
214583272|NCT04569643|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
214583273|NCT04569643|DIAGNOSTIC_TEST|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
214583274|NCT04569643|OTHER|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
214583275|NCT04569643|OTHER|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
214583276|NCT00371228|PROCEDURE|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
214583277|NCT04931082|DIETARY_SUPPLEMENT|Probiotics|Capsule
214583278|NCT04931082|DIETARY_SUPPLEMENT|Placebo|Capsule
214583279|NCT01337583|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
214583280|NCT01337583|OTHER|Placebo|Vaginal Ring containing no drug substance
214583281|NCT01337583|DRUG|Dapivirine|
214583282|NCT03299868|DEVICE|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
214583283|NCT06202586|PROCEDURE|low FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
214583284|NCT06202586|PROCEDURE|high FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
214583285|NCT01465347|DRUG|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
214583286|NCT00178100|BEHAVIORAL|Interpersonal Psychotherapy|
214583287|NCT00178100|DRUG|paroxetine|
214583288|NCT00125073|BEHAVIORAL|Postoperative nutritional counseling|
214583289|NCT03743454|OTHER|No intervention|No intervention will be applied.
214583290|NCT04486326|DRUG|Crofelemer|Crofelemer
214583291|NCT04486326|DRUG|Placebo|placebo
214583292|NCT03664089|BEHAVIORAL|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
214583293|NCT03664089|BEHAVIORAL|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
214583294|NCT04540250|OTHER|questionnaire|conventional intra-oral examination and questionnaire
214583295|NCT04772820|BEHAVIORAL|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
214583296|NCT01590082|DRUG|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
214583297|NCT01590082|DRUG|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
214583298|NCT01590082|DRUG|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
214583299|NCT02374684|DRUG|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
214583300|NCT02374684|DRUG|Placebo|Placebo to match with experimental groups
214583301|NCT04767139|BEHAVIORAL|counseling for family planning|all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
214583302|NCT06149910|OTHER|Multiple Myeloma Pathway|Use and adherence to a multiple myeloma pathway.
214583303|NCT06149910|OTHER|All4Cure Platform|Participant in the All4Cure platform.
214583304|NCT06149910|OTHER|Documentation Pathway|Use of multiple myeloma pathway through written documentation.
214583305|NCT00363870|BIOLOGICAL|Fluarix vaccine|
214583306|NCT00950326|PROCEDURE|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
214583307|NCT00950326|PROCEDURE|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
214583308|NCT00950326|PROCEDURE|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
214583309|NCT02414932|DRUG|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
214583310|NCT02414932|DRUG|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
214583311|NCT00561132|DIETARY_SUPPLEMENT|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
214583312|NCT00561132|OTHER|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
214583313|NCT00250939|BIOLOGICAL|Myozyme|20 mg/kg qow
214583314|NCT00398554|DRUG|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
214583315|NCT00398554|DRUG|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
214583316|NCT00398554|DRUG|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
214583317|NCT00398554|DRUG|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
214583318|NCT00398554|DRUG|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
214583319|NCT00398554|DRUG|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
214583320|NCT00398554|RADIATION|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
214583321|NCT00906945|DRUG|G-CSF|
214583322|NCT00906945|DRUG|Plerixafor|
214583323|NCT00906945|DRUG|Mitoxantrone|
214583324|NCT00906945|DRUG|Etoposide|
214583325|NCT00906945|DRUG|Cytarabine|
214583326|NCT00797251|PROCEDURE|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
214583327|NCT05429905|BIOLOGICAL|Phase I|"* Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."
214583328|NCT05429905|BIOLOGICAL|Phase II|RP2D will be determined in Phase I
214583329|NCT00294177|DEVICE|atomic force microscopy|
214583330|NCT00294177|DEVICE|dual polarisation interferometry|
214583331|NCT02434497|DRUG|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
214583332|NCT01425424|OTHER|Vitamin D supplementation|Vitamin D
214583333|NCT01602107|OTHER|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
214583334|NCT01210664|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
214583335|NCT02020759|DEVICE|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
214583336|NCT05134831|DIAGNOSTIC_TEST|Rhinomanometry|"At Day 0, before the hyaluronic acid injection, the patient's nasal breathing is assessed by 4-phase rhinomanometry (bilaterally: right nostril AND left nostril).~At Month 1, the patient's nasal breathing is re-assessed by 4-phase rhinomanometry, in the same conditions as Day 0."
214583337|NCT02958631|DRUG|Fimasartan|
214583338|NCT02958631|DRUG|Losartan|
214583339|NCT02632422|OTHER|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
214583340|NCT02632422|OTHER|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily room air (dSHAM).
214583341|NCT02632422|OTHER|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.~Walking practice will incorporate 5 walking-related tasks:~1. walking balance (e.g., walking with turns)~2. skilled walking tasks (e.g., negotiating obstacles)~3. walking with secondary task (e.g., walking and talking)~4. endurance~5. speed"
214583342|NCT01853644|DRUG|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
214583343|NCT05959954|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
214583344|NCT02657512|DRUG|rivaroxaban|rivaroxaban 40 mg/day (1 day)
214583345|NCT02657512|DRUG|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
214583346|NCT00621361|DRUG|AZD2171|Oral
214583347|NCT00621361|DRUG|Etoposide|Intravenous
214583348|NCT00621361|DRUG|Cisplatin|Intravenous
214583349|NCT00156637|BEHAVIORAL|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
214583350|NCT00156637|BEHAVIORAL|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
214583351|NCT00156637|BEHAVIORAL|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
214583352|NCT02891408|DRUG|Firsocostat|Capsule(s) administered orally on Day 1
214583353|NCT02891408|DRUG|Fenofibrate|Tablet administered orally on Day 1
214583354|NCT02407392|DRUG|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
214583355|NCT02407392|PROCEDURE|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
214583356|NCT00541021|DRUG|gemcitabine hydrochloride|
214583357|NCT00541021|DRUG|sorafenib tosylate|
214583358|NCT05857982|DRUG|Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
214583359|NCT00320827|DRUG|CS-1008 (humanized anti-DR5 antibody)|
214583360|NCT04621318|DRUG|Denosumab|60 mg, single-dose
214583361|NCT00619203|DRUG|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
214583362|NCT00619203|DRUG|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
214583363|NCT00619203|DRUG|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
214583364|NCT00619203|DRUG|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
214583365|NCT00619203|DRUG|Placebo|2 placebos, one po, one suppository
214583366|NCT00619203|DRUG|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
214583367|NCT00619203|DRUG|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
214583368|NCT04265820|DEVICE|unilateral implantation of IOL|unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
214583369|NCT04265820|DEVICE|bilateral implantation of IOL|bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
214583370|NCT05517837|DRUG|BMS-986421|Specified dose on specified days
214583371|NCT05517837|OTHER|Placebo|Specified dose on specified days
214583372|NCT00000473|BEHAVIORAL|dietary supplements|
214583373|NCT00000473|DRUG|fatty acids, omega-3|
214583374|NCT00000473|BEHAVIORAL|diet, fat-restricted|
214583375|NCT01054170|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
214583376|NCT01054170|DRUG|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
214583377|NCT00647491|BIOLOGICAL|adalimumab|20 mg sc eow
214583378|NCT00647491|BIOLOGICAL|adalimumab|40 mg sc eow
214583379|NCT00647491|BIOLOGICAL|adalimumab|80 mg sc eow
214583380|NCT00647491|BIOLOGICAL|placebo|placebo sc eow
214583381|NCT02175251|PROCEDURE|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
214583382|NCT02175251|PROCEDURE|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
214583383|NCT02175251|PROCEDURE|Sham Comparator|10 session in 5 days with sham-controlled
214583384|NCT02534298|OTHER|functional magnetic resonance imaging|functional magnetic resonance imaging
214583385|NCT03095001|DRUG|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
214583386|NCT03095001|DRUG|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
214583387|NCT03095001|DRUG|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
214583388|NCT05101967|PROCEDURE|Dynamic Cervical Implant|Cervical discectomy through anterior approach with replacement of disc by dynamic implant
214583389|NCT05101967|PROCEDURE|Anterior Cervical Discectomt and Fusion|Cervical discectomy through anterior approach with putting of cervical cage.
214583390|NCT00709852|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
214583391|NCT00709852|DRUG|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
214583392|NCT02951767|DRUG|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
214583393|NCT00757341|DRUG|SKI-606|
214583394|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
214583395|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
214583396|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
214583397|NCT06079541|DRUG|Placebo in Cohorts 1 to 7|oral once
214583398|NCT06079541|DRUG|Placebo in 3 Cohorts|oral once
214583399|NCT04545684|BEHAVIORAL|Motor imagery|The person will have to imagine different scenarios of manual gripping
214583400|NCT04545684|BEHAVIORAL|Placebo intervention|The placebo group will imagine a place without the presence of humans.
214583401|NCT01442779|DRUG|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
214583402|NCT05629754|DIAGNOSTIC_TEST|MRI, radiological assessment|MRI and radiological assessment of the involved knee
214583403|NCT06407596|DEVICE|high intensity laser|3 times per week, for 9 sessions
214583404|NCT06407596|DEVICE|tens+us|5 times per week, total 15 sessions for 3 weeks
214583405|NCT04664543|OTHER|Free diet|To follow the regular dietary habits with no restriction nor modification.
214583406|NCT04664543|OTHER|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
214583407|NCT01048671|DRUG|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
214583408|NCT01048671|DRUG|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
214583409|NCT01719419|DRUG|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
214583410|NCT01719419|DRUG|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
214583411|NCT03436251|DEVICE|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
214710393|NCT04984460|DIAGNOSTIC_TEST|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
214583412|NCT03436251|DEVICE|LEEP or cold knife|For patients with HPV+ / CIN-2
214583413|NCT03436251|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
214583414|NCT02968082|DRUG|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
214583415|NCT02968082|DRUG|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
214583416|NCT05033431|DRUG|Brazikumab|Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
214583417|NCT03650309|DEVICE|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
214583418|NCT06409429|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
214583419|NCT06409429|DRUG|GX|Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.
214583420|NCT06409429|DRUG|Placebo|Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
214583421|NCT02743156|PROCEDURE|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
214583422|NCT02743156|PROCEDURE|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
214583423|NCT03814187|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
214583424|NCT02703090|DRUG|Remifentanil|
214583425|NCT02703090|DRUG|Normal saline|
214583426|NCT00291850|DRUG|Paclitaxel, Cisplatin, Pegfilgrastim|
214583427|NCT02171416|DRUG|Rilonacept|
214583428|NCT02171416|DRUG|Placebo|
214583429|NCT01096277|DRUG|Sitagliptin|oral tablets 100 mg per day for two weeks
214583430|NCT01096277|DRUG|Placebo|oral tablet, one per day for two weeks
214583431|NCT01096277|OTHER|Control|no intervention
214583432|NCT02047864|DIETARY_SUPPLEMENT|Creatine monohydrate|
214583433|NCT03160508|PROCEDURE|Fracture fixation with the TFNA|Fracture fixation with the TFNA
214710394|NCT03716687|DEVICE|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
214583434|NCT00513604|BIOLOGICAL|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
214583435|NCT00513604|BIOLOGICAL|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
214583436|NCT00513604|DRUG|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
214583437|NCT00513604|DRUG|Fludarabine phosphate|Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
214583438|NCT00513604|RADIATION|Total body irradiation|600 cGy
214710395|NCT00132314|DRUG|IM risperidone|long-acting injectable risperidone
214710396|NCT00132314|DRUG|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
214710397|NCT00832312|OTHER|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
214583439|NCT04260880|OTHER|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
214583440|NCT04260880|OTHER|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
214583441|NCT04260880|OTHER|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
214583442|NCT04555980|DEVICE|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
214583443|NCT04555980|DEVICE|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
214583444|NCT04059653|DEVICE|Electrical stimulation|Electrical stimulation device
214583445|NCT04059653|OTHER|Treatment as usual|GP treatment as usual
214583446|NCT01335087|OTHER|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
214583447|NCT01335087|DEVICE|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
214710398|NCT00832312|OTHER|placebo (saline)|Injection of 1cc of saline into the knee joint
214583448|NCT03231501|DRUG|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
214583449|NCT00196976|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
214710399|NCT06087523|OTHER|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~* Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~* Systemic Lupus Activity Questionnaire~* Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
214710400|NCT06221956|BEHAVIORAL|relevis|Participants will receive access to the digital health intervention relevis in addition to TAU.
214710401|NCT03422640|DRUG|Apremilast|Open label treatment with apremilast
214710402|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
214583450|NCT00196976|BIOLOGICAL|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
214583451|NCT00196976|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
214583452|NCT00196976|BIOLOGICAL|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
214583453|NCT00196976|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
214583454|NCT01326754|DRUG|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
214583455|NCT01326754|DRUG|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
214710403|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
214710404|NCT04961476|DIETARY_SUPPLEMENT|1-MNA|1-MNA supplementation
214583456|NCT01326754|DRUG|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
214583457|NCT03228602|OTHER|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
214583458|NCT02105922|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
214583459|NCT02105922|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
214583460|NCT02105922|PROCEDURE|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
214583461|NCT04236115|DRUG|Articaine 4%|Articaine 4% is dental local anaesthetic agent
214583462|NCT04236115|DRUG|Prilocain 3%|prilocaine is dental local anaesthetic agent
214583463|NCT04236115|DRUG|Adrenalin|adrenaline is a vasoconstrictor
214583464|NCT04236115|DRUG|Felypressin|Felypressin is a vasoconstrictor
214583465|NCT01405365|DRUG|Metronidazole|Metronidazole 400mg TID for 10 days
214583466|NCT01405365|DRUG|Placebo|Placebo pill TID for 10 days
214583467|NCT01405365|PROCEDURE|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
214583468|NCT04860167|DRUG|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
214583469|NCT04860167|DRUG|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
214583470|NCT02689518|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
214583471|NCT00825825|DRUG|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
214583472|NCT00825825|DRUG|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
214583473|NCT00825825|DRUG|Placebo|Two weeks of placebo taken orally.
214583474|NCT04039477|DRUG|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
214583475|NCT02395146|PROCEDURE|Monitoring|intraoperative EBSLN monitoring
214583476|NCT03367650|DIETARY_SUPPLEMENT|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
214583477|NCT02328339|OTHER|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
214583478|NCT02328339|OTHER|Placebo|Placebo matched to tea with respect to taste and appearance
214583479|NCT04041531|OTHER|blood sampling|venous blood sampling for oxygen affinity in-vitro test
214583480|NCT02617680|DRUG|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
214583481|NCT02617680|DRUG|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
214583482|NCT02311868|DIETARY_SUPPLEMENT|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
214583483|NCT02311868|DIETARY_SUPPLEMENT|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
214583484|NCT01045395|DIETARY_SUPPLEMENT|Corn starch|90mg/d
214583485|NCT01045395|DIETARY_SUPPLEMENT|Unique Marine Algae Concentrate (UMAC)|90mg/d
214583486|NCT01045395|DIETARY_SUPPLEMENT|Golden brown algae|90mg/d
214583487|NCT01920854|DRUG|soluble ferric pyrophosphate|
214583488|NCT01920854|DRUG|Placebo|
214583489|NCT00000823|DRUG|Zidovudine|
214583490|NCT00000823|DRUG|Didanosine|
214583491|NCT00456677|DRUG|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
214583492|NCT00456677|DRUG|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
214583493|NCT04280068|BEHAVIORAL|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
214583494|NCT04280068|BEHAVIORAL|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
214583495|NCT02978573|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
214583496|NCT00300898|PROCEDURE|Nucleoplasty|
214583497|NCT00300898|PROCEDURE|Percutaneous decompression|
214583498|NCT00300898|PROCEDURE|Intervertebral electrothermal disc decompression (IDET)|
214583499|NCT00300898|BEHAVIORAL|Conservative treatment|
214583500|NCT04059003|DRUG|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
214583501|NCT05727969|DRUG|Dexmedetomidine|Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
214583502|NCT05727969|DRUG|Lactated Ringer|Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
214583503|NCT05727969|PROCEDURE|Hypospadias|Children who will undergone hypospadias surgery
214583504|NCT05727969|DEVICE|Surgical pleth index|The SPI value will be measured using Datex-Ohmeda (GE Healthcare,Madison,WI 53707-7550 USA) monitoring system.
214583505|NCT02686047|DEVICE|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
214583506|NCT02686047|DEVICE|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
214583507|NCT00201747|DRUG|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
214583508|NCT00201747|DRUG|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
214583509|NCT02293915|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
214583510|NCT02293915|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
214583511|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
214583512|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
214583513|NCT00757783|DRUG|darunavir|800 mg tablet once daily for 48 weeks
214583514|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
214583515|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
214583516|NCT00757783|DRUG|atazanavir|300 mg capsule once daily for 48 weeks
214583517|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
214583518|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
214583519|NCT01303731|DRUG|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
214583520|NCT01303731|DRUG|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
214583521|NCT04680754|OTHER|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
214583522|NCT04806217|OTHER|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
214583523|NCT03433248|DRUG|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
214583524|NCT03433248|DRUG|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
214583525|NCT03433248|DRUG|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
214583526|NCT04818333|DRUG|SHR-A1811|Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
214583527|NCT02054520|DRUG|HyperAcute®-Melanoma (HAM) Immunotherapy|
214583528|NCT02054520|DRUG|Ipilimumab|
214583529|NCT02054520|DRUG|Pembrolizumab|
214583530|NCT02054520|DRUG|Nivolumab|
214583531|NCT02757391|BIOLOGICAL|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
214583532|NCT02757391|BIOLOGICAL|Aldesleukin|Given SC
214583533|NCT02757391|DRUG|Cyclophosphamide|Given IV
214583534|NCT02757391|OTHER|Laboratory Biomarker Analysis|Correlative studies
214583535|NCT02757391|BIOLOGICAL|Pembrolizumab|Given IV
214583536|NCT02293031|DEVICE|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
214583537|NCT03032393|OTHER|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
214583538|NCT03032393|OTHER|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
214583539|NCT04320706|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
214583540|NCT04320706|DRUG|Oral Placebo|Administration of placebo orally
214583541|NCT01043393|DRUG|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
214583542|NCT05320549|BEHAVIORAL|Community Programme|Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
214583543|NCT00645554|DRUG|Galantamine oral solution|
214583544|NCT01775150|OTHER|health education|Health education via text messaging
214583545|NCT02660463|OTHER|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
214583546|NCT02372136|DIETARY_SUPPLEMENT|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
214583547|NCT02372136|DIETARY_SUPPLEMENT|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
214583548|NCT00280943|BEHAVIORAL|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
214583549|NCT00985946|DRUG|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
214583550|NCT01080833|DEVICE|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
214583551|NCT04480125|DRUG|Azacitidine|100mg D1-7
214583552|NCT04480125|DRUG|Chidamide|30mg BIW PO
214583553|NCT03093077|DEVICE|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
214583554|NCT05414487|DRUG|Ofatumumab|There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
214583555|NCT04937712|OTHER|RT-PCR SARS-COV2 in urine|proteinuria/renal phosphate leak/uricosuria/glycosuria/ aminoaciduria)
214583556|NCT06531161|DRUG|Suxiao Jiuxin Pill|Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
214583557|NCT06531161|DRUG|Placebo|Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
214583558|NCT00861523|DRUG|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
214583559|NCT02621671|BEHAVIORAL|Cognitive interview|
214583560|NCT02621671|OTHER|Survey|
214583561|NCT06015425|DEVICE|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214583562|NCT02739295|DRUG|recombinant granulocyte - colony stimulating factor|
214583563|NCT02739295|DRUG|NaCl 0.9%|
214583564|NCT02471833|DRUG|Telmisartan 20mg|Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
214583565|NCT02471833|DRUG|Telmisartan 40mg|Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
214583566|NCT02471833|DRUG|Placebo|Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
214583567|NCT02850211|DRUG|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
214583568|NCT02850211|DRUG|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
214583569|NCT02850211|DRUG|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
214583570|NCT00002565|BIOLOGICAL|bleomycin sulfate|
214583571|NCT00002565|DRUG|CHOP regimen|
214583572|NCT00002565|DRUG|cisplatin|
214583573|NCT00002565|DRUG|cyclophosphamide|
214583574|NCT00002565|DRUG|cytarabine|
214583575|NCT00002565|DRUG|doxorubicin hydrochloride|
214583576|NCT00002565|DRUG|etoposide|
214583577|NCT00002565|DRUG|idarubicin|
214583578|NCT00002565|DRUG|ifosfamide|
214583579|NCT00002565|DRUG|mesna|
214583580|NCT00002565|DRUG|methylprednisolone|
214583581|NCT00002565|DRUG|mitoxantrone hydrochloride|
214583582|NCT00002565|DRUG|prednisone|
214583583|NCT00002565|DRUG|vincristine sulfate|
214583584|NCT04222361|PROCEDURE|Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI|Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
214583585|NCT00496951|DEVICE|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
214710405|NCT00987636|DRUG|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
214583586|NCT05606835|OTHER|Postural stability assessment|The Biodex Balance System SD (BDS) (Biodex Medical Systems Inc., Shirley, New York, USA) assesses postural stability (PS). Both static PS (SPS) and dynamic PS (DPS) will be assessed. In the DPS assessment, the platform can be tilted 20° in any direction. For static measurement, participants will be asked to stand barefoot on the platform, stand on one leg, keep the knees in 20-30° flexion. Meanwhile the contralateral knee will be asked to keep in 90° flexion, and stabilize their feet until the end of the test. Upon completion of the SPS assessment, the DPS assessment will be performed. The difficulty level of the DPS test will accepted as 4. For both SPS and the DPS assessment, the test consists of 3 trials of 20 seconds each with a 10-second break between trials.
214583587|NCT05606835|OTHER|Frontal plan prjection angle|Frontal Plan Projection Angle (FPPA) is calculated as the angle between the thigh segment and the trunk segment based on the postural image, considering the position of the thigh and tibia. The FPPA will be evaluated using the Spark motion Pro™ application (2D). Before measurement, markers will be placed bilaterally at the SIAS, at the midpoint of the femoral condyles, and at the midpoint of the ankle bones. Participants will stand on the floor barefoot and arms crossed over the chest. Subjects will be asked to squat in a controlled manner and perform a 60° knee bend without losing balance before returning to the starting position. Test will be performed by using single leg squat test. The one-legged squat will be performed for 5 seconds at a standard pace with the researcher acting as the counter. Degrees smaller than 165 will be accepted as increase in knee valgus.
214583588|NCT05606835|OTHER|Foot and Ankle Ability Measure|The Foot and Ankle Ailability Measure (FAAM) is used to assess the self-reported overall functional level of patients with leg, foot, and ankle musculoskeletal injuries and conditions. It consists of 1) activities of daily living \[ADL\] and 2) sports \[S\] and can be scored from 0 to 100%. In the FAAM, there are 29 items that are scored from 0 to 4. There are 21 items related to various functional activities under the subtitle activities of daily living, and 8 items related to various activities related to participation in sports under the subtitle sports. Standardized response options are answered on five-point likert scales ranging from 0 (I cannot) to 4 (no difficulty). Point totals between 0 and 84 for the ADL subtitle and between 0 and 32 for the Sports subtitle are converted to percentage points.
214583589|NCT05606835|OTHER|Navicular Drop Test|The navicular drop test (NDT) is a clinical method for assessing the mobility of the medial longitudinal arch (MLA). The extent of navicular subsidence is assessed to determine the flexibility of the MLA and the position of the navicular with and without transfer of body weight. To assess navicular drop, the subtalar joint will be positioned in neutral position and the height of the navicular will be measured in non-weight bearing position. Then the measurement will be repeated in weightbearing position. The height difference between the two measurements in sitting and standing is recorded as the NDT value. Values more than 10mm is accepted as pathological.
214583590|NCT05606835|OTHER|Calcaneotibial Angle Measurement|Measurement of the calcaneotibial angle (CTA) is one of the methods used in the evaluation of the foot and ankle. By measuring this angle, it is assessed whether the ankle problems are related to the hindfoot. In the CTA measurement, the angle between the vertical axis of the calcaneus and the longitudinal axis of the achilles tendon is measured in the standing and prone positions, and the differences will be recorded. Values more than 8 degrees is accepted as calcaneal valgus.
214710406|NCT00987636|DRUG|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW
214710407|NCT00987636|DRUG|Treosulfan|12 g/m² d-5 to d-3
214583591|NCT05606835|OTHER|Tibial Torsion Angle|Tibial torsion is a rotational deformity which can be measured between the long axis of the tibia and the transmalleolar axes. This measurement can be used to determine the extent to foot malalignment is due to bone torsion. Measurement will be done by a goniometer. Participants will be asked to lie prone and will be positioned with the knee joint in 90° flexion and the ankle joint in a neutral position. Normal alignment is 20 degrees external rotation. Any increase or decrease accepted as pathological.
214583592|NCT05606835|OTHER|Femoral internal and external rotation measurement|Accurate assessment of hip joint range of motion (ROM) is an important component in the overall clinical evaluation of lower extremity injuries, particularly those of the hip and groin. The expected hip rotational range of motion for internal rotation (IR) is 45°, and for external rotation (ER) is 0° to 45°. In this study, a smartphone-based inclinometer will be used to measure femoral IR and ER. The inclinometer will be placed vertically so that the top edge is just below the tibial tuberosity and the bottom edge is pointed at the midpoint of the medial and lateral malleoli.
214583593|NCT02104843|DRUG|Daclatasvir, Asunaprevir and BMS-791325 FDC|
214583594|NCT02104843|DRUG|BMS-791325|
214583595|NCT02104843|DRUG|Rosuvastatin|
214583596|NCT05994404|PROCEDURE|ACDF|
214583597|NCT05994404|PROCEDURE|Posterior Cervical Fusion|
214583598|NCT05994404|PROCEDURE|Cervical Laminoplasty|
214583599|NCT05363462|DRUG|Vancomycin 1000 MG|Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
214583600|NCT00126230|DRUG|docetaxel and samarium|
214583601|NCT04567277|PROCEDURE|External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)|EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
214583602|NCT05660759|PROCEDURE|Portal vein embolization|Portal vein emboliazation with either NBCA or micro particles.
214583603|NCT01668901|DRUG|warfarin|anticoagulation
214583604|NCT01668901|DRUG|Aspirin|antiplatelet
214583605|NCT00066014|PROCEDURE|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
214583606|NCT01055301|DRUG|bortezomib|
214583607|NCT01055301|DRUG|cisplatin|
214583608|NCT01055301|DRUG|cyclophosphamide|
214583609|NCT01055301|DRUG|dexamethasone|
214583610|NCT01055301|DRUG|doxorubicin hydrochloride|
214583611|NCT01055301|DRUG|etoposide|
214583612|NCT01055301|DRUG|lenalidomide|
214583613|NCT01055301|DRUG|melphalan|
214583614|NCT01055301|DRUG|thalidomide|
214583615|NCT01055301|GENETIC|gene expression analysis|
214583616|NCT01055301|GENETIC|microarray analysis|
214583617|NCT01055301|OTHER|laboratory biomarker analysis|
214583618|NCT01055301|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
214583619|NCT03422198|RADIATION|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
214583620|NCT03422198|RADIATION|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
214583621|NCT00466375|GENETIC|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
214583622|NCT00466375|GENETIC|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
214583623|NCT03599609|DRUG|Simvastatin 40mg|Simvastatin 40mg, once daily
214583624|NCT01771640|BIOLOGICAL|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
214583625|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the morning|The patients in this group underwent impacted tooth surgery at 08:30 in the morning.
214583626|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the afternoon|Impacted tooth surgery was performed on the patients in this group at 15:30.
214583627|NCT00112047|DRUG|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
214583628|NCT00112047|DRUG|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
214583629|NCT00112047|DRUG|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
214583630|NCT00112047|DRUG|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
214583631|NCT00112047|DRUG|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
214583632|NCT00112047|DRUG|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
214583633|NCT01307579|DRUG|Caspofungin Acetate|Given IV
214583634|NCT01307579|DRUG|Fluconazole|Given IV or PO
214583635|NCT01307579|OTHER|Laboratory Biomarker Analysis|Correlative studies
214583636|NCT03612583|PROCEDURE|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
214583637|NCT03103451|DRUG|BCD-121|
214583638|NCT03103451|OTHER|Placebo|
214583639|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
214583640|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
214583641|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
214583642|NCT06907745|PROCEDURE|Bimaxillary Osteotomy|Maxillary LeFort I osteotomy and mandible osteotomy (BSSO) without intermediate splint.
214583643|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
214583644|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
214583645|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
214583646|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
214583647|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
214583648|NCT04310891|RADIATION|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
214583649|NCT01277367|BEHAVIORAL|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
214583650|NCT01277367|BEHAVIORAL|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
214583651|NCT01277367|BEHAVIORAL|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
214583652|NCT01277367|BEHAVIORAL|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
214583653|NCT01277367|BEHAVIORAL|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
214583654|NCT01277367|BEHAVIORAL|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
214583655|NCT00377091|DRUG|Fondaparinux|
214583656|NCT00812331|DRUG|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
214583657|NCT01506453|DRUG|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
214583658|NCT01506453|DRUG|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
214583659|NCT02560311|OTHER|observation|
214583660|NCT02866500|BEHAVIORAL|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
214583661|NCT05786989|DRUG|selinexor|Given PO
214583662|NCT01809496|BEHAVIORAL|Informational Counseling|
214583663|NCT01809496|BEHAVIORAL|Patient Centered Counseling|
214583664|NCT05346133|BEHAVIORAL|Suicide Prevention Intervention for Adolescents|Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
214583665|NCT01783847|DRUG|Recombinant human erythropoietin (EPO)|4000 units per vial
214583666|NCT01783847|OTHER|Observation|Just observation
214583667|NCT01783847|DRUG|Methyl prednisolone|250 mg every 6 hours for 3 days.
214583668|NCT05615493|DEVICE|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
214583669|NCT05615493|DEVICE|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), \& frequency 4 Hz every week for one month without operating the machine .
214583670|NCT01007643|OTHER|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
214583671|NCT01007643|OTHER|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
214583672|NCT05803031|DRUG|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
214583673|NCT05803031|PROCEDURE|Non-surgical periodontal debridement|Scaling and root surface debridement
214583674|NCT02610166|BEHAVIORAL|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
214583675|NCT02610166|OTHER|Usual Care|Children in usual care group receive standard medical care.
214583676|NCT01206036|DRUG|Docetaxel|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
214583677|NCT01206036|DRUG|Temsirolimus|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
214583678|NCT04323631|DRUG|Hydroxychloroquine|Oral
214583679|NCT04323631|OTHER|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
214583680|NCT03706313|DRUG|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
214583681|NCT03706313|PROCEDURE|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
214583682|NCT03706313|DRUG|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
214583683|NCT02877238|DRUG|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
214583684|NCT02877238|DRUG|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
214583685|NCT04789278|OTHER|Notification|Notification of coronary calcium to the patient and their clinician
214583686|NCT02455154|DRUG|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
214583687|NCT02455154|DRUG|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
214583688|NCT02455154|DRUG|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
214583689|NCT00612469|DRUG|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
214583690|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
214583691|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
214583692|NCT00612469|DRUG|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
214583693|NCT02480257|BEHAVIORAL|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
214583694|NCT05468346|DRUG|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
214583695|NCT06168097|PROCEDURE|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
214583696|NCT06168097|PROCEDURE|women with intraoperative and / or histopathology findings suggestive of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
214583697|NCT01377597|DRUG|ranibizumab|
214583698|NCT05921825|DIAGNOSTIC_TEST|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
214583699|NCT05921825|DIAGNOSTIC_TEST|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
214583700|NCT05448612|OTHER|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
214583701|NCT06208319|OTHER|data collection|data collection from the patient's medical record. The data will be that of routine care, with no procedures added by the research.
214583702|NCT00055601|DRUG|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
214583703|NCT00055601|DRUG|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
214583704|NCT00055601|DRUG|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
214583705|NCT00055601|RADIATION|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
214583706|NCT00055601|DRUG|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
214583707|NCT00055601|PROCEDURE|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
214583708|NCT02675868|DRUG|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
214583709|NCT02675868|DRUG|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
214583710|NCT02675868|DRUG|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
214583711|NCT02675868|DRUG|Placebo|NaCl 0.9% infusion
214583712|NCT00530907|DRUG|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
214583713|NCT00530907|DRUG|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
214583714|NCT04787497|DIETARY_SUPPLEMENT|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
214583715|NCT04555538|DIAGNOSTIC_TEST|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
214583716|NCT03272581|OTHER|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
214710408|NCT06248723|OTHER|Nutritional intervention|"The objectives of the dietary intervention will be in accordance with the principles of the Mediterranean diet. Weekly menus will be provided that ensure a balanced intake of the various nutrients, according to the objectives outlined in the study protocol, including a reduction in saturated fatty acids (with proportionately more mono- and polyunsaturated fatty acids), promotion of fiber sources and reduction of sugars, adequate protein and micronutrient intake. They will be accompanied by specific dietary patterns that can be individualized based on weight, comorbidities and personal preferences.~The need for weight loss or gain will be assessed on an individual basis. Dietary interventions will include group and individual sessions, and will be conducted by dietitians and nutritionists in a harmonized manner among the centers. The first meeting will be in-person and will be held at the subject's clinical center of enrollment. Follow-up will be conducted through online meetings."
214583717|NCT04536987|DEVICE|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
214583718|NCT00117845|BIOLOGICAL|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
214583719|NCT04112329|BEHAVIORAL|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
214583720|NCT05871567|PROCEDURE|colorectal resection|potential resective surgery
214583721|NCT03312452|DEVICE|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
214583722|NCT03312452|DEVICE|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
214583723|NCT05020288|DRUG|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
214583724|NCT00474877|DEVICE|Static resting splints|
214583725|NCT04369859|BEHAVIORAL|Examine the impact of COVID-19 during pregnancy|clinical data collection
214583726|NCT00036959|DRUG|ABT-751|
214583727|NCT03910686|COMBINATION_PRODUCT|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
214583728|NCT01789645|OTHER|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
214583729|NCT01789645|PROCEDURE|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
214583730|NCT01680484|DIETARY_SUPPLEMENT|Bitter chocolate|
214583731|NCT01680484|DIETARY_SUPPLEMENT|Orange juice|
214583732|NCT03644953|DRUG|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
214710409|NCT06248723|OTHER|Physical exercise|The physical activity protocol will be geared to the principles of progressive and individualized loading, in group sessions supervised by a physical therapist within gyms for the strength and balance training portion, and in moderate to intense aerobic activities based on individual preferences and characteristics. The physiotherapist will conduct an individual assessment and develop personalized programs for all participants. Exercise sessions will be held 2-3 times a week.
214583733|NCT04746053|OTHER|Pelvic ultrasound|Pelvic or vaginal ultrasound
214583734|NCT04746053|BIOLOGICAL|blood sample|blood sample (5ml)
214583735|NCT00909337|DRUG|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
214583736|NCT00071747|DRUG|lamotrigine|
214583737|NCT00910689|DRUG|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
214583738|NCT00910689|DRUG|Placebo control|Placebo
214583739|NCT00910689|BEHAVIORAL|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
214583740|NCT00910689|DRUG|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
214583741|NCT00618527|DRUG|mycophenolate mofetil (Cellcept)|1 gram po, bid
214583742|NCT00618527|DRUG|human interferon beta 1a (Rebif)|44mcg sq injection every other day
214583743|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
214583744|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
214583745|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
214583746|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
214583747|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
214583748|NCT00484289|DRUG|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
214583749|NCT00507195|DRUG|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
214583750|NCT04852367|DEVICE|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
214583751|NCT04852367|DRUG|Doxorubicin|Doxorubicin infusion
214583752|NCT04852367|DRUG|ThermoDox|ThermoDox infusion
214583753|NCT02727062|DEVICE|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
214583754|NCT02727062|DEVICE|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
214583755|NCT01849159|BIOLOGICAL|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
214583756|NCT01849159|OTHER|Reference therapy: 400 mL of 0.9% NaCl solution|
214583757|NCT00564460|DRUG|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
214583758|NCT00564460|DRUG|Placebo|Placebo once daily for 8 weeks
214583759|NCT04734093|DIAGNOSTIC_TEST|Evaluation of sonographic signs of gouty arthritis|the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
214583760|NCT06000137|DRUG|Dezocine|dezocine for patient-controlled analgesia
214583761|NCT06000137|DRUG|Sufentanil injection|sufentanil for patient-controlled analgesia
214583762|NCT06000137|DRUG|Flurbiprofen|Flurbiprofen for patient-controlled analgesia
214583763|NCT06000137|DRUG|Granisetron Injection|granisetron has antiemetic function.
214583764|NCT02349425|DRUG|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
214583765|NCT02349425|DRUG|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
214583766|NCT01832285|DRUG|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
214583767|NCT05568238|PROCEDURE|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM)|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM) in patients with open abdomen.
214583768|NCT01135407|OTHER|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
214583769|NCT01135407|OTHER|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
214583770|NCT01135407|OTHER|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
214583771|NCT03372707|DIAGNOSTIC_TEST|Cuff Leak Test|The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
214583772|NCT05548140|DEVICE|Novel Motorized Spiral Enteroscopy|This study involves performance of spiral enteroscopy in one arm and single balloon enteroscopy in the other arm in patients who satisfy inclusion criteria
214583773|NCT05339217|DRUG|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
214583774|NCT05339217|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
214583775|NCT04751266|PROCEDURE|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
214583776|NCT00775320|PROCEDURE|FLT-PET scan|Imaging test
214583777|NCT02594761|BIOLOGICAL|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
214583778|NCT02594761|BIOLOGICAL|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
214583779|NCT02594761|BIOLOGICAL|Herceptin US|Intravenous Infusion, 440 mg/vial
214583780|NCT04258501|OTHER|Mulberry fruit|
214583781|NCT04258501|OTHER|Mulberry leaf|
214583782|NCT04258501|OTHER|White bean|
214583783|NCT04258501|OTHER|Apple|
214583784|NCT04258501|OTHER|Elderberry|
214583785|NCT04258501|OTHER|Turmeric|
214710410|NCT06248723|OTHER|Cognitive training|Participants will be evaluated through a Cognitive and Psychological Assessment, which will allow measurement of each participant's cognitive functioning and well-being. Computerized cognitive training (CCT) using Brain HeadQuarter (BrainHQ) or similar software will be used as a cognitive intervention. The CCT includes game-based adaptive exercises that target attention, intelligence, memory, navigation, processing speed and social skills. The training will consist of 72 sessions for 24 weeks (about six months), at least three times a week.
214583786|NCT04258501|OTHER|Rice porridge|
214583787|NCT05479201|DIAGNOSTIC_TEST|Home based sleep test|Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
214583788|NCT03116737|DRUG|Benzocaine Otic Solution|
214583789|NCT03116737|DRUG|Placebo|
214583790|NCT04839874|OTHER|No intervention|Semi-structured qualitative interviews
214583791|NCT03382379|DEVICE|Active transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
214710411|NCT06248723|OTHER|Oral hygiene|"Participants will be referred for evaluation at dental hygiene offices. As part of the study, participants will also undergo anticholinergic burden calculation, screening for risk factors for oral diseases (smoking, alcohol), and reduction in the frequency of sugar intake through dietary intervention will be sought.~Participants will also undergo the Oral Health Assessment Tool rating scale."
214583792|NCT03382379|DEVICE|Sham transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
214583793|NCT05866068|DRUG|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
214583794|NCT02009254|OTHER|Dietary treatment|
214583795|NCT02830945|BEHAVIORAL|Motivational Interviewing Intervention Arm|
214583796|NCT02830945|OTHER|Control Brochure Arm|
214583797|NCT05015907|DRUG|Ropivacaine|The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
214583798|NCT05015907|OTHER|Control (without intervention)|No intervention
214583799|NCT04784260|OTHER|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
214583800|NCT01786473|DRUG|Testogel 1%|
214583801|NCT01786473|DRUG|Placebo|
214583802|NCT02683005|DRUG|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
214583803|NCT03341767|DRUG|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
214583804|NCT03341767|DRUG|Placebo|Oil-wax in gelatin capsule
214583805|NCT04953325|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
214583806|NCT04953325|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
214583807|NCT04953325|BIOLOGICAL|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
214583808|NCT04327076|DEVICE|Using robot system of endotracheal intubation and airway cleaning|"1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
214583809|NCT02761876|BEHAVIORAL|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
214583810|NCT02761876|BEHAVIORAL|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
214583811|NCT02761876|BEHAVIORAL|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
214583812|NCT00872677|BEHAVIORAL|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
214583813|NCT00872677|OTHER|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
214583814|NCT00444899|BEHAVIORAL|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
214583815|NCT00444899|OTHER|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
214583816|NCT00819962|DRUG|Bupivacaine|Local anesthetic
214583817|NCT00819962|OTHER|TAP|
214583818|NCT04017039|OTHER|Targeted Sleep Intervention|
214583819|NCT01403610|DRUG|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
214583820|NCT01403610|DRUG|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
214583821|NCT01403610|DRUG|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
214583822|NCT04123392|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
214583823|NCT04123392|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
214583824|NCT04123392|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
214583825|NCT00433524|PROCEDURE|computed tomography|
214583826|NCT00123552|DRUG|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
214583827|NCT00123552|DRUG|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
214583828|NCT00123552|DRUG|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
214583829|NCT03167931|OTHER|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
214583830|NCT03167931|OTHER|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
214583831|NCT03540953|DRUG|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
214583832|NCT05624320|DRUG|AGN-190584|miotic for treatment of presbyopia
214583833|NCT01657955|DRUG|Bendamustine Hydrochloride Injection|
214583834|NCT01657955|DRUG|Chlorambucil|
214583835|NCT00003555|DRUG|amifostine trihydrate|
214583836|NCT00003555|DRUG|paclitaxel|
214583837|NCT03200600|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
214583838|NCT03200600|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
214583839|NCT03200600|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
214710412|NCT06248723|OTHER|Sleep quality|"During the visits, participants' sleep will be assessed, either by clinical interview or by scales. Participants will also have the opportunity to assess their own sleep via wearable devices.~If sleep hygiene issues are detected, advice based on currently available scientific evidence will be provided. If, on the other hand, a suspicion of sleep disorders, including, for example, obstructive sleep apnea syndrome, restless legs syndrome, insomnia, or Rapid Eye Movement (REM) sleep disorder, is raised from the medical history, participants will be referred to the relevant specialists for diagnosis and treatment of such problems."
214710413|NCT06248723|OTHER|Control of cardiovascular, metabolic, and infectious risk factors|Measurements of blood pressure, weight, BMI, abdominal circumference, and advice on health promotion and healthy lifestyle will be provided. Recommendations on adherence to the Piano Nazionale di Prevenzione Vaccinale (PNPV) will also be provided.
214710414|NCT06248723|OTHER|Pharmacological evaluation|Evaluation of prescriptive appropriateness (STOP\&START and Beers criteria) and calculation of anticholinergic burden (ACB calculator) will be carried out by a geriatrician, with rationalization of therapy and, where possible, de-prescribing.
214583840|NCT03200600|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
214583841|NCT00445900|DRUG|cyclophosphamide|
214583842|NCT00445900|DRUG|prednisone|
214583843|NCT00445900|DRUG|thalidomide|
214583844|NCT00445900|OTHER|immunohistochemistry staining method|
214583845|NCT00445900|OTHER|laboratory biomarker analysis|
214583846|NCT00445900|PROCEDURE|biopsy|
214583847|NCT04834206|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
214583848|NCT04834206|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
214583849|NCT04834206|DRUG|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
214583850|NCT05344482|OTHER|Secukinumab|Included all the patients treated with secukinumab
214583851|NCT00533741|DRUG|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
214583852|NCT00533741|DRUG|Placebo|Saline for injection.
214583853|NCT00533741|BIOLOGICAL|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
214583854|NCT03023228|BEHAVIORAL|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
214583855|NCT05534256|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
214583856|NCT01954381|DEVICE|transthoracic echocardiographic|
214583857|NCT01954381|DEVICE|Doppler ultrasound.|
214583858|NCT01954381|BIOLOGICAL|blood samples|
214583859|NCT02001610|DIETARY_SUPPLEMENT|Acidophilus pearls|"* Acidophilus pearls are encapsulated using patented process~* Subjects take one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
214583860|NCT02001610|DIETARY_SUPPLEMENT|Hard shell gelatin capsules|"* Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~* Subjects consume one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
214583861|NCT04847726|DIAGNOSTIC_TEST|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
214583862|NCT04847726|DIAGNOSTIC_TEST|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
214583863|NCT04847726|DIAGNOSTIC_TEST|Liver MRI|Participants underwent liver MRI for hepatic lesion
214583864|NCT00118755|DRUG|capecitabine|850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
214583865|NCT00118755|DRUG|Oxaliplatin|130 mg/m\^2 IV on Day 1 of each 3-week cycle
214583866|NCT00118755|DRUG|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
214583867|NCT00118755|DRUG|capecitabine|1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
214583868|NCT00118755|DRUG|Oxaliplatin|85 mg/m\^2 IV on Day 1 of each 2-week cycle
214583869|NCT00118755|DRUG|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
214583870|NCT00728715|DRUG|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
214583871|NCT00728715|DRUG|High dose of budesonide|1600 mcg/d of budesonide
214583872|NCT00728715|DRUG|A|medium dose of budesonide-formoterol
214583873|NCT00728715|DRUG|B|High Dose Inhaled Budesonide
214583874|NCT04762654|OTHER|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
214583875|NCT01950026|PROCEDURE|cryotherapy application|"* Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
214583876|NCT03457207|PROCEDURE|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
214583877|NCT02650245|DIETARY_SUPPLEMENT|EAS Myoplex Protein Drink + 10gm lactulose|
214583878|NCT04254302|OTHER|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
214583879|NCT00260663|PROCEDURE|Group hearing aid fittings|
214583880|NCT00260663|PROCEDURE|Group hearing aid follow-up|
214583881|NCT03867058|BEHAVIORAL|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
214583882|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
214583883|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
214583884|NCT06148974|DIETARY_SUPPLEMENT|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
214583885|NCT06148974|OTHER|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
214583886|NCT00686725|DRUG|Temozolomide|
214583887|NCT00686725|RADIATION|Radiotherapy|
214583888|NCT04124081|DRUG|Hydronidone capsules& Entecavir capsules|take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
214583889|NCT04969887|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
214583890|NCT04969887|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
214583891|NCT02358382|DRUG|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
214583892|NCT05747053|DIAGNOSTIC_TEST|AlloSure|AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
214583893|NCT05747053|DIAGNOSTIC_TEST|PAXGene|1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
214583894|NCT03237351|DEVICE|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
214583895|NCT00629434|OTHER|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
214583896|NCT00629434|OTHER|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
214583897|NCT02562495|DEVICE|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
214583898|NCT06110325|OTHER|Cawthorne and Cooksey exercise program|Participants in this group will receive an exercise program based on Cawthorne and Cooksey exercises. The intervention will last for 4 weeks, taking place three times a week, with the first session conducted in person and the remaining two assisted via video from their homes.
214583899|NCT06110325|OTHER|Control|Control group will receive counseling focused on fall prevention and promotion of an active, healthy lifestyle through informational leaflets.
214583900|NCT04362605|PROCEDURE|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
214583901|NCT00002151|DRUG|Celgosivir hydrochloride|
214583902|NCT05694754|DEVICE|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
214583903|NCT05335720|DRUG|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
214583904|NCT03642951|DEVICE|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
214583905|NCT03642951|DEVICE|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
214583906|NCT00701233|DRUG|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
214583907|NCT00701233|DRUG|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
214583908|NCT00292162|PROCEDURE|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
214583909|NCT00292162|DRUG|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
214583910|NCT00292162|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
214583911|NCT00292162|DRUG|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
214583912|NCT05615090|PROCEDURE|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
214710415|NCT06248723|BEHAVIORAL|Socializing|"To encourage socialization, proposed activities will be carried out as much as possible in groups of 10-12 people, and outdoor group activities will be suggested on a biweekly basis (e.g., walks in parks). On a monthly basis, the nurse and psychologist will organize motivational and check-up meetings (in recreation centers/via telematics) in order to promote adherence to the protocol, collect questions and stimulate participants.~Social activity will also be implemented in the context of all interventions, for example through:~* Physical activity in groups or pairs, including dance or choir activities where possible~* Opportunities for further cognitive stimulation in groups through games (e.g., chess, cards, etc.)~* Proposal to cook, eat or shop together~* Group sessions with dietitian"
214583913|NCT05615090|PROCEDURE|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
214583914|NCT04581889|OTHER|Diagnostic test|Presence of antibodies in saliva
214583915|NCT02924974|DRUG|Morphine|mixed with bupivacaine
214583916|NCT02924974|DRUG|Lidocaine|sham procedure (s.c. lidocaïne)
214583917|NCT03064035|DRUG|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
214583918|NCT06385405|DEVICE|Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment|The target site for alpha frequency Transcranial Magnetic Stimulation (αTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
214583919|NCT06385405|DEVICE|10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)|Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.
214583920|NCT00233805|DEVICE|Sirolimus coated Bx Velocity™|drug-eluting stent
214583921|NCT00233805|DEVICE|Bare metal Bx Velocity™|bare-metal stent
214583922|NCT02118558|DEVICE|Negative Pressure Wound Therapy (NPWT)|
214583923|NCT02118558|DRUG|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
214710416|NCT06248723|OTHER|Self-administered interventions|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website. Such advice and information will be timed to encourage adherence. In addition, participants randomized to the self-guided intervention will receive an initial counseling session of 30-60 minutes on all domains covered by the study, where guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
214583924|NCT02839954|BIOLOGICAL|anti-MUC1 CAR-pNK cells|
214583925|NCT01143038|BIOLOGICAL|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
214583926|NCT01344512|DRUG|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
214583927|NCT01344512|DRUG|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
214583928|NCT01344512|DRUG|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
214583929|NCT00759018|BIOLOGICAL|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10\^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
214583930|NCT00582868|DEVICE|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
214583931|NCT00582868|OTHER|CSF|analysis of CSF for cleaved tau protein
214583932|NCT00582868|OTHER|Whole blood|Analysis of whole blood for cleaved-tau protein
214583933|NCT06236555|DIAGNOSTIC_TEST|8-iso Prostaglandin F2α and Adenosine Deaminase|We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
214583934|NCT02316860|OTHER|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
214583935|NCT04609306|OTHER|H2O2 application to incision|A lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes.
214583936|NCT00737373|DRUG|Docetaxel|50mg/m2 qd15
214583937|NCT00737373|DRUG|5-Fluorouracil|2600mg/m2 qd15
214583938|NCT00737373|DRUG|Oxaliplatin|85mg/m2 qd15
214583939|NCT00737373|DRUG|folinic acid|200mg/m2 qd15
214583940|NCT00461838|PROCEDURE|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
214583941|NCT00461838|OTHER|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
214583942|NCT04533568|DRUG|Ibuprofen 400 mg|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
214583943|NCT04533568|DRUG|Dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
214583944|NCT00234767|DEVICE|Pulmonary Artery Catheter|
214583945|NCT00234767|BEHAVIORAL|Protocolized Fluid Management|
214583946|NCT00809601|DEVICE|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
214583947|NCT02030301|BIOLOGICAL|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
214583948|NCT02030301|BIOLOGICAL|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
214583949|NCT02030301|BIOLOGICAL|PBS|Phosphate-buffered saline
214583950|NCT05811923|OTHER|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
214583951|NCT05811923|OTHER|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
214583952|NCT05811923|OTHER|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
214583953|NCT05811923|OTHER|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
214583954|NCT02999126|DRUG|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
214583955|NCT02999126|DRUG|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
214583956|NCT03768804|OTHER|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
214583957|NCT03768804|OTHER|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
214583958|NCT01234753|OTHER|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
214583959|NCT02877836|OTHER|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
214583960|NCT06359834|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion. Remimazolam 2mg is added in case of inadequate sedation.
214583961|NCT06359834|DRUG|Propofol|Patients in this group receives 1mg/kg of propofol to induce sedation prior to endoscope insertion. Propofol 20mg is added in case of inadequate sedation.
214710417|NCT04518345|DRUG|Azacitidine|Given IV
214583962|NCT02791425|DEVICE|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
214583963|NCT02791425|OTHER|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
214583964|NCT01683929|OTHER|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
214583965|NCT01683929|OTHER|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
214583966|NCT04020705|DEVICE|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
214583967|NCT04020705|OTHER|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
214583968|NCT01248065|DRUG|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
214583969|NCT01248065|DRUG|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
214583970|NCT00584649|PROCEDURE|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
214583971|NCT01762501|DRUG|Azilsartan|Azilsartan 20mg/day
214583972|NCT01762501|DRUG|Amlodipine|Amlodipine 5mg/day
214583973|NCT02220673|DRUG|BHT 0.1%|
214583974|NCT02220673|DRUG|BHT 0.5%|
214583975|NCT02220673|DRUG|Placebo for RMT-B|
214583976|NCT02220673|DRUG|Placebo for HFA-MDI|
214583977|NCT05970679|DRUG|Ezetimibe/Atorvastatin 10/5 mg|DW1125
214583978|NCT05970679|DRUG|Atorvastatin 5mg|DW1125A
214710418|NCT04518345|DRUG|Dubermatinib|Given PO
214710419|NCT05942170|DRUG|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
214710420|NCT03825172|DIAGNOSTIC_TEST|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
214583979|NCT05970679|DRUG|Ezetimibe 10mg|DW1125E
214583980|NCT05970679|DRUG|Atorvastatin 10mg|DW1125A-1
214583981|NCT05970679|DRUG|DW1125 placebo|Ezetimibe/Atorvastatin 10/5 mg placebo
214583982|NCT05970679|DRUG|DW1125A placebo|Atorvastatin 5mg placebo
214583983|NCT05970679|DRUG|DW1125E placebo|Ezetimibe 10mg placebo
214583984|NCT05970679|DRUG|DW1125A-1 placebo|Atorvastatin 10mg placebo
214583985|NCT04903587|DEVICE|Ultrasonography and MRI|Abdominal Ultrasonography and axial MRI
214583986|NCT02162589|PROCEDURE|POEM|Per oral endoscopic myotomy
214583987|NCT03010176|DRUG|Ulevostinag|IT injection
214583988|NCT03010176|BIOLOGICAL|Pembrolizumab|IV infusion
214583989|NCT01749904|DRUG|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
214583990|NCT01749904|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
214583991|NCT01749904|DRUG|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
214583992|NCT01176279|PROCEDURE|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
214583993|NCT01176279|PROCEDURE|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
214583994|NCT01404195|DIETARY_SUPPLEMENT|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
214583995|NCT00614601|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
214583996|NCT02738944|BEHAVIORAL|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
214634322|NCT04550130|DEVICE|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
214710421|NCT03250377|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg and 50 mg~* Route of administration: Oral use"
214710422|NCT06042478|DRUG|Remibrutinib|Active treatment
214583997|NCT02738944|BEHAVIORAL|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
214583998|NCT00140192|DRUG|creatine|
214583999|NCT00386373|DRUG|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
214584000|NCT00536783|DRUG|Quetiapine|
214584001|NCT00321373|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
214584002|NCT00321373|BIOLOGICAL|FluarixTM|Single dose, Intramuscular injection
214584003|NCT01774487|DRUG|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
214584004|NCT05600296|DRUG|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
214584005|NCT05600296|PROCEDURE|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
214584006|NCT05600296|PROCEDURE|IINB+ Spermatic cord block|IINB+ Spermatic cord block
214584007|NCT00731809|RADIATION|FDG PET CT|FDG PET CT
214584008|NCT05202639|OTHER|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
214584009|NCT00461032|DRUG|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
214584010|NCT00461032|DRUG|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
214584011|NCT04447846|DRUG|Cannabidiol|Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
214584012|NCT00074971|DRUG|Fabrazyme (agalsidase beta)|
214584013|NCT00767975|DRUG|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
214584014|NCT00767975|DRUG|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
214584015|NCT03212300|BEHAVIORAL|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
214584016|NCT05657015|DRUG|Lepidium Sativum|2 ml of LS in situ gel at baseline
214584017|NCT05657015|DRUG|Simvastatin|1.2% of SMV in situ gel at baseline
214584018|NCT00283218|DRUG|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
214584019|NCT02619487|OTHER|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
214584020|NCT02619487|OTHER|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
214584021|NCT05337358|PROCEDURE|endocrown|endocrown
214584022|NCT04059419|BEHAVIORAL|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
214584023|NCT04059419|BEHAVIORAL|Geriatric Care|Remain under geriatric care as usual
214584024|NCT05248074|OTHER|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
214584025|NCT05248074|DRUG|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
214584026|NCT03619070|OTHER|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
214584027|NCT03619070|OTHER|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
214584028|NCT03619070|OTHER|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
214584029|NCT03619070|OTHER|Control group, CG|The CG groups do not will performed the exercise.
214584030|NCT05729178|OTHER|observational study|analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
214584031|NCT01878214|BEHAVIORAL|Targeted messaging|6 targeted mailed messages and 6 booster text messages
214584032|NCT01878214|BEHAVIORAL|Standard messaging|1 informational letter
214584033|NCT04684251|PROCEDURE|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
214584034|NCT04962243|PROCEDURE|Repair surgery for Achilles tendon rupture|Repair surgery for Achilles tendon rupture
214710423|NCT06042478|DRUG|Placebo to remibrutinib|Placebo followed by active treatment
214710424|NCT06042478|DRUG|Placebo to omalizumab|Placebo followed by active comparator
214710425|NCT06042478|DRUG|Omalizumab|Active comparator
214584035|NCT00946101|BIOLOGICAL|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
214584036|NCT00946101|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
214584037|NCT03568331|DRUG|Tradipitant|Oral Capsule
214584038|NCT03568331|DRUG|Placebo|Oral Capsule
214584039|NCT04224571|DRUG|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
214584040|NCT04224571|DRUG|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
214584041|NCT01553305|OTHER|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
214584042|NCT01553305|OTHER|Exercise programme|Supervised exercise programme
214584043|NCT00819520|DRUG|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
214584044|NCT00819520|DRUG|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
214584045|NCT00079989|DRUG|tigecycline|
214584046|NCT02179099|DEVICE|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
214584047|NCT02236104|DEVICE|Plethysmography opto electronic|
214584048|NCT02236104|PROCEDURE|respiratory parameters|
214584049|NCT01562509|OTHER|Implementation tools|"* Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings."
214584050|NCT01562509|OTHER|Standard intervention|Standard intervention consists of audit\&feedback
214584051|NCT02318992|BIOLOGICAL|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
214584052|NCT00994500|DRUG|vorinostat|Given orally
214584053|NCT00994500|DRUG|bortezomib|Given IV
214584054|NCT00994500|OTHER|pharmacological study|Correlative studies
214584055|NCT00994500|OTHER|laboratory biomarker analysis|Correlative studies
214584056|NCT02196454|OTHER|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
214584057|NCT02052089|PROCEDURE|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
214584058|NCT02052089|PROCEDURE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (\<0.2 mJ/mm2) or high energy (\>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
214584059|NCT02052089|PROCEDURE|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
214584060|NCT02052089|PROCEDURE|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
214584061|NCT04687449|DIETARY_SUPPLEMENT|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
214584062|NCT04687449|OTHER|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
214584063|NCT04687449|OTHER|Standard care|The standard of care for COPD.
214584064|NCT01966393|OTHER|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
214584065|NCT01925287|DIETARY_SUPPLEMENT|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
214634323|NCT01495494|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
214584066|NCT00850785|BIOLOGICAL|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
214584067|NCT01928251|BEHAVIORAL|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
214584068|NCT01928251|BEHAVIORAL|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
214584069|NCT02358759|PROCEDURE|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
214584070|NCT01331486|DIETARY_SUPPLEMENT|Hawthorn|Hawthorn standardized extract liquid capsule
214584071|NCT01331486|DIETARY_SUPPLEMENT|Placebo capsule|Matched placebo liquid capsule
214584072|NCT04490382|DEVICE|32 channel external stimulator|Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
214584073|NCT05370001|OTHER|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
214584074|NCT04242953|DRUG|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
214584075|NCT04242953|DRUG|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
214584076|NCT03391401|PROCEDURE|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
214584077|NCT01944371|DRUG|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
214584078|NCT05490719|DRUG|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
214584079|NCT02611791|DEVICE|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
214584080|NCT02611791|DEVICE|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
214584081|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
214584082|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
214584083|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
214584084|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
214584085|NCT00552240|DRUG|Nevirapine 200 mg BID|200 mg BID
214584086|NCT00552240|DRUG|Atazanavir 300 mg|300 mg QD
214584087|NCT00552240|DRUG|Ritonavir 100 mg|100 mg QD
214584088|NCT04413773|OTHER|Treatment as usual + Video|Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
214584089|NCT04413773|OTHER|Treatment as usual|Explanation of standard procedures before, during and after surgery by nurse
214584090|NCT01453803|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
214584091|NCT00681460|DRUG|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
214584092|NCT00681460|DRUG|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
214584093|NCT06020742|PROCEDURE|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
214584094|NCT02784951|DRUG|Red blood cells (0Rh D-neg)|Fresh produced RBC
214584095|NCT02784951|DRUG|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
214584096|NCT02784951|DRUG|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
214584097|NCT02783768|DEVICE|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
214584098|NCT02783768|OTHER|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
214584099|NCT02783768|DRUG|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
214584100|NCT02783768|DRUG|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
214584101|NCT01934361|DRUG|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
214584102|NCT01934361|DRUG|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
214584103|NCT01934361|DRUG|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
214584104|NCT01934361|DRUG|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
214584105|NCT02938533|BEHAVIORAL|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
214584106|NCT01323647|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration
214584107|NCT01323647|BIOLOGICAL|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
214584108|NCT03486847|PROCEDURE|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
214584109|NCT03486847|PROCEDURE|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
214584110|NCT06227143|PROCEDURE|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
214584111|NCT04847076|BEHAVIORAL|m-health version of WWWT intervention|m-health version of Chilean adaptation of WWWT intervention: a) Psychoeducational information for understanding and managing infant behavior and on parenting. b) Contact with the program facilitator. c) A virtual group meeting
214584112|NCT04847076|OTHER|Treatment as usual|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age
214584113|NCT02262624|DRUG|Telmisartan|
214584114|NCT02262624|DRUG|Hydrochlorthiazide (HCTZ)|
214584115|NCT02262624|DRUG|Telmisartan/HCTZ fixed combination|
214584116|NCT04206033|OTHER|Observational study|Observational study
214584117|NCT00238147|DRUG|capecitabine|
214584118|NCT00238147|DRUG|carboplatin|
214584119|NCT00238147|DRUG|docetaxel|
214584120|NCT00238147|PROCEDURE|conventional surgery|
214584121|NCT00238147|PROCEDURE|neoadjuvant therapy|
214584122|NCT00238147|RADIATION|radiation therapy|
214584123|NCT05784220|BEHAVIORAL|DPP Curriculum for Lifestyle Intervention|See arms.
214584124|NCT05358106|BIOLOGICAL|AntiBKV|AntiBKV neutralising antibody
214584125|NCT05358106|BIOLOGICAL|Placebo|Solution with no active ingredients
214584126|NCT04589949|BIOLOGICAL|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
214584127|NCT04589949|BIOLOGICAL|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
214584128|NCT03293693|OTHER|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
214584129|NCT03293693|OTHER|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
214584130|NCT03293693|OTHER|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
214584131|NCT05319782|OTHER|Urethral stenosis assesment|Auto-questionnaires + Clinical examination + Flow metry and post-mictional residue
214584132|NCT03270397|BEHAVIORAL|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
214584133|NCT01927029|DRUG|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
214584134|NCT01927029|DRUG|Placebo|
214584135|NCT06124781|PROCEDURE|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
214584136|NCT06124781|PROCEDURE|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
214584137|NCT06124781|PROCEDURE|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
214584138|NCT05097222|DEVICE|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
214584139|NCT05097222|DEVICE|Sham device|Control
214584140|NCT00732225|DEVICE|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
214584141|NCT00732225|DEVICE|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
214584142|NCT00732225|DEVICE|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
214584143|NCT00732225|DEVICE|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
214584144|NCT00732225|DEVICE|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
214584145|NCT01704768|BEHAVIORAL|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
214584146|NCT01704768|BEHAVIORAL|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
214584147|NCT00440258|DRUG|Cabergoline|
214584148|NCT00440258|PROCEDURE|MR|
214584149|NCT00440258|PROCEDURE|Ultrasound|
214584150|NCT00440258|PROCEDURE|Blood Analysis|
214584151|NCT00250926|DRUG|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
214584152|NCT00250926|DRUG|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
214584153|NCT00250926|DRUG|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
214584154|NCT04101604|OTHER|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
214584155|NCT04698941|DRUG|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.
214584156|NCT04698941|DRUG|Simvastatin|20mg daily oral tablet taken.
214584157|NCT00676819|DRUG|insulin aspart|
214584158|NCT00676819|DRUG|human insulin|
214584159|NCT02319525|OTHER|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
214584160|NCT02319525|OTHER|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
214584161|NCT03005964|DRUG|AM001 Cream, 7.5%|Active Cream
214584162|NCT03005964|DRUG|Vehicle Cream|Placebo
214584163|NCT04890925|BEHAVIORAL|Community Support Network (CSN) intervention|The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.
214584164|NCT04890925|BEHAVIORAL|Usual care|Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
214584165|NCT04551625|DEVICE|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
214584166|NCT03075007|RADIATION|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
214584167|NCT03075007|PROCEDURE|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
214584168|NCT04246320|OTHER|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
214584169|NCT01517646|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214584170|NCT00824811|DRUG|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
214584171|NCT00824811|DRUG|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
214584172|NCT00824811|DRUG|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
214584173|NCT00938860|DRUG|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
214584174|NCT00938860|DRUG|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
214584175|NCT02222051|BEHAVIORAL|Tai Chi|traditional chinese martial art meditative movement technique
214584176|NCT02222051|BEHAVIORAL|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
214584177|NCT03035266|OTHER|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
214584178|NCT03035266|OTHER|Standard rehabilitation|Standard of care for post-operative condition
214584179|NCT02982733|OTHER|ABS|Ankaferd Blood Stopper
214584180|NCT02982733|DEVICE|TR Band|Transradial band
214584181|NCT02982733|OTHER|CS|Sterile Gauze
214584182|NCT00482950|DRUG|PHX1149T|
214584183|NCT06081023|BEHAVIORAL|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
214584184|NCT06529510|BEHAVIORAL|REThink therpeutic game|REThink is an online therapeutic game aimed at enhancing the emotional health of young people, grounded in Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who guides players through seven levels, each focused on teaching a specific emotional regulation skill. Each level has three sub-levels that progressively increase in difficulty. REThink can be used as a standalone intervention, an adjunct to self-help psychotherapeutic approaches, or for targeted skills training.
214584185|NCT05912582|RADIATION|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
214584186|NCT03913780|OTHER|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
214584187|NCT00232544|DEVICE|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
214584188|NCT00232544|OTHER|TLC-Control|A TLC system for providing general health education
214584189|NCT00672191|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
214584190|NCT00336895|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
214634324|NCT01495494|DEVICE|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
214634325|NCT04120155|PROCEDURE|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
214634326|NCT04120155|PROCEDURE|Preservation of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
214634327|NCT01859377|DRUG|V0498 - A mg|Single oromucosal administration
214634328|NCT01859377|DRUG|Ibuprofen|Single oral administration
214634329|NCT01228123|OTHER|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
214634330|NCT01228123|OTHER|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
214634331|NCT02754726|DRUG|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
214584191|NCT01239485|DRUG|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, \& 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~\*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
214584192|NCT03945682|OTHER|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
214584193|NCT03871023|DEVICE|Smith & Nephew PICO Negative wound pressure versus standard dresing|To investigate if negative wound pressure improves wound outcome
214584194|NCT03871023|DEVICE|PREVENA Negative pressure wound versus standard dressing|To investigate if negative wound pressure improves wound outcome
214584195|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
214584196|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
214584197|NCT01081054|OTHER|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
214584198|NCT05040984|DRUG|Solifenacin Oral Tablet|Solifenacin 1 tablet per day
214584199|NCT05040984|DRUG|Mirabegron 25mg|Mirabegron 1 tablet per day
214584200|NCT03426605|DRUG|Open Label LAM-003|LAM-003
214584201|NCT00329511|DRUG|methyldopa vs. clonidine|Comparison of compliance
214584202|NCT00329511|DRUG|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
214634332|NCT02754726|DRUG|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
214634333|NCT02754726|DRUG|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
214634334|NCT02754726|DRUG|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
214634335|NCT02754726|DRUG|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
214634336|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
214584203|NCT02865980|OTHER|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
214584204|NCT02865980|OTHER|Betadine|in control group, will be washed the Catheter with Betadine
214584205|NCT05332431|DEVICE|Optical coherence tomography (OCT)|"Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT."
214584206|NCT02754986|OTHER|Analysis of the holter electrocardiogram|
214584207|NCT02666846|DRUG|Ibuprofen|
214584208|NCT02666846|DRUG|Diclofenac|
214584209|NCT02666846|DRUG|Methyl-salicylate / Menthol|
214584210|NCT02666846|DRUG|Placebo|
214584211|NCT05529147|DRUG|Antihypertensive Agents|Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
214584212|NCT04565379|DRUG|NuSepin® 0.1 mg|NuSepin® 0.1 mg
214584213|NCT04565379|DRUG|NuSepin® 0.2 mg|NuSepin® 0.2 mg
214584214|NCT04565379|DRUG|Placebo|Normal Saline
214584215|NCT02791074|OTHER|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
214584216|NCT02791074|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
214584217|NCT02791074|OTHER|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
214584218|NCT00038974|DRUG|peginterferon alfa-2a|
214584219|NCT00038974|DRUG|Ribavirin|
214584220|NCT04212273|DIAGNOSTIC_TEST|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
214584221|NCT03019731|BEHAVIORAL|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
214584222|NCT03019731|BEHAVIORAL|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
214584223|NCT06385431|OTHER|observational study|obeservational study with none intervention
214584224|NCT02914977|DRUG|Daunorubicin|"* Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle"
214584225|NCT01535560|DRUG|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
214584226|NCT01535560|DRUG|AL-60371 Vehicle|Inactive ingredients used as placebo
214584227|NCT02009761|DRUG|BI 655064|subcutaneous injection
214584228|NCT00678184|DRUG|Atorvastatin|80 mg atorvastatin on two following days each
214584229|NCT05361525|PROCEDURE|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
214584230|NCT05361525|PROCEDURE|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
214584231|NCT05983224|DIETARY_SUPPLEMENT|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
214584232|NCT05983224|OTHER|Placebo|The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
214584233|NCT02878902|OTHER|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
214584234|NCT04270201|OTHER|Saliva collection|Saliva collection
214584235|NCT03334136|DRUG|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
214584236|NCT03334136|DRUG|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
214584237|NCT02673073|OTHER|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
214584238|NCT02673073|OTHER|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
214584239|NCT06276907|BIOLOGICAL|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
214584240|NCT06276907|OTHER|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
214584241|NCT01853774|BEHAVIORAL|Tailored navigation|
214584242|NCT02740374|DEVICE|ROTEM|ROTEM coagulation assessment and guided transfusion management.
214584243|NCT02740374|OTHER|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
214584244|NCT02901782|PROCEDURE|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
214584245|NCT04555382|DIAGNOSTIC_TEST|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
214584246|NCT04803331|DIAGNOSTIC_TEST|SPIO-enhanced MRI|SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
214584247|NCT04771949|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
214584248|NCT04771949|OTHER|Questionnaires|"After the periodontal chart, patients will be administered the italian version of 4 questionnaires regarding:~1. Adherence to Mediterranean Diet (Gnagnarella et al. 2018);~2. International Physical Activity Questionnaire (IPAQ) (Mannocci et al. 2010);~3. Pittsburgh Sleep Quality Index (PSQI) (Curcio et al. 2013);~4. Italian Perceived Stress Scale (Fossati, 2010)."
214584249|NCT06255327|OTHER|I COUGH care program|"The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees."
214584250|NCT02822586|RADIATION|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
214584251|NCT02822586|DRUG|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
214584252|NCT02628496|DRUG|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
214584253|NCT02628496|DEVICE|Confocal laser microlaryngoscopy|
214584254|NCT02628496|PROCEDURE|Biopsy (standard of care)|
214584255|NCT02628496|PROCEDURE|KTP laser photoablation (standard of care)|
214584256|NCT05830045|DRUG|QLP2117|Specified dose on specified days
214584257|NCT03241303|DRUG|Acarbose|Glucobay tablets on experimental day.
214584258|NCT03241303|DRUG|Placebo Oral Tablet|Placebo tablets on experimental day.
214584259|NCT03241303|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
214584260|NCT03241303|DRUG|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
214584261|NCT05636605|DIAGNOSTIC_TEST|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
214584262|NCT03386110|BEHAVIORAL|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
214584263|NCT03386110|BEHAVIORAL|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
214584264|NCT03915704|DEVICE|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
214584265|NCT03915704|PROCEDURE|Control|No intervention was made in the children.
214584266|NCT03915704|DEVICE|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
214584267|NCT00537693|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
214584268|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
214584269|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
214584270|NCT03770533|OTHER|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
214584271|NCT00006260|DRUG|cisplatin|cisplatin IV over 30 minutes on days 1-3.
214584272|NCT00006260|DRUG|etoposide|etoposide IV over 60-90 minutes on days 1-3.
214584273|NCT00006260|DRUG|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
214584274|NCT00006260|DRUG|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
214584275|NCT02309255|OTHER|no intervention|
214584276|NCT02697292|DRUG|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
214584277|NCT02697292|DRUG|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.
214584278|NCT02697292|DRUG|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
214584279|NCT04987086|DIAGNOSTIC_TEST|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
214584280|NCT03946150|DIAGNOSTIC_TEST|P/FP Ratio|PaO2/Fio2 X PEEP
214584281|NCT04555031|DEVICE|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
214584282|NCT04555031|DEVICE|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
214584283|NCT04555031|DEVICE|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
214584284|NCT04555031|DEVICE|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
214584285|NCT02418221|DIETARY_SUPPLEMENT|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
214584286|NCT02418221|PROCEDURE|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure \& pulse
214584287|NCT05169138|OTHER|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
214584288|NCT05169138|OTHER|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
214584289|NCT01063660|DRUG|Treosulfan|14 g/m²/d day -6 to -4
214584290|NCT04828200|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|The ultrasonographic assesment will be used to examine the rectus femoris, gastrocnemius medailalis and rectus abdominis subcutaneous and muscle thickness. Additionally, fascicle length and pennation angle were measured between the two parallel aponeuroses of the gastrocnemius muscle (bulkiest part of medial head) in the longitudinal view when subjects were in prone position with their ankles at 90°.
214584291|NCT04828200|DIAGNOSTIC_TEST|Dual-X-ray absorptiometry|The muscle masses of the patients were evaluated by measuring the fat mass (Fat Mass-FM), fat mass index (FMI), lean body mass (LBM) and skeletal muscle index (SMI) calculated by DEXA. Appendicular muscle mass (ASM) is calculated by summing the lean soft tissue of the two upper limbs and the two lower limbs. Skeletal muscle mass index is calculated by dividing the appendicular lean mass by the square of the neck height \[SMI = ASM / height2 (kg / m2)\].
214584292|NCT04828200|DIAGNOSTIC_TEST|Isokinetic dynamometer|Quadriceps-hamstring Peak Torque (PT) values and the ratio of PT values to body weight (PT / VA) (at 60 and 180 ° / sec speeds) were evaluated with an isokinetic dynamometer
214584293|NCT00645307|DRUG|Extended Release OROS® Paliperidone|
214584294|NCT00729872|BIOLOGICAL|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
214584295|NCT00729872|OTHER|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
214584296|NCT00407277|DRUG|Nicotine patch|21 mg of nicotine via a dermal patch
214584297|NCT00407277|OTHER|placebo|placebo via a dermal patch
214584298|NCT00407277|BEHAVIORAL|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
214584299|NCT02639598|DRUG|Flunarizine|"as in arm descriptions"
214584300|NCT02639598|DRUG|Topiramate|"as in arm descriptions"
214584301|NCT04612374|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
214584302|NCT04612374|BEHAVIORAL|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
214584303|NCT01398722|OTHER|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
214584304|NCT01398722|OTHER|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
214584305|NCT01235104|PROCEDURE|Total nephrectomy|Total nephrectomy
214584306|NCT01047293|DRUG|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
214584307|NCT01047293|DRUG|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
214584308|NCT01047293|DRUG|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
214584309|NCT00491829|DRUG|50 mg qhs|flibanserin 50 mg
214584310|NCT00491829|DRUG|100 mg|flibanserin 100mg
214584311|NCT00491829|DRUG|placebo|placebo
214584312|NCT02528383|BEHAVIORAL|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life"
214584313|NCT03300115|DRUG|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
214584314|NCT01272804|DRUG|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
214584315|NCT01272804|DRUG|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
214584316|NCT02881580|OTHER|No intervention : descriptive study|
214710426|NCT06264349|OTHER|Lifestyle Educational Intervention|The Lifestyle Educational Intervention (LEI) consists of promoting a healthy lifestyle during pregnancy and breastfeeding. In particular, the contents concern: i). macro- and micronutrient requirements during pregnancy/breastfeeding; ii). definition of the concept of the food pyramid and healthy plate also considering aspects of food sustainability; iii). definition of the principles of food safety during pregnancy; iv). importance of maternal and infant sleep quality; v). importance of maternal physical activity during pregnancy and lactation; vi). psychological aspects regarding the mother-child dyad.
214710427|NCT05678842|OTHER|Descriptive|Descriptive
214584317|NCT02318797|BEHAVIORAL|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
214584318|NCT02318797|BEHAVIORAL|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
214710428|NCT05646654|PROCEDURE|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
214584319|NCT05236478|OTHER|CoviMouv' program|"* An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
214584320|NCT05236478|OTHER|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
214584321|NCT03172182|BEHAVIORAL|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
214584322|NCT05077657|DEVICE|Early Bird® Bleed Monitoring System|The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
214584323|NCT05077657|DEVICE|Impella®|Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
214584324|NCT02990312|DRUG|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
214584325|NCT00001984|DRUG|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
214634337|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
214634338|NCT01885000|DRUG|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
214634339|NCT01885000|DRUG|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
214634340|NCT00497211|PROCEDURE|Intracoronary mononuclear cell infusion|
214584326|NCT06294132|PROCEDURE|Lumbar Manipulation|"The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed to the level to be manipulated, and the left foot is placed behind the right lower leg. The caregiver introduces rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver then rolls the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. If a cavitation pop is not heard the first time, a second attempt is made. The procedure is repeated on the opposite side."
214584327|NCT06294132|PROCEDURE|Sham Lumbar Manipulation|The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed SLIGHTLY, and the left foot is placed behind the right lower leg. The caregiver DOES NOT introduce rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver DOES NOT roll the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. NO ROTATION OCCURS IN THE SPINE. The procedure is repeated on the opposite side.
214584328|NCT03809741|OTHER|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
214584329|NCT03356457|DRUG|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
214584330|NCT03356457|DRUG|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
214584331|NCT01906554|OTHER|Egg Dose|Different quantities of eggs
214584332|NCT01987141|OTHER|EMR Intervention|Electronic medical record flag/notification in the patient's chart
214584333|NCT04217122|OTHER|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
214584334|NCT04217122|OTHER|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
214584335|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
214584336|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
214584337|NCT05488223|DIETARY_SUPPLEMENT|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
214584338|NCT02270138|BEHAVIORAL|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
214584339|NCT02949466|DRUG|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
214584340|NCT02949466|DEVICE|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
214584341|NCT04720872|OTHER|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
214584342|NCT01148147|DRUG|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
214584343|NCT01148147|DRUG|Placebo|Intracoronary Placebo administration
214584344|NCT05023681|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
214584345|NCT05023681|DRUG|normal saline|Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
214584346|NCT04466995|DEVICE|manometer|cuff pressure to be measured with manometer
214584347|NCT02112708|OTHER|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
214584348|NCT02112708|OTHER|Control Group usual care|In the control group the dysthymia is treated as usual with the conventional treatment.
214634341|NCT06092281|BEHAVIORAL|Questionnaire|"Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information:~1. General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)~2. Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.)~3. Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)"
214584349|NCT05563285|BEHAVIORAL|Exercise and Mindfulness-Based Intervention|"1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2\. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running"
214584350|NCT05563285|BEHAVIORAL|Control Group|The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
214584351|NCT02673515|BEHAVIORAL|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
214584352|NCT02695303|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214584353|NCT04310280|DRUG|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
214584354|NCT04310280|DRUG|Saline|Half of the wound surface is injected daily with topical saline solution
214584355|NCT01364103|OTHER|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
214584356|NCT02965677|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
214584357|NCT02965677|DEVICE|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
214584358|NCT01796548|DRUG|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
214584359|NCT02608957|DEVICE|Latella Knee Implant System|
214584360|NCT02174666|DIETARY_SUPPLEMENT|Red clover extract|Aglycone isoflavones 80mg/d
214584361|NCT02174666|DIETARY_SUPPLEMENT|Supplementation (placebo)|
214584362|NCT01193426|OTHER|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
214584363|NCT02547259|PROCEDURE|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
214584364|NCT02547259|PROCEDURE|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
214584365|NCT01614535|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
214584366|NCT03217682|OTHER|Music Therapy|Music therapy sessions
214584367|NCT03217682|OTHER|Massage Therapy|Massage therapy sessions
214584368|NCT03861208|OTHER|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
214584369|NCT03861208|OTHER|usual diet|foods representing the usually provided foods at childcare are offered
214584370|NCT01540331|DEVICE|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
214584371|NCT03450226|DRUG|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
214584372|NCT02377141|PROCEDURE|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
214584373|NCT02377141|PROCEDURE|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
214584374|NCT02807103|DRUG|Rituximab|1 g intravenous pulse at day1 and day15
214584375|NCT02807103|DRUG|Placebo-rituximab|intravenous pulses at day1 and day15
214584376|NCT02807103|DRUG|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
214584377|NCT02807103|DRUG|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
214584378|NCT03801473|OTHER|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
214584379|NCT03801473|OTHER|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
214584380|NCT04328454|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
214584381|NCT04377750|DRUG|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
214584382|NCT02743026|BEHAVIORAL|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
214584383|NCT05357118|BEHAVIORAL|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
214584384|NCT05334251|OTHER|combined spinal-epidural anesthesia|Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
214584385|NCT03218540|PROCEDURE|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV \> 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg
214584386|NCT02097940|OTHER|proprioceptive exercises|Exercises with movements, jumping and imbalance.
214584387|NCT01134952|DRUG|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
214584388|NCT03888053|BIOLOGICAL|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
214584389|NCT01389505|PROCEDURE|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
214584390|NCT01389505|PROCEDURE|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
214584391|NCT05614986|OTHER|5 minute Montreal Cognitive Assessment (mini MoCA)|The mini MoCA will be completed by the patient before TAVR, and 30 days and 6 months after TAVR
214584392|NCT00063752|DRUG|PI-0824|
214584393|NCT04452760|OTHER|Physical exercise|Physical exercise intervention
214584394|NCT04452760|OTHER|Testing sessions|Testing sessions
214584395|NCT00350233|DEVICE|ExAblate 2000|
214584396|NCT04635475|BEHAVIORAL|RISE Bundle|Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
214584397|NCT04227704|DRUG|Ketamine 50 MG/ML|Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
214584398|NCT04227704|DRUG|Control|Administration of 0.9% Sodium Chloride (N/S)
214634342|NCT06092281|BEHAVIORAL|Questionnaire without compliance-related education|Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)
214634343|NCT03124784|DEVICE|RD Disposable Sensors|Noninvasive pulse oximeter sensor
214634344|NCT00837109|BEHAVIORAL|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
214584399|NCT04092361|DEVICE|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
214584400|NCT02760277|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
214584401|NCT02760277|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
214584402|NCT02760277|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
214584403|NCT02760277|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
214584404|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|"The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
214584405|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle|"The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
214584406|NCT02892084|DEVICE|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
214584407|NCT02892084|DEVICE|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
214584408|NCT01300962|DRUG|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
214584409|NCT01300962|DRUG|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
214584410|NCT01300962|DRUG|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
214584411|NCT01300962|DRUG|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
214584412|NCT01300962|DRUG|Lapatinib|lapatinib daily for 21 days in each cycle.
214584413|NCT01324596|DRUG|Intravenous|Chemoimmunotheraphy
214584414|NCT01324596|DRUG|Bortezomib|Chemoimmunotheraphy
214584415|NCT02390050|DRUG|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
214584416|NCT02390050|DRUG|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
214584417|NCT01522469|DRUG|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
214584418|NCT04831073|PROCEDURE|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
214584419|NCT05860634|PROCEDURE|Catheter self-discontinuation|Self-discontinuation of a transurethral catheter
214584420|NCT03432260|DRUG|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
214584421|NCT03432260|DRUG|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
214584422|NCT03432260|DRUG|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
214584423|NCT06487845|DRUG|BAY3283142|IR tablets, oral
214584424|NCT06487845|DRUG|Placebo|Placebo matched to BAY3283142
214584425|NCT04763421|DEVICE|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
214584426|NCT05910944|PROCEDURE|Shunt surgery|Shunt surgery according to each local centers routine
214584427|NCT00165373|DRUG|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
214584428|NCT01775124|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
214584429|NCT03237546|PROCEDURE|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
214584430|NCT03237546|PROCEDURE|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
214584431|NCT06606301|DIAGNOSTIC_TEST|BioSB EGFR antibody|Appropriate sections from the tumor will be selected basing the choice on tumor content and viability eventually followed by EGFR application which will reveal a brown membrane positivity for the tumor. Total score for RGFR will be calculated by the histopathologists.
214584432|NCT05287711|BEHAVIORAL|Motivational Enhancement Therapy|In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.
214584433|NCT05287711|BEHAVIORAL|Alcohol Education Control|Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
214584434|NCT05287711|BEHAVIORAL|Treatment as Usual|Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.
214634345|NCT00837109|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
214634346|NCT02969798|DRUG|Dapagliflozin|10mg/day
214634347|NCT02969798|DRUG|Saxagliptin|5mg/day
214584435|NCT05287711|BEHAVIORAL|Strength at Home|IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
214584436|NCT06609525|DRUG|CTO0303-A|eye drop, 1 drop 3 times (every 5 minutes) a day
214584437|NCT06609525|DRUG|CTO0303-B|eye drop, 1 drop 3 times (every 5 minutes) a day
214584438|NCT06609525|DRUG|CTO0303-C|eye drop, 1 drop 3 times (every 5 minutes) a day
214584439|NCT06610500|OTHER|Questionnaires|Questionnaires investigating the prescription and dispensing of clozapine.
214584440|NCT06610513|BEHAVIORAL|Guided imagery|"First meeting: The women will be introduced to the clinic, the purpose of the study will be explained, and a written consent form will be filled out. A Personal Information Form and the Pregnancy Stress Assessment Scale (GSDS-36) and the Richard-Campbell Sleep Scale will be filled out. After the questionnaires are filled out, the vital signs of the pregnant woman will be measured and then a 15-minute guided imagery video will be shown. The vital signs of the patient will be measured again 10 minutes after the guided imagery video is watched."
214584441|NCT01064661|DIETARY_SUPPLEMENT|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10\^10 cfu total bacteria per day)
214584442|NCT01064661|DIETARY_SUPPLEMENT|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10\^10 cfu total bacteria per day)
214584443|NCT02533141|DEVICE|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
214584444|NCT02533141|DEVICE|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
214584445|NCT02533141|DRUG|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
214584446|NCT02533141|OTHER|Placebo|Placebo, once daily for 4 weeks
214584451|NCT06728839|DRUG|1L PEG + 50g magnesium sulfate|Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.
214584452|NCT06728839|DRUG|3L PEG|Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
214584453|NCT06728839|DRUG|4L PEG|Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
214584454|NCT01877473|PROCEDURE|Ablation|
214584455|NCT06729788|DRUG|ICON resin infiltration Material group in vivo|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK).
214584456|NCT06729788|DRUG|Resin-based fissure sealant group in vivo|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)
214584457|NCT06729788|DRUG|ICON resin infiltration in vitro|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK) in vitro
214584458|NCT06729788|DRUG|Resin-based fissure sealant in vitro|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael) in vitro
214634348|NCT02969798|DRUG|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
214584459|NCT01586637|OTHER|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
214584460|NCT01586637|OTHER|Walking|The group walked twice a week during one hour.
214584461|NCT06906432|DIAGNOSTIC_TEST|Multi-disciplinary assessment|Multi-disciplinary assessment including blood tests, CSF test, electrocardiograms, ultrasound, imaging, etc
214584462|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
214584463|NCT06905938|OTHER|no intervention|no intervention
214584464|NCT03520946|DRUG|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
214584465|NCT03520946|DRUG|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
214584466|NCT03887390|BEHAVIORAL|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
214584467|NCT02943811|DEVICE|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
214584468|NCT06116864|DEVICE|Endocuff and GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
214584469|NCT06116864|DEVICE|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
214584470|NCT03218748|BEHAVIORAL|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
214584471|NCT05598073|BEHAVIORAL|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
214584472|NCT05267340|BEHAVIORAL|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
214584473|NCT05267340|BEHAVIORAL|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
214584474|NCT05053607|BEHAVIORAL|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
214584475|NCT05053607|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
214584476|NCT01170611|DEVICE|PACEMAKER SYMPHONY 2550|
214584477|NCT06905951|OTHER|Exercise|Mouth, tongue, and throat exercise to strengthen the airway, reducing its collapsibility.
214584478|NCT05256446|DRUG|AMG 701|
214584479|NCT05623176|OTHER|Standardised laparotomy care|This is a cohort study and no intervention as part of the study has been introduced. We are studying two groups and comparing the two before and after the introduction of a standardised laparotomy care protocol as part of a clinical quality improvement measure.
214584480|NCT05746208|DRUG|Lenvatinib|Given orally
214584481|NCT05746208|DRUG|Pembrolizumab|Given IV
214584482|NCT05746208|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
214584483|NCT06544512|OTHER|progressive relaxation exercise|looking at pain and anxiety by practicing progressive relaxation exercises
214584484|NCT01589237|DRUG|LCQ908|
214584485|NCT03437343|PROCEDURE|Hip arthroplasty|
214584486|NCT02594163|DRUG|Brentuximab Vedotin|
214584487|NCT02594163|DRUG|Rituximab|
214584488|NCT02594163|DRUG|Bendamustine|
214584489|NCT03732313|PROCEDURE|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
214584490|NCT03732313|PROCEDURE|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
214584491|NCT02794168|DRUG|VAS203|Treatment
214584492|NCT02794168|DRUG|Saline|Placebo
214584493|NCT00448409|BIOLOGICAL|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
214584494|NCT00448409|DRUG|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
214584495|NCT04497142|DRUG|Perampanel|Tablet taken orally 1x daily.
214584496|NCT04497142|DRUG|Standard of Care|Predetermined standard of care drug and dosing
214584497|NCT03339700|DRUG|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
214584498|NCT03339700|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
214584499|NCT03339700|DRUG|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
214584500|NCT03339700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
214584501|NCT03715582|DRUG|trimetazidine|Pills of masking drug - trimetazidine
214584502|NCT03715582|DRUG|Placebo Oral Tablet|Pills of masking drug - placebo
214584503|NCT05555407|DIAGNOSTIC_TEST|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
214584504|NCT05555407|DEVICE|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
214584505|NCT04364243|OTHER|Digitally supported home exercises|The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
214584506|NCT04025346|OTHER|Capsimax|1 capsule to be taken before breakfast.
214584507|NCT04025346|OTHER|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
214584508|NCT03849950|OTHER|SMARTCare|"1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~2. An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~3. An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~4. Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
214584509|NCT03849950|OTHER|Control|1\. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
214584510|NCT04271631|OTHER|Mobile Application-Based Diabetes Education|Additional education was given using application, subjects were asked to open the application at least once a day
214584511|NCT04271631|OTHER|Health Coaching|Health coaching was given as face to face with a coach
214584512|NCT02176213|DRUG|Pomalidomide|4 mg PO x 21 days
214584513|NCT02176213|DRUG|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
214584514|NCT02176213|DRUG|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
214584515|NCT00189488|DRUG|Palifermin|Administered as an intravenous (IV) bolus.
214584516|NCT00189488|DRUG|Placebo|Administered as an intravenous (IV) bolus.
214584517|NCT00189488|OTHER|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])"
214584518|NCT00189488|PROCEDURE|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
214584519|NCT00189488|DRUG|Methotrexate|
214584520|NCT02145234|DRUG|BMS-986089|
214584521|NCT02145234|DRUG|Placebo matching with BMS-986089|
214584522|NCT00006373|DRUG|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
214584523|NCT00006373|DRUG|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
214584524|NCT00006373|DRUG|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
214584525|NCT00006373|PROCEDURE|autologous bone marrow transplantation|
214584526|NCT00006373|DRUG|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
214584527|NCT05696431|OTHER|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
214584528|NCT05696431|OTHER|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
214584529|NCT05696431|OTHER|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
214584530|NCT04758689|COMBINATION_PRODUCT|Laser, exercise, and methotrexate|Laser therapy at acupuncture points, aerobic exercise, and methotrexate
214584531|NCT04758689|COMBINATION_PRODUCT|Exercise, and methotrexate|Aerobic exercise, and methotrexate
214634349|NCT02969798|DRUG|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
214634350|NCT05143840|DRUG|Single Agent Asciminib|taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase. Asciminib is a potent allosteric inhibitor of BCR::ABL1.
214634351|NCT05143840|COMBINATION_PRODUCT|Low TKI|"Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion, may be added to asciminib in the following situations:~* Patients who have treatment failure at any time based on ELN criteria (Appendix 7)~* Patients who have a warning response after 12 months of single agent asciminib based on ELN criteria (Appendix 7)~* Patients who have not achieved MR4.5 after 24 months, but no later than 36 months, of single agent asciminib."
214584532|NCT04326517|PROCEDURE|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
214584533|NCT01893294|DRUG|gemcitabine hydrochloride|Given IT
214584534|NCT01893294|DRUG|fluorouracil|Given IV
214584535|NCT01893294|RADIATION|radiation therapy|Undergo radiation therapy
214584536|NCT01893294|OTHER|laboratory biomarker analysis|Correlative studies
214584537|NCT04330131|BEHAVIORAL|3Ts - Newborn|A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
214584538|NCT04330131|BEHAVIORAL|3Ts - Well Baby|Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
214584539|NCT04330131|BEHAVIORAL|3Ts - Let's Talk!|A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
214584540|NCT05402696|PROCEDURE|Endoscopic tissue resection|Endoscopic resection techniques for removal of large polyps
214584541|NCT02831387|DRUG|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
214584542|NCT02831387|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
214584543|NCT05617482|OTHER|General anesthesia|All patients undergoing ceaserian section under general anesthesia
214584544|NCT05617482|OTHER|Ilioinguinal, iliohypogastric nerve blocks|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
214584545|NCT05617482|OTHER|TAP block|In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.
214634352|NCT05143840|OTHER|Elective Free Treatment|Once central eligibility has been obtained the patient should discontinue asciminib and if applicable lowTKI within 14 days.
214584546|NCT05617482|OTHER|Quadratus lumborum block|For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
214584547|NCT04369716|OTHER|Whole oranges|Navel oranges (227 g total)
214584548|NCT04369716|OTHER|Whole Apples|Red Delicious apple with skin (230 g)
214584549|NCT04369716|OTHER|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
214584550|NCT04369716|OTHER|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
214584551|NCT04369716|OTHER|Orange juice|Orange Juice (250 g)
214584552|NCT04369716|OTHER|Apple juice|Apple Juice (235 g)
214584553|NCT01321385|OTHER|laboratory biomarker analysis|
214584554|NCT01321385|OTHER|study of socioeconomic and demographic variables|
214584555|NCT05641181|DRUG|CRB4101|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
214634353|NCT00875745|DRUG|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
214634354|NCT01514032|PROCEDURE|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
214584556|NCT05641181|DRUG|Placebo|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
214584557|NCT00053560|DRUG|Prasterone (GL701)|
214584558|NCT00192647|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
214584559|NCT00192647|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
214584560|NCT05446233|DRUG|[14C] Antaitavir Hasophate|100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
214584561|NCT00862147|BEHAVIORAL|ICDP|Parent training group
214584562|NCT00862147|BEHAVIORAL|Treatment as usual|Parent and/or child focused interventions
214584563|NCT01828073|DRUG|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
214584564|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
214584565|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
214584566|NCT00206661|DRUG|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
214584567|NCT00206661|DRUG|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
214584568|NCT00110110|BIOLOGICAL|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
214584569|NCT00110110|DRUG|Carboplatin|Given at 28 mg/kg/dose.
214584570|NCT00110110|DRUG|Cyclosporine|Given at 33 mg/kg/dose
214584571|NCT00110110|DRUG|Etoposide|Given at 12 mg/kg/dose
214584572|NCT00110110|DRUG|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
214584573|NCT00110110|PROCEDURE|cryosurgery|Local application of extreme cold to destroy residual tumor.
214584574|NCT00110110|PROCEDURE|laser therapy|Local and precise application of laser beams to destroy residual tumor.
214634355|NCT01514032|PROCEDURE|Retrograde intrarenal surgery|Retrograde intrarenal surgery
214634356|NCT00719927|BEHAVIORAL|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
214634357|NCT05243927|OTHER|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
214634358|NCT05243927|OTHER|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
214584575|NCT04970030|PROCEDURE|ML lithotripsy|we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
214584576|NCT04970030|PROCEDURE|EHL lithotripsy|after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
214584577|NCT00925431|BEHAVIORAL|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
214584578|NCT00925431|BEHAVIORAL|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
214584579|NCT00202293|DRUG|Olanzapine|
214584580|NCT00202293|DRUG|Lithium|
214584581|NCT00202293|DRUG|Chlorpromazine|
214584582|NCT02943291|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
214584583|NCT02943291|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
214584584|NCT02275000|OTHER|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
214584585|NCT02275000|OTHER|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
214584586|NCT04914299|BEHAVIORAL|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
214584587|NCT04914299|BEHAVIORAL|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
214584588|NCT00000241|DRUG|Flupenthixol|
214584589|NCT05157165|BIOLOGICAL|Convalescent plasma|Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
214634359|NCT01676714|DRUG|Dovitinib|
214584590|NCT05453123|BEHAVIORAL|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
214584591|NCT00286260|DRUG|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
214584592|NCT02110615|OTHER|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
214584593|NCT04200976|BEHAVIORAL|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
214584594|NCT04200976|BEHAVIORAL|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
214584595|NCT04552977|DRUG|fluzoparil|a PARP1 inhibitor
214584596|NCT04552977|DRUG|temozolomide|an alkylating chemotherapeutic agent
214584597|NCT00697333|PROCEDURE|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
214584598|NCT02423928|BIOLOGICAL|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
214584599|NCT02423928|DRUG|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
214584600|NCT02423928|DRUG|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
214584601|NCT04719884|PROCEDURE|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) \>10% and SI and CI \>10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of \>10% and the SVV still \>10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI \<10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
214584602|NCT03624348|BEHAVIORAL|meditation|10 minute per day, 8 week digital meditation
214584603|NCT01189084|BIOLOGICAL|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
214584604|NCT02789254|BIOLOGICAL|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA\* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~\* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
214584605|NCT02343874|OTHER|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
214584606|NCT00690443|DRUG|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
214584607|NCT00690443|DRUG|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
214584608|NCT05444153|DRUG|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
214584609|NCT05444153|DRUG|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
214584610|NCT00095732|DRUG|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
214584611|NCT00095732|DRUG|Placebo|Administered orally in either Size 2 or Size 5 capsules
214584612|NCT00316160|DRUG|Bupropion Hydrochloride Extended-release|
214584613|NCT00316160|DRUG|Extended-release Venlafaxine|
214584614|NCT04171453|DRUG|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
214584615|NCT02824666|DRUG|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
214584616|NCT02824666|RADIATION|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
214584617|NCT01877837|DRUG|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued \>48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
214584618|NCT01877837|DRUG|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
214584619|NCT01877837|DRUG|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
214584620|NCT01877837|PROCEDURE|Stem Cells|Infusion of Hematopoietic Stem Cells
214584621|NCT02726685|OTHER|respiratory training.|breathing exercise.
214584622|NCT02726685|OTHER|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
214584623|NCT05369273|OTHER|intra-articular injection|intra-articular injection
214584624|NCT05369273|RADIATION|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
214584625|NCT05369273|OTHER|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
214584626|NCT05369273|OTHER|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
214584627|NCT01135537|BIOLOGICAL|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
214584628|NCT00002521|DRUG|cisplatin|
214584629|NCT00002521|DRUG|cyclophosphamide|
214584630|NCT00002521|DRUG|etoposide|
214584631|NCT00002521|PROCEDURE|autologous bone marrow transplantation|
214584632|NCT00002521|PROCEDURE|bone marrow ablation with stem cell support|
214584633|NCT00002521|PROCEDURE|peripheral blood stem cell transplantation|
214584634|NCT00002521|PROCEDURE|syngeneic bone marrow transplantation|
214584635|NCT00002521|RADIATION|radiation therapy|
214584636|NCT06408974|DRUG|Ketamine|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition
214584637|NCT06408974|DRUG|dexamethasone|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
214584638|NCT02860780|DRUG|prexasertib|Administered IV
214584639|NCT02860780|DRUG|ralimetinib|Administered orally
214584640|NCT00716508|PROCEDURE|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
214584641|NCT00716508|PROCEDURE|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
214584642|NCT00645801|DRUG|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
214584643|NCT00645801|DRUG|Placebo|Amitiza Placebo
214584644|NCT01893931|BEHAVIORAL|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
214584645|NCT01893931|BEHAVIORAL|Placebo Comparator|
214584646|NCT03237637|DRUG|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
214584647|NCT03237637|DRUG|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
214584648|NCT04660604|DEVICE|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
214584649|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
214584650|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
214584651|NCT00705679|DRUG|Tenofovir disoproxil fumarate|300 mg tablet
214584652|NCT00705679|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet
214584653|NCT00705679|DRUG|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
214584654|NCT00705679|DRUG|Tenofovir placebo|placebo gel
214584655|NCT03129880|BEHAVIORAL|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
214584656|NCT03129880|BEHAVIORAL|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
214584657|NCT04628351|BEHAVIORAL|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
214584658|NCT00932113|DRUG|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
214584659|NCT00932113|DRUG|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
214584660|NCT03818685|DRUG|Nivolumab|Radiotherapy will be maintained in each Arm.
214584661|NCT03818685|DRUG|Ipilimumab|Radiotherapy will be maintained in each Arm.
214584662|NCT03818685|DRUG|Capecitabine|Radiotherapy will be maintained in each Arm.
214584663|NCT04217629|DRUG|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
214584664|NCT05938374|DRUG|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
214584665|NCT05938374|RADIATION|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
214584666|NCT06472193|PROCEDURE|Shanfield implantation technique in Mitroffanof procedure|a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
214584667|NCT04360317|DRUG|Combination of SH003 and Docetaxel|Combination of SH003 and Docetaxel
214584668|NCT05969743|DRUG|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
214584669|NCT04778241|PROCEDURE|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
214584670|NCT02335177|BEHAVIORAL|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
214584671|NCT05657886|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
214584672|NCT05657886|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
214584673|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
214584674|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
214584675|NCT00626678|DRUG|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
214584676|NCT00626678|DRUG|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
214584677|NCT00626678|DRUG|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
214584678|NCT00258063|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
214584679|NCT00306696|DRUG|Rosiglitazone|
214584680|NCT00306696|DRUG|spironolactone|
214584681|NCT00306696|DRUG|hydrochlorothiazide|
214584682|NCT00306696|DRUG|frusemide|
214584683|NCT00001407|DRUG|Interferon Gamma|
214584684|NCT01094860|DRUG|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
214584685|NCT05409833|DIAGNOSTIC_TEST|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
214584686|NCT03010930|OTHER|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
214584687|NCT03010930|OTHER|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
214584688|NCT01652599|DRUG|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
214584689|NCT02887807|DRUG|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
214584690|NCT02887807|DRUG|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
214584691|NCT04862871|BEHAVIORAL|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
214584692|NCT03969550|OTHER|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
214584693|NCT02774161|OTHER|Ultrasound Tomography|Undergo B-mode ultrasound imaging
214584694|NCT05022225|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
214584695|NCT00517907|DRUG|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
214584696|NCT06209346|OTHER|TeleRehab Group|"The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform."
214710429|NCT05646654|PROCEDURE|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
214710430|NCT03385174|OTHER|Carbon monoxide|Carbon monoxide inhalation
214584697|NCT06209346|OTHER|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
214710431|NCT02785146|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
214710432|NCT02785146|DRUG|Oxaliplatin|85 mg/m², ivdrip, D1
214710433|NCT02785146|DRUG|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
214584698|NCT06059781|OTHER|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
214584699|NCT06059781|OTHER|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
214584700|NCT01197833|DRUG|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
214584701|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
214584702|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
214584703|NCT02178670|BIOLOGICAL|CSC-DC|
214584704|NCT04900987|DEVICE|Steri-strips|Pneumatic TR band compression with use of steri-strips
214710434|NCT02785146|DRUG|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
214710435|NCT03657810|DRUG|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
214584705|NCT05760053|DRUG|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
214584706|NCT05114577|BEHAVIORAL|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (\~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
214584707|NCT05114577|BEHAVIORAL|Email recommendations|Receive recommendations (via email) to help improve sleep
214584708|NCT02998736|DRUG|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
214584709|NCT02998736|BIOLOGICAL|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
214584710|NCT03881488|DRUG|CTX-471|IV infusion every 2 weeks
214584711|NCT03881488|DRUG|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
214584712|NCT04119258|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
214584714|NCT04147117|DEVICE|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
214584715|NCT01776541|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
214584716|NCT04674696|OTHER|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
214584717|NCT01572376|PROCEDURE|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
214584718|NCT04408261|DRUG|Buqitongluo Granule|Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
214584719|NCT04408261|DRUG|Buqitongluo Granule Placebo|Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
214584720|NCT04408261|OTHER|Standard care|Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
214584721|NCT02704663|PROCEDURE|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
214584722|NCT02704663|PROCEDURE|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
214584723|NCT01280162|DRUG|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
214584724|NCT03051243|DRUG|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
214584725|NCT03051243|DRUG|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
214584726|NCT04084184|DRUG|HGP1812|Dapagliflozin (Forxiga) 10mg
214584727|NCT04084184|DRUG|HGP1602|Dapagliflozin 10mg
214584728|NCT02715349|BEHAVIORAL|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
214710436|NCT03657810|DRUG|Norco|hydrocodone 5 mg/APAP 325 mg
214710437|NCT03657810|DRUG|Placebo|Placebo matching CL-108
214710438|NCT00189787|DRUG|tacrolimus|
214710439|NCT01525056|RADIATION|ct and mri scans|ct and mri scan preradiation and postradiation
214710440|NCT01525056|RADIATION|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
214710441|NCT01525056|RADIATION|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
214710442|NCT00533611|DRUG|MK0524A, /Duration of Treatment : 4 Weeks|
214710443|NCT00533611|DRUG|Comparator : niacin /Duration of Treatment : 1 Weeks|
214710444|NCT04644055|DIAGNOSTIC_TEST|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
214710445|NCT02321683|DEVICE|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
214710446|NCT03911778|OTHER|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
214584729|NCT05443152|BEHAVIORAL|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
214584730|NCT04603651|DRUG|Bamlanivimab|Administered intravenously (IV).
214584731|NCT02938260|DRUG|Metoprolol vs Diltiazem|
214584732|NCT05753371|DRUG|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
214584733|NCT00156819|DRUG|fluticasone|fluticasone (100 microgram twice daily) treatment
214584734|NCT00156819|DRUG|montelukast|Montelukast (5 or 10 mg each night).
214584735|NCT00156819|DRUG|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
214584736|NCT02090959|DRUG|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
214710447|NCT04713579|OTHER|No intervention - observational study|There is no intervention in this study as it is purely observational.
214710448|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
214710449|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
214584737|NCT03480217|BEHAVIORAL|Multifaceted Implementation Strategy|"Key components include:~* educational presentations to primary care providers at grand rounds~* patient information materials on ABPM and HBPM~* training registered nurses to assist providers with teaching patients to conduct HBPM~* information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~* a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~* periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~* an accessible, culturally-adapted and locally tailored ABPM service"
214584738|NCT03480217|OTHER|Usual care|Primary care clinicians diagnose hypertension according to usual care
214584739|NCT00522873|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
214584740|NCT00522873|DRUG|0.5mg NETA / 1.0mg E2 (Activella)|One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
214584741|NCT02503878|DEVICE|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
214584742|NCT02536391|DRUG|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
214584743|NCT02536391|DRUG|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
214584744|NCT04617210|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
214584745|NCT04610437|PROCEDURE|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
214584746|NCT04556461|DRUG|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
214710450|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
214710451|NCT00886106|DRUG|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
214584747|NCT00326833|DRUG|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
214584748|NCT05496946|OTHER|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
214584749|NCT03169504|OTHER|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.
214584750|NCT03169504|DRUG|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
214584751|NCT03169504|OTHER|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
214584752|NCT02349646|DEVICE|Implantation with the commercially available Axium neurostimulator|
214584753|NCT02970474|DEVICE|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
214584754|NCT02970474|DEVICE|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
214710452|NCT00886106|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
214584755|NCT02072161|DRUG|ETC-1002|ETC-1002 capsules, taken once daily oral
214710453|NCT00343109|BIOLOGICAL|HER-2/neu intracellular domain protein|Given ID
214710454|NCT00343109|PROCEDURE|leukapheresis|Optional correlative studies
214710455|NCT00343109|OTHER|laboratory biomarker analysis|Correlative studies
214710456|NCT00343109|BIOLOGICAL|sargramostim|Given ID
214584756|NCT02072161|DRUG|Placebo|Placebo capsules, taken once daily oral
214710457|NCT00343109|OTHER|immunologic technique|Correlative studies
214710458|NCT00343109|BIOLOGICAL|synthetic tumor-associated peptide vaccine therapy|Given ID
214710459|NCT02701179|DRUG|Lignocaine 1% concentration solution|
214710460|NCT02701179|DRUG|Lignocaine 2% concentration solution|
214710461|NCT06643390|DRUG|MK-2225|Subcutaneous administration
214710462|NCT06643390|OTHER|Placebo|Subcutaneous administration
214710463|NCT04220138|PROCEDURE|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
214710464|NCT04426890|BIOLOGICAL|CT-P39|Prefilled syringe (PFS) of 1 mL solution
214584757|NCT02072161|DRUG|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
214584758|NCT03237039|RADIATION|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
214584759|NCT03237039|OTHER|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
214584760|NCT03237039|OTHER|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
214584761|NCT01184144|DRUG|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
214584762|NCT00599885|DRUG|telmisartan|telmisartan 40-80mg once per day for 8 months
214584763|NCT00599885|DRUG|valsartan|valsartan 80-160mg once per day for 8 months
214584764|NCT05310149|DEVICE|Prosthetic intervention with maxillary obturator prosthesis|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
214584765|NCT01148914|OTHER|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
214584766|NCT00406523|DEVICE|JANUS Stent|
214584767|NCT05039528|BEHAVIORAL|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
214584768|NCT05039528|OTHER|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
214584769|NCT02634489|DRUG|Tamsulosin HCl|Oral
214584770|NCT02634489|DRUG|Solifenacin Succinate|Oral
214584771|NCT02634489|DRUG|EC905|Oral
214584772|NCT04520360|DRUG|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
214584773|NCT01122251|DRUG|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
214584774|NCT01122251|DRUG|Lercanidipine or Valsartan|L10, L20, V80, V160
214584775|NCT01122251|DRUG|Placebo|Placebo of Lercanidipine and Valsartan
214584776|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
214584777|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
214584778|NCT05973695|OTHER|clamshell exercise|For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
214584779|NCT05973695|OTHER|Gluteal Bridge exercises|Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
214584780|NCT02907229|DEVICE|NCVC-CS1|Intervention Description
214584781|NCT05217498|DRUG|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
214584782|NCT05217498|DEVICE|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
214584783|NCT00539565|DRUG|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
214584784|NCT00539565|DRUG|placebo|
214710465|NCT04426890|BIOLOGICAL|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
214584785|NCT05273593|DEVICE|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
214584786|NCT03170037|PROCEDURE|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
214584787|NCT03170037|PROCEDURE|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
214584788|NCT03860285|OTHER|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
214584789|NCT00624923|DRUG|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
214584790|NCT00624923|DRUG|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
214584791|NCT04459013|OTHER|Salivary samples|The salivary samples will be collected at 5 defined times
214584792|NCT02661087|PROCEDURE|Hysteroscopic resection with bipolar energy|Hysteroscopic resection with bipolar energy
214584793|NCT02661087|PROCEDURE|Hysteroscopic resection with monopolar energy|Hysteroscopic resection with monopolar energy
214584794|NCT00276029|DRUG|Etanercept|
214584795|NCT01080495|PROCEDURE|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
214584796|NCT04037618|DRUG|[14C]-EYP001a|Oral drinking suspension
214584797|NCT01529203|DRUG|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
214584798|NCT01529203|DEVICE|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
214584799|NCT00893984|DRUG|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
214584800|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
214584801|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
214584802|NCT02725801|DEVICE|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
214584803|NCT02725801|DEVICE|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
214584804|NCT04256629|DRUG|Verinurad|Randomized subjects will receive oral dose of verinurad
214584805|NCT04256629|DRUG|Placebo|Randomized subjects will receive oral dose of placebo
214584806|NCT04256629|DRUG|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
214584807|NCT04686201|DEVICE|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
214584808|NCT04513184|DRUG|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
214584809|NCT04513184|DRUG|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
214584810|NCT02647866|DRUG|KHK4083|IV Infusion
214584811|NCT02647866|DRUG|Placebo|IV Infusion
214584812|NCT04994353|DIETARY_SUPPLEMENT|No supplementation|1st Week: No supplementation
214584813|NCT04994353|DIETARY_SUPPLEMENT|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
214584814|NCT04994353|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
214584815|NCT04994353|DIETARY_SUPPLEMENT|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
214584816|NCT04994353|DIETARY_SUPPLEMENT|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
214584817|NCT04994353|DIETARY_SUPPLEMENT|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
214584818|NCT00069108|DRUG|5 FU|As prescribed, in 2 week cycles
214584819|NCT00069108|DRUG|Leucovorin|As prescribed, in 2 week cycles
214584820|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 3 week cycles
214584821|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 2 week cycles
214584822|NCT00069108|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
214584823|NCT04810143|DEVICE|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
214584824|NCT05026333|OTHER|Cognitive Stress Testing|Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
214584825|NCT05318547|OTHER|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
214584826|NCT05318547|OTHER|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
214584827|NCT00801931|DRUG|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
214584828|NCT00801931|RADIATION|Total Body Irradiation|
214584829|NCT00801931|DRUG|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
214584830|NCT00801931|DRUG|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
214584831|NCT00801931|DRUG|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
214584832|NCT00801931|DRUG|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
214584833|NCT00801931|DRUG|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
214584834|NCT00801931|DRUG|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG \[horse\]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
214584835|NCT00801931|DRUG|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
214584836|NCT00801931|DRUG|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
214584837|NCT04247087|DRUG|phytomenadione|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
214584838|NCT04247087|DRUG|placebo solution|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
214584839|NCT01468467|DRUG|AC220|Oral Liquid
214584840|NCT04295876|BEHAVIORAL|The BRIDGES Project Intervention|The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
214584841|NCT00149760|BEHAVIORAL|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
214584842|NCT00149760|BEHAVIORAL|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
214584843|NCT02826915|DEVICE|Near Infra Red Spectroscopy (NIRS)|
214584844|NCT02826915|DEVICE|Electroencephalogram (EEG)|
214584845|NCT02652871|DRUG|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
214584846|NCT02652871|DRUG|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
214584847|NCT02652871|DRUG|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
214584848|NCT00458991|DRUG|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
214584849|NCT01245985|RADIATION|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
214584850|NCT05485467|DIAGNOSTIC_TEST|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
214584851|NCT01246739|PROCEDURE|Adrenalectomy|Adrenalectomy (open or laparoscopic)
214584852|NCT04912271|DRUG|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
214710466|NCT04798248|BEHAVIORAL|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
214584853|NCT04912271|DRUG|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
214584854|NCT04912271|DRUG|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
214584855|NCT04912271|DRUG|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
214584856|NCT04912271|DRUG|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
214584857|NCT01415531|DRUG|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
214584858|NCT01415531|DRUG|Placebo|Dose-match placebo
214584859|NCT02796157|DEVICE|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
214584860|NCT02796157|DEVICE|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
214584861|NCT04262973|OTHER|education|six-hour dementia care course
214584862|NCT04262973|OTHER|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
214584863|NCT00361010|DRUG|Levetiracetam|
214584864|NCT05976893|DRUG|Evolocumab|Evolocuma:420 mg every 4 weeks
214584865|NCT05976893|DRUG|Statin|The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
214584866|NCT04196101|DRUG|EDP-938|Four tablets daily for 5 days
214584867|NCT04196101|DRUG|Placebo|Four tablets daily for 5 days
214584868|NCT00601094|BIOLOGICAL|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
214584869|NCT00394082|DRUG|ABI-007|125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
214584870|NCT00394082|DRUG|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
214584871|NCT03293641|DIETARY_SUPPLEMENT|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
214584872|NCT03293641|DRUG|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
214584873|NCT00292721|DRUG|Celecoxib|celecoxib: loading and maintenance for 6 months
214584874|NCT03377309|DRUG|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
214584875|NCT03430531|DRUG|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
214584876|NCT03742921|DRUG|Istodax|Istodax
214710467|NCT04798248|BEHAVIORAL|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
214584877|NCT05068245|BEHAVIORAL|Preselected classical music|Preselected classical music
214584878|NCT00176397|PROCEDURE|Percutaneous coronary intervention (left main)|
214710468|NCT06247267|DRUG|Fortesta|Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
214710469|NCT06247267|DRUG|Estradiol|Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
214710470|NCT06247267|DRUG|Fortesta|Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
214710471|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
214710472|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
214710473|NCT06789432|DRUG|Atorvastatin 10 mg and ezetimibe 10 mg|Atorvastatin/Ezetimibe 10/10mg once daily
214584879|NCT01932554|DRUG|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
214584880|NCT01932554|DRUG|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
214584881|NCT01932554|OTHER|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
214584882|NCT01932554|DRUG|Ibuprofen|Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
214584883|NCT01932554|DRUG|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
214584884|NCT01932554|OTHER|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
214584885|NCT01932554|OTHER|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
214584886|NCT04384315|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
214710474|NCT06789432|DRUG|Atorvastatin 20 mg|Atorvastatin (20 mg) Monotherapy once daily
214584887|NCT01139060|BEHAVIORAL|organized care program for chronic or recurrent depression|
214584888|NCT02344004|DRUG|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
214584889|NCT01994668|DRUG|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
214584890|NCT01994668|DRUG|Placebo|A single intravenous administration of 0.9% saline over 1 minute
214584891|NCT02665637|DRUG|Trastuzumab|Each patient may receive single dose by intravenous infusion
214584892|NCT00411346|PROCEDURE|Nurse-led telemonitoring|
214584893|NCT03482154|PROCEDURE|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
214584894|NCT04463017|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
214584895|NCT03226236|RADIATION|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
214584896|NCT03226236|BIOLOGICAL|Autologous DC vaccine|The first dose (7 to 14 x 10\_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
214710475|NCT06665256|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
214710476|NCT06665256|OTHER|Active Comparator Option|Investigator choice of treatment as per protocol
214710477|NCT04353973|OTHER|Pre-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
214710478|NCT04353973|OTHER|Standard of Care|Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
214584897|NCT03226236|DRUG|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
214584898|NCT01583231|OTHER|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
214584899|NCT00010985|PROCEDURE|Acupuncture|
214584900|NCT00010985|PROCEDURE|Chiropractic|
214584901|NCT00010985|PROCEDURE|massage|
214584902|NCT04942730|DRUG|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
214584903|NCT04942730|DRUG|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
214584904|NCT04942730|DRUG|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
214584905|NCT04942730|DRUG|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
214584906|NCT04942730|DRUG|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
214584907|NCT04942730|DRUG|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
214584908|NCT04253574|DIAGNOSTIC_TEST|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
214584909|NCT02493543|OTHER|Blood collection|Blood collection from the subject's arm
214584910|NCT03690648|OTHER|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
214584911|NCT03690648|GENETIC|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
214584912|NCT03690648|GENETIC|Blood collection|Collection of 20 ml of blood with kit of blood collection
214584913|NCT04651517|DEVICE|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
214584914|NCT06164067|OTHER|abortus within 24 hours or 24-48 hours|second trimester medical termination
214584915|NCT06001931|OTHER|handgrip force and bioimpedance values in healthy Turkish children.|Demographic characteristics, calf circumference , Hand grip strength , TANITA BIA analysis
214584916|NCT05312788|OTHER|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
214584917|NCT00606970|DIETARY_SUPPLEMENT|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
214584918|NCT00606970|DIETARY_SUPPLEMENT|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
214584919|NCT00891345|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
214584920|NCT06318767|PROCEDURE|hemodynamic measure of the Systolic Time Rise|The hemodynamic measure of the Systolic Time Rise will be added in the routine doppler echography, planned in preoperative, postoperative and at 6 months of following up. This measure is taken on the foot, with ultrasound probe.
214584921|NCT03142126|DEVICE|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
214584922|NCT04901260|DEVICE|AMAZE™ Disease Management Platform|The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
214584923|NCT02364843|DIETARY_SUPPLEMENT|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
214584924|NCT04288999|DRUG|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
214584925|NCT04288999|RADIATION|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
214584926|NCT04288999|OTHER|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
214584927|NCT06182943|OTHER|electroacupuncture combined with surrounding acupuncture|electroacupuncture combined with surrounding acupuncture
214584928|NCT06182943|OTHER|sham electroacupuncture|sham electroacupuncture
214584929|NCT06182943|OTHER|ice compress combined with brake rest|ice compress combined with brake rest
214584930|NCT03367390|DEVICE|AID System|AID system
214584931|NCT03367390|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
214584932|NCT00623402|DRUG|Sorafenib|2x 400 mg orally per day (4 tablets)
214584933|NCT00623402|DRUG|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
214584934|NCT02481947|DRUG|BLI400 Laxative|21 gm BLI400 powder
214584935|NCT02481947|DRUG|Lubiprostone|24 mcg capsule bid
214584936|NCT02033161|BEHAVIORAL|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
214584937|NCT01258413|PROCEDURE|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
214584938|NCT01258413|PROCEDURE|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
214584939|NCT05578144|OTHER|Patients Decision Aids (PDA)|Patient Decision Aids (PDA) administer to case group
214584940|NCT03816267|DEVICE|Nebulizer|Nebulization via mask
214584941|NCT03816267|DRUG|Salbutamol|Delivery of appropriate dose according to weight
214584942|NCT03816267|DEVICE|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
214584943|NCT05249829|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
214584944|NCT05249829|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214584945|NCT05249829|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214584946|NCT00831337|DIETARY_SUPPLEMENT|VSL3|2 times daily 450 billion live bacteria (in each saschet)
214584947|NCT00060424|DRUG|Cyclosporine|Given PO
214584948|NCT00060424|DRUG|Fludarabine Phosphate|Given IV
214584949|NCT00060424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
214584950|NCT00060424|OTHER|Laboratory Biomarker Analysis|Correlative studies
214584951|NCT00060424|DRUG|Mycophenolate Mofetil|Given PO
214584952|NCT00060424|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
214584953|NCT00060424|RADIATION|Total-Body Irradiation|Undergo TBI
214584954|NCT04085965|BEHAVIORAL|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
214584955|NCT06140654|DIAGNOSTIC_TEST|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
214710479|NCT04353973|OTHER|Post-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
214710480|NCT02892201|DRUG|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
214584956|NCT06140654|DIAGNOSTIC_TEST|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
214584957|NCT06183957|OTHER|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
214584958|NCT03587051|DIETARY_SUPPLEMENT|Low glycemic index post-exercise diet|Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
214584959|NCT03587051|DIETARY_SUPPLEMENT|High glycemic index post-exercise diet|Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
214584960|NCT02842827|DRUG|bomedemstat|oral administration
214584961|NCT02842827|DRUG|tretinoin|oral administration
214584962|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
214584963|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
214584964|NCT06302517|DEVICE|BIS-guided|underwent intraoperative monitoring of BIS anesthesia depth
214584965|NCT01457989|DRUG|retigabine/ezogabine|dose range up to 1200 mg/day
214584966|NCT03009760|DRUG|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
214584967|NCT03009760|DRUG|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
214584968|NCT03009760|DRUG|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
214584969|NCT03009760|DRUG|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
214584970|NCT02364791|DEVICE|standard techniques used to achieve air leak control|
214584971|NCT02364791|DEVICE|Hemopatch|
214584972|NCT01474928|BEHAVIORAL|patient role played community video|Group two viewed the patient role played community video
214584973|NCT01474928|BEHAVIORAL|both videos group|Group three viewed both the knowledge and community videos
214584974|NCT01474928|BEHAVIORAL|Pamphlet group|Group four read an educational pamphlet only
214584975|NCT01474928|BEHAVIORAL|physician-led knowledge video|Group one viewed a physician-led knowledge video
214584976|NCT01474928|BEHAVIORAL|Community video group|Group two viewed the patient role played community video
214584977|NCT01474928|BEHAVIORAL|knowledge video|Group one viewed a physician-led knowledge video
214584978|NCT03426267|DRUG|SDN-037|twice daily
214584979|NCT03426267|DRUG|Placebo|twice daily
214584980|NCT04010825|OTHER|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
214584981|NCT01981772|DRUG|4% lidocaine with 1:100,000 epinephrine|see arm/group description
214584982|NCT01981772|DRUG|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
214584983|NCT04602416|BEHAVIORAL|Training sessions|
214584984|NCT03995693|DIETARY_SUPPLEMENT|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
214584985|NCT03995693|BEHAVIORAL|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
214584986|NCT03995693|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
214584987|NCT03995693|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
214584988|NCT03995693|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
214584989|NCT03995693|BEHAVIORAL|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
214584990|NCT03995693|DIAGNOSTIC_TEST|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
214584991|NCT03995693|DIAGNOSTIC_TEST|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
214584992|NCT03995693|DIAGNOSTIC_TEST|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
214584993|NCT03995693|PROCEDURE|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
214584994|NCT02125747|OTHER|No Respiratory Therapy|Patients received conventional treatment.
214584995|NCT02125747|OTHER|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
214584996|NCT01184261|BEHAVIORAL|behavioral intervention|8 session behavioral intervention.
214584997|NCT03587077|DRUG|Misoprostol|vaginal application
214584998|NCT03587077|DRUG|Placebos|vaginal application
214584999|NCT03587077|DRUG|isosorbide mononitrate|vaginal application
214585000|NCT00609765|DRUG|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
214585001|NCT00609765|DRUG|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
214585002|NCT00609765|DRUG|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
214585003|NCT00609765|DRUG|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
214585004|NCT00609765|DRUG|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
214585005|NCT00609765|DRUG|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
214585006|NCT03970070|OTHER|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
214585007|NCT03970070|OTHER|Quality-of-Life Assessment|Ancillary studies
214585008|NCT03970070|OTHER|Questionnaire Administration|Ancillary studies
214585009|NCT03970070|OTHER|Survey Administration|Ancillary studies
214585010|NCT05234112|BEHAVIORAL|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
214585011|NCT05234112|DIAGNOSTIC_TEST|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
214585012|NCT05234112|BEHAVIORAL|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
214585013|NCT05234112|DIAGNOSTIC_TEST|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
214585014|NCT05234112|PROCEDURE|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
214585015|NCT05234112|DIAGNOSTIC_TEST|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
214585016|NCT02526147|OTHER|Cash|
214585017|NCT02526147|OTHER|Voucher|
214585018|NCT02526147|OTHER|Food|
214585019|NCT01195051|OTHER|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
214585020|NCT05455515|PROCEDURE|IVL procedures|Intravascular Lithotripsy (IVL)
214585021|NCT04271501|PROCEDURE|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
214585022|NCT04271501|DEVICE|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
214585023|NCT04271501|DEVICE|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
214585024|NCT04271501|DEVICE|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
214585025|NCT02041234|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
214585026|NCT02041234|DRUG|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
214585027|NCT02041234|DRUG|Xenical|Xenical: Up to 120 mg tds
214585028|NCT02041234|DRUG|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
214585029|NCT02041234|DRUG|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
214585030|NCT02439073|BEHAVIORAL|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
214585031|NCT00464009|BEHAVIORAL|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
214585032|NCT05801744|BEHAVIORAL|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
214585033|NCT02094755|OTHER|Blood draw only|Blood draw only
214585034|NCT03548246|DRUG|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
214585035|NCT03548246|DRUG|Placebo|Daily placebo for 2 years.
214585036|NCT03548246|DRUG|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
214585037|NCT03548246|DRUG|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
214585038|NCT04897906|BEHAVIORAL|Education Group|Mother care, newborn care and breastfeeding education will be provided to pregnant women in the third trimester of pregnancy.
214585039|NCT06231446|OTHER|No intervention|This was an observational cohort study with no intervention for all enrolled patients.
214585040|NCT00882687|DRUG|Lifitegrast|Ophthalmic Solution
214585041|NCT00882687|OTHER|Placebo|Ophthalmic Solution
214585042|NCT02622009|PROCEDURE|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
214585043|NCT02919904|DEVICE|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~* NREM and REM sleep frequency and duration~* Duration and number of arousal~* Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~* Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~* Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~* Apnea/hypopnea index and respiratory disturbance index"
214585044|NCT00577356|DRUG|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
214585045|NCT00577356|BIOLOGICAL|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
214585046|NCT02690922|DRUG|Dasatinib|100mg (d1-d84)
214585047|NCT02690922|DRUG|prednisone|60mg/m2 d1-24
214585048|NCT02690922|DRUG|dexamethasone|10mg/d 3-7days
214585049|NCT02690922|DRUG|methotrexate|3g/m2 1day
214585050|NCT03631160|DEVICE|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
214585051|NCT03631160|DEVICE|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
214585052|NCT02290730|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
214585053|NCT01958307|BEHAVIORAL|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
214585054|NCT05405452|DEVICE|Vibration Anesthesia Device by Blaine Labs|Device which vibrates on top of skin
214585055|NCT05405452|DRUG|Gebauers Ethyl Chloride 100% Topical Spray|Sterile ethyl chloride spray
214585056|NCT04201782|DRUG|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214585057|NCT03186131|DRUG|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
214585058|NCT03186131|DRUG|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
214585059|NCT05342025|OTHER|PNF|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. Breathing PNF patterns, pressure, and stretches will be applied inward and upwards into the rib cage so that they do not cause pain. Diaphragmatic stimulation will be performed on both sides with repeated contractions, hand contacts, and stabilization techniques. Facilitation techniques will be used to stimulate the intrinsic respiratory muscles. Again, with respect to inspiration, the patterns will be studied in neck extension, upper and lower trunk extension, and upper extremities flexion patterns. Neck flexion, upper and lower trunk flexion, and extension patterns of the upper extremities will be applied in relation to expiration. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases.
214585060|NCT05342025|OTHER|Breathing exercises|Breathing exercises: diaphragmatic breathing, thoracic expansion, pursed-lip breathing and respiratory control for 15 minutes a day, every day of the week.
214585061|NCT01251731|DRUG|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
214585062|NCT01251731|DRUG|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
214585063|NCT01251731|DRUG|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
214585064|NCT01251731|DRUG|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
214585065|NCT02592408|DRUG|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
214585066|NCT02592408|DRUG|SDPQ|single dose primaquine on day 2
214585067|NCT02592408|DRUG|14DPQ|14 day primaquine starting on day 2
214585068|NCT02592408|DRUG|14DPQ on Day 42|14 day primaquine starting on day 42
214585069|NCT01708993|DRUG|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
214585070|NCT01708993|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
214585071|NCT01708993|DRUG|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
214585072|NCT01708993|DRUG|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
214585073|NCT03594604|DRUG|Norethindrone|Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
214585074|NCT03594604|DRUG|oral contraceptive pill|Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
214585075|NCT03614910|DEVICE|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
214585076|NCT02550665|DRUG|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
214585077|NCT03687047|DEVICE|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
214585078|NCT02783521|BEHAVIORAL|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
214585079|NCT02783521|BEHAVIORAL|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
214585080|NCT02649946|DEVICE|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
214585081|NCT02649946|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
214585082|NCT04097392|OTHER|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
214585083|NCT04097392|OTHER|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
214585084|NCT03862846|DRUG|REN001|Once daily
214585085|NCT02102477|PROCEDURE|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
214585086|NCT02102477|OTHER|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
214585087|NCT01871701|DRUG|Escitalopram|Escitalopram
214585088|NCT01871701|DRUG|Quetiapine|Quetiapine
214585089|NCT01871701|DRUG|Moxifloxacin|Moxifloxacin
214585090|NCT01871701|OTHER|Placebo|Placebo
214585091|NCT00950950|DRUG|Romosozumab|Administered by subcutaneous injection
214585092|NCT00950950|DRUG|Placebo|Administered by subcutaneous injection
214585093|NCT02957526|BEHAVIORAL|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
214585094|NCT02957526|BEHAVIORAL|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
214585095|NCT00104663|DRUG|Quinacrine|
214585096|NCT01809002|BIOLOGICAL|Processed Nerve Allograft (human)|
214585097|NCT01809002|DEVICE|Collagen Nerve Cuff|Bovine collagen based nerve cuff
214585098|NCT00784355|PROCEDURE|Laparoscopic cholecystectomy|Surgery
214585099|NCT02192021|DRUG|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
214585100|NCT04137094|BEHAVIORAL|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
214585101|NCT02375178|DRUG|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
214585102|NCT02375178|DRUG|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
214585103|NCT02375178|DRUG|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
214585104|NCT02589860|OTHER|Melphalan kinetic study|Concentration of Melphalan in plasma samples
214585105|NCT02589860|GENETIC|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
214585106|NCT02589860|GENETIC|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
214585107|NCT01127269|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
214585108|NCT01964885|DIETARY_SUPPLEMENT|IQP-AS-105|
214585109|NCT01964885|DIETARY_SUPPLEMENT|Placebo|
214585110|NCT00241852|BEHAVIORAL|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
214585111|NCT00241852|BEHAVIORAL|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
214585112|NCT02464033|DRUG|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
214585113|NCT02464033|DRUG|Vitamin D|
214585114|NCT02464033|DRUG|Etanercept|
214585115|NCT04294732|DRUG|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
214585116|NCT04294732|DRUG|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
214585117|NCT04547283|OTHER|Usual Care|No clinical team recommendation, patients will remain in their natural choice of position
214585118|NCT04547283|OTHER|APPS|Clinical team guidance on prone positioning of patients
214585119|NCT00502086|DIETARY_SUPPLEMENT|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
214585120|NCT00502086|OTHER|Placebo|Placebo three sachets daily during 96 weeks
214585121|NCT03102645|DRUG|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
214585122|NCT03102645|DRUG|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
214585123|NCT01413087|BIOLOGICAL|Biological/Vaccine: BC-819|"Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)"
214585124|NCT06103968|DEVICE|LMA BLOCKBUSTER|In this study we wish to evaluate weather gastric tube inserted through LMA helps in maintaining the LMA blockbuster placement by comparing fibreoptic bronchoscope (FOB) scores recorded immediately after LMA placement and at the end of the surgical procedure.
214585125|NCT01856556|DRUG|NRX-1074|Single IV or PO administration
214585126|NCT01856556|DRUG|Placebo|Single IV or PO placebo administration
214585127|NCT02232243|DRUG|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
214585128|NCT02232243|DRUG|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
214585129|NCT04689282|BIOLOGICAL|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
214585130|NCT01975870|OTHER|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
214585131|NCT03895905|DIAGNOSTIC_TEST|colposcopy and colposcopic biopsy|high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
214585132|NCT04300075|DEVICE|CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
214585133|NCT01959477|DRUG|busulfan|Given IV
214585134|NCT01959477|DRUG|etoposide|Given IV
214585135|NCT01959477|DRUG|cyclophosphamide|Given IV
214585136|NCT01959477|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
214585137|NCT01959477|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
214585138|NCT00080678|DRUG|Docetaxel|
214585139|NCT00080678|DRUG|Imatinib Mesylate|
214585140|NCT03130153|DRUG|Aspirin Powder|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
214585141|NCT03130153|DRUG|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
214585142|NCT00704405|DRUG|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
214585143|NCT00704405|DRUG|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
214585144|NCT00704405|DRUG|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.
214585145|NCT00704405|DRUG|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
214585146|NCT00928018|DRUG|Sirolimus|Taken orally for at least 12 months
214585147|NCT00928018|DRUG|Methotrexate|Given intravenously on the first, third and sixth day after transplant
214585148|NCT00928018|DRUG|Tacrolimus|Taken orally or given intravenously for at least 6 months
214585149|NCT00928018|DRUG|Cyclosporine|Taken orally or given intravenously for at least 6 months
214585150|NCT00928018|DRUG|MMF|Taken orally for about 2 months
214585151|NCT03031145|BIOLOGICAL|Felis Domesticus|Nasal Administration of Felis Domesticus
214585152|NCT02650687|PROCEDURE|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
214585153|NCT03218397|DEVICE|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
214585154|NCT03218397|DEVICE|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
214585155|NCT06460753|DIAGNOSTIC_TEST|CT of the chest organs, blood biochemical parameters|Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.
214585156|NCT02169167|DEVICE|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
214585157|NCT02169167|DEVICE|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
214585158|NCT00016939|DRUG|alvocidib|
214585159|NCT05769569|BIOLOGICAL|VRC07-523LS|VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
214585160|NCT05769569|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
214585161|NCT05769569|BIOLOGICAL|N-803|N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
214585162|NCT05769569|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
214585163|NCT05769569|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
214585164|NCT05769569|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
214585165|NCT05769569|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
214585166|NCT05769569|COMBINATION_PRODUCT|Antiretroviral Therapy (ART)|This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
214585167|NCT00943111|DRUG|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (\>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
214585168|NCT00943111|DRUG|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was \>=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
214585169|NCT02861469|OTHER|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
214585170|NCT02882529|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
214585171|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food - MAM|Each MAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
214585172|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF)|Each MAM child will be supplemented with RUSF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
214585173|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food (MDF) - SAM|Each SAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
214585174|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|Each SAM child will be supplemented with RUTF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
214585175|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
214585176|NCT01946438|BIOLOGICAL|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
214585177|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
214585178|NCT01946438|BIOLOGICAL|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
214585179|NCT04474509|BEHAVIORAL|FACT Module Engagement|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
214585180|NCT04474509|BEHAVIORAL|FACT Module Openness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
214585181|NCT04474509|BEHAVIORAL|FACT Module Awareness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
214585182|NCT01453868|OTHER|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
214585183|NCT01453868|OTHER|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
214585184|NCT03256981|RADIATION|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
214585185|NCT03256981|DRUG|TKI|Continued background TKI alone
214585186|NCT02144727|PROCEDURE|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
214585187|NCT02144727|PROCEDURE|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
214585188|NCT00353249|BEHAVIORAL|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
214585189|NCT04472000|DRUG|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
214585190|NCT04472000|DRUG|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
214585191|NCT04625179|OTHER|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
214585192|NCT04625179|PROCEDURE|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
214585193|NCT01427595|DRUG|Metformin|500-2000 mg PO BID (X12 weeks)
214585194|NCT01427595|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
214585195|NCT01427595|DRUG|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
214585196|NCT03738345|OTHER|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
214585197|NCT00038012|DRUG|Thrombopoietin|
214585198|NCT00038012|PROCEDURE|Platelet-pheresis|
214585199|NCT00038012|DRUG|Carboplatin|
214585200|NCT04538690|OTHER|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
214585201|NCT04538690|OTHER|Electrotherapy|TENS, US
214585202|NCT00567034|DRUG|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
214585203|NCT00567034|DRUG|placebo|lactose placebo, 1 capsule every day for 12 weeks
214585204|NCT02745574|PROCEDURE|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
214585205|NCT02745574|PROCEDURE|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
214585206|NCT00531700|OTHER|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
214585207|NCT00531700|OTHER|Health messages|community level health messages unrelated to the study originating exposures
214585208|NCT00061139|BEHAVIORAL|Pediatric Constraint-Induced Movement therapy|
214585209|NCT00061139|BEHAVIORAL|Conventional pediatric motor rehabilitation therapy|
214585210|NCT05408832|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
214585211|NCT05408832|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
214585212|NCT05408832|BEHAVIORAL|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
214585213|NCT02457559|DRUG|Tirabrutinib|Tablets or capsules administered orally
214585214|NCT04819776|DRUG|Iloperidone|Oral iloperidone
214585215|NCT04819776|DRUG|Iloperidone Placebo|Oral placebo
214585216|NCT00974376|DRUG|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
214585217|NCT00974376|DRUG|Placebo|1200mg/day of placebo for 12 weeks
214585218|NCT00974376|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
214585219|NCT00926627|DRUG|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight \< 40 kg/90 lb)
214585220|NCT00926627|DRUG|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
214585221|NCT02010853|OTHER|IRMf|"evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months"
214585222|NCT02691117|DRUG|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
214585223|NCT00231946|DRUG|VP4896|
214585224|NCT02762149|DEVICE|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
214585225|NCT00476710|DRUG|Colesevelam HCl|
214585226|NCT00235482|DRUG|Coxsackievirus A21|
214585227|NCT01232179|PROCEDURE|conventional prp|pan retinal photocoagulation
214585228|NCT01232179|PROCEDURE|targeted prp|1200-1600 spot in far periphery retin, anterior equator
214585229|NCT00875602|DEVICE|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
214585230|NCT00682669|BEHAVIORAL|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
214585231|NCT00682669|BEHAVIORAL|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
214585232|NCT04873739|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
214585233|NCT00998335|DRUG|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
214585234|NCT00998335|DRUG|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
214585235|NCT00457808|DRUG|Rapamycin, sirolimus|
214585236|NCT02942433|BEHAVIORAL|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
214585237|NCT02942433|BEHAVIORAL|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
214585238|NCT02942433|BEHAVIORAL|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
214585239|NCT00492362|BEHAVIORAL|ergometer exercise during hemodialysis|
214585240|NCT00492362|BEHAVIORAL|pedometer activity outside of hemodialysis|
214585241|NCT03854045|OTHER|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
214585242|NCT03494478|OTHER|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
214585243|NCT03494478|OTHER|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
214585244|NCT03494478|OTHER|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
214585245|NCT04230291|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
214585246|NCT04230291|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
214585247|NCT04532554|DRUG|Growth Hormone|Recombinant growth hormone will be used
214585248|NCT04532554|DRUG|Placebo|Saline injection with the same amount
214585249|NCT02883127|BEHAVIORAL|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.~2. Eat mainly carbohydrates of low glycaemic index.~3. Reduce the intake of carbohydrate of high glycaemic index.~4. Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
214585250|NCT00067509|DRUG|emergency contraception (estrogen/progesterone)|
214585251|NCT02700477|DIETARY_SUPPLEMENT|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
214585252|NCT02700477|OTHER|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
214585253|NCT01177982|BEHAVIORAL|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
214585254|NCT01177982|BEHAVIORAL|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
214585255|NCT01177982|BEHAVIORAL|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
214585256|NCT01177982|BEHAVIORAL|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
214585257|NCT01177982|BEHAVIORAL|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
214585258|NCT01177982|BEHAVIORAL|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
214585259|NCT01177982|BEHAVIORAL|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
214585260|NCT01177982|BEHAVIORAL|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
214585261|NCT01688687|PROCEDURE|Endoscopic submucosal dissection|
214585262|NCT00979810|DRUG|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
214585263|NCT01406964|OTHER|CAT test|A CAT test is performed in order to diagnose tubal factor causes
214585264|NCT01406964|OTHER|Histerosalpingography|A Histerosalpingography is performed.
214585265|NCT03169101|DRUG|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
214585266|NCT03169101|BEHAVIORAL|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
214585267|NCT06147050|DRUG|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
214585268|NCT06147050|OTHER|Placebo|Patients will receive matching placebo control twice daily.
214585269|NCT02775695|DRUG|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
214585270|NCT03106909|RADIATION|pulmonary computed tomography (CT)|Pulmonary CT imaging
214585271|NCT01219868|BEHAVIORAL|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
214585272|NCT03681847|PROCEDURE|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
214585273|NCT03681847|PROCEDURE|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
214585274|NCT03681847|PROCEDURE|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
214585275|NCT02570685|BEHAVIORAL|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
214585276|NCT02570685|BEHAVIORAL|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
214585277|NCT02570685|BEHAVIORAL|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
214585278|NCT01078454|DRUG|melphalan|Given PO
214585279|NCT01078454|DRUG|dexamethasone|Given PO
214585280|NCT01078454|DRUG|bortezomib|Given IV
214585281|NCT00756691|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
214585282|NCT02902939|DEVICE|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
214585283|NCT02902939|PROCEDURE|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
214585284|NCT01791374|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
214585285|NCT01791374|DRUG|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
214585286|NCT02274974|DRUG|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
214585287|NCT02274974|DRUG|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
214710486|NCT05162781|BEHAVIORAL|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
214585288|NCT04993482|OTHER|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
214585289|NCT02330289|BEHAVIORAL|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
214585290|NCT03957889|OTHER|Educational simulation|
214585291|NCT01720680|RADIATION|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
214585292|NCT01720680|DEVICE|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
214585293|NCT05188339|DRUG|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
214585294|NCT05188339|DRUG|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
214585295|NCT04672629|DEVICE|echocardiography|follow up echocardiography
214585296|NCT06071559|PROCEDURE|Laparoscopic Roux-en-y gastric bypass|Obesity surgery
214585297|NCT06298669|DEVICE|Biventricular Pacing|The CRT device will be reprogrammed to coordinate contractions of the left and right ventricles.
214585298|NCT06298669|DEVICE|Right Ventricular Pacing|The CRT device will be reprogrammed for right ventricular contractions.
214585299|NCT05428930|DRUG|CKDB-501B|Intramuscular injection CKDB-501B
214585300|NCT05428930|DRUG|Botox®50U|Intramuscular injection Botox®50U
214585301|NCT02641574|OTHER|compare complication|
214585302|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
214585303|NCT06056362|DIAGNOSTIC_TEST|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
214585304|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
214585305|NCT06056362|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
214585306|NCT06438497|PROCEDURE|RIRS with f-UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
214585307|NCT06438497|PROCEDURE|RIRS with f-UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
214585308|NCT06438497|PROCEDURE|RIRS with traditional UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
214585309|NCT06438497|PROCEDURE|RIRS with traditional UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
214585310|NCT05677997|BEHAVIORAL|Intervention|Sessions to go through goals, problem areas, areas they want to improve.
214585311|NCT06144970|BIOLOGICAL|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
214585312|NCT06144970|BIOLOGICAL|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
214585313|NCT06144970|BIOLOGICAL|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
214585314|NCT06144970|BIOLOGICAL|Sham Control|Single subcutaneous injection of normal saline
214585315|NCT04062968|OTHER|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
214585316|NCT00098501|DRUG|pelitinib|
214585317|NCT00098501|DRUG|temsirolimus|Given PO
214585318|NCT01372423|DRUG|Lubiprostone|24 mcg capsules
214585319|NCT01372423|DRUG|Placebo|24 mcg capsules
214585320|NCT06609395|BEHAVIORAL|Brief online CBT targeting excessiv worry|The intervention with a focus on excessive worry lasted five weeks and was delivered through five online modules with therapist support. Modules covered psychoeducation, problem-solving, reducing excessive media consumption, detached mindfulness, and shifting focus from worry. The final module offered relapse prevention strategies.
214585321|NCT06610565|DIETARY_SUPPLEMENT|FASTING-MIMICKING DIET PROGRAM|Nutritional intervention via fasting-mimicking diet. Patients receiving adjuvant therapy with aromatase inhibitors will be randomized 1:1 into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months,and a control one, where they will receive only nutritional counseling.
214585322|NCT06610435|PROCEDURE|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Soft tissue mobilization techniques were applied bilaterally on the trigger points in the masseter, temporal, lateral and medial pterygoid muscles of the masticatory muscles in the transverse direction from inside and outside the mouth. In addition, deep friction massage and myofascial relaxation techniques were applied to suprahyoid and infrahyoid muscles, sternocleidomastoid, scalene, upper trapezius, levator scapula and suboccipital muscles until relaxation was felt. In addition, distraction and bridging techniques were applied in the suboccipital region to release the tissue and fascia techniques were applied in the cervical region to loosen the fascia. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
214585323|NCT06610435|PROCEDURE|Home Exercise|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. These exercises consist of resistant isometric jaw movements to increase coordination and relaxation of the masticatory muscles (post isometric relaxation technique), Rocabado exercises, stretching and posture exercises for temporal, masseter and suprahyoid muscles as well as neck muscles. All individuals in this group were taught the programmed exercises practically and were asked to repeat the home exercises (lasting approximately 25 minutes) three times a week for 8 weeks. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
214585324|NCT06610773|BIOLOGICAL|hUC-MSCs|1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.
214585325|NCT06610773|BIOLOGICAL|Saline+albumin|Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs
214585326|NCT00230087|PROCEDURE|blood donation|phlebotomy until iron depleted
214585327|NCT04018638|OTHER|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
214585328|NCT04064398|PROCEDURE|Aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
214585329|NCT04973787|BIOLOGICAL|biological disease-modifying antirheumatic drugs (bDMARDs)|bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
214585330|NCT02869100|OTHER|Blood sample|
214585331|NCT02869100|PROCEDURE|Sodium fluoride Positron Emission Tomography|
214585332|NCT02869100|OTHER|Magnetic Resonance Imaging|
214585333|NCT02869100|OTHER|Radiography|
214585334|NCT06728826|PROCEDURE|Posterior Pericardiotomy|The surgeon will perform a posterior pericardiotomy while the patient is on cardiopulmonary bypass. In detail, the surgeon will use cautery to make a 4- to 5-cm opening in pericardium between the left inferior pulmonary vein and the diaphragm. Then a soft channel drain will be placed through the posterior pericardium, the pericardiotomy and into the left pleural space.
214585335|NCT06728202|PROCEDURE|A Horizontal Ridge Augmentation in Atrophic Maxillary Ridge|Aiming to enhance bone volume (Quantity) in horizontal maxillary bone defects and density (Quality) , providing a viable solution for implant stability and long-term success.
214585336|NCT06727643|OTHER|trunk muscle strength|force that represents the endurance of the body.
214585337|NCT06727643|OTHER|Core Strength|back and abdominal muscle endurance
214585338|NCT06727643|OTHER|Balance|steady state
214585339|NCT06727981|DRUG|ICI plus Chemothearpy|This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.
214585340|NCT06727981|DRUG|Chemotherapy|This intervention involves the administration of standard chemotherapy alone.
214585341|NCT06727487|BEHAVIORAL|Basic recommendations|Daily basis activity counseling by WHO recommendations
214585342|NCT06727487|BEHAVIORAL|Physical exercise|A complete program of active physical exercise of medium and high intensity
214585343|NCT06727487|BEHAVIORAL|Nutritional advice|A complete program of nutritional counseling
214585344|NCT06727487|BEHAVIORAL|Psycho-oncological support|A program related with a patient Psycho-oncological follow-up
214585345|NCT05978115|PROCEDURE|implant supported prosthesis|Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture
214585346|NCT06728163|OTHER|written education group|group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.
214585347|NCT06728163|OTHER|VR educational material + breathing relaxation with verbal instruction|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. Verbal instructions for breathing are provided for about 3 minutes and 3 seconds.
214585348|NCT06728163|OTHER|VR educational material + breathing relaxation with music intervention|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
214585349|NCT06728163|OTHER|written educational material + breathing relaxation with music intervention.|"group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.~The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion."
214585350|NCT06727656|COMBINATION_PRODUCT|Nitrate + Hypoxia|The combined effect of nitrate supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
214585351|NCT06727656|DIETARY_SUPPLEMENT|Placebo + Hypoxia|The combined effect of placebo supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
214585352|NCT06727656|OTHER|Control|The combined effect of placebo supplementation and normoxia training on both performance and health at sea-level and altitude conditions.
214585353|NCT06729307|DRUG|Oral ondansetron and dyclonine hydrochloride mucilage|Patients will take 8 mg oral ondansetron 2 hours prior to EGD process in addition to dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to EGD process.
214585354|NCT06729307|DRUG|Dyclonine hydrochloride mucilage|Patients will be instructed to gurgle 10 mL of dyclonine chloride mucilage (0.01 g/mL) and gurgle for 1 minute 15 minutes prior to endoscopic process.
214585355|NCT06727916|BEHAVIORAL|BBT-I|Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care. Healthcare provider provided BBT-I to the patients.
214585356|NCT06727916|OTHER|Non BBT-I|Patients in the control group will receive standard care.
214585357|NCT06728345|DRUG|Rimegepant|Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks
214585358|NCT06729177|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
214585359|NCT06729619|DRUG|The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.|Blood and cerebrospinal fluid concentrations of anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam and ceftazidime ababactam will be monitored after the drug reaches a steady state.
214585360|NCT02359682|OTHER|No intervention|No Intervention
214585361|NCT04731519|BEHAVIORAL|Continuous Identity Cognitive Therapy (CI-CT)|CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The recovery oriented CI-CT for post acute suicidal episode Veterans includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
214585362|NCT04731519|BEHAVIORAL|General Health Education|General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
214585363|NCT03620331|PROCEDURE|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
214585364|NCT03620331|PROCEDURE|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
214585365|NCT00031551|DRUG|Etanercept|
214585366|NCT00031551|DRUG|Placebo|
214585367|NCT02823535|BEHAVIORAL|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
214585368|NCT05717608|OTHER|high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects|oral ingestion of food supplement for 4 weeks
214585369|NCT02049164|DRUG|AR08|
214585370|NCT02049164|DRUG|Placebo|
214585371|NCT04595383|DEVICE|ti.care|Electronic platform for doctor-patient communication
214585372|NCT03788083|DRUG|Trimix|Intratumoral TriMix injection
214585373|NCT03788083|DRUG|Placebo|Intratumoral placebo injection
214585374|NCT02330146|DRUG|RCT-01|
214585375|NCT02330146|DRUG|Placebo|
214585376|NCT03527368|BEHAVIORAL|Time-restricted feeding|Participants consume food earlier in the day
214585377|NCT03527368|BEHAVIORAL|Usual feeding pattern|Participants consume food later in the day
214585378|NCT01416415|OTHER|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
214585379|NCT01416415|OTHER|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
214585380|NCT01133951|DRUG|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
214585381|NCT01133951|DRUG|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
214585382|NCT00409773|DRUG|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
214585383|NCT00409773|DRUG|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
214585384|NCT00409773|DRUG|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
214585385|NCT04121494|BIOLOGICAL|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
214585386|NCT04121494|BIOLOGICAL|ChadOx1 85A - IM|Intramuscular administration
214585387|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
214585388|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
214585389|NCT00153062|DRUG|Clopidogrel placebo|placebo
214585390|NCT00153062|DRUG|Clopidogrel placebo|placebo
214585391|NCT00153062|DRUG|Micardis|80 mg micardis
214585392|NCT00153062|DRUG|Micardis|80 mg micardis
214585393|NCT00153062|DRUG|Aggrenox placebo|placebo
214585394|NCT00153062|DRUG|Aggrenox placebo|placebo
214585395|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
214585396|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
214585397|NCT00153062|DRUG|Micardis placebo|placebo
214585398|NCT00153062|DRUG|Micardis placebo|placebo
214585399|NCT00081406|BEHAVIORAL|Individual Child CBT|
214585400|NCT00081406|BEHAVIORAL|Family CBT|
214585401|NCT00081406|BEHAVIORAL|Education/Support/Attention|
214585402|NCT00679393|PROCEDURE|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
214585403|NCT00679393|PROCEDURE|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
214585404|NCT01047423|DRUG|Simvastatin|40mg encapsulated once daily for 12 weeks
214585405|NCT01047423|DRUG|Placebo|Encapsulated oral once daily for 12 weeks
214585406|NCT06063785|DIAGNOSTIC_TEST|Acoustic Radiation Forced Impulse Imaging|Measurement of Liver stiffness
214585407|NCT06063785|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|Measurement of optoacoustic spectra in liver and gastrointestinal tract
214585408|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
214585409|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
214585410|NCT00676377|DRUG|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
214585411|NCT00676377|DRUG|Saline|Saline Placebo
214585412|NCT05596838|PROCEDURE|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
214585413|NCT02359877|DRUG|BCD-054|
214585414|NCT02359877|DRUG|Rebif|
214585415|NCT02359877|DRUG|Avonex|
214585416|NCT02396043|DRUG|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
214585417|NCT02396043|DRUG|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
214585418|NCT02396043|DRUG|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
214585419|NCT02396043|DRUG|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
214585420|NCT02396043|DRUG|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
214585421|NCT02396043|DRUG|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
214585422|NCT02396043|DRUG|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
214585423|NCT04461483|DRUG|TAK-935|TAK-935 Tablets
214585424|NCT04461483|DRUG|Placebo|TAK-935 placebo-matching tablets
214585425|NCT01919814|DIETARY_SUPPLEMENT|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
214585426|NCT01919814|OTHER|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
214585427|NCT04690842|DIAGNOSTIC_TEST|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
214585428|NCT01095107|DIETARY_SUPPLEMENT|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
214585429|NCT01095107|DIETARY_SUPPLEMENT|Increased fat intake|increased fat intake : Intake \> 50 grams of fat per day between meals and snacks
214585430|NCT00275262|DRUG|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
214585431|NCT00275262|DRUG|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
214585432|NCT00690040|DEVICE|Foley catheter|Single balloon catheter
214585433|NCT00690040|DEVICE|Atad catheter|Double balloon catheter
214585434|NCT04623970|PROCEDURE|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
214585435|NCT02164383|DRUG|Nicotine patch|4-week starter kit of nicotine patch
214585436|NCT02164383|BEHAVIORAL|Cessation Counseling|5 brief counseling sessions
214585437|NCT02164383|DEVICE|Mobile Games|
214585438|NCT02334501|DRUG|Lansoprazole|
214585439|NCT02334501|DRUG|Neratinib|
214585440|NCT04721028|DEVICE|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
214585441|NCT02110147|DRUG|uridine triacetate|
214585442|NCT05186194|DRUG|Vitamin D, Calcium|Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
214585443|NCT05186194|DRUG|Placebo|Placebo
214585444|NCT02345785|OTHER|urologic surgery and caudal block|
214585445|NCT04834453|DIAGNOSTIC_TEST|transcranial ultrasound|\- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
214585446|NCT02429674|BEHAVIORAL|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
214585447|NCT03531970|DRUG|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
214585448|NCT03531970|DRUG|Dexamethasone|Corticostroide
214585449|NCT03531970|DRUG|Placebo|Placebo
214585450|NCT01813370|OTHER|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
214585451|NCT03059225|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
214585452|NCT03059225|DEVICE|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
214585453|NCT02035592|OTHER|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
214585454|NCT02035592|OTHER|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
214585455|NCT02035592|OTHER|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
214585456|NCT01747525|DEVICE|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
214585457|NCT02050152|BEHAVIORAL|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
214585458|NCT02050152|DRUG|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
214585459|NCT02390830|OTHER|Falls Prevention|
214585460|NCT02390830|OTHER|Reduction of limitations at body function and activity levels|
214585461|NCT00831285|DIETARY_SUPPLEMENT|food product|food product given at one of six visits
214585462|NCT04483076|DRUG|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.
214585463|NCT04483076|PROCEDURE|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
214585464|NCT04483076|PROCEDURE|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
214585465|NCT02707731|PROCEDURE|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
214585466|NCT02340767|DEVICE|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
214585467|NCT02340767|DEVICE|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
214585468|NCT04448509|OTHER|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
214585469|NCT00221182|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
214585470|NCT00289432|BEHAVIORAL|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
214585471|NCT00289432|OTHER|Support group|Standard Hospital follow-up support group
214585472|NCT02576301|DRUG|Phase 1 - OXi4503|Determination of MTD of OXi4503
214585473|NCT02576301|DRUG|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
214585474|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
214585475|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
214585476|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
214585477|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
214585478|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
214585479|NCT00691405|DRUG|Placebo|Placebo inhalation solution BID
214585480|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
214585481|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
214585482|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
214585483|NCT00691405|DRUG|Placebo|Placebo inhalation solution QD
214585484|NCT00238524|DRUG|SPM 927|
214585485|NCT01703650|DRUG|iopromide|"1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤."
214585486|NCT01703650|PROCEDURE|CT|"1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
214585487|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
214585488|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
214585489|NCT01290029|DRUG|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
214585490|NCT02844725|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
214585491|NCT02844725|DRUG|Placebo|water for injection
214585492|NCT02745262|OTHER|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
214585493|NCT05223777|DEVICE|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
214585494|NCT05223777|DEVICE|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
214585495|NCT00987454|DRUG|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
214585496|NCT00987454|DRUG|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
214585497|NCT06071403|OTHER|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
214585498|NCT02819466|DEVICE|3D echography|ultrasound visualization of the stomach in fasting patients.
214585499|NCT02204176|OTHER|Exercise info|"Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries"
214585500|NCT02204176|OTHER|Implementation intentions|"Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans"
214710487|NCT05162781|BEHAVIORAL|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
214710488|NCT05162781|BEHAVIORAL|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
214585501|NCT02204176|OTHER|Industriousness|"Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise"
214585502|NCT02204176|DEVICE|pedometer|
214585503|NCT02445950|BEHAVIORAL|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
214585504|NCT02445950|BEHAVIORAL|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
214585505|NCT02466438|DRUG|Piperacillin-tazobactam|"* Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician"
214585506|NCT04266665|DRUG|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
214585507|NCT04266665|OTHER|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
214585508|NCT05031169|PROCEDURE|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
214585509|NCT04931186|OTHER|retrospective analyis|retrospective analysis of data
214710489|NCT05162781|BEHAVIORAL|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
214710490|NCT05162781|BEHAVIORAL|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 5 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
214710491|NCT05162781|BEHAVIORAL|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
214585510|NCT03404830|OTHER|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
214585511|NCT01001923|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
214585512|NCT01001923|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
214585513|NCT00782522|PROCEDURE|Eccentric training program|Eccentric training program
214585514|NCT00782522|PROCEDURE|Traditional training program|Traditional training program
214585515|NCT03681704|DRUG|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
214585516|NCT03681704|DRUG|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
214585517|NCT02179723|DEVICE|Leukosan Adhesive|Leukosan adhesive applied to one wound
214585518|NCT02179723|DEVICE|Transcutaneous suture|Transcutaneous suture applied to one wound
214585519|NCT02430974|DRUG|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
214585520|NCT02768051|PROCEDURE|AF Ablation|
214585521|NCT05419362|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
214585522|NCT05419362|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
214585523|NCT02306486|OTHER|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
214585524|NCT01481389|DIETARY_SUPPLEMENT|Theobromine|200 ml drink with added theobromine (no cocoa added)
214585525|NCT01481389|DIETARY_SUPPLEMENT|Cocoa|200 ml drink with cocoa (no theobromine added)
214585526|NCT01481389|DIETARY_SUPPLEMENT|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
214585527|NCT01481389|DIETARY_SUPPLEMENT|Placebo|200 ml drink (no added theobromine or cocoa)
214585528|NCT03413657|PROCEDURE|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
214585529|NCT00093171|DRUG|rFIX|
214585530|NCT04186299|DRUG|Clonidine|Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
214585531|NCT04186299|DRUG|Articaine Hydrochloride + Epinephrine|Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
214585532|NCT01095263|DEVICE|DBS|130Hz, 90us pulsewidth, 4V Amplitude
214585533|NCT01095263|DEVICE|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
214585534|NCT02954640|BIOLOGICAL|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
214585535|NCT06347653|DRUG|linperlisib combined with CHOP regimen|"Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles."
214585536|NCT01648738|OTHER|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
214585537|NCT01648738|OTHER|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
214585538|NCT01019512|OTHER|questionnaire administration|Ancillary studies
214585539|NCT01019512|OTHER|lymphedema management|
214710492|NCT05162781|BEHAVIORAL|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
214585540|NCT03939455|OTHER|Mobile Augmented Screening tool|Tablet-based intervention
214585541|NCT02490553|OTHER|heteroevaluation scale by a nurse or doctor|
214585542|NCT01838252|PROCEDURE|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
214585543|NCT01838252|PROCEDURE|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
214585544|NCT00261768|BEHAVIORAL|Digital noise reduction|
214585545|NCT04252768|DRUG|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
214585546|NCT04252768|DRUG|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
214585547|NCT02336178|DRUG|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
214710493|NCT01772836|DRUG|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
214710494|NCT01772836|DRUG|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
214585548|NCT05504863|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
214585549|NCT05504863|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
214585550|NCT05504863|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
214585551|NCT03641612|OTHER|one shape|canal fluid sample before and after root canal instrumentation
214585552|NCT03641612|OTHER|protaper next|canal fluid sample before and after root canal instrumentation
214585553|NCT01108250|GENETIC|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
214585554|NCT00009841|BIOLOGICAL|EGFR antisense DNA|
214585555|NCT00009841|BIOLOGICAL|growth factor antagonist therapy|
214585556|NCT00009841|DRUG|DC-cholesterol liposome|
214585557|NCT03181750|BEHAVIORAL|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
214585558|NCT02781272|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
214585559|NCT02781272|PROCEDURE|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
214585560|NCT02781272|PROCEDURE|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
214585561|NCT04552483|DRUG|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
214585562|NCT04552483|DRUG|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
214585563|NCT00618982|DRUG|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
214585564|NCT03637985|DEVICE|resistive exercise|resistive exercise by elastic band for 12 weeks
214585565|NCT03637985|DEVICE|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
214585566|NCT04988815|DRUG|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
214585567|NCT05692297|DRUG|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
214710495|NCT01772836|DRUG|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
214585568|NCT05692297|DRUG|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
214585569|NCT02394951|DRUG|Pregabalin|Anticonvulsant
214585570|NCT02394951|DRUG|Placebo|Identical, matching inactive substance
214585571|NCT02057978|PROCEDURE|EXCEL DES implatation|Implant DES for CAD cases
214585572|NCT02057978|PROCEDURE|EXCEL-II DES implantation|Implant DES for CAD cases
214585573|NCT01200420|DRUG|miravirsen|SC injection
214585574|NCT01200420|DRUG|saline|SC injection
214585575|NCT02863471|DRUG|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
214585576|NCT06349746|OTHER|therapeutic exercises|stretching exercise to posterior capsule and progressive resistance exercise for rotator cuff and scapula stabilizer and home exercise 3 sessions per week for 6 week.
214710496|NCT00635245|BIOLOGICAL|figitumumab|
214585577|NCT06349746|OTHER|mobilization exercise|cervical unilateral antero-posterior mobilization and thoracic central postro-anterior mobilization
214585578|NCT00871299|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
214585579|NCT00871299|BEHAVIORAL|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
214585580|NCT02312388|OTHER|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
214710497|NCT00635245|OTHER|imaging biomarker analysis|
214710498|NCT00635245|OTHER|laboratory biomarker analysis|
214710499|NCT00635245|OTHER|pharmacological study|
214710500|NCT00635245|PROCEDURE|conventional surgery|
214710501|NCT00635245|PROCEDURE|magnetic resonance spectroscopic imaging|
214585581|NCT02312388|OTHER|Thin-wall needle technique|using 18 - 21 G introducer needle
214585582|NCT00799513|DRUG|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
214710502|NCT00635245|PROCEDURE|neoadjuvant therapy|
214710503|NCT01673269|OTHER|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
214710504|NCT06249022|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
214585583|NCT04584775|OTHER|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
214585584|NCT04584775|OTHER|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
214585585|NCT03843931|BEHAVIORAL|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
214585586|NCT03843931|DRUG|Intra-articular saline injection|"Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
214585587|NCT03280667|DRUG|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
214585588|NCT04459247|DRUG|Vit D|Oral liquid formulation of 60000 IU
214585589|NCT00666679|DRUG|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
214585590|NCT00666679|DRUG|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
214585591|NCT00666679|DRUG|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
214585592|NCT02370810|BEHAVIORAL|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
214585593|NCT04317703|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
214585594|NCT04317703|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
214585595|NCT03690232|DRUG|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
214585596|NCT03690232|DRUG|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
214585597|NCT05062759|DRUG|Tezepelumab|210 mg SC injection Q4W.
214585598|NCT05062759|DRUG|Placebo|SC injection Q4W.
214585599|NCT05937334|DIAGNOSTIC_TEST|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
214585600|NCT04498091|BIOLOGICAL|Biological data|Biological data
214585601|NCT04498091|OTHER|Clinical data|Clinical data
214585602|NCT01830959|DRUG|Roflumilast|Roflumilast
214585603|NCT01830959|DRUG|Placebo|Placebo one a day
214585604|NCT03203031|PROCEDURE|General anesthesia|Standard general anesthesia
214585605|NCT03203031|PROCEDURE|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
214585606|NCT05682391|OTHER|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
214585607|NCT01820013|DEVICE|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
214585608|NCT01820013|DEVICE|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
214585609|NCT00236093|DRUG|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
214710505|NCT06249022|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
214585610|NCT02781844|DRUG|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
214585611|NCT02781844|DRUG|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
214585612|NCT02781844|DRUG|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
214585613|NCT00140751|DRUG|Lopinavir/ritonavir (drug)|
214585614|NCT02518490|DEVICE|Sapphire Lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
214585615|NCT02518490|DEVICE|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
214585616|NCT04078633|BEHAVIORAL|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
214585617|NCT02349373|BEHAVIORAL|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
214585618|NCT02349373|BEHAVIORAL|16 week training period|Receipt of a weekly running schedule through an online training diary.
214585619|NCT03720873|DRUG|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
214585620|NCT03720873|DRUG|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
214585621|NCT06098456|DRUG|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
214585622|NCT05690113|PROCEDURE|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
214585623|NCT00003849|BIOLOGICAL|rituximab|
214585624|NCT04695743|OTHER|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
214585625|NCT02551406|DEVICE|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
214585626|NCT01524601|DRUG|Rosuvastatin|20 mg rosuvastatin for 4 weeks
214585627|NCT05220787|BIOLOGICAL|Cold stored platelets in 100% plasma stored for 10-14 days|Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery
214585628|NCT05220787|BIOLOGICAL|Room temperature stored platelets in 100% plasma stored for up to 7 days|Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
214585629|NCT04100668|DEVICE|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
214585630|NCT04100668|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
214585631|NCT04100668|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
214585632|NCT00346632|DRUG|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
214585633|NCT00616057|DIETARY_SUPPLEMENT|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
214585634|NCT00616057|DIETARY_SUPPLEMENT|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
214585635|NCT00918580|BIOLOGICAL|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
214585636|NCT00277576|BIOLOGICAL|ppdpSC18 administered by PMED|
214585637|NCT06208098|DIAGNOSTIC_TEST|Salivary cortisol dosage|saliva sample at 8 - 9h \& at T30
214585638|NCT05991843|BEHAVIORAL|Instructions of breathing|Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
214585639|NCT04882995|DIETARY_SUPPLEMENT|Psyillium fiber|Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
214585640|NCT04253080|BIOLOGICAL|Blood sample|Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.
214585641|NCT04253080|BIOLOGICAL|Cutaneous melanoma biopsy|Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
214585642|NCT05074797|DIAGNOSTIC_TEST|laboratory|laboratory data
214585643|NCT03897764|PROCEDURE|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
214585644|NCT00477334|DRUG|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
214585645|NCT00477334|DRUG|Placebo|oral; two tablets twice a day; single day treatment
214585646|NCT05985421|OTHER|Fecal collection|approximate volume of 2 ml
214585647|NCT05985421|OTHER|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
214585648|NCT05985421|OTHER|Polysomnography|Polysomnography
214585649|NCT05985421|OTHER|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
214585650|NCT00014131|BIOLOGICAL|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
214585651|NCT02270918|DRUG|Kcentra|IV infusion
214585652|NCT02270918|DRUG|Apixaban|
214585653|NCT02270918|DRUG|Placebo|
214585654|NCT04593927|DRUG|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
214585655|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
214585656|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
214585657|NCT02418676|DRUG|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
214585658|NCT02418676|DRUG|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
214585659|NCT02418676|DRUG|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
214585660|NCT00226031|PROCEDURE|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
214585661|NCT03587974|BEHAVIORAL|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
214585662|NCT02907645|BEHAVIORAL|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
214585663|NCT02907645|BEHAVIORAL|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
214585664|NCT00628004|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
214585665|NCT00628004|DEVICE|Local best practice|"N/A - since intervention is local best practice"
214585666|NCT02868385|DRUG|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
214585667|NCT02868385|DRUG|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
214585668|NCT01028937|DEVICE|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
214585669|NCT01493232|OTHER|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
214585670|NCT03700073|OTHER|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
214585671|NCT03700073|OTHER|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
214585672|NCT02290132|DRUG|Rabbit Anti-human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
214585673|NCT03543657|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
214585674|NCT03543657|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
214585675|NCT03543657|DRUG|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
214585676|NCT03543657|DRUG|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
214585677|NCT02438501|RADIATION|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
214585678|NCT02438501|RADIATION|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
214585679|NCT02355080|BEHAVIORAL|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
214585680|NCT02355080|BEHAVIORAL|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
214585681|NCT04371198|OTHER|Biopsy|Tissue biopsy
214585682|NCT00760006|DRUG|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
214585683|NCT00760006|OTHER|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
214585684|NCT04910607|OTHER|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
214585685|NCT04910607|OTHER|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
214585686|NCT00160862|DRUG|SLV317|
214585687|NCT01604629|DRUG|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
214585688|NCT01604629|DRUG|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
214585689|NCT01455805|DEVICE|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
214585690|NCT01455805|PROCEDURE|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
214585691|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
214585692|NCT03486457|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
214585693|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
214585694|NCT00038168|DRUG|Estramustine|Intravenous dose
214585695|NCT00038168|DRUG|Taxol|Intravenous dose
214585696|NCT01378923|BEHAVIORAL|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
214585697|NCT01378923|BEHAVIORAL|TAU|have access to standard jail programs and services
214585698|NCT00372229|DRUG|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
214585699|NCT00372229|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
214585700|NCT00372229|DRUG|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
214585701|NCT00783900|OTHER|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
214585702|NCT06153953|DEVICE|vacuum device|use of vacuum device in dressing of diabetic wounds
214585703|NCT06153953|OTHER|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
214585704|NCT02797574|PROCEDURE|Punch Biopsy at a Lesional Site|
214585705|NCT02797574|PROCEDURE|Punch Biopsy at a Non- Lesional site|
214585706|NCT00398736|PROCEDURE|sonographic measurement of inferior caval vein diameter|
214710506|NCT06249022|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
214585707|NCT04061538|DIETARY_SUPPLEMENT|zinc sulfate|zinc 20mg tablets
214585708|NCT04061538|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
214585709|NCT02593409|DRUG|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
214585710|NCT02222636|DRUG|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
214585711|NCT02222636|DRUG|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
214585712|NCT02222636|DRUG|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
214585713|NCT02222636|DRUG|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
214585714|NCT02222636|DRUG|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
214585715|NCT01814202|OTHER|PTM202|
214585716|NCT01814202|OTHER|Placebo|
214585717|NCT03064386|PROCEDURE|Plate fixation|internal fixation with the plate
214585718|NCT03064386|PROCEDURE|Screw fixation|internal fixation with the screw
214585719|NCT04600232|DIAGNOSTIC_TEST|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
214585720|NCT00214838|DRUG|Atiprimod|
214585721|NCT00221169|PROCEDURE|Surgical resection|pet ct prior to surgery
214585722|NCT05030987|PROCEDURE|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
214585723|NCT05030987|PROCEDURE|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
214585724|NCT01333163|BIOLOGICAL|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
214585725|NCT01333163|BIOLOGICAL|Isotone NaCl|2 hours IV infusion.
214585726|NCT01746680|DRUG|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
214585727|NCT03354806|PROCEDURE|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
214585728|NCT03354806|PROCEDURE|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
214585729|NCT02873143|OTHER|No intervention|No intervention
214585730|NCT03956823|DRUG|telmisartan|Telmisartan group: telmisartan 80 mg once a day
214585731|NCT03956823|DRUG|amlodipine|amlodipine group: amlodipine 5 mg once a day
214585732|NCT03513874|DRUG|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
214585733|NCT03513874|DRUG|Insulin|Patients will continue insulin therapy following physicians' instructions.
214585734|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
214585735|NCT01589666|DRUG|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
214585736|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
214585737|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
214585738|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
214585739|NCT04599400|OTHER|There is no intervention in our study|There is no intervention in our study
214585740|NCT02467218|OTHER|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
214585741|NCT03539341|BEHAVIORAL|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
214585742|NCT03539341|OTHER|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
214585743|NCT02700945|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
214585744|NCT05963490|DRUG|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
214585745|NCT05963490|DRUG|Toripalimab|240 mg intravenously every 3 weeks
214585746|NCT05963490|RADIATION|Radiotherapy|hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).
214585747|NCT05963490|DRUG|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
214585748|NCT02428764|DRUG|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
214585749|NCT02428764|DRUG|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
214585750|NCT02428764|DRUG|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
214585751|NCT02428764|PROCEDURE|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
214585752|NCT03476707|OTHER|Anemia|Hematocrit less than 0.39
214585753|NCT02699034|PROCEDURE|ablation for typical atrial flutter|
214585754|NCT02699034|DEVICE|Vision-MR ablation catheter|
214585755|NCT05019378|PROCEDURE|SVF treatment|autologous SVF (10E8 cells)
214585756|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
214585757|NCT03805087|PROCEDURE|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
214585758|NCT03951506|OTHER|Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
214585759|NCT03951506|OTHER|Conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
214585760|NCT01568853|DRUG|Norepinephrine|Intravenously, 10 ug/min, 24 hours
214585761|NCT01568853|PROCEDURE|Open abdomen|IAH \>=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
214585762|NCT01568853|OTHER|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
214585763|NCT01568853|OTHER|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
214585764|NCT05537831|DEVICE|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
214585765|NCT00116337|PROCEDURE|Spinal Cord Stimulation to restore cough|Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
214585766|NCT00116337|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
214585767|NCT04100031|DEVICE|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
214585768|NCT04100031|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
214585769|NCT04256577|DIAGNOSTIC_TEST|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
214585770|NCT00262951|BIOLOGICAL|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
214585771|NCT00262951|DRUG|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
214585772|NCT00262951|DRUG|fluorouracil|administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
214585773|NCT00262951|RADIATION|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
214710507|NCT03582852|PROCEDURE|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
214710508|NCT06269575|BEHAVIORAL|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
214710509|NCT00972972|DIETARY_SUPPLEMENT|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
214585774|NCT00262951|PROCEDURE|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
214585775|NCT01577745|BIOLOGICAL|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
214585776|NCT02905136|OTHER|Fundamental research|serum, whole blood, cerebrospinal fluid
214585777|NCT02923687|DRUG|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
214585778|NCT02923687|DRUG|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
214585779|NCT05574491|BEHAVIORAL|Super Skills for Life: traditional version|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández."
214585780|NCT05574491|BEHAVIORAL|Super Skills for Life: computerized version|Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
214585781|NCT02963103|DRUG|Tacrolimus|Oral
214585782|NCT02910154|DIETARY_SUPPLEMENT|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
214585783|NCT02910154|BEHAVIORAL|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
214585784|NCT02910154|DRUG|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
214585785|NCT05175638|GENETIC|Gene Expression|the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.
214585786|NCT01759576|DRUG|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
214585787|NCT06189586|DRUG|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
214585788|NCT06189586|DRUG|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
214710510|NCT00972972|DIETARY_SUPPLEMENT|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
214585789|NCT05220384|BEHAVIORAL|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
214585790|NCT05220384|BEHAVIORAL|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
214585791|NCT01657513|DRUG|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
214585792|NCT06391060|PROCEDURE|Impact of Gender on Davinci rectal surgery|gender-specific considerations in the surgical management and post-operative care of rectal cancer patients undergoing robotic surgery
214585793|NCT02418273|DRUG|denosumab|These subjects will receive two doses of denosumab.
214585794|NCT03952429|BEHAVIORAL|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
214585795|NCT03952429|BEHAVIORAL|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
214585796|NCT02052830|BEHAVIORAL|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
214585797|NCT00055523|DRUG|Adalimumab (D2E7)|
214585798|NCT03869723|PROCEDURE|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
214585799|NCT03869723|PROCEDURE|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
214585800|NCT00000263|DRUG|30% Nitrous oxide|
214585801|NCT00000263|OTHER|0.25 g/Kg ethanol|
214585802|NCT00000263|OTHER|0.5 g/KG ethanol|
214585803|NCT00000263|OTHER|0 g/Kg ethanol|
214585804|NCT05521945|BEHAVIORAL|Intermittent Fasting|16 hours fasting and 8 hours eating window
214585805|NCT05521945|BEHAVIORAL|Calorie Restricted Diet|The customized diet plan will be given to the participants according to their calorie intake requirements
214585806|NCT05521945|BEHAVIORAL|Normal dietary intake|normal diet without any customization
214710511|NCT04227327|DRUG|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
214710512|NCT04227327|DRUG|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
214710513|NCT02091245|DRUG|KPT-330|
214585807|NCT04084470|DIETARY_SUPPLEMENT|Different types of bread|Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
214585808|NCT01136772|DRUG|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
214585809|NCT01136772|DRUG|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
214585810|NCT04658082|DEVICE|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
214585811|NCT05508620|DRUG|Sirolimus for Injection (Albumin-bound)|Intravenous infusion
214585812|NCT00279786|PROCEDURE|Blood draw|blood drawn
214585813|NCT02943226|DEVICE|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
214585814|NCT02943226|DEVICE|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
214585815|NCT02295657|DEVICE|standard double-lumen tube|intubation using standard double-lumen tube
214585816|NCT02295657|DEVICE|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
214710514|NCT00742807|DRUG|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
214585817|NCT04068259|DRUG|PBI-4547|PBI-4547 tablet
214585818|NCT04068259|OTHER|Placebo|Placebo tablet
214585819|NCT05210218|DIETARY_SUPPLEMENT|Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
214585820|NCT05210218|DIETARY_SUPPLEMENT|placebo|cellulose
214585821|NCT03495570|DIAGNOSTIC_TEST|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
214585822|NCT05336331|PROCEDURE|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
214585823|NCT05864261|DRUG|JT1801 60ug|JT1801, 60ug, IV injection
214585824|NCT05864261|DRUG|NESP 60ug|NESP, 60ug, IV injection
214710515|NCT00742807|DRUG|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
214710516|NCT05351333|OTHER|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
214585825|NCT03741569|DEVICE|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
214585826|NCT01041352|DEVICE|laryngeal mask|LMA Proseal
214585827|NCT01041352|DEVICE|endotracheal tube|Unomedical endotracheal tube
214585828|NCT03333239|BEHAVIORAL|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)
214585829|NCT03333239|BEHAVIORAL|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)
214585830|NCT03333239|BEHAVIORAL|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
214585831|NCT02279069|DEVICE|4-roll canne|
214585832|NCT06311604|DRUG|Isoflurane|"Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
214585833|NCT05997888|BEHAVIORAL|At-Home Strength Training Intervention|A six-week strength training intervention in which participants will choose workouts to complete on their own. These workouts are 20-25 minutes light-intensity strength training with light strength bands. Exercises will have multiple options to account for various levels of ability. Additionally, there will be a group counseling session once per week via Zoom and a group strength training program.
214585834|NCT00002428|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
214585835|NCT00002428|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
214585836|NCT02354443|BIOLOGICAL|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
214585837|NCT03444753|DRUG|BMS-986299|Specified dose on specified day
214585838|NCT03444753|BIOLOGICAL|Nivolumab|Specified dose on specified day
214585839|NCT03444753|BIOLOGICAL|Ipilimumab|Specified dose on specified day
214585840|NCT00354458|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
214585841|NCT00354458|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
214585842|NCT02996565|OTHER|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~1. Improved recognition of uncontrolled BP at primary care encounters,~2. Therapeutic action to address uncontrolled BP at primary care encounters,~3. Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
214585843|NCT02996565|OTHER|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~1. Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~2. Systematic home BP telemonitoring with data transmitted into patient medical record~3. Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
214585844|NCT00829582|DRUG|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
214585845|NCT00829582|OTHER|placebo|single intravenous infusion
214585846|NCT03463967|DIETARY_SUPPLEMENT|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
214585847|NCT03463967|OTHER|Energy-restricted diet|
214585848|NCT01208441|DRUG|letrozole|
214585849|NCT01208441|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
214585850|NCT01208441|PROCEDURE|therapeutic conventional surgery|
214585851|NCT01208441|PROCEDURE|breast biopsy|
214585852|NCT01208441|OTHER|diagnostic laboratory biomarker analysis|
214585853|NCT01208441|OTHER|pharmacological study|
214585854|NCT02202005|DRUG|Nevirapine|Nevirapine 400mg PR tablet
214585855|NCT02202005|DRUG|Viramune®|Viramune® 400 mg Retardtabletten
214585856|NCT01602562|DRUG|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
214585857|NCT05158556|OTHER|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
214585858|NCT05158556|OTHER|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
214585859|NCT00502827|BEHAVIORAL|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
214585860|NCT00502827|OTHER|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
214585861|NCT03493841|DRUG|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
214585862|NCT00828880|DEVICE|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
214585863|NCT01340820|DRUG|AERAS-422|rBCG
214585864|NCT01340820|DRUG|BCG Tice|1-8 x 10\^5 CFU
214585865|NCT05065333|OTHER|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
214585866|NCT05065333|OTHER|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
214585867|NCT03881553|DEVICE|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
214585868|NCT03881553|DEVICE|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
214585869|NCT02288533|DEVICE|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
214585870|NCT01098565|DEVICE|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
214585871|NCT01046890|DRUG|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
214585872|NCT01959516|DRUG|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
214710517|NCT05007015|PROCEDURE|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
214585873|NCT01959516|DRUG|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
214585874|NCT01959516|DRUG|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
214585875|NCT01959516|DRUG|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
214585876|NCT00536536|BEHAVIORAL|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
214585877|NCT04780022|OTHER|Clinical events at last follow-up|Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
214585878|NCT01568437|PROCEDURE|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
214585879|NCT01568437|OTHER|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
214585880|NCT02241954|DEVICE|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
214585881|NCT04834349|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
214585882|NCT04834349|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
214585883|NCT04834349|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214585884|NCT04834349|BIOLOGICAL|Pembrolizumab|Given IV
214585885|NCT04834349|OTHER|Quality-of-Life Assessment|Ancillary studies
214585886|NCT04834349|OTHER|Questionnaire Administration|Ancillary studies
214585887|NCT04834349|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214585888|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214585889|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
214585890|NCT01477333|DRUG|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
214585891|NCT01477333|DRUG|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
214585892|NCT05064189|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
214585893|NCT02501538|DEVICE|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
214585894|NCT00100386|PROCEDURE|Intensive Control Strategy|
214585895|NCT00100386|BEHAVIORAL|Standard Control Strategy|
214585896|NCT05121987|PROCEDURE|Erector Spinae Plane block|An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
214585897|NCT05121987|PROCEDURE|Continuous Wound Infusion|Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
214585898|NCT03035903|DEVICE|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
214585899|NCT03035903|DEVICE|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
214585900|NCT02088346|OTHER|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
214585901|NCT00979784|BEHAVIORAL|Better Weight|Standard cognitive behavioral treatment focused on dietary \& exercise behavior
214585902|NCT00979784|BEHAVIORAL|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
214710518|NCT03939637|DRUG|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
214585903|NCT02316366|DEVICE|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
214585904|NCT02628782|DEVICE|InSeal's Vascular Closure Device|Intravascular closure device
214585905|NCT02874274|BEHAVIORAL|Standard of Care|
214585906|NCT02874274|BEHAVIORAL|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
214585907|NCT00527592|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
214710519|NCT03939637|DRUG|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
214710520|NCT03939637|DRUG|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
214585908|NCT00527592|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
214585909|NCT05441241|DEVICE|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
214585910|NCT05441241|OTHER|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
214585911|NCT03801915|DRUG|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
214585912|NCT03801915|PROCEDURE|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
214585913|NCT06244446|OTHER|No intervention|No intervention. It is an observational study
214710521|NCT03939637|DRUG|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
214585914|NCT01736865|DRUG|Cholecalciferol|
214585915|NCT01736865|DRUG|Placebo|
214585916|NCT06062732|BEHAVIORAL|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
214585917|NCT06062732|BEHAVIORAL|Control|Services as usual
214585918|NCT05401760|PROCEDURE|Group A :combined phacoaspiration and angle surgery|"* Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture."
214585919|NCT05401760|PROCEDURE|Group B : phacoaspiration only|"* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture."
214585920|NCT04647812|BEHAVIORAL|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
214585921|NCT04647812|BEHAVIORAL|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
214585922|NCT04438577|DRUG|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
214585923|NCT02348762|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
214585924|NCT03056989|DRUG|SPX-101|Inhalation solution twice daily for 7 days.
214585925|NCT05143983|BEHAVIORAL|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
214710522|NCT05886348|DEVICE|Model-A Novel spectacle lens|Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months
214710523|NCT05886348|DEVICE|Model-B Novel spectacle lens|Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months
214710524|NCT05886348|DEVICE|Single vision spectacle lens|Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months
214710525|NCT06549218|DIAGNOSTIC_TEST|newborn genetic screening and whole genome sequencing|newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
214710526|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
214710527|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
214710528|NCT01631292|DIETARY_SUPPLEMENT|600 IU Vitamin D3|Once daily
214585926|NCT05143983|BEHAVIORAL|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
214585927|NCT02308020|DRUG|Abemaciclib|Administered orally
214585928|NCT02811185|DRUG|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
214585929|NCT02829788|OTHER|Non interventional|Peroperative data collection
214585930|NCT02641678|DEVICE|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
214585931|NCT02376374|OTHER|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
214585932|NCT01048580|DRUG|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
214585933|NCT01048580|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
214585934|NCT04061395|BIOLOGICAL|Guselkumab|See study arm description.
214585935|NCT01211288|DEVICE|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
214585936|NCT02475239|BEHAVIORAL|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
214585937|NCT02475239|BEHAVIORAL|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
214585938|NCT04524325|OTHER|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
214585939|NCT00690118|DRUG|pioglitazone|45 mg/day, 18 months
214585940|NCT00690118|DRUG|placebo|once daily, 18 months
214710529|NCT01631292|DIETARY_SUPPLEMENT|2000 IU Vitamin D3|Once daily
214585941|NCT01751074|DRUG|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
214585942|NCT01751074|DRUG|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
214585943|NCT04834856|DRUG|ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
214585944|NCT04217590|DRUG|Sodium Zirconium Cyclosilicate|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
214585945|NCT04217590|DRUG|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
214585946|NCT02866097|OTHER|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
214585947|NCT02866097|OTHER|Supportive supervision|Strengthening of supportive supervision using DHIS2
214710530|NCT01631292|DIETARY_SUPPLEMENT|4000 IU Vitamin D3|Once daily
214710531|NCT01353755|DRUG|Grass pollen specific immunotherapy|"* Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
214585948|NCT02866097|OTHER|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
214585949|NCT03667976|BEHAVIORAL|SATHI|see above
214585950|NCT02437461|DRUG|Triamcinolone hexacetonide|intraarticular knee injection
214585951|NCT01445587|DRUG|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
214585952|NCT01445587|DRUG|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
214585953|NCT01445587|DRUG|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
214710532|NCT01353755|DRUG|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
214710533|NCT01350713|DRUG|povidone iodine|one local application of 10% povidone iodine ointment
214585954|NCT01445587|DRUG|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
214585955|NCT04619251|DRUG|BI 1323495|BI 1323495
214585956|NCT04619251|DRUG|Placebo|Placebo
214585957|NCT04619251|DRUG|Itraconazole|Itraconazole
214585958|NCT02019303|PROCEDURE|FNA and Core biopsy|Both procedures will be performed on the same lymph node
214585959|NCT04262752|DEVICE|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
214585960|NCT02908919|PROCEDURE|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
214585961|NCT05709301|DRUG|Donepezil Hydrochloride|Donepezil 10mg once daily
214585962|NCT05709301|DRUG|Placebo|Matching placebo
214585963|NCT02730949|DIETARY_SUPPLEMENT|D-chiro-inositol|Treated group
214585964|NCT02730949|DIETARY_SUPPLEMENT|Folic Acid|Control group
214585965|NCT03347890|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
214585966|NCT00112424|PROCEDURE|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
214585967|NCT00112424|PROCEDURE|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
214585968|NCT02003573|DRUG|decitabine iv|decitabine iv fixed dose
214585969|NCT02003573|DRUG|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
214585970|NCT03324451|BEHAVIORAL|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
214585971|NCT03324451|BEHAVIORAL|Usual care|Regular patient education on insulin injection at the control arm hospital.
214585972|NCT00803751|DEVICE|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
214585973|NCT00803751|DEVICE|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
214585974|NCT05777096|DIAGNOSTIC_TEST|Standardised Nordic questionnaires|participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
214585975|NCT02531347|BEHAVIORAL|Telemedical home blood pressure measurements|
214585976|NCT02531347|BEHAVIORAL|Conventional blood pressure monitoring|
214585977|NCT02463110|DRUG|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
214585978|NCT02463110|DRUG|No treatment|
214585979|NCT02463110|DRUG|Placebo|
214585980|NCT02747199|DEVICE|SYNERGY stent|
214585981|NCT02747199|DEVICE|BVS ABSORB scaffold|
214585982|NCT02688907|DRUG|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
214585983|NCT04054518|DRUG|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
214585984|NCT03182452|OTHER|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
214585985|NCT00386269|DRUG|Codeine Phosphate Analgesia|
214585986|NCT03196895|BEHAVIORAL|Weight reduction training|6 one-hour sessions of conventional weight reduction training
214585987|NCT03196895|BEHAVIORAL|PPG training|Four 90-minute sessions of glycemic load and exercise training
214585988|NCT03196895|BEHAVIORAL|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
214585989|NCT03196895|BEHAVIORAL|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
214585990|NCT03782220|OTHER|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
214585991|NCT03782220|OTHER|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
214585992|NCT04310033|OTHER|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
214585993|NCT05379582|OTHER|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
214585994|NCT02746198|OTHER|probiotic dairy drink|
214585995|NCT02746198|OTHER|acidified milk|
214585996|NCT02858843|DRUG|lumacaftor-ivacaftor|Drug given for cystic fibrosis
214585997|NCT04757662|DRUG|Tadalafil|Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
214585998|NCT00188786|PROCEDURE|daily Cone Beam CT for imaging guidance for radiotherapy|
214585999|NCT05206097|DEVICE|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
214586000|NCT01535755|DEVICE|protocol|In this group, the patients were weaned as the protocol.
214586001|NCT01535755|OTHER|physician's orders|In this group, the patients were weaned as the clinicians' order.
214586002|NCT05110768|DRUG|Triferic AVNU|Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
214586003|NCT05110768|OTHER|Placebo|normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
214586004|NCT02433574|RADIATION|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
214586005|NCT03723252|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
214586006|NCT03723252|DRUG|Placebo|Participants will receive placebo po qd
214586007|NCT01242800|PROCEDURE|palliative surgery|Undergo standard palliative surgery
214586008|NCT01242800|PROCEDURE|therapeutic conventional surgery|Undergo early surgery
214586009|NCT01242800|RADIATION|palliative radiation therapy|Undergo standard palliative radiotherapy
214586010|NCT01242800|RADIATION|radiation therapy|Undergo radiotherapy
214586011|NCT00237289|DRUG|topiramate|
214586012|NCT01835418|DRUG|Amlodipine|crossover comparison of amlodipine vs lisinopril
214586013|NCT00953745|DRUG|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
214586014|NCT00953745|DRUG|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
214586015|NCT00953745|DRUG|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
214586016|NCT00953745|DRUG|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
214710534|NCT03733457|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
214586017|NCT02191410|PROCEDURE|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio \> 0.3, RR 60 breaths min-1 and a FGF of \< 2 L min-1, using a second identical ventilator with low compliant internal circuit
214586018|NCT02191410|PROCEDURE|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
214586019|NCT02165254|BEHAVIORAL|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
214586020|NCT02165254|BEHAVIORAL|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
214586021|NCT04824495|DIAGNOSTIC_TEST|Blood sample|Blood samples at different timepoints during SARS-CoV2 infection
214586022|NCT00127777|DRUG|Amantadine sulphate (in addition to standard treatment)|
214586023|NCT01534572|DIETARY_SUPPLEMENT|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
214586024|NCT01534572|DIETARY_SUPPLEMENT|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
214586025|NCT03527238|OTHER|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
214586026|NCT03527238|DRUG|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
214586027|NCT06341660|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
214586028|NCT01395888|DRUG|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
214586029|NCT01395888|DRUG|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
214586030|NCT00609375|DRUG|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
214586031|NCT00609375|DRUG|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
214586032|NCT03375567|PROCEDURE|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
214586033|NCT03375567|PROCEDURE|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
214586034|NCT02484053|DRUG|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
214586035|NCT02136082|BEHAVIORAL|Asha Support + Training|
214586036|NCT02136082|BEHAVIORAL|Asha Support + Food|
214586037|NCT02136082|BEHAVIORAL|Asha Support + Training + Food|
214586038|NCT02136082|BEHAVIORAL|Asha Support Only|
214586039|NCT03438500|DEVICE|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
214586040|NCT05267431|DRUG|Biological Drug|Different biological drugs
214586041|NCT03174587|BIOLOGICAL|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10\^6cells/kg Step 1 dose : 2.0x10\^6cells/kg Step 2 dose : 3.0x10\^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
214586042|NCT00982995|DRUG|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
214586043|NCT01027832|DRUG|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
214586044|NCT03900364|PROCEDURE|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
214586045|NCT05681689|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
214586046|NCT05681689|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.
214586047|NCT05681689|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
214586048|NCT05681689|COMBINATION_PRODUCT|Comparator Breath Test|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
214586049|NCT05681689|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patient's stool for H. pylori
214586050|NCT05369195|PROCEDURE|LAAC procedure with the use of transcatheter cerebral protection system|After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
214586051|NCT05369195|PROCEDURE|LAAC procedure without the use of transcatheter cerebral protection system|Only the aortography through radial access will be done before accessing the left atrium.
214586052|NCT06448832|DIAGNOSTIC_TEST|Ultrasound|An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
214586053|NCT02640157|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
214710535|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
214586054|NCT02640157|DRUG|Sofosbuvir|Tablet
214586055|NCT02640157|DRUG|Daclatasvir|Tablet
214586056|NCT06085001|DIAGNOSTIC_TEST|Lumella finger prick blood test|Finger prick blood test
214586057|NCT00465387|BEHAVIORAL|Falls, Fractures & Osteoporosis Risk Assessment & Management|
214586058|NCT00839657|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
214586059|NCT00839657|BEHAVIORAL|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
214586060|NCT00215735|DEVICE|debridement, dressing, and APC|ebridement, dressing, and APC
214586061|NCT04812275|PROCEDURE|Skin closure|Skin closure
214586062|NCT04138693|DEVICE|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
214586063|NCT04138693|DEVICE|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
214586064|NCT04138693|DEVICE|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
214586065|NCT03698812|COMBINATION_PRODUCT|Colonoscope|take off specimen
214586066|NCT00117923|DRUG|Resiquimod|
214586067|NCT02851225|OTHER|telemedicine transmission of biological results|telemedicine transmission of biological informations
214586068|NCT00271518|DRUG|growth hormone (somatropin)|dosing regimen is weight based.
214586069|NCT03858699|OTHER|Recording of electroencephalographic (EEG) data|Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
214586070|NCT01679405|DRUG|BIBW 2992|once daily per os
214586071|NCT02506517|DRUG|Afatinib|
214586072|NCT05253989|DEVICE|VR Intervention|VR Device that allows a patient to play games based on the EMG activity in the upper limb.
214586073|NCT05253989|DEVICE|FES|Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
214586074|NCT00271687|BEHAVIORAL|Exercise training|
214586075|NCT05790330|DRUG|Methotrexate|As per usual standard of care
214710536|NCT05204407|DIETARY_SUPPLEMENT|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
214710537|NCT05204407|DIETARY_SUPPLEMENT|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
214586076|NCT05790330|DRUG|Dupilumab|As per usual standard of care
214586077|NCT02142296|DRUG|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
214586078|NCT00126503|BIOLOGICAL|Bevacizumab|Given IV
214586079|NCT00126503|DRUG|Sorafenib Tosylate|Given PO
214586080|NCT00126503|OTHER|Pharmacological Study|Correlative studies
214586081|NCT00126503|OTHER|Laboratory Biomarker Analysis|Correlative studies
214586082|NCT00914901|DRUG|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
214586083|NCT03546764|DEVICE|Percutaneous catheter|tube inserted to drain hemothorax
214586084|NCT04289012|DIAGNOSTIC_TEST|Helicobacter Pylori screening by UBT|The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
214586085|NCT04966845|DIAGNOSTIC_TEST|measurement of concentration on exhaled Carbon Monoxide|exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]
214586086|NCT04677179|DRUG|LY3471851|administered SC
214586087|NCT04677179|DRUG|Placebo|administered SC
214586088|NCT00002674|BIOLOGICAL|filgrastim|
214586089|NCT00002674|DRUG|cytarabine|
214586090|NCT00002674|DRUG|etoposide|
214586091|NCT00002674|DRUG|hydroxyurea|
214586092|NCT00002674|DRUG|mitoxantrone hydrochloride|
214586093|NCT00002674|PROCEDURE|peripheral blood stem cell transplantation|
214634360|NCT04034160|OTHER|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
214586094|NCT04330352|BEHAVIORAL|"Mindfulness-based STOP touching your face practice"|1\. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
214586095|NCT00203762|BEHAVIORAL|Public sector antiretroviral treatment programmes|
214586096|NCT02575859|DRUG|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
214586097|NCT02575859|PROCEDURE|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
214586098|NCT02776384|OTHER|Observational study|
214586099|NCT00441662|DRUG|Sub-Tenon triamcinolone 40mg|
214586100|NCT05337085|DRUG|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
214586101|NCT05337085|DRUG|Midazolam|Midazolam
214586102|NCT03049033|OTHER|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
214586103|NCT03049033|OTHER|Occupational Therapy|Occupational Therapy uses traditional motor training.
214586104|NCT03049033|OTHER|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
214586105|NCT00355485|DEVICE|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
214586106|NCT02641496|BEHAVIORAL|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
214586107|NCT02641496|BEHAVIORAL|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
214586108|NCT03542773|DRUG|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
214586109|NCT02250092|DEVICE|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
214586110|NCT02250092|DEVICE|Placebo Comparator|
214586111|NCT01391039|DRUG|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
214586112|NCT01243632|DRUG|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
214586113|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
214586114|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
214586115|NCT05187468|DEVICE|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
214586116|NCT02571647|OTHER|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
214586117|NCT04949347|BIOLOGICAL|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
214586118|NCT03686332|DRUG|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
214586119|NCT03686332|DRUG|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
214586120|NCT05191992|OTHER|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
214586121|NCT03075410|DRUG|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
214586122|NCT03075410|DRUG|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
214586123|NCT03716115|DIETARY_SUPPLEMENT|Colostrum high protein powder (Neovite)|Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
214586124|NCT03716115|DRUG|N-Acetyl Glucosamine (GInNAC)|N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
214586125|NCT03716115|DRUG|Teduglutide|Teduglutide will be administered daily as subcutaneous injection
214586126|NCT03716115|DRUG|Budesonide|Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
214586127|NCT00531102|OTHER|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
214586128|NCT00531102|OTHER|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
214586129|NCT04406740|DEVICE|TwitchView EMG Unit|The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
214586130|NCT04406740|DEVICE|Novel QTOF Device|The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
214586131|NCT01274832|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
214586132|NCT06088147|DRUG|Methotrexate|A standard derma pen 12 pins with of 0,5 mm depth was used, dermapen as a tool of infusion of our treatments works in a few ways to target hair loss, firstly by breaking down the scar tissue that covers or compromises the hair follicles which are not growing, stimulating new hair growth and also by enhancing infusion of mesotherapy ingredients to increase hair follicle size and therefore hair volume ,here we will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2
214586133|NCT06088147|DRUG|Triamcinolone Acetonide|A standard derma pen 12 pins with of 0,5 mm depth was used, will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution
214586134|NCT05893628|OTHER|muscle length and muscle endurance assessment|Pectoralis Minor Length and muscle endurance evaluation
214586135|NCT01545154|DEVICE|Transperineal Ultrasound|
214586136|NCT02798965|BIOLOGICAL|serodiagnosis|
214586137|NCT03815786|DIETARY_SUPPLEMENT|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
214586138|NCT03815786|DIETARY_SUPPLEMENT|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
214586139|NCT00539773|DRUG|BCG, Interferon|Chemotherapy
214586140|NCT01321151|DRUG|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
214586141|NCT01321151|DRUG|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
214586142|NCT03166410|PROCEDURE|Cell injection|
214586143|NCT00807287|PROCEDURE|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
214586144|NCT00807287|PROCEDURE|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
214586145|NCT05744752|OTHER|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
214586146|NCT05744752|DIETARY_SUPPLEMENT|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
214586147|NCT05744752|DIETARY_SUPPLEMENT|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
214586148|NCT05744752|OTHER|Placebo|1ml NaCl 0.9% daily for 12 weeks
214586149|NCT05216887|BIOLOGICAL|Aducanumab|Administered as specified in the treatment arm.
214586150|NCT03824782|DEVICE|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
214586151|NCT00790751|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
214586152|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
214586153|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
214586154|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
214586155|NCT03716700|BIOLOGICAL|CUVITRU|CUVITRU
214586156|NCT06487611|BEHAVIORAL|A humanoid social robot|A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
214586157|NCT02973711|DRUG|Nilotinib|Nilotinib 300 mg BID
214586158|NCT02973711|DRUG|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
214586159|NCT02091453|BEHAVIORAL|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
214586160|NCT02091453|BEHAVIORAL|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
214586161|NCT04431167|BEHAVIORAL|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
214586162|NCT06239636|BIOLOGICAL|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
214586163|NCT02549014|DRUG|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
214586164|NCT02549014|DRUG|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
214586165|NCT03433079|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
214586166|NCT03433079|DIAGNOSTIC_TEST|Arterial lactate|Arterial lactate level was assessed in all patients.
214586167|NCT03433079|DIAGNOSTIC_TEST|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
214586168|NCT03433079|DIAGNOSTIC_TEST|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
214586169|NCT03433079|DIAGNOSTIC_TEST|Myoglobin|The level of myoglobin was assessed in all patients.
214586170|NCT02864030|DRUG|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
214586171|NCT01737554|OTHER|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
214586172|NCT06602635|DIAGNOSTIC_TEST|ECG and clinical score|The Hybrid Score (HS), detailed in previous literature involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.
214586173|NCT00642733|DRUG|erlotinib [Tarceva]|100mg po daily
214586174|NCT00642733|DRUG|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
214586175|NCT05027594|DRUG|NMS-03597812|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
214586176|NCT05027594|DRUG|NMS-03597812 + dexamethasone|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
214586177|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
214586178|NCT03496584|OTHER|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
214710538|NCT03814967|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
214710539|NCT06135415|DRUG|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
214586179|NCT03496584|OTHER|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
214586180|NCT06032832|OTHER|soy protein concentrate-meat analog|Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate
214586181|NCT06032832|OTHER|soy protein concentrate-meat analog_dephytinization|Baked dephytinized\_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate
214586182|NCT06032832|OTHER|pork meat|Meals made with minced pork meat labelled with 57Fe.
214586183|NCT02937233|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine|
214710540|NCT06135415|OTHER|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
214710541|NCT04946084|PROCEDURE|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
214586184|NCT02937233|OTHER|Placebo|
214586185|NCT03198182|DRUG|Placebo|Specified dose on specified days
214586186|NCT03198182|DRUG|BMS-986036|Specified dose on specified days
214586187|NCT05134441|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
214586188|NCT05134441|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
214586189|NCT00346268|DRUG|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
214586190|NCT00346268|DRUG|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
214586191|NCT01548079|DRUG|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
214710542|NCT04946084|OTHER|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
214586192|NCT02871856|DIAGNOSTIC_TEST|Low dose CT|low-dose screening CT of chest for lung cancer detection
214586193|NCT01149356|DRUG|Exemestane|Given orally
214710543|NCT04946084|OTHER|Blood Draw|Venipuncture
214710544|NCT01743170|OTHER|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
214710545|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
214710546|NCT05976243|DRUG|Remibrutinib|Remibrutinib treated groups and arms
214586194|NCT01149356|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
214586195|NCT01149356|DRUG|Goserelin Acetate|Given subcutaneously to premenopausal patients
214586196|NCT03368469|DEVICE|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
214586197|NCT05428761|OTHER|TP1|Participants will receive TP1 during one experimental visit.
214586198|NCT05428761|OTHER|TP2|Participants will receive TP2 during one experimental visit.
214586199|NCT05428761|OTHER|Placebo|Participants will receive placebo during one experimental visit.
214586200|NCT03407443|OTHER|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
214586201|NCT03407443|OTHER|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
214586202|NCT05569720|DRUG|ApTOLL|"ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
214586203|NCT05257031|DRUG|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
214586204|NCT04102306|OTHER|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
214586205|NCT05252052|OTHER|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
214586206|NCT00743275|BIOLOGICAL|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
214586207|NCT01966380|DEVICE|Leia|
214586208|NCT04191018|DIAGNOSTIC_TEST|Liver elastography|Liver stiffness measurement
214586209|NCT04191018|DIAGNOSTIC_TEST|Splenic elastography|Splenic stiffness measurement
214586210|NCT04191018|DIAGNOSTIC_TEST|Gastrointestinal endoscopy|Gastrointestinal endoscopy
214586211|NCT02882724|BEHAVIORAL|Exercise|8-week aquatic exercise training program
214710547|NCT05976243|OTHER|Placebo|Placebo treated groups and arms
214586212|NCT02882724|BEHAVIORAL|Control|Control group did not do the exercise training.
214586213|NCT00619762|DEVICE|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
214586214|NCT00575029|DRUG|megestrol acetate|600 mg by mouth daily
214586215|NCT04815967|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
214586216|NCT04815967|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
214586217|NCT04815967|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
214586218|NCT04815967|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
214586219|NCT04815967|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
214586220|NCT03195738|OTHER|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
214586221|NCT02609854|DEVICE|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
214586222|NCT02609854|DEVICE|Sham Device|Inactive ultrasound device
214586223|NCT03435523|PROCEDURE|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
214586224|NCT03730857|DRUG|Olanzapine|olanzapine tablet
214586225|NCT03730857|DRUG|risperidone|risperidone tablet
214586226|NCT03730857|DRUG|Paliperidone|paliperidone tablet
214710548|NCT01082367|DRUG|TOBI|TOBI (tobramycin inhaled solution)
214710549|NCT01082367|DRUG|Placebo|Placebo
214710550|NCT04965870|DRUG|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
214586227|NCT05003726|PROCEDURE|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
214586228|NCT05003726|PROCEDURE|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
214710551|NCT02016898|PROCEDURE|Placement of the sponge|
214710552|NCT02016898|DRUG|Mitomycin-C|
214710553|NCT03472794|OTHER|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
214710554|NCT00159718|DRUG|amlodipine|
214710555|NCT00159718|DRUG|atorvastatin|
214710556|NCT01817114|DEVICE|Auto Remote Ischemic Conditioning (AutoRIC) device|
214586229|NCT06225934|BEHAVIORAL|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
214586230|NCT01681056|BEHAVIORAL|Autosuggestion for 30 days|
214586231|NCT01588834|PROCEDURE|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
214586232|NCT02972463|DIETARY_SUPPLEMENT|Immunoglobulin Y|
214586233|NCT02972463|OTHER|Placebo|
214586234|NCT02133053|OTHER|Medical Device, drug-like|Ectoin Allergy Nasal Spray
214586235|NCT02133053|DRUG|Beclomethasone|Beclomethasone nasal spray
214586236|NCT03929744|DRUG|LY3502970|Administered orally.
214586237|NCT03929744|DRUG|Placebo|Administered orally.
214586238|NCT03929744|DRUG|Atorvastatin|Administered orally.
214586239|NCT03929744|DRUG|Simvastatin|Administered orally.
214586240|NCT03929744|DRUG|Midazolam|Administered orally.
214586241|NCT03938545|DRUG|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
214586242|NCT03938545|OTHER|Placebo (Administered via subcutaneous injection)|Placebo
214586243|NCT03200379|OTHER|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
214586244|NCT04605887|DRUG|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
214586245|NCT00195858|BEHAVIORAL|aerobic and resistance exercise|aerobic and resistance exercise
214586246|NCT01592500|DRUG|MOD-4023|Once weekly subcutaneous injection
214586247|NCT01592500|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin
214586248|NCT02157922|DRUG|alginate oligosaccharide|Inhalation
214586249|NCT00706199|PROCEDURE|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
214586250|NCT00567710|DRUG|BL - 1020|10 mg/day
214586251|NCT00567710|DRUG|BL - 1020|BL 1020 20-30 mg/day
214586252|NCT00567710|DRUG|Placebo|Capsules
214586253|NCT00567710|DRUG|Risperidone|Capsules
214710557|NCT03771443|DRUG|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
214586254|NCT02186223|DEVICE|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
214586255|NCT00004660|RADIATION|Radiotherapy|
214586256|NCT00004660|RADIATION|Sham treatment|
214586257|NCT00128076|PROCEDURE|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
214586258|NCT00128076|PROCEDURE|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
214586259|NCT02738736|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
214586260|NCT02203123|DEVICE|Ultrasound|
214586261|NCT02203123|DRUG|normal saline|
214586262|NCT01553097|OTHER|Neurocognitive impairment observation|None - observational
214586263|NCT02391272|DRUG|rhTPO|
214586264|NCT02550470|DEVICE|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
214586265|NCT02550470|DEVICE|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
214586266|NCT02550470|DRUG|Sevoflurane|
214586267|NCT03244085|DRUG|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
214586268|NCT05680064|BEHAVIORAL|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
214586269|NCT03013660|OTHER|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
214586270|NCT02071667|OTHER|Blood draw|
214586271|NCT05392153|OTHER|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
214586272|NCT05342220|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values \> 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
214586273|NCT05342220|PROCEDURE|Sham preconditioning|Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion
214586274|NCT02744326|BEHAVIORAL|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
214586275|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
214586276|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
214586277|NCT00285337|PROCEDURE|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
214586278|NCT01688674|DRUG|10% dextrose|
214586279|NCT02826330|OTHER|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
214586280|NCT04657419|OTHER|survey|"Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID"
214586281|NCT00261911|DRUG|sibutramine|
214586282|NCT05084443|DIETARY_SUPPLEMENT|Drink|Roselle and placebo drink for 6 months
214586283|NCT04788498|PROCEDURE|Laparoendoscpoic single site surgery LESS|• A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
214586284|NCT04788498|PROCEDURE|Conventional multiport laparoscopy|• It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
214586285|NCT04130529|BEHAVIORAL|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
214586286|NCT04130529|OTHER|Sleep lectures|Lectures on the topic of sleep.
214586287|NCT00336752|PROCEDURE|non operative treatment|non operative treatment -casting for 6 weeks
214586288|NCT00336752|PROCEDURE|operative treatment of ankle fractures|operative treatment of ankle fractures
214586289|NCT01902056|PROCEDURE|One layer allograft|The acellular dermal matrix was placed on the facial surface.
214586290|NCT01902056|PROCEDURE|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
214586291|NCT01111474|OTHER|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
214586292|NCT01111474|RADIATION|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
214586293|NCT01690312|DIETARY_SUPPLEMENT|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].
214586294|NCT01690312|DIETARY_SUPPLEMENT|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
214586295|NCT03575767|OTHER|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
214586296|NCT01016977|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
214586297|NCT01016977|DRUG|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
214586298|NCT03507374|DRUG|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
214586299|NCT03507374|DRUG|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
214586300|NCT02146651|DRUG|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
214586301|NCT02146651|DRUG|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
214586302|NCT02146651|DRUG|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
214586303|NCT02146651|DRUG|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
214586304|NCT05708404|BEHAVIORAL|Outpatient treatment of severe and enduring anorexia nervosa|A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm
214586305|NCT06026228|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit"
214586306|NCT06026228|OTHER|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
214586307|NCT04536753|PROCEDURE|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
214586308|NCT04439721|DRUG|γδT Cell infusion agent|γδT
214586309|NCT01782118|DIETARY_SUPPLEMENT|Lactobacillus GG|
214586310|NCT04450017|DIAGNOSTIC_TEST|The demographic, clinical, laboratory, and instrumental data|Measurement of the demographic, clinical data, laboratory data, and instrumental data
214586311|NCT01789151|DEVICE|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
214586312|NCT04743310|DRUG|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
214586313|NCT04743310|DEVICE|Canvas imaging system|imaging device attached to surgical microscope
214586314|NCT04743310|PROCEDURE|Surgical resection of tumor|Standard of care surgical resection of tumor
214586315|NCT06268223|OTHER|Chewing Exercise Training|All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.
214586316|NCT02698605|DEVICE|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
214586317|NCT01850732|OTHER|Ultrasound of aorta|
214586318|NCT05288153|DRUG|Metformin|Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
214586319|NCT05288153|DRUG|Folate|Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
214586320|NCT05867316|BEHAVIORAL|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
214586321|NCT04300998|BEHAVIORAL|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
214586322|NCT04300998|BEHAVIORAL|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
214586323|NCT04300998|BEHAVIORAL|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
214586324|NCT04300998|BEHAVIORAL|Cognition|Mini-Cognition test: CDT and 3-word recall
214586325|NCT04300998|BEHAVIORAL|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
214586326|NCT04300998|BEHAVIORAL|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
214586327|NCT04300998|BEHAVIORAL|Brief Test of Attention|assess selective auditory attention.
214586328|NCT04300998|BEHAVIORAL|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
214586329|NCT04300998|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency
214586330|NCT04300998|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
214586331|NCT04300998|OTHER|Blood draw|collection of blood tests
214586332|NCT01236365|DRUG|Atorvastatin|10 or 20 mg daily
214586333|NCT01236365|DRUG|Atorvastatin Placebo|10 or 20 mg daily
214586334|NCT06079125|PROCEDURE|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
214586335|NCT06079125|PROCEDURE|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
214586336|NCT04415723|OTHER|supportive care management programme|nurse-led management programme
214586337|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
214586338|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
214586339|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
214586340|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
214586341|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
214586342|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
214586343|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
214586344|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
214586345|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
214586346|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
214586347|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
214586348|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
214586349|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
214586350|NCT03489473|DIAGNOSTIC_TEST|18F-FES PET CT scan|PET CT scan with estrogen tracer
214586351|NCT00898898|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214586352|NCT04751708|PROCEDURE|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
214586353|NCT04751708|OTHER|best medical management|best medical management
214586354|NCT03060460|DIAGNOSTIC_TEST|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
214586355|NCT00166426|DRUG|Exisulind|
214586356|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
214586357|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
214586358|NCT01689337|DRUG|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
214586359|NCT01638234|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
214586360|NCT01638234|DIETARY_SUPPLEMENT|Placebo|starch pill
214586361|NCT05306405|DRUG|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
214586362|NCT05323201|BIOLOGICAL|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.
214586363|NCT05323201|DRUG|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)
214586364|NCT05323201|DRUG|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
214586365|NCT02742259|DEVICE|Blood Draw|Blood draws only - non-diagnostic, non-treatment
214586366|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
214586367|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
214586368|NCT02184650|OTHER|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
214586369|NCT04498455|DIETARY_SUPPLEMENT|Prebiotin|Fructo-oligosaccharide dietary supplement powder
214586370|NCT05378971|DRUG|Pomalidomide|Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
214586371|NCT00003382|BIOLOGICAL|filgrastim|
214586372|NCT00003382|DRUG|gemcitabine hydrochloride|
214586373|NCT00003382|DRUG|topotecan hydrochloride|
214586374|NCT00559702|DRUG|natalizumab|natalizumab
214586375|NCT00559702|OTHER|standard of care|standard of care as determined by the Investigator and Treating Neurologist
214586376|NCT05015933|PROCEDURE|Pump refill procedure at home|Implantable pump refill is performed at home
214586377|NCT02070003|BEHAVIORAL|Motivational Interviewing and Physician Guided Opioid Weaning|
214586378|NCT03972254|BEHAVIORAL|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
214586379|NCT00824161|DRUG|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
214586380|NCT02702726|OTHER|Congee and juice with coconut gel|25g coconut oleogel
214586381|NCT02702726|OTHER|Congee and juice with coconut oil|25g coconut oil
214586382|NCT02702726|OTHER|Congee and juice with sunflower gel|25g sunflower oleogel
214586383|NCT02702726|OTHER|Congee and juice with sunflower oil|25g sunflower oil
214586384|NCT01490671|DRUG|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
214586385|NCT01490671|DRUG|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
214586386|NCT00004468|DRUG|calcitriol|
214586387|NCT05757284|DIAGNOSTIC_TEST|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
214586388|NCT00411853|DRUG|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
214586389|NCT02344563|DRUG|Meropem|
214586390|NCT02344563|DRUG|Mepem|
214586391|NCT02843893|DEVICE|Measure the minimum intensity of a painful stimulation|With Neurolight device.
214586392|NCT03058835|DRUG|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
214586393|NCT04443101|OTHER|different types of intracular lens|different types of intracular lens
214586394|NCT02572882|DIETARY_SUPPLEMENT|p-inulin|12 week self-administered treatment phase
214586395|NCT00240045|DRUG|Midodrine, albumin, octreotide LAR|
214586396|NCT00240045|DRUG|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
214586397|NCT05333679|DEVICE|UTRA|Collect urine on intervention participants and screen for presence of TFV.
214586398|NCT05333679|BEHAVIORAL|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
214586399|NCT01218893|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
214586400|NCT01218893|BIOLOGICAL|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
214586401|NCT01218893|BIOLOGICAL|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
214586402|NCT01218893|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
214586403|NCT00580242|DRUG|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
214586404|NCT00580242|DRUG|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
214586405|NCT00580242|DRUG|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
214586406|NCT00580242|DRUG|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
214586407|NCT02354508|DRUG|Pasireotide LAR|Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
214586408|NCT03133052|BEHAVIORAL|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
214586409|NCT03133052|BEHAVIORAL|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
214586410|NCT04025112|DEVICE|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
214586411|NCT04025112|OTHER|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
214586412|NCT04298021|DRUG|AZD6738|"* In AZD6738+Durvalumab cohort~  \- AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"
214586413|NCT04298021|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
214586414|NCT04298021|DRUG|Olaparib|Olaparib 300 mg bid on D1-28 Every 4 weeks
214586415|NCT00139191|PROCEDURE|C-11 acetate PET scan|
214586416|NCT03536143|BIOLOGICAL|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
214586417|NCT03536143|BIOLOGICAL|Placebo gel|Placebo gel
214586418|NCT00050037|PROCEDURE|CBT|
214586419|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
214586420|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
214586421|NCT04754477|DEVICE|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
214586422|NCT04342793|DRUG|Placebo oral tablet|Placebo
214586423|NCT04342793|DRUG|ALS-L1023 1,200mg|ALS-L1023
214586424|NCT04342793|DRUG|ALS-L1023 1,800mg|ALS-L1023
214586425|NCT00146354|BEHAVIORAL|Hospitalists Results Manager|
214586426|NCT01347762|DRUG|Nabilone|nabilone titrated to 1 mg by mouth twice daily
214586427|NCT01347762|DRUG|Placebo|one placebo capsule by mouth twice daily
214586428|NCT01590017|DRUG|cisplatin|
214586429|NCT01590017|RADIATION|external beam radiation therapy|
214586430|NCT05049954|OTHER|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
214586431|NCT05049954|OTHER|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
214586432|NCT00000577|DRUG|Albuterol|
214586433|NCT00000577|DRUG|Colchicine|
214586434|NCT00000577|DRUG|Adrenal Cortex Hormones|
214586435|NCT00000577|DRUG|Adrenergic-Beta Agonists|
214586436|NCT00657670|DEVICE|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
214586437|NCT00657670|DEVICE|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
214586438|NCT03363763|DRUG|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
214586439|NCT03363763|DRUG|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
214586440|NCT03363763|DRUG|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
214586441|NCT01365949|GENETIC|microarray analysis|
214586442|NCT01365949|GENETIC|protein analysis|
214586443|NCT01365949|OTHER|immunohistochemistry staining method|
214586444|NCT01365949|OTHER|laboratory biomarker analysis|
214586445|NCT06069674|DIAGNOSTIC_TEST|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
214586446|NCT02255266|DRUG|liraglutide|No treatment given.
214586447|NCT02621320|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
214586448|NCT02621320|DIETARY_SUPPLEMENT|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
214586449|NCT03879837|DRUG|Fluticasone propionate pressurized metered dose inhaler|110 mcg per actuation
214586450|NCT03879837|DRUG|Flovent HFA pressurized metered dose inhaler|110 mcg per actuation
214586451|NCT03879837|DRUG|Placebo pressurized metered dose inhaler|no active content
214586452|NCT02927860|OTHER|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
214586453|NCT02878681|DRUG|Ranibizumab|0.5 mg intravitreal injections
214586454|NCT02878681|DRUG|Aflibercept|2 mg intravitreal injections
214586455|NCT00093808|BIOLOGICAL|trastuzumab|
214586456|NCT00093808|DRUG|capecitabine|
214586457|NCT00093808|DRUG|vinorelbine tartrate|
214586458|NCT00871780|DRUG|BG00002 (natalizumab)|
214586459|NCT03406260|DRUG|Lasmiditan|Administered orally.
214586460|NCT03406260|DRUG|Placebo|Administered orally.
214586461|NCT02931071|DRUG|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
214586462|NCT02931071|DRUG|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
214586463|NCT02799953|DEVICE|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
214586464|NCT02527343|DRUG|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
214586465|NCT02527343|DRUG|Placebo|Volanesorsen-matching placebo administered SC injection.
214586466|NCT06463925|OTHER|acneic participants group|Application of Effaclar Duo+M to the face and trunk twice daily (morning and evening) after washing with the cleansing gel.
214586467|NCT00407212|DRUG|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
214586468|NCT00701220|DRUG|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
214586469|NCT03965325|OTHER|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
214586470|NCT03235284|OTHER|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
214586471|NCT03235284|OTHER|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
214586472|NCT03235284|OTHER|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
214586473|NCT03428737|PROCEDURE|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
214586474|NCT03428737|PROCEDURE|Pressure support ventilation|use of a pressure support level identical during the night to the pressure support level at the end of the day.
214586475|NCT02640885|DEVICE|Foley's cather ballon|
214586476|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
214586477|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
214586478|NCT02769546|OTHER|Surveys|
214586479|NCT06082089|BEHAVIORAL|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
214586480|NCT00151957|DRUG|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
214586481|NCT04370977|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
214586482|NCT04370977|DRUG|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
214586483|NCT04294069|DRUG|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
214586484|NCT04294069|DRUG|Azithromycin Oral Product|1000mg azithromycin PO once at admission
214586485|NCT00521547|PROCEDURE|Electroacupuncture|
214586486|NCT00156884|DRUG|strontium-89|
214586487|NCT00156884|DRUG|cisplatin|
214586488|NCT00402038|DRUG|SC Methylnaltrexone|Dose 1
214586489|NCT00402038|DRUG|SC Placebo|
214586490|NCT03575754|DEVICE|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
214586491|NCT00440999|DRUG|Pyronaridine artesunate|
214586492|NCT00440999|DRUG|Chloroquine|
214586493|NCT05681858|DIAGNOSTIC_TEST|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
214586494|NCT01450254|DEVICE|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
214586495|NCT01450254|OTHER|Control|No intervention will be prescribed to the control group during participation in the study.
214586496|NCT04745026|DRUG|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
214586497|NCT04745026|DRUG|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
214586498|NCT02183051|DRUG|Meloxicam 7.5 mg|
214586499|NCT02183051|DRUG|Meloxicam 3.75 mg|
214586500|NCT02183051|DRUG|Meloxicam 1.875 mg|
214586501|NCT02183051|DRUG|Ibuprofen 200 mg|
214586502|NCT02183051|DRUG|Placebo|
214586503|NCT02183051|DRUG|Meloxicam 15 mg|
214586504|NCT02183051|DRUG|Ibuprofen 400 mg|
214586505|NCT06498544|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 nights at an altitude of 3600 m.
214586506|NCT00509678|DRUG|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
214586507|NCT01795664|RADIATION|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
214586508|NCT01795664|DRUG|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
214586509|NCT01795664|DRUG|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
214586510|NCT01795664|DRUG|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
214586511|NCT01795664|DRUG|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
214586512|NCT03259451|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
214586513|NCT04090255|PROCEDURE|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
214586514|NCT01205152|BIOLOGICAL|asfotase alfa|
214586515|NCT04924543|OTHER|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
214586516|NCT04924543|OTHER|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
214586517|NCT02667197|OTHER|Algorithm to determine overdose from opioid abuse|
214586518|NCT03256851|BEHAVIORAL|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week telephone call with an investigator."
214586519|NCT03256851|BEHAVIORAL|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
214586520|NCT04049799|OTHER|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
214586521|NCT04049799|OTHER|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
214586522|NCT04049799|BEHAVIORAL|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
214586523|NCT00249002|DRUG|ABI-007|
214586524|NCT02502123|OTHER|No Intervention|No intervention was administered in this study.
214586525|NCT05730062|DRUG|Oxycodone Hydrochloride|Oxycodone 10 mg IR
214586526|NCT05730062|DRUG|Placebo|placebo comparator
214586527|NCT01875549|DEVICE|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
214586528|NCT01875549|PROCEDURE|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
214586529|NCT03768583|OTHER|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
214586530|NCT03768583|OTHER|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
214586531|NCT03768583|OTHER|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
214586532|NCT03768583|OTHER|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
214586533|NCT04504604|DIAGNOSTIC_TEST|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
214586534|NCT02873091|PROCEDURE|Epidural analgesia|
214586535|NCT02873091|PROCEDURE|Continuous epidural infusion|
214586536|NCT02873091|PROCEDURE|Intermittent epidural bolus|
214586537|NCT02873091|DRUG|ropivacaine|
214586538|NCT02873091|DRUG|sufentanil|
214586539|NCT05126758|BIOLOGICAL|Deramiocel (CAP-1002)|Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
214586540|NCT05126758|BIOLOGICAL|Placebo|Placebo
214586541|NCT03869151|DIAGNOSTIC_TEST|CBC|lymphocyte and monocyte count
214586542|NCT05379660|DEVICE|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 \~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
214586543|NCT02208999|DEVICE|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
214586544|NCT03287531|OTHER|conventional therapy|Exercise therapeutic Ultrasound
214586545|NCT03287531|OTHER|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
214586546|NCT00319839|DRUG|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
214586547|NCT00319839|DRUG|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
214586548|NCT03765099|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
214586549|NCT02625727|OTHER|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
214586550|NCT02625727|OTHER|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
214586551|NCT02814201|BEHAVIORAL|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
214586552|NCT05712122|PROCEDURE|stellate block|stellate blockade effect on Ventricular arrytmia
214586553|NCT04647643|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
214710558|NCT04757922|PROCEDURE|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
214586554|NCT05293951|DEVICE|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
214586555|NCT05293951|DEVICE|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
214586556|NCT03017300|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
214586557|NCT03017300|DEVICE|PFLEX®|A device used to offer resisive to inspiratory muscle
214586558|NCT04694443|PROCEDURE|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
214586559|NCT04694443|OTHER|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
214710559|NCT01287546|DRUG|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
214710560|NCT01287546|DRUG|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
214710561|NCT01287546|DRUG|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
214586560|NCT02847247|DRUG|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
214586561|NCT03226951|DEVICE|Subthreshold 532nm laser|Subthershold 532nm laser
214586562|NCT05973435|OTHER|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
214586563|NCT01049295|DIETARY_SUPPLEMENT|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
214586564|NCT01049295|OTHER|corn oil pearls|corn oil pearls 3 times a day
214586565|NCT05279001|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
214586566|NCT02199704|OTHER|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study."
214586567|NCT00484731|PROCEDURE|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
214586568|NCT00484731|PROCEDURE|Infiltration with Bupivacaine|
214586569|NCT04894487|BEHAVIORAL|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
214586570|NCT01684332|OTHER|Strawberry Jam|
214586571|NCT04086654|DIAGNOSTIC_TEST|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
214586572|NCT06414694|PROCEDURE|Direct Oral Challenge|Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose
214586573|NCT02285465|DRUG|ASP3700|Oral
214586574|NCT02285465|DRUG|Placebo|Oral
214586575|NCT03553680|BEHAVIORAL|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
214586576|NCT04315051|DRUG|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
214586577|NCT04315051|OTHER|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
214586578|NCT02483585|DRUG|Erenumab|Administered once a month by subcutaneous injection
214586579|NCT02483585|DRUG|Placebo|Administered once a month by subcutaneous injection
214586580|NCT01485055|DRUG|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
214586581|NCT06336954|DRUG|Adibelimab|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)
214586582|NCT04891822|PROCEDURE|ERAS protocol|E: ERAS protocol C: control
214586583|NCT01653067|DRUG|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
214586584|NCT04175821|RADIATION|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
214586585|NCT04637854|PROCEDURE|Operating microscope|Third molar extraction using microscope
214586586|NCT04637854|PROCEDURE|Surgical loupes|Third molar extraction using loupes with co-axial illumination
214586587|NCT04637854|PROCEDURE|Naked eyes|Third molar extraction using naked eyes
214586588|NCT00912301|DRUG|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
214586589|NCT00912301|OTHER|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
214586590|NCT01324440|BIOLOGICAL|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
214586591|NCT01324440|BIOLOGICAL|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
214586592|NCT03404141|OTHER|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
214586593|NCT03404141|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
214586594|NCT04878653|DEVICE|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
214586595|NCT00903630|DRUG|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
214586596|NCT00903630|DRUG|liposomal doxorubicin|administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
214586597|NCT06147284|BEHAVIORAL|Preventive interventions|Parallel randomized controlled trial
214586598|NCT00454129|PROCEDURE|cholangiography via double-balloon enteroscopy|
214586599|NCT00454129|PROCEDURE|MR cholangiography|
214586600|NCT04076839|BEHAVIORAL|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
214586601|NCT04025580|BIOLOGICAL|Flucelvax|Seasonal influenza vaccine
214586602|NCT04025580|BIOLOGICAL|Fluvirin|Seasonal influenza vaccine
214586603|NCT04025580|BIOLOGICAL|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
214586604|NCT06352164|OTHER|Acupuncture treatment|The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
214586605|NCT00464607|DRUG|hMG-IBSA|
214586606|NCT00464607|PROCEDURE|Ovarian stimulation|
214586607|NCT02067117|DRUG|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
214586608|NCT00284986|DRUG|Prochymal®|Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
214586609|NCT02325557|DRUG|ADXS31-142|ADXS31-142 IV infusion
214586610|NCT02325557|DRUG|Pembrolizumab|Pembrolizumab IV infusion
214586611|NCT03154060|DEVICE|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
214586612|NCT03343457|BEHAVIORAL|Cognitive therapy|
214586613|NCT06347406|OTHER|Blood flow restriction combined with physiotherapy and education|Blood flow restriction Physiotherapy exercises Education
214586614|NCT00311285|DEVICE|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
214586615|NCT00138671|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
214586616|NCT00138671|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
214586617|NCT03609684|OTHER|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
214586618|NCT03609684|OTHER|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
214586619|NCT03609684|OTHER|Sedentary Group|People who are not interested in any sports and don't do any exercises
214586620|NCT02706912|BEHAVIORAL|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
214586621|NCT02534038|DRUG|AVP-786|d6-DM/Q
214586622|NCT02534038|DRUG|Placebo|matching placebo
214586623|NCT01488487|DRUG|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
214586624|NCT01488487|DRUG|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
214586625|NCT06367673|BIOLOGICAL|iPSC-NK cells|iPSC-NK cells
214586626|NCT04503343|OTHER|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
214586627|NCT01038063|DRUG|Artemether-lumefantrine combination|
214586628|NCT05898256|DRUG|Cadonilimab|10mg/kg administered intravenously (IV)
214586629|NCT05898256|DRUG|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
214586630|NCT05898256|DRUG|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
214586631|NCT03488641|DIAGNOSTIC_TEST|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
214586632|NCT00277706|PROCEDURE|Periodontal surgery|
214586633|NCT00277706|DRUG|FORTEO|parathyroid hormone; self-administration for 6 weeks
214586634|NCT00277706|DRUG|Placebo|placebo; self administration for 6 weeks
214586635|NCT00277706|DIETARY_SUPPLEMENT|Vitamin D and Calcium|PO, QD, for six weeks
214586636|NCT00264953|DRUG|Adriamycin|
214586637|NCT00264953|DRUG|Bleomycin|
214586638|NCT00264953|DRUG|Vinblastine|
214586639|NCT00264953|DRUG|DTIC|
214586640|NCT00264953|DRUG|Etoposide|
214586641|NCT00264953|DRUG|Procarbazine|
214586642|NCT00264953|DRUG|Prednisone|
214586643|NCT00264953|DRUG|Vincristine|
214586644|NCT00264953|RADIATION|radiation therapy|20 or 30Gy IF-RT
214586645|NCT03622554|OTHER|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
214586646|NCT03622554|OTHER|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
214586647|NCT02853357|OTHER|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
214710562|NCT01287546|DRUG|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
214586648|NCT02853357|OTHER|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
214586649|NCT02853357|OTHER|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
214586650|NCT03322787|DEVICE|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
214586651|NCT01849822|DEVICE|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
214586652|NCT01765465|DRUG|Rowachol|
214586653|NCT01765465|DRUG|Placebo|
214586654|NCT04129918|BEHAVIORAL|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
214586655|NCT03812497|BEHAVIORAL|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
214586656|NCT04417374|OTHER|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
214586657|NCT00669799|DRUG|gentamyacin|topical internasal
214586658|NCT00669799|DRUG|gentamyacin|intranasal
214586659|NCT00553956|BEHAVIORAL|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
214586660|NCT00144651|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
214586661|NCT06394440|COMBINATION_PRODUCT|Self-Adhesive Bulkfill Composite (Surefil One)|It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
214586662|NCT04065009|DRUG|Ropivacaine|Experimental drug will be administered intraperitoneally
214586663|NCT04065009|DRUG|Saline Solution|Placebo will be administered intraperitoneally
214586664|NCT00928746|DEVICE|Ipratropium bromide|
214586665|NCT02993484|DRUG|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
214586666|NCT02993484|BIOLOGICAL|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
214586667|NCT02993484|OTHER|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
214586668|NCT02993484|OTHER|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
214586669|NCT05736991|DIAGNOSTIC_TEST|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
214586670|NCT02711618|DEVICE|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
214586671|NCT04460677|BEHAVIORAL|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
214586672|NCT04460677|BEHAVIORAL|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
214586673|NCT05729880|DIAGNOSTIC_TEST|MRI, MRS|Scan of right calf and thigh
214586674|NCT05729880|DIAGNOSTIC_TEST|Ultrasound|Scan of right calf and thigh
214586675|NCT00523042|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
214586676|NCT00523042|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
214586677|NCT02475174|OTHER|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
214586678|NCT02475174|OTHER|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
214586679|NCT03559998|OTHER|lecture|"* Empathy (1 hour)~* Doctor- patient relationship (1, 5 hour)"
214586680|NCT03559998|OTHER|Simulation using Role play|"* serious illness announcement~* abuse demand management~* reticent patient management"
214586681|NCT03559998|OTHER|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
214586682|NCT03559998|OTHER|Simulation using Simulated patient|"* HIV announcement~* Refuse of antibiotic prescription"
214586683|NCT00779051|DRUG|Zolpidem 10mg tablets|
214586684|NCT03714204|BEHAVIORAL|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
214586685|NCT06475872|DRUG|Crecheck Tablet 2.5 mg|2 tablets orally once a day
214586686|NCT06475872|DRUG|Crestor Tablet 5 mg|1 tablet orally once a day
214586687|NCT00874341|OTHER|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
214586688|NCT04217928|PROCEDURE|Arthroscopic Debridement|Arthroscopic debridement will be performed under portal site local anaesthesia.
214586689|NCT04217928|PROCEDURE|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
214586690|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Newborns (Aged 1-7 Days)|Neonatal blood samples will be taken from healthy infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards.
214586691|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8 Days - 7 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
214586692|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8-18 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
214586693|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk Newborns (Aged 1-7 Days)|Blood samples will be taken from high-risk infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers.
214586694|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 Days- 7 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
214586695|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 - 18 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
214586696|NCT00001024|DRUG|Zidovudine|
214586697|NCT00001024|DRUG|Didanosine|
214586698|NCT05127538|DIAGNOSTIC_TEST|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
214586699|NCT05127538|DIAGNOSTIC_TEST|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
214586700|NCT03929315|BEHAVIORAL|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
214586701|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
214586702|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
214586703|NCT02825862|BEHAVIORAL|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
214586704|NCT02825862|BEHAVIORAL|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
214586705|NCT02955147|DRUG|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
214586706|NCT02955147|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
214586707|NCT06057194|DRUG|Letermovir 240 mg Oral Tablet|Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
214586708|NCT01744795|OTHER|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
214586709|NCT06441500|OTHER|Daily tooth brushing programme|Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
214586710|NCT01969370|BEHAVIORAL|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
214586711|NCT05597462|DRUG|Minocycline hydrochloride capsules|Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
214586712|NCT05597462|OTHER|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
214586713|NCT02341027|DEVICE|Jadelle|within 5 days of delivery and before discharge from hospital
214586714|NCT02341027|DEVICE|Jadelle|6-8 weeks (42-56 days) postpartum
214586715|NCT06437587|OTHER|Home-based rehabilitation appropriate technology (S-HRAT) training|The S-HRAT training instruction consists of two phases: in-hospital training and post-discharge remote home training. Based on the S-HRAT list, we select individualized home rehabilitation training exercises for the participants and conduct five offline training instruction sessions one week before discharge to ensure that the participants master the correct method for each exercise and clarify precautions. At discharge, participants will receive an S-HRAT brochures, which will include detailed text, pictures and video demonstrations of exercises, to visualize the rehabilitation instructions and make them easy to understand. Participants learn how to use the S-HRAT booklet and follow a daily training program to complete the prescribed content. They will be asked to record a video of their training and send it to the researcher via WeChat for monitoring purposes and feedback.
214586716|NCT04129216|DRUG|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
214586717|NCT04129216|DRUG|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
214586718|NCT04129216|DRUG|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
214586719|NCT04129216|DIAGNOSTIC_TEST|Blueprint|studies the genomics of the tumor and tumor behavior
214586720|NCT04129216|DIAGNOSTIC_TEST|Mammaprint|studies the genomics of the tumor
214586721|NCT05435768|DRUG|Denosumab|Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
214586722|NCT01477554|OTHER|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
214586723|NCT02835300|BEHAVIORAL|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
214586724|NCT02835300|BEHAVIORAL|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
214586725|NCT01181427|DRUG|ABT-267|See arm description
214586726|NCT01181427|DRUG|Placebo|See arms description
214586727|NCT01181427|PROCEDURE|Blood Sample Collection|See arm description
214710563|NCT05425095|OTHER|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
214586728|NCT01181427|DRUG|Cytochrome P450 inhibitor|See arm description
214586729|NCT01574378|DEVICE|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
214586730|NCT01574378|DEVICE|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
214586731|NCT02004353|DEVICE|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
214586732|NCT06119672|DRUG|Probiotic Blend Oral capsules|probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
214586733|NCT06119672|DRUG|Corticosteroids for Local Oral Treatment|topical clobetasol probionate in orabase application 4 times daily
214586734|NCT05142488|BIOLOGICAL|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
214710564|NCT05425095|OTHER|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
214586735|NCT01691768|DRUG|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
214710565|NCT03794713|DEVICE|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
214586736|NCT02581631|BIOLOGICAL|Nivolumab|
214586737|NCT02581631|DRUG|Brentuximab Vedotin|
214586738|NCT01690598|DRUG|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
214586739|NCT01690598|DRUG|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
214586740|NCT02830971|PROCEDURE|Doing Different ICU techniques and skills|
214586741|NCT04580576|PROCEDURE|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
214586742|NCT00898027|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214586743|NCT00819390|DRUG|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
214586744|NCT00819390|DRUG|Placebo|Taken orally, once daily for 12 weeks.
214586745|NCT00419510|BEHAVIORAL|Culturally Tailored Genetic Counseling|
214586746|NCT00912691|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
214586747|NCT01651442|BEHAVIORAL|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
214586748|NCT01651442|DRUG|Zolpidem|5mg or 10mg
214586749|NCT01651442|DRUG|Trazodone|50mg to 150mg
214586750|NCT01651442|BEHAVIORAL|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
214586751|NCT01759368|DEVICE|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
214710566|NCT04277832|DIAGNOSTIC_TEST|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
214586752|NCT06199674|DEVICE|photobiomodulation therapy|Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
214710567|NCT06380790|PROCEDURE|Laser-aided csf|Laser-aided csf before leveling and alignment
214710568|NCT06380790|OTHER|placebo laser-aided csf|placebo laser-aided csf before leveling and alignment
214710569|NCT01656811|DRUG|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
214710570|NCT01656811|DRUG|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
214586753|NCT06199674|OTHER|orthodontic fixed-appliance|All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
214586754|NCT01222026|DRUG|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
214586755|NCT01222026|DRUG|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
214586756|NCT01845909|OTHER|ECG and survey screening|
214586757|NCT03112564|OTHER|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
214586758|NCT03112564|DRUG|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
214710571|NCT01656811|DRUG|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
214710572|NCT01656811|DRUG|Placebo|Placebo 2 actuations QID
214710573|NCT01545024|DRUG|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
214710574|NCT02565498|RADIATION|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
214586759|NCT04768374|OTHER|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
214586760|NCT04768374|OTHER|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
214586761|NCT01191268|DRUG|Insulin Glargine|
214586762|NCT01191268|DRUG|LY2189265|
214586763|NCT01191268|DRUG|Insulin Lispro|
214586764|NCT05660460|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
214710575|NCT02565498|RADIATION|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
214586765|NCT00700973|BEHAVIORAL|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
214586766|NCT00700973|OTHER|Usual care|Substance use disorder usual care
214586767|NCT05054153|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214710576|NCT06300567|OTHER|data collection|"collection of data of generated by real world follow up"
214710577|NCT04503512|PROCEDURE|removal of fat pad|Removal removal of fat pad
214710578|NCT04503512|PROCEDURE|non removal of fat pad|non removal of fat pad
214586768|NCT05054153|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214710579|NCT05265962|DRUG|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
214710580|NCT05410197|DRUG|Envofolimab|400mg by subcutaneous injection every 3 weeks
214710581|NCT05410197|DRUG|Lenvatinib|8 mg orally once a day
214710582|NCT05410197|DRUG|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
214710583|NCT05410197|DRUG|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
214710584|NCT05873699|DRUG|Hyperpolarized 13-C-pyruvate|Given by Injection
214710585|NCT00226278|DRUG|ORG 34517|
214710586|NCT01665768|DRUG|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
214586769|NCT05054153|OTHER|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
214586770|NCT05692479|OTHER|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
214586771|NCT01177579|DIETARY_SUPPLEMENT|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
214586772|NCT02596165|DEVICE|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
214586773|NCT03772444|DIETARY_SUPPLEMENT|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
214586774|NCT03772444|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
214586775|NCT03772444|DIETARY_SUPPLEMENT|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
214586776|NCT00212160|PROCEDURE|omentectomy|RYGB with omentectomy
214586777|NCT00617474|DRUG|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
214586778|NCT00617474|DRUG|Placebo|placebo
214586779|NCT03139110|BEHAVIORAL|Presence of a mediator in the emergency departments|"The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
214586780|NCT01771120|OTHER|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
214586781|NCT02560714|DEVICE|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
214586782|NCT00002209|DRUG|CPI-1189|
214586783|NCT04690868|DRUG|AD-213-A|1 tablet administered before the breakfast during 5 days
214586784|NCT04690868|DRUG|AD-2131|1 tablet administered before the breakfast during 5 days
214586785|NCT02872883|PROCEDURE|Expectant management|
214586786|NCT02872883|PROCEDURE|Minimal Vaginal examinations (only when necessary)|
214586787|NCT02872883|PROCEDURE|Active management|
214586788|NCT02872883|PROCEDURE|Routine vaginal examinations|
214586789|NCT02521220|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
214586790|NCT02521220|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
214710587|NCT01665768|BIOLOGICAL|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
214710588|NCT01329341|OTHER|Service Dogs|Service dogs will be trained to help Veterans with PTSD
214586791|NCT01600573|DRUG|pazopanib in combination with weekly topotecan|"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
214586792|NCT00482560|DRUG|Sucrose solution 30%1 ml|
214586793|NCT00482560|BEHAVIORAL|Breastfeeding|
214586794|NCT02912676|DRUG|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
214586795|NCT01270971|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
214586796|NCT01270971|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
214586797|NCT00519311|BEHAVIORAL|Health Intervention Package|CHAP and Ask Diary
214586798|NCT02539953|DEVICE|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
214586799|NCT05566496|DIAGNOSTIC_TEST|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
214586800|NCT01958970|DRUG|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
214586801|NCT01958970|DRUG|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
214586802|NCT02457208|DRUG|Isoniazid (H)|
214586803|NCT02457208|DRUG|Rifampicin (R)|
214586804|NCT02457208|DRUG|Pyrazinamide (Z)|
214586805|NCT02457208|DRUG|Ethambutol (E)|
214586806|NCT03802942|DIETARY_SUPPLEMENT|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
214586807|NCT05008861|PROCEDURE|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
214586808|NCT05008861|DRUG|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
214586809|NCT05008861|DRUG|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
214586810|NCT00711893|DEVICE|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
214586811|NCT01789736|DRUG|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
214586812|NCT01789736|DRUG|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
214586813|NCT01789736|DRUG|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
214586814|NCT02722720|PROCEDURE|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
214710589|NCT03116373|OTHER|mandible fixation|Intubation device will be fixed on mandible
214710590|NCT03116373|OTHER|Maxilla fixation|Intubation device will be fixed on maxilla
214586815|NCT02722720|PROCEDURE|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
214586816|NCT02859363|GENETIC|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
214586817|NCT03188757|OTHER|hyperglycaemic clamp|2h hyperglyceamic clamp
214586818|NCT03759860|COMBINATION_PRODUCT|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
214586819|NCT02411357|BEHAVIORAL|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
214586820|NCT02411357|BEHAVIORAL|WHO contraception protocol|World Health Organization's contraception protocol
214586821|NCT02411357|BEHAVIORAL|Incentives|Financial incentives contingent on follow-up visit attendance
214586822|NCT03159533|BEHAVIORAL|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
214586823|NCT03159533|BEHAVIORAL|Wait List Control Group|4 education sessions beginning 6-12 months later.
214586824|NCT01588496|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214586825|NCT01588496|DRUG|Placebo|Administered by subcutaneous injection
214586826|NCT00549133|DRUG|Irbesartan|
214586827|NCT06115447|PROCEDURE|lung suturing with polyglactin|lung suturing with polyglactin
214586828|NCT06115447|PROCEDURE|ung suturing with polypropylene|ung suturing with polypropylene
214586829|NCT03126045|DEVICE|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
214586830|NCT03126045|DEVICE|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
214586831|NCT02791945|BEHAVIORAL|Medical Management Counseling|Brief alcohol counseling
214586832|NCT02791945|DRUG|N-acetylcysteine|Experimental supplement
214586833|NCT02791945|DRUG|Placebo|Placebo comparator
214586834|NCT03333837|BEHAVIORAL|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
214586835|NCT03333837|BEHAVIORAL|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
214586836|NCT03333837|BEHAVIORAL|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
214586837|NCT03333837|BEHAVIORAL|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
214586838|NCT03433053|BEHAVIORAL|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
214586839|NCT03433053|BEHAVIORAL|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
214586840|NCT03601533|DRUG|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
214586841|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
214586842|NCT01436188|PROCEDURE|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
214586843|NCT01436188|PROCEDURE|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
214586844|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
214586845|NCT01436188|PROCEDURE|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
214586846|NCT00705523|DRUG|varenicline|1.0 mg BID for 12 weeks
214586847|NCT00705523|DRUG|placebo|BID 12 weeks
214586848|NCT04654065|DRUG|IN-C004|One time dose of IN-C004 taken orally.
214586849|NCT04250441|DEVICE|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
214586850|NCT03178929|DRUG|S-Adenosyl Methionine|2000mg, po
214586851|NCT03311542|BIOLOGICAL|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
214586852|NCT05225350|BEHAVIORAL|Dietary Intervention|"See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months."
214586853|NCT00568945|DRUG|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
214586854|NCT03616925|BIOLOGICAL|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
214586855|NCT03616925|PROCEDURE|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
214586856|NCT03218241|BIOLOGICAL|PRT064445|Intravenous
214586857|NCT03218241|DRUG|Placebo|Intravenous to mimic PRT064445
214586858|NCT01013285|BIOLOGICAL|bevacizumab|
214586859|NCT01013285|DRUG|temozolomide|
214586860|NCT01013285|RADIATION|external beam radiation therapy|
214586861|NCT01911065|BIOLOGICAL|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
214586862|NCT01648335|DEVICE|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
214586863|NCT01648335|DEVICE|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
214586864|NCT06185647|OTHER|No intervention. Observational retrospective study|No intervention.
214586865|NCT02518126|OTHER|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
214586866|NCT03814772|PROCEDURE|Liver transplant|blood transfusion
214586867|NCT03402490|BEHAVIORAL|Motivational interviewing|
214586868|NCT01453829|PROCEDURE|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
214586869|NCT05003427|DRUG|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
214586870|NCT03358966|OTHER|Doubly-labelled water technique|
214586871|NCT03358966|OTHER|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
214586872|NCT03107234|OTHER|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
214586873|NCT03229070|OTHER|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
214586874|NCT03229070|OTHER|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
214586875|NCT03732560|OTHER|Non-Interventional|Non-Interventional
214586876|NCT01632670|OTHER|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
214586877|NCT05125484|OTHER|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
214586878|NCT05125484|OTHER|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
214586879|NCT01308944|DRUG|Propranolol|
214586880|NCT00417339|PROCEDURE|hemodialysis|individualised
214586881|NCT05860660|BEHAVIORAL|survey|questionnaires
214586882|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
214586883|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
214586884|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
214586885|NCT03952325|DRUG|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
214586886|NCT03952325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
214586887|NCT03952325|DRUG|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
214586888|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
214586889|NCT02926404|DEVICE|UNiD Rods|Spinal osteosynthesis
214586890|NCT06212401|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr
214586891|NCT06212401|DRUG|Ketofole|Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
214586892|NCT02244645|BEHAVIORAL|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
214586893|NCT02244645|BEHAVIORAL|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
214586894|NCT03107832|PROCEDURE|thoracic epidural anesthesia procedure|general anesthesia procedure
214586895|NCT02374671|DEVICE|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
214586896|NCT04913389|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
214586897|NCT04913389|DRUG|Placebo|Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
214586898|NCT00462332|DRUG|Fludarabine|Induction therapy
214586899|NCT00462332|DRUG|Campath|Induction therapy
214586900|NCT00462332|PROCEDURE|Transplant|Post-induction therapy
214586901|NCT00462332|DRUG|Campath|Post-induction therapy
214586902|NCT00462332|DRUG|Fludarabine|Induction therapy
214586903|NCT00462332|DRUG|Campath|Induction therapy
214586904|NCT00462332|DRUG|Campath|Post-induction therapy
214586905|NCT03866473|DEVICE|Retilux|670nm wavelength light
214586906|NCT03866473|DEVICE|Sham Light Device|Broad spectrum light device
214586907|NCT01261637|DRUG|Saline placebo|20ml saline
214586908|NCT01261637|DRUG|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
214586909|NCT01049932|DRUG|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
214586910|NCT02828878|BIOLOGICAL|Allogeneic MPBC transplantation from matched related donor|
214586911|NCT03110185|DEVICE|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
214586912|NCT03110185|DEVICE|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
214586913|NCT03110185|DEVICE|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
214586914|NCT02951364|DRUG|LDV/SOF|90/400 mg tablet administered orally once daily
214586915|NCT03143946|DIETARY_SUPPLEMENT|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
214586916|NCT03143946|OTHER|Diet advice|
214586917|NCT02845362|OTHER|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
214586918|NCT02825784|DIETARY_SUPPLEMENT|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
214586919|NCT01993173|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
214586920|NCT01993173|BIOLOGICAL|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
214586921|NCT01993173|BIOLOGICAL|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
214586922|NCT05737537|DIAGNOSTIC_TEST|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
214586923|NCT03865264|OTHER|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
214586924|NCT02822144|DRUG|Etomidate|
214586925|NCT02822144|DRUG|Succinylcholine|
214586926|NCT02822144|DRUG|Propofol|
214586927|NCT02822144|DRUG|Remifentanil|
214586928|NCT02822144|DRUG|Lidocaine|
214586929|NCT03510585|OTHER|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
214586930|NCT03510585|OTHER|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
214586931|NCT04967638|PROCEDURE|tumor resection and mandible reconstruction|The patients who underwent primary ablative tumor resection with segmental mandibulectomy and immediate VFF reconstruction were retrieved from the database
214586932|NCT05458700|OTHER|Collect information|Collect information from the patients to support the design of innovate clinical trials
214586933|NCT03997084|OTHER|phone interviews|phone interviews
214586934|NCT01911598|DRUG|5-FU|5-FU will be administered as per schedule specified in the respective arm.
214586935|NCT01911598|DRUG|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
214586936|NCT01911598|DRUG|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
214586937|NCT01911598|DRUG|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
214586938|NCT01911598|DRUG|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
214586939|NCT01417650|RADIATION|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
214586940|NCT01417650|RADIATION|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
214586941|NCT02072915|PROCEDURE|Suction|
214586942|NCT03443050|OTHER|Unstable|This group will train over unstable surfaces to enhance balance abilities
214586943|NCT03443050|OTHER|Stable|This group will train over stable surface to enhance balance abilities
214586944|NCT00600886|DRUG|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
214586945|NCT00600886|DRUG|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
214586946|NCT01843894|BIOLOGICAL|RU-101|Recombinant human serum albumin
214586947|NCT03047304|DIAGNOSTIC_TEST|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
214586948|NCT05984004|DRUG|0.9% NaCl isotonic saline solution|The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
214586949|NCT05984004|COMBINATION_PRODUCT|Bacillus subtilis DSM32444, inactivated|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
214586950|NCT02523599|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
214586951|NCT02523599|OTHER|Placebo|Plain collagen implant (vehicle)
214586952|NCT01427751|DRUG|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
214586953|NCT01427751|BIOLOGICAL|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
214586954|NCT02457169|BEHAVIORAL|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
214586955|NCT02457169|BEHAVIORAL|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
214586956|NCT03073954|OTHER|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
214586957|NCT03073954|BEHAVIORAL|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
214586958|NCT00510237|BEHAVIORAL|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
214586959|NCT04191473|PROCEDURE|EMR-P|After submucosal injection, we use ESD knife or the tip of the entrapment device to loop around the lesion, and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
214710591|NCT03621423|PROCEDURE|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
214586960|NCT04191473|PROCEDURE|CEMR|A liquid pad was formed by injecting 0.9% normal saline with meilan solution into submucosa,and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
214586961|NCT04309136|DRUG|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
214586962|NCT04309136|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
214586963|NCT04309136|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
214586964|NCT04780347|DRUG|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
214586965|NCT04780347|DRUG|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
214586966|NCT02112747|OTHER|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
214586967|NCT03981562|DRUG|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
214586968|NCT03981562|DRUG|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
214586969|NCT03618368|DEVICE|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
214710592|NCT05017714|DRUG|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
214586970|NCT03618368|DEVICE|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
214586971|NCT04014491|PROCEDURE|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
214586972|NCT04014491|PROCEDURE|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
214586973|NCT04014491|OTHER|No intervention|No intervention
214586974|NCT02764216|RADIATION|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
214586975|NCT01991054|DIETARY_SUPPLEMENT|vitamin D3|
214586976|NCT03044925|PROCEDURE|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
214586977|NCT03044925|PROCEDURE|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
214586978|NCT02817022|OTHER|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
214586979|NCT05330312|DEVICE|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
214586980|NCT05090280|DRUG|PF614 solution|PF614 solution is an oxycodone prodrug
214586981|NCT05090280|DRUG|Naltrexone Hydrochloride|Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
214710593|NCT03177265|BEHAVIORAL|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
214586982|NCT05090280|DRUG|Nafamostat Mesylate|Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
214586983|NCT03912376|DIAGNOSTIC_TEST|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
214586984|NCT06513065|DRUG|Mitomycin c|"Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy."
214586985|NCT03319849|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
214586986|NCT03319849|PROCEDURE|Sham|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
214586987|NCT01195285|PROCEDURE|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
214586988|NCT01195285|PROCEDURE|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
214586989|NCT03543800|DEVICE|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
214586990|NCT03543800|DEVICE|PRP kit|PRP kit legally marketed in Canada for PRP
214710594|NCT03177265|BEHAVIORAL|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
214710595|NCT03177265|BEHAVIORAL|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
214586991|NCT02904031|DRUG|5-fluorouracil|
214586992|NCT02904031|DRUG|oxaliplatin|
214586993|NCT02904031|DRUG|l-leucovorin|
214586994|NCT02904031|DRUG|panitumumab|
214586995|NCT05366426|OTHER|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
214586996|NCT05366426|OTHER|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
214586997|NCT05366426|OTHER|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
214586998|NCT03455608|BEHAVIORAL|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
214586999|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
214587000|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
214587001|NCT05353335|OTHER|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
214587002|NCT05353335|OTHER|Current regimen|The participants will begin on their current regimen.
214587003|NCT05433181|DRUG|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
214587004|NCT05433181|OTHER|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
214710596|NCT03177265|BEHAVIORAL|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
214710597|NCT03017846|DRUG|Cantharidin|Application of topical cantharidin
214710598|NCT03539913|BIOLOGICAL|Probiotic : Saccharomyces boulardii|Treatment for 5 days
214587005|NCT05611021|BEHAVIORAL|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
214587006|NCT05664893|DRUG|Ribociclib Oral Tablet|"600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance"
214587007|NCT05550818|OTHER|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
214587008|NCT05550818|OTHER|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
214710599|NCT03539913|BIOLOGICAL|Probiotic : Bacillus clausii|Treatment for 5 days
214710600|NCT01524237|DRUG|LY2979165|Capsules administered orally
214587009|NCT06457009|COMBINATION_PRODUCT|Multi-component Intervention Package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
214587010|NCT04448964|DRUG|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
214710601|NCT01524237|DRUG|LY2140023|Tablets administered orally
214710602|NCT01524237|OTHER|Placebo|Administered orally
214587011|NCT05189769|BEHAVIORAL|CP no REACT|Coping Power no REACT
214587012|NCT05189769|BEHAVIORAL|CP+/No REACT|CP+ and no REACT
214587013|NCT05189769|BEHAVIORAL|CP and REACT|Coping Power traditional and REACT
214587014|NCT05189769|BEHAVIORAL|CP+ and REACT|CP+ and REACT
214587015|NCT05562895|DEVICE|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
214710603|NCT01524237|OTHER|Ketamine|Administered intravenously (IV)
214710604|NCT01959399|DRUG|ASP015K|oral tablet
214710605|NCT01959399|DRUG|Rosuvastatin|oral tablet
214710606|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
214587016|NCT04963439|DRUG|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
214587017|NCT05549752|DRUG|Flecainide Injectable Solution|Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
214587018|NCT05549752|DRUG|Amiodarone Injectable Solution|Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
214587019|NCT05041036|DRUG|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
214587020|NCT00183365|BEHAVIORAL|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
214587021|NCT00183365|BEHAVIORAL|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
214587022|NCT04061447|DRUG|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
214587023|NCT04061447|DRUG|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
214587024|NCT01060540|GENETIC|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
214587025|NCT01060540|BEHAVIORAL|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
214587026|NCT01060540|BEHAVIORAL|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
214587027|NCT04288765|DRUG|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
214587028|NCT04502628|PROCEDURE|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
214587029|NCT03996499|DIAGNOSTIC_TEST|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
214587030|NCT02502097|DRUG|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
214587031|NCT02502097|OTHER|Placebo|Matching placebo to gefapixant, tablet administered by mouth
214587032|NCT01201317|DRUG|AZD2423|20 mg tablet
214587033|NCT01201317|DRUG|AZD2423|150 mg tablet
214587034|NCT01201317|DRUG|Placebo|Placebo
214587035|NCT05384444|OTHER|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
214587036|NCT02293148|DRUG|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
214587037|NCT02293148|DRUG|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
214587038|NCT02293148|DRUG|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
214587039|NCT02293148|DRUG|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
214587040|NCT02293148|DRUG|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
214587041|NCT04028882|OTHER|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
214587042|NCT00252733|DRUG|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
214587043|NCT04238065|DEVICE|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
214587044|NCT04238065|DEVICE|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
214587045|NCT04238065|DEVICE|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
214587046|NCT05283486|DRUG|MYMD-1 600MG|Cohort 1: 600mg drug
214587047|NCT05283486|DRUG|MYMD-1 750mg|Cohort 2: 750mg drug
214587048|NCT05283486|DRUG|MYMD-1 900mg|Cohort 3: 900mg drug
214587049|NCT05283486|DRUG|MYMD-1 1050mg|Cohort 4: 1050mg drug
214587050|NCT05283486|DRUG|placebo 600mg|Cohort 1: 600mg placebo
214587051|NCT05283486|DRUG|placebo 750mg|Cohort 2: 750mg placebo
214587052|NCT05283486|DRUG|placebo 900mg|Cohort 3: 900mg placebo
214587053|NCT05283486|DRUG|placebo 1050mg|Cohort 4: 1050mg placebo
214587054|NCT02872831|DEVICE|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
214587055|NCT02872831|DEVICE|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
214587056|NCT01350336|DEVICE|Alair System|Treatment of airways with the Alair System
214587057|NCT01874301|OTHER|High quantity probiotic|The intervention type is food product
214587058|NCT01874301|OTHER|Low quantity probiotic|The intervention type is food product
214587059|NCT01874301|OTHER|placebo|
214587060|NCT03742284|DEVICE|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
214587061|NCT00666523|DIETARY_SUPPLEMENT|phytalgic|3/day
214587062|NCT00666523|DIETARY_SUPPLEMENT|placebo|3/Day
214587063|NCT04265313|OTHER|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
214587064|NCT01491672|DRUG|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
214587065|NCT03390920|OTHER|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
214587066|NCT02835326|BEHAVIORAL|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
214587067|NCT02835326|BEHAVIORAL|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
214587068|NCT06108882|OTHER|Experimental: Manual Ischemic Compression with Strain Counter Strain technique|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
214587069|NCT06108882|OTHER|Active Comparator: Manual Ischemic Compression|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
214710607|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
214587070|NCT03775070|DRUG|Simvastatin|"* Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
214710608|NCT01079286|DRUG|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
214587071|NCT04121195|DRUG|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
214587072|NCT03967639|PROCEDURE|Elective cardiac surgery|Elective cardiac surgery
214587073|NCT04292678|BEHAVIORAL|Progressive muscle relaxation|The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
214587074|NCT04292678|OTHER|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
214587075|NCT00003600|BIOLOGICAL|epoetin alfa|
214587076|NCT00003600|OTHER|placebo|
214587077|NCT05405712|BEHAVIORAL|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
214587078|NCT05769127|OTHER|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
214587079|NCT06176677|DEVICE|Videolaryngoscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
214587080|NCT06176677|DEVICE|Boroscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
214587081|NCT05374161|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.
214587082|NCT05374161|OTHER|Waitlist Control Group|Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
214587083|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
214587084|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
214587085|NCT03933930|OTHER|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct\>30%. If Hct \>30%, dopamine infusion starts.
214587086|NCT03933930|OTHER|Goal-directed therapy|If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
214587087|NCT02066428|BIOLOGICAL|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
214587088|NCT02066428|BIOLOGICAL|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
214587089|NCT03279263|DRUG|MLR-1023|MLR-1023 Tablets
214587090|NCT03279263|OTHER|Placebo|Matching Placebo Tablets
214587091|NCT00491543|DRUG|ALT-2074|
214587092|NCT02795429|DRUG|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
214587093|NCT02795429|DRUG|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
214587094|NCT01669304|DRUG|Verapamil|
214587095|NCT01669304|DRUG|Sertraline|
214587096|NCT06115551|COMBINATION_PRODUCT|Fasting Mimicking Diet|FMD is a 5-day low calorie fasting-mimicking diet.
214587097|NCT00473941|BEHAVIORAL|Expressive writing|Behavioral intervention using writing about cancer to improve quality of life outcomes
214587098|NCT02783664|OTHER|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
214710609|NCT04616404|DIETARY_SUPPLEMENT|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
214710610|NCT04616404|OTHER|Placebo|Tablets with no active ingredient
214587099|NCT03310268|OTHER|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214587100|NCT03310268|OTHER|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214587101|NCT03310268|OTHER|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214587102|NCT02564354|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
214587103|NCT00679237|BEHAVIORAL|smoking cessation|NRT and varenicline
214587104|NCT00679237|DRUG|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
214587105|NCT00679237|DRUG|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
214587106|NCT00679237|BEHAVIORAL|training|daily walking
214587107|NCT00679237|BIOLOGICAL|influenza vaccine|vaccine (FLuarix, Influvac etc)
214587108|NCT00679237|DRUG|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
214587109|NCT00679237|BEHAVIORAL|weight reduction|diet tips
214587110|NCT04417946|BEHAVIORAL|PrEP messages|The peer leaders and the study staff will post PrEP related health messages
214587111|NCT04417946|BEHAVIORAL|Heath messages|The peer leaders and study staff will post general health messages that are not related to sexual health
214587112|NCT00923533|DRUG|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
214587113|NCT00923533|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
214587114|NCT04429997|PROCEDURE|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
214587115|NCT04429997|PROCEDURE|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
214587116|NCT06071273|OTHER|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
214587117|NCT06071273|OTHER|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
214587118|NCT06300385|DEVICE|Electromyostimulation|Electromyostimulation (EMS), a low-frequency current, will be used for electrical stimulation of the wrist flexor muscle group. Stimulation frequency will be applied as 25 Hertz. Care will be taken to ensure that the current intensity does not cause pain in the patient. The size of the EMS electrodes is 2 cm2 and they will be placed in the form of 4 electrodes on the wrist flexor muscles (inner wrist area) with a distance of 1 cm between them. Each strengthening session will be 15 minutes for 6 weeks, 3 days a week, for a total of 18 sessions. EMS application will be carried out together with strengthening exercises. Laica MD6078 branded device belonging to the researchers will be used.
214587119|NCT06300385|OTHER|Strengthening exercises|All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.
214587120|NCT05273853|PROCEDURE|Partial Adenoidectomy|Partial removal of adenoid
214587121|NCT00706433|DRUG|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
214587122|NCT00706433|OTHER|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
214587123|NCT05639400|DEVICE|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
214587124|NCT05639400|DEVICE|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
214587125|NCT06323577|PROCEDURE|Restricted kinematic alignment|TKA using restricted kinematic alignment under robotic assisted surgery (MAKO).
214587126|NCT06323577|PROCEDURE|Mechanical alignment|TKA using mechanical alignment under robotic assisted surgery (MAKO).
214710611|NCT03384628|DEVICE|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
214710612|NCT03384628|DEVICE|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
214710613|NCT03384628|DEVICE|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
214710614|NCT02780479|DRUG|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
214710615|NCT02780479|DRUG|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
214710616|NCT02465346|DEVICE|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
214710617|NCT02465346|DEVICE|Control stroke management|Conventional stroke management
214587127|NCT06355193|DRUG|Langenlianqiao|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
214587128|NCT06355193|DRUG|LianhuaQingWen|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
214587129|NCT06355193|OTHER|placebo control group|placebo control group
214587130|NCT05603130|OTHER|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
214710618|NCT02151682|DRUG|Tapentadol prolonged release|
214587131|NCT00199940|DRUG|Ziprasidone|
214587132|NCT02125708|DEVICE|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
214710619|NCT02151682|DRUG|Morphine prolonged release|
214587133|NCT01647269|PROCEDURE|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
214710620|NCT00518401|BIOLOGICAL|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
214710621|NCT05118542|DRUG|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
214710622|NCT05118542|DRUG|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
214710623|NCT02316626|DRUG|Subcutaneous progesterone|25 mg daily for 14 days
214710624|NCT02316626|DRUG|Vaginal progesterone|90 mg daily for 14 days
214587134|NCT04575506|OTHER|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
214587135|NCT05023421|OTHER|no intervention|no intervention
214587136|NCT04491669|DIAGNOSTIC_TEST|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~* Stage1 in which GFR\>90 mil/min but evidence of kidney damage.~* Stage 2 GFR 60-89 mil/min.~* Stage 3 GFR 30-95 mil/min.~* Stage 4 GFR 15-29 mil/min.~* Stage 5 GFR\<15 mil/min."
214587137|NCT05314790|OTHER|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
214587138|NCT02802826|BEHAVIORAL|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
214587139|NCT04845243|BEHAVIORAL|Emotionen Verstehen und Ausdrücken (E.V.A.)|The online training is focused on the strengthening of socioemotional competences and consists of different training tasks (up to 3 million) presented to the participant as mini games. These training tasks are specifically designed according to empirical findings to match the socio-emotional recognition needs of people with ASD. During these games, an adapted Elo-Algorithm allows to automatically evaluate the participants' performance and adapts the difficulty levels throughout the users' progress in the training.
214587140|NCT03183700|DEVICE|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
214710625|NCT04298190|BEHAVIORAL|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
214587141|NCT03183700|OTHER|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
214587142|NCT00129597|DRUG|ketalar|
214587143|NCT05467397|DRUG|[11C]acetate|Positron Emission Tomography (PET)
214587144|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
214587145|NCT05041101|DRUG|Eribulin Mesylate|Given IV
214587146|NCT05041101|DRUG|Grapiprant|Given PO
214587147|NCT04426851|DRUG|BI 1358894|Tablet
214587148|NCT04426851|DRUG|BI 1358894 (C-14) intravenous solution|BI 1358894 mixed with \[carbon labelled (C-14)\] BI 1358894
214587149|NCT04426851|DRUG|BI 1358894|Oral suspension
214587150|NCT05726630|DRUG|Divozilimab|anti CD20 monoclonal antibody
214587151|NCT05726630|DRUG|Placebo|Placebo
214587152|NCT02802254|BEHAVIORAL|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
214587153|NCT02802254|DEVICE|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
214587154|NCT03168607|DRUG|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
214587155|NCT04677166|DEVICE|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
214587156|NCT04677166|DEVICE|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
214587157|NCT00569556|OTHER|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
214587158|NCT03775889|BEHAVIORAL|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
214587159|NCT00632437|PROCEDURE|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
214587160|NCT00986674|BIOLOGICAL|cixutumumab|Given IV
214587161|NCT00986674|DRUG|carboplatin|Given IV
214587162|NCT00986674|DRUG|paclitaxel|Given IV
214587163|NCT00986674|BIOLOGICAL|cetuximab|Given IV
214587164|NCT02128542|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214587165|NCT02128542|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214587166|NCT02709213|DIAGNOSTIC_TEST|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
214587167|NCT04754308|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
214587168|NCT03085615|OTHER|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
214587169|NCT04528927|DRUG|HCQ|600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
214587170|NCT04528927|DRUG|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
214587171|NCT04528927|DRUG|Doxycycline|200 mg per day for 10 days
214587172|NCT04528927|DIETARY_SUPPLEMENT|Zinc|220 mg per day for 10 days
214587173|NCT02570932|BIOLOGICAL|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
214587174|NCT02825030|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation-SR15-78\_Y73-167).
214587175|NCT05629403|OTHER|observe|no intervention
214587176|NCT05109754|DEVICE|BiPAP EFL|Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
214587177|NCT05159869|BEHAVIORAL|User-Led Meaningful Activity Plan|The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
214587178|NCT00833131|RADIATION|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
214587179|NCT00833131|RADIATION|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
214587180|NCT05025046|DIAGNOSTIC_TEST|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
214587181|NCT01358487|BEHAVIORAL|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
214710626|NCT04298190|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
214587182|NCT01358487|BEHAVIORAL|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
214587183|NCT00671944|OTHER|Low protein diet|Low protein diet for 6.5 weeks
214587184|NCT00669526|BEHAVIORAL|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
214587185|NCT00669526|BEHAVIORAL|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
214587186|NCT00006165|BEHAVIORAL|'Ohana (Family) Support Lifestyle Intervention|
214587187|NCT03465098|OTHER|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
214587188|NCT06156618|DIETARY_SUPPLEMENT|Nitrate|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
214587189|NCT01853137|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
214587190|NCT00647725|PROCEDURE|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
214587191|NCT00647725|PROCEDURE|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
214587192|NCT05812287|OTHER|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
214587193|NCT04248231|OTHER|CINSARC signature|CINSARC molecular signature analysis
214587194|NCT00257062|DRUG|Levofloxacin|
214587195|NCT04822831|BEHAVIORAL|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
214587196|NCT04822831|BEHAVIORAL|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
214587197|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214587198|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214587199|NCT00825916|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214587200|NCT00638781|DRUG|Desmoteplase|Desmoteplase 62.5 µg/kg BW
214710627|NCT05121831|DRUG|DGX-001Dose 1|Dose level 1 of DGX-001
214710628|NCT05121831|DRUG|DGX-001 Dose 2|Dose level 2 of DGX-001
214587201|NCT00638781|DRUG|Desmoteplase|Desmoteplase 90 µg/kg BW
214587202|NCT00638781|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW
214587203|NCT00638781|DRUG|Placebo|Placebo
214587204|NCT04831294|DRUG|Cannabidiol|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
214587205|NCT04831294|DRUG|Placebo|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
214587206|NCT03475615|DRUG|Oxaliplatin|130mg/m2, d1, q3w
214587207|NCT03475615|DRUG|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
214587208|NCT03475615|DRUG|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
214710629|NCT05121831|DRUG|DGX-001 Dose 3|Dose level 3 of DGX-001
214710630|NCT05121831|DRUG|DGX-001 Dose 4|Dose level 4 of DGX-001
214710631|NCT05121831|DRUG|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
214587209|NCT03966807|BEHAVIORAL|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
214587210|NCT03966807|BEHAVIORAL|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
214587211|NCT02671370|OTHER|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
214587212|NCT03081754|RADIATION|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
214587213|NCT01532895|DRUG|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
214587214|NCT01414140|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
214587215|NCT05960617|DRUG|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count \> 1.0 × 10\^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
214587216|NCT05782023|BEHAVIORAL|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
214587217|NCT03832413|DIAGNOSTIC_TEST|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
214587218|NCT04866498|DRUG|Infusion Intravenous|
214587219|NCT05147961|OTHER|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
214587220|NCT05147961|OTHER|Standard care|Conventional recommendations on diet and exercise
214587221|NCT01821287|OTHER|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
214587222|NCT01778023|DRUG|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
214587223|NCT01990560|DRUG|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
214587224|NCT04733521|DRUG|SC-43|SC-43 oral, every day of 21-day cycle
214587225|NCT04733521|DRUG|Cisplatin|cisplatin 75mg/m2 on day 1 of 21-day cycle
214587226|NCT00140309|DRUG|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
214587227|NCT03875846|DIAGNOSTIC_TEST|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
214587228|NCT03875846|DIAGNOSTIC_TEST|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
214710632|NCT01306032|DRUG|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
214710633|NCT01306032|DRUG|Cyclophosphamide|
214587229|NCT01765166|BEHAVIORAL|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
214587230|NCT06063811|OTHER|Ablation|VT ablation
214587231|NCT02979392|DRUG|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
214587232|NCT01098097|BIOLOGICAL|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
214587233|NCT01098097|DRUG|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
214587234|NCT04141969|DIETARY_SUPPLEMENT|RLP|RLP nutraceutical
214587235|NCT04141969|OTHER|Placebo|Inert brown powder
214587236|NCT05748496|BEHAVIORAL|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
214587237|NCT01411215|DRUG|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
214587238|NCT00848926|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
214587239|NCT04333927|DRUG|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
214587240|NCT04333927|OTHER|Observation|Patients in observation group will not receive any anti-cancer therapy.
214587241|NCT04333927|PROCEDURE|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
214587242|NCT04333927|RADIATION|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
214587243|NCT05130853|BEHAVIORAL|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
214587244|NCT05130853|OTHER|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
214587245|NCT01224795|DRUG|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
214587246|NCT01224795|DRUG|Placebo Comparator|Placebo Peramivir, administered intravenously.
214587247|NCT01553123|DRUG|Ulipristal Acetate|once daily, oral
214587248|NCT01553123|DRUG|Iron|once daily, dried ferrous sulfate
214587249|NCT04621591|DEVICE|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
214587250|NCT04525872|OTHER|Full parenteral nutrition light protection of the bag, tubing and lipids|Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
214587251|NCT06254768|DEVICE|Continuous glucose monitor|its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
214587252|NCT03080831|DRUG|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
214587253|NCT03080831|DRUG|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
214587254|NCT03999320|OTHER|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
214587255|NCT03999320|OTHER|usual care|usual care
214587256|NCT00945308|DRUG|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
214587257|NCT00945308|DRUG|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
214587258|NCT04485182|OTHER|Underwater jet massage (Tangentor)|"Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks."
214587259|NCT04193488|BEHAVIORAL|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
214587260|NCT04193488|BEHAVIORAL|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
214587261|NCT04193488|BEHAVIORAL|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
214587262|NCT05127629|PROCEDURE|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
214587263|NCT05127629|PROCEDURE|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
214587264|NCT05127629|PROCEDURE|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
214587265|NCT05127629|PROCEDURE|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
214587266|NCT03488433|DEVICE|Abduction brace|Donjoy Ultrasling IV
214587267|NCT03488433|DEVICE|Antirotation sling|Donjoy shoulder immobilizer
214587268|NCT06033014|OTHER|PM HeartIHD prediction|The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.
214587269|NCT01362257|DRUG|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
214587270|NCT01362257|DRUG|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
214587271|NCT03656523|OTHER|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
214587272|NCT03086213|DRUG|Propofol|anaesthetic
214587273|NCT03086213|DRUG|Sulfentanyl|anaesthetic
214587274|NCT03086213|DRUG|Dexmedetomidine|anaesthetic
214587275|NCT03086213|DRUG|Lidocaine|local anaesthetics
214587276|NCT03086213|DRUG|Ropivacaine|local anaesthetics
214587277|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
214587278|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
214587279|NCT04293380|PROCEDURE|amniosyntesis|
214587280|NCT02995954|DRUG|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
214587281|NCT02924064|DRUG|Teneligliptin 20mg|
214587282|NCT02924064|DRUG|Placebo|
214587283|NCT02924064|DRUG|Metformin ≥ 1000 mg|
214587284|NCT03650257|BIOLOGICAL|gp96|25 mcg IH
214587285|NCT03650257|DRUG|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
214587286|NCT03650257|RADIATION|radiotherapy|Stupp regimen of radiotherapy
214587287|NCT04507126|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Vaccine
214587288|NCT03297723|OTHER|Therapeutic education Programm|"Intervention will include:~* an identification of educational needs and expectations,~* a bilateral agreement between patient and medical staff on the priority skills acquirement,~* a structured educational activities tailored to the patient's need.~* the making of an educational record."
214587289|NCT04011618|DRUG|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
214587290|NCT04011618|DRUG|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
214587291|NCT01798251|DRUG|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
214587292|NCT01798251|DRUG|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
214587293|NCT02080741|OTHER|Blood sample of 12 ml|
214587294|NCT03759951|BEHAVIORAL|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
214587295|NCT03759951|BEHAVIORAL|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
214587296|NCT03759951|BEHAVIORAL|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
214587297|NCT03759951|BEHAVIORAL|Control|No training will be performed during a 1-year period. Participation only in measurements.
214587298|NCT05721820|PROCEDURE|TAVR|Transcatheter aortic valve replacement
214587299|NCT00220753|DEVICE|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
214587300|NCT06109675|BEHAVIORAL|Nutrition Education|All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
214587301|NCT03866304|DEVICE|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
214587302|NCT06262685|OTHER|Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines|"Atorvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587303|NCT06262685|OTHER|Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines|"Simvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587304|NCT06262685|OTHER|Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines|"Pitavastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587305|NCT06262685|OTHER|Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines|"Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587306|NCT06262685|OTHER|Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines|"Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587307|NCT06262685|OTHER|Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines|"Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587308|NCT06262685|OTHER|Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines|"Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
214587309|NCT06262685|OTHER|Standard of Care (SoC) dosing of atorvastatin|Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
214587310|NCT06262685|OTHER|Standard of Care (SoC) dosing of simvastatin|Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
214587311|NCT06262685|OTHER|Standard of Care (SoC) dosing of pitavastatin|Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
214587312|NCT06262685|OTHER|Standard of Care (SoC) dosing of rosuvastatin|Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
214587313|NCT06262685|OTHER|Standard of Care (SoC) dosing of prasavastatin|Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
214587314|NCT06262685|OTHER|Standard of Care (SoC) dosing of lovastatin|Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
214587315|NCT06262685|OTHER|Standard of Care (SoC) dosing of fluvastatin|Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
214587316|NCT00972452|BEHAVIORAL|Exercise|short period of exercise training (5-10 days)
214587317|NCT03501641|OTHER|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
214587318|NCT03501641|OTHER|video-based learning|voice of the staffs and standard patients.
214587319|NCT00038909|DRUG|BDDrFVII|
214587320|NCT03253965|OTHER|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
214587321|NCT03253965|OTHER|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
214587322|NCT03253965|OTHER|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
214587323|NCT03253965|OTHER|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
214587324|NCT03253965|OTHER|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
214587325|NCT03253965|OTHER|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
214587326|NCT03253965|OTHER|No Auditory cueing|Steps are not timed with any auditory cue.
214587327|NCT05949112|DEVICE|soft bristle toothbrush|manual toothbrushes
214587328|NCT05949112|DEVICE|mechanical toothbrush|sonic toothbrush
214587329|NCT02832154|OTHER|Internet-Based Intervention|Complete online PA program
214587330|NCT02832154|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214587331|NCT02832154|OTHER|Questionnaire Administration|Ancillary studies
214587332|NCT01507818|DEVICE|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0\>
214587333|NCT01507818|DEVICE|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
214587334|NCT04989465|BIOLOGICAL|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
214587335|NCT04989465|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
214587336|NCT00075647|DRUG|temsirolimus|Given IV
214587337|NCT00075647|OTHER|laboratory biomarker analysis|Correlative studies
214587338|NCT00699920|DRUG|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
214587339|NCT00699920|DRUG|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
214587340|NCT01616056|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Wear bandage lenses
214587341|NCT01616056|OTHER|questionnaire administration|Ancillary studies
214587342|NCT01616056|PROCEDURE|optical coherence tomography|Optional ancillary studies
214587343|NCT00966277|DRUG|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
214587344|NCT00062049|BIOLOGICAL|recombinant interleukin-7|
214587345|NCT01008215|OTHER|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
214587346|NCT04213430|OTHER|diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
214587347|NCT01100034|DRUG|Etanercept|Expected duration of 24 weeks as one course
214587348|NCT01684267|DEVICE|Robotic Gait Rehabilitation (RGR) Trainer|
214587349|NCT01382420|PROCEDURE|surgery|adrenalectomy
214587350|NCT00547131|DRUG|temozolomide|
214587351|NCT00547131|OTHER|laboratory biomarker analysis|
214587352|NCT00547131|OTHER|liquid chromatography|
214587353|NCT00547131|OTHER|mass spectrometry|
214587354|NCT00547131|OTHER|pharmacological study|
214587355|NCT00547131|PROCEDURE|conventional surgery|
214587356|NCT00547131|RADIATION|stereotactic radiosurgery|
214587357|NCT04606043|PROCEDURE|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
214587358|NCT04606043|PROCEDURE|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
214587359|NCT05868174|DIAGNOSTIC_TEST|89Zr-TLX250|Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible). The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
214587360|NCT05868174|COMBINATION_PRODUCT|177Lu-TLX250 and Peposertib|"Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose.~All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle."
214587361|NCT01831856|DRUG|1g of F373280|Oral administration, one capsule each evening with dinner.
214587362|NCT01831856|DRUG|Placebo|Oral administration, one capsule each evening with dinner.
214587363|NCT01873222|DEVICE|OFDI-guided PCI & IVUS|"* Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up"
214587364|NCT01873222|DEVICE|IVUS-guided PCI & OFDI|"* Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up"
214587365|NCT01832233|PROCEDURE|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
214587366|NCT01561209|DRUG|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
214587367|NCT01561209|DRUG|Placebo|"Placebo pill~1 before bedtime"
214587368|NCT05050253|DEVICE|Super-oxidized solution (SOS)|Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
214587369|NCT05050253|DEVICE|Ringer's solution|Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
214587370|NCT00052182|BIOLOGICAL|EP HIV-1090|
214587371|NCT02424513|RADIATION|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
214587372|NCT02550717|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
214587373|NCT02550717|DRUG|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
214587374|NCT04015856|BEHAVIORAL|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
214587375|NCT04015856|BEHAVIORAL|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
214587376|NCT00693316|DRUG|ORM-12741|Alternating panel single dose escalation.
214587377|NCT04105309|BEHAVIORAL|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
214587378|NCT04105309|BEHAVIORAL|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
214587379|NCT04105309|BEHAVIORAL|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
214587380|NCT04105309|BEHAVIORAL|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
214587381|NCT00455325|DRUG|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
214587382|NCT00455325|DRUG|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
214587383|NCT00455325|DRUG|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
214587384|NCT00455325|DRUG|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
214587385|NCT04620811|DRUG|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
214587386|NCT04495803|OTHER|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
214587387|NCT02775799|OTHER|Registration|Registration according to approved data sets
214587388|NCT04208009|BEHAVIORAL|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
214587389|NCT02159196|DRUG|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
214587390|NCT02159196|DRUG|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
214587391|NCT02159196|DRUG|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
214587392|NCT04908462|DRUG|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
214587393|NCT04908462|DRUG|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
214587394|NCT01959334|DRUG|Nasal Glucagon (NG)|
214587395|NCT01959334|DRUG|Glucagon IM|
214587396|NCT03218345|PROCEDURE|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
214710634|NCT04789863|DEVICE|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
214587397|NCT03558373|DRUG|Immunosuppressive|Immunosuppressive therapies
214587398|NCT01620476|DRUG|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
214587399|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
214587400|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
214587401|NCT01620476|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
214587402|NCT02294227|BIOLOGICAL|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
214587403|NCT02294227|OTHER|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
214587404|NCT00851448|DIETARY_SUPPLEMENT|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
214587405|NCT00888004|DRUG|AFQ056|
214587406|NCT00888004|DRUG|Placebo|
214587407|NCT00267904|OTHER|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
214587408|NCT00267904|OTHER|Banana|Banana ingestion
214587409|NCT00267904|OTHER|Olives|Olives ingestion
214587410|NCT00267904|OTHER|Temp. manip.|Manipulate temperature at skin of the back
214587411|NCT06248385|DEVICE|2D ultrasound|2D TVUS
214587412|NCT01768637|DRUG|Aspirin|Aspirin 81 mg by mouth daily
214587413|NCT01768637|DRUG|Clopidogrel|Clopidogrel 75 mg by mouth once daily
214587414|NCT04238273|DIAGNOSTIC_TEST|Functional Echocardiography|Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
214587415|NCT02519400|DRUG|Amitriptyline|Single oral dosing
214587416|NCT00126373|DRUG|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
214587417|NCT06354231|DRUG|DV|2.0 mg/kg, intravenously administered every 2 weeks
214587418|NCT06354231|DRUG|Toripalimab|3.0mg/kg, intravenously administered every 2 weeks
214587419|NCT06354231|PROCEDURE|Laser surgery|Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
214587420|NCT02851485|DRUG|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
214587421|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
214587422|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
214587423|NCT00887432|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214587424|NCT00887432|OTHER|Laboratory Biomarker Analysis|Correlative studies
214587425|NCT00887432|OTHER|Patient Observation|
214587426|NCT00887432|DRUG|Placebo Administration|Given PO
214587427|NCT00887432|OTHER|Quality-of-Life Assessment|Ancillary studies
214587428|NCT00887432|OTHER|Questionnaire Administration|Ancillary studies
214587429|NCT03389906|OTHER|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
214587430|NCT06092619|OTHER|Vojta Therapy|The therapist applied pressure to defined zones on the body whilst positioned in prone, supine and side lying, where the stimulus leads to automatically and involuntarily complex movement.The parents were also instructed on at least one of the exercises from the first session, after the initial assessment. The home program was progressively increased and supervised until the three therapy positions were mastered, during weekly or fortnightly follow ups. The recommended dose was four times per day at home, in session no longer than 15-20 minutes; however, the daily frequency of each family due to different availability was also taken in account. The frequency of the dose was divided into 3 groups: families who could carry on therapy a) three times per day, b) four times per day, c) one or two times per day, d) less than seven times per week or therapy at the clinic
214587431|NCT06092619|OTHER|Conventional physiotherapy:|Conventional physiotherapy intervention included goal-directed functional training based on tasks. These motor skills will be performed in enhanced and adapted settings, but as similar as possible to the usual activities of daily living. Family and children participated in the goal setting, and the approach will focus on overcoming the limitations of the activities to reach these, instead of the modification of the movement patterns. This intervention is founded in motor learning and behavioral neuroscience, focusing on participation and activity acquisition.
214587432|NCT04945915|OTHER|blood sampling|There was no intervention because this reasearch is observational study.
214587433|NCT02927600|OTHER|Low GI Breakfast|Intake of low GI breakfast
214587434|NCT02927600|OTHER|High GI Breakfast|Intake of high GI breakfast
214587435|NCT02927600|OTHER|Low GI Dinner|Intake of Low GI dinner
214587436|NCT02927600|OTHER|High GI Dinner|Intake of high GI dinner
214587437|NCT01515397|DRUG|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
214587438|NCT01515397|DRUG|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
214587439|NCT02701140|PROCEDURE|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
214587440|NCT02701140|PROCEDURE|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
214587441|NCT02701140|PROCEDURE|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
214587442|NCT02701140|PROCEDURE|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
214587443|NCT02701140|PROCEDURE|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
214587444|NCT04619901|OTHER|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
214587445|NCT04619901|OTHER|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
214587446|NCT04619901|OTHER|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
214587447|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
214587448|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
214587449|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
214587450|NCT02567500|BEHAVIORAL|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
214587451|NCT02567500|BEHAVIORAL|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
214587452|NCT01129466|DIETARY_SUPPLEMENT|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
214587453|NCT01129466|DIETARY_SUPPLEMENT|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
214710635|NCT04789863|OTHER|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
214587454|NCT04331223|OTHER|Observation|observational
214587455|NCT04448197|OTHER|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
214587456|NCT00639353|DEVICE|senofilcon A toric soft contact lens|contact lens
214587457|NCT00639353|DEVICE|senofilcon A sphere soft contact lens|contact lens
214587458|NCT02838771|OTHER|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
214587459|NCT02838771|OTHER|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
214587460|NCT03554668|DIAGNOSTIC_TEST|Blood draw|We take blood samples at pre-op and subsequent time points, up to three months post op.
214587461|NCT03735212|BEHAVIORAL|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
214587462|NCT00669448|BEHAVIORAL|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
214587463|NCT04651075|OTHER|music listening|The music selected by the participants was played to the music listening group.
214587464|NCT04651075|OTHER|individual training|Individual training group was trained on coronary angiography.
214587465|NCT00479492|DRUG|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
214710636|NCT04787211|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
214710637|NCT04787211|DRUG|Placebo|Placebo given by intravenous administration
214710638|NCT02375984|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
214587466|NCT00479492|DRUG|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
214587467|NCT00479492|DRUG|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
214587468|NCT00479492|DRUG|placebo|placebo administered QD for 84 days
214587469|NCT05296720|BEHAVIORAL|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
214587470|NCT05664867|OTHER|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
214587471|NCT05664867|OTHER|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
214587472|NCT01762891|DRUG|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
214587473|NCT01762891|DRUG|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
214587474|NCT01762891|DRUG|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
214587475|NCT01762891|DRUG|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
214587476|NCT02245906|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214587477|NCT02245906|DIETARY_SUPPLEMENT|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214587478|NCT02245906|DIETARY_SUPPLEMENT|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214587479|NCT00132847|BIOLOGICAL|German Cockroach Allergen extract|
214587480|NCT03861377|DRUG|Remifentanil R2|0,7 microg/kg
214587481|NCT03861377|DRUG|Remifentanil R4|1,1 microg/kg
214587482|NCT03861377|DRUG|Remifentanil R8|1,7 microg/kg
214587483|NCT05963529|OTHER|Humidity-ramp protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
214587484|NCT05963529|OTHER|Above-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
214587485|NCT05963529|OTHER|Below-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
214587486|NCT05963529|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
214587487|NCT02733393|PROCEDURE|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
214587488|NCT02733393|DRUG|lidocaine|
214587489|NCT00334035|DRUG|Quetiapine|
214587490|NCT05560100|OTHER|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
214587491|NCT05205915|DEVICE|tDCS intervention applied by Starstim device|Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
214587492|NCT05522621|DRUG|TJAOA102|Once enrolled, participants will be administrated TJAOA102
214587493|NCT00461136|DRUG|Aliskiren|
214587494|NCT04490187|BEHAVIORAL|Motor Learning|"Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995)."
214587495|NCT01001559|DRUG|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
214587496|NCT01001559|DRUG|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
214587497|NCT01001559|DRUG|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
214587498|NCT02805881|DEVICE|Neurolief system|Non-invasive cephalic neurostimulation device
214587499|NCT01636960|BIOLOGICAL|PegIFN alfa-2b|
214587500|NCT00172484|PROCEDURE|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
214587501|NCT00172484|PROCEDURE|nursing program|To establish a systemic stroke prevention, education protocol
214587502|NCT00172484|PROCEDURE|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
214710639|NCT04477915|OTHER|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
214710640|NCT04477915|OTHER|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
214710641|NCT02654275|OTHER|Proprioceptive Intervention|
214587503|NCT06342271|OTHER|Nordic walking training|Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.
214587504|NCT06342271|OTHER|Free Walking training|Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
214587505|NCT05029479|OTHER|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
214587506|NCT01580969|DRUG|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
214587507|NCT01580969|DRUG|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
214587508|NCT01580969|RADIATION|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
214587509|NCT04510831|OTHER|Refined maize with extrinsic addition of labelled FeSO4|Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
214587510|NCT04510831|OTHER|T.molitor native chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
214587511|NCT04510831|OTHER|T molitor reduced chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
214587512|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
214587513|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
214710642|NCT06054503|DEVICE|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
214710643|NCT02995122|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)"
214710644|NCT02995122|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214710645|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
214587514|NCT01209780|BIOLOGICAL|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
214587515|NCT01209780|BIOLOGICAL|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
214587516|NCT01209780|BIOLOGICAL|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
214587517|NCT03034629|BEHAVIORAL|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
214587518|NCT05552885|OTHER|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
214587519|NCT03463161|DRUG|Pembrolizumab|Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
214587520|NCT03463161|DRUG|Epacadostat|Epacadostat (100mg) taken by mouth twice a day.
214587521|NCT00133146|BIOLOGICAL|Grass MATA MPL|
214710646|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
214710647|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
214710648|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
214710649|NCT04516655|DRUG|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
214710650|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
214710651|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
214587522|NCT01844947|DRUG|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance \>60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
214587523|NCT01844947|DRUG|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
214587524|NCT00102609|DRUG|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
214587525|NCT00102609|DRUG|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
214587526|NCT00102609|DRUG|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
214587527|NCT04234854|DIAGNOSTIC_TEST|Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent|IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
214587528|NCT05007808|DRUG|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
214587529|NCT05007808|DRUG|Vehicle|Vehicle Gel for topical administration
214587530|NCT04176146|BEHAVIORAL|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
214587531|NCT00005597|DRUG|temozolomide|200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
214587532|NCT02621125|DIETARY_SUPPLEMENT|Fertilix|daily supplementation
214587533|NCT02621125|OTHER|Placebo|Placebo
214587534|NCT00728585|DRUG|Palifermin|Given IV
214587535|NCT00728585|OTHER|Placebo|Given IV
214587536|NCT00645047|BEHAVIORAL|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
214587537|NCT00645047|BEHAVIORAL|In-Person CBT|In-Person Provision Of Cognitive Therapy
214587538|NCT02675504|OTHER|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
214587539|NCT01304433|DRUG|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
214587540|NCT02107053|DIETARY_SUPPLEMENT|PJ|
214587541|NCT02107053|DRUG|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
214587542|NCT02709096|DRUG|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
214587543|NCT02709096|DRUG|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
214587544|NCT00511472|DRUG|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
214587545|NCT00511472|DRUG|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
214587546|NCT00511472|DRUG|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
214587547|NCT02515877|RADIATION|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
214587548|NCT02515877|DRUG|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
214587549|NCT02515877|DRUG|Carboplatin|AUC= 2,5 (Calvert formula)
214587550|NCT02687022|DEVICE|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
214587551|NCT02687022|DEVICE|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
214587552|NCT06254547|OTHER|Daily updated ranking on leaderboard|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service and view a daily updated leaderboard ranking.~Leaderboards will demonstrate participant's ranking in their respective group, participant's (anonymized) name, cumulative point total, total case amount, and current level. Participant ranking will be based on the cumulative point total. All groups will have continual access to their personal score.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
214587553|NCT06254547|OTHER|Daily motivational message|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service encouraging training.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
214587554|NCT01091077|DIETARY_SUPPLEMENT|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
214587555|NCT02146456|DRUG|Tranexamic Acid|
214587556|NCT02574156|DRUG|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
214587557|NCT00505284|DRUG|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
214587558|NCT00505284|DRUG|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
214710652|NCT00707343|RADIATION|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
214587559|NCT00505284|DRUG|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
214587560|NCT00505284|DRUG|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
214587561|NCT00505284|DRUG|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
214587562|NCT01599715|BEHAVIORAL|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
214587563|NCT01599715|BEHAVIORAL|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
214587564|NCT04302441|DRUG|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
214587565|NCT04302441|DRUG|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
214587566|NCT03476213|PROCEDURE|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
214587567|NCT03476213|PROCEDURE|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
214587568|NCT03027492|OTHER|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
214587569|NCT00340691|DRUG|Doxycycline|
214587570|NCT02202954|OTHER|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
214587571|NCT06004011|OTHER|ARROW strategies|ARROW strategies are peer-to-peer support at the patient, provider and health system levels
214587572|NCT06004011|OTHER|One-time education|The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
214587573|NCT05822778|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
214587574|NCT05822778|DEVICE|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
214587575|NCT01981395|DRUG|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
214587576|NCT01981395|DRUG|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
214710653|NCT00003077|DIETARY_SUPPLEMENT|omega-3 fatty acid|
214710654|NCT03779893|COMBINATION_PRODUCT|BioCoat® by Premier®.|Bioactive pits and fissure sealant
214710655|NCT03779893|COMBINATION_PRODUCT|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
214710656|NCT00168064|DRUG|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
214710657|NCT00290589|DRUG|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
214587577|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Aerobic Walking Exercise Training|"This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance."
214587578|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Stretching and Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
214587579|NCT00731120|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
214587580|NCT00731120|DRUG|Placebo|Vortioxetine placebo-matching capsules
214587581|NCT02800239|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
214587582|NCT00073866|DRUG|celecoxib|
214587583|NCT00073866|DRUG|docetaxel|
214587584|NCT00073866|DRUG|irinotecan hydrochloride|
214587585|NCT01924520|DRUG|FK949E|Oral
214587586|NCT00978653|DRUG|allopurinol|150 mg once a day
214587587|NCT01762033|DRUG|ASONEP|Intravenous infusion
214587588|NCT04237766|OTHER|Experimental group|"The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively)."
214587589|NCT04470466|DEVICE|short pulse and Q-switched ND-YAG laser with topical carbon|application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
214587590|NCT04470466|DEVICE|fractional CO2 laser|single pass of fractional CO2 laser on the other side of the face
214587591|NCT01551212|DRUG|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
214587592|NCT01551212|DRUG|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
214587593|NCT01551212|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
214587594|NCT05385432|DRUG|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
214587595|NCT05385432|DRUG|Basiliximab|Simulect® IV 40mg D0 and D4
214587596|NCT00705861|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
214587597|NCT00705861|DRUG|SK3530|SK3530 100mg
214587598|NCT05806307|DRUG|Misoprostol|(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
214587599|NCT05806307|DEVICE|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
214587600|NCT05806307|DRUG|Carbetocin|(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
214587601|NCT05806307|DRUG|Oxytocin|(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
214587602|NCT05806307|DRUG|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
214587603|NCT05806307|DRUG|Vasopressin|15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
214587604|NCT05806307|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine|15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
214710658|NCT00290589|DRUG|Placebo|Normal saline intramuscular injection
214587605|NCT05503472|OTHER|observational|observational
214587606|NCT01741896|PROCEDURE|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
214587607|NCT03810131|OTHER|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
214587608|NCT01575028|DRUG|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
214587609|NCT01575028|DRUG|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
214587610|NCT04830423|PROCEDURE|Medical ozone injection|Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
214587611|NCT04830423|PROCEDURE|steroid injection group|In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
214587612|NCT00232674|DRUG|Pulmicort (budesonide) Turbuhaler|
214587613|NCT00529958|PROCEDURE|Patellar Tendon|Patellar Tendon autograft
214587614|NCT00529958|PROCEDURE|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
214587615|NCT00529958|PROCEDURE|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
214587616|NCT04308395|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
214587617|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
214587618|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
214710659|NCT04800120|OTHER|Hyperbaric Oxygen Therapy|Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
214710660|NCT00821665|DIETARY_SUPPLEMENT|Sucrose consumption|Sucrose
214710661|NCT00821665|DIETARY_SUPPLEMENT|water consumption|water
214710662|NCT04220671|BIOLOGICAL|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
214710663|NCT04220671|OTHER|Saline|0.9% NaCl
214710664|NCT01958879|DRUG|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
214710665|NCT01958879|DRUG|ringer without corticosteroid|200 mL Ringer solution
214710666|NCT06136819|COMBINATION_PRODUCT|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
214587619|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) attenuation measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
214587620|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) stiffness measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
214710667|NCT05014542|PROCEDURE|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
214710668|NCT05014542|DRUG|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
214710669|NCT06226714|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
214710670|NCT06226714|BIOLOGICAL|MPSV4|1 dose of MSPV4 on Day 0
214710671|NCT03604510|PROCEDURE|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
214710672|NCT03245502|BIOLOGICAL|Blood transfusion|The transfusion of erythrocyte suspension
214710673|NCT00145912|BEHAVIORAL|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
214710674|NCT00145912|BEHAVIORAL|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
214587621|NCT06102980|DEVICE|Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurement|"EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained.~In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation."
214587622|NCT03534284|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
214587623|NCT03534284|DRUG|Trazodone|trazodone tablet
214710675|NCT06968962|DRUG|Tadalafil|Target dose 40 mg OD
214587624|NCT03534284|DRUG|Placebo|Inactive pill manufactured to mimic trazodone tablets.
214587625|NCT02831543|DRUG|Motireb 5/100 mg|
214587626|NCT02831543|DRUG|Mosapride citrate|
214587627|NCT02831543|DRUG|Placebo|
214587628|NCT03316300|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
214587629|NCT03316300|PROCEDURE|Sham Procedure|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
214710676|NCT06968962|DRUG|Ambrisentan|Target dose 10 mg OD
214710677|NCT06968962|DRUG|Ambrisentan mimic|Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.
214710678|NCT06968962|DRUG|Tadalafil mimic|Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.
214710679|NCT06433375|PROCEDURE|Growth hormone application|Growth hormone application during non-surgical root canal treatment
214587630|NCT00001750|DRUG|Stemgen|
214710680|NCT06433375|PROCEDURE|Root canal treatment|Teeth undergo conventional root canal treatment without any additional intervention
214587631|NCT03383926|PROCEDURE|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
214587632|NCT03383926|PROCEDURE|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
214587633|NCT01747993|DRUG|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
214587634|NCT01747993|DRUG|Placebo|(1 tablet / day for 6 days)
214587635|NCT04737187|DRUG|Trifluridine/Tipiracil|Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
214710681|NCT06252311|BEHAVIORAL|Mindfulness-Based Breastfeeding Programme|Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
214587636|NCT04737187|DRUG|Bevacizumab|administered every 2 weeks (Day 1 and Day 15)
214587637|NCT06259552|BIOLOGICAL|SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody|SPX- 303 Injection
214587638|NCT03071367|OTHER|Clinical Simulation|
214587639|NCT05635305|DRUG|Zoliflodacin Patheon|"Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)"
214587640|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
214587641|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields sham|sham PEMF
214587642|NCT04007341|DRUG|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
214587643|NCT04598503|OTHER|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) \[10\]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
214587644|NCT03756129|DRUG|MIJ821|Different dosages and different regimen for MIJ821
214587645|NCT03756129|DRUG|Placebo|Infusion
214587646|NCT03756129|DRUG|Ketamine|Infusion
214587647|NCT05094557|BEHAVIORAL|Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual|The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
214587648|NCT05094557|BEHAVIORAL|Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
214587649|NCT05094557|BEHAVIORAL|Control Group: Psychoeducational video + Treatment As usual|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
214587650|NCT04289168|BEHAVIORAL|Music|Music class was provided for the intervention group
214587651|NCT02092688|DEVICE|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
214587652|NCT01224392|OTHER|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
214710682|NCT06000501|DRUG|Serdexmethylphenidate/dexmethylphenidate|Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
214587653|NCT01224392|RADIATION|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
214587654|NCT00061152|DRUG|Capsaicin Dermal Patch|
214587655|NCT04918446|OTHER|T-POSE|Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.
214587656|NCT04918446|OTHER|Usual Care|Printed instruction sheets on prescribed opioid.
214587657|NCT05538559|OTHER|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
214587658|NCT05538559|OTHER|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
214587659|NCT05451498|DIETARY_SUPPLEMENT|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
214587660|NCT05451498|DIETARY_SUPPLEMENT|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
214587661|NCT00120588|DRUG|magnesium|
214587662|NCT00001573|DRUG|SU101|
214587663|NCT04876872|OTHER|no intervention|no intervention
214587664|NCT02465853|DRUG|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
214587665|NCT02465853|DRUG|Physiological saline solution|Injection 0.9% Physiological saline solution\<1.0 ml
214587666|NCT02465853|OTHER|physical therapy and occupational therapy|rehabilitation
214710683|NCT03427866|DRUG|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
214710684|NCT04643795|DRUG|MGL-3196|Once daily oral dose for 6 days
214710685|NCT03488394|GENETIC|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously."
214587667|NCT05670873|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation given to the left dorsolateral prefrontal cortex
214587668|NCT02877914|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
214587669|NCT02877966|DIETARY_SUPPLEMENT|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
214587670|NCT02877966|OTHER|Placebo|
214587671|NCT00079066|BIOLOGICAL|cetuximab|
214587672|NCT00079066|PROCEDURE|quality-of-life assessment|
214587673|NCT04701892|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
214587674|NCT02857166|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
214587675|NCT05042232|OTHER|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
214587676|NCT05042232|OTHER|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
214587677|NCT06043752|DRUG|Remsima|The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is \>80 kg, 2 injections will be given.
214587678|NCT00159692|DRUG|Amlodipine|
214587679|NCT06253598|DRUG|Recombinant Human Adenovirus Type 5|Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
214587680|NCT06253598|DRUG|Lenvatinib|Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing ≥60 kg, the recommended daily dose was 12 mg once daily
214587681|NCT06253598|DRUG|Tislelizumab|Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.
214587682|NCT00351520|DRUG|Miltefose|
214587683|NCT04518605|DIETARY_SUPPLEMENT|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.
214587684|NCT04518605|DIETARY_SUPPLEMENT|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
214587685|NCT04518605|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
214587686|NCT05281159|BEHAVIORAL|Risk Information|This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
214587687|NCT05281159|BEHAVIORAL|Risk Information + Action|This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
214587688|NCT03705832|DRUG|Ginger Extract|2gm Capsule of Ginger extract
214587689|NCT03705832|DRUG|Placebo|Matching Placebo
214587690|NCT01050790|DRUG|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
214710686|NCT06976944|DRUG|Pembrolizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Pembrolizumab: Intravenous infusion(400 mg/body, every 6 weeks starting on Day 1 of Cycle 1)"
214587691|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
214587692|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
214587693|NCT00762736|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
214587694|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
214587695|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
214587696|NCT00762736|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
214587697|NCT04241601|DRUG|Interleukin-2 [IL-2]|Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
214587698|NCT04241601|OTHER|Placebo Dextrose 5% solution|Placebo Comparator: Dextrose 5% solution
214587699|NCT01880528|DRUG|lisinopril|Given PO
214587700|NCT01880528|DRUG|placebo|Given PO
214587701|NCT01439360|BIOLOGICAL|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
214587702|NCT01439360|BIOLOGICAL|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
214587703|NCT01439360|BIOLOGICAL|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
214587704|NCT01439360|BIOLOGICAL|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
214587705|NCT01439360|BIOLOGICAL|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
214587706|NCT06043167|DIAGNOSTIC_TEST|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
214587707|NCT04858087|OTHER|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
214587708|NCT03271554|DRUG|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
214587709|NCT05203068|DIAGNOSTIC_TEST|Recombinant tuberculosis allergen (RTA)|Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
214587710|NCT02852070|PROCEDURE|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
214587711|NCT02852070|PROCEDURE|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
214587712|NCT06143436|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
214710687|NCT06976944|DRUG|Paclitaxel|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Paclitaxel: Intravenous infusion(90 mg/m\^2, on Days 1, 8, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
214587713|NCT03045068|BIOLOGICAL|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient"
214587714|NCT03045068|BIOLOGICAL|FFP and Cryoprecipitate|"1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed"
214587715|NCT03045068|BIOLOGICAL|PRBC and cell saver Transfusion|1\. Transfuse for target Hematocrit \> 40 in neonates with SV physiology; Transfuse for Hematocrit\> 33 for 2-Ventricle physiology
214587716|NCT03045068|BIOLOGICAL|Factor Concentrate (Bebulin)|1\. Based on clinical bleeding and achievement of hemostasis
214587717|NCT06608290|PROCEDURE|parasternal block|Administration of parasternal block with ropivacaine, bilaterally at the sternum before the start of surgery.
214587718|NCT06608290|DIAGNOSTIC_TEST|Lactate serum level|Blood samples were taken to identify serum lactate levels greater than 2 mmol/l and those that remained below this limit.
214587719|NCT04186364|BEHAVIORAL|Assigned Ambassador|If assigned to the intervention group, participants will be assigned a medical student ambassador on arrival to the Emergency Department. A brief discussion may take place to review the child's history and survey results, and a copy of the survey will be placed near the patient's bedside for healthcare personnel to review. The student ambassador will accompany the child and their family through key points of their visit and will be expected to make accommodations for the child as determined by the accommodation survey results. The family will be required to allow the ambassador to stay throughout the ED visit.
214710688|NCT06976944|DRUG|Bevacizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Bevacizumabl: Intravenous infusion(10 mg/kg, on Days 1, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
214710689|NCT00318565|DEVICE|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
214710690|NCT01113840|BEHAVIORAL|Exercise|Exercise classes three times per week in a controlled, supervised environment.
214710691|NCT01113840|BEHAVIORAL|Control|Control group continues daily life as prior to randomization.
214710692|NCT04523818|DRUG|Capecitabine|Given PO
214710693|NCT04523818|DRUG|Fluorouracil|Given IV
214710694|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
214710695|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
214587720|NCT06599606|DIAGNOSTIC_TEST|Ultrasonographic Assessment|A researcher will perform all ultrasonographic measurements using the ESAOTE My Lab 70 model ultrasound device with a 4-13 MHz linear probe. System settings will be kept constant throughout each study, and all images will be obtained using this single ultrasound device. Only the depth will be adjusted to optimally assess the relevant muscle. The muscle thickness measurement protocol with ultrasound includes four muscles on the dominant side of each child: two proximal upper and lower extremity muscles (biceps brachii/brachialis and quadriceps) and two distal upper and lower extremity muscles (forearm flexors and tibialis anterior). In the assessment of muscle echogenicity, images will be transferred to ImageJ software to calculate luminance ratios (LR).
214587721|NCT03935321|DRUG|NG-101|6 intrathecal bolus injections, each of 45mg
214587722|NCT03935321|DRUG|Placebos|6 intrathecal bolus injections, each of 45mg
214587723|NCT06431477|DRUG|telmisartan|QD, PO
214587724|NCT06431477|DRUG|Losartan|QD, PO
214587725|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 1 - Stick pack of combination 1 of two polysaccharides mixed with a glass of water each morning
214587726|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 1 - stick pack of maltodextrin 1 mixed with a glass of water each morning
214710696|NCT06236464|OTHER|Multiparameter analysis of each sample|Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
214710697|NCT06212570|DEVICE|KeySuite|KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
214587727|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 2 - Stick pack of combination 2 of two polysaccharides mixed with a glass of water each morning
214587728|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 2 - stick pack of maltodextrin 2 mixed with a glass of water each morning
214587729|NCT06610188|DIETARY_SUPPLEMENT|Prebiotic group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
214587730|NCT06610188|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
214587731|NCT06609941|OTHER|Alternative nostril breathing|Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.
214710698|NCT01707368|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
214710699|NCT02578472|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
214587732|NCT06609941|DRUG|Pharmacological therapy|"Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist."
214587733|NCT06609993|DRUG|intravenous rescue opioid analgesia using fentanyl|intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
214587734|NCT06609993|DRUG|intravenous rescue atropine administration|atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50
214587735|NCT06609993|DRUG|intravenous rescue urapidil administration|urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg
214587736|NCT06609993|DRUG|intravenous rescue ephedrine administration|ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg
214587737|NCT06609993|BIOLOGICAL|concentrate of red blood cells|concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%
214587738|NCT06609993|BIOLOGICAL|red blood cells autotransfusion|red blood cells from the operation site will be retransfused using cell saver
214587739|NCT06609993|DRUG|primary treatment of postoperative nausea and vomiting (PONV)|dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
214587740|NCT06609993|DRUG|secondary treatment of postoperative nausea and vomiting (PONV)|Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
214587741|NCT06609993|DRUG|intraopertative fluid challenge (IFC)|3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre
214587742|NCT06609993|DRUG|postoperative rescue opioid analgesia using morphine|postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
214587743|NCT03439423|RADIATION|CT with contrast agent|
214587744|NCT03439423|DIAGNOSTIC_TEST|MR without contrast agent|"on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)"
214587745|NCT03439423|DIAGNOSTIC_TEST|Color-Doppler Ultrasound|
214587746|NCT03439423|OTHER|Questionnaire|regarding their perception of examinations
214587747|NCT00126477|PROCEDURE|cognitive assessment|
214587748|NCT00126477|PROCEDURE|management of therapy complications|
214587749|NCT00126477|PROCEDURE|psychosocial assessment and care|
214587750|NCT00126477|PROCEDURE|quality-of-life assessment|
214710700|NCT02578472|DRUG|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
214710701|NCT02578472|DRUG|Placebo|Matching Placebo will be administered orally.
214710702|NCT05603754|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
214710703|NCT05603754|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
214587751|NCT02871258|DEVICE|The MetaNeb® System|
214587752|NCT05502367|DRUG|ABI-2280 Vaginal Tablet/Insert|Vaginal Tablet
214587753|NCT01588132|DRUG|Anfibatide|"1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
214587754|NCT06610084|OTHER|progressive muscle relaxation exercise)|"Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls."
214587755|NCT06610084|OTHER|Hypno-breastfeeding|"Practices for experimental group 1 (Hypno-breastfeeding) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls."
214587756|NCT01122160|DRUG|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
214587757|NCT01122160|DRUG|placebo|Placebo with berries (blackberries + strawberries)
214587758|NCT02535936|PROCEDURE|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
214587759|NCT06419998|PROCEDURE|Group A: Pure transanal endorectal pull-through (TAERPT)|Patients of Group A will be treated totally by pure transanal endorectal pull-through without the assistance of laparoscopy
214587760|NCT06419998|PROCEDURE|Group B: Laparoscopic-assistance endorectal pull-through (LAERPT)|Patients of Group B will be treated transanal endorectal pull-through but with the assistance of laparoscopy
214710704|NCT00378755|DRUG|velcade|
214587761|NCT06708572|DRUG|Granulocyte Colony-Stimulating Factor|20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
214587762|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
214587763|NCT00790816|DRUG|Lapatinib|Lapatinib monotherapy
214587764|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
214587765|NCT06717672|DRUG|Lidocaine 2% without vessel constrictor|"1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.~2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.~3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies."
214587766|NCT06717672|DRUG|Normal Saline|Normal saline used is an iv fluid given for fluid replacement
214587767|NCT02824419|DRUG|Methionine|Subject undergoes imaging studies with FDG and with methionine.
214587768|NCT02824419|DRUG|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
214587769|NCT06729853|DRUG|SAP-001|a single oral dose of SAP-001
214587770|NCT06729203|DEVICE|Ultrasound cavitation|Ultrasound Fat Cavitation (USFC) is the method in handling obesity, especially in destroying fat and shaping a particular part of the body. As one of the non-surgical correction methods, USFC is preferred at decreasing the risk of complications due to obesity.
214587771|NCT06729203|OTHER|Exercise|The female will stand on the cushioned tread and grasp by her both hands the two arms of the treadmill. Treadmill will adjust to apply moderate intensity training. It was used for 30 minutes divided into five-minutes warming up, twenty-minutes active exercise and five-minutes cooling down and it was used twice a week for twelve weeks.
214587772|NCT06728943|PROCEDURE|ureteral dilatation|Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.
214587773|NCT06729281|DEVICE|kinesio tape|The application of kinesio tape is a relatively new method, first developed in 1973 by Kenzo Kase in Japan, also known as elastic bandage, which has become popular in the last 10 years following announcements at major events such as the Olympic Games.
214587774|NCT06727760|BEHAVIORAL|massage|"The mothers in the massage group applied colic massage according to the Educational Colic Massage Checklist twice a day for 15-20 minutes each time for three weeks, when the baby was calm and during colic attacks."
214587775|NCT06727760|BEHAVIORAL|kangroo care|"The mothers in the kangaroo care group applied kangaroo care according to the Educational Kangaroo Care Checklist twice a day for three weeks for 15-20 minutes each time when the baby was calm and during colic attacks."
214587776|NCT06728969|DEVICE|MT1 Auditory startle response patterns analysis algorithm|Objective measurements of attention and inhibition.
214587777|NCT06728969|DEVICE|T.O.V.A. Continuous Performance Test|Objective measurements of attention and inhibitory control.
214587778|NCT04847193|OTHER|Dietary Intervention 1: Placebo|Participants receive a study drink supplemented with a placebo for 5 days
214587779|NCT04847193|OTHER|Dietary Intervention 2: Xanthohumol and Iso-alpha acids|Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
214710705|NCT01017887|DEVICE|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
214710706|NCT01017887|DEVICE|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
214710707|NCT01896856|DRUG|SGI-110 Dose Escalation|"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"
214587780|NCT05599620|BEHAVIORAL|AWARE|AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
214587781|NCT05599620|BEHAVIORAL|General Health Promotion|General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
214587782|NCT02721173|DRUG|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
214587783|NCT02721173|DRUG|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
214634361|NCT04034160|OTHER|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
214634362|NCT01954693|DRUG|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
214710708|NCT01896856|DRUG|Regorafenib|160 mg taken orally
214710709|NCT01896856|DRUG|TAS-102|35 mg/m\^2 taken orally
214634363|NCT01954693|DRUG|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
214634364|NCT05202522|BEHAVIORAL|Virtual GERAS DANCE|Dance is a form of aerobic exercise that involves multicomponent training with physical, cognitive, and social dimensions and may have synergetic benefits when delivered in combination. GERAS DANcing for Cognition and Exercise (DANCE), a community-based rehabilitation program for older adults with cognitive decline and/or mobility impairments, has been adapted for virtual delivery through videoconferencing systems. Participants will receive twice-weekly (one hour per session) virtual dance sessions for a total of 6 weeks.
214634365|NCT04674631|OTHER|The effect of neuropathic pain on quality of life, depression and sleep quality|The effect of neuropathic pain on quality of life, depression and sleep quality
214710710|NCT01896856|DRUG|SGI-110|45 mg/m\^2 administered as a subcutaneous injection
214710711|NCT01896856|DRUG|Irinotecan|125 mg/m\^2 administered IV
214710712|NCT06043245|PROCEDURE|Duodenal Switch|Classic Duodenal Switch
214710713|NCT06043245|PROCEDURE|SADI-S|SADI-S with a 300cm common channel
214710714|NCT06043245|PROCEDURE|Minigastric Bypass|Classic minigastric bypass
214710715|NCT01879813|DIETARY_SUPPLEMENT|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
214587784|NCT06727591|PROCEDURE|Split Bone Block Technique|An intraoral crestal incision with/out vertical arms was performed on alveolar ridge using blade no.15. After flap reflection, patroning the defect to help guide the area to be grafted from the donor site. At the chin area (donor site) unicortical cuts will be made at least 5 mm inferior to root tips, 5 mm superior to inferior border of mandible and 5 mm away from the mental foramen. The graft was luxated and split into two bone shells each 1 \~ 2 mm in thickness using disc. The bone shells and the donor site were scrapped for autogenous graft particles. Decortication of the recipient site. The graft was stabilised into the recipient site using two or more self tapping titanium screws placed midway corono-apical in the bone shell following the ridge contour. The autogenous particles were packed into the space between the split bone block and the ridge. Collagen sponge was used to cover the donor site. After 4 months the site was approached for implant placement using crestal incision
214587785|NCT06728189|BIOLOGICAL|CAR-NKT Cells treatment|"Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC738 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2;"
214587786|NCT06729411|DEVICE|Minimal Offloading dressing|Metatarsal minimal offloading dressings (MODs) are standard offloading devices that are gaining attention. MODs offload a specific ulcerated area and could reduce variability when applying the device onto the skin. MODs are new predesigned devices that do not require any further adaptation or clinician skills and can be directly applied to an ulcerated metatarsal head using a non-irritating adhesive.
214587787|NCT06729411|DEVICE|Felted foam|The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.
214587788|NCT06727929|DIAGNOSTIC_TEST|Collection of gingival crevicular fluid, ELISA|GCF samples were collected at baseline and at the 6-8 -week follow-up appointment after non-surgical periodontal treatment . After removing the supragingival plaque from the interproximal surfaces with sterile curettes, these sample surfaces were isolated with cotton rolls and slightly air-dried to avoid contamination. Standardized paper strips were inserted 1 to 2 mm into the gingival sulcus and held for 30 seconds to collect GCF. Strips contaminated with blood or saliva were discarded and not evaluated. The paper strips were transferred to a precalibrated Periotron 8000 device to measure the fluid volume. Paper strips were placed in sterile Eppendorf tubes and stored at -80C, until laboratory analysis. The level of GCF Dkk-1 and sFRP5 levels was measured by ELISA using commercial kits.
214587789|NCT06729606|BIOLOGICAL|Aviptidil|Administered by IV infusion over 12 hours per day for 3 days. The Day 1 infusion rate is 50 pmol/kg/hr, the Day 2 infusion rate is 100 pmol/kg/hr, and the Day 3 infusion rate is 150 pmol/kg/hr.
214587790|NCT06729606|BIOLOGICAL|Aviptidil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
214587791|NCT06729606|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
214634366|NCT01272999|OTHER|No intervention|Non interventional
214634367|NCT04204174|DIETARY_SUPPLEMENT|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
214634368|NCT05912465|OTHER|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
214634369|NCT01564615|DEVICE|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
214634370|NCT01564615|DEVICE|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
214634371|NCT02009644|DEVICE|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
214587792|NCT06728475|DEVICE|virtual reality|"In Xbox, we will choose suitable games that aim to improve upper limb function like boxing, Darts, tennis, goalkeeping, basketball, disc throwing, balling, and volleyball.~The Kinect sensor has the advantage of auto adjustment of its camera according to the child's position and height that's to say the child can perform the game in sitting or standing according to their abilities.~They will receive 30 minutes of VR intervention in addition to the time required for the designed physical therapy program."
214587793|NCT06728475|OTHER|mirror therapy|Mirror Therapy A mirror of 30 × 20 inches was used for the MT, which was large enough to cover the entire affected limb while still allowing the reflection of the non-affected limb to be seen. The child was seated in a chair with the forearms resting on the table. In the mid-sagittal plane, the mirror box was positioned at an angle of 70° to 80° to the trunk. The affected limb was placed behind the mirror. The child was asked to perform the exercises bilaterally and symmetrically as much as possible. Even if the affected side did not move easily or fully, the child was advised to synchronize the motions with both hands and arms. The researcher constantly reminded the child to concentrate on the movement of the non-affected limb in front of the mirror, which helped to increase the mirror illusion
214587794|NCT06728475|OTHER|virtual reality with mirror therapy|group C will receive combined effect of both techniques (virtual reality and mirror therapy)
214587795|NCT06728371|DRUG|Methadone|0.2mg/kg intravenous methadone given at induction
214587796|NCT06728371|DRUG|Morphine|0.2mg/kg intravenous morphine given at induction
214587797|NCT06727617|DRUG|Serplulimab|intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)
214587798|NCT06727617|DRUG|Chemotherapy|"Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles."
214710716|NCT01879813|DIETARY_SUPPLEMENT|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
214587799|NCT06727617|RADIATION|radiotherapy|Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
214587800|NCT04415983|DRUG|Nitazoxanide|Nitazoxanide twice daily
214587801|NCT04415983|DRUG|Clarithromycin|Klacid twice daily
214587802|NCT04415983|DRUG|Metronidazole|Metronidazole twice daily
214587803|NCT04415983|DRUG|Proton pump inhibitor|Omeprazoe twice daily
214587804|NCT00564551|BEHAVIORAL|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
214587805|NCT00564551|BEHAVIORAL|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
214587806|NCT00904046|DRUG|Pioglitazone|30 mg orally daily for 6 months
214587807|NCT00904046|DRUG|Placebo|Placebo taken orally once a day for 6 months.
214587808|NCT03503058|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
214587809|NCT03503058|BIOLOGICAL|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
214587810|NCT03503058|OTHER|Normal Saline|0.9% Sodium chloride
214587811|NCT03503058|DRUG|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
214587812|NCT00171600|DRUG|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
214587813|NCT01528501|DRUG|Panobinostat (LBH589)|
214587814|NCT02058654|DRUG|Creatine|Creatine powder (5 g)
214587815|NCT02058654|DRUG|Placebo|Bulking agent powder (5 g)
214710717|NCT04054739|DEVICE|Robot-assisted gait training|intervention with robot-assisted gait training
214587816|NCT02383004|OTHER|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
214587817|NCT05717439|DIAGNOSTIC_TEST|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
214587818|NCT05717439|DIAGNOSTIC_TEST|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
214710718|NCT04054739|DEVICE|Treadmill gait training|intervention with treadmill gait training
214587819|NCT05374213|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
214587820|NCT05398744|OTHER|Group Exercise Program|At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
214587821|NCT04854980|OTHER|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
214587822|NCT02821741|DEVICE|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
214587823|NCT02821741|DEVICE|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
214587824|NCT06815445|PROCEDURE|None tourniquet|No tourniquet is used throughout the surgery.
214587825|NCT05406752|DRUG|paracetamol Uniflash (125 mg/ 1.25 mL)|Oromucosal solution (125 mg/ 1.25 mL) for buccal route
214587826|NCT00926549|DEVICE|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
214587827|NCT03362047|DRUG|Riciguat Group|Patients will be administered 12 weeks Riciguat
214587828|NCT03362047|DRUG|Macitentan Group|Patients will be administered 12 weeks Macitentan
214587829|NCT06835608|OTHER|Schroth Exercise Group|The study group will receive electrotherapy treatment (hot pack, ultrasound, tens) to the neck area for 30 minutes in each session. After electrotherapy treatment, kyphotic posture correction exercises will be applied with the help of proprioceptive and extroceptive stimuli in the sagittal plane with mirror control and specific corrective breathing. In the exercise program, exercise practices will be performed in specific positions in supine, prone, sitting and standing. The exercise program will be planned for approximately 40 minutes in each session. A total of 20 sessions of electrotherapy and exercise will be performed for 4 weeks. At the end of the 4th week, after the electrotherapy sessions are completed, exercise applications will continue for the other 4 weeks by the physiotherapist who performs the exercise 3 days a week.
214710719|NCT06854484|DEVICE|AVEIR™leadless pacemaker|AVEIR™ leadless pacemaker implantation
214710720|NCT02258867|DRUG|Placebo|Solution for subcutaneous injection
214710721|NCT02258867|DRUG|Gevokizumab|Solution for subcutaneous injection
214634372|NCT05929690|OTHER|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
214634373|NCT01695473|DRUG|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
214587830|NCT06835608|OTHER|Postural Exercises Group|Patients to be included in the control group will receive electrotherapy treatment (ultrasound, tens, hotpack) to the neck area for 30 minutes in each session. After the electrotherapy treatment, posture corrective exercises will be applied. Corrective exercise program for posture will consist of deep neck flexor muscle strengthening exercises, lower and middle trapezius strengthening, neck isometric exercises. All strengthening exercises will be given 3 sets of 10 repetitions per day, each repetition for 10 seconds. Stretching exercises will be given to the shortened upper trapezius and pectoralis major muscles. Stretching exercises will be given 2 sets of 5 repetitions per day, with each repetition lasting 20 seconds. In the first 4 weeks, a total of 20 sessions of electrotherapy and exercise will be performed in corrective exercises for posture. At the end of the 4th week, exercise applications will continue for the other 4 weeks 3 days a week.
214587831|NCT06557226|OTHER|oral and nutritional examination|Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
214587832|NCT03190447|DEVICE|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
214587833|NCT03190447|DEVICE|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
214587834|NCT03190447|DEVICE|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
214587835|NCT03190447|DEVICE|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
214587836|NCT03190447|DEVICE|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
214587837|NCT01912456|BIOLOGICAL|Low-volume C1-esterase inhibitor|
214587838|NCT01912456|BIOLOGICAL|Higher-volume C1-esterase inhibitor|
214587839|NCT01912456|BIOLOGICAL|Low-volume placebo|
214587840|NCT01912456|BIOLOGICAL|Higher-volume placebo|
214710722|NCT00282867|DRUG|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
214587841|NCT01201343|DRUG|Interferon beta-1a|
214587842|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
214587843|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
214587844|NCT00914160|DRUG|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
214587845|NCT05269810|DRUG|SA001 Low dose|3 tablets b.i.d for 8 weeks
214587846|NCT05269810|DRUG|SA001 Mid dose|3 tablets b.i.d for 8 weeks
214587847|NCT05269810|DRUG|SA001 High dose|3 tablets b.i.d for 8 weeks
214587848|NCT05269810|DRUG|Placebo|3 tablets b.i.d for 8 weeks
214710723|NCT00282867|OTHER|standard care|usual care
214710724|NCT00141180|DRUG|CP-481,715|
214587849|NCT01206543|OTHER|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
214587850|NCT00390585|DRUG|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
214587851|NCT00390585|DRUG|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
214587852|NCT01932567|OTHER|Physiotherapy|
214587853|NCT01932567|PROCEDURE|Electrical impedance tomography|
214587854|NCT02839642|DRUG|Rivastigmine|
214587855|NCT02839642|DRUG|Placebo|
214710725|NCT02881710|OTHER|contrast product used to assess biomarkers variations|
214587856|NCT00185679|DEVICE|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer"
214587857|NCT05968547|OTHER|Driving assessment in glaucoma patient|One group of patient will be given questionnaire while the other group will respond to a questionnaire while the other group will have vision assessment. Patients could participate in both groups.
214587858|NCT05432778|DRUG|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
214587859|NCT05397184|BIOLOGICAL|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
214587860|NCT05539274|DIAGNOSTIC_TEST|human papilloma virus testing and genotyping in cervical cancer cases|an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
214587861|NCT00552877|DEVICE|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
214587862|NCT01351103|DRUG|LGK974|
214587863|NCT01351103|BIOLOGICAL|PDR001|
214587864|NCT04450160|DRUG|Anhydrous Enol-Oxaloacetate (AEO)|Oral supplementation with AEO along with the Standard of Care (Temozolomide)
214587865|NCT04450160|OTHER|Standard of Care|Standard of Care Temozolomide
214587866|NCT00358553|DRUG|Insulin|
214587867|NCT01793220|OTHER|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
214587868|NCT04604548|DRUG|Oral administration of 100 mg KH176 twice daily|Drug: KH176
214587869|NCT00709696|DRUG|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
214587870|NCT00709696|DRUG|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
214587871|NCT00825617|DRUG|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
214587872|NCT00823056|DIETARY_SUPPLEMENT|probiotics|placebo
214587873|NCT00823056|DIETARY_SUPPLEMENT|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
214587874|NCT00133887|DRUG|rapamycin|3 to 5 mg/day
214587875|NCT00133887|DRUG|ciclosporine|Blood residual level \< or = to 125 ng/ml
214587876|NCT00133887|DRUG|tacrolimus|Blood residual level \< or = to 8 ng/ml
214587877|NCT04074863|PROCEDURE|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
214587878|NCT04074863|PROCEDURE|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
214587879|NCT01833715|DRUG|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
214587880|NCT01833715|DRUG|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
214587881|NCT01833715|DRUG|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
214587882|NCT03457038|BIOLOGICAL|Blood Test|"Addition to the current care but during the normal follow-up visit :~* At the entrance to the service: search for bacterial 16S RNA in the blood~* Additional blood tests (4) at T6-12-18 and 36h~* At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~* 1 time per day: Assay of CRP and PCT from samples taken in common practice~* J30: Assessment of the vital status of the patient"
214587883|NCT00001962|DRUG|Daclizumab|Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
214587884|NCT00458887|PROCEDURE|management of therapy complications|Undergo hearing tests
214587885|NCT02334774|PROCEDURE|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
214587886|NCT01672723|DRUG|Naltrexone|
214587887|NCT03674463|DRUG|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
214587888|NCT05833633|DIAGNOSTIC_TEST|MUSCLE MAGNETIC RESONANCE IMAGING (MRI)|To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
214587889|NCT04201132|DEVICE|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
214710726|NCT03436771|GENETIC|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
214587890|NCT00752310|DRUG|Darunavir|
214587891|NCT01836653|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214587892|NCT01836653|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214587893|NCT01836653|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214710727|NCT03436771|GENETIC|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
214710728|NCT03883490|DIAGNOSTIC_TEST|ECG|A 12-lead ECG will be taken for each participant.
214710729|NCT03883490|DIAGNOSTIC_TEST|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
214587894|NCT01836653|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214587895|NCT01836653|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214710730|NCT03883490|DIAGNOSTIC_TEST|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
214710731|NCT03883490|DIAGNOSTIC_TEST|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
214710732|NCT03883490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
214587896|NCT01836653|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214587897|NCT02070133|DRUG|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
214587898|NCT02070133|DRUG|Placebo|Placebo once a day during 12 weeks
214587899|NCT01236248|BEHAVIORAL|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
214587900|NCT01845220|DRUG|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
214587901|NCT01845220|DRUG|Placebo|80% acetone
214587902|NCT02314910|OTHER|Sample histology|
214587903|NCT02303522|OTHER|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
214587904|NCT00760903|OTHER|Conventional MRI of the brain|
214587905|NCT00760903|OTHER|MR spectroscopy (MRS)|
214587906|NCT00760903|OTHER|MR Diffusion Tensor Imaging (DTI)|
214587907|NCT06280326|OTHER|Sunflower oil|In the experimental group, patch removal will be performed using sunflower oil.
214587908|NCT06280326|OTHER|Slicone based spray|In the control group, clinical routine procedure will be used to remove the patch (silicone based spray.
214587909|NCT04153123|DRUG|Epinephrine|
214587910|NCT06954116|DRUG|Iparomlimab and Tuvonralimab (QL1706)|"Neoadjuvant phase: A single cycle of Iparomlimab and Tuvonralimab (7.5 mg/kg) will be administered within 1 week prior to surgery.~Adjuvant phase: Six cycles of Iparomlimab and Tuvonralimab (7.5 mg/kg, Q3W) will be initiated starting at 2 weeks postoperatively."
214587911|NCT06954116|PROCEDURE|Partial hepatectomy|Will be performed at an appropriate interval following neoadjuvant therapy initiation.
214587912|NCT01945541|DEVICE|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
214587913|NCT03454698|OTHER|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
214587914|NCT02216617|DRUG|Taxotere, Cisplatin, Afatinib|
214587915|NCT04729998|DRUG|Rivaroxaban film-coated tablet 20 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
214587916|NCT04729998|DRUG|Xarelto® film-coated tablet 20 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
214587917|NCT06085911|BEHAVIORAL|One day course|a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.
214587918|NCT06085911|BEHAVIORAL|Individual follow-ups|the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
214587919|NCT02712229|BEHAVIORAL|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
214587920|NCT04680494|OTHER|moderate intensity physical exercise|
214587921|NCT04680494|OTHER|high intensity physical exercise|
214587922|NCT04680494|OTHER|rest|
214587923|NCT03538249|OTHER|Aerobic training|
214587924|NCT03538249|OTHER|Inspiratory muscle training|
214587925|NCT03538249|OTHER|Resistance Training|
214587926|NCT03538249|OTHER|Aerobic and Inspiratory training|
214587927|NCT03538249|OTHER|Combined|Aerobic, inspiratory and resistance training
214587928|NCT01807013|PROCEDURE|ultrasound, liver elastometry, minilaparoscopy|"* conventional high-end ultrasound technique,~* small access laparoscopy with fine laparoscopes~* Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
214587929|NCT05205057|OTHER|Saliva|Unstimulated whole saliva is collected
214587930|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
214587931|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
214587932|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
214587933|NCT01177722|BIOLOGICAL|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
214634374|NCT04754451|DRUG|Group L|Attach two lidocaine patches for 12 hours, one above and below the incision site.
214587934|NCT04993612|DIAGNOSTIC_TEST|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
214587935|NCT01776801|OTHER|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
214587936|NCT02725346|PROCEDURE|Acromioplasty with planning|
214587937|NCT02725346|PROCEDURE|Acromioplasty without planning|
214587938|NCT02782689|DEVICE|Kit Biflex|Two-layer reusable compression system
214587939|NCT02782689|DEVICE|Profore|Four-layer compression system
214587940|NCT05234229|OTHER|Survey|Collection of immunization status by questionnaire
214587941|NCT06090877|DEVICE|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
214587942|NCT00160784|PROCEDURE|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
214587943|NCT00160784|PROCEDURE|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
214587944|NCT00160784|OTHER|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
214587945|NCT02049151|DRUG|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
214587946|NCT02049151|DRUG|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
214710733|NCT04145713|DIETARY_SUPPLEMENT|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
214710734|NCT04145713|OTHER|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
214710735|NCT02157246|OTHER|Pimonidazole|
214710736|NCT02157246|OTHER|F-MISO PET|
214710737|NCT02157246|OTHER|pCT|
214587947|NCT02049151|DRUG|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
214587948|NCT02049151|DRUG|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
214587949|NCT03572478|DRUG|Rucaparib|600 mg taken by mouth twice daily.
214587950|NCT03572478|DRUG|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
214710738|NCT02157246|OTHER|Functional MRI|
214710739|NCT02157246|PROCEDURE|Biopsy|
214710740|NCT02157246|PROCEDURE|Blood sample|
214710741|NCT03454204|OTHER|Pharmacokinetic|Analysis of blood samples
214710742|NCT00000937|DRUG|Antibiotics|
214587951|NCT00003998|DRUG|carboplatin|
214587952|NCT00003998|DRUG|docetaxel|
214587953|NCT00003998|DRUG|paclitaxel|
214587954|NCT00003998|PROCEDURE|surgical procedure|
214587955|NCT04728412|DEVICE|High Flow Oxygen Therapy (HFOT)|HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
214587956|NCT00596427|DRUG|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
214587957|NCT00596427|DRUG|Placebo|Placebo tablets: 3 tablets twice per day
214587958|NCT00320541|DRUG|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
214587959|NCT00320541|DRUG|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
214587960|NCT00320541|DRUG|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
214710743|NCT05766436|DRUG|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
214710744|NCT05766436|DRUG|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
214710745|NCT05766436|DRUG|Placebo|placebo ODF and 0.9% normal saline nebulizer
214710746|NCT06367972|PROCEDURE|Local Consolidation Therapy|Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
214710747|NCT06367972|PROCEDURE|Next-line Systemic Therapy|The specific next-line systemic therapy will be determined by your doctor.
214710748|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
214710749|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
214710750|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
214710751|NCT00979017|DRUG|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
214710752|NCT00979017|DRUG|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
214587961|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
214587962|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
214587963|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
214587964|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
214587965|NCT00284817|DRUG|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
214587966|NCT04706767|DRUG|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
214587967|NCT04706767|DRUG|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
214587968|NCT04706767|DRUG|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
214587969|NCT04706767|DRUG|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
214710753|NCT00979017|DRUG|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
214710754|NCT00027456|DRUG|Leptin A-100|
214587970|NCT02608593|PROCEDURE|Strattice|Implant based reconstruction with strattice cover of part or all of implant
214587971|NCT04293445|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
214587972|NCT03294746|OTHER|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
214587973|NCT03294746|OTHER|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
214587974|NCT01605292|PROCEDURE|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
214587975|NCT01605292|PROCEDURE|Palpation|Manual palpation for localizing radial artery for inserting needle.
214587976|NCT03057977|DRUG|Empagliflozin|once daily
214587977|NCT03057977|DRUG|Placebo|once daily
214587978|NCT04832425|DRUG|PRAX-114|40 mg once daily
214587979|NCT04832425|DRUG|Placebo|Placebo once daily
214587980|NCT02112331|OTHER|Raw human milk|
214710755|NCT03589885|DRUG|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
214587981|NCT02112331|OTHER|Pasteurized human milk|
214587982|NCT02112331|OTHER|Pasteurized-homogenized human milk|
214587983|NCT02112331|OTHER|Gastric samples|
214587984|NCT01688414|PROCEDURE|photoacoustic imaging|Undergo PAI
214587985|NCT01688414|PROCEDURE|fluorescence imaging|Undergo fluorescence imaging
214587986|NCT01688414|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
214587987|NCT01730794|OTHER|NAVA ventilation|Neurally adjusted ventilatory assist
214587988|NCT01730794|OTHER|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
214587989|NCT05510752|BEHAVIORAL|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
214587990|NCT05510752|BEHAVIORAL|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
214587991|NCT01459419|DRUG|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
214587992|NCT01459419|DRUG|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
214587993|NCT06137014|DRUG|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
214587994|NCT06137014|DIETARY_SUPPLEMENT|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
214587995|NCT06432894|COMBINATION_PRODUCT|Analgesia Nociception Index, remimazolam|"The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam.~During this study, remimazolam infusion rate is determined by the pharmacopoeia.~Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model.~ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery."
214587996|NCT04124393|PROCEDURE|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
214587997|NCT02669511|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
214587998|NCT03960307|OTHER|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
214587999|NCT04675021|DRUG|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
214588000|NCT04675021|DRUG|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
214588001|NCT04675021|DRUG|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
214588002|NCT05782452|PROCEDURE|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
214588003|NCT05782452|GENETIC|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
214588004|NCT02411500|DRUG|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
214588005|NCT00362453|BEHAVIORAL|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
214588006|NCT03187340|BEHAVIORAL|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
214588007|NCT03187340|BEHAVIORAL|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
214588008|NCT04398420|DEVICE|TVERP|Transurethral Vapor Enucleation Resection of the prostate
214588009|NCT04398420|DEVICE|TURis|Transurethral Vapor Enucleation Resection of the prostate
214588010|NCT04398420|DEVICE|HoLEP|Transurethral Vapor Enucleation Resection of the prostate
214588011|NCT05624294|DRUG|CS0159|Tablets administered orally
214588012|NCT05624294|DRUG|Placebo|Tablets administered orally
214588013|NCT01640054|DRUG|Fostamatinib|Fostamatinib 100mg once daily
214588014|NCT00165087|DRUG|asparaginase (E. Coli)|
214588015|NCT00165087|DRUG|asparaginase (Erwina)|
214588016|NCT00165087|DRUG|dexrazoxane|
214588017|NCT00165087|DRUG|doxorubicin|
214588018|NCT00165087|PROCEDURE|cranial radiation (once daily fractionation)|
214588019|NCT00165087|PROCEDURE|cranial radiation (twice-daily fractionation)|
214588020|NCT00165087|PROCEDURE|Intrathecal chemotherapy without radiation|
214588021|NCT04740008|DRUG|Low Nicotine Content Cigarettes|Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
214588022|NCT04740008|OTHER|Control message|Participants will read control message
214588023|NCT04740008|OTHER|Test message|Participants will read test message
214588024|NCT00029172|OTHER|case management|
214588025|NCT03448120|PROCEDURE|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
214588026|NCT03448120|PROCEDURE|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
214588027|NCT04248985|OTHER|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
214588028|NCT02839837|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
214588029|NCT02839837|DEVICE|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
214588030|NCT04923854|OTHER|No intervention|No intervention
214588031|NCT03125525|DEVICE|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
214588032|NCT04950088|OTHER|Hand-held video game device|
214588033|NCT04962802|BEHAVIORAL|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
214588034|NCT04962802|BEHAVIORAL|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
214588035|NCT05156632|BIOLOGICAL|Medium-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.
214588036|NCT05156632|BIOLOGICAL|High-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
214588037|NCT05156632|BIOLOGICAL|Placebo-comparator group|The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
214588038|NCT04980508|DIAGNOSTIC_TEST|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
214588039|NCT05486546|PROCEDURE|Contoura with Phorcides|Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
214588040|NCT05486546|DEVICE|WaveLight Wavefront Optimized|Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
214710756|NCT03589885|DRUG|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
214710757|NCT03589885|DRUG|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
214710758|NCT03589885|DRUG|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
214710759|NCT01995279|DEVICE|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
214588041|NCT01416688|PROCEDURE|assessment of therapy complications|Will be given by questionnaire
214588042|NCT01416688|PROCEDURE|psychosocial assessment and care|Will be given by questionnaire
214588043|NCT01416688|PROCEDURE|quality-of-life assessment|Will be given by questionnaire
214588044|NCT00002023|DRUG|Zidovudine|
214588045|NCT03175965|DEVICE|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
214588046|NCT02080221|DRUG|FOLFOXA|
214588047|NCT02047643|DEVICE|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
214588048|NCT04629001|DIAGNOSTIC_TEST|Covid-19 PCR , IGM|test for Covid-19
214588049|NCT01386788|OTHER|There is no intervention planned (observational)|No intervention foreseen
214588050|NCT03089151|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
214588051|NCT00581815|DEVICE|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
214588052|NCT00581815|DEVICE|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
214588053|NCT01432717|BIOLOGICAL|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
214588054|NCT01432717|OTHER|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
214588055|NCT05874115|OTHER|liquid biopsy|liquid biopsy
214588056|NCT04187053|PROCEDURE|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
214588057|NCT04187053|DRUG|Saline|Sham group will receive saline as a sham for methylene blue
214588058|NCT04187053|DRUG|Methylene Blue|Experimental arm will receive methylene blue
214588059|NCT04187053|DEVICE|Light emitting laser|Experimental arm will receive Light emitting laser
214710760|NCT01995279|OTHER|Sham Ultrasound|Ultrasound turned off.
214588060|NCT04187053|DEVICE|Non-light emitting laser|Sham group will receive Non-light emitting laser
214588061|NCT04001985|OTHER|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
214588062|NCT04001985|OTHER|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
214588063|NCT00120406|DEVICE|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
214588064|NCT00120406|PROCEDURE|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
214710761|NCT00553345|DRUG|selenium|
214710762|NCT00553345|DRUG|vitamin E|
214710763|NCT00553345|PROCEDURE|chemoprevention|
214588065|NCT06209671|BIOLOGICAL|INS19 CAR-T Cells|INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
214588066|NCT06381050|DRUG|SHR-7631|The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
214588067|NCT03703245|OTHER|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
214588068|NCT03703245|OTHER|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
214588069|NCT03542409|OTHER|MR Perfusion Scan|MR perfusion scan before and during surgery.
214588070|NCT03542409|OTHER|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
214588071|NCT03542409|OTHER|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
214588072|NCT05390983|PROCEDURE|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
214588073|NCT03590405|PROCEDURE|uterus transplantation surgery and IVF|IVF before surgery living donor uterus transplantation ET
214588074|NCT06283004|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
214588075|NCT06283004|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
214588076|NCT06283004|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
214588077|NCT05960565|DRUG|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
214588078|NCT04032626|DRUG|Lenalidomide 10 mg|Lenalid
214588079|NCT04032626|DRUG|Placebo|Placebo
214588080|NCT05588687|BEHAVIORAL|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
214588081|NCT05588687|DEVICE|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
214588082|NCT02808143|BIOLOGICAL|BCG Solution|Given intravesically
214588083|NCT02808143|OTHER|Laboratory Biomarker Analysis|Correlative studies
214588084|NCT02808143|BIOLOGICAL|Pembrolizumab|Given intravesically
214588085|NCT02808143|OTHER|Pharmacological Study|Correlative studies
214588086|NCT04964388|DRUG|GLP-1 receptor agonist|Diabetes medication
214588087|NCT03082742|DRUG|Hydrochlorothiazide|
214588088|NCT03082742|DRUG|Furosemide|
214588089|NCT02445001|PROCEDURE|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
214588090|NCT00675090|DRUG|GSK239512|GSK239512 oral tablets once a day
214588091|NCT00675090|DRUG|Placebo|Placebo tablets to match once a day
214588092|NCT06391502|BEHAVIORAL|Multi-component Exercise Intervention Program|"The Vivifrail program (http://vivifrail.com) is a home-based exercise program that focuses on personalized multi-component exercise prescriptions based on an elderly person's functional abilities, including resistance/strength, balance, flexibility, and cardiovascular endurance exercise (i.e., walking).~During hospitalization, patients who meet the criteria of sodium intake will be screened, and then divided into groups according to the method of randomized controlled trial. The experimental group will carry out corresponding exercise plan according to the results of SPPB."
214588093|NCT06436027|DIAGNOSTIC_TEST|Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling|Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.
214588094|NCT03507660|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
214588095|NCT04436939|DEVICE|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
214588096|NCT00259584|BEHAVIORAL|Management and Outcome of SVCO|
214588097|NCT05334745|OTHER|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
214588098|NCT03916289|OTHER|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
214588099|NCT00250679|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
214588100|NCT00250679|DRUG|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
214588101|NCT00250679|DRUG|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
214588102|NCT00250679|DRUG|Placebo|Placebo nebule or placebo aerolizer
214588103|NCT00187967|DEVICE|pumps used for cardiopulmonary bypass|
214588104|NCT05902182|DEVICE|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
214588105|NCT06226818|OTHER|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
214588106|NCT01093521|DRUG|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
214588107|NCT01093521|DRUG|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
214588108|NCT03211910|DEVICE|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
214588109|NCT03211910|OTHER|Standard Care of Treatment|Standard Care of Treatment
214588110|NCT02207881|DRUG|VDO gel|VDO gel
214588111|NCT02207881|DRUG|placebo|matching placebo gel
214588112|NCT00448279|DRUG|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
214588113|NCT00448279|DRUG|Chemotherapy|Schedule and dose at the investigator's discretion
214588114|NCT02179320|PROCEDURE|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
214588115|NCT02179320|DEVICE|acupuncture needle 0,25 x 40mm|
214588116|NCT03947437|BIOLOGICAL|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
214588117|NCT03947437|BIOLOGICAL|Placebo|Sterile normal saline for injection.
214588118|NCT02584582|DRUG|Liraglutide|
214588119|NCT02584582|DRUG|Exenatide|
214588120|NCT02584582|PROCEDURE|Liquid meal test|
214588121|NCT02584582|OTHER|No drug (Baseline day)|
214710764|NCT03638882|BEHAVIORAL|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
214710765|NCT03638882|BEHAVIORAL|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
214588122|NCT06409520|DIAGNOSTIC_TEST|thyroid function tests|(TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.
214588123|NCT06409520|DIAGNOSTIC_TEST|cardiac enzymes|troponine
214588124|NCT06409520|DIAGNOSTIC_TEST|ECG|Electrocardiogram
214588125|NCT02985320|BIOLOGICAL|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
214588126|NCT02985320|BIOLOGICAL|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
214588127|NCT02985320|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
214588128|NCT02985320|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
214588129|NCT02985320|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
214588130|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
214588131|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
214710766|NCT03638882|BEHAVIORAL|Passive Control|No Intervention.
214588132|NCT03907410|OTHER|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
214588133|NCT03907410|OTHER|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
214588134|NCT01326234|BEHAVIORAL|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
214588135|NCT01326234|BEHAVIORAL|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
214588136|NCT06648733|OTHER|Structured pharmaceutical discharge management|These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
214588137|NCT01166321|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
214588138|NCT03127254|BEHAVIORAL|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
214588139|NCT03127254|BEHAVIORAL|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
214588140|NCT03127254|BEHAVIORAL|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
214588141|NCT03127254|BEHAVIORAL|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
214588142|NCT03127254|BEHAVIORAL|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
214588143|NCT06186570|BEHAVIORAL|Online-Based Self-Help Intervention|See the description above.
214588144|NCT02391454|DEVICE|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
214588145|NCT02391454|OTHER|Usual care|
214588146|NCT03718533|DRUG|Eltrombopag|Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
214588147|NCT01295034|DIETARY_SUPPLEMENT|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
214588148|NCT01295034|DRUG|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
214588149|NCT03133325|DEVICE|GP0045|Hyaluronic acid gel
214588150|NCT03133325|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid gel
214588151|NCT02116101|DIETARY_SUPPLEMENT|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
214588152|NCT02116101|DIETARY_SUPPLEMENT|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
214588153|NCT03728322|BIOLOGICAL|iHSCs treatment group|iHSCs intravenous injection
214588154|NCT02530203|DEVICE|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
214588155|NCT02530203|DEVICE|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
214588156|NCT00135759|DRUG|Naltrexone|low dose naltrexone in addition to daily methadone taper
214588157|NCT00135759|DRUG|Placebo comparator|1 capsule/day for 6 days
214588158|NCT00135759|DRUG|naltrexone|0.125 mg capsule/day for 6 days
214588159|NCT00135759|DRUG|naltrexone|0.250 mg capsule/day for 6 days
214588160|NCT00903955|OTHER|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
214588161|NCT06456450|BIOLOGICAL|Biological Treatment for severe asthma patients|Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
214588162|NCT00781287|DRUG|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
214588163|NCT00781287|DRUG|Raltegravir|400 mg BID PO
214588164|NCT06116955|DRUG|Midazolam and sufentanil|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
214588165|NCT06116955|DRUG|Midazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
214588166|NCT06116955|DRUG|Remazolam and sufentanil.|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
214588167|NCT06116955|DRUG|Remazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
214588168|NCT05127252|DIAGNOSTIC_TEST|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
214588169|NCT04793659|DRUG|Oral Fasudil 90 mg/day|Oral tablet
214588170|NCT04793659|DRUG|Oral Fasudil 180 mg/day|Oral tablet
214588171|NCT04793659|DRUG|Oral Placebo|Oral tablet
214588172|NCT03748407|OTHER|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
214588173|NCT00549783|BIOLOGICAL|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
214588174|NCT00549783|BIOLOGICAL|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
214588175|NCT00557934|OTHER|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
214710767|NCT04325776|DRUG|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
214588176|NCT04806542|BEHAVIORAL|TMR-group|A mindfulness-based 8 week program.
214588177|NCT04806542|BEHAVIORAL|Treatment as usual|Individual counselling.
214588178|NCT04574050|OTHER|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
214710768|NCT04325776|DRUG|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
214588179|NCT02314182|PROCEDURE|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~* Within 3 weeks after randomization~* Immunonutrition given 7 days prior to PT resection~* Mechanical bowel preparation performed before surgery according to the local practices~* Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~* Must be performed within 4 weeks after surgery~* CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~* Within 4 weeks after the surgery~* Chemotherapy administered according to the usual scheme for the chosen protocol~* All validated and/or registered perioperative rectal cancer treatments authorized~* The duration of one treatment cycle depending on the type of treatment administered~* Radiotherapy is allowed after randomization if indicated"
214588180|NCT02314182|DRUG|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
214588181|NCT03856554|PROCEDURE|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
214588182|NCT03856554|PROCEDURE|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
214588183|NCT02536807|DRUG|Hyaluronan|HA gel injection
214588184|NCT02952378|DRUG|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
214588185|NCT00114413|DRUG|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
214588186|NCT00114413|PROCEDURE|eNO measurement|measured by Aerocrine® NIOX device
214588187|NCT00728611|BIOLOGICAL|PRGF|intra auricular injection 6mg
214588188|NCT00728611|DRUG|hyaluronic acid|20 mg / 2 ml
214588189|NCT00728611|DRUG|placebo|physiological water 3cc + lidocain 3cc
214588190|NCT02842606|OTHER|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
214588191|NCT02930356|OTHER|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
214588192|NCT02930356|OTHER|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
214588193|NCT02877979|DRUG|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
214588194|NCT02877979|DRUG|Placebo|
214588195|NCT04361188|PROCEDURE|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
214588196|NCT04361188|PROCEDURE|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
214588197|NCT04984525|DRUG|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
214588198|NCT04984525|DRUG|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
214588199|NCT01179425|OTHER|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
214588200|NCT04942834|DRUG|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
214588201|NCT04942834|DEVICE|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
214588202|NCT04253067|DEVICE|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
214588203|NCT04253067|DEVICE|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
214588204|NCT01174160|DRUG|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
214588205|NCT01174160|DRUG|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
214588206|NCT02289612|OTHER|Yellow Mustard Gum Fibre|
214588207|NCT02289612|OTHER|Soluble Flaxseed Gum Fibre|
214588208|NCT02289612|OTHER|Fenugreek Gum Fibre|
214588209|NCT03452358|PROCEDURE|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
214588210|NCT02899013|OTHER|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
214710769|NCT05109130|PROCEDURE|Surgical approach|Different surgical methods for rectal cancer resection
214710770|NCT04663139|DRUG|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
214588211|NCT03616197|PROCEDURE|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
214588212|NCT02744378|DRUG|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
214588213|NCT02744378|DRUG|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
214588214|NCT02116985|DEVICE|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
214588215|NCT02116985|DEVICE|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
214588216|NCT00108654|DRUG|VRC-HIVADV014-00-VP|
214588217|NCT03537287|DRUG|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
214588218|NCT03537287|DRUG|Vaginal progesterone|200 mg of vaginal progesterone daily
214588219|NCT03537287|DRUG|Oral dydrogesterone|2 tablets of dydrogesterone daily
214588220|NCT00892684|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
214588221|NCT00892684|DIETARY_SUPPLEMENT|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
214588222|NCT01840787|DEVICE|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
214588223|NCT01840787|DEVICE|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
214588224|NCT01840787|DEVICE|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
214588225|NCT04152460|DEVICE|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
214588226|NCT04152460|OTHER|Grandioso x-tra|Nanohybrid Bulk Resin Composite
214588227|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
214588228|NCT04218084|DRUG|Voxelotor|Participants are randomized 1:1 to receive voxelotor or placebo.
214588229|NCT04218084|DRUG|Placebo|Matching placebo.
214588230|NCT06962306|DRUG|Methadone hydrochloride|Initial dosing 0.2mg/kg, potential to escalate to 0.25mg/kg following interim analysis
214588231|NCT06962306|DRUG|Fentanyl/Hydromorphone|Per routine care
214588232|NCT05133778|DIETARY_SUPPLEMENT|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
214588233|NCT05133778|OTHER|Maltodextrin control|Supplementation with 760 mg maltodextrin
214588234|NCT06643143|DRUG|IkT-001Pro|IkT-001Pro
214588235|NCT06643143|DRUG|Placebo|Placebo
214588236|NCT05816122|DEVICE|MSCopilot® Detect mobile application|MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
214588237|NCT05580588|DRUG|SPH4336|400 mg SPH4336 PO QD
214588238|NCT04723420|OTHER|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
214588239|NCT04723420|OTHER|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
214588240|NCT06062147|BEHAVIORAL|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
214588241|NCT04912375|BEHAVIORAL|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
214588242|NCT05093699|DEVICE|Butterfly iQ+ ultrasound probe|Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
214588243|NCT05093699|DEVICE|Ultrasound probe|Standard single-view ultrasound probe
214588244|NCT00211185|DRUG|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
214588245|NCT00211185|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
214588246|NCT00211185|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
214588247|NCT00211185|DRUG|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
214588248|NCT00211185|DRUG|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
214588249|NCT00211185|OTHER|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
214588250|NCT05271292|DRUG|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
214588251|NCT00712673|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
214588252|NCT00712673|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
214588253|NCT00712673|DEVICE|Pen auto-injector|
214588254|NCT00712673|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
214588255|NCT02729428|DEVICE|MRI|Participants will undergo an MRI scan
214588256|NCT04581096|OTHER|no intervention|just descriptive analysis of clinical data
214710771|NCT04663139|DRUG|Placebo|Matching placebo
214710772|NCT01603030|DRUG|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
214710773|NCT01603030|DRUG|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
214588257|NCT05839496|OTHER|Cervical stabilization exercises|Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
214588258|NCT00969527|DIETARY_SUPPLEMENT|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
214588259|NCT00969527|DIETARY_SUPPLEMENT|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
214588260|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
214588261|NCT00471159|DRUG|docetaxel|
214588262|NCT00471159|DRUG|PF-3512676|
214588263|NCT01242358|DEVICE|Capnography|Capnographic monitoring
214588264|NCT01242358|DEVICE|Standard monitoring|Standard monitoring
214588265|NCT06483529|DIAGNOSTIC_TEST|compliance measurement|compliance can be measured by analyzing pressure volume curves generated through different methods
214588266|NCT04136665|OTHER|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
214588267|NCT01947985|DRUG|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
214588268|NCT01947985|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
214588269|NCT03728556|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
214588270|NCT03728556|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
214588271|NCT03794167|DRUG|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
214588272|NCT03794167|DRUG|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
214588273|NCT03794167|DRUG|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
214588274|NCT03794167|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
214588275|NCT04264078|BIOLOGICAL|CD7 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
214588276|NCT04264078|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
214588277|NCT04264078|DRUG|Cytoxan|600mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
214588278|NCT04264078|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
214588279|NCT06453785|DEVICE|Promaxo portable MRI|"The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel truly open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies."
214588280|NCT04457167|DEVICE|Robot-assisted|robot-assisted surgery
214588281|NCT04457167|PROCEDURE|Not robot-assisted surgery|Not robot-assisted surgery
214588282|NCT02701348|OTHER|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
214588283|NCT02701348|DRUG|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
214588284|NCT02701348|PROCEDURE|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
214588285|NCT02701348|OTHER|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
214588286|NCT01882933|DRUG|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
214588287|NCT01882933|PROCEDURE|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
214588288|NCT04088773|DIAGNOSTIC_TEST|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
214588289|NCT04088773|DIAGNOSTIC_TEST|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
214588290|NCT04088773|DIAGNOSTIC_TEST|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
214588291|NCT03305731|BEHAVIORAL|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
214588292|NCT03658668|DEVICE|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.
214588293|NCT03658668|DEVICE|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
214588294|NCT03658668|OTHER|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
214588295|NCT01874860|DRUG|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
214588296|NCT01874860|DRUG|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
214588297|NCT01874860|OTHER|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
214588298|NCT01874860|OTHER|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
214588299|NCT01874860|DRUG|Clindamycin|Recommended for daily use if rash returns (Topical cream)
214588300|NCT01874860|DRUG|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
214588301|NCT01049971|DEVICE|wound protector|after minilaparotomy, the wound protector is applied
214588302|NCT01049971|DEVICE|no wound protector|use of woven drape instead of wound protector
214588303|NCT01952054|DRUG|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
214588304|NCT00521560|DRUG|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
214588305|NCT02585479|DRUG|Pirarubicin|"1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
214588306|NCT02585479|DRUG|Oxaliplatin|"1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
214588307|NCT02585479|DRUG|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
214588308|NCT02585479|DEVICE|Gelfoam|Hepatic artery embolization with Gelfoam.
214588309|NCT05664386|DRUG|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
214588310|NCT05664386|DRUG|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
214588311|NCT00648817|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
214588312|NCT00648817|DRUG|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
214588313|NCT02742636|DEVICE|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
214588314|NCT02871310|DIETARY_SUPPLEMENT|IQP-AS-118|1 tablet in the morning
214588315|NCT02871310|DIETARY_SUPPLEMENT|Placebo|1 tablet in the morning
214588316|NCT04564651|OTHER|platelet transfusion|when the ADP inhibition \>70%, give one unit platelet tansfusion
214588317|NCT04572087|OTHER|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
214588318|NCT04572087|OTHER|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
214588319|NCT03760705|OTHER|Data Collection|"1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
214588320|NCT02051270|OTHER|Descriptive study|More than 65 years old elders
214588321|NCT02009995|BEHAVIORAL|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
214588322|NCT02009995|BEHAVIORAL|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
214588323|NCT01284660|DIETARY_SUPPLEMENT|DHA|DHA ingested orally by heavy smokers
214588324|NCT01284660|DIETARY_SUPPLEMENT|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
214588325|NCT02152657|OTHER|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
214588326|NCT01498653|DRUG|GW685698/GW642444|ICS/LABA
214588327|NCT01498653|DRUG|CCI18781|ICS
214588328|NCT03672656|DEVICE|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
214588329|NCT03672656|DEVICE|conventional laser|conventional laser multiple-session treatment
214588330|NCT02720614|RADIATION|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
214588331|NCT05208866|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
214588332|NCT06502873|PROCEDURE|biological samples collection|Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
214588333|NCT05895565|DRUG|PMG1015|Including 3 dose levels: level 1, level 2 and level 3
214588334|NCT05895565|DRUG|PMG1015 placebo|Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
214588335|NCT06084156|DRUG|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
214588336|NCT06084156|DRUG|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
214588337|NCT04646915|OTHER|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
214588338|NCT01442818|DRUG|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
214588339|NCT01442818|DRUG|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
214588340|NCT04524884|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
214588341|NCT04524884|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
214588342|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.
214588343|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
214588344|NCT00539890|DRUG|Technosphere Insulin|
214588345|NCT03459274|DEVICE|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
214710774|NCT02489565|OTHER|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
214710775|NCT04488848|OTHER|bolus glucose|bolus Glucose
214588346|NCT04112901|DEVICE|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
214588347|NCT04112901|DEVICE|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
214588348|NCT02601664|PROCEDURE|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
214588349|NCT02601664|PROCEDURE|Conventional PCI|Conventional PCI
214588350|NCT02070588|DEVICE|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
214588351|NCT02972125|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
214588352|NCT02972125|DRUG|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
214588353|NCT00298090|DEVICE|StO2 monitoring|placement of the StO2 device/ external noninvasive
214588354|NCT03840226|DRUG|Placebo Oral Tablet|Placebo tablets
214588355|NCT03840226|DRUG|Magnesium Oxide|Magnesium tablets
214588356|NCT00972205|DRUG|paclitaxel|Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
214588357|NCT00972205|DRUG|CBT-1(Registered Trademark)|CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
214588358|NCT00972205|RADIATION|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
214588359|NCT03316625|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone Densitometry and measurement of body composition
214588360|NCT05235321|DEVICE|Standard GAT|Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice
214588361|NCT05235321|DEVICE|Fixed force GAT|An investigational device similar to standard GAT
214588362|NCT05235321|DEVICE|Upright applanating prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device
214588363|NCT05235321|DEVICE|Supine Applanating Prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
214588364|NCT02682641|DRUG|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
214588365|NCT02682641|DRUG|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
214588366|NCT01306487|PROCEDURE|Vitrectomy|Macular hole surgery
214588367|NCT05525611|DRUG|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
214588368|NCT05525611|OTHER|Placebo|Placebo once a week in 12 weeks
214588369|NCT04409886|BIOLOGICAL|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
214588370|NCT04255069|DRUG|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
214588371|NCT04255069|DRUG|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
214710776|NCT04488848|OTHER|continuous clucose|continuous clucose
214588372|NCT04255069|DRUG|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
214710777|NCT02816125|DIETARY_SUPPLEMENT|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
214710778|NCT00641524|PROCEDURE|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
214710779|NCT02119234|DRUG|Beclometasone/formoterol/glycopyrrolate|
214710780|NCT02119234|DRUG|Placebo|
214710781|NCT02435641|OTHER|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
214588373|NCT05635539|DIETARY_SUPPLEMENT|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
214588374|NCT04795882|BIOLOGICAL|BCMA CAR T cells|Infusion with ATIMP: BCMA CAR T-cells
214588375|NCT04795882|BIOLOGICAL|BCMA/CD19 CAR T cells|Infusion with ATIMP: BCMA/CD19 CAR T-cells
214588376|NCT01718353|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
214588377|NCT01718353|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
214588378|NCT01718353|DRUG|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
214588379|NCT05516550|DRUG|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
214710782|NCT03722914|DRUG|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
214588380|NCT05516550|DRUG|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
214588381|NCT05516550|DRUG|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
214588382|NCT05516550|DRUG|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
214588383|NCT00882427|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
214588384|NCT02940938|OTHER|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
214588385|NCT04923841|OTHER|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
214588386|NCT04923841|OTHER|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
214588387|NCT04923841|OTHER|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
214588388|NCT04923841|OTHER|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
214588389|NCT02910661|OTHER|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
214588390|NCT01078675|DRUG|rosuvastatin calcium|5 mg, oral, once daily, 24 months
214588391|NCT01078675|DRUG|rosuvastatin calcium|10 mg, oral, once daily, 24 months
214588392|NCT01078675|DRUG|rosuvastatin calcium|20 mg, oral, once daily, 24 months
214588393|NCT03937726|OTHER|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
214710783|NCT03722914|DRUG|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
214588394|NCT03937726|OTHER|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
214588395|NCT05031403|OTHER|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
214710784|NCT04686019|OTHER|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
214588396|NCT05031403|OTHER|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
214588397|NCT01366495|BEHAVIORAL|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
214588398|NCT00509587|DRUG|pazopanib hydrochloride|Given orally
214588399|NCT00509587|PROCEDURE|pharmacological study|Correlative studies
214588400|NCT00509587|PROCEDURE|laboratory biomarker analysis|Correlative studies
214588401|NCT02326012|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents|
214588402|NCT02931799|BEHAVIORAL|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
214588403|NCT02931799|OTHER|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~* PRO-2 Scale for patients with Crohn's Disease~* 6-Point Mayo Score for patients with Ulcerative Colitis~* Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
214588404|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
214588405|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
214588406|NCT02931799|OTHER|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
214588407|NCT02745392|DRUG|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
214588408|NCT02745392|DRUG|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
214588409|NCT01306955|DRUG|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
214588410|NCT01306955|OTHER|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
214588411|NCT03794687|PROCEDURE|Left heart catheterization|Catheterization via the distal radial artery
214588412|NCT02145247|DRUG|hCG|"3\. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4\. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
214588413|NCT01055379|DRUG|Rasagiline|1 mg/day for 12 weeks; orally
214588414|NCT01055379|DRUG|Placebo|Once daily for 12 weeks; orally
214588415|NCT04927182|OTHER|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
214588416|NCT04927182|OTHER|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
214588417|NCT04927182|OTHER|Moderate Exercise Training (Age Group 3; Above 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
214588418|NCT02853747|BEHAVIORAL|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
214588419|NCT00447304|DRUG|moxifloxacin|
214588420|NCT00447304|PROCEDURE|cholecystectomy|
214588421|NCT00638131|DRUG|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
214588422|NCT00899548|GENETIC|DNA methylation analysis|laboratory analysis
214588423|NCT00899548|GENETIC|microarray analysis|laboratory analysis
214588424|NCT00899548|GENETIC|polymerase chain reaction|laboratory analysis
214588425|NCT00899548|OTHER|laboratory biomarker analysis|laboratory analysis
214588426|NCT02561065|BEHAVIORAL|Lifestyle intervention|"1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
214710785|NCT06432556|GENETIC|scRNAseq|A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
214710786|NCT06432556|PROCEDURE|two Skin biopsies|2 skin biopsies from a lesional area
214588427|NCT05347420|DIAGNOSTIC_TEST|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
214588428|NCT00291590|BEHAVIORAL|DHEP|
214588429|NCT04160767|DRUG|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
214588430|NCT04160767|BEHAVIORAL|Gluten free diet|Gluten free diet will be encouraged in both arms
214588431|NCT04160767|OTHER|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
214588432|NCT01393327|BEHAVIORAL|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
214588433|NCT04479631|DRUG|BRII-196|BRII-196 given intravenously
214588434|NCT04479631|DRUG|Placebo|Placebo given intravenously
214588435|NCT00351949|BIOLOGICAL|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
214588436|NCT06036303|DEVICE|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
214588437|NCT06036303|DEVICE|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
214588438|NCT02277002|DEVICE|Cabin Air Filtration|
214588439|NCT02277002|OTHER|Placebo|No Cabin Air Filtration
214588440|NCT01904123|OTHER|Laboratory Biomarker Analysis|Correlative studies
214588441|NCT01904123|OTHER|Pharmacological Study|Correlative studies
214588442|NCT01904123|DRUG|STAT3 Inhibitor WP1066|Given PO
214588443|NCT03324191|DIETARY_SUPPLEMENT|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
214588444|NCT03324191|DIETARY_SUPPLEMENT|Tea beverage|Tea beverage
214588445|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
214588446|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
214588447|NCT03324191|OTHER|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
214588448|NCT04379726|BEHAVIORAL|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
214588449|NCT03715439|DEVICE|Dental implant|A single dental implant was inserted 3 months after tooth extraction
214588450|NCT00454441|DRUG|MF101|
214588451|NCT01890304|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
214588452|NCT04781387|DRUG|CRS3123|Study drug dosed PO BID for a total of 10 days
214588453|NCT04781387|DRUG|Active Comparator|Active comparator dosed PO QID for 10 days
214588454|NCT00312143|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214588455|NCT04354896|DRUG|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
214588456|NCT04354896|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
214588457|NCT02587468|DIETARY_SUPPLEMENT|Juice Plus+(R)|before-after comparison of plasma phenolics
214588458|NCT06081517|BEHAVIORAL|Social Determinants of Health and toxicity questionnaires|Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
214588459|NCT03523429|DRUG|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
214710787|NCT06432556|PROCEDURE|one Skin biopsies|1 skin biopsies from a lesional area
214710788|NCT00928356|PROCEDURE|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
214710789|NCT00928356|PROCEDURE|Off Pump CABG|Standard of Care Off Pump CABG
214588460|NCT05837494|DRUG|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
214588461|NCT05837494|DRUG|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
214588462|NCT02637960|DRUG|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
214588463|NCT02637960|DRUG|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
214588464|NCT04639141|COMBINATION_PRODUCT|Synbiotic|Prebiotic + Probiotic
214588465|NCT04639141|BEHAVIORAL|Gut-directed Hypnotherapy|Psychotherapy sessions
214588466|NCT01542931|DRUG|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
214588467|NCT00645541|PROCEDURE|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
214588468|NCT01538927|DRUG|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
214588469|NCT01538927|DRUG|Suture|Black silk 000
214588470|NCT05685589|BEHAVIORAL|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
214588471|NCT00710021|DRUG|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
214588472|NCT00710021|DRUG|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
214588473|NCT00444171|PROCEDURE|insulin infusion rate controled by computer algorithm|
214588474|NCT00444171|PROCEDURE|insulin infusion rate guided by in-house glucose management protocol|
214588475|NCT03028038|DRUG|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
214588476|NCT03028038|DRUG|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
214588477|NCT03985085|OTHER|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
214588478|NCT03812393|DRUG|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
214588479|NCT00415077|PROCEDURE|PRK|PRK
214588480|NCT00415077|PROCEDURE|MMC PRK|mitomycin C PRK
214588481|NCT00415077|PROCEDURE|LASEK|LASEK
214588482|NCT02918227|PROCEDURE|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
214588483|NCT00832234|DRUG|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
214588484|NCT06106620|DIETARY_SUPPLEMENT|Placebo|Placebo drink consisting of 12 oz of flavor-matched water.
214588485|NCT06106620|DIETARY_SUPPLEMENT|Safety Shot|Safety Shot consisting of a 12 oz drink containing vitamins, mineral, and botanical extracts.
214588486|NCT00032526|DRUG|Corticosteroids|
214588487|NCT00032526|BEHAVIORAL|Classical conditioning to corticosteroid|
214588488|NCT00416234|PROCEDURE|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
214588489|NCT00416234|PROCEDURE|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
214588490|NCT01026285|DRUG|Risperidone Long-Acting injectable or oral antipsychotics|According to label
214588491|NCT06416709|DRUG|mesenchymal stem cells|Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times
214588492|NCT06416709|OTHER|saline|10 ml saline is used as placebo once every three days and for three times
214588493|NCT04329507|DIAGNOSTIC_TEST|Breath test|collection of an exhaled breath sample
214588494|NCT03557580|DRUG|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
214710790|NCT03848611|DRUG|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
214588495|NCT03557580|DRUG|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
214588496|NCT03557580|DRUG|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
214588497|NCT05322746|DEVICE|Focal muscle vibration|Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
214710791|NCT04179435|BEHAVIORAL|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
214710792|NCT04179435|OTHER|brain MRI|Brain MRI scans
214710793|NCT04179435|OTHER|TMS|Measure of the cortical inhibitory capacity using TMS measures
214710794|NCT05549648|OTHER|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
214588498|NCT04308161|DRUG|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
214588499|NCT04308161|DRUG|Miconazole Topical Gel|topical anti fungal agent
214710795|NCT01925651|RADIATION|No Bolus|no bolus use
214710796|NCT01925651|RADIATION|Alternate Bolus|0.5cm bolus use in alternate days
214710797|NCT01925651|RADIATION|Continuous Bolus|0.5 cm bolus use in continuous days
214588500|NCT04308161|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
214710798|NCT06390631|DEVICE|Continuous Positive Airway Pressure|Patients with COPD were recruited to breath under the atmosphere pressure and different levels of CPAP (4, 6, 8 and 10 cm H2O).
214710799|NCT04306055|OTHER|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
214710800|NCT04306055|OTHER|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
214710801|NCT04569916|RADIATION|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
214588501|NCT04308161|DRUG|Oracure gel|Topical analgesic gel
214588502|NCT04308161|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
214588503|NCT04646954|DIAGNOSTIC_TEST|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
214588504|NCT04646954|DIAGNOSTIC_TEST|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
214588505|NCT03689660|OTHER|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
214588506|NCT03689660|OTHER|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
214588507|NCT03689660|OTHER|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
214588508|NCT02112838|DRUG|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
214588509|NCT02112838|DRUG|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
214588510|NCT02112838|DRUG|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
214588511|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
214588512|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
214588513|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
214588514|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
214588515|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
214588516|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
214588517|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
214588518|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
214588519|NCT01822301|PROCEDURE|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
214634375|NCT01484626|DRUG|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m\^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m\^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m\^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m\^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
214588520|NCT03588286|PROCEDURE|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
214588521|NCT03588286|OTHER|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
214588522|NCT03588286|PROCEDURE|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
214588523|NCT05344781|OTHER|Questionnaire|Questionnaire regarding relationship and sexual satisfaction
214588524|NCT03948555|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)|All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
214588525|NCT00315900|DRUG|Depakote ER|depakote ER
214588526|NCT00315900|DRUG|Seroquel|seroquel
214588527|NCT01937156|DRUG|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
214588528|NCT01937156|DRUG|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
214588529|NCT04574167|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
214588530|NCT04574167|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
214588531|NCT04464785|DEVICE|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
214588532|NCT05456802|OTHER|Standard of care treatment|Standard of care treatment including percutaneous interventions was performed in all participants.
214588533|NCT01543932|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
214588534|NCT01543932|DRUG|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
214588535|NCT01543932|DRUG|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
214588536|NCT02761161|DRUG|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
214588537|NCT02761161|BEHAVIORAL|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
214588538|NCT03026985|OTHER|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
214588539|NCT02059785|DRUG|Pinocembrin for Injection|
214588540|NCT00557947|DEVICE|Suture|intradermal and topical suturing
214588541|NCT00557947|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
214710802|NCT04569916|DRUG|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
214710803|NCT04569916|DRUG|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
214710804|NCT04569916|DRUG|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
214710805|NCT01452555|BEHAVIORAL|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
214710806|NCT06161155|COMBINATION_PRODUCT|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
214710807|NCT04408118|DRUG|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
214710808|NCT04408118|DRUG|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
214710809|NCT04408118|DRUG|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
214588542|NCT02792751|DEVICE|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
214588543|NCT02792751|OTHER|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
214588544|NCT04939961|DIETARY_SUPPLEMENT|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
214588545|NCT04939961|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
214588546|NCT05317845|OTHER|No treatment given|The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
214588547|NCT04447196|OTHER|MDP|Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
214588548|NCT00415038|DRUG|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
214588549|NCT00415038|DRUG|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
214710810|NCT01795586|DRUG|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2"
214710811|NCT01795586|DRUG|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
214710812|NCT05946759|DEVICE|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
214710813|NCT05627700|DEVICE|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
214588550|NCT00415038|DRUG|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
214588551|NCT00415038|DRUG|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
214588552|NCT00415038|DRUG|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
214588553|NCT04002401|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of CAR-transduced autologous T cells administered intravenously
214588554|NCT04002401|DRUG|Rituximab|Administered intravenously
214588555|NCT04002401|DRUG|Fludarabine|Administered according to package insert
214588556|NCT04002401|DRUG|Cyclophosphamide|Administered according to package insert
214588557|NCT00423930|BIOLOGICAL|bevacizumab|
214588558|NCT00423930|DRUG|cisplatin|
214588559|NCT00423930|PROCEDURE|conventional surgery|
214588560|NCT00423930|RADIATION|intensity-modulated radiation therapy|
214588561|NCT06390878|OTHER|Biodiversity|In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
214588562|NCT06390878|OTHER|Playground equipment|Playground equipment that increase the physical activity of children will be added to the kindergarten yards.
214588563|NCT03696823|PROCEDURE|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
214588564|NCT00372645|DIETARY_SUPPLEMENT|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
214588565|NCT00372645|DIETARY_SUPPLEMENT|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
214588566|NCT00372645|DRUG|Placebo|Placebo
214588567|NCT00372645|OTHER|Folate rich foods|200 µg folate per day from folate-rich foods
214588568|NCT01622114|OTHER|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
214588569|NCT02217579|DIETARY_SUPPLEMENT|Protein|A food containing 5 grams/serving of supplemental protein.
214588570|NCT02217579|DIETARY_SUPPLEMENT|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
214588571|NCT02217579|DIETARY_SUPPLEMENT|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
214588572|NCT02217579|DIETARY_SUPPLEMENT|Control|An isocaloric food not containing the test protein and fiber.
214588573|NCT03914729|PROCEDURE|Primary Closure|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
214588574|NCT03914729|PROCEDURE|Gluteus Maximus Fascia Plasty Flap|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
214588575|NCT05867563|DRUG|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
214588576|NCT01459900|PROCEDURE|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
214588577|NCT01459900|PROCEDURE|Renal angiography|Renal angiography by femoral access.
214588578|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
214588579|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
214588580|NCT05028907|DRUG|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
214588581|NCT05028907|DRUG|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
214588582|NCT00096343|DRUG|carboplatin|
214588583|NCT00096343|DRUG|paclitaxel|
214588584|NCT00218660|DRUG|Naltrexone|150mg/day Naltrexone
214588585|NCT00218660|BEHAVIORAL|BRENDA|Psychosocial Treatment
214588586|NCT00218660|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
214588587|NCT00218660|DRUG|Placebo|
214588588|NCT05602389|OTHER|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
214588589|NCT05602389|OTHER|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
214588590|NCT05602389|OTHER|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
214588591|NCT02706132|BIOLOGICAL|Mesenchymal Stem Cells(MSCs)|Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
214588592|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish sauce|
214588593|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish/liver sauce|
214588594|NCT01724073|DIETARY_SUPPLEMENT|Misola|
214710814|NCT03889600|OTHER|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
214710815|NCT01913808|DRUG|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
214710816|NCT01913808|DRUG|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
214588595|NCT03242720|PROCEDURE|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
214588596|NCT05846347|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
214588597|NCT02105584|DEVICE|Implantation of LAA closure device|
214588598|NCT00822523|DRUG|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
214588599|NCT00822523|DRUG|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
214588600|NCT00822523|DRUG|Saline|Single Dose, Intramuscular into right EDB muscle
214588601|NCT01315353|PROCEDURE|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
214588602|NCT01315353|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
214588603|NCT03567434|OTHER|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
214588604|NCT02513719|DEVICE|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
214710817|NCT05165979|OTHER|Hospitalization due to COVID-19|Hospitalization due to COVID-19
214710818|NCT03428685|DRUG|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
214588605|NCT01009580|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
214588606|NCT01009580|DRUG|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
214588607|NCT00758277|DRUG|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
214588608|NCT00758277|DRUG|Placebo|Sugar Pill
214710819|NCT03428685|DRUG|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
214710820|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
214710821|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
214710822|NCT02486211|DRUG|Amantadine|100mg twice per day for 7 days at 0600 and 1200
214710823|NCT02486211|DRUG|Placebo|Placebo comparator
214710824|NCT04141553|DRUG|Diltiazem Injection|Randomization to one of to active comparator groups
214710825|NCT02500394|PROCEDURE|Ionosteril|biomarker guided volume substitution with Ionosteril
214710826|NCT05650931|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
214588609|NCT00361660|BEHAVIORAL|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
214588610|NCT00361660|BEHAVIORAL|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
214588611|NCT04491266|DIETARY_SUPPLEMENT|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
214588612|NCT04491266|DIETARY_SUPPLEMENT|placebo|maltodextrins
214588613|NCT01201733|OTHER|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
214588614|NCT01201733|OTHER|Ultrasound therapy and hot pack|
214588615|NCT04485858|DEVICE|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
214588616|NCT04848493|BIOLOGICAL|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
214588617|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
214588618|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
214588619|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
214588620|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
214588621|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
214588622|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
214588623|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
214588624|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
214588625|NCT03409627|BIOLOGICAL|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
214588626|NCT02785471|BEHAVIORAL|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
214588627|NCT02785471|BEHAVIORAL|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
214588628|NCT06854861|DRUG|Lyumjev 100 UNT/ML Injectable Solution|0.1 unit insulin Lyumjev /kg body weight is injected subcutaneously
214588629|NCT06854861|DRUG|Premixed Lyumjev|A solution of 5 ng glucagon /Unit Lyumjev is injcetd subcutaneously. 0.1 unit insulin / kg body weight is used.
214588630|NCT05722574|BEHAVIORAL|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
214588631|NCT05722574|BEHAVIORAL|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
214588632|NCT01018303|DIETARY_SUPPLEMENT|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
214588633|NCT02373943|OTHER|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
214588634|NCT02373943|OTHER|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
214588635|NCT02373943|OTHER|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
214588636|NCT06082908|DIAGNOSTIC_TEST|Diagnostic test|Subjective and objective measurement will be performed in older adults.
214588637|NCT06163911|DEVICE|ECG|Routine care 12-lead electrocardiogram
214588638|NCT06163911|DEVICE|Echocardiography|Routine care echocardiography
214588639|NCT04308343|DRUG|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
214588640|NCT04308343|DRUG|Letrozole|Drugs to treat undisturbed ectopic pregnancies
214588641|NCT04308343|DRUG|cetrotide|Drugs to treat undisturbed ectopic pregnancies
214588642|NCT02368678|PROCEDURE|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
214588643|NCT02368678|PROCEDURE|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
214588644|NCT00879112|DRUG|MB07811|Oral
214588645|NCT00879112|DRUG|Placebo|Oral
214588646|NCT04541498|OTHER|Impact of air pollution and climate changes|To assess the short- and long- term impact of air pollution and climate changes
214588647|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
214588648|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
214588649|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
214588650|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
214588651|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
214588652|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
214588653|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
214588654|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
214588655|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
214588656|NCT06606483|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
214588657|NCT06606483|DRUG|Placebo|Administered orally placebo
214588658|NCT04501211|DRUG|Granisetron|transdermal sancuso patch
214588659|NCT03944473|DRUG|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
214588660|NCT03944473|DRUG|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
214588661|NCT03095677|OTHER|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
214588662|NCT03095677|OTHER|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
214588663|NCT05615545|PROCEDURE|Cryoablation|Cryoablation of selected tumor lesions
214588664|NCT01659788|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|
214588665|NCT01659788|DIETARY_SUPPLEMENT|Placebo|
214588666|NCT00249054|DEVICE|ASR hip prosthesis|Implantation of resurfacing prosthesis
214588667|NCT00249054|DEVICE|ReCap hip prosthesis|Implantation of resurfacing prosthesis
214588668|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
214588669|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
214588670|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
214588671|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
214588672|NCT06609954|OTHER|Reduced Exertion High Intensity Training (REHIT)|Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform training sessions on a cycle ergometer. Each session will consist of a 3-minute warm-up period followed by two 20-second all-out sprints interspersed with 3 minutes of slow pedaling for recovery. Total of 18 sessions of REHIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
214588673|NCT06609954|OTHER|High Intensity Interval Training (HIIT)|Patients in this group will be provided with a caloric restriction plan by a nutritionist that will be followed throughout the training duration. Week 1 will be baseline fitness level and familiarization week. Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform a warm up of 5 min, then 4 bouts of 4 min of HIIT will be performed at 80%-95% of HRR separated by 3-min active recovery periods of moderate intensity cycling at 60%-70% of the HRR followed by 5 min cool down exercises. Pre and post session vitals will be noted. Total of 18 sessions of either HIIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
214588674|NCT06609785|BEHAVIORAL|Exercise|The volunteers successively completed both high intensity interval training (HIIT)and continuous aerobic training (CAT) under the supervision of a professional coach, and the interval between each type of exercise was 7 days. Each training session was initiated with a brief 2-minute standardized warm-up, followed by 20 minutes of cycling consisting of periods of 2 minutes at 80-95% maximal heart rate (HRmax) separated by 2 minutes of active recovery for the HIIT group or 20 minutes of cycling at 60-80% of HRmax for the CAT group.
214588675|NCT06610318|BEHAVIORAL|imagery rescripting|This condition has three stages. In the first stage, participants were asked to select their most distressing memory related to their appearance (not physical or sexual trauma). They were asked to visualize the selected memory, in detail, as if it were happening to them again. Then, interventionists used a downward arrow technique to identify two-to-three maladaptive core schema. In the second stage, participants were asked to identify a real or imagined trusted adult. Then, they were asked to imagine what their younger self might need to cope with or feel calmer in the situation of their selected memory. In the third stage, the participant was instructed to imagine asking the trusted adult for what they need and to imagine the trusted adult providing their selected interventions and describe how they feel afterwards. These procedures were then repeated with participants' most distressing memory related to eating. This session was remote delivered via Zoom.
214588676|NCT06610318|BEHAVIORAL|nutrition education|The active control condition consisted of a time- and attention-matched general nutrition education session. The curriculum for this intervention included information from the United States Department of Agriculture's Dietary Guidelines (e.g., food labels, describing the benefits of macronutrients). This session was remote delivered using Zoom.
214588677|NCT02390245|OTHER|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
214588678|NCT02390245|OTHER|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
214588679|NCT02390245|OTHER|Usual Care|This group will receive ophthalmic referral.
214588680|NCT06609772|OTHER|Individualised Pain Education|Individualised Pain Education
214588681|NCT02677480|DIETARY_SUPPLEMENT|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
214588682|NCT02677480|DIETARY_SUPPLEMENT|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
214588683|NCT03727438|BEHAVIORAL|Tele-Self CBTI|The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
214588684|NCT03727438|OTHER|Health Education Control|The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
214588685|NCT05396677|DRUG|Acetaminophen|2 x 500 mg acetaminophen (one time)
214588686|NCT05396677|OTHER|Placebo|2 x 500 mg microcrystalline cellulose (one time)
214588687|NCT01428232|OTHER|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
214588688|NCT01428232|OTHER|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
214588689|NCT06727890|DRUG|Danshen Dripping Pill|Danshen Dripping Pill, 10 pills once, three times a day
214588690|NCT06727890|DRUG|Placebo|Placebo, 10 pills once, three times a day
214588691|NCT06729827|DEVICE|Hypotension prediction Index - HPI|"Patients in the HPI group, in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA) with ClearSight non-invasive hemodynamic monitoring and with the HPI software enabled.~The patients will be treated with a bolus of norepinephrine 5 mcg each time that HPI is 85 or higher."
214588692|NCT00061529|DRUG|Brimonidine Tartrate Ophthalmic Solution|
214588693|NCT04985890|BIOLOGICAL|UB-421|10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy
214588694|NCT04985890|OTHER|UB-421+chidamide|10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
214588695|NCT02304796|BEHAVIORAL|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
214588696|NCT02304796|BEHAVIORAL|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
214588697|NCT02082236|DRUG|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
214588698|NCT02082236|DRUG|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
214588699|NCT02082236|DRUG|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
214588700|NCT02082236|DRUG|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
214588701|NCT00098852|DRUG|rosiglitazone maleate|
214588702|NCT05023603|DIAGNOSTIC_TEST|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
214588703|NCT00735020|BIOLOGICAL|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
214588704|NCT00735020|BIOLOGICAL|Influenza Vaccine|1 dose of Influenza Vaccine
214588705|NCT02647320|DRUG|Sitagliptin 100 mg|Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
214588706|NCT02647320|DRUG|DS-8500a 25mg|DS-8500a 25mg tablet for oral administration
214588707|NCT02647320|DRUG|Placebo Tablet|Placebo matching DS-8500a tablet for oral administration
214588708|NCT02647320|DRUG|Placebo Capsule|Placebo matching sitagliptin over-capsule for oral administration
214588709|NCT02941250|DEVICE|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
214588710|NCT02401360|DRUG|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
214588711|NCT02401360|DRUG|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
214588712|NCT03836989|DEVICE|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
214588713|NCT02263937|PROCEDURE|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
214588714|NCT02263937|PROCEDURE|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
214588715|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
214588716|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
214588717|NCT03553368|DIAGNOSTIC_TEST|MR|MRI data will be acquired without the use of any device as a reference.
214588718|NCT03553368|DIAGNOSTIC_TEST|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
214588719|NCT03553368|DIAGNOSTIC_TEST|CPAP-MR|MRI data will be acquired with the use of CPAP.
214588720|NCT01650246|DRUG|lesinurad|Tablets, 400 mg QD
214588721|NCT05003817|DEVICE|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
214588722|NCT04947423|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
214588723|NCT04947423|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
214588724|NCT01011426|DRUG|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
214588725|NCT01011426|DRUG|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
214588726|NCT02831803|DIETARY_SUPPLEMENT|Walnuts|28 gm/day in single-serve package
214588727|NCT02831803|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
214588728|NCT02539537|DRUG|Gemcitabine|
214588729|NCT02539537|DRUG|Folinic Acid|
214588730|NCT02539537|DRUG|5-Fluoro-uracil|
214588731|NCT02539537|DRUG|Oxaliplatin|
214588732|NCT02539537|DRUG|Irinotecan|
214588733|NCT02539537|DRUG|L-folinic|
214588734|NCT04249596|DRUG|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
214588735|NCT00953407|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214588736|NCT00953407|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214588737|NCT00953407|DEVICE|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214588738|NCT00953407|DEVICE|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214588739|NCT00953407|DEVICE|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214588740|NCT02913235|PROCEDURE|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
214588741|NCT04267783|DIAGNOSTIC_TEST|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
214588742|NCT02268474|DEVICE|532nm KTP Laser vs 595nm Pulse Dye Laser|Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
214588743|NCT04454177|DEVICE|HUAWEI watch|HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
214588744|NCT02050230|BIOLOGICAL|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
214588745|NCT03435497|BEHAVIORAL|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
214588746|NCT05943223|DRUG|Piperacillin/tazobactam|Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)
214588747|NCT05943223|DRUG|Normal saline|Post-operative normal saline 50 mL once daily
214588748|NCT05943223|DRUG|CefTRIAXone Injection|Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)
214588749|NCT05943223|DRUG|Metronidazole Injection|Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
214588750|NCT06124872|OTHER|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
214588751|NCT06124872|OTHER|Key informant interview|Semi-structured interview with selected key informants
214588752|NCT01719926|DRUG|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
214588753|NCT04685850|OTHER|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
214588754|NCT05199220|OTHER|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
214588755|NCT02530853|OTHER|Laser acupuncture|Laser acupuncture
214588756|NCT05220254|BEHAVIORAL|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
214588757|NCT05694104|OTHER|Malnutrition|For the diagnosis of malnutrition, we adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
214588758|NCT01557283|OTHER|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
214588759|NCT03644251|OTHER|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
214588760|NCT04820777|OTHER|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
214588761|NCT04820777|OTHER|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
214588762|NCT00862355|DRUG|SPARC147609|IV infusion
214588763|NCT00862355|DRUG|Reference147609|IV infusion
214588764|NCT02972866|DRUG|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
214588765|NCT01593306|DRUG|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
214588766|NCT01593306|DRUG|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
214588767|NCT02274818|BEHAVIORAL|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
214588768|NCT04638595|OTHER|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
214588769|NCT03603028|DEVICE|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
214588770|NCT03806387|DRUG|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
214588771|NCT04151797|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician"
214588772|NCT00699894|DRUG|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
214588773|NCT00699894|DRUG|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
214588774|NCT00081107|DRUG|epothilone D|
214588775|NCT02717572|RADIATION|Fludeoxyglucose F 18|
214588776|NCT02717572|DEVICE|Positron Emission Tomography|
214588777|NCT02717572|DEVICE|Computerized Tomography|
214588778|NCT02717572|DEVICE|Magnetic Resonance Imaging|
214588779|NCT04819984|DEVICE|TCM5 device (Radiometer) for PtC02 continuous measurement|Evaluation of PtC02 variation as a reflect of PaC02 during 30 minutes of weaning proof for mechanical ventilation (spontaneous ventilation on T-piece)
214634376|NCT01888458|DRUG|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
214634377|NCT02137564|DRUG|gamma secretase inhibitor PF-03084014|Given PO
214634378|NCT02137564|OTHER|pharmacological study|Correlative studies
214588780|NCT04398407|BEHAVIORAL|Coaching and Advancement for Peer Providers (CAPP)|The CAPP intervention will combine executive coaching approaches and techniques with the specific needs and environmental demands of individuals working as PSS. A person who has been a PSS and trainer of PSS nationally has developed the CAPP intervention using the expertise of Center staff, the Harvard Institute of Coaching (IOC) and our Peer Advisory Group. Individuals randomized to the experimental condition will receive 16 individual coaching sessions tailored to the specific job stressors they are experiencing. CAPP is designed to address the following issues: role confusion, lack of clarity about job tasks, conflict with other providers, burnout, lack of organizational commitment and job satisfaction.
214588781|NCT05898243|PROCEDURE|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
214588782|NCT04684602|BIOLOGICAL|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
214588783|NCT01990209|DRUG|Orteronel|
214588784|NCT00081042|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214588785|NCT01576250|OTHER|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
214588786|NCT00879866|BIOLOGICAL|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
214588787|NCT04395027|DEVICE|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
214588788|NCT01468831|DRUG|Minocycline|100 mg of minocycline in a pink opaque capsule
214588789|NCT01468831|OTHER|Placebo|Pill with inactive ingredients in a pink opaque capsule
214588790|NCT01468831|DRUG|Bevacizumab|1.25 mg bevacizumab injection
214588791|NCT03048799|DEVICE|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
214588792|NCT05540054|OTHER|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
214588793|NCT05540054|OTHER|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
214588794|NCT02764294|OTHER|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
214588795|NCT02764294|OTHER|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
214588796|NCT02764294|OTHER|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
214588797|NCT02801968|PROCEDURE|Tap block|
214588798|NCT02801968|OTHER|intravenous analgesia|
214588799|NCT01405586|DRUG|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
214588800|NCT01405586|DRUG|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
214588801|NCT01405586|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
214588802|NCT01131234|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214588803|NCT01131234|DRUG|Cediranib Maleate|Given PO
214588804|NCT01131234|OTHER|Pharmacological Study|Correlative studies
214588805|NCT01131234|OTHER|Laboratory Biomarker Analysis|Correlative studies
214588806|NCT04168853|DIAGNOSTIC_TEST|vascular reactivity of internal thoracic arteries|"1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis"
214588807|NCT04537182|PROCEDURE|Lung volume reduction surgery|Lung volume reduction by surgery
214588808|NCT04537182|PROCEDURE|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
214588809|NCT06044974|DEVICE|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
214588810|NCT06044974|DRUG|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
214588811|NCT03634020|DEVICE|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
214588812|NCT00241605|DRUG|rosiglitazone/metformin|
214588813|NCT06418828|OTHER|return to work|Ask patients if they are going back to work
214588814|NCT05103293|DIAGNOSTIC_TEST|patient-derived tumor-like cell clusters drug sensitivity test|Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
214588815|NCT01648881|RADIATION|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
214588816|NCT04439682|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
214588817|NCT04125030|OTHER|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
214588818|NCT00027495|DIETARY_SUPPLEMENT|curcumin|
214588819|NCT03561012|BEHAVIORAL|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
214588820|NCT03561012|OTHER|Control Condition|Standard of care
214588821|NCT06067568|DRUG|Lutikizumab Dose A|Injection; subcutaneous (SC)
214588822|NCT06067568|DRUG|Lutikizumab Dose B|Injection; subcutaneous (SC)
214588823|NCT00842985|DRUG|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
214588824|NCT00858884|OTHER|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
214588825|NCT00295594|DRUG|tacrolimus|Immunosuppression
214588826|NCT01037244|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
214588827|NCT01037244|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
214588828|NCT01548560|DRUG|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
214588829|NCT01548560|DRUG|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
214588830|NCT01742611|DRUG|ASP1585|oral
214634379|NCT02137564|OTHER|laboratory biomarker analysis|Correlative studies
214588831|NCT04833699|OTHER|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
214588832|NCT04269330|PROCEDURE|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
214588833|NCT04895683|BEHAVIORAL|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
214588834|NCT00690820|DRUG|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
214588835|NCT00690820|DRUG|Placebo Comparator|Placebo
214588836|NCT01147237|DEVICE|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
214588837|NCT02995577|OTHER|Feeding tolerant|
214588838|NCT02995577|OTHER|Feeding intolerant|
214588839|NCT02995577|OTHER|Necrotizing enterocolitis|
214588840|NCT04581668|OTHER|Neurally adjusted ventilatory assist first|Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
214588841|NCT04581668|OTHER|Conventional ventilation first|Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
214588842|NCT05237661|DIETARY_SUPPLEMENT|Moon Balance|Moon Balance is a blend of 6 food ingredients
214588843|NCT00624143|DRUG|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
214588844|NCT00585377|DRUG|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
214588845|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
214588846|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
214588847|NCT02934425|OTHER|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
214588848|NCT02934425|OTHER|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
214588849|NCT01207297|DRUG|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
214588850|NCT01207297|DRUG|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
214588851|NCT05232994|DRUG|Esomeprazole 20mg|Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
214588852|NCT03166826|OTHER|Modified Apgar Scoring System|Modified APGAR scoring system
214588853|NCT04532138|DEVICE|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
214588854|NCT04532138|DEVICE|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
214588855|NCT03784560|OTHER|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
214588856|NCT03784560|OTHER|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
214634380|NCT00557219|DRUG|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
214634381|NCT00557219|DRUG|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
214634382|NCT00557219|DRUG|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
214634383|NCT05493319|OTHER|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
214634384|NCT05730465|BEHAVIORAL|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
214634385|NCT03824847|DRUG|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
214588857|NCT03784560|OTHER|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (\<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
214588858|NCT03784560|OTHER|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington \& Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
214588859|NCT02953171|OTHER|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
214588860|NCT02953171|DIETARY_SUPPLEMENT|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
214588861|NCT02953171|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
214588862|NCT02953171|OTHER|Placebo capsule|Capsules without probiotics
214588863|NCT02838693|PROCEDURE|Not applicable. This is an observational study.|Not applicable. This is an observational study.
214588864|NCT01768117|BIOLOGICAL|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
214588865|NCT05638997|OTHER|Instrument assisted manipulation + Core exercises|The effect of Instrument assisted manipulation on chronic non-spesific low back pain
214588866|NCT05638997|OTHER|Mulligan mobilization with movement + Core exercises|The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
214710827|NCT05650931|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
214710828|NCT05650931|PROCEDURE|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
214710829|NCT00493974|DRUG|Zileuton|Zyflo tablets, 600 mg, 4 times a day
214710830|NCT00493974|DRUG|Placebo|Placebo 4 x daily
214588867|NCT05638997|OTHER|Core exercises|The effect of core exercises on chronic non-spesific low back pain
214588868|NCT02850367|DIETARY_SUPPLEMENT|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
214588869|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
214588870|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
214588871|NCT02850367|DIETARY_SUPPLEMENT|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
214588872|NCT02850367|BIOLOGICAL|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
214588873|NCT02850367|BIOLOGICAL|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
214588874|NCT01166867|DEVICE|Photo-plethysmography monitoring|monitoring vital sign in infant
214588875|NCT00622349|DRUG|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
214588876|NCT00622349|DRUG|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
214588877|NCT00622349|DRUG|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
214634386|NCT03824847|DRUG|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
214588878|NCT00873314|BEHAVIORAL|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
214588879|NCT00873314|BEHAVIORAL|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
214588880|NCT02447367|DRUG|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
214588881|NCT02447367|DRUG|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
214588882|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses with Molded Mark|
214588883|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses|
214588884|NCT01249274|DRUG|Progesterone|100mgs progesterone twice daily
214588885|NCT01249274|OTHER|Placebo|Matched placebo pills to be taken twice daily
214588886|NCT01562457|DRUG|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
214588887|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
214588888|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
214588889|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
214588890|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
214588891|NCT01000636|PROCEDURE|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
214588892|NCT00722930|DRUG|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
214588893|NCT05748691|DIAGNOSTIC_TEST|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
214710831|NCT02636920|OTHER|Therapeutic Education to the Patient (TEP)|"* Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients."
214588894|NCT01734174|PROCEDURE|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
214588895|NCT01734174|PROCEDURE|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
214588896|NCT01734174|PROCEDURE|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
214588897|NCT01725542|DRUG|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
214588898|NCT04509115|DRUG|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
214588899|NCT03258164|BIOLOGICAL|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
214588900|NCT03258164|BIOLOGICAL|Standard Lipofilling|Non-ASC enriched fat grafts
214588901|NCT02936167|BIOLOGICAL|Ringer Lactate|
214588902|NCT02936167|BIOLOGICAL|Plasmalyte|
214588903|NCT05941767|DRUG|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
214588904|NCT05941767|DRUG|Lidocaine nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
214588905|NCT05941767|DRUG|Dexmedetomidine IV|The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
214588906|NCT05941767|DRUG|Lidocaine IV|The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
214588907|NCT03451162|DRUG|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
214588908|NCT02598817|OTHER|Standard Infant Formula|Standard Infant Formula containing High Sn-2
214588909|NCT06027164|DEVICE|Portable Ultrasound System|EchoNous KOSMOS
214588910|NCT04616976|BIOLOGICAL|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
214588911|NCT01532726|DRUG|ESL|ESL 400/800/1200 mg tablets once daily
214588912|NCT05353673|DRUG|Sitagliptin|Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
214588913|NCT05353673|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
214588914|NCT04631172|OTHER|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
214588915|NCT00264927|DRUG|SR121463B|
214588916|NCT06279065|DIAGNOSTIC_TEST|Analysis of blood and microbiome samples (stool, oral lavage)|Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells
214588917|NCT06389253|OTHER|Histological Analysis|For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed
214588918|NCT00002060|DRUG|Inosine pranobex|
214588919|NCT03522480|DEVICE|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
214588920|NCT03522480|OTHER|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
214588921|NCT05199974|PROCEDURE|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
214588922|NCT03418948|DEVICE|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
214588923|NCT03418948|DEVICE|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
214588924|NCT03418948|DEVICE|2x EC|EC = endocuff assisted colonoscopy
214588925|NCT03418948|DEVICE|2x CC|CC = conventional colonoscopy
214588926|NCT06127056|DEVICE|High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
214588927|NCT06127056|DEVICE|sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
214588928|NCT04756960|DRUG|CHF6001|4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
214710832|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
214588929|NCT05612165|DEVICE|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(2000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
214588930|NCT05612165|DEVICE|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
214588931|NCT05337852|OTHER|Emotional Freedom Technique|"To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
214588932|NCT04175002|DRUG|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
214588933|NCT03572322|OTHER|Focus Group|Focus Group
214588934|NCT03572322|OTHER|Interviews|Interviews
214588935|NCT05402748|OTHER|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
214588936|NCT01708213|DEVICE|Aline HA|Implantable dermal filler
214588937|NCT03764956|OTHER|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
214588938|NCT03764956|OTHER|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
214588939|NCT02216357|DRUG|Ifetroban, Oral Capsule|
214588940|NCT02216357|DRUG|Placebo, Oral Capsule|
214588941|NCT01197859|DEVICE|Definitive Contact Lens|Daily wear contact lens
214588942|NCT01197859|DEVICE|Biofinity|Daily wear contact lens
214588943|NCT03354442|DEVICE|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
214588944|NCT00836095|DEVICE|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
214588945|NCT00836095|DEVICE|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
214710833|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
214710834|NCT02807363|DRUG|Leuprolide Depot|3.75 mg intramuscular depot injection
214710835|NCT02807363|DRUG|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
214710836|NCT03463096|OTHER|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
214710837|NCT06141941|DEVICE|CGM|Continuous glucose monitoring
214588946|NCT02681133|OTHER|Epidemiological study Survey|
214588947|NCT04207866|OTHER|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
214588948|NCT04207866|OTHER|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
214588949|NCT00816686|BIOLOGICAL|AGS-16M18|IV Infusion
214588950|NCT05373589|OTHER|conventional ventilation, group C|In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
214588951|NCT05373589|OTHER|pressure support, group PS|In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
214588952|NCT04428125|DIAGNOSTIC_TEST|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
214588953|NCT04428125|DIAGNOSTIC_TEST|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
214634387|NCT02554539|PROCEDURE|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
214588954|NCT03046784|OTHER|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
214588955|NCT03609853|DRUG|Placebo|Placebo vapor (distilled water)
214588956|NCT03609853|DRUG|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
214588957|NCT05355233|OTHER|bebo concept|techniques to remove urinary incontinence
214588958|NCT05355233|OTHER|diaphragmatic breathing|techniques to remove urinary incontinence
214588959|NCT05572268|DRUG|to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection|to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
214588960|NCT05821751|DIETARY_SUPPLEMENT|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
214588961|NCT05821751|DRUG|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
214588962|NCT05821751|DRUG|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
214710838|NCT03701217|DRUG|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
214588963|NCT04964414|OTHER|Smell Retraining|Smell practice with household scented items
214588964|NCT04964414|DRUG|Budesonide|Nasal irrigation with liquid steroid
214588965|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
214588966|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
214588967|NCT01728532|DEVICE|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
214588968|NCT01728532|DEVICE|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
214588969|NCT00526032|PROCEDURE|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
214588970|NCT05281965|DRUG|Retinoic acid|Retinoic acid oral
214588971|NCT02953366|DRUG|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
214588972|NCT02953366|DRUG|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
214588973|NCT03514212|BEHAVIORAL|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
214710839|NCT04367441|DRUG|608|recombinant humanized anti-IL17A monoclonal antibody injection
214710840|NCT04367441|DRUG|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
214588974|NCT01266135|DRUG|QAX576|QAX576 10 mg/kg intravenous infusion
214588975|NCT01266135|DRUG|Placebo|Placebo to QAX576 intravenous infusion
214588976|NCT00153361|BEHAVIORAL|Discussion Group|
214588977|NCT00153361|BEHAVIORAL|Video Discussion Group|
214588978|NCT01839500|DRUG|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
214588979|NCT03275844|PROCEDURE|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
214588980|NCT02145689|BIOLOGICAL|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
214588981|NCT02838485|OTHER|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
214588982|NCT02838485|OTHER|Imagery|The subject will be asked to imagine performing hand movements.
214588983|NCT02752321|DEVICE|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
214588984|NCT03539783|DIAGNOSTIC_TEST|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
214588985|NCT03776019|DEVICE|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
214588986|NCT02907931|OTHER|Point of Care Ultrasound|
214588987|NCT02673203|DEVICE|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
214588988|NCT02673203|BEHAVIORAL|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
214588989|NCT05116046|BIOLOGICAL|Recifercept|Recifercept
214588990|NCT06165939|DRUG|Intra-articular corticosteroid injection|Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
214588991|NCT06165939|DRUG|hydrodilation with 15% hypertonic dextrose|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
214588992|NCT06165939|DRUG|hydrodilation with Normal saline|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
214588993|NCT03311334|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
214588994|NCT03311334|DRUG|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
214588995|NCT03311334|DRUG|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
214588996|NCT03844542|DEVICE|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
214588997|NCT02639468|DEVICE|Stroke Volume estimation using electrical impedance tomography|
214588998|NCT04114630|DRUG|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
214588999|NCT03453320|DRUG|Albumin solution|Infusion rate and effects
214589000|NCT03286257|BEHAVIORAL|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
214589001|NCT05259020|COMBINATION_PRODUCT|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
214589002|NCT05259020|COMBINATION_PRODUCT|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
214589003|NCT04406090|OTHER|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
214710841|NCT02188719|BIOLOGICAL|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is \<50/mm\^3 or when the maximal dose of 4.5/mg/kg has been given.
214589004|NCT02269332|OTHER|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
214589005|NCT05528029|DEVICE|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
214589006|NCT05418023|OTHER|Salivary Collection|Collection of saliva via swab for miRNA processing
214589007|NCT05418023|OTHER|Adaptive Assessment|Includes Vineland Adaptive Behavior Scale or equivalent
214589008|NCT05418023|OTHER|Medical and Demographic questionnaire|Survey that collects basic medical and demographic information
214589009|NCT05418023|OTHER|Autism Assessment|Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
214589010|NCT05418023|OTHER|Intellectual Development Assessment|Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
214589011|NCT01196273|OTHER|Comprehensive non invasive cardiovascular examination|"The examination includes:~* Anamnesis incl. admission form~* Physical examination~* Documentation of the medical therapy (incl. HAART)~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* 6 minute walk test~* Blood collection~* Questionnaire to quality of life and health economics"
214589012|NCT05367232|DRUG|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
214589013|NCT03369990|DRUG|Botulinum toxin type A|Botulinum toxin type A(DWP450)
214589014|NCT03369990|DRUG|Placebos|Normal Saline
214589015|NCT05971667|DRUG|tadalafil|tadalafil 10 mg one tablet daily
214589016|NCT05971667|DRUG|Sildenafil|sildenafil 20 mg two tablets daily
214589017|NCT05971667|DRUG|pentoxifylline|pentoxifylline 400 mg two tabs daily
214589018|NCT00226837|DRUG|Nitrous oxide|nitrous oxide by inhalation during induction
214710842|NCT02188719|BIOLOGICAL|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
214589019|NCT01130233|PROCEDURE|robotic assisted rectal resection|robotic assisted rectal resection
214589020|NCT01130233|PROCEDURE|laparoscopic rectal resection|laparoscopic rectal resection
214589021|NCT00610467|DEVICE|Disease Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
214589022|NCT00610467|DEVICE|Control Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
214589023|NCT02920619|DEVICE|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
214589024|NCT02684253|DRUG|Nivolumab|
214589025|NCT02684253|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
214589026|NCT06024395|BEHAVIORAL|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
214589027|NCT00561054|DRUG|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
214589028|NCT03626519|OTHER|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
214589029|NCT03626519|OTHER|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
214589030|NCT02670031|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
214589031|NCT02670031|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
214589032|NCT02670031|OTHER|Electrocardiogram|To examine specific function of the heart.
214589033|NCT02670031|DEVICE|Ambulatory Blood Pressure Monitoring|A 24-hour test.
214589034|NCT02670031|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
214589035|NCT02084745|PROCEDURE|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
214589036|NCT02084745|PROCEDURE|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
214589037|NCT05822167|OTHER|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
214589038|NCT05822167|OTHER|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
214589039|NCT05822167|OTHER|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
214589040|NCT05822167|OTHER|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
214589041|NCT05822167|OTHER|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
214589042|NCT05822167|OTHER|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
214589043|NCT05822167|OTHER|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
214589044|NCT05822167|OTHER|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
214589045|NCT05822167|OTHER|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
214589046|NCT00519038|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
214589047|NCT00519038|OTHER|Usual Care|Usual care is the current practice actually performed in the hospital
214634388|NCT01777152|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
214634389|NCT01777152|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
214634390|NCT01777152|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
214634391|NCT01777152|DRUG|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
214634392|NCT01777152|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
214589048|NCT05699954|DIAGNOSTIC_TEST|Presence of Blink impression features for cancer in colorectal polyps|"1. 20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~2. A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~3. The survey asks for demographics of the participant endosopists (experience, country where they work).~4. The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~   * Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~  * If yes, why do you think that? (Free comment box)~  * What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~5. Study will be closed after 2 weeks.~6. Data analysis"
214589049|NCT00640887|DRUG|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
214589050|NCT00640887|DRUG|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
214589051|NCT00640887|DRUG|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
214589052|NCT03074760|DIAGNOSTIC_TEST|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
214589053|NCT03074760|DIAGNOSTIC_TEST|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
214589054|NCT03074760|DIAGNOSTIC_TEST|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
214589055|NCT03842254|DRUG|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
214589056|NCT02012114|OTHER|Cysteamine bitartrate|No intervention
214589057|NCT01745848|DRUG|Roflumilast|
214589058|NCT01687530|PROCEDURE|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
214634393|NCT02022982|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
214634394|NCT02022982|DRUG|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
214634395|NCT03931278|OTHER|learning and recall of a sequence of body movements|The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
214634396|NCT02534259|OTHER|Force monitoring of external fixator struts|
214634397|NCT02792842|DRUG|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
214634398|NCT02792842|DRUG|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
214634399|NCT02792842|DRUG|Placebo|Placebo infusion once daily on days 1-3 in each cycle
214589059|NCT03226210|DRUG|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
214589060|NCT00776126|DEVICE|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
214589061|NCT02026310|DRUG|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
214589062|NCT02026310|DRUG|glargine and metformin|
214589063|NCT02731794|DEVICE|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
214589064|NCT02731794|PROCEDURE|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
214589065|NCT00679627|DRUG|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
214589066|NCT00679627|DRUG|Placebo|Matching placebo
214589067|NCT06305377|DEVICE|Tandem Control IQ|Use of Tandem control IQ in a group of diabetic adolescents in not good glicaemic control
214589068|NCT00454766|BEHAVIORAL|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
214589069|NCT04432246|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
214589070|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
214589071|NCT05359497|DEVICE|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
214589072|NCT05359497|DEVICE|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
214589073|NCT05359497|DIAGNOSTIC_TEST|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
214710843|NCT02188719|DRUG|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
214710844|NCT02188719|DRUG|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
214710845|NCT02188719|DRUG|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
214710846|NCT02188719|DRUG|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
214710847|NCT02188719|DRUG|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
214589074|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
214589075|NCT05359497|DEVICE|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
214589076|NCT05359497|DEVICE|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
214589077|NCT02707237|OTHER|Verbal counseling|Verbal counseling done by physician
214589078|NCT02707237|OTHER|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
214589079|NCT01886378|DRUG|UX007|
214589080|NCT01248091|PROCEDURE|Nitroprusside Gel|10 cc nitroprusside gel
214589081|NCT01248091|PROCEDURE|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
214589082|NCT04553198|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
214589083|NCT03168386|PROCEDURE|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
214589084|NCT01014260|DRUG|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
214589085|NCT01014260|DRUG|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
214589086|NCT03975205|DRUG|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
214589087|NCT06299085|OTHER|50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
214589088|NCT05632445|DRUG|Apixaban vs. DAPT|Apixaban vs DAPT after LAAO
214589089|NCT02019043|OTHER|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
214589090|NCT02088918|DRUG|Nateglinide|
214589091|NCT02088918|DRUG|Nateglinide/Metformin|
214589092|NCT02088918|DRUG|Metformin|
214589093|NCT02803892|DRUG|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
214589094|NCT02803892|DRUG|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
214589095|NCT02803892|DRUG|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
214589096|NCT02803892|DRUG|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
214589097|NCT04076748|DRUG|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
214589098|NCT04076748|DRUG|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
214589099|NCT03646201|BEHAVIORAL|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
214589100|NCT05125263|OTHER|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
214589101|NCT05125263|OTHER|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
214589102|NCT01210066|DRUG|Fentanyl|IV fentanyl 1mcg/kg
214589103|NCT01210066|OTHER|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
214589104|NCT01210066|OTHER|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
214634400|NCT05056025|DIETARY_SUPPLEMENT|Postbotics and Vitamins|2 capsule 3 times a day, before meals
214710848|NCT02188719|DRUG|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
214710849|NCT02188719|DRUG|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
214634401|NCT05056025|DIETARY_SUPPLEMENT|Vitamins|2 capsule 3 times a day, before meals
214634402|NCT00874978|DRUG|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
214634403|NCT05053295|DRUG|autologous activated T lymphocyte|"Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV"
214634404|NCT04934761|PROCEDURE|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV\< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV \<10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV\<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
214634405|NCT04934761|PROCEDURE|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
214634406|NCT01617278|DEVICE|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
214634407|NCT01617278|DEVICE|HD Colon|High definition white light
214634408|NCT01617278|DEVICE|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
214634409|NCT00556660|DRUG|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
214589105|NCT03143816|DRUG|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
214589106|NCT00815685|DRUG|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
214589107|NCT02656160|DRUG|Placebo|Placebo 3 hrs before sleep
214589108|NCT02656160|DRUG|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
214589109|NCT01079741|BIOLOGICAL|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
214589110|NCT04182594|DRUG|Degarelix|Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days
214589111|NCT04182594|DRUG|GnRH agonist|GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
214589112|NCT00446992|DRUG|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
214589113|NCT00473135|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU
214589114|NCT00473135|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
214589115|NCT02778711|DRUG|secukinumab|anti-IL-17
214589116|NCT03601988|RADIATION|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
214589117|NCT03601988|DRUG|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
214589118|NCT03341208|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
214589119|NCT02590809|DRUG|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
214589120|NCT02590809|DRUG|Placebo|Placebo will be given for 30 days
214589121|NCT02590809|OTHER|Walk distance test|Walk distance test during 6 minutes
214589122|NCT02590809|OTHER|Exercise echocardiography|
214589123|NCT00351130|DRUG|valsartan|
214589124|NCT00351130|DRUG|amlodipine|
214589125|NCT05171023|DEVICE|ROTEM and standard coagulation tests|ROTEM and standard coagulation tests assessment
214589126|NCT02736305|DRUG|Regorafenib|Once a day for 21 days in a 28 days cycle
214589127|NCT02957864|DRUG|tenofovir alafenamide|
214589128|NCT02957864|DRUG|abacavir|
214589129|NCT02925637|OTHER|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
214589130|NCT01443715|BEHAVIORAL|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
214589131|NCT01443715|BEHAVIORAL|Treatment as Usual|Standard treatment in the community
214589132|NCT01275131|DRUG|Insulin aspart|
214589133|NCT01275131|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
214589134|NCT04320797|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
214589135|NCT02076178|DRUG|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
214589136|NCT02076178|DRUG|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
214589137|NCT02076178|DRUG|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
214589138|NCT02076178|DRUG|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
214589139|NCT01508715|OTHER|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
214589140|NCT03031860|OTHER|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
214589141|NCT01134120|DRUG|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
214589142|NCT00282204|BEHAVIORAL|antenatal hypnosis + audio compact disc on hypnosis|
214589143|NCT00282204|BEHAVIORAL|Audio compact disc on hypnosis|
214589144|NCT02400294|OTHER|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
214589145|NCT04112121|BEHAVIORAL|Meeting with a Chaplain coupled with Biblical Readings|
214589146|NCT06065969|RADIATION|Photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session.
214589147|NCT00414713|PROCEDURE|red blood cell transfusion|red blood cell transfusion
214589148|NCT00322673|DRUG|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
214589149|NCT02292654|DRUG|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
214589150|NCT02541760|DRUG|Monteleukast|4 ml monteleukast daily for one month
214589151|NCT02541760|DRUG|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
214589152|NCT02582567|OTHER|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
214589153|NCT02472769|DRUG|IBP-9414|
214589154|NCT02472769|DRUG|Placebo|Sterile water
214589155|NCT02142660|PROCEDURE|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
214589156|NCT00188175|RADIATION|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
214589157|NCT04681027|DRUG|Oxymorphone hydrochloride (HCl)|Opioid
214589158|NCT02169453|DRUG|BIA 9-1067|OPC, Opicapone
214589159|NCT02169453|DRUG|Placebo|PLC, Placebo
214589160|NCT02169453|DRUG|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
214589161|NCT02434939|DRUG|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
214589162|NCT02434939|DRUG|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
214589163|NCT03200015|DRUG|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
214589164|NCT04412915|OTHER|Labor induction|Labor induction with oxytocin or prostagladin
214589165|NCT05163587|COMBINATION_PRODUCT|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
214589166|NCT06372678|BIOLOGICAL|CM326|CM326 injection
214589167|NCT06372678|DRUG|Placebo|Placebo
214589168|NCT02926976|DRUG|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
214589169|NCT02926976|DRUG|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
214589170|NCT02926976|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
214589171|NCT02926976|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
214589172|NCT02926976|DEVICE|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
214589173|NCT02926976|DEVICE|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
214589174|NCT04154176|OTHER|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
214589175|NCT03942809|DEVICE|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
214589176|NCT02210234|DIETARY_SUPPLEMENT|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
214589177|NCT02210234|DIETARY_SUPPLEMENT|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
214589178|NCT04866446|DEVICE|endotracheal intubation and laringeal mask airway insertion|endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
214589179|NCT06423209|OTHER|Strength training program|Strength training program to be developed during 16 weeks. There will be 3 exercise sessions per week and those participants who perform at least 2 sessions during the program will be considered for the statistical analysis.
214589180|NCT01743625|DRUG|COV155|COV155 tablets
214589181|NCT01743625|DRUG|placebo|
214589182|NCT06373029|OTHER|Ultrasound examination|The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
214589183|NCT01190137|DIETARY_SUPPLEMENT|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
214589184|NCT05350579|OTHER|Yogurt Intervention|"Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract."
214589185|NCT05975957|DEVICE|Photomodulation Therapy with the Light-Aid system|Patients in the intervention group (FBM) will be submitted to 10 treatment sessions (twice a week/five weeks) with the Light-Aid system (Bright Photomedicine, SP, Brazil), operated in continuous mode, with 100 LEDs of 850nm wave per tip, with application time varying from 4 to 8 minutes. Irradiation parameters will be customized based on pain intensity, skin phototype and Body Mass Index (BMI).
214589186|NCT05975957|DEVICE|Control|Patients in the placebo group will undergo the same therapeutic protocol as the FBM group using a device with the same appearance as the Light-Aid System, but with inert light emission. In both groups, the treatment will be administered in contact with the skin over the knee, with the patient positioned in dorsal decubitus. The three tips of the device will be positioned horizontally over the anterior region of the knee with the central tip over the patella.
214589187|NCT01071525|DRUG|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
214589188|NCT00526487|DEVICE|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
214589189|NCT00526487|DEVICE|Endovascular Repair|Endovascular Repair
214589190|NCT00208923|DRUG|Busulfan, Cyclophosphamide and Fludarabine|"* Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
214589191|NCT02718937|DRUG|BTA-C585 oral capsule|
214589192|NCT02718937|DRUG|Matching placebo capsules|
214589193|NCT00219804|DRUG|tetrabenazine or placebo|
214589194|NCT03975166|DRUG|Test Product|2 inhalations in one study period
214589195|NCT03975166|DRUG|Reference Product|2 inhalations in one study period
214589196|NCT03438851|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
214589197|NCT01535950|DRUG|LFG316|
214589198|NCT01535950|DRUG|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
214589199|NCT02343055|OTHER|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
214589200|NCT02866110|BEHAVIORAL|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
214589201|NCT02866110|DEVICE|MRI|Echo-planar Imaging of brain BOLD signal
214589202|NCT02700763|OTHER|[18F]dabrafenib molecular imaging|A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
214589203|NCT02805608|DRUG|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
214589204|NCT02805608|DRUG|Injection of 18F-FDG|One injection intravenously of 18F-FDG
214589205|NCT02805608|DEVICE|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
214589206|NCT02805608|DEVICE|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
214589207|NCT05751772|OTHER|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;~2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
214589208|NCT00194519|DRUG|Generic acyclovir|400 mg twice-daily oral
214589209|NCT00194519|DRUG|Placebo|twice-daily oral
214589210|NCT05760391|RADIATION|Radiotherapy|IMRT or SABR for patients with ESCC.
214589211|NCT02011087|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
214589212|NCT05780892|BEHAVIORAL|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
214589213|NCT05780892|BEHAVIORAL|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
214634410|NCT05991856|PROCEDURE|radiofrequency ablation|The subjects is placed in a prone or lateral position under local anesthesia, and the electrodes are placed in the adrenal nodules under ultrasound guidance. A rapidly alternating radiofrequency current (300-500khz) generated around the electrode propagates through the adrenal nodules, causing resistance heating (Joule effect) and inducing cell death through coagulation necrosis. The choice of ablation time and frequency depends on the size, shape and location of the nodules within the adrenal gland.
214589214|NCT05780892|BEHAVIORAL|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
214589215|NCT05780892|BEHAVIORAL|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
214589216|NCT05031663|DIETARY_SUPPLEMENT|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
214589217|NCT05031663|DIETARY_SUPPLEMENT|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
214589218|NCT05163171|OTHER|questionnaire|questionnaire for conjugal violence prevalence
214710850|NCT02188719|PROCEDURE|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level \>/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
214589219|NCT00125502|BIOLOGICAL|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
214589220|NCT00125502|DRUG|MF59 adjuvant|Oil-in-water emulsion
214589221|NCT00125502|DRUG|Placebo|Normal saline solution
214589222|NCT04467528|DEVICE|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
214589223|NCT04467528|DRUG|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
214589224|NCT01088828|OTHER|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
214589225|NCT01045408|DIETARY_SUPPLEMENT|Berry extract|Berry extract for weeks
214589226|NCT04598568|DEVICE|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
214589227|NCT04705207|PROCEDURE|reflexology massage|the patient receive only foot reflexology massage
214589228|NCT04705207|PROCEDURE|sham massage|the patient receive only foot traditional massage
214589229|NCT06203015|DIAGNOSTIC_TEST|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
214589230|NCT06203015|DIAGNOSTIC_TEST|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
214589231|NCT06203015|DIAGNOSTIC_TEST|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
214589232|NCT06203015|DIAGNOSTIC_TEST|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
214589233|NCT06203015|OTHER|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
214589234|NCT02096315|DRUG|POL7080|Intravenous infusion
214589235|NCT00477321|DRUG|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
214589236|NCT01165931|DRUG|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
214589237|NCT05471830|DRUG|Apixaban|No drug will be provided to participants. Patients follow routine clinical practice/administration.
214589238|NCT00485498|DRUG|Olanzapine Hydrochloride|
214589239|NCT00485498|DRUG|Risperidone|
214589240|NCT00541398|BEHAVIORAL|Implementation of guideline|Outreach visits with interactive education for health staff
214589241|NCT00300521|GENETIC|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
214589242|NCT06060015|DRUG|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
214589243|NCT06060015|DRUG|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
214589244|NCT05420285|DRUG|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
214589245|NCT01561404|DRUG|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
214589246|NCT04421183|DIAGNOSTIC_TEST|draw blood|draw blood from the all of patients
214589247|NCT00557648|BEHAVIORAL|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
214589248|NCT00557648|BEHAVIORAL|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
214589249|NCT00547820|OTHER|placebo|
214589250|NCT00547820|DEVICE|Urinary sensor|
214589251|NCT02750280|DEVICE|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
214589252|NCT02750280|DEVICE|Mepilex® [Silicone foam dressing]|primary wound dressing
214589253|NCT02963740|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
214589254|NCT02963740|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
214589255|NCT02963740|BEHAVIORAL|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
214589256|NCT02963740|BEHAVIORAL|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
214589257|NCT00432146|DRUG|lugol's solution|
214589258|NCT00518466|DRUG|topiramate|25 mg modified-release capsules
214589259|NCT00518466|DRUG|phentermine|7.5 mg immediate-release capsules
214589260|NCT00518466|DRUG|topiramate|100 and 25 mg immediate-release tablets
214589261|NCT00518466|DRUG|phentermine|37.5 and 7.5 mg immediate-release tablets
214589262|NCT04463173|DRUG|Anaprazole|single dose, oral administration 30 minutes after breakfast with high fat food.
214589263|NCT04463173|DRUG|Anaprazole|single dose, oral administration before breakfast.
214589264|NCT02534987|OTHER|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
214589265|NCT00506987|DRUG|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
214589266|NCT00506987|DRUG|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
214589267|NCT01781507|DRUG|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
214589268|NCT01781507|DRUG|Placebo|This placebo ( sugar pill) will provide the negative control for this study
214589269|NCT03301896|DRUG|LHC165|LHC165 intratumoral injection
214589270|NCT03301896|BIOLOGICAL|PDR001|PDR001 infusion
214589271|NCT00309296|BEHAVIORAL|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
214589272|NCT03430206|DEVICE|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
214589273|NCT06161168|DEVICE|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
214589274|NCT00552487|DRUG|synacthen|1 µg synacthen in the vein
214589275|NCT05012891|OTHER|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
214589276|NCT04877730|DEVICE|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
214589277|NCT04877730|DEVICE|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
214589278|NCT04877730|DEVICE|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
214589279|NCT00190411|DRUG|celiprolol|celiprolol
214589280|NCT00190411|DRUG|Control|Untreated controls excluding betablockers
214589281|NCT04015999|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
214589282|NCT04015999|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
214589283|NCT01518933|DRUG|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
214589284|NCT01518933|DRUG|Saline|Placebo
214589285|NCT03466801|DRUG|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
214589286|NCT03466801|DRUG|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
214589287|NCT00201721|DRUG|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
214589288|NCT00201721|DRUG|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
214589289|NCT00201721|DRUG|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
214589290|NCT00405691|DEVICE|"TOPS System - Total Posterior Arthroplasty Implant"|
214589291|NCT03516929|DIAGNOSTIC_TEST|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
214589292|NCT04633551|DIETARY_SUPPLEMENT|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
214589293|NCT01992393|BEHAVIORAL|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
214589294|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
214589295|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
214589296|NCT03383315|DRUG|Tramadol|One dose of intravenous tramadol 50mg
214589297|NCT03383315|DRUG|Metoclopramide|One dose of intravenous metoclopramide 10mg
214589298|NCT03383315|DRUG|Placebo|Sodium chloride 0.9%
214589299|NCT05488015|OTHER|Global Postural Re-education (GPR)|GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
214589300|NCT05488015|OTHER|Lifestyle habits|No change in lifestyle habits during the 8-week trial.
214589301|NCT04386811|DRUG|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
214589302|NCT04386811|OTHER|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
214589303|NCT00556387|DRUG|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
214589304|NCT00556387|DRUG|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
214589305|NCT03243877|OTHER|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
214589306|NCT02388867|PROCEDURE|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
214710851|NCT02188719|PROCEDURE|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
214589307|NCT02388867|PROCEDURE|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
214589308|NCT01248546|PROCEDURE|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
214589309|NCT00652210|OTHER|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
214589310|NCT05955794|OTHER|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\]."
214589311|NCT05877313|OTHER|Sterile water foot bath|Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
214589312|NCT05877313|DRUG|Nitric Oxide|Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
214589313|NCT03503461|OTHER|exosomes analysis|Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
214710852|NCT02188719|PROCEDURE|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
214710853|NCT02188719|PROCEDURE|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
214710854|NCT04144075|BEHAVIORAL|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
214710855|NCT04144075|BEHAVIORAL|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
214589314|NCT01414985|BIOLOGICAL|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
214589315|NCT06108960|OTHER|Proprioceptive neuromuscular facilitation|Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
214589316|NCT06108960|OTHER|Pelvic stabilization exercises|"Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks."
214589317|NCT01666457|OTHER|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
214589318|NCT03050255|OTHER|Medical air|
214589319|NCT03050255|OTHER|Oxygen (2Liter/min)|
214589320|NCT03050255|OTHER|Oxygen (4Liter/min)|
214589321|NCT03070951|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
214710856|NCT04144075|OTHER|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
214710857|NCT03922633|DRUG|E3112|Intravenous infusion.
214710858|NCT03922633|OTHER|Placebo|Intravenous infusion.
214589322|NCT03070951|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
214710859|NCT01089829|OTHER|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
214710860|NCT00255294|DRUG|Cellulose sulfate vaginal gel|
214710861|NCT04046757|OTHER|Mechanical thrombectomy|Neuroradiological endovascular treatment
214710862|NCT04696874|PROCEDURE||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
214710863|NCT04209257|DEVICE|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
214710864|NCT05457348|PROCEDURE|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
214710865|NCT02633839|DRUG|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
214710866|NCT02633839|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
214710867|NCT06182930|OTHER|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.|They will receive routine home health care follow-up.
214710868|NCT06017648|DEVICE|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
214710869|NCT06017648|DEVICE|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
214589323|NCT03070951|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
214589324|NCT03070951|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
214589325|NCT00956748|DRUG|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
214710870|NCT04715048|DRUG|PrabotulinumtoxinA|Glabellar line correction
214710871|NCT04715048|DRUG|Onabotulinum toxin A|Glabellar line correction
214710872|NCT02789449|OTHER|assessment of DLNO and DLCO|
214710873|NCT04180995|DRUG|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
214589326|NCT00956748|DRUG|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
214710874|NCT01310218|OTHER|extended postoperative dressing|2 weeks of bulky dressing
214710875|NCT01310218|OTHER|short postoperative dressing|2 days bulky dressing followed by bandaid
214589327|NCT01213160|DRUG|AZD4547|film coated tablet, PO, twice daily
214589328|NCT05955287|BEHAVIORAL|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
214589329|NCT05955287|BEHAVIORAL|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
214589330|NCT05955287|BEHAVIORAL|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
214589331|NCT05955287|BEHAVIORAL|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
214589332|NCT01907360|DRUG|HLD200 (methylphenidate hydrochloride)|
214589333|NCT05576194|DEVICE|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
214589334|NCT05576194|DEVICE|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
214589335|NCT05576194|DRUG|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
214589336|NCT03747198|DIETARY_SUPPLEMENT|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
214589337|NCT03747198|OTHER|Placebo|Subjects will be given 2 g/day placebo (rice flour).
214589338|NCT04206579|DRUG|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
214589339|NCT04206579|DRUG|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
214589340|NCT03573726|OTHER|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
214589341|NCT05003440|DRUG|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
214589342|NCT05003440|DRUG|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
214589343|NCT02647567|OTHER|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
214589344|NCT02647567|OTHER|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
214589345|NCT00398645|DRUG|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
214589346|NCT05399420|DIAGNOSTIC_TEST|Blood sampling|One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
214589347|NCT03329560|BIOLOGICAL|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
214589348|NCT00348855|OTHER|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
214589349|NCT00348855|BEHAVIORAL|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
214589350|NCT00348855|BEHAVIORAL|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
214589351|NCT00348855|BEHAVIORAL|Stop Smoking|Minimal intervention
214589352|NCT00348855|BEHAVIORAL|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
214589353|NCT00348855|OTHER|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
214589354|NCT01822288|DRUG|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
214589355|NCT01822288|DRUG|Estradiol & medroxyprogesterone acetate|Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
214589356|NCT02636179|OTHER|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
214589357|NCT01676181|PROCEDURE|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
214589358|NCT01676181|PROCEDURE|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
214589359|NCT05331963|OTHER|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
214710876|NCT00861679|PROCEDURE|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided."
214589360|NCT02953860|DRUG|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
214589361|NCT05341596|PROCEDURE|repeat endotracheal intubation|repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
214589362|NCT01173406|BEHAVIORAL|CPAP education|Standard CPAP education plus an session and one telephone follow up
214589363|NCT00585195|DRUG|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
214589364|NCT00585195|DRUG|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
214589365|NCT00585195|DRUG|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
214589366|NCT03327337|PROCEDURE|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
214589367|NCT01523925|BEHAVIORAL|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
214589368|NCT01523925|BEHAVIORAL|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
214589369|NCT01523925|BEHAVIORAL|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
214710877|NCT01943318|PROCEDURE|Liver biopsy|Histologic evaluation
214710878|NCT01943318|DEVICE|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
214710879|NCT02492087|DRUG|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
214710880|NCT02492087|DRUG|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
214710881|NCT01754675|BEHAVIORAL|Soccer|Watching the soccer match at the time that the favorite team is playing
214710882|NCT01754675|BEHAVIORAL|Movie|Watching a movie at the time that the favorite team is playing
214589370|NCT01523925|BEHAVIORAL|Functional electrical stimulation|
214589371|NCT02796560|DRUG|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
214589372|NCT02796560|DRUG|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
214589373|NCT04375020|DRUG|GABA|GABA nutritional supplement 750mg per day for 6 months
214589374|NCT01455857|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
214589375|NCT01455857|OTHER|ITCA placebo|Formulation in DUROS (no exenatide)
214589376|NCT03020654|OTHER|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
214589377|NCT03020654|OTHER|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
214589378|NCT03422588|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
214589379|NCT02638480|DEVICE|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
214589380|NCT04244838|DIAGNOSTIC_TEST|Gait Analysis|The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
214589381|NCT06027593|BEHAVIORAL|Mixed methods intervention|"Investigators will implement the intervention at the completion of the rapid user-centered design process and consultation with CDC collaborators.~During the rapid user-centered design process, the team will engage key stakeholders to create and optimize feedback reports that will fit the prescribing context, and determine appropriate implementation supports that will be needed to accompany the introduction of the feedback reports to each setting.~Following the initial awareness-building activities, investigators will circulate the antibiotic prescribing feedback reports. After the first 3 months (approximately) of report dissemination, the team will assess the feasibility and acceptability of the reports and implementation activities by administering a brief survey to prescribers and also conducting interviews with them. No direct identifiers will be collected."
214589382|NCT00285220|PROCEDURE|Laparoscopic Truncal Vagotomy|
214589383|NCT04558749|OTHER|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
214589384|NCT04558749|OTHER|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
214589385|NCT05584787|PROCEDURE|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
214589386|NCT02714387|OTHER|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
214589387|NCT01468129|OTHER|Cell Saver|
214589388|NCT04248660|OTHER|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
214589389|NCT00907790|BEHAVIORAL|Usual Care (Control Group)|
214710883|NCT02535078|DRUG|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
214710884|NCT04632537|DRUG|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
214710885|NCT04632537|DRUG|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
214589390|NCT00907790|BEHAVIORAL|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
214589391|NCT04987437|DEVICE|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
214589392|NCT00760773|DRUG|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
214589393|NCT00760773|DRUG|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
214589394|NCT00760773|DRUG|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
214589395|NCT02087709|OTHER|Low-calorie diet|
214589396|NCT05060068|DRUG|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
214589397|NCT05060068|DRUG|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
214589398|NCT05060068|DRUG|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
214589399|NCT02880540|DRUG|Fentanyl|
214589400|NCT02880540|DRUG|Morphine|
214589401|NCT02880540|DRUG|Dexmedetomidine|
214589402|NCT00911287|DRUG|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
214589403|NCT04710160|DRUG|Novel fast-setting calcium silicate cement (Protooth)|In form of power and liquid to be mixed together to form a paste.
214589404|NCT00617253|DRUG|recombinant interleukin-21|3 mcg/kg, s.c. injection
214589405|NCT00617253|DRUG|sunitinib|Hard gelatine capsules, 12.5 mg
214589406|NCT00617253|DRUG|recombinant interleukin-21|10 mcg/kg, s.c. injection
214589407|NCT00617253|DRUG|recombinant interleukin-21|30 mcg/kg, s.c. injection
214589408|NCT00617253|DRUG|recombinant interleukin-21|100 mcg/kg, s.c. injection
214589409|NCT03163485|DEVICE|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
214589410|NCT03163485|DEVICE|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
214589411|NCT01516593|DRUG|Induction Phase|"* dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
214589412|NCT01516593|DRUG|Consolidation Phase (on day +50)|"* dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection."
214589413|NCT01516593|DRUG|Intensification phase|"1. One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~2. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~3. AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
214589414|NCT01516593|DRUG|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
214589415|NCT01516593|RADIATION|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
214589416|NCT04193124|DIAGNOSTIC_TEST|transcranial doppler.|Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
214589417|NCT02720367|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
214589418|NCT05802641|RADIATION|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
214589419|NCT02132013|BEHAVIORAL|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
214589420|NCT04581954|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
214589421|NCT04581954|DRUG|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
214589422|NCT04581954|OTHER|Standard of care|Standard of care treatment as per site-level policies and guidelines.
214589423|NCT01729143|OTHER|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
214589424|NCT00611312|BEHAVIORAL|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
214589425|NCT01607112|BIOLOGICAL|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
214589426|NCT02881957|DRUG|Cholecalciferol|
214589427|NCT02881957|OTHER|Placebo|Oral syrup placebo
214589428|NCT05742022|DRUG|"Phospholipovit"|500 mg orally 2 times a day, for 12 weeks
214589429|NCT05742022|DRUG|Placebo|500 mg orally 2 times a day, for 12 weeks
214589430|NCT05687526|BIOLOGICAL|Telitacicept|"12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.~5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks."
214589431|NCT05593237|DEVICE|High Frequency rTMS|Stimulation provided at 10 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (3,000 pulses/session)
214589432|NCT05593237|DEVICE|Low Frequency rTMS|Stimulation provided at 1 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (300 pulses/session)
214589433|NCT02568865|OTHER|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
214589434|NCT02568865|OTHER|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
214589435|NCT02568865|OTHER|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
214589436|NCT02568865|OTHER|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
214589437|NCT04041011|DRUG|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
214589438|NCT04041011|DRUG|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
214589439|NCT04041011|DRUG|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
214589440|NCT05137353|BEHAVIORAL|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
214589441|NCT05137353|BEHAVIORAL|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
214589442|NCT04816331|OTHER|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
214589443|NCT04179162|DRUG|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
214589444|NCT04179162|DRUG|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
214589445|NCT06041048|DRUG|Modafinil|Single dose (200 mg) of medication versus placebo given to healthy control subjects
214589446|NCT04317807|DRUG|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
214589447|NCT04317807|OTHER|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
214589448|NCT03868488|BEHAVIORAL|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
214589449|NCT00484458|DEVICE|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
214589450|NCT00484458|DEVICE|Total Disc Replacement|Total disc
214589451|NCT00345293|BIOLOGICAL|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
214589452|NCT00297336|DRUG|Topiramate|80 patients with diagnosed with migraine
214589453|NCT05209763|PROCEDURE|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
214589454|NCT05209763|DIETARY_SUPPLEMENT|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses"
214589455|NCT06598722|DRUG|BCL-2 inhibitors combined with the HyperCVAD regimen|BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
214589456|NCT06598722|OTHER|Propensity score matching historical data|Propensity score matching was conducted with historical data (matching factors included age, gender, initial LDH levels, and the presence or absence of a large mediastinal mass at diagnosis) to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols.
214589457|NCT06605495|COMBINATION_PRODUCT|fumigation with Chinese medicine|Eye fumigation with the Eyesight Eye Therapy,10 minutes once daily for 6 weeks.
214589458|NCT06605495|DRUG|Oral herbal medicine|Patients were identified into the appropriate group according to the individual evidence profile, and the herbal formula under the corresponding evidence profile was taken orally as one dose of 150 ml of water twice a day for 6 weeks.
214589459|NCT06605495|DRUG|Modern Western Medicine|Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
214634411|NCT05991856|PROCEDURE|laparoscopic adrenalectomy|The subjects was placed in a lateral position under general anesthesia. Using harmonic scalpel carefully separates the adrenal vessels and lates them. The adipose tissue around the adrenal gland is dissected carefully, the surrounding tissue is bluntly separated, and the adrenal gland is fully exposed and dissected. After adrenalectomy was completed, hemostasis was rechecked and specimens were removed.
214634412|NCT05991856|DRUG|Hypotensive Drugs|All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
214634413|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
214634414|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
214634415|NCT01405261|DRUG|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
214634416|NCT01405261|DRUG|oral placebo|Subjects will be randomised to receive a single dose of placebo.
214634417|NCT01660074|OTHER|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
214589460|NCT06589960|COMBINATION_PRODUCT|Health education and physical exercise|"Nine face to face sessions and group discussion health education sessions. An Educational booklet was prepared and distributed to all attendants.~Lab results were discussed individually with each participant.~Rheumatologist and physiotherapist also provided messages.~The exercise program targeted and strengthened the muscles around the knee especially quadriceps muscle, stretching the muscles of lower limbs, and stretching and increasing the range of motion of front and back lower limb muscles (quadriceps muscle, hamstring muscle, gluteus muscle and calf muscles).~Phone calls to follow up the participants and maximize their adherence to the health education program. WhatsApp groups was created, and messages were distributed to summarize the content of the booklet and the exercises videos.~Final reassessment to assess the effect of health education and lifestyle modification was carried out with participants who continued till the end of the study."
214589461|NCT06611254|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
214589462|NCT06609733|DEVICE|Twin block|The TB group used a single appliance continuously, with appropriate reduction of occlusal surface height by 1 mm when clinically indicated. Both groups had follow-up appointments every 6 weeks.
214589463|NCT06609733|DEVICE|Clear aligner with mandibular function|The MA group underwent stepwise mandibular forward movement with clear aligners (Invisalign, Align Inc, CA, USA) worn for 22 hours/day and replaced every 7 days.
214589464|NCT06610305|DRUG|Transdermal estradiol|0.1 mg/day delivered via weekly patch
214589465|NCT06610305|DRUG|Progesterone|100 mg twice daily (200 mg/day total) administered via oral capsule
214589466|NCT06610305|DRUG|Transdermal placebo patch|Once weekly via transdermal patch
214589467|NCT06610305|DRUG|placebo capsule|Twice daily via oral capsule
214589468|NCT06609759|DRUG|Standard chemotherapy regimen|In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
214589469|NCT06610149|DIETARY_SUPPLEMENT|Probiotic mixture|8 weeks treatment with Probiotic mixture
214589470|NCT01111747|PROCEDURE|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
214589471|NCT01111747|PROCEDURE|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
214589472|NCT06610292|OTHER|Pharmacist-led medication reconciliation services|"Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list.~Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved.~Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs)."
214589473|NCT06610123|DIETARY_SUPPLEMENT|Caffeine and Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
214589474|NCT06610123|DIETARY_SUPPLEMENT|Placebo and Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
214589475|NCT05553522|COMBINATION_PRODUCT|Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine|"SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle."
214589476|NCT02485054|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
214589477|NCT04417322|OTHER|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
214589478|NCT02788903|OTHER|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
214589479|NCT06286709|BIOLOGICAL|Faecal Microbiota Transplant|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
214589480|NCT06286709|OTHER|FMT Placebo|FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
214589481|NCT04420936|BEHAVIORAL|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
214589482|NCT04420936|BEHAVIORAL|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
214589483|NCT03220763|OTHER|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
214589484|NCT01972711|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
214589485|NCT01972711|DRUG|Amisulpride|Amisulpride as a single oral dose of 400 mg
214589486|NCT01972711|DRUG|Placebo|single oral dose placebo
214589487|NCT03701867|OTHER|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
214589488|NCT05224336|DRUG|Psilocybin|25mg oral psilocybin
214589489|NCT05224336|DRUG|Placebo Niacin|100mg oral niacin
214589490|NCT02648165|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
214589491|NCT02648165|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
214589492|NCT02648165|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
214589493|NCT00194857|DRUG|erythropoietin, GCSF|
214589494|NCT01440374|DRUG|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
214589495|NCT01440374|DRUG|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
214589496|NCT03542513|DEVICE|Colli-Pee|Urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium).
214589497|NCT03542513|DEVICE|Qvintip|Vaginal self-samples will be collected with the Qvintip (Aprovix AB, Uppsala, Sweden).
214589498|NCT01341756|RADIATION|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
214589499|NCT05768256|BEHAVIORAL|Mindfulness-Based Cognitive-behavioral Therapy for Distress|Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
214589500|NCT05288803|OTHER|Clinical decision support tool (CDS tool)|The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
214589501|NCT05730270|BEHAVIORAL|Stress reduction program 1|Participants will receive daily online lessons
214589502|NCT05730270|BEHAVIORAL|Stress reduction program 2|Participants will receive daily online lessons
214589503|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
214589504|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
214589505|NCT02593669|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
214589506|NCT02593669|DRUG|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
214589507|NCT02513420|BEHAVIORAL|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
214589508|NCT02725957|DRUG|Trehalose for IV Infusion|
214589509|NCT02725957|DRUG|Saline 0.9% IV|
214589510|NCT02966392|DEVICE|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
214589511|NCT02673151|PROCEDURE|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
214589512|NCT02673151|DRUG|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
214589513|NCT02673151|PROCEDURE|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
214589514|NCT01709747|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
214589515|NCT01709747|DEVICE|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
214589516|NCT00231153|DRUG|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
214589517|NCT00231153|DRUG|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
214589518|NCT05699135|DRUG|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
214589519|NCT05648526|DRUG|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
214589520|NCT05648526|DRUG|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
214589521|NCT04487834|DRUG|Simethicone Solution|Oral daily treatment for four weeks
214589522|NCT04487834|DIETARY_SUPPLEMENT|Vivatlac Baby|Oral daily treatment for four weeks
214589523|NCT04150601|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
214589524|NCT04150601|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
214589525|NCT04150601|OTHER|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
214589526|NCT04023721|DRUG|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
214589527|NCT04023721|DRUG|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
214589528|NCT00911079|PROCEDURE|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
214589529|NCT00911079|RADIATION|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
214589530|NCT03234790|OTHER|Filtered Air Exposure|Exposure to Filtered air
214589531|NCT03234790|OTHER|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
214589532|NCT03656978|BEHAVIORAL|dynamic|Use the according methods in dynamic arm descriptions.
214589533|NCT03656978|BEHAVIORAL|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
214589534|NCT00517777|DEVICE|continuous positive airway pressure ventilation|nighttime
214589535|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
214589536|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
214589537|NCT01969318|DRUG|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
214589538|NCT01969318|DRUG|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
214589539|NCT01969318|DRUG|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
214589540|NCT00433459|DRUG|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
214589541|NCT00433459|DRUG|dacarbazine|drug is used in first line treatment in combination (COPDAC)
214589542|NCT00433459|DRUG|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
214589543|NCT00433459|DRUG|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
214589544|NCT00433459|DRUG|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
214589545|NCT00433459|DRUG|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
214589546|NCT00433459|RADIATION|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
214710886|NCT06005298|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~* It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~* The screening is universal.~* One or more specific behaviors related to risky alcohol and drug use are targeted.~* The services occur in a public health non-substance abuse treatment setting.~* It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~* Strong research or experiential evidence supports the model's effectiveness."
214710887|NCT03116308|DRUG|Opicapone (OPC)|50 mg OPC capsules; oral route
214589547|NCT00433459|RADIATION|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
214589548|NCT06175390|RADIATION|68Ga-FAPI-46 PET/CT|"Cohort A:~Tumor assessments by 18F-FDG PET/CT (per PERCIST v1.0) will be performed at: baseline, after the first 2 treatment cycles (between C2D15 and C3D1), and before surgery (after the last administration of neoadjuvant chemotherapy) Tumor assessment by 68Ga-FAPI-46 PET/CT will be performed at: baseline and before surgery (after the last administration of neoadjuvant chemotherapy).~Cohort B:~Tumor assessments by 18F-FDG PET/CT per PERCIST v1.0 will be performed at baseline, every 8 weeks (+/- 1 week) for the first 24 weeks, and every 12 weeks (+/- 1 week) thereafter until disease progression or treatment discontinuation, whichever is later.~Tumor assessments by 68Ga-FAPI-46 PET/CT will be performed at baseline and after the first 2 treatment cycles and will be synchronized with 18F-FDG PET/CT."
214589549|NCT06175390|BIOLOGICAL|Tumor samples analysis|"Patients will undergo a mandatory biopsy of the primary tumor at baseline, after the first 2 treatment cycles and during the surgery. A lymph node biopsy will be performed at baseline if feasible in cohort A, and and in case of disease progression for cohort B (if clinically feasible).~In addition to the usual morphological and immunohistochemical (ER, PR, HER2+, CPS score, PD-L1 status with SP142 …) analyses in the cohort A and cohort B , exploratory analyses will be performed."
214589550|NCT06175390|BIOLOGICAL|Blood samples analysis: Circulating Tumor DNA|Blood samples will be collected at baseline. In addition for cohort A at cycles 2 and 3, within 21 days before surgery, 10 to 21 days after surgery and at cycle 8 after surgery. In addition for cohort B after the first 2 treatment cycles and in case of disease progression (if clinically feasible).
214589551|NCT03882411|BEHAVIORAL|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
214710888|NCT00599027|DRUG|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
214589552|NCT06243393|DRUG|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG)
214589553|NCT06243393|DRUG|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
214710889|NCT00599027|DRUG|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
214634418|NCT02266693|BEHAVIORAL|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
214589554|NCT04768387|DIETARY_SUPPLEMENT|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
214589555|NCT01725048|DRUG|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
214589556|NCT01725048|DRUG|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
214589557|NCT00989131|DRUG|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
214589558|NCT00989131|DRUG|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
214589559|NCT05178667|DIETARY_SUPPLEMENT|High dose|Food supplements are consumed during 3 months by healthy volunteers.
214589560|NCT05178667|DIETARY_SUPPLEMENT|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
214589561|NCT05178667|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
214589562|NCT04234425|BEHAVIORAL|Trauma-Informed Yoga|Trauma-Informed Yoga practice held within a high school weight training class
214589563|NCT01438684|DRUG|RPh201|400 microliter s.c. twice a week for 3 months
214589564|NCT01438684|DRUG|Saline|400 microliter Saline solution s.c. twice a week for 3 months
214589565|NCT06434376|BIOLOGICAL|Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology|Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
214589566|NCT03998254|DRUG|V503|9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
214589567|NCT03998254|DRUG|Gardasil|qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
214589568|NCT04662762|OTHER|Nursing intervention programme|educational information
214589569|NCT00491777|DEVICE|Noninvasive Hemodynamic Patient Monitor|
214589570|NCT00425984|PROCEDURE|Adult male circumcision|
214589571|NCT01466634|PROCEDURE|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
214589572|NCT00622453|OTHER|Screening|Electrocardiography Blood Test
214589573|NCT02634957|BEHAVIORAL|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
214589574|NCT01621113|DRUG|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
214589575|NCT01621113|DRUG|Placebo|Placebo tablet, twice daily, for 10 weeks.
214589576|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
214589577|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
214589578|NCT03266354|PROCEDURE|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
214589579|NCT03274960|COMBINATION_PRODUCT|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
214589580|NCT05276609|DRUG|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214589581|NCT05276609|DRUG|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214589582|NCT00518791|OTHER|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
214589583|NCT00518791|OTHER|Usual Care|No altered organisation of care
214589584|NCT00211497|DRUG|MBI 226 Acne Solutions|
214589585|NCT03823560|DEVICE|Celegyn®|Medical device Celegyn® presents itself as a cream.
214589586|NCT03823560|DEVICE|Matching placebo|IP placebo presents itself as a cream.
214589587|NCT06132126|DRUG|LY3938577|Administered SC.
214589588|NCT06132126|DRUG|Placebo|Administered SC.
214589589|NCT06132126|DRUG|Insulin degludec|Administered SC.
214589590|NCT01778660|OTHER|Type of Counselling (Mnemonic)|
214589591|NCT01778660|OTHER|Standard|
214589592|NCT04389736|BEHAVIORAL|Sitting|Participants sat in a chair with back, arms and legs supported.
214589593|NCT04389736|BEHAVIORAL|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
214589594|NCT04389736|BEHAVIORAL|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
214589595|NCT02042612|DRUG|Sedation with sevoflurane during 48-hr in ICU|
214589596|NCT01824160|DEVICE|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
214589597|NCT04530409|DRUG|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
214589598|NCT00077220|DRUG|carboplatin|
214589599|NCT00077220|DRUG|paclitaxel|
214589600|NCT00077220|PROCEDURE|adjuvant therapy|
214589601|NCT00077220|RADIATION|radiation therapy|
214589602|NCT03714932|DIAGNOSTIC_TEST|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
214589603|NCT02435758|PROCEDURE|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
214589604|NCT02296970|PROCEDURE|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
214589605|NCT04281004|BIOLOGICAL|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
214589606|NCT04281004|OTHER|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
214589607|NCT00701779|DRUG|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
214589608|NCT03432715|BEHAVIORAL|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
214589609|NCT03432715|BEHAVIORAL|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
214589610|NCT03628898|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
214589611|NCT00589082|DRUG|DaunoXome|
214589612|NCT00589082|DRUG|Daunorubicine|
214589613|NCT02946970|OTHER|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
214589614|NCT02946970|OTHER|Control|Intragastric administration of distilled water
214589615|NCT02137720|BEHAVIORAL|Telephonic Diabetes Self-Management Support|
214589616|NCT02137720|OTHER|Educational Print Materials|
214589617|NCT05149430|OTHER|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
214589618|NCT04999098|DRUG|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
214589619|NCT04999098|DRUG|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
214589620|NCT04999098|DRUG|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
214589621|NCT04700722|DIAGNOSTIC_TEST|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
214589622|NCT04040816|DRUG|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
214589623|NCT00450060|DEVICE|lumbar puncture with Quincke-design needles|
214589624|NCT00450060|DEVICE|lumbar puncture with Sprotte-design needles|
214589625|NCT00793000|DRUG|PF-04287881|75 mg oral dose (prepared solution) given once
214589626|NCT00793000|DRUG|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
214589627|NCT00793000|DRUG|PF-04287881|150 mg oral dose (prepared solution) given once
214589628|NCT00793000|DRUG|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
214589629|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
214589630|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
214589631|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
214589632|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
214589633|NCT00793000|DRUG|PF-04287881|1000 mg oral dose (prepared solution) given once
214710890|NCT04257227|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
214589634|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
214589635|NCT00793000|DRUG|PF-04287881|1250 mg oral dose (prepared solution) given once
214589636|NCT00793000|DRUG|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
214589637|NCT00793000|DRUG|PF-04287881|1500 mg oral dose (prepared solution) given once
214589638|NCT00793000|DRUG|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
214589639|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
214589640|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
214589641|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
214589642|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
214589643|NCT00793000|DRUG|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
214589644|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
214589645|NCT04648735|OTHER|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
214589646|NCT00344474|BEHAVIORAL|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
214589647|NCT02041741|BEHAVIORAL|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
214589648|NCT02041741|BEHAVIORAL|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
214589649|NCT00831831|BEHAVIORAL|Safety planning|See detailed description
214589650|NCT00271427|DRUG|L-Selenomethionine|
214589651|NCT04196608|DRUG|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
214589652|NCT04196608|DRUG|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
214589653|NCT01143974|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
214589654|NCT01217957|DRUG|Ixazomib|Ixazomib capsules
214589655|NCT01217957|DRUG|Lenalidomide|Lenalidomide capsules
214589656|NCT01217957|DRUG|Dexamethasone|Dexamethasone tablets
214589657|NCT01633983|DRUG|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
214589658|NCT01633983|DRUG|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
214589659|NCT00790608|DRUG|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
214589660|NCT05631431|DIETARY_SUPPLEMENT|Curalin|Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
214634419|NCT03833830|DIAGNOSTIC_TEST|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).
214710891|NCT05344027|DRUG|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
214634420|NCT04852120|OTHER|No intervention|Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
214634421|NCT00215384|DRUG|Formoterol Fumarate|
214634422|NCT02005757|DRUG|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
214634423|NCT02005757|DRUG|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
214634424|NCT01608412|DRUG|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
214589661|NCT04166890|DRUG|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
214589662|NCT02482870|DEVICE|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
214589663|NCT02482870|DEVICE|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
214589664|NCT02151422|BEHAVIORAL|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
214589665|NCT00061451|DRUG|Pemetrexed|
214589666|NCT00061451|DRUG|Gemcitabine|
214589667|NCT03345134|DRUG|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
214589668|NCT01873495|DRUG|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
214589669|NCT01206777|DRUG|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
214589670|NCT04637308|DRUG|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
214589671|NCT06450938|DEVICE|AI guidance for finding radiographic features|A secured website was made for the trial in which each student could log in using the assigned number. All the image datasets were uploaded to this website. The students will be randomly assigned to the experiment and control group. Both students were asked to segment the features associated with the quality of root canal treatment and predict the prognosis of treatment while the experiment group had access to AI guidance and the control group didn't.
214589672|NCT03490526|DEVICE|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
214634425|NCT01608412|DRUG|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
214634426|NCT05381129|OTHER|Detection of Pain, Quality of Life, Sleep and Functioning|All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.
214634427|NCT05381129|OTHER|Temporomandibular joint dysfunction|Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
214710892|NCT05647629|PROCEDURE|Total hip arthroplasty|hip prosthesis surgery
214589673|NCT03490526|DEVICE|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
214589674|NCT05535634|DIAGNOSTIC_TEST|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
214589675|NCT02153372|OTHER|BMC2012|
214589676|NCT02986334|DRUG|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
214589677|NCT02986334|DRUG|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
214710893|NCT02477722|OTHER|EFP-NF|
214710894|NCT02477722|OTHER|Sham|
214589678|NCT02986334|DRUG|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
214589679|NCT04265924|OTHER|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
214589680|NCT05252923|DRUG|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
214710895|NCT03879876|DRUG|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
214710896|NCT03996434|DRUG|Gonadotropin|withholding gonadotropin administration for at least 24 hours
214710897|NCT03996434|DRUG|Antagonist|Cetrorelix acetate 0.25 mg
214710898|NCT05781763|BEHAVIORAL|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
214589681|NCT00956514|DEVICE|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
214589682|NCT00001457|DRUG|Lamivudine|
214589683|NCT04641039|PROCEDURE|Anterior lumbar disc annulus removal versus replacement|Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
214589684|NCT00501514|DRUG|Growth hormone|
214589685|NCT02791373|DRUG|Vinorelbine|Mobilisation Chemotherapy
214589686|NCT02791373|DRUG|Gemcitabine|Mobilisation Chemotherapy
214589687|NCT06025162|DRUG|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
214589688|NCT04926220|DEVICE|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
214589689|NCT04926220|DEVICE|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
214589690|NCT04926220|DEVICE|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
214589691|NCT06051916|OTHER|residual urine|The study includes two group, A and B. Se previously
214589692|NCT00914264|DEVICE|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 \& 12 months
214589693|NCT00606567|OTHER|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
214589694|NCT01556893|DEVICE|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
214589695|NCT03982615|DEVICE|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
214589696|NCT03982615|DEVICE|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
214589697|NCT00571831|PROCEDURE|intraocular lens implantation|Intraocular lens implantation
214589698|NCT00184821|PROCEDURE|Ischemic preconditioning|
214589699|NCT00184821|PROCEDURE|Forearm ischemic exercise|
214710899|NCT05781763|OTHER|Control group|Continuing with exercise as usual during 12 months
214589700|NCT00184821|PROCEDURE|Annexin A5 scintigraphy|
214589701|NCT00184821|DRUG|Diazoxide|
214589702|NCT00184821|DRUG|glibenclamide|
214589703|NCT00184821|DRUG|adenosine|
214589704|NCT01989767|BEHAVIORAL|control Rehabilitation as usual|Rehabilitation as usual
214589705|NCT01989767|BEHAVIORAL|education|Education as add on to to rehabilitation as usual
214589706|NCT06524752|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
214589707|NCT06524752|OTHER|Non-existence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
214589708|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
214589709|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
214589710|NCT01002365|OTHER|Oxygen delivery|
214589711|NCT01002365|OTHER|Oxygen administration|
214589712|NCT00221247|PROCEDURE|Acupuncture|acupuncture
214589713|NCT05171101|OTHER|MAVEN|The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
214710900|NCT04214730|COMBINATION_PRODUCT|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
214710901|NCT04214730|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
214589714|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
214589715|NCT03982901|DIAGNOSTIC_TEST|Mental Stress Test|In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
214589716|NCT00001718|DEVICE|Electropalatography|
214589717|NCT05158582|OTHER|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
214589718|NCT05158582|OTHER|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
214589719|NCT03917680|DIAGNOSTIC_TEST|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
214589720|NCT03917680|GENETIC|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
214589721|NCT03917680|DIAGNOSTIC_TEST|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
214589722|NCT02170792|DRUG|BIBR 1048 MS|Low, medium or high dose
214589723|NCT02170792|DRUG|Ranitidine|150mg
214589724|NCT02440451|DEVICE|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
214589725|NCT06185361|DRUG|Fluoxetine 20 MG|fluoxetine
214589726|NCT06185361|DRUG|Desmopressin|desmopressin
214589727|NCT01749605|DRUG|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
214589728|NCT01749605|DRUG|ciprofloxacin 250 mg BID x 3 days|
214589729|NCT05785702|DEVICE|The anti-wandering system|During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
214589730|NCT00495287|DRUG|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
214589731|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
214589732|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
214589733|NCT03711851|OTHER|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
214589734|NCT00437580|DRUG|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
214589735|NCT00744185|DRUG|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
214589736|NCT00744185|DRUG|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
214710902|NCT04376606|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
214710903|NCT04376606|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
214589737|NCT02086123|PROCEDURE|Epidural Analgesia|Bupivacaine + Fentanyl
214589738|NCT02086123|PROCEDURE|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
214589739|NCT05293210|DRUG|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
214589740|NCT00655291|DRUG|XP20B|
214589741|NCT00655291|DRUG|Placebo|
214589742|NCT00000301|DRUG|Amantadine|
214589743|NCT03063112|DEVICE|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
214589744|NCT03063112|DRUG|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
214589745|NCT03063112|DEVICE|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
214589746|NCT03063112|DRUG|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
214589747|NCT00945126|OTHER|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
214710904|NCT04376606|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
214589748|NCT03785171|PROCEDURE|surgical revascularization|Indirect revascularization procedure
214589749|NCT00562705|BEHAVIORAL|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
214589750|NCT00562705|BEHAVIORAL|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
214589751|NCT01137968|DRUG|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
214589752|NCT01137968|DRUG|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
214589753|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214589754|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214589755|NCT00000837|BIOLOGICAL|Varicella Virus Vaccine (Live)|
214589756|NCT02686905|DIETARY_SUPPLEMENT|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
214589757|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
214589758|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
214589759|NCT02686905|DIETARY_SUPPLEMENT|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
214589760|NCT02686905|DIETARY_SUPPLEMENT|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
214589761|NCT02686905|DIETARY_SUPPLEMENT|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
214589762|NCT04242563|OTHER|VIRTUAL REALITY|Patient equipped with virtual reality in transfer room
214589763|NCT05335954|DRUG|noradrenaline|noradrenaline
214589764|NCT02322138|OTHER|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
214589765|NCT02322138|OTHER|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
214589766|NCT02322138|OTHER|Reference Group|Breast fed ad libitum
214589767|NCT01115660|BEHAVIORAL|stroke education|call by medication coach 2 weeks after hospital discharge
214589768|NCT01313637|DRUG|GSK573719/GW642444 125/25mcg|125/25mcg
214589769|NCT01313637|DRUG|GSK573719 125mcg|125mcg
214589770|NCT01313637|DRUG|GW642444 25mcg|25mcg
214589771|NCT01313637|DRUG|Placebo only|Placebo
214589772|NCT03692260|PROCEDURE|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
214589773|NCT04557111|DEVICE|remote monitoring|CIED monitoiring with remote monitoring device
214589774|NCT00816348|DRUG|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
214589775|NCT02088749|BEHAVIORAL|lifestyle intervention for obesity|
214589776|NCT02425709|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
214589777|NCT02425709|DRUG|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
214589778|NCT02425709|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
214589779|NCT05877287|OTHER|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
214589780|NCT04293315|BEHAVIORAL|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
214589781|NCT00629330|BEHAVIORAL|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
214589782|NCT05342909|OTHER|5x a week BFR training group|This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
214589783|NCT05342909|OTHER|2x a week BFR training group|This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
214589784|NCT02212210|DRUG|Methylprednisolone|
214589785|NCT02212210|DRUG|Normal saline|
214589786|NCT03422354|PROCEDURE|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
214589787|NCT03422354|DEVICE|Ultrasound|Ultrasound
214589788|NCT03422354|DRUG|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
214589789|NCT03422354|DRUG|General Aneasthesia|General Aneasthesia
214589790|NCT01383772|PROCEDURE|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
214589791|NCT01312012|DRUG|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
214589792|NCT04580966|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
214589793|NCT03680404|DRUG|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
214589794|NCT03680404|DRUG|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
214589795|NCT03680404|DRUG|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
214589796|NCT03680404|DRUG|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
214589797|NCT03752918|DRUG|MDMA|A single dose of 1.5mg/kg will be administered once orally.
214589798|NCT03752918|DRUG|Niacin|A single dose of 250mg will be administered once orally.
214589799|NCT03656237|OTHER|Usual Training|Training in a classroom setting of health care providers
214589800|NCT03656237|OTHER|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
214589801|NCT05491304|DRUG|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
214589802|NCT05491304|DRUG|Etoposide|Used in severe group combined with etoposide.
214589803|NCT05491304|DRUG|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
214589804|NCT03765320|PROCEDURE|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
214589805|NCT03765320|PROCEDURE|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
214589806|NCT00846391|DRUG|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
214589807|NCT00846391|DRUG|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
214589808|NCT00846391|DRUG|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
214589809|NCT01549054|DRUG|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
214589810|NCT01549054|DRUG|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
214589811|NCT01549054|DRUG|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
214589812|NCT01549054|DRUG|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
214589813|NCT01509131|DRUG|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
214589814|NCT01509131|DRUG|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
214589815|NCT00251420|PROCEDURE|writing about disease|writing about physical or emotional consequences of pulmonary disease
214589816|NCT02652273|DRUG|Abatacept|Abatacept 125mg/ml
214589817|NCT00122915|DEVICE|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
214589818|NCT00913120|DRUG|YM150|oral
214589819|NCT00913120|DRUG|Placebo|oral
214589820|NCT00913120|DRUG|Enoxaparin|injection
214589821|NCT00635856|DRUG|Gefitinib|Iressa
214589822|NCT02475902|BEHAVIORAL|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
214589823|NCT02475902|BEHAVIORAL|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
214589824|NCT03339570|PROCEDURE|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
214589825|NCT00648830|PROCEDURE|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
214589826|NCT00648830|DRUG|Clarithromycin|single-dose 250 mg immediate-release oral tablets
214589827|NCT00104559|BEHAVIORAL|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
214589828|NCT00104559|BEHAVIORAL|Standard paper consent form|Standard paper consent form
214589829|NCT04634825|BIOLOGICAL|Enoblituzumab|Anti-B7-H3 antibody
214589830|NCT04634825|BIOLOGICAL|Retifanlimab|Anti-PD-1 antibody
214589831|NCT04634825|BIOLOGICAL|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
214589832|NCT02688283|OTHER|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
214589833|NCT00286078|DEVICE|Precision|Implantable neurostimulator
214589834|NCT00293631|DRUG|Lornoxicam 8 mg|
214589835|NCT00293631|DRUG|Lornoxicam 16 mg|
214589836|NCT00293631|DRUG|Ketorolac 30 mg|
214589837|NCT00293631|DRUG|Placebo|
214589838|NCT02745743|DRUG|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
214589839|NCT03401541|DRUG|Calcifediol|One capsule of 900 micrograms of 25(OH)D
214589840|NCT03401541|DRUG|Calciferol|One capsule of 900 micrograms of Vitamin D
214589841|NCT02388646|OTHER|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
214589842|NCT02388646|DEVICE|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
214589843|NCT02388646|OTHER|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
214589844|NCT01462838|BIOLOGICAL|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
214589845|NCT01530022|DRUG|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
214589846|NCT01530022|DRUG|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
214589847|NCT02977208|PROCEDURE|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
214589848|NCT02977208|PROCEDURE|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
214589849|NCT02977208|PROCEDURE|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms
214589850|NCT02977208|DRUG|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
214589851|NCT06164509|DRUG|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
214589852|NCT03133520|DEVICE|High flow oxygen therapy|High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
214589853|NCT02170935|DRUG|BIBR 1048 capsule|
214634428|NCT03826927|OTHER|treatment with NOACs or VKAs|treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
214589854|NCT03369561|DIAGNOSTIC_TEST|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
214589855|NCT00272922|DEVICE|hernia repair|
214589856|NCT00721669|DRUG|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
214589857|NCT03128008|DRUG|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
214589858|NCT03128008|DRUG|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
214589859|NCT03128008|RADIATION|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
214589860|NCT04343638|DEVICE|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
214589861|NCT04343638|DEVICE|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
214589862|NCT03435757|PROCEDURE|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
214589863|NCT03435757|PROCEDURE|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
214589864|NCT04210869|DIETARY_SUPPLEMENT|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
214589865|NCT05311891|DIAGNOSTIC_TEST|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
214589866|NCT06227078|DEVICE|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
214589867|NCT00947674|DEVICE|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
214589868|NCT03709420|DRUG|Placebo|Placebo capsule to match active drug
214589869|NCT03709420|DRUG|FOR-6219|FOR-6219 capsule
214589870|NCT05217654|DRUG|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
214589871|NCT05217654|DRUG|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
214589872|NCT00037128|DRUG|GL701|
214634429|NCT06541223|OTHER|Standard informed consent procedure|Face-to-face informed consent procedure supported by informational brochure
214634430|NCT06541223|OTHER|Multimedia video|Multimedia presentation on implant-based reconstruction
214634431|NCT02672566|DRUG|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
214634432|NCT02672566|OTHER|Usual care|Patients will all benefit from the usual care
214589873|NCT05106829|OTHER|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
214634433|NCT06500091|DRUG|TQB2916 injection + doxorubicin hydrochloride for injection|"TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells."
214634434|NCT06500091|DRUG|TQB2916 injection+penpulimab injection|TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
214634435|NCT05388539|PROCEDURE|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
214589874|NCT05106829|OTHER|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
214589875|NCT05202548|OTHER|Immuno-histochemical staining|blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
214589876|NCT01999270|DRUG|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
214589877|NCT01999270|DRUG|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
214589878|NCT01999270|DEVICE|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
214589879|NCT01635400|DRUG|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
214589880|NCT04967534|BEHAVIORAL|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
214589881|NCT04967534|BEHAVIORAL|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
214589882|NCT01426763|BIOLOGICAL|CINRYZE with rHuPH20|
214589883|NCT02391857|PROCEDURE|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
214589884|NCT03021954|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
214589885|NCT02966951|BIOLOGICAL|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
214589886|NCT00004252|DRUG|fluorouracil|
214589887|NCT00004252|DRUG|leucovorin calcium|
214589888|NCT00004252|DRUG|semaxanib|
214589889|NCT00069238|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
214589890|NCT00069238|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
214589891|NCT03039257|DIETARY_SUPPLEMENT|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
214589892|NCT02652013|OTHER|cognitive evaluation|
214589893|NCT00000198|DRUG|Piracetam|
214589894|NCT03821389|DEVICE|NIOD Frequencer|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
214589895|NCT01346436|PROCEDURE|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
214589896|NCT02024763|BEHAVIORAL|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
214589897|NCT03201705|DEVICE|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
214589898|NCT00729768|DRUG|basiliximab|2 intravenous doses
214589899|NCT00729768|DRUG|efalizumab|Subcutaneous repeating dose
214589900|NCT00729768|DRUG|mycophenolate mofetil|Oral repeating dose
214589901|NCT00729768|DRUG|corticosteroids|Repeating doses
214589902|NCT00729768|DRUG|cyclosporine|Oral repeating dose
214589903|NCT04129853|DEVICE|Cyberlegs Xleg|Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
214589904|NCT00001563|BIOLOGICAL|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
214589905|NCT00001563|BIOLOGICAL|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
214589906|NCT00001563|DRUG|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
214589907|NCT04094025|DRUG|dATS|d-Amphetamine Transdermal System
214589908|NCT01729325|BEHAVIORAL|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
214589909|NCT01001832|DRUG|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
214589910|NCT01001832|DRUG|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
214589911|NCT05063825|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
214589912|NCT05063825|BEHAVIORAL|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
214589913|NCT03061630|DRUG|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
214589914|NCT03061630|DRUG|Cisplatin|D1: CISPLATIN 60G/M2
214589915|NCT01090622|DRUG|XPF-001|Oral capsule
214589916|NCT01090622|DRUG|Placebo|Oral capsule
214589917|NCT03080012|OTHER|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
214589918|NCT03080012|OTHER|Plasma/serum sampling|Simultaneously with saliva sampling.
214589919|NCT03770559|PROCEDURE|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
214589920|NCT03770559|PROCEDURE|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
214589921|NCT02453360|PROCEDURE|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
214589922|NCT02453360|DRUG|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
214589923|NCT04493190|PROCEDURE|Scapular control training|Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
214589924|NCT04493190|PROCEDURE|General exercise|Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
214589925|NCT02308826|BEHAVIORAL|Turtle Program|
214589926|NCT02308826|BEHAVIORAL|Cool Little Kids|
214589927|NCT04260425|OTHER|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
214589928|NCT04260425|OTHER|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
214589929|NCT06424626|DRUG|AK104+Axitinib|Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
214589930|NCT06424626|DRUG|AK112+Axitinib|Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
214589931|NCT04019548|DEVICE|Percutaneous Endoscopic Gastrotomy tube placement|placement of the PEG tube depends on arm
214589932|NCT04019548|DRUG|Cisplatin injection|"Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV"
214589933|NCT04019548|RADIATION|Radiotherapy|Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
214589934|NCT05884151|DRUG|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
214589935|NCT05884151|DRUG|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
214589936|NCT02722733|DRUG|G-CSF (filgrastim)|
214589937|NCT02722733|DRUG|Cytosine arabinoside with G-CSF (filgrastim)|
214589938|NCT06172881|DEVICE|Investigational Contact Lens|A soft contact lens that will be worn only at the study visit.
214589939|NCT01658722|DRUG|Bapineuzumab|
214589940|NCT02430688|PROCEDURE|Irreversible electroporation (IRE)|
214589941|NCT02430688|DEVICE|NanoKnife|
214589942|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10\^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
214589943|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
214589944|NCT02251288|DRUG|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
214589945|NCT04793802|OTHER|PHYSIO|session of physiotherapy
214589946|NCT01171105|DRUG|AZD5213|oral solution, multiple ascending doses
214589947|NCT01171105|DRUG|Placebo to AZD5213|
214589948|NCT02046824|DEVICE|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
214589949|NCT02046824|DEVICE|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
214589950|NCT02046824|DEVICE|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
214710905|NCT04819802|OTHER|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
214589951|NCT02046824|OTHER|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
214589952|NCT05537688|BEHAVIORAL|Identification of Graphic Markers|"The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team."
214589953|NCT02594826|BEHAVIORAL|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
214589954|NCT02594826|BEHAVIORAL|General health education control|General health and cancer education
214589955|NCT02254525|DRUG|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
214710906|NCT04819802|OTHER|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
214589956|NCT02254525|DRUG|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
214589957|NCT04660266|DIAGNOSTIC_TEST|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
214589958|NCT00549614|DRUG|acipimox|capsule, 250 mg, 4 times daily for 28 days
214589959|NCT00549614|DRUG|placebo|capsule, 250 mg, 4 times daily for 28 days
214589960|NCT03986281|OTHER|Omron Wearable Device|Omron wearable device compared to arterial line readings
214589961|NCT03986281|OTHER|Standard Arterial Line|Omron wearable device compared to arterial line readings
214589962|NCT04300686|BIOLOGICAL|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
214589963|NCT04300686|BIOLOGICAL|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
214589964|NCT03933527|BEHAVIORAL|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
214589965|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
214710907|NCT02320630|DRUG|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
214710908|NCT02320630|DRUG|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
214710909|NCT02320630|DRUG|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
214710910|NCT05687708|OTHER|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
214710911|NCT03721237|OTHER|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
214589966|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
214589967|NCT00795613|DRUG|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN\>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
214589968|NCT00795613|DRUG|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
214589969|NCT00160238|DRUG|Betahistine 24 mg bid (Betaserc)|
214589970|NCT01520493|OTHER|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
214589971|NCT03791671|OTHER|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
214589972|NCT03791671|OTHER|group balance training|Like the individual balance training
214589973|NCT02389114|OTHER|Soy Protein|Soy protein is commonly consumed in Asian diet.
214589974|NCT02389114|OTHER|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
214589975|NCT05918172|DEVICE|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
214589976|NCT05918172|DEVICE|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
214634436|NCT05388539|PROCEDURE|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
214589977|NCT05887817|DRUG|Finerenone|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
214589978|NCT05887817|DRUG|Placebo|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
214589979|NCT06150898|PROCEDURE|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
214589980|NCT06150898|DRUG|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
214589981|NCT06150898|DRUG|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
214589982|NCT06150898|DRUG|Omeprazole 20mg Capsule|Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
214589983|NCT06583720|PROCEDURE|Oral hygiene at home|Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
214589984|NCT06583720|PROCEDURE|aPDT|A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.
214589985|NCT06583720|DIETARY_SUPPLEMENT|Probiotics|Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
214589986|NCT01765179|DRUG|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
214589987|NCT01498029|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
214589988|NCT01498029|DEVICE|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
214589989|NCT06008327|DRUG|Topical 15% Trichloroacetic acid|Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
214589990|NCT05988359|PROCEDURE|Caries treatment with a dental turbine|G1 (n=30) conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
214589991|NCT05988359|PROCEDURE|Caries treatment with Er:YAG laser|G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
214589992|NCT01536015|DRUG|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
214589993|NCT01536015|DRUG|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
214589994|NCT00042406|DRUG|HuMax-CD4|HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
214589995|NCT00042406|DRUG|Placebo|Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
214589996|NCT00042406|DRUG|Humax-CD4|HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
214589997|NCT04788381|DRUG|Bevacizumab|Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
214589998|NCT03598088|DEVICE|Ovaprene|non-hormonal contraceptive ring
214589999|NCT03613987|DEVICE|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
214590000|NCT05277220|DEVICE|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
214590001|NCT03343847|BIOLOGICAL|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
214590002|NCT03343847|OTHER|Placebo|Placebo Comparator
214590003|NCT02508246|DRUG|Cisplatin|Given IV
214590004|NCT02508246|DRUG|Docetaxel|Given IV
214590005|NCT02508246|OTHER|Laboratory Biomarker Analysis|Correlative studies
214590006|NCT02508246|OTHER|Pharmacological Study|Correlative studies
214590007|NCT02508246|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214590008|NCT02508246|DRUG|WEE1 Inhibitor AZD1775|Given PO
214590009|NCT03581825|DEVICE|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
214590010|NCT03581825|DEVICE|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
214590011|NCT03581825|DEVICE|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
214590012|NCT03581825|DEVICE|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
214590013|NCT01668667|DRUG|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
214590014|NCT01668667|DRUG|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
214590015|NCT01668667|DRUG|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
214590016|NCT01668667|DRUG|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
214590017|NCT01582685|BEHAVIORAL|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
214590018|NCT04961723|DIAGNOSTIC_TEST|(OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
214590019|NCT04465747|OTHER|Publications|Reviewing published evidence
214590020|NCT06268769|DRUG|Tacrolimus Pill|Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
214590021|NCT06268769|DRUG|Tacrolimus capsule|Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
214590022|NCT03444350|DEVICE|Gaseous ozone|SRP plus gaseous ozone
214590023|NCT03444350|DEVICE|SRP plus placebo|only SRP
214590024|NCT01124032|DRUG|methylphenidate|a capsule containing 20 mg
214590025|NCT00515632|DRUG|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
214590026|NCT04838600|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
214590027|NCT02633579|DRUG|erythromycin lactobionate|intravenous administration of erythromycin
214590028|NCT02633579|DRUG|Atropine|intravenous administration of atropine
214590029|NCT02633579|DRUG|Erythromycin with atropine|intravenous administration of erythromycin with saline
214590030|NCT02633579|DRUG|Saline|intravenous administration of saline
214590031|NCT02867878|DRUG|Adenosine|
214590032|NCT02867878|DRUG|Saline solution|
214590033|NCT03366623|BEHAVIORAL|Hospital clown|Presence of the hospital clown
214590034|NCT03366623|BEHAVIORAL|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
214590035|NCT00182299|PROCEDURE|porcine small intestine submucosa (SIS)|
214590036|NCT00005082|PROCEDURE|biopsy|
214590037|NCT00005082|PROCEDURE|magnetic resonance imaging|
214590038|NCT03113903|BEHAVIORAL|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
214590039|NCT00511901|DRUG|placebo|
214590040|NCT00511901|DRUG|epoetin alpha|
214590041|NCT00511901|DRUG|Niferex|
214590042|NCT04579601|PROCEDURE|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
214590043|NCT00178126|DEVICE|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
214590044|NCT00178126|DEVICE|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
214590045|NCT00003890|DRUG|MG 98|
214590046|NCT04488718|OTHER|EnergieShake® Junior Powder Complete|Oral Nutritional Supplement
214590047|NCT02447172|DRUG|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
214590048|NCT02447172|OTHER|Placebo|Matching placebo sponge
214590049|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
214590050|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
214590051|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
214590052|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
214590053|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
214590054|NCT02637570|DIETARY_SUPPLEMENT|Hibiscus tea|
214590055|NCT02637570|DIETARY_SUPPLEMENT|green tea|
214590056|NCT02637570|DIETARY_SUPPLEMENT|placebo (dextrose)|
214590057|NCT04281446|DEVICE|Photobiomodulation|Application of light at specific wavelength for interaction with biological tissue
214590058|NCT03562247|OTHER|Usual Care of IPF|standard of care given to patients with IPF
214590059|NCT03562247|OTHER|Telenursing|scheduled phone calls with the patient and care giver
214590060|NCT03562247|OTHER|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
214590061|NCT02668484|DEVICE|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
214590062|NCT02668484|DEVICE|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
214590063|NCT01442831|DRUG|Human ADME|Oral single dose
214590064|NCT02299492|OTHER|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
214590065|NCT04925973|DRUG|Tofacitinib 10 MG [Xeljanz]|Tofacitinib 10mg PO BID
214590066|NCT02682745|DRUG|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
214590067|NCT02682745|DRUG|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
214590068|NCT03576170|OTHER|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
214590069|NCT00467168|BEHAVIORAL|Diet|
214590070|NCT00513643|DRUG|insulin aspart|6, 12, 24 U s.c.
214590071|NCT00513643|DRUG|human regular insulin|6, 12 and 24 IU sc
214590072|NCT05636722|BEHAVIORAL|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
214710912|NCT05474807|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
214590073|NCT04262817|DRUG|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
214590074|NCT04262817|OTHER|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
214590075|NCT01182194|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
214590076|NCT01182194|DRUG|YAZ®|3 mg/0.02 mg Tablets
214590077|NCT00681785|DRUG|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
214590078|NCT02756273|DEVICE|bridge device|
214590079|NCT02756273|DEVICE|no bridge device|
214590080|NCT04992182|BIOLOGICAL|Placebo|0.3 mL IM saline solution
214590081|NCT04992182|BIOLOGICAL|Inactivated vaccine booster|0.5 mL IM
214710913|NCT03153020|OTHER|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
214590082|NCT04992182|BIOLOGICAL|mRNA vaccine booster|0.3 mL IM
214590083|NCT04992182|DRUG|Viral vector vaccine booster|0.5 mL IM
214590084|NCT03343301|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
214590085|NCT03343301|DRUG|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
214590086|NCT00307502|DRUG|Nevirapine|tablets 200 mg, 400 mg/day
214590087|NCT00307502|DRUG|Efavirenz|tablets 600 mg, 600 mg/day
214590088|NCT00307502|DRUG|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
214590089|NCT00307502|DRUG|Nelfinavir|tablets 250 mg, 2500 mg/day
214590090|NCT00307502|DRUG|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
214590091|NCT00307502|DRUG|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
214590092|NCT00307502|DRUG|Atazanavir|capsules 200 mg, 400 mg/day
214590093|NCT00307502|DRUG|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
214590094|NCT00307502|DRUG|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
214590095|NCT00307502|DRUG|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
214710914|NCT00476996|DRUG|Leflunomide|Oral repeating dose
214590096|NCT00307502|DRUG|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
214590097|NCT05557227|OTHER|1-hour cycling|60 % VO2 max
214590098|NCT02325479|DRUG|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
214590099|NCT02325479|DRUG|tissue culture media|intrauterine administration after oocyte pickup as placebo
214590100|NCT05066737|PROCEDURE|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
214590101|NCT00368992|BIOLOGICAL|cetuximab|Given IV
214590102|NCT00368992|DRUG|paclitaxel|Given IV
214590103|NCT00368992|BIOLOGICAL|bevacizumab|Given IV
214590104|NCT05381610|DEVICE|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
214590105|NCT01998087|BEHAVIORAL|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
214590106|NCT02866136|DRUG|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
214590107|NCT02866136|DRUG|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
214590108|NCT02866136|DRUG|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
214590109|NCT02866136|DRUG|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
214590110|NCT02866136|DEVICE|Laser (local treatment)|
214590111|NCT02866136|DEVICE|cryoapplication (local treatment)|
214590112|NCT02866136|RADIATION|I125 radioactive plaques (local treatment)|
214590113|NCT02866136|DRUG|intravitreal Melphalan (local treatment)|
214590114|NCT05514782|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
214590115|NCT05514782|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
214710915|NCT00476996|DRUG|Methotrexate|Oral or parenteral repeating dose
214590116|NCT05514782|OTHER|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
214590117|NCT05247554|DRUG|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
214590118|NCT05247554|DRUG|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
214590119|NCT02902874|OTHER|Blood sample|
214590120|NCT02377804|OTHER|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
214590121|NCT02377804|OTHER|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
214590122|NCT02377804|DEVICE|stainless steel needles (0.3mm x 50mm)|
214710916|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (200mg)
214710917|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (500mg)
214710918|NCT00476996|DRUG|Placebo|Intravenous repeating dose
214710919|NCT05202223|BEHAVIORAL|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
214590123|NCT01685164|OTHER|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
214590124|NCT05620368|BEHAVIORAL|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
214590125|NCT05620368|BEHAVIORAL|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
214590126|NCT01013597|DRUG|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
214590127|NCT02790268|PROCEDURE|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
214590128|NCT04497454|OTHER|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O
214590129|NCT04497454|OTHER|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
214590130|NCT04535804|DRUG|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
214590131|NCT00862628|DRUG|Rebamipide|100mg tid, 4 or 8 weeks
214590132|NCT05129553|DEVICE|Béa Applicator and Béa Cervical Cap Device|Single-use of the investigational device
214590133|NCT01372098|BEHAVIORAL|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
214590134|NCT00976612|DRUG|Nilotinib|Nilotinib 400mg bid daily
214590135|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
214590136|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
214590137|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
214710920|NCT00852306|PROCEDURE|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
214590138|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
214590139|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
214590140|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
214590141|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
214590142|NCT04412291|DRUG|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
214590143|NCT04412291|DRUG|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
214590144|NCT04412291|DRUG|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
214590145|NCT04320394|DIAGNOSTIC_TEST|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
214710921|NCT03371342|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
214710922|NCT03371342|DRUG|Botox|Botox(Botulinum toxin type A)
214710923|NCT02443571|RADIATION|Fluciclovine (18F)|Not applicable. This is an observational study.
214710924|NCT05505097|DRUG|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
214710925|NCT04839991|DRUG|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
214590146|NCT01070030|DRUG|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
214590147|NCT01240031|OTHER|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~* Thorough sensory and nutrition assessment (questionnaire).~* Nutrition plan adjusted daily according to the assessment.~* Serving appetising, energy- and protein-dense meals, snacks and drinks."
214590148|NCT01240031|OTHER|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
214590149|NCT02644486|DRUG|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
214590150|NCT02644486|DRUG|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
214590151|NCT02644486|DRUG|Irbesartan|Irbesartan 300mg/d
214590152|NCT04340323|OTHER|Pelvic Floor Muscle Training (PFMT)|The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
214710926|NCT04955002|OTHER|No intervention|No intervention
214710927|NCT01214317|PROCEDURE|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
214710928|NCT00505895|DRUG|Melphalan|Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
214590153|NCT03728777|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
214590154|NCT05998538|PROCEDURE|Knee Replacement|Total vs Partial Knee Replacement
214590155|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
214710929|NCT00505895|DRUG|Fludarabine|30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
214710930|NCT00505895|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
214590156|NCT01502020|DRUG|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
214590157|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
214590158|NCT02622958|DRUG|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
214590159|NCT02622958|OTHER|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
214710931|NCT00505895|DRUG|Rituximab|375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
214710932|NCT05351710|BEHAVIORAL|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
214710933|NCT05351710|BEHAVIORAL|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
214590160|NCT00603720|DRUG|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
214590161|NCT00603720|DRUG|L-Arginine|aids in nitric oxide production
214590162|NCT00603720|DRUG|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
214590163|NCT03876860|DEVICE|Silicone Dilator|Addition of silicone band to standard vaginal dilator
214590164|NCT03876860|DEVICE|Standard Dilator|Standard vaginal dilator
214590165|NCT03322072|DEVICE|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
214590166|NCT06066450|DEVICE|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
214590167|NCT02533570|DRUG|Brentuximab vedotin|
214590168|NCT02533570|DRUG|Placebo|
214590169|NCT00960531|BIOLOGICAL|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
214590170|NCT00960531|BIOLOGICAL|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
214590171|NCT00960531|BIOLOGICAL|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
214590172|NCT03995667|OTHER|Questionnaire Administration|Ancillary studies
214590173|NCT03995667|DEVICE|Tumor Treating Fields Therapy|Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
214590174|NCT00637923|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
214590175|NCT00637923|DRUG|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
214590176|NCT00637923|BIOLOGICAL|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
214590177|NCT00637923|DRUG|Ribavirin|Weight-based ribavirin for 48 weeks.
214590178|NCT05321888|OTHER|Mechanical Ventilation|Standard Protocol
214590179|NCT05321888|OTHER|Mechanical Ventilation with Postural drainage|This Group will be treated by postural drainage and mechanical ventilation for two consecutive days
214590180|NCT05969054|DRUG|Lacosamide 100 mg|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
214590181|NCT05969054|DRUG|Levetiracetam 250mg|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
214590182|NCT01594008|OTHER|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
214590183|NCT01594008|OTHER|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
214590184|NCT01594008|OTHER|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
214590185|NCT01828788|DRUG|Ropivacaine|
214590186|NCT01828788|DRUG|placebo|
214590187|NCT02913534|RADIATION|whole brain radiotherapy|
214590188|NCT04886453|DRUG|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
214590189|NCT04886453|DRUG|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
214590190|NCT04886453|OTHER|Data collection|Data collection
214590191|NCT04886453|OTHER|Assessment of pain|visual analog scale
214590192|NCT04886453|OTHER|Recovery quality score|QoR15 questionnaire
214590193|NCT03679806|OTHER|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
214590194|NCT03679806|OTHER|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
214590195|NCT00348023|DRUG|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
214590196|NCT05004571|DRUG|EQU-001|EQU-001 in 10 and 20 mg capsules
214590197|NCT05004571|DRUG|Placebo|Matched placebo
214590198|NCT01408615|DRUG|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
214590199|NCT00226343|DRUG|Depakote-ER|
214590200|NCT05812833|BEHAVIORAL|Education|Pregnant women will be given online baby care training
214590201|NCT00155935|PROCEDURE|venous puncture|
214590202|NCT06397677|GENETIC|Research Testing Performed (Laboratory)|Blood collection (DNA, RNA)
214590203|NCT06397677|DIAGNOSTIC_TEST|Information Collected as Standard of Care|High Resolution CT Scan (Chest), Pulmonary Function Testing (PFT), 6-Minute Walk Test (6MWT)
214590204|NCT06397677|OTHER|Research Testing Performed|Blood collection (non-genetic), Buccal Swab, Rheumatologic Assessment, Pulmonary Assessment, Questionnaires
214590205|NCT00623701|BIOLOGICAL|Allerslit forte|sublingual placebo preparation, daily
214590206|NCT00623701|BIOLOGICAL|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
214590207|NCT02461329|DRUG|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
214590208|NCT02461329|DRUG|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
214590209|NCT06297759|OTHER|Questionnaire|Sense of Competence in Dementia Care Staff (SCIDS) Scale
214590210|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
214590211|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
214590212|NCT00143676|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
214590213|NCT04026659|OTHER|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
214590214|NCT03373201|DRUG|Tasimelteon|Oral capsule
214590215|NCT03373201|DRUG|Placebo|Oral capsule
214590216|NCT02711969|DRUG|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
214590217|NCT02434068|OTHER|CT|followup
214590218|NCT05727345|PROCEDURE|Interscalene brachial plexus block|Preoperative ultrasound-guided interscalene brachial plexus block application
214590219|NCT05727345|PROCEDURE|Shoulder anterior capsular block|Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
214590220|NCT02793076|OTHER|Bollywood Dance|8 week Bollywood Dance Program
214590221|NCT00416143|PROCEDURE|bed rest|
214590222|NCT00416143|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
214590223|NCT00832182|DRUG|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
214590224|NCT00832182|DRUG|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
214590225|NCT04667182|OTHER|Meal-Tagging App and Web-based Portal:|Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
214590226|NCT04667182|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 18 weeks.
214590227|NCT02391779|DIETARY_SUPPLEMENT|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
214590228|NCT02391779|BEHAVIORAL|Walking training|30-60 minutes walking training, 5 days/week.
214590229|NCT02391779|BEHAVIORAL|Flexibility training|5 days/week; e.g. stretching training at home
214590230|NCT02391779|DIETARY_SUPPLEMENT|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
214590231|NCT02391779|BEHAVIORAL|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
214590232|NCT01006473|OTHER|Exercise training|
214590233|NCT02486744|DRUG|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
214590234|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
214590235|NCT01613560|DRUG|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
214590236|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
214590237|NCT02656823|DEVICE|ANKYLOS C/X implant A 6.6|Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
214590238|NCT02070224|OTHER|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
214590239|NCT02070224|OTHER|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
214590240|NCT03661203|BEHAVIORAL|Focus group|Focus group for qualitative group only
214590241|NCT03661203|BEHAVIORAL|Individual interview|Individual interview for qualitative group only
214590242|NCT03661203|BEHAVIORAL|online self questionnaire|online self questionnaire
214590243|NCT03661203|BEHAVIORAL|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
214590244|NCT05663437|OTHER|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
214590245|NCT05663437|OTHER|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
214590246|NCT02842320|OTHER|biological samples|bone marrow and blood
214590247|NCT00353769|PROCEDURE|Hair Apposition Technique|
214590248|NCT05397834|DRUG|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
214590249|NCT05397834|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
214590250|NCT00408252|OTHER|biopsies|No intervention, only biopsy for translational project
214590251|NCT00408252|DRUG|SU011248|no intervention
214590252|NCT01350310|PROCEDURE|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
214590253|NCT01350310|PROCEDURE|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
214590254|NCT01350310|PROCEDURE|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
214590255|NCT02174042|DRUG|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
214590256|NCT04924842|OTHER|Review of medical file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
214590257|NCT04924842|OTHER|Phone call interview|less than 15 minutes phone call
214590258|NCT00665912|PROCEDURE|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
214590259|NCT00665912|PROCEDURE|Standard post-lobectomy wound care|Standard post-lobectomy wound care
214590260|NCT01000285|DRUG|Bortezomib|
214590261|NCT01000285|DRUG|Etoposide|
214590262|NCT01000285|DRUG|Vincristine|
214590263|NCT01000285|DRUG|Doxorubicin|
214590264|NCT01000285|DRUG|Prednisone|
214590265|NCT01000285|DRUG|Cyclophosphamide|
214590266|NCT01000285|DRUG|Raltegravir|
214590267|NCT05677152|DRUG|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
214590268|NCT04672226|DIETARY_SUPPLEMENT|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
214590269|NCT02662101|DEVICE|Exsalt SD7, Exsalt T7 Wound Dressing|
214590270|NCT06382454|DEVICE|Assist-On Arm Robot Group|30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
214590271|NCT06382454|OTHER|Control Group|For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
214590272|NCT04810754|DRUG|Daratumumab Injection|1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
214590273|NCT02855970|OTHER|completion of a quality of life questionnaire|
214590274|NCT04397341|DRUG|docetaxel, cisplatin, fluorouracil|Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
214590275|NCT00193999|DEVICE|Placement of nasogastric tube|
214590276|NCT05269355|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
214590277|NCT05269355|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
214590278|NCT05269355|OTHER|Placebo|Placebo will be administered as per the schedule specified in the arm description.
214590279|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|"DETECT is an elder mistreatment (EM) screening tool created for medics in the Fort Worth Texas area to use when responding to the homes of older adults, enabling them to screen for signs of elder mistreatment. DETECT-RPC is the adapted version of this tool designed specifically for use by home-based primary care (HBPC) clinicians.~The DETECT-RPC tool is designed to:~1. Be brief and easy to use.~2. Focus on the clinician's direct observations of the older adult and their physical and social environment.~3. Provide clear guidance on reporting suspected EM.~4. Integrate seamlessly into existing procedures and medical charting systems."
214590280|NCT05322850|BIOLOGICAL|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
214590281|NCT01315496|DRUG|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
214590282|NCT00081497|BIOLOGICAL|agalsidase beta|1.0 mg/kg every 2 weeks
214590283|NCT05027997|DRUG|Dipraglurant|Oral tablet
214590284|NCT05027997|DRUG|Placebo|Oral matching placebo tablet
214590285|NCT00134433|GENETIC|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
214590286|NCT00134433|DRUG|oral L-arginine supplementation (at a dose of 6 g/day)|
214590287|NCT05067465|DIETARY_SUPPLEMENT|Selected food groups|"Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)"
214590288|NCT01825733|DRUG|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
214590289|NCT01825733|DRUG|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
214590290|NCT06598449|DRUG|fenfluramine|Clear, cherry flavored oral solution
214590291|NCT03058029|DEVICE|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
214590292|NCT03058029|DEVICE|Placebo|Subject would take placebo capsules 2 times per day.
214590293|NCT06658366|DIAGNOSTIC_TEST|impression of the teeth|Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
214590294|NCT05591222|DRUG|Placebo|Placebo will be administered subcutaneously as two injections for each dose.
214590295|NCT05591222|DRUG|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
214590296|NCT06609967|PROCEDURE|application of PRF|PRF will be randomly administered into one group of patients undergoing any extractions group A (Right after the extraction) Group B will be a control group in which extraction sockets will be left to heal with the natural blood clot. Consenting patients will be assigned into groups randomly and not informed which group they were placed into. The PRF will be administered obtained from a tube of 10 ml blood and no material will be placed in the control group. The progress of healing and post-operative complications will be tracked over a period of 7 days with patients being called for follow-up on days 3, 5 and 7
214590297|NCT06609967|PROCEDURE|application of conventional surgicel|it will be a control group in which extraction sockets will be left to heal with the natural blood clot.
214590298|NCT06610058|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
214590299|NCT06610058|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
214590300|NCT06610734|DRUG|Adebrelimab|Adebrelimab combined with chemotherapy synchronous LDRT
214590301|NCT06610734|DRUG|Chemotherapy|Chemotherapy
214590302|NCT06610734|RADIATION|low dose radiotherapy|low dose radiotherapy
214590303|NCT06609551|DRUG|6-month adjuvant chemotherapy with 5-FU monotherapy|6 months of adjuvant chemotherapy with 5-FU monotherapy. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
214590304|NCT06609551|DRUG|XELOX intensive treatment group|XELOX intensive treatment group. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
214590305|NCT06609447|DIETARY_SUPPLEMENT|VSL#3|VSL#3 450 billion CFU/sachet
214590306|NCT06609447|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
214590307|NCT06609447|DRUG|Vedolizumab|Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
214590308|NCT00002331|DRUG|Ethambutol hydrochloride|
214590309|NCT00002331|DRUG|Clarithromycin|
214590310|NCT00002331|DRUG|Clofazimine|
214590311|NCT00959647|DRUG|Vismodegib|Vismodegib was supplied in capsules.
214590312|NCT00959647|DRUG|FOLFOX|FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
214590313|NCT00959647|DRUG|FOLFIRI|FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
214590314|NCT00959647|DRUG|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
214590315|NCT06704334|OTHER|Median nerve electrical stimulation treatment|Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
214590316|NCT06704334|DRUG|Huperzine A injection|intramuscular
214590317|NCT06704334|DRUG|Ginkgo leaf dropping pill|oral
214590318|NCT03095430|DEVICE|Monitoring|Monitoring
214590319|NCT04759664|DRUG|LUT014 Gel (Dose 1)|Topical gel
214590320|NCT04759664|DRUG|LUT014 Gel (Dose 2)|Topical gel
214590321|NCT04759664|DRUG|Placebo|LUT014 matching placebo topical gel
214590322|NCT03965611|PROCEDURE|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
214590323|NCT03965611|PROCEDURE|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
214590324|NCT03965611|PROCEDURE|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
214590325|NCT05209750|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
214590326|NCT05690100|DRUG|GeliO3|Anti-inflammatory Gel which has a beneficial role on wound healing
214590327|NCT05690100|DRUG|Gingi gel|Anti-inflammatory Gel which has a beneficial role on wound healing
214590328|NCT02258308|BEHAVIORAL|CHW intervention|Home education and support for asthma self management
214590329|NCT03141008|OTHER|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
214590330|NCT04677868|DRUG|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
214590331|NCT01786174|DRUG|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
214590332|NCT01786174|OTHER|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
214590333|NCT02315352|DRUG|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
214590334|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
214590335|NCT02315352|DRUG|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
214590336|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
214590337|NCT02315352|DRUG|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
214590338|NCT04712331|OTHER|Graduated abdominal strengthening exercises|"Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors)."
214590339|NCT04712331|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
214590340|NCT04712331|OTHER|Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation|"Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation."
214590341|NCT03569657|BEHAVIORAL|A positive psychology workshop|Group workshop
214590342|NCT03503253|DEVICE|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
214590343|NCT03503253|DEVICE|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
214590344|NCT03503253|DEVICE|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
214590345|NCT05112107|BEHAVIORAL|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
214590346|NCT01008293|DRUG|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
214590347|NCT01008293|DRUG|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
214590348|NCT04162613|OTHER|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
214590349|NCT00515320|DRUG|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
214590350|NCT00515320|DRUG|Placebo|Oral dispersible tablet placebo
214590351|NCT02867293|PROCEDURE|ultrasound guided ascitic fluid drainage|
214590352|NCT02867293|PROCEDURE|operative drainage of ascites through small skin incision after induction of anesthesia|
214590353|NCT02867293|DEVICE|ultrasound|
214590354|NCT05176535|DIETARY_SUPPLEMENT|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
214590355|NCT05545657|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
214590356|NCT05545657|OTHER|Simultaneous EEG-fMRI scan|EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.
214590357|NCT05545657|OTHER|Multimodal magnetic resonance imaging|3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.
214590358|NCT05545657|OTHER|Peripheral blood neuropathology biomarkers assay|Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
214590359|NCT05637385|BEHAVIORAL|Training of perception and oculo-motor control|Behavioral training of eye movements and perception
214590360|NCT03924739|BEHAVIORAL|Nurse-coordinated integrated care model for AF|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
214590361|NCT03442985|DRUG|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
214590362|NCT03442985|DRUG|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
214590363|NCT03442985|OTHER|Placebo|Subjects received placebo, once daily, for up to 24 months.
214590364|NCT00500162|BEHAVIORAL|Tri-Luma Maintenance regimen|
214590365|NCT01894633|DRUG|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
214590366|NCT01894633|RADIATION|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
214590367|NCT05040477|OTHER|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
214590368|NCT03077360|BEHAVIORAL|Lifestyle|Lifestyle changes to lose weight or become more fit
214590369|NCT04357860|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
214590370|NCT04357860|DRUG|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
214590371|NCT04357860|DRUG|Best available treatment|Best available treatment up to 14 days
214590372|NCT03478150|OTHER|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
214590373|NCT03478150|DEVICE|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
214590374|NCT05807607|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
214590375|NCT05807607|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
214590376|NCT05807607|PROCEDURE|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
214590377|NCT05302388|DRUG|SIBP-R002|SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
214590378|NCT05302388|DRUG|Dexamethasone or Methyl prednisolone|Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
214590379|NCT05302388|DRUG|Diphenhydramine|10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
214590380|NCT05302388|DRUG|Placebo|The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
214590381|NCT01716117|DEVICE|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
214590382|NCT01486771|DRUG|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
214590383|NCT04033848|PROCEDURE|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
214590384|NCT03645057|DRUG|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
214590385|NCT03645057|DRUG|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
214590386|NCT02366377|DRUG|SHR3824|
214590387|NCT02366377|DRUG|Placebo|
214590388|NCT02366377|DRUG|Metformin|
214590389|NCT00281333|BEHAVIORAL|"Karate exercises and strengthening exercises"|
214590390|NCT05998356|DEVICE|Balloon Eustachian Tuboplasty (BET) under general anesthesia.|Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer.
214590391|NCT05998356|DEVICE|Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia|Participants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study.
214590392|NCT01315223|OTHER|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
214590393|NCT04531553|PROCEDURE|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
214590394|NCT04531553|PROCEDURE|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
214590395|NCT04531553|PROCEDURE|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
214590396|NCT00674869|OTHER|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
214634437|NCT06112106|BEHAVIORAL|Intelligent Physical Exercise Training (IPET)|The intervention group will follow an Intelligent Physical Exercise training (IPET) program delivered via a mobile phone app. The scope of the physical exercise program is 50 minutes per week, and it is individually tailored according to questionnaire responses about work profile, physical capacity, health status and extent of musculoskeletal pain.
214590397|NCT05863312|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
214590398|NCT05863312|PROCEDURE|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
214590399|NCT05863312|OTHER|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
214590400|NCT05863312|OTHER|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
214590401|NCT00288509|BIOLOGICAL|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
214590402|NCT05741151|DIAGNOSTIC_TEST|PET-Neck Parkinsonian patients|Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
214590403|NCT06270433|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
214590404|NCT06270433|DRUG|Desvenlafaxine succinate sustained-release tablets|50 mg orally once daily dosing for 8 weeks
214590405|NCT05280587|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
214590406|NCT02601196|DRUG|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
214590407|NCT04547153|DRUG|5-fluorouracil|200mg/square metre/day civ D1-D21
214590408|NCT04547153|DRUG|Docetaxel|25mg/square metre ivdrip D1, D8, D15
214590409|NCT04642768|DIETARY_SUPPLEMENT|KetoneAid Ketone Ester|Commercially available ketone supplement
214590410|NCT04642768|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
214590411|NCT02489513|DRUG|[14C]-AG-120|Labeled investigational drug
214590412|NCT00988195|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
214590413|NCT00988195|DRUG|Doxorubicin|Weeks 13-24 (once every 3 weeks)
214590414|NCT01114061|DEVICE|Insupatch|Applying heat to the infusion site using the insupatch device
214590415|NCT00269347|PROCEDURE|Chiropractic Spinal Manipulation|
214590416|NCT00269347|PROCEDURE|Exercise|
214590417|NCT00269347|BEHAVIORAL|Self-care|
214590418|NCT03249025|DRUG|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
214590419|NCT03249025|DRUG|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
214590420|NCT05446688|DRUG|6MW3211|6MW3211 injection, 45mg/kg, Q2W
214590421|NCT06444685|OTHER|Exercise and cognitive training interventino|Exercise and cognitive training based on Table tennis and Tabletop games.
214590422|NCT00827801|BEHAVIORAL|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
214710934|NCT06055127|PROCEDURE|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
214590423|NCT03682549|DIAGNOSTIC_TEST|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
214590424|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
214590425|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
214590426|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
214590427|NCT04386707|BIOLOGICAL|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
214590428|NCT04017728|DEVICE|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
214590429|NCT04017728|DEVICE|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
214590430|NCT02463643|DRUG|Z-215 10mg|Z-215 10mg, capsules
214590431|NCT02463643|DRUG|Z-215 20mg|Z-215 20mg, capsules
214590432|NCT02463643|DRUG|Z-215 Placebo|Z-215 placebo-matching capsules
214590433|NCT02463643|DRUG|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
214590434|NCT02463643|DRUG|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
214590435|NCT04005053|DRUG|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
214590436|NCT04005053|DRUG|Placebo oral tablet|Placebo
214590437|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
214590438|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
214710935|NCT06055127|PROCEDURE|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
214590439|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
214590440|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
214590441|NCT05268614|RADIATION|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND \<95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
214590442|NCT05268614|DRUG|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition."
214590443|NCT05066308|DRUG|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
214590444|NCT05066308|OTHER|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
214590445|NCT02719678|OTHER|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
214590446|NCT00388453|DEVICE|Dx-pH Probe|24 hour ph monitoring
214590447|NCT00388453|PROCEDURE|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
214590448|NCT05417633|PROCEDURE|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
214590449|NCT00005652|DRUG|rituximab|
214590450|NCT00762970|DEVICE|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
214590451|NCT00762970|DEVICE|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
214590452|NCT00762970|DEVICE|Control Lens|Spectacle Lenses.
214590453|NCT01480674|DRUG|Trastuzumab|
214590454|NCT02689596|DRUG|Oxytocin|
214590455|NCT02689596|OTHER|Placebo|
214590456|NCT03818204|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
214590457|NCT06499714|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 days at an altitude of 3600 m.
214590458|NCT06426667|PROCEDURE|posterior tibial nerve radiofrequency|pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.
214590459|NCT06426667|PROCEDURE|plantar fasciitis radiofrequency|the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.
214590460|NCT00549809|PROCEDURE|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
214590461|NCT00348231|DRUG|dual-action insulin analog|
214590462|NCT04499274|DRUG|0 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron
214590463|NCT04499274|DRUG|0.2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron
214590464|NCT04499274|DRUG|2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron
214590465|NCT04499274|DRUG|20 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
214590466|NCT05316194|OTHER|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
214590467|NCT03800641|DRUG|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
214590468|NCT00598143|BEHAVIORAL|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
214590469|NCT00598143|BEHAVIORAL|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
214590470|NCT03385070|DIAGNOSTIC_TEST|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
214590471|NCT00315432|DRUG|Pegylated Interferon and Ribavirin|
214590472|NCT03177278|DRUG|[14C]-plazomicin|single intravenous dose
214590473|NCT02441166|PROCEDURE|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
214590474|NCT00795951|BIOLOGICAL|T.R.U.E. Test|48 hour application of 28 allergens and negative control
214590475|NCT03278951|BEHAVIORAL|Video Conferencing Group|
214590476|NCT03278951|BEHAVIORAL|In Person Group|
214590477|NCT03717948|OTHER|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
214590478|NCT03717948|OTHER|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
214590479|NCT02838147|DEVICE|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
214590480|NCT02838147|DEVICE|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
214590481|NCT00377247|BIOLOGICAL|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
214590482|NCT04312321|DEVICE|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
214590483|NCT04312321|DEVICE|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
214590484|NCT03141385|OTHER|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
214590485|NCT03141385|OTHER|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
214590486|NCT06004947|DRUG|CCX168|Administered orally.
214590487|NCT06004947|DRUG|Midazolam|Administered orally.
214590488|NCT06004947|DRUG|Celecoxib|Administered orally.
214590489|NCT06004947|DRUG|Itraconazole|Administered orally.
214590490|NCT06004947|DRUG|Rifampicin|Administered orally.
214590491|NCT04869943|DRUG|Enobosarm|Oral Enobosarm 9mg per day
214590492|NCT04869943|DRUG|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
214590493|NCT03355170|COMBINATION_PRODUCT|Lansoprazole/Domperidone|Experimental
214590494|NCT03355170|DRUG|Lansoprazole|Active comparator
214590495|NCT01222273|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
214590496|NCT05621031|DEVICE|Whole body Vibration|Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
214590497|NCT05621031|OTHER|Habitual Therapy|Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
214590498|NCT05621031|DEVICE|Placebo whole body vibration|Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
214590499|NCT01821716|BIOLOGICAL|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
214590500|NCT02442323|BEHAVIORAL|Walking Intervention|12-week walking program
214590501|NCT05310487|BIOLOGICAL|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
214590502|NCT05310487|OTHER|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
214590503|NCT05087485|OTHER|education|digital education in skin cancer diagnostics
214590504|NCT05624385|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
214590505|NCT02699112|OTHER|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
214590506|NCT05010187|BEHAVIORAL|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
214590507|NCT05010187|BEHAVIORAL|Behavioral: Health Coaching (HC)|Single-session health coaching.
214590508|NCT03281837|DEVICE|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
214590509|NCT03281837|OTHER|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
214590510|NCT00153517|DRUG|oral versus vaginal metronidazole|
214590511|NCT00573885|DRUG|defined green tea catechin extract|Given orally
214590512|NCT00573885|OTHER|placebo|Given orally
214590513|NCT05472948|DRUG|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
214590514|NCT05472948|DRUG|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
214590515|NCT05472948|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
214590516|NCT04681547|PROCEDURE|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
214590517|NCT04681547|PROCEDURE|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
214590518|NCT01211197|DRUG|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
214590519|NCT01211197|DRUG|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
214590520|NCT01211197|DRUG|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
214590521|NCT05822453|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
214590522|NCT05822453|DRUG|S1|S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
214590523|NCT05822453|DRUG|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
214590524|NCT04322942|DIAGNOSTIC_TEST|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
214590525|NCT04494581|OTHER|questionnaire|Questionnaire survey
214590526|NCT01756612|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
214590527|NCT00424866|DRUG|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
214590528|NCT00424866|DRUG|Placebo|Vehicle: 0 µg/kg
214590529|NCT04980937|PROCEDURE|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
214590530|NCT00261846|DRUG|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
214590531|NCT05604638|DRUG|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
214590532|NCT05604638|DRUG|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
214590533|NCT01228708|OTHER|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
214590534|NCT01660126|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
214590535|NCT01660126|DRUG|Placebo|
214590536|NCT00480246|DRUG|BL 1020|
214590537|NCT00480246|DRUG|Perphenazine|
214590538|NCT01360060|DRUG|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
214590539|NCT02652143|DEVICE|AneVivo (Medical device for in vivo culture of embryos)|
214590540|NCT02652143|OTHER|comparator for embryo culture in vitro|
214590541|NCT02045966|DRUG|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
214590542|NCT02045966|DRUG|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
214590543|NCT02045966|DRUG|BMS-791325|
214590544|NCT01009203|DRUG|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
214590545|NCT01009203|DRUG|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
214590546|NCT06475573|DIETARY_SUPPLEMENT|dietary fiber probiotic beverages|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner."
214590547|NCT06475573|OTHER|whole grain porridge|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner."
214590548|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214590549|NCT00892723|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214590550|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
214590551|NCT00150969|DIETARY_SUPPLEMENT|vitamin K1 (phylloquinone)|
214590552|NCT00150969|DIETARY_SUPPLEMENT|placebo|1 pill daily
214590553|NCT00615836|DRUG|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
214590554|NCT03993821|DRUG|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
214590555|NCT01696838|OTHER|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
214590556|NCT01696838|OTHER|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
214590557|NCT04700332|DRUG|DCFPyL PET/CT|Prostate Membrane Specific Antigen-specific imaging
214590558|NCT04835077|OTHER|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
214590559|NCT04835077|OTHER|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
214590560|NCT04641871|DRUG|Sym021|IV infusion over 30 minutes on day 1 and 15 of each cycle.
214590561|NCT04641871|DRUG|Sym022|IV infusion over 30 minutes on day 1 and 15 of each cycle.
214590562|NCT04641871|DRUG|Sym023|IV infusion over 30 minutes on day 1 and 15 of each cycle.
214590563|NCT04641871|DRUG|Irinotecan Hydrochloride|IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
214590564|NCT03109145|OTHER|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
214590565|NCT05111054|OTHER|Resistance Exercise|Acute leg-based resistance exercise bout (3 sets performed to volitional failure on leg extension and leg curl machines)
214590566|NCT03046693|DRUG|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
214590567|NCT03046693|DRUG|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
214590568|NCT01313689|DRUG|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
214590569|NCT01313689|DRUG|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
214590570|NCT01657851|DRUG|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
214590571|NCT01657851|DRUG|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
214590572|NCT01657851|DRUG|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
214590573|NCT05150951|BEHAVIORAL|Novel Exploration|Exploration of a novel 3D-environment in virtual reality.
214590574|NCT05150951|BEHAVIORAL|Threat conditioning|Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.
214590575|NCT05150951|BEHAVIORAL|Extinction|Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.
214590576|NCT05150951|BEHAVIORAL|Reinstatement|Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.
214590577|NCT05150951|BEHAVIORAL|Visual attention control task|Session 2. A visual attention task used as a control task instead of novel exploration.
214590578|NCT01007448|DRUG|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
214590579|NCT02224976|BEHAVIORAL|Intensified Training|Volunteers will increase exercise training by 30% from baseline
214590580|NCT06398977|DRUG|Dapagliflozin|Dapagliflozin10MG, PO once daily
214590581|NCT06195254|RADIATION|Stereotactic body radiotherapy (SBRT)|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.
214590582|NCT06195254|DRUG|PD-1 blocking antibody|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
214590583|NCT00078611|DRUG|natalizumab|
214590584|NCT06266715|DRUG|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
214590585|NCT06266715|DRUG|Placebo Group|Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
214590586|NCT05979454|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
214590587|NCT03407560|DEVICE|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
214590588|NCT06006689|DRUG|Qishen Yiqi Dripping Pills placebo 3 bags|Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
214590589|NCT06006689|DRUG|Low dose Qishen Yiqi Dripping Pills 3 bags|Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
214590590|NCT06006689|DRUG|High dose Qishen Yiqi Dripping Pills 3 bags|High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
214590591|NCT05998473|DIAGNOSTIC_TEST|Dynamic stability measurement|The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.
214590592|NCT01337115|PROCEDURE|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
214590593|NCT01337115|PROCEDURE|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
214590594|NCT03151096|DIETARY_SUPPLEMENT|Riboflavin|one pill of Riboflavin will be taken orally with water
214590595|NCT03151096|DIETARY_SUPPLEMENT|Placebo|one pill of placebo will be taken orally with water
214590596|NCT00396500|DRUG|Albendazole (400 mg) and/or Vitamin a|
214590597|NCT00448123|DRUG|Tamsulosin|Study Drug
214590598|NCT00448123|DRUG|Placebo|Placebo
214590599|NCT03676231|DRUG|SGM-1019|Active
214590600|NCT03676231|DRUG|Placebo|Inactive
214590601|NCT00419666|DRUG|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
214590602|NCT03991104|DRUG|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
214590603|NCT03991104|DRUG|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
214590604|NCT03991104|RADIATION|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
214634438|NCT06550167|DIETARY_SUPPLEMENT|Nano-PSO, Pomegranate seed oil (omega-5)|"During the intervention, Nano-PSO dietary supplement will be administered to the participants in the assigned group.~Participants will be followed before and after treatment to assess the effects of Nano-PSO on cognitive status, serum concentrations of trophic factors, and other relevant parameters . This randomized, double-blind, controlled clinical trial design allows for a rigorous evaluation of the potential benefits of Nano-PSO in patients with substance use disorders. The study aims to provide valuable insights into the neuroprotective and cognitive-enhancing properties of Nano-PSO in this population."
214634439|NCT06550167|OTHER|PLACEBO|In this arm of the study the participants will receive a placebo as a control treatment . The placebo is essential in clinical trials to compare the effects of the active intervention (Nano-PSO) with those of an inert substance.
214634440|NCT00575562|DRUG|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
214634441|NCT05075980|DRUG|Cisplatin|Given IV
214634442|NCT05075980|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
214634443|NCT05075980|OTHER|Quality-of-Life Assessment|Ancillary studies
214634444|NCT05075980|OTHER|Questionnaire Administration|Ancillary studies
214634445|NCT05075980|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214634446|NCT05075980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
214634447|NCT05075980|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
214634448|NCT05075980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214634449|NCT05075980|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214634450|NCT02085291|DRUG|Norepinephrine|Norepinephrine infusion to titrate MAP to usual level
214590605|NCT02027623|BEHAVIORAL|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
214590606|NCT02027623|BEHAVIORAL|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
214590607|NCT02504944|DRUG|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
214590608|NCT04305938|DIAGNOSTIC_TEST|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
214590609|NCT04465760|DRUG|Xisomab 3G3|Given IV or via catheter
214590610|NCT02066285|DRUG|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214590611|NCT00151151|BEHAVIORAL|Computer-Assisted Motivational Intervention|
214590612|NCT00151151|BEHAVIORAL|Didactic Educational Counseling|
214634451|NCT02085291|DRUG|Crystalloid|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
214590613|NCT06081582|DRUG|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
214590614|NCT04778956|DRUG|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
214590615|NCT04778956|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
214590616|NCT03997617|DIAGNOSTIC_TEST|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
214590617|NCT01808482|DRUG|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
214590618|NCT01808482|DRUG|Part A: matching placebo|Matching placebo
214590619|NCT01808482|DRUG|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
214590620|NCT01808482|DRUG|Part B: matching placebo|Matching placebo
214590621|NCT01808482|DRUG|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
214590622|NCT01105754|BEHAVIORAL|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
214590623|NCT05782426|DRUG|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
214590624|NCT00406653|DRUG|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
214590625|NCT00406653|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
214590626|NCT00406653|DRUG|abatacept|"\~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
214590627|NCT00818649|DRUG|bortezomib|1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
214590628|NCT00818649|DRUG|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
214590629|NCT02926144|DEVICE|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
214590630|NCT02926144|DEVICE|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
214590631|NCT05955313|DRUG|Naltrexone Hydrochloride|treatment of vulvodynia
214590632|NCT03169322|PROCEDURE|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
214590633|NCT02922309|BEHAVIORAL|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
214590634|NCT02922309|BEHAVIORAL|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
214590635|NCT03513588|DRUG|Placebo|tablet, 0 mg, 14 days, every 12 hours
214590636|NCT03513588|DRUG|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
214590637|NCT03513588|DRUG|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
214590638|NCT06367010|COMBINATION_PRODUCT|Iodine-125 brachytherapy combine with Anlotinib|Iodine-125 brachytherapy combine with Anlotinib
214590639|NCT00685633|DRUG|bicalutamide|Given orally
214590640|NCT00685633|DRUG|enzastaurin hydrochloride|Given orally
214590641|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
214590642|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
214590643|NCT01768520|DRUG|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg"
214590644|NCT01768520|DRUG|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
214590645|NCT01768520|DRUG|Placebo|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
214634452|NCT02792803|DRUG|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
214634453|NCT02792803|DRUG|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
214590646|NCT03149718|BEHAVIORAL|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
214590647|NCT03149718|BEHAVIORAL|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
214590648|NCT04842097|BEHAVIORAL|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
214590649|NCT05889481|GENETIC|cytogenetic analysis on tumour tissue|Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.
214590650|NCT05889481|BIOLOGICAL|Digital Pathology|Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma
214590651|NCT02075541|BIOLOGICAL|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214590652|NCT02075541|DRUG|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214590653|NCT06443554|PROCEDURE|Health Management Intervention Program|This study implemented a 12-week eye health management intervention program based on the Protection Motivation Theory (PMT). The intervention included eye health interventions conducted twice weekly at community health service locations.During the health management process, specialist doctors from higher-level comprehensive hospitals provided professional guidance, while community general practitioners took on a leading role. They provided personalized eye health management for patients under the guidance of the PMT theory. The intervention content included group education, individual guidance, experience sharing meetings, and traditional Chinese medicine appropriate technology, among other aspects.
214590654|NCT06443554|PROCEDURE|Standard Treatment|Each week, patients were subjected to standard treatment and follow-up procedures, including basic interventions, medication, and routine follow-up via phone or WeChat, during which general conditions were assessed.
214590655|NCT03931031|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
214590656|NCT04697303|OTHER|anorectal function test|anorectal function test
214590657|NCT04388774|DRUG|Ketamine|A single 40-minute intravenous infusion
214590658|NCT00594360|BEHAVIORAL|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
214590659|NCT01190982|DRUG|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
214590660|NCT04421521|PROCEDURE|Acupuncture|Acupuncture with disposable needles will be implemented
214590661|NCT00849277|DRUG|Lactobacillus casei Shirota|
214590662|NCT00722852|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
214590663|NCT00722852|DRUG|Placebo|100 mg (b.i.d.)
214590664|NCT05466773|BEHAVIORAL|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
214590665|NCT00008489|DRUG|Didanosine|
214590666|NCT04305080|OTHER|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
214590667|NCT04305080|OTHER|Untreated abutment|Abutment will be left untreated with its gray color.
214590668|NCT01203748|PROCEDURE|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
214590669|NCT01203748|PROCEDURE|PVI|Pulmonary vein antrum isolation
214590670|NCT01203748|PROCEDURE|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
214634454|NCT02792803|DRUG|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
214590671|NCT05807737|DEVICE|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
214590672|NCT03139357|OTHER|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
214590673|NCT03635307|OTHER|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
214590674|NCT04169230|DRUG|Citalopram|Single dose administration of citalopram (20mg)
214590675|NCT04169230|DRUG|Placebo oral tablet|Single dose administration lactose placebo tablet
214590676|NCT05458557|DIAGNOSTIC_TEST|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
214590677|NCT03905954|OTHER|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
214590678|NCT03143660|BEHAVIORAL|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
214590679|NCT03143660|BEHAVIORAL|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
214590680|NCT01314820|OTHER|normal saline injection|20 cc normal saline injection into knee joint
214590681|NCT01314820|OTHER|sham injection|no saline injection
214590682|NCT02275494|PROCEDURE|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
214590683|NCT01142596|DRUG|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
214590684|NCT01142596|DRUG|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
214590685|NCT00200460|DRUG|Nebivolol|
214590686|NCT06168552|DIAGNOSTIC_TEST|Injection of fluorescent developer (anti-EGFR-IR800CW)|The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
214590687|NCT00520169|DRUG|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
214590688|NCT05166980|DIETARY_SUPPLEMENT|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
214590689|NCT05166980|DIETARY_SUPPLEMENT|Iodized salt|Salt fortified with iodine
214590690|NCT01054846|OTHER|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
214590691|NCT01054846|OTHER|Bicycle helmet education only|As described under the respective arm
214590692|NCT03436108|DIAGNOSTIC_TEST|Measurement of Bisphenol in urine|to see level of this material in blood of women
214590693|NCT01852474|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
214590694|NCT03457363|DEVICE|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
214590695|NCT02982915|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
214590696|NCT02982915|BIOLOGICAL|Fluzone High Dose Vaccine|Intramuscular injection
214590697|NCT03872570|DRUG|Phenylephrine|intravenous administration
214590698|NCT03872570|DRUG|Norepinephrine|intravenous administration
214590699|NCT00350896|DEVICE|Thumb orthoses|
214590700|NCT01489410|DRUG|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
214590701|NCT01489410|DRUG|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
214590702|NCT04107376|DIAGNOSTIC_TEST|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
214590703|NCT00253994|PROCEDURE|Acupuncture|
214590704|NCT02441712|DEVICE|PENS|
214590705|NCT02446886|DRUG|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
214590706|NCT00928447|DRUG|rHuPH20|0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
214590707|NCT00928447|DRUG|Placebo|0.25 mL ID syringe push bolus injection of placebo control
214590708|NCT01919710|DRUG|rHSA/GCSF|for treatment of neutropenia
214590709|NCT04766931|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
214590710|NCT04766931|DRUG|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
214590711|NCT01259284|DRUG|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
214590712|NCT01259284|DIETARY_SUPPLEMENT|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
214590713|NCT01259284|OTHER|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
214590714|NCT02667717|BEHAVIORAL|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
214590715|NCT02667717|BEHAVIORAL|Usual care|Patients will have the usual care as an intervention.
214590716|NCT05889065|PROCEDURE|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
214590717|NCT05889065|PROCEDURE|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
214590718|NCT00613262|OTHER|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
214590719|NCT01173198|DEVICE|WAVEFRONT Optimized LASIK|30 patients
214590720|NCT01173198|DEVICE|WAVEFRONT GUIDED LASIK|30 patients
214590721|NCT02202668|DEVICE|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
214590722|NCT05268874|OTHER|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
214590723|NCT03448133|DEVICE|Magstim rTMS|The device is made in London,UK
214590724|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate
214590725|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot Placebo|Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate
214590726|NCT05611437|OTHER|Ultrafast ultrasonography|Ultrasonography of the neck, patient in supine position, neck hyper-extended. Three different scanning planes containing several landmarks. Carried out in the 12h prior extubation.
214590727|NCT05329545|DRUG|Upifitimab rilsodotin|Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
214590728|NCT05329545|OTHER|Placebo|Placebo controlled arm.
214590729|NCT00654342|PROCEDURE|Intraoperative injection (in vivo)|Intraoperative injection
214590730|NCT00654342|PROCEDURE|Postoperative injection (ex vivo)|postoperative injection
214710936|NCT01553071|DRUG|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
214710937|NCT01922245|DEVICE|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
214590731|NCT04613349|OTHER|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~1. New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~2. Gold standard: Intraoperative examination."
214590732|NCT04065178|BEHAVIORAL|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
214590733|NCT02259907|DRUG|KUC 7483 CL|
214590734|NCT02259907|DRUG|Placebo|
214590735|NCT02259907|OTHER|High fat meal|
214590736|NCT06328803|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
214590737|NCT06328803|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
214590738|NCT05208671|OTHER|NOURISH Food Box|Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
214590739|NCT00164645|BEHAVIORAL|Problem Solving intervention|
214590740|NCT03022279|PROCEDURE|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
214590741|NCT03022279|PROCEDURE|local wound infiltration|local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
214590742|NCT03154073|BEHAVIORAL|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
214590743|NCT03154073|BEHAVIORAL|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
214590744|NCT03599973|OTHER|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
214590745|NCT04007185|PROCEDURE|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
214590746|NCT03753672|DIAGNOSTIC_TEST|preload responsiveness|We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
214590747|NCT04598204|DRUG|Treatment with oral rapmycin|To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
214590748|NCT04419883|DEVICE|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
214590749|NCT04951401|OTHER|lipid profile|lipid profile
214590750|NCT04951401|OTHER|ECG|ECG
214590751|NCT01198353|DRUG|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
214590752|NCT01685671|DRUG|NESP 60μg|Administrated NESP 60μg once subcutaneously
214590753|NCT01685671|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
214590754|NCT04428827|PROCEDURE|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
214590755|NCT05131568|DEVICE|Layered thermal insulation system|No other intervention
214590756|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
214590757|NCT04584203|PROCEDURE|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
214590758|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
214590759|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
214590760|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
214590761|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
214590762|NCT04811209|OTHER|1.Baseline Measurements Before Surgery|"* Baseline demographic data~* Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~* Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~* Preoperative pain state using NRS (0-10)~* Preoperative functional state using the QoR-15 questionnaire~* Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~* Pain castastrophizing scale"
214590763|NCT04811209|OTHER|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
214590764|NCT04811209|OTHER|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~1. acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~2. NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~3. Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~4. In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
214590765|NCT04811209|OTHER|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
214590766|NCT04811209|OTHER|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
214590767|NCT04811209|OTHER|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
214590768|NCT04811209|OTHER|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
214590769|NCT04811209|OTHER|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
214590770|NCT02895451|BEHAVIORAL|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
214590771|NCT02624310|DRUG|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
214590772|NCT02624310|DRUG|Placebo|
214590773|NCT05011773|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
214590774|NCT02988622|DEVICE|Fraxel Laser|One half of the scar is treated with Fraxel Laser
214590775|NCT02988622|DEVICE|CO2 Laser|One half of the scar is treated with CO2 Laser.
214590776|NCT05172427|BEHAVIORAL|14 days of EMI|Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
214590777|NCT05172427|BEHAVIORAL|Uncertainty reappraisal training|CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
214590778|NCT02036879|DRUG|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
214590779|NCT01687907|BEHAVIORAL|Music|
214590780|NCT00334854|DRUG|doxorubicin hydrochloride|
214590781|NCT00334854|DRUG|ifosfamide|
214590782|NCT00334854|PROCEDURE|adjuvant therapy|
214590783|NCT00334854|PROCEDURE|conventional surgery|
214590784|NCT00334854|PROCEDURE|neoadjuvant therapy|
214590785|NCT00334854|RADIATION|radiation therapy|
214590786|NCT00421707|DRUG|GW876008|
214590787|NCT00421707|OTHER|Placebo|
214634455|NCT03822975|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
214634456|NCT03822975|DRUG|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
214634457|NCT04276584|DEVICE|Positive expiratory pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
214634458|NCT04276584|OTHER|Speaking loudly during about 3 minutes|A specified swedish text
214634459|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
214634460|NCT02959463|OTHER|Laboratory Biomarker Analysis|Correlative studies
214634461|NCT02959463|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
214634462|NCT02959463|BIOLOGICAL|Pembrolizumab|Given IV
214590788|NCT04578782|DRUG|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
214590789|NCT06020118|BIOLOGICAL|Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)|Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
214590790|NCT06020118|BIOLOGICAL|Sequential Vaccination (Influenza vaccine then mRNA COVID booster)|Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
214590791|NCT06020118|BIOLOGICAL|Sequential Vaccination (mRNA COVID booster then Influenza vaccine)|mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
214590792|NCT03261700|BEHAVIORAL|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
214590793|NCT03261700|OTHER|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
214590794|NCT01204398|DRUG|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
214590795|NCT00311727|BIOLOGICAL|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
214590796|NCT00544362|BIOLOGICAL|cetuximab|
214590797|NCT00544362|DRUG|cisplatin|
214590798|NCT00544362|DRUG|fluorouracil|
214590799|NCT00544362|PROCEDURE|conventional surgery|
214590800|NCT05225194|OTHER|COVID-19|SARS-CoV-2 infection
214590801|NCT05225194|OTHER|ARDS|Acute respiratory distress syndrome
214590802|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
214590803|NCT00983931|DRUG|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
214590804|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
214590805|NCT02843477|DEVICE|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
214634463|NCT02959463|RADIATION|Radiation Therapy|Undergo hemithoracic radiation therapy
214634464|NCT06962787|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214634465|NCT06962787|DRUG|axitinib|Oral administration, and twice daily with an interval of 12 hours.
214634466|NCT06962787|DRUG|pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
214634467|NCT05726318|DRUG|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
214634468|NCT01707407|DRUG|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
214634469|NCT01707407|DRUG|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
214634470|NCT01707407|DRUG|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
214634471|NCT01707407|DRUG|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
214634472|NCT05956041|DRUG|Pembrolizumab|400mg Intravenously
214634473|NCT05956041|DRUG|Mogamulizumab|1mg/kg Intravenously
214590806|NCT02847351|DIETARY_SUPPLEMENT|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
214590807|NCT04009850|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
214590808|NCT04009850|OTHER|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
214590809|NCT04331496|OTHER|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
214590810|NCT04331496|OTHER|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
214590811|NCT05386797|PROCEDURE|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
214590812|NCT01558011|DRUG|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
214590813|NCT01281969|DRUG|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
214590814|NCT01281969|DRUG|Placebo|Normal saline, IV (in the vein), over 2 days
214634474|NCT06451913|DRUG|Amoxicillin + Saccharomyces boulardii CNCM I-745|At inclusion visit (V1), the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + Saccharomyces boulardii 250 mg x 2 twice a day for 21 days
214634475|NCT06451913|DRUG|Amoxicillin + Placebo|At inclusion visit (V1),the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + a matching placebo bid for 21 days
214634476|NCT06451913|OTHER|Stool samples|"The subject will be asked to collect thanks to four OMNIgene® •GUT OMR-200 kits :~* an initial stool collection when returning home at D1 (in any case before any intake of amoxicillin and of the investigational medication and up to 1 day after D1).~* a stool collection at home after the phone call 1, Day 7 (stool collection up to Day 7 + 1 day)~* a stool collection at home after the phone call 2, Day 14 (stool collection up to Day 14 + 1 day)~* at home the day of the Visit 2, Day 21 (stool collection up to Day 21 + 1 day)"
214634477|NCT06451913|OTHER|BSFS : Bristol Stool Form Scale|All included subjects will have to complete a stool diary BSFS (Bristol Stool Form Scale) daily and at each bowel movement, from Day 1 until the end of study treatment (Day 21). The patient will fill the form with the date, the time, and the stool texture.
214590815|NCT06158685|OTHER|Study Group|"Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks"
214710938|NCT02665078|OTHER|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
214710939|NCT04328233|BEHAVIORAL|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
214590816|NCT06158685|OTHER|Control Group|"Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15"
214710940|NCT01225978|DEVICE|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
214590817|NCT04688073|BEHAVIORAL|Exercise|Running
214710941|NCT05578482|DRUG|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
214590818|NCT04688073|BEHAVIORAL|Rest|sit and rest
214590819|NCT01088373|DRUG|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
214710942|NCT05578482|DRUG|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
214710943|NCT00532428|DRUG|Raloxifene|60 mg QD
214590820|NCT01629602|PROCEDURE|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
214590821|NCT02652923|DRUG|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
214590822|NCT00662233|DRUG|cyclophosphamide|
214590823|NCT00662233|DRUG|doxorubicin hydrochloride|
214590824|NCT00662233|DRUG|etoposide|
214590825|NCT00662233|DRUG|ifosfamide|
214590826|NCT00662233|DRUG|vincristine sulfate|
214590827|NCT00662233|PROCEDURE|adjuvant therapy|
214710944|NCT00532428|DRUG|Raloxifene|120 mg QD
214710945|NCT00532428|DRUG|Placebo|Placebo
214710946|NCT04564716|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
214710947|NCT04564716|OTHER|Placebo|placebo comparator
214590828|NCT00662233|PROCEDURE|neoadjuvant therapy|
214590829|NCT00662233|PROCEDURE|therapeutic conventional surgery|
214590830|NCT00662233|RADIATION|brachytherapy|
214590831|NCT00662233|RADIATION|intraoperative radiation therapy|
214590832|NCT00662233|RADIATION|radiation therapy|
214710948|NCT06511440|DEVICE|Vision-700|OCT machines used for diagnostic purposes
214590833|NCT00628264|DRUG|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
214590834|NCT00628264|DRUG|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
214590835|NCT02675127|DRUG|Daktavira|1 tablet contains 60 mg Daclatasvir
214590836|NCT02675127|DRUG|Daklinza|1 tablet contains 60 mg Daclatasvir
214590837|NCT03743467|DIAGNOSTIC_TEST|Clinical evaluation of vision and eye tests|"* VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
214590838|NCT05981599|OTHER|There is no intervention|There is no intervention. Only retrieving clinical, biological and epidemiological data from patient files
214590839|NCT01864954|BEHAVIORAL|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
214590840|NCT03302351|DRUG|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
214590841|NCT03302351|DRUG|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
214590842|NCT03302351|DRUG|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
214590843|NCT00126893|DRUG|CC-401|
214590844|NCT03990831|DIAGNOSTIC_TEST|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
214590845|NCT04618445|BEHAVIORAL|some risk factors that might be correlated with TMD|Fonesca questionnaire
214590846|NCT04307251|DEVICE|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
214590847|NCT04307251|DEVICE|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
214590848|NCT03525431|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
214590849|NCT02767713|DRUG|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
214590850|NCT02767713|OTHER|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
214590851|NCT01723254|BIOLOGICAL|IGE-1|Intramuscular, multiple dose
214590852|NCT01723254|BIOLOGICAL|IGE-2|Intramuscular, multiple dose
214590853|NCT01723254|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
214590854|NCT04185454|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daily intake of Jarlsberg cheese
214590855|NCT01564628|DEVICE|CADScor1|Acoustic recording
214590856|NCT01735851|DRUG|Thoracic epidural analgesia|
214590857|NCT01735851|PROCEDURE|Bilateral Paravertebral block|
214590858|NCT00177034|DRUG|Narrow Band UVB Treatment|
214590859|NCT05610332|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
214590860|NCT05610332|DRUG|Albumin Taxol|Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle
214590861|NCT05610332|DRUG|FLOT scheme|"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"
214590862|NCT05088018|OTHER|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
214590863|NCT05088018|OTHER|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
214590864|NCT04625998|BEHAVIORAL|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
214590865|NCT04625998|BEHAVIORAL|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
214590866|NCT03006731|BEHAVIORAL|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
214590867|NCT03006731|BEHAVIORAL|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
214590868|NCT05231031|BEHAVIORAL|Aerobic exercise|continuous aerobic exercise on a treadmill
214590869|NCT05231031|BEHAVIORAL|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
214590870|NCT05231031|BEHAVIORAL|Relaxation training|continuous aerobic exercise plus relaxation training
214590871|NCT02422862|OTHER|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
214590872|NCT03956485|OTHER|Type of center|Tertiary versus non-tertiary
214590873|NCT04621773|PROCEDURE|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
214590874|NCT00434473|DRUG|A-001|A-001
214590875|NCT00434473|OTHER|Placebo|Placebo
214634478|NCT06451913|OTHER|GSRS : Gastrointestinal Symptom Rating Scale|All included subjects will have to complete a GSRS (Gastrointestinal Symptom Response Score) questionnaire weekly from Day 1 until the end of the study treatment (Day 21).
214590876|NCT03866707|OTHER|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
214590877|NCT03866707|OTHER|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
214590878|NCT03866707|OTHER|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
214590879|NCT02757027|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
214590880|NCT02757027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
214590881|NCT01201265|DRUG|Bevacizumab|15 mg/kg iv every 3 weeks
214590882|NCT01201265|DRUG|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
214590883|NCT01201265|DRUG|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
214590884|NCT02119845|DEVICE|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
214590885|NCT03991702|DIAGNOSTIC_TEST|diagnostic test|The overall motor function of the patient will be assessed using the Medical Research Council (MRC) scale and Palmar dynamometer strength
214590886|NCT04640077|OTHER|No Intervention|No intervention
214590887|NCT04640077|DRUG|donanemab|Administered IV
214590888|NCT02035644|DRUG|Jinlida granules|
214590889|NCT02035644|DRUG|placebo granules|
214590890|NCT03466996|BEHAVIORAL|Intervention group|More frequent follow up with face to face interaction.
214590891|NCT03466996|BEHAVIORAL|Standard of care group|Transition goal setting during annual follow up.
214590892|NCT01257425|DRUG|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
214590893|NCT02844647|OTHER|Hyperpolarized Pyruvate (13C)|MRI contrast agent
214590894|NCT00680680|DRUG|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
214590895|NCT01498367|PROCEDURE|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
214590896|NCT00304525|DRUG|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
214590897|NCT03795597|DRUG|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
214590898|NCT03795597|DRUG|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
214590899|NCT03795597|DRUG|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
214590900|NCT00004145|BIOLOGICAL|anti-thymocyte globulin|
214590901|NCT00004145|DRUG|cyclophosphamide|
214590902|NCT00004145|DRUG|fludarabine phosphate|
214590903|NCT00004145|PROCEDURE|peripheral blood stem cell transplantation|
214590904|NCT05314920|BEHAVIORAL|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
214590905|NCT05314920|BEHAVIORAL|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
214590906|NCT01374373|BIOLOGICAL|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
214590907|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
214590908|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
214590909|NCT00646633|PROCEDURE|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
214590910|NCT00088686|DRUG|Capsaicin (Intramucosal Injection)|
214590911|NCT02668185|DRUG|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
214590912|NCT02668185|DRUG|Placebo|Placebo
214590913|NCT00045513|DRUG|7-hydroxystaurosporine|
214590914|NCT00045513|DRUG|fludarabine phosphate|
214590915|NCT02870335|OTHER|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
214590916|NCT02870335|OTHER|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
214590917|NCT03172676|DRUG|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
214590918|NCT03172676|DRUG|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
214590919|NCT03172676|DRUG|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
214590920|NCT04600193|OTHER|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
214590921|NCT04600193|OTHER|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
214590922|NCT01168323|BEHAVIORAL|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
214590923|NCT04444544|OTHER|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
214590924|NCT03087019|RADIATION|Radiation|Standard use of radiation is administered
214590925|NCT03087019|DRUG|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
214590926|NCT02731573|DRUG|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
214590927|NCT02731573|PROCEDURE|Open heart surgery|Subject will undergo open heart surgery according to standard of care
214590928|NCT02373410|PROCEDURE|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
214590929|NCT02373410|PROCEDURE|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
214590930|NCT02373410|PROCEDURE|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
214710949|NCT06259864|OTHER|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
214590931|NCT02373410|PROCEDURE|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
214710950|NCT04595396|PROCEDURE|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
214710951|NCT03071380|DRUG|Repatoxaban|1 tablet contains 10 mg rivaroxaban
214710952|NCT03071380|DRUG|Xarelto|1 tablet contains 10 mg rivaroxaban
214590932|NCT02373410|DRUG|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
214590933|NCT02373410|DRUG|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
214590934|NCT02373410|DRUG|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
214590935|NCT02373410|DRUG|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
214590936|NCT03707197|BEHAVIORAL|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
214590937|NCT01058408|RADIATION|Intensity modulated radiotherapy|Administered daily 5 days per week
214590938|NCT01058408|DRUG|RAD001|Taken orally once a day
214590939|NCT01058408|DRUG|cisplatin|Administered intravenously once a week
214590940|NCT04017676|OTHER|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
214590941|NCT02279394|DRUG|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8
214590942|NCT02279394|DRUG|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
214590943|NCT02279394|DRUG|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
214590944|NCT03829293|DEVICE|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
214590945|NCT01895283|BEHAVIORAL|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
214590946|NCT00723021|DRUG|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
214590947|NCT00723021|DRUG|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
214590948|NCT00723021|DRUG|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
214590949|NCT00723021|DRUG|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
214590950|NCT00723021|DRUG|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
214710953|NCT05466734|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
214710954|NCT05466734|DRUG|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
214710955|NCT03073408|DRUG|Propofol|Closed loop control for propofol administration guided by the BIS.
214710956|NCT03073408|DRUG|Propofol|Manual control group: Propofol administration adjusted manually.
214710957|NCT03858608|DIETARY_SUPPLEMENT|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
214710958|NCT03858608|OTHER|Usual asthma care|Usual asthma management
214590951|NCT01848951|DRUG|Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
214634479|NCT00928538|OTHER|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
214710959|NCT03693118|BEHAVIORAL|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
214710960|NCT06204302|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
214710961|NCT06204302|DRUG|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
214710962|NCT06204302|DRUG|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
214710963|NCT04904003|OTHER|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
214590952|NCT01848951|DRUG|TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
214590953|NCT02673840|DRUG|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
214590954|NCT02673840|DRUG|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
214590955|NCT02667977|OTHER|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
214590956|NCT02667977|OTHER|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
214590957|NCT02388685|OTHER|Exercise|Home exercise therapy
214590958|NCT02006953|PROCEDURE|Bolus feeding schedule following gastrostomy tube placement|
214590959|NCT02006953|PROCEDURE|Continuous chimney feeds following gastrostomy tube placement|
214590960|NCT00770341|DRUG|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
214590961|NCT00770341|DRUG|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
214590962|NCT00770341|DRUG|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
214590963|NCT05146687|OTHER|Aflibercept|intravitreal injection
214590964|NCT05146687|OTHER|Ranibizumab|intravitreal injection
214590965|NCT05146687|OTHER|Bevacizumab|intravitreal injection
214590966|NCT05132283|DEVICE|3D Slicer|Navigational device used during surgery to locate abnormal lymph nodes.
214590967|NCT05132283|DEVICE|Monaco|Navigational device used during surgery to locate abnormal lymph nodes.
214590968|NCT03753620|DEVICE|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
214590969|NCT03753620|DEVICE|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
214590970|NCT00000550|BEHAVIORAL|health education|
214590971|NCT02709824|DRUG|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
214590972|NCT02709824|DRUG|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
214590973|NCT00515983|BIOLOGICAL|DC/Apo-Nec|
214590974|NCT04538456|OTHER|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
214590975|NCT03634514|DRUG|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
214590976|NCT03634514|DRUG|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
214590977|NCT02601651|DRUG|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
214590978|NCT02601651|DRUG|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
214590979|NCT04978142|DEVICE|transcranial Direct Current Stimulation (tDCS)|Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
214590980|NCT00046397|DRUG|Modified Vaccinia Virus Ankara TBC-M|
214590981|NCT05765669|PROCEDURE|Percutaneous screw fixation|Surgical intervention in the form of percutaneous screw fixation
214590982|NCT05765669|OTHER|Pain management|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
214590983|NCT05765669|OTHER|Physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
214590984|NCT00883051|DRUG|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
214590985|NCT00883051|DRUG|Placebo|Placebo
214590986|NCT01335451|DRUG|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
214590987|NCT01335451|DRUG|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
214590988|NCT00000201|DRUG|Selegiline|
214590989|NCT02632032|DRUG|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice"
214590990|NCT05765162|BEHAVIORAL|Patient reported ourcomes|Full screening for the perioperative periode
214590991|NCT03408561|OTHER|Internet-Based Intervention|Receive message via Twitter
214590992|NCT03408561|OTHER|Survey Administration|Ancillary studies
214590993|NCT00437541|DEVICE|Insulation retrofitted into house|
214590994|NCT01696669|DRUG|Chemotherapy|"* Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8."
214590995|NCT01696669|PROCEDURE|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
214590996|NCT01696669|RADIATION|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
214590997|NCT02011373|PROCEDURE|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
214590998|NCT00820196|DRUG|Nexagon®|
214590999|NCT00820196|DRUG|Nexagon® vehicle|
214591000|NCT05167305|OTHER|This is an observational study|This is an observational study
214591001|NCT04642872|OTHER|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
214591002|NCT04642872|OTHER|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
214591003|NCT04642872|OTHER|Conventional therapy|Following the usual therapy in the baby.
214591004|NCT04642872|OTHER|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
214591005|NCT05628168|OTHER|Neurodynamic Mobilization Techniques|The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.
214591006|NCT05628168|OTHER|Selected Physical Therapy Program|The participants only received a selected therapy program similar to the NMG with no change in duration.
214591007|NCT00080093|BEHAVIORAL|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
214591008|NCT00080093|BEHAVIORAL|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
214591009|NCT01637181|PROCEDURE|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
214591010|NCT02659800|OTHER|Laboratory Biomarker Analysis|Correlative studies
214591011|NCT02659800|BIOLOGICAL|NT-I7|Given IM
214591012|NCT02659800|OTHER|Placebo|Given IM
214591013|NCT02938091|OTHER|High-fat diet|Typical Western diet
214591014|NCT02938091|OTHER|Low-fat diet|Traditional Caribbean Hispanic diet
214591015|NCT02369640|PROCEDURE|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
214591016|NCT02337751|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
214591017|NCT03306017|OTHER|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
214591018|NCT00002291|DRUG|Pentamidine isethionate|
214634480|NCT06253156|BEHAVIORAL|virtual reality|It is planned to provide 4 sessions of standard disaster preparedness training to nursing students in the intervention group. After the standard training sessions are completed, nursing students will be shown disaster simulation videos and visuals using virtual reality glasses within the scope of the virtual reality-based disaster preparedness training program.
214634481|NCT05354986|OTHER|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
214591019|NCT02618642|RADIATION|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
214591020|NCT05444049|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
214591021|NCT06308848|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
214591022|NCT06308848|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
214591023|NCT01513577|OTHER|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
214591024|NCT01513577|OTHER|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
214591025|NCT01365832|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
214591026|NCT05810454|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
214591027|NCT05810454|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
214591028|NCT01380015|OTHER|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
214591029|NCT01380015|OTHER|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
214591030|NCT01910181|DRUG|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
214591031|NCT02482077|DRUG|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
214591032|NCT02482077|DRUG|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
214591033|NCT02482077|DRUG|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
214591034|NCT00136981|DRUG|torcetrapib/atorvastatin|
214591035|NCT00136981|DRUG|atorvastatin|
214591036|NCT04395898|PROCEDURE|pancreaticoduodenectomy|Whipple's procedure
214591037|NCT06609382|OTHER|Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)|Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
214591038|NCT02574754|DRUG|warfarin|warfarin 10 mg PO x 1
214591039|NCT00210977|DRUG|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
214591040|NCT06609746|DIETARY_SUPPLEMENT|Thyme extract|Three Gastrolit capsules daily with a low FODMAP diet for 8 weeks
214591041|NCT06609746|OTHER|Placebo|Placebo capsules daily with a low FODMAP diet for 8 weeks
214591042|NCT06674915|DRUG|HRS-5965 capsules|Oral 50 mg.
214591043|NCT06623344|OTHER|Magnetic Resonance Imaging with or without Contrast|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
214710964|NCT04546464|BEHAVIORAL|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
214591044|NCT07019233|DEVICE|Real Time Pressure Controller|The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance.
214591045|NCT07020299|DEVICE|Device : Digital electrical muscle stimulator is applied to induce diaphragm contraction.|TEDS group will be subjected to sessions of TEDS as follow : Digital electrical muscle stimulator (EV-906 Digital TENS/EMS made in TAIWAN) is applied to induce diaphragm contraction.
214591046|NCT07020208|BEHAVIORAL|Transition Shock skills|"* Assign experienced nurse mentors to new graduates.~* Conduct weekly one-on-one meetings for the first three months, then biweekly for ongoing support.~* Discuss challenges, successes, and strategies for coping with difficult situations.~* Provide case study reviews where mentors guide mentees through real-world nursing scenarios.~  * Skills Applied: interpersonal communication. 2. Peer Support Groups~ * Content:~* Establish weekly or biweekly group discussions where nurses share challenges and coping strategies.~* Use reflective journaling prompts to encourage discussion.~* Introduce role-playing exercises for dealing with complex patients, staff conflicts, and ethical dilemmas."
214591047|NCT03722147|BIOLOGICAL|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
214591048|NCT03824639|BEHAVIORAL|Structured exercise|Exercise instruction and encouragement
214591049|NCT03824639|BEHAVIORAL|Health Education|Provision of general information about a variety of health topics
214591050|NCT01079338|OTHER|caffeine|
214591051|NCT06305156|DIAGNOSTIC_TEST|Bone Mineral Density quantification|"In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications."
214591052|NCT06110143|OTHER|Periodontal treatment|Periodontal treatment
214591053|NCT05568524|OTHER|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
214591054|NCT05568524|OTHER|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
214591055|NCT05950022|PROCEDURE|Endoscopic tenotomy surgery of the iliopsoas tendon|The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
214591056|NCT04950322|DRUG|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
214591057|NCT04950322|DRUG|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
214591058|NCT05951933|OTHER|Strenghtening + TES|Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)
214591059|NCT03889743|DRUG|Dexamethasone treatment during 3 days|Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
214591060|NCT03889743|DRUG|placebo treatment during 3 days|1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
214591061|NCT05649852|OTHER|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
214591062|NCT05649852|OTHER|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
214591063|NCT06475183|DIETARY_SUPPLEMENT|Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum|Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
214591064|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
214591065|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
214591066|NCT00733928|DEVICE|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
214591067|NCT00733928|DEVICE|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
214591068|NCT04634929|PROCEDURE|bariatric surgery|bariatric surgery
214591069|NCT04634929|DIETARY_SUPPLEMENT|conservative diet|conservative diet
214591070|NCT03224351|DRUG|VX-659|Tablet for oral administration.
214591071|NCT03224351|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
214591072|NCT03224351|DRUG|IVA|Tablet for oral administration.
214591073|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
214591074|NCT03224351|DRUG|TEZ|Tablet for oral administration.
214591075|NCT03224351|DRUG|VX-561|Tablet for oral administration.
214591076|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
214591077|NCT01328717|DEVICE|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
214591078|NCT04321044|GENETIC|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
214710965|NCT01599702|DRUG|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
214591079|NCT03584568|BEHAVIORAL|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
214591080|NCT03584568|OTHER|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
214591081|NCT00894153|DRUG|chemotherapy plus p53|chemotherapy plus p53
214710966|NCT01565590|DRUG|Dexmedetomidine|0.2-1.5 mcg/kg/hr
214591082|NCT00894153|DRUG|chemotherapy|chemotherapy
214710967|NCT01565590|DRUG|propofol|5-80 mcg/kg/min
214710968|NCT03919838|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
214591083|NCT00894153|RADIATION|radiotherapy|radiotherapy
214591084|NCT03440320|BEHAVIORAL|MY-SKILLS - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
214591085|NCT03440320|BEHAVIORAL|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
214591086|NCT03883425|OTHER|interRAI-HC assessments|Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses
214710969|NCT03919838|DIETARY_SUPPLEMENT|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
214710970|NCT02027415|DIETARY_SUPPLEMENT|Beet juice|2 cups of beet juice will be given before the car ride
214710971|NCT02027415|DIETARY_SUPPLEMENT|Orange juice|2 cups of orange juice will be given before the car ride
214591087|NCT05869630|OTHER|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
214591088|NCT05869630|OTHER|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
214591089|NCT00597298|DEVICE|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
214591090|NCT00597298|DEVICE|sham threshold|non-training physical activity
214591091|NCT05077865|DRUG|MYMD-1|150 mg capsule
214591092|NCT05077865|DRUG|Placebo|Matching in appearance to MyMD-1 150mg capsule
214591093|NCT05916573|DRUG|HSK16149|single oral adminiatration, 20mg
214591094|NCT04674670|DRUG|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
214591095|NCT04674670|DRUG|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
214591096|NCT04674670|DRUG|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
214591097|NCT02037841|OTHER|Nursing-driven clinical pathway for management of inpatient asthma|
214591098|NCT02961296|OTHER|No intervention|No intervention will be needed.
214591099|NCT06963801|BEHAVIORAL|Moms2B|An established group-based pregnancy program focusing on improving nutrition, social, and medical support.
214591100|NCT06963801|BEHAVIORAL|DBT-P|An emotional skills group where emotion regulation skills are taught in the context of the pregnancy and expected life with an infant.
214591101|NCT01980654|DRUG|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
214591102|NCT01980654|DRUG|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
214591103|NCT00895674|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
214591104|NCT03102554|GENETIC|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
214591105|NCT06258915|DRUG|Adalimumab|Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)
214591106|NCT06258915|DRUG|Mycophenolate Mofetil|2 g/day orally for 36 weeks
214591107|NCT03270904|DEVICE|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
214710972|NCT00385463|DRUG|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
214710973|NCT02103881|DRUG|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
214710974|NCT02103881|DRUG|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
214591108|NCT04557462|DRUG|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
214591109|NCT04856644|DRUG|4-month rifapentine-based regimen|8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
214591110|NCT01602523|DRUG|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
214591111|NCT01602523|DRUG|Placebo|Placebo inhaler once daily 28 days
214591112|NCT00213291|DRUG|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
214591113|NCT05391477|DEVICE|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
214591114|NCT01620255|DRUG|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
214591115|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
214591116|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
214591117|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
214591118|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
214591119|NCT06108037|BEHAVIORAL|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
214591120|NCT01386060|OTHER|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
214591121|NCT03702556|DEVICE|MRI scan|7.0 tesla functional MRI scan
214591122|NCT03165929|DRUG|Flurbiprofen|oral flurbiprofen spray
214591123|NCT03165929|DRUG|placebo|oral placebo spray
214591124|NCT00499356|DEVICE|pressure reducing insole|
214591125|NCT00499356|DEVICE|GlideSoft®|
214591126|NCT05779397|DEVICE|Masimo RAD-GT|Non-contact infrared thermometry device
214591127|NCT03794908|DEVICE|Light therapy A (Bright) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
214591128|NCT03794908|DEVICE|Light therapy B (Dim) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
214591129|NCT02285426|DEVICE|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality \[visual scale adapted from Herth 2009 and Zaric 2013\] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
214591130|NCT04725825|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
214591131|NCT04725825|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
214591132|NCT04209699|DRUG|BMS-986165|Single dose
214591133|NCT04209699|DRUG|Famotidine|Single dose
214591134|NCT03459144|DRUG|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
214591135|NCT03459144|DRUG|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
214591136|NCT04854369|DRUG|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
214591137|NCT00451100|DRUG|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
214591138|NCT00451100|DRUG|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
214591139|NCT03607539|DRUG|Sintilimab|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
214591140|NCT03607539|DRUG|Pemetrexed|500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
214591141|NCT03607539|DRUG|Platinum|Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
214591142|NCT03607539|DRUG|Placebos|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
214591143|NCT04256603|DRUG|Gabapentin|Timing of gabapentin initiation
214591144|NCT04256603|OTHER|No gabapentin|No gabapentin
214591145|NCT01324115|DRUG|NG-nitro-L-arginine|
214591146|NCT01324115|OTHER|laboratory biomarker analysis|
214591147|NCT01324115|OTHER|pharmacological study|
214591148|NCT01324115|PROCEDURE|computed tomography|
214591149|NCT01324115|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214591150|NCT04620226|OTHER|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
214591151|NCT05385133|PROCEDURE|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
214591152|NCT05385133|PROCEDURE|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
214591153|NCT06397729|BEHAVIORAL|Wait-List Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
214591154|NCT06397729|BEHAVIORAL|PREVENT Tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
214591155|NCT05545605|DRUG|Sodium oligomannate|Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)
214591156|NCT05545605|DRUG|Placebo capsule|the control group (receiving placebo capsule) for 24 weeks.
214591157|NCT05768841|BEHAVIORAL|mental health issues|survey on mental health issues in endurance athletes
214591158|NCT03726957|BEHAVIORAL|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
214591159|NCT05296408|BEHAVIORAL|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
214591160|NCT05296408|BEHAVIORAL|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
214591161|NCT05296408|BEHAVIORAL|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
214591162|NCT02077595|DEVICE|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
214710975|NCT04169854|DRUG|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
214710976|NCT04169854|DRUG|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
214710977|NCT04125173|OTHER|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
214710978|NCT04125173|OTHER|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
214591163|NCT01092000|BEHAVIORAL|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
214591164|NCT01092000|OTHER|Education|Monthly exercise tips handout.
214591165|NCT04065152|DRUG|Talimogene laherparepvec|Talimogene laherparepvec
214591166|NCT00003193|DRUG|amifostine trihydrate|
214591167|NCT00003193|DRUG|paclitaxel|
214591168|NCT00003193|PROCEDURE|conventional surgery|
214591169|NCT00003193|RADIATION|radiation therapy|
214591170|NCT01400555|DRUG|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
214591171|NCT01400555|DRUG|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
214591172|NCT01400555|DRUG|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
214591173|NCT01400555|DRUG|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
214591174|NCT01155375|DRUG|Ferumoxytol|Experimental: Ferumoxytol
214591175|NCT01155375|DRUG|Oral Iron|Active Comparator: Oral iron
214591176|NCT01653184|DIETARY_SUPPLEMENT|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
214591177|NCT05239351|DEVICE|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
214591178|NCT01497600|DRUG|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
214591179|NCT01497600|DRUG|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
214591180|NCT03616041|DEVICE|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
214591181|NCT05605574|BEHAVIORAL|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
214591182|NCT03718078|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   \- Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
214591183|NCT04876677|DRUG|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
214591184|NCT01933113|DEVICE|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
214591185|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
214591186|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
214710979|NCT04125173|OTHER|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
214710980|NCT00719225|DRUG|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
214710981|NCT01511510|DRUG|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
214710982|NCT01511510|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
214591187|NCT04664439|DIAGNOSTIC_TEST|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
214591188|NCT00225693|DEVICE|drug eluting coronary stent|
214591189|NCT01809223|DRUG|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
214591190|NCT01809223|DRUG|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
214591191|NCT01809223|OTHER|sham injection|sham intravitreal injection per month, fixed injection
214591192|NCT01771328|DRUG|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
214591193|NCT01771328|DRUG|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
214591194|NCT02711111|DEVICE|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
214591195|NCT02711111|DEVICE|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
214591196|NCT00913354|DEVICE|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
214591197|NCT00913354|DEVICE|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
214591198|NCT02583087|PROCEDURE|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
214591199|NCT02723409|PROCEDURE|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
214710983|NCT01511510|DRUG|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
214591200|NCT02723409|PROCEDURE|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
214591201|NCT02723409|PROCEDURE|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
214591202|NCT02723409|PROCEDURE|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
214591203|NCT02723409|PROCEDURE|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
214591204|NCT02715531|DRUG|5-FU|5-FU (400 mg/m\^2) will be administered as an IV bolus, followed by 2400 mg/m\^2 by continuous IV infusion over 46 (± 1) hours, q2w.
214591205|NCT02715531|DRUG|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
214591206|NCT02715531|DRUG|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
214591207|NCT02715531|DRUG|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
214591208|NCT02715531|DRUG|Leucovorin|Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
214591209|NCT02715531|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
214591210|NCT02715531|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 will be administered IV over 120 (± 5) minutes q2w.
214591211|NCT02715531|DRUG|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
214591212|NCT02715531|DRUG|Cisplatin|Cisplatin will be administered as 80 mg/m\^2 IV over 120 minutes q3w (Group E2).
214591213|NCT03126708|DRUG|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
214710984|NCT01511510|DRUG|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
214591214|NCT03126708|DRUG|cisplatin plus paclitaxel|Chemotherapy
214710985|NCT01511510|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
214710986|NCT01693718|DRUG|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
214591215|NCT00186771|DEVICE|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
214591216|NCT00186771|DEVICE|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
214591217|NCT00427336|DRUG|Fludarabine|30 mg/m\^2 by vein daily over 30 minutes
214591218|NCT00427336|DRUG|Cyclophosphamide|300 mg/m\^2 by vein daily over 2 hours
214591219|NCT00427336|DRUG|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
214591220|NCT00465725|DRUG|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
214591221|NCT01057498|DRUG|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
214591222|NCT01057498|DRUG|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
214591223|NCT02136420|DRUG|Promethazine|Subject receives promethazine
214591224|NCT02136420|BEHAVIORAL|Hyper gravity training|Subject receives hypergravity training before testing
214591225|NCT02136420|DRUG|Placebo|Placebo
214591226|NCT02136420|BEHAVIORAL|No hypergravity training|Subjects do not receive normal Earth gravity
214591227|NCT04864106|DEVICE|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
214591228|NCT05403138|DRUG|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
214591229|NCT05403138|DRUG|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
214591230|NCT05718310|DRUG|Nitroglycerin|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
214591231|NCT05718310|DRUG|Saline|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
214591232|NCT06340399|DIETARY_SUPPLEMENT|BCAA|patients administering BCAA
214591233|NCT06340399|OTHER|patient not administered BCAA|patients not administered BCAA
214591234|NCT04384185|OTHER|Exercise protocol|"Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation"
214591235|NCT04384185|OTHER|Manual therapy|"1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles."
214591236|NCT00565474|DRUG|Fluvastatin|Graft vasculopathy
214591237|NCT00029497|PROCEDURE|Acupuncture|
214591238|NCT00029497|DRUG|Amitriptyline|
214591239|NCT06270927|DIAGNOSTIC_TEST|MRI|neuroimaging using MRI scanner
214591240|NCT06270927|DIAGNOSTIC_TEST|CT|neuroimaging using CT scanner
214591241|NCT01122862|DRUG|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
214591242|NCT01122862|OTHER|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
214591243|NCT01122862|OTHER|Sterile water|Sterile water
214591244|NCT01551160|OTHER|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
214591245|NCT01844245|PROCEDURE|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
214591246|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
214591247|NCT02699983|BEHAVIORAL|Behavioral Dietary Intervention|Use SparkPeople web-based program
214591248|NCT02699983|BEHAVIORAL|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
214591249|NCT02699983|DEVICE|Activity Monitoring Device|Wear Fitbit activity monitoring device
214591250|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
214591251|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
214591252|NCT04395430|BEHAVIORAL|Usual Care|"Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker"
214591253|NCT04395430|BEHAVIORAL|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
214591254|NCT00544388|DRUG|levocetirizine dihydrochloride|
214591255|NCT02796820|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
214591256|NCT03770637|DRUG|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
214591257|NCT03770637|OTHER|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
214591258|NCT03377426|DRUG|LYS228|LYS228 IV infusion
214591259|NCT03377426|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
214591260|NCT05277129|OTHER|Analysis of post-stroke immune responses|Analysis of immune responses in peripheral blood
214591261|NCT02673957|OTHER|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
214591262|NCT02529813|DRUG|Cyclophosphamide|Given IV
214591263|NCT02529813|DRUG|Fludarabine Phosphate|Given IV
214591264|NCT02529813|OTHER|Laboratory Biomarker Analysis|Correlative studies
214591265|NCT02529813|BIOLOGICAL|Tisagenlecleucel|Given IV
214591266|NCT00050388|GENETIC|Allovectin-7®|
214591267|NCT03421431|DRUG|EDP-305 Dose 1|Two tablets daily for 12 weeks
214591268|NCT03421431|DRUG|EDP-305 Dose 2|Two tablets daily for 12 weeks
214591269|NCT03421431|DRUG|Placebo|Two tablets daily for 12 weeks
214591270|NCT01581151|DRUG|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
214591271|NCT01581151|DRUG|Monthly Ranibizumab|30 days between treatments
214591272|NCT04923152|DRUG|moderate statin dose|5 mg rosuvastatin per day
214591273|NCT04923152|DRUG|high dose statin|40 mg rosuvastatin per day
214591274|NCT02522455|OTHER|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
214591275|NCT02522455|OTHER|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
214591276|NCT02548260|DEVICE|Syndactyly without compression|three week relative immobilization by syndactyly
214591277|NCT02548260|DEVICE|Syndactyly with compression|three week relative immobilization by syndactyly and compression
214591278|NCT02548260|DEVICE|Rigid splint without compression|three week rigid immobilization by splint
214591279|NCT02548260|DEVICE|Rigid splint with compression|three week rigid immobilization by splint and compression
214591280|NCT00141726|DRUG|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
214591281|NCT04626492|DIAGNOSTIC_TEST|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
214591282|NCT02053987|OTHER|Intensive rehabilitation in the home.|
214591283|NCT00828841|DRUG|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
214591284|NCT00828841|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
214591285|NCT00828841|DRUG|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
214591286|NCT00828841|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
214591287|NCT00828841|DRUG|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
214591288|NCT01694355|DRUG|Vitamin D|
214591289|NCT04147650|DRUG|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
214591290|NCT04147650|DRUG|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
214591291|NCT04147650|DRUG|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
214591292|NCT04147650|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
214710987|NCT01693718|DRUG|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
214591293|NCT02038439|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
214591294|NCT02038439|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
214591295|NCT02038439|BEHAVIORAL|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
214591296|NCT02108587|DEVICE|optical coherence tomography|Undergo optical coherence tomography
214591297|NCT03015818|OTHER|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
214591298|NCT01188213|DIETARY_SUPPLEMENT|Methylsulfonylmethane (MSM)|
214591299|NCT04415463|DEVICE|Multisegmented fully covered self-expandable metal stent|Esophageal FC-SEMS
214591300|NCT01734408|BIOLOGICAL|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
214591301|NCT01734408|BIOLOGICAL|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
214591302|NCT01734408|BIOLOGICAL|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
214591303|NCT01734408|BIOLOGICAL|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
214591304|NCT01734408|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo
214591305|NCT02203292|BEHAVIORAL|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb \< 9.0 g/dL
214591306|NCT02203292|BEHAVIORAL|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
214591307|NCT03741933|DRUG|Apremilast 30mg|Apremilast 30 mg tablet
214591308|NCT01354808|DRUG|Dual Anti-Platelet Therapy (DAPT)|"* Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
214591309|NCT01354808|DRUG|Triple Anti-Platelet Therapy (TAPT)|"* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
214591310|NCT04868539|OTHER|Artificial Light At Night|90 lux lighting for 19hr/day
214591311|NCT04868539|BEHAVIORAL|Sleep Restriction|5-hr of sleep/night
214591312|NCT05222763|BEHAVIORAL|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
214591313|NCT05222763|BEHAVIORAL|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
214591314|NCT04371653|DRUG|PRIM-DJ2727|administration orally
214591315|NCT04371653|DRUG|Placebo|administration orally placebo
214591316|NCT03958786|OTHER|Simplified Geriatric Evaluation|"* Questionnaires~* Self assessment questionnaires~* Mobility and balance tests"
214591317|NCT03958786|OTHER|Sampling|\- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
214591318|NCT04138797|PROCEDURE|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
214591319|NCT04138797|DEVICE|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
214591320|NCT02880033|DRUG|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
214591321|NCT02880033|DRUG|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
214591322|NCT04487574|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
214591323|NCT04487574|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 days
214591324|NCT02590263|RADIATION|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
214591325|NCT02590263|DRUG|Temozolomide|Temozolomide will be administered per label.
214591326|NCT02590263|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
214591327|NCT00010712|DRUG|Black Cohosh|
214591328|NCT01790126|DRUG|ARN-509|
214591329|NCT01790126|DRUG|LHRH Agonist|
214591330|NCT02894112|DIETARY_SUPPLEMENT|non-fat milk|1 serving of non-fat fluid milk
214591331|NCT02894112|DIETARY_SUPPLEMENT|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
214591332|NCT02894112|DIETARY_SUPPLEMENT|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
214591333|NCT02354313|DRUG|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
214591334|NCT00002646|DRUG|fenretinide|
214591335|NCT00002646|DRUG|tamoxifen citrate|
214591336|NCT04731766|BEHAVIORAL|Citrine 5 % sodium fluoride|Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
214591337|NCT04731766|BEHAVIORAL|concocted nano-silver fluoride|Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
214591338|NCT03639233|BEHAVIORAL|YESS!|Web based self-management education
214591339|NCT04027322|DRUG|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
214591340|NCT04027322|DRUG|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
214591341|NCT04027322|DRUG|Normal saline|Placebo for the control group.
214591342|NCT01128738|DRUG|GSK1358820|Onabotulinum toxin type A
214591343|NCT01128738|DRUG|Placebo|Placebo
214591344|NCT01178671|DRUG|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
214591345|NCT01178671|DRUG|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
214591346|NCT01178671|OTHER|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
214591347|NCT06406556|COMBINATION_PRODUCT|Pegaspargase combined with concurrent radiotherapy.|Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.
214591348|NCT04742322|DIETARY_SUPPLEMENT|Bifidobacterium Lactis CCT7858|Probiotic B Lactis
214591349|NCT04742322|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
214591350|NCT00490009|DRUG|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy"
214591351|NCT00490009|DRUG|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
214591352|NCT00490009|DRUG|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
214591353|NCT00490009|DRUG|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
214591354|NCT02827253|DEVICE|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
214591355|NCT06064513|OTHER|verbal empathy training|Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.
214591356|NCT06064513|OTHER|video based empathy training|Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
214591357|NCT03084224|GENETIC|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
214591358|NCT01917513|DEVICE|G-EYE™ colonoscopy|G-EYE™ colonoscopy
214591359|NCT01917513|DEVICE|Standard Colonoscopy|Standard Colonoscopy
214591360|NCT02652962|DEVICE|Gelesis200|3 capsules each containing 0.70 g
214591361|NCT02652962|OTHER|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
214591362|NCT04998734|DIAGNOSTIC_TEST|ASI-SR|Psychometric properties of ASI-SR
214591363|NCT02253303|OTHER|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
214591364|NCT00070863|BEHAVIORAL|Individual Cognitive Behavioral Therapy|
214591365|NCT02302690|BIOLOGICAL|Blood sample for immunology|
214591366|NCT02702973|OTHER|Observe the fundus characteristics after therapy.|
214591367|NCT03898115|BEHAVIORAL|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
214591368|NCT06200298|PROCEDURE|Erector spinae plane block with naropeine [3,75 mg/mL]|"Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process"
214591369|NCT06200298|PROCEDURE|ESPB with saline 0,9%|"Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process"
214591370|NCT05131620|PROCEDURE|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
214591371|NCT05131620|PROCEDURE|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
214591372|NCT02678013|PROCEDURE|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
214591373|NCT02678013|PROCEDURE|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
214591374|NCT04351022|BIOLOGICAL|CART-38|Split intravenous infusion of CART-38 cells \[dose escalating infusion of (5-20)x10\^6 CART-38 cells/kg\].
214591375|NCT00913666|DRUG|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
214591376|NCT03416998|OTHER|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
214591377|NCT05436080|DEVICE|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
214591378|NCT03252951|BEHAVIORAL|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
214591379|NCT03252951|BEHAVIORAL|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
214591380|NCT03252951|BEHAVIORAL|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
214591381|NCT03252951|BEHAVIORAL|Biofeedback|Standard of Care Biofeedback Training
214591382|NCT00489892|DRUG|Modafinil|
214591383|NCT06078280|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
214591384|NCT02767375|DRUG|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
214591385|NCT02767375|PROCEDURE|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
214591386|NCT04911556|DIETARY_SUPPLEMENT|Bifidobacterium longum|types of intestinal flora
214591387|NCT04911556|DIETARY_SUPPLEMENT|A placebo made of starch|placebo
214591388|NCT05427721|DRUG|Thymol|200 mg each 8 hours for 90 days
214591389|NCT02844881|DRUG|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
214591390|NCT02844881|BIOLOGICAL|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
214591391|NCT04571866|OTHER|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
214591392|NCT02349451|BIOLOGICAL|adalimumab|
214591393|NCT02349451|BIOLOGICAL|ABT-122|
214591394|NCT03643120|OTHER|Qualitative interview|Explorative study of gender dysphoria.
214591395|NCT01103635|BIOLOGICAL|CD40 agonist monoclonal antibody CP-870,893|Given IV
214591396|NCT01103635|BIOLOGICAL|tremelimumab|Given IV
214591397|NCT01103635|OTHER|laboratory biomarker analysis|Correlative studies
214591398|NCT05023395|DRUG|MEE-HU Medicus|This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
214591399|NCT05023395|OTHER|Placebo|Placebo
214591400|NCT02301650|DRUG|Lamivudine|mothers use Lamivudine in late pregnancy
214591401|NCT02301650|DRUG|Telbivudine|mothers use Telbivudine in late pregnancy
214591402|NCT02301650|DRUG|Tenofovir|mothers use Tenofovir in late pregnancy
214591403|NCT02290522|PROCEDURE|Tumor biopsy|Biopsy of lesion for molecular characterization
214591404|NCT01097239|DEVICE|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
214591405|NCT02386709|DEVICE|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
214591406|NCT04223869|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
214591407|NCT05737186|DRUG|SGLT-2 inhibitor|dapagliflozin
214591408|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214591409|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
214591410|NCT00429312|BIOLOGICAL|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
214591411|NCT02602054|PROCEDURE|Surgical treatment|Standard left thoracotomy
214710988|NCT01693718|DRUG|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.
214591412|NCT02602054|DRUG|Control group|"\- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~\- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
214591413|NCT02683941|DRUG|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
214591414|NCT02683941|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
214591415|NCT02683941|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator
214591416|NCT05751291|DRUG|Bupivacaine Hydrochloride|"Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve."
214591417|NCT03242551|DRUG|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
214591418|NCT04459065|DRUG|IRDye800CW-nimotuzumab|50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
214591419|NCT05843513|OTHER|Monitoring (observational study)|The relationship between dental wear and the behaviour of the participants will be analysed.
214591420|NCT02623153|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
214591421|NCT02623153|DRUG|capecitabine|capecitabine of 1000 mg/m2
214591422|NCT02623153|DRUG|S1|S1 of 40 mg/m2
214591423|NCT02623153|DRUG|Docetaxel|docetaxel 40 mg/m2
214591424|NCT06186453|BEHAVIORAL|Father-Preterm Newborn Bonding Program|B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
214591425|NCT03807674|PROCEDURE|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
214591426|NCT03630341|DRUG|Clomiphene Citrate 50mg|oral 50 mg tablets
214591427|NCT03630341|DRUG|L-carnitine|1000 mg oral tablet
214591428|NCT03630341|DRUG|Placebo Oral Tablet|oral tablets identical to L-carnitine
214591429|NCT05253495|DRUG|DOC Group B|Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
214591430|NCT05253495|DRUG|Pv-COMRAD 1 and 2 Group B|polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
214591431|NCT05253495|DRUG|Pv-R-CYM 1 and 2 Group B|polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
214591432|NCT05253495|DRUG|DOC Group C|cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
214591433|NCT05253495|DRUG|MAD CPR 1 and 2|methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
214591434|NCT05253495|DRUG|Pv-R CYVE 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
214591435|NCT05253495|DRUG|Pv-R CYVE-MTX 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
214591436|NCT05253495|DRUG|MAD CP|dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
214591437|NCT05253495|DRUG|Pv-Cytarabine/etoposide|polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
214591438|NCT05253495|DRUG|AD CP|polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
214591439|NCT05253495|DRUG|Bv-AVD-R 1 and 2: COHORT IIa|brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
214591440|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
214591441|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 SER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
214591442|NCT05253495|DRUG|Bv-AVD-R|Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
214591443|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 RER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
214591444|NCT05253495|DRUG|Bv-NAVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
214591445|NCT05253495|RADIATION|Involved Site Radiation Therapy|21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
214591446|NCT04579627|BEHAVIORAL|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
214591447|NCT06646445|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
214591448|NCT06646445|PROCEDURE|Watch-and-wait approach|"Watch-and-wait strategy:~* TAP-CT scan At months 3 and 6 during 8 cycles of treatment, at months 9 and 12, and during additional 9 cycles of treatment if performed, and every 3 months thereafter for up to 2 years,~* Colonoscopy with biopsies at months 3, 6, 9, 12, and 24."
214591449|NCT06646445|PROCEDURE|Surgery|Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from randomization.
214591450|NCT06646445|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) according to the current guidelines, at the investigator's discretion.
214591451|NCT02703493|RADIATION|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
214591452|NCT05614154|OTHER|hypochlorous active substance|Poviodin iyot
214591453|NCT01545323|GENETIC|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
214591454|NCT04854668|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
214591455|NCT04854668|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
214591456|NCT04854668|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
214591457|NCT04854668|DRUG|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
214591458|NCT00512460|DRUG|RTA 744|4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
214591459|NCT01959022|DRUG|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
214591460|NCT04327492|DIAGNOSTIC_TEST|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
214591461|NCT02770573|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
214591462|NCT02770573|OTHER|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
214591463|NCT02770573|OTHER|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
214591464|NCT04231942|DEVICE|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
214591465|NCT04231942|DEVICE|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
214591466|NCT02121834|DRUG|LY3050258|
214591467|NCT02121834|DRUG|Placebo|
214591468|NCT02991131|DRUG|Tedizolid (Sivextro, BAY1192631)|Antibiotic
214591469|NCT02991131|DRUG|Linezolid|Antibiotic
214591470|NCT04703231|DIAGNOSTIC_TEST|measurement of macular thickness, corneal thickness and lens opacities|The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
214591471|NCT04918667|COMBINATION_PRODUCT|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
214591472|NCT04918667|DIETARY_SUPPLEMENT|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
214591473|NCT00044031|BIOLOGICAL|G17DT Immunogen|
214591474|NCT00551460|DRUG|arsenic trioxide|
214591475|NCT00551460|DRUG|gemtuzumab ozogamicin|
214591476|NCT00551460|DRUG|mercaptopurine|
214591477|NCT00551460|DRUG|methotrexate|
214591478|NCT00551460|DRUG|tretinoin|
214591479|NCT00570050|DRUG|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
214591480|NCT00570050|DRUG|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
214591481|NCT05394376|OTHER|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
214591482|NCT01971203|DRUG|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
214591483|NCT01971203|BEHAVIORAL|CBT|16 weeks of treatment
214591484|NCT00860613|OTHER|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
214591485|NCT05368051|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
214591486|NCT05395910|DRUG|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
214591487|NCT05694572|DEVICE|Implantation of a CIED|Implantation of a CIED
214591488|NCT03353350|DRUG|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214591489|NCT03353350|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214591490|NCT05647850|OTHER|No intervention|No intervention
214591491|NCT00373815|DRUG|Everolimus|
214591492|NCT01285050|DRUG|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
214591493|NCT01285050|DRUG|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
214591494|NCT01285050|DRUG|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
214591495|NCT05427903|PROCEDURE|Cryotherapy|Ice packs application for 5 minutes after IANB injection
214591496|NCT05427903|PROCEDURE|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
214591497|NCT01690364|OTHER|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
214591498|NCT01690364|OTHER|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
214591499|NCT04950725|BEHAVIORAL|Strength RMT|2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
214591500|NCT04950725|BEHAVIORAL|Strength RMT and nasal breathing|2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
214591501|NCT04950725|BEHAVIORAL|Endurance RMT|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
214591502|NCT04950725|BEHAVIORAL|Endurance RMT and nasal breathing|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
214591503|NCT04950725|BEHAVIORAL|Low dose RMT|10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
214591504|NCT00767273|PROCEDURE|PET Scan|
214591505|NCT00767273|DRUG|FLT|
214591506|NCT00767273|DRUG|FDG|
214591507|NCT02367365|OTHER|No Intervention|No intervention
214591508|NCT02367365|OTHER|No Intervention|No intervention
214591509|NCT04051788|OTHER|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
214591510|NCT04051788|OTHER|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
214591511|NCT03030703|DIETARY_SUPPLEMENT|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
214591512|NCT06161935|OTHER|no intervention|no intervention, it is a retrospective study .
214591513|NCT03954795|PROCEDURE|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
214591514|NCT03954795|PROCEDURE|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
214591515|NCT00343135|DRUG|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
214591516|NCT00297570|DRUG|Pegylated Interferon and Imatinib|
214591517|NCT00470145|DRUG|SB-568859|
214591518|NCT05448781|DRUG|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
214591519|NCT01519466|DEVICE|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
214591520|NCT01519466|DEVICE|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
214591521|NCT02844049|DEVICE|Deep Brain Stimulation|surgical procedure
214591522|NCT02007889|DRUG|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
214591523|NCT03545009|DIETARY_SUPPLEMENT|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
214591524|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
214591525|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice|70ml Concentrated Beetroot Juice
214591526|NCT01279096|DRUG|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
214591527|NCT06085651|PROCEDURE|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
214591528|NCT02154789|DRUG|polidocanol|
214591529|NCT02154789|PROCEDURE|infra-red coagulation|
214591530|NCT02154789|PROCEDURE|cryotherapy|
214591531|NCT02831205|DEVICE|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
214591532|NCT02831205|DEVICE|everolimus-eluting cobalt-chromium (Xience) stent|
214591533|NCT04158596|DEVICE|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
214591534|NCT04370457|OTHER|Administration of the MyPal ePRO system|Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
214591535|NCT04311060|DIAGNOSTIC_TEST|Molecular panel|"* Detection of CBF rearrangements using PCR: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~* NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
214591536|NCT01210079|DRUG|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
214591537|NCT01210079|DRUG|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
214591538|NCT00147823|DEVICE|Vitoss Alone|Synthetic bone graft material
214591539|NCT00147823|DEVICE|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
214591540|NCT06233721|OTHER|Online education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
214591541|NCT06233721|OTHER|Face-to-face education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
214591542|NCT04256382|OTHER|dementia pain care education|Participants are educated about dementia pain care.
214591543|NCT04256382|OTHER|dementia care education|Participants are educated about dementia pain care.
214591544|NCT02426879|PROCEDURE|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
214591545|NCT02963181|DRUG|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
214591546|NCT02963181|DRUG|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
214591547|NCT00028743|DRUG|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
214591548|NCT00028743|DRUG|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
214591549|NCT00028743|DRUG|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
214591550|NCT00028743|DRUG|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
214591551|NCT06236282|DEVICE|ArtiSential®|Articulated laparoscopic device made by Livsmed Co, South Korea.
214591552|NCT03545776|OTHER|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
214591553|NCT05566314|DIETARY_SUPPLEMENT|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
214591554|NCT05566314|OTHER|Placebo|12 oz. flavored beverage
214591555|NCT04572412|RADIATION|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
214591556|NCT00219622|DRUG|tofimilast|
214591557|NCT01504750|PROCEDURE|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
214591558|NCT02379481|DIETARY_SUPPLEMENT|NS 550mg|
214591559|NCT02379481|DIETARY_SUPPLEMENT|NS 1100mg|
214591560|NCT02379481|DIETARY_SUPPLEMENT|placebo|
214591561|NCT05863858|DRUG|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
214591562|NCT05863858|DRUG|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
214591563|NCT05715853|OTHER|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
214591564|NCT02564939|DRUG|ramelteon|double-blind RCT
214591565|NCT02564939|DRUG|Placebo|double-blind RCT
214591566|NCT05803655|OTHER|36-hour duration between ovulation triggering and oocyte pick-up procedure|36-hour duration between ovulation triggering and oocyte pick-up procedure
214591567|NCT05803655|OTHER|38-hour duration between ovulation triggering and oocyte pick-up procedure|38-hour duration between ovulation triggering and oocyte pick-up procedure
214591568|NCT05263479|DRUG|HS-20089 (Phase Ia：Dose escalation )|Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
214710989|NCT05371470|DEVICE|Ellipsis Health Voice Application|Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
214591569|NCT05263479|DRUG|HS-20089 (Phase Ib: Dose expansion)|IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214591570|NCT03939091|DIAGNOSTIC_TEST|Ultrasonography|Renal Ultrasonography
214591571|NCT01012713|DRUG|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
214591572|NCT01012713|DRUG|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
214591573|NCT01012713|PROCEDURE|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
214591574|NCT00410397|PROCEDURE|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
214591575|NCT00410397|PROCEDURE|Sham Manipulation|Neutral positional, gentle palpation
214591576|NCT02540057|PROCEDURE|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
214591577|NCT02540057|PROCEDURE|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
214591578|NCT02571049|DRUG|DFN-11|Sumatriptan 3 mg versus 6 mg
214591579|NCT02954068|DRUG|IV Oxytocin + IM placebo|
214591580|NCT02954068|DRUG|IM Oxytocin + IV placebo|
214591581|NCT04271787|OTHER|questionnaire|Questionnaire
214591582|NCT00137124|DRUG|L-Arginine|oral administration of L-arginine for 4 weeks
214591583|NCT01055262|DEVICE|Heatwrap 1|8 hours continuous topically-applied heat
214591584|NCT01283698|DRUG|Experimental: LAS 41004 dosage 1|dosage 1, once daily
214591585|NCT01283698|DRUG|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
214591586|NCT01283698|DRUG|Experimental: LAS 41004 dosage 3|dosage 3, once daily
214591587|NCT01283698|DRUG|Placebo Comparator: placebo|once daily
214591588|NCT01283698|DRUG|Reference|Active Comparator,once daily
214591589|NCT00290043|DRUG|Insulin glulisine|
214591590|NCT05021094|DRUG|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
214591591|NCT05021094|DRUG|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
214591592|NCT03370471|BEHAVIORAL|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
214591593|NCT03370471|BEHAVIORAL|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
214591594|NCT03370471|BEHAVIORAL|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
214591595|NCT03370471|BEHAVIORAL|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
214591596|NCT00505869|BEHAVIORAL|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
214591597|NCT00505869|BEHAVIORAL|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
214710990|NCT01431261|OTHER|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
214591598|NCT00505869|BEHAVIORAL|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
214591599|NCT02072447|DRUG|YH4808 PO and [14C]-YH4808 IV|
214591600|NCT05969925|DIAGNOSTIC_TEST|new biomarkers for heart failure|assess efficacy of new biomarkers for heart failure
214591601|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
214591602|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
214591603|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
214591604|NCT04188691|BIOLOGICAL|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
214591605|NCT04188691|BIOLOGICAL|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
214591606|NCT01757808|DRUG|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
214591607|NCT01757808|DRUG|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
214591608|NCT02182557|DRUG|WAL 801 CL Dry Syrup|
214591609|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup|
214591610|NCT02182557|DRUG|WAL 801 CL Dry Syrup placebo|
214591611|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup placebo|
214591612|NCT01520298|DRUG|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
214591613|NCT01520298|DRUG|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
214591614|NCT03253874|BEHAVIORAL|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
214591615|NCT03275753|OTHER|Visual Function Tests|All subjects will undergo a battery of visual function tests
214591616|NCT02225951|DIETARY_SUPPLEMENT|Nutritional product|
214591617|NCT02225951|OTHER|Standard breakfast according to ADA recommendations|
214591618|NCT00561951|DRUG|fesoterodine fumarate|8mg tablets OD for 12 weeks
214591619|NCT00561951|DRUG|Placebo|Corresponding placebo tablets OD for 12 weeks
214710991|NCT01431261|BEHAVIORAL|Pain management|Educational sessions in pain management 4 times
214591620|NCT00561951|DRUG|fesoterodine fumarate|4mg tablets OD for 12 weeks
214591621|NCT02949505|BEHAVIORAL|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
214591622|NCT02852473|OTHER|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
214591623|NCT02608281|DEVICE|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
214591624|NCT00435890|BEHAVIORAL|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
214591625|NCT01581541|DRUG|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
214591626|NCT00392327|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214591627|NCT00392327|DRUG|Carboplatin|Given IV
214591628|NCT00392327|DRUG|Cisplatin|Given IV
214591629|NCT00392327|DRUG|Cyclophosphamide|Given IV
214591630|NCT00392327|BIOLOGICAL|Filgrastim|Given IV or SC
214710992|NCT02969447|DRUG|Administration of 10 units of intra venous oxytocin after fetal expulsion|
214710993|NCT02547636|OTHER|Observational study|No intervention will be used in this study.
214591631|NCT00392327|DRUG|Isotretinoin|Given PO
214591632|NCT00392327|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214591633|NCT00392327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214591634|NCT00392327|OTHER|Quality-of-Life Assessment|Ancillary studies
214591635|NCT00392327|RADIATION|Radiation Therapy|Undergo radiation therapy
214591636|NCT00392327|DRUG|Vincristine Sulfate|Given IV
214591637|NCT01414504|BIOLOGICAL|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
214710994|NCT01575405|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
214591638|NCT01414504|BIOLOGICAL|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
214591639|NCT01414504|BIOLOGICAL|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
214591640|NCT01414504|BIOLOGICAL|Control|control, 0.1mL Pneumovax at 3-5yrs
214591641|NCT01990118|DRUG|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
214591642|NCT01990118|DRUG|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
214591643|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
214591644|NCT01401192|DRUG|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks
214591645|NCT01401192|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks
214591646|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
214591647|NCT04359004|OTHER|Vagus Nerve Stimulation (VNS)|Vagus Nerve Stimulation (VNS) will be performed percutaneously through the internal jugular vein during the patient's routine VT ablation procedure. The nerve will be stimulated using standard pacing systems used for clinical purposes. A series of stimulation frequencies and pulse widths will be used to define optimal effects and 'dosing'. Activation recovery interval (ARI) will be measured from the unipolar electrograms. In addition, heart rate and blood pressure responses will be continuously recorded.
214591648|NCT06107725|DRUG|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
214591649|NCT04508023|DRUG|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
214591650|NCT04508023|OTHER|Placebo|Participants will receive matching placebo tablet orally once daily.
214591651|NCT04508023|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
214591652|NCT04498065|BIOLOGICAL|Biological data|Biological data
214591653|NCT04498065|OTHER|Clinical data|Clinical data
214591654|NCT03295110|OTHER|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
214591655|NCT03295110|OTHER|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
214591656|NCT00437736|DRUG|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
214591657|NCT05148143|DRUG|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
214591658|NCT01330173|DRUG|Vismodegib|Given PO
214591659|NCT01330173|OTHER|Pharmacological Study|Correlative studies
214591660|NCT01330173|OTHER|Laboratory Biomarker Analysis|Correlative studies
214591661|NCT04283331|DRUG|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
214591662|NCT03037164|DEVICE|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
214591663|NCT03037164|DEVICE|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
214591666|NCT00253877|OTHER|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
214591667|NCT02466633|OTHER|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
214591668|NCT00116727|DRUG|ENBREL®|50 mg/wk SC
214591669|NCT02341859|DEVICE|stenfilcon A|contact lens
214591670|NCT02341859|DEVICE|delefilcon A|contact lens
214591671|NCT02341859|DEVICE|narafilcon A|contact lens
214591672|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
214591673|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
214591674|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
214591675|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
214591676|NCT02237313|BEHAVIORAL|psychological support and therapeutic education program|
214591677|NCT03969147|DEVICE|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
214591678|NCT03969147|DEVICE|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
214591679|NCT03969147|DEVICE|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
214591680|NCT06324565|DIAGNOSTIC_TEST|D-Dimer test|All patients in whom preoperative diagnostics have not been able to exclude a surgical pathology and who are candidates for diagnostic-therapeutic surgery will be referred for minimally invasive abdominal exploration in the real suspicion of ovarian torsion. During the pre-operative phase, blood exams will be performed including coagulation which will be integrated with the D-dimer values. In addition, as usual, the clinical examination of the patients will be performed integrated with the various diagnostic image tools generally used in this category of patients (abdomen ultrasound +/- magnetic resonance in urgency).
214591681|NCT04229251|BEHAVIORAL|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
214591682|NCT04229251|BEHAVIORAL|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
214591683|NCT05735821|OTHER|Giving breastfeeding training|The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
214591684|NCT00556920|DRUG|COREG CR|
214591685|NCT05198908|OTHER|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
214591686|NCT05198908|OTHER|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
214591687|NCT06168188|DRUG|Neulasta® (pegfilgrastim)|Intravitreal injection of Neulasta® (pegfilgrastim) after TON
214591688|NCT01789125|DRUG|Nicotine Patch|
214591689|NCT01789125|BEHAVIORAL|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
214591690|NCT01789125|BEHAVIORAL|Education-Supportive Psychotherapy|
214591691|NCT03555474|PROCEDURE|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
214591692|NCT03555474|PROCEDURE|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
214591693|NCT03555474|PROCEDURE|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
214591694|NCT04729764|DRUG|GP681 Tablet|Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
214591695|NCT03878251|DEVICE|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
214591696|NCT04256434|DRUG|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
214591697|NCT04256434|DRUG|Nalbuphine HCl|20 mg Nalbuphine
214710995|NCT01575405|DRUG|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
214591698|NCT01439152|DRUG|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
214591699|NCT01439152|DRUG|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
214591700|NCT01439152|DRUG|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
214591701|NCT01439152|DRUG|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
214591702|NCT01546350|GENETIC|PGD|array CGH after blastocyst biopsy
214591703|NCT01546350|PROCEDURE|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
214591704|NCT00657202|DRUG|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
214634482|NCT05354986|OTHER|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
214591705|NCT05261048|OTHER|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
214591706|NCT05261048|OTHER|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
214591707|NCT00046254|DRUG|Zoledronic Acid|
214591708|NCT03411447|OTHER|Parenteral nutrition|
214591709|NCT03411447|OTHER|Enteral nutrition|
214591710|NCT02876198|DEVICE|Gonioscopy|Study of the trabecular structure by gonioscopy
214591711|NCT05717231|BEHAVIORAL|laughter yoga|laughter yoga
214591712|NCT02880631|DEVICE|BAROSTIM NEO™ System|
214591713|NCT02868866|BEHAVIORAL|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
214591714|NCT01074216|DRUG|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
214591715|NCT02870166|OTHER|blood sample|
214591716|NCT05848687|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
214591717|NCT05848687|DRUG|Mitoxantrone|Given IV
214591718|NCT05848687|DRUG|PEG asparaginase|Given IV
214591719|NCT05848687|DRUG|Bortezomib|Given IV
214591720|NCT05848687|DRUG|Vorinostat|Taken PO or NG
214591721|NCT05848687|DRUG|Mercaptopurine|Given PO or NG.
214591722|NCT05848687|DRUG|Methotrexate|Given IV, IM or PO
214591723|NCT05848687|DRUG|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
214591724|NCT05848687|DRUG|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
214591725|NCT05260515|BEHAVIORAL|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
214591726|NCT02763787|DRUG|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
214591727|NCT02763787|DRUG|Placebo|Identical placebo
214591728|NCT03451760|DRUG|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
214591729|NCT03451760|OTHER|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
214591730|NCT02976701|DRUG|DLBS1033|
214591731|NCT02976701|DRUG|Placebo|
214591732|NCT02976701|DRUG|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
214634483|NCT01084265|DRUG|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units \[IU\]) injection s.c. once daily.
214634484|NCT01084265|DRUG|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
214634485|NCT01084265|DRUG|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
214591733|NCT04364009|DRUG|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
214591734|NCT04364009|DRUG|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
214591735|NCT01323634|DRUG|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
214591736|NCT01323634|DRUG|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
214591737|NCT05056987|DEVICE|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
214591738|NCT05056987|DEVICE|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
214591739|NCT05056987|DEVICE|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
214591740|NCT02294916|DEVICE|AWS|Video-laryngoscopy 1
214591741|NCT02294916|DEVICE|Intubrite|Video-laryngoscopy 2
214591742|NCT02294916|DEVICE|AirTraq|Optical-laryngoscopy
214591743|NCT02294916|DEVICE|MIL|Direct-laryngoscopy
214591744|NCT04304573|DIAGNOSTIC_TEST|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
214591745|NCT04497922|DEVICE|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
214591746|NCT04497922|BEHAVIORAL|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
214591747|NCT00627211|PROCEDURE|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
214591748|NCT05532982|OTHER|Interviews and Surveys|Qualitative interviews and surveys
214591749|NCT03068065|DRUG|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
214591750|NCT03068065|DRUG|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
214591751|NCT03068065|DRUG|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
214591752|NCT03078426|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
214591753|NCT03078426|OTHER|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
214591754|NCT03717129|DRUG|Genvoya Oral dose|Single Genvoya oral dose directly observed
214591755|NCT03717129|DRUG|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
214591756|NCT00753272|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
214591757|NCT00753272|BIOLOGICAL|Fluarix TM|IM administration, two times one annual dose
214591758|NCT01941797|BEHAVIORAL|interruption of oral hygiene|
214591759|NCT02686060|DEVICE|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
214591760|NCT02513888|DIETARY_SUPPLEMENT|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
214591761|NCT02513888|DIETARY_SUPPLEMENT|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
214591762|NCT05631977|OTHER|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
214591763|NCT00414284|DRUG|Increased dose of Kaletra|
214591764|NCT04908111|BIOLOGICAL|ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
214591765|NCT04908111|BIOLOGICAL|MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
214591766|NCT04908111|COMBINATION_PRODUCT|Standard of care treatment|Patients will continue to receive SoC treatment (chemotherapy and checkpoint inhibitor).
214591767|NCT04908111|BIOLOGICAL|MVA-NYESO (Route = IM injection, Dose = 1.5×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
214591768|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
214591769|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
214591770|NCT04357197|DEVICE|Closed-loop|The system will be tested to see if it can avoid hypotension
214634486|NCT02743832|PROCEDURE|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
214634487|NCT02743832|PROCEDURE|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
214591771|NCT03207100|COMBINATION_PRODUCT|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
214591772|NCT03207100|COMBINATION_PRODUCT|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
214591773|NCT03604523|DEVICE|Dilation by Balloon|Esophageal dilation by balloon device.
214591774|NCT03604523|DEVICE|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
214591775|NCT03499197|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
214591776|NCT05258045|RADIATION|F18 FDG|Radioactive material
214591777|NCT01162317|OTHER|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
214591778|NCT01162317|OTHER|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
214591779|NCT05462886|DEVICE|Masimo INVSENSOR00057|Noninvasive wearable health monitoring device
214591780|NCT02280694|DRUG|Capecitabine|
214591781|NCT02280694|DRUG|Cyclophosphamide|
214591782|NCT02280694|DRUG|Methotrexate|
214591783|NCT02280694|DRUG|Celecoxib|
214591784|NCT03270423|DEVICE|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
214591785|NCT03270423|DEVICE|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
214591786|NCT05344729|DRUG|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
214591787|NCT01675479|DEVICE|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
214591788|NCT01104116|RADIATION|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
214591789|NCT05922293|OTHER|blow bottle|When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.
214591790|NCT05922293|OTHER|percussion|"Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises.~* Do this for a total of 10 breaths,~* Perform two huffs, and~* Cough.~* Close their mouth around the tube and exhale slightly forcefully for 3 seconds to produce bubbles. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized"
214591791|NCT02584803|RADIATION|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~1. Patient Acceptability of procedure~2. Patient Comfort:~3. Ease of exam for the examiner"
214591792|NCT06124287|DIAGNOSTIC_TEST|MR Enterography (MRE)|MRI scan
214591793|NCT00227474|DRUG|recombinant modified vaccinia Ankara-5T4 vaccine|
214591794|NCT00227474|PROCEDURE|adjuvant therapy|
214591795|NCT00227474|PROCEDURE|recombinant viral vaccine therapy|
214591796|NCT01722110|DRUG|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
214591797|NCT01722110|DRUG|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
214591798|NCT00565539|DRUG|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
214591799|NCT04754204|DEVICE|Arrhythmia Management System (AMS)|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
214591800|NCT04216901|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a pathological prediction of the lesion during colonoscopy.
214591801|NCT00125281|DRUG|S-adenosyl-methionine (SAMe) capsules|
214591802|NCT00024986|DRUG|Tenofovir DF|
214591803|NCT03622619|OTHER|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
214591804|NCT03622619|OTHER|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
214591805|NCT07021261|DRUG|Utidelone plus capecitabine|UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
214591806|NCT07021261|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
214591807|NCT07019337|DRUG|Pyrotinib|400mg or 320mg qd
214591808|NCT07019337|DRUG|Capecitabine|500mg tid
214591809|NCT07019428|PROCEDURE|Free gingival graft stabilized by Titanium fixation tacs|Free gingival graft stabilized by Titanium fixation tacs , in patients with inadequate keratinized gingiva
214591810|NCT07019428|PROCEDURE|Free gingival graft stabilized by sutures|Free gingival graft stabilized by sutures , in patients with inadequate keratinized gingiva
214591811|NCT07019454|DEVICE|Physician Modified Endografting|This is the only intervention in the study
214591812|NCT07019896|PROCEDURE|Minimal Vitrectomy Surgery|The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.
214591813|NCT07019896|PROCEDURE|Conventional Vitrectomy|Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.
214591814|NCT07020364|DEVICE|A single working element for bipolar enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~The bipolar energy will be used for cutting and coagulation during enucleation."
214591815|NCT07020364|DEVICE|A single working element for laser enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~Thulium or Holmium laser will be employed for tissue dissection and hemostasis."
214591816|NCT07019584|OTHER|Wai Ji Match Fun card games|Group intervention using game activities with Wai Ji Match Fun cards. A total of eight group sessions, which last for 60 minutes each, will be conducted once a week for a period of 8 weeks.
214591817|NCT07020884|DRUG|ZT002 Injection|Administered SC
214591818|NCT07020884|DRUG|ZT002 Placebo|Administered SC
214591819|NCT06187285|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
214591820|NCT06187285|DRUG|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
214591821|NCT07019545|DRUG|Belantamab Mafodotin|Belantamab mafodotin is administered intravenously (IV) at a dose of 1.9 mg/kg on Day 1 of every other 28-day cycle for the first two administrations and then 1.9 mg/kg on Day 1 of every third 28-day cycle.
214591822|NCT07019545|DRUG|Dexamethasone|Dexamethasone is administered IV or per OS (PO) at a dose of 40 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants \<75 years; at 20 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants ≥75 years.
214591823|NCT06693609|DRUG|EMP-01|EMP-01 capsules
214591824|NCT06693609|DRUG|EMP-01 Placebo|EMP-01 placebo capsules
214591825|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
214591826|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
214591827|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
214591828|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
214591829|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
214591830|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
214591831|NCT04687228|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
214591832|NCT04687228|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
214591833|NCT06697145|PROCEDURE|Cardioneuroablation|Ablation of parasympathetic ganglia of the heart
214591834|NCT07020793|PROCEDURE|green subthreshold laser therapy|The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.
214591835|NCT07020897|OTHER|Clinician-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by a physical therapist.
214591836|NCT07020897|OTHER|Self-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by the research participant.
214591837|NCT07020897|OTHER|Exercise-based physical therapy|In-clinic exercise-based physical therapy supervised by a physical therapist, with home exercises to be performed on days without a clinical visit.
214591838|NCT07019493|OTHER|No Intervention: Observational Cohort|Not applicable: Observational cohort study
214591839|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
214591840|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
214591841|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
214591842|NCT05938231|DEVICE|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
214591843|NCT05938231|BEHAVIORAL|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
214591844|NCT02139787|OTHER|Radio Story|
214591845|NCT02139787|OTHER|Control -listened to a brochure|
214591846|NCT03226275|DRUG|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
214591847|NCT03226275|DRUG|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
214591848|NCT03226275|DRUG|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
214591849|NCT01389427|DRUG|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591850|NCT01389427|DRUG|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591851|NCT01389427|DRUG|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591852|NCT01389427|DRUG|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591853|NCT01389427|DRUG|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591854|NCT01389427|DRUG|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214710996|NCT01575405|DRUG|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
214591855|NCT01389427|DRUG|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591856|NCT01389427|DRUG|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591857|NCT01389427|DRUG|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591858|NCT01389427|DRUG|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591859|NCT01389427|DRUG|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591860|NCT01389427|DRUG|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
214591861|NCT07019597|DEVICE|Non-invasive neuromodulation NESA(NNG)|NESA is a non-invasive monitoring device, which emits low frequency (1.3-14.28 Hz, depending on the programme), low intensity (0.1-0.9 mA), low voltage (±3 V) ultra low currents, and therefore imperceptible to the patient. It is based on neuromodulation of the autonomic nervous system.
214591862|NCT07019597|DEVICE|Non-invasive Neuromodulation Posterior Tibial (NTPG)|NTPG is an electrotherapy using a device called NEUROTRAC MYOPLUS PRO (brand name) to perform non-invasive TENS-type electrotherapy with biphasic currents.
214591863|NCT06728852|DRUG|Administration of Vorolanib|This study utilizes Vorolanib, a novel angiogenesis inhibitor, as a monotherapy for advanced non-small cell lung cancer (NSCLC) patients who have failed at least two lines of systemic therapy. Vorolanib is administered orally at a dosage of 300 mg daily. The intervention focuses on its efficacy and safety as a third-line or beyond treatment, aiming to improve progression-free survival (PFS) and other clinical outcomes. Vorolanib targets VEGFR, PDGFR, and other tyrosine kinases, distinguishing it from other therapies by its enhanced anti-angiogenesis properties and tolerable safety profile in late-stage cancer treatment.
214591864|NCT03337451|DRUG|OPN-305|Patients will receive study drug every 4 weeks
214591865|NCT05353933|OTHER|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
214591866|NCT05353933|DRUG|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
214591867|NCT06895122|PROCEDURE|High resistance training|Participants will perform the exercises at high speed, emphasizing explosive movements to maximize muscle power development.
214591868|NCT06895122|PROCEDURE|Multicomponent Training|Various exercise modalities are integrated, including aerobic training, mobility, strength, balance, and coordination exercises.
214591869|NCT06809270|BEHAVIORAL|Walking training intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
214591870|NCT06930664|BIOLOGICAL|Sotatercept|Subcutaneous Injection
214591871|NCT06930664|BIOLOGICAL|Sotatercept Autoinjector|Subcutaneous Auto Injection
214591872|NCT06766162|OTHER|Virtual reality pain distraction|The intervention group in this study will undergo their EMR and ESD procedure with the addition of virtual reality (VR) as a supportive tool. Participants in this group will use a VR headset during the procedure, designed to provide an immersive experience that may help manage pain and anxiety. The use of VR will be integrated alongside the standard care protocol, including routine sedation and pain management practices VR headset is from DRVR, Rescope innovation which is registered as medical device in the UK.
214591873|NCT06766162|OTHER|Standard analgesia and sedation|Standard local protocol for analgesia and sedation, incorporating fentanyl and midazolam.
214591874|NCT06829498|DRUG|BCAA|The three BCAAs will be combined together and dissolved in a flavored solution.
214591875|NCT06829498|OTHER|Placebo|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
214591876|NCT06112834|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
214591877|NCT02123433|BIOLOGICAL|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
214591878|NCT00285987|PROCEDURE|Reconstruction of the cruciate ligament|
214591879|NCT00948493|DRUG|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
214591880|NCT03797079|PROCEDURE|ESP block|A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
214591881|NCT03797079|PROCEDURE|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
214591882|NCT03797079|DEVICE|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
214591883|NCT03797079|DRUG|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
214591884|NCT00193687|DRUG|bifeprunox|
214591885|NCT04531150|DRUG|INV-101|Subjects will be randomized to receive INV-101 tablets
214591886|NCT04531150|DRUG|Placebo|Subjects will be randomized to receive placebo tablets
214591887|NCT02193191|DRUG|Plerixafor|
214591888|NCT02673905|OTHER|Tissue Engineered Product|Implantation of tissue engineered products
214591889|NCT05357781|DIAGNOSTIC_TEST|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
214591890|NCT06227000|BEHAVIORAL|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
214591891|NCT06227000|BEHAVIORAL|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
214591892|NCT06458218|COMBINATION_PRODUCT|Multi-component Interventions|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, EmoEase, for individuals with mental health issues among high-risk COPD population(very familiar with intelligent mobile phone);~3. NicQuit, digital health intervention to smokers;~4. Health education to smokers and individuals with mental health issues;~5. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~6. To actively include individuals whose blood pressure and glucose are higher than the normal value into the National Essential Public Health Service in China;~7. A CBT-based health education to the BMI abnormal;~8. Pay-for-performance incentives to medical workers."
214591893|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
214591894|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
214591895|NCT06785103|BEHAVIORAL|Risk assessment messaging|"Participants who are randomized to the HIV risk assessment arm will receive a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category."
214591896|NCT06785103|BEHAVIORAL|U=U messaging|"Participants who are randomized to the U=U arm will receive a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category."
214591897|NCT06785103|BEHAVIORAL|Healthy Living messaging|"Participants who are randomized to the Healthy Living arm will receive a brief video message at their baseline visit, containing information related to Healthy Living core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Healthy Living content category."
214591898|NCT06785103|BEHAVIORAL|Community benefits messaging|"Participants who are randomized to the Community benefits arm will receive a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category."
214634488|NCT06198673|DRUG|Antiplatelet Agents|Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
214634489|NCT06345677|COMBINATION_PRODUCT|ViXe Xombination|Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure
214591899|NCT06785103|BEHAVIORAL|Fresh start effect|"Participants who are randomized to the Fresh start effect arm will receive a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category."
214591900|NCT06785103|BEHAVIORAL|Education-based messaging (#1)|"Participants who are randomized to the Education-based #1 arm will receive a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based #1 content category."
214591901|NCT06785103|BEHAVIORAL|Education-based #2 messaging (gamification)|"Participants who are randomized to the Education-based #2 arm will receive a brief video message at their baseline visit, containing information related to HIV education/gamification core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based/gamification content category."
214591902|NCT06785103|BEHAVIORAL|Default appointment messaging|"Participants who are randomized to the Default appointment arm will receive a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category."
214591903|NCT06785103|BEHAVIORAL|Reserved for you messaging|"Participants who are randomized to the Reserved for you arm will receive a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
214591904|NCT06785103|BEHAVIORAL|Social norms messaging|"Participants who are randomized to the Social norms arm will receive a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category."
214591905|NCT06785103|BEHAVIORAL|Empowerment messaging|"Participants who are randomized to the Empowerment/goal setting arm will receive a brief video message at their baseline visit, containing information related to Empowerment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Empowerment content category."
214591906|NCT05695937|DIETARY_SUPPLEMENT|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
214591907|NCT05695937|DIETARY_SUPPLEMENT|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
214591908|NCT05695937|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
214591909|NCT05695937|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
214591910|NCT00235547|BEHAVIORAL|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
214591911|NCT02778256|DEVICE|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
214591912|NCT02778256|DEVICE|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
214591913|NCT06015178|OTHER|Intelligent Language Model|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
214591914|NCT06015178|OTHER|control|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
214591915|NCT01340196|DRUG|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
214591916|NCT04478656|BIOLOGICAL|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
214591917|NCT04929548|DRUG|Pyrotinib Maleate Tablets|Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
214591918|NCT01422226|DRUG|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
214591919|NCT01422226|OTHER|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
214591920|NCT03279133|DRUG|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
214591921|NCT05622617|DRUG|no intervention|no intervention
214591922|NCT04567290|DRUG|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
214591923|NCT04567290|DRUG|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
214591924|NCT00108212|BEHAVIORAL|Diet|
214591925|NCT05255367|COMBINATION_PRODUCT|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
214591926|NCT04773496|DIAGNOSTIC_TEST|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
214591927|NCT00873353|DRUG|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
214591928|NCT03005860|DRUG|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
214591929|NCT03005860|DRUG|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
214591930|NCT03005860|DRUG|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
214591931|NCT03005860|DRUG|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
214591932|NCT02086266|OTHER|PILATES|
214591933|NCT02086266|OTHER|PFMT and AES|
214591934|NCT05140525|DRUG|Macitentan Tablets|10 mg oral once daily
214591935|NCT05140525|DRUG|Riociguat|1 mg to 2.5mg oral three times daily
214591936|NCT05140525|DEVICE|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
214591937|NCT02640820|DRUG|Sensitizing DPCP Ointment|Sensitization
214591938|NCT02640820|DRUG|Treatment DPCP Ointment|Treatment
214591939|NCT00861263|DEVICE|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
214591940|NCT05407922|PROCEDURE|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
214591941|NCT00047203|DRUG|alvocidib|Given IV
214591942|NCT04220125|DRUG|Ketamine Group|Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
214591943|NCT04220125|DRUG|Midazolam injection|Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
214591944|NCT00286520|PROCEDURE|Transanal irrigation with Peristeen Anal Irrigation|
214591947|NCT05804760|DIAGNOSTIC_TEST|Measurement of implant parameters|"1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
214591948|NCT00887250|DRUG|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
214591949|NCT00887250|DRUG|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
214591950|NCT00887250|DRUG|Comparator: Placebo|Placebo to Losartan
214591951|NCT06239272|PROCEDURE|Surgical resection|Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
214591952|NCT06239272|RADIATION|Proton beam radiation therapy|Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
214591953|NCT06239272|DRUG|Pazopanib|Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
214591954|NCT06239272|DRUG|Ifosfamide|Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
214591955|NCT06239272|DRUG|Doxorubicin|Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
214591956|NCT06239272|DRUG|Selinexor|"High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3"
214591957|NCT03542461|DRUG|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
214591958|NCT03542461|OTHER|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
214591959|NCT05627713|OTHER|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
214591960|NCT05627713|OTHER|urine sample collection|urine sample collection at inclusion
214591961|NCT05116293|DRUG|Midazolam oral solution|Oral syrup
214591962|NCT05116293|DRUG|Digoxin Oral Tablet|Oral tablet
214591963|NCT05116293|DRUG|Acetaminophen Oral Tablet|Oral tablet
214591964|NCT00879762|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
214591965|NCT00879762|OTHER|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
214591966|NCT05847725|OTHER|Elastic bandaging|"The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally."
214591967|NCT05847725|OTHER|Short stretch bandaging|Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
214591968|NCT05847725|OTHER|Kinesio taping|Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
214591969|NCT02569554|DRUG|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
214591970|NCT02569554|DRUG|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
214591971|NCT00881608|DRUG|Placebo|Placebo, 1 capsule daily for five days
214591972|NCT00881608|DRUG|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
214591973|NCT03214094|DRUG|Vonoprazan|Vonoprazan tablets
214591974|NCT01274585|DEVICE|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
214591975|NCT01274585|DEVICE|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
214591976|NCT02013505|OTHER|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
214591977|NCT04308772|BEHAVIORAL|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
214591978|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
214591979|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
214591980|NCT00679653|DRUG|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
214591981|NCT00679653|DRUG|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
214591982|NCT00679653|DRUG|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
214591983|NCT00353379|DRUG|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
214591984|NCT00353379|DRUG|Placebo|Participants will take placebo for 6 weeks.
214591985|NCT02277405|DEVICE|Shikani Optical Stylet|Optical intubation
214591986|NCT02277405|DEVICE|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
214591987|NCT01832441|OTHER|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
214591988|NCT00922103|PROCEDURE|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
214591989|NCT00922103|PROCEDURE|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
214591990|NCT01625572|PROCEDURE|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
214591991|NCT01625572|PROCEDURE|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
214591992|NCT01419457|DRUG|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
214591993|NCT01419457|DRUG|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
214591994|NCT01419457|DRUG|Favipiravir|800 mg Single Dose
214591995|NCT02215538|DRUG|OROS methylphenidate|
214591996|NCT02215538|DRUG|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
214591997|NCT02579174|DEVICE|Medacta GMK Sphere|
214591998|NCT00984425|DRUG|Lapatinib and Sorafenib|Comparison of different dosages of two drug
214591999|NCT00655486|DRUG|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
214592000|NCT06008886|BEHAVIORAL|Vegan diet|Normocaloric diet based solely on foods of plant sources.
214592001|NCT06008886|BEHAVIORAL|Mediterranean diet|Diet with a predominance of plant foods fruits, vegetables, whole grains, nuts and legumes); moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
214592002|NCT05536609|PROCEDURE|Epineural suture|2 or three sutures
214592003|NCT05536609|PROCEDURE|Non-operative treatment|The injured finger is protected in a plaster cast
214592004|NCT05467254|BIOLOGICAL|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
214592005|NCT06510647|OTHER|Hormonal Therapy Agent|"With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy."
214592006|NCT02682472|OTHER|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
214592007|NCT06428136|DIAGNOSTIC_TEST|Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)|"Side-lying clamshells: 3 sets of 10 repetitions per leg, 3 times per week Hip abduction with theraband: 3 sets of 10 repetitions per leg, 3 times per week Bridge with hip abduction: 3 sets of 10 repetitions per leg, 3 times per week~Electrical muscle stimulation:~Applied to the gluteus medius and minimus muscles for 20 minutes per session, 3 times per week Frequency and intensity adjusted to individual tolerance"
214592008|NCT06428136|OTHER|Conservative Treatment (CT)|Stretching: Iliotibial band stretch: 30-second hold, 3 repetitions per leg, 2 times per day Quadriceps stretch: 30-second hold, 3 repetitions per leg, 2 times per day Hamstring stretch: 30-second hold, 3 repetitions per leg, 2 times per day
214592009|NCT05911841|DRUG|LY3454738|Administered SC
214592010|NCT05911841|DRUG|Placebo|Administered SC
214592011|NCT06845150|OTHER|Dual-task training|Combined simultaneous physical and cognitive training in an immersive environment
214592012|NCT06845150|OTHER|Single task training|Sequential cognitive and then physical training
214592013|NCT06235892|DRUG|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
214592014|NCT05885828|OTHER|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
214592015|NCT05885828|OTHER|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
214592016|NCT05885828|BEHAVIORAL|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
214592017|NCT05885828|OTHER|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
214592018|NCT05885828|OTHER|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
214634490|NCT06345677|COMBINATION_PRODUCT|Placebo + Sham|Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
214634491|NCT01098071|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
214634492|NCT06281639|DEVICE|RAPID|test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
214592019|NCT06101667|DRUG|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
214592020|NCT06101667|PROCEDURE|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
214592021|NCT06130306|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
214592022|NCT06130306|PROCEDURE|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
214592023|NCT06050577|DRUG|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
214592024|NCT06050577|DRUG|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
214592025|NCT06412393|DIETARY_SUPPLEMENT|Black tomato extract powder|take 2 packets per day for 8 weeks
214592026|NCT06412393|DIETARY_SUPPLEMENT|Placebo powder|take 2 packets per day for 8 weeks
214592027|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
214592028|NCT06644898|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
214592029|NCT06644898|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
214592030|NCT06644898|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
214592031|NCT06337838|DRUG|Desmopressin Injectable Solution|Intravenous desmopressin, 20 mcg, single dose administration.
214592032|NCT06337838|DRUG|Tranexamic Acid Injectable Product|Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
214592033|NCT06337838|OTHER|Placebo|Intravenous 0.9% saline solution
214592034|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
214592035|NCT03840486|DEVICE|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
214592036|NCT03840486|DEVICE|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 40% FiO2 for 3 minutes, 70% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
214592037|NCT03840486|DEVICE|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
214592038|NCT03840486|DRUG|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
214592039|NCT03840486|DRUG|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 40% FiO2, 70% FiO2 or 100% FiO2 for 3 minutes each.
214592040|NCT04426461|BEHAVIORAL|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
214592041|NCT04426461|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
214592042|NCT04426461|BEHAVIORAL|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
214592043|NCT05469399|OTHER|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
214592044|NCT05469399|OTHER|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
214592045|NCT06384911|BEHAVIORAL|Financial Incentives Program|Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.
214592046|NCT01210261|DEVICE|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
214592047|NCT01210261|DEVICE|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
214592048|NCT06257524|OTHER|Education and training|Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
214592049|NCT03105622|BEHAVIORAL|TV and music|Watching TV or listening to music while running on a treadmill
214592050|NCT02768870|DEVICE|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
214592051|NCT02361138|DRUG|SHR3824|
214592052|NCT02361138|DRUG|Placebo|
214592053|NCT04388397|PROCEDURE|Arteriovenous Grafts|Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
214592054|NCT03401229|BIOLOGICAL|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
214592055|NCT03401229|BIOLOGICAL|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
214592056|NCT05033873|OTHER|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
214592057|NCT05033873|OTHER|Sling Exercise Therapt (SET)|"1. The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~2. In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~3. The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~4. Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
214592058|NCT05033873|OTHER|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~* Active and passive joint movement~* Muscle strength training~* Bridging exercises~* Balance training in sitting and standing positions, according to the patients' functional state.~* Weight bearing exercises on affected Limbs"
214592059|NCT04801810|OTHER|Normobaric hypoxia|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
214592060|NCT04801810|OTHER|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
214592061|NCT01947972|DIETARY_SUPPLEMENT|Tailored protein fortification|4-4.5g of protein/kg/d
214592062|NCT02088437|OTHER|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
214592063|NCT02088437|OTHER|Usual Care|once daily physiotherapy whilst acute hospital inpatient
214710997|NCT07014267|DEVICE|Intervention Group (Virtual Reality intervention)|"Patients will experience the VR mindfulness intervention using the Tripp App or comparable applications.~Anxiety levels will be measured using the STAI before the VR experience, immediately after the VR experience, and after the procedure."
214592064|NCT04693494|OTHER|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
214592065|NCT01774110|OTHER|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
214592066|NCT00640016|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
214592067|NCT00640016|BIOLOGICAL|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
214592068|NCT00640016|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
214592069|NCT00640016|OTHER|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
214592070|NCT05617911|DEVICE|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
214592071|NCT05617911|PROCEDURE|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
214592072|NCT06154486|DRUG|semaglutide use|patient using semaglutide for at least 7 days
214592073|NCT04376853|DEVICE|Apple Watch Series 5|Digital monitoring via Apple Watch
214710998|NCT06875765|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
214710999|NCT06875765|OTHER|18F-PE2I PET-CT|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I.
214592074|NCT05908604|OTHER|Robot for madication management|The effect of a robot in medication management for older people's home care
214592075|NCT00003263|BIOLOGICAL|recombinant interferon alfa|vaccine
214592076|NCT00003263|DRUG|cisplatin|
214592077|NCT00003263|PROCEDURE|surgical procedure|
214592078|NCT00003263|RADIATION|radiation therapy|
214592079|NCT00338533|DEVICE|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
214592080|NCT04259073|DRUG|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
214592081|NCT04259073|DRUG|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
214592082|NCT04259073|DRUG|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
214592083|NCT00108147|PROCEDURE|Circuit Training|
214592084|NCT00108147|PROCEDURE|Cardiac Rehabilitation|
214592085|NCT00108147|PROCEDURE|Flexibility and toning|
214711000|NCT06875765|DIAGNOSTIC_TEST|MRI brain|Magnetic resonance imaging of brain volume.
214711001|NCT06396663|OTHER|Rapid Opioid de-escalation|"Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely"
214711002|NCT06396663|OTHER|Gradual Opioid de-escalation|Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
214592086|NCT03800459|BEHAVIORAL|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
214592087|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
214592088|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
214592089|NCT01287065|DRUG|Placebo AM|Inhalation powder
214592090|NCT01287065|DRUG|Placebo PM|Inhalation powder
214592091|NCT05916118|OTHER|Aerobic Exercise|Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
214592092|NCT00259987|DRUG|Lapatinib (GW572016) oral tablets|
214592093|NCT02875977|OTHER|Educational video|A 4-minute educational video describing PFPT
214592094|NCT02875977|OTHER|Educational handout|A 2-page educational handout describing PFPT
214592095|NCT06193460|DEVICE|low-level laser therapy|photobiomodulation mode of diode laser (low-level laser therapy).
214592096|NCT05318079|BEHAVIORAL|Virtual Reality Gaming|Peer-to-peer gaming.
214592097|NCT05049486|RADIATION|CT scan|Patients will undergone a pelvic CT scan.
214592098|NCT00005825|DRUG|cisplatin|
214592099|NCT00005825|DRUG|mitomycin C|
214592100|NCT00005825|DRUG|tretinoin|
214592101|NCT00005825|DRUG|vinorelbine tartrate|
214592102|NCT03904355|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
214592103|NCT03904355|DRUG|human chorionic gonadotropin|HCG triggering of ovulation
214592104|NCT03904355|PROCEDURE|Ovum pick up|34 to 36 hours after oocyte retrieval
214592105|NCT03904355|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
214592106|NCT01270087|DRUG|Adalimumab|40 mg IV every 14 days
214592107|NCT01362660|OTHER|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
214592108|NCT01718782|DEVICE|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
214592109|NCT01718782|DEVICE|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
214592110|NCT05591482|PROCEDURE|mesh repair|mesh repair of diaphragmatic hernia
214592111|NCT05902923|PROCEDURE|endovascular intervention|endovascular intervention
214592112|NCT03834987|OTHER|Neurodevelopmental Assessment|Developmental assessment at baseline and longitudinally as measured by age and ability-appropriate scales, including: the Mullen Scales of Early Learning, the Peabody Scales of Motor Development, the Vineland 3, and Beery Visual Motor Integration
214592113|NCT04367532|OTHER|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
214592114|NCT04367532|OTHER|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
214592115|NCT00098384|DRUG|rifaximin|
214592116|NCT01216033|DRUG|111-In-ABY-025|Intravenous injection of the agent
214711003|NCT06396663|OTHER|Continuation of opioids|Continue on opioids and review in 1 weeks time.
214592117|NCT03130010|DRUG|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
214592118|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
214592119|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
214592120|NCT01259726|OTHER|Placebo|10 mL placebo once daily for 14 days
214592121|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 14 days
214592122|NCT00841880|DRUG|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
214592123|NCT00841880|DRUG|Ramipril|10 mg once a day
214592124|NCT00841880|DRUG|Ramipril|5mg once a day
214711004|NCT00897325|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214711005|NCT00897325|OTHER|Laboratory Biomarker Analysis|Correlative studies
214592125|NCT02931825|BEHAVIORAL|Reminder letter|"The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
214592126|NCT02076217|DRUG|Copper T-380 IUD|
214592127|NCT02076217|DRUG|LNG IUD|
214592128|NCT02076217|DEVICE|Contraceptive implant Nexplanon|
214592129|NCT02076217|DRUG|Depo-Provera|
214592130|NCT02587429|BEHAVIORAL|Patient education|
214592131|NCT01586000|DRUG|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
214592132|NCT01586000|DRUG|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
214592133|NCT01586000|DRUG|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
214592134|NCT01679353|DRUG|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
214592135|NCT01679353|DRUG|normal saline 0.5ml|
214711006|NCT06627777|BEHAVIORAL|Laboratory tasks in early adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
214592136|NCT00244231|DRUG|Nidadd|
214592137|NCT05494060|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
214592138|NCT05494060|DRUG|Penpulimab Injection|Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
214592139|NCT05494060|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
214592140|NCT00634660|DRUG|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
214592141|NCT05226026|BEHAVIORAL|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
214592142|NCT05226026|OTHER|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
214592143|NCT00180921|DRUG|Imatinib|
214592144|NCT04097366|DIAGNOSTIC_TEST|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
214592145|NCT04097366|DIAGNOSTIC_TEST|CEM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
214592146|NCT04097366|DIAGNOSTIC_TEST|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
214592147|NCT00095069|DRUG|MK0928, gaboxadol / Duration of Treatment - 1 year|
214592148|NCT00095069|DRUG|Comparator: placebo / Duration of Treatment -1 year|
214592149|NCT00009620|DRUG|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
214592150|NCT00009620|DRUG|Saline|Infusion of normal sal
214592151|NCT02069210|OTHER|Blood transfusion|Intraoperative blood transfusion
214592152|NCT01886820|DRUG|[18F]NAV4694|
214592153|NCT01978262|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
214592154|NCT01847118|DRUG|Sevacizumab|
214592155|NCT03134157|DRUG|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
214592156|NCT03134157|DRUG|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
214592157|NCT03134157|DRUG|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
214592158|NCT03595605|BEHAVIORAL|Ambulation|This group will be encouraged twice daily to ambulate
214592159|NCT03595605|OTHER|Standard of Care|Care as usual at inpatient NYU Langone
214592160|NCT06017141|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214711007|NCT04465123|DRUG|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
214592161|NCT06017141|OTHER|Electronic Health Record Review|Ancillary studies
214592162|NCT06017141|DRUG|Fentanyl Citrate|Given via injection
214592163|NCT06017141|DRUG|Propofol|Given IV
214592164|NCT06017141|OTHER|Questionnaire Administration|Ancillary studies
214592165|NCT06017141|DRUG|Sevoflurane|Given via inhalation
214592166|NCT06017141|PROCEDURE|Surgical Procedure|Undergo SOC surgery
214592167|NCT06200064|OTHER|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
214592168|NCT06200064|OTHER|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
214592169|NCT04040400|RADIATION|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
214592170|NCT06135077|OTHER|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
214592171|NCT06135077|OTHER|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
214592172|NCT00460174|BIOLOGICAL|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
214592173|NCT00460174|DRUG|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
214592174|NCT00460174|PROCEDURE|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
214592175|NCT00460174|RADIATION|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
214592176|NCT02959450|DIETARY_SUPPLEMENT|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
214592177|NCT05785234|DRUG|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
214592178|NCT05785234|DRUG|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
214592179|NCT00399230|DRUG|Optive|
214592180|NCT01548157|DRUG|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
214592181|NCT06120348|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
214592182|NCT06120348|DEVICE|Sham Stimulation|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
214592183|NCT04540848|DRUG|Group A (Exparel plus supraclavicular block)|"Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
214634493|NCT00940355|BEHAVIORAL|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
214634494|NCT06093139|DIETARY_SUPPLEMENT|Probiotic capsule|probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules
214634495|NCT06093139|DIETARY_SUPPLEMENT|Placebo|placebo consisted of the same capsules filled with potato starch
214634496|NCT06063421|DEVICE|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
214592184|NCT04540848|DRUG|Group B (Bupivacaine HCL plus supraclavicular block)|"Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
214592185|NCT04540848|DRUG|Group C(supraclavicular block only)|"In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
214592186|NCT02148419|OTHER|no intervention|
214592187|NCT00027781|DRUG|sabarubicin|
214592188|NCT04578574|OTHER|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
214592189|NCT04578574|DEVICE|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
214592190|NCT04578574|OTHER|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
214592191|NCT03909217|PROCEDURE|TECAS Procedure|"Location:~1. Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~2. Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
214592192|NCT03909217|DRUG|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
214592193|NCT03909217|DRUG|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
214592194|NCT02742623|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
214592195|NCT06450431|OTHER|SF-36 questionnaire French version and PAS.fr questionnaire|Patients will receive both the SF-36 questionnaire (control generic questionnaire for QoL evaluation validated in French language) and the PAS.fr questionnaire at the designated time (before surgery, 6, 12 or 36 months after surgery) during the consultation, or by mail. For concurrent validation of the PAS.fr questionnaire, a second questionnaire will be sent to the patients 2-4 weeks thereafter.
214592196|NCT00196404|DRUG|DR-3001a|4mg daily vaginally
214592197|NCT00196404|DRUG|DR-3001b|6 mg vaginally daily
214592198|NCT00196404|OTHER|Placebo|Administered vaginally to match experimental arms
214592199|NCT01980550|DRUG|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
214592200|NCT05179720|OTHER|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
214592201|NCT00473681|BEHAVIORAL|Self-Help Intervention Program-High Blood Pressure|
214592202|NCT02435966|DEVICE|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
214592203|NCT02435966|DEVICE|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
214592204|NCT02435966|OTHER|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
214592205|NCT06494527|DRUG|RG002C0106|RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
214592206|NCT01268722|DEVICE|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
214592207|NCT01268722|DEVICE|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
214592208|NCT03136328|DRUG|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
214592209|NCT04334434|OTHER|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
214592210|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
214592211|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
214592212|NCT06048354|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
214592213|NCT05032079|PROCEDURE|cryoablation|single probe ultrasound guided cryoablation
214592214|NCT00490880|DRUG|gemcitabine|
214592215|NCT00490880|DRUG|cisplatin|
214592216|NCT00490880|PROCEDURE|radical cystectomy|
214592217|NCT00490880|PROCEDURE|radiotherapy|
214592218|NCT02168842|DRUG|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
214592219|NCT02168842|DRUG|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
214592220|NCT00325039|PROCEDURE|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
214592221|NCT00325039|PROCEDURE|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
214592222|NCT00418925|DRUG|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
214592223|NCT04873414|BIOLOGICAL|Convalescent plasma treatment|Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
214592224|NCT03749603|DEVICE|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
214592225|NCT02974088|DEVICE|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
214592226|NCT02974088|DEVICE|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
214592227|NCT00277108|DRUG|Escitalopram (Lexapro)|
214592228|NCT00426153|DRUG|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
214592229|NCT00426153|DRUG|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
214592230|NCT02962544|PROCEDURE|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
214592231|NCT02962544|PROCEDURE|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
214592232|NCT02962544|DEVICE|Visumax device|
214592233|NCT02962544|DEVICE|FS 200 device|
214592234|NCT05138367|PROCEDURE|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
214711008|NCT04465123|DRUG|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
214592235|NCT04433273|DEVICE|Electrical vestibular nerve stimulation|Electrical vestibular nerve stimulation using a headset device
214592236|NCT00509808|DEVICE|Electrostimulation|"1. 1st month GN wearing (activated or sham mode)~2. 2nd month wearing (opposite mode)~3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
214592237|NCT02891603|DRUG|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
214592238|NCT02891603|DRUG|Sirolimus|Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
214592239|NCT02891603|DRUG|Tacrolimus|Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
214592240|NCT02891603|PROCEDURE|Allogenic hematopoietic cell transplant (alloHCT)|Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
214711009|NCT02550314|DRUG|fiblast,gelatin sponge,fibrin glue|
214592241|NCT05172349|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
214592242|NCT00687973|DRUG|Valsartan/amlodipine 80/5 mg tablets|
214592243|NCT00687973|DRUG|Amlodipine 5 mg capsules|
214592244|NCT00687973|DRUG|Amlodipine 10 mg capsules|
214592245|NCT00687973|DRUG|Atenolol 50 mg tablets|
214592246|NCT00687973|DRUG|Atenolol 100 mg tablets|
214592247|NCT00219648|DRUG|PEP03|
214592248|NCT01656382|DRUG|ABLC|
214592249|NCT02816242|OTHER|concept map teaching|teaching anatomy using concept map to improve critical thinking
214592250|NCT02816242|OTHER|traditional teaching|teaching anatomy using lecture
214592251|NCT04932668|OTHER|Feasibility and Impact of Home-based Electrical Stimulation Program|"Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion."
214592252|NCT03049176|DRUG|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
214592253|NCT03049176|DRUG|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
214592254|NCT03049176|PROCEDURE|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
214592255|NCT03049176|PROCEDURE|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
214592256|NCT05169320|DEVICE|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
214592257|NCT05169320|PROCEDURE|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
214634497|NCT06063421|DRUG|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
214634498|NCT01507272|DRUG|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
214634499|NCT01507272|DRUG|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
214634500|NCT01507272|DRUG|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
214634501|NCT01507272|DRUG|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
214634502|NCT03648697|BIOLOGICAL|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
214634503|NCT03326843|DRUG|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
214634504|NCT03324997|DRUG|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
214634505|NCT03324997|DRUG|Saline|Saline as placebo
214634506|NCT03324997|DEVICE|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
214592258|NCT05169320|PROCEDURE|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~1. Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~2. Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity \[≤5 mm\] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
214592259|NCT03155256|PROCEDURE|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
214592260|NCT03155256|PROCEDURE|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
214592261|NCT05639335|OTHER|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
214592262|NCT05639335|OTHER|Experimental Characters|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
214592263|NCT02286778|DIETARY_SUPPLEMENT|Acetogenins|Acetogenins BID for 12 months
214592264|NCT02286778|DIETARY_SUPPLEMENT|Placebo|
214592265|NCT06099847|DEVICE|Sham TENS Stimulation|Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
214592266|NCT06099847|DEVICE|Sacral TENS Stimulation|Sacral TENS stimulation have been applied to directly the skin of sacral area.
214592267|NCT01005433|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
214592268|NCT01005433|DRUG|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
214592269|NCT03650478|DEVICE|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
214592270|NCT03650478|DEVICE|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
214592271|NCT05031208|DIAGNOSTIC_TEST|Memory task|Word recognition task
214634507|NCT00942474|DEVICE|Facilitate nerve stimulation lead placement with the nerve access tool|
214634508|NCT03703973|DIAGNOSTIC_TEST|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
214634509|NCT04192578|DEVICE|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
214634510|NCT00312910|DRUG|Probiotics-Bio-plus|
214634511|NCT05244681|OTHER|Semi-structured interview|Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
214711010|NCT03509571|OTHER|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
214592272|NCT05695625|OTHER|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
214592273|NCT05695625|OTHER|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
214592274|NCT00888446|BIOLOGICAL|tgAAC09|
214592275|NCT00888446|BIOLOGICAL|tgAAC09|
214592276|NCT00888446|BIOLOGICAL|tgAAC09|
214592277|NCT00888446|OTHER|Formulation buffer|Sterile isotonic buffered salt solution
214592278|NCT02749240|OTHER|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
214592279|NCT02483182|DRUG|ZEP-3 ointment 1.0%|
214592280|NCT02483182|DRUG|Acyclovir cream 5%|
214592281|NCT01731509|OTHER|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
214592282|NCT02261051|OTHER|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
214592283|NCT00343252|DRUG|teriparatide|20 ug/day, subcutaneous, 18 months
214592284|NCT00343252|DRUG|risedronate|35 mg/once weekly, oral, 18 months
214592285|NCT00343252|DRUG|placebo|once weekly, oral, 18 months
214592286|NCT00343252|DRUG|placebo|daily, subcutaneous, 18 months
214592287|NCT00572390|DRUG|oestrogen|Cyclic oestrogen substitution therapy
214592288|NCT00459160|PROCEDURE|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
214592289|NCT06087016|OTHER|Urine vibrational analysis|Urine vibrational analysis
214592290|NCT02490202|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
214592291|NCT02490202|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
214592292|NCT03378505|BEHAVIORAL|Mobile App|Purposeful Living Mobile App JOOL to be used daily
214592293|NCT03378505|BEHAVIORAL|Reflection|Bi-weekly online reflection question
214592294|NCT00096720|DRUG|levodopa|
214592295|NCT00096720|DRUG|Mirapex (pramipexole)|
214592296|NCT00096720|PROCEDURE|[123I]ß-CIT and SPECT imaging|
214592297|NCT03742167|OTHER|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
214592298|NCT01603186|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
214592299|NCT01603186|DRUG|Quetiapine Fumarate|25 mg tablet once a day
214711011|NCT03509571|OTHER|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
214592300|NCT02414581|DRUG|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
214592301|NCT02414581|DRUG|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
214592302|NCT02414581|DRUG|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
214592303|NCT00988871|DEVICE|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
214592304|NCT03090815|GENETIC|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
214592305|NCT03453931|DRUG|Corticosteroid injection|Intravenous high dose corticosteroids
214592306|NCT01740323|DRUG|Placebo|daily placebo for 6 weeks
214592307|NCT01740323|DRUG|Curcumin|500 mg BID
214592308|NCT02077569|DRUG|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
214592309|NCT05831813|BEHAVIORAL|Goal-Based Cognitive Behavioural Intervention|A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
214592310|NCT02083484|BIOLOGICAL|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
214592311|NCT05286697|DIAGNOSTIC_TEST|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
214592312|NCT02274194|DEVICE|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
214592313|NCT02274194|DEVICE|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
214592314|NCT04246567|PROCEDURE|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
214592315|NCT04246567|DRUG|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
214592316|NCT03975595|BEHAVIORAL|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
214592317|NCT03975595|BEHAVIORAL|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
214592318|NCT06486038|DIAGNOSTIC_TEST|MRI standard and qMRI|Non-contrast cervical spine MRI including morphological and quantitative MRI sequences on a 3 Tesla scanner. MRI examination includes conventional and experimental sequences
214592319|NCT06486038|OTHER|MEPs and SSEPs|Neurophysiological examination by motor and somatosensorial evocked potential using transcranial magnetic stimulation and electrical stimulation to the peripheral nerve
214592320|NCT06486038|OTHER|Neuromotor assessment|Upper and Lower limb assessment: Purdue Pegboard Test (PTT), Box and Block test (BBT), Nine Hole Peg Test (NHPT), gait analysis and 30 seconds sit to stand test (30CST)
214711012|NCT07026162|DRUG|Oliceridine|For gynecological laparoscopic surgery, general anesthesia was induced with Oliceridine at a dose of 0.06 mg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was administered with a total dose of Oliceridine ranging from 0.1 to 0.15 mg/kg. Postoperatively, Oliceridine was administered through a patient-controlled analgesia (PCA) system.
214592321|NCT06486038|PROCEDURE|Anterior cervical discectomy and fusion|If applicable: Anterior cervical discectomy and fusion surgery using PEEK or modern carbon fiber material
214592322|NCT01589354|PROCEDURE|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
214592323|NCT01589354|PROCEDURE|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
214592324|NCT01589354|DEVICE|Ultrasound guided technique|The block will be performed under U/S guidance
214592325|NCT01589354|DRUG|Ropivacaine|20ml of 0.375% Ropivacaine
214592326|NCT01589354|DRUG|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
214592327|NCT05709795|PROCEDURE|Confluent areas|Use of omnipolar technology to guide CTI ablation in sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
214592328|NCT05709795|PROCEDURE|Wave Speed|Use of omnipolar technology to guide CTI ablation in sites with low wave speed. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
214592329|NCT05709795|PROCEDURE|Voltage|Use of omnipolar technology to guide CTI ablation in sites with high voltage. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then CTI line (gold standard)
214592330|NCT05709795|PROCEDURE|CTI line|Do not use omnipolar information. CTI line performance
214592331|NCT04743154|OTHER|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
214592332|NCT04743154|OTHER|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
214592333|NCT02577757|DEVICE|MRI|MRI
214592334|NCT02875093|DRUG|ADI-PEG 20|Investigational Medicine
214592335|NCT02875093|DRUG|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
214592336|NCT05300360|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase enzyme deficiency test
214592337|NCT02976454|BEHAVIORAL|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
214592338|NCT02976454|BEHAVIORAL|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
214592339|NCT01704820|PROCEDURE|Retroflexion in the right colon|
214592340|NCT00609882|OTHER|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
214592341|NCT00609882|OTHER|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
214592342|NCT03421093|PROCEDURE|Surgeries|Surgeries or surgeries plus adjuvant therapies
214592343|NCT02019927|DEVICE|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
214592344|NCT02019927|DEVICE|Sham|Sham
214592345|NCT00705354|DRUG|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
214592346|NCT00705354|PROCEDURE|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
214592347|NCT01492465|DRUG|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
214592348|NCT03524300|PROCEDURE|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
214592349|NCT03524300|PROCEDURE|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
214592350|NCT02618031|PROCEDURE|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.
214592351|NCT00246402|DRUG|Acipimox|
214592352|NCT06176339|DRUG|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
214592353|NCT06176339|DRUG|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
214592354|NCT03945825|DRUG|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
214592355|NCT03945825|BIOLOGICAL|Delta Inulin-CpG55.2|A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
214592356|NCT03945825|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
214592357|NCT03945825|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
214592358|NCT00371046|PROCEDURE|Transvaginal ultrasound cervical length|
214592359|NCT00371046|PROCEDURE|Cervicovaginal fetal fibronectin|
214592360|NCT03741647|DIAGNOSTIC_TEST|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
214592361|NCT00705835|BIOLOGICAL|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
214592362|NCT02546895|OTHER|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
214592363|NCT02317081|DEVICE|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
214592364|NCT05041855|BEHAVIORAL|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
214592365|NCT05041855|BEHAVIORAL|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
214592366|NCT05488574|OTHER|Deep breathing with Yoga positioning|Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
214592367|NCT05397860|PROCEDURE|Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes|Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
214592368|NCT04716530|OTHER|No intervention is associated with the study.|No intervention is associated with the study.
214592369|NCT02373553|OTHER|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
214711013|NCT07026162|DRUG|Sufentanil|For gynecological laparoscopic surgery, general anesthesia was induced with Sufentanil at a dose of 0.3 µg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was provided with a total dose of Oliceridine ranging from 0.5 to 0.8 µg/kg. Postoperatively, Sufentanil was administered through a patient-controlled analgesia (PCA) system.
214592370|NCT02373553|OTHER|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
214592371|NCT05291767|OTHER|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
214592372|NCT05291767|BEHAVIORAL|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
214592373|NCT01610011|DIETARY_SUPPLEMENT|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
214592374|NCT05139433|BEHAVIORAL|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
214592375|NCT05139433|BEHAVIORAL|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
214592376|NCT00977054|DRUG|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
214592377|NCT00977054|DRUG|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
214592378|NCT01638117|OTHER|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
214592379|NCT01638117|DRUG|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
214592380|NCT01638117|DRUG|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
214592381|NCT01638117|DRUG|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
214592382|NCT01638117|OTHER|Saline|Saline, Daily for up to 21 days
214592383|NCT01638117|OTHER|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
214592384|NCT04270630|BEHAVIORAL|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
214592385|NCT02238522|DRUG|ZEN003365|
214592386|NCT02231853|BIOLOGICAL|MVST|MVST Infusion
214592387|NCT02231853|BIOLOGICAL|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
214592388|NCT04727853|DRUG|irinotecan liposome injection|Drug: irinotecan liposome injection
214592389|NCT06130748|DEVICE|Hybrid Hyrax|these patents will be treated using Two mini-screws supported hybrid hyrax
214592390|NCT01423253|DRUG|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
214592391|NCT06101433|DIETARY_SUPPLEMENT|Soy isoflavone|the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
214592392|NCT06101433|OTHER|Placebo|the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
214592393|NCT00701077|DRUG|3,4-Di-amino-Pyridine|a single 20 mg dosing
214592394|NCT00701077|DRUG|placebo|placebo
214592395|NCT03519165|DEVICE|EV1000(FloTrac System 4.0)|
214592396|NCT00307125|DRUG|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
214592397|NCT00307125|DRUG|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
214592398|NCT00051363|DEVICE|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
214592399|NCT00051363|DEVICE|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
214592400|NCT04746443|OTHER|NOT APPLICABLE (NA)|THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
214592401|NCT04722926|OTHER|PJI|patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
214592402|NCT01301820|DRUG|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
214592403|NCT01301820|DRUG|Lenalidomide|lenalidomide 10mg/d (d1- d21)
214592404|NCT03438786|PROCEDURE|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
214592405|NCT03438786|PROCEDURE|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
214592406|NCT00025103|BIOLOGICAL|dactinomycin|
214592407|NCT00025103|DRUG|carboplatin|
214592408|NCT00025103|DRUG|cyclophosphamide|
214592409|NCT00025103|DRUG|doxorubicin hydrochloride|
214592410|NCT00025103|DRUG|etoposide|
214592411|NCT00025103|DRUG|melphalan|
214592412|NCT00025103|DRUG|vincristine sulfate|
214592413|NCT00025103|PROCEDURE|autologous bone marrow transplantation|
214592414|NCT00025103|PROCEDURE|conventional surgery|
214592415|NCT00025103|PROCEDURE|peripheral blood stem cell transplantation|
214592416|NCT00025103|RADIATION|radiation therapy|
214592417|NCT01183078|PROCEDURE|free-hand|Free-hand technique utilizes x-rays to find screw holes.
214592418|NCT01183078|PROCEDURE|Wand technique|Wand technique is utilized to find screw holes.
214592419|NCT02437734|PROCEDURE|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
214592420|NCT00985153|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
214592421|NCT00985153|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
214592422|NCT00985153|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
214592423|NCT02319577|DRUG|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
214592424|NCT02319577|DRUG|Gefitinib|EGFR tyrosine kinase inhibitor
214592425|NCT06270472|PROCEDURE|hernioplasty|"The polysome repair was carried out as described by pelisse . In the case of a lateral hernia, the spermatic cord was mobilised and the cremasteric fibers were separated (in men). The hernia sac was dissected from the cord structures and reduced in the preperitoneal space through the internal ring. A dissection gauze was inserted through the internal ring to create the preperitoneal space. The medial border of the internal ring and the epigastric vessels were lifted with a refractor and blunt digital dissection was carried out in the preperitoneal space in all directions. A pocket was created to allow a complete expansion of the mesh. The conventional mesh was introduced with blunt forceps and, after the gauze has been removed, positioned in the preperitoneal space .~In the case of a medial hernia, the preperitoneal space was reached by incising the transversalis fascia around the base of the sac. Completion of the repair is the same as the lateral hernia procedure."
214592426|NCT03003559|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
214592427|NCT00865969|DRUG|Belinostat|
214592428|NCT04219397|OTHER|Medication take back|Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
214592429|NCT04219397|OTHER|Medication home disposal|Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
214592430|NCT03500250|OTHER|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
214592431|NCT05803616|DIAGNOSTIC_TEST|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
214592432|NCT03968393|DRUG|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
214592433|NCT02083666|DRUG|SOBI002|Test Product
214592434|NCT02083666|DRUG|Placebo|Reference product
214592435|NCT02039960|DRUG|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
214592436|NCT00546130|DRUG|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214592437|NCT00546130|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214592438|NCT00546130|DRUG|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
214592439|NCT00221741|DRUG|Fresh Frozen Plasma (blood product)|
214592440|NCT02748720|OTHER|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
214592441|NCT06441721|DEVICE|Vitamin b12 measure|Measure vitamin b12 in serum and its impact on Haemodialysis patient
214592442|NCT04157140|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
214592443|NCT04157140|DEVICE|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
214592444|NCT05101616|DRUG|camrelizumab+chemotherapy|camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
214592445|NCT05101616|DRUG|Chemotherapy|albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
214592446|NCT01329965|DRUG|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
214592447|NCT01941134|DRUG|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
214592448|NCT05830578|DEVICE|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
214592449|NCT02728882|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
214592450|NCT02997371|DRUG|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
214592451|NCT02997371|DRUG|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
214592452|NCT05147883|BEHAVIORAL|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
214592453|NCT06493331|OTHER|Talking Circle|"step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received."
214592454|NCT06257992|OTHER|Dry Needling|3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
214592455|NCT06257992|OTHER|Stretch|3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
214592456|NCT00001023|DRUG|Clarithromycin|
214592457|NCT00001023|DRUG|Azithromycin|
214592458|NCT00001023|DRUG|Rifabutin|
214592459|NCT02306382|PROCEDURE|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
214592460|NCT02306382|DEVICE|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
214592461|NCT01596621|DRUG|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
214592462|NCT02373254|DRUG|Ibuprofen|Ibuprofen 400 mg and 800 mg
214592463|NCT02373254|DRUG|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
214592464|NCT03846141|OTHER|Placebo|Inhalation of room air for 20 min per day during 7 days
214592465|NCT03846141|OTHER|Hydrogen|Inhalation of 4% hydrogen for 20 min per day during 7 days
214592466|NCT03868605|DEVICE|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
214592467|NCT03868605|DEVICE|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
214592468|NCT04329832|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
214592469|NCT04329832|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
214592470|NCT02521467|BIOLOGICAL|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
214592471|NCT02521467|OTHER|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
214592472|NCT02491268|DRUG|Cilostazol|
214592473|NCT02491268|DRUG|Placebo|
214592474|NCT04757350|OTHER|Observational research, not applicable|Observational research, not applicable
214592475|NCT01280110|DRUG|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
214592476|NCT01280110|DRUG|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
214592477|NCT01249989|BEHAVIORAL|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
214592478|NCT01249989|BEHAVIORAL|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
214592479|NCT01249989|BEHAVIORAL|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
214592480|NCT03197779|DRUG|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
214592481|NCT03197779|DRUG|Aspirin|Oral administration
214592482|NCT03197779|OTHER|Placebo|Oral administration
214592483|NCT03080428|DIAGNOSTIC_TEST|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
214592484|NCT02678247|DEVICE|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
214592485|NCT02678247|DEVICE|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
214592486|NCT02038491|PROCEDURE|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
214592487|NCT00352911|DRUG|VGX-410 (Mifepristone)|
214592488|NCT00352911|DRUG|Placebo for VGX-410 (Mifepristone)|
214592489|NCT05358028|OTHER|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
214592490|NCT05358028|OTHER|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
214592491|NCT03107897|OTHER|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
214592492|NCT00971243|DRUG|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
214592493|NCT00971243|DRUG|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
214592494|NCT00971243|DRUG|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
214592495|NCT00971243|DRUG|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
214592496|NCT00971243|DRUG|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
214592497|NCT00517582|DRUG|HOE-140|Subcutaneous at time 0 and 6 hours
214592498|NCT00517582|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
214592499|NCT04578613|DRUG|ICP-022|ICP-022 at a dose of 150mg, QD
214592500|NCT04578613|DRUG|Chlorambucil|0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
214592501|NCT04578613|DRUG|Rituximab|375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
214592502|NCT06078839|DRUG|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
214592503|NCT06078839|DRUG|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
214592504|NCT00369304|DRUG|pharmacokinetic (how the body absorbs and eliminates) interaction|
214592505|NCT00697723|PROCEDURE|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
214592506|NCT00916825|BEHAVIORAL|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
214592507|NCT02265367|DRUG|Levomilnacipran|
214592508|NCT02265367|DRUG|Placebo|
214592509|NCT01847053|OTHER|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
214592510|NCT01847053|OTHER|Oatmeal|Oatmeal control, around 70g; without cinnamon
214592511|NCT02889003|DRUG|Pioglitazone + TKI|
214592512|NCT00292877|DRUG|SB-240563 (Mepolizumab)|
214592513|NCT02092220|DEVICE|Bionic Pancreas|
214592514|NCT02092220|DEVICE|Insulin pump with or without CGM|
214592515|NCT05900960|DIETARY_SUPPLEMENT|Tea|Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
214592516|NCT02866539|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
214592517|NCT02866539|DRUG|Placebo|Similar looking inactive powder
214592518|NCT04734327|PROCEDURE|Orthokine periradicular injection|Ultrasound guided injections
214592519|NCT04734327|PROCEDURE|Orthokine epidural injection|Ultrasound guided injections
214592520|NCT01414374|DRUG|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
214592521|NCT01414374|DRUG|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
214592522|NCT02127918|DRUG|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
214592523|NCT02935933|DRUG|bupivicaine|Paravertebral block
214592524|NCT02935933|DRUG|morphine|
214592525|NCT02935933|DRUG|Dexmedetomidine|
214592526|NCT00687817|DRUG|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
214592527|NCT03993860|DIETARY_SUPPLEMENT|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
214592528|NCT03993860|DIETARY_SUPPLEMENT|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
214592529|NCT00606957|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
214592530|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
214592531|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
214592532|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
214592533|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
214592534|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
214592535|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
214592536|NCT05384262|DRUG|Rosuvastatin|Subjects will receive rosuvastatin orally.
214592537|NCT03844490|OTHER|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
214592538|NCT03844490|OTHER|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
214592539|NCT04326504|OTHER|No intervention|This will be an observational study, no intervention will be performed
214592540|NCT00437723|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
214592541|NCT00002997|PROCEDURE|cryosurgery|
214592542|NCT02097641|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
214592543|NCT02097641|BIOLOGICAL|Plasma-Lyte A|Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
214592544|NCT00680589|BIOLOGICAL|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
214592545|NCT03894254|OTHER|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
214592546|NCT01231516|DRUG|GSK1349572|50mg once daily
214592547|NCT01231516|DRUG|Raltegravir|400mg twice daily
214592548|NCT01231516|DRUG|GSK1349572 Placebo|Inactive placebo tablet once daily
214592549|NCT01231516|DRUG|Raltegravir Placebo|Inactive placebo tablet twice daily
214592550|NCT01670123|BEHAVIORAL|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
214592551|NCT02105350|DRUG|MEK 162|
214592552|NCT02105350|DRUG|Gemcitabine|
214592553|NCT02105350|DRUG|Oxaliplatin|
214592554|NCT00414687|DRUG|Ventavis (Iloprost, BAYQ6256)|
214592555|NCT00026208|DRUG|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
214592556|NCT00026208|DRUG|Cyclophosphamide|650 mg/m², on week 1 and 5
214592557|NCT00026208|DRUG|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
214592558|NCT00026208|DRUG|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
214592559|NCT00026208|DRUG|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
214592560|NCT00026208|DRUG|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
214592561|NCT00026208|RADIATION|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
214592562|NCT03244735|OTHER|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
214592563|NCT02751567|OTHER|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
214592564|NCT02751567|OTHER|Untreated skin|One site is patched without treatment as control
214592565|NCT05609201|DIAGNOSTIC_TEST|HRCT Thorax|HRCT Thorax at 0, 6 and 12 months
214592566|NCT05609201|DEVICE|Glycocheck Endothelial Glycocalyx Assessment|Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months
214592567|NCT05609201|DIAGNOSTIC_TEST|Blood biomarkers|Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months
214592568|NCT05609201|DIAGNOSTIC_TEST|Peripheral leucocyte telomere length|HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months
214592569|NCT05609201|DIAGNOSTIC_TEST|Pulmonary function testing|Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months
214592570|NCT05609201|DIAGNOSTIC_TEST|Patient reported outcome measures|Electronic collection of patient reported outcome measures
214592571|NCT00969410|BIOLOGICAL|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
214592572|NCT00359190|DRUG|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
214592573|NCT00103051|DRUG|cisplatin|
214592574|NCT00103051|DRUG|gefitinib|
214592575|NCT00103051|DRUG|gemcitabine hydrochloride|
214592576|NCT00103051|PROCEDURE|conventional surgery|
214592577|NCT00103051|PROCEDURE|neoadjuvant therapy|
214592578|NCT02225353|DRUG|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
214592579|NCT02225353|DRUG|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
214592580|NCT02225353|DRUG|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
214592581|NCT02284451|OTHER|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
214592582|NCT01117857|DRUG|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
214592583|NCT02074163|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
214592584|NCT02074163|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
214592585|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592586|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592587|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592588|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592589|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592590|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592591|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592592|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592593|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592594|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
214592595|NCT02074163|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214592596|NCT02074163|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214592597|NCT04750785|OTHER|No Intervention|Administered as specified in the treatment arm.
214592598|NCT03998982|DRUG|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
214592599|NCT03998982|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
214592600|NCT02730598|DEVICE|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
214592601|NCT02730598|DEVICE|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
214592602|NCT05427604|OTHER|Olive oil|ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
214592603|NCT05427604|OTHER|Olive Oil|ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
214592604|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
214592605|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
214592606|NCT02845843|DRUG|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
214592607|NCT02845843|DRUG|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
214592608|NCT02146326|BEHAVIORAL|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
214592609|NCT02146326|BEHAVIORAL|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
214592610|NCT05569031|DRUG|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
214592611|NCT05569031|DRUG|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
214592612|NCT02910739|DRUG|MK-8931|MK-8931 40 mg
214592613|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
214711014|NCT06127966|PROCEDURE|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
214592614|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
214592615|NCT04866251|DIAGNOSTIC_TEST|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
214592616|NCT03813420|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
214592617|NCT03813420|BEHAVIORAL|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
214592618|NCT03813420|BEHAVIORAL|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
214592619|NCT01340651|DRUG|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
214592620|NCT03531944|OTHER|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
214592621|NCT03531944|OTHER|Usual care|Usual care with physician and as needed visit to the nurse
214592622|NCT04058756|DRUG|PDR001|PDR001
214592623|NCT04361942|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
214592624|NCT04361942|OTHER|Placebo|Intravenous injection of 100 ml physiological saline solution containing no cells
214592625|NCT03774966|PROCEDURE|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter \& IPACK block
214592626|NCT03774966|PROCEDURE|Adductor canal block + catheter|Adductor canal block + catheter
214592627|NCT02181387|DRUG|Acetaminophen|administered every 6 hours by mouth up to 4 doses
214592628|NCT02181387|DRUG|Placebo|
214592629|NCT05678751|DIAGNOSTIC_TEST|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
214592630|NCT02715791|BEHAVIORAL|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
214592631|NCT02715791|OTHER|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
214592632|NCT01406340|DRUG|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
214592633|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
214592634|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & CS|Test meal consumed with the control supplement
214592635|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
214592636|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & CS|Test drink consumed with the control supplement
214592637|NCT05321147|BIOLOGICAL|lacutamab|Patients will receive a fixed dose of 750mg as 1-hour IV infusion
214592638|NCT03866161|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment
214592639|NCT03073265|DEVICE|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
214592640|NCT05367115|OTHER|longitudinal observational study|longitudinal observational study
214592641|NCT01822509|BIOLOGICAL|Ipilimumab|Given IV
214592642|NCT01822509|OTHER|Laboratory Biomarker Analysis|Correlative studies
214592643|NCT01822509|BIOLOGICAL|Nivolumab|Given IV
214592644|NCT02849288|DEVICE|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
214592645|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
214592646|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
214592647|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
214592648|NCT04740554|BEHAVIORAL|Control Group Typically Developing|Control group with tipical development.
214592649|NCT02823366|DRUG|Fenofibrate|
214592650|NCT02823366|DRUG|UDCA|
214592651|NCT01696942|DRUG|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
214592652|NCT01696942|DRUG|Mesalamine|mesalamine 800 mg orally three times daily
214592653|NCT05235230|DRUG|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
214592654|NCT05235230|DRUG|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
214592655|NCT04039256|DEVICE|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
214592656|NCT00921596|PROCEDURE|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
214592657|NCT00265746|DRUG|Metformin|
214592658|NCT00265746|BEHAVIORAL|Lifestyle intervention - diet, physical activity|
214592659|NCT06370260|DEVICE|Hydrogen Carbamide/Peroxide Gel|"UNISEPT® ORAL GEL is an oral gel containing 10% w/v urea peroxide which releases 3.50% w/w hydrogen peroxide, glycerin, propylene glycol, carbopol, disodium EDTA, sodium saccharin, methyl salicylate, menthol, and water, serving as the active ingredient.~Participants should apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0., i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following gel application.Participants are asked to maintain their usual oral hygiene routine.~UNISEPT® ORAL GEL is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A."
214592660|NCT06370260|DEVICE|Placebo Gel|"Placebo gel is a similar (look-and-taste-alike) product to UNISEPT® ORAL GEL, made by the same manufacturer, without active ingredients, containing glycerin, propylene glycol, carbomer, menthol, sodium saccharin, methyl salicylate, triethanolamine.~Participants are called upon to apply the gel in exactly the same way as the experimental product, i.e apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0."
214592661|NCT01668511|BIOLOGICAL|ABT-981|Injection
214592662|NCT01668511|BIOLOGICAL|Placebo|Placebo Injection
214592663|NCT05997498|PROCEDURE|mechanical cervical dilatation|mechanical cervical dilatation during elective cesarean section
214592664|NCT03666936|OTHER|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
214592665|NCT01142856|BIOLOGICAL|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
214592666|NCT04031716|BEHAVIORAL|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
214592667|NCT03413735|OTHER|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
214592668|NCT03413735|OTHER|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
214592669|NCT04790019|BEHAVIORAL|Low energy availability|Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
214592670|NCT04790019|BEHAVIORAL|High impact jumping|Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
214592671|NCT05560347|OTHER|Hot water application|Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
214592672|NCT00680784|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
214592673|NCT00680784|OTHER|Placebo Patch|Placebo Patch
214592674|NCT04042493|BEHAVIORAL|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
214592675|NCT06499727|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
214592676|NCT06499727|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
214592677|NCT05972564|DRUG|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
214592678|NCT05972564|DRUG|Placebo|Placebo consists of gelatin capsules.
214592679|NCT06820710|OTHER|Physical activity|Appropriate exercises for supervised small group sessions will be prescribed by a physiotherapist or expert in exercise science. Each session will last approximately 40 minutes, three times a week, and will be based on the international guidelines for physical exercise in the elderly population, and the VIVIFRAIL Multicomponent Physical Exercise Program to Prevent Frailty and the Risk of Falls. Accelerometers and other wearable sensors (smartwatches) will be used to monitor the physical activity performed.
214592680|NCT06820710|OTHER|Cognitive stimulation|Cognitive stimulation will be delivered by expert neuropsychologists twice a week (48 sessions in total) for approximately 30 minutes. Residents will be divided into small groups (3-5 people) of similar cognitive level, and the intervention will be delivered using a computerized tool (REmote stimulation for COgnitive DEcline (RECODE) developed by researchers at the University of Padova with the aim of stimulating different domains (i.e., attention, working memory, visual memory, language, orientation and executive functions) through exercises of increasing difficulty.
214592681|NCT06820710|OTHER|Nutritional Intervention|Participants in the intervention group will be advised to follow a Mediterranean diet and will also receive functional foods; in particular, they will be offered 80 g/day of sourdough bread fortified with vegetable matrix rich in polyphenols (e.g., olive leaves) and 100 g/day of probiotic artichokes on alternate days.
214592682|NCT06820710|OTHER|Vaccinations|Participants in the intervention group will be offered to receive appropriate vaccinations according to the national vaccination calendar. Vaccine doses will be provided by the Department of Preventive Medicine, Vaccine Office, National Health Service, on prescription from the general practitioners.
214592683|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
214592684|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
214592685|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
214592686|NCT04980443|DIAGNOSTIC_TEST|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
214592687|NCT06598605|BEHAVIORAL|Parental Reflective Functioning Workshop|Four online workshop sessions via Zoom will be based on psycho-educational knowledge concerning emotional regulation and specialized in autism. The group size will be up to 15 participants, with each session lasting an hour and a half, after which participants will be asked to complete a reflective journal.
214592688|NCT06610253|DIETARY_SUPPLEMENT|Protein|"Controlled, randomized, single-blind, parallel-group, prospective. Planned, parallel, randomized, single-blind, controlled clinical trial (RCT). Participants will be randomly assigned to one of four interventions: Whey Protein Concentrate - WPC, Pea Protein Isolate - PPI, Rice Protein ISOLATE - RPI, a combination of PPI and RPI to see if the intervention works together in synergy.~The experiment was scheduled for week 8. Each participant will consume 30g of a dedicated preparation every day for 8 weeks. The planned measurements will be performed three times - before the experiment begins, after 4 and 8 weeks."
214592689|NCT06610136|DIETARY_SUPPLEMENT|Caffeine plus Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
214592690|NCT06610136|OTHER|Placebo + Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
214592691|NCT06610006|PROCEDURE|High Intensity Interval Training (HIIT)|High intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio followed by 5-7 min of cool-down period..A total of 15 sessions of high intensity interval training alone , for thrice a week on alternative days for 5 consecutive weeks will be given. Warm-up session consisting of stretching exercises prior to intervention and cool down session after intervention will also be done and vitals before and after the session will be taken.
214592692|NCT06610006|PROCEDURE|Isometric Wall Squat|For isometric wall squat, each training session will be composed of 4 × 2-min bouts of IWS followed by 2-min rest periods. In first week, participants will do squat training or there will be a protocol for selecting exercise intensity in which participants will be given 30-s to perform a wall squat to select a position that they predict would elicit an target RPE score by varying the squat height. Based on the final squat height and RPE score, after bout 4, participants will be given a starting squat height for training session 1 and will then be progressed in each week
214592693|NCT02664727|BEHAVIORAL|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
214592694|NCT02664727|BEHAVIORAL|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
214592695|NCT05180669|OTHER|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
214592696|NCT05180669|OTHER|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
214592697|NCT04715178|OTHER|No intervention- registry only|No intervention- registry only
214592698|NCT06991803|OTHER|root canal treatment and irrigation activation|After the teeth were isolated with a rubber dam, the endodontic access cavity was opened. Then, #10-15 K-type hand files were inserted into the canals, and after determining point 0.0 with the electronic apex locator, the working length was determined to be 0.5 mm shorter than this point and confirmed radiographically. When a discrepancy was observed, the apex locator was considered correct. The root canals were prepared with ProTaper Next up to 3 sizes larger than the initial diameter via a torque-controlled endodontic motor in 300 rpm/2-5.2 Ncm rotation mode. Between each file, the canals were irrigated with 5 ml of 2.5% NaOCl. In retreatment cases, after opening the access cavity under rubber dam isolation, the guta percha was removed with RT files, and the rest of the procedure was performed in the same manner as for primary root canal treatment.
214592699|NCT00322205|DRUG|zyban|
214592700|NCT06609564|DEVICE|inspiratory muscle training|Inspiratory muscle training with a pressure-adjustable device
214592701|NCT06609564|OTHER|Convantional chest physiotherapy|Chest physiotherapy
214592702|NCT06610708|OTHER|Cardiac Prehabilitation Program|Patients begin with a one-on-one assessment by a program cardiologist and a CR nurse, followed by a symptom-limited cardiopulmonary exercise test (CPET) to tailor their exercise regimen. The exercise program, based on the FITT (frequency, intensity, time, and type) principle, includes biweekly sessions either at home or at a commercial gym, with ongoing oversight by SJHC CRSP rehabilitation trainers. Additionally, participants have access to dietary counseling to optimize heart-healthy nutrition.
214592703|NCT06609720|PROCEDURE|(guided tissue regeneration)|Randomized clinical and radiographic trial
214592704|NCT01313117|DRUG|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
214592705|NCT00434915|DRUG|DHEA|
214592706|NCT01350453|BEHAVIORAL|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
214592707|NCT01350453|BEHAVIORAL|Standard Care|Participants will receive their usual care from their NHS provider.
214592708|NCT07020000|DEVICE|Device: Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during standard interbody fusion surgeries.
214592709|NCT07019181|DRUG|Tislelizumab|Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
214592710|NCT07019181|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks
214592711|NCT07019181|DRUG|Nedaplatin|Nedaplatin 80mg/m2，day 1 of every 3 weeks
214592712|NCT07020416|DEVICE|Transcutaneous electrical acustimulation in automatic synchronization with breathing|This intervention will be carried out via the AutoSTEA device.
214592713|NCT07020182|OTHER|physical therapy program|Group A will performed a physical therapy program that completed two daily sessions till discharge from the hospital .Exercise training starts from randomisation until hospital discharge,and administered twice per day, seven times per week. The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
214592714|NCT07021014|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
214592715|NCT07021014|DEVICE|Sham NightWare|NightWare decive will not deliver an intervention (i.e., no vibration)
214592716|NCT07019623|DEVICE|Rüsch® Balloon Catheter Ch. 24|"After cesarean delivery, patients in the intervention group receive the following intervention: The Rüsch® Balloon Catheter Ch. 24 will be inserted directly into the uterus before uterotomy closure.~After insertion of the catheter, the catheter balloon is filled with 60 - 80 ml of 0.9% saline solution and connected to the vacuum device whereby an intrauterine vacuum of -60 to a maximum of -70 kPa is applied once the uterotomy is closed. Once the catheter has been positioned, it is left in place for one hour as a prophylactic measure while a vacuum is applied.~The device will be removed by draining the liquid in the balloon, after 1 hour of vacuum-induced tamponade. The final decision for removal of the catheter in this study is made by the senior physician responsible for the woman."
214592717|NCT07019623|OTHER|Ultrasonography|The position of the balloon catheter as well as the condition of the uterine cavity are assessed immediately postoperatively using ultrasonography.
214592718|NCT03442114|BEHAVIORAL|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
214592719|NCT03442114|BEHAVIORAL|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
214592720|NCT02903368|DRUG|Apalutamide|
214592721|NCT02903368|DRUG|Leuprolide|
214592722|NCT02903368|DRUG|Prednisone|
214592723|NCT02903368|DRUG|Abiraterone Acetate|
214592724|NCT06892210|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
214592725|NCT06892210|DRUG|Hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
214592726|NCT06828172|BEHAVIORAL|Exercise|Two conditions will be tested: Arm-cranking and control condition.
214592727|NCT06888817|DRUG|Bevacizumab|Intravenous bevacizumab at a 600 mg flat dose every three weeks for four courses over 12 weeks
214592728|NCT06888817|DRUG|Dexamethasone|Daily oral dexamethasone followed by a protocol-based tapering dose over 12 weeks
214592729|NCT06805136|BEHAVIORAL|Community-based social interaction intervention|The intervention focuses on free or low-cost social interaction by offering community initiatives and activities, online spaces for interaction, and social events to young and working-age adults in London. Activities include but are not limited to social walks, bingo nights, board game afternoons and pub quizzes.
214592730|NCT06023407|OTHER|Water Immersion Heat Therapy|10-weeks of 3 days per week in 1 of the 2 arms
214592731|NCT05474599|OTHER|conventional physical therapy|TENS
214592732|NCT05474599|OTHER|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
214592733|NCT00329342|BEHAVIORAL|Occupational ergonomic training|Adequate postural habits in activities of daily living
214592734|NCT03660553|DRUG|Insulin Glargine|0.40 units/kg body weight
214592735|NCT03660553|DRUG|Insulin Glargine|0.20 units/kg body weight
214592736|NCT03660553|DRUG|Insulin Aspart|0.20 units/kg body weight
214592737|NCT03660553|DRUG|Insulin Lispro|0.20 units/kg body weight
214592738|NCT00171704|DRUG|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
214592739|NCT00171704|DRUG|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
214592740|NCT02253108|DEVICE|Everolimus eluting bioresorbable polymer stent|
214592741|NCT02253108|DEVICE|Biolimus eluting bioresorbable polymer stent|
214592742|NCT03336151|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
214592743|NCT02586922|DEVICE|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
214592744|NCT04335240|OTHER|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
214592745|NCT02749630|DRUG|Placebo|Matching placebo to UTTR1147A administered intravenously
214592746|NCT02749630|DRUG|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
214592747|NCT03295994|PROCEDURE|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
214592748|NCT03295994|PROCEDURE|Non-Operative|Physical therapy (without surgery).
214592749|NCT03296891|OTHER|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
214592750|NCT04897451|OTHER|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
214592751|NCT04058613|DRUG|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
214592752|NCT04058613|OTHER|placebo|placebo
214592753|NCT06177249|BIOLOGICAL|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
214592754|NCT06177249|BIOLOGICAL|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
214592755|NCT01907802|DRUG|Dabrafenib|Given PO
214592756|NCT01907802|OTHER|Laboratory Biomarker Analysis|Correlative studies
214592757|NCT01907802|OTHER|Pharmacogenomic Study|Correlative studies
214592758|NCT01907802|OTHER|Pharmacological Study|Correlative studies
214592759|NCT00223522|DEVICE|MEMS caps|
214592760|NCT00915304|BEHAVIORAL|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
214592761|NCT05780411|OTHER|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
214592762|NCT00205491|DRUG|Venlafaxine|
214592763|NCT03225495|PROCEDURE|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
214592764|NCT03225495|PROCEDURE|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
214592765|NCT04412629|DRUG|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
214592766|NCT04412629|PROCEDURE|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
214592767|NCT04412629|PROCEDURE|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
214592768|NCT03171077|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
214592769|NCT03171077|OTHER|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
214592770|NCT03171077|OTHER|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
214592771|NCT00893282|DEVICE|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
214592772|NCT00893282|DEVICE|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
214592773|NCT03956537|DEVICE|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
214592774|NCT03956537|DEVICE|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
214592775|NCT04262947|DEVICE|Near Infrared Vein Imaging|Use of NI vein imaging device for visualization of veins during peripheral IV placement
214592776|NCT04262947|OTHER|Conventional IV placement|IV placement utilizing conventional methods
214592777|NCT00816400|DRUG|MEDI-575|MEDI-575 as an IV infusion
214592778|NCT01319188|DRUG|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
214592779|NCT01319188|PROCEDURE|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
214592780|NCT01319188|OTHER|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
214592781|NCT04127890|DIETARY_SUPPLEMENT|ELO Water|oxygen-enriched water
214592782|NCT04127890|DIETARY_SUPPLEMENT|Placebo drinking water|bottled drinking water
214592783|NCT02672215|BEHAVIORAL|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
214592784|NCT02672215|BEHAVIORAL|generic advice|general, non-tailored web-based generic advice with tips
214592785|NCT03207685|DEVICE|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
214592786|NCT05925179|PROCEDURE|Surgical crown lengthening|Surgical clinical crown lengthening with bone excision
214592787|NCT05925179|DRUG|Augmentin|Pre-operative antibiotic prophylaxis (2 g Augmentin)
214592788|NCT00428623|PROCEDURE|wound dressing|
214592789|NCT05946278|OTHER|Sample collection for gene expression|This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
214592790|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
214592791|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
214592792|NCT00081770|DRUG|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
214592793|NCT00081770|BIOLOGICAL|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
214592794|NCT00081770|DRUG|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
214592795|NCT01399333|DIETARY_SUPPLEMENT|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
214592796|NCT01399333|DIETARY_SUPPLEMENT|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
214592797|NCT01399333|DIETARY_SUPPLEMENT|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
214592798|NCT03408054|DRUG|Oxytocin|Oxytocin 10-5M solution
214592799|NCT03408054|DRUG|Nitroglycerin|Nitroglycerin 25-1000mcg
214592800|NCT00191867|DRUG|Teriparatide|
214592801|NCT02552641|OTHER|Food effect|
214592802|NCT02552641|DRUG|Esomeprazole|
214592803|NCT02552641|DRUG|Amoxicillin|
214592804|NCT02552641|DRUG|Clarythromycin|
214592805|NCT00247585|DRUG|Ethanol (Bourbon or Vodka)|
214592806|NCT05125666|OTHER|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
214592807|NCT05125666|OTHER|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
214592808|NCT06498505|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
214592809|NCT06498505|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
214592810|NCT00601419|DRUG|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
214592811|NCT06178926|DRUG|Propofol|Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
214592812|NCT06178926|DRUG|Ciprofol|Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
214592813|NCT04897672|OTHER|Observational study|Observational study
214592814|NCT01614197|DRUG|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
214592815|NCT01614197|DRUG|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
214592816|NCT01614197|DRUG|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
214592817|NCT01614197|DRUG|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
214592818|NCT01614197|DRUG|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
214592819|NCT01614197|DRUG|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age"
214592820|NCT00948142|DRUG|CEM-102|600 mg BID oral tablets for 10-14 days
214592821|NCT00948142|DRUG|Linezolid|600 mg BID oral tablets
214592822|NCT00948142|DRUG|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
214592823|NCT01896154|DIETARY_SUPPLEMENT|NPS|Comparison of multiple dietary non-digestible polysaccharides
214592824|NCT05657717|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
214592825|NCT02245672|DRUG|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
214592826|NCT02245672|DRUG|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
214592827|NCT02245672|DRUG|Placebo|Placebo administered via the CRC749 and Diskus devices
214592828|NCT00003657|BIOLOGICAL|filgrastim|
214592829|NCT00003657|DRUG|Amifostine|
214592830|NCT00003657|DRUG|Carboplatin|
214592831|NCT00003657|DRUG|Etoposide|
214592832|NCT00003657|DRUG|Ifosfamide|
214592833|NCT00003657|PROCEDURE|peripheral blood stem cell transplantation|
214592834|NCT03740594|BEHAVIORAL|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
214592835|NCT02980237|OTHER|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
214592836|NCT02980237|OTHER|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
214592837|NCT06475443|DRUG|pyrotinib plus capecitabine|oral
214592838|NCT00153504|BEHAVIORAL|Housing and Health Study housing rental assistance|
214592839|NCT00153504|BEHAVIORAL|Standard local practice housing assistance|
214592840|NCT02947776|BEHAVIORAL|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
214592841|NCT02947776|BEHAVIORAL|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
214592842|NCT02580695|BIOLOGICAL|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
214592843|NCT02580695|DRUG|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
214592844|NCT00889317|DEVICE|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
214592845|NCT00971932|DRUG|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.
214592846|NCT00971932|DRUG|Cisplatin/Carboplatin|Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
214592847|NCT00971932|DRUG|5-Fluorouracil|Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
214592848|NCT05363423|PROCEDURE|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
214592849|NCT05363423|PROCEDURE|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
214592850|NCT02451241|OTHER|acupuncture|electroacupuncture
214592851|NCT01749020|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
214592852|NCT01749020|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
214592853|NCT02301598|PROCEDURE|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
214592854|NCT01305525|DEVICE|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
214592855|NCT01097785|DRUG|Simvastatin|40 mg, P.O.,daily for 30 days
214592856|NCT01097785|DRUG|Placebo|1 capsule daily for 30 days
214592857|NCT04334733|OTHER|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
214592858|NCT04334733|OTHER|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
214592859|NCT04334733|OTHER|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
214592860|NCT03940053|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
214592861|NCT01765192|DRUG|Roflumilast|Roflumilast was supplied in tablets.
214592862|NCT01765192|DRUG|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
214592863|NCT01765192|DRUG|Montelukast|Montelukast was supplied in tablets.
214592864|NCT03194815|DRUG|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
214592865|NCT03194815|DRUG|Placebo|This is the control, or sham, treatment
214592866|NCT03194815|DRUG|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
214592867|NCT05032768|RADIATION|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
214592868|NCT01322048|DRUG|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
214592869|NCT01322048|DRUG|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
214592870|NCT02797353|OTHER|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
214592871|NCT06445309|OTHER|Sensory test of functional plant-based drink|Once the volunteers have been recruited, a telephone interview lasting less than 10 minutes will be carried out where what the study consists of will be explained as well as the information sheet for the participant will be read to them so that they understand what the study consists of. study. Once the necessary questions have been asked according to the inclusion criteria, if the participant enters the study, data such as name, surname, age, gender, smoker, consumer of vegetable drinks, pathologies and contact information will be collected. If the participant does not enter the study, their personal data will no longer be collected and they will be informed that according to the exclusion criteria they can no longer participate in the study. Once these data are obtained, it will be randomized using the EXCEL program.
214592872|NCT00084578|DRUG|celecoxib|
214592873|NCT00084578|DRUG|rosiglitazone maleate|
214592874|NCT00084578|PROCEDURE|conventional surgery|
214592875|NCT00084578|PROCEDURE|neoadjuvant therapy|
214592876|NCT00519961|DEVICE|Elecsys®proBNP|
214592877|NCT03258333|PROCEDURE|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
214592878|NCT04694898|BEHAVIORAL|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
214592879|NCT04694898|BEHAVIORAL|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
214592880|NCT01924351|RADIATION|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
214592881|NCT03282487|DRUG|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
214592882|NCT02918123|BIOLOGICAL|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
214592883|NCT04344600|DRUG|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
214592884|NCT04344600|OTHER|Saline|Saline subcutaneous injection
214592885|NCT00846339|DRUG|Bupropion|bupropion
214592886|NCT04261335|BIOLOGICAL|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
214592887|NCT00036686|DIETARY_SUPPLEMENT|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
214592888|NCT00036686|OTHER|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
214592889|NCT00837551|DRUG|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
214592890|NCT00876694|DRUG|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
214592891|NCT00876694|DRUG|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
214592892|NCT02773875|DEVICE|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
214592893|NCT03506282|OTHER|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
214592894|NCT03506282|OTHER|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
214592895|NCT03506282|OTHER|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
214592896|NCT04559880|DRUG|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
214592897|NCT01535014|DRUG|Dietressa|Comparison of different dosages (frequency) of drug
214592898|NCT01535014|DRUG|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
214592899|NCT01209845|DRUG|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
214592900|NCT04549337|BEHAVIORAL|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity."
214592901|NCT04350216|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
214592902|NCT04925206|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
214592903|NCT01215422|PROCEDURE|timed intubation|timed intubation
214592904|NCT01875172|DRUG|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
214592905|NCT01875172|DRUG|placebo|
214592906|NCT01875172|BEHAVIORAL|smoking cessation counseling|
214592907|NCT01816854|DEVICE|Stenting|
214592908|NCT01708122|DRUG|Fentanyl|100 mcg in 1 mL intranasal spray
214592909|NCT01708122|DRUG|saline|Sodium Chloride 0.9% intranasal spray
214592910|NCT05175651|BEHAVIORAL|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
214592911|NCT06096896|PROCEDURE|MWA|Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
214592912|NCT00294554|DRUG|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
214592913|NCT00294554|DRUG|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
214592914|NCT05817760|PROCEDURE|Z-scrotoplasty|Z shape incision of the penoscrotal web and closure
214592915|NCT05817760|PROCEDURE|Heineke-Mikulicz scrotoplasty|Transverse incision of the penoscrotal web with vertical closure
214592916|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
214592917|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
214592918|NCT00710281|RADIATION|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
214592919|NCT00219713|DRUG|nitrous oxide and oxygen|
214592920|NCT02822170|OTHER|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
214592921|NCT02909270|DEVICE|Mediclore|to apply mediclore fully around thyroid gland
214592922|NCT04788576|DIAGNOSTIC_TEST|Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)|In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
214592923|NCT00462865|DRUG|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
214592924|NCT03516851|PROCEDURE|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
214592925|NCT04592861|RADIATION|carbon ion RT|daily carbon ion radiotherapy
214592926|NCT04592861|DRUG|Chemotherapy drug|Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
214592927|NCT00863863|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
214592928|NCT00863863|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
214592929|NCT05477381|DIAGNOSTIC_TEST|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
214592930|NCT04886310|DIAGNOSTIC_TEST|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
214592931|NCT01438021|OTHER|pharmacological study|Correlative studies
214592932|NCT01438021|DRUG|methotrexate|Given intraventricularly
214592933|NCT02864381|DRUG|Andecaliximab|800 mg administered via IV infusion
214592934|NCT02864381|DRUG|Nivolumab|3 mg/kg administered via IV infusion
214592935|NCT04507061|DRUG|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
214592936|NCT04507061|OTHER|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
214592937|NCT00152139|PROCEDURE|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
214592938|NCT00152139|DRUG|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
214592939|NCT02245126|DRUG|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
214592940|NCT02245126|DRUG|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
214592941|NCT05995639|PROCEDURE|Dry Needling|Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.
214592942|NCT05995639|PROCEDURE|Ozone Injection|Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
214592943|NCT05871255|OTHER|Zantogin® Gel|Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
214592944|NCT01992042|DRUG|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
214592945|NCT01992042|DRUG|Pimonidazole|
214592946|NCT01769235|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
214592947|NCT01769235|DRUG|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
214592948|NCT01769235|DRUG|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
214592949|NCT00007917|DRUG|alvocidib|
214592950|NCT00007917|DRUG|gemcitabine hydrochloride|
214592951|NCT04292002|BEHAVIORAL|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
214592952|NCT04142450|DEVICE|CoolSculpting® System|Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
214592953|NCT02262143|DRUG|Rosuvastatin|Rosuvastatin 10 mg, qd, po
214592954|NCT02262143|DRUG|Fenofibrate|Fenofibrate 160mg, qd, po
214592955|NCT01767207|OTHER|mental disorders|mental disorders
214592956|NCT01767207|BEHAVIORAL|screening for mental disorders|screening for mental disorders
214592957|NCT00474669|DRUG|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
214592958|NCT05172167|DIAGNOSTIC_TEST|Levels of IgG and IgM SARS-CoV-2 antibodies blood test.|0,1,2 months
214592959|NCT05172167|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2 nasopharyngeal swab|0,1,2 months
214592960|NCT00480584|DRUG|gemcitabine|Levels 1 through 4: 1000 mg/m\^2
214592961|NCT00480584|DRUG|capecitabine|Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
214592962|NCT00480584|DRUG|erlotinib|Levels 1 through 4: 100 mg
214592963|NCT05579158|BEHAVIORAL|Mobile application and wearable device|Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
214592964|NCT05579158|BEHAVIORAL|Time-restricted eating|Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
214711015|NCT06127966|PROCEDURE|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
214592965|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
214592966|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
214592967|NCT01177605|OTHER|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
214592968|NCT03450798|DEVICE|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
214592969|NCT03450798|DEVICE|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
214592970|NCT00861835|OTHER|ROSE|rapid on-site evaluation by cytopathology
214592971|NCT02544217|DRUG|KH176|
214592972|NCT02544217|DRUG|placebo|
214592973|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
214592974|NCT06292650|DRUG|ZM-02-L|rAAV-PsCatCh2.0 intravitreal injection of low dose
214592975|NCT06292650|DRUG|ZM-02-H|rAAV-PsCatCh2.0 intravitreal injection of high dose
214592976|NCT06292650|PROCEDURE|ZM-02-S|sham intravitreal injection of ZM-02 (not actual injection)
214592977|NCT01727622|DRUG|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
214592978|NCT01727622|OTHER|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
214592979|NCT01727622|PROCEDURE|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
214592980|NCT05398016|BEHAVIORAL|low-intensity intervention for anxiety|Brief (6-8 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
214592981|NCT02736773|OTHER|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
214592982|NCT05171439|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
214592983|NCT00647673|DRUG|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
214592984|NCT00647673|DRUG|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
214592985|NCT02377791|GENETIC|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5\*1/\*1 vs CYP3A5\*1/\*3 or CYP3A5\*3/\*3
214592986|NCT05165147|OTHER|no intervention|no intervention
214592987|NCT02883283|PROCEDURE|Epidural loading dose|Labor epidural analgesia loading dose
214711016|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
214711017|NCT02601066|DEVICE|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
214711018|NCT01413048|DRUG|Carvedilol 25mg|Tablet, q.d.
214592988|NCT02883283|DEVICE|Epidural catheter|Epidural loading dose via epidural catheter
214592989|NCT02883283|DEVICE|Epidural needle|Epidural loading dose via epidural needle
214592990|NCT02752646|DRUG|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
214592991|NCT02752646|DRUG|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
214592992|NCT03651986|DIAGNOSTIC_TEST|ctDNA methylation analysis by NGS|A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)
214592993|NCT02598752|OTHER|Symptom-limited cardiopulmonary exercise test (CPET)|
214592994|NCT02598752|OTHER|Resting assessment of cardiac function by echocardiography|
214592995|NCT02598752|OTHER|Post-exercise assessment of cardiac function by echocardiography|
214592996|NCT02598752|OTHER|Pulmonary function|
214592997|NCT02598752|BEHAVIORAL|Patient-reported outcomes questionnaire|
214592998|NCT01744951|BEHAVIORAL|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
214711019|NCT01413048|DRUG|AGSCT101 12.5mg|Tablet, q.d.
214711020|NCT00780052|DRUG|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
214711021|NCT02746523|OTHER|Sensory Organization Test|Balance and proprioception test
214711022|NCT02746523|GENETIC|Biomarkers|Blood, urine, and saliva biomarkers
214592999|NCT01146054|DEVICE|CyberKnife based stereotactic radiotherapy|"1. Initial orthogonal images will be obtained to confirm location of fiducial seeds.~2. Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~3. Quality assurance will be performed as per standard practice at each participating institution."
214593000|NCT01146054|DRUG|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
214593001|NCT01146054|DRUG|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
214593002|NCT03439176|OTHER|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
214593003|NCT03439176|OTHER|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
214593004|NCT03439176|OTHER|PL4|This strip contains a new adhesive
214593005|NCT03439176|OTHER|PL16-L|This strip contains a new adhesive
214593006|NCT02422056|DRUG|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
214593007|NCT02422056|DRUG|Saline|Infusion of saline in the same rate used for the intervention group
214593008|NCT02237651|DEVICE|topical anesthesia multi-use device|
214593009|NCT02237651|DEVICE|topical anesthesia Intranasal Mucosal Atomization|
214593010|NCT02397811|DIETARY_SUPPLEMENT|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
214593011|NCT02397811|DIETARY_SUPPLEMENT|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
214593012|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
214593013|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
214593014|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
214593015|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
214593016|NCT04335812|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
214593017|NCT04643509|DEVICE|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
214593018|NCT02113241|DRUG|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
214593019|NCT02113241|DRUG|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
214593020|NCT02065141|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
214593021|NCT06328426|DIETARY_SUPPLEMENT|Vitamin D|The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
214593022|NCT06328426|DIETARY_SUPPLEMENT|Omega-3|The dose of omega-3 will be 1000 mg /day taken orally. The duration of the intervention will be 4 months.
214593023|NCT06328426|DRUG|Metformin|The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
214593024|NCT06328426|DIETARY_SUPPLEMENT|Placebo|The duration of the intervention will be 4 months.
214593025|NCT02818088|BEHAVIORAL|n-Back (Cognitive Training)|
214593026|NCT04847960|DIETARY_SUPPLEMENT|BioGaia Probiotic Lozenges|BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
214593027|NCT02090374|OTHER|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
214593028|NCT02090374|OTHER|Poly I:C|Single dose: 500ug
214593029|NCT02090374|OTHER|R848|High dose: 10ug Low dose: 1-2ug
214593030|NCT02090374|OTHER|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
214593031|NCT02090374|OTHER|Vitamin D|4000U orally
214593032|NCT02090374|OTHER|Tuberculin|Tuberculin PPD
214593033|NCT00216697|DRUG|bortezomib|
214593034|NCT02901041|DRUG|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
214593035|NCT02901041|BEHAVIORAL|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
214593036|NCT02901041|DRUG|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
214593037|NCT01249937|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
214593038|NCT01249937|DRUG|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
214593039|NCT03243045|PROCEDURE|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
214593040|NCT04744051|DRUG|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
214711023|NCT02746523|OTHER|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
214711024|NCT02746523|OTHER|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
214593041|NCT04744051|DRUG|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
214593042|NCT04744051|DRUG|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
214711025|NCT02746523|OTHER|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
214711026|NCT07036653|DIAGNOSTIC_TEST|spinal ultrasound|Coronal, axial, sagittal scans of the spine using ultrasound
214711027|NCT01265420|BIOLOGICAL|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
214593043|NCT04744051|DRUG|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
214593044|NCT00975507|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
214593045|NCT00975507|BIOLOGICAL|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
214593046|NCT00975507|BIOLOGICAL|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
214593047|NCT00975507|BIOLOGICAL|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
214593048|NCT04047238|OTHER|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~* Welcome to the patient and reality orientation therapy (7 minutes)~* Conducting the main activity of reminiscence (40 minutes)~* Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
214593049|NCT00493545|BIOLOGICAL|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
214593050|NCT06441188|DIAGNOSTIC_TEST|Thin layer conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.
214593051|NCT06441188|DIAGNOSTIC_TEST|Thick layer of conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.
214593052|NCT06441188|DIAGNOSTIC_TEST|Thin conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.
214593053|NCT06441188|DIAGNOSTIC_TEST|Thick conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
214593054|NCT00194766|DRUG|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
214593055|NCT03249714|DRUG|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
214593056|NCT03249714|DRUG|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
214593057|NCT06024681|OTHER|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
214593058|NCT02882113|DRUG|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
214593059|NCT05512754|DRUG|Ibuprofen 400 mg|400 mg tablet
214593060|NCT03906435|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
214593061|NCT00605644|DRUG|MOA-728|Oral Capsules
214593062|NCT00605644|DRUG|Placebo|Placebo
214593063|NCT00219453|DEVICE|Jet Injector with Protector Cap (HSI-500)|
214711028|NCT02667379|OTHER|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
214593064|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
214593065|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
214593066|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
214593067|NCT06016309|OTHER|There is no intervention.|There is no intervention.
214593068|NCT04805190|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
214593069|NCT04805190|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
214593070|NCT01306097|DRUG|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
214593071|NCT00379743|BEHAVIORAL|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
214593072|NCT00379743|BEHAVIORAL|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
214593073|NCT02679131|DRUG|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
214593074|NCT02866084|DEVICE|Device|"The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
214711029|NCT06884540|DRUG|Dexmedetomidine|"Intravenous bolus: between 0.2 and 0.5 mcg/kg.~followed by~Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
214593075|NCT03092895|BIOLOGICAL|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
214593076|NCT03092895|DRUG|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
214593077|NCT03092895|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
214593078|NCT03092895|DRUG|GEMOX|Subjects receive GEMOX treatment every 2 weeks
214593079|NCT01112306|DRUG|ACT-293987|Tablets, twice daily
214593080|NCT05085223|OTHER|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
214593081|NCT05085223|OTHER|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
214593082|NCT06082583|DEVICE|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
214593083|NCT06082583|DRUG|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
214593084|NCT04385420|DRUG|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
214593085|NCT04385420|DRUG|Placebo oral tablet|Placebo film-coated tablet administered via oral route
214593086|NCT03008707|PROCEDURE|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
214593087|NCT01074671|DEVICE|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
214593088|NCT00180570|DEVICE|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
214593089|NCT03832634|DIAGNOSTIC_TEST|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
214593090|NCT01208493|OTHER|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
214593091|NCT01208493|OTHER|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
214593092|NCT05831930|DRUG|Nituozumab|Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
214593093|NCT05166460|DEVICE|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
214593094|NCT04146415|DIAGNOSTIC_TEST|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
214593095|NCT02767401|DEVICE|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
214593096|NCT02767401|DRUG|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
214593097|NCT00790764|BIOLOGICAL|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
214593098|NCT00790764|OTHER|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
214593099|NCT01942720|DEVICE|Capsule endoscopy and Ileocolonoscopy tests|
214593100|NCT04588623|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair (OBSR)|OBSR is given orally once daily (3g) for 3 months
214593101|NCT04588623|OTHER|Placebo|Placebo is given orally once daily (3g) for 3 months
214593102|NCT02438319|OTHER|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
214593103|NCT02438319|OTHER|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
214593104|NCT05781776|OTHER|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
214593105|NCT05781776|OTHER|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
214593106|NCT01607554|DRUG|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
214593107|NCT03525899|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
214593108|NCT05401279|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
214593109|NCT05401279|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
214593110|NCT05401279|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four to six 21-day cycles.
214593111|NCT05722132|BEHAVIORAL|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
214593112|NCT05722132|BEHAVIORAL|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
214593113|NCT05722132|BEHAVIORAL|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
214593114|NCT05722132|BEHAVIORAL|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
214593115|NCT02695641|DRUG|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
214593116|NCT02695641|DRUG|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
214593117|NCT04174144|PROCEDURE|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
214593118|NCT01619150|DRUG|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
214593119|NCT01619150|DRUG|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
214593120|NCT00882453|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
214593121|NCT03726814|BIOLOGICAL|EPC treatment group|Brain injection EPC
214593122|NCT02229045|DRUG|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
214593123|NCT02229045|DRUG|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
214593124|NCT03952806|DRUG|Verdiperstat|300mg 2 oral tablets, twice daily
214593125|NCT03952806|DRUG|Placebo|Matching placebo
214593126|NCT01601483|DRUG|MC-1101|1% Ophthalmic Solution TID
214593127|NCT01601483|DRUG|MC-1101 Vehicle|Ophthalmic solution, TID
214593128|NCT03072277|DIETARY_SUPPLEMENT|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
214593129|NCT03072277|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
214593130|NCT00683176|DRUG|Choline Fenofibrate|135 mg
214593131|NCT00683176|DRUG|Placebo|Placebo
214593132|NCT04286568|BEHAVIORAL|WOW Intervention|Health education and coaching, health care navigation,
214593133|NCT06401460|OTHER|Yannianjiuzhuan method combined with reverse breathing training|"Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days."
214593134|NCT01138007|DRUG|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
214593135|NCT01138007|DRUG|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
214593136|NCT02827357|OTHER|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
214593137|NCT02897401|BIOLOGICAL|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
214593138|NCT02897401|BIOLOGICAL|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
214593139|NCT02897401|BIOLOGICAL|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
214593140|NCT02897401|BEHAVIORAL|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
214593141|NCT02897401|PROCEDURE|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
214593142|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
214593143|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
214593144|NCT01240083|DEVICE|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
214593145|NCT01240083|DEVICE|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
214593146|NCT01240083|DEVICE|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
214593147|NCT05834725|BEHAVIORAL|Promoting Resilience in Stress Management|Resilience coaching program.
214593148|NCT05834725|OTHER|Usual Care|Combination of physical therapy, occupational therapy, and psychological counseling as recommended by the treating provider.
214593149|NCT06582719|DEVICE|GPT-based counseling|AI-based counseling provided to the patient, accessible on their smartphone device at the time of Gestational Diabetes diagnosis
214593150|NCT06582719|OTHER|Nutritional Counseling|Standard Nutritional Counselling provided by a registered dietician at the time of Gestational Diabetes diagnosis
214593151|NCT05996783|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
214593152|NCT05996783|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
214593153|NCT03825484|DRUG|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
214593154|NCT06186726|RADIATION|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
214593155|NCT04661878|BEHAVIORAL|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
214593156|NCT04661878|BEHAVIORAL|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
214593157|NCT04661878|BEHAVIORAL|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
214593158|NCT04661878|BEHAVIORAL|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
214593159|NCT04560036|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
214593160|NCT06251453|DRUG|SGLT2 inhibitor|Dapagliflozin Empagliflzoin
214593161|NCT06634459|DEVICE|Reia System|Reia pessary
214593162|NCT06634459|DEVICE|Standard of Care Pessary|Gellhorn pessary or ring with/without support without knob pessary
214593163|NCT06447142|OTHER|Open kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
214593164|NCT06447142|OTHER|Closed kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
214593165|NCT04828486|DRUG|Futibatinib|Given PO
214593166|NCT04828486|BIOLOGICAL|Pembrolizumab|Given IV
214593167|NCT04828486|OTHER|Quality-of-Life Assessment|Ancillary studies
214593168|NCT06215573|DIETARY_SUPPLEMENT|Melatonin|5mg melatonin supplement, once daily, from Ritual BioSeries
214593169|NCT06215573|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement, once daily, from Ritual BioSeries
214593170|NCT01806129|OTHER|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
214593171|NCT01806129|OTHER|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
214593172|NCT06063564|BEHAVIORAL|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
214593173|NCT06063564|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
214593174|NCT06330779|OTHER|Trauma-adapted yoga|"Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time."
214593175|NCT05350631|OTHER|OnKO-Tips&Tricks digital phone application|Using daily OnKO-Tips\&Tricks digital phone application
214593176|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Manioc powder (placebo) 60 g/day
214593177|NCT00502021|DIETARY_SUPPLEMENT|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
214593178|NCT00502021|DIETARY_SUPPLEMENT|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
214593179|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Safflower oil 30 ml/day
214593180|NCT06311968|RADIATION|Proton radiotherapy|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
214593181|NCT06311968|OTHER|combined platinum based chemotherapy|combined platinum based chemotherapy
214593182|NCT00744523|DEVICE|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
214593183|NCT02904486|BEHAVIORAL|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
214593184|NCT01139021|BIOLOGICAL|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
214593185|NCT02564874|OTHER|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
214711030|NCT06884540|DRUG|lidocaine|"Intravenous bolus: between 0.5 and 1.5 mg/kg.~followed by~Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
214711031|NCT06884540|OTHER|control group|Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.
214593186|NCT00917605|OTHER|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
214593187|NCT04869423|BEHAVIORAL|Dog-Assisted Therapy|During seven weeks patients will assist one time per week (1 hour). The therapy will be conducted by an expert psychologist. The intervention will consist of 7 weeks conducted once a week (50 minutes each session). It will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to say goodbye to the dogs.
214593188|NCT02963610|DRUG|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
214593189|NCT02963610|DRUG|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
214593190|NCT03107104|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
214593191|NCT03107104|DEVICE|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
214593192|NCT03054480|DEVICE|Fractional Micro-Needle Radiofrequency|
214593193|NCT03054480|DRUG|Botulinum toxin type A|
214593194|NCT05333224|OTHER|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
214593195|NCT05333224|OTHER|Home-based|Family-centered, goal-oriented early physiotherapy approaches will be applied.
214593196|NCT06798363|DRUG|propranolol|different dose
214593197|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight sleep and morning wake|Overnight period and morning period device measurements
214593198|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight wake and morning sleep|Overnight period and morning period device measurements
214593199|NCT03558360|DIAGNOSTIC_TEST|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
214593200|NCT04822285|BEHAVIORAL|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
214593201|NCT04822285|BEHAVIORAL|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
214593202|NCT00063154|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
214593203|NCT06056167|DRUG|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
214593204|NCT03272425|DRUG|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
214593205|NCT03272425|DRUG|lesinurad 200 mg|Comparator 1
214593206|NCT03272425|DRUG|allopurinol 300 mg|Comparator 2
214593207|NCT01669876|DIETARY_SUPPLEMENT|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
214593208|NCT01669876|DIETARY_SUPPLEMENT|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
214593209|NCT01917019|DRUG|Placebo|matching placebo tablets
214593210|NCT01917019|DRUG|BIIB041 (fampridine)|fampridine prolonged-release tablets
214593211|NCT02497625|BEHAVIORAL|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
214593212|NCT02497625|BEHAVIORAL|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
214593213|NCT02497625|OTHER|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
214593214|NCT04579133|DRUG|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)
214593215|NCT04579133|DRUG|Durvalumab|Durvalumab 1500 mg IV
214593216|NCT02027701|BIOLOGICAL|IgPro20|
214593217|NCT02566265|BIOLOGICAL|Fluzone High Dose Vaccine|
214593218|NCT02566265|BIOLOGICAL|Standard of care/Placebo|
214593223|NCT03445351|OTHER|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
214593224|NCT04717284|OTHER|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
214593225|NCT04717284|OTHER|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
214593226|NCT00975351|DIETARY_SUPPLEMENT|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
214593227|NCT01837355|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
214593228|NCT01837355|DIETARY_SUPPLEMENT|Placebo|
214593229|NCT02853721|OTHER|iPTH|iPTH assay six hours after surgery
214593230|NCT02853721|OTHER|no dosage of iPTH|Ca and P on postoperative day 1 and 2
214593231|NCT05130242|PROCEDURE|Cement-augmented Pedicle Screws (CPS)|Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
214593232|NCT05130242|PROCEDURE|Hybrid Construct (HC)|Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
214593233|NCT01110876|DRUG|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
214593234|NCT01110876|DRUG|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
214593235|NCT01110876|DRUG|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
214593236|NCT02303691|BEHAVIORAL|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
214593237|NCT02303691|BEHAVIORAL|Neutral Training|A control version of computerized attention training.
214593238|NCT05203354|RADIATION|Narrowband Ultraviolet B|patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
214593239|NCT05203354|DRUG|Acitretin|patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
214593240|NCT02766894|DEVICE|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
214593241|NCT05309343|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
214593242|NCT03203720|BEHAVIORAL|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
214593243|NCT04589754|DRUG|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
214593244|NCT04589754|DRUG|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
214593245|NCT00482508|DRUG|Omalizumab|
214593246|NCT01947192|PROCEDURE|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
214593247|NCT01947192|PROCEDURE|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
214593248|NCT00265421|PROCEDURE|Suture technique for perineal repair after delivery|
214593249|NCT02893930|DRUG|Sapanisertib|Given PO
214593250|NCT02496520|BIOLOGICAL|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
214593251|NCT02496520|PROCEDURE|Surgery as needed by the patient´s tumor and stage|
214593252|NCT02496520|DRUG|Chemotherapy as needed by the patient´s tumor and stage|
214593253|NCT02496520|RADIATION|Radiation therapy as needed by the patient´s tumor and stage|
214593254|NCT04988256|DRUG|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
214593255|NCT04988256|DRUG|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
214593256|NCT00921960|OTHER|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
214593257|NCT02349360|BIOLOGICAL|L. johnsonii N6.2|L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
214593258|NCT02349360|BIOLOGICAL|Placebo|Encapsulated starch placebo administered for 8 weeks
214593259|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
214593260|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
214593261|NCT00751842|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
214593262|NCT03501160|OTHER|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
214593263|NCT00430261|DRUG|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
214593264|NCT00394953|DRUG|Darbepoetin alfa|As prescribed, iv.
214593265|NCT00394953|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
214593266|NCT04250987|DEVICE|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
214593267|NCT02629289|DRUG|HSP-130|
214593268|NCT02629289|DRUG|US-approved Neulasta|
214593269|NCT02629289|DRUG|EU-approved Neulasta|
214593270|NCT01769066|DRUG|Sequential Gefitinib With Pemetrexed/Platinum|
214593271|NCT01769066|DRUG|Pemetrexed/Platinum|
214593272|NCT01510522|DRUG|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
214593273|NCT01510522|DRUG|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month"
214593274|NCT00390182|DRUG|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study."
214593275|NCT00002184|DRUG|Nelfinavir mesylate|
214593276|NCT00002184|DRUG|Levocarnitine|
214593277|NCT00002184|DRUG|Adefovir dipivoxil|
214593278|NCT00002184|DRUG|Saquinavir|
214593279|NCT00002184|DRUG|Lamivudine|
214593280|NCT00002184|DRUG|Stavudine|
214593281|NCT00002184|DRUG|Zidovudine|
214593282|NCT04371861|DEVICE|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
214593283|NCT00308386|BEHAVIORAL|Nurse Case Management intervention|Intervention is meeting with nurse case managers
214593284|NCT01937325|DRUG|ivacaftor|active arm
214593285|NCT01937325|DRUG|placebo|active arm
214593286|NCT01354171|DEVICE|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
214593287|NCT04362410|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab single dose subcutaneously injection.
214593288|NCT04362410|OTHER|Placebo|Placebo single dose subcutaneously injection.
214593289|NCT04283721|OTHER|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
214593290|NCT03549312|DRUG|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48."
214593291|NCT03549312|DRUG|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
214593292|NCT03549312|DRUG|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96."
214593293|NCT02917278|DIETARY_SUPPLEMENT|Meals|High Protein renal-specific meals
214593294|NCT02802098|DRUG|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
214593295|NCT02802098|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
214593296|NCT02171325|DRUG|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
214593297|NCT04151953|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
214593298|NCT02271425|DRUG|Evacetrapib Tablet|Oral administration
214593299|NCT02271425|DRUG|Evacetrapib Intravenous|Intravenous administration
214593300|NCT00506233|BEHAVIORAL|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
214593301|NCT03353558|DEVICE|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
214593302|NCT05933187|DRUG|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
214593303|NCT05933187|DRUG|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
214593304|NCT05933187|DRUG|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
214593305|NCT05933187|DRUG|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
214593306|NCT00442299|DEVICE|Fractionated Plasma Separation and Adsorption (FPSA)|
214593307|NCT02369445|BEHAVIORAL|Moisture Pager Intervention for Toilet Training|
214593308|NCT02369445|BEHAVIORAL|Standard of Care|
214593309|NCT00326469|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
214593310|NCT03878498|OTHER|therapeutic management|therapeutic management of anal fistula in Crohn Disease
214593311|NCT02536703|DEVICE|Lotus Valve System|Lotus Valve System
214593312|NCT04079803|DRUG|Placebo oral tablet|Oral placebo tablet
214593313|NCT04079803|DRUG|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
214593314|NCT04079803|DRUG|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
214593315|NCT00158899|DRUG|GW501516 oral tablets|
214593316|NCT05620251|DIAGNOSTIC_TEST|Blood test|Assessment of humoral immune response
214593317|NCT02166866|OTHER|Quality of Life Questionairre and Education|
214593318|NCT00231387|DRUG|rosiglitazone|
214593319|NCT02600455|DRUG|Orencia|
214593320|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
214593321|NCT01321346|DRUG|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
214593322|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
214593323|NCT01279512|DRUG|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
214593324|NCT01279512|DRUG|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
214593325|NCT01566656|DRUG|total lymphoid irradiation and anti-thymocyte globulin|"* TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
214593326|NCT04318951|BEHAVIORAL|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[…\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
214593327|NCT04318951|BEHAVIORAL|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
214593328|NCT06023277|BIOLOGICAL|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
214593329|NCT04792658|BEHAVIORAL|Detailed interview with personal demographic data|, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
214593330|NCT04792658|BEHAVIORAL|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
214593331|NCT04792658|BEHAVIORAL|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
214593332|NCT04792658|BEHAVIORAL|the Hamilton Depression Rating Scale|it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
214593333|NCT04792658|BEHAVIORAL|The Hamilton Anxiety Rating Scale|it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
214593334|NCT04792658|BEHAVIORAL|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)|It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
214593335|NCT01294683|DRUG|Simvastatin|
214593336|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
214593337|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant (N/LRPT)|
214593338|NCT01294683|DRUG|Placebo|
214593339|NCT05891912|OTHER|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~* 1 session per week: 15min small TABLET and 15min LIGHTS game.~* 1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
214593340|NCT01215500|RADIATION|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy"
214593341|NCT00770237|BEHAVIORAL|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
214593342|NCT00770237|BEHAVIORAL|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
214593343|NCT01050348|DRUG|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
214593344|NCT01050348|DRUG|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
214593345|NCT01134016|DRUG|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
214593346|NCT01626703|OTHER|Reminding call|
214593347|NCT04476056|OTHER|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
214593348|NCT05161832|BEHAVIORAL|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
214593349|NCT05161832|BEHAVIORAL|Placebo|Placebo ultrasound with no diagnosis of injury.
214593350|NCT01764113|BEHAVIORAL|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
214593351|NCT01764113|BEHAVIORAL|Standard dietary counselling|
214593352|NCT06244758|DRUG|Finerenone 20 MG Oral Tablet|The intervention is administered orally.
214593353|NCT06244758|DRUG|Placebo|The intervention is administered orally.
214593354|NCT04669977|DIETARY_SUPPLEMENT|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
214593355|NCT00537368|DRUG|CNTO 888|
214593356|NCT00530296|BEHAVIORAL|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
214593357|NCT04258527|DRUG|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
214593358|NCT01975454|DRUG|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
214593359|NCT01975454|DRUG|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
214593360|NCT04646512|DIETARY_SUPPLEMENT|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
214593361|NCT04646512|OTHER|Physical training with Deep Water Running|There will be a physical training for eight weeks.
214593362|NCT00979433|DEVICE|Bubble CPAP|Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
214593363|NCT00979433|DEVICE|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
214593364|NCT03346941|DRUG|DAA treatment|Direct-acting antiviral-based treatment
214593365|NCT01032382|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
214593366|NCT01032382|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
214593367|NCT00367120|DRUG|Azithromycin Extended Release|
214593368|NCT00367120|DRUG|Amoxicillin/Clavulanate|
214593369|NCT02211144|DRUG|BIBR 796 BS|
214593370|NCT02211144|DRUG|Placebo|
214593371|NCT00412971|DRUG|Hexvix|Single installation, TURB
214593372|NCT00412971|OTHER|Standard white light cystoscopy|
214593373|NCT01051700|DRUG|GW786034|Investigational product
214593374|NCT01051700|OTHER|Placebo|Placebo
214593375|NCT00002566|DRUG|carboplatin|
214593376|NCT00002566|DRUG|cisplatin|
214593377|NCT00002566|DRUG|cyclophosphamide|
214593378|NCT00002566|DRUG|etoposide|
214593379|NCT00002566|DRUG|ifosfamide|
214593380|NCT00002566|DRUG|vinblastine sulfate|
214593381|NCT00002566|PROCEDURE|autologous bone marrow transplantation|
214593382|NCT00002566|PROCEDURE|conventional surgery|
214593383|NCT00002566|PROCEDURE|peripheral blood stem cell transplantation|
214593384|NCT02823626|DRUG|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
214593385|NCT04197726|OTHER|sbeIIa/b white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
214593386|NCT04197726|OTHER|Control white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
214593387|NCT05226754|DRUG|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
214593388|NCT05226754|DRUG|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
214593389|NCT05453019|DEVICE|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
214593390|NCT02934321|DIETARY_SUPPLEMENT|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
214593391|NCT02934321|DIETARY_SUPPLEMENT|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
214593392|NCT03651583|BEHAVIORAL|Kiko exercises-combines breathing and movement|
214593393|NCT01098136|OTHER|Chiropractic|Manual treatment of musculoskeletal complaints
214593394|NCT01098136|OTHER|Conventional medical intervention|Medical, physiotherapy
214593395|NCT01098136|OTHER|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
214593396|NCT01094379|PROCEDURE|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
214593397|NCT01094379|PROCEDURE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
214593398|NCT05295680|DRUG|Hymecromone|Hymecromone 400 mg 3 times daily by mouth.
214593399|NCT05528250|OTHER|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
214593400|NCT05528250|DEVICE|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
214593401|NCT06242054|DIAGNOSTIC_TEST|Motor Function Assessment System|Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
214593402|NCT06421896|BEHAVIORAL|motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is a systematic intervention that focuses on eliciting and strengthening a person's intrinsic motivation to change. MET is rooted in motivational interviewing principles, emphasizing empathy, autonomy, and the evocation of the patient's own motivations for change. The therapy typically involves several sessions where therapists help patients identify personal goals, explore ambivalence towards change, and develop actionable plans to achieve their desired outcomes.
214593403|NCT01793363|PROCEDURE|Tracheotomy|
214593404|NCT02708017|PROCEDURE|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
214593405|NCT02708017|PROCEDURE|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
214593406|NCT04005417|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
214593407|NCT04005417|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
214593408|NCT04005417|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
214593409|NCT01321359|DRUG|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
214593410|NCT02409368|DRUG|Nivolumab|
214593411|NCT01296347|DRUG|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
214593412|NCT04176302|DEVICE|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
214593413|NCT04176302|DIAGNOSTIC_TEST|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
214593414|NCT04176302|OTHER|Traditional clinical practice|The neurologists will receive the patient \& caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
214593415|NCT00186394|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
214593416|NCT03881618|PROCEDURE|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
214593417|NCT02705560|OTHER|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
214593418|NCT02705560|OTHER|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
214593419|NCT02705560|OTHER|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
214593420|NCT05467423|DIETARY_SUPPLEMENT|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
214593421|NCT06349928|OTHER|Focus group or interview|Focus groups and qualitative interview will be conducted with dancers investigating thoughts, beliefs and behaviors related to injury. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
214593422|NCT04910789|PROCEDURE|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
214593423|NCT04910789|PROCEDURE|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
214593424|NCT01585987|BIOLOGICAL|Ipilimumab|
214593425|NCT01585987|OTHER|Best Supportive care (BSC)|
214593426|NCT03634696|OTHER|mPCL|Smart phone application to support palliative care among late-stage cancer patients
214593427|NCT03634696|OTHER|Usual Care|Usual care through OCRI palliative care clinic
214593428|NCT05686382|PROCEDURE|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
214593429|NCT05686382|PROCEDURE|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
214593430|NCT02041520|DRUG|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
214593431|NCT02041520|OTHER|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
214593432|NCT05378230|DIETARY_SUPPLEMENT|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
214593433|NCT00551941|PROCEDURE|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
214593434|NCT00551941|PROCEDURE|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
214593435|NCT05521802|BIOLOGICAL|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
214593436|NCT01759407|DRUG|Ropivicaine|
214593437|NCT01759407|DRUG|Epinephrine|
214593438|NCT00486629|BEHAVIORAL|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
214593439|NCT02143557|OTHER|Fat-Modified Breast Milk|
214593440|NCT02143557|OTHER|MCT formula|
214593441|NCT01822236|OTHER|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
214593442|NCT01822236|OTHER|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
214593443|NCT03268122|OTHER|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
214593444|NCT03268122|OTHER|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
214593445|NCT03737474|DRUG|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
214593446|NCT04291820|PROCEDURE|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
214593447|NCT04291820|PROCEDURE|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
214593448|NCT03617341|PROCEDURE|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
214593449|NCT02513745|DEVICE|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
214593450|NCT02513745|DEVICE|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
214593451|NCT02542774|OTHER|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
214593452|NCT02331251|DRUG|Pembrolizumab|
214593453|NCT02331251|DRUG|Gemcitabine|
214593454|NCT02331251|DRUG|Docetaxel|
214593455|NCT02331251|DRUG|Nab-paclitaxel|
214593456|NCT02331251|DRUG|Vinorelbine|
214593457|NCT02331251|DRUG|Irinotecan|
214593458|NCT02331251|DRUG|Liposomal Doxorubicin|
214593459|NCT01209143|DRUG|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
214593460|NCT01209143|DRUG|Rosiglitazone|Rosiglitazone was supplied in tablets.
214593461|NCT01209143|DRUG|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
214593462|NCT02737709|DRUG|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
214593463|NCT04289766|OTHER|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
214593464|NCT04289766|OTHER|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
214593465|NCT04289766|OTHER|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
214593466|NCT01145755|DRUG|AZD2066|18 mg once daily
214593467|NCT01145755|DRUG|Placebo|
214593468|NCT01145755|DRUG|Duloxetine|60 mg once daily
214593469|NCT02954965|BEHAVIORAL|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
214593470|NCT02954965|BEHAVIORAL|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
214593471|NCT01704638|DRUG|fluvoxamine|
214593472|NCT01704638|DRUG|Digoxin|
214593473|NCT03876782|DIAGNOSTIC_TEST|IOLMaster|IOL power calculation will be done with IOLMaster
214593474|NCT03876782|DIAGNOSTIC_TEST|Verion|IOL power calculation will be done with Verion
214593475|NCT05749289|DRUG|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
214593476|NCT05635981|OTHER|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
214593477|NCT01775267|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy|
214593478|NCT01775267|PROCEDURE|Portal vein embolization or ligation|
214593479|NCT01783041|DRUG|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
214593480|NCT01783041|DRUG|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
214593481|NCT01827293|DRUG|Promethazine|
214593482|NCT01827293|DRUG|Lorazepam|
214593483|NCT05423886|OTHER|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
214593484|NCT03796260|DRUG|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
214593485|NCT03796260|DRUG|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
214593486|NCT05429333|OTHER|Artificial intelligence-assisted personalized diet|"The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings."
214593487|NCT01871753|OTHER|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
214593488|NCT01295177|DRUG|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
214593489|NCT00320125|DIETARY_SUPPLEMENT|Orange juice plus calcium|\> 1,200mg Ca (four glasses of orange juice plus calcium)per day
214593490|NCT00320125|DIETARY_SUPPLEMENT|Dairy products|\> 1,200mg Ca (by consuming milk, yogurt, and cheese)
214593491|NCT06046768|OTHER|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
214593492|NCT04919239|BIOLOGICAL|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
214593493|NCT04919239|BIOLOGICAL|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
214593494|NCT05918250|BIOLOGICAL|mRNA-2736|mRNA-2736 will be administered IV.
214593495|NCT00343954|DRUG|L-citrulline tablets, 1000 mg|
214593496|NCT00742053|DEVICE|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
214593497|NCT02739360|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
214593498|NCT02890394|OTHER|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
214593499|NCT04589429|DRUG|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
214593500|NCT04589429|DRUG|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
214593501|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
214593502|NCT01193920|OTHER|Saline solution|Subjects received two injection of saline solution.
214593503|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
214593504|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
214593505|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
214593506|NCT01193920|OTHER|saline solution|Subjects received one injection of saline solution.
214593507|NCT00913653|DRUG|LCZ696|
214593508|NCT00542529|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
214593509|NCT04760054|BEHAVIORAL|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
214593510|NCT04760054|BEHAVIORAL|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
214593511|NCT04760054|BEHAVIORAL|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
214593512|NCT04723186|DRUG|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
214593513|NCT02924142|DEVICE|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
214593514|NCT03602456|OTHER|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
214593515|NCT05507918|OTHER|Oral water and clear liquids|Measured oral intake of fluids prior to tonsillectomy
214593516|NCT04047589|BEHAVIORAL|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
214593517|NCT04047589|BEHAVIORAL|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
214593518|NCT01749449|OTHER|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
214593519|NCT01289171|DRUG|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
214593520|NCT05053425|DRUG|Venetoclax|given po.
214593521|NCT05053425|DRUG|Azacitidine|given sc.
214593522|NCT05053425|DRUG|Cladribine|given ivgtt.
214593523|NCT05053425|DRUG|Cytarabine|given sc or ivgtt.
214593524|NCT05053425|DRUG|Idarubicin|given ivgtt.
214593525|NCT00409214|DRUG|LS11 (talaporfin sodium)|
214593526|NCT00409214|DEVICE|Light source (interstitial light emitting diodes)|
214593527|NCT00409214|PROCEDURE|Intraoperative placement of device in glioma|
214593528|NCT00172107|DRUG|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
214593529|NCT00172107|DRUG|placebo|placebo powder for subcutaneous injection
214593530|NCT00172107|DRUG|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
214593531|NCT00172107|DRUG|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
214593532|NCT03170154|DEVICE|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
214593533|NCT02669420|PROCEDURE|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
214593534|NCT02846753|PROCEDURE|trans catheter heart valve replacement|trans catheter heart valve replacement
214593535|NCT06319456|DRUG|Lisaftoclax (APG-2575)|QD, oral administration, every 28 days for a dosing cycle.
214593536|NCT06319456|DRUG|Acalabrutinib|BID, oral administration, every 28 days for a dosing cycle.
214593537|NCT06319456|DRUG|Fludarabine|Every 28 days for a treatment cycle, administration of 6 cycles.
214593538|NCT06319456|DRUG|Cyclophosphamide，CTX|Every 28 days for a treatment cycle, administration of 6 cycles.
214593539|NCT06319456|DRUG|Rituximab|Every 28 days for a treatment cycle, administration of 6 cycles.
214593540|NCT06319456|DRUG|Chlorambucil|Every 28 days for a treatment cycle, administration of 6 cycles.
214593541|NCT05393284|DRUG|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
214593542|NCT05393284|DRUG|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
214593543|NCT05266586|DRUG|Obicetrapib|tablets
214593544|NCT05266586|DRUG|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
214593545|NCT05266586|OTHER|Obicetrapib placebo|tablets; no active ingredient
214593546|NCT05266586|OTHER|Ezetimibe placebo|capsules; no active ingredient
214593547|NCT00905112|OTHER|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
214593548|NCT00905112|OTHER|Standard OB Care|Receive standard obstetrical care
214593549|NCT00790322|DRUG|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
214593550|NCT00790322|OTHER|Placebo|Solution for oral use
214593551|NCT02905760|DRUG|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
214593552|NCT02905760|DRUG|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
214593553|NCT02905760|DRUG|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
214593554|NCT02905760|DRUG|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
214593555|NCT04002609|OTHER|oxygen|oxygen supplementation during brronchoscopy
214593556|NCT06385756|DRUG|Amobarbital|Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.
214593557|NCT06385756|DRUG|Propofol|propofol
214593558|NCT03528863|BEHAVIORAL|Online Mindfulness Meditation|Receive web-based mindfulness meditation
214593559|NCT03528863|OTHER|Questionnaire Administration|Ancillary studies
214593560|NCT04752878|DIAGNOSTIC_TEST|Ottawa sitting scale|The Ottawa Sitting Scale is a performance-based balance measurement consisting of 10 items that aims to evaluate the sitting balance in a comprehensive, specific, efficient and functional manner.
214593561|NCT03456271|OTHER||
214593562|NCT04012229|GENETIC|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
214593563|NCT03282240|BIOLOGICAL|QIV-HD|0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
214593564|NCT03282240|BIOLOGICAL|Licensed TIV-HD1|0.5 mL-dose was administered IM into the upper arm area.
214593565|NCT03282240|BIOLOGICAL|Investigational TIV-HD2|0.5 mL-dose was administered IM into the upper arm area.
214593566|NCT05907278|BEHAVIORAL|Advanced Cooking Education|"Participants attend the ACE Program for 12 weeks after school.~On one assigned day of the week, participants attend ACE virtually. The session will begin with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes).~On any day during the week, the students will make a dish using groceries they received (1 hour)."
214593567|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
214593568|NCT04041583|DEVICE|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis \[2\]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion \[2\].
214593569|NCT03017274|OTHER|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
214593570|NCT00229411|BEHAVIORAL|simulation training|
214593571|NCT05328323|OTHER|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
214593572|NCT03253926|DRUG|Lorcaserin|Lorcaserin 10mg BID
214593573|NCT03253926|DRUG|Placebo|Placebo capsule BID
214593574|NCT03253926|DRUG|Marijuana|Smoked marijuana cigarette
214593575|NCT01882751|DEVICE|Conformis CR Total Knee Replacement|iTotal CR by Conformis
214593576|NCT01882751|DEVICE|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
214593577|NCT02869776|BEHAVIORAL|Questionnaire|Behavioral questionnaires
214593578|NCT02869776|PROCEDURE|Rapid finger stick|HIV and HCV testing through rapid finger stick
214593579|NCT02869776|PROCEDURE|Venipuncture|HIV and HCV testing through venipuncture
214593580|NCT00906360|DRUG|sunitinib malate|Given orally or by percutaneous gastrostomy tube
214593581|NCT00906360|OTHER|pharmacological study|Correlative studies
214593582|NCT00906360|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
214593583|NCT00906360|BIOLOGICAL|cetuximab|Given IV
214593584|NCT02300909|PROCEDURE|Lumbar Decompression Surgery|Lumbar Decompression Surgery
214593585|NCT02300909|PROCEDURE|Microdiscectomy Surgery|Microdiscectomy Surgery
214593586|NCT02300909|OTHER|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
214593587|NCT00747825|DRUG|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
214593588|NCT05988554|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
214593589|NCT05988554|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract and collagen products|Consume 1 sachet daily
214593590|NCT02847741|OTHER|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
214593591|NCT03142763|OTHER|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
214593592|NCT03142763|DIETARY_SUPPLEMENT|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
214593593|NCT03437018|OTHER|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
214593594|NCT03675178|DRUG|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
214593595|NCT03675178|DRUG|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
214593596|NCT01101477|PROCEDURE|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~1. Patients become irritant and interfere procedures.~2. Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~1. Systolic blood pressure is less than 90mmHg;~2. Mean arterial blood pressure is less than 65mmHg;~3. Oxyhemoglobin saturation is less than 90 %~with any duration."
214593597|NCT00501527|BIOLOGICAL|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
214593598|NCT00501527|OTHER|Placebo|Placebo 2 drops daily
214593599|NCT03972007|DEVICE|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
214593600|NCT01179451|DEVICE|echocardiogram|echocardiogram
214593601|NCT03699436|OTHER|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
214593602|NCT03699436|OTHER|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
214593603|NCT00681746|DRUG|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
214593604|NCT00681746|DRUG|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
214593605|NCT04099017|OTHER|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~   Procedural detail:~   Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~2. Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~3. Kinesiotaping:"
214593606|NCT04099017|OTHER|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~   Procedural detail:~   i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:"
214711032|NCT06190405|DIAGNOSTIC_TEST|Hemoglobin A1c|Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.
214593607|NCT04099017|OTHER|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
214593608|NCT04160338|DEVICE|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
214593609|NCT04038593|OTHER|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
214593610|NCT04038593|DEVICE|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
214593611|NCT00520104|DRUG|intranasal ketamine|drug interaction
214593612|NCT06700096|GENETIC|ANB-002|Adeno-associated viral vector carrying the FIX gene single infusion
214593613|NCT02271516|RADIATION|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
214593614|NCT04179331|OTHER|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
214593615|NCT04179331|OTHER|Saline|Isotonic saline will serve as a placebo.
214593616|NCT01800266|BEHAVIORAL|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
214593617|NCT02956512|DRUG|Dexibuprofen|Dexibuprofen 300mg
214593618|NCT00209456|DRUG|DatSCAN|
214593619|NCT03520933|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
214593620|NCT03520933|DIAGNOSTIC_TEST|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
214593621|NCT01679795|DRUG|Tibolone|
214593622|NCT01679795|DRUG|Placebo|
214593623|NCT02870569|DRUG|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
214593624|NCT02870569|DRUG|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
214593625|NCT02579707|DRUG|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
214593626|NCT02382016|DRUG|Macitentan|Macitentan film-coated tablet 10 mg once daily.
214593627|NCT02382016|OTHER|Placebo|Matching placebo tablet once daily.
214593628|NCT00084266|DRUG|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
214593629|NCT00084266|DRUG|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
214593630|NCT03343951|OTHER|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~* diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~* if the patient needs a new appointment at the shoulder clinic~* if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
214593631|NCT00730171|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
214593632|NCT01729156|DRUG|Metformin|1000 mg metformin twice daily in 3 months
214593633|NCT01729156|DRUG|Placebo|2 tablets twice daily in 3 months
214593634|NCT00430443|DRUG|Liposomal Annamycin|3-day IV infusion
214593635|NCT00207701|DRUG|infliximab|
214593636|NCT01267877|OTHER|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
214593637|NCT01267877|OTHER|read favorable article prior to answering questions|"read A Backlash of Mistrust"
214593638|NCT00655863|DRUG|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
214593639|NCT00655863|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
214593640|NCT00655863|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
214593641|NCT02557321|DRUG|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
214593642|NCT02557321|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
214593643|NCT04930224|DIAGNOSTIC_TEST|The effect of GPER-1 on the formation of diabetic retinopathy|Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
214593644|NCT00096057|BIOLOGICAL|monoclonal antibody HuHMFG1|
214593645|NCT05541211|OTHER|Coeliac plexus neurolysis|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
214593646|NCT05541211|OTHER|Splanchnic nerve neurolysis|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
214593647|NCT04258488|DRUG|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects\_creatinine clearance 15-49 mL/min, 15mg once daily
214593648|NCT04258488|DRUG|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
214593649|NCT06555588|BEHAVIORAL|ENGAGE|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.
214593650|NCT06555588|BEHAVIORAL|Supportive Care|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
214593651|NCT06801860|BEHAVIORAL|Very brief smoking cessation advice|All participants will receive very brief smoking cessation advice (guided by the AWARD model, assess, warning, refer, and do-it-again) with a smoking cessation information booklet onsite at baseline.
214593652|NCT06801860|BEHAVIORAL|Chewing gum|Participants in the intervention group will receive 1-2 packs of chewing gum over a 1-week intervention period.
214593653|NCT06801860|BEHAVIORAL|Chewing gum usage leaflet|A leaflet of usage tips for chewing gum, including 1) the potential benefits of chewing gum, 2) suitable usage time and dosage, and 3) the proper disposal of used gum.
214593654|NCT03867175|RADIATION|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
214593655|NCT03867175|BIOLOGICAL|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
214593656|NCT04328337|DRUG|Intralipid, 20% Intravenous Emulsion|Infusion of Intralipid 20%
214593657|NCT04328337|DRUG|Placebos|saline 30 ml/hr for 12 hours through an IV
214593658|NCT03144999|BIOLOGICAL|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
214593659|NCT02416804|DRUG|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr
214593660|NCT02416804|DRUG|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
214593661|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
214593662|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
214593663|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
214593664|NCT04823221|DEVICE|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
214593665|NCT01115751|DRUG|LY2780301|"Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
214593666|NCT04248270|DRUG|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
214593667|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 80mg|The patient received one treatment of RC18 80mg in the test group
214593668|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 160mg|The patient received one treatment of RC18 160mg in the test group
214593669|NCT04235933|BIOLOGICAL|RC18 240mg|The patient received one treatment of RC18 240mg in the test group
214593670|NCT04354844|BEHAVIORAL|questionnaire|questionnaire
214593671|NCT00935194|DRUG|oseltamivir|75mg,bid,for 5 days
214593672|NCT00935194|OTHER|blank|no antiviral therapy
214593673|NCT00935194|DRUG|chinese medicinal herbs|200ml,p.o,qid,for 5 days
214593674|NCT00935194|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
214593675|NCT03588728|OTHER|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
214593676|NCT03588728|BEHAVIORAL|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
214593677|NCT00455338|BEHAVIORAL|Meal Composition|
214593678|NCT00189033|DRUG|psyllium fibre (dietary supplement)|
214593679|NCT00189033|DRUG|wheat bran (dietary supplement)|
214593680|NCT00189033|DRUG|rice wheat (placebo)|
214593681|NCT03392506|DEVICE|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
214593682|NCT00165633|DRUG|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
214593683|NCT00165633|DRUG|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
214593684|NCT00165633|DRUG|Placebo|Placebo capsule, orally, three times a day, after meals.
214593685|NCT05975151|DRUG|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
214593686|NCT00388557|DRUG|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
214593687|NCT04793152|DRUG|Vancomycin|Administration as outlined
214593688|NCT04747782|OTHER|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
214593689|NCT02019589|DRUG|Progesterone|
214593690|NCT02019589|DRUG|Placebo|
214593691|NCT06001489|BEHAVIORAL|360-degree Virtual Reality Patient Tour|A 360-degree video that encompasses the entire clinical pathway. Patients are able to familiarize themselves with the hospital settings (nursery ward, operating room, intensive care unit).
214593692|NCT06001489|DIAGNOSTIC_TEST|State Trait Anxiety Inventory|Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
214593693|NCT06001489|DIAGNOSTIC_TEST|Amsterdam Preoperative Anxiety and Information Scale|This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
214593694|NCT05703867|DEVICE|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
214593695|NCT03285178|DRUG|IW-1701|Oral Tablet
214593696|NCT03285178|DRUG|Placebo|Oral Tablet
214593697|NCT03292718|DEVICE|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
214593698|NCT01388790|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
214593699|NCT01388790|DRUG|Cisplatin|Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
214593700|NCT01388790|DRUG|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
214593701|NCT01128894|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
214593702|NCT01128894|DRUG|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
214593703|NCT03758287|DRUG|CT053PTSA|
214593704|NCT03758287|DRUG|Gefitinib|
214593705|NCT04785235|PROCEDURE|Non-Surgical Periodontal Therapy|
214593706|NCT00334724|PROCEDURE|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
214593707|NCT00334724|PROCEDURE|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
214593708|NCT02091050|OTHER|2D HDR planning|HDR planning using simple radiograph (2D)
214593709|NCT02091050|OTHER|3D HDR planning|HDR planning using computed tomography (3D)
214593710|NCT00755651|PROCEDURE|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
214593711|NCT02725099|DRUG|Chewing Ticagrelor|180 mg Chewing Ticagrelor
214593712|NCT02725099|DRUG|Oral Ticagrelor|180 mg oral Ticagrelor
214593713|NCT00195507|DRUG|Etanercept|
214593714|NCT00370409|PROCEDURE|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
214593715|NCT00973362|DEVICE|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
214593716|NCT00973362|DEVICE|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
214593717|NCT03754413|DEVICE|experimental|Neuramis® Deep Lidocaine
214593718|NCT03754413|DRUG|comparator|No-treatment
214593719|NCT02674789|BEHAVIORAL|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
214593720|NCT05543486|DEVICE|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
214593721|NCT05543486|DEVICE|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
214593722|NCT00897416|OTHER|laboratory biomarker analysis|
214593723|NCT03480256|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
214593724|NCT01702597|DEVICE|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
214593725|NCT01702597|OTHER|Physiotherapy|Patients will receive a standardized physical therapy.
214593726|NCT00592085|BEHAVIORAL|Questionnaires|Participants will use a computer to complete a series of questionnaires.
214593727|NCT00592085|BEHAVIORAL|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
214593728|NCT00592085|BEHAVIORAL|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
214593729|NCT03252054|DIAGNOSTIC_TEST|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
214593730|NCT04140383|PROCEDURE|Cataract Surgery|Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
214593731|NCT02843204|DRUG|Pembrolizumab|Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
214593732|NCT02843204|BIOLOGICAL|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
214593733|NCT00887679|DRUG|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
214593734|NCT02573454|BEHAVIORAL|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
214593735|NCT01347346|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
214593736|NCT01969825|BEHAVIORAL|Massage|
214593737|NCT00959166|OTHER|PET scan|PET brain scan
214593738|NCT04740892|OTHER|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
214593739|NCT04740892|OTHER|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
214593740|NCT00555542|DRUG|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
214593741|NCT04332601|BEHAVIORAL|Fatigue Management Therapy|14 sessions of 1h CBT intervention
214593742|NCT04332601|OTHER|TAU (Treatment as usual)|No CBT intervention
214593743|NCT05975801|OTHER|Dry Cupping Therapy|
214593744|NCT05975801|OTHER|Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound|
214593745|NCT04958850|OTHER|a cross-sectional survey|Collect the data of this year and compare it with that of ten years ago
214593746|NCT02558192|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
214593747|NCT02558192|DIETARY_SUPPLEMENT|PLACEBO|1 vials q12 for 15 days
214593748|NCT00210756|DRUG|epoetin alfa|
214593749|NCT02685943|BEHAVIORAL|Psychotherapy|
214593750|NCT03333187|PROCEDURE|Allogeneic stem cell transplantation|
214593751|NCT03333187|DRUG|Ruxolitinib continuous therapy|
214593752|NCT02311998|DRUG|Bosutinib|Given PO
214593753|NCT02311998|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214593754|NCT00769613|BIOLOGICAL|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
214593755|NCT00769613|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
214593756|NCT00769613|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214593757|NCT00769613|GENETIC|polymerase chain reaction|
214593758|NCT00769613|OTHER|flow cytometry|
214593759|NCT00769613|OTHER|immunological diagnostic method|
214593760|NCT00769613|OTHER|laboratory biomarker analysis|
214593761|NCT03241212|BEHAVIORAL|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
214593762|NCT00157183|DEVICE|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
214593763|NCT00303641|DEVICE|Medtronic Resting Heart Bypass System|
214593764|NCT03462472|BEHAVIORAL|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
214593765|NCT03462472|BEHAVIORAL|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
214593766|NCT01630434|DEVICE|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
214593767|NCT01630434|DEVICE|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
214593768|NCT00595023|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
214593769|NCT05445583|BEHAVIORAL|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
214593770|NCT05445583|BEHAVIORAL|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
214593771|NCT05445583|BEHAVIORAL|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
214593772|NCT05445583|BEHAVIORAL|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
214593773|NCT05592314|OTHER|No intervention|No intervention
214593774|NCT06310057|DRUG|Tofacitinib|Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
214593775|NCT02578862|DRUG|Propofol|
214593776|NCT02578862|DRUG|Sevoflurane|
214593777|NCT02159430|OTHER|Clinical and psychopathological assessment of HAE patients|
214593778|NCT05722054|OTHER|Diagnostic tests|"Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination."
214593779|NCT05722054|OTHER|Equilibrate diet|Nutritionally-balanced Alimentation
214593780|NCT01813708|BEHAVIORAL|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
214593781|NCT01813708|BEHAVIORAL|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
214593782|NCT05380492|BIOLOGICAL|VOY-101|Intravitreal injection of VOY-101
214593783|NCT01918553|OTHER|clinical parameters|
214593784|NCT01918553|OTHER|visual acuity exams|
214593785|NCT01918553|OTHER|retinophotography|
214593786|NCT01918553|OTHER|SD-OCT|
214593787|NCT01918553|OTHER|Intra ocular Pressure (IOP)|
214593788|NCT01918553|OTHER|retinal imaging (OPTOMAP)|
214593789|NCT01918553|OTHER|axial length (IOL master)|
214593790|NCT02920333|PROCEDURE|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
214593791|NCT02920333|DEVICE|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
214593792|NCT02920333|DEVICE|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
214593793|NCT02920333|DEVICE|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
214593794|NCT01871311|DRUG|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
214593795|NCT01026454|DRUG|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
214593796|NCT01026454|DRUG|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
214593797|NCT05158998|DRUG|propofol infusion|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
214593798|NCT05158998|DRUG|sevoflurane inhalation|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
214593799|NCT06058260|OTHER|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
214593800|NCT06189560|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
214593801|NCT06189560|DRUG|SGB|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
214593802|NCT01137526|DRUG|ABT-384|Subjects will take study drug once daily for 12 weeks
214593803|NCT01137526|DRUG|donepezil|Subjects will take study drug once daily for 12 weeks.
214593804|NCT01137526|DRUG|placebo|Subjects will take study drug once daily for 12 weeks
214593805|NCT03231930|DEVICE|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
214593806|NCT03231930|DEVICE|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
214593807|NCT01315951|BIOLOGICAL|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
214593808|NCT02325167|BEHAVIORAL|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
214593809|NCT02325167|BEHAVIORAL|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
214593810|NCT00512304|PROCEDURE|association chemotherapy and radiochemotherapy|
214593811|NCT02404207|OTHER|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
214593812|NCT02404207|OTHER|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
214593813|NCT02404207|OTHER|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
214593814|NCT02404207|OTHER|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
214593815|NCT01176773|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
214593816|NCT05593679|DIAGNOSTIC_TEST|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
214593817|NCT04875741|OTHER|Neural mobilization|Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.
214593818|NCT04875741|OTHER|Muscle energy technique|Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
214593819|NCT03586687|DRUG|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
214593820|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 soft gelatine capsules|
214593821|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 film-coated tablets|
214593822|NCT02183285|DIETARY_SUPPLEMENT|Placebo film-coated tablets (fct)|
214593823|NCT02183285|DIETARY_SUPPLEMENT|Placebo soft gelatine capsules|
214593824|NCT01614743|DRUG|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
214593825|NCT01614743|DRUG|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
214593826|NCT00118820|DRUG|IV Preoperative antibiotic or placebo|
214593827|NCT05712733|OTHER|Microbiological and histopathological investigation of bile and gallbladder wall specimens.|Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
214593828|NCT02854293|OTHER|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
214593829|NCT03313453|DEVICE|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
214593830|NCT03313453|DEVICE|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
214593831|NCT06026085|OTHER|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
214593832|NCT06026085|OTHER|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
214593833|NCT06026085|OTHER|0.9% normal saline|0.9% normal saline+routine sun protection
214593834|NCT01165645|DRUG|lopinavir|Given orally
214593835|NCT01165645|DRUG|ritonavir|Given orally
214593836|NCT01165645|GENETIC|polymerase chain reaction|Correlative studies
214593837|NCT01165645|OTHER|flow cytometry|Correlative studies
214593838|NCT01165645|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214593839|NCT01165645|OTHER|laboratory biomarker analysis|Correlative studies
214593840|NCT04328051|OTHER|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
214593841|NCT03286322|OTHER|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
214593842|NCT03286322|OTHER|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
214593843|NCT06435130|OTHER|Dietary intervention with chokeberry juices|The first stage of the dietary intervention lasted 8 weeks. Study participants consumed 100 ml of chokeberry juice daily. Chokeberry juice came from ecological cultivation (Poland). Participants qualified for the study had specific biochemical parameters tested: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. Blood tests were performed in a certified external laboratory before and after 8 weeks of intervention. In addition, blood pressure and waist circumference were tested.
214593844|NCT06435130|OTHER|Dietary intervention with chokeberry juices and fibers|The second stage of the dietary intervention lasted 4 weeks. Study participants consumed 100 ml of chokeberry juice daily and 10 g chokeberry fiber daily (from ecological cultivation, Poland). Blood tests were performed in a certified external laboratory after 4 weeks of intervention. The following blood tests were performed: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. In addition, blood pressure and waist circumference were tested.
214593845|NCT03672422|DIAGNOSTIC_TEST|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
214593846|NCT03672422|BEHAVIORAL|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
214593847|NCT03672422|DIAGNOSTIC_TEST|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
214593848|NCT03672422|DIAGNOSTIC_TEST|Urine sample|50 ml of urine in collection container.
214593849|NCT06018181|DRUG|Shuxuetong Injection|According to clinical real treatment records
214593850|NCT04003220|PROCEDURE|blood sample|The extra samples will be taken Blood sampling
214593851|NCT04003220|PROCEDURE|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
214593852|NCT03275129|DIAGNOSTIC_TEST|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
214593853|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
214593854|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
214593855|NCT02196714|DRUG|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
214593856|NCT02196714|DRUG|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
214593857|NCT00690833|DRUG|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
214593858|NCT05270174|OTHER|no intervention|no intervention
214593859|NCT03865147|DRUG|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
214593860|NCT03865147|DRUG|EMLA cream|Active Comparator
214593861|NCT03865147|DRUG|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
214593862|NCT03693456|OTHER|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
214593863|NCT01592864|DRUG|Stannous Fluoride|dentifice
214593864|NCT01592864|DRUG|Sodium Monofluorophosphate|dentifrice
214593865|NCT02660307|OTHER|PROGRESS group|
214593866|NCT05737290|DEVICE|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
214593867|NCT05737290|DEVICE|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
214593868|NCT05090748|DEVICE|Echocardiographic.|Echocardiographic test.
214593869|NCT04671134|OTHER|Biomimetic remineralizing agent|Self-assempling peptide
214593870|NCT04671134|OTHER|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
214593871|NCT00279773|DRUG|TKI258|
214593872|NCT04652167|DIAGNOSTIC_TEST|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
214593873|NCT04652167|DIAGNOSTIC_TEST|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
214593874|NCT04652167|DIAGNOSTIC_TEST|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
214593875|NCT04626895|DEVICE|Paxman Scalp Cooling Device|Paxman scalp cooling device
214593876|NCT01365143|PROCEDURE|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
214593877|NCT01365143|PROCEDURE|Open Radical Prostatectomy|Open radical prostatectomy
214593878|NCT01384422|DRUG|GLPG0634|
214593879|NCT05792969|BEHAVIORAL|Functional measures and public health outcomes|"Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)"
214593880|NCT01185925|DRUG|Sildenafil|Sildenafil, 50 mg 3 times/day
214593881|NCT01185925|DRUG|Placebo|Placebo
214593882|NCT04189237|OTHER|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
214593883|NCT01056133|OTHER|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be\< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
214593884|NCT00073112|DRUG|ABT-751|
214593885|NCT02425930|PROCEDURE|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
214593886|NCT02425930|DRUG|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
214593887|NCT02120716|BEHAVIORAL|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
214593888|NCT02858349|BEHAVIORAL|No intervention|No intervention
214593889|NCT02858349|BEHAVIORAL|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
214593890|NCT00200434|DRUG|Nebivolol|
214593891|NCT05659277|OTHER|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
214593892|NCT02582723|OTHER|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
214593893|NCT02582723|OTHER|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
214593894|NCT02582723|OTHER|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
214593895|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
214593896|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
214593897|NCT00550875|BIOLOGICAL|placebo|Sublingual. 2 drops/daily 2 years
214593898|NCT04078165|DEVICE|Zero-Gravity|Free-floating, suspended personal radiation protection
214593899|NCT04078165|DEVICE|Conventional radiation protection|Standard lead shields and aprons
214593900|NCT04609059|DRUG|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
214593901|NCT04609059|DRUG|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
214593902|NCT02803047|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
214593903|NCT00118443|BEHAVIORAL|Question, Persuade, Refer (QPR) training|
214593904|NCT02643836|DEVICE|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
214593905|NCT01504308|DEVICE|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
214593906|NCT01504308|DEVICE|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
214593907|NCT02687425|DRUG|Pioglitazone|15mg/day,po
214593908|NCT02687425|DRUG|imatinib mesylate|400mg/day,po
214593909|NCT05708625|DRUG|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
214593910|NCT05708625|PROCEDURE|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
214593911|NCT05708625|DRUG|Intralesional Voriconazole|Weekly intralesional Voriconazole
214593912|NCT05708625|DRUG|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
214593913|NCT04071353|DRUG|Interferon|Interferon combined with ribavirin antiviral therapy
214593914|NCT04071353|DRUG|ribavirin|Interferon combined with ribavirin antiviral therapy
214593915|NCT04071353|DRUG|DAAs|DAAs antiviral treatment
214593916|NCT05422287|OTHER|Virtual Reality Glasses|Group 1
214593917|NCT05422287|OTHER|Thermomechanical Stimulation Device|Group 2
214593918|NCT00477854|DRUG|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
214593919|NCT03373487|BEHAVIORAL|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
214593920|NCT05221463|BEHAVIORAL|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
214593921|NCT05221463|BEHAVIORAL|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
214593922|NCT00298909|BEHAVIORAL|physical exercise|physical exercise
214593923|NCT00298909|DRUG|niaspan (extended-release niacin)|niaspan (extended-release niacin)
214593924|NCT00298909|DRUG|niacin|niacin extended-release
214593925|NCT00298909|OTHER|control|control
214593926|NCT02941133|OTHER|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
214593927|NCT02941133|OTHER|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
214593928|NCT05591820|BEHAVIORAL|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's behavioral difficulties in three (bi)weekly sessions and optional booster sessions.
214593929|NCT05591820|BEHAVIORAL|Care as usual|The care that is usually provided by the clinical institutions to treat children's behavioral difficulties. There are no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
214593930|NCT01881750|BEHAVIORAL|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
214593931|NCT01881750|BEHAVIORAL|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
214593932|NCT04932538|OTHER|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
214593933|NCT00846456|BIOLOGICAL|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
214593934|NCT04617756|DRUG|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
214593935|NCT00508248|DIETARY_SUPPLEMENT|omega 3 fatty acids|1g daily
214593936|NCT00508248|DIETARY_SUPPLEMENT|placebo|olive oil capsule
214593937|NCT01135706|OTHER|No Intervention|This study does not include an intervention but is observational in nature.
214593938|NCT05223751|BEHAVIORAL|Meo Health Breathing and humming exercises|"The Intervention Group will receive training on the Meo Health breathing therapy, which will include:~* Being shown the Meo Health Breathing Therapy On-Boarding video~* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.~* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.~Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.~A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.~A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group."
214593939|NCT03193489|OTHER|Follow-up|
214593940|NCT03193489|OTHER|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
214593941|NCT03193489|OTHER|Control Parkinson group|No treatment.
214593942|NCT01779687|DRUG|raltegravir|Raltegravir 400 mg BID for 7 days
214593943|NCT01779687|DRUG|Atorvastatin|Atorvastatin 20 mg QD for 7 days
214593944|NCT00984763|BIOLOGICAL|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
214593945|NCT03379922|BEHAVIORAL|Stress balls|Squeezing stress balls while receiving ESWL treatment
214593946|NCT03379922|BEHAVIORAL|Headphones|Listening to music while receiving ESWL treatment
214593947|NCT03708822|DRUG|Docetaxel and Cisplatin and Nimotuzumab|Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
214593948|NCT01126151|BEHAVIORAL|parent handbook|parent handbook
214593949|NCT02975024|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
214593950|NCT02975024|DEVICE|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
214593951|NCT02975024|DEVICE|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
214593952|NCT03525990|OTHER|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
214593953|NCT04269005|OTHER|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
214593954|NCT01862133|OTHER|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
214593955|NCT00625950|PROCEDURE|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
214593956|NCT00298454|DRUG|Furosemide|
214593957|NCT02580396|DEVICE|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
214593958|NCT02645695|DEVICE|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
214593959|NCT02645695|DEVICE|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
214593960|NCT01074619|DRUG|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
214593961|NCT01074619|DRUG|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
214593962|NCT02841930|OTHER|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
214593963|NCT01578759|PROCEDURE|Salpingectomy|Removal of the fallopian tubes
214593964|NCT04668586|DEVICE|Holmium:YAG laser machine|Ureteroscopy with Holmium:YAG laser lithotripsy
214593965|NCT04668586|DEVICE|Thulium Fiber laser machine|Ureteroscopy with Thulium Fiber laser lithotripsy
214593966|NCT03675672|DRUG|Misoprostol Oral Tablet|Misoprostol 200mcg
214593967|NCT03675672|DRUG|Placebo Oral Tablet|Placebo Tablet
214593968|NCT03159741|OTHER|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
214593969|NCT03159741|OTHER|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
214593970|NCT03159741|OTHER|Placebo + GIP|Placebo and GIP are used as study tools.
214593971|NCT03159741|OTHER|Placebo + Saline|Placebo
214593972|NCT02804178|DRUG|ATR-101|125-1000 mg twice per week
214593973|NCT06243419|DEVICE|vein viewer|The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
214593974|NCT06243419|DEVICE|virtual reality|The child watched the application by wearing virtual glasses during the PIC insertion
214593975|NCT06243419|DEVICE|vein viewer and virtual reality|"The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion"
214593976|NCT00330850|DRUG|PRO-513|
214593977|NCT02920931|DRUG|Tenofovir disoproxil|
214593978|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
214593979|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
214593980|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
214593981|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
214593982|NCT00606073|OTHER|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
214593983|NCT00529022|DRUG|Azacitidine|75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
214593984|NCT00529022|DRUG|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
214593985|NCT00529022|DRUG|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
214593986|NCT05620043|DEVICE|Sculptra|Biostimulator
214593987|NCT05620043|DEVICE|Radiesse Plus|Semi-permanent filler
214593988|NCT05956054|OTHER|needle type|straight or curved
214593989|NCT02334033|OTHER|other|
214593990|NCT05169125|PROCEDURE|standard hemodialysis|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
214593991|NCT05169125|PROCEDURE|lower dialysate sodium dialysis|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
214593992|NCT01723813|BIOLOGICAL|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
214593993|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
214593994|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
214593995|NCT01106404|DEVICE|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
214593996|NCT00874666|OTHER|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
214593997|NCT00874666|DIETARY_SUPPLEMENT|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
214593998|NCT01290601|DRUG|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
214593999|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
214594000|NCT01290601|DRUG|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
214594001|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
214594002|NCT00635726|DRUG|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
214594003|NCT00635726|DRUG|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
214594004|NCT00635726|DRUG|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
214594005|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
214594006|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
214594007|NCT00635726|DRUG|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
214594008|NCT00639561|DIETARY_SUPPLEMENT|10 g of fibres per day|10 g of fibres per day
214594009|NCT00639561|DIETARY_SUPPLEMENT|40 g of fibres per day|40g of fibres per day
214594010|NCT02207270|BEHAVIORAL|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
214594011|NCT02207270|BEHAVIORAL|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
214594012|NCT02004548|DRUG|Metatinib Tromethamine|
214594013|NCT02190669|OTHER|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
214594014|NCT00704002|PROCEDURE|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
214594015|NCT00704002|PROCEDURE|conservative treatment|conservative treatment with 2-finger splint for one week
214594016|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
214594017|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
214594018|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
214594019|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
214594020|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
214594021|NCT03580772|DEVICE|Persona TKR|Persona® TKR (Zimmer Biomet)
214594022|NCT03580772|DEVICE|Attune TKR|Attune® TKR (Depuy synthes)
214594023|NCT00939679|PROCEDURE|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
214594024|NCT00939679|DIETARY_SUPPLEMENT|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
214594025|NCT03099317|OTHER|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
214594026|NCT03099317|OTHER|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
214594027|NCT04071795|BEHAVIORAL|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
214594028|NCT04071795|BEHAVIORAL|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
214594029|NCT06224608|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
214594030|NCT01066468|DRUG|Gleevec/Glivec|
214594031|NCT05270785|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
214594032|NCT05270785|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
214594033|NCT04140279|DRUG|Latanoprostene Bunod|Ophthalmic solution
214594034|NCT04140279|DRUG|Placebo|Ophthalmic solution, no active ingredient.
214594035|NCT00931333|PROCEDURE|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
214594036|NCT05107050|DEVICE|Normal Saline and Amorphous gel|Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
214594037|NCT05107050|DEVICE|BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel|"Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
214594038|NCT00438347|BEHAVIORAL|Aerobic Exercise|One hour per day three times a week for one year
214594039|NCT00438347|BEHAVIORAL|Stretching and toning|One hour per day three times a week for one year
214594040|NCT00803829|OTHER|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
214594041|NCT04460014|BEHAVIORAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
214594042|NCT04460014|BEHAVIORAL|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
214594043|NCT05332184|PROCEDURE|aortic valve surgery|
214594044|NCT03820089|DIAGNOSTIC_TEST|Ultrasonography TP|TP us will be made to the included women
214594045|NCT04727879|PROCEDURE|Synovial membrane biopsy with puncture of synovial fluid|The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
214594046|NCT04727879|PROCEDURE|Joint fluid sampling|In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
214594047|NCT04727879|PROCEDURE|Blood sample|A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
214594048|NCT00005074|DRUG|alvocidib|
214594049|NCT03772353|DRUG|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
214594050|NCT03772353|DRUG|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
214594051|NCT03772353|DRUG|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
214594052|NCT03772353|DRUG|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
214594053|NCT00772213|PROCEDURE|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
214594054|NCT00947713|DRUG|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
214594055|NCT00947713|DRUG|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
214594056|NCT03552822|OTHER|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
214594057|NCT01749540|DRUG|luspatercept|subcutaneous injection
214594058|NCT03730974|DEVICE|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
214594059|NCT04891328|OTHER|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
214594060|NCT03000361|PROCEDURE|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
214594061|NCT02729103|DRUG|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
214594062|NCT04864483|OTHER|Meal timing in relation to time of starting the fast|as described
214594063|NCT02174796|PROCEDURE|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
214594064|NCT02174796|PROCEDURE|orthopedic treatment|orthopedic treatment by vacuum bell.
214594065|NCT03506893|DEVICE|Alphapump|"Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking"
214594066|NCT03506893|PROCEDURE|Ascites puncture|Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
214594067|NCT05755035|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
214594068|NCT05755035|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
214594069|NCT00615238|BEHAVIORAL|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
214594070|NCT00615238|BEHAVIORAL|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
214594071|NCT00615238|BEHAVIORAL|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
214594072|NCT01474499|DRUG|Glycerine|
214594073|NCT01474499|DRUG|Docusate sodium and sorbitol rectal solution|
214594074|NCT00181987|DRUG|methylphenidate HCl (Concerta)|
214594075|NCT02263534|PROCEDURE|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
214594076|NCT02263534|PROCEDURE|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
214594077|NCT03935503|PROCEDURE|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
214594078|NCT03935503|PROCEDURE|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
214594079|NCT01585636|DRUG|SQ109|Single oral dose
214594080|NCT05526729|OTHER|Beovu|Prospective observational study. There was no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema were eligible to enroll into this study.
214594081|NCT03838107|BEHAVIORAL|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
214594082|NCT00419783|DRUG|bilastine|20 mg tablets.
214594083|NCT00419783|DRUG|Bilastine|100 mg (5 tablets of 20 mg)
214594084|NCT00419783|DRUG|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
214594085|NCT00419783|DRUG|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
214594086|NCT00419783|DRUG|Placebo|Placebo tablets
214594087|NCT04828083|DRUG|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
214594088|NCT04828083|DRUG|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
214594089|NCT04987892|DEVICE|UroLift System|Prostatic lift
214594090|NCT04987892|DRUG|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
214594091|NCT02761551|BEHAVIORAL|Reminder notifications via autodialer|
214594092|NCT00932685|DRUG|Midazolam|Midazolam 0.5mg/kg
214594093|NCT00932685|DEVICE|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
214594094|NCT05216900|RADIATION|Neoadjuvant radiotherapy|"The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap."
214594095|NCT05644457|GENETIC|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
214594096|NCT03589092|GENETIC|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
214594097|NCT05815290|DRUG|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
214594098|NCT04744441|PROCEDURE|CHOLECYSTECTOMY|Surgical treatment
214594099|NCT04744441|PROCEDURE|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
214594100|NCT04744441|PROCEDURE|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
214594101|NCT03186196|DIETARY_SUPPLEMENT|Diet containing Folate|
214594102|NCT04270357|PROCEDURE|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
214594103|NCT05438368|BIOLOGICAL|bi-4SCAR GD2/CD70 T cells|Infusion of bi-4SCAR GD2/CD70 T cells at 10\^6 cells/kg body weight via IV
214594104|NCT02776345|OTHER|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
214594105|NCT02776345|OTHER|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
214594106|NCT02776345|OTHER|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
214594107|NCT01004380|DRUG|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
214594108|NCT05137860|DRUG|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
214594109|NCT05317988|BEHAVIORAL|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
214594110|NCT05317988|BEHAVIORAL|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
214594111|NCT03706950|DRUG|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
214594112|NCT05844787|DRUG|MT101-5|Tablet
214594113|NCT05805098|DRUG|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
214594114|NCT05805098|DRUG|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
214594115|NCT05805098|DRUG|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
214594116|NCT02849301|DEVICE|Arabin cervical pessary|
214594117|NCT00954421|DEVICE|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
214594118|NCT00633061|DRUG|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
214594119|NCT05798611|DRUG|ART0380|Randomized patients will orally receive ART0380.
214594120|NCT06283979|COMBINATION_PRODUCT|STIMULAN VG|Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
214594121|NCT06283979|PROCEDURE|Standard of Care|Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
214594122|NCT06060392|DRUG|Semaglutide Pill|Patient will receive oral semaglutide
214594123|NCT06685575|PROCEDURE|Endoscopic Foraminotomy Surgery|Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis
214594124|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant low dose|The PA5108 Ocular Implant low dose is supplied preloaded into the needle of a single use administration device ready for use.
214594125|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant, high dose|The PA5108 Ocular Implant high dose is supplied preloaded into the needle of a single use administration device ready for use.
214594126|NCT06964191|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops at a concentration of 0.005%
214594127|NCT03123276|DRUG|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
214594128|NCT03123276|DRUG|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
214594129|NCT04559919|OTHER|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
214594130|NCT04559919|DIAGNOSTIC_TEST|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
214594131|NCT04559919|OTHER|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
214594132|NCT04559919|OTHER|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
214594133|NCT04559919|OTHER|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
214594134|NCT05245097|DEVICE|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
214594135|NCT05245097|OTHER|Standard of Care (SOC)|The standard of care (SOC) in the US for managing the fall risk of geriatric patients is the CDC's Stopping Elderly Accidents, Deaths, and Injuries (STEADI) initiative, which implements the America and British Geriatric Societies'' Clinical Practice Guidelines for fall risk management. The STEADI algorithm consists of tools and resources for healthcare providers for fall risk screening, assessment, and interventioniv,v. Screening and assessment includes identifying fall history and modifiable factors related to fall and fall injury risk (e.g. fear of falling, gait, strength, balance, medications, comorbidities, etc.); then interventions to reduce the fall and fall injury risk are applied based upon assessment findings, and can include physical therapy, medication adjustments, patient education, bed and chair alarms, bed rails, etc.
214594136|NCT04770493|DRUG|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
214594137|NCT04770493|DRUG|Placebo|Matching placebo (sugar pill)
214594138|NCT04700306|BEHAVIORAL|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
214594139|NCT06457503|DRUG|Toripalimab|Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
214594140|NCT06457503|DRUG|Cisplatin|Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
214594141|NCT06457503|DRUG|Gemcitabine|Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
214594142|NCT06457503|DRUG|Carboplatin|In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
214594143|NCT01979367|DEVICE|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
214594144|NCT06529380|DEVICE|DBS ON|Electrical stimulation of the nucleus accumbens.
214594145|NCT06529380|DEVICE|DBS OFF|DBS will remain OFF (on at 0V).
214594146|NCT05404685|DEVICE|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
214594147|NCT05404685|DEVICE|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
214594148|NCT02791737|BEHAVIORAL|Exercise Intervention|Complete individualized exercise program
214594149|NCT02791737|OTHER|Laboratory Biomarker Analysis|Correlative studies
214594150|NCT02791737|PROCEDURE|Physical Therapy|Complete individualized exercise program
214594151|NCT02791737|OTHER|Quality-of-Life Assessment|Ancillary studies
214594152|NCT02791737|OTHER|Questionnaire Administration|Ancillary studies
214594153|NCT05042505|DRUG|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
214594154|NCT05042505|DRUG|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
214594155|NCT05844228|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214711033|NCT06190405|DIAGNOSTIC_TEST|Risk-based screening by ACOG with two-step GTT|Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
214594157|NCT00692978|DRUG|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
214594158|NCT00692978|DRUG|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
214594159|NCT00692978|DRUG|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
214594160|NCT00692978|DRUG|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
214594161|NCT04540744|DRUG|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
214594162|NCT04540744|DRUG|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
214594163|NCT04540744|DRUG|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
214594164|NCT02504515|OTHER|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
214594165|NCT00607022|DEVICE|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
214594166|NCT04842656|OTHER|Post isometric relaxation|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
214594167|NCT04842656|OTHER|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
214594168|NCT03511313|DEVICE|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
214594169|NCT03511313|DIAGNOSTIC_TEST|Renal angiography|A renal angiography according to standard procedure.
214594170|NCT06565000|OTHER|AHA Not Instrumented then AHA Instrumented|First, the participant will undergo a performance assessment using the Assisting Hand Assessment test, following the standard protocol in the occupational therapy room. Subsequently, they will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Finally, a second round of assessment using the Assisting Hand Assessment will be conducted.
214594171|NCT06565000|OTHER|AHA Instrumented then AHA Not Instrumented|"First, the participant will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Then, will undergo a performance assessment using the Assisting Hand Assessment test.~Finally, they will go to the occupational therapy room where a second round of assessment using the Assisting Hand Assessment without markers will be conducted."
214594172|NCT06567808|DRUG|Cefazolin|administration as outlined
214594173|NCT06567808|DRUG|Vancomycin|administered as outlined
214594174|NCT05908045|OTHER|KAP Survey|This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
214594175|NCT05363371|BEHAVIORAL|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
214594176|NCT05363371|BEHAVIORAL|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
214594177|NCT04020354|BEHAVIORAL|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
214594178|NCT04020354|BEHAVIORAL|Usual Care|Usual customary care
214594179|NCT00834145|DEVICE|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
214594180|NCT01870232|PROCEDURE|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
214594181|NCT04296253|GENETIC|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
214594182|NCT02769377|DEVICE|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
214594183|NCT02769377|DEVICE|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
214594184|NCT02542111|DRUG|Bortezomib|Bortezomib IV
214594185|NCT02542111|DRUG|Gemcitabine|Gemcitabine IV
214594186|NCT02542111|DRUG|Dexamethasone|Dexamethasone IV
214594187|NCT02542111|DRUG|Cisplatin|Cisplatin IV
214594188|NCT03120247|DRUG|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
214594189|NCT03120247|DRUG|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
214594190|NCT03120247|DRUG|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
214594191|NCT03987178|BEHAVIORAL|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
214594192|NCT03987178|OTHER|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
214594193|NCT06096987|OTHER|Electronic medical record portal videos|Teen to teen videos reviewing information about electronic medical record portals and information shared in electronic medical record portals.
214594194|NCT06096987|OTHER|General adolescent health videos|Teen to teen videos reviewing information about general adolescent health issues.
214594195|NCT05425628|DEVICE|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
214594196|NCT04113083|OTHER|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
214594197|NCT04398953|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
214594198|NCT05748054|DRUG|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
214594199|NCT03328403|DEVICE|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
214594200|NCT03328403|DEVICE|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
214594201|NCT05778877|DRUG|SEL-302|"SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR"
214594202|NCT04599712|DRUG|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
214594203|NCT01791036|PROCEDURE|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
214594204|NCT01791036|PROCEDURE|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
214594205|NCT06799065|DRUG|ATX-295|ATX-295 Tablets will be taken orally
214594206|NCT06523114|DEVICE|Transcatheter Arterial Embolization|After accessing the common femoral artery or radial artery, embolization is performed using embolic material after confirming abnormal blood vessel abnormalities, lesion hypervascularity, and lesion enhancement findings.
214594207|NCT03711175|PROCEDURE|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
214594208|NCT03711175|DEVICE|Shoulder implant|Reverse shoulder arthroplasty device
214594209|NCT06380855|PROCEDURE|Flexible colonoscope assisted hybrid transanal total mesorectal resection|Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
214594210|NCT00627263|BEHAVIORAL|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
214594211|NCT01005459|DRUG|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
214594212|NCT01005459|DRUG|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
214594213|NCT05229731|PROCEDURE|Neurovisual evaluation|Standardized tests and scales classically used during a neurovisual evaluation,
214594214|NCT05229731|PROCEDURE|Cerebral MRI|"Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir"
214594215|NCT04633486|DIAGNOSTIC_TEST|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
214594216|NCT04903730|DRUG|AER-901 Solution for Nebulization|"Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 \& 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo)."
214594217|NCT04903730|DRUG|Placebo|0.45% sterile saline for injection delivered via the FOX MOBILE device.
214594218|NCT01927705|BIOLOGICAL|FURESTEM-AD Inj.|
214594219|NCT02949804|BEHAVIORAL|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
214594220|NCT06095700|PROCEDURE|first rib resection|standard first rib resection
214594221|NCT06095700|PROCEDURE|First rib avulsion|As the active treatment, just instead of resectioning the first rib, we will do an avulsion of the first rib through the same incision
214594222|NCT01905137|DRUG|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
214594223|NCT01905137|DRUG|placebo|
214594224|NCT00269893|DRUG|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
214594225|NCT00269893|DRUG|Placebo|Matching Placebo soulution either bolus or infusion.
214594226|NCT06176807|RADIATION|Venous Excess Ultrasound Score|"\-- The IVC diameter : Grade 0: \<5 mm with respiratory variation Grade I: 5-9 mm with respiratory variation Grade II: 10-19 mm with respiratory variation Grade III: \>20 mm with respiratory variation Grade IV: \>20 mm with minimal or no respiratory variation~\- Hepatic vein (HV) interrogation by pulsed wave Doppler identification and analysis of A, S, and D waves.~Grade 0: normal S \> D Grade I: S \< D with antegrade S Grade III: S flat or inverted or biphasic trace - Portal vein Doppler (PD)as follow: Grade 0: \<0.3 pulsatility index Grade I: 0.3-0.49 pulsatility index Grade III: 0.5-1.0 pulsatility index Pulsatility index is calculated as (Vmax - Vmin)/Vmax~\- VEXUS staging of venous congestion. (VEXUS ) Grade 0: IVC grade \<III, HD grade 0, PV grade 0 Grade I: IVC grade IV, but normal HV/PV pattern Grade II: IVC grade IV with mild flow pattern abnormalities in HV/PV Grade III: IVC grade IV with severe flow pattern abnormalities in HV/PV"
214594227|NCT00357851|DRUG|Aprotinin|
214594228|NCT05786495|OTHER|Early Discontinuation of Antibiotics|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
214594229|NCT05786495|OTHER|Standard of Care|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
214594230|NCT00369473|DRUG|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
214594231|NCT00369473|DRUG|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
214594232|NCT03254485|DRUG|IW-1973|Oral Tablet
214594233|NCT03254485|DRUG|Placebo Oral Tablet|Oral Tablet
214594234|NCT01225419|DRUG|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
214594235|NCT01767480|DEVICE|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
214594236|NCT01767480|BEHAVIORAL|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
214594237|NCT03375528|DEVICE|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
214594238|NCT03668184|OTHER|preeclampsia|occurrence of pre-eclampsia
214594239|NCT02867319|BIOLOGICAL|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
214594240|NCT00106418|DRUG|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
214594241|NCT02614456|DRUG|interferon-gamma and nivolumab|
214594242|NCT05764993|BIOLOGICAL|CUVITRU - Ig subcutaneous human 20%|Subcutaneous Immunoglobin Replacement Therapy, SCigR
214594243|NCT05764993|OTHER|Standard Medical Therapy|Standard Medical Therapy
214594244|NCT04265833|OTHER|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
214594245|NCT04265833|OTHER|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
214594246|NCT04265833|OTHER|Calcium hydroxide|Calcium hydroxide (Ca\[OH\]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
214594247|NCT01003678|DRUG|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
214594248|NCT00777946|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
214594249|NCT00777946|DRUG|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
214594250|NCT00777946|DRUG|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
214594251|NCT00777946|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
214594252|NCT00777946|DRUG|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
214594253|NCT04675151|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
214594254|NCT04675151|DRUG|Pilocarpine|Pilocarpine ophthalmic solution
214594255|NCT04675151|OTHER|Placebo|Topical sterile ophthalmic solution
214594256|NCT02911493|BEHAVIORAL|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
214594257|NCT02911493|BEHAVIORAL|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
214594258|NCT03221192|OTHER|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.
214594259|NCT03221192|OTHER|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
214594260|NCT03221192|OTHER|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
214594261|NCT03187574|DEVICE|Elevate Ant™|Surgery with Elevate Ant™
214594262|NCT03187574|DEVICE|Perigee™|Surgery with Perigee™
214594263|NCT05740436|OTHER|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
214594264|NCT00486460|DRUG|Gemcitabine|
214594265|NCT00486460|DRUG|Curcumin|
214594266|NCT00486460|DRUG|Celebrex|
214594267|NCT03263286|DEVICE|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
214594268|NCT00181064|BEHAVIORAL|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
214594269|NCT00763867|DRUG|Placebo|
214594270|NCT00763867|DRUG|Sildenafil|
214594271|NCT01658826|DRUG|AIC316|100 mg oral administration
214594272|NCT01658826|DRUG|Valacyclovir|500 mg oral administration
214594273|NCT01767805|PROCEDURE|Standard incubator|
214594274|NCT01767805|PROCEDURE|Mini incubator|
214594275|NCT01767805|PROCEDURE|5% oxygen|
214594276|NCT01767805|PROCEDURE|20% oxygen|
214594277|NCT01377753|DEVICE|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
214594278|NCT02739373|DRUG|BMS-986189|
214594279|NCT02739373|OTHER|Placebo|
214594280|NCT04290169|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
214594281|NCT04290169|DEVICE|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
214594282|NCT05312151|DRUG|Psilocybin|Open label
214711034|NCT03589820|OTHER|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
214711035|NCT01349686|PROCEDURE|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
214594283|NCT02979483|OTHER|14-EISCP|"The 14-EISCP starts with the end of the first visit medical for patients who have symptoms suspicious of or confirmed symptomatic aPDAC (ECOG PS ≥ 2 and/or initially ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel):~The The 14-EISCP will include:~* Pain management,~* Nutritional management,~* Pathological examination and site of biopsy,~* Imaging,~* Endoscopy for diagnosis purpose or for biliary/duodenal stenting.~After the 14-EISCP, patients will receive best supportive care or chemotherapy according to their ECOG PS status:~* ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~* ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patients will be treated by: FOLFOX7 lightened"
214594284|NCT03794570|DEVICE|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
214594285|NCT03794570|DEVICE|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
214594286|NCT01598311|DRUG|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
214594287|NCT01598311|DRUG|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
214594288|NCT01598311|DRUG|Placebo|Placebo size 00 opaque hard gelatin capsules.
214594289|NCT05380778|DRUG|Deep anesthesia|"Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45"
214594290|NCT05380778|DRUG|Shallow anesthesia|"Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45"
214594291|NCT01413854|DRUG|sugar pill|One tablet two times daily during four weeks
214594292|NCT01413854|DRUG|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
214594293|NCT00658684|DRUG|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
214594294|NCT00824447|DRUG|Oralgen|allergen solution sublingually
214594295|NCT00824447|OTHER|placebo|placebo control
214594296|NCT06265870|DRUG|Albendazole|Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
214594297|NCT06265870|DRUG|Ivermectin or albendazole|Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
214594298|NCT00688103|DRUG|ETN Alone|etanercept (25 mg, twice/week, s.c.)
214594299|NCT00688103|DRUG|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
214594300|NCT06610851|DIAGNOSTIC_TEST|Blood sample|Blood sample and centrifugation
214594301|NCT06996951|DIAGNOSTIC_TEST|:PULMONARY FUNCTION TEST|PATIENT WILL HAVE PULMONARY FUNCTION TESTING PERFORMED, MEASURING FEV1/FVC.
214594302|NCT06996951|DIAGNOSTIC_TEST|NASAL ENDOSCOPY|PATIENT WILL HAVE NASAL ENDOSCOPY TO RECORD LUND KENNEDY ENDOSCOPIC SCORE
214594303|NCT06996951|DIAGNOSTIC_TEST|LEUKOSORB FILTER PAPER APPLICATION TO NASAL CAVITY|LEUKOSORB FILTER PAPER STRIP WILL BE APPLIED INSIDE THE NOSTRIL TO SAMPLE NASAL MUCOUS TO OBTAIN IMMUNOGLOBULIN LEVELS TO MONITOR INFLAMMATION WITHIN THE NASAL MUCOUS
214594304|NCT06996951|BEHAVIORAL|SINONASAL OUTCOME TEST 22 QUESTIONNAIRE|PATIENT WILL COMPLETE THE SINONASAL OUTCOME TEST 22 QUESTIONNAIRE TO EVALUATE FOR SINONASAL SYMPTOMS DURING THE STUDY
214594305|NCT06996951|BEHAVIORAL|CYSTIC FIBROSIS QUESTIONNAIRE-REVISED|PATIENT WILL COMPLETE THE CYSTIC FIBROSIS QUESTIONNAIRE-REVISED TO EVALUATE FOR CYSTIC FIBROSIS RELATED SYMPTOMS DURING THE STUDY
214594306|NCT06996951|BEHAVIORAL|PATIENT HEALTH QUESTIONNAIRE-9|PATIENT WILL COMPLETE THE PATIENT HEALTH QUESTIONNAIRE-9 TO EVALUATE FOR QUALITY OF LIFE DURING THE STUDY
214594307|NCT06996951|DRUG|STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID|PATIENT WILL STOP USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
214594308|NCT06609369|BEHAVIORAL|Experimental health intervention|Behavioral health intervention
214594309|NCT06609369|DRUG|Varenicline|Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily; Days 8-56: 1.0mg twice daily.
214594310|NCT00724308|OTHER|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
214594311|NCT00724308|OTHER|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
214594312|NCT05647239|DEVICE|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
214594313|NCT06527794|BEHAVIORAL|RHYTHM (Remote Hypertension Tracking Help Management)|Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners
214594314|NCT06527794|BEHAVIORAL|Enhanced usual care (UC)|All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.
214594315|NCT07011628|OTHER|Same Day Discharge|Patients in the same day discharge arm will be discharged from the hospital within 6 hours of arriving to the recovery unit and without an overnight stay in the hospital.
214594316|NCT07006571|DEVICE|Real tDCS|The electrodes of the device will be positioned according to the following scheme: one electrode (anode) will be applied on the skin overlying the motor cortices, one electrode (cathode) will be applied on the skin overlying the cervical cord, in the area corresponding to C6. Dosage: 4 mA for the anodal electrode and 4 mA for the cathodal electrode (intensity could be reduced if not tollerate by the patient). Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
214594317|NCT07006571|DEVICE|Sham tDCS|The electrodes will be positioned in the same way as the active device, but the current flow will be limited to the ramp-up (start of stimulation) and ramp-down (end of stimulation) phase, mimicking the sensation of stimulation without providing actual treatment. Dosage: Simulation of stimulation without actual current. Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
214594318|NCT06614764|OTHER|AG (experimental Andiroba Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the AG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
214594319|NCT06614764|OTHER|KF2G (Potassium nitrate gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the KF2G received application of the potassium nitrate gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
214594320|NCT06614764|OTHER|PG (Placebo Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the PG group received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
214594321|NCT07012226|OTHER|Low-calorie diet|Low-calorie diet based on calculated calorie needs
214594322|NCT01661478|OTHER|Training on motivational interviewing|
214594323|NCT06459466|PROCEDURE|kinesiotherapy exercises with cervical mobilization|Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction
214594324|NCT06459466|PROCEDURE|cervical Mobilization|This includes Cervical lateral glide mobilization
214594325|NCT06684652|PROCEDURE|3TB+6SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained sextant six-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
214594326|NCT06684652|PROCEDURE|3TB+12SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained fore-zone 12-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
214594327|NCT07014722|DEVICE|MERITMEDICAL Careflow™ Two-Lumen Central Venous Catheter|7 Fr, 150 mm, radio-opaque polyurethane catheter (OD 2.4 mm)
214594328|NCT07014722|DEVICE|ARROW Two-Lumen Central Venous Catheter|7 Fr, 160 mm, radio-opaque polyurethane catheter (OD 2.5 mm)
214594329|NCT07014722|DEVICE|ARROWg+ard Blue Plus® Two-Lumen Central Venous Catheter|8 Fr, 160 mm, radio-opaque polyurethane catheter with antimicrobial coating
214594330|NCT07014722|DEVICE|Multicath 2 Expert UP Two-Lumen Central Venous Catheter|7.5 Fr, 160 mm, central venous catheter (OD 2.5 mm). Polyurethane shaft embedded with silver ions.
214594331|NCT07015632|OTHER|Performance of the Upper Limb, Brooke Scale, grip strength test|Thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms.
214594332|NCT03602261|DRUG|Calcifediol Oral Capsule|Capsule, weekly
214594333|NCT03602261|DRUG|Placebo oral capsule|Capsule, weekly
214594334|NCT06690216|DIAGNOSTIC_TEST|PET/CT （[18F]AlF-NOTA-PCP2）|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
214594335|NCT06690216|DIAGNOSTIC_TEST|[18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
214594336|NCT07019220|DRUG|Gemcitabine|Intravesical installation
214594337|NCT07020689|PROCEDURE|CABS|Following diagnosis, individuals with OHS were counseled on therapeutic options, including CPAP therapy, body weight reduction, or CABS. The final decision was made through a shared decision-making process. The CABS procedure was conducted under general anesthesia and integrated bariatric and multilevel airway surgery within a single operative session. This transdisciplinary approach aimed to address both sleep-disordered breathing and obesity-related ventilatory compromise. A general surgeon performed the bariatric procedure, while an otorhinolaryngologist conducted the airway surgery sequentially during the same operation. For the bariatric component, laparoscopic sleeve gastrectomy (LSG) was the primary procedure, while laparoscopic Roux-en-Y gastric bypass was reserved for individuals with significant gastroesophageal reflux or poorly controlled diabetes. Airway surgery encompassed interventions at the nasal, palatal, and lingual levels.
214594338|NCT07019194|DRUG|Senaparib capsules(20mg)|Single oral dose of Senaparib administered under fasting condition, 1\*20mg capsules in first intervention period and then 2\*10mg capsules in second intervention period (after washout period: at least 5 days)
214594339|NCT07019194|DRUG|Senaparib capsules(10mg)|Single oral dose of Senaparib administered under fasting condition, 2\*10mg capsules in first intervention period and then 1\*20mg capsules in second intervention period (after washout period: at least 5 days)
214594340|NCT07020767|PROCEDURE|Vestibular Socket Therapy (VST) Group|A minimally invasive vestibular incision technique for atraumatic tooth extraction, followed by immediate implant placement using BioHorizons implants. The socket is augmented with MegaOss™ allograft and covered with T-barrier™ collagen membrane, stabilized with membrane tacks. Soft tissue closure is achieved with 7/0 nylon sutures. Customized composite healing abutments are used, and zirconia crowns are delivered at 3 months.
214594341|NCT07020767|PROCEDURE|Flap Elevation Group|Traditional mucoperiosteal flap elevation with intrasulcular and vertical incisions, followed by atraumatic extraction and immediate implant placement using BioHorizons implants. The socket is grafted with MegaOss™ allograft, covered with T-barrier™ collagen membrane, and stabilized with tacks. The site is closed with 7/0 nylon sutures. Healing abutments and zirconia crowns are applied following the same timeline as the VST group.
214594342|NCT07019701|DEVICE|High flow oxygen through nasal cannula and face mask and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx|High flow oxygen through nasal cannula and face mask, and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions
214594343|NCT07020962|OTHER|laughter therapy|Laughter therapy/yoga, classified as complementary therapy in medicine, is a unique form of exercise consisting of a combination of laughter, yoga and breathing techniques that allows us to laugh without any sense of humour.
214594344|NCT07020962|OTHER|routine nursing care|routine nursing care
214594345|NCT07018882|DEVICE|Sullivan|Patients who are clinically eligible for cochlear implant surgery and can tolerate the surgery will be asked for their consent and then undergo the cochlear implant procedure. The outcome of the cochlear implant surgery will be evaluated through auditory performance assessments. Additionally, adverse effects will be monitored to assess the efficacy and safety of the cochlear implants on auditory function.
214594346|NCT07019467|OTHER|Bed Bath With Auditory Hypnosis|"In the bed bath protocol accompanied by audio suggestion, a 30-60 minute audio recording containing audio suggestions specific to the ICU patient will be prepared with the support of a specialist hypnotherapist. This audio recording will include the following messages: - The purpose of the bed bath, - Procedures to be performed during the bed bath, - The benefits of the bed bath, - Feeling safe during the bed bath, - Improvement in physiological parameters and comfort levels after the bed bath.~While it is noted that auditory suggestion typically lasts 30-60 minutes, even a 15-minute auditory suggestion has been reported to provide benefits."
214594347|NCT07021326|OTHER|there is no intervention|This is an observational, cross-sectional study with no intervention. Data were collected through a single body composition measurement without any treatment or manipulation. Biochemical, clinical and anthropometric data was collected directly from the patient's clinical records. No intervention was needed.
214594348|NCT07019740|OTHER|CASE GROUP|SYMPATHETIC SKIN RESPONSE, CUTANEOUS QUIET PERIOD AND COMPASS-31 QUESTIONNAIRE EVALUATED
214594349|NCT07019012|DRUG|SGLT2i+Metformin+Cofrogliptin|The combination of SGLT2i+Metformin+Cofrogliptin
214594350|NCT07019012|DRUG|SGLT2i+Metformin+Linagliptin|The combination of SGLT2i+Metformin+Linagliptin
214594351|NCT07019272|DRUG|Neratinib (HKI-272)|"Sequential neratinib extended adjuvant therapy will be initiated within 6 months after completing standard trastuzumab-based adjuvant therapy, continuing for 1 year.~As a real-world non-interventional study, treating physicians will determine neratinib regimens per the prescribing information and current clinical practice.~Neratinib Dosing:~Standard regimen: 240 mg (6 tablets) once daily with food for 1 year；~Dose escalation (to mitigate diarrhea, per latest CSCO Breast Cancer Guidelines and FDA labeling):~Week 1: 120 mg/day (days 1-7) Week 2: 160 mg/day (days 8-14) Week 3 onward: 240 mg/day (days 15-365)"
214594352|NCT07021339|PROCEDURE|Anterior temporal lobectomy (ATL)|"Patients assigned to the experimental group will undergo an anterior temporal lobectomy (ATL) according to established protocols adapted from epilepsy surgery. ATL is a reproducible and anatomically well-defined procedure routinely performed in patients with pharmacoresistant temporal lobe epilepsy. On the non-dominant hemisphere, the neocortical resection typically extends 6.5 cm posteriorly from the temporal pole, while on the dominant side, the resection length is limited to 4.0 cm, both measured along the superior temporal gyrus and guided by the Sylvian fissure. Language dominance is determined based on handedness, as specified in the inclusion criteria. In most cases, the lateral neocortical segment can be removed en bloc.~The mesial component of ATL encompasses resection of the uncus, amygdala, and the anterior hippocampus, typically including both the head and body. Resection is carried out to the level of the tectal plate or, at minimum, to the lateral mesencephalic sulcus."
214594353|NCT07021339|PROCEDURE|Gross Total Resection (GTR)|Patients will be surgically treated with GTR in terms of removing 100% of the tumor tissue in gadolinium-enhanced MRI.
214594354|NCT07020819|DRUG|Tanruprubart|Solution for IV infusion.
214594355|NCT07019714|BEHAVIORAL|Daoyin Technique|"On the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Daoyin Technique for treatment. For patients who are able to complete the respiratory guidance technique. For patients who are unable to complete the respiratory guidance technique but have stable vital signs (referring to the Expert Consensus on Respiratory Critical Care Rehabilitation Treatment Techniques in China), the supine guidance technique is selected. It is carried out 5 days a week, 2 times a day, and each training session lasts for 30 minutes."
214594356|NCT07019714|BEHAVIORAL|Routine Comprehensive Training|"On the basis of treatment guided by IIdiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,the experimental group was given Routine Comprehensive Training. According to the patient's condition, select aerobic training (such as walking) or upper - limb and lower - limb resistance training (such as lifting, chest - expanding, foot - pedaling movements, etc.) combined with respiratory training (such as pursed - lip breathing, abdominal breathing, etc.). The heart rate should reach the target heart rate range and last for more than 10 minutes. This training is carried out 5 days a week, 2 times a day."
214594357|NCT07020455|DRUG|prolotherapy solution of 20% dextrose|Polotherapy, it involves injecting an irritant solution into weakened joints, ligaments, or tendons to stimulate collagen production and tissue repair at fibro-osseous junctions.
214594358|NCT07020455|DRUG|Arthrocentesis with ringer solution|Integrating arthrocentesis with prolotherapy may enhance therapeutic outcomes by addressing both the mechanical and inflammatory aspects of TMJ hypermobility. This dual-modality technique presents a promising minimally invasive option for clinicians managing patients with joint instability.
214711036|NCT01349686|PROCEDURE|Fasting|No intake of fluids during labour.
214594359|NCT07018947|DRUG|Atezolizumab and Bevacizumab|"Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy).~The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity."
214594360|NCT07019805|DRUG|Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam|This intervention refers to the standard induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Induction typically involves the administration of intravenous anesthetic agents such as propofol and fentanyl, based on institutional protocols and the anesthesiologist's discretion. This study does not modify or introduce any new treatment; it merely observes and records peri-induction parameters to identify factors associated with the occurrence of post-induction hypotension.
214594361|NCT07019805|DEVICE|Blood Pressure Continous Monitoring, syrnge pump for the anesthesia agent, and vasoconstrictor drug|This intervention involves the standard clinical use of non-invasive continuous blood pressure monitoring during the induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Intravenous anesthetic agents (e.g., propofol, fentanyl) and vasopressors (e.g., ephedrine, norepinephrine) are administered via syringe pumps based on the anesthesiologist's clinical judgment. The study does not introduce any experimental treatment but observes blood pressure changes in real time to identify risk factors for post-induction hypotension. The integration of continuous hemodynamic monitoring distinguishes this observational approach from routine anesthetic induction without such monitoring.
214594362|NCT07021300|PROCEDURE|Early Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed within 72 hours of diagnosis of acute cholecystitis. Surgery is done under general anesthesia by an experienced surgeon. This group receives no prolonged preoperative conservative management. Timing aligns with Tokyo Guidelines 2013 recommendation for early intervention
214594363|NCT07021300|PROCEDURE|Interval Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed after 4 weeks of initial conservative management with antibiotics and analgesics. The procedure is conducted under general anesthesia by the same experienced surgeon, using the same technique as the early group. This approach represents delayed surgical management per traditional protocols.
214594364|NCT07020195|PROCEDURE|Traditional SYNTAX scoring|Using traditional SYNTAX scoring to guide the selection of revascularization strategies
214594365|NCT07020195|PROCEDURE|QFR-Based Functional SYNTAX Score System|Using QFR-Based Functional SYNTAX Score System to guide the selection of revascularization strategies
214594366|NCT04337515|DEVICE|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
214594367|NCT05677893|DRUG|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
214594368|NCT05677893|OTHER|Placebo|Normal saline
214594369|NCT00599976|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation
214594370|NCT05791760|BEHAVIORAL|Compassion-focused therapy (CFT) for complex PTSD|The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
214594371|NCT01485354|DEVICE|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
214594372|NCT00050726|DRUG|Interleukin-2|
214594373|NCT01862302|DRUG|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
214594374|NCT01862302|DRUG|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
214594375|NCT05452850|DIAGNOSTIC_TEST|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
214594376|NCT02016456|DEVICE|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
214594377|NCT02016456|DEVICE|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
214594378|NCT02101034|BIOLOGICAL|Cetuximab|
214594379|NCT02101034|DRUG|PD 0332991|
214594380|NCT01652950|BEHAVIORAL|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was \>3000 fitness points/month - equivalent to \>20 gym visits/month."
214594381|NCT06323200|PROCEDURE|lymphaticovenous anastomosis|The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
214594382|NCT04994327|OTHER|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
214594383|NCT04600700|DEVICE|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
214594384|NCT02827630|OTHER|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
214594385|NCT02827630|OTHER|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
214594386|NCT00247338|DRUG|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
214594387|NCT02787525|OTHER|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
214594388|NCT03081052|DRUG|iNO|Subject will receive inhaled Nitric Oxide in this intervention
214594389|NCT03081052|DRUG|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
214594390|NCT05987722|OTHER|Enoxolone|The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
214594391|NCT05987722|OTHER|Sensodyne|The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
214594392|NCT00261313|DRUG|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
214594393|NCT00261313|DRUG|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
214594394|NCT00215878|DRUG|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
214594395|NCT00457184|PROCEDURE|Blood tests|
214594396|NCT04109196|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
214594397|NCT02214433|DRUG|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
214594398|NCT02214433|DRUG|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
214594399|NCT02214433|DRUG|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
214594400|NCT02214433|DRUG|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
214594401|NCT02214433|DRUG|Debio 1450 Capsule|Debio 1450 40 mg capsules
214594402|NCT02214433|DRUG|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
214594403|NCT02214433|DRUG|Pantoprazole|Pantoprazole 40 mg orally
214594404|NCT03597412|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
214594405|NCT03597412|DRUG|Monorova|Rosuvastatin 20mg
214594406|NCT06236529|BEHAVIORAL|Health Behavior Change Counseling|A telephone-based intervention employing principles and practices of motivational interviewing.
214594407|NCT06236529|BEHAVIORAL|Self-management program|An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
214594408|NCT04111432|BIOLOGICAL|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
214594409|NCT04111432|BIOLOGICAL|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
214594410|NCT04111432|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
214594411|NCT05214196|DRUG|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
214594412|NCT05522933|OTHER|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health \& work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
214594413|NCT00432887|DRUG|caffeine administration|
214594414|NCT03635333|DRUG|Nicotine|Nicotine level (6 or 18 mg)
214594415|NCT03635333|DRUG|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
214594416|NCT06450756|BEHAVIORAL|Couples arm|The Couples Arm aims to improve family planning (FP) utilization in pastoralist communities, addressing significant disparities in contraceptive use and unmet FP needs between pastoralist and agrarian communities in Ethiopia. Pastoralist areas face challenges such as low contraceptive usage, high unmet FP needs, and elevated rates of maternal and child morbidity and mortality. In 2016, only 9.1% of women in pastoralist areas used contraceptives, compared to a 41% prevalence rate in 2019 for the general population in Ethiopia. Reasons for non-use of contraceptives include lack of knowledge, unwillingness, negative perceptions, desire for many children due to child mortality concerns, and male dominance in FP decision-making. The study hypothesizes that engaging men and educating women about FP could enhance FP utilization, increase male involvement in family planning, and empower women.
214594417|NCT06450756|BEHAVIORAL|Male arm|This arm focused on promoting male involvement in family planning (FP) through comprehensive health education and video messages. Husbands were encouraged to become supportive partners and share FP information with their wives. Separate education sessions were held for men, recognizing their greater exposure to social activities and information in pastoralist contexts. Pastoralist wives typically rely on their husbands for information due to limited social access. Women in pastoral communities have significant informal power in family decisions, influenced by factors such as age, husband's status, sons' ages, eloquence, and wisdom. Reproductive health discussions are primarily between husband and wife. Education aimed to improve modern contraceptive use, overcoming common barriers like husband objection and religious influence on decision-making.
214594418|NCT00604279|DRUG|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
214594419|NCT00604279|DRUG|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
214594420|NCT03348865|BEHAVIORAL|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
214594421|NCT02884427|DEVICE|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
214594422|NCT02884427|DEVICE|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
214594423|NCT02884427|DEVICE|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
214594424|NCT05802758|BEHAVIORAL|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
214594425|NCT00861224|OTHER|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
214594426|NCT01894373|DRUG|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
214594427|NCT01894373|BIOLOGICAL|CIK|
214594428|NCT00901277|BEHAVIORAL|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
214594429|NCT00901277|BEHAVIORAL|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
214594430|NCT03898947|PROCEDURE|Diagnostic hysteroscopy and targeted endometrial biopsy|Diagnostic hysteroscopy and targeted endometrial biopsy
214594431|NCT01489202|DEVICE|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
214594432|NCT01489202|DEVICE|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
214594433|NCT00733993|DRUG|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
214594434|NCT00733993|DRUG|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
214594435|NCT00733993|DRUG|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
214594436|NCT00733993|DRUG|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
214594437|NCT04201600|DEVICE|Continuous Glucose Monitoring System (CGMS)|Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
214594438|NCT02782403|DRUG|Axitinib|Given PO
214594439|NCT02782403|DRUG|Bosutinib|Given PO
214594440|NCT02782403|OTHER|Laboratory Biomarker Analysis|Correlative studies
214594441|NCT05351853|DIETARY_SUPPLEMENT|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
214594442|NCT05351853|DIETARY_SUPPLEMENT|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
214594443|NCT05351853|DIETARY_SUPPLEMENT|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
214594444|NCT02804776|DRUG|Gefitinib|250mg oral daily for 4 weeks
214594445|NCT00031187|DRUG|SGN-15 (cBR96-doxorubicin immunoconjugate)|
214594446|NCT00031187|DRUG|Taxotere (docetaxel)|
214711037|NCT05783453|OTHER|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~* Formula: 2039055 06~* Aspect: Emulsion~* Batch nº: RAUO0063~* Expiry date: 10/2022~* Application area: Face and Body~* Application mode: Apply to face and body twice a day.~* Quantity of product to be applied: About 1 flask (400g) per month"
214711038|NCT03805555|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
214711039|NCT03805555|PROCEDURE|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
214594447|NCT02952287|DEVICE|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
214594448|NCT00062894|DRUG|Iodine I 131 Tositumomab|
214594449|NCT02895438|DIETARY_SUPPLEMENT|gluten|
214594450|NCT00044915|DRUG|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
214594451|NCT00044915|DRUG|Placebo|All patients receive 1.25 mg of placebo
214594452|NCT00995020|PROCEDURE|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
214594453|NCT00995020|PROCEDURE|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
214594454|NCT04279938|DRUG|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
214594455|NCT04279938|DRUG|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
214594456|NCT04279938|DRUG|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
214594457|NCT02053038|DEVICE|iFR|Treatment guided by instantaneous wave-free ratio
214594458|NCT02053038|DEVICE|FFR|Treatment guided by Fractional Flow Reserve
214594459|NCT06284148|DIAGNOSTIC_TEST|Screening for intimate partner violence|confidential screening using exam computer
214594460|NCT06284148|OTHER|Assessment and referral|confidential assessment and referral of high-risk patients using decision-support templates
214594461|NCT02347228|DRUG|OB318 capsule|Oral qd, at least 30 minutes before breakfast
214594462|NCT03412370|OTHER|Cognitive Assessment|Complete cognitive assessments
214594463|NCT03412370|OTHER|Questionnaire Administration|Complete questionnaires
214594464|NCT02837835|DRUG|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
214594465|NCT02837835|DRUG|ceftazidime|20 mg/kg over 30 min every 8 h
214594466|NCT06409780|DIAGNOSTIC_TEST|Comparative analysis of CUS, CAD and CXR in pulmonary TB|The strumental analysis of pulmonary TB signs with chest ultrasound, chest x-ray and CAD will be compared in two different settings: index cases and household contacts
214594467|NCT04604678|DRUG|Metformin|Metformin at 1500 mg/day
214594468|NCT04604678|DRUG|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
214594469|NCT03325998|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
214594470|NCT04750174|OTHER|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
214594471|NCT03130543|DIETARY_SUPPLEMENT|Rice cereal|Standard formula thickened with rice cereal
214594472|NCT03130543|DIETARY_SUPPLEMENT|Enfamil AR|Enfamil AR formula
214594473|NCT00234546|BIOLOGICAL|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
214594474|NCT00234546|DRUG|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
214594475|NCT05877625|PROCEDURE|Expectoration care|"1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs"
214594476|NCT04471623|BEHAVIORAL|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
214594477|NCT05206019|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
214594478|NCT00100854|DRUG|erlotinib hydrochloride|Given orally
214594479|NCT00100854|DRUG|fulvestrant|Given intramuscularly
214594480|NCT01121120|DRUG|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
214594481|NCT01121120|DRUG|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
214594482|NCT04878731|BIOLOGICAL|PF-06741086|single dose SC injection of 300 mg PF-06741086
214594483|NCT02234245|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
214594484|NCT00699452|DRUG|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
214594485|NCT00699452|DRUG|placebo|placebo
214594486|NCT02800226|DEVICE|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
214594487|NCT02800226|DEVICE|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
214594488|NCT06411483|DEVICE|ObeEnd Band|The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
214594489|NCT06411483|OTHER|Placebo|The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
214594490|NCT00124852|BEHAVIORAL|n-3 Fatty Acid Supplementation|
214594491|NCT00510250|DRUG|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
214594492|NCT00510250|DRUG|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
214594493|NCT00510250|PROCEDURE|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
214594494|NCT02705144|OTHER|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
214594495|NCT02730988|BEHAVIORAL|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
214594496|NCT01141738|BEHAVIORAL|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
214594497|NCT01141738|BEHAVIORAL|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
214594498|NCT01364363|PROCEDURE|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
214594499|NCT02047292|DEVICE|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
214594500|NCT02047292|DEVICE|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
214594501|NCT02047292|DEVICE|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
214594502|NCT04510909|OTHER|COMMIT mHealth application|The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
214594503|NCT00439530|DRUG|oseltamivir|
214594504|NCT00439530|DRUG|probenecid|
214594505|NCT03268733|DRUG|Folic Acid|Tablet 5 mg
214594506|NCT02221986|BEHAVIORAL|Interdisciplinary rehabilitation|
214594507|NCT04206592|DEVICE|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
214594508|NCT00557388|DIETARY_SUPPLEMENT|Protein/Amino Acids|Casein Whey Leucine
214594509|NCT00557388|OTHER|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
214594510|NCT02208154|DRUG|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
214594511|NCT02208154|DRUG|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.
214594512|NCT02208154|DRUG|Selective Digestive Decontamination (SDD)|"SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
214594513|NCT04548414|OTHER|No.|This is an observational study with no intervention.
214594514|NCT02797210|DEVICE|Continuous theta-burst stimulation|
214594515|NCT03305068|DRUG|Celecoxib|
214594516|NCT05188326|DRUG|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
214594517|NCT05188326|OTHER|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
214594518|NCT03330457|BIOLOGICAL|Andexanet alfa (bolus)|fXa inhibitor antidote
214594519|NCT03330457|DRUG|Betrixaban 80 mg PO QD|fXa inhibitor
214594520|NCT03330457|BIOLOGICAL|Andexanet alfa (infusion IV)|fXa inhibitor antidote
214594521|NCT03538379|BEHAVIORAL|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
214594522|NCT00719563|DRUG|American ginseng|Given orally
214594523|NCT00719563|OTHER|placebo|Given orally
214594524|NCT01030679|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
214594525|NCT01030679|DRUG|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
214594526|NCT01030679|DRUG|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
214594527|NCT01030679|DRUG|Placebo|orally, 1 tablet once daily for 8 weeks
214594528|NCT03513172|DRUG|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
214594529|NCT02997488|DEVICE|Pentax Airwayscope|intubation using Pentax Airwayscope
214594530|NCT02997488|DEVICE|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
214594531|NCT05119426|BIOLOGICAL|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
214594532|NCT04183972|PROCEDURE|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
214594533|NCT00567268|DRUG|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
214594534|NCT00420017|DRUG|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
214594535|NCT00420017|OTHER|Control|No amiodarone
214594536|NCT02877472|DEVICE|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
214594537|NCT02877472|PROCEDURE|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
214594538|NCT00440804|DRUG|ibuprofen l-lysine iv solution (NeoProfen (R) )|
214711040|NCT05632224|DRUG|Aprepitant|The drug is given 1 hour before the start of the surgery
214594539|NCT03235622|DIAGNOSTIC_TEST|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
214711041|NCT05632224|DRUG|Granisetron|The drug is given 10 minutes before the patients's extubation
214711042|NCT02915952|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
214594540|NCT02950324|BEHAVIORAL|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
214594541|NCT02950324|BEHAVIORAL|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
214594542|NCT01868113|DRUG|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
214594543|NCT01868113|OTHER|Placebo|Placebo to be administered 12hourly
214594544|NCT01418820|DEVICE|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
214594545|NCT01418820|DEVICE|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
214594546|NCT01631604|DEVICE|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
214594547|NCT01631604|DRUG|Muscle/nerve injection|Injection to muscle or nerve
214594548|NCT01631604|PROCEDURE|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
214594549|NCT01631604|OTHER|Physical therapy treatment|
214594550|NCT05381831|DRUG|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
214594551|NCT03249077|BEHAVIORAL|Digital DPP|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
214594552|NCT03249077|BEHAVIORAL|In-person DPP|The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
214594553|NCT03249077|OTHER|DPP not enrolled|Access to usual care services without restrictions.
214711043|NCT02915952|OTHER|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
214594554|NCT03218462|BEHAVIORAL|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
214594555|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
214594556|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
214594557|NCT00376181|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
214594558|NCT05490979|BEHAVIORAL|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
214594559|NCT05490979|BEHAVIORAL|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
214594560|NCT03393715|DRUG|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
214594561|NCT00792805|DRUG|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214594562|NCT00792805|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214594563|NCT00792805|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214594564|NCT03224325|DRUG|TAK-831 Tablet T2|Tak-831 tablets.
214594565|NCT03224325|DRUG|Placebo|TAK-831 placebo-matching suspension.
214594566|NCT03224325|DRUG|TAK-831 Suspension|TAK-831 Suspension.
214594567|NCT02649153|DRUG|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
214594568|NCT02649153|DRUG|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
214594569|NCT01889056|DRUG|Erythropoietin (Epoetin beta)|
214594570|NCT01889056|DRUG|Placebo|0.9% sodium chloride solution
214594571|NCT00849719|DRUG|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
214594572|NCT00849719|DRUG|PCA MO only|When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
214594573|NCT00134316|BEHAVIORAL|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
214594574|NCT04434950|BEHAVIORAL|Promoting and implementing repeated HIV self-testing and online real-time counseling|At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
214711044|NCT01096043|DRUG|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
214711045|NCT01096043|DRUG|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
214711046|NCT01096043|DRUG|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
214711047|NCT01096043|DRUG|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
214711048|NCT00700895|DRUG|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
214594575|NCT02952001|DRUG|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
214594576|NCT02952001|DRUG|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
214594577|NCT03599557|BEHAVIORAL|STOP-HPV communication intervention|This intervention will be communication skills training.
214594578|NCT01535183|DRUG|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
214594579|NCT02604225|DRUG|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
214594580|NCT02604225|DRUG|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
214594581|NCT03531281|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
214594582|NCT03531281|DRUG|Cyclophosphamide|Given IV
214594583|NCT03531281|DRUG|Etoposide|Given IV
214594584|NCT03531281|DRUG|Goat Milk|Given human lysozyme goat milk PO
214594585|NCT03531281|OTHER|Laboratory Biomarker Analysis|Correlative studies
214594586|NCT03531281|BIOLOGICAL|Palifermin|Given IV
214594587|NCT03531281|DRUG|Sirolimus|Given PO
214594588|NCT03531281|DRUG|Tacrolimus|Given IV and PO
214594589|NCT03531281|RADIATION|Total-Body Irradiation|Undergo FTBI
214594590|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
214594591|NCT03686202|BIOLOGICAL|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
214594592|NCT05650099|DEVICE|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
214594593|NCT05792436|DEVICE|1-min interval oscillometric method|"Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period."
214594594|NCT05792436|DEVICE|arterial catheterization method|During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
214594595|NCT04533451|DRUG|Pembrolizumab|Given IV
214594596|NCT04533451|DRUG|Pemetrexed|Given IV
214594597|NCT04533451|DRUG|Carboplatin|Given IV
214594598|NCT04533451|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
214594599|NCT04533451|OTHER|Questionnaire Administration|Ancillary studies
214711049|NCT00907582|PROCEDURE|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
214594600|NCT04533451|OTHER|Quality-of-Life Assessment|Ancillary studies
214594601|NCT02537626|DEVICE|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
214594602|NCT02537626|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
214594603|NCT04576143|DRUG|Epirubicin|i.v. 90 mg/m2
214594604|NCT04576143|DRUG|Cyclophosphamid|i.v. 600 mg/m2
214594605|NCT04576143|DRUG|Docetaxel|i.v. 100 mg/m2
214594606|NCT04576143|DRUG|Paclitaxel|i.v. 175 mg/m2
214594607|NCT05134870|BEHAVIORAL|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
214594608|NCT05555056|DEVICE|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
214594609|NCT05555056|DEVICE|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
214594610|NCT04174079|DRUG|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
214594611|NCT00337519|PROCEDURE|allogeneic stem cell transplantation|see detailed description
214594612|NCT00337519|DRUG|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
214594613|NCT03890419|DEVICE|Green light|Green light exposure
214594614|NCT03890419|DEVICE|Clear light|Full spectrum light exposure
214594615|NCT03890419|DEVICE|Blue Light|Blue light exposure
214594616|NCT01659619|DRUG|Erythromycin|125mg in normal saline single use infusion for 5 min.
214594617|NCT03404765|BEHAVIORAL|Tai Chi|
214594618|NCT04877795|DIAGNOSTIC_TEST|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
214594619|NCT06357351|PROCEDURE|vestibular incision sub periosteal tunnel access ( VISTA) technique.|In comparison between the two groups, the first group uses collagen membrane and the other group uses advanced PRF using the same surgical technique (VISTA)
214594620|NCT05810272|BEHAVIORAL|Metabolic Trial|Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
214594621|NCT05810272|BEHAVIORAL|15 sit-to-stands with calf raises|Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
214594622|NCT01996813|DEVICE|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
214594623|NCT03497754|DEVICE|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
214594624|NCT03376945|DRUG|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
214594625|NCT03376945|DRUG|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
214594626|NCT02216643|PROCEDURE|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
214711050|NCT02729077|DEVICE|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
214594627|NCT02216643|DEVICE|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
214594628|NCT00056485|BEHAVIORAL|Pleasant Events-Based Behavioral Intervention|
214594629|NCT04446533|DRUG|Hydrogen Peroxide and Hyaluronic acid filming formulation|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
214594630|NCT04446533|DRUG|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
214594631|NCT04446533|DRUG|Placebo|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
214594632|NCT00852046|DRUG|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
214594633|NCT03278106|OTHER|Laboratory Biomarker Analysis|Correlative studies
214594634|NCT03278106|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
214594635|NCT04910854|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
214594636|NCT06494202|OTHER|Innovative rehabilitation|Conventional rehabilitation program associated with innovative therapies.
214594637|NCT06494202|OTHER|Conventional rehabilitation program.|Conventional rehabilitation program
214594638|NCT05711966|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
214594639|NCT05711966|DEVICE|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
214594640|NCT05381779|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
214594641|NCT05381779|OTHER|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
214594642|NCT05381779|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
214594643|NCT01956500|DIETARY_SUPPLEMENT|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
214594644|NCT01956500|DIETARY_SUPPLEMENT|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
214594645|NCT05826743|DEVICE|COLO BT™|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
214594646|NCT05826743|OTHER|Stoma Creation|Protective ileostomy
214594647|NCT02777723|DRUG|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
214594648|NCT02777723|DRUG|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
214594649|NCT06795230|OTHER|Muscle strengthening (BFRT)|"The experimental group will perform a low-intensity strengthening program (20% 1RM) in combination with the BFRT system consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, performing 4 sets of 30/15/15/15 repetitions as usual in this type of interventions.~Once the first exercise has been completed, a rest of 3 - 4 minutes should be taken depending on the fatigue perceived by the patient. Subsequently, the other two exercises will be performed following the scheme already outlined.~Taking into account the scientific evidence concerning the safety and adverse effects linked to the BFRT system, it is determined that the pressure applied in the experimental protocol will be 60% of the TRP of each subject, following the recommendations that locate the effective pressure between 50 - 80% of the TRP of each subject."
214594650|NCT06795230|OTHER|Conventional physical therapy|The control group will perform a conventional muscle strengthening protocol consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, with a dumbbell at 70% of 1RM, performing a total of 4 sets of 8 - 12 repetitions each, avoiding muscle failure in each set.
214594651|NCT04692415|DRUG|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
214594652|NCT04692415|DRUG|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
214594653|NCT00069316|DRUG|Omr-IgG-am|
214711051|NCT01905670|DEVICE|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
214594654|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
214594655|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
214594656|NCT00302419|DRUG|intracoronary infusion,|streptokinase, 250,000 units
214594657|NCT00302419|PROCEDURE|primary percutaneous coronary angioplasty|
214594658|NCT04200131|DIAGNOSTIC_TEST|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
214594659|NCT00452088|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
214711052|NCT04396743|PROCEDURE|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
214594660|NCT00452088|BIOLOGICAL|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
214594661|NCT00452088|BIOLOGICAL|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
214594662|NCT05300074|OTHER|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
214594663|NCT02982187|DEVICE|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
214594664|NCT02982187|DEVICE|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
214594665|NCT02982187|DEVICE|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
214594666|NCT02982187|DEVICE|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
214594667|NCT02982187|OTHER|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
214594668|NCT02982187|OTHER|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
214594669|NCT02982187|OTHER|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
214594670|NCT02982187|OTHER|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
214594671|NCT06159322|DRUG|Olanzapine|Antipsychotic medication
214594672|NCT06159322|DRUG|Clozapine|Antipsychotic medication
214594673|NCT02604433|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
214594674|NCT02604433|OTHER|Placebo|Placebo, Subcutaneous, every 21 days.
214594675|NCT02376075|DRUG|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
214594676|NCT02376075|DRUG|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
214594677|NCT01366287|DRUG|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
214594678|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
214594679|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
214594680|NCT03437278|DRUG|Ligelizumab|Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
214711053|NCT04396743|PROCEDURE|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
214711054|NCT06159829|BEHAVIORAL|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
214594681|NCT03437278|DRUG|Placebo|Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
214594682|NCT02202551|DRUG|ADS-5102|
214594683|NCT04196153|PROCEDURE|Pedicle screws instrumentation|The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
214594684|NCT01412099|BEHAVIORAL|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
214594685|NCT01412099|BEHAVIORAL|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
214594686|NCT05827211|PROCEDURE|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
214594687|NCT05827211|PROCEDURE|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
214594688|NCT00931554|PROCEDURE|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
214594689|NCT00288795|OTHER|Massage Therapy|Therapeutic Touch
214594690|NCT00288795|OTHER|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
214594691|NCT06091761|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
214594692|NCT06091761|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
214594693|NCT06091761|OTHER|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
214594694|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
214594695|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
214594696|NCT02147353|DRUG|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
214594697|NCT02147353|DRUG|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
214594698|NCT03774251|BIOLOGICAL|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
214594699|NCT03774251|DEVICE|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
214594700|NCT04934488|BEHAVIORAL|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
214594701|NCT01951781|OTHER|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
214594702|NCT05155241|BEHAVIORAL|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
214594703|NCT05155241|BEHAVIORAL|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
214594704|NCT05519397|DIAGNOSTIC_TEST|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
214594705|NCT04672174|DIAGNOSTIC_TEST|Questionnaire: DemTect|Questionnaire is handed out to subjects
214594706|NCT02919657|DIETARY_SUPPLEMENT|Genepro Protein|weekly blood draws to measure blood protein levels
214594707|NCT02919657|DIETARY_SUPPLEMENT|Whey Protein|weekly blood draws to measure blood protein levels
214594708|NCT00604812|DRUG|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
214594709|NCT00604812|DRUG|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
214594710|NCT00604812|DRUG|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
214594711|NCT00604812|DRUG|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
214594712|NCT02335125|BEHAVIORAL|Motivational Interviewing|
214594713|NCT02335125|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
214594714|NCT02335125|DRUG|Psychotropic Drugs|
214594715|NCT02335125|OTHER|Care Management|
214594716|NCT06321549|OTHER|The reference point of minimally invasive mastectomy procedure conducted|November 2018 as a temporal reference point was predicated on the milestone of the medical center's inaugural minimally invasive mastectomy procedure conducted
214594717|NCT01326533|DRUG|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
214594718|NCT01326533|OTHER|Placebo|Thirteen weeks of oral placebo provided as capsules
214594719|NCT04990492|DIAGNOSTIC_TEST|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
214594720|NCT04990492|DIAGNOSTIC_TEST|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
214594721|NCT00926211|DEVICE|ARTAS™ System|Hair harvest using a computer-assisted system
214594722|NCT00926211|PROCEDURE|Manual Hair Harvest|Hair harvesting via the manual technique
214594723|NCT00078754|DRUG|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
214594724|NCT00078754|DRUG|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
214594725|NCT00078754|DRUG|Placebo|Placebo capsules by mouth, up to 8 capsules daily
214594726|NCT02696772|OTHER|Energy intake|
214594727|NCT01520896|DRUG|NKTR-118|Oral 25 mg
214594728|NCT01520896|DRUG|Ketoconazole|Oral 400 mg
214594729|NCT03107650|PROCEDURE|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
214594730|NCT04579965|DRUG|medical treatment of isthmocele|comparison between different drugs
214594731|NCT04777526|OTHER|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
214594732|NCT04777526|OTHER|Joint protection program|Reeducation in the activities daily life
214594733|NCT04777526|OTHER|Thumb orthosis|Thumb night orthosis
214594734|NCT04777526|OTHER|Manual distraction|Manual distraction of CMC joint
214594735|NCT06498531|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
214594736|NCT06498531|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
214594737|NCT00991263|GENETIC|gene expression analysis|
214594738|NCT00991263|GENETIC|polymerase chain reaction|
214594739|NCT00991263|OTHER|laboratory biomarker analysis|
214594740|NCT05048537|RADIATION|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
214594741|NCT04117009|DRUG|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
214594742|NCT04117009|DIAGNOSTIC_TEST|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
214594743|NCT00248690|DEVICE|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
214594744|NCT03240757|DIETARY_SUPPLEMENT|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
214594745|NCT03240757|OTHER|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
214594746|NCT00894686|BIOLOGICAL|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
214594747|NCT00505817|DRUG|Cetrorelix and Leuprolide|
214594748|NCT05082129|DEVICE|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
214594749|NCT00287339|DRUG|Esomeprazole|40mg capsule BID for 12 weeks
214594750|NCT00287339|DRUG|Placebo|placebo capsule BID for 12 weeks
214594751|NCT00564018|DRUG|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
214594752|NCT00564018|DRUG|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
214594753|NCT00564018|DRUG|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
214594754|NCT04174456|DIAGNOSTIC_TEST|FDG PET|baseline and 6-month follow-up FDG PET
214594755|NCT06261164|DEVICE|Cytosorb® and Oxiris® adsorbents|The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
214594756|NCT03267940|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
214594757|NCT03267940|DRUG|CIS|CIS will be administered as per the schedule specified in the respective arms.
214594758|NCT03267940|DRUG|GEM|GEM will be administered as per the schedule specified in the respective arms.
214594759|NCT03267940|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
214594760|NCT00388154|DRUG|Gemcitabine|900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
214594761|NCT00388154|DRUG|Cisplatin|30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
214594762|NCT00312533|DRUG|Hylan F- 20|
214594763|NCT01869075|OTHER|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
214594764|NCT01340638|DEVICE|cookgas mask|This group will be assigned to use cookgas mask
214594765|NCT01340638|DEVICE|LMA mask|LMA mask
214594766|NCT00388622|BEHAVIORAL|Pharmacist intervention|
214594767|NCT02918604|DEVICE|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
214594768|NCT02960347|DEVICE|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
214594769|NCT04580329|PROCEDURE|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(\>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
214594770|NCT04580329|PROCEDURE|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
214594771|NCT04514666|OTHER|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
214594772|NCT01401907|OTHER|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
214594773|NCT05065372|DRUG|Metformin Hcl 1000Mg Tab|Agent used to modify insulin sensitivity
214594774|NCT05065372|DRUG|Aminohippurate Sodium 20 % Injection|Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
214594775|NCT05065372|DRUG|Iohexol 300 Mg/mL Injectable Solution|Diagnostic aid/agent used to measure glomerular filtration rate
214594776|NCT05065372|DRUG|Placebo|Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
214594777|NCT02607696|DRUG|Zolpidem Hemitartarate|
214594778|NCT04938024|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
214594779|NCT05617352|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
214594780|NCT01496482|OTHER|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
214594781|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
214594782|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
214594783|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
214594784|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
214594785|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
214594786|NCT00767468|DRUG|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
214594787|NCT00446667|DRUG|mannitol|400mg BD for 2 days
214594788|NCT06327308|DIAGNOSTIC_TEST|MRI|The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination.
214594789|NCT06327308|BIOLOGICAL|Blood sampling|Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
214594790|NCT02939547|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
214594791|NCT02240693|DRUG|BI 409306|
214594792|NCT02240693|DRUG|Placebo|
214594793|NCT02240693|DRUG|BI 409306|
214594794|NCT02240693|DRUG|Placebo|
214594795|NCT02240693|DRUG|Placebo|
214594796|NCT02240693|DRUG|BI 409306|
214594797|NCT02240693|DRUG|BI 409306|
214594798|NCT02240693|DRUG|Placebo|
214594799|NCT02240693|DRUG|Placebo|
214594800|NCT01948908|DRUG|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
214594801|NCT02350608|DEVICE|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
214594802|NCT03291587|OTHER|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
214594803|NCT03453437|BEHAVIORAL|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
214594804|NCT00796120|DRUG|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
214594805|NCT00796120|DRUG|Doxorubicin|Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
214594806|NCT00796120|DRUG|Ifosfamide|Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
214594807|NCT03739177|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
214594808|NCT02197767|DRUG|rituximab|1000 mg infusion
214594809|NCT02027220|DRUG|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
214594810|NCT02027220|DRUG|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
214594811|NCT02027220|DRUG|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
214594812|NCT02027220|DRUG|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
214594813|NCT06153927|DIAGNOSTIC_TEST|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
214594814|NCT02819206|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
214594815|NCT01386281|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
214594816|NCT02594605|DEVICE|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
214594817|NCT02594605|DEVICE|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
214594818|NCT03536299|OTHER|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
214594819|NCT03536299|OTHER|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
214594820|NCT03482583|DRUG|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
214594821|NCT03482583|OTHER|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
214594822|NCT04840641|DRUG|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
214594823|NCT03849001|BEHAVIORAL|Exercise Conditions|Light Exercise
214594824|NCT03849001|BEHAVIORAL|Exercise Conditions|Moderate Exercise
214594825|NCT03849001|BEHAVIORAL|Exercise Conditions|Vigorous Exercise
214594826|NCT03849001|BEHAVIORAL|Exercise Conditions|Seated Rest
214594827|NCT00003232|DRUG|clodronate disodium|
214594828|NCT00003232|DRUG|mitoxantrone hydrochloride|
214594829|NCT00003232|DRUG|prednisone|
214594830|NCT00003232|PROCEDURE|quality-of-life assessment|
214594831|NCT00413972|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
214594832|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
214594833|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
214594834|NCT00413972|DRUG|Placebo|Placebo once daily for a total of eight weeks
214594835|NCT03845569|OTHER|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
214594836|NCT03845569|OTHER|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
214594837|NCT04506268|BEHAVIORAL|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
214594838|NCT04506268|BEHAVIORAL|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
214594839|NCT00807261|DRUG|Gemcitabine and Docetaxel|"Drug and schedule~* Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~* Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~* Treatment should be delayed if the ANC\<1,500/ mm3, or if the platelet count \<75,000/mm3 on the first day of the next cycle.~* Gemcitabine \& docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
214594840|NCT06266884|OTHER|Kangaroo care|Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
214594841|NCT03418337|DRUG|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
214594842|NCT03418337|DRUG|lansoprazole (Takepron OD 30 mg)|lansoprazole group
214594843|NCT06375707|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS|"Docetaxel: 100mg/m2 IV every 21 days Paclitaxel: 175mg/m2 every 21 days, IV drip Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week.~Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral"
214594844|NCT06375707|DRUG|Ribociclib combined with NSAI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral
214594845|NCT00066989|DRUG|Staphylococcus aureus Immune Globulin (Human) 5%|
214594846|NCT01477320|DRUG|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
214594847|NCT01477320|OTHER|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
214594848|NCT05961904|OTHER|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
214594849|NCT05097027|DEVICE|Blood flow restriction recovery|Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to \~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
214594850|NCT05097027|OTHER|Active recovery|Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
214594851|NCT01898923|DRUG|ON101 Cream|
214594852|NCT01898923|OTHER|Aquacel® Hydrofiber® dressing|
214594853|NCT02730741|DRUG|Lcr restituo® sachet|symptomatic treatment of diarrhoea
214594854|NCT02730741|DRUG|Placebo|
214594855|NCT03140774|BIOLOGICAL|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
214594856|NCT01704924|DEVICE|Prevena|Device will be applied at end of procedure over closed incision
214594857|NCT01704924|PROCEDURE|Standard of Care Dressing|Dressing applied as Standard of Care
214594858|NCT04771468|DEVICE|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
214594859|NCT04771468|DEVICE|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
214594860|NCT01724853|PROCEDURE|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
214594861|NCT01724853|OTHER|Conservative|Injection
214594862|NCT01638494|DIETARY_SUPPLEMENT|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
214594863|NCT04130386|BEHAVIORAL|Motivational Interviewing|Participants receiving MI
214594864|NCT04130386|BEHAVIORAL|e-education|Participants receiving e-education
214594865|NCT00621387|DRUG|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
214594866|NCT00621387|DRUG|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
214594867|NCT01531647|DRUG|danoprevir|100 mg q12h Days 8-21
214594868|NCT01531647|DRUG|raltegravir|400 mg q12h Days 1-4 and 18-21
214594869|NCT01531647|DRUG|ritonavir|100 mg q12h Days 8-21
214594870|NCT03583177|DIAGNOSTIC_TEST|No intervention|No intervention
214594871|NCT04466826|OTHER|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
214594872|NCT04466826|DRUG|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
214594873|NCT04466826|DEVICE|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
214594874|NCT03013582|BIOLOGICAL|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
214594875|NCT03013582|PROCEDURE|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
214594876|NCT03924908|BEHAVIORAL|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
214594877|NCT03924908|BEHAVIORAL|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
214594878|NCT00381303|DRUG|darunavir|600mg bid for 48 wks
214594879|NCT00381303|DRUG|ritonavir|100mg bid for 48 wks
214594880|NCT00815672|BEHAVIORAL|Exercise|Progressive walking and resistance exercise treatment
214594881|NCT05965661|OTHER|virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
214594882|NCT05965661|OTHER|virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
214594883|NCT00333385|DRUG|ceftazidime|
214594884|NCT03536260|DEVICE|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
214594885|NCT03536260|DEVICE|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
214594886|NCT00167960|DRUG|Piperacillin/tazobactam and other β-lactam/β-lactamase|
214594887|NCT05622851|DEVICE|Restylane Contour|Hyaluronic Acid dermal filler
214594888|NCT05622851|DEVICE|Juvederm Voluma|Hyaluronic Acid dermal filler
214594889|NCT03322748|OTHER|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
214594890|NCT03322748|OTHER|Usual physical therapy|Usual physical therapy
214594891|NCT01800825|DRUG|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
214594892|NCT01800825|DRUG|Placebo|This will be an identical placebo comparator made of starch.
214594893|NCT06525961|DEVICE|iTEAR100 Neurostimulator|To apply an iTEAR100 Neurostimulator for the stimulation to the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
214594894|NCT04407585|DIAGNOSTIC_TEST|Covid-19 swab PCR test|Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
214594895|NCT03933774|DRUG|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
214594896|NCT03933774|DRUG|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
214594897|NCT04309344|DEVICE|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
214594898|NCT04309344|PROCEDURE|control|mechanical debridement
214594899|NCT03069612|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
214594900|NCT01121835|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
214594901|NCT01121835|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
214594902|NCT01121835|DRUG|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
214594903|NCT06089889|OTHER|ice application|"* Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential."
214594904|NCT06089889|OTHER|control group|"* Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential."
214594905|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
214594906|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
214594907|NCT01372865|DRUG|Mometasone furoate|
214594908|NCT01372865|DRUG|Mometasone furoate|
214594909|NCT04054752|BIOLOGICAL|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
214594910|NCT04054752|BIOLOGICAL|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
214594911|NCT04054752|BIOLOGICAL|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
214594912|NCT02877758|OTHER|Tomorrowlabs cosmeceutical formulation|
214594913|NCT02877758|OTHER|Sham cosmeceutical formulation|
214594914|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
214594915|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
214594916|NCT05634980|OTHER|FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam
214594917|NCT02216474|OTHER|Transcranial direct current stimulation|
214594918|NCT05709015|OTHER|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
214594919|NCT05709015|DRUG|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
214594920|NCT05709015|DRUG|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
214594921|NCT00502957|BEHAVIORAL|Biofeedback|
214594922|NCT03728374|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
214594923|NCT02652403|DEVICE|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
214594924|NCT02652403|DEVICE|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
214594925|NCT00001032|DRUG|Zidovudine|
214594926|NCT00001032|DRUG|Zalcitabine|
214594927|NCT01966471|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
214594928|NCT01966471|DRUG|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
214594929|NCT01966471|DRUG|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
214594930|NCT01966471|DRUG|Paclitaxel|IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
214594931|NCT01966471|DRUG|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
214594932|NCT01966471|DRUG|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
214594933|NCT01966471|DRUG|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
214594934|NCT01966471|DRUG|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
214594935|NCT01966471|DRUG|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
214594936|NCT02463565|OTHER|no intervention|
214594937|NCT00095654|DRUG|Ramipril|
214594938|NCT00095654|DRUG|Rosiglitazone|
214594939|NCT03336996|BIOLOGICAL|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
214594940|NCT03336996|PROCEDURE|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
214594941|NCT06323018|PROCEDURE|Remote Ischemic Preconditioning|4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)
214594942|NCT06323018|OTHER|SHAM|4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
214594943|NCT06507202|DRUG|Remimazolam|General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.
214594944|NCT06507202|DRUG|Propofol|General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
214594945|NCT04879771|PROCEDURE|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
214594946|NCT03252171|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
214594947|NCT05000892|DRUG|Sintilimab , Carboplatin, Nab-paclitaxel|Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
214594948|NCT01683487|PROCEDURE|Observation|Observational study only, no intervention.
214594949|NCT01583153|OTHER|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
214594950|NCT01583153|OTHER|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
214594951|NCT05767671|OTHER|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
214594952|NCT05557058|DEVICE|Gore Glaucoma Device Implant (GORE GDI)|Unilateral implantation of one of two different configurations of the GORE GDI
214594953|NCT05629481|PROCEDURE|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
214594954|NCT05629481|PROCEDURE|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
214594955|NCT06060093|DIETARY_SUPPLEMENT|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
214594956|NCT06060093|DIETARY_SUPPLEMENT|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
214594957|NCT03541382|DEVICE|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
214594958|NCT02343731|OTHER|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
214594959|NCT00461487|BEHAVIORAL|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
214594960|NCT00461487|BEHAVIORAL|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
214594961|NCT00494481|DRUG|Vandetanib (ZD6474)|once daily oral dose
214594962|NCT00494481|DRUG|Docetaxel|intravenous infusion
214594963|NCT01030198|DEVICE|RevLite (Laser Treatment)|
214594964|NCT04050137|OTHER|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
214594965|NCT00332189|DRUG|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
214594966|NCT04100642|DRUG|Hemay808|topical apply
214594967|NCT04100642|DRUG|Placebo|topical apply
214594968|NCT05959694|DRUG|TQB3909 tablet|TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
214594969|NCT03545659|OTHER|Mode of relapse/SMN detection|Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
214594970|NCT01748487|DRUG|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
214594971|NCT01453530|DRUG|Sugammadex|A single dose of sugammadex 2 mg/kg iv
214594972|NCT01453530|DRUG|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
214594973|NCT01453530|OTHER|Placebo|Placebo
214594974|NCT02370043|DRUG|KQ-791|Capsules administered orally while fasting, in up to 3 periods
214594975|NCT02370043|DRUG|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
214594976|NCT02370043|DRUG|Placebo|Capsules, administered orally, in 1 period
214594977|NCT06076603|DRUG|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
214594978|NCT03467503|DIETARY_SUPPLEMENT|Blueberry + soluble fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
214594979|NCT04341766|OTHER|No special intervention|No special intervention : Ultrasound data will be collected
214594980|NCT04233593|BIOLOGICAL|Lipopolysaccharide|Endotoxin E Coli
214594981|NCT05419063|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
214594982|NCT05419063|BEHAVIORAL|text-based and email feedback|Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
214594983|NCT03782025|DRUG|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
214594984|NCT03652025|PROCEDURE|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
214594985|NCT01454518|PROCEDURE|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
214594986|NCT01454518|PROCEDURE|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
214594987|NCT03093987|OTHER|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
214594988|NCT05198687|PROCEDURE|Long implant and partial overdentures|insertion of long implants anterior to the maxillary sinus to retain partial overdentures
214594989|NCT05198687|PROCEDURE|Sinus lift and long implant|performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
214594990|NCT05198687|PROCEDURE|short implant without sinus lift|placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
214594991|NCT05198687|DEVICE|Partial overdentures|Distal extension metallic partial dentures retained by attachments to the implants
214594992|NCT05198687|DEVICE|Metal ceramic prosthesis on long implants|porcelain fused to metal fixed screw-retained prosthesis supported by long implants
214594993|NCT05198687|DEVICE|Metal ceramic prosthesis on short implants|porcelain fused to metal fixed screw-retained prosthesis supported by short implants
214594994|NCT02727465|OTHER|Meningitis cases|None - blood draw only
214594995|NCT05665088|DRUG|BXCL501|Sublingual Film
214594996|NCT05665088|DRUG|Matching Placebo|Sublingual Placebo Film
214594997|NCT03048643|BEHAVIORAL|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
214594998|NCT03364712|OTHER|routine medical care, venipuncture|
214594999|NCT04137900|DRUG|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
214595000|NCT04137900|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
214595001|NCT02279862|DRUG|Ipilimumab|
214595002|NCT00499629|DRUG|FXR 450|capsule, single oral doses from 10 mg to 450 mg
214595003|NCT00499629|DRUG|placebo|capsule similar to active drug
214595004|NCT03371030|PROCEDURE|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
214595005|NCT05000502|BEHAVIORAL|Home-based exercise intervention|A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
214595006|NCT02928107|OTHER|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
214595007|NCT02928107|OTHER|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
214595008|NCT06328907|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214595009|NCT06328907|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214595010|NCT06328907|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214595011|NCT06250556|DIETARY_SUPPLEMENT|creatine|creatine supplementation (Creapure)
214595012|NCT02457312|DRUG|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
214595013|NCT02457312|DRUG|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
214595014|NCT04345835|PROCEDURE|Percutanous nephrolithotomy (PCNL)|different procedure positioning
214595015|NCT04563338|DRUG|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
214595016|NCT04563338|DRUG|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
214595017|NCT06370468|OTHER|Epidemiological investigation|Epidemiological investigation
214595018|NCT00662779|DRUG|arformoterol|15 mcg arformoterol nebulizer
214595019|NCT00662779|DRUG|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
214595020|NCT00662779|DRUG|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
214595021|NCT01461239|PROCEDURE|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
214595022|NCT01461239|PROCEDURE|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
214595023|NCT01461239|PROCEDURE|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
214595024|NCT02762812|BIOLOGICAL|BCD-055|
214595025|NCT02762812|BIOLOGICAL|Remicade®|
214595026|NCT04191044|OTHER|A complete cardiovascular and liver characterization will be carried out|A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
214595027|NCT01163721|DRUG|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
214595028|NCT01163721|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily
214595029|NCT00688181|DEVICE|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
214595030|NCT00321659|BEHAVIORAL|Aerobic|3x/week of walking and cycling
214595031|NCT00321659|BEHAVIORAL|Strength training|3x/week of resistance training activities
214595032|NCT00321659|BEHAVIORAL|Combination|3x/week of aerobic and strength training activities
214595033|NCT00321659|BEHAVIORAL|FSHC|Biweekly group education group meetings
214595034|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
214595035|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
214595036|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
214595037|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
214595038|NCT06348368|OTHER|Pentacam and autorefractometry|Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children
214595039|NCT01050205|BEHAVIORAL|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
214595040|NCT01050205|BEHAVIORAL|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
214595041|NCT03450720|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single dose
214595042|NCT04834687|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
214595043|NCT04834687|BEHAVIORAL|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~1. Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~2. According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
214595044|NCT03475017|DIETARY_SUPPLEMENT|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
214595045|NCT03475017|DIETARY_SUPPLEMENT|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
214595046|NCT01119001|DEVICE|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
214595047|NCT04793620|OTHER|TQL1055|Semisynthetic saponin adjuvant
214595048|NCT04793620|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis vaccine
214595049|NCT04569383|BIOLOGICAL|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
214595050|NCT04569383|BIOLOGICAL|Comirnaty|Vaccination with Comirnaty (21 day interval)
214595051|NCT03654313|BIOLOGICAL|MEDI6570|MEDI6570
214595052|NCT03654313|BIOLOGICAL|Placebo|Placebo
214595053|NCT03654313|BIOLOGICAL|Part B Placebo|Placebo
214595054|NCT06544902|OTHER|VR Stress Management|First Resort (FR) is an eight-week wellness program that comprises 22 modules, each lasting between 10 and 20 minutes, participants will complete modules weekly in person. Each module will teach participants about values-based goal setting/ behavioral activation, and cognitive restructuring.
214595055|NCT06544902|BEHAVIORAL|Education Control|Participants in this group will receive one-time educational material regarding stress. The participants can review the material remotely. American Heart Association (AHA) brochures and infographics regarding chronic stress and women's health, heart disease and mental health among black women, healthy for good sleep well, among other useful resources.
214595056|NCT06404060|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
214595057|NCT06404060|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
214595058|NCT04206488|DRUG|JNJ-70033093|Participants will receive JNJ-70033093 orally.
214595059|NCT04206488|DRUG|Digoxin|Participants will receive digoxin orally.
214595060|NCT04931836|BEHAVIORAL|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
214595061|NCT06035874|DRUG|Bempedoic acid|Patient willl be randomized 1:1 in both the arms
214595062|NCT05783375|OTHER|ADUNU program for delivery of RHD care services|The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
214595063|NCT05484206|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection.
214595064|NCT05484206|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection.
214595065|NCT04291599|DRUG|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
214595066|NCT04291599|DRUG|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
214595067|NCT04532203|DRUG|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
214595068|NCT04532203|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
214595069|NCT05720988|DRUG|Azacitidine|Given SC
214595070|NCT05720988|BIOLOGICAL|Tagraxofusp-erzs|Given IV
214595071|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
214595072|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
214595073|NCT05492500|DRUG|Main cohort (Cohort A): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
214595074|NCT05492500|OTHER|Main cohort (Cohort A): Matched placebo|Matched placebo subcutaneous injection
214595075|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab low dose|ponsegromab low dose subcutaneous injection
214595076|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
214595077|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
214595078|NCT05492500|DRUG|Optional Cohort C: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
214595079|NCT05492500|OTHER|Optional Cohort C: Matched placebo|Matched placebo subcutaneous injection
214595080|NCT05492500|DRUG|Optional Cohort D: Ponsegromab high dose|Ponsegromab high dose subcutaneous injection
214595081|NCT05492500|OTHER|Optional Cohort D: Matched placebo|Matched placebo subcutaneous injection
214595082|NCT00810394|DRUG|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
214595083|NCT00507364|DRUG|Local injection of activated macrophages to anal fissure|
214595084|NCT04742647|PROCEDURE|Double cerclage|Two cervical cerlages will be placed
214595085|NCT04742647|PROCEDURE|Single cerclage|One cerclage will be placed
214595087|NCT02913417|DEVICE|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
214595088|NCT02913417|DRUG|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
214595089|NCT02913417|DRUG|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
214595090|NCT01516242|OTHER|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
214595091|NCT03855423|DIETARY_SUPPLEMENT|Tocotrienol-rich Fraction (TRF)|TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
214595092|NCT02180022|DRUG|Placebo|After randomization, placebo was treated for 12 weeks
214595093|NCT02180022|DRUG|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
214595094|NCT03012607|DRUG|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
214595095|NCT04098757|DIETARY_SUPPLEMENT|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
214595096|NCT06307899|OTHER|Unilateral Corner Stretch|Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
214595097|NCT06307899|OTHER|Manual Stretching|Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
214595098|NCT06307899|OTHER|PNF Stretching|Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
214595099|NCT00162357|DRUG|Technetium Tc99m Sestamibi|
214595100|NCT03456284|DEVICE|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
214595101|NCT00002301|DRUG|Foscarnet sodium|
214595102|NCT01576653|OTHER|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
214595103|NCT02710903|PROCEDURE|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
214595104|NCT01491893|BIOLOGICAL|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
214595105|NCT06610786|PROCEDURE|foldable capsular scleral buckling|Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity
214595106|NCT06610786|PROCEDURE|vitrectomy|Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
214595107|NCT07020104|DRUG|Hydrochlorothiazide|"Each patient will receive 1 tablet of hydrochlorothiazide 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dosage is doubled to 2 tablets of hydrochlorothiazide 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
214595108|NCT07020104|DRUG|Spironolactone|"Each patient will receive 1 tablet of spironolacton 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of spironolacton 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
214595109|NCT07020104|DRUG|Lercanidipine|"Each patients will receive 1 tablet of lercanidipine 10mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of lercanidipine 10mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
214595110|NCT07020104|DIETARY_SUPPLEMENT|High sodium dietary intake (>200mmol/l)|The patients will receive a 2-week high sodium diet. The patients will receive dietary advice to achieve this goal of \>200mmol/l sodium (\>12g salt) intake per day.
214595111|NCT07020104|DIETARY_SUPPLEMENT|Low sodium dietary intake (<50mmol/l)|The patients will receive a 2-week low sodium diet. The patients will receive dietary advice to achieve this goal of \<50mmol/l sodium (\<3g salt) intake per day.
214595112|NCT07020104|DIETARY_SUPPLEMENT|High water intake|During the increased water intake period, the patients will be instructed to drink 1 L more than their mean 24-hour urine volume at screening and baseline.
214595113|NCT07020104|DIETARY_SUPPLEMENT|Habitual water intake|During this part of the intervention, the patients will be instructed to maintain their habitual water intake.
214595114|NCT07021001|BEHAVIORAL|UP-A, a cognitive-behavioral structured group intervention, was adapted as a universal preventive intervention to be delivered in school settings (UP-A Kind).|The UP-A Kind is a school-based universal prevention intervention that aims to promote adaptive emotion regulations strategies, enhance mental well-being and prevent emotional disorders with the following contents: motivating to take care of mental well-being, psychoeducation about emotions, awareness of physical sensations, cognitive lexibility, behavioral experiences, recognizing warning signs, and promoting a compassionate attitude towards the self and others.
214595115|NCT07019090|DRUG|HSK44459|HSK44459
214595116|NCT07020975|DEVICE|VR Glasses|VR Glasses is used to help people be in a virtual reality other than their real life. What we use this for; to get away infertile women from her stressfull environment to another virtual reality before their embryo transfer.
214595117|NCT07019649|BEHAVIORAL|AYUDA Program|Participants randomized to the intervention arm will be enrolled in the AYUDA program, where they will receive text messages twice a week over 12 weeks containing diabetes education and self-management resources, including links to resources available to all KPNC members.
214595118|NCT07018817|BEHAVIORAL|motor execution motor imagery|Participants will perform motor execution tasks and motor imagery tasks following standardized instructions under controlled conditions.
214595119|NCT07020078|RADIATION|Salivary redox biomarkers|Salivary redox biomarkers
214595120|NCT07019103|DRUG|Gabapentin (Neurontin® (Registered Trademark))|Additionally, during this phase, patients will be educated on how to report their perceived pain, rated from 0 to 10 on the visual analog scale (VAS). Subsequently, another dedicated pain-management specialist will engage with each patient to formulate and document an individualized pain management plan, taking into consideration the patient's medical history, previous pain experiences, and preferences for pain management strategies. As part of preemptive analgesia, patients receive 300 mg of gabapentin orally 2 hours prior to surgery, unless contraindicated.
214595121|NCT07016581|DIAGNOSTIC_TEST|Daily survey|All patients undergoing an spinal cord stimulation trial procedure (which will be conducted in accordance to standard clinical practices per site) will be given daily surveys to assess their analgesic and functional benefit.
214595122|NCT07019363|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard endocrine therapy
214595123|NCT07019363|DRUG|Standard endocrine therapy combined with CDK4/6 Inhibitor|CDK4/6 inhibitor therapy for 2 years in combination with standard endocrine therapy
214595124|NCT04496986|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
214595125|NCT04496986|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
214595126|NCT04496986|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
214595127|NCT04496986|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
214595128|NCT04496986|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
214595129|NCT04496986|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
214595130|NCT06693115|DEVICE|CGM with alerts|"CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."
214595131|NCT06700707|OTHER|Survey using a questionnaire.|"Permission was obtained from the original owner of the Athlete Disability Index Questionnaire (ADI) for the Turkish cultural adaptation, validity and reliability study.~120 athletes, determined by the number of questions times the rule of 10, will be asked to fill out the ADI, Oswestry Disability Index (ODI), and Roland-Morris Disability (RMDQ) questionnaires and 60 athletes will be asked to fill out the ADI questionnaire again 7 days later for test-retest reliability."
214595132|NCT06698328|DEVICE|Transauricular Vagus Nerve Stimulation|"Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area."
214595133|NCT06698328|DEVICE|Sham Stimulation|"Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area."
214595134|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
214595135|NCT06886581|BEHAVIORAL|Evidence-based leadership training|The structure of the course will follow the steps of the evidence-based approach: (1) each participant will identify their specific unit problem to be solved together with the team and unit leader will work with this problem during the course; (2) organisational data will be collated and analysed to understand the key problem of the unit; (3) scientific literature will be searched for, and critically appraised; (4) the views of stakeholders (patients, family members, etc.) will be considered along with implications; and (5) all sources of information will be collated together and the solution will be implemented into practice; the real situation will be evaluated. Each module includes specific learning material (power points, scientific articles), peer-group discussions, clinical exercises, and self-assessment and self-reflection. The unit leaders will work together their unit members. The course will be run in small group (about 15/agroup) and supported by tutors.
214595136|NCT06884384|BIOLOGICAL|Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml)|"At inclusion, the blood sample is used to perform thrombin generation tests (activated protein C resistance profile and ratio), classical and innovative aPL assays centrally to limit the fluctuation inherent in the tests used and enable comparison between patients, immunothrombosis markers: circulating neutrophil extracellular traps (NETs) assay, sTREM-1 assay~In the event of recurrence, blood sampling can be used to confirm compliance with treatment by measuring the anti Xa activity of the drug or INR"
214595137|NCT06884384|BEHAVIORAL|Completion of a questionnaire on compliance with anticoagulant treatment|The Girerd questionnaire (6 questions) will be proposed to patients in order to estimate the degree of compliance with AODs and VKAs at inclusion and at each follow-up visit for the duration of their participation in the study.
214595138|NCT06884384|BEHAVIORAL|Completion of a questionnaire on satisfaction with treatment anticoagulant|The ACTS questionnaire (15 questions) will be proposed to them in order to estimate their satisfaction with their anticoagulant treatment (AOD or AVK) at inclusion and at each follow-up visit for the duration of their participation in the study.
214595140|NCT06830031|BIOLOGICAL|C402-CD19-CAR|Enrolled subjects will undergo apheresis to acquire peripheral blood mononuclear cells. C402-CD19-CAR will be generated from the subject's autologous T cells modified from the apheresis product. After C402-CD19-CAR production and product release, subjects will be administered with a single dose of C402-CD19-CAR via subcutaneous injection.
214595141|NCT04420884|DRUG|Dazostinag|Dazostinag intravenous infusion.
214595142|NCT04420884|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
214595143|NCT04420884|DRUG|Platinum|Carboplatin or Cisplatin intravenous infusion
214595144|NCT04420884|DRUG|5-fluorouracil|5-fluorouracil intravenous infusion
214595145|NCT06196892|DIETARY_SUPPLEMENT|Probiotic BBr60|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
214595146|NCT06196892|DIETARY_SUPPLEMENT|Placebo|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking maltodextrin.
214595147|NCT06769438|OTHER|ERAS|ERAS
214595148|NCT06769438|OTHER|ROFIM|teleexpertise solution connecting extra-hospital and intra-hospital practitioners
214595149|NCT06769438|OTHER|DEEPSEN|virtual reality headset to reduce anxiety
214595150|NCT06769438|OTHER|RDS|patch to continuously monitor patients' physiological parameters at home
214595151|NCT06769438|OTHER|Get ready|digital solution for managing patients at home
214595152|NCT06769438|OTHER|Lumiradx|taking CRP at home
214595153|NCT06769438|OTHER|Digital Surgery|recording of the different operating times
214595154|NCT06755554|DRUG|Endoscopic injection of Indocyanine green|ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.
214595155|NCT05643963|OTHER|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
214595156|NCT06786884|DEVICE|paraffin wax|This is the treatment group that will receive exercise and paraffin wax
214595157|NCT06786884|DEVICE|standard of care exercise therapy|This is the group that will only receive exercise therapy and no paraffin wax.
214595160|NCT06810947|DEVICE|ALLERSPRAY-G (device A)|Symptomatic treatment consists of 3 sprays of medical device A in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
214595161|NCT06810947|DEVICE|PCNS (device B)|Symptomatic treatment consists of 3 sprays of medical device B in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
214595162|NCT06752421|PROCEDURE|Group B: Low tidal volume|In the LTV group, mechanical ventilation will be maintained with low tidal volume parameters after the aortic cross-clamp procedure. This intervention includes a tidal volume of 3-4 mL/kg, respiratory rate of 12-14 breaths/min, PEEP of 5-8 cmH₂O, and FiO₂ of 50%. Minute ventilation (MV) will not exceed 12 L, and the parameters are adjusted according to ideal body weight. This group is designed to evaluate the protective effects of low tidal volume ventilation during surgery.
214595163|NCT06900751|DRUG|NEU-627|Investigational medicinal product
214595164|NCT06900751|OTHER|Placebo|Placebo
214595165|NCT06903715|DRUG|Belzutifan|Oral administration
214595166|NCT06903715|DRUG|Phenytoin|Oral administration
214595167|NCT06790823|DRUG|The probiotic supplement (Moodamin capsuls)|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
214595168|NCT06790823|DRUG|Placebo|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
214595169|NCT06515483|DEVICE|Brushing and Flossing of teeth|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects in the experimental group will brush and floss with the provided stretchable loop floss at least twice a day. To assess compliance, each subject will be asked to fill out a diary every time they brush/floss. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
214595170|NCT06515483|OTHER|Brushing Only|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects assigned to the control group will brush their teeth at least twice a day only. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
214595171|NCT05401214|DRUG|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
214595172|NCT05401214|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
214595173|NCT06908473|DRUG|Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.|"Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions.~Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for Qi-deficiency and Blood Stasis syndrome, reflecting personalized and precision intervention.~Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC.~Control Design: The study employs a double-blind, randomized, placebo-controlled method."
214595174|NCT06908473|DRUG|A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC|Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.
214595175|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
214595176|NCT06795659|DRUG|Esketamine (Intranasal Spray)|Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).
214595177|NCT06795659|BEHAVIORAL|Massed Prolonged Exposure (PE)|Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)
214595178|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
214595179|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
214595180|NCT06862609|OTHER|Quadro iliac plane block|Patients in Group Q will be placed in the lateral position. A low-frequency convex transducer and a 100-mm block needle will be used. Following sterilization, the transducer will be placed parasagittally at the distal attachment of the quadratus lumborum muscle to the iliac crest. The iliac crest and quadratus lumborum muscle will be visualized, with the erector spinae muscle above and the psoas major muscle below. Using an in-plane technique, the needle will be directed toward the iliac crest. After confirmation with 5 mL of isotonic sodium chloride, 40 mL of 0.25% bupivacaine will be injected incrementally with intermittent aspiration.
214595181|NCT06862609|OTHER|Control group|All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
214595182|NCT06931522|OTHER|Mat Pilates|In Mat Pilates training, exercise balls and elastic bands will be used. The exercises will be done with 10 repetitions for the first 4 weeks, and with 20 repetitions for the last 4 weeks. The difficulty level of the exercises will be increased in the following weeks according to the patient's condition.
214595183|NCT06931522|OTHER|Reformer Pilates|In the Reformer Pilates group, the difficulty level of the exercises will be provided by different positions, and the springs' resistance will be increased.
214595184|NCT06508021|DRUG|Andecaliximab|Dose level A or B
214595185|NCT06508021|DRUG|Placebo|Blinded
214595186|NCT06508021|DRUG|Andecaliximab|Dose level A or B (or age adjusted dose)
214595187|NCT06248554|DRUG|PD-1 Inhibitors|Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
214595188|NCT05184686|OTHER|noise expose|simulate noise expose environments
214595189|NCT05184686|OTHER|RF expose|simulate RF expose environments
214595190|NCT01103245|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
214595191|NCT01103245|DRUG|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
214595192|NCT01103245|DRUG|Spironolactone (SPL 25)|spironolactone 25mg daily
214595193|NCT01103245|DRUG|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
214595194|NCT01103245|DRUG|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
214595195|NCT01409616|DRUG|darexaban|oral
214595196|NCT01409616|DRUG|darexaban (double dose)|oral
214595197|NCT01409616|DRUG|Acetyl Salicylic Acid|oral
214595198|NCT01409616|DRUG|clopidogrel|oral
214595199|NCT02332109|DEVICE|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
214595200|NCT01121978|PROCEDURE|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
214595201|NCT06491407|DIAGNOSTIC_TEST|Chewing and swallowing performance assessment and related factors|In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
214595202|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
214595203|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
214595204|NCT02870699|DEVICE|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
214595205|NCT02870699|DEVICE|Placebo excipient|film forming excipient solution
214595206|NCT00076492|DRUG|CoQ10|
214595207|NCT00076492|DRUG|GPI 1485|
214595208|NCT00355056|OTHER|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
214595209|NCT00355056|DEVICE|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
214595210|NCT01072877|DRUG|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
214595211|NCT01072877|DRUG|Placebo Vehicle|Placebo vehicle
214595212|NCT00133692|DRUG|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
214595213|NCT00133692|DRUG|Atenolol/HCTZ/Trandolapril|
214595214|NCT05858268|GENETIC|Whole-genome sequencing|Whole-genome sequencing
214711055|NCT06898099|OTHER|"Standard care control group (without hypnosis)"|"Randomization stratification on insomnia severity. In the Standard care group, the investigating physician will not change his or her current practice as part of the study. Treatment will be the same as usual, whether drug-based or not (psychotherapy, etc.), with the exception of hypnosis. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
214595215|NCT04484181|OTHER|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
214595216|NCT04484181|OTHER|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
214595217|NCT02720536|DRUG|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
214595218|NCT01048567|OTHER|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
214595219|NCT01048567|OTHER|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
214595220|NCT06783751|PROCEDURE|Modified Vertical Sleeve Gastrectomy (mVSG)|The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).
214595221|NCT06783751|PROCEDURE|Conventional Vertical Sleeve Gastrectomy (cVSG)|Vertical Sleeve Gastrectomy as standard procedure
214595222|NCT02411682|OTHER|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
214595223|NCT02411682|OTHER|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
214595224|NCT04643860|DIAGNOSTIC_TEST|Differential Leucocyte Count (CLDC) device and algorithm|Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
214595225|NCT02706301|BEHAVIORAL|Telephone-Based Coping Skills Training (CST)|
214595226|NCT04603664|DIAGNOSTIC_TEST|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
214595227|NCT01903018|DRUG|P276-00|
214595228|NCT01903018|RADIATION|Radiation Therapy|
214595229|NCT01903018|DRUG|Cisplatin|
214595230|NCT00528164|BEHAVIORAL|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
214595231|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
214595232|NCT02120625|DEVICE|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
214595233|NCT00230438|PROCEDURE|External Beam Radiotherapy|
214595234|NCT04062773|BEHAVIORAL|TRF|time restricted feeding group
214595235|NCT04062773|BEHAVIORAL|Normal timing of food intake|no time restricted feeding
214595236|NCT02571127|DRUG|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
214595237|NCT05327933|PROCEDURE|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
214595238|NCT05327933|PROCEDURE|Surgery alone|Evacuation of cSDH
214595242|NCT05442424|BEHAVIORAL|Produce Voucher|see arm/group description
214595243|NCT05442424|BEHAVIORAL|Wait-List Control|see arm/group description
214595244|NCT05350384|DRUG|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
214595245|NCT00638612|BIOLOGICAL|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
214595246|NCT00638612|DRUG|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
214595247|NCT00597467|DEVICE|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
214595248|NCT00597467|DEVICE|Acuvue 2 Soft Contact Lens|Control device
214595249|NCT00420251|DRUG|Genotropin|
214595250|NCT03458065|DEVICE|ICD|Implantable Cardioverter Defibrillator
214595251|NCT00475618|PROCEDURE|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
214595252|NCT00475618|PROCEDURE|professional cleaning|Daily use fluoride toothpaste 500 ppm.
214595253|NCT00475618|PROCEDURE|No fluoride toothpaste|Daily use no fluoride toothpaste.
214595254|NCT05604833|BEHAVIORAL|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
214595255|NCT04344691|PROCEDURE|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
214595256|NCT03540472|DRUG|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
214595257|NCT02253368|OTHER|sleep|
214595258|NCT02243098|DRUG|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
214595259|NCT02243098|DRUG|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
214595260|NCT02243098|DRUG|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
214595261|NCT01927328|DRUG|Iron isomaltoside 1000|
214595262|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
214595263|NCT05714007|DRUG|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
214595264|NCT05714007|DRUG|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
214595265|NCT05543044|BEHAVIORAL|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
214595266|NCT00465244|DRUG|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
214595267|NCT00465244|DRUG|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
214595268|NCT03434782|DRUG|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
214595269|NCT03434782|DRUG|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
214595270|NCT03434782|DRUG|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
214595271|NCT01006928|OTHER|Questionaire|Questionaire to mothers
214595272|NCT00820027|DRUG|Etoricoxib 90 mg|One 90 mg tablet once daily
214595273|NCT00820027|DRUG|Etoricoxib 120 mg|Two 60 mg tablets once daily
214595274|NCT00820027|DRUG|Ibuprofen 600 mg|One tablet three times daily
214595275|NCT00820027|DRUG|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
214595276|NCT00820027|DRUG|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
214595277|NCT00820027|DRUG|Matching Placebo for Ibuprofen|One tablet three times daily
214595278|NCT00820027|DRUG|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
214595279|NCT00820027|DRUG|Oxycodone|5 mg as needed
214595280|NCT05535465|OTHER|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
214595281|NCT04849936|DIAGNOSTIC_TEST|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
214595282|NCT04143750|DRUG|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
214595283|NCT04581967|GENETIC|polymorphism analysis|"* DNA will be purified from whole blood samples by commercial DNA isolation kits.~* Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
214595284|NCT04581967|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
214595285|NCT05781217|DRUG|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
214595286|NCT04201756|DRUG|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
214595287|NCT06108180|OTHER|Dry Needling|3 treatment to eliminate active trigger points that patients have
214595288|NCT00908232|DRUG|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
214595289|NCT00908232|DRUG|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
214595290|NCT00908232|DRUG|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
214595291|NCT00908232|DRUG|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
214595292|NCT02025569|OTHER|Strain Counterstrain|
214595293|NCT02025569|OTHER|Sham strain counterstrain|
214595294|NCT02357381|DEVICE|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
214595295|NCT00233844|PROCEDURE|"Venipuncture with cough-trick"|
214595296|NCT00548054|BIOLOGICAL|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
214595297|NCT00548054|BIOLOGICAL|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
214595298|NCT04034550|OTHER|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
214595299|NCT00872196|DRUG|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
214595300|NCT02779725|BEHAVIORAL|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
214595301|NCT02779725|BEHAVIORAL|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
214595302|NCT02779725|BEHAVIORAL|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
214595303|NCT02779725|BEHAVIORAL|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
214595304|NCT02779725|BEHAVIORAL|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
214595305|NCT03291704|DEVICE|Thermal therapy device|Thermal therapy of blocked Meibomian glands
214595306|NCT00954174|DRUG|Carboplatin|Given IV
214595307|NCT00954174|DRUG|Ifosfamide|Given IV
214595308|NCT00954174|DRUG|Paclitaxel|Given IV
214595309|NCT00954174|OTHER|Quality-of-Life Assessment|Ancillary studies
214595310|NCT04307082|DRUG|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
214595311|NCT01822977|DRUG|omeprazole|
214595312|NCT05823701|DRUG|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
214595313|NCT05823701|DRUG|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
214595314|NCT05823701|BIOLOGICAL|obinutuzumab|1000mg d4 intravenous infusion per cycle
214595315|NCT05823701|DRUG|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
214595316|NCT01329016|DRUG|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
214595317|NCT01329016|DRUG|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
214595318|NCT01329016|DRUG|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
214595319|NCT05175612|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
214595320|NCT02949960|DRUG|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
214595321|NCT02949960|DRUG|Vehicle Control|Topical Vehicle Gel applied twice daily
214595322|NCT02877160|DRUG|AL-794 suspension|
214595323|NCT02877160|DRUG|AL-794 tablet|
214595324|NCT02287376|DRUG|Diclofenac Potassium for Oral Solution|NSAID
214595325|NCT02785497|OTHER|Control group|will be turn on the equipment, positioning the patient but no put intensity
214595326|NCT02785497|OTHER|Treatment group|This group will receive electrostimulation
214595327|NCT05474066|DEVICE|ERP Testing|"* Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:"
214595328|NCT02796001|BIOLOGICAL|human rhinovirus|human rhinovirus
214595329|NCT02796001|OTHER|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
214595330|NCT03484520|DRUG|Venetoclax|tablet, oral
214595331|NCT03484520|DRUG|Dinaciclib|intravenous
214595332|NCT00524719|PROCEDURE|Open Reduction and Internal Fixation|Fixation with volar locked plate
214595333|NCT00524719|PROCEDURE|Non-Spanning External Fixation|Radio-radial external fixation
214595334|NCT00524719|PROCEDURE|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
214595335|NCT01995877|PROCEDURE|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
214595336|NCT03840239|DRUG|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
214595337|NCT03840239|RADIATION|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
214595338|NCT03840239|PROCEDURE|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
214595339|NCT03840239|OTHER|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
214595340|NCT03623685|DIAGNOSTIC_TEST|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
214595341|NCT00350662|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
214595342|NCT00350662|DRUG|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
214595343|NCT01569360|DEVICE|Corset|the patients are assigned the use of a custome made corset during daytime
214595344|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 2.5 mg, twice daily, oral
214595345|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 5 mg, twice daily, oral
214595346|NCT01776424|DRUG|Aspirin|Tablet, 100 mg, once daily, oral
214595347|NCT01776424|DRUG|Aspirin placebo|Aspirin matching placebo, once daily, oral
214595348|NCT01776424|DRUG|Rivaroxaban placebo|Rivaroxaban matching placebo, twice daily, oral
214595349|NCT01776424|DRUG|Pantoprazole|Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
214595350|NCT01776424|DRUG|Pantoprazole placebo|Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
214595351|NCT04575753|OTHER|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
214595352|NCT05601791|PROCEDURE|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
214595353|NCT05601791|PROCEDURE|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
214595354|NCT04112446|DRUG|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
214595355|NCT00404456|DRUG|Melatonin|Melatonin 3 mg once-daily
214595356|NCT02262923|DRUG|metoclopramide|
214595357|NCT03886792|BEHAVIORAL|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
214595358|NCT03886792|BEHAVIORAL|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
214595359|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
214595360|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
214595361|NCT03948217|OTHER|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
214595362|NCT05411367|DRUG|SI-614|1 drop in each eye
214595363|NCT05411367|DRUG|Vehicle|1 drop in each eye
214595364|NCT04987567|DIETARY_SUPPLEMENT|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
214595365|NCT04987567|DIETARY_SUPPLEMENT|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
214595366|NCT05406804|BEHAVIORAL|Olfactory stimulation|1\) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time \> 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
214595367|NCT05406804|BEHAVIORAL|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
214595368|NCT01088191|BIOLOGICAL|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
214595369|NCT01088191|DRUG|Hyaluronan|Hyaluronan alone
214595370|NCT03152357|DEVICE|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
214595371|NCT04773613|OTHER|Experimental SLP|SLP was given to the infant during bottle-feeding.
214595372|NCT04773613|OTHER|Experimental SEP|SEP was given to the infant during bottle-feeding.
214595373|NCT04193267|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
214595374|NCT04156217|BIOLOGICAL|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
214595375|NCT05392530|DRUG|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
214595376|NCT03985215|OTHER|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
214595377|NCT01246934|OTHER|ASR METHOD|
214595378|NCT04653168|DRUG|LY3041658|Administered SC
214595379|NCT01430806|DRUG|Dronedarone arm|PO Dronedarone 400 mg BID
214595380|NCT01430806|DRUG|Dronedarone|Dronedarone PO 400 MG BID
214595381|NCT00186069|DRUG|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
214595382|NCT00186069|OTHER|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
214595383|NCT02913729|RADIATION|partial breast irradiation|irradiation
214595384|NCT00403728|DRUG|ciclosporine A|
214595385|NCT05615753|BEHAVIORAL|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
214595386|NCT04704011|OTHER|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
214595387|NCT04704011|OTHER|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
214595388|NCT04704011|OTHER|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
214595389|NCT04704011|OTHER|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
214595390|NCT04704011|OTHER|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
214595391|NCT04707651|DIETARY_SUPPLEMENT|Formula diet|Formula diet for 12 weeks
214595392|NCT02569203|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition
214595393|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
214595394|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
214595395|NCT02784197|DEVICE|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
214595396|NCT04200157|OTHER|Online survey|Subjects will complete a single survey that takes 5-10 minutes to complete
214595397|NCT00885651|DRUG|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
214595398|NCT00885651|DRUG|Placebo|
214595399|NCT03931720|BIOLOGICAL|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
214595400|NCT03644407|OTHER|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
214595401|NCT00759291|DRUG|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
214595402|NCT00759291|DRUG|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
214595403|NCT06140043|OTHER|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
214595404|NCT04101708|DRUG|Lansoprazole, Amoxicillin|high dose dual regimen
214595405|NCT04101708|DRUG|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
214595406|NCT01091753|DRUG|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
214595407|NCT03313921|DIAGNOSTIC_TEST|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
214595408|NCT02580955|DEVICE|LEGFLOW DCB|
214595409|NCT05708326|BEHAVIORAL|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
214595410|NCT05708326|BEHAVIORAL|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
214595411|NCT02498470|PROCEDURE|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
214595412|NCT05441254|DRUG|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
214595413|NCT02305537|BEHAVIORAL|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
214595414|NCT02020629|DRUG|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
214595415|NCT02626754|DRUG|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
214595416|NCT00004253|DRUG|carboplatin|
214595417|NCT00004253|DRUG|paclitaxel|
214595418|NCT00004253|RADIATION|radiation therapy|
214595419|NCT03181451|DRUG|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
214595420|NCT02729389|BEHAVIORAL|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
214595421|NCT02729389|BEHAVIORAL|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
214595422|NCT06134206|DIAGNOSTIC_TEST|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
214595423|NCT00652860|BIOLOGICAL|aerosol sargramostim|
214595424|NCT00652860|BIOLOGICAL|sargramostim|
214595425|NCT00652860|DRUG|cisplatin|
214595426|NCT00652860|DRUG|doxorubicin hydrochloride|
214595427|NCT00652860|DRUG|ifosfamide|
214595428|NCT00652860|DRUG|mitomycin C|
214595429|NCT00652860|OTHER|flow cytometry|
214595430|NCT00652860|OTHER|immunological diagnostic method|
214595431|NCT00652860|OTHER|laboratory biomarker analysis|
214595432|NCT00652860|PROCEDURE|adjuvant therapy|
214595433|NCT00652860|PROCEDURE|multimodality therapy|
214595434|NCT00652860|PROCEDURE|neoadjuvant therapy|
214595435|NCT00652860|PROCEDURE|therapeutic conventional surgery|
214595436|NCT00652860|RADIATION|intraoperative radiation therapy|
214595437|NCT00652860|RADIATION|selective external radiation therapy|
214595438|NCT01603329|OTHER|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
214595439|NCT04384848|OTHER|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
214595440|NCT05666388|PROCEDURE|Rescue stenting|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
214595441|NCT00604864|DRUG|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
214595442|NCT00604864|DRUG|placebo|Placebo
214595443|NCT01640275|DRUG|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
214595444|NCT01640275|DRUG|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
214595445|NCT02318823|OTHER|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
214595446|NCT02318823|OTHER|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
214595447|NCT01658098|BEHAVIORAL|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
214595448|NCT05127369|DRUG|Dental pulp mesenchymal cell injection|Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
214595449|NCT05127369|DRUG|Dental pulp mesenchymal cell vehicle|Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
214595450|NCT05127369|DRUG|fluoxetine hydrochloride capsule|fluoxetine hydrochloride capsule
214595451|NCT04615767|DIETARY_SUPPLEMENT|D-chiro-inositol|as described previously
214595452|NCT03008447|DRUG|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
214595453|NCT03008447|DRUG|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
214595454|NCT03008447|DRUG|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
214595455|NCT03008447|DRUG|PBO|Single dose of placebo administered within 5 minutes before bedtime.
214595456|NCT03124095|BEHAVIORAL|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
214595457|NCT02655302|OTHER|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
214595458|NCT02655302|OTHER|Lung function measure|Measure lung function and follow it during 4 years
214595459|NCT01118611|DRUG|Aurora B/C kinase inhibitor GSK1070916A|
214595460|NCT01118611|OTHER|laboratory biomarker analysis|
214595461|NCT01118611|OTHER|pharmacological study|
214595462|NCT01118611|PROCEDURE|diffusion-weighted magnetic resonance imaging + PET CT|
214595463|NCT01118611|RADIATION|fludeoxyglucose F 18 dynomic contrast|
214595464|NCT04644458|OTHER|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
214595465|NCT03916848|PROCEDURE|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
214595466|NCT00730834|DEVICE|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
214595467|NCT03458286|DEVICE|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
214595468|NCT06563362|RADIATION|De-escalation of irradiated volume|De-escalation of elective clinical target volumes as recommended by a model-based approach
214595469|NCT00256451|DRUG|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
214595470|NCT00256451|DRUG|placebo|placebo pills
214595471|NCT00256451|OTHER|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
214595472|NCT00256451|OTHER|Sham alcohol|non-alcoholic placebo alcohol
214595473|NCT00447759|DRUG|Celecoxib|200-400mg daily in divided doses
214595474|NCT00447759|DRUG|Diclofenac|prescribed medication taken orally
214595475|NCT04290442|PROCEDURE|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
214595476|NCT04290442|PROCEDURE|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
214595477|NCT04290442|DRUG|Ropivacaine|ropivacaine 0.5% will be use in the block
214595478|NCT03920709|OTHER|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
214595479|NCT00316134|PROCEDURE|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
214595480|NCT05140733|PROCEDURE|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
214595481|NCT05140733|PROCEDURE|Fusion surgery|Fusion surgery for patients with foraminal stenosis
214595482|NCT03321734|DRUG|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
214595483|NCT03321734|DRUG|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
214595484|NCT01493648|DRUG|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
214595485|NCT01493648|DRUG|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
214595486|NCT03295656|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
214595487|NCT04855266|DRUG|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
214595488|NCT04855266|DRUG|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
214595489|NCT04855266|DIAGNOSTIC_TEST|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
214595490|NCT04916522|DRUG|Colchicine|0.5 mg once daily
214595491|NCT04916522|DRUG|Placebo|Once daily
214595492|NCT00079742|DRUG|Nutropin AQ [somatropin (DNA origin) injection]|
214595493|NCT03780426|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
214595494|NCT03780426|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
214595495|NCT00472329|PROCEDURE|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
214595496|NCT00472329|DRUG|fludarabine|
214711056|NCT06898099|OTHER|"Experimental group: E2R hypnosis"|"Randomization stratification on insomnia severity. For the patients randomized to the Hypnosis E2R arm, patients summoned within 15 days to 3 weeks of inclusion for their first hypnotherapy session with the hypnotherapist. All patients will receive 4 hypnotherapy sessions over 6 weeks using the E2R method.~The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Practice of self-hypnosis requested of the patient (patient diary), Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
214595497|NCT00472329|PROCEDURE|TBI|
214595498|NCT04359251|OTHER|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
214595499|NCT04359251|OTHER|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
214595500|NCT04359251|OTHER|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
214595501|NCT04905147|DRUG|Mosapride|Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
214595502|NCT04905147|DRUG|Placebo|Placebo drug 15 mg
214595503|NCT00458809|DRUG|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
214595504|NCT04782388|DRUG|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
214595505|NCT04782388|OTHER|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
214595506|NCT03661164|PROCEDURE|corneal cross linking|Iontophoretic corneal cross linking
214595507|NCT03478163|DRUG|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
214595508|NCT03478163|DRUG|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
214595509|NCT02018835|DEVICE|MRI|
214595510|NCT02018835|DEVICE|cardiac echography transthoracic|
214595511|NCT00056355|DRUG|UVADEX and UVAR XTS Photopheresis System|
214595512|NCT02422251|DEVICE|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
214595513|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
214595514|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
214595515|NCT04089969|DIAGNOSTIC_TEST|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
214595516|NCT04089969|DIAGNOSTIC_TEST|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
214595517|NCT00261001|BIOLOGICAL|Transcutaneous mode of administration|
214595518|NCT00261001|BIOLOGICAL|Intramuscular mode of administration|
214595519|NCT00707512|DRUG|natalizumab|Administered as specified in the TOUCH Prescribing Program
214595520|NCT05828043|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
214595521|NCT04251650|OTHER|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
214595522|NCT04251650|OTHER|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
214595523|NCT04744285|OTHER|Cigarette packaging|receive normal packet cigarette
214595524|NCT04744285|OTHER|Data capture|Attend video sessions
214595525|NCT04744285|OTHER|Questionnaire administration|Ancillary studies
214595526|NCT00895336|BIOLOGICAL|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
214595527|NCT03959371|DRUG|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
214595528|NCT04003935|OTHER|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
214595529|NCT04003935|DIETARY_SUPPLEMENT|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
214595530|NCT02614573|DEVICE|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is \> 4, then verification by venous measure and refer to general practitioner."
214595531|NCT02022319|DEVICE|Ultrasonographic Shear Wave Elastography|
214595532|NCT04239521|OTHER|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
214595533|NCT04664673|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
214595534|NCT04664673|BEHAVIORAL|Regular care|customary or usual treatment given to any adult stroke survivor
214595535|NCT00934141|OTHER|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
214595536|NCT00934141|OTHER|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
214595537|NCT00934141|OTHER|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
214595538|NCT00934141|OTHER|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
214595539|NCT01337804|DRUG|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
214595540|NCT01337804|DRUG|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
214595541|NCT05185544|OTHER|Neoadjuvant pemetrexed and cisplatin chemotherapy|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
214595542|NCT05945966|OTHER|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
214595543|NCT05945966|OTHER|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
214595544|NCT03351881|OTHER|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
214595545|NCT03057314|DRUG|Amorphous Calcium Carbonate|"Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
214595546|NCT01349725|DRUG|ARRY-502|Oral; multiple dose, escalating
214595547|NCT01349725|DRUG|Placebo|Oral; matching placebo
214595548|NCT05145062|DRUG|BIVV003|Solution for intravenous administration
214595549|NCT05145062|DRUG|ST-400|Solution for intravenous administration
214595550|NCT05532254|DRUG|Aripiprazole 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
214595551|NCT05532254|DRUG|Abilify® 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
214595552|NCT01704963|DRUG|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
214595553|NCT03057808|BEHAVIORAL|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
214595554|NCT03057808|BEHAVIORAL|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
214595555|NCT06101823|BIOLOGICAL|OpSCF|Monoclonal Antibody
214595556|NCT06101823|BIOLOGICAL|Placebo|Formulation buffer without active agent
214595557|NCT06101823|BIOLOGICAL|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
214595558|NCT03154762|DEVICE|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
214595559|NCT03154762|DEVICE|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
214595560|NCT01788267|OTHER|scan examination HR-pQCT|
214595561|NCT00447850|PROCEDURE|endometrial biopsy|
214595562|NCT03984903|OTHER|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
214595563|NCT03984903|OTHER|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
214595564|NCT03984903|OTHER|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
214595565|NCT03984903|OTHER|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
214595566|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
214595567|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
214595568|NCT00752622|BIOLOGICAL|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
214595569|NCT05829590|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
214595570|NCT01023854|PROCEDURE|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
214595571|NCT00576836|BIOLOGICAL|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not \>18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
214595572|NCT00576836|OTHER|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest \& transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced \& placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
214595573|NCT05917041|DEVICE|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
214595574|NCT01523639|DRUG|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
214595575|NCT05635916|DRUG|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
214595576|NCT05635916|DRUG|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
214595577|NCT03661944|DIAGNOSTIC_TEST|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
214595578|NCT03608540|DEVICE|Endomina|Suturing system with sutures apposition then bulging then cutting
214595579|NCT06183749|OTHER|hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit|diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment
214595580|NCT03731507|DEVICE|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
214595581|NCT05286177|PROCEDURE|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for \> 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
214595582|NCT05286177|PROCEDURE|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
214595583|NCT05810831|DIAGNOSTIC_TEST|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
214595584|NCT05810831|DIAGNOSTIC_TEST|Massage|conservative physiotherapy protocol including massage
214595585|NCT02925013|PROCEDURE|Blood sampling|Blood sampling for lipid profile
214595586|NCT02925013|OTHER|Dietary- Normal western diet|Normal western diet
214595587|NCT00096811|DRUG|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
214595588|NCT00182403|DRUG|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
214595589|NCT03054402|DRUG|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
214595590|NCT03054402|DRUG|Placebo|Single dose of placebo
214595591|NCT04844801|PROCEDURE|Risk control strategy|"* Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance \>30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
214595592|NCT04844801|PROCEDURE|Rate control strategy:|"* Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
214595593|NCT04844801|PROCEDURE|Rhythm control strategy:|"* Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~\- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses \> 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus."
214595594|NCT00658099|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
214595595|NCT00658099|DRUG|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
214595596|NCT04603950|PROCEDURE|CACB+IPACK|continue adductor canal block plus Infiltration between the Popliteal Artery and Capsule of the Knee
214595597|NCT04603950|PROCEDURE|CACB|continue adductor canal block
214595598|NCT03756246|BIOLOGICAL|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
214595599|NCT02520284|BIOLOGICAL|Andecaliximab|Andecaliximab 150 mg administered via SC injection
214595600|NCT02520284|BIOLOGICAL|Placebo|Placebo matched to andecaliximab administered via SC injection
214595601|NCT03726710|BEHAVIORAL|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
214595602|NCT04776785|DEVICE|Curodont™ Repair|"It is a product used in biomimetic remineralization of initial carious lesions. The product consists of smart P11-4 peptide molecules (CUROLOX® TECHNOLOGY) that within the lesion the molecules self-assemble to a 3D matrix. This bio-matrix enables the regeneration of the tooth tissue.~Test 1 lesions will be cleaned with a prophylaxis paste and isolated with cotton rolls. Then, the pellicle will be removed using 2% sodium hypochlorite (20 sec) and the inorganic deposits will be removed using 35% phosphoric acid (20 sec). The tooth surface will be rinsed with water and dried. Thereafter, Curodont™ Repair will be applied in compliance with the manufacturers' instructions and left for 5 minutes."
214595603|NCT04776785|DEVICE|MI Varnish™|"MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
214595604|NCT04776785|DEVICE|Profluorid® Varnish|"Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
214595605|NCT02926625|BEHAVIORAL|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~* Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~* Children who are getting worse should come back immediately or at any time for a re-assessment~* All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~* HEW should fill out a loose child assessment form~* If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
214595606|NCT02926625|BEHAVIORAL|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
214595607|NCT03556241|DEVICE|Case management|Case management consists keeping patient's current pacemaker mode during surgery
214595608|NCT04679688|OTHER|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
214595609|NCT04597528|OTHER|Elective Induction|"All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet."
214595610|NCT01251250|OTHER|laboratory biomarker analysis|Correlative studies
214595611|NCT01251250|GENETIC|western blotting|Correlative studies
214595612|NCT01251250|GENETIC|gene expression analysis|Correlative studies
214595613|NCT01251250|OTHER|pharmacological study|Correlative studies
214595614|NCT01251250|OTHER|flow cytometry|Correlative studies
214595615|NCT01251250|GENETIC|fluorescence in situ hybridization|Correlative studies
214595616|NCT01251250|BIOLOGICAL|azadirachta indica|Given orally
214595617|NCT01251250|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214595618|NCT03444727|OTHER|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
214595619|NCT03444727|OTHER|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
214595620|NCT02951741|OTHER|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
214595621|NCT05387226|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
214595622|NCT04792957|DIAGNOSTIC_TEST|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
214595623|NCT06000020|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
214595624|NCT06046963|DRUG|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
214595625|NCT06046963|OTHER|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
214595626|NCT01211522|DRUG|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
214595627|NCT01211522|DRUG|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
214595628|NCT01211522|DRUG|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
214595629|NCT02441062|DRUG|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
214595630|NCT06382025|OTHER|showing cartoons -storybook|A goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period
214595631|NCT06382025|OTHER|showing cartoons - standard|standard
214595632|NCT02641223|DEVICE|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
214595633|NCT02787954|PROCEDURE|TACE|Procedure for giving chemotherapy directly to tumor cells.
214595634|NCT02787954|PROCEDURE|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
214595635|NCT02787954|PROCEDURE|MWA|Using heat to kill tumor cells.
214595636|NCT02787954|PROCEDURE|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
214595637|NCT05213910|DIETARY_SUPPLEMENT|Lactichoc|dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days
214595638|NCT05213910|OTHER|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
214595639|NCT05242185|OTHER|Observational study|\- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
214595640|NCT02740972|DRUG|NS-065/NCNP-01|
214595641|NCT02740972|DRUG|Placebo|
214595642|NCT01116882|PROCEDURE|PCI|
214595643|NCT00547365|BIOLOGICAL|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
214595644|NCT04983641|OTHER|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
214595645|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
214595646|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
214595647|NCT01744223|BIOLOGICAL|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
214595648|NCT01744223|DRUG|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
214595649|NCT01744223|BIOLOGICAL|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
214595650|NCT01744223|BIOLOGICAL|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
214595651|NCT01744223|BIOLOGICAL|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
214595652|NCT01744223|PROCEDURE|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
214595653|NCT00504881|DRUG|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
214595654|NCT00504881|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
214595655|NCT01777269|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
214595656|NCT01777269|DRUG|Placebo|Take one capsule daily
214595657|NCT03557723|OTHER|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~1. Cultural mediation workshop~2. Supervised visit and tour of the museum~3. Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
214595658|NCT04997759|DRUG|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
214595659|NCT05227885|OTHER|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
214595660|NCT02879422|GENETIC|genetic analysis|
214595661|NCT05078216|OTHER|Physical exercise intervention|"12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity."
214595662|NCT05830409|BEHAVIORAL|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
214595663|NCT03120767|BEHAVIORAL|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
214595664|NCT03120767|BEHAVIORAL|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
214595665|NCT01018121|BEHAVIORAL|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
214595666|NCT01018121|OTHER|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
214595667|NCT04115085|PROCEDURE|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
214595668|NCT04115085|PROCEDURE|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
214595669|NCT04115085|PROCEDURE|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
214595670|NCT04115085|PROCEDURE|Sham ultrasound group (18 treatments)|Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
214595671|NCT01530165|BEHAVIORAL|Life style intervention|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
214595672|NCT03032471|OTHER|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
214595673|NCT04694404|DRUG|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
214595674|NCT04825483|OTHER|Weight loss|"Participants will receive resources to support the weight loss program including a recipe book, activities book and how-to guide. The diet program comprises two phases: 1) intensive weight loss through a ketogenic Very Low Calorie Diet (VLCD), including meal replacements for two meals/day, and 2) transition from ketogenic VLCD onto a longer-term eating plan for weight maintenance. Meal replacements will be provided free of charge for up to 6 months. Participants will be encouraged to lose at least 10% body weight."
214595675|NCT04825483|OTHER|Exercise|"Participants will receive resources to facilitate the physiotherapy management plan, including information about the video-conference platform, osteoarthritis information, an exercise plan/log book and a booklet of possible exercises. The physiotherapist consultations include a structured, progressive exercise and physical activity plan. Participants will be given exercise resistance bands and a ankle weight for home exercises.~Physiotherapists will choose from a list of exercises, aiming to prescribe 5-6 at once. Intensity is determined using a modified Rating of Perceived Exertion (RPE) scale, where it should feel hard to very hard to perform a full set of each exercises. Participants are encouraged to complete exercises three times per week. Physiotherapists encourage the participant to increase their general and incidental levels of physical/aerobic activity based on their individual needs and goals, as well as their current level of activity."
214595676|NCT04233736|PROCEDURE|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
214595677|NCT03498482|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
214595678|NCT02647229|OTHER|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
214595679|NCT02647229|OTHER|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
214595680|NCT00282282|DRUG|tacrolimus|Given orally just prior to and following stem cell transplant
214595681|NCT00282282|DRUG|sirolimus|Given orally just prior to and following stem cell transplant
214595682|NCT00282282|DRUG|fludarabine|Given once daily over 30 minutes for 4 days
214595683|NCT00282282|DRUG|busulfex|Given intravenously over 3 hours for 4 days
214595684|NCT04779372|BEHAVIORAL|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
214595685|NCT04779372|BEHAVIORAL|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
214595686|NCT00803270|DRUG|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
214595687|NCT00803270|PROCEDURE|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
214595688|NCT04748900|DIAGNOSTIC_TEST|spirometer|different values are measured on the spirometer after training in respiratory physiotherapy.
214595689|NCT05584267|RADIATION|radiotherapy|Different cohorts received different doses of radiotherapy
214595690|NCT05584267|DRUG|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
214595691|NCT02737917|OTHER|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
214595692|NCT02737917|OTHER|Standard of care|Rapid sequence intubation
214595693|NCT02583139|BEHAVIORAL|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
214595694|NCT04278001|DEVICE|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
214595695|NCT04048954|DEVICE|Applitabac|Smartphone application in screening on tabagism complications
214595696|NCT06341153|BEHAVIORAL|Breast Milk Odor Stimulation|In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
214595697|NCT06341153|BEHAVIORAL|Stimulation of Breast Milk Smell and Taste|In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
214595698|NCT00569595|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
214595699|NCT00569595|BEHAVIORAL|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
214595700|NCT00302627|DRUG|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
214595701|NCT00302627|DRUG|vitamin D|baseline, 6,12 months
214595702|NCT00302627|DRUG|Calcium Carbonate|baseline, 6,12 months
214595703|NCT00210730|DRUG|epoetin alfa|
214595704|NCT02949258|DRUG|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
214595705|NCT02949258|DRUG|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
214595706|NCT02949258|DRUG|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
214595707|NCT02949258|DRUG|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
214595708|NCT06415006|PROCEDURE|Measurement of hemodynamic parameters.|The measurement and recording of Heart Rate (HR), Systolic Arterial Blood Pressure (ABPsys), Diastolic Arterial Blood Pressure (ABPdias), Mean Arterial Blood Pressure (ABPmean), and age parameters.
214595709|NCT03875677|DEVICE|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of \~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
214595710|NCT03875677|DEVICE|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
214595711|NCT03875677|DEVICE|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
214595712|NCT03695666|OTHER|Clerical policy|Clerical policy introduction
214595713|NCT03349892|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
214595714|NCT06178406|BEHAVIORAL|dysmenorrhea|Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.
214595715|NCT00327054|DRUG|Nigella sativa seed|
214595716|NCT02020382|DEVICE|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
214595717|NCT00596778|OTHER|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
214595718|NCT05274984|DRUG|Placebo|the control group will be given the same volume of saline.
214595719|NCT05274984|DRUG|Lidocaine|the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
214595720|NCT00234806|OTHER|Health-e-Access|telemedicine intervention
214595721|NCT05319275|DRUG|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
214595722|NCT05319275|DRUG|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
214595723|NCT05657483|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
214595724|NCT05657483|OTHER|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
214595725|NCT00593957|DRUG|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
214595726|NCT00593957|DRUG|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
214595727|NCT01604707|OTHER|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
214595728|NCT03481023|DEVICE|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
214595729|NCT03481023|PROCEDURE|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
214595730|NCT03717831|OTHER|Observational study of standard of care|Observational cohort study
214595731|NCT02172339|DRUG|Tiotropium, solution ampoules|
214595732|NCT01394653|DRUG|YM060|oral, with water
214595733|NCT04144634|OTHER|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
214595734|NCT04144634|OTHER|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
214595735|NCT00246428|BEHAVIORAL|Individual Motivational Interview (IMI)|Individual counseling sessions with emphasis in personal responsibility, exploration of motivation for drinking and review of potential negative consequences. will be evaluated 6, 9, and 12 months
214595736|NCT00246428|BEHAVIORAL|Individual Motivational Interview + Family Check-Up|One hour videotaped session of family assessment
214595737|NCT04386187|OTHER|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
214595738|NCT04386187|OTHER|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
214595739|NCT04386187|OTHER|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
214595740|NCT03707925|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
214595741|NCT03707925|PROCEDURE|Conventional Surgery|Undergo standard resection
214595742|NCT03707925|PROCEDURE|Laser Ablation|Undergo bronchoscopic laser ablation
214595743|NCT00797498|OTHER|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
214595744|NCT05089136|DEVICE|transcatheter paravalvular leak closure|Transcatheter paravalvular leak closure (PVLc) was first described in 1992 and has since then emerged as an attractive alternative to repeat surgery. Many implantable devices that can be used for transcatheter PVLc have been marketed, although few are specifically designed for this purpose. It consist in implanting an occluder in the paravalvular leak to stop or reduce the regurgitant flow.
214595745|NCT03688607|PROCEDURE|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
214595746|NCT05204693|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
214595747|NCT05204693|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
214595748|NCT05033418|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|4-session CBT-I group in addition to IPRP
214595749|NCT05033418|BEHAVIORAL|Interdisciplinary Pain Rehabilitation Program (IPRP)|10-week IPRP usual care
214595750|NCT00723879|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214595751|NCT00723879|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214595752|NCT00723879|BEHAVIORAL|Patient assistance program|"Patient assistance programs will be classified as follows:~1. medications, including psychiatric medications (antidepressants);~2. other interventions, including nurse telephone calls and nurse support in the office: and~3. educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
214595753|NCT01168739|DIETARY_SUPPLEMENT|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
214595754|NCT01168739|DIETARY_SUPPLEMENT|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
214595755|NCT00225576|OTHER|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
214595756|NCT01786239|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
214595757|NCT01786239|DRUG|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
214595758|NCT01786239|DRUG|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
214595759|NCT00208897|DRUG|Fluoxetine|
214595760|NCT02511678|DEVICE|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
214595761|NCT01295281|DEVICE|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
214595762|NCT01295281|DEVICE|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
214595763|NCT04110119|DRUG|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
214595764|NCT04110119|OTHER|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
214595765|NCT05300269|DRUG|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w"
214595766|NCT05255081|DEVICE|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
214595767|NCT05255081|PROCEDURE|Placebo-control|Spray with saline would be applied to organs under incision
214595768|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
214595769|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
214595770|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
214595771|NCT02414724|DRUG|Gemcitabine Hydrochloride|Given IV
214595772|NCT02414724|OTHER|Laboratory Biomarker Analysis|Correlative studies
214595773|NCT02414724|OTHER|Pharmacological Study|Correlative studies
214595774|NCT02414724|DRUG|Ribociclib|Given PO
214595775|NCT04398641|OTHER|Evaluation of pre- and postoperative gastrointestinal functional outcomes|Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
214595776|NCT05625412|DRUG|BMS-986360|Specified dose on specified days
214595777|NCT05625412|DRUG|Docetaxel|Specified dose on specified days
214595778|NCT05625412|DRUG|Nivolumab|Specified dose on specified days
214595779|NCT05625412|DRUG|Capecitabine|Specified dose on specified days
214595780|NCT05773950|DRUG|fosaprepitant|"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
214595781|NCT05773950|DRUG|normal saline|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."
214595782|NCT02721823|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
214595783|NCT02721823|BEHAVIORAL|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
214595784|NCT05328583|DRUG|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
214595785|NCT06461429|DRUG|Erythromycin|Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
214595786|NCT06461429|DRUG|Amoxicillin and Erythromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
214595787|NCT06461429|DRUG|Azithromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
214595788|NCT06461429|DRUG|Caffeine citrate 20 mg/kg load and 10 mg/kg daily maintenance.|Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
214595789|NCT06461429|DRUG|Caffeine citrate 30 mg/kg load and 15 mg/kg daily maintenance.|Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
214595790|NCT06461429|DRUG|Caffeine citrate 40 mg/kg load and 20 mg/kg daily maintenance|Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
214595791|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 1)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
214595792|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 2)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)"
214595793|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 3)|"* 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
214595794|NCT06320535|PROCEDURE|Fine needle aspiration (FNA)|Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
214595795|NCT05163288|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
214595796|NCT05163288|OTHER|Placebo|Matching Placebo Sachet
214595797|NCT06005064|DIETARY_SUPPLEMENT|Krill oil|Superba krill oil
214595798|NCT06005064|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
214595799|NCT05838300|DEVICE|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
214595800|NCT05838300|DEVICE|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
214595801|NCT04738825|BEHAVIORAL|Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)|"Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5)."
214595802|NCT05101707|DEVICE|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
214595803|NCT05101707|OTHER|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
214595804|NCT06559527|DRUG|NNC0487-0111|Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
214595805|NCT01630044|DEVICE|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
214595806|NCT04181684|DEVICE|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
214595807|NCT04181684|RADIATION|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
214595808|NCT06385652|DRUG|68Ga-NB381|"Lei Kang from Peking University First Hospital and Bing Jia's team from the School of Basic Medical Sciences at Peking University have developed a targeted CD38 nanobody sequence using genetic engineering technology. They have optimized its structure, functionalized it with labeling, and conducted imaging and other evaluations, ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381. The post-labeling quality control of the drug meets clinical trial requirements with a radiochemical purity (PCR) greater than 98% and in vitro stability not less than 90%.~Preliminary PET imaging results of 68Ga-NB381 indicate that the nanobody is primarily concentrated in the kidneys, bladder, and MM.1S and Ramos or H929 tumors (CD38+). Additionally, the cold antibody NB381 significantly inhibits the uptake of 68Ga-NB381 in tumors, confirming the high specificity of this nanobody's binding to the CD38 protein."
214595809|NCT05428254|OTHER|Capacitive and Resistive Radiofrequency therapy|"TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues."
214595810|NCT05428254|OTHER|Exercise therapy|Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
214595811|NCT02940821|OTHER|Toothbrushing|Mechanical plaque removal
214595812|NCT02940821|OTHER|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
214595813|NCT02940821|OTHER|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
214595814|NCT02940821|OTHER|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
214595815|NCT02940821|OTHER|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
214595816|NCT00584597|DRUG|Saline|Saline Control
214595817|NCT00584597|DRUG|Traumeel S|Traumeel S 1 mL
214595818|NCT00584597|DRUG|Traumeel S|Traumeel S 2mL
214595819|NCT00584597|DRUG|Traumeel S|Traumeel S 3mL
214595820|NCT02822638|OTHER|STEMI PATIENT Cohort|PCI
214595821|NCT05833074|BEHAVIORAL|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
214595822|NCT05833074|BEHAVIORAL|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
214595823|NCT00898183|GENETIC|gene expression analysis|
214595824|NCT00898183|GENETIC|polymorphism analysis|
214595825|NCT01411839|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
214595826|NCT03733639|DRUG|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
214595827|NCT03733639|DEVICE|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
214595828|NCT06053723|OTHER|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
214595829|NCT06053723|OTHER|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
214595830|NCT06053723|OTHER|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
214595831|NCT05958641|OTHER|Questionnaires|Participants will be asked to complete the questionnaire including general demographic information, the cognition, resistance and use of NPS as well as the behavioral expression of addiction susceptibility genes and adverse childhood experience.
214595832|NCT04211272|DRUG|Macitentan|Macitentan will be administrated as film-coated tablet in Part A and Part B.
214595833|NCT04211272|DRUG|Sildenafil|Sildenafil will be administrated as film-coated tablet in Part A.
214595834|NCT04211272|DRUG|Riociguat|Riociguat will be administrated as film-coated tablet in Part A.
214595835|NCT04211272|DRUG|Rosuvastatin|Rosuvastatin will be administrated as film-coated tablet in Part B.
214595836|NCT00376454|DRUG|GW493838|
214595837|NCT01787409|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214595838|NCT01787409|OTHER|Laboratory Biomarker Analysis|Correlative studies
214595839|NCT06389838|DEVICE|Kranus Mictera|An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
214595840|NCT03952754|BEHAVIORAL|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
214595841|NCT03952754|BEHAVIORAL|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
214595842|NCT05461794|DRUG|Sitravatinib|100 mg orally once daily
214595843|NCT05461794|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
214595844|NCT05461794|DRUG|Docetaxel|75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle
214595845|NCT05461794|DRUG|Irinotecan|125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle
214595846|NCT02769559|PROCEDURE|Reduction mammaplasty|Surgical removal of excess breast tissue
214595847|NCT06235944|PROCEDURE|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
214595848|NCT06235944|PROCEDURE|Sacral erector spinae block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
214595849|NCT05525013|DRUG|Simvastatin Powder|Simvastatin gel placed as an intracanal medication
214595850|NCT05525013|DRUG|Calcium Hydroxide|Calcium hydroxide intracanal medication
214595851|NCT00381277|DRUG|Gatorade|
214595852|NCT00381277|DRUG|Performance|
214595853|NCT05373160|OTHER|Assessment study|Assessment of functional tests with and without dual tasks
214595854|NCT03736473|DRUG|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
214595855|NCT03751059|DRUG|Bromfenac 0.07% Oph Susp|Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
214595856|NCT03751059|DRUG|Dexamethasone|Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
214595857|NCT06068595|OTHER|musculoskeletal ultrasound|After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
214595858|NCT05764941|DRUG|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
214595859|NCT05764941|DRUG|Pyrotinib|400mg, oral, every day.
214595860|NCT05764941|DRUG|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
214595861|NCT03272126|DRUG|Vitamin D|vitamin D given as bolus versus daily dosing
214595862|NCT03272126|DRUG|Placebo|identical looking as vitamin D
214595863|NCT00109382|DRUG|Aspirin|
214595864|NCT00109382|DRUG|Clopidogrel|
214595865|NCT00109382|DRUG|Simvastatin|
214595866|NCT04848532|BEHAVIORAL|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
214595867|NCT01362777|BEHAVIORAL|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~* 15' start warming up muscles~* 30' muscle strengthening exercise for arms and abdominal muscles~* 45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~* 15' stretching~* 15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
214595868|NCT01362777|BEHAVIORAL|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~* Physiological mechanisms of apneas/hypopneas~* Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~* Beneficials effects of CPAP and/or advanced mandibular orthosis~* Description of sleep stages and physiological roles of sleep~* Known effects of exercise on sleep and metabolism~* Importance of good nutritional status and sleep hygiene on quality of life~* How to apply theses lessons of rehabilitation in daily life"
214595869|NCT02941562|RADIATION|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
214595870|NCT02941562|DRUG|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
214595871|NCT02941562|RADIATION|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
214595872|NCT02941562|DRUG|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
214595873|NCT02941562|PROCEDURE|Radical rectal cancer resection|Radical rectal cancer resection
214595874|NCT02941562|DRUG|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
214595875|NCT06347887|DIAGNOSTIC_TEST|ColonAiQ test and Colonoscopy|Diagnostic Test
214595876|NCT03857074|DEVICE|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
214595877|NCT02684357|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
214595878|NCT02684357|DRUG|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
214595879|NCT02684357|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
214595880|NCT02684357|DRUG|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
214595881|NCT01079130|DRUG|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
214595882|NCT01079130|DRUG|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
214595883|NCT01079130|DRUG|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
214595884|NCT01079130|DRUG|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
214595885|NCT01988623|BEHAVIORAL|Pivotal Response Treatment (PRT)|
214595886|NCT00190567|DRUG|duloxetine|
214595887|NCT00190567|DRUG|Placebo|
214595888|NCT03714425|DEVICE|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
214595889|NCT03019796|DRUG|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
214595890|NCT05517304|DEVICE|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
214595891|NCT05517304|DEVICE|sham|sham stimulation
214595892|NCT05001594|DEVICE|Active vibratory knee device|The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
214595893|NCT02215382|DRUG|sugammadex|sugammadex 2 mg/kg
214595894|NCT02215382|DRUG|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
214595895|NCT04789512|OTHER|Respiratory functions|Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
214595896|NCT03543501|DEVICE|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
214595897|NCT03543501|DEVICE|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
214595898|NCT02440230|DRUG|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
214595899|NCT02440230|DRUG|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
214595900|NCT05991687|OTHER|In-home drug disposal pouch|Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
214595901|NCT05991687|OTHER|Mail-in prepaid envelope|Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
214595902|NCT02948023|BIOLOGICAL|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
214595903|NCT05044273|DEVICE|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
214595904|NCT00410085|DRUG|L-NMMA (N-mono.methyl-L-arginine)|
214595905|NCT05773989|DRUG|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
214595906|NCT05773989|DRUG|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
214595907|NCT00753051|DRUG|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
214595908|NCT00753051|DRUG|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
214595909|NCT00591045|DRUG|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
214595910|NCT03744325|DIETARY_SUPPLEMENT|Hen's egg OIT|Increasing doses of egg white protein administered orally
214595911|NCT00508352|PROCEDURE|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
214595912|NCT03516968|DRUG|Monthly bolus of cholecalciferol per os|Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks
214595913|NCT03516968|DRUG|Daily dose of cholecalciferol per os|Daily substitution, 1200 IU per day (4 drops), for 3 months
214595914|NCT02447757|DRUG|remifentanil|Remifentanil analgesia during delivery
214595915|NCT00985322|DRUG|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
214595916|NCT00985322|DRUG|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
214595917|NCT04770311|BEHAVIORAL|Microbiome friendly diet|Families in the intervention group will have a microbiome-friendly nutrition assessment and will also receive groceries one time per week for four weeks to help achieve a more microbiome-friendly diet.
214595918|NCT06001541|BEHAVIORAL|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
214595919|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
214595920|NCT05073068|BEHAVIORAL|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
214595921|NCT05073068|BEHAVIORAL|Control|No exercise
214595922|NCT04821869|DRUG|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
214595923|NCT04821869|DEVICE|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
214595924|NCT03543267|OTHER|MRI exam|MRI before and after resection surgery
214595925|NCT03583528|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
214595926|NCT03583528|DIAGNOSTIC_TEST|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
214595927|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires.
214595928|NCT00006203|DRUG|Naltrexone 50 Mg|Daily 50 mg for 3 weeks
214595929|NCT00006203|DRUG|Placebo|Daily doses of placebo for 3 weeks
214595930|NCT04955743|DRUG|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
214595931|NCT04955743|DRUG|Lenvatinib|20 mg orally (PO) is administered daily
214595932|NCT03444324|BIOLOGICAL|BT524|BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
214595933|NCT03444324|BIOLOGICAL|FFP/Cryo|FFP/Cryo was administered intravenously; dosage according to local standards. FFP, 15 mL per kg body weight (BW); Cryoprecipitate, fixed dose of 10 units.
214595934|NCT06307977|BEHAVIORAL|Couples Health Project|A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
214595935|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
214595936|NCT01377051|DRUG|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
214595937|NCT01377051|DRUG|Placebo|Dry powered, same to study drug, only one inhalation
214595938|NCT02729623|DRUG|Kite Systems cannaHALER cannabis Inhaler.|
214595939|NCT03686319|OTHER|Reflexology|Reflexology: foot massage
214711057|NCT05444348|BEHAVIORAL|Advance consultation concerning your life and treatment (ACT )|The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
214711058|NCT06762366|BEHAVIORAL|Additional Incentive|During this behavioral intervention, participants will be given additional compensation for correct answers.
214595940|NCT04328636|DRUG|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
214595941|NCT04328636|DRUG|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
214595942|NCT06814743|BEHAVIORAL|Pelvic floor exercises program guided with an intravaginal biofeedback device|Use of the mobile application to perform a exercise program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure. Behavioral: mobile application with access to information about pelvic floor and direct communication with healthcare team.
214595943|NCT06814743|BEHAVIORAL|Pelvic floor exercises program|"Use of the mobile application to perform a exercise program for pelvic floor musculature.~Behavioral: Information about pelvic floor and communication with health professionals Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team."
214595944|NCT06814743|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team.
214595945|NCT06588699|DRUG|Digoxin|Taken orally once daily
214595946|NCT06588699|DRUG|Placebo|Matched Placebo taken orally once daily
214595947|NCT06014710|OTHER|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
214595948|NCT06150534|OTHER|No Intervention|This is a non-interventional study.
214595949|NCT06979752|PROCEDURE|Tran canula|After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
214595950|NCT06979752|PROCEDURE|augmented irrigation|After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.
214595953|NCT06588582|OTHER|Water Temperature Variation - WW|Participants are assigned to warm water temperature.
214595954|NCT06588582|OTHER|Water Temperature Variation - CW|Participants are assigned to cold water temperature and are video recorded.
214595955|NCT06599671|PROCEDURE|Transvaginal niche resection|In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.
214595956|NCT06017986|OTHER|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
214595957|NCT06017986|OTHER|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
214595958|NCT06017986|OTHER|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
214595959|NCT06017986|OTHER|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
214595960|NCT06017986|OTHER|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
214595961|NCT06017986|OTHER|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
214595962|NCT01455493|DRUG|GDC-0980|Oral daily dose
214595963|NCT06611124|PROCEDURE|k -wires fixation for metacarpals fractures|reduction and fixation of metacarpal fracture with k-wire
214595964|NCT06609915|DEVICE|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany)|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany). Initially FiO2 at 1.0, reduced to 0.3 during laser interventions. Frequency and pressure set according to the local standards
214595965|NCT06609915|DEVICE|High-flow nasal supplemental oxygen via nasal cannula with the Optiflow (Fisher & Paykel, Auckland, New Zealand)|up to 70 L/min FiO2 1.0 high flow oxygen via nasal cannula with the Optiflow (Fisher \& Paykel, Auckland, New Zealand) initially. Reduced FiO2 to 0.3 during laser intervention.
214595966|NCT06610916|OTHER|Reinforced Communautary Support Program (PARC)|"Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \&amp;#34;before\&amp;#34;. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\&amp;#34;after\&amp;#34;) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\&amp;#39; course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach"
214595967|NCT06610409|DIAGNOSTIC_TEST|blood sampling|Blood sample for CXCL5 Level
214595968|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
214595969|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
214595970|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
214595971|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
214595972|NCT01131871|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
214595973|NCT01131871|BEHAVIORAL|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
214595974|NCT06993116|DRUG|SHR-4712 Injection|SHR-4712 injection.
214595975|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
214595976|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
214595977|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
214595978|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
214595979|NCT03944135|OTHER|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
214595980|NCT04326127|DEVICE|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
214595981|NCT05217888|DEVICE|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
214595982|NCT06092372|BEHAVIORAL|Diet intervention program|"Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI."
214595983|NCT06863259|DRUG|Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone|"Subjects will receive a course of inotuzumab ozogamicin administered by central venous catheter over 60 minutes on days 1, 8, and 15.~Venetoclax (by mouth or NG) and dexamethasone (by mouth, NG, or IV) are given daily per assigned dose level. Venetoclax and dexamethasone are started 2 days prior to inotuzumab to limit risk of tumor lysis syndrome with a two-day venetoclax ramp up in cycle 1. On days 1 and 8, venetoclax administration should be scheduled for 4 hours after the beginning of inotuzumab ozogamicin administration. If the patient is not able to ingest venetoclax at the scheduled time, it may still be given later in the day, but efforts should be made to administer the venetoclax within 2 hours of the scheduled time whenever possible."
214595984|NCT06862323|BEHAVIORAL|Time-Restricted Eating|TRE will be defined as a 16 hour fast with an 8 hour feeding window, with the option of a longer feeding window one day per week. All participants will adhere to the fasting intervention for either 90 days (3 months) or 180 days (6 months) based on their preference. Participants will be provided guidance (see appendix 7, Fasting Guidelines) on how to achieve an 8 hour feeding window by day 9 of the study and are recommended to adhere to the 16 hour fast/8 hour feeding window daily for the remainder of the study.
214595985|NCT06588257|BIOLOGICAL|Non-infectious adjuvanted recombinant nonavalent HPV vaccine|Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
214595986|NCT05437185|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
214595987|NCT05437185|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
214595988|NCT04530331|BEHAVIORAL|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
214595989|NCT07020832|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214595990|NCT07020832|OTHER|Placebo|Sterile solution of equal volume to active arm
214595991|NCT06688916|BEHAVIORAL|Behavioral assessment|A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.
214711059|NCT06762366|BEHAVIORAL|Response Delay|During this behavioral intervention, participants will not be allowed to respond with their judgements until after a certain amount of time has passed.
214711060|NCT06762366|BEHAVIORAL|Baseline Performance|In this intervention, the participant completes the task as it is typically administer for a baseline performance measure. The participant can respond at will and does not receive incentive for correct responses.
214595992|NCT06688916|BEHAVIORAL|Functional Magnetic Resonance Imaging (fMRI)|"Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment."
214595993|NCT07020468|DRUG|NALIRIFOX|The patients with Locally Advanced Colorectal Cancer and Upper Rectal Cancer will undergo neoadjuvant treatment with irinotecan liposome combined with oxaliplatin + 5-FU/LV (NALIRIFOX), with each treatment cycle lasting 2 weeks, for a total of 3-6 cycles.
214595994|NCT06881511|OTHER|No intervention (Control Group)|Patients in this group will receive standard care and undergo regular follow-up and monitoring without any additional treatment.
214595995|NCT06881511|DIETARY_SUPPLEMENT|Oral betaine hydrochloride (2 capsules, 3 times daily)|Oral betaine hydrochloride (with pepsin). Patients will take 2 capsules (648 mg per capsule) of betaine hydrochloride, 3 times daily with meals.
214595996|NCT07020325|PROCEDURE|Bipolar Enucleation of the Prostate|Bipolar enucleation of the prostate involves the removal of prostate tissue using a bipolar electrode. This procedure is performed for patients with benign prostatic hyperplasia (BPH), with different electrode types used for comparison in this study
214595997|NCT07020325|DEVICE|Bipolar electrode From Wolf company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
214595998|NCT07020325|DEVICE|Bipolar electrode From Storz company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
214595999|NCT07020325|DEVICE|Bipolar electrode From Olympus company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
214596000|NCT07020325|DEVICE|Bipolar electrode From Lamidey company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
214596001|NCT06746337|BEHAVIORAL|IMAGINE|IMAGINE is a digital group cognitive behavioral therapy intervention
214596002|NCT06859697|PROCEDURE|Herbal medicine treatment|Herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients
214596003|NCT06859697|PROCEDURE|Life Guidance|Educational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices.
214596004|NCT06897137|OTHER|Surveys/Questionnaires|Participants will complete self-report questionnaires via Slice MR's secure, web-based platform. The questionnaires should take less than 30 minutes and will include the following options based on their relevance to each sample : 1) sociodemographic and clinical information) newly developed item pools for body image, fertility, and financial burden) legacy measures for body image, fertility, and financial burden) the PROMIS AYA Health Status Profile) the PROMIS Global) items about meditation practices (for descriptive purposes to inform future research).
214596005|NCT06747182|OTHER|mobile phone-based intervention|Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
214596006|NCT02591199|DRUG|URG101|
214596007|NCT02591199|DRUG|Placebo|
214596008|NCT02591199|DRUG|Lidocaine|
214596009|NCT02591199|DRUG|Heparin|
214596010|NCT00413738|DEVICE|Antiseptic-coated central venous catheters|
214596011|NCT00265447|BEHAVIORAL|Strength training|3 months of strength training
214596012|NCT00265447|BEHAVIORAL|Aerobic conditioning|3 months of aerobic conditioning
214596013|NCT00265447|BEHAVIORAL|Delayed exercise|delayed exercise control group
214596014|NCT01390181|DRUG|Cozaar|Angiotensin II Receptor Blocker
214711061|NCT07067346|DRUG|IR-101|IR-101 Dose Escalation
214596015|NCT02805725|DRUG|Phase 1: Trabectedin|"Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)"
214596016|NCT02805725|DRUG|Phase 2: Trabectedin|"Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial."
214596017|NCT02805725|DRUG|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
214596018|NCT02805725|DRUG|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
214596019|NCT01195545|DEVICE|Veritas® Collagen Matrix|biological mesh in hernia repair
214596020|NCT01062945|DRUG|Placebo|Matching administration of a placebo pill.
214596021|NCT01062945|DRUG|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
214596022|NCT02425644|DRUG|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
214596023|NCT02425644|DRUG|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
214596024|NCT03668353|BIOLOGICAL|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
214596025|NCT02549560|DEVICE|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
214596026|NCT00225992|DRUG|Arsenic Trioxide|
214596027|NCT04131400|DIAGNOSTIC_TEST|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
214596028|NCT00657059|DRUG|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
214596029|NCT00657059|DRUG|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
214596030|NCT00657059|DRUG|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
214596031|NCT04424797|OTHER|Prone Positioning|Intervention is patient in prone positioning
214596032|NCT04424797|OTHER|Supine Positioning|Intervention is patient in supine positioning
214596033|NCT02714725|DRUG|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
214596034|NCT02714725|DRUG|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
214596035|NCT02714725|DRUG|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
214596036|NCT06374355|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
214596037|NCT05997927|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
214596038|NCT05997927|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
214596039|NCT00091117|DRUG|bortezomib|Given IV
214596040|NCT00091117|OTHER|pharmacological study|Correlative studies
214596041|NCT00280046|DRUG|biphasic insulin aspart|
214596042|NCT02772523|OTHER|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
214596043|NCT00909792|DEVICE|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
214596044|NCT00909792|DEVICE|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
214596045|NCT00659893|DRUG|PEP005 Topical gel|0.05%, two day dose
214596046|NCT05210296|BEHAVIORAL|Exercises|Therapeutic exercise will be applied to the elderly
214596047|NCT02570893|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
214596048|NCT02570893|RADIATION|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
214596049|NCT02570893|DRUG|Paclitaxel and carboplatin|
214596050|NCT03473704|BEHAVIORAL|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
214596051|NCT03473704|BEHAVIORAL|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
214596052|NCT05882669|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
214596053|NCT01361295|PROCEDURE|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
214596054|NCT01361295|PROCEDURE|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
214596055|NCT03259594|PROCEDURE|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
214711062|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- low risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the low risk of overdiagnosis arm will view a version of the decision aid the describes a low risk of overdiagnosis.
214596056|NCT03259594|DRUG|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
214596057|NCT02405923|OTHER|HRF|The subject will take the formula for a period of 12 months.
214596058|NCT02405923|OTHER|eHF|The subject will take the formula for a period of 12 months.
214596059|NCT00315003|DRUG|Telithromycin|
214711063|NCT07071415|BEHAVIORAL|Breast cancer decision aid -- moderate risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the moderate risk of overdiagnosis arm will view a version of the decision aid the describes a moderate risk of overdiagnosis.
214596060|NCT00315003|DRUG|Azithromycin|
214596061|NCT02376751|DRUG|sebelipase alfa|
214596062|NCT03096366|DEVICE|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
214596063|NCT03096366|OTHER|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
214596064|NCT01012843|DRUG|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
214596065|NCT01012843|DRUG|Placebo|oral Placebo tablets two times a day for 10 days
214711064|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- high risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the high risk of overdiagnosis arm will view a version of the decision aid the describes a high risk of overdiagnosis.
214711065|NCT07071415|OTHER|Control condition|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the control arm will view a version of the decision aid that does not contain any information about overdiagnosis.
214711066|NCT07077317|OTHER|Airway Assessment Using Standard Clinical Tools|Preoperative airway evaluation using routine physical measurements (e.g., Mallampati score, neck circumference, STOP-Bang questionnaire), and intraoperative/postoperative observation of airway-related parameters.
214711067|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.03%|A topical drop of 0.03% BRM421 ophthalmic solution.
214711068|NCT07078955|DRUG|Vehicle Ophthalmic Solution|A topical drop of vehicle (minus active) ophthalmic solution.
214711069|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.06%|A topical drop of 0.06% BRM421 ophthalmic solution.
214596066|NCT05715970|DIAGNOSTIC_TEST|PoCT+questionnaire administration|"In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital."
214596067|NCT04862247|BEHAVIORAL|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
214596068|NCT04862247|BEHAVIORAL|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
214596069|NCT04519112|PROCEDURE|Catheter Ablation|Catheter Ablation with RMN and MCN
214596070|NCT05531253|OTHER|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
214596071|NCT06460844|GENETIC|RTx-015|Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
214596072|NCT06480370|DEVICE|ISIS IOM System|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
214596073|NCT05080166|OTHER|Interview with Clinicians|One time, qualitative interview of clinicians for feedback on UPLYFT intervention
214596074|NCT05080166|OTHER|Field Test of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors for feedback
214596075|NCT05080166|BEHAVIORAL|Pilot of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors
214596076|NCT06378450|BEHAVIORAL|Mindfulness meditation guided practice|Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.
214596077|NCT01177787|DEVICE|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
214596078|NCT01177787|DEVICE|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
214596079|NCT00002765|BIOLOGICAL|LMB-2 immunotoxin|
214596080|NCT03265834|OTHER|< 10 days of antibiotics|Antibiotic duration
214596081|NCT03265834|OTHER|28 days of antibiotics|Antibiotic duration
214596082|NCT02711488|BEHAVIORAL|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
214596083|NCT02170454|PROCEDURE|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
214596084|NCT03314597|OTHER|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
214596085|NCT03314597|OTHER|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
214596086|NCT02158520|BIOLOGICAL|Bevacizumab|Given IV
214596087|NCT02158520|BIOLOGICAL|Ipilimumab|Given IV
214596088|NCT02158520|OTHER|Laboratory Biomarker Analysis|Correlative studies
214596089|NCT02158520|DRUG|Nab-paclitaxel|Given IV
214596090|NCT02158520|OTHER|Pharmacological Study|Correlative studies
214596091|NCT00381368|DRUG|Ibandronic acid|
214596092|NCT00402363|DRUG|omega-3-acid ethyl esters|
214596093|NCT00402363|DRUG|Placebo|
214596094|NCT04298463|DRUG|Xydalba|Drugs were administered i.v.
214596095|NCT04298463|DRUG|vancomycin, teicoplanin or daptomycin|Drugs were administered i.v.
214596096|NCT05024630|PROCEDURE|Renal artery cryoablation|Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
214596097|NCT05024630|PROCEDURE|Pulmonary vein cryoablation|Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
214596098|NCT05024630|PROCEDURE|Renal arteriography|Renal artery was examined by renal arteriography
214596099|NCT00293722|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
214596100|NCT00819260|DEVICE|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
214596101|NCT00819260|DEVICE|Electrocautery|Electrocautery used to reduce breast on this side
214596102|NCT04381091|DRUG|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
214596103|NCT04011254|PROCEDURE|haemodialysis|Routine haemodialysis session
214596104|NCT00820976|DRUG|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
214596105|NCT04139265|DIAGNOSTIC_TEST|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
214596106|NCT01539304|DRUG|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
214596107|NCT01539304|DRUG|Placebo|Placebo dry syrup, b.i.d
214596108|NCT05678023|OTHER|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
214596109|NCT03025399|DRUG|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
214596110|NCT03025399|DRUG|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
214596111|NCT02634346|DRUG|ALK3831|Daily dosing
214596112|NCT02634346|DRUG|Olanzapine|Daily dosing
214596113|NCT02634346|DRUG|Placebo|Daily dosing
214596114|NCT01246752|BIOLOGICAL|Human Stem Cell Transplantation|Human allogenic stem cells
214596115|NCT01246752|DRUG|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
214596116|NCT03426254|BIOLOGICAL|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
214596117|NCT03426254|DRUG|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
214596118|NCT00167817|DRUG|Aripiprazole|
214596119|NCT03155854|PROCEDURE|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
214596120|NCT03155854|PROCEDURE|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
214596121|NCT01266733|BEHAVIORAL|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
214596122|NCT01266733|BEHAVIORAL|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
214596123|NCT03394430|DRUG|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
214596124|NCT03394430|DRUG|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
214596125|NCT03394430|DRUG|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
214596126|NCT00309556|DRUG|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
214596127|NCT00309556|DRUG|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
214711073|NCT07086092|OTHER|Serum magnesium, uric acid, and vitamin D levels and motor recovery and ambulation stages|Serum magnesium, uric acid, and vitamin D levels, as well as motor recovery and ambulation levels, measured during the patients' rehabilitation stay will be obtained from past medical records.
214596128|NCT00309556|DRUG|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
214596129|NCT00309556|DRUG|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
214711074|NCT06928753|BIOLOGICAL|IXCHIQ|Group of vaccinated arm will be with the IXCHIQ vaccine
214711075|NCT07091708|OTHER|Acupuncture|Acupuncture
214711076|NCT07090096|OTHER|A whole food plant based diet|A whole food plant based (WFPB) diet
214596130|NCT04481477|OTHER|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
214596131|NCT05859438|OTHER|Communication aid support|Support to use voice input voice output communication aids
214596132|NCT03811353|DIAGNOSTIC_TEST|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
214596133|NCT00572520|BEHAVIORAL|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
214596134|NCT00572520|BEHAVIORAL|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
214596135|NCT00572520|BEHAVIORAL|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
214596136|NCT02672709|DRUG|apixaban|
214596137|NCT03252275|OTHER|Peer learning|Peer learning plus HBB and ECEB
214596138|NCT04780308|PROCEDURE|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
214596139|NCT00421200|DRUG|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
214596140|NCT00421200|DRUG|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
214596141|NCT02824263|OTHER|CPAP withdrawal|CPAP is discontinued for 3 nights.
214596142|NCT04386343|DRUG|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
214596143|NCT04386343|DRUG|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
214596144|NCT04386343|DRUG|Placebos|The placebo was used on patients as a control for the doses of CH1701
214596145|NCT01285466|DRUG|BEZ235 + paclitaxel|
214596146|NCT01285466|DRUG|BKM120 + paclitaxel|
214596147|NCT01285466|DRUG|BEZ235 + paclitaxel + trastuzumab|
214596148|NCT01285466|DRUG|BKM120 + paclitaxel + trastuzumab|
214596149|NCT01008696|DRUG|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
214711077|NCT07092423|DIETARY_SUPPLEMENT|Semi-elemental formula|Treatment: Semi-elemental enteral nutrition Objective: To assess the efficacy of semi-elemental enteral nutrition in enhancing gastrointestinal tolerance in patients with severe traumatic brain injury.
214596150|NCT01008696|DRUG|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
214596151|NCT06470802|BEHAVIORAL|Familiar voice|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
214596152|NCT06470802|BEHAVIORAL|Nature sounds|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
214711078|NCT07092423|DIETARY_SUPPLEMENT|Standard formula|Treatment: Standard enteral nutrition Objective: To serve as the control for evaluating the efficacy and safety of semi-elemental enteral nutrition versus standard nutritional therapy
214596153|NCT06470802|BEHAVIORAL|Control|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
214596154|NCT06150638|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
214596155|NCT06150638|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
214596156|NCT00568321|DRUG|RN624|50 mcg/kg
214596157|NCT00568321|DRUG|RN624|200 mcg/kg
214596158|NCT00568321|DRUG|Placebo|placebo
214596159|NCT00937833|PROCEDURE|Prostatectomy|
214596160|NCT00937833|DEVICE|Surgisis Male Sling|
214596161|NCT01771068|BEHAVIORAL|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
214596162|NCT04047693|DRUG|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
214596163|NCT02929797|BIOLOGICAL|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
214596164|NCT02929797|DRUG|Gemcitabine|gemcitabine
214596165|NCT02636933|OTHER|Lung Function Assessment|Lung Function Assessment
214596166|NCT03608267|DEVICE|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
214596167|NCT02271074|OTHER|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
214596168|NCT02271074|BEHAVIORAL|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
214596169|NCT02271074|OTHER|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
214596170|NCT04595253|OTHER|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
214596171|NCT06250348|OTHER|Non invasive measure of endogenous exhaled Nitric Oxyde in exhaled gaz, by a laser spectrometer|A sample of exhaled gases is taken from the expiratory part of the respirator circuit (same way as a capnometry measurement). A laser spectrometer continuously and non-invasively monitors online the concentrations of endogenous NO exhaled by patients.
214596172|NCT01676909|BEHAVIORAL|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
214711079|NCT07090499|DRUG|PF-08046876|Intravenous administration
214711080|NCT07092020|DEVICE|EDF|Extended depth of focus
214711081|NCT07092020|DEVICE|Monofocal IOL|Monofocal
214596173|NCT01676909|BEHAVIORAL|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
214596174|NCT01707225|DRUG|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
214596175|NCT03399487|DRUG|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
214596176|NCT04730544|DRUG|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
214596177|NCT04730544|DRUG|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
214596178|NCT00014326|RADIATION|radiation therapy|
214596179|NCT03306836|DRUG|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
214596180|NCT03306836|DRUG|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
214596181|NCT02336750|DRUG|Aprepitant|125mg D1, 80mg D2-3
214596182|NCT02336750|DRUG|Mirtazapine|15mg D2-4
214596183|NCT06960317|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
214596184|NCT06960317|OTHER|Sham Comparator|None - capped needle will not be injected nor will it contain any medication.
214596185|NCT06960317|DRUG|Unbuffered lidocaine|To determine if a 20 cc unbuffered (1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
214596186|NCT06960317|DRUG|Xylocaine jelly 2%|To determine if a Xylocaine jelly (2% infused lidocaine) decreases pain with paracervical block
214596187|NCT06960317|DRUG|Surgilube|To determine if a placebo gel is inferior to lidocaine gel for pain with paracervical block
214596188|NCT04984954|DRUG|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
214596189|NCT03260595|DRUG|Crisaborole ointment 2%|Crisaborole ointment 2%
214596190|NCT03260595|DRUG|Vehicle|Vehicle
214596191|NCT03412305|DRUG|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
214596192|NCT03412305|OTHER|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
214596193|NCT01677897|DRUG|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
214596194|NCT01440712|DRUG|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
214596195|NCT01440712|DRUG|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
214596196|NCT01680068|PROCEDURE|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
214596197|NCT02573220|BIOLOGICAL|Cetuximab|Given IV
214596198|NCT02573220|DRUG|Fluorouracil|Given IV
214596199|NCT02573220|DRUG|Irinotecan Hydrochloride|Given IV
214596200|NCT02573220|DRUG|Leucovorin Calcium|Given IV
214596201|NCT01803568|OTHER|Exercise|12 weeks of exercise; 4 times pr week
214596202|NCT00221195|DRUG|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
214596203|NCT00978692|DEVICE|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
214596204|NCT00978692|DEVICE|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
214596205|NCT04651907|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
214596206|NCT04651907|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
214596207|NCT04291352|DIETARY_SUPPLEMENT|Taurine|675mg taurine four times daily
214596208|NCT04291352|OTHER|Placebo|placebo four times daily
214596209|NCT03686280|OTHER|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
214596210|NCT03686280|OTHER|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
214596211|NCT03686280|OTHER|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
214596212|NCT03686280|OTHER|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
214596213|NCT03686280|OTHER|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
214596214|NCT03686280|OTHER|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
214596215|NCT03686280|OTHER|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
214596216|NCT04056936|PROCEDURE|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
214596217|NCT01080378|PROCEDURE|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
214596218|NCT01308957|DIETARY_SUPPLEMENT|Omega-3 fatty acids|4 grams per day for 24 weeks
214596219|NCT01308957|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 24 weeks
214596220|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- real tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, 2 mA stimulation with 1x1 tDCS mini-CT device by Soterix Medical
214596221|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- sham tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, sham stimulation with tDCS mini-CT device by Soterix Medical
214596222|NCT06416553|BEHAVIORAL|Lee-Silverman voice treatment|Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
214596223|NCT06397807|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.
214596224|NCT06397807|DRUG|Analgesic injectables|Opioids, NSAIDs or acetamol will be administrated as need.
214596225|NCT06397807|DRUG|Enteral analgesics|Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
214596226|NCT02718807|OTHER|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
214596227|NCT04782843|OTHER|HEP score assessement|Assessement of the HEP score between 2 physician.
214596228|NCT05057923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
214596229|NCT04873219|DEVICE|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
214596230|NCT02189356|BEHAVIORAL|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
214596231|NCT02189356|BEHAVIORAL|standard care|standard pregnancy follow up
214596232|NCT01297413|BIOLOGICAL|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
214596233|NCT00328900|DRUG|Administration of 0,7 mg of atropine|
214596234|NCT00328900|DEVICE|Measurement of skin conductance with Pain detector|
214596235|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
214596236|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
214596237|NCT00010062|DRUG|fluorouracil|
214596238|NCT00010062|RADIATION|radiation therapy|
214596239|NCT00162032|DRUG|Sestamibi|Sestamibi
214596240|NCT04350554|OTHER|Pregnancy|To measure and characterize pregnancies and describe the clinical course during pregnancy
214596241|NCT04350554|OTHER|Pregnancy|To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
214596242|NCT02031289|DRUG|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
214596243|NCT02841228|RADIATION|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
214596244|NCT04286698|OTHER|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes \[25\]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
214596245|NCT04286698|OTHER|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point \[3\]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
214596246|NCT04376970|DRUG|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
214596247|NCT04376970|DRUG|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
214596248|NCT00065325|DRUG|Fulvestrant|intramuscular injection
214596249|NCT00065325|DRUG|Exemestane|oral capsule
214596250|NCT02842840|BEHAVIORAL|Patient-based intervention|
214596251|NCT02842840|BEHAVIORAL|Family based intervention|
214596252|NCT02842840|OTHER|Routine counseling|
214596253|NCT02485535|OTHER|Laboratory Biomarker Analysis|Correlative studies
214596254|NCT02485535|DRUG|Selinexor|Given PO
214596255|NCT00833911|DRUG|Tramadol Once A Day|
214596256|NCT02701426|BEHAVIORAL|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
214596257|NCT00559442|OTHER|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
214596258|NCT02463825|DRUG|Pimozide 2 mg per day|
214596259|NCT02463825|DRUG|Pimozide 4 mg per day|
214596260|NCT02463825|DRUG|Placebo (Lactose tablet)|
214596261|NCT00718640|DRUG|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
214596262|NCT00718640|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
214596263|NCT01835197|DRUG|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
214596264|NCT01835197|DRUG|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
214596265|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
214596266|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
214596267|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
214596268|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
214596269|NCT01835197|DRUG|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
214596270|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
214596271|NCT01835197|DRUG|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
214596272|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
214596273|NCT02709525|DRUG|hyaluronic acid|
214596274|NCT02709525|OTHER|Placebo|
214596275|NCT04100473|DRUG|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
214596276|NCT04100473|DRUG|Insulin Lispro (Humalog U-100)|Lispro
214596277|NCT01888835|DRUG|Mirtazapine|
214596278|NCT01888835|DRUG|Placebo|
214596279|NCT02431650|DRUG|OZ439|
214596280|NCT02431650|DRUG|Primaquine|
214596281|NCT05628116|DRUG|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
214596282|NCT05628116|DRUG|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
214596283|NCT05628116|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
214596284|NCT05628116|DRUG|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
214596285|NCT05628116|DRUG|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
214596286|NCT05628116|DRUG|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
214596287|NCT05628116|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
214596288|NCT00764933|BEHAVIORAL|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
214596289|NCT00764933|OTHER|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
214596290|NCT01742598|DEVICE|Portico Transapical Aortic Valve System|
214596291|NCT04559828|OTHER|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
214596292|NCT02272855|BIOLOGICAL|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
214596293|NCT01596907|DRUG|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
214596294|NCT01596907|DRUG|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
214596295|NCT00818389|DRUG|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
214596296|NCT00818389|DRUG|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
214596297|NCT00818389|DRUG|placebo|an inactive substance
214596298|NCT02885298|PROCEDURE|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
214596299|NCT01207596|DRUG|Hydromorphone|Oral hydromorphone extended release, once daily
214596300|NCT01494454|DEVICE|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
214596301|NCT01494454|DEVICE|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
214596302|NCT03548987|DRUG|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
214596303|NCT03548987|DRUG|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
214596304|NCT00119145|DRUG|artesunate-amodiaquine|
214596305|NCT00119145|DRUG|coartem|
214596306|NCT00119145|DRUG|artesunate-lapdap|
214596307|NCT04427150|BEHAVIORAL|Auditory Training|A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
214596308|NCT04427150|BEHAVIORAL|Non-auditory training|A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
214596309|NCT03761511|DRUG|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
214596310|NCT03761511|DRUG|Placebo|Matching Placebo (capsules) once daily
214596311|NCT02741583|OTHER|altitude rehabilitation program|altitude exposure
214596312|NCT02741583|OTHER|rehabilitation program|Rehabilitation at low altitude
214596313|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
214596314|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
214596315|NCT05550740|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
214596316|NCT06423248|DIETARY_SUPPLEMENT|Ginger|3g of dried powdered Ginger daily for 12 weeks
214596317|NCT06423248|DIETARY_SUPPLEMENT|black seed|3g of dried powdered Black Seed daily for 12 weeks
214596318|NCT06423248|DIETARY_SUPPLEMENT|cinnamon|3g of dried powdered Cinnamon daily for 12 weeks.
214596319|NCT06423248|OTHER|Placebo|3g of powdered corn starch daily for 12 weeks.
214596320|NCT05541315|DRUG|JNJ-88260237|JNJ-88260237 will be administered orally.
214596321|NCT05541315|DRUG|Placebo|Matching placebo will be administered orally.
214596322|NCT03686267|OTHER|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
214596323|NCT03686267|OTHER|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
214596324|NCT03686267|OTHER|titanium abutment with no color masking|color masking methods are avoided in this arm
214596325|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
214596326|NCT06311981|OTHER|targeted therapy|targeted therapy
214596327|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
214596328|NCT04088864|DRUG|Fludarabine|Fludarabine is a purine antagonist antimetabolite
214596329|NCT04088864|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
214596330|NCT04088864|DRUG|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
214596331|NCT03844360|DRUG|Bortezomib|bortezomib was administered follow the doctor's advice.
214596332|NCT03844360|DRUG|Eltrombopag|eltrombopag was administered follow the doctor's advice.
214596333|NCT03844360|DRUG|Imatinib|imatinib was administered follow the doctor's advice.
214596334|NCT03844360|DRUG|dasatinib|dasatinib was administered follow the doctor's advice.
214596335|NCT03844360|DRUG|Pegaspargase|pegaspargase was administered follow the doctor's advice.
214596336|NCT03844360|DRUG|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
214596337|NCT03844360|DRUG|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
214596338|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
214596339|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
214596340|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
214596341|NCT01106014|DRUG|Selexipag|Selexipag 200 µg tablets
214596342|NCT01106014|DRUG|Placebo|Placebo tablets matching selexipag
214596343|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
214596344|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
214596345|NCT04281550|OTHER|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
214596346|NCT04835701|BEHAVIORAL|Music|Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
214596347|NCT00830648|BIOLOGICAL|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
214596348|NCT00784693|BIOLOGICAL|Tanezumab|15 mg IV single dose
214596349|NCT00784693|DRUG|Placebo|Placebo IV single dose
214596350|NCT02650882|PROCEDURE|Device POWERbreathe|
214596351|NCT05848505|DRUG|Dexmedetomidine|Intranasal administration Dosage 2 mcg/kg
214596352|NCT02456077|BEHAVIORAL|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
214596353|NCT03289377|BEHAVIORAL|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
214596354|NCT03673865|DEVICE|office-based 3-dimensional printers (OB3DP)|In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.
214596355|NCT03673865|DEVICE|standard stock orbital plate|In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
214596356|NCT02647294|DIETARY_SUPPLEMENT|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
214596357|NCT02647294|OTHER|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
214596358|NCT00602394|DRUG|Lithium|
214596359|NCT00121277|DRUG|capecitabine|
214596360|NCT00121277|DRUG|vorinostat|
214596361|NCT04557605|OTHER|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
214596362|NCT00756470|DRUG|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
214596363|NCT00756470|DRUG|Paclitaxel|80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
214596364|NCT00756470|DRUG|5-Fluorouracil (5-FU)|500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
214596365|NCT00756470|DRUG|Epirubicin|75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
214596366|NCT00756470|DRUG|Cyclophosphamide|500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
214596367|NCT03159923|OTHER|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
214596368|NCT05213754|PROCEDURE|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
214596369|NCT05042518|BEHAVIORAL|Experiment|breathing control and self-talk with objectives
214596370|NCT05042518|OTHER|Control|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month)
214596371|NCT04227548|DIAGNOSTIC_TEST|needle electromyography|Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
214596372|NCT03227796|DRUG|LEVI-04|LEVI-04 intravenous infusion
214596373|NCT03227796|DRUG|Placebo|Placebo intravenous infusion
214596374|NCT01642173|DEVICE|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
214596375|NCT01964807|OTHER|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
214596376|NCT01964807|OTHER|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
214596377|NCT01964807|OTHER|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
214596378|NCT01964807|OTHER|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
214596379|NCT01964807|OTHER|Moist snuff|Use moist snuff for 30 minutes
214596380|NCT01964807|OTHER|Sham Smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
214596381|NCT01964807|OTHER|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
214596382|NCT01964807|OTHER|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
214596383|NCT01964807|OTHER|Sham Moist Snuff|Chew gum for 30 minutes
214596384|NCT03678987|DIAGNOSTIC_TEST|P-MPA concentration|We will calculate AUC\_0-12 of MPA based on 4 measurements of P-MPA
214596385|NCT03678987|DRUG|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
214596386|NCT02260882|BIOLOGICAL|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
214596387|NCT00516451|DRUG|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
214596388|NCT02876666|BEHAVIORAL|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
214596389|NCT02119325|DIETARY_SUPPLEMENT|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
214596390|NCT02119325|DIETARY_SUPPLEMENT|0% fibre|Placebo is an energy matched powdered beverage
214596391|NCT05309434|BEHAVIORAL|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
214596392|NCT02274636|DIETARY_SUPPLEMENT|Xylitol|A comparison between discs and gel
214596393|NCT06140212|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
214596394|NCT06140212|BEHAVIORAL|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
214596395|NCT06140212|BEHAVIORAL|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
214596396|NCT05706012|OTHER|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
214596397|NCT04100850|OTHER|Aquatic Exercises|twice a week, lasting 50 minutes, for two months.
214596398|NCT04100850|OTHER|Watsu|twice a week, lasting 50 minutes, for two months.
214596399|NCT03423823|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
214596400|NCT03423823|DRUG|Ranibizumab|Anti-VEGF standard of care injection
214596401|NCT02091895|PROCEDURE|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
214596402|NCT00438503|PROCEDURE|Procedure|
214596403|NCT04442360|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
214596404|NCT04032769|OTHER|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~\- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
214596405|NCT03733067|DRUG|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
214596406|NCT03733067|OTHER|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
214596407|NCT00550368|BIOLOGICAL|Biological intervention: Enteropathogenic E. coli|5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
214596408|NCT00338364|BEHAVIORAL|PAT|Coping and Distraction Intervention
214596409|NCT04213027|PROCEDURE|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
214596410|NCT00562211|DRUG|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
214596411|NCT00562211|DRUG|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
214596412|NCT03392025|OTHER|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
214596413|NCT03392025|OTHER|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
214596414|NCT03392025|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
214596415|NCT00126022|DRUG|Tedisamil sesquifumarate|
214596416|NCT03082703|BEHAVIORAL|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
214596417|NCT01762722|DEVICE|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
214596418|NCT02624323|PROCEDURE|Real-time ultrasound-guided central vein catheterization.|
214596419|NCT01644344|OTHER|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
214596420|NCT01644344|OTHER|Xray|
214596421|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream low-dose|travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
214596422|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream mid-dose|travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
214596423|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream high-dose|travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
214596424|NCT06152861|DRUG|Timolol maleate ophthalmic solution, 0.5%|timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes
214596425|NCT06152861|DRUG|Travoprost Ophthalmic Solution, 0.004%|travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
214596426|NCT00260117|BEHAVIORAL|Exercise|Referal to a website
214596427|NCT04922489|PROCEDURE|Dental implant placement|Dental implant placemente on edentulous jaw.
214596428|NCT00642551|DIETARY_SUPPLEMENT|menaquinone-7|180 µg menaquinone-7 daily for three years
214596429|NCT00642551|DIETARY_SUPPLEMENT|placebo|1 placebo capsule daily for three years
214596430|NCT01938469|OTHER|Liquid Meal|
214596431|NCT01938469|OTHER|Solid Meal|
214596432|NCT00696930|DRUG|90Y-SMT487|
214596433|NCT01207661|BIOLOGICAL|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
214596434|NCT03037619|BEHAVIORAL|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
214596435|NCT03037619|BEHAVIORAL|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
214596436|NCT05176184|DIAGNOSTIC_TEST|A deep learning model for predicting a difficult laryngoscopy based on a cervical spine lateral X-ray image|"The deep learning model uses the input of preprocessed C-spine lateral X-ray images and outputs the level of difficulty of a laryngoscopy. The easy laryngoscopy is defined as a combination of the Cormack-Lehane grades 1-2 and the difficult laryngoscopy is defined as a combination of grades 3-4.~In addition, before general anesthesia, airway evaluations related to the difficulty of laryngoscopy are performed and the results are compared with the actual level of difficulty."
214596437|NCT02843971|DEVICE|Intraocular pressure measurement with the Sensimed triggerfish Device|
214596438|NCT03442049|OTHER|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
214596439|NCT03442049|OTHER|Physiotherapy - control group|Home exercise program
214596440|NCT04265560|OTHER|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
214596441|NCT00802009|DRUG|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
214596442|NCT00802009|DRUG|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
214596443|NCT02873507|OTHER|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
214596444|NCT04242160|OTHER|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
214596445|NCT04242160|OTHER|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
214596446|NCT02755623|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
214596447|NCT02755623|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
214596448|NCT04162223|BIOLOGICAL|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
214596449|NCT04162223|BIOLOGICAL|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
214596450|NCT01146626|DRUG|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
214596451|NCT01146626|DRUG|Peg+ Ribavirine|Peg+ Ribavirine
214596452|NCT03208322|OTHER|Non-Interventional|Non-Interventional
214596453|NCT03294109|DRUG|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
214596454|NCT04709822|BEHAVIORAL|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
214596455|NCT00735735|OTHER|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
214596456|NCT05997251|OTHER|Keeping a 1-day food consumption record by the patient|Checking and receiving the 1-day food consumption record recorded by the patient by the researcher
214596457|NCT05997251|OTHER|Measurement of adiponectin level|Adiponectin level will be measured for each group
214596458|NCT00759330|DRUG|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
214596459|NCT00759330|DRUG|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
214596460|NCT00759330|DRUG|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
214596461|NCT00759330|DRUG|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
214596462|NCT01794923|DRUG|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
214596463|NCT01794923|DRUG|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
214596464|NCT01794923|DRUG|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
214596465|NCT01794923|DRUG|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
214596466|NCT00090090|DRUG|Elsamitrucin|
214596467|NCT00443638|BEHAVIORAL|nurse home visitation|Nurse home visitation
214596468|NCT00245934|DRUG|Enbrel|
214596469|NCT06431009|OTHER|Treatment-as-usual|Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
214596470|NCT03212430|DRUG|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
214596471|NCT03318809|DRUG|AMG 986|tablets for oral administration
214596472|NCT04181151|OTHER|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
214596473|NCT01525719|DRUG|Everolimus|10 mg everolimus
214596474|NCT02073734|DRUG|Dexamethasone|Dexamethasone 8mg/IV
214596475|NCT02073734|DRUG|Placebo|Placebo given IV
214596476|NCT04600479|DIAGNOSTIC_TEST|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
214596477|NCT03270332|DRUG|Albuterol|inhalation of 270μg albuterol through a spacer
214596478|NCT03270332|DRUG|Placebo|inhalation of placebo through a spacer
214596479|NCT04694872|OTHER|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
214596480|NCT04694872|OTHER|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
214596481|NCT00414128|DRUG|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
214596482|NCT00414128|DRUG|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
214596483|NCT05374720|PROCEDURE|salpingectomy|Removal of one of the fallopian tubes.
214596484|NCT05374720|PROCEDURE|hysterectomy|remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.
214596485|NCT04641507|DRUG|Tadalafil versus tamsulosin as MET|166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
214596486|NCT05483400|DRUG|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
214596487|NCT03681886|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
214596488|NCT03681886|PROCEDURE|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
214596489|NCT02463188|BEHAVIORAL|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
214596490|NCT01691391|BEHAVIORAL|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
214596491|NCT02918760|DRUG|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
214596492|NCT02918760|OTHER|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
214596493|NCT02292966|DRUG|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
214596494|NCT01050907|DRUG|Miltefosine|2.5 mg/kg/day for 28 days
214596495|NCT03836755|DIAGNOSTIC_TEST|Metacos|Evaluation of stability of implant by RSA technique
214596496|NCT01317225|DRUG|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
214596497|NCT01317225|DRUG|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
214596498|NCT02030405|DRUG|Ixazomib|Given orally (PO)
214596499|NCT03508167|DEVICE|Thermal Band|Thermal Band used 8 hours per day
214596500|NCT03508167|DRUG|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
214596501|NCT03508167|DRUG|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
214596502|NCT06331780|DEVICE|Visual acuity|VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
214596503|NCT06331780|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
214596504|NCT06331780|DEVICE|Objective monocular accommodation amplitude measurement|Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance
214596505|NCT06331780|DEVICE|"Subjective monocular accommodation amplitude measurement with the Push-Up method"|"The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived."
214596506|NCT06331780|DEVICE|"Subjective monocular accommodation facility measurement with the Rock method:"|"The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc… You have to do the maximum number of rotations in one minute."
214596507|NCT06331780|OTHER|CISS Questionnaire|This questionnaire relating to the use of the near vision will be submitted
214596508|NCT06331780|OTHER|Difficulty assessment questionnaire|After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.
214596509|NCT06331780|OTHER|Subjective evaluation questionnaire|A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
214596510|NCT05817253|BEHAVIORAL|Portrait|In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
214596511|NCT05817253|BEHAVIORAL|Therapeutics Letter|The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
214596512|NCT06277336|DRUG|Placebo|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)"
214596513|NCT06277336|DRUG|Apelin Low Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 1 nmol/min (60ml per h)"
214596514|NCT06277336|DRUG|Apelin High Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 10 nmol/min (60ml per h)"
214596515|NCT06277336|DRUG|Selected Apelin Dose|"Study infusions (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours based on the best performing apelin dose (from Low Dose or High Dose) in healthy volunteers corresponding to one of the following options:~  1. at an infusion rate of 1 nmol/min (60ml per h) OR~ 2. at an infusion rate of 10 nmol/min (60ml per h)~In case both apelin dosis performed equally well in the healthy volunteers population the lower dose will be selected."
214596516|NCT02039804|DRUG|Corticosteroids|Intra-bursal injection
214596517|NCT02039804|DEVICE|Hyaluronic acid|Intra-bursal injection
214596518|NCT00986440|DRUG|CS-7017|CS-7017
214596519|NCT00986440|DRUG|Placebo|Placebo
214596520|NCT00622882|OTHER|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
214596521|NCT00301223|DRUG|Pregabalin|
214596522|NCT03968120|OTHER|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
214596523|NCT03832296|BEHAVIORAL|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
214596524|NCT03832296|BEHAVIORAL|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
214596525|NCT05706753|DRUG|Milvexian|Milvexian will be administered orally.
214596526|NCT05706753|DRUG|Midazolam|Midazolam will be administered orally.
214596527|NCT05706753|DRUG|Ethinylestradiol|Ethinylestradiol will be administered orally.
214596528|NCT05706753|DRUG|Drospirenone|Drospirenone will be administered orally.
214596529|NCT02973048|DRUG|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
214596530|NCT02973048|DRUG|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
214596531|NCT02842892|OTHER|Tissue stiffness|
214596532|NCT00368160|DRUG|Eszopiclone|eszopiclone 3 mg
214596533|NCT00368160|DRUG|Placebo|Placebo tablet
214596534|NCT06001086|DRUG|Disitamb Vedotin ,pyrotinib|Disitamb Vedotin combined with pyrotinib
214596535|NCT03787225|DRUG|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
214596536|NCT03787225|DRUG|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
214596537|NCT00867282|DRUG|Treatment A|PF-00241939 750ug using inhaler A
214596538|NCT00867282|DRUG|Treatment B|PF-00241939 750ug using inhaler B
214596539|NCT00504010|DRUG|Arnica Montana|Applied to lower extremity once a day for 3 days
214596540|NCT00504010|DRUG|placebo cream|placebo cream applied to leg daily for 3 days
214596541|NCT02340091|DEVICE|HA IDF plus|
214596542|NCT02340091|DEVICE|HA IDF|
214596543|NCT04025463|BEHAVIORAL|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
214596544|NCT02638935|DEVICE|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
214596545|NCT02902627|DEVICE|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
214596546|NCT02311946|DRUG|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
214596547|NCT02311946|DRUG|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
214596548|NCT01244451|DRUG|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
214596549|NCT01244451|DRUG|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
214596550|NCT03328533|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
214596551|NCT03328533|DRUG|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
214596552|NCT03328533|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
214596553|NCT04483986|PROCEDURE|Rectus muscle re-approximation|Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
214596554|NCT02460666|BEHAVIORAL|Tai-Chi-Chih (TCC)|
214596555|NCT02460666|BEHAVIORAL|Health Education and Wellness Classes (HEW)|
214596556|NCT04673565|BEHAVIORAL|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
214596557|NCT02901366|DRUG|14C-FYU-981|14C-FYU-981, (Oral single dosing)
214596558|NCT00373750|PROCEDURE|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
214596559|NCT04168684|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
214596560|NCT04168684|BEHAVIORAL|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
214596561|NCT01258335|DIETARY_SUPPLEMENT|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
214596562|NCT01258335|OTHER|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
214596563|NCT02880202|OTHER|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
214596564|NCT05939466|DRUG|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
214596565|NCT04523766|BEHAVIORAL|Mindfulness of Breath|The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
214596566|NCT04523766|BEHAVIORAL|Mindful Interoceptive Mapping|The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
214596567|NCT01849484|RADIATION|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
214596568|NCT01849484|RADIATION|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
214596569|NCT04021251|DEVICE|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
214596570|NCT01936142|DEVICE|Use of RenalGuard|
214596571|NCT03099200|OTHER|No Intervention|
214596572|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
214596573|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
214596574|NCT01220232|DRUG|Lersivirine|Lersivirine 750 mg QD for 10 days
214596575|NCT04888325|OTHER|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
214596576|NCT04888325|OTHER|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
214711082|NCT07091396|DEVICE|Soterix® tDCS - Home treatment|"Participants will receive transcranial direct current stimulation (tDCS) via the Soterix device at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current.~Each participant will be asked to perform tDCS on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions). The research team will decide on a number of therapy sessions depending on the patient's baseline condition and tolerance. Patients who receive 10 sessions of therapy over two weeks will have 4 weeks of washout. Patients who receive 12 sessions over four weeks will have 8 weeks of washout."
214596577|NCT00227890|BEHAVIORAL|MI/CBT|
214596578|NCT00227890|BEHAVIORAL|RT/TU|
214596579|NCT02957721|OTHER|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
214596580|NCT02484339|DRUG|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
214596581|NCT02484339|OTHER|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy
214596582|NCT03782142|DRUG|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
214596583|NCT03782142|DRUG|Rilpivirine|NNRTI
214596584|NCT03782142|DRUG|Prezcobix|PI
214596585|NCT03782142|DRUG|Dolutegravir|II
214596586|NCT03431857|DEVICE|TESS V2|Patients requiring the TESS V2 prosthesis.
214596587|NCT06227663|BEHAVIORAL|KOALOU(®) digital application|Digital app that prepares children for the ambulatory surgery care pathway by assessing their anxiety and educating them about anesthesia and surgery
214596588|NCT03099005|DRUG|Cannabis|vaporization of cannabis
214596589|NCT05292820|OTHER|Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure|Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
214596590|NCT05809817|PROCEDURE|Periodontal treatment|Scaling and root planing
214596591|NCT01088100|GENETIC|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
214596592|NCT04195958|DRUG|Omalizumab|Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
214596593|NCT01323621|DRUG|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
214596594|NCT01323621|DRUG|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
214596595|NCT01323621|DRUG|Double-dummy placebo|inhalation powder
214596596|NCT01323621|DRUG|Salbutamol as needed|inhalation powder
214596597|NCT03732508|DRUG|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
214596598|NCT03732508|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
214596599|NCT03732508|DRUG|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
214596600|NCT00818181|DRUG|Biological: AL0206st|
214596601|NCT06419751|BEHAVIORAL|Regular exercise|Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1\~2 muscle groups each time, 4\~5 movements, repeat each action 8\~12 times, repeat 2\~3 sets)
214596602|NCT06419751|BEHAVIORAL|Baduanjin|A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
214596603|NCT05121363|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
214596604|NCT05121363|DRUG|Anlotinib Hydrochloride capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
214596605|NCT00651157|BIOLOGICAL|wild-type reovirus|Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
214596606|NCT01208090|DRUG|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
214596607|NCT01208090|DRUG|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
214596608|NCT00666809|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
214596609|NCT00666809|DRUG|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
214596610|NCT02648750|BEHAVIORAL|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
214596611|NCT05440266|DIAGNOSTIC_TEST|Study Intervention: 25 ms half-sine wave stimulation|Part I: Threshold detection and Flare response: 6 pulses of 25 ms half-sine are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 25 ms half-sine is administered continuously.
214711083|NCT07091396|BEHAVIORAL|Cognitive-linguistic therapy|Participants will be instructed to perform home activity based cognitive-linguistic task-based exercises. Each participant will be asked to perform tDCS concurrently with individualized activity based cognitive-linguistic therapy on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions)
214596612|NCT05440266|DIAGNOSTIC_TEST|Control Intervention: 500 µs rectangular shaped stimulation|Part I: Threshold detection and Flare response: 6 pulses of 500 µs rectangular shaped stimulation are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 500 µs rectangular shaped stimulation is administered continuously.
214596613|NCT03501186|OTHER|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
214596614|NCT01721603|DRUG|Dabrafenib|150 mg capsule by mouth twice daily
214596615|NCT01721603|PROCEDURE|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
214596616|NCT01721603|DRUG|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
214596617|NCT00290108|DRUG|Propofol|
214596618|NCT04657757|OTHER|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
214596619|NCT02472080|DRUG|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
214596620|NCT00593801|DRUG|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
214596621|NCT00593801|DRUG|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
214596622|NCT04508634|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
214596623|NCT04508634|DRUG|Metformin Pill|Metformin 1000mg bid
214596624|NCT01104142|DEVICE|CGM|Continuous Glucose Monitoring System
214596625|NCT04441112|DRUG|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
214596626|NCT04441112|DRUG|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
214596627|NCT02884765|PROCEDURE|Non-surgical|Non-surgical treatment in both condylar fractures
214596628|NCT02884765|PROCEDURE|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
214596629|NCT02884765|PROCEDURE|Surgical|Surgical treatment in both condylar fractures
214596630|NCT02779738|DRUG|Merestinib|Administered orally
214596631|NCT02422485|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
214711084|NCT07091396|DEVICE|Soterix® tDCS - Lab treatment|Participants will receive transcranial direct current stimulation (tDCS) in person, via the same Soterix device the home based participants will use at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current. They will undergo 12 sessions over four weeks.
214596632|NCT03975023|DEVICE|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
214596633|NCT00413296|DRUG|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
214596634|NCT00413296|DRUG|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
214596635|NCT00413296|DRUG|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
214596636|NCT02216487|DRUG|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
214596637|NCT02506478|OTHER|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
214711085|NCT07090694|PROCEDURE|Graftless Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention involves a minimally invasive internal (crestal) sinus lift performed without the use of any grafting material. The sinus membrane is elevated using sequential osteotomy drills, and a dental implant is immediately placed into the prepared site. The implant fixture acts as a tent pole, maintaining the lifted membrane and allowing for spontaneous bone regeneration through blood clot formation alone. This graftless method eliminates the need for additional biomaterials and is intended for patients with residual alveolar bone height of 5-7 mm
214596638|NCT01885325|OTHER|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
214596639|NCT05871866|PROCEDURE|"minimally invasive internal fixation device infix"|An INFIX involves the insertion of spinal pedicle screws in the anterior pelvis (supra-acetabular entry) and the placement of a connecting rod in the subcutaneous tissue of the patient
214596640|NCT00364156|DRUG|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
214596641|NCT00364156|DRUG|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
214596642|NCT01472380|DRUG|efavirenz|600 mg
214596643|NCT01472380|DRUG|fenofibric acid 105 mg|fenofibric acid 105 mg
214596644|NCT06312280|BEHAVIORAL|Mediterranean diet|The composition of the diet will be distributed as follows: 55-60% of carbohydrates (45-50% complex carbohydrates and no more than 10% of simple sugars), 25-30% of lipids and 15% of proteins. It will be studied in accordance with the LARN (Italian Society of Human Nutrition, 2014) guidelines.
214596645|NCT00292461|DRUG|Zonisamide|Tablet once or twice daily orally for 16 weeks
214596646|NCT00292461|DRUG|Lamotrigine|Tablet once daily orally for 16 weeks
214596647|NCT02496910|DRUG|YH22162|
214596648|NCT02496910|DRUG|Telmisartan/Amlodipine 80/5 mg (FDC)|
214596649|NCT02496910|DRUG|Chlorthalidone 25mg|
214596650|NCT06071910|DEVICE|ER-REBOA catheter|To achieve rapid aortic occlusion
214596651|NCT00420602|DIETARY_SUPPLEMENT|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
214596652|NCT00680823|DRUG|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
214596653|NCT00680823|DRUG|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
214596654|NCT05484050|OTHER|Immunohistochemistry analysis|Estimation of VEGF through Immunohistochemistry
214596655|NCT00892619|PROCEDURE|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
214596656|NCT00892619|PROCEDURE|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
214596657|NCT04894162|OTHER|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
214596658|NCT06502106|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
214596659|NCT03536390|DRUG|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
214596660|NCT03536390|DRUG|Placebo|Placebo
214596661|NCT01891721|BEHAVIORAL|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
214596662|NCT01891721|BEHAVIORAL|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
214596663|NCT01891721|BEHAVIORAL|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
214596664|NCT02075411|DRUG|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
214596665|NCT02075411|DRUG|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
214596666|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
214596667|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
214596668|NCT04850157|DRUG|Tislelizumab|200mg, Q3W
214596669|NCT04850157|RADIATION|IMRT|4 Gy\* 5 Fx,5Fx/Week
214596670|NCT05638750|OTHER|Rehabilitation Intervention|12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
214596671|NCT04687761|DRUG|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle
214596672|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
214596673|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
214596674|NCT04687761|DRUG|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
214596675|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
214596676|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
214596677|NCT06262854|DEVICE|Calcium-sulphate granules with tobramicina+vancomicina|Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
214596678|NCT05488236|OTHER|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
214596679|NCT00979251|DRUG|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
214596680|NCT00979251|DRUG|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
214596681|NCT02208297|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
214596682|NCT02208297|DRUG|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
214596683|NCT00902954|DRUG|anastrozole|anastrozole 1 mg qd
214596684|NCT00902954|DRUG|letrozole|letrozole 2.5 mg qd
214596685|NCT00902954|DRUG|exemestane|exemestane 25 mg qd
214596686|NCT04160351|DEVICE|Theranova 400|medium cut-off dialyser
214596687|NCT04160351|DEVICE|Elisio-19H|high flux dialyser
214596688|NCT03430219|DEVICE|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
214596689|NCT05912803|DEVICE|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed."
214596690|NCT05912803|OTHER|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
214596691|NCT00347165|DRUG|bevacizumab intravitreal injection|
214596692|NCT05409287|PROCEDURE|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
214596693|NCT05409287|PROCEDURE|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
214596694|NCT05629962|DRUG|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
214596695|NCT05629962|DRUG|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
214596696|NCT01320982|DRUG|minocycline|minocycline 100 mg/bid
214596697|NCT01320982|DRUG|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
214596698|NCT01320982|DRUG|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
214596699|NCT01320982|DRUG|placebo|placebo bid
214596700|NCT05241782|OTHER|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks"
214596701|NCT03156751|DIAGNOSTIC_TEST|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
214596702|NCT06087679|BEHAVIORAL|PPS guided selfcare based intervention program|Guided selfcare programme (Please refer to project description)
214596703|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
214596704|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
214596705|NCT05953064|OTHER|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
214596706|NCT05953064|OTHER|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
214596707|NCT04887324|OTHER|no intervention|no intervention
214596708|NCT04385108|BIOLOGICAL|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
214596709|NCT04385108|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
214596710|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
214596711|NCT05457582|DRUG|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
214596712|NCT05457582|DRUG|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
214596713|NCT06472908|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
214596714|NCT06472908|DRUG|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
214596715|NCT06472908|DRUG|Placebo|Placebo, one pill a day, oral intake
214596716|NCT05640648|BEHAVIORAL|User-Centered Implementation Strategy|"1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
214596717|NCT05640648|BEHAVIORAL|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
214596718|NCT06779591|OTHER|CareAide® Medication Adherence Mobile Application|CareAide® app is one of the mobile apps in assisting and improving patients' adherence to medications. It is an unique health-tech and insure-tech company with expertise in behavioural science, chronic condition management and technology. The app aims to help patients with chronic conditions live a better everyday life and empower their families and the ecosystem around the patients to drive better outcomes. They have the clinically validated approach to improving adherence. Using behavioural science and smart tech, they improve the day-to-day life of patients, and importantly, empower both patients and health care providers with the digital tools and near real-time insights to proactively manage risks, intervene early to avoid patient emergencies and to help to provide a better customer satisfaction.
214596719|NCT05828927|BEHAVIORAL|Eco-mapping tool|The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
214596720|NCT05828927|BEHAVIORAL|Caregiver-coach study visits|Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
214596721|NCT04124341|DEVICE|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
214596722|NCT06445608|DEVICE|Percutaneous Mechanical Circulatory Support|Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
214596723|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
214596724|NCT04908189|DRUG|Deucravacitinib|Specified dose on specified days
214596725|NCT04908189|OTHER|Placebo|Specified dose on specified days
214596726|NCT04908189|DRUG|Apremilast|Specified dose on specified days
214596727|NCT05207917|PROCEDURE|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
214711086|NCT07090694|BIOLOGICAL|Platelet-Rich Fibrin (PRF)-Assisted Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention utilizes autologous platelet-rich fibrin (PRF) as the sole grafting material during transcrestal sinus floor elevation. PRF is prepared from the patient's own venous blood using centrifugation and inserted into the osteotomy site after sinus membrane elevation. A dental implant is placed simultaneously to support the sinus membrane and stabilize the graft. The biologically active PRF matrix provides a scaffold rich in growth factors (e.g., TGF-β, PDGF, VEGF), promoting accelerated healing and enhanced bone formation beneath the elevated sinus floor. This technique is performed in a single-stage procedure, eliminating the need for synthetic or allogeneic grafts.
214711087|NCT07089940|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214711088|NCT07089940|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214596728|NCT05207917|PROCEDURE|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
214596729|NCT05207917|PROCEDURE|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
214596730|NCT06107153|DRUG|Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
214596731|NCT06107153|DRUG|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
214596732|NCT06107153|DRUG|Pioglitazone 30mg|Pioglitazone 30mg
214711089|NCT07089940|PROCEDURE|Computed Tomography|Undergo CT
214711090|NCT07089940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214711091|NCT07089940|DRUG|Myc Inhibitor OMO-103|Given IV
214711092|NCT07090889|DRUG|KM-023|solution for oral administration
214711093|NCT07090889|DRUG|Placebo|solution for oral administration
214596733|NCT05666050|BEHAVIORAL|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
214596734|NCT02366819|DRUG|Oxaliplatin|Given IV
214596735|NCT02366819|DRUG|Leucovorin Calcium|Given IV
214596736|NCT02366819|DRUG|Irinotecan Hydrochloride|Given IV
214596737|NCT02366819|DRUG|Fluorouracil|Given IV
214596738|NCT02366819|PROCEDURE|Conventional Surgery|Undergo surgery
214596739|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
214596740|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
214596741|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
214596742|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
214596743|NCT06105723|BEHAVIORAL|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
214711094|NCT07092189|OTHER|Pre-colposcopy counseling by a clinical nurse|"In the intervention group, the clinical nurse conducted a structured pre-colposcopy counseling session covering the following topics: verification of the patient's understanding of the reason for the colposcopy referral, explanation of the cervical cytology result, the procedure of the colposcopy, expectations regarding pain, the role of HPV in the development of precancerous and cancerous cervical lesions, counseling on HPV vaccination, and smoking cessation."
214711095|NCT07092189|OTHER|Treatment as usual: regular call to schedule the appointment without pre-procedure conseilling|In the control group, patients simply received a phone call to notify them of their appointment and, upon arrival, were given an information sheet about colposcopy. No pre-colposcopy discussion was conducted.
214711096|NCT07090967|OTHER|Project Planning Course|The Project Planning Course is conducted as a two-hour theoretical class per week. This course is being introduced for the first time in the nursing faculty curriculum. The course was conducted by two faculty members, both of whom have knowledge and experience in research and project writing. Since the goal at the end of the course was for students either to carry out a research project or to apply for a patent/utility model, it was planned for 20 students to enroll; however, 19 students chose the course. The course lasted 14 weeks in total. In the first week, topics such as what a project is, its characteristics, and its components were introduced to the students. As part of the course, students were asked to brainstorm solutions for problems they encountered in clinical settings. During the first seven weeks, theoretical lectures were delivered, and during the following five weeks, students worked with their academic advisors on research projects or patent/utility model topics.
214596744|NCT06458205|COMBINATION_PRODUCT|Multi-component intervention for smokers|"1. Community-based spirometry pulmonary function tests and result interpretations and health education;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for smokers whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to smokers with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients or asthma patients;~7. To actively include smokers whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than11.1mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \<18.5;~9. Pay-for-population mechanism for medical practitioners."
214596745|NCT04494360|OTHER|No intervention|No investigational medicinal product will be administered as a part of this study.
214596746|NCT05236231|DRUG|Macitentan 10 mg|Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
214596747|NCT05236231|DRUG|Tadalafil 20 mg|Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
214596748|NCT05236231|DRUG|Macitentan 10 mg/Tadalafil 20mg FDC|FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
214596749|NCT06111807|DIAGNOSTIC_TEST|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
214596750|NCT05596799|BEHAVIORAL|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
214596751|NCT05834816|BEHAVIORAL|Negative Affect Task|fMRI stress task
214596752|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
214596753|NCT06443203|OTHER|Trimodal prehabilitation|Trimodal prehabilitation program (4-week physical exercise before surgery, nutritional optimization, and psychological support) in patients undergoing ERAS colorectal resection for cancer
214596754|NCT03685175|DRUG|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
214596755|NCT03685175|DRUG|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
214596756|NCT05492396|DEVICE|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
214596757|NCT06538597|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
214596758|NCT02857998|DRUG|HMPL-523|Oral administration, once daily
214596759|NCT05055414|DRUG|UI030|Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
214596760|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
214596761|NCT05656560|OTHER|Clinician education|Brief, online education module for primary care clinicians
214596762|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
214596763|NCT02932007|DRUG|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
214596764|NCT06528067|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
214596765|NCT06528067|BEHAVIORAL|Mindful Motivation|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
214596766|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
214596767|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
214596768|NCT05714995|OTHER|hypnosis|"The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
214596769|NCT05714995|OTHER|Hypnosis with aromatherapy|"for patients in the hypnosis with aromatherapy group, before starting the hypnosis session, they will first choose an essential oil among the 5 proposed.~They will pour a drop on their wrist then they will rub it and inhale deeply.~The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
214596770|NCT06161402|BEHAVIORAL|Elastic band-based progressive resistance training (EB-PRT)|EB-PRT will be implemented during week 1-14. The EB-PRT comprises a 4-week training phase, 6-week consolidation phase and a 4-week maintenance phase.
214596771|NCT05274152|DEVICE|Immersive Virtual Reality Lower Limb and Knee Rehabilitation|Patients wore a VR headset while undergoing their rehabilitation session
214596772|NCT05455138|PROCEDURE|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
214596773|NCT06248346|DRUG|Dexmedetomidine|whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
214596774|NCT06477822|PROCEDURE|Sequence of manual therapy techniques|Receive a sequence of manual therapy techniques composed by: suboccipital decompression technique, suboccipital release technique, fourth ventricle compression technique, vagus nerve neurodynamic technique
214596775|NCT06477822|PROCEDURE|Simulated manual therapy techniques|Receive a sequence of simulated manual therapy techniques composed by four maneuvers without effect on autonomic nervous system
214596776|NCT01262703|DEVICE|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
214596777|NCT04568720|DIAGNOSTIC_TEST|blood sample|Isolated the blood sample and detected the CTC
214596778|NCT00076362|DRUG|Sandostatin LAR|
214596779|NCT05898464|BIOLOGICAL|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
214596780|NCT05309265|OTHER|Multidisciplinary vocational rehabilitation intervention|"* Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
214596781|NCT02958267|BIOLOGICAL|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
214596782|NCT02958267|BIOLOGICAL|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
214596783|NCT02958267|DEVICE|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution \[10 mg/mL\], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
214596784|NCT01210118|BEHAVIORAL|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
214596785|NCT01210118|BEHAVIORAL|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
214596786|NCT01928498|DEVICE|Paclitaxel Eluting Balloon Angioplasty|
214596787|NCT01928498|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|
214596788|NCT01853982|DRUG|Ceftolozane/Tazobactam|
214596789|NCT01853982|DRUG|Piperacillin/Tazobactam|
214596790|NCT06245720|OTHER||
214596791|NCT01839487|DRUG|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
214596792|NCT01839487|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
214596793|NCT01839487|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
214596794|NCT01839487|DRUG|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
214596795|NCT01839487|DRUG|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
214596796|NCT03457454|OTHER|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
214596797|NCT03457454|OTHER|Patient Participant Interview|-Approximately 45-60 minute interview
214596798|NCT03457454|OTHER|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
214596799|NCT03457454|OTHER|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
214596800|NCT05066724|DRUG|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
214596801|NCT00436033|DRUG|milnacipran|
214596802|NCT00436033|DRUG|Placebo|
214596803|NCT06108804|OTHER|mulligan pain release phenomenon with tapping|Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks
214596804|NCT06108804|OTHER|mulligan pain release phenomenon|Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
214596805|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
214596806|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
214596807|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
214596808|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
214596809|NCT01108107|BIOLOGICAL|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
214596810|NCT01211743|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
214596811|NCT01211743|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
214596812|NCT04470167|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
214596813|NCT04470167|OTHER|Placebo|Ultrasound-guided intratendinous placebo injection
214596814|NCT00475033|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
214596815|NCT00475033|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
214596817|NCT05923957|OTHER|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
214596818|NCT02069353|DEVICE|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
214596819|NCT02069353|DEVICE|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
214596820|NCT00000730|DRUG|Trimetrexate glucuronate|
214596821|NCT00000730|DRUG|Methylprednisolone|
214596822|NCT00000730|DRUG|Pentamidine isethionate|
214596823|NCT00000730|DRUG|Sulfamethoxazole-Trimethoprim|
214596824|NCT00000730|DRUG|Leucovorin calcium|
214596825|NCT04724226|DRUG|Camrelizumab; Apatinib|"Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD"
214596826|NCT05466539|DRUG|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
214596827|NCT05466539|DRUG|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
214596828|NCT04891432|PROCEDURE|Lateral lumbar interbody fusion|oblique lumbar interbody fusion or direct lateral interbody fusion
214596829|NCT00713115|PROCEDURE|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
214596830|NCT00675805|DEVICE|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
214596831|NCT00675805|DEVICE|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
214596832|NCT02858869|BIOLOGICAL|Pembrolizumab|Given IV
214596833|NCT02858869|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214596834|NCT03584113|OTHER|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
214596835|NCT03584113|OTHER|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase \[5mg\] and alteplase \[10mg\] Q12hours).
214596836|NCT04239716|OTHER|regional anesthesia|combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
214596837|NCT04628468|DEVICE|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
214596838|NCT04628468|OTHER|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
214596839|NCT04081454|BEHAVIORAL|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
214596840|NCT04081454|BEHAVIORAL|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
214596841|NCT00846651|OTHER|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
214596842|NCT00846651|OTHER|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
214596843|NCT00846651|DRUG|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
214596844|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
214596845|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
214596846|NCT00181584|DRUG|Zoledronic acid|Given intravenously once.
214596847|NCT00181584|OTHER|Placebo|Given intravenously once.
214596848|NCT02261038|OTHER|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
214596849|NCT00315081|DRUG|Bromocriptin|
214596850|NCT02069925|BEHAVIORAL|Early Detection (ED)|This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
214596851|NCT02069925|BEHAVIORAL|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
214596852|NCT06383156|DEVICE|Double lumen endotracheal tube|correct position of LDLT during single lung ventilation
214596853|NCT03670706|BEHAVIORAL|Exercise|Package of care
214596854|NCT03670706|OTHER|analgesic optimisation|optimisation
214596855|NCT02423304|GENETIC|blood samples collected from all patients|blood samples collected from brachial pluxes
214596856|NCT02125305|DRUG|Metformin|
214596857|NCT05774444|DIETARY_SUPPLEMENT|Krill oil|Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
214596858|NCT05774444|DIETARY_SUPPLEMENT|Krill protein|Krill protein will be given to the participant following a resistance exercise bout.
214596859|NCT05774444|DIETARY_SUPPLEMENT|Vegetable oil|This will be the control against the Krill oil
214596860|NCT05774444|DIETARY_SUPPLEMENT|Carbohydrate|This will be the control for the Krill protein
214596861|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
214596862|NCT05728515|DRUG|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
214596863|NCT05187052|OTHER|Tracheal intubation|Video-assisted intubation technique
214596864|NCT06450249|BEHAVIORAL|Humanitude® Care Methodology (HCM) training sessions|During a five-day training session healthcare professionals are trained to the HCM within their own care unit
214596865|NCT06450249|BEHAVIORAL|Self-administered questionnaire|The self-administered questionnaire will be completed before and after participation in Humanitude® Care Methodology training sessions
214596866|NCT03803501|OTHER|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
214596867|NCT00421473|DRUG|Atovaquone / Proguanil|
214596868|NCT00281021|DRUG|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
214596869|NCT03549000|OTHER|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
214596870|NCT03549000|OTHER|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
214596871|NCT03549000|DRUG|NIR178|NIR178 Specified dose on specified days, Orally
214596872|NCT06095713|DRUG|Pegunigalsidase-alfa|Standard of care
214596873|NCT03594344|PROCEDURE|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
214596874|NCT04189757|DRUG|Acalabrutinib|Given PO
214596875|NCT04356183|OTHER|SWET: Supervised Weight loss and Exercise Training|Weight loss will occur via a dietitian-led intervention targeting weight loss over 16 weeks, with weekly weigh-ins and group support sessions. Exercise training will consist of three times per week of an interval-based aerobic program plus twice-weekly resistance training. Both weight loss and exercise training will be supervised to maximize safety and adherence.
214596876|NCT04356183|OTHER|CHAT: Counseling Health As Treatment|Control Arm over 16 weeks.
214596877|NCT06490432|DEVICE|Transient elastography|Device that measures stiffness of liver tissue
214596878|NCT05679011|OTHER|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
214596879|NCT03289897|DIAGNOSTIC_TEST|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
214596880|NCT03681197|DRUG|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
214596881|NCT03681197|DRUG|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
214596882|NCT03681197|DRUG|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
214596883|NCT01410136|PROCEDURE|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
214596884|NCT03245970|DRUG|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
214596885|NCT03245970|DRUG|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
214596886|NCT03245970|DRUG|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
214596887|NCT02259998|DRUG|Persantin® new formulation|
214596888|NCT02259998|DRUG|Persantin® commercial formulation|
214596889|NCT00320333|PROCEDURE|pulmonary rehabilitation programme|
214596890|NCT00249353|DRUG|methylphenidate hydrochloride|
214596891|NCT05933408|DIAGNOSTIC_TEST|TREM-1|The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
214596892|NCT01570036|DRUG|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
214596893|NCT01570036|DRUG|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
214596894|NCT01570036|DRUG|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
214596895|NCT03546933|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
214596896|NCT00802425|DRUG|AM-111|single intratympanic injection
214596897|NCT00802425|DRUG|placebo|single intratympanic injection
214596898|NCT01690611|PROCEDURE|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
214596899|NCT01690611|OTHER|Visual Feedback|Real time feedback regarding body motion while walking.
214596900|NCT03962452|GENETIC|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
214596901|NCT02170389|OTHER|Laboratory Biomarker Analysis|Correlative studies
214596902|NCT02170389|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
214596903|NCT02170389|BIOLOGICAL|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
214596904|NCT00190632|DRUG|Duloxetine|
214596905|NCT00171574|DRUG|Valsartan|
214596906|NCT00171574|DRUG|Valsartan plus HCTZ|
214596907|NCT00171574|DRUG|Lisinopril|
214596908|NCT04107350|DEVICE|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
214596909|NCT04372407|DRUG|Surufatinib|Surufatinib: 200 mg as single dose on Days 1 and 9
214596910|NCT04372407|DRUG|Itraconazole|Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
214596911|NCT04242511|DIAGNOSTIC_TEST|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
214596912|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
214596913|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
214596914|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
214596915|NCT03149471|DIAGNOSTIC_TEST|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
214596916|NCT05009745|PROCEDURE|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
214596917|NCT06062225|PROCEDURE|Kamikawa|Kamikawa reconstruction after proximal gastrectomy
214596918|NCT06062225|PROCEDURE|STJI|Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy
214596919|NCT06062225|PROCEDURE|SOFY|SOFY reconstruction after proximal gastrectomy
214596920|NCT02679742|DIETARY_SUPPLEMENT|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
214596921|NCT02679742|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
214596922|NCT01409863|PROCEDURE|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
214596923|NCT03318705|DEVICE|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
214596924|NCT00667355|BIOLOGICAL|adalimumab|40 mg or 80 mg every other week, subcutaneous
214596925|NCT02141542|DRUG|Tremelimumab|
214596926|NCT02141542|DRUG|MEDI3617|
214596927|NCT01859078|DRUG|Baricitinib|Administered orally
214596928|NCT01859078|DRUG|Digoxin|Administered orally
214596929|NCT04212988|PROCEDURE|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
214596930|NCT04226807|OTHER|Early Postpartum Phone Call|Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
214596931|NCT01159379|DRUG|ertapenem|intravenous, 1 gram, once
214596932|NCT00003941|BIOLOGICAL|bleomycin sulfate|
214596933|NCT00003941|BIOLOGICAL|filgrastim|
214596934|NCT00003941|DRUG|cisplatin|
214596935|NCT00003941|DRUG|etoposide|
214596936|NCT00003941|DRUG|ifosfamide|
214596937|NCT00003941|PROCEDURE|bone marrow ablation with stem cell support|
214596938|NCT00003941|PROCEDURE|peripheral blood stem cell transplantation|
214596939|NCT00506428|BEHAVIORAL|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
214596940|NCT01475552|DRUG|Abciximab|Patients, who showed PRU \>270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
214596941|NCT01475552|DRUG|control|"Patients,who showed PRU \>270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
214596942|NCT01649570|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
214596943|NCT00912652|BEHAVIORAL|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
214596944|NCT00912652|BEHAVIORAL|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
214596945|NCT02610153|DRUG|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
214596946|NCT00016029|OTHER|screening questionnaire administration|
214596947|NCT00016029|PROCEDURE|barium enema injection|
214596948|NCT00016029|PROCEDURE|computed tomography|
214596949|NCT00016029|PROCEDURE|computed tomography colonography|
214596950|NCT00016029|PROCEDURE|diagnostic colonoscopy|
214596951|NCT00016029|PROCEDURE|screening colonoscopy|
214596952|NCT00227188|DRUG|Pneumococcal 7-valent conjugate vaccine Prevnar|
214596953|NCT00285883|DRUG|Invirase|
214596954|NCT00285883|DRUG|Norvir|
214596955|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
214596956|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
214596957|NCT03163979|BIOLOGICAL|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
214596958|NCT03163979|BIOLOGICAL|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
214596959|NCT04874181|DEVICE|Silverfit 3D|Virtual reality game used for rehabilitation of stroke patients
214596960|NCT02281279|BIOLOGICAL|rituximab|Given IV
214596961|NCT02281279|DRUG|lenalidomide|Given PO
214596962|NCT02281279|DRUG|romidepsin|Given IV
214596963|NCT02281279|OTHER|laboratory biomarker analysis|Correlative studies
214596964|NCT04879641|BEHAVIORAL|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
214596965|NCT04879641|BEHAVIORAL|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
214596966|NCT04879641|BEHAVIORAL|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
214596967|NCT04879641|BEHAVIORAL|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
214596968|NCT03549533|OTHER|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
214596969|NCT00004051|DRUG|irinotecan hydrochloride|
214596970|NCT05020431|OTHER|Biological measuring of collagen fragments biomarker during orthodontic tooth movement|Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
214596971|NCT04577196|OTHER|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
214596972|NCT02075268|DRUG|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
214596973|NCT04500431|BIOLOGICAL|Targeting CD269 chimeric antigen receptor engineered T cells|Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
214596974|NCT01244776|DEVICE|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
214596975|NCT06088212|OTHER|Disease management program|"The components of our DMP include:~1. Intensive post-discharge education~2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~4. Exercise program delivered by an exercise physiologist~5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly."
214596976|NCT04455438|RADIATION|SBRT dose escalation|Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
214596977|NCT03558594|BEHAVIORAL|Hypnosis|Behavioral Condition
214596978|NCT03558594|BEHAVIORAL|Mindfulness|Behavioral Condition
214596979|NCT05059834|BEHAVIORAL|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
214596980|NCT05059834|BEHAVIORAL|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
214596981|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
214596982|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
214596983|NCT04388241|BEHAVIORAL|The Balance Program|The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
214596984|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
214596985|NCT01270945|PROCEDURE|Standard of Care|
214596986|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
214596987|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
214596988|NCT03265041|DIAGNOSTIC_TEST|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
214596989|NCT00122694|DRUG|carbon monoxide|
214596990|NCT02960854|BIOLOGICAL|Nivolumab|Specified dose on specified days
214596991|NCT03138720|DRUG|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
214596992|NCT05793918|OTHER|Therapeutic Percutaneous Electrolysis an neuromodulation|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
214596993|NCT05793918|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
214596994|NCT00701870|DRUG|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
214596995|NCT00212628|DRUG|Minodronic acid hydrate|
214596996|NCT06611241|BEHAVIORAL|Hazard Anticipation Program for Parents of Teen Drivers|Parents and teens who receive the intervention will complete a web-based training that provides parents with guidance on how to teach their teen to identify potential hazards on the roadway. The program begins by providing background on teens' difficulty learning this skill and the motivational interviewing techniques that are being used in the course. Parents then engage with a series of hazard videos. For each hazard, parents watch the hazard unfold, provide an example of what they might say to their teen in that, and are provided with examples of how to coach their teen through the hazard before it becomes a critical event. Parents and teens then jointly watch 12 videos depicting hazards unfolding on the roadway. Teens are asked to identify the hazard without parental input by pressing a spacebar. Teens must also indicate what they believe was the key event that caused the hazard. Then parents and teens are given an opportunity to replay the video and discuss the hazard together.
214596997|NCT03257020|DIAGNOSTIC_TEST|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
214596998|NCT04367987|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
214596999|NCT05363696|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting surgery procedure
214597000|NCT05363696|PROCEDURE|Heart valve surgery|Heart valve surgery procedure
214597001|NCT03188926|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
214597002|NCT00823901|DRUG|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
214597003|NCT00823901|DRUG|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
214597004|NCT04828694|DRUG|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
214597005|NCT04828694|DRUG|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
214597006|NCT00226850|BEHAVIORAL|hypnosis|
214597007|NCT01369511|DRUG|LY2495655|Administered subcutaneously
214597008|NCT01369511|DRUG|Placebo|Administered subcutaneously
214597009|NCT01247571|DRUG|Pazopanib Hydrochloride|Given PO
214597010|NCT04208776|DRUG|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
214597011|NCT04208776|DRUG|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
214597012|NCT02852161|DEVICE|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
214597013|NCT02809573|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
214597014|NCT02809573|DRUG|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
214597015|NCT02809573|DRUG|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.
214597016|NCT02809573|DRUG|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.
214597017|NCT02809573|DRUG|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
214597018|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
214597019|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
214597020|NCT05181865|DRUG|1 mg/kg IV FL-301|N = 1
214597021|NCT05181865|DRUG|3 mg/kg IV FL-301|N = 3-6
214597022|NCT05181865|DRUG|10 mg/kg IV FL-301|N = 3-6
214597023|NCT05181865|DRUG|20 mg/kg IV FL-301|N = 3-6
214597024|NCT05181865|DRUG|30 mg/kg IV FL-301|N = 3-6
214597025|NCT05181865|DRUG|RP2D, IV FL-301|Pancreatic Cancer N = 30
214597026|NCT05181865|DRUG|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
214597027|NCT05181865|DRUG|RP2D, IV FL-301|Other Solid Tumors N = 30
214597028|NCT01376349|DRUG|prasterone|Applied vaginally
214597029|NCT01376349|OTHER|placebo|Applied vaginally
214597030|NCT01363167|DIETARY_SUPPLEMENT|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
214597031|NCT05784987|DRUG|Rituximab|375 mg/m2, d0, Cycle 1\~4
214597032|NCT05784987|DRUG|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1\~4
214597033|NCT05784987|DRUG|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1\~4
214597034|NCT05784987|DRUG|Etoposide|65 mg/m2, d1-3, Cycle 1\~4
214597035|NCT05784987|DRUG|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2\~4
214597036|NCT05784987|DRUG|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4
214597037|NCT05784987|DRUG|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2\~4
214597038|NCT05784987|DRUG|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2\~4
214597039|NCT01180998|DEVICE|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
214597040|NCT01180998|DEVICE|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
214597041|NCT06206369|OTHER|No intervention, retrospective study|No intervention, retrospective study
214597042|NCT04780750|DRUG|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
214597043|NCT02442713|DRUG|fluvoxamine|fluvoxamine: 50-300mg/day
214597044|NCT02215837|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
214597045|NCT02215837|BIOLOGICAL|Ag-D-CIK|8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
214597046|NCT01762670|DRUG|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
214597047|NCT01762670|DRUG|Metronidazole|500 mg twice daily for 7 days
214597048|NCT03236051|PROCEDURE|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
214597049|NCT03236051|PROCEDURE|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
214597050|NCT04213924|DRUG|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
214597051|NCT04213924|DRUG|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
214597052|NCT01842685|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
214597053|NCT02521311|DRUG|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
214597054|NCT02521311|DRUG|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
214597055|NCT02849340|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
214597056|NCT02849340|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214597057|NCT04058951|OTHER|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
214597058|NCT04058951|OTHER|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
214597059|NCT01176968|DRUG|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
214597060|NCT01176968|DRUG|Placebo|Matching placebo tablets
214597061|NCT00483314|DRUG|N-acetylcysteine|2 g p.o. BID x 60 days
214597062|NCT04660071|OTHER|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
214597063|NCT04660071|OTHER|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
214597064|NCT01137955|DRUG|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
214597065|NCT01137955|DRUG|Placebo|Placebo orally three times a day for 10 days total
214597066|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
214597067|NCT02661698|DIETARY_SUPPLEMENT|Placebo|3 x 1 g capsules Placebo: olive oil
214597068|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
214597069|NCT06356961|BEHAVIORAL|(Feedback Informed Therapy) with Clinical Support Tools and ah hoc training|Therapists in the condition (OPM-F) will receive specific training on the procedures and techniques inherent in feedback informed therapy (FIT); during the intervention phase (lasting 15 sessions) the Clinical Support System in FIT will guide them in the clinical application of the procedures. In addition, they will receive monthly supervision (for three months) apt to provide on-going clinical support on FIT and ROM, with practical discussion of the most difficult clinical cases and possible solutions to be implemented in therapy.
214597070|NCT06356961|BEHAVIORAL|Feedback and ROM (basic)|Process and outcome monitoring (OPM) in which patients will complete process and outcome measures related to each psychotherapy session but therapists will receive basic feedback on these measures
214597071|NCT02863887|BEHAVIORAL|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
214597072|NCT05386550|DRUG|Xevinapant|Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle.
214597073|NCT05386550|RADIATION|IMRT|Participants received 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days per week.
214597074|NCT05386550|DRUG|Placebo|Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle.
214597075|NCT06236347|BEHAVIORAL|Smoking cessation e-visit|Electronic visits (e-visits) for smoking cessation
214597076|NCT06236347|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
214597077|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
214597078|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
214597079|NCT00068588|BIOLOGICAL|GTI-2040|Given IV
214597080|NCT00068588|DRUG|capecitabine|Given orally
214597081|NCT04822168|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
214597082|NCT04822168|OTHER|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
214597083|NCT05193500|BEHAVIORAL|Verbs|New verbs are introduced that are personally relevant to the child or neutral.
214597084|NCT05193500|BEHAVIORAL|Pronouns|Pronouns are used that directly refer to the child or are neutral.
214597085|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
214597086|NCT05614323|OTHER|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
214597087|NCT04823299|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation ablation
214597088|NCT04823299|PROCEDURE|Radiofrequency catheter ablation +EPS guided trigger and substrate ablation|RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
214597089|NCT04098068|DRUG|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
214597090|NCT05489887|DRUG|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
214597091|NCT03098589|DRUG|Revlimid|Revlimid
214597092|NCT03871829|DRUG|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
214597093|NCT03871829|DRUG|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m\^2 will be administered IV.
214597094|NCT03871829|DRUG|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
214597095|NCT03871829|DRUG|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
214597096|NCT03871829|DRUG|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
214597097|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
214597098|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
214597099|NCT05645588|BEHAVIORAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
214597100|NCT05645588|BEHAVIORAL|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
214597101|NCT06078878|DEVICE|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
214597102|NCT06110611|DEVICE|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
214597103|NCT06774066|OTHER|High volume image guided injection|High volume image guided injection consists of 9.5ml of bupivacaine, 0.5ml 20mg Depo-medrol, and 40ml of injectable saline. This procedure will be commenced with a thorough disinfection of the injection site. The mid-portion of the Achilles tendon will then be imaged in the short axis to obtain a cross-sectional view of the tendon, alongside the anterior region, including Kager's fat pad, particularly in areas of maximal pain and increased neovascularity. Once the needle is correctly positioned, the high-volume fluid will be infiltrated under pressure, with ultrasound guidance confirming the reduction or complete disappearance of neovascularisation.
214597104|NCT06774066|OTHER|Progressive rehabilitation exercise programme|A comprehensive explanation of the progressive exercise program will be provided to patients, along with a detailed booklet that includes four tiers of exercises, ranging from the easiest to the most challenging. Exercises include several eccentrics, isometrics and heavy slow resistance exercises. These exercises are to be performed once a day and the intensity and number of repetitions will be based on the patients' status. The progressive exercise program is designed to avoid exacerbating the patient's symptoms; however, some pain is permitted during the sessions following the pain monitoring model proposed by Thomee (1997)
214597105|NCT00006332|DRUG|Tetrathiomolybdate|
214597106|NCT04092101|OTHER|Cigarettes with varying nicotine content|1\) Altering the nicotine content of the tobacco research cigarette
214597107|NCT04092101|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
214597108|NCT02283554|PROCEDURE|open flap debridement (OFD)|
214597109|NCT02283554|OTHER|Platelet rich fibrin (PRF)|
214597110|NCT02283554|DRUG|Metformin|
214597111|NCT02149082|DEVICE|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
214597112|NCT04977726|BEHAVIORAL|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
214597113|NCT01720173|BIOLOGICAL|Dalantercept|Given SC
214597114|NCT01720173|OTHER|Laboratory Biomarker Analysis|Correlative studies
214597115|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
214597116|NCT00655694|PROCEDURE|sputum, blood, urine, exhaled breath, lung function|
214597117|NCT05276115|OTHER|Interview|Interview discussion with individuals with ptsd.
214597118|NCT00621647|DRUG|Quetiapine Fumarate|
214597119|NCT00621647|DRUG|Quetiapine Fumarate|
214597120|NCT00621647|DRUG|Placebo|
214597121|NCT02645188|OTHER|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
214597122|NCT02851082|OTHER|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
214597123|NCT02624765|DRUG|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
214597124|NCT02624765|DRUG|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
214597125|NCT02624765|DRUG|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
214597126|NCT02624765|DRUG|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
214597127|NCT02624765|DRUG|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
214597128|NCT02624765|DRUG|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
214597129|NCT05058625|DEVICE|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
214597130|NCT05058625|OTHER|Control Group|Normal volleyball training
214597131|NCT02973074|DIETARY_SUPPLEMENT|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
214597132|NCT02215460|PROCEDURE|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597133|NCT02215460|PROCEDURE|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597134|NCT02215460|DRUG|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597135|NCT02215460|DRUG|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597136|NCT02215460|DRUG|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597137|NCT02215460|DRUG|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597138|NCT02215460|DRUG|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597139|NCT02215460|DRUG|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597140|NCT02215460|DRUG|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597141|NCT02215460|DRUG|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
214597142|NCT01067157|BEHAVIORAL|LOGIC|"Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
214597143|NCT03299257|DRUG|donepezil treatment|30-day donepezil treatment
214597144|NCT05987397|DRUG|idebenone 30 mg for 14 days|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
214597145|NCT05987397|DRUG|idebenone 30 mg for 3 months|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
214597146|NCT01324323|DRUG|Romidepsin|14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
214597147|NCT01324323|DRUG|Rifampin|600 mg oral once daily on Days 4-8
214597148|NCT01148966|DRUG|aminolevulinic acid|Given PO
214597149|NCT01148966|OTHER|laboratory biomarker analysis|Correlative studies
214597150|NCT01148966|PROCEDURE|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
214597151|NCT01821378|DRUG|Lurasidone|Lurasidone 20 mg once daily
214597152|NCT01821378|DRUG|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
214597153|NCT01821378|DRUG|Placebo|Once Daily
214597154|NCT02367326|OTHER|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
214597155|NCT03296462|OTHER|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
214597156|NCT03296462|OTHER|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
214597157|NCT02888665|DRUG|Doxorubicin Hydrochloride|Given IV
214597158|NCT02888665|OTHER|Laboratory Biomarker Analysis|Correlative studies
214597159|NCT02888665|BIOLOGICAL|Pembrolizumab|Given IV
214597160|NCT04045951|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
214597161|NCT01728051|DRUG|Melphalan|
214597162|NCT01728051|DEVICE|Percutaneous Hepatic Perfusion|
214597163|NCT00993915|DRUG|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
214597164|NCT01513525|DRUG|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
214597165|NCT01875822|DIETARY_SUPPLEMENT|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
214597166|NCT01386658|DRUG|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
214597167|NCT05398510|DRUG|SHR-2010 injection|Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
214597168|NCT05398510|DRUG|SHR-2010 injection placebo|Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
214597169|NCT02267356|DRUG|VT-1161|
214597170|NCT02267356|DRUG|Placebo|
214597171|NCT04052529|OTHER|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
214597172|NCT03575390|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
214597173|NCT03575390|DIETARY_SUPPLEMENT|Pomegranate|Pomegranate extract 500mg
214722082|NCT05666908|DEVICE|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
214597174|NCT05659355|OTHER|Constraint Induced Movement Therapy (CIMT)|I will apply CIMT on effected hand to observe the hand dexterity and grip strength
214597175|NCT05659355|OTHER|Mirror Therapy (MT)|I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
214597176|NCT06267573|DEVICE|Fenestrated and branched endovascular devices for TAAA|Devices for TAAA
214597177|NCT04845360|DEVICE|pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)|The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.
214597178|NCT02690779|OTHER|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
214597179|NCT02690779|OTHER|Routine Care Instructions|patients will follow routine care and instructions
214597180|NCT00672061|DRUG|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
214597181|NCT00592761|BEHAVIORAL|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
214597182|NCT02783131|DEVICE|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
214597183|NCT03930368|OTHER|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
214597184|NCT00435474|PROCEDURE|Wound treatment|wound treatment (silver product, alginate and foam dressing)
214597185|NCT00435474|PROCEDURE|wound treatment|wound treatment (honey product, alginate and foam dressing)
214597186|NCT00435474|OTHER|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
214597187|NCT00435474|OTHER|relaxation therapy|relaxation therapy
214597188|NCT04624451|DRUG|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
214597189|NCT02900469|BIOLOGICAL|denosumab|denosumab: 120 mg subcutaneous injection
214597190|NCT02900469|PROCEDURE|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
214597191|NCT05373953|DRUG|CHF6001|CHF6001 will be administered using the NEXThaler® DPI device
214597192|NCT02157350|PROCEDURE|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
214597193|NCT01919320|DEVICE|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
214597194|NCT01919320|DEVICE|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
214597195|NCT05878301|OTHER|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
214597196|NCT02465463|PROCEDURE|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
214597197|NCT02465463|DEVICE|flexible sigmoidoscopy|
214597198|NCT04720404|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
214597199|NCT04720404|OTHER|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
214597200|NCT04720404|OTHER|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
214597201|NCT02719431|DRUG|Warfarin|
214597202|NCT02719431|DRUG|K-877|
214597203|NCT02191020|DRUG|Total glucosides of paeony & Acitretin Capsules|
214597204|NCT02191020|DRUG|Acitretin Capsules|
214597205|NCT05044026|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
214597206|NCT02905994|DRUG|Volasertib|Polo-Like Kinase Inhibitor
214597207|NCT02905994|DRUG|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
214597208|NCT02905994|DRUG|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
214597209|NCT02905994|PROCEDURE|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
214597210|NCT02361151|BEHAVIORAL|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
214597211|NCT02361151|BEHAVIORAL|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
214597212|NCT01487031|OTHER|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
214597213|NCT01487031|OTHER|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
214597214|NCT01379391|DRUG|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
214597215|NCT01414777|DRUG|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
214597216|NCT01414777|DRUG|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
214597217|NCT03622853|DRUG|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
214597218|NCT05051137|BIOLOGICAL|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
214597219|NCT05051137|DRUG|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
214597220|NCT06372028|DEVICE|transcutaneous vagus nerve stimulation (tVNS)|tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
214597221|NCT04777253|OTHER|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
214597222|NCT04777253|OTHER|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
214597223|NCT02727166|DIETARY_SUPPLEMENT|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
214722083|NCT01847690|DRUG|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
214722084|NCT04695236|DEVICE|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
214597224|NCT02727166|DIETARY_SUPPLEMENT|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
214597225|NCT04581616|PROCEDURE|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
214597226|NCT04581616|PROCEDURE|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
214597227|NCT05572333|DRUG|EP395|Capsule for oral use
214597228|NCT05572333|DRUG|Placebo|Capsule for oral use
214597229|NCT05615532|DRUG|LY3209590 (SC)|Administered SC.
214597230|NCT05615532|DRUG|LY3209590 (IV)|Administered IV.
214597231|NCT00577161|DRUG|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
214722085|NCT04695236|OTHER|Standard Treatment|Standard Treatment for Ischemic Strokre
214722086|NCT01013090|DRUG|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
214597232|NCT00577161|DRUG|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
214597233|NCT00002863|DRUG|chemotherapy|
214597234|NCT00002863|PROCEDURE|conventional surgery|
214597235|NCT00002863|PROCEDURE|cryosurgery|
214597236|NCT05997524|DRUG|Trastuzumab|Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).
214597237|NCT05997524|DRUG|Oxaliplatin|Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.
214597238|NCT05997524|DRUG|Capecitabine|Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
214597239|NCT06445283|OTHER|Determination of VTE risk levels|Determination of VTE risk levels of patients using IMPROVE risk assessment tool according to deep vein thrombosis and pulmonary embolism risk factors
214597240|NCT00292799|DRUG|Orlistat Vs Metformin|
214597241|NCT04127149|DIAGNOSTIC_TEST|Ultrasound scan|The group uses an ultrasound device for the consultation.
214597242|NCT00695253|DEVICE|Talent Endoluminal Spring Graft System|Endovascular repair for patients with AAA who meet the inclusion criteria for the study
214597243|NCT02652650|DRUG|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
214597244|NCT02652650|DRUG|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
214597245|NCT02652650|DRUG|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
214597246|NCT02645513|BEHAVIORAL|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
214597247|NCT02645513|BEHAVIORAL|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
214597248|NCT02645513|BEHAVIORAL|Control|No text message reminders
214597249|NCT05049278|DRUG|Norepinephrine|"* Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
214597250|NCT05049278|DRUG|Phenylephrine|"* Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
214597251|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume
214597252|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume
214597253|NCT00617032|GENETIC|tgAAC94 placebo|Single dose
214597254|NCT01498289|DRUG|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
214597255|NCT01498289|DRUG|docetaxel|30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
214597256|NCT01498289|DRUG|fluorouracil|400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
214597257|NCT01498289|DRUG|irinotecan hydrochloride|65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
214597258|NCT01498289|DRUG|leucovorin calcium|400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
214597259|NCT01498289|DRUG|oxaliplatin|85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
214597260|NCT03715309|DRUG|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
214597261|NCT04430465|DIETARY_SUPPLEMENT|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
214597262|NCT04430465|DIETARY_SUPPLEMENT|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
214597263|NCT00124098|DRUG|Aranesp® (darbepoetin alfa)|
214597264|NCT00597441|BIOLOGICAL|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
214597265|NCT00141323|DRUG|lasofoxifene|0.5 mg once per day, orally
214597266|NCT00141323|OTHER|placebo|placebo
214597267|NCT00141323|DRUG|lasofoxifene|0.25 mg once per day, orally
214597268|NCT00786396|BEHAVIORAL|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
214597269|NCT05033808|DRUG|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
214597270|NCT05033808|DRUG|Placebo|NaCl is given once over 15 Minutes via a central line
214597271|NCT03786939|PROCEDURE|On-pump CABG.|On-pump coronary artery bypass grafting.
214597272|NCT03786939|PROCEDURE|Off-pump CABG.|Off-pump coronary artery bypass grafting.
214597273|NCT03786939|PROCEDURE|Pump-assisted CABG.|Pump-assisted CABG.
214597274|NCT00906919|BEHAVIORAL|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
214597275|NCT00906919|BEHAVIORAL|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
214597276|NCT02535663|DIETARY_SUPPLEMENT|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
214597277|NCT02535663|DIETARY_SUPPLEMENT|Placebo|Same product without RG
214597278|NCT01774084|DIETARY_SUPPLEMENT|Experimental: PreOp, NutriciaNordica AB|
214597279|NCT01774084|DIETARY_SUPPLEMENT|Placebo Comparator: Water|
214597280|NCT06459193|DRUG|Trimetazidine|Trimetazidine 35 mg tab once daily
214597281|NCT06459193|DRUG|Placebo|Placebo once daily
214597282|NCT03739541|DRUG|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
214597283|NCT00416169|DRUG|galantamine hydrobromide|
214597284|NCT03655379|DEVICE|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
214597285|NCT06248931|DRUG|Valproic acid|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214597286|NCT06248931|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214597287|NCT00821431|DEVICE|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
214597288|NCT00821431|DEVICE|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
214597289|NCT01349023|OTHER|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
214597290|NCT01629784|BEHAVIORAL|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
214597291|NCT03595592|DRUG|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
214597292|NCT03595592|DRUG|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
214597293|NCT03595592|DRUG|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
214597294|NCT03595592|DRUG|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
214597295|NCT03595592|DRUG|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
214597296|NCT03595592|DRUG|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
214597297|NCT03595592|DRUG|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
214597298|NCT03595592|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
214597299|NCT00243360|BEHAVIORAL|diagnostic and treatment clinical algorithms|
214597300|NCT03854396|DRUG|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
214597301|NCT03854396|DRUG|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
214597302|NCT03885830|DRUG|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
214597303|NCT03885830|DRUG|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
214597304|NCT03885830|DRUG|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
214597305|NCT03885830|DRUG|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
214597306|NCT02281929|DRUG|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
214597307|NCT02281929|DRUG|Placebo|Placebo in three daily doses during 30 days
214597308|NCT02281929|DRUG|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
214597309|NCT06509178|OTHER|Peyton group|The same procedures were applied to the students in the experimental group as the students in the control group, except for laboratory applications. Students were asked to watch the video contents after the theoretical course, and in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach. Before the skill demonstration, students were given information about the research. Students were given 15-20 minutes to fill out the voluntary consent form and the urinary catheterization success pre-test. Students were taught the sterile urinary catheter procedure in accordance with Peyton's 4-step approach.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
214597310|NCT06509178|OTHER|Halsed group|After the control group students attended the course in accordance with the routine procedures, the students were asked to watch videos of the online urinary catheter application course and the students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice. Students were informed about the research and voluntary consent forms were obtained. Students were given 15-20 minutes to complete the urinary catheterization success pre-test. During the demonstration, the students' questions were answered, the researcher went over the points that the student did not understand, corrected any incorrect behavior, and gave feedback. Afterwards, each student was asked to demonstrate the skill steps individually.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
214597311|NCT04409249|DIAGNOSTIC_TEST|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
214597312|NCT04056065|DRUG|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
214597313|NCT04056065|DRUG|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
214597314|NCT00294385|DRUG|Docetaxel|
214597315|NCT00294385|DRUG|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
214597316|NCT00294385|DRUG|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
214597317|NCT03475810|DEVICE|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
214597318|NCT03475810|DRUG|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
214597319|NCT00959972|DRUG|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
214597320|NCT00959972|DRUG|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
214597321|NCT06502899|OTHER|Cardiac MRI|Patients with a diagnosis of MINOCA and completed CMR were included in this study
214597322|NCT06057545|DRUG|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
214597323|NCT06057545|DRUG|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
214597324|NCT01938807|BEHAVIORAL|CareCoach mobile application to assist in diabetes management|
214597325|NCT01491217|DRUG|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
214597326|NCT05217303|DRUG|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
214597327|NCT05208801|DRUG|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
214597328|NCT05208801|DRUG|Morphine|Intrathecal injection of morphine 400mcg
214597329|NCT05208801|DRUG|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
214597330|NCT02248220|DRUG|Pramipexole|
214597331|NCT05761730|DRUG|Dexamethasone Oral|For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
214597332|NCT01367964|DRUG|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
214722087|NCT01013090|DRUG|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
214597333|NCT04201405|DRUG|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
214597334|NCT01348386|DRUG|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
214597335|NCT01348386|DRUG|Placebo|
214597336|NCT00279630|PROCEDURE|Orthoses and Exercise|orthrose and exercise - daily
214597337|NCT02294123|OTHER|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
214711097|NCT07091045|OTHER|Robot-Assisted Foot-Ankle Training|"Stage 1: Vibration Training Applied for Proper Stepping on the Sole of the Foot and Proper Pressure Distribution: The first step of the training will be constant vibration, and the second step will be sensory localization training with vibration.~Stage 2: Passive Joint Range of Motion Training with Virtual Reality: The platform will move the ankle passively (passive stretching).~Stage 3: Joint Position Sense Training: The platform will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the platform initially brought.~Stage 4: Active Joint Range of Motion Training with Virtual Reality: Along with active dorsiflexion, when necessary, assistance will be provided with the Assistance as Needed (AAN) control paradigm, a feature of the robotic device.~Stage 5: It is the same as Stage 1"
214722088|NCT04921657|DRUG|Rosuvastatin 10mg|
214722089|NCT00033592|OTHER|placebo|
214722090|NCT00033592|DRUG|bupropion hydrochloride|
214722091|NCT00033592|DRUG|nicotine|
214722092|NCT01841489|DRUG|Treatment A|1600 mg GS-9973 (Formulation 1)
214597338|NCT04061551|OTHER|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses"
214597339|NCT02896504|DRUG|Exposure: Adjuvant chemotherapy treatment|
214597340|NCT02896504|DRUG|Exposure: Adjuvant hormonal therapy treatment|
214597341|NCT05981911|DEVICE|XIENCE Skypoint™ stent|Percutaneous coronary intervention with Xience-Skypoint™ stent
214597342|NCT05944042|OTHER|Observational Transplant Analysis|Identify more accurate predictive models of transplant risk
214597343|NCT00684229|PROCEDURE|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
214597344|NCT00684229|DRUG|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
214597345|NCT05332301|OTHER|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
214597346|NCT05921396|PROCEDURE|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
214597347|NCT05921396|PROCEDURE|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
214597348|NCT02070796|DRUG|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
214597349|NCT02070796|DRUG|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
214597350|NCT04526197|DRUG|ALXN1840|ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.
214597351|NCT04526197|DRUG|Celecoxib|Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
214597352|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
214597353|NCT00101881|DEVICE|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
214597354|NCT03271203|OTHER|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
214597355|NCT03271203|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
214597356|NCT00372385|DRUG|Ribavirin|tablet
214597357|NCT00372385|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
214597358|NCT00372385|DRUG|Placebo|tablet
214597359|NCT00372385|DRUG|Telaprevir|tablet
214597360|NCT01558895|RADIATION|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
214597361|NCT01558895|OTHER|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
214597362|NCT01879215|PROCEDURE|Intramedullary nailing of the tibia|Standard care surgery
214597363|NCT04805775|DRUG|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
214597364|NCT05914441|OTHER|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
214597365|NCT04134676|DRUG|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
214597366|NCT05918939|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
214597367|NCT05918939|BIOLOGICAL|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
214597368|NCT03882242|BEHAVIORAL|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
214597369|NCT02912325|DIETARY_SUPPLEMENT|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
214597370|NCT00052754|DRUG|gefitinib|
214597371|NCT05313126|OTHER|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
214597372|NCT00405470|DEVICE|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
214597373|NCT02600338|OTHER|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
214597374|NCT06317896|DIAGNOSTIC_TEST|circulating tumor cells|blood sample and tissue specimen for circulating tumor cell and DNA will be done to patient with hepatocellular carcinoma
214597375|NCT00541723|DRUG|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
214597376|NCT00541723|DRUG|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
214597377|NCT01699789|OTHER|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
214597378|NCT01699789|BEHAVIORAL|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
214722093|NCT01841489|DRUG|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
214597379|NCT01699789|BEHAVIORAL|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
214597380|NCT02148614|DRUG|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
214597381|NCT02148614|DRUG|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
214597382|NCT01222260|DRUG|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
214597383|NCT01222260|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
214597384|NCT03211650|DRUG|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
214597385|NCT03211650|DRUG|hyaluronic acid|Intra-articular injections of hyaluronic acid
214597386|NCT03211650|DRUG|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
214597387|NCT04870853|OTHER|Electronic Health Record Review|Medical records reviewed
214597388|NCT03745482|OTHER|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
214597389|NCT05062083|DRUG|11C-MC1|Up to 20 mCi injected IV followed by PET scanning
214597390|NCT05062083|DRUG|11C-PS13|Up to 20 mCi injected IV followed by PET Scanning
214597391|NCT05062083|DRUG|Ketoprofen|Ketoprofen 75 mg orally once
214597392|NCT05062083|DRUG|Celecoxib|celecoxib 600 mg orally once
214597393|NCT04094792|DEVICE|Happify Breather App|Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
214597394|NCT03905161|OTHER|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
214722094|NCT01841489|DRUG|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
214722095|NCT01841489|DRUG|Treatment D|1600 mg GS-9973 (Formulation 2)
214597395|NCT05691556|PROCEDURE|HABIT ILE rehabilitation course|"The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course"
214597396|NCT05691556|PROCEDURE|botulinum toxin injections|"Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy."
214597397|NCT03975452|RADIATION|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
214597398|NCT05937087|OTHER|Community engaged research|The university is working with Navajo communities to conduct an intervention study integrating community based participatory research using an Indigenous research paradigm. The innovative proposed project uses two approaches to build a research partnership to create capacity in the community for community-engaged multilevel behavioral and mental health research. Members from the three Navajo communities have never previously been involved in health research focused on wellbeing. Integrating CBPR with DCSR methodology becomes a powerful innovative intervention as the: 1) the community is driving the research to identify culture-based solutions for health related disparities; 2) the community is provided opportunities through research to center their perspectives and understandings about behavioral and mental health interventions; and 3) the community draws upon their collective community Indigenous knowledge.
214597399|NCT00703144|DRUG|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
214597400|NCT00703144|PROCEDURE|Pharmacokinetic|
214597401|NCT01510496|PROCEDURE|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
214597402|NCT01510496|PROCEDURE|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
214597403|NCT01510496|PROCEDURE|Thoracotomy .|Thoracotomy (non laparoscopic).
214597404|NCT06428591|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|Participants will use the Tandem Freedom system for 3 day/nights in a supervised hotel setting, performing meal and exercise challenges.
214597405|NCT03559478|PROCEDURE|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
214597406|NCT03559478|PROCEDURE|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
214722096|NCT01841489|DRUG|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
214597407|NCT03397849|BEHAVIORAL|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
214597408|NCT01375361|DRUG|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
214597409|NCT01375361|DRUG|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
214597410|NCT02411578|DRUG|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
214597411|NCT02411578|OTHER|Glucose Tablets|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
214597412|NCT01369901|BEHAVIORAL|A functional exercise program|
214597413|NCT01369901|BEHAVIORAL|A stretching exercise program|
214597414|NCT04300582|PROCEDURE|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
214597415|NCT04300582|PROCEDURE|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
214597416|NCT01209312|OTHER|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
214597417|NCT04097522|OTHER|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
214597418|NCT05419089|PROCEDURE|Robotic surgery|Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
214597419|NCT02320955|PROCEDURE|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
214597420|NCT05497648|BEHAVIORAL|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
214597421|NCT05415384|DEVICE|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
214597422|NCT05415384|PROCEDURE|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
214597423|NCT02880826|BEHAVIORAL|Measure the culture of safety in the reanimation units|
214597424|NCT04009317|DRUG|TQ-B3139|a multi-target protein kinase inhibitor.
214597425|NCT04009317|DRUG|Crizotinib|a multi-target protein kinase inhibitor.
214597426|NCT00137813|DRUG|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
214597427|NCT00137813|DRUG|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
214597428|NCT01674335|BEHAVIORAL|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
214722097|NCT01841489|DRUG|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
214597429|NCT01674335|BEHAVIORAL|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
214597430|NCT05227872|DEVICE|ultrasound|POCUS
214597431|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: IV solution
214597432|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV solution
214597433|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: SC solution
214597434|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC solution
214597435|NCT06290141|DRUG|IVIg|Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution
214597436|NCT06290141|DRUG|Placebo|Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
214597437|NCT03565276|DRUG|Tranexamic Acid|A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
214597438|NCT06239298|DRUG|ZG005 Powder for Injection|intravenous infusion(IV), once every 3 weeks
214597439|NCT06239298|DRUG|Donafenib Tosilate Tablets|The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
214597440|NCT00792454|BEHAVIORAL|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
214597441|NCT04343248|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
214597442|NCT04343248|DRUG|Placebo|Placebo administered orally twice daily for six weeks
214597443|NCT04343248|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
214597444|NCT03571529|DEVICE|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
214597445|NCT03571529|OTHER|Conventional physiotherapy|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale"
214597446|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 1.0 (intervention discontinued, modified to 2.0. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
214597447|NCT04438031|BEHAVIORAL|Control Intervention|Brief information will be provided about pregnancy prenatally and child development at 12, 24, and 36 months.
214597448|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
214597449|NCT04388501|DRUG|Milvexian|Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
214597450|NCT04388501|DRUG|Atorvastatin|Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
214597451|NCT04354090|DRUG|JY09|Subcutaneous injection
214597452|NCT05125679|DRUG|Guselkumab|Guselkumab will be administered by subcutaneous injection.
214597453|NCT04731857|GENETIC|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
214597454|NCT04484259|DRUG|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
214597455|NCT04484259|DRUG|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
214597456|NCT04484259|DRUG|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
214597457|NCT02989636|OTHER|Laboratory Biomarker Analysis|Correlative studies
214597458|NCT02989636|BIOLOGICAL|Nivolumab|Given IV
214597459|NCT02989636|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214597460|NCT05639972|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
214597461|NCT05639972|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
214597462|NCT05057806|DRUG|Empagliflozin 25 MG|Empagliflozin 25MG will be administered orally once per day for 3 months
214597463|NCT05057806|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
214597464|NCT03140423|DRUG|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
214597465|NCT03140423|DRUG|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
214597466|NCT05928403|OTHER|total knee prosthesis|Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
214597467|NCT04108897|DRUG|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
214597468|NCT04108897|DRUG|Ivermectin Topical|1% topical ivermectin.
214597469|NCT04577547|OTHER|DGA diet WL & exercise|Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise
214597470|NCT04577547|OTHER|DGA diet WL & no exercise|Intake of DGA weight loss 8 day rotating menu \& no exercise
214597471|NCT04577547|OTHER|DGA diet WM & exercise|Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise
214597472|NCT04577547|OTHER|DGA diet WM & no exercise|Intake of DGA weight maintenance 8 day rotating menu \& no exercise
214597473|NCT04577547|OTHER|Western diet WL & exercise|Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise
214597474|NCT04577547|OTHER|Western diet WL & no exercise|Intake of Western-type weight loss 8 day rotating menu \& no exercise
214597475|NCT04577547|OTHER|Western diet WM & exercise|Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise
214597476|NCT04577547|OTHER|Western diet WM & no exercise|Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
214597477|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
214597478|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
214597479|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
214597480|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
214597481|NCT05277883|RADIATION|CT scan|CT of the lower limb
214597482|NCT05825261|OTHER|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
214597483|NCT05825261|OTHER|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
214597484|NCT06506058|DEVICE|EVS and EEG|"The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included)."
214597485|NCT03187977|BEHAVIORAL|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
214597486|NCT00329485|DRUG|CORvalen (D-Ribose)|
214597487|NCT00416377|BIOLOGICAL|bleomycin sulfate|
214597488|NCT00416377|DRUG|chlorambucil|
214597489|NCT00416377|DRUG|dacarbazine|
214597490|NCT00416377|DRUG|doxorubicin hydrochloride|
214597491|NCT00416377|DRUG|prednisolone|
214597492|NCT00416377|DRUG|procarbazine hydrochloride|
214597493|NCT00416377|DRUG|vinblastine sulfate|
214597494|NCT00416377|DRUG|vincristine sulfate|
214597495|NCT00416377|RADIATION|radiation therapy|
214597496|NCT06241508|DEVICE|Transcranial magnetic stimulation|A standard 600-pulse TBS \[16\] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology \[3, 9\]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 \[17\], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 \[4, 6\]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes \[2, 3\]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
214597497|NCT03454308|BEHAVIORAL|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
214597498|NCT03454308|BEHAVIORAL|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
214597499|NCT04569695|DRUG|JNJ-70033093|JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
214597500|NCT05848271|OTHER|Patient Registry|Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.
214597501|NCT05848271|OTHER|Dry blood spots sampling|Dry blood splots require 500nl of blood.
214597502|NCT04634656|DRUG|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
214597503|NCT04634656|DRUG|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
214597504|NCT01197885|DRUG|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
214722098|NCT01841489|DRUG|Treatment G|1600 mg GS-9973 (Reference formulation)
214597509|NCT02874339|DEVICE|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
214597510|NCT02874339|DEVICE|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
214597511|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg with phytase supplement 176mg (800FTU)|zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day
214597512|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg|zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.
214597513|NCT00890487|OTHER|hyaluronic acid pill|pill, 220 mg, once a day, three months
214597514|NCT05603091|PROCEDURE|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
214597515|NCT06419829|OTHER|psychoprophylactic program aimed at normalizing body weight through medical training|"Based on the assessment of body weight and composition, a 12-week physiophylactic program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that reduce fat mass, increase the flexibility and productivity of muscle mass. The classes will be conducted as part of medical training with a training load increasing to at least 85% of HR Max.~The project will include theoretical classes for parents, children and seniors on eating habits, a proper age-appropriate diet, diet changes depending on the subject's health condition and physical activity, and the impact of diet on the process of puberty, adulthood and aging."
214597516|NCT06419829|OTHER|psychoprophylactic program aimed at improving body posture|"Based on the body posture assessment, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that strengthen the muscle corset, reducing asymmetrical positioning, habitual and during the implementation of professional tasks. The classes will be conducted using medical training and resistance exercises.~The project will include theoretical classes for parents on sitting habits, the importance of physical activity in a child's development, the selection of footwear..."
214722099|NCT01841489|DRUG|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
214722100|NCT01841489|DRUG|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
214722101|NCT01841489|DRUG|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
214597517|NCT06419829|OTHER|psychoprophylactic program aimed at improving physical fitness|Based on the assessment of physical fitness, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the participants. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises aimed at improving physical fitness, with particular emphasis on impaired motor skills. The classes will be conducted using functional training, resistance and stretching exercises, strengthening all muscle groups. In the case of children, special attention will be paid to the strength of the upper limbs, in the case of seniors, balance and coordination exercises will be introduced to improve time and space orientation. In all groups, the main goal is to improve functional fitness The project will include theoretical classes for parents, children and seniors on the importance of physical activity in the quality of life, in the process of maturation and aging.
214597518|NCT06419829|DIAGNOSTIC_TEST|Body composition assessment|"Body composition assessment will be carried out using the BIA method on an eight-electrode body composition analyzer from TAnita. They will be marked:~total mass, Total fat mass (FM) and segmental fat mass for five body segments: right leg (RL FM), Left leg (LL FM), right arm (RA FM), Left Arm (LA FM) trunk (TR FM).~total fat-free mass (FFM) and segmental for five body segments: right leg (RL FFM), Left leg (LL FFM), right arm (RA FFM), Left Arm (LA FMM) trunk (TR FMM).~Predicted total and segmental muscle mass (PMM) for five body segments: right leg (RL PMM), Left leg (LL PMM), right arm (RA PMM), Left Arm (LA PMM) trunk (TR PMM).~Total water content (TBW) including intracellular water (ICW) and extracellular water (ECW)"
214597519|NCT06419829|DIAGNOSTIC_TEST|assessment of body posture using the Kasperczyk method|The Kasperczyk method was used to assess body posture, including physiotherapeutic assessment in both standing and sitting positions. The symmetry of the head, shoulders, spine curvatures, knee joints and foot positioning were assessed. The symmetry of the head position was examined in all three planes and in all movements, i.e. flexion - extension, right turn - left turn, rotation and combined movements. The lateral curvatures of the spine (scoliosis) and their physiological curvatures, their deepening or shallowing in all sections of the spine, as well as the mobility of the spine in all physiological planes of movement were assessed. The position of the shoulder and hip girdle was assessed, as well as the position of the upper limbs at the level of the knees and feet. The mobility of the lower and upper limbs was examined.
214597520|NCT06419829|DIAGNOSTIC_TEST|Assessment of physical fitness|It depends on the age of the person being examined. In the case of children, the EUROFIT physical fitness test is carried out with modifications for age and gender. For the senior group, the Rikli and Jones test is used
214597521|NCT06419829|DIAGNOSTIC_TEST|Balance assessment|"Balance assessment using the Zebris platform Static measurement - with eyes open and closed, assessing the load on the limbs during standing expressed in %, Balance analysis measurement - with eyes open and closed, test in a standing position, barefoot. The measurement duration is 30 seconds and the break between measurements is 30-60 seconds.~Deflections of the center of gravity in the frontal and sagittal planes Length of the center of gravity swing path CoP - SPL \[cm\]. Inside the calculated ellipse lies 95% of the CoP location measurement data: amplitude, amplitude height, ellipse area (orientation of the direction of the ellipse's longitudinal axis relative to the platform's longitudinal axis, indicating clockwise rotation)."
214597522|NCT02950064|DRUG|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
214597523|NCT02330783|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
214597524|NCT02330783|DRUG|Sorafenib|400mg twice daily by oral of each 4-week cycle
214597525|NCT00958620|PROCEDURE|Shock Wave Therapy|Extracorporal shock-wave therapy
214597526|NCT00276588|DRUG|carboplatin|
214597527|NCT00276588|DRUG|gemcitabine hydrochloride|
214597528|NCT00276588|DRUG|paclitaxel|
214597529|NCT06387368|DRUG|Huaier Granule|Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
214597530|NCT06387368|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
214597531|NCT03178539|DRUG|diclofenac|non steroidal anti-inflammatory drug
214597532|NCT03178539|DRUG|ketorolac|non steroidal anti-inflammatory drug
214597533|NCT06062446|PROCEDURE|Modified Lumbar Puncture|The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
214597534|NCT04225221|DRUG|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
214597535|NCT04225221|DRUG|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
214597536|NCT04225221|DRUG|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
214597537|NCT04225221|DRUG|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
214597538|NCT03635593|DRUG|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
214597539|NCT03635593|DRUG|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
214597540|NCT03635593|OTHER|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
214597541|NCT01795027|DRUG|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
214597542|NCT01795027|DRUG|S-1 single|16 courses S-1 single after d D2 resection
214597543|NCT04596696|BIOLOGICAL|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
214597544|NCT03645954|PROCEDURE|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
214597545|NCT03645954|PROCEDURE|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle \& Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
214597546|NCT00000193|DRUG|Gamma hydroxybutyric|
214597547|NCT01422850|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
214597548|NCT01909687|DEVICE|Blood glucose monitoring systems|
214597549|NCT02947477|BEHAVIORAL|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
214597550|NCT04484831|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
214597551|NCT04484831|OTHER|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
214597552|NCT04525482|OTHER|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
214597553|NCT03188354|DIAGNOSTIC_TEST|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
214597554|NCT03188354|DIAGNOSTIC_TEST|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
214597555|NCT03188354|DIAGNOSTIC_TEST|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
214597556|NCT02370082|DEVICE|Localization of breast lesion|localization of breast lesion for removal
214597557|NCT04423354|PROCEDURE|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
214597558|NCT04778774|PROCEDURE|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
214597559|NCT02916680|PROCEDURE|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
214597560|NCT03330353|DIAGNOSTIC_TEST|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
214597561|NCT02244996|DIETARY_SUPPLEMENT|Lycium Barbarum|Traditional Chinese Herbs
214597562|NCT02244996|DIETARY_SUPPLEMENT|Placebo|Placebo
214597563|NCT04556058|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
214597564|NCT04556058|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
214597565|NCT01335009|BIOLOGICAL|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
214597566|NCT04492605|DIETARY_SUPPLEMENT|Placebo|consume 1 capsule per day for 2 months
214597567|NCT04492605|DIETARY_SUPPLEMENT|TCI378 Probiotics|consume 1 capsule per day for 2 months
214597568|NCT04492605|DIETARY_SUPPLEMENT|TCI507 Probiotics|consume 1 capsule per day for 2 months
214597569|NCT06281964|DRUG|PLB1004|Participants received oral PLB1004 240mg on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 240mg and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
214597570|NCT06281964|DRUG|Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab|Participants received IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 and 500 mg/m\^2 of pemetrexed on Day 1 q3w and Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. until disease progression in the maintenance period.
214597571|NCT06666322|DRUG|Standard of care|"2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum"
214597572|NCT06666322|DRUG|Oteseconazole - antifungal therapy 1|"Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)~* Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.~* Liposomal Amphotericin B 10 mg/kg IV once.~* No fluconazole or 5FC to be given."
214597573|NCT06666322|DRUG|Sfu-AM2-19 Injection - antifungal therapy 2|Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
214597574|NCT06666322|DRUG|Antifungal therapy 3|To be determined
214597575|NCT06666322|DRUG|Antifungal therapy 4|To be determined
214597576|NCT06609707|BEHAVIORAL|Tuning in to Kids|Tuning in to Kids is an evidence-based, emotion-focused, group parenting program designed to teach caregivers skills in recognizing, understanding, and managing their own and their children's emotions. The program includes six 90-minute, weekly, online group sessions and two optional 'booster' sessions to consolidate skills. Parents are taught five steps of emotion coaching and participate in exercises sequentially targeting each step. Intervention components include psychoeducation, emotion coaching demonstrations, role plays, group discussion, written resources, and home practice exercises. The program teaches parents skills in emotion coaching as a way of responding to their child's emotions. These skills help children to understand and regulate their emotions. As per the Tuning in to Kids manual, two trained, licensed health professionals will co-facilitate each group.
214597577|NCT06825338|OTHER|CATCH My Breath|CATCH My Breath (CMB) is a school-based vaping prevention curriculum based on best practices from earlier prevention studies that works by fostering social competence and social influence resistance skills. The curriculum design and content targets two key constructs of Social Cognitive Theory: self-efficacy and behavioural capacity (i.e., knowledge and skills). The curriculum provides students with knowledge of why and how to resist vaping. It is delivered through two 60-minute lessons by a trained Public Health Unit presenter. The curriculum lessons provide information about: 1) the physical, mental, and addiction risks associated with vaping, 2) social norms of vaping (e.g., most youth don't vape), 3) media literacy (e.g., how to recognize and decipher marketing of vapes), 4) strategies to resist and avoid vaping, 5)school and provincial policies about vaping. To solidify the content, in-class activities allow students to discuss what they are learning and practice refusal skills.
214597578|NCT02918578|OTHER|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
214597579|NCT02918578|OTHER|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
214597580|NCT02918578|OTHER|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
214597581|NCT06991192|BEHAVIORAL|Rehabilitation with Exercise and Psychological Support (REPS)|Rehabilitation with Exercise and Psychological Support (REPS) is a rehabilitation approach that integrates exercise with psychological support provided by physical therapist and patient training videos.
214597582|NCT07006090|DEVICE|Histolog Scanner|Histolog Scanner intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture.
214597583|NCT06496646|BEHAVIORAL|Reminders|We will send daily text messages to participants for 12 weeks reminding them to take their antidepressant medication. These reminders will be tailored, personalized and patient-centric, grounded in behavioral economics principles.
214597584|NCT06496646|BEHAVIORAL|Incentives|In addition to daily text messages, participants will receive financial incentives for 6 weeks based on contingency management principles. Participants assigned to the Reminders and Incentives arm of the study will receive a $2/day incentive, increasing by $1/day conditioned on each week that they consistently take their antidepressant over the first 6 weeks, for a maximum total payment of $189 ($2, $3, $4, $5, $6, $7 in weeks 1 through 6, respectively).
214597585|NCT07010146|DRUG|transdermal 17β-E2 with cyclic progestin|100-mcg transdermal 17β-E2 patch (to be applied twice weekly) (continuous use), with 200 mg micronized progesterone given for 12 days of every month
214597586|NCT07010146|DRUG|oral 17β-E2 with cyclic progestin|2 mg of oral 17β-E2 pills daily, with 200 mg micronized progesterone given for 12 days of every month
214597587|NCT07010146|DRUG|transdermal EE+LNG|transdermal EE (30 mcg) + LNG (120 mcg) contraceptive patch (TWIRLA). Patch will be applied once a week for 3 consecutive weeks, with the 4th week off the patch (to be repeated after 4 weeks).
214597588|NCT03237182|DRUG|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
214597589|NCT03237182|DRUG|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
214597590|NCT07020338|OTHER|Yoga Exercise Program|Participants in the intervention group received a structured yoga-based exercise program consisting of 50-minute sessions, conducted twice per week over a period of approximately 10-12 weeks (three menstrual cycles). The program was based on Hatha Yoga principles
214597591|NCT07020156|DRUG|OX118 or placebo|OX118 is a human monoclonal antibody targeting OX40 ligand (OX40L).
214597592|NCT07020845|OTHER|Observation only|This is an observational study with no intervention applied to participants. Data were collected through questionnaires and clinical assessments only
214597593|NCT07020442|OTHER|integrated neuromuscular training|a 12-week integrated neuromuscular training (NMT) program. All participants completed two NMT sessions weekly.
214597594|NCT07019610|DEVICE|ClearGuard HD|The ClearGuard HD end cap is a male luer lock end cap that incorporates an antimicrobial treatment (Chlorhexidine) on its surface designed to reduce microbial colonisation within a haemodialysis catheter hub.
214597595|NCT07019610|DEVICE|B Braun Combi-stopper|Standard practice caps used within the Metro North Kidney Health Service
214597596|NCT07019142|DIETARY_SUPPLEMENT|HFD|Luminal challenge with standardized volume, amount, calories of fat
214597597|NCT07019870|DIAGNOSTIC_TEST|EBV biomarker testing|"15 ml of blood will be collected for EBV EA IgA serology and plasma EBV DNA testing by a trained nursing/phlebotomy staff. If the initial plasma EBV DNA test is positive, a second blood draw will be performed for repeat plasma EBV DNA testing.~Additionally, 2-3 ml of saliva will be collected for EBV strain identification, however, this information is not used for risk stratification in this study.~Demographic characteristics, clinical history and symptoms will be collected through a questionnaire."
214597598|NCT07021287|OTHER|mixed ice and water, continuous ice application|the ice pack was placed on the knee joint immediately after returning to the ward for 24 hours, and the ice pack was replaced every 3 to 4 hours, if it melted, replaced immediately.
214597599|NCT07021287|OTHER|mixed ice and water, intermittent ice compress|within 72 hours after operation, the patients were given ice compress for 20 minutes each time, with an interval of 2 hours, 3 times a day
214597600|NCT07021287|OTHER|full ice, continuous ice compress|After returning to the ward, an ice pack should be placed on the knee for 24 hours. The ice pack should be replaced every 3-4 hours and replaced immediately if melted
214597601|NCT07021287|OTHER|full ice, intermittent ice compress|Within 72h after surgery, the patient applied ice for 20min each time, with an interval of 2h,3 times a day.
214597602|NCT07018999|DEVICE|Immersive virtual reality operating theatre tour|In a joint project involving the Department of Computing of Hong Kong Polytechnic University, the Department of Computer science Center for Innovative Applications of Internet and Multimedia Technologies of the City University of Hong Kong and the Hong Kong Children's Hospital (HKCH), an immersive VR operating theatre tour will be designed as part of preoperative education for participants. A simulation of the perioperative journey in HKCH operating theatre will be created to help participants form realistic expectations of their perioperative journey, and virtual exposure of different medical equipment helps participants cope with their worries for the anticipated procedures. Parents/legal guardians will be able to monitor the VR experience on tablets via the monitoring software, which displays what the participants see in VR.
214597603|NCT07019311|OTHER|Thera-Band exercises|Participants in the first experimental group performed a Thera-Band exercise program 3 sessions weekly, for 8 weeks with progressive resistance, divided into four 2-week phases. Each 60-minute session included a 10-min warm-up (walking, jogging, and calisthenics), 45-min Thera-Band exercises, and 5-min cool-down. Phase 1 focused on major muscle groups (e.g., shoulder press, biceps curl). Phase 2 included trunk and leg-focused moves (e.g., reverse flies, lunge). Phase 3 added advanced resistance (e.g., chest press, deadlift). Phase 4 targeted core and lower body (e.g., diagonal chop, squat). Exercises changed every phase to progressively strengthen different muscle groups.
214722102|NCT05478538|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
214597604|NCT07019311|OTHER|Swiss ball exercises|Participants in the second experimental group performed Swiss ball exercises 3 sessions weekly, for 8 weeks. Exercises included warm-up (15-5 mins), core Swiss ball training (progressing from 1 to 4 sets), and cool-down. Each session focused on abdominal, back, leg, trunk, and balance training using varied exercises performed for 30 seconds with rest. Exercise intensity ranged from 80-95% of max effort, increasing weekly. The Swiss ball size was selected based on patient height to ensure proper posture. Sessions gradually increased in duration and difficulty, ending with breathing and stretching for recovery.
214597605|NCT07019311|OTHER|Traditional physical therapy program|Participants in both experimental groups performed a traditional physical therapy program in the form of complex decongestive physical therapy(CDPT), including (manual lymphatic drainage, compression, exercise and skin care) and balance training, 3 sessions weekly, for 8 weeks.
214597606|NCT07020715|BIOLOGICAL|Tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
214597607|NCT07020247|DRUG|Anti-PD-1 antibody drug named Serplulimab|Serplulimab
214597608|NCT07020247|RADIATION|Radiotherapy|Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/ 25-28f(1.8-2.0Gy/d, 5f/w). For patients in the experimental group who achieve partial remission (PR) or better during the induction phase, an additional local boost dose of 6Gy/3f(2.0Gy/d, 5f/w) is administered to the PGTV.(No PGTV dose was given in the control group). For the treatment of lymph node metastasis in the lateral pelvic wall outside the mesorectal area: no additional dose is required when surgery is feasible, a sequential boost dose of 15Gy/3f is added when the lymph nodes are not surgically resectable.
214597609|NCT07020247|DRUG|Chemotherapy|Capox
214722103|NCT00040950|BIOLOGICAL|rituximab|
214722104|NCT00040950|DRUG|agatolimod sodium|
214597610|NCT07020754|DIETARY_SUPPLEMENT|L-arginine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-arginine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
214597611|NCT07020754|DIETARY_SUPPLEMENT|L-glutamine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-glutamine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
214597612|NCT07020754|DIETARY_SUPPLEMENT|Maltodextrin Oral Suspension (Control)|"Type: Placebo comparator~Dosage: 10 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
214597613|NCT07019675|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
214597614|NCT07020260|OTHER|CAR T-cell and Cellular Therapies|A single IV infusion of huCAR 19 T-cells on day 0. In phase I 3 dose levels are tested to determine the RP2D.
214597615|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training with Motor Imagery|Participants will perform the game consisting of 3 different stages during one session. The motor task will include crossing the street between cars and walking on the sidewalk without hitting people. The difference between the stages will be the cognitive task, which becomes more difficult with each stage. The cognitive task in the first stage of the game will involve the colors that the patient will see and the simultaneous sound of the colors. The cognitive task in the second stage of the game will involve writing the names of some colors with black paint and reading them simultaneously. In the third stage of the game, the patient will see color names written with some colors. Every 5 seconds a new match will appear and the number of errors made during the matches will be recorded. In addition, upper extremity strengthening with PNF methods such as hold relaxation, rhythmic stabilization and repetitive stretches will be studied.
214597616|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training without Motor Imagery|The difference of this group from the first group is that they will see that they provide mobility with a wheelchair instead of walking, which is a motor task. In this case, there will be no motor imagery of walking. Simultaneously with the game, an environment where the wheelchair can move safely will be created in order to prevent symptoms such as dizziness and nausea in the patients and the wheelchair will be moved in this environment by the researcher. The difference between the stages will be the cognitive task that becomes more difficult at each stage and it will take a total of 20 minutes to complete all stages of the game. In addition, upper extremity strengthening will be practiced with PNF methods of hold and relax, rhythmic stabilization and repetitive stretches.
214597617|NCT07019207|BEHAVIORAL|Proprioceptive Neuromuscular Facilitation|The patients in the group will be applied only the resistance band strengthening methods including the upper extremity proprioceptive neuromuscular facilitation (PNF) patterns and methods applied as standard in rehabilitation. Strengthening will be worked on in all upper extremity PNF patterns using the resistance band with the PNF methods of hold-relax, rhythmic stabilization and repetitive stretching.
214597618|NCT07017751|OTHER|Heart failure medication|intervention group will receive 45 minutes online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. Two weeks, one month, and two months after the initial education, participants will be contacted to obtain feedback on their post-education dietary behaviours, medication compliance, and symptoms.
214597619|NCT07021131|PROCEDURE|new type of peripheral block Serratus Posterior Plane Block|Intervention will be Serratus Posterior Plane Block.
214597620|NCT07019480|PROCEDURE|implant insertion|"Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden).~The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol)."
214597621|NCT07019662|DEVICE|Decannulation with a medical device|Wound Closure with a medical device
214597622|NCT07019662|PROCEDURE|Decannulation using surgical removal or manual compression|Wound closure using surgical removal or manual compression
214597623|NCT07020624|OTHER|SAPB|Ultrasound guided serratus anterior plane block will be performed.
214597624|NCT07020624|OTHER|SPSIPB|Ultrasound guided serratus posterior superior intercostal plane block will be performed.
214597625|NCT07018921|DIETARY_SUPPLEMENT|rebaudioside A|rebaudioside A encapsulated in a vegetarian capsule
214597626|NCT07018921|DIETARY_SUPPLEMENT|Placebo|carboxymethylcellulose encapsulated in a vegetarian capsule
214597627|NCT07020403|BEHAVIORAL|Mindfulness-Based Emotional Eating Reduction Program (MB-EER)|The MB-EER program was delivered to participants in the intervention arm over 7 weeks. Each session lasted 2 hours and was conducted weekly via Zoom. Participants attended in small groups, and sessions were led by trained facilitators. The intervention focused on guided mindfulness practices, mindful eating exercises, and group discussions.
214597628|NCT04740528|DIAGNOSTIC_TEST|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
214597629|NCT06096389|OTHER|100 Drop Jumps|100 drop jumps from 60 cm height. Divided into 5 sets of 20 reps
214597630|NCT06096389|DIETARY_SUPPLEMENT|Whey supplementation|Consume whey protein isolate based on subjects' daily protein intake
214597631|NCT06096389|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Consume carbohydrate (isocaloric to whey)
214597632|NCT06096389|DIETARY_SUPPLEMENT|House cricket supplementation|Consume defatted house cricket powder based on subjects' daily protein intake
214597633|NCT06686693|DRUG|Injectafer|Injectafer - 15 mg/kg up to 1000 mg
214597634|NCT06686693|OTHER|Placebo|Placebo
214597635|NCT03187210|DRUG|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
214597636|NCT03187210|DRUG|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
214597637|NCT07020286|PROCEDURE|Structural heart interventions|The study allows us to understand the trend of transcatheter interventions in structural heart disease, clinical outcomes and allows the comparison of the outcomes of structural heart interventions to medical therapy and surgery at PWH, and to HA hospitals.
214597638|NCT07019519|OTHER|Saline/Placebo|NaCl(9mg/ml)
214597639|NCT07019519|OTHER|GIPR antagonist|GIP(3-30)NH2
214597640|NCT07019519|OTHER|GLP-1R antagonist|GLP-1(9-39)NH2
214597641|NCT07019519|OTHER|CCK agonist|CCK-8
214597642|NCT07020169|PROCEDURE|an AI-based real-time image-guided kidney model system|Use the AI-model to locate kidney and tumour, assisting surgeon with the operation
214597643|NCT06452186|DEVICE|direct EMG controlled prosthetic ankle|Patients are trained to use the powered prosthetic ankles
214597644|NCT06452186|BEHAVIORAL|PT guided prosthetic training|Amputees are trained to use prosthetic ankles
214597645|NCT07019298|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling.
214597646|NCT07019298|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
214597647|NCT07019298|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
214597648|NCT07019298|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability.
214597649|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
214597650|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
214597651|NCT04600791|DEVICE|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
214597652|NCT03516461|PROCEDURE|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
214722105|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
214722106|NCT03320486|DRUG|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
214597653|NCT06713811|OTHER|Telemonitoring|Cureety is a digital telemonitoring platform specially designed to monitor cancer patients through self-reporting of adverse events. It supports patients and medical teams to complement existing care practices.
214597654|NCT05414032|BIOLOGICAL|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
214597655|NCT04730882|DIETARY_SUPPLEMENT|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
214597656|NCT06526832|BIOLOGICAL|BST02|BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.
214722107|NCT03320486|DRUG|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
214597657|NCT03024853|BEHAVIORAL|BPS PAST|
214597658|NCT03024853|BEHAVIORAL|BPS PRESENT|
214597659|NCT03024853|BEHAVIORAL|BPS FUTURE|
214597660|NCT03024853|BEHAVIORAL|CONTROL|
214597661|NCT06334302|OTHER|"Omega Galil Hazelnut Chocolate Spread O'Sweet Spread"|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
214597662|NCT06334302|OTHER|Active Control-Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
214597663|NCT02112487|DRUG|Macitentan|10 mg once daily
214597664|NCT06734130|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) analog|The choice of the standard of care LHRH analog will be at the discretion of the treating physician.
214597665|NCT06734130|DRUG|Androgen Receptor Signal Inhibitor (ARSI)|The choice of the standard of care ARSI will be at the discretion of the treating physician.
214597666|NCT06734130|DRUG|Docetaxel|Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.
214634512|NCT03979092|BEHAVIORAL|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
214597667|NCT06733792|BEHAVIORAL|CBT-based intervention|"* 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use).~* 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use).~* 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use).~* 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan."
214597668|NCT06733792|BEHAVIORAL|Self-help guide|Psychoeducation on cannabis.
214597669|NCT06895005|DEVICE|Transcutaneous auricular vagus nerve stimulation + rehabilitation therapy|Transcutaneous auricular vagus nerve stimulation using INPULSE 3 times a week for six consecutive weeks. The stimulation parameters will be a frequency of 30Hz with a pulse width of 300 us and a stimulation time of 1.5 seconds for each respiratory cycle. The electrical current will be gradually increased to a maximum of 5 mA (0.25-mA increments) to allow adaptation to the stimulation until a comfortable tolerance level is achieved. Patients will receive physical rehabilitation therapy during stimulation, which will include reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
214597670|NCT06895005|OTHER|sham stimulation + rehabilitation therapy|Patients will receive physical rehabilitation therapy during placebo stimulation (No electrical stimulation), including reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
214597671|NCT06902064|DEVICE|Transcranial temporal interference stimulation|Transcranial temporal interference stimulation (tTIS) is a novel neurostimulation technique that utilizes two or more electric fields of specific frequencies to modulate the oscillations of neurons at the desired spatial location in the brain. The physics of tTIS offers the advantage of non-invasively regulating deep brain structures and minimally stimulating the overlying cortex outside the selected target.
214597672|NCT06902064|DEVICE|sham tTIS|"The sham tTIS is enabled by checking the Pseudo-Stimulation option on the screen. After the rising phase, the current will drop directly to 0mA, imitating the sensation of a real stimulation."
214597673|NCT06903143|BEHAVIORAL|Screening, brief intervention, and referral to treatment (SBIRT)|The intervention will consist of a 30 minute alcohol brief intervention based on CETA' substance use reduction element; if warranted, referral will be made for the full CETA intervention, which consists of 6-12 weekly cognitive behavioral therapy-based sessions.
214597674|NCT05671419|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
214597675|NCT03882229|DEVICE|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
214597676|NCT06146621|BEHAVIORAL|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
214634513|NCT03979092|BEHAVIORAL|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
214634514|NCT01898065|DRUG|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
214634515|NCT00825565|DRUG|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
214597677|NCT06146621|BEHAVIORAL|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
214597678|NCT06146621|BEHAVIORAL|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
214597679|NCT06146621|BEHAVIORAL|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
214597680|NCT06120881|DRUG|Metformin|Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
214597681|NCT03470675|DRUG|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
214597682|NCT03470675|DRUG|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
214597683|NCT03470675|DRUG|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
214597684|NCT05798403|DEVICE|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
214597685|NCT05798403|DRUG|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
214597686|NCT05668338|DEVICE|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
214597687|NCT04354246|DRUG|Dose escalation: COM902 monotherapy.|COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
214597688|NCT04354246|COMBINATION_PRODUCT|Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)|Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
214597689|NCT04354246|DRUG|Cohort expansion: COM902 (RDFE) monotherapy.|COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
214597690|NCT04354246|DRUG|Cohort expansion: COM902 in combination with COM701 (both at the RDFE).|COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
214597691|NCT04354246|COMBINATION_PRODUCT|Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.|Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
214597692|NCT04596384|OTHER|Best Practice|Participate in a surgeon-only perioperative care program
214597693|NCT04596384|PROCEDURE|Functional Assessment|Complete a functional assessment
214597694|NCT04596384|OTHER|Medical Device Usage and Evaluation|Wear an actigraph
214597695|NCT04596384|PROCEDURE|Nutritional Assessment|Complete a nutritional assessment
214597696|NCT04596384|OTHER|Quality-of-Life Assessment|Ancillary studies
214597697|NCT04596384|OTHER|Questionnaire Administration|Ancillary studies
214597698|NCT04596384|OTHER|TapCloud|Use TapCloud app
214597699|NCT05684068|PROCEDURE|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
214597700|NCT05684068|PROCEDURE|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
214597701|NCT04751656|BEHAVIORAL|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
214597702|NCT04694508|DEVICE|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
214634516|NCT02188316|DEVICE|Jumbo forceps|comparison of different polypectomy devices
214634517|NCT02188316|DEVICE|Hot biopsy forceps|comparison of different polypectomy devices
214634518|NCT01992783|DIETARY_SUPPLEMENT|Hi-maize resistant starch|13.5 g/day
214634519|NCT01992783|DIETARY_SUPPLEMENT|Maltodextrin|13.5 g/day
214634520|NCT02750163|DRUG|paracetamol|Paracetamol will be given to febrile septic patients
214597703|NCT04631627|DRUG|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
214597704|NCT05280951|OTHER|Focused-PPC Care|Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
214597705|NCT05280951|OTHER|Usual Care|Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
214597706|NCT01062048|DRUG|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
214597707|NCT01062048|DRUG|Sulfonylurea|Sulfonylurea administered in general use according to the local label
214597708|NCT01062048|BIOLOGICAL|Insulin|Insulin administered in general use according to the local label
214597709|NCT00955487|DRUG|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
214597710|NCT00955487|DRUG|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
214597711|NCT03786250|PROCEDURE|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
214597712|NCT04699734|DIAGNOSTIC_TEST|Xylocaine 1%|Nerve block
214597713|NCT04699734|DIAGNOSTIC_TEST|NaCl 9mg/ml|Nerve block
214597714|NCT02445196|BEHAVIORAL|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
214597715|NCT02445196|DEVICE|Smartphone|All participants must have a smartphone, either apple or android.
214597716|NCT05765006|BIOLOGICAL|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
214597717|NCT03874325|DRUG|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
214597718|NCT03874325|DRUG|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
214597719|NCT03874325|DRUG|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
214597720|NCT03874325|DRUG|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
214597721|NCT03930147|PROCEDURE|ASV ventilation|Ventilation on ASV mode
214597722|NCT05149183|OTHER|cervical stability training|cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
214597723|NCT05149183|OTHER|traditional treatment|TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
214597724|NCT04968197|DEVICE|Vestibular Intervention via Portable Electrical Stimulator (VIPES) system|A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
214597725|NCT00234507|BIOLOGICAL|Botulinum toxin type A|
214597726|NCT01733342|DEVICE|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
214597727|NCT01733342|PROCEDURE|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
214597728|NCT01733342|DEVICE|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
214597729|NCT04586595|OTHER|REVISiT intervention|REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
214597730|NCT03873766|DRUG|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
214597731|NCT03873766|PROCEDURE|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
214597732|NCT03873766|PROCEDURE|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
214597733|NCT03873766|PROCEDURE|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (\>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
214597734|NCT03873766|RADIATION|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
214597735|NCT03873766|OTHER|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
214597736|NCT03873766|RADIATION|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
214597737|NCT03873766|BEHAVIORAL|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
214597738|NCT06617494|OTHER|Pain modulation testing|During the visit, noxious heat stimuli will be applied bilaterally to the face and distant body sites as part of conditioned pain modulation (CPM) testing. The test stimuli will be individually tailored to be moderately painful, while the conditioning stimulus will vary in intensity: moderately painful, non-painful, and sham heat. Participants will also record daily TMD pain intensity ratings for seven days before and after the visit.
214597739|NCT01805596|DRUG|clopidogrel|
214597740|NCT01805596|DRUG|Ticagrelor|
214597741|NCT05048953|DIAGNOSTIC_TEST|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~1. Muscle thickness~2. Muscle echogenicity~3. Muscle fasciculations"
214597742|NCT03985475|OTHER|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
214597743|NCT02877563|OTHER|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
214597744|NCT01128361|BEHAVIORAL|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
214597745|NCT01128361|BEHAVIORAL|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
214597746|NCT00626704|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
214597747|NCT00626704|OTHER|Placebo|Inactive dummy AMG 655 (to maintain blind)
214597748|NCT00626704|DRUG|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
214597749|NCT00910351|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
214597750|NCT05933330|OTHER|Brain MRI|All included patients receive an MRI of the brain
214597751|NCT04703478|OTHER|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
214597752|NCT03509233|OTHER|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
214597753|NCT03509233|OTHER|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
214597754|NCT03509233|OTHER|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
214597755|NCT03509233|OTHER|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
214597756|NCT03903874|BEHAVIORAL|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
214597757|NCT03513510|BEHAVIORAL|iChoose|
214597758|NCT03840850|OTHER|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
214597759|NCT04556643|OTHER|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
214597760|NCT01257789|PROCEDURE|laparoscopic gastric bypass|laparoscopic gastric bypass
214597761|NCT00146328|DRUG|Tipranavir|
214597762|NCT01256658|DRUG|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
214597763|NCT00300781|DRUG|neratinib|
214597764|NCT00841893|DIETARY_SUPPLEMENT|Mustard (dijon)|The specific spice added to a brunch meal
214597765|NCT00841893|DIETARY_SUPPLEMENT|Placebo|Placebo added to a brunch meal
214597766|NCT05898386|BEHAVIORAL|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
214597767|NCT05813717|DRUG|BMS-986325|Specified dose on specified days
214597768|NCT05813717|DRUG|Placebo|Specified dose on specified days
214597769|NCT00470210|DRUG|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
214597770|NCT00470210|DRUG|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
214597771|NCT00470210|DRUG|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
214597772|NCT03533621|DIETARY_SUPPLEMENT|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
214597773|NCT03533621|DIETARY_SUPPLEMENT|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
214597774|NCT02715167|DRUG|Budesonide novolizer|
214597775|NCT02715167|DRUG|Placebo|
214597776|NCT02882919|BEHAVIORAL|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
214597777|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
214597778|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
214597779|NCT00122928|BEHAVIORAL|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
214597780|NCT00122928|BEHAVIORAL|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
214597781|NCT00122928|BEHAVIORAL|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
214597782|NCT05202717|DEVICE|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
214597783|NCT05202717|DEVICE|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
214597784|NCT00529724|BEHAVIORAL|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
214597785|NCT05898893|DEVICE|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
214597786|NCT02823756|PROCEDURE|Physical Therapy|Exercise, education, spinal manipulation
214597787|NCT02410941|BEHAVIORAL|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
214597788|NCT05039398|BEHAVIORAL|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
214597789|NCT05039398|BEHAVIORAL|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
214597790|NCT05039398|BEHAVIORAL|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
214597791|NCT02702622|OTHER|Provitamin A-biofortified transgenic bananas|
214597792|NCT03970551|OTHER|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
214597793|NCT03970551|OTHER|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
214597794|NCT03970551|OTHER|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
214597795|NCT00732628|DEVICE|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
214597796|NCT02328287|DRUG|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
214597797|NCT02693613|DRUG|ASP1517|Oral
214597798|NCT02693613|DRUG|Kremezin®|Oral
214597799|NCT04100395|DEVICE|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
214597800|NCT01351012|OTHER|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
214597801|NCT01351012|OTHER|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
214597802|NCT01351012|OTHER|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
214597803|NCT01351012|OTHER|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
214597804|NCT01351012|OTHER|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
214597805|NCT01123954|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
214597806|NCT05055986|DEVICE|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
214597807|NCT02072434|DRUG|Edoxaban|Edoxaban 30 mg tablets for oral administration
214597808|NCT02072434|DRUG|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
214597809|NCT02072434|DRUG|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
214597810|NCT04058379|RADIATION|CT scan|3 ct scans : D0, D1 and D3
214597811|NCT01320267|PROCEDURE|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
214597812|NCT02964637|OTHER|Observational Study|
214597813|NCT05279703|DRUG|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
214597814|NCT05279703|DRUG|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
214597815|NCT05279703|DRUG|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
214597816|NCT00619190|DRUG|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
214597817|NCT02217943|PROCEDURE|Roux-en-Y gastric bypass|
214597818|NCT02217943|PROCEDURE|Sleeve gastrectomy|
214597819|NCT04544345|DEVICE|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
214597820|NCT04544345|DEVICE|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
214597821|NCT04010513|BEHAVIORAL|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
214597822|NCT04010513|OTHER|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
214597823|NCT00120913|DRUG|Birth control pills|
214597824|NCT00149422|DEVICE|NT-proBNP measurements|
214597825|NCT05555511|OTHER|Control Group|Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
214597826|NCT04586517|OTHER|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
214597827|NCT04586517|OTHER|Control|Activity as usual during chemotherapy
214597828|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
214597829|NCT00253487|DRUG|O6-benzylguanine|
214597830|NCT00253487|DRUG|busulfan|
214597831|NCT00253487|DRUG|temozolomide|
214597832|NCT00253487|PROCEDURE|adjuvant therapy|
214597833|NCT00253487|PROCEDURE|autologous bone marrow transplantation|
214597834|NCT00253487|PROCEDURE|conventional surgery|
214597835|NCT00253487|PROCEDURE|peripheral blood stem cell transplantation|
214597836|NCT00253487|RADIATION|radiation therapy|
214597837|NCT03711890|PROCEDURE|Optical Coherence Tomography|Undergo OCT
214597838|NCT03711890|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection will be undertaken
214597839|NCT03711890|DIAGNOSTIC_TEST|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
214597840|NCT05717426|OTHER|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
214597841|NCT05717426|OTHER|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
214597842|NCT02589717|DRUG|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
214597843|NCT04469166|PROCEDURE|tourniquet|Use of tourniquet
214597844|NCT04469166|PROCEDURE|No tourniquet|No use of tourniquet
214597845|NCT05397353|OTHER|Sleepio (TM)|Sleepio is a mobile Digital Cognitive Behavior Therapy for Insomnia (dCBT-I) app.
214597846|NCT00594529|PROCEDURE|Surgery|Liver resection for metastatic liver lesions
214597847|NCT04841551|DRUG|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
214597848|NCT02656498|DRUG|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
214597849|NCT02525861|BIOLOGICAL|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
214597850|NCT00438321|DRUG|Zoladex|
214597851|NCT00438321|DRUG|Testosterone gel|
214597852|NCT00438321|DRUG|Anastrozole Pill|
214597853|NCT00438321|OTHER|Placebo|
214597854|NCT02715154|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
214597855|NCT02715154|DRUG|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
214597856|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
214597857|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
214597858|NCT01117454|DRUG|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
214597859|NCT01117454|DRUG|Placebo|placebo, similar in appearance to flecainide
214597860|NCT01117454|DRUG|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
214597861|NCT06018272|BEHAVIORAL|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
214597862|NCT06018272|BEHAVIORAL|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (\>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
214597863|NCT06326957|OTHER|SELF-BREATHE|SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
214597864|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CBF|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
214597865|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CSP|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
214597866|NCT06459323|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214597867|NCT04276766|OTHER|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
214597868|NCT00888433|DEVICE|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
214597869|NCT06287723|BIOLOGICAL|Blood sample/Liquid biopsy|ctDNA analysis
214597870|NCT06046911|OTHER|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
214597871|NCT06046911|OTHER|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
214597872|NCT06196983|OTHER|Rhythmic aerobic exercises|The experimental group's pattern of functional movements includes both right and left foot movements. To improve muscle strength and the capacity to maintain balance, exercises including running in place, side steps, walking while eating, and turning in place can also be used. The rhythmic aerobic group linked their motions to the rhythmic auditory stimuli in order to perform in a rhythmic manner.
214597873|NCT06196983|OTHER|Control group, strength and balance exercises|The control group engaged in strength and balance exercises where they stood with weight on one leg and raised the other leg to the side or back. In a tandem stance, place your foot heel directly in front of your toe. Get out of a chair, then take a seat without using your hands.
214597874|NCT01500850|DRUG|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
214597875|NCT01500850|DRUG|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
214597876|NCT01500850|DRUG|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
214597877|NCT01500850|DRUG|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
214597878|NCT02817230|DRUG|Statin|
214597879|NCT04426955|DRUG|Camrelizumab|IV infusion
214597880|NCT04426955|DRUG|Paclitaxel|IV infusion
214597881|NCT04426955|DRUG|Cisplatin|IV infusion
214597882|NCT04426955|DRUG|Placebo|IV infusion
214597883|NCT04426955|RADIATION|Radiation|Concurrent Radiation
214597884|NCT01726452|DRUG|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
214597885|NCT01726452|DRUG|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
214597886|NCT01726452|DRUG|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
214597887|NCT01726452|RADIATION|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
214597888|NCT01726452|DRUG|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
214597889|NCT01726452|DRUG|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
214597890|NCT01726452|DRUG|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
214597891|NCT01726452|DRUG|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
214597892|NCT01726452|DRUG|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
214597893|NCT01726452|DRUG|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
214597894|NCT01681628|BEHAVIORAL|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
214597895|NCT00375557|DRUG|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
214597896|NCT00375557|DRUG|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
214597897|NCT05629195|DEVICE|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
214597898|NCT03904745|DRUG|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
214597899|NCT02762825|BEHAVIORAL|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
214597900|NCT02762825|BEHAVIORAL|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
214597901|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
214597902|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
214597903|NCT02794454|OTHER|HeezOn Ultra-1|
214597904|NCT02794454|OTHER|HeezOn Ultra-2|
214597905|NCT02794454|OTHER|Placebo|
214597906|NCT01096888|BEHAVIORAL|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
214597907|NCT00227565|DRUG|carboplatin|
214597908|NCT00227565|DRUG|pemetrexed disodium|
214597909|NCT00227565|RADIATION|radiation|
214597910|NCT06211192|OTHER|retrospective data collection|retrospective data collecting from medical records
214597911|NCT05809310|PROCEDURE|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
214597912|NCT01621997|BEHAVIORAL|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
214597913|NCT03786159|OTHER|No intervention|No intervention
214597914|NCT02679950|GENETIC|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
214597915|NCT01794520|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
214597916|NCT01794520|DRUG|Dexamethasone|Tablets were administered by mouth per the dexamethasone prescribing information.
214597917|NCT04155268|BEHAVIORAL|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
214597918|NCT04155268|BEHAVIORAL|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
214597919|NCT02212873|OTHER|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
214597920|NCT04214314|BEHAVIORAL|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
214597921|NCT01768897|DRUG|CPI-613|Given IV
214597922|NCT01768897|DRUG|cytarabine|Given IV
214597923|NCT01768897|DRUG|mitoxantrone hydrochloride|Given IV
214597924|NCT01768897|OTHER|laboratory biomarker analysis|Optional correlative studies
214597925|NCT01768897|OTHER|pharmacological study|Correlative studies
214597926|NCT01468220|OTHER|Endurance training|Endurance training three times per week over six weeks
214597927|NCT06241742|DRUG|HT-6184|Single, oral dose of HT-6184
214597928|NCT06241742|DRUG|HT-6184 Placebo|Single, oral dose of placebo
214597929|NCT00962156|DRUG|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
214597930|NCT00962156|DRUG|Ringers acetate|Infusion for volume expansion in the ICU
214597931|NCT03459599|DRUG|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
214597932|NCT03459599|OTHER|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
214597933|NCT05038462|DIETARY_SUPPLEMENT|Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
214597934|NCT05038462|OTHER|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
214597935|NCT01474798|DRUG|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
214597936|NCT06010498|BEHAVIORAL|eye mask|"* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
214597937|NCT06010498|BEHAVIORAL|standart care|"Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
214597938|NCT00495404|BEHAVIORAL|Physician Treatment Guidelines|
214597939|NCT04500808|DRUG|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
214597940|NCT04500808|DRUG|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
214597941|NCT04500808|DRUG|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
214597942|NCT04500808|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
214597943|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
214597944|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
214597945|NCT03312348|DEVICE|Infrared imaging|Infrared image image acquisition of study participants
214597946|NCT03382184|DEVICE|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
214597947|NCT03382184|DEVICE|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
214597948|NCT00108186|DRUG|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
214597949|NCT04516707|OTHER|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
214597950|NCT04796896|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214597951|NCT04796896|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214597952|NCT04796896|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214597953|NCT03613116|DIETARY_SUPPLEMENT|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
214597954|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
214597955|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
214597956|NCT01612741|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
214597957|NCT05104008|OTHER|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
214597958|NCT05104008|OTHER|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
214597959|NCT02029820|DEVICE|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
214597960|NCT05968287|DIAGNOSTIC_TEST|The Leukocyte ImmunoTest™ (LIT™)|The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
214597961|NCT06079489|OTHER|Brochure-Based Exercise Program|Simple posture exercises
214597962|NCT06079489|OTHER|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
214597963|NCT05737966|OTHER|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
214597964|NCT05577078|PROCEDURE|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
214597965|NCT06348940|BEHAVIORAL|behavioral activation|Behavioral activation, an emerging psychological intervention approach, has potential in alleviating negative emotions among cancer patients. The intervention group underwent an eight-week behavioral activation program designed to promote engagement in meaningful activities that are physically and emotionally rewarding while reducing involvement in maladaptive emotional cycles.
214597966|NCT02300051|BEHAVIORAL|STPGP and RPGT|
214597967|NCT02300051|DRUG|TAU|
214597968|NCT00690625|DRUG|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
214597969|NCT00690625|DRUG|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
214597970|NCT04726462|OTHER|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
214597971|NCT04726462|OTHER|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
214597972|NCT00701207|DRUG|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
214597973|NCT03696615|OTHER|Tabata Kettlebell Swing Workout|See description of experimental arm.
214597974|NCT03696615|OTHER|Control|see description of control arm
214597975|NCT00538304|DRUG|bimatoprost eye drops|1 drop in each eye daily for 1 month
214597976|NCT00538304|DRUG|placebo|1 drop in each eye daily for 1 month
214597977|NCT00960960|DRUG|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
214597978|NCT00960960|DRUG|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
214597979|NCT00960960|DRUG|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
214597980|NCT00960960|DRUG|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
214597981|NCT00960960|DRUG|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
214597982|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
214597983|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
214597984|NCT02698969|DRUG|Sugammadex|
214597985|NCT02698969|DEVICE|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
214597986|NCT02698969|DRUG|Neostigmine|
214597987|NCT02698969|DRUG|Atropine|
214597988|NCT02698969|DEVICE|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
214597989|NCT02698969|DRUG|Rocuronium|Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
214597990|NCT02698969|DRUG|Fentanyl|Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
214597991|NCT02698969|DRUG|Propofol|Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia
214597992|NCT02698969|DRUG|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
214597993|NCT00969878|DRUG|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
214597994|NCT00969878|OTHER|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
214597995|NCT05561829|BEHAVIORAL|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
214597996|NCT05561829|BEHAVIORAL|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
214597997|NCT05561829|BEHAVIORAL|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
214597998|NCT05561829|BEHAVIORAL|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
214597999|NCT05561829|BEHAVIORAL|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
214598000|NCT04316208|PROCEDURE|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
214598001|NCT05178550|DRUG|Heparin|intravenous \[iv\] injection
214598002|NCT02175004|DRUG|Inotersen|Inotersen SC
214598003|NCT05937139|OTHER|Breastfeeding education|Breastfeeding education will be given to fathers.
214598004|NCT00498134|DRUG|Triple therapy for H. pylori infection|
214598005|NCT00498134|DRUG|Cox-2 inhibitor|
214598006|NCT01383161|DRUG|Curcumin|Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
214598007|NCT01383161|OTHER|Placebo|Six capsules per day for 18 months.
214598008|NCT05147623|PROCEDURE|Any surgery/procedure|Any surgery/procedure in all adult patients that were performed in an operating room
214598009|NCT05873946|DIAGNOSTIC_TEST|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
214598010|NCT00710827|DRUG|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
214598011|NCT00710827|DRUG|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
214598012|NCT04852263|OTHER|Group I|Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
214598013|NCT04852263|OTHER|Group II (NPA group)|Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
214598014|NCT01736085|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
214598015|NCT01736085|BEHAVIORAL|Voucher|"Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
214598016|NCT01736085|DRUG|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
214598017|NCT05903872|OTHER|aromatherapy massage|aromatherapy massage was applied using essential oils
214598018|NCT05903872|OTHER|back massage|back massage was applied using only almond oil
214598019|NCT03080688|DEVICE|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
214598020|NCT04377828|DEVICE|Pigment laser|one to two session of pigment laser (532 nm)
214598021|NCT03942406|COMBINATION_PRODUCT|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
214598022|NCT04910321|OTHER|diet, physical activities, sleep|lifestyle factors
214598023|NCT05964803|DIAGNOSTIC_TEST|Questionnaires|MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
214598024|NCT06146023|DEVICE|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
214598025|NCT06146023|PROCEDURE|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
214598026|NCT03509896|OTHER|Non-Interventional|Non-Interventional
214598027|NCT05297617|DRUG|Anti-aromatase inhibitor|"Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily"
214598028|NCT00819286|DEVICE|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
214598029|NCT00819286|DEVICE|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
214598030|NCT03366493|COMBINATION_PRODUCT|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
214598031|NCT03366493|OTHER|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
214598032|NCT03366493|OTHER|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
214598033|NCT03366493|PROCEDURE|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
214598034|NCT03366493|PROCEDURE|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
214598035|NCT03366493|PROCEDURE|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
214598036|NCT03945006|OTHER|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
214598037|NCT03945006|OTHER|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
214598038|NCT03945006|OTHER|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
214598039|NCT03945006|OTHER|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
214598040|NCT00216203|DRUG|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
214598041|NCT00216203|DRUG|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
214598042|NCT01290705|BEHAVIORAL|High exercise therapy|
214598043|NCT01290705|BEHAVIORAL|Low exercise therapy|
214598044|NCT06560996|OTHER|Very low calorie diet with low protein content (VLCD-LP group)|Very low calorie diet (850 kcals per day) with low protein content (10%)
214598045|NCT06560996|OTHER|Very low calorie diet with high protein content (VLCD-HP group)|Very low calorie diet (850 kcals per day) with high protein content (30%)
214598046|NCT06568068|BEHAVIORAL|training|"The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days"
214598047|NCT06428487|DRUG|Prolgolimab|Prolgolimab infusions 1 mg/kg
214598048|NCT06321289|BIOLOGICAL|Allogeneic CD19-STAR T cell|Phase 1 dose escalation (3+3): dose 1 (2×10\^6 cells/kg), dose 2 (6×10\^6 cells/kg), dose 3 (1.8×10\^7 cells/kg); Phase 2: dose of RP2D. No more than 5 × 10\^4 per kilogram of allogenic residual TCR-positive T cells harbouring in grafts can only be released for recipient infusion.
214598049|NCT06321289|DRUG|Fludarabine|Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.
214598050|NCT06321289|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
214598051|NCT06120582|GENETIC|ANB-002, dose 1|Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
214598052|NCT06120582|GENETIC|ANB-002, dose 2|Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
214598053|NCT06120582|GENETIC|ANB-002, dose 3|Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.
214598054|NCT06296875|DIETARY_SUPPLEMENT|Vegetable oil|mixed vegetable oil
214598055|NCT06296875|DIETARY_SUPPLEMENT|Krill oil|Krill oil
214598056|NCT00105950|DRUG|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
214598057|NCT04633707|DEVICE|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.
214598058|NCT04633707|DEVICE|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
214598059|NCT04633707|DEVICE|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
214598060|NCT05731050|DRUG|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
214598061|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
214598062|NCT06138132|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
214598063|NCT06138132|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
214598064|NCT04263909|DRUG|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
214598065|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
214598066|NCT04477330|OTHER|Transcranial direct current stimulation (tDCS)|1 mA tDCS
214598067|NCT04477330|OTHER|Ankle motor training|Visuomotor target tracking task
214598068|NCT04477330|BEHAVIORAL|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
214598069|NCT06555198|BEHAVIORAL|Foot(at)Work intervention|Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
214598070|NCT04562987|BEHAVIORAL|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
214598071|NCT04562987|BEHAVIORAL|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
214598072|NCT04532424|DEVICE|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
214598073|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
214598074|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
214598075|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
214598076|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
214598077|NCT05173597|DRUG|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
214598078|NCT06506565|DRUG|Ketamine|Infusion during wound care
214598079|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
214598080|NCT06300957|OTHER|Help Wanted Prevention Intervention|"The intervention includes an introductory welcome place, five training sessions that deliver core intervention content, and a resources page that provides links to external sources of support.~The Help Wanted Prevention Intervention is a free, online, self-help course to address the needs of people with a sexual attraction to children. Help Wanted aims to provide knowledge, skills, and resources to support help-seekers' commitments to living safe, healthy, and fulfilling lives."
214598081|NCT06300957|OTHER|Waitlist Control|Participants will be provided with information on how to access alternative resources and help lines to support mental health, suicide prevention, and child sexual abuse prevention. After one month, they will be granted access to Help Wanted.
214598082|NCT06801886|DRUG|Silymarine supplementation|900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.
214598083|NCT06801886|OTHER|Placebo Supplementation|Placebo supplementation during the early post-transplant period (30 days) under standard treatment
214598084|NCT06084494|DIAGNOSTIC_TEST|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
214598085|NCT06268990|PROCEDURE|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
214598086|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
214598087|NCT04380649|DEVICE|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
214598088|NCT04288778|DRUG|Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
214598089|NCT03945747|DIAGNOSTIC_TEST|Blood draw|Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.
214598090|NCT03945747|DIAGNOSTIC_TEST|Urine sample collection|Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.
214598091|NCT03945747|DIAGNOSTIC_TEST|DXA scan|Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.
214598092|NCT03963687|OTHER|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
214598093|NCT03963687|OTHER|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
214598094|NCT05482152|BEHAVIORAL|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
214598095|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
214598096|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
214598097|NCT02860663|DIETARY_SUPPLEMENT|25OHD|10 ug/d of vitamin D3 for 6 weeks
214598098|NCT00587353|OTHER|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
214598099|NCT02691260|BEHAVIORAL|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
214598100|NCT02691260|BEHAVIORAL|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
214598101|NCT02691260|BEHAVIORAL|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
214598102|NCT03118674|DRUG|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
214598103|NCT05023343|DRUG|Ropivacaine|30 mL Ropivacaine 0,75% administered as a unilateral TQL block
214598104|NCT05023343|OTHER|Quadriceps muscle strength|Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after
214598105|NCT05023343|OTHER|Timed Up and Go|To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after
214598106|NCT05023343|OTHER|Single-leg 6 meter timed hop test|To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after
214598107|NCT05023343|OTHER|Temperature discrimination|Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration
214598108|NCT05023343|OTHER|Pinprick test|"Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.~Approximately 60 minutes after block administration"
214598109|NCT05023343|DIAGNOSTIC_TEST|Blood samples|As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration
214598110|NCT05023343|DIAGNOSTIC_TEST|Non-invasive blood pressure measurement|Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration
214598111|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
214598112|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
214598113|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
214598114|NCT06320613|OTHER|Acupuncture therapy|After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.
214598115|NCT06320613|OTHER|Ginger Acupuncture Point Patch|Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.
214598116|NCT04910646|DRUG|orange peel fermentation|To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
214598117|NCT04910646|DRUG|Placebo|Placebo without orange peel fermentation
214598118|NCT03153137|DRUG|Macitentan 10 mg|film-coated tablet; oral use
214598119|NCT03153137|DRUG|Placebo|film-coated tablet; oral use
214598120|NCT04921007|PROCEDURE|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
214598121|NCT04921007|PROCEDURE|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
214598122|NCT04921007|DRUG|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
214598123|NCT05197023|DRUG|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
214598124|NCT00400309|BIOLOGICAL|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
214598125|NCT00400309|BIOLOGICAL|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
214598126|NCT05151848|DRUG|Adalimumab Injection|Adalimumab Injection injected subcutaneously every other week for 78 weeks
214598127|NCT05151848|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 78 weeks
214598128|NCT00309868|DRUG|neseritide|
214598129|NCT01688583|DRUG|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
214598130|NCT01522157|DIETARY_SUPPLEMENT|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
214598131|NCT01522157|DIETARY_SUPPLEMENT|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
214598132|NCT01522157|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
214598133|NCT01956656|DRUG|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
214598134|NCT03909204|PROCEDURE|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
214598135|NCT04209621|DRUG|Duvelisib|twice daily as tolerated until disease progression
214598136|NCT04209621|DRUG|Ibrutinib|daily for the first six 28-day cycles
214598137|NCT05851274|PROCEDURE|transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm
214598138|NCT05851274|PROCEDURE|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
214598139|NCT04664010|DRUG|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
214598140|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
214598141|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
214598142|NCT02249767|DRUG|Tretinoin|Treatment of acne once daily in evening
214598143|NCT06494917|OTHER|pelvic floor exercises|First arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied.
214598144|NCT06494917|OTHER|Pelvic floor exercises and manual therapy techniques|Second arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied. In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods such as momentum minus mobilisation, sphincter opening, colon massage, global fascia manipulation, trigger point and myofascial release will be applied.
214598145|NCT01372410|DRUG|GSK573719|125 mcg once daily
214598146|NCT01372410|DRUG|GSK573719|62.5 mcg once daily
214598147|NCT01372410|DRUG|GSK573719|31.25 mcg once daily
214711098|NCT07091045|OTHER|Conventional Foot-Ankle Training|Stage 1: Sensory Training to the Sole of the Foot: In the first step of the training, the physiotherapist will manually apply constant pressure with a blunt object, and in the second step, sensory localization training with a blunt object will be performed. Stage 2: Passive Joint Range of Motion Training: The ankle will be manually moved passively (passive stretching) by the physiotherapist. Stage 3: Joint Position Sense Training: The physiotherapist will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the physiotherapist initially brought. Stage 4: Active Joint Range of Motion Training: This stage will be performed with manual assistance provided by the physiotherapist when necessary, along with active dorsiflexion. Stage 5: It is the same as Stage 1
214711099|NCT06908694|DRUG|Semaglutide Pen Injector|The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.
214711100|NCT07090603|OTHER|Knee extension exercise|Maximum repetitions of knee extension exercise at 20%, 30%, 40%, 50%, 60% and 70% of participants one rep max with and without blood flow occlusion
214711101|NCT07090590|BEHAVIORAL|Thrive Digital Peer Platform (TDPP)|The Thrive Digital Peer Platform (TDPP) is a fully asynchronous, web-based training program designed to support the professional development of Peer Recovery Support Specialists (PRSS). The platform includes 11 interactive modules structured around the Connect, Grow, Apply (CGA) learning model. Content includes peer-led stories, behavioral simulations, scenario-based learning, and formative assessments. The intervention is intended to build competencies in professionalism, communication, and application of recovery-oriented peer support principles.
214711102|NCT07090538|DRUG|Eliglustat|Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor
214598148|NCT01372410|DRUG|GSK573719|15.6 mcg once daily
214598149|NCT01372410|DRUG|GSK573719|31.25 mcg twice daily
214598150|NCT01372410|DRUG|GSK573719|15.6 mcg twice daily
214598151|NCT01372410|DRUG|Tiotropium|18 mcg once daily
214598152|NCT01372410|DRUG|Placebo|once or twice daily
214598153|NCT00187772|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|
214598154|NCT05232123|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
214711103|NCT07090473|DEVICE|transcutaneous spinal cord stimulation|Transcutaneous spinal stimulation will be delivered using the experimental ARC-EX device (ONWARD Medical), via skin surface electrodes placed over the spine (stimulating electrodes) and bilaterally on the iliac crests (reference electrodes) during the intervention.
214598155|NCT05232123|DRUG|Cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
214598156|NCT02936063|PROCEDURE|Surgical staples|Closure of surgical wound at skin level with surgical staples
214598157|NCT02936063|PROCEDURE|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
214598158|NCT04585646|DEVICE|Orion daily disposable contact lens|Subjects will be randomized to wear Orion lens for 2 weeks.
214598159|NCT04585646|DEVICE|Gemini daily disposable contact lens|Subjects will be randomized to wear Gemini lens for 2 weeks.
214598160|NCT02736136|BEHAVIORAL|joint observation and video feedback|
214598161|NCT04580797|DRUG|PF-06700841 IR|Immediate release formulation
214598162|NCT04580797|DRUG|PF-06700841 MR1|Modified release formulation 1
214598163|NCT04580797|DRUG|PF-06700841 MR2|Modified release formulation 2
214598164|NCT04580797|DRUG|PF-06700841 MR3|Modified release formulation 3
214598165|NCT04580797|OTHER|Placebo|Matching placebo
214598166|NCT02223403|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
214598167|NCT02223403|DIETARY_SUPPLEMENT|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
214598168|NCT05932004|OTHER|Reformer pilates exercise|The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
214598169|NCT06050954|DRUG|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
214711104|NCT07090473|DEVICE|sham transcutaneous spinal cord stimulation|For sham transcutaneous spinal stimulation electrodes will be placed on the skin surface over the spine and bilaterally on the iliac crests and will be attached to the experimental ARCEX device (ONWARD Medical), however no electrical current will be delivered.
214711105|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium breve and Bifidobacterium longum
214711106|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium and Lactobacillus
214711107|NCT07092111|DEVICE|Auricular acupuncture treatment|Auricular acupuncture is an innovative intradermal acupuncture, which can directly use the meridian system of the ear skin to directly transmit the received stimulation to the lesion. Its stimulation time is long, and the amount of stimulation is strong. Studies have shown that needle pricking continuously delivers an adequate dose of acupuncture stimulation by continuously stimulating Aβ, Aδ, and/or C afferent fibers from the skin and transmitting them to the brain nucleus through the ventrolateral cord of the spinal cord. It is also believed that by stimulating the cranial nerves, especially the auricular branch of the vagus nerve, the effect of sensory afferent peripheral stimulation can be enhanced, and the analgesic effect of the auricular acupoints can be achieved.
214598170|NCT06050954|DRUG|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
214598171|NCT06050954|DIAGNOSTIC_TEST|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
214598172|NCT01368809|DRUG|Saline|2 ml at induction 1-2 ml boluses as needed
214598173|NCT01368809|DRUG|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
214598174|NCT02804243|DEVICE|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
214711108|NCT07092111|DEVICE|Sham acupuncture group|The treatment regimen is the same as that of the auricular acupuncture treatment group, but with a sham acupuncture (Seirin Pyonex Needles).
214711109|NCT07090161|DRUG|iloperidone|iloperidone
214711110|NCT07090161|DRUG|Placebo|placebo comparator
214711111|NCT07090200|COMBINATION_PRODUCT|Pulmonary Rehabilitation Care Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. The Pulmonary Rehabilitation Care Group received the Pulmonary rehabilitation exercise and usual care for three months. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function of the two groups of patients one year after the intervention.
214598175|NCT01606020|OTHER|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
214598176|NCT01606020|OTHER|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
214598177|NCT00800787|BIOLOGICAL|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly"
214598178|NCT02789527|DRUG|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
214598179|NCT02789527|GENETIC|Genotyping|DNA sampling from a saliva sample
214598180|NCT03864445|DRUG|KHK7791|oral administration
214598181|NCT03864445|DRUG|Placebp|oral administration
214598182|NCT04559204|BIOLOGICAL|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
214598183|NCT04559204|BIOLOGICAL|IIV4|administrated with IIV4 only
214598184|NCT04559204|BIOLOGICAL|PPV23|administrated with PPV23 only
214598185|NCT03135171|DRUG|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
214598186|NCT03135171|DRUG|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
214598187|NCT03135171|DRUG|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
214598188|NCT05303870|OTHER|Improving access to psychological therapies (IAPT)|"IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles:~1. Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes.~2. Appropriately trained and supervised workforce.~3. Routine outcome monitoring."
214598189|NCT01115842|DRUG|Vitamin D|Vitamin D 4000IU per day for 5 days
214598190|NCT02615821|BEHAVIORAL|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
214598191|NCT04143399|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
214598192|NCT04143399|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
214598193|NCT03773198|OTHER|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
214598194|NCT03773198|OTHER|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
214598195|NCT03952494|GENETIC|Genomind®Professional PGx Express TM|The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
214598196|NCT02228655|DRUG|FMX-8|
214598197|NCT04395703|OTHER|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
214598198|NCT03841682|BEHAVIORAL|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
214598199|NCT03376607|OTHER|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
214598200|NCT03376607|BEHAVIORAL|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
214598201|NCT04496063|DRUG|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
214598202|NCT04496063|DRUG|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
214598203|NCT02807792|DEVICE|Perianal access device|Perianal access device
214598204|NCT00642382|DEVICE|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
214598205|NCT00642382|DEVICE|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
214598206|NCT03446729|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
214598207|NCT01087931|DRUG|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
214598208|NCT01087931|OTHER|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
214598209|NCT05021523|OTHER|Hot ambient conditions exposures|Participants rest or exercise for 40min to 1h daily in hot ambient conditions
214598210|NCT05021523|OTHER|Immobilization|Participants are wearing a walking boot (with crutches) for 2 weeks
214598211|NCT01067326|DRUG|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
214598212|NCT01067326|DRUG|Placebo|1 pill per day by mouth for 4 months
214598213|NCT02044211|BEHAVIORAL|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
214634521|NCT03755648|OTHER|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
214711112|NCT07090200|OTHER|The Routine Care (Non-Pharmacological and Pharmacological Treatments ) Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function one year after the intervention.
214711113|NCT07091643|BEHAVIORAL|Cognitive Behavioural Therapy|12 weeks of Cognitive Behavioural Therapy (CBT) will be administered. The first session will be accomplished in-person at Baycrest Hospital. After that, therapy will be conducted virtually, via video-conference. Individuals will undergo therapy once a week for approximately 1 hour, for 12-weeks. Following the 12-week period, individuals will receive three follow-up assessments with their therapist at 3, 6, and 9 months.
214711114|NCT02992158|BEHAVIORAL|behavioral activation|
214711115|NCT02992158|BEHAVIORAL|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
214711116|NCT06934538|BIOLOGICAL|STC-1010 + IS regimen + SOC therapy|STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)
214711117|NCT06935461|BEHAVIORAL|Families Moving Forward Bridges|Ten, 60-minute manualized FMF Bridges intervention sessions over 3-5 months (approximately every other week)
214711118|NCT05562284|PROCEDURE|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
214711119|NCT05562284|OTHER|conservative treatments|conservative treatments
214711120|NCT06388330|OTHER|low FODMAP diet|strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
214711121|NCT04622670|OTHER|Media Intervention|Receive DVD
214711122|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
214711123|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
214711124|NCT04622670|OTHER|Survey Administration|Ancillary studies
214711125|NCT04622670|PROCEDURE|Yoga|Attend yoga class
214711126|NCT06549972|OTHER|Acute Ischemic Stroke|first-ever anterior circulation AIS (Acute Ischemic Stroke)
214711127|NCT02596828|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
214598214|NCT02044211|BEHAVIORAL|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
214598215|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
214598216|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
214598217|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
214598218|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
214598219|NCT01207726|DRUG|Azacitidine|Given SC
214598220|NCT01207726|DRUG|Entinostat|Given PO
214598221|NCT01207726|OTHER|Laboratory Biomarker Analysis|Correlative studies
214598222|NCT06294522|PROCEDURE|reconstruction of alveolar cleft|after elevation of mucoperiosteal flap related to cleft side. suturing of nasal floor and palatal tissue. harvesting of autogenous graft and reconstruction of nasal floor and labial plate of cleft then suturing of flap labially without tension
214598223|NCT03851614|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
214598224|NCT03851614|DRUG|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
214634522|NCT03755648|OTHER|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
214598225|NCT03851614|DRUG|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
214598226|NCT02623881|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
214711128|NCT02596828|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
214711129|NCT02596828|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
214711130|NCT02596828|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
214711131|NCT04884945|PROCEDURE|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
214711132|NCT04884945|DEVICE|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
214711133|NCT02332798|DRUG|PF-04958242|Administered as specified in the treatment arm
214711134|NCT02332798|DRUG|Placebo|Administered as specified in the treatment arm
214711135|NCT05406440|DRUG|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
214711136|NCT05406440|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
214711137|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
214711138|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
214711139|NCT02071641|DRUG|Sunitinib|
214711140|NCT05810389|COMBINATION_PRODUCT|Fluoride|Application methods of delivery of topical fluoride
214711141|NCT02297646|BEHAVIORAL|Endurance Training|
214711142|NCT00805818|DRUG|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
214711143|NCT00805818|DRUG|Placebo|Sodium Chloride 0.9% Injection
214711144|NCT00259389|BEHAVIORAL|Directly observed therapy (DOT)|
214711145|NCT03751969|DRUG|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
214711146|NCT05223699|BIOLOGICAL|MGTA-117|MGTA-117 will be administered as an IV infusion
214711147|NCT06271239|OTHER|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
214711148|NCT06271239|OTHER|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
214598227|NCT02623881|DRUG|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
214598228|NCT01174654|BEHAVIORAL|Contingency management|A 12-week contingency management intervention
214598229|NCT00000274|DRUG|Flupenthixol|
214598230|NCT01230788|DRUG|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
214598231|NCT00295360|BEHAVIORAL|no intervention, pathophysiological study|
214598232|NCT00714597|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214598233|NCT00714597|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214598234|NCT02225496|PROCEDURE|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
214598235|NCT02225496|PROCEDURE|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
214598236|NCT02225496|BEHAVIORAL|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
214598237|NCT02092974|PROCEDURE|tDCS|
214598238|NCT02092974|DRUG|Citalopram|
214598239|NCT02092974|OTHER|sham-tDCS + placebo|
214598240|NCT02785224|DRUG|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
214598241|NCT00189566|DRUG|Paclitaxel|
214598242|NCT00189566|DRUG|Topotecan|
214598243|NCT00189566|DRUG|Carboplatin|
214598244|NCT00769860|DRUG|Arimoclomol|Arimoclomol 100 mg TID for 4 months
214598245|NCT00769860|OTHER|Placebo|Placebo for 4 months
214598246|NCT05424913|OTHER|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
214598247|NCT00969046|DRUG|EPO906 (patupilone)|
214598248|NCT01603082|DRUG|Ticagrelor|180 mg loading dose
214598249|NCT01603082|DRUG|Clopidogrel|600 mg loading dose
214598250|NCT02528565|DEVICE|Adhesix Bioring|
214598251|NCT02498496|DRUG|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
214598252|NCT02498496|DRUG|Placebo|Administration of 100 mL of Normal Saline
214598253|NCT06266819|OTHER|chewing gum|In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
214598254|NCT01522105|DRUG|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
214598255|NCT06296745|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
214598256|NCT00196872|DRUG|Epirubicine|Epirbubicne is given
214598257|NCT00196872|DRUG|Cyclophosphamide|Cyclophosphamide is given
214598258|NCT00196872|DRUG|Taxol|Taxol is given
214598259|NCT00196872|DRUG|Xeloda|Xeloda is given
214598260|NCT00196872|DRUG|Ibandronat|Ibandronat is given
214598261|NCT00852592|DEVICE|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
214598262|NCT00852592|DEVICE|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
214598263|NCT04806698|DEVICE|Menicon Z Night|Children wearing Menicon Z Night orthokeratology contact lenses
214598264|NCT04806698|DEVICE|Control|Children wearing distance single-vision glasses or distance single-vision soft contact lenses
214598265|NCT00283257|BEHAVIORAL|Patients and caregivers are taught problem solving skills|
214598266|NCT06441084|BIOLOGICAL|NCR300 injection|Subjects will receive at least 1 cycle of NCR300 injection.
214598267|NCT04854629|OTHER|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
214598268|NCT05467774|BEHAVIORAL|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
214598269|NCT01849666|DRUG|phenprocoumon|6 mg oral single dose
214598270|NCT01849666|DRUG|vemurafenib|960 mg bid orally
214634523|NCT03755648|OTHER|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
214598271|NCT04607525|DRUG|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\]."
214598272|NCT04607525|DRUG|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
214598273|NCT01019317|DRUG|Cytarabine|0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).
214598274|NCT01019317|DRUG|Fludarabine|15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
214598275|NCT00005002|DRUG|Lamivudine/Zidovudine|
214598276|NCT00005002|BIOLOGICAL|HIV-1 Immunogen|
214598277|NCT00005002|DRUG|Nelfinavir mesylate|
214598278|NCT02233283|OTHER|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
214598279|NCT02233283|OTHER|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
214598280|NCT02233283|OTHER|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
214598281|NCT02233283|OTHER|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
214598282|NCT00947778|OTHER|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
214598283|NCT00947778|OTHER|1 training session|20 sessions of 30 minutes by week during 24 semaines
214598284|NCT02827136|DRUG|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
214598285|NCT02827136|DRUG|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
214598286|NCT02979925|DEVICE|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
214598287|NCT02979925|DEVICE|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
214598288|NCT05358951|BEHAVIORAL|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
214598289|NCT05358951|BEHAVIORAL|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
214598290|NCT03460379|DRUG|Escitalopram|Patients are tested for their normal prescription escitalopram medication
214598291|NCT01548924|DRUG|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
214598292|NCT01548924|DRUG|Dovitinib + Paclitaxel|"* Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
214598293|NCT04536610|BEHAVIORAL|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
214598294|NCT04536610|BEHAVIORAL|Giving informative leaflet|Leaflets containe the same information as the OP education program
214598295|NCT05269836|DEVICE|Surgify Safety Burr|Use of Surgify Safety Burr in hard tissue cutting, head and spine area
214598296|NCT02000427|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
214598297|NCT01655927|DRUG|Tranexamic Acid|
214598298|NCT01655927|DRUG|Placebo: Saline|
214598299|NCT01109836|BEHAVIORAL|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
214598300|NCT02992483|DRUG|MIK665|MIK665
214598301|NCT03859726|DIAGNOSTIC_TEST|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
214598302|NCT03859726|DIAGNOSTIC_TEST|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
214598303|NCT02304848|OTHER|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
214598304|NCT06179329|PROCEDURE|Coronary artery bypass graft|Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
214598305|NCT01288872|DRUG|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
214598306|NCT01162213|DIETARY_SUPPLEMENT|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
214598307|NCT02708095|DRUG|Baricitinib|Administered orally
214598308|NCT02708095|DRUG|Placebo|Administered orally
214598309|NCT02749448|OTHER|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
214598310|NCT01955447|DIETARY_SUPPLEMENT|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
214598311|NCT01955447|DIETARY_SUPPLEMENT|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
214598312|NCT01955447|DIETARY_SUPPLEMENT|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
214598313|NCT01955447|DIETARY_SUPPLEMENT|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
214598314|NCT04641143|DRUG|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
214598315|NCT04641143|DRUG|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
214598316|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
214598317|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
214598318|NCT04483245|BIOLOGICAL|Blood sampling|Blood sampling
214598319|NCT01313650|DRUG|62.5/25mcg|GSK573719/GW64244
214598320|NCT01313650|DRUG|62.5mcg|GSK573719
214598321|NCT01313650|DRUG|25mcg|GW642444
214598322|NCT01313650|DRUG|Placebo|Placebo
214598323|NCT03275103|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
214598324|NCT03275103|DRUG|Tocilizumab|Tocilizumab will be administered as premedication during Cycle 1.
214598325|NCT04209790|RADIATION|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
214598326|NCT04209790|DRUG|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
214598327|NCT04209790|PROCEDURE|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
214598328|NCT06571149|DRUG|Tenecteplase or Alteplase|Patients randomized to intravenous thrombolysis (IVT) treatment will receive intravenous Tenecteplase or Alteplase.
214598329|NCT05393037|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214598330|NCT05393037|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
214598331|NCT05393037|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
214598332|NCT05393037|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214598333|NCT05393037|BIOLOGICAL|PCV15 - Part B|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
214598334|NCT06483204|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|Medrol tapered dosepak given to experimental arm patients to determine if there is a significant difference in pain, nausea, edema and ecchymosis outcomes in the postoperative period after a functional rhinoplasty procedure.
214598335|NCT01012739|DRUG|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
214711149|NCT03983460|DRUG|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
214711150|NCT03983460|DRUG|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
214598336|NCT01012739|DRUG|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
214598337|NCT01012739|DRUG|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
214598338|NCT01012739|DRUG|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
214598339|NCT03160651|DRUG|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
214598340|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
214598341|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
214598342|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
214598343|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
214598344|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
214598345|NCT04113668|DRUG|BMS-986165|Specified Dose on Specified Days
214598346|NCT04113668|DRUG|diflunisal|Specified Dose on Specified Days
214598347|NCT00458341|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
214598348|NCT02217189|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
214598349|NCT01810237|DRUG|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
214598350|NCT04026061|BEHAVIORAL|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
214598351|NCT04026061|BEHAVIORAL|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
214598352|NCT04988386|DRUG|Acoramidis (AG10)|Acoramidis (AG10) twice daily
214598353|NCT05746624|BEHAVIORAL|keypresses|benign behavioral intervention-- keypresses
214598354|NCT05378126|OTHER|Neurological assessment|"No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation."
214598355|NCT04908176|DRUG|Avapritinib|avapritinib tablets
214598356|NCT04908176|DRUG|midazolam|midazolam syrup
214598357|NCT06969664|DRUG|SHR7280 Tablet|Oral SHR7280 tablet.
214598358|NCT06969664|DRUG|SHR7280 Placebo Tablet|Oral SHR7280 placebo tablet.
214598359|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
214598360|NCT05520281|BEHAVIORAL|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
214598361|NCT06039306|DIETARY_SUPPLEMENT|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
214598362|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
214598363|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
214598364|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
214598365|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
214598366|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
214598367|NCT05165537|DEVICE|NIMM_MRS|evaluation of new MRS methods
214598368|NCT06731335|DRUG|Psilocybin|PSILOCYBIN (PEX010) 25 mg PO single dose
214598369|NCT06731335|DRUG|Active Placebo|Dextromethorphan 400 mg PO single dose
214598370|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
214598371|NCT03938701|DEVICE|Fluorescence Imaging|"Rheumatoid arthritis: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals open-air by using a black-box.~Inflammatory bowel disease: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
214634524|NCT03105570|PROCEDURE|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
214598372|NCT06081010|BEHAVIORAL|Community Health Worker Intervention|Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
214598373|NCT03073226|DEVICE|Olympus Elite|New generation Olympus endoscope
214598374|NCT03073226|DEVICE|Olympus Spectrum|Current generation Olympus endoscope
214598375|NCT04534504|PROCEDURE|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
214598376|NCT04046718|DEVICE|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
214598377|NCT01893437|DRUG|RO6799477|Single doses of RO6799477
214711151|NCT03983460|PROCEDURE|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion"
214598378|NCT00390910|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
214598379|NCT00390910|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
214598380|NCT04531215|DRUG|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
214598381|NCT04531215|DRUG|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
214598382|NCT02694939|BEHAVIORAL|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
214598383|NCT02694939|BEHAVIORAL|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
214598384|NCT04585776|DRUG|LY900014|Administered SC
214598385|NCT04585776|DRUG|Insulin Degludec|Administered SC
214598386|NCT05282615|DEVICE|Emanate Tray|Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
214598387|NCT01620112|DRUG|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
214598388|NCT01620112|DRUG|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
214598389|NCT01620112|DRUG|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
214598390|NCT01620112|DRUG|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
214598391|NCT02159560|DEVICE|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
214598392|NCT02258165|DEVICE|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
214598393|NCT04421833|BEHAVIORAL|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
214598394|NCT04421833|BEHAVIORAL|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
214598395|NCT03171831|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
214598396|NCT03171831|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
214598397|NCT03171831|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
214598398|NCT03171831|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
214598399|NCT03171831|DRUG|Tacrolimus|Tacrolimus（0.03mg/kg/day）
214598400|NCT03171831|DRUG|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
214598401|NCT03171831|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
214598402|NCT03171831|DRUG|Basiliximab|Basiliximab（10mg on day 0 and +4）
214598403|NCT02762253|DRUG|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
214598404|NCT02902003|BEHAVIORAL|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
214598405|NCT02314767|BEHAVIORAL|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
214598406|NCT02314767|BEHAVIORAL|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
214598407|NCT01276431|DRUG|Buprenorphine transdermal patch|
214598408|NCT02612753|PROCEDURE|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
214598409|NCT02612753|DEVICE|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
214598410|NCT02612753|DEVICE|tDCs|
214598411|NCT01389765|DRUG|LY2216684|Administered orally
214598412|NCT03565120|RADIATION|Aggressive Thoracic Radiotherapy|The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
214598413|NCT00510679|BEHAVIORAL|Health worker supports (supervision, job aids, incentives)|
214598414|NCT01439919|DRUG|SSR411298|"Form: tablet~Route: oral administration with food"
214598415|NCT01439919|DRUG|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
214598416|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
214598417|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
214598418|NCT03450967|DRUG|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
214598419|NCT01216384|DRUG|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
214598420|NCT01216384|DRUG|placebo|Subjects will receive according to the dose group matching number of placebo tablets
214598421|NCT02753140|DRUG|Cetuximab|
214598422|NCT02753140|RADIATION|radiation|
214598423|NCT02753140|DRUG|Docetaxel|
214598424|NCT02753140|DRUG|Cisplatin|
214598425|NCT04598048|BEHAVIORAL|Questionnaire|Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
214634525|NCT00369356|DRUG|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
214634526|NCT00369356|DEVICE|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
214634527|NCT00369356|DEVICE|Bare metal coronary stent|Stenting with BMS only
214634528|NCT06096558|DIETARY_SUPPLEMENT|Melatonin|5 mg Melatonin in one tablet, 30 minutes before night sleep
214634529|NCT06096558|OTHER|placebo|1 tablet of placebo (starch)
214634530|NCT01119170|OTHER|Starter formula|standard starter formula given from birth to 6 months of age
214634531|NCT01119170|OTHER|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
214634532|NCT01851850|DRUG|Opicapone|25mg or 50mg once per day
214634533|NCT01207622|DRUG|Atomoxetine|
214634534|NCT01207622|DRUG|Placebo|
214634535|NCT01441752|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
214634536|NCT01441752|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
214598426|NCT06223204|OTHER|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
214598427|NCT02292368|BEHAVIORAL|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
214598428|NCT02292368|PROCEDURE|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
214598429|NCT02292368|PROCEDURE|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
214598430|NCT02882087|DRUG|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
214598431|NCT02882087|DRUG|RC18 160 mg plus MTX|
214598432|NCT02960841|OTHER|Intracavitary Manual Lymphatic Drainage|
214598433|NCT02960841|OTHER|Conventional treatment|
214598434|NCT04497194|OTHER|not applicable (observational study)|not applicable (observational study)
214598435|NCT04637477|BEHAVIORAL|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
214598436|NCT04727086|DRUG|BP1.3656|BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
214598437|NCT04727086|DRUG|Placebo|Administered once daily in tablet form.
214598438|NCT00516243|OTHER|placebo|Given PO
214598439|NCT00516243|OTHER|quality-of-life assessment|Ancillary studies
214598440|NCT00516243|PROCEDURE|questionnaire administration|Ancillary studies
214598441|NCT00516243|PROCEDURE|laboratory biomarker analysis|Correlative studies
214598442|NCT00516243|DRUG|defined green tea catechin extract|Given PO
214598443|NCT02455219|DEVICE|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
214598444|NCT02642510|OTHER|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
214598445|NCT02642510|OTHER|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
214634537|NCT03064477|BEHAVIORAL|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
214634538|NCT03064477|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
214598446|NCT03877432|DEVICE|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
214598447|NCT05223465|OTHER|Survey|Google form distributed for students and faculties
214598448|NCT05786833|DRUG|Dexmedetomedine|Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
214598449|NCT05786833|DRUG|Ketofol|Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.
214598450|NCT05786833|DRUG|isotonic saline 0.9%|Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
214598451|NCT01110811|PROCEDURE|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
214598452|NCT06249373|DEVICE|Low intensity pulse ultrasound （LIPUS） intervention for arteriovenous fistula anastomosis|The LIPUS intervention group for arteriovenous fistula should receive forearm wearable portable low-intensity pulse ultrasound （LIPUS） intervention at the anastomotic site no more than 3 days after suture removal two weeks after the fistula surgery. If the ultrasound examination indicates the presence of stenosis in the outflow tract, the intervention should also be performed at the same time. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
214598453|NCT02802709|DEVICE|SB-061|delivered via intra-articular injection
214598454|NCT02802709|OTHER|Placebo|Placebo
214598455|NCT01299987|RADIATION|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
214598456|NCT04038853|DRUG|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
214598457|NCT04038853|DRUG|Placebo|Placebo identical to the study intervention drug
214598458|NCT06151054|DIAGNOSTIC_TEST|Measure of aortic inflammation|Standard Uptake Value (SUV) measures of aortic wall
214598459|NCT04758182|DEVICE|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
214598460|NCT04758182|DEVICE|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
214598461|NCT01998126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
214598462|NCT01998126|DRUG|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
214598463|NCT01998126|DRUG|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
214598464|NCT01998126|DRUG|Nivolumab|
214598465|NCT06378411|DEVICE|Music Game Intervention|Use of music to induce improvements in cognitive and motor outcomes.
214598466|NCT05512637|DIAGNOSTIC_TEST|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
214598467|NCT00174265|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
214598468|NCT00174265|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
214598469|NCT01473160|DEVICE|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
214598470|NCT01473160|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
214598471|NCT06503562|OTHER|central nervous system focused treatment program|Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery
214598472|NCT06503562|OTHER|Classical Physiotherapy|All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
214598473|NCT05539833|DRUG|KSH01 injection|TCR-T cell injection
214598474|NCT03471871|DRUG|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
214598475|NCT03471871|DRUG|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
214598476|NCT03471871|DRUG|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
214598477|NCT03471871|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
214598478|NCT03471871|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
214598479|NCT00372021|PROCEDURE|optic nerve neurotomy|
214598480|NCT02577601|DRUG|Ulipristal Acetate|
214598481|NCT02577601|DRUG|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
214598482|NCT03728413|BIOLOGICAL|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
214598483|NCT04273698|BEHAVIORAL|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
214598484|NCT04335383|BIOLOGICAL|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
214598485|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
214598486|NCT04600336|DRUG|Placebo Administration|Given PO
214598487|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
214598488|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
214598489|NCT00207805|PROCEDURE|autologous PBSC transplant|optimal timining of a second autologous transplant
214598490|NCT01998009|OTHER|fecal occult blood tests|
214598491|NCT00308269|DRUG|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
214598492|NCT00308269|DRUG|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
214598493|NCT05826574|DRUG|Brensocatib|Oral tablets.
214711152|NCT03983460|PROCEDURE|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm"
214598494|NCT05826574|DRUG|Rifampin|Oral capsules.
214598495|NCT05826574|DRUG|Esomeprazole|Oral capsules.
214598496|NCT02561533|OTHER|BRAF detection on fine needle aspiration biopsy (FNAB)|
214598497|NCT06029725|DEVICE|radiofrequency microneedling combined with 1927 nm thulium laser|"1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy"
214598498|NCT06029725|DEVICE|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
214598499|NCT01685190|RADIATION|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
214598500|NCT01685190|RADIATION|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
214598501|NCT03834038|DRUG|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
214598502|NCT04291261|DRUG|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
214598503|NCT06999239|PROCEDURE|laser therapy in TMD|"In this study patients will receive the Low-level laser therapy with a 635 nm wavelength diode laser (Lasotronix, Diode Laser DiodeLX model SMART M; Zytnia, Piaseczno, Poland) with 200 mW in a continuous mode, using a handpiece with a cylindrical applicator with a diameter of 8 mm in contact mode extra-orally, fiber-optic applicator with a diameter of 8 mm in contact mode intraorally, with a power density of 400 mW/cm2, delivering 10-12 J/cm2 on each application point, over a period of 20 sec.~There are two methods for examination of lateral pterygoid muscle: digital palpation and functional manipulation.~For digital palpation of lateral pterygoid muscle, we place our index finger or tip of our little finger in the vestibular area adjacent to the maxillary third molar.~Functional manipulation of the inferior head of lateral pterygoid muscle: It is best accomplished by having the patient make a protrusive movement against resistance to contract it since this muscle is the primary pro"
214598504|NCT06999005|PROCEDURE|Fluoride Varnish Application (Preventive Protocol)|Single application of Duraphat® fluoride varnish on permanent molars and incisors, repeated every 3 months.
214598505|NCT06999005|PROCEDURE|Fluoride Varnish for Active Enamel Lesions|Weekly fluoride varnish applications for 4 weeks, followed by quarterly maintenance applications.
214598506|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART) Sealant|Sealant placement with high-viscosity glass ionomer using the ART technique, with quarterly fluoride varnish.
214598507|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART)|Manual caries removal and cavity restoration with glass ionomer cement, followed by fluoride varnish every 3 months.
214598508|NCT01786187|BEHAVIORAL|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
214598509|NCT01786187|OTHER|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
214598510|NCT07008209|BEHAVIORAL|Reconstrual Strategy Training|"Participants receive training in the reconstrual strategy, which involves recognizing and reinterpreting initial negative appraisals of emotionally challenging situations. The training guides participants to:~Identify the situation and their initial negative interpretation.~Generate alternative, balanced explanations that reduce negative emotional impact.~The goal is to help participants view events from a different, realistic perspective to decrease negative emotions by modifying how they interpret situations."
214598511|NCT07008209|BEHAVIORAL|Repurposing Strategy Training|"Participants receive training in the repurposing strategy, which involves adjusting or replacing personal goals to better align with the current situation. The training guides participants to:~Identify the situation and the original goal that was not met.~Develop alternative, realistic goals or modify existing ones to reduce the emotional impact of unmet expectations.~This approach helps participants manage negative emotions by creating meaningful, adaptable goals that fit the reality of the situation."
214598512|NCT07008209|BEHAVIORAL|Active Control|Participants are asked to carefully copy a neutral descriptive passage without making any changes, focusing solely on transcription accuracy. This task serves as an active control by engaging participants in a cognitive task that requires attention and effort, but does not involve emotion regulation strategies. The task controls for the effects of engagement and time spent on a task without influencing participants' emotional processing.
214598513|NCT07013708|DEVICE|Laser|High frequency laser device
214598514|NCT07013708|OTHER|Placebo|Same device but without pressing the ON button
214598515|NCT07016633|DRUG|IMM-H014|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
214598516|NCT07016633|DRUG|Placebo|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
214598517|NCT07010120|DRUG|Tislelizumab|200mg IV Q3W
214598518|NCT07010120|DRUG|Afatinib|30mg PO QD
214598519|NCT07010120|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
214598520|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Solfeggio Frequencies|Music featuring Solfeggio frequencies (174 Hz, 285 Hz, 396 Hz, 528 Hz) is played through standardized speakers in a sound-isolated room during IDT. Duration includes five minutes before and throughout the procedure
214598521|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Traditional Turkish Music|Selected Turkish Classical Music pieces (makams: Rast, Hicaz, Uşşak, Neva, Saba) are played via speakers in a sound-isolated room during IDT. Music begins five minutes prior and continues during the procedure.
214598522|NCT07019025|OTHER|Therapeutic patient education on the use of a insulin bolus calculator app|Therapeutic patient education on the use of a insulin bolus calculator app
214598523|NCT07020806|DRUG|[68Ga]Ga DOTA-5G|Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.
214598524|NCT07019415|DRUG|Vitamin D 5000 IU+ placebo|vitamin D 5000 IU + placebo in the experimental group
214598525|NCT07019415|DRUG|Placebo : calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate|this placebo group receive placebo tablet ( calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate )
214598526|NCT07020377|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg tab once daily for NAFLD patient
214598527|NCT07020377|DRUG|Placebo|placebo
214598528|NCT07020377|OTHER|Negative control|Baseline sample serum without either drug or placebo
214598529|NCT07020949|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
214598530|NCT07020949|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
214598531|NCT07021183|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria tailored to PSP. The Sleep Course has been slightly adapted for PSP by including relevant statistics and literature pertaining to sleep disturbance in PSP. The Sleep Course has four lessons and includes optional therapist support for up to 8 - 12 weeks. Should clients request support, clients will be contacted by their therapist by secure emails on their designated check-in dates. The therapist also reviews client progress in the Course and emails clients on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
214598532|NCT06901895|COMBINATION_PRODUCT|Hylorunic acid|Hylorunic acid (hylo) eye drop is prescribed and check the curative effect after phacoemulsification after 2nd and 4th week.
214598533|NCT06901895|DIAGNOSTIC_TEST|Lipid coated carbomer gel|Lipid coated carbomer gel (visole)is prescribed and check yhe curative effect after phacoemulsification in diabetic patients post operatively in 2nd and 4th week.
214598534|NCT06181136|DRUG|DNL126|intravenous repeating dose
214598535|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
214598536|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
214598537|NCT06439056|DRUG|NEX-22A, a prolonged release formulation of liraglutide|NEX-22A, a prolonged release formulation of liraglutide
214598538|NCT06650254|OTHER|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed."
214598539|NCT05648825|DEVICE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
214598540|NCT06678659|DRUG|REC-1245|Oral
214598541|NCT06317285|DRUG|GSK3915393|GSK3915393 will be administered.
214598542|NCT06317285|DRUG|Placebo|Placebo will be administered.
214598543|NCT06819956|DRUG|Ketorolac|Ketorolac 15 mg IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The ketorolac will be diluted in a 0.9% normal saline 10 mL syringe.
214598544|NCT06819956|DRUG|Placebo|Matching placebo IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The matching placebo will be diluted in a 0.9% normal saline 10 mL syringe.
214711153|NCT03983460|PROCEDURE|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
214598545|NCT06811909|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method, which, briefly includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C, and electron beam sterilization.
214598546|NCT06811909|OTHER|Standard Care|"Standard Care is defined as:~* Sharp debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and~* The UrgoK2™ dual compression system providing around 40 mmHg."
214598547|NCT06060717|DEVICE|F&P Caramel|Nasal mask
214598548|NCT06831383|BEHAVIORAL|STOP-HPV-Online|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.
214598549|NCT06831383|BEHAVIORAL|STOP-HPV-LC|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.
214598550|NCT02935257|BIOLOGICAL|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
214598551|NCT06399263|DRUG|Psilocybin|The psilocybin will include two dose administration sessions, first a 20mg administration, and second an administration of up to 30mg.
214598552|NCT06399263|BEHAVIORAL|Preparation and Integration Sessions|The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.
214598553|NCT06089421|OTHER|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
214598554|NCT06089421|OTHER|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
214598555|NCT06030570|OTHER|Rehabilitation program (Revita)|Multidisciplinary programs in an outpatient hospital setting are coordinated by specialists in Physical and Rehabilitation Medicine. These programs combine a physical part (e.g., specific exercises, manual techniques) with at least one other element (psychological, social, educational or occupational intervention). In a multidisciplinary spine rehabilitation program, a maximum of 36 sessions over a maximum time period of 6 months is offered. Afterwards, a (monodisciplinary) follow-up trajectory (K15) is possible, consisting of maximum 104 sessions a year.
214598556|NCT04750928|DRUG|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
214598557|NCT02316314|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
214598558|NCT02316314|PROCEDURE|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
214598559|NCT02316314|PROCEDURE|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
214598560|NCT02316314|PROCEDURE|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
214598561|NCT04993690|DRUG|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
214598562|NCT06243458|DRUG|RVU120 (SEL120)|RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
214598563|NCT02445222|GENETIC|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
214598564|NCT05333458|BIOLOGICAL|Atezolizumab|Given IV
214598565|NCT05333458|PROCEDURE|Biopsy Procedure|Undergo biopsy
214598566|NCT05333458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214598567|NCT05333458|PROCEDURE|Computed Tomography|Undergo CT
214598568|NCT05333458|PROCEDURE|Echocardiography Test|Undergo ECHO
214598569|NCT05333458|DRUG|Selinexor|Given PO
214711154|NCT06156891|PROCEDURE|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
214598570|NCT04720157|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
214598571|NCT04720157|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
214598572|NCT04720157|DRUG|ARDT|Administered orally on a continuous basis as per package insert and guideline
214598573|NCT04720157|DRUG|ADT|ADT are administered as per physician order
214598574|NCT06007924|DRUG|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
214598575|NCT06007924|DRUG|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
214598576|NCT05847426|OTHER|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
214598577|NCT05847426|OTHER|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
214598578|NCT05995964|DRUG|PF-07275315|subcutaneous injection
214598579|NCT05995964|DRUG|PF-07264660|subcutaneous injection
214598580|NCT05995964|OTHER|Placebo|subcutaneous injection
214598581|NCT06551324|DRUG|PF-06821497|875 mg BID (2 times a day)
214598582|NCT06551324|DRUG|Docetaxel|75 mg/m2 IV (every 21 days)
214598583|NCT06551324|DRUG|Enzalutamide|160 mg QD
214598584|NCT06101329|DRUG|Lenacapavir Tablet|Tablets administered orally without regard of food
214598585|NCT06101329|DRUG|Lenacapavir Injection|Injection administered subcutaneously
214598586|NCT06101329|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
214598587|NCT05886036|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214598588|NCT05886036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214598589|NCT05886036|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214598590|NCT05886036|PROCEDURE|Computed Tomography|Undergo PET/CT
214598591|NCT05886036|OTHER|Fludeoxyglucose F-18|Receive FDG
214598592|NCT05886036|BIOLOGICAL|Mosunetuzumab|Given SC
214598593|NCT05886036|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214598594|NCT05886036|BIOLOGICAL|Rituximab|Given IV
214598595|NCT05886036|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214598596|NCT05594563|DRUG|DFMO|DFMO orally twice a day
214598597|NCT05594563|DRUG|Placebo|Placebo orally twice a day
214598598|NCT03769181|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214598599|NCT03769181|DRUG|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214598600|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
214598601|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
214598602|NCT05934786|BEHAVIORAL|Cognitive rehabilitation|Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
214598603|NCT06188481|OTHER|whole-body electromyostimulation training|The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.
214598604|NCT06188481|OTHER|activity tracker|Participants wear the activity tracker on their wrist for the entire 16-week study period.
214598605|NCT06188481|OTHER|evidence-based lifestyle education program|Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).
214598606|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
214598607|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
214598608|NCT05945641|BEHAVIORAL|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,
214598609|NCT05945641|BEHAVIORAL|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
214634539|NCT03988595|OTHER|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
214634540|NCT05581732|DIETARY_SUPPLEMENT|Nutrinidrink with Dietary Fiber|Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
214598610|NCT04244487|PROCEDURE|laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation|"The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm."
214598611|NCT04960423|PROCEDURE|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
214598612|NCT06963827|DRUG|Mezagitamab|Mezagitamab injections administered SC.
214598613|NCT06963827|DRUG|Placebo|Mezagitamab-matching placebo injections administered SC.
214598614|NCT03566810|DRUG|Test GXR|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
214598615|NCT03566810|DRUG|Reference GXR|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
214598616|NCT03217266|DRUG|Navtemadlin|Given PO
214598617|NCT03217266|RADIATION|Radiation Therapy|Undergo radiation therapy
214598618|NCT03217266|PROCEDURE|Surgical Procedure|Undergo surgery
214598619|NCT00301522|DEVICE|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
214598620|NCT00301522|DEVICE|Express2|Coronary Stent System
214598621|NCT00164125|DRUG|polyethyleneglycol3350|
214598622|NCT02087748|DRUG|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
214598623|NCT02087748|DRUG|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
214598624|NCT01475604|DEVICE|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
214598625|NCT01475604|DEVICE|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
214598626|NCT01674751|OTHER|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
214598627|NCT06493981|DRUG|Eltrombopag|Treatment with eltrombopag in a dose of (50-150mg/d)
214598628|NCT01686854|BEHAVIORAL|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
214634541|NCT00902785|OTHER|no drug|observational no drug
214634542|NCT03334331|OTHER|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
214634543|NCT03334331|OTHER|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
214634544|NCT04624165|OTHER|Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
214634545|NCT04372927|DRUG|Cisplatin|Given IV
214634546|NCT04372927|BIOLOGICAL|Durvalumab|Given IV
214634547|NCT04372927|DRUG|Etoposide|Given IV
214634548|NCT04372927|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214634549|NCT04372927|DRUG|Pemetrexed|Given IV
214634550|NCT01665807|BIOLOGICAL|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
214634551|NCT01665807|BIOLOGICAL|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
214634552|NCT06053424|DRUG|AZD7798|Participants will receive IV infusion of AZD7798 as stated in arm description.
214634553|NCT06053424|DRUG|[11C]AZ14132516|Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.
214634554|NCT04393610|DRUG|Lidocaine|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
214634555|NCT04393610|DRUG|Magnesium Sulphate|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
214634556|NCT04393610|DRUG|Fentanyl|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
214598629|NCT01686854|OTHER|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
214598630|NCT05640466|DEVICE|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
214598631|NCT05808686|OTHER|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
214598632|NCT04260451|OTHER|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1\. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
214598633|NCT04158635|DRUG|Bosentan|Given PO
214598634|NCT04158635|DRUG|Gemcitabine|Given IV
214598635|NCT04158635|DRUG|Nab-paclitaxel|Given IV
214598636|NCT04158635|OTHER|Quality-of-Life Assessment|Ancillary studies
214598637|NCT04158635|OTHER|Questionnaire Administration|Ancillary studies
214598638|NCT01508546|PROCEDURE|axillary dissection|Conservative breast surgery with or without axillary dissection
214598639|NCT05223114|OTHER|Not applicable (N/A)|Not applicable to this study
214598640|NCT01611064|DRUG|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
214598641|NCT01611064|DRUG|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
214598642|NCT00509665|DRUG|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
214598643|NCT00509665|DRUG|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
214598644|NCT00444392|BEHAVIORAL|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
214598645|NCT01969591|PROCEDURE|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
214598646|NCT01969591|OTHER|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
214598647|NCT06198751|DRUG|6.0 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.
214598648|NCT06198751|DRUG|7.5 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
214598649|NCT03078907|DRUG|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
214598650|NCT03078907|DRUG|Placebo|Matching film coated tablets
214598651|NCT03878004|BIOLOGICAL|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
214598652|NCT03878004|BIOLOGICAL|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
214598653|NCT01955122|DEVICE|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
214598654|NCT00584168|DRUG|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
214598655|NCT00584168|DRUG|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
214598656|NCT06140472|BEHAVIORAL|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
214598657|NCT06140472|BEHAVIORAL|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
214634557|NCT06467890|BEHAVIORAL|Educational programme about vital pulp therapy|An awareness educational material based on the recent AAPD and AAE guidelines on vital pulp therapy will be sent to the participants right after they answer the questionnaire for the first time
214598658|NCT05193240|DIAGNOSTIC_TEST|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
214598659|NCT05903339|DRUG|V3G CH848 Pr-NP1 60mcg|(60 mcg)
214598660|NCT05903339|DRUG|3M-052-AF 5mcg|(5 mcg)
214598661|NCT05903339|DRUG|Alum 500 mcg|(500 mcg)
214598662|NCT05903339|DRUG|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
214598663|NCT05903339|DRUG|ACU-026-001-1 2.0mg|(2.0 mg)
214598664|NCT05903339|DRUG|V3G CH848 Pr-NP1 100mcg|(100 mcg)
214598665|NCT05737199|DRUG|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
214598666|NCT05452811|PROCEDURE|Burch colposuspension|Anti-incontinence surgery for stress urinary incontinence
214598667|NCT00826111|DRUG|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
214598668|NCT00826111|DRUG|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
214598669|NCT04229953|DEVICE|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
214598670|NCT01672788|DRUG|Empagliflozin|empagliflozin tablets and metformin tablet
214598671|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
214598672|NCT01672788|DRUG|Metformin|empagliflozin tablets and metformin tablet
214598673|NCT01672788|DRUG|Metformin|empagliflozin tablet and metformin tablet
214598674|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
214598675|NCT01672788|DRUG|Empagliflozin|empagliflozin tablet and metformin tablet
214598676|NCT04219813|OTHER|Urinary test|Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
214598677|NCT01728220|COMBINATION_PRODUCT|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
214598678|NCT01728220|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
214598679|NCT01782365|DEVICE|SHAM stimulation|no stimulation
214598680|NCT01782365|DEVICE|0,75 Hz stimulation|
214598681|NCT00261612|DRUG|bortezomib|
214598682|NCT00261612|DRUG|rituximab|
214598683|NCT00261612|DRUG|dexamethasone|
214598684|NCT00261612|PROCEDURE|treatment protocol|
214598685|NCT00112931|BIOLOGICAL|rituximab|
214598686|NCT00112931|OTHER|No treatment|
214598687|NCT01099163|DIETARY_SUPPLEMENT|Tonalin SG1000T FFA|
214598688|NCT01910909|RADIATION|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
214598689|NCT01837069|DRUG|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
214598690|NCT01837069|DRUG|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
214598691|NCT01837069|DRUG|Atorvastatin|80mg PO QD at preadmission testing
214598692|NCT01837069|BEHAVIORAL|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
214598693|NCT06083922|DRUG|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
214598694|NCT06083922|DRUG|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
214598695|NCT06083922|DRUG|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
214598696|NCT06083922|DRUG|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
214598697|NCT03511053|PROCEDURE|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
214598698|NCT06678555|DRUG|Lorlatinib|Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.
214598699|NCT03157505|DRUG|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
214598700|NCT03157505|OTHER|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
214598701|NCT01929980|DRUG|Bortezomib|
214598702|NCT03030170|DEVICE|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
214598703|NCT03030170|DEVICE|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
214598704|NCT03368911|DEVICE|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
214598705|NCT03368911|DEVICE|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
214598706|NCT01721005|OTHER|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
214598707|NCT00649090|DRUG|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
214598708|NCT00985166|BIOLOGICAL|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
214598709|NCT00985166|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
214711155|NCT06156891|PROCEDURE|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
214711156|NCT02455388|DIETARY_SUPPLEMENT|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
214711157|NCT02455388|DIETARY_SUPPLEMENT|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
214711158|NCT03263741|DRUG|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
214711159|NCT00525785|DRUG|5-Fluorouracil|"2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
214598710|NCT00985166|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
214598711|NCT00985166|BIOLOGICAL|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
214598712|NCT06785818|OTHER|Tisagenlecleucel|This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.
214598713|NCT04973878|PROCEDURE|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
214598714|NCT04973878|PROCEDURE|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
214598715|NCT02765607|PROCEDURE|Heart surgery|
214598716|NCT05241275|DRUG|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
214598717|NCT02855424|OTHER|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
214711160|NCT00525785|DRUG|Folinic Acid|200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
214598718|NCT02855424|OTHER|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
214598719|NCT02523053|PROCEDURE|Hepatectomy|Surgical removal of all lesions
214598720|NCT02523053|DRUG|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
214598721|NCT02915471|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
214598722|NCT04007510|COMBINATION_PRODUCT|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
214598723|NCT04007510|DIAGNOSTIC_TEST|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
214598724|NCT04025723|OTHER|Downhill running|60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
214598725|NCT02732054|BIOLOGICAL|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
214598726|NCT01580280|OTHER|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
214598727|NCT01580280|OTHER|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
214598728|NCT02532153|DRUG|Ketamine Hydrochloride|Single open-label infusions
214598729|NCT01028222|DRUG|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
214598730|NCT01028222|DRUG|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
214598731|NCT02235974|BEHAVIORAL|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
214598732|NCT02235974|BEHAVIORAL|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
214598733|NCT02235974|BEHAVIORAL|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
214598734|NCT02235974|BEHAVIORAL|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
214598735|NCT05573087|OTHER|Aquatic Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
214598736|NCT05573087|OTHER|Land Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
214598737|NCT06296134|BEHAVIORAL|perineal massage|"women affected by LAM co-activation allocated to the intervention perineal massage are asked to perform the perineal massage once daily from 34 gestational weeks until delivery. Women are trained to correctly perform the perineal massage at 30 gestaitonal weeks."
214598738|NCT00679588|DRUG|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214711161|NCT00525785|DRUG|Oxaliplatin|"100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
214598739|NCT00679588|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214598740|NCT00679588|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
214598741|NCT04393051|DRUG|Baricitinib Oral Tablet|Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
214598742|NCT04745767|DRUG|TAK-994|T2 formulation.
214598743|NCT04745767|DRUG|TAK-994|T1 formulation.
214598744|NCT04745767|DRUG|TAK-994|T3 formulation.
214598745|NCT04745767|DRUG|TAK-994|T4 formulation.
214598746|NCT04745767|DRUG|TAK-994|T5 formulation.
214598747|NCT04903808|DRUG|Allium Sativum Oil|Garlic oil Captain Company (CAP-PHARM)
214598748|NCT04903808|DRUG|Mineral Tri-Oxide Aggregate|ProRoot MTA, Dentsply
214598749|NCT05330637|OTHER|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
214598750|NCT02558933|DIETARY_SUPPLEMENT|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
214598751|NCT06383026|DIAGNOSTIC_TEST|Breast Cancer Screening|Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
214598752|NCT06383026|OTHER|Survey/Interview|A mixed-methods approach including electronic surveys and one on one interviews.
214598753|NCT06383026|OTHER|Focus Group|A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.
214598754|NCT02685670|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
214598755|NCT02685670|DRUG|Fludarabine|
214598756|NCT02685670|DRUG|Cyclophosphamide|
214598757|NCT00647322|OTHER|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
214598758|NCT00647322|PROCEDURE|No drug change|No change in anti-epileptic treatment
214598759|NCT02477579|DEVICE|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
214598760|NCT04697264|DIAGNOSTIC_TEST|Blood and tissue sample collection from patients|Blood and tissue sample (endometrial and adipose tissue) collection from endometrial cancer patients. Blood from all control patients, endometrial sample from benign patients having surgery for benign gynaecological conditions.
214598761|NCT04162925|BEHAVIORAL|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
214598762|NCT04722523|DRUG|Cisplatin|Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8
214598763|NCT04722523|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 2, 5, and 8
214598764|NCT04722523|DRUG|Docetaxel|Docetaxel 75mg/m2 on weeks 2, 5, and 8
214598765|NCT04722523|DRUG|Cetuximab|Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10
214598766|NCT04722523|DRUG|Cemiplimab|Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37
214711162|NCT00525785|RADIATION|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
214711163|NCT00525785|PROCEDURE|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
214711164|NCT01011088|OTHER||Not any artificial interventions were given
214598767|NCT04722523|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
214711165|NCT01541111|DRUG|Magnesiun|75mg pills; each 12h; 12wk
214711166|NCT02205164|DRUG|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
214598768|NCT04722523|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of \>0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines \[2\]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
214598769|NCT04722523|DRUG|Paclitaxel|If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
214711167|NCT02205164|DRUG|Palonosetron|Aloxi 0.25mg
214711168|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams once daily
214711169|NCT01316939|DRUG|Placebo|Placebo
214711170|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams twice daily
214598770|NCT05781919|OTHER|Immersive virtual reality imaging|Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
214598771|NCT05781919|OTHER|Gold standard imaging|Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
214598772|NCT05809128|OTHER|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
214598773|NCT01034293|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
214598774|NCT01034293|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
214598775|NCT05954780|DRUG|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
214598776|NCT00485160|DRUG|Continuous indomethacin|
214598777|NCT00485160|DRUG|ibuprofen|
214598778|NCT04916041|DEVICE|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
214598779|NCT06769945|BEHAVIORAL|Nursing Care Based on Kolcaba's Comfort Theory|In practice, patient education, pain management, emotional support, appropriate environmental arrangements and individualised care come to the fore. Studies show that with this approach, patients' physical comfort increases, anxiety levels decrease and overall satisfaction improves. It is stated that nursing care based on Kolcaba's theory offers an effective model to improve the quality of life of postoperative patients.
214598780|NCT01141348|BEHAVIORAL|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
214598781|NCT01141348|BEHAVIORAL|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
214598782|NCT06332508|DEVICE|Pulsed electromagnetic fields (PEMFs)|"Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment."
214634558|NCT05968729|OTHER|Active Comparator: 0.25 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.
214598783|NCT06332508|DRUG|Anthracycline-based chemotherapy|"Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy."
214598784|NCT03236246|DRUG|KRX-0502|Oral ferric citrate with meals
214598785|NCT05794113|DEVICE|Mobile app - CanImmunize|Using a mobile app
214598786|NCT05794113|DEVICE|Web based notification|Using a web-based version of a survey
214598787|NCT00056511|DRUG|Fresh garlic or garlic supplements|
214598788|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
214598789|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
214598790|NCT01856166|DRUG|Levobupivacaine|
214598791|NCT01856166|DRUG|Sufentanil|
214598792|NCT01398293|DRUG|danoprevir|100 mg single dose orally
214598793|NCT01398293|DRUG|danoprevir|400 mg single dose orally
214598794|NCT01398293|DRUG|danoprevir placebo|single oral dose
214598795|NCT01398293|DRUG|moxifloxacin|400 mg single dose orally
214598796|NCT01398293|DRUG|moxifloxacin placebo|single oral dose
214598797|NCT01398293|DRUG|ritonavir|100 mg single dose orally
214598798|NCT01398293|DRUG|ritonavir placebo|single oral dose
214598799|NCT01317212|DRUG|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
214598800|NCT02598557|DRUG|Exemestane|Given PO
214598801|NCT02598557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214598802|NCT02598557|OTHER|Pharmacological Study|Correlative studies
214598803|NCT02598557|OTHER|Placebo Administration|Given PO
214598804|NCT02598557|OTHER|Quality-of-Life Assessment|Ancillary studies
214598805|NCT02598557|OTHER|Questionnaire Administration|Ancillary studies
214598806|NCT02598557|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214598807|NCT05629650|BEHAVIORAL|Tai Chi for memory|The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
214598808|NCT00269568|DRUG|mifepristone and misoprostol|
214598809|NCT01343589|DIETARY_SUPPLEMENT|milk fat|39 g milk fat per day in 12 weeks
214598810|NCT03483558|OTHER|Control|A standardized diet without any vegetables was provided.
214598811|NCT03483558|OTHER|Spinach|A standardized diet with 200g spinach was provided.
214598812|NCT03483558|OTHER|Celery|A standardized diet with 200g celery was provided.
214598813|NCT03483558|OTHER|Onion|A standardized diet with 200g onion was provided.
214598814|NCT03483558|OTHER|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
214598815|NCT00796848|DEVICE|Navigator Continuous Glucose Monitor|
214598816|NCT00647751|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
214598817|NCT00647751|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fed
214598818|NCT00720655|OTHER|Dietary intervention|Fatty fish at least 4 meals per week.
214598819|NCT00720655|OTHER|Dietary intervention|Lean fish at least 4 meals per week.
214598820|NCT00720655|OTHER|Dietary intervention|Control diet with lean meat and chicken.
214598821|NCT06288321|DRUG|Microdrop Mydrin-P|Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.
214598822|NCT06288321|DRUG|Standard Mydrin-P|Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
214598823|NCT03205215|OTHER|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
214598824|NCT03205215|OTHER|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
214598825|NCT01516658|DEVICE|Hydrogel coil|at least one Hydrogel coil have to use for embolization
214598826|NCT01516658|DEVICE|Bare platinum coil|only bare platinum coil have to use for embolization
214598827|NCT01810692|DEVICE|Group1:Spiriva® Respimat®|COPD patients using Respimat®
214711171|NCT02150512|DEVICE|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
214711172|NCT02150512|DEVICE|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
214711173|NCT02156752|BEHAVIORAL|ACT|Treatment is based on Acceptance and Commitment Therapy
214711174|NCT02156752|BEHAVIORAL|SR|Treatment is based on Self-Regulation theory.
214711175|NCT02156752|BEHAVIORAL|WLO|Treatment is based on cooking tips and demonstrations.
214711176|NCT01291706|DEVICE|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
214711177|NCT05351463|PROCEDURE|papila suture technique|simple interupted vs internal horoizontal matress suture
214711178|NCT00929136|BIOLOGICAL|USP endotoxin|Continuous intra-arterial infusion
214711179|NCT01729663|BIOLOGICAL|CSF470 vaccine, BCG, Molgramostim|
214711180|NCT01729663|DRUG|interferon alpha 2b|
214711181|NCT03624439|DEVICE|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
214711182|NCT03624439|DEVICE|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
214598828|NCT01810692|DEVICE|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
214598829|NCT06429384|DRUG|Y-3 Injection/Y-3 blank injection|The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;
214598830|NCT03685864|OTHER|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
214598831|NCT03685864|OTHER|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
214711183|NCT02463136|BEHAVIORAL|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
214711184|NCT02463136|DEVICE|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
214711185|NCT01760759|BEHAVIORAL|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
214711186|NCT01760759|BEHAVIORAL|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
214711187|NCT02846051|PROCEDURE|venous mapping|clinical examination + doppler echo
214711188|NCT05247385|DRUG|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
214711189|NCT05247385|DRUG|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
214711190|NCT00745953|DRUG|Valsartan|Valsartan 320mg PO daily for 8 months
214711191|NCT00745953|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
214598832|NCT01937936|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
214598833|NCT01937936|BEHAVIORAL|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
214598834|NCT06845319|DRUG|Carboplatin|Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).
214598835|NCT06845319|DRUG|Paclitaxel|80mg/m2 weekly
214598836|NCT06845319|DRUG|Pembrolizumab|200 mg every 3 weeks for 4 cycles
214598837|NCT04883671|OTHER|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
214598838|NCT04883671|RADIATION|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
214598839|NCT04424979|DEVICE|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
214598840|NCT06560294|DRUG|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
214598841|NCT06560294|OTHER|Glue embolization|Patients will receive transcatheter glue embolization.
214598842|NCT06580938|BIOLOGICAL|PF-07921585|IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously
214598843|NCT06580938|BIOLOGICAL|Sasanlimab|Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
214598844|NCT05205382|OTHER|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
214598845|NCT05205382|OTHER|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
214598846|NCT05205382|OTHER|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
214598847|NCT06528210|DRUG|Gonadotropin Releasing Hormone Agonists and Antagonists|Given PO, IM, Sub-Q injection or Sub-Q implant
214598848|NCT06528210|DRUG|Bicalutamide|Given PO
214598849|NCT06528210|PROCEDURE|Biopsy Procedure|Undergo prostate biopsy
214598850|NCT06528210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214598851|NCT06528210|PROCEDURE|Computed Tomography|Undergo CT scan
214598852|NCT06528210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214598853|NCT06528210|BIOLOGICAL|Pembrolizumab|Given IV
214598854|NCT06528210|OTHER|Questionnaire Administration|Ancillary study
214598855|NCT06528210|RADIATION|Radiation Therapy|Undergo radiation therapy
214598856|NCT06528210|PROCEDURE|Bone Scan|Undergo bone scan
214598857|NCT06135714|DRUG|Systemic therapy for 12 weeks after primary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
214598858|NCT06135714|PROCEDURE|Radiation therapy (SBRT/conventional RT)|Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
214598859|NCT06135714|PROCEDURE|Surgery|Surgery for the oligometastases
214634559|NCT05968729|OTHER|Active Comparator: 0.50 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
214634560|NCT02059200|BEHAVIORAL|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
214634561|NCT01707615|DRUG|GSPE|GSPE 240 mg/day (120mg bid)
214634562|NCT01707615|OTHER|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
214634563|NCT06500416|DEVICE|Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL|Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts.
214634564|NCT01701739|DRUG|aleglitazar|Multiple doses of aleglitazar
214634565|NCT01701739|DRUG|digoxin|Single dose of digoxin
214634566|NCT01081795|DRUG|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
214598860|NCT06135714|DRUG|Same systemic therapy after secondary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
214598861|NCT04241172|DEVICE|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
214711192|NCT01234896|DRUG|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
214711193|NCT01234896|DRUG|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
214711194|NCT01234896|DRUG|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
214711195|NCT01234896|DRUG|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
214711196|NCT02679794|BEHAVIORAL|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
214711197|NCT02679794|BEHAVIORAL|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
214598862|NCT04241172|PROCEDURE|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
214598863|NCT04241172|PROCEDURE|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
214711198|NCT04909216|OTHER|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
214598864|NCT04954820|DRUG|Lutathera|2 additional infusions of Lutathera®
214711199|NCT01788280|DRUG|Fluciclitite , PET imaging, and Bevacizumab|\[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
214711200|NCT04159818|DRUG|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
214598865|NCT05490121|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
214598866|NCT05842512|DRUG|ADI-PEG20|Treatment for NASH
214598867|NCT05842512|OTHER|Placebo|Treatment for NASH
214598868|NCT06313528|DRUG|LY3437943|Administered SC
214711201|NCT04159818|DRUG|Cisplatin|40mg/m2, weekly for two weeks
214711202|NCT04159818|DRUG|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
214711203|NCT03466307|DEVICE|Ultrasonography|Ultrasonographic examination of shoulder
214711204|NCT05063617|DEVICE|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
214711205|NCT00801892|DEVICE|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
214711206|NCT00801892|DEVICE|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
214598869|NCT06313528|OTHER|Placebo|Administered SC
214598870|NCT04396236|DRUG|Lasmiditan|Administered orally
214598871|NCT04396236|DRUG|Placebo|Administered orally
214598872|NCT05814575|BEHAVIORAL|NEXUS intervention|During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.
214598873|NCT05814575|BEHAVIORAL|Standardized Non-Medical fetal ultrasound|A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
214598874|NCT06262607|DRUG|CLE-400|Topical CLE400 gel 0.28% administered once daily
214598875|NCT06262607|DRUG|Vehicle|Topical vehicle gel administered once daily
214598876|NCT04396574|DRUG|Lasmiditan|Administered orally
214598877|NCT04959175|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
214598878|NCT04959175|PROCEDURE|Allogeneic HSCT|Stem cell transplant
214598879|NCT04959175|DRUG|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
214598880|NCT04959175|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
214598881|NCT04959175|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
214598882|NCT04959175|DRUG|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
214598883|NCT04959175|DRUG|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
214598884|NCT04959175|PROCEDURE|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
214598885|NCT05726227|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
214711207|NCT06302998|DRUG|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
214711208|NCT06302998|DRUG|Standard of Care|This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
214711209|NCT06167278|OTHER|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
214711210|NCT01521806|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to snack foods
214711211|NCT00647972|DRUG|Olanzapine Tablets 20 mg|20mg, single dose fasting
214711212|NCT00647972|DRUG|Zyprexa® Tablets 20 mg|20mg, single dose fasting
214711213|NCT01016678|DRUG|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
214598886|NCT05726227|DRUG|Placebo|Placebo will be administered subcutaneously once-weekly.
214598887|NCT06012149|BEHAVIORAL|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
214598888|NCT06012149|BEHAVIORAL|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
214598889|NCT04171310|DRUG|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
214711214|NCT01016678|DRUG|Placebo|Dummy pill comparator
214598890|NCT03263351|BEHAVIORAL|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
214598891|NCT03263351|BEHAVIORAL|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
214598892|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive generic/regular PSAs that address vaping harms more broadly; during the second six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products.
214598893|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products; during the second six months, they will receive generic/regular PSAs that address vaping harms more broadly.
214598894|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (no message exposure)|Participants will not receive any message intervention in this arm.
214598895|NCT06452654|DRUG|Comirnaty Injectable Product|Vaccination
214598896|NCT06452654|DRUG|Sodium Chloride 0.9% Inj|Vaccination
214598897|NCT06675357|RADIATION|FAPI|5 +/- 2 mCi of Ga-FAPI-46
214598898|NCT06675357|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
214598899|NCT06675357|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214598900|NCT04669158|DRUG|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
214598901|NCT04669158|DRUG|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
214598902|NCT05870748|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
214598903|NCT05870748|DRUG|Pegfilgrastim|Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.
214598904|NCT05870748|DRUG|Gemcitabine|Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.
214598905|NCT05870748|DRUG|Paclitaxel|Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.
214598906|NCT05870748|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
214598907|NCT05870748|DRUG|Topotecan|Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
214598908|NCT06334120|DRUG|Darolutamide (Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
214598909|NCT06078579|DIAGNOSTIC_TEST|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
214598910|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
214598911|NCT02076750|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
214598912|NCT04823520|DRUG|TCA|All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
214598913|NCT05311098|DEVICE|cryoablation|Treatment of atrial fibrillation with cryoablation catheters
214598914|NCT00747630|OTHER|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
214598915|NCT04337333|DEVICE|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
214598916|NCT01594866|DRUG|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
214598917|NCT01594866|DRUG|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
214598918|NCT01637623|DRUG|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
214598919|NCT01637623|DRUG|Allopurinol|Allopurinol 300 mg daily for 6 weeks
214598920|NCT01637623|DRUG|Placebo|Placebo capsule daily for 6 weeks
214598921|NCT01647750|DRUG|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
214598922|NCT01647750|DRUG|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
214598923|NCT06420895|OTHER|Clinical follow-up|Clinical follow-up of patients
214598924|NCT06420895|OTHER|Transthoracic Echocardiogram (TTE)|Transthoracic Echocardiogram
214598925|NCT06420895|OTHER|Magnetic resonance imaging (MRI)|Magnetic resonance imaging
214711215|NCT01610908|OTHER|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
214711216|NCT01610908|OTHER|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
214598926|NCT06420895|OTHER|Transesophageal echocardiogram (TEE)|Transesophageal echocardiogram
214598927|NCT03829709|OTHER|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
214598928|NCT04680351|PROCEDURE|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
214598929|NCT01777087|OTHER|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
214598930|NCT05745844|OTHER|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
214598931|NCT01685710|DRUG|GTN patch|
214598932|NCT01685710|DRUG|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
214598933|NCT02415465|PROCEDURE|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
214598934|NCT02415465|PROCEDURE|General|General Intraoperative Anesthesia
214598935|NCT02415465|PROCEDURE|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
214598936|NCT02415465|PROCEDURE|Spinal|Spinal Intraoperative Anesthesia
214598937|NCT01475578|DRUG|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
214598938|NCT01475578|DRUG|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
214598939|NCT01727583|DIETARY_SUPPLEMENT|meal intake|Intake of meals characterized by lipid composition
214598940|NCT01727583|DIETARY_SUPPLEMENT|Placebo|
214598941|NCT00000913|DRUG|Ritonavir|
214598942|NCT00000913|DRUG|Nelfinavir mesylate|
214598943|NCT00000913|DRUG|Saquinavir|
214598944|NCT05740657|DRUG|Fentanyl|The drugs were administered in the course of a surgery or for pain management.
214598945|NCT04791969|DRUG|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
214598946|NCT04791969|DRUG|Placebo|Intermittent Oral Placebo
214598947|NCT04791969|BEHAVIORAL|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
214598948|NCT04630847|BIOLOGICAL|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
214598949|NCT05074420|DRUG|Baricitinib|Given Orally
214598950|NCT04615247|OTHER|Yoga Program|The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.
214598951|NCT04615247|OTHER|Physical Conditioning Program|The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
214598952|NCT03260231|DIETARY_SUPPLEMENT|Milled seed mix|Dietary intervention with or without seed mix
214598953|NCT00247377|PROCEDURE|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
214598954|NCT00247377|PROCEDURE|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
214598955|NCT02743377|OTHER|Brain PET Imaging with 11C Rolipram|Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
214598956|NCT02743377|DRUG|Whole Body PET Baseline with 11C Rolipram|Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
214598957|NCT02743377|DRUG|Whole Body PET Blocked with Roflumilast|Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
214598958|NCT05987852|DEVICE|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
214598959|NCT05987852|OTHER|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
214598960|NCT06469346|OTHER|Nordic Hamstring Eccentric Exercise Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~Nordic eccentric exercise protocol:~* Week 1: 2 sets x 5 repetitions~* Week 2: 2 sets x 6 repetitions~* Week 3: 3 sets x 6 repetitions~* Week 4-6: 3 sets x 8 repetitions"
214598961|NCT06469346|OTHER|Passive Hamstring Static Stretching Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~* Week 1-2: 1 set x 2 repetitions of 30 seconds~* Week 3: 1 set x 3 repetitions of 30 seconds~* Week 4-6: 1 set x 3 reps of 40 seconds"
214598962|NCT06469346|OTHER|Control Group|No intervention
214598963|NCT04085627|DRUG|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg\& Amlodipine 5mg
214598964|NCT02942238|PROCEDURE|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
214598965|NCT02942238|PROCEDURE|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
214598966|NCT03953443|OTHER|Not interventional|
214598967|NCT03113253|DRUG|Tranexamic Acid|
214598968|NCT03113253|DRUG|Placebo|0.9% sodium chloride to mimic tranexamic acid
214598969|NCT02076113|PROCEDURE|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
214598970|NCT02076113|PROCEDURE|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
214598971|NCT02076113|PROCEDURE|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
214598972|NCT04682977|OTHER|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
214598973|NCT04682977|OTHER|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
214598974|NCT06072781|DRUG|avutometinib|Avutometinib: administered orally
214598975|NCT06072781|DRUG|Defactinib|Defactinib: administered orally
214598976|NCT06072781|DRUG|Pegylated liposomal doxorubicin|administered intravenously
214598977|NCT06072781|DRUG|Paclitaxel|administered intravenously
214598978|NCT06072781|DRUG|Letrozole|administered orally
214598979|NCT06072781|DRUG|Anastrozole|administered orally
214598980|NCT05395481|DRUG|LY3849891|Administered SC
214598981|NCT05395481|DRUG|Placebo|Administered SC
214598982|NCT04908605|DRUG|Mirtazapine|Every patient will be given mirtazapine 30 mg tablet
214598983|NCT04908605|DRUG|Melatonin|Every patient will be given melatonin 5 mg tablet
214598984|NCT04908605|DRUG|Placebo|Every patient will be given a matching placebo tablet
214598985|NCT06832306|DEVICE|Phrenic Nerve Stimulation|During controlled MV when patients are not breathing, continuous diaphragm neurostimulation-assisted ventilation (DNAV) will be delivered in synchrony with each ventilator-delivered breath.
214598986|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
214598987|NCT06199466|DRUG|Gemcitabine|Given by IV
214598988|NCT06199466|DRUG|Nab-paclitaxel|Given by IV
214598989|NCT06199466|DRUG|YL-13027|Given by PO
214598990|NCT00692302|BEHAVIORAL|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
214598991|NCT00692302|BEHAVIORAL|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
214598992|NCT06736574|DRUG|Omecamtiv Mecarbil (OM)|Oral Tablet
214598993|NCT06736574|DRUG|Placebo|Oral Tablet
214598994|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Bolus)|IM in the deltoid
214598995|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
214598996|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Bolus)|SC in the upper arm
214598997|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
214598998|NCT06033209|BIOLOGICAL|SMNP (IM, Bolus)|IM in the deltoid
214598999|NCT06033209|BIOLOGICAL|SMNP (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
214599000|NCT06033209|BIOLOGICAL|SMNP (SC, Bolus)|SC in the upper arm
214599001|NCT06033209|BIOLOGICAL|SMNP (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
214599002|NCT06076486|DRUG|Elagolix|Elagolix 200 mg tablets administered orally BID
214599003|NCT06076486|DRUG|Elagolix placebo|Elagolix placebo administered orally BID
214599004|NCT05713188|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
214599005|NCT06518174|DIAGNOSTIC_TEST|MRI, SWE, and US evaluation|"We will perform SWE and MRI sampling of the uterus from fundus to lower uterine segment with at least two points each from the upper, mid, and lower thirds of the uterus. SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, we will also collect transvaginal US. MRI images will also be sampled from existing pretreatment studies performed as standard of care. All images will be evaluated for the presence and degree of fibrosis. We will compare SWE and MRI post-treatment. We will also compare pre-and post-treatment MRI.~We will perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to age-matched controls"
214599006|NCT06836375|DIAGNOSTIC_TEST|Spirometry test with bronchodilation|this test measures how much air you can breathe in and out of your lungs, as well as how easily and fast you can then blow the air out of your lungs
214599007|NCT06836375|DIAGNOSTIC_TEST|Methacholine challenge|test used to diagnose asthma where the patient breaths in methacholine
214599008|NCT06836375|DIAGNOSTIC_TEST|impulse oscillometry|test that uses sound waves to measure how much resistance there is to the normal movement of air in and out of your lungs when you are breathing at rest
214599009|NCT06836375|OTHER|Measurement of the exhaled FeNO fraction|Measure the level of nitric oxide in parts per billion (PPB) in the air the patient slowly exhales
214599010|NCT06193863|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|At the discretion of the treating physician, based on the recommendations written in the local product information.
214599011|NCT06834685|DEVICE|Photobiomodulation sessions|The treatment will be administered by an ATP38 device delivering a power of 4 Joules/cm2 at wavelengths of 620 and 820 nm
214599012|NCT01245075|OTHER|Deep brain stimulation|Deep brain stimulation on
214599013|NCT01245075|OTHER|Placebo|deep brain stimulation off
214599014|NCT03399409|BEHAVIORAL|Motivational Interviewing|Motivation techniques
214599015|NCT03399409|BEHAVIORAL|Anti-inflammatory Information|Provision of information on anti-inflammatory products
214599016|NCT04500665|DRUG|Colchicine|Colchicine
214599017|NCT04500665|DRUG|Placebo|Placebo
214599018|NCT01621230|DRUG|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
214599019|NCT01621230|DRUG|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
214599020|NCT02596620|DRUG|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
214599021|NCT02596620|DRUG|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
214599022|NCT02596620|DRUG|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
214599023|NCT02596620|DRUG|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
214599024|NCT02067442|DRUG|oral acetaminophen|1000 milligrams given orally before surgery
214599025|NCT02067442|DRUG|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
214599026|NCT04285242|OTHER|Observational assessments|Clinical assessments
214599027|NCT04899661|DRUG|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
214599028|NCT01054144|DRUG|Lenalidomide|"* Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~* Dose Level -4: Discontinue"
214599029|NCT01054144|DRUG|Prednisone|"* Starting Dose: 100 mg PO days 1-5 every 28 days;~* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~* Dose level -3: Discontinue"
214599030|NCT01054144|DRUG|Dexamethasone|"* Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~* Dose level -3: Discontinue"
214599031|NCT04620551|DEVICE|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
214599032|NCT03976349|DRUG|BIIB094|Administered as specified in the treatment arm.
214711217|NCT03185416|OTHER|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
214711218|NCT03958318|OTHER|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
214711219|NCT03958318|OTHER|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
214711220|NCT01233700|BEHAVIORAL|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
214711221|NCT01233700|BEHAVIORAL|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
214711222|NCT00323024|DRUG|NX1011|
214599033|NCT03976349|DRUG|Placebo|Administered as specified in the treatment arm.
214599034|NCT03997266|DRUG|Ampicillin|Intravenous ampicillin
214599035|NCT03997266|DRUG|Gentamycin|Intravenous gentamycin
214599036|NCT03997266|DRUG|Normal saline|Intravenous normal saline
214599037|NCT06518564|DRUG|Avelumab|Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
214711223|NCT01766219|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214711224|NCT01126684|DRUG|Atorvastatin|10 mg of atorvastatin once daily for six months
214711225|NCT01126684|DRUG|Placebo|placebo once daily for six months
214711226|NCT01711541|DRUG|Carboplatin|Given IV
214711227|NCT01711541|DRUG|Cisplatin|Given IV
214711228|NCT01711541|DRUG|Fluorouracil|Given IV
214599038|NCT06518564|DRUG|M1774|Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
214599039|NCT04265547|BEHAVIORAL|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
214599040|NCT04981509|BIOLOGICAL|Atezolizumab|Given PO
214711229|NCT01711541|DRUG|Hydroxyurea|Given PO
214711230|NCT01711541|OTHER|Laboratory Biomarker Analysis|Correlative studies
214711231|NCT01711541|DRUG|Paclitaxel|Given IV
214711232|NCT01711541|OTHER|Placebo Administration|Given PO
214711233|NCT01711541|RADIATION|Radiation Therapy|Undergo radiation therapy
214711234|NCT01711541|DRUG|Veliparib|Given PO
214711235|NCT03161171|OTHER|This is an observational study|This is an observational study
214599041|NCT04981509|BIOLOGICAL|Bevacizumab|Given IV
214711236|NCT00728936|DRUG|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
214711237|NCT00728936|DRUG|Saline placebo|saline placebo given subcutaneously
214711238|NCT04301583|DIETARY_SUPPLEMENT|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
214599042|NCT04981509|PROCEDURE|Biopsy Procedure|Undergo biopsy
214599043|NCT04981509|PROCEDURE|Biospecimen Collection|Undergo blood collection
214711239|NCT00801346|OTHER|laboratory biomarker analysis|
214711240|NCT00801346|OTHER|metabolic assessment|
214711241|NCT00801346|OTHER|questionnaire administration|
214711242|NCT00801346|PROCEDURE|assessment of therapy complications|
214711243|NCT00801346|PROCEDURE|fatigue assessment and management|
214711244|NCT00801346|PROCEDURE|quality-of-life assessment|
214711245|NCT02691481|DIETARY_SUPPLEMENT|Oatmeal breakfast|
214711246|NCT02691481|DIETARY_SUPPLEMENT|Glucerna formula|
214711247|NCT02691481|DIETARY_SUPPLEMENT|Ultra Glucose Control formula|
214711248|NCT06104722|OTHER|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
214711249|NCT06104722|OTHER|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
214711250|NCT06443749|PROCEDURE|appendectomy|the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
214711251|NCT00541736|DRUG|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
214711252|NCT03602989|DEVICE|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
214599044|NCT04981509|PROCEDURE|Bone Scan|Undergo bone scan
214711253|NCT03514238|BEHAVIORAL|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
214711254|NCT03514238|BEHAVIORAL|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
214711255|NCT03514238|BEHAVIORAL|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
214711256|NCT06376188|OTHER|communication training|The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
214599045|NCT04981509|PROCEDURE|Computed Tomography|Undergo CT without contrast
214599046|NCT04981509|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
214599047|NCT04981509|DRUG|Erlotinib|Given PO
214599048|NCT04981509|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214599049|NCT04981509|PROCEDURE|Positron Emission Tomography|Undergo PET
214599050|NCT04981509|DRUG|Sodium Fluoride F-18|Given F-18 sodium fluoride
214599051|NCT05628285|DEVICE|Sentio 1|Sound processor
214599052|NCT05733546|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
214599053|NCT05719415|OTHER|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
214599054|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
214711257|NCT05254652|DRUG|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
214711258|NCT05254652|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
214711259|NCT02391974|DEVICE|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
214711260|NCT00973180|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
214711261|NCT02802072|DEVICE|Enterprise stent implantation|Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
214711262|NCT02802072|DRUG|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
214711263|NCT00707460|BEHAVIORAL|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
214711264|NCT04748913|DEVICE|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
214599055|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
214711265|NCT04748913|DEVICE|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
214711266|NCT04748913|DEVICE|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
214599056|NCT06331078|OTHER|Square Stepping Exercise training|The experimental group will have Square Stepping Exercise training.
214599057|NCT06331078|OTHER|Aerobic Exercise Training|Individuals in the aerobic control cohort will partake in a treadmill walking session.
214711267|NCT04748913|DIAGNOSTIC_TEST|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
214599058|NCT06530563|DRUG|Oliceridine Injection [Olinvyk]|"Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
214599059|NCT06530563|DRUG|Sufentanil Citrate|"Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
214599060|NCT04507074|DEVICE|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
214599061|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
214599062|NCT06046040|DRUG|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
214599063|NCT05402332|DRUG|AVTX-801|D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
214599064|NCT05402332|DRUG|Placebo|placebo equivalent
214599065|NCT05050682|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
214599066|NCT05471700|DRUG|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
214599067|NCT05471700|DRUG|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
214599068|NCT06963034|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
214599069|NCT06963034|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
214599070|NCT06961565|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1m and 4mg strength tablets, intended for oral administration once daily.
214599071|NCT04992325|DIAGNOSTIC_TEST|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
214599072|NCT05664763|DRUG|[18F]FPEB with PET|radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
214599073|NCT05664763|BEHAVIORAL|Cannabis abstinence|Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
214599074|NCT03720262|COMBINATION_PRODUCT|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
214599075|NCT03720262|OTHER|No reinforcement|Suturing the abdominal wall without mesh reinforcement
214599076|NCT05735730|OTHER|Blood draw|The study intervention consists of a blood draw for genetic analysis.
214599077|NCT04118283|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
214599078|NCT04118283|BEHAVIORAL|Health and Wellness|Health \& Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
214599079|NCT02042430|DRUG|Epacadostat|Given PO
214599080|NCT02042430|OTHER|Laboratory Biomarker Analysis|Correlative studies
214599081|NCT02042430|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214599082|NCT06387966|DRUG|Flonoltinib Maleate Tablets|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
214599083|NCT06387966|DRUG|Flonoltinib Maleate Tablets placebo|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
214599084|NCT02853019|OTHER|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
214599085|NCT02853019|BEHAVIORAL|Cognitive tasks|\- clinical scales and subjective assessments of emotional and motivational stimuli
214599086|NCT02853019|BEHAVIORAL|subjective evaluation scales|\- clinical scales and subjective assessments of emotional and motivational stimuli
214599087|NCT05940662|PROCEDURE|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
214599088|NCT05940662|PROCEDURE|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
214599089|NCT05940662|PROCEDURE|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
214599090|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after oncological surgery.|In patients who will undergo oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
214599091|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after non-oncological surgery.|In patients who will undergo non-oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
214599092|NCT06631339|OTHER|Light Intervention|LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
214599093|NCT06631339|BEHAVIORAL|Digital Intervention|Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
214599094|NCT06631339|OTHER|Control Group|Standard Classroom Lighting + Sham LightUP phone application
214599095|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
214599096|NCT06380842|OTHER|Necrotizing Pancreatitis patients' organ dysfunction progression|Study the dynamic nature of organ dysfunction
214599097|NCT06561425|GENETIC|GLPG5101|Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
214599098|NCT06561386|DRUG|Nivolumab|Specified dose on specified days
214599099|NCT06561386|DRUG|Relatlimab|Specified dose on specified days
214599100|NCT06561386|DRUG|Pembrolizumab|Specified dose on specified days
214599101|NCT06561386|DRUG|Carboplatin|Specified dose on specified days
214599102|NCT06561386|DRUG|Pemetrexed|Specified dose on specified days
214599103|NCT06561386|DRUG|Cisplatin|Specified dose on specified days
214599104|NCT05156398|DRUG|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
214599105|NCT05156398|DRUG|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
214634567|NCT01081795|DRUG|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
214634568|NCT01358656|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith \& Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
214599106|NCT06085092|BEHAVIORAL|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
214599107|NCT06085092|BEHAVIORAL|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
214711268|NCT04939532|BEHAVIORAL|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
214599108|NCT04743141|DRUG|Rimegepant (PF-07899801)|Rimegepant 75 mg, 50 mg or 35 mg ODT
214599109|NCT06397313|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
214599110|NCT06397313|DRUG|Ruxolitinib|Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
214599111|NCT03768986|BEHAVIORAL|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
214599112|NCT03768986|BEHAVIORAL|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
214599113|NCT03768986|BEHAVIORAL|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
214599114|NCT05615844|DRUG|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
214599115|NCT05615844|DEVICE|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
214599116|NCT06770452|DRUG|HRS-4642|HRS-4642 is a KRAS G12D inhibitor
214599117|NCT06770452|DRUG|Nimotuzumab|Nimotuzumab is a humanized IgG 1 monoclonal antibody targeting EGFR
214599118|NCT06770452|DRUG|gemcitabine + nab-paclitaxel|Albumin paclitaxel 125mg/m2 intravenous infusion, gemcitabine 1000mg / m2, D1,8, a cycle every 3 weeks
214599119|NCT00202566|DRUG|Ivabradine|
214599120|NCT00334347|DRUG|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
214599121|NCT00334347|DRUG|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
214599122|NCT02404974|BEHAVIORAL|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
214599123|NCT01859780|OTHER|Visual distractor|
214599124|NCT04294563|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
214599125|NCT04294563|OTHER|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
214599126|NCT03489174|OTHER|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
214599127|NCT03489174|OTHER|Usual Care|Usual care.
214599128|NCT00139087|BEHAVIORAL|Telephone Outreach for Therapy|
214599129|NCT02904434|OTHER|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
214599130|NCT06339619|DRUG|Adebrelimab|20mg/kg ivgtt D1 Q3W
214599131|NCT06339619|DRUG|Apatinib|250mg PO QD
214599132|NCT06339619|DRUG|Tegafur|dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
214599133|NCT04261023|DRUG|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
214599134|NCT05073237|OTHER|Placebo|Daily placebo tablet
214599135|NCT05073237|DRUG|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
214599136|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
214599137|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
214599138|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
214599139|NCT01284062|OTHER|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
214599140|NCT00559585|DRUG|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
214599141|NCT00559585|DRUG|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
214599142|NCT02047825|OTHER|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
214599143|NCT02047825|OTHER|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
214599144|NCT03027375|DRUG|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
214599145|NCT03027375|DRUG|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
214599146|NCT04111042|DEVICE|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
214599147|NCT02716467|OTHER|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
214599148|NCT02716467|RADIATION|Radiotherapy|All participants will receive treatment by radiotherapy
214599149|NCT04608669|DRUG|Paracetamol|Give paracetamol or placebo and compare temperature
214599150|NCT04028908|DIAGNOSTIC_TEST|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
214599151|NCT02329665|DEVICE|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
214599152|NCT00279110|BEHAVIORAL|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
214599153|NCT00286884|PROCEDURE|Monitoring of heart rate variability|
214599154|NCT00842881|DEVICE|Healingstone navel belt|6\~8hours/day for 3months
214599155|NCT05015946|BEHAVIORAL|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
214599156|NCT01633814|DRUG|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
214599157|NCT01633814|DRUG|Placebo|placebo patch.
214599158|NCT04830956|OTHER|FID123238|Lubricant applied to the ocular surface
214599159|NCT04830956|OTHER|Systane Hydration|Drops applied to the ocular surface
214599160|NCT01372670|DRUG|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
214599161|NCT01372670|DRUG|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
214599162|NCT01372670|OTHER|Placebo|Placebo given 3 times per day
214599163|NCT04706351|OTHER|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
214599164|NCT01717768|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
214599165|NCT00827762|DRUG|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
214599166|NCT02407184|OTHER|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
214599167|NCT04410250|BEHAVIORAL|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
214599168|NCT00809523|DEVICE|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
214599169|NCT00809523|DEVICE|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
214599170|NCT03417518|DRUG|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
214599171|NCT03417518|DRUG|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
214599172|NCT04195581|DEVICE|comfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
214599173|NCT04195581|DEVICE|fanfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
214599174|NCT01881581|BIOLOGICAL|Saline Solution|Saline Solution is used as control in all arms.
214599175|NCT01881581|BIOLOGICAL|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
214599176|NCT01881581|BIOLOGICAL|M-GPE|M-GPE is used in Arm D,E,F,G and H
214599177|NCT06472583|DRUG|Keytruda|Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
214599178|NCT06472583|RADIATION|Preoperative radiation therapy|Boost of preoperative robotic stereotactic radiotherapy
214599179|NCT06472583|DRUG|Placebo|0,9% NaCl in the volume 100 ml
214599180|NCT03965078|DRUG|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
214599181|NCT00446238|BEHAVIORAL|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
214599182|NCT00446238|BEHAVIORAL|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
214599183|NCT05515120|DRUG|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
214599184|NCT05515120|DRUG|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
214599185|NCT05515120|DRUG|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
214711269|NCT04939532|BEHAVIORAL|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
214711270|NCT04773704|DIAGNOSTIC_TEST|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
214711271|NCT00457756|DIETARY_SUPPLEMENT|BiosLife Complete|
214711272|NCT00457756|DIETARY_SUPPLEMENT|Placebo|
214711273|NCT00719524|DRUG|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
214599186|NCT05506501|PROCEDURE|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
214599187|NCT05506501|PROCEDURE|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
214599188|NCT02646748|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
214711274|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, two days treatment
214711275|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, two days treatment
214711276|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, two days treatment
214711277|NCT00700063|DRUG|Vehicle gel|two days treatment
214599189|NCT02646748|DRUG|itacitinib|Itacitinib tablets administered orally once daily.
214599190|NCT02646748|DRUG|INCB050465|INCB050465 tablets administered orally once daily.
214599191|NCT05175313|RADIATION|transthoracic ultrasonography|"1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound"
214599192|NCT05175313|DEVICE|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
214599193|NCT04693260|DEVICE|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
214711278|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, three days treatment
214711279|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, three days treatment
214711280|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, three days treatment
214599194|NCT04858854|OTHER|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
214599195|NCT02576236|OTHER|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
214711281|NCT00700063|DRUG|Vehicle gel|three days treatment
214711282|NCT00931294|BEHAVIORAL|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
214711283|NCT00931294|BEHAVIORAL|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
214711284|NCT03639922|DRUG|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
214711285|NCT03639922|DRUG|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
214711286|NCT03162094|DRUG|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
214711287|NCT03162094|DRUG|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
214711288|NCT03162094|DRUG|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
214711289|NCT05010772|DRUG|Decitabine and Cedazuridine|Given PO
214711290|NCT05010772|DRUG|Enasidenib|Given PO
214711291|NCT05010772|DRUG|Gilteritinib|Given PO
214599196|NCT02576236|OTHER|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
214599197|NCT04721821|DRUG|Tofacitinib|Patients who received Tofacitinib for RA
214599198|NCT01237340|DRUG|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
214599199|NCT01382264|OTHER|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
214599200|NCT03598322|PROCEDURE|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
214599201|NCT03598322|PROCEDURE|Dextrose 2mL injection|Dextrose 2mL injection
214599202|NCT03598322|PROCEDURE|Dextrose 4mL injection|Dextrose 4mL injection
214599203|NCT01205997|DRUG|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
214599204|NCT01205997|DRUG|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
214599205|NCT01205997|DRUG|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
214599206|NCT06425276|DRUG|Melphalan Hydrochloride for Injection|During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
214599207|NCT06254911|BIOLOGICAL|Atezolizumab|Given IV
214599208|NCT06254911|PROCEDURE|Transoral Surgery with cervical lymphadenctomy (neck dissection)|Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck
214599209|NCT06254911|PROCEDURE|Computed Tomography|Undergo CT scan
214599210|NCT06254911|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214599211|NCT00183768|BEHAVIORAL|Cognitive Behavioral Therapy|
214599212|NCT00183768|BEHAVIORAL|Psychopharmacology|
214711292|NCT05010772|DRUG|Ivosidenib|Given PO
214711293|NCT05010772|DRUG|Venetoclax|Given PO
214711294|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
214711295|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
214599213|NCT02802930|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214599214|NCT02802930|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214599215|NCT02802930|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214599216|NCT02802930|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
214599217|NCT04549519|OTHER|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
214599218|NCT04978311|BEHAVIORAL|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
214599219|NCT04978311|BEHAVIORAL|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
214599220|NCT04978311|BEHAVIORAL|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
214599221|NCT05683535|DRUG|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
214599222|NCT02959567|DEVICE|Aqueduct 100 dilation|
214599223|NCT02981654|DEVICE|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
214599224|NCT00151736|DRUG|Chlorambucil|Chlorambucil 2mg tablets
214599225|NCT00151736|DRUG|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
214599226|NCT00243750|DRUG|Methotrexate|
214599227|NCT01217268|BEHAVIORAL|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
214711296|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
214599228|NCT03197363|OTHER|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
214599229|NCT01562951|DRUG|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
214599230|NCT01562951|DRUG|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
214599231|NCT00909454|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
214599232|NCT00909454|DIETARY_SUPPLEMENT|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
214599233|NCT01400789|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
214599234|NCT00014313|DRUG|cisplatin|
214599235|NCT00014313|DRUG|etoposide|
214599236|NCT02519309|OTHER|Virta Program|
214599237|NCT06220903|OTHER|Complex Decongestive Therapy|"1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
214599238|NCT01906346|DRUG|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
214599239|NCT01906346|DRUG|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
214599240|NCT01487356|OTHER|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
214599241|NCT06075238|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
214599242|NCT04959955|DIAGNOSTIC_TEST||
214599243|NCT04896138|OTHER|Interstitial Lung Disease|Not applicable - this is not an interventional trial
214599244|NCT00737919|DIETARY_SUPPLEMENT|Plant Stanol|Plant stanols in margarines daily 2 grams
214711297|NCT02966353|DRUG|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
214711298|NCT03013257|DEVICE|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
214711299|NCT06062342|BEHAVIORAL|FPI|The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
214711300|NCT04632407|DIETARY_SUPPLEMENT|"Flax milk"|See above
214711301|NCT04632407|DIETARY_SUPPLEMENT|"Oat fibre milk"|See above
214599245|NCT00737919|DIETARY_SUPPLEMENT|Plant Sterol|Plant sterols in margarines daily 2 grams
214599246|NCT04226833|DRUG|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
214599247|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
214599248|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
214599249|NCT04957550|DRUG|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
214599250|NCT02088788|DEVICE|Board|Also has radio-dense pelvic shielding
214599251|NCT02088788|DEVICE|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
214599252|NCT02774551|BEHAVIORAL|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
214599253|NCT05452590|PROCEDURE|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
214599254|NCT01230853|DRUG|Active Comparator: A|Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
214599255|NCT01230853|DRUG|Placebo Comparator B|Placebo Matching Placebo Infusion
214599256|NCT01230853|DRUG|Active Comparator B|Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
214599257|NCT01230853|DRUG|Placebo Comparator A|Placebo Matching Placebo Infusion
214599258|NCT02423239|DRUG|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
214599259|NCT02423239|DRUG|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
214599260|NCT02423239|DRUG|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
214599261|NCT02423239|DRUG|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
214599262|NCT02701738|DIETARY_SUPPLEMENT|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
214599263|NCT04288895|DRUG|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
214599264|NCT01115972|DRUG|ASP1585|oral
214599265|NCT01115972|DRUG|valsartan|oral
214599266|NCT00730431|DRUG|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
214599267|NCT00730431|DRUG|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
214599268|NCT04462341|DEVICE|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
214599269|NCT04462341|DEVICE|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
214599270|NCT00198549|DRUG|Vitrase (ovine hyaluronidase) Lyophilized|
214599271|NCT02876835|DRUG|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
214599272|NCT02876835|DRUG|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
214599273|NCT02876835|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
214599274|NCT02876835|DRUG|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
214599275|NCT04537169|PROCEDURE|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
214599276|NCT05383404|DIAGNOSTIC_TEST|blood and urine samples|complete blood count, blood glucose, blood gases, serum bicarbonates, serum electrolytes, serum albumin ,serum creatinine. blood urea nitrogen, urine analysis.
214599277|NCT02540538|BIOLOGICAL|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
214599278|NCT02540538|BIOLOGICAL|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
214599279|NCT03318939|DRUG|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID"
214599280|NCT04338828|DRUG|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
214599281|NCT04338828|OTHER|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
214599282|NCT00003741|BIOLOGICAL|monoclonal antibody HeFi-1|
214599283|NCT06165614|DRUG|Artesunate pessary|Subjects will self-administer 200 mg of Artesunate pessary (vaginal insert) daily for 5 days, on weeks 1, 3, 5, 7.
214599284|NCT06165614|PROCEDURE|Colposcopy|Colposcopy is a procedure that allows close examination of the cervix, vagina, and vulva, performed on weeks 8 and 14.
214599285|NCT00403754|DRUG|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
214599286|NCT00403754|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214599287|NCT00403754|DRUG|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
214599288|NCT00640055|OTHER|Coordinator|Coordinator (non-physician) assigned cause of death
214599289|NCT00640055|OTHER|Physician-assigned cause of death|Physician (gold standard) cause of death
214599290|NCT00614705|DRUG|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
214599291|NCT00614705|DRUG|Placebo|oral capsule form, once daily for 28 days
214599292|NCT05585528|PROCEDURE|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
214599293|NCT06972719|BEHAVIORAL|Experimental Arm|Participants will be randomized to SOC plus the video.
214599294|NCT06972719|BEHAVIORAL|SOC Arm|Participants will be randomized to SOC counseling.
214599295|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
214599296|NCT05025423|DRUG|Venetoclax Oral Tablet [Venclexta]|Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
214599297|NCT05483296|OTHER|Dim light condition|"During the Dim light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
214599298|NCT05483296|OTHER|Moderate light condition|"During the Moderate light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
214599299|NCT05483296|OTHER|Bright light condition|"During the Bright light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
214599300|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
214599301|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
214599302|NCT05701189|DRUG|Efgartigimod Alfa-Fcab|Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
214599303|NCT05701189|DRUG|Intravenous Immunoglobulin (IVIg)|IVIg is the standard-of-care treatment for GBS. Brand of IVIG used may vary per institutional standards
214599304|NCT04260217|DRUG|APG2575 400 mg|APG2575 400 mg
214599305|NCT04260217|DRUG|APG2575 600 mg|APG2575 600 mg
214599306|NCT04260217|DRUG|APG2575 800 mg|APG2575 800 mg
214599307|NCT05256238|OTHER|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~* week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…~* week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~* maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
214599308|NCT06602856|OTHER|Point-of-care ultrasound examination|We are investigating the extent to which pre-hospital point-of-care ultrasound examination influences the further deployment tactics, medical treatment and choice of destination hospital for patients.
214599309|NCT06353438|OTHER|Exercise Program|Concentric strengthening of multiple muscle groups 2x/week for 6 weeks.
214599310|NCT04543487|OTHER|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
214599311|NCT02271477|DEVICE|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
214711302|NCT06123390|OTHER|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
214711303|NCT00749268|DEVICE|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
214711304|NCT00749268|DEVICE|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
214711305|NCT03418272|DIAGNOSTIC_TEST|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis"
214599312|NCT04382274|PROCEDURE|Quadratus Lumborum Block|transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
214599313|NCT04382274|PROCEDURE|Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
214599314|NCT01118689|DRUG|MLN0128|MLN0128 administered orally once daily for 28 days
214711306|NCT00093470|PROCEDURE|Clinical Observation|Undergo observation
214711307|NCT00093470|DRUG|Tipifarnib|Given PO
214711308|NCT00877006|DRUG|bendamustine|
214711309|NCT00877006|DRUG|rituximab|
214711310|NCT00877006|DRUG|vincristine|
214711311|NCT00877006|DRUG|prednisone|
214711312|NCT00877006|DRUG|cyclophosphamide|
214711313|NCT00877006|DRUG|doxorubicin|
214711314|NCT04397926|DRUG|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
214711315|NCT06270563|OTHER|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
214599315|NCT03723876|BEHAVIORAL|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
214599316|NCT03049735|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
214711316|NCT06270563|OTHER|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
214599317|NCT03049735|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
214599318|NCT03049735|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
214599319|NCT03049735|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
214599320|NCT04029935|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
214599321|NCT04029935|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
214599322|NCT03153111|DRUG|Macitentan|macitentan 10 mg; film-coated tablet; oral use
214599323|NCT03153111|DRUG|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
214599324|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
214599325|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
214599326|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
214599327|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
214599328|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
214599329|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
214599330|NCT02749656|DRUG|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
214599331|NCT02749656|DRUG|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
214599332|NCT02749656|DRUG|Placebo|apply on the scalp psoriasis lesion twice a day
214599333|NCT00713726|DRUG|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
214599334|NCT00713726|DRUG|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
214599335|NCT02882932|PROCEDURE|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
214599336|NCT03341351|OTHER|Instructional video|Instructional video using the modified beef tongue model
214599337|NCT03341351|OTHER|Instructional workshop|Instructional workshop using the modified beef tongue model.
214599338|NCT01349335|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
214599339|NCT01349335|DRUG|Tolvaptan|tablet, 30 mg, Qd, 7 days
214599340|NCT01349335|DRUG|placebo|tablet, 30 mg, Qd, 7days.
214599341|NCT01572922|DEVICE|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
214711317|NCT06270563|OTHER|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
214599342|NCT01572922|DEVICE|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
214599343|NCT01572922|PROCEDURE|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
214599344|NCT02736604|DRUG|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
214599345|NCT02736604|DRUG|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
214599346|NCT02736604|DEVICE|laryngeal mask airway (LMA Supreme Size 3/4|
214599347|NCT02736604|DRUG|sevoflurane|
214599348|NCT03040622|DEVICE|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
214599349|NCT04231266|DRUG|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
214599350|NCT04231266|OTHER|Placebo|Placebo
214599351|NCT06335862|OTHER|Randomisation between the PPT- and no-PPT-group|Randomisation is performed between two possible treatment options for tracheomalacia in OA patients; the PPT or the wait-and-see policy (no-PPT).
214599352|NCT06335862|PROCEDURE|Primary Posterior Tracheopexy|The PPT involves fixating the posterior membrane of the trachea to the spinal ligament with sutures, to prevent the trachea from collapsing.
214599353|NCT06335862|DIAGNOSTIC_TEST|Preoperative tracheobronchoscopy|Prior to OA correction, a flexible and a rigid tracheobronchoscopy will be performed, in addition to a flexible tracheobronchoscopy through the endotracheal tube. Preoperative evaluation of TM through a tracheobronchoscopy is part of standard care for all participating centres.
214599354|NCT06335862|DIAGNOSTIC_TEST|Intraoperative tracheobronchoscopy|After the PPT is performed, or in case of the no-PPT group at the stage of the surgery when the PPT would usually be performed, a flexible tracheobronchoscopy through the endotracheal tube is carried out. This tracheobronchoscopy is routine care for all patients undergoing a PPT, and is additional for patients in the no-PPT-group.
214711318|NCT06270563|OTHER|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
214711319|NCT01945268|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
214711320|NCT01945268|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
214711321|NCT00381719|DRUG|AGN 203818|3 mg Capsule twice daily for 4 weeks
214711322|NCT00381719|DRUG|AGN 203818|20 mg Capsule twice daily for 4 weeks
214711323|NCT00381719|DRUG|AGN 203818|60 mg Capsule twice daily for 4 weeks
214599355|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy through the endotracheal tube during extubation|A postoperative flexible tracheobronchoscopy is performed in the neonatal or pediatric intensive care unit (ICU), through the endotracheal tube during extubation. This procedure is a study intervention.
214599356|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy after 2-6 months|Two to six months after OA correction, a follow-up flexible and a rigid tracheobronchoscopy will be performed, under general anesthesia in the surgical theatre. This postoperative evaluation of TM through a tracheobronchoscopy is part of standard care for the Karolinska University Hospital and Great Ormond Street Hospital. At the University Medical Centre Utrecht and Erasmus Medical Centre Rotterdam, this tracheobronchoscopy is performed on indication in approximately half of patients. For the other half of patients, this is a study intervention.
214599357|NCT05880277|DIAGNOSTIC_TEST|POCUS|Point of Care Ultrasound
214599358|NCT01802489|DRUG|Amiloride|
214599359|NCT01802489|DRUG|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
214599360|NCT00809081|PROCEDURE|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
214599361|NCT00160381|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
214599362|NCT00160381|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
214711324|NCT00381719|DRUG|placebo capsule|Capsule twice daily for 4 weeks
214711325|NCT05076097|DRUG|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
214711326|NCT01415908|DEVICE|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
214711327|NCT01415908|OTHER|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
214711328|NCT06337162|DRUG|INCB099280|400 mg Tablet
214599363|NCT00160381|DRUG|Placebo|Tablet, oral Daily for 12 months
214599364|NCT00445068|DRUG|LBH589|
214711329|NCT05693688|DRUG|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
214711330|NCT05595551|BEHAVIORAL|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
214599365|NCT05636891|BIOLOGICAL|Stimus|"* NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
214599366|NCT00447382|DRUG|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
214599367|NCT00447382|DRUG|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
214599368|NCT00447382|DRUG|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
214599369|NCT05651750|DRUG|Montelukast|receiving 2 months treatment with Montelukast once a day
214599370|NCT05651750|DRUG|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
214599371|NCT03861819|BEHAVIORAL|Vigorous-intensity interval training (VIIT)|Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
214599372|NCT04119973|OTHER|standard treatment|standard medical treatment
214599375|NCT05915000|DIAGNOSTIC_TEST|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
214599376|NCT04067375|OTHER|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
214599377|NCT00538889|DRUG|Lecozotan SR|
214599378|NCT00538889|DRUG|Citalopram|
214599379|NCT04059016|OTHER|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
214711331|NCT01770041|OTHER|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
214599380|NCT01115790|DRUG|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
214599381|NCT00780754|DRUG|dutasteride|0.5mg
214599382|NCT00780754|PROCEDURE|prostate biopsy|prostate biopsy
214599383|NCT06286007|DIAGNOSTIC_TEST|PCR|Depending on the symptoms presented and date of symptom onset, for pertussis, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 3 weeks For RSV, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 72 hours.
214599384|NCT00091585|DRUG|SNS-595|
214599385|NCT03144804|DRUG|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
214599386|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
214599387|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
214599388|NCT02100397|BIOLOGICAL|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
214599389|NCT06514326|BEHAVIORAL|DPT-TP|"This intervention includes all the ingredients of DPT-STD, but with additional features that correspond to the conceptual model of therapeutic persuasiveness. Each theme in the program comprises a learning phase followed by a 1-2 week focusing phase.~Accordingly, the program utilizes the following features:~1. Call to action: Parents receive timely triggers via text messages that are related to the specific goals and therapeutic activities of the modules they have completed.~2. Monitoring and ongoing feedback of user state: Specific practices currently taught are documented within the system through a brief daily report, on which parents receive feedback.~3. Adaptation to user state: Parents' reports on their activities are used to acknowledge their success and to suggest additional actions based on the specific goals reported by parents. Effort related to desired therapeutic activities is adapted based on graded tasks."
214599390|NCT06514326|BEHAVIORAL|DPT-STD|"This intervention is similar in its features to other programs that deliver DPT, and is suitable for use on computers or on mobile devices. An icon is positioned on the mobile device home screen in order to enable quick access to the program. The DPT-STD comprises seven 10- to 25-minute modules, each corresponding to one of the themes mentioned above. Each module's content includes videos and texts guiding the parent through the training process, and interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials and a questions and answers section that contains frequently asked questions."
214711332|NCT04302272|DEVICE|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
214711333|NCT02405806|DIETARY_SUPPLEMENT|low carbohydrate food|low carbohydrate food
214711334|NCT02405806|DIETARY_SUPPLEMENT|standard food|standard food
214711335|NCT02601443|DEVICE|Cervical Pessary|
214711336|NCT02034552|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
214711337|NCT02034552|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
214711338|NCT02034552|DRUG|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
214711339|NCT02034552|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
214711340|NCT03278652|OTHER|Consumption of drugs for analgesic use|"* Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)"
214711341|NCT04511780|OTHER|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
214711342|NCT00546429|DEVICE|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
214599391|NCT03278730|DRUG|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
214599392|NCT03278730|DRUG|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
214599393|NCT06610110|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
214599394|NCT06610110|DIETARY_SUPPLEMENT|Placebo|Placebo (3 mg/kg maltodextrin)
214599395|NCT03459014|OTHER|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
214599396|NCT03459014|OTHER|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
214599397|NCT02778243|BIOLOGICAL|steroids concentrations determination|
214599398|NCT04369989|OTHER|No intervention|No intervention
214599399|NCT06616324|DEVICE|Virtual Reality|Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
214711343|NCT01188096|DRUG|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
214711344|NCT03728504|DRUG|ASN002|Daily dose of ASN002 for 32 weeks
214711345|NCT03728504|DRUG|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
214599400|NCT06997419|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
214599401|NCT06997419|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
214599402|NCT06993623|DIAGNOSTIC_TEST|heparin binding protien|compare between Heparin binding protien and platelet count and mean platelet volume kinetics in diagnosis and prognosis of VAP
214599403|NCT06999122|DIAGNOSTIC_TEST|Brain Scan|"The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.~The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues."
214599404|NCT06992609|DRUG|Durvalumab|Durvalumab (IV) every 4 weeks until a maximum of 24 months.
214599405|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
214599406|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
214599407|NCT07008495|PROCEDURE|varicocelectomy|to detect testicular sperm retrieval rate after varicocelectomy in men with non obstructive azoospermia.
214599408|NCT07016009|BEHAVIORAL|Thrive Program|Thrive is a person-centered planning intervention that is based on self-determination theory and integrates elements of social network interventions. The proposed Thrive intervention has four phases: 1) Strengths \& Network Assessment, 2) Network Engagement, 3) Goal Setting \& Planning, and 4) Plan Implementation \& Monitoring. It involves about 10-13 sessions and is delivered by a trained facilitator over Zoom.
214599409|NCT07021092|OTHER|Interventions will be developed in aim 2 of the study.|Person-centred package that connects patients to service delivery, builds rapports and improves engagement in care leading to sustained viral load suppressions
214599410|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
214599411|NCT04091451|DRUG|Placebo|2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
214599412|NCT06885151|OTHER|Evidence-based IVF website content|The Evidence-based IVF website has been developed through a robust co-design process with IVF patients and clinicians, and the information about effectiveness and safety of add-ons was produced following established systematic review methodology of Cochrane (including risk of bias, GRADE, and TRACT assessment). They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
214599413|NCT06885151|OTHER|Control|Participants will view information that has been generated by combining information from the top 3 websites retrieved on Google search of the add-on name. They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
214599414|NCT04135066|OTHER|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214711346|NCT04235439|DRUG|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
214599415|NCT04135066|OTHER|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214599416|NCT04135066|OTHER|Oral Glucose Tolerance test (75g 2-hour)|75 g pure glucose with 300 mL water per time per person is applied. In the following 3 hours, participants are advised to rest in a seated position, avoiding unnecessary walking or exercise. Energy-giving food items were still prohibited within this interval.
214599417|NCT05472714|OTHER|Educational Video|Investigators will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
214599418|NCT06689891|DEVICE|Pelvic Floor Muscle Therapy Website|8-week video-based, self-directed PFMT course
214599419|NCT06466577|DIAGNOSTIC_TEST|CT 5400 RT System|Computed Tomography X-RAY System is intended to produce images of the head and body by computer reconstruction of x-ray transmission data taken at different angles and planes.
214599420|NCT04757532|DRUG|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
214599421|NCT04757532|DRUG|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
214599422|NCT04757532|DRUG|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
214599423|NCT04757532|DRUG|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
214599424|NCT04757532|DRUG|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
214599425|NCT06936670|DEVICE|Inspiratory Muscle Strength Training (IMST)|A novel form of physical training that uses the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device, generating large negative intrathoracic pressures. The device can be set to different levels of resistance, meaning the intervention and sham groups will undergo the same training, but at 75% and 15% of their maximal inspiratory pressure respectively.
214599426|NCT06936670|DEVICE|Sham Training|The same training regiment but at much lower resistance, offering little to strength training impact.
214599427|NCT04124614|DRUG|Brexpiprazole|3 mg pill
214599428|NCT04124614|DRUG|Sertraline|150 mg pill
214599429|NCT04124614|OTHER|Placebo|Pill
214599430|NCT00703898|DRUG|nevirapine|200 mg/day twice a day
214599431|NCT05772156|DRUG|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
214599432|NCT05772156|DRUG|Placebo|Matching saline placebo
214599433|NCT01278251|PROCEDURE|Distal Biceps Re-Insertion|
214599434|NCT04286516|DEVICE|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
214599435|NCT02685098|BIOLOGICAL|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
214599436|NCT06391554|OTHER|PRT|An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week. The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks. After the 12 weeks, participants will receive 8 booster sessions and are given a membership to a fitness center where they will be encouraged to continue the exercise program on their own.
214599437|NCT06391554|OTHER|EDU|Three EDU sessions provided by a trained physiotherapist involving important disease-specific information. The sessions will address knowledge of OA, treatment options with a specific focus on physical activity recommendations, advice on self-management and more. All three sessions will emphasize on engaging the participants actively and sharing experiences with each other.
214599438|NCT06781801|OTHER|Intervention|"The intervention group follows a structured flowchart for annual health check-ups, focusing on assessing the cardiometabolic profile, considering sex and ethnicity. This assessment includes tracking changes in cardiometabolic parameters, alongside overall cardiometabolic risk using SCORE2 and if the criteria for metabolic syndrome are met.~Lifestyle habits are evaluated based on health status, illness, and benefits of quitting unhealthy behaviors. Education sessions educate participants and families on the link between psychotic disorders, lifestyle choices, and cardiometabolic health.~Gradual lifestyle changes are tailored to individual needs, addressing stress and cognitive challenges, and follow national health guidelines with personalized advice and motivational tools. Regular follow-ups assess progress, while motivational tools body composition analyzer and QRISK3 enhance engagement. Contact with internal and external resources is based on the assessment and motivational work."
214599439|NCT04337177|DRUG|VAL-413|a flavored preparation of orally administered irinotecan
214599440|NCT04337177|DRUG|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
214599441|NCT04104529|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
214599442|NCT04104529|OTHER|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
214599443|NCT04450836|DRUG|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
214599444|NCT04450836|DRUG|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
214599445|NCT02703220|OTHER|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
214599446|NCT02703220|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
214599447|NCT02703220|DRUG|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
214599448|NCT05433675|DRUG|Macitentan|Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
214599449|NCT05781152|DRUG|Anti-TNF therapy|Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
214599450|NCT00551109|DRUG|placebo|placebo, oral administration, once daily for 8 weeks
214599451|NCT00551109|DRUG|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
214711347|NCT06282419|OTHER|USE OF MOBILE ULTRASOUND|"First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth."
214599452|NCT00551109|DRUG|SA4503 High|High dose, oral administration, once daily for 8 weeks
214599453|NCT06794996|DRUG|Inaxaplin|Tablets for Oral Administration.
214599454|NCT00530868|OTHER|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
214599455|NCT00530868|DRUG|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
214599456|NCT04778969|DEVICE|drug-eluting stent|A group of percutaneous coronary intervention (PCI) using drug-eluting stents (DES)
214599457|NCT04778969|DEVICE|drug-coated balloon|A group of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB)
214599458|NCT00278460|DRUG|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
214599459|NCT00278460|DRUG|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
214599460|NCT06679140|DRUG|ibuzatrelvir|ibuzatrelvir tablets
214599461|NCT06679140|DRUG|placebo|placebo tablets
214599462|NCT04536454|DRUG|[18F]FPyGal|Radiotracer for PET-imaging
214599463|NCT01831544|DEVICE|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
214599464|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
214599465|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
214599466|NCT04563364|OTHER|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
214599467|NCT04563364|OTHER|Convencional treatment|Control group will receive a conventional treatment given by the institutions
214599468|NCT05539859|PROCEDURE|Endoscopic surgery|Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management
214599469|NCT05539859|OTHER|Medical management|Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
214599470|NCT06274671|OTHER|Magnetic Resonance Imaging|A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
214599471|NCT06572111|DRUG|BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) formulation 1
214599472|NCT06572111|DRUG|BI 1839100|BI 1839100
214599473|NCT06572111|DRUG|BI 1839100 (C-14) formulation 2|BI 1839100 (C-14) formulation 2
214599474|NCT04450654|DRUG|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
214599475|NCT04450654|DRUG|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
214599476|NCT05843643|DRUG|Upadacitinib|Oral Tablets
214599477|NCT05843643|DRUG|Placebo|Oral Tablet
214599478|NCT05599295|DRUG|Orbactiv|Solution for IV infusion
214711348|NCT06282419|OTHER|ultrasound image taken from the internet|First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
214711349|NCT01273493|DRUG|Trabectedin|Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
214711350|NCT01273493|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
214599479|NCT05599295|DRUG|Kimyrsa|Solution for IV infusion
214599480|NCT06261333|OTHER|Questionnaires|No Intervention
214599481|NCT05028829|DRUG|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
214599482|NCT05028829|DRUG|Placebo|Oral administration of placebo
214599483|NCT02704546|DRUG|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
214599484|NCT02704546|DRUG|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
214599485|NCT04175808|DRUG|Omecamtiv Mecarbil (OM)|Oral solution
214599486|NCT04175808|DRUG|Placebo|Placebo oral solution
214599487|NCT04175808|DRUG|Moxifloxacin|400 mg moxifloxacin oral tablet
214599488|NCT06847191|DRUG|NE3107|20 mg Capsule
214599489|NCT06847191|DRUG|Placebo|placebo capsule
214599490|NCT05706896|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
214599491|NCT06284486|DRUG|Venetoclax|Given by PO
214599492|NCT06284486|DRUG|Revumenib|Given by PO
214599493|NCT06129864|DRUG|volrustomig|volrustomig
214599494|NCT05598814|BIOLOGICAL|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
214599495|NCT05598814|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
214711351|NCT06376370|OTHER|Application of computer-assisted cognitive rehabilitation program|Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
214711352|NCT00851253|RADIATION|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
214711353|NCT05473104|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Social training targeting adolescents with ASD and focused on making and keeping friends
214599496|NCT05499130|DRUG|TEV-48574|Subcutaneous infusion
214599497|NCT05499130|DRUG|Placebo|Matching Placebo
214599498|NCT04033263|OTHER|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
214599499|NCT04033263|OTHER|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
214599500|NCT04033263|OTHER|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
214711354|NCT04698512|DEVICE|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
214711355|NCT00043212|DRUG|Dendritic cell immunotherapy|
214711356|NCT05616169|DEVICE|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
214599501|NCT04033263|OTHER|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
214711357|NCT00565214|DIETARY_SUPPLEMENT|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
214711358|NCT00565214|DIETARY_SUPPLEMENT|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
214711359|NCT03909555|OTHER|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
214599502|NCT04733027|COMBINATION_PRODUCT|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
214599503|NCT06635057|DRUG|Tirzepatide|Administered SC
214599504|NCT06625190|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
214711360|NCT03625154|PROCEDURE|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
214711361|NCT03625154|OTHER|non operative management|closed reduction and splinting followed by progressive weight bearing
214599505|NCT06625190|DRUG|Zoledronic acid|"All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion."
214599506|NCT05537740|DRUG|BAY3375968|Intravenous (IV) infusion
214599507|NCT05537740|DRUG|Pembrolizumab|IV infusion
214599508|NCT06112613|OTHER|Electronic Health Record Review|Ancillary studies
214599509|NCT06112613|OTHER|Health Promotion and Education|Receive access to educational materials
214599510|NCT06112613|PROCEDURE|Health Telemonitoring|Utilize the WiseBag medication dispenser
214599511|NCT06112613|OTHER|Interview|Complete an interview
214599512|NCT06112613|BEHAVIORAL|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
214599513|NCT06112613|OTHER|Survey Administration|Ancillary studies
214599514|NCT06112613|OTHER|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
214599515|NCT03413371|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
214599516|NCT03413371|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
214599517|NCT03413371|DRUG|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
214599518|NCT03413371|DRUG|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
214599519|NCT05531786|DRUG|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
214599520|NCT05907291|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
214635070|NCT07001748|PROCEDURE|Computed Tomography|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
214599521|NCT03099850|OTHER|Data Management and Monitoring|"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.~* Study participants will complete questionnaires at baseline and during yearly follow-up. In the event a participant does not complete all or part of the patient or coordinator questionnaire, the study coordinator will complete questions via medical record review (e.g., demographics and family history) or via a telephone interview.~* Biospecimen collection: blood, urine, saliva, stool. Biospecimens will be collected and processed in accordance with the CPDPC specimen collection procedures.~* EUS or EGD with pancreatic fluid collection~* imaging studies performed at baseline and at follow-up.~  * IV contrast-enhanced MRI and MRCP with secretin~ * IV contrast-enhanced CT Scan abdomen"
214599522|NCT05993949|DRUG|Dasatinib|3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
214599523|NCT06637917|DEVICE|OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System|The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.
214599524|NCT06637917|DEVICE|LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter|The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.
214599525|NCT06637917|DEVICE|1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor|Market-released ECG monitoring system
214599526|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
214599527|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
214599528|NCT05833048|PROCEDURE|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
214599529|NCT05712200|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
214599530|NCT05712200|DRUG|Placebo|"Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab"
214599531|NCT04844528|DRUG|Nicotinamide|Oral nicotinamide 500 mg twice daily (BID).
214599532|NCT04844528|DRUG|Placebo|Oral placebo twice daily for the first year.
214599533|NCT06034522|DEVICE|Adipearl|Injection of the investigational device in the face.
214599534|NCT03992469|DRUG|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
214599535|NCT03992469|DRUG|Placebo|Placebo capsules made of cornstarch
214599536|NCT04285476|DIAGNOSTIC_TEST|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
214599537|NCT03957954|BIOLOGICAL|cLSC|Transplantation of cLSC
214599538|NCT03957954|DEVICE|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
214599539|NCT05355701|DRUG|PF-07799933|Tablet
214599540|NCT05355701|DRUG|binimetinib|Tablet
214599541|NCT05355701|BIOLOGICAL|cetuximab|Injection for intravenous use
214599542|NCT06565455|BEHAVIORAL|Growing Healthy Children and Families in Rural Arkansas|The intervention will consist of seven healthy eating culturally developed modules, which will be implemented/delivered in the participants home and two cooking demonstration/tasting workshops for the participants in the intervention group (mothers in the church setting and individual and collective goal settings for the intervention group.
214599543|NCT05719558|DRUG|ASP1002|intravenous (IV) infusion
214599544|NCT05097911|DRUG|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
214599545|NCT05097911|DRUG|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
214599546|NCT05097911|DRUG|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
214711362|NCT01621854|DRUG|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
214711363|NCT02062398|DEVICE|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
214599547|NCT06489340|DRUG|2HPβCD|2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
214599548|NCT05603793|BEHAVIORAL|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
214711364|NCT01277497|DRUG|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
214711365|NCT01277497|DRUG|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
214711366|NCT03924310|DEVICE|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
214711367|NCT03924310|DEVICE|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
214711368|NCT03230513|OTHER|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
214711369|NCT03230513|OTHER|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
214711370|NCT02646150|PROCEDURE|Magnetic Resonance Perfusion Imaging|
214711371|NCT01779648|DEVICE|DVT-3000|
214711372|NCT01779648|DEVICE|SCD Express|
214711373|NCT02099487|RADIATION|Radiation|hypofractionated IMRT
214711374|NCT00415519|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
214711375|NCT00415519|DRUG|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
214599552|NCT06152575|DRUG|Elranatamab|Elranatamab will be administered subcutaneously
214599553|NCT06152575|DRUG|Elotuzumab|Elotuzumab will be administered intravenously
214599554|NCT06152575|DRUG|Pomalidomide|Pomalidomide will be administered orally
214599555|NCT06152575|DRUG|Dexamethasone|Dexamethasone will be administered orally
214599556|NCT06152575|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
214599557|NCT06152575|DRUG|Carfilzomib|Carfilzomib will be administered intravenously
214599558|NCT03918681|OTHER|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
214599559|NCT04928846|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
214599560|NCT04928846|DRUG|Docetaxel|IV Infusion
214599561|NCT04720209|OTHER|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
214599562|NCT04720209|OTHER|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
214599563|NCT04720209|OTHER|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
214599564|NCT03801902|RADIATION|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
214599565|NCT03801902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214599566|NCT03801902|PROCEDURE|Computed Tomography|Undergo brain CT and chest CT
214599567|NCT03801902|BIOLOGICAL|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
214599568|NCT03801902|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
214599569|NCT03801902|BIOLOGICAL|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
214599570|NCT03801902|BIOLOGICAL|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
214599571|NCT03801902|RADIATION|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
214711376|NCT03154307|DEVICE|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
214599572|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
214599573|NCT06644937|DRUG|TACE combined with Acoradine|"Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) ."
214599574|NCT06505044|PROCEDURE|aerobic exercise|"aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake."
214599575|NCT06505044|PROCEDURE|resistance exercise|resisted exercise program for 12 weeks
214711377|NCT02416778|DRUG|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
214711378|NCT03485222|DRUG|Empagliflozin|6 months
214599576|NCT06378528|DRUG|Ketamine|3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
214599577|NCT06378528|DEVICE|SmartSleep EEG recording headband|Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
214599578|NCT05363280|DRUG|AL8326 low dose group|Taken AL3826 at low dose orally
214599579|NCT05363280|DRUG|AL8326 middle dose group|Taken AL3826 at middle dose orally
214599580|NCT05363280|DRUG|AL8326 high dose group|Taken AL3826 at high dose orally
214599581|NCT06312358|BEHAVIORAL|Building Capacity for Infant Achievements in Child Care|All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
214599582|NCT06127979|PROCEDURE|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
214599583|NCT06127979|OTHER|blood draw|blood draw
214599584|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
214599585|NCT05796362|DRUG|Azithromycin Oleogel (Oral and Rectal)|"Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)"
214599586|NCT00552201|DRUG|Tacrolimus|Administration Twice a day after adjustment to blood level
214599587|NCT06515093|OTHER|PelloGraft|dual layer amnion/chorion-derived allograft
214599588|NCT06515093|OTHER|SanoGraft|single layer amnion-derived allograft
214711379|NCT03485222|DRUG|Placebos|placebo equivalent for 6 months
214711380|NCT01618422|OTHER|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
214711381|NCT01618422|OTHER|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
214599589|NCT03258554|BIOLOGICAL|Cetuximab|Given IV
214711382|NCT03983226|PROCEDURE|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
214711383|NCT03983226|DRUG|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
214711384|NCT03983226|DRUG|Niraparib|Niraparib maintenance therapy
214711385|NCT02157012|DRUG|The effectiveness of Xeljanz in rheumatoid arthritis patients|
214711386|NCT02699853|OTHER|Questionnaire Administration|Ancillary studies
214711387|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo RRC
214599590|NCT03258554|BIOLOGICAL|Durvalumab|Given IV
214599591|NCT03258554|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214599592|NCT03258554|OTHER|Laboratory Biomarker Analysis|Correlative studies
214599593|NCT03258554|OTHER|Quality-of-Life Assessment|Ancillary studies
214599594|NCT03258554|OTHER|Questionnaire Administration|Ancillary studies
214599595|NCT06135402|DEVICE|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
214599596|NCT06135402|DRUG|Treatment with Clobetasol|Application of Clobetasol twice per week
214599597|NCT06629090|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
214599598|NCT06629090|DRUG|Prazosin|A dose of prazosin will be administered based on body weight
214599599|NCT06629090|DRUG|Placebo|Oral placebo
214599600|NCT05645575|DEVICE|Open-label TMS|Customized, Open-Label Transcranial Magnetic Stimulation
214599601|NCT05197881|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
214599602|NCT04782466|BEHAVIORAL|Physical Activity (PA) Intervention|The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
214599603|NCT04782466|BEHAVIORAL|Waitlist attention-control|For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
214599604|NCT06802536|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
214599605|NCT06802536|DEVICE|NeoPutty (calcium silicate-based cement) (Avalon Biomed, Bradenton, USA)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
214599606|NCT03995797|PROCEDURE|Laser therapy|Erbium YAG laser
214599607|NCT02523560|OTHER|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
214599608|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
214599609|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Dietary supplement I (WPowDSI)|The WPowDSI group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding supplementation, participants were randomly assigned to receive their daily dose.
214599610|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Placebo (WPowPl)|The WPowCr group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding placebo, participants were randomly assigned to receive their daily dose.
214711388|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo ORC
214711389|NCT03514888|PROCEDURE|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
214711390|NCT01886885|BEHAVIORAL|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
214711391|NCT05599113|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
214599611|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Dietary supplement I (EBPowDSI)|The EBPowDSI group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
214711392|NCT02691364|PROCEDURE|Blood withdrawal|
214711393|NCT02040155|DEVICE|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
214599612|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Placebo (EBPowPl)|The EBPotPl group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition,) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
214599613|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)|The EBEccDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
214599614|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Placebo (EBEccPl)|The EBEccPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding placebo, participants were randomly assigned to receive their daily dose.
214599615|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)|The EBMaxDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
214599616|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Placebo (EBMaxPl)|The EBMaxPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
214599617|NCT06620666|DIETARY_SUPPLEMENT|Control + Placebo (CPl)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding placebo, participants were randomly assigned to receive their daily dose.
214711394|NCT00263250|PROCEDURE|watchful waiting or tension-free hernia repair|
214711395|NCT04406012|PROCEDURE|paravertebral block|paravertebral block group
214711396|NCT03554850|DEVICE|Trevo® Retriever|Stent retriever procedure
214711397|NCT05972395|OTHER|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
214711398|NCT00577915|OTHER|Radiology/MRI scan|MRI spectroscopy
214711399|NCT05441943|PROCEDURE|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
214599618|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement I (CDSI)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
214599619|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement (CDSII)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
214599620|NCT06620666|DIETARY_SUPPLEMENT|Active Comparator: Aerobic training + Placebo (AerPl)|The group will perform aerobic exercise for 20-40 minutes with easy execution exercise. Regarding placebo, participants were randomly assigned to receive their daily dose.
214599621|NCT03798223|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
214599622|NCT03865823|PROCEDURE|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
214599623|NCT01353625|DRUG|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
214599624|NCT00528866|DRUG|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
214599625|NCT00528866|DRUG|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
214599626|NCT00528866|DRUG|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
214599627|NCT00528866|DRUG|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
214599628|NCT00528866|RADIATION|3-dimensional conformal radiation therapy|
214711400|NCT05951543|OTHER|plyometric exercises|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
214711401|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
214711402|NCT02566616|DEVICE|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
214599629|NCT00528866|RADIATION|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
214599630|NCT05474586|OTHER|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
214599631|NCT05474586|OTHER|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
214599632|NCT05474586|OTHER|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
214711403|NCT03043846|OTHER|Follow-up every 3 months during 1 year (data collection in eCRF)|
214711404|NCT03043846|OTHER|Follow-up every month to follow the pre-defined strategy|
214711405|NCT06231914|DEVICE|StarWalker® PQX|Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
214599633|NCT02887872|OTHER|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
214599634|NCT01601847|DIETARY_SUPPLEMENT|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
214599635|NCT01601847|DRUG|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
214599636|NCT00711256|OTHER|sunscreen MATAS sunlotion SPF 8|
214599637|NCT00711256|RADIATION|UVB light|duration 4 times 1 minute radiation on the trunk.
214599638|NCT06001918|DRUG|Nectero EAST System|Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
214599639|NCT02234323|BIOLOGICAL|rFVIIIFc|Administered as specified in arm description
214599640|NCT04333654|DRUG|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
214599641|NCT04333654|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
214599642|NCT01060826|OTHER|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
214599643|NCT01060826|DRUG|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
214599644|NCT01060826|DRUG|somatostatin|Intravenous bolus 250 micrograms
214599645|NCT00670189|DRUG|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
214599646|NCT02886767|OTHER|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
214599647|NCT06191471|OTHER|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis
214599648|NCT00725634|BIOLOGICAL|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
214599649|NCT00725634|BIOLOGICAL|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
214599650|NCT00019084|BIOLOGICAL|aldesleukin|
214599651|NCT00019084|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
214711406|NCT05145803|DEVICE|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
214711407|NCT03470311|BIOLOGICAL|Benralizumab|30mg in 1mL pre-filled syringe
214711408|NCT03470311|BIOLOGICAL|Placebo|Matched placebo (1mL) in pre-filled syringe
214711409|NCT04801641|DRUG|Placebo|Six placebo capsules taken orally twice daily
214599652|NCT00019084|BIOLOGICAL|ras peptide cancer vaccine|
214599653|NCT00019084|BIOLOGICAL|sargramostim|
214599654|NCT00019084|BIOLOGICAL|therapeutic autologous lymphocytes|
214599655|NCT00019084|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214599656|NCT02644941|BIOLOGICAL|Human Acellular Vessel (HAV)|HAV-tissue-engineered vascular conduit (6mm diameter)
214599657|NCT02644941|DEVICE|ePTFE graft|One of two commercially available comparators (Bard Impra® and Gore PROPATEN®)
214599658|NCT03506685|OTHER|Dry needling and STM|dry needling and soft tissue mobilization
214599659|NCT00762749|DRUG|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
214599660|NCT04614662|BEHAVIORAL|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
214599661|NCT04649242|DRUG|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
214599662|NCT04649242|DRUG|Matching placebo|Matching 75 mg or 50 mg ODT placebo
214599663|NCT06113237|DRUG|Epidiolex|Oral solution
214599664|NCT02782546|PROCEDURE|Graft cell infusion|-Day 0
214599665|NCT02782546|DRUG|Tacrolimus|-GVHD prophylaxis
214599666|NCT02782546|DRUG|Mycophenolate mofetil|-GVHD prophylaxis
214599667|NCT02782546|DRUG|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
214599668|NCT02782546|PROCEDURE|CIML NK cell infusion|-Day +7
214599669|NCT02782546|DRUG|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
214599670|NCT02782546|PROCEDURE|Leukapheresis|-Day +6
214599671|NCT04549025|DRUG|Pimivalimab|Specified dose on specified days
214711410|NCT04801641|DRUG|Nabilone|Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
214599672|NCT04549025|DRUG|Vopratelimab|Specified dose on specified days
214599673|NCT02147665|OTHER|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
214599674|NCT05166785|OTHER|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
214599675|NCT05166785|OTHER|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
214599676|NCT06348264|DRUG|Rezvilutamide|Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
214599677|NCT06348264|DRUG|Leuprolide Acetate|The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
214599678|NCT05066477|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
214599679|NCT05066477|OTHER|Placebo|Pure maltodextrin
214599680|NCT03767582|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
214599681|NCT03767582|DRUG|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
214599682|NCT03767582|DRUG|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
214599683|NCT03767582|DRUG|GVAX|Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
214599684|NCT04325308|PROCEDURE|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
214599685|NCT04325308|PROCEDURE|Usual human milk diet|Human-based protein will not be added to the human milk administered.
214599686|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
214599687|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
214599688|NCT06117098|DEVICE|Mobile application|Individual lifestyle intervention via an mobile application
214599689|NCT06117098|BEHAVIORAL|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"
214599690|NCT06117098|BEHAVIORAL|Group-based lifestyle intervention|Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
214599691|NCT05486559|OTHER|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
214599692|NCT05486559|OTHER|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
214599693|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
214599694|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
214599695|NCT05508789|DRUG|Donanemab|Administered IV
214599696|NCT05508789|DRUG|Placebo|Administered IV
214599697|NCT01562171|OTHER|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
214599698|NCT01562171|OTHER|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
214599699|NCT00730561|BIOLOGICAL|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
214635071|NCT07001748|PROCEDURE|Diagnostic Laparoscopy|After induction of general anesthesia, administration of preoperative antibiotics and placement of appropriate laparoscopic ports, peritoneal lavage will be performed by instillation of 200 ml of normal saline in the left upper quadrant and allowed to dwell for 5 minutes after which it will be aspirated for cytology. Extent of peritoneal disease burden will be ascertained as per the Peritoneal Cancer Index (PCI) scoring system as outlined in Appendix V.
214635072|NCT07001748|PROCEDURE|Intraperitoneal Port Placement|Patients assigned to Arm B will undergo placement of indwelling tunneled intraperitoneal port with Teflon cuff following Step 1 randomization and during the diagnostic laparoscopy procedure.
214599700|NCT05532748|DEVICE|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
214599701|NCT05532748|DEVICE|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
214599702|NCT05049746|OTHER|Discussion|Participate in discussion
214599703|NCT05049746|OTHER|Interview|Participate in interview
214599704|NCT05049746|OTHER|Questionnaire Administration|Complete questionnaire
214599705|NCT05548296|DRUG|ACR-368|ACR-368 is an experimental drug
214599706|NCT05548296|DRUG|Gemcitabine|Sensitization of tumor cells is provided through administration of ULDG
214599707|NCT05548296|DIAGNOSTIC_TEST|OncoSignature|Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy
214599708|NCT06107881|BEHAVIORAL|Low Vision Rehabilitation|Evaluation and training with magnification or visual assistive devices for visually-impaired adults
214599709|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
214599710|NCT03731260|DRUG|Placebo|Placebo tablet
214599711|NCT05160441|BIOLOGICAL|Platelet Rich Plasma Injection|"Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols."
214599712|NCT05160441|BIOLOGICAL|Corticosteroid Injection|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
214599713|NCT05160441|BIOLOGICAL|Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure|Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
214599714|NCT04280536|DRUG|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
214599715|NCT04280536|DRUG|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
214599716|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone"
214599717|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Indian Costus|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements"
214599718|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Quinine pills|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)"
214599719|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Anise seed capsule|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)"
214599720|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg"
214599721|NCT04553705|DRUG|Active Comparator|Standard protocol care of COVID-19 infection
214599722|NCT05117697|OTHER|lateral subcutaneous sphincterotomy|"Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."
214599723|NCT04394481|DRUG|Dexmedetomidine|IV injection (1 µg/kg - 100 mL) before anesthetic induction
214599724|NCT04394481|DRUG|Ropivacaine|Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
214599725|NCT04394481|DRUG|Dexamethasone|IV injection (0.15 mg/kg) during anesthetic induction
214599726|NCT02371122|DEVICE|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
214599727|NCT02371122|DEVICE|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
214599728|NCT02371122|DEVICE|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
214599729|NCT02371122|DEVICE|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
214599730|NCT03590015|OTHER|Old invitation letter|Invitation Letter written by researchers/doctors
214599731|NCT03590015|OTHER|New invitation Letter|Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
214599732|NCT04438213|DRUG|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
214599733|NCT04438213|DRUG|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
214711411|NCT04148768|DEVICE|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
214599734|NCT04438213|DRUG|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
214599735|NCT01843218|OTHER|Evaluation of erectile dysfunction|Assessment (at night) of erctile dysfunction using R/P recording (RIGISCAN® PLUS / polysomonography)
214599736|NCT01136811|DEVICE|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
214599737|NCT06534411|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214599738|NCT06534411|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214599739|NCT06534411|DRUG|Tirzepatide|Participants will receive once-weekly tirzepatide subcutaneously.
214599740|NCT05062902|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
214599741|NCT05062902|DRUG|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
214599742|NCT06145282|DRUG|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
214599743|NCT02315599|DRUG|anti-CD19 CAR|
214599744|NCT03015441|OTHER|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
214599745|NCT05972629|DRUG|SAR444836|Infusion pump, intravenous infusion (IV)
214599746|NCT06042010|DRUG|Oral zinc supplement|patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
214599747|NCT06042010|DRUG|triamcinolone acetonide Oral paste|patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
214599748|NCT03199937|BEHAVIORAL|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
214599749|NCT03199937|OTHER|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
214599750|NCT06044402|OTHER|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
214599751|NCT06044402|OTHER|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
214599752|NCT00911794|OTHER|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
214599753|NCT00911794|OTHER|Neutral (Sham) Writing|Patients write about neutral subjects
214599754|NCT01009554|DEVICE|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
214599755|NCT01009554|DRUG|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
214599756|NCT04258436|PROCEDURE|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
214599757|NCT01605253|DRUG|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
214599758|NCT01605253|DRUG|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
214599759|NCT05803590|DRUG|Green tea mouthwash|effictive against caries and periodontal diseases
214599760|NCT05803590|DRUG|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
214599761|NCT01405937|DRUG|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
214599762|NCT01405937|BIOLOGICAL|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
214599763|NCT01405937|DRUG|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
214599764|NCT00177983|BEHAVIORAL|(relapse rate)|
214599765|NCT02949089|DRUG|ACH04|The subjects will receive the study medication in each group
214599766|NCT04527120|OTHER|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
214599767|NCT04888520|DEVICE|Adhesive elastic bandage|"The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist."
214599768|NCT00364026|DRUG|darusentan|
214599769|NCT00822588|DEVICE|Sangvia® System|Sangvia® Intra- and Post-op System
214599770|NCT00395148|DRUG|rHDL|
214599771|NCT05606133|DIAGNOSTIC_TEST|NavDx(R)|NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
214599772|NCT03321487|DEVICE|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
214599773|NCT03510988|DIAGNOSTIC_TEST|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
214599774|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
214711412|NCT04148768|DEVICE|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
214599775|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
214599776|NCT03552861|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
214599777|NCT04331041|DEVICE|Adaptive stereotactic body radiation therapy|"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"
214599778|NCT04331041|DRUG|Defactinib|-Oral drug 400 mg twice a day
214599779|NCT04331041|PROCEDURE|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
214599780|NCT04331041|PROCEDURE|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
214599781|NCT01794585|BEHAVIORAL|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
214599782|NCT01794585|BEHAVIORAL|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
214599783|NCT06186245|OTHER|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
214711414|NCT06195943|BEHAVIORAL|Exercise Intervention with use of El-Fit App|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
214711415|NCT03325556|DRUG|Placebo|Placebo, tablets, once daily by mouth
214599784|NCT05974592|OTHER|Education|Diabetic Foot Self-Management Training Program will be implemented.
214599785|NCT03773822|COMBINATION_PRODUCT|Hydrocortisone + Flucortac|Low dose steroids
214599786|NCT03773822|OTHER|Placebo|Placebo
214599787|NCT00408603|DRUG|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
214711416|NCT03325556|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
214711417|NCT03325556|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
214711418|NCT01155596|BEHAVIORAL|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
214711419|NCT00595257|DEVICE|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
214711420|NCT04489927|DEVICE|Tcore|Temperature Measurement of standard care versus the Tcore measurement
214711421|NCT02487277|DRUG|PEGPH20|
214711422|NCT02487277|DRUG|Gemcitabine|
214599788|NCT01238289|BEHAVIORAL|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
214711423|NCT02487277|DRUG|Nab-paclitaxel|
214599789|NCT01238289|BEHAVIORAL|Control|This group continues with standard care at the community health center
214599790|NCT04626817|DEVICE|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
214599791|NCT04612387|BEHAVIORAL|Mind-body therapy|Online yoga, meditation and nutrition tips.
214599792|NCT06124053|BEHAVIORAL|Group Voice Therapy|"The group voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. Each group is composed of three participants. The session durations are planned to be 45-60 minutes each."
214599793|NCT06124053|BEHAVIORAL|Individual Voice Therapy|"The individual voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. The session durations are planned to be 45-60 minutes each."
214599794|NCT06124053|BEHAVIORAL|Vocal Hygiene Education|Regarding vocal hygiene training, information related to voice production and respiratory characteristics will be provided, and guidance on correct and incorrect voice use will be given.
214599795|NCT05583201|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
214599797|NCT04775251|OTHER|Upward rotation exercise|Treatment for correction of depressed scapular Alignment by exercise ( Upward Rotation Exercises) for 6 weeks.
214599798|NCT00324701|BEHAVIORAL|Telepsychology|therapy done at patients house
214599799|NCT00324701|BEHAVIORAL|Face-to-face therapy|therapy delivered at the VAMC
214599800|NCT01561222|DRUG|Calcitriol|0.25 ug per day for one year
214599801|NCT01561222|DRUG|placebo|one pill per day
214711424|NCT01705587|DRUG|teriparatide|20 microgram once-daily subcutaneous injection
214599802|NCT06188585|DEVICE|UI-EWD|Hemostatic powder administered at index endoscopy
214599803|NCT06188585|DEVICE|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy
214599804|NCT04742634|DRUG|DEC-C|"* DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant."
214599805|NCT04742634|DEVICE|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
214599806|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
214599807|NCT06092554|DIETARY_SUPPLEMENT|LactoLevure|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
214711425|NCT05456152|DRUG|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
214711426|NCT02119026|DRUG|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
214711427|NCT02119026|DRUG|Capecitabine|1000mg/m2 bid d1-14,
214711428|NCT02119026|DRUG|Bevacizumab|7,5 mg/kg given on d1 q3w
214711429|NCT02119026|DRUG|Oxaliplatin|130mg/m2 iv. d 1 q3w
214711430|NCT02119026|DRUG|Irinotecan|200mg/m2 iv. d 1 q3w .
214711431|NCT01373918|DRUG|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
214711432|NCT01373918|DRUG|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
214711433|NCT00657722|OTHER|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
214599808|NCT06092554|OTHER|Placebo|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The placebo capsules contain a powdered glucose polymer that is unharmful for the patient and will be provided by the sponsor. The placebo capsules look identical to the probiotic capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
214599809|NCT05680558|DRUG|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
214599810|NCT05680558|DEVICE|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
214599811|NCT05464030|DRUG|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.
214599812|NCT05464030|DRUG|M9140|M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.
214599813|NCT05464030|DRUG|Bevacizumab|Bevacizumab will be administered intravenously as per standard of care.
214599814|NCT05464030|DRUG|Capecitabine|Capecitabine will be administered orally as per standard of care.
214599815|NCT05464030|DRUG|5-fluorouracil (5-FU)|5-FU will be administered intravenously as per standard of care.
214599816|NCT05464030|DRUG|Folinic acid|Folinic acid will be administered intravenously as per standard of care.
214599817|NCT05532397|DRUG|QPOP category 1|combination regimens with published data in the setting of gliomas
214599818|NCT05532397|DRUG|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
214599819|NCT03432286|DRUG|Galcanezumab|Administered SQ
214599820|NCT03432286|DRUG|Placebo|Administered SQ
214599821|NCT02500381|DRUG|SRP-4045|SRP-4045 solution for IV infusion
214599822|NCT02500381|DRUG|SRP-4053|SRP-4053 solution for IV infusion
214599823|NCT02500381|DRUG|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
214599824|NCT06392477|DRUG|DR-0201|DR-0201 is a bispecific antibody
214599825|NCT05332444|DRUG|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1\. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
214599826|NCT05332444|DRUG|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
214599827|NCT06245889|DRUG|Paclitaxel|chemotherapy
214599828|NCT06245889|DRUG|Carboplatin|chemotherapy
214599829|NCT06245889|DRUG|Pembrolizumab|immunotherapy
214599830|NCT06245889|DRUG|Doxorubicin|additional chemotherapy - neoadjuvant or adjuvant rescue
214599831|NCT06245889|DRUG|Cyclophosphamide|additional chemotherapy - adjuvant rescue
214599832|NCT06245889|DRUG|Olaparib|adjuvant rescue
214599833|NCT06245889|DRUG|Capecitabine|adjuvant rescue
214599834|NCT03829319|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
214599835|NCT03829319|DRUG|Carboplatin|IV infusion Q3W
214599836|NCT03829319|DRUG|Cisplatin|IV infusion Q3W
214599837|NCT03829319|DRUG|Pemetrexed|IV infusion Q3W
214599838|NCT03829319|DRUG|Lenvatinib|Oral capsule once daily
214599839|NCT03829319|DRUG|Placebo matching lenvatinib|Oral capsule once daily
214599840|NCT05067998|DIETARY_SUPPLEMENT|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
214599841|NCT05067998|DRUG|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
214599842|NCT04457895|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
214599843|NCT04457895|OTHER|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
214599844|NCT06518239|DEVICE|Peep Belt|Belt will be placed on the nipple line of the patient prior to the surgery start in the operating room. Data will be collected prior to the initial incision after the patient has been intubated, and then at the end of surgery before the patient has been extubated.
214711434|NCT00461422|DRUG|Ganirelix|sc injection of Ganirelix 0.25 mg per day
214711435|NCT04324788|OTHER|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
214711436|NCT04324788|OTHER|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
214711437|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
214711438|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
214599845|NCT05142189|BIOLOGICAL|BNT116|Intravenous injection
214599846|NCT05142189|BIOLOGICAL|Cemiplimab|Intravenous infusion
214599847|NCT05142189|DRUG|Docetaxel|Intravenous infusion
214711439|NCT06027944|OTHER|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
214711440|NCT03135288|DEVICE|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
214711441|NCT05859971|DRUG|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
214599848|NCT05142189|DRUG|Carboplatin|Intravenous infusion
214599849|NCT05142189|DRUG|Paclitaxel|Intravenous infusion
214599850|NCT05142189|BIOLOGICAL|BNT316|Intravenous infusion
214599851|NCT05142189|BIOLOGICAL|anti-B7-H3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
214599852|NCT05142189|BIOLOGICAL|anti-HER3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
214599853|NCT05142189|BIOLOGICAL|Bispecific antibody for PD-L1 and VEGF-A|Intravenous infusion
214599854|NCT05045157|PROCEDURE|Percutaneous A1 Pulley Release Under Ultrasound Guidance|the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.
214599855|NCT05045157|DRUG|Corticosteroid injection|corticosteroid injection is performed
214599856|NCT04047186|DRUG|Tislelizumab Injection|Patients in the experimental group receive Tislelizumab Injection
214599857|NCT06777524|BEHAVIORAL|skin-to-skin contact education|For the intervention group, additional education on the importance and clinical benefits of mother-infant skin-to-skin contact will be provided (including an educational video). They will be instructed to engage in a minimum of 6 hours of skin-to-skin contact per day with the infant's and mother's chests exposed for at least 15 minutes per session, and to keep a record of the contact time, as well as the time spent holding the clothed infant and a daily feeding diary.
214599858|NCT04498832|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214599859|NCT04498832|BIOLOGICAL|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
214599860|NCT05607095|BIOLOGICAL|Lifileucel (LN-144/LN-145)|Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
214599861|NCT05509777|DRUG|Mirikizumab|Administered IV or SC
214599862|NCT04369066|DIAGNOSTIC_TEST|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
214599863|NCT04369066|DIAGNOSTIC_TEST|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
214599864|NCT05833087|BEHAVIORAL|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
214599865|NCT05833087|BEHAVIORAL|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
214599866|NCT05833087|OTHER|Standard care package content|"Standard care packages: The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances.~Expanded package: In one center, specialized treatment is offered for difficult-to-treat depression. Up to 9 months of psychotherapy is offered, as well as close follow-up on adjustment in medicine."
214599867|NCT05602142|DRUG|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
214711442|NCT05859971|DEVICE|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
214599868|NCT05671874|BEHAVIORAL|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
214599869|NCT05877521|BEHAVIORAL|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
214711443|NCT00340834|DRUG|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
214711444|NCT00340834|DRUG|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
214599870|NCT05877521|OTHER|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
214599871|NCT05556824|DRUG|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
214599872|NCT05556824|OTHER|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
214599873|NCT05326308|DRUG|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
214599874|NCT05326308|DRUG|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
214599875|NCT05183360|DRUG|BI 706321|BI 706321, tablet, oral use
214599876|NCT05183360|DRUG|Placebo|Placebo, tablet, oral use
214711445|NCT00340834|DRUG|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
214711446|NCT03004976|BIOLOGICAL|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
214711447|NCT03004976|OTHER|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
214711448|NCT06045728|OTHER|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
214711449|NCT06045728|BEHAVIORAL|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
214599877|NCT06253494|BIOLOGICAL|AdHER2DC vaccine|AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12
214599878|NCT06253494|BIOLOGICAL|Pembrolizumab|Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16
214599879|NCT06253494|BIOLOGICAL|N-803|N-803 is given by subcutaneous injections on Day 1 of cycles 1-16
214599880|NCT06253494|DRUG|Lenvatinib|Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16
214599881|NCT06253494|DEVICE|PATHWAY HER2 (4B5) assay|Used during screening to estimate eligibility
214599882|NCT01729455|BIOLOGICAL|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
214599883|NCT01729455|OTHER|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
214599884|NCT05514132|DRUG|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
214599885|NCT05514132|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
214599886|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
214599887|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
214599888|NCT06222450|BEHAVIORAL|Vestibular Rehabilitation Therapy (VRT)|customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
214599889|NCT06852820|DRUG|Lu-PSMA-617|Given IV
214599890|NCT05579990|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
214599891|NCT02530463|DRUG|Azacitidine|Given IV
214599892|NCT02530463|BIOLOGICAL|Ipilimumab|Given IV
214599893|NCT02530463|OTHER|Laboratory Biomarker Analysis|Correlative studies
214599894|NCT02530463|BIOLOGICAL|Nivolumab|Given IV
214599895|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
214599896|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
214599897|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
214599898|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
214599899|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
214599900|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
214599901|NCT05865457|DEVICE|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
214599902|NCT05865457|DEVICE|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
214599903|NCT06840899|DRUG|CBD|Twice daily 100mg cannabidiol (CBD)
214599904|NCT05827016|DRUG|Iberdomide|Specified dose on specified days
214599905|NCT05827016|DRUG|Lenalidomide|Specified dose on specified days
214599906|NCT05961592|DRUG|R-2487 DP|Probiotic
214599907|NCT05381038|DEVICE|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
214635073|NCT07001748|PROCEDURE|Magnetic Resonance Imaging|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
214599908|NCT05381038|DEVICE|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
214599909|NCT05381038|DRUG|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
214599910|NCT05381038|DRUG|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
214599911|NCT05381038|DRUG|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
214599912|NCT06965699|DIETARY_SUPPLEMENT|ProSauce|10g additional protein from ProSauce
214599913|NCT06965699|DIETARY_SUPPLEMENT|low-protein sauce|Commercially available standard low-protein sauce
214599914|NCT06263283|OTHER|session of Kine-Yoga|"Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment"
214711450|NCT04687488|OTHER|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
214711451|NCT04687488|OTHER|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
214599915|NCT06025578|DRUG|BMS-986278|Specified dose on specified days
214599916|NCT06025578|DRUG|BMS-986278 Placebo|Specified dose on specified days
214599917|NCT06322043|DEVICE|Adipearl|Injection of the investigational device in subcutaneous tissue.
214599918|NCT06206837|DRUG|vepdegestrant|Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
214599919|NCT06206837|DRUG|PF-07220060|Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
214599920|NCT05413850|DRUG|Lutetium (177Lu) rhPSMA-10.1 Injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
214599921|NCT05413850|DIAGNOSTIC_TEST|18F-rhPSMA-7.3 injection (in phase 1 only)|18F-rhPSMA-7.3 (in phase 1 only) at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
214599922|NCT06122649|DRUG|apremilast|Oral tablet
214599923|NCT06122649|DRUG|Placebo|Oral tablet
214599924|NCT05026983|DRUG|Binimetinib|Given PO
214599925|NCT05026983|DRUG|Encorafenib|Given PO
214599926|NCT05026983|OTHER|Questionnaire Administration|Ancillary studies
214711452|NCT02194556|DRUG|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
214599927|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
214599928|NCT04664829|DRUG|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m\^2
214711453|NCT02194556|DRUG|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
214711454|NCT01609725|DEVICE|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
214599929|NCT04664829|DRUG|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m\^2
214599930|NCT04321200|DIAGNOSTIC_TEST|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
214599931|NCT04321200|OTHER|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
214599932|NCT04685616|RADIATION|Involved site radiotherapy|"Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.~Recommended dose 30Gy"
214599933|NCT04685616|DRUG|Doxorubicin|See arm description
214599934|NCT04685616|DRUG|Bleomycin|See arm description
214599935|NCT04685616|DRUG|Brentuximab vedotin|See arm description
214599936|NCT04685616|DRUG|Vinblastine|See arm description
214599937|NCT04685616|DRUG|Dacarbazine|See arm description
214599938|NCT04685616|DRUG|Haematopoietic growth factor|See arm description
214599939|NCT04088396|DRUG|Baricitinib|Administered orally
214599940|NCT04088396|DRUG|Tocilizumab|Administered SC
214711455|NCT01609725|DEVICE|Oral prophylaxis|One session of supraginigval calculus removal
214711456|NCT00723671|PROCEDURE|MRI|
214711457|NCT05868980|OTHER|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
214711458|NCT06293365|BIOLOGICAL|VAY736 1ml PFS|Solution for injection.
214711459|NCT06293365|BIOLOGICAL|VAY736 2 ml PFS|Solution for injection
214599941|NCT06682988|DRUG|Mirvetuximab Soravtansine|intravenous (IV) infusion
214599942|NCT03223610|DRUG|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214599943|NCT03223610|DRUG|Ibrutinib|Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214711460|NCT06293365|BIOLOGICAL|VAY736 2ml AI|Solution for injection.
214599944|NCT03223610|DRUG|Prednisone|Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214599945|NCT03223610|BIOLOGICAL|Obinutuzumab|Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214599946|NCT03223610|DRUG|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214599947|NCT06559150|DRUG|Nebulized Ensifentrine Suspension; 3 mg|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
214599948|NCT06559150|DRUG|Nebulized Placebo Solution|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
214599949|NCT05394714|BIOLOGICAL|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
214599950|NCT02938793|DRUG|Durvalumab|intravenous administration
214599951|NCT02938793|DRUG|Tremelimumab|intravenous administration
214599952|NCT06390956|DRUG|Pirtobrutinib|Administered once daily as an oral medication.
214599953|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
214599954|NCT06390319|DRUG|Vincristine|Given IV.
214599955|NCT06390319|DRUG|Daunorubicin|Given IV.
214599956|NCT06390319|DRUG|Calaspargase pegol|Given IV.
214599957|NCT06390319|DRUG|Dasatinib|Given PO
214599958|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
214711461|NCT00291499|DRUG|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
214599959|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
214599960|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
214599961|NCT06390319|DRUG|Cyclophosphamide|Given IV.
214599962|NCT06390319|DRUG|Cytarabine|Given IV or IT.
214599963|NCT06390319|DRUG|Mercaptopurine|Given PO.
214599964|NCT06390319|DRUG|Nelarabine|Given IV
214599965|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
214599966|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
214599967|NCT03964233|DRUG|BI 907828|Film-coated tablets
214599968|NCT03964233|DRUG|ezabenlimab|Solution for infusion
214599969|NCT03964233|DRUG|BI 754111|Solution for infusion
214599970|NCT05849181|DEVICE|Moona Device|Moona Device pillow pad
214599971|NCT05849181|DEVICE|Inactive Moona Device|Inactive Moona Device pillow pad
214599972|NCT05396105|DRUG|deucrictibant selected dose|deucrictibant soft capsule for oral use
214711462|NCT00291499|OTHER|Placebo|800 mg placebo/day for 6 months
214711463|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
214711464|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
214711465|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
214711466|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
214711467|NCT05474872|DEVICE|BIS monitoring|The depth of anesthesia will be monitored using Bispectral Index values.
214711468|NCT02539524|OTHER|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
214711469|NCT02539524|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
214711470|NCT02030249|BEHAVIORAL|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
214711471|NCT02030249|BEHAVIORAL|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
214599973|NCT06269081|BEHAVIORAL|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
214599974|NCT06269081|BEHAVIORAL|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
214599975|NCT06667609|OTHER|Any treatments regimen|Participants may receive any treatments in accordance with standard clinical practice, based on physicians' recommendations and patients' preferences.
214599976|NCT05794958|DRUG|Axicabtagene Ciloleucel|Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
214599977|NCT05632315|DRUG|PMT|Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
214599978|NCT05016323|DRUG|HR19042 Capsules|HR19042 Capsules
214599979|NCT05016323|DRUG|Placebo|Placebo
214599980|NCT04282187|DRUG|Decitabine|Given IV
214599981|NCT04282187|DRUG|Ruxolitinib|Given PO
214599982|NCT04282187|DRUG|Fedratinib|Given PO
214711472|NCT02030249|BEHAVIORAL|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
214711473|NCT01939093|DRUG|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
214711474|NCT01939093|DIETARY_SUPPLEMENT|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
214711475|NCT01939093|DRUG|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
214711476|NCT06331312|BIOLOGICAL|Secukinumab|2 x 150mg/1mL PFS secukinumab
214599983|NCT04282187|OTHER|Questionnaire Administration|Ancillary studies
214599984|NCT04282187|DRUG|Pacritinib|Given PO
214599985|NCT04282187|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow samples
214599986|NCT03975959|OTHER|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
214599987|NCT06976216|DRUG|KarXT|Specified dose on specified days
214599988|NCT06976216|DRUG|KarX-EC|Specified dose on specified days
214599989|NCT06976216|OTHER|Placebo|Specified dose on specified days
214599990|NCT06976203|DRUG|KarXT|Specified dose on specified days
214599991|NCT06976203|DRUG|KarX-EC|Specified dose on specified days
214599992|NCT06976203|OTHER|Placebo|Specified dose on specified days
214599993|NCT06806046|DRUG|M9140|M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level.
214599994|NCT06805825|DRUG|NN3201|A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.
214599995|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
214599996|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
214599997|NCT05520255|DRUG|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
214599998|NCT06574620|GENETIC|Genetic testing|Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
214599999|NCT06574620|PROCEDURE|Optional biopsy|Optional collection of tumour tissue and normal tissue after the last dose of treatment.
214600000|NCT06574620|PROCEDURE|Tissue collection|Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.
214600001|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
214600002|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
214600003|NCT06090539|DRUG|Glofitamab/Obinutuzumab|Specified dose on specified days
214600004|NCT06090539|DRUG|Mosunetuzumab|Specified dose on specified days
214600005|NCT04003818|DRUG|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
214600006|NCT05662241|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
214600007|NCT05662241|OTHER|Placebo|Placebo
214600008|NCT03824483|DRUG|Zanubrutinib|zanubrutinib (160mg by mouth BID)
214600009|NCT03824483|DRUG|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter)."
214600010|NCT03824483|DRUG|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
214600011|NCT02802969|PROCEDURE|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete."
214600012|NCT02802969|RADIATION|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
214600013|NCT02802969|DRUG|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
214600014|NCT05558982|DRUG|BXCL701|BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days
214600015|NCT05558982|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
214600016|NCT04600362|DRUG|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
214600017|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
214600018|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
214600019|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
214600020|NCT06976086|DEVICE|Active transcutaneous bone conduction system|The Sentio system consists of the Sentio 1 Mini sound processor (SP) and Sentio Ti implant with fixation band and screws.
214600021|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
214600022|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
214600023|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
214600024|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
214600025|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
214600026|NCT05652686|DRUG|Peluntamig (PT217)|A bispecific antibody (bsAb) against DLL3 and CD47.
214600027|NCT05652686|DRUG|Carboplatin + Etoposide|Administered per Standard of Care.
214600028|NCT05652686|DRUG|Paclitaxel.|Administered per Standard of Care.
214600029|NCT05652686|DRUG|Atezolizumab|Administered per Standard of Care.
214600030|NCT06434948|DRUG|Omega-3 Ethyl Esters 4 g|4 grams = 4 capsules, once daily
214711477|NCT05989308|BEHAVIORAL|Email|Email message sent to guardian with proxy information.
214600031|NCT06434948|DRUG|Omega-3 Ethyl Esters 2 g|2 grams = 2 capsules, once daily
214600032|NCT03456531|DEVICE|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
214600033|NCT03456531|DRUG|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
214600034|NCT01474863|DRUG|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
214600035|NCT01474863|DRUG|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
214600036|NCT01474863|DRUG|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
214600037|NCT03365050|OTHER|No Intervention Given|No Intervention to be given
214600038|NCT01119326|PROCEDURE|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
214600039|NCT03231943|DRUG|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
214600040|NCT03231943|DRUG|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
214711478|NCT05989308|BEHAVIORAL|Text|Text message sent to guardian with proxy information.
214711479|NCT05989308|BEHAVIORAL|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
214711480|NCT06134414|DRUG|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
214600041|NCT01798277|PROCEDURE|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
214600042|NCT01798277|DRUG|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
214600043|NCT04710888|DRUG|use of basil extract gel in treatment of aphthus ulcer|This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
214600044|NCT04710888|OTHER|muco adhesive placebo gel|mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
214600045|NCT04710888|OTHER|no treatment|(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
214600046|NCT02211352|DRUG|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
214600047|NCT02211352|DRUG|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
214600048|NCT02810899|DRUG|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
214600049|NCT02810899|DRUG|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
214600050|NCT04575480|PROCEDURE|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
214600051|NCT02944994|OTHER|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
214600052|NCT02944994|OTHER|Routine Care|This arm will reflect typical care received in routine mental health care
214600053|NCT05187156|BEHAVIORAL|Behavioral Activation and Social Engagement|brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
214600054|NCT05187156|BEHAVIORAL|Treatment as usual|treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
214600055|NCT04687150|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
214600056|NCT04687150|OTHER|Colored water|Colored water (placebo)
214600057|NCT02795416|DRUG|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
214600058|NCT00121693|BEHAVIORAL|Music therapy (listening to specific music)|Listening to Music
214600059|NCT04818424|DEVICE|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
214600060|NCT04818424|BEHAVIORAL|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
214600061|NCT01946841|DIETARY_SUPPLEMENT|RealDiet®Renal|
214600062|NCT05138991|PROCEDURE|Echocardiogram Recording|Undergo assessment via echo
214600063|NCT05138991|OTHER|Questionnaire Administration|Ancillary Studies
214600064|NCT05138991|PROCEDURE|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
214600065|NCT05138991|DEVICE|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
214600066|NCT06245642|DRUG|Compound Ciwujia Granules, Guipi Granules|Experimental group: Basic treatment + Compound Ciwujia Granules + Guipi Granules simulator orally for 6 weeks; Positive drug control group: basic treatment + Guipi Granules + Compound Ciwujia Granules simulant orally for 6 weeks.
214711481|NCT03277508|DEVICE|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
214600067|NCT00551902|PROCEDURE|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
214600068|NCT00551902|PROCEDURE|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
214600069|NCT05564299|DIAGNOSTIC_TEST|Rapid 30-minute Desktop Assay|"Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols."
214711482|NCT03277508|DEVICE|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
214600070|NCT04824521|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
214600071|NCT00523120|DRUG|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
214600072|NCT00523120|DRUG|dexotc|aural drops
214600073|NCT06277908|PROCEDURE|Elective Surgery for gastric cancer|Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
214600074|NCT02537535|OTHER|survey|This is a cross-sectional study without specific intervention
214711483|NCT05438251|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
214711484|NCT01826526|DEVICE|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
214711485|NCT00209326|DRUG|FE200440|
214711486|NCT00002391|DRUG|Abacavir sulfate|
214711487|NCT00002391|DRUG|Lamivudine|
214711488|NCT00002391|DRUG|Zidovudine|
214600075|NCT06096207|DEVICE|Medtronic SenSight Directional DBS lead|At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
214600076|NCT05183750|PROCEDURE|High tibial osteotomy|Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
214600077|NCT06451614|DEVICE|SpaceIT Hydrogel System|"SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque."
214600078|NCT06451614|DEVICE|Commercially available Boston Scientific Spacer|Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
214600079|NCT05514054|DRUG|Imlunestrant|Administered orally.
214600080|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
214711489|NCT02428907|BEHAVIORAL|simulation training|teamtraining of endoscopy staff
214600081|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
214600082|NCT05514054|DRUG|Letrozole|Administered per local approved label.
214600083|NCT05514054|DRUG|Exemestane|Administered per local approved label.
214600084|NCT05950139|BIOLOGICAL|Peptide vaccine|Peptide vaccine
214600085|NCT05612347|DIAGNOSTIC_TEST|FIT|Annual FIT
214600086|NCT05612347|DIAGNOSTIC_TEST|Colonoscopy|One time surveillance colonoscopy
214600087|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
214600088|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
214600089|NCT06507813|DRUG|ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
214711490|NCT00289549|DRUG|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
214600090|NCT06507813|DRUG|Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
214600091|NCT06507813|DRUG|Placebo of ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
214711491|NCT03858270|DRUG|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
214711492|NCT03858270|OTHER|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
214600092|NCT06507813|DRUG|Placebo of Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.
214600093|NCT06507813|DRUG|ADC189 granules|"For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once."
214600094|NCT06507813|DRUG|Placebo of ADC189 granules|Placebo. Given once only.
214600095|NCT06507813|DRUG|Placebo of Oseltamivir granules|For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).
214600096|NCT06507813|DRUG|Oseltamivir granules|For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
214600097|NCT00396435|DRUG|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
214600098|NCT02989948|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
214600099|NCT06027983|DRUG|Chimeric receptor T-cells + Trastuzumab|Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
214600100|NCT06027983|DRUG|Fludarabine and Cyclophosphosphamide|3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
214600101|NCT02458014|BIOLOGICAL|Blinatumomab|Given IV
214600102|NCT02458014|OTHER|Laboratory Biomarker Analysis|Correlative studies
214600103|NCT07118852|DEVICE|Remote Human Milk Sample Collection|"Three commercially available products will be evaluated for their ability to preserve RNA in human milk samples.~* RNAlater (ThermoFisher©) (ratio variable)~* DNA/RNA Shield (Zymo©) (ratio variable)\*~* NucleoProtect RNA (Takara©) (ratio variable)\*~  * Product volume mixed with human milk samples will vary by product and may be titrated as part of protocol development."
214600104|NCT05305131|DRUG|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
214600105|NCT05305131|DRUG|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
214600106|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
214600107|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
214600108|NCT04378855|OTHER|Questionnaire|Quality of life assessment
214600109|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
214600110|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
214600111|NCT06809985|PROCEDURE|Hamilton maneuver|The Hamilton maneuver is performed by inserting one or two fingers through the internal cervical os and carefully producing a circumferential rotational movement through the uterine segment in order to separate the fetal membranes from the decidua. This maneuver is recommended in order to reduce the need for formal induction.
214600112|NCT06655623|BEHAVIORAL|Schema therapy|Schema therapy is a form of psychotherapy invented to address more complex clinical cases. It consists of elements from Cognitive Behavioral Therapy as well as psychodynamic, emotion-focused and gestalt therapies, with a distinct focus on experiential interventions. A therapy manual was developed for use in this study.
214600113|NCT05020236|DRUG|Elranatamab|subcutaneous
214600114|NCT05020236|DRUG|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
214600115|NCT05020236|DRUG|Pomalidomide|oral
214600116|NCT05020236|DRUG|Dexamethasone|oral
214600117|NCT03298685|OTHER|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
214600118|NCT04829929|DEVICE|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
214600119|NCT00915733|DRUG|cilostazol|100 mg twice daily for at least 1 month
214600120|NCT00915733|DRUG|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
214600121|NCT00915733|GENETIC|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
214600122|NCT00915733|DRUG|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
214600123|NCT06841536|DRUG|Atorvastatin 80mg|"Daily intake of 80 mg of the approved drug Atorvastatin. Starting at dose 40 mg with 40 mg weekly increment reaching the maintenance dosage of 80 mg on week two, which is the approved maximum dosage of Atorvastatin. Participants who don't tolerate this fast up-titration may have prolonged tritation protocol (up to four weeks).~Under special circumstances, participants with intolerable side-effects may stay at a lower dose (40 mg/day).~The dosage and applied up-tritation is based on recommendations from trained cardiologists at the National Hospital of the Faroe Islands."
214600124|NCT06841536|BEHAVIORAL|Exercise|Exercise will be performed as aerobic interval training sessions on cycling ergometers lasting \~45 min, four times weekly for 12 weeks. All exercise sessions will be supervised. Participants will wear HR monitor system during all sessions (Polar Electro Oy, Kempele, Finland) and the Borg 6-to-20 scale will also be used to assess the rate of perceived exertion during exercise sessions. A 4-week ramp-up phase will be applied, consisting of two sessions in weeks 1 and 2, three sessions in weeks 3 and 4 after which participants will complete 4 sessions a week from weeks 5 to 12.
214600125|NCT06139185|OTHER|Data collection|Data collection
214600126|NCT06340568|DRUG|BNT323/DB-1303|intravenous (IV) infusion
214600127|NCT06340568|DRUG|Doxorubicin|IV bolus or infusion
214600128|NCT06340568|DRUG|Paclitaxel|IV infusion
214600129|NCT06981962|OTHER|Pressure ulcer prevention program|Interventions will consist of proper positioning, frequent change of patients' posture to limit or decrease pressure over the skin, skincare, such as maintaining adequate hydration, keep skin clean, prevent excessive dryness of skin, prevent message over bony prominence, and control moisture.
214600130|NCT06983496|BEHAVIORAL|Post-ICU Telehealth Follow-up|The post-ICU clinic follow-up will be conducted by a pharmacist via a telehealth visit. A collaborating physician (i.e. intensivist) will provide clinical support and oversight as needed. The appointments will be 30-60 minute telephone/video calls. Participants be assessed for PICS and recommended interventions to improve their care.
214600131|NCT06656338|OTHER|Higher HEI-2020 diet followed by lower HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
214600132|NCT06656338|OTHER|Lower HEI-2020 diet followed by higher HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
214600133|NCT06629077|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
214600134|NCT06629077|DRUG|Prazosin|A dose of prazosin will be administered based on body weight.
214600135|NCT06629077|DRUG|Placebo|Oral placebo
214600136|NCT06651970|DRUG|Acalabrutinib|Acalabrutinib Monotherapy
214600137|NCT06651970|OTHER|Investigator's choice of treatment|control arm treatment type will be defined by the PI prior to randomisation
214600138|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
214600139|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
214600140|NCT06652113|DRUG|hydroxychloroquine and levothyroxine|Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
214600141|NCT06652113|DRUG|Levothyroxine|Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
214600142|NCT06979453|DRUG|Deucravacitinib|Specified dose on specified days
214600143|NCT06979453|OTHER|Placebo|Specified dose on specified days
214600144|NCT06986798|OTHER|Local standard medical care|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood and of available clinical data are the only activities performed in addition.
214600145|NCT06662292|BEHAVIORAL|Mobile STRIDES app (psychoeducation features)|Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.
214600146|NCT06662292|BEHAVIORAL|Mobile STRIDES app (self-regulation features)|Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.
214600147|NCT06662292|BEHAVIORAL|Mobile STRIDES app (social support training features)|For the experimental group, the Mobile STRIDES app also includes five social support training lessons/modules (during the course of the 3-month intervention) focused on providing guidance related to effective communication when exchanging social support for physical activity within a team. In addition, six team feedback messages will be delivered to respective teams throughout the course of the 3-month intervention to reinforce content taught via the training lessons/modules. A weekly poll will also be administered that complements the social support training lessons, with cumulative results displayed.
214600148|NCT06661122|DRUG|Darolutamide (BAY1841788) + docetaxel + ADT|Follow clinical practice/administration. ADT=androgen deprivation therapy.
214600149|NCT06665594|PROCEDURE|Hyaluronic Acid (HA)|Injectable gel
214600150|NCT06665594|DRUG|Tranexamic Acid (TXA)|Injection of TXA
214600151|NCT06665594|DRUG|Saline (placebo)|Injection of saline
214600152|NCT06817382|GENETIC|INS1201|Suspension for IT injection.
214600153|NCT06605391|BEHAVIORAL|Caregiving While Black-LIVE|Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
214600154|NCT06592677|BEHAVIORAL|Condensed internet-delivered prolonged exposure (CIPE)|'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.
214600155|NCT06592677|BEHAVIORAL|Treatment-as-usual (TAU)|There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
214600156|NCT06601686|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
214600157|NCT06601686|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
214600158|NCT06601686|DEVICE|Sham stimulation|TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current. It will also include periods with no stimulation and a ramping up period followed by no stimulation.
214600159|NCT06602765|OTHER|Tooth brushing, tooth paste containing 1450ppm fluoride|brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
214600160|NCT05317481|BEHAVIORAL|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
214600161|NCT05317481|BEHAVIORAL|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
214600162|NCT06593912|PROCEDURE|Early Functional Training|Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.
214600163|NCT06593912|PROCEDURE|Standard protocol|Cast 6 weeks after peroneal tendon surgery (standard protocol)
214600164|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
214600165|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
214600166|NCT02132546|DRUG|Chlorhexidine|
214600167|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
214600168|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
214600169|NCT06988124|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
214600170|NCT06988124|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
214600174|NCT06655766|PROCEDURE|socket-plug technique with putty bone|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material."
214600175|NCT06655766|PROCEDURE|Ice cream cone technique|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane"
214600176|NCT05573906|COMBINATION_PRODUCT|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
214600177|NCT05573906|COMBINATION_PRODUCT|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
214600178|NCT06352047|OTHER|The effect of positioning on respiratory functions of preterm infants after extubation.|Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
214600179|NCT06991179|DRUG|LY4064809|Administered orally
214600180|NCT06990997|BEHAVIORAL|Aphasia identification (ID) card|Participants will view an aphasia ID card for a speaker with aphasia. The card will disclose the speaker's aphasia, define aphasia, and request time to communicate.
214600181|NCT05785767|DRUG|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
214600182|NCT05785767|DRUG|cemiplimab|Q3W as IV co-infusion
214600183|NCT05785767|DRUG|Placebo|Q3W as IV co-infusion
214600184|NCT06346405|OTHER|Subthreshold Micropulse Laser Treatment|Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
214711493|NCT01532570|DRUG|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
214600185|NCT05585853|OTHER|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
214600186|NCT06992544|OTHER|Pistachio-enriched diet|1 packet/day of approximately 1.25 oz (35 g) of dry roasted, unsalted, shelled pistachio kernels
214600187|NCT06992544|OTHER|Usual diet|Usual diet (while abstaining from pistachio consumption and limiting other nut consumption to ≤1 serving/week)
214600188|NCT05215327|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
214600189|NCT05215327|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
214600190|NCT06665685|DEVICE|BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will be the patient wearing the device during their Nursing Home stay for 30-days.
214600191|NCT06665685|DEVICE|Providing Clinical Care with BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will provide care for patients wearing the BioButton device during their Nursing Home stay for 30-days.
214600192|NCT06855537|PROCEDURE|PCI strategy|-In the intervention group, vulnerable plaque lesions (quantitative flow ratio, QFR \>0.8) to be treated at the operator's discretion using second-generation drug eluting stent (DES).
214600193|NCT06855537|DRUG|OMT strategy|"* Lifestyle modifications and intensive medical therapy (based on current guideline-directed secondary prevention).~* Both groups to receive statin or other therapies to achieve LDL-C \<1.4 mmol/L and decrease by 50% compared to the baseline.~* Lifestyle and risk factor management to include smoking cessation, nutritional optimization, physical activity, adherence to prescribed medications, and control of diabetes and hypertension."
214600194|NCT06611267|OTHER|Pain without cream on|Participants will be inflicted with pain without cream on.
214600195|NCT06611267|OTHER|Pain with cream on|Patients are inflicted with pain after getting a cream on, which has previously had pain-relieving effects
214600196|NCT06996756|BIOLOGICAL|AAV8hAAT(AVL)|AAV8hAAT(AVL) gene transfer vector
214600197|NCT05139069|BEHAVIORAL|Trauma-Informed Toolkit|Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.
214600198|NCT06616194|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablets
214600199|NCT06616194|DRUG|Placebo|Matching placebo oral disintegrating tablets
214600200|NCT06991556|DRUG|JSB462|JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
214600201|NCT06991556|DRUG|Abiraterone|Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
214600202|NCT06991556|DRUG|Enzalutamide|Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
214600203|NCT06995898|PROCEDURE|Biospecimen Collection|Undergo blood collection
214600204|NCT06995898|DEVICE|Device Usage|Evaluation of MCD tests
214600205|NCT06995898|OTHER|Electronic Health Record Review|Obtain health data
214600206|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Shield MCD test
214600207|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Avantect MCD test
214600208|NCT06995898|OTHER|Questionnaire Administration|Study specific questionnaires
214600209|NCT05903196|DEVICE|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
214600210|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
214600211|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
214600212|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
214600213|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
214600214|NCT06287502|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB)|Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.
214635074|NCT07001748|DRUG|Intraperitoneal Paclitaxel|"Patients on Arm B will start systemic therapy + intraperitoneal paclitaxel as early as the day after Step 1 randomization and must start within 30 calendar days (including holidays) after Step 1 randomization as per the schedule shown in the table below.~Therapy will be administered on Days 1 and 8 of a 21-day cycle for 4 cycles."
214635075|NCT06617143|OTHER|mindfulness-based cognitive therapy|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
214600215|NCT06287502|BEHAVIORAL|Resistance, aerobic, flexibility and balance exercise training|The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
214600216|NCT06996496|OTHER|Postpartum educational tool after hypertensive pregnancy|postpartum educational tool for patients having experienced a hypertensive disorder of pregnancy
214600217|NCT07004023|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
214600218|NCT07004023|OTHER|Placebo|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
214600219|NCT04536337|DRUG|ALG-000184|Single or multiple doses of ALG-000184
214600220|NCT04536337|DRUG|Placebo|Single or multiple doses of Placebo
214600221|NCT04536337|DRUG|Entecavir|multiple doses of Entecavir
214600222|NCT05435300|OTHER|PET Scan|Participants will undergo two PET scans throughout the study.
214600223|NCT04480723|OTHER|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
214600224|NCT04480723|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
214600225|NCT07102212|BEHAVIORAL|mHealth Intervention|Participants are randomized to the FOCUS app or Information Control section of the app and will have six weeks to complete the app. Randomization, via the app, is stratified by geographic location (rural vs other), cancer type, and demographics so experimental arms are equivalent. Participants will complete 5 assessments online over a 12-mo period. The participants will have weekly telehealth professional support during the six-week intervention. Participants wear GeneActiv watches for sleep/activity recording for 7 days and provide blood and saliva samples at baseline, 6 and 12 weeks, and 6 and 12 months.
214600226|NCT06868628|DRUG|Foralumab Nasal|Foralumab is an anti-CD3 monoclonal antibody administered as a nasal spray. Participants will complete eight 3-week dosing cycles over the study. During each cycle, Foralumab will be administered intranasally three times per week for the first two weeks, with no administration in the third week.
214600227|NCT06870383|DRUG|Erector spinae plane block|The block will be done under ultrasound guidance using 20 ml bupivacaine 0.25% that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose.
214600228|NCT06870383|DRUG|Combined Pecto-intercostal and recto-intercostal fascial plane block|The blocks will be done under ultrasound guidance using 10-15 ml of 0.25% bupivacaine that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose..
214600229|NCT06866405|BIOLOGICAL|RSVpreF|Single Dose
214600230|NCT06866405|BIOLOGICAL|Placebo|Single Dose
214600231|NCT07010965|DEVICE|NyokAssist™|The NyokAssist™ Ventricular Assist Device can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta .
214600232|NCT07010965|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide coronary flow
214600233|NCT06674109|DRUG|Empagliflozin 10 mg|For the empagliflozin arm, participants will take 10 mg daily.
214600234|NCT06674109|DRUG|Placebo|Participants in the placebo arm will take a placebo daily.
214600235|NCT06624462|OTHER|Treatment in the Meta Care Clinic|"* Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention."
214600236|NCT06624462|OTHER|Standard care with general practitioner and/or outpatient clinics|"Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes."
214600237|NCT06625151|BEHAVIORAL|Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI)|The PCPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and coping processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in perceived criticism, self-blame, perceived control, avoidant coping, and event stress are connected to increases negative affect; (b) how changes in perceived social support, positive reinterpretation, perceived control, avoidant coping, and problem-focused coping are linked to increases in positive affect; (c) how self-critical perfectionism and maladaptive stress and coping tendencies explain enduring mood problems; (d) how healthy striving, adaptive appraisal, and coping tendencies can identify personal strengths; and, most important, (e) what the person needs to do to manage and improve his or her mood.
214600238|NCT06625151|BEHAVIORAL|Perfectionism and Emotion Regulation Processes Model - Explanatory Feedback Intervention (PERPM-EFI)|The PERPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and emotion regulation processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in event stress, mindfulness, self-compassion, experiential avoidance, and rumination are connected to increases in negative affect, (b) how changes in event stress, mindfulness, reappraisal, self-compassion, and experiential avoidance are linked to increases in positive affect, (c) how self-critical perfectionism and maladaptive stress and emotion regulation tendencies explain enduring mood problems, (d) how healthy striving, adaptive appraisal, and emotion regulation tendencies can identify personal strengths, and, most important, (e) what the person needs to do to manage and improve his or her mood.
214600239|NCT07012395|DRUG|SPY001|Experimental
214600240|NCT07012395|DRUG|SPY002|Experimental
214600241|NCT07012395|DRUG|SPY003|Experimental
214600242|NCT07012395|OTHER|Placebo|Placebo
214600243|NCT06173661|DRUG|Fremanezumab|The intervention will be active medication.
214600244|NCT06173661|OTHER|Placebo|The intervention will be placebo injection.
214600245|NCT06684613|DEVICE|PrEP Decision Aid|Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.
214600246|NCT06684613|OTHER|Generic Information|"Participants will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid."
214600247|NCT06628310|DRUG|ABBV-400|Intravenous (IV) Infusion
214600248|NCT06628310|DRUG|Budigalimab|IV Infusion
214600249|NCT06628310|DRUG|Fluorouracil|IV Infusion; IV Injection
214600250|NCT06628310|DRUG|Leucovorin|IV Infusion; IV Injection
214600251|NCT06628310|DRUG|Oxaliplatin|IV Infusion
214600252|NCT07012031|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214600253|NCT07012031|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600254|NCT07012031|PROCEDURE|Computed Tomography|Undergo CT
214600255|NCT07012031|PROCEDURE|Echocardiography Test|Undergo ECHO
214600256|NCT07012031|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214600257|NCT07012031|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214600258|NCT07012031|DRUG|Sotorasib|Given PO
214600259|NCT07012031|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214600260|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 5 g dehydrated nopal powder from highly mature cladodes|Group I received 5 g of dehydrated Opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia.
214600261|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 15 g dehydrated nopal powder from highly mature cladodes|Group II received 15 g plus the diet, and Group III followed only the diet.
214600262|NCT07018908|OTHER|Control Group (only diet)|No dehydrated nopal or placebo. Diet: 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
214600263|NCT07020611|DEVICE|Cygnum Aneurysm Sac Management Device (ASMD)|Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks
214600264|NCT07014670|OTHER|Validation and Reability study|Validation and Reability study
214600265|NCT07020533|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600266|NCT07020533|OTHER|Electronic Health Record Review|Ancillary studies
214600267|NCT07020533|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo HCT
214600268|NCT07020533|DRUG|Letermovir|Given IV or PO
214600269|NCT07020533|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214600270|NCT07020533|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning
214600271|NCT07020533|PROCEDURE|Pheresis|Undergo apheresis
214600272|NCT07020533|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given G-CSF
214600273|NCT06067438|DRUG|Amiodarone Hydrochloride|Given IV and via feeding tube
214600274|NCT06067438|OTHER|Saline|Given IV
214600275|NCT06690424|DRUG|Remimazolam|remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
214600276|NCT06690424|DRUG|Propofol|Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
214600277|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
214600278|NCT06112379|DRUG|Dato-DXd|Experimental drug IV infusion
214600279|NCT06112379|DRUG|Durvalumab|Experimental drug IV Infusion
214600280|NCT06112379|DRUG|Pembrolizumab|IV Infusion Active comparator
214600281|NCT06112379|DRUG|Doxorubicin|IV infusion Experimental/Active Comparator
214600282|NCT06112379|DRUG|Epirubicin|IV Infusion Experimental/Active Comparator
214600283|NCT06112379|DRUG|Cyclophosphamide|IV infusion Experimental/Active Comparator
214600284|NCT06112379|DRUG|Paclitaxel|IV infusion Experimental/Active Comparator
214600285|NCT06112379|DRUG|Carboplatin|IV infusion Experimental/Active Comparator
214600286|NCT06112379|DRUG|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
214600287|NCT06112379|DRUG|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
214600288|NCT03425279|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
214600289|NCT03425279|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
214600290|NCT06687395|OTHER|Skill training on different models|Skill training on different models (medium/high fidelity vs. self-made model)
214600291|NCT06710548|BEHAVIORAL|REVITALIZE Intervention|A remotely delivered tele-health intervention to address cancer fatigue that is based on an acceptance-based approach. The intervention includes 8 one-on-one weekly sessions and 2 booster sessions with trained psychology doctoral students based at University of Colorado. Sessions will focus on fatigue education, Acceptance and Commitment Therapy (ACT) skills, and behavior changes. Wi-Fi enabled tablets and keyboards will be provided to participants if needed. All sessions will be conducted via the Zoom platform and will either be videotaped or audiotaped.
214635076|NCT06617143|OTHER|routine treatment and care|routine treatment and care
214635077|NCT07006441|OTHER|Preoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
214635078|NCT07006441|OTHER|Postoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
214635079|NCT05469386|DRUG|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
214635080|NCT05469386|BEHAVIORAL|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
214635081|NCT05469386|DRUG|Placebo|Placebo capsule
214635082|NCT05469386|BEHAVIORAL|General Classroom|General education classroom procedures
214635083|NCT05469386|BEHAVIORAL|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
214635084|NCT07025343|OTHER|Lipid emulsion|Patients (\>70kg will receive 100 ml, \<70 will receive 1.5ml/kg) of 20% intravenous lipid emulsion at the end of surgery as a study group.
214635085|NCT07135453|BIOLOGICAL|Pneumococcal Vaccine|PCV
214635086|NCT07078760|PROCEDURE|CTI radiofrequency ablation.|Cavotricuspid Isthmus ablation
214635087|NCT07097545|BEHAVIORAL|Mindfulness|15 minute daily guided meditation
214635088|NCT07097545|BEHAVIORAL|Social Media Reduction|Reduce social media use at least 30 minutes daily and exercise instead
214635089|NCT07097545|BEHAVIORAL|Exercise|Participants will exercise at least 30 minutes daily. Participants are given examples of common exercises (walking, yoga, strength training, etc.), but are allowed to choose any type, although dissuaded from activities with high potential for injury.
214600292|NCT06710548|BEHAVIORAL|Educational Materials|The educational materials arm will receive specialized cancer survivorship educational materials created by the National Cancer Institute
214600293|NCT07132645|PROCEDURE|Computed Tomography|Undergo CT scan
214600294|NCT07132645|DRUG|Gallium Ga 68-DOTA-FAPI-04|Given IV
214600295|NCT07132645|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214600296|NCT07131787|DEVICE|Blood flow restriction training (smart-cuff pro device)|This group will undergo low load strength training consisting of calf, thigh, glute and core exercises. A Blood flow restriction cuff will be added during selected exercises in rehabilitation program (targeting quadriceps and calf muscles)
214600297|NCT07131787|OTHER|Standardised strength training|This group will undergo standard, traditional strength training consisting of calf, thigh, glute and core exercises.
214600298|NCT06711718|OTHER|Qualitative interview (patients)|Qualitative interviews to be carried out by an experienced researcher with patients who have had their diabetes diagnosis reviewed as a result of the running of the tool.
214600299|NCT06711718|OTHER|Qualitative interview (staff)|Qualitative interviews to be carried out by an experienced researcher with practice staff who have run the tool and reviewed patients flagged by the tool.
214600300|NCT06714357|DRUG|irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes
214600301|NCT06714357|DRUG|panitumumab|Administered as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion at the dosage of 6 mg/kg
214600302|NCT06714357|DRUG|Valproic Acid (VPA)|"VPA will be administered in each patient with a titration strategy to improve the compliance for the treatment, looking for a target serum level between 50 and 100 μg/mL that represents the recommended values for the treatment of epilepsy and also a useful concentration to produce the desired synergistic effect with chemotherapy based on preclinical studies.~Administrated at the dosage of 500 mg/three times a day (after 7 days of gradual dose escalation)."
214600303|NCT07039422|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
214600304|NCT07037966|DEVICE|MRI|Standard 3T MRI Scan
214600305|NCT07037966|DEVICE|MRI|Low-field MRI scan using the NextMRI prototype
214600306|NCT04732273|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
214600307|NCT04732273|OTHER|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
214600308|NCT07042295|DRUG|Amivantamab and Recombinant Human Hyaluronidase|Given SC
214600309|NCT07042295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600310|NCT07042295|BIOLOGICAL|Cetuximab|Given IV
214600311|NCT07042295|PROCEDURE|Computed Tomography|Undergo CT scan
214600312|NCT07042295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214600313|NCT06716502|DEVICE|Portable CPAP efficacy|The device will be tested in providing a PEEP comprised between 4-7,5 cmH2O
214600314|NCT06716502|DEVICE|Portable CPAP usability assessment|The device usability will be evaluated in individual's self-experience tests, i.e., in conditions where the volunteer will self-apply the device.
214600315|NCT06925789|DRUG|Ropivacaine|The nerve block is performed when the patients are admitted to the hospital with diagnosed hip fractures. And another nerve block with catheter is performed for post-operative pain control in geriatric population with 0.25% Ropivacaine 30mls.
214600316|NCT07045935|DRUG|Cabergoline (Dopamine Agonist)|Cabergoline is available in tablet form, with doses of 0.5 mg per tablet. The standard dosing for hyperprolactinemia typically starts at 0.25 mg to 0.5 mg per week, which can be gradually increased based on the patient's response, with a usual range of 0.25 mg to 2 mg per week. The dose required to achieve the target prolactin levels (pre- defined for each intervention arm) may vary between patients, so a fixed dose is not specified. This allows for individualized treatment based on each patient's response.
214600317|NCT07052474|BEHAVIORAL|Intensive trauma-focused treatment|"The treatment program includes components of Trauma focused cognitive behavioral therapy (TF-CBT), Eye Movement Desensitization and Reprocessing Therapy (EMDR), physical activity, as well as parent sessions. The intensive treatment largely follows the Dutch intensive trauma treatment program Korte Intensieve Traumabehandeling (KIT) (Albisser et al., 2024).~The intensive treatment incorporates core components from TF-CBT for children and adolescents (Cohen \& Mannarino, 2008) as well as the standard EMDR protocol (Shapiro, 2018)."
214600318|NCT06787612|DRUG|Ubamatamab|Administered per the protocol
214600319|NCT06787612|DRUG|Bevacizumab|Administered per the protocol
214600320|NCT06787612|DRUG|Cemiplimab|Administered per the protocol
214600321|NCT06787612|DRUG|Fianlimab|Administered per the protocol
214600322|NCT06787612|DRUG|PLD|Administered per the protocol
214600323|NCT06787612|DRUG|Sarilumab|Prophylaxis administered per the protocol
214600324|NCT03989492|OTHER|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
214600325|NCT06802549|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material
214600326|NCT06802549|DEVICE|Theracal PT (resin modified calcium silicate-based cement) (Bisco Inc., Schaumburg, IL, USA)|It will be placed on the exposed pulp with the help of its injection tip and the exposed pulp will be covered with material
214600327|NCT06809309|OTHER|Positive pressure ventilation during cardiopulmonary resuscitation|"The primary exposures of interest are the observed ventilation rate, tidal volume and minute ventilation during cardiopulmonary resuscitation.~Ventilation data are obtained by inspiratory and expiratory air flow measurements using the EOlife (Archeon, Besançon, France) to which healthcare providers are blinded."
214600328|NCT07072481|BEHAVIORAL|Activities|"Activities include the implementation of the three main components of 4YBY that include;~1\) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruited youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants."
214600329|NCT07072481|BEHAVIORAL|Benefits|The benefits are conceptualized at the individual, community and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
214600330|NCT07072481|BEHAVIORAL|Capacity|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconferences, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
214600331|NCT07072481|BEHAVIORAL|Activities-S|Activities include the implementation of the three main components of 4YBY that include; 1) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruit youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants.
214600332|NCT07072481|BEHAVIORAL|Benefits-S|The benefits are conceptualized at the individual, community, and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
214711494|NCT03337425|BEHAVIORAL|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
214600333|NCT07072481|BEHAVIORAL|Capacity-S|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconference, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
214600334|NCT07072481|BEHAVIORAL|People|Sustainability teams will be established in CBOs to lead the implementation of their sustainability blueprint for 4YBY. These teams will train staff, monitor goals, and provide feedback on performance and progress over time
214600335|NCT07072481|BEHAVIORAL|Learning Meetings|CBOs will participate in bi-weekly collaborative meetings to enhance their sustainability efforts, share lessons learned, and support one another. These meetings will focus on creating a supportive learning environment and reinforcing leadership that promotes continuous learning.
214600336|NCT07072481|BEHAVIORAL|Adaptation Monitoring|CBOs will adapt best practices for their sustainability plans using the FRAME-IS framework to ensure that strategies meet local needs while documenting the modifications and maintained elements over time.
214600337|NCT07072481|BEHAVIORAL|Nurturing Coaches|Trained coaches will provide individualized support to CBOs, holding weekly office hours to assist with their sustainability plans, monitor progress, and address site-specific barriers to change.
214600338|NCT06506448|DIAGNOSTIC_TEST|CT Coronary Angiography|CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
214600339|NCT05566795|DRUG|Tovorafenib|Oral Tablet Powder for Oral Suspension
214711495|NCT03337425|BEHAVIORAL|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
214600340|NCT05566795|DRUG|Chemotherapeutic Agent|Intravenous solution for injection
214600341|NCT06788535|DRUG|I-124 evuzamitide|I-124 evuzamitide, single dose imaging agent, administered intravenously.
214600342|NCT04844606|DRUG|Mirikizumab|Administered SC
214600343|NCT04844606|DRUG|Mirikizumab|Administered IV
214600344|NCT06764303|DRUG|NTQ5082 100mg qd|NTQ5082 100mg qd
214600345|NCT06764303|DRUG|NTQ5082 200mg qd|NTQ5082 200mg qd
214711496|NCT03337425|OTHER|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
214711497|NCT01890317|PROCEDURE|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
214711498|NCT01612377|DRUG|Prednisolone-Dipyridamole|Oral, QD
214711499|NCT01612377|DRUG|Prednisone|Oral QD Prednisone 5mg
214711500|NCT01612377|DRUG|prednisone|Oral, QD prednisone 7.5mg
214711501|NCT04263363|DRUG|Sugammadex 100 MG/ML [Bridion]|Sugammadex administered to patients within the clinical best practice pathway.
214711502|NCT01807949|DRUG|Placebo|Matching placebo tablet
214711503|NCT01807949|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
214600346|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
214600347|NCT07179003|PROCEDURE|Standard of care breast abscess drainage|All subjects will receive ultrasound-guided percutaneous abscess drainage in a procedure room. The site will be prepared and dressed following standard of care sterile procedure, and a needle/catheter will be advanced under ultrasound guidance into the abscess. The abscess will be drained by syringe aspiration, and the cavity will be flushed with sterile saline. Aspirated abscess fluid will be delivered to the Clinical Microbiology Laboratory for processing, including bacterial identification and antibiotic susceptibility testing.
214600348|NCT07179003|DRUG|Methylene Blue|Following standard of care breast abscess drainage, for subjects randomized to the photodynamic therapy arm, sterile, clinical-grade methylene blue will be infused into the abscess cavity at a concentration of 100 µg/mL via the same needle/catheter used for drainage. The volume introduced will be matched to the amount of abscess material aspirated during the standard of care drainage. After a 10-minute incubation interval, methylene blue will be aspirated and the cavity flushed with sterile saline to remove methylene blue that has not been taken up by microbes.
214600349|NCT07179003|DRUG|Lipid Emulsion|For subjects randomized to the photodynamic therapy arm, immediately prior to illumination a lipid emulsion will be administered directly to the abscess through the drainage needle/catheter at a concentration of 0.1%. This lipid emulsion will be either Intralipid or Nutrilipid. The lipid emulsion serves to gently distend the cavity, and through light scattering, homogenize the light dose to the walls of the cavity. The volume administered will be matched to the amount of abscess material aspirated during the standard of care drainage. Following laser illumination, the lipid emulsion will be aspirated and the cavity flushed with sterile saline.
214600350|NCT07179003|DEVICE|Insertion of optical fiber|For subjects randomized to the photodynamic therapy arm, a sterile, single-use optical fiber will be advanced to the approximate center of the abscess cavity via the same needle/catheter used for abscess drainage under ultrasound guidance. This will be connected to the clinical laser system via SMA connector for delivery of treatment light.
214600351|NCT07179003|DEVICE|Laser illumination|For subjects randomized to the photodynamic therapy arm, laser illumination for photodynamic therapy will be delivered by a laser system operating at 665 nm (ML7710, Modulight, Tampere, Finland) at a fluence rate of 20 mW/cm\^2. The laser power required to achieve this fluence rate will be calculated based on abscess size. Illumination will be delivered for \~20 minutes, resulting in a total delivered fluence of 25 J/cm\^2.
214600352|NCT07179003|PROCEDURE|Photodynamic therapy|For subjects randomized to the photodynamic therapy arm, the photodynamic therapy procedure comprises the methylene blue, lipid emulsion, insertion of optical fiber, and laser illumination interventions.
214600353|NCT07179133|PROCEDURE|Craniocervical Flexion Training alone|"10-minute hot pack treatment before starting the protocol. Week 1: Muscle Activation, • Hold for 5-10 seconds.~* Perform in supine with a sphygmomanometer device.~* Nod head gently as if saying yes, aiming for 20-22 mmHg. Week 2: Endurance Training Goal: • Hold for 10-15 seconds. Increase holding time and precision.~Exercise:~• Maintain the contraction at 24-26 mmHg on the device. Week 3: Strength and Postural Training •Hold for 15 seconds.~Exercise:~* Perform CCFT in sitting or standing. Week 4: Functional Integration~* Maintain contraction during functional tasks (e.g., desk work).~* Hold for 15-20 seconds.~* Sets/Reps: 3 sets of 8-12 repetitions."
214600354|NCT07179133|PROCEDURE|Semispinalis Cervicis strengthening with Craniocervical Flexion Training:|"Craniocervical flexion training will be same as given to group A.~Week 1: Semispinalis Cervicis Activation:~* Patient sits upright with neutral spine.~* Therapist applies gentle manual resistance at C2 vertebra while the patient resists backward motion.~* Hold for 3-5 seconds, then relax.~Week 2: Progressive Activation with Increased Resistance:~* Apply moderate manual resistance at C2.~* Hold for 5 seconds, focusing on controlled movement.~Week 3: Strength and Functional Coordination with Dynamic Resistance:~* Introduce light movement (e.g., slight backward head tilt) under resistance.~* Therapist adjusts resistance dynamically.~Week 4: Advanced Endurance and Functional Integration with Functional Movements:~* Combine resistance training with controlled head rotations or slight lateral flexion.~* Maintain resistance and stability.~* Reps/Sets: 3-4 sets of 12 reps."
214711504|NCT01807949|DRUG|Ivacaftor|Film-coated tablet
214600355|NCT07178223|PROCEDURE|Arthroplasty CMC-1|Touch Touch® dual-mobility Arthroplasty CMC-1 joint (Kerimed). Dorsal approach. Conical cup. Soft dressing 3 weeks. Loading allowed after 2 months.
214600356|NCT07181551|BEHAVIORAL|Forward to Quit (F2Q)|A mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. Delivered via a secure website accessible by smartphone or tablet.
214600357|NCT07179770|DRUG|Belzutifan|120 mg orally daily for 28 days
214600358|NCT07179770|DRUG|89Zr-DFO-girentuximab|10 mg single slow intravenous (IV) administration
214600359|NCT07179770|DEVICE|89Zr-DFO-girentuximab PET|89Zr-DFO-Girentuximab PET before and after 4 weeks of treatment with standard-of-care (SOC) belzutifan.
214600360|NCT07186270|BEHAVIORAL|Positively framed FOP labels (present versus absent) x Price (high versus low)|"The intervention combines either a front-of-pack (FOP) label that frames high nutrition or no FOP label with price variation. Products are randomly assigned to either receive a positively-framed FOP label or no label, and to either a high or a low price.~This yields four experimental arms:~1. Positively framed FOP label with high price~2. Positively framed FOP label with low price~3. No label with high price~4. No label with low price"
214635090|NCT07102433|OTHER|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.
214635091|NCT06057090|BEHAVIORAL|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
214635092|NCT05554133|DEVICE|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
214635093|NCT05554133|DEVICE|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
214600361|NCT07186270|BEHAVIORAL|Graded FOP labels (no label vs. high rating (grade A) vs. low rating (grade D)) x Price (average vs. premium)|"The intervention combines either a graded front-of-pack (FOP) labelling or no FOP labelling with price variation. Products are randomly assigned to either receive a graded label or no label, and to either a premium or an average price.~This yields six experimental arms:~1. High grade (A) with premium price~2. Low grade (D) with premium price~3. No label with premium price~4. High grade (A) with average price~5. Low grade (D) with average price~6. No label with average price"
214600362|NCT07188350|OTHER|Conventional Physical Therapy|Individualized physical therapy including progressive mobility (e.g., bed exercises, sitting on the edge of the bed, standing, transfers, and ambulation) and respiratory therapy tailored to the patient's clinical condition. Delivered daily by trained professionals.
214600363|NCT07188350|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES will be applied to both lower limbs once or twice daily for 20 consecutive days. Electrodes will be positioned on the vastus lateralis, vastus medialis, tibialis anterior, hamstrings, and gastrocnemius muscles. The stimulation protocol includes progressive parameters to induce visible and effective muscle contractions.
214711505|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
214600364|NCT07187804|DRUG|Intravitreal faricimab injection|"* Initial loading injections : every 4 weeks by 12weeks~* Treat and extend injection(\~76 week) : Week 20 - Week 76~TAE is initiated with a minimum injection interval of 8 weeks. If no recurrence is observed, the interval is extended by 2 weeks at a time, up to a maximum of 16 weeks. In the event of recurrence, the injection interval is reduced to 8 weeks, regardless of the previous schedule. The minimum injection interval remains 8 weeks."
214600365|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine ganlion block with 2ml of 2% lidocaine and 0.5ml of diluted adrenaline after general anesthesia in patients undergoing enoscopic hypophysectomy.
214600366|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine and 0.5ml saline after general anesthesia in patients undergoing enoscopic hypophysectomy.
214600367|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine in addition to 0.5ml of diluted adrenaline. after general anesthesia in patients undergoing enoscopic hypophysectomy.
214600368|NCT07187856|DRUG|PG-102|PG-102 is administered subcutaneously once weekly with a titration regimen.
214600369|NCT07187856|DRUG|Placebo|Placebo is administered subcutaneously once weekly.
214600370|NCT07187856|DRUG|Semaglutide|Open-label semaglutide is administered subcutaneously once weekly with titration regimen.
214600371|NCT07189377|DRUG|Entecavir|Recipients will receive 1mg administered orally, beginning pre-transplant as soon as the patient arrives to the hospital for surgery, and then 1mg post-operatively administered orally or via nasogastric tube once daily for 28 days.
214600372|NCT07189377|BIOLOGICAL|HBIG|Recipients will receive 4500 IU intravenously pre-transplant and then at day 3 and 7 post-transplant (3 doses total).
214600373|NCT07189377|DEVICE|EVLP UV Light Treatment|UV light therapy will be administered to the organ during EVLP prior to transplantation. For minimum 2 hours, maximum 6 hours (duration determined by time clinically required for EVLP based on standard clinical assessment of lung).
214600374|NCT07187687|PROCEDURE|Early Minimally Invasive Surgery with Thrombolysis (eMIST)|Subjects will undergo minimally invasive catheter evacuation in the early stage of intracranial hemorrhage. Up to 10 doses of 50000U of urokinase will be administered through the catheter that was placed directly into the intracerebral hemorrhage.
214600375|NCT07187609|PROCEDURE|Immediate implant with bovine drived hydroxyapatite xenograft.|patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.
214600376|NCT07187609|PROCEDURE|immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft|patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
214711506|NCT04325906|DEVICE|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
214600377|NCT07179627|DEVICE|Ankle exoskeleton|The ankle exoskeleton provides bilateral torque assistance at the ankle joints during common functional tasks such as level-ground walking, stair and ramp ascent, and other daily activities, thereby reducing the mechanical workload and supporting more effective community ambulation. In particular, the device is designed to address drop-foot on the paretic side by delivering bidirectional assistance, which helps improve toe clearance during swing as well as push-off during stance. As a wearable assistive device, assistance is applied only while the device is worn.
214711507|NCT04325906|PROCEDURE|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
214711508|NCT00614653|DRUG|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
214711509|NCT00614653|DRUG|Erlotinib|100 mg by mouth Once Daily on days with radiation.
214600378|NCT07179627|OTHER|Baseline (no ankle exoskeleton)|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing an ankle exoskeleton.
214600379|NCT07187427|PROCEDURE|Spinal analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal SPINAL Group: Bupivacaine 0.25% Isobaric 1 ml + Fentanyl 15 mcg, (0,3ml)~STEP 2: Epidural SPINAL group: 0.9% NaCl 2 ml."
214711510|NCT00614653|DRUG|Capecitabine|400 mg/m\^2 PO Twice Daily on days with radiation.
214711511|NCT00614653|RADIATION|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
214711512|NCT05914883|DIAGNOSTIC_TEST|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
214711513|NCT03381209|DRUG|Sugammadex|sugammadex given based on 3 measurements of body weights
214711514|NCT06067308|DIAGNOSTIC_TEST|Performance of CTPA|Exposure to CT scan and injection of IV contrast
214711515|NCT04254432|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
214600380|NCT07187427|PROCEDURE|Epidural Analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal EPI Group: Bupivacaine 0.25% Isobaric 1 ml + NaCl 0.9% 0.3 ml~STEP 2: Epidural EPI group: Fentanyl 100 mcg, (2 ml of a concentration of 50 mcg/ml)"
214600381|NCT07187869|DRUG|Cabozantinib|Given by IV
214600382|NCT07187869|DRUG|Nivolumab|Given by IV
214600383|NCT07187557|OTHER|A self-compassion based birth preparation program|A self-compassion based birth preparation program
214600384|NCT07188389|BEHAVIORAL|Acute exercise-moderate intensity|30 minutes of cycling exercise at moderate (90% of first ventilatory threshold)
214600385|NCT07188389|BEHAVIORAL|Acute effects-heavy intensity|Participants will cycle 30 minutes at heavy (110% of first ventilatory threshold) intensity
214600386|NCT07187570|DRUG|Dapagliflozin 10 mg once daily|Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.
214600387|NCT07187986|OTHER|Sound acupuncture|Best medical therapy + soundpuncture
214600388|NCT07189013|DEVICE|Mechanical infusion pump|Patients with earlier experience on electronic infusion pumps will crossover to the mechanical infusion pump for three month's period
214600389|NCT07188090|DRUG|Plerixafor|Plerixafor is an antagonist of chemokine receptor-4 (CXCR4) receptor that can release stem cells from the bone marrow niche into the peripheral blood circulation
214600390|NCT07188090|DRUG|Gcsf|All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.
214600391|NCT07187440|OTHER|No intervention|This is a non-interventional study
214600392|NCT07188883|OTHER|Birth Education|The population consisted of all pregnant women between 24-36 weeks of gestation residing in Izmir province, and the study was completed with a total of 80 pregnant women, 40 pregnant women as intervention and 40 as control in line with the snowball sampling method. Ege Birth Perception Scale, Risk Assessment Form, Individual Introduction Form, Prenatal Self-Assessment Scale, Birth Education Evaluation Form were used to collect the data. Pregnant women who agreed to participate in the study were randomly divided into intervention and control groups; the intervention group received nine hours of online training, while the control group did not receive any intervention.
214600393|NCT07188597|BEHAVIORAL|Cognitive Behavior Therapy for those at risk of first episode psychosis|Participants will receive a culturally adapted manualised Cognitive Behavioural Therapy (CBT) for those at risk of first episode psychosis (FEP). The intervention aims to reduce symptoms, normalise psychosis-like experiences, and prevent catastrophic appraisals that may lead to delusions. It integrates psychoeducation, behavioural experiments, and techniques addressing cognitive biases. By reframing unusual experiences as perceptual or reasoning biases, distress and emotional arousal are reduced, lowering the chance of fixed, frightening beliefs. Homework tasks further support coping. CBT for At-Risk Mental States has shown effectiveness in reducing transition to psychosis and improving recovery. This study will adapt and field test the manual, with potential for remote delivery via phone, video, or AI tools to enhance accessibility.
214600394|NCT07188480|DIAGNOSTIC_TEST|bronchial lavage for NGS analysis|NGS analysis conducted on bronchoscopic cytological samples in patients with NSCLC
214600395|NCT07188792|OTHER|HORTICULTURAL THERAPY|"* Introduction~* Explanation of the training content for horticultural activities using visual materials~* Explanation of the program's scope, duration, and expected participant roles and responsibilities"
214600396|NCT07186946|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
214600397|NCT07186946|DRUG|Placebo|Placebo
214600398|NCT07189143|DIETARY_SUPPLEMENT|Belinal® (Abies alba branch extract)|Belinal® capsules, 900 mg/day (4 × 225 mg), orally for 14 consecutive days.
214600399|NCT07189364|BEHAVIORAL|Peer Comparison Feedback Report|The intervention will be an electronic, individualized, peer-comparison feedback report on the participant's antimicrobial prescribing practices, combined with a knowledge toolkit focused on optimizing antimicrobial use.
214600400|NCT06957756|DRUG|BI 1584862|BI 1584862
214600401|NCT01544699|DEVICE|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
214600402|NCT03122275|OTHER|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
214600403|NCT03122275|OTHER|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
214600404|NCT03122275|OTHER|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
214635094|NCT05554133|DRUG|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
214635095|NCT07100964|DRUG|nerandomilast|nerandomilast
214635096|NCT07100964|DRUG|carbamazepine|carbamazepine
214600405|NCT03122275|OTHER|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
214600406|NCT03122275|OTHER|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
214600407|NCT06224309|DIAGNOSTIC_TEST|18F-BL40 PET/CT|Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
214600408|NCT06224309|DIAGNOSTIC_TEST|18F-FDG PET/CT|"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
214600409|NCT06224309|DIAGNOSTIC_TEST|Routine Blood Draw - Phase 1 only|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
214600410|NCT00000387|BEHAVIORAL|Self-management therapy|Behavioral
214600411|NCT00000387|BEHAVIORAL|Self-management therapy|
214600412|NCT03338192|OTHER|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
214600413|NCT05003713|DRUG|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
214600414|NCT05003713|DRUG|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
214600415|NCT05003713|DRUG|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
214600416|NCT00222573|DRUG|clopidogrel and metoprolol|
214600417|NCT02991508|DRUG|Placebo|
214600418|NCT02991508|DRUG|Adrecizumab|
214600419|NCT00244127|DRUG|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
214600420|NCT03808688|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
214600421|NCT03329196|DRUG|MT-6548|Oral tablet
214600422|NCT03329196|DRUG|Darbepoetin alfa|Subcutaneous
214600423|NCT04070755|DRUG|FMX-101|
214600424|NCT00528983|DRUG|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
214600425|NCT00528983|DRUG|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
214600426|NCT00528983|DRUG|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
214600427|NCT04401163|DIAGNOSTIC_TEST|Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.
214600428|NCT03974399|DIETARY_SUPPLEMENT|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
214600429|NCT03912272|BEHAVIORAL|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
214600430|NCT03912272|BEHAVIORAL|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
214600431|NCT01753583|DEVICE|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
214600432|NCT01753583|OTHER|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
214600433|NCT04229472|DIAGNOSTIC_TEST|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
214600434|NCT04229472|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
214600435|NCT01017068|DRUG|OME|4g/100ml) dose: п gutt tid x 1/52
214600436|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
214600437|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
214600438|NCT01017068|DRUG|OME|(4g/100ml) dose: п gutt tid x 1/52
214600439|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
214600440|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
214600441|NCT02843685|DRUG|Drotrecogin alfa activated|
214600442|NCT05577286|OTHER|regular care|the regular medical treatment without change of their daily activity routine
214600443|NCT05577286|OTHER|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
214600444|NCT02021292|DRUG|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
214600445|NCT02021292|DRUG|Placebo|Matching placebo oral tablet, to be taken once daily.
214600446|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
214600447|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
214600448|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
214600449|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
214600450|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
214600451|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
214600452|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
214600453|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
214600454|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
214635097|NCT07110064|DRUG|QL1706+Lenvatinib+AG Regimen|Participants will receive QL1706 combination with Lenvatinib and AG regimen for 8 cycles. Subsequently, the enrolled patients will continue to receive maintenance therapy with QL1706 and Lenvatinib until disease progression (PD) is observed, intolerable adverse events occur, or the investigator deems it inappropriate for the subject to continue treatment.
214635098|NCT07111936|BEHAVIORAL|CONNECT Intervention for multilingual populations|The program includes interactive Video Doctor visits to provide participants with information tailored to their individual responses and outreach via brief telephone calls and text messaging to follow-up and connect smokers with evidence-based resources for smoking cessation.
214635099|NCT07111936|OTHER|Saliva Sample|Undergo saliva collection
214635100|NCT07111936|OTHER|Interview|Attend a focus group
214600455|NCT06396897|OTHER|Indiana University Health Hospital at Home Program|Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, \& perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.
214600456|NCT03946514|DRUG|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
214600457|NCT03946514|DRUG|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
214600458|NCT04147234|DRUG|BI 1387446 50 μg|Participants received 50 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
214600459|NCT04147234|DRUG|BI 754091|Participants received BI 754091 (ezabenlimab) intravenously at a dose of 240 mg once every 21-day cycle.
214600460|NCT04147234|DRUG|BI 1387446 100 μg|Participants received 100 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
214600461|NCT04147234|DRUG|BI 1387446 200 μg|Participants received 200 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
214600462|NCT04147234|DRUG|BI 1387446 400 μg|Participants received 400 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
214600463|NCT06439394|DRUG|Optive MEGA-3 (OM3)|Eye Drops
214600464|NCT00022048|BIOLOGICAL|bevacizumab|
214600465|NCT05329935|BIOLOGICAL|Cultured Thymus Tissue|Product will be surgically administered into the quadriceps
214600466|NCT02022085|DEVICE|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
214600467|NCT05576350|BEHAVIORAL|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
214635101|NCT07144098|DRUG|GZR18 injection|3 mg-Control group
214635102|NCT07144098|DRUG|GZR18 injection|3 mg-mild liver insufficiency
214635103|NCT07144098|DRUG|GZR18 injection|3 mg-moderate liver insufficiency
214635104|NCT07144098|DRUG|GZR18 injection|3 mg-severe liver insufficiency
214600468|NCT05576350|BEHAVIORAL|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.
214600469|NCT05576350|BEHAVIORAL|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
214600470|NCT04464603|DEVICE|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
214711516|NCT05847933|DEVICE|rTMS (cTBS 50Hz experiment)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
214711517|NCT05847933|DEVICE|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 0%~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
214711518|NCT05847933|DEVICE|rTMS (cTBS 50 Hz active control)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: Right superior frontal cortex~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
214711519|NCT05847933|DEVICE|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics:~* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
214711520|NCT05847933|DEVICE|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 30 minutes, continuously~* Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
214711521|NCT05847933|DEVICE|rTMS (high frequency sham)|"* Frequency: 20 Hz~* Intensity: 10% of MSO~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
214711522|NCT05847933|DEVICE|rTMS (high frequency active control)|"* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: right superior frontal cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
214711523|NCT05847933|DEVICE|rTMS (low frequency active control )|"* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: Right superior frontal cortex of the dominant brain hemisphere~* Duration: 6 minutes~* Timing: Starting 1 minutes before and continuing during the memory task (Online)"
214711524|NCT05847933|DEVICE|rTMS ( cTBS 30 Hz active control)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on right superior frontal cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
214711525|NCT05847933|DEVICE|rTMS (cTBS 30 Hz)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
214711526|NCT02232594|DRUG|Berodual®|
214711527|NCT06411249|DRUG|Belimumab (GSK1550188)|GSK1550188 will be administered subcutaneously.
214600471|NCT04464603|OTHER|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
214600472|NCT06616389|DRUG|ODX (Osteodex)|Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
214600473|NCT05972733|BIOLOGICAL|HIL-214|HIL-214
214600474|NCT04012437|DEVICE|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
214600475|NCT04012437|BEHAVIORAL|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
214600476|NCT05467878|OTHER|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
214600477|NCT00884338|OTHER|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
214600478|NCT00884338|OTHER|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
214600479|NCT00905138|DRUG|GLPG0259|single ascending doses, oral solution
214600480|NCT00905138|DRUG|placebo|single dose, oral solution
214600481|NCT00905138|DRUG|GLPG0259|multiple dose, oral solution, 5 days
214600482|NCT00905138|DRUG|placebo|oral solution, 5 days
214600483|NCT04864509|DRUG|Melatonin 10 MG|Nightly dose
214600484|NCT04864509|DRUG|Placebo|Nightly dose
214600485|NCT04662151|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
214600486|NCT04662151|PROCEDURE|Air-sham|room air for intratracheal administration
214600487|NCT01753154|DRUG|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
214600488|NCT01753154|DRUG|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
214600489|NCT04395118|BEHAVIORAL|Mailed Outreach|The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
214600490|NCT00982215|DRUG|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
214600491|NCT00982215|DRUG|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
214600492|NCT04987658|DRUG|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
214600493|NCT06431880|OTHER|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block
214600494|NCT06431880|OTHER|Thoracic paravertebral block|Patients will receive thoracic paravertebral block
214600495|NCT05334017|DRUG|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
214600496|NCT05334017|DRUG|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
214600497|NCT01157013|OTHER|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
214600498|NCT02869555|OTHER|Data collection|
214600499|NCT03492788|OTHER|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
214600500|NCT03492788|OTHER|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
214600501|NCT05443087|OTHER|Blood sampling to build population pharmacokinetics model|"Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received"
214600502|NCT01091597|PROCEDURE|usual PV ablation|usual PV ablation, per above
214600503|NCT01091597|PROCEDURE|Box isolation of pulmonary veins|as above
214600504|NCT04844450|DRUG|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
214600505|NCT04844450|DRUG|Placebo|Matching placebo will be administered subcutaneously.
214600506|NCT02734394|BEHAVIORAL|Exercise|Cardiovascular and resistance exercise training
214600507|NCT05845866|BEHAVIORAL|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
214600508|NCT05845866|BEHAVIORAL|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
214600509|NCT05845866|BEHAVIORAL|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
214600510|NCT04225078|DRUG|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
214600511|NCT04225078|OTHER|Placebo|Matching loperamide placebo capsules will be administered orally.
214600512|NCT04225078|DRUG|Moxifloxacin|Moxifloxacin tablets will be administered orally.
214600513|NCT03865940|DRUG|Lidocaine|6 mL of 1% lidocaine
214600514|NCT03865940|DRUG|Guanfacine|250 mcg
214600515|NCT06338670|DEVICE|Cochlear Osia 3 Sound Processor|Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
214600516|NCT06338670|DEVICE|Cochlear™ Osia® 2 Sound Processor|Osia® 2 Sound Processor
214600517|NCT06345833|DRUG|1%Tranexamic acid with standard local|1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
214600518|NCT06345833|DRUG|3% TXA|3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
214600519|NCT06345833|DRUG|1% TXA with local plus 3% TXA-soaked pledgets|1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
214600520|NCT01205256|DRUG|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
214600521|NCT05034536|DRUG|Pembrolizumab|Intravenous infusion
214600522|NCT05034536|DRUG|Infliximab|Intravenous infusion
214600523|NCT05034536|DRUG|Placebo|Intravenous infusion
214600524|NCT05034536|DRUG|Relatlimab|Intravenous infusion
214600525|NCT05034536|DRUG|Nivolumab|Intravenous infusion
214600526|NCT04982588|DEVICE|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
214600527|NCT01025024|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214600528|NCT06342284|RADIATION|Proton Beam Radiation with or without concurrent chemotherapy|Curative-intent fractionated proton beam thoracic radiotherapy, with or without concurrent chemotherapy
214600529|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
214600530|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
214600531|NCT02183636|DRUG|Linagliptin tablet|5 mg
214600532|NCT02183636|DRUG|pioglitazone tablet (Actos®)|45 mg
214600533|NCT06371287|BEHAVIORAL|Treinamento Auditivo Musical|Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.
214600534|NCT06371287|BEHAVIORAL|Placebo|"This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009)."
214600535|NCT02366728|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
214600536|NCT02366728|BIOLOGICAL|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
214600537|NCT02366728|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
214600538|NCT02366728|BIOLOGICAL|111In-labeled DCs|111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
214600539|NCT02366728|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
214600540|NCT02366728|DRUG|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
214600541|NCT02366728|DRUG|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
214600542|NCT00980681|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
214600543|NCT00980681|OTHER|Time of Flight|Each subject will undergo a TOF MRA
214600544|NCT01704833|BEHAVIORAL|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
214600545|NCT04381455|DEVICE|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
214600546|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
214600547|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
214600548|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
214600549|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
214600550|NCT02091583|DIETARY_SUPPLEMENT|Butter, sunflower and safflower oil|
214600551|NCT02091583|DIETARY_SUPPLEMENT|High Oleic Canola Oil and DHA (HOCO-DHA)|
214600552|NCT02091583|DIETARY_SUPPLEMENT|Barley beta-glucan|
214600553|NCT02091583|DIETARY_SUPPLEMENT|HOCO-DHA and Barley beta-glucan|
214600554|NCT01747304|DEVICE|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
214600555|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
214600556|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
214600557|NCT05030103|DEVICE|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
214600558|NCT03730441|DEVICE|Colonoscopy|Endoscopic examination of large bowel
214600559|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
214600560|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
214600561|NCT00844207|DRUG|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
214600562|NCT00844207|DRUG|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
214600563|NCT03442790|PROCEDURE|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
214600564|NCT03442790|PROCEDURE|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
214600565|NCT03858790|DEVICE|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
214600566|NCT01979224|OTHER|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
214600567|NCT01318954|BIOLOGICAL|Allergen immunotherapy|
214600568|NCT04304976|DEVICE|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
214600569|NCT06149390|DRUG|consolidation with ASCT|high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
214600570|NCT04014036|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
214600571|NCT03499236|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
214600572|NCT03499236|OTHER|Control|Right heart catheterization, invasive echocardiography.
214600573|NCT05317884|BEHAVIORAL|Reminder|Email
214600574|NCT05581667|OTHER|post isometric relaxation|PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
214600575|NCT05581667|OTHER|Swedish Massage|classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
214600576|NCT00182390|PROCEDURE|Red blood cell transfusion|
214600577|NCT03537859|OTHER|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
214600578|NCT03537859|OTHER|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
214711528|NCT03506100|OTHER|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
214711529|NCT00925145|PROCEDURE|Single Incision Laparoscopic Appendectomy|
214711530|NCT01594567|OTHER|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
214711531|NCT05651841|DRUG|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
214711532|NCT05651841|OTHER|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
214711533|NCT01978600|DRUG|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
214711534|NCT01978600|DRUG|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
214711535|NCT03114423|OTHER|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
214600579|NCT05453032|DEVICE|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
214711536|NCT03114423|OTHER|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
214711537|NCT06119425|DIAGNOSTIC_TEST|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
214600580|NCT06390462|BEHAVIORAL|Interpersonal counseling|A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.
214600581|NCT06390462|BEHAVIORAL|Treatment as usual|Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.
214600582|NCT06390462|OTHER|No support, intervention or other treatment|The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
214600583|NCT05136131|PROCEDURE|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
214600584|NCT05136131|OTHER|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
214600585|NCT00411125|DRUG|Oral salmon calcitonin|
214600586|NCT05481879|DRUG|DYNE-101|Administered by IV infusion
214600587|NCT05481879|DRUG|Placebo|Administered by IV infusion
214600588|NCT06510309|DRUG|Venetoclax|B-cell lymphoma inhibitor, tablets taken orally per protocol.
214600589|NCT06510309|DRUG|Rituximab|Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.
214600590|NCT04151264|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
214600591|NCT02993523|DRUG|Azacitidine|Solution for subcutaneous or intravenous administration.
214600592|NCT02993523|DRUG|Venetoclax|Tablet
214600593|NCT02993523|DRUG|Placebo|Matching placebo tablet
214600594|NCT03694418|BEHAVIORAL|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.
214600595|NCT05180097|DRUG|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
214600596|NCT05180097|DRUG|Dexamethasone|40mg daily PO, D1-D4
214600597|NCT05180097|DRUG|Cisplatin|75mg/m2 IV, 1 hour, D1
214600598|NCT05180097|DRUG|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
214600599|NCT05180097|DRUG|Pembrolizumab|200mg IV, 30 mins, Q 21 days
214600600|NCT00482924|OTHER|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
214600601|NCT02018367|DRUG|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
214600602|NCT00082303|BEHAVIORAL|Music Imagery|
214600603|NCT04589182|DEVICE|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
214600604|NCT04589182|DEVICE|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
214600605|NCT05931835|DEVICE|VERAFEYE System|The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.
214600606|NCT02363400|DRUG|MEP|Adjuvant Chemotherapy
214600607|NCT02876302|DRUG|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
214600608|NCT02876302|DRUG|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
214600609|NCT02876302|DRUG|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
214600610|NCT02876302|DRUG|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
214600611|NCT05557331|DEVICE|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
214600612|NCT02731716|BEHAVIORAL|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
214600613|NCT02731716|BEHAVIORAL|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
214600614|NCT02731716|BEHAVIORAL|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
214600615|NCT06084299|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
214600616|NCT05726864|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
214600617|NCT05423158|BEHAVIORAL|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
214600618|NCT03960840|BIOLOGICAL|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
214600619|NCT03960840|DRUG|Ibrutinib|Tablets or capsules for oral daily use
214600620|NCT05913973|DRUG|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
214600621|NCT06263582|DRUG|Artesunate pessary|Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
214600622|NCT06263582|DIAGNOSTIC_TEST|blood draws for pharmacokinetics of the study drug|On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
214711538|NCT02992873|DEVICE|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
214711539|NCT02992873|DEVICE|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
214711540|NCT01877590|DRUG|alpha-lipoic acid|
214711541|NCT02343419|OTHER|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
214711542|NCT02482649|BEHAVIORAL|EAA/T|bi-weekly for 12weeks
214711543|NCT02482649|DRUG|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
214600623|NCT05560763|DEVICE|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism via mechanical thrombectomy of thrombus in the pulmonary arteries.
214600624|NCT03021460|DRUG|Ibrutinib|Given PO
214600625|NCT03021460|OTHER|Laboratory Biomarker Analysis|Correlative studies
214600626|NCT03021460|BIOLOGICAL|Pembrolizumab|Given IV
214600627|NCT05245851|DEVICE|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
214600628|NCT05718869|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600629|NCT05718869|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214600630|NCT05718869|PROCEDURE|Computed Tomography|Undergo CT scan
214600631|NCT05718869|BIOLOGICAL|Tafasitamab|Given IV
214600632|NCT05718869|DRUG|Zanubrutinib|Given PO
214600633|NCT06851039|DIETARY_SUPPLEMENT|Potato starch supplementation|Participants will receive potato starch supplement, undergoing gut microbial fermentation and acting as an endogenous source of the short-chain fatty acids, including butyrate. Effects of these compounds on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
214600634|NCT06851039|DIETARY_SUPPLEMENT|Sodium butyrate supplementation|Participants will receive sodium butyrate supplement, acting as an exogenous source of the short-chain fatty acid butyrate. Effects of such compound on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
214600635|NCT06851039|DIETARY_SUPPLEMENT|Accessible starch supplementation|Participants will receive the accessible (digestible) waxy maze starch as placebo.
214600636|NCT04912765|BIOLOGICAL|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
214600637|NCT04912765|DRUG|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
214600638|NCT06315829|DEVICE|Spasm Vision|Machine learning software developed to analyze videos and accurately distinguish infantile spasms from visually similar movements.
214600639|NCT04721132|BIOLOGICAL|Atezolizumab|Given IV
214600640|NCT04721132|BIOLOGICAL|Bevacizumab|Given IV
214600641|NCT04721132|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214600642|NCT04941222|OTHER|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
214600643|NCT05704647|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
214600644|NCT05704647|DRUG|Nivolumab|Given by IV (vein)
214600645|NCT05704647|DRUG|Relatlimab|Given by IV (vein)
214600646|NCT06411925|DRUG|Atock Dry Syrup with placebo patch|Atock Dry syrup (TID) with placebo patch (QD)
214711544|NCT02482649|DRUG|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
214600647|NCT06411925|DRUG|Tulobuterol patch with placebo dry syrup|Tulobuterol patch (QD) with placebo dry syrup (TID)
214600648|NCT05106608|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
214711545|NCT05786534|DIETARY_SUPPLEMENT|Green Seaweed|400 mg per day
214711546|NCT03844503|DIETARY_SUPPLEMENT|Cereal Bar no fiber|Cereal Bar no fiber
214600649|NCT05106608|DEVICE|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
214600650|NCT05106608|DEVICE|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
214600651|NCT04760886|OTHER|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
214711547|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
214711548|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
214711549|NCT02162121|PROCEDURE|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
214711550|NCT02162121|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
214600652|NCT05425706|OTHER|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
214600653|NCT02323763|OTHER|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
214600654|NCT02673619|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
214600655|NCT02673619|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
214600656|NCT04284293|BIOLOGICAL|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
214600657|NCT05327452|BEHAVIORAL|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
214600658|NCT05327452|BEHAVIORAL|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
214600659|NCT05327452|BEHAVIORAL|Attention Control|Stretching Program
214600660|NCT03591302|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
214600661|NCT03591302|RADIATION|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
214600662|NCT00002123|DRUG|Delavirdine mesylate|
214600663|NCT00002123|DRUG|Didanosine|
214600664|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
214600665|NCT00805038|BEHAVIORAL|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
214600666|NCT00805038|BEHAVIORAL|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
214600667|NCT07002086|PROCEDURE|Total knee replacement|"* Is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap.~* In the surgical procedure of these surgeries, cement is used to fix the prosthesis."
214600668|NCT06364137|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
214600669|NCT06364137|OTHER|Standard videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform
214600670|NCT06917885|BIOLOGICAL|CUE-102|A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.
214600671|NCT06586892|BEHAVIORAL|Radiotherapy followed by chemotherapy|"Researchers would like to test the accuracy of the MRI data being used for this study. If you agree, you will have 2 additional MRI scans within 2 weeks before Visit 1.~The first 90 participants who agree will be selected to have the following scans:~* 35 participants will be scanned 2 times on one MRI device (Device #1).~* 35 participants will be scanned 2 times on another MRI device (Device #2).~* 20 participants will be scanned 1 time on both MRI devices (Device #1 and #2). If you agree and you are chosen, the study doctor will tell you if you will have scans on~  1. or 2 MRI devices."
214600672|NCT07003321|DRUG|HRS-4508 tablet|HRS-4508 tablet
214600673|NCT05902819|BEHAVIORAL|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
214600674|NCT05902819|DRUG|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
214600675|NCT05902819|DRUG|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
214600676|NCT07129863|DIETARY_SUPPLEMENT|Placebo: Mouth rinse with plain water|Placebo: Mouth rinse with plain water, containing no caffeine, serving as the control condition.
214600677|NCT07129863|DIETARY_SUPPLEMENT|Experimental: Low mouth rinse caffeine concentration (1%)|Arm Description: Low caffeine concentration: Mouth rinse containing 1% caffeine solution (based on weight/volume).
214600678|NCT07129863|DIETARY_SUPPLEMENT|Moderate caffeine concentration (2% caffeine solution weight/volume).|Moderate caffeine concentration: Mouth rinse containing 2% caffeine solution (weight/volume).
214600679|NCT07129863|DIETARY_SUPPLEMENT|High caffeine concentration (3% caffeine solution weight/volume).|High caffeine concentration: Mouth rinse containing 3% caffeine solution (weight/volume).
214600680|NCT07010601|BEHAVIORAL|Experimental Tobacco Marketplace|This study will have three different scenarios in the Experimental Tobacco Marketplace (ETM) for participants who reported being cigarette and/or e-cigarette users. These will consist of hypothetical purchase scenarios where a variety of different tobacco products are available to purchase. The three ETM scenarios will be adjusting price cigarettes, adjusting price e-cigarettes, and both adjusting price cigarettes and e-cigarettes.
214600681|NCT07010601|BEHAVIORAL|Hypothetical Novel Nicotine Product Purchase Tasks|This study will have a set of hypothetical demand tasks for novel nicotine products. These tasks consist of different novel hypothetical products (combusted, oral, and vaporized) of differing nicotine content (high and low), and different flavors (preferred alcoholic flavor, no characterizing flavor) where likelihood to try is assessed at a variety of price points.
214600682|NCT04469621|DRUG|SAR443122|Pharmaceutical form:capsule Route of administration: oral
214600683|NCT04469621|DRUG|Placebo|Pharmaceutical form:capsule Route of administration: oral
214600684|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600685|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214600686|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
214600687|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
214600688|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
214600689|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214600690|NCT06685185|DRUG|NNC0363-1063|NNC0363-1063 will be administered subcutaneously.
214600691|NCT06685185|DRUG|Placebo|Placebo will be administered subcutaneously.
214600692|NCT06685185|DRUG|Insulin degludec|Insulin degludec will be administered subcutaneously.
214600693|NCT06685185|DRUG|Insulin detemir|Insulin detemir will be administered subcutaneously.
214600694|NCT07019961|DEVICE|the GMA-TULIP laryngeal mask|insert GMA-TULIP laryngeal masks after anesthesia induction
214600695|NCT07019961|DEVICE|the i-gel laryngeal mask|insert i-gel laryngeal masks after anesthesia induction
214600696|NCT07018401|DRUG|Pomalidomide|Oral pomalidomide up to 4 mg daily
214600697|NCT07020065|DRUG|Cemiplimab|cemiplimab IV 350 mg, day 1
214600698|NCT07020065|DRUG|Carboplatin|carboplatin IV AUC 3 day 1
214600699|NCT07020065|DRUG|Pemetrexed & Gemcitabine|pemetrexed IV 300 mg/m2 day 1 gemcitabine IV 600 mg/m2 day 1, d8
214600700|NCT07020065|DRUG|Paclitaxel|paclitaxel IV 50 mg/m2 day 1, d8
214600701|NCT07019987|OTHER|PEEP Titration Using Electrical Impedance Tomography (EIT)|"EIT will be used to guide individualized PEEP titration in mechanically ventilated patients with AHRF. Each subject will receive mechanical ventilation at two PEEP levels:~PEEP\_CLIN (set by the treating clinician)~PEEP\_TIT (identified using EIT to minimize alveolar collapse and overdistension)~Both levels will be maintained for 30 minutes in each body position, with continuous physiologic data collected during each phase."
214600702|NCT07019987|PROCEDURE|Body Positioning: Supine and Prone|Each subject will be ventilated in both the supine and prone positions. Positioning will follow institutional protocols and be coordinated with clinical staff to ensure safety. After supine assessments are completed, the patient will be transitioned to prone, followed by a recruitment maneuver to standardize lung volume history. The PEEP titration protocol will then be repeated in the prone position.
214600703|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
214600704|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
214600705|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.
214600706|NCT03716739|DRUG|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
214600707|NCT03716739|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
214600708|NCT06629779|DRUG|PF-06821497|Oral continuous
214600709|NCT06629779|DRUG|Placebo|Oral continuous
214600710|NCT06629779|DRUG|Enzalutamide|Oral continuous
214600711|NCT06698744|BIOLOGICAL|UF-KURE-BCMA CAR T-cells|"Experimental anti-BCMA CAR T-cells manufactured with a proprietary ultrafast process. Patients will receive a single dose of CAR T-cells at one of three potential doses:~* Dose -1: 3x10\^6 cells~* Dose 1: 10x10\^6 cells~* Dose 2: 15x10\^6 cells"
214600712|NCT06698744|DRUG|Cyclophosphamide|Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
214600713|NCT06698744|DRUG|Fludarabine|Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
214600714|NCT07024979|BEHAVIORAL|Music Therapy Songwriting Intervention|The music therapy songwriting intervention is an active, client-centered music therapy approach in which the participant collaboratively create an original song with a professional music therapist. This evidence-based method combines: 1) lyric writing: the participant can express personal experience/emotions through guided lyric creation; 2) musical composition: the participant will choose or improvise their favorite melody, harmony, and rhythm with a music therapist; 3) therapeutic processing: discussion of song meaning and emotional connections between the participant and music therapist.
214600715|NCT07029581|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
214600716|NCT07029581|DRUG|Placebo|Provided as 1 capsule, to be taken orally once daily
214600717|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
214600718|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
214600719|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
214600720|NCT04915768|BIOLOGICAL|CH505 TF chTrimer|Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
214600721|NCT04915768|BIOLOGICAL|3M-05-AF|Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
214600722|NCT04915768|BIOLOGICAL|Aluminum hydroxide suspension|Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle
214711551|NCT02162121|PROCEDURE|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
214600723|NCT07031245|BEHAVIORAL|Evidence-based quality improvement (EBQI)|Evidence-based quality improvement (EBQI) is a multi-level implementation strategy that aids in the development and implementation of evidence-based interventions to reduce burnout. Preliminary survey, interview, and systematic review data on burnout, turnover intent, burnout drivers, and burnout interventions will be presented to an expert panel for each intervention site. These panels will collectively decide on the top categories of burnout drivers to target and burnout interventions to implement. These top drivers and intervention categories will be presented to site-level providers and staff and proposals will be solicited for quality improvement (QI) interventions to reduce burnout that reflect these categories and address these drivers. The expert panels will then choose one or more of these QI interventions to implement and evaluate at each intervention site.
214600724|NCT06690710|BIOLOGICAL|allogeneic engineered Gingival Fibroblasts (aeGF)|single intra-articular injection of the study drug (aeGF) in the knee joint
214600725|NCT06712823|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
214600726|NCT07031531|COMBINATION_PRODUCT|AI-Enabled Stratified Management System|After discharge, participants install SMART-CHD, sync their EHR data, and complete a 10-minute orientation. They then use the app's OCR-assisted surveys to report lifestyle, lab, and event data, while paired wearables stream continuous vitals. AI voice calls and a CRC-managed WeChat group deliver reminders and support. The app's embedded predictive models stratify them into risk tiers and generate tier-specific follow-up schedules. Personalized lifestyle modification guidance, dietary plans, and medication adjustment recommendations are generated by the platform's module. Automated alerts and teleconsultation options are triggered upon detection of high-risk signs or abnormal results, ensuring timely clinical intervention and enhanced secondary prevention.
214600727|NCT07031531|COMBINATION_PRODUCT|Usual Post-Discharge Care|Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.
214600728|NCT07037004|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214600729|NCT07037004|DRUG|Clostridium butyricum CBM588 Strain|Given PO
214600730|NCT07037004|PROCEDURE|Computed Tomography|Undergo CT
214600731|NCT07037004|BIOLOGICAL|Pembrolizumab|Given IV
214600732|NCT05884242|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
214600733|NCT05884242|DRUG|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
214600734|NCT06884332|RADIATION|Sparing irradiation|"For Sparing irradiation arm the Clinical Target Volume (CTV) = Growth Tumor Volume (GTV) + entire vertebra opposite."
214600735|NCT06884332|RADIATION|Conventional spinal irradiation|"For conventional spinal irradiation arm, Clinical Target Volume (CTV ) = Growth Tumor Volume (GTV) + entire vertebra opposite + 1 vertebra above and below."
214600736|NCT06883500|BEHAVIORAL|Energy diary|A prospective observational study is conducted at two German rehabilitation centers in a co-design approach with repeated feedback loops (expert consensus, patient interviews). Daily energy-changes will be analyzed and validated using the Multidimensional Fatigue Inventory-20 (MFI-20).
214600737|NCT06725420|OTHER|Ultrasound-guided local Injection|Ultrasound-Guided steroid injection and splinting in patients with carpal tunnel syndrome
214600738|NCT06725420|OTHER|Intramuscular Steroid Injection|Intramuscular gluteal steroid injection and Splinting in Patients With Carpal Tunnel Syndrome
214600739|NCT06725420|DEVICE|Splinting|wrist night splint
214600740|NCT05371548|DEVICE|SAM mobile application|See description of intervention group
214600741|NCT07045766|DIETARY_SUPPLEMENT|FibreGum chewing gum|Chewing gum containing galactooligosaccharides (GOS), delivering a total daily dose of 3 g of dietary fiber.
214600742|NCT07044596|DEVICE|Functional near-infrared spectroscopy (fNIRS)|fNIRS is a non-invasive imaging technique which takes advantage of the light scattering and absorption differences between oxygenated (HbO) and de-oxygenated hemoglobin (HbDO) to characterize changes in cerebral hemodynamics in response to a given task or stimulus.
214600743|NCT07044596|DEVICE|V1 stimulation electrodes|The V1 electrodes will be placed on the forehead with some gel and held in place with a headband or cap (a conductive adhesive gel may be placed under the electrodes to help with stimulation). Participants will receive short electrical stimulations through these electrodes that will differ in intensity.
214600744|NCT07044596|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo 2 90-minute MRI sessions
214600745|NCT06716814|DRUG|Efanesoctocog alfa|Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
214600746|NCT06732323|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
214600747|NCT06732323|DRUG|Investigator's Choice Chemotherapy|Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
214600748|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation (SpO₂) Group|FiO₂ adjusted based on pulse oximetry to maintain SpO₂ ≥98%
214600749|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation and Oxygen Reserve Index (SpO₂-ORI) Group|FiO₂ adjusted using both SpO₂ and ORI to maintain ORI between 0-0.3
214600750|NCT07049926|DRUG|Belzutifan|Oral Tablet
214600751|NCT07049926|DRUG|Zanzalintinib|Oral Tablet
214600752|NCT07049679|BEHAVIORAL|ActiveHeal Diabetes (AHD) Program|Biweekly phone/Zoom calls to support physical activity and dietary behavior change, focused on history, experience, benefits and adaptation
214600753|NCT07049939|DRUG|MK-3543|Capsule for oral administration
214711552|NCT02162121|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times a day
214600754|NCT07043725|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
214600755|NCT07043725|DRUG|Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection|TCbHP is a commonly used chemotherapy scheme for HER2 positive breast cancer. H represents Trastuzumab injection, P represents Pertuzumab Injection, T represents Docetaxel injection and C represents Carboplatin injection.
214711553|NCT02162121|PROCEDURE|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS\>4
214711554|NCT02162121|DRUG|Mepivacaine 1%|
214711555|NCT02162121|DRUG|Levobupivacaine 0,5%|
214711556|NCT02162121|DRUG|Ropivacaine 0,2%|
214711557|NCT02162121|DRUG|Ketorolac 30mg|
214600756|NCT04012879|COMBINATION_PRODUCT|CD19 CART|CD19 CART
214600757|NCT06892197|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
214600758|NCT06892197|DRUG|hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
214600759|NCT06743516|PROCEDURE|Pancreaticojejunostomy with external stent|Inserting ureteric stent at the pancreaticojejunostomy site
214600760|NCT06743516|PROCEDURE|Pancreaticojejunostomy without external stent|Only Pancreaticojejunostomy without inserting external stent
214600761|NCT06894108|DIETARY_SUPPLEMENT|Proprietary Blend of Botanical Extracts|Participants consumed 2.4ml of the supplement each night before bed.
214600762|NCT06894108|DIETARY_SUPPLEMENT|Melatonin|Participants consumed 1mg melatonin each night before bed.
214600763|NCT07052266|GENETIC|MyRisk Hereditary Cancer Test|Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.
214600764|NCT07052682|DRUG|Ontamalimab|Ontamalimab SC injection.
214600765|NCT07053085|PROCEDURE|Lumpectomy or mastectomy|Resection of the primary breast tumor (ie. lumpectomy when possible or mastectomy when breast conservation not possible). Surgical resection of the primary breast tumor is to be performed per standard guidelines as applied to localized disease. Breast conserving surgery (ie. lumpectomy) is allowable per patient preference when supported by standard surgical practice. Mastectomy is preferred when breast conservation is declined by the patient, or if breast conservation would otherwise not be feasible in the early-stage setting (e.g. large tumor:breast volume ratio, inability to achieve negative margins with breast conservation, etc)
214600766|NCT07053085|RADIATION|Radiotherapy|"Radiotherapy will be delivered using external beam radiation per the guidelines.Radiotherapy will be delivered using external beam radiation per the guidelines set forth below, targeting two main compartments:~1. Patients will undergo radiotherapy to the breast/chest wall, and regional nodal basins (including the axilla, supraclavicular fossa and internal mammary chain) per the standard adjuvant approach for locally advanced disease, and~2. Patient will undergo stereotactic body radiotherapy (SBRT) or similarly-ablative approaches to sites of distant disease, including all observable foci and those that may have since resolved radiographically during systemic therapy"
214600767|NCT07053085|DRUG|Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs|Continue to receive the standard treatment you have already started, which includes trastuzumab, pertuzumab, paclitaxel, or a combination of these drugs. This treatment is not part of the study and will be decided by your regular treating physician.
214600768|NCT05503797|DRUG|Plixorafenib|Oral tablets
214600769|NCT06807086|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia|The Survivorship Sleep Program is a virtual program based on cognitive behavioral therapy for insomnia (CBT-I), which teaches evidence based skills to improve sleep-related behaviors, expectations, and environment, to promote relaxation, and to reduce worry. It also involves reducing the time spent in bed in order to improve the quantity and quality of sleep over time. The Survivorship Sleep Program is delivered in 4 weekly sessions by a trained facilitator and includes considerations specific to managing insomnia after cancer diagnosis and treatment. Additionally, 1 booster session is offered at week 6.
214600770|NCT06807086|BEHAVIORAL|Enhanced Usual Care|A sleep hygiene handout and a referral for CBT-I offered through MGH or community partners.
214600771|NCT06750146|DEVICE|Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System|The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
214600772|NCT07054853|DEVICE|Induced rotator cuff fatigue by isokinetic biodex|"Each subject will undergo two separate fatigue protocols from distinct shoulder abduction angles (30° and 90°), referred to as Protocol A and Protocol B, respectively.~Fatigue will be induced using the Biodex System 4 Pro Isokinetic .Participants will be seated with the tested arm positioned at the designated shoulder abduction angle and elbow flexed at 90°. The arm will be secured using a shoulder adapter to ensure standardized positioning. Hand Grip strength will be assessed using a Jamar Plus+ Digital. Participants will perform three maximal grip trials, each lasting 3 seconds, with verbal encouragement provided. The average of the three trials will be used as the maximum voluntary contraction"
214600773|NCT06761976|DRUG|Sevabertinib|Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration
214600774|NCT06764485|DRUG|BMS-986365|Specified dose on specified days
214600775|NCT06764485|DRUG|Enzalutamide|Specified dose on specified days
214600776|NCT06764485|DRUG|Abiraterone|Specified dose on specified days
214600777|NCT06764485|DRUG|Docetaxel|Specified dose on specified days
214600778|NCT06764485|DRUG|Predinsone/Prednisolone|Specified dose on specified days
214600779|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 1|For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
214600780|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 2|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
214711558|NCT02162121|DRUG|Buprenorphine 0,2mg|
214711559|NCT02162121|DEVICE|Stimulong, Pajunk, Germany.|
214600781|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 3|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
214600782|NCT06550791|BEHAVIORAL|Anticancer Learning Circle|All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
214600783|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for 7 days
214600784|NCT06641466|DRUG|Placebo Comparator|Matching placebo oral disintegrating tablets for 7 days
214600785|NCT06641466|DRUG|Standard of Care|Standard of care for acute treatment as needed
214600786|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for acute treatment as needed
214600787|NCT06237452|BIOLOGICAL|VE303|VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.
214600788|NCT06237452|BIOLOGICAL|Placebo|Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
214600789|NCT06872125|DRUG|zorevunersen|Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg on Day 169 and Day 281.
214600790|NCT06872125|OTHER|Sham Comparator|Sham group will not have drug administered. Sham group will have a lumbar puncture with CSF withdrawal.
214600791|NCT07060235|OTHER|fascial exercise home brochure|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. He/she remembers the exercises from the home brochure.
214600792|NCT07060235|OTHER|Fascial exercise based mobile application|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. Performs the exercises by watching videos on the mobile application. The physiotherapist intervenes in motivation with instant notifications via the mobile application.
214600793|NCT07060235|OTHER|lumbal stabilizasyon home brochure|"Participants assigned to the intervention group will receive a structured home-based lumbar stabilization exercise program designed to improve spinal stability, core muscle control, and functional performance. The program will target deep trunk stabilizer muscles, including the transversus abdominis and multifidus, through low-load, motor control-based exercises.~The intervention will last for 14 days, with exercises to be performed 3 times for everyday, Each session will last approximately 20-30 minutes and consist of:~Warm-up (1 minutes): Breathing exercises and gentle mobility~Core Stabilization (15-20 minutes): Exercises such as abdominal hollowing, bridging, bird-dog, side plank, and dead bug - progressing from static holds to dynamic movements as tolerated~Cool-down (1 minutes): Light stretching and relaxation"
214600794|NCT07067034|BEHAVIORAL|Ridikullus Nursing İntervention|A one-session, nurse-led psychosocial intervention designed to reduce anxiety in university students. Participants identified personal metaphors related to their anxiety and were guided to reconstruct them into less distressing, humorous, or calming mental images. The intervention was delivered in a structured format by an academic nurse trained in therapeutic communication
214600795|NCT07063745|DRUG|BMS-986504|Specified dose on specified days
214600796|NCT07063745|DRUG|Pembrolizumab|Specified dose on specified days
214600797|NCT07063745|OTHER|Placebo|Specified dose on specified days
214600798|NCT07063745|DRUG|Cisplatin|Specified dose on specified days
214600799|NCT07063745|DRUG|Carboplatin|Specified dose on specified days
214600800|NCT07063745|DRUG|Pemetrexed|Specified dose on specified days
214600801|NCT07063745|DRUG|Paclitaxel|Specified dose on specified days
214600802|NCT07063745|DRUG|Nab-paclitaxel|Specified dose on specified days
214600803|NCT06770439|DRUG|IBI343|IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate
214600804|NCT06770439|DRUG|Gemcitabine+Albumin-bound paclitaxel|Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
214600805|NCT06344884|PROCEDURE|Early catheter removal|Catheter removal the day after surgery as opposed to standard of care (3 to 4 days after surgery)
214600806|NCT06780449|DRUG|Cagrilintide|Participants will receive cagrilintide subcutaneously.
214600807|NCT06780449|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
214600808|NCT06780449|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
214600809|NCT06780449|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
214600810|NCT07071194|PROCEDURE|OMT|Patients in the treatment group will undergo OMT using sub-occipital release, rib raising, doming the diaphragm, thoracic inlet release and myofascial techniques.
214711560|NCT02162121|PROCEDURE|Continuous lumbar plexus: non-stimulating catheter|
214600811|NCT07071194|OTHER|Light touch|Patients in the control group will undergo light touch in similar locations to OMT.
214600812|NCT07071623|DRUG|MK-8527|Oral tablet
214600813|NCT07071623|DRUG|Emtricitabine/tenofovir disoproxil (FTC/TDF)|Oral tablet
214600814|NCT07071623|DRUG|Placebo matched to MK-8527|Placebo oral tablet matched to MK-8527
214600815|NCT07071623|DRUG|Placebo matched to FTC/TDF|Placebo oral tablet matched to FTC/TDF
214600816|NCT07069699|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214600817|NCT07069699|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214600818|NCT07069699|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214600819|NCT07069699|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214600820|NCT07069699|DRUG|Pidnarulex|Given IV
214600821|NCT07069699|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214600822|NCT07070232|DRUG|BNT326|Intravenous (IV) infusion
214711561|NCT02489006|DRUG|Olaparib|
214711562|NCT02489006|DRUG|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
214600823|NCT07070232|DRUG|BNT327|IV infusion
214600824|NCT07070232|DRUG|Itraconazole|Oral administration
214711563|NCT01916993|DRUG|NBI-98854 50 mg capsule|
214711564|NCT02890043|PROCEDURE|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
214600825|NCT07070232|DRUG|Paroxetine|Oral administration
214600826|NCT06388083|DRUG|Tinlarebant|5 mg tablet
214600827|NCT06388083|DRUG|Placebo|Placebo tablets
214600828|NCT06759558|DRUG|Zuranolone|Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
214600829|NCT06765434|OTHER|Music ( Dmitri Shostakovich's Jazz Waltz Suite)|Music
214600830|NCT06765434|OTHER|Music( Personalized music)|Music
214711565|NCT02890043|PROCEDURE|free-hand surgery|traditional free-hand surgery
214711566|NCT02890043|DEVICE|TiRobot system|a robot-assisted spine surgery system
214711567|NCT01899677|OTHER|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
214711568|NCT01899677|DRUG|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
214600831|NCT07072468|DRUG|VMD-3866 Gel|"Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose).~Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home."
214600832|NCT07072468|DRUG|Placebo Gel|Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose). Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home.
214600833|NCT03773965|DRUG|Baricitinib|Administered orally.
214600834|NCT06832722|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
214600835|NCT06832722|DRUG|Placebo|Application of placebo
214600836|NCT05843864|DEVICE|Photobiomodulation Therapy with Standard Physical Therapy|Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.
214600837|NCT05843864|OTHER|Sham Photobiomodulation Therapy with Standard Physical Therapy|Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
214600838|NCT06659341|DRUG|BAY3498264|Oral
214600839|NCT06468228|DRUG|Lutikizumab|Subcutaneous injection
214600840|NCT06468228|DRUG|Placebo|Subcutaneous injection
214711569|NCT01925391|DRUG|Tono-pen XL Applanation tonometer + Ocu-film +|
214711570|NCT01213264|OTHER|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
214711571|NCT01213264|DRUG|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
214711572|NCT01213264|DRUG|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
214711573|NCT06450353|BEHAVIORAL|Patient Ancestry Questionnaires|Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
214711574|NCT05389384|DEVICE|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
214711575|NCT05389384|BEHAVIORAL|Fatigue protocol|Participants complete a fatiguing protocol
214711576|NCT05389384|DEVICE|No exoskeleton support|Exoskeleton is worn, but no support provided
214711577|NCT05389384|BEHAVIORAL|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
214711578|NCT02682160|OTHER|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
214600841|NCT06806150|BEHAVIORAL|INSPIRE Life Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their daily lives. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful moments.
214600842|NCT06806150|BEHAVIORAL|INSPIRE Work Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their work experiences. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful professional interactions.
214600843|NCT05866419|DEVICE|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
214600844|NCT07078448|OTHER|Foam Roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
214600845|NCT06665399|OTHER|Observation|"In this study, the definition of observation is that participants cannot receive the following treatments currently considered to have a clear efficacy for NL-GLM/PDM, including surgical treatments (minimally invasive excision or open excision, incision and drainage), ultrasound-guided aspiration, oral corticosteroid therapy, antibiotic treatment, anti-tuberculosis therapy, or ductal lavage therapy. As symptomatic management for pain, the use of NSAIDs is permitted. Additionally, for patients with fistulas or skin lesions, routine wound care is also allowed. These two interventions are not considered as receiving treatment intervention in this study."
214600848|NCT06453720|PROCEDURE|Colonoscopy|A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
214600849|NCT03843463|DRUG|Escitalopram 10mg|Escitalopram tablet
214711579|NCT02884271|PROCEDURE|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
214711580|NCT04671069|DRUG|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
214711581|NCT04671069|DRUG|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
214600850|NCT03843463|DRUG|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
214600851|NCT03843463|BEHAVIORAL|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
214600852|NCT06575192|DEVICE|ARTIA Reconstructive Tissue Matrix|Surgical Implant
214600853|NCT06575192|OTHER|No Intervention|No ADM
214600854|NCT04532645|DRUG|Olaparib|Olaparib
214600855|NCT07079228|DRUG|QLS31905|QLS31905 will be administered as an IV infusion.
214600856|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion.
214600857|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
214600858|NCT07079228|DRUG|Placebo for QLS31905|Placebo will be administered as an IV infusion.
214600859|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion
214600860|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
214600861|NCT05411081|BIOLOGICAL|Atezolizumab|Given IV
214600862|NCT05411081|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214600863|NCT05411081|PROCEDURE|Bone Scan|Undergo bone scans
214600864|NCT05411081|DRUG|Cabozantinib S-malate|Given PO
214600865|NCT05411081|PROCEDURE|Computed Tomography|Undergo CT scans
214600866|NCT05411081|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214600867|NCT06903676|DEVICE|TRP-2 Urine Dipstick|Urine dipstick testing for Trypsinogen-2
214600868|NCT04617834|OTHER|Quality Surveillance Data Collection|Data will be retrospectively collected through EHR queries
214600869|NCT07093307|BEHAVIORAL|Docudrama|Participants at docudrama sites will watch a 30-minute docudrama (two episodes of 15 minutes each) immediately after blood donation while waiting to recover and to be refreshed.
214600870|NCT07093307|BEHAVIORAL|Control|"Participants randomized at control sites will receive the standard NBSG communications for blood donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to when they are due for their next blood donation."
214600871|NCT07090135|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
214600872|NCT07090122|PROCEDURE|Radiofrequency ablation and bone augmentation with radiotherapy|employs radiofrequency-generated heat to eradicate cancer cells, followed by the application of a bone-stabilizing agent
214600873|NCT07090122|PROCEDURE|Radiotherapy alone|High-energy radiation
214600874|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1
214600875|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 2
214600876|NCT06908252|DRUG|Pre-Exposure Prophylaxis (PrEP)|Oral Pre-Exposure Prophylaxis (PrEP) pills
214600877|NCT07096362|DRUG|5-Fluorouracil|Participants will be administered 2400 mg/m\^2 of 5-Fluorouracil via continuous intravenous infusion over a 46-hour period beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
214600878|NCT07096362|DRUG|Oxaliplatin|Participants will be administered 85 mg/m\^2 of Oxaliplatin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
214600879|NCT07096362|DRUG|Leucovorin|Participants will be administered 400 mg/m\^2 of Leucovorin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
214600880|NCT07096362|DRUG|Irinotecan|Participants will be administered 150 mg/m\^2 of Irinotecan via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
214600881|NCT07096362|DRUG|Gemcitabine|Participants will be administered 1000 mg/m\^2 of Gemcitabine standard of care (SOC) via intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
214600882|NCT07096362|DRUG|Nab Paclitaxel|Participants will be administered 125 mg/m\^2 of Nab Paclitaxel standard of care (SOC) by intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
214600883|NCT07096362|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* Every weeks 2 beginning at weeks 2, 4, 6 and 8 of standard of care therapy.~* Every 4 weeks beginning at week 10 of standard of care therapy until disease progression.~ctDNA will be measured to obtain participant tumor methylation scores (TMS)."
214711582|NCT02539303|DRUG|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
214600884|NCT07098286|OTHER|high intensity home-based rehabilitation|Whereas standard home healthcare would include 1-3 visits per week of therapy services after a stroke, the HIHR intervention will include at least therapy visits per week. Between occupational, physical, and speech therapy, the frequency for each will match individual patient needs based on the type and severity of their stroke-related deficits.
214600885|NCT06910657|BIOLOGICAL|IDOV-Immune (oncolytic vaccinia virus)|IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
214711583|NCT03512470|DEVICE|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
214711584|NCT03512470|OTHER|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
214711585|NCT03051828|PROCEDURE|fencing|No intervention: practice fencing
214711586|NCT04261452|DIAGNOSTIC_TEST|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
214711587|NCT04261452|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
214600886|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
214600887|NCT07091500|BEHAVIORAL|Exercise training|Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.
214600888|NCT07091500|DRUG|Semaglutide|semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling
214600889|NCT07098182|PROCEDURE|Clamping and restauration of arterial blood of the inferior mesenteric artery|"* Injection of Indocynianine green (INFRACYANINE 25mg diluted in 10 mL solvent, IV injection of 3ml at a concentration of 2.5 mg/mL or 7.5 mg), (excluding NaCl), purge 10ml NaCl,~* Camera model (STORZ)~* Camera/target distance: 5cm~* Camera recording time (since Indocynianine green injection): 2 to 5 min with temporal identification of the injection time.~Extracorporeal evaluation (by mini laparatomy extraction in colorectal surgery minimally invasive, by laparotomy in case of ovarian cancer with lights of the room switched off (laparotomy)"
214600890|NCT06880835|DEVICE|Control IQ + sleep activity with TI|TI for meal bolus with Control IQ + sleep activity pump setting
214600891|NCT04776434|DEVICE|SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)|This study will capture data from the use of the SELUTION SLR according to its approved labelling.
214600892|NCT04613206|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
214600893|NCT04613206|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
214600894|NCT07105111|DRUG|Valbenazine|Valbenazine capsules for oral administration.
214600895|NCT07105098|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
214600896|NCT07105098|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
214600897|NCT05952167|OTHER|Intensive cervical traction protocol|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
214600898|NCT05952167|OTHER|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
214600899|NCT04759586|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214600900|NCT04759586|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214600901|NCT04759586|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214600902|NCT04759586|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214600903|NCT04759586|DRUG|Cyclophosphamide|Given IV
214600904|NCT04759586|DRUG|Doxorubicin Hydrochloride|Given IV
214600905|NCT04759586|PROCEDURE|Echocardiography Test|Undergo ECHO
214600906|NCT04759586|DRUG|Etoposide Phosphate|Given IV
214600907|NCT04759586|BIOLOGICAL|Filgrastim|Given SC
214600908|NCT04759586|PROCEDURE|Lumbar Puncture|Undergo LP
214600909|NCT04759586|BIOLOGICAL|Nivolumab|Given IV
214600910|NCT04759586|BIOLOGICAL|Pegfilgrastim|Given SC
214600911|NCT04759586|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214600912|NCT04759586|DRUG|Prednisolone|Given PO
214600913|NCT04759586|DRUG|Prednisone|Given PO
214600914|NCT04759586|RADIATION|Radiation Therapy|Undergo radiation therapy
214600915|NCT04759586|BIOLOGICAL|Rituximab|Given IV
214711588|NCT04261452|DIAGNOSTIC_TEST|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
214600916|NCT04759586|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214600917|NCT04759586|DRUG|Vincristine Sulfate|Given IV
214600918|NCT06488716|DRUG|RO7759065|Specified dose on specified days
214600919|NCT06488716|DRUG|Atezolizumab|Specified dose on specified days
214600922|NCT04880265|DEVICE|Vivalink wearable life sensors|Collection of EKG data
214600925|NCT06915480|BEHAVIORAL|Reminder message and patient navigation|This study will evaluate the combination of pre-appointment messages and patient navigation services.
214600926|NCT07111130|OTHER|12-week Lifestyle Intervention|Eligible participants within the existing ELEGANCE cohort will undergo a structured 12-week lifestyle intervention comprising a low-carbohydrate, high-fibre dietary plan and a prescribed physical activity program targeting at least 150 minutes of moderate-intensity exercise per week. Standardized meal provision and wearable fitness tracking devices will be used to support adherence throughout the intervention period.
214600927|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
214600928|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
214600929|NCT07105605|BEHAVIORAL|Intervention Group|pediatric nursing student
214600930|NCT07106554|BEHAVIORAL|holotropic breathwork|participants will engage in holotropic breathwork
214600931|NCT07112339|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection.
214600932|NCT07112339|DRUG|Basal insulin analogues|Basal insulin analogues will be administered as subcutaneous injection.
214600935|NCT05845047|BEHAVIORAL|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~1. Single words depicted in the picture, then with written and spoken labels~2. 2-word phrases depicted in the picture and then with written and spoken word~3. Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~4. Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~5. Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
214600936|NCT05845047|BEHAVIORAL|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun, phrase, or sentence. The spoken word, phrase, or sentence either will or will not fit the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
214600937|NCT07113912|DEVICE|counterforce forearm brace|a flexible band that fits around the proximal forearm, applying pressure to underlying tissues during activity to potentially reduce acceleration forces and alleviate pain associated with conditions like lateral epicondylitis.
214600938|NCT07113912|PROCEDURE|thoracic immobilization|the methods and devices used to restrict movement of the thoracic spine, which is the upper and middle part of the back.
214600939|NCT06914518|OTHER|viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight > 1500 kDa (10 mg/ml, 1%)|At the end of the standardized peri-implant non-surgical therapy a viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight \> 1500 kDa (10 mg/ml, 1%) (REGENFASTe, Mastelli S.r.l., Sanremo, Italy) will be injected in the peri-implant sulcus.
214600940|NCT06914518|PROCEDURE|Non-Surgical Intervention|Standardized peri-implant non-surgical therapy will be performed as follows: local anaesthesia (articaine 4% and adrenaline 1:100,000), debridement of the implant surfaces with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the H3 dental ultrasonic scaler (H3, Satelec Acteon; Olliergues, France), curettage of the bone defect (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) and supra- and submucosally cleaning using an air polisher with sub- gingival tip (EMS Air-flow® with erythritol-based powder containing
214600941|NCT06920004|BIOLOGICAL|empasiprubart|Intravenous infusion of empasiprubart
214600942|NCT06920004|BIOLOGICAL|IVIg|Intravenous infusion of IVIg
214600943|NCT06920004|OTHER|empasiprubart-placebo|A placebo resembling the empasiprubart treatment
214600944|NCT06920004|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
214600945|NCT06920043|DRUG|Efimosfermin|Efimosfermin will be administered as a subcutaneous injection.
214600946|NCT06920043|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
214600947|NCT06921200|PROCEDURE|Cryotherapy|Cryotherapy is one of the non-pharmacological pain-relieving techniques, which involves chilling specific body areas with ice packs, ice cubes, ice water, or ethyl chloride sprays. The present study intervention will be conducted on 50 post-partum women to assist in relieve episiotomy pain. The researchers will assess the baseline level of episiotomy pain for each woman then the researchers will instruct women to perform perineal care. After cleaning the perineum, the researchers will ask the women to maintain her knee more flexed and apply ice gel pad against the episiotomy line for about 20 minutes then remove it and keep it in the freezer for reusing and assess the level of episiotomy pain using the Numeric Rating Scale for Pain after two hours from delivery. Ice gel pad will be applied for the second time after the episiotomy.
214711589|NCT04261452|DIAGNOSTIC_TEST|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
214711590|NCT04261452|DIAGNOSTIC_TEST|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
214711591|NCT04261452|DIAGNOSTIC_TEST|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
214600948|NCT05640843|OTHER|Whole Foods Plant-based Diet|The meals will have a low glycemic index and contain legumes, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to education materials. Patients will also receive dietary education and counselling from a research dietitian every 4 weeks for the 12-week intervention period. They will have access to the team for questions and support as needed
214600949|NCT05640843|DIETARY_SUPPLEMENT|Algae Omega 3 + Curcumin|For 52 weeks on the supplement arm, patients will be given algae omega 3 supplements and curcumin supplements (Sabinsa pharmaceuticals) twice daily
214600950|NCT05640843|OTHER|Placebo supplements|For 25 weeks on the placebo arm, patients will be given placebo supplements twice daily (Veggie Doctor/M and M pharmaceuticals and Sabinsa pharmaceuticals).
214600951|NCT06919588|BEHAVIORAL|comedy therapy|Before the transplant surgery, the patients were shown 10-minute Turkish comedy films prepared by the researchers.
214600952|NCT07123350|DRUG|Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care|This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.
214600953|NCT07127185|DIAGNOSTIC_TEST|LS/MS|Quantitative determination of ceftobiprole concentrations in plasma and urine was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
214600954|NCT07126990|BIOLOGICAL|Novel oncolytic virus Ad-TD-nsIL12|Ommaya capsule was placed for intratumoral injection at a dose of 1×10\^10vp
214600955|NCT07133139|DEVICE|Dry Needling|"The examiner will use the repeated tapping technique of Travel and Simmons in the active condition in the painful tender points and TPs. In the sham treatment, the needle tip retracts when pushed against the skin (like a ballpoint pen), and the subject feels a pointy object on their skin, which does not penetrate. Prior studies have shown that this is a credible placebo condition. Prior studies have also shown that one dry needling session is effective at least temporarily for 1-2 weeks, AND that US correlates of TPs improve as well"
214600956|NCT07133139|DEVICE|Sham Dry Needling|Half of the subjects will receive a sham needle instead which puts pressure on the skin but does not penetrate the skin (like a ballpoint pen with the tip retracted pushing on the skin). Since manual pressure over myofascial tender and trigger points is also an accepted treatment, the sham procedure could also be therapeutic, although we do not think it will be very effective.
214600957|NCT07133139|OTHER|NUN Biomarker|"A NUN biomarker measurement means checking the level of a certain substance (the NUN biomarker) in your body that can give investigators clues about your condition.~Measuring the NUN biomarker helps investigators see if a treatment is working or if your condition is changing."
214600958|NCT07141381|DRUG|VRN110755|VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.
214600959|NCT07141381|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.
214600960|NCT03827460|BEHAVIORAL|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
214600961|NCT03827460|BEHAVIORAL|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
214600962|NCT03827460|DRUG|Intravenous Alcohol|During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
214600963|NCT06832189|DRUG|Everolimus|"The starting dose of EVR will be based on the maintenance TAC dose of the subject at study entry:~1. EVR 1 mg PO BID if TAC dose is \<=2 mg BID~2. EVR 2 mg PO BID if TAC dose is 2.5-7 mg BID~3. EVR 3 mg PO BID if TAC dose is \>7 mg BID~The dosage will be adjusted as needed to achieve and maintain EVR trough concentration of 5-8 ng/mL."
214600964|NCT06832189|DRUG|Epoetin alfa|The dose used in this study is 10,000 units SC every 8 weeks (at study weeks 16, 24, 32, 40 and 48) for five doses
214600967|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
214600968|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
214600969|NCT05670379|COMBINATION_PRODUCT|Exenatide Implant|Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
214600970|NCT05670379|DRUG|Bydureon BCise (exenatide extended release)|glucagon-like peptide-1 (GLP-1) receptor agonist
214600971|NCT05670379|DRUG|Semaglutide, 1.0 mg/mL|glucagon-like peptide-1 (GLP-1) receptor agonist
214600972|NCT04522765|DIAGNOSTIC_TEST|Assessment of 24 hour blood pressure and arterial stiffness|Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device
214600973|NCT07145957|OTHER|Prehabilitation|subjects randomized to the IRTx cohort will also be instructed by a Physical or Occupational Therapist to perform the exercises described in the RSA IR Prehab Exercise Protocol handout, 5-7 times per week for 6 weeks.
214600974|NCT07139132|BEHAVIORAL|Health Wellness Coaching|Health wellness coach will provide education and guidance about cultural nutrition
214600975|NCT07139132|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
214600976|NCT07139132|BEHAVIORAL|School-age nutritional education program|Educational program will teach students about healthy Native American food choices
214600977|NCT07139132|DIAGNOSTIC_TEST|Cognitive Testing|Participants will undergo a cognitive test.
214600978|NCT07139132|DIAGNOSTIC_TEST|Blood work|Participants will undergo blood work.
214600979|NCT06947031|DEVICE|AHCL|The downloaded data will be analyzed prior to the surgical procedure. In accordance with standard clinical practice, a TBR time-under-range % (\<54 mg/dL) or TBR time-under-range % (\<70 mg/dL) greater than 4% will be identified, and the target glucose will be increased by 10 mg/dL relative to the previously established value. This is intended to reduce the risk of perioperative hypoglycemia.
214600980|NCT06944626|DEVICE|tDCS|tDCS will be applied to the dorsalateral prefrontal cortex with a current of 2 mA for 30 minutes on 3 consecutive days.
214600981|NCT06944626|DEVICE|Sham tDCS|The tDCS application will be increased to 2 mA for the first 30 seconds and will be reduced to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 min in total).
214600982|NCT06944626|OTHER|Conventional physiotherapy|"Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.~While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises."
214600983|NCT06946225|BIOLOGICAL|IMA203|Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.
214600984|NCT06946225|BIOLOGICAL|mRNA-4203|mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.
214600985|NCT07147725|DEVICE|AI Stethoscope|"Patients attending routine echocardiography who satisfy the inclusion and exclusion criteria will be approached before their echocardiography appointment to obtain informed consent to participate in the study. On providing informed consent, each patient will receive a non-invasive, external examination with a smart stethoscope that records a 3-lead electrocardiogram (ECG) and phonocardiogram (PCG) waveforms. This examination will require only one study visit (during routine echocardiography) and no additional visits. The stethoscope is a fully CE-marked device.~In addition to echocardiography parameters and smart stethoscope waveforms, baseline demographics, clinical and medication history will be recorded. These data points will be re-examined at 24 months following enrolment (via chart review)."
214600986|NCT07141342|DEVICE|The Fast In-Bed Tracking System (FIT) Weight Scale|It is hypothesized that wheelchair users who are randomized into the FIT Weight Scales group will lose a significantly greater percent of body weight over time (6 months, 12 months) than wheelchair users randomized to the control group.
214711592|NCT00118911|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
214600987|NCT07141342|BEHAVIORAL|Group Lifestyle Balance Adapted for Individuals with Impaired Mobility (GLB-AIM) intervention|The GLB-AIM is a direct adaptation of the Diabetes Prevention Program (DPP) - Group Lifestyle Balance (DPP-GLB) which has successfully yielded an average 6 percent weight loss at 12 months and reduced diabetes risk over 2.8 years by 58 percent, which was 39 percent lower than participants randomized to the metformin group. The GLB-AIM which has been proven feasible and effective in a pilot study and a randomized control trial (RCT) with 67 mobility impaired individuals randomized to the intervention group or a waitlist control group. There were significant between group differences in weight loss at 6 months (-1.7 kg loss vs 0.05 kg gain, p \<0.05) and combined results from both groups after receiving the intervention revealed an average weight loss at 12 months of 3.3 percent of their starting weight. Notably, the average loss was lower than the 5 to 7 percent achieved by diverse participants in the DPP-GLB trials.
214600988|NCT07147231|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214600989|NCT07147231|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214600990|NCT07147231|BIOLOGICAL|Cemiplimab|Given IV
214600991|NCT07147231|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214600992|NCT07147231|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214600993|NCT07147231|DRUG|Pidnarulex|Given IV
214600994|NCT07147231|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214600995|NCT06951698|DRUG|KarXT|Specified dose on specified days
214600996|NCT06951698|OTHER|Placebo|Specified dose on specified days
214600997|NCT06954987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
214600998|NCT06954987|PROCEDURE|Biospecimen Collection|Undergo blood, urine and buccal swab collection
214600999|NCT06954987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214601000|NCT06954987|DRUG|Busulfan|Given IV
214601001|NCT06954987|PROCEDURE|Chest Radiography|Undergo chest x-ray
214601002|NCT06954987|PROCEDURE|Computed Tomography|Undergo CT scan
214601003|NCT06954987|PROCEDURE|Echocardiography Test|Undergo echocardiography
214601004|NCT06954987|DRUG|Fludarabine|Given IV
214601005|NCT06954987|DRUG|Melphalan|Given IV
214601006|NCT06954987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214601007|NCT06954987|DRUG|Placebo Administration|Given PO
214601008|NCT06954987|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214601009|NCT06954987|RADIATION|Total-Body Irradiation|Undergo total body irradiation
214601010|NCT06954987|DRUG|Venetoclax|Given PO
214601011|NCT06951269|BEHAVIORAL|Live entrained music therapy|This study will use live, improvised, entrainment-based music. The music will be applied to synchronize with the newborns' breathing patterns, adapting the tempo to the breathing rate, with characteristics that seek to induce a state of relaxation in the patient: moderate volume (below 65 dB; this measure will be validated using the ambient noise indicator of the neonatal intensive care unit), simple harmonic sequences (tonic-subdominant-dominant), melodies that avoid large intervals (beyond a third), medium registers, and a stable pulse. Once the music therapist synchronizes the pulse of the music with the newborn's breathing, the music will be gradually become slower (approximately 10-15%), the volume will be adjusted, and the complexity of the music will be reduced until the patient can transition to a state of greater relaxation. The music therapy session will last 10 minutes, after which the music therapist will leave the room.
214601012|NCT07147023|OTHER|LLM SIC Summary Email|"A Large Language Model-based platform is integrated with the Health Vision Platform, a HIPAA-compliant, electronic health record data management system. Real-time summaries of prior SIC with be sent to clinicians caring for participants in the intervention arm.~An email will be sent to the inpatient attending and responding clinician encouraging the team to review the SIC summary, discuss care preferences with the patient and ensure care is aligned with preferences and goals. If no SIC documentation is found, the email will instead encourage the outpatient oncologist to share information regarding undocumented SICs that may have occurred, as well as prompt inpatient and outpatient teams to engage the patient in SIC.~For patients with no SIC documentation who are still admitted 72 hours later, the RA will send an additional email prompting SIC or asking the clinician to indicate that an SIC is not appropriate. Patients will also receive standard of care."
214601013|NCT07146750|COMBINATION_PRODUCT|SAR445229|Single dose
214601014|NCT07152197|OTHER|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training Supervised (RET) focusing on lower limbs. Warm-up (5 min cycling), followed by 5 sets of leg press, leg extension, leg curl, and weighted dorsiflexion. Cool-down with flexibility exercises. Load progression from 60% to 80% of 1Repetition Maximum across 8 weeks. Participants must complete ≥80% of sessions. Evaluators of pre- and post-intervention outcomes will be blinded.
214601015|NCT07151937|DRUG|LAD191|LAD191 subcutaneous injection.
214601016|NCT07151937|OTHER|Placebo|LAD191 Placebo subcutaneous injection.
214601017|NCT07151937|DRUG|Adalimumab|Adalimumab subcutaneous injection.
214601018|NCT07154654|DRUG|Mexiletine|Non interventional
214601019|NCT07158112|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214601020|NCT07158112|DRUG|Test Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214601021|NCT07158112|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214601022|NCT07155421|OTHER|Early Cardiopulmonary Rehabilitation|An individualized CPR program including positioning, deep breathing exercises (diaphragmatic and segmental breathing exercises), pursed-lip breathing exercises, breathing exercises using incentive spirometry, and progressive mobilization exercises (in-bed range of motion exercises, sitting, standing, and walking exercises)
214601023|NCT07155421|OTHER|Routine in-hospital care|Routine in-hospital care for acute decompansated heart failure
214601024|NCT07152249|OTHER|AW-D Clinical Decision Support Tool|The AW-D Clinical Decision Support Tool will test the automatic delivery of best practice advisories for antiemetic medications at critical timepoints in the perioperative period.
214601025|NCT07155707|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
214601026|NCT07155707|OTHER|Standard Videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform.
214601027|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|Low dose
214601028|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.4%|High dose
214601029|NCT07163182|BIOLOGICAL|CHF6467 Part 1 (SAD)|Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts
214601030|NCT07163182|BIOLOGICAL|CHF6467 Part 2 (MAD)|Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts
214601031|NCT07163182|DRUG|Placebo|Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2
214601032|NCT07161219|DEVICE|inspiratory muscle training|inspiratory muscle training for intervention group
214601033|NCT07162493|BEHAVIORAL|ATTACH|"ATTACH(TM) is a manualized, 10-session, mentalizing/reflective functioning-based parenting program, with one 45-60-minute weekly session. It is conducted individually with one parent focusing on one child throughout the program; however, a co-parent/parental support person will participate in session 7 and session 9. A session includes three components to facilitate parental reflective functioning: 1)Video-review of parent-child interaction, 2) reflection on a hypothetical situation (pre-defined for each session), and 3) reflection on a mildly stressful situation from the parent's everyday life with the child. The parent's reflective process is supported by handouts, e.g., emotion cards. All material used in the sessions have been translated into Danish, and the wording have been modified to fit with the cultural context, based on feedback from two pilot studies. ATTACH is facilitated by professionals employed at the family centers, who have been trained and certified in ATTACH."
214601034|NCT07162493|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual (TAU) consists of the standard services and support typically offered to families by the local social- and healthcare systems within each municipality. These services vary depending on individual needs, risk assessment of the family, and municipal practices, but often include individual and/or group-based parenting support or therapeutic services at the trial site and/or in the parent's home. TAU may also involve referrals to additional resources or interventions deemed necessary by social authorities or healthcare providers (e.g., psychiatric treatment in the region). The control group will not receive the ATTACH™ program but will have access to all relevant standard care options available within their municipality. TAU can be delivered by different professionals, such as health visitors, social workers, family therapists/counsellors or clinical psychologists. For more details on TAU services at each trial site, see the attached project protocol.
214601035|NCT07167589|PROCEDURE|Cataract surgery with implantation of a single-piece microincisional IOL|
214601036|NCT07161713|BEHAVIORAL|Oncology-informed yoga|8 weekly sessions of cancer informed-yoga incorporating light movement, breathing techniques, and some meditation practices
214601037|NCT07161713|BEHAVIORAL|SMART|SMART, developed by the Impact Foundation, is an adaptation of Mindfulness-based Stress Reduction (MBSR) approach that incorporates other elements like mindful self-compassion, emotional literacy, and positive psychology principles to address the unique stressors faced by teachers.
214601038|NCT07168772|DIETARY_SUPPLEMENT|Lactibane Iki|Patients will receive a probiotic sachet twice a day for six months. The probiotic, Lactibiane iki (Pileje; Paris, France), is composed of Bifidobacterium lactis LA 304, Lactobacillus acidophilus LA 201, and Lactobacillus salivarius LA 302 and contains 4x10E10 CFU/sachet.
214601039|NCT07168772|OTHER|Placebo|Patients will receive a placebo (starch) sachet twice a day for six months.
214711593|NCT00118911|OTHER|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
214601040|NCT07162805|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg are titrated if insertion is unsuccessful.
214601041|NCT07162428|BEHAVIORAL|Art Therapy|"The art therapy sessions will be conducted by a certified art therapist who has completed a two-year training program, together with a psychiatric nurse who has completed a 4-hour training course on Severe Personality Disorders and Therapeutic Interventions - Art Therapy. A clinical nurse and a psychiatry resident will also participate as observers. The therapist will deliver the intervention through semi-structured sessions, following a predefined content and method. These sessions are referred to as Semi-Structured Art Therapy Sessions."
214601042|NCT07164443|BIOLOGICAL|Pasritamig|Pasritamig will be administrated through IV infusion.
214601043|NCT07164443|OTHER|Placebo|Placebo will be administrated through IV infusion.
214601044|NCT07164443|DRUG|Best Supportive Care (BSC)|BSC will be administered as per physician.
214601045|NCT07160244|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
214601046|NCT07160244|BIOLOGICAL|Placebo|Saline Control
214601047|NCT07160244|BIOLOGICAL|Infanrix hexa|Vaccine administered in a subset of infant participants as per the national immunization schedule
214601048|NCT07160244|BIOLOGICAL|Prevenar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
214601049|NCT07160244|BIOLOGICAL|Pediarix|Vaccine administered in a subset of infant participants as per the national immunization schedule
214601050|NCT07160244|BIOLOGICAL|Prevnar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
214601051|NCT07160244|BIOLOGICAL|Infanrix|Vaccine administered in a subset of infant participants as per the national immunization schedule
214601052|NCT07155148|OTHER|observational study|Observational registry without clinical interventions
214601053|NCT07173660|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
214601054|NCT07174297|DRUG|Acotiamide|Both these drugs are used for the management of PDS type of FD
214601055|NCT07157865|DEVICE|Prism adaptation training combined with TENS|Subjects in the experimental group will receive both prism adaptation training and TENS to identify affects on USN. To date there are no published studies combining these treatments to minimize USN.
214601056|NCT07157865|OTHER|PAT only|Subjects will receive prism adaptation training (PAT) only wearing prism goggles during a functional reaching task during occupational therapy.
214601057|NCT07173205|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
214601060|NCT07173634|OTHER|Speaking Valve Trial|The speaking valve group ascertains a patient's eligibility for decannulation following the results of the speaking valve test. A patient who can endure a 4-hour trial with a speaking valve, maintaining a pulse oxygen saturation (SpO₂) of at least 95%, a breathing rate (RR) below 20 per minute, and exhibiting no signs of distress throughout the trial, qualifies for decannulation.
214601061|NCT07173634|OTHER|Capping Trial|The capping valve group determines a patient's eligibility for decannulation based on the results of the capping test. A patient who can tolerate 48 hours of capping with a pulse oxygen saturation (SpO₂) of ≥95%, a breathing rate (RR) of \<20/min, and no signs of distress during the 48-hour trial, is eligible for decannulation.
214601062|NCT07175233|DRUG|SIM0278 injection|SIM0278 injection
214601063|NCT07175233|OTHER|Placebo|placebo
214601064|NCT07172958|BIOLOGICAL|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
214601065|NCT07179861|OTHER|AI Suggestions (Anonymized 5-tool panel)|"What: Display of AI-generated suggestions for each vignette, aggregated from five large language model tools (names not shown to participants).~When/Who: Shown only in Group 2, after the physician's initial answer and confidence score.~Purpose: Measure AI performance (primary) and quantify the effect of AI suggestions on physicians' answers (secondary).~Applies to: Group 2."
214601066|NCT07179861|OTHER|Confidence Rating Task (1-10 Likert)|"What: Self-rated confidence for the initial answer on a 1-10 scale. When/Who: Group 2 before viewing AI suggestions. Purpose: Quantify confidence changes pre- vs post-AI and relate confidence to correctness.~Applies to: Group 2."
214601067|NCT07167316|DRUG|DMTN|Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine by inhibiting activity in the locus coeruleus, a key brain region involved in arousal and stress responses. In this study, dexmedetomidine will be administered as an oro-dispersible tablet applied buccally, allowing for rapid absorption through the oral mucosa.
214601068|NCT07167316|OTHER|Auditory Stimulation|Auditory tones will be presented throughout the night at individually calibrated intensities, adjusted to each participant's hearing threshold, in order to induce controlled sleep fragmentation without full awakenings.
214601069|NCT07167316|DRUG|Placbo|Oro-dispersible placebo tablet identical in appearance and packaging to the active Dexmedetomidine tablet.
214601070|NCT07182045|OTHER|Temporary clamping of uterine and ovarian vessels|Surgeon will temporarily clamp uterine and ovarian vessels.
214601071|NCT07172152|BEHAVIORAL|HRV Biofeedback Training|Participants will be trained to use HRV biofeedback through paced breathing exercises (6 breaths per minute) twice daily over a four-week period.
214601072|NCT07182188|DEVICE|Vascular Interventional Robotic System|The cerebral angiography will be performed by using the vascular interventional robotic system
214601073|NCT07182162|OTHER|Remote supervision + simulation|teacher use remote supervision to assist peer training Hospital-at-Home scenario simulation
214601074|NCT07179354|DEVICE|Rapid Maxillary Expansion with Face Mask (RME/FM)|A tooth- and tissue-borne rapid maxillary expansion appliance with an expansion screw was used to achieve transverse maxillary expansion, followed by Petit-type face mask therapy. Expansion protocol: two quarter-turns per day for 10-14 days, then one quarter-turn per day until cusp-to-cusp relationship was achieved. Face mask elastics applied 16 hours/day at 350-500 g per side, with a 30° downward and forward vector relative to the occlusal plane.
214601075|NCT07179354|DEVICE|Mini Maxillary Protractor (MMP)|An intraoral mini maxillary protraction appliance was used to advance the maxilla. Force was applied through intraoral elastics connected to intraoral anchorage units. The protocol was designed to deliver orthopedic forward traction of the maxilla without an external face mask.
214601076|NCT07179354|DEVICE|Modified Splint with Elastics and Chin Cup (Modified SEC III)|A modified splint appliance combined with intraoral elastics and an orthopedic chin cup was used to achieve skeletal mandibular retrusion and Class III correction. The appliance applied orthopedic forces through combined vertical and horizontal components, promoting backward positioning of the mandible while maintaining transverse maxillary relationships.
214601077|NCT07179224|DEVICE|Treatment with EXOMIND (BTL-699-2)|Transcranial magnetic stimulation with the EXOMIND (BTL-699-2) device will be delivered across various stimulation locations. The intensity will be carefully adjusted based on subject feedback, but it should not exceed 70% of the motor threshold.
214601078|NCT07172594|DRUG|Lactium|Lentra sachet (containing 150 mg Lactium) will be totally dissolved in 100 ml water and 50 ml will be given to cases, 2 hours before surgery.
214601079|NCT07172594|OTHER|Placebo control|50 ml water added to it powdered vanilla flavor will be given to cases 2 hours before surgery.
214601080|NCT07180472|DRUG|Cilostazol|Oral administration of cilostazol
214601081|NCT07180472|DRUG|Aspirin|Oral administration of Asprin
214601082|NCT07180472|DRUG|Clopidogrel|Oral administration of Clopidogrel
214601083|NCT07179458|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
214601084|NCT07182097|DRUG|Fentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia|Patients will receive fentanyl 2 µg/kg IV bolus at induction, followed by a continuous infusion of 1-2 µg/kg/h during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
214601085|NCT07182097|DRUG|Remifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia|Patients will receive remifentanil 1 µg/kg IV bolus at induction, followed by a continuous infusion of 0.1-1 µg/kg/min during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
214601086|NCT07182227|GENETIC|PS-002|Adeno-associated viral vector containing the human Complement Factor I (CFI) gene
214601087|NCT07180810|DRUG|Dexmedetomidine infusion low dose|low dose dexmedetomidine infusion at rate 0.6mcg/kg/hour rate .
214601088|NCT07180810|DRUG|Group B receiving normal saline|Normal saline infusion at rate 0.6mcg/kr/hour rate
214601089|NCT07176767|DEVICE|Positive airway pressure therapy|Initiation of continuous or bilevel positive airway pressure therapy
214601090|NCT07184385|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
214601091|NCT07184385|BIOLOGICAL|Placebo|Normal Saline
214601092|NCT07179367|OTHER|Escape Room-Based Teaching Method on Patient Safety|Intervention Description: This intervention is a patient safety-themed escape room simulation specifically designed for nursing students. The activity consists of three phases structured in accordance with INACSL standards: pre-briefing, escape room simulation, and post-briefing assessment. Working in small groups, students solve knowledge- and skill-based patient safety tasks in three different rooms (patient safety, mother-baby room, and adult intensive care unit). Correct answers ensure progress, while post-briefing assessment using the PEARLS method supports reflection and learning. Unlike traditional teaching, this innovative method emphasizes teamwork, active participation, and experiential learning to increase self-efficacy and satisfaction with patient safety practices.
214601093|NCT07174622|DEVICE|Renal Denervation (Symplicity Spyral™)|Symplicity Spyral™ multi-electrode renal denervation system
214601094|NCT07175402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos. The intervention is expected to have the following overall structure: Session 0: Individual videoconference meeting, introduction. Session 1: Creative hopelessness and mindfulness. Session 2: The body, acceptance, and values. Session 3: Compassion. Session 4: Cognitive defusion and committed action. Session 5-7: Personalised content (in-depth material and tasks based on individual difficulties assessed with diary). Session 8: Summary of intervention.
214601095|NCT07175402|OTHER|Psychoeducation|Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company. Session 0: Individual session, introduction. Session 1-8: The content will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS.
214601096|NCT07182019|BEHAVIORAL|Connecting Today|Connecting today is a facilitated remote visiting program for people living with moderate to severe dementia in care homes. The program offers residents up to 60 minutes of scheduled contact with a family member, friend or volunteer by video call. An onsite facilitator supports the video calls which are delivered via ipad/zoom.
214601097|NCT07177430|DEVICE|Inspiratory Muscle Training|"Participants will perform inspiratory muscle training using a respiratory muscle trainer. The initial training load will be set at 30% of PImax.~The intervention will last for 8 weeks and will be carried out 5 days per week, twice daily, in 3 sets of 10 repetitions.~The training load will be increased in the 2nd, 4th, and 6th week of the program, each time by an additional 10% relative to the initial PImax."
214601098|NCT07177430|DEVICE|Inspiratory Muscle Training (Sham)|"The training intervention in the Sham Group will differ from the experimental group only in terms of training load.~This load will remain constant at 15% PImax, which does not cause any changes in the functioning of the inspiratory muscles.~All other training parameters will be identical to those in the IMT group."
214601099|NCT07181447|DIAGNOSTIC_TEST|Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy|This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations.
214601100|NCT07188363|PROCEDURE|Ligament reconstruction|Retensioning involves restoring the tension in a ligament or soft tissue that has become lax, often due to injury or joint instability. This technique is typically used for ligaments that do not require complete reconstruction but have lost their functional tension. Ligament reconstruction is a surgical procedure to replace or repair a damaged ligament, often using grafts (autografts or allografts). It aims to restore joint stability and function, particularly in cases of significant ligament damage or rupture. Syndesmosis surgery involves repairing or reconstructing the fibrous joint between two bones (e.g., the tibia and fibula). It may involve screw fixation, suture-button devices, or grafts to restore the alignment and stability of the syndesmosis.
214711594|NCT04699071|DRUG|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
214601101|NCT07187492|DRUG|Bacillus coagulans|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Bacillus coagulans 1050 mg three times daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Bacillus coagulans 1050 mg three times daily."
214601102|NCT07187492|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency)."
214601103|NCT07189026|DIAGNOSTIC_TEST|Airway opening pressure|Airway opening pressure will be measured within one hour of intensive care unit admission (using a standardized low-flow insufflation maneuver flow 5-6 LPM). The inflection point on the pressure-time or pressure-volume waveform- depending on ventilator model-will define the airway opening pressure.
214601104|NCT07188636|OTHER|No Intervention: Observational Cohort|Participants underwent non-cardiac surgery and were followed retrospectively without any experimental intervention. Data were collected from electronic medical records and national death registry to assess postoperative mortality outcomes.
214601105|NCT07188610|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.
214601106|NCT07188818|DEVICE|Decoria Essence|Decoria® Essence is a hyaluronic acid based, BDDE-crosslinked dermal filler. Decoria® Essence dermal fillers are injected into dermal tissue to improve the volume and the contouring of the lips to desired level of correction by supporting the overlying tissue. Injection volume will be determined by the treating investigator according to the instructions for Use (IFU).
214601107|NCT07188688|DEVICE|Musculoskeletal Ultrasound Device|Musculoskeletal Ultrasound assessment by LOGIQ P10 from General Electric (GE) Healthcare, each patient will be evaluated by grey scale, power doppler MSUS and Shear Wave Elastography (SWE)
214601108|NCT07188584|RADIATION|Reduced-Target Radiotherapy|Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).
214601109|NCT07188584|RADIATION|Conventional Full-Target Radiotherapy|Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.
214601110|NCT07188701|BEHAVIORAL|Telerehabilitation Exercise Program|"1. Telerehabilitation Exercise Program~   Intervention Description:~   A 6-week structured telerehabilitation exercise program delivered via Zoom under the supervision of a physiotherapist. Sessions were conducted 4 days per week, approximately 20-30 minutes each. Exercises focused on posture correction, cervical stabilization, mobility, and pain management strategies.~2. Home Exercise Program~Intervention Description:~A 6-week home exercise program for chronic non-specific neck pain. Exercises were demonstrated once weekly via Zoom by a physiotherapist, and participants performed them independently at home on the remaining days. Each session lasted 20-30 minutes and included stretching, strengthening, and posture training."
214601111|NCT07187895|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
214601112|NCT07188168|DEVICE|Miller mobility measurement|Tooth mobility at different levels of mobility was assessed using Miller, Periotest and Osstell, and was evaluated both subjectively and objectively.
214601113|NCT07189325|DRUG|Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)|"Patients randomized in the experimental group will be treated with platform therapies (Dimethyl Fumarate, Diroximel Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) according to treatments' authorization from the day of randomization to M36 described below.~Patients will receive appropriate information and recommendation for the initiation of the chosen platform treatment as mention in the SmPC by treating neurologist or a member of the investigating team. If therapies are not tolerated, a therapeutic switch to other platform therapies will be possible. Any switch to a disease modifying therapy not listed as platform therapy will be considered as a major protocol deviation (see statistics).~Patients are allowed to switch from any platform DMT to another platform DMT."
214601114|NCT07189325|DRUG|Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)|"Patients randomized in the control group will be treated every 6 months (or at previous extended interval dosing) for patients with anti-CD20 (Ocrelizumab, Rituximab) or every 4 weeks for patients with subcutaneous anti-CD20 (Ofatumumab) from the day of randomization to M36. If therapies are not tolerated, a therapeutic switch to other anti-CD20 therapy will be possible. Any switch to a disease modifying therapy not listed as anti-CD20 therapy will be considered as major protocol deviation (see statistics).~Patients are allowed to switch from any anti-CD20 to another anti-CD20."
214601115|NCT07188376|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each iTBS session includes 600 pulses delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), in 2 sec on / 8 sec off cycles at 110% resting motor threshold (RMT). Stimulation is ramp-up from 80% to 110% RMT (\~90 pulses). Two iTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
214601116|NCT07188376|DEVICE|Continuous Theta Burst Stimulation|Continuous Theta Burst Stimulation (cTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each cTBS session includes 2 bouts of 1800 pulses separated by a 1 minute rest period. Each bout is delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), continuously for \~120 seconds at 110% resting motor threshold (RMT). Stimulation is ramped up from 80% to 110% RMT over the first 30 seconds. Two cTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
214601117|NCT07188376|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation (TMS) is delivered to the left DLPFC using the sham side of a MagVenture TMS coil, paired with synchronized scalp electrodes to mimic the sensation of real TMS. The sham procedure matches the timing and auditory cues of either iTBS or cTBS protocols, depending on random assignment. Two sham stimulation sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
214601118|NCT07187622|OTHER|examine the impact of education|The mothers in the study group were given education about neonatal jaundice and were trained to increase the mothers' knowledge level and to prevent neonatal jaundice.
214601119|NCT07188116|OTHER|COVID-19|The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
214601120|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|Keep vein open rate
214601121|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements
214601122|NCT07187323|OTHER|Saliva sampling|Unstimulated, whole saliva was collected from all participants across the six study groups following a detailed explanation of the procedure. Initially, individuals were asked to rinse their mouths with filtered water and remain seated in a relaxed position for five minutes. Then, they were instructed to passively drool into a sterile collection tube over a 10-minute period.31 The collected saliva samples were then centrifuged at 3000 ×g for 10 minutes to remove debris and prepare them for storage at -80°C .
214601123|NCT07187323|OTHER|Amino Acid Analysis|Saliva samples were deproteinized by mixing with 6% sulfosalicylic acid in a 1:1 ratio, followed by incubation at room temperature for 5 minutes. The mixtures were then centrifuged at 15,000 rpm for 5 minutes. A 10 µL aliquot of the resulting supernatant was diluted with 800 µL of 2 mM tridecafluoroheptanoic acid containing 0.375 M glucosaminic acid and internal standards. The prepared solutions were transferred into autosampler vials for analysis. Calibration standards were generated by combining known concentrations of amino acid standards.
214601124|NCT07188545|DRUG|Intervention|"GLP-1RA and/or SGLT2i adult users with ≥1 prescription for the intervention GLP-1RA or SGLT2i medications (including combination drugs or mixed therapies with comparator medications).~GLP-1RAs include: Exenatide, Liraglutide, Semaglutide, Dulaglutide, Lixisenatide, Albiglutide, Tirzepatide.~SGLT2is include: Canagliflozin, Dapagliflozin, Bexagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin."
214601125|NCT07188545|DRUG|Active Comparator|"DPP4i or Oral Obesity Agent adult users with ≥1 prescription for the comparator DPP4i or Oral Obesity Agent medications AND no intervention GLP-1RA or SGLT2i prescriptions in first 30 days of follow up.~DPP4is include: Alogliptin, Saxagliptin, Linagliptin, Sitagliptin.~Oral Obesity Agents include: Orlistat, Naltrexone-bupropion, Phentermine-topiramate, Phentermine, Diethylpropion, Bupropion (off-label), Topiramate (off-label)"
214711595|NCT05656287|OTHER|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
214601126|NCT07188714|PROCEDURE|VATs decortication|"A long thoracoscopic instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniportal procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.~Irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura."
214601127|NCT07188714|PROCEDURE|VATs debridement|"Removal of pus, debris, granulation tissue is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations.~Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion"
214601128|NCT07189234|BEHAVIORAL|Time-restricted eating (TRE) + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hour eating window for the course of the study as well as receive nutritional counseling from the study dietician.
214601129|NCT07189234|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt the 10-hour eating window.
214601130|NCT07188129|DEVICE|Test Algorithm and Test Device|Test Algorithm analysis of 24-hour ECG Data collected with a Test Device
214601131|NCT07187505|DRUG|Venetoclax|Venetoclax is a selective BCL-2 inhibitor administered orally once daily. The dose will be adjusted according to the study protocol and patient tolerance.
214601132|NCT07187505|DRUG|All-trans retinoic acid|All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.
214601133|NCT07187505|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide (ATO) is administered intravenously once daily, in combination with ATRA and venetoclax, during induction and consolidation therapy.
214601134|NCT07187973|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
214601135|NCT07188246|RADIATION|Radiation|Stereotactic body radiation therapy to the breast
214601136|NCT07188246|DRUG|Pembrolizumab (KEYTRUDA®)|Two injections
214601137|NCT07187726|DEVICE|XAINET AI tool|The AI-based prediction of arm lymphedema risk is communicated to the patient and treating physician.
214601138|NCT07188753|OTHER|transcranial magnetic stimulation by accelerated & high-dose theta-burst, functional imaging guided, i|Participants will then be treated with 1,800 pulses of iTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) per session at 90% resting motor threshold and depth-adjustment to the personalized functional target. Each session will last 10 min followed by a 50-minute intersession interval. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 total pulses).
214601139|NCT07188571|DIAGNOSTIC_TEST|Gastric emptying scintigraphy|To assess gastric emptying rates in patients with simple obesity and diagnose the presence of gastric motility abnormalities.
214601140|NCT03660826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214601141|NCT03660826|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspiration and biopsy
214601142|NCT03660826|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214601143|NCT03660826|DRUG|Capivasertib|Given PO
214601144|NCT03660826|DRUG|Cediranib Maleate|Given PO
214601145|NCT03660826|PROCEDURE|Computed Tomography|Undergo CT scan
214601146|NCT03660826|BIOLOGICAL|Durvalumab|Given IV
214601147|NCT03660826|PROCEDURE|Echocardiography|Undergo Echo
214601148|NCT03660826|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214601149|NCT03660826|DRUG|Olaparib|Given PO
214601150|NCT07188051|DIETARY_SUPPLEMENT|Ovolux brand eggshell membrane powder|Unhydrolyzed eggshell membrane powder
214601151|NCT07188051|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
214601152|NCT07187908|DRUG|Efbemalenograstim alfa Injection|The patients with solid tumor who were at high risk for febrile neutropenia or intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia would be injected Efbemalenograstim alfa for primary/secondary prevention.
214601153|NCT07189221|BEHAVIORAL|Life Style Intervention|"The intervention consists of seven related components:~I. A Bluetooth-enabled weighing scale that syncs with the app to facilitate self-monitoring of weight.~II. Synchronous coaching sessions conducted on a 1:1 basis between the mHealth coach and participants. There will be 2 synchronous sessions, the first at enrolment and the second between 6-8 weeks postpartum. These sessions typically last 45-50 minutes in length with a follow-up summary video message of the goals discussed and, at the beginning of the mother's journey, the establishing of a change agreement. This is mediated through the live-video feature in the B2B\&Me+ mHealth coaching app, but the length and thus number of these sessions is determined by the woman. If the woman is diagnosed with GDM, there will be an opportunity for a third 15-minute synchronous coaching session to review and adjust any lifestyle goals to align with the individual's diabetes management plan.~III. Asynchronous mHealth coaching that uses a combi"
214711596|NCT05656287|OTHER|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
214711597|NCT05656287|OTHER|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
214711598|NCT04904588|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
214711599|NCT04904588|DRUG|Busulfan|Given IV pre-transplant as part of conditioning regimen
214711600|NCT04904588|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
214601154|NCT07189260|DEVICE|positive expiratory pressure|PEP therapy
214601155|NCT07188805|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 90±3 days
214601156|NCT07188805|DRUG|Placebo|Placebo to finerenone, treatment duration will be 90±3 days
214601157|NCT07189078|PROCEDURE|Restrictive intubation strategy|"Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:~1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.~2. SpO₂/FiO₂ \< 88.~3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels."
214601158|NCT07189078|PROCEDURE|Liberal intubation strategy|"Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.~In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes."
214601159|NCT07187674|DRUG|Iparomlimab and tuvonralimab combined with olaparib and paclitaxel|The main objective of this study is to evaluate the tpCR of early high-risk TNBC with HRD positive treated with Iparomlimab and tuvonralimab combined with olaparib and paclitaxel as neoadjuvant therapy
214601160|NCT07189299|DRUG|LSD 10 μg every Day|Participants will receive 10 μg LSD every day during the luteal phase
214601161|NCT07189299|DRUG|LSD 10 μg every other day|Participants receive 10μg LSD every second day during the luteal phase
214601162|NCT07189299|DRUG|Placebo|Participants receive inactive placebo during the luteal phase
214601163|NCT07188844|DRUG|Batoclimab|Batoclimab 340 mg SC QW
214601164|NCT07187934|DEVICE|AI algorithm|iDAScore® is a deep learning-based tool that provides fully automated analysis of embryo time-lapse images. It automatically generates a score (1-9.9) for each embryo in the patient's embryo cohort, which correlates to the likelihood of achieving a fetal heartbeat (clinical pregnancy).
214601165|NCT07188974|PROCEDURE|Arthrocentesis (lavage only)|A minimally invasive procedure in which the temporomandibular joint (TMJ) space is washed with sterile solution to remove inflammatory mediators and improve joint mobility.
214601166|NCT07188974|PROCEDURE|Arthrocentesis + Injectable Platelet-Rich Fibrin (i-PRF)|Autologous platelet-rich fibrin prepared by centrifugation of the patient's blood and injected intra-articularly into the TMJ following arthrocentesis. i-PRF contains platelets, leukocytes, and growth factors, which may promote tissue regeneration and healing.
214601167|NCT07187362|BIOLOGICAL|Use iliac bone graft|
214601168|NCT07187362|BIOLOGICAL|use bone morphogenetic protein|
214601169|NCT07187362|BIOLOGICAL|use bone derived allograft MSCs|
214601170|NCT07187362|BIOLOGICAL|Use adipose tissue derived MSCs|
214601171|NCT07187362|BIOLOGICAL|Use amnion/placental derived MSCs|
214601172|NCT07187661|DRUG|Intra-articular Bevacizumab|This clinical trial investigates the intra-articular injection of Bevacizumab, a recombinant humanized monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). The intervention functions by binding to and neutralizing VEGF-A, thereby blocking the pathogenic angiogenesis and vascular permeability that characterizes chronic hemophilic synovitis. For administration, the first four patients will receive a dose of 20 mg in 0.8 mL per injection, and if this is well-tolerated without major toxicities, the dose for all subsequent patients will be increased to 40 mg in 1.6 mL. Each injection will be administered directly into the target joint (knee, elbow, or ankle) once every 28 days for a total of four doses. Crucially, all injections will be performed only after appropriate prophylactic factor replacement to mitigate any procedure-related bleeding risk.
214601173|NCT07187583|DRUG|increased dosing interval of biological therapy|Increasing dosing interval of biological therapy for CRSwNP from every 4 weeks to every 6 weeks and if continued satisfactory response then to every 8 weeks.
214601174|NCT07189286|BEHAVIORAL|PAVE intervention|The commercial virtual reality app that will be used for the intervention, Supernatural, provides participants a trainer as they use their arms and legs (e.g., seated knee strikes) to smash targets to 500+ musical tracks. In this manner, this study employs fun as a motivator for exercise commencement and adherence while hospitalized. The research assistant will implement the intervention using the four-step approach including: (1) patient mobility screen, (2) orientation to the technology and intervention, (3) goal setting for physical activity, and (4) ongoing assessment, adaptation, and motivation.
214601175|NCT07189286|BEHAVIORAL|Education control|"Education control participants will receive and physical activity education using the NIH Get Fit for Life booklet."
214601176|NCT07187635|PROCEDURE|Second Transurethral Resection of Bladder Tumor (re-TURBT)|Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, in accordance with current clinical guidelines.
214601177|NCT07187635|DIAGNOSTIC_TEST|utDNA Testing (Urine Tumor DNA Detection)|"Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing.~If utDNA is positive, the patient will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery.~If utDNA is negative, re-TURBT will be omitted and patients will proceed to guideline-based adjuvant therapy or surveillance."
214601178|NCT07188779|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
214601179|NCT07188142|DRUG|Drug/Agent: Gluma Desensitizer|Gluma desensitizer applied to prepared tooth surface, followed by universal bonding agent and composite restoration. Application done during the first visit of restorative treatment. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
214601180|NCT07188142|DRUG|Drug/Agent: No desensitizer (Control)|Universal bonding agent applied followed by composite restoration without prior use of Gluma desensitizer. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
214601181|NCT07187882|PROCEDURE|Autologous Non-cultured Epidermal Cell Suspension transplantation|"1. Thin split thickness skin grafts were taken from the donor site (anterolateral thigh) after application of topical anaesthesia under complete aseptic precautions.~2. The cell suspension was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd).~3. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared.~4. The cell suspension was applied onto the dermabraded recipient area.~5. The recipient site was then fixed firmly with dressings and elastic bandage. The dressings were removed 10 days after transplantation."
214601182|NCT07188649|BEHAVIORAL|oxygen deficiency|The aim of this study is to evaluate the effect of the Reverse Trendelenburg position on oxygenation (SpO₂/FiO₂ ratio) in the early postoperative period in patients undergoing laparoscopic surgery. In our study, obesity is considered as a comparative subgroup in terms of variability of this effect; additionally, the STOP-BANG score, which measures the risk of obstructive sleep apnea syndrome, is examined as an auxiliary indicator.
214601183|NCT07188038|PROCEDURE|Low positive end-expiratory pressure|Low (4 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
214601184|NCT07188038|PROCEDURE|Medium positive end-expiratory pressure|Medium (10 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
214601185|NCT07188038|PROCEDURE|High positive end-expiratory pressure|High(16 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
214601186|NCT07188012|GENETIC|mRNA|mRNA therapy delivered by extracellular vesicles (EVs)
214601187|NCT07189195|DRUG|TR-002|Weekly intravenous infusion
214601188|NCT07187752|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)
214601189|NCT07187752|DRUG|Pertuzumab|Pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks)
214601190|NCT07187752|DRUG|Chemotherapy|Chemotherapy chosen by the investigators.
214601191|NCT07187752|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
214711601|NCT04904588|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
214711602|NCT04904588|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
214601192|NCT07189351|OTHER|Bowen Therapy|Participants received a hot pack, followed by Bowen Therapy performed in prone lying position on a plinth. Bowen moves were applied to soft tissues and muscles of the neck and upper back, aiming to reduce muscle tension and pain. Sessions lasted 15-20 minutes, administered on alternate days for 6 weeks. Assessments were conducted at baseline, 3rd week, 6th week, and at 3-week follow-up.
214601193|NCT07189351|OTHER|Muscle Energy Technique (Post-Isometric Relaxation)|Participants received a hot pack applied over the neck and upper back area for 7-10 minutes, followed by Muscle Energy Technique in supine lying position. Post-isometric relaxation was used for upper trapezius, levator scapulae, scalenus, and sternocleidomastoid muscles. A moderate isometric contraction was held for 5 seconds, followed by 3 seconds of relaxation, with 5 repetitions per muscle. Sessions were given on alternate days for 6 weeks. Assessments were performed at baseline, 3rd week, 6th week, and at 3-week follow-up.
214601194|NCT07187778|DRUG|Pembrolizumab|Oral administration
214601195|NCT07187778|DRUG|Belzutifan|Oral administration
214601196|NCT07189156|OTHER|Immediate Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be immediately weight bearing as tolerated after surgery.
214601197|NCT07189156|OTHER|Delayed Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
214601198|NCT07189156|OTHER|Immediate Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be immediately weight bearing as tolerated after surgery.
214601199|NCT07189156|OTHER|Delayed Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
214601200|NCT07187739|OTHER|Mediterranean diet|All individuals in the intervention group will be instructed to adhere to Mediterranean diet recommendations for a period of three months following the activation of the deep brain stimulation device. Nutritional training sessions focusing on the Mediterranean diet will be provided and reinforced during monthly follow-up interviews. In line with these recommendations, olive oil will be promoted as the primary dietary fat. Participants will be encouraged to consume a minimum of 300-400 grams of vegetables daily and 450 grams of fresh fruit or alternatively, 300 grams of fresh fruit and 30 grams of dried fruit. The consumption of bakery products, sugary snacks, and carbonated beverages will be discouraged. White meat will be favored over red meat in meal planning. Participants will also be advised to include 450 grams of fish, 30 grams of oilseeds, and 180 grams of legumes in their weekly diets. There is no routine Mediterranean diet recommendation after STN DBS.
214601201|NCT07188948|DEVICE|Skin conditions|Participants with skin conditions such as AK or participants without any skin conditions (healthy skin)
214601202|NCT07188948|DEVICE|Skin Condition|Participants with Skin conditions or participants without any skin conditions (Healthy)
214601203|NCT07189182|DEVICE|Origin Intubation System|This device leverages self-deploying geometry to guide intubation.
214601204|NCT07187388|DEVICE|Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS|"TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on.~Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place."
214601205|NCT07187791|DEVICE|CT scan|All Patients will undergo CT KUB cyst evaluation Qualitatively regarding Gross Picture in Imaging and Quantitavely using Hausfield units then patients will undergo Abdomianl ultrasound
214601206|NCT07189000|BEHAVIORAL|App-based prehabilitation program|A lightweight mobile/web application delivering a patient-centered prehabilitation program from randomization until surgery. Features include: weekly home six-minute walk tests (6MWT) logged in the app; brief daily check-ins for exercise performed, simple nutrition targets, and mood/stress; push reminders; short educational video/handout content; and CSV export for analysis. The app provides standardized instructions and safety prompts for the home 6MWT and basic validity checks (continuous 6 minutes, pause limits, outlier flags). No additional study-specific clinic visits are required beyond routine preoperative admission and one routine postoperative outpatient visit.
214601207|NCT07189000|OTHER|Usual care (ERAS-standard perioperative care)|Standard perioperative counseling/education and routine mobilization per institutional ERAS practice. No study app is provided and no remote 6MWT logging is required. Outcome assessments are collected at routine preoperative admission (including in-hospital 6MWT per protocol) and at one routine postoperative outpatient visit (≈3 or 6 months per unified site policy). No additional study-specific clinic visits are required.
214601208|NCT07188909|DRUG|Patient-Donor Derived Probiotics|To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
214601209|NCT07188740|DRUG|Metformin|Start at 500 mg twice daily, titrate to 2000 mg/day for 6 months
214601210|NCT07188558|BIOLOGICAL|rondecabtagene autoleucel|An autologous, dual-targeting CD19/20 CAR T-cell candidate.
214601211|NCT07188558|BIOLOGICAL|axicabtagene ciloleucel|An autologous CD19 CAR T-cell therapy
214601212|NCT07188558|BIOLOGICAL|lisocabtagene maraleucel|An autologous CD19 CAR T-cell therapy
214601213|NCT07187531|DRUG|High Dose SAB-142|High Dose SAB-142
214601214|NCT07187531|DRUG|Low Dose SAB-142|Low Dose SAB-142
214601215|NCT07187531|OTHER|Placebo|Placebo
214601216|NCT07189208|DRUG|Benzathine penicillin 2.4 million units|IM injection of BPG
214601217|NCT07189208|BEHAVIORAL|Counseling and intensified testing.|Brazilian Ministry of Health guidelines for the prevention and diagnosis of maternal syphilis consist of counseling about STI prevention and syphilis testing at the first pre-natal consultation, at a subsequent consultation during or after 28 weeks of pregnancy, at delivery, and in case of abortion or stillbirth. In this study, intensified testing refers to treponemal and non-treponemal tests once every four weeks beginning as of the 28th week of pregnancy.
214601218|NCT07187401|DRUG|ALN-CFB|Administered as defined in the protocol
214601219|NCT07187401|DRUG|Placebo|Administered as defined in the protocol
214601220|NCT07189065|DRUG|Rocbrutinib|200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc.
214601221|NCT07189065|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 28 days) 90 mg/m2 Bendamustine (IV infusion) on Days 1 and 2 of Cycles 1-6.
214601222|NCT07189065|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 28 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
214601223|NCT07189065|DRUG|Lenalidomide|20mg qd PO day 1-21
214601224|NCT07187830|DRUG|Semaglutide (1 Mg Dose)|standard of care treatment
214601225|NCT07188207|DRUG|Oxytocin|"Intravenous oxytocin administered per hospital protocol immediately after delivery of the baby and placenta (example regimen: 10 IU slow IV bolus followed by infusion e.g., 20 IU in 500-1000 mL isotonic crystalloid run over 2-4 hours; actual dosing adjusted per anesthesiologist/obstetrician and hospital policy). Document exact time, dose, and infusion rate in each case.~Single rectal dose of misoprostol 600-1000 µg (select dose based on patient risk profile; e.g., 600 µg for routine prophylaxis, 800-1000 µg for high-risk cases) inserted into the rectum immediately after delivery of the baby and placenta. No dilution required."
214601226|NCT07188025|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX). Duration of treatment will be 3 months (12 weeks).
214601227|NCT07188311|DRUG|Pucotenlimab ,Lenvatinib|A total of 24 cases are planned to be enrolled. All subjects will receive Pucotenlimab (3mg/kg, on Day 1, with a maximum dose not exceeding 200mg) once every 3 weeks (Q3W), in combination with Lenvatinib and Irinotecan. The chemotherapy regimen is fixed: Lenvatinib capsules 7mg/m2 (maximum 12mg) orally from Day 1 to 21 and Irinotecan 50mg/m2 from Day 1 to 5. Chemotherapy will be administered for 2 to 4 cycles, once every 3 weeks (Q3W).
214601228|NCT07188961|OTHER|kinesiologic taping|This intervention is distinguished from other studies by its combined assessment of trunk and extremity kinesiology taping in children with both hemiplegic and diplegic cerebral palsy over a four-week period.
214601229|NCT07187375|DRUG|Crinecerfont|Oral solution
214711603|NCT04904588|DRUG|Melphalan|Given IV pre-transplant as part of conditioning regimen
214601230|NCT07188831|OTHER|Agarwood Aromatherapy Inhalation|The experimental group will receive agarwood essential oil sachets as the aromatherapy intervention, and participants will place the sachet 60 cm from the nose during sleep for one week.
214601231|NCT07188155|BEHAVIORAL|Exposure Therapy for Anorexia (Exp-AN)|"Exp-AN is specifically designed to target anxiety about weight gain. Exp-AN helps participants identify their specific feared consequences of weight gain (e.g., I will permanently hate myself if I gain weight), and combines in vivo (i.e., in real life) and imaginal (i.e., mental) exposure exercises to address these fears."
214601232|NCT07188064|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|Somatic to autonomic nerve grafting procedure which uses a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
214601233|NCT07188662|PROCEDURE|group (B) Prehabilitation care combine with ERAS post-operative care|intervention will includes receiving prehabilitation care combine with ERAS post-operative care.
214601234|NCT07187960|DRUG|TQB2825 Injection|TQB2825 is a Cluster of Differentiation 3 (CD3) × Cluster of Differentiation 20 (CD20) bispecific antibody.
214601235|NCT07187960|DRUG|Rituximab Injection|Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA, Dexamethasone)
214601236|NCT07188103|DRUG|Ivonescimab+Radiotherapy|Short-course hypofractionated radiotherapy was administered to progressive lesions after first-line treatment, with a prescribed dose of 20 Gy in 5 fractions (95% PTV). The monoclonal antibody was initiated within 1 week after completing the radiotherapy regimen, at a dose of 20 mg/kg. Ivonescimab was administered every three weeks until disease progression, intolerable toxicity, or patient refusal.
214601237|NCT07188272|DIETARY_SUPPLEMENT|DASH diet|Eating vegetables, fruits, and whole grains Including fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils Limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and tropical oils such as coconut, palm kernel, and palm oils Limiting sugar-sweetened beverages and sweets
214601238|NCT07188272|PROCEDURE|High Intensity Interval Training|High Intensity Interval Training
214601239|NCT07188415|DEVICE|Ankle-foot Orthoses|Group 1 will consist of individuals who have CMT and have undergone surgical correction (OP) and Group 2 will be AFO users who have CMT but have not undergone major surgical correction (NonOP).
214601240|NCT07188441|DRUG|Teniposide Injection|teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days
214601241|NCT07188402|OTHER|Prevalence of sleep disturbances in patients with bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
214601242|NCT07188402|OTHER|Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
214601243|NCT07187453|BEHAVIORAL|Personalized Oral Hygiene Advice using AI assisted mHealth Tool by Non-Dental Personnel|The intervention involve the delivering personalized oral hygiene advice using AI assisted gum disease screening tool by non-dental personnel social workers. Our proposed intervention involve AI to assist in the self-detection of gum disease, and emphasizes the use of mHealth for disease prevention and monitoring. Moreover, the proposed project focuses on providing personalized oral hygiene instruction, which can be utilized or provided by non-dental personnel volunteers. This combination of AI, mHealth, and personalized instruction in addition with regular service of non-dental personnel volunteers is a novel approach in managing periodontal health among older adults.
214601244|NCT07189169|DRUG|QA108 granules|Take the medication as required for 24 weeks
214601245|NCT07189169|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
214601246|NCT07189338|PROCEDURE|Apneic oxygenation|"* Preoxygenation will be performed using NIV for 3-5 min With nasal cannulas placed in standby beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0)~* Rapide sequence induction~* Hypoventilation phase will be continue for 1 min using NIV~* At the time of laryngoscopy :~After removing the facemask, the nasal cannulas of HFNO will be placed in the patient's nares then the laryngoscopy will be performed.~\* Use of capnography to confirm the success of procedure"
214601247|NCT07189338|PROCEDURE|Usual Care|"* Preoxygenation will be performed using NIV for 3-5 min without HFNO~* Rapide sequence induction~* Hypoventilation phase will be continue using NIV for 1min~* At the time of laryngoscopy :~After removing the facemask, laryngoscopy will be performed without oxygen.~\* Use of capnography to confirm the success of procedure"
214601248|NCT07188454|BEHAVIORAL|Mindfulness-Based Digital Intervention (AIZEN Program)|The intervention consisted of a 5-week mindfulness program designed for caregivers. Participants attended one live, instructor-led online class each week (90 minutes per session) delivered via Microsoft Teams. Between classes, they were asked to complete at least 10 minutes of daily guided mindfulness practice using the AIZEN digital platform. To encourage adherence, participants also received automated daily reminders through the LINE messaging service.
214601249|NCT07188233|DEVICE|Transcatheter Mitral Valve Repair|Mitral valve repair with the CathHELIX Transcatheter Mitral Annuloplasty System in subjects with functional Mitral Regurgitation
214601250|NCT07187544|DRUG|Calcium Chloride|Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.
214601251|NCT07187544|OTHER|Placebo|Intravenous administration of 100ml normal saline, over 10 minutes.
214601252|NCT07187544|DRUG|Carbetocin|50 mcg intravenous carbetocin.
214601253|NCT07187713|DRUG|ACE Reno|1 ml sublingual 4 times daily for 12 weeks
214601254|NCT07188532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214601255|NCT07188532|DRUG|Chemotherapy|Given chemotherapy
214601256|NCT07188532|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214601257|NCT07188532|PROCEDURE|Conventional Radiotherapy|Undergo conventional radiotherapy
214601258|NCT07188532|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
214601259|NCT07188532|RADIATION|Dose-escalated Radiation Therapy|Undergo hypofractionated or conventional radiotherapy
214601260|NCT07188532|OTHER|Electronic Health Record Review|Ancillary studies
214601261|NCT07188532|RADIATION|External Beam Radiation Therapy|Undergo definitive radiotherapy
214601262|NCT07188532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214601263|NCT07188532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214601264|NCT07188532|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214601265|NCT07188532|OTHER|Questionnaire Administration|Ancillary studies
214601266|NCT07188532|RADIATION|Radiation Therapy|Undergo hypofractionated or conventional standard radiotherapy
214601267|NCT07188519|OTHER|expressive writing|Each of the four rounds consisted of three consecutive days of writing followed by a gap week.
214601268|NCT07187947|DRUG|Feminizing GAHT|Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.
214601269|NCT07187947|DRUG|Masculinizing GAHT|Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)
214601270|NCT07187336|PROCEDURE|Shoulder MSAT Group|"Shoulder Motion Style Acupuncture Treatment (MSAT) involves inserting acupuncture needles into specific points around the shoulder joint, then guiding or assisting the patient's shoulder movements while the needles remain in place. This combined technique is intended to maximize acupuncture effects by stimulating both the needles and the joint motion.~In this study, MSAT will be performed once daily for three consecutive days (hospital days 2-4), in addition to standard integrative Korean medicine treatment (acupuncture, pharmacopuncture, Chuna manual therapy, and herbal medicine). Each MSAT session lasts about 10-20 minutes.~This distinguishes the intervention from the comparator arm, which receives integrative Korean medicine treatment only, without MSAT."
214601271|NCT07187336|PROCEDURE|Integrative Korean Medicine Only Group|"Participants in this group receive only standard integrative Korean medicine treatments, without MSAT. Treatments include acupuncture (6-10 points, 15-20 minutes per session), pharmacopuncture (injection of herbal extracts at acupuncture points), Chuna manual therapy (10-15 minutes daily), and herbal medicine (oral decoction extracts taken twice daily).~This arm serves as the comparator to distinguish the additional effects of MSAT, since both groups receive the same integrative Korean medicine but only the experimental arm includes Shoulder MSAT."
214601272|NCT06464562|BEHAVIORAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|An adapted dialectical behavioral therapy skills training intervention
214601273|NCT05490004|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
214601274|NCT05868811|BEHAVIORAL|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
214601275|NCT05868811|BEHAVIORAL|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
214601276|NCT03462342|DRUG|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
214601277|NCT03462342|DRUG|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
214601278|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
214601279|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
214601280|NCT02413840|BEHAVIORAL|Baduanjin qigong|
214601281|NCT06179576|BEHAVIORAL|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
214601282|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
214601283|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
214601284|NCT03620890|DRUG|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
214601285|NCT03620890|DRUG|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
214601286|NCT05976087|DEVICE|SensoExo|combination of sensory feedback and the use of soft exoskeleton
214601287|NCT04358263|DEVICE|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
214601288|NCT04358263|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
214601289|NCT02537418|DRUG|durvalumab|
214601290|NCT02537418|DRUG|tremelimumab|
214601291|NCT06018844|OTHER|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
214601292|NCT05163210|BEHAVIORAL|AO+VR|The experimental treatment will consist of 15 hours (min. 15, max. 20), and will be carried out 4 days/week for a total duration of 5 weeks. During the rehabilitation sessions, the patient will be instructed to carefully watch videos lasting about 1.5 minutes, presented on Liquid Crystal Display (LCD) monitor, consisting in unimanual or bimanual actions performed by an actor, from a lateral perspective. Subsequently, the patient will be asked to imitate the actions presented for at least 3 consecutive times, within a time window of 3 min., using the same objects observed in the video, in a virtual scenario (VR), through the Khymeia Virtual Reality Rehabilitation System (VRRS).
214601293|NCT05163210|BEHAVIORAL|CO+VR|Patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist. Thus, the general setting for carrying out the rehabilitation sessions will be identical to that of the experimental treatment, except for the fact that the control group will not be involved in action observation before preforming the exercises. Thus, the control treatment is not based on action imitation, but on purely motor execution.
214601294|NCT05818436|PROCEDURE|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
214601295|NCT05818436|DEVICE|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
214601298|NCT06010303|DRUG|LBL-007|LBL-007 will be administered at a standard dose intravenously.
214601299|NCT06010303|DRUG|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
214601300|NCT06010303|DRUG|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
214601301|NCT03633747|DRUG|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
214601302|NCT05249426|DRUG|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
214601303|NCT05249426|DRUG|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
214601304|NCT05249426|DRUG|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
214601305|NCT05249426|DRUG|Cetuximab|Cetuximab
214601306|NCT05249426|OTHER|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
214601307|NCT03884075|DRUG|Semaglutide|Semaglutide injection once weekly
214601308|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
214601309|NCT06457997|DRUG|PHN-010|PHN-010 is an ADC
214601310|NCT00210301|DRUG|Provigil (modafinil)|
214601311|NCT06088862|DRUG|Nicoderm|21mg nicotine patch daily; maximum usage 9 weeks
214601312|NCT06088862|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
214711604|NCT04904588|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
214711605|NCT04904588|PROCEDURE|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
214711606|NCT04904588|DRUG|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
214711607|NCT04904588|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
214711608|NCT04904588|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
214711609|NCT04904588|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
214711610|NCT04904588|OTHER|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
214711611|NCT06270602|OTHER|Data collection (retrospective)|Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
214711612|NCT06270602|OTHER|Data collection (prospective)|Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
214601313|NCT06088862|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
214601314|NCT06088862|OTHER|BIDI e-cigarette|BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks
214601315|NCT06088862|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks
214711613|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
214711614|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
214711615|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
214711616|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
214711617|NCT06533644|PROCEDURE|Partial Oncolysis|Partial tumor oncolysis will be completed by cryolysis.
214711618|NCT06533644|DRUG|SV-102|Intratumoral infusion of SV-102
214711619|NCT05507580|DRUG|Upadacitinib|Oral tablet
214711620|NCT00278096|BEHAVIORAL|occupational therapy|
214711621|NCT04702984|DEVICE|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
214711622|NCT04702984|DEVICE|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
214711623|NCT06169995|DRUG|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
214711624|NCT00092482|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
214711625|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
214711626|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
214711627|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
214711628|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
214711629|NCT04144179|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
214711630|NCT06226779|BEHAVIORAL|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
214711631|NCT06226779|BEHAVIORAL|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
214711632|NCT06226779|BEHAVIORAL|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
214601316|NCT04700046|DRUG|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
214601317|NCT04700046|DRUG|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
214601318|NCT04593888|BEHAVIORAL|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
214601319|NCT04697043|PROCEDURE|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
214601320|NCT03564743|DIAGNOSTIC_TEST|Evaluation of ASAS criteria|Perform ASAS criteria at the time of physician diagnosis of chronic low back pain in rheumatological practice.
214601321|NCT01992120|OTHER|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
214601322|NCT01992120|OTHER|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
214601323|NCT01509326|OTHER|chiropractic treatment|12 sessions over 4 weeks
214601324|NCT01509326|DEVICE|Dr. Zaxx pillow|Daily use of an acupressure pillow
214601325|NCT04264429|DEVICE|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
214601326|NCT04264429|OTHER|Elastic band|Orthotic device which is positioned over the patellar tendon
214601327|NCT00627029|BEHAVIORAL|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
214601328|NCT03248583|OTHER|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
214601329|NCT03248583|OTHER|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
214601330|NCT03248583|OTHER|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
214601331|NCT02198625|OTHER|Moderate FiO2 and Protective Lung Ventilation Using|
214601332|NCT01178320|DRUG|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
214601333|NCT04612036|DEVICE|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
214601334|NCT04612036|DEVICE|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
214601335|NCT04612036|DEVICE|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
214601336|NCT01191372|DRUG|placebo control|sterile saline for injection
214601337|NCT01191372|DRUG|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
214601338|NCT01460095|OTHER|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
214601339|NCT02014415|PROCEDURE|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
214601340|NCT05299775|DIAGNOSTIC_TEST|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
214601341|NCT04041089|BEHAVIORAL|Recognition of objects|"* Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects"
214601342|NCT04041089|BEHAVIORAL|Location of objects|"* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible"
214601343|NCT04041089|BEHAVIORAL|Manipulation of objects|"* Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)"
214601344|NCT00526409|DRUG|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
214601345|NCT00526409|DRUG|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
214601346|NCT00526409|DRUG|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
214601347|NCT00526409|DRUG|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
214601348|NCT00526409|DRUG|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
214601349|NCT00526409|DRUG|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
214601350|NCT00526409|DRUG|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
214601351|NCT04221763|DEVICE|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
214601352|NCT06178445|DRUG|SOC plus trastuzumab and pembrolizumab|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
214601353|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
214601354|NCT01545570|DRUG|GSK2376497|GSK2376497 Active Comparator
214601355|NCT01545570|DRUG|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
214601356|NCT01059136|DRUG|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
214601357|NCT06798454|DRUG|PVT201|"Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor.~PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells.~IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections.~PVT201 will be administered intravenously."
214601358|NCT06798454|OTHER|Placebo|Participants randomized to placebo will be administered normal saline IV.
214601359|NCT02926131|OTHER|Blood sampling|"* One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
214601360|NCT04436237|OTHER|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
214601361|NCT03855553|BEHAVIORAL|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
214601362|NCT03855553|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
214711633|NCT06973902|DEVICE|Cardiac Contractility Modulation (CCM) implant|"Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device OPTIMIZER Smart Mini by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.~The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.~The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium."
214601363|NCT01486953|DRUG|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
214601364|NCT01486953|DRUG|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
214601365|NCT01708239|OTHER|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
214601366|NCT05083338|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214601367|NCT05083338|PROCEDURE|Pain Assessment|Undergo pain assessment
214601368|NCT05083338|OTHER|Questionnaire Administration|Complete questionnaires
214601369|NCT04721093|DEVICE|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
214601370|NCT03891303|OTHER|Allogenic blood transfusion (ABT)|During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
214601371|NCT00594126|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
214601372|NCT00754143|DRUG|FG-3019|Placebo every 2 weeks IV for all infusions
214601373|NCT00754143|DRUG|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
214601374|NCT00754143|DRUG|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
214601375|NCT03736161|DRUG|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
214601376|NCT03736161|DRUG|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
214601377|NCT02367235|PROCEDURE|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
214601378|NCT02367235|PROCEDURE|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
214601379|NCT05839756|DRUG|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
214601380|NCT05839756|DRUG|normal saline|5 ml normal saline will be nebulized preoperatively
214601381|NCT06316531|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214601382|NCT06316531|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
214601383|NCT05887453|DEVICE|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
214601384|NCT00292656|PROCEDURE|NAET|
214601385|NCT04492345|OTHER|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
214601386|NCT04492345|OTHER|Conventional reeducation|Conventional rehabilitation session during 7 weeks
214601387|NCT03811639|PROCEDURE|Radio-frequency ablation|Ablation for atrial fibrillation
214601388|NCT03811639|PROCEDURE|Cryoballoon ablation|Ablation for atrial fibrillation
214601389|NCT04985305|BEHAVIORAL|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
214601390|NCT04985305|BEHAVIORAL|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
214601391|NCT04985305|BEHAVIORAL|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
214601392|NCT04985305|BEHAVIORAL|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
214601393|NCT04985305|BEHAVIORAL|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
214601394|NCT02960113|DRUG|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
214601395|NCT02960113|DEVICE|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
214601396|NCT05245409|OTHER|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
214711634|NCT05893420|DEVICE|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
214601397|NCT03756350|DEVICE|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
214601398|NCT04165590|OTHER|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
214601399|NCT05212454|DRUG|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
214601400|NCT06503029|DEVICE|Invisalign Cleaning Crystals|Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
214601401|NCT06503029|DEVICE|Fittey Dent Cleaning Tablet|Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
214601402|NCT06503029|DRUG|Listeren Mouthwash|Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
214601403|NCT06503029|DEVICE|Toothbrush and Water|Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
214601404|NCT03157232|DEVICE|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
214601405|NCT00561496|DRUG|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
214601406|NCT04656509|OTHER|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
214601407|NCT04405700|OTHER|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
214601408|NCT00514761|DRUG|AZD6244|oral vial
214601409|NCT00514761|DRUG|Capecitabine|oral tablet
214601410|NCT02090153|DRUG|S-1|40\~60mg bid，d1\~7 q2W
214711635|NCT05893420|OTHER|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
214711636|NCT06220838|DRUG|SC-101|All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
214711637|NCT04609280|RADIATION|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
214601411|NCT02090153|DRUG|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
214601412|NCT00109499|DRUG|AdGVPEDF.11D|
214601413|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
214601414|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
214601415|NCT04202952|DRUG|HEC110114 Tablet|administered orally once daily
214601416|NCT04202952|DRUG|Sofosbuvir Tablet|administered orally once daily
214601417|NCT05428137|DIETARY_SUPPLEMENT|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
214601418|NCT05428137|DIETARY_SUPPLEMENT|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
214601419|NCT05428137|OTHER|Placebo|Placebo in a form of a capsule given for 16 weeks
214601420|NCT04678323|DRUG|Lifestyle Management|Participants in this group will receive lifestyle management.
214601421|NCT01096342|DRUG|dinaciclib|Given IV
214601422|NCT01096342|OTHER|laboratory biomarker analysis|Correlative studies
214601423|NCT02513186|DRUG|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
214601424|NCT02513186|DRUG|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
214601425|NCT02513186|DRUG|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
214601426|NCT02513186|DRUG|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
214601427|NCT02513186|DRUG|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
214601428|NCT02014155|OTHER|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
214601429|NCT02014155|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
214601430|NCT04317950|OTHER|Vojta|Reflex locomotion stimulus
214601431|NCT04317950|OTHER|Sham|sham stimulus
214601432|NCT03298568|DIETARY_SUPPLEMENT|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
214601433|NCT03638934|OTHER|Videos about ACP|Three videos about advanced care planning are provided for self-education.
214601434|NCT03638934|OTHER|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
214601435|NCT06402981|OTHER|High risk prediction model for liver injury|Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
214601436|NCT02183532|DRUG|BI 1356 BS|single dose
214601437|NCT02183532|DRUG|BI 1356 BS|multiple doses
214601438|NCT02864420|OTHER|Home hospitalization|
214601439|NCT02864420|OTHER|Inpatient Hospitalization|
214601440|NCT03434353|DRUG|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
214711638|NCT05539807|BEHAVIORAL|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
214711639|NCT06206226|BEHAVIORAL|OHDC-DC|90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
214711640|NCT03496662|DRUG|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
214711641|NCT03496662|DRUG|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
214601441|NCT03434353|DRUG|TAF|Administered orally once daily with food
214601442|NCT00125879|BIOLOGICAL|Myozyme|20 mg/kg qow or 40 mg/kg qow
214601443|NCT00419718|DRUG|inhaled human insulin|
214601444|NCT01449877|DRUG|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
214601445|NCT01572701|DRUG|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
214601446|NCT01580150|OTHER|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
214711642|NCT03496662|DRUG|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
214711643|NCT03496662|DRUG|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
214601447|NCT01580150|OTHER|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
214601448|NCT03665896|DEVICE|intubation with VivaSight double-lumen tube|
214601449|NCT03665896|DEVICE|intubation with standard double-lumen tube|
214601450|NCT03665896|PROCEDURE|fiberoptic bronchoscopy|
214601451|NCT00244972|OTHER|Laboratory Biomarker Analysis|Correlative studies
214601452|NCT00244972|DRUG|Sorafenib Tosylate|Given PO
214601453|NCT00244972|DRUG|Tipifarnib|Given PO
214601454|NCT04906616|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
214601455|NCT04774770|BEHAVIORAL|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
214601456|NCT03255837|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
214601457|NCT02872077|OTHER|Auricular acupuncture|
214601458|NCT04358510|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
214601459|NCT04793269|OTHER|No intervention|no intervention
214601460|NCT06494709|OTHER|photographs|"Standardized photographs presenting 10 control subjects (class I) and patients with dentofacial deformities (10 class II and 10 class III) before and after surgery - from the front and from the side - will be used to form an approximately 10 min video sequence using the Tobii Pro Lab® software (Tobii Pro AB, Danderyd, Sweden). The naive participants will look at the percept during which the faces of the controls and the patients will alternate, with the only instruction being free visual exploration of the percept.~The fixation duration in the defined areas of interest (eyes, nose, mouth, chin) will be recorded with a Tobii® Pro X3-120 eye-tracking device and the results will be processed with the Tobii Pro Lab® software."
214601461|NCT06512272|OTHER|Video recorded shared using a mobile application|"The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times"
214601462|NCT01889303|DRUG|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
214601463|NCT01889303|DRUG|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
214601464|NCT01889303|RADIATION|radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
214601465|NCT05092633|DEVICE|Miniscrew|Application of laser on miniscrew
214601466|NCT02464228|DRUG|Tipifarnib|oral
214601467|NCT01538563|DRUG|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
214601468|NCT03138811|DRUG|CSJ117|inhaled once daily dose
214601469|NCT03138811|DRUG|Placebo Comparator|inhaled once daily dose
214601470|NCT03932825|DRUG|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
214601471|NCT03932825|DRUG|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
214601472|NCT01990534|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
214711644|NCT03496662|PROCEDURE|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
214711645|NCT03496662|PROCEDURE|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
214601473|NCT04258371|DRUG|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
214601474|NCT04258371|DRUG|Placebo oral tablet|Placebo once daily for 12 weeks
214601475|NCT01580033|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
214601476|NCT01580033|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
214601477|NCT01580033|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
214601478|NCT01580033|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
214601479|NCT02030756|DEVICE|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
214601480|NCT02030756|DEVICE|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
214601481|NCT03597971|DRUG|HMPL004-6599|For each cohort, 6 subjects will receive HMPL004-6599
214601482|NCT03597971|DRUG|Placebo|For each cohort, 2 subjects will receive placebo
214601483|NCT04159766|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
214601484|NCT04159766|DRUG|Placebo|normal saline
214601485|NCT05087160|OTHER|mitigation measures against COVID 19|no intervention
214601486|NCT00234494|DRUG|Cisplatin|Cisplatin 70 mg/m2, day 1
214601487|NCT00234494|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
214601488|NCT00234494|DRUG|Bevacizumab|Bevacizumab 15mg/kg, day 1
214601489|NCT01774851|DRUG|MM-111|MM-111 (IV)
214601490|NCT01774851|DRUG|Paclitaxel|Paclitaxel (IV)
214601491|NCT01774851|DRUG|Trastuzumab|Trastuzumab (IV)
214601492|NCT03641053|OTHER|Honey|Substance is given topically after the wound has been sutured
214601493|NCT03641053|OTHER|Povidone-iodine|Substance is given topically after the wound has been sutured
214711646|NCT06620835|BIOLOGICAL|Blood samples for Hematology|Complete blood count will include erythrocytes, neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, leukocytes, hemoglobin, hematocrit.
214711647|NCT06620835|BIOLOGICAL|Blood samples for Chemistry|Clinical chemistry will include serum electrolytes (sodium, potassium, calcium, corrected calcium for hypoalbuminemia), creatinine, CrCl with local formula, and fasting blood glucose.
214711648|NCT06620835|BIOLOGICAL|Blood sample for liver function tests|Laboratory tests to assess liver function will include Aminotransferase Alanine (ALAT), Aminotransferase Aspartate (ASAT), Phosphatase Alkaline (ALP), Gamma-glutamyl Transferase (GGT), total and conjugated bilirubin.
214711649|NCT06620835|BIOLOGICAL|Pregnancy test|Pregnancy test will be performed in women of childbearing potential, including women who have had a tubal ligation. Childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy or not being postmenopausal (≥12 months of amenorrhea). Urine pregnancy tests will be based on the measurement of β-Human Chorionic Gonadotropin (HCG). If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed at screening.
214711650|NCT06620835|PROCEDURE|Tumour assessment|Tumor assessment according to the RECIST v1.1 include the following radiological evaluation: thoracic CT scan, brain MRI or CT scan (MRI is preferred), abdominopelvic scan, PET-CT scan mandatory and at the Investigator's discretion, if needed bone scintigraphy and chest X-ray.
214711651|NCT06620835|PROCEDURE|Local Ablative Therapy (LAT)|Local Ablative Treatment (LAT) (stereotactic body radiotherapy, surgery, thermal ablation)
214711652|NCT06015932|BEHAVIORAL|Cognitive Behavior Therapy|Participate in CBCSM group sessions
214601494|NCT03641053|OTHER|Paraffin gauze|Substance is given topically after the wound has been sutured
214601495|NCT02801903|DRUG|SB204 4%|Topically Once Daily (AM)
214601496|NCT04354805|DRUG|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
214601497|NCT03436706|OTHER|exposure|exposure to chronic stress
214601498|NCT04182503|OTHER|No intervention|This is a multi-city observational cohort study without intervention.
214601499|NCT03579849|DIAGNOSTIC_TEST|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
214601500|NCT05754554|PROCEDURE|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
214601501|NCT04486157|DRUG|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
214601502|NCT04486157|DRUG|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
214601503|NCT00609843|OTHER|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
214601504|NCT00390611|DRUG|Sorafenib|
214711653|NCT06015932|OTHER|Questionnaire Administration|Complete questionnaires
214601505|NCT00390611|DRUG|Paclitaxel|Paclitaxel
214601506|NCT00390611|DRUG|Carboplatin|Carboplatin
214601507|NCT04691999|BEHAVIORAL|Intermittent Fasting|16-18 hour fasting period four times per week
214601508|NCT05114915|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
214601509|NCT00148954|DEVICE|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
214601510|NCT00148954|DEVICE|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
214601511|NCT02193360|DRUG|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
214601512|NCT06168136|OTHER|protein diet|this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)
214601513|NCT06168136|OTHER|Normal protein diet|this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
214601514|NCT05388877|DRUG|Dabrafenib|Given PO
214601515|NCT05388877|DRUG|MEK-1/MEKK-1 Inhibitor E6201|Given IV
214601516|NCT05388877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214601517|NCT05388877|PROCEDURE|Computed Tomography|Undergo CT
214601518|NCT05388877|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214601519|NCT04849182|DIETARY_SUPPLEMENT|Vertistop D|Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals
214601520|NCT04849182|DIETARY_SUPPLEMENT|Vertistop L|Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
214601521|NCT01521897|BIOLOGICAL|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
214601522|NCT04090853|DEVICE|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
214601523|NCT00257686|DRUG|Pitavastatin|
214601524|NCT00257686|DRUG|Pravastatin|
214711654|NCT06310824|DRUG|MAB-22|60mg dose of a single subcutaneous injection
214601525|NCT06206512|DRUG|Extended release torsemide|This is an extended-release formulation of torsemide
214601526|NCT06206512|DRUG|Immediate release torsemide|This is the generic, immediate release formulation of torsemide
214601527|NCT06206512|DRUG|Extended release torsemide placebo|Placebo of extended release torsemide
214601528|NCT06206512|DRUG|Immediate release torsemide placebo|Placebo of immediate release torsemide
214711655|NCT06310824|DRUG|EU-Prolia®|60mg dose of a single subcutaneous injection
214601529|NCT05211310|OTHER|High-Activity Arthroplasty Score (HAAS)|The questionnaire developed by Talbot et al. in 2010 consists of 4 sub-dimensions. 0-18 points can be obtained from the survey. High scores are associated with higher functional ability.
214601530|NCT05211310|OTHER|Western Ontario and McMaster Universities osteoarthritis score (WOMAC)|It is used to evaluate disability in patients with hip and knee osteoarthritis. Each sub-dimension is standardized within the range of 0-100 points, with high scores indicating poor health.
214711656|NCT06310824|DRUG|US-Prolia®|60mg dose of a single subcutaneous injection
214601531|NCT05211310|OTHER|The Knee injury and Osteoarthritis Outcome Score (KOOS)|It is calculated between 0 and 100 points. 0 points indicate severe knee problem, 100 points no knee problem
214601532|NCT05211310|OTHER|The Forgotten Joint Score-12 (FJS-12)|It evaluates how much an individual can forget an artificial joint during activities of daily living. A total of 100 points can be obtained. A high score is associated with the ability to forget.
214601533|NCT05211310|OTHER|EQ-5D-5L|It is a questionnaire evaluating the quality of life. The higher the total score, the higher the quality of life.
214601534|NCT05211310|OTHER|Numerical pain scale (NPS)|It is the numerical expression of perceived pain intensity. It is rated from 0-10 points. 10 points indicate the highest pain intensity, 0 points the absence of pain.
214601535|NCT04919525|DEVICE|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
214601536|NCT02467348|DRUG|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
214601537|NCT02467348|DRUG|Ascitic fluid|
214601538|NCT04471948|DEVICE|Fractional picosecond 1064 nm laser|The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
214601539|NCT06514235|OTHER|Observational study (Non-interventional study)|This is an observational study.
214601540|NCT04235270|COMBINATION_PRODUCT|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
214601541|NCT04235270|DRUG|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
214601542|NCT04235270|DRUG|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
214601543|NCT03560947|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
214601544|NCT03560947|OTHER|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
214601545|NCT02801955|PROCEDURE|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
214601546|NCT02801955|PROCEDURE|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
214601547|NCT03433495|OTHER|Melodic Intonation Therapy|
214601548|NCT03308942|DRUG|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
214601549|NCT03308942|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
214601550|NCT03308942|BIOLOGICAL|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
214601551|NCT05962047|OTHER|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
214601552|NCT05962047|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
214601553|NCT02194062|DRUG|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
214601554|NCT02194062|DRUG|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
214601555|NCT02194062|DRUG|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
214601556|NCT04434599|DEVICE|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
214601557|NCT04434599|DEVICE|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
214601558|NCT04434599|DEVICE|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
214601559|NCT01747967|OTHER|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
214601560|NCT00719550|DRUG|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
214601561|NCT00719550|DRUG|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
214601562|NCT00719550|DRUG|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
214601563|NCT00719550|DRUG|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
214601564|NCT00719550|DRUG|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
214601565|NCT06583733|BEHAVIORAL|KOKU Bladder|"In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
214601566|NCT06583733|BEHAVIORAL|recommendations|"In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
214601567|NCT04870125|DRUG|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
214601568|NCT04870125|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
214601569|NCT02276872|DRUG|oral treprostinil|
214601570|NCT05584670|DRUG|SAR445877|Concentrate for solution for infusion
214601571|NCT05584670|DRUG|Cetuximab|Solution for infusion
214601572|NCT05888493|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells taken intravenously (i.v.).
214601573|NCT05888493|DRUG|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
214601574|NCT05888493|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
214601575|NCT05888493|DRUG|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
214601576|NCT05888493|OTHER|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
214601577|NCT06847815|OTHER|Sweet corn|Fresh and processed sweet corn
214601578|NCT06847815|OTHER|Glucose Tolerance Drink|Beverage providing 50 g of glucose
214601579|NCT03588182|OTHER|Virtual Reality Experience|Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
214601580|NCT05249634|DRUG|Jatenzo Pill|oral tablet daily
214601581|NCT06493812|PROCEDURE|Fascia lata|This intervention involves the harvesting of fascia lata from the thigh and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left thigh, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
214601582|NCT06493812|PROCEDURE|Temporal fascia|This intervention involves the harvesting of temporal muscle fascia from the temporal region of the head and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left temporal region, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
214711657|NCT05700201|BEHAVIORAL|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
214601583|NCT05112198|DEVICE|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
214711658|NCT05700201|OTHER|standard care|Standard care (psychotherapy)
214601584|NCT03099668|OTHER|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
214601585|NCT00347672|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
214601586|NCT06341608|BEHAVIORAL|Telehealth for opioid use disorder treatment delivery|A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests
214601587|NCT05594199|BEHAVIORAL|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
214711659|NCT04592237|DRUG|Cabazitaxel|Given IV
214601588|NCT04166604|DRUG|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
214601589|NCT04053634|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
214601590|NCT04053634|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
214601591|NCT06293625|DRUG|Folfox|Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
214601592|NCT06293625|PROCEDURE|Surgery|Experimental arm: Surgery should take place 21 days after the last dose of neoadjuvant chemotherapy Control arm: upfront surgery as soon as possible
214711660|NCT04592237|DRUG|Carboplatin|Given IV
214711661|NCT04592237|BIOLOGICAL|Cetrelimab|Given IV
214711662|NCT04592237|DRUG|Niraparib|Given PO
214711663|NCT06731764|DRUG|Levothyroxine|"Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily."
214711664|NCT06731764|DRUG|Levothyroxine/Liothyronine once daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
214711665|NCT06731764|DRUG|Levothyroxine/Liothyronine twice daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
214711666|NCT05873205|BIOLOGICAL|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
214711667|NCT05756621|DRUG|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution."
214711668|NCT05756621|DRUG|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
214601593|NCT05132387|OTHER|ECMO assisted CPR in out-of-hospital cardiac arrest|Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
214601594|NCT00140231|DRUG|r-metHuLeptin|recombinant human leptin
214601595|NCT00140231|OTHER|placebo|placebo (no active drug)
214601596|NCT06526351|DEVICE|Early implant placement with immediate provisional restoration|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.
214601597|NCT06526351|DEVICE|Early implant placement with delayed loading|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
214601598|NCT06362798|OTHER|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
214601599|NCT03111693|OTHER|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
214601600|NCT01939054|DRUG|Nimotuzumab|
214601601|NCT01939054|DRUG|docetaxel|
214601602|NCT01939054|DRUG|capecitabine|
214711669|NCT02140619|BEHAVIORAL|multiple health education interventions|
214711670|NCT03037307|OTHER|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
214711671|NCT03037307|OTHER|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
214711672|NCT03037307|OTHER|Negative Control|No adhesive
214601603|NCT03304353|OTHER|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
214711673|NCT04860011|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
214711674|NCT04860011|DRUG|Metolazone Tablets|Metolazone 5MG or 10MG once daily
214711675|NCT03118453|BEHAVIORAL|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
214601604|NCT03304353|OTHER|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
214601605|NCT02858830|OTHER|High fat mixed meal|
214601606|NCT04356248|BEHAVIORAL|Endurance Training|Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
214711676|NCT03118453|BEHAVIORAL|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
214711677|NCT04786730|DRUG|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
214711678|NCT04788849|DIAGNOSTIC_TEST|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
214601607|NCT04356248|BEHAVIORAL|Education|Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
214601608|NCT03831425|DIETARY_SUPPLEMENT|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
214601609|NCT03831425|OTHER|Placebo|6 week trial of either treatment with Placebo
214601610|NCT00601991|BIOLOGICAL|VEGF Trap|Drug under investigation
214601611|NCT00601991|PROCEDURE|Bone marrow biopsy|To determine response to treatment
214711679|NCT00051129|DRUG|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
214711680|NCT00051129|OTHER|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
214601612|NCT00601991|PROCEDURE|bone marrow aspiration|To determine response to treatment
214601613|NCT00601991|PROCEDURE|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
214601614|NCT01119482|BIOLOGICAL|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
214601615|NCT06511063|DRUG|tenofovir disoproxil/emtricitabine|Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
214601616|NCT06511063|DRUG|Selzentry|Participants will take Selzentry for 90 days.
214601617|NCT06511063|DRUG|Placebo|Matching placebo.
214601618|NCT02039791|BIOLOGICAL|Nimotuzumab|200mg/w,weekly, 6 weeks
214601619|NCT02039791|DRUG|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
214601620|NCT02039791|DRUG|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
214601621|NCT05150652|DRUG|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
214601622|NCT05150652|DRUG|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
214601623|NCT05150652|DRUG|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
214601624|NCT05150652|DRUG|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
214601625|NCT05398887|RADIATION|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
214601626|NCT05398887|RADIATION|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
214601627|NCT05398887|OTHER|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
214601628|NCT06435754|PROCEDURE|Intervention group Vestibular Socket Preservation|After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
214711681|NCT00691093|DRUG|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
214601629|NCT06435754|PROCEDURE|Control Group ice cream cone technique|After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
214601630|NCT00471796|BEHAVIORAL|Biofeedback|
214711682|NCT02892825|OTHER|Music|headphones with music
214711683|NCT02892825|OTHER|No Music|headphones without music
214711684|NCT02241928|BIOLOGICAL|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
214711685|NCT02294006|DRUG|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
214601631|NCT00867113|DRUG|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
214601632|NCT03327116|DRUG|Methotrexate|oral, 15 mg per week, 24 weeks
214601633|NCT02209155|DRUG|R-verapamil 75 mg tablet|
214601634|NCT02209155|DRUG|Placebo|
214601635|NCT06159023|DEVICE|bronchial washing using a thin bronchoscope|For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
214601636|NCT04431401|DEVICE|Magstim rTMS|The device is made in London,UK
214601637|NCT05291000|BEHAVIORAL|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
214601638|NCT03765411|PROCEDURE|Proctectomy|Resection of the rectum
214601639|NCT03045601|DIAGNOSTIC_TEST|CT-FFR|Invasive FFR and CCTA With CT-FFR
214601640|NCT03045601|DIAGNOSTIC_TEST|Stress echocardiography|Stress echocardiography and invasive FFR
214601641|NCT00567216|DRUG|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
214601642|NCT02934022|DRUG|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
214601643|NCT00385372|PROCEDURE|elimination diet|
214601644|NCT00385372|PROCEDURE|provocation diet|
214601645|NCT02906839|OTHER|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
214601646|NCT06226831|OTHER|Structured interview|In-person structured interviews will be performed by the investigators.
214711686|NCT01588353|DRUG|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
214601647|NCT05103696|DRUG|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
214601648|NCT05103696|DRUG|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
214601649|NCT05518864|DEVICE|IALURIL Prefill|GAG therapy (bladder instillations with glycosaminoglycans)
214601650|NCT05339321|GENETIC|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
214601651|NCT05339321|BIOLOGICAL|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
214601652|NCT01387230|DRUG|GSK573719|62.5 mcg
214601653|NCT01387230|DRUG|GSK573719|125mcg
214601654|NCT01387230|OTHER|Placebo|Placebo
214601655|NCT00006159|BEHAVIORAL|lifestyle (exercise, diet, and family and community support)|
214601656|NCT05823025|OTHER|PWV measurement|Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
214601657|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
214601658|NCT01306422|OTHER|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
214601659|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
214601660|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
214601661|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
214601662|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
214601663|NCT05189262|OTHER|Blood and urine collection|No intervention - Biological specimen collection
214601664|NCT02066051|DEVICE|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
214601665|NCT02066051|PROCEDURE|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
214711687|NCT05653804|PROCEDURE|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
214601666|NCT02257957|DRUG|PRP injection|
214601667|NCT02257957|DRUG|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
214601668|NCT06583980|BEHAVIORAL|Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact|A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
214601669|NCT04561765|DEVICE|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
214601670|NCT04561765|DEVICE|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
214601671|NCT03027557|DRUG|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
214601672|NCT03027557|DRUG|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
214601673|NCT03027557|OTHER|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
214601674|NCT03027557|OTHER|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
214601675|NCT05066698|BIOLOGICAL|ST266|Topical ocular application: one drop four times a day for eight weeks
214601676|NCT05066698|OTHER|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
214601677|NCT05066698|BIOLOGICAL|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
214711688|NCT06444165|DRUG|Lebrikizumab Pen|Injected into a practice pad.
214711689|NCT05489081|BEHAVIORAL|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
214711690|NCT01213498|DRUG|Atorvastatin|Zarator, 80 mg pr. day for 5 days
214711691|NCT01213498|DRUG|Unikalk|1 tablet Unikalk pr day for 5. days
214711692|NCT02600741|OTHER|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
214711693|NCT02600741|OTHER|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
214711694|NCT02600741|DRUG|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
214711695|NCT02600741|DRUG|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711696|NCT02600741|DRUG|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711697|NCT02600741|DRUG|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711698|NCT02600741|DRUG|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711699|NCT02600741|DRUG|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711700|NCT02600741|DRUG|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214601678|NCT04649268|DEVICE|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
214601679|NCT04649268|OTHER|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
214601680|NCT04289740|BEHAVIORAL|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
214601681|NCT04289740|BEHAVIORAL|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
214711701|NCT02600741|DRUG|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711702|NCT02600741|DRUG|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711703|NCT02600741|DRUG|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711704|NCT02600741|DRUG|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711705|NCT02600741|DRUG|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711706|NCT02600741|DRUG|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711707|NCT02600741|DRUG|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711708|NCT02600741|DRUG|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711709|NCT02600741|DRUG|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711710|NCT02600741|DRUG|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711711|NCT02600741|DRUG|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711712|NCT02600741|DRUG|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214601682|NCT02155036|OTHER|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
214601683|NCT00565383|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural
214601684|NCT00565383|PROCEDURE|Intravenous fentanyl (50mcg)|Intravenous fentanyl
214601685|NCT01610687|DRUG|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
214601686|NCT01831830|BEHAVIORAL|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
214601687|NCT00486876|DRUG|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
214601688|NCT06428981|OTHER|degenerative cervical diseases|Including herniation of the intervertebral disc, ossification of the posterior longitudinal ligament, and spinal stenosis, resulting in cervical radiculopathy, or degenerative cervical myelopathy, and were scheduled to undergo anterior discectomy with fusion surgery.
214601689|NCT01615380|BEHAVIORAL|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
214601690|NCT01615380|BEHAVIORAL|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
214601691|NCT03836807|DRUG|OKITASK®|A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
214601692|NCT03836807|OTHER|Placebo|A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
214601693|NCT01012479|DRUG|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
214601694|NCT00365898|DRUG|Hydromorphone Hydrochloride Extended-Release|
214601695|NCT02430051|BEHAVIORAL|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
214711713|NCT02600741|DRUG|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214711714|NCT02600741|DRUG|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
214601696|NCT01019291|OTHER|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
214601697|NCT01019291|OTHER|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
214601698|NCT02679339|DRUG|CNTX-2022 (lidocaine gel, 40%)|
214601699|NCT02679339|DRUG|Placebo|
214601700|NCT06027125|OTHER|Action observation Therapy|The patients in the AOT group will be required to observe the upper limb movements or functional actions in video clips and to execute what they had observed to the best of their ability.
214601701|NCT06027125|OTHER|Mirror Therapy|The patients will be seated in front of a mirror box placed at their midsagittal plane to perform the movements. The affected arm of the participants was placed inside of the mirror box, and the unaffected arm was infront ofthe mirror.
214601702|NCT01961661|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
214601703|NCT01961661|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
214601704|NCT03045042|DRUG|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
214601705|NCT03272763|DEVICE|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
214601706|NCT04315987|BIOLOGICAL|NestaCell®|A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
214601707|NCT04315987|BIOLOGICAL|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
214601708|NCT02019420|DRUG|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
214601709|NCT02019420|DRUG|Linezolid|Linezolid IV 600 mg twice daily
214711715|NCT05514145|DEVICE|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
214711716|NCT05514145|DEVICE|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
214601710|NCT04048265|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
214711717|NCT04942119|OTHER|Multifactorial intervention|"1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
214711718|NCT03345732|DIAGNOSTIC_TEST|ICG and SPY system for wound complications|
214711719|NCT02645591|PROCEDURE|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
214711720|NCT02645591|BIOLOGICAL|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
214711721|NCT02645591|BEHAVIORAL|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
214711722|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every week
214601711|NCT02630732|BEHAVIORAL|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
214711723|NCT01101243|RADIATION|Broadband UVB|UVB dose: 4 SED every second week
214711724|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every second week
214711725|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every month
214711726|NCT01101243|OTHER|Control group|No intervention
214711727|NCT00810810|BIOLOGICAL|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
214711728|NCT00810810|BIOLOGICAL|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
214711729|NCT00810810|BIOLOGICAL|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
214711730|NCT03661892|DRUG|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
214711731|NCT03444571|PROCEDURE|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
214711732|NCT01429610|DRUG|Rituximab+mVPDL|"1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   \- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT"
214601712|NCT02630732|BEHAVIORAL|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
214601713|NCT05520541|OTHER|Exercise|Both groups will receive exercise-based training
214601714|NCT02780050|OTHER|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
214601715|NCT00025454|DRUG|tipifarnib|
214601716|NCT01647529|DRUG|Ganciclovir|Treatment with topical ganciclovir ointment
214601717|NCT02592512|OTHER|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
214601718|NCT02592512|OTHER|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
214601719|NCT05913310|DRUG|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
214601720|NCT05913310|DRUG|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
214601721|NCT04722250|DEVICE|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
214601722|NCT04722250|DEVICE|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
214601723|NCT00472173|DRUG|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
214601724|NCT00472173|DRUG|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
214601725|NCT03521414|DEVICE|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
214601726|NCT03521414|DRUG|Sevoflurane|we used sevoflurane drug at inoperative
214601727|NCT06330883|DIAGNOSTIC_TEST|Prognosis|survival/mortalite
214601728|NCT03088722|OTHER|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
214601729|NCT00573599|DRUG|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
214601730|NCT00573599|DRUG|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
214601731|NCT04853355|DRUG|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
214601732|NCT04263012|OTHER|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
214601733|NCT03769064|DRUG|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
214601734|NCT03769064|DRUG|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
214601735|NCT03769064|DRUG|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
214601736|NCT03769064|DRUG|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
214711733|NCT01080144|OTHER|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
214711734|NCT01069367|BIOLOGICAL|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
214711735|NCT01501669|DRUG|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
214711736|NCT04104295|DIAGNOSTIC_TEST|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
214711737|NCT00553657|DRUG|DETROL LA (drug)|
214711738|NCT06978309|OTHER|No Interventions|Observational study.
214601737|NCT03769064|DRUG|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
214601738|NCT03769064|DRUG|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
214601739|NCT06374368|PROCEDURE|jejuno-ileal diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
214601740|NCT06374368|PROCEDURE|jejuno-colic diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
214601741|NCT01127945|DRUG|statin|"1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy"
214601742|NCT00555490|DIETARY_SUPPLEMENT|Soy protein|35 % of protein from soy protein for 4-years
214601743|NCT04614441|DRUG|OFEV®|nintedanib
214711739|NCT01664156|DRUG|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
214711740|NCT01664156|DRUG|Placebo|
214711741|NCT04055987|BEHAVIORAL|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
214711742|NCT01700985|DRUG|122-0551|Applied twice daily for two weeks
214711743|NCT01700985|DRUG|Vehicle|Applied twice daily for two weeks
214711744|NCT00206778|DRUG|Lamotrigine|
214711745|NCT00206778|DRUG|Sodium Valproate|
214711746|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Plasma
214711747|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Serum
214601744|NCT02307864|DRUG|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
214601745|NCT02307864|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
214601746|NCT02307864|DRUG|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
214601747|NCT02307864|DRUG|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
214601748|NCT03595839|PROCEDURE|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
214601749|NCT03595839|PROCEDURE|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
214601750|NCT04026841|DRUG|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
214601751|NCT02575820|PROCEDURE|Old red blood cells transfusion|Red blood cells (shelf life \> 14 days) transfusion during the operation (total hip replacement arthroplasty)
214601752|NCT02575820|PROCEDURE|New red blood cells transfusion|Red blood cells (shelf life =\< 14 days) transfusion during the operation (total hip replacement arthroplasty)
214711748|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Urine
214711749|NCT05474911|DEVICE|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
214711750|NCT05474911|OTHER|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
214711751|NCT01409993|DRUG|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
214711752|NCT01409993|DRUG|Placebo|Matching placebo three times a day for three months
214711753|NCT01409993|DIAGNOSTIC_TEST|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
214601753|NCT04473183|DIAGNOSTIC_TEST|Specimen Collection|"Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container."
214601754|NCT04473183|DIAGNOSTIC_TEST|Surveys|Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
214601755|NCT02737839|OTHER|Stepping On Education Program|
214601756|NCT02737839|OTHER|Home visit|
214601757|NCT02737839|OTHER|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
214601758|NCT02737839|OTHER|Mini-Balance Evaluation Systems Test|"* The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes."
214601759|NCT02737839|OTHER|GAITRite|"* Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
214601760|NCT02737839|OTHER|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
214601761|NCT03628365|DIETARY_SUPPLEMENT|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
214601762|NCT03769012|DIETARY_SUPPLEMENT|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
214601763|NCT03769012|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
214601764|NCT01068353|BIOLOGICAL|Etanercept|50 mg given as a once weekly subcutaneous injection
214601765|NCT01068353|OTHER|Placebo|Placebo injection given once weekly
214601766|NCT03251196|OTHER|No Intervention, and Observational Study|Observational Study
214601767|NCT03502954|BIOLOGICAL|ABY-039|ABY-039
214601768|NCT03502954|BIOLOGICAL|Placebo|Placebo
214601769|NCT01492530|BEHAVIORAL|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
214601770|NCT01492530|BEHAVIORAL|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
214601771|NCT03753633|OTHER|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
214601772|NCT03753633|OTHER|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
214601773|NCT00186641|PROCEDURE|high dose chemo and auto hematopoietic cell transplant|
214601774|NCT01210989|DRUG|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
214601775|NCT01210989|DRUG|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
214601776|NCT02554903|DRUG|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
214601777|NCT02554903|DRUG|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
214601778|NCT01764048|DRUG|Fix protocol|Please see arm description
214601779|NCT01764048|DRUG|medications following demand protocol|Please see arm description
214601780|NCT00800943|BIOLOGICAL|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
214601781|NCT05679856|RADIATION|Hypofractionated single vocal cord irradiation|Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
214601782|NCT05679856|RADIATION|Whole laryngeal radiotherapy|The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
214601783|NCT00366704|DRUG|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
214601784|NCT00366704|DRUG|risperidone|4mg, QD, 8 week treatment
214601785|NCT00109720|BEHAVIORAL|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
214601786|NCT00109720|BEHAVIORAL|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
214711754|NCT01409993|DIAGNOSTIC_TEST|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
214711755|NCT06290271|OTHER|Intracranial artery flow pattern|the cerebral blood flow patterns observed after the occluded artery has been recanalized.
214601787|NCT03594851|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
214601788|NCT03594851|BEHAVIORAL|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
214601789|NCT03594851|BEHAVIORAL|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
214601790|NCT03594851|BEHAVIORAL|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
214601791|NCT03594851|BEHAVIORAL|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
214601792|NCT03594851|BEHAVIORAL|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
214601793|NCT03594851|BEHAVIORAL|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
214601794|NCT03594851|BEHAVIORAL|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
214601795|NCT03594851|BEHAVIORAL|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses \& includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
214601796|NCT03408782|PROCEDURE|Insertion of drainage|
214601797|NCT04173065|DRUG|VK2809|Capsule
214601798|NCT04173065|DRUG|Placebos|Capsule
214601799|NCT06061016|OTHER|No intervention|No intervention
214601800|NCT02730364|DRUG|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
214601801|NCT03700749|DRUG|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
214601802|NCT03700749|DRUG|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
214601803|NCT03700749|DRUG|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
214601804|NCT03700749|DRUG|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
214601805|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care|"Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio."
214711756|NCT00249977|DRUG|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
214601806|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning|The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
214601807|NCT02628756|PROCEDURE|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
214601808|NCT02742766|DRUG|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
214601809|NCT02742766|DRUG|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
214601810|NCT02518022|DRUG|Insulin|Insulin for beer
214601811|NCT00238667|DRUG|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
214601812|NCT00238667|DRUG|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
214601813|NCT00999713|DRUG|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
214601814|NCT00999713|OTHER|Air placebo|Endotracheal air administration
214601815|NCT03674125|BIOLOGICAL|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
214601816|NCT02084641|OTHER|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
214601817|NCT01567982|DEVICE|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
214711757|NCT05067452|OTHER|Food support|Diabetes-tailored food support. Project Open Hand (POH) will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
214711758|NCT05067452|OTHER|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
214711759|NCT00609011|DRUG|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
214711760|NCT00163904|BEHAVIORAL|High mono-unsaturated fat/low carbohydrate diet|
214601818|NCT05275712|OTHER|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
214711761|NCT00163904|BEHAVIORAL|High carbohydrate/low fat diet|
214601819|NCT04974515|DEVICE|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
214711762|NCT03380338|BEHAVIORAL|Combined aerobic and strength exercise|
214601820|NCT01482663|BEHAVIORAL|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
214601821|NCT00124371|BEHAVIORAL|a nurse led home-based education and support programme|
214601822|NCT04427553|DEVICE|Percutaneous Peripheral Nerve Stimulation|Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
214601823|NCT04427553|OTHER|Control Group|No intervention
214601824|NCT05285488|OTHER|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
214601825|NCT01677351|DRUG|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
214601826|NCT01677351|DRUG|placebo|
214711763|NCT00019227|DRUG|pentetic acid calcium|
214711764|NCT00019227|RADIATION|yttrium Y 90 daclizumab|
214711765|NCT00067470|DRUG|Placebo|
214711766|NCT00067470|DRUG|N-acetylgalactosamine 4-sulfatase|
214711767|NCT03859960|DIAGNOSTIC_TEST|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
214601827|NCT05612763|DEVICE|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
214601828|NCT02873273|DRUG|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
214601829|NCT04910477|DRUG|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
214601830|NCT04910477|DRUG|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
214601831|NCT04910477|OTHER|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
214601832|NCT01236651|DRUG|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
214601833|NCT01236651|DRUG|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
214601834|NCT03230656|OTHER|Early cognitive-communication therapy|
214601835|NCT04640389|OTHER|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
214601836|NCT01444209|RADIATION|Iodine Implants|Interstitial Radioactive Iodine Implants
214601837|NCT00195923|DRUG|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
214601838|NCT02016833|PROCEDURE|Blood Sampling|Sampling of 80mL of whole blood
214601839|NCT03228381|DEVICE|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
214601840|NCT03298321|OTHER|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
214601841|NCT02479334|OTHER|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
214601842|NCT02479334|OTHER|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
214601843|NCT02479334|OTHER|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
214601844|NCT02479334|OTHER|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
214601845|NCT03739437|BEHAVIORAL|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
214601846|NCT03739437|BEHAVIORAL|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
214601847|NCT04586582|DIAGNOSTIC_TEST|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
214601848|NCT02798263|OTHER|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
214601849|NCT02798263|OTHER|Acupuncture|30 minutes of classical acupuncture using predefined points.
214601850|NCT02798263|OTHER|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
214601851|NCT01846325|DIETARY_SUPPLEMENT|vitamin E|
214601852|NCT01846325|DIETARY_SUPPLEMENT|DHA|
214601853|NCT01846325|OTHER|placebo|
214601854|NCT00180362|DEVICE|procedure|
214601855|NCT04803136|PROCEDURE|spine surgeries|all spine surgeries including stabilization and fusion surgeries
214601856|NCT01800422|DRUG|telapristone acetate|Given orally
214601857|NCT01800422|OTHER|placebo|Given orally
214601858|NCT01800422|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214601859|NCT01800422|OTHER|laboratory biomarker analysis|Correlative studies
214601860|NCT01800422|OTHER|questionnaire administration|Ancillary studies
214601861|NCT02618824|DRUG|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
214601862|NCT02618824|OTHER|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
214601863|NCT00086034|DRUG|Motexafin gadolinium|
214601864|NCT04438161|BEHAVIORAL|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
214601865|NCT04962789|DIAGNOSTIC_TEST|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
214601866|NCT02138721|PROCEDURE|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
214601867|NCT01052688|OTHER|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
214601868|NCT00690235|DRUG|Pramlintide|180mg subcutaneous injections, twice daily
214601869|NCT00690235|DRUG|Placebo|180mg subcutaneous injections, twice daily
214601870|NCT01172509|DRUG|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
214601871|NCT04221386|BEHAVIORAL|Melodic Intonation Therapy (MIT)|Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
214601872|NCT00560053|DRUG|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
214601873|NCT00560053|PROCEDURE|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
214601874|NCT00560053|DRUG|Maintenance|"At 3 months of transplantation or with \>1.500 neutrophiles/ \> 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
214601875|NCT00560053|PROCEDURE|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
214601876|NCT00560053|PROCEDURE|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
214601877|NCT03056911|DRUG|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
214601878|NCT03600623|DRUG|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
214601879|NCT03600623|DRUG|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
214601880|NCT01143103|DEVICE|Cough assist (Philips,respironics)|
214601881|NCT01143103|OTHER|Usual respiratory therapy|
214601882|NCT00839943|OTHER|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
214601883|NCT00768391|BIOLOGICAL|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
214601884|NCT05295316|OTHER|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
214601885|NCT02750098|OTHER|Glucose measurement|"1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test"
214601886|NCT01395316|DRUG|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
214601887|NCT00569816|DRUG|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
214601888|NCT01868139|DEVICE|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
214601889|NCT02960373|OTHER|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
214601890|NCT02960373|OTHER|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
214601891|NCT02960373|OTHER|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
214601892|NCT02960373|OTHER|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
214601893|NCT03359590|DRUG|Sitagliptin 100 mg|The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
214601894|NCT03359590|DRUG|Placebo|The treatment consists of placebo tablets for up to 24 weeks.
214601895|NCT05399121|BEHAVIORAL|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
214601896|NCT05399121|BEHAVIORAL|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
214601897|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
214601898|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
214601899|NCT03425981|OTHER|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
214601900|NCT05627206|BEHAVIORAL|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
214601901|NCT03139825|OTHER|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
214601902|NCT00522912|PROCEDURE|Trichiasis surgery|Posterior lamella tarsal rotation
214601903|NCT00522912|PROCEDURE|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
214601904|NCT02128451|DRUG|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
214601905|NCT02128451|DRUG|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
214711768|NCT03859960|DIAGNOSTIC_TEST|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
214711769|NCT03538132|OTHER|dental regenerative techniques|dental regenerative techniques
214601906|NCT04795934|PROCEDURE|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
214601907|NCT02846532|DRUG|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
214711770|NCT01539785|PROCEDURE|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
214601908|NCT02846532|DRUG|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
214601909|NCT05440825|DEVICE|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
214601910|NCT05440825|OTHER|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
214601911|NCT05752123|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
214601912|NCT06238778|DRUG|HDV-Lispro|HDV-L will be used as the mealtime insulin
214601913|NCT06238778|DRUG|Lispro|Lispro will be used as the mealtime insulin
214601914|NCT05121974|DRUG|Tebipenem Pivoxil|Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.
214601915|NCT05121974|DRUG|Azithromycin|Oral Azithromycin antibiotic (Macrolides)
214601916|NCT05121974|DRUG|Ceftriaxon|IV Ceftriaxone (Cephalosporin)
214601917|NCT03951220|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
214601918|NCT03951220|OTHER|DXA scan|Used to assess bone density
214601919|NCT03951220|OTHER|Bloods and urine|Samples will be taken to assess bone biomarkers
214601920|NCT05620901|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
214601921|NCT05620901|DRUG|Pred Forte|To treat perioperative ocular inflammation and pain;
214601922|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
214601923|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
214601924|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
214601925|NCT04598477|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
214601926|NCT04598477|DRUG|prednisone|Oral prednisone tablets
214601927|NCT04468841|DIAGNOSTIC_TEST|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
214601928|NCT04468841|OTHER|sample of saliva or fingernail clipping|collected in clinic one time
214601929|NCT04468841|DIAGNOSTIC_TEST|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
214601930|NCT04468841|DIAGNOSTIC_TEST|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
214601931|NCT02520986|DEVICE|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
214601932|NCT02520986|DEVICE|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
214601933|NCT05512364|DRUG|Elacestrant|400mg QD orally on a continuous dosing schedule
214601934|NCT05512364|DRUG|Tamoxifen|20 mg QD orally on a continuous dosing schedule
214601935|NCT05512364|DRUG|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
214601936|NCT05512364|DRUG|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
214601937|NCT05512364|DRUG|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
214601938|NCT05900037|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
214601939|NCT05900037|DEVICE|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
214601940|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
214601941|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
214711771|NCT01539785|PROCEDURE|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
214711772|NCT04869176|DIAGNOSTIC_TEST|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
214601942|NCT05829031|BEHAVIORAL|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
214601943|NCT05595837|OTHER|Standard organ transplant|Standard organ transplant procedures and follow up care
214601944|NCT05530590|OTHER|Training to Serve (TTS) in person training|Participants receive in person training.
214601945|NCT05530590|OTHER|Training to Serve online training (eTTS)|Participants receive online training.
214601946|NCT04017325|OTHER|no intervention (post study follow up)|No intervention (post study follow up)
214601947|NCT05771909|OTHER|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
214601948|NCT05771909|OTHER|Control|"The Control Group does not receive the NeurodigitX application."
214711773|NCT04869176|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
214711774|NCT04869176|DRUG|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
214711775|NCT00050622|DRUG|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
214711776|NCT00050622|BEHAVIORAL|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
214711777|NCT00050622|DRUG|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
214711778|NCT00050622|DRUG|Placebo|
214711779|NCT00050622|DRUG|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
214601949|NCT00617188|DRUG|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
214601950|NCT02564926|DRUG|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
214601951|NCT02564926|DRUG|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
214601952|NCT05541432|OTHER|Supervised strength training (group 1)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of 10-12 repetitions at an intensity of \~70% of estimated 1 repetition maximum.
214601953|NCT05541432|OTHER|Supervised strength training (group 2)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of \~4-6 repetitions at an intensity of 85% of estimated one repetition maximum, with a warm-up set of 8 repetitions at their estimated 70% estimated one repetition maximum to attempt to match the volume performed in the other resistance training group.
214601954|NCT05541432|OTHER|Home exercise|Participants in this arm will complete twice-weekly upper and lower body exercises at home, focused on posture and balance. Participants will meet 1:1 with an exercise physiologist who will select and prescribe exercises. Participants will also be invited to attend twice monthly virtual exercise and education sessions.
214601955|NCT05052554|DRUG|QR-504a|Intravitreal (IVT) injection
214711780|NCT00050622|BEHAVIORAL|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
214711781|NCT06248463|DIAGNOSTIC_TEST|BP measurement in waiting room for 20 minutes|"Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted."
214711782|NCT05269641|OTHER|Food: whole almonds|60g of whole almonds will be consumed daily.
214711783|NCT05269641|OTHER|Food: non-nut snack|A non-nut snack will be consumed daily.
214601956|NCT01298518|DRUG|PF-04620110|5 mg of PF-04620110 given once daily
214601957|NCT01298518|DRUG|PF-04620110|2.5 mg of PF-04620110 given twice daily
214601958|NCT01298518|DRUG|Placebo|Matching placebo giving for 4 weeks
214601959|NCT02089841|DRUG|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
214601960|NCT02823808|DRUG|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
214711784|NCT04371627|DRUG|Viaskin Peanut|Daily epicutaneous delivery
214711785|NCT04970849|OTHER|observation|IBD doctors who perform the endoscopy perform the questionnaire
214711786|NCT05915936|PROCEDURE|LVMR|laoparoscopic ventral mesh rectopexy
214711787|NCT05915936|PROCEDURE|PSR|perineal stapler resection
214601961|NCT02823808|DRUG|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
214711788|NCT06343025|OTHER|Pilates Exercises Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
214711789|NCT06343025|OTHER|Tai Chi Exercises Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
214711790|NCT01192204|DRUG|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
214711791|NCT01192204|DRUG|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
214711792|NCT06587360|OTHER|fertiShare intervention - sharing bad news eLearning course|"two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.~Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN."
214711793|NCT06587360|OTHER|fertiShare control - basic communication skills eLearning course|"self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.~Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying)."
214601962|NCT03006354|DEVICE|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
214601963|NCT03006354|DEVICE|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
214601964|NCT03267693|DIAGNOSTIC_TEST|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
214601965|NCT05001854|DRUG|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
214601966|NCT05001854|DRUG|Placebo|100 μg every 6 hours of placebo per os
214601967|NCT04338555|PROCEDURE|Transcutaneous electrical acupoint stimulation|TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.
214601968|NCT00132223|DRUG|Contrast agent|
214601969|NCT05750537|BEHAVIORAL|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
214601970|NCT02628301|DIETARY_SUPPLEMENT|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
214601971|NCT02628301|OTHER|Normocaloric diet|Normocaloric diet
214601972|NCT01019980|DRUG|Diclofenac potassium|Diclofenac potassium
214601973|NCT01019980|DRUG|Acetaminophen|Acetaminophen
214601974|NCT01351753|DRUG|Metformin|
214601975|NCT01351753|DRUG|Orlistat|
214601976|NCT01351753|DRUG|Topiramate|
214601977|NCT01351753|DRUG|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
214601978|NCT02921204|OTHER|Vitamin D status|There is no intervention in this study
214601979|NCT04293289|OTHER|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
214601980|NCT00012298|BIOLOGICAL|rituximab|Given IV
214601981|NCT00012298|BIOLOGICAL|yttrium Y 90 ibritumomab tiuxetan|Given IV
214711794|NCT04323150|DEVICE|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
214711795|NCT04323150|DEVICE|Conventional suction system|The using of open (conventional) suctioning
214711796|NCT04990102|DRUG|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
214711797|NCT04879654|PROCEDURE|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
214601982|NCT00012298|BIOLOGICAL|indium In 111 ibritumomab tiuxetan|Given IV
214711798|NCT01372644|DRUG|SOM 230 / Pasireotide|
214711799|NCT02146248|DRUG|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
214601983|NCT00012298|BIOLOGICAL|oprelvekin|Given subcutaneously
214601984|NCT00012298|BIOLOGICAL|filgrastim|Given subcutaneously
214601985|NCT02038920|DRUG|Vedolizumab|Vedolizumab IV injection
214601986|NCT02038920|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
214601987|NCT02204566|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
214601988|NCT02626286|OTHER|HIV quarterly global care|
214601989|NCT02383589|DRUG|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
214601990|NCT02383589|DRUG|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
214601991|NCT02383589|DRUG|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
214601992|NCT02383589|DRUG|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
214601993|NCT00047320|DRUG|carboplatin|Given IV
214601994|NCT00047320|DRUG|etoposide|Given IV
214711800|NCT02146248|DRUG|DepoProvera|injectable hormonal contraceptive
214711801|NCT05090358|DIETARY_SUPPLEMENT|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
214601995|NCT00047320|DRUG|ifosfamide|Given IV
214601996|NCT00047320|DRUG|thiotepa|Given IV
214601997|NCT00047320|PROCEDURE|adjuvant therapy|
214601998|NCT00047320|PROCEDURE|conventional surgery|
214601999|NCT00047320|PROCEDURE|neoadjuvant therapy|
214602000|NCT00047320|PROCEDURE|peripheral blood stem cell transplantation|
214602001|NCT00047320|RADIATION|radiation therapy|craniospinal irradiation
214602002|NCT04010773|OTHER|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
214602003|NCT00866697|DRUG|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
214602004|NCT00866697|DRUG|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
214602005|NCT00450905|DEVICE|PRIMA Device|
214602006|NCT00496795|OTHER|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
214711802|NCT05090358|DIETARY_SUPPLEMENT|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
214602007|NCT00510523|DEVICE|Whole Body Vibration machine|
214602008|NCT04396314|BEHAVIORAL|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
214602009|NCT04396314|BEHAVIORAL|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
214602010|NCT04597814|OTHER|No Intervention|No Intervention
214602011|NCT04376060|DEVICE|Gen-Os®; The soft lamina (OsteoBiol®)|"The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects."
214602012|NCT05555667|DRUG|Remimazolam besylate|Sedation drug
214602013|NCT05555667|DRUG|Propofol|Propofol. Sedation drug
214602014|NCT04275297|BEHAVIORAL|Psychosocial Treatment|The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
214602015|NCT04275297|BEHAVIORAL|Attention Control|The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
214602016|NCT02818920|DRUG|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
214602017|NCT05740020|DEVICE|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
214602018|NCT05740020|OTHER|The traditional exercise program|"The selected physical therapy program:~1. Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~2. Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~3. Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~4. Strengthening exercise: aims to improve the functional ability (figure 7).~5. Spider suspension exercise for 30 minutes (figure 8).~5\. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
214711803|NCT05090358|DRUG|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
214711804|NCT05090358|DRUG|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
214711805|NCT05090358|DRUG|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
214711806|NCT00086944|BIOLOGICAL|oblimersen sodium|Given IV
214711807|NCT00086944|BIOLOGICAL|rituximab|Given IV
214711808|NCT00086944|DRUG|ifosfamide|Given IV
214711809|NCT00086944|DRUG|carboplatin|Given IV
214711810|NCT00086944|DRUG|etoposide|Given IV
214602019|NCT02887027|BEHAVIORAL|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
214602020|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
214602021|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
214602022|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
214602023|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
214602024|NCT05386784|DRUG|Raloxifene plus cholecalciferol|Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
214602025|NCT05386784|DRUG|Cholecalciferol|D3 oral base drop, 4 drops once daily (800 IU)
214602026|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
214711811|NCT00086944|BIOLOGICAL|filgrastim|Given SC
214711812|NCT00086944|BIOLOGICAL|pegfilgrastim|Given SC
214711813|NCT00086944|OTHER|laboratory biomarker analysis|Correlative studies
214711814|NCT04003337|OTHER|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
214711815|NCT01315847|DRUG|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
214711816|NCT01315847|DRUG|[11C]MK-4232|Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
214602027|NCT07129265|OTHER|Working group|Participants will: 1) take a 10-min demographic survey; 2) join 3 x 60-min working group meetings in which they will review preliminary results, collaborate on curriculum design, and provide feedback; and 3) respond to prompts in 3 emails (approx 5-10 mins each).
214602028|NCT07129265|OTHER|Focus group|Participants will take a 10-min demographic survey and join 1 x 30-min focus group meeting in which they will provide feedback on the curriculum in development.
214602029|NCT07130773|DEVICE|Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT|"FARAWAVE Nav without pre-ablation CT (Intervention Group, n = 29)~Description of the investigation-specific intervention:~Participants in the intervention group will undergo pulmonary vein isolation (PVI) using the second-generation FARAWAVE Nav pulsed field ablation (PFA) catheter without the use of pre-ablation CT imaging. The FARAWAVE Nav catheter integrates magnetic navigation and electroanatomical mapping capabilities, allowing real-time visualization of left atrial anatomy and electrical signals. Energy delivery is based on non-thermal pulsed electric fields (irreversible electroporation), specifically targeting myocardial tissue while sparing surrounding structures."
214602030|NCT07130773|DEVICE|FARAPULSE with pre-ablation CT|"FARAPULSE with pre-ablation CT (Control Group, n = 29)~Description of the investigation-specific intervention:~Participants in the control group will undergo pulmonary vein isolation (PVI) using the first-generation FARAPULSE pulsed field ablation (PFA) catheter. All patients in this group will undergo pre-procedural cardiac CT imaging to evaluate pulmonary vein anatomy and assist in procedural planning. The FARAPULSE catheter delivers non-thermal pulsed electric fields for selective myocardial ablation, aiming to achieve electrical isolation of the pulmonary veins."
214602031|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
214602032|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
214602033|NCT07007533|DRUG|DA-5223-R|once a day
214602034|NCT07007533|DRUG|DA-5223|once a day
214602035|NCT07130305|OTHER|whole body vibration plus usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this vibration group who will receive vitamin D and their traditional colchicine doses daily for six months. vibration group will also receive three sessions of 20-min whole body vibration in the week for 6 months
214602036|NCT07130305|OTHER|usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this control group who will receive vitamin D and their traditional colchicine doses daily for six months.
214602037|NCT05731492|DRUG|Macitentan|Macitentan will be administered orally.
214602038|NCT06625697|BEHAVIORAL|Mindfulness Meditation|Participants will be instructed on how to wear the physiological monitoring equipment during the 14-unit mindfulness meditation curriculum. Participants will then complete 2-10 minute guided seated Equa training lessons on a laboratory smartphone device while physiological measures are tracked. After training lessons, a respiration biosignal feedback chart will appear on the smartphone screen. Participants will also complete a brief mindfulness survey before and after training lessons.
214602039|NCT07020026|DRUG|[18F]PI-2620|All participants will undergo PET imaging using the \[18F\]PI-2620 tau-binding tracer.
214602040|NCT07019558|OTHER|Neurological assessment|Collect retrospective and current clinical data and assess motor impairment
214602041|NCT07019558|DIAGNOSTIC_TEST|Ophthalmological assessment|Ophthalmological assessment of possible optic nerve or retinal damage.
214602042|NCT07021105|PROCEDURE|ESP Plane block|Group E (n=20): Bilateral erector spinae plane (ESP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) at the T12 level, approximately 3-4 cm laterally from the midline, in the neurofascial plane between the transverse processes and the erector spinae muscle.
214602043|NCT07021105|PROCEDURE|QLB plane block|Group Q (n=20): Bilateral quadratus lumborum block (QLB) will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side), placed between the psoas major and quadratus lumborum muscles under US guidance, between the iliac crest and the 12th rib.
214711817|NCT01105221|DEVICE|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
214711818|NCT01105221|DRUG|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
214711819|NCT03228498|DRUG|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
214711820|NCT03228498|DRUG|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
214711821|NCT01066884|DRUG|erlotinib [Tarceva]|150mg po daily
214711822|NCT03034408|DRUG|Nalmefene|
214602044|NCT07021105|PROCEDURE|TAP Block|Group T (n=20): Bilateral transversus abdominis plane (TAP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) in the neurofascial plane between the internal oblique and transversus abdominis muscles.
214602045|NCT07021105|OTHER|No intervention|Group C (Control group, n=20): No block will be applied, only the standard intravenous patient-controlled analgesia (PCA) protocol will be used.
214602046|NCT06894888|OTHER|artifial intelligence education|With the start of the use of artificial intelligence in the field of nursing, we are trying to increase the skills of students by providing them with training in this field.
214602047|NCT07054463|OTHER|FSN Therapy Combined with Rehabilitation Training|"Prior to treatment, blinding will be ensured through the use of eye masks. Based on the affected muscle theory, all forearm muscles within the splint-immobilized area will be considered as an affected muscle group and further subdivided into flexor and extensor subgroups according to functional anatomy.~Two needle insertion points will be selected approximately 5 cm distal to the cubital crease, corresponding to the flexor and extensor muscle groups.~Following standard disinfection of the insertion device and sites, a disposable FSN needle will be inserted subcutaneously into the superficial fascial layer, with the needle tip directed toward the affected muscle group. The needle core will then be retracted into the soft tube, ensuring no tip exposure, and the tube base will be secured within the handle slot. A 30° fan-shaped sweeping motion will be performed bilaterally at a frequency of 100 sweeps/min for 2 minutes."
214602048|NCT07054463|OTHER|Sham FSN Therapy Combined with Rehabilitation Training|"Patients randomized to this group will undergo the sham intervention in the same predetermined anatomical region. Prior to the procedure, eye masks will be applied to ensure blinding. The Sham FSN device, featuring a blunt tip, will generate a pricking sensation upon spring-loaded actuator deployment without actual skin penetration, maintaining parallel alignment to the epidermal surface.~Following standard aseptic preparation, the acupuncturist will stabilize the needle body with the non-dominant hand while simulating insertion motions with the dominant hand, replicating the authentic FSN technique by retracting the stylet to the locking groove. The practitioner will then perform sweeping manipulations (ensuring continuous dermal contact during the procedure). Both the operational protocol and treatment course will be identical to those of the genuine FSN intervention group."
214602049|NCT06895967|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
214602050|NCT06895967|BIOLOGICAL|HyQvia|Participants will receive SC infusion of HyQvia.
214602051|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
214602052|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
214602053|NCT05334069|OTHER|Questionnaire Administration|Complete questionnaire
214602054|NCT05334069|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
214602055|NCT06891456|DEVICE|RFA Ablation|RFA ablation of VT substrate using FlexAbility or ThermoCool ST catheter
214602056|NCT06891456|DEVICE|PFA Ablation|PFA ablation of VT substrate using FARAPOINT catheter
214602057|NCT07058155|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.
214602058|NCT07058155|PROCEDURE|Sleeve Gastrectomy|Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.
214602059|NCT07058155|DRUG|Anti-Obesity Pharmacotherapy (Class Effect)|Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.
214602060|NCT07058155|BEHAVIORAL|Lifestyle Counseling - Diet & Physical-Activity Program|Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.
214711823|NCT03034408|DRUG|Baclofen|
214711824|NCT03034408|DRUG|Placebo Oral Capsule|
214711825|NCT02790710|DRUG|Propanolol|Active treatment
214711826|NCT02790710|DRUG|Placebo|
214711827|NCT06613100|DRUG|Xaluritamig|Intravenous (IV) infusion
214711828|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
214711829|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
214602061|NCT07130955|DEVICE|Six-channel RF Renal Denervation System|DSA-guided percutaneous renal sympathetic denervation using a six-channel RF renal denervation system-comprising the six-channel radiofrequency generator (specification model: 25D1G, software release version: SRG-V1) and the ultra-guiding radiofrequency denervation catheter (specification model: 25C6W127F115T)
214602062|NCT07130955|PROCEDURE|Parallel controln with sham operation(there is no rade and/or generic name,It is a blank control sham operation)|Sham procedure including femoral artery puncture and selective renal angiography; the six-channel radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
214602063|NCT07130539|OTHER|MIND HIIT|4 week intervention consisting of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in combination with 3 days per week of High-Intensity Interval Training (HIIT) exercise
214602064|NCT03354741|OTHER|laser therapy|stimulation of the acupuncture point P6 by laser therapy
214602065|NCT05838508|BEHAVIORAL|Exercise intervention|Research participants will be assigned to two exercise conditions.
214602066|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
214602067|NCT06912867|BEHAVIORAL|Blood Flow Restriction (BFR) Exercise Program|Participants performed supervised low-load resistance training with BFR using KAATSU C3 equipment twice a week for 8 weeks.
214602068|NCT04024748|DEVICE|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
214602069|NCT06946355|OTHER|In-hospital food support intervention|The in-hospital food support intervention will provide two meals for up to two parents per day.
214602070|NCT06946355|OTHER|Post-discharge food support intervention|The post-discharge intervention will provide families with grocery gift cards and frozen meals at the time of discharge.
214602071|NCT06953336|OTHER|Fruit and Vegetable Voucher Support Program|Participants will receive a monthly food voucher in the form of an Electronic Benefit Transfer (EBT) card, mailed to their home and refilled each month for 6 months. The EBT cards are provided and managed by an external community-based organization in partnership with the research team. The intervention is designed to supplement household food purchases, reduce food insecurity, and support nutritional well-being among pediatric and young adult kidney transplant recipients who have recently screened positive for food insecurity. Pre- and post-intervention surveys will be used to assess food security status and dietary quality.
214602072|NCT07187843|OTHER|Clinical assessments|standardized neurological examination, motor and non-motor symptom scales, cognitive testing, and autonomic symptom questionnaires.
214602073|NCT07187843|OTHER|Phenotypic classification|patients will be stratified into Brain-First and Body-First phenotypes based on the presence of RBD and instrumental findings.
214602074|NCT03188562|OTHER|PET/CT|Positron Emission Tomography (PET/CT)
214602075|NCT03188562|PROCEDURE|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
214602076|NCT03188562|PROCEDURE|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
214602077|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
214602078|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
214602079|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
214602080|NCT04890054|OTHER|Fecal Immunochemical Test|Patients due for CRC screening are mailed a FIT test by the clinic or health plan
214602081|NCT04890054|OTHER|Interview|Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations
214602082|NCT04890054|BEHAVIORAL|Patient Navigation|Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
214602083|NCT03531736|DRUG|Antithymocyte globulin (Rabbit)|ATG (2 mg/kg/d IV on days-8 through -7)
214602084|NCT03531736|DRUG|fludarabine|fludarabine (30 mg/m2/d on days -5 through -2)
214602085|NCT03531736|RADIATION|total body irradiation|TBI 200 cGy (days -2 and -1) given post stem cell infusion
214602086|NCT03531736|DRUG|cyclophosphamide|cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
214602087|NCT03531736|DRUG|Rituxan|Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia
214602088|NCT03531736|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
214711830|NCT07000058|DRUG|Hyaluronidase and Lidocaine 1% mixture|in group A hyaluronidase is expected to shorten the onset of action and prolong the duration of action of lidocaine 1% mixture than in group B where lidocaine 1% mixture only will be given
214711831|NCT07000058|DRUG|lidocaine 1 % mixture|lidocaine 1 % mixture includes; A mixture of ( epinephrine 1:200,000 and lidocaine 1% ) buffered by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.
214602089|NCT06018363|BIOLOGICAL|Allogenic B7-H3 CAR-γδT cell(QH104)|"Dose escalation (3+3) : dose 1 (1 × 10\^7 CAR+cells) , dose 2 (3 × 10\^7 CAR+cells), dose 3 (6× 10\^7 CAR+cells), once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 1: dose of RP2D, once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 2: 3 × 10\^7 CAR+cells, every two weeks for three consecutive months, then changed to once every 4 weeks via an Ommaya reservoir or intrathecal administration."
214602090|NCT06261567|DRUG|Biologic treatment|Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
214602091|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
214711832|NCT06998576|BEHAVIORAL|Animated educational video on antibiotic use|The intervention features a concise animated video on antibiotic use and AMR. The video's content and format will be developed based on the results of a survey conducted among the community residents in the two neighborhoods. Through the survey, the participants evaluated multiple message options including the various delivery formats. The animated video was designed incorporating the community's preferred key message and delivery method. The resulting video uses graphics, voice-overs, captions \[in all 4 official national languages\] to convey key messages about appropriate antibiotic use and AMR.
214711833|NCT05371067|OTHER|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
214711834|NCT04699305|DEVICE|ActiGraft|Whole blood clot (WBC) gel
214711835|NCT05073965|DIETARY_SUPPLEMENT|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
214711836|NCT05073965|OTHER|Placebo|Subject were assigned to receive a placebo
214602092|NCT06957743|BEHAVIORAL|Mindfulness Meditation|The Mindfulness Meditation trainings will teach participants Shamatha Vipassana, which is the specific form of Mindfulness Meditation typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Participants will be invited to lie flat on their back (i.e., to mimic conditions in the MRI scanner) and will listen to the clinician read a standardized Mindfulness Meditation script.
214602093|NCT06957743|BEHAVIORAL|Self-Hypnosis|In the Self-Hypnosis group, participants will relax with their eyes closed and, as with Mindfulness Meditation, will lie flat on their lack and will listen to the clinician read a standardized hypnotic script. The Self-Hypnosis practice will include an induction followed by suggestions for decreased pain and improvement in comorbid symptoms (e.g., mood).
214602094|NCT05180578|OTHER|Goat milk diet|Elimination of cow milk from diet . Goat milk containing diet.
214602095|NCT02018757|DRUG|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
214711837|NCT07000864|OTHER|No intervention|Lab-based correlative study; no intervention
214711838|NCT01721031|PROCEDURE|DPNB|Patients receive DPNB 30min before extubation at the end of operation
214711839|NCT01721031|DRUG|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
214711840|NCT05778019|OTHER|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
214711841|NCT03017482|DEVICE|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~* Questionnaires about the utility and impact of the device~* Use of the device in children younger than the current FDA approval range"
214602096|NCT02018757|DRUG|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
214602097|NCT00228397|DRUG|CCI-779|
214602098|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
214602099|NCT01135680|DRUG|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
214602100|NCT01135680|DRUG|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
214602101|NCT01135680|DRUG|Moxifloxacin|single oral 400-mg dose on study Day 3
214602102|NCT01135680|DRUG|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
214602103|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
214602104|NCT00238173|BIOLOGICAL|filgrastim|
214602105|NCT00238173|DRUG|acetylcysteine|administered i.v. over 30 to 60 minutes
214602106|NCT00238173|DRUG|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
214602107|NCT00238173|DRUG|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
214602108|NCT00238173|DRUG|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
214602109|NCT00238173|DRUG|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
214602110|NCT00238173|DRUG|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
214602111|NCT05137496|DRUG|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
214602112|NCT05137496|DRUG|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
214602113|NCT05222607|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
214602114|NCT04682171|OTHER|Low level laser therapy|"* Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~* Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~* On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
214602115|NCT04682171|OTHER|Conventional Exercise Therapy|"1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
214602116|NCT01940354|DEVICE|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
214602117|NCT01940354|DEVICE|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
214602118|NCT01538953|OTHER|handwashing|participants received weekly in-home handwashing promotion and soap as needed
214602119|NCT01538953|OTHER|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
214602120|NCT01538953|OTHER|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
214602121|NCT03993197|BEHAVIORAL|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
214602122|NCT00002790|DRUG|cyclosporine|
214602123|NCT00002790|DRUG|methotrexate|
214602124|NCT00002790|DRUG|sirolimus|
214602125|NCT05273957|OTHER|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
214602126|NCT05273957|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
214602127|NCT03837314|DEVICE|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
214602128|NCT03872453|DRUG|Zavegepant|A single dose of zavegepant
214602129|NCT03872453|DRUG|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
214711842|NCT04199208|OTHER|Prehabilitation and Immunonutrition|See study synopsis
214711843|NCT04199208|OTHER|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
214602130|NCT03872453|DEVICE|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
214602131|NCT00352885|DRUG|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
214711844|NCT03403894|BEHAVIORAL|Asking caregivers in their practice|A questionary is given to caregivers
214711845|NCT04198896|OTHER|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
214711846|NCT01872091|OTHER|cryotherapy by immersion|
214711847|NCT01872091|OTHER|Control group|
214711848|NCT00808782|DEVICE|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
214711849|NCT00808782|DEVICE|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
214711850|NCT04528797|DRUG|Levothyroxine|
214711851|NCT04528797|DRUG|Methylprednisolone|
214711852|NCT02247401|DRUG|2 DAA|ABT-450/r/ABT-267 tablets
214711853|NCT02247401|DRUG|RBV|Ribavirin tablets
214711854|NCT02995330|PROCEDURE|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
214711855|NCT02995330|DRUG|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
214711856|NCT02995330|DRUG|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
214711857|NCT00740922|DRUG|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
214711858|NCT06330285|OTHER|e-learning|"CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
214711859|NCT06330285|OTHER|face to face learning|"CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
214711860|NCT05001061|DRUG|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
214711861|NCT03910647|DRUG|pantoprazole|effect of this drug on renal function
214602132|NCT00352885|DRUG|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
214602133|NCT00352885|DRUG|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
214602134|NCT01377077|PROCEDURE|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
214602135|NCT01377077|PROCEDURE|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
214711862|NCT03583320|DIAGNOSTIC_TEST|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
214711863|NCT03411850|BIOLOGICAL|Orencia|FDA approved biologic
214602136|NCT03873493|DRUG|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
214602137|NCT03873493|DRUG|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
214602138|NCT01616433|BEHAVIORAL|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
214602139|NCT01616433|BEHAVIORAL|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
214711864|NCT03411850|OTHER|Placebo|
214602140|NCT00863109|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
214602141|NCT00863109|DRUG|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
214602142|NCT04123314|DRUG|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
214711865|NCT04091334|DEVICE|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
214602143|NCT05185986|BEHAVIORAL|Home-Based Pilates exercise|The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.
214602144|NCT05185986|OTHER|Home-based Cognitive Rehabilitation|Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.
214602145|NCT05185986|OTHER|waiting list group|This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
214602146|NCT04283981|DEVICE|Control group without use of VSP|The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)
214602147|NCT04283981|DEVICE|Treatment Group with use of VSP|The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
214602148|NCT00696982|DRUG|sitagliptin|sitagliptin 100 mg once daily for 3 months
214602149|NCT00696982|DRUG|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
214602150|NCT01099423|PROCEDURE|timing of surgery|
214602151|NCT01099423|GENETIC|gene expression analysis|
214602152|NCT01099423|OTHER|biologic sample preservation procedure|
214602153|NCT01099423|OTHER|laboratory biomarker analysis|
214602154|NCT01099423|PROCEDURE|therapeutic conventional surgery|
214602155|NCT06101953|BEHAVIORAL|Stress management|It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
214602156|NCT00256334|DRUG|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
214602157|NCT05048420|PROCEDURE|surgery|ACL reconstruction and RAMP lesion repair
214711866|NCT04091334|OTHER|Standard care|Standard care and evaluation and monitoring
214711867|NCT01766479|RADIATION|CT colonography|
214711868|NCT02624011|BEHAVIORAL|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
214711869|NCT02746848|BIOLOGICAL|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
214711870|NCT04113148|OTHER|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
214602158|NCT03592290|DIAGNOSTIC_TEST|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
214602159|NCT00440700|BEHAVIORAL|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
214711871|NCT01241396|OTHER|Any MMY treatment|Any line of treatment for MMY
214711872|NCT01117012|DRUG|Ivacaftor|
214711873|NCT00824928|PROCEDURE|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
214602160|NCT00440700|BEHAVIORAL|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
214602161|NCT00440700|BEHAVIORAL|Control 2: Standard of Care|Usual ICU nursing care.
214602162|NCT05584228|DRUG|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
214602163|NCT05584228|PROCEDURE|Intestinal resection|Ileocolonic or small bowel resection
214602164|NCT05713279|DRUG|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
214602165|NCT02614534|DRUG|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
214602166|NCT02614534|PROCEDURE|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
214602167|NCT04767737|OTHER|Topically Administered Lavender Aromatherapy|3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
214602168|NCT04767737|OTHER|Topically Administered Water|3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
214602169|NCT01834196|DEVICE|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
214602170|NCT02284048|DRUG|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
214602171|NCT05207735|DRUG|Sintilimab|"* Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
214602172|NCT02106754|BEHAVIORAL|Brief Intervention|
214602173|NCT02106754|BEHAVIORAL|Brief Intervention with Coaching|
214602174|NCT02106754|BEHAVIORAL|Treatment as Usual|
214602175|NCT06787937|BEHAVIORAL|VLNC messages|Participants will be exposed to messaging about VLNCs and reduced nicotine policy through multiple formats, including inserts placed in cigarette packs, printed advertisements, and video materials presented during their weekly visits.
214602176|NCT06787937|BEHAVIORAL|Control message|Participants will be exposed to control messages, such as advertisements for bottled water, during their weekly visits.
214602177|NCT03581201|DIAGNOSTIC_TEST|Laboratory measurements|"Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry"
214602178|NCT03581201|DIAGNOSTIC_TEST|Stool samples|For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
214602179|NCT03581201|DIAGNOSTIC_TEST|Bioimpedance analysis|The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
214602180|NCT04560569|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
214602181|NCT04560569|DRUG|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
214602182|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
214602183|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
214602184|NCT04830150|BEHAVIORAL|Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).|This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
214602185|NCT00003653|DRUG|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214711874|NCT03695393|BEHAVIORAL|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
214711875|NCT00673894|DRUG|Sitagliptin|Glutamine 30g +sitagliptin 100mg
214602186|NCT00003653|DRUG|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214602187|NCT00003653|DRUG|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214602188|NCT00003653|DRUG|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214602189|NCT00003653|DRUG|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214711876|NCT00673894|DRUG|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
214711877|NCT04282057|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
214711878|NCT04282057|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
214711879|NCT04282057|DEVICE|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
214711880|NCT02411526|DRUG|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
214711881|NCT02411526|DRUG|Risperdal Consta|Risperdal Consta administered as a IM injection
214711882|NCT02411526|DRUG|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
214602190|NCT00003653|DRUG|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214602191|NCT00003653|DRUG|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
214602192|NCT05925166|DRUG|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
214602193|NCT05925166|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
214602194|NCT04541056|BEHAVIORAL|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
214602195|NCT04541056|BEHAVIORAL|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
214602196|NCT05500755|DEVICE|Implant Treatment|Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
214711883|NCT01164865|DEVICE|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
214711884|NCT01164865|DEVICE|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
214711885|NCT01164865|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
214711886|NCT05894044|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
214711887|NCT05894044|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
214711888|NCT05894044|OTHER|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
214711889|NCT05894044|OTHER|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
214711890|NCT01852695|BEHAVIORAL|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
214711891|NCT01861054|DRUG|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
214711892|NCT04201977|OTHER|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
214711893|NCT04201977|OTHER|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
214711894|NCT04201977|OTHER|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
214711895|NCT04201977|OTHER|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
214602197|NCT00135239|PROCEDURE|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
214711896|NCT04178577|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
214711897|NCT04176744|OTHER|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
214711898|NCT05321940|BIOLOGICAL|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
214711899|NCT05321940|BIOLOGICAL|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
214711900|NCT01205958|PROCEDURE|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
214711901|NCT01434264|PROCEDURE|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
214711902|NCT00002017|DRUG|Interleukin-2, Polyethylene Glycolated|
214711903|NCT04143672|DEVICE|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
214711904|NCT04143672|DIAGNOSTIC_TEST|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
214711905|NCT03796182|DRUG|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
214711906|NCT03796182|DRUG|PF-04965842|PF 04965842 100 mg tablets
214711907|NCT02626741|DIETARY_SUPPLEMENT|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
214711908|NCT02626741|BEHAVIORAL|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
214711909|NCT05052541|DRUG|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
214711910|NCT05052541|DRUG|THC|Oral solution containing 5mg THC per 1 ml
214711911|NCT05052541|DRUG|Placebo|Oral solution containing no active drug
214711912|NCT01213368|DRUG|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
214711913|NCT01213368|DRUG|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
214711914|NCT00405821|DRUG|Acyclovir|400mg twice daily for 24 months
214711915|NCT00405821|DRUG|Placebo|Placebo tablet twice daily for 24 months
214711916|NCT00000113|OTHER|Progressive Addition Lenses|Varilux comfort with +2.00 addition
214711917|NCT00000113|OTHER|single vision lenses|
214711918|NCT03007121|DRUG|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
214711919|NCT03007121|DRUG|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
214711920|NCT03007121|DRUG|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
214602198|NCT00135239|PROCEDURE|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
214711921|NCT03277703|BIOLOGICAL|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
214602199|NCT01903070|DRUG|Linagliptin|
214602200|NCT04180748|OTHER|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
214602201|NCT00715195|BEHAVIORAL|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
214602202|NCT05476042|DRUG|Prescription of placebo|Normal saline
214602203|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
214602204|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
214602205|NCT04942795|DEVICE|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
214602206|NCT01595984|DRUG|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
214602207|NCT01595984|DRUG|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
214602208|NCT04202770|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
214602209|NCT04080284|DRUG|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
214602210|NCT04629963|OTHER|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
214602211|NCT04629963|OTHER|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
214711922|NCT05423002|OTHER|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
214711923|NCT05423002|OTHER|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
214711924|NCT05423002|OTHER|Dim light|This light condition is the baseline (≤10 lux).
214602212|NCT05460507|DRUG|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
214602213|NCT06170736|PROCEDURE|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
214602214|NCT06170736|PROCEDURE|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
214602215|NCT05853965|DRUG|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
214602216|NCT03457545|BEHAVIORAL|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
214602217|NCT03457545|OTHER|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
214602218|NCT05039099|DRUG|AP-101|Participants receive AP-101 by intravenous infusion (IV).
214602219|NCT05039099|DRUG|Placebo|Participants receive placebo by IV.
214711925|NCT04962503|DRUG|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
214602220|NCT04788615|DRUG|Ofatumumab|20mg Subcutaneous injection
214602221|NCT04788615|DRUG|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
214602222|NCT00398970|DEVICE|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
214602223|NCT04295980|PROCEDURE|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
214602224|NCT05594823|OTHER|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
214711926|NCT05530278|DRUG|Galicaftor|Oral
214711927|NCT05530278|DRUG|ABBV-576|Oral
214711928|NCT05530278|DRUG|Navocaftor|Oral
214711929|NCT05530278|DRUG|Midazolam|Oral
214602225|NCT05594823|OTHER|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
214602226|NCT03819010|DRUG|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
214602227|NCT03819010|DRUG|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
214602228|NCT03913975|OTHER|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
214602229|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
214602230|NCT06637514|OTHER|Placebo|Placebo Tablet: BID
214602231|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
214602232|NCT05390359|OTHER|High-intensity and short-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
214602233|NCT05390359|OTHER|Low-intensity and long-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds."
214602234|NCT05390359|OTHER|High-intensity, short-duration and 20 Hz|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
214602235|NCT05390359|OTHER|Sham electrolysis|The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
214602236|NCT06412484|BEHAVIORAL|Pain Free Session|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.
214602237|NCT06412484|BEHAVIORAL|Low Back Pain Session (= clinically relevant pain)|On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.
214602238|NCT06412484|BEHAVIORAL|Experimental Pain Session (= clinically irrelevant pain)|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
214602239|NCT03815643|DRUG|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
214602240|NCT05766709|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously once weekly.
214602241|NCT05766709|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
214602242|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/3.20 mg/mL)|NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
214602243|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/0.33mg/mL)|NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
214711930|NCT06252766|BEHAVIORAL|Experiment (Clown)|Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
214711931|NCT01324934|DRUG|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
214602244|NCT06737783|OTHER|Thoracic mobility exercises + Conventional therapy|mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) , Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.
214602245|NCT06737783|OTHER|Self myofascial release with foam roller, T6- T7 Maitland mobilization + Conventional therapy|Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins. Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets).
214602246|NCT04644380|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
214602247|NCT04330846|PROCEDURE|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
214602248|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Sharkskin Forceps|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
214711932|NCT03241238|OTHER|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
214711933|NCT01586806|DRUG|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
214711934|NCT01586806|DRUG|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
214711935|NCT01586806|DRUG|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
214711936|NCT00633308|DEVICE|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
214711937|NCT01303432|DIETARY_SUPPLEMENT|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
214711938|NCT01303432|DIETARY_SUPPLEMENT|Yogurt|One yogurt (125mL) per day
214711939|NCT04791787|OTHER|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
214711940|NCT04791787|OTHER|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
214711941|NCT04791787|DIETARY_SUPPLEMENT|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
214602249|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Standard Forceps|25g Grieshaber Standard ILM Forceps
214711942|NCT05684952|DRUG|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
214602250|NCT05051033|PROCEDURE|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
214711943|NCT04218799|DRUG|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
214711944|NCT00890071|OTHER|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
214711945|NCT01208571|OTHER|"Booster session"|Motivational interview
214711946|NCT01769469|DRUG|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
214711947|NCT05208723|BEHAVIORAL|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
214711948|NCT04911699|BEHAVIORAL|breast adenocarcinoma receiving chemotherapy|for chemotherapy
214711949|NCT04911699|BEHAVIORAL|Control-for|hormonal drug treatment
214711950|NCT05161312|BEHAVIORAL|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
214711951|NCT00361894|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
214711952|NCT00361894|DRUG|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
214711953|NCT00643357|DRUG|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
214711954|NCT00643357|DRUG|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
214602251|NCT05051033|DEVICE|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
214602252|NCT01978860|DEVICE|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
214602253|NCT00409253|DRUG|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
214602254|NCT00409253|DRUG|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
214602255|NCT02890758|BIOLOGICAL|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
214602256|NCT02890758|BIOLOGICAL|ALT803|given at 6mcg/kg weekly for four weeks
214602257|NCT05439434|OTHER|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
214602258|NCT06267157|DEVICE|virtual reality training|Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
214602259|NCT06267157|OTHER|theoretical breastfeeding training|Classic 2-hour theoretical breastfeeding training with ppt
214602260|NCT06027190|DEVICE|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~2. 70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
214602261|NCT06027190|DEVICE|Sham|Placebo coil (Magstim Company, Whitland, UK):
214602262|NCT01054651|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
214602263|NCT01054651|DRUG|Praziquantel|
214602264|NCT05138523|COMBINATION_PRODUCT|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
214602265|NCT06476574|DEVICE|Vacuum-formed retainer|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer)."
214602266|NCT06476574|DEVICE|Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.|"* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0."
214602267|NCT06476574|DEVICE|Lingual bonded retainer from canine-to-canine|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer)."
214602268|NCT00813163|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214602269|NCT02627222|OTHER|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
214602270|NCT02627222|OTHER|White cassava|Conventional white cassava
214602271|NCT01165372|DRUG|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
214602272|NCT01423812|DRUG|Twice-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
214602273|NCT01423812|DRUG|Once-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
214602274|NCT06041620|BIOLOGICAL|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
214602275|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
214602276|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
214602277|NCT05385042|DIETARY_SUPPLEMENT|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
214602278|NCT05385042|DIETARY_SUPPLEMENT|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
214602279|NCT01179672|DRUG|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
214602280|NCT01179672|DRUG|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
214711955|NCT00984880|DRUG|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
214711956|NCT01382199|DRUG|Lactoferrin|
214711957|NCT05677295|DRUG|duloxetine|Duloxetine 30 mg per day
214711958|NCT05677295|DRUG|Imipramine|Imipramine 25 mg per day
214711959|NCT03076918|DEVICE|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
214711960|NCT03076918|DEVICE|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
214711961|NCT01055418|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
214602281|NCT04345081|PROCEDURE|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
214602282|NCT04345081|PROCEDURE|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
214602283|NCT01292447|DRUG|2% lidocaine gel|120mg lidocaine x 1
214602284|NCT01292447|DRUG|Placebo gel|Inert gel x 1
214602285|NCT06235450|DEVICE|iLIDS100|Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
214602286|NCT01686009|DRUG|Intra-nasal ketamine|
214711962|NCT00350311|DRUG|nicotine transdermal patch/lozenge|
214711963|NCT03448900|BEHAVIORAL|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
214711964|NCT03448900|BEHAVIORAL|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
214711965|NCT02031432|DRUG|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
214711966|NCT01338935|DRUG|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
214711967|NCT01338935|DRUG|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
214602287|NCT01617590|DRUG|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
214602288|NCT01617590|DRUG|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
214602289|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
214711968|NCT01338935|DRUG|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
214711969|NCT01617187|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
214711970|NCT01617187|DRUG|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
214711971|NCT01617187|DRUG|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
214711972|NCT01617187|DRUG|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
214602290|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
214602291|NCT00004172|BIOLOGICAL|filgrastim|
214602292|NCT00004172|DRUG|carboplatin|
214602293|NCT00004172|DRUG|cyclophosphamide|
214602294|NCT00004172|DRUG|ifosfamide|
214602295|NCT00004172|DRUG|thiotepa|
214602296|NCT00004172|PROCEDURE|peripheral blood stem cell transplantation|
214602297|NCT00004172|RADIATION|radiation therapy|
214602298|NCT06516900|DEVICE|OrthoFeet HandsFree Therapeutic Shoe|Patients with foot pain will be recruited for this study and will go for an intervention of wearing OrthoFeet therapeutic shoes for 6 weeks. Each patient will be evaluated and will participate in data collection before and after intervention.
214602299|NCT05674994|DRUG|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
214602300|NCT05674994|OTHER|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
214602301|NCT00977457|GENETIC|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602302|NCT00977457|GENETIC|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602303|NCT00977457|GENETIC|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602304|NCT00977457|GENETIC|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602305|NCT00977457|GENETIC|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602306|NCT00977457|OTHER|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
214602307|NCT00977457|PROCEDURE|therapeutic conventional surgery|
214711974|NCT06882460|OTHER|Low glycemic load|Low glycemic load diet
214711975|NCT06882460|OTHER|Electrical stimulation exercise|Lower-body electrical stimulation exercise for 1-h after eating
214711976|NCT06882460|OTHER|High glycemic load diet|High glycemic load diet
214711977|NCT06396572|PROCEDURE|IVR-Procedure|Using immersive virtual reality to learn urinary catheterisation procedure
214711978|NCT06396572|PROCEDURE|Nursing Clinical Laboratory practice|Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
214711979|NCT06710158|DRUG|SC-102|SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.
214711980|NCT00503178|PROCEDURE|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
214602308|NCT05945355|DEVICE|Pro2 - Low Dose - 40% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
214711981|NCT04430283|DRUG|FDY-5301|FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
214711982|NCT04430283|OTHER|Placebo|Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
214711983|NCT06890013|DIAGNOSTIC_TEST|Observation group|Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.
214711984|NCT07091721|BEHAVIORAL|Mentalization based therapy (MBT)|Mentalization based therapy for conduct disorder
214711985|NCT07091721|OTHER|Support as usual|Support usually provided by FCAMHS which may include advice/guidance to the professional network around the child/adolescent, psychoeducation, other mental health treatment e.g. CBT
214711986|NCT07091071|DEVICE|CochSyn device|The CochSyn device is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn device records and analyses biopotential waveforms that can be used for hearing screening and diagnostic applications.
214711987|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 60-70% HR reserve for 30 minutes.
214711988|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 20-30% HR reserve for 30 minutes.
214711989|NCT07090291|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is used to examine the inner lining of the colon and rectum. During the procedure, if suspicious growths (e.g., polyps) are detected, they will be biopsied and sent for pathological examination.
214711990|NCT07090291|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
214711991|NCT07090291|DIAGNOSTIC_TEST|Blood test|Blood test based on cfDNA methylation will be performed.
214711992|NCT07089966|OTHER|HTS counselor-led PrEP care model|PrEP delivery ,including HIV testing, eligibility assessment, dispensing, adherence counseling, and provision of refills, provided by an HTS counselor
214711993|NCT01165697|OTHER|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
214711994|NCT00257023|DRUG|paliperidone|
214711995|NCT07092137|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
214602309|NCT05945355|DEVICE|Pro2 - High Dose - 75% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
214711996|NCT07092137|OTHER|Nano-crystalline Megestrol Acetate Oral Suspension placebo|Nano-crystalline Megestrol Acetate placebo+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
214711997|NCT07091552|DEVICE|CAD/CAM monolithic denture|"Based on the workflow suggested by the Ivoclar digital denture, conventional complete dentures will be scanned by using desktop scanner (Medit T710). The cameo and intaglio surfaces of the complete dentures will be scanned, and the scanned data will be exported as Standard Tessellation Language (STL) file to start the milling process.~For the milling process, monolithic denture will be milled from a bicolored disk (Ivotion). One side is the denture base material made of high impact optimized polymethyl methacrylate (PMMA) while the other is the teeth material made of highly cross-linked PMMA with no filler. The bicolor disk is milled in a 5-axis milling machine in wet condition, through an uninterrupted milling process. Following the fast milling process the dentures will be finished and polished."
214711998|NCT07091552|DEVICE|Conventional denture|The conventional set will be fabricated with the 5-appointment process: preliminary impressions (first appointment); definitive impressions (second appointment); interocclusal records and tooth selection (third appointment), the size of the teeth will be selected according to the library provided by 3Shape Dental System software to match the disc size; wax trial placement (fourth appointment); and denture adjustment and placement (fifth appointment). Conventional CD will be fabricated with the conventional lost wax technique and heat-polymerizing acrylic resin. The heat-polymerized CDs will be finished, and polished before placement. Adjustments will be made for the polished surface, tissue surface, borders, and occlusion. Occlusal errors will be adjusted through clinical remount of the finished dentures.
214602310|NCT05945355|DEVICE|Pro2 - SHAM - 15% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
214602311|NCT02652455|DRUG|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
214602312|NCT02652455|PROCEDURE|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
214602313|NCT02652455|DRUG|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
214711999|NCT01929265|DRUG|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
214712000|NCT00954317|PROCEDURE|epidural placed low|epidural placed low
214602314|NCT02652455|DRUG|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
214602315|NCT02652455|DRUG|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
214602316|NCT02652455|BIOLOGICAL|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
214602317|NCT02652455|DRUG|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
214602318|NCT02315898|DRUG|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
214602319|NCT05882344|PROCEDURE|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
214712001|NCT00954317|PROCEDURE|high epidural|high epidural
214712002|NCT06300346|DRUG|Propofol|Ondansetron
214712003|NCT05090098|OTHER|None intervention|None intervention
214712004|NCT00977587|DRUG|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
214712005|NCT00977587|DRUG|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
214602320|NCT05882344|DEVICE|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
214712006|NCT01770145|DRUG|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
214602321|NCT06404086|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
214602322|NCT06404086|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
214602323|NCT06404086|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
214602324|NCT06404086|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
214602325|NCT06404086|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
214602326|NCT06404086|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
214602327|NCT06404086|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
214602328|NCT06404086|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
214602329|NCT05014893|COMBINATION_PRODUCT|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
214602330|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
214602331|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
214602332|NCT06563583|OTHER|Group 1 will include patients aged 18-40 years|Group 1 will include patients aged 18-40 years.
214602333|NCT06563583|OTHER|Group 2 will include patients aged 40-64 years|Group 2 will include patients aged 40-64 years, and finally.
214712007|NCT01770145|DRUG|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
214602334|NCT06563583|OTHER|Group 3 will include patients aged 65-85 years|Group 3 will include patients aged 65-85 years.
214602335|NCT01660607|BIOLOGICAL|CD34+ Hematopoietic Progenitor Cells (HSPC)|Purified CD34+ hematopoietic progenitor cells used in transplantation.
214602336|NCT01660607|BIOLOGICAL|Regulatory T-Cells (Treg)|Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.
214602337|NCT01660607|BIOLOGICAL|Conventional T-Cells (Tcon)|Conventional CD3+ T cells used for immune reconstitution and graft enhancement.
214712008|NCT01770145|DRUG|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
214712009|NCT00062205|DRUG|imatinib mesylate|
214602338|NCT01660607|PROCEDURE|Myeloablative Conditioning Regimen|Chemotherapy or total body irradiation used before hematopoietic cell transplantation.
214602339|NCT03346772|BIOLOGICAL|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
214602340|NCT04526600|OTHER|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
214602341|NCT06773871|OTHER|Exercise|Weekly supervised exercise for 12 weeks followed by 12 weeks of non-supervised exercise
214602342|NCT06773871|OTHER|Control|Remain usual activity level
214602343|NCT02782130|BEHAVIORAL|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
214602344|NCT02782130|BEHAVIORAL|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
214602345|NCT00010972|PROCEDURE|Acupuncture|
214602346|NCT05641064|DRUG|Placebo|Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
214602347|NCT05641064|DRUG|Dexmedetomidine 0.5mcg/kg/h|Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
214602348|NCT05641064|DRUG|Dexmedetomidine 1 mcg/kg/h|Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
214602349|NCT00578786|DRUG|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
214602350|NCT04029220|BEHAVIORAL|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
214602351|NCT02771314|DRUG|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
214602352|NCT04998019|BEHAVIORAL|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
214602353|NCT00006098|DRUG|bortezomib|
214602354|NCT01560689|DRUG|Budesonide/formoterol|800 µg/j twice a day, every day
214602355|NCT01560689|DRUG|Placebo|Twice a day, every day
214602356|NCT01243697|DRUG|desogestrel|Tablets of 75 µg, once daily during 112 days
214602357|NCT02914691|DRUG|Dapagliflozine 10 mg once daily tablet treatment|
214602358|NCT02914691|DRUG|Placebo identical once daily tablet treatment|
214712010|NCT00595868|DRUG|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
214712011|NCT00595868|DRUG|Placebo|same as Varenicline arm
214602359|NCT05105789|DIAGNOSTIC_TEST|BinaxNOW Test|diagnostic test for SARS-CoV-2
214602360|NCT05105789|DIAGNOSTIC_TEST|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
214602361|NCT03024177|DRUG|Vapendavir|Vapendavir Tablets, 264 mg
214602362|NCT03024177|DRUG|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
214712012|NCT03905824|BIOLOGICAL|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
214602363|NCT05810337|DIETARY_SUPPLEMENT|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
214602364|NCT05810337|DIETARY_SUPPLEMENT|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
214602365|NCT05810337|DIETARY_SUPPLEMENT|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
214602366|NCT00389233|DRUG|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
214602367|NCT00389233|DRUG|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
214712013|NCT03905824|PROCEDURE|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
214712014|NCT03632668|DRUG|AD-2071 10/20mg|AD-2071 10/20 mg tablet
214712015|NCT03632668|DRUG|AD-2072 80/5mg|AD-2072 80/5mg tablet
214712016|NCT03632668|DRUG|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
214602368|NCT02005081|DEVICE|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
214602369|NCT02005081|DEVICE|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
214602370|NCT00037791|DRUG|(PN-152,243)/PN-196,444|
214602371|NCT00198952|DRUG|DietPro|
214712017|NCT04345302|BEHAVIORAL|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
214712018|NCT04345302|BEHAVIORAL|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
214712019|NCT04478110|BEHAVIORAL|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
214602372|NCT00198952|DRUG|Placebo|
214602373|NCT01222637|DRUG|CetuGEX™|
214602374|NCT03706339|OTHER|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
214602375|NCT03706339|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
214602376|NCT03706339|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
214602377|NCT05029960|DRUG|Brivaracetam|Dose of 50 mg twice daily for 6 months
214602378|NCT06522750|OTHER|7-day ambulatory caloric restriction intervention using the Buchinger-Wilhelmi method|Buchinger-Wilhelmi method, will be administered in an ambulatory setting under physician guidance. It involves an initial bowel cleanse followed by 7-day fasting period. The initial bowel cleanse will be performed according to the standard procedure commonly used for colonoscopy preparation. During the fasting period, subjects will be provided with a dietary energy supply of a maximum of 350 kcal per day, primarily consisting of vegetable broths as well as fresh vegetable juices. Patients will only be allowed to consume calorie-free and unsweetened water or tea in addition to the prescribed diet.
214602379|NCT06191770|PROCEDURE|Morphine,|Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
214602380|NCT02797067|DRUG|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
214602381|NCT02797067|DRUG|Glycerin Suppository|30min before ESWL
214602382|NCT00482196|DRUG|MK0493|
214602383|NCT05325697|COMBINATION_PRODUCT|Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement|The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
214602384|NCT06057675|DRUG|Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.
214602385|NCT06057675|DRUG|Control (1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
214602386|NCT03943862|BEHAVIORAL|2Share|"The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
214602387|NCT01893892|DIETARY_SUPPLEMENT|levocarnitine|Given PO
214602388|NCT01893892|OTHER|placebo|Given PO
214712020|NCT04478110|BEHAVIORAL|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
214602389|NCT01893892|OTHER|questionnaire administration|Ancillary studies
214602390|NCT00323297|DRUG|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
214712021|NCT02402621|DRUG|fentanyl|fentanyl with antiemetic drug
214712022|NCT01221818|DRUG|E6007|E6007 25mg single dose or matching placebo
214712023|NCT01221818|DRUG|E6007|E6007 50mg single dose or matching placebo
214712024|NCT01221818|DRUG|E6007|E6007 100mg single dose or matching placebo
214712025|NCT01221818|DRUG|E6007|E6007 200mg single dose or matching placebo
214712026|NCT01221818|DRUG|E6007|E6007 400mg single dose or matching placebo
214712027|NCT01221818|DRUG|E6007|E6007 600 mg single dose or matching placebo
214712028|NCT03380026|DRUG|Triamcinolone|Apply up to three times daily on select lesions.
214712029|NCT03380026|DRUG|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
214712030|NCT05373082|OTHER|questionnaire completion|Questionnaire to be completed by patients
214712031|NCT00151541|DRUG|Dapsone Topical Gel + adapalene gel 0.1%|
214712032|NCT00151541|DRUG|Dapsone Topical Gel + benzoyl peroxide gel 4%|
214712033|NCT00151541|DRUG|Dapsone Topical Gel + vehicle control|
214712034|NCT04285372|PROCEDURE|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
214712035|NCT04285372|PROCEDURE|No side branch protection/ballooning|No intervention on the side branch
214712036|NCT04268303|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Sublingual film containing dexmedetomidine (BXCL501)
214712037|NCT04268303|DRUG|Placebo Film|Placebo Film for BXCL501
214602391|NCT00323297|OTHER|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
214602392|NCT00323297|DRUG|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
214602393|NCT00323297|DRUG|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
214602394|NCT02182570|DRUG|WAL 801 CL dry syrup|
214602395|NCT01003990|DRUG|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
214602396|NCT01003990|DRUG|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
214602397|NCT01003990|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
214602398|NCT01003990|DRUG|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
214602399|NCT04910022|DRUG|NMS-03305293|Route of administration: Oral
214602400|NCT04910022|DRUG|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
214602401|NCT00688831|DRUG|AZD1305|Solution for iv infusion , single dose
214602402|NCT00688831|DRUG|Placebo|NaCl solution for iv infusion, single dose
214602403|NCT04823715|OTHER|TACE + hypofractionated EBRT|One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
214602404|NCT04823715|PROCEDURE|Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
214602405|NCT02393274|DEVICE|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
214602406|NCT02302404|DRUG|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
214602407|NCT02302404|DRUG|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
214602408|NCT02302404|DRUG|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
214602409|NCT02302404|DRUG|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
214602410|NCT05061784|PROCEDURE|Routine thymectomy, which has been performed|There is no intervention
214602411|NCT03047759|DEVICE|water flosser|Powered
214602412|NCT03047759|DEVICE|air floss|Powered
214602413|NCT03889431|DIETARY_SUPPLEMENT|Iodine capsule|225 µg of iodine daily as a capsule of potassium iodide
214602414|NCT03889431|OTHER|Iodized Salt|450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
214602415|NCT05115604|BEHAVIORAL|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
214712038|NCT01232192|BEHAVIORAL|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis"
214602416|NCT04086433|DEVICE|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
214602417|NCT06528639|BEHAVIORAL|HIIT|Three times a week, 10 sets each session, for 24 weeks of high-intensity interval training.
214602418|NCT01343485|BEHAVIORAL|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
214712039|NCT03249753|DRUG|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
214602419|NCT02129153|BEHAVIORAL|LIFT (Parent Information)|"1. Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~2. Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
214602420|NCT00934804|DEVICE|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
214602421|NCT01809184|DRUG|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
214602422|NCT01809184|DRUG|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
214602423|NCT01809184|DRUG|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
214602424|NCT05798533|BIOLOGICAL|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
214602425|NCT05798533|COMBINATION_PRODUCT|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
214602426|NCT05798533|COMBINATION_PRODUCT|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
214602427|NCT01695915|PROCEDURE|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
214602428|NCT05192304|DRUG|TPN-672|single dose of TPN-672 maleate tablet
214602429|NCT02309060|BEHAVIORAL|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
214602430|NCT03931733|OTHER|Music Therapy|Single thirty minute receptive music therapy intervention.
214602431|NCT05332405|DRUG|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
214602432|NCT00634010|DRUG|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
214602433|NCT00634010|DRUG|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
214602434|NCT04052568|DRUG|Psilocybin|Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
214602435|NCT00114192|DRUG|docetaxel|
214602436|NCT00114192|DRUG|thalidomide|
214602437|NCT00132613|PROCEDURE|Observation alone after pericardial drainage|
214602438|NCT00132613|DRUG|Pericardial instillation of bleomycin after drainage|
214602439|NCT01303263|BEHAVIORAL|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
214602440|NCT04811638|OTHER|Validation of the Chelsea Critical Care Physical Assesment Tools|The validation of the CPAX tools will focus on the validity of constructs, internal consistency reliability and test-retest reliability. PFIT used for criterion validity.
214602441|NCT02160704|DRUG|Enclomiphene citrate|25 mg daily for 16 weeks
214602442|NCT02160704|OTHER|Placebo|placebo daily for 16 weeks
214602443|NCT05247138|DEVICE|BioRootTM RCS|BioRoot™ RCS is a hydrophilic mineral root canal sealer prepared from the mixture of a powder part and a liquid part. BioRoot™ RCS is a class III implantable medical device. This device is intended to be used in dentistry for permanent obturation of root canals of permanent and mature teeth with adjunction of gutta-percha points. Exposure to the sealer BioRootTM RCS starts from the day when the root canal treatment is performed until the end of individual observational period or the removal of the sealer in case of extraction or retreatment, if this event occurs before the end of individual observational period.
214602444|NCT01339741|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
214602445|NCT01339741|DRUG|Placebo|Placebo, oral route, 12 weeks
214602446|NCT00758056|GENETIC|polymorphism analysis|
214602447|NCT00758056|OTHER|laboratory biomarker analysis|
214602448|NCT00758056|OTHER|questionnaire administration|
214602449|NCT02616523|DRUG|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
214602450|NCT02616523|DRUG|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
214602451|NCT02616523|OTHER|placebo|The participants will be given infusion of normal saline intravenously.
214602452|NCT02616523|DRUG|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
214602453|NCT05089409|DRUG|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
214602454|NCT05089409|DRUG|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
214602455|NCT05089409|DRUG|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
214602456|NCT05089409|DRUG|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
214602457|NCT05089409|DRUG|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
214602458|NCT05089409|OTHER|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
214602459|NCT00151554|BEHAVIORAL|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
214602460|NCT01313403|OTHER|Antidepressant (SSRI)|
214602461|NCT02471950|PROCEDURE|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
214602462|NCT03461874|BEHAVIORAL|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
214602463|NCT03461874|BEHAVIORAL|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
214602464|NCT03461874|DRUG|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
214602465|NCT06360809|BEHAVIORAL|Prehabilitation exercise program|After the allocation, the intervention will consist of a prehabilitation program lasting 4 weeks. Each week, there will be three sessions, with one being face-to-face and the other two being unsupervised sessions but with online video-support. Face-to-face sessions will be organized in small groups, and each patient of the PEP group will have an individualized plan based on data obtained during the initial assessment. Each session will include a combination of strength training and moderate aerobic training in a circuit format with movements especially involving the upper body.
214602466|NCT04423913|OTHER|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
214602467|NCT05781568|DIAGNOSTIC_TEST|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
214602468|NCT01521819|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
214712040|NCT03249753|DRUG|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
214712041|NCT05141357|DRUG|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
214712042|NCT01340404|PROCEDURE|Stem cell transplantation|Stem cell transplantation
214602469|NCT01521819|DRUG|Lucentis|Intravitreal injection of Lucentis as needed.
214602470|NCT01463384|DRUG|Minocycline|50mg, twice daily for 6 months.
214602471|NCT00448435|DRUG|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
214602472|NCT00448435|DRUG|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
214602473|NCT04202250|PROCEDURE|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
214602474|NCT04202250|PROCEDURE|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
214602475|NCT04989699|DRUG|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
214602476|NCT04989699|DRUG|Aflibercept/Sham|Aflibercept administered every 8 weeks
214602477|NCT01822522|DRUG|Cabozantinib S-malate|Given PO
214602478|NCT01822522|OTHER|Laboratory Biomarker Analysis|Correlative studies
214602479|NCT01822522|OTHER|Pharmacological Study|Correlative studies
214602480|NCT06430944|PROCEDURE|Placing a hip spica cast for patients with femur fractures|Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
214602481|NCT00372749|BEHAVIORAL|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
214602482|NCT05212896|DRUG|BC006|BC006 monoclonal antibody injection
214602483|NCT00890929|DRUG|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
214602484|NCT00890929|DRUG|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
214602485|NCT03712189|DEVICE|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
214602486|NCT01768988|DRUG|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
214602487|NCT01768988|DRUG|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
214602488|NCT04231136|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
214602489|NCT04231136|DRUG|EAPA115|EAPA115
214602490|NCT04231136|DRUG|RAPA115|RAPA115
214602491|NCT02977117|OTHER|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
214602492|NCT02977117|OTHER|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
214602493|NCT04632472|DEVICE|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
214602494|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
214602495|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
214602496|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
214602497|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
214602498|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
214602499|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
214602500|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
214602501|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
214602502|NCT05757115|BEHAVIORAL|Play Skills Training|"Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised."
214602503|NCT01006265|DRUG|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
214602504|NCT01006265|DRUG|Placebo|Matching placebo administered orally once daily
214602505|NCT01006265|DRUG|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
214602506|NCT01006265|DRUG|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
214602507|NCT02033603|DRUG|Ropivacaine|30mls of 0.5% ropivacaine
214602508|NCT04611620|BEHAVIORAL|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
214602509|NCT03951779|DIAGNOSTIC_TEST|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
214602510|NCT03629743|DEVICE|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
214602511|NCT03629743|DEVICE|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
214712043|NCT01340404|PROCEDURE|Transfusion program|Transfusion program
214602512|NCT02765880|OTHER|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
214602513|NCT02765880|OTHER|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
214602514|NCT04780490|OTHER|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
214602515|NCT04780490|OTHER|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
214602516|NCT01272947|DRUG|Diclofenac sodium|Topical gel 1%- 4 times daily
214602517|NCT01272947|OTHER|Placebo|Topical gel - 4 times daily
214712044|NCT00628225|BEHAVIORAL|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
214712045|NCT00628225|BEHAVIORAL|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
214712046|NCT02979444|BEHAVIORAL|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
214602518|NCT03531788|DEVICE|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
214602519|NCT03531788|DEVICE|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
214602520|NCT05803304|BEHAVIORAL|PATH Intervention|The PATH intervention guides participants in making changes in their lifestyle and PA habits to support long-term adherence to the minimum threshold of PA Guidelines (150 MVPA minutes per week). The health coach provides participants with access the PATH website and a detailed orientation on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA by about 10 minutes per week. The PA prescription process begins by identifying a suitable PATH level for each participant. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA).
214712047|NCT02740712|DRUG|Caffeine|200 mg (4 x 50mg) Tablet
214712048|NCT02740712|DRUG|Warfarin|10 mg (2 x 5mg) Tablet
214712049|NCT02740712|DRUG|Omeprazole|40 mg Tablet
214712050|NCT02740712|DRUG|Midazolam|5 mg/mL
214712051|NCT02740712|DRUG|digoxin|.25 mg Tablet
214712052|NCT02740712|DRUG|Vitamin K|10 mg Tablet
214712053|NCT02740712|DRUG|Rucaparib|200 \& 300 mg tablet
214712054|NCT01067313|DEVICE|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
214712055|NCT01067313|DEVICE|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
214602521|NCT05803304|BEHAVIORAL|Attention Control Intervention|"A health coach will have a zoom meeting with each control group participant where they will be provided with an electronic copy of the Be Active Your Way booklet, developed by the Centers for Disease Control and Prevention (CDC) to help individuals integrate PA into their daily lives. The coach will orient the participant to the key strategies used in the booklet and encouraged them to use it regularly and to self-monitor PA using the Fitbit during the entire course of the study. In addition, the group will be introduced to www.health.com, a jargon free website that focuses on general health topics and latest medical news. At the end of the meeting, the participants will be asked to provide a schedule for zoom meetings the study team twice per month during the 6 month study. The meetings will focus on their progress in using the Be Active Your Way handout and the health.com website."
214602522|NCT05803304|OTHER|Physical activity tracker|Participants will be asked to wear Fitbit Charge 5 on their non-dominant hand for the entire duration of the study using a 24hr wear protocol.
214602523|NCT05803304|BEHAVIORAL|Dietary education|Diet quality and barriers to healthy eating will be evaluated at baseline, and then all study participants will be provided with educational materials that are curated to promote diet quality. Participants will receive a monthly email with a brief PDF addressing a diet component focused on improving diet quality to reduce CVD risk and improve general health.
214602524|NCT04193878|DRUG|Inhaled budesonide and formoterol|aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
214602525|NCT04193878|DRUG|Inhaled placebo|aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
214602526|NCT02510560|DRUG|NTRA-2112|
214602527|NCT02510560|DRUG|Placebo|
214602528|NCT05149365|DRUG|Sitagliptin + Standard Prophylaxis|Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
214602529|NCT05149365|DRUG|Standard Prophylaxis|Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
214602530|NCT04978181|DRUG|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
214602531|NCT00132496|DRUG|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
214602532|NCT05743504|DRUG|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
214602533|NCT03645265|BEHAVIORAL|Auditory|Use of auditory cues to improve speech production
214602534|NCT03645265|BEHAVIORAL|Gestures|Use of gestures to improve speech production
214602535|NCT03059927|PROCEDURE|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design
214602536|NCT03059927|PROCEDURE|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design
214602537|NCT03059927|PROCEDURE|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
214602538|NCT00197808|BIOLOGICAL|menjugate|men C conjugate vaccine
214602539|NCT00197808|BIOLOGICAL|Men C conjugate vaccine|men C conjugate vaccine
214602540|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
214602541|NCT00197808|BIOLOGICAL|Men C Conjugate|men C conjugate vaccine
214602542|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
214602543|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
214602544|NCT06396793|OTHER|no intervention because it is an observational study|it is an observational study thus there is no intervention
214602545|NCT04509960|DEVICE|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
214602546|NCT02374398|DRUG|Tranexamic Acid|see arm/group descriptions
214602547|NCT02374398|DEVICE|Aquamantys System|see arm/group descriptions
214602548|NCT02374398|OTHER|Control|Standard Electro-cautery and Saline
214602549|NCT02238951|OTHER|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
214602550|NCT02238951|OTHER|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
214602551|NCT01093625|DEVICE|Narafilcon B Contact Lens|
214602552|NCT01093625|DEVICE|Spectacles|spectacle wearers
214602553|NCT04567667|DRUG|[14C] BMS-986278|Specified dose on specified days
214602554|NCT04567667|DRUG|Kinevac®|Specified dose on specified days
214602555|NCT02693769|DRUG|fluticasone propionate/formoterol fumarate breath actuated inhaler|
214602556|NCT02693769|DRUG|Indacaterol maleate / glycopyrronium bromide capsules|
214602557|NCT00437671|DRUG|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
214602558|NCT00437671|BIOLOGICAL|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
214602559|NCT00148265|DRUG|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
214602560|NCT00533026|DRUG|Duloxetine|
214602561|NCT00533026|DRUG|Warfarin|
214602562|NCT02673606|DRUG|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
214602563|NCT02673606|DRUG|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
214602564|NCT02673606|DRUG|Placebo Pills|inactive placebo pills
214602565|NCT02014740|DRUG|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
214602566|NCT02014740|DRUG|Metformin|
214602567|NCT05426642|OTHER|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
214602568|NCT05426642|OTHER|Brochure|The brochure contain the information regarding cervical cancer and its screening
214602569|NCT06085027|PROCEDURE|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
214602570|NCT01069250|OTHER|There are no interventions in this study|
214602571|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
214602572|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
214602573|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
214602574|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
214602575|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
214602576|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
214602577|NCT02992314|DEVICE|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
214602578|NCT02992314|DEVICE|Placebo|Placebo formulation with out the active ingredients
214602579|NCT03173079|OTHER|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
214602580|NCT02472379|BEHAVIORAL|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
214602581|NCT02472379|OTHER|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
214602582|NCT03234166|OTHER|Non interventional study|Only data will be taken of patient's file.
214602583|NCT04272541|BEHAVIORAL|Psychoeducation program|Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.
214602584|NCT04272541|DRUG|Psychopharmacology intervention|Intervention program consisted of psychopharmacology. This will be executed during 3 months.
214602585|NCT03404284|BEHAVIORAL|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
214602586|NCT01431534|DRUG|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
214602587|NCT06154213|BEHAVIORAL|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
214602588|NCT06154213|BEHAVIORAL|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
214602589|NCT06497127|DRUG|BW-00112|BW-00112 or volume-matched placebo on Day 1 and Day 90
214602590|NCT05267860|DEVICE|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
214602591|NCT02608541|OTHER|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
214602592|NCT04308525|BEHAVIORAL|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
214602593|NCT04308525|BEHAVIORAL|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
214602594|NCT04308525|OTHER|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
214602595|NCT04308525|PROCEDURE|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
214712056|NCT03185923|DRUG|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
214712057|NCT03185923|DRUG|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
214712058|NCT05685394|DRUG|Dapagliflozin|Dapagliflozin 10mg P.O. daily
214712059|NCT00947934|DEVICE|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
214712060|NCT03614819|PROCEDURE|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
214712061|NCT03614819|PROCEDURE|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
214712062|NCT04797312|DRUG|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
214602596|NCT04308525|PROCEDURE|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
214602597|NCT04308525|OTHER|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
214602598|NCT04308525|OTHER|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
214602599|NCT00182351|PROCEDURE|D-dimer|
214602600|NCT00182351|PROCEDURE|Serial Compression Ultrasound|
214602601|NCT02032303|PROCEDURE|Assessment of coronary flow reserve|
214602602|NCT02032303|PROCEDURE|Percutaneous Coronary Intervention|
214602603|NCT02032303|DRUG|Ticagrelor loading|
214602604|NCT02032303|DRUG|Prasugrel loading|
214602605|NCT05100485|DIAGNOSTIC_TEST|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
214602606|NCT05100485|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
214602607|NCT03537950|DRUG|PLC|Single oral dose of PLC.
214602608|NCT03537950|DRUG|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
214602609|NCT03537950|DRUG|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
214602610|NCT02939248|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
214602611|NCT02939248|DRUG|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
214602612|NCT01759212|BIOLOGICAL|Allogeneic stem cells implantation|
214602613|NCT01241097|DRUG|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
214602614|NCT03575455|BEHAVIORAL|Exercise|HR-controlled treadmill walking
214602615|NCT04561752|DRUG|ZN-c5|ZN-c5 is the study drug.
214602616|NCT02993653|RADIATION|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
214602617|NCT01387048|DRUG|skinoren|gel 15%, twice daily, 36 weeks
214602618|NCT01387048|DRUG|differin|0.1% gel, once daily in the evening
214602619|NCT01387048|DRUG|skinoren|12 weeks treatment, the following 24 months only observation
214602620|NCT00691886|DRUG|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
214602621|NCT04144504|DEVICE|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
214602622|NCT04144504|DEVICE|Plastic stenting|Use of plastic stents
214602623|NCT04427501|DRUG|LY3819253|Administered IV
214602624|NCT04427501|DRUG|LY3832479|Administered IV
214602625|NCT04427501|DRUG|LY3853113|Administered IV
214602626|NCT04427501|DRUG|Placebo|Administered IV
214602627|NCT01975818|DRUG|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
214602628|NCT01975818|BIOLOGICAL|Epoetin alfa/beta|
214602629|NCT01973946|OTHER|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
214602630|NCT04566627|BEHAVIORAL|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
214602631|NCT00893646|BEHAVIORAL|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
214602632|NCT05093725|DEVICE|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
214602633|NCT03926156|DRUG|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
214602634|NCT03926156|DRUG|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
214712063|NCT04797312|DRUG|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
214712064|NCT00436020|DEVICE|TMS|Transcranial Magnetic Stimulation
214712065|NCT00436020|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
214712066|NCT04833920|DEVICE|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
214712067|NCT06066840|DRUG|Basiliximab|Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
214712068|NCT06066840|DRUG|Vedolizumab|Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
214712069|NCT04055467|DRUG|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
214712070|NCT04055467|BEHAVIORAL|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
214712071|NCT03027219|DRUG|Alprostadil|Vasodilator for anastomosis-site of free flap
214602635|NCT04936841|DRUG|NKTR-214|Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
214602636|NCT04936841|DRUG|anti-PD-1 therapy|immunotherapy drug, monoclonal antibody
214602637|NCT04936841|RADIATION|Palliative Radiation|radiation to relieve symptoms
214602638|NCT00639223|DIETARY_SUPPLEMENT|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
214602639|NCT00639223|DRUG|Pravastatin|One 20mg capsule twice daily for 12 weeks
214602640|NCT00639223|BEHAVIORAL|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
214712072|NCT04510402|DRUG|Povidine iodine nasal swabs|Daily versus twice daily nasal application
214712073|NCT05742841|DRUG|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
214602641|NCT03963752|DRUG|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
214602642|NCT03963752|DRUG|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
214602643|NCT03963752|DRUG|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
214712074|NCT04005807|DRUG|BPN-14967|BPN-14967 oral capsules
214712075|NCT04005807|DRUG|Placebo|Oral capsules
214712076|NCT06153069|DRUG|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
214712077|NCT06153069|DRUG|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
214712078|NCT02747407|BIOLOGICAL|Hepatitis A Vaccine|
214712079|NCT02747407|OTHER|Laboratory Biomarker Analysis|Correlative studies
214712080|NCT02747407|BIOLOGICAL|Tetanus Toxoid Vaccine|
214602644|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
214602645|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
214602646|NCT01884233|BEHAVIORAL|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
214712081|NCT02747407|BIOLOGICAL|Trivalent Influenza Vaccine|
214712082|NCT03872193|OTHER|Exercise|Virtual Reality Exercies
214712083|NCT02471209|DRUG|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
214712084|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
214712085|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214602647|NCT01884233|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
214602648|NCT02400450|DIETARY_SUPPLEMENT|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
214602649|NCT02400450|DIETARY_SUPPLEMENT|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
214602650|NCT04801134|OTHER|Education|as per previous description
214602651|NCT06147570|DRUG|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
214602652|NCT06334393|BIOLOGICAL|VLA1601|0.45mL (milliliter), Day 1 and 29
214602653|NCT06334393|BIOLOGICAL|CpG 1018®|CpG 1018® will be investigated in combination with VLA1601 Low dose
214602654|NCT06334393|BIOLOGICAL|3M-052-AF|3M-052-AF will be investigated in combination with VLA1601 Low dose
214602655|NCT05999929|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
214602656|NCT04649229|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
214602657|NCT04649229|DRUG|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
214602658|NCT04649229|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
214602659|NCT04649229|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
214602660|NCT04649229|DRUG|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
214602661|NCT06409585|DIAGNOSTIC_TEST|68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR|200MBq of the above named radiotracer will be administered for PET-MR
214602662|NCT06409585|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 1 year follow-up
214602663|NCT06409585|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
214602664|NCT05739123|DRUG|Relugolix-Containing Product|Any relugolix-containing therapy
214602665|NCT05745883|DRUG|DISC-0974|DISC-0974 is administered subcutaneously
214602666|NCT05745883|DRUG|Placebo|Placebo is administered subcutaneously
214602667|NCT05330455|DRUG|GSK3965193|GSK3965193 will be administered
214602668|NCT05330455|DRUG|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
214602669|NCT05330455|DRUG|Bepirovirsen|Bepirovirsen will be administered
214602670|NCT03376152|BEHAVIORAL|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
214602671|NCT06219356|DRUG|GLB-002|Administered orally according to the assigned treatment schedule.
214602672|NCT01701596|PROCEDURE|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
214602673|NCT01701596|PROCEDURE|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
214712086|NCT03039049|DRUG|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
214602674|NCT05533515|DIAGNOSTIC_TEST|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
214602675|NCT01052922|OTHER|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
214602676|NCT01052922|OTHER|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
214602677|NCT01052922|OTHER|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
214602678|NCT02767128|DRUG|Triferic|
214602679|NCT02767128|DRUG|Fer-In-Sol|
214602680|NCT02767128|DRUG|Shohl's solution|
214602681|NCT00632398|BEHAVIORAL|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
214602682|NCT00632398|BEHAVIORAL|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
214602683|NCT05359965|DEVICE|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
214602684|NCT01644110|DRUG|INCB018424/CC-4047|"Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily."
214712087|NCT00888212|PROCEDURE|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
214712088|NCT03197350|DIAGNOSTIC_TEST|cMR|cardiac MRI done to complete the diagnosis
214712089|NCT03197350|BIOLOGICAL|biomarker|Biomarker correlation with cMR parameters Prognostic information
214602685|NCT05475652|OTHER|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
214602686|NCT05475652|OTHER|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
214602687|NCT01395979|BEHAVIORAL|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
214602688|NCT01395979|BEHAVIORAL|Supportive Psychotherapy|Eight weekly sessions
214602689|NCT01395979|BEHAVIORAL|Sexual Risk Reduction Intervention|Two weekly sessions.
214602690|NCT01202214|DRUG|1440115|
214602691|NCT01202214|DRUG|Placebo|matching placebo
214602692|NCT02020070|DRUG|Degarelix|
214602693|NCT02020070|DRUG|Ipilimumab|
214602694|NCT02020070|PROCEDURE|Radical Prostatectomy|
214602695|NCT01144767|BEHAVIORAL|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
214602696|NCT01144767|BEHAVIORAL|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
214602697|NCT03523260|DEVICE|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
214602698|NCT02936128|OTHER|TruSkin|
214602699|NCT02936128|OTHER|Wound Cover|
214602700|NCT05493085|PROCEDURE|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
214602701|NCT05493085|PROCEDURE|Caudal epidural injection|Single Caudal epidural injection
214602702|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
214602703|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
214602704|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
214602705|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
214602706|NCT01080677|DRUG|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
214602707|NCT01080677|DRUG|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
214602708|NCT01739153|OTHER|Dietary intervention: CHEESE (High cheese intake)|
214602709|NCT01739153|OTHER|Dietary intervention: MEAT (High Meat intake)|
214602710|NCT01739153|OTHER|Dietary intervention: CARB (High Carbohydrate intake)|
214602711|NCT01096134|BIOLOGICAL|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
214602712|NCT03588507|COMBINATION_PRODUCT|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
214712090|NCT02733146|OTHER|cardiac arrest|
214602713|NCT03719755|PROCEDURE|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
214602714|NCT03719755|PROCEDURE|Normal Saline|Cystoscopic distention media of normal saline
214602715|NCT02475486|DEVICE|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
214602716|NCT05742737|OTHER|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
214602717|NCT06079684|DEVICE|Intermittent vacuum therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days."
214602718|NCT02499770|DRUG|Carboplatin|
214602719|NCT02499770|DRUG|Placebo|
214602720|NCT02499770|DRUG|Trilaciclib|
214602721|NCT02499770|DRUG|Etoposide|
214602722|NCT05134051|DEVICE|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
214602723|NCT03230526|DRUG|[18F]DPA-714 PET scan|"One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24"
214602724|NCT03193788|DRUG|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
214712091|NCT04379960|OTHER|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
214712092|NCT06305091|DIAGNOSTIC_TEST|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
214712093|NCT04733001|DRUG|HSG4112|Once-daily oral administration
214712094|NCT01629901|DEVICE|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
214602725|NCT03193788|DRUG|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
214602726|NCT03193788|DRUG|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
214602727|NCT03193788|DRUG|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
214602728|NCT04805554|OTHER|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
214602729|NCT00006380|BIOLOGICAL|monoclonal antibody muJ591|
214602730|NCT00006380|RADIATION|iodine I 131 monoclonal antibody muJ591|
214602731|NCT02273726|DRUG|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
214602732|NCT02273726|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
214602733|NCT05197751|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
214602734|NCT05877378|DEVICE|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
214602735|NCT01568645|DRUG|Carvedilol|
214602736|NCT01568645|DRUG|Imatinib|
214602737|NCT01301651|BEHAVIORAL|balance training|30 minute each time, 2 times per week for 6 weeks.
214602738|NCT00628303|BIOLOGICAL|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
214602739|NCT00628303|OTHER|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
214602740|NCT06119009|OTHER|non interventions|
214602741|NCT03653533|DEVICE|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
214602742|NCT03653533|DEVICE|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
214602743|NCT03653533|DEVICE|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
214712095|NCT03148158|DEVICE|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
214712096|NCT04848415|OTHER|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
214602744|NCT04093427|OTHER|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
214602745|NCT02129205|DRUG|PF-06650808|Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
214602746|NCT02129205|DRUG|PF-06650808|Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
214602747|NCT01554488|DRUG|Inhaled Fluticasone Propionate|Inhaled corticosteroid
214602748|NCT00184977|DRUG|N-acetylcysteine|
214602749|NCT00184977|DRUG|fluticasone propionate|
214602750|NCT00770835|DRUG|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
214602751|NCT00770835|DRUG|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
214602752|NCT05196672|BEHAVIORAL|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
214602753|NCT02877927|DRUG|Omadacycline|po tablets
214602754|NCT02877927|DRUG|Linezolid|po tablets
214602755|NCT05447533|OTHER|Comprehensive geriatric assessment (CGA)|"Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe)."
214602756|NCT05447533|OTHER|Continued geriatric care|"Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured."
214602757|NCT05447533|OTHER|Faecal microbiota transplantation (FMT)|When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
214602758|NCT05447533|OTHER|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
214602759|NCT05880550|OTHER|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
214602760|NCT05880550|OTHER|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
214602761|NCT05419843|OTHER|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
214602762|NCT00708175|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
214602763|NCT00708175|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
214602764|NCT03641105|DIAGNOSTIC_TEST|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
214602765|NCT03196232|DRUG|Epacadostat|Given PO
214602766|NCT03196232|DRUG|Pembrolizumab|Given IV
214602767|NCT05110274|PROCEDURE|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
214602768|NCT05110274|PROCEDURE|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
214602769|NCT05906823|OTHER|Detection of pleural effusion|Detection of pleural effusion
214602770|NCT04744571|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
214602771|NCT04744571|DEVICE|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
214602772|NCT04744571|OTHER|drug-coated balloon|Drug-coated balloon including all sizes and all brands
214602773|NCT04744571|DEVICE|drug-eluting stent|Drug-eluting stent including all sizes and all brands
214602774|NCT02257216|OTHER|Vayarin®|Medical Food
214602775|NCT02257216|OTHER|Placebo|Cellulose
214602776|NCT03722056|PROCEDURE|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
214602777|NCT00036894|DRUG|lenalidomide|
214602778|NCT05326113|OTHER|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
214602779|NCT05326113|DRUG|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
214602780|NCT00064389|DRUG|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
214602781|NCT00064389|DRUG|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
214602782|NCT06044844|DRUG|Tofacitinib|tofacitinib efficacy
214602783|NCT00361491|DRUG|SSR149415|
214602784|NCT04411927|OTHER|assessment of postural stability|assessment of postural stability
214602785|NCT00007813|BIOLOGICAL|filgrastim|
214602786|NCT00007813|DRUG|carboplatin|
214602787|NCT00007813|DRUG|cyclophosphamide|
214602788|NCT00007813|DRUG|etoposide|
214602789|NCT00007813|PROCEDURE|autologous bone marrow transplantation|
214602790|NCT00007813|PROCEDURE|peripheral blood stem cell transplantation|
214602791|NCT04165993|DRUG|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
214602792|NCT04165993|DRUG|KN026 monotherapy|30 mg/kg Q3W KN026
214602793|NCT04165993|DRUG|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
214602794|NCT05686226|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
214602795|NCT05686226|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
214602796|NCT03543696|RADIATION|Single Dose Radiotherapy (SDRT)|
214602797|NCT04237922|DRUG|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
214602798|NCT04237922|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
214602799|NCT01829399|DRUG|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
214602800|NCT01829399|DRUG|Normal Saline|
214602801|NCT02555696|DRUG|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
214602802|NCT04312464|OTHER|non|no intervention
214602803|NCT02150330|DRUG|Dehydroepiandrosterone (DHEAS)|
214602804|NCT04513704|DRUG|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
214602805|NCT04751760|BIOLOGICAL|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
214602806|NCT00650572|DRUG|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
214602807|NCT02900534|OTHER|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
214602808|NCT00851123|BEHAVIORAL|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
214602809|NCT00851123|BEHAVIORAL|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
214602810|NCT01685424|DRUG|Etoricoxib|As per routine clinical practice in the United Kingdom
214602811|NCT05777473|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
214602812|NCT05777473|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
214602813|NCT05777473|BEHAVIORAL|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
214602814|NCT03228758|PROCEDURE|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
214602815|NCT01791647|DRUG|metformin 1500 mg|
214602816|NCT01791647|DRUG|myoinositol 1500 mg|
214602817|NCT04118517|OTHER|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing \>50% of the protein.
214602818|NCT03457883|DEVICE|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
214602819|NCT03457883|DEVICE|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
214602820|NCT00261404|DRUG|TNFerade™|
214602821|NCT02906787|BEHAVIORAL|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
214602822|NCT02906787|BEHAVIORAL|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
214602823|NCT02435589|OTHER|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
214602824|NCT02435589|OTHER|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
214712097|NCT02833519|BEHAVIORAL|group exercise|"1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email."
214712098|NCT05565157|PROCEDURE|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
214712099|NCT02581670|RADIATION|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
214602825|NCT03715088|BEHAVIORAL|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
214602826|NCT03050151|DRUG|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
214602827|NCT03050151|DEVICE|Auto-injector Device|Delivery of Dupilumab by auto-injector device
214602828|NCT03050151|DEVICE|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
214602829|NCT01974596|DIETARY_SUPPLEMENT|Probiotic tablets of Lactobacillus reuteri|
214602830|NCT01974596|DIETARY_SUPPLEMENT|Placebo tablets|
214602831|NCT00074022|BIOLOGICAL|GTI-2040|Given IV
214602832|NCT00074022|DRUG|docetaxel|Given IV
214602833|NCT00074022|OTHER|laboratory biomarker analysis|Correlative studies
214602834|NCT00074022|OTHER|pharmacological study|Correlative studies
214602835|NCT03342248|OTHER|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
214602836|NCT03576703|OTHER|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
214602837|NCT03435016|DIAGNOSTIC_TEST|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
214602838|NCT06378437|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
214602839|NCT04586062|DRUG|Plasminogen|Human Plasminogen
214602840|NCT03002519|BIOLOGICAL|PLX-R18|Intramuscular (IM) administration of PLX-R18
214602841|NCT05306457|BIOLOGICAL|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
214602842|NCT00411281|DRUG|cytarabine|Given subcutaneously
214602843|NCT00411281|PROCEDURE|observation|No intervention
214602844|NCT05145335|DEVICE|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
214602845|NCT05145335|DEVICE|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
214602846|NCT04849624|OTHER|No Intervention|This is an observational study and involved no intervention
214602847|NCT06804226|BEHAVIORAL|Video conversation aid|A video conversation aid which provides information regarding life-sustaining care and encourages further goals of care discussions with a healthcare provider will be shown to patients or their surrogates (for those incapacitated and unable to make their own decisions) on admission or within 48 hours whenever feasible
214602848|NCT06804226|BEHAVIORAL|Usual Care|Participants and/or surrogates will participate in discussions surrounding life-sustaining care at healthcare provider discretion.
214602849|NCT06554418|BEHAVIORAL|Communities Care|Communities Care is a violence prevention program targeting social norms and behavioral change
214602850|NCT05619224|OTHER|Neurodevelopmental stimulation + Oral stimulation|"Neurodevelopmental intervention seeks to reduce abnormal postures and movement patterns in premature infants, allowing them to experience physiological postures in flexion and receive sensory stimulation. To this is added oral stimulation.~These stimulations are performed on alternate days."
214602851|NCT05619224|OTHER|Oral stimulation|This intervention consists of performing a sensorimotor stimulation of oral structures: stimulating for 7 minutes perioral structures( cheeks, lips and jaw)intraoral structures for 5 minutes and in the last 3 minutes non-nutritive suction stimulation with pacifier or finger.
214602852|NCT05156281|DRUG|Remibrutinib|tablet taken orally
214602853|NCT05156281|DRUG|Teriflunomide|capsule taken orally
214602854|NCT06510361|DRUG|Epcoritamab|Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
214602855|NCT04833322|DIETARY_SUPPLEMENT|D-Galactose|Galactose supplementation, once per day, up to 1.5g/kg per day
214602856|NCT06173193|BEHAVIORAL|Multicomponent exercise regimen|"A multicomponent exercise regimen applied is comprised of the step-aerobic and resistance training programs alternating every two weeks. The trainees participate in supervised training sessions 3 times a week for 8 months. Each session will include a 10-minutes warm-up, 30-minutes of effective training part and a 10-minutes period for cooling down.~Step-aerobic: The program includes accelerating and decelerating through forwards and sideways movements with stops and turns to music. The degree of difficulty of movements and steps as well as training intensity will be gradually increased by increasing the height of the step benches.~Resistance training: The participants will undergo a progressive resistance training program. Resistance training will emphasize training of following muscle groups: Quadriceps and hamstrings, hip abductors, adductors and extensors, and calf muscles. In addition to lower limb exercises, trunk and upper body exercises will be applied at intervals."
214602857|NCT06173193|BEHAVIORAL|Standard rehabilitative management|The treatments that will be provided to the members of a reference group represent the standard rehabilitative management for knee OA patients. The home exercises focus on functional exercises maintaining lower extremity flexibility and muscle function. The home exercises are instructed to be carried out three times a week, each work-out lasting 30 minutes.
214712100|NCT03277625|PROCEDURE|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
214712101|NCT00362050|DRUG|Treatment with 3 dose groups of RBx11160 over 7 days|
214712102|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
214712103|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
214602858|NCT05731414|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
214602859|NCT05731414|BEHAVIORAL|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
214602860|NCT05731414|BEHAVIORAL|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
214602861|NCT05731414|BEHAVIORAL|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
214602862|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training via Just-In-Time Training (JITT) implementation strategy|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support."
214602863|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) implemented via usual training|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~Usual training involves (a) a one-day virtual training conducted by an IPT-AST expert prior to the beginning of the intervention, and (b) synchronous evidence-based supervision strategies."
214602864|NCT07129499|DRUG|Shenbai Granules|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
214602865|NCT07129499|DRUG|Placebo|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
214602866|NCT07130175|DEVICE|Radiofrequency Catheter Ablation|An invasive procedure performed under local anesthesia. An electroanatomic mapping system (CARTO 3) was used to identify the arrhythmogenic substrate of the PMVT. Radiofrequency energy was delivered via an irrigated-tip catheter (30-35 W, 43°C, 17 mL/min saline irrigation) to ablate the target sites. The procedural endpoint was the non-inducibility of the clinical arrhythmia. Post-procedure, patients were prescribed amiodarone.
214602867|NCT07130175|DRUG|Guideline-Directed Medical Therapy (GDMT)|Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily). Doses were titrated according to patient tolerance and clinical guidelines.
214602868|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
214712104|NCT02565732|BIOLOGICAL|Placebo comparator|Placebo, Dose C, Topical
214602869|NCT07128758|BEHAVIORAL|Music Group Implementation Before surgery, children were asked whether they enjoyed listening to music and what styles of music they liked.|"All procedures required for developing a music pool to be used for music listening intervention in children undergoing appendectomy were completed and are outlined as follows:~* Children were asked about their music preferences.~* Songs were selected from the Ministry of National Education's music books.~* Music with proven effectiveness was selected from music platforms.~* A music pool was created by the researcher based on these inputs.~* Expert opinions were obtained from 12 academicians and 10 healthy children regarding the music pool.~* Necessary revisions were made in line with expert feedback, and the final version of the music pool was determined.~* A pilot application was conducted (data from the pilot were not included in the main data set).~* Children were randomly assigned to the music and control groups using randomization (https://www.random.org).~* A neutral observer (not the researcher/a blinded observer) was trained to administer the scales after the music intervention"
214602870|NCT04025567|DRUG|vancomycin|1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
214602871|NCT04435782|DRUG|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
214712105|NCT04653389|DRUG|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
214712106|NCT04653389|DRUG|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
214712107|NCT04653389|RADIATION|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
214712108|NCT03633591|DRUG|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
214712109|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
214712110|NCT03633591|DRUG|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
214712111|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
214712112|NCT00519610|OTHER|Chart Review|Patients' charts will be reviewed for relevant medical information.
214712113|NCT03796234|OTHER|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
214712114|NCT03796234|OTHER|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
214712115|NCT02911818|BEHAVIORAL|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
214602872|NCT06824376|DEVICE|Manual acupuncture|After sterilisation, the sharp needles will be inserted into the deep tissue layers of acupoints. Acupuncturists will tried to elicit acupuncture de-qi sensation by the manual manipulation of needles. Within a 30-minute period, manual manipulation for each acupoint will last at least 10 seconds and wil repeated four times with intervals of 10-minute.
214602873|NCT06824376|DEVICE|Sham acupuncture|After sterilisation, Streitberger placebo needles with blunt tip will be used. It can be fixed on the surface of the sham points without piercing the skin. Within a 30-minute period, each point will undergo a simulated twisting motion of the needle for at least 10 seconds, and this will be repeated four times at 10-minute intervals.
214712116|NCT02911818|DRUG|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
214712117|NCT02911818|OTHER|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
214712118|NCT02911818|DRUG|Placebo Oral Tablet|
214712119|NCT02911818|DRUG|Phentermine 15 MG|
214712120|NCT02911818|BEHAVIORAL|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
214602874|NCT03672461|OTHER|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
214602875|NCT03672461|OTHER|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
214602876|NCT06744751|BIOLOGICAL|Fecal Microbiota Transplantation|Patients take the capsules twice daily, with a dose of 6 or 10 capsules per day, for a total of 6 days (72 or 120 capsules in total). Select the capsule dosage based on age. For children under 18 years old, take 10 capsules at a time. For adults aged 18 and above, take 6 capsules at a time. Both the FMT and placebo capsules are identical in appearance, size, color, form, weight, and taste, with the placebo containing starch as the main ingredient.
214602877|NCT06744751|DRUG|Placebo|Manufactured by the same company, the placebo capsules contain starch as the main ingredient and are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. They are administered twice daily, 6 or 10 capsules per dose (selected by age), for 6 days.
214602878|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
214602879|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
214602880|NCT06605534|BEHAVIORAL|LungTalk|Tailored lung screening intervention
214602881|NCT06605534|OTHER|Non-tailored lung screening|Non-tailored lung screening. It involves the addition of education to Social Determinants of Health (SDOH) screening and referral with patient navigation. Patients will be identified, and screened for SDOH needs using the UniteUs SDOH screener that is embedded in the Electronic Health Record (EHR), and connected to geographically-tailored resources (as described above under Arm 1). Participants will then be sent a non-tailored lung screening educational brochure via email to review that details lung cancer risk, lung screening facts, benefits, and potential harms. Within 48 hours, the Community Outreach and Engagement (COE) Patient Navigator will contact the patient to answer questions and provide navigation services as described above in Arm 1.
214602882|NCT06432946|OTHER|Video|A 7-minute video demonstrating the sensing-glove system, how it can be used to assess manual therapy biomechanics, and its relevance in research and clinical contexts. The video was created by the research team via a voiceover PowerPoint presentation.
214602883|NCT06432946|OTHER|Practice session|A 20-minute practice session during which participants received verbal information about the sensing-glove system. While wearing the sensing glove, participants performed palpation and manual therapy techniques (palpation, spinal mobilization/manipulation to the cervical and thoracic spine) on a human-sized manikin, guided by the researcher.
214602884|NCT06673524|PROCEDURE|Group T (Transversus Abmoninis Plane Block)|TAP Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position, the ultrasound (USG) probe is placed in an oblique position lateral to the xiphoid process at the lower border of the rib cage. The rectus abdominis muscle and its posterior sheath are visualized above the transversus abdominis muscle. At this level, only the aponeurosis of the internal oblique muscle can be seen between the transversus and external oblique muscles. By applying some pressure and tilt to the probe, the image of the myofascial planes is better optimized. Using a 22-25G, 50-100 mm block needle, an in-plane technique is applied, advancing either medially to laterally or vice versa. In the fascial plane between the rectus abdominis and transversus abdominis or between the internal oblique and transversus abdominis muscles, 20 ml of 0.25% bupivacaine is injected. The same procedure is then applied to the opposite side.
214602885|NCT06673524|PROCEDURE|Group R (Rectus-Intercostal Fascial Plane Block)|Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
214602886|NCT07001046|OTHER|Mobile app-directed exercise program|The mobile app-guided exercise program initially asks the mother questions to collect information. These questions were about their motivation for exercise, the main exercise goal, and the area of focus in the exercise program
214602887|NCT07001046|OTHER|Traditional Abdominal Exercises|The traditional abdominal exercises program consisted of simple static abdominal exercises, graduated curl-ups, and corrected abdominal crunches with posterior pelvic tilting
214602888|NCT04542382|DRUG|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
214602889|NCT04542382|DRUG|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
214602890|NCT04542382|DRUG|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
214602891|NCT05319028|DRUG|Mivavotinib|oral tablet
214602892|NCT06999187|DRUG|DR-0202|DR-0202 is a bispecific antibody
214602893|NCT06033911|DEVICE|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information such as calories or the Nutrition Facts table through FoodFlip©
214602894|NCT06033911|DEVICE|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Canada's 'high-in' NS
214602895|NCT00528255|DRUG|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
214602896|NCT02126943|DRUG|Opsumit (macitentan)|10 mg tablets
214602897|NCT07129148|OTHER|Device: No specific devices|Routine doctor-patient interaction.
214602898|NCT07129148|OTHER|Device: CGM,CGM management platform|Wearable monitoring + CGM management platform-assisted administration
214602899|NCT07129148|OTHER|"Device: Professor Tang WeChat Mini-program"|Mini-program-assisted health management
214602900|NCT07129148|OTHER|"Device: CGM, Smart Bracelet, Professor Tang WeChat Mini-program"|Wearable monitoring + mini-program integrated management
214602901|NCT07128680|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214602902|NCT07128680|PROCEDURE|Bone Scan|Undergo bone scan
214602903|NCT07128680|PROCEDURE|Computed Tomography|Undergo CT
214602904|NCT07128680|DIETARY_SUPPLEMENT|Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01|Given PO
214602905|NCT07128680|BIOLOGICAL|Ipilimumab|Given IV
214602906|NCT07128680|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214602907|NCT07128680|BIOLOGICAL|Nivolumab|Given IV
214602908|NCT07130903|DRUG|Fruquintinib|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
214712121|NCT03550365|OTHER|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
214602909|NCT07130903|DEVICE|TheraBionic P1|TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device
214602910|NCT07130045|OTHER|Hybrid Endurance Strength Training|HybEST will be delivered three times weekly over eight weeks, with two supervised sessions at the center and 22 unsupervised sessions at home. The exercise characteristics of supervised HybEST and unsupervised HybEST are described. Monitoring methods for unsupervised HybEST include a wearable tracking device that collects data on patients' health parameters (arterial oxygen saturation (SpO2), heart rate, and blood pressure) and weekly phone calls. The unsupervised sessions will include video material on the home-based exercise program.
214602911|NCT07130045|OTHER|Usual Care|The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
214602912|NCT07128979|DRUG|Neoven 225 mg capsules|Patients in this group will only use Neoven 225 mg capsules orally. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. A total of 378 mg of total ruscogenin (ruscogenin/neoruscogenin mixture obtained by extraction method) will be taken orally using one Neoven capsule orally with meals twice a day. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
214602913|NCT07128979|DRUG|Placebo|Patients in this group will only receive an oral placebo capsule designed for this study. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. During this period, one placebo capsule will be taken orally twice a day with meals. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
214602914|NCT07128836|OTHER|proprioceptive training exercise and receive insole vibrator|The treatment for the participants in the experimental group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with in-sole vibrator, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
214602915|NCT07128836|OTHER|proprioceptive training exercise along with simple insoles without vibration|The treatment for the participants in the control group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with non-vibrating insole, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
214602916|NCT07130851|PROCEDURE|vestibular schwannoma resection|Vestibular schwannoma resection leads to partial or combined acute unilateral peripheral or combined vestibular lesion.The organism responds with the process of central vestibular compensation.
214602918|NCT07128654|DRUG|CTL02|FDC tablet, single dose, oral administration
214602919|NCT07128654|DRUG|CTL0201|Nesina, tablet, single dose, oral administration
214602920|NCT07128654|DRUG|CTL0202|Jardiance, tablet, single dose, oral administration
214712122|NCT03550365|OTHER|Rye bread intervention|4 week dietary intervention rich in rye bread
214712123|NCT03550365|OTHER|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
214712124|NCT00809861|PROCEDURE|volar locking plating|open reduction and internal fixation
214712125|NCT00809861|PROCEDURE|external immobilisation|closed reduction and external fixation
214712126|NCT05474469|OTHER|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
214602921|NCT07129551|PROCEDURE|preop virtual 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively
214602922|NCT07129551|PROCEDURE|postop 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated
214602923|NCT07130578|DIAGNOSTIC_TEST|urine tumor DNA/RNA testing|The test analyzes DNA and RNA fragments shed by urothelial carcinoma cells into urine, detecting tumor-specific genetic and epigenetic alterations.
214602924|NCT05462951|RADIATION|Standard|Radiation then brachytherapy
214602925|NCT06868433|BIOLOGICAL|Autologous Tumor Membrane Vesicles Vaccine|Given intradermally
214602926|NCT06868433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214602927|NCT06868433|PROCEDURE|Computed Tomography|Undergo CT
214602928|NCT06868433|PROCEDURE|Echocardiography|Undergo echocardiography
214602929|NCT06868433|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214602930|NCT06868433|BIOLOGICAL|Pembrolizumab|Given IV
214602931|NCT06868433|PROCEDURE|Positron Emission Tomography|Undergo PET
214602932|NCT06868433|PROCEDURE|Surgical Procedure|Provide tissue from standard of care surgery
214602933|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 200J (® Zoll)|Cardioversion
214602934|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 360J (® Physio-Control)|Cardioversion
214602935|NCT06632847|OTHER|IMT based Resistance training|IMT with device group is trained twice daily, with the morning session and afternoon session. The intensity will increase progressively in this group, starting at 60% Maximal Inspiratory Pressure (MIP) and reaching 75% by the end of study. POSITION: Patient will be in sitting position. FREQUENCY: 4 TO 5 times per week. INTENSITY: 60 to 75% of MIP (gradually increment the load by 10%every 2 weeks to reach 75 to 80 %MIP). Time: 15 to 20 minutes.
214602936|NCT06632847|OTHER|Theraband Resistive training|IMT training is form of exercise designed to strengthen the muscle that are involve in inhalation, primarily the diaphragm and intercostal muscles. Thera-band resistive training perform twice daily, with morning and afternoon session. Training will be perform 3 times per week. POSITION: patient will be in standing position. INTENSITY: moderate intensity (black and green thera-band used to provide medium resistance). Time: 15 to 20 minutes
214602937|NCT06761677|DRUG|Brincidofovir|Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).
214602938|NCT06773117|DRUG|Susu Xiao'er Zhike Granules|Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
214602939|NCT06773117|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
214602940|NCT07059000|BIOLOGICAL|Kedrion IVIG 10%|(Intravenous) Human Normal Immunoglobulin (IVIg) 10%
214602941|NCT06752356|BIOLOGICAL|Immune globulin (human) 10% solution for intravenous administration|Kedrion intravenous immunoglobulin (IVIg) 10%
214602942|NCT06739356|DEVICE|Fetal Treatment arm (FETO Group)|Participants will undergo FETO surgery at at 27 weeks 0 days - 29 weeks 6 days gestation.Balloon insertion into the fetal trachea will be performed. This will be followed by weekly \\ ultrasound monitoring and MRI at 3 weeks following FETO insertion and removal of the balloon which will be performed at at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age
214602943|NCT06861153|BEHAVIORAL|Pulses 1.5 cups Group|Participants will receive 1.5 cup-equivalents of pulses per week.
214602944|NCT06861153|BEHAVIORAL|Pulses 3 cups Group|Participants will receive 3 cup-equivalents of pulses per week.
214602945|NCT06861153|BEHAVIORAL|My Plate Group (Control)|Participants will continue with their usual dietary practices, receiving no additional pulses. They are encouraged to follow My Plate general recommendations.
214602946|NCT04047654|DRUG|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
214602947|NCT06770569|DRUG|HRS-3802|HRS-3802
214602949|NCT06774404|DEVICE|Use of FreeStyle Libre 14 day Flash Glucose Monitoring System|Women with GDM in the intervention arm will use Flash Glucose Monitoring (FGM) from diagnosis until the end of pregnancy
214602950|NCT06774404|OTHER|No intervention|Only using SMBG
214602951|NCT06739785|OTHER|SCAT6-tr|"Step 1: Initial Translation At this stage, two independent bilingual translators whose native language is Turkish will translate the content into Turkish. Step 2: Integration of Translations~A single translation will be created by comparing the two Turkish versions of SCAT 6.~Step 3: Back-translation The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. These two English versions will be compared, differences will be resolved by consensus and a new combined version will be created. If consensus cannot be reached, a third person will be asked for help. Step 4: Expert Evaluation"
214602952|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
214602953|NCT04491175|DEVICE|M-Stim|"The casing for the device is a 54 belt with 3-button haptic controller for on-off, therapy cycles(8) and intensity(5) levels."
214602954|NCT04491175|DEVICE|TENS|LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
214602955|NCT07065240|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
214602956|NCT07065240|DRUG|Placebo|Placebo for SPT-300
214602957|NCT05356000|OTHER|Special low-oxalate diet followed by all-day visit to University of Chicago research clinic|"Active participation in this study will last for around one week. For the first two days, participants will be asked to eat a special diet at home. From Days 3-5, they will eat special meals that will be delivered to their home from a research clinic at the University of Chicago. They will also collect urine at home on Days 4 and 5.~On Day 6, subjects will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. They will receive a special liquid that contains oxalate, and will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect their urine and blood throughout the day. We will draw blood 4 separate times."
214602958|NCT06841991|BEHAVIORAL|Teach Back Education|The relatives of patients who will undergo colonoscopy will be trained with the teach-back technique.
214602959|NCT06889389|BEHAVIORAL|Education|The intervention consists of 20 minutes of pain neuroscience education, focused on concepts related to movement-related fear and the benefits of exercise for managing pain. Specific exercises, mentioned in the generic part of the procedure, will be discussed during this session. This intervention aims to modify the subjects' beliefs regarding exercises and their neck pain.
214602960|NCT06889389|OTHER|Excercise|The exercise intervention includes performance tests and variations of these tests used as exercises, such as the Closed Kinetic Chain Upper Extremity Stability Test, Single Arm Military Press, and Seated Medicine Ball Throw. Variations of these performance tests will be implemented, with adjustments made to the load or execution time until the participant reports a perceived fatigue of 4-6 (moderate to strong) on the modified Borg scale.
214602961|NCT06889389|OTHER|Placebo|The placebo intervention involves the application of a TENS device, which will be placed on the participant and kept turned off for 15 minutes. Subjects will be informed that the device is working at a very low intensity, too weak to be perceived. This intervention aims to simulate the experience of treatment without delivering any therapeutic effect.
214635105|NCT07143760|DEVICE|Gengigel|Free gingival graft (FGG) surgery leaves an open wound at the palatal donor site, which heals by secondary intention and can cause patient discomfort. Various adjunctive materials, such as stents, collagen sponges, platelet-rich fibrin, and hyaluronic acid (HA), have been explored to improve healing. HA is a naturally occurring glycosaminoglycan with hydrating, anti-inflammatory, and pro-regenerative properties that support fibroblast and keratinocyte activity and promote angiogenesis. These qualities make HA a promising adjunct for enhancing wound healing in periodontal surgery. However, few studies have assessed its clinical impact on palatal donor site healing after FGG, and in existing studies HA was applied only once by the operator rather than used consistently by patients. This study evaluates daily, patient-applied HA gel to address this gap and compare outcomes in smokers and non-smokers.
214602962|NCT06890260|OTHER|Electroacupuncture combined with Microneedle Knife|The patient takes the supine position, the acupoints take bilateral Yingxiang acupoints and upper Yingxiang acupoints, the tip of the needle is stabbed obliquely towards the root of the nose for 5-10mm, to the extent that there is a feeling of soreness and distension in the nose, and perform the flat tonic and flat cathartic method, the waveform of electroacupuncture is selected as sparse and dense wave, the frequency is 2/100Hz, the strength of the current is taken as the degree that the patient can tolerate it, and the time of energizing is 30min; and then the patient takes the seated position, with his head hanging down low on the therapeutic pillow, and the therapeutic point of occipitocervical segment is selected, Then the patient is placed on the therapeutic pillow in a sitting position with the head hanging low, the treatment point of the occipitocervical segment is selected, the treatment point of the cervicothoracic junction is marked, and the micro-needle knife cuts and loose
214602963|NCT06890260|DRUG|Cetirizine hydrochloride tablets combined with nasal budesonide spray.|Cetirizine hydrochloride tablets (specification: 10mg\*24 tablets, Suzhou Sinochem Pharmaceutical Industry Co., Ltd., State Pharmaceutical License: H20030447) shall be given, 1 tablet daily. At the same time, nasal budesonide spray (specification: 64μg\*120 sprays, AstraZeneca Pharmaceuticals Co., Ltd, State Pharmaceutical License: J20090079) shall be used: the starting dose shall be 2 sprays in each nostril twice a day, and after 3 days, it shall be reduced to 1 spray in each nostril twice a day, and then changed to 1 spray once a day after 1 week, which shall be used as the maintenance dose. The dosage will be increased or decreased at the patient's discretion according to the symptomatic condition during the course of treatment for a total of 4 weeks of treatment and observation. No other drugs for allergic rhinitis will be used during the treatment period.
214602964|NCT04624126|DEVICE|3D-Erect|3D-printed erectile device for intercourse
214602965|NCT06404047|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
214712127|NCT05474469|OTHER|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
214712128|NCT06196619|DIAGNOSTIC_TEST|SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level|Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
214712129|NCT03384004|DEVICE|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
214602966|NCT06404047|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
214602967|NCT06404047|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
214602968|NCT06404047|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
214602969|NCT04112654|PROCEDURE|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
214602970|NCT04112654|PROCEDURE|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
214602971|NCT05061563|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
214712130|NCT03384004|DEVICE|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
214712131|NCT01985165|DRUG|Imrecoxib|
214602972|NCT05061563|DRUG|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
214602973|NCT05649033|OTHER|data collection|Work-related stress evaluation
214712132|NCT01175590|DRUG|Besivance|Ocular administration to affected eye for 7 days
214712133|NCT01175590|DRUG|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
214712134|NCT01107704|BEHAVIORAL|Family Support Intervention|Multifaceted family support intervention
214712135|NCT05557097|DIAGNOSTIC_TEST|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
214602974|NCT01310803|DRUG|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
214602975|NCT01310803|OTHER|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
214602976|NCT02378454|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
214602977|NCT01306890|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
214602978|NCT05102084|DEVICE|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
214602979|NCT03219320|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
214602980|NCT03219320|DRUG|Placebo|Matching Placebo capsules.
214602981|NCT04066803|DRUG|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
214602982|NCT04066803|DRUG|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
214602983|NCT04066803|DRUG|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
214602984|NCT01865396|BEHAVIORAL|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
214602985|NCT01865396|BEHAVIORAL|Standard oncologic care|Patients will receive standard oncologic care.
214602986|NCT05906342|OTHER|20% fat meal|Provided to participants once throughout duration of study, contains 20% fat
214602987|NCT05906342|OTHER|40% fat meal|Provided to participants once throughout duration of study, contains 40% fat
214602988|NCT05906342|OTHER|60% fat meal|Provided to participants once throughout duration of study, contains 60% fat
214602989|NCT05906342|OTHER|80% fat meal|Provided to participants once throughout duration of study, contains 80% fat
214602990|NCT00597077|OTHER|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
214602991|NCT00597077|OTHER|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
214602992|NCT02350179|DRUG|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
214602993|NCT02350179|DRUG|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
214712136|NCT04775394|OTHER|Bronchoscopy|Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
214712137|NCT05851092|DRUG|HRS-2189 Tablets|HRS-2189 Tablets
214602994|NCT00142051|DRUG|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
214602995|NCT00142051|DRUG|oxygen|oxygen fi02 21% (room air)
214602996|NCT03739762|BEHAVIORAL|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
214602997|NCT03739762|OTHER|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
214602998|NCT05013853|PROCEDURE|Restoration teeth|Remove caries and restore with resin composite
214602999|NCT05737043|DIAGNOSTIC_TEST|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
214603000|NCT06335992|OTHER|Exercise regime|Exercise
214603001|NCT01873716|DRUG|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
214603002|NCT01695577|OTHER|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
214603003|NCT01695577|OTHER|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
214603004|NCT06074003|OTHER|Seated Rest (Non-exercise control)|Sitting for 30 minutes
214603005|NCT06074003|OTHER|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
214603006|NCT04103697|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
214603007|NCT04103697|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
214603008|NCT04103697|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
214603009|NCT04103697|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
214603010|NCT04103697|PROCEDURE|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
214603011|NCT00765986|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
214603012|NCT00765986|OTHER|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
214603013|NCT02950402|OTHER|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
214603014|NCT02950402|OTHER|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
214603015|NCT00006036|DRUG|cisplatin|
214603016|NCT00006036|DRUG|lurtotecan liposome|
214603017|NCT06401564|DEVICE|Virtual Reality Therapy|Each participant will receive one or two 20 minute VR sessions during their admission. Participants are able to pause or discontinue at any time. During each VR session, participants will use the REAL Immersive VR system and be equipped with a VR headset and 6 sensors attached to the torso, waist, and upper extremities. Patient will then undergo various virtual challenges guided by the physical or occupational therapist facilitating movements of the upper extremity, core, head, and neck.
214603018|NCT04480060|DIAGNOSTIC_TEST|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
214603019|NCT06167603|DIAGNOSTIC_TEST|FDG-PET|Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.
214603020|NCT06167603|DIAGNOSTIC_TEST|Blood test and clinical examination.|baseline, 12-months and 24 months.
214603021|NCT01681810|DRUG|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
214603022|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid
214603023|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid.
214603024|NCT02080351|BEHAVIORAL|Simple cognitive task|
214603025|NCT02248948|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
214603026|NCT02248948|DIETARY_SUPPLEMENT|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
214603027|NCT02618005|DIETARY_SUPPLEMENT|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
214603028|NCT05940922|OTHER|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
214603029|NCT06603818|BIOLOGICAL|Tiragolumab|Tiragolumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
214603030|NCT06603818|BIOLOGICAL|Atezolizumab|Atezolizumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
214603031|NCT06603818|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will occur on Days 1, 3, and 5 of Cycle 1 only
214603032|NCT05759065|BEHAVIORAL|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
214603033|NCT05759065|BEHAVIORAL|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
214603034|NCT03819881|BIOLOGICAL|STMC-103H|Live bacterial product
214603035|NCT03819881|BIOLOGICAL|Placebo|Inactive placebo substance
214603036|NCT05993936|DEVICE|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
214603037|NCT02079090|DRUG|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
214603038|NCT02079090|DRUG|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
214603039|NCT01131351|DRUG|Delamanid|OPC-67683 film-coated tablets
214603040|NCT01131351|DRUG|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
214603041|NCT00854698|OTHER|exercise training|subjects are asked to exercise 20 or 30 minutes.
214603042|NCT00854698|OTHER|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
214603043|NCT02294682|DRUG|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
214603044|NCT03226314|PROCEDURE|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
214603045|NCT03010306|OTHER|CASITA|
214603046|NCT03420794|OTHER|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
214603047|NCT00298129|DEVICE|Ambulatory blood pressure monitoring|
214603048|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
214603049|NCT00162864|DRUG|montelukast sodium|
214603050|NCT01281007|DRUG|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
214603051|NCT01281007|DRUG|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
214603052|NCT05028725|DEVICE|EsophaCap Sponge|Non-invasive strategy to sample esophageal tissue
214712138|NCT00223652|BEHAVIORAL|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
214603053|NCT05028725|PROCEDURE|Chromoendoscopy|Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus
214603054|NCT05028725|DEVICE|EsoCAN assay|Biomarker Test
214603055|NCT02461030|DRUG|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
214603056|NCT02461030|DRUG|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
214603057|NCT02461030|PROCEDURE|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
214603058|NCT02545621|OTHER|RAGE TXNIP Inflammasome axis|
214603059|NCT04332224|DEVICE|Blanketrol cooling device and water-perfused blankets|Blanketrol and water-perfused blankets
214603060|NCT04332224|DEVICE|Blanketrol and Kool Kit|Blanketrol cooling device with water-perfused vest, hood and lower body blanket
214603061|NCT04332224|DEVICE|Arctic Sun|Arctic Sun cooling device with gel cooling pads
214603062|NCT03422172|DRUG|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
214603063|NCT03422172|DRUG|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
214603064|NCT06629441|DIETARY_SUPPLEMENT|Probiotic group|taking 10 billion CFU probiotic one sachet one time, lasting 56 days.
214603065|NCT06629441|DIETARY_SUPPLEMENT|Placebo group|taking maltodaxtrin one sachet one time, lasting 56 days.
214603066|NCT00556153|DRUG|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
214603067|NCT03329443|DRUG|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
214603068|NCT03329443|DRUG|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
214603069|NCT03182166|DRUG|Golimumab (Optimization)|"Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
214603070|NCT03182166|DIAGNOSTIC_TEST|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
214603071|NCT03182166|BIOLOGICAL|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
214635106|NCT07143136|DRUG|Colchicine|Administration of Colchicine 1 day before and 90 days after PCI in Non-STEMI Patients
214635107|NCT07143136|DRUG|Placebo|Matching Placebo Regimen
214635108|NCT07143318|DRUG|KLA578-1 for injection|Intravenous injection, single dose
214635109|NCT07143318|DRUG|Etopcoxib Tablets|P.O., single dose
214635110|NCT07144085|DRUG|68Ga-FXX489|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
214635111|NCT07144085|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes.
214635112|NCT07144085|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
214635113|NCT07143344|OTHER|Fermented lingonberry juice sprey|Patented fermented lingonberry juice sprey
214635114|NCT07143292|DRUG|Famitinib + Camrelizumab|Famitinib + Camrelizumab
214635115|NCT07144397|PROCEDURE|TOLS|"Standard AC plus bilateral lateral suspension using non-absorbable sutures passed through the obturator foramen to support lateral vaginal wall."
214603072|NCT06246617|DEVICE|da Vinci SP Surgical System for Single-Port Thoracic Surgeries|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
214603073|NCT03932734|OTHER|survey|Face-Q conversion table
214603074|NCT05197517|DRUG|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
214603075|NCT05054595|BEHAVIORAL|Standard Pain Management|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
214603076|NCT05054595|BEHAVIORAL|Audio-Recorded Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
214603077|NCT05054595|BEHAVIORAL|Nurse-Led Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
214603078|NCT06414681|DRUG|Tagraxofusp|Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
214603079|NCT06414681|DRUG|Pacritinib|Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
214603080|NCT05716750|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vit D treatment for 8 weeks
214603081|NCT05400642|DEVICE|THRIVE|Apneic ventilation
214603082|NCT05400642|DEVICE|mechanical ventilation|mechanical ventilation in Positive Pressure
214603083|NCT01002456|OTHER|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
214603084|NCT01002456|OTHER|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
214603085|NCT03152279|DIAGNOSTIC_TEST|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
214603086|NCT03152279|DIAGNOSTIC_TEST|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
214603087|NCT00382603|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
214603088|NCT02479945|OTHER|Obtaining biospecimen|
214712139|NCT04754113|OTHER|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
214603089|NCT04317560|PROCEDURE|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
214603090|NCT04317560|PROCEDURE|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
214603091|NCT00059839|DRUG|doxorubicin hydrochloride|Given IV
214603092|NCT00059839|DRUG|mercaptopurine|Given by mouth
214603093|NCT00059839|DRUG|methotrexate|Given IV and intrathecally
214603094|NCT00059839|DRUG|prednisone|Given by mouth
214603095|NCT00059839|DRUG|vinblastine sulfate|Given IV
214603096|NCT00059839|DRUG|vincristine sulfate|Given IV
214603097|NCT01444014|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
214603098|NCT00003181|BIOLOGICAL|aldesleukin|
214603099|NCT00003181|BIOLOGICAL|sargramostim|
214603100|NCT00003181|DRUG|vinblastine sulfate|
214603101|NCT00799279|BEHAVIORAL|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
214603102|NCT00799279|BEHAVIORAL|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
214603103|NCT00395551|DRUG|ranibizumab|0.5mg intravitreal injection
214603104|NCT04248582|DEVICE|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
214603105|NCT04440787|PROCEDURE|Three point cuff palpation technique|the ETT is finally positioned according to the Three point cuff technique.
214603106|NCT03089242|OTHER|observation of microRNA expression|no intervention
214603107|NCT05880940|DEVICE|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
214603108|NCT05880940|BEHAVIORAL|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
214603109|NCT06007742|OTHER|parent-administered pediatric tuina|"Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention."
214603110|NCT01755845|DRUG|paclitaxel|
214603111|NCT01755845|DRUG|cisplatin|
214603112|NCT01755845|RADIATION|radiotherapy|
214603113|NCT05197036|PROCEDURE|Total Knee Arthroplasty|A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
214603114|NCT00238550|DRUG|Cannabis based medicine extract (CBME)|
214603115|NCT00129623|DRUG|Placebo|po monthly for 1 year
214712140|NCT05536154|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
214712141|NCT05536154|DRUG|Cytarabine|Day 1\~Day 2: 200mg/m\^2, q12h
214712142|NCT05536154|DRUG|PEG-rhG-CSF|Day 6: 6mg
214603116|NCT00129623|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
214603117|NCT01619111|DRUG|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
214603118|NCT01619111|DRUG|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib~\+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
214603119|NCT03155373|DIAGNOSTIC_TEST|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
214603120|NCT03155373|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
214603121|NCT03155373|DIAGNOSTIC_TEST|Pulmonary function tests|Pre and post-operative pulmonary function tests
214603122|NCT03155373|DIAGNOSTIC_TEST|Cardiac MRI|Pre and post-operative cardiac MRI
214603123|NCT03155373|OTHER|Quality of life survey|Pre and post-operative quality of life survey (SF36)
214603124|NCT03155373|PROCEDURE|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
214603125|NCT03155373|PROCEDURE|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
214603126|NCT04315545|DIAGNOSTIC_TEST|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
214603127|NCT04236882|OTHER|Focus Group|Attend focus group
214603128|NCT04236882|BEHAVIORAL|Health Education|Receive educational material on healthy homes
214603129|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based sleep intervention
214603130|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based health coaching sessions
214603131|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based counseling sessions
214603132|NCT04236882|OTHER|Interview|Complete interview
214603133|NCT04236882|OTHER|Questionnaire Administration|Ancillary studies
214603134|NCT05178134|BIOLOGICAL|Etvax|"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."
214603135|NCT05178134|BIOLOGICAL|Etvax|Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
214603136|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
214603137|NCT01479933|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
214603138|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
214603139|NCT06411938|OTHER|Self-collection of vaginal swabs|Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
214603140|NCT05090371|DRUG|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
214603141|NCT05090371|DRUG|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
214603142|NCT04504357|BEHAVIORAL|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
214603143|NCT04504357|OTHER|Text messages|Monthly text messages reinforcing intervention content
214603144|NCT05467800|DRUG|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
214603145|NCT06000423|DRUG|Tranexamic acid|1300mg TXA taken three times per day for five days
214603146|NCT06000423|OTHER|Placebo|Placebo pills taken three times daily for five days.
214603147|NCT06339567|DIAGNOSTIC_TEST|Thrombotic profile|several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
214603148|NCT06155331|DRUG|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
214603149|NCT06155331|OTHER|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
214603150|NCT06155331|DRUG|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
214603151|NCT06155331|DRUG|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
214603152|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
214603153|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
214603154|NCT05177107|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
214712143|NCT05784870|DRUG|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
214603155|NCT05177107|OTHER|Placebo|Placebo (normal saline)
214603156|NCT05352048|DEVICE|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
214603157|NCT05352048|DEVICE|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
214603158|NCT06361810|DRUG|Pembrolizumab|"Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase."
214603159|NCT06361810|DRUG|177Lu-PNT2002|"177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles."
214603160|NCT06361810|DRUG|(F-18)-DCFPyL|Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
214712144|NCT05784870|DRUG|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
214712145|NCT00656578|DRUG|4975|Single dose, solution
214712146|NCT00656578|DRUG|Placebo|Single dose, solution
214712147|NCT01639456|BIOLOGICAL|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
214603161|NCT02412566|DRUG|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
214603162|NCT05586360|DRUG|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
214603163|NCT04648904|RADIATION|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
214603164|NCT06804928|BEHAVIORAL|Virtual Reality Glasses|During the procedure, the patient will wear virtual reality glasses and watch a video. The video will be played through the virtual reality glasses throughout the entire procedure.
214603165|NCT06181266|DRUG|ZH9|ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
214603166|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
214603167|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
214603168|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
214603169|NCT04951154|OTHER|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
214603170|NCT04951154|OTHER|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
214603171|NCT05602948|BEHAVIORAL|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation (see Move \& Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
214603172|NCT05602948|BEHAVIORAL|'Move & Learn' intervention|"The physical activities in Move \& Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
214603173|NCT05466123|BEHAVIORAL|Virtual Reality|Simulated travel destination or activity of the participants choosing that would otherwise be inaccessible
214603174|NCT06802523|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
214603175|NCT06802523|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214603176|NCT06802523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214603177|NCT06802523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214603178|NCT06802523|DRUG|Decitabine and Cedazuridine|Given PO
214603179|NCT06802523|DRUG|Venetoclax|Given PO
214603180|NCT01526070|DRUG|Intravitreal injection of Aflibercept|
214603181|NCT05538273|OTHER|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
214603182|NCT05538273|OTHER|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
214603183|NCT02885090|PROCEDURE|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
214603184|NCT03600857|OTHER|Home administration of misoprostol|First dose of misoprostol administration at home
214603185|NCT01214187|DRUG|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
214603186|NCT01214187|OTHER|Oxygen|Room air oxygen concentrations will be administered as placebo
214603187|NCT04534556|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
214603188|NCT04534556|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
214603189|NCT01662115|DRUG|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
214603190|NCT01662115|OTHER|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
214603191|NCT00998426|PROCEDURE|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
214603192|NCT00998426|BIOLOGICAL|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
214603193|NCT04011228|DIAGNOSTIC_TEST|Blood sampling|After a fasting period over night blood samples will be taken.
214603194|NCT04011228|DIAGNOSTIC_TEST|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
214603195|NCT04011228|DIAGNOSTIC_TEST|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
214712148|NCT01639456|BIOLOGICAL|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
214603196|NCT05781633|DRUG|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
214603197|NCT01584154|PROCEDURE|cryoablation|cryoablation with an 8mm-tip catheter
214603198|NCT01584154|PROCEDURE|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
214603199|NCT02231125|DRUG|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
214603200|NCT02231125|DRUG|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
214603201|NCT02724124|OTHER|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
214603202|NCT02724124|OTHER|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
214603203|NCT02724124|OTHER|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
214603204|NCT02724124|OTHER|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
214603205|NCT02724124|OTHER|Control|No intervention
214603206|NCT04287842|DRUG|Desflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
214635116|NCT07144449|BEHAVIORAL|Nurse-Led ePRO System|A nurse-designed electronic patient-reported outcome (ePRO) system for chemotherapy patients. Participants complete weekly symptom assessments for 12 weeks through an electronic platform. The system provides automated feedback, evidence-based self-care advice, and alerts to oncology nurses. Nurses follow up with weekly phone calls if severe symptoms are reported. This intervention is intended to improve symptom self-management, quality of life, and health literacy.
214635117|NCT07144449|BEHAVIORAL|Usual Care|Participants will receive standard oncology care without the use of an ePRO system. Symptom monitoring and management will be provided according to routine clinical practice by the treating oncology team, typically during scheduled visits or when patients proactively report problems.
214635118|NCT07144020|BIOLOGICAL|CD117 CAR T-cells|Each subject receive CD117 CAR T-cells by intravenous infusion
214635119|NCT07142785|PROCEDURE|Epiretinal membrane peeling|All patients will receive standard pars plana vitrectomy, followed by only epiretinal membrane peeling.
214635120|NCT07142785|PROCEDURE|Epiretinal membrane peeling combined with internal limiting membrane peeling|All patients will receive standard pars plana vitrectomy, followed by epiretinal membrane peeling and internal limiting membrane peeling.
214635121|NCT07142915|OTHER|light-blocking lenses|Subjects will be instructed to wear light-blocking lenses full-time for 12 months.
214635122|NCT07142915|OTHER|single-vision lenses|Subjects will be instructed to wear single-vision lenses full-time for 12 months.
214635123|NCT07143747|OTHER|Hyperpolarized 129Xe MRI|Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.
214635124|NCT07143747|OTHER|Tc-99m Technegas Ventilation Imaging|Inhalation of Tc-99m-labeled carbon aerosol (Technegas) followed by SPECT imaging to assess lung ventilation.
214635125|NCT07142746|PROCEDURE|Digital intra oral scanning|One groups prepared teeth will be scanned by a digital intra oral scanner.
214635126|NCT07142746|PROCEDURE|Conventional impression|One group will recieve impressions conventionally in a tray with dental impression polyvinly siloxane.
214635127|NCT07144059|OTHER|ECG by the SMUR after medical interrogation by the SAMU|Patients who had the qualifying ECG by the SMUR after medical interrogation by the SAMU
214603207|NCT04287842|DRUG|Sevoflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
214603208|NCT04287842|PROCEDURE|Cardiac arrest|Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
214603209|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 200 mg of bosutinib
214603210|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
214603211|NCT01233869|DRUG|Placebo|Once daily oral dose of placebo
214603212|NCT06494020|OTHER|Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)|Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
214603213|NCT05264428|DIETARY_SUPPLEMENT|Honey|Participants need to drink honey every day for four weeks.
214603214|NCT05264428|DIETARY_SUPPLEMENT|Water|Participants need to drink water every day for four weeks.
214603215|NCT00312325|DRUG|Prednisolone|
214603216|NCT03678103|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
214603217|NCT02887937|DRUG|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
214603218|NCT00537485|DRUG|SPM 962|transdermal application, 1 time per day
214603219|NCT00537485|DRUG|placebo|transdermal application, 1 time per day
214603220|NCT03383549|OTHER|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
214603221|NCT02315677|DEVICE|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
214603222|NCT02315677|DEVICE|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
214603223|NCT00486798|DRUG|Quetiapine|
214603224|NCT00486798|PROCEDURE|Rating Scales|
214603225|NCT00486798|PROCEDURE|Self Assessment Form|
214603226|NCT00486798|PROCEDURE|Blood and urine samples|
214603227|NCT00486798|PROCEDURE|Sleeping pattern|
214603228|NCT02967354|RADIATION|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
214603229|NCT05141214|BEHAVIORAL|Virtual Reality Application|In VR application, Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
214635128|NCT07144059|OTHER|ECG performed by a non-medical vector|Patients who have called the emergency services with either an ECG performed by a non-medical vector (SP or ambulance), or a decision to reinforce SMUR during the first aid assessment
214635129|NCT07144605|OTHER|CAD-CAM, indirect restorations|Indirect restorations that we think will last longer than traditional filling materials in teeth with molar hypomineralization.
214635130|NCT07143968|DRUG|Resmetirom|Resmetirom - 80mg or 100mg based on participant weight
214635131|NCT07143968|DRUG|Placebo Control|Placebo - an identical looking tablet with no medicinal properties
214712149|NCT01639456|DEVICE|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
214603230|NCT05461482|OTHER|Pre-procedural consultation and audiovisual tools|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
214603231|NCT00650065|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
214603232|NCT00650065|DRUG|Zyrtec® Tablets 10 mg|10mg, single dose fasting
214712150|NCT01639456|DEVICE|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
214603233|NCT01611753|OTHER|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
214603234|NCT05614310|OTHER|Magnetic Resonance Imaging (MRI)|Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.
214603235|NCT05614310|OTHER|Blood Glucose Assessment|A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg/dl (3.9-6 mmol/L). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.
214603236|NCT05614310|OTHER|Positron Emission Tomography (PET)|Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.
214603237|NCT05614310|OTHER|Cognitive Assessment|Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.
214603238|NCT03165539|DEVICE|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
214712151|NCT01639456|DRUG|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
214712152|NCT01639456|DRUG|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
214712153|NCT01639456|DRUG|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
214603239|NCT00399386|PROCEDURE|EP|
214603240|NCT00399386|PROCEDURE|ICD|
214712154|NCT05321966|OTHER|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
214712155|NCT03948451|DRUG|[14C]AZD5718 Oral Suspension|200 mg dose of \[14C\]AZD5718 Oral Suspension
214603241|NCT00399386|PROCEDURE|Ablation|
214603242|NCT04029350|DRUG|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
214603243|NCT05645835|BEHAVIORAL|intervention|the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.
214603244|NCT05645835|BEHAVIORAL|waitlist control|Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
214603245|NCT05645835|OTHER|No Interventions|No intervention. Only baseline fMRI and EEG assessment.
214603246|NCT01260727|BIOLOGICAL|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
214603247|NCT01260727|BIOLOGICAL|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
214603248|NCT01260727|BIOLOGICAL|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
214603249|NCT01260727|BIOLOGICAL|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
214603250|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
214603251|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
214603252|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
214603253|NCT00930514|DRUG|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
214712156|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
214603254|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
214603255|NCT05829707|DRUG|Diclofenac Sodium|"A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4"
214603256|NCT05829707|DRUG|Levobupivacaine bolus analgesia|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4."
214603257|NCT05829707|DRUG|Levobupivacaine PCA group|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4."
214603258|NCT03180749|OTHER|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
214603259|NCT01241552|BIOLOGICAL|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
214603260|NCT01241552|BIOLOGICAL|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
214603261|NCT01241552|BIOLOGICAL|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
214603262|NCT01241552|BIOLOGICAL|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
214712157|NCT04137146|DEVICE|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
214603263|NCT01241552|DRUG|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
214603264|NCT01158651|DRUG|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
214603265|NCT01296035|BIOLOGICAL|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
214603266|NCT01264367|DRUG|Clevudine|30mg,QD
214603267|NCT01264367|DRUG|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
214603268|NCT00564785|DRUG|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
214603269|NCT00564785|OTHER|Placebo patch|placebo patch applied 20 minutes prior to epidural
214603270|NCT03240913|BEHAVIORAL|Baseline and Follow-up Surveys|(completed online)
214603271|NCT03240913|OTHER|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
214603272|NCT03240913|OTHER|Pamphlet|(usual care)
214712158|NCT00042562|DRUG|duloxetine|
214603273|NCT02478723|DEVICE|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
214603274|NCT01717963|DRUG|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
214603275|NCT01717963|DRUG|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
214603276|NCT00324129|DRUG|MGCD0103|MGCD0103 given orally three times per week.
214603277|NCT03267953|BEHAVIORAL|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
214603278|NCT03267953|BEHAVIORAL|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
214712159|NCT01089816|BIOLOGICAL|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
214712160|NCT04598711|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
214712161|NCT04598711|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
214712162|NCT04598711|BEHAVIORAL|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
214712163|NCT04598711|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
214712164|NCT04598711|BEHAVIORAL|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
214712165|NCT02026518|DIETARY_SUPPLEMENT|Soy isoflavones|
214712166|NCT02026518|DIETARY_SUPPLEMENT|cholecalciferol|
214712167|NCT02026518|DIETARY_SUPPLEMENT|Placebo of soy isoflavones|
214712168|NCT02026518|DIETARY_SUPPLEMENT|placebo of cholecalciferol|
214712169|NCT02122926|OTHER|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
214712170|NCT00979719|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
214712171|NCT00979719|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
214603279|NCT03267953|BEHAVIORAL|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
214603280|NCT00695851|DRUG|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
214603281|NCT00695851|DRUG|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
214603282|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
214603283|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
214603284|NCT05073679|DRUG|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
214603285|NCT05073679|OTHER|Control|Methylcellulose and gelatin capsule only
214603286|NCT01765868|DRUG|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
214603287|NCT03508258|OTHER|Non-interventional|Non-interventional
214603288|NCT03508258|OTHER|Non-Interventional|Non-Interventional
214603289|NCT05364268|DEVICE|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
214603290|NCT00533468|DRUG|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
214603291|NCT00533468|DRUG|Placebo|inactive placebo without LMX4
214603292|NCT04080791|DEVICE|Virtual Reality (VR) System|The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.
214603293|NCT04080791|PROCEDURE|Standard of care|Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
214603294|NCT06503094|DRUG|CD19&CD20 bispecific CAR-T cells|Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
214712172|NCT02053558|DRUG|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
214603295|NCT00973154|DRUG|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
214603296|NCT02613351|DEVICE|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
214603297|NCT00301158|BEHAVIORAL|exercise intervention|
214603298|NCT00301158|OTHER|counseling intervention|
214603299|NCT00301158|OTHER|educational intervention|
214603300|NCT00301158|PROCEDURE|complementary or alternative medicine procedure|
214603301|NCT05696236|DEVICE|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
214603302|NCT05696236|DEVICE|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
214603303|NCT05341700|BEHAVIORAL|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
214603304|NCT05341700|BEHAVIORAL|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
214712173|NCT02053558|DRUG|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
214603305|NCT01829360|BEHAVIORAL|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
214603306|NCT01622179|PROCEDURE|sewed indirectly|The epitenon was repaired and sewed indirectly.
214603307|NCT01622179|PROCEDURE|sewed directly|The epitenon was unrepaired and sewed directly.
214603308|NCT05558176|DRUG|Sildenafil citrate|The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
214603309|NCT03388255|DRUG|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication."
214603310|NCT04876534|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Intravenous administration
214603311|NCT04876534|DRUG|MethylPREDNISolone Injectable Solution|Intravenous administration
214603312|NCT00366483|DRUG|Lecozotan SR|
214603313|NCT00201838|DRUG|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
214603314|NCT00201838|DRUG|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
214603315|NCT06298812|DEVICE|REFLECT Scoliosis Correction System|The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials.
214603316|NCT06277102|OTHER|music listening|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
214603317|NCT00897143|GENETIC|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
214603318|NCT00897143|GENETIC|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
214603319|NCT00897143|OTHER|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
214603320|NCT00897143|OTHER|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
214603321|NCT05128721|BIOLOGICAL|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
214603322|NCT01145495|OTHER|Laboratory Biomarker Analysis|Correlative studies
214603323|NCT01145495|DRUG|Lenalidomide|Given PO
214603324|NCT01145495|BIOLOGICAL|Rituximab|Given IV
214603325|NCT03198598|BEHAVIORAL|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
214603326|NCT03198598|BEHAVIORAL|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
214712174|NCT02006498|DRUG|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
214712175|NCT02006498|DRUG|Placebo|Placebo capsule with same appearances as study drug
214712176|NCT00688545|DRUG|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
214603327|NCT05532436|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
214603328|NCT02347033|DRUG|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
214603329|NCT02347033|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
214603330|NCT04147325|DRUG|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
214603331|NCT04379336|BIOLOGICAL|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
214603332|NCT04379336|OTHER|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
214603333|NCT06073236|BEHAVIORAL|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
214603334|NCT00028821|DRUG|2-methoxyestradiol|Given orally
214603335|NCT00028821|OTHER|pharmacological study|Correlative studies
214603336|NCT00028821|OTHER|laboratory biomarker analysis|Correlative studies
214603337|NCT03216421|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
214603338|NCT03426826|BIOLOGICAL|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
214603339|NCT06400498|BEHAVIORAL|Prompted Palliative Care Consult|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. If the treating clinician feels a palliative care consultation would be indicated for the patient, the clinical decision support tool will facilitate the placement of a palliative care consultation by the treating clinician. If the treating clinician feels that a palliative care consultation would not be indicated, then the clinical decision support will record a reason it is not indicated.
214603340|NCT02187614|DRUG|Diclofenac|
214603341|NCT02187614|DRUG|Morphine|
214603342|NCT02187614|DRUG|Paracetamol|
214603343|NCT02187614|DRUG|Placebos|
214603344|NCT04393025|DEVICE|Intracranial Stenting by Intracranial Stent Device|Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted
214603345|NCT04393025|DRUG|Optimum medical treatment|Optimum Medical treatment
214603346|NCT05834686|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC
214603347|NCT00633165|DRUG|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
214712177|NCT00688545|DRUG|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
214712178|NCT03029676|DRUG|benzodiazepines|sedative
214603348|NCT04347850|OTHER|blood sample|Collection
214603349|NCT00859950|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
214603350|NCT00847184|DEVICE|Intubation|Intubation using the standard MacIntosh blade
214603351|NCT00847184|DEVICE|Airtraq|Intubation with the use of the Airtraq technique
214603352|NCT05881967|DIAGNOSTIC_TEST|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
214603353|NCT01886313|DRUG|Civamide Nasal Spray|
214603354|NCT01886313|DRUG|Placebo|
214603355|NCT00136409|DRUG|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
214603356|NCT03838198|BEHAVIORAL|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
214603357|NCT03838198|BEHAVIORAL|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
214603358|NCT03838198|BEHAVIORAL|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
214603359|NCT01159613|OTHER|Responders|Responders
214603360|NCT01159613|OTHER|Non Responders|Non Responders
214603361|NCT04611854|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
214603362|NCT04611854|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
214603363|NCT00283036|DRUG|Irbesartan|
214603364|NCT02378220|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
214603365|NCT05589779|OTHER|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
214603366|NCT05811715|OTHER|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
214712179|NCT03029676|DRUG|opioid|analgetic, sedative
214712180|NCT03029676|PROCEDURE|spinal anesthesia|
214712181|NCT00209872|DRUG|Gabapentin|
214712182|NCT00209872|DRUG|Lidocaine|
214603367|NCT05811715|OTHER|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
214603368|NCT00992979|PROCEDURE|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
214603369|NCT00992979|PROCEDURE|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
214603370|NCT06524583|DRUG|Doxorubicin|60 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
214603371|NCT06524583|DRUG|Trabectedin|1.1 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
214603372|NCT05503550|DRUG|Talquetamab|Talquetamab will be administered subcutaneously (SC).
214603373|NCT00697879|DRUG|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
214603374|NCT00593749|BEHAVIORAL|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
214603375|NCT00593749|BEHAVIORAL|Control|control group in study
214603376|NCT04668651|OTHER|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
214603377|NCT04512443|DRUG|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
214603378|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
214712183|NCT00209872|DRUG|S-ketamine|
214712184|NCT00209872|PROCEDURE|Epidural analgesia|
214603379|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
214603380|NCT00312221|DRUG|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
214712185|NCT03911869|DRUG|encorafenib|taken orally
214712186|NCT03911869|DRUG|binimetinib|taken orally
214712187|NCT06047990|DEVICE|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
214712188|NCT03636113|DEVICE|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
214712189|NCT01878097|BEHAVIORAL|Green Dot Bystander Intevention|Intervention allocated at the school level
214712190|NCT01878097|BEHAVIORAL|Control|Awareness Education
214712191|NCT04488081|DRUG|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
214712192|NCT04488081|DRUG|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
214712193|NCT04488081|DRUG|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
214712194|NCT04488081|DRUG|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
214603381|NCT06033781|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
214603382|NCT05804279|DRUG|BPDO-1603|donepezil/mematine
214603383|NCT01207232|BEHAVIORAL|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
214603384|NCT01207232|BEHAVIORAL|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
214603385|NCT03882905|DRUG|Ezetimibe|10 mg tablet, oral, once daily
214603386|NCT03882905|DRUG|Placebo|one tablet, oral, once daily
214603387|NCT03882905|DRUG|Simivastatin|Once daily administration at dose to be determined
214603388|NCT03882905|DRUG|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
214603389|NCT01805167|OTHER|Electrophysiological study of the interindividual variability of vocal performance|
214603390|NCT04674514|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
214603391|NCT04674514|DRUG|Rd|Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
214603392|NCT00193869|DRUG|Dexamethasone|
214603393|NCT02060721|DRUG|Macitentan|Macitentan 10mg, oral tablet, once daily
214603394|NCT00117507|DRUG|Deferasirox|
214603395|NCT00866723|DRUG|bevacizumab|
214603396|NCT04066790|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
214603397|NCT04066790|DRUG|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
214603398|NCT04066790|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
214603399|NCT04066790|DRUG|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
214603400|NCT04066790|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
214603401|NCT05882097|OTHER|Transform program|International Care Ministries' (ICM) Transform is a 15-lesson, 15-week long values, health, and livelihood program that targets some of the poorest households in Uganda. The health dimension focuses on increasing health knowledge and behaviours on a range of health topics such as malnutrition, respiratory infection, lifestyle, sanitations, family planning and infant care. The livelihood dimension focuses on increasing the amount and sources of household income. Participants will learn about business ideas and farming techniques to diversify their income sources. Additionally, a savings group will be formed at the end of Transform to promote a sustainable strategy to reduce poverty among the participants. The values dimension will focus on relationships, personal character and decision making aspects of an individual.
214603402|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
214603403|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
214603404|NCT05590936|DRUG|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
214603405|NCT05590936|DRUG|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
214603406|NCT00263744|BIOLOGICAL|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
214603407|NCT00263744|OTHER|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
214603408|NCT04072289|DEVICE|Visumax spherocylindrical treatment|treatment of low cylinder (\<0.75D)
214712195|NCT04488081|DRUG|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
214712196|NCT04488081|DRUG|Apremilast|oral, 30 mg bid × 14 days.
214603409|NCT05928130|OTHER|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
214603410|NCT01538797|DRUG|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
214603411|NCT01538797|DRUG|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
214603412|NCT03613285|DEVICE|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
214603413|NCT03613285|DEVICE|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
214603414|NCT03613285|DEVICE|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
214603415|NCT05162638|PROCEDURE|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
214603416|NCT01610362|BIOLOGICAL|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
214603417|NCT03995901|BIOLOGICAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
214603418|NCT01271803|DRUG|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
214603419|NCT01271803|DRUG|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
214603420|NCT01236105|DRUG|LY2624803|Administered orally (po), once.
214603421|NCT01236105|OTHER|Activated Charcoal|Administered po
214603422|NCT04092062|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
214603423|NCT04092062|DEVICE|powered toothbrush|regular powered toothbrush with no RF
214603424|NCT02812901|PROCEDURE|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
214603425|NCT02812901|PROCEDURE|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
214603426|NCT06246708|OTHER|Self-help app with information for grieving Syrian Refugees|This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.
214603427|NCT06246708|OTHER|Wait-list|Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
214603428|NCT04098965|OTHER|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
214603429|NCT04098965|OTHER|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
214603430|NCT00460057|DRUG|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
214603431|NCT05997862|DEVICE|HFFS|This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
214603432|NCT03428074|PROCEDURE|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
214603433|NCT00162890|BEHAVIORAL|Therapeutic exercise|
214712197|NCT04488081|BIOLOGICAL|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
214712198|NCT04488081|DRUG|Celecoxib|Oral: 400 mg BID for 7 days.
214712199|NCT04488081|DRUG|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
214712200|NCT04488081|BIOLOGICAL|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
214712201|NCT04488081|DRUG|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
214712202|NCT04488081|BIOLOGICAL|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
214603434|NCT03938077|DEVICE|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
214603435|NCT04822623|DIAGNOSTIC_TEST|MRI|MRI examination
214603436|NCT00320021|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
214712203|NCT04488081|DRUG|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
214603437|NCT02623374|BEHAVIORAL|self-help CBT intervention (SHCBT)|See 'Arms' section
214603438|NCT06226311|OTHER|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
214603439|NCT06226311|OTHER|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
214603440|NCT02042196|DRUG|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
214603441|NCT02042196|DRUG|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
214603442|NCT02042196|DRUG|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
214603443|NCT02042196|DRUG|Climara|0.075mg/d transdermal patch will be placed on skin.
214603444|NCT02042196|DRUG|Placebo transdermal patch|Inactive transdermal patch
214712204|NCT04488081|DRUG|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
214712205|NCT00224783|BIOLOGICAL|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
214712206|NCT00224783|BIOLOGICAL|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
214712207|NCT00367341|DRUG|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
214712208|NCT00367341|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
214712209|NCT05568927|OTHER|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
214712210|NCT03858296|BEHAVIORAL|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
214603445|NCT05367180|OTHER|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
214712211|NCT03858296|BEHAVIORAL|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
214712212|NCT03858296|BEHAVIORAL|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
214712213|NCT00129740|DRUG|Nilotinib|400 mg orally twice daily
214712214|NCT04516577|OTHER|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
214603446|NCT05367180|OTHER|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
214603447|NCT05367180|OTHER|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
214603448|NCT00846885|DRUG|Sumatriptan Succinate|100 mg Tablet
214603449|NCT00846885|DRUG|Imitrex®|100 mg Tablet
214603450|NCT01862640|DRUG|Brexpiprazole, OPC-34712|Once-daily, tablets
214603451|NCT01862640|DRUG|Placebo Oral Tablet|Once-daily, tablets
214603452|NCT05211739|DEVICE|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
214603453|NCT05211739|DEVICE|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
214603454|NCT05211739|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
214603455|NCT01554735|BEHAVIORAL|Exercise and diet|24 weeks of exercise and diet counselling
214603456|NCT06456996|COMBINATION_PRODUCT|Multi-component intervention package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
214603457|NCT02429622|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
214603458|NCT02429622|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
214603459|NCT02429622|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
214603460|NCT02429622|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
214603461|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
214603462|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
214603463|NCT00462189|DRUG|Immunotoxin therapy|
214603464|NCT00462189|DRUG|CAT-8015 Immunotoxin|
214603465|NCT00462189|PROCEDURE|Biological therapy|
214603466|NCT02178553|DRUG|Epidural|
214603467|NCT02178553|DRUG|Intercostal Bupivicaine (Exparel)|
214603468|NCT04053530|OTHER|restorative materials|glass ionomer and bulk fill flowable composite
214603469|NCT01975428|DEVICE|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
214603470|NCT01975428|BEHAVIORAL|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
214603471|NCT04141254|OTHER|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
214603472|NCT04141254|OTHER|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
214603473|NCT00003251|DRUG|amifostine trihydrate|
214603474|NCT00003251|DRUG|cisplatin|
214603475|NCT00003251|DRUG|paclitaxel|
214603476|NCT00003251|RADIATION|radiation therapy|
214603477|NCT02187809|DRUG|Clobazam|
214603478|NCT05085665|DRUG|Ivermectin|single dose, 150 ug/kg
214603479|NCT03559920|DRUG|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
214603480|NCT03559920|DRUG|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
214603481|NCT02129920|OTHER|This is an observational study|
214603482|NCT02622880|DIETARY_SUPPLEMENT|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
214603483|NCT02622880|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
214712215|NCT05166395|DEVICE|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
214712216|NCT05455736|OTHER|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
214712217|NCT03967509|BEHAVIORAL|Comet|
214603484|NCT01261754|RADIATION|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
214603485|NCT01261754|RADIATION|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
214603486|NCT01549366|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
214603487|NCT01549366|DEVICE|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
214603488|NCT04069351|DIETARY_SUPPLEMENT|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
214603489|NCT04069351|OTHER|Resistance Training|All participants will complete a 6-week supervised resistance training program.
214712218|NCT02451488|DRUG|GM-CSF|14 days in a dose of 125 µg/m\^2
214712219|NCT02451488|OTHER|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
214603490|NCT01394471|DRUG|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
214603491|NCT04719767|DEVICE|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
214603492|NCT03283280|OTHER|Ever X Posterior|Resin composite restoration can be made as a direct onlay
214603493|NCT03118349|DRUG|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
214603494|NCT03118349|DRUG|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
214712220|NCT00432913|DRUG|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
214712221|NCT00432913|PROCEDURE|Endoscopy|At baseline, month 3 and month 6.
214712222|NCT00432913|PROCEDURE|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
214712223|NCT00432913|PROCEDURE|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
214712224|NCT00432913|PROCEDURE|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
214712225|NCT00432913|PROCEDURE|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
214712226|NCT00432913|PROCEDURE|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
214603495|NCT02927743|BEHAVIORAL|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
214603496|NCT05638893|DRUG|Placebo Tablet|Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
214603497|NCT05638893|DRUG|Metformin Hcl 500Mg Tab|Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
214603498|NCT00160355|PROCEDURE|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
214603499|NCT00160355|DEVICE|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
214603500|NCT00160355|DRUG|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
214603501|NCT03988322|OTHER|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
214603502|NCT03988322|OTHER|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
214603503|NCT02185209|DRUG|Placebo|Place capsule to mimic antibiotics
214603504|NCT02185209|DRUG|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
214603505|NCT02185209|DRUG|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
214603506|NCT02185209|DRUG|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
214603507|NCT02037646|OTHER|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
214603508|NCT02037646|OTHER|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
214603509|NCT02037646|PROCEDURE|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
214603510|NCT02037646|OTHER|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
214603511|NCT02037646|OTHER|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
214603512|NCT02037646|OTHER|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
214603513|NCT02099903|DEVICE|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
214603514|NCT00179725|DRUG|CC-5013|
214603515|NCT00179725|DRUG|liposomal doxorubicin|
214603516|NCT04890678|DEVICE|22 residentsat risk for PU development|"mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning."
214603517|NCT04890678|DEVICE|18 residents at least one PU category III-IV in the sacral area|"mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed."
214603518|NCT01641809|DRUG|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
214603519|NCT01641809|DRUG|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
214603520|NCT01641809|DRUG|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
214712227|NCT00432913|PROCEDURE|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
214603521|NCT01641809|DRUG|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
214603522|NCT01641809|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
214603523|NCT01641809|DRUG|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
214603524|NCT01641809|DRUG|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
214603525|NCT00913250|DRUG|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
214712228|NCT00432913|PROCEDURE|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
214603526|NCT00913250|DRUG|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
214712229|NCT02786836|DRUG|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
214712230|NCT03617913|DRUG|Avelumab|Given IV
214712231|NCT03617913|DRUG|Cisplatin|Given IV
214712232|NCT03617913|DRUG|Fluorouracil|Given IV
214712233|NCT03617913|DRUG|Mitomycin|Given IV
214712234|NCT03617913|OTHER|Quality-of-Life Assessment|Ancillary studies
214712235|NCT03617913|RADIATION|Radiation Therapy|Undergo RT
214712236|NCT01143714|DRUG|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
214603527|NCT02583035|OTHER|Nurse telephone contact|Nurse will contact patient 3 days before consultation
214712237|NCT01143714|OTHER|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
214712238|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
214712239|NCT05063968|DRUG|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
214712240|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
214712241|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
214712242|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
214712243|NCT05063968|DRUG|Placebo|Tablet is administered orally once daily for 14 Days continuously
214712244|NCT01387074|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
214712245|NCT05285267|BEHAVIORAL|Behavioral Parent Support|Parent training on effective child management strategies
214712246|NCT05285267|BEHAVIORAL|Shared Parent-Child Activities|Structured parent-child activities
214712247|NCT05285267|BEHAVIORAL|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
214712250|NCT02373163|DRUG|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
214712251|NCT02373163|DRUG|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
214712252|NCT02373163|DRUG|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
214603528|NCT03690141|DRUG|eFT508|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
214603529|NCT05432869|OTHER|ES and lifestyle advices|"The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs."
214603530|NCT05432869|OTHER|Lifestyle advices|The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
214603531|NCT00778622|DRUG|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
214603532|NCT06137222|DEVICE|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
214712253|NCT00736788|DRUG|AZD1704|single dose oral suspension, 4 different dose levels
214603533|NCT06137222|OTHER|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
214603534|NCT03067155|GENETIC|CMV-specific T cells|
214603535|NCT03067155|DRUG|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
214603536|NCT04008758|DIAGNOSTIC_TEST|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
214603537|NCT00901030|PROCEDURE|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
214712254|NCT00736788|DRUG|Placebo|single dose oral suspension
214603538|NCT01505010|PROCEDURE|Renal denervation|Renal denervation in the intervention group
214603539|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with hysterectomy|After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.
214712255|NCT05541523|BEHAVIORAL|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
214712256|NCT05541523|BEHAVIORAL|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
214603540|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with cervical amputation|After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
214603541|NCT01483833|DRUG|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
214603542|NCT01483833|DRUG|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
214603543|NCT02512198|BEHAVIORAL|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
214603544|NCT03837379|BEHAVIORAL|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
214603545|NCT03837379|COMBINATION_PRODUCT|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
214712257|NCT04183946|BEHAVIORAL|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
214712258|NCT01458496|BEHAVIORAL|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
214603546|NCT00201435|DRUG|Paclitaxel weekly in combination with capecitabine|
214603547|NCT00201435|DRUG|Docetaxel every 3 week in combination with capecitabine|
214603548|NCT02642484|DRUG|Gabapentin|Gapapentin twice daily
214603549|NCT02642484|DRUG|Calcium Carbonate|calcium carbonate twice daily
214712259|NCT06528730|DIAGNOSTIC_TEST|DCM|Confirm degenerative cervical myelopathy by Orthopaedic surgeon and MRI
214603550|NCT02821468|DRUG|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
214603551|NCT02821468|DRUG|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
214603552|NCT02403622|DRUG|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
214603553|NCT01605981|DRUG|AMN107|
214603554|NCT02558231|DRUG|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
214603555|NCT02558231|DRUG|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
214712260|NCT03119246|OTHER|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
214603556|NCT02558231|DRUG|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
214603557|NCT05290688|GENETIC|50 ml blodd sampling|50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
214603558|NCT00004239|DRUG|Compound 506U78|
214603559|NCT03367715|DRUG|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
214603560|NCT03367715|DRUG|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
214603561|NCT03367715|RADIATION|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
214603562|NCT01686360|BEHAVIORAL|Decision Aid|
214603563|NCT00399451|DRUG|Polidocanol Sclerotherapy|
214603564|NCT06027723|DRUG|Nicotine|Nicotine delivered through a vape
214712261|NCT00102934|DRUG|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
214712262|NCT02293824|DRUG|Caffeine|Given per standard of care.
214712263|NCT02866734|OTHER|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
214712264|NCT02866734|OTHER|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
214712265|NCT02866734|OTHER|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
214712266|NCT05034614|DIAGNOSTIC_TEST|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
214712267|NCT05034614|DIAGNOSTIC_TEST|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
214603565|NCT06027723|OTHER|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
214603566|NCT03553654|DIAGNOSTIC_TEST|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
214603567|NCT02536755|DRUG|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
214603568|NCT00557583|DRUG|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
214603569|NCT02301936|DRUG|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
214603570|NCT01638091|BEHAVIORAL|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
214603571|NCT01638091|BEHAVIORAL|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
214603572|NCT01416987|DRUG|Pergoveris®|Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
214603573|NCT05261971|DRUG|Etodolac 400 MG|Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
214603574|NCT05261971|DRUG|Thiocolchicoside|Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
214603575|NCT01923116|DRUG|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
214603576|NCT03065023|DRUG|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
214603577|NCT05487339|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopy device
214603578|NCT01750541|DRUG|Haloperidol|
214712268|NCT01385319|DEVICE|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
214603579|NCT01750541|DRUG|Valproate|
214603580|NCT04029961|OTHER|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
214603581|NCT04029961|OTHER|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
214603582|NCT04897269|PROCEDURE|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
214603583|NCT04356911|OTHER|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
214603584|NCT04356911|OTHER|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
214603585|NCT04356911|OTHER|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
214603586|NCT04356911|OTHER|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
214603587|NCT04895072|PROCEDURE|Standard group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a standard injection rate.
214603588|NCT04895072|PROCEDURE|Long group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a long injection rate.
214603589|NCT00067951|DRUG|rosiglitazone/metformin|
214603590|NCT04692038|DEVICE|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
214603591|NCT03427125|DRUG|Tenapanor|Active Drug
214603592|NCT03427125|DRUG|Placebo|Inactive Drug
214603593|NCT03427125|DRUG|Sevelamer Carbonate|Active control
214603594|NCT03976791|PROCEDURE|enlarged internal incision|enlarging the internal incision about 0.4mm
214603595|NCT03976791|PROCEDURE|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
214603596|NCT00824824|DRUG|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
214712269|NCT01385319|DEVICE|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
214712270|NCT03892707|DRUG|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
214603597|NCT00824824|DRUG|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
214603598|NCT01167751|BIOLOGICAL|MNC|Implantation of BM derived MNC
214603599|NCT01167751|BIOLOGICAL|AC 133|Implantation of BM derived AC133
214603600|NCT01167751|BIOLOGICAL|Control|Injection of cell carrier
214603601|NCT04525339|PROCEDURE|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
214603602|NCT01395251|DRUG|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
214603603|NCT04853329|DRUG|CPO107|CD20-CD47 Bispecific Fusion Protein
214603604|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_B|Participants received 2 doses of 375\_B vaccine formulation by intramuscular injection in the non-dominant arm.
214603605|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_A|Participants received 2 doses of 375\_A vaccine formulation by intramuscular injection in the non-dominant arm.
214712271|NCT02428712|DRUG|FORE8394|
214712272|NCT03029858|OTHER|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
214712273|NCT03819764|BEHAVIORAL|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
214712274|NCT03819764|BEHAVIORAL|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
214712275|NCT04932044|BEHAVIORAL|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
214712276|NCT04932044|OTHER|Routine care|Receives routine care and provide general discharge care and nursing guidance.
214712277|NCT05711199|DRUG|Glyceroltrinitrat|transdermal patch
214712278|NCT06364761|PROCEDURE|Bag in the lens cataract surgery|Cataract surgery using the Morcher 89A intraocular lens
214603606|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_B|Participants received 2 doses of 750\_B vaccine formulation by intramuscular injection in the non-dominant arm.
214603607|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_A|Participants received 2 doses of 750\_A vaccine formulation by intramuscular injection in the non-dominant arm.
214603608|NCT06965452|DEVICE|Spinal angiography and embolization/ Embozene Microspheres|"Once consent is obtained the patient will be scheduled for spinal angiography and embolization. The patient will undergo the procedure at North Shore University Hospital. After embolization the patient will be monitored in recovery for 5 hours and then discharged to home.~The primary objective of this study is to examine the safety and feasibility of trans arterial embolization of the facet joint using Embozene Microspheres for the treatment of back pain from facet arthropathy and osteoarthritis."
214603609|NCT05956249|OTHER|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
214603610|NCT05956249|OTHER|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
214603611|NCT05180279|BEHAVIORAL|7-day sleep lab|Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
214603612|NCT06574893|OTHER|physical exercise|physical exercise
214603613|NCT05127434|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
214603614|NCT05127434|DRUG|mRNA-1345|Sterile liquid for injection
214603615|NCT04508478|BEHAVIORAL|Aerobic training|Aerobic training
214603616|NCT04508478|BEHAVIORAL|Resistance training|Resistance training
214712279|NCT01841918|BIOLOGICAL|Avian Flu Vaccine|
214712280|NCT01113554|OTHER|questionnaire administration|
214603617|NCT04508478|BEHAVIORAL|Control physical exercise|Control physical exercise
214603618|NCT04023825|DRUG|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
214603619|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
214603620|NCT05501678|DRUG|Placebo|Matching Placebo given orally
214603621|NCT06081283|DRUG|Phenobarbital Sodium Injection|"\*This drug can only be selected as part of the intervention for the subgroup of patients with a Glasgow Coma Score of 8 or less.~Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day."
214603622|NCT06081283|DRUG|Levetiracetam|Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
214712281|NCT01113554|BEHAVIORAL|exercise intervention|
214712282|NCT01113554|PROCEDURE|quality-of-life assessment|
214712283|NCT01113554|OTHER|survey administration|
214712284|NCT01113554|PROCEDURE|management of therapy complications|
214712285|NCT01113554|PROCEDURE|psychosocial assessment and care|
214603623|NCT06081283|DRUG|Lacosamide Injectable Product|Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.
214603624|NCT06081283|DRUG|Valproate Sodium|Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day
214712286|NCT06213610|DRUG|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
214603625|NCT06081283|DRUG|Phosphenytoin|Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
214603626|NCT04725617|DRUG|Varenicline|Standard smoking cessation treatment.
214603627|NCT04725617|BEHAVIORAL|Smoking Cessation Counseling|Standard smoking cessation treatment
214603628|NCT04725617|BEHAVIORAL|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
214712287|NCT06213610|DRUG|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
214603629|NCT04725617|OTHER|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
214712288|NCT06216587|DIETARY_SUPPLEMENT|BLa80|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
214712289|NCT02137837|DRUG|Fulvestrant|
214712290|NCT02137837|DRUG|Anastrozole|
214712291|NCT02137837|DRUG|Everolimus|
214712292|NCT02137837|DRUG|Placebo - Anastrozole|
214603630|NCT04014361|DRUG|LY3154885 - Capsule|Administered orally.
214603631|NCT04014361|DRUG|Placebo - Capsule|Administered orally.
214603632|NCT04014361|DRUG|Itraconazole|Administered orally.
214603633|NCT04014361|DRUG|LY3154885 - Tablet|Administered orally.
214603634|NCT04757883|OTHER|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
214603635|NCT02170090|DRUG|Gemcitabine|Gemcitabine 1000mg/m2
214603636|NCT02170090|DRUG|Cisplatin|Cisplatin 25mg/m2
214603637|NCT02170090|DRUG|Capecitabine|Capecitabine 1250mg/m2
214603638|NCT05225103|BEHAVIORAL|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
214603639|NCT06163326|DRUG|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
214603640|NCT06163326|DRUG|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
214603641|NCT06163326|DRUG|Placebo|Matching capsule once daily
214603642|NCT03189043|DEVICE|Antimicrobial Surface|Antimicrobial Surface
214603643|NCT03370848|DIETARY_SUPPLEMENT|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
214603644|NCT03370848|DRUG|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
214712293|NCT02137837|DRUG|Placebo - Everolimus|
214712294|NCT02141217|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
214712295|NCT02141217|DRUG|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
214712296|NCT01786863|PROCEDURE|Neuromuscular blockade|
214712297|NCT03845049|OTHER|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
214712298|NCT03845049|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
214712299|NCT03845049|DRUG|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
214712300|NCT03845049|OTHER|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
214712301|NCT03515213|DRUG|Fenofibrate|145mg of fenofibrate
214712302|NCT03515213|DRUG|Placebo|Placebo
214712303|NCT04806633|DRUG|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
214712304|NCT04806633|DRUG|Placebo|Patients randomized in this arm will receive placebo.
214603645|NCT01507558|PROCEDURE|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
214603646|NCT02898311|DEVICE|immediate loading of posterior implants with chairside CAD-CAM composite crown|
214603647|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
214603648|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
214603649|NCT02789735|DEVICE|Active laser therapy|Laser therapy at predetermined sites
214603650|NCT02789735|DEVICE|Sham laser therapy|Sham therapy at predetermined sites
214603651|NCT04543604|BEHAVIORAL|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
214603652|NCT04543604|BEHAVIORAL|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
214603653|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
214712305|NCT02187341|DIETARY_SUPPLEMENT|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
214603654|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
214603655|NCT02612025|BEHAVIORAL|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
214603656|NCT03398525|OTHER|usual care|usual care following local standard operational procedures
214603657|NCT03398525|OTHER|Musical intervention|Musical intervention using a marketed music program validated for music therapy
214603658|NCT02632565|DRUG|Lidocaine|
214603659|NCT02632565|DRUG|Saline|
214603660|NCT06679205|BEHAVIORAL|Multidisciplinary and multimodal intervention|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of 2 parts: a 2-hour education session called Empowered Relief® and 2 1-hour pain neuroscience education sessions.~* Psychotherapy: The psychotherapy part consists of 1 group session of 1 hour, face-to-face and with groups of up to 15 people.~* Therapeutic exercise: The therapeutic exercise module consists of 3 sessions of 1 hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
214603661|NCT06679205|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
214603662|NCT04252287|DRUG|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
214603663|NCT04252287|DRUG|Placebo|Participants will receive matching placebo capsules orally once daily.
214603664|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
214603665|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
214603666|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
214603667|NCT01217216|BEHAVIORAL|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
214603668|NCT01217216|BEHAVIORAL|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
214712306|NCT02187341|DIETARY_SUPPLEMENT|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
214712307|NCT00203255|DRUG|Soy Isoflavones|
214712308|NCT02284945|PROCEDURE|Open fixation|
214712309|NCT02284945|PROCEDURE|Keyhole surgery|
214712310|NCT05936593|DEVICE|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
214712311|NCT05936593|DEVICE|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
214603669|NCT04612413|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
214603670|NCT04612413|OTHER|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
214603671|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
214603672|NCT06267521|OTHER|Healthy Minds Program|Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.
214603673|NCT06267521|OTHER|Sham Meditation Didactic Material|Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.
214603674|NCT06267521|DEVICE|Sham Stimulation in Lab|On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night
214603675|NCT06267521|DEVICE|Stimulation in Lab|Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
214603676|NCT06267521|DEVICE|MRI Scanner|Imaging protocol will include: structural T1-weighted and T2-weighted images, resting-state functional MRI, task-based functional MRI, and multi-shell diffusion weighted MRI, total scan time will be approximately 2 hours
214603677|NCT02715466|DRUG|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
214603678|NCT02715466|DRUG|Balanced electrolyte solution|Sterofundin ISO
214603679|NCT04452487|BEHAVIORAL|decisions of limitations and stop processing|Compliance of the modalities of decisions of limitations and stop processing
214603680|NCT00464230|PROCEDURE|Bipolar hemiarthroplasty (Charnley/Hastings)|
214603681|NCT00464230|PROCEDURE|Internal fixation with two parallel screws (Olmed)|
214603682|NCT02852486|DRUG|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
214603683|NCT02852486|OTHER|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
214603684|NCT01843868|DRUG|Standard anti-emetics in conjunction with R-CHOP|
214603685|NCT00473421|PROCEDURE|Barium Sulphate and Zirconium Oxide|
214603686|NCT04768270|OTHER|no intervention|It is an observation trial.
214603687|NCT02407366|DRUG|Icotinib|Icotinib (125 mg ,Three times daily)
214603688|NCT02407366|DRUG|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
214603689|NCT02407366|DRUG|Carboplatin|Carboplatin (AUC，5) every 21 days
214603690|NCT02407366|RADIATION|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
214603691|NCT06046755|OTHER|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
214603692|NCT06046755|BEHAVIORAL|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
214603693|NCT05420883|OTHER|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
214603694|NCT05420883|OTHER|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
214603695|NCT05420883|OTHER|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
214603696|NCT03610165|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
214603697|NCT03610165|DEVICE|Control|Arterial waveform and pressures
214603698|NCT03125213|DRUG|AL-3778|AL-3778 tablets
214603699|NCT03125213|DRUG|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
214603700|NCT03125213|DRUG|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
214603701|NCT03040310|OTHER|Back Rx program|The Back Rx program can be viewed via a smartphone app.
214603702|NCT05743322|DEVICE|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
214603703|NCT05150496|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
214603704|NCT05150496|BIOLOGICAL|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
214603705|NCT03217149|DRUG|heliox combined with MV|heliox combined with MV is given to infant with ARDS
214603706|NCT03217149|DRUG|MV|MV is given to infant with ARDS
214603707|NCT02488889|DRUG|Varenicline|
214603708|NCT02488889|DRUG|Placebo pill (for varenicline)|
214603709|NCT02488889|DRUG|Alcohol|
214603710|NCT02488889|DRUG|placebo beverage (for alcohol)|
214603711|NCT06586723|BEHAVIORAL|PBIS|Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.
214603712|NCT06586723|OTHER|HELM|Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
214603713|NCT06593470|BEHAVIORAL|MINDS-UP|MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.
214603714|NCT06593470|BEHAVIORAL|Prevention Plus Wellness|PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45-60 minute session between an adolescent and a trained PPW teacher.
214603715|NCT06593470|DIAGNOSTIC_TEST|fMRI|Functional MRI to investigate preliminary neural mechanisms of MINDS-UP
214603716|NCT05838586|BEHAVIORAL|prolonged SB|4 hours of prolonged SB
214603717|NCT05838586|BEHAVIORAL|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
214603718|NCT05838586|BEHAVIORAL|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
214603719|NCT06615544|DEVICE|Placement of indirect dental restoration|The newly developed dual-cure adhesive will be used for the placement of indirect restorations.
214603720|NCT06996353|PROCEDURE|PTK-PRK refractive treatment|The PTK-PRK refractive treatment will be done according to routine clinical practice.
214712312|NCT04342416|BEHAVIORAL|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
214712313|NCT01181141|DRUG|DU-176b (edoxaban)|
214712314|NCT01181141|DRUG|Enoxaparin sodium 20mg|
214603721|NCT06672705|PROCEDURE|Biopsy|Undergo biopsy
214603722|NCT06672705|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214603723|NCT06672705|PROCEDURE|Computed Tomography|Undergo PET/CT
214603724|NCT06672705|BIOLOGICAL|Epcoritamab|Given SC
214603725|NCT06672705|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214603726|NCT06854718|BEHAVIORAL|Caregiver-Assisted Pain Coping Skills Training (CG-PCST)|Patient-caregiver dyads will receive five, forty-to-sixty-minute sessions over a six-to-eight-week period with a therapist to learn pain coping skills. These include training caregivers in strategies for assessing patient pain, including nonverbal pain behaviors (e.g., grimacing, bodily tension, labored breathing), which will become increasingly important as the patient's ability to express pain verbally decreases. The therapist will also train the caregiver to coach the patient in the use of the skills during activities that are challenging because of pain. We will focus on increasing positive patient-caregiver interactions and patient engagement in valued activities. Throughout the training, the therapist will help the patient and caregiver learn strategies for fostering regular home practice and application of the skills, identify challenges in using the skills, and find strategies for coping with challenges.
214603727|NCT06812377|OTHER|Maitland joint mbilization|Posteroanterior mobilization of the radial head in motion. This method is gliding over the radial head posteriorly to anteriorly while the patient executes (and relaxes) the painful action (e.g., clutching). Repeat the method six to ten times if there is a noticeable increase in your ability to grip without pain
214712315|NCT03714061|OTHER|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
214603728|NCT06812377|OTHER|mulligan mobilization|Using this approach, the patient performs (and relaxes) the painful action (e.g., clutching) while a lateral humeroulnar auxiliary glide is applied and maintained. If you notice a noticeable increase in your ability to grip without pain, repeat the method six to ten times. You can use a belt to help you glide.Three sets of it were performed, with a 30-second break in between
214603729|NCT06812377|OTHER|radial nerve mobilization|The subjects will be placed in a reclining supine position. The arm will be internally rotated, the wrist, thumb, and fingers will be flexed, the shoulder girdle will be depressed, and the elbow will be stretched. Elbow flexion and wrist extension will be used to maintain shoulder depression after the radial nerve will be strained by these motions. Before beginning the gentle elbow extension test, the subject's wrist and fingers will be stabilized. The elbow will be then gently extended for about two seconds, just into the range where the participant felt tension but no pain, and then flexed. In a single session, three sets of six to eight oscillations will be executed
214603730|NCT06801041|DRUG|Psilocybin|Participants will recive treatment by mouth on an outpatient basis.
214603731|NCT05546554|DRUG|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
214603732|NCT05546554|DRUG|Placebo|Matching Placebo given orally
214603733|NCT07130032|COMBINATION_PRODUCT|reICB regimen (NSCLC)|"* ICI (one of the following): Atezolizumab 1200 mg every 3 weeks/Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
214603734|NCT07130032|COMBINATION_PRODUCT|reICB regimen (melanoma)|"* ICI (one of the following): Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
214603735|NCT07129733|OTHER|Oral hygiene bundle|Implementation of the standardized oral hygiene bundle, which consists of the following key components: Standardization of materials used during the oral hygiene procedure, standardization of oral hygiene frequency, training of nursing staff involved in patient care on proper oral hygiene practices, discontinuation of routine application of chlorhexidine oral solution, and implementation of a standardized oral hygiene technique.
214603736|NCT07128992|OTHER|Control visit interval|Study investigates whether it is safe to extend the interval of routine calendar-based follow-up visits from every 12 to every 24 months in patients with type 1 diabetes.
214603737|NCT07130513|DIETARY_SUPPLEMENT|Krill oil supplementation|Krill oil supplementation program providing 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks.
214712316|NCT03714061|OTHER|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
214712317|NCT04848584|BIOLOGICAL|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
214712318|NCT04848584|BIOLOGICAL|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
214712319|NCT04848584|BIOLOGICAL|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
214603738|NCT07130513|DIETARY_SUPPLEMENT|Control|Vegetable oil supplementation (4 g/day)
214603739|NCT07128641|BIOLOGICAL|Odronextamab|A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.
214603740|NCT07128433|PROCEDURE|milk expression|Following one-on-one antenatal manual colostrum expression instruction by a midwife at the breastfeeding clinic, participants will initiate twice-daily practice from 37 weeks gestation onward, performing 3-5 minutes of manual expression per breast per session (total duration ≤10 minutes per session).
214603741|NCT07129941|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format
214603742|NCT07130357|DEVICE|Collagen Scaffold|The bioinductive collagen scaffold will be placed over the repair site and secured with soft tissue anchors.
214603743|NCT07130357|PROCEDURE|Achilles tendon repair|Upon diagnosis of an Achilles tendon rupture, the participant will receive a temporary slab and surgical repair will be scheduled, and the operation will be performed under general anaesthesia with the patient lying prone. The ruptured ends of the right Achilles tendon will be marked, and a 3 cm longitudinal skin incision will be made along the medial border of the tendon. A standardized end-to-end direct surgical repair using non-absorbable sutures in a 2-strand core in a krackow locking fashion will be performed. The surgical site will be closed in layers using 3-0 vicryl and 4-0 ethilon.
214712320|NCT02323399|DRUG|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
214712321|NCT06382948|DRUG|Everolimus|Patients will receive 7.5 mg of everolimus orally once daily.
214603744|NCT07129057|OTHER|MBSR program|The MBSR program lasts eight consecutive weeks (two months), with group sessions lasting two and a half hours each and an intensive 8-hour full-day practice session. At each session, the participants receive audio tracks for daily home practice.
214603745|NCT06470893|BEHAVIORAL|OCD-NET|OCD-NET is bibliotherapy with coaching and its content is reflective of standard care for OCD. OCD-NET is a self-paced intervention that participants complete entirely online with the support of an assigned individual therapist. Most participants complete this treatment in up to twelve weeks. On average, participants are expected to spend between one to five hours per week during the first half of treatment. In the second half of treatment when participants begin regular exposure and response prevention (ERP) exercises, participants are expected to spend about one hour per day.
214603746|NCT06901427|BEHAVIORAL|Mediterranean Diet and exercise|A structured dietary intervention promoting Mediterranean-style eating patterns and regular exercise for 12 weeks.
214603747|NCT06902727|DEVICE|VR-based exercise bike|For the intervention group, participations exercised on an immersive VR-based exercise bike for one hour, twice per week, for 4 weeks. Participants in the control group were asked to maintain their usual routine after the baseline test for 4 weeks. Participants were scheduled separately coming to lab for the post-test after 4 weeks and all participants received the identical assessments in aforementioned physiological and psychological outcomes.
214603748|NCT06902727|OTHER|Usual routine|Participants were asked to maintain their usual activities, without engaging in any other physical activity intervention during the 4-week study period.
214603749|NCT06902844|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
214603750|NCT06903221|DRUG|Tdap-IPV|intramuscular injection
214603751|NCT06903221|DRUG|Td-IPV|intramuscular injection
214603752|NCT06902753|OTHER|Questionnaire and Physical Exam|"Neuropsychological assessment:~* Phase 1: MMS-LS (overall cognitive efficiency) + fluency tasks (verbal flexibility)~* Phase 2: MMS-LS (if the participant did not take part in phase 1), RL-RI LSF (verbal memory), Rey Complex Figure (visuospatial abilities and visual memory), Progressive Matrices, Symbols and Code (executive functions)"
214603753|NCT06901557|COMBINATION_PRODUCT|Jing-Si Herbal Tea|The JSHT group will receive the standard medical treatment along with Jing-Si Herbal Tea, one packet daily for three months.
214603754|NCT06901557|COMBINATION_PRODUCT|Placebo|The UC group will receive standard medical treatment, with one placebo packet daily for three months.
214603755|NCT06901986|DIETARY_SUPPLEMENT|Montmorency tart cherry|Montmorency tart cherry 60ml per day for 6 weeks.
214603756|NCT06901986|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
214603757|NCT06902428|DRUG|HSK44459|HSK44459, bid p.o.
214603758|NCT06902428|DRUG|Placebo|Placebo, bid p.o.
214603759|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by PSMA PET/CT|The patient will undergo pelvic non-contrast CT imaging. After co-registration of the CT images with 68Ga-PSMA PET/CT data at corresponding anatomical levels, a percutaneous gluteal approach will be utilized for CT-guided prostate biopsy.
214603760|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by mpMRI/US|The patient will undergo transrectal ultrasound (TRUS) prostate scanning. After co-registration and precise image fusion of TRUS findings with multiparametric MRI (mpMRI) data, a transperineal percutaneous approach will be employed to perform TRUS-guided prostate biopsy.
214603761|NCT06901492|DIAGNOSTIC_TEST|Systematic prostate biopsy|The patient will undergo systematic prostate biopsy under TRUS guidance.
214603762|NCT06902831|PROCEDURE|Endoscopic Carpal Tunnel Release|Release of carpal tunnel with endoscopic device
214603763|NCT06902831|PROCEDURE|Open carpal tunnel release|Release of carpal tunnel with open tecnique
214712322|NCT06382948|DRUG|Elacestrant|Patients will receive elacestrant 345 mg orally once daily
214712323|NCT06382948|DRUG|Placebo|Patients will receive placebo orally once daily
214712324|NCT06382948|DRUG|Auxiliary Medicinal Product - Dexamethasone|10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
214712325|NCT06382948|DRUG|Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues|According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
214603764|NCT06902831|DRUG|Neurotrophic supplementation|Neurotrophic supplementation after surgery
214603765|NCT06901453|PROCEDURE|Low shrinkage Giomer restorative material (Beautifil II LS)|Enamel margins are etched with 37% phosphoric acid for 15 seconds, then the cavity is bonded using FL bond two-step self-etch adhesive. Giomer is applied in increments (maximum 2mm thickness) and light-cured for 20 seconds with a properly calibrated LED curing light.
214712326|NCT00448760|DRUG|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
214712327|NCT00448760|DRUG|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
214712328|NCT00448760|DRUG|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
214712329|NCT00448760|DRUG|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
214712330|NCT00448760|GENETIC|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
214712331|NCT00448760|GENETIC|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
214712332|NCT00448760|PROCEDURE|Conventional surgery|Surgical removal of tumor for correlative studies
214712333|NCT01226706|DRUG|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
214603766|NCT06901453|PROCEDURE|RMGI alone - Control|Cavities will be restored with light-cured resin modified glass ionomer (GC Fuji II LC) only. After applying conditioner for 20 seconds, rinsing, and gentle drying, the RMGI will fill the entire cavity and be light-cured
214603767|NCT06902311|RADIATION|Breast Radiotherapy|The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).
214603768|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using LuminoMark|This group used LuminoMark as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, comparing it to existing methods (charcoal staining, needle targeting, ultrasound-guided skin marking) to assess its safety and effectiveness, with procedural differences based on neoadjuvant chemotherapy status.
214603769|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using conventional method|This group used conventional method (charcoal staining, needle targeting, ultrasound-guided skin marking) as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, with procedural differences based on neoadjuvant chemotherapy status.
214603770|NCT00790465|DIETARY_SUPPLEMENT|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
214603771|NCT00790465|DIETARY_SUPPLEMENT|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
214603772|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
214603773|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
214712334|NCT01226706|DRUG|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
214712335|NCT01165099|PROCEDURE|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
214712336|NCT03296865|DEVICE|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
214712337|NCT03792451|DRUG|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
214603774|NCT06901856|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
214603775|NCT06901856|PROCEDURE|mEMR-L procedure|First, install the ligation device (provided by Jiangsu Gerrit) at the front end of the endoscope. After inserting the endoscope into the rectum, suck the lesion into the ligation device, release the ligator to ligate the lesion. Then, use a snare to resect the lesion below the ligator. Finally, uniformly suture the wound surface with metal clips.
214603776|NCT06902493|OTHER|No intervention|No intervention
214712338|NCT03810001|BEHAVIORAL|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
214603777|NCT06902155|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)|Urinary incontinence was assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), a validated instrument with a Cronbach's alpha of 0.88. This tool consists of four items: three scored questions evaluating leakage frequency (0-5), volume (0-6), and impact on quality of life (0-10), summing to a total score of 0-21, and one unscored question identifying situations where incontinence occurs. Two separate analyses were performed: total ICIQ-SF score and responses to question, which identified UI-triggering situations
214712339|NCT06435182|DRUG|OT202 conc 0.5%|Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
214712340|NCT06435182|DRUG|OT202 conc 0.1%|Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
214712341|NCT06435182|DRUG|Placebo|Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
214712342|NCT01789346|DEVICE|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
214712343|NCT01789346|DEVICE|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
214712344|NCT05003063|DRUG|Donepzil|Test
214603778|NCT06901518|DRUG|Galcanezumab-Gnlm|Subcutaneous injection
214603779|NCT06901817|DRUG|Intraventricular Pemetrexed|Intraventricular injection of 30 mg pemetrexed via Ommaya reservoir, once every 4 weeks until disease progression.
214603780|NCT06901817|DRUG|Intraventricular Nivolumab|Intraventricular injection of 40 mg nivolumab via Ommaya reservoir, once every 4 weeks until disease progression.
214603781|NCT06901817|DRUG|Intraventricular Dexamethasone|Intraventricular injection of 5mg/2ml pemetrexed via Ommaya reservoir before injection of pemetrexed and nivolumab.
214712345|NCT05003063|DRUG|Placebo oral tablet|Test
214712346|NCT01770899|DRUG|Montelukast|
214712347|NCT01770899|DRUG|Placebo|Gelatin capsule given every 24 hours
214712348|NCT03999112|OTHER|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
214712349|NCT03049995|PROCEDURE|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
214603782|NCT06907043|DRUG|EIK1004-001 (IMP1707-001)|PARP1 selective inhibitor
214712350|NCT03049995|PROCEDURE|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
214712351|NCT03049995|PROCEDURE|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
214712352|NCT03049995|PROCEDURE|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
214712353|NCT03049995|PROCEDURE|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
214712354|NCT03049995|PROCEDURE|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
214712355|NCT03049995|PROCEDURE|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
214712356|NCT05112484|DIAGNOSTIC_TEST|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
214712357|NCT05112484|DIAGNOSTIC_TEST|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
214712358|NCT05112484|DIAGNOSTIC_TEST|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
214603783|NCT07099001|OTHER|Educational materials on the Alzheimer's disease assay|Between Round 1 and Round 2 virtual patient case administration, Intervention participants will receive educational materials describing the clinical validation and use cases of the Alzheimer's disease assay. These materials will approximate the type of information physicians would receive to introduce them to the Alzheimer's disease assay and may be comprised of a slide deck, fact sheet, sample test report, and/or example case scenarios.
214603784|NCT07099001|OTHER|Alzheimer's disease assay results|Within each of their virtual patient cases in Round 2 of case administration, Intervention participants will receive Alzheimer's disease assay results at the clinically appropriate point for each case.
214603785|NCT06163404|DEVICE|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
214603786|NCT04667247|DRUG|FoTv|8 capsules three times a day for 14 consecutive days.
214603787|NCT06904625|OTHER|Taking blood samples before starting treatment|"For each patient included, a blood sample will be taken (37 mL in total) for the CTCs detection using the 3 techniques (CellSearch®, Parsortix® and SmartCatch®).~For 3 patients only, an additional blood volume (18 mL) will also be collected for tcDNA detection (exploratory analysis of 3 patients)."
214603788|NCT06913231|DEVICE|Whole body vibration device|Whole-body vibration (WBV) training using the Power Plate Pro 7HC (Northbrook, USA). The vibration frequency was set between 30-40 Hz, with an amplitude of 2-4 mm.
214603789|NCT06913231|OTHER|Sham Whole body vibration|A sham Whole body vibration will be used . participants will stand on the device without actual vibrations.This control condition will be used to isolate the effects of WBV from other potential influences such as standing posture and time spent on the the platform.
214603790|NCT06796660|DRUG|Nephropathy Formula No. 1|On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum, Paeonia lactiflora Pall. , Scutellaria baicalensis Georgi , Pinellia ternata (Thunb.) Breit. , Smilax glabra Roxb. , Oldenlandia diffusa (Willd.) Roxb. , Tussilago farfara L. , Poria cocos (Schw.) Wolf , decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
214603791|NCT06796660|DRUG|integrated basic treatment for chronic kidney disease|"The integrated basic treatment for CKD includes the following:~Dietary Nutrition: α-Keto acid tablets (2.6 g tid) may be used. Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected. β-blockers or α-blockers may be used in combination if necessary.~Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.~Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.~Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.~Regulation of Water, Electrolyte, and Acid-Base Metabolic Balance."
214603792|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
214712359|NCT05112484|OTHER|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
214712360|NCT02253641|BEHAVIORAL|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
214603793|NCT07128953|DRUG|Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula|Left Qing San Decoction (25g of Cai Yin + 30g of Eucommia + 25g of Sophora flavescens + 25g of Anemarrhena asphodeloides + 15g of Lithospermum erythrorhizon, prepared in the Pharmacy Department of Anhui University of Traditional Chinese Medicine), add 1000mL of water, boil, then steam and wash the wound surface. The temperature is 40 ± 2℃. Do it once a day, for 15 minutes each time, for 7 consecutive days.
214603794|NCT07128953|OTHER|Equal-volume placebo inhalation rinse|Equal-volume placebo inhalation rinse
214603795|NCT06940505|OTHER|Telemedicine Follow-up|Oncological follow-up in a general hospital close to the patient, with aid of Telemedicine evaluation of the endoscopy video's by a Head and Neck surgeon in a specialised oncology centre
214603796|NCT06941545|DEVICE|Alimetry|High resolution gastric mapping of electrical gastric activity.
214603797|NCT06941545|DEVICE|tVNS|Transcutaneous Auricular Vagal Nerve Stimulation, electrical stimulation to the ear.
214603798|NCT06941545|DEVICE|Gastroduodenal Manometry|Pressure catheter evaluating gastric and duodenal pressure profiles at rest and with certain stimuli applied
214603799|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
214603800|NCT06445946|DRUG|Metformin|Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
214603801|NCT06445946|DRUG|Insulin|Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
214603802|NCT04708613|DIAGNOSTIC_TEST|Cognitive/Neuropsychological Testing|Comprehensive testing of cognitive function and brain health.
214603803|NCT04708613|DIAGNOSTIC_TEST|Vestibular/Ocular-Motor Testing|A series of tests and questionnaires that asses vestibular function, balance, ocular-motor coordination, and reflexes.
214603804|NCT04708613|DIAGNOSTIC_TEST|Sleep Evaluation|A full assessment of sleep health, including insomnia (duration, frequency, daytime consequences) and other sleep disorders such as obstructive sleep apnea. Overnight sleep study is included.
214603805|NCT04708613|DIAGNOSTIC_TEST|MRI, High-Resolution|A high-resolution MRI to provide qualitative and quantitative assessments of brain structure.
214603806|NCT04708613|DIAGNOSTIC_TEST|Health & Physical Exam|Participants will undergo an executive history and physical exam of all body systems.
214603807|NCT04708613|DIAGNOSTIC_TEST|Physical Function|These assessments will involve a series of tests and questionnaires that focus on physical function.
214712361|NCT02253641|BEHAVIORAL|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
214603808|NCT04708613|DIAGNOSTIC_TEST|Blood Testing and Biomarker Analysis|"A blood draw will be performed to measure standard clinical labs as part of a full history and physical, as well as additional analysis of biomarkers indicative of brain health.~An optional lumbar puncture will be performed and CSF samples (20-30 mL) stored in the NCTC Biorepository until shipment to the CLIA-certified laboratory.~Both CSF and blood samples will be analyzed for t-tau, p-tau, and Aβ42 and stored for future testing,"
214603809|NCT04708613|DIAGNOSTIC_TEST|Applanation Tonometry|Hearth health is evaluated through testing of arterial stiffness and pulse wave reflections using a high fidelity applanation tonometer.
214603810|NCT04708613|DIAGNOSTIC_TEST|PET brain imaging|PET imaging of the brain using tau and amyloid ligands.
214603811|NCT04708613|DRUG|[C-11]6-OH-BTA-1|PET imaging of the brain using an amyloid ligand.
214603812|NCT04708613|DRUG|[F-18]AV-1451|PET imaging of the brain using a tau ligand.
214603813|NCT06950879|OTHER|Measurement|"A wooden construction was built consisting of two plates with dimensions of 35 x 29 cm: a bottom plate, with a measuring mat glued to it, a movable middle plate and a smaller top plate, allowing to mount a standardized overhead camera.~Participants were seated and placed one hand palm down on the measuring mat on the bottom plate. The hand was aligned with the midline of the body, lay flat with the fingers straight and lightly spread. First the actual landmarks were marked on the computer. Subsequently the participants hand was occluded by adding the middle plate. Participants were verbally cued to mark a certain landmark with their contralateral hand. These indicated points were marked on the computer. Before and after each trial, a picture was taken without the occluding board to ensure that the hand had not moved from its original position by digitally overlaying the images"
214603814|NCT04900792|DRUG|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
214603815|NCT04900792|DRUG|Pharmacological ascorbate|Intravenous ascorbate
214603816|NCT04900792|RADIATION|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
214603817|NCT04900792|DRUG|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
214603818|NCT05333328|DRUG|Ovarian function suppression with endocrine treatments|"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."
214603819|NCT06185530|DIAGNOSTIC_TEST|Detection of obstructive coronary disease|Detection of obstructive coronary disease
214603820|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
214603821|NCT03658746|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
214603822|NCT03658746|DRUG|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
214603823|NCT03658746|DRUG|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
214603824|NCT02296151|OTHER|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
214603825|NCT02296151|OTHER|iliotibial band stretches|Iliotibial band stretches
214603826|NCT01944735|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
214603827|NCT01944735|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
214712362|NCT06186804|DRUG|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
214712363|NCT00188357|BEHAVIORAL|Education|
214603828|NCT04160143|PROCEDURE|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
214603829|NCT02198612|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
214603830|NCT04907747|DRUG|Vonoprazan|Potassium-competitive acid blocker
214712364|NCT02722772|DRUG|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
214712365|NCT02722772|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
214603831|NCT04907747|DRUG|Esomeprazole|Proton pump inhibitor
214603832|NCT04907747|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
214603833|NCT04907747|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214712366|NCT04938388|DRUG|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
214603834|NCT04907747|DRUG|Furazolidone|Antibiotic for H. pylori eradication
214603835|NCT03774160|BEHAVIORAL|Generacion Actual|See description in arm description.
214603836|NCT00652392|DRUG|budesonide/formoterol|
214603837|NCT00652392|DRUG|budesonide and placebo|
214603838|NCT06475391|DIETARY_SUPPLEMENT|L-arginine|2 grams iof L-arginine will be ingested before an acute testing bout of exercise tasks in 250 mL of cranberry juice.
214712367|NCT04938388|DIETARY_SUPPLEMENT|Fresh organic vegetables|Prescriptions of organic vegetables
214712368|NCT04265898|DEVICE|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
214712369|NCT02287870|DRUG|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
214712370|NCT02287870|DRUG|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
214712371|NCT05060172|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
214712372|NCT00888069|DRUG|CTAP101 Capsules|Single dose oral administration
214712373|NCT00888069|DRUG|CTAP101 Injection|single IV injection
214712374|NCT00188968|PROCEDURE|Nasal Continuous Positive Airway Pressure|
214712375|NCT00188968|PROCEDURE|Synchronized Nasal Positive Pressure Ventilation|
214712376|NCT04914871|BEHAVIORAL|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
214603839|NCT06475391|DIETARY_SUPPLEMENT|Placebo|Placebo
214603840|NCT06104202|OTHER|Early Maladaptive Schemas|"Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory"
214603841|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
214603842|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
214603843|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
214603844|NCT05762523|BIOLOGICAL|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
214603845|NCT05867459|DIAGNOSTIC_TEST|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
214603846|NCT05867459|DIAGNOSTIC_TEST|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
214603847|NCT05867459|DIAGNOSTIC_TEST|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
214603848|NCT05867459|DIAGNOSTIC_TEST|Urine analysis|It is mirror of kidney
214603849|NCT05867459|DIAGNOSTIC_TEST|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
214603850|NCT05867459|DIAGNOSTIC_TEST|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
214712377|NCT04914871|BEHAVIORAL|Educational session accident prevention and wound management|It will be provided to the control group
214712378|NCT03729661|BEHAVIORAL|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
214712379|NCT06481020|DIETARY_SUPPLEMENT|Plant sterols 2g/day|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
214712380|NCT06481020|DIETARY_SUPPLEMENT|Placebo|Sachet containing the powdered excipients of the dietary supplement during 8 weeks
214712381|NCT04687007|BEHAVIORAL|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
214712382|NCT04687007|BEHAVIORAL|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
214712383|NCT02456792|PROCEDURE|IVF|Women will undergo one IVF cycle
214712384|NCT02456792|PROCEDURE|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
214712385|NCT05823870|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
214712386|NCT05267418|DEVICE|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
214712387|NCT01229891|DIETARY_SUPPLEMENT|plain yogurt drink|daily intake of two bottle of plain yogurt drink
214712388|NCT01229891|DIETARY_SUPPLEMENT|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
214712389|NCT01229891|DIETARY_SUPPLEMENT|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
214712390|NCT00003250|DRUG|fenretinide|
214603851|NCT05867459|OTHER|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm \> 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
214603852|NCT04206995|OTHER|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
214603853|NCT04206995|OTHER|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
214603854|NCT01444651|DRUG|Tadalafil|20 mg Tadalafil taken once a day for 3 months
214603855|NCT01444651|DRUG|Placebo|Placebo tablet taken by mouth once a day for 3 months
214603856|NCT06117371|DRUG|BEBT-607Tablets|"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."
214603857|NCT04727203|BEHAVIORAL|AHAA|Multi-component healthy lifestyle program
214712391|NCT03299036|DEVICE|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
214712392|NCT04030949|OTHER|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
214712393|NCT00028639|DRUG|bortezomib|
214712394|NCT03810378|BEHAVIORAL|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
214603858|NCT06426043|DRUG|Lusutrombopag|Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×109/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
214603859|NCT05653323|DRUG|VX-993|Suspension for oral administration.
214603860|NCT05653323|DRUG|Placebo|Suspension for oral administration.
214603861|NCT05679284|RADIATION|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
214603862|NCT00237822|BEHAVIORAL|Adherence Feedback (AF)|
214603863|NCT00237822|BEHAVIORAL|AF + Contingency Management (AF + CM)|
214603864|NCT00237822|BEHAVIORAL|AF + Motivational Enhancement Therapy (AF + MET)|
214603865|NCT05837182|PROCEDURE|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
214603866|NCT04824638|BIOLOGICAL|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
214603867|NCT04824638|BIOLOGICAL|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
214603868|NCT03840694|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
214603869|NCT03840694|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
214712395|NCT03810378|BEHAVIORAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
214603870|NCT00338663|DEVICE|knee immobilization splint|
214603871|NCT00459966|PROCEDURE|Preoperative rehabilitation|
214603872|NCT03431181|BEHAVIORAL|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
214603873|NCT03431181|BEHAVIORAL|Usual care|Patients in the control arm will receive usual care (as per local practices).
214603874|NCT03901573|DRUG|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
214603875|NCT03901573|DRUG|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
214712396|NCT03970707|OTHER|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
214712397|NCT03970707|OTHER|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
214603876|NCT03981471|BEHAVIORAL|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
214603877|NCT00589498|DIETARY_SUPPLEMENT|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
214603878|NCT06548269|DIAGNOSTIC_TEST|Cardiologic work-up|Noninvasive prolonged ECG monitoring with a duration of 7 days measuring AF burden； Echocardiography measuring LA volume or volume index, LA diameter or diameter index； Cardiac CTA measuring LAA morphologies, cardiac thrombus.
214603879|NCT02529267|OTHER|Standard of care|
214712398|NCT05378048|DRUG|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
214712399|NCT05378048|DRUG|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
214712400|NCT02264171|DRUG|Tamsulosin HCl|
214603880|NCT05779202|OTHER|No intervention is planned.|No intervention is planned.
214712401|NCT02264171|DRUG|Ketoconazole|
214603881|NCT04346498|OTHER|Chest-to-back|
214603882|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
214603883|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
214603884|NCT03383289|OTHER|R-REM training|three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
214603885|NCT02721745|BEHAVIORAL|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
214603886|NCT02721745|DEVICE|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
214603887|NCT02721745|DEVICE|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
214603888|NCT05068518|OTHER|No intervention|no intervention
214603889|NCT04652154|OTHER|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
214603890|NCT06489756|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
214603891|NCT02884726|DRUG|BMS-986148|Specified dose on specified days
214603892|NCT00832117|DRUG|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
214603893|NCT00832117|DRUG|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
214603894|NCT00832117|DRUG|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
214603895|NCT00832117|DRUG|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
214603896|NCT05717478|COMBINATION_PRODUCT|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
214712402|NCT06391476|OTHER|Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age|"* Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years."
214712403|NCT04767295|DRUG|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
214603897|NCT05717478|DEVICE|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
214603898|NCT00264524|PROCEDURE|venipuncture to withdraw patient's blood|
214603899|NCT00498251|DRUG|inhalation of salbutamol (5 mg)|
214603900|NCT00498251|DRUG|ipratropium|
214603901|NCT02241291|PROCEDURE|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
214603902|NCT04008147|DIETARY_SUPPLEMENT|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
214603903|NCT04008147|DIETARY_SUPPLEMENT|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
214603904|NCT00644553|DRUG|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
214603905|NCT00644553|DRUG|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
214603906|NCT01668407|DEVICE|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
214603907|NCT01668407|PROCEDURE|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
214603908|NCT04571827|OTHER|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
214603910|NCT00044551|DRUG|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
214603911|NCT02709590|DRUG|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
214603912|NCT02709590|DRUG|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
214603913|NCT06388681|DEVICE|The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography|The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
214603914|NCT03100799|PROCEDURE|Arthroscopy|Arthroscopy of the target knee
214603915|NCT03100799|PROCEDURE|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
214603916|NCT03100799|DIAGNOSTIC_TEST|MRI|MRI with and without a gadolinium-based contrast agent
214603917|NCT00404066|DRUG|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
214603918|NCT00404066|DRUG|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
214603919|NCT00404066|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
214603920|NCT00404066|DRUG|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
214603921|NCT00404066|DRUG|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
214603922|NCT00404066|DRUG|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
214603923|NCT00404066|DRUG|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
214603924|NCT00404066|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
214603925|NCT03177616|OTHER|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports"
214603926|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
214603927|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
214603928|NCT00303420|DRUG|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
214603929|NCT00303420|DRUG|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
214603930|NCT01426516|DEVICE|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
214603931|NCT01524133|DRUG|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
214603932|NCT01524133|BEHAVIORAL|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
214603933|NCT04323839|OTHER|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
214603934|NCT04323839|OTHER|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
214603935|NCT05740085|OTHER|Patient information form|Patients will be asked to fill out a patient information form and an osteoporosis awareness form
214603936|NCT06231576|OTHER|Prehabilitation|"* Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention."
214603937|NCT00862303|BIOLOGICAL|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
214603938|NCT00862303|DRUG|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
214603939|NCT01878643|DRUG|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
214603940|NCT01878643|DRUG|Placebo|normal saline administered to patient via nebulization
214603941|NCT04635683|DRUG|Lenalidomide|Given PO
214603942|NCT04635683|BIOLOGICAL|Ublituximab|Given IV
214603943|NCT04635683|DRUG|Umbralisib|Given PO
214603944|NCT05794750|DRUG|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
214603945|NCT05794750|PROCEDURE|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
214603946|NCT05794750|DRUG|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
214603947|NCT05794750|DRUG|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
214603948|NCT05937633|OTHER|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
214603949|NCT03619538|DRUG|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
214603950|NCT03619538|OTHER|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
214603951|NCT00786825|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
214603952|NCT01920945|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
214603953|NCT04311567|DRUG|Tofacitinib|Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
214603954|NCT04311567|DRUG|Methotrexate|Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
214603955|NCT02612051|DRUG|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
214603956|NCT02612051|DRUG|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
214603957|NCT02612051|RADIATION|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
214603958|NCT05861687|DRUG|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
214603959|NCT05861687|DRUG|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg
214603960|NCT05861687|DRUG|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
214603961|NCT05861687|DRUG|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
214603962|NCT01156233|PROCEDURE|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
214603963|NCT01156233|PROCEDURE|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
214603964|NCT02722382|OTHER|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
214603965|NCT00759733|PROCEDURE|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
214603966|NCT00759733|PROCEDURE|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
214603967|NCT04914143|OTHER|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
214603968|NCT04914143|OTHER|placebo|the control group was treated with placebo after chemotherapy
214603969|NCT05821530|DEVICE|HFIT|At least 1 hour daily for 4 weeks
214603970|NCT05821530|DEVICE|TENS|At least 1 hour daily for 4 weeks
214603971|NCT05821530|OTHER|Control|Users will continue to use the digital MSK program as needed
214603972|NCT01161901|PROCEDURE|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
214603973|NCT04027231|OTHER|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
214603974|NCT05050942|DRUG|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
214603975|NCT05050942|DRUG|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
214603976|NCT05050942|DRUG|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
214603977|NCT02685553|DEVICE|NIR|Laparoscopic use of NIR
214603978|NCT02136745|BEHAVIORAL|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
214603979|NCT05802992|DRUG|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
214603980|NCT05802992|DRUG|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
214603981|NCT00963833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
214603982|NCT03632109|DRUG|gentamicin 360mg IM|360mg IM of gentamicin
214603983|NCT02885948|DRUG|Naloxone|used to block the effects of opioids, especially in overdose
214603984|NCT02885948|DRUG|Placebo|Placebo, ineffective control arm
214603985|NCT05575154|DEVICE|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
214603986|NCT00966823|DEVICE|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~\- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
214603987|NCT04866368|PROCEDURE|The ultrasound-guided Sacral Erector spinae plane block|postoperative pain procedure
214603988|NCT04866368|PROCEDURE|The dorsal penile block|postoperative pain procedure
214603989|NCT04888130|GENETIC|Phylogenetic Analysis|The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
214603990|NCT04888130|OTHER|Data collection|Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
214603991|NCT00807963|DRUG|rHuPH20|recombinant human hyaluronidase PH20 injection
214603992|NCT00807963|DRUG|zoledronic acid|subcutaneous injection
214603993|NCT00648089|DRUG|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
214603994|NCT01956734|PROCEDURE|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
214603995|NCT01969097|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
214603996|NCT01969097|BEHAVIORAL|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
214603997|NCT04611438|DRUG|Cannabidiol|"Intervention schedule for each patient is as follows:~1. Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~2. Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~   * Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~  * Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~  * Maintenance: no change in medication dosage"
214603998|NCT01693081|DRUG|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
214603999|NCT01693081|DRUG|placebo|
214604000|NCT05545033|DEVICE|Virtual reality|5 to 15 minutes of virtual reality exposure
214604001|NCT03106181|DEVICE|iStent inject®|Insertion of iStent inject®
214604002|NCT03106181|PROCEDURE|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
214604003|NCT00158873|DRUG|midazolam|
214604004|NCT00158873|DRUG|lorazepam|
214604005|NCT00158873|DRUG|fentanyl|
214604006|NCT00158873|DRUG|morphine|
214604007|NCT00158873|DRUG|remifentanil|
214604008|NCT00158873|DRUG|propofol|
214604009|NCT03842163|DIAGNOSTIC_TEST|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
214604010|NCT02675023|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
214604011|NCT01479114|DRUG|rh-GCSF|10 ug/kg/day intravenously for 3 days
214604012|NCT02575040|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
214604013|NCT04110548|PROCEDURE|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
214604014|NCT04110548|PROCEDURE|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
214604015|NCT02700243|BEHAVIORAL|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
214604016|NCT03829241|DRUG|Troriluzole|100 mg capsule
214604017|NCT03829241|DRUG|Placebo|Placebo matched to troriluzole
214604018|NCT03415126|DRUG|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
214604019|NCT03415126|DRUG|ASN007 RD|Oral drug for the treatment of advanced solid tumors
214604020|NCT01418651|DRUG|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
214604021|NCT00469001|PROCEDURE|Treatment according NT Pro BNP level|
214604022|NCT06494215|OTHER|Pressure Support Variation and Calculation of Respiratory Mechanics|Patients will be submitted to different levels of pressure support (PS) in a randomly assigned order. First 30 minutes shall be recorded at the clinical PS. Next, blood gas samples shall be collected. Subsequently, three inspiratory pauses of at least 2 seconds shall be performed with an interval of at least 8 respiratory cycles between them. The same shall be performed with three expiratory pauses. Next, the PS shall be varied to 50% less or 50% more than clinical PS (based on randomization) and the same procedures shall be performed after 30 minutes of data recording (blood gas sample collection, inspiratory and expiratory pauses). All data shall be analyzed offline using a software that will be able to compare three different methods to calculate Pendelluft magnitude based on the literature. After completion of the protocol, ventilatory parameters shall be returned to the original settings. If the patient becomes tachypneic during lower PS, the protocol shall be interrupted.
214604023|NCT04752020|DRUG|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
214604024|NCT00698451|DRUG|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
214604025|NCT05290922|DIAGNOSTIC_TEST|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
214604026|NCT01924013|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
214604027|NCT01924013|DIETARY_SUPPLEMENT|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
214604028|NCT01899625|BEHAVIORAL|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
214604029|NCT01899625|BEHAVIORAL|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
214604030|NCT03525106|BEHAVIORAL|Booklet|Receive positive psychology manual
214604031|NCT03525106|BEHAVIORAL|Exercise Intervention|Complete positive psychology exercises
214604032|NCT03525106|OTHER|Quality-of-Life Assessment|Ancillary studies
214604033|NCT03525106|OTHER|Survey Administration|Ancillary studies
214604034|NCT03525106|BEHAVIORAL|Telephone-Based Intervention|Participate in phone sessions
214604035|NCT01447368|DRUG|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
214604036|NCT01447368|PROCEDURE|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
214604037|NCT04262050|DEVICE|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
214604038|NCT00005036|DRUG|irinotecan hydrochloride|Given IV
214604039|NCT00005036|DRUG|oxaliplatin|Given IV
214604040|NCT00005036|DRUG|leucovorin calcium|Given IV
214604041|NCT00005036|DRUG|fluorouracil|Given IV
214604042|NCT00005036|PROCEDURE|quality-of-life assessment|Ancillary studies
214604043|NCT02224599|BIOLOGICAL|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
214604044|NCT02224599|DRUG|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
214604045|NCT02224599|DRUG|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
214604046|NCT03174418|PROCEDURE|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
214604047|NCT00174590|DRUG|risperidone|
214604048|NCT00868426|DRUG|Budesonide/Formoterol Batch 1|Single, inhaled dose
214604049|NCT00868426|DRUG|Budesonide/Formoterol Batch 2|Single, inhaled dose
214604050|NCT00868426|DRUG|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
214604051|NCT04922463|DEVICE|PLASOMA|Treatment with cold plasma device
214604052|NCT03410849|DIAGNOSTIC_TEST|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
214604053|NCT04973020|DRUG|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
214604054|NCT00733304|DRUG|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
214604055|NCT02041260|DRUG|Cabozantinib|
214604056|NCT01187550|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.
214604057|NCT01627002|BIOLOGICAL|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
214604058|NCT01627002|OTHER|Placebo|Subcutaneous
214604059|NCT01855698|OTHER|Observation|
214604060|NCT04498208|BEHAVIORAL|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome \& Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
214604061|NCT04498208|BEHAVIORAL|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
214604062|NCT04498208|BEHAVIORAL|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
214604063|NCT04498208|BEHAVIORAL|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
214604064|NCT05805943|DRUG|IMM0306|IMM0306 is an bi-specific antibody
214604065|NCT00117546|DRUG|alpha methyldopa|500 mg twice a day
214604066|NCT02616614|DRUG|Onexton|Topical gel for treating acne
214604067|NCT02616614|DRUG|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
214604068|NCT02616614|DRUG|Placebo|Vehicle gel used as a placebo
214604069|NCT00943774|OTHER|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
214604070|NCT00000491|DRUG|aspirin|
214604071|NCT01085617|BIOLOGICAL|palifermin|
214604072|NCT01085617|BIOLOGICAL|rituximab|
214604073|NCT01085617|DRUG|cyclophosphamide|
214604074|NCT01085617|DRUG|cytarabine|
214604075|NCT01085617|DRUG|daunorubicin hydrochloride|
214604076|NCT01085617|DRUG|etoposide|
214604077|NCT01085617|DRUG|fludarabine phosphate|
214604078|NCT01085617|DRUG|imatinib mesylate|
214604079|NCT01085617|DRUG|melphalan|
214604080|NCT01085617|DRUG|mercaptopurine|
214604081|NCT01085617|DRUG|methotrexate|
214604082|NCT01085617|DRUG|nelarabine|
214604083|NCT01085617|DRUG|pegaspargase|
214604084|NCT01085617|DRUG|vincristine sulfate|
214604085|NCT01085617|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214604086|NCT01085617|RADIATION|total-body irradiation|
214604087|NCT06849388|BEHAVIORAL|Heart Math program|Heart Math program is behavior intervention through several sessions
214604088|NCT05258435|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
214604089|NCT03927040|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
214604090|NCT01978795|OTHER|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
214604091|NCT01978795|OTHER|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
214604092|NCT00596934|DRUG|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
214604093|NCT00636688|BEHAVIORAL|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
214604094|NCT00636688|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
214604095|NCT03509636|DRUG|Fluzoparib|Fluzoparib capsule will be given twice daily orally
214604096|NCT04638959|OTHER|collect gastric tissue and stool samples|collect gastric tissue and stool samples
214712404|NCT05666440|PROCEDURE|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
214604097|NCT05533242|DRUG|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
214604098|NCT03008954|DEVICE|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
214604099|NCT03008954|DIETARY_SUPPLEMENT|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
214604100|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
214604101|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
214604102|NCT03239483|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
214604103|NCT03239483|DRUG|Placebo gel|Universal HEC placebo gel; administered rectally
214604104|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
214604105|NCT06799338|DRUG|Lenacapavir Injection|"Patients will be included if they initiated LEN from 20 June 2023 to 30 June 2024.~All collected data are routinely reported by clinicians in medical records. All clinical decisions All collected data are routinely reported by clinicians in medical records, and will be collected using a dedicated electronic case report form (eCRF) created on this purpose, to ensure confidentiality of data."
214604106|NCT06309225|RADIATION|Modified dose and fields intensity modulated radiotherapy|Instead of standard bilateral or extensive neck fields, the current radiation fields will cover disease with only 3cm expansion. The clinical target volumes doses are biologically equivalent to the standard but given in a shorter hypofractionated approach.
214604107|NCT05241444|BIOLOGICAL|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood."
214604108|NCT05250908|DEVICE|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
214604109|NCT05250908|DEVICE|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
214604110|NCT04331054|DRUG|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
214604111|NCT04331054|OTHER|1: Usual practice|Usual practice
214604112|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
214604113|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
214604114|NCT00728481|DRUG|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
214604115|NCT00728481|DRUG|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
214604116|NCT06414915|DRUG|Surufatinib|250 mg, po, qd, q3w
214604117|NCT06414915|DRUG|Tislelizumab|200mg, iv, q3w
214604118|NCT00629655|OTHER|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
214712405|NCT05666440|PROCEDURE|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
214712406|NCT02098005|OTHER|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
214604119|NCT00288353|DRUG|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
214604120|NCT00288353|DRUG|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
214604121|NCT02862860|BIOLOGICAL|blood sample|
214604122|NCT02862860|BIOLOGICAL|urine sample|
214604123|NCT02862860|DEVICE|installation of Holter|
214604124|NCT00270478|DRUG|Erythropoietin and Hydroxyurea|
214604125|NCT01824680|BEHAVIORAL|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
214604126|NCT00514657|DRUG|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
214604127|NCT01068925|DRUG|GSK1349572|"1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
214604128|NCT00168480|BIOLOGICAL|Botulinum Toxin Type A|100 U, repeated treatments at \> 4 month intervals up to Month 32, over a 36-month study period
214604129|NCT00816309|DEVICE|Acapella Physiotherapy|twice daily- around 20 minutes
214604130|NCT04677699|DIAGNOSTIC_TEST|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
214604131|NCT05860023|OTHER|Exercise|Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
214604132|NCT02748837|DRUG|ERY974|
214604133|NCT06264778|DRUG|Dabrafenib|"Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery."
214604134|NCT01071135|DRUG|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
214604135|NCT00350805|PROCEDURE|EEG|One 20 minutes session
214604136|NCT00146081|BEHAVIORAL|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
214604137|NCT01832363|DRUG|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
214604138|NCT01832363|OTHER|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
214604139|NCT03030235|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
214604140|NCT03030235|DRUG|Dapagliflozin matching placebo|Dapagliflozin matching placebo
214604141|NCT04497909|BEHAVIORAL|Mindfulness|Mindfulness online training
214712407|NCT02098005|OTHER|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
214604142|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
214604143|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
214604144|NCT02183922|DIETARY_SUPPLEMENT|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
214604145|NCT01243541|PROCEDURE|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
214604146|NCT01243541|OTHER|questionnaire administration|Ancillary studies
214604147|NCT01243541|PROCEDURE|quality-of-life assessment|Ancillary studies
214604148|NCT01243541|PROCEDURE|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
214604149|NCT01243541|PROCEDURE|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
214604150|NCT01891435|DRUG|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
214604151|NCT01891435|DRUG|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
214604152|NCT01891435|DRUG|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
214604153|NCT00993135|DRUG|methotrexate|
214604154|NCT00993135|OTHER|medical chart review|
214604155|NCT00993135|PROCEDURE|assessment of therapy complications|
214604156|NCT04970043|DRUG|Camrelizumab+ pemetrexed + platinum|"Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years)."
214604157|NCT04249414|DEVICE|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
214604158|NCT04370288|DRUG|MCN (Methylene blue, vitamin C, N-acetyl cysteine)|A mixture of MCN will be injected to covid-19 patients.
214604159|NCT02749032|OTHER|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
214712408|NCT02189304|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
214712409|NCT02189304|DRUG|PT009|PT009 administered as 2 inhalations
214712410|NCT02189304|DRUG|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
214604160|NCT02749032|DRUG|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
214604161|NCT02749032|DRUG|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
214604162|NCT02749032|DRUG|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
214604163|NCT02749032|DRUG|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
214604164|NCT02749032|OTHER|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
214604165|NCT03558022|DIETARY_SUPPLEMENT|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
214604166|NCT03558022|DIETARY_SUPPLEMENT|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
214604167|NCT00154076|DRUG|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
214604168|NCT00154076|DRUG|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
214604169|NCT04530461|DIAGNOSTIC_TEST|Serological test|Positive serological test of SARS Cov2
214604170|NCT01460186|OTHER|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
214604171|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
214712411|NCT01171287|PROCEDURE|Driving with an Aircast Walker|
214712412|NCT01171287|PROCEDURE|Driving with a walking cast|
214712413|NCT01171287|PROCEDURE|Driving with a running shoe|
214712414|NCT01245205|DRUG|Akt inhibitor MK2206|Given PO
214712415|NCT01245205|DRUG|lapatinib ditosylate|Given PO
214712416|NCT01245205|OTHER|pharmacological study|Correlative studies
214712417|NCT01245205|OTHER|laboratory biomarker analysis|Correlative studies
214604172|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
214604173|NCT00698464|DRUG|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
214604174|NCT00270465|DRUG|VRC-HIVDNA016-00-VP|
214604175|NCT00270465|DRUG|VRC-HIVADV014-00-VP|
214604176|NCT03271346|BEHAVIORAL|intensive trauma-focused therapy|
214604177|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
214604178|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
214604179|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
214604180|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
214604181|NCT00626210|DRUG|modafinil|100-400 mg daily for 4 weeks
214604182|NCT01251120|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
214604183|NCT01251120|DRUG|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
214604184|NCT01839721|DRUG|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
214604185|NCT01839721|OTHER|placebo|
214604186|NCT04553068|DRUG|EVO100|EVO100 vaginal gel
214604187|NCT04553068|DRUG|Placebo|Placebo vaginal gel
214604188|NCT01922479|DRUG|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
214604189|NCT01922479|DRUG|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
214604190|NCT01722149|GENETIC|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
214604191|NCT02080455|DRUG|lomitapide|20 mg dose
214604192|NCT02080455|DRUG|Atorvastatin|80 mg
214604193|NCT04081584|DEVICE|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
214604194|NCT05344768|OTHER|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
214604195|NCT05344768|OTHER|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
214604196|NCT05344768|OTHER|resistance exercise training|resistance exercise training will be applied
214604197|NCT04268043|DEVICE|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
214604198|NCT04268043|DEVICE|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
214604199|NCT02877940|DEVICE|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
214604200|NCT02877940|DEVICE|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
214604201|NCT02877940|DEVICE|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
214604202|NCT02830997|DEVICE|Stereotactic guidance system|
214604203|NCT03605563|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
214712418|NCT03763799|PROCEDURE|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
214712419|NCT03763799|PROCEDURE|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
214604204|NCT03605563|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
214604205|NCT01561781|DRUG|Digoxin|Oral tablets 0.25mg, single dose
214604206|NCT01561781|DRUG|Vandetanib|Oral tablets, 300 mg, single dose
214604207|NCT01807923|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
214712420|NCT04828369|PROCEDURE|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
214712421|NCT04828369|PROCEDURE|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
214712422|NCT03689387|OTHER|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
214604208|NCT01807923|DRUG|Ivacaftor|Film-coated tablet
214604209|NCT01807923|DRUG|Placebo|Matching placebo tablet
214604210|NCT06493487|OTHER|integrated neuromuscular inhibition technique|integrated neuromuscular inhibition technique for gastrocniemus muscle
214712423|NCT02272283|DEVICE|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
214604211|NCT06493487|OTHER|instrument assissted soft tissue mobilization|instrument assissted soft tissue mobilization for calf muscle
214604212|NCT06493487|OTHER|convential treatment|convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
214604213|NCT00108069|DRUG|Tamoxifen citrate|oral dose 120 mg twice a day, every day
214604214|NCT00108069|DRUG|Bortezomib|intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
214604215|NCT01473316|DRUG|GDC-0980|Single oral dose
214604216|NCT01473316|DRUG|Ketoconazole|Repeating Oral Dose
214712424|NCT05479305|DEVICE|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
214604217|NCT03051581|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
214712425|NCT05128604|DEVICE|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
214712426|NCT04122586|DRUG|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
214712427|NCT05816252|DRUG|SKB264|intravenous (IV) infusion (Q2W or Q3W)
214712428|NCT05816252|DRUG|Pembrolizumab|intravenous (IV) infusion (400mg, Q6W)
214712429|NCT05816252|DRUG|Carboplatin|intravenous (IV) infusion (AUC5, Q3W)
214712430|NCT05816252|DRUG|Osimertinib|80mg, QD
214712431|NCT05038592|DRUG|Decitabine|Given IV
214712432|NCT05038592|BIOLOGICAL|Tagraxofusp-erzs|Given IV
214712433|NCT02515708|DEVICE|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
214712434|NCT02891980|BIOLOGICAL|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
214712435|NCT02891980|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
214712436|NCT02908633|PROCEDURE|canaloplasty and phacoemulsification|
214712437|NCT03594864|PROCEDURE|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
214712438|NCT02307318|DEVICE|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
214712439|NCT01438307|DRUG|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
214712440|NCT01438307|DRUG|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
214604218|NCT04696991|BEHAVIORAL|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
214604219|NCT00995007|DRUG|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
214604220|NCT00995007|DRUG|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
214604221|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
214604222|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
214604223|NCT02670681|BEHAVIORAL|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
214604224|NCT01612143|DRUG|setrobuvir|200 mg capsule formulation, single oral dose
214604225|NCT01612143|DRUG|setrobuvir|200 mg tablet formulation, single oral dose
214604226|NCT04641780|DRUG|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
214604227|NCT04939662|DRUG|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
214604228|NCT03732079|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
214604229|NCT06068660|BEHAVIORAL|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
214604230|NCT06068660|BEHAVIORAL|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
214604231|NCT01910116|DRUG|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
214604232|NCT01910116|DRUG|Placebo|The study medication and placebo were identical in appearance.
214604233|NCT03956368|DRUG|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
214604234|NCT03956368|DRUG|Placebos|20mg (every evening orally) for 8 weeks.
214604235|NCT01037907|DRUG|Pleneva TM BGC20-0134|Placebo or 5 g dose
214604236|NCT01037907|DRUG|Placebo|Placebo or 5 g dose
214604237|NCT05384379|DRUG|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
214604238|NCT05206591|BIOLOGICAL|Secukinumab|Secukinumab 300 s.c.
214604239|NCT05206591|OTHER|Placebo|Placebo
214604240|NCT06072560|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214604241|NCT06072560|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214604242|NCT03606980|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
214604243|NCT03606980|PROCEDURE|Iontophoresis|Iontophoresis on affected knee
214604244|NCT03606980|PROCEDURE|Physical Therapy|Physical therapy of affected knee
214604245|NCT00565942|PROCEDURE|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
214604246|NCT00565942|PROCEDURE|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
214604247|NCT00194844|BEHAVIORAL|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
214604248|NCT00194844|BEHAVIORAL|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
214604249|NCT00194844|BEHAVIORAL|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
214604250|NCT02218190|DRUG|Alvimopan|
214604251|NCT02218190|DRUG|Placebo|
214604252|NCT02469896|DRUG|Tocilizumab|IV Infusion
214604253|NCT02469896|OTHER|Placebo|IV Infusion
214604254|NCT05709236|DEVICE|Maxillary screw-retained prosthesis|Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
214604255|NCT03937284|OTHER|Patients not treated|
214604256|NCT02839057|PROCEDURE|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
214604257|NCT02839057|PROCEDURE|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
214604258|NCT04862624|BEHAVIORAL|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
214604259|NCT04862624|BEHAVIORAL|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
214604260|NCT01294150|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
214604261|NCT01294150|OTHER|Cystoscopy|The Control Group will undergo cystoscopy.
214604262|NCT01294150|DEVICE|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
214604263|NCT03708120|OTHER|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
214604264|NCT00127920|DRUG|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
214604265|NCT05231486|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
214604266|NCT03675776|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
214604267|NCT03675776|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration).
214604268|NCT02368067|PROCEDURE|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
214604269|NCT02368067|PROCEDURE|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
214604270|NCT03914404|DRUG|γ-linoleic acid and placebo(Thioctic Acid)|"* γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
214604271|NCT03914404|DRUG|Thioctic Acid and placebo(γ-linoleic acid)|"* Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
214604272|NCT03327441|OTHER|Almonds|Almonds will be provided as 15% energy
214604273|NCT03327441|OTHER|Omelette|Omelettes will be provided as 15% energy
214604274|NCT01519076|DEVICE|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
214604275|NCT00080496|DRUG|Tigecycline|
214604276|NCT00080496|DRUG|Imipenem|
214604277|NCT00080496|DRUG|Cilastatin|
214604278|NCT05191069|OTHER|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
214604279|NCT05191069|OTHER|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
214604280|NCT00076557|GENETIC|Adeno-Associated Viral with Human Factor IX|
214604281|NCT01464229|DRUG|Iloperidone|Iloperidone 1-8 mg for 4 weeks
214604282|NCT01464229|DRUG|Placebo|Placebo
214604283|NCT01249820|DRUG|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
214604284|NCT01249820|DRUG|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
214604285|NCT04233164|DRUG|Solu-Medrol 1mg/kg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
214604286|NCT04233164|DRUG|Solu-Medrol 250 mg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
214604287|NCT05614973|PROCEDURE|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
214604288|NCT05614973|PROCEDURE|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
214604289|NCT01840605|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
214604290|NCT01840605|DRUG|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
214604291|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
214604292|NCT00521742|DRUG|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
214604293|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
214604294|NCT00521742|DRUG|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
214604295|NCT01326195|BEHAVIORAL|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
214604296|NCT01326195|BEHAVIORAL|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
214712441|NCT03239639|BEHAVIORAL|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
214604297|NCT02896179|DEVICE|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
214604298|NCT02896179|DEVICE|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
214712442|NCT03239639|OTHER|Wait list control|No intervention
214712443|NCT01917890|DIETARY_SUPPLEMENT|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
214712444|NCT01917890|DIETARY_SUPPLEMENT|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
214604299|NCT01499472|DEVICE|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
214604300|NCT01499472|DEVICE|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
214604301|NCT01499472|PROCEDURE|standard of care|regular care including debridement and bandaging.
214604302|NCT04561804|PROCEDURE|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
214604303|NCT01351623|DRUG|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
214604304|NCT01959048|DRUG|fecal microbiota transplantation|
214604305|NCT03726762|BEHAVIORAL|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
214604306|NCT03726762|BEHAVIORAL|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
214604307|NCT04273256|DRUG|Myo-inositol|patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
214604308|NCT05097014|DRUG|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
214604309|NCT05097014|DRUG|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
214604310|NCT05097014|OTHER|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
214604311|NCT05564351|OTHER|eye mask and ear plug|black eye mask and silicon ear plug
214604312|NCT03920813|DRUG|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
214604313|NCT01130974|DEVICE|Bausch & Lomb contact lens|Bausch \& Lomb daily disposable cosmetic tint contact lens
214604314|NCT01130974|DEVICE|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
214712445|NCT05960513|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
214712446|NCT00555568|BEHAVIORAL|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
214712447|NCT00555568|BEHAVIORAL|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
214712448|NCT04436588|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
214712449|NCT02565446|PROCEDURE|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
214712450|NCT03167541|DRUG|Test|RB naproxen sodium tablets (2x220mg)
214604315|NCT01484730|DEVICE|Multi-Spectral and Laser Speckle Imaging|Changes in skin tissue and blood flow.
214604316|NCT00387764|DRUG|pazopanib|800 mg daily dosing continously until progression
214604317|NCT06062433|DEVICE|AsthmaTuner|Phone application and spirometer for self-management of asthma
214604318|NCT06062433|OTHER|Asthma-Guidance and Prediction System|Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
214604319|NCT02903082|BIOLOGICAL|Residue of blood further to NFS|
214604320|NCT02903082|BIOLOGICAL|Residue of blood further to preoperative workup|
214604321|NCT02903082|BIOLOGICAL|Bone marrow collected during a myelogram carried out for hematological pathology workup|
214604322|NCT02903082|BIOLOGICAL|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
214712451|NCT03167541|DRUG|Reference|Aleve naproxen sodium tablets (2x220mg)
214604323|NCT02536573|OTHER|Radlink Surgical Positioning Software|
214604324|NCT04399122|DRUG|acetaminophen/codeine vs acetaminophen/oxycodone|pain medications
214604325|NCT00179166|DRUG|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
214604326|NCT02849158|OTHER|Biopsy|Rectoscopy with biopsy
214604327|NCT03200340|DRUG|EC-18|Oral administration of EC-18 twice daily
214604328|NCT03200340|DRUG|Placebo|Placebo to match EC-18 capsule administration
214604329|NCT01083628|BEHAVIORAL|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
214604330|NCT01083628|BEHAVIORAL|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
214604331|NCT02086851|BEHAVIORAL|Lifestyle Intervention|
214604332|NCT02086851|BEHAVIORAL|Parent Motivational Interviewing|
214604333|NCT06073379|OTHER|Korean manupuncture|Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
214604334|NCT06073379|OTHER|Placebo session|Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
214604335|NCT00187395|PROCEDURE|Randomized to either a 'less tight' group or a 'tight' group|
214604336|NCT01493258|OTHER|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
214604337|NCT00000268|DRUG|Bupropion|
214712452|NCT02590419|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
214604338|NCT01391585|OTHER|Text Message prompts|In this single armed intervention, patients will receive text message prompts
214604339|NCT00051480|GENETIC|TNFerade|
214604340|NCT01322984|BEHAVIORAL|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
214604341|NCT01322984|BEHAVIORAL|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
214604342|NCT01102803|BEHAVIORAL|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
214604343|NCT01102803|DRUG|D-Cycloserine|D-Cycloserine
214604344|NCT01102803|DRUG|Placebo|Sugar Pill
214604345|NCT05315453|BEHAVIORAL|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
214604346|NCT05408104|DRUG|tolvaptan|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
214604347|NCT05279209|PROCEDURE|catheter-directed sclerotherapy|Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.
214604348|NCT05279209|PROCEDURE|surgical resection|Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
214604349|NCT02326714|OTHER|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
214604350|NCT02326714|OTHER|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
214712453|NCT00638417|BEHAVIORAL|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
214604351|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
214604352|NCT00393952|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
214604353|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
214604354|NCT00393952|DRUG|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
214604355|NCT00393952|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
214604356|NCT04688723|DRUG|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
214604357|NCT04688723|DRUG|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
214712454|NCT00638417|BEHAVIORAL|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
214712455|NCT06489782|OTHER|Model 1|Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
214712456|NCT06489782|OTHER|Model 2|Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
214712457|NCT01989871|BEHAVIORAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
214712458|NCT04517227|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
214712459|NCT04517227|PROCEDURE|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
214604358|NCT03005951|OTHER|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
214712460|NCT04517227|PROCEDURE|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
214712461|NCT02538939|DRUG|Sodium thiosulfate|
214712462|NCT03948269|BEHAVIORAL|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
214712463|NCT05521971|OTHER|multifaceted pharmacist-led intervention|"* Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone."
214712464|NCT05521971|OTHER|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
214712465|NCT02525887|OTHER|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
214712466|NCT03991182|OTHER|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
214712467|NCT03991182|OTHER|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
214712468|NCT03991182|BEHAVIORAL|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
214712469|NCT03991182|OTHER|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
214712470|NCT05718453|COMBINATION_PRODUCT|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
214712471|NCT05333640|DEVICE|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
214712472|NCT05333640|DEVICE|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
214712473|NCT02060968|DEVICE|Promus PREMIER|
214712474|NCT06967961|OTHER|For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:|A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
214712475|NCT02378883|DEVICE|Apollo™ Onyx™ Delivery Micro Catheter|
214712476|NCT04694625|OTHER|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
214712477|NCT04694625|OTHER|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
214712478|NCT04649619|PROCEDURE|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
214604359|NCT03005951|OTHER|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
214712479|NCT02220361|DRUG|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
214604360|NCT00613054|DRUG|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations."
214604361|NCT02877212|DRUG|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
214604362|NCT04779190|DEVICE|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
214604363|NCT04779190|DEVICE|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
214604364|NCT04779190|OTHER|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
214604365|NCT02684279|DRUG|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
214604366|NCT02204384|OTHER|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
214604367|NCT02204384|DIETARY_SUPPLEMENT|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
214604368|NCT02204384|OTHER|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
214604369|NCT06056674|BEHAVIORAL|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
214604370|NCT06056674|BEHAVIORAL|SAU|Participants in this group will continue to receive standard of care within their school clinic.
214604371|NCT06606444|DEVICE|Surfactant Administration Through Laryngeal or Supraglottic Airways|While the child is spontaneously breathing on nasal CPAP treatment, the neonatal intensive care (NICU) physician will place the LMA and assess for adequate airway by CO2-detection, chest movement, pulmonary auscultation of bilateral breath sounds, gastric insufflation, oxygen saturation and heart rate. A placement attempt should not last more than 30 seconds. Surfactant will be administered slowly in 1-2 ml aliquots (Curosurf 200 mg/kg) via an appropriate size laryngeal mask airway. The neonate should primarily be spontaneously breathing and if needed receives gentle supportive positive pressure ventilation (PPV). Gentle supportive PPV is given for 30 seconds after surfactant is administered, before LMA is removed.
214604372|NCT02733185|DRUG|disodium EDTA|IV Disodium Ethylene diamine tetra acetic acid in 500 cc
214604373|NCT02733185|DIETARY_SUPPLEMENT|Oral Multi Vitamins/Minerals (OMVM)|6 tablets of Multi-vitamin/Multimineral daily
214604374|NCT02733185|DRUG|Placebo disodium EDTA|IV Placebo comparator- 500 normal saline
214604375|NCT02733185|DIETARY_SUPPLEMENT|Placebo Oral Multi Vitamins/Minerals (OMVM)|6 tablets of a placebo Multi-vitamin/Multimineral daily
214712480|NCT02220361|DRUG|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
214712481|NCT02220361|DRUG|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
214712482|NCT00707538|DRUG|BMS747158|2 IV injection of \~11 mCi (total) F-18 labeled compound
214712483|NCT04090268|OTHER|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
214712484|NCT04762953|DRUG|Paclitaxel|Intraperitoneal Paclitaxel
214712485|NCT04762953|DRUG|Paclitaxel|IV Paclitaxel
214604376|NCT06604026|DEVICE|BD PosiFlush™ SafeScrub|"Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
214712486|NCT04762953|DRUG|Leucovorin|IV Leucovorin
214712487|NCT04762953|DRUG|Fluorouracil|IV 5-FU
214712488|NCT04593875|DEVICE|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
214712489|NCT04593875|DEVICE|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
214712490|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
214712491|NCT03024840|DRUG|Sevoflurane|Sevoflurane: 1%\~2%
214712492|NCT03024840|DRUG|Propofol|Propofol: 9-15 mg/kg/h
214712493|NCT03909672|OTHER|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
214712494|NCT03703362|OTHER|Resistance training|30 supervised training-sessions over 12 weeks
214604377|NCT06604026|DEVICE|BD PosiFlush™|"Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
214604378|NCT06974916|PROCEDURE|Staged bilateral Exablate thalamotomy|Staged bilateral Exablate thalamotomy in ET patients
214604379|NCT06974916|OTHER|Local standard medical treatment after previous Exablate unilateral thalamotomy.|Local standard medical treatment
214604380|NCT05932251|DRUG|Metformin|All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
214604381|NCT02338349|DRUG|Elacestrant|
214604382|NCT02023255|DRUG|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
214604383|NCT02023255|OTHER|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
214604384|NCT00198627|DRUG|Co-Trimoxazole; TMP-SMZ|
214712495|NCT03790384|DRUG|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
214712496|NCT01118715|DEVICE|Compression glove|A compression glove worn during recovery from distal radius fracture
214712497|NCT00702247|PROCEDURE|Hematopoietic Stem Cell Transplantation|
214712498|NCT03123055|DRUG|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
214604385|NCT00188422|PROCEDURE|low dose CT|
214604386|NCT03998293|DRUG|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
214604387|NCT00583570|BEHAVIORAL|dietary education|dietary education
214604388|NCT03029169|DRUG|Propafenone i.v.|Treatment
214604389|NCT03029169|DRUG|Amiodarone i.v.|Treatment
214604390|NCT01353456|DRUG|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
214604391|NCT01353456|DRUG|Normal Saline|Same volume as dexmedetomidine given
214604392|NCT01088256|DRUG|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
214604393|NCT01088256|DRUG|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
214604394|NCT05608902|OTHER|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
214712499|NCT03123055|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
214604395|NCT00782288|DRUG|digitoxin|0.05mg tabs, once daily for 28 days
214604396|NCT00782288|DRUG|digitoxin|0.1mg pills, once daily for 28 days.
214712500|NCT02904187|OTHER|Positron Emission Tomography (PET)|
214712501|NCT02904187|OTHER|Electroencephalogram (EEG)|
214712502|NCT02131246|DRUG|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
214712503|NCT02131246|DRUG|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
214712504|NCT01566201|DRUG|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
214712505|NCT01566201|DRUG|placebo|water for injection
214712506|NCT05431569|DRUG|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
214604397|NCT00782288|OTHER|placebo|pill taken once daily for 28 days
214604398|NCT04775225|DRUG|Lidocaine|denervation of the obturator and femoral genicular branches by Lidocaine 2 %
214604399|NCT04775225|DRUG|Placebo|an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
214604400|NCT04775225|DRUG|Steroid|Intra-articular injection of 80mg of triamcinolone
214712507|NCT03814005|DRUG|Azacitidine|Azacitidine subcutaneous or intravenous injection.
214712508|NCT03814005|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
214712509|NCT06218511|BIOLOGICAL|Peptide-based hepatocellular carcinoma vaccine IMA970A|IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
214712510|NCT06218511|COMBINATION_PRODUCT|Durvalumab|anti-PD-L1
214712511|NCT06218511|OTHER|Montanide (Adjuvant)|Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
214712512|NCT06270316|DRUG|AMT-191|"A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease."
214712513|NCT04026971|PROCEDURE|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
214712514|NCT05736978|DRUG|Azacitidine|75mg/m2 d1-7
214712515|NCT05736978|DRUG|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
214712516|NCT05736978|DRUG|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
214604401|NCT04547673|DIAGNOSTIC_TEST|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
214604402|NCT02764450|DEVICE|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
214712517|NCT00975026|PROCEDURE|Massages ± Stretches|Chair Massage
214712518|NCT01379170|DRUG|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
214712519|NCT02284230|DRUG|Liraglutide|
214712520|NCT02284230|DRUG|Placebo|
214712521|NCT05552807|DRUG|SCT-I10A|Administered intravenously
214712522|NCT05552807|DRUG|SCT200|Administered intravenously
214712523|NCT05552807|DRUG|paclitaxel|Administered intravenously
214604403|NCT02764450|DEVICE|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
214604404|NCT00903656|DRUG|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
214712524|NCT05552807|DRUG|docetaxel|Administered intravenously
214712525|NCT00895778|OTHER|Neuromuscular blockade with rocuronium and reversal with sugammadex|
214712526|NCT01267344|DRUG|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
214712527|NCT01267344|DRUG|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
214712528|NCT01113190|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
214604405|NCT01028456|OTHER|Light Therapy|10,000 lux / 30 minutes a day
214604406|NCT01028456|OTHER|100 lux|Placebo light
214604407|NCT00671554|BIOLOGICAL|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
214604408|NCT03374098|BEHAVIORAL|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
214604409|NCT03374098|BEHAVIORAL|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
214604410|NCT02079012|BEHAVIORAL|10-week walking program|
214604411|NCT04339114|OTHER|Breakfast: control meal|The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
214712529|NCT01113190|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
214604412|NCT04339114|OTHER|Breakfast: Cinnamon meal|The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
214604413|NCT04339114|OTHER|Breakfast: Italian herbs meal|The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
214604414|NCT04339114|OTHER|Breakfast: pumpkin spice|The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
214604415|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
214604416|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
214604417|NCT00781820|DRUG|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
214604418|NCT00781820|DRUG|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
214604419|NCT02342756|DEVICE|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
214604420|NCT01810016|BIOLOGICAL|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
214604421|NCT01810016|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
214604422|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
214604423|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
214604424|NCT01116518|PROCEDURE|physiotherapy|
214604425|NCT01116518|PROCEDURE|acromioplasty|
214604426|NCT01116518|PROCEDURE|acromioplasty and rotator cuff reconstruction|
214712530|NCT01113190|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
214712531|NCT01113190|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
214712532|NCT00035152|DRUG|Paclitaxel and carboplatin|
214712533|NCT03819478|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
214712534|NCT03819478|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
214604427|NCT05877183|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
214604428|NCT05877183|DEVICE|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
214604429|NCT03176563|DRUG|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
214712535|NCT03819478|DIETARY_SUPPLEMENT|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
214712536|NCT03819478|DIETARY_SUPPLEMENT|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
214712537|NCT03819478|DIETARY_SUPPLEMENT|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
214712538|NCT05896046|DRUG|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
214604430|NCT03176563|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
214604431|NCT03176563|DRUG|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
214604432|NCT03176563|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
214604433|NCT05018260|BEHAVIORAL|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
214604434|NCT05018260|BEHAVIORAL|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
214604435|NCT02978079|DEVICE|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
214604436|NCT04513262|PROCEDURE|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
214604437|NCT05574634|BEHAVIORAL|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
214604438|NCT05574634|BEHAVIORAL|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
214604439|NCT06162000|OTHER|The group that will use the developed software in case studies|"In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups."
214604440|NCT05201937|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
214604441|NCT02427880|DRUG|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
214604442|NCT02427880|DRUG|Furosemide and Hydrochlorothiazide Followed by Furosemide|
214604443|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
214604444|NCT01703663|DEVICE|EPAP|
214604445|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
214604446|NCT04326647|OTHER|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
214604447|NCT04326647|OTHER|Exercise|Exercises about balance and gait
214604448|NCT05056324|DEVICE|Online vestibular rehabilitation tool|For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)
214604449|NCT05056324|OTHER|Standard care (written instructions leaflet)|For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
214604450|NCT06666192|OTHER|Cancer Screening|Undergo cancer screening
214604451|NCT06666192|OTHER|Discussion|Participate in discussions
214604452|NCT06666192|OTHER|Educational Activity|Receive coaching calls
214604453|NCT06666192|OTHER|Educational Intervention|Receive educational materials
214604454|NCT06666192|BEHAVIORAL|Focus Group|Participate in focus group
214604455|NCT06666192|OTHER|Health Care Delivery|Integrate new activities into usual clinic processes
214604456|NCT06666192|OTHER|Health Promotion|Promote screening and wellness visits
214604457|NCT06666192|OTHER|Health Promotion and Education|Participate in educational sessions
214604458|NCT06666192|OTHER|Health Promotion and Education|Participate in early wave MLI
214604459|NCT06666192|OTHER|Health Promotion and Education|Participate in late wave MLI
214604460|NCT06666192|BEHAVIORAL|Health Risk Assessment|Incorporate risk assessments
214604461|NCT06666192|PROCEDURE|Implementation|Implement MLI
214604462|NCT06666192|OTHER|Informational Intervention|Review MLI materials
214604463|NCT06666192|OTHER|Internet-Based Intervention|Receive educational online materials
214604464|NCT06666192|OTHER|Interview|Participate in interview
214604465|NCT06666192|BEHAVIORAL|Outreach|Receive outreach activities
214604466|NCT06666192|BEHAVIORAL|Patient Navigation|Receive access to CHW
214604467|NCT06666192|OTHER|Survey Administration|Ancillary studies
214604468|NCT05045040|BEHAVIORAL|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
214604469|NCT07130097|DRUG|PF-07220060|Cyclin-dependent kinase-4 inhibitor
214604470|NCT07130487|BEHAVIORAL|Relational Agent ( RA) Alex|The intervention is an RA (chatbot) integrated into a genetic care delivery portal for primary care patients. The RA provides hereditary cancer education and risk evaluation through an interactive interface. Primary care patients will use the RA to complete questionnaires about their hereditary cancer risk, track their progress through the education component and assessment process, and obtain downloadable summaries of their cancer risk and family tree. Additionally, the chat feature stores past conversations, and a menu guides participants through key steps.
214604471|NCT07122011|OTHER|Low-Intensity Resistance Training with BFR|"Warm-up: Five minutes of light-intensity cycling on a stationary bike.~Exercises:~1. Bilateral half squat (0°-90°)~2. Single-leg step-down from a 20 cm step~3. Knee extension (90°-0°) at 30% of one-repetition maximum (1RM)~4. Single-leg shallow squat (0°-45°)~Protocol: One set of 30 repetitions (or until volitional fatigue) followed by three sets of 15 repetitions for each exercise.~Rest periods: One minute between sets and two minutes between exercises.~BFR Application: Pneumatic cuff (The Occlusion Cuff Pro®) placed proximally on the dominant thigh, inflated to 60% of complete arterial occlusion (determined via Doppler ultrasound). The cuff remains inflated during sets and rest periods, and is deflated after completion of each exercise."
214604472|NCT06717854|OTHER|transanal irrigation|The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. the catheter is gently and slowly inserted 7-10 cm through the anus. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
214712539|NCT05896046|DRUG|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
214712540|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
214712541|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
214712542|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
214604473|NCT06717854|OTHER|antegrade enema|The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. Using a disposable catheter, insert it about 20 cm. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
214604474|NCT07128966|OTHER|Observation|This is non-interventional, observational only
214604475|NCT07129031|DRUG|low-titer O-group whole blood|Arm Description: During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.
214604476|NCT07129031|DRUG|1:1:1 component transfusion|"Following the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition), implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets)."
214604477|NCT07129031|DRUG|ABO- and Rh-compatible whole blood|"Administer type-specific whole-blood transfusion in accordance with the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)."
214604478|NCT07129967|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
214604479|NCT07129707|OTHER|Exercise testing|Each participant performs a constant work-rate exercise test (70% peak work rate) under the 4 experimental conditions (referred as arms).
214604480|NCT03331016|BEHAVIORAL|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
214604481|NCT05167123|DRUG|Light cured tri-calcium silicate base material|TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
214712543|NCT01080612|DRUG|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
214604482|NCT06020807|DIAGNOSTIC_TEST|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
214604483|NCT04822012|DIAGNOSTIC_TEST|Anti COVID19 IgG Antibodies|Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
214604484|NCT02618954|OTHER|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
214604485|NCT06148857|DIAGNOSTIC_TEST|IOLMaster 700|"The IOLMaster 700, one of the most commonly used optical biometers for IOL power calculation, measures the anterior corneal surface radius using a telecentric keratometry. Additionally, it employs swept-source optical coherence tomography (SS-OCT) technology to simultaneously measures the posterior cornea surface radius and central corneal thickness (CCT).~The AK formula, described by Abulafia et al., is a regression formula that calculates an estimated TCA using K astigmatism.~The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements."
214604486|NCT02274168|PROCEDURE|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
214604487|NCT02274168|PROCEDURE|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
214604488|NCT03828292|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
214604489|NCT03828292|DRUG|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
214604490|NCT03828292|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally.
214604491|NCT03828292|DRUG|Pomalidomide|Pomalidomide capsules will be administered orally.
214604492|NCT00291811|DRUG|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
214712544|NCT05876104|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
214712545|NCT00111111|DRUG|Etanercept|
214712546|NCT03965793|DEVICE|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
214712547|NCT04095468|RADIATION|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
214604493|NCT00285077|DRUG|SR57667B|
214604494|NCT03067012|OTHER|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
214604495|NCT03325478|OTHER|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
214604496|NCT06807203|OTHER|Behavioral observation|Behaviors will be observed in children's natural environment. With a digital health assessment.
214604497|NCT04227951|DEVICE|Avoid drain placement|In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
214604498|NCT04227951|DEVICE|Drain placement|In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
214712548|NCT06325306|BEHAVIORAL|Traditional APA|12 sessions of 1,5 hour are organized (once per week). The first session is primarily focused on the PL assessment, followed by a comprehensive introduction to physical conditioning exercises. Each of the subsequent sessions (n=10), participants will receive an intervention focused on the development of their physical fitness (endurance, strength, flexibility, balance). Each session will commence with a 15 minute warm-up comprising of a blend of cardiovascular and joint mobilization exercises. The core part of each session will be dedicated to session-specific exercises targeting key physical competencies such as endurance, strength, flexibility, and balance, along with other motor skills. . The size of the group will never exceed a number of 15 participants. At the conclusion of each session, participants will be guided through a return-to-calm sequence that included stretching and relaxation exercises.
214604499|NCT06153160|DEVICE|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
214604500|NCT06985056|BEHAVIORAL|Supervised 12-week Resistance and Endurance Exercise Program|60 Minute home-based and supervised endurance, resistance and coordination training 2x/week for 12 weeks, self-administered 20 minute home-based multimodal training 1x/week
214604501|NCT02247908|OTHER|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~1. SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~2. SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~3. SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~4. SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
214604502|NCT02247908|OTHER|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~1. Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~2. Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~3. Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~4. Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
214604503|NCT03896464|PROCEDURE|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
214604504|NCT03896464|PROCEDURE|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
214604505|NCT00478101|DRUG|oxycodone fentanyl|
214604506|NCT06658899|DRUG|CRD-4730|Oral CRD-4730 in tablet form
214604507|NCT06658899|DRUG|Placebo|Placebo to match CRD-4730 in tablet form
214604508|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
214604509|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
214604510|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
214604511|NCT06604741|OTHER|Assigned Interventions for LVIMT|"IMT is a form of exercise designed to strengthen the muscle involved inhalation, primarily the diaphragm and intercostal muscles.~The LVIMT group will perform IMT once daily, 5 days a week, maintaining 60% of maximal inspiratory pressure (MIP) throughout the 6-week intervention.~The intervals are typically longer in duration (e.g., 2-4 minutes) with a work-to-rest ratio of 1:1 or 1:0.5.~POSITION: rested and seated position. FREQUENCY: more frequency, once a day. 2-3 sessions per week. INTENSITY: Low resistance. Only 60%% MIP. TIME: shorter duration of 10-20 mint."
214604512|NCT06604741|OTHER|Assigned interventions for HVIMT|"The HVIMT group is trained twice daily, with the morning session matching the LV-IMT protocol, and an additional afternoon session. The HVIMT group also experienced a progressive increase in intensity, starting at 60% MIP and reaching 80% by the end of the study. LVIMT works for beginner or individuals with limited respiratory capacity while HVIMT is used for individual with high baseline respiratory fitness.~The intervals are typically shorter in duration (e.g., 30 seconds to 2 minutes) with a work-to-rest ratio of 1:1 or 1:2.~POSITION; Seated upright position. FREQUENCY: more frequency two session per week. 4-5 sessions per week. INTENSITY: high resistance. 60%-80% MIP.~(gradual increment the load by 10% every 2 weeks to reach 80% MIP)~TIME: longer duration 20-30 mint."
214604513|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
214604514|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
214604515|NCT05524987|BEHAVIORAL|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months
214604516|NCT06102577|DIETARY_SUPPLEMENT|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
214604517|NCT06102577|OTHER|1gr Placebo|ake 1g. of placebo at the end of an osteopathic manual treatment
214604518|NCT06102577|OTHER|control group|control
214604519|NCT04693351|DRUG|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
214604520|NCT04693351|DRUG|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
214604521|NCT07130006|PROCEDURE|PENG and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect hyperechogenic iliopsoas notch and psoas tendon, between anterior inferior iliac spine and iliopubic eminence. Then needle needs to be inserted in-plane and 20mL of levobupivacaine 0.25% administered along the fascial plane. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Curvilinear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
214604522|NCT07130006|PROCEDURE|FN and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect both femoral artery and vein medial to it. Then needle needs to be inserted in-plane and 15mL of levobupivacaine 0.5% need to be administered underneath fascia iliaca, lateral to femoral nerve. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles, where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Linear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
214604523|NCT07130006|PROCEDURE|FIC peripheral nerve block with spinal anesthesia|Suprainguinal approach will be performed. At first, one needs to detect anterior inferior iliac spine, sartorius and internal oblique muscles creating a bow-tie. Deep circumflex iliac artery will be seen between transversus abdominis and iliacus muscle. Then needle needs to be inserted in-plane and 40mL of levobupivacaine 0.25% administered along the fascial plane so that fascia separates from iliacus muscle. The needle is inserted from caudal to cranial, to achieve the widest possible spread of local anesthetic under the fascia, to the cranial side, as this reaches both lateral femoral cutaneous nerve and femoral nerve. The spread of anesthetic will appear hypoechoic on ultrasound. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
214604524|NCT07130006|PROCEDURE|Fentanyl (IV) with spinal anesthesia|A total dose of 2 mcg/kg of fentanyl will be given to patients before positioning to spinal. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
214712549|NCT06325306|BEHAVIORAL|APA+PL|The general content and duration of this intervention is the same as in the traditional APA intervention, but with an extra particular and explicit emphasis on PL dimensions (6) during the sessions. While the dimension of physical competence is consistently incorporated into the sessions, the remaining 5 dimensions of PL are addressed twicely over the course of the semester with the setting of specific goals and intervention content. This could involve quizzes or games integrated into circuits or exercise workshops, role-play exercises simulating real-life situations, or social interactions between participants with a particular focus on PL-related topics. In addition to the sessions, a follow-up telephone call is scheduled between the educator and each participant during the 2 weeks following the initial PL assessment to share individual PL assessment results and assist participants in setting person-centered goals using a motivational interviewing technique.
214712550|NCT02967094|DRUG|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
214712551|NCT02967094|DRUG|Administration of water before upper endoscopy|
214604525|NCT07130435|BEHAVIORAL|Salutogenic Model-Based Healthy Aging Program|The Salutogenic Model-Based Healthy Aging Program is designed to enhance the sense of coherence and promote healthy aging among older adults aged 60-70. The program focuses on strengthening participants' internal resources, building resilience, and improving overall quality of life. It includes educational sessions, group discussions, and practical strategies for managing hypertension and diabetes, all while emphasizing physical, emotional, and mental well-being. The program aims to empower participants to make informed lifestyle choices and cope with the challenges of aging. Participants will receive regular follow-up assessments to track progress and ensure continued support throughout the study period.
214604526|NCT07129083|OTHER|Structured assessment interview|Participants completed a structured, in-person assessment conducted during one to three dialysis sessions. The assessment included validated instruments to measure overall quality of life (ACSA), health-related quality of life (EQ-5D-3L, EORTC QLQ-C30, QLQ-MY20), and various clinical, psychological, functional, and sociodemographic factors.
214604527|NCT07129824|OTHER|Observation|Observe the effect of eating habits and food preferences on symptoms of chronic gastritis
214604528|NCT07129109|DIETARY_SUPPLEMENT|small-quantity lipid-based nutrient supplements (SQ-LNS)|All caregivers will receive 2 months of SQ-LNS in this cross-over design. Half of the participants will be randomized to receive the 7-day packaging first, and half will receive the 1-day packaging first.
214604529|NCT07130916|DRUG|Aumolertinib|In Part A, participants will receive aumolertinib 110 mg (2 × 55 mg tablet) once daily, orally administrated under fasted condition (fasting from 2 hours before to 1 hour after dosing) in 21-day treatment cycles. In Part B, participants may continue study intervention (aumolertinib 110 mg once daily) until PD, death, intolerable toxicity, Investigator's decision, lost of follow-up, receiving another anti-cancer therapy, or any other pre-defined discontinuation criteria.
214604530|NCT07130383|DRUG|MHB036C for Injection|Intravenous administration
214604531|NCT07130383|DRUG|MHB039A for Injection|Intravenous administration
214604532|NCT07128511|BEHAVIORAL|Multiple Inhalation Breathing Pattern|"This behavioral intervention involves a breathing pattern characterized by brief, rapid successive inhalations within each breath cycle. The timing of each short inhalation is coordinated with fast, cyclical auditory tones, providing a consistent rhythm for participants to follow. Visual cues are also displayed to reinforce the timing and sequence of breaths.~During training, participants first practice the breathing pattern without any cognitive task, followed by practice while performing the psychomotor vigilance task (PVT). The technique is then applied during the main experimental condition, where participants wear a chest wall force antagonistic device set at 25 cmH₂O to simulate the added work of breathing experienced underwater. The PVT lasts for 10 minutes, requiring participants to respond as quickly as possible to visual stimuli, allowing researchers to measure sustained attention and reaction time."
214712552|NCT01824264|DRUG|LIK066|Experimental treatment doses
214712553|NCT01824264|DRUG|Sitagliptin|Active comparator treatment dose
214712554|NCT01824264|DRUG|Placebo|Placebo comparator dose
214712555|NCT00909519|DRUG|naproxcinod|naproxcinod 750 mg bid
214712556|NCT00909519|DRUG|Naproxen|Naproxen 500 mg bid
214712557|NCT00909519|DRUG|placebo|placebo
214604533|NCT07128511|BEHAVIORAL|Tactical Breathing Technique|"This behavioral intervention uses a slow, paced breathing cycle incorporating four distinct phases: inhale, hold, exhale, and hold. Each phase is precisely timed and synchronized with distinct auditory tones for inhalation, hold phase, and exhalation. Participants also receive visual cues to reinforce correct timing and ensure consistency throughout the exercise.~Training begins with participants practicing the breathing pattern without any cognitive task, followed by practice while completing the psychomotor vigilance task (PVT). The full experimental condition involves performing the 10-minute PVT while wearing a chest wall force antagonistic device set at 25 cmH₂O to simulate the restrictive breathing load experienced in underwater environments. The PVT requires quick responses to visual stimuli, allowing measurement of sustained attention and reaction time under load."
214604534|NCT04422756|DIAGNOSTIC_TEST|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."
214604535|NCT04422756|DIAGNOSTIC_TEST|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."
214604536|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
214604537|NCT06869785|BIOLOGICAL|Ofatumumab approved dose|Approved dosage
214604538|NCT06869785|BIOLOGICAL|Ofatumumab new dose|New dosage
214604539|NCT06283394|BEHAVIORAL|Storefront Choice Architecture|An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
214604540|NCT06283394|BEHAVIORAL|Fresh Funds|The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
214604541|NCT06283394|BEHAVIORAL|Loss Framing|They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
214604542|NCT07020507|OTHER|Product gel RV3895A|The product is applied twice a day to the scar(s) under study, avoiding all contact with natural orifices (and avoiding ingestion by children in the case of application to the hands in particular). The product is applied using a specific massage technique developed for the product and which is explained by the investigator at visit 1. The product is applied in sufficient quantity to cover the application area.
214604543|NCT07013383|BEHAVIORAL|"I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy Program"|The training program includes topics such as environmental pollution, recycling behaviors, and the protection of natural resources and ecosystems. In addition, the program incorporates activities such as games, puzzle, brainstorming sessions, and the creation of painted cloth bags.
214604544|NCT05488782|BEHAVIORAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
214604545|NCT05488782|OTHER|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
214604546|NCT01608867|BIOLOGICAL|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
214604547|NCT06902012|DRUG|Infusion of Axicabtagene Ciloleucel|"Drug: Axicabtagene Ciloleucel (CD19 CAR-T cells), 2×106 cells/kg, IV infusion at Day 0 and 30-90 days post-first infusion.~Drug: Cyclophosphamide (500 mg/m²) + Fludarabine (30 mg/m²), IV on Days -5, -4, -3.~Procedure: ctDNA monitoring via liquid biopsy at pre-lymphodepletion and Months 1, 2, 3, 6, 9, 12 post-infusion."
214604548|NCT01744353|DRUG|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
214604549|NCT01744353|DRUG|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
214604550|NCT01744353|DRUG|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
214604551|NCT06875778|OTHER|Pelvic Floor Exercises|Low intensity Warm Up Pelvic Floor Exercises and Cool down training
214604552|NCT07024940|OTHER|Ethiopian Coffee|Ethiopian Coffee is used as a real-world example of one of the most common drinks in the world.
214604553|NCT07024940|DIETARY_SUPPLEMENT|Supplement|A pre-workout supplement that contains anthocyanins and caffeine as ergogenic aids
214604554|NCT07024940|OTHER|Water (Placebo)|Bottled water acting as the placebo
214712558|NCT00909519|DRUG|furosemide|furosemide
214712559|NCT02136511|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
214604555|NCT06696430|BEHAVIORAL|Educational Intervention on TENS Usage|"Educational sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management."
214604556|NCT06696430|BEHAVIORAL|Nudging Intervention to Promote TENS Usage|Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
214604557|NCT07023822|DEVICE|Hyaluronic acid (HLA) Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
214604558|NCT07023822|DEVICE|Polycarbophil Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
214604559|NCT07023822|BEHAVIORAL|Hypnotic Relaxation|Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.
214604560|NCT07023822|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Listen to PMR audio file at least 3x/week for weeks 3-8.
214604561|NCT07029438|DRUG|Mouthwash|Antiplaque/Antigingivitis Mouthwash
214604562|NCT07029438|DEVICE|Floss|Dental Floss
214604563|NCT07029438|DEVICE|Toothbrush|Soft bristled, manual toothbrush
214604564|NCT07029438|DRUG|Toothpaste|Sodium Monofluorophosphate 0.76 % (0.15% w/v fluoride ion) toothpaste
214604565|NCT07024641|DRUG|GIGA-2339|Administered by intravenous infusion
214604566|NCT07024641|DRUG|Placebo|Administered by intravenous infusion
214604567|NCT06376643|DEVICE|Augmented reality supportive tool|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario.~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
214604568|NCT06376643|OTHER|Conventional method (AHA pocket reference card)|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
214604569|NCT07030699|DRUG|Epcoritamab|Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12
214604570|NCT07030699|DRUG|Lenalidomide|Oral, daily on days 1-21 of a 28-day cycle
214604571|NCT07030699|DRUG|Tafasitamab|Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12
214712560|NCT02136511|DRUG|Rituximab|Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
214712561|NCT00929045|DRUG|Growth Hormone Replacement|
214712562|NCT01135017|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
214712563|NCT01135017|DRUG|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
214712564|NCT03351439|DRUG|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
214712565|NCT03351439|DRUG|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
214712566|NCT03351439|DRUG|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
214604572|NCT06703879|DRUG|Anesthesia induction with propofol|Establishment of a database of clinical characteristics of propofol-induced loss of consciousness in patients with complete clinical information Acquisition of basic perioperative monitoring data and extended monitoring data: 1,000 patients aged ≥18 years who needed to undergo surgical treatment were included (according to the machine learning diagnosis results, if the poor model fit was due to the small sample size, the necessary number of samples could be continued to be collected), and perioperative monitoring and management of the patients was performed, and a video recorder was used to videotape the whole anesthesia induction process in real time, so as to facilitate the postoperative integration of various data. The basic characteristics of the patients and the perioperative monitoring characteristics were extracted from the surgical anesthesia recording system, including gender, age, height, weight, blood pressure, ASA classification, electroencephalographic parameters, the a
214604573|NCT07130084|OTHER|Virtual Reality Educational Film|The Virtual Reality Educational Film will be viewed during the antenatal appointment, post randomisation. The women will have access to the film at home should they want to watch it more than once.
214604574|NCT07130279|BEHAVIORAL|Postural Exercises + Post-Isometric Relaxation (PIR) Technique|Participants will perform a standardized postural exercise program (strengthening, stretching, and mobility exercises for the cervical and thoracic regions) three times per week for six weeks. In addition, the Post-Isometric Relaxation (PIR) technique will be applied to jaw muscles during each session to reduce muscle tension and improve mandibular mobility.
214604575|NCT07130279|BEHAVIORAL|Postural Exercises|Participants will perform a standardized postural exercise program designed to improve cervical and thoracic mobility and postural alignment. The program will include strengthening, stretching, and mobility exercises targeting the cervical spine, thoracic spine, and related musculature. Each session will last approximately 30-40 minutes and will be conducted three times per week for six weeks under the supervision of a trained therapist.
214712567|NCT03351439|DRUG|Percocet|Standard of Care
214712568|NCT03351439|DRUG|Naprosyn|Standard of Care
214712569|NCT03178812|PROCEDURE|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
214712570|NCT03178812|DIAGNOSTIC_TEST|Laboratory Blood test|Laboratory Blood Test
214712571|NCT03076125|BEHAVIORAL|SCORRE|3 components based on the Health Belief Model
214712572|NCT03076125|BEHAVIORAL|Attention-Control Activity|sexual health education
214712573|NCT03688685|DRUG|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
214712574|NCT03048942|DRUG|Cabazitaxel|3 weekly cyctotoxic chemotherapy
214604576|NCT07130747|OTHER|Myofascial release|The study involves women in both groups receiving myofascial release technique for twenty minutes three times per week for eight weeks. The technique requires the patient's skin to be dry and not oily, and all techniques must be applied at the barrier of tissue resistance. The technique involves gentle, sustained pressure held at the barrier for at least five minutes to allow the patient to respond to the treatment and relax. The technique involves skin stretching and desensitization around the scar, using up and down, side-to-side, and circular maneuvers.
214604577|NCT07130747|OTHER|Deep friction massage|Women in both groups (C) will receive a deep friction massage three times a week for eight weeks, applying a fingertip pad perpendicularly to post-cesarean scar tissue, moving across the band and back-and-forth motion along the scar tissue's length.
214604578|NCT07130747|OTHER|Routine daily scar care advices|Each woman in all groups (A, B, and C) will receive full instructions for daily post-cesarean-section scar care. Weekly revision for post-cesarean-section scar care will conduct by the researcher
214604579|NCT07130890|DEVICE|Health for All Mobile health application|This interventional study is implemented by using Health for All Mobile health application among pregnant women in the intervention group and in the control group pregnant women were those who took the routine ANC contact . The effect of the intervention is mainly depend on the women themselves.
214604580|NCT07031973|DIETARY_SUPPLEMENT|Active Effervescent Powder|Participants receive a daily sachet of effervescent powder that is Orange flavored, containing multiple vitamins and minerals
214604581|NCT07031973|DIETARY_SUPPLEMENT|Placebo Effervescent powder|Participants receive a daily sachet of effervescent powder that is Orange flavored containing no active ingredients
214604582|NCT07031973|OTHER|Nutrition training and healthy lifestyle coaching|Participants receive Nutrition training and healthy lifestyle coaching
214604583|NCT07035730|DEVICE|Unilateral hip exoskeleton|Unilateral hip exoskeleton assisted gait training. Gait training will consist of overground walking with the exoskeleton SHAJA for 30-40 minutes.
214712575|NCT03048942|DRUG|Paclitaxel|Weekly cyctotoxic chemotherapy
214712576|NCT00229229|OTHER|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
214712577|NCT00229229|OTHER|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
214712578|NCT00229229|OTHER|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
214604584|NCT07035730|BEHAVIORAL|Conventional gait training|Conventional gait training will consist of overground walking without the exoskeleton SHAJA for 30-40 minutes.
214604585|NCT06602076|BEHAVIORAL|ECHO (Empowering Our Community & Health Outcomes)|Additive intervention design wherein study participants receive remotely-delivered standard smoking cessation support (i.e., behavioral support plus nicotine replacement therapy) and engage in community-serving volunteer activities.
214604586|NCT07042152|OTHER|Smartwatch App for Movement Variability|This app measures movement variability in the upper extremity as described in our previous study (doi:10.3390/s24165266).
214604587|NCT07042152|OTHER|Smartwatch App for Active Time|The other software we are using measures total active time of the upper extremity.
214604588|NCT07042152|BEHAVIORAL|Motivational Interviewing (Within Subjects)|Motivational Interviewing is an established therapeutic technique designed to increase patient adherence to therapy by addressing ambivalence. The motivational Interviewing sessions will include a variety of techniques such as: Open ended questions, Active Listening, Affirmation, Summarization, Questions focused on change talk, and Providing Information.
214604589|NCT05571735|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
214604590|NCT05571735|BIOLOGICAL|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
214604591|NCT05571735|BIOLOGICAL|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
214604592|NCT06727682|BEHAVIORAL|Stress management|Ten-hour, three-course stress management programme with a psychologist via video conferencing over a 2 month period. The classes will be delivered in small groups of maximum seven care workers. Carers can be brought together in the same room, but the speaker will necessarily be at a distance, via videoconferencing. The formation will adress the following issues: i) Understanding the mechanisms of stress, ii) Identifying sources of stress and triggers, iii) Anticipate stressful situations and use their resources to prevent them, and iv) Use the most appropriate stress-reduction techniques, depending on their sensitivity.
214604593|NCT06738277|DRUG|Bmab 1200 (Biosimilar Ustekinumab)|Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
214712579|NCT00229229|OTHER|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
214712580|NCT02794090|BEHAVIORAL|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
214712581|NCT02794090|BEHAVIORAL|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
214712582|NCT01530555|DRUG|Rabbit ATG, Thymoglobuline (Genzyme)|"1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
214604594|NCT06894134|OTHER|Team-based learning|The intervention will include 4 two-hour modules assessing healthy diet, physical activity and screen time, regular sleep, and tobacco and alcohol use. Each module has specific learning objectives (attachment 1). The TBL is a structured active learning approach that fosters collaboration, critical thinking, and accountability. Each module will involve four key steps: (1) Preparation Phase, where students independently will review pre-class materials to build foundational knowledge; (2) Readiness Assurance Process (RAP), which assesses understanding through an individual quiz (iRAT), a team quiz (tRAT), and an instructor-led clarification session; (3) Application Activities
214604595|NCT05556954|PROCEDURE|Wound debridement|"Participant that are having usual care visits for management of diabetic foot ulcers will be enrolled into this study. The procedure is done as part of standard of care. Tissue from the samples will be analyzed for this study.~Aliquoting and Deoxyribonucleic acid (DNA) extraction will be done on the specimens. Bacterial DNA from biospecimens will be isolated, quantified, amplified, and sequenced."
214604596|NCT07074392|DEVICE|Electrical Stimulation|Custom stimulator will deliver a 1hour stimulation protocol post-operatively at 20 Hz, with biphasic pulses (100 µs duration, 0-2mA amplitude range).
214604597|NCT07129421|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
214604598|NCT07129642|BIOLOGICAL|Allogeneic CAR-T|The participants will receive one dose of allogeneic CAR-T
214604599|NCT07129902|BEHAVIORAL|Contingency Management|Participants in the active arm will receive payment (monetary incentive) contingent on outpatient MOUD treatment attendance.
214604600|NCT07129902|BEHAVIORAL|Usual care as prescribed by the ED physicians|All participants will receive standard outpatient care at their clinic.
214604601|NCT07128784|OTHER|Aerobic exercise|continuous, moderate intencity aerobic exercise, 3 days a week, 30 minutes per day, 150/min per week for a total of 6 weeks
214604602|NCT07129668|BEHAVIORAL|Condition A|Condition A consists of performing the Finger Kazoo exercise without inducing oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, but without modifying tongue position, soft palate height, or pharyngeal wall expansion to increase the oropharyngeal space.
214604603|NCT07129668|BEHAVIORAL|Condition B|Condition B consists of performing the Finger Kazoo exercise with intentional oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, while simultaneously modifying tongue position, elevating the soft palate, and expanding the pharyngeal walls to increase the oropharyngeal space.
214712583|NCT05767372|OTHER|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
214604604|NCT07130526|DEVICE|Intravascular Lithotripsy (IVL) plus DCB|"The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries.~The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer.~An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue,"
214604605|NCT07130526|DEVICE|POBA plus DCB|Standard of Care
214604606|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients will be positioned prone on the operation table. Intravenous access is opened. Monitorization for vital signs is performed. Light sedation with midazolam is performed. Under fluoroscopic guidance, medial branch nerve of each lumbar facet joint is found by searching the specific response to the stimulations of the radiofrequency needle. When the tip of the radiofrequency needle is close enough to the corresponding medial branch nerve, ablation with 80 degrees Celsius for 90 seconds is performed. Average 6-10 nerves are ablated in each procedure and the average duration of the procedure is 20-60 minutes.
214604607|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients are positioned prone on the operation table. Intravenous access is opened and monitorization of vital signs is applied. Skin is cleaned by povidone iodine solution. Light sedation is applied by midazolam. Lumbar vertebral region is seen under C-arm fluoroscopic view. Medial branch nerve of the lumbar facet joints is searched by 22 G width, 10-cm length radiofrequency needles. When the needle tip is close enough to the nerve, an 80 Celsius, 90-second radiofrequency ablation is applied. In each procedure, average 5-10 nerves is ablated and the duration of the procedure is 20-60 minutes.
214712584|NCT05767372|DEVICE|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks."
214712585|NCT00650598|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
214604608|NCT07078500|DRUG|orelabrutinib combined with the Pola-R-CHP regimen|Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
214604609|NCT05784688|DRUG|TU2218 + KEYTRUDA® (Pembrolizumab)|TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered
214604610|NCT06902948|OTHER|upper limb function training|Intervention selection included stretching and mobilization exercise, strengthening exercise, electrical stimulation, acupuncture, functional or task specific training and mirror therapy.
214712586|NCT00650598|DRUG|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
214712587|NCT03702426|DRUG|GMCSF|GMCSF 1.5mcg/Kg
214604611|NCT06901973|PROCEDURE|Intrafocal pinning|Intrafocal pinning involves the percutaneous insertion of Kirschner wires to stabilize the distal radius fracture, often followed by plaster immobilization.
214604612|NCT06901830|DRUG|YZJ-4729|Loading dose + demand dose
214604613|NCT06901830|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
214604614|NCT06901830|DRUG|Active Comparator: Morphine|Loading dose + demand dose
214712588|NCT03702426|DRUG|Norfloxacin|Tablet Norfloxacin 400 mg
214712589|NCT05285033|DRUG|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
214712590|NCT04679558|DRUG|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
214712591|NCT04679558|BEHAVIORAL|Preventive protocol|Preventive protocol
214712592|NCT03165864|DRUG|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
214712593|NCT03165864|OTHER|Placebo|Saline .9%
214712594|NCT00453232|BIOLOGICAL|bleomycin sulfate|
214712595|NCT00453232|BIOLOGICAL|pegfilgrastim|
214712596|NCT00453232|DRUG|cisplatin|
214712597|NCT00453232|DRUG|etoposide|
214712598|NCT03584438|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
214604615|NCT06901622|DRUG|Camrelizumab, anlotinib, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, iv, q3w. Anlotinib: 10 mg, taken orally once a day, day 1\~14, q3w. For patients with intolerance, the dose can be reduced to 8 mg.~Nab-paclitaxel: 200 mg/m\^2, day 1, iv, q3w. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the feasibility of surgery was evaluated. Operable patients: radical surgical resection, followed by 4 cycles of S-1 combined with carrelizumab (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + anlotinib + S-1 were treated until intolerance or disease progression."
214604616|NCT06901622|DRUG|Camrelizumab, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, intravenous drip, 3 weeks as a treatment cycle. Nab-paclitaxel: 200 mg/m\^2, day 1, intravenous drip, 3 weeks as a treatment cycle. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the patient's surgical feasibility was evaluated.~Operable patients: radical surgical resection, followed by S-1 (4 cycles) combined with carrelizumab treatment (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + S-1 treatment until intolerance or disease progression."
214604617|NCT06901843|COMBINATION_PRODUCT|Mobilizations Exercises|Group A was treated with mobilizations exercises for 40 minutes for 3 sessions per week for 6 weeks. Patients received hip mobilizations. Therapist perform anterior posterior glide, caudal glide, posterior anterior glide with abduction, flexion and lateral rotation in 3 sets with 10 repetitions .Mobilization grades were performed according to patients tolerance level with duration 30-second rest .Hip strengthening exercises were performed 3 sets with 10 repetition with hip abduction in side lying, hip extension in prone position, sideway walk, hip abduction in a stand up position.
214604618|NCT06901843|COMBINATION_PRODUCT|Closed Kinetic Chain Exercises|Group B was treated with Closed Kinetic Chain Exercises for 40 minutes for 3 sessions per week for 6 weeks. Closed kinetic chain exercises were performed with 5 minute break between each exercise. Leg press in horizontal position ,Stationary bicycling and Stairmaster climbing.
214604619|NCT06903507|DEVICE|RT-Comfort Mattress|This dedicated RT-Comfort Mattress was newly developed (patent pending) for increasing comfort without compromising radiotherapy treatment quality.
214604620|NCT06902090|DRUG|Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)|IV, 30 mg
214604621|NCT06902090|DRUG|Meloxicam Nanocrystal Injection (ANJESO®)|IV, 30 mg
214604622|NCT06902415|DEVICE|QDSA (Quantitative Digital Subtraction Angiography)|QDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.
214604623|NCT03904134|OTHER|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
214604624|NCT07092436|DEVICE|Robotic bilateral upper limb rehabilitation training|Bilateral upper limb rehabilitation using PhiCube, a modular robotic end-effector device with two motorized axes that can assist or resist patient movements. Treatment consists of 30 sessions over 3 months (3 sessions/week, 45 minutes each) combining motor training with gaming elements specifically designed for pediatric populations. The device's modular design allows customization for individual patient needs and bilateral coordination training. Sessions focus on improving range of motion, precision, dexterity, and movement fluidity through controlled, repetitive, high-intensity exercises in children aged 4-18 years with neuromotor disorders and developmental coordination disorder.
214604625|NCT05756127|OTHER|Observational - no intervention given|Observational - no intervention given
214604626|NCT07090642|OTHER|Digital escape room game|"Concurrent with the module training, the intervention group will be given the four-part escape room game M.E.R.C.I. The game's sections will be developed in parallel with the weekly topics of the disaster midwifery module training."
214604627|NCT06902688|OTHER|ML-based intervention|A ML-based model will predict and identify participants that are at high-risk of receiving a targeted medication within three months after their hospital admission date.
214604628|NCT07093463|DIETARY_SUPPLEMENT|Colon-delivered riboflavin|10 mg of colon-delivered riboflavin
214604629|NCT07093463|DIETARY_SUPPLEMENT|Conventional riboflavin|10 mg of conventional riboflavin
214604630|NCT07093463|OTHER|Microcrystalline Cellulose|10 mg microcrystalline cellulose
214604631|NCT06730646|BEHAVIORAL|Health effects|Participants in this arm will watch 3 short videos about the smoking-related diseases during the survey data collection.
214604632|NCT06730646|BEHAVIORAL|Tobacco industry manipulation|Participants in this arm will watch 3 short videos about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults during the survey data collection.
214604633|NCT06730646|BEHAVIORAL|Secondhand smoke|Participants in this arm will watch 3 short videos about the risks of secondhand smoke exposure during the survey data collection.
214712599|NCT03584438|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214712600|NCT01170221|DRUG|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
214604634|NCT06730646|BEHAVIORAL|Mentral health|Participants in this arm will watch 3 short videos about the effects of smoking on mental health during the survey data collection.
214604635|NCT06730646|BEHAVIORAL|Social acceptability|Participants in this arm will watch 3 short videos about how smoking is socially unacceptable in China during the survey data collection.
214712601|NCT01170221|DRUG|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
214712602|NCT00432562|DRUG|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
214712603|NCT02693691|DEVICE|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
214712604|NCT00440336|DRUG|Cosopt|
214712605|NCT00440336|DRUG|Xalatan|
214604636|NCT06730646|BEHAVIORAL|Control|Participants in this arm will watch 3 short videos about drinking bottled water during the survey data collection. These messages display specific water products and describe hydration as a healthy activity.
214604637|NCT04419766|OTHER|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
214712606|NCT05800509|BEHAVIORAL|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
214712607|NCT05800509|DEVICE|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
214604638|NCT06901752|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care,inpatient rehabilitation,outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management, soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive skin
214604639|NCT06901752|BEHAVIORAL|Exercise|Cat Camel Exercise, Bridge Exercise, Lateral Flexion, Cross Walking, Ipsilateral and Contralateral Stretching Exercises
214604640|NCT07109024|DIAGNOSTIC_TEST|Generation of a comprehensive and single-lesion resistance profile|AI-supported image analysis of functional imaging (PET-CT) and previous imaging data and specialized molecular methods (next-generation sequencing) will be combined into a comprehensive resistance profile.
214604641|NCT01264653|DRUG|adrenalin|adrenalin 0.01%
214604642|NCT05608382|OTHER|sterile Phosphate Buffer Saline|control group
214604643|NCT05608382|OTHER|SGW13|active comparator
214604644|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
214604645|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
214604646|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
214604647|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
214604648|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
214604649|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
214604650|NCT05051345|OTHER|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
214604651|NCT05051345|OTHER|Informational Intervention|Receive tobacco cessation self-help materials
214604652|NCT05051345|OTHER|Informational Intervention|Receive Smoke-Free Homes mailings
214604653|NCT05051345|OTHER|Media Intervention|Download and use the Wellness app
214604654|NCT05051345|OTHER|Questionnaire Administration|Ancillary studies
214604655|NCT05051345|BEHAVIORAL|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
214604656|NCT05051345|OTHER|Survey Administration|Ancillary studies
214604657|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive telephone counseling sessions
214604658|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
214604659|NCT05051345|OTHER|Tobacco Cessation Counseling|Receive telephone counseling sessions
214604660|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
214604661|NCT02430350|DRUG|Compound Edaravone Injection|
214604662|NCT02430350|DRUG|Edaravone Injection|
214604663|NCT05427162|DRUG|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
214604664|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
214604665|NCT06525675|DRUG|Fulvestrant Injectable Product|500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.
214604666|NCT06525675|DRUG|Letrozole 2.5mg|2.5 mg letrozole per day, administered orally (continuous treatment)
214604667|NCT06525675|DRUG|Palbociclib 125mg|orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
214604668|NCT05866770|DEVICE|U8|The U8 Research System
214604669|NCT05866770|DEVICE|N8 sound processor|Nucleus 8 sound processor
214712608|NCT02591043|PROCEDURE|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
214712609|NCT05603494|DEVICE|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
214604670|NCT06956742|DEVICE|Active intermittent intrapulmonary deflation.|"Intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. The device power setting (25%, 50%, 75%, or 100%) will be individualized according to the parameters determined during the familiarization visit by a trained physiotherapist. Patients will be instructed to perform tidal volume inspirations followed by passive expirations into the device through a mouthpiece, up to their maximal tolerance. The device will be activated by the patient during expiration using a manual remote control.~Each device usage cycle consists of 10 expirations, with oscillations generated at 12 Hz during the first 8 cycles and at 6 Hz during the last 2 cycles. Rest periods will be allowed during the session, and a mandatory pause will be imposed every 10 expirations. The session duration is fixed at 20 minutes, with patients performing one session in the"
214712610|NCT01020968|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
214712611|NCT01020968|OTHER|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
214712612|NCT04327050|PROCEDURE|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
214712613|NCT00790530|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
214712614|NCT00790530|OTHER|Usual Care|Usual Care
214712615|NCT01250457|DRUG|topical Timolol|topical Timolol 0.5% solution applied twice daily
214712616|NCT05845489|DRUG|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
214712617|NCT05845489|OTHER|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
214712618|NCT02820441|DRUG|Zopiclone|
214712619|NCT02820441|DRUG|Placebo|
214712620|NCT02951897|PROCEDURE|lobectomy|
214712621|NCT02951897|PROCEDURE|segmentecomy|
214712622|NCT02951897|DRUG|chemotherapy（pemetrexed+CISPLATIN）|
214712623|NCT02951897|PROCEDURE|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
214712624|NCT02951897|OTHER|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
214712625|NCT03288441|DRUG|Hold|Hold antithrombotic therapy
214604671|NCT06956742|DEVICE|Placebo intermittent intrapulmonary deflation.|"Placebo intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. Due to the physiological mechanism of action of the device (intermittent negative pressure with increasing intensity, inversely proportional to airflow resistance), it is assumed that device use under placebo conditions will be infra-therapeutic.~To ensure this, the device will be set to the same setting as the active intermittent intrapulmonary deflation session but an intentional air leak will be introduced into the circuit at the device's output (not visible to the participant) to prevent the generated negative pressure from exceeding t The validity of this placebo condition will be confirmed through bench tests.~All other conditions will remain identical to the active intermittent intrapulmonary deflation sessions. Patients will be instructed to perform tidal vo"
214604672|NCT04532372|OTHER|Best Practice|Receive standard of care drugs
214604673|NCT04532372|DRUG|Leflunomide|Given PO
214604674|NCT04532372|DRUG|Placebo Administration|Given PO
214604675|NCT06165302|BEHAVIORAL|Exercise Intervention|12 weeks of prescribed exercise intervention.
214604676|NCT03435003|DRUG|Aprepitant 80 mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
214604677|NCT03435003|DRUG|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
214604678|NCT03435003|PROCEDURE|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
214604679|NCT03435003|DRUG|Dexamethasone|Dexamethasone 8 mg intraoperatively
214604680|NCT03435003|DRUG|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
214604681|NCT03435003|DRUG|Reglan|Postoperatively scheduled Reglan
214604682|NCT03435003|DRUG|Ondansetron|Postoperatively scheduled ondansetron
214604683|NCT03435003|DRUG|Compazine|Postoperatively as needed compazine for breakthrough PONV
214604684|NCT03435003|DRUG|Sugammadex|Reversal with sugammadex
214604685|NCT03435003|DRUG|Propofol|Intravenous anesthesia will be maintained through IV propofol
214604686|NCT03435003|DRUG|dexmedetomidine|maintenance of anesthesia in the intervention arm
214604687|NCT03435003|DRUG|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
214712626|NCT03288441|DRUG|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
214712627|NCT03288441|DRUG|Change antithrombotic Drug|Change in type of antithrombotic therapy
214712628|NCT03288441|BIOLOGICAL|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
214712629|NCT03288441|DRUG|Full dose antithrombotics|Continue full dose antithrombotic therapy
214712630|NCT03288441|DEVICE|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
214712631|NCT03288441|DRUG|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
214712632|NCT02312115|DRUG|Furosemide|Diuretic
214712633|NCT02312115|DRUG|Placebo|Saline
214712634|NCT04202549|DRUG|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
214712635|NCT04580823|DIETARY_SUPPLEMENT|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
214712636|NCT04580823|DIETARY_SUPPLEMENT|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
214712637|NCT03335618|OTHER|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
214712638|NCT03335618|OTHER|Passive Activity Monitoring|Passive step tracking without check-ins
214604688|NCT03435003|DRUG|Sevoflurane|inhalational anesthesia
214604689|NCT03435003|DRUG|Desflurane|inhalational anesthesia
214604690|NCT04285398|OTHER|Ophthalmic examinations|Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
214604691|NCT04285398|OTHER|Mobility Test|Functional test to evaluate mobility and postural condition of patients
214604692|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
214604693|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
214604694|NCT04184440|DIETARY_SUPPLEMENT|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
214604695|NCT06955702|DEVICE|cryotherapy for chemotherapy-induced madarosis|Application of temperature-controlled cold devices (-4°C to -7°C) to the supraorbital area (up to 3 cm above the eyelid margin), administered 15 minutes before chemotherapy infusion and maintained for 20 minutes post-infusion.
214604696|NCT01153802|DRUG|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
214604697|NCT00222053|DRUG|Thalidomide|Per os thalidomide
214604698|NCT00222053|DRUG|Biphosphonates|Biphosphonates
214604699|NCT04918238|OTHER|Conventional program|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
214604700|NCT04918238|OTHER|Muscle energy technique|The patient was in the lateral recumbent position on the side opposite to his, her side-bending dysfunction while the physiotherapist stood facing the subject. The physiotherapist monitored the lumbar area with one hand while with the other hand flexed the subject's knees and hips until the barrier was engaged at the vertebral segment being treated.
214604701|NCT05470946|DEVICE|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
214604702|NCT02665065|DRUG|Iomab-B|
214604703|NCT02665065|DRUG|Conventional Care|
214604704|NCT02665065|PROCEDURE|HCT|
214604705|NCT04907110|DIETARY_SUPPLEMENT|Niagen|Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day
214604706|NCT04907110|OTHER|Exercise|During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
214604707|NCT01557023|DRUG|barrier methods|
214604708|NCT01557023|DRUG|barrier methods|
214604709|NCT06476314|DEVICE|Virtual Reality Glasses Group|Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
214604710|NCT06476314|DEVICE|Stress Ball Group|Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
214604711|NCT00646061|DRUG|buscopan|
214604712|NCT00186862|DRUG|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
214604713|NCT06267287|DIAGNOSTIC_TEST|Microbiological examination of the patient's biological material and determination of antibiotic resistance|Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
214604714|NCT02410655|DRUG|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
214604715|NCT02410655|DRUG|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
214604716|NCT01436071|DRUG|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
214604717|NCT01436071|DRUG|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
214604718|NCT04026139|OTHER|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
214604719|NCT04026139|OTHER|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
214604720|NCT03839407|DEVICE|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
214712639|NCT02042339|DRUG|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
214712640|NCT04350736|DRUG|TD-0903|Study drug to be administered by inhalation
214604721|NCT02774902|DRUG|TAK-438|TAK-438 tablets
214604722|NCT02774902|DRUG|Clarithromycin|Clarithromycin tablets
214604723|NCT00238628|DRUG|Bexarotene|
214712641|NCT04350736|DRUG|Placebo|Placebo to be administered by inhalation
214712642|NCT00141700|DRUG|Rituximab|
214712643|NCT00461578|DRUG|Chlorproguanil-dapsone + artesunate|
214712644|NCT03553602|RADIATION|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])"
214604724|NCT00238628|DRUG|Iressa|
214712645|NCT00238225|DIETARY_SUPPLEMENT|calcitriol|
214712646|NCT00238225|DRUG|dexamethasone|
214712647|NCT00238225|DRUG|ketoconazole|
214712648|NCT01458314|OTHER|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
214712649|NCT01458314|OTHER|Rehabilitation without NIV|Training in patients without NIV adoption
214712650|NCT04419818|BEHAVIORAL|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
214712651|NCT01142284|DRUG|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
214712652|NCT00981318|DRUG|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
214712653|NCT02303171|DRUG|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
214712654|NCT02303171|DRUG|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
214712655|NCT00013455|DEVICE|Hearing|
214604725|NCT00789867|DRUG|pGM169/GL67A|Received a nebulized dose via an breath-actuated nebulizer
214604726|NCT03047551|PROCEDURE|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
214604727|NCT03047551|PROCEDURE|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
214604728|NCT05214417|DRUG|Ketamine Injectable Solution|2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
214604729|NCT05214417|OTHER|Naturalistic Control|Continuation of pre-existing conventional treatment
214604730|NCT00257829|DRUG|Methazolamide|
214604731|NCT00257829|DRUG|Cisplatin|
214604732|NCT00726622|PROCEDURE|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
214604733|NCT00726622|PROCEDURE|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
214604734|NCT05983549|PROCEDURE|fluid balance|patients will receive fluids with the aim to achieve a neutral balance
214604735|NCT01388231|BEHAVIORAL|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
214604736|NCT01388231|BEHAVIORAL|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
214712656|NCT04169061|DRUG|Acthar|Acthar gel for subcutaneous injection
214712657|NCT02602171|OTHER|Oldenburger sentence test, localization test|
214712658|NCT02275598|DRUG|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
214712659|NCT02275598|DRUG|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
214712660|NCT01714297|DRUG|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
214712661|NCT04196205|BIOLOGICAL|Anti-CD19 CAR-T|1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
214604737|NCT01462136|DRUG|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
214604738|NCT04311892|DIAGNOSTIC_TEST|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
214604739|NCT02462928|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
214712662|NCT01661920|OTHER|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
214604740|NCT02462928|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
214604741|NCT02462928|OTHER|Sham Procedure|Sham injection.
214604742|NCT02901496|BEHAVIORAL|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
214712663|NCT01661920|OTHER|Control group|Those antibiotic duration treatments which are not modified by their doctors.
214712664|NCT01948141|DRUG|nintedanib|Given PO
214712665|NCT04529421|BEHAVIORAL|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
214712666|NCT04529421|BEHAVIORAL|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
214712667|NCT02022956|DRUG|Lorcaserin|
214712668|NCT04297826|BEHAVIORAL|Harvest for Health|Please see previous description
214604743|NCT02901496|BEHAVIORAL|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
214604744|NCT02901496|BEHAVIORAL|No Exercise|Control to exercise
214604745|NCT02901496|DRUG|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
214604746|NCT02901496|DRUG|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
214604747|NCT02954146|BEHAVIORAL|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
214604748|NCT01493557|DRUG|pantoprazole|40 mg q.a.m, p.o.
214604749|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
214604750|NCT01493557|DRUG|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
214604751|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
214604752|NCT00314678|DRUG|Topotecan|
214604753|NCT00314678|DRUG|Cisplatin|
214604754|NCT00314678|DRUG|Paclitaxel|
214712669|NCT03219892|DEVICE|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
214604755|NCT02941887|BEHAVIORAL|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
214604756|NCT03998176|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
214604757|NCT02656420|DRUG|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
214604758|NCT02656420|DRUG|Placebos|Placebo as comparison to broccoli sprout-derived beverages
214604759|NCT00335465|DRUG|Insulin glargine|once a daily, sc injection, 100IU/ml
214604760|NCT01640210|DEVICE|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
214604761|NCT01088464|BIOLOGICAL|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
214604762|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, every 2 weeks
214604763|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
214604764|NCT01611948|DRUG|Aprepitant|125mg/day for 8 weeks
214604765|NCT01611948|DRUG|Placebo|125mg/d placebo pill for 8 weeks
214712670|NCT03219892|DEVICE|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
214712671|NCT05425719|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
214712672|NCT05425719|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
214604766|NCT01611948|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
214604767|NCT01508104|DRUG|BEZ235|dose escalation 400mg- 1000mg per day
214712673|NCT04682353|DRUG|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
214712674|NCT04682353|DRUG|Depo-subQ Provera|SC injection of 104 mg/0.65 mL
214604768|NCT01508104|DRUG|Everolimus|dose escalation 2.5 to 5 mg per day
214604769|NCT03629236|OTHER|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
214604770|NCT03629236|OTHER|Control|Debridement, dressing application, standard compression therapy
214604771|NCT03707132|PROCEDURE|Tourniquet: Folley catheter in the low segment of the uterus|
214712675|NCT00980421|DIETARY_SUPPLEMENT|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
214712676|NCT00102557|DRUG|Hydroxychloroquine|
214712677|NCT04702048|DRUG|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
214604772|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
214604773|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
214604774|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
214604775|NCT05713773|DRUG|coated beads glucose (8 g)|After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
214604776|NCT05713773|DRUG|uncoated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
214604777|NCT00512746|OTHER|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
214604778|NCT00512746|OTHER|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
214604779|NCT00512746|PROCEDURE|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
214712678|NCT04702048|DRUG|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
214712679|NCT04070118|PROCEDURE|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
214604780|NCT00512746|PROCEDURE|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
214604781|NCT03018587|DEVICE|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
214604782|NCT01283230|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
214604783|NCT02791282|OTHER|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
214604784|NCT05199675|BEHAVIORAL|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
214604785|NCT00175955|DRUG|Levetiracetam|
214604786|NCT03662139|OTHER|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
214604787|NCT04389190|OTHER|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
214604788|NCT06235814|PROCEDURE|Molecular Analysis for Thyroid Resection|"Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care."
214604789|NCT00749879|DRUG|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
214712680|NCT03489681|DEVICE|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
214712681|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
214712682|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
214712683|NCT04736329|DRUG|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
214604790|NCT01909648|OTHER|Blood withdrawal|
214604791|NCT01909648|GENETIC|Blood withdrawal|
214604792|NCT02967081|PROCEDURE|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
214604793|NCT01249430|DRUG|Azacitidine|Given IV
214604794|NCT01249430|DRUG|Cytarabine|Given IV
214604795|NCT01249430|DRUG|Etoposide Phosphate|Given IV
214604796|NCT01249430|OTHER|Laboratory Biomarker Analysis|Correlative studies
214604797|NCT01249430|DRUG|Mitoxantrone Hydrochloride|Given IV
214604798|NCT01249430|OTHER|Pharmacological Study|Correlative studies
214712684|NCT04152642|DEVICE|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
214712685|NCT04152642|OTHER|Water control|negative control
214712686|NCT04152642|DEVICE|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
214712687|NCT03579992|BEHAVIORAL|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
214712688|NCT03579992|BEHAVIORAL|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
214712689|NCT03579992|BEHAVIORAL|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
214712690|NCT03129412|RADIATION|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
214604799|NCT06359366|PROCEDURE|perineal massage combined hip joint training|pregnant women take the lithotomy position, disinfect the vulva, and wear sterile gloves. Then thumbs, forefingers, and middle fingers dip massage oil to do a 2 minutes pressurized dilatation massage from inside to outside gently to loosen the fascia. Then rest 30s. All steps need to be repeated 2 to 3 times. When the pregnant women feel a slight sense of acidity and tingling sensation disappears, researchers sterilize the perineal body again. left side pelvic floor receives the same intervention as right. The whole process takes 15-20min, 5 times a week until delivery. Additionally, while using the pelvic floor fascia manipulation, pregnant women are instructed to perform specific movements of internal and external hip rotation, adduction and abduction, upward and downward.
214604800|NCT01235559|DRUG|Placebo|Oral doses, once a day for 52 weeks
214604801|NCT01235559|DRUG|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
214604802|NCT01235559|DRUG|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
214604803|NCT02435108|DRUG|crizotinib|crizotinib 250mg bid daily
214604804|NCT00613353|OTHER|Behavioral|Participants will be asked to wear an accelerometer
214604805|NCT05670769|OTHER|Education|The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
214604806|NCT06460883|OTHER|eccentric cable leg curls|The players will undergo eccentric cable leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
214604807|NCT06460883|OTHER|eccentric banded leg curls|The players will undergo eccentric banded leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
214604808|NCT01453777|PROCEDURE|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
214604809|NCT01890148|DRUG|AZD5069|oral BD administration of 45 mg AZD5069
214604810|NCT01215175|BIOLOGICAL|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
214604811|NCT01215175|BIOLOGICAL|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
214604812|NCT01215175|BIOLOGICAL|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
214604813|NCT05732922|DEVICE|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
214604814|NCT06399874|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|A psychotherapy that uses exposure to nightmare images for trauma activation in order to facilitate trauma memory reconsolidation
214604815|NCT06399874|DEVICE|NightWare|Wristband device that detects physiologic signals during sleep that indicate a possible nightmare and gently vibrates to rouse the sleeper without fully waking them.
214604816|NCT01678209|OTHER|fMRI scans|2 fMRI scans 6-8 weeks apart
214604817|NCT01678209|DRUG|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
214604818|NCT01678209|DRUG|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
214604819|NCT05529823|BEHAVIORAL|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
214604820|NCT00256880|DRUG|GW786034|
214604821|NCT00350922|BEHAVIORAL|Psychoeducation|
214604822|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
214604823|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
214604824|NCT03527914|OTHER|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
214604825|NCT03527914|OTHER|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
214604826|NCT01882218|DRUG|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
214604827|NCT01882218|DRUG|Standard Treatment|Standard liver surgery.
214604828|NCT00656123|BIOLOGICAL|Colon GVAX|Dose escalation: 1.4x10\^8 to 7x10\^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
214604829|NCT00656123|DRUG|cyclophosphamide|200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
214604830|NCT00880035|DEVICE|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
214604831|NCT00702845|DRUG|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
214604832|NCT00702845|DRUG|recFSH (follitropin beta)|150 IU recFSH SC injection
214604833|NCT00702845|DRUG|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
214604834|NCT00702845|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
214604835|NCT00702845|BIOLOGICAL|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
214604836|NCT00702845|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
214604837|NCT00702845|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
214604838|NCT00702845|BIOLOGICAL|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
214604839|NCT00682565|DRUG|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
214604840|NCT00682565|DRUG|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
214604841|NCT00682565|DRUG|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
214604842|NCT00682565|DRUG|CK-1827452 25mg capsule|25mg oral immediate release capsule
214604843|NCT00682565|DRUG|Placebo iv infusion|Matching placebo iv infusion
214604844|NCT00682565|DRUG|Placebo capsule|Matching placebo oral immediate release capsule
214604845|NCT00442065|DEVICE|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
214604846|NCT06225635|DRUG|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
214604847|NCT06225635|DRUG|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
214604848|NCT05370066|DEVICE|CS6BP watches will be used in the study.|CS6BP watches will be used with FDA approved Blood pressure monitors
214604849|NCT02973425|BEHAVIORAL|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience \& Suite of mHealth motivational tools and mini-games.
214604850|NCT02973425|BEHAVIORAL|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
214604851|NCT04094896|DRUG|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
214604852|NCT02598609|BEHAVIORAL|Education program for NICU caregivers|"* standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries"
214604853|NCT01419353|DRUG|estradiol valerate|2 mg P.O / day for 1-6 days.
214604854|NCT00577850|DRUG|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
214604855|NCT00577850|DRUG|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
214604856|NCT03538353|OTHER|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
214604857|NCT02454335|PROCEDURE|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
214604858|NCT05276557|COMBINATION_PRODUCT|PyloPlus Urea Breath Test System|System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
214604859|NCT05276557|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patients' stool for H. pylori
214604860|NCT01571765|OTHER|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
214604861|NCT03876171|BEHAVIORAL|Haitian youth family-based intervention study: family functioning|A weekly group therapy with the youth in presence of a parent or caretaker in the family.
214604862|NCT03876171|BEHAVIORAL|Haitian youth intervention study: youth psychoeducational|Weekly one and one psychoeducational module will be delivered to the youth.
214604863|NCT03876171|BEHAVIORAL|Haitian family-based intervention study: psychoeducational|Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.
214604864|NCT03876171|BEHAVIORAL|Diversion Programs|Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
214712691|NCT00587769|DRUG|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
214604865|NCT02700204|DEVICE|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
214712692|NCT03467295|PROCEDURE|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
214712693|NCT03467295|PROCEDURE|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
214712694|NCT01064219|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
214604866|NCT02700204|DEVICE|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
214604867|NCT03503513|DRUG|Gentamicin Sulfate|Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
214604868|NCT05495139|DEVICE|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
214604869|NCT00454532|DRUG|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
214604870|NCT04495010|BIOLOGICAL|Nivolumab|Specified dose on specified days
214604871|NCT04495010|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214604872|NCT03329222|OTHER|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
214604873|NCT03329222|OTHER|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
214604874|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
214604875|NCT00298168|DRUG|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
214604876|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
214604877|NCT00929656|PROCEDURE|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
214604878|NCT00929656|PROCEDURE|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
214604879|NCT00929656|PROCEDURE|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
214604880|NCT02619968|OTHER|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
214604881|NCT04144751|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
214604882|NCT00607880|PROCEDURE|vascular access device placement|
214604883|NCT04321980|DRUG|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
214604884|NCT02112435|DEVICE|Somnyx ®|Active mandibular advancement splint
214604885|NCT02112435|DEVICE|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
214604886|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
214604887|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
214604888|NCT03207113|BEHAVIORAL|Ned|Prostate cancer survivorship application.
214604889|NCT01170039|DRUG|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
214604890|NCT01170039|DRUG|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
214604891|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
214604892|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
214604893|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
214604894|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
214604895|NCT03763851|RADIATION|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
214604896|NCT03763851|RADIATION|Radiotherapy|Palliative RadioTherapy to the symptomatic site
214604897|NCT03053258|DEVICE|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
214604898|NCT00908583|DRUG|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
214604899|NCT00908583|DRUG|Bortezomib|Patients will receive bortezomib as described in protocol
214604900|NCT00908583|DRUG|Rituximab|Patients will receive rituximab as described in protocol
214604901|NCT00908583|DRUG|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
214712695|NCT02683018|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
214604902|NCT04328779|OTHER|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
214604903|NCT04328779|DEVICE|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
214604904|NCT04328779|OTHER|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
214604905|NCT00993954|PROCEDURE|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
214604906|NCT02722876|OTHER|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
214604907|NCT02722876|OTHER|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
214604908|NCT00617136|DEVICE|Intraoperative warming (Bair Hugger)|Intraoperative warming
214604909|NCT00617136|DEVICE|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
214604910|NCT00617136|DEVICE|Intraoperative warming (HotDog)|Intraoperative warming
214604911|NCT06142760|RADIATION|MR-guided radiation|Dayly artifical intelligence-based treatment adaptation under weekly offline MR-guidance
214604912|NCT02338011|DRUG|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
214604913|NCT02338011|RADIATION|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
214604914|NCT00860951|DEVICE|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
214712696|NCT02683018|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
214604915|NCT04312373|OTHER|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
214604916|NCT02645929|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
214604917|NCT03234062|OTHER|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214604918|NCT03234062|OTHER|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214604919|NCT03234062|OTHER|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214604920|NCT06178965|PROCEDURE|Incisional Hernia Repair by Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|patients with incisional hernia will be operated by hernia reduction and sac closure followed by placement of onlay mesh after creating suitable flaps.
214604921|NCT00727649|DRUG|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
214604922|NCT00727649|DRUG|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
214604923|NCT01326208|PROCEDURE|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
214604924|NCT02921568|DEVICE|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
214604925|NCT02921568|DEVICE|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
214712697|NCT02061579|BEHAVIORAL|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
214604926|NCT06198842|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
214604927|NCT03611283|OTHER|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
214604928|NCT03611283|OTHER|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
214604929|NCT03611283|OTHER|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
214604930|NCT03611283|OTHER|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
214604931|NCT03627767|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
214604932|NCT03627767|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
214604933|NCT03627767|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
214604934|NCT01726244|BEHAVIORAL|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
214604935|NCT01873417|DRUG|BG00012 (DMF)|
214604936|NCT00785044|DRUG|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
214712698|NCT03210779|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
214712699|NCT03210779|DIETARY_SUPPLEMENT|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
214712700|NCT05575284|PROCEDURE|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
214604937|NCT04558463|DRUG|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
214604938|NCT04558463|DRUG|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
214604939|NCT02931942|OTHER|blood withdrawn|venous blood sampling
214604940|NCT04030039|DRUG|Interferon|chronic hepatitis B patients with interferon therapy
214604941|NCT04030039|DRUG|nucleoside analogues|chronic hepatitis B patients with interferon therapy
214604942|NCT00385203|DRUG|AZD2171|45 mg oral tablet once daily dose
214604943|NCT02728661|BEHAVIORAL|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
214604944|NCT02728661|BEHAVIORAL|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
214604945|NCT05926154|PROCEDURE|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
214604946|NCT04296279|DRUG|FMP014|Falciparum Malaria Protein-14
214604947|NCT04296279|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
214604948|NCT01798992|DRUG|Carvedilol|
214604949|NCT01798992|DRUG|Metoprolol succinate|
214604950|NCT01798992|DRUG|Metoprolol succinate + doxazosin|
214604951|NCT03809455|DRUG|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
214604952|NCT03809455|DRUG|Placebo|one intake of placebo (intranasal or buccal)
214604953|NCT06466031|OTHER|MRI & PET fusion|MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.
214604954|NCT06466031|OTHER|MRI+T1C|MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
214604955|NCT03823404|DRUG|COR388 capsule|BID (twice daily)
214604956|NCT03823404|DRUG|Placebo capsule|BID
214604957|NCT03035695|DEVICE|Axiostat®|
214712701|NCT04082702|BEHAVIORAL|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
214712702|NCT04082702|BEHAVIORAL|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
214712703|NCT05650515|OTHER|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
214712704|NCT06528015|DRUG|probiotics combined with enteric-coated budesonide capsule|"In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
214712705|NCT06528015|DRUG|probiotics placebo combined with enteric-coated budesonide capsules|"In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
214712706|NCT03587870|OTHER|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
214712707|NCT04424199|BEHAVIORAL|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
214604958|NCT03035695|DEVICE|Cotton Gauze|
214604959|NCT04778345|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging after 18F-FDG PET/CT scan during 2 days and 1 week.
214604960|NCT05495711|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
214604961|NCT05495711|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
214604962|NCT02308007|DRUG|Terconazole|
214604963|NCT02308007|DRUG|Metronidazole|
214604964|NCT02308007|DRUG|Terconazole/metronidazole|
214604965|NCT03498846|PROCEDURE|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
214604966|NCT03498846|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
214604967|NCT05011682|BEHAVIORAL|Regular diet|participant's usual diet during 2 weeks
214604968|NCT05011682|BEHAVIORAL|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
214712708|NCT04424199|BEHAVIORAL|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
214712709|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
214712710|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
214712711|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
214712712|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
214712713|NCT05711680|DEVICE|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
214712714|NCT00071851|BIOLOGICAL|VRC-HIVDNA009-00-VP|
214712715|NCT04796428|DRUG|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
214604969|NCT01432834|OTHER|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
214604970|NCT01432834|OTHER|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
214604971|NCT02316184|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
214604972|NCT02316184|BEHAVIORAL|Brief Advice|
214604973|NCT03331653|OTHER|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
214604974|NCT03331653|OTHER|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
214604975|NCT04785339|BEHAVIORAL|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
214604976|NCT05252156|DEVICE|eXciteOSA|eXciteOSA
214604977|NCT06433804|DIAGNOSTIC_TEST|HER2 IHC|Immunohistochemistry for HER2
214712716|NCT04796428|DRUG|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
214712717|NCT04796428|DRUG|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
214712718|NCT02340468|DEVICE|diffuse optical spectroscopy|diffuse optical spectroscopy
214604978|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
214604979|NCT02563093|BIOLOGICAL|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
214604980|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
214604981|NCT02563093|BIOLOGICAL|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
214604982|NCT06154551|DIAGNOSTIC_TEST|Paxillin biomarker|Paxillin used as a salivary biomarker
214604983|NCT04622033|BIOLOGICAL|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
214604984|NCT05881980|DRUG|Terbinafine Tablets|Terbinafine 250 mg/day
214604985|NCT05881980|DRUG|Itraconazole|Itraconazole 200 mg/day
214604986|NCT05949151|PROCEDURE|dental implants (K1 line conical connection double thread, OXY, Italy)|Six dental implants inserted on the edentulous mandible
214604987|NCT05949151|DEVICE|Occlusense (Bausch GmbH & Co. KG)|sensor used to evaluate the equilibration of occlusal forces.
214604988|NCT05949151|DEVICE|"electromyography (EMG) (Nemus II)."|EMG recordings were accomplished by a computer electromyography-based data acquisition system
214712719|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
214712720|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
214712721|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
214604989|NCT05949151|OTHER|oral health-related quality of life (OHRQoL)|Oral Health-related Quality of Life (OHRQoL) was estimated by employing the Oral Health Impact Profile questionnaire which comprises nineteen multiple questions that were translated into Arabic.
214604990|NCT03715023|DRUG|PC786|PC786 suspension for inhalation
214604991|NCT03715023|DRUG|Placebo|Placebo solution for inhalation
214604992|NCT03715023|DRUG|SOC|Standard treatment for RSV infection at study site
214604993|NCT05671913|DRUG|Ketamine|Treatment arm
214604994|NCT05671913|DRUG|Placebo|Control arm
214604995|NCT05508750|OTHER|New Infant Formula|New infant formula fed daily ad libitum
214604996|NCT05508750|OTHER|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
214604997|NCT00528567|DRUG|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
214604998|NCT00528567|DRUG|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
214604999|NCT01869257|DEVICE|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
214605000|NCT01869257|DEVICE|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
214605001|NCT00331812|PROCEDURE|Mitochondrial functions and oxidative stress|
214605002|NCT03455192|DRUG|Synbiotic Supplement|
214605003|NCT03455192|DRUG|Placebo Oral Tablet|
214605004|NCT04658459|PROCEDURE|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
214605005|NCT00226187|PROCEDURE|Supplement of fatty acid (DHA and AA)|
214605006|NCT04586998|DEVICE|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
214605007|NCT06005389|PROCEDURE|cryotherapy|Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.
214605008|NCT06005389|DIAGNOSTIC_TEST|serum Galectin-3 assay|From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
214605009|NCT02221232|DRUG|Chloraprep|Apply topically.
214605010|NCT02221232|DRUG|ZuraPrep|Apply topically.
214605011|NCT02221232|DRUG|ZuraPrep Vehicle|Apply topically.
214605012|NCT00163423|DRUG|Ciclesonide|
214605013|NCT03371758|OTHER|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
214605014|NCT02970734|BEHAVIORAL|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
214605015|NCT02970734|BEHAVIORAL|Resource Webpage|Static webpage listing anxiety resources.
214605016|NCT01839162|PROCEDURE|Coronary angiography|Diagnostic coronary angiography
214605017|NCT01839162|PROCEDURE|PCI|Percutaneous coronary intervention
214605018|NCT01839162|PROCEDURE|Right approach|Right transradial access
214605019|NCT01839162|PROCEDURE|Left approach|Left transradial access
214605020|NCT02505581|DRUG|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
214605021|NCT02505581|PROCEDURE|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
214605022|NCT02505581|DRUG|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
214605023|NCT02505581|DRUG|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
214605024|NCT02505581|DRUG|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
214605025|NCT02505581|DRUG|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
214605026|NCT00908063|DRUG|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
214605027|NCT00908063|DRUG|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
214605028|NCT03352011|BEHAVIORAL|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
214605029|NCT03352011|BEHAVIORAL|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
214605030|NCT01233453|DEVICE|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
214605031|NCT01233453|DEVICE|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
214605032|NCT01338129|DIETARY_SUPPLEMENT|vitamin c|1000 mg of vitamin c for 45 days
214605033|NCT01338129|DRUG|placebo|placebo pills
214605034|NCT05326425|DRUG|lazertinib(YH25448)|\- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
214605035|NCT05961280|PROCEDURE|Mastectomy with sentinel lymph node biopsy|
214605036|NCT04825769|DEVICE|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
214605037|NCT01764126|DRUG|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
214605038|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
214605039|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
214605040|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
214605041|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
214605042|NCT02920086|BEHAVIORAL|Nutrition Education Program|"* The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
214605043|NCT02920086|OTHER|Decision Support Program|"* Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care"
214605044|NCT05659433|PROCEDURE|CEUS-guided percutaneous biopsy|A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
214605045|NCT05659433|PROCEDURE|B-mode US-guided percutaneous biopsy|Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
214605046|NCT03085758|BIOLOGICAL|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
214605047|NCT03085758|BIOLOGICAL|Placebo|Single i.v. dose of placebo (control group)
214605048|NCT04004429|DRUG|50 mg AP1189|50 mg AP1189 powder in bottle
214605049|NCT04004429|DRUG|AP1189|100 mg AP1189 powder in bottle
214605050|NCT04004429|DRUG|Placebo|Placebo powder in bottle
214605051|NCT01191541|DRUG|DNR:|DNR：45mg/m2 d1-3
214605052|NCT01191541|DRUG|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
214605053|NCT01132066|OTHER|tDCS|tDCS will lead to an increase in cortical excitability
214605054|NCT01132066|OTHER|Sham|Sham will provide identical subjective sensation as tDCS
214605055|NCT02790125|DRUG|BMS-986166|
214605056|NCT02790125|DRUG|Placebo matching BMS-986166|
214605057|NCT01448122|OTHER|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
214605058|NCT00631189|DRUG|Rosuvastatin|5mg oral
214605059|NCT00631189|DRUG|Pravastatin|40mg oral
214605060|NCT00631189|DRUG|Atorvastatin|10mg oral
214605061|NCT06227208|DEVICE|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
214605062|NCT04359875|BEHAVIORAL|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~* How are you doing? (with a Likert scale from 1=very bad to 10=very well)~* Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~* Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
214605063|NCT03601936|DEVICE|Evivo Infant Gut Bifidobacterium Screening Test|Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
214712722|NCT01663844|BEHAVIORAL|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
214712723|NCT05995925|OTHER|Clinical Observation|Clinical Observation
214605064|NCT04357145|OTHER|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
214605065|NCT04357145|OTHER|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
214605066|NCT04464265|OTHER|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
214605067|NCT03892512|DRUG|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
214605068|NCT03892512|DRUG|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
214605069|NCT02323633|DEVICE|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
214605070|NCT02323633|DEVICE|Sham|No transcranial Pulsed Current Stimulation (tPCS)
214605071|NCT01782079|DIETARY_SUPPLEMENT|L. brevis|
214605072|NCT03272542|DIETARY_SUPPLEMENT|Prebiotic: soluble corn fiber|prebiotic
214605073|NCT03272542|DIETARY_SUPPLEMENT|Placebo: maltodextrin|placebo
214605074|NCT01063829|DRUG|60 mg AIC246|Oral administration
214605075|NCT01063829|DRUG|120 mg AIC246|Oral administration
214605076|NCT01063829|DRUG|240 mg AIC246|Oral administration
214605077|NCT01063829|OTHER|Placebo|Oral administration
214605078|NCT04580862|OTHER|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
214605079|NCT06449950|BEHAVIORAL|Behavioral: Verbal Oral Hygiene Instructions|OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).
214605080|NCT06449950|BEHAVIORAL|Behavioral: Video-Based Oral Hygiene Instructions|OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
214605081|NCT02423018|DRUG|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
214712724|NCT05181904|OTHER|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
214712725|NCT05491044|DRUG|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
214712726|NCT00232440|DEVICE|BodyFIX|
214712727|NCT05165992|DRUG|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
214712728|NCT02486367|DRUG|Clopidogrel|Standard ADP receptor blockade
214712729|NCT02486367|DRUG|Ticagrelor|High potency ADP receptor blockade
214712730|NCT01300364|DRUG|Reboxetine|8mg/day.
214712731|NCT01300364|DRUG|citalopram (SSRI)|30mg/day
214712732|NCT03859492|DEVICE|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
214712733|NCT00546286|DRUG|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
214712734|NCT00546286|DRUG|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
214712735|NCT02138396|DRUG|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
214712736|NCT02138396|DRUG|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
214712737|NCT02138396|DRUG|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
214712738|NCT04377269|OTHER|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
214605082|NCT02423018|DRUG|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
214605083|NCT00974090|DRUG|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
214605084|NCT00974090|DRUG|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
214605085|NCT00665743|DRUG|PN400|naproxen 500 mg /esomeprazole 20 mg
214605086|NCT00665743|DRUG|naproxen|naproxen 500 mg tablet
214605087|NCT00665743|DRUG|naproxen|naproxen 500 mg
214605088|NCT03189862|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
214605089|NCT05265910|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
214605090|NCT05265910|DRUG|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
214605091|NCT05265910|DRUG|Tears Naturale|Tears Naturale® II (eyedrop)
214605092|NCT05265910|DRUG|Placebo|Placebo tablet (tablet)
214605093|NCT02643160|OTHER|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
214605094|NCT06466863|OTHER|Validity and Reliability|"Participants were included in the study after obtaining consent from both the participants and their parents. Participants were informed about the study prior to the survey, and only those who volunteered were included in the study. The data collection process was conducted online via Google Forms. The assessment form was sent to the participants through social media platforms, messages, and emails. Participants completed the YAP-T twice, 7 days apart, and all measurements were taken on weekdays under similar conditions by the same evaluators (4 evaluators) in the same region (Istanbul).~Test-retest reliability will be determined by calculating the Intraclass Correlation Coefficient (ICC) between the total scores obtained from the two assessments."
214605095|NCT02626325|OTHER|High-carbohydrate or High-monounsaturated fat diets|
214605096|NCT00849654|DRUG|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
214605097|NCT02390817|DRUG|Sugammadex|Administration of Sugammadex
214605098|NCT02390817|DRUG|Neostigmine|Administration of Neostigmine
214605099|NCT02939872|DRUG|aspirin and clopidogrel|at the discretion of investigator
214605100|NCT02939872|DRUG|Clopidogrel only|at the discretion of investigator
214605101|NCT02955576|DEVICE|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
214605102|NCT02955576|DEVICE|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
214605103|NCT02955576|OTHER|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
214605104|NCT00056862|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
214605105|NCT00056862|DRUG|Peginterferon alfa-2a|180 mcg/week
214712739|NCT05808842|OTHER|CeraVe|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
214712740|NCT05808842|OTHER|CeraVe and Calecim|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
214712741|NCT03096444|DRUG|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
214712742|NCT03096444|DRUG|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
214712743|NCT03096444|DRUG|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
214712744|NCT03096444|COMBINATION_PRODUCT|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
214605106|NCT00056862|DRUG|Ribavirin|800 mg/day
214605107|NCT03519958|DIAGNOSTIC_TEST|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
214605108|NCT06313073|RADIATION|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
214712745|NCT03096444|DRUG|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
214712746|NCT03505749|BEHAVIORAL|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
214605109|NCT06313073|RADIATION|adjuvant radiotherapy|The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
214605110|NCT03778814|BIOLOGICAL|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
214605111|NCT03447366|DIAGNOSTIC_TEST|mitral doppler|Mitral doppler before and after vascular filling
214605112|NCT03902561|DEVICE|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
214605113|NCT05798078|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
214605114|NCT05798078|BEHAVIORAL|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
214712747|NCT03505749|BEHAVIORAL|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
214712748|NCT02288611|DIETARY_SUPPLEMENT|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
214712749|NCT02288611|DIETARY_SUPPLEMENT|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
214712750|NCT03846219|DRUG|IMU-838 (30 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
214605115|NCT03274583|DIAGNOSTIC_TEST|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
214605116|NCT01122576|DEVICE|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
214605117|NCT01122576|DEVICE|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
214605118|NCT01122576|DEVICE|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
214605119|NCT00052039|DRUG|interferon-gamma 1b|This study was terminated prior to enrollment.
214605120|NCT00052039|DRUG|azathioprine|This study was terminated prior to enrollment.
214605121|NCT05029466|DRUG|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
214605122|NCT00564824|DRUG|Caffeine|Caffeine 200 mg tablet
214605123|NCT00564824|DRUG|Placebo|Placebo pills
214605124|NCT05953779|BEHAVIORAL|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
214605125|NCT02740296|OTHER|No intervention|
214605126|NCT03836820|OTHER|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
214605127|NCT03836820|OTHER|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
214712751|NCT03846219|DRUG|IMU-838 (45 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
214712752|NCT03846219|DRUG|Placebo|"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
214712753|NCT03846219|DRUG|IMU-838 (10 mg/day)|"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
214605128|NCT03836820|OTHER|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
214712754|NCT01688635|DRUG|LY2963016|Administered subcutaneously
214712755|NCT01688635|DRUG|US Approved Lantus|Administered subcutaneously
214605129|NCT03265535|DIAGNOSTIC_TEST|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
214605130|NCT02540863|OTHER|myofascial release protocol and Rocabado exercise therapy|
214605131|NCT02540863|OTHER|exercise therapy|
214605132|NCT05742503|OTHER|Depo-Provera|Injectable progesterone
214605133|NCT05742503|OTHER|Implanon|Etonogestrel implant
214605134|NCT05742503|OTHER|Norgestrel|Pill containing progesterone
214605135|NCT05742503|OTHER|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
214605136|NCT06416735|DRUG|Amiloride|administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
214605137|NCT04281589|OTHER|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
214605138|NCT01550913|BEHAVIORAL|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
214605139|NCT01550913|OTHER|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
214605140|NCT05987566|OTHER|Morning meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten after 1 hour of waking up in the morning
214605141|NCT05987566|OTHER|Evening meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten within 1 hour of going to bed
214605142|NCT00034450|DRUG|L-carnitine|
214605143|NCT02066623|DEVICE|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
214605144|NCT04054609|DIAGNOSTIC_TEST|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
214605145|NCT05564871|OTHER|occupation-based teleintervention|Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.
214605146|NCT00072332|DRUG|cisplatin|
214605147|NCT00072332|DRUG|edotecarin|
214605148|NCT04636866|OTHER|NO intervention|NO intervention
214605149|NCT02169817|DRUG|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
214605150|NCT02169817|DRUG|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
214605151|NCT03971656|DIETARY_SUPPLEMENT|Nutritional Supplement|Oral nutritional supplementation
214605152|NCT03971656|BEHAVIORAL|Preoperative Dietitian Consult|Nutritional assessment
214605153|NCT03971656|BEHAVIORAL|Education|Informational materials about nutrition
214605154|NCT03366051|PROCEDURE|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
214605155|NCT03366051|PROCEDURE|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
214605156|NCT03574441|DEVICE|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
214605157|NCT03574441|DEVICE|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
214605158|NCT03574441|DEVICE|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
214605159|NCT00307528|BIOLOGICAL|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
214605160|NCT00307528|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection.
214605161|NCT03471936|DIAGNOSTIC_TEST|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
214605162|NCT04259294|BEHAVIORAL|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
214605163|NCT02556866|DRUG|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
214605164|NCT02556866|DRUG|Prednisone|
214605165|NCT02556866|DRUG|Placebo|
214605166|NCT05835089|DIAGNOSTIC_TEST|serum kisspeptin levels|Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
214605167|NCT03068000|BEHAVIORAL|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
214605168|NCT03068000|BEHAVIORAL|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
214605169|NCT03518138|DRUG|Q-122|oral capsule of Q-122
214605170|NCT03518138|DRUG|Placebo|oral capsule of placebo
214605171|NCT00146679|BEHAVIORAL|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
214605172|NCT00146679|BEHAVIORAL|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
214605173|NCT00146679|BEHAVIORAL|Usual Care|Usual Care provided by providers
214605174|NCT04891341|OTHER|Technology Supported Task-Oriented Circuit Training|"Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~1. Sit to stand~2. Standing and trunk training~3. Standing and lower limb training~4. Stepping~5. Walking~6. Walking with object manipulation~7. Climbing and descending stairs~8. Unilateral upper extremity activity training (VR)~9. Bilateral upper extremity activity training (VR)~10. Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching)."
214605175|NCT04891341|OTHER|Home-based Telerehabilitation|Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
214712756|NCT05279716|DRUG|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
214712757|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
214712758|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
214712759|NCT03428451|DRUG|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
214712760|NCT05504577|DRUG|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
214605176|NCT02613689|BEHAVIORAL|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
214605177|NCT02613689|BEHAVIORAL|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
214605178|NCT00381563|DEVICE|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
214712761|NCT05504577|DEVICE|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
214712762|NCT05504577|DEVICE|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
214605179|NCT00381563|DEVICE|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
214712763|NCT03351569|DRUG|Intravenous immunoglobulin|Intravenous drip.
214712764|NCT00939939|DRUG|sitagliptin|sitagliptin 100 mg/d for 10 weeks
214712765|NCT00939939|DRUG|glimepiride|glimepiride 1 mg/d for 10 weeks
214712766|NCT01655238|OTHER|BMI|Screening guideline to assess body mass index.
214712767|NCT00888615|DRUG|Elesclomol Sodium|Given IV
214712768|NCT00888615|DRUG|Paclitaxel|Given IV
214712769|NCT02586987|DRUG|Selumetinib|Selumetinib oral
214712770|NCT02586987|DRUG|MEDI4736|MEDI4736 IV
214712771|NCT02586987|DRUG|Tremelimumab|Tremelimumab, IV
214712772|NCT00372034|DEVICE|Temporary Collagen Inserts|
214712773|NCT05428800|BEHAVIORAL|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
214712774|NCT03923439|DEVICE|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
214712775|NCT04073628|DEVICE|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
214712776|NCT05890313|DIAGNOSTIC_TEST|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
214605180|NCT01248702|OTHER|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
214605181|NCT02906345|DEVICE|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
214605182|NCT05040893|BEHAVIORAL|Physiotherapy|"Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
214605183|NCT03326895|DEVICE|Left-sided colon resection|Left-sided colon resection with powered stapler
214605184|NCT01366261|DEVICE|semirigid thoracoscopy|thoracoscopy with semirigid instrument
214605185|NCT01366261|DEVICE|rigid thoracoscopy|thoracoscopy with rigid instrument
214605186|NCT04937244|DIAGNOSTIC_TEST|5ALA exoscopic fluorescence filter|Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
214605187|NCT00364871|DRUG|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
214712777|NCT05890313|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
214605188|NCT03640468|DRUG|Ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg
214605189|NCT03640468|DRUG|Ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
214605190|NCT03640468|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg
214605191|NCT03640468|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
214605192|NCT03640468|DRUG|Normal saline|This group will receive normal saline 10 mL
214605193|NCT05547282|RADIATION|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
214605194|NCT01558583|OTHER|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
214605195|NCT01558583|OTHER|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
214605196|NCT01558583|OTHER|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
214605197|NCT04564144|DRUG|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
214605198|NCT02690220|DEVICE|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
214605199|NCT00931944|DRUG|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
214605200|NCT03187171|OTHER|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
214605201|NCT03187171|DEVICE|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
214605202|NCT00850850|DRUG|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
214605203|NCT00850850|DRUG|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
214605204|NCT02225717|PROCEDURE|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
214605205|NCT06111482|DEVICE|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
214605206|NCT06111482|DEVICE|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
214605207|NCT06111482|DEVICE|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
214605208|NCT06111482|DEVICE|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
214605209|NCT01132612|DRUG|AIN457|AIN457A 150 mg powder for solution
214605210|NCT01132612|DRUG|Placebo|Placebo to AIN457A 150 mg powder for solution
214605211|NCT04608513|DRUG|ACT-1014-6470|Soft capsules for oral administration
214605212|NCT04608513|DRUG|Placebo|Soft capsules for oral administration
214605213|NCT02252536|DRUG|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
214605214|NCT02252536|DRUG|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
214605215|NCT03876990|DIAGNOSTIC_TEST|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
214605216|NCT03876990|DIAGNOSTIC_TEST|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
214605217|NCT02777229|DRUG|Dolutegravir 50 mg|1 tablet once a day
214712778|NCT05890313|DEVICE|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
214605218|NCT02777229|DRUG|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
214605219|NCT02777229|DRUG|Efavirenz 400 mg|1 tablets once a day
214605220|NCT02236884|PROCEDURE|no-scar transanal total mesorectal excision(TME)|
214712779|NCT01896908|OTHER|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY \_\_ / \_\_ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
214712780|NCT06700148|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
214712781|NCT06700148|BIOLOGICAL|MPSV4|1 dose of MPSV4 on Day0
214605221|NCT05107804|OTHER|Exercise+CR|Exercise with caloric-restriction
214605222|NCT05107804|OTHER|Light Conditioning|Light Conditioning Exercise
214605223|NCT04044183|BEHAVIORAL|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
214605224|NCT04044183|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
214712782|NCT04567446|OTHER|Stool|collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
214712783|NCT04567446|OTHER|Blood sample|20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
214712784|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Mental health education|The intervention group will cover educational topics around mental health including: mental health literacy, individual coping skills, stigma reduction strategies, resources for mental health support, and mental health rights.
214712785|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Resources in the community|The control group will cover topics including: mental health resources in the community, violence (i.e. domestic violence), employment and education opportunities, housing and tenant rights, immigration and acculturation, and community team building and empowerment.
214605225|NCT01438151|DRUG|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
214605226|NCT01486641|PROCEDURE|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
214605227|NCT00551551|OTHER|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
214605228|NCT00551551|OTHER|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
214605229|NCT02340728|DEVICE|ERCP with SEMS plus radiofrequency ablation|
214605230|NCT02340728|DEVICE|ERCP with SEMS alone (standard of care)|
214605231|NCT04537273|OTHER|Descriptive and analytical|
214605232|NCT06306287|BEHAVIORAL|ePACE Personalized Intervention|The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.
214605233|NCT06306287|BEHAVIORAL|eFACE Fixed Intervention|The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
214605234|NCT03989076|PROCEDURE|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
214605235|NCT02822950|DRUG|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
214605236|NCT00006392|DRUG|Vitamin E|400 IU daily by mouth for 7-12 years
214605237|NCT00006392|DRUG|Selenium|200 mcg daily for 7-12 years
214605238|NCT00006392|OTHER|Vitamin E placebo|daily for 7-12 years
214605239|NCT00006392|OTHER|selenium placebo|daily for 7-12 years
214605240|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
214605241|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
214605242|NCT00652730|DRUG|Buspar|Tablets, 30 mg, single-dose, fed conditions
214712786|NCT06745206|DRUG|Lyophilized Recombinant Human Brain Natriuretic Peptide|rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. Patients should receive at least the first 500μg dose infusion, with a recommended duration of 72 hours. The specific timing of discontinuation will be determined by the attending physician. Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
214712787|NCT07057986|DEVICE|Trans cervical or abdominal ultrasound|ultrasound assessment before the scheduled upper endoscopy.
214605243|NCT03623594|PROCEDURE|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
214605244|NCT01188473|OTHER|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
214605245|NCT04103489|DRUG|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
214605246|NCT01294488|BEHAVIORAL|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
214712788|NCT07071376|OTHER|cold dialysis|Patients who meet the inclusion criteria will receive 3 sessions of cold dialysis treatment by reducing the dialysate temperature from 36.5°C to 36°C. Patients will receive this treatment for 1 week, i.e. 3 dialysis sessions. Each dialysis session will last 4 hours. During each dialysis session, the thermal comfort status of the patients will be evaluated by applying the Temperature Comfort Perception Scale at the beginning of dialysis, at the 1st, 2nd and 3rd hours of dialysis and at the end of dialysis. In addition, the day after each session, the patients will be called by phone and the Postdialysis Fatigue Scale will be re-administered and their fatigue levels will be evaluated.
214712789|NCT06901258|BEHAVIORAL|Genius Pillbox|Participants will be mailed a Genius Pillbox to their home address. Along with the pillbox, they will also receive a detailed written description to orient them to the Genius Pillbox. Participants will be expected to use the Genius pill box organizer daily for four weeks as part of their usual medication routine. Participants are also expected to fill the designated compartments with their daily pills.
214712790|NCT03862131|DEVICE|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
214712791|NCT06765161|DRUG|efgartigimod administration|efgartigimod infusion
214712792|NCT06893081|DRUG|MK-8527|Oral Tablet
214712793|NCT06893081|DRUG|CBZ|Oral Extended-release Capsule
214605247|NCT01049243|DRUG|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
214605248|NCT03612362|DEVICE|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence \& HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements \& suitably short follow-up period to decrease attrition."
214605249|NCT03752099|DRUG|VERU-111|VERU-111
214605250|NCT04866654|DRUG|Nivolumab 10 MG/ML|Nivolumab, 100 mg, 10 mg/ml
214605251|NCT02545322|RADIATION|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
214605252|NCT02515578|OTHER|Enhanced practice transformation support|
214712794|NCT07090512|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal ultrasound data collection will be conducted on all organ donors meeting the research criteria.
214712795|NCT07091110|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
214712796|NCT07091812|DEVICE|Ultrasound Vagus Nerve Stimulation (U-VNS)|Ultrasound stimulation of the auricular branch of the vagus nerve using the ZenBud device manufactured by NeurGear (Rochester, New York, USA), a CE-compliant over-the-ear headset. It delivers low-intensity focused ultrasound to the auricular branch of the vagus nerve through several layers of skin (centre frequency 5.3 MHz, pulse repetition rate 41 hertz, 50% duty cycle, average intensity of 1.03 MPa).
214712797|NCT07091812|DEVICE|Sham U-VNS|Sham device, also produced by NeurGear, which is identical in appearance to the true ZenBud device, emits the same sound and warms up slightly where the transducer sits on the skin.
214712798|NCT07090031|DRUG|TAS-102 in combination with oxaliplatin|"Induction : TAS102 35mg/m2, twice a day for 5 days, on 1st, 3rd, 5th week; Oxliplatin 85mg/m2 on 1st and 2nd week; Rectal radiotherapy 50GY/25f in 5 weeks. 2 weeks no treatment.~Consolidation: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 3 cycles. 4 weeks no treatment.~Surgery Adjuvant chemotherapy: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 16 cycles."
214605253|NCT02515578|OTHER|Standard practice transformation support|
214605254|NCT02370680|DRUG|Aspirin|steady-state run-in prior to Durlaza treatment
214605255|NCT02370680|DRUG|Durlaza™|comparison of different numbers of capsules
214605256|NCT06363279|OTHER|Conducting questionnaires|The questionnaires will be administered online or in person.
214605257|NCT02401412|DEVICE|Test Ostomy Barrier|
214605258|NCT02401412|DEVICE|Control Ostomy Barrier|
214605259|NCT00603655|OTHER|Low glycemic load diet|Low glycemic load diet
214605260|NCT00603655|OTHER|High glycemic load diet|High glycemic load diet
214605261|NCT01184053|DRUG|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
214605262|NCT04418544|DEVICE|Device used to record voice for screening|voice recording
214605263|NCT04557085|DRUG|Cenobamate|Cenobamate tablets
214605264|NCT04557085|DRUG|Placebo|Matching placebo tablets
214605265|NCT01636791|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
214712799|NCT07090265|PROCEDURE|non-surgical periodontal therapy|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes
214605266|NCT01636791|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
214605267|NCT03624205|DEVICE|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
214605268|NCT01174238|DRUG|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
214605269|NCT01174238|DRUG|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
214605270|NCT01174238|DRUG|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
214712800|NCT07090265|PROCEDURE|non-surgical periodontal therapy + I-PRF|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes following by subgingival application of I-PRF
214605271|NCT02674191|DEVICE|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
214605272|NCT02674191|PROCEDURE|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
214605273|NCT02674191|PROCEDURE|Administration of , Mepivacaine-l|local anesthesia
214605274|NCT02674191|PROCEDURE|BETADINE povidone-iodine 10%|a local disinfectant
214605275|NCT02674191|DRUG|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
214712801|NCT07090434|DEVICE|Mobile App + psychoeducation program|"Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation. In addition to that, participants will receive access to the BEI mobile app, designed to reinforce education and exercise strategies outside clinical sessions. Participants will be instructed to use the app daily, guided by a to-do list including:~* 1 educational module (interactive format) + 3 questions self-exam~* 1 physical activity (video-guided, adapted by fatigue and pain level)~* 1 gamified cognitive task (for memory, attention, speed processing and/or executive function)~* Daily mood and symptom check-in"
214712802|NCT07090434|BEHAVIORAL|Psychoeducation program|Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation.
214712803|NCT07092449|DRUG|Neoadjuvant chemo-immunotherapy|Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)
214605276|NCT02674191|DRUG|(Cataflam 25mg), are prescribed post-operatively|an analgesic
214605277|NCT04603586|RADIATION|SBRT|SBRT: in 5-6 fractions with CyberKnife
214605278|NCT04603586|DRUG|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
214605279|NCT05235399|OTHER|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
214605280|NCT02022345|PROCEDURE|Percutaneous Coronary Intervention|
214605281|NCT02448693|DEVICE|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
214712804|NCT07091136|DRUG|manidipine|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
214712805|NCT07091136|DRUG|Placebo|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
214712806|NCT07092007|BIOLOGICAL|NWRD09 administered by intramuscular injection|NWRD09 administered by intramuscular injection according to the study protocol.
214712807|NCT07090044|DRUG|Bromfenac Sodium 0.07%|Bromfenac sodium 0.07% is a nonsteroidal anti-inflammatory drug to be administered as one topical drop, one time 5 minutes prior to the regularly scheduled standard of care intravitreal injection.
214712808|NCT07090044|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Loteprednol etabonate 0.38% ophthalmic gel is a steroidal drug to be administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
214712809|NCT07090044|DRUG|Propylene Glycol Preservative-free Artificial Tears|Propylene Glycol Preservative-free Artificial Tears is a placebo compartor administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
214712810|NCT07092358|OTHER|None of intervention|No specific intervention was implemented in this study.
214712811|NCT07092163|DEVICE|QLF Imaging (Qraypen C®)|Fluorescence-based assessment of restoration margins using Qraypen C® device to measure autofluorescence loss (ΔF) and red fluorescence (ΔR). Imaging was performed during routine 18-month follow-up to detect micro-leakage or marginal biofilm activity.
214605282|NCT02448693|DEVICE|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
214605283|NCT02435342|DRUG|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
214605284|NCT02435342|DRUG|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
214605285|NCT05732662|RADIATION|SBRT|24-50Gy/8-12.5Gy/3-4f
214605286|NCT05732662|DRUG|Cadonilimab|10 mg/kg,q3w
214605287|NCT04964570|BEHAVIORAL|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
214605288|NCT05797233|BIOLOGICAL|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
214605289|NCT05797233|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
214605290|NCT05797233|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
214605291|NCT06221553|BIOLOGICAL|B7H3 specific CAR T cell with IL-7Ra signaling domain|Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter
214605292|NCT01012154|DEVICE|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
214605293|NCT05251623|OTHER|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
214605294|NCT04470609|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214605295|NCT04470609|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214605296|NCT04470609|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214605297|NCT04470609|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
214605298|NCT02593786|DRUG|Nivolumab|
214605299|NCT00199433|DRUG|Istradefylline (KW-6002)|
214605300|NCT02659579|BEHAVIORAL|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
214605301|NCT02659579|BEHAVIORAL|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
214605302|NCT05467475|DRUG|BI 1819479|BI 1819479
214605303|NCT05467475|DRUG|Esomeprazole|Esomeprazole
214605304|NCT01479829|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
214605305|NCT01479829|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug
214605306|NCT01479829|DRUG|Placebo|Placebo is a manufactured capsule with no active ingredient
214605307|NCT01578967|DRUG|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
214605308|NCT01578967|DRUG|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
214605309|NCT00527254|DEVICE|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
214605310|NCT03759977|OTHER|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
214605311|NCT06129123|BEHAVIORAL|Live Free From E-cigarettes|This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
214605312|NCT03165318|DEVICE|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
214605313|NCT03165318|DEVICE|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
214605314|NCT05179642|OTHER|OPTIM-EHPAD tool|"This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
214605315|NCT04221932|DEVICE|CRRT KPI Reports|This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
214605316|NCT01791803|BEHAVIORAL|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
214605317|NCT01791803|DRUG|Nicotine|free one month supply after hospital discharge
214605318|NCT03823768|DRUG|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
214605319|NCT03823768|DRUG|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
214605320|NCT04621929|DRUG|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
214605321|NCT04621929|COMBINATION_PRODUCT|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
214605322|NCT07130799|OTHER|Immunomonitoring|To analyse monocyte HLA-DR expression (mHLA-DR) and CD4+ T lymphocyte count (CD4) in both group
214605323|NCT07128875|OTHER|Exercise + TENS + Hot Pack|"Therapeutic Exercises with Hot Pack and TENS This intervention focuses on improving physical function and reducing pain through structured therapeutic exercises for knee OA patients. The program includes Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5. Cool Down (5-10 min): Breathing and relaxation. 6. Hot Pack (15 min) + TENS (10 min): Applied pre and post exercises for pain relief and muscle relaxation."
214605324|NCT07128875|OTHER|Exercise|"Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5."
214605325|NCT06421545|BEHAVIORAL|Resilient Together for Dementia|A novel live video dyadic resiliency intervention
214605326|NCT06809192|BEHAVIORAL|4-session Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, c) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, and autogenic relaxation, and d) goal setting and problem-solving barriers to integrate relaxation practices into daily routine.
214605327|NCT06809192|BEHAVIORAL|4-session Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
214605328|NCT06809192|BEHAVIORAL|4-session Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, c) labeling thoughts as helpful, unhelpful, or neutral, d) using distraction to cope with unhelpful thoughts, e) challenging and changing unhelpful thoughts, f) problem-solving barriers to coping with or changing unhelpful thoughts.
214605329|NCT07129005|OTHER|No intervention (observational study)|No intervention (observational study)
214605330|NCT07128498|BEHAVIORAL|Tinker-Fun|A cognitive flexibility intervention revolves around a hands-on experience where participants design and build a craft or device. The process emphasizes active learning through observing, exploring, t
214605331|NCT06522035|DRUG|Allocetra|Intra-articular injecton of Allocetra into the target joint.
214605332|NCT07118514|BEHAVIORAL|Progressive Resistance Training|A 12-week supervised resistance training program, performed twice weekly for 50 minutes per session. Exercises are based on 1-repetition maximum (1-RM) tests, using fixed machines and progressive loads (50-65% of 1-RM). Exercises include leg press, leg curl, knee extension, chest press, biceps/triceps curls, seated row, and lat pulldown.
214605333|NCT07118514|BEHAVIORAL|Stretching and Relaxation Activities|A 12-week supervised program focused on flexibility and relaxation, performed twice weekly for approximately 50 minutes. Includes static stretching of major muscle groups and guided breathing exercises aimed at reducing muscle tension and promoting mental relaxation.
214605334|NCT02320929|PROCEDURE|Intraoperative flexor tendon sheath irrigation|
214605335|NCT02320929|PROCEDURE|Postoperative flexor tendon sheath irrigation|
214605336|NCT07123740|PROCEDURE|Intrathecal Morphine|"An intrathecal injection of morphine 300μg will be administered at the L3-L4 or L4-L5 level.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214605337|NCT07123740|PROCEDURE|Bi-level Erector Spinae Plane Block|"Bi-level erector spinae plane block will be performed on the patients using a total of 40 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214605338|NCT07123519|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3E6 STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
214605339|NCT07125235|BEHAVIORAL|reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention|The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.
214605340|NCT07125235|DEVICE|urine tenofovir point-of-care self-test|urine tenofovir point-of-care self-test
214605341|NCT07123987|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
214605342|NCT07123987|OTHER|traditional medical treatment for PHN|Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
214605343|NCT04279054|DRUG|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
214712812|NCT07092163|PROCEDURE|Clinical evaluation|Restorations were evaluated both at baseline (1-week recall) and at 18-month follow-up using the FDI World Dental Federation Clinical Evaluation Criteria, which allow structured and sensitive assessment of indirect restorations across three domains: Functional properties (e.g., marginal adaptation, fracture, retention, occlusion), Biological properties (e.g., recurrent caries, hypersensitivity, pulp status), Esthetic properties (e.g., marginal discoloration, surface texture, shade matching). Each criterion was scored on a 5-point ordinal scale: 1 = Clinically excellent / very good, 2 = Good (minor corrections), 3 = Satisfactory (acceptable with no significant clinical impact), 4 = Unsatisfactory (repair required), 5 = Clinically poor (replacement required). Scores of 1-3 were considered clinically acceptable, while scores of 4 or 5 indicated restorative failure.
214605344|NCT04279054|DRUG|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
214605345|NCT07128810|OTHER|Parent Child Interaction Therapy|Parent was trained in a structured way during two phases of PCIT that are Phase 1: Child Directed Intervention and Phase 2: Parent Directed Intervention to encourage Language Development with frequency of sessions as 12 sessions; minimum 30 mins each day, 3x per week.
214605346|NCT07128810|OTHER|Conventional Parent Led Therapy|Parent was trained in an unstructured way by using different language development strategies (Imitation, Focused Stimulations, Milieu Teaching, and others) to encourage Language Development with frequency of session as 12 sessions; minimum 30 mins each day, 3x per week.
214712813|NCT07092176|OTHER|Steady Strides|"Participants in the control arm will receive a one-time assessment by a trained research assistant at baseline and once more at 2 month follow up. Research assistant will measure and document the specified demographic and clinical variables to be compared between the control and intervention groups.~Participants in the intervention arm will receive a multifactorial intervention, including: Medical Intervention: Provided by physician(s) and/or nurse practitioners (NPs) or physician assistants (PAs) trained in the Steady Strides fall prevention protocol via the hybrid online and in person course on the Steady Strides fall prevention protocol . Rehabilitation Intervention: Provided by occupational therapists (OTs) and physical therapists (PTs) trained through a hybrid online and in person course on the Steady Strides fall prevention protocol"
214712814|NCT07090525|DRUG|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled
214712815|NCT07090525|DRUG|cisplatin 40mg/m2 intracavity injection|cisplatin 40mg/m2 intracavity injection
214712816|NCT07091994|DRUG|edaravone dexborneol injection|The experimental intervention involved twice-daily administration of edaravone dexborneol injection at a dose of 37.5 mg (containing 30 mg edaravone and 7.5 mg dexborneol), with doses spaced exactly 12 hours apart. For each infusion, the study medication was first diluted in 100 mL of normal saline (0.9% sodium chloride solution) and then administered as a controlled intravenous infusion over a precisely timed 30-minute period. This standardized dosing regimen was maintained consistently throughout the 10-14 day treatment course for all participants in the experimental group.
214712817|NCT07091994|DRUG|Standard therapeutic protocol|The standard treatment regimen, which may include antiplatelet therapy, anticoagulation (if indicated), blood pressure management, and other evidence-based interventions, will be administered continuously for 10 to 14 days according to current clinical guidelines.
214712818|NCT07092072|DEVICE|MYOFIX FULL FIELD PERIPHERAL DEFOCUS SPECTACLE|This is a plus peripheral add spectacle with the central part for the myopic correction.
214605347|NCT07128940|OTHER|Meat vs fish|Metabolite differences: Meat vs fish
214605348|NCT07128940|OTHER|Meat vs Vegetarian|Metabolite differences: Meat vs Vegetarian
214605349|NCT07128940|OTHER|Fish vs Vegetarian|Metabolite differences: Fish vs Vegetarian
214605350|NCT07130240|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"Drug: Neoadjuvant Chemotherapy paclitaxel, 135-175mg/m2, q3w, 2-3 cycles~Drug: Neoadjuvant Chemotherapy cisplatin, 75-80mg/m2, q3w, 2-3 cycles~Drug: Immunotherapy Ivonescimab, 20mg/kg, q3w, 2-3cycles~Procedure: Type A hysterectomy After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Type A hysterectomy + sentinel lymph node dissection / pelvic lymphadenectomy"
214605351|NCT07130110|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|The c-TBB procedure was performed under general anesthesia with rigid bronchoscopy guidance. The biopsy site was selected based on the area of highest involvement seen on thoracic CT. After evaluating the trachea and main bronchi with a rigid bronchoscope, a flexible bronchoscope was advanced into the target segment. Using a 1.9 mm, 90 cm cryoprobe, tissue was frozen and rapidly retracted with the bronchoscope to obtain the biopsy. The specimen was placed in formalin without damage. Hemorrhage control was achieved with a Fogarty balloon. A chest X-ray was taken two hours later to check for pneumothorax risk.
214605352|NCT07130110|DIAGNOSTIC_TEST|Bronchoalveolar Lavage|The BAL protocol, including pre-procedural preparations and the procedure itself, was performed in accordance with the American Thoracic Society (ATS) guidelines. In cases of diffuse involvement, BAL was performed from the middle lobe or lingula, while in localized involvement, it was done from the affected area. The target segment was occluded with the bronchoscope, and room-temperature 0.9% NaCl solution was instilled in 20 cc portions and gently aspirated to prevent airway collapse. A minimum of 100 mL (maximum 300 mL) saline was used, with at least 30% recovery required. Cellular analysis of BAL fluid was conducted per ATS guidelines. Normal cell distribution: alveolar macrophages \>85%, lymphocytes 10-15%, neutrophils ≤3%, eosinophils ≤1%, squamous/ciliated columnar epithelial cells ≤1%.
214605353|NCT07130565|DIAGNOSTIC_TEST|18F-92/AV45/TPZA/FT8, 11CPIB|Each subject receive a single intravenous injection of 18F-92/AV45/TPZA/FT8, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
214605354|NCT07128914|DRUG|GO306|"Part 1: A 3+3 single-dose escalation phase:~Low-dose cohort: 3.0E+07 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Medium-dose cohort: 3.0E+08 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~High-dose cohort: 1.0E+09 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Part 2: A multiple-dose expansion phase at the RP2D level to explore preliminary efficacy in specific tumor type:~RP2D; Intratumoral or intracavitary injection of GO306; Cohort Size: 20 subjects in specific tumor type; Dosing Schedule: QW or Q2W administration."
214605355|NCT07129564|OTHER|treatment react|Reverse remodeling of the LA was defined as at least a 15% reduction in the max LA volume after electrical or pharmacological cardioversion for 3 months
214605356|NCT07130721|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Test|Blood samples will be collected once from all participants to measure CRP levels
214605357|NCT07130721|DIAGNOSTIC_TEST|D-dimer Test|D-dimer levels will be assessed once to evaluate thrombotic risk.
214605358|NCT07130721|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|A standard 12-lead ECG will be performed once per participant to assess cardiovascular status
214605359|NCT07128797|DRUG|B1344|Subcutaneous injection
214605360|NCT07128797|OTHER|Placebo|Subcutaneous injection
214605361|NCT07130682|RADIATION|Pencil Beam Proton Therapy Treatment Machine|2 fractions will be delivered to treat low- or intermediate- risk prostate cancer
214605362|NCT07128745|BEHAVIORAL|Shared Medical Appointment + Self-Management Strategy|Participants assigned to this arm will receive a self-management intervention delivered through shared medical appointments (SMAs). The SMA intervention will be conducted once every two months for a total of three sessions over six months. Each session includes structured medical consultation, health education, behavioral guidance based on the Behavior Change Wheel (BCW) framework, and facilitated peer discussion.
214605363|NCT07128745|BEHAVIORAL|Usual Care + Self-Management Handbook|Participants receive routine one-on-one GP care plus a printed COPD self-management education handbook.
214605364|NCT07128719|DRUG|Modafinil|dose of modafinil preoperatively for for active comparator
214605365|NCT07130617|DRUG|Low dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.
214605366|NCT07130617|DRUG|Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 625 mg/day, administered once daily (QD) for 7 consecutive days.
214605367|NCT07130617|DRUG|High dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 937.5 mg/day, administered once daily (QD) for 7 consecutive days.
214605368|NCT07130617|DRUG|Megestrol Acetate Oral Suspension Placebo combined with standard therapy|A single dose of 5 mL/day, administered once daily (QD) for 7 consecutive days.
214605369|NCT07128628|DRUG|Lifitegrast/Perfluorohexyloctane Fixed Dose Combination|Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
214605370|NCT07128628|DRUG|Lifitegrast|Topical ocular drop of lifitegrast administered for 4 weeks
214605371|NCT07128628|DRUG|Perfluorohexyloctane|Topical ocular drop of perfluorohexyloctane administered for 4 weeks
214605372|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
214605373|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
214605374|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
214605375|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with tislelizumab|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Tislelizumab，200 mg, iv, d1, Q3W, until disease progression or intolerable toxicity."
214605376|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with anlotinib|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Anlotinib 12mg QD po d1-14，Q3W,until disease progression or intolerable toxicity."
214605377|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 2 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
214605378|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 4 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
214605379|NCT07130149|PROCEDURE|Sonodynamic Therapy (SDT)|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted.
214605380|NCT07130149|OTHER|Standard Treatment|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
214605381|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
214605382|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
214605383|NCT05775510|DEVICE|Commercially available neurostimulation systems|Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
214605384|NCT06827470|BIOLOGICAL|Biological: Bordetella pertussis J820|Intranasal inoculation of Bordetella pertussis J820 in each naris on Day 1 of the study.
214605385|NCT06809790|BEHAVIORAL|Therapeutic Exercise Program|Participants in this group will receive a therapeutic exercise program (including cervical range of motion and trapezius stretching) during the study period.
214605386|NCT06809790|PROCEDURE|Dry Needling|Participants in this group will receive dry needling treatment for active trigger points in addition to the therapeutic exercise program. Dry needling treatment will be applied in a total of 3 sessions at 0, 1, and 2. weeks, one week apart.
214605387|NCT00639210|OTHER|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
214605388|NCT05552209|DEVICE|Elbow MID 500|15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.
214605389|NCT05552209|OTHER|Control group Elbow MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.
214605390|NCT05552209|DEVICE|Elbow STRAP|15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.
214605391|NCT05552209|OTHER|Control group Elbow STRAP|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
214605392|NCT00846547|DRUG|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
214605393|NCT03248674|DIAGNOSTIC_TEST|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
214605394|NCT02750150|DRUG|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
214605395|NCT02750150|DRUG|Fresh-frozen plasma|
214605396|NCT01768650|BEHAVIORAL|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
214605397|NCT01768650|BEHAVIORAL|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
214605398|NCT03872232|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
214605399|NCT03872232|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
214605400|NCT01093326|DRUG|Ponesimod 10 mg|Ponesimod 10 mg oral use
214605401|NCT01093326|DRUG|Ponesimod 20 mg|Ponesimod 20 mg oral use
214605402|NCT01093326|DRUG|Ponesimod 40 mg|Ponesimod 40 mg oral use
214605403|NCT00359151|DRUG|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
214605404|NCT00359151|DRUG|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
214605405|NCT04628884|DRUG|Conventional dose|Conventional dose used to calculated the protamine dose
214605406|NCT04628884|DRUG|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
214605407|NCT04260009|DRUG|Brigatinib|Brigatinib tablets
214605408|NCT04260009|DRUG|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
214605409|NCT05343026|DEVICE|Hearing aids|As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
214605410|NCT05060731|DRUG|Oral iron supplementation|Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
214605411|NCT05060731|DRUG|Intravenous iron supplementation|One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
214605412|NCT04924244|OTHER|Music Therapy|We will play music of the subject's choice of genre during the procedure.
214605413|NCT04924244|OTHER|No Music|No music will be played during the subject's interventional procedure
214605414|NCT06820034|OTHER|Empowering Cessation for the ACS South|All participants (N=400) will receive remotely-delivered smoking cessation support comprised of the National Cancer Institute's (NCI) free smoking cessation app and 12 weeks of mailed over-the-counter NRT (nicotine patches, gum or lozenges).. While receiving smoking cessation support, participants in the intervention group (n=200) will also engage in SGM-serving online volunteer activities (≥4 weekly sessions lasting \~1.5 hours each), the protocols for which will be developed in Phase 1 to address the needs of OK, AR, and TX communities. Volunteer sessions will be facilitated by an SGM culturally-competent facilitator employed by the research team (i.e., community partner organizations will not run volunteer sessions). The intervention group will also be added to a digital hub (i.e., a private Reddit group) for 12 weeks to foster social support and exchange of ideas between participants/community partners across the three states.
214605415|NCT03565731|BEHAVIORAL|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
214605416|NCT06987240|PROCEDURE|Ultrasonography-guided combined spinal epidural anesthesia application|patients with BMI\>30
214605417|NCT06987240|PROCEDURE|Combined spinal epidural anesthesia with Landmark|Patients with BMI\>30
214605418|NCT06658912|OTHER|TOPS Classes|Attend Dietician-Led Sessions
214605419|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
214605420|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
214605421|NCT04159337|OTHER|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
214605422|NCT04263896|DRUG|Polyethylene Glycol 3350|Participants will take 1 17g pack per day for 10 days preceding surgery.
214605423|NCT05553470|DRUG|Miricorilant|600 mg miricorilant
214605424|NCT04084964|OTHER|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
214605425|NCT06609213|OTHER|Medical Food|Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.
214605426|NCT07001280|OTHER|No intervention|No intervention will be administered as part of this study.
214605427|NCT07105176|DRUG|Cyclophosphamide|Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.
214605428|NCT07105176|DRUG|Fludarabine|Fludarabine is administered once daily via intravenous infusion for 4 consecutive days.
214712819|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by mechanical articulator|"The therapeutic jaw position will be determined by the following steps:~1. Pre-treatment Jaw Position Recording Participants were seated upright with relaxed posture, eyes facing forward, and the Frankfort plane parallel to the floor. Intercuspal position (ICP) was recorded using silicone registration material. Edge-to-edge position of central incisors was recorded for protrusive position. Left/right lateral positions were recorded with opposing canines aligned.~2. Transfer of Jaw Positions Following the manufacturer's protocol for the Artex CR mechanical facebow (Amann Girrbach, Austria) to transfer Participants' jaw positions.~3. Determination of Therapeutic Position The Glenoid fossa was divided into 7 grids in the oblique-sagittal plane using Gelb's method, identifying grid 4 (Gelb 4/7) as the target condylar position.Condylar displacement knobs were set per VTO analysis.~Incisal pin height was increased to establish vertical dimension."
214712820|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual articulator|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Jaw Models CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The mandibular/maxillary bone models and dental arches were exported as .ply files. These .ply files were then imported into Exocad software.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The composite mandibular model was repositioned to the target occlusion using the Move Mesh function based on: Optimal mean joint space measurements and physiological condylar position."
214605429|NCT07105176|DRUG|IL-2 (interleukin 2)|IL-2 administered subcutaneously once daily. Dosing may be adjusted based on subject tolerance, including modifications to dose quantity, administration frequency, or complete treatment discontinuation, with a maximum treatment duration of 3 days.
214605430|NCT07105176|DRUG|HS-IT101 monotherapy|TIL Injection administered by intravenous infusion over 30-60 minutes.
214605431|NCT07110389|BEHAVIORAL|A tele-CR program|"The tele-CR program is divided into three parts: motivational interviewing, app delivery, and self-management and tracking. Motivational interviewing was conducted during hospitalization and involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR app (approximately 30-60 minutes per session).~After discharge, researchers monitored app usage and conducted seven follow-up sessions via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge. These follow-ups, each lasting approximately 5-15 minutes, aimed to assess patients' living conditions, address any issues promptly, and provide encouragement or praise based on their engagement with the app.~After the completion of the 6-month tele-CR intervention, participants could still actively contact the researchers via LINE or the app to seek health-related assistance according to their personal needs, up to 12 months post-discharge."
214605432|NCT07110389|OTHER|Attention-controlled|The researchers conducted face-to-face communication with participants in the control group prior to discharge, aiming to establish a professional relationship and advise them to follow routine health education and adopt an appropriate lifestyle. After discharge, follow-up care was provided regularly via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge-a total of seven sessions, each lasting approximately 3-5 minutes-to inquire about any symptoms of discomfort.
214605433|NCT07110623|DEVICE|LIP device|The LIP device uses polarized Raman spectroscopy to enhance the early detection and diagnosis of oral cancer by facilitating more accurate guiding of biopsies. This non-invasive technology utilizes polarized laser light to generate Raman scattering that can be used to analyze molecular vibrations, which in the future will provide clinicians with insights into tissue composition and structure for identifying cancerous abnormalities.
214605434|NCT07110714|OTHER|Cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), four times daily during the 3-week program and once daily during the 6-month follow-up period. Hydrotherapy interventions are individually tailored to each subject based on their responses and include various washing and pouring techniques.
214605435|NCT07115927|DRUG|Dostarlimab|Arm 1: Patients in the initial cohort will be treated with two doses of dostarlimab prior to surgery, receiving dostarlimab 500mg IV on day 1 and day 22.
214605436|NCT03315975|BIOLOGICAL|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
214605437|NCT07113860|BEHAVIORAL|Views on Aging Intervention|This intervention was developed by Wolff, Warner (47) in 2013-2014; refined by Beyer, Wolff (59) in 2017-2018; and further refined for this project. It will be delivered through three in-person one-hour sessions by two psychologists. it will include homework between sessions two and three. The first session will consist of a quiz on aging with questions about healthy aging and aging in general to detect own negative personal views on aging and misconceptions regarding aging. The second session will provide information on the benefits of more positive views on aging on health, functional and cognitive abilities, and longevity. During the third session participants are thought a technique to modify negative automatic thoughts about aging and asked/invited to put in practice this technique. Finally, the intervention ends with a focus on positive views on aging and their importance for one's health and wellbeing.
214605438|NCT07113860|BEHAVIORAL|Projecte Moviment|The intervention lasts 12 weeks and is based on international guidelines of physical exercise. Participants will be instructed to walk briskly in one continuous bout (45 minutes for 5 days, 225 minutes per week). Intensity, duration, and times per week will be initiated in a stepwise manner to reduce the possibility of injury. During the first week participants will be asked to walk 30 minutes at 9-10 on the Borg Rating of Perceived Exertion Scale (i.e., light intensity). During the second week, participants will be asked to walk 45 minutes with the same intensity. During the remaining weeks, participants will be asked to maintain the duration of 45 minutes and increase the intensity of the activity to a moderate-high effort that corresponds with 12-14 in the Borg Rating of Perceived Exertion Scale.
214605439|NCT07117097|PROCEDURE|Minimally Invasive Non- Surgical Periodontal Therapy (MINST)|The procedure consists of thorough debridement of the root surface through a subpapillary access using exclusively piezoelectric devices with specific thin and delicate tips (EMS, Switzerland) and 4X magnification loupes, taking care to minimize the soft tissue trauma and to stimulate the formation of a stable blood clot
214605440|NCT07117097|PROCEDURE|conventional Non-Surgical Periodontal Treatment (cNSPT)|The intervention consists of thorough debridement of the root surface under local anaesthesia, using conventional piezoelectric devices and hand instruments
214605441|NCT07123246|OTHER|Rigid Tape|Inelastic rigid tape (Strappal) applied to discharge the Achilles tendon
214605442|NCT07123246|OTHER|Placebo Control|A pre-tape and a short piece of rigid tape applied without tension.
214605443|NCT07123194|BEHAVIORAL|An Arts-Based Nursing Intervention Program to Help Develop Healthy Digital Habits|Session Time: Arts-Based Nursing Intervention Program Sessions to Help Develop Healthy Digital Habits Week 1, Session 1 - Introductions and Group Agreement Formation (60 minutes) Week 2, Session 2 - Where Am I in the Digital World? (60 minutes) Week 3, Session 3 - Digital Addiction: Are You Connected or Addicted? (90 minutes) Week 4, Session 4 - Digital Addiction and Its Effects (90 minutes) Week 5, Session 5 - Digital Danger: Cyberbullying (90 minutes) Week 6, Session 6 - Discovering Strengths: The Relationship Between Digital Addiction and Self-Efficacy (90 minutes) Week 7, Session 7 - Digital Detox and Alternatives (90 minutes) Week 8, Session 8 - Evaluation and Closing (90 minutes)
214605444|NCT07122479|OTHER|Three-Pronged Approach to Reduce Hospital Acquired Deconditioning|The intervention includes 1) providing and demonstrating a set of daily physical exercises to patient according to their baseline performance status as assessed by physical therapist, 2) maintaining a patient-completed daily log of physical exercise adherence and 3) standardize the monitoring of physical exercise by the healthcare team by its inclusion in daily progress notes.
214605445|NCT07123259|DIETARY_SUPPLEMENT|WHOLE WHEAT MUFFIN|400g whole wheat flour was used for the development of muffins
214605446|NCT07123259|COMBINATION_PRODUCT|1.5g enriched pomegranate muffins|1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy
214605447|NCT07123259|COMBINATION_PRODUCT|3g enriched pomegranate muffins|3 g of pomegranate peel powder (PPP), alongside conventional medical therapy
214605448|NCT07123077|OTHER|Functional Exercises|"Warm-Up Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions.~Strengthening Exercises (40 min):~In a seated position:~Ankle plantar flexion and dorsiflexion exercises, ankle circumduction, knee extension, hip flexion, shoulder joint range of motion exercises in all directions, elbow and hand flexion-extension exercises~In a standing position:~Hip extension, toe raises, mini squats, standing on one leg, 360-degree turning, tandem walking exercises Each exercise was performed for 8 repetitions.~Cool-Down Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions."
214605449|NCT07123077|OTHER|Music Intervention|Slow-paced pieces in the Rast mode were selected for the warm-up and cool-down exercises, while more upbeat pieces in the Mahur mode were chosen for strength and balance exercises and played to the participants throughout the sessions alongside the exercises. To enhance participants' concentration, instrumental compositions in these selected Turkish classical music modes were used. Traditional Turkish instruments such as qanun, ney, kudüm, and oud were preferred in the performance of the compositions.
214605450|NCT07128381|DRUG|Axatilimab (SNDX-6352)|Taken orally
214605451|NCT07128381|DRUG|Ruxolitinib|Taken orally
214605452|NCT07128446|OTHER|Standard physical and occupational therapy|Participants admitted to the Pediatric Intensive Care Unit (PICU) will receive standard occupational therapy as part of routine clinical care. Interventions will be tailored to each patient's medical status and functional needs and may include activities of daily living (ADL) training, positioning, range of motion exercises, sensory stimulation, and caregiver education. No additional experimental treatment will be introduced for study purposes. The primary focus of the study is to evaluate patient-centered outcomes using the Canadian Occupational Performance Measure (COPM), without altering the standard therapeutic approach.
214605453|NCT07129304|COMBINATION_PRODUCT|Collaborative Virtual Reality with Routine Physical Therapy|patients will receive routine Physiotherapy treatment and additional treatment in a Collaborative Virtual Reality Environment for 30 minutes per session 3 times /week for minimum of 8 weeks. There will be a real time interaction in this group between patients and Physiotherapist in the virtual environment. The tasks in the CVE will focus on motor control, balance, coordination, and social engagement while routine Physical Therapy session will consist of performing exercises based on similar goals of improving motor skills, enhanced coordination, functional mobility, muscle strength and stretching exercises.
214605454|NCT07129304|COMBINATION_PRODUCT|Non-Immersive Virtual Reality with Routine Physical Therapy|Patients will receive routine physiotherapy treatment along with the engagement with computer-based virtual rehabilitation content displayed on a standard computer monitor/ LED screen. There will be no real time interaction in this group between patients and Physiotherapist in the virtual environment. Patients will be viewing pre-recorded videos of therapeutic exercises, demonstration, and / or on-screen instructions and cues for performing exercises. This group's patients will be treated with non- immersive virtual reality along with routine physical therapy for 30 minutes session 3 times /week for 8 weeks. Routine Physical Therapy session will consist of performing exercise based on the goal of improving motor skills, enhanced coordination, posture correction, gait efficiency, functional mobility, muscle strength and endurance training, stretching exercises where required.
214605455|NCT07129681|OTHER|dextrose 5%|Dextrose, is an osmotic proliferant which acts by dehydrating the cells at the injection site which utlimately leads to release of cellular fragments that act as chemo attractants and start the inflammatory cascade leading todeposition of collagen
214605456|NCT07129681|OTHER|Arthrocentesis/Saline|Arthrocentesis , a highly successful, simple and minimally invasive procedure is a safe and simple method for treatment of anterior disc displacement with reduction of TMJ both in short term and long term follow up period, where it is a procedure of removing damaged tissues \&inflammatory mediators.it can be the treatment modality for the for control group
214605457|NCT07130812|OTHER|blood flow restriction|The SAGA blood flow restriction tourniquet system will be used for each training sessions for the rowers within the light load restriction group. The 4 inch-wide tourniquet will be applied to both upper thighs during the strength and endurance exercises. Tourniquet setting will be determined as the pressure needed to achieve 40-80% arterial occlusion to the extremity (as measured by the SAGA BFR unit). The SAGA units provides a consistent amount of pressure to the extremity throughout the ROM of the exercise. The settings will be determined at baseline and then recalibrated weekly.
214605458|NCT07130812|OTHER|Heavy load resistance training|For the resistance prescription, rowers will do strengthening exercises at 70-80% 1 RM. Exercises will be performed in series following 6 sets by 5 reps, with 120 seconds of rest between sets for each exercise.
214605459|NCT07130227|OTHER|Session 1: Preparatory Session|\*Meeting the patients \*Introducing the content of mindfulness-based stress reduction training \*Emphasizing the importance of regular and timely attendance at training \*Determining training dates \*Sharing individuals' experiences and expectations
214605460|NCT07130227|OTHER|Session 2: Mindfulness|\*What is mindfulness? \*Being aware of daily activities. \*Raisin meditation.
214605461|NCT07130227|OTHER|Session 3: Our Perspectives on Ourselves and the World|\*Breathing meditation. \*Habit Breaker: Watching the Sky.
214605462|NCT07130227|OTHER|Session 4: Body Scan *Body scan meditation.|\*Ten-finger gratitude practice. \*Habit Breaker: Spending some time in nature.
214605463|NCT07130227|OTHER|Session 5: Recognizing Schizophrenia|\*What is schizophrenia? \*What are its symptoms? \*What does treatment involve?
214605464|NCT07130227|OTHER|Session 6: Mindful Movement|\*Mindfulness movement meditation practice \*
214605465|NCT07130227|OTHER|Session 7: Mindful Breathing|\*Breathing meditation \*
214605466|NCT07130227|OTHER|Session 8: Treatment Evaluation|\*The importance of medication \*Things to consider when using medication \*Side effects of medication \*What is a flare-up in schizophrenia? \*What are the precursor symptoms?
214605467|NCT07130227|OTHER|Session 9: Mindful Thinking|\*Sounds and thoughts meditation \*Cinema activity.
214605468|NCT07130227|OTHER|Session 10: Coping with Anger|\*What is anger? \*What are its symptoms? \*What are the coping methods?
214605469|NCT07130227|OTHER|Session 11: Coping with Difficult Emotions|\*Facing Difficulties meditation \*
214712821|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual patient|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Virtual Patients:~   CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The trajectory of mandibular movement was recorded by an electronic facebow.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The therapeutic position was determined based on: Optimal mean joint space measurements, physiological condylar position and optimal trajectory of mandibular movement."
214712822|NCT07090369|DRUG|Olaparib (300 mg BID)|oral tablet
214712823|NCT07090369|DRUG|Pembrolizumab|IV infusion
214712824|NCT07090369|RADIATION|177Lu-PSMA-I&T|PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen. PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen
214712825|NCT07090798|DIAGNOSTIC_TEST|Static Head posture|After the participant sit down and put on the VR glasses, the VR will detect how many degrees the head position has displaced from the neutral position (X= 0, Y = 0, Z = 0). The x, y and z describe the head alignment, and in the table (3.3), they explain the 3D axis (X, Y, Z). Also in fig 3.3 the participant's head is in X=5.027058 Y=2.466827 Z=2.93206, which explains the degree of deviation from the neutral position.
214712826|NCT07090798|DIAGNOSTIC_TEST|"Angular distance ROM"|"Cervical range of motion assessment is achieved through virtual reality. After detecting the static head posture, Participants will be asked to flex their necks as far as possible toward their chins and anterior chests. Then elevate the head to the neutral and extend the neck to the most tolerable range. Following that, he/she performs maximal neck side-bending in both directions along the coronal plane. Lastly, each participant is required to return the neck to an upright position for the examination of the maximum angle of neck rotation by turning the chin toward the right and then left shoulders without shrugging the shoulders. All of the tests will be repeated three times, and the averaged values of neck movement in each direction will be taken for analysis"
214605470|NCT07130227|OTHER|Session 12: Mindful Communication|\*Communication \& mindful communication \*The importance of communication skills \*Fundamentals of communication, self-language practice \*Ways to prevent communication accidents
214605471|NCT07130227|OTHER|Session 13: Different Connections|\*Breathing meditation. \*Habit Breaker: Thought and Emotional Play.
214605472|NCT07130227|OTHER|Session 14: The Joy of Small Things|\*Treasure of Pleasure Meditation \*Habit Breaker: Letter to Self.
214712827|NCT07090915|OTHER|nature sound|Modern audio technology is used to create a 3D natural atmosphere.
214605473|NCT07130227|OTHER|Session 15: Dwelling on the Past or Living in the Present?|\*Friendship-Building Meditation \*Habit Breaker: Random Acts of Kindness.
214712828|NCT07090421|DIETARY_SUPPLEMENT|Cellulose Powder|Participants consumed an inert cellulose powder dissolved in water, containing no active caffeine. The placebo was ingested orally 60 minutes prior to the rowing performance test. This condition served as the control and was administered once per session in a randomized, double-blind, crossover design.
214712829|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 3 mg/kg Oral Powder|Participants consumed caffeine in powder form at a dose of 3 milligrams per kilogram of body weight. The powder was dissolved in water and ingested orally approximately 60 minutes before the start of the 2000-meter rowing ergometer performance test. The intervention was administered once per session in a randomized, double-blind, crossover design.
214712830|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 6 mg/kg Oral Powder|Participants ingested caffeine in powder form, dissolved in water, at a dose of 6 milligrams per kilogram of body mass. The solution was consumed orally 60 minutes prior to the 2000-meter rowing performance test. This intervention was administered once per session as part of a randomized, double-blind, crossover design.
214712831|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 9 mg/kg Oral Powder|A powdered caffeine dose of 9 milligrams per kilogram was dissolved in water and consumed orally by participants 60 minutes before a 2000-meter rowing ergometer trial. The intervention was administered once per session under a randomized, double-blind, crossover design.
214712832|NCT07091331|PROCEDURE|Personalized 3D-printed pediatric ceromer crown|After primary molar crown preparation, digital impression using intraoral scanner (i700, Medit, Seoul, South Korea), crown will be designed with CAD software (CliniCAD, medit, South Korea) and fabricated using a 3D printer, (Sonic mini 4k, Phrozen, Taipei, Taiwan). Crown will be cemented by passive seating using a self-adhesive dual cure cement (Beauticem, shofu, San Marcos, CA, USA)
214605474|NCT07130227|OTHER|Session 16: Evaluation|\*Reinforcing What Has Been Learned. \*Evaluating the Program. \*Obtaining Feedback.
214605475|NCT07130227|OTHER|Session 1: Group 2, Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
214605476|NCT07130227|OTHER|Session 2: Group 2, Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
214605477|NCT07130227|OTHER|Session 3: Group 2, Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
214605478|NCT07130227|OTHER|Session 4: Group 2, What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
214605479|NCT07130227|OTHER|Session 5: Group 2, Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
214605480|NCT07130227|OTHER|Session 6: Group 2, What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
214605481|NCT07130227|OTHER|Session 7: Group 2, Relaxation|Practicing the relaxation CD with patients
214605482|NCT07130227|OTHER|Session 8: Group 2, Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
214605483|NCT07128927|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|Web-based, self-administered, and interactive cognitive behavioral therapy for insomnia
214605484|NCT07128927|BEHAVIORAL|Patient education|Website that describes insomnia, including factors that may increase or decrease insomnia symptoms, and provides information about addressing insomnia symptoms.
214605485|NCT07130292|BEHAVIORAL|Abdominal Muscle Strengthening Exercises with Stabilizer Pressure Biofeedback|A supervised exercise program designed to strengthen abdominal and lumbar muscles, incorporating the use of a stabilizer pressure biofeedback device to enhance activation of deep stabilizing muscles such as the transversus abdominis. The program is delivered three times per week for 6 weeks (excluding menstruation weeks) and includes mobility, stretching, and strengthening exercises.
214605486|NCT07130994|DEVICE|Mitral Valve Replacement|Implant of SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation
214605487|NCT07129291|COMBINATION_PRODUCT|Experimental: Dual-Language Dysarthria Self-Assessment and Management Software (D-SAMS)|D-SAMS is a bilingual (Urdu and English) digital tool designed for adult dysarthria patients. It enables users to assess their speech through interactive tasks (e.g., repetition, reading, and pronunciation exercises), receive feedback, and track progress over time. The software includes audio-visual prompts, self-rating scales, and progress charts, and is tailored to accommodate varying levels of dysarthria severity. It supports independent practice and helps speech-language pathologists monitor patients remotely
214605488|NCT07130162|DIAGNOSTIC_TEST|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
214605489|NCT07129889|DRUG|gradual withdrawal of medication|The dose was reduced by one day each month, ultimately reducing atropine treatment from seven days per week to complete withdrawal within six months, with a six-month follow-up.
214605490|NCT07129889|PROCEDURE|Auricular acupressure|First, treat the ear acupoint on one side, then leave the tape in place for 5 days. On the 6th day, remove the tape, rest for 2 days, and on the 8th day, apply new tape to the other side of the ear. Changing the tape aims to minimize adverse event (AE) that may result from prolonged stimulation on one side. Additionally, participants will be instructed to self-administer vertical pressure on the Wangbuluxing seeds 15-20 times to achieve sensation, with a duration of 4-5 times daily. The treatment process will last for 18 months, with a follow-up at 6 months.
214605491|NCT07129889|PROCEDURE|Sham auricular acupressure|Acupuncturists will use a gradual reduction method with 0.01% atropine eye drops, as used in the control group, and apply skin-colored adhesive tape without Wang Bu Liu Xing seeds to the ear acupoints. During treatment, no massage or acupoint pressure will be applied. The SAA group will follow the same protocol as the AA group for compensatory AA treatment at the end of the study.
214605492|NCT07129629|DRUG|Bedaquiline (B)|Bedaquiline tablets administered orally. Dosing: 400 mg once daily for the first 2 weeks, then 200 mg three times per week for weeks 3-17. Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
214605493|NCT07129629|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally once daily before or after meals throughout the entire treatment period (17 weeks). Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
214605494|NCT07129629|DRUG|Pyrazinamide (PZA)|Pyrazinamide tablets administered orally once daily in the morning during intensive phase (8 weeks). Dosing by weight: 1000 mg for 40.0-49.9 kg, 1500 mg for 50.0-70.9 kg, 2000 mg for ≥75.0 kg. Used in both experimental arms (BZMD and BZMH groups) and control group as part of tuberculosis treatment regimen.
214605495|NCT07129629|DRUG|Delamanid (D)|Delamanid tablets administered orally at 100 mg twice daily (total daily dose 200 mg) throughout the entire treatment period (17 weeks). Used only in the BZMD experimental arm as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
214605496|NCT07129629|DRUG|Isoniazid (H)|Isoniazid tablets administered orally at 300 mg once daily in the morning throughout the entire treatment period. Used in the BZMH experimental arm (17 weeks) and in the standard control group (26 weeks) as part of tuberculosis treatment regimens.
214605497|NCT07129629|DRUG|Rifampicin (R)|Rifampicin tablets administered orally once daily in the morning throughout the entire treatment period (26 weeks). Dosing by weight: 450 mg for 40.0-49.9 kg, 600 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
214605498|NCT07129629|DRUG|Ethambutol (E)|Ethambutol tablets administered orally during the intensive phase (8 weeks). Dosing by weight: 750 mg for 40.0-49.9 kg, 1000 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
214712833|NCT07091331|DEVICE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparation of the tooth, the crown will be filled and cemented with type-1 glass ionomer cement (Ketac Cem easymix, 3M ESPE, Minnesota, USA)
214605499|NCT07128862|OTHER|Heavy-Load Resistance Training with Blood Flow Restriction|"Blood Flow Restriction (BFR) Training (also known as Kaatsu training is an innovative and increasingly popular exercise technique to improve muscle strength and hypertrophy with relatively low loads. Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy."
214605500|NCT07128862|OTHER|Heavy-Load Resistance Training Only|Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy.
214605501|NCT07130214|DRUG|Biodentine|Biodentine is used in the treatment of existing dentin damage thanks to active bio-silicate technology.
214605502|NCT07131046|PROCEDURE|Combination of superficial cervical plexus block and supraorbital block|The combined anaesthesia technique involves the use of general anaesthesia and regional block in the superficial cervical plexus and supraorbital areas, with 6 ml of 0.25% bupivacaine injected into the superficial cervical plexus area and 2 ml into the supraorbital area.
214605503|NCT07131046|PROCEDURE|Scalp block with bupivacaine alone|A combination anaesthesia technique is used that involves general anaesthesia and scalp block. Scalp block using 0.25% bupivacaine in the supraorbital area (2 ml), supratrochlear (2 ml), zygomaticotemporal (2 ml), auriculotemporal (2 ml), major occipital (2 ml) and minor occipital (2 ml).
214605504|NCT07130708|DEVICE|Telesurgery utilizing Microport Medbot Robotic Platform|A robotic surgery for prostate disease via telesurgery, where a highly trained surgeon performs the operation remotely using a secure internet connection.
214605505|NCT07129746|DEVICE|Metallic clip ligation of the appendicular stump|The group A patients will be having the appendicular stump ligated using the metallic clip, and assessed in terms of length of surgery and associated intra operative complications.
214605506|NCT07129746|DEVICE|Suture ligation of appendicular stump|The appendicular stump in the second arm will be ligated using appropriate suture material and assessed in terms of length of surgery and rate of intraoperative complications.
214605507|NCT07130123|PROCEDURE|Suctionning extubation|We will remove the intubation tube with endotracheal suctioning during the extubation procedure and maintain positive end expiratory pressure (PEEP) and pressure support. The PEEP level will be 10 cmH2O and the pressure support 7 cmH2O for 2 minutes prior to extubation. The vacuum level will be the maximum level (standard procedure in the unit), i.e. 450 mmHg. The closed-system suction probe is inserted up to the last mark corresponding to 40cm. The size of our closed system is identical for all patients, i.e. 14 french.
214605508|NCT07130123|PROCEDURE|No suctionning Extubation|In the control group, removal of the intubation tube during the extubation procedure is performed with PEEP maintained, without endotracheal suctioning. The PEEP level will be set at 10 cmH2O and the pressure at 7 cmH2O in the 2 minutes prior to extubation.
214605509|NCT07131033|DRUG|Esketamine|Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
214605510|NCT07131033|DRUG|Magnesium sulfate|Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.
214605511|NCT07131033|DRUG|Esketamine and Magnesium sulfate|Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.
214605512|NCT07131033|DRUG|Saline|Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.
214605513|NCT07129200|OTHER|Hot environment|Hot environment of 35 degrees Celsius
214605514|NCT07129200|OTHER|Thermoneutral environment|Thermoneutral environment of 18 degrees Celsius
214712834|NCT07091487|BEHAVIORAL|Diabetes Homeless Medication Support|There will be 10 one-on-one sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors and psychologiccal wellness to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool matched to the patient's needs/goals and tailored diabetes education as needed.
214712835|NCT07091487|BEHAVIORAL|Enhanced Usual Care/ Education|Trained diabetes wellness coaches will provide approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will use the ask-offer-ask method to review these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
214605515|NCT07128407|BEHAVIORAL|Protection Motivation Theory-Based Radiation Protection Training|A structured educational program designed according to Protection Motivation Theory (PMT). The program targets both threat appraisal (perceived severity and vulnerability) and coping appraisal (response efficacy, self-efficacy, and response cost) processes to improve nurses' knowledge, awareness, motivation, and safety behaviors regarding radiation protection.
214605516|NCT07129239|OTHER|Maintenance|Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response
214605517|NCT07130825|OTHER|8 hours simulated mental workday|During a simulated 8-hour mental work day, subjects will complete a set of cognitive tests (ANAM4, version 4; Vista Life Science, Norman, OK, USA) 8 times (1 session approximately 45 minutes), with a break of approximately 10 minutes after each session.
214605518|NCT07130825|OTHER|Moderate intensity aerobic activity|In one of the conditions, subjects will perform moderate intensity aerobic activity (cycle veloergometer) for 30 min before 8 hours simulated mental workday and after.
214605519|NCT07130825|OTHER|Combined work model|In one of the conditions, subjects will perform cognitive test during 8 hours simulated mental workday applying combined work model (they will work standing and sitting on a balance ball).
214605520|NCT07128563|DEVICE|piriform cortex-DBS|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral piriform cortex.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
214605521|NCT07130630|OTHER|Completion of Vietnamese Pain Self-Efficacy Questionnaire (PSEQ)|Participants completed the Vietnamese version of the Pain Self-Efficacy Questionnaire (PSEQ) to assess self-efficacy beliefs related to pain management.
214605522|NCT05686187|OTHER|AR's platform for gender empowerment|The intervention of the experimental group is to accept the courses of the gender empowerment platform introduced by AR. The preliminary plan is 50-60 minutes each time. The content of the teaching plan course will adopt the course module design. Group content, and among the three module courses, there must be a core module course unit that is the workplace sexual harassment prevention unit
214605523|NCT07128537|PROCEDURE|Scheduled Oropharyngeal Suctioning Every 4 Hours|"The intervention in this study involves scheduled oropharyngeal suctioning every 4 hours, which distinguishes it from other oral care protocols used in clinical practice. In this arm, patients will receive systematic suctioning of the oropharyngeal area using a sterile suction catheter every 4 hours throughout their ICU stay, starting from the first day of mechanical ventilation. This frequent suctioning is designed to remove accumulated secretions that can harbor bacteria, reducing the risk of aspiration into the lungs, which is a major cause of early-onset Ventilator-Associated Pneumonia (VAP).~This intervention is not based on clinical need or visible signs of discomfort (as with traditional on-demand suctioning). Instead, it follows a standardized protocol of proactive, scheduled suctioning. The procedure will be performed by trained ICU staff and will involve suctioning for 10-15 seconds per session, ensuring adequate removal of secretions while minimizing patient discomfort. In"
214605524|NCT07128537|PROCEDURE|Standard Oral Care (Twice-Daily Brushing)|Participants in this group will receive standard oral care as part of ICU routine practice. This includes brushing of teeth, gums, and tongue twice a day to clear accumulated secretions and reduce bacterial growth. Additionally, on-demand suctioning will be performed if clinically indicated (e.g., when visible secretions or discomfort are observed). The control group will not receive the scheduled 4-hourly suctioning intervention, serving as a comparison to evaluate the effectiveness of regular suctioning in preventing VAP.
214605525|NCT06936722|OTHER|ELDOA + Conventional PT|"ELDOA, the protocol consists of 4 positions. Each position is maintained for 1 min with constant correction of posture throughout with 2 to 4 min rest within each position. The Exercise was performed in 10 to 25 mins. 4 positions of ELDOA are Decoarctation of C0/C1/C2, Decoarctation of C4/C5, Decoarctation of C5/C6, Decoarctation of C6/C7. All positions are attained in lying.~Hot pack 2. isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold."
214605526|NCT06936722|OTHER|McKenzie Protocol + Conventional PT|Extension Dysfunction Retraction Retraction with patient overpressure Retraction with therapist overpressure Retraction with extension Lateral Flexion Dysfunction Lateral flexion: Lateral flexion with patient overpressure Lateral flexion therapist overpressure Rotation Dysfunction Rotation Rotation with patient overpressure Hot pack, isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold Rotation with therapist overpressure
214605527|NCT06789185|DRUG|0.1mg/kg esketamine|Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery
214605528|NCT06789185|DRUG|0.2mg/kg esketamine|Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery
214605529|NCT06789185|DRUG|0.1ml/kg normal saline|Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery
214605530|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
214605531|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
214605532|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
214605533|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
214605534|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
214605535|NCT06964555|DRUG|Intravenous Ketamine Infusions|Ketamine group received ketamine at 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery.
214605536|NCT06964555|DRUG|Intravenous lignocaine|IV Lignocaine was given at the rate of 1 mg/kg/hr.
214605537|NCT02688673|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
214605538|NCT01277770|DRUG|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
214605539|NCT01277770|OTHER|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
214605540|NCT01277770|DRUG|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
214605541|NCT00893126|PROCEDURE|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
214605542|NCT02952391|OTHER|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol
214605543|NCT00177138|DRUG|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
214605544|NCT00177138|DRUG|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)
214712836|NCT07092306|DRUG|Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)|（NALIRI-VT，Nanoliposomal Irinotecan，Vincristine，Temozolomide）， Nanoliposomal Irinotecan：35 mg/m2/d，iv，D1，8，15， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
214712837|NCT07092306|DRUG|Irinotecan Combined with Temozolomide and Vincristine (VIT)|（VIT，Vincristine，Irinotecan，Temozolomide） Irinotecan：50 mg/m2/d，iv，D1-5， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
214605545|NCT06261086|DIAGNOSTIC_TEST|evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)|2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
214605546|NCT03746951|DRUG|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
214605547|NCT03146468|DRUG|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
214605548|NCT02901873|DEVICE|Electrical Impedance Spectroscopy|
214605549|NCT00182182|BEHAVIORAL|Primary care based disease management strategy|
214712838|NCT07091006|DRUG|VAH|For R/R AML patients, VAH bridging to conditioning regimen for allo-HCT.
214605550|NCT02017041|DEVICE|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
214712839|NCT07090824|DRUG|Diluted Humalog U-200 Insulin|Commercially available U-200 Humalog (insulin lispro) diluted 1:1 with a dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
214712840|NCT07090824|DRUG|Diluted U-500 Humulin Insulin|Commercially available U-500 Humulin (regular insulin) diluted 1:4 with dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
214712841|NCT07090824|DRUG|Lyumjev U-100 Insulin|Commercially available U-100 Lyumjev (insulin lispro-aabc) administered unmodified as comparator. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
214605551|NCT02017041|DEVICE|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
214605552|NCT03136419|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
214605553|NCT03136419|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
214605554|NCT03765775|BIOLOGICAL|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
214605555|NCT03765775|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
214605556|NCT04283266|DIETARY_SUPPLEMENT|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
214605557|NCT04283266|DIETARY_SUPPLEMENT|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
214605558|NCT06274008|DRUG|Exparel|Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
214605559|NCT00638560|DIETARY_SUPPLEMENT|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
214605560|NCT00638560|DIETARY_SUPPLEMENT|Antioxidant treatment|no treatment
214605561|NCT01194453|DRUG|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
214605562|NCT01194453|DRUG|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
214605563|NCT03452293|DEVICE|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
214605564|NCT01877863|OTHER|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
214605565|NCT04035850|DRUG|Vortioxetine Tablets|Strength 5-20 mg
214605566|NCT02567539|RADIATION|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
214605567|NCT02567539|DRUG|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
214712842|NCT07090824|DIETARY_SUPPLEMENT|Boost Mixed Meal Test|Standardized mixed meal (Boost drink) administered at 8.0 mL/kg body weight (17.3 g carbohydrates per 100 mL) consumed immediately before insulin injection at each visit.
214712843|NCT07090356|OTHER|Instrument-Assisted Soft Tissue Mobilization|IASTM therapy will be provided to participants in whom a specialized instrument will be used to apply controlled pressure over the piriformis muscle as well as surrounding soft tissues.
214712844|NCT07090356|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|PNF stretching (contract relax; hold relax) will be implemented to stretch participants' muscles as flexibly and with as much control as possible.
214712845|NCT07092098|COMBINATION_PRODUCT|tDCS combined with resistance training|Transcranial direct current stimulation combined with resistance training
214712846|NCT07092098|BEHAVIORAL|Resistance training|low-limb resistance training
214712847|NCT07092098|DEVICE|tDCS|Transcranial direct current stimulation
214712848|NCT07092098|DEVICE|sham tDCS|Sham transcranial direct current stimulation
214605568|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
214605569|NCT00594516|DRUG|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
214605570|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
214605571|NCT01641211|BEHAVIORAL|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
214605572|NCT01641211|OTHER|Nutrition video|Children in this group will watch a 2-minute nutrition video.
214605573|NCT04540549|BEHAVIORAL|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
214605574|NCT03339869|OTHER|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
214712849|NCT07089979|DEVICE|Glunovo CGM device|Group 1 (Subjects that will use Glunovo CGM device) will be compared to Group 2 (subject that will use their glucometer)
214712850|NCT07089979|DEVICE|BG-meter|BG-meter
214712851|NCT07091786|DEVICE|Implant supported prosthesis|implant supported full arch prosthesis
214712852|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
214712853|NCT02293902|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214605575|NCT00088907|DRUG|docetaxel|Given IV
214605576|NCT00088907|OTHER|placebo|Given orally
214605577|NCT00088907|DRUG|gefitinib|Given orally
214605578|NCT04946825|DRUG|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
214605579|NCT04946825|DRUG|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
214605580|NCT04946825|BEHAVIORAL|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
214605581|NCT04946825|BEHAVIORAL|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
214605582|NCT05935124|DIAGNOSTIC_TEST|WLE first, then B-NBI|
214605583|NCT05747508|COMBINATION_PRODUCT|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
214605584|NCT05747508|COMBINATION_PRODUCT|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
214605585|NCT05747508|COMBINATION_PRODUCT|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
214605586|NCT03426787|BEHAVIORAL|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
214605587|NCT05060263|DRUG|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
214605588|NCT00105404|DRUG|Triamcinolone Acetonide|
214605589|NCT02217436|DEVICE|iPad|iPad with age-appropriate applications, videos, and music
214605590|NCT02217436|OTHER|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
214605591|NCT05327374|DIAGNOSTIC_TEST|calculation of the inferior vena cava collapsibility index|the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure
214605592|NCT00900354|GENETIC|molecular genetic technique|
214605593|NCT00900354|OTHER|mass spectrometry|
214605594|NCT00900354|OTHER|pharmacological study|
214605595|NCT04641299|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
214605596|NCT04641299|DRUG|Placebo|Placebo solution
214605597|NCT05510765|BEHAVIORAL|Transportation service|Improved transportation assets applied to all aspects of subjects life
214605598|NCT00830245|DRUG|Erlotinib|Erlotinib 150mg/day
214605599|NCT05195944|DRUG|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
214605600|NCT05195944|DRUG|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
214605601|NCT04807699|OTHER|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
214605602|NCT04672564|DRUG|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
214605603|NCT04672564|DRUG|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
214605604|NCT04271007|DRUG|Mometasone Furoate|mometasone furoate
214605605|NCT04650282|COMBINATION_PRODUCT|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
214605606|NCT04650282|COMBINATION_PRODUCT|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
214605607|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4|Testmeal with free FeSO4
214605608|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
214605609|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
214605610|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
214605611|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
214605612|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
214605613|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
214605614|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
214605615|NCT03332602|DIETARY_SUPPLEMENT|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
214605616|NCT03040440|DEVICE|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
214605617|NCT03040440|DEVICE|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
214605618|NCT04701177|DIAGNOSTIC_TEST|AltoidaML|Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
214712854|NCT02293902|OTHER|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214712855|NCT02293902|DRUG|Methotrexate|Dispensed according to local practice.
214712856|NCT02293902|DRUG|Folic acid|Dispensed according to local practice.
214605619|NCT04198506|OTHER|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.
214605620|NCT04198506|OTHER|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
214605621|NCT01016964|DEVICE|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
214605622|NCT01016964|DEVICE|Sham Device|Sham Device
214605623|NCT06281769|DIAGNOSTIC_TEST|3D multi-parametric ultrasound targeted biopsy pathway using PcaVision|The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.
214605624|NCT06281769|DIAGNOSTIC_TEST|MRI targeted biopsy pathway|MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
214605625|NCT00516620|BEHAVIORAL|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
214605626|NCT00516620|BEHAVIORAL|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
214712857|NCT00225290|DRUG|Thalidomide(Thado)|
214712858|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
214712859|NCT05173961|OTHER|Survey Administration|Complete survey
214712860|NCT03120637|DRUG|Methylene Blue|
214605627|NCT00516620|BEHAVIORAL|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214605628|NCT00516620|BEHAVIORAL|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214605629|NCT00516620|BEHAVIORAL|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214605630|NCT00516620|BEHAVIORAL|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214712861|NCT03968341|OTHER|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
214712862|NCT00472355|DRUG|apomorphine|
214712863|NCT00330525|DRUG|sibutramine|
214605631|NCT00516620|BEHAVIORAL|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214605632|NCT00516620|BEHAVIORAL|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
214605633|NCT00003108|DRUG|bryostatin 1|
214605634|NCT00003108|DRUG|cisplatin|
214605635|NCT05737134|OTHER|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
214712864|NCT02947022|DRUG|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
214712865|NCT02947022|DRUG|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
214712866|NCT06948760|DEVICE|Control-IQ insulin pump with Lyumjev insulin|Control-IQ insulin pump with insulin using settings determined by experimental conversion factor
214605636|NCT04624880|DEVICE|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
214605637|NCT02249754|BEHAVIORAL|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
214605638|NCT02249754|BEHAVIORAL|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
214712867|NCT06948760|DEVICE|Control-IQ insulin pump with Humalog or Novolog|Control-IQ insulin pump with Humalog or Novolog using optimized insulin settings
214712868|NCT03893773|DEVICE|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
214712869|NCT03129204|BEHAVIORAL|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
214712870|NCT06954428|COMBINATION_PRODUCT|NT-301 1 mg|unidose of 1 mg apomorphine through nasal spray
214712871|NCT06954428|COMBINATION_PRODUCT|NT-301 2 mg|unidose of 2 mg apomorphine through nasal spray
214605639|NCT04147026|DEVICE|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
214605640|NCT04147026|OTHER|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
214605641|NCT00220558|DEVICE|Coronary placement of bare metal stent vs. drug eluting stent|
214605642|NCT02833480|DRUG|Fluticasone group|
214605643|NCT02833480|DRUG|Budesonide group|
214605644|NCT02833480|DRUG|Formoterol group|
214605645|NCT01096212|DRUG|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
214605646|NCT01096212|DRUG|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
214605647|NCT04603365|DRUG|Pamiparib|Given PO
214605648|NCT04603365|DRUG|Temozolomide|Given PO
214605649|NCT02597803|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
214605650|NCT02597803|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
214605651|NCT06165822|DRUG|TQB3909 tablets|TQB3909 100mg/tablet.
214605652|NCT06165822|DRUG|Itraconazole capsule|Itraconazole capsule is a strong inhibitor of CYP3A4.
214605653|NCT06165822|DRUG|Rifampicin capsule|Rifampicin capsule is a strong inducer of CYP3A4.
214712872|NCT06954428|COMBINATION_PRODUCT|Placebo 1 mg|Matching Placebo to NT-301 1 mg
214712873|NCT06954428|COMBINATION_PRODUCT|Placebo 2 mg|Matching Placebo to NT-301 2 mg
214605654|NCT03987724|OTHER|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
214605655|NCT00221650|DRUG|Peginterferon alfa2a|
214605656|NCT00221650|DRUG|Ribavirin|
214605657|NCT04962217|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
214605658|NCT03511547|DEVICE|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.
214605659|NCT03511547|DEVICE|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
214605660|NCT03971994|BEHAVIORAL|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
214712874|NCT06954428|COMBINATION_PRODUCT|Placebo 3 mg|Matching Placebo to NT-301 3 mg
214712875|NCT06954428|COMBINATION_PRODUCT|NT-301 3 mg|unidose apomorphine nasal spray 3 mg
214712876|NCT06954428|COMBINATION_PRODUCT|NT-301 4 mg|unidose apomorphine nasal spray 4 mg
214712877|NCT06954428|COMBINATION_PRODUCT|Placebo 4 mg|Matching placebo to NT-301 4 mg
214712878|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
214712879|NCT06508788|DEVICE|CO2 laser|Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
214712880|NCT02245230|DRUG|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
214712881|NCT02245230|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
214712882|NCT02245230|DRUG|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
214605661|NCT02809742|DRUG|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
214605662|NCT01650285|DRUG|Cabazitaxel|"Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2"
214712883|NCT03424213|OTHER|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
214712884|NCT01830244|DRUG|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
214712885|NCT04481880|DIAGNOSTIC_TEST|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
214605663|NCT03956316|DEVICE|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
214605664|NCT02608060|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
214605665|NCT00900523|GENETIC|protein expression analysis|protein expression analysis
214605666|NCT00900523|OTHER|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
214605667|NCT01145716|PROCEDURE|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
214605668|NCT00659529|DRUG|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
214605669|NCT03719638|DEVICE|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
214605670|NCT03719638|OTHER|simulated difficult airway|extension of head will be limited by using collar.
214605671|NCT03719638|DEVICE|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
214712886|NCT01482572|PROCEDURE|biopsy|percutaneous lung biopsy and aspiration
214712887|NCT04983810|DRUG|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
214712888|NCT02558283|DEVICE|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
214712889|NCT02558283|DEVICE|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
214712890|NCT06527261|OTHER|Real-time electronic data input into REDCap|"During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation."
214712891|NCT00198094|DRUG|Sertraline and Alprazolam XR|
214712892|NCT06121362|DIETARY_SUPPLEMENT|Protocatechuic Acid or PCA|PCA 1000 mg capsule
214712893|NCT06121362|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
214712894|NCT03970018|OTHER|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
214712895|NCT03948113|OTHER|Dialysis|
214605672|NCT03222739|DEVICE|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
214605673|NCT05623397|OTHER|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
214712896|NCT05823610|DIAGNOSTIC_TEST|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
214712897|NCT04985240|DIETARY_SUPPLEMENT|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
214712898|NCT04985240|DIETARY_SUPPLEMENT|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
214605674|NCT04047160|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
214605675|NCT05803408|OTHER|gluten-free oats|Early vs late introduction of gluten free oats
214605676|NCT01794533|DRUG|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
214605677|NCT01794533|DRUG|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
214712899|NCT03439111|DIETARY_SUPPLEMENT|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
214712900|NCT05128695|OTHER|there is no intervention; the study is observational|there is no intervention; the study is observational
214712901|NCT00800475|DRUG|Gemfibrozil Tablets|
214712902|NCT03105661|DRUG|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
214712903|NCT03105661|DRUG|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
214712904|NCT03105661|DRUG|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
214712905|NCT05137275|BIOLOGICAL|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
214712906|NCT06201169|PROCEDURE|implant placement|All patients received four implants in the lower arch
214712907|NCT05993572|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
214712908|NCT00081328|DRUG|Metformin|capsule, 1000 mg bid
214712909|NCT00081328|DRUG|Rosiglitazone|capsule, 4 mg bid
214605678|NCT06070844|BEHAVIORAL|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
214605679|NCT02053909|DRUG|Aspirin|
214605680|NCT02053909|DRUG|Ticagrelor|
214605681|NCT02925572|OTHER|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
214605682|NCT00558155|DRUG|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
214605683|NCT00558155|DRUG|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
214605684|NCT00558155|DRUG|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
214712910|NCT00081328|BEHAVIORAL|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
214712911|NCT04671342|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
214605685|NCT00558155|DRUG|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
214605686|NCT00907257|DRUG|benzoyl peroxide wash|5% benzoyl peroxide wash
214605687|NCT00907257|DRUG|Tretinoin gel|0.04% tretinoin gel
214605688|NCT05531487|OTHER|Questionnaire Survey|All students received a 'QR code' link to the survey.
214605689|NCT05102851|DIAGNOSTIC_TEST|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
214605690|NCT05491252|BEHAVIORAL|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
214605691|NCT00283049|DRUG|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
214605692|NCT00283049|DRUG|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
214605693|NCT02228187|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
214605694|NCT06833255|OTHER|Interview|Ancillary studies
214605695|NCT06833255|OTHER|Questionnaire Administration|Ancillary studies
214605696|NCT06833255|OTHER|Support|Attend 1:1 peer mentoring sessions
214605697|NCT06833255|PROCEDURE|Support Group Therapy|Attend survivorship group support sessions
214605698|NCT00194181|DRUG|TPA Infusion|
214605699|NCT03269851|RADIATION|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
214605700|NCT05594316|DRUG|Trichloroacetic acid|5\. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
214605701|NCT02041208|PROCEDURE|kidney transplantation|kidney transplantation
214605702|NCT00960908|DEVICE|Endeavor Resolute stents|2nd generation ZES
214712912|NCT05982145|OTHER|Individual interviews|Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
214712913|NCT05982145|OTHER|Focus groups|Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
214605703|NCT00960908|DEVICE|Endeavor Sprint stent|1st generation ZES
214605704|NCT02507622|OTHER|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
214605705|NCT02507622|OTHER|Parabolic flight|
214605706|NCT04863079|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
214605707|NCT01782573|DRUG|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
214605708|NCT01782573|DRUG|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
214605709|NCT00250653|DRUG|Saredutant succinate (SR48968C)|
214605710|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
214605711|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
214605712|NCT00295633|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
214605713|NCT00295633|DRUG|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
214605714|NCT00295633|DRUG|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
214605715|NCT00295633|DRUG|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
214605716|NCT01048749|OTHER|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
214605717|NCT01048749|OTHER|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
214605718|NCT00234936|DRUG|Adalimumab|
214605719|NCT00234936|DRUG|Methotrexate|
214605720|NCT04467944|OTHER|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
214605721|NCT00763971|DRUG|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
214605722|NCT00763971|DRUG|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
214605723|NCT00763971|DRUG|Placebo|Placebo capsule once per day (Overencapsulated)
214605724|NCT03881228|BEHAVIORAL|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
214605725|NCT04021199|GENETIC|Mody test|"Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test."
214605726|NCT05761054|RADIATION|RT|"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
214605727|NCT01923142|BIOLOGICAL|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
214605728|NCT01923142|BIOLOGICAL|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
214605729|NCT05525728|OTHER|Neurosensory|Physiological and neurophysiological investigations
214605730|NCT00853398|PROCEDURE|surgical technique|
214605731|NCT06161662|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
214605732|NCT06161662|OTHER|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
214605733|NCT03653104|BEHAVIORAL|Melodica Intervention|The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
214605734|NCT03653104|BEHAVIORAL|Pulmonary Health Education|A single session including education about COPD and related health topics.
214605735|NCT00757536|PROCEDURE|Encircling Band|ppVE and encircling band
214712914|NCT05982145|OTHER|Questionary and measures|To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
214712915|NCT06362447|DRUG|Gentamicin Injectable Solution|Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
214712916|NCT05304000|BEHAVIORAL|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
214712917|NCT05304000|BEHAVIORAL|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
214712918|NCT05304000|BEHAVIORAL|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
214605736|NCT00757536|PROCEDURE|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
214605737|NCT01997762|DIETARY_SUPPLEMENT|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
214605738|NCT01997762|DIETARY_SUPPLEMENT|Placebo|
214605739|NCT05155787|DEVICE|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
214605740|NCT05155787|DEVICE|Shame neurofeedback|shame neurofeedback
214605741|NCT04322006|DRUG|TJ004309|Antibody to CD73
214605742|NCT04322006|DRUG|Toripalimab|Humanized monoclonal antibody to PD-1
214605743|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
214605744|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
214712919|NCT05304000|BEHAVIORAL|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
214712920|NCT03491930|DEVICE|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
214712921|NCT03491930|BEHAVIORAL|Telephone Coaching|Weekly Telephone Coaching
214605745|NCT05977296|DEVICE|CPAP|To use CPAP
214605746|NCT01800357|DRUG|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
214605747|NCT01800357|DRUG|placebo|infusion of plabcebo once a day and for 14 days
214605748|NCT01800357|DRUG|aspirin|infusion of aspirin (100mg) once a day for days
214605749|NCT04439071|DRUG|PTC299|Oral tablets
214605750|NCT04439071|OTHER|SOC|As defined per local written policies or guidelines.
214605751|NCT04439071|DRUG|Placebo|Oral tablets
214712922|NCT03491930|BEHAVIORAL|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)"
214712923|NCT00901381|DRUG|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
214712924|NCT05628155|OTHER|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
214605752|NCT06038825|DEVICE|topical vibration|topical vibration (Aprilla brand, giving 6000 vibrations per minute) is a device for pain relief during injection of local anesthetic.
214605753|NCT06447818|OTHER|Change in airway markers|Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
214605754|NCT06228651|DEVICE|Tourniquet|
214605755|NCT06228651|OTHER|The leg without the tourniquet|
214605756|NCT02827123|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
214605757|NCT02827123|DRUG|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
214605758|NCT06386640|OTHER|Intervention Development|Phase I: Research to inform intervention design, Phase II: Co-design and production of intervention with relevant stakeholders, Phase IIa: Physical activity accelerometer data collection and analysis to develop an individualised rehabilitation programme, Phase III: Pilot and refine the intervention across to two NHS sites (University Hospitals of Leicester NHS Trust, Portsmouth Hospitals University NHS Trust).
214605759|NCT01434550|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
214605760|NCT01434550|RADIATION|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~1. Necrosis/apoptosis~2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1\. Aposense-PET imaging"
214605761|NCT00179504|BEHAVIORAL|Relaxation Response|Relaxation training
214605762|NCT02163460|PROCEDURE|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
214605763|NCT02163460|PROCEDURE|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
214605764|NCT02645760|OTHER|Core stabilization exercise|7-weeks of core stabilization exercise
214605765|NCT02645760|OTHER|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
214605766|NCT04032691|DRUG|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
214605767|NCT01062139|DRUG|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
214605768|NCT01062139|DRUG|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
214605769|NCT00143091|DRUG|CP-316,311|
214605770|NCT00143091|DRUG|Placebo|
214605771|NCT00143091|DRUG|Sertraline|
214605772|NCT02514408|PROCEDURE|Catheter Management|Insertion of venous catheter under ultrasound guidance
214605773|NCT02514408|OTHER|Cytology Specimen Collection Procedure|Collection of blood samples
214605774|NCT02514408|OTHER|Laboratory Biomarker Analysis|Correlative studies
214712925|NCT03696940|DRUG|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
214605775|NCT03447938|PROCEDURE|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
214605776|NCT03447938|PROCEDURE|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
214605777|NCT06006325|DEVICE|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
214605778|NCT06006325|DEVICE|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
214605779|NCT02693782|DIETARY_SUPPLEMENT|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
214605780|NCT02693782|DIETARY_SUPPLEMENT|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
214605781|NCT05874713|BIOLOGICAL|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
214605782|NCT05874713|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
214605783|NCT05874713|BIOLOGICAL|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
214712926|NCT03696940|DRUG|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
214605784|NCT05874713|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
214605785|NCT05874713|BIOLOGICAL|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
214605786|NCT02785965|DEVICE|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
214605787|NCT02785965|BEHAVIORAL|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
214605788|NCT00024167|DRUG|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
214605789|NCT00024167|DRUG|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
214605790|NCT00024167|DRUG|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
214605791|NCT00024167|DRUG|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
214605792|NCT00024167|DRUG|Prednisone|5 mg orally 2 x daily, weeks 1-14
214605793|NCT00024167|DRUG|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
214712927|NCT00162526|DRUG|Tocopherol|
214712928|NCT02678637|OTHER|MRI and muscle dynamometer|
214605794|NCT00024167|RADIATION|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
214605795|NCT00024167|DRUG|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
214605796|NCT03691090|DRUG|SHR-1210|SHR-1210 200mg
214605797|NCT03691090|DRUG|Placebo|Placebo
214605798|NCT03691090|DRUG|paclitaxel|paclitaxel 175mg/m2
214605799|NCT03691090|DRUG|cisplatin|cisplatin 75mg/m2
214605800|NCT04095078|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
214605801|NCT03122496|DRUG|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
214605802|NCT03122496|DRUG|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
214712929|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
214712930|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
214712931|NCT05690698|DRUG|Quatiapine|Atypical antipsychotic
214712932|NCT05690698|DRUG|Haloperidol|Antipsychotic
214712933|NCT01934933|DRUG|celebrex|
214712934|NCT01934933|DRUG|Enbrel|
214712935|NCT01934933|DRUG|Enbrel plus Celebrex|
214712936|NCT00028106|DRUG|[131]I-MIBG|
214712937|NCT00028106|DRUG|6-[18F]Fluorodopamine|
214712938|NCT00028106|DRUG|[123]I-MIBG|
214712939|NCT00270413|DRUG|SU11248|sutent 50 mg daily 4w on 2w off
214712940|NCT03518632|BEHAVIORAL|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
214605803|NCT03122496|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
214605804|NCT00038584|DRUG|SCH66336|
214605805|NCT03610399|DRUG|Primaquine|Different total dose and supervision.
214605806|NCT00729781|DEVICE|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
214712941|NCT03518632|OTHER|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
214712942|NCT03351478|DRUG|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
214712943|NCT03351478|DRUG|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
214605807|NCT05942430|PROCEDURE|Autologous costal osteochondral transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Trim the autograft according to the size of the lesion;~5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
214605808|NCT05942430|PROCEDURE|Autologous iliac osteoperiosteal transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
214605809|NCT02764164|DEVICE|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
214605810|NCT04939519|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
214605811|NCT04939519|BEHAVIORAL|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
214605812|NCT05785572|PROCEDURE|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
214605813|NCT05785572|PROCEDURE|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
214605814|NCT00706550|BIOLOGICAL|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
214605815|NCT00706550|BIOLOGICAL|Placebo|Placebo
214605816|NCT05242757|OTHER|Mixed-activated Killer Immune Cells|Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
214712944|NCT03351478|DRUG|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
214712945|NCT03351478|DRUG|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
214712946|NCT04963881|DIAGNOSTIC_TEST|Antibody testing|Blood samples were taken and analyzed for APS antibodies
214712947|NCT02270801|DRUG|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
214712948|NCT04991272|OTHER|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
214712949|NCT03002285|BEHAVIORAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
214712950|NCT03002285|BEHAVIORAL|Control group|Group with typical development that performed the Fitts law in a computer task
214712951|NCT02425436|DRUG|Ginkgo Biloba Extract|
214712952|NCT02425436|OTHER|Placebo|
214712953|NCT01174836|OTHER|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
214712954|NCT05027113|BEHAVIORAL|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
214605817|NCT03599037|OTHER|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
214605818|NCT00120640|DRUG|17 hydroxyprogesterone caproate intramuscular injections|
214605819|NCT00806676|DRUG|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
214605820|NCT06313450|RADIATION|de-escalated radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.
214605821|NCT06313450|RADIATION|conventional radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.
214605822|NCT02676388|PROCEDURE|Freeze-dried, Capsulized FMT|
214605823|NCT02676388|PROCEDURE|Fresh FMT|
214605824|NCT02924298|BEHAVIORAL|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
214605825|NCT05514704|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
214605826|NCT05514704|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
214712955|NCT02583997|PROCEDURE|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
214712956|NCT02583997|PROCEDURE|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
214712957|NCT05531513|BEHAVIORAL|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
214712958|NCT05531513|BEHAVIORAL|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
214712959|NCT00116324|DRUG|Montelukast|
214712960|NCT02836483|DRUG|LCB01-0371 800mg, QD|Oral administration
214712961|NCT02836483|DRUG|LCB01-0371 400mg, BID|Oral administration
214712962|NCT02836483|DRUG|LCB01-0371 800mg, BID|Oral administration
214712963|NCT02836483|DRUG|Tubes 3~5Tablet, QD|Oral administration
214712964|NCT02836483|DRUG|Zyvox 600mg, BID|Oral administration
214712965|NCT02836483|DRUG|LCB01-0371 1200mg, QD|Oral administration
214605827|NCT01573078|BEHAVIORAL|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
214605828|NCT04608760|DRUG|Meksibel|2 ml solution
214605829|NCT03702751|PROCEDURE|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
214605830|NCT03702751|PROCEDURE|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
214605831|NCT03406143|PROCEDURE|CGF injection|CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
214712966|NCT05420415|OTHER|CSTME|Tumor microenvironment collagen signature
214712967|NCT00510484|DRUG|Pancrelipase Delayed Release|24000 unit Capsule
214712968|NCT00510484|DRUG|Placebo Comparator|Placebo
214712969|NCT05953207|OTHER|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
214712970|NCT05953207|OTHER|Standard Of Care|Sleep hygiene and safety education session
214605832|NCT03406143|PROCEDURE|Control|Saline will be injected into expanded skin
214605833|NCT02594423|DEVICE|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
214605834|NCT02594423|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
214712971|NCT00109005|DRUG|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
214605835|NCT06474910|OTHER|Connective tissue massage|In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
214605836|NCT06474910|OTHER|Exercise|Only exercise program will be applied to 15 patients in this group. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
214605837|NCT02933632|OTHER|Physical Therapy-SAP|"* Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date."
214712972|NCT05320328|DEVICE|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
214712973|NCT00192595|DRUG|Tenofovir|
214712974|NCT00192595|DRUG|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
214712975|NCT00762268|DRUG|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
214712976|NCT00762268|DRUG|Placebo|
214712977|NCT00978224|DIETARY_SUPPLEMENT|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
214712978|NCT00978224|DIETARY_SUPPLEMENT|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
214712979|NCT00961441|DRUG|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
214712980|NCT02533401|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
214712981|NCT02533401|DRUG|Fludarabine|Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
214712982|NCT02533401|DRUG|Rituximab|Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
214712983|NCT00799760|DRUG|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
214712984|NCT00799760|DRUG|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
214712985|NCT00799760|DRUG|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
214712986|NCT04570514|PROCEDURE|PCI|percutaneous coronary intervention (PCI)
214712987|NCT02925559|DRUG|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
214712988|NCT02925559|DRUG|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
214712989|NCT00154193|DRUG|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
214605838|NCT02933632|OTHER|Physical Therapy-ARP|"* Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach."
214605839|NCT04758299|OTHER|decision science-based design|decision science-based design explaining actions to take for a negative or positive COVID-19 test
214605840|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
214605841|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
214605842|NCT02131441|PROCEDURE|laparoscopic hepatectomy|
214605843|NCT02131441|PROCEDURE|open liver resection|
214605844|NCT01534013|DEVICE|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
214605845|NCT01534013|DEVICE|Open loop|glucose sensor and pump
214712990|NCT01767181|OTHER|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
214712991|NCT01767181|OTHER|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
214712992|NCT01752075|DRUG|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
214712993|NCT03791216|OTHER|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
214605846|NCT00864890|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
214605847|NCT00864890|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
214605848|NCT03579082|DRUG|Decitabine|Given ivgtt
214712994|NCT00703469|DRUG|MDX1106-02|Single dose
214712995|NCT00703469|DRUG|Placebo|Placebo single dose
214712996|NCT02996955|BEHAVIORAL|social support|behaviour change intervention
214712997|NCT02996955|BEHAVIORAL|treatment of illness perceptions|educational interview
214712998|NCT02996955|DEVICE|Activ8|wearing a move monitor
214712999|NCT02996955|OTHER|activity advice|walking or cycling 5 days a week during at least half an hour
214713000|NCT05200429|DRUG|Trikafta|Highly Effective CFTR Modulator Therapy
214713001|NCT04591145|OTHER|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
214713002|NCT02204033|DRUG|99mTc - labelled hMAb BIWA 4|
214713003|NCT02204033|DRUG|186 Re - labelled hMAb BIWA 4|
214713004|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - low dose|
214713005|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - medium dose|
214713006|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - high dose|
214713007|NCT05655858|OTHER|Management of allergic rhinitis|Collection of patient data in real-life
214713008|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
214713009|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
214713010|NCT00973622|DEVICE|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
214605849|NCT01186796|DRUG|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
214605850|NCT02459769|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
214605851|NCT00245310|PROCEDURE|Indocyangreen (ICG) clearance|
214605852|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
214605853|NCT03083704|DRUG|Apixaban 5 MG|factor Xa inhibitor
214713011|NCT04814407|DIAGNOSTIC_TEST|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
214605854|NCT03083704|DRUG|Rivaroxaban 20 MG|factor Xa inhibitor
214605855|NCT03083704|DRUG|Enoxaparin sodium|low molecular weight heparin
214605856|NCT03083704|DRUG|Edoxaban 60 MG|factor Xa inhibitor
214605857|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
214605858|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
214605859|NCT03083704|DRUG|Apixaban 10 MG|factor Xa inhibitor
214605860|NCT03083704|DRUG|Rivaroxaban 10 MG|factor Xa inhibitor
214605861|NCT05022394|BIOLOGICAL|Nivolumab|Given IV
214605862|NCT05022394|DRUG|Sapanisertib|Given PO
214605863|NCT05070039|GENETIC|Expression of Cortactin anti body|assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
214605864|NCT01657474|OTHER|Weekly application of EpiFix plus standard of care|
214605865|NCT01657474|OTHER|Biweekly application of EpiFix plus standard of care|
214605866|NCT00314509|DRUG|Ciclesonide/Formoterol Combination|
214605867|NCT02807051|DRUG|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
214605868|NCT02807051|DRUG|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
214605869|NCT02807051|DRUG|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
214605870|NCT05869292|DEVICE|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
214713012|NCT04831567|RADIATION|MIBG-I131|Radiopharmaceutical
214605871|NCT05869292|DEVICE|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
214605872|NCT05829642|BEHAVIORAL|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
214605873|NCT00904293|OTHER|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
214713013|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
214713014|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
214713015|NCT05592041|DRUG|Banaba Leaf Extract|a herbal extract in the form of Bigel
214713016|NCT00352066|DRUG|apricitabine|
214713017|NCT03064347|DIETARY_SUPPLEMENT|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713018|NCT03064347|DIETARY_SUPPLEMENT|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713019|NCT03064347|DIETARY_SUPPLEMENT|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214605874|NCT00904293|OTHER|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
214605875|NCT03214133|OTHER|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
214605876|NCT03214133|OTHER|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
214605877|NCT01287364|DRUG|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
214605878|NCT01287364|DRUG|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
214605879|NCT01958788|BEHAVIORAL|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
214605880|NCT02094833|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
214605881|NCT02094833|BIOLOGICAL|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
214605882|NCT01379573|DRUG|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
214605883|NCT06326892|PROCEDURE|Natural Orifice Specimen Extraction (NOSE)|Low rectal cancer resection with Total Mesorectal Excision (TME) and Natural Orifice Specimen Extraction (NOSE)
214605884|NCT06326892|PROCEDURE|Traditional specimen extraction|Low rectal cancer resection with Total Mesorectal Excision (TME) and specimen extraction through Pfannenstiel incision
214605885|NCT01936909|DRUG|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
214605886|NCT01936909|DRUG|Anakinra (weeks 3-12)|
214605887|NCT01936909|DRUG|Placebo|
214605888|NCT01138579|DRUG|FBTA05|
214605889|NCT00383357|DRUG|zolpidem|
214605890|NCT05019157|OTHER|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
214605891|NCT05019157|OTHER|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
214605892|NCT03670043|DRUG|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
214605893|NCT03670043|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
214605894|NCT04646681|BEHAVIORAL|ConnectCare|increased monitoring between clinical mental health visits
214605895|NCT03808389|OTHER|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
214605896|NCT03808389|OTHER|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
214605897|NCT06439173|BIOLOGICAL|CAR-T cell therapy|Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy at the University Hospital of Salamanca
214605898|NCT02794142|PROCEDURE|renal transplantation|
214605899|NCT02794142|OTHER|No intervention|
214605900|NCT05543278|DRUG|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
214605901|NCT00962390|DRUG|S-equol|10mg S-equol 50mg S-equol, \& 150mg S-equol
214605902|NCT00962390|DRUG|Placebo|Placebo
214605903|NCT00278850|BEHAVIORAL|Educational|three 1 hour long educational seminars
214605904|NCT02914054|DRUG|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
214605905|NCT02914054|DRUG|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
214605906|NCT05506579|OTHER|Exercises for knees, lower back, hip/groin and pelvic floor muscles in an expanded warm up program|Rhythmic gymnastics clubs allocated to the intervention group will be visited by a physiotherapist (the PhD candidate), which will perform thorough teaching of coaches and gymnasts on how to perform the exercises in the expanded warm up program. During the same visit, before commencing PFMT, the gymnasts will have an individual session were a portable 2D ultrasound machine (GE Healthcare -Logiq e R7, GE\>12L-RS - 5-13 MHz Wideband Linear Probe) will be used to teach and assess ability to perform a correct PFM contraction. The probe is placed suprapubically and provides concurrent visible biofeedback of the PFM contraction. Adherence to the intervention will be registered weekly by the coach in a training diary and asked for as an additional question in the monthly OSTRC-H2 sent to the gymnasts. Reminders will be sent by phone to the coaches every week. To assure proper execution and motivation, the PhD candidate will perform one extra visit midterm.
214605907|NCT03889275|BIOLOGICAL|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
214605908|NCT03889275|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
214605909|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
214605910|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
214605911|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
214605912|NCT00152282|DRUG|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
214605913|NCT00744211|DRUG|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
214605914|NCT00744211|DRUG|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
214605915|NCT00744211|OTHER|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
214713020|NCT03064347|DIETARY_SUPPLEMENT|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713021|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713022|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214605916|NCT05057260|OTHER|No drug invervention|No clinical trial
214605917|NCT00000125|DRUG|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
214605918|NCT02959749|DRUG|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
214605919|NCT02959749|DRUG|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
214713023|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713024|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
214713025|NCT00493467|DRUG|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
214605920|NCT03881384|OTHER|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
214605921|NCT01788657|BEHAVIORAL|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
214605922|NCT01788657|BEHAVIORAL|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
214713026|NCT00493467|DRUG|Rituximab|250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
214713027|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
214713028|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
214605923|NCT04969445|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
214605924|NCT05315050|OTHER|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
214605925|NCT05315050|OTHER|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
214713029|NCT03395223|DRUG|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
214605926|NCT00470236|RADIATION|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
214605927|NCT00470236|RADIATION|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
214713030|NCT01236794|BEHAVIORAL|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
214713031|NCT04503863|DRUG|NPC-22|Single administration of middle dose NPC-22
214713032|NCT04503863|DRUG|NPC-22|Single administration of high dose NPC-22
214713033|NCT04503863|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
214713034|NCT03753815|DEVICE|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
214713035|NCT03753815|DEVICE|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
214713036|NCT04446299|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
214713037|NCT02275910|DRUG|E7090|
214605928|NCT00470236|RADIATION|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
214605929|NCT00470236|RADIATION|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
214605930|NCT06094751|BEHAVIORAL|ACT Guide for Insomnia|ACT Guide for Insomnia includes 2 modules. Module 1 will include sleep/insomnia education, ACT skills (acceptance, defusion), and behavioral change. Module 2 will include sleep restriction, sleep hygiene, ACT skills (values, committed action), and behavioral change.
214605931|NCT02488499|BEHAVIORAL|Coping Power|15 sessions of concurrent parent and child group treatment
214605932|NCT02488499|BEHAVIORAL|Individualized Treatment|15 sessions of individualized child and parent treatment
214605933|NCT06317818|OTHER|Mesenchymal Stem Cells|Suspension of mesenchymal stromal cells for intratissular injection
214605934|NCT06317818|OTHER|Comparative placebo|Cell-free cell suspension solution devoid of cells for intratissular injection
214605935|NCT05378997|DRUG|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
214605936|NCT05378997|DRUG|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
214605937|NCT05378997|DRUG|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
214605938|NCT03114865|DRUG|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
214713038|NCT06980350|DRUG|PD-1 Inhibitors|Patients received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.
214605939|NCT03114865|DRUG|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
214605940|NCT03114865|DRUG|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
214713039|NCT00516412|DRUG|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214713040|NCT00516412|GENETIC|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
214713041|NCT01855945|BIOLOGICAL|Swine Influenza|Comparison of different dosages of vaccines
214713042|NCT01148693|DRUG|gentamicin|10mg per 10ml of contrast media
214713043|NCT01148693|DRUG|Placebo|Distilled water
214713044|NCT04105647|BEHAVIORAL|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
214713045|NCT04105647|BEHAVIORAL|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
214713046|NCT03313856|DRUG|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
214713047|NCT03313856|DRUG|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
214713048|NCT04114344|PROCEDURE|TAPP|Trans Abdominal Pre Peritoneal approach
214605941|NCT03114865|DRUG|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
214605942|NCT06419192|OTHER|dietary advice|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
214605943|NCT06419192|OTHER|dietary advice alone|Advise to eat 7 dates a day from 37SA until delivery. The food will not be provided.
214605944|NCT06419192|OTHER|food supplied|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
214605945|NCT04374643|OTHER|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
214605946|NCT02577744|OTHER|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
214605947|NCT02577744|OTHER|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
214605948|NCT01316185|DRUG|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
214605949|NCT05446428|OTHER|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
214605950|NCT00006448|BEHAVIORAL|cognitive therapy|
214605951|NCT00006448|PROCEDURE|Physical Therapy|
214605952|NCT00006448|DRUG|Methadone|
214605953|NCT02179879|OTHER|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
214605954|NCT04338373|COMBINATION_PRODUCT|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
214605955|NCT00324051|DRUG|olanzapine therapy|
214605956|NCT02104154|DEVICE|Samsung LABGEO PT10 Hepatic Panel|
214605957|NCT00510081|DEVICE|Calcium Hydroxylapatite injection|filler injection
214713049|NCT04114344|PROCEDURE|TEP|Total Extra Peritoneal approach
214605958|NCT00888420|OTHER|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
214713050|NCT02219711|DRUG|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
214605959|NCT01657097|DRUG|INCS|
214605960|NCT01657097|DRUG|Placebo|
214605961|NCT02307487|DRUG|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
214605962|NCT02307487|DRUG|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
214605963|NCT02307487|DRUG|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
214605964|NCT02307487|DRUG|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
214605965|NCT02307487|DRUG|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
214605966|NCT02307487|DRUG|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
214605967|NCT00113230|DRUG|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
214605968|NCT00113230|DRUG|Capecitabine|900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
214605969|NCT00113230|RADIATION|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
214605970|NCT00440076|DRUG|Velcade|
214605971|NCT01087099|DRUG|Albendazole|Treatment with albendazole
214605972|NCT02679599|OTHER|B-MOBILE-CARDIAC smartphone application|
214605973|NCT02679599|BEHAVIORAL|Cardiac rehabilitation as usual|
214605974|NCT04373954|OTHER|Forgiveness Therapy|The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.
214605975|NCT04373954|OTHER|Carey Guides|The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
214605976|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
214605977|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Mini PCNL will be performed.
214605978|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
214605979|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
214713051|NCT04099849|DIETARY_SUPPLEMENT|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
214713052|NCT04099849|DIETARY_SUPPLEMENT|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
214605980|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
214605981|NCT02522676|PROCEDURE|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
214605982|NCT00003757|BIOLOGICAL|rituximab|
214605983|NCT04098042|DEVICE|Scaffold|implantation of a Magmaris scaffold
214605984|NCT01439542|RADIATION|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
214605985|NCT01439542|DRUG|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
214605986|NCT04042870|BEHAVIORAL|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
214605987|NCT00112775|DRUG|dasatinib|
214605988|NCT00112775|DRUG|imatinib mesylate|
214605989|NCT00797875|PROCEDURE|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
214605990|NCT00797875|PROCEDURE|passive stretching|passive stretching x 5 repetitions continue 3 days
214605991|NCT04328246|DEVICE|IES System|The IES system is composed of a stimulator and self-adhesive surface gel electrodes.
214605992|NCT04328246|OTHER|Standard of Care Therapy|Standard institutional practices for treating pressure injury.
214605993|NCT05090553|PROCEDURE|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
214605994|NCT05090553|BIOLOGICAL|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
214605995|NCT05090553|GENETIC|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
214605996|NCT05090553|GENETIC|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
214605997|NCT00046085|BEHAVIORAL|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
214605998|NCT00046085|BEHAVIORAL|Customary care|Participants received care as usual.
214605999|NCT00465946|BEHAVIORAL|Salt Supplementation|
214606000|NCT03966261|OTHER|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
214606001|NCT03991819|DRUG|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
214606002|NCT03991819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
214606003|NCT01543724|DRUG|Lithium|10mg/kg/day for 12 weeks
214606004|NCT00890149|DRUG|Ondansetron|Ondansetron (4ug/kg bid),
214606005|NCT00890149|DRUG|Placebo|Placebo bid
214606006|NCT00890149|BEHAVIORAL|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
214606007|NCT02428543|DRUG|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
214606008|NCT04656314|DIAGNOSTIC_TEST|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
214606009|NCT03646500|PROCEDURE|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
214606010|NCT03646500|PROCEDURE|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
214606011|NCT06072443|BEHAVIORAL|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
214606012|NCT01673568|DEVICE|ETO garments|patients wearing abdominal binder for 7 days postoperatively
214606013|NCT03279874|OTHER|Interviews|Semi-structured one-on-one interviews
214713053|NCT04099849|DIETARY_SUPPLEMENT|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
214606014|NCT03740997|DRUG|Optison|Optison is administered intravenously
214606015|NCT04251260|OTHER|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
214606016|NCT05924685|BIOLOGICAL|COVID-19 vaccination|Vaccination
214606017|NCT01993446|DRUG|DRM02|
214606018|NCT01993446|OTHER|Vehicle|
214606019|NCT00952172|BEHAVIORAL|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
214606020|NCT02220309|DRUG|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
214606021|NCT05087355|DIAGNOSTIC_TEST|PCR or antigen test for Covid 19 or Inluenza|PCR or antigen test for Covid 19 or Inluenza
214606022|NCT03570853|BEHAVIORAL|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
214606023|NCT02861443|BEHAVIORAL|practice of colonic irrigation|
214606024|NCT00169520|DRUG|docetaxel|
214606025|NCT00169520|DRUG|SB-715992|
214606026|NCT01026142|DRUG|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
214606027|NCT01026142|DRUG|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
214606028|NCT01026142|DRUG|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
214606029|NCT01026142|DRUG|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
214606030|NCT04663100|OTHER|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
214606031|NCT04663100|OTHER|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
214606032|NCT04663100|OTHER|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
214606033|NCT01829425|DRUG|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
214606034|NCT01829425|BEHAVIORAL|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
214606035|NCT03210350|DIAGNOSTIC_TEST|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
214606036|NCT04178967|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
214606037|NCT04178967|OTHER|Placebo|Subcutaneous Injection
214606038|NCT00628251|DRUG|AZD2281|400mg Oral twice daily
214606039|NCT00628251|DRUG|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
214606040|NCT00628251|DRUG|AZD2281|200mg oral twice daily
214606041|NCT02715661|OTHER|exercise|six-month interval of exercise
214606042|NCT00378768|BIOLOGICAL|anti-thymocyte globulin|
214606043|NCT05915897|DIAGNOSTIC_TEST|Specimen Donation|blood donation
214606044|NCT00002951|DRUG|fluorouracil|
214606045|NCT00002951|DRUG|hydroxyurea|
214606046|NCT00002951|PROCEDURE|surgical procedure|
214606047|NCT00002951|RADIATION|radiation therapy|
214606048|NCT02761746|BEHAVIORAL|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
214606049|NCT02911090|OTHER|Data Registry|Data Registry
214606050|NCT01549782|DIETARY_SUPPLEMENT|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
214606051|NCT01549782|DIETARY_SUPPLEMENT|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
214606052|NCT04846374|DEVICE|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
214713054|NCT03748485|BEHAVIORAL|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
214606053|NCT00041067|BIOLOGICAL|filgrastim|
214713055|NCT03748485|DRUG|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
214713056|NCT02899741|DRUG|Omega-3|1000mg every day for 90 days
214713057|NCT03228394|DRUG|Ganaxolone|Ganaxolone IV
214713058|NCT03228394|DRUG|Placebo|Placebo IV
214713059|NCT01551472|DEVICE|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
214713060|NCT03831737|BEHAVIORAL|stretching exercises|"Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch"
214606054|NCT00041067|BIOLOGICAL|trastuzumab|
214606055|NCT00041067|DRUG|docetaxel|
214606056|NCT00041067|DRUG|vinorelbine|
214606057|NCT05593874|DIAGNOSTIC_TEST|Histones H3.1 blood levels|Measure of blood concentrations of histone subtype H3.1
214713061|NCT04024072|DRUG|Brinzolamide 1% ophthalmic suspension|Test product
214713062|NCT04024072|DRUG|Azopt 1% Ophthalmic Suspension|Reference product
214713063|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
214713064|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
214713065|NCT04823546|OTHER|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
214713066|NCT04823546|OTHER|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
214713067|NCT02706119|DRUG|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
214713068|NCT02706119|DRUG|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
214713069|NCT02715050|DEVICE|Active or Placebo Phototherapy (MR4)|
214713070|NCT02249026|DRUG|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
214606058|NCT01266525|DRUG|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
214606059|NCT01266525|DRUG|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
214606060|NCT01266525|DRUG|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
214606061|NCT02634203|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
214606062|NCT02634203|DRUG|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
214606063|NCT06159192|DEVICE|Low intensity extracorporeal shock wave|Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.
214606064|NCT00328822|DRUG|Quetiapine|
214606065|NCT00328822|DRUG|placebo|
214606066|NCT02354781|BIOLOGICAL|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
214606067|NCT01033435|OTHER|No intervention|
214606068|NCT00021450|DRUG|bicalutamide|
214606069|NCT00021450|DRUG|goserelin acetate|
214606070|NCT00021450|PROCEDURE|adjuvant therapy|
214606071|NCT00021450|RADIATION|radiation therapy|
214606072|NCT01968070|DRUG|LY3127760|Administered orally
214606073|NCT01968070|DRUG|Celecoxib|Administered orally
214606074|NCT01968070|DRUG|Placebo|Administered orally
214713071|NCT02249026|DRUG|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
214606075|NCT03617965|DIAGNOSTIC_TEST|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
214606076|NCT00497601|DRUG|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
214606077|NCT00497601|DRUG|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
214606078|NCT00497601|DRUG|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
214606079|NCT02883530|PROCEDURE|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
214606080|NCT01449318|DEVICE|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
214606081|NCT02150525|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO (by mouth) daily
214606082|NCT02150525|OTHER|placebo|Given PO(by mouth)daily
214606083|NCT02150525|BEHAVIORAL|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
214606084|NCT03100201|OTHER|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
214606085|NCT03100201|OTHER|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
214606086|NCT00813332|DRUG|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
214606087|NCT00813332|DRUG|Placebo plus Docetaxel|Placebo plus Docetaxel
214606088|NCT00839709|PROCEDURE|blood sampling|peripheral blood draw
214606089|NCT02024451|DEVICE|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
214606090|NCT02024451|DEVICE|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
214606091|NCT02863627|OTHER|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
214606092|NCT01375257|DRUG|Oral treatment with antibiotics for endocarditis|
214606093|NCT01375257|DRUG|Guideline treatment with parenteral antibiotics|
214606094|NCT00836251|DIETARY_SUPPLEMENT|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
214606095|NCT05750797|DRUG|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
214606096|NCT05788003|DIAGNOSTIC_TEST|self-collected and operator-collected swab followed by molecular analysis|A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples.
214606097|NCT01701076|DRUG|Bendamustine|"Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
214606098|NCT00120861|DRUG|valopicitabine|
214606099|NCT00120861|DRUG|pegylated interferon|
214606100|NCT00120861|DRUG|ribavirin|
214606101|NCT03742635|OTHER|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
214606102|NCT05134090|DEVICE|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
214606103|NCT01609751|DIETARY_SUPPLEMENT|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
214606104|NCT03429439|OTHER|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
214606105|NCT03429439|DRUG|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
214606106|NCT02755168|PROCEDURE|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
214606107|NCT02755168|PROCEDURE|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
214606108|NCT06124898|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.
214606109|NCT06124898|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
214606110|NCT06124898|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
214606111|NCT06124898|DEVICE|Higher tech facilitation|Participants will use an app developed during the study that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
214606112|NCT06124898|BEHAVIORAL|Attention control psychoeducation|Brief 25/30-minute psychoeducation on a topic not related to alcohol use that will be developed in the course of the study.
214606113|NCT06124898|DEVICE|Attention control technology|App or other form of technology that will be developed in the course of the study to deliver information not related to alcohol use
214606114|NCT02282566|OTHER|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
214606115|NCT00058474|DRUG|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
214606116|NCT00058474|DRUG|fluorouracil|225 mg/m2 IV daily continuous infusion
214606117|NCT00058474|DRUG|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
214713072|NCT04296916|DRUG|IOP lowering eye drops|"1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
214713073|NCT00091962|BEHAVIORAL|Psychoeducation; Treatment recommendations|Counseling program
214713074|NCT00091962|DRUG|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
214713075|NCT00091962|OTHER|Usual Care|Physicians' Usual care
214606118|NCT00058474|RADIATION|radiation therapy|Given 5 days a week for 5-6 weeks
214606119|NCT00526396|DRUG|cisplatin|80 mg/m2 on day 1 for 6 cycles
214606120|NCT00526396|DRUG|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
214606121|NCT00526396|DRUG|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
214606122|NCT00526396|DRUG|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
214606123|NCT01585220|DEVICE|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
214606124|NCT00882310|DRUG|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
214606125|NCT00882310|DRUG|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
214606126|NCT00882310|DRUG|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
214606127|NCT00780819|DEVICE|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
214606128|NCT05106504|DRUG|Medical Cannabis|Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
214606129|NCT01770613|BIOLOGICAL|Stem cells|Allogeneic mesenchymal stem cells
214606130|NCT04119960|DEVICE|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
214606131|NCT02376608|DIETARY_SUPPLEMENT|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
214606132|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
214713076|NCT04402619|BEHAVIORAL|Cognitive behavior therapy|"The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future"
214713077|NCT05816291|DIETARY_SUPPLEMENT|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
214606133|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
214606134|NCT02376608|DIETARY_SUPPLEMENT|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
214606135|NCT01186900|PROCEDURE|ultrasound-guided needle aspiration|one time drainage at time of randomization
214606136|NCT02756351|DEVICE|CytaCoat Nasal Prong|
214606137|NCT02756351|DEVICE|Inspiration Healthcare Inspire nCPAP Nasal Prong|
214606138|NCT00249210|DRUG|levofloxacin|
214606139|NCT05135221|BIOLOGICAL|dual biological therapy|Simultaneous use of two biologicals.
214606140|NCT03244748|PROCEDURE|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
214606141|NCT05558306|PROCEDURE|Surgery of distal radius fracture|Surgery of distal radius fracture for displaced fractures
214606142|NCT05558306|PROCEDURE|Reduction and cast treatment of distal radius fracture|Reduction and cast treatment of distal radius fracture for minimally displaced fractures
214606143|NCT04275141|OTHER|oral glucose load|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
214606144|NCT04275141|OTHER|exercise test|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
214606145|NCT04246801|DRUG|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
214606146|NCT04246801|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
214606147|NCT03684642|DRUG|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
214606148|NCT03684642|DRUG|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
214606149|NCT03684642|DRUG|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
214606150|NCT05533879|OTHER|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
214606151|NCT06495385|DIAGNOSTIC_TEST|Evolution of renal function|Plasma creatinine levels and glomerular filtration rate estimated using the CKD-Epi formula adjusted for 1.73 m2 body surface area will be measured.
214606152|NCT06495385|DIAGNOSTIC_TEST|Measurement of haemoglobin levels|Haemoglobin levels will be measured.
214606153|NCT06495385|DIAGNOSTIC_TEST|Measurement of biological parameters|Plasma levels of urea, calcium, phosphorus and parathyroid hormone, as well as alkaline reserve, will be measured.
214606154|NCT06495385|DIAGNOSTIC_TEST|Measure sodium and protein consumption|24-hour urine volume, proteinuria, urea and sodium, will be measured.
214606155|NCT06495385|BEHAVIORAL|Quality of life questionnaire EUROQOL 5 dimensions (EQ-5D-5L)|"The descriptive system comprises five dimensions: mobility, personal care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The figures for the five dimensions can be combined into a 5-digit number describing the patient's state of health. Scores close to 1 indicate the best health you can imagine and those close to 0 the worst health you can imagine."
214606156|NCT06010771|OTHER|Listening to fairy tales|Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
214606157|NCT06010771|OTHER|Watching Cartoon Film|The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
214606158|NCT00717054|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
214606159|NCT00717054|DRUG|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
214606160|NCT02743351|BIOLOGICAL|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
214606161|NCT02743351|BIOLOGICAL|Control Arm|Untreated mobilized peripheral blood (mPB) cells
214606162|NCT00161486|DRUG|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
214606163|NCT00161486|DRUG|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
214606164|NCT00161486|DRUG|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
214606165|NCT00161486|DRUG|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
214606166|NCT04556396|DIAGNOSTIC_TEST|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
214606167|NCT01763151|DEVICE|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
214606168|NCT01763151|PROCEDURE|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
214606169|NCT01643525|DEVICE|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
214606170|NCT01522482|DIETARY_SUPPLEMENT|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
214606171|NCT01522482|DIETARY_SUPPLEMENT|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
214606172|NCT01522482|DIETARY_SUPPLEMENT|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
214606173|NCT04445181|DRUG|The physician's prescription in routine clinical practice|This is an Observational study that will not involve prescription of the drugs.
214606174|NCT04713202|DRUG|Telotristat ethyl|Telotristat Ethyl, 250mg
214606175|NCT04713202|DRUG|Peptide Receptor Radionuclide Therapy|Peptide Receptor Radionuclide Therapy
214606176|NCT04713202|OTHER|Placebo|Placebo
214606177|NCT05509985|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
214606178|NCT01087112|BEHAVIORAL|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
214606179|NCT01087112|BEHAVIORAL|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
214606180|NCT05429151|DRUG|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
214606181|NCT04201821|BIOLOGICAL|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
214606182|NCT02636153|OTHER|normal diet|Diet containing 1500mg of phosphorus
214606183|NCT02636153|OTHER|restricted phosphate diet|Diet containing 500mg of phosphorus
214606184|NCT04062253|DIAGNOSTIC_TEST|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
214606185|NCT04228809|DEVICE|tDCS|transcranial direct current stimulation
214606186|NCT02929745|PROCEDURE|Skin biopsy|Four 4-5 mm punch biopsies of the skin
214606187|NCT02929745|PROCEDURE|Blood draw|Blood will be drawn to test for HLA-cw6 status
214713078|NCT04730310|PROCEDURE|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
214713079|NCT05204758|DRUG|TCM Formula|three packages of TCM preparations with each meal three times a day
214713080|NCT05204758|DRUG|Placebo|three packages of placebo preparations with each meal three times a day
214713081|NCT01488409|DRUG|Acipimox|250 mg by mouth (PO) three times daily
214713082|NCT01488409|DRUG|Placebo|0 mg by mouth (PO) three times daily
214606188|NCT01326728|BIOLOGICAL|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
214606189|NCT00688012|DRUG|SPC3649|
214606190|NCT03785678|BIOLOGICAL|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
214606191|NCT03785678|OTHER|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
214606192|NCT05511623|DRUG|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
214606193|NCT05511623|OTHER|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
214606194|NCT00094796|PROCEDURE|Exercise cardiopulmonary metabolic testing|
214606195|NCT00094796|PROCEDURE|Skeletal muscle biopsy|
214606196|NCT00094796|PROCEDURE|Brachial artery reactivity testing|
214606197|NCT05767866|DRUG|YK-029A|Daily dose of YK-029A
214606198|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)
214606199|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
214606200|NCT06441526|DRUG|anti-tumour necrosis factor α antibodies|Biological drug
214606201|NCT06441526|PROCEDURE|Advancement plasty|Surgical closure of the internal opening
214606202|NCT04379648|OTHER|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
214606203|NCT00628173|PROCEDURE|AGV implantation|
214606204|NCT00528892|DRUG|Raltegravir|switching PI to raltegravir
214606205|NCT00528892|DRUG|boosted PI|continue on boosted-PI
214606206|NCT05861154|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation."
214606207|NCT05861154|DRUG|Benzocaine Gel|a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
214606208|NCT03358511|DIETARY_SUPPLEMENT|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
214606209|NCT02231788|DRUG|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
214606210|NCT02231788|DRUG|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
214606211|NCT02169180|DRUG|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
214606212|NCT01013766|DRUG|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
214606213|NCT01013766|DRUG|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
214606214|NCT03620019|DRUG|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
214606215|NCT03620019|DRUG|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
214606216|NCT03620019|DRUG|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
214606217|NCT04728126|OTHER|Survey|"The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales."
214606218|NCT05973097|DRUG|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
214606219|NCT05973097|OTHER|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
214606220|NCT05973097|OTHER|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
214606221|NCT01883986|BEHAVIORAL|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
214606222|NCT03792386|PROCEDURE|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
214606223|NCT03792386|PROCEDURE|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
214606224|NCT02067182|DRUG|Dabigatran|"* Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
214606225|NCT01927185|DEVICE|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
214713083|NCT00587834|DEVICE|Gintuit|Application of Gintuit at Day 0 to the gingival bed
214713084|NCT00587834|OTHER|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
214713085|NCT00002268|DRUG|Sevirumab|
214713086|NCT00897936|GENETIC|DNA methylation analysis|
214606226|NCT01927185|DEVICE|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
214606227|NCT02374021|DRUG|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
214606228|NCT02374021|DRUG|Sulfasalazine|1 gm bid
214606229|NCT02374021|DRUG|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
214606230|NCT02374021|DRUG|Etanercept|50 mg SC weekly
214606231|NCT02374021|DRUG|Adalimumab|40 mg SQ every other week
214606232|NCT03142971|PROCEDURE|focused shock wave therapy|
214606233|NCT03142971|PROCEDURE|ultrasound therapy|
214606234|NCT00256425|BEHAVIORAL|Cognitive rehabilitation|
214606235|NCT00002313|DRUG|Nystatin|
214606236|NCT00002313|DRUG|Didanosine|
214606237|NCT06010069|DIAGNOSTIC_TEST|body temperature measurament|body temperature of every patient was measured with tympanic thermometer during surgical procedure
214606238|NCT04872881|PROCEDURE|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
214606239|NCT04872881|PROCEDURE|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
214713087|NCT00897936|GENETIC|comparative genomic hybridization|
214713088|NCT00897936|GENETIC|fluorescence in situ hybridization|
214606240|NCT04872881|PROCEDURE|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
214606241|NCT04872881|PROCEDURE|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
214606242|NCT04872881|DIAGNOSTIC_TEST|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
214606243|NCT04872881|DIAGNOSTIC_TEST|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
214606244|NCT04872881|DRUG|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
214606245|NCT04872881|DRUG|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
214606246|NCT04872881|DRUG|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
214606247|NCT03350776|BEHAVIORAL|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
214606248|NCT00555555|BIOLOGICAL|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
214606249|NCT00611195|DRUG|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
214606250|NCT00000712|DRUG|Zidovudine|
214606251|NCT00000712|DRUG|Acyclovir|
214606252|NCT05079412|OTHER|Chest ultrasound|Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
214606253|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
214606254|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
214606255|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
214606256|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
214606257|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
214606258|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
214606259|NCT05109676|OTHER|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
214606260|NCT03253939|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
214606261|NCT03253939|PROCEDURE|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
214606262|NCT02798822|PROCEDURE|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
214606263|NCT00020501|DRUG|FOLFIRI regimen|
214606264|NCT00020501|DRUG|floxuridine|
214606265|NCT00020501|DRUG|fluorouracil|
214713089|NCT00897936|GENETIC|microarray analysis|
214713090|NCT00897936|GENETIC|polymerase chain reaction|
214606266|NCT00020501|DRUG|irinotecan hydrochloride|
214606267|NCT00020501|DRUG|leucovorin calcium|
214606268|NCT00020501|DRUG|melphalan|
214606269|NCT00020501|PROCEDURE|hyperthermia treatment|
214606270|NCT01667107|DRUG|Posaconazole|
214606271|NCT01667107|DRUG|Calogen®|
214606272|NCT01980420|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
214606273|NCT05697731|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
214606274|NCT03359525|DRUG|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
214606275|NCT01162239|DRUG|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
214606276|NCT01162239|BEHAVIORAL|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
214606277|NCT01162239|BEHAVIORAL|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
214606278|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
214606279|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
214606280|NCT03410459|DIAGNOSTIC_TEST|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
214713091|NCT00897936|OTHER|diagnostic laboratory biomarker analysis|
214713092|NCT00897936|OTHER|immunologic technique|
214713093|NCT05531968|BIOLOGICAL|BMI2006|IM
214713094|NCT05531968|BIOLOGICAL|BOTOX®|IM
214606281|NCT00228566|DRUG|Armodafinil|
214606282|NCT04357821|DRUG|Combination Intervention|"1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34"
214606283|NCT00074854|DRUG|CP-547,632|
214606284|NCT05960929|COMBINATION_PRODUCT|Infasurf Aero™|A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
214713095|NCT00953004|DIETARY_SUPPLEMENT|fiber drink and fiber bread|fiber drink or fiber bread three times daily
214713096|NCT00767845|OTHER|questionnaire/survey administration|
214713097|NCT00125372|DRUG|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
214713098|NCT01162304|DRUG|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
214713099|NCT01162304|DRUG|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
214713100|NCT01652937|DRUG|BIIB057|Oral
214713101|NCT01652937|DRUG|Placebo|Oral
214713102|NCT04054102|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
214713103|NCT04054102|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
214713104|NCT05968625|DEVICE|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
214713105|NCT05968625|DEVICE|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
214713106|NCT02178306|DRUG|Telmisartan low dose|
214713107|NCT02178306|DRUG|Telmisartan high dose|patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment
214713108|NCT02178306|DRUG|Placebo|Run-in phase
214713109|NCT05883839|OTHER|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
214713110|NCT02656901|DEVICE|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
214713111|NCT02656901|DEVICE|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
214713112|NCT02656901|DEVICE|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
214606285|NCT05705193|OTHER|NeuroFlex (computerized gamified tasks)|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant."
214606286|NCT05232253|DEVICE|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
214713113|NCT02656901|DEVICE|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
214713114|NCT02798562|DEVICE|Native and dynamic contrast-enhanced CT|
214713115|NCT02644148|PROCEDURE|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
214713116|NCT02644148|PROCEDURE|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
214713117|NCT04075773|BEHAVIORAL|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
214713118|NCT04000087|OTHER|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
214713119|NCT00983359|RADIATION|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
214606287|NCT03585556|DRUG|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
214606288|NCT03585556|BIOLOGICAL|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
214722265|NCT04379609|OTHER|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
214606289|NCT03585556|DRUG|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
214606290|NCT04448756|DRUG|M5049|Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
214606291|NCT04448756|DRUG|M5049|Participants received M5049 100 mg orally twice daily for 14 days.
214606292|NCT04448756|DRUG|Placebo|Participants received placebo tablets matched to M5049 daily for 14 days.
214606293|NCT06068465|DRUG|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
214606294|NCT06068465|DRUG|placebo|placebo, capsule, once daily by mouth for 6 weeks
214722266|NCT00112684|DRUG|alvocidib|Given IV
214722267|NCT00112684|OTHER|pharmacological study|Correlative studies
214722268|NCT00112684|OTHER|laboratory biomarker analysis|Correlative studies
214722269|NCT00488059|DRUG|enfuvirtide [Fuzeon]|90 mg SC twice daily
214606295|NCT04454437|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214606296|NCT05359549|DEVICE|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
214606297|NCT03902847|BEHAVIORAL|motor imagery|All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
214606298|NCT03902847|BEHAVIORAL|Action observation|A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
214722270|NCT00488059|DRUG|Optimized background ARV|As prescribed
214722271|NCT00488059|DRUG|Integrase inhibitor|As prescribed
214713120|NCT04158986|BEHAVIORAL|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
214606299|NCT03902847|BEHAVIORAL|Motor Control Exercises|The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
214606300|NCT06006338|OTHER|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
214606301|NCT04571281|DIAGNOSTIC_TEST|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
214606302|NCT06292000|BEHAVIORAL|AM Exercise|Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
214606303|NCT06292000|BEHAVIORAL|PM Exercise|Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
214606304|NCT00835120|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
214606305|NCT01624259|DRUG|LY2189265|Administered SC
214606306|NCT01624259|DRUG|Liraglutide|Administered SC
214606307|NCT01624259|DRUG|Metformin|
214606308|NCT03813290|DEVICE|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
214606309|NCT00232141|DRUG|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
214606310|NCT00232141|DRUG|Placebo|Placebo
214606311|NCT06031896|OTHER|No interventions|No interventions
214606312|NCT01152762|PROCEDURE|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
214606313|NCT00339170|BEHAVIORAL|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
214606314|NCT00339170|BEHAVIORAL|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
214606315|NCT06072287|DIAGNOSTIC_TEST|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
214606316|NCT01608542|DRUG|Fostamatinib 100mg|oral tablet
214606317|NCT01608542|DRUG|Fostamatinib 200mg|oral tablet
214606318|NCT03474471|BEHAVIORAL|Pulmonary rehabilitation|Following a PR program
214606319|NCT03474471|DEVICE|EBV treatment|Bronchoscopic lung volume reduction using endobronchial valves (EBV)
214713121|NCT00615251|DRUG|DR-2011|Progesterone vaginal ring for approximately 10 weeks
214713122|NCT00615251|DRUG|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
214606320|NCT00771563|DRUG|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
214606321|NCT00771563|DRUG|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
214606322|NCT02307760|OTHER|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
214606323|NCT02307760|OTHER|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
214606324|NCT02885805|DRUG|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
214606325|NCT02885805|DRUG|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
214713123|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
214606326|NCT05511896|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
214606327|NCT05057286|PROCEDURE|Clinical crown lengthening surgery|"* Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection."
214606328|NCT04689997|BEHAVIORAL|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
214606329|NCT02403843|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
214606330|NCT00150332|DRUG|linezolid|
214606331|NCT02121496|BEHAVIORAL|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
214606332|NCT04203862|DRUG|NPC-22|Single administration of low dose NPC-22
214606333|NCT04203862|DRUG|NPC-22|Single administration of low/middle dose NPC-22
214606334|NCT04203862|DRUG|NPC-22|Single administration of middle dose NPC-22
214606335|NCT04203862|DRUG|NPC-22|Single administration of middle/high dose NPC-22
214606336|NCT04203862|DRUG|NPC-22|Single administration of high dose NPC-22
214606337|NCT04203862|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
214606338|NCT04304781|DRUG|KSP/QRH dimer|Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
214606339|NCT04572854|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214722272|NCT00488059|DRUG|enfuvirtide [Fuzeon]|180 mg SC once daily
214606340|NCT06812858|DRUG|Nivolumab, Pembrolizumab|"The choice of drug and its dose for maintenance therapy is at the discretion of the study centre (e.g. nivolumab, pembrolizumab). Maintenance therapy should be initiated no later than 60 days after D0, exceptions may be made due to reasonable justification in consultation with the Study PI and will not be considered a protocol deviation.~Nivolumab maintenance therapy regimens:~* Nivolumab (40 mg, fixed dose) IV D1 of each 14-days cycle up to 12 cycles~* Nivolumab (3 mg/kg) IV D1 of each 14-days cycle up to 12 cycles~Pembrolizumab maintenance therapy regimen:~-Pembrolizumab (200 mg, fixed dose) IV D1 of each 21-days cycle up to 8 cycles"
214606341|NCT03850782|DRUG|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
214606342|NCT07007520|DRUG|DA-5223(Fasting)|once a day
214606343|NCT07007520|DRUG|DA-5223(Fed)|once a day
214606344|NCT07130669|BEHAVIORAL|Cognitive Remediation|computerized cognitive training with a closed-loop human machine interface that monitor facial expression as engagement status of the person
214606345|NCT07130669|BEHAVIORAL|Cognitive Remediation II|traditional computerized cognitive training
214606346|NCT07129876|OTHER|Simulator Motion|Motion fidelity of the simulator.
214713124|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
214606347|NCT07128589|DEVICE|3MTM FiltekTM Supreme Flowable Composite|"3M ™ Supreme Flowable Restorative contains BisGMA,TEGDMA and Procrylat resins. The fillers are a combination of ytterbium trifluoride filler with a range of particles sizes from 0.1 to 5.0 microns, a non-agglomerated/non-aggregated surface modified 20nm silica filler, a non-agglomerated/non/aggregated surface modified 75nm silica filler, and a surface modified aggregated zirconia/silica cluster filler (comprised of 20 nm silica and 4 to 11nm zirconia particles). The aggregate has an average cluster particle size of 0.6 to 10 microns. The inorganic filler loading is approximately 65% by weight (46% by volume).~3M (TM) Filtek(TM) Supreme Flowable Restorative is a modification of predicate device 3M(TM) Filtek(TM) XT Flowable Restorative (which was a modification of 3M(TM) Filtek(TM) Flow. 3M Filtek Supreme Flowable Composites are used per indication and its approved labeling in this study."
214606348|NCT07130929|OTHER|Functional Electrical Stimulation|Physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb, associated with functional electrical stimulation.
214606349|NCT07130929|OTHER|Conventional physiotherapy|Conventional physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb.
214606350|NCT07130396|DIETARY_SUPPLEMENT|Multivitamin and a Probiotic|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of the study products (PhytoMulti® Multivitamin, 2 tablets/day and UltraFlora® Balance Probiotic, 1 capsule/day) are taken daily with breakfast
214606351|NCT07129759|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
214606352|NCT07130188|DIAGNOSTIC_TEST|PCI|Coronary angiography then SYNTAX score calculation
214606353|NCT07129356|BEHAVIORAL|Combined Exercise|"Participants engaged in a hybrid exercise program that included:~In-field sessions held twice weekly at a local sports facility (45-60 minutes per session, including rest).~Remote sessions delivered via pre-recorded videos through WhatsApp, with ongoing monitoring and feedback.~Exercises included walking, jogging, full-body stretching, and strength training targeting the trunk, limbs, and weak muscle groups (shoulders, back, knees).~The program aimed to reduce joint and muscle pain, improve strength and flexibility, and support daily functional activities.~Pre- and post-intervention assessments included muscle strength (via hand dynamometer), flexibility tests, BMI, and self-reported pain using the NRS-11 scale."
214606354|NCT07130422|PROCEDURE|CABG surgery|CABG surgery
214606355|NCT07129915|BEHAVIORAL|Linguistic Nudging Training|Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques
214606356|NCT07129915|DEVICE|Medication Preference App|Patients use WeChat-based mini-program to record daily medication preferences and concerns
214606357|NCT07129915|OTHER|Standard Diabetes Care|Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol
214606358|NCT07129343|BIOLOGICAL|VONVENDI|VONVENDI is administered by intravenous injection.
214713125|NCT06430710|DEVICE|Intrusion|2 different methods for incisor intrusion
214713126|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
214713127|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
214713128|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
214713129|NCT01112423|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
214713130|NCT03833375|OTHER|Decision Aid|Shared-decision making tool
214713131|NCT02293096|DRUG|metoprolol succinate|
214713132|NCT02293096|GENETIC|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
214713133|NCT02293096|PROCEDURE|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
214606359|NCT07129343|BIOLOGICAL|ADVATE|ADVATE is administered by intravenous injection.
214606360|NCT06937372|DRUG|Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.|Unlike low molecular weight heparin (LMWH), which requires daily subcutaneous injections, aspirin is taken orally, making it more comfortable and acceptable for patients, particularly the elderly or those with mobility issues. Aspirin is significantly less expensive than injectable anticoagulants like LMWH or newer oral anticoagulants, making it a potentially cost-effective alternative for thromboprophylaxis.
214606361|NCT06937372|DRUG|Low molecular weight heparin (LMWH)|"LMWH is administered via daily subcutaneous injection, typically starting shortly after surgery and continued for a defined period as per each hospital's local policy, often 14 to 28 days. LMWH has a proven track record of reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgery.~However, it carries a risk of bleeding and may be challenging for some frail or elderly patients to tolerate, especially if self-injection is required post-discharge."
214606362|NCT06938386|DIETARY_SUPPLEMENT|Haskap|A whole, frozen Haskap berry puree blended with water in a 2:1 ratio of berry to water.
214713134|NCT02616016|DEVICE|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
214713135|NCT03071003|DRUG|SENS-401|Oral Administration
214713136|NCT03071003|DRUG|Placebo|Oral Administration
214713137|NCT00326417|DRUG|Fludarabine|Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
214713138|NCT00326417|DRUG|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
214606363|NCT06954142|OTHER|Fluid restriction|Fluid restriction strategy (fluid target 135 ±5 mL/kg/d)
214606364|NCT06954142|OTHER|Liberal fluid intake|Liberal fluid intake strategy (fluid target 165 ± 5 mL/kg/d)
214606365|NCT07129954|BEHAVIORAL|Motor rehabilitation|Motor rehabilitation will be characterized by sessions of 45 minutes each with a patient (total sessions 36): physiotherapist ratio of 1:1. The rehabilitation project will be defined by the PM\&R specialist and the physiotherapist who will take charge of the patient. The treatment will focus on the maintenance of active and passive joint ranges, on the training of balance and gait, and on exercises of proprioception and scenic reinforcement. Specific devices (rehabilitation beds, verticalizer, posturography platform) will be used during motor treatment
214606366|NCT07129954|BEHAVIORAL|Motor Rehabilitation and Cognitive Behavioral Therapy|"1 session per week of 45 minutes of cognitive behavioral therapy and 2 sessions per week of 45 minutes of motor rehabilitation. The length of the treatment is the same as the control group: 12 weeks for 12 CBT sessions and 24 motor rehabilitation sessions (a total of 36 sessions).~Motor rehabilitation will be the same as that provided to the control group. In addition, participants will receive Cognitive-Behavioral Therapy (CBT), consisting of individual 45-minute sessions (one psychotherapist per patient).~The sessions will focus on the relationship between cognition, emotions, and behavior. Specifically, the therapist will work with the patient to identify and modify automatic thoughts, cognitive distortions, and underlying beliefs or patterns associated with the fear of falling."
214606367|NCT04256421|DRUG|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
214606368|NCT04256421|DRUG|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
214606369|NCT04256421|DRUG|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
214606370|NCT04256421|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
214606371|NCT04256421|DRUG|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
214606372|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
214606373|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
214606374|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
214606375|NCT06053255|DEVICE|High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR|HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.
214713139|NCT00326417|DRUG|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
214606376|NCT02423551|OTHER|MRE|MRE consumption
214606377|NCT03292289|PROCEDURE|Pre- and post-operative consultation|Before and between the two interventions
214606378|NCT03292289|PROCEDURE|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
214606379|NCT03292289|PROCEDURE|Questionnaires|"* QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
214606380|NCT02047539|DRUG|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
214606381|NCT02047539|DRUG|Placebo|
214606382|NCT04313153|DRUG|Vadadustat|oral tablets
214606383|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
214606384|NCT06830525|COMBINATION_PRODUCT|ACDP® and growth hormone treatment|A cohort of 40 families of children undergoing growth hormone treatment using a connected injector devices that quantifies treatment adherence will be recruited via the ACDP®, to capture additional data that combine Patient Reported Outcomes and Adherence Data.
214606385|NCT05586269|BEHAVIORAL|Meal Kit Delivery|Dyads (caregiver + child) receive one meal kit delivery per week. One meal kit is designed to include two recipes and ingredients to prepare 10 servings (\~2 meals for a household 5 people). Meal kits come with printed picture-based recipes in English or Spanish and access to online cooking demonstrations.
214606386|NCT05586269|BEHAVIORAL|Newsletter + Food Pantry Referral|Dyads (caregiver + child) receive a printed newsletter in English and Spanish that lists additional local food assistance resources. Dyads receive a referral to the clinic's associated food pantry.
214606387|NCT04491383|DRUG|Tocovid Suprabio (HOV-12020)|Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
214606388|NCT04491383|OTHER|Placebo|Dietary supplement: Placebo. Placebo.
214606389|NCT06143085|PROCEDURE|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
214713140|NCT00326417|DRUG|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
214713141|NCT00593658|DRUG|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
214713142|NCT01867814|PROCEDURE|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
214713143|NCT02441855|DEVICE|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
214713144|NCT00096590|OTHER|coagulation study|
214606390|NCT04712825|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
214606391|NCT04712825|DEVICE|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
214606392|NCT06424470|BIOLOGICAL|Stapokibart|Stapokibart Injection
214606393|NCT06424470|OTHER|Placebo|Placebo
214606394|NCT02428010|DEVICE|TMVR Implant|Implantation of the Twelve TMVR System
214713145|NCT00096590|OTHER|immunoenzyme technique|
214606395|NCT02871973|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
214606396|NCT02871973|BEHAVIORAL|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
214606397|NCT03404089|DEVICE|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
214606398|NCT03404089|DEVICE|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
214606399|NCT00067392|PROCEDURE|Dental Implant|Dental Implant 4 month time frame
214606400|NCT00176345|BEHAVIORAL|Exercise Training|
214606401|NCT04885088|DEVICE|Wisdom bracelet|Wisdom bracelet
214606402|NCT04828187|DIAGNOSTIC_TEST|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
214606403|NCT04063241|OTHER|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
214606404|NCT04063241|OTHER|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
214606405|NCT04564963|OTHER|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
214606406|NCT00774280|DRUG|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
214713146|NCT00096590|OTHER|laboratory biomarker analysis|
214713147|NCT00096590|OTHER|physiologic testing|
214713148|NCT00096590|PROCEDURE|study of high risk factors|
214713149|NCT00844285|DRUG|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
214722273|NCT02289716|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
214606407|NCT04662398|DEVICE|JT Device|Shocker giving electrical shocks on testes
214606408|NCT01974089|OTHER|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
214606409|NCT01098981|DEVICE|Transcranial ultrasound as an adjunctive therapy to tPA|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes"
214606410|NCT01098981|DRUG|Standard of care tPA therapy for acute ischemic stroke|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
214606411|NCT01256151|DRUG|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
214606412|NCT01256151|DRUG|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
214606413|NCT02154360|DRUG|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
214606414|NCT05963789|OTHER|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
214606415|NCT05963789|OTHER|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
214606416|NCT01454245|DRUG|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
214713150|NCT05510206|DEVICE|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
214713151|NCT04045626|PROCEDURE|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
214713152|NCT01352065|DRUG|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
214606417|NCT01454245|DRUG|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
214606418|NCT05510154|BEHAVIORAL|Brief advice|A single, brief advice session on switching to electronic cigarettes.
214606419|NCT05510154|BEHAVIORAL|Single Training|A single, in-depth training session on switching to electronic cigarettes.
214606420|NCT05510154|BEHAVIORAL|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
214606421|NCT06472154|OTHER|Experimental|The experimental group intervened based on the midnight-noon ebb-flow theory, listening to music corresponding to the five organs at different time periods.
214713153|NCT01352065|DRUG|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
214713154|NCT01352065|DRUG|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
214713155|NCT03485092|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
214713156|NCT03485092|DRUG|Placebo Oral Tablet|placebo tablets for oral self administration once a day
214713157|NCT01648829|DRUG|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
214713158|NCT01648829|DRUG|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
214713159|NCT02697630|DRUG|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
214713160|NCT02697630|DRUG|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
214722274|NCT02289716|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
214606422|NCT06472154|OTHER|Control|The control group listened to Chinese five elements music pieces from 13:00 to 18:00 p.m., each music piece for within 30 minutes for, 5 days per week, 4 weeks for a cycle, 3 cycles in total.
214606423|NCT00494728|BEHAVIORAL|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
214606424|NCT00494728|DRUG|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
214606425|NCT00494728|BEHAVIORAL|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
214606426|NCT05142800|DEVICE|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
214606427|NCT05142800|DEVICE|SOZO device|The machine measures the amount of fluid on the arm(s)
214606428|NCT00126633|BIOLOGICAL|bevacizumab|
214606429|NCT00126633|DRUG|cisplatin|
214606430|NCT00126633|DRUG|gemcitabine hydrochloride|
214606431|NCT01920594|DRUG|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
214606432|NCT01920594|DRUG|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
214606433|NCT00235820|DRUG|adalimumab|40 mg every other week following an 80 mg dose
214606434|NCT00235820|DRUG|MTX|MTX 7.5 to 25 mg once weekly
214606435|NCT00235820|DRUG|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
214606436|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
214606437|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
214606438|NCT01437696|OTHER|placebo|No liquid cholecalciferol will be added to the food.
214606439|NCT05571046|DRUG|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
214606440|NCT05571046|OTHER|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
214606441|NCT00274404|DRUG|valacyclovir|
214606442|NCT01033656|DRUG|anakinra|100 mg subcutaneous injection daily
214606443|NCT01033656|DRUG|comparators|po drugs, comparators
214606444|NCT00016263|BIOLOGICAL|oblimersen sodium|
214606445|NCT00016263|DRUG|dacarbazine|
214606446|NCT00319332|DRUG|Ibritumomab Tiuxetan|
214606447|NCT00319332|DRUG|Iodine I 131 Tositumomab|
214606448|NCT01131949|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
214606449|NCT03707509|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
214606450|NCT03707509|DRUG|Placebos|Maximum 6 cycles for combined therapy.
214606451|NCT03707509|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
214606452|NCT03707509|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
214606453|NCT04570111|OTHER|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
214606454|NCT04570111|OTHER|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
214606455|NCT03272568|DRUG|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
214606456|NCT03272568|DRUG|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
214606457|NCT03272568|DEVICE|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
214606458|NCT04398511|DRUG|L brevis|Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.
214606459|NCT04398511|DRUG|Placebo|Placebo lozenges after breakfast, lunch and dinner for 21 days.
214713161|NCT01678716|BEHAVIORAL|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
214606460|NCT00928564|DRUG|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
214606461|NCT00928564|DRUG|Placebo|5ml of saline at each block site.
214606462|NCT04946903|DRUG|RLD2007|Take it once per period.
214606463|NCT04946903|DRUG|RLD2008|Take it once per period.
214606464|NCT04946903|DRUG|HCP1902|Take it once per period.
214606465|NCT03203421|BIOLOGICAL|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
214606466|NCT03203421|BIOLOGICAL|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
214606467|NCT02206165|DRUG|Candesartan 8mg|Once a day, 8 weeks
214606468|NCT02206165|DRUG|Candesartan 16mg|Once a day, 8 weeks
214606469|NCT02206165|DRUG|Amlodipine 5mg|Once a day, 8 weeks
214606470|NCT02206165|DRUG|Amlodipine 10mg|Once a day, 8 weeks
214713162|NCT01678716|DIETARY_SUPPLEMENT|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
214713163|NCT01678716|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
214606471|NCT01569165|PROCEDURE|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
214606472|NCT04218955|COMBINATION_PRODUCT|Silver Diamine Flouride|Material used to arrest caries in children
214606473|NCT01244243|DEVICE|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
214606474|NCT01332565|DRUG|GSK1349572|50mg tablet
214606475|NCT02039726|DRUG|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
214606476|NCT02039726|DRUG|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
214606477|NCT03336255|BEHAVIORAL|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
214606478|NCT00288977|PROCEDURE|Islet Infusion|
214606479|NCT04100629|BEHAVIORAL|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
214606480|NCT02460497|DRUG|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
214606481|NCT01504256|DRUG|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
214606482|NCT01504256|DRUG|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
214606483|NCT03679156|DEVICE|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
214606484|NCT01891097|PROCEDURE|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
214606485|NCT01891097|PROCEDURE|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
214606486|NCT00643669|DRUG|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
214606487|NCT05047783|DRUG|Masitinib Mesylate|3CL-protease inhibitor
214606488|NCT05047783|DRUG|Placebo|Placebo
214713164|NCT00192036|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
214713165|NCT00192036|DRUG|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
214713166|NCT00192036|RADIATION|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
214713167|NCT01287481|BEHAVIORAL|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
214713168|NCT01287481|BEHAVIORAL|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
214713169|NCT01287481|BEHAVIORAL|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
214713170|NCT01995812|BEHAVIORAL|Hula and heart health education|
214713171|NCT01907841|OTHER|Ischemic Preconditioning|
214713172|NCT01562704|DRUG|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
214606489|NCT05905510|DRUG|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
214606490|NCT05905510|DRUG|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
214606491|NCT05905510|DRUG|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
214606492|NCT04013516|BEHAVIORAL|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
214606493|NCT04013516|BEHAVIORAL|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
214606494|NCT03274609|COMBINATION_PRODUCT|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
214606495|NCT02992886|RADIATION|Preoperative radiation|Radiation treatment before surgery
214606496|NCT02992886|DRUG|Raltitrexed|concurrent chemotherapy
214606497|NCT02992886|PROCEDURE|Pelvic surgery|
214606498|NCT03846739|DRUG|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
214606499|NCT03846739|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
214606500|NCT01556035|DRUG|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
214606501|NCT02393677|DRUG|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
214606502|NCT02393677|DRUG|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
214606503|NCT02607553|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
214606504|NCT05196581|DRUG|Dispersible NaCl powder 10 sessions|Dispersible NaCl powder 10 sessions
214606505|NCT05196581|DRUG|Dispersible NaCl powder 5 sessions|Dispersible NaCl powder 5 sessions
214606506|NCT00813319|BEHAVIORAL|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
214606507|NCT00752531|BEHAVIORAL|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
214606508|NCT02838082|BEHAVIORAL|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
214606509|NCT02838082|BEHAVIORAL|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
214606510|NCT05146362|OTHER|Vermont RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
214606511|NCT02012296|DRUG|enzalutamide|Given PO
214606512|NCT02012296|DRUG|mifepristone|Given PO
214713173|NCT05937217|OTHER|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
214606513|NCT02012296|OTHER|laboratory biomarker analysis|Correlative studies
214606514|NCT02012296|OTHER|pharmacological study|Correlative studies
214606515|NCT01916863|DRUG|LX4211 400 mg|
214606516|NCT01916863|DRUG|canagliflozin 300 mg|
214606517|NCT01916863|DRUG|LX4211 Placebo|
214713174|NCT05937217|DEVICE|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
214606518|NCT01448213|DRUG|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
214606519|NCT01448213|DRUG|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
214606520|NCT00919087|DEVICE|Avivo System|Non invasive external monitoring deive
214606521|NCT02485990|DRUG|Tremelimumab|
214606522|NCT02485990|DRUG|Olaparib|
214713175|NCT00091923|DEVICE|Eye patch|
214713176|NCT00091923|DEVICE|Spectacles|
214713177|NCT00965406|DRUG|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
214713178|NCT02490917|DEVICE|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
214606523|NCT06318351|PROCEDURE|transcutaneous acupoint electrical stimulation|This is a safe and non-invasive procedure, similar to an electrode sheet, which applies a weak current to a specific site to achieve the purpose of acupoint stimulation.
214606524|NCT05452096|BEHAVIORAL|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
214606525|NCT03786978|BEHAVIORAL|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
214606526|NCT03786978|BEHAVIORAL|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
214606527|NCT04249323|DRUG|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
214606528|NCT04249323|DRUG|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
214606529|NCT04249323|DRUG|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
214606530|NCT00141895|DRUG|Misoprostol|2 tablets 200 micrograms Vaginal route
214606531|NCT00141895|DRUG|Misoprostol|2 tablets of 200 micrograms Sublingual route
214606532|NCT05320562|PROCEDURE|Kinesio taping|"Additionally, they received kinesio taping application for 7 days. Blue color kinesio tape (manufactured by Theraband®, USA) was used. Kinesio taping was done by experienced physiotherapist with 5 years of experience. Two Y shape bands were applied for lymphatic taping and to improve anterior upper leg muscle function (lymphatic correction and muscle correction techniques were integrated together).~Then two I shape bands (75-100% tension) were applied above the patella tendon and medial/lateral collateral ligaments in order to improve mechanoreceptor stimulation, proprioception and knee stability."
214606533|NCT05320562|PROCEDURE|Sham taping|Additionally, they received sham (placebo) taping: usual white patch was applied to the painful knee for 7 days. The technique of taping used was the same as in kinesiotaping group, but without stretching.
214606534|NCT02917668|OTHER|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
214606535|NCT02917668|OTHER|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %
214606536|NCT01326078|DRUG|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
214606537|NCT02611661|DEVICE|PET/MRI|
214606538|NCT02611661|RADIATION|Percutaneous ablation|
214606539|NCT02611661|RADIATION|Stereotactic body radiotherapy|
214606540|NCT03332914|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
214606541|NCT00613444|DEVICE|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
214606542|NCT04309279|BEHAVIORAL|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
214606543|NCT03700151|BEHAVIORAL|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
214606544|NCT01009892|DRUG|Codeine Sulfate|Tablet
214606545|NCT05315362|DEVICE|solid microneedle skin patch|intradermal vaccination with a skin patch
214606546|NCT05315362|BIOLOGICAL|mRNA-1273|administration of mRNA-1273 vaccine
214606547|NCT05315362|DEVICE|standard needle|intramuscular vaccination with a standard needle
214606548|NCT02615470|BEHAVIORAL|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
214606549|NCT02615470|OTHER|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
214606550|NCT02596243|BIOLOGICAL|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
214606551|NCT02596243|BIOLOGICAL|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
214713179|NCT02490917|DEVICE|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
214606552|NCT02433171|PROCEDURE|Standard of Care FDG-PET Imaging|\[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
214713180|NCT03347240|PROCEDURE|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
214606553|NCT04121611|DRUG|Unfractionated heparin|"1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
214713181|NCT03347240|PROCEDURE|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
214606554|NCT04121611|DRUG|Acetylsalicylic Acid (ASA)|"1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose"
214713182|NCT03347240|DEVICE|Deep brain stimulation|Bilateral DBS
214713183|NCT03347240|DEVICE|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
214722275|NCT02289716|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
214606555|NCT01817907|DRUG|Placebo pill|Subjects will receive a sugar pill during the placebo arm
214606556|NCT01817907|DRUG|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
214606557|NCT03420079|DRUG|FCN-411 Dose-escalation|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
214606558|NCT03420079|DRUG|FCN-411 Dose-expansion|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
214606559|NCT03343392|DRUG|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
214606560|NCT03343392|DRUG|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
214606561|NCT04628299|OTHER|Sham Laser|Sham Laser in plantar fascia
214606562|NCT04628299|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
214606563|NCT00916539|DEVICE|Cast that immobilizes the thumb|Cast that immobilizes the thumb
214606564|NCT00916539|DEVICE|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
214606565|NCT03161288|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
214606566|NCT03161288|DRUG|Placebo|Matched placebo
214606567|NCT01826851|DRUG|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
214606568|NCT01826851|DRUG|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
214606569|NCT01671020|DRUG|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
214606570|NCT01671020|DRUG|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
214606571|NCT01817283|DRUG|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
214606572|NCT01817283|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
214606573|NCT01817283|DRUG|placebo|Placebo pills produced the same as Triptolide wilfordii.
214606574|NCT04115579|OTHER|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
214606575|NCT04115579|OTHER|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
214606576|NCT04472143|DRUG|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
214606577|NCT04163900|DRUG|NUC-1031|IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes
214606578|NCT04163900|DRUG|Gemcitabine|IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert
214606579|NCT04163900|DRUG|Cisplatin|IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol
214606581|NCT03746899|BIOLOGICAL|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
214606582|NCT01971502|DRUG|Placebo to BI 1060469|single rising doses
214606583|NCT01971502|DRUG|BI 1060469|food effect
214606584|NCT01971502|DRUG|BI 1060469|single rising doses
214606585|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
214606586|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
214606587|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
214606588|NCT01830855|BIOLOGICAL|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
214606589|NCT01830855|BIOLOGICAL|Saline|0.5 mL dose of sterile normal saline for injection.
214606590|NCT02675842|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
214606591|NCT02675842|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
214606592|NCT01410682|OTHER|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
214606593|NCT01410682|OTHER|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
214606594|NCT03059095|BEHAVIORAL|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
214606595|NCT00515255|DRUG|Minocycline|Capsules
214606596|NCT02509104|DRUG|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
214606597|NCT02509104|DRUG|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
214606598|NCT06372951|DEVICE|Ultrasound|A device that use ultrasonic waves as a way to image the internal organs and tissues of the body in order to diagnose the different diseases.
214606599|NCT01667081|DRUG|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
214606600|NCT01840891|BEHAVIORAL|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
214606601|NCT00565591|DRUG|Albuterol sulfate|Single dose dry powder by inhalation
214606602|NCT00930722|DRUG|quinapril|per label as non interventional study
214606603|NCT03034460|DRUG|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
214606604|NCT03034460|DRUG|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
214606605|NCT03034460|DRUG|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
214606606|NCT03034460|DRUG|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
214606607|NCT05260853|OTHER|Weaning Board|structured care concept
214606608|NCT01187069|BEHAVIORAL|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
214606609|NCT00343616|PROCEDURE|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
214606610|NCT00343616|PROCEDURE|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
214606611|NCT00343616|PROCEDURE|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
214606612|NCT00343616|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
214606613|NCT00914992|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
214606614|NCT00914992|OTHER|Squatting|Squatting
214606615|NCT02963038|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
214606616|NCT01964261|DEVICE|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
214606617|NCT00095082|DRUG|insulin detemir|
214606618|NCT00095082|DRUG|insulin glargine|
214606619|NCT00095082|DRUG|insulin aspart|
214606620|NCT00419120|BIOLOGICAL|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
214606621|NCT00520455|DRUG|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
214606622|NCT04853836|COMBINATION_PRODUCT|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
214606623|NCT04853836|PROCEDURE|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
214606624|NCT04853836|DRUG|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
214606625|NCT04853836|DRUG|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
214606626|NCT06043115|OTHER|covid-19 survival cohort|consists of surviving patients
214606627|NCT06043115|OTHER|covid-19 mortality cohort|consists of deceased patients
214606628|NCT06244979|OTHER|Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)|100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
214606629|NCT00771641|PROCEDURE|conventional surgery|
214606630|NCT00771641|RADIATION|low-LET cobalt-60 gamma ray therapy|
214713184|NCT05406557|PROCEDURE|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
214713185|NCT05406557|PROCEDURE|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
214713186|NCT00321022|BEHAVIORAL|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
214606631|NCT00771641|RADIATION|low-LET electron therapy|
214606632|NCT00771641|RADIATION|low-LET photon therapy|
214606633|NCT00771641|RADIATION|radiation therapy|
214606634|NCT06460129|OTHER|Brugger's Exercises|"1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds."
214606635|NCT06460129|OTHER|Kendal Exercise|"1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position."
214606636|NCT01958723|OTHER|Hospitalists|Introduction of Problem Specific Templates
214606637|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
214606638|NCT04302584|DRUG|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
214606639|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the Stereotactic Body Radiation Therapy (SBRT) schedule is completed within 1.5-2 weeks.
214606640|NCT05849480|DRUG|oxaliplatin|Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
214606641|NCT05849480|DRUG|capecitabine|Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
214606642|NCT05849480|BIOLOGICAL|Keytruda|Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
214606643|NCT05849480|BIOLOGICAL|CDX-1140|CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
214606644|NCT05079464|OTHER|tDCS|All participants randomized to tDCS will receive active tDCS
214606645|NCT05079464|OTHER|Exercise|Participants will exercise at Toronto Rehab.
214713187|NCT03633994|DRUG|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
214713188|NCT03633994|DRUG|Normal saline|Normal saline bladder instillation
214713189|NCT02140203|OTHER|Yoga Training|one-year experimental training (three times per week and one hour per session)
214722276|NCT00179998|DRUG|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
214722277|NCT00179998|DRUG|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
214606646|NCT05079464|OTHER|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
214606647|NCT05079464|OTHER|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
214606648|NCT02496897|BIOLOGICAL|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
214606649|NCT02496897|OTHER|Placebo|Placebo
214606650|NCT02496897|OTHER|IC31® Adjuvant|IC31® Adjuvant
214606651|NCT00931242|DRUG|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
214606652|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
214606653|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
214606654|NCT05168891|PROCEDURE|Surgical therapy|Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
214713190|NCT00954837|PROCEDURE|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
214606655|NCT05168891|PROCEDURE|Non-surgical therapy of peri-implantitis|Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
214606656|NCT06248814|DRUG|BMS-986326|Specified dose on specified days
214606657|NCT06248814|OTHER|Placebo|Specified dose on specified days
214606658|NCT03631667|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
214606659|NCT03631667|DRUG|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
214722278|NCT02221960|BIOLOGICAL|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
214606660|NCT00519155|DRUG|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
214606661|NCT00519155|PROCEDURE|Open flap debridement|Open flap debridement alone
214606662|NCT03162887|OTHER|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
214606663|NCT03162887|OTHER|Counseling|Undergo a web-based decision counseling session
214606664|NCT03162887|OTHER|Informational Intervention|"Receive a next steps document"
214606665|NCT00346099|DRUG|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
214606666|NCT00346099|DRUG|Panitumumab with capecitabine and radiation|
214606667|NCT03281057|BEHAVIORAL|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
214606668|NCT02398448|DRUG|Zyloprim® 300 mg|
214606669|NCT02398448|DRUG|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
214606670|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
214606671|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 3|
214606672|NCT04699175|DRUG|HR021618|Treatment group A:HR021618; high dose
214606673|NCT04699175|DRUG|HR021618|Treatment group B:HR021618; low dose
214606674|NCT04699175|DRUG|Placebo|Treatment group C: HR021618 blank preparation.
214606675|NCT04830033|OTHER|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
214606676|NCT05046574|OTHER|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
214606677|NCT03173066|DRUG|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
214606678|NCT04613856|OTHER|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
214606679|NCT04613856|OTHER|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
214606680|NCT04640844|BIOLOGICAL|blood sample|measuring the expression and function of lymphocyte A2A receptors.
214713191|NCT01440907|OTHER|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
214713192|NCT01644981|OTHER|blood sampling|blood sampling
214713193|NCT01273389|DRUG|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
214713194|NCT01273389|DRUG|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
214713195|NCT04163640|OTHER|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
214713196|NCT04284280|DIETARY_SUPPLEMENT|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
214713197|NCT04326023|DRUG|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
214606681|NCT03890991|BEHAVIORAL|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
214713198|NCT02220946|DEVICE|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
214606682|NCT03890991|BEHAVIORAL|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
214606683|NCT03890991|BEHAVIORAL|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
214606684|NCT01580865|DRUG|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
214606685|NCT01679366|DRUG|Placebo|1 tablet 2 times daily
214713199|NCT04997824|PROCEDURE|Artificial Intelligence-based atrial fibrillation catheter ablation|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above."
214713200|NCT04997824|PROCEDURE|Medical Therapy|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure"
214722279|NCT02221960|BIOLOGICAL|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
214722280|NCT01945788|DRUG|Teriparatide (rDNA origin)|
214606686|NCT01679366|DRUG|Probiotics|1 tablet twice daily
214606687|NCT04127825|PROCEDURE|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
214606688|NCT04055181|DEVICE|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
214606689|NCT04055181|DEVICE|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
214606690|NCT04055181|DEVICE|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
214606691|NCT04055181|DEVICE|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
214606692|NCT02321826|BEHAVIORAL|Music|Participants choice among 4 genres of music matched on music characteristics
214606693|NCT02321826|BEHAVIORAL|Audiobook|Participants choice among 4 types of audiobooks
214606694|NCT00050765|DRUG|MyoCell™ Autologous Myoblasts|
214713201|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Plan + CHW|"* Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
214606695|NCT04114188|DRUG|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
214722281|NCT00169013|DRUG|Gabapentin|
214606696|NCT02734823|OTHER|Cytology Specimen Collection Procedure|Undergo collection of serum
214606697|NCT02734823|OTHER|Laboratory Biomarker Analysis|Correlative studies
214606698|NCT02734823|OTHER|Questionnaire Administration|Ancillary studies
214606699|NCT02734823|PROCEDURE|Ultrasonography|Undergo transvaginal pelvic ultrasonography
214606700|NCT01758263|DRUG|Metoprolol|Metoprolol, oral administration
214722282|NCT02037204|OTHER|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
214606701|NCT01758263|DRUG|Nebivolol|Nebivolol, oral administration
214606702|NCT04549727|OTHER|Organoids creation|Organoids are created from discarded tissue
214722283|NCT02660060|DRUG|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
214606703|NCT02432313|DRUG|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
214606704|NCT06508112|DEVICE|Masimo Radical-7® Pulse CO-Oximeter|Masimo Radical-7® Pulse CO-Oximeter device was attached to the index finger of the patients in the supine position and photoplethysmographic perfusion index and plethysmographic variability index were measured noninvasively, rapidly and continuously.
214606705|NCT01905124|DRUG|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
214606706|NCT01905124|DRUG|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
214606707|NCT01446016|DRUG|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
214606708|NCT01446016|DRUG|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
214606709|NCT01446016|DRUG|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
214606710|NCT01446016|DRUG|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
214606711|NCT02267603|OTHER|Laboratory Biomarker Analysis|Ancillary studies
214606712|NCT02267603|BIOLOGICAL|Pembrolizumab|Given IV
214606713|NCT02525055|OTHER|Infectious titre 1 (H3N2)|Infectious titre 1: 2.8 x 10\*3 TCID50/mL
214606714|NCT02525055|OTHER|Infectious titre 2 (H3N2)|Infectious titre 2: 2.5 x 10\*4 TCID50/mL
214606715|NCT02525055|OTHER|Infectious titre 3 (H3N2)|Infectious titre 3: 3.6 x 10\*5 TCID50/mL
214606716|NCT02525055|OTHER|Infectious titre 4 (H3N2)|Infectious titre 4: 4.7 x 10\*6 TCID50/mL
214606717|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
214606718|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
214606719|NCT01520311|DEVICE|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
214606720|NCT00049452|DRUG|zoledronic acid|
214606721|NCT04621734|DEVICE|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
214606722|NCT04621734|DEVICE|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
214606723|NCT03517189|PROCEDURE|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
214606724|NCT06494865|DEVICE|MRI device|"Standered breast coils with small field of veiw and thin sections will be used for the examinatio.~MRI breast including Axial T1WI, T2WI Stir contrast DWI and Stir sagittal T1WI with contrast traction and subtraction"
214606725|NCT05436769|DRUG|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
214606726|NCT05436769|DRUG|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
214606727|NCT05488210|DIETARY_SUPPLEMENT|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
214606728|NCT04573751|DRUG|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
214606729|NCT04573751|DRUG|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
214606730|NCT04573751|DRUG|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
214606731|NCT04573751|DRUG|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
214606732|NCT02626481|DRUG|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
214606733|NCT02626481|DRUG|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
214606734|NCT00298467|DRUG|MDX-060|
214606735|NCT02091154|BEHAVIORAL|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim"
214606736|NCT02091154|BEHAVIORAL|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
214606737|NCT02091154|BEHAVIORAL|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
214606738|NCT01582022|DRUG|Bupivacaine|local application for 5 minutes
214606739|NCT01582022|DRUG|normal saline|local application for 5 minutes
214606740|NCT00408330|DRUG|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
214606741|NCT00408330|DRUG|Inactive 15% gel base|placebo, topically applied daily for six weeks
214606742|NCT01087957|DEVICE|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
214606743|NCT01087957|OTHER|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
214713202|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Management Plan|"* Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
214606744|NCT01291199|DRUG|vardenafil|10 mg p.o. bid for 6 weeks
214606745|NCT01291199|DRUG|Placebo|Placebo p.o. 6 weeks bid
214606746|NCT03743883|DRUG|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
214606747|NCT01186939|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
214606748|NCT02851420|OTHER|spectroscopy|
214606749|NCT02313298|RADIATION|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
214606750|NCT02692664|DEVICE|Endovascular aorto-iliac repair|
214606751|NCT04420754|BIOLOGICAL|AIC100 CAR T Cells|Autologous CAR T cells directed against ICAM-1
214606752|NCT04179747|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
214713203|NCT02190617|BEHAVIORAL|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
214606753|NCT04179747|DRUG|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
214606754|NCT00987688|OTHER|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
214606755|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
214606756|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with 5mm suction irrigation blunt dissection starting from fundus
214713204|NCT00477555|DEVICE|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
214713205|NCT03718702|OTHER|ePain|Electronic pain management programme (ePain)
214713206|NCT04526119|DRUG|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
214713207|NCT04526119|DRUG|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
214606757|NCT05559021|OTHER|Myofascial Therapy Treatments|"• Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat"
214606758|NCT05559021|OTHER|Passive Mobilizations Approach|"• Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage"
214713208|NCT04269655|DEVICE|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
214713209|NCT02201355|RADIATION|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
214606759|NCT00296179|DRUG|zolpidem tartrate|
214606760|NCT02560064|PROCEDURE|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
214713210|NCT04009746|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
214713211|NCT02618343|DRUG|IPA|IPA Aromatherapy for the experimental arm
214713212|NCT02618343|DRUG|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
214713213|NCT00467714|PROCEDURE|rhinoplasty|COLUMELLA STRUT PLACEMENT
214713214|NCT05389059|PROCEDURE|CAF+CM|Periodontal surgery including CAF+CM application
214713215|NCT05389059|PROCEDURE|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
214713216|NCT00001911|DRUG|Interleukin-12|
214713217|NCT06281405|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
214713218|NCT06281405|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
214713219|NCT06281405|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
214713220|NCT00862654|DRUG|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
214713221|NCT00862654|DRUG|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
214713222|NCT00862654|DRUG|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
214713223|NCT00862654|DRUG|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
214606761|NCT05286983|BEHAVIORAL|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
214606762|NCT01754857|DRUG|Bendamustine|Given IV
214606763|NCT01754857|DRUG|Rituximab|Given IV
214606764|NCT01754857|DRUG|Lenalidomide|Given PO
214606765|NCT01509079|DRUG|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
214606766|NCT01509079|DRUG|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
214606767|NCT01925352|DRUG|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
214606768|NCT03910712|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
214606769|NCT03910712|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
214606770|NCT03910712|DRUG|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
214713224|NCT05367219|DEVICE|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
214713225|NCT04840017|OTHER|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
214713226|NCT01750944|PROCEDURE|Ankle first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured."
214713227|NCT01750944|PROCEDURE|Toe first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured."
214606771|NCT05788822|DIETARY_SUPPLEMENT|Mevalproic acid|Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
214606772|NCT00328991|DEVICE|duct tape occlusion therapy|
214606773|NCT03938038|DIAGNOSTIC_TEST|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
214606774|NCT03938038|DIAGNOSTIC_TEST|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
214713228|NCT02750267|DEVICE|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
214606775|NCT05263063|OTHER|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
214606776|NCT01399190|BIOLOGICAL|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
214606777|NCT01399190|BIOLOGICAL|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
214606778|NCT01399190|DRUG|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
214606779|NCT00525889|DRUG|IL-2|Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
214606780|NCT00525889|DRUG|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
214606781|NCT00264225|DRUG|Lamaline® , 3 different doses, Dafalgan codeine|
214606782|NCT06325618|OTHER|No intervention other than obtaining biopsies|Skin, fat, and muscle biopsies will be obtained
214606783|NCT06325618|DRUG|Indocyanine green (ICG)|Indocyanine green will be injected to evaluate the lymphatic system.
214606784|NCT04353453|DEVICE|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
214606785|NCT04353453|DEVICE|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
214606786|NCT04157504|OTHER|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
214606787|NCT02412020|DRUG|PA101|
214606788|NCT02412020|DRUG|Placebo|
214606789|NCT06466811|OTHER|Patients of intensive care unit|Patients of intensive care unit having an EVD
214606790|NCT06466811|OTHER|Patients of surgical intensive care unit|Patients of surgical intensive care unit having an EVD.
214606791|NCT02686021|DRUG|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
214606792|NCT02686021|DRUG|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
214606793|NCT02686021|DRUG|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
214606794|NCT00611962|DRUG|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
214606795|NCT01636414|PROCEDURE|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
214606796|NCT01636414|PROCEDURE|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
214606797|NCT01636414|PROCEDURE|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
214606798|NCT05248451|OTHER|Not an Interventional Study|Not an Interventional Study
214606799|NCT03150316|DRUG|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
214606800|NCT00005920|DRUG|L-743,872|
214606801|NCT04474457|DRUG|Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
214606802|NCT00436618|DRUG|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
214606803|NCT06343012|OTHER|Caring leadership Intervention program|Caring leadership intervention program
214606804|NCT00698204|DRUG|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
214713229|NCT06356948|DRUG|Tranexamic Acid (TXA)|Study drug administration
214713230|NCT01476748|DEVICE|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
214713231|NCT04019769|DRUG|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
214713232|NCT04631068|PROCEDURE|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
214713233|NCT03089658|DRUG|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
214713234|NCT03219567|DEVICE|Optical Coherence Tomography (OCT)|"Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye."
214713235|NCT03219567|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
214713236|NCT05314881|GENETIC|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
214713237|NCT03451500|DRUG|carbidopa-levodopa|See previous
214713238|NCT03258697|DRUG|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
214606805|NCT00698204|DRUG|placebo|Subject was asked to take placebo each day that radiation therapy was given.
214606806|NCT03001973|OTHER|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
214606807|NCT01949155|DRUG|OTO-201|Single, intratympanic injection
214606808|NCT01949155|DRUG|Sham|Simulated single, intratympanic injection
214606809|NCT00314249|DRUG|Placebo|Placebo, oral administration, twice daily for 12 weeks
214606810|NCT00314249|DRUG|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID \[twice a day\])
214713239|NCT06437145|OTHER|Type of Exercise|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak. The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
214713240|NCT00356395|DRUG|ramipril, candesartan|
214606811|NCT04292028|OTHER|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
214606812|NCT04292028|OTHER|Home exercises|Control group were given a home-based exercise program.
214606813|NCT00217191|DRUG|Ibuprofen|
214606814|NCT03120806|PROCEDURE|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
214606815|NCT03120806|PROCEDURE|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
214606816|NCT03347981|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
214606817|NCT03347981|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
214606818|NCT04825171|DRUG|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
214606819|NCT05165355|DRUG|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
214606820|NCT00210184|DRUG|Irinotecan associated to fluorouracil and leucovorin|
214606821|NCT04997187|DIETARY_SUPPLEMENT|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
214713241|NCT02392494|DRUG|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
214713242|NCT06372886|PROCEDURE|portal/superior vein resection|portal/superior vein resection
214713243|NCT01313208|DRUG|etanercept|Administered by subcutaneous injection once weekly.
214713244|NCT01313208|DRUG|Placebo|Placebo subcutaneous injection
214713245|NCT01313208|DRUG|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
214606822|NCT04997187|DIETARY_SUPPLEMENT|Control group|Placebo 400 mg/day for 12 weeks
214606823|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
214606824|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
214606825|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
214606826|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
214606827|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
214606828|NCT04146428|BEHAVIORAL|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
214606829|NCT04146428|BEHAVIORAL|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
214606830|NCT05988541|DIAGNOSTIC_TEST|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
214606831|NCT05988541|DIAGNOSTIC_TEST|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~1. Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~2. Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~3. Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
214606832|NCT05988541|DIAGNOSTIC_TEST|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
214606833|NCT05988541|DIAGNOSTIC_TEST|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
214606835|NCT06495502|OTHER|semi-structured interview|Semi-structured interviews by qualitative health researchers
214606836|NCT06249204|BEHAVIORAL|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
214606837|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
214606838|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214606839|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
214606840|NCT05941520|OTHER|Questionnaire Administration|Ancillary studies
214606841|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
214606842|NCT05941520|DRUG|Tamoxifen|Given PO
214606843|NCT05222204|DRUG|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
214606844|NCT06435676|DRUG|HRS9531|Single dose escalation of HRS9531 tablets in healthy subjects
214606845|NCT06435676|DRUG|Placebo|Single dose of placebo in healthy adults
214606846|NCT06435676|DRUG|HRS9531|Multiple dose escalation of HRS9531 tablets in healthy subjects
214606847|NCT06435676|DRUG|Placebo|Multiple dose of placebo in healthy adults
214606848|NCT04607954|BIOLOGICAL|Durvalumab|Given IV
214606849|NCT04607954|DRUG|Lurbinectedin|Given IV
214606850|NCT05003895|DRUG|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
214606851|NCT05003895|BIOLOGICAL|CAR-T cell|Single infusion on Day 0
214606852|NCT05003895|DRUG|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
214606853|NCT01118325|DRUG|ticagrelor|Drug oral treatment
214606854|NCT01118325|DRUG|clopidogrel|Drug oral treatment
214713246|NCT01654523|DEVICE|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
214606855|NCT05694520|OTHER|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
214606856|NCT03589690|DIETARY_SUPPLEMENT|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
214606857|NCT03589690|DIETARY_SUPPLEMENT|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
214606858|NCT03532646|PROCEDURE|upper endoscopy|endoscopy of the gastrointestinal tract
214606859|NCT04392453|DEVICE|Robotic therapy|The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
214606860|NCT03114007|BEHAVIORAL|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
214606861|NCT03114007|BEHAVIORAL|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
214606862|NCT03114007|BEHAVIORAL|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
214713247|NCT06268587|COMBINATION_PRODUCT|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
214713248|NCT01270100|BEHAVIORAL|Recovery management|
214713249|NCT06224972|DEVICE|Vlab|The study is observational, there is no intervention.
214713250|NCT02877849|DEVICE|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
214606863|NCT03258125|GENETIC|real time PCR (rPCR)|A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
214606864|NCT03334409|DRUG|Ascorbic Acid|Given IV
214606865|NCT03334409|DRUG|Pazopanib Hydrochloride|Given PO
214606866|NCT00000820|DRUG|Aldesleukin|
214606867|NCT03496480|DIAGNOSTIC_TEST|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
214606868|NCT00975715|DRUG|TRI476|TRI476 oral suspension doses, based on body weight twice daily
214606869|NCT00975715|DRUG|Placebo to TRI476|Placebo oral suspension, taken twice daily
214606870|NCT00975715|DRUG|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
214606871|NCT04116424|OTHER|nurse training of the patient|visit + telephone follow-up
214606872|NCT04116424|OTHER|neurologist accompaniement|presentation during consultation by neurologist
214606873|NCT03270566|DEVICE|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
214606874|NCT01245634|DRUG|Placebo|iv infusion every 4 weeks, 32 weeks
214606875|NCT01245634|DRUG|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
214606876|NCT05683587|OTHER|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
214606877|NCT06048692|DRUG|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
214606878|NCT06048692|DRUG|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
214606879|NCT05592067|OTHER|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
214606880|NCT05592067|OTHER|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
214606881|NCT05592067|OTHER|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day
214606882|NCT03552796|OTHER|Pharmacokinetic Study|Correlative studies
214606883|NCT03552796|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given intravesically
214606884|NCT00418951|DRUG|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
214606885|NCT00418951|DRUG|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
214606886|NCT00418951|DRUG|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
214606887|NCT02717663|BEHAVIORAL|Adaptive Goals|Prescribed goals change daily based on participant's performance
214606888|NCT02717663|BEHAVIORAL|Static Goals|Prescribed goals remain the same throughout study
214606889|NCT02717663|BEHAVIORAL|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
214606890|NCT02717663|BEHAVIORAL|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
214606891|NCT00872664|DIETARY_SUPPLEMENT|carotenoids|beta-carotene, lycopene, lutein
214606892|NCT04214301|DRUG|BLI800|BLI800 Bowel Preparation
214606893|NCT00727233|DRUG|Nexavar (BAY 43-9006) (Sorafenib)|
214606894|NCT00727233|DRUG|Toxicity, Pharmacokinetics|
214606895|NCT00727233|DRUG|Pharmacodynamics|
214606896|NCT00727233|DRUG|Radiographic Evaluation|
214606897|NCT00727233|DRUG|QOL assessment, Neuropsychological|
214606898|NCT00727233|DRUG|Bony Toxicity|
214606899|NCT00001333|DRUG|topotecan|
214606900|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
214606901|NCT01674712|DRUG|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
214606902|NCT01674712|DRUG|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
214606903|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
214606904|NCT01674712|DRUG|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
214606905|NCT04579744|OTHER|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
214606906|NCT02279823|DRUG|CB-03-01 solution|Investigational drug solution
214606907|NCT02279823|DRUG|Minoxidil Solution 5%|FDA approved marketed product
214606908|NCT02279823|DRUG|Placebo solution|Vehicle solution
214606909|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
214606910|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
214606911|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
214713251|NCT04081376|DRUG|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
214606912|NCT00874770|DRUG|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
214606913|NCT00874770|DRUG|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
214606914|NCT00874770|DRUG|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
214606915|NCT03686956|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
214606916|NCT01200108|DRUG|Budesonide|
214606917|NCT01200108|DRUG|Budesonide|
214606918|NCT01200108|DRUG|Budesonide|
214606919|NCT05573321|OTHER|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
214606920|NCT05573321|OTHER|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
214606921|NCT03659279|BEHAVIORAL|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
214606922|NCT00490633|BEHAVIORAL|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
214606923|NCT00490633|BEHAVIORAL|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
214713252|NCT04101435|BIOLOGICAL|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
214713253|NCT00538746|DEVICE|BIPAP|
214606924|NCT00325962|DRUG|6R-BH4 (sapropterin dihydrochloride)|
214606925|NCT06394596|OTHER|Prognostic factors affecting graft survival|The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation
214606926|NCT01047696|DEVICE|Plancha|locally developed chimney stove
214606927|NCT00445562|OTHER|biologic sample preservation procedure|
214606928|NCT00445562|OTHER|informational intervention|
214606929|NCT04225468|BEHAVIORAL|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
214713254|NCT00538746|DEVICE|PSV|
214713255|NCT00538746|DEVICE|PSV + CPAP|
214713256|NCT05137886|DRUG|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
214713257|NCT01829217|DRUG|Sunitinib|
214713258|NCT03486210|BEHAVIORAL|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
214606930|NCT03623451|DRUG|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
214606931|NCT05395104|DRUG|Midazolam|Syrup for oral administration
214606932|NCT05395104|DRUG|Cefiderocol|Liquid for intravenous infusion
214606933|NCT01617850|OTHER|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
214606934|NCT01617850|OTHER|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
214606935|NCT03974334|BEHAVIORAL|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
214606936|NCT05135026|DIAGNOSTIC_TEST|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
214606937|NCT00378833|DRUG|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
214606938|NCT00378833|DRUG|niacin|Duration of Treatment: 18 Weeks
214606939|NCT00002016|DRUG|Sevirumab|
214606940|NCT03210103|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
214606941|NCT03210103|PROCEDURE|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
214606942|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
214606943|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
214606944|NCT01109173|OTHER|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
214606945|NCT01109173|OTHER|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
214606946|NCT01892306|BEHAVIORAL|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
214606947|NCT01892306|DRUG|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
214606948|NCT04263350|DRUG|Atazanavir/Cobicistat|Specified Dose on Specified Days
214606949|NCT04263350|DRUG|Reyataz Atazanavir|Specified Dose on Specified Days
214606950|NCT04263350|DRUG|Cobicistat|Specified Dose on Specified Days
214722284|NCT02660060|DRUG|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
214606951|NCT05671783|OTHER|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
214606952|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
214606953|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
214606954|NCT04123990|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
214606955|NCT02068365|DRUG|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
214606956|NCT06417463|PROCEDURE|thyroidectomy opeartion|correlation between TIRADS and Bethesda scoring system (preoperative) and final histopathology (postoperative) in cases of thyroidectomy
214606957|NCT00190710|DRUG|Gemcitabine|
214606958|NCT00190710|DRUG|Carboplatin|
214606959|NCT00684450|PROCEDURE|Titration protamine|10\. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
214606960|NCT00684450|DRUG|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
214606961|NCT05067426|OTHER|Exercise|high-intensity interval training sessions
214606962|NCT03341572|OTHER|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
214606963|NCT04582942|DRUG|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
214606964|NCT04582942|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
214606965|NCT00686270|DRUG|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
214606966|NCT04347070|OTHER|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
214606967|NCT00018850|DRUG|ondansetron|
214606968|NCT00018850|BEHAVIORAL|neuropsychological testing|
214606969|NCT00018850|DRUG|nicotine|
214606970|NCT00018850|DRUG|haloperidol|
214606971|NCT02336841|OTHER|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
214606972|NCT02336841|OTHER|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
214606973|NCT05896371|DRUG|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I\&T injected activity
214606974|NCT05896371|DRUG|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I\&T injected activity
214606975|NCT04184492|DRUG|GP-40081|biphasic insulin aspart 30 in doses 0.4 IU/kg
214606976|NCT04184492|DRUG|NovoMix® 30 Penfill®|biphasic insulin aspart 30 in doses 0.4 IU/kg
214606977|NCT01053442|DIETARY_SUPPLEMENT|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
214606978|NCT01053442|DIETARY_SUPPLEMENT|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
214606979|NCT05668039|PROCEDURE|Enhanced external counterpulsation|15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
214606980|NCT04035226|OTHER|No intervention|No intervention will be administered as a part of this study.
214606981|NCT00002296|DRUG|Inosine pranobex|
214606982|NCT03725579|DRUG|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
214606983|NCT03725579|DRUG|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
214606984|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
214606985|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
214606986|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
214606987|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
214606988|NCT01921855|DRUG|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
214606989|NCT01358890|OTHER|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
214606990|NCT01358890|OTHER|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
214606991|NCT03054207|DRUG|Clopidogrel 300Mg Tablet|
214713259|NCT03486210|OTHER|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
214606992|NCT03054207|DRUG|Prasugrel 60Mg|
214606993|NCT00334386|DRUG|Torasemide Prolonged Release (loop diuretic)|
214606994|NCT00334386|DRUG|Torasemide Immediate Release (loop diuretic)|
214606995|NCT00770770|DRUG|Fluocinolone Acetonide|0.2 µg/day
214606996|NCT00770770|DRUG|Fluocinolone Acetonide|0.5 µg/day
214606997|NCT01961375|DRUG|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
214606998|NCT03568045|DEVICE|standard light|usual care
214606999|NCT03568045|DEVICE|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
214607000|NCT03568045|DEVICE|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
214607001|NCT01089920|OTHER|Green tea|Infusion (tea bags) from commercially available green tea
214607002|NCT01089920|OTHER|Coffee|Soluble coffee commercially available
214713260|NCT02679495|BEHAVIORAL|Active measures of lifestyle modification|
214713261|NCT00226395|DRUG|Oxymorphone immediate release|
214713262|NCT00440895|DRUG|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
214713263|NCT04077736|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
214607003|NCT05407233|DEVICE|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
214713264|NCT04552717|OTHER|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
214713265|NCT01572818|PROCEDURE|phlebotomy|7 ml/kg without exceeding 500 mL
214713266|NCT01572818|BEHAVIORAL|dietary and lifestyle counseling|dietary and lifestyle counseling
214713267|NCT01536106|OTHER|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
214713268|NCT01536106|OTHER|Placebo control|Intracoronary infusion of autologous peripheral blood.
214713269|NCT05163717|COMBINATION_PRODUCT|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
214713270|NCT05163717|COMBINATION_PRODUCT|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
214713271|NCT05486936|RADIATION|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
214713272|NCT01557764|DRUG|lapatinib ditosylate|Given PO
214713273|NCT01557764|BIOLOGICAL|trastuzumab|Given IV
214607004|NCT05407233|DEVICE|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
214607005|NCT02483559|OTHER|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (\~470 nm) to be worn prior to desired sleep onset time.
214607006|NCT02483559|OTHER|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
214607007|NCT01761279|PROCEDURE|High definition white light endoscopy|
214607008|NCT00572026|DRUG|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
214713274|NCT04180501|COMBINATION_PRODUCT|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
214713275|NCT04377672|BIOLOGICAL|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
214713276|NCT05893667|DIAGNOSTIC_TEST|Inflammatory markers|analysis of inflammatory scores
214607009|NCT02484976|BEHAVIORAL|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
214607010|NCT03714191|OTHER|Patient Outcomes|The intervention includes different versions of the BPA design and message.
214607011|NCT03714191|OTHER|Billing documentation|The intervention includes different versions of the BPA design and message.
214607012|NCT03714191|OTHER|Regulatory|The intervention includes different versions of the BPA design and message.
214607013|NCT02775084|DIETARY_SUPPLEMENT|Fish Oil|4 capsules twice daily with food for 6 weeks
214713277|NCT03954444|DRUG|Oxymetazoline Hydrochloride|Test Comparator
214713278|NCT03954444|DRUG|Rhofade Cream, 1%|Reference Comparator
214607014|NCT02775084|DIETARY_SUPPLEMENT|Olive Oil|4 capsules twice daily with food for 6 weeks
214607015|NCT04124484|DRUG|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
214713279|NCT03954444|DRUG|Placebo|Placebo Comparator
214607016|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
214607017|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
214607018|NCT04124484|DRUG|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
214607019|NCT05372653|DRUG|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
214607020|NCT02271997|DRUG|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
214607021|NCT02271997|DRUG|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
214607022|NCT02271997|DRUG|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
214607023|NCT04894123|DRUG|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
214607024|NCT04894123|DRUG|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
214607025|NCT04808622|DRUG|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
214607026|NCT04808622|DRUG|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
214607027|NCT01381354|OTHER|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
214607028|NCT01381354|DEVICE|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
214607029|NCT01381354|OTHER|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
214607030|NCT01381354|DIETARY_SUPPLEMENT|Omega 3 fatty acids|4 grams daily by mouth.
214607031|NCT01381354|DIETARY_SUPPLEMENT|Full Spectrum vitamin|Two capsules daily.
214607032|NCT01381354|DIETARY_SUPPLEMENT|Essential - hydroxytyrosol|Two capsules twice daily.
214607033|NCT01381354|DIETARY_SUPPLEMENT|Maltodextrin fiber supplement|One scoop daily.
214607034|NCT01381354|DIETARY_SUPPLEMENT|Mineral boost (magnesium)|Two capsules daily
214607035|NCT01381354|DIETARY_SUPPLEMENT|Niacinamide|500 mg daily
214607036|NCT01381354|DIETARY_SUPPLEMENT|Methyl B12|Methyl B12 1000 mcg daily
214607037|NCT01381354|DIETARY_SUPPLEMENT|Taurine|one gram daily
214607038|NCT01381354|DIETARY_SUPPLEMENT|creatine|one teaspoon daily
214607039|NCT01381354|DIETARY_SUPPLEMENT|thiamine|100 mg daily
214607040|NCT01381354|DIETARY_SUPPLEMENT|riboflavin|200 mg daily
214607041|NCT01381354|DIETARY_SUPPLEMENT|N acetylcysteine|1 gram daily
214607042|NCT01381354|DIETARY_SUPPLEMENT|alpha lipoic acid|300 mg twice daily
214607043|NCT01381354|DIETARY_SUPPLEMENT|L acetyl carnitine|500 mg twice daily
214607044|NCT01381354|DIETARY_SUPPLEMENT|methyl folate|1000 mcg one pill four times a week
214607045|NCT01381354|DIETARY_SUPPLEMENT|coenzyme Q|100 mg daily
214607046|NCT01381354|BEHAVIORAL|meditation|meditation 15 minutes daily
214607047|NCT01381354|BEHAVIORAL|self massage|self massage of hands, feet, ears 15 minutes daily
214713280|NCT01492296|PROCEDURE|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
214713281|NCT01492296|PROCEDURE|conventional fasting|patients were evaluated after fasting for 8 hours
214713282|NCT02447458|DRUG|MLN3126|MLN3126 tablets
214607048|NCT01381354|BEHAVIORAL|learning|completing puzzles or learning 15 minutes daily
214607049|NCT01381354|DIETARY_SUPPLEMENT|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
214607050|NCT03267160|DIAGNOSTIC_TEST|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
214607051|NCT00711529|BEHAVIORAL|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
214607052|NCT00711529|DRUG|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
214607053|NCT02083874|DRUG|CBD|
214713283|NCT02447458|DRUG|MLN3126 Placebo|MLN3126 placebo-matching tablets
214713284|NCT04914117|DRUG|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
214607054|NCT04128345|DEVICE|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
214607055|NCT03411460|DEVICE|FreeStyle Libre™ system|Measured non-invasively via scanner
214607056|NCT03411460|PROCEDURE|Finger prick|Blood test
214607057|NCT02444481|DRUG|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
214607058|NCT06238674|OTHER|indirect calorimetry and nitrogen balance|"nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance"
214713285|NCT02602717|OTHER|lymph nodes cyto-punction|
214607059|NCT06238674|OTHER|Indirect calorimetry (Standard care nutrition arm)|indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
214607060|NCT00038727|BEHAVIORAL|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
214607061|NCT00038727|DRUG|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
214607062|NCT00038727|BEHAVIORAL|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
214607063|NCT00038727|BEHAVIORAL|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
214607064|NCT00928174|DRUG|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
214607065|NCT02173041|OTHER|Prevention Awareness Groups (PAG)|
214607066|NCT02173041|OTHER|Standard Care|
214713286|NCT04282681|OTHER|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
214713287|NCT06044519|BIOLOGICAL|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
214713288|NCT02305875|OTHER|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
214607067|NCT00920920|RADIATION|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
214607068|NCT01748409|OTHER|Biopsies of peripheral autonomic nervous system|
214713289|NCT05200052|DRUG|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
214713290|NCT01176370|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
214713291|NCT01637870|DEVICE|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
214713292|NCT00405652|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
214713293|NCT04376099|DIAGNOSTIC_TEST|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
214713294|NCT02133742|DRUG|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
214713295|NCT02133742|DRUG|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
214607069|NCT01748409|OTHER|Autonomic dysfunction questionnaires|
214607070|NCT01748409|OTHER|Electrophysiological tests|
214607071|NCT03681951|DRUG|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
214607072|NCT03681951|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
214607073|NCT01020448|DRUG|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
214607074|NCT05793177|BEHAVIORAL|Everyday Life is Rehabilitation|Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
214607075|NCT01230554|DEVICE|Daily disposable cosmetic tint lens|Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
214607076|NCT03082950|DIAGNOSTIC_TEST|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
214607077|NCT03750383|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
214607078|NCT03750383|DRUG|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
214607079|NCT03750383|DRUG|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
214607080|NCT03750383|DRUG|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
214607081|NCT02681250|PROCEDURE|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
214607082|NCT02681250|PROCEDURE|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
214607083|NCT02790957|DRUG|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
214607084|NCT02790957|DRUG|Placebo|Single injection of an equal volume of NaCl solution
214607085|NCT01524341|DRUG|KAE609|KAE609 was supplied as capsules for oral use.
214607086|NCT04088383|OTHER|Amnios™ RT|Acellular human allograft
214607087|NCT04088383|OTHER|Saline|Sterile saline
214607088|NCT04194853|DEVICE|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
214607089|NCT04194853|OTHER|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
214607090|NCT00972426|DRUG|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
214607091|NCT01481623|OTHER|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
214607092|NCT01481623|OTHER|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
214713296|NCT00435994|DRUG|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
214607093|NCT00814567|RADIATION|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
214607094|NCT04408014|DIAGNOSTIC_TEST|Serological test|IgM and IgG for SARS-CoV-2
214607095|NCT04408014|DIAGNOSTIC_TEST|Nasopharyngeal Swab|PCR for SARS-CoV-2
214607096|NCT04408014|DIAGNOSTIC_TEST|Oropharyngeal Swab|PCR for SARS-CoV-2
214607097|NCT04652713|OTHER|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
214607098|NCT04652713|OTHER|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
214607099|NCT04652713|OTHER|No breakfast|1 glas of water (150 ml)
214607100|NCT05330403|PROCEDURE|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
214607101|NCT00619905|DRUG|ACZ885|
214607102|NCT00619905|DRUG|ACZ885|
214607103|NCT03755791|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
214607104|NCT03755791|DRUG|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
214607105|NCT03755791|DRUG|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
214607106|NCT03755791|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
214607107|NCT04869254|OTHER|Lower lymphocyte/ATG ratio|
214607108|NCT04869254|OTHER|Higher lymphocyte/ATG ratio|
214607109|NCT00566917|PROCEDURE|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
214607110|NCT00566917|PROCEDURE|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
214607111|NCT02677376|OTHER|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a second NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
214607112|NCT00685685|DRUG|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
214607113|NCT00685685|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
214607114|NCT06494007|DRUG|Sodium chloride|The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.
214607115|NCT06494007|DRUG|90 mg of calcium|The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.
214607116|NCT06494007|DRUG|180 mg Calcium|The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.
214607117|NCT02710617|DEVICE|Blood glucose monitoring systems for point-of-care-testing|
214607118|NCT03841695|DEVICE|RMTC finger-hand robot (Mirror Hand)|The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
214607119|NCT03841695|OTHER|Conventional OT|The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
214607120|NCT02140333|DRUG|Erlotinib|100mg vs. 150mg
214607121|NCT01558427|PROCEDURE|Surveillance|Active clinical surveillance
214607122|NCT01558427|PROCEDURE|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
214607123|NCT06138964|DRUG|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
214607124|NCT06138964|DRUG|siSPARC microneedle patch|siSPARC microneedle patch
214607125|NCT04029181|OTHER|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
214607126|NCT00108914|DRUG|GW685698X|
214607127|NCT05522049|DEVICE|hyperangulated videolaryngoscope|Intubation using a hyperangulated videolaryngoscope
214607128|NCT05522049|DEVICE|Macintosh videolaryngoscope|Intubation using a Macintosh videolaryngoscope
214607129|NCT03819036|OTHER|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
214607130|NCT06245096|BEHAVIORAL|Cognitive Behavioral Therapy|Sessions will focus on skills such as behavioral activation, mood tracking, identifying and reframing automatic thoughts, assertion training and smart goals.
214607131|NCT06245096|BEHAVIORAL|Acceptance and Commitment Therapy|Sessions will focus on skills such as mindfulness, acceptance and willingness training, values clarification, committed action, defusion, and self-as-context.
214607132|NCT03533413|PROCEDURE|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
214607133|NCT03533413|PROCEDURE|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
214607134|NCT04341168|OTHER|this study is non- interventional|this study is non- interventional
214607135|NCT01791023|OTHER|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
214607136|NCT04236895|DRUG|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
214607137|NCT00445523|BIOLOGICAL|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
214607138|NCT00445523|DRUG|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
214607139|NCT02650336|DRUG|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
214607140|NCT05511493|DEVICE|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
214607141|NCT05511493|DEVICE|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
214607142|NCT00252304|DRUG|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
214713297|NCT00435994|OTHER|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
214713298|NCT03823599|BEHAVIORAL|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
214713299|NCT03823599|BEHAVIORAL|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
214713300|NCT02941289|PROCEDURE|visual search performance of everyday objects in realistic scenes|
214713301|NCT05757089|DIETARY_SUPPLEMENT|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
214713302|NCT04794946|BIOLOGICAL|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
214713303|NCT00772694|DRUG|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
214713304|NCT02155348|PROCEDURE|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
214607143|NCT00252304|DRUG|Placebo|Placebo
214713305|NCT02155348|PROCEDURE|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
214713306|NCT02155348|DEVICE|Lentis LS-313|
214713307|NCT03288324|DRUG|Tofacitinib|Tofacitinib 5 mg twice daily
214713308|NCT03404635|DRUG|Apixaban|Apixaban as standard of care for VTE
214713309|NCT03404635|DRUG|Rivaroxaban|Rivaroxaban as standard of care for VTE
214713310|NCT02790463|BEHAVIORAL|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
214713311|NCT00002717|DRUG|cisplatin|
214713312|NCT00002717|DRUG|paclitaxel|
214713313|NCT04078334|OTHER|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
214713314|NCT04078334|OTHER|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
214722285|NCT06219876|DEVICE|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
214722286|NCT06219876|DEVICE|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
214607144|NCT06116227|DEVICE|Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.|Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.
214607145|NCT06116227|OTHER|Conventional Physical Therapy Exercise Program.|The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
214607146|NCT05516823|OTHER|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
214607147|NCT05373524|BIOLOGICAL|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
214722287|NCT06219876|OTHER|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
214713315|NCT04078334|OTHER|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
214607148|NCT05033652|OTHER|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR\<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
214713316|NCT00181935|DRUG|risperidone (Risperdal)|
214713317|NCT00181935|DRUG|olanzapine (Zyprexa)|
214713318|NCT01017341|DEVICE|PSU hip protector|hip protetor
214713319|NCT00886717|DRUG|carboplatin|
214713320|NCT00886717|DRUG|paclitaxel-loaded polymeric micelle|
214713321|NCT02472795|DRUG|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
214713322|NCT02472795|DRUG|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
214713323|NCT01125618|OTHER|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
214713324|NCT01125618|OTHER|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
214713325|NCT00525408|BIOLOGICAL|Mycobacterium w.|Immunomodulator
214713326|NCT00525408|DRUG|Docetaxel|Chemotherapeutic agent
214607149|NCT02939989|DRUG|Sofosbuvir|Tablet for oral administration
214607150|NCT02939989|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
214607151|NCT02939989|DRUG|Ribavirin|Tablet for oral administration
214607152|NCT01615653|PROCEDURE|EUS|EUS Guided Therapy
214607153|NCT04645771|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
214713327|NCT02990455|DRUG|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
214713328|NCT04370912|DIAGNOSTIC_TEST|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
214713329|NCT01396902|BEHAVIORAL|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
214713330|NCT01396902|BEHAVIORAL|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
214713331|NCT02366390|BEHAVIORAL|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
214713332|NCT06190743|OTHER|Prevention events organized by participating centers|Cardiovascular disease primary prevention events organized by centers participating in the study where capillary sampling will be performed on subjects to quantify plasma levels of cardiovascular risk factors and validated questionnaires will be administered
214607154|NCT01660451|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
214607155|NCT02052063|DEVICE|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
214713333|NCT05109702|DRUG|0.25% Tanfanercept Ophthalmic Solution|Tanfanercept ophthalmic solution.
214713334|NCT05109702|DRUG|Placebo|Placebo vehicle solution.
214713335|NCT03812588|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
214607156|NCT02052063|DEVICE|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
214607157|NCT02690805|DEVICE|MR-compatible scinti-mammography (MRI-SMM) system|
214607158|NCT05745454|BIOLOGICAL|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
214607159|NCT06188169|PROCEDURE|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
214607160|NCT04998487|DRUG|LY3471851|Administered SC.
214607161|NCT02210377|OTHER|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
214713336|NCT03812588|DRUG|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
214607162|NCT02210377|OTHER|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
214607163|NCT05042037|DIETARY_SUPPLEMENT|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
214713337|NCT06049615|DEVICE|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
214722288|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
214607164|NCT05042037|OTHER|Placebo|Placebo sachet with no microbial cell preparation
214607165|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
214607166|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
214607167|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
214607168|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
214607169|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
214607170|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
214607171|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
214607172|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
214607173|NCT04561596|DEVICE|OnComfort autohypnosis|"Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
214607174|NCT04561596|OTHER|Treatment as usual, without the OnComfort autohypnosis system|"The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
214607175|NCT05141123|PROCEDURE|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
214607176|NCT04574479|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
214607177|NCT04574479|DRUG|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
214607178|NCT06102603|OTHER|the biobased polyester cast|long arm casting
214607179|NCT06102603|OTHER|the synthetic fiberglass cast|long arm casting
214713338|NCT05099237|DEVICE|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
214713339|NCT05099237|DEVICE|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
214722289|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
214722290|NCT03329664|BIOLOGICAL|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
214607180|NCT06374914|DRUG|Intravesical Solution|Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
214607181|NCT04733339|BEHAVIORAL|Secondary Prevention|behavioral changes in dieting and exercising up to one year after clinical discharge
214607182|NCT00726934|OTHER|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
214607183|NCT00726934|OTHER|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~1. Avoid raw vegetables and fruit (Oranges and bananas are okay.)~2. Avoid take-out foods and fast foods and fountain drinks.~3. Avoid aged cheese (blue, Roquefort, Brie).~4. Cook all produce to well done. Eggs must be hard-boiled.~5. Avoid deli meats.~6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~7. No well water~8. No yogurt"
214607184|NCT05922020|OTHER|Oxygen gas|Administration of Oxygen by inhalation
214607185|NCT05844371|DRUG|tirelizumab|Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.
214607186|NCT05844371|DRUG|chemotherapy with oxaliplatin + heroda|chemotherapy with oxaliplatin + heroda
214607187|NCT02493894|DRUG|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
214607188|NCT02493894|DRUG|placebo|placebo each 8 hours for 24 hours
214607189|NCT02493894|DRUG|Cefazolin|cefazolin 1gram, every 6hours for 2 days
214713340|NCT05099237|DRUG|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
214713341|NCT05099237|OTHER|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
214607190|NCT03082131|DIETARY_SUPPLEMENT|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
214607191|NCT01841463|DRUG|P1446A-05|\- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
214713342|NCT05099237|DIAGNOSTIC_TEST|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~* Baseline blood sample during study enrolment~* Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~* Post CAR T-cell infusion:~  * Day 1~ * Day 3~ * Day 6~ * Day 9~ * Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
214713343|NCT05099237|OTHER|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
214713344|NCT00475800|DRUG|Lumiracoxib|
214713345|NCT02747771|BEHAVIORAL|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
214713346|NCT00180271|DEVICE|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
214713347|NCT00180271|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
214713348|NCT01725256|DRUG|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
214713349|NCT02679807|BIOLOGICAL|Bifidobacterium animalis subsp. lactis Bl-04|
214713350|NCT02679807|OTHER|sucrose|
214607192|NCT01841463|DRUG|Vemurafenib (Zelboraf®)|"* In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
214607193|NCT03344419|DRUG|CI-581a|Medication infusion intravenously over 1 hour.
214607194|NCT03344419|DRUG|CI-581b|Medication infusion intravenously over 1 hour.
214607195|NCT03344419|BEHAVIORAL|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
214607196|NCT03344419|BEHAVIORAL|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
214607197|NCT03219450|DRUG|NeoVax|It stimulates the immune system to attack cancer cells.
214607198|NCT03219450|DRUG|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
214607199|NCT03219450|DRUG|Pembrolizumab|Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
214607200|NCT06493877|OTHER|Retraining program after thoracic surgery|"An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2)."
214607201|NCT06455150|OTHER|Assessment of pelvic floor dysfunctions' symptoms and sings, pelvic floor muscle strength and quality of life|"It will be assessed the presence of urinary incontinence, anal incontinence, pelvic organ prolapse and female sexual dysfunction' symptoms by using the questionaries validated to Spanish population International Consultation on Incontinence Questionnaire-Short Form, Pelvic Floor Distress Inventory Short Form and Female Sexual Function Index; in addition, the sign of stress urinary incontinence and pelvic organ prolapse will be assessed by using the cough stress test and Pelvic Organ Prolapse Quantification System, the pelvic floor muscle strength by using manometry, and quality of life by using SF-12 questionnaire."
214607202|NCT01499953|DRUG|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
214607203|NCT01499953|DRUG|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
214607204|NCT00660270|PROCEDURE|Pancreatic Surgery|
214607205|NCT00660270|RADIATION|Radiation therapy|
214607206|NCT00660270|DRUG|Cisplatin|
214607207|NCT00660270|DRUG|5-FU|
214607208|NCT00660270|DRUG|Alpha-interferon|
214607209|NCT00660270|DRUG|Gemcitabine|
214607210|NCT06447207|BEHAVIORAL|Occupational Therapy Led Social Prescription|The intervention includes encouragement to participate in the co-designed social prescription with 6 monthly sessions with an occupational therapist or occupational therapy doctoral student.
214607211|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
214713351|NCT02322411|DEVICE|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
214713352|NCT02322411|BEHAVIORAL|Compensatory approaches|
214713353|NCT01025011|DEVICE|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
214713354|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214713355|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214713356|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
214713357|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214607212|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
214607213|NCT02270866|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
214607214|NCT06975644|DRUG|nab-paclitaxel, carboplatin, and bemotuzumab|nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W
214607215|NCT06975644|DRUG|epirubicin, cyclophosphamide, and bemotuzumab|epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W
214607216|NCT03819738|DIAGNOSTIC_TEST|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
214607217|NCT02509897|OTHER|Hypoxic training|Hypoxic training 3 times per week four four weeks
214607218|NCT02509897|OTHER|Normoxic training|Normoxic training 3 times per week four four weeks
214607219|NCT05638022|DIAGNOSTIC_TEST|Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test|Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.
214607220|NCT05638022|DIAGNOSTIC_TEST|DNA testing|DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
214607221|NCT02710773|OTHER|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
214607222|NCT02710773|OTHER|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
214607223|NCT07128459|PROCEDURE|The Five-Step lip reduction surgery|The Five-Step lip reduction surgery: (1) measurement and design; (2) incision and reduction of lip volume; (3) fixation and shape of the dry lip; (4) fixation and shape of the skin (the SMISS approach); (5) shaping of the wet lip mucosa (the SMISS approach).
214607224|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
214607225|NCT06207864|PROCEDURE|Return of Results|Receive results
214607226|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
214607227|NCT02108860|DRUG|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
214607228|NCT02108860|DRUG|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
214607229|NCT04859946|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
214607230|NCT04859946|DRUG|Busulfan|Given IV
214607231|NCT04859946|DRUG|Cyclophosphamide|Given IV
214713358|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214607232|NCT04859946|DRUG|Fludarabine|Given IV
214607233|NCT04859946|DRUG|Itacitinib|Given PO
214713359|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
214607234|NCT04859946|DRUG|Tacrolimus|Given IV or PO
214607235|NCT04859946|DRUG|Thiotepa|Given IV
214607236|NCT02765087|OTHER|Medical History|Oriented Survey and complete physical exam.
214607237|NCT02765087|DEVICE|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
214607238|NCT02765087|OTHER|Chest CT|
214607239|NCT02765087|OTHER|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
214607240|NCT04661722|OTHER|No intervention|No intervention
214607241|NCT04286087|PROCEDURE|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
214607242|NCT04286087|PROCEDURE|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
214713360|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214713361|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214722291|NCT03329664|OTHER|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
214607243|NCT03507673|DIAGNOSTIC_TEST|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
214607244|NCT00410293|PROCEDURE|NT-proBNP testing|
214607245|NCT05091086|DRUG|Continuous Denosumab|Active comparator: persistent treatment of denosumab.
214607246|NCT05091086|DRUG|Administer zoledronate and denosumab on an alternating schedule|In the experimental group, zoledronic acid was administered for one year, followed by two years of denosumab. This cycle was repeated, with the regimen concluding with one year of zoledronic acid.
214607247|NCT01125943|DRUG|Acetylcholine|Intra-arterial infusion
214607248|NCT01125943|DRUG|Nitroprusside|Intra arterial infusion
214607249|NCT01125943|DRUG|Bevacizumab|Intra arterial infusion
214607250|NCT00523718|DRUG|riluzole|50 mg PO bid, 12 weeks
214607251|NCT00523718|DRUG|placebo|placebo, 1 capsule PO bid, 12 weeks
214607252|NCT04184960|DIAGNOSTIC_TEST|Gastroscopy and gastric biopsies|Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
214607253|NCT04308824|OTHER|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
214607254|NCT04308824|OTHER|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
214607255|NCT00049556|DRUG|gefitinib|
214607256|NCT00049556|OTHER|immunohistochemistry staining method|
214607257|NCT00049556|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
214607258|NCT00049556|PROCEDURE|biopsy|
214607259|NCT00049556|PROCEDURE|sentinel lymph node biopsy|
214713362|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
214713363|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214713364|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214607260|NCT06212635|DIAGNOSTIC_TEST|T-TAS|Blood test, laboratory assays
214607261|NCT02753790|RADIATION|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume \[PTV\] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
214607262|NCT02827305|DRUG|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
214607263|NCT02827305|PROCEDURE|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
214607264|NCT02944253|OTHER|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
214607265|NCT02944253|OTHER|Low energy diet 100 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
214607266|NCT02944253|OTHER|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
214607267|NCT02113579|DEVICE|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
214607268|NCT02113579|OTHER|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
214607269|NCT02060383|DRUG|Pasireotide s.c.|Administered to Cushing's disease participants.
214607270|NCT02060383|DRUG|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
214607271|NCT02060383|DRUG|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
214607272|NCT02060383|DRUG|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
214607273|NCT02060383|DRUG|Pasireotide LAR|Administered to Acromegaly participants.
214607274|NCT02060383|DRUG|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
214607275|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
214607276|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
214607277|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
214607278|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
214607279|NCT04056481|DRUG|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
214607280|NCT00332839|DRUG|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
214607281|NCT00332839|DRUG|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
214607282|NCT00332839|DRUG|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
214607283|NCT00332839|DRUG|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
214607284|NCT00332839|DRUG|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
214607285|NCT03311321|DIETARY_SUPPLEMENT|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
214607286|NCT03311321|DIETARY_SUPPLEMENT|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
214607287|NCT03202823|PROCEDURE|blood samples|3 tubes (5 ml volume) collected during surgery
214607288|NCT03202823|PROCEDURE|recover samples of atheromatous plaque|a carotid sample collected during surgery
214607289|NCT01762176|PROCEDURE|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
214607290|NCT01762176|PROCEDURE|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
214607291|NCT03187951|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
214607292|NCT03187951|BEHAVIORAL|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
214607293|NCT03187951|OTHER|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
214607294|NCT03187951|BEHAVIORAL|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
214607295|NCT03187951|BEHAVIORAL|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
214607296|NCT03187951|BEHAVIORAL|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
214607297|NCT01109329|BIOLOGICAL|HMPV challenge virus|Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
214607298|NCT01851278|DRUG|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
214607299|NCT01851278|DRUG|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
214607300|NCT01999569|DRUG|Letrozole|Letrozole administered daily through the time of ovulation.
214713365|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
214713366|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214713367|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
214607301|NCT01514487|DRUG|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
214607302|NCT03725514|PROCEDURE|Conventional|Conventional Blood Clot Technique
214607303|NCT03725514|PROCEDURE|PRF|Platelet Rich Fibrin Technique
214607304|NCT01406288|OTHER|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
214713368|NCT04172337|BEHAVIORAL|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
214607305|NCT02791113|OTHER|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
214607306|NCT02476825|DRUG|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
214607307|NCT02476825|DEVICE|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
214607308|NCT02873650|DRUG|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
214607309|NCT03791242|DEVICE|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
214607310|NCT06098625|DRUG|Empagliflozin 25 MG|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
214607311|NCT06098625|DRUG|Linagliptin 5 mg Oral Tablet|linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
214607312|NCT02830672|PROCEDURE|Surgical release A1 pulley for Trigger finger of the hand|
214713369|NCT04172337|BEHAVIORAL|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
214713370|NCT02610205|OTHER|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
214713371|NCT04350905|OTHER|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
214713372|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
214713373|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
214607313|NCT02020057|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
214607314|NCT02347475|OTHER|Observational Study|Ultrasound and NIRS
214607315|NCT04703036|DIETARY_SUPPLEMENT|Glycine|Glycine is an amino-acid (protein)
214607316|NCT04703036|DIETARY_SUPPLEMENT|N-acetylcysteine|This is a donor of the amino-acid cysteine (protein)
214607317|NCT04703036|DIETARY_SUPPLEMENT|Alanine|Alanine is an amino-acid (protein)
214607318|NCT04670497|PROCEDURE|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
214607319|NCT00000225|DRUG|Buprenorphine|
214607320|NCT05952245|BEHAVIORAL|iCBTI-based EMI|Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).
214607321|NCT05952245|BEHAVIORAL|Education-based EMI|Stroke and brief sleep hygiene education with chat-based support on the topics.
214607322|NCT02642770|DEVICE|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
214607323|NCT05161091|DEVICE|Topical application of Orosol®|Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
214607324|NCT05161091|DEVICE|Topical application of Placebo comparator|Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
214607325|NCT04339907|OTHER|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
214607326|NCT04339907|OTHER|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
214607327|NCT03013283|OTHER|self questionnaire|"* Interface side effects and degree of satisfaction of the patients~* Technician evaluation and device measures."
214607328|NCT01361243|BEHAVIORAL|NOURISH+|6 week face-to-face parent intervention.
214607329|NCT01361243|BEHAVIORAL|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
214607330|NCT05316402|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
214607331|NCT05316402|OTHER|dosimetry|dosimetry
214607332|NCT01863940|DEVICE|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
214607333|NCT05335499|DRUG|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
214607334|NCT05335499|DRUG|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
214607335|NCT05335499|DRUG|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
214713374|NCT01473329|OTHER|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
214713375|NCT01977339|DRUG|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
214713376|NCT01977339|DRUG|Bupivacaine|20 cc of 0.25% bupivacaine
214607336|NCT05335499|DRUG|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
214607337|NCT05335499|DRUG|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
214607338|NCT05335499|DRUG|Placebo|"* Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD"
214607339|NCT01121523|BEHAVIORAL|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
214607340|NCT05516589|DRUG|Nab-paclitaxel|260mg/m\^2 IV Q3W
214607341|NCT05516589|DRUG|Cisplatin|75mg/m\^2 IV Q3W
214607342|NCT05516589|BIOLOGICAL|Tislelizumab|200mg IV Q3W
214607343|NCT05516589|DRUG|Afatinib|30mg PO QD
214607344|NCT02020863|DEVICE|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
214607345|NCT01491048|PROCEDURE|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
214607346|NCT01491048|PROCEDURE|No physiotherapy after THA|No physiotherapy after THA
214713377|NCT03655392|BEHAVIORAL|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
214713378|NCT03655392|DIAGNOSTIC_TEST|Induced sputum collection|All participants performed induced sputum collection
214713379|NCT03655392|DIAGNOSTIC_TEST|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
214607347|NCT01226823|DRUG|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
214607348|NCT01226823|DRUG|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
214607349|NCT02713035|BEHAVIORAL|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
214607350|NCT04085341|DRUG|GB-102|Intravitreal injection of GB-102
214607351|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
214607352|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
214607353|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Coleman technique
214607354|NCT02677012|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery
214607355|NCT04764851|DRUG|ecopipam HCl ~2mg/kg/day|oral tablet
214607356|NCT04764851|COMBINATION_PRODUCT|Cohort 1 Probe Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
214607357|NCT04764851|COMBINATION_PRODUCT|Cohort 2 Probe Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
214607358|NCT04764851|COMBINATION_PRODUCT|Cohort 3 Probe Cocktail|bupropion
214607359|NCT02460705|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
214607360|NCT03247036|DRUG|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
214607361|NCT01526044|DEVICE|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
214607362|NCT00707850|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
214607363|NCT02488187|DEVICE|ABUS|Automated breast ultrasound
214607364|NCT06793033|PROCEDURE|Advanced Cardiac Life Support (ACLS)|Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.
214607365|NCT06793033|DEVICE|Aortic balloon occlusion (ABO)|"Aortic balloon occlusion (ABO) is a technique that diverts blood ﬂow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest.~In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest."
214607366|NCT01968395|DRUG|Caspofungin 70 mg|Intravenous use
214607367|NCT04110964|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
214607368|NCT04900558|PROCEDURE|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
214607369|NCT05244707|BEHAVIORAL|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
214607370|NCT05244707|BEHAVIORAL|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
214607371|NCT04433806|BEHAVIORAL|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
214607372|NCT05125094|DEVICE|TACE,Ablation|Transcatheter arterial chemoembolization
214607373|NCT05597709|PROCEDURE|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
214607374|NCT02761824|OTHER|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
214607375|NCT02422888|DRUG|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
214607376|NCT02422888|DRUG|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
214607377|NCT00760396|DRUG|VGX-1027|Subjects will
214607378|NCT01025492|DRUG|Trilipix|135 mg po daily
214607379|NCT01025492|DRUG|placebo|one tablet po daily
214607380|NCT05024305|DRUG|TWP-102 injection|IV infusion
214607381|NCT03915808|DIETARY_SUPPLEMENT|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
214607382|NCT03915808|DIETARY_SUPPLEMENT|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
214607383|NCT02742597|BEHAVIORAL|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
214607384|NCT02616757|DEVICE|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
214607385|NCT04157816|OTHER|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
214607386|NCT04157816|OTHER|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
214713380|NCT03655392|DIAGNOSTIC_TEST|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
214607387|NCT04157816|OTHER|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
214607388|NCT04841980|DRUG|Rifaximin|Administration route: PO Rifaximin 400mg TDS for 2 weeks
214607389|NCT04841980|OTHER|Low FODMAP diet|Low FODMAP diet under dietitian guidance for 4 weeks
214607390|NCT01825642|PROCEDURE|nerve-sparing radical prostatectomy|
214607391|NCT01825642|PROCEDURE|seminal vesicle-sparing radical prostatectomy|
214607392|NCT02047682|BEHAVIORAL|Biopsychosocial|
214607393|NCT02047682|BEHAVIORAL|Reference|
214607394|NCT04968041|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
214607395|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
214607396|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
214607397|NCT02146742|DRUG|ASP1707|oral
214607398|NCT02146742|DRUG|Placebo|oral
214607399|NCT03253757|OTHER|This study is non-interventional.|This study is non-interventional.
214713381|NCT03655392|OTHER|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
214607400|NCT03523728|DRUG|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
214713382|NCT03655392|OTHER|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
214713383|NCT03655392|DIAGNOSTIC_TEST|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
214713384|NCT03655392|DIAGNOSTIC_TEST|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
214713385|NCT04588831|DEVICE|Mouthguard|Protective device for orofacial complex for patients playing contact sports
214713386|NCT02037451|PROCEDURE|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
214607401|NCT03523728|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
214607402|NCT01821833|DIETARY_SUPPLEMENT|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
214713387|NCT02261883|DRUG|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
214607403|NCT01821833|DIETARY_SUPPLEMENT|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
214713388|NCT02261883|DRUG|Placebo|Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
214713389|NCT02266732|DEVICE|Stimuplex HNS 12|
214713390|NCT05606978|BEHAVIORAL|FASTb|FAST blended
214607404|NCT01821833|DRUG|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
214607405|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
214607406|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
214713391|NCT05606978|BEHAVIORAL|FASTr|FAST regular
214722292|NCT00564200|DRUG|Bortezomib|"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~\- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"
214607407|NCT00621751|DRUG|Carbamazepine|800 mg daily
214607408|NCT00621751|DRUG|Placebo|Placebo
214607409|NCT01377025|DRUG|Placebo|two tablets in the morning and two in the evening.
214607410|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
214722293|NCT00564200|DRUG|dexamethasone|"PREACONDICIONAMIENTO:~\- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
214722294|NCT00564200|DRUG|Fludarabine|"ACONDICIONAMIENTO:~\- Days -9 al -5: Fludarabine"
214722295|NCT00564200|DRUG|Melphalan|"ACONDICIONAMIENTO:~\- Days -4 and -3: Melphalan."
214607411|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
214607412|NCT05136365|DRUG|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
214607413|NCT05242055|OTHER|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
214607414|NCT03262454|DRUG|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
214607415|NCT04918199|DEVICE|Computer based assessment (iBox)|Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
214607416|NCT04918199|OTHER|Physician assessement|Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
214607417|NCT05166915|DEVICE|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
214607418|NCT05166915|DEVICE|Sham Control Catheter|Sham Control Device
214607419|NCT01667536|DRUG|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
214607420|NCT05353049|BEHAVIORAL|Bathing technique based on Basale Stimulation|"The relaxing somatic modelling technique will be applied, framed within the concept of Basal Stimulation®. To do this, the user remains seated and the parts of the body that are not being washed at that moment are covered with a towel, favouring the preservation of the user's privacy. The user is lathered up with soft mittens previously moistened with lukewarm water and lathered up. This process shall be carried out starting from the shoulder in a proximal to distal direction on the upper limbs, lower limbs and trunk (taking into account the sagittal anatomical plane) and in a cephalic to caudal direction (taking into account the transverse anatomical plane).~Subsequently, rinsing is carried out following the same guidelines as described above, using moistened soft mittens. Finally, intimate hygiene is performed with a disposable soapy sponge and the soap is rinsed off again with moistened soft terrycloth mittens. Throughout the whole process, the activity is explained to the user."
214607421|NCT03228303|DRUG|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
214607422|NCT03228303|DRUG|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
214607423|NCT00575536|PROCEDURE|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
214607424|NCT00164047|DRUG|Nitrous Oxide|
214607425|NCT03040791|DRUG|Nivolumab|Nivolumab
214607426|NCT03088475|BEHAVIORAL|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
214607427|NCT03088475|BEHAVIORAL|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
214607428|NCT02075242|DRUG|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
214607429|NCT02075242|DRUG|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
214607430|NCT03582930|COMBINATION_PRODUCT|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
214607431|NCT01950247|DRUG|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
214607432|NCT01950247|DRUG|SOC|
214607433|NCT02791022|DEVICE|SPYDER ECG sensor|
214607434|NCT02649049|OTHER|there is no intervention|
214607435|NCT01831921|BEHAVIORAL|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
214607436|NCT01831921|BEHAVIORAL|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
214607437|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
214607438|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
214607439|NCT01724840|PROCEDURE|GraftJacket|Interposition with GraftJacket
214607440|NCT01724840|PROCEDURE|Tendon Interposition|Tendon Interposition with the FCR tendon
214722296|NCT05743517|BEHAVIORAL|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
214607441|NCT05149898|DRUG|ZYN002|"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."
214607442|NCT01956149|DRUG|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
214607443|NCT00710879|DEVICE|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
214607444|NCT04254588|OTHER|Abdominal examination|Examination by in-person physician vs. remote physician.
214607445|NCT01043679|DRUG|Utapine|Efficacy and Safety of Utapine
214713392|NCT05657951|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
214713393|NCT00517283|DRUG|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
214713394|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
214713395|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
214607446|NCT01043679|DRUG|Seroquel|Efficacy and Safety of Seroquel
214607447|NCT01519804|DRUG|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
214607448|NCT01519804|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
214607449|NCT01519804|DRUG|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
214607450|NCT01519804|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
214607451|NCT03486886|DIAGNOSTIC_TEST|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
214607452|NCT01809132|DRUG|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
214607453|NCT01809132|DRUG|Pentoxifylline|Pentoxifylline, generic
214607454|NCT01809132|DRUG|Zinc Sulfate|Zinc Sulfate, nutritional supplement
214607455|NCT01809132|DRUG|Methylprednisolone|Methylprednisolone, corticosteroid
214607456|NCT00259779|DRUG|budesonide/formoterol|
214607457|NCT00259779|DRUG|Prednisolone|
214607458|NCT05526742|DRUG|CKD-510 capsule (reference)|Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
214607459|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
214607460|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fed state.
214607461|NCT03066908|DEVICE|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
214607462|NCT06344819|PROCEDURE|Acupuncture|Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
214607463|NCT06344819|OTHER|Sham Acupuncture|During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
214607464|NCT00434421|DRUG|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
214713396|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
214607465|NCT00434421|DRUG|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
214607466|NCT05691231|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
214607467|NCT05492734|DRUG|EDG-5506|single oral dose
214607468|NCT01582542|DRUG|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
214607469|NCT01688466|DRUG|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
214607470|NCT03133806|DEVICE|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
214607471|NCT01205438|DRUG|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
214607472|NCT01205438|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
214607473|NCT01205438|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
214607474|NCT05370716|DRUG|Polmacoxib|Polmacoxib
214607475|NCT05370716|DRUG|Pregabalin|Pregabalin
214607476|NCT05020444|DRUG|TriPRIL CAR T Cells|Intravenous infusion
214607477|NCT05020444|DRUG|Cyclophosphamide|Intravenous infusion
214607478|NCT05020444|DRUG|Fludarabine|Intravenous infusion
214607479|NCT03145545|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
214607480|NCT00378469|BEHAVIORAL|45 minute exercise on ergocycle|
214607481|NCT03891342|DRUG|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
214607482|NCT02334787|DRUG|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
214713397|NCT01892644|OTHER|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
214713398|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
214713399|NCT00629525|DRUG|RAD001|RAD001 at a dose of 10 mg PO daily
214713400|NCT01752439|DEVICE|Anodal transcranial direct current stimulation|
214607483|NCT02334787|DRUG|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
214607484|NCT02334787|DRUG|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
214607485|NCT02334787|DRUG|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
214607486|NCT06438848|OTHER|Physical therapy program|group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions
214607487|NCT06438848|OTHER|Physical therapy program with lymphedema drainage|physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks
214607488|NCT03461172|PROCEDURE|Surgery of breast cancer|Surgery of breast cancer
214607489|NCT03461172|OTHER|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
214607490|NCT04466644|DIAGNOSTIC_TEST|ELISA|Antibody test (serology) in the blood samples to determine if the subject was previously infected.
214607491|NCT04466644|DIAGNOSTIC_TEST|RT-PCR|For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
214713401|NCT01752439|DEVICE|Sham transcranial direct current stimulation|
214607492|NCT06337084|DRUG|MNPR-101-DFO*-89Zr|Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans
214607493|NCT06337084|DIAGNOSTIC_TEST|PET/CT Diagnostic Imaging|PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
214607494|NCT06305949|DEVICE|Optimized transcranial Direct Current Stimulation|transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
214607495|NCT06305949|DEVICE|Sham transcranial Direct Current Stimulation|transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
214607496|NCT03385720|PROCEDURE|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
214713402|NCT00048789|PROCEDURE|Extracorporeal Photopheresis|
214607497|NCT03385720|PROCEDURE|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
214607498|NCT05560256|OTHER|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
214607499|NCT04674267|OTHER|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
214607500|NCT01875536|DEVICE|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
214607501|NCT01875536|BEHAVIORAL|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
214607502|NCT01981239|DEVICE|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
214607503|NCT00251381|DRUG|Cetuximab|
214607504|NCT05378646|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
214607505|NCT02637115|DIETARY_SUPPLEMENT|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
214713403|NCT04564066|BIOLOGICAL|efgartigimod IV|intravenous infusions of efgartigimod
214713404|NCT04564066|BIOLOGICAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
214713405|NCT06206902|DRUG|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
214713406|NCT03159806|DEVICE|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
214713407|NCT04696237|OTHER|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
214607506|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
214607507|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
214713408|NCT03788863|DRUG|Diflucortolone valerate (BAY866146)|Follow clinical administration
214607508|NCT02637115|DIETARY_SUPPLEMENT|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
214713409|NCT00532714|DRUG|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
214713410|NCT01052519|OTHER|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
214607511|NCT04495855|DRUG|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
214607512|NCT04029116|DRUG|Fluconazole Tablet|150 mg every 72 hours for 3 doses
214607513|NCT04029116|DRUG|IBREXAFUNGERP|300 mg BID (one day) every 4 weeks for a total of 6 dosing days
214607514|NCT04029116|DRUG|Placebo oral tablet|BID (one day) every 4 weeks for a total of 6 dosing days
214607515|NCT03967782|BEHAVIORAL|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214607516|NCT03967782|BEHAVIORAL|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214607517|NCT03967782|BEHAVIORAL|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214607518|NCT02843763|OTHER|Blood sample|Blood sample (28 ml)
214607519|NCT00738413|DRUG|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
214607520|NCT00738413|DRUG|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
214713411|NCT05247541|DRUG|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
214713412|NCT05500183|BEHAVIORAL|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
214607521|NCT00771004|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
214607522|NCT00771004|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
214607523|NCT06290063|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
214607524|NCT06290063|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
214607525|NCT06290063|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
214607526|NCT00313040|BEHAVIORAL|Brief Consultation with Health Counselor, workbook|
214607527|NCT00313040|BEHAVIORAL|Usual Care wait list|
214607528|NCT05972382|DIAGNOSTIC_TEST|Quantitative Sensory and Neurophysiological Testing|"Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded."
214607529|NCT05549778|DRUG|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
214607530|NCT05549778|DRUG|Control group|Abiraterone, radio- or chemotherapy
214607531|NCT04404322|OTHER|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
214607532|NCT04404322|OTHER|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
214607533|NCT05102578|BEHAVIORAL|Digital Decision Aid Tool|The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
214607534|NCT03566433|PROCEDURE|Tep surgery for inguinal hernia|TEP surgery
214607535|NCT03566433|PROCEDURE|Lichtenstein|Lichtenstein surgery for inguinal hernia
214607536|NCT04475900|DIAGNOSTIC_TEST|Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)|To measure corneal biomechanics with Scheimpflug based tonometry
214607537|NCT04475900|DIAGNOSTIC_TEST|Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)|To measure corneal topography and tomography with Scheimpflug tomograph
214607538|NCT04475900|DIAGNOSTIC_TEST|Optic nerve head measurement|To measure optic nerve excavation
214607539|NCT02013453|DRUG|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
214607540|NCT02013453|DRUG|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
214607541|NCT02013453|DRUG|5FU|Administered by infusion.
214607542|NCT02013453|DRUG|Paclitaxel|Administered by infusion.
214607543|NCT02013453|DRUG|Pemetrexed|Administered by infusion.
214607544|NCT00515957|GENETIC|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2"
214713413|NCT05500183|BEHAVIORAL|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
214713414|NCT05380713|DRUG|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
214713415|NCT05380713|DRUG|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
214713416|NCT05380713|DRUG|Durvalumab|tremelimumab-durvalumab in adjuvant setting
214607545|NCT03281967|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
214607546|NCT01688856|DEVICE|Electrical Stimulator|"The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
214607547|NCT00502489|PROCEDURE|Closed-loop sytem for5 weaning from mechanical ventilation|
214607548|NCT02607449|DRUG|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
214607549|NCT02607449|DRUG|Placebo|Placebo without any active pharmaceutical ingredients
214607550|NCT05692856|DRUG|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
214607551|NCT05692856|DRUG|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
214607552|NCT01514136|DEVICE|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
214607553|NCT02486809|DRUG|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
214607554|NCT05261035|BEHAVIORAL|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos \& pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
214607555|NCT05261035|OTHER|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
214607556|NCT03139708|DRUG|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
214607557|NCT03139708|DRUG|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
214607558|NCT03139708|DRUG|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
214607559|NCT02770443|DRUG|withdrawal|withdrawal of beta blocker and ACE inhibitors
214607560|NCT02770443|DRUG|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
214607561|NCT05125289|OTHER|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
214607562|NCT05125289|OTHER|Active release technique group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~ART steps:~* Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~* Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~* Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
214607563|NCT05125289|OTHER|Proprioceptive Neuromuscular Facilitation stretching group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~PNF technique steps:~* The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~* The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~* Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~* This sequence is repeated 5 times at a 20 second interval."
214607564|NCT00356616|DRUG|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
214607565|NCT00356616|DRUG|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
214607566|NCT01613495|DRUG|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
214607567|NCT01613495|DRUG|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
214607568|NCT00003865|DRUG|toremifene|
214607569|NCT04349878|DIAGNOSTIC_TEST|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
214607570|NCT00447486|DRUG|GW842166|
214607571|NCT01925898|DRUG|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
214607572|NCT01925898|DRUG|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
214607573|NCT02451579|DRUG|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
214607574|NCT02451579|OTHER|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
214607575|NCT05483205|DRUG|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
214607576|NCT02818166|PROCEDURE|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
214607577|NCT02765620|OTHER|drug&radiation|"1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
214607578|NCT03364582|OTHER|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
214607579|NCT03039166|DEVICE|MRI 7T|
214607580|NCT03039166|DEVICE|MRI 3 T|
214607581|NCT03039166|BIOLOGICAL|blood sample|
214607582|NCT01827579|BIOLOGICAL|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
214607583|NCT02019225|OTHER|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
214607584|NCT04711148|OTHER|placebo|placebo
214607585|NCT04711148|DRUG|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
214607586|NCT05597865|BEHAVIORAL|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
214607587|NCT05597865|BEHAVIORAL|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
214607588|NCT01930149|BEHAVIORAL|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
214607589|NCT05902078|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
214607590|NCT05902078|DRUG|Calcitriol capsules|Oral calcitriol 0.5μg daily
214607591|NCT00809419|DEVICE|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
214607592|NCT01852604|DRUG|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
214607593|NCT01852604|DRUG|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
214607594|NCT01852604|DRUG|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
214607595|NCT01852604|DRUG|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
214607596|NCT01852604|DRUG|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
214607597|NCT01852604|BIOLOGICAL|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
214607598|NCT01852604|OTHER|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
214607599|NCT02941926|DRUG|Ribociclib|Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
214607600|NCT02941926|DRUG|Letrozole|Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
214607601|NCT02941926|DRUG|Goserelin|Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
214607602|NCT02941926|DRUG|Leuprolide|Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
214607603|NCT03056950|DEVICE|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
214607604|NCT02910765|DRUG|methylene blue|
214607605|NCT02910765|DRUG|ozone|
214607606|NCT02910765|OTHER|saline infusion|
214607607|NCT02910765|OTHER|oxygen|
214607608|NCT03126526|BEHAVIORAL|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
214607609|NCT03126526|BEHAVIORAL|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
214607610|NCT03126526|BEHAVIORAL|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
214607611|NCT02739750|OTHER|No intervention|There is no intervention for this study. It is a MRS.
214607612|NCT03661125|DRUG|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
214607613|NCT03661125|DRUG|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
214607614|NCT01552655|RADIATION|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
214607615|NCT02729740|DEVICE|Penumbra Smart Coil|
214607616|NCT02729740|DEVICE|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
214607617|NCT02031939|DRUG|Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
214607618|NCT02031939|RADIATION|standard chemoradiotherapy|All rectal patients in this group will receive standard radiotherapy and surgical resection.
214607619|NCT03217942|DRUG|NGF|Intramuscular injection
214607620|NCT06113484|OTHER|DIET + EXERCISE|At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.
214607621|NCT06113484|OTHER|WITHOUT DIET + EXERCISE|"An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases."
214607622|NCT00307333|DEVICE|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
214607623|NCT06032338|OTHER|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
214607624|NCT06032338|OTHER|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
214607625|NCT06032338|OTHER|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
214607626|NCT02537938|DRUG|NGP 555|
214607627|NCT00531882|DRUG|Pioglitazone|30 mg once a day
214607628|NCT00531882|DRUG|Simvastatin|40 mg once a day
214607629|NCT00531882|DRUG|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
214607630|NCT04195035|DEVICE|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.
214607631|NCT04195035|DEVICE|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.
214607632|NCT02768233|BEHAVIORAL|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
214607633|NCT02319291|DEVICE|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
214607634|NCT03686098|DIETARY_SUPPLEMENT|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
214607635|NCT03686098|DIETARY_SUPPLEMENT|Soy Supplement|Soy isoflavones delivered in extracted form
214607636|NCT04766476|DRUG|BMS-963272|Specified dose on specified days
214607637|NCT04766476|OTHER|Placebo matching BMS-963272|Specified dose on specified days
214607638|NCT01318720|OTHER|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
214607639|NCT00549627|DEVICE|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
214607640|NCT03948360|DEVICE|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
214607641|NCT03948360|OTHER|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
214607642|NCT06469099|OTHER|excercises|exercises for strength and balance
214607643|NCT04609332|DIAGNOSTIC_TEST|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
214607644|NCT05646212|OTHER|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
214607645|NCT05646212|OTHER|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
214607646|NCT00601705|DRUG|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
214607647|NCT00601705|DRUG|epirubicin hydrochloride|50 mg/m2 IV bolus
214607648|NCT00601705|DRUG|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
214607649|NCT00601705|DRUG|oxaliplatin|130 mg/m2 IV infusion over 2 hours
214607650|NCT00601705|PROCEDURE|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
214607651|NCT00601705|PROCEDURE|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
214607652|NCT02277977|OTHER|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
214607653|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp CBD|Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.
214607654|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp Placebo Capsule|Vantage Hemp Placebo Capsule Intervention
214607655|NCT03579420|BEHAVIORAL|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
214607656|NCT03579420|BEHAVIORAL|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
214607657|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
214607658|NCT02445118|OTHER|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
214607659|NCT06131333|PROCEDURE|Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation|PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
214607660|NCT00630851|DRUG|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
214607661|NCT00630851|DRUG|Placebo|Matching placebo tablets orally once daily for 6 months
214607662|NCT05071495|DEVICE|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
214607663|NCT01653964|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
214607664|NCT02232282|DEVICE|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
214607665|NCT02232282|DEVICE|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
214607666|NCT03422679|DRUG|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
214607667|NCT02608879|PROCEDURE|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
214607668|NCT02608879|PROCEDURE|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
214607669|NCT02608879|PROCEDURE|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
214607670|NCT02608879|OTHER|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
214607671|NCT03812484|BEHAVIORAL|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
214607672|NCT03812484|BEHAVIORAL|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
214607673|NCT06470789|BEHAVIORAL|Shoulder blood restriction training|Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
214607674|NCT05035576|DRUG|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
214607675|NCT05017220|OTHER|Nature-based sensory stimuli|A program based on stimulation using nature-based sensory stimuli will be implemented
214607676|NCT05017220|OTHER|Control group intervention|An activity based on a placebo intervention will be implemented
214607677|NCT00978835|BEHAVIORAL|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
214607678|NCT00978835|BEHAVIORAL|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
214607679|NCT04588194|DRUG|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
214607680|NCT04588194|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
214607681|NCT04588194|DRUG|Dexamethasone|40 mg IV/PO days 1-4
214607682|NCT03254654|DRUG|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
214607683|NCT03254654|DRUG|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
214607684|NCT06490393|OTHER|Questionnaires|EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department
214607685|NCT00002920|DRUG|medroxyprogesterone|
214607686|NCT00002920|DRUG|tamoxifen citrate|
214607687|NCT00002920|PROCEDURE|adjuvant therapy|
214607688|NCT00002970|DRUG|nelarabine|Given IV
214607689|NCT00002970|DRUG|methotrexate|Given IT
214607690|NCT00002970|DRUG|cytarabine|Given IT
214607691|NCT00002970|DRUG|therapeutic hydrocortisone|Given IT
214607692|NCT02201121|OTHER|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
214607693|NCT01882842|PROCEDURE|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
214607694|NCT01882842|DEVICE|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
214607695|NCT06216184|DIAGNOSTIC_TEST|Vortexing|use combined of vortexing and Maki techniques
214607696|NCT00000604|PROCEDURE|cardiopulmonary bypass|
214607697|NCT00000604|PROCEDURE|heart arrest, induced|
214607698|NCT04919252|DRUG|Vedolizumab|"* Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
214607699|NCT02730052|DEVICE|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
214607700|NCT02730052|DEVICE|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
214607701|NCT00243698|DRUG|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
214607702|NCT02116257|DRUG|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
214607703|NCT02116257|DRUG|PCA regimen|
214607704|NCT05812040|DIAGNOSTIC_TEST|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
214607705|NCT00077051|DRUG|cisplatin|
214607706|NCT00077051|DRUG|cytochlor|
214607707|NCT00077051|DRUG|tetrahydrouridine|
214607708|NCT00077051|RADIATION|radiation therapy|
214607709|NCT01665547|DRUG|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
214607710|NCT05449626|DIAGNOSTIC_TEST|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
214607711|NCT02846350|BEHAVIORAL|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
214607712|NCT06273670|OTHER|screening and data collection|"Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data."
214607713|NCT06110260|DIETARY_SUPPLEMENT|AstraGin (Ginseng and Astragalus Saponin Extract)|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
214607714|NCT06110260|DIETARY_SUPPLEMENT|Placebo|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
214607715|NCT01811784|BEHAVIORAL|Ask people not to drink raw sap|
214607716|NCT01811784|BEHAVIORAL|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
214607717|NCT01811784|OTHER|No Intervention|
214607718|NCT01811784|OTHER|No Intervention|
214607719|NCT03453658|PROCEDURE|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
214607720|NCT03453658|PROCEDURE|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
214607721|NCT00760669|DRUG|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
214607722|NCT00760669|DRUG|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
214607723|NCT06474975|DEVICE|AURA 10 PET/CT|The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
214607724|NCT02241369|BIOLOGICAL|INO-3106, INO-9012|
214607725|NCT00209365|PROCEDURE|exposure to grass pollen/starch granules|
214607726|NCT04352192|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
214607727|NCT06417112|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|All participants have been referred for a transthoracic echocardiogram by a clinician.
214607728|NCT02113384|OTHER|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
214607729|NCT01572675|DRUG|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
214607730|NCT01572675|DRUG|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
214607731|NCT03618784|BIOLOGICAL|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals"
214607732|NCT03618784|OTHER|sterile saline|"sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
214607733|NCT03476564|DRUG|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
214607734|NCT03476564|DRUG|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
214607735|NCT01910805|BEHAVIORAL|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
214607736|NCT02832700|DIETARY_SUPPLEMENT|Casein glycomacropeptide|
214607737|NCT02832700|DIETARY_SUPPLEMENT|Placebo|
214713417|NCT04777318|OTHER|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
214607738|NCT04437160|DRUG|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
214607739|NCT04437160|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
214607740|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
214713418|NCT04777318|OTHER|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
214607741|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
214607742|NCT04622189|DEVICE|Action observation training|"Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform."
214713419|NCT04777318|OTHER|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
214607743|NCT00800423|DRUG|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
214607744|NCT00800423|DRUG|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
214607745|NCT00106522|DRUG|Methotrexate|10-25mg weekly
214607746|NCT00106522|DRUG|Placebo|iv every 4 weeks
214607747|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
214607748|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
214607749|NCT03702803|DIETARY_SUPPLEMENT|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
214607750|NCT03702803|DRUG|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
214607751|NCT03940547|OTHER|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
214607752|NCT03940547|OTHER|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
214607753|NCT01692691|DRUG|Dacarbazine|Dacarbazine IV - Day 1
214607754|NCT01692691|DRUG|Carmustine|Carmustine IV- Day 2
214607755|NCT01692691|DRUG|Neulasta|Neulasta SC - Day 3
214713420|NCT03742206|DEVICE|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
214713421|NCT03742206|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
214607756|NCT04867889|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
214607757|NCT04867889|DEVICE|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
214607758|NCT03220087|OTHER|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
214607759|NCT03351166|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
214722297|NCT04186546|DEVICE|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
214607760|NCT04134364|DRUG|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
214607761|NCT02907138|OTHER|Medical Yoga|
214607762|NCT02907138|OTHER|Treatment as Usual (physical therapy)|
214607763|NCT00223678|DRUG|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
214607764|NCT00334555|OTHER|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
214607765|NCT00334555|OTHER|partner delivered meds|patient given meds to give to her partner
214607766|NCT00334555|OTHER|field intervention|health worker finds partners
214607767|NCT05570474|DIETARY_SUPPLEMENT|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
214607768|NCT05570474|DIETARY_SUPPLEMENT|Placebo|Daily placebo drink
214607769|NCT03346057|DRUG|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
214607770|NCT03346057|DRUG|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
214607771|NCT03346057|DRUG|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
214607772|NCT03346057|DRUG|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
214607773|NCT03346057|DRUG|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
214607774|NCT03346057|DRUG|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
214607775|NCT03200964|OTHER|anesthesia given as required for surgical procedure|
214607776|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
214607777|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
214607778|NCT00185250|DRUG|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
214607779|NCT00185250|DRUG|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
214607780|NCT04423861|DRUG|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
214607781|NCT04423861|DRUG|Placebo|Patients will receive matching placebo BID for 7 days.
214722298|NCT03798678|DRUG|Carfilzomib|Given IV
214607782|NCT04836663|DRUG|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
214607783|NCT06558786|OTHER|EORTC QLQ-C30 questionnaire|"The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life."
214607784|NCT06558786|OTHER|QLQ-OGS25 questionnaire|The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
214713422|NCT05205278|OTHER|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
214713423|NCT03752333|DRUG|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
214713424|NCT05073627|DRUG|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
214713425|NCT05386927|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
214713426|NCT03700268|OTHER|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
214713427|NCT04228562|OTHER|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
214713428|NCT04228562|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
214713429|NCT02016469|OTHER|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
214713430|NCT02016469|OTHER|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
214713431|NCT02016469|DIETARY_SUPPLEMENT|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
214713432|NCT01499901|PROCEDURE|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
214713433|NCT01499901|PROCEDURE|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
214713434|NCT05464472|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
214713435|NCT02111967|OTHER|Questionnaire administration|
214713436|NCT02111967|OTHER|Laboratory biomarker analysis|
214713437|NCT05720767|DRUG|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
214713438|NCT05720767|DRUG|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
214713439|NCT05720767|DRUG|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
214713440|NCT04491240|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
214713441|NCT04491240|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
214607785|NCT06323122|DEVICE|2.0 miniplates|2.0 miniplates
214607786|NCT06323122|DEVICE|2.3 high profile miniplates|2.3 high profile miniplates
214607787|NCT06323122|DEVICE|3D miniplates|3D miniplates
214607788|NCT04720222|DEVICE|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
214607789|NCT05689723|PROCEDURE|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
214607790|NCT05689723|PROCEDURE|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
214607791|NCT05009186|OTHER|PSA value|We measure PSA value during and after covid-19 infection
214607792|NCT00897351|GENETIC|mutation analysis|
214607793|NCT00897351|GENETIC|polymorphism analysis|
214607794|NCT00897351|GENETIC|protein expression analysis|
214607795|NCT00897351|OTHER|immunohistochemistry staining method|
214607796|NCT00897351|OTHER|laboratory biomarker analysis|
214607797|NCT03692572|DIETARY_SUPPLEMENT|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
214607798|NCT03692572|DIETARY_SUPPLEMENT|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
214607799|NCT01375335|DRUG|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
214607800|NCT02542384|DRUG|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
214607801|NCT02542384|DRUG|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
214713442|NCT04491240|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
214722299|NCT03798678|DRUG|Dexamethasone|Given PO
214722300|NCT03798678|DRUG|Telaglenastat Hydrochloride|Given PO
214713443|NCT03549117|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
214607802|NCT02542384|DRUG|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
214713444|NCT03549117|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
214713445|NCT00003735|DRUG|topotecan hydrochloride|given by mouth
214713446|NCT01249963|DIETARY_SUPPLEMENT|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
214713447|NCT01249963|DIETARY_SUPPLEMENT|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
214713448|NCT01312324|DRUG|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
214713449|NCT02205918|OTHER|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
214713450|NCT02205918|OTHER|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
214713451|NCT01319019|DRUG|GSK961081|Comparison of different doses and dosing regimens of the drug
214713452|NCT01319019|DRUG|Salmeterol|Positive control
214713453|NCT01319019|DRUG|Placebo|Placebo arm
214713454|NCT04679441|DEVICE|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
214607803|NCT05001451|BIOLOGICAL|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
214607804|NCT02966223|RADIATION|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
214607805|NCT00674193|OTHER|pharmacological study|Correlative studies
214607806|NCT00674193|OTHER|laboratory biomarker analysis|Correlative studies
214607807|NCT02003014|DRUG|Pioglitazone|Pioglitazone Tablets
214607808|NCT03805009|DEVICE|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
214607809|NCT01159912|DRUG|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
214607810|NCT01159912|DRUG|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
214607811|NCT01159912|DRUG|Placebo|Placebo inhalation powder
214607812|NCT00499954|PROCEDURE|Microdialysis|
214607813|NCT00499954|DEVICE|Guardian RT|
214607814|NCT00499954|DEVICE|Glucoday S|
214607815|NCT06026683|DEVICE|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
214607816|NCT05245019|BIOLOGICAL|cardamom|cardamom is used as a flavoring agent in foods as well as for treating various cardiovascular, gastrointestinal, and neural problems
214607817|NCT05245019|BIOLOGICAL|fennel|fennel is Known for its anti-inflammatory, anti-spasmodic, and analgesic properties, it is also widely used for treating gastroenteritis and indigestion.
214607818|NCT04515069|PROCEDURE|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
214607819|NCT04515069|PROCEDURE|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
214607820|NCT00916630|DRUG|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
214607821|NCT01387919|BEHAVIORAL|Prolonged fasting|48 hours of fasting
214607822|NCT03920722|DRUG|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
214607823|NCT03920722|DRUG|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
214607824|NCT05099653|OTHER|physical activity|physical activity
214713455|NCT04679441|DEVICE|Brain HQ Double Decision|Cognitive speed training program
214607825|NCT00248846|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
214607826|NCT05426759|DEVICE|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
214607827|NCT05073887|PROCEDURE|Current Targets|blockade and radio frequency stimulation of genicular nerves
214607828|NCT03697434|BEHAVIORAL|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
214607829|NCT02456662|DRUG|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
214607830|NCT02456662|DRUG|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
214607831|NCT04923048|BIOLOGICAL|GB261|Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
214607832|NCT02499081|DRUG|Ixazomib|
214607833|NCT03426423|OTHER|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB\_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
214607834|NCT03426423|OTHER|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
214607835|NCT00724295|DRUG|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
214607836|NCT00724295|DRUG|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
214607837|NCT03979560|OTHER|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
214607838|NCT05138913|DRUG|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
214607839|NCT05138913|DRUG|Saline|After the arthroscopic operation was completed, a local saline injection was performed
214607840|NCT00716053|DRUG|BLVR|BLVR 20 mL
214607841|NCT00961753|DRUG|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
214607842|NCT00961753|DRUG|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
214713456|NCT04086602|DRUG|IZD334|Active Drug
214713457|NCT04086602|DRUG|Placebos|Placebo to Match
214713458|NCT03764579|BEHAVIORAL|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
214607843|NCT04032730|DEVICE|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
214607844|NCT03663881|DRUG|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
214713459|NCT00960713|DRUG|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
214713460|NCT05142449|DRUG|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
214607845|NCT00805025|DRUG|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
214713461|NCT05142449|OTHER|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
214713462|NCT00061503|DRUG|Travoprost|
214713463|NCT05569564|PROCEDURE|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
214713464|NCT05569564|PROCEDURE|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
214713465|NCT00471003|DRUG|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
214607846|NCT01353079|BIOLOGICAL|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
214607847|NCT01353079|BIOLOGICAL|Placebo|Placebo: Glycero-COCAs sublingual
214607848|NCT00375219|DRUG|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
214713466|NCT01683084|DRUG|Telmisartan|
214713467|NCT01683084|DRUG|Placebo|
214713468|NCT00367432|DRUG|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
214713469|NCT00191737|DRUG|Atomoxetine|
214713470|NCT03950999|OTHER|Placebo|Sugar pill
214713471|NCT00903370|PROCEDURE|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
214713472|NCT00903370|DEVICE|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
214713473|NCT00610285|OTHER|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
214607849|NCT00526981|OTHER|Prone position|Prone position during spontaneous breathing.
214713474|NCT03683056|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
214713475|NCT02963415|BEHAVIORAL|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
214713476|NCT00014911|PROCEDURE|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
214607850|NCT03859713|BEHAVIORAL|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
214607851|NCT03859713|BEHAVIORAL|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
214607852|NCT03859713|BEHAVIORAL|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
214607853|NCT03653221|OTHER|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
214607854|NCT03653221|OTHER|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
214607855|NCT03665389|DEVICE|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
214607856|NCT02205411|DEVICE|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
214607857|NCT02205411|DEVICE|Control VAD|The HeartMate II® VAD or HVAD®
214607858|NCT06013657|PROCEDURE|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
214607859|NCT02082899|DRUG|Active Comparator EBI-005 5 mg/mL|
214607860|NCT02082899|DRUG|Placebo Comparator|
214607861|NCT02281357|BIOLOGICAL|Tralokinumab|Tralokinumab dose
214607862|NCT02281357|OTHER|Placebo|Placebo dose
214607863|NCT00025441|BIOLOGICAL|dactinomycin|
214607864|NCT00025441|BIOLOGICAL|filgrastim|
214607865|NCT00025441|DRUG|carboplatin|
214607866|NCT00025441|DRUG|cyclophosphamide|
214607867|NCT00025441|DRUG|doxorubicin hydrochloride|
214607868|NCT00025441|DRUG|epirubicin hydrochloride|
214607869|NCT00025441|DRUG|etoposide|
214607870|NCT00025441|DRUG|ifosfamide|
214607871|NCT00025441|DRUG|vincristine sulfate|
214607872|NCT00025441|PROCEDURE|peripheral blood stem cell transplantation|
214607873|NCT00025441|RADIATION|radiation therapy|
214607874|NCT05144568|OTHER|Nutrition education|Nutrition education will be given to improve PMS
214713477|NCT00014911|DRUG|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
214713478|NCT00014911|DRUG|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
214607875|NCT06325748|BIOLOGICAL|SENTI-202|"SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles to achieve optimal response with the optionality of an additional consolidation cycle thereafter. Additional dosing schedules may be explored depending on study data."
214607876|NCT06295068|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|Replacement of the aortic valve with use of the OpSens SavvyWire
214607877|NCT06295068|DEVICE|Balloon Aortic Valvuloplasty (BAV)|Dilation of the narrowed aortic valve by balloon inflation with use of the OpSens SavvyWire
214607878|NCT01813851|DEVICE|Exercise training in addition to nutritional support|
214607879|NCT05314712|BEHAVIORAL|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
214713479|NCT00014911|DRUG|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
214713480|NCT00014911|DRUG|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
214607880|NCT06235931|DRUG|Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib|"Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day)."
214607881|NCT06012383|DRUG|Bortezomib|Alvocade® was given with a dose of 1.3 mg/m2.
214607882|NCT04582981|DRUG|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
214607883|NCT04582981|DRUG|Fruquintinib|Fruquintinib 5mg qd monotherapy
214607884|NCT02785679|DIETARY_SUPPLEMENT|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
214607885|NCT01208688|DEVICE|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
214607886|NCT01208688|DEVICE|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
214713481|NCT00014911|DRUG|Ganciclovir|An antiviral used to kill viruses and stop viral replication
214607887|NCT01208688|OTHER|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
214713482|NCT00014911|DRUG|Trimethoprim|An antibacterial used to prevent opportunistic infections
214713483|NCT00014911|DRUG|Pentamidine|An antiprotozoal used to prevent disease
214713484|NCT02452177|DRUG|Vitamin D|
214713485|NCT05113498|DIETARY_SUPPLEMENT|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
214713486|NCT04320290|DRUG|Direct Acting Antivirals|8 weeks of DAA treatment
214607888|NCT04417101|DRUG|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
214607889|NCT04759261|OTHER|SMAD4 expression and methylation|Effect of SMAD4 methylations on smad4 expression
214607890|NCT00636467|OTHER|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
214607891|NCT04800588|DIAGNOSTIC_TEST|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
214607892|NCT06382519|DRUG|Thalidomide|thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
214607893|NCT03007979|DRUG|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
214607894|NCT03007979|DRUG|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
214607895|NCT03007979|DRUG|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
214607896|NCT03007979|PROCEDURE|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
214713487|NCT02165345|DRUG|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
214713488|NCT03256409|OTHER|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
214713489|NCT03256409|OTHER|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
214713490|NCT05599698|OTHER|Chemotherapy|Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
214713491|NCT02847845|DIETARY_SUPPLEMENT|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
214713492|NCT02847845|DIETARY_SUPPLEMENT|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
214713493|NCT05278676|DRUG|Dotinurad|Dotinurad oral tablet.
214713494|NCT06193694|BEHAVIORAL|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
214607897|NCT03007979|DRUG|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
214607898|NCT03007979|PROCEDURE|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression"
214607899|NCT03007979|PROCEDURE|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
214607900|NCT03007979|PROCEDURE|Tumor biopsy (optional)|-Baseline and progression
214607901|NCT00482703|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily
214713495|NCT06195293|BIOLOGICAL|Neoantigen Polypeptide Vaccine|Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
214713496|NCT04391972|DEVICE|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
214713497|NCT05836129|BEHAVIORAL|Transcendental Meditation (TM) practice|See previous description
214713498|NCT05836129|OTHER|Stress reduction class (online)|See previous description
214713499|NCT06063239|OTHER|Test Group|Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days
214713500|NCT06063239|OTHER|Positive Control|Subjects will receive orally administred probiotics based on placebo 90 days
214713501|NCT06063239|OTHER|Negative Control|Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
214607902|NCT00482703|DRUG|dasatinib|tablets, Oral, 50 mg, twice daily
214607903|NCT06969989|OTHER|10 % water extract of Boswellia Sacra|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant( 10 % water extract of Boswellia sacra) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
214713502|NCT01078987|PROCEDURE|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
214713503|NCT04711499|BEHAVIORAL|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
214713504|NCT04270487|OTHER|IBS Diet|Patients will be randomized to a diet or a mediation treatment
214713505|NCT04270487|DRUG|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
214713506|NCT03936270|DRUG|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
214713507|NCT03936270|DRUG|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
214713508|NCT06006442|BEHAVIORAL|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
214713509|NCT05370742|PROCEDURE|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
214607904|NCT06969989|OTHER|1 % Sodium Hypochlorite|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant ( 1 % NaOCl ) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
214607905|NCT06969989|OTHER|0.9 % Normal Saline|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant (0.9 % saline) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
214607906|NCT04685915|DRUG|Ibrutinib|Capsule, taken by mouth once daily
214607907|NCT04685915|DRUG|Copanlisib|Intravenous Infusion
214607908|NCT04685915|DRUG|Acalabrutinib|Capsule, taken by mouth twice daily
214607909|NCT05565846|COMBINATION_PRODUCT|NTX-001|One-time use surgical product of three solutions and a device
214607910|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
214607911|NCT06541262|DRUG|Silmitasertib|Capsules
214607912|NCT06541262|DRUG|Irinotecan|IV
214607913|NCT06541262|DRUG|Temozolomide|Oral
214607914|NCT06541262|DRUG|Vincristine|IV
214607915|NCT04739072|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214607916|NCT04739072|OTHER|Electronic Health Record Review|Review of medical records
214607917|NCT04447807|BEHAVIORAL|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
214607918|NCT04447807|OTHER|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
214607919|NCT04777747|OTHER|viral infection|a child is infected by virus only
214607920|NCT04777747|OTHER|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
214607921|NCT01117584|DRUG|ipragliflozin|oral tablet
214607922|NCT01117584|DRUG|Placebo|oral tablet
214607923|NCT01117584|DRUG|Metformin|oral tablet
214607924|NCT05114746|RADIATION|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
214713510|NCT01924299|DRUG|Baricitinib|Administered orally
214607925|NCT05114746|RADIATION|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 259 MBq (3 - 7 mCi).
214607926|NCT05114746|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
214607927|NCT04887454|BEHAVIORAL|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
214607928|NCT04887454|BEHAVIORAL|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
214607929|NCT04887454|OTHER|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
214607930|NCT00823303|DRUG|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
214607931|NCT00823303|DRUG|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
214607932|NCT04692454|OTHER|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
214607933|NCT04272970|DIAGNOSTIC_TEST|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
214607934|NCT01559194|BEHAVIORAL|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
214607935|NCT01559194|BEHAVIORAL|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
214607936|NCT04817384|OTHER|Graston technique|For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
214607937|NCT04817384|OTHER|Classical Massage|In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
214607938|NCT05503563|PROCEDURE|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
214607939|NCT04765241|BEHAVIORAL|Physical Activity|The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
214607940|NCT04726007|DRUG|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
214607941|NCT03298672|DRUG|NDX-1017|Solution of NDX-1017 for subcutaneous injection
214607942|NCT03298672|DRUG|Placebo|Placebo solution for subcutaneous injection
214607943|NCT00591825|DRUG|D-cycloserine|D-cycloserine
214607944|NCT00591825|DRUG|Placebo|Placebo
214607945|NCT02482766|DRUG|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
214607946|NCT02482766|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
214713511|NCT01924299|DRUG|Ketoconazole|Administered orally
214713512|NCT01924299|DRUG|Fluconazole|Administered orally
214713513|NCT02826993|DEVICE|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
214713514|NCT02518776|BEHAVIORAL|Neuropsychological tests|Neuropsychological tests
214713515|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
214713516|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
214713517|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
214607947|NCT02482766|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
214607948|NCT01174511|DRUG|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
214607949|NCT04319302|PROCEDURE|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
214607950|NCT05005455|DRUG|bevacizumab with new manufacturing process.|3mg/kg,I.V.,single dose
214607951|NCT05005455|DRUG|bevacizumab with old manufacturing process.|3mg/kg,I.V.,single dose
214607952|NCT04202523|RADIATION|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
214607953|NCT04202523|DEVICE|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
214607954|NCT01553877|DIETARY_SUPPLEMENT|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
214713518|NCT02398084|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
214713519|NCT00005092|DRUG|Cyclophosphamide|IV over 2 hours on days 2 and 3
214713520|NCT00005092|DRUG|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
214713521|NCT00005092|DRUG|Thiotepa|IV over 2 hours on day 1
214713522|NCT00005092|PROCEDURE|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
214713523|NCT00005092|PROCEDURE|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
214713524|NCT00005092|RADIATION|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
214713525|NCT00871091|PROCEDURE|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
214607955|NCT01553877|DIETARY_SUPPLEMENT|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
214607956|NCT01553877|DIETARY_SUPPLEMENT|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
214713526|NCT00871091|PROCEDURE|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
214713527|NCT00871091|PROCEDURE|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
214713528|NCT00568282|PROCEDURE|phlebotomy|Standard of care
214713529|NCT00605072|DRUG|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
214607957|NCT06197334|DEVICE|Gastro-intestinal biopotentials recording|Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.
214607958|NCT00186264|DRUG|venlafaxine XR|
214607959|NCT00186264|DRUG|hydrocortisone|
214607960|NCT01428661|DRUG|tasimelteon|20 mg once daily
214607961|NCT01428661|DRUG|placebo|once daily
214607962|NCT01387165|DRUG|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
214607963|NCT05622825|BIOLOGICAL|DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
214607964|NCT00630461|BIOLOGICAL|Clinical Center Reference Endotoxin|single inhalation challenge
214607965|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214607966|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
214607967|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214607968|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
214607969|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
214607970|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
214607971|NCT04412538|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
214607972|NCT04412538|BIOLOGICAL|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
214607973|NCT04806139|BEHAVIORAL|Remote Enhance Fitness|The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
214607974|NCT05805566|OTHER|Blood collection|Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
214607975|NCT03882710|DRUG|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
214607976|NCT01306188|BIOLOGICAL|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
214607977|NCT01306188|BIOLOGICAL|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
214607978|NCT02834416|BEHAVIORAL|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
214607979|NCT02834416|BEHAVIORAL|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
214607980|NCT05251818|OTHER|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
214607981|NCT05251818|OTHER|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
214607982|NCT02927418|BEHAVIORAL|Strength & Conditioning|
214607983|NCT02927418|BEHAVIORAL|Control|
214607984|NCT00126074|DRUG|Tedisamil sesquifumarate|
214713530|NCT00605072|DRUG|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
214713531|NCT00605072|DRUG|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
214713532|NCT00605072|DRUG|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
214607985|NCT05149664|DEVICE|Therapeutic ultrasound (TUS)|As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
214607986|NCT04248309|DRUG|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
214607987|NCT00506545|DRUG|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
214607988|NCT00506545|DRUG|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
214607989|NCT03197688|OTHER|Notapplicable|Not applicable as non-interventional study
214713533|NCT00605072|DRUG|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
214607990|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
214713534|NCT04451291|BIOLOGICAL|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
214713535|NCT06383689|OTHER|Seizure placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
214713536|NCT06383689|OTHER|Well-being placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
214607991|NCT07128849|OTHER|upper limb exercise with arm ergometer|upper limb exercise on arm ergometer lasting 5 min at 30 rpm (Rotation per minute) 3 times a day for 7 days and standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
214607992|NCT07128849|OTHER|upper limb exercise with out arm ergometer|standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
214713537|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
214607993|NCT03491709|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
214607994|NCT03491709|DRUG|Cetuximab injection|Cetuximab injection
214607995|NCT04803110|PROCEDURE|Dental implant placement after tooth extraction|Immediate implant placement after partial or complete tooth extraction.
214713538|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
214713539|NCT01305304|OTHER|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
214713540|NCT01305304|OTHER|Other|No history of endurance sports activity
214713541|NCT02625987|PROCEDURE|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
214713542|NCT02625987|PROCEDURE|Separated stitches|Appendectomy wound closure with a separated stitches.
214713543|NCT05064332|DRUG|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
214713544|NCT05064332|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
214713545|NCT06197737|OTHER|Moderate Intensity Interval Training|Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.
214713546|NCT06197737|OTHER|Sprint Interval Training|sprint interval training in which they will do stair climbing 3 times a week with a fast pace.
214713547|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
214713548|NCT01672528|OTHER|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
214713549|NCT01672528|OTHER|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
214713550|NCT03714009|BEHAVIORAL|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
214607996|NCT06179771|DEVICE|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
214607997|NCT06976567|DEVICE|Telemedicine for urology consultations|The patients that are assigned to the intervention group will receive a virtual urology consultation with urologists from Ahmadu Bello University in Zaria, Nigeria as opposed to physically presenting for the consultation.
214607998|NCT06843174|DRUG|Rectal Methadone administer during spinal surgery|Rectal Methadone administered during spinal surgery for post-operative pain management
214607999|NCT06843174|OTHER|Placebo: Rectal saline solution|Placebo: Rectal saline solution single dose received during surgery
214608000|NCT00972777|DRUG|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
214608001|NCT00972777|DRUG|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
214608002|NCT06985628|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|tVNS will be applied at the cervical level of the vagal nerve.
214608003|NCT06985628|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be applied facially on the trigeminal nerve.
214608004|NCT05336253|BEHAVIORAL|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
214713551|NCT03714009|BEHAVIORAL|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
214608005|NCT05336253|BEHAVIORAL|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
214608006|NCT05334537|OTHER|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
214608007|NCT05334537|OTHER|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
214608008|NCT05619978|OTHER|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
214608009|NCT05619978|OTHER|T315I|Patients with chronic myeloid leukemia with T315I mutation
214608010|NCT06984159|DRUG|Leuprolide Injectable Emulsion (CAMCEVI®)|Leuprolide Injectable Emulsion (CAMCEVI®)，Subcutaneous injection，Once every 24 weeks for a total of 2 doses
214608011|NCT05568602|DIAGNOSTIC_TEST|Dexamethasone suppression test|1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
214608012|NCT03612284|DEVICE|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
214608013|NCT01540383|BEHAVIORAL|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, \>=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
214713552|NCT05805670|OTHER|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
214713553|NCT04101734|DEVICE|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
214713554|NCT04101734|DEVICE|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
214713555|NCT05799209|DEVICE|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
214713556|NCT05799209|DEVICE|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
214713557|NCT04283357|OTHER|Exercise|Short Foot Exercises
214713558|NCT04283357|DEVICE|Virtual Reality|Exercise with virtual reality
214713559|NCT00005015|DRUG|Fluoxetine|
214713560|NCT05833971|DRUG|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
214713561|NCT03118011|OTHER|No smoking|No smoking
214713562|NCT03118011|OTHER|Smoking|Ability to go out to smoke
214713563|NCT03541655|DRUG|Bupivacaine HCl|0.25% Bupivacaine HCl
214713564|NCT03541655|DRUG|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
214713565|NCT01768234|OTHER|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
214713566|NCT03657667|PROCEDURE|Ureteroscopy|Endoscopic removal of kidney stones
214608014|NCT01540383|BEHAVIORAL|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
214608015|NCT02752750|OTHER|MRI|MR imaging (MRI) at 3 Tesla
214608016|NCT04631796|DEVICE|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
214608017|NCT04631796|DEVICE|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
214608018|NCT00563667|PROCEDURE|pterygium excision|
214608019|NCT06863155|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|PCI with SupraFlex Cruz® stent in de novo coronary stenosis of patients under chronic oral anticoagulation.
214608020|NCT06607172|DEVICE|oral irrigator|water flosser device
214608021|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
214608022|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
214608023|NCT05835713|DRUG|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
214608024|NCT05835713|DRUG|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
214608025|NCT07130019|PROCEDURE|Fluorescence guided thermal ablation of epidermal tissue|Thermal ablation of epidermal tissue under fluorescence control.
214608026|NCT07130019|PROCEDURE|Thermal ablation of epidermal tissue|Thermal ablation of skin tissue a vue
214608027|NCT07032818|OTHER|Additional post discharge phone call|24-72 hours after hospital discharge, a nurse will call participants to review the written After Visit Summary (AVS) given at discharge, including primary diagnosis, self-care instructions, emergency plan, medication changes, how and why to take medication, and scheduled follow up. These phone calls will take on average 10-15 minutes.
214608028|NCT06725225|BEHAVIORAL|Symptom cluster-based care intervention|The patient symptoms were surveyed to develop a symptom cluster care intervention plan. The specific steps were as follows: a research team was established, relevant literature was reviewed, and qualitative interviews were conducted. Guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, a draft of the care intervention was created. This draft was then refined through expert consultation to finalize the intervention plan.
214608029|NCT06725225|BEHAVIORAL|Conventional care intervention|Standard nursing intervention. This refers to routine clinical care without a specific care plan tailored to the patient's symptoms. For example, if a patient has symptoms, the nurse assists the patient in notifying the doctor but does not provide any special treatment themselves
214608030|NCT06708611|DRUG|torsemide|Extended release formulation of torsemide
214608031|NCT02247154|BIOLOGICAL|Vigam® (Human Normal Immunoglobulin)|
214608032|NCT06741761|OTHER|12-hour time-restricted feeding (TRF12)|The 12 hour feeding group will receive tube feeding only over a 12 hour period (6:00 AM to 6:00 PM feeding schedule).
214608033|NCT06741761|OTHER|Continuous 24 hour feeding (CONT24).|Patients in this control group will receive the standard of care which is tube feeding continuously over 24 hours.
214608034|NCT01978821|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
214608035|NCT06148987|OTHER|Questionnaire|The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
214608036|NCT00001181|DRUG|Testolactone|
214608037|NCT00729378|OTHER|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
214608038|NCT03683940|DIAGNOSTIC_TEST|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
214608039|NCT01330134|DRUG|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
214608040|NCT01330134|DRUG|lidocaine|1% lidocaine subcutaneous injection alone
214608041|NCT06200844|BIOLOGICAL|ROTAVAC 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.
214608042|NCT06200844|OTHER|Placebo|Placebo is administered as three doses 4 weeks apart
214608043|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
214608044|NCT04790136|DRUG|GLA-015|administration followed by PK blood sampling
214608045|NCT04790136|DRUG|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|administration followed by PK blood sampling
214608046|NCT01606267|OTHER|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
214713567|NCT03896113|DRUG|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
214713568|NCT03047850|DIAGNOSTIC_TEST|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
214608047|NCT04389021|DEVICE|Virtual Reality|"The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol."
214608048|NCT02246582|DEVICE|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
214608049|NCT02246582|DEVICE|Guardian Mobile App|
214608050|NCT02246582|DEVICE|640G Insulin Pump|
214608051|NCT02899078|DRUG|Ibrutinib|Given PO
214608052|NCT02899078|DRUG|Nivolumab|Given IV
214608053|NCT01171352|PROCEDURE|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
214608054|NCT04156503|OTHER|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
214608055|NCT06379425|DRUG|Acetaminophen|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
214608056|NCT06379425|DRUG|Celecoxib|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
214608057|NCT06379425|DRUG|Gabapentin|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
214608058|NCT04139044|PROCEDURE|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
214608059|NCT04139044|PROCEDURE|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
214608060|NCT05452330|OTHER|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
214608061|NCT05452330|OTHER|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
214608062|NCT05099094|GENETIC|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
214608063|NCT03441334|DEVICE|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
214608064|NCT03441334|DEVICE|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
214608065|NCT00866450|DIETARY_SUPPLEMENT|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
214608066|NCT00866450|DIETARY_SUPPLEMENT|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
214608067|NCT00024050|DRUG|busulfan|
214608068|NCT00024050|DRUG|cyclophosphamide|
214608069|NCT00024050|DRUG|cyclosporine|
214608070|NCT00024050|DRUG|methotrexate|
214608071|NCT00024050|PROCEDURE|allogeneic bone marrow transplantation|
214608072|NCT00024050|PROCEDURE|peripheral blood stem cell transplantation|
214608073|NCT00316355|BEHAVIORAL|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
214713569|NCT03328585|BEHAVIORAL|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
214713570|NCT03328585|BEHAVIORAL|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
214608074|NCT00316355|BEHAVIORAL|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
214713571|NCT03328585|OTHER|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
214713572|NCT05578235|PROCEDURE|stapled side-to-side anastomosis|Standard procedure for CD
214608075|NCT04485273|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
214608076|NCT04485273|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
214608077|NCT04485273|PROCEDURE|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
214608078|NCT04485273|DRUG|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
214608079|NCT04485273|DRUG|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
214608080|NCT05867082|OTHER|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
214608081|NCT04072055|DEVICE|MOTO Medial|MOTO medial unicompartmental knee system
214608082|NCT00880659|BEHAVIORAL|Soap|Promotion of handwashing with soap
214608083|NCT00182832|BEHAVIORAL|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
214608084|NCT00182832|BEHAVIORAL|Standard Care|Standard care for hospitalized older patients with cognitive impairment
214608085|NCT02768337|DRUG|Afatinib|
214608086|NCT02768337|RADIATION|2 Gy targeted radiotherapy|
214608087|NCT02768337|RADIATION|4 Gy targeted radiotherapy|
214608088|NCT05052073|DIAGNOSTIC_TEST|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
214608089|NCT05052073|DIAGNOSTIC_TEST|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
214608090|NCT04677673|DRUG|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
214608091|NCT04677673|PROCEDURE|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
214608092|NCT02592551|DRUG|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
214713573|NCT05578235|PROCEDURE|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
214713574|NCT06874556|BEHAVIORAL|CP-HF Management|Community Paramedics will visit patients up to twice daily. Visits will include patient care discussion with Heart Failure APP, IV placement, lab phlebotomy, heart failure education, and IV medication administration. Community Paramedics will administer up to 120 mg IV furosemide twice daily.
214713575|NCT01999946|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
214608093|NCT02592551|DRUG|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
214608094|NCT02592551|OTHER|no other name|Neither MEDI4736 nor Tremelimumab will be used.
214608095|NCT02839408|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
214608096|NCT02839408|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn
214608097|NCT02839408|OTHER|Talc powder|Sachet containing talc powder and tablet containing talc powder
214608098|NCT02839408|PROCEDURE|Periodontal treatment Scaling and root planning|
214608099|NCT05151081|OTHER|basicly|Do not repeat information already included in arm/group descriptions.
214608100|NCT01876251|DRUG|PF-03084014|Tablet, 10 mg, twice a day
214608101|NCT01876251|DRUG|PF-03084014|Tablet, 50 mg, twice a day
214608102|NCT01876251|DRUG|PF-03084014|Tablet, 100 mg, twice a day
214608103|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 75 mg/m\^2, every 3 weeks
214608104|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 100 mg/m\^2, every 3 weeks
214713576|NCT02595840|DRUG|Afatinib|
214713577|NCT02595840|DRUG|Pemetrexed|
214608105|NCT00933179|DRUG|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
214713578|NCT06876012|OTHER|Tai Chi Program|Twelve sessions (six weeks) of a Tai Chi Program to assist with balance and fall risk.
214713579|NCT06876636|DRUG|Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)|zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel Concurrent immunotherapy is permitted: pembrolizumab or toripalimab
214713580|NCT03032081|OTHER|High intensity exercise|High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
214713581|NCT03032081|OTHER|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
214713582|NCT05442294|BEHAVIORAL|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
214713583|NCT07044310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214713584|NCT07044310|PROCEDURE|Bone Mineral Density Test|Undergo BMD
214713585|NCT07044310|OTHER|Questionnaire Administration|Ancillary studies
214713586|NCT07044310|DRUG|WBF-038|Given WBF-038 PO
214713587|NCT04545099|DRUG|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
214713588|NCT04545099|DRUG|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
214713589|NCT03229681|BEHAVIORAL|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
214713590|NCT03229681|BEHAVIORAL|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
214608106|NCT00933179|DRUG|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
214608107|NCT00268437|DRUG|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
214608108|NCT00268437|DRUG|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
214608109|NCT00268437|PROCEDURE|conventional surgery|
214608110|NCT00268437|PROCEDURE|neoadjuvant therapy|
214713591|NCT00325650|DRUG|Rimonabant|Tablet, oral administration
214713592|NCT00325650|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214713593|NCT00889980|OTHER|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
214713594|NCT05607004|DRUG|(Z)-endoxifen|(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
214713595|NCT05607004|DRUG|exemestane|exemestane tablets 25 mg
214713596|NCT05607004|DRUG|goserelin|goserelin 3.6 mg subcutaneous implant
214713597|NCT07091084|DIETARY_SUPPLEMENT|MZRW|MZRW herbal formula consists of a 7:1 extract of Huo Ma Ren \[Hemp Seed 33.4%\]; Da Huang (Sheng) \[Rhubarb (Fresh) 22.2%\]; Bai Shao \[Peony (White) 11.1%\]; Zhi Shi \[Aurantium Immaturus 11.1%\]; Hou Po \[Magnolia Bark 11.1%\]; and Xing Ren \[Apricot Kernel 11.1%\] - Taken for 2 weeks intervention and 2 weeks follow-up
214713598|NCT07091630|BIOLOGICAL|Empasiprubart IV|Intravenous infusion of empasiprubart
214713599|NCT07091630|OTHER|Placebo IV|Intravenous infusion of placebo
214608111|NCT00268437|RADIATION|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
214608112|NCT01355484|DRUG|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
214608113|NCT01355484|DRUG|placebo|subject will receive placebo for the duration of the trial
214608114|NCT03715842|OTHER|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
214608115|NCT03715842|OTHER|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
214608116|NCT00418990|DRUG|Multivitamin/Mineral supplements|
214608117|NCT03667534|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
214608118|NCT01295528|DEVICE|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
214608119|NCT00222170|DRUG|Rabeprazole|
214608120|NCT01182402|DEVICE|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
214608121|NCT05725070|DRUG|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
214608122|NCT00575627|DRUG|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
214713600|NCT07090980|OTHER|epilepsy education via podcast|Epilepsy education via podcast has never been provided in any clinical study in Turkey before. By providing education via podcast, we have made health education more accessible and repeatable.
214608123|NCT02137512|DEVICE|Closed-Loop Control System|"This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
214608124|NCT02137512|DEVICE|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump"
214608125|NCT05259371|DRUG|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
214608134|NCT06788938|DRUG|Tarlatamab treatment|"* 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle"
214608135|NCT05406388|PROCEDURE|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
214608136|NCT05406388|PROCEDURE|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
214608137|NCT05241509|DRUG|Cymbopogon citratus (lemongrass) oil gel|Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
214608138|NCT00004022|BIOLOGICAL|aldesleukin|
214608139|NCT00004022|BIOLOGICAL|autologous tumor cell vaccine|
214608140|NCT00004022|BIOLOGICAL|muromonab-CD3|
214608141|NCT00004022|BIOLOGICAL|therapeutic autologous lymphocytes|
214608142|NCT00004022|PROCEDURE|surgical procedure|
214608143|NCT05170425|DEVICE|Prospera|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
214608144|NCT05340725|DRUG|DEX-IV|patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
214608145|NCT05340725|DRUG|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
214608146|NCT05340725|DRUG|DEX-Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
214608147|NCT04414371|OTHER|Yoga|Yoga Namaskar and Nadi Shuddhi
214608148|NCT03712436|COMBINATION_PRODUCT|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
214608149|NCT03712436|COMBINATION_PRODUCT|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
214608150|NCT01338623|DRUG|Tansulosine|capsule 0,4 mg
214608151|NCT00237575|DRUG|gemcitabine|
214608152|NCT00237575|DRUG|cisplatin|
214608153|NCT00237575|DRUG|sargramostim|
214608154|NCT00237575|DRUG|filgrastim|
214608155|NCT01068197|BEHAVIORAL|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
214608156|NCT01628107|BIOLOGICAL|Epoetin Hospira|Intravenous (IV) injection
214608157|NCT05008536|BIOLOGICAL|Anti-BCMA CAR-NK Cells|1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion
214608158|NCT05008536|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
214608159|NCT05008536|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
214608160|NCT01086410|DRUG|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
214608161|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
214608162|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
214608163|NCT01086410|DRUG|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
214608164|NCT01086410|DRUG|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
214608165|NCT02256605|DIETARY_SUPPLEMENT|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
214608166|NCT06319313|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.
214608167|NCT06319313|DRUG|docetaxel|50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.
214608168|NCT06319313|DRUG|HB1801|75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.
214608169|NCT02953639|DRUG|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
214608170|NCT02953639|DRUG|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
214608171|NCT00171444|BEHAVIORAL|Medical education|
214608172|NCT03569046|DRUG|local anaesthetic injection|ear block by 0.25% bupivacaine
214608173|NCT03569046|DRUG|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
214608174|NCT03569046|DRUG|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
214608175|NCT03569046|DRUG|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
214713601|NCT07091474|BEHAVIORAL|Educational Workshops for Parents and Early Educators|A structured series of age-specific educational workshops designed for parents, caregivers, and early childhood educators of children aged 0-36 months. The workshops are organized into three cohorts (0-12 months, 13-24 months, 25-36 months) and focus on typical motor milestones, active play, early stimulation strategies, and recognition of early warning signs of motor delays. Sessions include interactive activities, discussions, and distribution of educational resources. Pre- and post-workshop surveys and semi-structured interviews are conducted to evaluate changes in knowledge and attitudes.
214608176|NCT01956825|DIETARY_SUPPLEMENT|"slim water"|
214608177|NCT01386918|DEVICE|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
214608178|NCT03921320|PROCEDURE|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
214608179|NCT03921320|PROCEDURE|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
214713602|NCT07091474|OTHER|Motor Development Assessment in Children 0-36 Months|Comprehensive motor development assessments performed on infants aged 0-36 months using validated tools (Standardized Infant Hand Assessment \[s-HAI\], Hammersmith Infant Neurological Examination \[HINE\], Infant Motor Profile \[IMP\], and Ages and Stages Questionnaire \[ASQ-3\]). These evaluations aim to collect normative data on typical early motor development and to identify early signs of motor delays or neurological conditions, enabling timely referral and intervention. Assessments are conducted annually for typically developing infants and monthly for those identified as at risk.
214608180|NCT03921320|PROCEDURE|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
214713603|NCT07092319|PROCEDURE|deferred cord clamping|DCC: deferred cord clamping successfully for 60 seconds;MISA: Surfactant administration by minimally invasive methods that allow for spontaneous breathing.
214713604|NCT07091773|DEVICE|OLIZ Photobiomodulation Device|OLIZ device utilizes dual-wavelength technology combining specific red (660nm) and near-infrared (850nm) light parameters optimized for post-surgical tissue healing. The device features controlled power density, precise treatment duration protocols, and targeted application to knee arthroplasty surgical sites. Treatment parameters include specific irradiance levels, treatment session duration of 15 minutes, and 3 times of daily application frequency designed.
214608181|NCT01145014|DRUG|BI 660848|2 mg oral drinking solution
214608182|NCT01145014|DRUG|BI 660848|10 mg oral drinking solution
214608183|NCT01145014|DRUG|BI 660848|20 mg oral drinking solution
214608184|NCT01145014|DRUG|BI 660848|50 mg oral drinking solution
214608185|NCT01145014|DRUG|BI 660848|100 mg oral drinking solution
214608186|NCT01145014|DRUG|BI 660848|150 mg oral drinking solution
214608187|NCT01145014|DRUG|BI 660848|200 mg oral drinking solution
214608188|NCT01145014|DRUG|BI 660848|400 mg oral drinking solution
214713605|NCT07091227|DRUG|AK112+oxaliplatin+capecitabine|participants will receive standard dose treatment of AK112 combined with oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery.
214608189|NCT01145014|DRUG|BI 660848|600 mg oral drinking solution
214608190|NCT01145014|DRUG|BI 660848|10,0 mg immediate release tablet
214608191|NCT01145014|DRUG|BI 660848|50,0 mg immediate release tablet
214608192|NCT01145014|DRUG|Placebo|matching placebo (oral drinking solution and IR tablets)
214608193|NCT04196803|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
214608194|NCT04196803|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
214608195|NCT01033526|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
214608196|NCT01033526|DRUG|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
214608197|NCT06348550|DIETARY_SUPPLEMENT|Berberol® K|Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®
214713606|NCT07091227|DRUG|oxaliplatin+capecitabine|participants will receive standard dose treatment of oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery
214608198|NCT06348550|DIETARY_SUPPLEMENT|Placebo|Placebo
214608199|NCT04742881|PROCEDURE|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
214608200|NCT04742881|PROCEDURE|Low pressure + standard instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of standard instruments (5mm and 10mm instruments)
214608201|NCT05990751|BIOLOGICAL|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
214608202|NCT01022996|DRUG|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
214608203|NCT03832803|BEHAVIORAL|Empty bladder|No drinking protocol.
214608204|NCT03832803|BEHAVIORAL|Full bladder|Followed drinking protocol
214608205|NCT03712748|BEHAVIORAL|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
214608206|NCT00453648|OTHER|White-fleshed sweet potatoes|
214608207|NCT00453648|OTHER|Orange-fleshed sweet potatoes (boiled)|
214608208|NCT00453648|OTHER|Orange-fleshed sweet potatoes (fried)|
214608209|NCT00453648|OTHER|WFSP and capsule of retinyl palmitate|
214608210|NCT03887845|PROCEDURE|Surgery|The respective surgical approach for any gastric and colorectal surgery
214608211|NCT06426251|DEVICE|Photobiomodulation|Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
214608212|NCT03349775|DRUG|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
214608213|NCT03349775|DRUG|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
214608214|NCT01516970|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
214608215|NCT01516970|DRUG|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
214608216|NCT01516970|DRUG|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
214608217|NCT01516970|DRUG|NRTIs|The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
214608218|NCT01516970|DRUG|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
214608219|NCT00612950|DRUG|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
214608220|NCT00612950|DRUG|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
214608221|NCT00612950|DRUG|Saline|continuous infusion of Saline for 120 min
214608222|NCT01786200|DRUG|Aspirin|
214608223|NCT01786200|DRUG|Ibuprofen|
214608224|NCT05486520|DEVICE|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
214608225|NCT02080442|OTHER|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
214608226|NCT01756040|DRUG|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
214608227|NCT03642756|DEVICE|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
214608228|NCT05982093|DRUG|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
214608229|NCT05982093|DRUG|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
214608230|NCT04457076|DRUG|LevoCept|Levonorgestrel-Releasing Intrauterine System
214608231|NCT05660369|DRUG|CARv3-TEAM-E T cells|Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
214608232|NCT01903642|OTHER|proteomic analysis|
214608233|NCT06459596|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
214713607|NCT07091760|OTHER|Su Jok Application|The patient's hands will be preferred for the application due to the comfort and convenience of the woman after cesarean section. Su Jok therapy, massage and seed will be applied to the reflection points on the hand based on the area to be treated.
214713608|NCT07091760|OTHER|Placebo Application|"Placebo Intervention:~The placebo group will be massaged and seed will be applied to an area where there is no reflection of the Su Jok organ."
214713609|NCT07091825|DEVICE|LACRIFRESH OCU-DRY 0.3% OSD|Use LACRIFRESH OCU-DRY 0.3% OSD as the daily contact lens lubricant product.
214713610|NCT07091825|DEVICE|Rigid contact lens lubricant|Use Rigid contact lens lubricant as the daily contact lens lubricant product.
214608234|NCT03323476|OTHER|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
214608235|NCT03323476|DRUG|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
214608236|NCT05053477|DRUG|mehylprednisolone injection|(40 mg)
214608237|NCT05053477|DEVICE|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
214608238|NCT05053477|BIOLOGICAL|platelet-rich plasma|2 ml of PRP
214608239|NCT02730273|DEVICE|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
214608240|NCT03754140|DRUG|Polidocanol Injection|Sclerotic agent
214608241|NCT03305289|PROCEDURE|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
214608242|NCT03305289|PROCEDURE|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
214608243|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
214608244|NCT00427232|DRUG|BQ-123 and BQ-788|
214713611|NCT07091266|DEVICE|Sacral Neuromodulation (SNM)|A standardized two-stage implantation protocol was used. In Stage 1, a temporary lead (InterStim 3093, Medtronic) was implanted at the S3 sacral foramen under fluoroscopic guidance. Patients with ≥50% improvement in urinary symptoms over a 7-day test period proceeded to Stage 2, where a permanent neurostimulator (InterStim 3058, Medtronic) was implanted subcutaneously. Stimulation parameters were adjusted (amplitude: 0.5-10 V; frequency: 14 Hz; pulse width: 210 μs) to optimize symptom control.
214713612|NCT07091266|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|Patients received two 20-session courses (5 sessions/week) in a hyperbaric chamber at 2.0 atmospheres absolute (ATA). Each session consisted of 60 minutes of 100% oxygen inhalation, bracketed by compression and decompression periods.
214608245|NCT04683978|OTHER|Position|Neck extension
214608246|NCT04678596|DEVICE|EonAligner|EonAligner system is one stage system.
214608247|NCT04678596|DEVICE|Clearfix|Clearfix system is three-stage system.
214608248|NCT00884325|DRUG|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
214608249|NCT00884325|DRUG|placebo|One tablet taken orally at night for 28 days
214608250|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
214608251|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
214608252|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
214608253|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
214608254|NCT01540825|DRUG|Placebo|Powder for oral solution
214608255|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
214608256|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
214608257|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
214608258|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
214608259|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
214608260|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
214608261|NCT02247765|DEVICE|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
214608262|NCT02247765|DEVICE|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
214608263|NCT01546974|DEVICE|HME filter Twin Star 55, Drager Medical, Germany|
214608264|NCT01546974|DEVICE|Heated humidification|
214608265|NCT01681134|DRUG|Advagraf®|oral
214608266|NCT01681134|DRUG|Prograf®|oral
214608267|NCT04236648|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
214608268|NCT05075837|BIOLOGICAL|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
214608269|NCT06188819|PROCEDURE|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
214608270|NCT05679466|BIOLOGICAL|randomized, double-blinded, placebo-controlled|Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
214608271|NCT00623974|DRUG|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
214608272|NCT00623974|DRUG|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
214608273|NCT00623974|DRUG|Calcitriol|0.25 micrograms PO Every 12 Hours
214713613|NCT07091526|DIAGNOSTIC_TEST|serum uric acid test|Detect the serum uric acid in blood sample
214608274|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
214608275|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
214608276|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
214608277|NCT00892177|BIOLOGICAL|bevacizumab|Given intravenously
214608278|NCT00892177|DRUG|dasatinib|Given orally
214608279|NCT00892177|OTHER|placebo|Given orally
214608280|NCT04290299|OTHER|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
214608281|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
214608282|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
214608283|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
214608284|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
214608285|NCT00347334|BEHAVIORAL|infant home positioning|
214608286|NCT00005081|DRUG|O6-benzylguanine|
214608287|NCT00005081|DRUG|carmustine|
214608288|NCT00393796|DRUG|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
214608289|NCT00393796|OTHER|Placebo|
214608290|NCT00955851|OTHER|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
214608291|NCT00227487|OTHER|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
214713614|NCT07091461|DEVICE|HOME Kit Tablet-based Telerehabilitation|Device-based behavioral intervention (motor, cognitive, and communication rehabilitation)
214608292|NCT00227487|OTHER|Administration of carbohydrate solution during clinically indicated endoscopy|"* A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
214608293|NCT00227487|OTHER|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
214608294|NCT06637462|DIAGNOSTIC_TEST|Endoscopy|Standard of care endoscopy
214713615|NCT07091461|OTHER|Conventional Home Physiotherapy|Participants in this arm will follow a conventional home rehabilitation protocol, focusing on upper limb function and postural control. The protocol includes traditional exercises prescribed and explained by a physiotherapist. Follow-up will be conducted through weekly phone calls to reinforce adherence and resolve concerns.
214608295|NCT02336789|OTHER|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
214608296|NCT02336789|OTHER|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
214608297|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
214608298|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
214608299|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
214608300|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
214713616|NCT07092059|DEVICE|Smartphone digital therapeutic system|This intervention is composed of a smartphone app (Apple iOS or Android type) that prompts patients with Stimulant Use Disorder to (1) complete self-assessment questionnaires in the app about their health, health care needs and the services they receive and other health-related functions in life, (2) read educational modules about health and wellness and answer questions about these readings, (3) speak periodically with a Guide about their use of the app, and (4) take periodic saliva substance tests using video-selfies with their smartphone camera. The intervention includes testing and interviews with the study staff over a 12 month period. There is a follow-up period to measure the longer-term results at 15 months, as well.
214713617|NCT07090733|OTHER|Interscalene brachial plexus block|Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.
214608301|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
214608302|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
214608303|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
214608304|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
214608305|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
214608306|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
214713618|NCT07090733|OTHER|Suprascapular nerve block|Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.
214713619|NCT07090733|OTHER|Anterior glenoid block|Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.
214608307|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
214608308|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
214608309|NCT00943709|BIOLOGICAL|insulin glargine recombinant|Given subcutaneously
214608310|NCT00943709|DRUG|therapeutic insulin|Given subcutaneously
214608311|NCT03171844|OTHER|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
214608312|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
214608313|NCT04130633|DRUG|THC|Pure THC vapor
214608314|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
214608315|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
214608316|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
214608317|NCT04695496|DEVICE|Theta bust stimulating|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
214608318|NCT00616434|DRUG|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
214608319|NCT00616434|DRUG|Placebo|Placebo IM injection, self-administered per protocol.
214608320|NCT02455934|DIETARY_SUPPLEMENT|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
214608321|NCT03302000|OTHER|Early Visual Stimulation|Early visual stimulation
214608322|NCT03302000|OTHER|standard care|standard care
214608323|NCT02420132|OTHER|Ranibizumab|Ranibizumab administered as part of standard-of-care
214608324|NCT04229511|DIAGNOSTIC_TEST|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
214608325|NCT04288830|BEHAVIORAL|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
214608326|NCT04288830|BEHAVIORAL|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
214608327|NCT03664154|BEHAVIORAL|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
214608328|NCT03945591|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
214608329|NCT03945591|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
214608330|NCT03207711|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
214608331|NCT03207711|BEHAVIORAL|Mindfulness|Mindful eating app-use and instruction
214608332|NCT06837181|OTHER|observational study|This is an observational study.
214608333|NCT04216186|DRUG|Atomoxetine|Atomoxetine once daily
214608334|NCT04216186|DRUG|Coenzyme Q|Coenzyme Q once daily
214608335|NCT01464125|DRUG|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
214608336|NCT01464125|DRUG|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
214608337|NCT02213432|BIOLOGICAL|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
214608338|NCT06141044|PROCEDURE|Avoid surgical drainage|Patients who undergo distal pancreatectomy, avoid placing a drain.
214608339|NCT00437385|DRUG|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
214713620|NCT07090733|OTHER|Suprascapular nerve block + Anterior glenoid block|Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.
214608340|NCT00437385|PROCEDURE|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
214608341|NCT00437385|BEHAVIORAL|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
214608342|NCT03099239|BIOLOGICAL|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
214608343|NCT03355313|RADIATION|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
214713621|NCT07092410|DRUG|Encorafenib & Binimetinib Treatment|The SuRage-EB post approval study will evaluate prospectively the potential impact of local treatment of melanoma metastases under encorafenib (E) + binimetinib (B) combination therapy while continuing EB therapy thereafter. It focusses on single melanoma metastases which develop resistance or show no response during EB treatment. These metastases will be treated locally before registration of the patients into the study. Directly after or during local treatment, EB combination therapy will be resumed. Locally treated EB-resistant melanoma cells cannot continue to grow during targeted therapy and the positive response may be prolonged.
214713622|NCT07091877|BEHAVIORAL|Cognitive Reappraisal|Cognitive Reappraisal (CR) is a cognitive-behavioral technique and will complete the Cognitive Reappraisal task.
214713623|NCT07091877|BEHAVIORAL|Control cue-reactivity task|Participants will complete a control cue-reactivity task.
214608344|NCT05682079|OTHER|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
214608345|NCT03341741|DRUG|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
214608346|NCT03341741|DRUG|Colistin|Colistin solution 2 x daily 1 Mega continuously
214608347|NCT03706404|DIAGNOSTIC_TEST|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
214608348|NCT00335894|DRUG|hMG-IBSA|
214608349|NCT00621231|DIETARY_SUPPLEMENT|Placebo|Placebo
214608350|NCT00621231|DIETARY_SUPPLEMENT|Protein|30 E% from protein
214608351|NCT03957395|DEVICE|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
214608352|NCT05798234|DEVICE|high flow oxygen device|no intervention
214608353|NCT01698866|BIOLOGICAL|Vaccin GenHevac B Pasteur|
214608354|NCT01262937|DEVICE|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
214608355|NCT03269643|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214608356|NCT03269643|DEVICE|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214608357|NCT00518414|OTHER|Marketed infant formula with DHA and ARA|
214608358|NCT00518414|OTHER|Milk-based infant formula with DHA and ARA|
214608359|NCT00518414|OTHER|Milk-based formula with DHA, ARA, prebiotics|
214608360|NCT03819062|DEVICE|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
214608361|NCT03877978|BIOLOGICAL|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
214608362|NCT02811055|BIOLOGICAL|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
214608363|NCT02811055|PROCEDURE|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
214713624|NCT07091903|OTHER|Diaphragmatic breathing exercise|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. Diaphragmatic breathing exercise was performed with the participants in a supine position with bent knees, 10 repetitions and 3 sets.
214608364|NCT02811055|DEVICE|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
214608365|NCT02811055|PROCEDURE|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
214608366|NCT02811055|DRUG|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
214608367|NCT02811055|DRUG|Administration of placebo|Administration of placebo once per day during 14 days
214608368|NCT05140122|DRUG|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
214608369|NCT05140122|OTHER|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
214608370|NCT05097729|DEVICE|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
214608371|NCT03109548|OTHER|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
214608372|NCT04170712|OTHER|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
214608373|NCT05489692|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
214608374|NCT03540082|OTHER|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
214608375|NCT03540082|OTHER|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
214608376|NCT02934997|OTHER|Observational study|
214608377|NCT02805049|DRUG|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
214608378|NCT00929604|OTHER|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
214608379|NCT04757441|OTHER|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire|"ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
214608380|NCT04757441|OTHER|Group B: Conventional treatment|"Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
214608381|NCT03146767|DEVICE|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
214608382|NCT02941653|DEVICE|Potassium nitrate 2% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
214608383|NCT02941653|DEVICE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
214608384|NCT03083847|DRUG|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
214608385|NCT03083847|DRUG|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
214608386|NCT03083847|BIOLOGICAL|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
214608387|NCT03714321|DEVICE|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
214608388|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFU IM, 1.0 mL
214608389|NCT00376090|BIOLOGICAL|Placebo|1.0 mL IM
214608390|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^6 PFU ID, 0.1 mL
214608391|NCT00376090|BIOLOGICAL|Placebo|0.1 mL ID
214608392|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^8 PFU IM, 1.0 mL
214608393|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFD ID, 0.1 mL
214608394|NCT00741325|DRUG|granulocyte colony-stimulating factor (G-CSF)|
214608395|NCT00741325|DRUG|plerixafor|
214608396|NCT00741325|DRUG|Placebo|
214608397|NCT02290860|PROCEDURE|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
214608398|NCT04216251|DRUG|AMR101|AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
214608399|NCT04122404|DIAGNOSTIC_TEST|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
214608400|NCT05264818|PROCEDURE|Glycocheck|Assessment of the sublingual microvascularization
214608401|NCT05264818|PROCEDURE|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
214608402|NCT06121453|BEHAVIORAL|Multicomponent Adherence Intervention|multi-part intervention to reduce barriers to medication use
214608403|NCT01053299|OTHER|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
214608404|NCT01887951|DRUG|Penthrox Inhaler|
214608405|NCT01887951|DRUG|Tramadol Injection|
214608406|NCT06231420|OTHER|Encourage using pedometer|Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
214608407|NCT06231420|DEVICE|pedometer|pedometer
214608408|NCT02595021|PROCEDURE|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
214608409|NCT02595021|PROCEDURE|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
214608410|NCT00184626|DRUG|biphasic insulin aspart|
214608411|NCT00184626|DRUG|insulin glargine|
214608412|NCT00184626|DRUG|metformin|
214608413|NCT03821818|BEHAVIORAL|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise \> 75% max heart rate, 5/day)
214608414|NCT00287274|DEVICE|computerized physician order entry|
214608415|NCT06047847|DIETARY_SUPPLEMENT|TOTUM-448|The study is divided in two phases. The first clinical phase of the project is aimed at determining TOTUM-448's metabolites absorption peak (two galenic forms will be tested: capsules and powder). Then, human circulating metabolites from polyphenols will be quantified and characterized by ultra-high performance liquid chromatography hyphenated with tandem mass spectrometry (UPLC-MS/MS). Once the absorption profile is characterized, volunteers will visit once again the clinical center for the collection of serum fractions either naïve (before ingestion) or enriched (containing circulating metabolites following TOTUM-448 ingestion). The enriched fraction (circulating bioactive collection) will be collected at t-max as characterized in the first phase (absorption profil's peak). Finally, biological activity of TOTUM-448 on human hepatocytes will be studied by comparing naïve serum and serum containing circulating metabolites according to an in vitro protocol.
214608416|NCT01599910|OTHER|Scribes|Scribe
214608417|NCT02603367|OTHER|Communication Intervention|Undergo communication coaching
214608418|NCT02603367|OTHER|Educational Intervention|Receive COMFORT communication curriculum
214608419|NCT02603367|OTHER|Psychosocial Support for Caregiver|Undergo communication coaching
214608420|NCT02603367|OTHER|Questionnaire Administration|Complete questionnaires
214608421|NCT05119621|DEVICE|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
214608422|NCT00058552|DRUG|Pertuzumab (rhuMAb 2C4)|
214608423|NCT04587011|DRUG|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
214713625|NCT07091903|OTHER|Conventional physiotherapy and post-isometric relaxation technique|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included conventional physiotherapy and post-isometric relaxation technique. Conventional treatment included an exercise program consisting of Wand, Codman, and finger ladder exercise, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities. Each of the exercises was applied as 10 repetitions and 1 sets. Post-isometric relaxation technique was applied with 5 seconds of isometric contraction in the direction of flexion, abduction, internal and external rotation, 5 repetitions, 2 sets.
214713626|NCT07090343|DRUG|Wegovy ®|Semaglutide 2.4 mg subcutaneous once-weekly starting 3 months prior TAVR and continued 24 months post-TAVR. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose as an add-on to standard-of-care. The treatment will continue until the 'end of treatment' visit followed by a 8 weeks follow-up period.
214713627|NCT07090343|DRUG|Placebo|Matching placebo subcutaneous once-weekly.
214608424|NCT04587011|DRUG|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
214608425|NCT04587011|DRUG|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
214608426|NCT04587011|DRUG|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
214608427|NCT04290520|OTHER|bioassay|Serum progesterone level (ng/ml)
214608428|NCT04188795|PROCEDURE|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
214608429|NCT03260634|DRUG|Voriconazole|
214608430|NCT00105716|BEHAVIORAL|Telephone behavioral education|
214608431|NCT00105716|BEHAVIORAL|Computer behavioral education|
214608432|NCT04532216|PROCEDURE|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
214608433|NCT04532216|PROCEDURE|Traditional surgery|Tendon transfer
214713628|NCT06910202|BEHAVIORAL|Manipulation of nicotine/tobacco product price and availability|"This study does involve experimental manipulation of nicotine/tobacco product price and availability to understand consumers' behavior. Participants will be provided with a commercially available e-cigarette to use during the study, if they wish.~Every participant will purchase tobacco products in an online store under four different scenarios: a) cigarette flavor restricted and e-cigarette flavor restricted, b) cigarette flavor unrestricted and e-cigarette flavor restricted, c) cigarette flavor restricted and e-cigarette flavor unrestricted, d) cigarette flavor unrestricted and e-cigarette flavor unrestricted."
214713629|NCT07089953|OTHER|Questionnaire|Complete 3 questionnaires about your emotions and your trust in doctors.
214713630|NCT07089953|OTHER|Video|Four (4) videos, each 4 minutes long, have been made for use in this study.
214713631|NCT07090551|DEVICE|occlusal splint therapy|Patients with myofascial pain will receive occlusal splint therapy, which is a clinically accepted treatment method.
214608434|NCT02319668|DRUG|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
214608435|NCT02319668|DRUG|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
214713632|NCT07092345|BEHAVIORAL|adaptive intervention|We will utilize an adaptive interventions via Sequential Multiple Assignment Randomized Trial (SMART) design provide a tailored, stepped-care approach for the type, intensity, and dose of treatment, thus, providing the most intensive care to only those who need it, particularly treatment non-response. First, youth and caregivers (dyads) will be randomized to receive 1st-stage interventions in the ED, either the digital psychosocial-only (PS) condition or the psychosocial with digital health communication (PS+text) condition. If identified as non-response at 2-weeks, then dyads will be re-randomized to 2nd-stage intervention(s). Specifically, the PS condition non-responders will be re-randomized to the PS+text condition or the PS+text+FN condition. The 1st-stage PS+text condition non-responders will receive the PS+text+FN condition only.
214713633|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF neutral pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
214713634|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
214713635|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µM|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
214713636|NCT07092215|DRUG|LPS 5 ng / SIF neutral pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
214713637|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
214713638|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH + BCTC 1 µM|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
214713639|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
214608436|NCT06240000|PROCEDURE|Radiofrequency ablation|Firstly, the posterior superior iliac spine was showed in the transverse plane, and it was gradually moved proximally until gluteus maximus muscle disappears and gluteus medius arises. Medial branch of the SCN is seen between iliac crest and thoracolumbar fascia as an ovoid structure. Radiofrequency device was utilized with 22-gauge 10-cm, 5 mm RF cannulas for all procedures. Cannula was placed thorough the SCN area and Sensory fiber stimulation was started between 0.3 and 0.5 V. The patient was asked for feedback on symptoms such as numbness, paresthesia or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was given up to 1.5 V and it was checked whether there was any contraction or not. If there is no contraction detected, the SCN was ablated at 42° degrees centigrade for 240 seconds.
214608437|NCT05641870|PROCEDURE|Sample collection|Tumor samples will be collected as standard diagnostic procedure at diagnosis. Plasma samples from whole blood extractions will also be collected at diagnosis, after chemoradiotherapy, and every 3 months from there until completing one year of follow-up.
214608438|NCT05641870|DIAGNOSTIC_TEST|Characterization of the tumoral tissue genomic alterations|Genomic alterations of tumor tissue samples will be analyzed locally by next-generation sequencing when material is adequate, as standard diagnostic procedure.
214608439|NCT05641870|DRUG|Chemoradiation treatment regimen and maintenance (if amenable)|Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
214608440|NCT05641870|DIAGNOSTIC_TEST|Genomic and methylation analysis in liquid biopsy|"Blood samples for ctDNA genomic and methylation analysis (4 mL of plasma for each sample) will be sent to the Guardant Health Laboratories in the US and analyzed after Contractual Agreement signature, using the Guardant Reveal test.~This liquid biopsy test uses ctDNA to detect presence of MRD and monitor for recurrence after definitive surgical/systemic therapy for patients with cancer. It has been validated in early-stage colorectal cancer and integrates assessment of somatic alterations with an epigenomic cancer signature to identify the presence of methylation signatures associated with cancer versus normal DNA."
214608441|NCT00277420|BEHAVIORAL|Comprehensive weight management|
214608442|NCT03427567|PROCEDURE|Sublobar dissection|Sublobar dissection plus lymphadenectomy
214608443|NCT00006254|BIOLOGICAL|salmonella VNP20009|
214608444|NCT00461344|DRUG|Docetaxel|
214608445|NCT00461344|DRUG|Doxorubicin|
214608446|NCT02783443|OTHER|General anesthesia|General anesthesia
214608447|NCT02783443|OTHER|Regional anesthesia|Regional anesthesia
214608448|NCT02640833|DRUG|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
214608449|NCT02640833|DRUG|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
214608450|NCT04823572|PROCEDURE|A-PRF/OFD|Comparing healing effect of an autologous and open flap debridement
214608451|NCT03017638|OTHER|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
214608452|NCT02316340|DRUG|Vorinostat|400mg by mouth daily
214608453|NCT02316340|DRUG|Hydroxychloroquine|600mg by mouth daily
214608454|NCT02316340|DRUG|Regorafenib|160 mg by mouth daily
214608455|NCT01794572|DRUG|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
214608456|NCT01794572|BIOLOGICAL|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
214608457|NCT00859599|DEVICE|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
214608458|NCT00859599|DEVICE|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
214608459|NCT06170138|OTHER|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
214608460|NCT00319280|PROCEDURE|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
214608461|NCT00703001|BEHAVIORAL|Educational Intervention|students in this arm will receive several oral health educational modules in class
214608462|NCT00703001|BEHAVIORAL|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
214608463|NCT01986920|DRUG|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
214608464|NCT01986920|DRUG|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
214608465|NCT01986920|DRUG|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
214608466|NCT01986920|DRUG|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
214608467|NCT02238704|DIETARY_SUPPLEMENT|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
214608468|NCT02238704|DIETARY_SUPPLEMENT|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
214608469|NCT06847269|DRUG|Fludarabine|Given IV
214608470|NCT06847269|DRUG|Cyclophosphamide|Given IV
214608471|NCT06847269|DRUG|Mesna|Given IV
214608472|NCT06847269|BIOLOGICAL|CD19-CAR T cell Infusion|Patients will receive the CD19-CAR T cells by vein, through either an IV or a central line.
214608473|NCT05511428|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
214608474|NCT05511428|OTHER|Questionnaire Administration|Ancillary studies
214608475|NCT05511428|OTHER|Quality-of-Life Assessment|Ancillary studies
214608476|NCT05511428|OTHER|Interview|Ancillary studies
214608477|NCT02091661|PROCEDURE|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
214608478|NCT02091661|RADIATION|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
214713640|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to 5.7)
214608479|NCT04611165|DRUG|Nivolumab|"* Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~* EBRT begins 2-7 days after the first dose of nivolumab.~* The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
214608480|NCT05218785|DRUG|Botox|75 U in medial gastrocbemius head. x 3
214608481|NCT06169241|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
214713641|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
214608482|NCT06169241|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
214608483|NCT06218901|DRUG|immunotherapy|
214608484|NCT06218901|DRUG|Targeted Therapy Agent|
214608485|NCT04788264|OTHER|Medical Device Usage and Evaluation|Receive Fitbit
214608486|NCT04788264|OTHER|Consultation|Receive consultation from a physical therapist
214608487|NCT04788264|OTHER|Exercise Intervention|Attend exercise training sessions
214608488|NCT04788264|BEHAVIORAL|Behavioral Intervention|Attend sessions with a behavioral therapist
214608489|NCT04788264|OTHER|Questionnaire Administration|Ancillary studies
214608490|NCT04788264|OTHER|Quality of Life Assessment|Ancillary studies
214608491|NCT05541263|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
214608492|NCT06962397|DEVICE|Active Touch-Based Sensory Training|This intervention combines functional electrical stimulation with active tactile exploration of virtual textures. Using a touch-sensitive screen and a programmable functional electrical stimulator (MotionStim 8), participants explore two invisible virtual textures by moving their index finger across the screen. Each time the finger crosses a virtual texture line, an electrical pulse is delivered to the finger, simulating tactile sensation. Participants are asked to compare the density of two virtual textures and select the denser one. The stimulation is synchronized with finger movement to ensure real-time sensory feedback. The training consists of 50 trials divided into 5 blocks, and is designed to enhance tactile discrimination and proprioception through sensorimotor integration. The paradigm is interactive, personalized based on individual sensory thresholds, and aims to promote neural plasticity in stroke survivors.
214713642|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4 to pH 5.7)
214713643|NCT04482244|DRUG|Cannabidiol|Liquid taken orally
214713644|NCT04482244|OTHER|Placebo|Liquid taken orally
214713645|NCT06928155|DEVICE|Immersive Virtual Reality with Head Mounted Display|"The intervention will be carried out with an immersive virtual reality device, specifically, with a head mounted display. Specifically, it is the MetaQuest 3 model."
214713646|NCT06928155|OTHER|Aerobic exercise and strength training|The combination of aerobic and strength training is part of the conventional physiotherapy treatment carried out at the center.
214608493|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
214608494|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
214713647|NCT06928922|BIOLOGICAL|BMD006 monotreatment|After receiving the first dose of BMD006 treatment on Day 1, the patient will complete a single-treatment DLT observation (14 days). If the treatment is deemed safe and tolerable by the investigator, the patient will proceed to multiple-treatment DLT observation (14 days), with BMD006 treatment administered on Day 15 and Day 22. On Day 28, if the treatment is again assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level following a QW (once weekly) regimen for 6 doses. After that, starting from Week 11, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
214608495|NCT03575078|DRUG|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
214608496|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
214608497|NCT05720455|DRUG|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
214608498|NCT04872452|PROCEDURE|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
214608499|NCT03508570|BIOLOGICAL|Ipilimumab|Given i.p.
214608500|NCT03508570|OTHER|Laboratory Biomarker Analysis|Correlative studies
214608501|NCT03508570|BIOLOGICAL|Nivolumab|Given i.p.
214608502|NCT03508570|OTHER|Pharmacokinetic Study|Correlative studies
214608503|NCT01338415|DRUG|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
214608504|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
214608505|NCT05109208|DIAGNOSTIC_TEST|Ulrasound Vibroelastography (UVE)|Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).
214608506|NCT02887690|DEVICE|Modular Prosthetic Limb|
214608507|NCT05755074|PROCEDURE|Ablation through left arm|Ablation through left arm
214608508|NCT05755074|PROCEDURE|Ablation through femoral vein|Ablation through femoral vein
214608509|NCT04235023|OTHER|myeloid PTP1B expression analysis|peripheral blood macrophage PTP1B expression
214608510|NCT02150499|DRUG|levalbuterol tartrate HFA inhalation aerosol|
214608511|NCT02150499|DRUG|placebo|
214608512|NCT04092972|OTHER|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
214608513|NCT04092972|OTHER|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
214608514|NCT03990857|OTHER|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
214608515|NCT05940610|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
214608516|NCT00467389|DRUG|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
214608517|NCT00467389|OTHER|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
214608518|NCT02087072|OTHER|Collaborative visit with provider and pharmacist|
214608519|NCT00139646|DRUG|Parecoxib|
214713648|NCT06928922|BIOLOGICAL|BMD006 in combination with PD-1 antibody|Once the dose escalation of BMD006 monotreatment is completed and the MTD (Maximum Tolerated Dose) is determined (i.e., the RP2D for this study), a dose escalation exploration of BMD006 in combination with PD-1 antibody will be conducted. On Day 1, patients will receive BMD006 in combination with PD-1 antibody treatment, followed by BMD006 treatment on Days 8 and 15. The DLT observation period will be 21 days. On Day 21, if the treatment is assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level according to the QW (once weekly) regimen for 6 doses. After Week 10, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
214608520|NCT00139646|DRUG|Diclofenac|
214608521|NCT03480412|PROCEDURE|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
214608522|NCT03480412|PROCEDURE|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
214608523|NCT00866749|DRUG|Daunorubicin|Starting Dose 25 mg/m\^2 by vein weekly
214608524|NCT00866749|DRUG|Vincristine|Starting Dose 2 mg by vein weekly
214608525|NCT00866749|DRUG|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
214608526|NCT00866749|DRUG|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
214608527|NCT00866749|DRUG|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
214608528|NCT00866749|DRUG|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
214713649|NCT01091909|PROCEDURE|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
214713650|NCT04690257|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
214713651|NCT06393894|DIAGNOSTIC_TEST|Near infrared spectroscopy|Near infrared spectroscopy (NIRS) is an intravascular imaging technique. Patients after coronary angiography with or without angioplasty will undergo NIRS if deemed suitable by the interventionalist. NIRS has a high sensitivity and specificity for lipid core plaque detection.
214713652|NCT06393894|GENETIC|Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.|Patients without explicit atherosclerosis risk factors and known genetic disorders will undergo genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 genes in order to evaluate the presence of gene variations as a cause for early atherosclerosis. MiRNA-126, -145 and -155 expression in patients serum samples will be evaluated and correlated with plaque lipid core in near infrared spectroscopy (NIRS) imaging.
214713653|NCT01962285|DRUG|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
214713654|NCT06921473|DRUG|Norepinephrine|Intravenous bolus of norepinephrine (5-10 µg) to treat spinal anesthesia-induced hypotension during cesarean section.
214713655|NCT06921473|DRUG|Ephedrine|Intravenous bolus of 5-10 mg ephedrine administered as needed to treat maternal hypotension following spinal anesthesia during elective cesarean section. The drug is prepared in identical, unlabeled syringes to ensure blinding.
214713656|NCT03516734|DIETARY_SUPPLEMENT|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
214713657|NCT03516734|OTHER|Non Iron-fortified lentils|Non-fortified lentils will be provided
214713658|NCT03516734|OTHER|Usual Intake|No lentils will be provided.
214713659|NCT01379924|BEHAVIORAL|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
214713660|NCT01379924|OTHER|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
214608529|NCT00866749|DRUG|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
214608530|NCT00866749|DRUG|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
214608531|NCT00866749|DRUG|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
214608532|NCT00866749|DRUG|Thioguanine|60 mg/m2 by mouth daily for two weeks
214608533|NCT04880447|BIOLOGICAL|BNT162b2|COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
214608534|NCT03877107|DIAGNOSTIC_TEST|Urinary symptoms profile questionnaire|Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
214608535|NCT03877107|DIAGNOSTIC_TEST|Micturition calendar|Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
214608536|NCT02126449|OTHER|Fasting mimicking diet|
214713661|NCT03258463|OTHER|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
214608537|NCT03096925|BEHAVIORAL|Guided self-help|Web-based guided self-help intervention
214608538|NCT03184324|DRUG|DWP14012|tablet
214608539|NCT03184324|DRUG|Esomeprazole|tablet
214608540|NCT03184324|DRUG|DWP14012 placebo|tablet
214608541|NCT03184324|DRUG|Esomeprazole placebo|tablet
214608542|NCT03255057|DEVICE|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
214608543|NCT03255057|DEVICE|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
214608544|NCT00173745|DRUG|botulinum toxin A injection|
214608545|NCT02294084|DRUG|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
214608546|NCT02294084|DRUG|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
214608547|NCT00432536|OTHER|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
214608548|NCT02952040|DRUG|ASP1517|Oral dose
214608549|NCT02952040|DRUG|Lanthanum carbonate hydrate|Oral dose
214608550|NCT06237543|OTHER|hypotension|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
214608551|NCT05125068|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
214608552|NCT01970488|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
214608553|NCT01970488|BIOLOGICAL|ABP 501|Administered by subcutaneous injection
214608554|NCT01313715|BIOLOGICAL|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
214608555|NCT01313715|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
214608556|NCT01313715|BIOLOGICAL|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
214608557|NCT01313715|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
214608558|NCT01805960|BIOLOGICAL|Canakinumab|
214713662|NCT02005224|OTHER|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
214713663|NCT06924814|BEHAVIORAL|Standard of Care|Participant is allowed to use what they will use as a distraction tool while they are receiving treatment.
214713664|NCT06924814|BEHAVIORAL|Immersive technology|Participants will be randomly assigned to one of the following four groups; VR headsets, a bluetooth haptic device (Buddy Guard), a screen and projector (BERT), and a tablets with a game. Participant's anxiety will be assessed and pre- and post-intervention assessments will be completed.
214713665|NCT06829277|COMBINATION_PRODUCT|Sodium fluoride varnish|Sodium fluoride varnish
214608559|NCT01805960|BIOLOGICAL|Placebo|
214713666|NCT06829277|OTHER|Curodont De Senz|Curodont De Senz
214713667|NCT06829277|COMBINATION_PRODUCT|Curodont De Senz plus laser irradiation|Curodont De Senz plus laser irradiation
214713668|NCT06829277|DEVICE|Laser irradiation|Laser irradiation
214713669|NCT02158702|DRUG|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
214608560|NCT05146804|OTHER|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
214608561|NCT05146804|OTHER|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
214608562|NCT00141804|DRUG|Sirolimus|
214608563|NCT03457350|PROCEDURE|cervical negotiation|trial to bypass severe cervical stenosis
214608564|NCT03858452|PROCEDURE|Muscles exercises program|
214608565|NCT04635566|DRUG|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
214608566|NCT04635566|DRUG|Placebo|Placebo one time/day at the evening.
214608567|NCT00401739|DRUG|CSL360|Weekly IV Infusion. Dose escalation study.
214608568|NCT04060563|DEVICE|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
214608569|NCT01507467|RADIATION|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
214608570|NCT01507467|RADIATION|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
214608571|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
214608572|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
214608573|NCT02257996|BEHAVIORAL|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
214608574|NCT02137122|DEVICE|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
214608575|NCT02137122|DEVICE|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
214608576|NCT03049787|OTHER|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
214608577|NCT03049787|OTHER|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
214608578|NCT03514030|DIAGNOSTIC_TEST|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
214608579|NCT05872490|OTHER|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
214608580|NCT05872490|OTHER|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
214608581|NCT01131416|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
214608582|NCT05506826|OTHER|fine motor activities|patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy
214608583|NCT05506826|OTHER|conventional therapy and mirror therapy|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
214608584|NCT02112136|OTHER|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
214608585|NCT01033552|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
214608586|NCT01033552|DRUG|Fludarabine|40 mg/m\^2/day intravenously on Days -6, -5, -4, -3 and -2.
214608587|NCT01033552|DRUG|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
214608588|NCT01033552|DRUG|Myeloablative Busulfan|Targeting AUC 1000 umol/min
214608589|NCT01033552|PROCEDURE|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
214608590|NCT01033552|RADIATION|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
214608591|NCT01033552|PROCEDURE|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
214608592|NCT00789750|DRUG|Colesevelam|Colesevelam 625 mg tablets
214608593|NCT00789750|DRUG|Placebo|Placebo tablets appearing to be colesevelam
214608594|NCT00789750|DRUG|Pioglitazone|30 mg or 45 mg pioglitazone therapy
214608595|NCT05349526|OTHER|None, pure observational study|None, pure observational study
214608596|NCT04811404|DRUG|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
214608597|NCT02613884|DRUG|Treatment|
214608598|NCT00005641|BIOLOGICAL|anti-thymocyte globulin|
214608599|NCT00005641|DRUG|busulfan|
214608600|NCT00005641|DRUG|cyclophosphamide|
214608601|NCT00005641|DRUG|cyclosporine|
214608602|NCT00005641|DRUG|leucovorin calcium|
214608603|NCT00005641|DRUG|methotrexate|
214608604|NCT00005641|DRUG|methylprednisolone|
214608605|NCT00005641|PROCEDURE|allogeneic bone marrow transplantation|
214608606|NCT00005641|PROCEDURE|in vitro-treated bone marrow transplantation|
214608607|NCT00005641|RADIATION|radiation therapy|
214608608|NCT00619970|PROCEDURE|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
214608609|NCT00619970|DRUG|xifaxan|xifaxan 550mg TID x10days
214608610|NCT00619970|DRUG|placebo|placebo TID x 10days
214608611|NCT00619970|PROCEDURE|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
214608612|NCT04409899|DIAGNOSTIC_TEST|Blood tests|RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
214608613|NCT01436136|OTHER|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
214608614|NCT01436136|OTHER|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
214608615|NCT00433914|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
214608616|NCT00433914|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
214608617|NCT02942914|DRUG|LY3209590|Administered SC
214608618|NCT02942914|DRUG|Placebo|Administered SC
214608619|NCT02942914|DRUG|Insulin Glargine|Administered SC
214608620|NCT02194036|BEHAVIORAL|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
214608621|NCT02194036|BEHAVIORAL|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
214608622|NCT04973579|PROCEDURE|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
214713670|NCT03801356|DRUG|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
214713671|NCT01606293|BEHAVIORAL|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
214608623|NCT00004047|DRUG|exatecan mesylate|
214608624|NCT06317675|OTHER|Osteopathic manipulative treatment (OMT)|Manual therapy on different area of the body.
214608625|NCT05836142|PROCEDURE|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
214608626|NCT02486653|DRUG|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
214608627|NCT02486653|DRUG|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
214608628|NCT05131984|DRUG|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
214608629|NCT02131675|DIETARY_SUPPLEMENT|Boost shake|Blood draw after mixed-meal consumption
214608630|NCT02324959|DEVICE|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
214608631|NCT02324959|DEVICE|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
214608632|NCT04565886|DEVICE|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
214608633|NCT04565886|DEVICE|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
214713672|NCT05740579|PROCEDURE|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
214713673|NCT04021706|DRUG|Anamorelin Hydrochloride|Ghrelin receptor agonist
214713674|NCT04021706|DRUG|Placebo|placebo is a inert substance
214713675|NCT02504697|OTHER|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
214713676|NCT03040817|PROCEDURE|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
214713677|NCT03040817|DRUG|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
214713678|NCT02354092|PROCEDURE|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
214608634|NCT06052163|DRUG|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
214608635|NCT06052163|DRUG|Placebo|A placebo has no active properties and is taken orally.
214608636|NCT05836636|OTHER|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
214608637|NCT00441415|DRUG|Adapalene BPO|
214608638|NCT00143663|DRUG|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
214608639|NCT00143663|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
214608640|NCT06002308|OTHER|Age|The retrospective study included 540 patients with primary ACL tears (71 pediatric patients and 469 adults) whose MRI examination and pivot-shift test were conducted within 14 days after injury. To detect concomitant KF and ALL injury in knees with ACL injury using MRI in both adult and pediatric patients and compare the effect of KF injury and multiple risk factors on anterolateral rotatory laxity as measured by the pivot-shift test in a clinical setting.
214608641|NCT04272658|DIAGNOSTIC_TEST|value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI"
214608642|NCT01578408|PROCEDURE|Total Hip Arthroplasty|
214608643|NCT01578408|DEVICE|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
214608644|NCT01578408|DEVICE|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
214608645|NCT04350385|OTHER|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.
214608646|NCT04350385|OTHER|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week
214608647|NCT02518997|OTHER|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
214608648|NCT05183113|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
214608649|NCT01050686|PROCEDURE|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
214608650|NCT01050686|PROCEDURE|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
214608651|NCT05351047|DRUG|AZD2373 subcutaneous injection|Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
214608652|NCT05351047|DRUG|Placebo|Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
214713679|NCT02354092|PROCEDURE|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
214713680|NCT02354092|PROCEDURE|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
214713681|NCT02354092|PROCEDURE|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
214713682|NCT02354092|BEHAVIORAL|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
214713683|NCT02354092|DRUG|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
214608653|NCT02945150|DRUG|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
214608654|NCT01134835|OTHER|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
214608655|NCT01134835|DRUG|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
214608656|NCT01568398|DRUG|TAK-438|
214608657|NCT04900922|DEVICE|isokinetic dynamometer|We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
214608658|NCT03248830|DEVICE|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
214608659|NCT00427089|DRUG|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
214608660|NCT00427089|DRUG|Sodium Phosphate solution (NaP)|45 ml solution; BID
214608661|NCT04450511|DEVICE|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
214608662|NCT04450511|OTHER|Bladder Training (BT)|Bladder Training (BT)
214608663|NCT03530917|DRUG|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
214713684|NCT02999815|PROCEDURE|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
214713685|NCT02999815|PROCEDURE|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
214608664|NCT03530917|DRUG|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
214608665|NCT01581944|DRUG|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
214608666|NCT01581944|DRUG|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
214608667|NCT01106820|OTHER|Supervised progressive resistance training|Supervised progressive resistance training
214608668|NCT01106820|OTHER|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
214608669|NCT03920553|BIOLOGICAL|Hyaluronic acid|Topical application of hyaluronic acid following Laser assisted frenectomy
214608670|NCT03407404|COMBINATION_PRODUCT|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
214608671|NCT03407404|COMBINATION_PRODUCT|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
214608672|NCT00189189|BEHAVIORAL|parent management training|
214608673|NCT04039854|DRUG|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
214608674|NCT04039854|DRUG|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
214713686|NCT04008199|OTHER|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
214713687|NCT01923571|OTHER|intraoperative BGC measure|
214713688|NCT05031572|OTHER|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
214713689|NCT02870257|OTHER|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
214713690|NCT02870257|OTHER|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
214713691|NCT05728762|DEVICE|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
214713692|NCT01756638|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
214713693|NCT01756638|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
214608675|NCT03312088|DEVICE|Freedom Knee PCK Components|Total Knee Revision
214608676|NCT00409929|DRUG|AEB071|
214608677|NCT00067457|DRUG|alosetron|
214608678|NCT01480921|BEHAVIORAL|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~* 5-10 min warm-up~* 30 min aerobic interval training (walking or stationary bicycle)~* 10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
214608679|NCT01480921|BEHAVIORAL|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~* 5-10 min of warm-up~* 30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~* 10 min of cool down~Exercise will be tracked by the participant in exercise log books."
214608680|NCT02977754|OTHER|This is an observational study|Imaging
214713694|NCT01300585|OTHER|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
214608681|NCT00048620|DRUG|N-acetylgalactosamine 4-sulfatase|
214608682|NCT03558256|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
214608683|NCT03558256|DRUG|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
214608684|NCT03100669|PROCEDURE|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
214608685|NCT01584076|DRUG|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
214608686|NCT01584076|OTHER|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
214608687|NCT05542485|DIAGNOSTIC_TEST|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
214608688|NCT02819076|OTHER|pain scale|
214608689|NCT01968850|DRUG|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
214608690|NCT02232620|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
214608691|NCT04822610|PROCEDURE|interscalene block|peripheral nerve block
214608692|NCT04822610|PROCEDURE|suprascapular block + axillary block|peripheral nerve block
214713695|NCT00355134|DRUG|Fingolimod|Fingolimod capsules for oral administration
214608693|NCT03753009|PROCEDURE|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
214608694|NCT05594758|DRUG|Olverembatinib|Oral Olverembatinib
214608695|NCT02936934|DRUG|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
214608696|NCT02936934|DRUG|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
214608697|NCT02468596|OTHER|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
214713696|NCT00355134|DRUG|Placebo|Matching placebo capsules for oral administration.
214608698|NCT02468596|OTHER|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
214608699|NCT00409097|DRUG|Rosiglitazone|
214608700|NCT04645043|OTHER|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
214608701|NCT01983397|OTHER|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
214608702|NCT01983397|OTHER|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
214608703|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
214713697|NCT05912348|BEHAVIORAL|Low Physical Activity and Added Carbohydrate Group|Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
214608704|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
214608705|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
214608706|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
214713698|NCT05912348|BEHAVIORAL|Low physical Activity Control|Young men and women will transition into a low physically active lifestyle for 10 days.
214713699|NCT05912348|BEHAVIORAL|High Physical Activity and Added Carbohydrate Group|Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
214608707|NCT04199234|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
214608708|NCT04199234|DIETARY_SUPPLEMENT|Comparator product consumption (Iron sulphate)|Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
214608709|NCT01318252|DRUG|AL-54478 0.005%|
214608710|NCT01318252|DRUG|Latanoprost 0.005%|
214608711|NCT01318252|DRUG|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
214608712|NCT01848353|BEHAVIORAL|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
214608713|NCT02414568|DRUG|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
214608714|NCT02414568|DRUG|Prednisone|Prednisone 40 mg/m² PO
214713700|NCT06278155|OTHER|Social relation training with social robot|"The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response"
214713701|NCT06278155|OTHER|Traditional social relations training|Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
214713702|NCT01257672|DRUG|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
214713703|NCT01257672|DRUG|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
214608715|NCT02414568|DRUG|Vinblastine|Vinblastine 6 mg/m² IV
214608716|NCT02414568|DRUG|Doxorubicin|Doxorubicin 40 mg/m² IV
214608717|NCT03933397|OTHER|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
214608718|NCT03933397|OTHER|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
214608719|NCT03933397|DRUG|Morphine|4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
214608720|NCT03933397|DRUG|Hydromorphone|1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
214608721|NCT00953719|DEVICE|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
214608722|NCT00953719|DEVICE|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
214608723|NCT03856307|DIAGNOSTIC_TEST|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
214713704|NCT01257672|DRUG|placebo|placebo
214713705|NCT04928313|DRUG|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
214713706|NCT00533299|DRUG|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
214713707|NCT00533299|DRUG|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
214713708|NCT01412151|DRUG|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
214713709|NCT04898868|PROCEDURE|cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
214608724|NCT00935272|DEVICE|Restylane®|Restylane® injections in the lips
214608725|NCT00935272|DEVICE|Non-Treatment|Non- Treatment
214608726|NCT00611338|BEHAVIORAL|HIV Skills-based Prevention|
214608727|NCT04085796|OTHER|ICCI|Intentional Compassionate Communication Intervention
214608728|NCT02742467|DRUG|Perindopril plus Amlodipine|Group 1
214608729|NCT02742467|DRUG|Perindopril plus Hydrochlorothiazide|Group 2
214608730|NCT02742467|DRUG|Amlodipine plus Hydrochlorothiazide|Group 3
214608731|NCT01478360|DRUG|AIN457 (secukinumab)|Secukinumab intravenous injection
214608732|NCT01478360|DRUG|Placebo|Placebo intravenous injection
214608733|NCT06885294|BEHAVIORAL|Physiotherapy|Stroke patients will be randomly assigned to join one of the three groups. The first group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
214608734|NCT06885294|BEHAVIORAL|Physiotherapy and Hypnosis|Stroke patients will be randomly assigned to join one of the three groups. The second group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. Patients will continue their standard physiotherapy care during these 4 weeks. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
214608735|NCT06885294|BEHAVIORAL|Control group Physiotherapy and Hypnosis|The control group will be assessed initially and then after 4 weeks. After the second assessment, they will receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. All evaluation sessions will last approximately 1 hour.
214608736|NCT06894784|DRUG|Intervention Period 1: Semaglutide + Empagliflozin|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
214608737|NCT06894784|DRUG|Intervention Period 2: Semaglutide + Empagliflozin Placebo|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet, matched in appearance to empagliflozin (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
214608738|NCT06894784|DRUG|Intervention Period 3: Semaglutide Placebo + Empagliflozin|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
214608739|NCT06894784|DRUG|Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet (2.5 mg), matched in appearance to empagliflozin, administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
214713710|NCT04898868|PROCEDURE|Umbilical cord miking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
214713711|NCT04540783|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
214713712|NCT00049972|DRUG|paroxetine CR|
214608740|NCT06749444|OTHER|CBT-I|Cognitive therapy tailored for insomnia symptoms.
214608741|NCT06749444|OTHER|CBT|Cognitive behavioral therapy for general psychopathology
214608742|NCT06733935|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
214608743|NCT06733935|DRUG|Fludarabine|Lymphodepletion
214608744|NCT06733935|DRUG|Cyclophosphamide|Lymphodepletion
214608745|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate consumption (Ilex paraguayensis) A|Yerba mate of the begining of the harvest time
214608746|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate comsuption (ilex paraguayencis) B|Yerba mate of the final time of the harvest
214608747|NCT07061470|DIETARY_SUPPLEMENT|Ferrous Sulfate|Dosing of the iron supplement will be based on weight.
214608748|NCT07061470|OTHER|Placebo|Placebo pills will be provided to participants in the placebo arm
214713713|NCT00520650|DRUG|Aripiprazole|
214713714|NCT02868164|DRUG|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
214713715|NCT02868164|DRUG|Standard Treatment|Standard Treatment
214608749|NCT06023537|BEHAVIORAL|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
214608750|NCT04223791|DRUG|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
214608751|NCT04223791|DRUG|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
214608752|NCT04223791|DRUG|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
214713716|NCT02868164|OTHER|Weight Reduction|routine exercise for weight reduction
214713717|NCT02811172|OTHER|BEhavior of biomarkers during pregnanCy and lactatiOn|
214713718|NCT00713284|DRUG|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
214713719|NCT03127852|DEVICE|Medly|
214713720|NCT01451866|OTHER|resistance training|hypertrophic resistance training
214713721|NCT01451866|OTHER|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
214713722|NCT01318668|BIOLOGICAL|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
214608753|NCT04223791|DRUG|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
214608754|NCT06752031|BEHAVIORAL|OSCAR-S Care Transition Model|Patients and families in the intervention arm will receive touch points from the surgery nurse coach to support their care transition from hospital to home after surgery.
214608755|NCT03273296|DRUG|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
214713723|NCT00741104|DRUG|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
214713724|NCT02813590|OTHER|Ascitic fluid puncture|
214713725|NCT02813590|OTHER|Skin swaps from puncture side|
214713726|NCT02813590|OTHER|Stool samples|
214713727|NCT01560104|DRUG|Veliparib|
214713728|NCT01560104|DRUG|Carboplatin|
214713729|NCT01560104|DRUG|paclitaxel|
214608756|NCT03273296|DRUG|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
214608757|NCT03273296|DRUG|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
214713730|NCT01560104|DRUG|placebo|
214713731|NCT00859573|DRUG|Modafinil|400 mg/day
214713732|NCT00859573|DRUG|Placebo|inactive substance
214713733|NCT00041704|DRUG|Anidulafungin, VER002|
214713734|NCT00250068|DRUG|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
214713735|NCT02123394|OTHER|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
214713736|NCT02123394|OTHER|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
214713737|NCT03383055|BIOLOGICAL|CMV-MVA Triplex Vaccine|"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"
214608758|NCT06773364|DRUG|Levetiracetam|Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH
214608759|NCT06773364|OTHER|Guide-recommended management|To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.
214608760|NCT06773364|OTHER|The lying flat (0°) head position|Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.
214608761|NCT06773364|OTHER|The sitting-up (≥30°) head position|Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.
214608762|NCT07066345|DEVICE|My Pelvic Plan|My Pelvic Plan is comprised of a self-guided program that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring techniques that can help to manage chronic pelvic pain symptoms.
214608763|NCT07066345|BEHAVIORAL|Bend|Bend is a highly rated physical activity application that helps guide users through gentle stretching and yoga poses.
214608764|NCT06895135|OTHER|Amoxicillin|Participants in this group will receive oral amoxicillin at a dosage of 30mg/kg/day. The treatment will be administered in divided doses for the duration of the study, with the aim of resolving symptoms of acute otitis media in children.
214608765|NCT06895135|OTHER|Clavulanic Acid|Participants in this group will receive a combination of oral amoxicillin and clavulanic acid at a dosage of 30mg/kg/day. The medication will be given in divided doses, and participants will be monitored for symptom resolution and any potential side effects.
214608766|NCT06897488|RADIATION|Adjuvant Radiotherapy|Participants will receive treatment following Lumpectomy
214608767|NCT05845658|DEVICE|Active VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
214608768|NCT05845658|DEVICE|Sham VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
214608769|NCT02529007|DEVICE|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
214608770|NCT02529007|OTHER|Standard colonoscopy|Standard colonoscopy without end-cuff
214608771|NCT05610735|DRUG|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
214608772|NCT05610735|DRUG|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
214608773|NCT05610735|DRUG|Ashwagandha|Administered orally on daily basis twice a day
214608774|NCT05610735|DRUG|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
214608775|NCT06900348|DIAGNOSTIC_TEST|PSA-Activated PSA-PAH1|Intravenous blood sample
214608776|NCT03910621|DRUG|Miglustat|capsule, oral use
214608777|NCT06895291|DIAGNOSTIC_TEST|Whole Body-Magnetic Resonance Imaging (WB-MRI)|"This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed:~* at staging~* at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients."
214608778|NCT06895707|OTHER|BioFlx crown|NuSmile® BioFlx crown (Group A) will be placed on primary lower second molar.
214608779|NCT06895707|OTHER|Zirconia crown|Zirconia crown (Group B) will be placed on the contralateral primary lower second molar.
214608780|NCT07128732|OTHER|Peer mentoring training|As part of the intervention, a 15-hour peer mentoring training program was implemented, covering topics such as self-management and self-awareness, stress management, coaching and mentoring, critical thinking, problem-solving and decision-making, effective communication and relationship management.
214713738|NCT06111404|PROCEDURE|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
214713739|NCT06111404|PROCEDURE|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
214713740|NCT06111404|DEVICE|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
214713741|NCT06206772|DIAGNOSTIC_TEST|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
214608781|NCT07131020|BEHAVIORAL|Yifei moxibustion|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.The Yifei moxibustion is applied from the Dazhui to Yaoshu acupoints along the Governor Vessel. Ginger juice is spread over the treatment area, followed by sprinkling moxa powder and covering with mulberry bark paper. A 2.5 cm thick layer of ginger paste and a 3 cm thick layer of moxa wool are then placed on the mulberry bark paper. The moxa wool is ignited and allowed to burn out naturally, being replaced every 30 minutes. After 90 minutes, the ginger paste is removed. The treatment is performed once every 15 days, with 6 sessions constituting one course of treatment, totaling 3 months.
214608782|NCT07131020|DRUG|Conventional Western medicine treatment|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.
214713742|NCT06283134|BIOLOGICAL|BioTTT001 hepatic artery infusion|"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."
214713743|NCT06283134|DRUG|toripalimab|BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
214713744|NCT06283134|DRUG|regorafenib|BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
214713745|NCT00952601|DIETARY_SUPPLEMENT|Modified Atkins diet|Low carbohydrate diet
214713746|NCT02717676|PROCEDURE|Episiotomy|episiotomy will be done after crowning of the fetal head
214608783|NCT07131020|DRUG|TCM syndrome differentiation treatment|The conventional Western medicine treatment followes the same protocol as described above. The diagnosis of TCM pattern-based therapy is made in accordance with the TCM Syndrome Diagnostic Criteria for Chronic Obstructive Pulmonary Disease issued by the Pulmonary Disease Committee of the Internal Medicine Branch, China Association of Chinese Medicine and the treatment is based on the 2019 Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease issued by the China Association of Chinese Medicine.
214608784|NCT06927609|OTHER|kendall exercises|Stretching of Cervical Extensors Strengthening Deep Cervical Flexors Strengthening Shoulder Retraction Stretching Pectoralis Muscle
214608785|NCT06927609|OTHER|Conventional therapy group|Cervical Traction Neck Isometric Exercises (Cervical flexors), Static Stretching (Cervical extensors) General Cervical Extension and Flexion Exercises Shoulder Shrugs
214608786|NCT05540574|DRUG|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
214608787|NCT05540574|DRUG|Placebo|Matching Placebo given orally
214608788|NCT07075016|DRUG|Venetoclax 400|day 1-28 per cycle
214608789|NCT07075016|DRUG|Placebo|day 1-28 per cycle
214608790|NCT07079865|DEVICE|SPRINT PNS modulation system|Participants will receive treatment using the commercially available SPRINT PNS system. Their pain levels will be assessed using qualified scales including NRS and BPI and their quality of life using the PROMIS scale.
214608791|NCT06903325|OTHER|As an observational study, we did not intervene|Interventions
214608792|NCT06895109|OTHER|improvement of cognitive functions and psychological aspects|To analyze the neuropsychological, motor and functional profile of a sample of patients with severe acquired brain injury, who underwent craniotomy and subsequent opercular reapposition surgery
214608793|NCT06901609|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.
214608794|NCT06893237|OTHER|virtual reality goggles and inhalation treatment|Video recording will be started after the consent is obtained. One minute before the procedure, the child's physical parameters (peak heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be fitted with virtual reality goggles and inhalation treatment will be started by watching the aquarium and sea creatures video. Inhalation treatment will last for 10 minutes with the most appropriate air flow rate of 6-8 L/min. Then, the virtual reality goggles will be removed and the child's physiological parameters and anxiety will be measured and recorded again after 1 minute. For participants who want to participate in the study but do not approve the video recording, the evaluations will be made by a nurse independent of the study.
214713747|NCT03192514|OTHER|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
214713748|NCT00952770|PROCEDURE|transradial coronary intervention|percutaneous coronary intervention with transradial approach
214608795|NCT06893237|OTHER|distraction cards and inhalation therapy|After the consent is obtained, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be shown distraction cards and inhalation therapy will be started simultaneously. Playing with the distraction cards will continue for 10 minutes until the end of the inhalation therapy. Then, the use of the toys will be stopped and the child's physiological parameters and anxiety will be recorded after 1 minute. The video recording will be ended. For participants who want to participate in the study but do not consent to being video recorded, the evaluations will be made by a nurse independent of the study.
214608796|NCT06893237|OTHER|inhalation therapy|After the consent is received, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, inhalation therapy will be started with routine service application. The child will receive inhalation therapy for 10 minutes. 1 minute after the procedure, physiological parameters and anxiety will be measured and recorded again. The video recording will be ended. For participants who want to participate in the study but do not approve of being video recorded, evaluations will be made by a nurse independent of the study.
214608797|NCT06902870|OTHER|Scenario-Based Online Simulation Training Program|"Classroom-Based Teaching and Online Simulation-Assisted Instruction~Classroom-Based Instruction:~Participants were provided with a QR code to access the Moodle platform and download the electronic course materials.~The classroom instruction covered the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Care I Decide! Online Simulation-Assisted Teaching:~A detailed explanation of the operational process for the Care I Decide! online simulation-assisted teaching materials was provided.~The session integrated classroom knowledge with the Care I Decide! online simulation. It presented clinical scenarios involving changes in vital signs and symptoms of chest trauma patients, guiding participants through clinical decision-making processes."
214608798|NCT06902870|OTHER|Classroom-Based Teaching|"Classroom-Based Teaching~Delivery of Course Materials:~Participants were provided with a QR code to access the Moodle platform, where they could download the electronic course handouts.~Classroom Instruction Content:~The classroom teaching session included the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Chest Trauma Case Sharing~Case Presentation and Reflection:~Clinical cases involving chest trauma were presented to participants. They were guided to describe the case details, reflect on the management process, and receive constructive feedback.~Discussion and Problem Solving:~During the discussion, questions and uncertainties raised by participants were addressed to enhance understanding and clarify key concepts."
214608799|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose
214608800|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose
214608801|NCT06903247|OTHER|Neurosonographic Findings of Vitamin D Deficiency in Single Healthy Pregnancies Presenting for Routine Antenatal Care Between 20-30 Weeks of Gestation.|Comparison of Neurosonographic Findings in Patients with and without Vitamin D Deficiency.
214608802|NCT06902675|OTHER|Artificial Intelligence|Artificial Intelligence as a decision making tool
214608803|NCT06902675|OTHER|Retrospective Data Extraction of 10,000 Neurology ER Cases|This intervention involves collecting and de-identifying clinical data from 10,000 patients previously evaluated by neurologists in the Emergency Department. The data are then used retrospectively to refine and fine-tune a large language model (LLM). No real-time clinical decisions or recommendations are made for these patients, as the purpose is to improve the model's accuracy and relevance for future use.
214608804|NCT06903013|OTHER|Non vitalPulp therapy|Pulp therapy deals about management of inflamed vital dental pulp With complete pulp removal and obturation with resorbable materi
214608805|NCT06903013|OTHER|Vital pulp therapy|Pulp therapy through partial root removal and using of regenerative capping material
214608806|NCT06902818|DRUG|AD-115A, AD-1151|AD-115A , AD-1151 Oral Tablet
214608807|NCT06901934|OTHER|junctional adhesion molecule3 expression by immunhistochemistry|"* Data record of patient will be reviewed for the following:~* Clinical features:~* Age~* Performance status~* Risk factors(smoking,stones or bilharziasis)~* Comorbidities~* Family history~* Pathological features:~* Histological subtype~* Grade~* Muscle invasion~* Carcinoma in situ~* Immunohistochemistry(IHC):~JAM3 expression by IHC~* TNM staging~* Number of chemotherapy cycles received~* Radical surgery or~* CCRT and type of concurrent~* Post treatment histological response~* . Follow-Up and Survival Analysis:~* During treatment: Monitoring for adverse events of chemotherapy and clinical response.~* After treatment: Imaging and clinical examination every 3 months for 2 years.~* Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS).."
214608808|NCT06927206|OTHER|Experimental Group A: Segmental vibrator only on dorsiflexor|"Segmental vibrator only on dorsiflexor:~After standard physiotherapy session this group received the intervention of segmental vibration. Tibialis anterior muscle targeted for dorsiflexor. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
214713749|NCT05596474|DIETARY_SUPPLEMENT|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
214713750|NCT05596474|RADIATION|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
214713751|NCT05596474|DIETARY_SUPPLEMENT|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
214713752|NCT05596474|RADIATION|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
214713753|NCT04446494|PROCEDURE|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
214713754|NCT02050828|DRUG|AKB-9778|
214713755|NCT02050828|DRUG|ranibizumab|
214713756|NCT02050828|DRUG|Placebo|
214608809|NCT06927206|OTHER|Experimental Group B: Segmental vibrator + Electrical stimulation on dorsiflexors|"Segmental vibrator + Electrical stimulation on dorsiflexors:~After standard physiotherapy session this group received the intervention of neuromuscular electrical stimulations by means of EMS. Two electrodes were used for this procedure. Tibialis anterior muscle targeted for dorsiflexor. One pad of electrode was placed on anterior of lower leg just below tibial tuberisty and other was 5cm below to it .With a 250-microsecond pulse duration, the EMS device was set up to provide a biphasic current with a symmetrical waveform at 50 Hz for 15 seconds. It was also tuned for a 3-second ramp up time and a 30-second rest period. Each respondent set the intensity to the highest level they could tolerate. Secondly, segmental vibrator was applied for focal vibrations on tibialis anterior. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
214608810|NCT06902363|DEVICE|Macroduct Advanced|Sweat stimulation and collection using the Macroduct Advanced system on two anatomical sites (forearm and thigh) in infants under 6 months of age.
214608811|NCT07103733|PROCEDURE|Cardiac Magnetic Resonance Imaging|Non-invasive imaging test that uses powerful magnets and radio waves to create detailed pictures of the heart without using radiation.
214608812|NCT07103733|DEVICE|ZioPatch Monitoring|ZioPatch is a small, wearable heart monitor that sticks to the chest and records the heart's electrical activity continuously for up to 14 days. It helps doctors detect irregular heart rhythms (arrhythmias) without the need for bulky wires or equipment.
214608813|NCT07103733|PROCEDURE|Myocardial Tissue Biopsy|During the MVr procedure, surgeons will biopsy approximately 50 μg of tissue from the endocardial and subendocardial myocardium in the inferobasilar and control areas using a surgical rongeur.
214608814|NCT07104539|BEHAVIORAL|Strength Training|Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
214608815|NCT07104539|OTHER|Wait first, then strength training|Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
214608816|NCT06827171|COMBINATION_PRODUCT|aerobic exercise + low-level laser therapy|low- level laser parameters: The wavelength: 808 +/- 5nm The power: output is 450 Mw Type of beam: red laser beam. Beam Divergent \>,025 rad+/- ,005rad Nominal Distance of Sight hazard \>8m The duration: is 20 min for each artery. Treatment period: 3 times/week for 3 months.
214608817|NCT06827171|OTHER|Aerobic exercise|Aerobic exercise Frequency = 3sessions/week duration: 10 min warm up and 10 min cool down/ 30 min stance phase Intensity: moderate intensity initiating with 50% HR max to end 75% HR max
214713757|NCT02050828|DRUG|Sham|
214608818|NCT03337698|DRUG|Atezolizumab|Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
214608819|NCT03337698|DRUG|Cobimetinib|Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
214608820|NCT03337698|DRUG|RO6958688|"Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle."
214608821|NCT03337698|DRUG|Docetaxel|Docetaxel is administered by IV on Day 1 of each 21 day cycle.
214608822|NCT03337698|DRUG|CPI-444|CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
214713758|NCT04990531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
214713759|NCT04990531|DIAGNOSTIC_TEST|Blood sample|Blood sample for diagnostic testing
214608823|NCT03337698|DRUG|Pemetrexed|Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
214608824|NCT03337698|DRUG|Carboplatin|Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
214608825|NCT03337698|DRUG|Gemcitabine|Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
214608826|NCT03337698|DRUG|Linagliptin|Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
214608827|NCT03337698|DRUG|Tocilizumab|Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
214608828|NCT03337698|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
214608829|NCT03337698|DRUG|Bevacizumab|Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
214608830|NCT03337698|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
214608831|NCT03337698|OTHER|Radiation|Radiotherapy up to 21 days
214608832|NCT03337698|DRUG|Evolocumab|Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
214608833|NCT03337698|DRUG|Tiragolumab|Tiragolumab is administered on Day 1 of each 21 day cycle.
214608834|NCT03337698|DRUG|XL092|XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
214608835|NCT03337698|DRUG|Camonsertib|Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
214608836|NCT07102264|DEVICE|CPMX1|Compressibility of thyroid nodules using CPMX1 during pre surgery planning visit
214608837|NCT07111013|DRUG|Lifitegrast/perfluorohexyloctane (PFHO)|fixed-dose combination (FDC) (5%/95%)
214608838|NCT07104123|OTHER|Social drivers of health screening|Patients will undergo a structured and protocoled screening for social drivers of health and be linked to support services
214608839|NCT07104123|BEHAVIORAL|Patients will undergo a program of contingency management|Patients will enter into a 12 week program of contingency management
214713760|NCT04366128|DRUG|CAPA indution immunotherapy|"1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1."
214608840|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
214608841|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
214608842|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
214713761|NCT05900466|DRUG|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
214713762|NCT05900466|DRUG|Placebo|Matching tablets once daily in the morning for 8 weeks
214713763|NCT06380348|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
214713764|NCT06380348|DRUG|Osimertinib tablet|Osimertinib 160mg once po everyday
214608844|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
214608845|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
214608846|NCT07121166|BEHAVIORAL|tgCBFI programme|a six-week online group intervention programme for dyads of service users and caregivers
214608847|NCT07121166|BEHAVIORAL|Treatment as Usual (TAU)|Integrated community psychiatric care with psychiatric outpatient follow-up
214608848|NCT07119983|BEHAVIORAL|Stress ball|The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.
214713765|NCT06380348|DRUG|Cisplatin injection|Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
214713766|NCT06380348|DRUG|Pemetrexed injection|Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
214713767|NCT00769236|OTHER|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
214608849|NCT07123064|BEHAVIORAL|Individual Level|A 8-weekly, 1hour telephone-delivered sessions using mindfulness and SOLUS-D program. Key contents include: introduction to mindfulness - Body awareness and present moment experiences, emotional awareness and mind-body labeling, relaxation techniques and sensory discrimination, deepening awareness and accepting feelings, personal values, interconnection between thought patterns and emotions, identifying and analyzing of thought traps, and challenging thoughts and future planning. Booster sessions which focus on embedding mindfulness practices and SOLUS-D program among older adults as a persistent habit will be conducted.
214608850|NCT07123064|BEHAVIORAL|Interpersonal Level|A 8 weekly, 1hr sessions through telephone or Zoom using the Group 4 Health and community navigator prgram. Key contents include: understanding the benefits of social connections, exploring self and community, community and action, support and breakthrough, summary and moving forward. Booster sessions which focus on continuous practice of support and community will be conducted.
214608851|NCT07123064|BEHAVIORAL|Community Level|A 4 weekly, 2hour in-person sessions through (1) strengthening collective efficacy via neighbor identification with the community. Key contents include: building neighbourhood connections, getting to know each other, health aging, neighbourhood care, vibrant exploration, thriving community, connecting the dots.
214608852|NCT07123064|BEHAVIORAL|Usual Care Control|Monthly SMS over a period of 6 months will be sent out. Key content includes: healthy diet tips, recognizing warning signs of health, understanding dementia, fall prevention tips, health message, and anti-fraud tips.
214713768|NCT00769236|OTHER|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
214713769|NCT00769236|OTHER|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
214608853|NCT07130604|DRUG|D-2570|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
214713770|NCT01450475|PROCEDURE|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
214713771|NCT00030030|DRUG|Silymarin (milk thistle)|
214713772|NCT04088565|OTHER|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
214713773|NCT04088565|OTHER|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
214713774|NCT04088565|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
214713775|NCT03349580|BEHAVIORAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
214713776|NCT03393689|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
214713777|NCT01072968|DRUG|BF2.649|1 capsule per day in the morning before the breakfast
214608854|NCT07130604|DRUG|Placebo|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
214608855|NCT07130695|DRUG|Olutasidenib Investigational Agent Administration|Twice daily olutasidenib maintenance therapy
214713778|NCT01072968|DRUG|Placebo|1 capsule per day in the morning before the breakfast
214713779|NCT03460470|DRUG|Sildenafil|PDE5 Inhibitor
214713780|NCT03460470|DRUG|Placebo oral capsule|Placebo for Sildenafil
214713781|NCT00247559|BIOLOGICAL|Botulinum toxin type A|
214713782|NCT03648463|PROCEDURE|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
214713783|NCT02944669|DEVICE|ReWalk Personal Device|
214713784|NCT00409916|DEVICE|BioZ Dx|
214713785|NCT05477446|BIOLOGICAL|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
214713786|NCT00028418|DRUG|Clofarabine|
214713787|NCT00531908|DRUG|furosemide|furosemide
214608856|NCT07129512|PROCEDURE|Intracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using an ultrasonic scalpel with advanced hemostasis mode.
214608857|NCT07129512|PROCEDURE|Extracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using a monopolar energy device and surgical clips.
214608858|NCT07128901|DEVICE|Ekso Indego Therapy|User-balancing lower Limb exoskeleton
214608859|NCT07128901|DEVICE|Wandercraft Atalante X|Self-balancing lower limb exoskeleton
214608860|NCT07128472|DRUG|Humira|Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.
214608861|NCT07130838|BEHAVIORAL|MB-EAT program|Phase 2 will include 12 modules, delivered across 12 weeks. The program will contain seated and guided mindfulness practices designed to cultivate better awareness of hunger cues, sensory-specific satiety, as well as external and emotional food-related triggers through body scans, taste satiety and mindful eating practices, self-compassion meditations, and diaphragmatic breathing. The intervention will also include mindful movements. Each session will be focused on a specific theme related to promoting healthy eating behaviours and emotional regulation. Each module will be unlocked as the participant progresses through the program. AmDTx-Epiq also incorporates goal setting, daily feedback, prompts for change, and positive reinforcement in the form of an encouraging text messages from the study coach.
214608862|NCT07130838|BEHAVIORAL|Feasibility study|"Phase 1 will include 4 modules, delivered across 4 weeks. All participants will receive a modified, shortened version of the MB-EAT program through AmDTx-Epiq within the AmDTx app. Participants will also complete the Keep in Balance questionnaire every week on the app, a questionnaire which assesses weekly physically activity and eating habits, as well as associated thoughts and feelings to these. Participants will receive regular check-ins twice per week from a coach (unblinded study coordinator) via text designed to promote engagement and answer questions participants may have during the 4-week intervention period."
214608863|NCT07130838|BEHAVIORAL|Psychoeducation|Patients in the control group will receive audio-recorded psychoeducation in the form of standard diet/exercise information. The comparator is publicly available psychoeducational information available on nutrition, physical activity, and weight management through best practice guidelines, clinical guidelines, and public health guidelines. These comparators were chosen as they are easily accessible standard of care practices and interventions available in the community (i.e., the general public have access to it in the community), such as through consultation with a dietician, community care provider, or family physician.
214608864|NCT07129473|DRUG|Metformin Extended Release Oral Tablet|"Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) once daily with the evening meal starting prior to conception. The dosing will begin at 500 mg daily and increase gradually over an eight week period (+500mg every 2 weeks, as tolerated) to a maximum tolerated dose of up to 2,000 mg daily. Treatment at highest tolerated dose will continue (maintenance phase) until either two weeks after a positive pregnancy test or 12 months from treatment initiation, whichever comes first. Participants will attend three clinic visits and provide blood samples at baseline, after dose escalation, and during early pregnancy to assess GDF15 levels. Daily dosing, adherence, and any side effects are recorded via MyCap; clinical visits at baseline, post-escalation (week 8), and after pregnancy confirmation include vital signs, PUQE-24/HELP scores, and blood draws for CBC, creatinine, and GDF15 levels."
214608865|NCT07128394|DRUG|Recombinant Luteinizing Hormone (rLH)|Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.
214608866|NCT07128394|DRUG|Recombinant Follicle-Stimulating Hormone (rFSH)|Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.
214608867|NCT07128394|DRUG|Gonadotropin-Releasing Hormone Agonist (GnRH-a)|Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.
214608868|NCT07128823|OTHER|(High-frequency segmental vibration and ASAP with Routine Physical Therapy)|"A Segmental vibration device was used to provide vibratory stimulation with a frequency of 100 Hz and an amplitude of 1.0 mm. This stimulation was used because vibratory stimulation with a high frequency (80-120 Hz) and low amplitude can elicit strong activity in Ia afferents from the muscle spindles. 100 Hz frequency vibration was applied perpendicularly along the muscle fibers of the forearm extensor muscle (extensor carpi ulnaris (ECU), extensor carpi radialis (ECR), triceps).~The Accelerated Skill Acquisition Programme (ASAP), a structured, taskoriented motor training program for the upper extremities, is a best-practice synthesis implementing neuroscientific evidence regarding motor training approaches and schedules. The Accelerated Skill Acquisition Program (ASAP) for subacute stroke patients focuses on integrating motor training with motivational enhancement and impairment mitigation."
214608869|NCT07128823|OTHER|(Accelerated Skill Acquisition Programme with Routine Physical Therapy)|"Exercises within the ASAP typically include:~Task-Specific Training: Patients engage in activities that mimic daily tasks, such as reaching, grasping, and manipulating objects, to improve their functional abilities Repetitive Practice: Patients perform repetitive movements to strengthen neural pathways and improve motor skills. This can involve tasks like buttoning a shirt, picking up small objects, or pouring water Bilateral Arm Training: This approach involves using both arms simultaneously to perform coordinated tasks, enhancing bimanual skills and improving upper extremity functions Motivational Strategies: The program incorporates motivational techniques to enhance patient engagement and adherence to the exercises, ensuring sustained practice and better outcomes."
214608870|NCT07129369|BEHAVIORAL|PASIM program|The program consists of 5 modules for ROP patients (translated, refined and validated by research team) and 4 group sessions (1.5 hours per session; 8-10 members/group; in-between completion of the 5 modules) facilitated by a peer-support worker over 5 months. The 5 modules include: Module 1-Patient's well-being; Module 2-Getting the best out of support services; Module 3-Acceptance and insight toward psychosis and long-term self-care; Module 4-Dealing with psychosocial effects of the illness- I; and Module 5-Dealing with physical/mental health effects of the illness- II. The 4 group sessions will be conducted at the orientation and after reading the 1st, 3rd and 5th module to introduce the program, encourage to complete the module per month, performing value clarifying and acceptance (psychological flexibility) exercises, and clarify and discuss self-care learning and and challenges.
214608871|NCT07129369|BEHAVIORAL|Psychoeducation|The psychoeducation group (5 subgroups with 12-14 patients per group) will be led by one trained psychiatric nurse experienced in psychiatric rehabilitation and psychoeducation group. The program consists of 12 two-hour sessions held weekly or biweekly (similar to the PASIM) over 5 months with four key components, including introduction and goal setting; an education workshop on psychosis care and community service; learning effective coping and self-care skills with rehearsals/reviews; and skills practices and preparing for future life.
214608872|NCT07129369|BEHAVIORAL|Usual-Care-only|Participants receive usual community mental healthcare services provided by POPCs and ICCMWs.
214608873|NCT07129044|BEHAVIORAL|Flipped Classroom Training on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. The training was delivered using a flipped classroom model over 4 weeks. Students were provided with pre-class educational materials, including video lectures, readings, and lecture notes. In-class sessions included interactive activities, discussions, case-based learning, and problem-solving exercises. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
214608874|NCT07129044|BEHAVIORAL|Self-Directed Learning on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. Students were provided with the same pre-class educational materials as the intervention group, including video lectures, readings, and lecture notes, for self-study without any interactive activities or instructor-led sessions. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
214608875|NCT07130331|DRUG|Secikinumab|secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks
214608876|NCT07130760|PROCEDURE|Intraligamentary Injection|Intraligamentary local anesthesia will be administered using a standard dental syringe with 2% lidocaine and 1:100,000 epinephrine.
214608877|NCT07130760|PROCEDURE|Inferior Alveolar Nerve Block|Inferior alveolar nerve block will be performed with 2% lidocaine and 1:100,000 epinephrine using the conventional technique.
214608878|NCT07130942|PROCEDURE|Inhalation using a molecular hydrogen generator|"Hydrogen inhalation will be performed by using a hydrogen gas generator similar in terms of capabilities to the generator Hycellvator ET100 (Helix Japan, Co., Ltd., Tokyo, Japan). The apparatus will be generating 30.0 mL/s gas mixture, consisting of 68.0% hydrogen (hydrogen purity, 99.99%) and 32.0% of oxygen. All gases will be supplied through a nasal cannula connected to the gas generators. Although we could not measure directly the hydrogen and oxygen An average inspiratory flow rate will be adjusted to 500 mL/s at rest, the hydrogen concentration in the inspired gas must have been around 4.08% at most.~Control population will have inhalation with the use of gas generator that has the same outer shape as the used generator to produce Placebo (30.0 mL/s, ambient air 400 m above sea level) consisting of 0.00005% of hydrogen and 20.9% of oxygen."
214608879|NCT07129434|BEHAVIORAL|ECoFam|Mother-infant dyads randomized into the intervention group receive four personal coaching sessions to facilitate emotional connection via multisensory channels including comfort touch and communication of face-to-face affect during holding time.
214608880|NCT07130500|BEHAVIORAL|Financial incentives for adherence to long-acting injectable medication|This intervention is a randomized controlled trial where patients in the treatment group are offered financial incentives for taking long-acting injectable (LAI) versions of the antipsychotic and substance use disorder medications they need and the control group receives the status quo standard of care.
214608881|NCT07130500|BEHAVIORAL|Standard of care with monthly surveys|Receives standard outpatient care and incentives for completing monthly surveys.
214608882|NCT07129525|RADIATION|Radiation therapy|Patients treated with radiotherapy will be evaluated within a period of five to seven weeks, during which time radiation-induced skin toxicities will be assessed.
214713788|NCT01441518|OTHER|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
214713789|NCT01441518|OTHER|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
214713790|NCT02606396|PROCEDURE|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
214713791|NCT02606396|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
214608883|NCT07129330|PROCEDURE|RSPO3/SDC-1 pathway profiling assay|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage Subcutaneous Fat: 100-200 mg obtained during elective procedures, preserved in RNAlater at 4 °C for 24 h, then frozen at -80 °C 3D Alveolar Organoid Assay: Lung tissue-derived organoids are cultured in Matrigel and treated ex vivo with recombinant RSPO3 or SDC-1 neutralizing antibody; epithelial repair is assessed over 7 days by Ki-67 immunostaining and wound-closure measurement"
214713792|NCT02606396|PROCEDURE|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
214713793|NCT00124813|DRUG|thalidomide|
214713794|NCT00124813|DRUG|idarubicin|oral idarubicin
214713795|NCT04714944|DIETARY_SUPPLEMENT|Placebo|Supplementation period 12 weeks
214713796|NCT04714944|DIETARY_SUPPLEMENT|Whole fiber product|Supplementation period 12 weeks
214713797|NCT02099760|DEVICE|STD testing (GC/Ct/trich)|
214713798|NCT01544478|BIOLOGICAL|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
214713799|NCT03874416|OTHER|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
214713800|NCT03874416|OTHER|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
214713801|NCT00132158|DRUG|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
214608884|NCT07129330|PROCEDURE|Blood and Saliva|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage"
214608885|NCT07129278|BEHAVIORAL|Breathwork|Participants will complete their single-session, 2-hour training in a small group with the Breathwork instructor.
214713802|NCT00621010|DRUG|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
214608886|NCT04665570|DRUG|BAY81-9783 (Acarbose/Metformin)|Tablet (FDC of 25/50mg acarbose + 500mg metformin), three times daily
214608887|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
214608888|NCT06925451|OTHER|sourdough bread 24|fermentation time=24 hours
214713803|NCT01843634|DRUG|ODSH|
214713804|NCT00761358|DRUG|Z-338|Oral
214713805|NCT00761358|DRUG|Placebo|Oral
214608889|NCT06925451|OTHER|sourdough bread 48|fermentation time=48 hours
214608890|NCT06925451|OTHER|sourdough bread 72|fermentation time=72 hours
214608891|NCT06925451|OTHER|yeast bread|no fermentation
214608892|NCT05294354|BEHAVIORAL|aerobic exercise group (AE)|The participants will ride the cycle ergometer for 35 minutes. The training consisted of a 5-minute warm-up period followed by 25 minutes of moderate exercise and a 5-minute recovery.
214608893|NCT05294354|BEHAVIORAL|aerobic exercise with virtual reality group (AE-VR)|The participants will receive the 3D VR training program and ride the cycle ergometer at the same time. The training protocol is similar to the aerobic exercise group.
214608894|NCT05294354|BEHAVIORAL|combined exercise group (CE)|The intervention consists of 5-minutes aerobic warm-up, 25-minutes bodyweight exercise, and 5-minutes mindfulness meditation for recovery. The participants will follow the video to do the program.
214608895|NCT05294354|BEHAVIORAL|Control group|Participants will watch a 35-min video about exercise science.
214608896|NCT00269165|PROCEDURE|Balloon Aortic Valvuloplasty|
214608897|NCT00269165|PROCEDURE|External Beam Radiation|
214608898|NCT06936384|BEHAVIORAL|In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form be|White Noise Sleep Mask Group In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form before the surgery and fill out a patient information form.
214608899|NCT06936202|OTHER|Spirulina capsules|active intervention
214608900|NCT06936202|OTHER|Placebo|no active ingredient
214608901|NCT02705209|OTHER|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
214608902|NCT02705209|OTHER|Placebo Cataplasm|Poultice of Kaolin and Water
214608903|NCT02296450|BEHAVIORAL|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
214608904|NCT07130253|DRUG|Vonoprazan based ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy
214608905|NCT07130253|DRUG|Vonoprazan based SGT|Susceptibility testing guided therapy Based onsusceptibility test:Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin quadruple therapy
214608906|NCT06291831|DRUG|nirmatrelvir, ritonavir|Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
214608907|NCT06291831|OTHER|Controls|Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
214608908|NCT06433947|DRUG|OPN-6602|orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
214608909|NCT06433947|DRUG|Dexamethasone|Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
214608910|NCT05351775|DEVICE|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
214608911|NCT05351775|DEVICE|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
214608912|NCT05351775|DEVICE|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
214608913|NCT05351775|DEVICE|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
214608914|NCT06177028|DRUG|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
214608915|NCT03907631|OTHER|Standard of care|care decisions driven by local physicians; this is an observational cohort
214608916|NCT00143065|DRUG|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
214608917|NCT00143065|DRUG|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
214608918|NCT00143065|DRUG|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
214608919|NCT03465631|DEVICE|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
214608920|NCT03465631|DEVICE|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
214608921|NCT04977102|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
214608922|NCT04977102|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
214608923|NCT04450563|DRUG|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
214608924|NCT05726539|BEHAVIORAL|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
214608925|NCT00464347|DRUG|Avastin|
214608926|NCT00464347|PROCEDURE|Photodynamic Therapy (PDT)|
214608927|NCT00464347|DRUG|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
214608928|NCT03307434|OTHER|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
214608929|NCT03307434|OTHER|regular training|The regular training will be performed by control group according to the standard practice.
214608930|NCT05377190|OTHER|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
214608931|NCT05377190|OTHER|Standard of care for the follow-up|No mobile application or digital therapeutics are used
214608932|NCT05377190|OTHER|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
214608933|NCT02008279|BIOLOGICAL|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
214608934|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
214608935|NCT02008279|BIOLOGICAL|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
214608936|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
214608937|NCT02008279|DRUG|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
214608938|NCT03409848|DRUG|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
214608939|NCT03409848|DRUG|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
214608940|NCT03409848|DRUG|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
214608941|NCT05831826|BIOLOGICAL|the inactivated COVID-19 vaccines|receive the doses of inactivated COVID-19 vaccines
214608942|NCT06474416|GENETIC|BD111 Injection (Investigative New Drug)|BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).
214608943|NCT06474416|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
214713806|NCT04592848|OTHER|Questionnaires|"Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery"
214713807|NCT04518722|RADIATION|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
214713808|NCT04518722|RADIATION|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
214713809|NCT04518722|OTHER|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
214713810|NCT02574481|DEVICE|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
214713811|NCT02574481|DEVICE|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
214713812|NCT01461824|DRUG|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
214713813|NCT04134728|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
214713814|NCT04134728|BIOLOGICAL|Sarilumab|Sarilumab solution in PFS to be administered SC.
214713815|NCT04134728|DRUG|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
214713816|NCT04134728|DRUG|csDMARDs|Stable dose of csDMARD(s) as SoC.
214608944|NCT00005666|PROCEDURE|PET scan use in radiotherapy planning|
214608945|NCT00395863|DRUG|Multihance|0.5 M at a single injection
214713817|NCT04059874|DRUG|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
214713818|NCT02168712|OTHER|Moderate continuous exercise training|
214713819|NCT02168712|OTHER|Interval exercise training|
214713820|NCT01791790|DEVICE|Stimulation|
214713821|NCT01791790|DEVICE|SHAM|no stimulation
214713822|NCT04131244|PROCEDURE|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
214713823|NCT02519062|OTHER|No intervention|This is a retrospective study
214608946|NCT00395863|DRUG|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
214608947|NCT04673227|DIAGNOSTIC_TEST|Blood draw|Blood draw and the analysis of blood in laboratory
214608948|NCT03137186|DRUG|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
214608949|NCT02349399|DRUG|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
214608950|NCT02107495|DEVICE|Samsung LABGEO IVD-A20 CHF Test|
214608951|NCT01069120|DRUG|Proellex|2, 25 mg capsules once per day
214608952|NCT01069120|DRUG|Proellex|1, 25 mg capsule once per day
214608953|NCT00299052|DEVICE|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
214713824|NCT04013165|BEHAVIORAL|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
214608954|NCT00299052|BIOLOGICAL|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
214608955|NCT00003440|DRUG|paclitaxel|Given IV over 1 hour or 3 hours
214608956|NCT00003440|BIOLOGICAL|trastuzumab|Given IV
214608957|NCT00003440|PROCEDURE|quality-of-life assessment|Ancillary studies
214608958|NCT00003440|OTHER|laboratory biomarker analysis|Correlative studies
214608959|NCT05097716|DRUG|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
214608960|NCT05097716|DRUG|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
214608961|NCT05781230|BEHAVIORAL|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
214608962|NCT05781230|BEHAVIORAL|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity
214608963|NCT00917527|DRUG|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
214608964|NCT04795726|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
214608965|NCT04795726|DRUG|Placebo|Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
214608966|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
214608967|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
214608968|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
214608969|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
214608970|NCT01286454|DRUG|fesoterodine|single dose of tablet
214608971|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
214722301|NCT03648606|OTHER|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
214608972|NCT03299634|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
214608973|NCT02615704|DEVICE|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
214608974|NCT02615704|DEVICE|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
214608975|NCT02615704|DEVICE|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
214608976|NCT02615704|DEVICE|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
214608977|NCT02367066|DRUG|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
214608978|NCT02367066|OTHER|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
214608979|NCT04616391|DEVICE|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
214608980|NCT02678416|DRUG|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
214608981|NCT02678416|DRUG|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
214608982|NCT02678416|DRUG|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
214608983|NCT02678416|OTHER|Morphine (Treatment D)|Morphine administered by IV infusion
214608984|NCT04556136|DEVICE|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
214608985|NCT04556136|DIETARY_SUPPLEMENT|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
214608986|NCT00017121|BIOLOGICAL|sargramostim|
214608987|NCT03483467|OTHER|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
214608988|NCT03483467|OTHER|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
214608989|NCT01170546|OTHER|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
214608990|NCT01170546|OTHER|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
214608991|NCT01170546|OTHER|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
214608992|NCT04046796|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
214608993|NCT05617651|DRUG|IY-NT-T|Ilaprazole 20mg
214608994|NCT05617651|DRUG|IY-NT-R|Ilaprazole 10mg
214608995|NCT06473376|PROCEDURE|arthrocentesis|TMJ arthrocentesis and arthroscopy
214608996|NCT00163462|DRUG|Ciclesonide|
214608997|NCT02017379|DRUG|Erythromycin|
214608998|NCT02017379|DRUG|Metoclopromide|
214608999|NCT02612740|BIOLOGICAL|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
214609000|NCT02612740|DEVICE|granules of deproteinized bovine bone (Bio-Oss)|
214609001|NCT05967117|DRUG|Iohexol (320mgI/mL) with 120kVp|Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
214609002|NCT05967117|DRUG|Iohexol (320mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
214609003|NCT05967117|DRUG|Iohexol (270mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
214609004|NCT05967117|DRUG|Iohexol (240mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
214609005|NCT04465097|DRUG|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
214609006|NCT04465097|DRUG|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
214609007|NCT04465097|DRUG|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
214609008|NCT01639768|DRUG|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
214609009|NCT00172653|PROCEDURE|functional tasks|
214609010|NCT05895162|DRUG|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
214609011|NCT05895162|DRUG|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
214609012|NCT06079944|PROCEDURE|Progressive resistance training|"* 6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~* 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~* Speed of movement will be 2 seconds for both the eccentric and concentric phases.~* To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
214609013|NCT06079944|PROCEDURE|Traditional physical therapy|"* TENS+ Hot pack~* Pendulum exercises and stretching exercises"
214609014|NCT01727765|OTHER|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
214609015|NCT02556125|DEVICE|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
214609016|NCT00480688|BIOLOGICAL|BCG|
214609017|NCT00331123|DRUG|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
214609018|NCT00331123|DRUG|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
214609019|NCT00268307|DRUG|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
214609020|NCT00004639|PROCEDURE|Furlow double z-plasty palatoplasty palate repair|
214609021|NCT00004639|PROCEDURE|Von Langenbeck palatoplasty palate repair|
214609022|NCT03244410|DIAGNOSTIC_TEST|complete blood picture|complete blood picture
214609023|NCT02289352|DRUG|Brimonidine|
214609024|NCT02289352|DRUG|placebo|
214609025|NCT00497783|DRUG|Lactoserum|
214609026|NCT06310954|DIETARY_SUPPLEMENT|Early ketogenic diet combined with conventional pharmacotherapy.|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
214609027|NCT06310954|DRUG|Common diet combined with conventional pharmacotherapy|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, and inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.We know that drug information for registering clinical information is necessary, but our research design is to add ketogenic diets as a supplementary treatment plan when traditional drug treatment is ineffective. Therefore, in terms of specific drug selection, this is not absolutely the same. Depending on individual differences, the choice of drugs will also vary. Control the number of episodes, time, etc., and everyone uses different drugs. Therefore, we cannot decide on a single drug for comparison like traditional content.
214609028|NCT04340557|DRUG|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
214609029|NCT05362383|DEVICE|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
214609030|NCT02671045|GENETIC|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
214609031|NCT02671045|GENETIC|Genomic profile by other methods|Genomic profiling by other testing methods.
214609032|NCT06125379|BEHAVIORAL|brief mindfulness|The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
214609033|NCT06582316|OTHER|Brain Health Training Programme|"Train Your Brain (TYB) - group-based cognitive intervention programme for mild cognitive impairments. This programme equips participants with knowledge on cognition and brain health, provide cognitive coping strategies and boost their confidence and maintain independence in daily activities."
214609034|NCT02365753|DEVICE|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
214609035|NCT02627352|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
214609036|NCT04710953|DEVICE|Continuous positive airway pressure machine|CPAP device set at 6-8cmH2O for several hours
214609037|NCT01177384|DRUG|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
214609038|NCT01177384|DRUG|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
214609039|NCT01177384|DRUG|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
214609040|NCT01177384|DRUG|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
214609041|NCT02663284|DRUG|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
214609042|NCT04869163|OTHER|Non-red meat|Red meat analogues and alternatives
214609043|NCT01672034|PROCEDURE|Laparoscopic gastric bypass surgery|
214609044|NCT03641495|OTHER|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
214609045|NCT03641495|OTHER|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
214609046|NCT04435379|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
214609047|NCT04435379|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
214609048|NCT03525535|OTHER|data collection|data from patient included will be collected during the study
214609049|NCT01845454|DEVICE|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
214609050|NCT00579683|OTHER|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
214609051|NCT00797836|PROCEDURE|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods"
214609052|NCT02649296|OTHER|Skanlab bodywave|The intervention will be done twice a week
214609053|NCT00951301|DRUG|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
214609054|NCT00951301|DRUG|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
214722302|NCT06086236|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
214722303|NCT03622541|DRUG|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
214609055|NCT04048980|BEHAVIORAL|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
214609056|NCT01849497|BIOLOGICAL|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
214609057|NCT01849497|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
214609058|NCT04841512|BIOLOGICAL|XT-150|non-viral Plasmid DNA encoding an IL-10 variant transgene
214609059|NCT01091688|BEHAVIORAL|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
214609060|NCT02897232|OTHER|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
214609061|NCT04458103|DEVICE|Percutaneous RVAD|ProtekDuo or Impella RP
214609062|NCT01442116|PROCEDURE|stress echocardiography|safety and efficacy of stress echocardiography
214609063|NCT02830763|DIETARY_SUPPLEMENT|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
214609064|NCT01772004|DRUG|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
214609065|NCT03948633|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
214609066|NCT06214871|DEVICE|rTMS|Transcranial Magnetic Stimulation
214609067|NCT03595319|DRUG|Sevoflurane|Inhaled sevoflurane until allocated dose (see adaptive protocol)
214609068|NCT01458704|OTHER|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
214609069|NCT00911625|DRUG|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
214609070|NCT00911625|DRUG|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
214609071|NCT01549626|DIETARY_SUPPLEMENT|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
214609072|NCT01549626|DIETARY_SUPPLEMENT|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
214609073|NCT01549626|DIETARY_SUPPLEMENT|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
214609074|NCT00529451|DRUG|Aliskiren|Aliskiren
214609075|NCT00529451|DRUG|Ramipril|comparator
214609076|NCT02101515|OTHER|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
214609077|NCT05729295|PROCEDURE|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
214609078|NCT01217151|DEVICE|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
214609079|NCT01217151|OTHER|Usual treatment|Hemodynamic monitoring based on common practice
214609080|NCT04665336|BEHAVIORAL|Circadian Timing Program|"Sleep hygiene training will be provided to the participants. They will be asked to make lifestyle changes according to the Circadian Timing Program created by the researcher."
214609081|NCT04665336|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training will be given by the researcher. There will also be sleep hygiene training sections on the website.
214609082|NCT05342181|OTHER|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~1. supine bridge~2. plank~3. oblique crunch~4. side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
214609083|NCT05342181|OTHER|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~1. bridging~2. straight leg raise in prone lying~3. straight leg raise with hand raise in prone lying~4. pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
214609084|NCT02183155|DRUG|Meloxicam - low|
214609085|NCT02183155|DRUG|Meloxicam - medium|
214609086|NCT02183155|DRUG|Meloxicam - high|
214609087|NCT02183155|DRUG|Placebo|
214609088|NCT02183155|DRUG|Extended-release indomethacin|
214609089|NCT01095367|PROCEDURE|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
214609090|NCT00184080|DRUG|Elsamitrusin|
214609091|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
214609092|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
214609093|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
214609094|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
214609095|NCT01289821|DRUG|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
214609096|NCT01289821|DRUG|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
214609097|NCT01289821|DRUG|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
214609098|NCT01289821|DRUG|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
214609099|NCT02024568|DRUG|Pregabalin|See arm description
214609100|NCT02024568|DRUG|Placebo|See arm description
214609101|NCT02379767|DEVICE|Electroconvulsive therapy|
214609102|NCT02379767|OTHER|Positron emission tomography of the brain using [11C]harmine|
214609103|NCT02379767|OTHER|Structural magnetic resonance imaging|
214609104|NCT03591354|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.
214609105|NCT03591354|DEVICE|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
214609106|NCT00302510|PROCEDURE|immunoadsorption|immunoadsorption
214609107|NCT03923751|OTHER|Invitation to regional anesthesia survey|An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
214609108|NCT05440396|DIAGNOSTIC_TEST|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
214609109|NCT02478905|OTHER|Influenza|
214609110|NCT02231463|OTHER|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
214609111|NCT02231463|OTHER|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
214609112|NCT02231463|OTHER|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
214609113|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
214609114|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
214609115|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
214609116|NCT02955420|DRUG|BC 007|
214609117|NCT02955420|DRUG|NaCl 0.9 %|
214609118|NCT01329887|DRUG|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
214609119|NCT00273936|DRUG|AVN-944 capsules for oral administration|
214609120|NCT00909233|DRUG|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
214609121|NCT06035991|PROCEDURE|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
214609122|NCT00572962|PROCEDURE|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
214609123|NCT00053924|DRUG|perifosine|
214609124|NCT01054950|BEHAVIORAL|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
214609125|NCT01054950|BEHAVIORAL|Placebo phone call|Phone call w/ no behavioral counseling
214609126|NCT02218957|PROCEDURE|Extended Pouch RYGB|
214609127|NCT02218957|PROCEDURE|Standard RYGB|
214722304|NCT00969488|OTHER|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
214722305|NCT00254163|DRUG|Fludarabine|
214609128|NCT05586750|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
214609129|NCT05586750|DRUG|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
214609130|NCT01974388|PROCEDURE|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
214609131|NCT01974388|PROCEDURE|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
214609132|NCT02437617|PROCEDURE|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
214609133|NCT00518427|DRUG|Insulin Glargine|"Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
214609134|NCT02901574|DEVICE|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
214609135|NCT02901574|DEVICE|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
214722306|NCT00254163|DRUG|Cyclophosphamide|
214722307|NCT00254163|DRUG|Rituximab|
214722308|NCT00254163|DRUG|Pentostatin|
214609136|NCT02901574|BEHAVIORAL|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
214609137|NCT02907710|DRUG|Endostar|intravenous infusion
214609138|NCT02907710|DRUG|DDP|
214609139|NCT02844621|DRUG|Omeprazole|20mg orally once daily
214609140|NCT00773136|DRUG|Bimatoprost Suspension|see prior
214609141|NCT01475929|DIETARY_SUPPLEMENT|Probiotic supplement|A single strain probiotic supplement given at two doses
214609142|NCT03945357|DRUG|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
214609143|NCT03945357|DRUG|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
214609144|NCT06301672|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214609145|NCT06301672|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214609146|NCT06301672|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214609147|NCT01010633|DRUG|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
214609148|NCT01010633|DRUG|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
214722309|NCT04880681|DEVICE|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
214609149|NCT01648894|PROCEDURE|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
214609150|NCT01648894|PROCEDURE|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
214609151|NCT01040065|PROCEDURE|distal clavicle resection|Presence of tenderness at 2 years after surgery
214609152|NCT01929239|DRUG|Anti-PSMA Designer T Cells|
214609153|NCT05110339|DRUG|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
214609154|NCT05110339|DRUG|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
214609155|NCT04711798|OTHER|passive leg raising maneuver (PLR)|Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
214609156|NCT04711798|OTHER|lung recruitment maneuver (LRM)|lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
214609157|NCT04711798|OTHER|echographic evaluation of the right cardiac function|echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
214609158|NCT04980950|DIETARY_SUPPLEMENT|Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science|Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
214609159|NCT04666350|OTHER|Direct Skin Feeding Assay (DSFA)|In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.
214609160|NCT04666350|DRUG|Primaquine|Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.
214609161|NCT04666350|DRUG|Artemether/Lumefantrine|Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
214609162|NCT04650724|DRUG|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
214609163|NCT00097773|DRUG|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
214609164|NCT00097773|DRUG|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
214609165|NCT00097773|DRUG|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
214609166|NCT01961401|BEHAVIORAL|exercise|
214722310|NCT04880681|DEVICE|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
214722311|NCT01952288|DRUG|simvastatin|simvastatin 40 mg/day for 12 months
214722312|NCT01952288|DRUG|Placebo Oral Tablet|placebo comparator
214722313|NCT00519168|PROCEDURE|Urine sample|Standard of care
214609167|NCT00003702|BIOLOGICAL|Dactinomycin|Given IV
214609168|NCT00003702|DRUG|Methotrexate|Given intramuscularly
214609169|NCT04637893|OTHER|Colonoscopy|Pt. underwent colonoscopy
214609170|NCT01009034|OTHER|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
214609171|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
214609172|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
214609173|NCT02427230|DRUG|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
214609174|NCT03763669|DIETARY_SUPPLEMENT|Myoinositol|myo-inositol (2 g. twice a day)
214609175|NCT03763669|DIETARY_SUPPLEMENT|Placebo (for myoinositol)|(twice a day)
214609176|NCT01761825|DRUG|ivabradine|
214609177|NCT05656625|OTHER|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
214609178|NCT04577729|PROCEDURE|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
214609179|NCT04577729|PROCEDURE|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
214609180|NCT04521829|OTHER|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
214609181|NCT02180620|OTHER|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
214609182|NCT02180620|OTHER|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
214722314|NCT00519168|DEVICE|Electrode sleep recorder|Standard of care
214609183|NCT02180620|OTHER|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
214609184|NCT04077541|BEHAVIORAL|internet platform|The trauma care bundles combined with the internet platform.
214609185|NCT01923350|BEHAVIORAL|Weight Reduction Intervention|"The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
214609186|NCT01923350|BEHAVIORAL|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
214609187|NCT01923350|BEHAVIORAL|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
214609188|NCT01923350|BEHAVIORAL|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
214609189|NCT03621527|OTHER|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
214609190|NCT03621527|OTHER|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
214609191|NCT04016831|BEHAVIORAL|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
214609192|NCT04016831|OTHER|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
214609193|NCT02654249|DEVICE|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
214609194|NCT02654249|PROCEDURE|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
214609195|NCT02654249|DEVICE|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
214609196|NCT02654249|DEVICE|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
214609197|NCT04119141|DIAGNOSTIC_TEST|X ray imaging|"Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions."
214609198|NCT01494350|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
214609199|NCT00698932|DRUG|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
214713825|NCT04013165|BEHAVIORAL|Village-based intervention|"1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
214609200|NCT00698932|DRUG|Placebo|oral tablet, once daily for 24 weeks
214609201|NCT06395233|DEVICE|BetterPoints App|The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
214609202|NCT05638451|DRUG|Sintilimab plus Bevacizumab and Temozolomide|200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
214609203|NCT02753660|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
214609204|NCT02753660|PROCEDURE|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
214609205|NCT06061679|DEVICE|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
214609206|NCT00714467|BEHAVIORAL|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
214609207|NCT00714467|BEHAVIORAL|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
214609208|NCT01245387|DRUG|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
214609209|NCT00757003|DEVICE|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
214609210|NCT05440838|DIAGNOSTIC_TEST|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
214609211|NCT05274802|DRUG|ALS-4|Single dose of ALS-4 before Breakfast
214609212|NCT05274802|DRUG|Placebo|Single dose of placebo before Breakfast
214609213|NCT05274802|DRUG|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
214609214|NCT05274802|DRUG|ALS-4|Multiple dose of ALS-4 up to two times daily
214609215|NCT05274802|DRUG|Placebo|Multiple dose of placebo up to two times daily
214609216|NCT06178250|OTHER|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
214609217|NCT00627783|OTHER|a bicycle exercise test|
214609218|NCT01892514|PROCEDURE|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
214609219|NCT00471900|DRUG|dehydroepiandrosterone (DHEA)|
214713826|NCT02114489|DRUG|ibandronate|Unique perfusion of ibandronate 3 mg IV
214713827|NCT02114489|DRUG|Placebo|
214609220|NCT04643080|OTHER|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
214609221|NCT03723317|PROCEDURE|Liver transplantation|First deceased-donor liver transplantation
214609222|NCT04349982|DIAGNOSTIC_TEST|Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)|Factorial
214713828|NCT03382262|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
214713829|NCT03382262|DRUG|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
214722315|NCT00519168|PROCEDURE|phlebotomy|Standard of care
214609223|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
214609224|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
214609225|NCT00396994|DEVICE|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
214609226|NCT00396994|DEVICE|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
214609227|NCT02390479|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
214609228|NCT05144113|BEHAVIORAL|Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.|"The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program."
214609229|NCT02146599|OTHER|Administration of patient self-assessment|
214609230|NCT03391206|DIAGNOSTIC_TEST|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
214609231|NCT00005950|DRUG|nelarabine|Given IV
214609232|NCT02426528|OTHER|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
214609233|NCT06461182|DRUG|Ga-68-CXCR4|Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
214609234|NCT05214170|DEVICE|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
214609235|NCT00905684|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
214609236|NCT00905684|DRUG|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
214609237|NCT05948475|DRUG|Tinengotinib 8 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
214609238|NCT05948475|DRUG|Tinengotinib 10 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
214609239|NCT05948475|DRUG|Physician's Choice|For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
214609240|NCT00000808|DRUG|Nevirapine|
214722316|NCT05068388|DRUG|Z-Endoxifen|Z-Endoxifen
214609241|NCT00908024|DRUG|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
214609242|NCT00908024|DRUG|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
214609243|NCT05708950|DRUG|KVA12123 - Dose Escalation|Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
214609244|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Escalation|Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
214609245|NCT05708950|DRUG|KVA12123 - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
214609246|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
214609247|NCT01799187|PROCEDURE|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
214722317|NCT05068388|DRUG|Placebo|Placebo
214722318|NCT00391248|DRUG|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
214722319|NCT02478918|OTHER|Phone call|Automated phone call reminder
214609248|NCT01799187|PROCEDURE|apexification|apexification uses calcium hydroxide as root medication
214609249|NCT01766271|BEHAVIORAL|Health Coaching|biweekly health coaching for 5 months
214609250|NCT01766271|GENETIC|9p21|Genetic testing results of 9p21
214609251|NCT01766271|OTHER|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
214609252|NCT04267770|DRUG|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
214609253|NCT04267770|DRUG|Insulin (flat rate)|Participant's own insulin set to flat basal rates
214609254|NCT06490341|DRUG|GP Regimen, Nimotuzumab, Sintilimab|gemcitabine,ciplatin, nimotuzumab, sintilimab
214609255|NCT01687140|DRUG|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
214609256|NCT01687140|DRUG|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
214609257|NCT02821923|DIETARY_SUPPLEMENT|E967-Xylitol|24g xylitol/d
214609258|NCT02821923|DIETARY_SUPPLEMENT|E968-Erythritol|36g erythritol/d
214609259|NCT01770470|DIETARY_SUPPLEMENT|Chitosan|The product chitosan is contained in a chewing gum formulation
214609260|NCT02705807|DRUG|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.
214609261|NCT02705807|DRUG|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
214609262|NCT04345770|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
214609263|NCT04345770|DRUG|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
214609264|NCT04345770|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
214609265|NCT00995475|DRUG|Fluticasone propionate|
214609266|NCT00995475|DRUG|Placebo|
214609267|NCT03061175|OTHER|Internet-Based Intervention|Receive web-based CPM-DA
214609268|NCT03061175|OTHER|Survey Administration|Ancillary studies
214609269|NCT01655420|PROCEDURE|LASIK|Laser eye surgery
214609270|NCT02613845|OTHER|no intervention|
214722320|NCT01230918|RADIATION|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
214609271|NCT01713270|PROCEDURE|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
214609272|NCT01713270|DRUG|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
214609273|NCT01713270|PROCEDURE|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
214609274|NCT05151120|BIOLOGICAL|blood sample|In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
214609275|NCT06057584|BEHAVIORAL|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
214609276|NCT06057584|BEHAVIORAL|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
214609277|NCT06057584|BEHAVIORAL|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
214609278|NCT05755295|OTHER|horse therapy|equitherapy and hippotherapy once a week during 16 weeks
214609279|NCT04173884|OTHER|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
214609280|NCT04173884|OTHER|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
214609281|NCT02243865|DEVICE|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
214609282|NCT02243865|DEVICE|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
214609283|NCT03854929|DRUG|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
214609284|NCT03854929|DRUG|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
214609285|NCT00474734|DEVICE|Intravascular ultrasound of the liver|
214609286|NCT02800070|BIOLOGICAL|Lentivirus Alpha-gal A transduced stem cells|
214609287|NCT00440479|DRUG|Bortezomib|dose as determined (observational study) by treating physician
214609288|NCT06491082|DRUG|Cisplatin, Carboplatin, Paclitaxel, Docetaxel|Solid cancer Patients receiving any one drug or in combination
214609289|NCT03197857|BEHAVIORAL|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
214609290|NCT03197857|BEHAVIORAL|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
214609291|NCT03197857|BEHAVIORAL|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
214609292|NCT03197857|BEHAVIORAL|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
214609293|NCT02018198|DIAGNOSTIC_TEST|FebriDx|Point of Care Host Immune Response Test
214609294|NCT03908320|OTHER|Menstrual Cycle Timing|Quit date is set to menstrual phase.
214609295|NCT03908320|OTHER|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
214609296|NCT03908320|DRUG|NRT Patch|NRT patch is provided
214609297|NCT03908320|BEHAVIORAL|Cessation Counseling|Cessation counseling is provided
214609298|NCT02431897|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
214609299|NCT02431897|DRUG|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
214609300|NCT00546299|DRUG|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
214609301|NCT00560742|PROCEDURE|Control|Coronary artery bypass grafting without bone marrow cells injection
214609302|NCT00560742|PROCEDURE|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
214609303|NCT00560742|PROCEDURE|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
214609304|NCT01758458|BIOLOGICAL|Aldesleukin|Given SC
214609305|NCT01758458|OTHER|Laboratory Biomarker Analysis|Correlative studies
214609306|NCT01758458|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
214609307|NCT01758458|RADIATION|Radiation Therapy|Undergo radiation therapy
214609308|NCT01758458|BIOLOGICAL|Recombinant Interferon Beta|Given intralesionally
214713830|NCT01596192|OTHER|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
214609309|NCT03044249|DRUG|MP-101|Capsules
214609310|NCT03044249|DRUG|Placebo|Capsules
214609311|NCT03527082|OTHER|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
214609312|NCT00515736|DRUG|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
214609313|NCT00515736|DRUG|Placebo|vehicle
214609314|NCT05380011|OTHER|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
214609315|NCT05380011|OTHER|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
214609316|NCT06373471|OTHER|Comprehensive geriatric assessment (CGA) and treatment|"CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include:~* Assessment of comorbidity and treatments~* Review of medications including potential adjustment~* Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue~* Objective examination including blood tests and electrocardiogram~* Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires~* Assessment of domestic conditions, including need for assistance~* Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required"
214609317|NCT00398671|DEVICE|Application of cool cap after primary successful CPR|
214609318|NCT02101021|DRUG|Momelotinib|Tablet (s) administered orally once or twice daily
214609319|NCT02101021|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
214609320|NCT02101021|DRUG|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
214609321|NCT02101021|DRUG|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
214609322|NCT01621542|BIOLOGICAL|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
214609323|NCT05296642|OTHER|Moderate Cycling|Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
214609324|NCT05296642|OTHER|Personalized Tourniquet System|An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
214609325|NCT02369107|OTHER|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
214609326|NCT02369107|OTHER|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
214609327|NCT03111485|DRUG|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
214609328|NCT03111485|DRUG|Placebo oral capsule|Capsule taken at bedtime
214609329|NCT00955279|DRUG|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
214609330|NCT00955279|DRUG|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
214609331|NCT00955279|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
214609332|NCT00279019|DRUG|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
214609333|NCT00279019|DRUG|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
214609334|NCT00279019|DRUG|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
214609335|NCT04533087|OTHER|No intervention|No intervention
214609336|NCT04057534|BEHAVIORAL|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
214609337|NCT04057534|BEHAVIORAL|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
214609338|NCT04057534|BEHAVIORAL|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
214609339|NCT04057534|BEHAVIORAL|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
214609340|NCT00110981|DEVICE|NB-UVB|Three times a week (TIW) for 12 weeks
214609341|NCT00110981|DRUG|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
214609342|NCT00110981|DRUG|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
214609343|NCT01166100|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
214609344|NCT02383095|BEHAVIORAL|Art therapy|
214609345|NCT02383095|BEHAVIORAL|metacognitive therapy|
214609346|NCT03078712|OTHER|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
214609347|NCT03078712|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
214609348|NCT03201913|DRUG|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
214609349|NCT05016206|DRUG|Danicopan|Danicopan tablets administered as a single oral dose.
214609350|NCT05016206|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo was administered as a single oral dose.
214609351|NCT05016206|DRUG|Danicopan-matching placebo|Danicopan-matching placebo was administered as a single oral dose.
214609352|NCT05016206|DRUG|Moxifloxacin|Moxifloxacin 400 mg was administered as a single tablet oral dose.
214609353|NCT03694613|OTHER|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
214609354|NCT02632721|DRUG|Decitabine|
214609355|NCT02632721|DRUG|BI 836858|
214609356|NCT02221349|DEVICE|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
214609357|NCT02221349|DRUG|Sodium fluoride paste|Toothpaste used by subject
214609358|NCT02221349|DRUG|Stannous fluoride paste|Toothpaste used by subject
214609359|NCT04207801|DRUG|AUR101|Inhibitor of RORγ
214609360|NCT04207801|DRUG|Matching Placebo|Drug-Placebo of AUR101 tablet
214609361|NCT05997433|PROCEDURE|7days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days
214609362|NCT05997433|PROCEDURE|14 days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days
214609363|NCT05380258|OTHER|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
214609364|NCT05380258|OTHER|chewing gum|Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
214609365|NCT00003784|DRUG|CHOP regimen|
214609366|NCT00003784|DRUG|cyclophosphamide|
214609367|NCT00003784|DRUG|doxorubicin hydrochloride|
214609368|NCT00003784|DRUG|prednisone|
214609369|NCT00003784|DRUG|vincristine sulfate|
214609370|NCT00003784|RADIATION|tositumomab and iodine I 131 tositumomab|
214609371|NCT02694770|BIOLOGICAL|Neihulizumab Treatment|Monoclonal antibody
214609372|NCT02694770|BIOLOGICAL|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
214609373|NCT00544648|DRUG|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
214609374|NCT00544648|DRUG|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
214609375|NCT00544648|RADIATION|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
214609376|NCT05950295|OTHER|Intranasal lavage with hypochlorous acid solution|intranasal lavage for ten days
214609377|NCT02663271|DRUG|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
214609378|NCT02663271|DEVICE|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
214609379|NCT02663271|OTHER|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
214609380|NCT02663271|OTHER|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
214609381|NCT05788744|DIAGNOSTIC_TEST|ctDNA|ctDNA guided surveillance
214609382|NCT05529849|DRUG|TCMCB07|Subcutaneous injection of TCMCB07
214609383|NCT05529849|DRUG|Placebo|Matching subcutaneous placebo
214609384|NCT01235793|DRUG|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
214609385|NCT05798130|OTHER|No intervention group.|No intervention group.
214609386|NCT00175214|BEHAVIORAL|Multifaceted intervention (patient education, physician guidelines, reminders)|
214609387|NCT04204187|BEHAVIORAL|service learning|service learning for university students
214722321|NCT02792660|DEVICE|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
214609388|NCT00053703|DRUG|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
214609389|NCT00053703|DRUG|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
214609390|NCT00053703|DRUG|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
214609391|NCT01931787|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214609392|NCT05744570|PROCEDURE|Epidural anesthesia|Regional anesthesia for labor pain
214609393|NCT03277326|PROCEDURE|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
214609394|NCT03277326|PROCEDURE|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
214609395|NCT03277326|PROCEDURE|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
214609396|NCT01947452|BEHAVIORAL|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
214722322|NCT03193450|BEHAVIORAL|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
214722323|NCT03193450|BEHAVIORAL|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
214609397|NCT01947452|BEHAVIORAL|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
214609398|NCT01172405|DRUG|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
214609399|NCT01172405|DRUG|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
214722324|NCT01122888|DRUG|Cilengitide|Given IV
214722325|NCT01122888|OTHER|Clinical Observation|Patients undergo a 2-week rest period
214609400|NCT03308409|OTHER|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
214609401|NCT05133401|DEVICE|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
214609402|NCT03718663|OTHER|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
214609403|NCT03718663|OTHER|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
214609404|NCT03602274|DIAGNOSTIC_TEST|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
214609405|NCT03602274|DIAGNOSTIC_TEST|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
214609406|NCT03602274|OTHER|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
214609407|NCT03689647|DEVICE|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
214609408|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
214609409|NCT04993833|DEVICE|NPi-200 and NPi-300 pupillometers|Device which measures PLR.
214609410|NCT03698890|DEVICE|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
214609411|NCT04771585|OTHER|Community Mask|Fabric mask, no medical device
214609412|NCT04771585|OTHER|Surgical Mask|Medical face mask (personal protective equipment), CE-certified
214609413|NCT04771585|OTHER|FFP2 respirator|Filtering Face Piece with no less than 94% filtering capacity, CE-certified
214609414|NCT04771585|OTHER|FFP3 respirator|Filtering Face Piece with no less than 99% filtering capacity, CE-certified
214609415|NCT00267709|DRUG|Visilizumab|
214609416|NCT02209337|DEVICE|SRS|
214722326|NCT01122888|OTHER|Laboratory Biomarker Analysis|Correlative studies
214609417|NCT04166383|BIOLOGICAL|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
214609418|NCT04166383|DRUG|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
214609419|NCT04787250|BIOLOGICAL|Phage Therapy|Phage will be administered based on patient's matching results.
214609420|NCT04787250|PROCEDURE|Two-Stage Exchange Arthroplasty|Performed per the study center's standard of care. No investigational products are used.
214609421|NCT05192538|DEVICE|Endoscopic endoloop pre-test treatment|A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
214609422|NCT00460551|BIOLOGICAL|Zalutumumab|8 mg/kg
214609423|NCT00460551|DRUG|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
214609424|NCT00460551|RADIATION|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
214609425|NCT02870413|BEHAVIORAL|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
214609426|NCT00253188|DRUG|galantamine hydrobromide|
214609427|NCT00680563|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
214609428|NCT04997928|OTHER|Serum PAI-1 alpha analysis.|After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
214609429|NCT01543386|DRUG|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
214609430|NCT03044886|DIETARY_SUPPLEMENT|vitamin D|Subjects took vitamin D or placebo
214609431|NCT00576433|DRUG|Methotrexate|As prescribed
214609432|NCT00576433|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214609433|NCT04001907|BEHAVIORAL|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
214609434|NCT04001907|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate|
214609435|NCT04001907|DIETARY_SUPPLEMENT|placebo|
214609436|NCT03626584|OTHER|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
214609437|NCT03725163|BEHAVIORAL|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
214609438|NCT05169216|BEHAVIORAL|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided."
214609439|NCT02921269|DRUG|Atezolizumab|Given IV
214609440|NCT02921269|BIOLOGICAL|Bevacizumab|Given IV
214609441|NCT02921269|OTHER|Laboratory Biomarker Analysis|Correlative studies
214722327|NCT01519349|BIOLOGICAL|rAAV1.CMV.huFollistatin344|"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
214722328|NCT01917552|DRUG|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
214609442|NCT05927922|DRUG|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
214609443|NCT00683566|PROCEDURE|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
214722329|NCT02463318|DRUG|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
214722330|NCT02463318|OTHER|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
214722331|NCT01152411|OTHER|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
214609444|NCT04702282|DIAGNOSTIC_TEST|ropivacain concentration measurements|Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
214609445|NCT06249724|DEVICE|Active stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused low-intensity ultrasound stimulation
214609446|NCT06249724|DEVICE|Sham stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused zero-intensity ultrasound stimulation
214609447|NCT06207357|PROCEDURE|optical trocar to create the pneumoperitoneum for bariatric surgery|The technique involves the use of 4 12 mm trocars. Pneumoperitoneum is induced by a 0° optical trocar and maintained at 15 mmHg. The first trocar is usually inserted along the left mid-clavicular line approximately 2 fingers from the costal arch, another trocar along the left axillary line, a third trocar 1 cm to the right of the midline, and the fourth trocar along the right mid-clavicular line. A 10 mm, 30 ° laparoscope is used.
214609448|NCT02494466|DRUG|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
214609449|NCT01995578|DRUG|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
214609450|NCT00703053|BIOLOGICAL|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
214609451|NCT00703053|BIOLOGICAL|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
214609452|NCT02054325|DRUG|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
214609453|NCT02054325|DRUG|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
214609454|NCT00935545|BIOLOGICAL|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
214609455|NCT00984035|OTHER|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
214609456|NCT00984035|OTHER|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
214609457|NCT00984035|OTHER|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
214609458|NCT00004912|DRUG|megestrol acetate|
214722332|NCT00606177|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
214722333|NCT00606177|DRUG|placebo|oral, 0mg(4tablets)/day
214609459|NCT00004912|PROCEDURE|physical therapy|
214609460|NCT01039025|DRUG|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.
214609461|NCT01039025|DRUG|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
214609462|NCT01039025|DRUG|Melphalan|After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.
214609463|NCT01039025|OTHER|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
214609464|NCT01557933|OTHER|No interventions will be used|No interventions will be used
214609465|NCT04697121|DIETARY_SUPPLEMENT|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
214609466|NCT04697121|COMBINATION_PRODUCT|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
214609467|NCT00378235|DRUG|IL13-PE38QQR|
214609468|NCT05216757|DRUG|Iguratimod|iguratimod, 25mg bid po.
214609469|NCT05216757|DRUG|placebo|placebo 1 tablet bid po.
214609470|NCT03575286|DIAGNOSTIC_TEST|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
214609471|NCT04535180|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
214609472|NCT06174051|BEHAVIORAL|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
214722334|NCT06396988|OTHER|Novamin application|Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
214722335|NCT06396988|OTHER|Parodontax application|Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
214722336|NCT05722977|DRUG|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
214609473|NCT06174051|BEHAVIORAL|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
214609474|NCT03020238|PROCEDURE|BiClamp group|electric energy
214609475|NCT03020238|PROCEDURE|water jet group|water jet energy
214609476|NCT03247426|OTHER|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
214609477|NCT00822354|DRUG|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
214609478|NCT02407522|DIETARY_SUPPLEMENT|Black rice|They asked to keep their normal life style during intervention
214609479|NCT02407522|OTHER|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
214609480|NCT00594321|DEVICE|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
214609481|NCT00594321|DEVICE|standard vertebroplasty|standard vertebroplasty
214609482|NCT04563000|DRUG|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
214609483|NCT04563000|DRUG|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
214609484|NCT02629471|BEHAVIORAL|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
214609485|NCT05356468|OTHER|Structured pain neuroscience education|"Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT"
214609486|NCT05356468|OTHER|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)"
214609487|NCT06427291|BIOLOGICAL|Herpes virus T3011 injection|T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
214609488|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
214609489|NCT00982007|DRUG|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
214609490|NCT00982007|DRUG|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
214609491|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
214609492|NCT00504153|DRUG|dasatinib|
214609493|NCT00504153|OTHER|laboratory biomarker analysis|Correlative studies
214609494|NCT03445260|OTHER|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
214609495|NCT03445260|OTHER|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
214722337|NCT03571113|OTHER|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
214722338|NCT05872698|DRUG|Carvedilol|Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
214722339|NCT05872698|DRUG|Placebo|Placebo
214722340|NCT04878289|BEHAVIORAL|TOTAL with Motivational Telemedicine Sessions|Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
214609496|NCT00407654|DRUG|aflibercept|Given intravenously
214609497|NCT00074581|DRUG|Atazanavir|300 mg taken orally once daily
214609498|NCT00074581|DRUG|Didanosine|400 mg taken orally once daily
214609499|NCT00074581|DRUG|Efavirenz|600 mg taken orally once daily
214609500|NCT00074581|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
214609501|NCT00074581|DRUG|Lamivudine|300 mg taken orally once daily
214609502|NCT00074581|DRUG|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
214609503|NCT00074581|DRUG|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
214609504|NCT00074581|DRUG|Stavudine|Dosage depends on weight
214609505|NCT00074581|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally once daily
214609506|NCT00074581|DRUG|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
214609507|NCT02926469|DEVICE|Virtual Reality|Using Virtual Reality during labor
214609508|NCT00108992|DRUG|Diclofenac, topical|
214609509|NCT00002355|DRUG|Fomivirsen sodium|
214609510|NCT00348062|DRUG|Bimatoprost|
214609511|NCT04733781|DRUG|Tumescent Lidocaine and Epinephrine|Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
214609512|NCT04411953|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
214609513|NCT04411953|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
214609514|NCT04087954|BEHAVIORAL|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
214609515|NCT02794077|DRUG|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
214609516|NCT02322229|DRUG|Ocriplasmin 0.125 mg in a 0.1 mL volume|
214609517|NCT01859468|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|
214609518|NCT01859468|OTHER|Placebo|
214609519|NCT03613662|DRUG|SP-102|Injection
214609520|NCT02838095|BEHAVIORAL|Nap|A 1-hour daytime nap opportunity
214609521|NCT05459285|BIOLOGICAL|14028 injection|14028 injection, single dose, s.c. injection
214609522|NCT05459285|BIOLOGICAL|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
214609523|NCT00115791|DRUG|RSD1235|IV
214609524|NCT00115791|DRUG|placebo|IV
214609525|NCT00617604|DRUG|Alefacept|IV and subcutaneous injection
214609526|NCT00617604|DRUG|placebo|IV and subcutaneous injection
214609527|NCT00617604|DRUG|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
214609528|NCT00617604|DRUG|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
214609529|NCT00617604|DRUG|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
214609530|NCT03250832|DRUG|TSR-033|TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
214609531|NCT03250832|DRUG|Dostarlimab|Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
214609532|NCT03250832|DRUG|mFOLFOX6|mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
214609533|NCT03250832|DRUG|FOLFIRI|FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
214609534|NCT03250832|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
214609535|NCT02303704|PROCEDURE|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
214609536|NCT02303704|PROCEDURE|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
214609537|NCT03410836|DRUG|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
214609538|NCT03410836|OTHER|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
214609539|NCT02176187|DRUG|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
214609540|NCT02176187|DRUG|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
214609541|NCT02862405|OTHER|vision tests|
214722341|NCT00136357|BEHAVIORAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
214722342|NCT03405974|DRUG|Aspirin|Aspirin (acetylsalicylic acid)
214609542|NCT05880017|PROCEDURE|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
214609543|NCT05880017|PROCEDURE|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
214609544|NCT05880017|DRUG|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
214609545|NCT05880017|DRUG|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
214609546|NCT05629429|DRUG|Olaparib|Olaparib 300mg BID PO
214609547|NCT05629429|DRUG|Chemotherapy drug|Continue platinum based chemotherapy
214609548|NCT05355779|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
214609549|NCT03407651|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
214609550|NCT01518283|DRUG|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
214609551|NCT03142438|DEVICE|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
214609552|NCT00154336|DRUG|Imatinib|
214609553|NCT00154336|DRUG|Methotrexate|
214609554|NCT00154336|DRUG|Imatinib Placebo|
214609555|NCT06306079|DEVICE|Lateral Wedge insole|Insoles with lateral wedges are placed in patients' shoes to control biomechanical knee loading on the medial side of the knee. Insoles with lateral wedges are designed to be thinner on the inside (medially of the foot) and thicker on the outside (laterally of the foot) to relieve knee biomechanical loading parameters.
214609556|NCT00705432|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
214609557|NCT00705432|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
214609558|NCT00705432|DRUG|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
214609559|NCT00705432|DRUG|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
214609560|NCT04181944|OTHER|Exercise Treatment Group|be specific
214609561|NCT05955404|OTHER|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
214609562|NCT00355979|DEVICE|intragastric balloon|
214609563|NCT01512563|DEVICE|Biliary stent|palliative treatment for malignant patients
214609564|NCT04411628|DRUG|LY3819253|Administered IV.
214609565|NCT04411628|DRUG|Placebo|Administered IV.
214609566|NCT01372722|DEVICE|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
214609567|NCT01372722|DEVICE|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
214609568|NCT02827240|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
214609569|NCT00598260|PROCEDURE|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
214609570|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.
214722343|NCT03405974|DRUG|Placebo|Placebo
214609571|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with only physiological saline|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
214609572|NCT00521053|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
214609573|NCT00732251|DRUG|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
214609574|NCT06328998|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
214609575|NCT06328998|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
214609576|NCT06328998|DRUG|Lidocaine Hydrochloride|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
214609577|NCT01034540|DRUG|POM3|4 g/day
214609578|NCT01034540|DRUG|Placebo|matching placebo capsule, 4 g/day
214609579|NCT04286425|OTHER|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
214609580|NCT04286425|OTHER|saline solution|saline solution
214609581|NCT04243603|BEHAVIORAL|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
214609582|NCT03511404|OTHER|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
214609583|NCT00351416|DRUG|Letrozole|Letrozole 20 mg orally one time
214609584|NCT00351416|DRUG|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
214609585|NCT05096351|OTHER|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
214609586|NCT00143481|DRUG|Tolterodine ER 4mg QD|
214609587|NCT03772470|OTHER|1X airtime incentive|An incentive given in the form of airtime
214609588|NCT03772470|OTHER|2X airtime incentive|An incentive given in the form of airtime
214609589|NCT03772470|OTHER|Lottery airtime incentive|An incentive given in the form of airtime
214609590|NCT02803853|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
214609591|NCT03519867|DRUG|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
214609592|NCT03519867|DRUG|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
214609593|NCT06083831|OTHER|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
214609594|NCT05419401|DRUG|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
214609595|NCT05419401|DRUG|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
214609596|NCT01252810|DRUG|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
214609597|NCT05551767|DRUG|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
214609598|NCT02885194|OTHER|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
214609599|NCT02447692|OTHER|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
214609600|NCT02447692|OTHER|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
214609601|NCT02347488|DEVICE|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
214609602|NCT02347488|PROCEDURE|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
214609603|NCT02693522|DRUG|somatropin|Subcutaneous injection
214609604|NCT02693522|DRUG|Eutropin|Subcutaneous injection
214609605|NCT05723354|PROCEDURE|axillary block guided by ultrasound|axillary block using local anesthetics
214609606|NCT04796922|DRUG|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
214609607|NCT04796922|DRUG|rituximab|rituximab will be administered intravenously on select days as per protocol.
214609608|NCT04796922|DRUG|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
214609609|NCT01347775|DEVICE|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
214609610|NCT01347775|DEVICE|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
214609611|NCT04468620|BEHAVIORAL|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
214609612|NCT01367353|PROCEDURE|surgery or debulking surgery|surgery or debulking surgery
214609613|NCT05666037|BEHAVIORAL|Mobile health intervention(mHealth)|The intervention group will receive mobile health messaging intervention on behavior change to uptake early postpartum modern contraceptive method.
214609614|NCT04379921|DEVICE|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
214609615|NCT06970496|DRUG|B019|B019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg
214609616|NCT00667823|DRUG|Macitentan|Tablet, oral administration, 10 mg dose once daily
214609617|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
214609618|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
214609619|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
214609620|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
214609621|NCT02575404|DRUG|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
214609622|NCT02575404|DRUG|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
214609623|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
214609624|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
214609625|NCT07129538|OTHER|inspiratory muscle retraining|Familial mediterranean fever (FMF adolescents ) will be inspiratory muscle retraining group (IMR group) that will contain 20 FMF adolescents. IMR group will receive two IMR sessions daily, five times weekly, for eight weeks (every IMR session will contain 3 sets of IMR and the set will contain 10 breath cycles).. this group will receive their prescribed colchicine medications daily
214609626|NCT07129538|OTHER|colchicine only|Familial mediterranean fever (FMF adolescents ) will be collected in this group OF FMF that will contain 20 FMF adolescents. this group will receive their prescribed colchicine medications daily for eight weeks
214609627|NCT07130643|DRUG|CDK4/6 inhibitors+Endocrine Therapy|CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib
214609628|NCT05733273|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
214609629|NCT05733273|OTHER|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
214609630|NCT05733273|OTHER|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
214609631|NCT06736613|DIAGNOSTIC_TEST|Cerebral Spinal Fluid ctDNA|MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
214609632|NCT05228067|DEVICE|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
214609633|NCT05228067|DEVICE|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
214609634|NCT05228067|DEVICE|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
214609635|NCT06487832|OTHER|Subcutaneous GLP1-RA|Subcutaneous administration of semaglutide
214609636|NCT06487832|OTHER|Subcutaneous placebo|Subcutaneous administration of NaCl
214722344|NCT00763178|DRUG|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
214722345|NCT01799161|BIOLOGICAL|gp96-Ig Vaccine|
214722346|NCT01799161|DRUG|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
214722347|NCT01799161|OTHER|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
214609637|NCT06773169|OTHER|IAMABLE web-based app|The Intervention Group will use the IAMABLE app for 4 months. IAMABLE users identify activities that they are having difficulty with because of their health problem and set goals they want to work toward. Self-management (SM) modules help them reach their goals, providing information and rehabilitation strategies about exercise, fall prevention, fatigue management, pain management, physical activity, and stress management. Users complete a self-assessment associated with each module, and receive tailored recommendations that guide them to access relevant module topics. Users create 7-day action plans using the strategies in the module to address their activity goals. Users receive automated notifications when it is time to evaluate action plans and activity goals, as well as weekly messages to remind them to engage with the app. Users have access to therapist support using the Ask a Therapist feature and receive individual consultations in response to queries about SM.
214609638|NCT06773169|OTHER|General health information|The Control Group will receive a monthly email with general health information (not specific to rehabilitation or chronic diseases) for 4 months. Topics will include Nutrition, Vision Care, Foot Care, Hearing, Skin Care and Oral Care. Each email will include an introduction to the topic and links for additional information.
214609639|NCT07130318|BEHAVIORAL|exercise plus diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)
214609640|NCT07130318|BEHAVIORAL|diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.
214609641|NCT07130136|DEVICE|Cochlear™ Osia® System|The Osia System consists of the OSI300 Implant, Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, Osia 2 Sound Processor Magnet Tool, Osia Fitting Software 2 (OFS 2), and Osia Smart App.
214609642|NCT07130136|DEVICE|Cochlear™ Baha® System|The Baha Connect System consists of the BIA300 (BI300 Implant and BA300 Abutment), Baha 7 Sound Processor, and Baha Fitting Software 7 (BFS 7).
214609643|NCT07129720|BEHAVIORAL|Educational Program on MIH|"A 30-minute interactive educational session that includes a PowerPoint presentation, clinical images, and case-based discussions on Molar-Incisor Hypomineralization (MIH).~The session covers the definition, eatiology , clinical features, diagnosis and evidence-based treatment options of MIH.~The goal is to improve the participants' knowledge ,attitude and awareness . Evaluation will be conducted through pre- and post-intervention questionnaire."
214609644|NCT07129590|OTHER|Expired carbon monoxide (CO)|Expired CO will be measured using a non-investigational device
214609645|NCT07129590|OTHER|Interviews|Participants will be interviewed via video conference or in person
214609646|NCT07129590|OTHER|Questionnaires|Participants will receive questionnaires to complete through the course of the study
214609647|NCT07130864|PROCEDURE|Early cholecystectomy|Early cholecystectomy is performed within 72 hours of ERCP.
214609648|NCT07130864|PROCEDURE|Late cholecystectomy|Late cholecystectomy is performed after 72 hours of ERCP
214609649|NCT07128420|DEVICE|Application of 3 sessions of microneedle therapy|"Enrolled study participants will receive 3-4 treatments of microneedling to the affected area.~Study participants will microneedling (Fusion Tip Potenza Fractional Radiofrequency Microneedle Electrosurgical Unit, Jeisys Medical Inc, Seoul, KR) at a depth of 2.0 to 2.75mm."
214609650|NCT06771817|BEHAVIORAL|Written Exposure Therapy|WET may be an optimal treatment for pregnant or postpartum adolescents and youth with PTSD in a low resource setting. WET addresses many of the barriers above. It is delivered in just 5 sessions, with no homework, and may promote a sense of self-efficacy in adolescents and youth due to the nature of writing assignments and brief therapist involvement. It is attractive in resource-poor settings because just 10-15 min of direct therapist time per follow-up session is needed.
214609651|NCT05515861|PROCEDURE|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
214609652|NCT03045783|DRUG|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
214609653|NCT07083479|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 (10.0 mg) admixed with ELI-002 Amph-Peptides 7P (4.9 mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing).
214609654|NCT06902025|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 15 years.
214609655|NCT06902974|DRUG|Psilocybin 25 mg|Single dose, 25mg psilocybin, encapsulated, oral administration
214722348|NCT01799161|PROCEDURE|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response \[frequency of CD4+, FoxP3 (Treg), et al\] in treated patients.
214722349|NCT00415753|BEHAVIORAL|No antibiotics if se-procalcitonin is below stated limit|
214722350|NCT00675688|DRUG|Bazedoxifene/Conjugate Estrogens (CE)|
214722351|NCT00675688|DRUG|Raloxifene|
214722352|NCT00675688|DRUG|Placebo|
214609656|NCT06901804|DIAGNOSTIC_TEST|Experimental Group (training and stabilization)|"Plyometric Shoulder Training \[28\] and Pilates Core Stabilization \[27\]~Exercise 1-2 weeks (rep × kg) 3-4 weeks (rep × kg) 5-6 weeks (rep × kg) Throwing Movements Medicine ball chest pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball step and pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball side throw 8 × 1 kg 10 × 2 kg 12 × 3 kg Tubing Plyos IR/ER 8 × 10 10 × 10 12 × 12 Tubing Plyos Diagonal 8 × 10 10 × 10 12 × 12 Tubing Plyos Biceps 8 × 10 10 × 10 12 × 12 Plyo Push-ups (boxes) 8 × 10 10 × 10 12 × 12 Push-ups (clappers) 8 × 10 10 × 10 12 × 12"
214609657|NCT06901804|COMBINATION_PRODUCT|Control Group (physiotherapy and exercise)|Physiotherapy Care for Low Back Pain \[30\] Exercise Week 1-2 (Sets x Reps/Duration) Week 3-4 (Sets x Reps/Duration) Week 5-6 (Sets x Reps/Duration) Plank 3 x 20 sec 3 x 30 sec 4 x 45 sec Bicycle Crunches 3 x 12 3 x 15 4 x 20-25 Leg Raises 3 x 12 3 x 15 4 x 20-25 Russian Twists 3 x 20 3 x 25 4 x 30-35 Slump Exercise 3 x 10 3 x 12 4 x 15-18 Bridge Exercise with Swiss Ball 3 x 12 3 x 15 4 x 18
214609658|NCT06902649|BEHAVIORAL|Internet-based parenting support|An internet-based parent training program with 5 active modules and a final summarizing module, based on social learning theory/cognitive behavior therapy. All parents participate in this intervention (Step 1) before being randomized to the other three arms of the stepped care model in the randomized controlled trial (Step 2).
214609659|NCT06902649|BEHAVIORAL|"YourSkills for children/youth"|Cognitive behavioral therapy for children/youth with role-plays in virtual reality. A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
214609660|NCT06902649|BEHAVIORAL|Step-by-step parent support|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), including some sessions where virtual reality may be used for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality can be used as an additional way to practice skills.
214609661|NCT06902649|BEHAVIORAL|Intervention/support as usual and prolonged use of internet-based parenting support|Based on other available support, interventions, courses at the units. Parents have access to the internet-based parenting support provided in Step 1 (the first intervention of the study). After 10 weeks with intervention/support as usual, the parents are asked if they want to participate in the CBT-VR-intervention for children (YourSkills) or for parents (Step-by-Step parent support).
214609662|NCT06902467|DRUG|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrong 8 and modified by GEICO 18: IV paclitaxel 175 mg /m2 (day 1) + IP cisplatin 100 mg/m2 (day 2) + IP paclitaxel 60 mg/m2 (day 8).
214609663|NCT06901921|DIAGNOSTIC_TEST|PT-intervention|60 participants undergoing PT-intervention for about 3 months will be taken and questionnaire (KOOS-12) will be filled by them at regular intervals of baseline, 4, 8 and 12 weeks respectively while global rating of change questionnaire will be filled by them at start and end of intervention and these values will be compared to see if patients' condition has improved or not.
214713831|NCT02483065|OTHER|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
214713832|NCT02310360|RADIATION|Fallypride|
214713833|NCT00227968|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
214713834|NCT00227968|BEHAVIORAL|Clinical Status and Symptom Response Therapy (CSSRT)|
214713835|NCT01802268|DRUG|Conversion from Tacrolimus to Sirolimus|
214713836|NCT01802268|DRUG|Maintenance on tacrolimus|
214713837|NCT05498025|OTHER|Deterra activated charcoal pouch|drug disposal pouch
214713838|NCT03404219|BEHAVIORAL|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
214713839|NCT06067724|OTHER|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
214713840|NCT01736709|BIOLOGICAL|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
214713841|NCT01072240|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
214609664|NCT06902116|PROCEDURE|No Mechanical Bowel Preparation|In this group patients will not receive any mechanical bowel preparation prior to undergoing colostomy reversal.
214713842|NCT02880735|DEVICE|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
214713843|NCT01318421|DRUG|ELND002|
214713844|NCT02038790|DRUG|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
214713845|NCT02038790|DRUG|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
214722353|NCT01735097|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (200 mg, soft capsule)
214722354|NCT01735097|DIETARY_SUPPLEMENT|Nigella sativa|Nigella sativa (200 mg, soft capsule)
214609665|NCT06902116|PROCEDURE|Mechanical Bowel Preparation|In this group patients will receive 3 days mechanical bowel preparation prior to undergoing colostomy reversal.
214609666|NCT06901479|OTHER|Blood was drawn for proteomics testing and Magnetic Resonance Imaging.|The function of the glymphatic system was assessed by MRI before the surgery. Blood was drawn before the surgery. Delirium was assessed on postoperative days 1 to 5. Blood was drawn on the second day after surgery. The function of the glymphatic system was assessed again by MRI on the fifth day after surgery.
214609667|NCT06902623|RADIATION|Radiation|Radiation only to 66Gy
214609668|NCT06902038|DRUG|PD-1 inhibitor|100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2
214609669|NCT06902038|DRUG|Sidarbenamide|Sidarbenamide 10mg biw orally for 2 weeks
214609670|NCT06902038|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline 50ml Q3W ×2
214609671|NCT05469269|BEHAVIORAL|Passive Education|Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
214609672|NCT05469269|BEHAVIORAL|Education by Community Navigator|A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
214609673|NCT05469269|BEHAVIORAL|Education at Community Outreach Screening Event|The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
214609674|NCT06903156|DRUG|Mexidol|Neuroretinoprotector
214609675|NCT06903156|OTHER|Placebo|Placebo therapy
214609676|NCT03543098|PROCEDURE|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
214609677|NCT03543098|PROCEDURE|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
214609678|NCT03543098|PROCEDURE|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
214609679|NCT03543098|PROCEDURE|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
214609680|NCT06808932|DRUG|VK4-116|D3R antagonist
214609681|NCT06808932|DRUG|Placebo|Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.
214609682|NCT06902987|DRUG|Upadacitinib|Enrolled patients received oral upatinib treatment with a conventional induction dose of 45mg/d for 12 weeks, followed by a maintenance dose of 15m/d or 30mg/d
214609683|NCT06901791|DIETARY_SUPPLEMENT|Conventional treatment and Probiotic|Participants will continuously take Lactobacillus rhamnosus LRa05 from the time of enrollment until delivery.
214609684|NCT06902298|DEVICE|LTFUS to SCC|Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
214609685|NCT06902298|DEVICE|LTFUS to ALIC|Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule
214609686|NCT06902259|OTHER|randomised controlled trial|"Breathing exercise group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group.~Reiki group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group."
214609687|NCT06901661|BEHAVIORAL|Telerehabilitation|Exercise program include Warm-up, Targeted muscle Strengthening, Joint mobilization, and Proprioception
214609688|NCT06901661|BEHAVIORAL|Standard care|Education session on their pain, disability, and functional activities
214609689|NCT06903377|BIOLOGICAL|ZG005 for Injection|intravenous infusion
214609690|NCT06903377|DRUG|Gecacitinib Hydrochloride Tablets|Oral
214609691|NCT05124080|DRUG|Deucravacitinib|All participants will receive 6 mg of Deucravacitinib daily.
214609692|NCT06660342|DRUG|Vonoprazan|Oral tablet.
214713846|NCT06338813|DEVICE|Digital Manometry|"The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted."
214713847|NCT01089751|DRUG|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
214713848|NCT01089751|DRUG|placebo|Placebo once daily on an empty stomach for 14 weeks.
214713849|NCT03300258|DEVICE|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
214713850|NCT03300258|DEVICE|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
214713851|NCT03121066|DEVICE|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
214713852|NCT03121066|DEVICE|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
214713853|NCT01818986|DRUG|Sipuleucel-T|
214713854|NCT01818986|RADIATION|Stereotactic Ablative Body Radiation|
214713855|NCT03487887|DEVICE|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
214713856|NCT00250081|PROCEDURE|Upper Extremity Tendon transfer|
214713857|NCT00250081|PROCEDURE|Botulinum Toxin injections in Upper Extremity|
214713858|NCT00250081|PROCEDURE|Regularly ongoing therapy|
214713859|NCT02942706|DRUG|Cetuximab|anti-EGFR monoclonal antibody
214713860|NCT02942706|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
214609693|NCT06618807|DEVICE|Active tPBM device|The Neuro RX Gamma (version 2) delivers a synchronized pulse frequency of 40 Hz from all LED clusters. The gamma pulse frequency of 40 Hz has been demonstrated to attenuate amyloid beta proteins production in the hippocampus and modulate microglial activity resulting in increased scavenging of amyloid beta which may lead to improving cognition in MCI. Finally, the Vielight Neuro RX Gamma (version 2) has been designed to target the delivery of NIR energy to particular brain regions; specifically the default mode network (DMN). The active intervention device proceeds to deliver light to each LED at 40 Hz with a 50% duty cycle for 20 minutes and stops automatically. During the 20 minute treatment the power indicator LED on the controller flashes green at 40 Hz. The operator is notified that the treatment is finished when the power indicator LED on the controller stops flashing and the device beeps 2 times.
214609694|NCT06618807|DEVICE|Sham device|The sham device delivers infrared light for only a few seconds before stopping. The controller will still show a green light to maintain the study\&#39;s blinding. If the headset is removed, the device will emit a beep and cease functioning.
214713861|NCT02942706|DRUG|FOLFIRI|Irinotecan+LV5FU2
214609695|NCT00537498|DRUG|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l"
214609696|NCT01839253|DRUG|b-blocker(Atenolol)|
214609697|NCT01839253|DRUG|ACE inhibitor(Enapril)|
214609698|NCT01839253|OTHER|control|
214609699|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
214609700|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
214609701|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
214609702|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
214609703|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
214609704|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
214713862|NCT01027104|OTHER|Education|Firearm injury prevention anticipatory guidance curriculum
214713863|NCT01726816|DRUG|Probucol 250mg/day|Probucol 250mg + Placebo
214609705|NCT04266756|DRUG|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
214609706|NCT04266756|DRUG|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
214713864|NCT01726816|DRUG|Probucol 500mg/day|Probucol 500mg + Placebo
214713865|NCT01726816|DRUG|Placebo|Probucol matching placebo
214713866|NCT02031198|DRUG|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
214713867|NCT00690417|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
214713868|NCT03949543|OTHER|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
214713869|NCT03949543|OTHER|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
214713870|NCT00438464|DRUG|Finasteride|Given PO
214713871|NCT00438464|OTHER|Placebo|Given PO
214713872|NCT00438464|PROCEDURE|Prostatectomy|Undergo prostatectomy
214713873|NCT00438464|OTHER|Laboratory biomarker analysis|Correlative studies
214713874|NCT03822702|OTHER|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
214609707|NCT04266756|DRUG|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
214609708|NCT01932242|BIOLOGICAL|ETI-204|Monoclonal Antibody
214609709|NCT01932242|OTHER|Placebo|Placebo for ETI-204
214609710|NCT01715220|DRUG|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
214609711|NCT01085552|DRUG|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
214609712|NCT00399789|DRUG|Perifosine|Perifosine will be tested in 3 dose forms
214609713|NCT05162027|DRUG|Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
214609714|NCT05162027|DRUG|Placebo|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
214609715|NCT04284202|DRUG|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
214609716|NCT02036632|DEVICE|Eye Patching|
214713875|NCT03822702|OTHER|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
214713876|NCT03537092|DEVICE|Vaginal Film|"2 x 2 vaginal film with no active drug"
214713877|NCT03057912|BIOLOGICAL|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
214713878|NCT03057912|BIOLOGICAL|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
214609717|NCT00452049|PROCEDURE|parathyroidectomy|parathyroidectomy
214713879|NCT03943446|DRUG|TAK-018|TAK-018 immediate-release tablets.
214713880|NCT03943446|DRUG|TAK-018 Placebo|TAK-018 placebo-matching tablets.
214713881|NCT03055572|OTHER|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
214713882|NCT03055572|OTHER|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
214713883|NCT03214328|DIAGNOSTIC_TEST|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
214713884|NCT00392119|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
214713885|NCT01759160|PROCEDURE|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
214713886|NCT01759160|PROCEDURE|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
214713887|NCT05094076|RADIATION|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis \[ILO, 1980\]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
214609718|NCT06070077|PROCEDURE|Chest compressions|2 minutes of chest compressions
214609719|NCT06227364|DIAGNOSTIC_TEST|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
214713888|NCT05333003|DRUG|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
214713889|NCT05333003|OTHER|Placebo|Placebo will be provided to participants
214713890|NCT02394418|DRUG|Sevoflurane|Treatment of delirium by inhaled sevoflurane
214713891|NCT02394418|DRUG|Propofol|Treatment of delirium by propofol i.v. infusion
214713892|NCT02394418|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
214713893|NCT05325398|DIETARY_SUPPLEMENT|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
214713894|NCT05325398|DIETARY_SUPPLEMENT|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
214713895|NCT05970068|PROCEDURE|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
214713896|NCT05970068|DEVICE|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
214713897|NCT00716339|BEHAVIORAL|motivation|
214713898|NCT00640276|DRUG|pitavastatin|Pitavastatin 2mg daily once
214713899|NCT00640276|BEHAVIORAL|Lifestyle Modification|conducting mainly exercises and diet
214713900|NCT05745025|DEVICE|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
214713901|NCT05745025|DEVICE|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
214713902|NCT05745025|OTHER|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
214713903|NCT01943188|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214713904|NCT01943188|DRUG|cyclophosphamide|Given PO
214713905|NCT01943188|BIOLOGICAL|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
214713906|NCT01943188|OTHER|laboratory biomarker analysis|Correlative studies
214713907|NCT05309733|GENETIC|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
214713908|NCT00905268|DRUG|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
214713909|NCT00905268|DRUG|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
214713910|NCT06241820|PROCEDURE|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
214713911|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
214609720|NCT06227364|DIAGNOSTIC_TEST|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
214713912|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
214713913|NCT00013767|BEHAVIORAL|Individual and Community education|
214713914|NCT06166888|DRUG|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
214609721|NCT06289322|OTHER|Digital toolkit for assessment|The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
214609722|NCT04296877|DEVICE|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
214609723|NCT05331040|DIAGNOSTIC_TEST|MRI|Radiomic analysis of newly diagnosed rectal cancers
214609724|NCT03361150|PROCEDURE|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
214609725|NCT03361150|PROCEDURE|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
214609726|NCT03443505|DIAGNOSTIC_TEST|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
214609727|NCT06302647|OTHER|Questionnaires|Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment
214609728|NCT03868852|DRUG|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
214609729|NCT03868852|RADIATION|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
214609730|NCT00886704|DIETARY_SUPPLEMENT|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
214713915|NCT02905825|DEVICE|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
214713916|NCT02905825|DRUG|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
214713917|NCT02905825|DIAGNOSTIC_TEST|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
214713918|NCT03079557|DRUG|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
214713919|NCT03714347|DEVICE|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
214713920|NCT03714347|DEVICE|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
214713921|NCT03507192|DEVICE|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
214713922|NCT05710770|DEVICE|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
214609731|NCT00886704|DIETARY_SUPPLEMENT|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
214609732|NCT01129050|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
214609733|NCT01129050|DIETARY_SUPPLEMENT|Flaxseed Oil|Flaxseed oil capsule
214713923|NCT00422123|DRUG|Quetiapine fumarate (Seroquel) SR|
214713924|NCT01281189|DRUG|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
214713925|NCT01281189|DRUG|Placebo|Oral tablet twice daily for up to 18 months.
214609734|NCT01129050|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule
214609735|NCT04183816|OTHER|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
214609736|NCT04183816|OTHER|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
214609737|NCT03846570|DRUG|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
214609738|NCT03846570|DRUG|Placebo|Matching placebo (identically package) administered BID
214609739|NCT02767323|DEVICE|rTMS|excitatory 5Hz rTMS will be used
214713926|NCT02356328|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
214713927|NCT05355818|DRUG|Delgocitinib|Cream for topical application
214713928|NCT05355818|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
214713929|NCT05848973|OTHER|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
214609740|NCT02767323|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
214609741|NCT05341648|OTHER|Aerobic Exercise Training|Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
214609742|NCT05341648|OTHER|Home Plan|"* Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks."
214609743|NCT01865526|DIETARY_SUPPLEMENT|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
214722355|NCT01735097|DIETARY_SUPPLEMENT|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
214609744|NCT01865526|DIETARY_SUPPLEMENT|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
214609745|NCT05558826|DEVICE|HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software|After induction of anesthesia, intra-arterial catheterization will be done for invasive blood pressure monitoring and blood sampling as routine clinical practice for major laparoscopic surgery. Arterial line will be connected to HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software for arterial pressure waveform analysis. Dynamic indices including pulse pressure variation (PPV), stroke volume variation (SVV), Hypotension Prediction Index (HPI), Dynamic arterial elastance (Eadyn) and dP/dt will be continuously recorded. Changes in levels of intra-abdominal pressure and angles of Trendelenburg position will be recorded. Data analysis and statistics will be particularly performed to explore the effects of levels of intra-abdominal pressure and angles of Trendelenburg position on dynamic indices of arterial pressure waveform.
214609746|NCT05957250|DIAGNOSTIC_TEST|[68Ga]Ga-FAPI-46 PET/CT|one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
214609747|NCT00745199|DRUG|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
214609748|NCT00745199|DRUG|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
214609749|NCT02895620|BIOLOGICAL|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
214609750|NCT01847430|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
214713930|NCT05848973|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
214609751|NCT01686776|OTHER|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
214713931|NCT03543527|OTHER|no intervention|no intervention
214609752|NCT01104038|BEHAVIORAL|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
214609753|NCT01104038|BEHAVIORAL|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
214609754|NCT01104038|BEHAVIORAL|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
214609755|NCT05362422|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
214609756|NCT05362422|DEVICE|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
214609757|NCT04553848|BEHAVIORAL|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
214609758|NCT04553848|BEHAVIORAL|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
214609759|NCT04553848|BEHAVIORAL|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait"
214609760|NCT06396585|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
214609761|NCT06396585|DRUG|Anlotinib|Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
214609762|NCT06396585|DRUG|Oxaliplatin|Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
214609763|NCT06396585|DRUG|Tegafur|Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
214609764|NCT00633711|DEVICE|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
214609765|NCT00633711|DEVICE|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
214609766|NCT01375842|DRUG|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
214609767|NCT00542464|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
214609768|NCT05326945|OTHER|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
214609769|NCT03886753|OTHER|Registry|Collect data on subjects
214609770|NCT03886753|OTHER|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
214609771|NCT00388505|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
214713932|NCT01375738|PROCEDURE|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
214609772|NCT00388505|DRUG|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
214609773|NCT03449498|OTHER|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
214609774|NCT03449498|OTHER|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
214713933|NCT01375738|PROCEDURE|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
214713934|NCT02883920|OTHER|Allergy and respiratory functional tests|
214713935|NCT00274066|DRUG|Tiotropium + placebo|
214713936|NCT00274066|DRUG|Tiotropium + ipratropium|
214713937|NCT00274066|DRUG|Tiotropium + fenoterol|
214713938|NCT03245710|OTHER|Placebos|starch
214713939|NCT03245710|DIETARY_SUPPLEMENT|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
214713940|NCT02228772|DRUG|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
214713941|NCT02228772|DRUG|Vincristine|Standard chemotherapy dosage and duration
214713942|NCT02228772|DRUG|Cytarabine|Standard chemotherapy dosage and duration
214609775|NCT03339388|DEVICE|Enhanced Lithotripsy System|Stone treatment with the Enhanced Lithotripsy System
214713943|NCT02228772|DRUG|Doxorubicin|Standard chemotherapy dosage and duration
214713944|NCT02228772|DRUG|Mercaptopurine|Standard chemotherapy dosage and duration
214713945|NCT02228772|DRUG|Cyclophosphamide|Standard chemotherapy dosage and duration
214713946|NCT02228772|DRUG|Methotrexate|Standard chemotherapy dosage and duration
214713947|NCT05215678|OTHER|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
214713948|NCT05215678|OTHER|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
214722356|NCT04316286|PROCEDURE|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
214722357|NCT04316286|OTHER|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
214609776|NCT00094692|DEVICE|Eye patch|
214609777|NCT00094692|DEVICE|spectacles|
214609778|NCT00094692|DRUG|atropine|
214609779|NCT05831748|OTHER|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
214609780|NCT05831748|OTHER|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
214609781|NCT02982369|OTHER|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
214609782|NCT02982369|OTHER|Pain Education|Subjects will receive pain education based in biopsychosocial approach
214609783|NCT02982369|OTHER|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
214609784|NCT01187966|DRUG|Safinamide|
214609785|NCT01187966|DRUG|Safinamide|
214609786|NCT01187966|DRUG|Placebo|
214609787|NCT05287971|BEHAVIORAL|Lifestyle advice|Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.
214609788|NCT04449770|DEVICE|double lumen tube|prospective cohort study
214609789|NCT01471314|BEHAVIORAL|Headache day versus non-headache day|
214609790|NCT03094351|PROCEDURE|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
214609791|NCT03094351|PROCEDURE|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
214609792|NCT05503784|OTHER|BITE Deodorant|BITE natural Deodorant
214609793|NCT04311697|DRUG|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
214609794|NCT04311697|DRUG|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
214609795|NCT04782284|OTHER|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
214609796|NCT04782284|OTHER|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
214609797|NCT04465448|OTHER|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
214609798|NCT00064220|DRUG|soblidotin|
214609799|NCT04739267|DEVICE|CardioFlux|Not an intervention
214609800|NCT04195048|OTHER|Risk factors|Risk factors: modifiable and unmodifiable risk factors
214609801|NCT03055754|PROCEDURE|Argon randomized arm|Endoscopic argon plasma coagulation
214609802|NCT03055754|PROCEDURE|Control arm|No Endoscopic procedure
214609803|NCT05444842|OTHER|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor\_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
214609804|NCT05444842|OTHER|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
214609805|NCT05444842|OTHER|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
214609806|NCT04625842|OTHER|Focus group interview|Group interview with patients who received radiation treatment
214609807|NCT06041399|DRUG|hypoglycemic Agents(metformin)|patients treated with hypoglycemic Agents(metformin)
214609808|NCT06041399|DRUG|lipid-lowering drug(Statin)|patients treated with lipid-lowering drug(Statin)
214609809|NCT06046222|DRUG|NS-229|Experimental
214609810|NCT06046222|DRUG|Placebo|Placebo comparator
214609811|NCT05002569|BIOLOGICAL|Nivolumab|Specified dose on specified days
214609812|NCT05002569|BIOLOGICAL|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
214609813|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
214609814|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
214609815|NCT05546164|OTHER|Assessment of hand grip strength|Assessment of hand grip strength
214609816|NCT05546164|OTHER|Assessment of pinch strength|Assessment of pinch strength
214609817|NCT05546164|OTHER|Assessment of upper limb dexterity|Assessment of upper limb dexterity
214609818|NCT02424942|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
214609819|NCT02424942|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
214609820|NCT05224908|DEVICE|EOS|pelvimetry by EOS in standing and sitting position
214609821|NCT05321914|BEHAVIORAL|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
214609822|NCT01480284|DRUG|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
214609823|NCT01480284|DRUG|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
214609824|NCT01641237|DRUG|sodium fluoride|fluoride as sodium fluoride
214609825|NCT01641237|DRUG|no added fluoride in a silica base|no added fluoride
214609826|NCT00709111|DRUG|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
214609827|NCT02716675|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
214609828|NCT02716675|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
214609829|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
214609830|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214713949|NCT05256316|OTHER|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
214713950|NCT01589263|DRUG|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
214713951|NCT01589263|DRUG|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
214713952|NCT01135745|DEVICE|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
214713953|NCT02100202|OTHER|Placebo|
214713954|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
214609831|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214609832|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214609833|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
214609834|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214609835|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214609836|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
214609837|NCT01301456|BIOLOGICAL|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
214609838|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
214609839|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
214609840|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
214609841|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
214609842|NCT05704686|DEVICE|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
214609843|NCT03138187|BEHAVIORAL|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
214713955|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
214713956|NCT02100202|DIETARY_SUPPLEMENT|MaQxan (Tagetes erecta flower extract)|
214713957|NCT03498092|DRUG|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
214713958|NCT03498092|DRUG|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
214713959|NCT03498092|DRUG|General anesthesia|Normal saline in a volume of 0.5 ml/kg
214609844|NCT03138187|BEHAVIORAL|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
214609845|NCT04442191|BIOLOGICAL|Convalescent plasma|This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
214609846|NCT04442191|BIOLOGICAL|Placebo|The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
214609847|NCT05337579|OTHER|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
214609848|NCT05337579|PROCEDURE|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
214609849|NCT00267683|DRUG|insulin aspart|
214609850|NCT00267683|DRUG|glibenclamide|
214609851|NCT00918853|PROCEDURE|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
214609852|NCT00220168|DRUG|Irinotecan, Capecitabine|
214609853|NCT04256460|BEHAVIORAL|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
214609854|NCT00915772|DRUG|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
214609855|NCT00915772|DRUG|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
214609856|NCT00915772|DRUG|Metformin|Metformin 1000 mg tablet bid
214609857|NCT01194713|BEHAVIORAL|Sleep deprivation|subjects will undergo one night of full sleep deprivation
214609858|NCT03583450|DEVICE|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
214609859|NCT05023863|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
214609860|NCT05023863|OTHER|Placebo tablets|placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
214609861|NCT05023863|RADIATION|radiation or concurrent chemoradiation|radiation or concurrent radiotherapy plus platinum-based chemotherapy
214609862|NCT04012034|DEVICE|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
214609863|NCT04012034|DEVICE|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
214609864|NCT02202291|GENETIC|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
214609865|NCT03374995|OTHER|Best Practice|Receive standard of care
214609866|NCT03374995|OTHER|Quality-of-Life Assessment|Ancillary studies
214713960|NCT04815538|BEHAVIORAL|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
214609867|NCT03374995|DEVICE|Topical Keratin|Given topically
214713961|NCT02320240|DRUG|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713962|NCT02320240|DRUG|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713963|NCT02320240|DRUG|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713964|NCT02320240|DRUG|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713965|NCT02320240|DRUG|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713966|NCT02320240|DRUG|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713967|NCT02320240|DRUG|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713968|NCT02320240|DRUG|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713969|NCT02320240|DRUG|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
214713970|NCT06348758|OTHER|questionnaire|E-Questionnaire will be sent to the students
214713971|NCT01397045|OTHER|VATS|Video-assisted lung segmentectomy
214713972|NCT01397045|PROCEDURE|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
214713973|NCT03955055|DEVICE|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
214713974|NCT01431651|DIETARY_SUPPLEMENT|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
214713975|NCT03362203|OTHER|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
214713976|NCT03362203|OTHER|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
214713977|NCT05757479|PROCEDURE|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
214713978|NCT05757479|DRUG|Steroid nasal spray|1 spray into each nostril once a day.
214713979|NCT05757479|PROCEDURE|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
214713980|NCT01136746|DRUG|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
214713981|NCT01136746|DRUG|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
214609868|NCT03504514|DEVICE|speech trials during different ventilation conditions|ventilator parameters are modified
214713982|NCT01136746|DRUG|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
214713983|NCT05460390|OTHER|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
214609869|NCT03504514|OTHER|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
214609870|NCT02783716|PROCEDURE|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
214713984|NCT00756093|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
214713985|NCT00756093|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
214713986|NCT00756093|OTHER|Blink Tears|Blink Tears one drop each eye one time
214713987|NCT00756093|OTHER|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
214713988|NCT00092677|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
214713989|NCT00092677|DRUG|Comparator: Placebo|matching Placebo
214713990|NCT05459480|OTHER|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
214713991|NCT04251624|BEHAVIORAL|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
214713992|NCT04251624|BEHAVIORAL|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
214713993|NCT05116891|DRUG|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
214713994|NCT05116891|DRUG|mFOLFOX|mFOLFOX/CAN04
214713995|NCT05116891|DRUG|DTX|DTX/CAN04
214713996|NCT05116891|DRUG|G/C|G/C/CAN04
214713997|NCT05983016|DEVICE|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
214609871|NCT02783716|DIAGNOSTIC_TEST|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
214609872|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
214609873|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
214713998|NCT02509611|OTHER|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
214609874|NCT04559191|DEVICE|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
214609875|NCT00564005|OTHER|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
214609876|NCT00564005|OTHER|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
214609877|NCT00564005|OTHER|Combined therapy (CT)|combined different treatment approaches
214609878|NCT00564005|BEHAVIORAL|Control intervention|Conventional treatment program
214609879|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
214609880|NCT01383096|DRUG|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
214609881|NCT01383096|DRUG|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
214609882|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
214609883|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
214609884|NCT04679779|OTHER|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
214609885|NCT04679779|OTHER|Wii virtual reality games|"1. Bowling~2. Frisbee~3. Basketball~4. Boxing"
214609886|NCT01211535|DEVICE|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
214609887|NCT01211535|DEVICE|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
214609888|NCT01211535|DEVICE|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
214609889|NCT03288870|DRUG|BCD-100|monoclonal antibody to PD-1 receptor
214609890|NCT03288870|DRUG|Docetaxel|Chemotherapy drug (taxane)
214609891|NCT04747834|DEVICE|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
214609892|NCT05368961|BEHAVIORAL|Distraction|Distraction (interactive tablet)
214609893|NCT05368961|OTHER|Usual care|Anxiolytic ordered by anesthesiologist is usual care
214609894|NCT02342366|DRUG|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
214609895|NCT02342366|DRUG|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
214609896|NCT04187300|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
214609897|NCT03974087|DEVICE|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
214609898|NCT00670501|DRUG|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
214609899|NCT00670501|DRUG|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
214609900|NCT00670501|DRUG|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
214609901|NCT00670501|DRUG|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
214609902|NCT00670501|DRUG|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
214609903|NCT03485248|DIETARY_SUPPLEMENT|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
214609904|NCT03485248|DIETARY_SUPPLEMENT|Placebo|140ml of Beetroot Juice (nitrate free)
214609905|NCT02781142|OTHER|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
214609906|NCT01411020|PROCEDURE|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
214609907|NCT00164073|PROCEDURE|Liver biopsy|
214609908|NCT03289936|DEVICE|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
214609909|NCT03289936|DEVICE|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
214609910|NCT02508051|BEHAVIORAL|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
214609911|NCT02508051|BEHAVIORAL|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
214609912|NCT02782936|OTHER|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
214609913|NCT02782936|DEVICE|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
214609914|NCT01612468|DRUG|Liraglutide|1.8 mg/day subcutaneous
214609915|NCT01612468|DRUG|Placebo|1.8 mg/day subcutaneous
214609916|NCT03593850|BEHAVIORAL|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
214609917|NCT03593850|BEHAVIORAL|Silence Group|Audio file that contained no sounds.
214609918|NCT02539420|DEVICE|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
214609919|NCT02946242|DEVICE|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
214609920|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
214609921|NCT05582395|OTHER|Placebo|Specified dose on specified days
214609922|NCT03357315|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
214609923|NCT01735279|DRUG|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
214609924|NCT01735279|DRUG|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
214609925|NCT05340361|DEVICE|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
214609926|NCT05340361|DEVICE|Optical coherence tomography-guided Onyx family stent expansion|"1. Expansion of 2.25, 3.0, and 4.0 mm Onyx family stent@ nominal pressure~2. OCT pullback~3. Expansion with over 0.5mm sized non-compliant balloon of each stent~4. OCT pullback~5. Expansion with over 1.0mm sized non-compliant balloon of each stent~6. OCT pullback~7. Expansion with over 1.25\~1.5mm sized non-compliant balloon of each stent~8. OCT pullback~9. Evaluation of polymer status with overexpansion assessed by an electric microscope"
214609927|NCT05460611|DEVICE|Sciton HALO 1470nm Non-ablative laser|Patients will be treated with the 1470nm non-ablative laser.
214609928|NCT01817855|DRUG|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
214609929|NCT01817855|DRUG|Placebo to match|Multiple doses inhaled placebo via a nebulizer
214609930|NCT06033885|DEVICE|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
214609931|NCT00119041|BEHAVIORAL|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
214609932|NCT00119041|BEHAVIORAL|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
214609933|NCT00119041|BEHAVIORAL|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
214713999|NCT00617617|DIETARY_SUPPLEMENT|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
214714000|NCT00617617|OTHER|Placebo|Control Group - Control Group participants will receive an identical placebo.
214714001|NCT04903886|OTHER|observational|observational
214722358|NCT05567224|OTHER|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
214609934|NCT03157141|PROCEDURE|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
214609935|NCT03157141|PROCEDURE|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
214609936|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
214609937|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
214609938|NCT03305939|BEHAVIORAL|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
214609939|NCT04748653|BEHAVIORAL|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
214609940|NCT02383290|OTHER|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
214609941|NCT00805662|DRUG|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
214609942|NCT00922480|DRUG|Fimasartan|Fimasartan 60 \~ 120mg/po take one tablets once a day
214609943|NCT00922480|DRUG|Losartan (Control)|Losartan 50 mg \~ 100 mg/po, take one tablets once a day
214609944|NCT02745366|PROCEDURE|BFPSC+FDBA+PRF|
214609945|NCT02745366|PROCEDURE|FDBA+PRF|
214609946|NCT01017367|DRUG|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
214609947|NCT01017367|DRUG|Placebo|Placebo
214609948|NCT01200004|DRUG|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
214609949|NCT01200004|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
214609950|NCT01200004|DRUG|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
214609951|NCT00006345|BIOLOGICAL|denileukin diftitox|
214609952|NCT00006345|DRUG|dexamethasone|
214609953|NCT01312454|DRUG|AL-59412C injectable solution|Concentration 1 and Concentration 2
214609954|NCT01312454|DRUG|Travoprost injectable solution|
214609955|NCT01312454|DRUG|AL-59412C Vehicle|Inactive ingredients used as placebo
214609956|NCT01011439|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
214609957|NCT03660709|BEHAVIORAL|Intervention|"1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5."
214609958|NCT03660709|BEHAVIORAL|Control|Standard-of-care HIV testing and counseling
214609959|NCT03558165|DIAGNOSTIC_TEST|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
214609960|NCT04511832|DRUG|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
214609961|NCT05931796|OTHER|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
214609962|NCT05931796|OTHER|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
214609963|NCT02302352|OTHER|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
214609964|NCT02302352|OTHER|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
214609965|NCT01372150|DRUG|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
214609966|NCT01372150|DRUG|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
214609967|NCT01372150|DRUG|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
214609968|NCT06247436|DIETARY_SUPPLEMENT|Branch Chained Amino Acids|postoperative BCAA consumption
214609969|NCT01444482|BIOLOGICAL|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
214609970|NCT01444482|BIOLOGICAL|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
214609971|NCT06075342|BEHAVIORAL|exercise|Exercise intervention according to the training program
214609972|NCT01688128|DEVICE|Phase I U-SMART (4 wks)|Intervention\_Control Group, 4-weeks U-SMART(2 session/week); Control\_Intervention Group, no intervention
214609973|NCT01688128|OTHER|Washout (2 wks)|2-weeks wash out period in both arms
214609974|NCT01688128|DEVICE|Phase II U-SMART (4 wks)|Intervention\_Control Group, no intervention; Control\_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
214609975|NCT01213875|BEHAVIORAL|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
214609976|NCT02558114|DRUG|Ribavirin|
214609977|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
214609978|NCT06298721|BEHAVIORAL|Standard of Care TKA|\- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
214609979|NCT00536809|DRUG|lapatinib|onced daily Days 1-21
214609980|NCT00536809|DRUG|oxaliplatin|Day one of each cycle
214609981|NCT00536809|DRUG|capecitabine|given BID days 1-14
214609982|NCT04679753|DEVICE|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
214609983|NCT04679753|DEVICE|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
214609984|NCT01526551|OTHER|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
214609985|NCT01526551|OTHER|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
214609986|NCT00284323|DRUG|Adenosine|
214609987|NCT00164827|DEVICE|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
214609988|NCT01129726|DEVICE|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
214609989|NCT06388304|BEHAVIORAL|THRIVE Online PAT Program|Online program: behavioral intervention based on Positive Affect Training (PAT)
214609990|NCT00164619|BEHAVIORAL|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]
214609991|NCT00164619|BIOLOGICAL|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
214609992|NCT05215262|BEHAVIORAL|Treat Act Know Engage (T.A.K.E.) Steps|Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.
214609993|NCT05215262|BEHAVIORAL|Standard or Care|S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
214609994|NCT03708172|DEVICE|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
214609995|NCT03708172|OTHER|Cognitive Training|Computer-based cognitive training designed to enhance executive function
214609996|NCT03708172|OTHER|sham Cognitive Training|Computer-based inactive sham training
214609997|NCT01672567|DIETARY_SUPPLEMENT|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
214609998|NCT01672567|DIETARY_SUPPLEMENT|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
214609999|NCT01672567|DIETARY_SUPPLEMENT|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
214610000|NCT01659372|RADIATION|low level laser therapy|
214610001|NCT01659372|DRUG|Naproxen|
214610002|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
214610003|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
214610004|NCT03109158|DRUG|NC-6004|NC-6004 provided by NanoCarrier
214610005|NCT03109158|DRUG|Cetuximab|Commercially Available
214610006|NCT03109158|DRUG|5-FU|Commercially Available
214610007|NCT03934255|OTHER|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
214610008|NCT00156351|BEHAVIORAL|Physical activity promotion|
214610009|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214610010|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214610011|NCT04817241|DRUG|Cytarabine|Given IV
214610012|NCT04817241|DRUG|Daunorubicin|Given IV
214610013|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
214610014|NCT04817241|DRUG|Venetoclax|Given PO
214610015|NCT00761852|DRUG|Ruboxistaurin|32 mg daily for 2 weeks
214610016|NCT00761852|DRUG|Placebo|1 tab po QD for 2 weeks
214714002|NCT05849896|DEVICE|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
214714003|NCT04753749|DRUG|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
214714004|NCT04753749|DRUG|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
214610017|NCT04227886|RADIATION|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
214610018|NCT04227886|DRUG|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
214610019|NCT01364623|DRUG|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
214610020|NCT01364623|DRUG|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
214714005|NCT05276765|PROCEDURE|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
214714006|NCT05276765|PROCEDURE|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
214714007|NCT03385694|DIAGNOSTIC_TEST|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
214714008|NCT01607294|DRUG|ETC-1002|ETC-1002 Daily for 4 weeks
214714009|NCT01607294|DRUG|Placebo|Placebo Daily for 4 weeks
214714010|NCT01601704|DRUG|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
214714011|NCT01601704|DRUG|PBO|Placebo. Administered in addition to the weight management program.
214714012|NCT01601704|BEHAVIORAL|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
214610021|NCT01364623|DRUG|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
214714013|NCT01090102|DRUG|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
214610022|NCT01364623|DRUG|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
214610023|NCT01092975|DRUG|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
214610024|NCT03505385|BEHAVIORAL|Co-created intervention - Get Ready (GR)|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
214610025|NCT02443649|BEHAVIORAL|Sleep hygiene program|Sleep hygiene program
214610026|NCT02443649|BEHAVIORAL|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
214610027|NCT06379308|OTHER|questionaries|"Questionaries will be administered :~* Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI)~* Tegner Activity Scale (TAS)~* Simple Knee Value (SKV)~* International Knee Documentation Commitee (IKDC)"
214610028|NCT06379308|OTHER|datas of medical record|datas of medical record will be collected : epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication.
214610029|NCT00718549|DRUG|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
214610030|NCT00718549|DRUG|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
214610031|NCT00718549|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
214610032|NCT02746666|BEHAVIORAL|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
214714014|NCT01090102|DRUG|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
214714015|NCT05211609|DIAGNOSTIC_TEST|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
214714016|NCT04391088|OTHER|vaccine coverage assessment|vaccine coverage assessment
214610033|NCT01353508|DRUG|LCZ696|200 mg and 400 mg tablets
214610034|NCT01353508|DRUG|Valsartan|160 mg tablets
214610035|NCT00004152|DRUG|iodinated contrast dye|
214610036|NCT00004152|PROCEDURE|computed tomography|
214610037|NCT00004152|PROCEDURE|positron emission tomography|
214610038|NCT00004152|RADIATION|fludeoxyglucose F 18|
214714017|NCT02283957|DRUG|CNTX-4975|
214714018|NCT02283957|OTHER|Placebo|
214714019|NCT03341234|DRUG|Bupivacaine|30 ml %0,25 bupivacaine
214714020|NCT03341234|DRUG|Saline|2 ml saline subcutaneously
214714021|NCT03341234|DEVICE|Ultrasound|Ultrasound guided block
214714022|NCT03518034|DRUG|AndroGel®|testosterone administered topically
214714023|NCT03518034|DRUG|Placebo|placebo administered topically
214714024|NCT02814448|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
214714025|NCT02814448|DEVICE|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
214714026|NCT02814448|DEVICE|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
214714027|NCT03200093|DRUG|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
214714028|NCT03200093|DRUG|Placebo|Ora-Sweet 5mL taken by mouth once daily.
214714029|NCT04655924|DEVICE|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
214714030|NCT00568620|PROCEDURE|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
214714031|NCT00568620|PROCEDURE|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
214714032|NCT01283867|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
214714033|NCT00010803|DRUG|Ginkgo biloba|120mg twice a day
214610039|NCT02792179|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
214610040|NCT05745051|DIAGNOSTIC_TEST|CVAid Flow|CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
214610041|NCT03356171|PROCEDURE|Cardiac Coherence|"* 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
214610042|NCT03356171|PROCEDURE|Adapted Physical Activity|\- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
214610043|NCT05986513|BEHAVIORAL|Cold Pressor Gel Test|This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.
214610044|NCT02905253|DRUG|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
214610045|NCT02905253|DRUG|Placebo|Placebo capsules matching AC-084 capsules
214610046|NCT05933486|DRUG|Tongluo-Kaibi tablet plus placebo of pregabalin|Tongluo-Kaibi Tablet 0.93g qd； Placebo of pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
214610047|NCT05933486|DRUG|placebo of Tongluo-Kaibi tablet plus pregabalin|placebo of Tongluo-Kaibi Tablet 0.93g qd； Pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
214610048|NCT02606461|DRUG|Selinexor|Selinexor 60mg
214610049|NCT02606461|DRUG|Placebo|
214610050|NCT03520478|DRUG|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
214610051|NCT03520478|DRUG|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
214610052|NCT03226405|OTHER|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
214610053|NCT03226405|OTHER|Usual Care|the standard of care provided by the institution
214610054|NCT02320136|BEHAVIORAL|cognitive testing|patients perform simple tasks like watching a video or memorizing items
214610055|NCT01536236|DEVICE|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
214610056|NCT01536236|DEVICE|Placebo|Placebo
214610057|NCT04047550|DIAGNOSTIC_TEST|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
214610058|NCT03747978|DRUG|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
214610059|NCT03747978|DRUG|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
214610060|NCT02061605|DEVICE|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
214610061|NCT04374409|DIETARY_SUPPLEMENT|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
214610062|NCT04374409|DIETARY_SUPPLEMENT|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
214610063|NCT00057356|DRUG|conivaptan|IV
214610064|NCT00057356|DRUG|placebo|IV
214610065|NCT04924504|OTHER|No interventions|No interventions
214610066|NCT02172287|DRUG|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
214610067|NCT02172287|DRUG|Salmeterol|Inhalation aerosol twice daily
214610068|NCT02172287|DRUG|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
214610069|NCT02172287|DRUG|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
214610070|NCT03654014|DEVICE|SofPulse|SofPulse PEMF device treatment of the brain after traumatic injury
214610071|NCT00446524|DRUG|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
214610072|NCT06473883|OTHER|Training recommendation|The players in the intervention group are also given specific training recommendations for the prevention of head injuries, which are compiled by experts (sports scientists, physiotherapists and neuroscientists). The exercise selection covers several areas that can be affected after a head injury. Each section contains 8 different exercises with increasing levels of difficulty (3x Basic-3x Intermediate-2x Advanced). The recommendations should be used as a warm-up program throughout the season before each training session. The coach or athletic coach will lead the warm-up program and ensure that each player follows the sequence and completes each phase according to the scheduled weeks. The warm-up program should be conducted as an 8-week cycle.
214610073|NCT01131026|DRUG|Levofloxacin|tablet, 500 mg, once a day for ten days
214610074|NCT01131026|DRUG|Amoxicillin|tablet, 1000 mg, once a day for ten days
214610075|NCT01131026|DRUG|Lansoprazole|capsule, 30 mg, twice a day for ten days
214610076|NCT02251925|BIOLOGICAL|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
214610077|NCT02251925|DRUG|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
214610078|NCT02251925|DRUG|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
214610079|NCT02251925|DRUG|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
214714034|NCT00010803|DRUG|Placebo|One pill twice daily
214714035|NCT00044525|DRUG|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
214714036|NCT00224692|DRUG|Low dose ketamine|
214610080|NCT03130179|DRUG|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
214610081|NCT03130179|DRUG|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
214610082|NCT03496324|DRUG|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
214610083|NCT03496324|DRUG|Algifor® Junior|Algifor® Junior 400 mg/20 ml
214610084|NCT02297360|DIETARY_SUPPLEMENT|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
214610085|NCT02297360|OTHER|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
214610086|NCT00780013|DRUG|metformin hydrochloride liquid 500 mg per 5 mL|
214610087|NCT04714528|OTHER|Physical Exercise|Physical exercise as described before.
214722359|NCT05387135|DEVICE|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
214722360|NCT01285414|DRUG|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
214610088|NCT04714528|OTHER|Relaxation Therapy|Relaxation therapy as described before.
214610089|NCT02032602|OTHER|Deep Dry Needling|
214610090|NCT00300287|DRUG|Vildagliptin|
214722361|NCT01285414|DRUG|Temozolomide & Radiation Therapy|Temozolomide \& Radiation Therapy
214722362|NCT00289614|DRUG|Iopamidol 370 mgI/dL|
214610091|NCT06209008|DRUG|Intravesical injection of Platlet Rich Plasma (PRP)|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
214610092|NCT05045326|BEHAVIORAL|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
214610093|NCT05045326|BEHAVIORAL|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
214610094|NCT01795300|RADIATION|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
214610095|NCT01795300|RADIATION|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
214610096|NCT01795300|RADIATION|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
214610097|NCT01795300|RADIATION|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.
214610098|NCT04323826|OTHER|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
214610099|NCT04323826|OTHER|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
214722363|NCT01011595|PROCEDURE|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
214610100|NCT04323826|OTHER|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
214714037|NCT04381533|BEHAVIORAL|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
214714038|NCT04381533|BEHAVIORAL|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
214610101|NCT04323826|OTHER|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
214610102|NCT04532736|DRUG|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
214714039|NCT01019252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
214714040|NCT01223040|OTHER|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
214714041|NCT05132595|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
214714042|NCT05132595|DRUG|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
214610103|NCT04532736|DRUG|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
214714043|NCT05132595|DRUG|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
214714044|NCT05132595|DRUG|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
214610104|NCT04532736|DRUG|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
214610105|NCT04727320|DRUG|Tauroursodeoxycholic acid|Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
214610106|NCT04727320|DRUG|Placebo|Oral placebo, once a day, one tablet at a time for 6 months
214714045|NCT05132595|DRUG|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
214722364|NCT01011595|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
214722365|NCT01011595|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
214610107|NCT03382015|OTHER|BKR-013 or Placebo|Encapsulated L-glutamine
214610108|NCT04323085|BEHAVIORAL|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
214610109|NCT04323085|BEHAVIORAL|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
214610110|NCT06175546|DEVICE|Compression socks|Wearing of compression sock in prescribed regimen
214610111|NCT00892320|DRUG|ER OROS paliperidone|
214610112|NCT02092350|DRUG|Grazoprevir|Grazoprevir 100 mg tablet
214610113|NCT02092350|DRUG|Elbasvir|Elbasvir 50 mg tablet
214610114|NCT02092350|DRUG|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
214610115|NCT02092350|DRUG|Placebo to Elbasvir|Placebo tablet matched to elbasvir
214610116|NCT00002326|DRUG|Adefovir|
214610117|NCT00002326|DRUG|Zidovudine|
214610118|NCT01068392|DRUG|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
214610119|NCT05361109|DRUG|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
214610120|NCT03262792|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
214610121|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 150 mg
214610122|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 300 mg
214610123|NCT06411587|DIAGNOSTIC_TEST|Ultrasound imaging and functional assessment|Participants in this study will undergo two types of assessments: capturing muscle images using ultrasound and evaluating their function through clinical scales.
214610124|NCT03635814|DRUG|YD312 50mg|YD312 50mg \* 1 + placebo 6 tablets
214610125|NCT03635814|DRUG|YD312 150mg|YD312 50mg \* 3 + placebo 6 tablets
214714046|NCT03241667|DEVICE|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
214714047|NCT02273037|DEVICE|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
214714048|NCT02273037|PROCEDURE|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
214714049|NCT01371526|DRUG|depot tetracosactide|1mg, 3x weekly by sc injection
214610126|NCT03635814|DRUG|YD312 350mg|YD312 50mg \* 7 tablets
214610127|NCT03635814|DRUG|Placebo|YD312 0mg \* 7 tabets
214610128|NCT06493682|BEHAVIORAL|Experimental (Motivational Interviews)|Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
214610129|NCT00239226|PROCEDURE|IAS pacing - study group|site of implant and permanent pacing
214610130|NCT00239226|PROCEDURE|IAS pacing control group|site of implant and permanent pacing
214610131|NCT00239226|PROCEDURE|Pacing RAA study group|site of implant and permanent pacing
214610132|NCT00239226|PROCEDURE|Pacing RAA control group|site of implant and permanent pacing
214610133|NCT01614821|DRUG|PCI-32765|Taken orally, once daily in the morning
214610134|NCT00041301|OTHER|QoL assessment|qol questionnaires
214610135|NCT04107883|BIOLOGICAL|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
214610136|NCT04107883|DIAGNOSTIC_TEST|blood sample|get blood samples at several specific points in time during perioperation
214610137|NCT05335148|DRUG|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
214610138|NCT04559945|DEVICE|Aveir VR Leadless Pacemaker System|Patients will undergo an attempted leadless pacemaker implant
214610139|NCT06048315|DRUG|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
214610140|NCT06048315|DRUG|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
214610141|NCT00005007|DRUG|Etanercept|
214610142|NCT00000138|DRUG|Prednisolone Phosphate|
214610143|NCT00000138|DRUG|Acyclovir|
214610144|NCT04706611|PROCEDURE|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
214610145|NCT00161876|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
214610146|NCT00646906|DRUG|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
214610147|NCT00646906|DRUG|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
214610148|NCT00646906|DRUG|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
214610149|NCT00646906|DRUG|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
214610150|NCT00646906|DRUG|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
214610151|NCT03042078|DEVICE|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
214610152|NCT03042078|DEVICE|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
214610153|NCT02584322|OTHER|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
214610154|NCT01106495|DEVICE|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
214610155|NCT01106495|DRUG|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
214610156|NCT00486772|DRUG|Sevelamer (Renagel), calcium acetate (Phos-ex)|
214610157|NCT02882542|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
214610158|NCT00050648|DRUG|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
214610159|NCT00050648|DRUG|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
214610160|NCT00050648|DRUG|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
214610161|NCT00910195|DEVICE|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
214610162|NCT00910195|DEVICE|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
214610163|NCT05001282|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
214610164|NCT01303965|DRUG|Sirolimus|Start on Day -3 and continue for 1 year
214610165|NCT01303965|DRUG|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
214610166|NCT01303965|DRUG|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
214714050|NCT00756678|DRUG|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
214610167|NCT00956657|BEHAVIORAL|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
214610168|NCT00729482|DRUG|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
214610169|NCT00510991|DEVICE|nippv|
214610170|NCT02177890|DEVICE|Transcutaneous vagal nerve stimulation|
214610171|NCT02177890|DEVICE|Sham vagal nerve stimulation|
214610172|NCT02931136|DRUG|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
214610173|NCT02931136|DRUG|Placebo|The participants will treatment by the placebo in 52 weeks.
214610174|NCT00809211|DRUG|nilotinib|
214610175|NCT00809211|GENETIC|cytogenetic analysis|
214610176|NCT00809211|GENETIC|mutation analysis|
214610177|NCT00809211|GENETIC|polymerase chain reaction|
214610178|NCT00809211|OTHER|pharmacological study|
214610179|NCT02265861|DRUG|HCG|
214610180|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
214714051|NCT00756678|DRUG|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
214610181|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FSPG PET/CT
214610182|NCT02448225|RADIATION|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
214610183|NCT02448225|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
214714052|NCT00004467|DRUG|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
214714053|NCT00004467|DRUG|Placebo|Infusion of 5% dextrose
214610184|NCT02448225|OTHER|Laboratory Biomarker Analysis|Correlative studies
214610185|NCT02448225|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
214610186|NCT02448225|PROCEDURE|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
214610187|NCT01433757|DRUG|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
214610188|NCT01433757|DRUG|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
214610189|NCT02111460|RADIATION|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
214714054|NCT06185478|DIAGNOSTIC_TEST|MRI scan|MRI scan
214714055|NCT03523949|BEHAVIORAL|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
214610190|NCT02941874|OTHER|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
214610191|NCT03042182|BIOLOGICAL|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
214610192|NCT00851682|DEVICE|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
214610193|NCT04858906|DEVICE|McGrath laryngoscope|The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).
214714056|NCT02104323|DRUG|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
214714057|NCT00017628|DRUG|cyclophosphamide|
214714058|NCT00017628|DRUG|filgrastim|
214714059|NCT00017628|DRUG|methylprednisolone|
214610194|NCT04858906|DEVICE|C-MAC D-blade laryngoscope|The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
214610195|NCT00029913|OTHER|Observation|Observation of participants who received HIV preventive vaccine and became infected.
214610196|NCT03178708|DRUG|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
214610197|NCT03178708|OTHER|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
214610198|NCT05971862|DRUG|SKI-G-801|Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
214610199|NCT06186713|OTHER|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
214610200|NCT04454697|DEVICE|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
214610201|NCT01797497|BEHAVIORAL|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
214610202|NCT02004951|DEVICE|Misago RX|
214610203|NCT02004951|DEVICE|Zilver PTX|
214610204|NCT04354545|DRUG|Xiidra (Lifitegrast ophthalmic solution) 5%|FDA approved lifitegrast opthalmic solution eye drop
214610205|NCT06281067|DIAGNOSTIC_TEST|"full-physiology approach arm"|"* All MB patients belonging to the full-physiology arm will undergo functional assessment of the intramural artery with basal Pd/Pa, FFR (after intravenous adenosine), RFR, CFR and IMR.~* In the presence of a negative functional assessment (Pd/Pa\> 0.92, FFR\> 0.80, RFR\> 0.89, CFR≥ 2.0 and IMR\< 25), FFR, CFR and IMR will be measured after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d) to exalt the epicardial hemodynamic significance of MB or its impact on structural microvascular remodelling (impaired endothelium-independent vasodilatation).~* In the absence of epicardial hemodynamic significance (FFR-d\> 0.75) and structural microvascular dysfunction (CFR≥ 2.0 and IMR\< 25), ACH provocative test will be performed to evaluate the presence of epicardial or microvascular spasm (impaired endothelium-dependent vasodilatation)."
214610206|NCT06281067|DIAGNOSTIC_TEST|"standard approach arm"|"In the standard approach arm patients will undergo an angiographic evaluation of the tunnelled artery"
214610207|NCT02551614|PROCEDURE|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
214610208|NCT02551614|PROCEDURE|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
214610209|NCT02551614|PROCEDURE|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
214610210|NCT01105676|PROCEDURE|skin biopsy|Two skin biopsies will be taken one time
214610211|NCT00943891|PROCEDURE|Tumor biopsies|
214610212|NCT06282276|BEHAVIORAL|cross sectional survey|filling out the electronic survey form
214610213|NCT04602169|PROCEDURE|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise \>38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
214714060|NCT00017628|PROCEDURE|Autologous Stem Cell Transplantation|
214714061|NCT04399824|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
214714062|NCT04399824|OTHER|Quality-of-Life Assessment|Ancillary studies
214714063|NCT04399824|OTHER|Questionnaire Administration|Ancillary studies
214714064|NCT04399824|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214714065|NCT01752725|DEVICE|BiCision®|
214714066|NCT01752725|DEVICE|Ultracision® Har-monic Scalpel(Ethicon)|
214714067|NCT00757640|PROCEDURE|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
214714068|NCT01324128|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
214714069|NCT01324128|DRUG|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
214714070|NCT01324128|DRUG|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
214714071|NCT05018637|DRUG|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
214610214|NCT04602169|PROCEDURE|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
214610215|NCT05744622|OTHER|KetacTM Universal AplicapTM|chemically cured conventional GICs
214714072|NCT05018637|DRUG|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
214714073|NCT02988492|DEVICE|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
214714074|NCT02639923|PROCEDURE|Drawing of 7ml peripheral blood|puncture peripheral vein
214714075|NCT04368897|DIAGNOSTIC_TEST|CAG length <22|CAG repeat length in exon 1 of AR gene
214714076|NCT04368897|DIAGNOSTIC_TEST|CAG length >=22|CAG repeat length in exon 1 of AR gene
214714077|NCT04814524|DEVICE|Fitbit|Wear Fitbit
214714078|NCT04814524|OTHER|Questionnaire Administration|Ancillary studies
214714079|NCT04814524|DEVICE|Virtual Reality Device|Use VR
214714080|NCT00706394|DEVICE|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
214714081|NCT00666380|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
214714082|NCT04258293|DIAGNOSTIC_TEST|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
214714083|NCT04675697|DRUG|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
214714084|NCT01529814|DEVICE|Implant with new abutment connection|New abutment connection implant system
214714085|NCT01529814|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
214610216|NCT05744622|OTHER|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
214610217|NCT00534820|PROCEDURE|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
214714086|NCT04402346|PROCEDURE|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
214714087|NCT04402346|PROCEDURE|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
214714088|NCT05815680|DRUG|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
214714089|NCT05815680|DRUG|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
214714090|NCT05815680|DRUG|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
214714091|NCT05815680|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
214714092|NCT05815680|DRUG|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
214714093|NCT00792701|DRUG|cisplatin|Given IV
214714094|NCT00792701|DRUG|gemcitabine hydrochloride|Given IV
214714095|NCT03943888|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
214610218|NCT05242731|DEVICE|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
214610219|NCT05242731|DEVICE|"Video calling program Better-close"|Video calling program.
214610220|NCT05242731|DEVICE|Researchmanager program|Case Report Form, Datamanagement program
214610221|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
214610222|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
214714096|NCT03943888|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
214610223|NCT00659620|BIOLOGICAL|mesenchymal stem cell|transplantation of mesenchymal stem cell
214610224|NCT03916887|BEHAVIORAL|Golf instruction|Non-golfers instructed to golf over 10 weeks
214610225|NCT02742064|OTHER|Cogito Companion Mobile Phone Application|
214610226|NCT06374472|PROCEDURE|Osteosynthesis|Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
214610227|NCT01937533|PROCEDURE|Magnetic Resonance Imaging using an endovaginal receiver coil|
214610228|NCT00073151|DRUG|ABT-751|
214610229|NCT04702776|DRUG|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
214610230|NCT04702776|DRUG|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
214610231|NCT04702776|DRUG|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
214610232|NCT01723215|BEHAVIORAL|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
214610233|NCT01723215|BEHAVIORAL|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
214714097|NCT03943888|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
214714098|NCT03943888|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
214714099|NCT02690324|BEHAVIORAL|cognitive stress (serial 7)|
214714100|NCT01769495|OTHER|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
214610234|NCT01723215|BEHAVIORAL|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
214610235|NCT03831867|OTHER|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
214610236|NCT06156436|DEVICE|ResAppDx v.20|Software application used to aid diagnosis of respiratory disorders
214610237|NCT05662475|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
214610238|NCT05662475|PROCEDURE|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
214610239|NCT05662475|DIAGNOSTIC_TEST|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
214610240|NCT03627897|DRUG|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
214610241|NCT03627897|DRUG|saline|No drugs or interventions were administered to the control group.
214610242|NCT05275348|BEHAVIORAL|Tele-Enhance Fitness|"Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode."
214610243|NCT05275348|BEHAVIORAL|In-person Enhance Fitness|Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
214610244|NCT02355249|PROCEDURE|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
214610245|NCT02355249|PROCEDURE|OE|Patients will be treated with traditional three incisions esophagectomy.
214610246|NCT04429854|BIOLOGICAL|Convalescent Plasma|"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."
214610247|NCT04429854|DRUG|Standard of care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
214610248|NCT00713479|DRUG|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
214610249|NCT00713479|DRUG|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
214610250|NCT01750320|DEVICE|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
214610251|NCT02648516|COMBINATION_PRODUCT|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
214610252|NCT03789461|PROCEDURE|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
214610253|NCT02844920|DEVICE|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
214610254|NCT01966614|DRUG|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
214610255|NCT01966614|OTHER|Placebo|Single intraprostatic bilateral injection of vehicle only
214610256|NCT02429726|DRUG|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
214610257|NCT02429726|DRUG|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
214610258|NCT02429726|DRUG|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
214610259|NCT00224094|DRUG|Premarin® (oral) vs. Alora® (transdermal)|
214714101|NCT01624688|PROCEDURE|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
214610260|NCT02224313|DRUG|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
214610261|NCT02224313|DRUG|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
214610262|NCT04862533|DRUG|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
214610263|NCT04862533|DRUG|Placebo|Participants will receive matching placebo three times a day
214610264|NCT04862533|PROCEDURE|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
214610265|NCT05281107|DIETARY_SUPPLEMENT|Placebo, 500 mg calcium|Berry flavoured sachet powder (500 mg calcium)
214610266|NCT05281107|DIETARY_SUPPLEMENT|600 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
214610267|NCT05281107|DIETARY_SUPPLEMENT|1200 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
214610268|NCT05281107|DIETARY_SUPPLEMENT|4000 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
214610269|NCT01520233|GENETIC|RNA analysis|
214610270|NCT01520233|GENETIC|gene expression analysis|
214610271|NCT01520233|OTHER|laboratory biomarker analysis|
214610272|NCT04092348|OTHER|complete blood count|"1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
214610273|NCT05952674|DEVICE|Vagus Nerve Stimulation (VNS)|The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
214610274|NCT05952674|OTHER|Best Medical Treatment|Best Medical Treatment for resistant depression.
214610275|NCT03092206|DRUG|F/TAF|antiretroviral therapy
214610276|NCT03092206|DRUG|E/C/F/TAF|antiretroviral therapy
214610277|NCT03092206|DRUG|R/F/TAF|antiretroviral therapy
214610278|NCT02193321|BIOLOGICAL|Amniotic Membrane Patch|
214610279|NCT05005806|DRUG|Omega 3 fatty acid|omega 3 fatty acid soft gel
214714102|NCT01229514|OTHER|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
214610280|NCT05005806|DRUG|Placebo|placebo soft gel
214610281|NCT05963958|COMBINATION_PRODUCT|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
214610282|NCT05963958|COMBINATION_PRODUCT|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
214610283|NCT05339581|RADIATION|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
214610284|NCT05339581|COMBINATION_PRODUCT|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.
214610285|NCT05339581|DRUG|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
214610286|NCT05339581|DRUG|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
214610287|NCT05339581|DRUG|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
214610288|NCT05339581|DRUG|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
214610289|NCT00053950|DRUG|pyrazoloacridine|Given IV
214610290|NCT00053950|BIOLOGICAL|filgrastim|Given IV or SC
214610291|NCT00053950|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
214610292|NCT00053950|PROCEDURE|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
214610293|NCT00053950|OTHER|laboratory biomarker analysis|Correlative studies
214610294|NCT00053950|OTHER|pharmacological study|Correlative studies
214610295|NCT05750875|DRUG|Loratadine|Participants were given loratadine 10mg, oral, daily, for 4 weeks
214610296|NCT05750875|DRUG|Gabapentin|Participants were given gabapentin 100mg, oral, daily, for 4 weeks
214610297|NCT01948336|DRUG|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
214610298|NCT01948336|DRUG|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
214610299|NCT01948336|DRUG|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
214610300|NCT05801328|DEVICE|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
214610301|NCT04344470|DEVICE|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
214610302|NCT04344470|DEVICE|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
214610303|NCT00721370|DEVICE|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
214714103|NCT03290170|PROCEDURE|Measured Resection|Bony landmarks are used to set femoral component rotation.
214714104|NCT03290170|PROCEDURE|Gap Balancing|Relies on ligament releases prior to bone cuts.
214714105|NCT02135900|DRUG|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
214714106|NCT00472017|DRUG|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
214610304|NCT04472520|DEVICE|AliveCor Heart Monitor|Records single-channel ECG rhythms
214610305|NCT00047671|DRUG|Citalopram|PDA Approved antidepressant
214610306|NCT05244291|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
214610307|NCT05284279|OTHER|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
214610308|NCT00240981|DRUG|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
214610309|NCT00240981|DRUG|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
214610310|NCT00699465|DRUG|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
214714107|NCT05096546|OTHER|No intervention|No intervention will be applied for the observational study.
214714108|NCT03568695|DIAGNOSTIC_TEST|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
214714109|NCT03257618|DRUG|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
214714110|NCT03257618|OTHER|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
214714111|NCT03862495|DIAGNOSTIC_TEST|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
214610311|NCT00699465|DRUG|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
214610312|NCT00800436|DRUG|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
214610313|NCT00766090|DRUG|GW685698X|Inhaled Corticosteroid
214610314|NCT00021320|DRUG|cisplatin|
214610315|NCT00021320|DRUG|fluorouracil|
214610316|NCT00021320|DRUG|paclitaxel|
214714112|NCT03862495|DRUG|Azithromycin|Azithromycin 1g administered as a single oral dose
214714113|NCT03862495|OTHER|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
214610317|NCT00021320|PROCEDURE|conventional surgery|
214610318|NCT00021320|PROCEDURE|neoadjuvant therapy|
214610319|NCT00021320|RADIATION|radiation therapy|
214610320|NCT03331770|DRUG|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
214610321|NCT05172414|OTHER|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
214610322|NCT02386748|DIETARY_SUPPLEMENT|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
214610323|NCT02386748|DIETARY_SUPPLEMENT|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
214610324|NCT02386748|OTHER|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
214610325|NCT03331861|DRUG|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
214610326|NCT03331861|DRUG|Placebo|Similar dosing regime as active comparator
214610327|NCT04858763|OTHER|No Intervention|There will be no intervention during this study.
214610328|NCT03250260|OTHER|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
214610329|NCT03250260|OTHER|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
214610330|NCT04195854|DEVICE|P4HB product|Retrospective use of P4HB in various anatomies
214610331|NCT05417607|BEHAVIORAL|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
214610332|NCT05929560|OTHER|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
214610333|NCT05929560|OTHER|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
214610334|NCT00528580|DRUG|Simvastatin|80 mg once daily PO/NG x 4 days
214610335|NCT00528580|DRUG|Identical-appearing placebo|once daily x 4 days
214610336|NCT06170112|OTHER|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
214610337|NCT02855671|DEVICE|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
214610338|NCT00587392|DEVICE|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
214714114|NCT01467661|DRUG|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
214714115|NCT02048267|PROCEDURE|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
214714116|NCT02533778|DEVICE|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
214610339|NCT02198092|OTHER|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
214610340|NCT01106027|DRUG|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
214610341|NCT02115425|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
214610342|NCT02115425|OTHER|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
214610343|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
214610344|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
214610345|NCT02115425|OTHER|add name here|
214610346|NCT03875989|PROCEDURE|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
214610347|NCT03875989|PROCEDURE|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
214610348|NCT02871778|DRUG|VX-371|
214610349|NCT02871778|DRUG|Hypertonic Saline|
214610350|NCT02871778|DRUG|Placebo (0.17% saline)|
214610351|NCT02871778|DRUG|VX-371 + HS|
214610352|NCT02871778|DRUG|Ivacaftor|
214610353|NCT03149614|OTHER|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
214610354|NCT03149614|OTHER|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
214610355|NCT02078635|BEHAVIORAL|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
214610356|NCT02078635|BEHAVIORAL|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
214610357|NCT02653300|BIOLOGICAL|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
214714117|NCT06342648|DRUG|Sterile Water Injection|Injection of intracutaneous sterile water
214714118|NCT06342648|DRUG|Diclofenac Sodium injection|Injection of intramuscular diclofenac sodium
214714119|NCT03673956|DRUG|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
214714120|NCT03673956|DRUG|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
214610358|NCT05217563|BEHAVIORAL|Memory-reframing intervention (Reframe the Pain)|Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
214610359|NCT02927587|DRUG|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
214610360|NCT04646070|PROCEDURE|Reduction mammaplasty|Breast reduction surgery
214610361|NCT04457466|DRUG|Nerve Growth Factor|Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
214610362|NCT02761486|DRUG|Aspirin|325mg aspirin per day
214610363|NCT02761486|DRUG|Placebo|placebo in matching capsules
214610364|NCT04554238|DEVICE|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
214714121|NCT03673956|DRUG|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
214610365|NCT04554238|OTHER|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
214610366|NCT00842738|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
214610367|NCT00842738|OTHER|No meditation|Health care services as usual
214610368|NCT00842738|OTHER|Controls|No intervention
214610369|NCT00277251|DRUG|Alendronate|
214610370|NCT02119754|DRUG|Plurogel PN|
214610371|NCT02170779|BEHAVIORAL|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
214610372|NCT02170779|OTHER|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
214610373|NCT00369785|DRUG|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
214610374|NCT00369785|DRUG|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
214610375|NCT02946632|DRUG|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
214610376|NCT02946632|DRUG|Stepwise add-on therapy|metformin -\> glimepirde -\> sitagliptin
214610377|NCT00800683|DRUG|BI 1356|BI 1356 dosed once daily
214714122|NCT03673956|DRUG|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
214714123|NCT04955496|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
214610378|NCT00800683|DRUG|placebo|placebo matching BI 1356 taken once daily
214610379|NCT05182996|BEHAVIORAL|smoking education|Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
214610380|NCT03623581|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
214610381|NCT01883479|BEHAVIORAL|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
214610382|NCT01883479|BEHAVIORAL|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
214610383|NCT05221723|BEHAVIORAL|High Intensity Interval Exercise Training Group|Participants will participate in a maximum of twice weekly exercise classes (90 minutes each class) for a total of 6 months. While participants will be encouraged to attend as many classes as able, there is no minimum requirement for class attendance. During the exercise classes, participants will participate in a 10-minute warm up, followed by 30-60 minutes of aerobic, resistance and/or balance training up to a maximum intensity of 8/10 on the rating of perceived exertion scale. Participants will finish each class with a 10-minute cool-down consisting of lower intensity exercise.
214610384|NCT01636479|DRUG|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
214610385|NCT03244514|OTHER|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
214610386|NCT00457873|DRUG|0.9% saline in 5% dextrose (intravenous)|
214610387|NCT00457873|DRUG|0.45% saline in 5% dextrose (intravenous)|
214610388|NCT02827669|BEHAVIORAL|One Drop Experts Program|
214610389|NCT02827669|BEHAVIORAL|One Drop Experts Program + Apple Watch|
214610390|NCT02231021|DRUG|alogliptin|alogliptin 25 mg add-on background medication metformin
214610391|NCT02231021|DRUG|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
214610392|NCT02231021|DRUG|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
214610393|NCT01898689|DRUG|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
214610394|NCT01898689|DRUG|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
214610395|NCT03628937|DIETARY_SUPPLEMENT|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
214610396|NCT03628937|OTHER|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
214610397|NCT00570817|OTHER|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
214610398|NCT00627302|DRUG|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
214610399|NCT00627302|DRUG|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
214610400|NCT03788395|DEVICE|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
214610401|NCT03788395|DRUG|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
214610402|NCT00786123|DIETARY_SUPPLEMENT|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
214610403|NCT00786123|DIETARY_SUPPLEMENT|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
214610404|NCT04749966|OTHER|This is an observational study, there are no interventions|This is an observational study, there are no interventions
214610405|NCT05807880|DRUG|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
214610406|NCT04575142|DEVICE|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
214610407|NCT03248934|OTHER|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
214610408|NCT03248934|OTHER|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
214610409|NCT01182766|DRUG|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
214610410|NCT01182766|DRUG|Placebo with brief behavioral enhancement therapy|placebo
214610411|NCT00037869|DRUG|I-131 Metaiodobenzylguanidine|
214610412|NCT03492554|OTHER|1-Lead ECG|All participants will record three single-lead ECGs
214610413|NCT03492554|DEVICE|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
214610415|NCT04384393|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight.
214610416|NCT00662350|DEVICE|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
214610417|NCT05803434|DRUG|Cannabidiol oral solution|"Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks."
214610418|NCT01504490|DRUG|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
214610419|NCT02900183|DRUG|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
214714124|NCT05982834|DRUG|Disitamab Vedotin combined with fruquintinib and Tislelizumab|Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
214714125|NCT02120144|OTHER|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
214714126|NCT02120144|OTHER|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
214714127|NCT03242161|DIAGNOSTIC_TEST|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
214610420|NCT01052896|DRUG|Gabapentin|300mg po TID
214610421|NCT01052896|DRUG|Placebo|Look-alike of gabapentin 300mg given po tid
214610422|NCT02794467|DRUG|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
214610423|NCT02794467|DRUG|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
214714128|NCT00520637|DRUG|EZN-2208|
214714129|NCT00603850|DEVICE|ForeseeHome|human factor
214714130|NCT00466024|BEHAVIORAL|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
214714131|NCT00466024|BEHAVIORAL|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
214714132|NCT00425113|DRUG|Metronidazole|
214610424|NCT01678482|DEVICE|light based device for treatment of acne|
214610425|NCT04654520|OTHER|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
214714133|NCT00425113|PROCEDURE|Blood Draw|
214714134|NCT00425113|PROCEDURE|CT Scan|
214714135|NCT00425113|PROCEDURE|PET Scan|
214714136|NCT05390307|DRUG|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
214714137|NCT05390307|DRUG|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
214714138|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
214714139|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
214714140|NCT05390307|OTHER|Usual care|Usual standard care
214610426|NCT01196533|DEVICE|Non invasive peripheral blood monitoring|non invasive monitoring
214714141|NCT06173609|PROCEDURE|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
214610427|NCT01984944|OTHER|Autistic functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
214610428|NCT01984944|OTHER|Control functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
214610429|NCT01398865|PROCEDURE|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
214610430|NCT02560363|DRUG|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
214610431|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
214714142|NCT04989088|DEVICE|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
214714143|NCT04989088|DEVICE|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
214714144|NCT00864344|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
214714145|NCT00864344|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
214714146|NCT01695213|PROCEDURE|uncemented total hip arthroplasty|
214714147|NCT02410096|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
214714148|NCT02410096|OTHER|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
214714149|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
214714150|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
214714151|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
214714152|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
214610432|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
214610433|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
214714153|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
214714154|NCT01074658|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
214714155|NCT02879916|DRUG|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
214714156|NCT02879916|DRUG|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
214714157|NCT01342952|DRUG|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
214610434|NCT00219050|DRUG|aliskiren|
214610435|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
214610436|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
214610437|NCT00481897|BEHAVIORAL|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
214714158|NCT02156804|DRUG|Nivolumab (BMS-936558)|
214714159|NCT04348994|DEVICE|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
214714160|NCT04581863|DEVICE|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
214714161|NCT04581863|OTHER|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
214714162|NCT02789826|PROCEDURE|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
214714163|NCT02789826|PROCEDURE|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
214714164|NCT02533219|DRUG|18 F-DOPA|Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
214610438|NCT02884154|DEVICE|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
214610439|NCT05240183|DIAGNOSTIC_TEST|Daily SARS-CoV-2 PCR Testing for 10 days|Each participant will undergo daily SARS-CoV-2 PCR testing to assess viral dynamics
214610440|NCT05132270|DRUG|hydroxyurea and thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
214610441|NCT01937572|OTHER|Visionaire system (Knee MRI)|
214610442|NCT01937572|OTHER|No Knee MRI|
214610443|NCT03015519|DRUG|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
214610444|NCT03015519|DRUG|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
214610445|NCT03966781|PROCEDURE|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
214610446|NCT03966781|PROCEDURE|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
214610447|NCT03966781|PROCEDURE|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
214610448|NCT03966781|PROCEDURE|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
214610449|NCT01561495|RADIATION|Proton Therapy|
214610450|NCT02463071|DRUG|AZD0585|1g soft capsule
214610451|NCT02463071|DRUG|AZD0585 placebo|1g soft capsule
214610452|NCT02629796|OTHER|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
214610453|NCT01759004|OTHER|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
214714165|NCT00875303|BEHAVIORAL|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
214714166|NCT00875303|BEHAVIORAL|Control|Routine primary care.
214610454|NCT01116141|DRUG|CH-4051|Different doses CH-4051 to be compared
214610455|NCT01116141|DRUG|Methotrexate (MTX)|20 mg MTX weekly
214610456|NCT01116141|DRUG|Folic Acid|1 mg folic acid daily
214610457|NCT04353479|DRUG|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
214610458|NCT04353479|DRUG|Decitabine|A DNA methyltransferase inhibitor
214610459|NCT03428022|DRUG|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
214610460|NCT06143150|OTHER|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
214610461|NCT00211848|DRUG|Polyenylphosphatidylcholine (PPC)|
214714167|NCT00436202|BEHAVIORAL|Iron supplement|
214610462|NCT00211848|DRUG|Pegylated Interferon|
214714168|NCT04969211|DRUG|VHX-896 and iloperidone|oral tablet
214714169|NCT04969211|DRUG|Iloperidone and VHX-896|oral tablet
214714170|NCT01803711|DRUG|Desvenlafaxine|
214714171|NCT01803711|DIETARY_SUPPLEMENT|Omega 3 Fatty acids|
214714172|NCT01803711|DRUG|Placebo (for Omega 3 fatty acid supplement)|
214714173|NCT02658981|BIOLOGICAL|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
214714174|NCT02658981|BIOLOGICAL|Anti-PD-1|Given IV
214714175|NCT02658981|OTHER|Pharmacological Study|Correlative Studies
214714176|NCT02658981|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214610463|NCT00211848|DRUG|Ribavirin|
214610464|NCT01891708|OTHER|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
214610465|NCT00910572|DEVICE|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
214610466|NCT02937194|BEHAVIORAL|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
214610467|NCT02937194|BEHAVIORAL|Pamphlets distribution|Oral health pamphlets distribution
214610468|NCT03975101|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
214610469|NCT04387955|DIAGNOSTIC_TEST|Biological Sample Collection|"* Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2"
214610470|NCT00298025|DRUG|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
214610471|NCT00298025|DRUG|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
214610472|NCT00298025|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
214610473|NCT00298025|DRUG|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
214610474|NCT00298025|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
214610475|NCT04635410|OTHER|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
214610476|NCT05662696|OTHER|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
214610477|NCT00888381|BIOLOGICAL|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
214610478|NCT00362349|DRUG|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
214610479|NCT04695067|BEHAVIORAL|Central fatigue group|a fatigue protocol that pitchers need to pitch 80 trials in a simulated game
214714177|NCT02658981|BIOLOGICAL|Anti-CD137|Given IV
214714178|NCT01463657|DEVICE|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
214714179|NCT01463657|DEVICE|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
214610480|NCT04943003|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
214610481|NCT02670941|DRUG|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
214610482|NCT02670941|DRUG|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
214610483|NCT02670941|DRUG|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
214610484|NCT02670941|DRUG|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
214610485|NCT03707613|PROCEDURE|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
214610486|NCT00535275|DRUG|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
214610487|NCT00535275|DRUG|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
214610488|NCT04160169|OTHER|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
214610489|NCT00000626|DRUG|Vinblastine sulfate|
214610490|NCT00000626|DRUG|Dacarbazine|
214610491|NCT00000626|DRUG|Filgrastim|
214610492|NCT00000626|DRUG|Bleomycin sulfate|
214610493|NCT00000626|DRUG|Doxorubicin hydrochloride|
214610494|NCT02806154|OTHER|DEXA|The appendicular muscle mass measured by DEXA
214610495|NCT05406843|OTHER|Preoperative cognitive functions of participants undergoing open heart surgery|Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
214610496|NCT05406843|OTHER|Postoperative cognitive functions of particiants undergoing open heart surgery|Changes in mini mental test scores were recorded in the postoperative period.
214610497|NCT00932984|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
214610498|NCT04326699|PROCEDURE|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
214610499|NCT06306885|BEHAVIORAL|Action observation plus motor imagery followed by sleep|Participants will be asked to observe video-clips showing motor contents immediately before sleeping
214610500|NCT06306885|BEHAVIORAL|Action observation plus motor imagery|Participants will be asked to observe video-clips showing motor contents at least 12 hours before sleeping
214610501|NCT06306885|BEHAVIORAL|Control|Participants will be asked to observe video-clips showing landscapes before sleeping
214610502|NCT03536975|OTHER|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
214610503|NCT03986866|OTHER|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
214610504|NCT05738811|OTHER|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
214610505|NCT05738811|OTHER|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
214610506|NCT05738811|OTHER|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
214610507|NCT04820374|PROCEDURE|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
214610508|NCT04295096|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
214610509|NCT00024414|DRUG|DHA-paclitaxel|
214610510|NCT01560923|BIOLOGICAL|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
214610511|NCT01560923|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
214610512|NCT01560923|OTHER|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
214610513|NCT00201669|DRUG|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
214610514|NCT04158921|OTHER|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. \> 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
214610515|NCT05093322|DRUG|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
214610516|NCT05710926|BEHAVIORAL|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
214610517|NCT05710926|BEHAVIORAL|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
214610518|NCT02452281|DRUG|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
214610519|NCT02452281|DRUG|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
214610520|NCT01079897|DEVICE|Atopiclair|topical applied cream, twice daily
214610521|NCT01079897|DEVICE|EHK02-01|topical applied cream containing 7% ectoine
214610522|NCT01033253|BEHAVIORAL|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
214610523|NCT01792804|DRUG|Trimethoprim-Sulfamethoxazole|study drug 1
214610524|NCT01792804|DRUG|Clindamycin|study drug 2
214610525|NCT01792804|DRUG|Linezolid|study drug 3
214610526|NCT01792804|DRUG|Flucloxacillin|study drug 4
214610527|NCT01792804|DRUG|Cloxacillin|study drug 5
214610528|NCT01792804|DRUG|Vancomycin|study drug 6
214610529|NCT01792804|DRUG|Daptomycin|study drug 7
214610530|NCT01792804|DRUG|Cefazolin|study drug 8
214610531|NCT05691998|OTHER|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
214610532|NCT00137228|PROCEDURE|figure-of-eight hand measurements|
214610533|NCT00137228|PROCEDURE|water volumetry hand measurements|
214610534|NCT05473910|DRUG|SOC + TSC-100|HA-1 positive
214610535|NCT05473910|DRUG|SOC + TSC-101|HA-2 positive or HA-1 negative
214610536|NCT05473910|OTHER|Control|SOC alone
214610537|NCT00522054|OTHER|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
214610538|NCT05546450|BEHAVIORAL|Diet|"Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician."
214610539|NCT05546450|DIETARY_SUPPLEMENT|Cornus mas L.(Cornelian Cherry)|"Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement."
214610540|NCT01688284|DEVICE|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14\_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
214610541|NCT02823795|BEHAVIORAL|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
214610542|NCT00574145|PROCEDURE|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
214610543|NCT00574145|PROCEDURE|fatigue assessment and management|duration
214610544|NCT00574145|PROCEDURE|psychosocial assessment and care|duration
214610545|NCT00574145|PROCEDURE|quality-of-life assessment|duration
214610546|NCT00574145|PROCEDURE|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
214610547|NCT02536768|BEHAVIORAL|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
214610548|NCT03377842|DRUG|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
214610549|NCT03377842|DRUG|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
214610550|NCT03419039|DIETARY_SUPPLEMENT|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
214610551|NCT03419039|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules.
214610552|NCT01819649|DIETARY_SUPPLEMENT|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
214610553|NCT04778982|DRUG|KN026 combined with Palbociclib and Fulvestrant|HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
214610554|NCT02549430|DRUG|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
214610555|NCT02549430|DRUG|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
214610556|NCT02549430|DRUG|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
214610557|NCT02549430|DRUG|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
214610558|NCT02549430|DRUG|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
214610559|NCT00372242|BEHAVIORAL|Prospective Longitudinal Interventional Stury|
214610560|NCT02198339|DRUG|BIBN 4096 BS|
214610561|NCT02198339|DRUG|Placebo|
214610562|NCT05732090|OTHER|therapeutic exercise program|therapeutic exercise program (3 sessions/week/two months).
214610563|NCT05732090|OTHER|diaphragmatic myofascial release|therapeutic exercise program in addition to diaphragmatic myofascial release (3 sessions/week/two months).
214610564|NCT05988450|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
214610565|NCT02737852|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
214610566|NCT00364520|OTHER|Shanghai workers|
214610567|NCT02171845|OTHER|surgical biopsies|
214610568|NCT03173131|BEHAVIORAL|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
214610569|NCT03193645|DRUG|Degarelix|Injection
214610570|NCT02245438|DRUG|Tipranavir low dose|
214610571|NCT02245438|DRUG|Tipranavir high dose|
214610572|NCT02245438|DRUG|Ritonavir low dose|
214610573|NCT02245438|DRUG|Ritonavir high dose|
214610574|NCT02245438|DRUG|Norethindrone-Ethinyl Estradiol|
214610575|NCT00761306|DRUG|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
214610576|NCT06054191|DRUG|Dabrafenib + Trametinib|Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
214610577|NCT06054191|DRUG|Capmatinib|Capmatinib 400mg BID/（2 cycles）
214610578|NCT04729673|DEVICE|Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
214610579|NCT02623127|DRUG|Sunitinib|
214610580|NCT03015675|DRUG|ascorbic acid|20g/day, D1-3, every 2 weeks
214610581|NCT03015675|DRUG|mFOLFOX6|"mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
214610582|NCT04042740|DRUG|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
214610583|NCT03868969|DRUG|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
214610584|NCT00838214|DRUG|budesonide|3mg capsule, 3x per day for 6 months
214610585|NCT00838214|DRUG|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
214610586|NCT03380351|BEHAVIORAL|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
214610587|NCT06074991|OTHER|musıc therapy|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
214610588|NCT04741386|BIOLOGICAL|SARS-CoV-2 vaccination|All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
214610589|NCT02114775|DRUG|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
214610590|NCT02114775|DRUG|Sildenafil|50 mg by mouth daily
214610591|NCT02114775|DRUG|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
214610592|NCT02960178|BEHAVIORAL|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
214610593|NCT02960178|BEHAVIORAL|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
214610594|NCT04634981|PROCEDURE|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
214610595|NCT02419326|BEHAVIORAL|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
214610596|NCT02530372|DEVICE|UriCap-F|non-invasive urine collection device for women
214610597|NCT01971983|OTHER|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
214610598|NCT01971983|OTHER|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
214610599|NCT01971983|OTHER|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
214610600|NCT02276664|BEHAVIORAL|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
214714180|NCT00167362|BEHAVIORAL|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
214714181|NCT00167362|BEHAVIORAL|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
214610601|NCT02276664|BEHAVIORAL|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
214610602|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
214610603|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
214610604|NCT03405805|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
214610605|NCT03294226|DEVICE|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
214610606|NCT03294226|DEVICE|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
214610607|NCT01587378|DRUG|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
214610608|NCT01587378|DRUG|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
214610609|NCT05948007|DEVICE|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
214610610|NCT05948007|DEVICE|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
214610611|NCT05948007|BEHAVIORAL|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
214610612|NCT05049980|DRUG|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
214610613|NCT05049980|PROCEDURE|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
214610614|NCT05837520|DEVICE|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
214610615|NCT05837520|BEHAVIORAL|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
214610616|NCT01938131|DEVICE|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
214610617|NCT03561792|OTHER|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
214610618|NCT02475226|OTHER|type of the brain injury|epidural hematoma
214610619|NCT02475226|OTHER|type of the brain injury|subdural hematoma
214610620|NCT02475226|OTHER|type of the brain injury|subarachnoid hematoma
214610621|NCT02475226|OTHER|type of the brain injury|intraparenchymal hematoma
214610622|NCT02475226|OTHER|type of the brain injury|scull fracture
214610623|NCT02475226|OTHER|type of the brain injury|brain contusion
214610624|NCT01651104|BIOLOGICAL|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
214610625|NCT02794818|BEHAVIORAL|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
214610626|NCT03453073|BEHAVIORAL|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
214610627|NCT03453073|OTHER|physician diagnosis of first occurrence of serious chronic disease|
214610628|NCT01421927|DRUG|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~\- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~\- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant"
214610629|NCT05894174|BEHAVIORAL|Board Game|Food Hunter board game intervention, which includes various nutrient cards and question cards and is played with pawns and dice, will be played with children for approximately 4 weeks, one day a week and one session (40 minutes) with the researcher dietitian. By talking about the nutrients in the game on the game cards, children will be able to recognize the nutrients and important points will be emphasized for the participants with the answers to the cards containing various questions about healthy nutrition.
214610630|NCT02718599|DRUG|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
214610631|NCT02718599|DRUG|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
214714182|NCT01282567|OTHER|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
214714183|NCT02126813|PROCEDURE|increased interventional threshold for urinary bladder catheterization (800 ml)|
214714184|NCT02126813|PROCEDURE|Current used interventional threshold for urinary bladder catheterization (500 ml)|
214610632|NCT02614391|OTHER|Active distraction using a tablet|Playing a videogame using a computer tablet
214610633|NCT02614391|OTHER|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
214610634|NCT06417320|DRUG|ACEI, SGLT-2i|"Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)"
214610635|NCT06171620|DEVICE|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
214714185|NCT02126813|DEVICE|Intermittent bladder catheter|
214714186|NCT02284022|DEVICE|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
214714187|NCT04394689|BIOLOGICAL|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
214714188|NCT04394689|BIOLOGICAL|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
214610636|NCT06171620|OTHER|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
214610637|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
214610638|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
214610639|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
214610640|NCT02982590|DRUG|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
214610641|NCT02982590|DRUG|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
214610642|NCT03340649|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
214610643|NCT00350584|BEHAVIORAL|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
214610644|NCT00350584|BEHAVIORAL|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
214610645|NCT02676999|PROCEDURE|Implantation of a Scheker total distal radioulnar joint prosthesis|
214610646|NCT01168973|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
214714189|NCT04394689|OTHER|PLA-MNP|One placebo dose of a dissolving microneedle patch
214714190|NCT04394689|OTHER|PLA-SC|Placebo saline as subcutaneous injection
214714191|NCT00636441|DRUG|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
214714192|NCT01085604|OTHER|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
214610647|NCT01168973|DRUG|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
214610648|NCT01168973|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
214610649|NCT00087347|DRUG|ferumoxytol|
214714193|NCT03295604|PROCEDURE|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
214714194|NCT03295604|PROCEDURE|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
214610650|NCT00087347|PROCEDURE|magnetic resonance imaging|
214610651|NCT03975270|DRUG|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
214610652|NCT04860375|PROCEDURE|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
214610653|NCT04860375|OTHER|Standard care|Standard care in Sweden
214610654|NCT00906893|PROCEDURE|18F]-FMISO PET-CT|pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.
214610655|NCT06021899|OTHER|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
214610656|NCT00827684|DRUG|Irinotecan|
214610657|NCT00827684|DRUG|Temsirolimus|
214610658|NCT05902377|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
214610659|NCT00349167|DRUG|PR-104|
214610660|NCT00349167|OTHER|laboratory biomarker analysis|
214610661|NCT00349167|OTHER|pharmacological study|
214610662|NCT02408705|DRUG|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
214610663|NCT02408705|DRUG|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
214610664|NCT02408705|DRUG|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
214610665|NCT00699803|DRUG|T-PRED|T-PRED sterile ophthalmic solution
214610666|NCT00699803|DRUG|Pred Forte|Pred Forte sterile ophthalmic solution
214610667|NCT04688151|DRUG|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
214610668|NCT03505047|DEVICE|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
214610669|NCT00003370|DRUG|irofulven|
214610670|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in PD|Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).
214610671|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in PD|STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).
214610672|NCT06323564|DEVICE|International Affective Picture System (IAPS)|Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).
214610673|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in AN|Verbal Fluencies, Tower of London, TMT-A \& B
214610674|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in AN|STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).
214610675|NCT06323564|DIAGNOSTIC_TEST|Analysis of bio-humoral parameters|the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1
214610676|NCT00625989|DRUG|Aeroallergen|
214610677|NCT04424160|BIOLOGICAL|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
214610678|NCT02106286|DRUG|Bisoprolol|
214610679|NCT00215995|DRUG|Cisplatin|As outlined in Detailed Description
214610680|NCT00215995|DRUG|Irinotecan|As outlined in Detailed Description
214610681|NCT00215995|DRUG|ZD 1839|As outlined in Detailed Description
214610682|NCT02361450|DEVICE|Retrograde Colonic Irrigation|
214610683|NCT02361450|OTHER|Usual Care|
214714195|NCT02629536|DRUG|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
214714196|NCT05488704|DIAGNOSTIC_TEST|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken"
214714197|NCT05228080|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
214714198|NCT04324086|DEVICE|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
214610684|NCT01586884|PROCEDURE|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
214610685|NCT02218281|BEHAVIORAL|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
214610686|NCT02218281|BEHAVIORAL|NCI's QuitSTART app|NCI's smoking cessation app
214610687|NCT02218281|BEHAVIORAL|Written smoking cessation materials only|Receipt of written smoking cessation materials
214610688|NCT00338039|DRUG|Cetuximab|500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
214610689|NCT00338039|DRUG|Gemcitabine|"Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off."
214610690|NCT00338039|DRUG|Oxaliplatin|Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
214610691|NCT00338039|DRUG|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
214610692|NCT00338039|RADIATION|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
214610693|NCT05578859|DRUG|AMG 510|Single oral dose of AMG510.
214610694|NCT04479436|DRUG|Patritumab Deruxtecan|U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
214610695|NCT02176473|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
214610696|NCT02675816|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
214610697|NCT06256315|PROCEDURE|Hyper-ERAS Program|Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.
214610698|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow oxygen
214610699|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow air
214610700|NCT02357134|OTHER|Quality-of-Life Assessment|Ancillary studies
214610701|NCT02357134|OTHER|Questionnaire Administration|Ancillary studies
214610702|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow oxygen
214610703|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow air
214610704|NCT04745013|BEHAVIORAL|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
214610705|NCT04745013|BEHAVIORAL|Usual care|Only a written personalized exercise prescription will be provided.
214610706|NCT01380730|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214610707|NCT01380730|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
214610708|NCT00068211|DRUG|ILX651|
214610709|NCT03268434|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
214610710|NCT03268434|BEHAVIORAL|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
214714199|NCT04324086|DEVICE|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
214714200|NCT04324086|DEVICE|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
214714201|NCT01679522|PROCEDURE|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
214714202|NCT01679522|PROCEDURE|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
214610711|NCT01111942|OTHER|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)"
214610712|NCT01111942|PROCEDURE|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
214610713|NCT05925556|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
214610714|NCT00697450|DRUG|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
214610715|NCT00610545|DRUG|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
214610716|NCT00610545|DRUG|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
214610717|NCT00625352|DRUG|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
214610718|NCT03883191|OTHER|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
214610719|NCT03883191|OTHER|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
214610720|NCT00467779|DRUG|cobimetinib|Repeating oral dose
214610721|NCT00467779|DRUG|dextromethorphan|In Stage III only: single dose of dextromethorphan
214610722|NCT00467779|DRUG|midazolam|In Stage III only: single dose of midazolam
214610723|NCT02790255|OTHER|Cold air|
214610724|NCT02790255|OTHER|Cold water|
214610725|NCT04170790|DRUG|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
214610726|NCT04170790|DRUG|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
214714203|NCT00716326|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
214610727|NCT03413852|DEVICE|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
214610728|NCT01195090|DRUG|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
214610729|NCT01195090|DRUG|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
214610730|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
214714204|NCT00716326|DEVICE|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
214610731|NCT01701999|BIOLOGICAL|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
214610732|NCT05111041|BEHAVIORAL|#EnufSnuff.TXT- First Responder|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
214610733|NCT05111041|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
214610734|NCT01205230|DRUG|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
214610742|NCT01322503|BIOLOGICAL|Norovirus|Norovirus challenge pool administered to each subject
214610743|NCT03770949|DEVICE|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
214610744|NCT02520375|OTHER|Prebiotic|
214610745|NCT02520375|OTHER|Control|
214610746|NCT02575248|DRUG|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
214610747|NCT02575248|DRUG|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
214610748|NCT02712151|PROCEDURE|Abdominal Wall Block|bilateral TAP and RS blocks.
214610749|NCT02712151|PROCEDURE|Surgical infiltration|distributed between the 4 laparoscopic port sites.
214610750|NCT02712151|DRUG|Sterile saline|Placebo injection
214610751|NCT02712151|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
214610752|NCT02712151|DEVICE|Ultrasound|For nerve localization
214610753|NCT02712151|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
214610754|NCT04217304|DRUG|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
214610755|NCT00004754|DRUG|epoprostenol|
214610756|NCT05851742|DEVICE|TENS|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
214610757|NCT05851742|OTHER|Myofascial trigger point release|Release of trigger points
214610758|NCT01480453|DEVICE|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
214714205|NCT06609317|DEVICE|Digital therapeutic motion-based device|This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training
214714206|NCT06334172|DRUG|Oxytocin|Oxytocin
214714207|NCT06334172|OTHER|Placebo|Saline
214714208|NCT05238987|DIETARY_SUPPLEMENT|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
214610759|NCT04713423|DIAGNOSTIC_TEST|Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.
214610760|NCT06219070|OTHER|Core straining|The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
214610761|NCT00791258|DRUG|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
214610762|NCT00791258|DRUG|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
214610763|NCT05285709|DIAGNOSTIC_TEST|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
214610764|NCT05285709|DIAGNOSTIC_TEST|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
214610765|NCT02599454|DRUG|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
214610766|NCT02599454|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
214610767|NCT00774813|DEVICE|Nexalin 1.3mA Device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant"
214610768|NCT00774813|DEVICE|Nexalin 15mA device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant"
214610769|NCT00774813|DRUG|placebo device and Citalopram|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)"
214610770|NCT02678338|DRUG|Hu5F9-G4|
214610771|NCT03979222|DEVICE|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
214610772|NCT05439668|OTHER|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
214610773|NCT05439668|OTHER|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
214610774|NCT00041080|DRUG|tamoxifen citrate|Given orally
214610775|NCT00041080|DRUG|thalidomide|Given orally
214610776|NCT00041080|OTHER|laboratory biomarker analysis|Correlative studies
214610777|NCT00156234|BEHAVIORAL|One-knee extension ergometer|
214610778|NCT04784897|DRUG|Brilacidin|Brilacidin IV infusion
214610779|NCT04784897|DRUG|Placebo|Placebo IV infusion
214610780|NCT04784897|DRUG|Standard of Care (SoC)|SoC therapies for COVID-19
214610781|NCT01893229|DRUG|Lithium|Lithium is used as a mood stabiliser
214610782|NCT01893229|DRUG|Valproate|Valproate is used as a mood stabiliser
214610783|NCT01893229|DRUG|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
214610784|NCT01893229|DRUG|Quetiapine|Quetiapine is used as a mood stabiliser
214610785|NCT01893229|DRUG|Olanzapine|Olanzapine is used as a mood stabiliser.
214610786|NCT01893229|DRUG|Ziprasidone|Ziprasidone is used as a mood stabiliser
214610787|NCT04918745|DEVICE|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~* A - Baseline stimulation, no modulation stimulation~* B - Baseline stimulation, modulated stimulation~* C - Reduced baseline stimulation, modulated stimulation"
214610788|NCT00502073|DRUG|cyclosporine|
214610789|NCT02879227|DRUG|Cisplatin|Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
214610790|NCT02879227|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
214610791|NCT04841824|OTHER|Observational study|Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
214610792|NCT03878173|OTHER|No intervention|No intervention
214610793|NCT04667377|DRUG|BI 456906|BI 456906
214610794|NCT04667377|DRUG|Placebo|Placebo
214610795|NCT04722120|RADIATION|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
214610796|NCT04722120|RADIATION|Conventional CT (radiation)|Underwent liver CT without change of radiation.
214610797|NCT04722120|DRUG|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
214610798|NCT04722120|DRUG|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
214610799|NCT04722120|OTHER|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
214610800|NCT03687645|DIAGNOSTIC_TEST|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
214610801|NCT02428855|DRUG|Dasatinib|
214610802|NCT01887067|PROCEDURE|Renal denervation therapy|
214610803|NCT02057796|DEVICE|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
214610804|NCT02057796|DRUG|ART (Atripla, Truvada, Efavirenz, Combivir)|"* ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
214610805|NCT02057796|DRUG|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
214610806|NCT02066311|DRUG|Nelfinavir|
214610807|NCT00006151|BEHAVIORAL|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
214610808|NCT05623930|DEVICE|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
214610809|NCT05623930|OTHER|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
214610810|NCT00702364|DRUG|atomoxetine|
214610811|NCT00702364|DRUG|placebo|
214610812|NCT01312038|DRUG|Simethicone|single 125 mg chewable tablet
214610813|NCT01312038|DRUG|Placebo|chewable calcium tablet
214610814|NCT04781231|DEVICE|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
214610815|NCT04781231|DEVICE|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
214610816|NCT04781231|OTHER|Usual management of anxiety|No specific intervention
214610817|NCT04624464|OTHER|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
214610818|NCT04624464|OTHER|Examination of patient room|Only performed for cohort 2
214610819|NCT00655954|PROCEDURE|Induced sputum|Used Ultrasonic nebuliser
214610820|NCT03487809|DRUG|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
214610821|NCT03099642|RADIATION|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
214610822|NCT02607592|DRUG|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
214610823|NCT02607592|DRUG|nedaplatin+pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
214610824|NCT05784779|DRUG|GH509|Orally, once daily before bedtime (qhs)
214610825|NCT05784779|DRUG|Placebo|Orally, once daily before bedtime (qhs)
214610826|NCT03198520|DEVICE|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
214610827|NCT01670539|DEVICE|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
214610828|NCT06340048|DRUG|HiCM-188 therapy|Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
214610829|NCT05223634|OTHER|Collection of oral and/or nasal samples|Collection of oral and/or nasal samples after SOC test performed
214610830|NCT01684072|BIOLOGICAL|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
214610831|NCT01684072|BIOLOGICAL|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
214610832|NCT04353596|DRUG|ACE inhibitor, angiotensin receptor blocker|In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
214610833|NCT01599520|BEHAVIORAL|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
214610834|NCT01599520|BEHAVIORAL|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
214610835|NCT05418673|DRUG|BIIB122|Administered as specified in the treatment arm.
214610836|NCT05418673|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
214610837|NCT02968069|DEVICE|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
214610838|NCT05088642|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet
214610839|NCT02463721|OTHER|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
214610840|NCT01141114|OTHER|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
214610841|NCT01141114|OTHER|Usual care|Usual care
214610842|NCT05224063|DEVICE|Individualized CEN-targeted rTMS|Delivers patterned magnetic stimulation based on individualized CEN targeting
214610843|NCT05224063|DEVICE|Neuronavigated rTMS|Delivers patterned magnetic stimulation based on MRI images
214610844|NCT05224063|DEVICE|Scalp-targeted rTMS|Delivers patterned magnetic stimulation based on BEAM F3 targeting
214610845|NCT05224063|DEVICE|Sham rTMS|Delivers placebo magnetic stimulation
214610846|NCT00490178|DRUG|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
214610847|NCT05488600|BEHAVIORAL|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
214610848|NCT04492098|DIAGNOSTIC_TEST|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
214610849|NCT04717518|OTHER|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
214610850|NCT00659568|DRUG|metformin hydrochloride|
214610851|NCT00659568|DRUG|temsirolimus|
214610852|NCT03568474|DRUG|Silver Diamine Fluoride|Indirect pulp capping material
214610853|NCT03568474|DRUG|Glass Ionomer|Indirect pulp capping material
214610854|NCT02665052|DEVICE|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
214610855|NCT02665052|DEVICE|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
214610856|NCT02665052|BEHAVIORAL|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
214610857|NCT00082524|DRUG|caspofungin acetate|Duration of Treatment - 7-90 days
214610858|NCT00823823|OTHER|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
214610859|NCT00823823|OTHER|Circumferential cast|Circumferential cast will be applied following closed reduction
214610860|NCT03044938|DRUG|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
214610861|NCT03044938|DRUG|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
214610862|NCT06290349|DRUG|DA5221-T1|DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
214610863|NCT06290349|DRUG|DA5221-T2|DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
214610864|NCT06290349|DRUG|Placebo|DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
214610865|NCT06290349|DRUG|DA5221-B1|DA5221-B1, orally, daily for background therapy
214610866|NCT06290349|DRUG|DA5221-B2|DA5221-B2, orally, daily for background therapy
214610867|NCT04973982|DRUG|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
214610868|NCT04973982|DRUG|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
214610869|NCT03923556|DRUG|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
214610870|NCT03923556|DRUG|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
214610871|NCT02887664|PROCEDURE|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
214610872|NCT05840926|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12|Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
214610873|NCT05840926|OTHER|No probiotic supplementation|Children who did not receive any probiotic supplementation
214610874|NCT00097747|DRUG|Placebo|
214610875|NCT00097747|DRUG|peginesatide|
214610876|NCT06005337|BEHAVIORAL|Blogshots 1-3|"1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection"
214610877|NCT06005337|BEHAVIORAL|Blogshots 4-6|"1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media"
214610878|NCT00352287|DRUG|Recombinant human growth hormone; pioglitazone|
214610879|NCT06396091|DRUG|zolbetuximab|Zolbetuximab will be administered intravenously on day 1 then every two weeks.
214610880|NCT06396091|DRUG|mFOLFIRINOX|Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
214610881|NCT01202851|OTHER|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
214610882|NCT01202851|BEHAVIORAL|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
214610883|NCT01202851|OTHER|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
214610884|NCT00550654|OTHER|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
214610885|NCT00550654|RADIATION|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
214610886|NCT00550654|RADIATION|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
214610887|NCT00550654|RADIATION|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
214610888|NCT00550654|RADIATION|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
214610889|NCT06016179|DRUG|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
214610890|NCT03406299|DRUG|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
214610891|NCT03406299|DRUG|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
214610892|NCT03406299|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
214610893|NCT03406299|DRUG|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
214610894|NCT03406299|DRUG|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
214610895|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
214610896|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
214610897|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
214610898|NCT04762316|DRUG|SB-UF|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
214610899|NCT04762316|DEVICE|SB-UF Placebo|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
214610900|NCT03128567|DEVICE|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
214610901|NCT05955391|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
214610902|NCT05996523|BIOLOGICAL|PRGN-2009|PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
214610903|NCT05996523|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
214610904|NCT05133440|DRUG|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
214610905|NCT05133440|DIAGNOSTIC_TEST|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
214714209|NCT02157168|BEHAVIORAL|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
214714210|NCT03746067|DRUG|TS-134|5 mg, 10 mg, or 20 mg oral solution
214714211|NCT03746067|DRUG|Placebo|Matched Placebo oral solution
214714212|NCT01884168|BIOLOGICAL|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
214714213|NCT06092853|OTHER|Gingival crevicular fluid (GCF) and serum samples|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
214714214|NCT02680405|PROCEDURE|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
214714215|NCT02680405|PROCEDURE|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
214714216|NCT02680405|PROCEDURE|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
214714217|NCT04637971|OTHER|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
214714218|NCT04637971|OTHER|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
214714219|NCT03357913|OTHER|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
214610906|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
214610907|NCT00215124|DRUG|Filgrastim|
214610908|NCT04329351|PROCEDURE|Guided Bone regeneration|Guided bone regeneration to ridge preservation
214714220|NCT02011867|DEVICE|Cork Electrode|
214714221|NCT03332472|OTHER|Telemedicine group|
214714222|NCT03332472|OTHER|Conventional group|
214714223|NCT03495817|DRUG|ATI-50002|ATI-50002 Topical Solution
214714224|NCT02781454|DRUG|Mexiletine|
214714225|NCT02781454|DRUG|Placebo|
214714226|NCT04585451|DIAGNOSTIC_TEST|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
214714227|NCT04693689|OTHER|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
214714228|NCT04693689|OTHER|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
214610909|NCT03469583|DRUG|EYP001|EYP001 self administered capsules, morning, with non carbonated water
214610910|NCT03469583|DRUG|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
214610911|NCT04328948|RADIATION|Chemoradiotherapy|Chemoradiotherapy
214610912|NCT06330350|OTHER|Qualitative interview|Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
214714229|NCT04693689|OTHER|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
214714230|NCT04693689|OTHER|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
214714231|NCT04693689|OTHER|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
214714232|NCT04693689|OTHER|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
214714233|NCT04693689|OTHER|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
214714234|NCT01682070|BIOLOGICAL|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
214714235|NCT01682070|BIOLOGICAL|Placebo|
214714236|NCT00000196|DRUG|Naltrexone|
214714237|NCT02183623|DRUG|Simvastatin|
214714238|NCT02183623|DRUG|10 mg BI 1356 BS|
214714239|NCT02372097|DRUG|SYR-472|SYR-472 25mg, 50mg
214714240|NCT05366530|OTHER|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
214714241|NCT01097148|DRUG|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
214714242|NCT03198780|OTHER|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
214714243|NCT02608229|DRUG|BVD-523|
214610913|NCT03884712|DEVICE|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
214610914|NCT05451563|DEVICE|Double-S|Wearable device for intercourse
214610915|NCT05362929|DEVICE|Sciton Halo|Laser treatment
214714244|NCT02608229|DRUG|Nab-paclitaxel|
214714245|NCT02608229|DRUG|Gemcitabine|
214714246|NCT02608229|PROCEDURE|Tumor biopsy|
214714247|NCT01519401|DRUG|3 mg drospirenone and 20 µg ethinyl-estradiol|
214714248|NCT01519401|DRUG|3 mg drospirenone and 30 µg ethinyl-estradiol|
214714249|NCT02714504|DRUG|Voriconazole or posaconazole|Azole with activity against molds
214610916|NCT00190827|DRUG|duloxetine|
214610917|NCT00190827|DRUG|placebo|
214610918|NCT05119218|OTHER|No Intervention|No Intervention
214610919|NCT04992962|DRUG|CBD/CBN|A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
214610920|NCT04992962|DRUG|CBD/THC|A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
214714250|NCT03009812|PROCEDURE|Longitudinal uterine incision|
214714251|NCT03009812|PROCEDURE|Transverse uterine incision|
214714252|NCT05101395|OTHER|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
214714253|NCT02159261|DRUG|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
214714254|NCT05875376|BEHAVIORAL|Couple group therapy|"1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection"
214714255|NCT02849626|DRUG|Perampanel|E2007
214714256|NCT03941691|DEVICE|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
214714257|NCT03941691|DEVICE|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
214610921|NCT04992962|DRUG|Placebo|An inactive compound.
214610922|NCT02441673|DRUG|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
214610923|NCT02441673|DRUG|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
214714258|NCT05589844|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
214714259|NCT05589844|PROCEDURE|Biospecimen Collection|Correlative studies
214714260|NCT05589844|BIOLOGICAL|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
214714261|NCT01957787|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
214714262|NCT04393077|BEHAVIORAL|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
214714263|NCT04176445|DEVICE|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
214714264|NCT04176445|OTHER|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
214610924|NCT02441673|DRUG|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
214610925|NCT02441673|DRUG|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
214610926|NCT02441673|DRUG|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
214610927|NCT02441673|DRUG|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
214610928|NCT02441673|DRUG|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
214610929|NCT06399848|OTHER|Skip one day of peritoneal dialysis treatment|Skip one day of peritoneal dialysis treatment
214610930|NCT05857540|PROCEDURE|Plyometric and strengthening exercises|Each session includes 2 upper-extremity plyometric exercises in bodyweight or with weight ball for 15-20 minutes and 4-5 strengthening exercises with band, dumbbell or barbell for 30-35 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
214610931|NCT05857540|PROCEDURE|Strengthening exercise|Each session includes 5 upper-extremity strengthening exercises with band, dumbbell or barbell for 50 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
214610932|NCT00217529|BIOLOGICAL|pegfilgrastim|
214610933|NCT00217529|DRUG|carboplatin|
214610934|NCT00217529|DRUG|docetaxel|
214610935|NCT00217529|DRUG|erlotinib hydrochloride|
214610936|NCT04005651|DEVICE|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
214610937|NCT04005651|DEVICE|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
214610938|NCT04005651|DEVICE|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
214610939|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 1|2 doses of study intervention are administered to participants intramuscularly.
214610940|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 2|2 doses of study intervention are administered to participants intramuscularly.
214610941|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 3.|2 doses of study intervention are administered to participants intramuscularly.
214610942|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 4|2 doses of study intervention are administered to participants intramuscularly.
214610943|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 5|2 doses of study intervention are administered to participants intramuscularly.
214610944|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 6|2 dose of study intervention is administered to participants intramuscularly.
214610945|NCT06382311|BIOLOGICAL|Influenza virus vaccine|2 doses of Influenza virus vaccine are administered to participants intramuscularly.
214610946|NCT06382311|DRUG|Placebo|2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 2 dose is administered to participants in Phase 2 Part B.
214610947|NCT02868177|DIETARY_SUPPLEMENT|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
214610948|NCT02868177|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
214610949|NCT03607123|OTHER|programing of pacemaker|Different programing parameters will be set in different group/stage
214610950|NCT03607123|PROCEDURE|AF ablation|AF ablation can only be performed in Step 3
214610951|NCT03607123|DRUG|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
214610952|NCT00000180|DRUG|AIT-082|
214610953|NCT01561625|OTHER|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
214610954|NCT04092517|OTHER|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
214610955|NCT04092517|OTHER|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
214610956|NCT06155747|OTHER|Epidemiologic investigation|"Identification of:~1. overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~2. environmental NTM isolates that are highly related to respiratory isolates.~3. common water source exposure among subjects with clustered NTM infections via shared home of residence watershed."
214610957|NCT04731038|DRUG|Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin|This is a single-arm study with all patients receiving these four drugs.
214610958|NCT01274936|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
214610959|NCT01274936|DRUG|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
214610960|NCT00646594|DRUG|budesonide/formoterol (Symbicort)|
214610961|NCT00646594|DRUG|fluticasone/salmeterol (Advair)|
214610962|NCT02439996|DRUG|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
214610963|NCT02439996|DRUG|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
214610964|NCT02439996|DRUG|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
214610965|NCT00473551|DRUG|Rituximab|375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.
214610966|NCT00473551|DRUG|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
214610967|NCT00473551|DRUG|Fludarabine|40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
214610968|NCT00473551|DRUG|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
214610969|NCT00473551|RADIATION|Radiation Treatment|2Gy Total body radiation day before transplantation
214610970|NCT00473551|PROCEDURE|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
214610971|NCT00473551|DRUG|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
214610972|NCT00473551|PROCEDURE|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
214610973|NCT00463268|DRUG|alendronate|alendronate 70 mg every 2 weeks
214610974|NCT00463268|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
214610975|NCT00463268|DRUG|placebo|identical placebo every 2 weeks
214610976|NCT01460953|BEHAVIORAL|health literacy training video|participants will watch a training video
214610977|NCT04351763|DRUG|Amiodarone|Ion channel blocker
214610978|NCT04351763|DRUG|Verapamil|Ion channel blocker
214610979|NCT02902081|DRUG|Cannabidiol|
214610980|NCT02902081|DRUG|Placebo|
214610981|NCT03390543|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
214610982|NCT03390543|DEVICE|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
214610983|NCT03512639|DRUG|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
214610984|NCT03512639|DRUG|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
214610985|NCT04307160|PROCEDURE|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
214610986|NCT04422990|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
214610987|NCT04422990|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
214610988|NCT04422990|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
214610989|NCT00196638|DRUG|Antiretroviral combination (drugs)|
214610990|NCT00196638|DRUG|Pegylated Interferon alpha (drug)|
214610991|NCT01490814|PROCEDURE|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
214610992|NCT01490814|PROCEDURE|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
214610993|NCT01127659|DRUG|testosterone|intramuscular every 2 weeks
214610994|NCT01127659|DRUG|placebo|saline intramuscular every 2 weeks
214610995|NCT03024970|DEVICE|stenfilcon A lens with solution additive (test)|silicone hydrogel lens
214610996|NCT03024970|DEVICE|stenfilcon A lens (control)|contact lens
214610997|NCT00814671|DRUG|Rifapentine 450|rifapentine 450 mg
214610998|NCT00814671|DRUG|Rifapentine 600|rifapentine 600 mg
214610999|NCT00814671|DRUG|Rifampin|rifampin 600 mg
214714265|NCT01148316|DRUG|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
214611000|NCT06232928|DEVICE|Early Class II elastics|Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
214611001|NCT06232928|DEVICE|Conventional Class II elastics|patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
214611002|NCT04557319|BIOLOGICAL|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
214611003|NCT04557319|BIOLOGICAL|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
214611004|NCT04557319|BIOLOGICAL|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
214611005|NCT01221727|DRUG|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
214611006|NCT01221727|DRUG|Midazolam|All subjects will receive two oral dose administrations of midazolam.
214611007|NCT04006340|COMBINATION_PRODUCT|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
214611008|NCT04006340|COMBINATION_PRODUCT|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
214611009|NCT04006340|DIAGNOSTIC_TEST|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
214611010|NCT03750578|BEHAVIORAL|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
214611011|NCT03241199|DRUG|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
214611012|NCT03084406|OTHER|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
214611013|NCT01881945|OTHER|Non-invasive physiological signal recording on healthy volunteer|
214611014|NCT05060705|DRUG|Efesovir|Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
214611015|NCT03965936|PROCEDURE|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
214611016|NCT03965936|PROCEDURE|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
214611017|NCT02654366|BEHAVIORAL|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
214611018|NCT05421962|DRUG|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
214611019|NCT01408433|OTHER|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
214611020|NCT01408433|OTHER|Double embryo transfer|two (2) embryo transfer of untested embryos
214611021|NCT05010954|DRUG|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
214611022|NCT05010954|DRUG|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
214714266|NCT01148316|BEHAVIORAL|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
214611023|NCT00225979|DRUG|Octreotide LAR|
214611024|NCT05864742|DRUG|Ibrutinib|560 mg daily continuously
214611025|NCT05864742|DRUG|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
214611026|NCT05864742|DRUG|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
214611027|NCT05864742|DRUG|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
214611028|NCT02616744|DRUG|Ibandronic acid|150 mg per month oral ibandronate
214611029|NCT02616744|DRUG|Placebo|1 oral capsule of placebo per month
214611030|NCT00189618|DRUG|Aspirin|100mg p.o. OD
214611031|NCT00189618|DRUG|Clopidogrel|75mg p.o. OD
214611032|NCT02790138|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
214611033|NCT02790138|DRUG|Ciprofloxacin|Ciprofloxacin tablets
214611034|NCT02790138|DRUG|Vedolizumab|Vedolizumab IV infusion
214611035|NCT04360499|OTHER|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
214611036|NCT04360499|OTHER|Pilates training|Pilates style exercise training
214611037|NCT02903251|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
214611038|NCT02903251|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
214611039|NCT02408107|BEHAVIORAL|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
214611040|NCT06343935|DRUG|Linperlisib|Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
214611041|NCT05300321|DEVICE|frame lens|The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
214611042|NCT01786603|DRUG|Rasagiline|Rasagiline 2mg once a day for 12 months.
214611043|NCT01786603|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
214611044|NCT02985099|DRUG|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
214611045|NCT02985099|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
214611046|NCT01226459|DRUG|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
214611047|NCT01226459|DRUG|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
214611048|NCT03848754|DRUG|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
214611049|NCT03848754|DRUG|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
214611050|NCT03848754|DRUG|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
214611051|NCT03848754|DRUG|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
214611052|NCT01059110|DRUG|Salicylate ointment|cream, one application every night, for 90 days
214611053|NCT01059110|DRUG|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
214611054|NCT01059110|DRUG|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
214611055|NCT01059110|DRUG|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
214611056|NCT01112176|PROCEDURE|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
214611057|NCT00474708|DRUG|Effexor|
214611058|NCT00474708|DRUG|SSRI|
214611059|NCT01030159|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
214611060|NCT03770091|DRUG|Theraworx|Theraworx foam applied to skin and/or compression wrap
214611061|NCT03770091|DRUG|Placebo|Placebo foam
214611062|NCT00187213|DEVICE|Cardiac Resynchronization Therapy|
214611063|NCT00625495|DRUG|Esomeprazole|40mg Intravenous infusion over 3 minutes
214611064|NCT00625495|DRUG|Esomeprazole|40mg Oral
214714267|NCT04571918|PROCEDURE|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
214714268|NCT04571918|PROCEDURE|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
214714269|NCT04922034|DRUG|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
214714270|NCT02496117|PROCEDURE|Electrical mapping, nerve stimulation checked renal denervation procedure|
214714271|NCT02496117|PROCEDURE|Electrial mapping, nerve stimulation guided renal denervation procedure|
214714272|NCT05113719|OTHER|Exercise|Both groups will perform bridge exercise
214714273|NCT02581618|OTHER|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
214714274|NCT01713855|BIOLOGICAL|Inactivated Trivalent Influenza vaccine|
214714275|NCT03173612|DRUG|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
214714276|NCT02780596|OTHER|Item1|Does CHILD NAME often wake one or more times during the night?
214714277|NCT02780596|OTHER|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
214714278|NCT02780596|OTHER|Item3|Do you think CHILD'S SLEEP is a problem?
214714279|NCT02780596|OTHER|Item4|Do you think CHILD NAME has a sleep problem?
214714280|NCT02780596|OTHER|Item5|Do you have any concerns about CHILD NAME'S sleep?
214714281|NCT04715412|OTHER|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
214714282|NCT01887106|DRUG|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
214611065|NCT00136526|DRUG|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
214611066|NCT03700320|DRUG|Standard of Care (SOC) Migraine Preventive Medication|Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
214611067|NCT03700320|DRUG|Atogepant|Atogepant tablets taken orally, once daily for 52 weeks.
214611068|NCT00480181|DRUG|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
214611069|NCT00480181|OTHER|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
214611070|NCT03193762|OTHER|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
214611071|NCT03951051|DRUG|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
214611072|NCT03951051|DRUG|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
214611073|NCT03039231|DEVICE|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
214611074|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
214611075|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
214611076|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
214611077|NCT01504165|DRUG|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
214611078|NCT01504165|DRUG|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
214611079|NCT02841202|DRUG|oral contraceptive pills|
214611080|NCT01391403|DRUG|Artemisinin|400 mg/day
214611081|NCT01391403|OTHER|Placebo|400mg/day
214611082|NCT01083524|DRUG|Dichloroacetate Sodium|3 mg po bid for 28 weeks
214611083|NCT01083524|DRUG|Dichloroacetate Sodium|6.25 mg po bid
214611084|NCT01083524|DRUG|Dichloroacetate Sodium|12.5 mg po bid
214611085|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Consult
214611086|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Control - Standard of Care
214611087|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Newsletter
214611088|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Parent Letter
214611089|NCT04970550|OTHER|Non intervention|Non intervention
214611090|NCT00838292|DIETARY_SUPPLEMENT|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
214611091|NCT00838292|OTHER|nutrition counseling|
214611092|NCT00175877|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
214611093|NCT01978535|DRUG|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
214611094|NCT01978535|DRUG|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
214611095|NCT03306355|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
214714283|NCT01887106|DRUG|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
214714284|NCT01887106|DRUG|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
214714285|NCT01887106|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
214714286|NCT04014270|DEVICE|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
214611096|NCT03306355|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
214611097|NCT05311670|BEHAVIORAL|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
214611098|NCT04961268|DRUG|TraMADol 50 Mg Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
214611099|NCT04961268|DRUG|Tramadol 100 MG Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
214611100|NCT04961268|DRUG|Ibuprofen 600Mg Tab|The patients were randomly given the medication by mouth 60 min before administering IANB.
214714287|NCT04014270|OTHER|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
214714288|NCT01090219|PROCEDURE|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
214714289|NCT04649762|BEHAVIORAL|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
214611101|NCT04961268|DRUG|ibuprofen 600 mg/acetaminophen 1000 mg|The patients were randomly given the medication by mouth 60 min before administering IANB.
214611102|NCT04961268|DRUG|Placebo|The patients were randomly given the medication by mouth 60 min before administering IANB.
214611103|NCT02042651|DEVICE|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
214611104|NCT02042651|DEVICE|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
214611105|NCT05520437|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
214611106|NCT05520437|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
214611107|NCT04278300|BIOLOGICAL|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
214611108|NCT04278300|BIOLOGICAL|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
214611109|NCT03456648|DRUG|apixaban|non-vitamin K oral anticoagulant (NOAC)
214611110|NCT05680571|DEVICE|BulbiCam|BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
214714290|NCT03780491|OTHER|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
214714291|NCT02248857|OTHER|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
214611111|NCT05511974|DIAGNOSTIC_TEST|BASET score|The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
214611112|NCT03171766|DIAGNOSTIC_TEST|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
214611113|NCT03171766|DIAGNOSTIC_TEST|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
214611114|NCT03171766|DIAGNOSTIC_TEST|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
214611115|NCT04961151|OTHER|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
214611116|NCT04961151|OTHER|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
214611117|NCT04514120|OTHER|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
214611118|NCT05117255|BEHAVIORAL|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
214611119|NCT05117255|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
214611120|NCT05538520|OTHER|Traditional Pilates|This group will perform a traditional Pilates session, which consists of stretching exercises, followed by exercises to strengthen the core (trunk flexors and extensors), lower limbs and upper limbs. The total duration of the intervention in this group should be approximately 50 minutes.
214611121|NCT05538520|OTHER|Pilates without stretching|This group will conduct a non-traditional Pilates session. This is because stretching exercises will be excluded. The muscle strengthening exercises will be the same as in the TP group, so that it is possible to discuss the influence of the inclusion/exclusion of stretching for the considered outcomes. The total duration of the intervention in this group should be approximately 35 minutes.
214611122|NCT01092143|DRUG|BI 671800|BI 671800
214611123|NCT01092143|DRUG|Fluticasone propionate placebo|Placebo matching Fluticasone propionate
214611124|NCT01092143|DRUG|Fluticasone propionate|Fluticasone propionate
214611125|NCT01092143|DRUG|BI 671800 Placebo|Placebo matching BI 671800
214611126|NCT02407470|DRUG|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
214611127|NCT02407470|PROCEDURE|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
214611128|NCT02407470|PROCEDURE|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
214611129|NCT05189613|BIOLOGICAL|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
214611130|NCT04643314|OTHER|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
214611131|NCT00786812|DRUG|Nilotinib|
214611132|NCT01380639|OTHER|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
214611133|NCT00919555|DRUG|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
214611134|NCT00919555|DRUG|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
214611135|NCT00919555|DRUG|Placebo|Placebo
214611136|NCT02743416|OTHER|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
214611137|NCT04575103|DRUG|Antipsychotic|Antipsychotic treatment \>0.5 DDD
214611138|NCT04301362|DIAGNOSTIC_TEST|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
214611139|NCT02357823|OTHER|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
214611140|NCT02357823|OTHER|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
214611141|NCT01491295|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
214611142|NCT01491295|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
214611143|NCT04382196|OTHER|Online survey|An online survey will be administered
214611144|NCT06211465|PROCEDURE|Total joint arthroplasty|Hip or knee total joint arthroplasty
214611145|NCT05831553|DIAGNOSTIC_TEST|Tissue Immune Profile|Tissue samples of the patients will be analized for the presence of TILs, CD73 and PDL1 (\>=1%)
214611146|NCT01528813|DEVICE|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
214611147|NCT01528813|DRUG|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
214611148|NCT05613166|DRUG|Everolimus|Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.
214611149|NCT05613166|DRUG|Placebo|Vitamin C
214611150|NCT04254744|DRUG|Sevoflurane|Sevoflurane inhalation for anesthesia
214611151|NCT06375434|OTHER|No intervention|No intervention
214611152|NCT02345304|DRUG|Omeprazole|
214611153|NCT02345304|DRUG|Warfarin|
214611154|NCT02345304|DRUG|BI 1181181|
214611155|NCT02345304|DRUG|Midazolam|
214611156|NCT02345304|DRUG|Omeprazole|
214611157|NCT02345304|DRUG|BI 1181181|
214611158|NCT02345304|DRUG|Midazolam|
214611159|NCT02345304|DRUG|Midazolam|
214611160|NCT02345304|DRUG|Warfarin|
214611161|NCT02345304|DRUG|BI 1181181|
214611162|NCT02345304|DRUG|Digoxin|
214611163|NCT02345304|DRUG|Digoxin|
214611164|NCT00103428|BIOLOGICAL|CG7870|
214611165|NCT03920150|DRUG|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
214611166|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
214611167|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
214611168|NCT02495350|OTHER|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
214611169|NCT00189072|DRUG|gabapentin|
214611170|NCT04115826|PROCEDURE|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
214611171|NCT04115826|PROCEDURE|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
214714292|NCT02248857|OTHER|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
214714293|NCT03949140|PROCEDURE|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
214611172|NCT04215614|DRUG|Lidocaine and Bupivacaine solution|1:1 ratio 2% lidocaine, and 0.5% bupivacaine
214611173|NCT04215614|DEVICE|Costoclavicular block|Ultrasound-guided costoclavicular brachial plexus block
214611174|NCT04215614|DEVICE|Lateral Sagittal block|Ultrasound-guided lateral sagittal brachial plexus block
214611175|NCT05584254|DIETARY_SUPPLEMENT|yeast-beta glucan|
214611176|NCT00286351|DRUG|Combined treatment with Arimidex and Zoladex before IVF|
214714294|NCT03384524|DRUG|Bromocriptine 2.5 MG|Administered daily
214611177|NCT01515293|PROCEDURE|Single Incision Laparoscopic Appendectomy|
214611178|NCT01515293|PROCEDURE|Conventional appendectomy|
214611179|NCT01961206|OTHER|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
214611180|NCT06178237|DEVICE|Purabond|Application of Purabond to surgical field
214611181|NCT04295616|DEVICE|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
214714295|NCT03384524|DRUG|Metoprolol 25 MG|Administered daily
214714296|NCT03384524|DRUG|Tamsulosin 0.4 MG|Administered daily
214714297|NCT03384524|OTHER|Placebo|Three pills, matching active drugs to be administered daily
214714298|NCT06524596|DRUG|tartaric acid butorphanol|The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
214714299|NCT06524596|DRUG|normal saline|The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
214714300|NCT06524596|DRUG|propofol and remifentanil|Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
214611182|NCT04295616|BEHAVIORAL|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
214611183|NCT01400581|BEHAVIORAL|Collaborative Care Intervention|See description of Intervention arm
214611184|NCT00620568|DRUG|SLV-313 SR|sustained release tablets taken once daily for 14 days
214611185|NCT00932425|DEVICE|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
214611186|NCT02774616|DEVICE|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
214611187|NCT02774616|DEVICE|Plexa ICD lead|predefined follow-up schedule
214611188|NCT00137163|DEVICE|Dermafill Dressing|
214611189|NCT00334126|DRUG|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
214611190|NCT03050996|PROCEDURE|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
214611191|NCT02975492|DRUG|Cholecalciferol sequential dose|sequential dose administration of the treatment
214611192|NCT02975492|DRUG|Cholecalciferol daily dose|daily dose administration of the treatment
214611193|NCT04253535|OTHER|questionnaries|Study on questionnaries
214611194|NCT04915651|DEVICE|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
214611195|NCT01910350|BEHAVIORAL|Kin KeeperSM Cancer Prevention Intervention|
214611196|NCT01910350|OTHER|Standard of care|
214611197|NCT04420650|DEVICE|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
214611198|NCT00514163|DRUG|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
214611199|NCT00514163|DRUG|gemcitabine|gemcitabine DIV on day one , 8th and 15th
214611200|NCT05173142|DRUG|HMPL-453|HMPL-453 administered orally.
214611201|NCT05173142|DRUG|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
214611202|NCT05173142|DRUG|toripalimab|Toripalimab administered intravenously.
214611203|NCT05173142|DRUG|Docetaxel|Docetaxel administered intravenously.
214611204|NCT00397033|DRUG|Paliperidone ER|6mg/day paliperidone er for 6 weeks
214611205|NCT00397033|DRUG|Paliperidone ER|12mg/day paliperidone er for 6 weeks
214611206|NCT00397033|DRUG|Placebo|Placebo for 6 weeks
214611207|NCT02630446|OTHER|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
214611208|NCT00502346|DRUG|PM10|
214611209|NCT03533595|DEVICE|Barbed|Barbed Suture
214611210|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
214611211|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
214611212|NCT00067860|DRUG|recombinant human growth hormone|
214611213|NCT00067860|BEHAVIORAL|diet modification|
214611214|NCT01984164|DRUG|Candesartan|blinded
214611215|NCT01984164|DRUG|Lisinopril|Blinded
214611216|NCT05881889|DEVICE|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
214611217|NCT05881889|DEVICE|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
214611218|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with novel Dynamic Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.
214611219|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with Standard Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
214611220|NCT00584883|DRUG|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
214611221|NCT03031379|OTHER|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
214611222|NCT05187624|DRUG|RO7428731|Participants will receive RO7428731 as described.
214611223|NCT02546765|DRUG|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
214611224|NCT02546765|DRUG|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
214611225|NCT02546765|DRUG|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
214611226|NCT02546765|DRUG|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
214611227|NCT02763228|BEHAVIORAL|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
214611228|NCT02763228|BEHAVIORAL|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
214714301|NCT03453918|DIETARY_SUPPLEMENT|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
214611229|NCT02763228|BEHAVIORAL|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
214611230|NCT02763228|BEHAVIORAL|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
214611231|NCT02763228|BEHAVIORAL|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
214611232|NCT02763228|BEHAVIORAL|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
214611233|NCT02763228|BEHAVIORAL|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
214611234|NCT05327621|DRUG|Pamiparib|40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
214611235|NCT06039462|BEHAVIORAL|Application of a virtual reality headset|Use of a headset to experience a different reality
214611236|NCT00086970|DRUG|ifosfamide|Given IV
214611237|NCT00086970|DRUG|O6-benzylguanine|Given IV
214611238|NCT02064920|DRUG|Placebo|Placebo for donepezil hydrochloride capsule
214611239|NCT02064920|DRUG|Donepezil|5 mg donepezil hydrochloride capsule.
214611240|NCT02064920|DRUG|Donepezil|10 mg donepezil hydrochloride capsule.
214611241|NCT06043674|DRUG|Glofitamab|"2:1 T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol."
214611242|NCT06043674|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, administered via intravenous infusion per protocol.
214611243|NCT06043674|DRUG|Polatuzumab Vedotin|Antibody-drug conjugate, administered via intravenous infusion per protocol.
214611244|NCT06043674|DRUG|Atezolizumab|Humanized immunoglobulin monoclonal antibody, administered via intravenous infusion per protocol.
214611245|NCT06043674|DRUG|Tocilizumab|For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, administered via intravenous infusion per protocol.
214611246|NCT06043674|DRUG|Pirtobrutinib|Selective inhibitor of BTK, 50 mg or 100 mg tablet, via oral administration per protocol.
214611247|NCT06537778|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 45 h.
214611248|NCT06537778|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
214611249|NCT04085315|DRUG|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
214611250|NCT04085315|DRUG|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
214611251|NCT03573609|DEVICE|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
214611252|NCT04749342|OTHER|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
214722366|NCT02948504|PROCEDURE|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
214611253|NCT03447951|DRUG|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
214611254|NCT06970704|OTHER|Erector Spinae Plane Block using 0.25 % bupivacaine|After induction of anesthesia and prone positioning and before surgery, Erector Spinae Plane Block was performed bilaterally using a low-frequency curved ultrasound transducer placed in a longitudinal orientation 3 cm lateral to the spinous process one vertebral level above a predetermined marked surgical incision. An 8-cm 22-gauge block needle was inserted in a cephalad to caudad direction until the tip lay in the interfascial plane below the erector spinae muscle, the block was performed by injection of 20 ml of 0.25% bupivacaine. Fentanyl 1 µg/kg as a rescue analgesia was given based on hemodynamic parameters.
214611255|NCT05834348|DRUG|lorlatinib|As provided in real world practice
214611256|NCT05834348|DRUG|crizotinib|As provided in real world practice
214611257|NCT05834348|DRUG|brigatinib|As provided in real world practice
214611258|NCT05834348|DRUG|ceritinib|As provided in real world practice
214611259|NCT05834348|DRUG|alectinib|As provided in real world practice
214611260|NCT05834348|DRUG|atezolizumab|As provided in real world practice
214611261|NCT05834348|DRUG|bevacizumab|As provided in real world practice
214611262|NCT05834348|DRUG|paclitaxel|As provided in real world practice
214611263|NCT05834348|DRUG|carboplatin|As provided in real world practice
214611264|NCT05834348|DRUG|docetaxel|As provided in real world practice
214611265|NCT05834348|DRUG|erlotinib|As provided in real world practice
214611266|NCT05834348|DRUG|gefitinib|As provided in real world practice
214722367|NCT02524535|OTHER|Therapeutic alliance|
214611267|NCT05834348|DRUG|afatinib|As provided in real world practice
214611268|NCT05834348|DRUG|dacomitinib|As provided in real world practice
214611269|NCT05834348|DRUG|osimertinib|As provided in real world practice
214611270|NCT05834348|DRUG|pembrolizumab|As provided in real world practice
214611271|NCT05834348|DRUG|nivolumab|As provided in real world practice
214611272|NCT05834348|DRUG|entrectinib|As provided in real world practice
214611273|NCT05992025|BEHAVIORAL|Physical activity|Intervention with physical activity more than 150 minutes of medium to high intensity per week.
214611274|NCT05992025|BEHAVIORAL|Sleep hygiene|Intervention with sleep hygiene to optimize sleep duration and quality.
214611275|NCT05770102|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214611276|NCT03188393|PROCEDURE|Biopsy of Breast|Undergo stereotactic biopsy
214611277|NCT02620267|DEVICE|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
214611278|NCT05051150|DRUG|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
214611279|NCT05051150|DRUG|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
214611280|NCT05051150|DRUG|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
214714302|NCT03453918|OTHER|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
214714303|NCT05317013|DRUG|CBD|CBD
214714304|NCT05317013|OTHER|Placebo|Placebo
214714305|NCT01412060|DRUG|Placebo|Placebo was supplied in capsules.
214714306|NCT01412060|DRUG|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
214714307|NCT04712266|DRUG|Glucagon|calculated IV insulin:Glucagon molar ratio
214714308|NCT04712266|DRUG|Insulin|calculated IV Insulin dose infused at a constant rate
214611281|NCT01320787|DRUG|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
214611282|NCT03608982|OTHER|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
214611283|NCT03608982|OTHER|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
214611284|NCT01710592|DRUG|Epirubicin|
214611285|NCT01710592|DRUG|Oxaliplatin|
214611286|NCT01710592|DRUG|Capecitabine|
214611287|NCT01710592|DRUG|Docetaxel|
214611288|NCT03926845|OTHER|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
214611289|NCT03926845|OTHER|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
214714309|NCT01043848|PROCEDURE|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
214714310|NCT04029324|PROCEDURE|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
214714311|NCT04029324|PROCEDURE|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
214714312|NCT04029324|PROCEDURE|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
214714313|NCT04029324|PROCEDURE|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
214714314|NCT02219841|PROCEDURE|radiofrequency catheter ablation|
214714315|NCT06281379|PROCEDURE|Total mesogastrectomy|More extended resection type with better oncological outcomes when compared to standard technique
214714316|NCT00505102|DRUG|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
214714317|NCT00170742|DRUG|Octreotide, 30 mg i.m. LAR formulation|
214714318|NCT03303287|BEHAVIORAL|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
214714319|NCT00004732|PROCEDURE|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
214714320|NCT00004732|DEVICE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
214714321|NCT03742115|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
214714322|NCT03742115|DRUG|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
214714323|NCT03742115|DRUG|Etoposide|150 mg/m2 weekly
214714324|NCT03742115|DRUG|IVIG|0.5 g/kg, once every 4 weeks
214714325|NCT03441347|BEHAVIORAL|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
214714326|NCT03441347|OTHER|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
214714327|NCT00442767|DRUG|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
214714328|NCT00442767|DRUG|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
214714329|NCT01183312|DRUG|Flumazenil|Sublingual flumazenil
214714330|NCT04097015|DEVICE|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
214714331|NCT04373785|RADIATION|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
214611290|NCT01129921|DEVICE|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
214611291|NCT01129921|DEVICE|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
214611292|NCT05785390|DRUG|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
214611293|NCT05785390|OTHER|Placebo|Identical placebo
214611294|NCT02672098|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
214714332|NCT04373785|DRUG|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
214611295|NCT02672098|DRUG|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
214611296|NCT04194281|OTHER|Action Observation Training [AOT]|Parents are instructed to show their child repetitive arm, hand and finger movements in a playful and age-appropriate way for about 20 minutes a day, divided into several short sequences. AOT is to be carried out for four weeks at home by the parents and, if necessary, other caregivers. The parents receive instructions which contain background information on the possible importance of AOT for improving the functions of the upper limb, information about positions, promoting motivation, attention and interest as well as tips for promoting movement observation in everyday life.
214611297|NCT06980519|BIOLOGICAL|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.
214611298|NCT01794364|DRUG|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
214611299|NCT01794364|OTHER|placebo|Correspondingly, placebo doses will be administered as suspension.
214611300|NCT06986252|OTHER|Consultation|Consultations at a specialist surgical nurse-led clinic
214611301|NCT06986018|DRUG|RD06-04 Cell Injection Infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
214611302|NCT06984198|BEHAVIORAL|Sandplay Therapy|Sandplay Therapy - The objects involved in this form of therapy are: sandtray, sand, multiple figurines in all categories (people, animals, buildings, vehicles, vegetation, structures, natural objects and symbolic objects). The subject engaging in this therapy is instructed to build a sand picture with the minatures present. There is no time limit to these sessions; however, they tend to be 20-30 minutes long. Upon completion of their sand picture the child, if comfortable, may elaborate on their creation.
214611303|NCT06984198|BEHAVIORAL|Art Therapy|"Art Therapy - The instruments used in this form of therapy are: a blank 8 x 11 paper and coloring utensils (markers, crayons, and color pencils). During each 30-minute session, the subject is informed to draw whatever they feel with the coloring utensils provided. Possible drawing topics may include: their family, a memory of their life back in their country of origin, or something from their imagination."
214611304|NCT06986044|DIAGNOSTIC_TEST|Serum Total Oxidant Status|Serum total oxidant status
214611305|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Oxidant Status|Salivary Total Oxidant Status
214611306|NCT06986044|DIAGNOSTIC_TEST|Serum Total Antioxidant Status|Serum Total Antioxidant Status
214611307|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Antioxidant Status|Salivary Total Antioxidant Status
214611308|NCT06986044|DIAGNOSTIC_TEST|Serum Oxidative Stress Index|Serum Oxidative Stress Index
214611309|NCT06986044|DIAGNOSTIC_TEST|Salivary Oxidative Stress Index|Salivary Oxidative Stress Index
214611310|NCT06986044|DIAGNOSTIC_TEST|Serum Arylesterase|Serum Arylesterase
214611311|NCT06986044|DIAGNOSTIC_TEST|Salivary Arylesterase|Salivary Arylesterase
214611312|NCT06986044|DIAGNOSTIC_TEST|Serum Heme Oxygenase|Serum Heme Oxygenase
214611313|NCT06986044|DIAGNOSTIC_TEST|Salivary Heme Oxygenase|Salivary Heme Oxygenase
214714333|NCT04373785|DRUG|NG101m|Oral NG101m capsule continuously twice daily.
214714334|NCT04011800|PROCEDURE|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
214611314|NCT06986044|DIAGNOSTIC_TEST|Serum Nuclear Factor Erythroid 2 Related Factor 2|Serum Nuclear Factor Erythroid 2 Related Factor 2
214714335|NCT04011800|COMBINATION_PRODUCT|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
214714336|NCT01593228|DRUG|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214611315|NCT06986044|DIAGNOSTIC_TEST|Salivary Nuclear Factor Erythroid 2 Related Factor 2|Salivary Nuclear Factor Erythroid 2 Related Factor 2
214714337|NCT01593228|DRUG|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214714338|NCT01593228|DRUG|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214714339|NCT01593228|DRUG|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214611316|NCT06986044|DIAGNOSTIC_TEST|Gingival Index|Gingival Index
214611317|NCT06986044|DIAGNOSTIC_TEST|Plaque Index|Plaque Index
214611318|NCT06986044|DIAGNOSTIC_TEST|Bleeding on Probing Index|Bleeding on Probing Index
214611319|NCT06986044|DIAGNOSTIC_TEST|Clinical Attachment Loss|Clinical Attachment Loss
214611320|NCT06986044|DIAGNOSTIC_TEST|Pocket Deep|Pocket Deep
214714340|NCT01593228|DRUG|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214714341|NCT01593228|DRUG|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214611321|NCT06984016|OTHER|Work-related Musculoskeletal Disorders Risk Among Physical Therapists|217 Males and females Egyptian physical therapists at will be included in the study.
214611322|NCT06984458|BEHAVIORAL|Robot Dementia Prevention Course|"It is expected that through the eight-week course design activities, the cognitive functions, social activities, emotional management (such as alleviating depression), well-being, reduce loneliness and can be achieved, thereby preventing or delaying cognitive decline.~The experimental group conducted a two-month Robot Dementia Prevention Course intervention. The research subjects were 40 people. Each group of 5 people was assigned a Kebbi robot. The course intervention was divided into 8 groups. The Kebbi robot mainly taught and communicated with the elderly interactively. There is a well-trained teaching assistant in the class to enhance the learning effect of the elderly. The two classes per week are about 2 hours long, with 50 minutes of course knowledge introduction, 10 minutes of rest, 50 minutes of interaction with Kebbi Artificial Intelligence-based board games, and 10 minutes of prize-based quizzes after class."
214611323|NCT01467453|DEVICE|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
214611324|NCT06985524|DRUG|Weipi Formula（Wu SiSi Formula）|take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
214611325|NCT06985524|OTHER|Placebo|Take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
214611326|NCT06985537|DRUG|Ultrasound guided intralesional Steroids injection (Triamicinolone)|Radiological guided steroid injection of IGM
214611327|NCT06984588|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,
214714342|NCT01593228|DRUG|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
214714343|NCT02013128|DRUG|Ublituximab|Ublituximab (IV infusion)
214714344|NCT02013128|DRUG|Ibrutinib|Ibrutinib oral daily dose
214611328|NCT06984588|DRUG|Toripalimab|240 mg on Day 1, once every 3 weeks (Q3W)
214611329|NCT06984588|DRUG|Pembrolizumab|200 mg on Day 1, once every 3 weeks (Q3W)
214611330|NCT06985420|OTHER|Resistance exercise|Resistance Exercise Protocols: Participants will perform exercises, including belt squats, hex bar deadlifts, and plyometric drop jumps. The load and intensity will be standardized based on each participant's 1-repetition maximum (1RM) to ensure uniformity across trials.
214611331|NCT06985420|OTHER|Menstrual Cycle Phases|Menstrual Cycle Phases: The key exposure variable is the phase of the menstrual cycle, with participants being assessed during the early follicular, late follicular, and mid-luteal phases.
214611332|NCT06985160|OTHER|Specific single nucleotide polymorphisms|Next-generation sequencing was performed to analyze the TLR4, LTA, and RFP175 genes, with a focus on specific single nucleotide polymorphisms
214611333|NCT04711668|DRUG|Ketamine|intraoperative ketamine bolus and infusion
214714345|NCT04457128|BEHAVIORAL|Just-in-Time Adaptive Intervention|Randomized factorial design
214714346|NCT04286828|OTHER|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
214722368|NCT01492738|PROCEDURE|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
214611334|NCT04711668|DRUG|Lidocain|intraoperative lidocain bolus and infusion
214611335|NCT04711668|DRUG|Saline|intraoperative saline bolus and infusion
214611336|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
214611337|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
214611338|NCT00640484|DRUG|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
214611339|NCT00640484|DRUG|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
214611340|NCT06599476|DEVICE|BioProtect Balloon Implant™ System|The BioProtect Balloon Implant System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, and by creating this space, to reduce the radiation dose delivered to the anterior rectum. The balloon is inserted into the perirectal space and inflated to its pre-defined size. The Balloon is made of biodegradable materials that maintain the space for the entire course of prostate radiation treatment and are absorbed by the patient's body over time
214611341|NCT03732651|PROCEDURE|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
214611342|NCT05694819|DRUG|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
214611343|NCT05694819|DRUG|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
214611344|NCT00583024|BIOLOGICAL|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
214611345|NCT04437537|DEVICE|Bioresorbable 3D electrospun synthetic matrix|All participants in this study will receive PHOENIX Wound Matrix® in addition to the SOC treatment for their chronic DFU.
214611346|NCT05953272|OTHER|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
214611347|NCT05953272|OTHER|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
214611348|NCT05804643|PROCEDURE|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
214611349|NCT06099210|DIAGNOSTIC_TEST|Glasgow coma scale|Closed tach brain injury due to external force was included according to the GCS score
214611350|NCT00271778|PROCEDURE|mastoidotympanoplasty and tympanoplasty|
214611351|NCT03779919|DEVICE|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
214611352|NCT02684513|DIETARY_SUPPLEMENT|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
214611353|NCT02684513|DIETARY_SUPPLEMENT|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
214611354|NCT02564107|DRUG|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
214611355|NCT06902220|DEVICE|continuous high-frequency oscillation therapy|Once patients' CPOT score reaches 0, intubated patients will receive continuous high-frequency oscillation (CHFO) therapy three times daily, with 8-hour intervals and 10-minute sessions. Extubated patients will receive CHFO and continuous positive expiratory pressure (CPEP) therapy twice daily, with 12-hour intervals and 10-minute sessions.
214714347|NCT04286828|OTHER|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
214722369|NCT03038516|DRUG|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
214722370|NCT03038516|DEVICE|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
214611356|NCT06850883|OTHER|A person-centered dementia home care scenario-based training program|"The training program primarily consists of three major themes in dementia care scenario-based training: Empathy, Challenging Behavior Management, and Interactive Activity Design."
214611357|NCT06850883|OTHER|Routine Treatment|Routine Treatment
214611358|NCT06902207|DRUG|Faricimab Injection [Vabysmo]|The procedures followed local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of an eye speculum, topical 5% povidone-iodine disinfection, 33G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in the supertemporal or the inferotemporal quadrant, sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
214611359|NCT06903390|BEHAVIORAL|QPL-based Communication Intervention|"This QPL-based communication intervention stands out with the following key features:~Patient-Centered \& Cancer-Specific QPL: The intervention uses a QPL tailored for cancer patients, culturally adapted to enhance empowerment and manage anxiety.~Structured Training \& Support: Patients receive training before consultations, with additional guidance for effective QPL use at subsequent visits.~Multiple Assessment Points: The QPL's impact is measured after the first, second, and third consultations, allowing for longitudinal evaluation.~RCT Design: This study is a randomized controlled trial (RCT), comparing the intervention group (QPL) to a control group receiving standard care.~Focus on Empowerment \& Anxiety: Unlike prior studies, this intervention focuses on empowering patients and reducing anxiety, with outcomes measured through validated scales (Patient Empowerment Scale and HADS).~These features differentiate this intervention by offering a structured, culturally relevant approach."
214611360|NCT06902792|DRUG|treated group|This study marks the first application of Adebrelimab in pediatric patients with Langerhans Cell Histiocytosis (LCH). The initial dose is 20 mg/kg, delivered via a 60-minute intravenous infusion. If no Dose-Limiting Toxicity (DLT) occurs, the second dose of 20 mg/kg will be administered in the second cycle. Treatment cycles consist of dosing every 4 weeks, up to a maximum of 6 cycles.
214611361|NCT06903273|DRUG|Tislelizumab|"Tislelizumab plus chemotherapy (14 days as one cycle) 3 cycles every 2 weeks as neoadjuvant therapy and followed by a curative surgery.~Tislelizumab 200 mg fixed-dose IVD on day 1. Gemcitabine 800 mg/m2 on day 1 with a fixed-infusion rate of 80 mins. Cisplatin 25 mg/m2 on day 1. S-1 70 mg/m2 daily as a BID dosing per oral on day 1 to 7. (daily total dose determined by body surface area (BSA): \<1.25 m2, 80 mg; 1.25-1.50 m2, 100 mg; ≥1.50 m2, 120 mg)"
214611362|NCT06902935|DIAGNOSTIC_TEST|Diagnosis of Breast Cancer by Traditional Chinese Medicine Four Examinations|The Daosheng TCM Four-Diagnostic Instrument (DS01-A) comprehensively collects patients' TCM four-diagnostic information, covering tongue (e.g., overall color, coating color/thickness/greasiness, tooth marks, etc.), pulse (e.g., position, force, rhythm, etc.), face (e.g., overall color, luster, lip color/dryness, etc.) and constitution scores (quantifying 9 constitutions via the TCM Constitution Classification Table).
214611363|NCT06902935|DIAGNOSTIC_TEST|Ultrasound diagnosis of breast cancer|Professional ultrasound physicians use B - ultrasound equipment of the same model to accurately collect detailed parameters of breast masses according to a standardized process. These parameters include shape (oval, round, irregular), orientation (parallel, non - parallel), margin (smooth, non - smooth, with non - smooth including blurred, angular, microlobulated, spiculated, etc.), echo pattern (anechoic, hyperechoic, complex cystic - solid echo, hypoechoic, isoechoic, heterogeneous echo), posterior echo characteristics (no change, enhancement, shadowing, mixed), calcification (microcalcification and coarse calcification within the mass, calcification outside the mass, intraductal), and vascular supply (no blood supply, internal blood supply, marginal blood supply), etc.
214611364|NCT06902597|PROCEDURE|Dual energy X-ray absorptiometry|Very low radiation dose technique to show fat mass (FM) and lean mass (LM)
214611365|NCT06901999|DRUG|Orelabrutinib|150 mg qd po. D1-21, 6 cycles, 21 days per cycle For patients continue transplant, maitaining for 1 year follow-up; otherwise maintaining during 2 years of follow-up，unless disease progression or intolerable toxicity occurs.
214611366|NCT06901999|DRUG|RCHOP+MTX or Thiotepa|rituximab: 375 mg/m2, D0; cyclophosphamide: 750 mg/m2, D1; doxorubicin: 50 mg/m2, D1; vincristine: 1.4 mg/m2, D1; prednisone: 100 mg, D1-5; MTX: 3.5 g/m2, D0; Thiotepa: 40 mg/m2, D3; Induction therapy, 6 cycles, 21 days a cycle
214611367|NCT06729905|DIETARY_SUPPLEMENT|Yerba mate tea|Consumption of three cups per day of a beverage prepared with yerba mate
214611368|NCT06729905|DIETARY_SUPPLEMENT|Control drink|Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
214611369|NCT06903260|COMBINATION_PRODUCT|Mixed Reality|Virtual reality (VR) is defined as an artificial 3D visual environment and augmented reality (AR), as virtual objects superimposed on the real world; mixed reality is the association between VR and AR. The images were exported from CT image in DICOM (Digital Imaging and Communications in Medicine) and applied in Brainlab Elements software (Brainlab AG, Munich, Germany), where the images and 3D drawing were rendered in partnership with the collaborating bioengineer of this work to obtain the VR. AG was obtained during the intraoperative through the Magic Leap 1 goggle (Magic Leap Inc., Plantation, FL, USA)
214611370|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
214611371|NCT06749899|DRUG|QL1706|QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
214611372|NCT06749899|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
214611373|NCT06749899|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214714348|NCT04286828|OTHER|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
214611374|NCT06749899|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
214611375|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
214611376|NCT06108648|OTHER|Control|Standard care according to national standards.
214611377|NCT06901765|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care, inpatient rehabilitation, outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management\[5\], soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive
214611378|NCT06901765|BEHAVIORAL|Exercise|Range of Motion Exercise, Stretching Exercises
214611379|NCT06901674|PROCEDURE|Modified surgical approach|An electrode typically placed under the temporalis muscle will be placed into the cochlear helicotrema instead.
214611380|NCT06901674|DEVICE|Cochlear Nucleus CI632 cochlear implant|Cochlear implant (CI) system where stimulation from one of the intracochear electrodes is grounded via one of two (or both) extra cochlear electrodes in the device.
214611381|NCT02706561|BEHAVIORAL|questionnaires|
214611382|NCT02706561|BEHAVIORAL|three in-person sessions|
214611383|NCT02706561|BEHAVIORAL|monthly phone calls|
214722371|NCT04480749|DIAGNOSTIC_TEST|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
214722372|NCT04480749|DIAGNOSTIC_TEST|Syphilis Self-Test|Rapid Treponemal Test kit
214611384|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
214611385|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
214611386|NCT02522507|BEHAVIORAL|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
214611387|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
214611388|NCT06290193|BIOLOGICAL|Acute Normovolemic Hemodilution/ANH|For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
214611389|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
214611390|NCT04890314|OTHER|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
214611391|NCT06934720|BEHAVIORAL|aPAVRCT|"* We offered a system integrated with an indoor bike (for physical activity) and a multisensory VR environment (for cognitive training, such as reminiscence).~* Participants will actively navigate the virtual environment by pedaling and steering the handlebar.~* Care professionals will deliver the intervention using this system."
214611392|NCT01148706|DEVICE|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
214611393|NCT04344340|DIAGNOSTIC_TEST|clinical examination|clinical examination
214611394|NCT04968977|PROCEDURE|PCI vs. CABG|PCI vs. CABG
214611395|NCT00992940|PROCEDURE|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
214611396|NCT00992940|PROCEDURE|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
214611397|NCT04492462|OTHER|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
214611398|NCT04492462|OTHER|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
214611399|NCT01969487|OTHER|Preoperative warm-up on simulator|
214611400|NCT01925924|OTHER|Resin-modified glass ionomer cement|This material contains fluoride
214611401|NCT01925924|OTHER|Composite resin|This material does not include fluoride
214611402|NCT02670824|DRUG|CN-105|Single and multiple intravenous (IV) doses of CN-105
214611403|NCT02670824|DRUG|Placebo|Normal Saline
214611404|NCT06206564|DRUG|Artesunate ointment|Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
214611405|NCT06206564|DRUG|Placebo|Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
214611406|NCT06165536|BEHAVIORAL|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
214611407|NCT03200327|PROCEDURE|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
214611408|NCT03200327|PROCEDURE|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
214611409|NCT01198860|DRUG|CTH Chronic Hepatitis B|"Drug:~* Tenofovir/ 300mg daily~* Phyllanthus Urinaria/300mg daily~* Adenosma Glutinosum/150mg daily~* Eclipta Prostrata/150mg daily~* Ascorbic Acid / 500mg daily"
214714349|NCT02915887|OTHER|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
214611410|NCT02229539|DRUG|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
214611411|NCT02229539|DRUG|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
214611412|NCT02229539|OTHER|Placebo|2.5 mL placebo and 2.5 mL water administered orally
214611413|NCT00246909|DRUG|Pantoprazole|
214611414|NCT01907542|PROCEDURE|stapled skin closure|as above
214611415|NCT01907542|PROCEDURE|monocryl skin suture|as above
214611416|NCT01864187|DRUG|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
214611417|NCT01944293|DRUG|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
214611418|NCT01944293|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
214611419|NCT05767554|BEHAVIORAL|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can begin a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
214611420|NCT06083441|DIAGNOSTIC_TEST|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
214611421|NCT06083441|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score \>2, or an arousal score \> 0 means that a subject is responding to commands
214611422|NCT00121836|DRUG|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
214611423|NCT00121836|DRUG|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
214611424|NCT03227471|DRUG|IVA|IVA tablet for oral administration
214611425|NCT03227471|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
214611426|NCT03227471|DRUG|VX-445|VX-445 tablet for oral administration.
214611427|NCT03227471|DRUG|Matched Placebo|Matched placebo.
214611428|NCT03227471|DRUG|TEZ|Tablet for oral administration.
214611429|NCT03227471|DRUG|VX-561|Tablet for oral administration.
214611430|NCT03227471|DRUG|VX-445|VX-445 IV injection
214611431|NCT04516317|OTHER|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
214611432|NCT04516317|OTHER|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
214611433|NCT02777697|OTHER|chronic pain|
214611434|NCT00345189|DRUG|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
214611435|NCT05571748|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
214611436|NCT05571748|OTHER|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
214611437|NCT04494230|BEHAVIORAL|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
214611438|NCT02525393|DEVICE|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
214611439|NCT02525393|DEVICE|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
214611440|NCT02525393|DEVICE|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
214611441|NCT01855763|DRUG|Metformin|
214611442|NCT01855763|DRUG|Insulin|
214611443|NCT00382720|DRUG|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
214611444|NCT00382720|DRUG|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
214611445|NCT00382720|DRUG|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
214611446|NCT01095406|DEVICE|S1 ventilation|Ventilation with a O2 and CO2 controller
214611447|NCT00682448|DRUG|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
214611448|NCT00682448|DRUG|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
214611449|NCT01740960|DRUG|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
214611450|NCT01740960|DRUG|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
214611451|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
214714350|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
214611452|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
214611453|NCT04714242|DRUG|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
214611454|NCT00311376|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
214611455|NCT00311376|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval
214611456|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
214611457|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval
214611458|NCT00257166|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
214611459|NCT00257166|DRUG|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
214611460|NCT00829049|DRUG|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
214611461|NCT00829049|DRUG|Adapalene|1 pea-size amount, QD x 16 weeks
214611462|NCT04223895|DRUG|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
214611463|NCT04223895|DRUG|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
214611464|NCT04223895|DRUG|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
214611465|NCT00993642|DRUG|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
214611466|NCT05570942|DIETARY_SUPPLEMENT|Oral Lactobacillus rhamnosus TCELL-1|A kind of probiotics which was isolated from the intestinal mucosa of health Taiwanese people
214611467|NCT05865444|BEHAVIORAL|Values alignment wise intervention|"The intervention includes: (1) reading materials, such as recent journalistic works that expose the deceptive and manipulative marketing practices of food companies and the harmful effects of these practices on society, with particular emphasis on harm to young children and the economically disadvantaged. Stories from other young people will also be included in order to contribute to the perception of widespread outrage and to suggest how that outrage can be channeled into taking a stand against the injustice perpetrated by food companies by eating less unhealthy or healthier food; (2) writing exercises, such as a story with a brief statement of what the participants would tell a younger child about the ads; and (3) an interactive activity, called Make It Real in which they are shown pictures of food ads and allowed to write and draw about them, making whatever changes (e.g., crossing out and substituting words) they feel necessary to make the ad real (i.e., no longer misleading)."
214611468|NCT05865444|BEHAVIORAL|Educational traditional intervention|The educational intervention includes information on nutrition and physical exercise. It includes reading and writing exercises.
214611469|NCT04175106|OTHER|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
214611470|NCT04175106|OTHER|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
214714351|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
214714352|NCT01294982|DRUG|Placebo|Placebo Oral Capsules twice daily
214714353|NCT02461394|DEVICE|Blood glucose monitoring systems for self-testing|
214714354|NCT02289274|DRUG|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
214714355|NCT02289274|DRUG|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
214714356|NCT02072382|DRUG|Metformin|metformin 850mg twice a day for eight weeks
214714357|NCT02072382|DRUG|Placebo|
214714358|NCT02713789|DRUG|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
214714359|NCT02713789|DRUG|Placebo (PBS-20% sucrose)|
214611471|NCT04175106|OTHER|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
214611472|NCT04175106|OTHER|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
214611473|NCT04193020|OTHER|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
214611474|NCT03862144|DRUG|Netupitant/Palonosetron|
214611475|NCT00077532|BIOLOGICAL|gp100 antigen|
214611476|NCT00077532|BIOLOGICAL|incomplete Freund's adjuvant|
214611477|NCT00077532|BIOLOGICAL|ipilimumab|
214714360|NCT03059472|BEHAVIORAL|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
214714361|NCT03059472|BEHAVIORAL|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
214714362|NCT01564667|BEHAVIORAL|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
214611478|NCT04788251|OTHER|Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)|"The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31)."
214611479|NCT04788251|OTHER|Wait-list control|To receive fall prevention resources while waiting for their programme to start
214611480|NCT01454375|BEHAVIORAL|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
214611481|NCT05026281|DEVICE|Quantra analyzer|one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
214611482|NCT00521924|BIOLOGICAL|infliximab|infliximab 3 mg/kg and basic treatment
214714363|NCT05082506|BEHAVIORAL|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
214714364|NCT03674333|DIETARY_SUPPLEMENT|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
214611483|NCT00521924|DRUG|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
214611484|NCT04050670|DRUG|Tirzepatide|Tirzepatide administered SC
214611485|NCT05564975|OTHER||
214611486|NCT03317470|OTHER|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
214714365|NCT03674333|OTHER|Placebo|Placebo - a sugar pill
214714366|NCT00897052|GENETIC|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
214714367|NCT00897052|OTHER|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
214611487|NCT03317470|BEHAVIORAL|Life Navigator|"* The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
214611488|NCT03317470|OTHER|Follow-up survey|-5 questions about the acceptability of the basic needs survey
214611489|NCT03317470|OTHER|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
214611490|NCT04146194|OTHER|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
214714368|NCT03161782|OTHER|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
214714369|NCT03161782|OTHER|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
214714370|NCT03161782|OTHER|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
214714371|NCT03161782|OTHER|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
214714372|NCT00387270|DRUG|Dimebon|Dimebon 10 or 20 mg TID x 7 days
214714373|NCT05594433|DRUG|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
214714374|NCT01634945|DRUG|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
214714375|NCT01634945|DIETARY_SUPPLEMENT|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
214714376|NCT01634945|DRUG|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
214714377|NCT01634945|DIETARY_SUPPLEMENT|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
214714378|NCT01634945|OTHER|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
214714379|NCT00671983|PROCEDURE|Neurocognitive Testing|
214714380|NCT00615797|BIOLOGICAL|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
214714381|NCT00615797|DRUG|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
214714382|NCT04000347|DRUG|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
214714383|NCT04000347|DRUG|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
214611491|NCT00982865|DRUG|MSC1936369B|
214611492|NCT00982865|DRUG|MSC1936369B|
214611493|NCT00982865|DRUG|MSC1936369B|
214611494|NCT00982865|DRUG|MSC1936369B|
214611495|NCT03882138|PROCEDURE|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
214611496|NCT02225470|DRUG|E7389 (Eribulin Mesylate)|
214611497|NCT02225470|DRUG|Vinorelbine injection|
214611498|NCT05560542|DRUG|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
214611499|NCT02348775|DIETARY_SUPPLEMENT|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
214611500|NCT00714675|DIETARY_SUPPLEMENT|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
214714384|NCT05877703|OTHER|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
214611501|NCT00714675|DIETARY_SUPPLEMENT|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
214611502|NCT01687075|DEVICE|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
214611503|NCT03335163|DRUG|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
214611504|NCT03251742|DEVICE|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
214611505|NCT01689675|BEHAVIORAL|Computer based pain management|
214611506|NCT00525044|DRUG|Ambroxol|
214611507|NCT00525044|DRUG|Placebo|
214611508|NCT05596682|DEVICE|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
214714385|NCT05877703|OTHER|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
214714386|NCT04144855|DRUG|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
214714387|NCT05997017|DRUG|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
214714388|NCT01790009|DIETARY_SUPPLEMENT|Flavanol rich drink|
214714389|NCT01790009|DRUG|Acetaminophen|2x500 mg Acetaminophen
214611509|NCT05497596|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
214611510|NCT05497596|OTHER|Placebo|Placebo
214611511|NCT01745250|DEVICE|Emervel Lips|Lip treatment of both upper and lower lip
214611512|NCT01745250|DEVICE|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
214714390|NCT05640856|PROCEDURE|intubation|Endotracheal tube placement
214611513|NCT01131533|PROCEDURE|Vitrectomy|vitrectomy following intravitreal erythropoietin
214611514|NCT04125550|DRUG|Propofol|2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
214611515|NCT04125550|DRUG|Sevoflurane|sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
214611516|NCT03652038|DRUG|TD-8236|Study drug to be administered via inhaler device
214611517|NCT03652038|DRUG|Placebo|Placebo to be administered via inhaler device
214611518|NCT02125227|DRUG|Rosuvastatin, Metformin, YH14755|single dose
214611519|NCT02125227|DRUG|YH14755|single dose
214611520|NCT03286062|COMBINATION_PRODUCT|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
214714391|NCT04213508|DRUG|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
214714392|NCT04213508|DRUG|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
214714393|NCT02850952|OTHER|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
214611521|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
214714394|NCT02091921|DRUG|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
214611522|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
214611523|NCT05251740|DEVICE|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
214611524|NCT03333720|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
214611525|NCT06466629|BIOLOGICAL|Triaxis, Sanofi Pasteur|tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine
214611526|NCT04758442|OTHER|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
214714395|NCT03601208|DIAGNOSTIC_TEST|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
214714396|NCT06373276|OTHER|multiplanar balance training exercise with education|7 minute daily balance training exercises
214714397|NCT06373276|BEHAVIORAL|education only|5 educational broshures
214714398|NCT04657653|PROCEDURE|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
214714399|NCT02447120|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
214714400|NCT05698043|DRUG|CKD-386(5)|Test
214714401|NCT05698043|DRUG|D013, D326, D337|Reference
214714402|NCT06082869|DRUG|Protegera™ toothpaste (NaF)|Plaque Reduction
214714403|NCT06082869|DRUG|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
214714404|NCT01862432|OTHER|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
214611527|NCT06331442|OTHER|Photodynamic therapy|Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
214611528|NCT06331442|OTHER|Tricalcium phosphate (TCP) varnish with 5% NaF|Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
214611529|NCT06331442|OTHER|Chlorhexidine varnish|Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
214611530|NCT03426371|DRUG|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
214611531|NCT03426371|DRUG|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
214611532|NCT00483561|DRUG|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
214611533|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
214611534|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
214611535|NCT01458912|DRUG|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
214611536|NCT01458912|DRUG|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
214611537|NCT02220842|DRUG|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
214611538|NCT02220842|DRUG|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
214611539|NCT02220842|DRUG|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
214611540|NCT01164774|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
214611541|NCT01164774|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
214611542|NCT04750759|DRUG|Niclosamide + Camostat|Niclosamide will be applied in combination with camostat.
214611543|NCT04750759|OTHER|Placebo|Placebo to interventional drug
214611544|NCT00443807|DEVICE|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
214611545|NCT00443807|DEVICE|EEGo vs BIS|comparison of two processed EEG monitors.
214611546|NCT00000761|DRUG|Interferon gamma-1b|
214611547|NCT01908985|PROCEDURE|high intensity focused ultrasound for cyclodestruction in the eye|
214611548|NCT01810185|DRUG|Low dose naltrexone|4.5 mg daily for 12 weeeks
214714405|NCT02994381|DRUG|RPC1063|
214611549|NCT01810185|DRUG|Placebo|
214611550|NCT04265846|DEVICE|bifocal IOL|The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
214611551|NCT04265846|DEVICE|mix bifocal IOL|The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
214714406|NCT07043426|OTHER|THRIVE-DM|Low-SS and High-SS will be referred by the CHW to appropriate community-based organizations through the THRIVE Directory. High-SS participants will also receive additional support from a patient navigator (PN), who will follow up to facilitate service connection and address barriers to engagement. CHWs and PNs will coordinate care to ensure services are aligned with the patient's assessed needs.
214714407|NCT07043426|OTHER|Standard of care|Standard of care may include support from the primary care team, health related social needs (HRSN) screening via the THRIVE screener, printed resource guides, and referrals to community-based organizations initiated at the discretion of clinic staff using the THRIVE Directory.
214714408|NCT06723392|DRUG|Oral nitrofurantoin monohydrate/macrocrystals|7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)
214714409|NCT06723392|OTHER|Placebo|7-day course of oral placebo 100 mg twice daily (total of 14 doses)
214714410|NCT03307629|DRUG|NOX66|NOX66 delivered as rectal suppository.
214714411|NCT03307629|RADIATION|Irradiation Therapy|Radiation per selected tumour lesion.
214714412|NCT04339270|DRUG|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
214611552|NCT04265846|DEVICE|trifocal IOL|The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
214611553|NCT04265846|DEVICE|EDOF IOL|The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
214611554|NCT04265846|DEVICE|different IOLs|The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
214611555|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
214611556|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
214611557|NCT02688491|DRUG|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
214611558|NCT02553265|DRUG|Carbidopa Low-Dose|300 mg/day
214611559|NCT02553265|OTHER|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
214611560|NCT02553265|DRUG|Carbidopa High-Dose|600 mg/day
214611561|NCT05574595|OTHER|Music theraphy|In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
214611562|NCT01653288|BEHAVIORAL|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
214611563|NCT00635037|DRUG|bupivacaine and acupuncture|"* trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week"
214611564|NCT03471039|DRUG|PACAP27|Infusion of PACAP27 over 20 minutes.
214611565|NCT03471039|DRUG|Saline|Infusion of Saline over 20 minutes.
214611566|NCT06426485|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablets|orally once a day
214611567|NCT06426485|DRUG|placebo|orally once a day
214714413|NCT04339270|DRUG|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
214714414|NCT03296787|DRUG|TAK-954|TAK-954 intravenous infusion.
214714415|NCT02874183|BEHAVIORAL|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
214611568|NCT03764163|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
214611569|NCT03764163|DIAGNOSTIC_TEST|CT Scans|volume scans, perfusion scan, ventilation scan
214611570|NCT03764163|BEHAVIORAL|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
214611571|NCT03764163|DIAGNOSTIC_TEST|MRI|proton scans, hyperpolarized 3-Helium scan
214611572|NCT03764163|BIOLOGICAL|Xenon gas|ventilation CT scans
214611573|NCT02978534|DRUG|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
214611574|NCT06013592|DIETARY_SUPPLEMENT|0 kcal liquid meal|Flavoured water, given as one meal at one study visit only
214611575|NCT06013592|DIETARY_SUPPLEMENT|600 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
214611576|NCT06013592|DIETARY_SUPPLEMENT|900 kcal liquid meal (only for group without obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
214611577|NCT06013592|DIETARY_SUPPLEMENT|1200 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
214611578|NCT06013592|DIETARY_SUPPLEMENT|1800 kcal liquid meal (only for group with obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
214611579|NCT03713034|OTHER|PlayTest!|Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
214611580|NCT03713034|OTHER|Control games|Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
214611581|NCT02500667|DRUG|N91115|200 mg BID
214611582|NCT02500667|DRUG|Rifampin|600 mg QD
214714416|NCT01771211|DEVICE|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
214611583|NCT00713817|DRUG|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
214714417|NCT02691221|BEHAVIORAL|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
214611584|NCT00713817|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
214611585|NCT02293850|BIOLOGICAL|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
214611586|NCT03846349|DEVICE|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
214611587|NCT03846349|DEVICE|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
214611588|NCT05443230|DIAGNOSTIC_TEST|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
214714418|NCT05963295|DIAGNOSTIC_TEST|toxoplasma igG|Dignosis of toxoplasma
214611589|NCT02982239|BEHAVIORAL|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
214611590|NCT02982239|DEVICE|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
214611591|NCT02982239|DEVICE|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
214611592|NCT02982239|DEVICE|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
214611593|NCT02982239|OTHER|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q\&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
214611594|NCT02982239|BEHAVIORAL|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
214611595|NCT06495528|DEVICE|Pain management with BLISS DTx|Bliss DTx is a Digital Therapeutics (DTx) which uses virtual reality augmented with sound and visual stimuli to reduce pain during Port-A-Cath setting
214611596|NCT06495528|OTHER|Pain Management with site standard of care sedation protocol|Sedation (morphine and/or hypnotics and/or anxiolytics and/or conversational hypnosis) reduces pain during Port-A-Cath setting
214611597|NCT00668070|DRUG|ASP9831|Oral
214611598|NCT00668070|DRUG|Placebo|Oral
214611599|NCT03042780|DRUG|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
214611600|NCT03042780|DRUG|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
214611601|NCT04415658|DRUG|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
214611602|NCT04415658|DRUG|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
214714419|NCT05884359|DIAGNOSTIC_TEST|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
214714420|NCT00719953|DIETARY_SUPPLEMENT|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
214714421|NCT06894862|DRUG|NYR-BI03|Participants receive NYR-BI03 nanosuspension formulated for continuous intravenous infusion to be given over 3 hours or 6 hours.
214611603|NCT03580239|DRUG|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
214611604|NCT03580239|DRUG|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
214611605|NCT02581293|PROCEDURE|Group 1: Only visceral peritoneum will be closed|
214611606|NCT02581293|PROCEDURE|Group 2 : Only parietal peritoneum will be closed|
214611607|NCT02581293|PROCEDURE|Group 3 : Both of them will be closed|
214611608|NCT02581293|PROCEDURE|Group 4: None of them will be closed|
214611609|NCT02465983|BIOLOGICAL|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
214611610|NCT02465983|DRUG|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
214611611|NCT03528278|BEHAVIORAL|Motivational interviewing and environmental interventions|"* Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~* Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~* Training equipment~* Motivational Interviewing (MI) techniques applied by staff~* Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
214714422|NCT06894862|DRUG|Matching placebo (all cohorts)|Administered as a continuous intravenous infusion over 3 hours or 6 hours
214611612|NCT03767036|DRUG|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
214611613|NCT03767036|DRUG|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
214611614|NCT02000596|DRUG|Trastuzumab plus Pertuzumab|
214611615|NCT02000596|DRUG|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
214611616|NCT02000596|DRUG|Chemotherapy with Eribulin|
214611617|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
214714423|NCT06728098|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
214714424|NCT06728098|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
214611618|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
214611619|NCT01764971|OTHER|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
214611620|NCT01764971|OTHER|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
214714425|NCT01626989|DEVICE|BiPAP auto Advanced|Auto Servo Ventilation Device
214714426|NCT01626989|DEVICE|BiPAP auto SV4|Auto Servo Ventilation Device
214714427|NCT07057466|OTHER|Traditional 12-lead Electrocardiogram|12-lead ECG investigation is a standard, non-invasive diagnostic procedure used as an intervention to assess participants' cardiac electrical activity. For the purposes of this study, 12-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
214611621|NCT03662672|PROCEDURE|Rib raising and lumbar release|Rib raising per protocol described in arm description.
214611622|NCT03662672|PROCEDURE|Sham procedure|Sham procedure per protocol described in arm description
214611623|NCT03029741|DRUG|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
214611624|NCT03029741|DRUG|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
214714428|NCT07057466|OTHER|Apple Watch Series 4 Single-lead Electrocardiogram|Single-lead ECG taken using an Apple Watch Series 4 is a non-invasive, participant-initiated recording of cardiac electrical activity through a wearable device. While more limited than a 12-lead ECG, it can capture rhythm abnormalities-such as atrial fibrillation-and offers a convenient method for remote or continuous heart monitoring during the study. For the purposes of this study, single-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
214611625|NCT02744300|BEHAVIORAL|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
214611626|NCT05500820|DRUG|CIN-107|A repeat oral dose of CIN-107 once daily for 10 days.
214611627|NCT05500820|DRUG|Matching Placebo|A repeat oral dose of matching placebo once daily for 10 days.
214611628|NCT04485143|DEVICE|Wisdom bracelet|routine medical
214611629|NCT02975193|BEHAVIORAL|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
214611630|NCT02975193|BEHAVIORAL|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
214611631|NCT02975193|PROCEDURE|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
214611632|NCT06414928|OTHER|Acute Heart Failure|Consecutive patients presented at Emergency Departement with Acute Heart Failure
214714429|NCT07057466|OTHER|Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram|Three-lead ECG recorded using the Eko CORE 500 digital stethoscope is a non-invasive, clinician-operated cardiac assessment tool that captures real-time electrical activity of the heart during auscultation. It provides enhanced diagnostic information compared to single-lead recordings, allowing detection of arrhythmias and signs of structural heart disease at the point of care, supporting integrated clinical and digital assessment. For the purposes of this study, 3-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
214714430|NCT07057466|OTHER|AliveCor KardiaMobile Single- and 6-lead Electrocardiogram|A single- or 6-lead ECG recorded using the AliveCor KardiaMobile 6L device which is a portable, non-invasive method for capturing cardiac electrical activity. Operated by the participant or clinician, the device enables rapid rhythm assessment and detection of abnormalities such as atrial fibrillation. The 6-lead configuration offers more comprehensive data than single-lead recordings, supporting enhanced arrhythmia and conduction analysis in both in-clinic and remote settings. For the purposes of this study, single- and 6-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
214722373|NCT05468580|PROCEDURE|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
214611633|NCT06387654|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
214611634|NCT06387654|BIOLOGICAL|Remainders of samples taken as part of the treatment|blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
214611635|NCT06236295|DRUG|SHR6508|SHR6508 will be administered to all the eligible subjects
214611636|NCT01161602|DRUG|Pumosetrag|
214611637|NCT01161602|DRUG|Pumosetrag|
214611638|NCT01161602|OTHER|Placebo|
214611639|NCT01161602|DRUG|Pumosetrag|
214611640|NCT00647153|OTHER|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
214611641|NCT00647153|PROCEDURE|single photon emission computed tomography|One day post infusion
214611642|NCT00647153|RADIATION|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
214611643|NCT00415506|DRUG|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
214611644|NCT00151970|DRUG|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
214611645|NCT00151970|DRUG|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
214611646|NCT00151970|DRUG|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
214722374|NCT05468580|PROCEDURE|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
214611647|NCT04666467|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
214611648|NCT06208384|DRUG|Statin eye drop|Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
214611649|NCT06208384|DRUG|Placebo|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
214611650|NCT00492830|DRUG|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
214611651|NCT05291442|OTHER|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
214611652|NCT02023242|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
214611653|NCT02023242|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
214611654|NCT03358199|PROCEDURE|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
214611655|NCT03995732|DRUG|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
214611656|NCT03995732|DRUG|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
214611657|NCT02375152|PROCEDURE|Anterior Capsulotomy|
214611658|NCT06466785|DRUG|Efepoetin Alfa|Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
214611659|NCT06466785|DRUG|Darbepoetin Alfa|Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
214722375|NCT00927576|BEHAVIORAL|Digit span testing|Testing of short-term verbal memory with digit span
214611660|NCT05327413|OTHER|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
214611661|NCT03805997|DEVICE|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
214611662|NCT03805997|OTHER|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
214611663|NCT03805997|OTHER|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
214611664|NCT03805997|BIOLOGICAL|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
214611665|NCT03805997|OTHER|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
214611666|NCT03805997|OTHER|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
214611667|NCT03805997|OTHER|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
214611668|NCT03805997|OTHER|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
214611669|NCT02528370|DEVICE|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
214611670|NCT02019576|RADIATION|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
214611671|NCT01389167|DRUG|Vivitrol|An extended release naltrexone formulation for intramuscular injection
214611672|NCT01389167|DRUG|Naltrexone (oral)|Naltrexone 50 mg pills, daily
214611673|NCT01389167|BEHAVIORAL|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
214611674|NCT01389167|BEHAVIORAL|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
214714431|NCT07057466|OTHER|Phlebotomy for N-terminal pro-B-type natriuretic peptide|A minimally invasive biomarker assessment used to evaluate cardiac wall stress and function. Elevated levels can indicate the presence or severity of heart failure and other forms of structural heart disease, making it a valuable tool for diagnosis, risk stratification, and monitoring of cardiac status throughout the study period. For the purposes of this study, NT-proBNP will be collected to assess its accuracy at detecting HF, PH, and VHD with comparison with AI-ECG detections. The investigators will also evaluate the accuracy of AI-ECG detections combined with NT-pro-BNP, for detecting HF, VHD, and PH. The investigators will not be using NT-proBNP results to inform or alter patients' standard NHS care.
214714432|NCT03358654|DRUG|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
214714433|NCT02437487|DRUG|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
214714434|NCT02437487|DRUG|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
214714435|NCT07075484|DRUG|YTS109 cell|Subjects will receive YTS109 cell, and dose escalation will commence at 5E6 cells/kg or the starting dose may be adjusted based on accumulated data.
214714436|NCT07075991|DRUG|1 μm [14C]-labelled Polystyrene Microplastic|A single test day during which participants will orally ingest a single micro dose of 100 μg 1 µm \[14C\]-labelled PS-MP. Prior to and following ingestion of the labelled PS-MP, biological samples (i.e. blood, urine, faeces) will be collected at regular intervals, throughout the 5-day study period. Participants will spend the first 24h in the clinical laboratory, after which they are allowed to spend the remainder of the 5-day study period at home but with daily visits to the laboratory for blood sampling and home collection of urine and faeces.
214714437|NCT04409652|PROCEDURE|Head on bed|During emergence, head is kept on bed without pillow.
214714438|NCT04409652|PROCEDURE|Head on pillow|During emergence, head is kept on pillow.
214714439|NCT06783296|PROCEDURE|Renal Denervation|Renal denervation performed using the Symplicity Spyral™ multi-electrode renal denervation system, which is approved for interventional treatment of hypertension. This procedure involves catheter-based radiofrequency ablation of the renal nerves to reduce sympathetic activity and lower blood pressure.
214714440|NCT06783296|PROCEDURE|Renal Angiography|A sham procedure involving renal angiography without the application of radiofrequency energy. This control intervention is used to maintain blinding.
214714441|NCT07091695|BIOLOGICAL|Nivolumab + relatlimab|As prescribed by the treating clinician
214714442|NCT07091695|BIOLOGICAL|Nivolumab + ipilimumab|As prescribed by the treating clinician
214714443|NCT07090850|BEHAVIORAL|Puzzle education group|It was evaluated the effect of using puzzles as a teaching technique in a nursing practice course.
214722376|NCT00927576|BEHAVIORAL|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
214611675|NCT05689970|DIAGNOSTIC_TEST|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
214611676|NCT04327765|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
214611677|NCT04327765|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
214611678|NCT04327765|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
214611679|NCT02991742|OTHER|contrast media|Compare 2 contrast media
214611680|NCT00653042|DRUG|Nesiritide|
214611681|NCT03932656|BEHAVIORAL|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
214611682|NCT03932656|DRUG|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
214611683|NCT05349851|OTHER|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
214611684|NCT00139347|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
214722377|NCT00927576|BEHAVIORAL|Finger tapping|Testing motor speed with a finger tapping test.
214611685|NCT00773721|DEVICE|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
214611686|NCT01434420|GENETIC|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
214611687|NCT04891094|DIAGNOSTIC_TEST|Ultrasound|daily ultrasound of the lung and the diaphragm
214611688|NCT02596477|DRUG|Vepoloxamer|
214611689|NCT02596477|OTHER|5% dextrose in water|
214714444|NCT07090941|PROCEDURE|Endovascular Treatment|The vascular access route is selected based on the patient's anatomical characteristics and operator discretion. Endovascular treatment (EVT) procedures must adhere to each participating center's standardized operating protocols. Upon confirmation of vascular occlusion, EVT may be performed using devices approved by China's National Medical Products Administration (NMPA). Based on lesion-specific features and operator judgment, permissible techniques include stent retriever thrombectomy, aspiration thrombectomy, balloon angioplasty with or without stenting, or intra-arterial thrombolysis. Investigational devices are strictly prohibited.
214611690|NCT04671277|OTHER|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
214611691|NCT04540146|DIAGNOSTIC_TEST|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
214611692|NCT01796587|DEVICE|LoFric Origo|
214611693|NCT03108547|OTHER|Determination of scalp hair steroids|
214611694|NCT04026347|DEVICE|Vesair Balloon|Indwelling, intravesical balloon
214611695|NCT04026347|OTHER|Sham balloon placement|Sham balloon placement procedure
214611696|NCT03988348|PROCEDURE|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
214611697|NCT03988348|PROCEDURE|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
214611698|NCT00069927|DRUG|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
214611699|NCT00069927|DRUG|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
214611700|NCT03010124|PROCEDURE|Blood sample|
214611701|NCT05507775|DRUG|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
214611702|NCT06354582|DRUG|Vitamin C Injection|Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.
214611703|NCT06354582|OTHER|Normal saline|The placebo comparator will receive normal saline with the same volume and be administered after the induction of epidural labor anesthesia.
214611704|NCT02679014|DRUG|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
214611705|NCT02679014|DRUG|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
214611706|NCT02326454|DRUG|talaporfin sodium|1 mg/kg
214611707|NCT02326454|DRUG|Saline|
214611708|NCT02326454|DEVICE|Drug Activator 100 J/cm|Light Dose: 100 J/cm
214611709|NCT02326454|DEVICE|Drug Activator 200 J/cm|Light Dose: 200 J/cm
214611710|NCT02650999|DRUG|Pembrolizumab|200mg intravenously (IV)
214611711|NCT03556553|DEVICE|Vertise Flow|Composite resin
214611712|NCT03556553|DEVICE|LuxaFlow|Composite resin
214611713|NCT03556553|DEVICE|Teco Adhesive|Adhesive system
214714445|NCT07091656|OTHER|there is no intervention|NO INTERVENTION
214722378|NCT00927576|BEHAVIORAL|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
214611714|NCT02018406|DRUG|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
214611715|NCT02018406|DRUG|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
214611716|NCT02389023|OTHER|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
214611717|NCT02389023|OTHER|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
214611718|NCT01440842|OTHER|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
214611719|NCT01440842|OTHER|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
214611720|NCT03195751|DEVICE|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
214611721|NCT03195751|DEVICE|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
214611722|NCT02251379|DRUG|Flovent Diskus|Inhaled corticosteroids
214611723|NCT02251379|OTHER|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
214611724|NCT02251379|DRUG|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
214611725|NCT02258789|OTHER|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
214611726|NCT04935892|BEHAVIORAL|Slippers|Patients in the intervention group wear slippers when out of bed
214611727|NCT05066321|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
214611728|NCT00618436|DRUG|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
214611729|NCT00618436|DRUG|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
214611730|NCT05548348|DRUG|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
214611731|NCT02071212|DRUG|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
214611732|NCT03897907|OTHER|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
214611733|NCT03897907|OTHER|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
214611734|NCT00299962|BIOLOGICAL|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
214611735|NCT00299962|BIOLOGICAL|SCH 721015|Comparison of different doses and frequency of investigational agent
214611736|NCT04680728|OTHER|collection of biological parameters|haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
214722379|NCT00927576|BEHAVIORAL|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
214722380|NCT00927576|BEHAVIORAL|Verbal fluency|Evaluating how many words are produced in 90s.
214714446|NCT07092371|BEHAVIORAL|Digital Multimodal Intervention|Participants will undergo a 6-month multimodal intervention via a digital platform, which includes: (1) Personalized cognitive training; (2) Self-monitoring and management of stroke risk factors including hypertension, dyslipidemia, diabetes, smoking and obesity; (3) Smart wristband-based exercise monitoring and management; (4) Smart wristband-based sleep monitoring and management; (5) Health dietary recording and guidance
214611737|NCT04680728|OTHER|collection of echographic parameters|echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
214714447|NCT07090707|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
214714448|NCT07090707|RADIATION|radiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
214611738|NCT04680728|OTHER|collection of clinical parameters|eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
214611739|NCT05092178|BEHAVIORAL|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
214611740|NCT05092178|BEHAVIORAL|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
214611741|NCT00654914|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
214611742|NCT00370227|BIOLOGICAL|10 valent pneumococcal conjugate (vaccine)|
214611743|NCT05435170|DRUG|linerixibat|linerixibat will be administered per the treatment sequence
214611744|NCT03439436|DRUG|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
214611745|NCT03439436|DRUG|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
214611746|NCT04854434|DRUG|Selinexor|Participants will receive selinexor oral tablets.
214611747|NCT04854434|DRUG|Pembrolizumab|Participants will receive pembrolizumab intravenously.
214611748|NCT04854434|DRUG|Trifluridine|Participants will receive trifluridine oral tablets as SOC.
214611749|NCT04854434|DRUG|Tipiracil|Participants will receive tipiracil oral tablets as SOC.
214611750|NCT02709694|OTHER|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
214714449|NCT07091799|DIAGNOSTIC_TEST|P2X4 receptors in blood samples|This is an interventional study designed to assay P2X4 receptors in blood samples from ALS patients and healthy volunteers by comparing the mean levels of P2X4 expression.
214714450|NCT07090109|BEHAVIORAL|Genetic testing education video|patient education video about genetic testing for hereditary cancers
214714451|NCT07090954|DRUG|GR1803 injection|Participants will receive GR1803 injection.
214714452|NCT07090954|DRUG|Anti-CD38 Monoclonal Antibody|Participants will receive anti-CD38 monoclonal antibody.
214611751|NCT01231256|BEHAVIORAL|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
214611752|NCT01974492|PROCEDURE|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
214611753|NCT01974492|PROCEDURE|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
214611754|NCT04368572|BEHAVIORAL|Hypnosis|"An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase"
214611755|NCT06289244|DIAGNOSTIC_TEST|Ultrasound|"The thickness of the diaphragm and quadriceps will be assessed using bedside ultrasound, utilizing a 13-6 MHz cm linear probe. The measurement of the right hemidiaphragm's end-expiratory thickness will be conducted via diaphragm ultrasound. For accurate positioning, the ultrasound probe will be placed along the right anterior axillary line, specifically between the ninth and tenth intercostal spaces, in a sagittal oblique orientation. To enhance measurement consistency, the probe's position on the skin will be marked.~To ascertain accuracy, the operator will conduct each measurement three times, and the mean of these three values will be used for analysis. Similarly, for diaphragmatic assessment and peripheral assessments (Qthick and CSA) of the lower limbs, the examination areas will be demarcated on the skin with a dermatographic pen, ensuring measurement reproducibility over different timepoints."
214611756|NCT06289244|DIAGNOSTIC_TEST|Muscle strength measurement|"The assessment of limb muscle strength in this study will be conducted using the Medical Research Council (MRC) Score. For a more precise evaluation of quadriceps strength, a dynamometer will be employed.~Furthermore, the study will incorporate an invasive method for gauging inspiratory muscle strength, utilizing the negative inspiratory force (NIF) metric. Post-extubation, the maximum inspiratory pressure (MIP) will be determined using an electronic manometer. Three separate MIP measurements will be executed, and the highest reading among these will be recorded as the definitive measurement."
214611757|NCT03832491|OTHER|Home based therapy|Airway clearence techniques
214611758|NCT03832491|OTHER|Game and home based therapy|Game based approach programme and airway clearence techniques
214714453|NCT07090187|DEVICE|LegoPress , Novel assistive device|novel assistive device for rehabilitation using functional electrical stimulation
214714454|NCT06890039|DRUG|Placebo|"Matching placebo for TAK-242: 5% dextrose solution and commercially available 20% intralipid (prepared by hospital pharmacy staff)~Matching placebo for G-CSF: identical to vehicle for filgrastim (prepared for injection by hospital pharmacy staff)"
214611759|NCT04458662|PROCEDURE|Interval running protocol / eccentric-based resistance exercise protocol|
214611760|NCT00514514|DRUG|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
214611761|NCT00514514|DRUG|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
214611762|NCT00514514|DRUG|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
214714455|NCT06890039|DRUG|TAK-242|"TAK-242 concentrate for solution for infusion (80 mg/ mL in 3 mL ethanol) ): 240 mg TAK-242 per vial. To be reconstituted with 5% dextrose (36 mL) and commercially available 20% intralipid (21 mL).~TAK-242) will be administered as a continuous IV infusion starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 10 days.~PLUS placebo for G- CSF"
214714456|NCT06890039|DRUG|G-CSF (Filgrastim)|"Commercially available vials for subcutaneous injection. Quantitative composition (per mL):~Filgrastim: 300 mcg Acetate: 0.59 mg Sorbitol: 50.0 mg Tween® 80: 0.04 mg Sodium: 0.035 mg Water for Injection USP q.s. ad 1.0 mL~G-CSF will be given subcutaneously once daily at a dose of 5 µg/kg for 5 days (Day 1-5) and at Day 8 (6 injections in total)"
214611763|NCT00514514|DRUG|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
214611764|NCT01975740|OTHER|Sham manual diaphragm release technique|
214611765|NCT01975740|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
214714457|NCT06805617|DRUG|Ivonescimab|An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial, via intravenous (into the vein) infusion per protocol.
214714458|NCT07091929|DRUG|SGC001|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
214611766|NCT05347186|OTHER|Systematic corrective exercises and non-biomechanical functional exercises|"1. Restraint exercise or self-release: will involve the gastrocnemius muscle, soleus muscle, fibula, knee compressor muscles, adductors of the thighs, the short head of the biceps femoris, and iliotibial band for 30 seconds, using a foam roller.~2. Static stretching drills: involving the soleus and gastrocnemius muscles on an inclined plane, tensor fasciae latae muscle, short head of the biceps femoris, and ilio- psoas muscle;~3. Resistance exercises: will consist of strengthening the eccentric muscles of the feet including dorsiflexion and knee inversion, adduction, and extension, external rotation of the hip joint with TheraBand exercise band, and strengthening the intrinsic muscles of the foot.~4. Integrative exercises: including the star balance test on all planes and resistive exercises."
214611767|NCT05347186|OTHER|Non biomechanical functional exercises|Conventional treatment involved Non biomechanical Functional exercises (NBF), these exercises indicated for the control group consists of dorsal and plantar flexion of the metatarsophalangeal joints in unloading of the subject in a long sitting position on a chair or couch with the knee at 90◦ for a period of eight weeks. Feet will be in hanging position to allow plantar flexion smoothly. The exercises will carry out daily without any kind of resistance for a period of 30s. A total of five series will be completed for each foot. These exercises will be considered as non-therapeutic which might have affected the foot's posture.
214611768|NCT00954720|OTHER|No Intervention|There is no intervention on this trial
214714459|NCT07091929|DRUG|Placebo|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
214714460|NCT07091019|OTHER|TKIs|There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.
214714461|NCT07090070|PROCEDURE|Cohort 1 Intervention group|Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins.
214714462|NCT07090070|PROCEDURE|Cohort 2 severe/CIS margins clear|Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear
214714463|NCT07090070|PROCEDURE|Cohort 2 p53 and severe/CIS margins clear|Excision of the lesion ensuring final negative p53 and severe/CIS margins
214714464|NCT07090070|PROCEDURE|Cohort 3 Excision and END|Excision of primary lesions with 5+mm margins and immediate elective neck dissection
214714465|NCT07090070|PROCEDURE|Cohort 3 Excision and Close follow up|Excision of primary lesion with 5+mm margins and close follow up with salvage elective neck dissection if development of nodal disease
214714466|NCT07090720|DRUG|Melatonin|Neonates were given Melatonin.
214714467|NCT07090720|OTHER|Placebo|Neonates received placebo.
214714468|NCT07092124|DEVICE|test visionumVR|Two evaluation sessions with VisionumVR one month apart
214714469|NCT07090928|DRUG|5 ml of 0.5% bupivacaine infiltrated at each port site|5 ml of 0.5% bupivacaine infiltrated at each port site after the arthroscopic procedures
214714470|NCT07090928|DRUG|Placebo|5ml 0.9%normal saline infiltrated at port site
214714471|NCT07090902|BEHAVIORAL|Progressive Relaxation-Based Childbirth Preparation Program|This intervention consists of a childbirth preparation program that integrates progressive muscle relaxation (PMR) exercises. Participants receive face-to-face education by trained health professionals, a printed booklet explaining both childbirth preparation and PMR techniques, and an audio CD with guided relaxation sessions produced by the Turkish Psychological Association. The participants are instructed to perform the relaxation exercises daily at home until delivery. The goal of this intervention is to reduce labour pain, support informed mode of delivery preference, and enhance breastfeeding comfort in the early postpartum period.
214714472|NCT07091383|OTHER|Exercise|Static stretching
214714473|NCT07091383|OTHER|Exercise|Soft Tissue Mobilization
214714474|NCT07091383|OTHER|Exercise|Functional soft tissue mobilization
214714475|NCT07092202|DRUG|Firmonertinib|Firmonertinib 160mg po qd
214714476|NCT07092202|DRUG|Intrathecal injection of pemetrexed|Intrathecal injection of pemetrexed. Weight above 50kg: Induction period: 40mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 40mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative); Weight below 50kg: Induction period: 30mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 30mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative)
214611769|NCT00693914|BEHAVIORAL|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
214611770|NCT02667275|DRUG|A-101 Solution|
214714477|NCT07092332|BEHAVIORAL|Multimodal treatment|"Vulvodynia Intervention adapted for late adolescents and young adults. A multimodal treatment for provoked vulvodynia~The treatment consists of 11 treatment sessions. Working with goal-directed behavior change that has both physiological and psychosocial components. The treatment sessions will be conducted with various professionals, bot simultaneously and separately.~The intervention is based on physiological and psychosocial components working with goal-directed behavioral change; both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are between 60 to 90 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions."
214714478|NCT06919614|DIAGNOSTIC_TEST|Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing|Xpert® CT/NG and TV testing
214714479|NCT00315978|DEVICE|Heart-to-Heart Decision Aid|
214714480|NCT00642018|DRUG|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
214714481|NCT00642018|DRUG|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
214611771|NCT02667275|OTHER|Vehicle Solution|Placebo
214714482|NCT00642018|DRUG|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
214714483|NCT06935591|PROCEDURE|Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with Pulmonary Vein Isolation per standard of care.
214714484|NCT06935591|DEVICE|vMap® + Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with the use of the vMap® system and Pulmonary Vein Isolation.
214714485|NCT06937580|BEHAVIORAL|Peer Support and Baby Box|The intervention consists of five one-on-one peer support sessions and a Baby Box consisting of a woolen hat and socks for infant warmth, a cloth wrap to position the baby securely for skin-to-skin contact and improve comfort, a bar of soap for hygiene, and a real-time continuous temperature monitoring device for hypothermia detection
214714486|NCT04552431|DRUG|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
214714487|NCT04552431|DRUG|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
214714488|NCT04552431|DRUG|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
214611772|NCT04857801|DRUG|Teduglutide|effect of teduglutide on intestinal rehabilitation
214611773|NCT03164057|DRUG|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
214611774|NCT03164057|DRUG|Decitabine|Administered intravenously (IV) over approximately one hour.
214611775|NCT03164057|DRUG|Cytarabine|Given IV or intrathecally (IT).
214714489|NCT04552431|DRUG|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
214611776|NCT03164057|DRUG|Daunorubicin|Given IV.
214611777|NCT03164057|DRUG|Etoposide|Given IV.
214611778|NCT03164057|COMBINATION_PRODUCT|ITMHA|Given IT.
214611779|NCT03164057|DRUG|Idarubicin|Given IV.
214611780|NCT03164057|DRUG|Fludarabine|Given IV over approximately 30 minutes.
214611781|NCT03164057|DRUG|Mitoxantrone|Given IV.
214611782|NCT03164057|DRUG|Erwinia asparaginase|Given IV or intramuscularly (IM).
214611783|NCT03164057|DRUG|Sorafenib|Given PO.
214611784|NCT03164057|DRUG|G-CSF|Given IV.
214611785|NCT03164057|DRUG|Dexrazoxane|Given IV immediately before idarubicin administration.
214611786|NCT03164057|BIOLOGICAL|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
214611787|NCT03164057|DRUG|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
214611788|NCT00932204|DEVICE|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
214714490|NCT01736631|BEHAVIORAL|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
214714491|NCT01230749|DRUG|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
214714492|NCT01230749|DRUG|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
214714493|NCT01230749|DRUG|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
214611789|NCT02999542|OTHER|Music|Children will be randomised to receive either music via headphones or silence via headphones
214611790|NCT02999542|OTHER|No music|Children will be randomised to receive either music via headphones or silence via headphones
214611791|NCT02205203|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
214714494|NCT00556621|DRUG|cisplatin|
214714495|NCT00556621|DRUG|gemcitabine hydrochloride|
214714496|NCT00556621|PROCEDURE|biopsy|
214714497|NCT00556621|PROCEDURE|cystoscopy|
214714498|NCT00556621|PROCEDURE|therapeutic conventional surgery|
214714499|NCT00556621|RADIATION|radiation therapy|
214714500|NCT05440487|OTHER|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
214714501|NCT01060098|DRUG|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
214714502|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine QIV 0.5mL|
214714503|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine TIV 0.5mL|
214611792|NCT02205203|OTHER|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
214611793|NCT01487642|DEVICE|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
214611794|NCT01487642|DEVICE|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
214714504|NCT01819441|DRUG|Azelnidipine|8mg or 16mg
214714505|NCT01819441|DRUG|Perindopril|4mg or 8mg
214714506|NCT01819441|DRUG|hydrochlorothiazide|12.5mg or 25mg
214714507|NCT02979561|DRUG|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
214611795|NCT01487642|DEVICE|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
214611796|NCT01487642|DEVICE|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
214611797|NCT01414881|DRUG|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
214611798|NCT01414881|DRUG|Placebo|Placebo administered subcutaneously (SC) once weekly
214611799|NCT02925702|DRUG|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
214611800|NCT06388850|BEHAVIORAL|Healthy Relationships Project|The Healthy Relationships Project (HRP), created by the community-based organization Prevent Child Abuse Vermont (PCAVT), will be the focus of this rigorous evaluation study. The program is fully manualized with a widely accepted curriculum designed for Pre-K to 2nd graders (Care for Kids) and 3rd to 6th graders (We Care Elementary, though implementation will stop at 5th grade for this study). The HRP uses an upstream universal public health approach for the primary prevention of child and youth perpetration of child sexual abuse with developmentally appropriate intervention elements for children, faculty and staff at their schools, and for their caregivers.
214611801|NCT04308070|DEVICE|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
214611802|NCT04308070|DEVICE|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
214611803|NCT04229433|DRUG|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
214714508|NCT02979561|DRUG|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
214611804|NCT04229433|DRUG|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
214611805|NCT05681000|DRUG|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
214611806|NCT05700305|OTHER|12-week, low threshold physical rehabilitation intervention with protein supplementation|12 week, low threshold, rolling exercise intervention with protein supplementation
214611807|NCT02318862|PROCEDURE|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
214611808|NCT01274715|BEHAVIORAL|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
214714509|NCT01499797|OTHER|The CareWell programme|"The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions"
214714510|NCT00005905|DRUG|hu Leptin (A-100)|
214714511|NCT06318260|DRUG|Dobutrex|Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
214714512|NCT01855841|DRUG|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
214714513|NCT01855841|DRUG|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
214714514|NCT02152150|OTHER|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
214714515|NCT02152150|OTHER|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
214714516|NCT03674307|OTHER|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
214714517|NCT03674307|OTHER|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
214714518|NCT03582267|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
214714519|NCT03526341|DEVICE|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
214714520|NCT05610241|DEVICE|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
214714521|NCT05610241|DEVICE|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
214714522|NCT02816476|DRUG|Daratumumab|
214714523|NCT04746157|OTHER|Nurse intervention|Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
214611809|NCT04816929|OTHER|Bobath Method|Neurodevelopmental Treatment
214714524|NCT00290303|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
214714525|NCT03621189|DEVICE|intermittent theta burst stimulation|stimulatory protocol
214611810|NCT04816929|OTHER|Task-Oriented Approach|Task-Oriented Treatment
214611811|NCT03422562|DIETARY_SUPPLEMENT|Florababy|Probiotic supplement
214611812|NCT02407262|DIETARY_SUPPLEMENT|Black seed oil|
214611813|NCT02407262|OTHER|Placebo|vegetable oil
214611814|NCT06069336|DRUG|Hypertonic saline|Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
214611815|NCT06069336|DRUG|Normal saline|0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
214611816|NCT04248101|PROCEDURE|Double Ligation|
214611817|NCT04248101|DRUG|Topical Silver Nitrate|
214714526|NCT04412772|DRUG|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
214714527|NCT04412772|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
214611818|NCT03506711|DIAGNOSTIC_TEST|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
214611819|NCT03947983|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
214611820|NCT03947983|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
214611821|NCT00363324|PROCEDURE|intracoronary injection of bone marrow cells|
214611822|NCT02834169|OTHER|Non interventional|Data collection
214611823|NCT05410613|COMBINATION_PRODUCT|electromagnetic field and a plantar resistance exercise|"Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening)."
214611824|NCT05410613|DEVICE|Pulsed electromagnetic field|Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
214611825|NCT05410613|OTHER|usual care|standard general advice according to hospital protocol
214611826|NCT03075813|OTHER|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
214611827|NCT02302508|DRUG|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
214611828|NCT03242265|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
214611829|NCT04169750|BEHAVIORAL|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
214611830|NCT04169750|BEHAVIORAL|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
214714528|NCT03968081|BEHAVIORAL|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
214714529|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
214722381|NCT00927576|BEHAVIORAL|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
214714530|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
214714531|NCT03665493|BEHAVIORAL|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
214714532|NCT03665493|DRUG|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
214714533|NCT03665493|DRUG|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
214714534|NCT02443051|BEHAVIORAL|Attention Bias Modification|Computer delivered modification in 80% of trials
214714535|NCT03850210|DEVICE|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
214714536|NCT03850210|DEVICE|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
214714537|NCT00574366|DRUG|erlotinib|"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"
214714538|NCT00574366|DRUG|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"
214714539|NCT05595135|OTHER|Text Message-Based Navigation Intervention|Receive interactive text messaging.
214714540|NCT05595135|OTHER|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
214611831|NCT04169750|BEHAVIORAL|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
214611832|NCT03228472|DEVICE|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
214611833|NCT03228472|DEVICE|sham stimulation|Placebo treatment
214611834|NCT00376116|DEVICE|Cardiac resynchronisation therapy|
214611835|NCT00376116|DEVICE|Implantable cardioverter-defibrillator|
214611836|NCT00130702|DRUG|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
214611837|NCT02097524|DRUG|Sarilumab|
214611838|NCT02097524|DRUG|Tocilizumab|
214611839|NCT02921191|DRUG|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
214611840|NCT05694351|BEHAVIORAL|Healthy meals and physical activity in families with type 2 diabetes|Families will participate in telehealth family education on diabetes management and prevention through lifestyle modifications in their everyday occupations regarding current recommendations for physical activity, grocery shopping, meal preparation, and family meal routines. Each family will be assisted in setting tailored goals for the family as a whole and individually regarding physical activity and dieting habits. The goals will be incorporated into family daily routines, to secure manageability and sustainability of the new lifestyle habits. Local facilities and communy networks will be engaged in this process to empower and motivate the participants. Working with the goals will be monitored and facilitated throughout the intervention period of 3 months. Before discharge, each family will co-produce a maintenance plan for physical activity and healthy dieting.
214714541|NCT05595135|OTHER|Survey Administration|Ancillary studies
214714542|NCT05595135|OTHER|Quality-of-Life Assessment|Ancillary studies
214714543|NCT00529698|BIOLOGICAL|Biologically active recombinant Tat protein|
214714544|NCT01746810|RADIATION|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
214611841|NCT05893979|DEVICE|Spectacle Lenses|Standard Spectacle Lenses
214611842|NCT03199820|DEVICE|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
214611843|NCT03199820|DRUG|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
214611844|NCT04405154|BIOLOGICAL|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
214611845|NCT04405154|DRUG|Cisplatin|75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
214611846|NCT04405154|RADIATION|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
214611847|NCT03129087|BEHAVIORAL|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
214611848|NCT00012220|DRUG|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
214611849|NCT00012220|DRUG|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
214611850|NCT00012220|DRUG|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle"
214714545|NCT04984564|OTHER|None. As this was an observational study.|Observational study.
214714546|NCT01256320|OTHER|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
214714547|NCT01256320|OTHER|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
214714548|NCT05586815|DRUG|Colistin|150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
214714549|NCT05586815|DRUG|Minocycline|200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
214714550|NCT05586815|DRUG|Placebo|Capsule without active compound
214714551|NCT01909609|OTHER|AAP Documents|
214714552|NCT01909609|OTHER|Parent Survival Guide|
214611851|NCT00012220|DRUG|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
214611852|NCT06473675|PROCEDURE|Hysterectomy with adnexal surgery|Robotic-assisted and laparoscopic hysterectomy with adnexal surgery for benign disease.
214611853|NCT04942717|BEHAVIORAL|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
214611854|NCT02285920|DRUG|Spironolactone|The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
214714553|NCT03221712|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
214714554|NCT00653094|DEVICE|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
214611855|NCT01102348|OTHER|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
214611856|NCT05401799|DEVICE|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
214611857|NCT05401799|PROCEDURE|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
214714555|NCT02500277|DEVICE|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
214714556|NCT02500277|DEVICE|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
214722382|NCT00927576|BEHAVIORAL|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
214722383|NCT00927576|BEHAVIORAL|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
214714557|NCT05571904|PROCEDURE|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
214611858|NCT06016465|DRUG|Dexamethasone Oral|Two 4mg pills
214611859|NCT06016465|DRUG|Placebo|2 placebo pills
214611860|NCT01101438|DRUG|metformin hydrochloride|Given orally
214611861|NCT01101438|OTHER|placebo|Given orally
214611862|NCT02713542|DEVICE|ACP|Autologous Conditioned Plasma
214611863|NCT02713542|OTHER|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
214611864|NCT00003765|DRUG|O6-benzylguanine|
214714558|NCT01630941|DRUG|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
214714559|NCT02226419|DIETARY_SUPPLEMENT|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
214714560|NCT01120821|DRUG|Gleevec|400 mg once daily for 12 months
214611865|NCT00003765|DRUG|carmustine|
214611866|NCT06196645|BEHAVIORAL|Physical Activity Intervention Based on Theory of Planned Behavior|The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in.
214611867|NCT06210698|DIAGNOSTIC_TEST|Venipuncture|venipuncture
214611868|NCT02475070|DRUG|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
214611869|NCT02475070|DRUG|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
214714561|NCT02508519|PROCEDURE|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
214714562|NCT04587921|DEVICE|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
214714563|NCT04181957|DRUG|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
214714564|NCT04181957|DRUG|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
214714565|NCT00083304|DRUG|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
214611870|NCT06155110|DRUG|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
214611871|NCT05827653|DRUG|NX210c|3 times a week, for 28 days
214611872|NCT05827653|DRUG|Placebo|3 times a week, for 28 days
214611873|NCT04956042|DRUG|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
214611874|NCT04956042|DRUG|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
214611875|NCT01219647|BEHAVIORAL|exercise|subjects will participate in one of two forms of exercise
214611876|NCT01219647|BEHAVIORAL|stretching|subjects will particiopate in supervised stretching as described in arm description.
214611877|NCT04638582|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
214611878|NCT04638582|DRUG|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
214714566|NCT00083304|RADIATION|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
214714567|NCT00083304|OTHER|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
214714568|NCT04569617|OTHER|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
214714569|NCT04569617|OTHER|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
214714570|NCT04569617|OTHER|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
214714571|NCT04569617|OTHER|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
214714572|NCT03077243|RADIATION|Intensity Modulated Radiotherapy (IMRT)|60- 70 Gy at 2 Gy/fx
214714573|NCT03077243|DRUG|Cisplatin (or alternative)|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
214611879|NCT04638582|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
214611880|NCT04638582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
214611881|NCT01820936|DRUG|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
214611882|NCT01820936|DRUG|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
214611883|NCT01820936|DRUG|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
214611884|NCT01820936|DRUG|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
214611885|NCT01820936|DRUG|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
214611886|NCT01756469|BEHAVIORAL|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
214611887|NCT05885867|BEHAVIORAL|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
214611888|NCT02274181|DRUG|Androxal|
214611889|NCT04366050|DRUG|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
214611890|NCT04366050|DRUG|Placebo oral capsule|Placebo
214611891|NCT04563780|DEVICE|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
214714574|NCT03077243|PROCEDURE|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
214714575|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
214714576|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
214714577|NCT01432457|DRUG|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
214714578|NCT01089166|DRUG|Metformin|
214611892|NCT00097942|DRUG|memantine HCl|
214611893|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
214611894|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
214611895|NCT01516840|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
214611896|NCT01516840|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
214611897|NCT04091490|DRUG|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
214611898|NCT01750931|DRUG|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
214611899|NCT01750931|DRUG|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
214611900|NCT02504359|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214611901|NCT02504359|DRUG|Carmustine|Given BEAM chemotherapy
214611902|NCT02504359|DRUG|Cytarabine|Given BEAM chemotherapy
214611903|NCT02504359|DRUG|Etoposide|Given BEAM chemotherapy
214611904|NCT02504359|DRUG|Ixazomib Citrate|Given PO
214611905|NCT02504359|DRUG|Melphalan|Given BEAM chemotherapy
214611906|NCT02504359|DRUG|Methotrexate|Given IV
214611907|NCT02504359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214611908|NCT02504359|OTHER|Quality-of-Life Assessment|Ancillary studies
214611909|NCT02504359|DRUG|Tacrolimus|Given IV or PO
214611910|NCT00496236|DRUG|TNFerade biologic|
214611911|NCT00590044|DRUG|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
214611912|NCT00590044|DRUG|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
214611913|NCT00606450|DRUG|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
214611914|NCT00606450|DRUG|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
214611915|NCT00606450|DRUG|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
214611916|NCT00041925|DRUG|CGT003 (E2F Duplex Decoy)|
214714579|NCT03459157|DRUG|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
214714580|NCT02848313|DRUG|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
214714581|NCT04814511|DRUG|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
214611917|NCT00195312|BIOLOGICAL|HIV-1 gag DNA (formulated with bupivacaine)|
214714582|NCT04814511|DRUG|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
214714583|NCT04814511|DRUG|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
214714584|NCT00045591|DRUG|celecoxib|100 mg PO bid
214611918|NCT00195312|BIOLOGICAL|IL-15 DNA (formulated with bupivacaine)|
214611919|NCT00195312|BIOLOGICAL|IL-12 DNA (formulated with bupivacaine)|
214611920|NCT00195312|BIOLOGICAL|Sodium chloride injection USP (0.9%)|
214714585|NCT00045591|DRUG|Celecoxib|400 mg PO bid
214714586|NCT04658810|OTHER|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
214714587|NCT01234519|DRUG|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
214714588|NCT01234519|DRUG|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
214714589|NCT01117025|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
214611921|NCT00943020|DIETARY_SUPPLEMENT|Nutricia PreOp nutritional supplement|nutritional supplement
214611922|NCT00943020|DIETARY_SUPPLEMENT|Lipid|Drink
214611923|NCT00943020|DIETARY_SUPPLEMENT|Glutamine|Drink
214611924|NCT06038240|BEHAVIORAL|Savoring Meditation|Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).
214611925|NCT06038240|BEHAVIORAL|Pain Self-Management and Education|Participants will learn about the biopsychosocial drivers of chronic pain.
214611926|NCT06027736|OTHER|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
214611927|NCT01244295|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
214611928|NCT01244295|BEHAVIORAL|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
214611929|NCT00000580|DRUG|immunoglobulins, intravenous|
214611930|NCT03126396|DEVICE|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
214611931|NCT03199040|DRUG|Durvalumab|-Human monoclonal antibody
214611932|NCT03199040|BIOLOGICAL|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
214611933|NCT03199040|DEVICE|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
214611934|NCT03199040|PROCEDURE|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
214611935|NCT03882203|DRUG|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
214611936|NCT02580942|DEVICE|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
214611937|NCT02580942|DEVICE|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
214611938|NCT02580942|DRUG|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
214611939|NCT03838055|PROCEDURE|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
214611940|NCT04290338|OTHER|PIOMI|Intraoral and extraoral stimulation.
214611941|NCT03778567|DRUG|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
214611942|NCT06059924|OTHER|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
214611943|NCT05838079|OTHER|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
214714590|NCT01117025|PROCEDURE|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
214611944|NCT02433197|DEVICE|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
214611945|NCT05168748|DRUG|IMJ995 single agent|Single intravenous administration of IMJ995
214611946|NCT01236664|BEHAVIORAL|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
214611947|NCT01236664|BEHAVIORAL|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
214714591|NCT03154294|DRUG|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
214714592|NCT03154294|DRUG|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
214714593|NCT03154294|DRUG|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
214714594|NCT02868255|PROCEDURE|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
214714595|NCT03444467|DRUG|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
214714596|NCT03444467|DRUG|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
214611948|NCT00588510|OTHER|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
214611949|NCT01652742|DRUG|BI 135585 XX|one single dose
214611950|NCT01089998|DRUG|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
214611951|NCT01089998|DRUG|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
214611952|NCT01089998|DRUG|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
214611953|NCT01089998|DRUG|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
214611954|NCT04541979|DRUG|aerosolized DNase|DNase
214611955|NCT04541979|DRUG|NaCl|NaCl 0.9%, isotonic saline
214611956|NCT01937598|DRUG|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
214611957|NCT01937598|OTHER|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
214611958|NCT01937598|DRUG|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
214611959|NCT01937598|DRUG|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
214611960|NCT02566291|DEVICE|Success|Success rate and time for insertion
214611961|NCT01700270|DRUG|dovitinib (TKI258)|
214611962|NCT01700270|DRUG|fluvoxamine|perpetrator drug; 7 days of dosing
214611963|NCT02984579|DEVICE|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
214611964|NCT02984579|DEVICE|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
214611965|NCT02984579|DEVICE|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
214611966|NCT02951286|DEVICE|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
214611967|NCT02951286|DEVICE|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
214611968|NCT00069732|BEHAVIORAL|qigong|
214611969|NCT00069732|BEHAVIORAL|acupressure-TAT|
214611970|NCT00199836|BIOLOGICAL|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
214611971|NCT02301663|OTHER|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
214611972|NCT02301663|OTHER|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
214611973|NCT02301663|OTHER|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
214611974|NCT00449384|BEHAVIORAL|Diagnostic Screening|
214611975|NCT01390766|DRUG|Azathioprine|
214611976|NCT00940381|DRUG|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
214611977|NCT00940381|DRUG|Cetuximab|Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
214611978|NCT02674698|OTHER|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
214611979|NCT02674698|OTHER|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
214611980|NCT02674698|OTHER|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
214611981|NCT02674698|OTHER|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
214611982|NCT02582320|DRUG|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
214611983|NCT01638078|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
214611984|NCT01638078|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
214611985|NCT02967705|BEHAVIORAL|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
214611986|NCT01114282|DRUG|velcade|
214611987|NCT01114282|DRUG|Pralatrexate|
214611988|NCT05353400|OTHER|Early urinary catheter removal|Early catheter removal
214611989|NCT05353400|OTHER|Urinary catheter removal on POD 3|Catheter removal on POD 3
214611990|NCT02237404|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
214611991|NCT01909427|DRUG|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
214611992|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
214611993|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
214611994|NCT01909427|DRUG|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
214611995|NCT01909427|DRUG|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
214611996|NCT01909427|DRUG|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
214611997|NCT01909427|DRUG|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
214611998|NCT04267718|OTHER|Application of Padua and IMPROVE Bleeding scores|Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
214611999|NCT05355025|BEHAVIORAL|WiserAD|"See Arms"
214612000|NCT05355025|BEHAVIORAL|Attention control|"See Arms"
214612001|NCT01431326|DRUG|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
214612002|NCT05298982|BEHAVIORAL|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
214612003|NCT02400034|OTHER|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
214612004|NCT01708291|BEHAVIORAL|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
214612005|NCT01708291|BEHAVIORAL|only pre and post evaluation measures|
214612006|NCT02543827|BIOLOGICAL|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
214612007|NCT02543827|BIOLOGICAL|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
214612008|NCT00096668|DRUG|TOCOSOL(R) Paclitaxel|
214612009|NCT02290626|DRUG|Elmental diet|elemental diet is administered using PEG.
214612010|NCT02290626|DRUG|Semi-solid diet|Semi-solid diet is administered using PEG.
214612011|NCT03392272|DEVICE|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
214612012|NCT03392272|OTHER|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
214612013|NCT00503243|DRUG|Delayed and extended release mesalazine|
214612014|NCT05033665|BEHAVIORAL|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
214612015|NCT05033665|BEHAVIORAL|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
214714597|NCT03444467|DRUG|Placebo|Participants will receive single dose of placebo (for double dummy injections).
214714598|NCT00095810|DRUG|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
214612016|NCT03228069|PROCEDURE|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
214612017|NCT03093779|OTHER|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
214612018|NCT03870516|PROCEDURE|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
214612019|NCT03870516|DEVICE|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
214612020|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 6
214612021|NCT01843972|DRUG|BI 691751|oral solution
214612022|NCT01843972|DRUG|Placebo|placebo solution
214612023|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 2
214612024|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 5
214612025|NCT01843972|DRUG|BI 691751|1 tablet
214612026|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 3
214612027|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 4
214612028|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 7
214612029|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 1
214612030|NCT02336763|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214612031|NCT02336763|OTHER|Laboratory Biomarker Analysis|Correlative studies
214612032|NCT02232126|OTHER|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
214612033|NCT04257565|DEVICE|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
214612034|NCT04257565|OTHER|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
214612035|NCT00041054|DRUG|carboplatin|
214612036|NCT00041054|DRUG|etoposide|
214612037|NCT00041054|DRUG|exisulind|
214612038|NCT03817866|DIAGNOSTIC_TEST|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
214612039|NCT00393809|DRUG|DTA-H19|
214612040|NCT05425069|DRUG|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
214612041|NCT02980120|OTHER|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig \& Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
214612042|NCT02980120|OTHER|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner \& Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
214714599|NCT03786406|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
214714600|NCT00247273|DRUG|risedronate|tablet, 5 mg risedronate, once a day for 2 years
214714601|NCT00247273|DRUG|risedronate|oral, 150 mg risedronate, once a month for 2 years
214714602|NCT01309373|OTHER|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
214714603|NCT06849427|OTHER|multicomponent exercise intervention|"Multicomponent Exercise Program~A. Flexibility B. Targeted Strength Training C. Balance and Mobility~1. Center of Gravity Control Training~2. Multisensory Training~3. Postural Strategy Training~4. Gait Pattern Development Variation Training~5. Dual Task Exercises . D. Cardiovespiratory Fitness"
214714604|NCT00821145|PROCEDURE|conventional surgery|AAA patients operated using a conventional incision
214714605|NCT00821145|PROCEDURE|laparoscopic AAA resection|laparoscopic AAA resection
214714606|NCT00821145|PROCEDURE|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
214714607|NCT04238572|DEVICE|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
214714608|NCT04238572|DEVICE|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
214714609|NCT05059938|BEHAVIORAL|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
214612043|NCT02980120|OTHER|EDI-2|The Eating Disorder Inventory 2 (Paul \& Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
214612044|NCT02980120|OTHER|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig \& Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
214612045|NCT02980120|OTHER|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke \& Krischer, 2011).
214714610|NCT00599170|DRUG|Rituximab|375 mg/m2 IV
214714611|NCT04492787|DRUG|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
214714612|NCT04492787|DRUG|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
214714613|NCT00356668|DEVICE|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
214714614|NCT02977533|DRUG|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214714615|NCT02977533|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214714616|NCT02977533|DRUG|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
214714617|NCT00001753|PROCEDURE|Magnetic resonance imaging|
214714618|NCT04456595|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
214714619|NCT04456595|BIOLOGICAL|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
214714620|NCT01454479|DRUG|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
214612046|NCT02980120|OTHER|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann \& Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
214612047|NCT02980120|DEVICE|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
214612048|NCT00000551|BEHAVIORAL|health education|
214612049|NCT02465385|DRUG|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
214612050|NCT05378854|OTHER|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
214612051|NCT04297501|DRUG|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
214612052|NCT05116150|DIETARY_SUPPLEMENT|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
214612053|NCT05116150|DIETARY_SUPPLEMENT|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
214612054|NCT01212978|BEHAVIORAL|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
214714621|NCT01419015|DEVICE|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
214714622|NCT04861519|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
214714623|NCT04209530|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
214714624|NCT06552923|OTHER|ECHO Tele-Education|A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
214714625|NCT02972957|BIOLOGICAL|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
214714626|NCT02972957|DRUG|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
214714627|NCT03588611|DRUG|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
214714628|NCT03588611|DRUG|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
214714629|NCT06347783|DEVICE|Insulin pump|Continuous subcutaneous insulin therapy.
214612055|NCT00518388|BEHAVIORAL|Focus Group|Focus groups each lasting about 2 hours.
214612056|NCT00518388|BEHAVIORAL|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
214612057|NCT02154542|DEVICE|Neurovent Monitor XIII|
214714630|NCT01192711|DEVICE|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
214714631|NCT04491214|OTHER|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
214714632|NCT00602381|DRUG|Lithium|
214714633|NCT02784977|DEVICE|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
214714634|NCT02784977|DEVICE|Intraoral device (IOD)|Treatment of OSA with IOD
214714635|NCT02784977|PROCEDURE|Uvuloplasty|Uvuloplasty
214714636|NCT02784977|OTHER|Conservative treatment|No active intervention
214714637|NCT02822651|BIOLOGICAL|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
214714638|NCT02822651|OTHER|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
214714639|NCT01192841|OTHER|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
214714640|NCT00586638|BEHAVIORAL|Video game based training|36 one-hour sessions over 12 weeks
214714641|NCT02053519|DRUG|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
214714642|NCT02053519|DRUG|Mygliol Oil|Matched placebo comparator
214612058|NCT03982342|DEVICE|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
214612059|NCT03982342|OTHER|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
214612060|NCT00024401|DRUG|DHA-paclitaxel|
214612061|NCT03410017|OTHER|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
214714643|NCT01395355|BEHAVIORAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
214714644|NCT01395355|BEHAVIORAL|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
214714645|NCT03625492|BEHAVIORAL|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
214714646|NCT03625492|BEHAVIORAL|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
214714647|NCT01660230|BIOLOGICAL|3K3A-APC, diluted in 0.9% sodium chloride in water|
214612062|NCT01542268|DRUG|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
214714648|NCT01660230|DRUG|0.9% NaCl in water|
214714649|NCT02580240|DRUG|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
214714650|NCT02580240|DRUG|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
214714651|NCT00607919|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
214612063|NCT01542268|DRUG|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
214612064|NCT04682704|DEVICE|Parasym|Tragus stimulation
214612065|NCT03171727|DRUG|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
214612066|NCT02627755|DEVICE|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
214612067|NCT02627755|DEVICE|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
214612068|NCT05218681|OTHER|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
214612069|NCT05218681|OTHER|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
214612070|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
214612071|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
214612072|NCT01028326|BIOLOGICAL|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
214612073|NCT01854645|DRUG|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
214612074|NCT01854645|DRUG|GP MDI|GP MDI administered as two puffs BID
214612075|NCT01854645|DRUG|FF MDI|FF MDI administered as two puffs BID
214714652|NCT00607919|DRUG|Placebo|oral, daily, for 16 weeks
214714653|NCT00760045|DRUG|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
214714654|NCT00760045|DRUG|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
214714655|NCT04466787|DIAGNOSTIC_TEST|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
214722384|NCT00927576|BEHAVIORAL|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
214612076|NCT01854645|DRUG|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
214612077|NCT01854645|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID
214612078|NCT03759483|DIAGNOSTIC_TEST|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
214612079|NCT02149212|DRUG|Phlebotonic|Aminaftone -- 75 mg BID
214612080|NCT02149212|DEVICE|Stent|Iliac Vein Stenting
214612081|NCT02149212|PROCEDURE|Limb elastic compression support|CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages
214612082|NCT02149212|PROCEDURE|Unna boot dressing|CEAP 6 \> Unna boot dressing
214722385|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
214722386|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
214722387|NCT00216086|PROCEDURE|EUS|biopsy per EUS
214722388|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
214714656|NCT04466787|DIAGNOSTIC_TEST|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
214714657|NCT03857607|GENETIC|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
214612083|NCT03517384|BEHAVIORAL|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
214612084|NCT05614687|BEHAVIORAL|Community-informed art-based programme|The Community-informed art-based programme is an intervention incorporating art in the form of for example poetry and drawings in addressing trauma and encouraging community attitudes towards the positive reintegration of ex-offenders.
214612085|NCT05614687|OTHER|Government Media Intervention|Government Media Intervention involving media content from the National Orientation Agency and other media sources
214612086|NCT01903291|DRUG|dimethyl fumarate|As described in the treatment arm
214612087|NCT02748850|BIOLOGICAL|blood sample|a blood sample 20 milliliter
214612088|NCT02748850|BIOLOGICAL|Stem cell donation|The volume of stem cells remained in the tube is recovered
214612089|NCT04553510|DRUG|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
214612090|NCT04553510|DRUG|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
214612091|NCT01223521|DEVICE|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
214612092|NCT01773642|BEHAVIORAL|Cognitive behavioral intervention to support pediatric HIV disclosure|
214612093|NCT01714778|OTHER|e-Cigarette|
214612094|NCT05354076|DRUG|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
214612095|NCT03086265|DEVICE|THRIVE|active nasal oxygen delivery system
214612096|NCT03086265|DEVICE|Endotracheal tube|Plastic tube for supporting ventilation during surgery
214612097|NCT01001468|DRUG|VB-201|Single daily dose of oral VB-201 20 mg
214612098|NCT01001468|DRUG|VB-201|Single daily dose or oral VB-201 80 mg
214714658|NCT04933409|PROCEDURE|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
214612099|NCT01001468|OTHER|Placebo|Single daily dose of oral placebo
214612100|NCT05487898|DEVICE|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
214612101|NCT01202279|DRUG|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
214612102|NCT01202279|DEVICE|Placebo|Placebo bid for 7 days
214612103|NCT05877222|DRUG|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
214612104|NCT05877222|DRUG|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
214612105|NCT03970850|DIAGNOSTIC_TEST|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
214612106|NCT03970850|DIAGNOSTIC_TEST|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
214612107|NCT04054089|DRUG|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
214612108|NCT04054089|DRUG|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
214612109|NCT00514774|DRUG|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
214612110|NCT00514774|DRUG|placebo|placebo 600mg twice daily for study days 0 through 28
214612111|NCT02041754|DEVICE|IQP-AK-102|
214612112|NCT02041754|DEVICE|Placebo|
214612113|NCT05802394|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
214612114|NCT00686296|OTHER|Taliderm™|taliderm™ dressing application once
214612115|NCT00686296|OTHER|Taliderm™|Taliderm™ dressing application up to three applications
214612116|NCT00686296|OTHER|standard wet to dry dressing with gauze|wet to dry dressing standard of care
214612117|NCT05923749|DEVICE|Biatain Ag|Biatain with silver
214612118|NCT05923749|DEVICE|Cutimed Siltec Sorbact|comparator device
214612119|NCT03516890|PROCEDURE|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
214612120|NCT04353466|PROCEDURE|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
214612121|NCT04353466|DRUG|Elelyso|intravenous (IV) infusions of Elelyso
214612122|NCT00000420|DRUG|Ortho-Novum 777|
214612123|NCT05852041|PROCEDURE|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
214612124|NCT05852041|GENETIC|Decipher Prostate Cancer Test|Undergo decipher
214612125|NCT05852041|OTHER|Flotufolastat F-18 Gallium|Given IV
214612126|NCT05852041|PROCEDURE|Magnetic Resonance Imaging|Undergo PET-MRI
214612127|NCT05852041|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214612128|NCT05852041|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
214612129|NCT05852041|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214612130|NCT04747093|BIOLOGICAL|CAR-ITNK cells|CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
214612131|NCT01908972|DRUG|Prednisolone|2mg/kg/day for 16weeks
214612132|NCT01908972|DRUG|Propranolol|2mg/kg/day for 16weeks
214612133|NCT02366975|DRUG|Testosterone gel 2%|testosterone gel 2% (50mg/die).
214714659|NCT04933409|PROCEDURE|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
214714660|NCT02005783|DRUG|DBD|DBD:one dose of medicine twice per day, orally
214714661|NCT02005783|DRUG|Epirubicin|Epirubicin:90mg/m2, d1, q3w\*4
214714662|NCT02005783|DRUG|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w\*4
214612134|NCT02366975|OTHER|Placebo|placebo gel
214714663|NCT02005783|DRUG|Docetaxel|Docetaxel:75mg/m2, d1, q3w\*4
214714664|NCT00646581|DRUG|Placebo|Placebo
214612135|NCT05197413|DIETARY_SUPPLEMENT|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
214612136|NCT02026921|DRUG|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
214612137|NCT02026921|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
214612138|NCT02380950|BEHAVIORAL|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
214612139|NCT02698748|DRUG|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
214714665|NCT00646581|DRUG|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
214714666|NCT01527110|DRUG|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
214714667|NCT01714713|DRUG|EVP-6124|Arm 1, 2
214714668|NCT06516458|DIAGNOSTIC_TEST|Camera Based Kinematic Analysis|Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
214722389|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
214722390|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
214722391|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
214722392|NCT01446991|DRUG|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
214612140|NCT02698748|DRUG|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
214612142|NCT00475722|BEHAVIORAL|1 Healthy Eating|6 months telephone counseling
214612143|NCT00475722|BEHAVIORAL|2 Mediterranean|6 months telephone counseling
214612144|NCT03182985|BEHAVIORAL|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
214612145|NCT04291248|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
214612146|NCT04291248|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
214612147|NCT03687073|DRUG|Indole-3-Carbinol|Cohorts 2, 3, \& 4: 400 mg PO BID
214612148|NCT03687073|DRUG|Silibinin|Cohorts 1 \& 4: 720mg
214714669|NCT05281068|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
214612149|NCT03687073|DRUG|Silibin|Cohort 3: 360mg
214612150|NCT03128970|OTHER|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
214612151|NCT01377064|BEHAVIORAL|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
214612152|NCT01377064|OTHER|Standard Care Group|No intervention, the group will be followed under their standard medical care.
214612153|NCT04095728|DIETARY_SUPPLEMENT|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
214612154|NCT04095728|OTHER|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
214612155|NCT01021787|DRUG|Titanium dioxide|Topical cream
214612156|NCT00916279|DEVICE|Lutonix Paclitaxel-Coated Balloon|PTCA
214612157|NCT00865397|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
214612158|NCT02441465|DRUG|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
214612159|NCT02441465|DRUG|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
214612160|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
214612161|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
214612162|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
214714670|NCT05281068|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
214714671|NCT02589743|DEVICE|Sealant|Application of preventive agent
214612163|NCT00310804|BIOLOGICAL|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
214612164|NCT02109562|DRUG|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
214612165|NCT02109562|DRUG|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
214612166|NCT02109562|DRUG|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
214714672|NCT02589743|DEVICE|Adhesive and Sealant|Application of preventive agent and technique for control moisture
214714673|NCT02007252|DRUG|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
214714674|NCT02007252|DRUG|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
214714675|NCT05143918|OTHER|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
214722393|NCT01446991|DRUG|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
214722394|NCT01495260|DRUG|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
214722395|NCT01495260|DRUG|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
214722396|NCT01495260|DRUG|vitamin E|vitamin E, 150-300 mg daily for 2 months
214612167|NCT03877536|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
214714676|NCT06039150|PROCEDURE|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
214714677|NCT06039150|PROCEDURE|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
214714678|NCT02403141|OTHER|Questionnaire|
214612168|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
214612169|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
214612170|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
214714679|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
214612171|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
214612172|NCT04700384|BEHAVIORAL|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
214714680|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
214714681|NCT00985738|DRUG|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
214612173|NCT04700384|BEHAVIORAL|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
214612174|NCT02198443|DRUG|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
214612175|NCT02198443|DRUG|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
214612176|NCT03598647|BEHAVIORAL|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
214612177|NCT03598647|BEHAVIORAL|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
214612178|NCT05744336|OTHER|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
214612179|NCT05744336|OTHER|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
214612180|NCT00688155|BEHAVIORAL|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
214612181|NCT00688155|BEHAVIORAL|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
214612182|NCT00688155|BEHAVIORAL|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
214612183|NCT04310085|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
214612184|NCT04310085|BIOLOGICAL|PfSPZ-DVI Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
214612185|NCT06456528|DRUG|QL0911|QL0911
214612186|NCT06456528|DRUG|QL0911 plus Placebo|QL0911 plus Placebo
214612187|NCT06456528|DRUG|Placebo|Placebo
214612188|NCT05492695|DRUG|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
214612189|NCT05492695|OTHER|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
214612190|NCT03543111|BEHAVIORAL|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
214714682|NCT00985738|OTHER|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
214612191|NCT02366559|DEVICE|Hyfrecator|
214714683|NCT02757404|DRUG|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
214714684|NCT02757404|DRUG|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
214612192|NCT02366559|DEVICE|532 nm Q-switched Nd:YAG laser|
214612193|NCT03044782|OTHER|53-Item Survey|
214612194|NCT01248286|OTHER|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
214612195|NCT01248286|OTHER|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
214612196|NCT02484833|DRUG|Cetuximab|
214612197|NCT02484833|DRUG|FOLFIRI|
214612198|NCT04549870|DRUG|Roflumilast|Treatment according to national roflumilast guidelines
214612199|NCT05520099|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
214714685|NCT02757404|DRUG|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
214714686|NCT01619488|DEVICE|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
214722397|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
214612200|NCT00068575|BIOLOGICAL|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
214612201|NCT00068575|DRUG|Cisplatin|30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
214612202|NCT00068575|DRUG|Fluorouracil|175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
214612203|NCT00068575|RADIATION|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
214612204|NCT01241799|PROCEDURE|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
214612205|NCT01241799|PROCEDURE|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
214612206|NCT01043341|BEHAVIORAL|educative folder|folder about HPV infection and vaccines
214612207|NCT05132374|OTHER|I-T CHILD|This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
214612208|NCT00745693|DRUG|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
214612209|NCT00745693|DRUG|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
214612210|NCT05112627|PROCEDURE|Biospecimen Collection|Undergo blood collection
214612211|NCT05432882|BIOLOGICAL|bi-4SCAR CD19/22 T cells|Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
214612212|NCT00052351|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
214612213|NCT00052351|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
214612214|NCT00052351|BIOLOGICAL|sargramostim|
214612215|NCT00052351|DRUG|cyclophosphamide|
214612216|NCT00052351|DRUG|doxorubicin hydrochloride|
214612217|NCT00052351|DRUG|paclitaxel|
214612218|NCT00052351|RADIATION|radiation therapy|
214612219|NCT06073990|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
214612220|NCT00215800|DRUG|Ampligen|
214612221|NCT06315738|BIOLOGICAL|ST266|Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
214612222|NCT01316094|DRUG|ASP1941|oral
214612223|NCT01316094|DRUG|placebo|oral
214612224|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
214612225|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
214612226|NCT04887155|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
214612227|NCT03318978|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
214612228|NCT05296837|DRUG|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
214612229|NCT05296837|DRUG|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
214612230|NCT05296837|DRUG|Placebo|Placebo to be administered in tablet form twice daily
214612231|NCT01292798|DRUG|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
214612232|NCT04629352|DEVICE|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
214612233|NCT04629352|DEVICE|Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
214612234|NCT00000353|DRUG|Buprenorphine/naloxone|
214612235|NCT04453293|BIOLOGICAL|BCG (Tokyo 172) vaccine|Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
214612236|NCT04453293|DRUG|Placebo|Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
214612237|NCT04451850|OTHER|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
214612238|NCT01200238|DRUG|STA-9090|
214612239|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
214612240|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
214612241|NCT02823249|DIETARY_SUPPLEMENT|50 g Xylitol|
214612242|NCT02823249|DIETARY_SUPPLEMENT|75 g Erythritol|
214612243|NCT02823249|DIETARY_SUPPLEMENT|75 g Glucose|
214612244|NCT02823249|DIETARY_SUPPLEMENT|Tap water|
214612245|NCT02823249|DIETARY_SUPPLEMENT|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
214612246|NCT02823249|DEVICE|Nasogastric Tube|
214612247|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
214612248|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
214714687|NCT02653352|BEHAVIORAL|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
214714688|NCT03736551|BEHAVIORAL|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
214612253|NCT03548285|RADIATION|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
214612254|NCT04154917|OTHER|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
214612255|NCT06972888|DRUG|AC-201|AC-201 tablets will be administered orally
214612256|NCT06972888|DRUG|Placebo|Matching placebo tablets will be administered orally.
214612257|NCT03933670|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214612258|NCT03933670|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214612259|NCT03933670|PROCEDURE|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
214714689|NCT03736551|BEHAVIORAL|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
214714690|NCT02227849|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
214714691|NCT02227849|DRUG|GLP-1 analogue|
214714692|NCT03982238|DRUG|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
214612260|NCT05234554|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
214612261|NCT05234554|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
214612262|NCT06984809|BEHAVIORAL|Intervention|The intervention group will receive Invest in Play (iiP), a 12 session group-based parent program, which is led by two trained group leaders.
214612263|NCT06984146|DRUG|Nivolumab|40 mg day 1 and 15
214612264|NCT06984146|DRUG|Doxorubicin|25 mg/m2 day 1 and 15
214612265|NCT06984146|DRUG|Vinblastine|6 mg/m2 (not exceeding 10 mg) day 1 and 15
214612266|NCT06984146|DRUG|Dacarbazine|375 mg/m2 day 1 and 15
214612267|NCT06984640|DIETARY_SUPPLEMENT|Curcumin|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin. Longvida® is a trademark of Vendure Sciences, Noblesville, IN, USA.
214612268|NCT06984640|DIETARY_SUPPLEMENT|Placebo|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin.
214612269|NCT06985017|BEHAVIORAL|Playing Playfully to Overcome Adversity|This training is provided via virtual group sessions (Telehealth) and consists of five 45-minute-long weekly sessions addressing ways to promote children's play and playfulness in the classroom and techniques to reduce teacher/caregiver burnout.
214612270|NCT05323188|OTHER|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
214612271|NCT04133818|BEHAVIORAL|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation"
214612272|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
214612273|NCT06510205|DEVICE|Mentor Breast implants|"Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form."
214612274|NCT03706417|DIAGNOSTIC_TEST|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
214612275|NCT04882098|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
214612276|NCT04882098|DRUG|Placebo|Participants will receive matching placebo as SC injection.
214612277|NCT04590950|OTHER|Non interventional study|Non interventional study
214612278|NCT05938998|BEHAVIORAL|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
214612279|NCT06159621|DRUG|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg. Commercially available PD-1 inhibitor may be substituted.
214714693|NCT03982238|DRUG|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
214714694|NCT03982238|DRUG|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
214612280|NCT06159621|DRUG|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
214612281|NCT05263739|DRUG|ESG206|Administered via intravenous (IV) infusion
214612282|NCT05450367|OTHER|Data collection|Data collection
214612283|NCT06833983|DRUG|GS1191-0445 injection|A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg
214612284|NCT04045795|DRUG|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
214612285|NCT04045795|DRUG|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
214612286|NCT04045795|DRUG|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
214612287|NCT04045795|DRUG|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214612288|NCT04045795|DEVICE|Investigational injector device|Subcutaneous administration
214612289|NCT01360541|PROCEDURE|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
214612290|NCT01360541|OTHER|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
214612291|NCT03022318|DRUG|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
214612292|NCT05198934|DRUG|Sotorasib|Sotorasib will be administered orally
214612293|NCT05198934|DRUG|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
214612294|NCT05198934|DRUG|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
214612295|NCT05198934|DRUG|Regorafenib|Regorafenib will be administered orally
214612296|NCT04969770|OTHER|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
214612297|NCT04230278|BEHAVIORAL|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
214612298|NCT04230278|BEHAVIORAL|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
214612299|NCT05050318|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
214612300|NCT05050318|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
214612301|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
214612302|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
214612303|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
214612304|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
214612305|NCT06097962|DRUG|NK510|Intravenous infusion
214612306|NCT06097962|DRUG|Tislelizumab，atezolizumab or sugemalimab|Administer according to the instructions
214612307|NCT04675931|DRUG|KAE609|"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."
214612308|NCT04675931|DRUG|IV Artesunate|Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
214612309|NCT04675931|DRUG|Coartem|Oral Standard of Care
214612310|NCT05667142|DRUG|XEN1101|XEN1101 capsules
214612311|NCT05667142|DRUG|Placebo|Placebo capsules
214612312|NCT06293430|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.
214612313|NCT05045066|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214612314|NCT05045066|OTHER|Quality-of-Life Assessment|Ancillary studies
214612315|NCT05045066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214612316|NCT04750798|DEVICE|BWI Medical Device|Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
214612317|NCT04750798|DEVICE|Varipulse Catheter|Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
214612318|NCT06131840|DRUG|PF-08046050|Given into the vein (IV; intravenous)
214612319|NCT06131840|DRUG|bevacizumab|Given into the vein (IV; intravenous)
214612320|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
214612321|NCT06785012|DRUG|JNJ-89495120|JNJ-89495120 will be administered.
214612322|NCT06785012|DRUG|Placebo|Placebo will be administered.
214612323|NCT05740735|OTHER|"Use of expressive sounds"|"Use of expressive sounds, that is to say the own first name pronounced by the voice of the relative to generate the P300 and a sound with an approaching character of the subject to generate the MMN.~The investigators will thus be able to compare:~* MMN: present/absent for each modality (neutral vs approaching sounds)~* Wave P3a: latencies and amplitudes for each modality (own first name voice of the near vs unfamiliar)."
214612324|NCT05740735|OTHER|Having benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)|"Retrospective inclusion Have already had an assessment with event related potentials without emotional modalities (VF and similar sounds) as part of their care between April 2022 and December 2022 in intensive care at Cochin hospital."
214612325|NCT06790693|DRUG|Inavolisib|Participants will receive oral inavolisib once daily (QD).
214612326|NCT06790693|DRUG|Placebo|Participants will receive oral placebo QD.
214612327|NCT06790693|DRUG|CDK4/6i|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
214612328|NCT06790693|DRUG|Letrozole|Participants will receive oral letrozole QD.
214612329|NCT03730636|PROCEDURE|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
214612330|NCT05532904|BEHAVIORAL|Personalized multidisciplinary day-hospital intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
214612331|NCT04586426|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
214612332|NCT04586426|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
214612333|NCT04586426|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
214612334|NCT06963125|DIETARY_SUPPLEMENT|Low-Dose Prune Juice|Intervention Name: Prune Juice 100 mL/day Description: 100 mL prune juice daily (1.07 g dietary fiber), administered once each morning for 4 weeks.
214612335|NCT06963125|DIETARY_SUPPLEMENT|Medium-Dose Prune Juice|Intervention Name: Prune Juice 150 mL/day Description: 150 mL prune juice daily (1.61 g dietary fiber), administered once each morning for 4 weeks.
214714695|NCT00812604|DRUG|Ping On Ointment|Ping On Ointment
214714696|NCT00812604|DRUG|Vaseline|Placebo
214612336|NCT06963125|DIETARY_SUPPLEMENT|High-Dose Prune Juice|Intervention Name: Prune Juice 200 mL/day Description: 200 mL prune juice daily (3.22 g dietary fiber), administered once each morning for 4 weeks.
214612337|NCT04244916|BIOLOGICAL|AUC of MPA measure|"Plasmatic AUC determination of MPA requires 3 blood punctures at H0, H30 and H2.~These punctures will be made at inclusion after 6 weeks, 12 weeks, 6 months and one year."
214612338|NCT05748171|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
214612339|NCT05748171|DRUG|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
214612340|NCT02142738|DRUG|Pembrolizumab|Pembrolizumab IV solution
214612341|NCT02142738|DRUG|Paclitaxel|Paclitaxel IV solution
214714697|NCT01590212|OTHER|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
214612342|NCT02142738|DRUG|Carboplatin|Carboplatin IV solution
214612343|NCT02142738|DRUG|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
214612344|NCT02142738|DRUG|Cisplatin|Cisplatin IV solution
214612345|NCT02142738|DRUG|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
214612346|NCT02110368|DRUG|Testosterone Topical Gel, 1.62% Metered Pump|
214612347|NCT02110368|DRUG|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
214612348|NCT03688880|DEVICE|MAR-CUTIS|MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds \>8 cm, 2 syringes were required.
214612349|NCT03688880|DEVICE|Dermabond Advanced|Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
214612350|NCT00979706|DRUG|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
214612351|NCT00979706|DRUG|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
214612352|NCT02847455|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
214612353|NCT02847455|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214612354|NCT02847455|DRUG|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214612355|NCT00011908|DRUG|hLL2 (Epratuzumab)|
214612356|NCT00737256|DRUG|Aripiprazole|15-30 mg
214612357|NCT00737256|DRUG|Perphenazine|8-16 mg
214612358|NCT03621865|DIETARY_SUPPLEMENT|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
214612359|NCT03621865|DIETARY_SUPPLEMENT|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
214612360|NCT03621865|DIETARY_SUPPLEMENT|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
214612361|NCT03621865|DIETARY_SUPPLEMENT|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
214612362|NCT03621865|DIETARY_SUPPLEMENT|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
214612363|NCT04591730|OTHER|First time father questionnaire self-administration|The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
214612364|NCT05371977|PROCEDURE|Trabeculectomy|trabeculectomy glaucoma surgery
214612365|NCT05371977|PROCEDURE|Deep Sclerectomy|deep sclerectomy glaucoma surgery
214612366|NCT01262768|BEHAVIORAL|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
214612367|NCT00284206|DRUG|long-acting injectable risperidone|
214612368|NCT01858532|DRUG|Atrasentan|Film-coated tablet
214612369|NCT01858532|DRUG|Placebo|Film-coated tablet
214612370|NCT00333671|DRUG|Glycerol|
214612371|NCT06489639|BEHAVIORAL|DOCT-SAD|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder is a 10-session, combined individual/group clinical intervention for treating social anxiety in adolescents. It consists of four individual and six group sessions during ten weeks. DOCT-SAD groups are formed for 4-6 adolescnts. One parent or both parents attend two of the individual sessions.
214612372|NCT06489639|BEHAVIORAL|SC|Standard Counseling (SC) is a intervention consisting of counseling sessions delivered by a school health and welfare (SHWS) professional (i.e., school nurse, school social worker, or school psychologist) to support a student with social anxiety. The defined length of intervention is ten weeks, and number of sessions will be according to what is routinely agreed between the professional and the adolescent. In SC, routine professional working methods and procedures available to the SHWS professional delivering the intervention are used.
214612373|NCT00066742|DRUG|tirapazamine|Given IV
214714698|NCT01590212|OTHER|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
214612374|NCT00066742|DRUG|cisplatin|Given IV
214612375|NCT00066742|DRUG|etoposide|Given IV
214612376|NCT00066742|RADIATION|radiation therapy|Undergo radiation therapy
214612377|NCT00066742|OTHER|laboratory biomarker analysis|Correlative studies
214612378|NCT06239337|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra in stools and urine|All children with presumptive TB had at least 1 sample collected of respiratory or extrapulmonary specimen (considered as gold standard) and 1 sample of stools and 1 sample of urine. All of them were analyzed with Xpert MTB/RIF Ultra.
214612379|NCT05075525|OTHER|High Intensity Laser Therapy Group|High Intensity Laser Therapy (HILT) and exercises will be used.
214612380|NCT05075525|OTHER|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Transcutaneous electrical nerve stimulation(TENS), ultrasound (US) will be applied.
214612381|NCT05075525|OTHER|Ultrasound and Interferential Current Stimulation Group|Ultrasound (US) ,interferential current stimulation and exercise will be used.
214612382|NCT01490853|DRUG|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
214612383|NCT03450291|OTHER|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
214714699|NCT06157372|DIAGNOSTIC_TEST|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
214612384|NCT02558920|OTHER|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
214612385|NCT01456650|DRUG|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
214612386|NCT02244320|DRUG|Tamsulosin|
214612387|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
214612388|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
214612389|NCT04860986|DEVICE|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
214612390|NCT03203499|DRUG|ANS-6637 Oral Tablet|Ascending single doses administered orally.
214612391|NCT03203499|DRUG|Placebo Oral Tablet|Placebo administered orally.
214612392|NCT03585985|PROCEDURE|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
214714700|NCT00081939|DRUG|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
214714701|NCT00081939|DRUG|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
214612393|NCT03585985|PROCEDURE|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
214612394|NCT00774865|PROCEDURE|MIBI and CTA|Rest and Stress MIBI and CT Angiography
214612395|NCT00188565|DRUG|Celecoxib|
214612396|NCT02088814|BEHAVIORAL|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
214612397|NCT00689702|DRUG|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
214612398|NCT00791336|DRUG|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
214612399|NCT03073668|PROCEDURE|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
214612400|NCT03073668|DRUG|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
214612401|NCT04601623|OTHER|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
214612402|NCT02177396|DRUG|Telmisartan|
214612403|NCT02177396|DRUG|Valsartan|
214612404|NCT02177396|DRUG|Placebo|
214612405|NCT00127868|DRUG|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
214612406|NCT03794583|DRUG|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
214612407|NCT01440868|PROCEDURE|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
214612408|NCT01488279|DRUG|Dexamethasone 2.5 mg and Sitagliptin 100 mg|Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
214612409|NCT01488279|DRUG|Dexamethasone 2.5 mg and placebo tablet|Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
214612410|NCT05568108|PROCEDURE|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
214612411|NCT05568108|PROCEDURE|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
214612412|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
214612413|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
214612414|NCT00929877|DRUG|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
214612415|NCT01172197|DRUG|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
214612416|NCT01172197|DRUG|Ropivacaine|Bolus and infusion
214612417|NCT00415857|BIOLOGICAL|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
214612418|NCT00415857|DRUG|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
214714702|NCT01463124|BEHAVIORAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
214612419|NCT00415857|DRUG|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
214612420|NCT00415857|DRUG|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
214612421|NCT01518881|DRUG|TKM-100201|IV Infusion
214612422|NCT01518881|DRUG|Placebo|IV infusion
214612423|NCT03182647|PROCEDURE|Surgically treatment of the ACL|Surgical initial ACL treatment
214612424|NCT03182647|OTHER|Non surgical initial ACL treatment|Non surgical initial ACL treatment
214612425|NCT05316532|DEVICE|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
214612426|NCT02953353|DEVICE|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
214612427|NCT02953353|OTHER|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
214612428|NCT02953353|OTHER|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
214612429|NCT04103905|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
214612430|NCT06330961|OTHER|Isometric exercise|Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.
214612431|NCT06330961|OTHER|Aerobic exercise|After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.
214612432|NCT06330961|OTHER|Placebo intervention|A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
214612433|NCT02825004|BEHAVIORAL|Psychological Intervention|
214612434|NCT02429297|OTHER|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
214612435|NCT02429297|OTHER|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
214612436|NCT01288222|OTHER|KIR genotype|KIR genotype data from unrelated donor are collected
214612437|NCT04697810|DRUG|Namodenoson|25 mg q12hours x 36 weeks
214612438|NCT04697810|DRUG|Placebo|Matching capsules q12hours x 36 weeks
214714703|NCT01463124|BEHAVIORAL|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
214612439|NCT03399981|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
214612440|NCT00674583|BIOLOGICAL|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
214714704|NCT00338260|DRUG|MK0954, /Duration of Treatment : 5 Years|
214714705|NCT00338260|DRUG|Comparator : atenolol /Duration of Treatment : 5 Years|
214714706|NCT05796349|DIAGNOSTIC_TEST|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
214612441|NCT00674583|BIOLOGICAL|Menjugate|Intramuscular administration, 1 dose
214612442|NCT00314626|DRUG|efavirenz|Efavirenz
214612443|NCT00314626|DRUG|Abacavir+lamivudine|Abacavir+lamivudine
214612444|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
214714707|NCT04897594|DRUG|TERN-201|Investigational drug
214714708|NCT04897594|OTHER|Placebo|Matching placebo
214714709|NCT03387891|DEVICE|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
214714710|NCT04319640|BEHAVIORAL|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
214714711|NCT04319640|BEHAVIORAL|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
214714712|NCT00257868|DRUG|Rivastigmine prevention of delirium|
214714713|NCT03703960|OTHER|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
214714714|NCT03703960|OTHER|music|calm music conducive to relaxation
214612445|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
214612446|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
214612447|NCT00051675|DRUG|ING-1(heMAb)|
214612448|NCT04227314|DRUG|Apremilast|Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
214612449|NCT04227314|DRUG|Placebo oral tablet|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
214612450|NCT02240979|DEVICE|cardiac MRI|cardiac MRI
214612451|NCT04972981|DRUG|ADCT-901|Intravenous infusion
214714715|NCT01721629|PROCEDURE|Sudden wean of nasal CPAP|
214714716|NCT01721629|PROCEDURE|Gradual wean of nasal CPAP|
214714717|NCT02849184|DRUG|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
214714718|NCT02849184|OTHER|Placebo|Placebo once daily before bedtime.
214612452|NCT06425484|OTHER|Bilateral US TAP block|epidural plus bilateral US guided TAP block
214714719|NCT00853190|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
214612453|NCT06461767|DEVICE|transcranial magnetic stimulation device|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30"
214612454|NCT00163267|DRUG|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
214714720|NCT00853190|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
214714721|NCT01865838|DEVICE|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
214714722|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, early treatment
214714723|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, deferred treatment
214714724|NCT01242254|BIOLOGICAL|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
214612455|NCT01009827|OTHER|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
214612456|NCT02877862|BEHAVIORAL|mAGIC app|7-day app to encourage uptake of genetic counseling
214612457|NCT00233688|DEVICE|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
214612458|NCT00233688|PROCEDURE|Open surgical repair|Open surgical repair
214612459|NCT02509182|DRUG|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
214612460|NCT02509182|DRUG|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
214612461|NCT01994382|DRUG|Cerdulatinib|Oral capsule
214714725|NCT03980626|BEHAVIORAL|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
214714726|NCT04441554|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI of cervical spine
214714727|NCT04526067|BEHAVIORAL|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
214714728|NCT04526067|BEHAVIORAL|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
214714729|NCT01661868|DRUG|Olaparib|Tablet formulation will be used.
214714730|NCT00805610|BIOLOGICAL|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
214612462|NCT01994382|BIOLOGICAL|Rituximab|IV infusion
214612463|NCT05919654|DEVICE|MyoCare|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
214612464|NCT05919654|DEVICE|ClearView|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
214612465|NCT00139282|DRUG|Squalamine Lactate|
214612466|NCT03528759|DIAGNOSTIC_TEST||phenotypic and genotypic Method
214612467|NCT06462300|BEHAVIORAL|A meaning-centered intervention for young women with weight and shape concerns|"* adapted version of the manualized meaning-centered psychotherapy for cancer patients developed by van der Spek et al. (2017)~* six weekly individual online sessions, each lasting one hour~* sessions led by a certified trainer~* four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
214612468|NCT00587548|OTHER|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
214612469|NCT01442194|DRUG|other disease-modifying therapy|
214612470|NCT01442194|DRUG|Fingolimod|
214612471|NCT02116504|PROCEDURE|Sampling of blood|Sampling of blood for dosage of antibodies
214612472|NCT02603770|DRUG|XueZhiKang|
214612473|NCT02603770|DRUG|Lovastatin|
214612474|NCT04578860|OTHER|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
214612475|NCT04578860|OTHER|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
214612476|NCT04578860|OTHER|Treatment as usual for sleep disorders|No intervention
214612477|NCT05947994|PROCEDURE|Intracranial stenting with Credo® stent|Symptomatic ischemic stroke patients were treated with Credo® Stent
214714731|NCT02402712|DRUG|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
214714732|NCT02402712|DRUG|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
214612478|NCT05415475|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214612479|NCT02793440|OTHER|cortivazol treatment|
214612480|NCT02793440|OTHER|lumbar traction|
214612481|NCT02234284|BEHAVIORAL|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
214714733|NCT02402712|DRUG|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
214714734|NCT02835898|OTHER|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
214714735|NCT01288586|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
214714736|NCT01457924|DRUG|Ofatumumab 3mg|3mg of investigational product
214714737|NCT01457924|DRUG|Ofatumumab 30mg|30mg of investigational product
214714738|NCT01457924|DRUG|Ofatumumab 60mg|60mg of investigational product
214714739|NCT01457924|DRUG|Placebo|Placebo
214714740|NCT03815123|DIAGNOSTIC_TEST|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
214714741|NCT05157776|DRUG|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
214612482|NCT05599542|OTHER|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
214612483|NCT05599542|OTHER|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
214612484|NCT06261073|DIAGNOSTIC_TEST|blood sample and tissue biopsy|Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
214612485|NCT01610180|DRUG|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
214612486|NCT03738969|PROCEDURE|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
214612487|NCT03738969|PROCEDURE|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
214714742|NCT01639391|PROCEDURE|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
214714743|NCT01002404|PROCEDURE|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
214714744|NCT02394327|DEVICE|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
214714745|NCT02394327|DEVICE|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
214714746|NCT06043401|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
214714747|NCT01581996|DRUG|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
214714748|NCT01785498|BEHAVIORAL|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
214714749|NCT04759222|DIAGNOSTIC_TEST|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
214714750|NCT00469872|PROCEDURE|Context-focused compared to child-focused interventions|
214612488|NCT06189846|DEVICE|International Cohort|"Assessing tumour response following neoadjuvant treatment in rectal cancer include :~* Digital rectal examination~* Rectal MRI~* Rectoscopy ( Lumeneye device)~The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment."
214612489|NCT02912299|PROCEDURE|Skin biopsies|2 3mm skin biopsies will be taken
214612490|NCT02912299|OTHER|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
214612491|NCT02912299|OTHER|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
214714751|NCT00720824|BEHAVIORAL|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
214714752|NCT00720824|BEHAVIORAL|Office routine|Standard vaccine administration
214714753|NCT01216345|DRUG|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
214714754|NCT02001688|DRUG|Kamada-AAT for Inhalation, 80mg|
214714755|NCT02001688|DRUG|Placebo|
214714756|NCT02001688|DRUG|Kamada-AAT for Inhalation, 160mg|
214714757|NCT06445569|DIETARY_SUPPLEMENT|KH-1|3 capsules and one stick packet consumed daily around the same time
214714758|NCT06445569|OTHER|Placebo|3 capsules and one stick packet consumed daily around the same time
214714759|NCT01628393|DRUG|Ozanimod|Oral capsule taken once a day
214612492|NCT01410435|DRUG|Monofer|Infusion according to current HB level
214714760|NCT01628393|DRUG|Placebo|Oral capsule taken once a day
214714761|NCT04673812|DRUG|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
214714762|NCT00052936|BIOLOGICAL|filgrastim|
214714763|NCT00052936|BIOLOGICAL|rituximab|
214612493|NCT03166163|DRUG|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
214612494|NCT03166163|DRUG|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
214612495|NCT00233363|DRUG|Rebamipide|
214612496|NCT01495858|DRUG|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
214612497|NCT01495858|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
214612498|NCT01495858|DRUG|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
214714764|NCT00052936|DRUG|CHOP regimen|
214714765|NCT00052936|DRUG|cyclophosphamide|
214714766|NCT00052936|DRUG|doxorubicin hydrochloride|
214612499|NCT03000088|DEVICE|intubate with 60° angled stylet|
214714767|NCT00052936|DRUG|prednisone|
214612500|NCT03000088|DEVICE|intubate with 60° angled stylet|
214714768|NCT00052936|DRUG|vincristine sulfate|
214714769|NCT00052936|RADIATION|radiation therapy|36Gy on BULK and extranodal involvement
214714770|NCT04989881|DEVICE|da Vinci Simulator|Single training session
214714771|NCT04989881|DEVICE|Laparascopic training box|Single training session
214714772|NCT02273414|DRUG|BIIL 284 BS - rising dose|
214714773|NCT02273414|DRUG|Placebo|
214714774|NCT01089569|DRUG|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
214714775|NCT01089569|DRUG|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
214714776|NCT02527941|DRUG|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
214612501|NCT01541579|OTHER|Cx601|120 million cells administered by intralesional injection.
214612502|NCT01541579|OTHER|Saline solution|24 mL saline solution by intralesional injection
214612503|NCT02334124|OTHER|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
214612504|NCT02334124|OTHER|Ward|Admission to a hospital based ward
214612505|NCT02334124|DRUG|ceftriaxone|50mg/kg once daily
214612506|NCT02334124|DRUG|flucloxacillin|50mg/kg 6 hourly
214612507|NCT04743479|DIAGNOSTIC_TEST|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
214612508|NCT02493504|DRUG|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
214612509|NCT04615468|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
214612510|NCT00873366|DRUG|dextromethorphan hydrobromide|
214612511|NCT00873366|DRUG|tamoxifen citrate|
214612512|NCT00873366|OTHER|high performance liquid chromatography|
214612513|NCT00873366|OTHER|laboratory biomarker analysis|
214612514|NCT00873366|OTHER|pharmacogenomic studies|
214612515|NCT00873366|OTHER|pharmacological study|
214612516|NCT00873366|PROCEDURE|fluorescence imaging|
214612517|NCT00752687|DRUG|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
214612518|NCT00752687|DRUG|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
214612519|NCT04668053|OTHER|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
214612520|NCT04668053|OTHER|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
214612521|NCT01576172|DRUG|Abiraterone Acetate|Given PO
214612522|NCT01576172|OTHER|Laboratory Biomarker Analysis|Correlative studies
214612523|NCT01576172|DRUG|Prednisone|Given PO
214612524|NCT01576172|DRUG|Veliparib|Given PO
214612525|NCT00473577|DRUG|CRA-24781|
214612526|NCT01731314|BEHAVIORAL|Learning and Memory of Pain|
214612527|NCT00648804|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
214612528|NCT00648804|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fed
214612529|NCT00343876|DRUG|aspirin|
214612530|NCT00343876|DRUG|clopidogrel|
214612531|NCT03706495|BEHAVIORAL|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
214612532|NCT03706495|BEHAVIORAL|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
214612533|NCT00344565|DRUG|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
214612534|NCT00344565|BEHAVIORAL|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
214612535|NCT04597957|DIETARY_SUPPLEMENT|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
214612536|NCT00328744|BEHAVIORAL|Standard|18-month standard behavioral weight loss intervention
214714777|NCT03611998|BEHAVIORAL|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
214612537|NCT00328744|BEHAVIORAL|Limited Variety|Two chosen snack foods
214612538|NCT03899363|PROCEDURE|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
214612539|NCT02237963|PROCEDURE|Posterolateral thoracotomy|
214612540|NCT02237963|PROCEDURE|Axillary thoracotomy|
214612541|NCT05553483|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
214612542|NCT05553483|OTHER|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
214612543|NCT03076931|PROCEDURE|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
214612544|NCT03076931|PROCEDURE|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
214612545|NCT03076931|PROCEDURE|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
214612546|NCT04048590|OTHER|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
214612547|NCT03512691|BEHAVIORAL|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
214612548|NCT03512691|BEHAVIORAL|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
214612549|NCT00324753|BEHAVIORAL|Communication|Communication sheet
214612550|NCT00324753|BEHAVIORAL|Standard of care|Standard of care brochures
214612551|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
214612552|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
214612553|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
214612554|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
214612555|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
214612556|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
214612557|NCT02180971|PROCEDURE|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
214612558|NCT02180971|PROCEDURE|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
214612559|NCT01086020|DRUG|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
214612560|NCT01086020|DRUG|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
214612561|NCT00050141|DRUG|ZARNESTRA, tipifarnib, R115777|
214612562|NCT02489643|PROCEDURE|Individualized practical training|
214612563|NCT05175573|DEVICE|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
214612564|NCT05175573|DEVICE|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
214612565|NCT01792349|BEHAVIORAL|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
214612566|NCT00656240|DRUG|DE-104 ophthalmic solution|
214612567|NCT00656240|DRUG|DE-104 vehicle|
214612568|NCT00006469|DRUG|carboplatin|
214612569|NCT00006469|DRUG|paclitaxel|
214612570|NCT00006469|PROCEDURE|conventional surgery|
214612571|NCT00006469|PROCEDURE|neoadjuvant therapy|
214612572|NCT00006469|RADIATION|radiation therapy|
214612573|NCT04420611|OTHER|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
214612574|NCT04420611|OTHER|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
214612575|NCT04420611|OTHER|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
214612576|NCT04420611|OTHER|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
214612577|NCT04234672|DRUG|TAK-831 Oral Tablet|TAK-831 tablet.
214612578|NCT04234672|DRUG|[14C]TAK-831 IV Infusion|\[14C\]TAK-831 IV infusion.
214612579|NCT04234672|DRUG|[14C]TAK-831 Oral Suspension|\[14C\]TAK-831 oral suspension.
214612580|NCT00779792|DRUG|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
214612581|NCT00779792|DRUG|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
214612582|NCT00779792|DRUG|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
214612583|NCT00779792|DRUG|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
214612584|NCT00779792|DRUG|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
214612585|NCT02153554|BEHAVIORAL|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
214612586|NCT04792567|DRUG|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
214612587|NCT04792567|DRUG|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
214612588|NCT04792567|BIOLOGICAL|BNT162|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
214714778|NCT01313832|OTHER|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
214714779|NCT00858936|DRUG|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
214714780|NCT00858936|DRUG|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
214714781|NCT05441540|DEVICE|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
214612589|NCT04792567|BIOLOGICAL|mRNA-1273|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
214612590|NCT03533972|DRUG|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
214612591|NCT03533972|OTHER|Placebo|placebo capsules given twice daily after meals for 1 month
214714782|NCT00813917|DRUG|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
214714783|NCT00813917|DRUG|placebo|12 weeks of placebo (double blinded) by mouth twice per day
214612592|NCT00239811|DRUG|FTY720|
214612593|NCT00005798|DRUG|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
214612594|NCT00005798|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
214612595|NCT00005798|DRUG|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
214612596|NCT03163251|BEHAVIORAL|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
214612597|NCT04049955|PROCEDURE|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
214612598|NCT01231659|DRUG|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
214612599|NCT01231659|DRUG|Letrozole|Letrozole 2.5 mg once daily
214714784|NCT02227056|DRUG|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
214714785|NCT01080456|DRUG|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
214714786|NCT01349972|DRUG|alvocidib|Given IV
214612600|NCT03526770|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
214612601|NCT03526770|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214714787|NCT01349972|DRUG|daunorubicin hydrochloride|Given IV
214714788|NCT01349972|DRUG|mitoxantrone hydrochloride|Given IV
214612602|NCT03526770|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
214612603|NCT03526770|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
214714789|NCT01349972|DRUG|cytarabine|Given IV
214714790|NCT02137707|DRUG|Gilenya|All patients will receive Gilenya
214714791|NCT03043807|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
214714792|NCT03043807|DRUG|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
214714793|NCT03043807|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
214612604|NCT03526770|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
214612605|NCT03526770|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
214612606|NCT03708549|DRUG|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
214612607|NCT03708549|DRUG|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
214612608|NCT02355899|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
214612609|NCT03936283|BEHAVIORAL|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
214612610|NCT01010698|DRUG|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
214612611|NCT04785170|DRUG|Amino Acid|"A novel non-protein amino acid secreted by skeletal muscles which aids the cross-talk between skeletal muscles, liver, and adipose tissue at molecular levels. amino acid is generated by catabolism of the branched-chain amino acid valine. Existing literature states, amino acid induces body fat loss by increasing energy expenditure, stimulating free fatty acid (FFA) oxidation in the liver and skeletal muscle cell, and by enhancing oxygen consumption by adipose tissue and hepatocytes. It was observed that amino acid stimulated differentiation of energy storing white adipose tissue preadipocytes to an energy burning beige (brown to white) phenotype."
214612612|NCT04216745|DIAGNOSTIC_TEST|bile culture|Bile samples will be collected for microbial cultures and antimicrobial susceptibility testing using COMPACT-15 automated system (Bio Merieux, Marcy I'Etoile, France) for bacteria and saboroud's agar for fungal culture.
214612613|NCT03764891|PROCEDURE|Uphold|Uphold system in treating women with cystocele
214612614|NCT03764891|PROCEDURE|Perigee|Perigee system in treating women with cystocele
214612615|NCT03295877|DRUG|RO7171009|Patients will receive RO7171009 via ITV injection.
214612616|NCT01990092|OTHER|Metanx|Metanx is a prescription medical food.
214612617|NCT01990092|OTHER|Placebo|
214612618|NCT05141162|BEHAVIORAL|case and control group|randomized controlled experimental study
214612619|NCT03038750|OTHER|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
214612620|NCT03038750|OTHER|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
214612621|NCT03038750|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
214612622|NCT03038750|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
214612623|NCT03038750|OTHER|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
214612624|NCT03038750|OTHER|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
214612625|NCT03038750|OTHER|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
214612626|NCT03038750|OTHER|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
214612627|NCT03038750|OTHER|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
214612628|NCT03038750|OTHER|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
214612629|NCT03038750|OTHER|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
214714794|NCT03043807|RADIATION|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
214612630|NCT03038750|OTHER|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
214612631|NCT03038750|OTHER|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
214612632|NCT03038750|OTHER|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
214612633|NCT03038750|OTHER|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
214612634|NCT03038750|OTHER|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
214612635|NCT03038750|OTHER|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
214612636|NCT03038750|OTHER|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
214612637|NCT03038750|OTHER|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
214612638|NCT03038750|OTHER|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
214612639|NCT01624987|BEHAVIORAL|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
214612640|NCT01624987|OTHER|Control group|The control group receives no intervention.
214612641|NCT06493539|PROCEDURE|Standard of Care group|The control group will receive standard of care wound treatment
214612642|NCT06493539|DEVICE|CINPWT|Subject will receive CINPWT until discharged
214612643|NCT01022502|DRUG|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
214612644|NCT01022502|DRUG|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
214612645|NCT01073241|PROCEDURE|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
214612646|NCT01073241|PROCEDURE|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
214612647|NCT00003172|BIOLOGICAL|filgrastim|
214612648|NCT00003172|BIOLOGICAL|recombinant interferon alfa|
214612649|NCT00003172|DRUG|docetaxel|
214612650|NCT00003172|DRUG|doxorubicin hydrochloride|
214612651|NCT00003172|DRUG|fluorouracil|
214612652|NCT00003172|DRUG|hydroxyurea|
214612653|NCT06200649|OTHER|massage|Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
214612654|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
214612655|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
214714795|NCT03043807|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
214714796|NCT03670498|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214714797|NCT03670498|DEVICE|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214612656|NCT01390272|BEHAVIORAL|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
214612657|NCT01390272|BEHAVIORAL|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
214612658|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
214612659|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
214612660|NCT01958190|DRUG|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
214612661|NCT01958190|DRUG|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
214612662|NCT04183283|DRUG|LY3526318|Administered orally.
214612663|NCT04183283|DRUG|Placebo|Administered orally.
214714798|NCT01422772|BIOLOGICAL|VM202RY|0.5mg intramuscular injection
214612664|NCT02910960|DEVICE|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
214612665|NCT02910960|DEVICE|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
214612666|NCT03931967|DIAGNOSTIC_TEST|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
214612667|NCT01466530|DRUG|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
214612668|NCT01466530|DRUG|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
214612669|NCT03342313|OTHER|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
214612670|NCT00051285|DRUG|Enoximone|Participants receive oral enoximone
214612671|NCT00051285|DRUG|Enoximone placebo|Participants receive placebo to match enoximone
214612672|NCT01982721|DEVICE|Locking mechanism for prosthetic knee|
214612673|NCT05232006|DRUG|Niraparib|Niraparib, once daily
214612674|NCT04190433|DRUG|Carvedilol|Given PO
214612675|NCT04190433|DRUG|Lisinopril|Given PO
214612676|NCT04190433|DRUG|Pravastatin|Given PO
214714799|NCT01422772|BIOLOGICAL|VM202RY|1mg intramuscular injection
214714800|NCT01422772|BIOLOGICAL|VM202RY|2mg intramuscular injection
214714801|NCT00493441|DRUG|AVN944|150, 200, 250, 300, or 400 mg q12h
214714802|NCT02274415|BIOLOGICAL|Vaccination with the combined vaccine (Prevenar13 ®)|
214612677|NCT04190433|DRUG|Spironolactone|Given PO
214612678|NCT03300167|DEVICE|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
214612679|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
214612680|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
214612681|NCT00354081|DRUG|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
214612682|NCT00354081|DRUG|placebo|placebo, in a capsule, taken orally once a day
214612683|NCT01210170|DRUG|placebo|placebo inhalation before albuterol.
214612684|NCT01210170|DRUG|mometasone 400 mcg|mometasone inhalation before albuterol.
214612685|NCT01210170|DRUG|mometasone 200 mcg|200ug mometasone before albuterol.
214612686|NCT04239105|DEVICE|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
214612687|NCT04046081|DRUG|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
214612688|NCT03612011|OTHER|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
214612689|NCT03052504|OTHER|Registration of complications|Prospective registration
214612690|NCT05855057|PROCEDURE|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
214612691|NCT05855057|PROCEDURE|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
214714803|NCT02274415|BIOLOGICAL|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
214714804|NCT03157843|DRUG|low-molecular-weight heparin|
214612692|NCT05855057|PROCEDURE|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
214612693|NCT02284620|PROCEDURE|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
214612694|NCT02284620|PROCEDURE|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
214612695|NCT01033617|PROCEDURE|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
214714805|NCT04390997|PROCEDURE|Non-surgical Periodontal Treatment|Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
214714806|NCT06374524|PROCEDURE|greater occipital nerve block|Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
214714807|NCT00430885|DRUG|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
214612696|NCT02887404|OTHER|Spine surgery analgesic pathway|Enhanced pain management care
214612697|NCT02887404|OTHER|Usual Care|Standard of pain management care
214612698|NCT03196986|DRUG|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
214612699|NCT03196986|DRUG|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
214612700|NCT00247936|PROCEDURE|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
214612701|NCT03648008|DRUG|Hydromorphone|0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
214612702|NCT03648008|DRUG|Morphine|0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
214612703|NCT04169490|OTHER|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
214612704|NCT04169490|OTHER|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
214714808|NCT03030768|DRUG|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
214714809|NCT03030768|BEHAVIORAL|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
214714810|NCT05224817|OTHER|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
214714811|NCT03504462|PROCEDURE|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
214714812|NCT02708615|OTHER|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
214612705|NCT04169490|OTHER|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
214612706|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
214612707|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
214714813|NCT01201707|PROCEDURE|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
214612708|NCT01536951|DRUG|LY3009104|administered orally
214612709|NCT01536951|DRUG|Placebo|Administered orally
214714814|NCT01201707|OTHER|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
214714815|NCT05267197|OTHER|3D Telemedicine|3D Telemedicine system
214714816|NCT05267197|OTHER|2D Telemedicine|2D Telemedicine system
214612710|NCT01536951|DRUG|moxifloxacin|Administered orally
214612711|NCT05916781|DRUG|Mycophenolate Mofetil|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
214612712|NCT05916781|DRUG|Tacrolimus|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
214612713|NCT05916781|DRUG|Glucocorticoid|"Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare."
214612714|NCT04403750|PROCEDURE|Combined laser-surgical technology of RRD treatment|"1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
214612715|NCT03061461|DEVICE|rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
214612716|NCT03061461|DEVICE|Sham rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
214612717|NCT02422342|DEVICE|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
214612718|NCT02896829|BEHAVIORAL|Interruption of the treatment by Imatinib|
214612719|NCT03827772|OTHER|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
214612720|NCT03827772|OTHER|Standard of care treatment|Nutritional supplementation, supportive management.
214612721|NCT01669967|DRUG|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
214612722|NCT01669967|DRUG|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
214612723|NCT04607928|DRUG|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
214612724|NCT04607928|DRUG|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
214612725|NCT04164576|GENETIC|Transplant patients|Study the specific immunity against Polyomavirus
214714817|NCT00574457|OTHER|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
214714818|NCT04950842|BIOLOGICAL|JB-101|induced T cell with suppressive function
214714819|NCT03027843|DRUG|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
214612726|NCT01881893|BEHAVIORAL|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
214612727|NCT01765842|BIOLOGICAL|Rituximab|Only one cycle of rituximab will be administered in this arm.
214714820|NCT05855681|OTHER|therapeutic exercises|strengthening exercise and stretching exercise
214714821|NCT02302144|BEHAVIORAL|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
214612728|NCT05147064|PROCEDURE|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
214612729|NCT05147064|PROCEDURE|conventional open surgery|open interlaminar lumbar decompression
214612730|NCT00010920|DRUG|Ginkgo Biloba Extract|
214612731|NCT00430482|BEHAVIORAL|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
214612732|NCT00430482|BEHAVIORAL|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
214612733|NCT01898897|PROCEDURE|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
214612734|NCT01898897|PROCEDURE|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
214612735|NCT00545402|DRUG|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
214714822|NCT01084109|OTHER|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
214714823|NCT01084109|OTHER|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
214714824|NCT05251298|OTHER|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
214612736|NCT00545402|DRUG|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
214612737|NCT00545402|DRUG|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
214714825|NCT00456833|DRUG|RAD001|
214714826|NCT00456833|DRUG|erlotinib|
214714827|NCT01062919|PROCEDURE|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
214714828|NCT01062919|PROCEDURE|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
214714829|NCT01998438|DRUG|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
214612738|NCT00545402|DRUG|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
214612739|NCT00545402|DRUG|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
214612740|NCT01486797|DRUG|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~* 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
214612741|NCT00555477|DRUG|anastrozole|1 mg tablet by mouth once a day
214612742|NCT03178968|OTHER|Orange juice|3 immersion times in orange juice were investigated
214612743|NCT05443893|DEVICE|Application Research of key points detection technology|"Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis"
214714830|NCT00979108|OTHER|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
214612744|NCT01721876|DRUG|Placebo|Placebo matching Volasertib
214612745|NCT01721876|DRUG|Volasertib|Volasertib
214612746|NCT01721876|DRUG|Cytarabine|Cytarabine
214714831|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
214714832|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
214714833|NCT00971542|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
214714834|NCT02143141|DRUG|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
214612747|NCT06280222|DEVICE|The VR instrument - Oculus Quest 2|Patients in the interventional group will watch 20-minute scenery movies in the VR instrument before entering the oocyte retrieval procedure.
214612748|NCT03862365|GENETIC|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
214612749|NCT05757336|DRUG|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
214612750|NCT01721057|DRUG|Placebo|Administered orally
214612751|NCT01721057|DRUG|Baricitinib|Administered orally
214612752|NCT01721057|DRUG|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
214612753|NCT01848886|PROCEDURE|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
214612754|NCT01848886|PROCEDURE|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
214612755|NCT01848886|PROCEDURE|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
214612756|NCT01848886|PROCEDURE|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
214612757|NCT05407597|DRUG|Icatibant|"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
214612758|NCT05407597|DRUG|0.9% Sodium Chloride Injection|"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
214714835|NCT02143141|DRUG|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
214714836|NCT01179867|OTHER|Electronic Medication Reconciliation|"1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
214714837|NCT02549248|OTHER|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
214714838|NCT02549248|OTHER|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
214714839|NCT02549248|OTHER|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
214714840|NCT02549248|OTHER|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
214612759|NCT03805750|DRUG|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
214612760|NCT03805750|DRUG|Placebo oral capsule|Matched Placebo
214612761|NCT01177683|DRUG|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
214612762|NCT01177683|DRUG|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
214612763|NCT01177683|DRUG|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
214612764|NCT01177683|DRUG|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
214612765|NCT01177683|DRUG|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000"
214714841|NCT02549248|OTHER|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
214714842|NCT04636320|DEVICE|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
214714843|NCT04636320|DIAGNOSTIC_TEST|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
214714844|NCT04636320|BIOLOGICAL|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
214714845|NCT04636320|DIAGNOSTIC_TEST|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
214714846|NCT04636320|DIAGNOSTIC_TEST|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
214612766|NCT06270342|OTHER|dual task assessment|The Minnesota Manual Dexterity Test was used to evaluate the upper extremity function of the participants in single and dual task conditions, and the Dual Task Questionnaire was used to evaluate the difficulties experienced during dual tasks. In the dual-task turning test, in addition to the single-task turning test, they were given a cognitive task, the task of counting the months of the year backwards from December to January. The dual-task turning test was continued by changing hands at the end of each turn until the last disk was turned. Meanwhile, verbal fluency and hand errors made while spinning the disc were recorded.
214612767|NCT00789880|DRUG|Vitamin D3|Administration of oral vitamin D3 at 4000IU
214612768|NCT00789880|DRUG|Placebo|Administration of oral Vitamin D3 placebo
214612769|NCT02859376|DIETARY_SUPPLEMENT|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
214612770|NCT00217243|OTHER|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
214612771|NCT03745833|DEVICE|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
214612772|NCT04416347|OTHER|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
214612773|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612774|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612775|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612776|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612777|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612778|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
214612779|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
214612780|NCT06387849|OTHER|Aromatherapy|women enrolled in the experimental group received aromatherapy with lavender essential oil (EO) through dry inhalation (inhalation via a cotton support soaked in a few drops of EO)
214612781|NCT06387849|OTHER|Placebo|women enrolled in the placebo group received ihaled a cotton support soaked in a few drops of distilled water
214612782|NCT00946504|DRUG|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
214612783|NCT00946504|DRUG|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
214612784|NCT01112020|DEVICE|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
214612785|NCT01112020|DEVICE|Biopatch|Biopatch applied to 7 sites
214612786|NCT01112020|DEVICE|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
214612787|NCT00003111|DRUG|carboplatin|
214612788|NCT00003111|DRUG|cisplatin|
214612789|NCT00003111|DRUG|irinotecan hydrochloride|
214612790|NCT00003111|DRUG|paclitaxel|
214612791|NCT00003111|PROCEDURE|neoadjuvant therapy|
214612792|NCT00003111|PROCEDURE|surgical procedure|
214612793|NCT00003111|RADIATION|radiation therapy|
214612794|NCT06035796|DEVICE|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
214612795|NCT05995015|BIOLOGICAL|Universal CD19-specific CAR gene-engineered T cells|Infusion of 4SCAR19U cells
214612796|NCT05546294|DEVICE|Aerobic and home exercise|"A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
214612797|NCT05546294|OTHER|Home exercise|"The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
214612798|NCT05546294|OTHER|Healthy control group|Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
214612799|NCT02219321|DRUG|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
214612800|NCT02219321|DRUG|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
214612801|NCT04538872|BEHAVIORAL|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
214612802|NCT04538872|BEHAVIORAL|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
214612803|NCT00617539|DRUG|irinotecan hydrochloride|
214612804|NCT00617539|DRUG|temozolomide|
214612805|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
214612806|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
214612807|NCT04687332|OTHER|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
214612808|NCT00493090|BEHAVIORAL|modification of an interactive seminar|
214612809|NCT03057613|DRUG|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
214612810|NCT03057613|RADIATION|IMRT 60-66Gy|60-66Gy for 6 weeks
214612811|NCT01640912|DRUG|RXI-109|Single intradermal injection of RXI-109 at incision sites
214612812|NCT01640912|DRUG|Placebo|Single intradermal injection of placebo at incision sites
214612813|NCT02098642|OTHER|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
214612814|NCT02098642|OTHER|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
214612815|NCT01710995|DRUG|Zegerid|
214612816|NCT01710995|DRUG|Losec|
214612817|NCT01977820|DRUG|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
214612818|NCT01977820|DRUG|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
214612819|NCT02081404|DRUG|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
214612820|NCT02081404|DRUG|Placebo|placebo
214612821|NCT03001960|DRUG|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
214612822|NCT03001960|DRUG|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
214612823|NCT03043521|DRUG|Dexlansoprazole 60 MG|
214612824|NCT03043521|DRUG|CJ-12420 50mg|
214612825|NCT03043521|DRUG|CJ-12420 100mg|
214612826|NCT03043521|DRUG|CJ-12420 200mg|
214612827|NCT05201027|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
214612828|NCT04468789|OTHER|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
214612829|NCT02568475|BEHAVIORAL|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
214612830|NCT05659784|OTHER|Telerehabilitation|Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
214612831|NCT02324855|OTHER|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
214612832|NCT02495220|DRUG|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
214612833|NCT02495220|DRUG|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
214612834|NCT04765475|BEHAVIORAL|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
214612835|NCT04765475|BEHAVIORAL|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
214612836|NCT04765475|BEHAVIORAL|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
214612837|NCT04765475|OTHER|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
214612838|NCT06346184|DRUG|HCP2303|Take 1 tablet once per period
214612839|NCT06346184|DRUG|RLD2302|Take 1 tablet once per period
214612840|NCT06346184|DRUG|RLD2102|Take 1 tablet once per period
214612841|NCT02762279|OTHER|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
214612842|NCT01298583|BEHAVIORAL|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
214612843|NCT05799599|BEHAVIORAL|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
214612844|NCT05799599|BEHAVIORAL|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
214612845|NCT05799599|BEHAVIORAL|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
214612846|NCT04190979|DEVICE|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
214612847|NCT06491108|DRUG|Vardenafil 5 Mg Oral Tablet|Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
214612848|NCT02426476|BEHAVIORAL|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
214612849|NCT02426476|BEHAVIORAL|sham HRVB training|passive relaxation
214612850|NCT05184673|OTHER|Behavioral and environmental|These are all active comparator yoga sequences
214612851|NCT02580851|OTHER|diagnostic test - cardiac magnetic resonance imaging|
214612852|NCT02580851|OTHER|diagnostic test - coronary angiography|
214612853|NCT02453373|DEVICE|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
214612854|NCT02453373|DRUG|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
214612855|NCT02453373|DRUG|tPA|tPA will be administered intravenously if indicated
214612856|NCT02453373|DRUG|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
214612857|NCT02453373|DRUG|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
214714847|NCT02409147|PROCEDURE|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
214612858|NCT02453373|PROCEDURE|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
214612859|NCT02691208|OTHER|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
214612860|NCT02691208|OTHER|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
214612861|NCT05273879|PROCEDURE|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
214612862|NCT05273879|PROCEDURE|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
214612863|NCT03631030|DEVICE|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
214612864|NCT04334707|PROCEDURE|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
214714848|NCT06366334|DRUG|Ketamine Hydrochloride|See arm description
214714849|NCT06366334|DRUG|Normal saline|See arm description
214714850|NCT04383613|OTHER|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
214714851|NCT00270998|BEHAVIORAL|Behavioral Therapy|Pelvic muscle training and exercises
214714852|NCT00270998|DEVICE|Intravaginal Pessary|Intravaginal pessary
214714853|NCT00270998|DEVICE|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
214612865|NCT04801875|OTHER|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
214612866|NCT05149222|DEVICE|Digital ACT|This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
214612867|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
214612868|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
214612869|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
214612870|NCT03388632|DRUG|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
214612871|NCT03388632|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
214612872|NCT03388632|DRUG|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
214612873|NCT02844816|DRUG|Atezolizumab|Given IV
214612874|NCT06598241|DEVICE|Borate-base Bioactive Glass Fiber Matrix (BBGFM)|Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
214612875|NCT03661307|DRUG|Decitabine|Given IV
214612876|NCT03661307|DRUG|Quizartinib|Given PO
214612877|NCT03661307|DRUG|Venetoclax|Given PO
214612878|NCT05744908|OTHER|Pentosan Polysulphate|300mg 3 times a day
214612879|NCT05635669|DEVICE|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
214612880|NCT05635669|DEVICE|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
214612881|NCT05635669|DEVICE|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
214612882|NCT06557122|DEVICE|SOC and Advanced Bioengineered Skin Substitute|SOC primary dressing with Helicoll®
214612883|NCT06557122|OTHER|SOC and Active Comparator|SOC primary dressing with Epifix® or Grafix®
214612884|NCT03977402|OTHER|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
214612885|NCT05425914|DRUG|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
214612886|NCT05425914|DRUG|Artificial tear|Conventional dry eye treatment
214612887|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
214714854|NCT00563368|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
214714855|NCT00563368|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
214714856|NCT00563368|DRUG|topiramate|topiramate 46 mg, po once daily
214714857|NCT00563368|DRUG|topiramate|topiramate 92 mg, po once daily
214714858|NCT00563368|DRUG|phentermine|phentermine 7.5 mg, po once daily
214714859|NCT00563368|DRUG|phentermine|phentermine 15 mg, po once daily
214714860|NCT00563368|DRUG|VI-0521|placebo, po once daily
214612888|NCT02479438|OTHER|Diagnosed with GERD|Recording of patient outcomes
214612889|NCT05566613|RADIATION|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
214612890|NCT00997451|BEHAVIORAL|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
214612891|NCT00997451|BEHAVIORAL|Symptom monitoring|Daily symptom via web diary
214612892|NCT06968052|OTHER|Strength and Feldenkrais Exercise|This is a behavioral, non-drug and non-device-based intervention combining somatic awareness through Feldenkrais principles with neuromuscular re-education. Movements emphasize minimal effort, reduced muscle tension, and improved self-perception of posture. The approach supports individualized progression and complements conventional physiotherapy without the use of pharmacological agents or medical equipment.
214612893|NCT06968052|OTHER|Strength Exercise|This is a non-drug, non-device corrective exercise program tailored for adults with forward head posture. It includes postural muscle strengthening and stretching, such as deep neck flexor activation, scapular retraction, and pectoral stretching. Additionally, participants perform diaphragmatic and thoracic breathing exercises.
214714861|NCT02366793|OTHER|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
214714862|NCT02366793|OTHER|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
214714863|NCT02525952|PROCEDURE|Hepatectomy|Surgical removal of all lesions
214714864|NCT02525952|PROCEDURE|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
214714865|NCT04889612|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
214714866|NCT04889612|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
214714867|NCT02721654|DRUG|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
214714868|NCT02721654|DRUG|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
214714869|NCT04323423|BEHAVIORAL|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
214714870|NCT04630964|DRUG|Psilocybin|psilocybin 25 mg Single Oral Dose
214714871|NCT04630964|DRUG|Niacin|niacin 100mg Single Oral Dose
214714872|NCT00395837|BEHAVIORAL|Aerobic exercise|
214714873|NCT03963804|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
214714874|NCT01395641|DRUG|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
214714875|NCT05789849|DEVICE|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
214714876|NCT02253017|OTHER|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
214714877|NCT05019651|DEVICE|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
214714878|NCT02842788|PROCEDURE|Prone positioning|Turning the patient face down for several consecutive hours
214714879|NCT01969513|PROCEDURE|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
214612894|NCT05054738|BEHAVIORAL|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
214612895|NCT05054738|BEHAVIORAL|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
214612896|NCT05505682|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
214612897|NCT03613753|DRUG|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
214612898|NCT03613753|DRUG|irinotecan|irinotecan chemotherapy alone
214612899|NCT02373215|DRUG|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
214612900|NCT02717754|DRUG|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
214612901|NCT02717754|DRUG|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
214612902|NCT03659851|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
214612903|NCT01350830|PROCEDURE|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
214612904|NCT01350830|PROCEDURE|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
214612905|NCT05469555|PROCEDURE|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
214612906|NCT03520959|BIOLOGICAL|LV305|Administered via subcutaneous (SC) injection.
214612907|NCT03520959|BIOLOGICAL|G305|Administered via intramuscular (IM) injection.
214612908|NCT03520959|OTHER|LV305-matching placebo|Administered via SC injection.
214612909|NCT03520959|OTHER|G305-matching placebo|Administered via IM injection.
214612910|NCT06970470|DEVICE|Triple-Adjustable Posture Corrector Manufacturer: Mercur®, Santa Cruz do Sul, Brazil|"The Triple-Adjustable Posture Corrector is a thoracic spinal orthosis designed to provide biomechanical support and postural correction in individuals with excessive thoracic kyphosis. It consists of elastic and adjustable non-rigid bands positioned around the shoulders and thorax, allowing individualized tension regulation. The brace promotes scapular retraction and axial alignment by increasing proprioceptive feedback and limiting thoracic flexion.~Participants randomized to this intervention will be instructed to wear the orthosis for a minimum of four consecutive hours per day, during waking hours, for 16 weeks. The orthosis is to be removed during bathing, aquatic activities, and sleep. Individualized fitting will be provided at baseline by trained personnel, following the manufacturer's guidelines. Adherence will be monitored through self-reported daily logbooks. Participants will be advised to report discomfort, adverse effects, or perceived benefits.~The primary clinical obje"
214612911|NCT06970470|DEVICE|Generation Dynamic Osteoporosis Brace Manufacturer: Bort®, Weinstadt, Germany|"The Generation Dynamic Osteoporosis Brace is a semi-rigid thoracic orthosis designed to stabilize the spine and counteract the progression of hyperkyphosis, especially in populations at risk for vertebral fragility. The brace is composed of lightweight, breathable material, with anterior and posterior structural support and adjustable tension straps. It is intended to reduce spinal flexion, improve sagittal alignment, and facilitate back extensor activation.~Participants assigned to this group will wear the orthosis for a minimum of four hours daily during waking hours, excluding sleep and aquatic activities, over a 16-week period. The orthosis will be individually fitted at the initial session by a trained physical therapist, following manufacturer protocols to ensure comfort, stability, and effectiveness. Participants will receive a daily logbook to record usage duration, comfort level, and perceived effects. Adherence will be monitored weekly.~The brace is intended to improve trun"
214612912|NCT06966596|DRUG|Ketamine only|Group A received ketamineat 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery. W
214612913|NCT06966596|OTHER|Placebo Normal Saline (NS)|Control group received normal saline to maintain double blinding
214612914|NCT06970886|BEHAVIORAL|Rhythm-Based Music Intervention|The rhythm-based music intervention is designed to reduce anxiety and improve emotional well-being in pregnant women with gestational diabetes. This intervention involves structured music sessions, utilizing rhythm as a therapeutic tool to engage participants in either active creation or passive listening. The intervention aims to promote relaxation, reduce stress, and support overall psychological health by leveraging the emotional and cognitive effects of rhythm and music.
214612915|NCT06646354|DRUG|Ezetimibe/Rosuvastatin/Candesartan/Amlodipine|PO, QD, 8 weeks
214612916|NCT06646354|DRUG|Candesartan/Amlodipine|PO, QD, 8 weeks
214612917|NCT06646354|DRUG|Candesartan/Rosuvastatin/Ezetimibe|PO, QD, 8 weeks
214612918|NCT05257941|DRUG|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
214612919|NCT05257941|DRUG|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
214714880|NCT01969513|PROCEDURE|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
214714881|NCT02253472|DEVICE|Deep Brain Stimulation|
214714882|NCT00134017|DRUG|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
214714883|NCT00134017|DRUG|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
214612920|NCT02470299|DRUG|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
214612921|NCT02470299|OTHER|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
214612922|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
214612923|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
214612924|NCT04187105|DEVICE|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
214612925|NCT04187105|DRUG|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
214612926|NCT04187105|DRUG|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
214612927|NCT04187105|DEVICE|Arm 1|Total body irradiation 2Gy on day -1.
214612928|NCT04187105|OTHER|Arm1|Stem cell infusion on day 0.
214612929|NCT04187105|DRUG|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
214714884|NCT00879437|DRUG|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
214612930|NCT04187105|DRUG|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
214612931|NCT06241807|DRUG|Camrelizumab Plus Chemotherapy|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
214612932|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
214612933|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
214612934|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
214612935|NCT02420860|DRUG|Lenalidomide|Given PO
214612936|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
214612937|NCT02484326|OTHER|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
214612938|NCT03947125|DRUG|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
214612939|NCT02878551|OTHER|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
214612940|NCT00794443|DRUG|YM529 / ONO-5920|Oral
214612941|NCT01979835|DEVICE|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
214612942|NCT04063254|RADIATION|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
214612943|NCT04623372|PROCEDURE|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
214612944|NCT04623372|PROCEDURE|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
214612945|NCT01777412|DRUG|Bevacizumab|
214612946|NCT03203551|OTHER|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
214612947|NCT02624466|OTHER|CKD progress|CKD progress
214612948|NCT00605592|PROCEDURE|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
214612949|NCT02848950|DRUG|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
214612950|NCT01879787|OTHER|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
214612951|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
214612952|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
214612953|NCT02807649|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|Two tablets consume daily with meal.
214612954|NCT00021151|BIOLOGICAL|alemtuzumab|
214612955|NCT00376584|DRUG|MK-0524A|
214612956|NCT00376584|DRUG|ER Niacin|
214612957|NCT00376584|DRUG|Placebo|
214612958|NCT00567684|DEVICE|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
214612959|NCT00567684|OTHER|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
214612960|NCT04633174|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
214612961|NCT02903069|DRUG|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
214612962|NCT02903069|DRUG|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
214612963|NCT02903069|RADIATION|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
214612964|NCT02903069|DEVICE|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
214612965|NCT00878852|BEHAVIORAL|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
214612966|NCT00878852|BEHAVIORAL|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
214612967|NCT05031988|OTHER|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
214612968|NCT00890253|DRUG|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
214612969|NCT00890253|DRUG|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
214612970|NCT00890253|DRUG|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
214612971|NCT00890253|DRUG|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
214612972|NCT02747953|DRUG|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
214612973|NCT02592018|DRUG|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
214612974|NCT02638350|DEVICE|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
214612975|NCT02422407|PROCEDURE|Biopsy|Salivary Gland
214612976|NCT04230707|OTHER|Endogenous Melatonin Levels|High Endogenous Melatonin Levels is Group 1 Low Endogenous Melatonin Levels is group 2
214612977|NCT00314353|DRUG|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
214612978|NCT00314353|DRUG|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
214612979|NCT00314353|DRUG|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
214612980|NCT00314353|DRUG|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
214612981|NCT06363669|DIETARY_SUPPLEMENT|multi-ingredient pre-workout dietary supplement (caffeine-based)|The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
214612982|NCT04416061|DIAGNOSTIC_TEST|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
214612983|NCT02964299|DEVICE|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
214612984|NCT03599895|PROCEDURE|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
214612985|NCT03599895|PROCEDURE|non 3D printing model|da Vinci robot assisted radical gastrectomy
214612986|NCT01255969|OTHER|Exercise|Personalized exercise program
214714885|NCT00879437|DRUG|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
214612987|NCT03800290|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
214612988|NCT03800290|DRUG|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
214612989|NCT02558478|GENETIC|blood sampling|
214612990|NCT02710136|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
214612991|NCT00418665|BIOLOGICAL|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
214612992|NCT00418665|DRUG|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
214612993|NCT02483377|OTHER|Quality-of-Life Assessment|Ancillary studies
214612994|NCT02483377|OTHER|Questionnaire Administration|Complete questionnaires
214612995|NCT00891319|DEVICE|Electrical stimulator|"• 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
214612996|NCT00918047|DRUG|SPN-804O|Open Label study
214612997|NCT01871636|PROCEDURE|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
214612998|NCT01871636|PROCEDURE|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
214612999|NCT01871636|DEVICE|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
214613000|NCT01177436|BIOLOGICAL|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
214613001|NCT04084106|DRUG|Phenoxymethylpenicillin|Oral administration
214613002|NCT04084106|DRUG|Amoxicillin|Oral administration
214613003|NCT04084106|DRUG|Amoxicillin-clavulanic acid|Oral administration
214613004|NCT03662217|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
214613005|NCT03662217|OTHER|ADA- based diet|The American standard of care dietary guidelines for diabetes.
214613006|NCT00246597|DRUG|epoetin alfa|
214613007|NCT04952740|PROCEDURE|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
214613008|NCT04952740|PROCEDURE|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
214613009|NCT04180150|DRUG|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
214613010|NCT04180150|DRUG|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
214613011|NCT04180150|DRUG|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
214613012|NCT01557179|DEVICE|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
214613013|NCT01557179|DEVICE|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
214613014|NCT00407589|DRUG|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
214613015|NCT04363073|DEVICE|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
214613016|NCT04363073|DEVICE|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
214613017|NCT01133379|DEVICE|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
214613018|NCT01133379|DEVICE|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
214613019|NCT01133379|DEVICE|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
214613020|NCT02795533|BEHAVIORAL|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
214613021|NCT04280965|DRUG|Quetiapine Fumarate|Atypical antipsychotic
214613022|NCT04280965|OTHER|Standard of care meducations|SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
214613023|NCT00591214|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
214613024|NCT00841204|DRUG|sulindac|Given orally
214613025|NCT00841204|OTHER|placebo|Inactive agent
214613026|NCT00841204|OTHER|laboratory biomarker analysis|Correlative studies
214613027|NCT02072928|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
214613028|NCT00161460|BEHAVIORAL|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
214613029|NCT05466812|DRUG|Sr-89|"1. strontium-89 chloride treatment~2. periodical evaluation and follow-up"
214613030|NCT05741281|BEHAVIORAL|Physical exercises program|\- Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
214613031|NCT05529056|DRUG|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
214613032|NCT05529056|DRUG|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
214613033|NCT05529056|DRUG|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
214613034|NCT05529056|DRUG|Placebo|Placebo ophthalmic solution
214613035|NCT02937012|DRUG|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
214613036|NCT02937012|DRUG|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
214613037|NCT02937012|DRUG|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
214613038|NCT06505239|DIETARY_SUPPLEMENT|FSD-F2R6-A-CP|FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
214613039|NCT06505239|DIETARY_SUPPLEMENT|Placebo|Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
214613040|NCT03585218|BIOLOGICAL|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
214613041|NCT00130195|DRUG|imatinib|
214613042|NCT00130195|DRUG|cyclophosphamide|
214613043|NCT00130195|DRUG|daunorubicin|
214613044|NCT00130195|DRUG|vincristine|
214613045|NCT00130195|DRUG|prednisolone|
214613046|NCT00130195|DRUG|methotrexate|
214613047|NCT00130195|DRUG|cytarabine|
214613048|NCT00130195|DRUG|dexamethasone|
214613049|NCT00282178|DRUG|Hydrochlorothiazide|25-50 mg once daily
214613050|NCT00282178|DRUG|Placebo|Once daily
214613051|NCT00282178|DRUG|Candesartan|16-32 mg once daily 12 weeks
214613052|NCT00331695|DRUG|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
214613053|NCT02000076|BEHAVIORAL|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
214613054|NCT02000076|BEHAVIORAL|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
214714886|NCT00879437|RADIATION|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
214613055|NCT02724384|DEVICE|MOE Plasma Delivery System A|Plasma treatment
214714887|NCT01423955|DRUG|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
214714888|NCT01423955|DRUG|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
214613056|NCT02724384|DEVICE|MOE Plasma Delivery System B|Plasma treatment
214613057|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) at baseline|Detailed imaging of coronary arteries
214613058|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) after 1 year|Detailed imaging of coronary arteries
214613059|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
214613060|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
214613061|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
214613062|NCT01516151|DRUG|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
214714889|NCT06377072|DRUG|Shenqi Sherong Pill|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
214613063|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|4 capsules of 1 g total per day for 8 weeks.
214613064|NCT00049803|DRUG|sodium oxybate|
214613065|NCT03800888|OTHER|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
214613066|NCT03800888|OTHER|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
214613067|NCT03800888|OTHER|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
214613068|NCT01166503|PROCEDURE|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
214613069|NCT01166503|PROCEDURE|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
214613070|NCT01166503|PROCEDURE|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
214613071|NCT01166503|PROCEDURE|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
214613072|NCT01166503|PROCEDURE|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
214714890|NCT06377072|DRUG|Placebo|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
214613073|NCT03587714|DIAGNOSTIC_TEST|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
214613074|NCT02786134|RADIATION|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
214714891|NCT04461028|DRUG|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
214714892|NCT04461028|DRUG|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
214714893|NCT00540306|DEVICE|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
214714894|NCT00388167|DRUG|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
214613075|NCT02786134|RADIATION|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
214613076|NCT05957952|PROCEDURE|Motor control exercise with dynamic taping|Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape
214613077|NCT05957952|PROCEDURE|Motor control exercise|Subjects will learn how to control their scapula during motor control exercise without taping
214714895|NCT05316480|DRUG|Nimotuzumab|nimotuzumab 200mg/week
214714896|NCT03212807|DRUG|Durvalumab|Investigational Medicinal Product
214714897|NCT03212807|DRUG|Lenalidomide|Investigational Medicinal Product
214714898|NCT04795492|BEHAVIORAL|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
214613078|NCT05470465|DRUG|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
214714899|NCT04795492|BEHAVIORAL|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
214714900|NCT05806112|BEHAVIORAL|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
214613079|NCT05470465|DRUG|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
214714901|NCT05806112|BEHAVIORAL|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
214613080|NCT05470465|DRUG|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
214613081|NCT05906576|DRUG|Infliximab|Infliximab in the treatment of Crohn's disease in children
214613082|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
214613083|NCT06653426|DIETARY_SUPPLEMENT|Sodium Butyrate (NaBu)|Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
214613084|NCT06973252|BEHAVIORAL|Eye masks|The intervention group patients were fitted with an eye mask designed by the researcher by placing a black fabric in the size of the mask between two three-layer surgical masks with Asfor brand soft elastic earphones and stapling the edges. The designed eye mask was cut with scissors according to the shape of the nose so that the mask would fit the eye exactly and prevent the light from entering the eye. A separate mask was used for each patient in the intervention group. Patients who were admitted to the NICU after surgery were evaluated for agitation-pain-delirium at 23:00 on postoperative days 0, 1, and 2, were told to wear their eye masks after the scale application, and the patients were allowed to sleep at 23:00 at the latest. Patients were allowed to remove the eye patch for short periods of time (10 minutes or less at a time) and then put it back on when uncomfortable and when necessary.
214714902|NCT05806112|BEHAVIORAL|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
214714903|NCT02843750|BEHAVIORAL|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home"
214714904|NCT02843750|OTHER|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
214714905|NCT00228033|DRUG|Elemental calcium (as carbonate)|
214714906|NCT05462457|PROCEDURE|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
214714907|NCT00446758|DIETARY_SUPPLEMENT|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
214714908|NCT05660889|OTHER|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
214714909|NCT06349850|DIAGNOSTIC_TEST|serum uric acid level to plasma HDL-c level ratio (UHR)|high UHR is considered to be a risk factor for development of DKI in type 2 DM
214613085|NCT06978855|DEVICE|Wrist band acupressure application to P6 point|"The intervention group received standardized instructions for applying the wristband to the P6 acupressure point on their wrist, with daily application scheduled from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift the intervention was applied for 30 days.~At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over."
214613086|NCT06978855|DEVICE|Wrist band acupressure application to sham point|the control group will receive standardized instructions to apply the wristband to a sham point, with daily application from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift. This will occur for 30 days. At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over.
214613087|NCT06854913|OTHER|Post-Operative monitoring using wearable biosensor|The protocol involves the use of the Medtronic Zephyr BioPatch™, a wearable biosensor, to monitor sleep quality and patterns in patients recovering from shoulder surgery. The device tracks physiological signals (ECG, HRV, respiratory rate) and postural changes, providing objective data on sleep profiles. Patients are assessed at three key time points: before surgery (baseline), two weeks after surgery (early recovery phase), and 30 days post-surgery (mid-recovery phase). The primary goal is to evaluate changes in sleep quality and patterns during the post-operative period, while also monitoring improvements in shoulder functionality and pain levels. This approach aims to provide insights into the relationship between sleep quality and recovery outcomes following shoulder surgery.
214613088|NCT06854913|OTHER|Usability Assessment and Patient Willingness to Use Technology Description|The usability of the Medtronic Zephyr BioPatch™ is evaluated through patient feedback and questionnaires, focusing on comfort, ease of use, and reliability. Additionally, patient willingness to continue using the wearable sensor for sleep monitoring is assessed. This evaluation helps determine the practicality and acceptance of the technology in real-world rehabilitation settings, providing insights into its potential for long-term use in clinical practice.
214613089|NCT06593249|OTHER|No Intervention: Observational Cohort|no intervention, observational study
214613090|NCT01978353|BEHAVIORAL|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
214613091|NCT01978353|BEHAVIORAL|Psychoeducation|Participants receive information about memory functioning and aging
214714910|NCT01244204|DIETARY_SUPPLEMENT|Vitamin D|Daily dose of 800IU of vitamin D
214613092|NCT06656455|DRUG|sevoflurane via LMA|In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
214714911|NCT01244204|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules
214714912|NCT04777604|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
214714913|NCT00739960|DRUG|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
214613093|NCT06656455|DRUG|Propofol with oxygen via simple mask|"In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min."
214613094|NCT06655909|OTHER|consumption of maize porridge containing stable iron isotope|consumption of maize porridge containing stable iron isotope
214613095|NCT05470322|DEVICE|Er: YAG laser|Patients will be treated with laser for their HS scarring.
214613096|NCT06985810|OTHER|Accentuated Eccentric Loading training|18 particpants will train in AEL group for three days a week for eight weeks and each session will take about 60-75 minutes, focusing on eccentric exercises like back squats, leg press, and hip thrusts at 90% 1RM intensity. Sessions, supervised by coaches, include free weight and weight machine exercises. Performance tests (20m sprint, T-agility, broad jump, 1RM assessments) will evaluate progress at the study's start and end.
214613097|NCT06985810|OTHER|Flywheel exercises|18 particpants will train in FW group for three days a week for eight weeks and each session will take about 60-75 minutes, incorporating compound movements, Flywheel exercises (squats, sprints, jumps), and relevant free weight and weight machine exercises. Supervised sessions maintain consistent parameters. Performance tests (20m speed, T-agility, broad jump, 1RM assessments) will measure improvements at study start and end for evaluation.
214613098|NCT06985602|COMBINATION_PRODUCT|Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery|"* Adebrelimab: Given concurrently with chemotherapy, 1200mg by intravenous infusion every three weeks for four cycles.~* Chemotherapy: Oxaliplatin 130mg/m² on day 1 + Capecitabine 1000mg/m² bid (XELOX regimen), from day 1 to day 14, repeated every three weeks for four cycles;~* Radiotherapy: Unresectable limited metastatic lesions with SBRT; Potentially resectable lesions with low-dose radiotherapy.~* Surgery: Performed 3-5 weeks after the completion of conversion therapy."
214613099|NCT06984237|DIAGNOSTIC_TEST|TNF-α Analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be instructed to refrain from eating, drinking, brushing, or chewing gum for at least one hour before collection. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
214613100|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be asked to avoid eating, drinking, brushing their teeth, or chewing gum for at least one hour prior to sampling. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. IL-17A levels will be determined using ELISA.
214613101|NCT06984237|DIAGNOSTIC_TEST|YKL-40 Analysis in saliva|Unstimulated whole saliva samples will be obtained from participants in the morning, at least one day after the periodontal clinical assessment. They will be instructed not to eat, drink, chew gum, or brush their teeth for at least one hour before collection. Samples will be centrifuged at 1500 rpm for 10 minutes, and the clear supernatants will be stored at -80°C until the time of analysis. YKL-40 levels will be measured using ELISA.
214613102|NCT06984237|DIAGNOSTIC_TEST|TNF-α analysis in serum|A total of 8 mL of venous blood will be collected from the antecubital fossa of seated participants. Samples will be transferred into BD Vacutainer® SST™ II Advance serum separator tubes containing acrylic gel and will be allowed to clot for 30 minutes at room temperature. The samples will then be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The resulting serum will be transferred into Eppendorf tubes using a Pasteur pipette and will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
214613103|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in serum|A total of 8 mL of venous blood will be obtained from the antecubital fossa of participants in a seated position. After collection, the blood will be placed into BD Vacutainer® SST™ II Advance tubes with acrylic gel and will rest for 30 minutes to allow clotting. The samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The serum will be extracted using a Pasteur pipette and stored in Eppendorf tubes at -80°C until analysis. IL-17A levels will be analyzed using ELISA.
214613104|NCT06984237|DIAGNOSTIC_TEST|YKL-40 analysis in serum|Venous blood (8 mL) will be drawn from the antecubital fossa of seated participants. The samples will be placed in BD Vacutainer® SST™ II Advance tubes containing acrylic gel and will be left to clot for 30 minutes at room temperature. Following this, the samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The supernatant serum will be separated with a Pasteur pipette and transferred into Eppendorf tubes. All samples will be stored at -80°C until analysis. YKL-40 levels will be measured using ELISA.
214613105|NCT06984237|DIAGNOSTIC_TEST|Clinical periodontal evaluation|Clinical periodontal parameters will be recorded from participants who meet the inclusion criteria. The following indices will be measured from all teeth present in the oral cavity: Plaque Index (PI; Silness \& Löe, 1964), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), and Bleeding on Probing (BOP). Radiographic evaluations will also be performed. All measurements will be conducted by the same calibrated clinician (HD) using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA).
214613106|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein level prior to IUT|One milliliter of cord blood will be collected before each IUT procedure to measure S100B protein concentration. The sample will be labeled with the mother's name, date of birth, collection date, and IUT indication, then sent to the laboratory for centrifugation.
214613107|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis prior to IUT|Half a milliliter of cord blood will be collected before each IUT procedure for immediate umbilical cord blood gas analysis, including pH, base excess (BE), and lactate levels.
214613108|NCT06984445|DIAGNOSTIC_TEST|Fetal blood count evaluation prior to IUT|Fetal blood count data, including hemoglobin and hematocrit levels, will be collected before each IUT procedure.
214613109|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein concentration at birth|After delivery, one milliliter of blood will be collected from the severed umbilical cord to measure the concentration of S100B protein. The sample will be labeled with the mother's name, the child's birth date and sex, and the collection date, before being sent to the laboratory for centrifugation.
214613110|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis at birth|After birth, 0.5 mL of blood will be collected from the severed umbilical cord to assess pH, base excess (BE), and lactate levels in an umbilical cord blood gas analysis.
214613111|NCT06984445|DIAGNOSTIC_TEST|Complete blood count after birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured within six hours after birth.
214613112|NCT06984445|DIAGNOSTIC_TEST|Ultrasound evaluation of fetal blood flow|Fetal cerebral blood flow will be routinely assessed via ultrasound, including measurements of MCA-PSV values.
214613113|NCT06984445|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination will. be performed to assess for any abnormalities in the newborn.
214613114|NCT06984445|DIAGNOSTIC_TEST|Complete blood count analysis in cord blood at birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured in cord blood samples collected at birth.
214613115|NCT06985511|PROCEDURE|Immediate implant placement|Tooth extraction was performed atraumatically on one side, followed by immediate implant placement, right after extraction.
214613116|NCT06985511|PROCEDURE|Early implant placement|The tooth was extracted, and the implant was placed four weeks later (early placement).
214613117|NCT06984393|OTHER|home tele-rehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. The sessions will be organised as follows: one session will be conducted via tele-rehabilitation with the support of a physiotherapist in small groups of up to 5 patients; in the remaining two sessions, the patient will perform the exercises independently at home. BTS TELEREHAB is the platform that will allow the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. Before starting the rehabilitation program, the patient will receive training with the technology in the hospital, in the presence of the physiotherapist. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device.
214613118|NCT06984393|OTHER|Usual care|Participants will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
214613119|NCT06986005|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.|All participants will receive neoadjuvant chemotherapy appropriate to the characteristics of their breast cancer as part of their standard care.
214613120|NCT06984471|OTHER|Palliative care consult|A palliative care (PC) consult involves a specialized palliative care team to provide symptom management, psychosocial support, and assistance with goals-of-care discussions for patients with serious or life-limiting illnesses.
214613121|NCT06984978|COMBINATION_PRODUCT|AI-assisted, village doctors and express services-involved personalized fall prevention strategy|"The EXPRESS trial implements a pragmatic, community-based, AI-assisted fall prevention strategy tailored to the needs of older adults in rural China. The intervention is structured around five core components-SAFER:~1. Screening: multidimensional fall risk screening and assessment tailored to rural older adults;~2. AI-assisted recommendations: AI-assisted personalized fall prevention recommendations;~3. Fitness: Tailored balance and strength training via Health Intervention Cartoon Brochure and Action Demonstration Video;~4. Events-based engagement: culturally integrated seasonal intervention packages following the traditional Chinese calendar;~5. Reach-home delivery: home delivery of fall prevention services through local couriers."
214613122|NCT06986057|DRUG|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy
214613123|NCT06985030|DEVICE|gyroscope embedded eye-sheild|Small pcb with gyroscope and lithium polymer battery embedded eyeshield will be distributed right after surgery
214613124|NCT06985225|COMBINATION_PRODUCT|Hyperpolarized 129 Xenon|Xenon gas contrast agent for MRI
214613125|NCT06985316|DRUG|Tunlametinib combined with Fruquintinib|Tunlametinib combined with Fruquintinib
214613126|NCT06985290|DRUG|Dexmedetomidine Infusion|Dexmedetomidine infusion given for sedation during therapeutic hypothermia. Dexmedetomidine infusion at a starting dose of 0.2 μg/kg/h, with titration in 0.1 μg/kg/h increments with a maximum of 0.5 μg/kg/h based on objective assessment of sedation.
214613127|NCT06985290|DRUG|Morphine Infusion|Morphine infusion given for sedation during therapeutic hypothermia. Morphine infusion at a starting dose of 4 μg/kg/h, with titration in 2 μg/kg/h increments with a maximum of 10 μg/kg/h based on objective assessment of sedation.
214613128|NCT06984887|DIAGNOSTIC_TEST|Diagnostic procedures|This study will be evaluated by conducting a non-inferiority diagnostic trial within routine ACF settings by comparing the New Diagnostic tests (NAT) to the reference standard test (Xpert MTB/Rif Assay) to determine how well it can detect and diagnose TB. All samples will be tested for MTB using cultures.
214613129|NCT06985693|PROCEDURE|Medipixel XA-Assisted Percutaneous Coronary Intervention|"Medipixel XA-Assisted Percutaneous Coronary Intervention (MPXA-PCI) is an AI-assisted coronary intervention procedure utilizing Medipixel XA (MPXA), an artificial intelligence-based quantitative coronary analysis (AI-QCA) software. MPXA analyzes angiographic images in real-time to assist in lesion assessment, optimal balloon and stent selection, and procedural decision-making during percutaneous coronary intervention (PCI).~In this study, all participants will undergo MPXA-assisted PCI, where the software provides automated vessel segmentation, diameter measurement, and lesion quantification to optimize procedural outcomes. Operators will follow a predefined protocol incorporating MPXA measurements for balloon sizing, stent selection, and post-dilation strategies.~The study evaluates the safety, feasibility, and clinical impact of MPXA-assisted PCI in real-world coronary artery disease patients."
214613130|NCT06984770|BEHAVIORAL|Virtual peer support group intervention|The virtual peer support group aims to improve emotional well-being, reduce isolation, and help caregivers cope by offering a safe space to share experiences and receive support from others facing similar caregiving demands.
214613131|NCT06984770|BEHAVIORAL|Caregiver Support intervention|The caregiver support intervention is a personalized program designed to improve quality of life, reduce fatigue and caregiver burden, and build resilience.
214613132|NCT06984770|OTHER|Resources|Participants will be given a list of resources to contact in case of emotional or psychological distress.
214613133|NCT06984081|PROCEDURE|CAPA IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
214613134|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
214613135|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
214613136|NCT06681467|OTHER|Respiratory monitoring band|The only intervention in this study is the application of two CE marked study approved chest bands- the Go direct respiratory sensor and a biosignal respiration belt
214613137|NCT06249711|DEVICE|Active stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation
214613138|NCT06249711|DEVICE|Sham stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation
214613139|NCT00291798|PROCEDURE|rate of remission|
214613140|NCT06044714|PROCEDURE|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
214613141|NCT06044714|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
214613142|NCT06100887|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
214613143|NCT06100887|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
214613144|NCT06100887|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
214613145|NCT06100887|DRUG|Placebo|Placebo is administered orally once per day
214613146|NCT00177775|DRUG|MucoMilk product|
214613147|NCT06336720|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The active PoNS device delivers amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes.
214613148|NCT00836628|DRUG|Busulfan|
214613149|NCT01704287|BIOLOGICAL|Pembrolizumab|IV infusion
214613150|NCT01704287|DRUG|Carboplatin|Carboplatin per institutional standard
214613151|NCT01704287|DRUG|Paclitaxel|Paclitaxel per institutional standard
214613152|NCT01704287|DRUG|Dacarbazine|Dacarbazine per institutional standard
214613153|NCT01704287|DRUG|Temozolomide|Temozolomide per institutional standard
214613154|NCT00645814|DRUG|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
214613155|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
214613156|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
214613157|NCT04533282|DIAGNOSTIC_TEST|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
214613158|NCT04533282|DIAGNOSTIC_TEST|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
214613159|NCT04533282|DIAGNOSTIC_TEST|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
214613160|NCT04533282|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
214613161|NCT04490395|BEHAVIORAL|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
214613162|NCT04490395|OTHER|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
214613163|NCT02456597|DRUG|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
214613164|NCT02456597|DRUG|Isotonic Saline|Isotonic saline injected through the novel Catheter
214613165|NCT02809014|OTHER|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
214613166|NCT02809014|OTHER|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
214613167|NCT02809014|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
214613168|NCT02809014|OTHER|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
214613169|NCT05014360|DRUG|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
214613170|NCT03128398|DRUG|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
214613171|NCT04383379|BEHAVIORAL|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
214613172|NCT02230254|DEVICE|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
214613173|NCT04512053|DRUG|TAS-303 18 mg/day|Oral administration for 12 weeks, once daily
214613174|NCT04512053|DRUG|Placebo|Oral administration for 12 weeks, once daily
214613175|NCT02897492|OTHER|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
214613176|NCT03999723|DIETARY_SUPPLEMENT|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
214613177|NCT03999723|DIETARY_SUPPLEMENT|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
214613178|NCT00022867|DRUG|Nondigestible oligosaccharide (NDO)|
214613179|NCT04144270|OTHER|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
214613180|NCT04660513|PROCEDURE|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
214613181|NCT03215550|PROCEDURE|CEA|Carotid Endarterectomy
214613182|NCT03215550|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
214613183|NCT03215550|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
214613184|NCT00330395|DRUG|caspofungin acetate|Duration of Treatment 28 Days
214613185|NCT03853811|DEVICE|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
214613186|NCT03156348|OTHER|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
214613187|NCT03277742|BEHAVIORAL|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
214613188|NCT03277742|DRUG|Standard of care|DOTS plus standard DM2 care
214613189|NCT06433609|DRUG|SHR-A1811|Via intravenous infusion
214613190|NCT06433609|DRUG|SHR-A1921|Via intravenous infusion
214613191|NCT06433609|DRUG|Adebrelimab|Via intravenous infusion
214714914|NCT05171881|OTHER|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
214613192|NCT00268632|DRUG|risedronate|
214613193|NCT05140655|DRUG|Fulvestrant|Medicine for Advanced breast cancer
214613194|NCT01462435|DRUG|Diclofenac Test (lower dose)|Capsules
214613195|NCT01462435|DRUG|Diclofenac Test (upper dose)|Capsules
214613196|NCT01462435|DRUG|Celecoxib|200 mg Capsules
214613197|NCT01462435|DRUG|Placebo|Capsules
214613198|NCT02995486|OTHER|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
214613199|NCT01414699|BEHAVIORAL|Variety|These conditions will have snack served with an increase of fruit variety.
214613200|NCT01414699|BEHAVIORAL|Non-Variety|These conditions will receive a snack without a variety of fruit.
214613201|NCT03239366|OTHER|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
214613202|NCT03239366|OTHER|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
214613203|NCT05899244|OTHER|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
214613204|NCT05899244|OTHER|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
214613205|NCT05899244|OTHER|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
214613206|NCT05075070|BIOLOGICAL|Inactivated COVID-19 vaccine|two doses inactivated COVID-19 vaccine
214714915|NCT00095719|DRUG|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
214714916|NCT00095719|DRUG|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
214714917|NCT00169039|DRUG|Clozapine|
214613207|NCT00161187|BIOLOGICAL|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
214714918|NCT00169039|DRUG|Chlorpromazine|
214714919|NCT00763243|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
214613208|NCT01931748|DRUG|MELSMON|
214613209|NCT01931748|DRUG|UNCNT|
214714920|NCT03251872|DRUG|Olaparib|Olaparib tablets
214714921|NCT01082588|DRUG|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
214714922|NCT01082588|DRUG|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
214714923|NCT03689868|BEHAVIORAL|Virtual Reality|Virtual Reality headset with calming scenery
214613210|NCT01161355|DRUG|AZD9668|Tablets of AZD9668 and IV dose of \[C14\]AZD9668
214613211|NCT00063141|DRUG|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
214613212|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
214613213|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
214613214|NCT03529721|OTHER|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
214613215|NCT03529721|OTHER|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
214613216|NCT02821611|BEHAVIORAL|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
214613217|NCT01942148|DRUG|Aripiprazole|
214714924|NCT00000339|DRUG|Risperidone|
214714925|NCT04489004|PROCEDURE|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
214714926|NCT04489004|PROCEDURE|Stepwise ablation|Patients receive stepwise ablation.
214714927|NCT00756704|BEHAVIORAL|Smoking cessation guideline implementation|"1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff"
214714928|NCT05480839|PROCEDURE|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
214714929|NCT05480839|PROCEDURE|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
214714930|NCT05480839|PROCEDURE|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
214613218|NCT03371979|DRUG|Pegzilarginase|Administered IV
214714931|NCT00993304|DRUG|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
214613219|NCT03371979|DRUG|Pembrolizumab|Administered IV
214613220|NCT00844155|DRUG|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
214613221|NCT03143010|DRUG|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
214613222|NCT03143010|DRUG|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
214613223|NCT03143010|DRUG|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
214613224|NCT03143010|DRUG|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
214613225|NCT04950179|OTHER|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
214613226|NCT04162496|DEVICE|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
214613227|NCT04452045|DEVICE|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
214613228|NCT02114411|PROCEDURE|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
214613229|NCT02114411|PROCEDURE|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
214613230|NCT02644564|OTHER|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
214613231|NCT06098365|OTHER|segmental cervical stabilization exercises|Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
214613232|NCT06098365|OTHER|cervical isometric exercises|Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
214613233|NCT06353828|DRUG|CBD, synthetic form|Cannabidiol enema
214613234|NCT06353828|DRUG|Placebo|placebo enema
214613235|NCT06433830|DRUG|Hetrombopag Olamine|The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
214613236|NCT02556502|DEVICE|18F-Florbetaben PET|
214613237|NCT00258336|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
214613238|NCT00258336|BIOLOGICAL|rituximab|
214613239|NCT00258336|BIOLOGICAL|sargramostim|
214613240|NCT00792194|OTHER|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
214613241|NCT02965521|BEHAVIORAL|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
214613242|NCT00319150|DRUG|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
214613243|NCT01309542|DRUG|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
214613244|NCT01775332|OTHER|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
214613245|NCT04106882|DRUG|Ketones|Supplement administered mid-scan.
214613246|NCT04106882|DRUG|Glucose|Supplement administered mid-scan.
214714932|NCT00993304|DRUG|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
214714933|NCT00439504|DRUG|Lobeline|
214714934|NCT00424034|DRUG|GSK1325760A|
214714935|NCT01209806|DRUG|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
214613247|NCT02418780|OTHER|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
214613248|NCT03479996|DRUG|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
214613249|NCT00857532|DRUG|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
214613250|NCT03134742|OTHER|Control Group|No interventions this is the control group-no additional scans
214613251|NCT03134742|DIAGNOSTIC_TEST|CT Scan|CT Scan of affected and contralateral limb
214613252|NCT03134742|DIAGNOSTIC_TEST|DEXA Scans|DEXA Scan of affected and contralateral limb
214613253|NCT03134742|DIAGNOSTIC_TEST|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
214613254|NCT01719315|OTHER|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
214613255|NCT03119961|DEVICE|SONOCLOUD®|BBB opening by ultrasound
214613256|NCT02573870|DRUG|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
214613257|NCT02573870|DRUG|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
214613258|NCT02573870|DRUG|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
214613259|NCT00257725|DRUG|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
214613260|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
214613261|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
214613262|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
214613263|NCT05002270|DRUG|Cetuximab (EGFR inhibitor)|Administered IV
214613264|NCT03271814|BIOLOGICAL|LPS|0.6 by/kg LPS single dose iv
214613265|NCT03271814|OTHER|Placebo|Sterile Water
214613266|NCT00366275|PROCEDURE|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes \>1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
214613267|NCT02753322|OTHER|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
214613268|NCT02753322|OTHER|Single-task training|Balance and walking exercises and and attention demanding task performed separately
214613269|NCT02753322|OTHER|Limbs exercise|Stretching and strengthening exercises
214613270|NCT03785925|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
214613271|NCT03785925|BIOLOGICAL|Nivolumab|Specified dose on specified days
214613272|NCT03370536|DEVICE|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
214613273|NCT03370536|PROCEDURE|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
214613274|NCT03370536|DRUG|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
214613275|NCT06389864|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
214613276|NCT00806195|BIOLOGICAL|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
214613277|NCT00806195|BIOLOGICAL|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
214613278|NCT00806195|BIOLOGICAL|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
214613279|NCT00806195|BIOLOGICAL|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
214613280|NCT00806195|BIOLOGICAL|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
214613281|NCT00806195|BIOLOGICAL|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
214613282|NCT00806195|BIOLOGICAL|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
214613283|NCT00806195|BIOLOGICAL|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
214613284|NCT04897022|DRUG|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
214613285|NCT04897022|RADIATION|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
214613286|NCT04192851|PROCEDURE|Tent Pole Technique|"* All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material"
214613287|NCT02490475|DRUG|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
214613288|NCT02490475|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
214613289|NCT02075489|OTHER|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
214613290|NCT02075489|OTHER|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
214613291|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
214613292|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
214613293|NCT04375579|OTHER|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
214613294|NCT05563519|PROCEDURE|I-PRF with collagen|The products will be applied to the sockets after tooth extractions
214613295|NCT05563519|PROCEDURE|L-PRF|The products will be applied to the sockets after tooth extractions
214613296|NCT01369420|DEVICE|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
214613297|NCT04675164|DEVICE|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
214613298|NCT04675164|PROCEDURE|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
214613299|NCT04186975|DEVICE|Non-Invasive fetal ECG|Non-Invasive fetal ECG
214613300|NCT04186975|DEVICE|Fetal heart rate monitor|Fetal heart rate monitor
214613301|NCT02510092|DEVICE|Percutaneous coronary intervention with new generation fully resorbable scaffold|
214613302|NCT01472770|DRUG|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
214613303|NCT03755895|OTHER|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
214613304|NCT03755895|DRUG|Kalinox|patients will have brachytherapy detachment under Kalinox
214613305|NCT01512836|BEHAVIORAL|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching"
214613306|NCT06324006|DRUG|LIB-01|LIB-01 oral suspension
214714936|NCT01611298|BIOLOGICAL|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
214613307|NCT06324006|OTHER|Placebo|Placebo oral suspension
214613308|NCT00428909|DRUG|Imatinib/Acetaminophen|
214613309|NCT02275585|OTHER|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
214613310|NCT03869281|PROCEDURE|Pancreas transplantation alone|Pancreas transplantation
214714937|NCT02372110|DRUG|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
214613311|NCT00357214|DIETARY_SUPPLEMENT|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
214613312|NCT00357214|DIETARY_SUPPLEMENT|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
214613313|NCT00357214|DIETARY_SUPPLEMENT|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
214613314|NCT00357214|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
214613315|NCT06820853|DEVICE|Diaphragmatic excursion evaluation|They will receive 10 ml of 0.5% bupivacaine over 10 minutes
214613316|NCT00657865|DRUG|ramipril|oral intake
214613317|NCT00657865|DRUG|placebo|placebo
214613318|NCT06182150|BEHAVIORAL|Moderate-Intensity Indoor Cycling Exercise|The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
214613319|NCT00544050|DRUG|Levetiracetam|
214613320|NCT04062019|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
214613321|NCT06465251|DEVICE|Home-based CIMT|Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.
214714938|NCT02372110|DRUG|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
214613322|NCT06465251|DEVICE|Clinic-based CIMT|Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour. Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day
214613323|NCT06465251|DEVICE|Control|Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
214613324|NCT00955812|DRUG|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
214613325|NCT00897806|GENETIC|Microarray analysis|
214613326|NCT00897806|OTHER|Laboratory biomarker analysis|
214613327|NCT05606250|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
214613328|NCT05788887|OTHER|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
214613329|NCT05788887|OTHER|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
214613330|NCT03801954|BEHAVIORAL|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
214613331|NCT03175354|DRUG|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
214613332|NCT03175354|DRUG|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
214613333|NCT02472041|DEVICE|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
214613334|NCT02472041|DEVICE|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
214613335|NCT01186120|DEVICE|Biolimus A9-eluting stent|drug-eluting stent
214613336|NCT01186120|DEVICE|Everolimus-eluting stent|drug-eluting stent
214613337|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 200 mg"|"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
214613338|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 400 mg"|Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
214613339|NCT00587002|PROCEDURE|IVUS|Intravascular ultrasound with virtual histology
214613340|NCT01429818|DRUG|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
214613341|NCT01429818|DRUG|Metformin|1000 mg tablets once daily for eight weeks
214613342|NCT01368536|DRUG|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
214613343|NCT01368536|DRUG|Amlodipine|Amlodipine 5 mg and 10 mg capsule
214613344|NCT01368536|DRUG|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
214613345|NCT01368536|DRUG|Placebo of Valturna Tablet|Matching placebo of valturna tablet
214613346|NCT01368536|DRUG|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
214613347|NCT03010969|PROCEDURE|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
214613348|NCT06372938|DIAGNOSTIC_TEST|Ultrasound measurement|The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).
214613349|NCT06372938|DIAGNOSTIC_TEST|Laboratory Tests and Inflammatory Markers|"The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL)."
214613350|NCT05260905|BEHAVIORAL|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
214613351|NCT02436564|GENETIC|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
214613352|NCT01553175|GENETIC|DNA analysis|
214613353|NCT01553175|GENETIC|gene expression analysis|
214613354|NCT01553175|GENETIC|mutation analysis|
214613355|NCT01553175|GENETIC|protein expression analysis|
214613356|NCT01553175|OTHER|immunohistochemistry staining method|
214613357|NCT01553175|OTHER|laboratory biomarker analysis|
214613358|NCT06245876|OTHER|Blood collection|Blood collection
214613359|NCT00659399|DRUG|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
214613360|NCT03861936|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
214613361|NCT03861936|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
214613362|NCT00359021|DRUG|TMC125|200 mg twice daily until commercially available
214613363|NCT04530903|DRUG|Clonidine|75 µg (0.5mL) per injection site
214613364|NCT04530903|DRUG|Levobupivacaine|0.25% (10 ml) per injection site
214613365|NCT04530903|DRUG|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
214613366|NCT05863975|DRUG|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
214613367|NCT01247636|OTHER|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
214613368|NCT01247636|OTHER|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
214613369|NCT01534104|PROCEDURE|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI \& DSI, neurological/physical testing \& brain MRI showing tumor \&/or edema located in or near (\<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), \&/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately \<48 hours before surgery\*) fMRI to localize gray matter DTI, DSI \& tractography to localize white matter, DSI \& updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray \&/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (\<48 hours after surgery)
214613370|NCT05322928|BEHAVIORAL|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
214613371|NCT03280654|OTHER|overactive bladder|Association between groups and over active bladder symptoms
214613372|NCT01232543|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
214613373|NCT03496220|DEVICE|Angulus|Feedback on patient recumbency
214613374|NCT02700152|DEVICE|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
214613375|NCT00374686|DRUG|Valganciclovir|
214613376|NCT03735927|OTHER|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
214613377|NCT02909075|DEVICE|PET/CT scans|
214613378|NCT02909075|DEVICE|MRI|
214613379|NCT02150148|BEHAVIORAL|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
214613380|NCT00066768|DRUG|suramin|Given IV
214613381|NCT00066768|DRUG|docetaxel|Given IV
214613382|NCT00066768|DRUG|gemcitabine hydrochloride|Given IV
214613383|NCT00066768|OTHER|laboratory biomarker analysis|Correlative studies
214613384|NCT00066768|OTHER|pharmacological study|Correlative studies
214613385|NCT01659242|DRUG|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
214613386|NCT01659242|DRUG|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
214613387|NCT05240911|DRUG|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
214613388|NCT02330887|OTHER|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
214613389|NCT02330887|OTHER|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
214613390|NCT01835015|DRUG|CLG561|Administered by intravitreal injection, Day 1
214613391|NCT02242084|DRUG|Intravenuse Alteplase|
214613392|NCT01257815|DRUG|Ranibizumab|
214613393|NCT02036242|DRUG|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
214613394|NCT02036242|DRUG|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
214613395|NCT02036242|DRUG|Ropivacaine|
214613396|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
214613397|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
214613398|NCT04785768|DRUG|Morphine Sulfate Sustained-release Tablets|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;"
214613399|NCT06067971|DEVICE|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
214613400|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.
214613401|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.
214613402|NCT02676856|DRUG|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
214613403|NCT02676856|DRUG|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
214613404|NCT04637698|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
214613405|NCT02442726|DEVICE|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
214613406|NCT01187849|DRUG|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
214613407|NCT01187849|DRUG|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
214613408|NCT00034190|DRUG|S-8184 Paclitaxel Injectable Emulsion|
214613409|NCT04569032|DRUG|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
214613410|NCT04569032|DRUG|cyclophosphamide|750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
214613411|NCT04569032|DRUG|doxorubicin|50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
214613412|NCT04569032|DRUG|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
214613413|NCT00588536|DRUG|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
214613414|NCT00588536|DRUG|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
214613415|NCT00588536|DRUG|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
214613416|NCT00701090|DRUG|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
214613417|NCT00701090|DRUG|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
214613418|NCT00701090|DRUG|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
214613419|NCT06321926|DEVICE|ActiveWaiting App|"The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field."
214613420|NCT03056560|BEHAVIORAL|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
214613421|NCT05970497|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
214613422|NCT05970497|DRUG|Opdualag|Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
214613423|NCT05970497|DRUG|KEYTRUDA ®( Pembrolizumab)|Immunotherapy (PD-1 immune checkpoint inhibitor)
214613424|NCT03090087|BIOLOGICAL|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
214714939|NCT05452824|OTHER|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
214613425|NCT03090087|DRUG|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
214613426|NCT05923021|OTHER|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
214613427|NCT04450667|DIETARY_SUPPLEMENT|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
214613428|NCT01085786|DRUG|14-day sequential treatment|"* 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
214613429|NCT01085786|DRUG|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
214613430|NCT03633526|DRUG|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
214613431|NCT03633526|DRUG|IVA|IVA mono tablet.
214613432|NCT02147366|BEHAVIORAL|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
214613433|NCT02147366|BEHAVIORAL|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
214613434|NCT00105144|DRUG|Micafungin|IV
214613435|NCT00105144|DRUG|Caspofungin|IV
214613436|NCT03320928|OTHER|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
214613437|NCT02201420|DRUG|Tc 99m tilmanocept|
214613438|NCT03856853|DRUG|Pirfenidone|pirfenidone for SSc-ILD treatment
214613439|NCT03856853|OTHER|placebo|as control
214613440|NCT00001096|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
214613441|NCT00001096|BIOLOGICAL|QS-21|
214613442|NCT00001096|BIOLOGICAL|rgp120/HIV-1MN|
214613443|NCT04935398|OTHER|Physiotherapy|The aim is to test two treatment techniques against each other to see how effective they are.
214613444|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
214613445|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
214613446|NCT00227292|DRUG|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
214613447|NCT00227292|DRUG|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
214613448|NCT05728931|BIOLOGICAL|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
214613449|NCT06091085|DRUG|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
214613450|NCT06091085|DRUG|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
214613451|NCT01214694|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
214714940|NCT05452824|OTHER|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
214714941|NCT01923649|DRUG|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
214613452|NCT01214694|BEHAVIORAL|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
214613453|NCT01214694|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
214613454|NCT02831192|BIOLOGICAL|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
214613455|NCT04497896|OTHER|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
214613456|NCT04534491|DRUG|Oxybutynin (Oxytrol, BAY839380)|Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
214613457|NCT05501938|PROCEDURE|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
214613458|NCT03366675|DRUG|AZD2811|AZD2811 100mg/vial
214613459|NCT01219049|DRUG|Tyrosine|1000 mg / day
214613460|NCT01219049|DRUG|Tyrosine|2000 mg / day
214613461|NCT01219049|DRUG|Placebo|Placebo daily
214613462|NCT06432829|BEHAVIORAL|Unified Protocol for the transdiagnostic treatment of emotional disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
214714942|NCT01923649|DRUG|Placebo|Placebo for somatuline slow release 90 mg
214714943|NCT00753623|DRUG|Ramelteon|ramelteon (8 mg)
214613463|NCT05040802|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
214613464|NCT05063721|BIOLOGICAL|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
214613465|NCT05837442|OTHER|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
214613466|NCT02197338|OTHER|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
214613467|NCT02162524|BEHAVIORAL|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
214613468|NCT03920189|DIAGNOSTIC_TEST|echocariographic ultrasound|left ventricular diastolic function description
214613469|NCT02851381|DRUG|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~* Dose: 35 mg/kg~* Route: IV over one hour following completion of gemcitabine infusion~* Schedule:~  * Days 1, 8, and 15~ * Please note that Day 8 infusion will on be completed during the first treatment cycle"
214613470|NCT04637607|OTHER|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
214613471|NCT03863600|BEHAVIORAL|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
214613472|NCT01314963|DEVICE|Prototype intraoperative handheld gamma camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
214613473|NCT01314963|DEVICE|Lymphoscintigraphy with intraoperative gamma probes (GP)|Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
214613474|NCT01314963|RADIATION|radioactive Tc99M|Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
214613475|NCT04898920|DRUG|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
214613476|NCT04898920|DRUG|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
214613477|NCT01147328|OTHER|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
214613478|NCT00113074|DRUG|Nicotine Replacement Therapy|Nicotine replacement therapy program
214613479|NCT00113074|BEHAVIORAL|Diet|Diet program
214613480|NCT05377268|PROCEDURE|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy
214613481|NCT03705637|DRUG|Exparel|"* Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
214613482|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
214613483|NCT02114268|DRUG|Placebo|Participants received placebo on Day 1.
214613484|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
214613485|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
214613486|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
214613487|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
214613488|NCT02741804|DIETARY_SUPPLEMENT|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
214613489|NCT02741804|OTHER|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
214613490|NCT02741804|DIETARY_SUPPLEMENT|Brain Health Placebo|Treatment with placebo consisting of soybean oil
214714944|NCT00753623|DRUG|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
214714945|NCT03332303|DRUG|Estrace® Cream|Estrace® Cream
214613491|NCT04981314|DRUG|Equinacea Arkopharma|Echinacea hard caplets
214714946|NCT03332303|DRUG|Estradiol Vaginal Cream|Estradiol Vaginal Cream
214714947|NCT03332303|DRUG|Vehicle Cream|Vehicle Cream
214613492|NCT04981314|OTHER|Placebo|Placebo hard caplets
214714948|NCT04926844|DRUG|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
214613493|NCT06042777|BEHAVIORAL|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
214613494|NCT06044064|PROCEDURE|A blood sample for CA 19-9 (cancer detection test)|"* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline.~* Contrast CT abdomen - Pancreas protocol will be done at baseline.~* EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you.~* If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done."
214613495|NCT03988231|DRUG|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
214714949|NCT04926844|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
214714950|NCT04926844|DRUG|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
214714951|NCT05172531|DRUG|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
214714952|NCT05172531|DRUG|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
214714953|NCT00107822|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
214714954|NCT03365336|DRUG|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
214714955|NCT03365336|DRUG|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
214714956|NCT00001890|DRUG|Estrogen therapy|
214714957|NCT05146934|RADIATION|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
214714958|NCT04322240|DRUG|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
214613496|NCT03988231|DRUG|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
214613497|NCT03875209|BIOLOGICAL|10E8.4/iMab|bispecific monoclonal antibody
214613498|NCT01997736|DEVICE|Ablation|
214613499|NCT01737385|PROCEDURE|Measurement with O2C|Measurement of microcirculation using O2C light probes.
214613500|NCT03962738|DRUG|Lasmiditan|Administered orally
214613501|NCT03962738|DRUG|Placebo|Administered orally
214714959|NCT03639987|DRUG|Aducanumab|Administered as specified in the treatment arm.
214714960|NCT03639987|DRUG|Placebo|Administered as specified in the treatment arm.
214714961|NCT01816256|PROCEDURE|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
214613502|NCT04782271|DRUG|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
214613503|NCT04782271|DRUG|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
214613504|NCT04782271|DRUG|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
214613505|NCT04782271|DRUG|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
214613506|NCT05348148|DRUG|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
214613507|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
214714962|NCT06065904|BEHAVIORAL|Nutrilect|This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
214714963|NCT00776321|DRUG|Eprotirome|
214714964|NCT00776321|DRUG|Placebo|
214714965|NCT01224587|DRUG|D1000078|Oral, one single dose
214714966|NCT01224587|DRUG|D1000082|Oral, one single dose
214714967|NCT01224587|DRUG|D1000083|Oral, one single dose
214714968|NCT01224587|DRUG|D1000085|Oral, one single dose
214714969|NCT00425100|DRUG|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
214714970|NCT03292341|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
214714971|NCT03292341|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
214714972|NCT03292341|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
214613508|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
214613509|NCT00509067|DRUG|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
214613510|NCT00509067|DRUG|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
214613511|NCT00509067|DRUG|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
214613512|NCT00509067|DRUG|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
214613513|NCT00131469|DRUG|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
214613514|NCT00131469|DRUG|Placebos|
214613515|NCT02520323|OTHER|Blood draw|
214613516|NCT02520323|PROCEDURE|Bronchoscopy|
214613517|NCT02520323|BEHAVIORAL|Questionnaires|
214613518|NCT03463733|DRUG|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
214613519|NCT03463733|DRUG|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
214613520|NCT00574288|DRUG|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
214613521|NCT00574288|DRUG|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
214613522|NCT00574288|OTHER|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
214613523|NCT00574288|OTHER|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
214613524|NCT02094963|DRUG|Ticagrelor|180mg loading and 90mg bid
214613525|NCT02094963|DRUG|Clopidogrel|600mg loading and 75mg qd
214714973|NCT03292341|OTHER|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
214714974|NCT05452109|OTHER|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
214714975|NCT05452109|OTHER|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
214613526|NCT02577614|DRUG|FEIBA|Administration of FEIBA after cardiopulmonary bypass
214613527|NCT02577614|DRUG|Normal Saline|Administration of placebo after cardiopulmonary bypass
214613528|NCT04087278|DIETARY_SUPPLEMENT|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
214613529|NCT04087278|DIETARY_SUPPLEMENT|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
214613530|NCT01479179|DRUG|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
214613531|NCT01479179|DRUG|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
214613532|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
214613533|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
214613534|NCT03255707|DEVICE|eye patch|Occluding the better seeing eye for a given number of hours daily
214613535|NCT03255707|DEVICE|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
214613536|NCT00204971|DIETARY_SUPPLEMENT|Enteral glutamine powder|nutritional supplement
214714976|NCT05705895|PROCEDURE|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process."
214714977|NCT01249534|OTHER|gastroesophageal cancer surgery|gastroesophageal cancer surgery
214714978|NCT01227304|DEVICE|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
214714979|NCT03249948|PROCEDURE|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
214714980|NCT03249948|PROCEDURE|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
214714981|NCT05161637|DRUG|TLC590|TLC590 490mg or 588mg
214714982|NCT05161637|DRUG|Bupivacain|Bupivacaine 75mg
214714983|NCT05161637|DRUG|Ropivacaine|Ropivacaine 150mg
214714984|NCT05161637|DRUG|Normal saline|Normal saline 20mL or 24mL
214714985|NCT03157440|DIAGNOSTIC_TEST|Ring oxymetry|a new type oxymetry wear on index finger like a ring
214714986|NCT03277768|DEVICE|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
214714987|NCT01876394|OTHER|Coconut Oil|Shake with 50 g Coconut oil
214613537|NCT00204971|OTHER|placebo|placebo control
214613538|NCT06288945|OTHER|Educational Program|The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
214613539|NCT05489835|BEHAVIORAL|Nutritional counseling|Nutritional counseling
214714988|NCT01876394|OTHER|Canola Oil|Shake with 50 g Canola oil
214714989|NCT01876394|OTHER|Grapeseed Oil|Shake with 50 g Grapeseed oil
214714990|NCT01876394|OTHER|Chia Oil|Shake with 50 g Chia oil
214714991|NCT01876394|OTHER|Butter|Shake with 50 g Butter
214714992|NCT05494749|OTHER|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
214714993|NCT05494749|OTHER|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
214714994|NCT00219232|DRUG|Rivastigmine Transdermal Patch|
214714995|NCT00931060|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
214714996|NCT00555906|DRUG|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
214714997|NCT00555906|DRUG|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
214714998|NCT00555906|DRUG|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
214613540|NCT02695433|DIETARY_SUPPLEMENT|Active|Active Treatment Diet Plan
214613541|NCT02695433|DIETARY_SUPPLEMENT|Control|Control Diet Plan
214613542|NCT02575768|OTHER|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
214613543|NCT02651051|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
214613544|NCT02651051|OTHER|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
214613545|NCT00530283|OTHER|PET-CT|
214613546|NCT05731570|BEHAVIORAL|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
214613547|NCT06097117|DIAGNOSTIC_TEST|MultiplexPCR|PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.
214613548|NCT03926754|DRUG|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
214613549|NCT04494139|BEHAVIORAL|Behavioral and Canteen intervention|Behavioral intervention: 16 weeks
214613550|NCT04494139|OTHER|Canteen|Canteen changes to introduce health foods
214613551|NCT06227273|DIETARY_SUPPLEMENT|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
214613552|NCT02261779|DRUG|Tranylcypromine|
214613553|NCT02261779|DRUG|Tretinoin|
214613554|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
214613555|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
214613556|NCT00807326|DRUG|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
214613557|NCT01025596|DRUG|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
214613558|NCT06115941|DEVICE|Pre-Op Incentive Spirometer|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
214613559|NCT03202784|DRUG|BCX7353|BCX7353
214613560|NCT02700568|DRUG|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
214613561|NCT01419782|OTHER|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
214613562|NCT06072989|BIOLOGICAL|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
214613563|NCT02247960|DRUG|Ciprofloxacin|
214613564|NCT00356889|DRUG|erlotinib hydrochloride|Given orally, 150 mg, once daily.
214613565|NCT00356889|BIOLOGICAL|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
214613566|NCT02131909|PROCEDURE|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
214613567|NCT02131909|PROCEDURE|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
214613568|NCT00750971|PROCEDURE|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
214613569|NCT00702325|DRUG|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
214613570|NCT00702325|DRUG|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
214613571|NCT04756037|DRUG|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
214613572|NCT03910426|OTHER|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
214613573|NCT03910426|OTHER|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
214613574|NCT03910426|OTHER|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
214613575|NCT03910426|OTHER|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
214613576|NCT03910426|OTHER|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
214613577|NCT05744765|OTHER|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
214613578|NCT04621396|OTHER|Observational screening study|
214613579|NCT06023316|DEVICE|mGain system|passive, noninvasive surface electromyography measurement device and gaming mobile application
214613580|NCT02417155|BEHAVIORAL|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
214613581|NCT02417155|BEHAVIORAL|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
214613582|NCT00395889|PROCEDURE|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
214613583|NCT00395889|PROCEDURE|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
214613584|NCT00936403|DRUG|NNC126-0083|One single dose administered in four dose levels in an escalating order
214613585|NCT00936403|DRUG|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
214613586|NCT05924737|OTHER|Sleep deprivatin|40 hours of continuous awakening
214613587|NCT05924737|OTHER|Sleep recovery|sleep recovery after 40 hours of continuous awakening
214613588|NCT01456689|DRUG|LGH447|
214613589|NCT01456689|DRUG|midazolam|
214613590|NCT03368950|OTHER|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
214613591|NCT02049268|DRUG|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
214613592|NCT02049268|DRUG|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
214613593|NCT02049268|DRUG|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
214613594|NCT01118416|BEHAVIORAL|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
214613595|NCT00736034|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
214613596|NCT05889455|DRUG|Sildenafil|Oral administration of 100mg
214613597|NCT05889455|OTHER|Placebo|Placebo
214613598|NCT01591317|DRUG|Prasugrel|Tablets orally
214613599|NCT05479279|OTHER|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
214613600|NCT05479279|OTHER|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
214613601|NCT03716050|DRUG|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
214613602|NCT03716050|DEVICE|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
214613603|NCT03716050|OTHER|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
214613604|NCT03716050|OTHER|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
214613605|NCT03123250|DEVICE|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
214613606|NCT01812889|DRUG|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
214613607|NCT01812889|DRUG|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
214613608|NCT01587339|DRUG|retigabine/ezogabine|oral - all doses
214613609|NCT01587339|DRUG|lacosamide|oral - all doses
214613610|NCT01587339|DRUG|zonisamide|oral - all doses
214613611|NCT01587339|DRUG|pregabalin|oral - all doses
214613612|NCT01587339|DRUG|eslicarbazepine|oral - all doses
214613613|NCT03229421|OTHER|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
214613614|NCT02361944|DRUG|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
214613615|NCT02361944|DRUG|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
214714999|NCT01729650|BEHAVIORAL|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
214715000|NCT03628950|PROCEDURE|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
214715001|NCT03628950|PROCEDURE|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
214613616|NCT04135339|OTHER|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
214613617|NCT04135339|OTHER|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
214613618|NCT04135339|OTHER|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
214715002|NCT00234208|PROCEDURE|Medical thoracoscopy|
214715003|NCT00234208|PROCEDURE|Simple chest tube drainage|
214715004|NCT05135351|DIETARY_SUPPLEMENT|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
214613619|NCT03963414|COMBINATION_PRODUCT|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
214715005|NCT05135351|DIETARY_SUPPLEMENT|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
214613620|NCT03963414|COMBINATION_PRODUCT|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
214613621|NCT05973552|OTHER|CO-rebreathing|In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
214613622|NCT05973552|OTHER|Oral iron isotope administration (54Fe)|Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
214613623|NCT05973552|OTHER|Intravenous iron isotope administration (58Fe)|Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
214613624|NCT05893602|OTHER|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
214613625|NCT00087750|DRUG|Quetiapine|
214613626|NCT05053516|OTHER|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
214613627|NCT00300768|DRUG|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
214613628|NCT00300768|DRUG|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
214613629|NCT00300768|DRUG|4 mg moxidectin|Single dose, tablets encapsulated for blinding
214613630|NCT00300768|DRUG|8 mg moxidectin|single dose, tablets encapsulated for blinding
214613631|NCT01600976|DRUG|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
214613632|NCT00524849|BIOLOGICAL|Zoledronic acid|Zometa 1 mg weekly (intravenous)
214613633|NCT00524849|DRUG|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
214613634|NCT04143360|DEVICE|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
214613635|NCT04143360|DEVICE|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
214715006|NCT05568498|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
214715007|NCT05568498|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
214715008|NCT05693870|DEVICE|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
214613636|NCT01214863|DEVICE|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
214613637|NCT01214863|DEVICE|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
214613638|NCT01214863|DEVICE|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
214613639|NCT02566577|BIOLOGICAL|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
214613640|NCT02566577|BIOLOGICAL|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
214613641|NCT02566577|DEVICE|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
214613642|NCT06154655|OTHER|E-zine|Health education will be delivered through an electronic magazine
214613643|NCT00861913|OTHER|Laboratory Biomarker Analysis|Correlative studies
214613644|NCT00861913|DRUG|Pazopanib Hydrochloride|Given orally
214613645|NCT00861913|OTHER|Pharmacological Study|Correlative studies
214613646|NCT00350168|DRUG|valsartan + amlodipine|
214613647|NCT03851003|PROCEDURE|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
214613648|NCT03851003|PROCEDURE|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
214613649|NCT03851003|DEVICE|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
214613650|NCT03851003|OTHER|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
214613651|NCT04812067|DRUG|TTHX1114|engineered FGF-1
214613652|NCT03200054|OTHER|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
214613653|NCT04651543|OTHER|X-Ray|X-ray obtained at one-week of the fracture
214613654|NCT00596661|DEVICE|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
214613655|NCT04760951|DIETARY_SUPPLEMENT|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
214613656|NCT04760951|DIETARY_SUPPLEMENT|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
214613657|NCT01751399|DRUG|LY2605541|
214613658|NCT02032550|OTHER|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
214613659|NCT02558387|DRUG|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
214613660|NCT05301920|DEVICE|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
214715009|NCT05260892|DEVICE|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
214715010|NCT06386172|OTHER|Clinical decision support trigger|Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
214613661|NCT02630342|BEHAVIORAL|Mock MRI scanner|Using a mock scanner for preparation for MRI
214613662|NCT02630342|BEHAVIORAL|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
214613663|NCT02630342|BEHAVIORAL|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
214613664|NCT02630342|BEHAVIORAL|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
214613665|NCT01866397|OTHER|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
214613666|NCT03960073|DIETARY_SUPPLEMENT|MitoQ|4 week 20mg oral daily dose of Mito Q
214613667|NCT03960073|DIETARY_SUPPLEMENT|Placebo|4 week oral daily dose of TTP placebo
214613668|NCT00073528|DRUG|Lapatinib|1500 mg orally once a day
214613669|NCT00073528|DRUG|Letrozole|2.5 mg orally once a day
214613670|NCT00073528|DRUG|Placebo|Placebo (which matched with lapatinib tablet)
214613671|NCT02467283|GENETIC|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
214613672|NCT02769663|BEHAVIORAL|questionnaires and neuropsychological assessments|
214715011|NCT06155240|BEHAVIORAL|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
214715012|NCT00889681|DEVICE|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
214715013|NCT03043729|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
214613673|NCT05891184|DEVICE|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
214613674|NCT03086057|BEHAVIORAL|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
214613675|NCT03086057|BEHAVIORAL|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
214613676|NCT02207998|DRUG|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
214613677|NCT02207998|DRUG|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
214613678|NCT06011564|DEVICE|Reminder function on Android computer tablet|Computer tablet with reminder function
214613679|NCT03979690|DEVICE|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
214613680|NCT01733966|DRUG|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
214613681|NCT01733966|DRUG|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
214613682|NCT02341703|DRUG|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
214613683|NCT02341703|DRUG|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
214613684|NCT02341703|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
214613685|NCT02341703|OTHER|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
214613686|NCT03924336|PROCEDURE|Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
214613687|NCT03924336|PROCEDURE|Open flap debridement (OFD) alone|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
214613688|NCT01485341|DIETARY_SUPPLEMENT|gluten|gluten is administered once a day at 10g/day for 15 days
214613689|NCT01485341|DIETARY_SUPPLEMENT|rice starch|rice starch is administered once a day at 10 g/day for 15 days
214613690|NCT00775736|DRUG|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
214613691|NCT00775736|DRUG|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
214613692|NCT00775736|DRUG|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
214613693|NCT01406236|PROCEDURE|Transradial PCI|Transradial PCI
214715014|NCT03043729|DRUG|5-FU|5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
214613694|NCT01406236|PROCEDURE|Transfemoral PCI|Transfemoral PCI
214715015|NCT03043729|DRUG|Leucovorin|Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
214715016|NCT03043729|BIOLOGICAL|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
214715017|NCT05079763|OTHER|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
214715018|NCT05079763|OTHER|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
214715019|NCT02855242|BEHAVIORAL|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
214715020|NCT02855242|OTHER|Controls Group|Subjects not participating in any lifestyle counseling
214715021|NCT00830570|OTHER|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
214715022|NCT03165942|OTHER|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
214715023|NCT03165942|OTHER|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
214715024|NCT03165942|DRUG|Ethanol|
214715025|NCT03169049|DEVICE|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214715026|NCT03169049|DEVICE|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214715027|NCT03258632|BEHAVIORAL|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
214715028|NCT03082053|DRUG|varlitinib|IMP
214715029|NCT03082053|DRUG|capecitabine|Companion Medication
214715030|NCT00187889|DRUG|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
214715031|NCT00187889|DRUG|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
214715032|NCT02195934|OTHER|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
214715033|NCT02195934|OTHER|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
214715034|NCT02993055|DRUG|Ulimorelin|
214715035|NCT02993055|OTHER|Placebo|
214715036|NCT04046341|BEHAVIORAL|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
214715037|NCT05998655|OTHER|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
214715038|NCT00276770|OTHER|fluorine F 18 fluorothymidine|
214715039|NCT00276770|PROCEDURE|positron emission tomography|
214715040|NCT04665414|DIAGNOSTIC_TEST|MRI|preoperative MRI
214715041|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound|preoperative transvaginal ultrasound
214715042|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
214715043|NCT03094832|DRUG|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
214715044|NCT02027922|OTHER|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
214715045|NCT02745301|OTHER|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
214715046|NCT01575899|DRUG|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
214613695|NCT03180164|OTHER|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
214613696|NCT04088825|OTHER|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
214613697|NCT04874519|BEHAVIORAL|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
214715047|NCT01575899|DRUG|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
214715048|NCT02562183|DRUG|kallikrein|Using kallikrein
214715049|NCT06187948|OTHER|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
214715050|NCT04643665|PROCEDURE|Double-lung transplantation|
214715051|NCT01469572|DRUG|Pasireotide|Pasireotide is given as an injection.
214715052|NCT01469572|PROCEDURE|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
214715053|NCT01469572|DRUG|Everolimus|Given orally every day for the duration of the study
214715054|NCT02576886|DEVICE|Gamma Camera|All images acquired with the General Electric Discovery 530c
214715055|NCT02576886|PROCEDURE|Prone Imaging|
214715056|NCT00661102|DRUG|Corticosteroids|As prescribed
214715057|NCT00661102|DRUG|Placebo|As prescribed
214715058|NCT00661102|DRUG|capecitabine [Xeloda]|As prescribed
214613698|NCT03459118|BEHAVIORAL|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
214613699|NCT05496179|DRUG|Prucalopride|Prokinetic
214613700|NCT05496179|DRUG|Metoclopramide|Prokinetic
214613701|NCT01622192|DEVICE|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
214613702|NCT05712135|OTHER|supine position|The patient group whose cuff pressure was measured in the supine position
214715059|NCT00661102|DRUG|dexpantenol [Bepantol]|As prescribed
214715060|NCT00353184|DRUG|Montelukast 5-mg orally added to standard therapy|
214715061|NCT02758223|BIOLOGICAL|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
214715062|NCT04403854|DIAGNOSTIC_TEST|MRI|If possible with spectroscopy
214715063|NCT04403854|PROCEDURE|Spinal Tap|together with CSF pressure estimate
214715064|NCT05793216|BEHAVIORAL|VestibulOTherapy|"For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud."
214715065|NCT01027013|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
214715066|NCT01027013|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
214715067|NCT00034203|DRUG|efalizumab|
214715068|NCT05883007|RADIATION|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
214715069|NCT00815204|PROCEDURE|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
214715070|NCT00815204|PROCEDURE|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
214715071|NCT05622357|RADIATION|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
214715072|NCT01441791|PROCEDURE|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
214613703|NCT05712135|OTHER|prone position|The patient group whose cuff pressure was measured in the prone position
214613704|NCT05712135|OTHER|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
214613705|NCT01129830|DIETARY_SUPPLEMENT|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
214715073|NCT01530282|OTHER|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
214715074|NCT01530282|OTHER|Non invasive method|Non\_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
214715075|NCT02333006|OTHER|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
214715076|NCT03855033|BEHAVIORAL|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
214715077|NCT04477109|DEVICE|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
214715078|NCT04477109|OTHER|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
214715079|NCT01236859|DRUG|Gabapentin|Neurontin®, Pfizer
214715080|NCT00806689|PROCEDURE|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
214613706|NCT01728415|OTHER|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
214613707|NCT04305275|DRUG|SAGE-324|SAGE-324 oral tablet
214613708|NCT04305275|DRUG|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
214613709|NCT02867124|DRUG|XR-NTX|Vivitrol
214613710|NCT02867124|OTHER|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
214613711|NCT02867124|OTHER|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
214613712|NCT00348920|PROCEDURE|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
214613713|NCT05360173|BEHAVIORAL|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
214613714|NCT05360173|BEHAVIORAL|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
214613715|NCT03978221|OTHER|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
214613716|NCT05881174|PROCEDURE|acupuncture|acupuncture
214613717|NCT02525250|PROCEDURE|Realization of 3 Blood samples during study during treatment with lenalidomide|
214613718|NCT03959124|DEVICE|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz
214613719|NCT03959124|DRUG|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
214613720|NCT05604820|BEHAVIORAL|Progressive Muscle Relaxation Exercise|Training on progressive muscle relaxation exercises will be given to the experimental group in the chemotherapy unit. Before going to sleep in the evening and during the day, they will be asked to do progressive muscle relaxation exercises in line with the instruction of the video. They will be asked to do the application every day for 8 weeks. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. Only routine care will be applied to the control group and no intervention will be made. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. After the evaluations, information about progressive muscle relaxation exercises will be given.
214613721|NCT02524548|OTHER|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
214613722|NCT03163784|BIOLOGICAL|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
214613723|NCT03163784|BIOLOGICAL|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
214613724|NCT03163784|DRUG|Antibiotic|Antibiotic pre-treatment
214613725|NCT03163784|DRUG|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
214613726|NCT00458796|DRUG|zoledronic acid|
214613727|NCT00458796|PROCEDURE|quality-of-life assessment|
214613728|NCT01067755|DEVICE|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
214613729|NCT00749476|BIOLOGICAL|Factor IX recovery|
214715081|NCT00806689|DEVICE|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
214613730|NCT01022242|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
214613731|NCT01022242|DRUG|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
214613732|NCT03566355|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
214613733|NCT04810182|DRUG|Regorafenib 40 MG Oral Tablet [STIVARGA]|As per the treating physicians discretion
214613734|NCT05520151|DIETARY_SUPPLEMENT|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
214613735|NCT05520151|OTHER|control|no intervention
214613736|NCT00545727|BEHAVIORAL|Diet|Whole-foods, low glycemic index diet
214613737|NCT00545727|OTHER|Standard diet|Standard diet meeting American Diabetes Association guidelines
214613738|NCT05340894|PROCEDURE|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
214715082|NCT03174613|DRUG|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
214715083|NCT03174613|DRUG|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
214613739|NCT05340894|PROCEDURE|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
214613740|NCT05839275|DRUG|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
214613741|NCT05839275|DRUG|Sintilimab|200mg, d1, q3w
214613742|NCT05839275|RADIATION|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
214715084|NCT00703859|DRUG|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
214613743|NCT01762215|BEHAVIORAL|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
214613744|NCT02782520|DRUG|Ringer Lactate (10ml/kg) fluid expansion|
214613745|NCT02782520|DRUG|Hypertonic saline (3ml/kg) fluid expansion|
214613746|NCT00002400|DRUG|Indinavir sulfate|
214613747|NCT00002400|DRUG|Delavirdine mesylate|
214613748|NCT00002400|DRUG|Lamivudine|
214613749|NCT00002400|DRUG|Zidovudine|
214613750|NCT01640652|BIOLOGICAL|MenPF-1.|A new vaccine against meningococcal disease.
214613751|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
214613752|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
214715085|NCT05567393|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
214715086|NCT05567393|DRUG|TAK-951|TAK-951 SC injection
214715087|NCT00884715|DRUG|Octreotide|short acting octreotide
214715088|NCT04101578|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
214613753|NCT00117598|DRUG|Investigator's choice|"Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
214613754|NCT02032563|DRUG|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
214613755|NCT05069506|OTHER|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214613756|NCT05069506|OTHER|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214613757|NCT05069506|OTHER|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214613758|NCT05069506|OTHER|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214613759|NCT05069506|OTHER|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214613760|NCT05069506|OTHER|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
214613761|NCT05069506|OTHER|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
214613762|NCT05992103|PROCEDURE|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
214613763|NCT05992103|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
214613764|NCT05992103|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
214613765|NCT04040075|DRUG|Biktarvy Tab|Antiretroviral drug
214613766|NCT01616420|OTHER|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
214613767|NCT01702714|DRUG|RO5083945|multiple ascending doses
214613768|NCT01702714|DRUG|carboplatin|up to 6 cycles
214613769|NCT01702714|DRUG|cisplatin|up to 6 cycles
214613770|NCT01702714|DRUG|gemcitabine|up to 6 cycles
214613771|NCT01702714|DRUG|paclitaxel|up to 6 cycles
214613772|NCT03470038|DRUG|NGF|Intramuscular injection
214613773|NCT03470038|DRUG|Isotonic saline|Intramuscular injection
214613774|NCT00839670|OTHER|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
214613775|NCT00839670|OTHER|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
214613776|NCT00449683|DRUG|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
214715089|NCT03374644|DEVICE|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
214715090|NCT01874873|DRUG|Anlotinib|
214715091|NCT02278081|DRUG|lansoprazole|the lansoprazole will be taken orally.
214613777|NCT04173689|DEVICE|Threshold IMT|7 days a week, 2 times a day 15 min each
214613778|NCT04173689|OTHER|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
214715092|NCT02278081|DRUG|placebo|the lansoprazole placebo will be taken orally.
214613779|NCT04144374|DRUG|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
214613780|NCT04144374|PROCEDURE|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
214613781|NCT00525993|DRUG|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
214613782|NCT00525993|DRUG|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
214613783|NCT03853681|DIAGNOSTIC_TEST|additional blood sampling|additional blood sampling
214613784|NCT03648775|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
214613785|NCT02179671|DRUG|Gefitinib|Gefitinib once daily followed by MEDI4736
214715093|NCT05803369|BEHAVIORAL|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
214613786|NCT02179671|DRUG|AZD9291|AZD9291 once daily followed by MEDI4736
214613787|NCT02179671|DRUG|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
214715094|NCT05803369|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
214715095|NCT00765713|DEVICE|Nasal continuous positive airway pressure|Nocturnal
214613788|NCT02179671|DRUG|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
214613789|NCT02887287|DRUG|EEN|
214613790|NCT05421312|DRUG|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
214613791|NCT05421312|DRUG|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
214613792|NCT05421312|DRUG|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
214613793|NCT01775735|DEVICE|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
214613794|NCT02247895|DEVICE|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
214715096|NCT03615118|OTHER|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
214715097|NCT03615118|OTHER|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
214715098|NCT00429390|BEHAVIORAL|Ramadan Fasting|
214715099|NCT03120364|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
214715100|NCT03120364|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
214613795|NCT02247895|DEVICE|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
214715101|NCT01560611|DEVICE|Near infrared spectroscopy|
214715102|NCT04199793|DEVICE|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
214613796|NCT01053390|DRUG|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
214613797|NCT01053390|DRUG|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
214715103|NCT04199793|DEVICE|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
214715104|NCT02687932|DRUG|LCZ696|
214715105|NCT02687932|DRUG|Valsartan|
214715106|NCT05130372|OTHER|Static Stretching Method Group|Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.
214715107|NCT05130372|OTHER|PNF Stretching Method Group|The contract-relax technique was used in the PNF stretching method.
214715108|NCT05130372|OTHER|Myofascial Relaxation Method Group- Roller Massage|A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
214715109|NCT03292393|BEHAVIORAL|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
214613798|NCT04688775|DRUG|Eptinezumab|Eptinezumab - concentrate for solution for infusion, intravenously
214613799|NCT04688775|DRUG|Placebo|Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
214613800|NCT05573659|OTHER|time of cutaneous recoloration|In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
214613801|NCT05573659|OTHER|video assisted cutaneous recoloration|"Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second."
214715110|NCT03292393|BEHAVIORAL|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
214715111|NCT03292393|DEVICE|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
214613802|NCT05159154|DEVICE|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
214613803|NCT03156127|DRUG|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
214715112|NCT03292393|DEVICE|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
214613804|NCT05198479|RADIATION|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
214613805|NCT00433342|DRUG|Flucloxacillin|500 mg QD oral
214613806|NCT02483624|DRUG|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
214613807|NCT02483624|DRUG|Placebo|Placebo
214613808|NCT02017639|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
214613809|NCT02017639|DRUG|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
214613810|NCT04824781|OTHER|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
214613811|NCT03724734|DEVICE|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
214613812|NCT03724734|DEVICE|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
214613813|NCT00002860|PROCEDURE|Surgery|Complete surgical resection of metastatic melanoma
214613814|NCT01770912|DRUG|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
214613815|NCT01770912|DRUG|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
214613816|NCT03644654|PROCEDURE|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
214715113|NCT05611515|PROCEDURE|TORS|"* Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)"
214715114|NCT00271934|BIOLOGICAL|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
214715115|NCT05744323|OTHER|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
214715116|NCT06184542|BIOLOGICAL|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
214613817|NCT03644654|PROCEDURE|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
214613818|NCT00581685|DRUG|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
214613819|NCT00391664|BEHAVIORAL|Psychosocial|
214613820|NCT01918423|BEHAVIORAL|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
214613821|NCT01864772|DRUG|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
214613822|NCT03378323|DRUG|Multiple injection local anesthetic|Multiple injection local anesthetic
214613823|NCT03378323|DRUG|Single injection local anesthetic|Single injection local anesthetic
214613824|NCT01193881|DRUG|Erlotinib Hydrochloride|Given PO
214715117|NCT06184542|BIOLOGICAL|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
214715118|NCT06184542|BIOLOGICAL|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
214715119|NCT06184542|BIOLOGICAL|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
214715120|NCT06184542|BIOLOGICAL|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
214715121|NCT06184542|BIOLOGICAL|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
214715122|NCT06184542|BIOLOGICAL|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
214715123|NCT03731546|PROCEDURE|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
214715124|NCT03010267|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
214715125|NCT03010267|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
214715126|NCT03010267|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
214613825|NCT01193881|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214613826|NCT01193881|OTHER|Laboratory Biomarker Analysis|Correlative studies
214613827|NCT01193881|OTHER|Pharmacological Study|Correlative studies
214613828|NCT05259579|PROCEDURE|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
214613829|NCT00615472|DRUG|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
214715127|NCT05216913|BEHAVIORAL|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
214715128|NCT05216913|DRUG|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
214715129|NCT05216913|OTHER|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
214715130|NCT01608607|OTHER|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
214715131|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
214715132|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
214613830|NCT00615472|DRUG|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
214613831|NCT00615472|DRUG|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
214613832|NCT03128476|DIETARY_SUPPLEMENT|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
214613833|NCT03128476|DIETARY_SUPPLEMENT|Placebo (Energy matched)|
214613834|NCT05149703|OTHER|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
214613835|NCT06292572|PROCEDURE|Retinal Detachment Surgery|Retinal Detachment Surgery that consists in either Pars Plana Vitrectomy or Scleral Buckling or a combination of both techniques, and with or without use of intraocular tamponade
214613836|NCT04261504|BEHAVIORAL|IBMT|mindful presence in a non-judgmental way
214613837|NCT04261504|BEHAVIORAL|RT|progressive muscle relaxation
214613838|NCT03765242|OTHER|Non-Interventional|Non-Interventional
214613839|NCT06098898|DRUG|NK510|NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.
214613840|NCT06098898|DRUG|Tislelizumab，atezolizumab or Trastuzumab|Administer according to the instructions.
214613841|NCT04426604|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
214613842|NCT04426604|DIAGNOSTIC_TEST|Laser-induced fluorescence device|Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
214613843|NCT04426604|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
214613844|NCT05218590|DEVICE|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
214613845|NCT05392504|OTHER|Core stability exercise|The core stability training consist of three phases
214613846|NCT05392504|OTHER|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
214613847|NCT01817751|DRUG|sorafenib tosylate|Given by mouth
214613848|NCT01817751|DRUG|valproic acid|Given by mouth
214613849|NCT01817751|DRUG|sildenafil citrate|Given by mouth
214613850|NCT02946593|BEHAVIORAL|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
214613851|NCT02946593|BEHAVIORAL|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
214613852|NCT02193048|OTHER|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
214613853|NCT03617250|OTHER|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
214613854|NCT02849197|PROCEDURE|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
214613855|NCT00382018|DRUG|chemotherapy|No administration details available
214613856|NCT01852682|DRUG|PA21|
214613857|NCT03898492|OTHER|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
214613858|NCT02073071|OTHER|Preterm infant formula per standard of care|Commercially available preterm infant formula
214613859|NCT03752008|BEHAVIORAL|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
214613860|NCT03752008|BEHAVIORAL|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
214613861|NCT06272786|PROCEDURE|conventional physiotherapy program.|It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.
214613862|NCT06272786|PROCEDURE|Suprascapular nerve block|Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
214715133|NCT05542693|BIOLOGICAL|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
214715134|NCT05542693|BIOLOGICAL|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
214715135|NCT03776097|OTHER|observational study|Observational study
214613863|NCT02611804|DRUG|Diclofenac sodium|
214613864|NCT02611804|DRUG|Diclofenac sodium|
214613865|NCT02611804|DRUG|Placebo|
214613866|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
214613867|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
214613868|NCT01537536|DRUG|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
214613869|NCT00123292|DRUG|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
214613870|NCT00123292|DRUG|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
214715136|NCT03481569|OTHER|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
214715137|NCT02758119|OTHER|Serious Game|
214613871|NCT00123292|DRUG|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
214715138|NCT02758119|OTHER|Online course|
214715139|NCT06338007|DEVICE|Hand Dynamometer|Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.
214715140|NCT06338007|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.
214715141|NCT06338007|OTHER|Modified Frailty Index|The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
214715142|NCT03519841|DEVICE|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
214715143|NCT02677623|DRUG|Pyridium|
214715144|NCT02677623|DRUG|Sodium Fluorescein|
214715145|NCT02677623|DRUG|Mannitol|
214715146|NCT02677623|OTHER|Normal Saline|
214715147|NCT03717636|OTHER|medical evaluation|return of medical evaluation after discharge
214715148|NCT02733679|DRUG|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
214715149|NCT02733679|DRUG|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
214715150|NCT00430547|DRUG|Carbimazole, radio-active iodine (I131)|
214613872|NCT03860675|DIAGNOSTIC_TEST|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
214613873|NCT00493220|DRUG|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
214613874|NCT00493220|DRUG|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
214613875|NCT00493220|DRUG|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
214613876|NCT02743884|DEVICE|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
214613877|NCT02743884|DEVICE|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
214613878|NCT02625233|DEVICE|senofilcon C|
214613879|NCT02625233|DEVICE|comfilcon A|
214715151|NCT00829127|DRUG|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
214715152|NCT00829127|DRUG|Placebo|Oral suspension
214715153|NCT00370890|DRUG|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
214715154|NCT02715492|DRUG|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
214715155|NCT02715492|PROCEDURE|TACE|Trans arterial chemoembolization
214715156|NCT04348539|OTHER|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
214715157|NCT01882244|BEHAVIORAL|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
214715158|NCT01882244|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
214715159|NCT05704439|DRUG|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
214715160|NCT05704439|OTHER|Placebo|Usual care
214715161|NCT04213040|DIAGNOSTIC_TEST|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
214613880|NCT02866799|OTHER|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
214613881|NCT02866799|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
214613882|NCT02254577|DRUG|Endometrin® plus Progesterone in Oil (PIO)|
214613883|NCT02254577|DRUG|Progesterone in Oil (PIO) Only|
214613884|NCT01906775|OTHER|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
214613885|NCT06243406|OTHER|Intravitreal injection of anti-VEGF|Intravitreal injection of anti- vascular endothelial growth factor (VEGF) treatment
214613886|NCT02043821|DRUG|Capecitabine|14days
214613887|NCT02043821|OTHER|placebo|14 days
214613888|NCT01379469|DRUG|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
214613889|NCT01379469|DRUG|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
214613890|NCT01157754|DRUG|levonorgestrel and ethynilestradiol|
214613891|NCT00075595|DRUG|FOLFIRI regimen|
214613892|NCT00075595|DRUG|fluorouracil|
214613893|NCT00075595|DRUG|irinotecan hydrochloride|
214613894|NCT00075595|DRUG|leucovorin calcium|
214613895|NCT01856244|BEHAVIORAL|treadmill walking|
214613896|NCT01856244|DEVICE|Treadmill|
214613897|NCT04248387|DRUG|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
214613898|NCT01449461|DRUG|Brigatinib|Brigatinib tablets and capsules.
214613899|NCT06970990|PROCEDURE|HFNC:50L/min|Under high-flow oxygen therapy at a flow rate of 50 L/min, record/monitor for 5 minutes
214613900|NCT06970990|PROCEDURE|HFNC:flow=40L/min|Under high-flow oxygen therapy at a flow rate of 40 L/min, record/monitor for 5 minutes.
214613901|NCT06970990|PROCEDURE|HFNC:flow=30L/min|Under high-flow oxygen therapy at a flow rate of 30 L/min, record/monitor for 5 minutes.
214613902|NCT06970990|PROCEDURE|Face mask oxygen:8L/min|Under face mask oxygen at a flow rate of 8 L/min, record/monitor for 5 minutes.
214613903|NCT06970990|PROCEDURE|Face mask oxygen:5L/min|Under face mask oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
214613904|NCT06970990|PROCEDURE|Nasal cannula oxygen:5L/min|Under nasal cannula oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
214613905|NCT06970990|PROCEDURE|Nasal cannula oxygen:3L/min|Under nasal cannula oxygen at a flow rate of 3 L/min, record/monitor for 5 minutes.
214613906|NCT00389792|DRUG|ATI-2042|no intervention
214613907|NCT00389792|DRUG|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
214613908|NCT02416752|DRUG|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
214613909|NCT02416752|DRUG|choice of intra-operative opioids were left to the discretion of anesthesiologist|
214613910|NCT04609813|DIAGNOSTIC_TEST|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
214613911|NCT00971763|BIOLOGICAL|rituximab|
214613912|NCT00971763|DRUG|cyclophosphamide|
214613913|NCT00971763|DRUG|gemcitabine hydrochloride|
214613914|NCT00971763|DRUG|prednisolone|
214613915|NCT00971763|DRUG|vincristine sulfate|
214613916|NCT01038804|DRUG|YM155|intravenous infusion
214613917|NCT01038804|DRUG|Docetaxel|intravenous infusion
214613918|NCT02524470|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
214613919|NCT02524470|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
214613920|NCT01766128|DRUG|Zonisamide|The first arm will be treated by zonisamide
214613921|NCT01766128|DRUG|Placebo|The second arm will receive placebo
214613922|NCT04972240|OTHER|customization of abutment|we will customize abutment for every patient not ready made
214613923|NCT05667948|DRUG|Chemotherapy|different treatments based on the molecular analysis
214613924|NCT01708070|BEHAVIORAL|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
214613925|NCT05179226|DRUG|Ferric Derisomaltose|All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
214613926|NCT06980506|DIAGNOSTIC_TEST|MNPR-101-DFO*-89Zr|MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.
214613927|NCT01357577|BEHAVIORAL|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
214613928|NCT03372850|DRUG|HIP1601|Test Drug
214613929|NCT03372850|DRUG|HGP1705|Reference Drug
214613930|NCT06984549|OTHER|DED diagnosis using PAOSID|A non-invasive diagnostic approach using the Portable Automatic Ocular Surface Imaging Device (PAOSID) to capture anterior segment images and videos for the assessment of dry eye disease (DED).
214613931|NCT06984549|OTHER|DED diagnosis using slit lamp|A non-invasive diagnostic approach using the slit lamp to capture anterior segment images and videos for the assessment of dry eye disease (DED).
214613932|NCT06985797|OTHER|Funfitness program with no music|Group A will undergo FunFitness program without music (Control Group)
214613933|NCT06985797|OTHER|funfitness program with slow music|Group B will undergo FunFitness program with slow music (Experimental Group)
214613934|NCT06985797|OTHER|Funfitness program with fast music|Group C will undergo FunFitness program with fast music (Experimental Group)
214613935|NCT06984991|DIAGNOSTIC_TEST|fine needle aspiration|Different needle sizes will be used in FNA sampling ; 5ml syringe with 21G needle, 3ml syringe with 23G needle or 22G Quincke tip spinal needle will be used for FNA. Needle insertion will be directed either trans-isthmic or lateral cervical approach. Aspirations will be conducted at different angles and within different nodule regions using a to-and-fro motion till getting blood stain in the needle hub to obtain representative samples. Maximum number of four passes will be performed within the nodule in a single session. Samples will be primarily obtained without suction via the capillary method. However, aspiration with suction will be applied if no aspirates could be obtained in the needle hub after routine capillary method. For mixed cystic solid lesions; FNA will be done from the solid component after aspiration of the cystic component
214613936|NCT06984796|DEVICE|Photobiomodulation|The irradiated region will cover the lumbar and thoracic spine, specifically from T10 to L4, using the Light Emitting Diode panel in a vertical orientation. Photobiomodulation in the experimental group will be administered using 132 Light Emitting Diodes with wavelengths of 660 nm and 850 nm, applied in contact mode. Each Light Emitting Diode has an emission area of 0.5 cm², with an application time of 20 minutes, an irradiance of 16 mW/cm², and an energy delivery of 4.8 J per Light Emitting Diode, resulting in a radiant exposure of 9.6 J/cm².
214613937|NCT06984796|OTHER|Simulation of Photobiomodulation|"The researcher responsible for the photobiomodulation application will simulate irradiation by positioning the device in the exact location as in the Photobiomodulation Group; however, the equipment will remain turned off.~To prevent participants from identifying the group to which they belong, the device's activation sound (beep) will be pre-recorded and played during the application."
214613938|NCT06985823|OTHER|Rotational exercises|14 participants will be in experimental group A, giving them rotational exercises (Rotational Crunch exercise, Single leg romanian deadlift with rotation, rotational medicine ball throws for six weeks. Measure all values before giving them protocol and after protocol.
214613939|NCT06985823|OTHER|Anti-Rotational exercises|14 participants will be in experimental group B, giving them anti-rotational exercises (Quadruped exercise 3 sets of 15 repetition, planks 3 sets of 60 second hold, pallof press 3 sets of 15 repetition) for six weeks. Measure all values before giving them protocol and after protocol.
214613940|NCT06986239|BIOLOGICAL|PCV-LITE|Fractional dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
214715162|NCT00336778|DRUG|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
214715163|NCT04950140|PROCEDURE|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
214715164|NCT04950140|PROCEDURE|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
214715165|NCT04492878|DRUG|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
214613941|NCT06986239|BIOLOGICAL|PCV-LITE+LVA|Fractional dose of pneumococcal polysaccharide conjugate vaccine with 1 mg of LiteVax Adjuvant (LVA)
214613942|NCT06986239|BIOLOGICAL|PCV20|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
214613943|NCT06986239|BIOLOGICAL|PCV20+LVA|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine with LiteVax Adjuvant (LVA)
214613944|NCT06655454|DRUG|Supplemental Postoperative Bupivacaine|This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention.
214613945|NCT06655454|DRUG|Placebo Injection|This intervention will appear to give patients an additional injection, but no additional drug will be given.
214613946|NCT03122717|DRUG|Gefitinib|gefitinib is a EGFR inhibitor
214613947|NCT03122717|DRUG|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
214613948|NCT06986213|BEHAVIORAL|Heart Pillow Intervention|"Self-Care:~Teach techniques to perform diminished or dependent self-care. Demonstrate assistive devices for self-care. Teach and train techniques and the use of assistive devices.~Scare Tissue:~Perform massage techniques on scar tissue: gliding and friction. Teach and train massage technique."
214613949|NCT06985849|OTHER|Feldenkrais method|"Activating flexors The pelvic clocktwisting).Side lying lesson for improving the integration of arms, shoulders and spine (reaching motion of shoulders in different directions).Transitioning from supine to side lying to sitting (lying supine involving flexion, extension, and twisting).Twisting on the side Twisting from supine with head fixed to the side (by limiting the movement of the head, the rib cage is forced to participate in the twisting motion) Lengthening the hamstrings Arm circles (lying on side, circling arms in different directions). Rolling from supine to prone via hip rotation"
214613950|NCT06985849|OTHER|Otago exercise protocol.|The study began by completing all 3-outcome measures by first asking about their pain intensity then by checking their balance through Berg Balance Scale and then checking the level of function through ODI questionere. The OEP included the following exercises: knee extension and knee flexion, hip abduction, calf raises, toe raises, sit to stand, semi squats from a standing position, tandem stand, tandem walk, sideways walking, backwards walking, heel walking, toe walking, one leg stand, and walking and turning around. All exercises will be performed with 10-20 repetitions, which will be progressed after 2 week.(12)
214613951|NCT06985615|DRUG|Single dose of HDM1002 on Day 1|Single dose of HDM1002 will be administered on Day 1
214613952|NCT06984575|OTHER|No interventions|No interventions
214613953|NCT06985082|OTHER|THERE IS NOT A INTERVENTION|THERE IS NOT A INTERVENTION
214613954|NCT06986265|OTHER|Collection of clinical data and biological sampling|Multiple measures relevant to cachexia, such as body weight, body mass index (BMI), muscle mass (handgrip strength using a Jamar hand dynamometer, mid-upper arm muscle circumference), appetite (Functional Assessment of Anorexia/Cachexia Therapy \[FAACT\], Simplified Nutritional Appetite Questionnaire \[SNAQ\], Automated Self- Administered Dietary Assessment Tool \[ASA24\]) will be recorded at inclusion (T0), after 6 months (T6) and after one year of follow-up (T12). Body composition will be assessed by bioelectrical impedance analysis at T0, T6 and T12, and by CT-scan at T0 and T12. In parallel, gut microbiota composition on feces collection will be determined at the two time points (T0 and T12). Markers of systemic and intestinal inflammation will be assessed at T0 and T12. Serum levels of uremic toxins will be measured at T0 and T12. Human muscle biopsies will be performed at the time of a surgical intervention.
214613955|NCT06985680|BEHAVIORAL|LINE@ Diabetes Health Education Chatbot|"Upon opening the LINE application, the research subjects need to enter Diabetes Smart Helper in the LINE@ Diabetes Health Education Chatbot. Once added to the program, the LINE interface will directly display six small windows for diabetes symptoms/complications, diet, medication, exercise, mental health, and others, facilitating self-selection by users."
214613956|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
214613957|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
214715166|NCT06034015|DRUG|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
214613958|NCT06984757|DEVICE|Deep-brain Stimulation|a neurosurgical procedure that uses implanted electrodes and electrical stimulation to treat movement disorders and certain neuropsychiatric conditions when medications are ineffective or cause significant side effects.
214613959|NCT06984757|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive treatment that uses magnetic fields to stimulate specific areas of the brain.
214613960|NCT06984757|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive brain stimulation technique that uses weak, alternating electrical currents applied to the scalp to modulate brain activity and potentially influence cognitive processes by entraining brain oscillations.
214613961|NCT06985095|OTHER|Nutrition educational program|"Participants in the intervention group will attend a structured nutrition education program consisting of four monthly sessions, each lasting approximately 40 to 60 minutes. These sessions will be conducted in small groups by the researcher.~Each session includes: A 20-30 minute presentation delivered by the researcher using visual aids, such as slides and educational images. A 20-30 minute interactive discussion to address participants' questions, clarify concepts.~Session Topics:~Treatment Goals in Diabetes Care: Overview of blood glucose targets and the importance of achieving glycemic control.~Key Nutritional Components of Food: Roles of carbohydrates, proteins, fats, fiber, and their impact on blood glucose.~Principles of Meal Planning: Adjusting energy intake based on physical activity levels and BMI.~Understanding the Food Exchange System: Introduction to food exchange lists; selecting the appropriate number of food exchanges to meet individual energy needs."
214613962|NCT06687356|PROCEDURE|Surgery with Intraoperative Optical Coherence Tomography application|Surgery with the application of intraoperative optical coherence tomography technique. Intraoperative optical coherence tomography technique can provide intraocular images and show changes in intraocular structures, assisting in analyzing the correlation between preoperative, intraoperative anterior segment structural changes and postoperative surgical effects in patients with lens diseases.
214613963|NCT06687356|PROCEDURE|Conventional surgery|Conventional lens surgery, without the application of intraoperative optical coherence tomography technique.
214613964|NCT06734741|DIAGNOSTIC_TEST|COVID/Flu Detect™ Rapid Self-Test|The COVID/Flu Detect™ Rapid Self-Test is an investigational qualitative lateral flow immunoassay designed for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. It is intended for non-prescription over-the-counter (OTC) use.
214613965|NCT01255852|DRUG|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
214613966|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
214715167|NCT06034015|DRUG|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
214613967|NCT06906796|OTHER|Diaphragmatic breathing exercise and posture exercises|"Diaphragmatic breathing exercise: Before starting the exercise protocol, individuals in the exercise group will be given training on diaphragmatic breathing exercises. During the exercise sessions, individuals will be advised to place one hand on their abdomen and the other on their chest while lying on their back and to increase abdominal movement by breathing slowly through the nose, thus decreasing rib cage movement. The diaphragmatic breathing exercise will be performed for 5 minutes.~Posture exercises: Individuals will be given posture exercise training before starting the exercise protocol. The smoothness of the movements will be checked throughout the exercise. Chin tuck, shoulder rotation, neck extension with exercise rubber and right-left lateral flexion, pectoral stretching with hands behind, pectoral stretching in the corner and head rib cage extension exercises will be applied as posture exercises. Each exercise will be done with 10 repetitions."
214613968|NCT05910502|BEHAVIORAL|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
214613969|NCT04396002|DIAGNOSTIC_TEST|Life Space Questionnaire|This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
214613970|NCT04396002|DIAGNOSTIC_TEST|Low Luminance Questionnaire|This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
214613971|NCT04396002|DIAGNOSTIC_TEST|Contrast sensitivity under dim illumination|Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
214613972|NCT04396002|DIAGNOSTIC_TEST|Visual field under dim illumination (MAIA)|Sensitivity in the central visual area will be assessed under dim illumination
214613973|NCT04396002|DIAGNOSTIC_TEST|Macular Pigment Optical Density (MPOD)|Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
214613974|NCT04396002|DIAGNOSTIC_TEST|Dark Adaptation|After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
214613975|NCT02946658|PROCEDURE|lipoaspiration|Closed syringe harvesting subdermal fat
214613976|NCT02946658|PROCEDURE|ADcSVF|Isolation of AD-cSVF
214613977|NCT02946658|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
214613978|NCT03788772|OTHER|Multiple blood sampling|ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
214613979|NCT03788772|OTHER|Simple blood sampling|Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
214613980|NCT05617677|DRUG|Deucravacitinib|Specified dose on specified days
214613981|NCT05617677|OTHER|Placebo|Specified dose on specified days
214613982|NCT03831659|OTHER|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
214613983|NCT05704387|PROCEDURE|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
214715168|NCT02417896|DRUG|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
214715169|NCT05418569|DEVICE|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
214613984|NCT05704387|PROCEDURE|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
214613985|NCT03096041|DEVICE|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
214613986|NCT03096041|DEVICE|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
214613987|NCT03553914|DRUG|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
214613988|NCT00938717|DRUG|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
214613989|NCT00998049|DRUG|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
214613990|NCT00998049|DRUG|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
214613991|NCT00170612|BIOLOGICAL|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
214613992|NCT00170612|BIOLOGICAL|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
214613993|NCT05926388|OTHER|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
214613994|NCT05860075|DRUG|IMM01|IMM01 will be administered once a week for 4 weeks.
214613995|NCT05092919|OTHER|Flavor|Sweet flavored vs. non-flavored cigarillos.
214613996|NCT06155500|OTHER|OTQ923|There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
214613997|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
214715170|NCT05418569|OTHER|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
214715171|NCT04378699|OTHER|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
214613998|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
214613999|NCT02248259|DRUG|BI 409306|Oral single dose of BI 409306
214614000|NCT02248259|DRUG|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
214614001|NCT02470468|BIOLOGICAL|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
214715172|NCT04378699|OTHER|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
214715173|NCT00063310|DRUG|Leuprolide acetate|
214614002|NCT02470468|BIOLOGICAL|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
214614003|NCT02470468|OTHER|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
214715174|NCT01721512|OTHER|Breastfeeding|
214715175|NCT01721512|OTHER|Infant formula|
214715176|NCT04124055|DIAGNOSTIC_TEST|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
214715177|NCT01005199|DRUG|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
214715178|NCT01005199|DRUG|sorafenib tosylate|Sorafenib 2 x 400 mg daily
214715179|NCT02318745|BEHAVIORAL|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
214614004|NCT00739011|DEVICE|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
214614005|NCT01329250|DRUG|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
214715180|NCT02318745|BEHAVIORAL|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
214715181|NCT04458363|BIOLOGICAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
214614006|NCT04956003|BEHAVIORAL|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
214614007|NCT05972200|DEVICE|Active HD-tDCS over V5/MT|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V5/MT, whereas the other 4 electrodes return electrical currents that flow away from that area. V5/MT will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
214614008|NCT05972200|DEVICE|Active HD-tDCS over V1|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V1, whereas the other 4 electrodes return electrical currents that flow away from that area. V1 will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
214614009|NCT05972200|DEVICE|Sham HD-tDCS over V5/MT or V1|Sham HD-tDCS will be delivered over left V5/MT or left V1. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. .
214715182|NCT04458363|DRUG|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
214715183|NCT04397315|PROCEDURE|Pulpotomy to the level of canal orifices|Pulp tissue will be removed till the level of canal orifices.
214715184|NCT04397315|PROCEDURE|Pulpotomy up to superficial 2-3 mm of pulp chamber|Only superficial pulp from the chamber will be removed
214715185|NCT06112912|OTHER|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
214715186|NCT01582958|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
214715187|NCT01582958|OTHER|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
214715188|NCT05564676|DIETARY_SUPPLEMENT|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
214715189|NCT05564676|DIETARY_SUPPLEMENT|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
214614010|NCT04425603|DEVICE|Anthology Hip Replacement System|
214614011|NCT04501068|DEVICE|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
214715190|NCT02583516|DRUG|vemurafenib and cobimetinib|Comparison between different treatment regimens
214715191|NCT00618904|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
214715192|NCT00618904|DIETARY_SUPPLEMENT|Placebo|Placebo administered bid for 6 weeks.
214715193|NCT04959604|PROCEDURE|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
214715194|NCT03825510|RADIATION|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
214715195|NCT00500812|DRUG|Cethrin|
214715196|NCT05865210|OTHER|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
214715197|NCT05865210|OTHER|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
214715198|NCT04186663|DRUG|Silver Diamine Fluoride|38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
214715199|NCT01569087|BIOLOGICAL|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
214614012|NCT00029874|DRUG|Minocycline|
214614013|NCT02656459|OTHER|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
214614014|NCT02905370|BEHAVIORAL|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
214614015|NCT02905370|BEHAVIORAL|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
214614016|NCT01035775|PROCEDURE|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
214614017|NCT01035775|PROCEDURE|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
214614018|NCT04391348|RADIATION|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
214614019|NCT01575106|DEVICE|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
214614020|NCT01206062|DRUG|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
214614021|NCT01206062|DRUG|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
214614022|NCT00245544|DRUG|MK0759|
214614023|NCT03537144|DRUG|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
214614024|NCT03537144|DRUG|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
214614025|NCT01305642|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
214614026|NCT04092712|DRUG|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
214614027|NCT05429970|BEHAVIORAL|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
214614028|NCT05429970|BEHAVIORAL|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
214614029|NCT05429970|DRUG|Propranolol|Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
214614030|NCT05429970|DRUG|Etodolac|Etodolac 400 mg PO BID (for 21 consecutive days)
214614031|NCT01848288|DEVICE|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
214614032|NCT01848288|DEVICE|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
214614033|NCT02091778|DEVICE|Fast gelling dressing|
214614034|NCT05237232|OTHER|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
214614035|NCT05237232|OTHER|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure"
214614036|NCT04110457|PROCEDURE|spinal decompression|spinal surgery by decompression or fixation
214614037|NCT04292808|DRUG|Methoxyflurane|Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
214614038|NCT01025960|PROCEDURE|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
214614039|NCT01025960|PROCEDURE|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
214614040|NCT05843721|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
214614041|NCT01737918|PROCEDURE|TOT|
214614042|NCT01737918|DRUG|solifenacin|
214614043|NCT00677820|BIOLOGICAL|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
214614044|NCT00677820|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
214614045|NCT05252429|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
214614046|NCT05252429|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
214614047|NCT04253184|DEVICE|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
214614048|NCT05322018|DIAGNOSTIC_TEST|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
214614049|NCT04653636|OTHER|Arthrographic distension|"The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance"
214614050|NCT04653636|OTHER|Immediate joint mobilization|"This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period."
214614051|NCT01554644|DEVICE|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
214614052|NCT01554644|DEVICE|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
214614053|NCT01673919|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
214614054|NCT05534347|BIOLOGICAL|Blood sample|Addtional tube of blood needed for follow up of patients
214614055|NCT05534347|BIOLOGICAL|Joint puncture|Joint puncture if needed according to routine care of the patients
214614056|NCT03776487|DRUG|Fluorouracil|Given IV
214614057|NCT03776487|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214614058|NCT03776487|BIOLOGICAL|Ipilimumab|Given IV
214614059|NCT03776487|BIOLOGICAL|Nivolumab|Given IV
214614060|NCT03776487|DRUG|Oxaliplatin|Given IV
214614061|NCT03776487|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
214614062|NCT02722538|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
214614063|NCT00001520|DRUG|neostigmine|
214614064|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .
214614065|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
214614066|NCT04237649|DRUG|KAZ954|KAZ954 will be administered in every arm.
214614067|NCT04237649|DRUG|PDR001|KAZ954 + PDR001
214614068|NCT04237649|DRUG|NIR178|KAZ954 + NIR178
214614069|NCT04237649|DRUG|NZV930|KAZ954 + NZV930
214614070|NCT05865327|PROCEDURE|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
214614071|NCT05865327|PROCEDURE|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
214614072|NCT00986544|PROCEDURE|no drain|drain positioned on the skin
214614073|NCT00986544|PROCEDURE|drain positioned|drain positioned in the subhepatic space
214614074|NCT00986544|PROCEDURE|drain not positioned|Drain positioned in the abdominal wall
214614075|NCT02414269|GENETIC|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
214614076|NCT02414269|DRUG|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
214614077|NCT02414269|DRUG|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
214614078|NCT06536023|DRUG|IBI362|IBI362 SA.QW
214614079|NCT06536023|DRUG|IBI362 placebo|IBI362 placebo SA.QW
214614080|NCT05990439|BEHAVIORAL|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
214614081|NCT05990439|BEHAVIORAL|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
214614082|NCT01407640|PROCEDURE|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
214614083|NCT06477341|DIETARY_SUPPLEMENT|various available nutrition as those contain high protein content as ensure milk|note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
214614084|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, on day 1.
214614085|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
214614086|NCT04594382|DIAGNOSTIC_TEST|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
214715200|NCT01569087|BIOLOGICAL|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
214715201|NCT02062476|DIETARY_SUPPLEMENT|Lactobacillus GG|
214715202|NCT02033655|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
214715203|NCT02033655|BEHAVIORAL|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
214715204|NCT03649334|DRUG|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
214715205|NCT03649334|DRUG|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
214715206|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
214715207|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
214715208|NCT04223063|BEHAVIORAL|Exercise program|As per the intervention arm
214715209|NCT00771173|DRUG|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
214715210|NCT00771173|OTHER|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
214614087|NCT04594382|DIAGNOSTIC_TEST|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
214614088|NCT03194282|OTHER|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
214614089|NCT05069064|OTHER|music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
214614090|NCT05069064|OTHER|no music|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
214614091|NCT05217199|OTHER|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
214614092|NCT03515798|DRUG|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
214614093|NCT03515798|DRUG|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
214614094|NCT03333642|PROCEDURE|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
214715211|NCT01153477|BEHAVIORAL|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
214614095|NCT06527625|BEHAVIORAL|Cultural Arts Program|9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression
214614096|NCT06527625|BEHAVIORAL|Treatment as usual|Treatment as usual provided in local community aged care centres
214715212|NCT04026763|PROCEDURE|prostate biopsy|standard of care
214715213|NCT04026763|PROCEDURE|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
214715214|NCT04026763|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
214715215|NCT02608034|DRUG|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
214715216|NCT02608034|DRUG|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
214715217|NCT02608034|DRUG|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
214715218|NCT01602549|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
214715219|NCT01602549|DRUG|Placebo|matching placebo tablet
214715220|NCT05200455|DEVICE|Microelectrodes|Microelectrode implantation
214715221|NCT04368468|OTHER|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
214715222|NCT04868747|DRUG|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
214715223|NCT04868747|DRUG|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
214715224|NCT00719862|DRUG|Placebo nasal spray|Placebo
214614097|NCT06580340|OTHER|AFA (Adapted Physical Activity)|An exercise program to improve joint mobility, muscle strength, static and dynamic balance, motor coordination will be performed 2 times/week for 6 months.
214614098|NCT05757869|DRUG|Milvexian|Milvexian will be administered orally.
214614099|NCT05757869|DRUG|Apixaban|Apixaban will be administered orally.
214614100|NCT05757869|DRUG|Placebo|Milvexian matching milvexian placebo will be administered orally.
214614101|NCT05757869|DRUG|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
214614102|NCT06543290|DRUG|Azithromycin Pill|Azithromycin 2 grams to be administered prior to start of induction for those randomized to intervention group
214614103|NCT06543290|DRUG|Placebo|4 magnesium oxide tablets prior to the start of induction for those randomized to placebo
214614104|NCT00616915|DRUG|Wellbutrin XL|Wellbutrin XL 300mg daily
214614105|NCT05316155|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
214614106|NCT04827719|DRUG|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
214614107|NCT01888120|DRUG|Ziconotide|
214614108|NCT03778528|PROCEDURE|cataract surgery|tissue collection.
214614109|NCT04814342|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
214614110|NCT06631638|DEVICE|EMPHASYS Cup with VHN|Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
214614111|NCT01864499|PROCEDURE|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
214614112|NCT01871220|DEVICE|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
214614113|NCT01871220|DEVICE|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
214614114|NCT02508142|DRUG|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
214614115|NCT03576599|DRUG|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
214614116|NCT03576599|DRUG|Placebo|Placebo
214614117|NCT05542407|DRUG|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
214614118|NCT05542407|DRUG|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
214614119|NCT03896542|DEVICE|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
214614120|NCT03896542|DEVICE|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
214614121|NCT05102344|BEHAVIORAL|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
214614122|NCT05102344|BEHAVIORAL|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
214614123|NCT01825057|BEHAVIORAL|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
214614124|NCT01825057|BEHAVIORAL|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
214614125|NCT01825057|BEHAVIORAL|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
214614126|NCT06268171|OTHER|ultrasound measurement of the cross-sectional area of the rectus femoris|ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
214614127|NCT06144632|DEVICE|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
214614128|NCT06144632|DEVICE|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
214614129|NCT01688596|DRUG|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
214614130|NCT06552338|OTHER|Observational|No intervention. Study is observational
214614131|NCT03023020|DRUG|Aspirin|Dosing per current guidelines and local practice
214614132|NCT03023020|DRUG|P2Y12 inhibitor|Dosing per current guidelines and local practice
214614133|NCT00794599|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
214715225|NCT00719862|DRUG|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
214715226|NCT03217201|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
214614134|NCT00794599|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
214614135|NCT03831061|OTHER|Cognitive stimulation|
214614136|NCT06455098|DEVICE|OMNYPULSE™ Catheter with the TRUPULSE Generator|OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
214614137|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
214614138|NCT00975299|DRUG|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
214614139|NCT00975299|DRUG|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
214614140|NCT04788654|DRUG|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
214614141|NCT04788654|PROCEDURE|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
214614142|NCT05865379|DEVICE|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
214614143|NCT05865379|DEVICE|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
214614144|NCT02075372|OTHER|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
214614145|NCT00547872|PROCEDURE|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
214614146|NCT04746833|BEHAVIORAL|SUMMIT|multicomponent web-based application focused on pain self-management skills
214614147|NCT04746833|BEHAVIORAL|control|My Pain Diary app
214614148|NCT03380455|DRUG|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
214614149|NCT03380455|DRUG|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
214614150|NCT01776762|DIETARY_SUPPLEMENT|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
214614151|NCT03968614|OTHER|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
214614152|NCT03968614|OTHER|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
214614153|NCT06549816|DRUG|sigvotatug vedotin|Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
214614154|NCT04925167|DRUG|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
214614155|NCT04925167|DRUG|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
214614156|NCT00541320|DRUG|GW813893|
214614157|NCT05570812|DRUG|Placebo|(4-week ramp, 4-week steady dosing)
214614158|NCT05570812|DRUG|Pregnenolone|(4-week ramp, 4-week steady dosing)
214614159|NCT03965676|OTHER|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
214614160|NCT06490549|OTHER|RSV infection observation cohort|No intervention; Epidemiological Study. Participants will receive standard care based on local clinical practice
214614161|NCT03662165|BEHAVIORAL|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
214614162|NCT03662165|BEHAVIORAL|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
214614163|NCT03662165|BEHAVIORAL|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
214614164|NCT04906356|GENETIC|Genetic sub-study|One time saliva sample collection
214614165|NCT02865018|DRUG|cetirizine|
214614166|NCT05109286|BEHAVIORAL|CrossFit|CrossFit training
214614167|NCT04942652|DRUG|Itraconazole 200 mg|Itraconazole 100 mg capsule x 2
214614168|NCT04942652|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet x 1
214614169|NCT05250973|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
214614170|NCT05250973|DRUG|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
214614171|NCT05250973|DRUG|Bortezomib|Bortezomib will be administered by SC injection or IV.
214614172|NCT05250973|DRUG|Dexamethasone|Dexamethasone will be administered orally or IV.
214614173|NCT01163812|PROCEDURE|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
214614174|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
214614175|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
214614176|NCT05336916|BEHAVIORAL|Buddy|Mindfulness-based Cognitive Behavioural Therapy
214614177|NCT03503409|DRUG|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
214614178|NCT02015442|DIETARY_SUPPLEMENT|Sucrose|
214614179|NCT00290290|DRUG|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
214614180|NCT00290290|DRUG|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
214614181|NCT06491056|DEVICE|Focal Therapy for Prostate Cancer|Ablation of \<75% of the prostate gland for limited volume prostate cancer
214715227|NCT03217201|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
214614182|NCT06398899|DRUG|Group S: sugammadex injection|Reversal agent: sugammadex
214614183|NCT06398899|DRUG|Group N: neostigmine/glycopyrrolate|Reversal agent: glycopyrrolate and neostigmine
214614184|NCT02809131|DRUG|polymixin/bacitracin|Antibacterial irrigation
214614185|NCT02809131|DRUG|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
214614186|NCT02809131|DRUG|Saline|Saline irrigation
214715228|NCT05976477|OTHER|educational intervention|"1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt."
214614187|NCT04067479|DIETARY_SUPPLEMENT|Amino Acids|Oral bolus of essential amino acids
214614188|NCT02438891|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
214715229|NCT02130154|OTHER|18-FDG PET CT scan and 123I-MIBG SPECT scan|
214715230|NCT01781871|BIOLOGICAL|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
214715231|NCT01781871|BIOLOGICAL|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
214715232|NCT03291158|DRUG|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
214614189|NCT06473311|DEVICE|whole bady vibration and virtual reality|study group I received a whole body vibration program in addition to a conventional physical therapy program, and study group II received a Wii-fit therapy program (a virtual reality treatment program) in addition to the same. A two-month treatment program was implemented for both groups. Every child in both groups had the same evaluation processes, which included using the Physical Self Maintenance Scale (PSMS) for daily living activities and a dynamometer to measure quadriceps muscular strength. Evaluation was done prior to the start of treatment and was done again after one month (post I) and two months (post II).
214614190|NCT01062633|DIETARY_SUPPLEMENT|A, erythritol|2,5 g 3 times a day
214614191|NCT01062633|DIETARY_SUPPLEMENT|xylitol|2,5 g 3 times a day
214614192|NCT01062633|DIETARY_SUPPLEMENT|C, sorbitol|2,5 g 3 times aday
214614193|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
214614194|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
214614195|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
214614196|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
214614197|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
214715233|NCT04586556|DIAGNOSTIC_TEST|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
214614198|NCT04603885|BEHAVIORAL|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
214614199|NCT04603885|BEHAVIORAL|Stretching exercise|stretching exercise
214614200|NCT02124395|OTHER|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
214614201|NCT05317507|DRUG|CBD oil|50 mg
214614202|NCT05317507|DRUG|CBD oil|100 mg CBD
214614203|NCT05317507|DRUG|Placebo|Placebo
214614204|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
214614205|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
214715234|NCT03264833|OTHER|TempTraq|no intervention
214715235|NCT00897091|GENETIC|comparative genomic hybridization|
214715236|NCT00897091|GENETIC|microarray analysis|
214715237|NCT00897091|GENETIC|reverse transcriptase-polymerase chain reaction|
214715238|NCT00897091|OTHER|diagnostic laboratory biomarker analysis|
214715239|NCT00293046|BIOLOGICAL|ALK Grass tablet - use of compliance device|
214614206|NCT00286481|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
214614207|NCT05149027|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
214715240|NCT03328624|DEVICE|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
214715241|NCT04019652|DRUG|CS-3150|Single, oral administration; 10-mg or 40-mg dose
214715242|NCT04019652|DRUG|Moxifloxacin|Single, oral administration; 400 mg-tablet
214715243|NCT04019652|DRUG|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
214614208|NCT06455592|BEHAVIORAL|practice adapted physical activity|practice daily adapted physical activity during 4 days
214614209|NCT06455592|OTHER|control arm|practice once adapted physical activity during 4 days
214614210|NCT05841030|OTHER|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
214715244|NCT04019652|DRUG|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
214715245|NCT00816855|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
214715246|NCT01184846|BIOLOGICAL|10% liquid formulation of human immunoglobulin|
214614211|NCT04013789|DEVICE|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
214614212|NCT04013789|DEVICE|DACP contact lenses|Nelfilcon A soft contact lenses
214715247|NCT06079034|PROCEDURE|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
214715248|NCT06079034|PROCEDURE|Venoarterial ECMO|Initial support type of venoarterial ECMO
214715249|NCT04261049|DRUG|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
214715250|NCT06329999|DRUG|CMGV|"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
214715251|NCT03052387|OTHER|assigned intervention|"\* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures."
214715252|NCT01894763|DEVICE|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
214715253|NCT02483078|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214715254|NCT02483078|DRUG|Placebo|
214715255|NCT02483078|DRUG|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
214715256|NCT02853032|DEVICE|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
214715257|NCT02853032|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
214715258|NCT02853032|DEVICE|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
214715259|NCT01330563|DRUG|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
214614213|NCT01482585|OTHER|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
214614214|NCT06538584|DRUG|Caffeine citrate 15mg/kg|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 15mg/kg Caffeine citrate 15 minutes post surgery.
214614215|NCT06538584|DRUG|0.9% Sodium Citrate|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
214614216|NCT03399799|DRUG|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
214614217|NCT00192387|BIOLOGICAL|CAIV-T, Liquid|
214614218|NCT01247987|PROCEDURE|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
214614219|NCT01247987|PROCEDURE|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
214614220|NCT03319407|DEVICE|EPAD monitoring system|EPAD system will be used as part of routine care
214614221|NCT04092296|OTHER|resin infiltration|using infiltrant resin intervene proximal caries
214715260|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
214715261|NCT04329494|DRUG|Cisplatin|Given via PIPAC
214614222|NCT04092296|OTHER|remineralization|using fluoride to remineralize proximal caries
214715262|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
214614223|NCT04092296|OTHER|sham|replace resin with water
214614224|NCT04244526|OTHER|Talking a urine sample|Just taking a urine sample
214614225|NCT02342496|DIETARY_SUPPLEMENT|Placebo|Powder
214614226|NCT02342496|DIETARY_SUPPLEMENT|Active, only probiotics|Powder
214614227|NCT02342496|DIETARY_SUPPLEMENT|Active, blend of berries and probiotics|Powder
214614228|NCT02617186|PROCEDURE|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
214614229|NCT02617186|PROCEDURE|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
214614230|NCT00549939|DRUG|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
214614231|NCT00549939|DRUG|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
214715263|NCT04329494|DRUG|Fluorouracil|Given IV
214715264|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
214715265|NCT04329494|DRUG|Irinotecan|Given IV
214715266|NCT04329494|DRUG|Leucovorin|Given IV
214715267|NCT04329494|DRUG|Mitomycin|Given via PIPAC
214715268|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
214715269|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
214715270|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
214715271|NCT01520584|DIETARY_SUPPLEMENT|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
214715272|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
214715273|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
214715274|NCT01769144|DEVICE|Acticoat Absorbent|wound dressing
214614232|NCT06584942|DRUG|Suvorexant|Subjects will titrate up to 20 mg of suvorexant daily. Subjects will follow a titration schedule with 10 mg once daily on days 1-3, 15 mg once daily on days 4-6, then 20 mg on day seven and for the remainder of the study. If participants report AEs (worsening depression/suicidal ideation, complex sleep behaviors, sleep paralysis, etc.) dose may be decreased to the previous dose taken. Participants will be treated for 14 days in total; however, due to scanner availability, the second scan may occur more than 14 days after the first scan. In this case, participants will be allowed to continue taking this dose for up to 14 additional days until the final scan occurs (28 days total).
214715275|NCT01769144|DEVICE|BCT|wound dressing
214715276|NCT02952833|DRUG|Saline|Sodium chloride solution.
214715277|NCT02952833|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
214715278|NCT03366844|DRUG|Pembrolizumab|checkpoint inhibitor
214715279|NCT03366844|RADIATION|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
214715280|NCT00107172|PROCEDURE|surgery|
214715281|NCT00107172|RADIATION|brachytherapy|
214715282|NCT00789724|DRUG|Anakinra|100 mg daily subcutaneous injection for 14 days
214614233|NCT03677596|DRUG|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
214614234|NCT03677596|DRUG|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
214614235|NCT03685383|DEVICE|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
214614236|NCT03685383|DEVICE|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
214614237|NCT00036439|DRUG|Infliximab|
214614238|NCT05257083|DRUG|Daratumumab|Daratumumab will be administered SC.
214715283|NCT00789724|DRUG|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
214715284|NCT03199144|DRUG|Chemotherapy|3 cycles of Gemzar-Abraxane
214715285|NCT03199144|RADIATION|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
214715286|NCT03199144|PROCEDURE|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
214715287|NCT01102140|DRUG|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
214715288|NCT01102140|DRUG|Sugar Pill|Matching sugar pill
214715289|NCT03823898|BEHAVIORAL|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
214715290|NCT03823898|BEHAVIORAL|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
214715291|NCT03823898|BEHAVIORAL|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
214614239|NCT05257083|DRUG|Bortezomib|Bortezomib will be administered SC.
214614240|NCT05257083|DRUG|Lenalidomide|Lenalidomide will be administered orally.
214614241|NCT05257083|DRUG|Dexamethasone|Dexamethasone will be administered orally.
214614242|NCT05257083|DRUG|Cilta-cel|Cilta-cel will be administered intravenously
214614243|NCT05257083|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
214614244|NCT05257083|DRUG|Fludarabine|Fludarabine will be administered intravenously.
214614245|NCT04726384|DEVICE|Assessment of physical activity level|Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (\>3MET) and moderate ( \>6MET) exercise.
214614246|NCT04457180|DRUG|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
214614247|NCT04457180|DRUG|Repaglinide|Repaglinide will be administered daily on D1 and D12
214614248|NCT04457180|DRUG|Bupropion|Bupropion will be administered daily on D2 and D13
214614249|NCT00305968|BEHAVIORAL|patient education|Patient education group
214614250|NCT06108713|OTHER|Addition of juggling|Participants will not change ther daily activities, and participate in juggling intervention lasted 4 weeks and consisted of 12 meetings (3 trainings per week), each lasting 45 minutes.
214614251|NCT01345136|DRUG|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
214614252|NCT04372108|DRUG|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
214614253|NCT04372108|DRUG|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
214614254|NCT00768326|DRUG|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
214614255|NCT00768326|DRUG|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
214614256|NCT00768326|DRUG|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
214614257|NCT00768326|DRUG|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
214614258|NCT00768326|DRUG|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
214614259|NCT00768326|DRUG|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
214614260|NCT05342662|DEVICE|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
214614261|NCT05342662|DEVICE|Glasses with clear lenses|Non-blue light-blocking glasses
214614262|NCT03936621|DRUG|Omega 3 fatty acid|To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
214614263|NCT04932850|BIOLOGICAL|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
214614264|NCT04932850|OTHER|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
214614265|NCT05201781|DRUG|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
214614266|NCT06216379|DIAGNOSTIC_TEST|Assessment|Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
214614267|NCT00003895|BIOLOGICAL|HPV 16 E7:12-20|Given SC
214614268|NCT00003895|BIOLOGICAL|gp100:209-217(210M)|Given SC
214614269|NCT00003895|OTHER|laboratory biomarker analysis|Correlative studies
214614270|NCT04520048|OTHER|Determination of the UEMP levels|Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.
214614271|NCT04520048|PROCEDURE|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical) and/or Popmetre.
214614272|NCT04520048|OTHER|Vascular biomarker assay|Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.
214614273|NCT04520048|PROCEDURE|Measurement of the uterine artery diameter|This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
214614274|NCT06132165|DRUG|Deoxycholic Acid|Injection into the cutaneous Neurofibromas lesion.
214614275|NCT06132165|DRUG|Polidocanol|Injection into the cutaneous Neurofibromas lesion.
214614276|NCT06132165|DEVICE|1064nm Nd:YAG laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.
214614277|NCT06132165|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
214614278|NCT05140512|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
214614279|NCT05140512|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
214614280|NCT04632303|OTHER|Early Palliative Care|Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
214715292|NCT01614340|BEHAVIORAL|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
214715293|NCT00125229|DRUG|Mannitol|
214715294|NCT00125229|DRUG|Hypertonic Saline|
214715295|NCT00134342|OTHER|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
214715296|NCT01340560|PROCEDURE|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
214715297|NCT05316818|DRUG|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
214715298|NCT02479295|DEVICE|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
214715299|NCT04545034|OTHER|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
214715300|NCT03125018|DEVICE|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
214715301|NCT03030183|DRUG|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
214715302|NCT01673490|DRUG|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
214614281|NCT02994277|DEVICE|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
214614282|NCT06228820|DRUG|Aspirin 81Mg Ec Tab|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
214715303|NCT00379236|DEVICE|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
214715304|NCT00379236|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
214715305|NCT02683707|OTHER|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
214715306|NCT02683707|DRUG|Fentanyl|IV peri-procedural analgesia
214715307|NCT02683707|DRUG|Lidocaine|Local Anesthetic
214715308|NCT02683707|DRUG|Midazolam|IV sedation
214715309|NCT03825445|DRUG|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
214715310|NCT03825445|DRUG|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
214715311|NCT03562624|DRUG|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
214715312|NCT03562624|DRUG|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
214715313|NCT04914767|DRUG|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
214715314|NCT04914767|DRUG|Placebo|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
214715315|NCT01783470|DRUG|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
214715316|NCT01510834|BEHAVIORAL|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
214614283|NCT03761381|DEVICE|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
214614284|NCT03761381|DEVICE|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
214715317|NCT05200728|DRUG|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
214715318|NCT05200728|DRUG|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
214715319|NCT01999907|DIETARY_SUPPLEMENT|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
214715320|NCT01999907|DIETARY_SUPPLEMENT|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
214715321|NCT01999907|OTHER|Placebo|placebo given in a 2ml dose by mouth at baseline.
214614285|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
214614286|NCT03634397|BEHAVIORAL|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
214614287|NCT03634397|BEHAVIORAL|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
214614288|NCT04024150|BIOLOGICAL|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
214614289|NCT06295731|DRUG|INBRX-106|INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
214614290|NCT06295731|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
214614291|NCT00861250|DRUG|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
214614292|NCT04912245|BEHAVIORAL|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
214614293|NCT05784636|DEVICE|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
214614294|NCT05784636|DEVICE|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
214614295|NCT02751593|DRUG|Dexamethasone|dexamethasone 40mg/d for 4 days
214614296|NCT06429280|DEVICE|N/A this is an observational study of Standard of Care|Medical Device which treats unilateral amblyopia through therapeutic software which stimulate vision
214614297|NCT06540976|BEHAVIORAL|Cognitive testing|Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
214614298|NCT01150175|PROCEDURE|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
214614299|NCT01150175|PROCEDURE|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
214614300|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
214614301|NCT05822843|DRUG|ESG206|Administered via intravenous (IV) infusion
214614302|NCT06506812|BIOLOGICAL|High-Dose Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
214614303|NCT06506812|BIOLOGICAL|Standard-Dose Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the governmental influenza vaccine programs may be used.
214614304|NCT05198726|DEVICE|alpha tACS|2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
214715322|NCT03276572|DRUG|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
214614305|NCT05198726|BEHAVIORAL|Speed of Processing Training|SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
214614306|NCT03520543|DRUG|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of \[11C\]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of \[11C\]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of \[11C\]Yohimbine.
214614307|NCT03520543|DRUG|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following \[11C\]Yohimbine PET scan (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after \[11C\]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of \[11C\]Yohimbine (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of \[11C\]Yohimbine obtained at baseline (part A)."
214614308|NCT05150600|PROCEDURE|Inverse Ratio Ventilation|The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
214614309|NCT03364153|DRUG|avacincaptad pegol|Intravitreal Injection
214614310|NCT03364153|DRUG|Sham|Intravitreal Injection
214614311|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
214614312|NCT01119742|DRUG|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
214614313|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
214614314|NCT01119742|DRUG|Vehicle A|Twice daily application for 7 days
214614315|NCT01119742|DRUG|Vehicle B|Twice daily application for 7 days
214614316|NCT02910947|PROCEDURE|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
214614317|NCT06537440|OTHER|Electroacupuncture|Electroacupuncture TE6 Zhigou (double), ST36 Zusanli (double), ST25 Tianshu (double), CV12 Zhongwan
214614318|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
214614319|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
214614320|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
214614321|NCT01134614|BIOLOGICAL|Ipilimumab|Given IV
214614322|NCT01134614|BIOLOGICAL|Sargramostim|Given SC
214614323|NCT06169475|DRUG|Dexmedetomidine Hydrochloride|The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
214614324|NCT06169475|DRUG|Esmolol Hydrochloride|The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
214614325|NCT06959511|DRUG|Zanzalintinib|Given by po
214614326|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
214614327|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
214614328|NCT06577025|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
214614329|NCT06577025|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214614330|NCT06577025|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
214614331|NCT06577025|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
214614332|NCT06577025|DRUG|Bortezomib|Bortezomib will be administered subcutaneously as a part of induction.
214614333|NCT06577025|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of induction.
214614334|NCT06577025|DRUG|Dexamethasone|Dexamethasone will be administered orally as a part of induction.
214614335|NCT06577025|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
214614336|NCT06577025|DRUG|Fludarabine|Fludarabine will be administered intravenously as a part of conditioning regimen.
214614337|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
214614338|NCT02752035|DRUG|gilteritinib|Tablet, oral
214614339|NCT02752035|DRUG|azacitidine|Subcutaneous injection or intravenous infusion
214614340|NCT06407648|OTHER|Personalized Assessments|Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
214614341|NCT06407648|OTHER|Standard of Care|The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
214614342|NCT05677971|DRUG|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
214614343|NCT05677971|OTHER|Placebo|Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
214715323|NCT04238611|DEVICE|Microneedle|Lactate microneedle applied on the skin of participant
214614344|NCT02849470|PROCEDURE|Intradermal Injection in hair loss|Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss
214614345|NCT02849470|PROCEDURE|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
214614346|NCT02849470|PROCEDURE|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
214614347|NCT02849470|PROCEDURE|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
214614348|NCT02849470|PROCEDURE|MatriStem Matrix (ACell) - Current Standard of Care|
214614349|NCT02849470|PROCEDURE|HD-PRP (High Density Platelet Rich Plasma)|
214614350|NCT02849470|PROCEDURE|Emulsified AD-tSVF|
214715324|NCT04238611|DIAGNOSTIC_TEST|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
214614351|NCT02849470|PROCEDURE|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
214614352|NCT06116786|DRUG|JNJ-86974680|JNJ-86974680 will be administered.
214614353|NCT06116786|DRUG|Cetrelimab|Cetrelimab will be administered.
214614354|NCT06116786|RADIATION|Radiation Therapy|Radiation therapy will be administered.
214614355|NCT00533143|OTHER|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
214715325|NCT04238611|OTHER|Exercise regimen|Standardised aerobic exercise regimen
214715326|NCT04483297|DRUG|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
214715327|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
214715328|NCT01709708|DRUG|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
214715329|NCT01709708|DRUG|Saline|Saline
214614356|NCT04858984|DEVICE|Virtual Reality|A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
214715330|NCT02396693|DEVICE|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
214614357|NCT06075576|DIAGNOSTIC_TEST|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
214614358|NCT04289480|DEVICE|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
214715331|NCT02396693|DEVICE|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
214715332|NCT02396693|DEVICE|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
214715333|NCT00527072|BIOLOGICAL|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
214614359|NCT04701385|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
214614360|NCT05097521|OTHER|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
214614361|NCT05097521|OTHER|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
214614362|NCT05097521|OTHER|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
214614363|NCT03804736|BIOLOGICAL|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
214614364|NCT03804736|BIOLOGICAL|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
214614365|NCT03802279|OTHER|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
214614366|NCT03802279|OTHER|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
214614367|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
214614368|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
214715334|NCT05551260|OTHER|Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition|"Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests"
214715335|NCT02080494|DRUG|Tranexamic Acid|
214614369|NCT04344795|DRUG|TPST-1495 twice daily|TPST-1495 administered orally twice daily
214614370|NCT04344795|DRUG|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
214614371|NCT04344795|DRUG|Pembrolizumab|Pembrolizumab dosed per label recommendations
214614372|NCT04886648|BEHAVIORAL|Music Therapy|
214614373|NCT05242042|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
214614374|NCT05242042|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
214614375|NCT00698724|DRUG|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
214614376|NCT00698724|DRUG|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
214614377|NCT03442036|DEVICE|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
214614378|NCT03442036|DEVICE|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
214614379|NCT03941678|DIETARY_SUPPLEMENT|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
214614380|NCT03941678|DIETARY_SUPPLEMENT|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
214715336|NCT02480803|DRUG|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
214715337|NCT02480803|DEVICE|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
214614381|NCT01161043|DEVICE|Sensor wear|All subjects to wear sensors
214614382|NCT02200354|DRUG|pemetrexed with bevacizumab|
214614383|NCT02999867|DIETARY_SUPPLEMENT|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
214614384|NCT02999867|DIETARY_SUPPLEMENT|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
214614385|NCT06127927|DEVICE|Interventional Left Ventricular Assist System|Interventional left ventricular assist system for cardiogenic shock patients
214614386|NCT04654442|DIAGNOSTIC_TEST|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
214614387|NCT06153875|OTHER|Sensory Thresold, Burst High Frecuency|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 5 trains of 5 seconds, 55 seconds apart, at a frequency of 100Hz, making 5 minutes of total treatment. The intensity will be set 200 microamperes (μA) above the detection threshold for each patient, guaranteeing a sensitive but not painful perception.
214614388|NCT06153875|OTHER|Theta-Burst Stimulation|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 40 trains separated by 7 seconds from each other, where each train contains 5 trains separated by 200ms, at a frequency of 5Hz, resulting in 6 minutes and 45 seconds of total treatment. The intensity will be set at the motor threshold of the patient, ensuring a non-painful stimulation.
214715338|NCT05857007|DEVICE|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
214715339|NCT03770676|DIETARY_SUPPLEMENT|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
214614389|NCT06153875|OTHER|Transcutaneous Electrical Nerve Stimulation|The transcutaneous electrical nerve stimulation will be applied on the trapezius or low back and internal calf muscles at a frequency of 80Hz and a pulse width of 250 microseconds, for 15 minutes. The intensity will be set at the detection threshold of each patient generating a sensitive but non-painful perception.
214614390|NCT01236573|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214715340|NCT00003760|DRUG|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
214715341|NCT01576666|DRUG|LDE225|
214715342|NCT01576666|DRUG|BKM120|
214614391|NCT01236573|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
214715343|NCT02546310|DRUG|HTL0009936|
214715344|NCT02546310|DRUG|HTL0009936 matching placebo|
214715345|NCT06133985|OTHER|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
214614392|NCT01236573|BIOLOGICAL|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
214614393|NCT00330876|DRUG|Pitavastatin|
214614394|NCT02164929|PROCEDURE|TAP block|
214614395|NCT02164929|PROCEDURE|Epidural|
214614396|NCT02164929|PROCEDURE|Paravertebral block|
214614397|NCT02164929|DRUG|Acetaminophen 1g IV|
214614398|NCT02164929|DRUG|Dexamethasone 4mg|
214614399|NCT02164929|DRUG|Midazolam up to 2mg|
214614400|NCT02164929|DRUG|Propofol 1-2.5 mg/kg|
214614401|NCT02164929|DRUG|Sevoflurane to keep a bispectral index of between 40-60|
214614402|NCT02164929|DRUG|Local infiltration with 10 mL of plain ropivacaine 0.25%|
214614403|NCT02164929|DRUG|Lidocaine|1.5% lidocaine
214614404|NCT02164929|DRUG|Epinephrine|1:200,000 epinephrine
214614405|NCT02164929|DRUG|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
214614406|NCT06482736|DEVICE|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy could reduce the pain of myofascial pain syndrome by pain signal alteration, promoting angiogenesis and increasing perfusion in ischemic tissues induced by sensitization of nociceptors and muscle ischemia.
214614407|NCT00971178|DRUG|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
214614408|NCT00971178|DRUG|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
214614409|NCT00971178|DRUG|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
214614410|NCT03364244|DRUG|Sildenafil|"\[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
214614411|NCT01846728|DRUG|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
214614412|NCT02614365|BEHAVIORAL|Aerobic exercise|Cardiovascular fitness
214715346|NCT06133985|OTHER|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
214715347|NCT04494529|DRUG|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
214614413|NCT02614365|BEHAVIORAL|Stretch exercise|Muscle stretch
214614414|NCT02161575|DRUG|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
214614415|NCT01418807|PROCEDURE|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
214614416|NCT01418807|PROCEDURE|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
214614417|NCT05281133|OTHER|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
214614418|NCT01925573|DEVICE|Optune(NOVOTTF-100A)|
214614419|NCT04404387|DRUG|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
214614420|NCT04404387|DRUG|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
214614421|NCT05753072|OTHER|Carer Support Nurse|Specialist community nursing role to support unpaid family/carers with complex health-related support needs or unresolved health-related support needs that cannot be met by their usual health care team
214614422|NCT00424749|DRUG|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m\^2.
214614423|NCT00424749|DRUG|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
214614424|NCT01667770|PROCEDURE|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
214614425|NCT06387511|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax|"1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm.~2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions.~3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward.~4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth.~5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first.~6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program."
214614426|NCT06387511|BEHAVIORAL|Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices|"1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages."
214614427|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler|
214614428|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
214614429|NCT03060044|DRUG|Seretide Diskus|
214614430|NCT03060044|DRUG|Seretide Diskus with charcoal|
214614431|NCT04107415|OTHER|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
214614432|NCT03753646|OTHER|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
214614433|NCT01879995|PROCEDURE||
214614434|NCT00938808|DIETARY_SUPPLEMENT|day formula diet|The Cambridge Programme. Formula diet
214614435|NCT02446314|DIETARY_SUPPLEMENT|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
214614436|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
214614437|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
214614438|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
214614439|NCT04670185|BEHAVIORAL|BIP SAMBA|Behavioral parent management training
214614440|NCT00182312|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
214614441|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 3mg/0.5ml
214614442|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 1mg/0.5ml
214614443|NCT05138809|BEHAVIORAL|Exercise|Use online exercise platform
214614444|NCT01540253|DRUG|PI3K inhibitor BKM120|Given PO
214614445|NCT01540253|DRUG|docetaxel|Given IV
214614446|NCT01540253|OTHER|pharmacological study|Correlative studies
214614447|NCT01540253|OTHER|questionnaire administration|Ancillary studies
214614448|NCT01540253|OTHER|laboratory biomarker analysis|Correlative studies
214614449|NCT06850077|BEHAVIORAL|Cognitive-Balance dual task|"The cognitive-balance dual task consists of three levels of difficulty and is performed simultaneously.~The cognitive tasks include the N-back test, while the balance tasks consist of static balance tasks."
214614450|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
214614451|NCT06440616|DEVICE|Spectral CT images generated by a photon counting CT scanner|The reading radiologist will in the experimental arm have access to spectral CT images in the form of low virtual monoenergetic images, virtual non-contrast images, iodine maps and effective atomic number. In the non-interventional arms the reading radiologist will only have access to conventional CT images.
214614452|NCT04117776|OTHER|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
214614453|NCT04117776|OTHER|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
214614454|NCT04109222|BIOLOGICAL|Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214614455|NCT04109222|BIOLOGICAL|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214614456|NCT06449651|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
214614457|NCT06449651|DRUG|Placebo|Placebo will be administered intravenously.
214715348|NCT04494529|DRUG|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
214715349|NCT03780985|PROCEDURE|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
214715350|NCT03780985|PROCEDURE|Cesarean section|to delivery of the fetus
214715351|NCT03780985|PROCEDURE|Suture|to fix the intrauterine device
214715352|NCT02281981|DIETARY_SUPPLEMENT|Curcumin|333mg CurcuWin OAHTCUR002-2014
214614458|NCT05644652|OTHER|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training."
214614459|NCT05644652|OTHER|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
214614460|NCT03023059|DRUG|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
214614461|NCT06055257|DRUG|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
214614462|NCT06055257|DRUG|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
214614463|NCT04696809|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
214614464|NCT02138617|DRUG|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
214614465|NCT02138617|DRUG|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
214614466|NCT02138617|DRUG|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
214614467|NCT02138617|DRUG|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
214614468|NCT05660083|DRUG|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
214614469|NCT05628727|OTHER|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
214614470|NCT05628727|OTHER|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
214715353|NCT02281981|DIETARY_SUPPLEMENT|Placebo|OAHTCUR005-2014
214715354|NCT03443895|DRUG|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
214715355|NCT03443895|DRUG|Placebo oral capsule|Matching placebo capsule
214715356|NCT00297128|DRUG|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
214715357|NCT00297128|DRUG|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
214715358|NCT00810043|DEVICE|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
214715359|NCT05330624|BIOLOGICAL|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
214715360|NCT01220505|PROCEDURE|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
214715361|NCT02251678|DIETARY_SUPPLEMENT|Elimune Capsules|2 capsules BID for 28 days
214614471|NCT02609776|DRUG|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
214614472|NCT02609776|DRUG|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
214614473|NCT02609776|DRUG|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
214614474|NCT02609776|DRUG|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
214614475|NCT02609776|DRUG|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
214614476|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
214614477|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
214715362|NCT01989754|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
214715363|NCT01989754|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
214715364|NCT01989754|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
214715365|NCT00201981|DRUG|Rebamipide|"1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
214715366|NCT04705987|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
214715367|NCT04705987|DRUG|Placebo|Placebo 1c/24h Treatment 8 weeks
214715368|NCT00003777|DRUG|amifostine trihydrate|
214715369|NCT00003777|DRUG|cisplatin|
214715370|NCT00003777|DRUG|fluorouracil|
214614478|NCT06106945|DRUG|AZD0305|AZD0305
214614479|NCT06150417|DRUG|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
214715371|NCT00003777|PROCEDURE|surgical procedure|
214715372|NCT00003777|RADIATION|radiation therapy|
214715373|NCT01994317|OTHER|Algorithm|IV sedation dosing calculated by algorithm
214715374|NCT01994317|OTHER|Standard care|IV sedation dosing calculated by standard care.
214715375|NCT01659268|OTHER|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
214715376|NCT01659268|OTHER|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
214715377|NCT01618526|DIETARY_SUPPLEMENT|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
214614480|NCT06150417|DRUG|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
214614481|NCT06150417|OTHER|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection"
214614482|NCT06150417|RADIATION|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
214614483|NCT06435858|DRUG|Empagliflozin|Empagliflozin 10mg
214614484|NCT06435858|DRUG|Placebo|Placebo capsule
214614485|NCT05788042|DEVICE|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
214614486|NCT05788042|DEVICE|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
214614487|NCT02686125|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
214614488|NCT05083182|DRUG|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
214614489|NCT05083182|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214614490|NCT06961968|DRUG|iloperidone|iloperidone LAI
214614491|NCT06961968|DRUG|placebo|matching placebo
214614492|NCT06550895|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
214614493|NCT06550895|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214715378|NCT01618526|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
214614494|NCT04153344|OTHER|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
214614495|NCT04153344|OTHER|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
214614496|NCT05957276|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
214614497|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
214614498|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
214614499|NCT06452238|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
214614500|NCT06452238|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound-guided transversus abdominis plane block.
214614501|NCT00606346|BIOLOGICAL|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
214614502|NCT00606346|DRUG|No Biologics|Treatments will be prescribed according to investigator judgement.
214614503|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
214614504|NCT06129591|DRUG|Vantage Hemp CBD Isolate + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
214614505|NCT06129591|DRUG|Silicone patch|"Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
214614506|NCT06351020|DRUG|LM-302|LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
214614507|NCT06351020|DRUG|Apatinib|The subjects will receive Apatinib orally,qd
214614508|NCT06351020|DRUG|Irinotecan|The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
214614509|NCT00125762|DEVICE|FibroScan|
214614510|NCT05343897|BEHAVIORAL|Low intensity exercise - Ping-Shuai Gong (PSG)|Participants were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
214614511|NCT05343897|BEHAVIORAL|Low intensity exercise - Arm-Swing Exercise (ASE)|Participants were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
214614512|NCT06166979|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)
214614513|NCT06166979|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
214614514|NCT05486026|DRUG|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
214614515|NCT05486026|DRUG|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
214614516|NCT05888324|OTHER|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
214715379|NCT01110226|DRUG|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
214715380|NCT01110226|DRUG|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
214715381|NCT02379312|DIETARY_SUPPLEMENT|Very low energy aerated beverage|
214614517|NCT04689659|BIOLOGICAL|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
214614518|NCT03648359|PROCEDURE|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
214614519|NCT05911750|DIAGNOSTIC_TEST|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
214614520|NCT03372109|DIETARY_SUPPLEMENT|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
214614521|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral capsules|Multivitamin/mineral supplement
214614522|NCT03372109|DIETARY_SUPPLEMENT|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
214614523|NCT03372109|DIETARY_SUPPLEMENT|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
214614524|NCT03372109|DIETARY_SUPPLEMENT|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
214614525|NCT03372109|DIETARY_SUPPLEMENT|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
214715382|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 1|
214614526|NCT03372109|DIETARY_SUPPLEMENT|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
214614527|NCT03372109|DIETARY_SUPPLEMENT|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
214715383|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 2|
214715384|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 3|
214715385|NCT01789658|OTHER|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
214715386|NCT02595268|DRUG|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
214614528|NCT03372109|DIETARY_SUPPLEMENT|Saffron extract capsule|Saffron extract 88.25mg/capsule
214614529|NCT03372109|DIETARY_SUPPLEMENT|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
214614530|NCT03372109|DIETARY_SUPPLEMENT|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
214614531|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
214614532|NCT01951079|DRUG|Intra-amniotic injection of DIGOXIN|
214614533|NCT03373981|DEVICE|rTMS|repetitive transcranial magnetic stimulation
214614534|NCT04434196|DRUG|CC-99282|CC-99282
214614535|NCT04434196|DRUG|Obinutuzumab|Obinutuzumab
214614536|NCT01017588|DEVICE|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
214614537|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
214614538|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
214614539|NCT03021148|OTHER|Questionnaire|Administration of questionnaire.
214614540|NCT02015325|BEHAVIORAL|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
214614541|NCT03019250|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
214614542|NCT03019250|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
214614543|NCT04301232|OTHER|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg \> preanesthetic level, 20 - 50 mm Hg \> preanesthetic level, 50 mm Hg \> preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 \> 92% on room air, Supplemental O2 required to maintain SpO2 \> 90%,SpO2 \< 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
214715387|NCT02595268|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
214715388|NCT04857788|OTHER|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
214715389|NCT01498588|DRUG|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
214715390|NCT01498588|DRUG|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
214715391|NCT01498588|DRUG|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
214715392|NCT01498588|DRUG|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
214715393|NCT00480207|DIETARY_SUPPLEMENT|folic acid|
214715394|NCT00480207|DIETARY_SUPPLEMENT|omega-3|
214715395|NCT00480207|DIETARY_SUPPLEMENT|vit B12|
214715396|NCT00480207|OTHER|folic acid placebo|
214715397|NCT00480207|OTHER|omega-3 placebo|
214715398|NCT03364491|DRUG|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
214715399|NCT03364491|DRUG|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
214614544|NCT04301232|OTHER|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)\<15%, Blood pressure 15-30%, Blood pressure\>30%, Level of consciousness,(Awake\&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value\>90% on room air, Requires supplemental oxygen, Saturation\<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea\&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score\<1 in any individual category)would be required for a patient after general anesthesia
214614545|NCT04301232|OTHER|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in room air Y/N, Pain Control (VAS \< 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
214614546|NCT04095780|OTHER|Advanced oral hygiene care programme|"1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education"
214715400|NCT06357884|PROCEDURE|Callus debridement|Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
214614547|NCT04095780|OTHER|Oral hygiene instruction|Oral hygiene education
214614548|NCT04431336|BEHAVIORAL|movement|movement
214614549|NCT04537546|DEVICE|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
214614550|NCT05573776|OTHER|Exercise Therapy, High Protein supplement|patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
214614551|NCT00779922|DRUG|lenalidomide|
214614552|NCT05394220|DIAGNOSTIC_TEST|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
214614553|NCT01039077|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
214715401|NCT01369225|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
214715402|NCT01369225|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
214715403|NCT01369225|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
214614554|NCT00702754|BIOLOGICAL|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
214614555|NCT05374382|BEHAVIORAL|Strengthening|3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery
214614556|NCT05374382|BEHAVIORAL|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
214614557|NCT03165435|BIOLOGICAL|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
214614558|NCT03165435|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
214614559|NCT05534906|OTHER|Blood & Urine Samples|Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
214614560|NCT05534906|OTHER|Imaging|MRI \& MRE Scans
214614561|NCT03172832|PROCEDURE|PTBD|Percutaneous access and tube placement into the bile duct
214614562|NCT03172832|PROCEDURE|ERC|Endoscopic access and stent placement in the bile duct
214614563|NCT04994197|OTHER|Observational study only - no intervention|Observational study only - no intervention
214715404|NCT01369225|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
214715405|NCT01369225|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
214715406|NCT05127291|OTHER|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
214715407|NCT04354441|DRUG|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
214715408|NCT04354441|DRUG|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
214614564|NCT02432222|BEHAVIORAL|Visual Arts Training|Visual arts training
214614565|NCT02432222|BEHAVIORAL|Music Training|Music training
214614566|NCT06397417|OTHER|Data collection|The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
214614567|NCT00006090|DRUG|arsenic trioxide|
214614568|NCT00520728|BEHAVIORAL|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
214614569|NCT04094753|DIAGNOSTIC_TEST|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
214614570|NCT04094753|DIAGNOSTIC_TEST|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
214614571|NCT04094753|DIAGNOSTIC_TEST|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
214614572|NCT04094753|DIAGNOSTIC_TEST|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
214614573|NCT04094753|DIAGNOSTIC_TEST|Questionaires|"Patients have to fulfill the following questionaires~* ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~* TILBURG FRAILTY INDICATOR~* SF-36 Quality of Life score~* N- QOL"
214614574|NCT04094753|DIAGNOSTIC_TEST|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
214614575|NCT04094753|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
214614576|NCT06267170|DRUG|Adebrelimab|Treatment with adbelizumab
214614577|NCT04269148|OTHER|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
214614578|NCT02295345|OTHER|Cognitive Behavioural Therapy for Insomnia|
214614579|NCT02403362|DRUG|EPO-018B|
214614580|NCT00894062|DEVICE|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
214614581|NCT00894062|DEVICE|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
214614582|NCT00596947|DRUG|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
214614583|NCT00596947|DRUG|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
214614584|NCT00596947|DRUG|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
214614585|NCT00596947|DRUG|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
214614586|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
214715409|NCT02108834|PROCEDURE|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
214715410|NCT02108834|PROCEDURE|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
214715411|NCT00695513|DIETARY_SUPPLEMENT|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
214614587|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
214614588|NCT02427451|DRUG|Bcl-2 Inhibitor GDC-0199|Given PO
214614589|NCT02427451|BIOLOGICAL|Obinutuzumab|Given IV
214614590|NCT02427451|DRUG|Ibrutinib|Given PO
214614591|NCT02427451|OTHER|Pharmacological Study|Correlative studies
214614592|NCT02427451|OTHER|Laboratory Biomarker Analysis|Correlative studies
214614593|NCT02427451|OTHER|Quality-of-Life Assessment|Ancillary studies
214614594|NCT02884063|PROCEDURE|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
214614595|NCT00496730|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
214614596|NCT00496730|DRUG|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
214614597|NCT01984372|DRUG|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
214614598|NCT04383873|DEVICE|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
214614599|NCT04383873|OTHER|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
214614600|NCT04383873|OTHER|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
214614601|NCT03556436|DRUG|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
214614602|NCT04646785|BEHAVIORAL|Mindfulness-based cognitive therapy + TAU|The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).
214614603|NCT04646785|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
214614604|NCT05541822|DRUG|Vabametkib|"Tablets~Route of Administration: Oral"
214614605|NCT05541822|DRUG|Lazertinib|"Tablets~Route of Administration: Oral"
214614606|NCT00016380|DRUG|dexamethasone|
214614607|NCT00016380|DRUG|ondansetron|
214614608|NCT00016380|PROCEDURE|quality-of-life assessment|
214614609|NCT02923089|OTHER|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614610|NCT02923089|OTHER|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614611|NCT02923089|OTHER|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614612|NCT02923089|OTHER|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614613|NCT02923089|OTHER|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614614|NCT02923089|OTHER|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614615|NCT02923089|OTHER|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614616|NCT02923089|OTHER|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614617|NCT02923089|OTHER|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
214614618|NCT00152555|BEHAVIORAL|Physical Therapy or Relaxation Therapy|
214614619|NCT00990054|DRUG|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
214614620|NCT01365585|DRUG|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
214614621|NCT06006663|DRUG|Ibuprofen 400 mg.|synthetic intracanal medicament
214614622|NCT06006663|DRUG|modified triple antibiotic paste|synthetic intracanal medicament
214614623|NCT06006663|DIETARY_SUPPLEMENT|curcumin|herbal intracanal medicament
214614624|NCT06006663|DIETARY_SUPPLEMENT|olive leaves extract|herbal intracanal medicament
214614625|NCT01507779|BIOLOGICAL|IVACFLU|IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
214614626|NCT01507779|OTHER|Placebo|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
214614627|NCT00143195|DRUG|Amlodipine|
214614628|NCT00143195|DRUG|iso- 5 - mononitrate|
214614629|NCT00143195|PROCEDURE|Blood tests|
214614630|NCT00143195|PROCEDURE|Exercise Stress Test|
214614631|NCT04843046|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
214614632|NCT04843046|DRUG|Pioglitazone|Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.
214614633|NCT04843046|DRUG|Placebo|Placebo capsules will be filled with corn starch and riboflavin.
214614634|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II hemispherical cup
214614635|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II Tritanium cup
214614636|NCT06115187|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
214614637|NCT06115187|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
214614638|NCT00255762|DRUG|carboplatin|Given IV
214614639|NCT00255762|DRUG|paclitaxel|Given IV
214614640|NCT00255762|BIOLOGICAL|bevacizumab|Given IV
214614641|NCT00255762|OTHER|laboratory biomarker analysis|Correlative studies
214614642|NCT02801136|BEHAVIORAL|ReACT|
214614643|NCT02801136|BEHAVIORAL|Supportive Therapy|
214614644|NCT01037491|DRUG|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
214614645|NCT03502291|BIOLOGICAL|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
214614646|NCT03502291|BIOLOGICAL|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
214614647|NCT03502291|BIOLOGICAL|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
214614648|NCT03502291|BIOLOGICAL|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
214614649|NCT04237727|DEVICE|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
214614650|NCT04053647|OTHER|Non-interventional study|Non-interventional study
214614651|NCT00745407|DRUG|fenofibrate|
214614652|NCT05344794|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-6 and NE levels were detected.
214614653|NCT03654976|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
214614654|NCT03654976|OTHER|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
214614655|NCT05718817|DRUG|XEN1101|XEN1101 capsules
214614656|NCT05404399|BEHAVIORAL|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
214614657|NCT05404399|BEHAVIORAL|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
214614658|NCT00771134|DRUG|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
214614659|NCT00771134|DRUG|Placebo|B.I.D. for 8 weeks
214614660|NCT00771134|DRUG|Quetiapine|300mg/day for 8 weeks
214614661|NCT00956397|DRUG|Rifaximin|rifaximin 550 mg TID PO x 10 days
214614662|NCT00956397|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
214614663|NCT00956397|DRUG|Placebo|placebo TID x 10 days
214614664|NCT02354014|DRUG|Bedaquiline (TMC207)|Bedaquiline (TMC207) oral tablet adult formulation (containing 100 mg bedaquiline (TMC207) per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg bedaquiline . Bedaquiline tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of bedaquiline 8 mg/kg qd for the first 2 weeks, followed by bedaquiline 4 mg/kg times weekly (TIW) with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, bedaquiline (TMC207) qd for the first 2 weeks, followed by bedaquiline TIW with intakes at least 2 days (48 hours) apart for 22 weeks.
214614665|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
214614666|NCT04451577|OTHER|No intervention|No intervention, analysis of biological samples
214614667|NCT03956914|OTHER|Placebo|Placeob water 440 ml/day for 8 weeks
214614668|NCT03956914|OTHER|Deep sea water|Deep sea water 440 ml/day for 8 weeks
214614669|NCT00901771|DEVICE|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
214614670|NCT05095870|OTHER|No intervention|Pure observational study
214715412|NCT01153906|OTHER|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
214715413|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
214715414|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
214614671|NCT02198703|DIETARY_SUPPLEMENT|Probiotics bacterial strains|
214614672|NCT02198703|DIETARY_SUPPLEMENT|Placebo|
214614673|NCT00595322|OTHER|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
214614674|NCT00788281|PROCEDURE|laparoscopic surgery|surgery would be performed by laparoscope
214614675|NCT00788281|PROCEDURE|open surgery|surgery would be performed by traditional surgery.
214614676|NCT06492616|DRUG|Elacestrant|Administered as oral tablets
214614677|NCT06492616|DRUG|Anastrozole|Administered as oral tablets
214614678|NCT06492616|DRUG|Letrozole|Administered as oral tablets
214614679|NCT06492616|DRUG|Exemestane|Administered as oral tablets
214614680|NCT06492616|DRUG|Tamoxifen|Administered as oral tablets
214614681|NCT03295370|PROCEDURE|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
214614682|NCT00236925|DRUG|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
214614683|NCT00236925|DRUG|Placebo|Placebo
214614684|NCT03098836|DRUG|ARN-509|240 mg orally daily
214614685|NCT03098836|DRUG|Abiraterone Acetate|1000 mg orally daily
214614686|NCT03098836|DRUG|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
214715415|NCT00646568|DRUG|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
214715416|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
214715417|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
214715418|NCT05352867|OTHER|Placebo|0.5ml/person
214614687|NCT04820400|OTHER|Immersive VR Video|"The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft."
214614688|NCT00617500|OTHER|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
214614689|NCT00617500|OTHER|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
214614690|NCT00617500|OTHER|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
214614691|NCT00617500|DRUG|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
214614692|NCT04118296|DRUG|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
214614693|NCT03521375|PROCEDURE|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
214614694|NCT03521375|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
214614695|NCT04227262|OTHER|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
214614696|NCT01586351|DEVICE|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
214614697|NCT04970225|OTHER|1 blood sample|4 tubes of 7 ml per sample (a single sample)
214614698|NCT04970225|OTHER|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
214614699|NCT06284265|DRUG|Raphamin|Tablet for oral use.
214614700|NCT06284265|DRUG|Placebo|Tablet for oral use.
214614701|NCT05834309|OTHER|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
214614702|NCT03843281|DRUG|Paracetamol|s. above
214614703|NCT03843281|DRUG|Placebo|s. above
214614704|NCT03843281|DRUG|Morphine|s. above
214614705|NCT05088408|DIETARY_SUPPLEMENT|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
214715419|NCT04198519|OTHER|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
214715420|NCT02980692|DRUG|SUNPG1623 I|injection
214715421|NCT02980692|DRUG|SUNPG1623 II|injection
214715422|NCT02980692|DRUG|SUNPG1623 III|injection
214715423|NCT02980692|DRUG|SUNPG1623 IV|injection
214715424|NCT02980692|DRUG|PLACEBO|injection
214715425|NCT01788150|DEVICE|Coronary Stenting|
214715426|NCT05657509|OTHER|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.
214715427|NCT05657509|OTHER|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
214715428|NCT02972112|BEHAVIORAL|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
214715429|NCT02972112|OTHER|Sham|standard birth preparation sessions.
214614706|NCT05088408|OTHER|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
214614707|NCT03208751|BEHAVIORAL|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
214614708|NCT01965977|DRUG|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
214614709|NCT02803528|DRUG|Biodentine|Biodentine is going to be used as the direct pulp capping material
214614710|NCT02803528|DRUG|MTA|MTA is going to be used as the direct pulp capping material in the second group
214614711|NCT00631501|DRUG|Placebo|
214614712|NCT00631501|DRUG|Doxycycline|
214715430|NCT03368326|DIAGNOSTIC_TEST|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
214715431|NCT03040765|DRUG|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
214614713|NCT00898443|OTHER|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
214614714|NCT00898443|OTHER|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
214614715|NCT01028950|DRUG|YM150|oral
214715432|NCT03040765|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
214715433|NCT05491447|DRUG|BMX-010|Ointment
214715434|NCT05491447|DRUG|Placebo|Ointment
214715435|NCT01478295|BEHAVIORAL|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
214715436|NCT01478295|OTHER|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
214715437|NCT05561894|OTHER|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
214715438|NCT00000324|DRUG|Tryptophan|
214715439|NCT06211127|DEVICE|Cold laser plaque ablation|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
214715440|NCT06211127|DEVICE|The excimer laser|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
214614716|NCT05998083|OTHER|exercise|"In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations."
214715441|NCT03607071|DRUG|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
214614717|NCT05998083|OTHER|control|The control group continued only the individual support education program.
214614718|NCT00656773|DRUG|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
214715442|NCT03140124|BEHAVIORAL|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
214715443|NCT03140124|BEHAVIORAL|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
214614719|NCT00656773|DRUG|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
214614720|NCT05022849|DRUG|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
214614721|NCT05022849|DRUG|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
214614722|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
214715444|NCT00064077|DRUG|Cisplatin|Given IV
214614723|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
214614724|NCT06001112|OTHER|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
214614725|NCT06001112|DRUG|Etoricoxib|etoricoxib 120mg
214614726|NCT05330247|OTHER|Carbohydrate-reduced high-protein (CRHP) Diet|Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.
214614727|NCT05330247|OTHER|Conventional diabetes (CD) Diet|Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
214614728|NCT05784441|DRUG|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
214614729|NCT03591848|BEHAVIORAL|Online support decision tool|Online support decision tool, in addition of the standard oral information
214614730|NCT03591848|BEHAVIORAL|standard oral information|standard oral information
214715445|NCT00064077|DRUG|Gemcitabine Hydrochloride|
214715446|NCT00064077|DRUG|Paclitaxel|Given IV
214715447|NCT00064077|OTHER|Quality-of-Life Assessment|Ancillary studies
214715448|NCT00064077|DRUG|Topotecan Hydrochloride|Given IV
214715449|NCT00064077|DRUG|Vinorelbine Tartrate|Given IV
214715450|NCT00182507|DRUG|Olanzapine|
214614731|NCT06235840|BEHAVIORAL|working memory adaptive training|The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each
214614732|NCT06235840|BEHAVIORAL|multi-domain non-adaptive control training|The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
214614733|NCT04695392|OTHER|R2 Bundle|"During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries."
214614734|NCT00422526|DRUG|Micronised progesterone (Utrogestan)|
214614735|NCT04444960|PROCEDURE|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
214614736|NCT00691990|PROCEDURE|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
214614737|NCT05370885|BIOLOGICAL|VE202|VE202 is a rationally defined, live biotherapeutic product for oral administration.
214614738|NCT05370885|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection
214614739|NCT05370885|OTHER|VE202 Placebo|VE202 Placebo
214614740|NCT05370885|OTHER|Vancomycin Placebo|Vancomycin Placebo
214614741|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
214614742|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
214614743|NCT03929081|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
214614744|NCT03929081|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
214614745|NCT02871804|PROCEDURE|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
214614746|NCT02871804|PROCEDURE|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
214614747|NCT03517787|OTHER|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
214614748|NCT03517787|OTHER|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
214614749|NCT03517787|OTHER|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
214614750|NCT03517787|OTHER|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
214614751|NCT04620850|DEVICE|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
214614752|NCT03484286|DEVICE|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
214614753|NCT03484286|OTHER|Standard care|Patients in the control group will be subject to standard heart failure care.
214614754|NCT06004648|PROCEDURE|Upper extremity surgery|Comparison of 2 different peripheral nerve blocks
214715451|NCT01204307|DRUG|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
214715452|NCT01204307|DRUG|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
214715453|NCT05913518|DEVICE|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
214715454|NCT05913518|DEVICE|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
214715455|NCT05318040|DRUG|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
214715456|NCT05318040|DRUG|Placebo|Placebo will be provided as visually matching placebo capsules.
214715457|NCT01100294|BIOLOGICAL|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
214715458|NCT04414488|PROCEDURE|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
214715459|NCT03497611|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
214715460|NCT03459404|COMBINATION_PRODUCT|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
214715461|NCT05544071|DEVICE|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
214614755|NCT05009927|DRUG|Imatinib tablets|Imatinib interruption
214715462|NCT04280406|DRUG|Azithromycin|azithromycin 500mg one hour before implant placement
214715463|NCT04280406|DRUG|Placebo oral tablet|identical placebo one hour before implant placement
214715464|NCT00948038|DIETARY_SUPPLEMENT|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
214715465|NCT00948038|DIETARY_SUPPLEMENT|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
214614756|NCT02741869|DEVICE|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
214614757|NCT04123236|OTHER|Age 0-18|Patients under 18 years of age
214614758|NCT04123236|OTHER|Age 18-26|Patients over18 years of age
214715466|NCT00683007|OTHER|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
214715467|NCT00683007|OTHER|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
214715468|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
214715469|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
214715470|NCT05097157|DEVICE|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
214614759|NCT04123236|OTHER|Girls|Girls
214614760|NCT04123236|OTHER|Boys|Boys
214614761|NCT00427349|DRUG|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
214614762|NCT00427349|DRUG|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
214614763|NCT04743921|DEVICE|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
214614764|NCT01651858|DRUG|Nurigra Chewable tablet|1 tablet of 100mg, once a day
214614765|NCT00924105|DRUG|CYT013-IL1bQb|s.c. injection
214614766|NCT00924105|DRUG|Placebo|s.c. injection
214614767|NCT01660321|DRUG|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
214614768|NCT04860271|PROCEDURE|Manual Acupuncture|Manual acupuncture treatment using different types of needle
214614769|NCT00441181|DRUG|Travoprost|
214614770|NCT00698997|BEHAVIORAL|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
214614771|NCT00698997|BEHAVIORAL|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
214614772|NCT00978549|DRUG|docetaxel|
214614773|NCT00978549|DRUG|steroid therapy|
214614774|NCT00978549|OTHER|questionnaire administration|
214614775|NCT00978549|PROCEDURE|nausea and vomiting therapy|
214614776|NCT00978549|PROCEDURE|pain therapy|
214614777|NCT00978549|PROCEDURE|quality-of-life assessment|
214614778|NCT00978549|PROCEDURE|standard follow-up care|
214614779|NCT00978549|RADIATION|radiation therapy|
214614780|NCT00002128|DRUG|Adefovir dipivoxil|
214614781|NCT02720770|DRUG|norditropine simplex|
214614782|NCT03041350|OTHER|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
214614783|NCT03256955|DEVICE|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
214614784|NCT03256955|DEVICE|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
214614785|NCT03491007|DRUG|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
214614786|NCT05082376|DRUG|CLM Original|Sunscreen lip balm.
214614787|NCT03130062|OTHER|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
214614788|NCT01350921|DRUG|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
214614789|NCT01350921|DRUG|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
214614790|NCT00360906|DRUG|Triomar™ (omega-3 fatty acids)|
214614791|NCT06198803|DRUG|L Carnitine|The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
214614792|NCT05453903|DRUG|Bleximenib|Participants will receive bleximenib.
214614793|NCT05453903|DRUG|Venetoclax (VEN)|Participants will receive VEN.
214614794|NCT05453903|DRUG|Azacitidine (AZA)|Participants will receive AZA.
214614795|NCT05453903|DRUG|Cytarabine|Participants will receive cytarabine.
214614796|NCT05453903|DRUG|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin.
214614797|NCT00649259|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
214614798|NCT00649259|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
214614799|NCT05911659|DRUG|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
214614800|NCT02478970|DEVICE|Konan SP4000|current standard of care at Kellogg Eye Center
214715471|NCT01604096|OTHER|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
214614801|NCT02478970|DEVICE|NIDEK CEM-350|newly marketed device
214614802|NCT02513849|DRUG|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
214614803|NCT00538330|DRUG|Tamoxifen|Tamoxifen
214614804|NCT01398020|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
214614805|NCT01398020|DRUG|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
214614806|NCT04722770|DEVICE|PhotoniCare OtoSight Middle Ear Scope|PhotoniCare OtoSight imaging using a near-infrared laser
214614807|NCT02802748|DRUG|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
214614808|NCT02802748|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
214614809|NCT00162760|DRUG|Thalidomide|
214614810|NCT06015139|DEVICE|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
214614811|NCT06015139|DEVICE|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
214614812|NCT01415128|DRUG|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
214614813|NCT01415128|DRUG|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
214614814|NCT01415128|DRUG|Desipramine|Single dose of Desipramine (50 mg) for 1 day
214614815|NCT04825795|DRUG|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
214614816|NCT04825795|DRUG|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
214614817|NCT04354220|DIAGNOSTIC_TEST|capnography monitoring|routinely used capnography monitoring
214614818|NCT04354220|DIAGNOSTIC_TEST|arterial blood gas|Routinely taken arterial blood gas values
214614819|NCT03388918|DEVICE|Telerehabilitation|Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
214614820|NCT05167682|OTHER|Prehabilitation program|Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
214614821|NCT00071942|BIOLOGICAL|recombinant vaccinia-MUC1 vaccine|Given intradermally
214614822|NCT00071942|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|Given intradermally
214614823|NCT00071942|OTHER|laboratory biomarker analysis|Correlative studies
214614824|NCT00071942|PROCEDURE|quality-of-life assessment|Ancillary studies
214614825|NCT02911506|OTHER|Polysomnography|
214614826|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
214614827|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
214614828|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
214614829|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
214614830|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
214614831|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
214614832|NCT05269342|BEHAVIORAL|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
214614833|NCT01877915|DRUG|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
214614834|NCT01877915|DRUG|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
214715472|NCT01647425|BEHAVIORAL|physician assessment|"* Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0"
214715473|NCT00054444|DRUG|Topotecan Hydrochloride Liposomes|Given IV
214715474|NCT00054444|RADIATION|3-Dimensional Conformal Radiation Therapy|
214715475|NCT00054444|DRUG|Cisplatin|Given IV
214715476|NCT05446922|OTHER|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
214715477|NCT06149754|DEVICE|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
214715478|NCT01112982|OTHER|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
214715479|NCT01112982|DRUG|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
214715480|NCT01112982|DRUG|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
214715481|NCT06359704|BEHAVIORAL|Caregivers Of dementia Processing Emotions (COPE) program|a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
214715482|NCT00361023|DRUG|losartan|
214715483|NCT06364384|COMBINATION_PRODUCT|PD-1 and CRT|Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
214715484|NCT00649168|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
214715485|NCT00649168|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
214715486|NCT00314041|BIOLOGICAL|Meningococcal C|
214715487|NCT00314041|BIOLOGICAL|DTP/Hib|
214715488|NCT00088114|DRUG|STA-4783/paclitaxel|
214715489|NCT02979028|DEVICE|TEAS|Transcutaneous electrical acupoint stimulation
214715490|NCT04430790|DRUG|Doxapram|Loading dose and continuous doxapram infusion.
214715491|NCT04430790|DRUG|Placebo|Loading dose and continuous placebo infusion.
214715492|NCT05263349|OTHER|Typical Dreams Questionnaire|"Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003)."
214715493|NCT05263349|OTHER|HAD Questionnaire|"The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21)."
214715494|NCT05263349|OTHER|Dream Booklet|The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
214614835|NCT01877915|OTHER|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
214614836|NCT00626249|DRUG|Technosphere Inhalation Powder|Technosphere Inhalation Powder
214614837|NCT04839601|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
214614838|NCT06118268|DEVICE|iTBS (Active)|"The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands)."
214614839|NCT06118268|DEVICE|iTBS (Sham)|DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
214614840|NCT02678143|DRUG|Alemtuzumab|
214614841|NCT02678143|DRUG|Cyclophosphamide|
214614842|NCT02678143|DRUG|Mycophenolate mofetil|
214614843|NCT02678143|DRUG|Sirolimus|
214614844|NCT02678143|DRUG|Fludarabine|
214614845|NCT02678143|RADIATION|Total body irradiation|
214614846|NCT02678143|PROCEDURE|Hematopoietic stem cell transplant|
214614847|NCT00612261|PROCEDURE|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
214614848|NCT00612261|PROCEDURE|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
214614849|NCT00943579|DRUG|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
214614850|NCT00546767|BEHAVIORAL|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
214614851|NCT00546767|BEHAVIORAL|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
214715495|NCT05392166|DIAGNOSTIC_TEST|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
214715496|NCT00300534|DEVICE|Abbott Laboratories Determine test for syphilis|
214715497|NCT00300534|DEVICE|Investigational syphilis immunochromatographic strip test|
214715498|NCT00004234|PROCEDURE|management of therapy complications|
214715499|NCT00004234|RADIATION|radiation therapy|
214715500|NCT04994704|DRUG|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
214715501|NCT04994704|DRUG|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
214715502|NCT03504436|DEVICE|LEO +|LEO +: self-expanding intracranial stent
214715503|NCT05800834|DRUG|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
214614852|NCT00546767|BEHAVIORAL|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
214614853|NCT00546767|BEHAVIORAL|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
214614854|NCT06781632|DRUG|ropivacaine|Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)
214614855|NCT06236724|DRUG|Asciminib|Given by PO
214715504|NCT05800834|DRUG|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
214715505|NCT02295800|OTHER|Standard of care|
214715506|NCT02295800|OTHER|Semi-structured interviews|
214715507|NCT05774613|DIETARY_SUPPLEMENT|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
214614856|NCT05876221|DRUG|Cablivi|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
214614857|NCT06149559|DRUG|rozanolixizumab|rozanolixizumab solution for injection
214715508|NCT00702728|DRUG|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
214614858|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
214614859|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
214614860|NCT06316102|BEHAVIORAL|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|Multilevel intervention with 4 components
214614861|NCT05961085|PROCEDURE|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
214614862|NCT05338515|DRUG|Selpercatinib|Administered orally.
214715509|NCT00702728|DRUG|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
214614863|NCT05714969|BIOLOGICAL|TAK-755|TAK-755 IV infusion
214614864|NCT05036603|OTHER|chest physiotherapy|diffferent chest physiotherapy methods
214614865|NCT01315639|BIOLOGICAL|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
214715510|NCT00049504|DRUG|cyclophosphamide|Given IV
214715511|NCT00049504|DRUG|fludarabine phosphate|Given IV
214715512|NCT00049504|DRUG|tacrolimus|Given IV or orally
214715513|NCT00049504|DRUG|mycophenolate mofetil|Given orally
214715514|NCT00049504|GENETIC|polymerase chain reaction|Correlative studies
214715515|NCT00049504|GENETIC|fluorescence in situ hybridization|Correlative studies
214715516|NCT00049504|GENETIC|polymorphism analysis|Correlative studies
214715517|NCT00049504|GENETIC|gene expression analysis|Correlative studies
214715518|NCT00049504|RADIATION|total-body irradiation|Undergo total-body irradiation
214715519|NCT00049504|PROCEDURE|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
214614866|NCT05405803|BEHAVIORAL|Web-App based Lifestyle Physical Activity Promotion Program|"WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences.~The program includes 3 components in 2 languages (English and Korean):~1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers.~2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity.~3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.).~Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls."
214614867|NCT05405803|BEHAVIORAL|The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines|A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.
214614868|NCT05977959|BEHAVIORAL|Mentoring Program|Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.
214614869|NCT05977959|BEHAVIORAL|Enhanced Resources|Schools in this group will receive extra resources such as program incentives to aid in program implementation.
214614870|NCT05977959|BEHAVIORAL|Enhanced Engagement|Schools in this group will participate in program contests to aid program implementation.
214614871|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
214614872|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
214614873|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
214614874|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
214614875|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
214614876|NCT04753853|PROCEDURE|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
214614877|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
214614878|NCT05925803|DRUG|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
214614879|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
214614880|NCT05848089|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
214614881|NCT05848089|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
214614882|NCT05848089|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
214614883|NCT02414399|DRUG|Azithromycin|oral administration of Azithromycin
214614884|NCT02414399|DRUG|Placebo|5 days of taste/appearance/bottle-matched inactive substance
214614885|NCT03755128|OTHER|No intervention|No investigational drugs will be administered as part of the study
214614886|NCT06361290|OTHER|Data collection from hospital medical records|Data collection from hospital medical records of patients concerning the 5 years following the resection of the tumor.
214614887|NCT02088112|DRUG|Gefitinib|Gefitinib QD
214614888|NCT02088112|DRUG|MEDI4736|MEDI4736 IV Q2W
214614889|NCT00929175|DEVICE|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
214614890|NCT00929175|DEVICE|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
214715520|NCT00049504|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
214614891|NCT06302348|DRUG|Sepiapterin|Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
214614892|NCT02715375|DEVICE|CREON2000A|
214614893|NCT00985803|OTHER|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
214614894|NCT00985803|OTHER|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
214614895|NCT02834221|DEVICE|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
214614896|NCT02834221|OTHER|Anatomical landmark guided puncture|Anatomical landmark puncture
214614897|NCT01502709|DEVICE|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
214614898|NCT01502709|DEVICE|placebo|Matching placebo device
214614899|NCT00732511|DRUG|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
214614900|NCT00732511|DRUG|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
214614901|NCT05745675|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
214715521|NCT02252757|DEVICE|CoVa|
214715522|NCT04717895|DIAGNOSTIC_TEST|Rocking environment forward (B) followed by a translation environment|Start by the virtual reality session by viewing a rocking environment followed by a translation environment
214614902|NCT03724071|BIOLOGICAL|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
214614903|NCT03724071|DRUG|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
214614904|NCT00959036|DRUG|ATN-103|10 mg every 4 weeks until week 12
214614905|NCT00959036|DRUG|ATN-103|10 mg every 8 weeks until week 12
214614906|NCT00959036|DRUG|ATN-103|30 mg every 4 weeks until week 12
214614907|NCT00959036|DRUG|ATN-103|80 mg every 4 weeks until week 12
214614908|NCT00959036|DRUG|ATN-103|80 mg every 8 weeks until week 12
214614909|NCT00959036|DRUG|Placebo|Placebo every 4 weeks
214614910|NCT00959036|DRUG|Methotrexate|
214614911|NCT04745871|DIAGNOSTIC_TEST|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA or 1,8-2,2 MBq/kg of 68Ga-PSMA-11 will be performed to patient by a single intravenous injection.
214614912|NCT01529177|DRUG|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
214614913|NCT01529177|DRUG|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
214614914|NCT04617938|BEHAVIORAL|TACUNA plus Wellness Circle|TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.
214614915|NCT04617938|BEHAVIORAL|Opioid Education Workshop|The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
214614916|NCT03110926|DRUG|mFOLFOX6|Induction Chemotherapy
214614917|NCT03110926|COMBINATION_PRODUCT|Chemoradiation|Chemoradiation
214614918|NCT06777641|OTHER|remote supervision|teacher use remote supervision to assist peer training
214614919|NCT00937937|DRUG|Dinaciclib|Given IV
214614920|NCT06138522|BEHAVIORAL|Semi-structured interviews|Semi-structured interviews
214614921|NCT06138522|BEHAVIORAL|Child Post-Traumatic Stress Response Index (CPTS-RI) scale|Child Post-Traumatic Stress Response Index (CPTS-RI) scale
214614922|NCT06138522|BEHAVIORAL|- Therapeutic Alliance Questionnaire (HAQ-CP)|\- Therapeutic Alliance Questionnaire (HAQ-CP)
214614923|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
214715523|NCT04717895|DIAGNOSTIC_TEST|Translation environment followed by a rocking environment|Start by the virtual reality session by viewing a translation environment followed by a rocking environment
214614924|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
214614925|NCT02715921|OTHER|Tele-exercise|
214614926|NCT04221815|DEVICE|Eagle Eye Platinum digital IVUS catheter with optional SyncVision|IVUS catheter
214614927|NCT04221815|DEVICE|Resolute Onyx Drug Eluting Stent|Stent
214614928|NCT04221815|DEVICE|Onyx Frontier Drug Eluting Stent|Stent
214614929|NCT04221815|DEVICE|Onyx TruStar Drug Eluting Stent|Stent
214614930|NCT04221815|DEVICE|Onyx TruCor Drug Eluting Stent|Stent
214614931|NCT06208787|BEHAVIORAL|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
214614932|NCT06208787|BEHAVIORAL|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
214715524|NCT00736593|DRUG|Nexagon™ or Nexagon™ vehicle|
214715525|NCT00334204|DEVICE|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
214715526|NCT02163772|PROCEDURE|Intracordal hyaluronate injection|
214614933|NCT04356664|DRUG|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
214715527|NCT00045357|BIOLOGICAL|therapeutic autologous lymphocytes|
214614934|NCT06790641|BEHAVIORAL|Program in Support of Moms (PRISM)|Program in Support of Moms (PRISM): a practice-level intervention with implementation support that helps obstetric practices integrate mental health care for perinatal individuals. To help obstetric practices implement pathways for screening, assessment, and a stepped intervention response for mental health problems and social determinants of health. PRISM offers training in trauma informed and equitable care, technical assistance, and implementation and change management support.
214614935|NCT06790641|BEHAVIORAL|PSI Peer Support|Postpartum Support International (PSI) Peer Support: a service administered by PSI that pairs perinatal individuals with a volunteer peer mentor who provides support, psychoeducation, behavioral activation, and navigation services, which includes planning, goal setting, and practical tools to manage parenting and mental health symptoms.
214614936|NCT06837129|DRUG|A single dose of 4 mg iv nalbuphine|prevention of nausea vomiting
214614937|NCT06157957|DIAGNOSTIC_TEST|Lung cancer screening with low dose CT scan|Low dose CT scan in active smokers or ex-smokers with an age between 50 and 75 years old
214614938|NCT04712396|DRUG|Capivasertib|Subects will be administered single doses of capiversatib on Day 1 and Day 6.
214614939|NCT04712396|DRUG|Itraconazole|Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
214614940|NCT03776474|BIOLOGICAL|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
214614941|NCT05238129|OTHER|No intervention - standard care is assessed|No intervention - standard care is assessed
214614942|NCT00532181|BEHAVIORAL|Savings Behavior and Consumer's Approach to Risk|
214614943|NCT00984490|DRUG|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
214614944|NCT00984490|OTHER|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
214614945|NCT00941161|DRUG|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
214614946|NCT00941161|DRUG|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
214614947|NCT00941161|DRUG|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
214614948|NCT00297635|DEVICE|GlucoDYNAMIX™ intervention system|
214614949|NCT00297635|DEVICE|GlucoMON™ telemetry device|
214614950|NCT04024228|BIOLOGICAL|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214614951|NCT04024228|BIOLOGICAL|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214614952|NCT01704040|DRUG|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
214614953|NCT01704040|DRUG|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
214614954|NCT01704040|DRUG|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
214614955|NCT01704040|DRUG|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
214614956|NCT01704040|OTHER|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
214614957|NCT04384484|DRUG|Loncastuximab Tesirine|Intravenous Infusion
214614958|NCT04384484|DRUG|Rituximab|Intravenous Infusion
214614959|NCT04384484|DRUG|Gemcitabine|Intravenous Infusion
214614960|NCT04384484|DRUG|Oxaliplatin|Intravenous Infusion
214614961|NCT01570764|DRUG|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
214614962|NCT01570764|DRUG|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
214614963|NCT02875249|OTHER|patients stool collection|patients stool collection
214614964|NCT05262699|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
214715528|NCT04702204|DRUG|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
214715529|NCT02378493|BIOLOGICAL|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
214715530|NCT03781388|DRUG|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
214715531|NCT04432467|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
214715532|NCT04432467|OTHER|standard treatment|standard treatment according to clinical protocols
214715533|NCT05229991|DRUG|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
214715534|NCT05229991|DRUG|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
214715535|NCT00660075|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
214715536|NCT00660075|DRUG|Placebo|Placebo for 6 weeks
214715537|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
214715538|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
214715539|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
214715540|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
214715541|NCT00905372|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
214715542|NCT00905372|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
214614965|NCT05262699|OTHER|Placebo Control|Devices mounted, no stimulation
214614966|NCT03053700|DRUG|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
214614967|NCT03053700|DEVICE|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
214614968|NCT01573871|OTHER|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
214614969|NCT06386211|DRUG|MAGNE-B6 Oral Solution|Oral solution.
214614970|NCT06386211|DRUG|MAGNE-B6 New Formulation Tablet|New formulation tablet.
214715543|NCT01045434|DRUG|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
214715544|NCT05428449|DRUG|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
214715545|NCT05428449|DRUG|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
214715546|NCT02842541|DRUG|EBI-031|
214715547|NCT00385034|DEVICE|Interactive computer based health-risk survey before doctor's visit|
214715548|NCT00596804|DRUG|veltuzumab|once weekly intravenous dosing for 4 weeks
214715549|NCT03994276|DIETARY_SUPPLEMENT|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
214614971|NCT05358171|OTHER|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
214614972|NCT05358171|OTHER|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
214614973|NCT02800434|PROCEDURE|hand allograft|
214715550|NCT02657876|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
214715551|NCT04463225|OTHER|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
214715552|NCT05168176|DRUG|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
214715553|NCT05168176|DRUG|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
214715554|NCT06060704|DRUG|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
214715555|NCT06060704|DRUG|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
214614974|NCT06074406|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
214614975|NCT06220604|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
214614976|NCT06220604|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
214614977|NCT06220604|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
214614978|NCT06220604|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
214614979|NCT06226909|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
214715556|NCT06060704|DRUG|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
214715557|NCT00778713|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
214715558|NCT03790072|BIOLOGICAL|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
214614980|NCT04829357|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
214614981|NCT05438043|DRUG|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
214614982|NCT05438043|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
214614983|NCT05438043|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
214614984|NCT05438043|DRUG|Lenalidomide|Lenalidomide will be administered orally.
214614985|NCT05438043|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214614986|NCT04154670|BIOLOGICAL|MGTA-145|MGTA-145 will be given intravenously
214614987|NCT06244355|OTHER|Extra blood tubes|Extra blood tubes
214614988|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
214614989|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
214614990|NCT03145181|DRUG|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
214614991|NCT03145181|DRUG|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
214614992|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
214614993|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
214614994|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
214614995|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
214614996|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
214614997|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
214614998|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
214715559|NCT03379376|OTHER|Questionnaire Administration|Receive questionnaire
214614999|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
214615000|NCT05439486|DEVICE|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
214615001|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
214615002|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
214615003|NCT02718781|BEHAVIORAL|Health talk|Health talk on zero-time exercise.
214615004|NCT02718781|BEHAVIORAL|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
214615005|NCT02718781|DEVICE|Handgrip|This is a home-based equipment
214615006|NCT02932410|DRUG|Macitentan|Dispersible tablet; Oral use
214615007|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
214615008|NCT00760019|DRUG|salsalate|1.5 grams orally 3 times daily
214615009|NCT00760019|DRUG|placebo|matching placebo
214615010|NCT00002142|DRUG|Cidofovir|
214615011|NCT00002142|DRUG|Probenecid|
214615012|NCT06427408|OTHER|Non applicable|Placental transcriptomic analysis
214615013|NCT04193046|OTHER|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
214615014|NCT03785158|OTHER|Liquid Melatonin|Melatonin is a natural supplement.
214615015|NCT03785158|OTHER|Placebo|Similar looking/tasting placebo syrup
214615016|NCT05021107|OTHER|FDM with isometrics|FDM with isometrics will be done
214615017|NCT05021107|OTHER|FDM without isometrics|FDM without isometrics will be done
214615018|NCT05270837|DRUG|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
214615019|NCT05270837|OTHER|Diet Only|Diet Control
214615020|NCT06449066|OTHER|Non applicable|Non applicable (data collection)
214615021|NCT03514537|PROCEDURE|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
214615022|NCT03514537|DEVICE|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
214615023|NCT03514537|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
214615024|NCT03514537|DRUG|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
214615025|NCT03514537|DRUG|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
214615026|NCT05005026|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
214715560|NCT03379376|PROCEDURE|Supportive Care|Undergo eHealth mindful moving and breathing
214715561|NCT00735761|DRUG|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
214715562|NCT00735761|DRUG|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
214615027|NCT05005026|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
214615028|NCT05506956|DRUG|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
214615029|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
214615030|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
214615031|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
214615032|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
214615033|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
214715563|NCT04300881|DRUG|Eplerenone|Following intravitreal ocriplasmin therapy
214715564|NCT04513405|DIAGNOSTIC_TEST|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
214615034|NCT05895006|DEVICE|Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214715565|NCT04513405|PROCEDURE|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
214715566|NCT03183960|BEHAVIORAL|Mentor|Traditional rehabilitation.
214715567|NCT05059847|OTHER|Training|Training routine assigned by randomized chart
214715568|NCT02713945|DRUG|Simvastatin|Experimental drug administrated orally
214715569|NCT02713945|DRUG|Placebo|Treatment for the control group
214615035|NCT05895006|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214615036|NCT05895006|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214615037|NCT01007032|BIOLOGICAL|Cixutumumab|Cixutumumab intravenously
214615038|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
214615039|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
214715570|NCT00558740|OTHER|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
214615040|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
214615041|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
214615042|NCT06254495|DRUG|PF-08046044/SGN-35C|Given into the vein (IV; intravenously)
214615043|NCT04774250|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
214615044|NCT04774250|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
214615045|NCT06211517|OTHER|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
214615046|NCT06211517|OTHER|Semi-structured interviews|Semi-structured interviews
214615047|NCT04314401|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
214615048|NCT04314401|PROCEDURE|Computed Tomography|Undergo CT
214615049|NCT04314401|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214615050|NCT04314401|OTHER|Medical Chart Review|Medical charts are reviewed and data is collected
214715571|NCT04992377|DRUG|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
214615051|NCT04314401|PROCEDURE|Paracentesis|Undergo paracentesis
214615052|NCT04314401|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214715572|NCT04259060|DRUG|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
214715573|NCT04259060|DRUG|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
214715574|NCT04738604|OTHER|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
214715575|NCT04738604|OTHER|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
214715576|NCT05381675|OTHER|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
214715577|NCT05381675|OTHER|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
214615053|NCT06361693|OTHER|Auto-preoxygenation|"Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%."
214615054|NCT06361693|OTHER|APAIS scale|APAIS scale
214615055|NCT06361693|OTHER|Visual analog anxiety scale (VAS-A)|Visual analog anxiety scale (VAS-A)
214715578|NCT03121456|OTHER|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
214715579|NCT03121456|OTHER|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
214615056|NCT06361693|OTHER|Visual analog comfort scale (VAS-C)|Visual analog comfort scale (VAS-C)
214615057|NCT05988658|DEVICE|ESTOP - AKI 2.0|Medical software as a Noninvasive medical device, which at the time of the project will not implement directly into subject/clinical care.
214615058|NCT05772572|OTHER|Questionnaires|"Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life"
214615059|NCT03420014|DRUG|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
214615060|NCT03420014|COMBINATION_PRODUCT|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
214715580|NCT01270724|DRUG|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
214715581|NCT05839639|DRUG|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
214715582|NCT05839639|DRUG|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
214715583|NCT05839639|DRUG|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
214715584|NCT03713424|DRUG|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
214715585|NCT03713424|DRUG|Placebo oral capsule|placebo
214715586|NCT00928512|DRUG|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
214715587|NCT00928512|DRUG|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
214715588|NCT01963780|DEVICE|OCS Lung Preservation|
214715589|NCT04153929|DRUG|BI 456906|Solution for Injection
214715590|NCT04153929|DRUG|Placebo|Solution for Injection
214715591|NCT04153929|DRUG|Semaglutide|Solution for Injection
214715592|NCT06238011|DRUG|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
214715593|NCT06238011|DRUG|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
214715594|NCT00493480|DRUG|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
214715595|NCT00493480|DRUG|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
214715596|NCT01060683|BIOLOGICAL|Hemoglobin determination + NaCl 0.9% bolus|
214715597|NCT01060683|BIOLOGICAL|hemoglobin determination + Venofundin bolus|
214715598|NCT01894867|DIETARY_SUPPLEMENT|magnesium|supply magnesium oxide for 6 weeks
214715599|NCT01894867|DIETARY_SUPPLEMENT|Placebo|
214715600|NCT04177875|DRUG|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
214715601|NCT05678478|OTHER|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
214715602|NCT01386567|DRUG|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
214715603|NCT01386567|DRUG|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
214715604|NCT03383614|DRUG|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
214715605|NCT04673344|DEVICE|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
214715606|NCT01170949|DRUG|Miltefosine|50 or 100 or 150mg per day
214715607|NCT01170949|DRUG|Placebo|Placebo
214715608|NCT00460629|PROCEDURE|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
214715609|NCT02872324|OTHER|Procurement questionnaires|
214715610|NCT04974190|DEVICE|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
214715611|NCT03504267|OTHER|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
214715612|NCT03907449|DIAGNOSTIC_TEST|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
214615061|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
214615062|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
214715613|NCT05621018|DEVICE|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
214715614|NCT03549819|DRUG|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
214715615|NCT03549819|DRUG|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
214715616|NCT03623022|DRUG|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
214715617|NCT03623022|DRUG|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
214715618|NCT03395327|OTHER|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
214715619|NCT05609383|OTHER|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
214715620|NCT05275452|OTHER|No intervention|No intervention
214715621|NCT04995900|OTHER|Community education|Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
214715622|NCT03250156|BEHAVIORAL|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
214715623|NCT03250156|BEHAVIORAL|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
214715624|NCT00640952|DRUG|acamprosate|333 mg 2 tabs tid
214615063|NCT05567185|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
214615064|NCT05714982|OTHER|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
214615065|NCT05714982|OTHER|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
214615066|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
214615067|NCT05179876|DRUG|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
214615068|NCT05179876|DRUG|Selexipag|Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
214615069|NCT05179876|DRUG|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
214615070|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
214615071|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
214615072|NCT06581471|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
214615073|NCT01279577|DRUG|Low dose TSO|Low dose TSO suspension
214615074|NCT01279577|DRUG|Medium dose TSO|Medium dose TSO suspension
214615075|NCT01279577|DRUG|High dose TSO|High dose TSO suspension
214615076|NCT01279577|DRUG|Placebo|Placebo solution
214615077|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
214615078|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
214615079|NCT03127267|DRUG|Placebo|treatment per os
214615080|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
214615081|NCT02123758|DRUG|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
214615082|NCT02123758|DRUG|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
214615083|NCT02123758|DRUG|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
214615084|NCT06380660|DRUG|ACE-86225106 tablet|ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
214615085|NCT00015054|DRUG|Methylphenidate|
214615086|NCT05455320|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214615087|NCT05455320|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
214615088|NCT05455320|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214615089|NCT05455320|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
214615090|NCT05160584|OTHER|No intervention|There is no interventional treatment component for participants with RRMM in this study.
214615091|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
214615092|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
214615093|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
214615094|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
214615095|NCT04769050|DRUG|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
214615096|NCT04769050|DRUG|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
214615097|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
214615098|NCT05648058|DRUG|Nefopam ampule|nefopam ampule 50 mg
214615099|NCT05648058|DRUG|diphenhydramine ampule|diphenhydramine ampule 10 mg
214615100|NCT02677948|DRUG|Pacritinib|
214615101|NCT02677948|DRUG|Ibrutinib|
214615102|NCT00786747|BEHAVIORAL|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
214615103|NCT00786747|BEHAVIORAL|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
214615104|NCT05636189|PROCEDURE|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
214615105|NCT05636189|PROCEDURE|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
214615106|NCT04263064|DRUG|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
214615107|NCT04263064|DRUG|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
214615108|NCT05466786|OTHER|Standard Management|Standard Management
214615109|NCT01612182|OTHER|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
214615110|NCT00309465|DRUG|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
214615111|NCT00309465|OTHER|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
214615112|NCT00309465|DRUG|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
214615113|NCT02902354|OTHER|Nifedipine for tocolysis|observational
214615114|NCT06402175|OTHER|follow up|follow up
214715625|NCT00807300|RADIATION|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
214615115|NCT05279144|OTHER|Ventroguleal|Vastus Lateralis
214615116|NCT05794386|PROCEDURE|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
214615117|NCT03101228|BEHAVIORAL|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
214615118|NCT00530114|DRUG|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
214615119|NCT00530114|DRUG|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
214615120|NCT04212455|OTHER|Non-interventional study|This is an observational, non-interventional study
214615121|NCT06559306|DRUG|Seltorexant|Seltorexant will be administered orally.
214615122|NCT06559306|DRUG|Placebo|Matching Placebo tablets will be administered orally.
214615123|NCT06559306|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|SSRI/SNRI will be administered orally.
214615124|NCT04183829|PROCEDURE|induced termination of pregnancy|Medically, induced termination of pregnancy (I-TOP) is defined as an intervention to voluntarily terminate a pregnancy (ie, induced abortion) by either surgical or medical means so it does not result in a live birth.
214615125|NCT01990638|OTHER|exercise capacity test|
214615126|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-8mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
214615127|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-8mmHg), and use standard room temperature with dry insufflation.
214615128|NCT02577406|DRUG|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
214715626|NCT00807300|PROCEDURE|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
214615129|NCT02577406|OTHER|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
214615130|NCT02577406|DRUG|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
214615131|NCT02577406|DRUG|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
214615132|NCT02577406|DRUG|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
214615133|NCT03742349|BIOLOGICAL|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
214615134|NCT03742349|BIOLOGICAL|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
214615135|NCT03742349|DRUG|NIR178|Capsule
214615136|NCT03742349|DRUG|capmatinib|Tablet
214615137|NCT03742349|BIOLOGICAL|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
214615138|NCT03742349|BIOLOGICAL|canakinumab|LIVI (Liquid in vial) Solution for injection
214615139|NCT05884398|DRUG|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
214615140|NCT05884398|DRUG|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
214615144|NCT06323980|DEVICE|Reverse Total Shoulder|Uncemented Reverse Total Shoulder
214615145|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
214615146|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered intravenously.
214615147|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
214615148|NCT04829058|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
214715627|NCT01091051|DRUG|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
214715628|NCT01091051|DRUG|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
214615149|NCT04397276|DRUG|JNJ-70218902|JNJ-70218902 will be administered.
214615150|NCT03006172|DRUG|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
214615151|NCT03006172|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
214615152|NCT03006172|DRUG|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
214615153|NCT03006172|DRUG|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
214615154|NCT03006172|DRUG|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
214615155|NCT03006172|DRUG|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
214615156|NCT03006172|DRUG|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
214615157|NCT04611568|OTHER|Educational Intervention|Receive educational and training material
214615158|NCT04611568|OTHER|Educational Intervention|Receive educational lecture
214615159|NCT04611568|BEHAVIORAL|Health Education|Receive melanoma curriculum
214615160|NCT04611568|BEHAVIORAL|Media Campaign|View digital media strategies
214615161|NCT04611568|OTHER|Survey Administration|Complete survey
214615162|NCT04175600|DRUG|Selexipag|Selexipag tablet will be administered orally.
214615163|NCT04175600|DRUG|Placebo|Matching placebo tablets will be administered orally.
214615164|NCT06091488|OTHER|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
214615165|NCT04033445|DRUG|Placebo|Participants will receive matching placebo IV or SC.
214615166|NCT04033445|DRUG|Guselkumab|Participants will receive guselkumab IV or SC.
214715629|NCT05934721|OTHER|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
214715630|NCT05380908|OTHER|None of any intervention|The patients did not have any intervention.
214615167|NCT06639659|PROCEDURE|Sphenopalatine Ganglion Block|patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
214615168|NCT06639659|DRUG|Dexmedetomidine|patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
214615169|NCT06639659|OTHER|General Anesthesia (control group)|patients will be operated under general anesthesia including routine protocol for these cases
214615170|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
214615171|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
214615172|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
214615173|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
214615174|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
214615175|NCT01648478|OTHER|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)"
214615176|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
214615177|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
214615178|NCT05272631|DEVICE|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
214615179|NCT05272631|DEVICE|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
214615180|NCT05702034|DRUG|Milvexian|Milvexian will be administered orally.
214615181|NCT05702034|DRUG|Placebo|Placebo will be administered orally
214615182|NCT06408935|DRUG|Guselkumab|Guselkumab will be administered IV and SC.
214615183|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
214615184|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
214615185|NCT05851066|DRUG|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
214715631|NCT04150354|BEHAVIORAL|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
214715632|NCT01997697|OTHER|behavior change program|behavior change program among patients with obesity
214715633|NCT01012349|DRUG|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
214715634|NCT01012349|DRUG|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
214715635|NCT02077803|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
214715636|NCT02077803|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
214615186|NCT05851066|DRUG|0.9% NaCl|placebo
214615187|NCT02531516|DRUG|Apalutamide|
214615188|NCT02531516|DRUG|Bicalutamide|
214615189|NCT02531516|DRUG|Bicalutamide Placebo|
214615190|NCT02531516|DRUG|Apalutamide Placebo|
214715637|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
214615191|NCT02531516|DRUG|GnRH (agonist)|
214615192|NCT02531516|RADIATION|74-80 Grays (units of radiation)|
214615193|NCT06521762|DRUG|Etrasimod|2 mg/day oral tablet
214615194|NCT06521762|DRUG|Placebo|matching placebo oral tablet
214615195|NCT06521762|DRUG|Corticosteroids|Corticosteroids will be given in conjunction with study drug or placebo
214615196|NCT06471829|DRUG|Lu AG13909|Solution for injection/infusion
214615197|NCT04630171|DEVICE|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
214615198|NCT04630171|DEVICE|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
214615199|NCT04630171|OTHER|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
214615200|NCT00647166|DRUG|corticosteroid and azathioprine|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
214615201|NCT00647166|DRUG|corticosteroid and placebo|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
214615202|NCT04550715|BEHAVIORAL|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
214615203|NCT04550715|BEHAVIORAL|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
214615204|NCT04550715|BEHAVIORAL|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
214615205|NCT03561870|DRUG|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
214615206|NCT04057976|DIAGNOSTIC_TEST|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
214615207|NCT04162015|DRUG|Nivolumab|nivolumab 360 mg
214615208|NCT04162015|DRUG|Pemetrexed|500 mg/m\^2
214615209|NCT04162015|DRUG|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
214615210|NCT05368038|DIAGNOSTIC_TEST|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
214615211|NCT05500274|OTHER|Education|Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.
214615212|NCT05500274|OTHER|Motivational|This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content
214615213|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
214615214|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
214615215|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
214615216|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
214615217|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
214615218|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
214615219|NCT04077463|DRUG|Lazertinib|Lazertinib will be administered orally.
214615220|NCT04077463|DRUG|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
214615221|NCT04077463|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
214615222|NCT04077463|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
214615223|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
214615224|NCT03485209|DRUG|tisotumab vedotin|Given into the vein (IV; intravenously)
214615225|NCT03485209|DRUG|pembrolizumab|200mg or 400mg given by IV
214615226|NCT03485209|DRUG|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
214615227|NCT03485209|DRUG|cisplatin|100mg/m\^2 given by IV
214615228|NCT06807424|DRUG|Icotrokinra|Icotrokinra will be administered.
214715638|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
214715639|NCT03499340|BEHAVIORAL|text-only PWL|control condition (no image)
214715640|NCT03499340|BEHAVIORAL|low arousal graphic PWL|pictorial warning
214615229|NCT06807424|DRUG|Placebo|Placebo will be administered.
214615230|NCT05678010|DRUG|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
214615231|NCT05678010|RADIATION|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
214615232|NCT05074810|DRUG|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
214615233|NCT05074810|DRUG|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
214615234|NCT04133636|DRUG|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
214615235|NCT04133636|DRUG|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
214615236|NCT04133636|DRUG|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
214615237|NCT04133636|DRUG|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
214715641|NCT03499340|BEHAVIORAL|high arousal graphic PWL|pictorial warning
214715642|NCT03499340|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
214715643|NCT03499340|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
214715644|NCT00621088|PROCEDURE|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
214715645|NCT05190107|DIAGNOSTIC_TEST|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
214715646|NCT01306851|DRUG|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
214715647|NCT06526598|PROCEDURE|PMI-targeted pressure support setting and adjustment|During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.
214615238|NCT04133636|DRUG|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
214615239|NCT05734391|DIAGNOSTIC_TEST|Routine Infection control|routine part of hospital IPC activities
214615241|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
214615242|NCT05467150|DIETARY_SUPPLEMENT|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
214615243|NCT06008093|DRUG|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles as induction treatment. Durvalumab will also be given during the maintenance treatment period q4w until disease progression or unacceptable toxicity.
214615244|NCT06008093|DRUG|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-days cycles as induction treatment. Tremelimumab will also be given during the maintenance therapy phase at week 16 and week 104 (at the investigators discretion).
214615245|NCT06008093|DRUG|Pemetrexed|Participants in Arm A and Arm B will receive IV pemetrexed q3w for four 21-day cycles as induction treatment. In the maintenance therapy phase, Treatment Arm A will receive Pemetrexed q4w, Treatment Arm B will receive Pemetrexed q3w until disease progression or unacceptable toxicity.
214615246|NCT06008093|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-days cycles as induction treatment. Pembrolizumab will also be given in the maintenance treatment phase q3w until disease progression or unacceptable toxicity or up to 24 months.
214715648|NCT06526598|PROCEDURE|VT/RR-targeted pressure support setting and adjustment|During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
214715649|NCT03079245|OTHER|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
214615247|NCT06008093|DRUG|Carboplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
214615248|NCT06008093|DRUG|Cisplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
214615249|NCT05836987|DEVICE|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
214615250|NCT05836987|DRUG|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
214615251|NCT06616285|BEHAVIORAL|Self-Guided Multidomain Lifestyle Intervention|Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
214715650|NCT03079245|OTHER|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
214715651|NCT03079245|OTHER|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (\>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
214715652|NCT06282536|DRUG|Iruplinalkib|60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.
214715653|NCT06282536|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
214715654|NCT01614912|DRUG|SM-13496|40 or 80 mg once daily orally
214715655|NCT05110599|DRUG|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
214715656|NCT05110599|OTHER|Placebo|Lactose with adaption in appearance and tast
214715657|NCT04798313|DRUG|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
214715658|NCT04798313|DRUG|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
214715659|NCT04406389|DRUG|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
214715660|NCT04406389|DRUG|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
214615252|NCT06616285|BEHAVIORAL|Folk Dance Multidomain Lifestyle Intervention|"Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored."
214715661|NCT04406389|DRUG|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily"
214615253|NCT05380141|BEHAVIORAL|Individual patient interviews|"Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview."
214615254|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
214615255|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
214615256|NCT06798532|OTHER|Collection of data from the patient's medical file.|Collection of data from the patient's medical file.
214715662|NCT04406389|DRUG|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
214715663|NCT02971293|DRUG|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
214715664|NCT02971293|DRUG|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
214715665|NCT02971293|DRUG|Placebo|The subject will receive Placebo single dose DPI.
214615257|NCT06799819|BEHAVIORAL|Mobility group|Free mobility between FDG injection and scanning (without exiting the Nuclear Medicine Department)
214615258|NCT02113930|BIOLOGICAL|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
214615259|NCT02113930|GENETIC|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
214615260|NCT04754802|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
214615261|NCT04754802|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
214615262|NCT05064579|OTHER|Questionnaires|Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
214615263|NCT05400941|BEHAVIORAL|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
214615264|NCT04577833|DRUG|Niraparib|Niraparib will be administered orally.
214615265|NCT04577833|DRUG|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
214615266|NCT04577833|DRUG|Prednisone|Prednisone will be administered orally.
214615267|NCT03653247|BIOLOGICAL|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
214615268|NCT03653247|DRUG|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
214615269|NCT03653247|GENETIC|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
214715666|NCT00729326|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
214715667|NCT00729326|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
214715668|NCT00729326|DRUG|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
214715669|NCT00729326|DRUG|placebo|oral administration (100mg), once a day in the morning
214615270|NCT04451161|BEHAVIORAL|Beliefs and Attitudes for Successful Implementation in Schools (BASIS)|BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.
214615271|NCT04451161|BEHAVIORAL|Trauma-Focused Cognitive-Behavioral Therapy|TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.
214615272|NCT04451161|BEHAVIORAL|Treatment as Usual|Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
214615273|NCT04451161|BEHAVIORAL|Attention Control|Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
214715670|NCT02451540|RADIATION|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
214715671|NCT02451540|DRUG|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
214715672|NCT02451540|DRUG|Roflumilast|Roflumilast, once a day in the morning during 3 months
214715673|NCT01235728|DRUG|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
214715674|NCT01235728|DRUG|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
214715675|NCT01235728|DRUG|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
214715676|NCT01808404|BEHAVIORAL|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
214715677|NCT01478893|BIOLOGICAL|SEL-068|Sub-cutaneous injection, multiple dose
214715678|NCT01478893|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
214715679|NCT04312438|DIAGNOSTIC_TEST|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
214715680|NCT04664140|OTHER|QFR-based virtual PCI|Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
214715681|NCT04664140|OTHER|angiography-based PCI|PCi according to international guidelines, local protocols and practice
214715682|NCT03686865|DEVICE|dental implants|extraction sockets regenerated with xenograft
214615274|NCT06029660|DEVICE|IMPEDE-FX RapidFill Implants|Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
214615275|NCT06029660|PROCEDURE|EndoVascular Aneurysm Repair|Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
214715683|NCT03603834|DRUG|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
214715684|NCT02559713|DRUG|Vedolizumab|Vedolizumab IV infusion
214615276|NCT02344433|BEHAVIORAL|VICKY|Relational agent/virtual counselor
214615277|NCT02344433|BEHAVIORAL|MFHP|US Surgeon General's family history tool
214615278|NCT02246725|OTHER|Contact with palliative care unit.|
214615279|NCT00993408|DEVICE|ACT-293987 (NS-304)|
214615280|NCT01555151|DRUG|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
214615281|NCT01555151|DEVICE|Concept 1|A single dose dry powder inhaler (SDDPI)
214615282|NCT01555151|DEVICE|Twisthaler|A single dose dry powder inhaler (SDDPI)
214615283|NCT03596866|DRUG|Brigatinib|Brigatinib Tablets.
214615284|NCT03596866|DRUG|Alectinib|Alectinib Capsules.
214715685|NCT05487313|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
214615285|NCT06366074|DEVICE|Watch-TEA group|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
214615286|NCT06366074|DEVICE|Tethered TEA device|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
214615287|NCT04105907|DEVICE|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
214615288|NCT06406855|OTHER|BCI-TSCS|BCI-TSCS therapy, completed 3-4 times per week, that will include activity-based training, with TSCS activated by BCI system detecting movement attempt.
214615289|NCT00144612|DRUG|MRA(Tocilizumab)|8mg/kg/2weeks
214615290|NCT05629234|DRUG|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
214615291|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
214615292|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
214615293|NCT05525689|BEHAVIORAL|IntelliCare|Application with patient-facing tools for depression symptom monitoring, self-management, and care manager communication as well as care manager dashboards for workflow optimization
214615294|NCT05525689|OTHER|COMPASS-Care|Website with content specific to perinatal depression and standard EHR-based tools for patient communication
214615295|NCT00122811|DRUG|Indapamide SR 1.5mg; Perindopril 2-4mg|
214615296|NCT05098392|BEHAVIORAL|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
214615297|NCT03725124|OTHER|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
214615298|NCT05696275|BEHAVIORAL|exercise|20-30 minutes of walking and elastic band exercise per day
214615299|NCT03042104|DEVICE|Edwards SAPIEN 3 / SAPIEN 3 Ultra THV|Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
214615300|NCT05554796|PROCEDURE|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
214615301|NCT05554796|PROCEDURE|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
214615302|NCT02056197|OTHER|Placebo|Shortwave
214615303|NCT02056197|OTHER|Stable surface exercises|Stable surface exercises
214615304|NCT02056197|OTHER|Unstable surface exercises|
214615305|NCT01671111|DRUG|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
214615306|NCT05774925|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214615307|NCT06079983|DRUG|JSKN003|Administered intravenously according to protocol.
214615308|NCT06079983|DRUG|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214615309|NCT06079983|DRUG|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214615310|NCT06079983|DRUG|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214615311|NCT06079983|DRUG|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214615312|NCT06079983|DRUG|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214615313|NCT06079983|DRUG|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
214715686|NCT04101760|DRUG|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
214715687|NCT04101760|DRUG|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
214715688|NCT03306485|OTHER|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
214715689|NCT03694041|DRUG|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
214715690|NCT03694041|DRUG|SAD: Placebo|Drug: Placebo Placebo for 1day
214615314|NCT04032470|DEVICE|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
214615315|NCT05312424|DIETARY_SUPPLEMENT|Placebo|300 mg olive oil
214615316|NCT05312424|DIETARY_SUPPLEMENT|Low GG|150 mg GG
214615317|NCT05312424|DIETARY_SUPPLEMENT|High GG|300 mg GG
214615318|NCT06686615|DRUG|Bempedoic acid|No drug was administered in this observational study.
214615319|NCT06686615|DRUG|Ezetimibe|No drug was administered in this observational study.
214615320|NCT06686615|DRUG|Rosuvastatin|No drug was administered in this observational study.
214615321|NCT06686615|DRUG|Atorvastatin|No drug was administered in this observational study.
214715691|NCT03694041|DRUG|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
214715692|NCT03694041|DRUG|MAD: Placebo|Matching study drug will be repeatedly administered.
214715693|NCT03694041|OTHER|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
214715694|NCT03694041|OTHER|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
214715695|NCT02855320|OTHER|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
214615322|NCT02938130|OTHER|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
214615323|NCT06526195|DEVICE|CardioMEMS HF System|The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
214615324|NCT06526195|DEVICE|HeartMate 3 Left Ventricular Assist System|The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
214615325|NCT06526195|OTHER|Guideline Medical Directed Therapy|Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
214615326|NCT00578110|DEVICE|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
214615327|NCT04923893|DRUG|Bortezomib|Bortezomib will be administered SC.
214615328|NCT04923893|DRUG|Dexamethasone|Dexamethasone will be administered orally.
214615329|NCT04923893|DRUG|Lenalidomide|Lenalidomide will be administered orally.
214615330|NCT04923893|DRUG|Cilta-cel|Cilta-cel infusion will be administered.
214615331|NCT04923893|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
214715696|NCT03418051|OTHER|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
214615332|NCT04923893|DRUG|Fludarabine|Fludarabine will be administered intravenously.
214615333|NCT03680911|DRUG|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
214715697|NCT03418051|OTHER|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
214615334|NCT03680911|DRUG|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
214715698|NCT05684653|DRUG|Orelabrutinib Tablets|50 mg, single oral dose
214715699|NCT04587960|PROCEDURE|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
214715700|NCT04587960|PROCEDURE|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
214715701|NCT00103597|DRUG|Fludrocortisone|
214715702|NCT00103597|DRUG|Domperidone|
214615335|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214615336|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
214615337|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
214615338|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
214615339|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
214615340|NCT00889226|DRUG|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
214615341|NCT00889226|DRUG|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
214615342|NCT04154410|OTHER|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
214615343|NCT04154410|OTHER|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
214615344|NCT04991467|BEHAVIORAL|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
214615345|NCT04991467|BEHAVIORAL|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
214615346|NCT04991467|BEHAVIORAL|CARE Program|Participant will take part in 12 week CARE program.
214615347|NCT04991467|BEHAVIORAL|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
214615348|NCT04991467|BEHAVIORAL|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
214615349|NCT04829175|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
214715703|NCT00103597|BEHAVIORAL|Conservative Measures for Orthostatic Hypotension|
214715704|NCT06362460|DRUG|[14C] RAY1216|400 mg suspension containing 100μCi of \[14C\]RAY1216
214715705|NCT04227392|DEVICE|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
214715706|NCT05150834|OTHER|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
214715707|NCT01928563|DRUG|Dapoxetine|
214715708|NCT01928563|DRUG|Udenafil|
214715709|NCT01928563|DRUG|Udenafil+Dapoxetine|
214715710|NCT00002718|BIOLOGICAL|anti-thymocyte globulin|
214715711|NCT00002718|BIOLOGICAL|filgrastim|
214715712|NCT00002718|DRUG|cyclophosphamide|
214715713|NCT00002718|DRUG|cytarabine|
214715714|NCT00002718|DRUG|methylprednisolone|
214615350|NCT03434171|BEHAVIORAL|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
214615351|NCT03434171|DIETARY_SUPPLEMENT|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
214615352|NCT06493149|OTHER|Massage therapy|Participants receive a Swedish massage based on the tensegrity principle.
214615353|NCT04634552|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression.
214615354|NCT01862068|OTHER|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
214615355|NCT01862068|OTHER|Blood sample|Blood sample will be performed at inclusion from all healthy patients
214615356|NCT05627557|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
214615357|NCT05627557|DRUG|MMF|MMF will be administered as per schedule specified in the respective arm.
214715715|NCT00002718|DRUG|thiotepa|
214715716|NCT00002718|PROCEDURE|in vitro-treated bone marrow transplantation|
214715717|NCT00002718|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214715718|NCT00002718|RADIATION|radiation therapy|
214715719|NCT03046342|DIAGNOSTIC_TEST|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
214615358|NCT05627557|DRUG|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
214715720|NCT03400137|DIAGNOSTIC_TEST|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
214715721|NCT02193828|BIOLOGICAL|Collagenase clostridium histolyticum|Single injection into nodule
214715722|NCT02193828|BIOLOGICAL|Placebo|Single injection into nodule
214715723|NCT02487888|OTHER|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
214715724|NCT02487888|OTHER|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
214715725|NCT03587571|PROCEDURE|Surgical intervention|Open reduction and plate osteosynthesis.
214715726|NCT06460597|OTHER|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
214715727|NCT06460597|OTHER|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
214715728|NCT01292044|OTHER|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
214715729|NCT00226967|DRUG|Sandostatin|Calculated per patient
214615359|NCT05627557|DRUG|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
214615360|NCT05627557|DRUG|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
214615361|NCT05627557|DRUG|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
214715730|NCT00717535|OTHER|cryopreservation|
214715731|NCT00717535|OTHER|questionnaire administration|
214615362|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
214615363|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
214715732|NCT00717535|OTHER|study of socioeconomic and demographic variables|
214715733|NCT00549510|DRUG|COREG CR and lisinopril (FDC)|
214615364|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
214615365|NCT01135862|DRUG|platelets|6 packs of platelets will be administered
214615366|NCT05829356|BIOLOGICAL|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
214615367|NCT05829356|BIOLOGICAL|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
214615368|NCT05597475|DIAGNOSTIC_TEST|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
214615369|NCT05347095|DRUG|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
214615370|NCT05347095|DRUG|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
214615371|NCT04838665|DRUG|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
214615372|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
214615373|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
214615374|NCT04510688|DRUG|Cabozantinib|Observation of treatment with Cabozantinib
214615375|NCT02715336|DRUG|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
214615376|NCT02019823|BEHAVIORAL|Informational SMS-text|
214615377|NCT02019823|BEHAVIORAL|Interactive SMS-text|
214615378|NCT02019823|BEHAVIORAL|Enhanced usual care|
214615379|NCT04045704|PROCEDURE|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
214615380|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
214615381|NCT06075160|DIAGNOSTIC_TEST|Resting full-cycle ratio (RFR)-guided revascularization|The decision of coronary intervention is based on an RFR cut-value of 0.89. If RFR ≤ 0.89, target lesion will be revascularized, and if RFR \> 0.89, PCI will be deferred. However, even if RFR ≤ 0.89, PCI can be deferred if the RFR gradient of the lesion ≤ 0.02, or if the diffused type of stenosis, because physiological gain is expected to be very low.
214615382|NCT06075160|DIAGNOSTIC_TEST|Fractional flow ratio (FFR)-guided revascularization|Study participants of FFR-guided PCI arm will be selected from a large-scaled, ongoing FFR registry. The decision of coronary intervention is based on an FFR cut-value of 0.80. If FFR ≤ 0.80, target lesion will be revascularized, and if RFR \> 0.80, PCI will be deferred.
214615383|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
214615384|NCT02867176|DRUG|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
214615385|NCT02867176|DRUG|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
214615386|NCT06308432|OTHER|Low intensity|The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
214615387|NCT06308432|OTHER|Low temperature|The performance test will be carried out in a room conditioned to a temperature of 22º.
214615388|NCT06308432|OTHER|Low Humidity|The performance test will be carried out in a room conditioned to 40% humidity.
214615389|NCT06308432|OTHER|High intensity|The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
214615390|NCT06308432|OTHER|High temperature|The performance test will be carried out in a room conditioned to a temperature of 35º.
214615391|NCT06308432|OTHER|High humidity|The performance test will be carried out in a room conditioned to 65% humidity.
214615392|NCT02510781|DRUG|Epirubicin|75mg/m2 d1 evry 21days
214615393|NCT02510781|DRUG|Docetaxel|75mg/m2 d1 evry 21days
214615394|NCT02510781|DRUG|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
214615395|NCT02510781|DRUG|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
214615396|NCT03412279|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
214615397|NCT03412279|BEHAVIORAL|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
214615398|NCT05643612|DIAGNOSTIC_TEST|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
214615399|NCT05138666|BIOLOGICAL|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
214615400|NCT05138666|BIOLOGICAL|blood sample|Blood sampling drawn from an existing arterial line twice a week
214715734|NCT05912712|OTHER|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
214615401|NCT02492477|PROCEDURE|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
214615402|NCT02492477|DRUG|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
214615403|NCT02492477|DRUG|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
214715735|NCT05912712|OTHER|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
214715736|NCT05912712|DRUG|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
214715737|NCT05912712|BIOLOGICAL|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
214715738|NCT03106012|PROCEDURE|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
214715739|NCT03106012|PROCEDURE|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
214715740|NCT04250012|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
214715741|NCT04250012|BEHAVIORAL|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
214615404|NCT05868551|PROCEDURE|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
214615405|NCT03947840|BEHAVIORAL|Physical activity|Se their physical activity level
214615406|NCT05222529|DRUG|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
214615407|NCT05222529|DRUG|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
214615408|NCT05222529|DRUG|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
214615409|NCT01120548|OTHER|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
214615410|NCT02504554|DRUG|oral Vancomycin|an antibiotic
214615411|NCT02504554|DRUG|MoviPrep|a bowel cleanse
214615412|NCT02504554|DRUG|Prilosec|a stomach acid suppressan
214615413|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
214615414|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
214615415|NCT02187679|DRUG|Abobotulinum toxin A|
214615416|NCT03364361|PROCEDURE|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
214615417|NCT01806857|DRUG|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
214715742|NCT06431178|OTHER|General Anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
214715743|NCT06431178|OTHER|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
214715744|NCT06067282|OTHER|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
214715745|NCT05057143|DEVICE|Implants|3D printed implants
214715746|NCT05057143|DEVICE|Plates|Titanium plates
214715747|NCT01383967|DRUG|LY2979165|Administered orally
214715748|NCT01383967|DRUG|placebo|Administered orally
214715749|NCT02993458|OTHER|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
214715750|NCT02993458|OTHER|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
214715751|NCT02993458|OTHER|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
214715752|NCT02993458|OTHER|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
214715753|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)
214715754|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)
214715755|NCT01185704|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
214715756|NCT01185704|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
214615418|NCT01806857|DRUG|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
214615419|NCT05963074|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
214615420|NCT05963074|DRUG|Venetoclax|Venetoclax tablets will be administered orally.
214615421|NCT04754750|DRUG|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
214615422|NCT04754750|DRUG|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
214715757|NCT02958904|OTHER|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
214715758|NCT03865459|OTHER|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
214715759|NCT00022152|DRUG|vinorelbine tartrate|
214715760|NCT00159159|DRUG|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
214715761|NCT00159159|DRUG|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
214715762|NCT03788187|OTHER|Blood test sample|
214715763|NCT03788187|OTHER|Peritumoral adipose tissue sample|
214715764|NCT02026206|DEVICE|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
214715765|NCT02026206|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
214715766|NCT02790333|PROCEDURE|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
214715767|NCT02790333|PROCEDURE|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
214715768|NCT03231215|DRUG|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
214615423|NCT01020591|OTHER|Osteopathic evaluation|evaluation of movement and tissue mobility
214715769|NCT01671956|BIOLOGICAL|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
214715770|NCT01671956|BIOLOGICAL|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
214715771|NCT03864809|BEHAVIORAL|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
214715772|NCT00212485|PROCEDURE|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
214715773|NCT00212485|PROCEDURE|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
214615424|NCT01020591|OTHER|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
214615425|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
214615426|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
214715774|NCT03013829|BEHAVIORAL|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
214715775|NCT05647018|PROCEDURE|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
214715776|NCT00680160|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
214715777|NCT01686958|DEVICE|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
214715778|NCT00013481|PROCEDURE|Stroke Rehabilitation|
214615427|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
214615428|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
214615429|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
214615430|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
214615431|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
214715779|NCT01241019|DRUG|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
214715780|NCT02675738|OTHER|good clinical practice|
214715781|NCT00920478|OTHER|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
214715782|NCT00920478|OTHER|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
214715783|NCT03162458|DRUG|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
214715784|NCT03162458|DRUG|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
214715785|NCT02832596|DRUG|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
214615432|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
214615433|NCT04702737|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
214615434|NCT00121784|DRUG|mycophenolate mofetil [CellCept]|1
214615435|NCT02811549|DEVICE|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
214615436|NCT00580372|DRUG|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
214615437|NCT00580372|DRUG|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
214615438|NCT00580372|PROCEDURE|Hemopoietic stem cell procurement|Collection target = 10 x 10\^6 cells/kg
214615439|NCT00580372|DRUG|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
214715786|NCT02832596|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
214715787|NCT02741219|DRUG|Normal saline|Control Group receives normal saline bolus after delivery
214615440|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
214615441|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
214615442|NCT00580372|DRUG|Maintenance|3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
214615443|NCT05897814|OTHER|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
214615444|NCT00236769|DRUG|norelgestromin + ethinyl estradiol|
214615445|NCT03472924|DEVICE|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
214615446|NCT03726606|DEVICE|Intraocular lens|Bilateral implantation of the same intraocular lens.
214615447|NCT03713749|DEVICE|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
214615448|NCT03389295|RADIATION|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
214615449|NCT00241995|DRUG|Anticonvulsants|
214615450|NCT02685579|OTHER|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
214615451|NCT05484479|BEHAVIORAL|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
214615452|NCT03911973|DRUG|Gedatolisib|Gedatolisib, 150-180MG IV
214615453|NCT03911973|DRUG|Talazoparib|.75-1.00mg
214715788|NCT02741219|DRUG|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
214715789|NCT02741219|DRUG|Sufentanil|sufentanil PCA after surgery
214715790|NCT02741219|DRUG|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
214715791|NCT04871581|DEVICE|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
214715792|NCT04871581|DEVICE|Placebo|Similar to Device, but having no influence on clenching intensity
214715793|NCT06303492|PROCEDURE|GUS|Aspiration risk assessment by GUS
214715794|NCT01151540|DRUG|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
214615454|NCT05651555|BEHAVIORAL|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
214615455|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
214615456|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
214615457|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
214615458|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
214615459|NCT03591822|BEHAVIORAL|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
214615460|NCT03591822|BEHAVIORAL|B : Systemic evaluation of the pain|A systematic evaluation of the pain
214615461|NCT06087887|OTHER|no interventions|no interventions
214615462|NCT00036751|DRUG|imatinib mesylate|Given orally
214615463|NCT00036751|OTHER|laboratory biomarker analysis|Correlative studies
214615464|NCT06378671|PROCEDURE|General treatment|routine bronchoscopy examination, lavage, and mucosal biopsy
214615465|NCT06378671|PROCEDURE|Cryotherapy Treatment|local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
214615466|NCT00278759|PROCEDURE|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
214715795|NCT00979680|RADIATION|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
214715796|NCT00979680|RADIATION|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
214715797|NCT06327620|COMBINATION_PRODUCT|Daivobet ointment, topical steroids|"Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information."
214715798|NCT04183894|BEHAVIORAL|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
214715799|NCT03380624|DRUG|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
214715800|NCT03380624|DRUG|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
214715801|NCT04413721|PROCEDURE|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
214715802|NCT01213693|DRUG|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
214615467|NCT05403320|DEVICE|Continuous cuff pressure regulation|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)
214615468|NCT05403320|DEVICE|Intermittent cuff pressure regulation|ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O
214615469|NCT05403320|DEVICE|Automatic subglottic secretion drainage|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)
214615470|NCT05403320|DEVICE|Manual subglottic secretion drainage|Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen
214615471|NCT05403320|DIAGNOSTIC_TEST|Tracheobronchial colonization assessment|Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture
214615472|NCT05403320|DIAGNOSTIC_TEST|Microaspiration assessment|Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase
214615473|NCT05403320|DIAGNOSTIC_TEST|VAP assessment|Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
214615474|NCT05442255|OTHER|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
214715803|NCT01213693|DRUG|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
214615475|NCT01886339|OTHER|SNIF test (Sniff Nasal Inspiratory Force)|
214615476|NCT00417040|OTHER|internet-based intervention|Use the STAR database system
214615477|NCT00417040|OTHER|assessment of therapy complications|Use the STAR database system
214615478|NCT00417040|OTHER|Questionnaire Administration|Ancillary studies
214615479|NCT01436084|DRUG|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
214615480|NCT05664542|OTHER|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
214615481|NCT05664542|DRUG|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
214615482|NCT02957591|DIETARY_SUPPLEMENT|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
214615483|NCT02957591|OTHER|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
214615484|NCT04319848|OTHER|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
214615485|NCT01898936|PROCEDURE|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
214615486|NCT01898936|DEVICE|Only photodynamic therapy|
214615487|NCT05561361|PROCEDURE|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
214615488|NCT05561361|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
214615489|NCT02447055|BIOLOGICAL|Tocilizumab|
214615490|NCT02447055|DRUG|Melphalan|
214615491|NCT02447055|DRUG|Fludarabine|
214615492|NCT02447055|DRUG|Cyclophosphamide|
214615493|NCT02447055|DRUG|Tacrolimus|
214615494|NCT02447055|DRUG|Mycophenolate mofetil|
214615495|NCT02447055|DRUG|Filgrastim|
214615496|NCT04784728|DRUG|Lidocaine topical system 1.8%|lidocaine patch
214615497|NCT03023930|OTHER|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
214615498|NCT03023930|OTHER|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
214615499|NCT04021836|OTHER|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
214615500|NCT00199446|DRUG|Istradefylline (KW-6002)|
214615501|NCT04647877|DRUG|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
214615502|NCT04647877|OTHER|Placebo cream|Placebo cream to be applied on the neuropathic pain area
214615503|NCT04712877|DIAGNOSTIC_TEST|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
214715804|NCT02576015|PROCEDURE|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
214715805|NCT02576015|PROCEDURE|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
214715806|NCT02576015|DRUG|lidocaine|
214715807|NCT02576015|DEVICE|ultrasound|
214715808|NCT02576015|DEVICE|insulated needle (Contiplex B Braun, Melsungen, Germany)|
214615504|NCT04425720|DEVICE|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.
214615505|NCT04425720|OTHER|Standard of Care|This group will be treated based on standard of care at our institution.
214715809|NCT02576015|DRUG|ropivacaine|
214715810|NCT02576015|DRUG|saline|
214715811|NCT00003893|DRUG|CMF regimen|
214715812|NCT00003893|DRUG|cyclophosphamide|
214615506|NCT04221698|OTHER|Gait retraining|5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
214615507|NCT00947700|BEHAVIORAL|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
214615508|NCT03778853|DRUG|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
214715813|NCT00003893|DRUG|doxorubicin hydrochloride|
214715814|NCT00003893|DRUG|epirubicin hydrochloride|
214715815|NCT00003893|DRUG|fluorouracil|
214715816|NCT00003893|DRUG|methotrexate|
214715817|NCT00003893|DRUG|mitomycin C|
214715818|NCT00003893|DRUG|mitoxantrone hydrochloride|
214615509|NCT01550861|PROCEDURE|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
214615510|NCT01550861|PROCEDURE|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
214615511|NCT02703415|DRUG|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
214615512|NCT02703415|DRUG|Tramadol|caudal block with tramadol 1 mg/kg
214615513|NCT01614938|DRUG|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
214615514|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
214615515|NCT01614938|DRUG|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
214715819|NCT00003893|PROCEDURE|adjuvant therapy|
214715820|NCT00003893|RADIATION|radiation therapy|
214615516|NCT01614938|RADIATION|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
214615517|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
214615518|NCT05517928|DRUG|Omeprazole|40 MG oral capsules daily
214615519|NCT05517928|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
214615520|NCT05517928|DRUG|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
214615521|NCT00290186|DEVICE|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
214615522|NCT00290186|DEVICE|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
214615523|NCT00445224|OTHER|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
214615524|NCT00445224|OTHER|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
214615525|NCT04952103|OTHER|no intervention|The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
214615526|NCT04752176|DEVICE|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
214615527|NCT02882490|BEHAVIORAL|Parent Training|
214615528|NCT02882490|OTHER|Supportive Therapy|
214615529|NCT02124278|DRUG|PUL-042 Inhalation Solution|
214615530|NCT00253396|DRUG|Unfractionated heparin|
214715821|NCT05121909|OTHER|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
214715822|NCT05121909|DEVICE|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
214715823|NCT05121909|OTHER|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
214615531|NCT00253396|DRUG|Enoxaparin|
214615532|NCT02895503|BEHAVIORAL|Yoga|Participate in yoga
214615533|NCT02895503|BEHAVIORAL|Support Group Therapy|Participate in emotional support group therapy
214615534|NCT02895503|OTHER|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
214615535|NCT02895503|OTHER|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
214715824|NCT05121909|OTHER|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
214615536|NCT03327012|DRUG|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
214615537|NCT03327012|DRUG|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
214615538|NCT02639611|OTHER|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
214615539|NCT02639611|OTHER|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
214615540|NCT00833950|DEVICE|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
214615541|NCT04247958|PROCEDURE|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
214715825|NCT05121909|OTHER|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
214715826|NCT05121909|OTHER|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
214715827|NCT05121909|OTHER|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
214715828|NCT04001309|OTHER|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
214715829|NCT00788697|DRUG|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
214615542|NCT01431196|BIOLOGICAL|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
214615543|NCT05500001|BEHAVIORAL|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
214615544|NCT01771055|PROCEDURE|Galactose|Galactose dripped into the abdomen after surgery
214615545|NCT01771055|PROCEDURE|Standard surgical methods|
214615546|NCT04391036|DEVICE|High Eudragit® Content Vaginal Film|High (12.8%) Eudragit® Content Vaginal Film
214715830|NCT00788697|OTHER|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
214615547|NCT04391036|DEVICE|Low Eudragit® Content Vaginal Film|Low (6.4%) Eudragit® Content Vaginal Film
214615548|NCT00873340|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
214615549|NCT04194359|DRUG|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
214615550|NCT06273267|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
214615551|NCT00912002|DRUG|MK-0941|A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
214615552|NCT04266184|OTHER|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
214615553|NCT04266184|OTHER|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
214715831|NCT02650297|OTHER|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
214715832|NCT02650297|DEVICE|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
214715833|NCT04994080|DRUG|Paricalcitol|Paricalcitol QD Treatment
214715834|NCT04994080|DRUG|Placebo|Placebo QD or TIW
214715835|NCT03891394|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
214615554|NCT04266184|OTHER|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
214615555|NCT02509806|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
214615556|NCT01675635|DRUG|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
214615557|NCT01675635|OTHER|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
214615558|NCT05390112|BIOLOGICAL|DNA|ctDNA; cfDNA
214615559|NCT05050708|OTHER|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
214615560|NCT06362252|DRUG|Ifinatamab deruxtecan|Intravenous administration
214615561|NCT06362252|DRUG|Atezolizumab|Intravenous administration
214615562|NCT06362252|DRUG|Carboplatin|Intravenous administration
214615563|NCT02904915|DRUG|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
214615564|NCT02904915|OTHER|No analgesia|IUD placement without analgesia.
214615565|NCT02904915|DEVICE|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
214715836|NCT01998880|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
214715837|NCT01998880|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
214715838|NCT01998880|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
214715839|NCT05626244|BEHAVIORAL|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
214715840|NCT01104363|PROCEDURE|Snow white plaster 2|Test. Plaster impression not splinted.
214715841|NCT01104363|PROCEDURE|Primopattern LC gel + PVS|Control PVS impression
214715842|NCT03199638|DRUG|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
214715843|NCT03199638|BEHAVIORAL|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
214615566|NCT03241953|PROCEDURE|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
214615567|NCT06633367|OTHER|Increasing time in nature|This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.
214715844|NCT02584413|DEVICE|Magnetic resonance imaging|-Standard of care
214715845|NCT02584413|DRUG|Gadolinium contrast|-Standard of care
214715846|NCT05002699|DIAGNOSTIC_TEST|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
214615568|NCT03159091|DRUG|Rengalin|Oral administration.
214615569|NCT03159091|DRUG|Placebo|Oral administration.
214615570|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
214615571|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
214715847|NCT04613999|DRUG|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
214715848|NCT03831893|OTHER|Nopal food product 1|Dried Nopal incorporated in a food product
214715849|NCT03831893|OTHER|Nopal food product 2|Dried Nopal incorporated in a food product
214715850|NCT03831893|OTHER|control|Food Product without nopal
214715851|NCT01237028|DRUG|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
214715852|NCT06187311|DRUG|Rivaroxaban 20 MG|Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
214715853|NCT06187311|DRUG|Rivaroxaban 15 MG|Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
214715854|NCT02671461|DRUG|BMS-986141|
214715855|NCT02671461|DRUG|Aspirin|
214715856|NCT02671461|OTHER|Placebo|
214715857|NCT03226561|PROCEDURE|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
214715858|NCT04527276|OTHER|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
214715859|NCT01390480|DRUG|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
214715860|NCT02807844|DRUG|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
214715861|NCT02807844|DRUG|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
214715862|NCT02166229|DRUG|Divalproex sodium|
214715863|NCT06580860|DRUG|Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids|Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
214715864|NCT04278482|DIETARY_SUPPLEMENT|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
214715865|NCT02238548|BIOLOGICAL|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
214715866|NCT02238548|OTHER|Raw milk|
214715867|NCT04889963|BIOLOGICAL|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
214615572|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
214615573|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
214615574|NCT05865535|BIOLOGICAL|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
214615575|NCT03929666|DRUG|ZW25 (Zanidatamab)|"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
214615576|NCT03929666|DRUG|Capecitabine|Administered orally twice daily (PO bid)
214615577|NCT03929666|DRUG|Cisplatin|Administered IV
214615578|NCT03929666|DRUG|Fluorouracil|Administered IV
214615579|NCT03929666|DRUG|Leucovorin|Administered IV
214615580|NCT03929666|DRUG|Oxaliplatin|Administered IV
214615581|NCT03929666|DRUG|Bevacizumab|Administered IV
214615582|NCT03929666|DRUG|Gemcitabine|Administered IV
214615583|NCT04687787|OTHER|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
214615584|NCT04687787|OTHER|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
214615585|NCT06436066|OTHER|Self-Acupressure|"Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)"
214615586|NCT04814823|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
214615587|NCT04875715|OTHER|Almond Oil|Almond oil
214715868|NCT01343017|OTHER|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
214715869|NCT00709124|DEVICE|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
214615588|NCT04875715|DRUG|Hydroquinone Topical|Hydroquinone 2% cream
214615589|NCT04557059|RADIATION|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
214715870|NCT00709124|DEVICE|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
214715871|NCT05752786|BEHAVIORAL|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
214715872|NCT00373490|DRUG|Vorinostat|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
214615590|NCT04557059|DRUG|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
214615591|NCT04557059|DRUG|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
214615592|NCT06280482|DRUG|Nicotinamide riboside (NR)|Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
214615593|NCT02798549|OTHER|blood draw|blood draw of 150ml, twice
214615594|NCT06683937|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file
214615595|NCT06228352|OTHER|Feces collection|"A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers."
214615596|NCT04769856|OTHER|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
214615597|NCT04769856|OTHER|Satisfaction scale|Satisfaction scale
214615598|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
214615599|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
214615600|NCT06211569|OTHER|Usual follow-up|Usual follow-up
214615601|NCT05488314|DRUG|Capmatinib|Capmatinib will be administered orally.
214615602|NCT05488314|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
214615603|NCT05912517|DRUG|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
214615604|NCT05912517|DRUG|Placebo|Placebo will be administered as an intravenous infusion.
214615605|NCT04722146|DRUG|Teclistamab|Participants will receive teclistamab.
214615606|NCT04722146|DRUG|Daratumumab|Participants will receive daratumumab.
214615607|NCT04722146|DRUG|Pomalidomide|Participants will receive pomalidomide.
214715873|NCT00373490|DRUG|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
214615608|NCT04722146|DRUG|Lenalidomide|Participants will receive lenalidomide.
214615609|NCT04722146|DRUG|Bortezomib|Participants will receive bortezomib.
214615610|NCT04722146|DRUG|Nirogacestat|Participants will receive nirogacestat.
214615611|NCT05908734|DRUG|Cetrelimab|Cetrelimab will be administered as IV infusion.
214615612|NCT05908734|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
214615613|NCT06218472|OTHER|Day Hospital Treatment|Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).
214615614|NCT06218472|OTHER|"Multidisciplinary follow-up as usual within the service"|"Multidisciplinary follow-up as usual within the service"
214615615|NCT06218472|OTHER|Conduct semi-structured qualitative interviews|Conduct semi-structured qualitative interviews
214615616|NCT04119050|DRUG|M281|M281 injection administered as intravenous infusion
214615617|NCT04119050|DRUG|Placebo|Placebo administered as intravenous infusion
214615618|NCT03523442|DRUG|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
214615619|NCT04936308|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
214615620|NCT04936308|DRUG|Placebo|Participants will receive matching placebo as SC injection.
214615621|NCT04157985|DRUG|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
214615622|NCT04157985|OTHER|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
214615623|NCT05327114|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
214615624|NCT05327114|DRUG|Placebo|Placebo will be administered intravenously.
214715874|NCT00431821|BEHAVIORAL|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
214615625|NCT05741307|BEHAVIORAL|Self-hypnosis application|"The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment."
214615626|NCT05741307|OTHER|Questionnaires|"Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2"
214615627|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
214615628|NCT06083844|DRUG|Pembrolizumab|Given by IV (vein)
214615629|NCT06083844|DRUG|Bevacizumab|Given by IV (vein)
214615630|NCT06083844|DRUG|Cyclophosphamide|Given by mouth
214615631|NCT06598059|DEVICE|Cochlear implant|CI632D cochlear implant
214615632|NCT06598059|DRUG|Dexamethasone|CI632D, dexamethasone-eluting cochlear implant
214615633|NCT06852222|DRUG|Bleximenib|Bleximenib will be administered orally.
214615634|NCT06852222|DRUG|Venetoclax (VEN)|VEN will be administered orally.
214615635|NCT06852222|DRUG|Azacitidine (AZA)|AZA will be administered intravenously or subcutaneously.
214615636|NCT06852222|DRUG|Placebo|Placebo will be administered orally.
214615637|NCT03706482|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
214615638|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
214615639|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
214615640|NCT04815044|OTHER|Pregnancy|Experiences from being pregnant when having a history of eating disorder
214615641|NCT04815044|OTHER|Post-Partum|Experiences from the post-partum period when having a history of eating disorder
214615642|NCT06284902|DRUG|Fexofenadine HCl Coated tablet|Film-coated tablet.
214615643|NCT06284902|DRUG|Fexofenadine HCl New Formulation Tablet|New formulation tablet.
214615644|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
214615645|NCT04272892|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
214615646|NCT04272892|BEHAVIORAL|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
214615647|NCT06275048|OTHER|Wrist/hand immobilization|Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
214615648|NCT03583983|BEHAVIORAL|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
214615649|NCT03583983|BEHAVIORAL|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
214615650|NCT04610021|BIOLOGICAL|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
214615651|NCT01164566|PROCEDURE|endoscopic procedure|
214615652|NCT01164566|OTHER|questionnaire administration|Ancillary studies
214615653|NCT06807619|DRUG|Sotorasib|Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care
214615654|NCT03427333|DEVICE|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
214615655|NCT06979804|DEVICE|Semiconducting fabric sleeves|This intervention includes semiconductor embedded sleeves that patients will wear for 4 months post-operatively.
214615656|NCT06979804|DEVICE|Non-semiconducting fabric sleeves|This intervention includes sleeves absent of semiconductors that will be worn for 4 months post-operatively.
214615657|NCT04142528|DEVICE|ParkinPal|Wear and periodic recording of motion data during daily wear
214615658|NCT06985771|OTHER|Observational study, with no intervention.|Observational study, with no intervention.
214715875|NCT00431821|OTHER|Stroke education|Stroke education program with matched attention phone calls
214715876|NCT02729805|DRUG|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
214715877|NCT02729805|DRUG|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
214615659|NCT06985563|COMBINATION_PRODUCT|HMME-PDT|Prior to treatment, patients or their guardians provided written informed consent. Then patients were then prepared for the procedure by fully exposing the treatment area and shielding the surrounding normal skin with a black cloth. Hemoporfin (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) was administrated intravenously at a dosage of 5.0 mg/kg. Subsequently, patients underwent light radiation at 532 nm (Wuhan Yage Optic and Electronic Technique, Wuhan, China) for 18 to 25 minutes, with a power density randing form 75 to 110 mW/cm2.
214615660|NCT06985563|DEVICE|Ultrasound examinations|Ultrasound examinations were performed using three types of devices: a Paragon XHD equipped with a L38-22 probe operating at a frequency of 20-30 MHz (Kolo Medical Co., Ltd, Suzhou, China), a DUB Skin Scanner with a 22 MHz probe (Taberna Pro Medicum, German), or a Mindray Resona 7 featuring an L14-5WU linear probe set to a frequency range of 11-12 MHz frequency (Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, China).
214615661|NCT06985836|OTHER|Mulligan Mobilization and Niel Asher technique|"* Mulligan mobilization technique for shoulder external rotation and abduction as described by Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets, 3 times a week for 4 weeks are performed~* Niel Asher technique provided for 3 sessions a week for 4 weeks"
214615662|NCT06985836|OTHER|Mulligan Mobilization and Conventional physiotherapy.|"* Modalities i.e. heating pad and TENS for ten Minutes~* Postural correction exercises / Scapular retraction~* Therapeutic Exercise : Codman' s, finger ladder, wand exercises~* End Range Gleno-humeral joint stretching Both groups will come four times per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed."
214615663|NCT06986135|OTHER|Box Breathing|Box breathing consisted of a 4 second inhale, 4 second hold, 4 second exhale, 4 second hold; for 4 minutes.
214615664|NCT06986135|OTHER|Prolonged Exhalation|Prolonged Exhalation consisted of a deep, 3 second inhale, followed by a slow 6 second exhale through pursed lips, once every 30 seconds for 4 minutes.
214615665|NCT06986135|OTHER|Normal Breathing|This was the placebo, normal breathing group was instructed to breath as they normally would for the entirety of the 4 minute period.
214615666|NCT06984185|DIAGNOSTIC_TEST|combined assay on capillary blotting paper|combined assay on capillary blotting paper
214615667|NCT00232583|DRUG|Metformin|Metformin 1000mg/BID
214615668|NCT00232583|DRUG|Insulin|Insulin Novolg 70/30 per protocol titration
214615669|NCT00232583|DRUG|Metfomin|Metformin 1000mg/BID
214615670|NCT00232583|DRUG|Pioglitazone|Pioglitazone 45mg
214615671|NCT00232583|DRUG|glyburide|Glyburide per protocol titration
214615672|NCT06984614|OTHER|Snoezelen room|'Snoezelen room' is a meaning a room designed to stimulate people's senses. The history of the Snoezelen room dates back to people with mild or severe disabilities. It provides muscle relaxation for people with severe pain. This has become part of complementary medicine that promotes effective comfort and relaxation, which causes the release of endorphins and alleviates a person's capacity to cope with pain. The Snoezelen environment can be used to distract from pain by focusing on various senses, including visual and auditory. Describing multi-sensory therapeutic activity in a special room filled with stimuli that aim to stimulate all senses provides participants with feelings of relaxation and self-control (Nielsen, Overgaard, 2020; Jamshidi Manesh et. al., 2015; Anderson et. al.2011). In the study, the Snoezelen room was designed and the pregnant women in the intervention group will complete their labor in this room, while the control group will complete their labor in the
214615673|NCT03977974|DRUG|LY3526318|Administered orally
214615674|NCT03977974|DRUG|Placebo|Administered orally
214615675|NCT06618001|DRUG|JNJ-89853413|JNJ-89853413 will be administered.
214615676|NCT05556096|COMBINATION_PRODUCT|ALXN1720|Combination product consisting of syringe prefilled with ALXN1720.
214615677|NCT05556096|COMBINATION_PRODUCT|Placebo|Combination product consisting of syringe prefilled with placebo.
214615678|NCT07017335|DRUG|R1_PBK_M2301(Levocloperastine 60mg)|R1\_PBK\_M2301 is a test drug containing 60mg of levocloperastine per tablet. It is administered orally to evaluate pharmacokinetic characteristics and potential drug-drug interactions with R2\_PBK\_M2301 in healthy adult volunteers.
214615679|NCT07017335|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|R2\_PBK\_M2301 is an oral tablet containing 20 mg of Pelargonium sidoides 11% ethanol extract, used as a comparator to evaluate potential pharmacokinetic interactions with R1\_PBK\_M2301.
214615680|NCT00804531|DRUG|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
214615681|NCT00804531|DRUG|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
214615682|NCT06812078|DRUG|TAK-360|TAK-360 tablet.
214615683|NCT06812078|OTHER|Placebo|TAK-360 matching placebo tablet.
214615684|NCT04000282|DRUG|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
214615685|NCT06735833|DEVICE|Middle Meningeal Artery embolization|Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system
214615686|NCT06757712|OTHER|non linear periodization exercise|The non-linear periodized resistance training program follows a 12-week schedule with varying intensity levels across three training days per week. The intensity fluctuates between very light (VL), light (L), moderate (M), heavy (H), and very heavy (VH) workouts, distributed strategically throughout the week. Each training day implements different intensity levels, and an active rest day follows any workout session.
214715878|NCT02729805|DRUG|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
214715879|NCT03487393|DEVICE|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
214715880|NCT03574415|DRUG|DWP14012|DWP14012 tablets
214715881|NCT03574415|DRUG|Placebo|DWP14012 placebo-matching tablets
214715882|NCT03443609|DIAGNOSTIC_TEST|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
214715883|NCT04294095|OTHER|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
214615687|NCT06757712|OTHER|linear periodization exercise|The linear periodization exercise program spans 12 weeks with systematically varied training parameters. During weeks 1-2, participants perform 3 sets of 10 repetitions, followed by 3 sets of 8 repetitions in weeks 3-4. The program progresses to 4 sets of 6 repetitions in weeks 5-6, then 3 sets of 6 repetitions during weeks 7-8. The final phases consist of 4 sets of 4 repetitions in weeks 9-10, concluding with 3 sets of 4 repetitions in weeks 11-12. Training loads advance through autoregulatory progression, where participants progress at their individual pace under supervision. While sets and repetitions remain fixed within each phase, load progression is determined by performance in the final set of each exercise, ensuring safe and effective advancement.
214615688|NCT06757712|DRUG|medical treatment|The medical treatment will be received for 12 weeks.
214615689|NCT05238116|DRUG|PC945|Sterile aqueous liquid for Nebulization
214715884|NCT04294095|OTHER|Control|This is a 12-week basic prenatal education class.
214715885|NCT00306241|BIOLOGICAL|HPV-16/18 L1 VLP AS04|
214715886|NCT03159819|GENETIC|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
214715887|NCT04818541|DEVICE|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
214715888|NCT04818541|DEVICE|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
214715889|NCT00992602|DRUG|methotrexate|Given IV
214615690|NCT05238116|DRUG|Placebo|Sterile aqueous liquid for Nebulization
214615691|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
214615692|NCT06600490|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
214615693|NCT06714123|DRUG|Senicapoc|administering 30 mg senicapoc a day, in addition to standard of care.
214615694|NCT06714123|DRUG|Placebo|Tablets similar in size and color
214715890|NCT00992602|DRUG|liposomal cytarabine|Given IT or via LP
214715891|NCT00992602|OTHER|quality-of-life assessment|Ancillary studies
214715892|NCT00992602|OTHER|laboratory biomarker analysis|Correlative studies
214715893|NCT00003203|BIOLOGICAL|filgrastim|Given IV
214715894|NCT00003203|DRUG|carboplatin|Given IV
214715895|NCT00003203|DRUG|cisplatin|Given IV
214715896|NCT00003203|DRUG|cyclophosphamide|Given IV
214715897|NCT00003203|DRUG|vincristine sulfate|Given IV
214715898|NCT00003203|PROCEDURE|adjuvant therapy|
214715899|NCT00003203|RADIATION|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
214715900|NCT00860119|DRUG|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
214715901|NCT00860119|DRUG|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
214715902|NCT04863937|DEVICE|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
214715903|NCT05075707|OTHER|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
214715904|NCT05075707|OTHER|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
214715905|NCT05950971|DRUG|Amiodarone, diltiazem or esmolol|Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
214715906|NCT02629614|DEVICE|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
214715907|NCT02414971|OTHER|There is no intervention|There is no intervention
214715908|NCT01331720|DRUG|hMG-HP|
214715909|NCT01425229|DRUG|Bosentan|"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
214715910|NCT02873364|DRUG|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
214715911|NCT02873364|DRUG|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
214615695|NCT06903416|OTHER|Transcutaneous Cervical Spinal Cord Stimulation|"Cervical transcutaneous spinal cord stimulation will be delivered following previously reported guidelines. Circular (1.25) electrodes will be placed over the cervical spinal cord between the C3 and C4 vertebral level, with rectangular return electrodes placed either over the clavicles or iliac crests. Biphasic stimulation will be delivered continuously at 30Hz, with a 1ms pulse width, and overlapping 10kHz carrier frequency (Gelenitis et al 2024; Moritz et al 2024). Stimulation will be delivered at a current intensity below motor threshold, that is below the intensity required to elicit a muscle twitch. Cervical tSCS will be delivered for at least 60 minutes during each training session, and FTP will occur during the active stimulation."
214615696|NCT06903416|OTHER|Paired Corticospinal Motoneuronal Stimulation|Paired transcranial magnetic stimulation and nerve stimulation will be implemented following a previously-published protocol for individuals with SCI (Jo et al 2023). Two figure-eight coils will be used to deliver bilateral magnetic stimulation of the motor cortex and will be combined with synchronous electrical stimulation of the brachial plexus and ulnar nerves, bilaterally. The timing of stimuli will be determined to ensure that electrical volleys arrive at the corticospinal motoneuronal synapse at an appropriate interval to induce long term potentiation. During each session, 360 paired stimuli will be delivered at a frequency of 0.2 Hz. The stimulation paradigm should take approximately 30 minutes. Following this, participants will then complete 60 minutes of FTP.
214715912|NCT00373100|DRUG|Zinc acetate|
214715913|NCT00373100|DRUG|Placebo|Placebo
214715914|NCT02818127|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
214715915|NCT01095341|OTHER|No intervention performed|
214715916|NCT05840978|DIETARY_SUPPLEMENT|Probiotics|Oral capsules
214715917|NCT05840978|DIETARY_SUPPLEMENT|Placebo|Oral capsules
214715918|NCT04780945|DIAGNOSTIC_TEST|Functional RAD51 assay|ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
214715919|NCT04780945|DRUG|Olaparib Oral Product|300 mg bid
214715920|NCT00744848|DRUG|Bupivacaine HCl|100 mg Bupivacaine HCl
214715921|NCT00744848|DRUG|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
214715922|NCT00976248|DRUG|RAD001|Taken orally once a day
214715923|NCT00002544|DRUG|docetaxel|
214715924|NCT00002544|DRUG|mitoxantrone hydrochloride|
214715925|NCT02213822|OTHER|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
214715926|NCT04103775|BEHAVIORAL|Cognitive Remediation|See Cognitive Remediation Arm description.
214715927|NCT04103775|BEHAVIORAL|Active Control|See Active Control Arm description.
214715928|NCT01753388|DEVICE|Liberty Stent|
214715929|NCT02030470|OTHER|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
214715930|NCT03583788|BEHAVIORAL|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
214715931|NCT03583788|OTHER|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
214715932|NCT00113178|DEVICE|Catheter-based cardiac cryoablation|
214715933|NCT00358501|DRUG|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
214715934|NCT05448599|DRUG|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
214715935|NCT03297333|OTHER|Resistance training|The resistance training group
214715936|NCT03297333|OTHER|Aerobic interval training|The aerobic interval training group
214715937|NCT04384432|OTHER|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
214715938|NCT04384432|OTHER|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
214715939|NCT04186715|DEVICE|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
214715940|NCT00141037|DRUG|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
214615697|NCT06903416|OTHER|Functional Task Practice|A typical rehabilitation program will be defined and delivered in consultation with physical and occupational therapists. The program will consist of functional tasks including repetitive activities of gross upper extremity movement, isolated finger movements, simple and complex pinch, and grasping activities. For each category, 4-10 activities with various difficulty levels will be identified. Each participant will perform at least 1-2 exercises within each category during each treatment session. Activities in each category will be chosen according to the participants' ability and adjusted based on the evolution of the ability to perform the functional task over time (graded training).
214615698|NCT06914141|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
214715941|NCT00141037|DRUG|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m\^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m\^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
214715942|NCT00141037|DRUG|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40 kg and 1.5 mg/kg/day in subjects weighing \>40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
214715943|NCT00141037|DRUG|Tacrolimus|Taken orally from immediately preoperatively to those\>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects \<age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) \&5-7 ng/mL \>= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 \& 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
214715944|NCT00141037|DRUG|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
214715945|NCT00141037|DRUG|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
214715946|NCT00141037|DRUG|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
214715947|NCT03457311|DRUG|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
214715948|NCT03341611|BEHAVIORAL|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
214615699|NCT06914141|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the reference.
214615700|NCT06934226|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
214615701|NCT06934226|DRUG|Matching Placebo to JNJ-77242113|Matching placebo will be administered orally.
214615702|NCT06934226|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously.
214615703|NCT06934226|DRUG|Matching Placebo to Ustekinumab|Matching placebo will be administered subcutaneously.
214615704|NCT07141888|DIETARY_SUPPLEMENT|Placebo (no active ingredient)|Placebo product containing the same ingredients as the active intervention but without the active compounds
214615705|NCT07141888|DIETARY_SUPPLEMENT|Probiotics|Product contains two probiotic strains
214615706|NCT07141888|DIETARY_SUPPLEMENT|Probiotics plus fibre|Product contains two probiotic strains plus a fibre (beta-glucan)
214615707|NCT06936657|OTHER|optimized carbohydrate diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 15-20% of daily starch intake (around 40 g/day), slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 75-80%, with dietary fiber at 20-40g per 1000 kcal and free sugars contributing less than 5% of total energy.
214615708|NCT06936657|OTHER|conventional diabetes diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 5% of daily starch intake, slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 90%, with dietary fiber at 14g per 1000 kcal and free sugars contributing less than 5% of total energy.
214615709|NCT07143578|DEVICE|Operative hysteroscopy using tissue removal device|Operative hysteroscopy using tissue removal device
214715949|NCT00260429|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
214715950|NCT00628758|DRUG|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
214715951|NCT00628758|DRUG|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
214715952|NCT04179786|BIOLOGICAL|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
214715953|NCT04404803|OTHER|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
214715954|NCT05082064|DIAGNOSTIC_TEST|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
214715955|NCT00393003|DEVICE|Closed-loop anesthesia system|
214615710|NCT07143578|DEVICE|suction curettage|suction curettage using plastic scution curette
214615711|NCT07140211|DRUG|Low-dose low-molecular-weight heparin|"Low-molecular-weight heparin given for 7-10 days after delivery:~* enoxaparin 4000-6000IU o.d.~* nadroparin 3800-5700IU o.d.~* dalteparin 5000-7500IU o.d.~* tinzaparin 4500-7000IU o.d."
214615712|NCT01719055|DEVICE|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
214722108|NCT04894357|OTHER|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02\_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
214615713|NCT05934331|DRUG|LM-302|Q2W/Q3W，Administered intravenously
214615714|NCT05934331|DRUG|Toripalimab|Q2W/Q3W,Administered intravenously
214615715|NCT05934331|DRUG|Capecitabine|BID,Oral Administration
214615716|NCT05934331|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules|BID,Oral Administration
214615717|NCT05934331|DRUG|Nivolumab|Q4W,Administered intravenously
214615718|NCT05934331|DRUG|Apatinib|QD,Oral Administration
214615719|NCT05934331|DRUG|Gemcitabine|Q4W,Administered intravenously
214615720|NCT06161571|DRUG|Efruxifermin|Administered by subcutaneous (SC) injection
214615721|NCT06161571|DRUG|Placebo|Administered by SC injection
214615722|NCT05517174|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
214615723|NCT05517174|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
214615724|NCT07143227|DRUG|XW003 injection|Subcutaneous injection
214615725|NCT07143227|DRUG|placebo with matching volume|Subcutaneous injection
214615726|NCT07145827|DRUG|Metfomin|Metformin Tab. 500mg twice daily for 12 months (titrated to tolerance if needed).
214615727|NCT07145827|DRUG|tamoxifen|Standard prescribed oncological dose.
214615728|NCT07145827|DRUG|Placebo matching Metformin|"An inert, film-coated tablet identical in appearance and packaging to metformin 500 mg (same size, shape, color, coating, weight, and dosing schedule), manufactured without active ingredient using standard excipients (e.g., microcrystalline cellulose, starch/croscarmellose, povidone, magnesium stearate) and identical film coat (e.g., hypromellose, polyethylene glycol, titanium dioxide). Packaged in sealed blisters to minimize odor/taste cues. Dispensed by the investigational pharmacy per randomization; to be taken twice daily"
214615729|NCT06951919|BEHAVIORAL|Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program specifically for people who have multiple sclerosis. It incorporates education about these conditions and cognition into the education module.
214615730|NCT06948500|OTHER|Immersive Virtual Reality|"Participants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback.~To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events."
214615731|NCT06948500|OTHER|Physical Activity|Participants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload.
214615732|NCT06948799|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 1 following protocol requirements
214615733|NCT06948799|DRUG|Placebo|Subjects will receive the administration dose on Day 1 following protocol requirements
214615734|NCT06945887|PROCEDURE|embolization therapy|Identification of the main vessels afferent to the tumor to be treated. -Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters. - Injection of embolizing material (hydrogel microspheres) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
214615735|NCT07162675|DEVICE|Huawei Fit 2 Smartwatch|Participants will receive a Huawei Fit 2 smartwatch within the first week of initiating neoadjuvant systemic therapy. The device will be worn throughout the treatment period to continuously monitor step counts, physical activity intensity, sleep duration, and heart rate. It is used solely for non-invasive monitoring and does not alter the standard oncological treatment.
214615736|NCT07170254|GENETIC|BD114VLP, or BD114|"CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion."
214715956|NCT06106243|PROCEDURE|The conventional heat pressing temporary flexible maxillary removable partial denture|An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material
214715957|NCT06106243|PROCEDURE|3D-printed and digitally designed temporary flexible maxillary removable partial denture|3D-printed and digitally designed temporary flexible maxillary removable partial denture
214715958|NCT04117399|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
214715959|NCT00001127|BIOLOGICAL|Influenza virus vaccine (CAIV-T)|
214715960|NCT01095068|BEHAVIORAL|Physical exercise|
214715961|NCT03638557|OTHER|Nutritious Lunch|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
214715962|NCT01938001|DRUG|Rituximab|Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
214715963|NCT01938001|DRUG|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
214715964|NCT01938001|DRUG|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
214715965|NCT05320380|DRUG|Anti-CD123 ADC IMGN632|Given IV
214615737|NCT07170254|GENETIC|BD114VLP or BD114 plus Gel|"Genetic: BD114VLP or BD114 plus Gel CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~Multiple dosing BD114 gel (BD114 injection :Gel, 1:1) topical application on HSIL, one time every other day, total 5 times (D0, D2, D4, D6, and D8) ."
214715966|NCT05320380|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
214715967|NCT05320380|DRUG|Cytarabine|Given IT and IV
214615738|NCT07171580|OTHER|Remote Home Monitoring - Education|A virtual platform will be used to provide education to ACS patients post discharge.
214615739|NCT07171580|OTHER|Remote Home Monitoring - Education and Support|A virtual platform will be used to provide education and support to ACS patients post discharge.
214615740|NCT07170033|OTHER|Dietary Approach to Stop Hypertension (DASH) Diet|"Dietary intervention: DASH diet Participants in the intervention group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for 12 weeks. The diet plan will be personalized based on each participant's 24-hour physical activity level and basal metabolic rate. Dietary adherence will be monitored through 3-day dietary intake records and DASH diet scores calculated using the Nutrition Information System (BeBiS). The intervention aims to assess the effect of the DASH diet on inflammatory markers, disease activity scores, functional status, and quality of life in adults diagnosed with seropositive rheumatoid arthritis."
214615741|NCT07170007|OTHER|Physiotherapeutic protocol|"The women randomized to the Intervention Group will receive the following interventions:~During hospitalization: Pelvic Floor Muscle Contraction, observing the participant's ability to contract and advising on how to perform it, associated with cryotherapy and information on physiotherapy in women's health, pelvic floor muscles and its dysfunctions, as well as guidance on the care to be taken during hospitalization and after discharge, including guidance on postures to be adopted or avoided, breathing control, load management, intimate hygiene and the use of cryotherapy at home for pain relief.~After hospitalization, up to 3 months after delivery: Pelvic Floor Muscle Training in weekly online sessions and guidance to carry out the training daily at home, with the same protocols and without supervision. A total of 12 individual online sessions."
214615742|NCT07170007|OTHER|Usual maternity care|Participants in the control group will receive standard postpartum care for perineal trauma from the maternity hospital, which includes suturing the injury and oral analgesic medication.
214615743|NCT07171008|OTHER|Ney music|Ney music concert
214615744|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein + Collagen|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.
214615745|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.
214615746|NCT07171411|DIETARY_SUPPLEMENT|Collagen Peptides|Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.
214615747|NCT07171411|OTHER|Maltodextrin (Placebo)|Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.
214615748|NCT07171567|DEVICE|Vacuum erection device|"A vacuum erection device (VED) is a mechanical device designed to enhance blood flow to the corpora cavernosa by creating a vacuum environment. When combined with a constriction ring at the base of the penis, VEDs can promote and sustain an erection.~This is a prospective, uncontrolled, hypothesis-generating pilot study. Eight adult male participants with penile insensitivity will be enrolled and asked to use a VED daily for six months. Monthly self-reported questionnaire data and biweekly follow-up calls will be used to assess feasibility and to collect exploratory outcome data."
214615749|NCT07170657|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.
214615750|NCT07171268|BEHAVIORAL|Yoga Asana Chandra Harmoni|"Description: Participants randomized to the intervention group will receive the Yoga Asana Chandra Harmoni program. This program is designed to improve psychological well-being, sleep quality, and self-directed learning readiness.~Components:~Initial Face-to-Face Session: Participants will attend one in-person session led by a qualified yoga instructor. This session will introduce the principles of Yoga Asana Chandra Harmoni and provide instruction on the core asana sequence, breathing techniques (pranayama), and meditation.~Weekly Yoga Sessions: Participants will engage in three 45-minute yoga sessions per week for four weeks, practicing the Yoga Asana Chandra Harmoni sequence.~Video Support: Participants will be provided with a video demonstrating the Yoga Asana Chandra Harmoni sequence to support their home practice. The video will be shared individually via Whatsapp.~Home Practice: Participants are expected to practice the Yoga Asana Chandra Harmoni sequence independently at home,"
214715968|NCT05320380|DRUG|Fludarabine Phosphate|Given IV
214615751|NCT07170293|DRUG|Tunlametinib|Do not chew, dissolve or open the capsule. If you miss a dose of medication, you can take the missed dose 8 hours before the next dose. If the time until the next medication is less than 8 hours, it is not recommended to take it again. Every 21 days for one cycle, subjects will use the investigational drug until the treatment termination criteria specified in the protocol are met. The recommended dosage for the first dose reduction is 9mg, twice daily. The recommended second dose reduction is 6mg, twice daily.
214615752|NCT07169955|OTHER|Motivational Interviewing|Implementation of the Research in the Experimental Group Since the patients in the experimental group come from many different cities and regions, the interviews will be conducted online. It was planned to conduct weekly online individual motivational interviews with the patients for 40 minutes on one day of the week for 6 weeks. In the last session of the motivational interview (6th week), Oswetry Low Back Pain Disability Index and World Health Organization Quality of Life Scale - Short Form will be administered. Post-tests will be administered 6 weeks after these forms are administered. Three months (12 weeks) after the first interview, the tests will be administered again.
214615753|NCT07170462|DRUG|Cranberry powder|Cranberry whole powder equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols), and approximately 3.6 g of fiber.
214715969|NCT05320380|DRUG|Hydrocortisone Sodium Succinate|Given IT
214615754|NCT07170462|DIETARY_SUPPLEMENT|Placebo|placebo powder (9 g powder, no (poly)phenols, no fibers
214615755|NCT07160413|DEVICE|Electric and electromagnetic stimulation|Application of electromagnetic and electric stimulation using coils of different designs and electrodes to assess peripheral nerve sensitivity. The stimulation is momentary, non-therapeutic, and performed for basic science research purposes
214615756|NCT07170995|DRUG|SHR-8068，adebelizumab and platinum-based chemotherapy|SHR-8068，adebelizumab and platinum-based chemotherapy
214615757|NCT07170995|DRUG|tislelizumab, and platinum-based chemotherapy|tislelizumab, and platinum-based chemotherapy
214615758|NCT07169643|DRUG|Darbepoetin (DP)|Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)
214715970|NCT05320380|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214715971|NCT05320380|DRUG|Methotrexate|Given IT
214715972|NCT05320380|DRUG|Prednisolone|Given IT
214715973|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
214715974|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
214615759|NCT07170813|OTHER|Spinal hyperextension brace|The Jewett brace is a hyperextension spinal orthosis designed to limit spinal flexion and promote proper posture by applying anterior and posterior forces to the thoracolumbar spine. It is commonly used for spinal fractures, postural disorders, and to reduce spinal load. Participants will wear the Jewett brace during the intervention phase, and spinal mobility and posture will be assessed.
214615760|NCT07171047|DIETARY_SUPPLEMENT|Placebo then Verum|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
214615761|NCT07171047|DIETARY_SUPPLEMENT|Verum then Placebo|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
214615762|NCT01798368|DEVICE|PBASE system 2.0|
214615763|NCT06039124|OTHER|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
214615764|NCT03690076|OTHER|Endocarditis|Comparison : Endocarditis vs. control
214615765|NCT03690076|OTHER|Obese vs. control|Comparisons : Obese vs. control
214615766|NCT01155362|BIOLOGICAL|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
214615767|NCT01155362|DRUG|Vehice Control|
214615768|NCT06272461|DRUG|Lidocaine IV|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
214615769|NCT06272461|DRUG|Ketamine Injectable Solution|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
214615770|NCT04086394|PROCEDURE|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
214615771|NCT04086394|PROCEDURE|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
214615772|NCT03697720|DRUG|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
214615773|NCT04031144|PROCEDURE|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
214615774|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
214615775|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
214615776|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
214615777|NCT05396079|OTHER|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
214615778|NCT05396079|OTHER|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
214615779|NCT03045445|DIAGNOSTIC_TEST|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
214615780|NCT03045445|DIAGNOSTIC_TEST|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
214615781|NCT00645957|PROCEDURE|penrose drain|incision and drainage of the infection with placement of a penrose drain
214615782|NCT00645957|PROCEDURE|red rubber drain|incision and drainage of infection and placement of a red rubber drain
214615783|NCT03433014|PROCEDURE|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
214615784|NCT03433014|OTHER|Control|No infiltration
214615785|NCT00003398|BIOLOGICAL|anti-thymocyte globulin|
214615786|NCT00003398|BIOLOGICAL|filgrastim|
214615787|NCT00003398|DRUG|cyclophosphamide|
214615788|NCT00003398|DRUG|thiotepa|
214615789|NCT00003398|PROCEDURE|allogeneic bone marrow transplantation|
214715975|NCT01548794|PROCEDURE|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
214715976|NCT03056729|DRUG|BIIB076|Administered as single intravenous (IV) infusion
214615790|NCT00003398|PROCEDURE|bone marrow ablation with stem cell support|
214615791|NCT00003398|RADIATION|radiation therapy|
214615792|NCT03235648|PROCEDURE|cardiophrenic lymph nodes resection|surgical resection
214615793|NCT03464994|DIAGNOSTIC_TEST|ophthalmological examination|"* Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis"
214615794|NCT04336670|DEVICE|Immersive Virtual Reality exercise program|Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
214615795|NCT04336670|OTHER|Usual care|Usual center therapies (Physical therapy, occupational therapy..)
214615796|NCT01720342|PROCEDURE|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
214615797|NCT04024033|DIETARY_SUPPLEMENT|pine cone extract|pine cone extract capsule
214615798|NCT04024033|OTHER|placebo|placebo capsule
214615799|NCT01490099|DRUG|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
214615800|NCT01987206|DEVICE|MPC control algorithm|
214615801|NCT01987206|DEVICE|PID control algorithm|
214615802|NCT04678570|OTHER|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
214615803|NCT04678570|OTHER|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
214615804|NCT01156272|DEVICE|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
214615805|NCT03852251|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
214615806|NCT03852251|DRUG|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
214615807|NCT03852251|DRUG|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
214615808|NCT03731650|PROCEDURE|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
214615809|NCT01593293|DRUG|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
214615810|NCT01593293|DRUG|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
214615811|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
214615812|NCT04305522|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
214615813|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
214615814|NCT00350948|DRUG|Telcyta|Day 1 of 28 day Cycle.
214615815|NCT00350948|DRUG|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
214615816|NCT00751777|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
214615817|NCT00751777|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
214715977|NCT03056729|DRUG|Placebo|Administered as single IV infusion
214715978|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
214715979|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
214715980|NCT03310580|DRUG|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
214715981|NCT03162029|OTHER|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
214715982|NCT03139929|DIAGNOSTIC_TEST|MSFP|MSFPhold and MSFParm
214615818|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
214615819|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
214615820|NCT04856787|DRUG|placebo、 BP102、 XELOX|"Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
214615821|NCT00675922|DRUG|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
214715983|NCT00110474|DRUG|Glucosamine sulfate|
214715984|NCT00110474|DRUG|Acetaminophen|
214615822|NCT02863731|OTHER|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
214615823|NCT02863731|OTHER|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
214615824|NCT04615221|OTHER|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
214615825|NCT04175665|DRUG|Semaglutide|Prescription for semaglutide as part of usual clinical practice
214615826|NCT02214602|DRUG|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
214715985|NCT02326389|BEHAVIORAL|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
214715986|NCT02326389|BEHAVIORAL|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
214715987|NCT06229067|DRUG|Adebrelimab|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214715988|NCT06229067|DRUG|Vinorelbine|Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214715989|NCT06229067|DRUG|Cyclophosphamide (tablet)|Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214715990|NCT06229067|DRUG|Capecitabine|Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214715991|NCT05715944|DRUG|AZD 1222|Vaccine
214615827|NCT06051513|DRUG|treatment with or without colistin|For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
214615828|NCT05114395|OTHER|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
214615829|NCT05114395|OTHER|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
214615830|NCT01094587|PROCEDURE|Gastroschisis closure with suture|
214615831|NCT01094587|PROCEDURE|Gastroschisis closure without suture|
214615832|NCT00201968|DEVICE|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
214615833|NCT00201968|DEVICE|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
214615834|NCT00201968|OTHER|Conventional Exercise|An aerobic and resistance training program.
214615835|NCT02524522|DEVICE|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
214615836|NCT02524522|DEVICE|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
214615837|NCT02712476|DRUG|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
214615838|NCT02712476|DRUG|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
214615839|NCT02712476|DRUG|placebo|mannitol alone is compared with placebo
214615840|NCT05341479|PROCEDURE|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
214615841|NCT05341479|RADIATION|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
214615842|NCT05341479|RADIATION|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
214615843|NCT05341479|OTHER|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
214615844|NCT05341479|PROCEDURE|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
214615845|NCT00210808|DRUG|topiramate|
214615846|NCT00641550|OTHER|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
214615847|NCT00366964|DEVICE|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
214715992|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
214615848|NCT00366964|DEVICE|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
214615849|NCT01979159|BEHAVIORAL|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
214615850|NCT05283759|OTHER|No intervention because it is a patient registry|
214615851|NCT00906802|PROCEDURE|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
214615852|NCT03281668|BEHAVIORAL|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
214615853|NCT02471703|DEVICE|Total hip arthroplasty|Total hip arthroplasty
214715993|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
214615854|NCT01424111|DRUG|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
214615855|NCT01424111|OTHER|Healthy Control|No Treatment
214615856|NCT03870542|PROCEDURE|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
214615857|NCT02541279|PROCEDURE|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
214615858|NCT04425291|BIOLOGICAL|4-valent HPV Vaccine|Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
214615859|NCT04425291|BIOLOGICAL|9-valent HPV Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
214615860|NCT04425291|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
214615861|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
214615862|NCT00949832|DIETARY_SUPPLEMENT|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
214615863|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D2|50,000 IU given orally once
214615864|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU given orally once
214615865|NCT00540137|DRUG|nevirapine|400mg once daily
214615866|NCT00540137|DRUG|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
214615867|NCT01901575|DRUG|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
214615868|NCT06090214|DIAGNOSTIC_TEST|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
214715994|NCT06530108|BEHAVIORAL|PLISSIT model based sexual health education|the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
214715995|NCT02836132|BEHAVIORAL|Weight Watchers Online|
214715996|NCT02836132|BEHAVIORAL|Experience Success Virtual Reality Platform|
214715997|NCT02584777|BIOLOGICAL|Pacritinib|QD (Once a day)
214715998|NCT00002577|RADIATION|radiation therapy|
214715999|NCT06151860|OTHER|Static stretching|Stretching exercises performed by maintaining the point of muscular discomfort without changing position for a certain period of time.
214716000|NCT06151860|OTHER|Pilates stretching|Stretching exercises performed dynamically, following the six basic principles of Pilates: concentration, control, center, precision, breathing and fluidity.
214615869|NCT04347707|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
214615870|NCT03717909|DRUG|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
214716001|NCT01061320|DRUG|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
214716002|NCT01061320|DRUG|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
214716003|NCT04559269|OTHER|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
214716004|NCT04258007|DRUG|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
214716005|NCT04258007|DRUG|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
214716006|NCT00828503|DRUG|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
214716007|NCT00828503|DRUG|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
214716008|NCT02626364|DRUG|crenolanib|single-agent crenolanib at 100 mg PO TID
214716009|NCT04466072|DIAGNOSTIC_TEST|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
214716010|NCT01576120|OTHER|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
214716011|NCT01576120|OTHER|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
214716012|NCT06044129|DEVICE|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
214716013|NCT06372808|OTHER|The Plyometric Exercise|The training group will perform plyometric exercises for eight weeks in addition to their regular training program.
214716014|NCT06372808|OTHER|The Regular Training|The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
214716015|NCT03108625|DRUG|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
214716016|NCT01003613|DRUG|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
214716017|NCT01003613|OTHER|Beriplast P|0.1 ml to attach graft
214716018|NCT04537754|DEVICE|bleaching device|activated bleaching
214716019|NCT03707262|BIOLOGICAL|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
214716020|NCT00004999|DRUG|Lamivudine/Zidovudine|
214615871|NCT03717909|DRUG|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
214615872|NCT02466711|DRUG|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
214615873|NCT02466711|DRUG|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
214615874|NCT06151912|OTHER|Postoperative Nausea and Vomiting scala|The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
214615875|NCT06151912|OTHER|Quality of life|The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
214615876|NCT03066128|DIAGNOSTIC_TEST|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
214615877|NCT03066128|OTHER|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
214615878|NCT01489670|DRUG|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
214615879|NCT01129362|BIOLOGICAL|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
214615880|NCT01129362|BIOLOGICAL|Other Pertussis Vaccines|0.5 mL, Intramuscular
214615881|NCT00445874|DRUG|Ketotifen with a Contact Lens (no generic name)|
214615882|NCT00169689|PROCEDURE|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
214615883|NCT00169689|OTHER|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
214716021|NCT00004999|DRUG|Capravirine|
214615884|NCT05843435|BEHAVIORAL|Go-Nogo-task during functional magnetic resonance imaging|Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.
214615885|NCT05843435|OTHER|Resting-state functional magnetic resonance imaging|An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.
214615886|NCT00744133|BIOLOGICAL|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
214615887|NCT05947500|DRUG|Avelumab|Given IV
214615888|NCT05947500|PROCEDURE|Biopsy Procedure|Undergo biopsy
214615889|NCT05947500|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
214615890|NCT05947500|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214615891|NCT05947500|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214716022|NCT00004999|DRUG|Nelfinavir mesylate|
214716023|NCT01258517|DEVICE|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
214722109|NCT04979962|DEVICE|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
214615892|NCT05947500|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214615893|NCT05947500|DRUG|Tuvusertib|Given PO
214615894|NCT06243198|DRUG|Lebrikizumab|Administered subcutaneously (SC)
214615895|NCT06243198|DRUG|Placebo|Administered subcutaneously (SC)
214615896|NCT04606381|DRUG|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
214716024|NCT03001323|DRUG|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
214716025|NCT03001323|DRUG|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
214716026|NCT03738189|OTHER|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
214716027|NCT00002257|DRUG|Ganciclovir|
214716028|NCT02190630|DEVICE|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
214615897|NCT04606381|DRUG|Ami-LC|Participants will receive amivantamab SC infusion.
214615898|NCT04606381|DRUG|Ami-HC|Participants will receive amivantamab SC infusion.
214615899|NCT04606381|DRUG|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
214615900|NCT04606381|DRUG|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
214615901|NCT04878770|DRUG|Topical corticosteroids|Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
214615902|NCT04878770|DRUG|Systemic cyclosporine|"Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months."
214615903|NCT04878770|DRUG|Systemic dupilumab|Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
214615904|NCT03270189|DEVICE|prism glasses|orthoptic treatment by wearing prisms when writing
214615905|NCT00665899|BEHAVIORAL|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
214615906|NCT00665899|BEHAVIORAL|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
214615907|NCT06127160|DRUG|Cephalexin|Cephalexin 1000 mg by mouth 3 times daily for 10 days
214615908|NCT06127160|DRUG|Cephalexin or placebo|Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
214615909|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
214615910|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
214615911|NCT03419338|PROCEDURE|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
214615912|NCT03419338|PROCEDURE|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
214615913|NCT03419338|PROCEDURE|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
214615914|NCT03419338|PROCEDURE|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
214615915|NCT03419338|DEVICE|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
214615916|NCT04787094|OTHER|Yoga|Yoga
214716029|NCT06076772|DRUG|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
214716030|NCT05521646|OTHER|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
214716031|NCT04614350|BIOLOGICAL|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
214716032|NCT04614350|BIOLOGICAL|AlloDerm|AlloDerm tissue matrix
214615917|NCT04787094|OTHER|Spinal Stabilization Exercise|Spinal Stabilization Exercise
214615918|NCT06440109|OTHER|Emotional freedom technique (EFT)|İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.
214615919|NCT06440109|OTHER|Therapeutic touch (TD)|İntervention groups will be followed for six weeks and one of the six TD therapies will be applied, one session every week.
214615920|NCT05796375|PROCEDURE|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
214615921|NCT05796375|DIAGNOSTIC_TEST|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
214615922|NCT05796375|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
214716033|NCT02539914|OTHER|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
214716034|NCT02539914|OTHER|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
214716035|NCT02877667|DEVICE|planar acoustic wave device|accessory to laser treatment
214716036|NCT01620450|DRUG|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
214716037|NCT01670812|DRUG|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
214716038|NCT05754801|DRUG|Yunzhi Essence|Yunzhi Essence capsule
214716039|NCT05754801|OTHER|Placebo|Placebo capsules
214716040|NCT00527969|DRUG|HT1001 extract of Panax quinquefolius L|
214615923|NCT05139849|DRUG|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
214615924|NCT05139849|DRUG|Sodium chloride|Sodium chloride 9 mg/ml
214615925|NCT05304650|DEVICE|iTEAR100|Controlled Stimulation External Nasal Nerve to stimulate tear production
214615926|NCT03482687|BEHAVIORAL|Me & You: Building Healthy Relationships|Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
214615927|NCT00151983|DRUG|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
214615928|NCT02132884|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
214615929|NCT02132884|PROCEDURE|therapeutic procedure|Receive standard of care treatment
214615930|NCT02132884|DRUG|targeted therapy|Receive specific targeted therapy
214615931|NCT02132884|OTHER|laboratory biomarker analysis|Correlative studies
214615932|NCT01965639|OTHER|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
214615933|NCT00907751|DRUG|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
214615934|NCT01940471|DRUG|TAF|25 mg tablet administered orally once daily
214615935|NCT01940471|DRUG|TDF|300 mg tablet administered orally once daily
214615936|NCT01940471|DRUG|TAF Placebo|Tablet administered orally once daily
214615937|NCT01940471|DRUG|TDF Placebo|Tablet administered orally once daily
214615938|NCT04941066|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
214615939|NCT04941066|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
214615940|NCT00454285|DRUG|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
214615941|NCT06090526|DIAGNOSTIC_TEST|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
214615942|NCT01191866|BEHAVIORAL|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
214615943|NCT05039333|DEVICE|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
214615944|NCT04592744|DRUG|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
214615945|NCT04592744|DRUG|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
214615946|NCT05253651|DRUG|tucatinib|300mg given by mouth (orally) twice daily
214615947|NCT05253651|DRUG|trastuzumab|8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
214716041|NCT01495923|PROCEDURE|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
214716042|NCT01495923|PROCEDURE|Sham epidural steroid injection|Injection of saline into the back muscles
214716043|NCT01495923|DRUG|Gabapentin|Titration of gabapentin to effect
214716044|NCT01495923|DRUG|Placebo gabapentin|Titration of placebo gabapentin
214716045|NCT02762708|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
214615948|NCT05253651|DRUG|bevacizumab|5mg/kg given by IV every 2 weeks
214615949|NCT05253651|DRUG|cetuximab|400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
214615950|NCT05253651|DRUG|oxaliplatin|85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
214615951|NCT05253651|DRUG|leucovorin|400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
214615952|NCT05253651|DRUG|levoleucovorin|200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
214615953|NCT05253651|DRUG|fluorouracil|400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
214615954|NCT03193151|PROCEDURE|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
214615955|NCT06285318|OTHER|Teclistamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
214615956|NCT06285318|OTHER|Talquetamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
214615957|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
214615958|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
214615959|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
214615960|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
214615961|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
214615962|NCT06162676|BEHAVIORAL|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
214615963|NCT06264752|OTHER|Level A|Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
214615964|NCT06264752|OTHER|Level B|The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
214615965|NCT06264752|OTHER|Passive Alert|Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
214615966|NCT06532032|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
214615967|NCT06532032|DRUG|Docetaxel|Docetaxel will be administered as IV infusion.
214615968|NCT03461419|PROCEDURE|Microcannula Harvest Adipose Stroma|Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
214615969|NCT03461419|DEVICE|Centricyte 1000|Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
214615970|NCT03461419|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
214615971|NCT05620719|BEHAVIORAL|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
214615972|NCT05620719|OTHER|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
214615973|NCT05620719|OTHER|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
214615974|NCT05652335|DRUG|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
214615975|NCT06293040|DRUG|Cannabis|Cannabis will be vaporized using the Mighty Medic
214615976|NCT06293040|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
214615977|NCT06293040|DRUG|Placebo Cannabis|Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
214615978|NCT06293040|DRUG|Placebo Alcohol|A non-alcoholic, placebo, flavored drink will be orally ingested.
214615979|NCT05432323|BEHAVIORAL|Multi-family therapy|8 sessions of Multi-family therapy of 3 hours each during 24 weeks
214615980|NCT03740165|BIOLOGICAL|Pembrolizumab|IV infusion
214615981|NCT03740165|DRUG|Placebo for pembrolizumab|IV infusion
214615982|NCT03740165|DRUG|Carboplatin|IV infusion
214615983|NCT03740165|DRUG|Paclitaxel|IV infusion
214615984|NCT03740165|DRUG|Olaparib|Oral tablet
214615985|NCT03740165|DRUG|Placebo for olaparib|Oral tablet
214615986|NCT03740165|BIOLOGICAL|Bevacizumab|IV infusion
214615987|NCT03740165|DRUG|Docetaxel|IV infusion
214615988|NCT02044133|OTHER|Dosage Vitamine D|
214615989|NCT05901649|DRUG|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
214615990|NCT05901649|DRUG|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
214615991|NCT04883619|OTHER|Placebo|Placebo will be administered intravenously.
214615992|NCT04883619|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
214615993|NCT04883619|DRUG|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
214615995|NCT06851507|DRUG|Fluorouracil 5-FU|Participants in the fluorouracil arm will apply fluorouracil twice daily for 2-3 weeks (depending on body area).
214615996|NCT06851507|DRUG|Fluorouracil/Calcipotriene|Participants in the fluorouracil/calcipotriene will apply fluorouracil/calcipotriene twice daily for 4 days to the affected area.
214615997|NCT06582173|OTHER|Face-to-face interviews assisted by a biographical grid|"Face-to-face interviews assisted by a biographical grid.~Healthcare event of the adolescent :~* medical specialist appointment~* general practitioner appointment~* emergency services use~* hospital admission~* diagnostic test~* medication use~* non-pharmacological treatment~* nursing or physical therapy~* alternative care~Biographical of the adolescent :~* Education event~  * Class/level~ * School~ * Attendance~ * Special arrangements~ * Grades~ * Off school education~* Family event~  * Separation/union~ * Birth/death~ * Leave/Arrival~ * Location/Moving~ * Disease/accident~* Peer events~  * Friendships~ * Love interests~ * Bullying~* Leisure \& interests events~  * Activity~ * Frequency"
214615998|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
214615999|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
214616000|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
214616001|NCT05208762|DRUG|PF-08046054|Given into the vein (IV; intravenously)
214616002|NCT05208762|DRUG|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
214616003|NCT06150157|DRUG|JNJ-88549968|JNJ-88549968 will be administered.
214616004|NCT05424822|DRUG|JNJ-80948543|JNJ-80948543 will be administered as SC or IV injection.
214716046|NCT02762708|BEHAVIORAL|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
214716047|NCT02762708|DRUG|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
214716048|NCT02762708|DRUG|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
214616005|NCT06553625|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
214616006|NCT05754957|DRUG|Milvexian|Milvexian will be administered orally.
214616007|NCT05754957|OTHER|Placebo|Placebo will be administered orally.
214616008|NCT04540796|DRUG|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
214616009|NCT06012435|DRUG|sigvotatug vedotin|Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
214716049|NCT01496170|DRUG|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
214716050|NCT01496170|DRUG|Placebo|Placebo capsules, orally, once per day for 7 days
214616010|NCT06012435|DRUG|docetaxel|75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
214616011|NCT05089799|BEHAVIORAL|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~1. welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~2. providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~3. providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~4. providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~5. Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
214616012|NCT05318937|DRUG|SAGE-718-matching placebo|Oral capsules
214616013|NCT05318937|DRUG|SAGE-718|Oral capsules
214616014|NCT01208792|PROCEDURE|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
214616015|NCT01208792|OTHER|Blood Sample|a blood sample will be collected
214616016|NCT05272150|DRUG|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
214616017|NCT05272150|DRUG|Placebo|Participants will receive placebo as subcutaneous injection.
214616018|NCT05441488|DRUG|Placebo|treatment per os
214616019|NCT05441488|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
214616020|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
214616021|NCT06295692|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
214616022|NCT04209153|OTHER|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
214616023|NCT02699645|DRUG|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 pill taken orally once daily for average of 72 months
214616024|NCT02699645|DRUG|Placebo|1 pill taken orally once daily for average of 72 months
214616025|NCT05359679|BEHAVIORAL|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
214616026|NCT05359679|OTHER|No Intervention|Usual clinical care - no value champion present at this clinical setting
214616027|NCT06965881|DRUG|Radiprodil with Carbamazepine|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 30mg along with oral doses of Carbamazepine in the range of 100mg to 300mg twice daily over a period of 27 days.
214616028|NCT06965881|DRUG|Radiprodil with Itraconazole|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 15mg along with oral doses of Itraconazole 200mg twice daily over a period of 21 days.
214616029|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active|The study will utilize the H4 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the bilateral insula, a core salience network node.
214716051|NCT01115088|DIETARY_SUPPLEMENT|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
214616030|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham|The study will utilize an identical protocol using the H4 coil to administer a sham condition.
214616031|NCT04130997|BIOLOGICAL|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
214616032|NCT03320902|BEHAVIORAL|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
214616033|NCT04221854|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|Stool-based SDC2 DNA methylation test
214616034|NCT04221854|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test
214616035|NCT04149015|DRUG|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
214616036|NCT06312943|OTHER|Collection of joint fluid or tissue sample|During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
214616037|NCT06275789|PROCEDURE|Alveolar ridge preservation|Premolar tooth will be extracted flapless and ridge preservation procedure with bone grafting material will be done.
214616038|NCT06948591|DEVICE|Anterior cruciate ligament reconstruction with BioBrace® augmentation|An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.
214616039|NCT06948591|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction|An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.
214616040|NCT06393127|DRUG|BI 1015550 Formulation C2|BI 1015550 Formulation C2
214616041|NCT06393127|DRUG|BI 1015550 Formulation C1|BI 1015550 Formulation C1
214616042|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
214616043|NCT03970096|DRUG|Thiotepa|Given IV
214616044|NCT03970096|DRUG|Fludarabine|Given IV
214616045|NCT03970096|DRUG|Tacrolimus|Given IV
214616046|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
214616047|NCT03970096|DRUG|Methotrexate|Given IV
214616048|NCT03970096|DRUG|Cyclophosphamide|Given IV
214616049|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
214616050|NCT03970096|DRUG|Cyclosporine|Given IV
214616051|NCT03970096|DRUG|Sirolimus|Given IV
214616052|NCT03970096|DRUG|Busulfan|Given IV
214616053|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
214616054|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
214616055|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214616056|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214616057|NCT03339011|BEHAVIORAL|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
214616058|NCT03521024|OTHER|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
214616059|NCT03521024|OTHER|lithium disilicate|well documented in the literatures as successful restoration modality.
214616060|NCT06404125|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities. Flexion, extension, abduction, adduction, internal and external rotation angles of the shoulder complex will be evaluated in the measurement.
214616061|NCT06404125|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 10 seconds. The test will be repeated for both upper extremities separately.
214616062|NCT06404125|DIAGNOSTIC_TEST|Numeric Rating Scale|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
214616063|NCT06404125|DIAGNOSTIC_TEST|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point"
214616064|NCT06404125|DIAGNOSTIC_TEST|Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH)|The arm, shoulder and hand problems rapid questionnaire is a shortened version of a questionnaire designed to detect symptoms and loss of function secondary to musculoskeletal problems of the upper extremity. The questionnaire will be used to assess quality of life related to upper extremity function.
214616065|NCT06404125|DIAGNOSTIC_TEST|Short Form-36|The scale was developed by Ware in 1987 and consists of 36 questions in which 8 sub-parameters related to the health status of the person are questioned. These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception. The Turkish validity and reliability of the scale was performed by Pınar et al. It is one of the leading methods used in the evaluation of quality of life in our country as well as all over the world.
214616066|NCT06404125|DIAGNOSTIC_TEST|Central Sensitization Scale|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization are questioned. In part B, the presence of diseases with a well-defined relationship with central sensitization is questioned without participating in the scoring. Patients who score 40 points or more out of a total of 100 points are considered to have central sensitization. Düzce et al. stated that the Central Sensitization Scale can be used as a valid method in the Turkish population to screen the presence of central sensitization in patients presenting with chronic pain.
214616067|NCT06404125|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
214616068|NCT06851091|DIAGNOSTIC_TEST|Biodex Balance System|Biodex Balance System \[Biodex Balance System SD (Biodex, Inc, Shirley, NY) (BBS)\]:The Biodex Balance System is a computer-assisted device that assesses postural stability. It measures static and dynamic balance, fall risk, and proprioception through different difficulty levels and test protocols. In our study, this system will be used to investigate the relationship between balance and central sensitization. Participants will be evaluated using the postural stability test, fall risk test, athlete single leg test, and limits of stability test protocols, and they will be trained before the testing process.
214616069|NCT06851091|DIAGNOSTIC_TEST|Pressure Pain Threshold (PPT) Measurement with Algometer|Pressure pain threshold (PPT) is defined as the minimum force applied that causes pain. This measurement is commonly used for assessing tender points and has been shown to be useful.
214616070|NCT06851091|DIAGNOSTIC_TEST|Conditioned Pain Modulation (CPM)|According to this protocol, a pressure stimulus, referred to as the test stimulus, will first be applied to the trapezius muscle to induce a pain intensity of 4 on a 10-point Numeric Rating Scale (NRS). Subsequently, a conditioning stimulus will be introduced by immersing the participant's right hand in 7°C water for 20 seconds. Following this conditioning stimulus, the same test stimulus will be reapplied to the trapezius muscle, and participants will be asked to rate their pain using the NRS. If participants are unable to keep their hands in the water for the full 20 seconds, the test stimulus will be applied immediately after hand removal. The CPM score will be calculated as the ratio of the initial NRS score to the second NRS score, multiplied by 100. Scores above 100 are considered indicative of a normal CPM response, with higher scores reflecting greater descending pain inhibition.
214616071|NCT06851091|DIAGNOSTIC_TEST|Slowly Repeated Evoked Pain Assessment Protocol (SREP)|"Responses to induced pain indicate the presence of allodynia and hyperalgesia in FMS patients. The Slow Repetitive Evoked Pain (SREP) protocol consists of nine suprathreshold painful stimuli applied to the nail bed for five seconds each, with 30-second intervals. Painful stimulation will be administered using a pressure algometer with a 1 cm² stimulation surface. Nailbed pain stimuli are commonly used to assess pain sensitivity.~The intensity of pain perception from each SREP stimulus will be evaluated using a 10-point Numerical Rating Scale (NRS) (0 = no pain, 10 = extremely painful). The SREP sensitization index will be calculated as the difference between the final and initial pain scores.~Higher positive SREP sensitization index values indicate a greater increase in perceived pain intensity across the nine stimuli, reflecting higher pain sensitization."
214616072|NCT06851091|DIAGNOSTIC_TEST|Central Sensitization Inventory (CSI)|"The Central Sensitization Inventory (CSI) is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization.~The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.~This scale has been shown to be a reliable and valid tool in the Turkish population with chronic pain (test-retest reliability = 0.92, Cronbach's alpha = 0.93)"
214616073|NCT06851091|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Numeric Rating Scale (NRS) will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
214616074|NCT06851091|DIAGNOSTIC_TEST|Revised Fibromyalgia Impact Questionnaire (FIQ)|Revised Fibromyalgia Impact Questionnaire (FIQ) consists of three sections: function, general, and symptoms, with a total of 21 questions. It evaluates the limitations and functional disability that occur in patients with fibromyalgia. All questions are scored on the Numeric Rating Scale (NRS), ranging from 0 to 10. As the score from the questionnaire increases, it indicates a higher level of disability related to fibromyalgia. In our study, the Turkish version of the questionnaire, which has been validated and shown to be reliable, will be used.
214616075|NCT06851091|DIAGNOSTIC_TEST|S-LANSS Pain Score (Self-administered Leeds Assessment of Neuropathic Symptoms and Signs)|The S-LANSS pain score is a 7-item self-administered scale developed and validated to recognize neuropathic pain in chronic pain patients and distinguish it from nociceptive pain. It evaluates neuropathic symptoms and signs through a series of questions that help identify features like hyperalgesia, allodynia, and paresthesia, which characterize the chronic pain sensation associated with neuropathic pain. These features are often seen in fibromyalgia (FMS) pain. In our study, the Turkish version of the questionnaire, which has undergone validity and reliability testing, will be used.
214716052|NCT01115088|DIETARY_SUPPLEMENT|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
214716053|NCT01115088|DIETARY_SUPPLEMENT|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
214616076|NCT06851091|DIAGNOSTIC_TEST|Tampa Kinesiophobia Scale (TKS)|"The Tampa Kinesiophobia Scale is a 17-item measure designed to assess fear of movement/re-injury. The scale evaluates fear-avoidance behaviors related to work activities, injury/re-injury concerns, and fear-avoidance parameters. It is used in the context of acute and chronic low back pain, fibromyalgia (FMS), musculoskeletal injuries, and whiplash-associated disorders.~The scale uses a 4-point Likert scoring system (1 = Strongly disagree, 4 = Strongly agree). After reversing the scores for items 4, 8, 12, and 16 (for example, if a participant selects 1 for these items, it is counted as 4; 2 is counted as 3, etc.), the total score is calculated. The participant receives a score between 17 and 68. A higher score on the scale indicates a higher level of kinesiophobia. In our study, the Turkish version of the scale, which has undergone validity and reliability testing, will be used."
214616077|NCT06851091|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale (HAD)|"This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21:~* 0-7 points: No symptoms or very mild symptoms~* 8-10 points: Moderate symptoms~* 11 points or higher: Symptoms likely corresponding to a clinical diagnosis of anxiety and depression According to the 2016 diagnostic criteria for Fibromyalgia Syndrome (FMS), the presence of depression contributes to the diagnosis of FMS. The HAD scale has been shown to be a suitable tool for assessing FMS and related patient education programs.~In our study, the Turkish version of the HAD scale, which has been validated and shown to be reliable, will be used."
214616078|NCT06851091|DIAGNOSTIC_TEST|SF-12 Health Survey (SF-12 Quality of Life Scale)|The SF-12 Health Survey is one of the most widely used scales for assessing health-related quality of life. In our study, the Turkish version of the SF-12, which has been validated and shown to be reliable, will be used. The scores will be calculated using an online calculation tool, and two types of scores-Physical Component Summary (PCS) and Mental Component Summary (MCS)-will be obtained.
214616079|NCT06851091|DIAGNOSTIC_TEST|Fatigue Severity Scale (FSS)|The Fatigue Severity Scale (FSS) is a 9-item questionnaire used to assess the severity, frequency, and impact of fatigue on daily life. Each item is rated on a scale from 1 to 7. A lower score indicates a decrease in fatigue severity. In our study, the Turkish version of the scale, which has been validated and shown to be reliable, will be used.
214616080|NCT06851091|DIAGNOSTIC_TEST|Timed Up and Go Test (TUG)|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for participants to stand up and walk. The patient begins by sitting on a standardized chair (height of 46 cm). During the test, the patient is asked to stand up from the chair, walk 3 meters, turn around, and return to sit back on the chair. The time taken to complete this process is measured. Lower values indicate better stability. A cut-off value of 13.5 seconds is used to identify individuals at higher risk of falling.
214616081|NCT03970954|DRUG|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
214616082|NCT05983133|DRUG|PF-08046052|Given into the vein (IV; intravenously)
214716054|NCT01062009|DRUG|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
214716055|NCT03145597|DEVICE|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
214716056|NCT03145597|DEVICE|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
214716057|NCT05199883|OTHER|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
214716058|NCT00217009|PROCEDURE|Narrowband Ultraviolet B (TL-01UVB) Therapy|
214716059|NCT00217009|PROCEDURE|Topical Psoralen plus ultraviolet A (PUVA)|
214716060|NCT04100291|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
214616083|NCT06012786|DIAGNOSTIC_TEST|Diagnostic Criteria of Myofascial Pain Syndrome|"Major criteria:~1. The patient's complaint of regional pain~2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point~3. Presence of palpable taut band~4. Presence of palpable and tender points along the length of the taut band~5. Restriction of ROM in the area of the affected muscle~Minor criteria:~1. Pain/sensory change with pressure palpation of the trigger point~2. Local twitch response with palpation/injection of the trigger point in the taut band~3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis"
214616084|NCT06012786|DIAGNOSTIC_TEST|The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer|Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
214616085|NCT06012786|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
214616086|NCT06012786|DIAGNOSTIC_TEST|VAS|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
214616087|NCT06012786|DIAGNOSTIC_TEST|Quick DASH|The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
214616088|NCT06012786|DIAGNOSTIC_TEST|Lymqol-Arm|Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
214616089|NCT06012786|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
214616090|NCT04289402|OTHER|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
214616091|NCT04289402|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
214616092|NCT00881218|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
214616093|NCT05981209|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214616094|NCT05981209|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214616095|NCT05981209|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214616096|NCT05981209|PROCEDURE|Computed Tomography|Undergo CT
214616097|NCT05981209|DRUG|Dexamethasone|Given IV or PO
214616098|NCT05981209|PROCEDURE|Echocardiography|Undergo ECHO
214616099|NCT05981209|BIOLOGICAL|Elotuzumab|Given IV
214616100|NCT05981209|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214616101|NCT05981209|BIOLOGICAL|Mezigdomide|Given PO
214616102|NCT05981209|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214616103|NCT04297085|BIOLOGICAL|Biologic sample|Biological samples will be taken from the subjects included
214616104|NCT03232411|OTHER|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
214616105|NCT03232411|OTHER|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
214716061|NCT04100291|OTHER|Placebo|Placebo by daily enema with placebo mixture
214716062|NCT00821860|OTHER|talc|Talc pleurodesis
214716063|NCT00821860|PROCEDURE|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
214716064|NCT00821860|PROCEDURE|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
214616106|NCT03232411|OTHER|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
214616107|NCT05678257|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
214616108|NCT05678257|DRUG|Leucovorin|Intravenous infusion
214616109|NCT05678257|DRUG|Irinotecan|Intravenous infusion
214616110|NCT05678257|BIOLOGICAL|Bevacizumab|Intravenous infusion
214616111|NCT05678257|DRUG|5-FU|Intravenous infusion
214616112|NCT06518954|OTHER|Interview|The athletes contributes with experience exchange through individual interviews, following a interview template
214616113|NCT05145998|DIETARY_SUPPLEMENT|Glucola|50 grams of Glucola sugar beverage
214616114|NCT05145998|DIETARY_SUPPLEMENT|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
214716065|NCT00000440|DRUG|naltrexone (Revia)|
214716066|NCT00000440|DRUG|sertraline (Zoloft)|
214716067|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
214716068|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
214616115|NCT05145998|DIETARY_SUPPLEMENT|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
214616116|NCT05145998|DIETARY_SUPPLEMENT|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
214616117|NCT05145998|DIETARY_SUPPLEMENT|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
214616118|NCT05338775|DRUG|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
214616119|NCT05338775|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
214616120|NCT05338775|DRUG|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
214616121|NCT04996823|DRUG|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
214616122|NCT04996823|DRUG|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
214716069|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
214716070|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
214616123|NCT00806247|DRUG|tapentadol HCl|
214616124|NCT06065462|DRUG|Dostarlimab|Given by vein (IV)
214616125|NCT06065462|DRUG|LB-100|GIven by vein (IV)
214616126|NCT06970314|DEVICE|Lokomat|Exoelectric walking aid for patients who have suffered a stroke
214616127|NCT06970314|DEVICE|C-Mill|Exoelectric walking aid for patients who have suffered a stroke
214616128|NCT04445675|OTHER|Support for breastfeeding and the feeding of infants' with breast milk|The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
214716071|NCT04429412|BEHAVIORAL|MCT+|Metacognitive training
214616129|NCT06969898|OTHER|Single Ultramarathon runners|All participants underwent the same protocol: two laboratory assessments, a 106 km race, and post-race physiological parameter evaluations at 24 hours and 48 hours.
214616130|NCT03832179|DRUG|Bevacizumab|Bevacizumab
214616131|NCT03832179|DRUG|Ranibizumab|Ranibizumab
214616132|NCT03832179|DRUG|Aflibercept|Aflibercept
214616133|NCT03832179|DRUG|Ozurdex|Ozurdex
214616134|NCT06970756|BIOLOGICAL|26-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.
214616135|NCT06970756|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.
214716072|NCT04366713|DRUG|Neratinib|Administered orally once daily as a single daily dose of 240 mg
214716073|NCT04366713|DRUG|Capecitabine|Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
214716074|NCT04366713|DRUG|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
214616136|NCT05835843|OTHER|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
214616137|NCT06647511|DEVICE|Nokia-Withings BPM Connect Blood Pressure Monitor|At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.
214616138|NCT06647511|DEVICE|Smartwatch Devices|Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
214616139|NCT06233799|DRUG|extended-release naltrexone (XR-NTX)|Once per three weeks injections of extended-release naltrexone
214616140|NCT06233799|DRUG|extended release bupropion (BUP-XL) tablets (BUP-XL)|Daily oral extended release bupropion tablets
214616141|NCT06233799|DRUG|iPLB|Once per three weeks injections of placebo
214616142|NCT06233799|DRUG|oPLB|Daily oral placebo tablets
214616143|NCT06437717|OTHER|application of different topical nasal solutions|each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients
214616144|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
214616145|NCT06046339|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
214616146|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
214716075|NCT02532387|OTHER|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
214716076|NCT05409846|DIAGNOSTIC_TEST|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
214716077|NCT01781663|DEVICE|KAM2904 Face Cream|
214716078|NCT01781663|DEVICE|KAM3008 Body Lotion|
214716079|NCT01781663|OTHER|petrolatum-based moisturizer|
214616147|NCT06138509|OTHER|Dosage of serotonin and metabolites|The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.
214616148|NCT06138509|OTHER|Blood parameters|The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
214616150|NCT04678882|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
214616151|NCT04678882|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
214616152|NCT05002816|DRUG|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
214616153|NCT05002816|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
214616154|NCT04590170|BEHAVIORAL|Post-intensive Care unit syndrome|Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19
214616155|NCT04590170|OTHER|Spatiotemporal measurements of walking|Spatiotemporal measurements of walking in asymptomatic participants from the general population.
214616156|NCT04389632|DRUG|sigvotatug vedotin|Administered into the vein (IV; intravenously)
214616157|NCT04389632|DRUG|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
214616158|NCT04389632|DRUG|cisplatin|75 mg/m2 every 3 weeks, given by IV
214616159|NCT04389632|DRUG|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
214716080|NCT00892957|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
214716081|NCT00892957|OTHER|Surgical gauze pads|Manual compression with surgical gauze pads
214716082|NCT00554138|DRUG|placebo|1 dd for 7-10 days
214716083|NCT00554138|DRUG|rosuvastatin|1 dd 20 mg for 7-10 days
214716084|NCT01989182|DEVICE|Spiration Valve System|
214716085|NCT01989182|OTHER|Medical Management|
214716086|NCT05904353|PROCEDURE|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
214716087|NCT05904353|PROCEDURE|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
214616160|NCT02822846|OTHER|lung ultrasound|
214616161|NCT05314517|DRUG|Namilumab|Namilumab administered subcutaneously
214616162|NCT05314517|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
214616163|NCT06168942|DEVICE|Experimental: Laminar Left Atrial Appendage Closure System|Treatment with the Laminar Left Atrial Appendage Closure System.
214616164|NCT06168942|DEVICE|Active Comparator: WATCHMAN / Amulet|Treatment with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder.
214616165|NCT04969276|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
214616166|NCT04969276|BIOLOGICAL|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
214616167|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
214616168|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
214616169|NCT05424926|OTHER|collection of clinical parameters and blood sample|"* A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
214616170|NCT05285566|DRUG|Exparel|106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
214616171|NCT05285566|DRUG|Xylocaine|8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
214616172|NCT06501820|DEVICE|Transcranial direct current stimulation|2mA transcranial direct current stimulation, applied bilaterally on the scalp, over the brain vestibular cortex
214616173|NCT05721846|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
214616174|NCT05721846|DRUG|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
214616175|NCT05721846|RADIATION|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
214616176|NCT05721846|BIOLOGICAL|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
214616177|NCT04692675|DIAGNOSTIC_TEST|mpMRI|3T endorectal coil MR imaging of the prostate gland
214616178|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
214616179|NCT04312672|BIOLOGICAL|AAV5-hRKp.RPGR|Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
214616180|NCT04551677|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"
214616181|NCT04551677|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"
214616182|NCT03289923|DEVICE|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
214616183|NCT03289923|DEVICE|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
214616184|NCT06976008|OTHER|blood sampling|Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
214616185|NCT05092269|DRUG|Ustekinumab|Ustekinumab will be administered as a SC injection.
214616186|NCT06804538|PROCEDURE|Insemination between 42 and 43 hours post hCG|Patients will be stimulated by gonadotropins, ovulation will be blocked by a GnRH antagonist then triggered by hCG allowing IU to occur between 42 and 43 hours post hCG
214616187|NCT06804538|PROCEDURE|Insemination between 36 and 37 hours post hCG|Patients will be stimulated with gonadotropin and GnRH antagonist whose ovulation will be triggered and for which intrauterine insemination will be carried out between 36 and 37 hours post hCG
214616188|NCT05316311|DEVICE|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
214616189|NCT06255496|DIAGNOSTIC_TEST|Quantra Hemostasis Analyzer with the QStat Cartridge|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214616190|NCT04808427|DEVICE|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
214616191|NCT04655144|DRUG|Dexamethasone|Dexamethasone delivered to the uterine arterial bed, prior to embolization.
214616192|NCT04655144|DRUG|Saline|Saline delivered to the uterine arterial bed, prior to embolization.
214616193|NCT01656148|DRUG|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
214616194|NCT03470584|OTHER|Diet Exposure|Vegetarian diet vs nonvegetarian diet
214616195|NCT06545071|BEHAVIORAL|NEAT-O program|NEAT-O's curriculum is designed to interrupt the cycle of negative emotions and opioid use through a multifaceted approach encompassing physiological, psychological, and behavioral strategies. The program includes interactive modules that capture the core therapeutic components of CBT and teach skills to support OUD recovery.
214616196|NCT01430286|BEHAVIORAL|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
214616197|NCT01430286|BEHAVIORAL|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
214616198|NCT03543865|BEHAVIORAL|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
214616199|NCT03543865|BEHAVIORAL|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
214616200|NCT03543865|OTHER|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
214616201|NCT06057181|GENETIC|Exome sequencing|Exome sequencing will be completed on each sample submitted.
214616202|NCT05039619|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
214616203|NCT05039619|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
214616204|NCT05039619|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
214616205|NCT05039619|DRUG|Acetaminophen/paracetamol|Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
214616206|NCT05039619|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
214616207|NCT05039619|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
214616208|NCT05039619|DRUG|Prednisone|Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
214616209|NCT06967753|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Enrolled participants will be switched to a dual therapy regimen consisting of 50-mg DTG plus 300-mg 3TC tablet (as a single pill fixed dose combination) orally administered once daily with or without food. No dose reductions, modifications in dosage, or changes in the frequency of dosing will be allowed in this study.
214616210|NCT06311188|BEHAVIORAL|ITR Healing intervention|This is a nonrandomized test of the culturally adapted ITR healing intervention that is based on the ITR framework. The ITR Healing intervention comprises six 60-minute sessions based on Intersectionality theoretical framework, Healing Centered Engagement (HCE) activities that were integrated into the intervention, as well as participant's feedback about the intervention. Also, the participants' behavioral experiences per the Theoretical Domains Framework targets was used to adapt the intervention activities. HCE focuses on building a holistic approach and empathy for each session, i.e., using music, dance/movement, meditation, breathing and journaling.
214616211|NCT04413331|OTHER|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
214616212|NCT04413331|OTHER|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
214616213|NCT04490018|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
214616214|NCT04490018|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
214616215|NCT04490018|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214616216|NCT04490018|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214616217|NCT06227884|OTHER|APN intervention|"Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
214616218|NCT06227884|OTHER|No APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months)
214616219|NCT04714073|DRUG|BI 706321|Treatment period 1: Single oral dose of 1 film-coated tablet administered with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) Treatment period 2: On day 1 of period 2 (1 h after the itraconazole administration) a single oral dose of 1 film-coated tablet administered with 240 mL of water after an overnight fast of at least 10 h.
214616220|NCT04714073|DRUG|Itraconazole|Treatment period 2: Administered as an oral solution formulation once daily for 14 days orally with 240 mL of water after an overnight fast of at least 9 h, starting from day -3 up to day 11 of period 2.
214616221|NCT05091983|OTHER|Sensory Processing Scale Inventory (SPSI)|The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire
214616222|NCT05091983|OTHER|Autism Spectrum Screening Quotient (ASSQ)|"The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents."
214616223|NCT05091983|OTHER|GAD 7|"The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire."
214616224|NCT05091983|OTHER|Conners abridged|"The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents."
214616225|NCT05091983|OTHER|EAT 26|"The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire."
214616226|NCT04829994|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
214616227|NCT04863664|DEVICE|Defibrillation (RV Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
214616228|NCT04863664|DEVICE|Defibrillation (LBBAP Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
214616229|NCT04287218|BEHAVIORAL|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
214616230|NCT04287218|BEHAVIORAL|aTAU|Active control group
214616231|NCT04672265|OTHER|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
214616232|NCT06376968|DEVICE|BioLogic Fusion|Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
214616233|NCT06099158|OTHER|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
214616234|NCT01212653|DRUG|Simponi|Golimumab 50mg monthly
214616235|NCT01212653|OTHER|0.9ml sodium chloride|0.9ml sodium chloride
214616236|NCT00784290|DRUG|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
214616237|NCT05161390|DRUG|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
214616238|NCT04636424|OTHER|assesment of gait|speed and weight distribution during gait
214616239|NCT00937261|DRUG|Risperidone|2mg - 8mg per day, for the duration of participation in the study
214616240|NCT00937261|DRUG|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
214616241|NCT03653130|BEHAVIORAL|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
214616242|NCT00002243|DRUG|Calanolide A|
214616243|NCT03181230|OTHER|No intervention|No intervention
214616244|NCT00193089|DRUG|Docetaxel|Docetaxel
214616245|NCT00193089|DRUG|Vinorelbine|Vinorelbine
214616246|NCT00193089|DRUG|Trastuzumab|Trastuzumab
214616247|NCT04416399|DRUG|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
214616248|NCT02760979|DRUG|Denosumab|Denosumab treatment one year after surgery
214616249|NCT02760979|DRUG|Placebo|Serum one year after surgery
214616250|NCT02919592|DEVICE|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
214616251|NCT02919592|DEVICE|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
214616252|NCT02919592|PROCEDURE|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
214616253|NCT05023408|DRUG|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
214616254|NCT05023408|PROCEDURE|Cryotherapy|Cryotherapy used for comparison of efficacy.
214616255|NCT05584982|DEVICE|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
214616256|NCT03836495|DIETARY_SUPPLEMENT|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
214616257|NCT04755348|OTHER|Product A|A 4mg nicotine pouch product
214616258|NCT04755348|OTHER|Product B|A 4mg nicotine pouch product
214616259|NCT04755348|OTHER|Product C|A 2mg nicotine lozenge product
214616260|NCT04755348|OTHER|Product D|A 2mg nicotine lozenge product
214616261|NCT04755348|OTHER|Product E|A 2mg nicotine lozenge product
214616262|NCT04755348|OTHER|Product F|A 2mg nicotine lozenge product
214616263|NCT00887120|DRUG|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"* BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
214616264|NCT00887120|DRUG|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"* BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
214616265|NCT01362361|DRUG|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
214616266|NCT01362361|DRUG|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
214616267|NCT00282295|BIOLOGICAL|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
214616268|NCT00282295|BIOLOGICAL|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
214616269|NCT02351479|BEHAVIORAL|Hula|
214616270|NCT03337542|BIOLOGICAL|AR101|AR101
214616271|NCT01630655|DRUG|Torrent's Felodipine Extended-Release Tablets|
214616272|NCT00000536|BEHAVIORAL|sodium, dietary|
214616273|NCT01401842|OTHER|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
214616274|NCT01401842|OTHER|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
214616275|NCT02876120|OTHER|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
214616276|NCT02486848|DRUG|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
214616277|NCT02486848|DRUG|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
214616278|NCT04616534|PROCEDURE|Biopsy Procedure|Undergo biopsy (dose expansion cohort only)
214616279|NCT04616534|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214716088|NCT05891691|BEHAVIORAL|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
214716089|NCT01549223|DRUG|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
214716090|NCT01549223|DRUG|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
214716091|NCT04591210|DRUG|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
214716092|NCT04591210|DRUG|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
214716093|NCT03944070|DRUG|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
214716094|NCT04984512|DRUG|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
214716095|NCT04984512|DRUG|Placebo-matching tablets|Placebo will be administered with food.
214716096|NCT03700736|BEHAVIORAL|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
214716097|NCT01410799|DRUG|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
214616280|NCT04616534|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
214616281|NCT04616534|DRUG|Elimusertib|Given PO
214616282|NCT04616534|DRUG|Gemcitabine|Given IV
214616283|NCT01181076|DIETARY_SUPPLEMENT|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
214616284|NCT05013190|OTHER|No intervention|This is a non-interventional study.
214616285|NCT00121108|BIOLOGICAL|Motavizumab|Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
214616286|NCT00121108|OTHER|Placebo|Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
214722110|NCT01207674|OTHER|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
214722111|NCT04949425|DRUG|Adavosertib|Patients will receive Adavosertib orally.
214616287|NCT04861181|BIOLOGICAL|Pharmacokinetics, Dosage of Niraparib|The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
214616288|NCT01380379|BEHAVIORAL|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
214616289|NCT00904800|DRUG|AZD0837|tablet, oral, once daily, 1+5 days
214616290|NCT00904800|DRUG|Placebo|Placebo
214616291|NCT02971631|OTHER|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
214616292|NCT02971631|OTHER|Placebo|Infusion of 1% human albumin in normal saline
214616293|NCT04943081|PROCEDURE|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
214616294|NCT05204823|OTHER|Experimental product|Chocolate milk shakes
214616295|NCT05204823|OTHER|Control product|Glucose
214616296|NCT06385080|BIOLOGICAL|Amivantamab|Amivantamab will be administered subcutaneously.
214616297|NCT06385080|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously.
214616298|NCT06385080|DRUG|Paclitaxel|Paclitaxel will be administered intravenously.
214616299|NCT06385080|DRUG|Carboplatin|Carboplatin will be administered intravenously.
214616300|NCT03208764|DRUG|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
214616301|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
214616302|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
214616303|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
214616304|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214616305|NCT05261763|OTHER|Dry Needling|abc
214616306|NCT05261763|OTHER|Sham Dry Needing|xyz
214616307|NCT05789082|DRUG|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
214616308|NCT05789082|DRUG|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
214616309|NCT05789082|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
214616310|NCT05789082|DRUG|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
214616311|NCT05789082|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W.
214616312|NCT05199753|DRUG|LM-108|Administered intravenously
214716098|NCT04030676|PROCEDURE|Biopsies|Two more biopsies in inflammatory zone will be collected.
214616313|NCT05199753|DRUG|An Anti-PD-1 Antibody|Administered intravenously
214616314|NCT05911295|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
214616315|NCT05911295|DRUG|pembrolizumab|400mg given by IV every 6 weeks
214616316|NCT05911295|DRUG|gemcitabine|1000 mg/m\^2 given by IV on days 1 and 8 of every 3-week cycle
214616317|NCT05911295|DRUG|cisplatin|70 mg\^2 given by IV on day 1 of every 3-week cycle
214616318|NCT05911295|DRUG|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
214616319|NCT04335669|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
214616320|NCT04335669|DRUG|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
214616321|NCT03603912|DRUG|Metformin|Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.
214616322|NCT03603912|BEHAVIORAL|Lifestyle/Risk Factor Modification|Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
214616323|NCT06031714|OTHER|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
214616324|NCT06031714|OTHER|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
214616325|NCT06031714|OTHER|Interviews|V2 and/or V3
214616326|NCT06031714|OTHER|Clinical examination|V2 and/or V3
214716099|NCT04030676|BIOLOGICAL|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
214722112|NCT05212402|DIETARY_SUPPLEMENT|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
214716100|NCT06011603|DEVICE|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
214616327|NCT04707885|DEVICE|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
214616328|NCT05640193|BIOLOGICAL|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
214616329|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
214616330|NCT04300192|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214616331|NCT01734122|OTHER|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
214616332|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214616333|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
214616334|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
214616335|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
214616336|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
214616337|NCT06005610|DRUG|Estradiol|Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
214616338|NCT03321370|DIAGNOSTIC_TEST|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
214616339|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
214616340|NCT07122167|DEVICE|Peripheral Drug-eluting Stent System|Drug-eluting stents (DES) are increasingly used in the treatment of PAD. These stentsare coated with antiproliferative drugs designed to provide mechanical support within the artery while releasing the drug gradually to reduce the risk of restenosis. Commonly used drugs include paclitaxel, sirolimus, and everolimus, which inhibit vascular smooth muscle cell proliferation, thereby reducing the likelihood of re-occlusion.
214616341|NCT07116837|BEHAVIORAL|Vaping prevention video ads|Participants will view and rate 5 vaping prevention video ads. The vaping prevention video ads cover a variety of different topics and were identified in a previous study activity.
214616342|NCT06977360|OTHER|Routine care|Routine care provided by NCCS
214716101|NCT06837792|DRUG|Experimental treatment arm|"Trastuzumab deruxtecan (T-DXd) 5.4mg/kg intravenous infusion every 3 weeks.~(1 cycle = 3 weeks)"
214716102|NCT06837792|DRUG|Control treatment arm|"1. Fulvestrant intramuscular injection of two 250mg injection every 4 weeks (every 2 weeks for the first cycle, 1 cycle = 4 weeks)~2. Fulvestrant (administered same as above) + alpelisib 300mg oral administration every day~   (1 cycle = 4 weeks)\*~3. Exemestane 25mg oral administration every day (1 cycle = 4 weeks)~4. Exemestane 25mg + everolimus 10mg oral administration every day (1 cycle = 4 weeks)~5. Tamoxifen 20mg oral administration every day (1 cycle = 4 weeks)~6. Fulvestrant (administered same as above) + Capivasertib 400mg oral administration twice a day(dosed on Days 1 to 4 in each week of a 28-day treatment cycle)~   * fulvestrant + alpelisib can be selected in PIK3CA activating mutation positive patients~  * Fulvestrant + Capivasertib can be selected in 1 or More mutation positive of PIK3CA/AKT1/PTEN"
214716103|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
214716104|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
214616343|NCT06977360|OTHER|Routine care + iCareBreast+ mobile app|Routine care provided by NCCS (identical to the control group) along with access to the iCareBreast+ mobile app
214716105|NCT01840436|DEVICE|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
214716106|NCT01840436|DEVICE|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
214616344|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
214616345|NCT07128329|DRUG|Nicotine Pouches|Nicotine pouches
214616346|NCT05123339|OTHER|Questionnaire|Questionnaire
214616347|NCT06319820|COMBINATION_PRODUCT|TAR-210|TAR-210 will be administered intravesically.
214616348|NCT06319820|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
214616349|NCT06319820|DRUG|MMC|MMC will be administered intravesically.
214616350|NCT06155032|PROCEDURE|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
214716107|NCT06398951|DEVICE|Two nare high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
214716108|NCT02688153|DEVICE|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
214616351|NCT06155032|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
214616352|NCT01071850|DRUG|ipragliflozin|oral tablet
214616353|NCT01071850|DRUG|Metformin|oral tablet
214616354|NCT01071850|DRUG|Placebo|oral tablet
214616355|NCT06902714|DRUG|oral tranexamic acid|one group of subjects will receive oral tranexamic acid and the other will receive oral placebo
214616356|NCT06902714|DRUG|Placebo|one group of randomized subjects will receive placebo and the other will receive oral tranexamic acid
214616357|NCT00878111|DRUG|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
214616358|NCT03372928|DIETARY_SUPPLEMENT|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
214616359|NCT03372928|DIETARY_SUPPLEMENT|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
214616360|NCT06979674|DRUG|ESG406|Administered via intravenous (IV) infusion.
214616361|NCT06980025|DRUG|162mg Aspirin|"Two 81mg aspirin tablets in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
214616362|NCT06980025|DRUG|81mg Aspirin|"One 81mg aspirin tablet in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
214616363|NCT05962853|OTHER|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
214616364|NCT06979544|DRUG|LPCN 1154A|Oral LPCN 1154A tablets for 48 hours
214616365|NCT06979544|DRUG|Placebo|Oral Placebo Tablets for 48 hours
214616366|NCT06983899|OTHER|Aerobic Exercise|Complete virtual home-based aerobic interval training sessions
214616367|NCT06983899|OTHER|Exercise Intervention|Receive stationary bike, HR monitor, BP monitor, SPO2 monitor
214616368|NCT06983899|OTHER|Educational Intervention|Receive general healthy lifestyle guidebook
214616369|NCT06983899|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
214616370|NCT06983899|OTHER|Electronic Health Record Review|Ancillary studies
214616371|NCT06983899|OTHER|Cardiopulmonary Exercise Testing|Ancillary studies
214616372|NCT06983899|OTHER|Physical Performance Testing|Ancillary studies
214616373|NCT06983899|OTHER|Questionnaire Administration|Ancillary studies
214616374|NCT06983899|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214616375|NCT06983899|PROCEDURE|Pulmonary Function Test|Undergo PFT
214616376|NCT05088902|DIAGNOSTIC_TEST|TERABio Ltd.|Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).
214616377|NCT03347331|DRUG|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~\*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
214616378|NCT03347331|DRUG|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min
214616379|NCT04354909|OTHER|s-CD95-L|levels of s-CD95-L (ELISA test)
214616380|NCT06651229|DRUG|JNJ-90189892|JNJ-90189892 will be administered.
214616381|NCT06984718|BIOLOGICAL|AK104+lenvatinib|Subjects will receive AK104+lenvatinib until disease progression
214616382|NCT06984718|DRUG|lenvatinib|Subjects will receive lenvatinib until disease progression
214616383|NCT06984068|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
214616384|NCT06984068|DRUG|Placebo|Placebo will be used for 6 months
214616385|NCT06985589|PROCEDURE|Fire needle|At the beginning of the fire needle therapy, the patient was instructed to exposure the lesion in a comfortable position. And the Ashi point (lesion area) was disinfected with iodophor. The 95% alcohol lamp was lit and held by the left hand. Then the needle was held by the right hand in the outer flame of the alcohol lamp to heat the needle body, making the tip of the needle whiten. Subsequently, the needle was quickly and accurately puncted into the base of the herpes at a depth of about 2-5 mm, straight in and out. According to the number of herpes, the early-onset herpes was puncted first, and about 5 to 10 blisters were selected for each puncture. The acupuncture was performed 1-5 times according to the size of the herpes. The treatment was performed once every other day for total 5 sessions.
214716109|NCT02688153|DEVICE|Stented aortic bioprostheses|In comparison to control valves available on the market.
214716110|NCT04640753|PROCEDURE|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
214616386|NCT06985589|DRUG|Cortex Phellodendri compound fluid wet compress|For the Chinese herbal wet compress treatment, CPCF (Shandong Hanfang Pharmaceutical Co., LTD.) was decocted using forsythia, honeysuckle, phellodendron, dandelion, and centipede. Appropriate amount of liquid was diluted with 5 times the volume of water. Then according to the area of skin lesions, several pieces of medical fat-free cotton gauze with thickness of 8 layers were put into the liquid completely wet. After wringing out to a semi-dry state, the gauze was applied to the lesion for 15 minutes/time, 3 times a day, for 10 days.
214616387|NCT06985589|DRUG|basic treatment|The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
214616388|NCT06985004|OTHER|PIODO Questionnaire|An original PIODO Questionnaire is a structured protocol that has been developed by the investigators of this study for the preoperative assessment of patients undergoing RARP. It evaluates not only clinical data on the prostate cancer, but also patient characteristics, including anthropometric measurements of the pelvis. The aim is to develope a tool that can be used to predict the risk of operational difficulties and possible outcomes of RARP.
214616389|NCT06984874|OTHER|Erector spinae plane block|Patients will receive bilateral erector spinae plane block after the induction of general anesthesia as a study group.
214616390|NCT06984874|OTHER|General anesthesia|Patients will not receive the block after the induction of general anesthesia as a control group.
214616391|NCT06985394|DIETARY_SUPPLEMENT|Antioxidant cocktail|"Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of the following concentrations of antioxidants:~600 mg of α-lipoic acid, 1,000 mg of vitamin C, and 600 IU of vitamin E."
214616392|NCT06985394|DIETARY_SUPPLEMENT|Placebo|Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of placebo pills made from microcrystalline cellulose, designed to match the antioxidants in taste, color, and appearance.
214616393|NCT06984666|BEHAVIORAL|language|Language cues are used to provide participants with psychological suggestions in order to achieve the goal of shifting their focus in gaze patterns.
214616394|NCT06588621|OTHER|Questionnaire on physical and mental health among healthcare professionnals|Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting
214616395|NCT05533034|OTHER|Rehabilitation|"* 1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs.~* 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence."
214616396|NCT05613517|OTHER|Eye examination|"* orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition"
214616397|NCT06663332|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214616398|NCT06660563|DRUG|JNJ-80948543|JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
214616399|NCT06660563|DRUG|JNJ-75348780|JNJ-75348780 will be administered as SC injection.
214616400|NCT06662786|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
214616401|NCT06662786|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
214616402|NCT06662786|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
214616403|NCT06662786|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
214616404|NCT06662786|DRUG|Oxaliplatin|Oxaliplatin will be administered as chemotherapy regimen.
214616405|NCT06662786|DRUG|Irinotecan Hydrochloride|Irinotecan hydrochloride will be administered as chemotherapy regimen.
214616406|NCT05070988|OTHER|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
214616407|NCT06979700|DIAGNOSTIC_TEST|Automated Pupillometry|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment for both pupils and include: Neurological pupil index, pupillary size, pupillary minimum diameter, pupillary constriction amplitude, pupillary constriction velocity, pupillary maximum constriction velocity, pupillary latency and pupillary dilation velocity.
214616408|NCT06979700|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both middle cerebral arteries and include the following: Peak systolic velocity, end diastolic velocity, mean velocity, pulsatility index and resistance index.
214616409|NCT06979700|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both eyes using ultrasound and include the following: optic nerve sheath diameter of right and left side and mean optic nerve sheath diameter.
214716111|NCT05124262|OTHER|Low- FODMAPdiet group intervention|Diet intervention
214616410|NCT06979700|DIAGNOSTIC_TEST|Continuous EEG and EEG Reactivity|"Continuous 4-channel EEG:~Will be established on participants as soon as possible within 0-6 hours. Measurements will be performed on sedated participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment and include: Spectral edge frequency, median frequency, peak power frequency, total power, suppression ratio and frequency band ratio (delta, theta, alpha and beta). Continuous EEG data will be manually analyzed for malignant patterns by experts in the field.~EEG Reactivity:~Will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment and include visual, auditory and pain stimuli."
214616411|NCT06608485|DEVICE|HARMONIC 700 Shears|There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
214616412|NCT04870411|BIOLOGICAL|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
214616413|NCT06590493|DRUG|doxecitine and doxribtimine|TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.
214616414|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule]|1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.
214616415|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]|"1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months."
214616416|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
214616417|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
214616418|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
214616419|NCT06981806|DRUG|Balixafortide|Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly
214616420|NCT06981806|DRUG|Balixafortide|Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly
214616421|NCT06981806|DRUG|Cosibelimab|Dose: 800 mg Route: IV (60 min) Frequency: Weekly
214616422|NCT06981806|DRUG|Balixafortide|Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly
214616423|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
214616424|NCT06984341|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.
214616425|NCT06984341|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
214616426|NCT06984341|DRUG|Fludarabine|Fludarabine will be administered intravenously.
214616427|NCT06984341|DRUG|Rimiducid|Rimiducid will be used as a rescue therapy in the event of the occurrence of severe or life-threatening adverse events. It will be administered intravenously.
214716112|NCT01062828|DIAGNOSTIC_TEST|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
214716113|NCT00014170|DRUG|gefitinib|Given orally
214716114|NCT00014170|OTHER|pharmacological study|Correlative studies
214616428|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
214616429|NCT01410019|OTHER|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
214616430|NCT06996080|DRUG|KSI-101|Intravitreal injection
214616431|NCT06996080|OTHER|Sham Comparator|Sham injections
214616432|NCT06433752|OTHER|No Intervention|No Intervention
214616433|NCT03996980|DEVICE|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
214616434|NCT06864858|DEVICE|etafilcon A with PVP with cosmetic pattern contact lens|Test Lens
214616435|NCT06864858|DEVICE|1-DAY ACUVUE® DEFINE® with LACREON®, FRESH Honey|Control Lens
214716115|NCT00014170|OTHER|laboratory biomarker analysis|Correlative studies
214716116|NCT00014170|OTHER|questionnaire administration|Ancillary studies
214716117|NCT00014170|PROCEDURE|quality-of-life assessment|Ancillary studies
214716118|NCT02540876|DRUG|Ilorasertib|Given PO
214716119|NCT02540876|OTHER|Laboratory Biomarker Analysis|Correlative studies
214716120|NCT05182424|BEHAVIORAL|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
214616436|NCT06667076|DRUG|Amivantamab|Amivantamab will be administered.
214616437|NCT06667076|DRUG|Lazertinib|Lazertinib tablet will be administered.
214616438|NCT06667076|DRUG|Chemotherapy: Pemetrexed|Pemetrexed will be administered.
214616439|NCT06667076|DRUG|Chemotherapy: Carboplatin|Carboplatin will be administered.
214616440|NCT05572515|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
214716121|NCT01209975|PROCEDURE|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
214716122|NCT02542813|DRUG|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
214716123|NCT02542813|DRUG|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
214616441|NCT05572515|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214616442|NCT05572515|DRUG|Bortezomib|Bortezomib will be administered subcutaneously.
214616443|NCT05572515|DRUG|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
214616444|NCT05572515|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
214616445|NCT06862986|OTHER|Ear massage|At least one Intervention must be specified for an Interventional study. Patients included in the study group will receive ear massage in addition to the routine treatment and care practices of the clinic. Ear massage application will be started in the evening of the first day after surgical intervention (at 19:30) and will be applied twice a day at least 30 minutes after morning and evening meals (07:30 am, 19:30 pm) for 3 minutes each, similar to the literature (8,9,12). The bowel sounds of the patients will be re-evaluated before and 10 minutes after the ear massage application, and the excretory activities form will be filled out. Ear massage application will be terminated when the patient defecates or when the patient is given an enema.
214616446|NCT00733915|DEVICE|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
214616447|NCT04892342|DRUG|ESG401|Administered via intravenous (IV) infusion
214716124|NCT02542813|DRUG|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
214716125|NCT02542813|DRUG|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
214716126|NCT02542813|DRUG|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
214716127|NCT02542813|DRUG|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
214716128|NCT01966653|DRUG|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
214716129|NCT01966653|DRUG|fosfomycin|fosfomycin 3g po single dose
214716130|NCT03596970|DRUG|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
214616448|NCT06647615|DEVICE|VR headset|The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
214616449|NCT06857175|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214616450|NCT06857175|DRUG|Docetaxel or Paclitaxel|Administration by intravenous infusion for a cycle of 3 weeks.
214616451|NCT07002034|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
214616452|NCT04117646|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|Subjects respond to the translated questionnaire twice at 15 days apart.
214616453|NCT06349733|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
214616454|NCT06868199|DRUG|LM-168|Q3W,Intravenous Drip
214616455|NCT06868199|DRUG|Toripalimab|Q3W,Intravenous
214616456|NCT06675123|PROCEDURE|Biopsy|Undergo optional tissue biopsy
214616457|NCT06675123|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214616458|NCT06675123|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214616459|NCT06675123|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214616460|NCT06675123|DRUG|BTK Inhibitor|Given BTK inhibitor
214616461|NCT06675123|PROCEDURE|Computed Tomography|Undergo PET/CT
214616462|NCT06675123|DRUG|Pacritinib|Given PO
214616463|NCT06675123|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214616464|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
214616465|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
214616466|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
214616467|NCT06043141|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
214616468|NCT06043141|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
214616469|NCT06043141|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
214616470|NCT03969953|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban is an orally administered selective direct factor Xa inhibitor.
214616471|NCT03969953|OTHER|Placebo|Rivaroxaban matched placebo
214616472|NCT05027919|DRUG|Hydromorphone|Up to 120mg oral per day in q4 dosing to manage withdrawal
214616473|NCT05027919|DRUG|Naloxone + lofexidine pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
214616474|NCT05027919|DRUG|Naloxone + placebo pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge
214616475|NCT05027919|DRUG|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
214616476|NCT07003282|BEHAVIORAL|"The intervention includes 1) the First Breath app, 2) reminders during the follow-up period and 3) only for women- cotinine concentration measurement (a biomarker of secondhand smoke exposure)"|"The intervention focus on raising knowledge about the health consequences of prenatal secondhand smoke exposure, proposing strategies to avoid exposure at home and in the car, and raising motivation to implement a smoke-free home and car. An exposure score of each participant is calculated, based on his perception of secondhand smoke exposure, smoking rules within the home and strategies used to reduce exposure. Participants are guided in setting specific goals, with a detailed action plan, and receive ongoing feedback throughout follow up. In addition, for pregnant women, urine cotinine measurements at baseline, 4-weeks and 12-weeks study visit are integrated into the intervention and personalized biofeedback provided to them . Participants of the intervention arm also receive remiders (by WhatsApp) to re-use the App during all the follow-up period (3 times during the first week, 2 times/week during the 2nd, 3th and 4th weeks, and then once a week until the end of follow-up)."
214616477|NCT05875129|DEVICE|VAVA prototype|Cognitive behavioral therapy for insomnia
214616478|NCT03424460|BIOLOGICAL|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
214616479|NCT03424460|BIOLOGICAL|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
214616480|NCT03424460|GENETIC|RNA extraction|RNA extraction from liver tissue
214616481|NCT05077904|DRUG|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
214616482|NCT05077904|OTHER|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
214616483|NCT07010224|OTHER|Retrospective Medical Record Review|Review of archived medical, surgical, and radiological records of patients diagnosed with elastofibroma dorsi and treated surgically. No active intervention was administered as part of the study.
214716131|NCT03596970|DRUG|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
214616484|NCT06862869|DRUG|Alectinib|"Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice.~NOTE: No intervention will be provided in this study as the study is observational."
214616485|NCT06051617|DRUG|Seladelpar|"* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis."
214616486|NCT06051617|DRUG|Placebo|One capsule daily for up to 36 months.
214616487|NCT06128824|OTHER|MR Imaging|Serial magnetic resonance imaging (MRI)
214616488|NCT06694428|OTHER|Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed|"The CMV serology results of the patients will have been previously interpreted as part of the care on the basis of the entire virological file according to the reference method.~These results will be reinterpreted using the MyCMV tool on the basis of the serology results performed (IgM, IgG, avidity), CMV PCR, the date of sampling and the date of the start of pregnancy (or last period). This reinterpretation by the tool will be carried out as part of the study and will not be communicated to the patient or to the doctor prescribing the virological analyses."
214616489|NCT06707935|BEHAVIORAL|Descriptive social norm nudges|A set of messages with descriptive social norm nudges sent to participants.
214616490|NCT06707935|BEHAVIORAL|Pictorial social norm nudges|A set of messages with pictorial social norm nudges sent to participants.
214616491|NCT06707935|BEHAVIORAL|Service as usual|Traditional mental health education information disseminated to participants.
214616492|NCT06720038|BIOLOGICAL|0.5 mL of the low dose VAX-31|31 valent pneumococcal conjugate vaccine
214616493|NCT06720038|BIOLOGICAL|0.5 mL of the mid dose VAX-31|31 valent pneumococcal conjugate vaccine
214616494|NCT06720038|BIOLOGICAL|0.5 mL of the high dose VAX-31|31 valent pneumococcal conjugate vaccine
214616495|NCT06720038|BIOLOGICAL|0.5 mL dose of PCV20|20 valent pneumococcal conjugate vaccine
214616496|NCT06720038|BIOLOGICAL|0.5 mL of the High-PFS dose VAX-31|31 valent pneumococcal conjugate vaccine
214616497|NCT06731478|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
214616498|NCT06731478|DRUG|pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg IV Q3W
214616499|NCT06731478|DRUG|Trastuzumab|Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W
214616500|NCT06731478|DRUG|Chemotherapy|"For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered."
214616501|NCT07049848|DRUG|Atezolizumab|Given by IV
214616502|NCT07049848|DRUG|Doxorubicin Hydrochloride|Given by IV
214616503|NCT06778005|DIAGNOSTIC_TEST|Ultrasonography|Measurements will be performed using a 7-12 MHz Sonosite M-Turbo device (Fujifilm, USA) with a linear probe by an operator trained in peripheral nervous system ultrasonography. Cross-sectional area (CSA) and echogenicity measurements of the bilateral tibial, common peroneal, and sural nerves will be conducted using the ultrasound device. Tibial nerve assessment will be performed 3 cm proximal to the level of the medial malleolus. Common peroneal nerve assessment will be performed by identifying the nerve at the fibular head and tracking it proximally to image it at the level of the popliteal fossa. Sural nerve assessment will be conducted 10 cm proximal to the upper level of the lateral malleolus. All nerve measurements will be conducted twice in the transverse plane, and the obtained images will be recorded and uploaded into the ImageJ programming system.
214716132|NCT00111436|DRUG|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
214716133|NCT01201304|BEHAVIORAL|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
214716134|NCT01201304|BEHAVIORAL|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
214616504|NCT06778005|DIAGNOSTIC_TEST|Biodex Balance System|"The Biodex is a computer-assisted device with a movement system capable of providing surface inclinations ranging from 360 degrees to 20 degrees. It allows movement in anterior/posterior and mediolateral planes. The device has 12 levels of difficulty, where level 12 represents the highest stability and level 1 represents the lowest stability. It can be used for balance training with different therapy protocols and includes standardized programming systems for evaluating both static and dynamic balance. It provides numerical data for key parameters such as balance, fall risk, and proprioception. In this study, patients will be assessed using the fall risk test and postural stability evaluation test protocols on the Biodex balance system. All participants will be trained and familiarized with the system before the test.~Postural Stability Test: The difficulty level will be set to 8. Fall Risk Test: The difficulty level will progressively decrease from 6 to 2."
214616505|NCT06778005|DIAGNOSTIC_TEST|Douleur Neuropathique 4 (DN4) Pain Scale|"The Douleur Neuropathique 4 (DN4) pain scale score will be used to screen for diabetic peripheral neuropathic pain. The DN4 scale consists of 10 questions, 7 of which inquire about symptoms, and 3 that assess the patient's clinical examination for neuropathy. The symptoms assessed include a burning sensation, pain from cold, electric shock sensations, tingling, pins and needles, numbness, and itching. The sensory exams assess touch hypoesthesia, pin-prick hypoesthesia, and brush allodynia. Each yes response to a question receives 1 point. To calculate the total score, points obtained from the symptom inquiry and clinical examination are added together. The maximum total score is 10, and a score of 4 or higher is considered indicative of neuropathic pain"
214616506|NCT06778005|DIAGNOSTIC_TEST|Numeric Rating Scale|The numeric pain scale will be used to assess the intensity of neuropathic pain. The patient is asked to provide a value between 0 and 10 to indicate the intensity of their pain. Higher scores are associated with an increase in pain severity.
214616507|NCT06778005|DIAGNOSTIC_TEST|Toronto Clinical Neuropathy Score|The Toronto Clinical Neuropathy Score (TCNS) will be used to assess the severity of Diabetic Peripheral Polyneuropathy (DPPN). The Turkish version of the Toronto clinical scoring system is a reliable and valid tool for assessing polyneuropathy in Turkish-speaking patients. The TCNS is preferred in clinical studies because of its ease of use, patient acceptability, ability to classify the severity of DPPN, and its representation of clinical changes related to the progression of DPPN. The scale consists of three sections: symptom scores, sensory test scores, and reflex scores.The first section includes scoring symptoms in the upper and lower extremities .The second section includes scoring the bilateral Achilles and patellar reflexes. The third section involves scoring the sensation in the toe. The total score ranges from a minimum of 0 (no neuropathy) to a maximum of 19 points.
214616508|NCT06778005|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test (6MWT) is a commonly used test to assess functional capacity. The test area should be a corridor with a minimum length of 30 meters, flat, and firm surface. The corridor should be marked every 3 meters. Turnaround points are indicated with objects such as orange traffic cones. A line is drawn for the start and end of the test. Recommended materials for the test include a stopwatch, a device to count laps, cones to mark turning points, a chair placed within easy reach, oxygen support (to be given if necessary), and a blood pressure cuff. The patient should wear comfortable clothing and shoes suitable for walking. They can use any walking aids such as crutches or a walker. Medications or treatments should be taken as usual. The patient should have had a light meal before the test and should not have engaged in heavy physical activity within the 2 hours preceding the test. There should be no warm-up period before the test.
214616509|NCT06778005|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale will be calculated using an online calculator tool, providing two types of scores: physical and mental scores.
214616510|NCT06778005|COMBINATION_PRODUCT|International Physical Activity Questionnaire-Short Form (IPAQ)|The IPAQ scale was developed to address the general health problem of insufficient physical activity, which necessitates large population studies and allows for cross-country comparisons. Validity studies conducted across multiple countries have proven that this questionnaire is valid and reliable. This survey assesses individuals based on the types of physical activities they perform in their daily lives. The questions asked pertain to the time spent physically active over the past 7 days.
214616511|NCT06778005|DIAGNOSTIC_TEST|Tuning Fork Vibration Sense|"Vibration sense will be assessed using a traditional 128 Hz tuning fork. When the stem of a 128 Hz tuning fork is placed on the dorsal aspect of the interphalangeal joint of the hallux, a healthy person can feel the vibration as long as it continues (15-20 seconds). In conditions leading to peripheral nerve damage (such as polyneuropathy), vibration sense is impaired. The examiner holds the proximal end of the tuning fork with one hand, while the distal end is struck strongly against the palm of the examiner's other hand. The examiner should try to strike the tuning fork with consistent force for each assessment. After striking, the tuning fork is placed just proximal to the nail bed, on the dorsal aspect of the distal phalanx of the hallux.Before applying the tuning fork, the participant is instructed to verbally respond with yes if they can initially feel the vibration, and they should also indicate now when they stop feeling the vibration."
214716135|NCT01201304|BEHAVIORAL|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
214716136|NCT01201304|BEHAVIORAL|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
214716137|NCT03682055|DRUG|VK-2019|EBNA1 inhibitor
214616512|NCT06778005|DIAGNOSTIC_TEST|Timed Up and Go Test|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for patients to stand up and walk, providing quantitative results. The patient starts the test by sitting on a standardized chair (46 cm high). During the test, the patient is instructed to stand up from the chair, walk 3 meters away, turn around, and then return to sit back down on the chair. The duration of this process is measured. Lower values indicate better stability. A cutoff value of 13.5 seconds has been used to identify high fall risk in the TUG test.
214716138|NCT04597515|PROCEDURE|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
214716139|NCT01352767|DEVICE|InsuPad|Heating pad
214716140|NCT03596255|DIAGNOSTIC_TEST|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
214716141|NCT03596255|DIAGNOSTIC_TEST|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
214716142|NCT03556982|BIOLOGICAL|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
214616513|NCT06778005|DIAGNOSTIC_TEST|Physical Examination|"Manual Muscle Test: Muscle strength is evaluated using the MRC (Medical Research Council) muscle strength scale.~Reflexes:Patellar reflex: The reflex hammer is struck on the patella, and extension of the leg is observed. Achilles reflex: With one hand, the patient's foot is lightly dorsiflexed, and the Achilles tendon is struck; plantar flexion is observed in the ankle."
214616514|NCT06743022|DIAGNOSTIC_TEST|Chest CT|Repeated chest CT for automated ILD quantification
214616515|NCT06715943|DRUG|HRS-5965 capsule|HRS-5965 capsule treatment
214716143|NCT04691557|OTHER|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
214716144|NCT04691557|OTHER|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
214716145|NCT01069094|DRUG|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
214716146|NCT01069094|DRUG|Progenta|25 mg, administered as a once daily oral dose for 90 days.
214716147|NCT01069094|DRUG|Progenta|50 mg, administered as a once daily oral dose for 90 days.
214716148|NCT01069094|DRUG|Lucron Depot|3.75 mg IM monthly
214716149|NCT01069094|DRUG|Placebo|Administered as a once daily oral dose for 90 days.
214616516|NCT06740968|DEVICE|transcranial alternating current stimulation (tACS)|During each of the 3 stimulation visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).
214616517|NCT07053345|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
214616518|NCT07053345|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
214616519|NCT06749496|DEVICE|Test Lens|ACUVUE® OASYS MAX 1-Day for ASTIGMATISM (AOM1DfA).
214616520|NCT06749496|DEVICE|Control Lens|Alcon DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA).
214616521|NCT07059065|DEVICE|FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute|"FIBERGRAFT™ Aeridyan Matrix is a next generation synthetic bone graft that is resorbable, bioactive, and osteoconductive. FIBERGRAFT Aeridyan Matrix is composed of ultra-porous 45S5 bioactive glass granules, boron-based bioactive glass microspheres, and bovine type 1 collagen. The granules are made entirely of 45S5 bioactive glass fibers and feature a porous outer shell encasing an intricate nest of micro- and nano- fibers and microspheres. The nonporous microspheres are made entirely of boron-based bioactive glass and feature essential metallic ions such as zinc, copper, magnesium, and potassium. The highly biocompatible type 1 collagen5 serves as a carrier for the bioactive glass components.~FIBERGRAFT Aeridyan Matrix is designed to have an adequate structural integrity for its application as a bone graft substitute material, while optimizing radiopacity and resorption."
214616522|NCT07059065|DEVICE|Demineralized Bone Matrix|Demineralized Bone Matrix is to be used with bone marrow aspirate and mixed with autograft bone in accordance with approved indications per the IFU
214616523|NCT03084523|DRUG|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
214616524|NCT06312553|BEHAVIORAL|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring described in study arm
214616525|NCT06312553|BEHAVIORAL|Standard Diabetes Self Management Education|Standard Diabetes Self Management Education described in study arm
214616526|NCT07065552|DRUG|Tirzepatide|Tirzepatide will be administered once weekly, subcutaneously, and patients will be taught how to administer this drug at home. Patients will be started on a dose of 5 mg tirzepatide weekly for four weeks prior to surgical staging. .
214616527|NCT06748417|DEVICE|Acute Cognitive Training|Participants will receive the intervention in person once within in the study for 30 minutes. During the intervention, participants will receive a cognitive training session consisting of an upper extremity, lower extremity, and whole-body reaction time task. The device (5 LED) will be placed in front of participants in all tasks, and participants will be asked to deactivate lights that illuminate for a period of 30 seconds with 30 seconds of rest. For the upper and lower extremity tasks, these will be repeated on both limbs. The purpose of the tasks are to pre-train reaction time in an isolated fashion, requiring participants to use either hands or feet to deactivate the lights, as well as incorporate whole-body movement in the third task along with a decision-making (color-matching) component.
214616528|NCT06748417|OTHER|Non-stimulating Rest|Participants will receive the intervention in person once within the study for 30 minutes. During the intervention, participants will watch, while seated, a 30-minute segment of a nature documentary. The purpose of this intervention is to ensure no additional cognitive or movement training that would improve performance on the dual-task test occurs during the intended rest period.
214716150|NCT06263725|OTHER|Restricted dietary protein|Participants will be allocated to 5 week isocaloric restricted protein intake
214716151|NCT06263725|OTHER|Habitual diet|Participants will be follow their habitual, high protein intake
214716152|NCT05278936|OTHER|The cataract surgery and the anterior vitrectomy|Surgical
214716153|NCT04430868|BEHAVIORAL|lifestyle redesign program|In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
214722113|NCT05212402|OTHER|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
214722114|NCT01319513|OTHER|whey protein bolus|single dose of 25 g whey protein
214722115|NCT01319513|OTHER|whey protein pulses|10 2.5 g pulses of whey protein
214616529|NCT05198674|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
214616530|NCT07071324|BEHAVIORAL|CF Wellness Program|Intervention modules are 1) Introduction \& Fatigue Explained, 2) Finding Balance between Activity \& Rest, 3) Physical Activity, Self-Review \& Planning, 4) Improving Your Sleep, 5) Managing Emotions, 6) Changing Less Helpful Thoughts, 7) Learning to Relax \& Manage Stress, and 8) Accessing Social Support and Preparing for the Future.
214616531|NCT05645523|DRUG|Indocyanine Green|Given in to the vein (IV)
214616532|NCT07069712|DRUG|AZD0901|AZD0901 will be administered as an IV infusion.
214616533|NCT07069712|DRUG|Rilvegostomig|Rilvegostomig will be administered as an IV infusion.
214616534|NCT07069712|DRUG|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered as an IV infusion.
214616535|NCT07069712|DRUG|Capecitabine|Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.
214616536|NCT07069712|DRUG|5-Fluorouracil (5-FU)|5-FU (Fluoropyrimidine) will be administered as an IV infusion as chemotherapy standard of care.
214616537|NCT07069712|DRUG|FLOT Chemotherapy|FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.
214616538|NCT06774846|DRUG|Acetylsalicylic acid/Aspirin (100 mg)|Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
214616539|NCT06774846|DRUG|Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride|patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
214616540|NCT06663319|DRUG|JNJ-89402638|JNJ-89402638 will be administered.
214616541|NCT04670965|BIOLOGICAL|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
214616542|NCT04670965|BIOLOGICAL|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
214616543|NCT04670965|BIOLOGICAL|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
214616544|NCT04670965|BIOLOGICAL|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
214616545|NCT06863610|OTHER|Extension Deficit (>5 degrees)|Patients who had a knee extension ROM deficit of more than 5 degrees will included
214616546|NCT06863610|OTHER|Extension Deficit (<5 degrees)|Patients who had a knee extension ROM deficit of less than 5 degrees will included
214616547|NCT06449222|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
214616548|NCT06449222|DRUG|BNT327 Dose Level 1 (DL2)|IV infusion
214616549|NCT06449222|DRUG|Nab-placlitaxel|IV infusion
214616550|NCT06449222|DRUG|Carboplatin|IV infusion
214616551|NCT06449222|DRUG|Gemcitabine|IV infusion
214616552|NCT06449222|DRUG|Paclitaxel|IV infusion
214616553|NCT06449222|DRUG|Eribulin|IV infusion
214616554|NCT06449222|DRUG|BNT327 Optimized Dose|IV infusion
214616555|NCT06449222|DRUG|BNT327 Equivalent Q3W Dose|IV infusion
214616556|NCT06768489|DRUG|JNJ-79635322|JNJ-79635322 will be administered subcutaneously.
214616557|NCT06768489|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
214616558|NCT06768489|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214616559|NCT06768489|DRUG|Lenalidomide|Lenalidomide will be administered orally.
214616560|NCT06120140|DRUG|Amivantamab IV|Amivantamab will be administered.
214616561|NCT06120140|DRUG|Amivantamab SC|Amivantamab will be administered as SC injection.
214616562|NCT06120140|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
214616563|NCT06120140|DRUG|Doxycycline|Doxycycline tablet will be administered orally.
214616564|NCT06120140|DRUG|Minocycline|Minocycline capsule will be administered orally.
214616565|NCT06120140|DRUG|Clindamycin|Clindamycin lotion will be used as topical application on the scalp.
214616566|NCT06120140|DRUG|Chlorhexidine|Chlorhexidine solution will be used as topical application on hands and feet.
214616567|NCT06120140|OTHER|Noncomedogenic skin moisturizer|Noncomedogenic skin moisturizer will be used as topical application.
214616568|NCT06120140|OTHER|Ruxolitinib|Ruxolitinib will be used to the affected skin area.
214616569|NCT06120140|OTHER|Tacrolimus|Tacrolimus will be used as topical application to the affected skin area.
214616570|NCT06120140|DRUG|Zinc gluconate|Zinc gluconate tablet will be administered.
214616571|NCT06120140|DRUG|Propranolol|Propranolol tablet will be administered.
214616572|NCT06120140|DRUG|Timolol|Timolol will be used to the affected skin area.
214616573|NCT06120140|DRUG|Clobetasol|Clobetasol shampoo will be used on the scalp.
214616574|NCT07072819|BEHAVIORAL|Crisis Ready Training|Crisis Ready Training combines Crisis Line Facilitation with Take Home Naloxone training. The intervention is delivered in a group format.
214616575|NCT07078682|DIETARY_SUPPLEMENT|Elix Daily Harmony|"Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:~Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)"
214616576|NCT07072910|DRUG|Cabergoline 0.5 MG|Participants will receive cabergoline 0.5 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 0.5 mg during the double-blind phase will continue with the same 0.5 mg dose in the open-label phase.
214616577|NCT07072910|DRUG|Placebo|Participants will receive placebo as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. In the open-label phase, these participants will transition to active cabergoline treatment, receiving either 0.5 mg or 1.0 mg once weekly, depending on their randomized allocation at the start of the open-label phase. The placebo tablets will be formulated to match the cabergoline tablets in size, shape, and color, and should be taken under the same conditions.
214616578|NCT07072910|DRUG|Cabergoline 1 MG|Participants will receive cabergoline 1.0 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 1.0 mg during the double-blind phase will continue with the same 1.0 mg dose in the open-label phase.
214616579|NCT04168827|BEHAVIORAL|Questionnaire|Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
214616580|NCT06821698|DRUG|KP-001|KP-001 100 mg dry syrup
214616581|NCT06821698|DRUG|Rosuvastatin calcium10mg|A oral dose of 10 mg tablet
214616582|NCT06821698|DRUG|Caffeine citrate|100 mg oral solution
214616583|NCT06821698|DRUG|Fluvoxamine|50 mg tablet
214716154|NCT04409496|BEHAVIORAL|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
214716155|NCT04409496|BEHAVIORAL|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
214716156|NCT04409496|BEHAVIORAL|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
214616584|NCT06635148|DRUG|JNJ-81201887|No study intervention will be administered as part of this LTE study.
214616585|NCT06635148|OTHER|Sham Procedure|No study intervention will be administered as part of this LTE study.
214616586|NCT06741969|DRUG|Nipocalimab|Nipocalimab SC.
214716157|NCT05759390|DIAGNOSTIC_TEST|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
214616587|NCT06741969|DRUG|Placebo|Placebo SC.
214616588|NCT06741969|DRUG|Standard of care treatment|Protocol-defined topical and systemic standard of care background treatments.
214616589|NCT06895187|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing PAF ablation.
214616590|NCT07079995|BEHAVIORAL|Mentoring program|Schools in this group will participate in meetings and receive newsletters to help with program implementation.
214716158|NCT01135394|DRUG|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
214716159|NCT04624529|OTHER|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
214616591|NCT07079995|BEHAVIORAL|Waitlist|Schools in this group will wait 1 year to receive HSRC. Schools will not add or remove any current physical activity and/or healthy eating programs.
214616592|NCT07079904|OTHER|Ultrasound Guided Peripheral Vein Catheterization With or Without Laser-Assisted.|In group T, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique. In group L, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique with laser-assisted.
214616593|NCT07079839|DEVICE|Transcranial Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214616594|NCT07079839|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214616595|NCT07079839|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
214616596|NCT07080177|PROCEDURE|Free gingival graft simultaneous with delayed implant placement|XCM grafts (of bovine origin)
214616597|NCT07080177|PROCEDURE|Xenogeneic collagen matrix simultaneous with delayed implant placement|A FGG will be harvested from the palate between first premolar and first molar
214716160|NCT02839811|PROCEDURE|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
214716161|NCT00191386|DRUG|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
214716162|NCT03914651|DRUG|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
214716163|NCT03914651|DRUG|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
214716164|NCT04202796|PROCEDURE|Catheter ablation|Catheter ablation of arrhythmia
214716165|NCT01191424|DRUG|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
214716166|NCT01191424|DRUG|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
214716167|NCT03552900|BEHAVIORAL|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
214716168|NCT03552900|BEHAVIORAL|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
214716169|NCT01970735|BIOLOGICAL|Blood test|
214616598|NCT06893302|BIOLOGICAL|Bone Marrow Aspirate (BMA)|Bone marrow aspirate (BMA) is being investigated as an augmentation to arthroscopic debridement surgery of the knee to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
214616599|NCT06893302|PROCEDURE|Arthroscopic Debridement Surgery|Arthroscopic debridement surgery of the knee is performed to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
214616600|NCT06893302|OTHER|Saline|Patients in the control arm of the study will receive arthroscopic debridement surgery along with a saline injection. This will be compared to the experimental arm, in which patients will receive arthroscopic debridement surgery along with a bone marrow aspirate injection.
214616601|NCT06746064|DRUG|CHF10073 (Part 1 - SAD)|Single doses of CHF10073 for each cohort
214616602|NCT06746064|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF10073 for each cohort
214716170|NCT03422744|PROCEDURE|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
214616603|NCT06746064|DRUG|CHF10073 (Part 2 - MAD)|Multiple doses of CHF10073 for each cohort
214616604|NCT06746064|DRUG|CHF10073 (Part 3)|Single dose of CHF10073
214616605|NCT06746064|DRUG|Placebo (Part 2 - MAD)|Multiple doses of placebo matching CHF10073 for each cohort
214616606|NCT06746064|DRUG|itraconazole (Part 4)|Multiple dose of itraconazole in treatment period 2
214616607|NCT06746064|DRUG|CHF10073 (Part 4)|Single dose of CHF10073 in Treatment Period 1 and 2
214616608|NCT06668584|DRUG|Olutasidenib|Given by mouth
214616609|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 1 )
214616610|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 2 )
214616611|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given intravenously (dose level 3)
214616612|NCT07076160|DEVICE|INFUSE® One Day Multifocal|Test Lens
214616613|NCT07076160|DEVICE|ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens|Control Lens
214716171|NCT03422744|PROCEDURE|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
214716172|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
214716173|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
214716174|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
214616614|NCT05450354|OTHER|Questionnaires|"Questionnaires will be completed only once :~* Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~* Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~* Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~* Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects."
214616615|NCT05450354|OTHER|Questionnaire|Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
214616616|NCT06929572|PROCEDURE|Autologous umbilical cord patch|Surgery will occur from birth to 24 hours of age. The autologous umbilical cord patch is harvested at time of delivery and immediately processed in a sterile setting in order to create a dural patch as a spinal cord cover to close the developmental defect within a few hours after birth.
214616617|NCT06754462|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection.
214716175|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
214716176|NCT02187133|DRUG|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"
214716177|NCT02187133|DRUG|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"
214616618|NCT06754462|DRUG|Placebo|Administered once weekly by subcutaneous injection.
214716178|NCT02187133|DRUG|Rituximab|Given IV; 375 mg/m\^2
214616619|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
214616620|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
214616621|NCT06549595|DRUG|AZD0486|a fully human bispecific monoclonal IgG4 antibody
214616622|NCT06549595|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
214616623|NCT06549595|DRUG|R-CVP|Rituximab, Cyclophosphamide, Vincristine and Prednisone
214716179|NCT00590941|PROCEDURE|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
214716180|NCT00733473|DRUG|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
214616624|NCT06549595|DRUG|BR|Bendamustine, Rituximab
214616625|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
214616626|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
214716181|NCT00733473|DRUG|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
214716182|NCT01788111|OTHER|Low back exercises 1|Excentric / concentric extension type exercises
214716183|NCT01788111|OTHER|Low back exercise 2|Traditional low back training
214716184|NCT03592927|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
214716185|NCT03592927|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
214722116|NCT00619606|DEVICE|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
214616627|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
214716186|NCT04116619|OTHER|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
214716187|NCT05395728|OTHER|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
214716188|NCT05395728|OTHER|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
214716189|NCT05616624|DRUG|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
214716190|NCT05616624|DRUG|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
214716191|NCT05616624|DRUG|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
214616628|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
214616629|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
214616630|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
214616631|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
214616632|NCT06647745|DRUG|THP-00101|Dapagliflozin 10 mg
214616633|NCT06647745|DRUG|THP-00102|Telmisartan 80 mg
214716192|NCT00848445|DEVICE|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
214616634|NCT06647745|DRUG|THP-00103|Telmisartan 40 mg
214616635|NCT06647745|DRUG|THP-00104|Placebo of Dapagliflozin 10mg
214616636|NCT06647745|DRUG|THP-00105|Placebo of Telmisartan 80mg
214616637|NCT06647745|DRUG|THP-00106|Placebo of Telmisartan 40mg
214716193|NCT00848445|DEVICE|Atrial pacing preference turned on or off|programing changes in the device
214616638|NCT07116525|DEVICE|Paddle-Shaped, High-Density, Multi-Electrode Mapping Catheter|High-density, multi-electrode mapping catheter will be used for the procedure.
214616639|NCT06916806|DRUG|AZD5492|IMP: subcutaneous.
214616640|NCT07117266|OTHER|radiologists reference AI reports|Radiologists generate reports with reference to AI reports
214716194|NCT00184652|DRUG|somatropin|
214616641|NCT05629546|BIOLOGICAL|Cytokine-induced memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
214616642|NCT05629546|BIOLOGICAL|Relatilmab|Standard of care
214616643|NCT05629546|BIOLOGICAL|Nivolumab|Standard of care
214616644|NCT05642507|DRUG|AC01|AC01 microtablets
214616645|NCT07127471|DEVICE|Water exchange with AI-assisted detection|The study employs standard high-definition colonoscopy video processors with integrated CADe system (CAD-EYE, EW10-EC02, Fujifilm) The ELUXEO 7000 system (Fujifilm) will be used in this study. During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe device will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe systems, ensuring readiness before study initiation.
214716195|NCT03636308|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
214716196|NCT03636308|DRUG|S1|S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
214716197|NCT03636308|DRUG|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
214716198|NCT05711862|DRUG|suvorexant (SUVO)|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
214616646|NCT07127471|DEVICE|Water exchange with AI-assisted detection and LCI|The study employs high-definition colonoscopy video processors with integrated CADe (CAD-EYE, EW10-EC02, Fujifilm) and LCI systems (Fujifilm).The ELUXEO 7000 system will be used . During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe and LCI devices will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe and LCI systems, ensuring readiness before study initiation.
214616647|NCT07133191|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration.~A single dose of 16 mg selatogrel will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system."
214616648|NCT07133191|COMBINATION_PRODUCT|Matching placebo|A single dose of placebo will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.
214616649|NCT07138937|PROCEDURE|Root canal treatment in primary molars with irreversible pulpitis|Root canal treatment in primary molars with irreversible pulpitis followed by coronal restoration with stainless-steel crowns in a single visit.
214616650|NCT07138937|DEVICE|EDDY system for sonic activation of irrigation|sonic activation of irrigation with EDDY system during root canal treatment in primary molars
214716199|NCT05711862|DRUG|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
214716200|NCT02061748|DRUG|Observational|Retrospective Chart Review
214716201|NCT04059991|BIOLOGICAL|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
214716202|NCT01742091|DRUG|LY2541546 - SC|Administered SC
214716203|NCT01742091|DRUG|LY2541546 - IV|Administered IV
214716204|NCT01742091|DRUG|Placebo - SC|Administered SC
214716205|NCT01742091|DRUG|Placebo - IV|Administered IV
214616651|NCT07138937|DEVICE|side-vented needle|conventional irrigation with side-vented needle without activation during root canal treatment in primary molars
214716206|NCT05227768|DRUG|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
214716207|NCT05227768|DRUG|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
214716208|NCT05227768|DRUG|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
214716209|NCT05227768|DRUG|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
214716210|NCT05227768|DRUG|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
214716211|NCT04681924|OTHER|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
214716212|NCT03750240|DIAGNOSTIC_TEST|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR"
214716213|NCT03750240|DIAGNOSTIC_TEST|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
214716214|NCT05286567|DRUG|RGRN-305|Heat shock protein 90 inhibitor
214716215|NCT05286567|DRUG|Placebo|Placebo (blinded)
214722117|NCT00619606|DEVICE|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
214722118|NCT00619606|DEVICE|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
214722119|NCT00619606|DEVICE|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
214722120|NCT02944513|DEVICE|Quell|
214722121|NCT04203108|DRUG|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
214616652|NCT07138807|BEHAVIORAL|Muscle Energy Technique|Participants in this group received Muscle Energy Techniques targeting the upper trapezius trigger points. Treatment was provided 3 sessions per week for 4 weeks. Each session included post-isometric relaxation techniques with stretching, along with baseline TENS therapy.Participants performed Neck Calliet Exercises focusing on cervical flexion, extension, rotation, and lateral flexion. Exercises were done under supervision, 3 times per week for 4 weeks. All participants also received baseline TENS therapy.
214616653|NCT07138807|OTHER|Neck Calliet exercise|Neck Calliet exercise
214616654|NCT07140705|OTHER|Transformative Virtual Reality Experience and ACT for General Practitioners|"This intervention consists of an individual, in-person session in which each participant engages in a 10-minute transformative Virtual Reality (VR) experience entitled The River and the Leaf, delivered through the Meta Quest 3 headset. Drawing on Acceptance and Commitment Therapy (ACT) metaphors, participants are guided to reflect on key aspects of the experience, their professional challenges, and the personal resources available to them. Following the VR session, participants are supported in clarifying the values that guide their everyday actions. After the in-person session, all participants are encouraged to identify and implement committed actions aligned with their values over the subsequent two weeks, supported by two dedicated audio tracks."
214616655|NCT06935656|OTHER|Tablet-based executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented in a gamified environment, and each executive function is stimulated for an equal amount of time through activities that children complete on a tablet.
214616656|NCT06935656|OTHER|Traditional executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time through activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks.
214616657|NCT06935656|OTHER|Mixed executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time. Half of the intervention sessions utilize activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks, and the other half are activities that are completed on a tablet.
214616658|NCT07145190|DRUG|SL-APO|"Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an ON response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better ON response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode."
214616659|NCT07144683|PROCEDURE|Patients Undergoing Colorectal Resection with Anastomosis|All eligible patients undergoing elective/emergency colorectal surgery with primary anastomosis (e.g., ileocolic, colocolic, colorectal, or coloanal)
214616660|NCT06946524|DRUG|Risankizumab|Subcutaneous Injection
214616661|NCT06946797|DRUG|Nivolumab|Specified dose on specified days
214616662|NCT06946797|DRUG|Ipilimumab|Specified dose on specified days
214616663|NCT06946797|DRUG|Carboplatin|Specified dose on specified days
214616664|NCT06946797|DRUG|Paclitaxel|Specified dose on specified days
214716216|NCT02069249|BEHAVIORAL|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
214616665|NCT06946797|DRUG|Pemetrexed|Specified dose on specified days
214616666|NCT06946797|DRUG|Cisplatin|Specified dose on specified days
214616667|NCT07143513|DRUG|Sotorasib|Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.
214616668|NCT06948903|DIAGNOSTIC_TEST|Central Sensitization Inventory|The Central Sensitization Inventory is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization. The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.
214722122|NCT04203108|DRUG|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
214722123|NCT04203108|DRUG|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
214722124|NCT04203108|DRUG|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
214722125|NCT05537506|DEVICE|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
214616669|NCT06948903|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment|The Montreal Cognitive Assessment was initially developed as a test for mild cognitive impairment, but has also been determined to match qualities of the mini mental state examination 80. It assesses seven areas of cognition for a total possible score of 30 points. A score of 21 or less is indicative of cognitive impairment in Turkish population.
214616670|NCT06948903|DIAGNOSTIC_TEST|Cognitive Symptom Severity Scale-Extended|The Cognitive Symptom Severity Scale extends the scale of the original cognitive symptom severity scale. Participants are asked to rate their cognitive symptoms related to concentration and memory on a single scale ranging from 1-5, rather than the original 1-3, where higher scores indicate greater severity.
214616671|NCT06948903|OTHER|Fibromyalgia Impact Questionnaire|The Fibromyalgia Impact Questionnaire is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression. The maximum scale score is 100, with higher scores associated with increasing disability.
214616672|NCT06948903|OTHER|Numeric rating scale|Numeric Rating Scale will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
214616673|NCT06948903|OTHER|Hospital Anxiety and Depression Scale|This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21: • 0-7 points: No symptoms or very mild symptoms • 8-10 points: Moderate symptoms • 11 points or higher
214616674|NCT06955806|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
214616675|NCT07141199|DRUG|ABBV-8736|Intravenous (IV) Infusion
214616676|NCT07141199|DRUG|Placebo|IV Infusion
214616679|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
214616680|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
214616681|NCT07101510|BEHAVIORAL|sV-CPR|In the sV-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone. To simulate challenging conditions, they must carry out the task in near-total darkness, with the phone's flashlight as the only light source.
214616682|NCT07101510|BEHAVIORAL|V-CPR|In the V-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone.
214616683|NCT07101510|BEHAVIORAL|T-CPR|In the T-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only).
214716217|NCT02069249|BEHAVIORAL|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
214616684|NCT07101510|BEHAVIORAL|sT-CPR|In the sT-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only). To simulate challenging conditions, they must carry out the task in higher environmental noises (traffic), generated by a loudspeaker.
214722126|NCT05537506|DEVICE|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
214722127|NCT02130752|DEVICE|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
214616685|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine Only|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care. No additional regional block is performed. Postoperative analgesia is maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs as per institutional protocol.
214616686|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine plus Bilateral TAP Block|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care, plus bilateral ultrasound-guided transversus abdominis plane (TAP) block performed at the end of surgery. The TAP block will be performed in-plane with a high-frequency linear probe, using 0.25% bupivacaine, 20 mL per side, injected between the internal oblique and transversus abdominis muscles. Postoperative analgesia will be maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs.
214616687|NCT07149324|BEHAVIORAL|Single Session for Overevaluation|A single session informed by the principles of Cognitive Behavioural Therapy-Enhanced and motivational intervening.
214616688|NCT07154433|DRUG|Opioid Analgesic Regimen|Participants will take 5 mg/325 mg of oxycodone - acetaminophen every 6 hours as needed for pain, with a maximum of 4 doses per day. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
214616689|NCT07154433|DRUG|Non-opioid analgesic regimen|Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
214616690|NCT07160673|DEVICE|VR-based Respite|Caregivers and homebound older adults will receive 4 weeks of VR-based respite sessions. 4 weeks (1 session/week; 30 min/session) of immersive VR sessions using SilVR Adventures platform. Sessions include virtual travel destinations (e.g., cities, natural wonders) and social activities (e.g., group tours). Facilitated by trained research staff, with 5-10 minutes viewing and 20 minutes reflection/discussion.
214616691|NCT07160673|DEVICE|Video-based Respite|Caregivers and homebound older adults will receive 4 weeks of video-based respite sessions. 4 weeks (1 session/week; 30 min/session) of non-immersive video sessions with content similar to VR themes (e.g., landscapes, cultural events). Facilitated by trained research staff, with post-video discussion. EEG data collected during viewing to assess emotional states.
214616692|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with extracoronal adhesive attachments|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the extracoronal adhesive attachment and the RPD.~* Evaluation of the attachment's condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
214616693|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with conventional clasps|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the clasps and the RPD.~* Evaluation of the clasps' condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
214616694|NCT07171281|BEHAVIORAL|Early Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
214616695|NCT07171281|BEHAVIORAL|Late Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
214616696|NCT07170735|DIAGNOSTIC_TEST|Plasma MTB cfDNA assay|Quantitative measurement of MTB cfDNA level in the plasma
214616697|NCT07171385|OTHER|Nordic Hamstring Curl (NHC)|Knee-dominant eccentric hamstring strengthening exercise performed on a padded surface. Participants control the descent of the torso while knees remain fixed, emphasizing eccentric activation of hamstring muscles.
214616698|NCT07171385|OTHER|Kettlebell Swing (KS)|Hip-dominant ballistic movement involving rapid hip flexion-extension using a kettlebell (16-20 kg depending on participant's ability). Each repetition includes concentric, isometric, and eccentric phases standardized by metronome pacing.
214616699|NCT07171385|OTHER|Supine Sliding Single-Leg Curl (SSLC)|Closed-chain exercise performed in supine position with heels placed on sliding discs. One leg is extended while the other leg performs concentric-eccentric sliding curl.
214616700|NCT07171034|DRUG|KLA318-2 Nanocrystal Injection|Intravenous injection, single dose
214616701|NCT07171034|DRUG|Celebrex Capsule|P.O., single dose
214616702|NCT07170111|PROCEDURE|Greater Occipital Nerve (GON) Blockade|The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions
214616703|NCT07171606|DRUG|SSGJ-706|PD-1/PD-L1 bispecific antibody
214616704|NCT07171606|DRUG|pemetrexed /carboplatin|chemotherapy
214616705|NCT07171606|DRUG|Carboplatin/Paclitaxel|chemotherapy
214616706|NCT07171606|DRUG|PD-1 Inhibitor + Chemotherapy|control group
214616707|NCT07171632|OTHER|monitoring of clinical and ventilatory variables|Monitoring clinical data
214616708|NCT07170839|OTHER|ESWT Aplication|All three groups received a total of five ESWT sessions, once a week for five weeks. All ESWT sessions were administered by the same physiotherapist, and the patients were positioned with their elbows flexed to 90 degrees and supported. ESWT was applied to sensitive points on the lateral epicondyle using a shock wave dose of 2000 pulses/session, with an intensity of 1.6 bar, a frequency of 10 Hz, and 1.6 bar. No analgesics or local anesthetics were administered before, during, or after the treatment.
214716218|NCT05488418|OTHER|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
214716219|NCT04544124|BEHAVIORAL|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
214716220|NCT04764968|DRUG|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
214716221|NCT05243004|OTHER|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions."
214716222|NCT03706040|BIOLOGICAL|Placebo|subcutaneous (SC) injection
214616709|NCT07170839|OTHER|ECCENTRIC EXERCISE|Patients in the eccentric exercise group underwent a protocol consisting of slow-progressive eccentric wrist extensor exercises combined with static stretching exercises three times a week for 5 weeks. Eccentric exercises were performed without any resistance to eliminate gravity in the first week, and the intensity of the resistance was gradually increased using yellow elastic resistance bands in weeks 2-3 and red elastic resistance bands in weeks 4-5. Eccentric exercises were performed with the elbow extended, the forearm pronated, the wrist extended, and hanging down from the support surface. Patients were asked to slowly bend the wrist downward, count to 30, and then return to the starting position. Eccentric contractions were then performed in the same manner, and so on. Patients were instructed to continue the exercise if mild pain occurred but to stop the exercise if the pain increased to the point of preventing movement. Once patients tolerated the exercise, the lo
214716223|NCT03706040|BIOLOGICAL|Risankizumab|subcutaneous (SC) injection
214616710|NCT07170839|OTHER|COMBINED ISOTONIC EXERCISE|Patients in the combined isotonic exercise group underwent an eccentric-concentric exercise protocol combined with wrist isometric exercises three days a week for 5 weeks. Similar to the eccentric training group, this group completed the training with resistance applied in the first week and elastic bands in subsequent weeks. In the first week, exercise training began with the patients' elbows in full extension, forearms in pronation, wrists in extension, and hanging from the support surface. Participants were asked to slowly bend their wrists for a count of 30, and the wrist extensors were eccentrically exercised. Immediately afterward, patients performed a concentric contraction while returning to the starting position (extension). Then, isometric contraction of the wrist extensors was maintained in the starting position for 30-45 seconds. Once the isometric contraction was achieved, concentric contraction continued, completing the exercise protocol.
214616711|NCT07171697|BEHAVIORAL|Mindfulness and psycho-education|4 week tailored mindfulness and psychoeducation programme for medical interns
214716224|NCT03658317|DIAGNOSTIC_TEST|renal arterial resistive index|done by dupplex on renal arteries
214616712|NCT07171151|OTHER|cyst fluid examination|Participants will not undergo any procedures outside of the routine for the study. The cyst fluid obtained during the puncture will be collected in a tube and centrifuged at 3000 rpm for 20 minutes at 4 degrees Celsius. The Eppendorf tubes will be stored at -80 °C until the clear liquid remaining above is taken and examined, without removing the particles that have settled at the bottom of the tube. The biochemical parameters of the cyst fluid obtained from the study participants will be analyzed using the ELISA method. MMP-8, MMP-9, RANKL, and MIP1alpha will be analyzed using commercially available ELISA kits, following the manufacturer's instructions.
214616713|NCT07170618|DEVICE|balloon microcatheter|The balloon microcatheter simultaneously possesses both balloon dilatation and device delivery functions.
214616714|NCT07171489|DEVICE|TNM at a sham-point (AccelBand) - randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
214616715|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
214616716|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- open-label|After 4 weeks of blinded treatment sham participants will be given the option to continue open-label TNM treatment at a leg point acupoint. Participants that agree to this will be re-trained and allowed to keep the AccelBand for another 2 weeks. During this stage, participants will be asked to complete daily home-based TNM treatment and complete the daily online symptom questionnaires. Participants will complete a visit following this additional treatment.
214616717|NCT07171255|BEHAVIORAL|RemoteEx+ Programming|The exercise program will include video instruction for all exercises, motivational cues, and ADRD risk education throughout the 16-week exercise program to encourage exercise adherence. RemoteEx+ is optimized to enhance exercise knowledge surrounding dementia risk factors to facilitate ADRD risk reduction and overall health improvement. The purpose of this study is to investigate the efficacy of RemoteEx+ on health outcomes associated with dementia risk in underactive rural adults.
214616718|NCT07170176|DEVICE|Percutaneous Patent Foramen Ovale Closure|Percutaneous transcatheter closure of patent foramen ovale (PFO) is a minimally invasive procedure. Under local anesthesia, a closure device is delivered via a catheter through the femoral vein to the heart to seal the PFO tunnel. The procedure is performed under fluoroscopic and echocardiographic guidance. This intervention aims to eliminate right-to-left shunt, which is hypothesized to improve migraine symptoms and glymphatic function.
214616719|NCT07170176|OTHER|No Intervention|This arm does not receive the PFO closure procedure. Patients in this control group are observed under their standard care regimen without any study-specific intervention.
214616720|NCT07170436|BEHAVIORAL|Short version of cognitive testing during surgery|Cognitive testing in 3 blocks of 3 minutes during awake surgery
214616721|NCT07170904|OTHER|Not applicable- observational study|This is an observational study; no interventions are administered to participants.
214616722|NCT07170943|OTHER|Blueberry|Daily consumption of blueberries
214616723|NCT07170943|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder|Daily consumption of a freeze-dried blueberry powder
214616724|NCT07170943|DIETARY_SUPPLEMENT|Placebo powder|Daily consumption of a placebo powder
214616725|NCT07169760|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
214616726|NCT07171671|OTHER|exercises|manuel therapy and exercises
214716225|NCT03658317|DIAGNOSTIC_TEST|uric acid level|serum sample for doing the test
214616727|NCT07171359|DEVICE|TMS Low-Dose|one 3-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
214616728|NCT07171359|DEVICE|TMS High-Dose|One 9-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
214616729|NCT07171112|DRUG|Standard Varenicline Dosing (1 mg BID)|Varenicline PO (oral) 1mg twice daily
214616730|NCT07171112|DRUG|Bupropion 150 mg twice daily|Bupropion 150 mg PO twice daily
214616731|NCT07171112|DRUG|Increased Varenicline Dosing (1mg TID)|Varenicline 1mg PO (oral) three times daily
214716226|NCT03658317|DIAGNOSTIC_TEST|serum urea and creatinine|serum samples for doing the test
214716227|NCT03658317|DIAGNOSTIC_TEST|24 hours urinary proteins|urine collected over 24 hours for doing the test
214716228|NCT03658317|DIAGNOSTIC_TEST|lipogram|serum sample for doing the test
214716229|NCT03658317|DIAGNOSTIC_TEST|HbA1c level|serum sample for doing the test
214716230|NCT03658317|DIAGNOSTIC_TEST|urine analysis|urine sample for doing the test
214716231|NCT03658317|DIAGNOSTIC_TEST|abdominal ultrasonography|done by the ultrasonography device
214716232|NCT04011319|BEHAVIORAL|group culture|Four embryos were cultured in the same droplet by a special dish.
214716233|NCT00927758|DRUG|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
214716234|NCT01475318|DRUG|mifepristone|200 mg mifepristone on day 1
214716235|NCT01475318|DRUG|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
214716236|NCT01475318|DRUG|Misoprostol|misoprostol 800mcg PV on day 3
214716237|NCT02401113|DIETARY_SUPPLEMENT|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
214616732|NCT07170605|BEHAVIORAL|Mental health, positive coping strategies promoting self-regulation and adaptive skills|"The BRP manual includes eight modules delivered over eight weeks: introduction to resilience, identifying and communicating emotions, emotional regulation, coping strategies for self-regulation (2 parts), breath awareness/meditation, applying positive coping strategies, and review/group session with caregiver. Sessions utilize play as the primary occupation, introducing resiliency concepts through 40-60 minute sessions three times each week to provide repetition and application of concepts with multiple opportunities to review, repeat and apply.~Each BRP session will be implemented by two occupational therapists, one occupational therapy student, and one YWCA staff member. Group size has been determined to approach therapeutic limits with 8-10 students, requiring this staffing ratio for optimal intervention delivery."
214616733|NCT07170605|OTHER|Standard care/School Readiness Condition|The School Readiness protocol supplements existing preschool curriculum while mitigating positive researcher interaction effects. Sessions start with a song and warm-up, including active listening, sharing and turn-taking while targeting different domains each week: perceptual motor, fine motor (tool use), fine motor (coloring), problem solving, teamwork, coordination and motor planning, problem solving (teams), and gross and fine motor (teams). These skills were selected based on feasibility study observations and designed not to overlap with social-emotional skills embedded in the BRP.
214616734|NCT07169981|DRUG|Empagliflozin 10 MG [Jardiance]|This intervention consists of Empagliflozin 10 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
214616735|NCT07169981|DRUG|empagliflozin (Jardiance) 25 mg|This intervention consists of Empagliflozin 25 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
214616736|NCT07171294|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
214616737|NCT07169799|OTHER|trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)|This treatment consists of performing a diagnostic EGD to identify GAVE lesions. A catheter advances through the therapeutic channel to treat target areas with cryotherapy.
214616738|NCT07171177|DEVICE|Foot Orthoses|To compare the use of handmade plantar orthoses versus the use of splints in the management of low back pain.
214616739|NCT07170098|DEVICE|EDDY sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
214616740|NCT07170098|DEVICE|EndoActivator (EA) sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
214616741|NCT07170098|DEVICE|980-nm diode laser|Diode laser irradiation during endodontic treatment.
214616742|NCT07170202|OTHER|Mindfulness Smartphone Application|A mindfulness mobile health smartphone application that has mindfulness information and practice videos.
214716238|NCT01668134|RADIATION|Stereotactic radiation|
214616743|NCT07170722|DEVICE|Subtreshhold DRG-S|Continuous electrical stimulation delivered through an implanted DRG neurostimulator. Amplitude is set individually to 80% of each participant's perception threshold, ensuring no paresthesia is produced. Frequency and pulse width remain unchanged from the participant's established therapeutic settings. This sub-threshold programming distinguishes the intervention from suprathreshold (paresthesia-based) DRG stimulation used in earlier studies.
214616744|NCT07170722|OTHER|Sham|The implanted DRG stimulator remains switched off for the entire 5-day period. Device interrogation logs are masked to maintain blinding. No electrical stimulation is delivered, allowing a placebo-controlled comparison with active sub-threshold stimulation.
214716239|NCT04260841|DEVICE|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
214716240|NCT03068936|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
214716241|NCT03068936|DRUG|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
214716242|NCT03010904|OTHER|Dietary intervention|
214716243|NCT00439725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
214716244|NCT00439725|DRUG|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
214716245|NCT01444183|BEHAVIORAL|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
214722128|NCT02130752|DEVICE|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
214616745|NCT07170345|DIAGNOSTIC_TEST|Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC|This intervention is an artificial intelligence-based computer-aided diagnosis (CAD) system developed to predict microvascular invasion (MVI) in patients with hepatocellular carcinoma using preoperative multiphase CT imaging. The system integrates deep learning, radiomics, and expert-defined imaging features to provide risk assessment and visualization of MVI prior to surgery. In this study, the CAD system will be evaluated retrospectively and prospectively in an observational manner only. The results will not influence clinical decision-making or patient management, and all treatments will follow standard of care.
214616746|NCT02231151|BEHAVIORAL|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
214616747|NCT01509495|DEVICE|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
214616748|NCT00683163|DRUG|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
214616749|NCT00683163|DRUG|Ibandronate|150mg by mouth once monthly
214616750|NCT00683163|OTHER|Placebo injection|Daily injections as placebo for PTS 1-84
214616751|NCT00683163|OTHER|Placebo pills|Monthly pills as placebo for oral ibandronate
214616752|NCT03919279|DEVICE|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
214616753|NCT01027611|DRUG|proparacaine HCL 0.5%|
214616754|NCT01027611|DRUG|proparacaine HCL 0.5% + 4% lidocaine solution|
214616755|NCT01027611|DRUG|3.5% viscous lidocaine gel|
214616756|NCT05488587|DIAGNOSTIC_TEST|magnesium and zinc levels|measuring magnesium and zinc levels
214616757|NCT02025868|BEHAVIORAL|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
214722129|NCT04263415|DRUG|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
214616758|NCT02025868|DRUG|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
214616759|NCT05048368|DRUG|Larotinib|Capsules, Oral, 350 mg, single dose, one day
214616760|NCT04456764|BEHAVIORAL|SaFTiE|A multi-modal fatigue risk management program.
214616761|NCT04456764|BEHAVIORAL|Attention Placebo Control|A multi-modal teamwork assessment program.
214616762|NCT05696483|DRUG|OLX-07010 Active|25 and 75 mg capsules
214616763|NCT05696483|DRUG|OLX-07010 Placebo|25 and 75 mg capsules
214616764|NCT06789198|DRUG|Vaccination of Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).~A total of two vaccinations are planned, 4 weeks apart from each other. If no sufficient T cell response is achieved at the end of treatment visit (28 days after last vaccination) a booster vaccination at day 56 (+7 days) after the second vaccination can be applied"
214616765|NCT04635800|DRUG|MHU650|MHU650 powder for solution for injection
214616766|NCT03140358|DRUG|Atropine sulfate 0.01%|Atropine 0.01%
214616767|NCT03140358|DRUG|Placebo|placebo
214616768|NCT05431595|DRUG|Haloperidol|Given by Vein (IV)
214616769|NCT05431595|DRUG|Chlorpromazine|Given by Vein (IV)
214616770|NCT05431595|DRUG|Valproate|Given by Vein (IV)
214616771|NCT05431595|DRUG|Placebo|Given by Vein (IV)
214616772|NCT06956651|OTHER|FIT SA|Self Adhesive Flowable giomer restorative material
214616773|NCT06956651|OTHER|Beautifil Flow Plus F00|Conventional Flowable giomer composite
214616774|NCT03116997|DRUG|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
214616775|NCT03116997|DRUG|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
214616776|NCT05854316|DIAGNOSTIC_TEST|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
214716246|NCT01444183|BEHAVIORAL|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
214616777|NCT05281666|DEVICE|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
214616778|NCT05281666|DEVICE|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
214616779|NCT03496012|GENETIC|BIIB111|Administered as specified in the treatment arm.
214616780|NCT04116086|DIAGNOSTIC_TEST|Prostate Biopsy Test|see earlier information
214616781|NCT02671357|PROCEDURE|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
214616782|NCT02322125|DEVICE|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
214616783|NCT02861768|BIOLOGICAL|Pharyngeal swab|
214716247|NCT04061941|BEHAVIORAL|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
214716248|NCT03788616|DRUG|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
214716249|NCT03788616|DRUG|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
214616784|NCT01199588|DRUG|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
214616785|NCT01199588|DRUG|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
214616786|NCT01199588|DRUG|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
214716250|NCT00212758|DRUG|Nutropin AQ|Nutropin AQ
214716251|NCT04936204|DEVICE|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
214722130|NCT04263415|OTHER|Placebo|once-weekly injection with placebo pen for 16 weeks
214616787|NCT04429906|DEVICE|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
214616788|NCT06195982|DIETARY_SUPPLEMENT|ketone ester|500 mg/kg of ketone ester administered approximately 1 hour prior to the maximal exercise testing and 250 mg/kg administered approximately 30 minutes prior to submaximal exercise testing
214616789|NCT06195982|DIETARY_SUPPLEMENT|placebo|ketone-free placebo administered approximately 1 hour prior to the maximal exercise testing and ketone-free placebo administered approximately 30 minutes prior to submaximal exercise testing
214616790|NCT01815047|DIETARY_SUPPLEMENT|Vitamin D3 Supplementation|
214616791|NCT03085979|PROCEDURE|Burch Colposuspension|Anti-incontinent surgery
214616792|NCT03085979|PROCEDURE|trans obturator tape|Anti-incontinent surgery
214616793|NCT03085979|PROCEDURE|tension free vaginal tape|Anti-incontinent surgery
214616794|NCT05996159|DEVICE|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
214616795|NCT05996159|DEVICE|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
214616796|NCT01463670|DRUG|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
214616797|NCT05502042|BEHAVIORAL|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
214616798|NCT02034942|OTHER|Non-sedation|
214616799|NCT02034942|OTHER|Sedation, control|
214616800|NCT01395199|DRUG|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
214616801|NCT00565253|DRUG|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
214616802|NCT03029715|DRUG|Propofol|Total intravenous anaesthesia.
214616803|NCT03029715|DRUG|Remifentanil|Narcotics
214716252|NCT04936204|DEVICE|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
214716253|NCT01755325|DRUG|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
214716254|NCT01755325|DRUG|placebo|
214716255|NCT03510910|DRUG|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
214716256|NCT03510910|DRUG|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
214716257|NCT00141310|DRUG|Sildenafil citrate|
214716258|NCT04988321|PROCEDURE|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
214616804|NCT03029715|DRUG|Dexmedetomidine|Total intravenous anaesthesia
214616805|NCT03029715|DRUG|Desflurane|Inhalation anaesthesia.
214616806|NCT02055651|BEHAVIORAL|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
214616807|NCT05045898|OTHER|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
214616808|NCT05045898|OTHER|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
214616809|NCT02280395|DRUG|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
214616810|NCT02280395|DRUG|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
214716259|NCT02338856|DRUG|MB12066 200mg|100mg bid (multiple dose, day 8)
214716260|NCT02338856|DRUG|Placebo|100mg bid (multiple dose, day 8)
214716261|NCT00110591|DRUG|PRO 140|Monoclonal antibody to CCR5
214716262|NCT02244229|DRUG|Tamsulosin|
214616811|NCT00665873|DEVICE|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
214616812|NCT00665873|DRUG|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
214616813|NCT05261958|OTHER|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
214616814|NCT03395548|DRUG|Macrogol|Used drug: Macrogol (osmotic laxative)
214716263|NCT02244229|DRUG|Finasteride|
214716264|NCT02244229|DRUG|Placebo|
214716265|NCT06198218|OTHER|Scapular mobilization|Group A: will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula.Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 min
214616815|NCT04507542|BEHAVIORAL|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
214716266|NCT06198218|OTHER|Conventional physical therapy program|Group B:will receive conventional physical therapy program including (heating to improve circulation and release muscle tension,EMS,stretching for stiff muscle,weight bearing, strengthening exercises \& graduated active exercises)for 20 min along with activity based scapular mobilization (Codman pendulum exercises,band wall apart,wall ball circles, scapular pushups and advance study wall pushups)for 20 min with 5 min resting interval.
214716267|NCT03346291|BEHAVIORAL|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
214716268|NCT02506491|OTHER|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
214716269|NCT02506491|OTHER|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
214716270|NCT02506491|OTHER|Control Group|No exercise
214616816|NCT04507542|BEHAVIORAL|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
214716271|NCT01279967|DRUG|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
214716272|NCT05637957|DEVICE|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
214716273|NCT05637957|DEVICE|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
214716274|NCT01301404|DIETARY_SUPPLEMENT|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
214716275|NCT00866060|DRUG|Memantine|20mg memantine
214716276|NCT00866060|DRUG|Donepezil|10mg donepezil
214616817|NCT02308631|PROCEDURE|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
214616818|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
214616819|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
214716277|NCT00866060|DRUG|Placebo donepezil|Placebo donepezil
214716278|NCT00866060|DRUG|Placebo memantine|Placebo memantine
214722131|NCT03921606|BEHAVIORAL|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
214616820|NCT00349375|DRUG|Simvastatin|Simvastatin 40 mg
214616821|NCT01270308|DRUG|Lansoprazole|Lansoprazole DR Capsules 30 mg
214616822|NCT03805945|DRUG|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
214616823|NCT03805945|DRUG|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
214616824|NCT05288218|DEVICE|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
214616825|NCT05288218|DEVICE|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
214616826|NCT01841944|DRUG|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
214616827|NCT01841944|OTHER|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
214616828|NCT03388359|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
214616829|NCT03388359|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
214616830|NCT03388359|OTHER|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
214716279|NCT02940860|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
214616831|NCT03388359|OTHER|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
214616832|NCT03388359|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
214616833|NCT03388359|DEVICE|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
214616834|NCT03388359|BIOLOGICAL|Eosinophils|Eosinophils are isolated from peripheral blood
214616835|NCT03388359|BIOLOGICAL|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
214616836|NCT03388359|BIOLOGICAL|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
214616837|NCT02554747|DEVICE|Navigated laser|Aflibercept, Navilas®
214616838|NCT02554747|DEVICE|Conventional laser|Aflibercept, Pascal
214616839|NCT00095875|DRUG|carboplatin|Given IV
214616840|NCT00095875|DRUG|cisplatin|Given IV
214616841|NCT00095875|DRUG|docetaxel|Given IV
214616842|NCT00095875|DRUG|fluorouracil|Given IV
214716280|NCT02940860|DRUG|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
214616843|NCT04203732|PROCEDURE|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
214616844|NCT00766038|DRUG|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
214616845|NCT00766038|DRUG|Placebo|SC injection daily
214616846|NCT04436536|OTHER|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
214716281|NCT02047968|BEHAVIORAL|wake therapy|
214716282|NCT06422572|OTHER|No Intervention|No Intervention
214616847|NCT04436536|OTHER|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
214616848|NCT00169455|BIOLOGICAL|Live attenuated human rotavirus vaccine|
214616849|NCT05679128|DIAGNOSTIC_TEST|identification of the cricothyroid membrane using Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
214616850|NCT05679128|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane using ultrasonography|identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
214616851|NCT06087796|DRUG|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
214616852|NCT06087796|DRUG|Pentoxifylline|Topical treatment modality for alopecia areata.
214616853|NCT06087796|DRUG|Metformin|Topical treatment modality for alopecia areata.
214616854|NCT05651165|DEVICE|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
214616855|NCT05651165|DEVICE|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
214616856|NCT05049096|DEVICE|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
214616857|NCT05049096|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
214616858|NCT00971165|DRUG|losartan|Oral losartan up to 100 mg daily fo 18 months
214616859|NCT00971165|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
214616860|NCT05490173|OTHER|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
214616861|NCT05566951|OTHER|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
214616862|NCT05566951|OTHER|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
214616863|NCT02681536|DRUG|Triptorelin|
214616864|NCT02681536|DRUG|Combined oral contraceptive pills|
214616865|NCT02681536|DRUG|HMG|
214616866|NCT03284671|OTHER|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
214616867|NCT02998775|DRUG|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
214616868|NCT02227732|DEVICE|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
214616869|NCT04701138|DIETARY_SUPPLEMENT|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
214616870|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
214616871|NCT00449670|BIOLOGICAL|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
214616872|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
214616873|NCT06080828|DEVICE|Percutaneous Posterior Tibial Nerve Stimulation|20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
214616874|NCT06080828|DEVICE|Placebo Percutaneous Posterior Tibial Nerve Stimulation|placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
214616875|NCT06080828|BEHAVIORAL|Home instructions|they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
214616876|NCT00767052|DRUG|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
214616877|NCT00767052|DRUG|Placebo|Placebo tablet matching to the active in multiple dose part.
214616878|NCT00767052|DRUG|AZD1236|75mg single dose will be administered in relative bioavailability part.
214616879|NCT00767052|DRUG|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
214616880|NCT01973712|PROCEDURE|Locked Compression Plating|
214616881|NCT01973712|PROCEDURE|Retrograde Intramedullary Nailing (RIMN)|
214616882|NCT00234468|DRUG|Iressa (Gefitinib)|
214616883|NCT04163796|DEVICE|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
214616884|NCT01258244|OTHER|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
214616885|NCT03682679|DIAGNOSTIC_TEST|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
214616886|NCT02950090|BEHAVIORAL|MobilWise|see arm description for MobilWise above
214616887|NCT02950090|BEHAVIORAL|Fitbit Only|see arm description for Fitbit above
214616888|NCT05549700|OTHER|Neuromodulation|Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
214616889|NCT03743311|PROCEDURE|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
214616890|NCT03743311|DRUG|Detralex|Conservative treatment of Hemorhoid
214616891|NCT03743311|OTHER|Combined therapy|Surgical + conservative treatment of Hemorhoid
214616892|NCT03151863|DRUG|Opioids|The usual opioid treatment used for nursing care
214616893|NCT03151863|DRUG|Dexmedetomidine|Dexmedetomidine is provided intranasally
214616894|NCT03151863|DRUG|Placebo|Normal saline is either given subcutaneously or intranasally
214616895|NCT03059238|DRUG|Celecoxib 200mg oral capsule|
214616896|NCT03059238|DRUG|parecoxib sodium|
214716283|NCT04914819|BEHAVIORAL|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
214716284|NCT04914819|BEHAVIORAL|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
214716285|NCT01500863|DRUG|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
214716286|NCT01500863|DRUG|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
214716287|NCT01500863|DRUG|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
214716288|NCT01500863|DRUG|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
214616897|NCT03059238|DRUG|controlled-release oxycodone|
214616898|NCT00003281|DRUG|paclitaxel|
214616899|NCT00003281|DRUG|topotecan hydrochloride|
214716289|NCT01500863|DRUG|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
214716290|NCT01500863|DRUG|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
214716291|NCT04410913|DRUG|Psilocybin plus Visual Healing Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
214716292|NCT04410913|DRUG|Psilocybin plus Standard Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
214716293|NCT00215813|DRUG|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
214716294|NCT00033059|DRUG|Tolcapone|
214716295|NCT04090697|DRUG|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
214716296|NCT03587467|OTHER|collect fecal specimens|collect fresh fecal specimens of participants
214616900|NCT00003281|RADIATION|radiation therapy|
214716297|NCT02164604|DRUG|intravitreal injection of 0.03ml ranibizumab|
214716298|NCT03665207|DRUG|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
214716299|NCT03820908|DRUG|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
214716300|NCT03582436|PROCEDURE|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
214716301|NCT02715804|OTHER|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
214716302|NCT02715804|DRUG|Placebo|Matching placebo for PEGPH20
214716303|NCT02715804|DRUG|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
214716304|NCT02715804|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
214716305|NCT04816786|OTHER|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
214716306|NCT05287724|DRUG|N-acetyl cysteine|1,500 mg twice daily for seven days
214716307|NCT05287724|DRUG|Placebo|Placebo taken twice daily for seven days
214716308|NCT04506281|DRUG|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
214716309|NCT04038385|BEHAVIORAL|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
214716310|NCT02550119|DRUG|Aprepitant|Given PO
214716311|NCT02550119|DRUG|Dexamethasone|Given PO or IV
214716312|NCT02550119|DRUG|Dolasetron Mesylate|Given PO or IV
214716313|NCT02550119|DRUG|Placebo|Given PO
214716314|NCT04431141|DRUG|Teneligliptin|Teneligliptin alone
214716315|NCT04431141|DRUG|Empagliflozin|Empagliflozin alone
214716316|NCT04431141|DRUG|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
214716317|NCT02435394|BEHAVIORAL|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
214716318|NCT02435394|BEHAVIORAL|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
214716319|NCT02435394|BEHAVIORAL|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
214716320|NCT02656862|OTHER|No intervention|
214716321|NCT04524091|OTHER|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
214716322|NCT03961295|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
214716323|NCT00005792|DRUG|etoposide phosphate|Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
214716324|NCT00005792|DRUG|melphalan|Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
214616901|NCT00748280|PROCEDURE|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
214616902|NCT00748280|PROCEDURE|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
214616903|NCT04183790|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
214616904|NCT04183790|DRUG|IVA|Mono tablet for oral administration.
214616905|NCT04272840|BEHAVIORAL|Low Glycemic Index Education|Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
214616906|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
214616907|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
214616908|NCT01251653|DRUG|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
214616909|NCT01251653|DRUG|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
214616910|NCT03716271|DEVICE|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
214616911|NCT01825291|PROCEDURE|CPAP treatment|
214616912|NCT03410433|DEVICE|Silk 4.0|Silk suture 4.0
214616913|NCT03410433|DEVICE|PG 910 4.0|PG 910 4.0
214616914|NCT03410433|DEVICE|PP 4.0|PP 4.0
214616915|NCT03410433|DEVICE|Silk 5.0|Silk 5.0
214616916|NCT03410433|DEVICE|PG910 5.0|PG910 5.0
214616917|NCT03410433|DEVICE|PP 5.0|PP 5.0
214616918|NCT03410433|DEVICE|APG 5.0|APG 5.0
214616919|NCT03410433|DEVICE|ePTFE 5.0|ePTFE 5.0
214616920|NCT04876170|OTHER|Brain-computer-interface: EEG-based musical Neurofeedback task|Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.
214616921|NCT02268279|DRUG|solithromycin|
214616922|NCT00861120|DRUG|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
214616923|NCT00861120|DRUG|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
214616924|NCT04268251|DIAGNOSTIC_TEST|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
214616925|NCT00847145|BIOLOGICAL|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
214616926|NCT00847145|BIOLOGICAL|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
214616927|NCT00847145|BIOLOGICAL|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
214616928|NCT00847145|BIOLOGICAL|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
214616929|NCT00847145|BIOLOGICAL|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
214616930|NCT00847145|BIOLOGICAL|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
214616931|NCT00847145|BIOLOGICAL|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
214616932|NCT00847145|BIOLOGICAL|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
214616933|NCT01012791|OTHER|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
214616934|NCT06156683|OTHER|Multiple sclerosis disease modifying drug|There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.
214716325|NCT00005792|DRUG|topotecan|Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
214716326|NCT00005792|PROCEDURE|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
214616935|NCT03075800|BEHAVIORAL|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
214616936|NCT06206174|DRUG|TGRX-814|Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
214616937|NCT05554484|BIOLOGICAL|Autologous peripheral blood-derived tolerogenic dendritic cells|AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1\~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
214616938|NCT04161820|BEHAVIORAL|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
214616939|NCT01798589|DRUG|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
214616940|NCT02833974|DRUG|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
214616941|NCT02833974|DRUG|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
214616942|NCT06236477|BEHAVIORAL|Personalized Music|Music that is familiar to the child will be played via bluetooth speaker throughout their immediate perioperative care
214616943|NCT06236477|BEHAVIORAL|No Music|Participants will receive standard care without music.
214616944|NCT05068570|OTHER|ARMEROMTERY|ARMERGOMTERY TRAINING FOR UPPERLIMB
214616945|NCT03906097|OTHER|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
214616946|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
214616947|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
214616948|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
214616949|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
214616950|NCT04289337|DIETARY_SUPPLEMENT|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
214616951|NCT04289337|DIETARY_SUPPLEMENT|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
214716327|NCT04687436|DEVICE|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
214616952|NCT01781715|DEVICE|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
214616953|NCT06379386|PROCEDURE|Transcatheter aortic valve replacement|A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
214616954|NCT04058340|DIETARY_SUPPLEMENT|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
214616955|NCT04058340|OTHER|Placebo|0.9% NaCl solution in nebulization
214716328|NCT01507623|DEVICE|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
214716329|NCT04376424|DIAGNOSTIC_TEST|Hand Held Ultrasound|Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
214616956|NCT04225130|BEHAVIORAL|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
214616957|NCT04225130|BEHAVIORAL|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
214616958|NCT01739985|DRUG|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
214616959|NCT01739985|DRUG|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
214616960|NCT04419610|BIOLOGICAL|TRV027|peptide for infusion
214616961|NCT04419610|OTHER|sodium chloride 0.9%|placebo comparator for infusion
214616962|NCT01439282|DRUG|eribulin mesylate|Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
214616963|NCT01439282|DRUG|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
214616964|NCT01524198|DRUG|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
214616965|NCT01524198|DRUG|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
214616966|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
214616967|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
214616968|NCT03592706|BIOLOGICAL|IKC (Immune Killer Cells)|
214616969|NCT03592706|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization)|
214616970|NCT03380260|BEHAVIORAL|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
214616971|NCT00790686|PROCEDURE|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
214616972|NCT00634634|DRUG|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
214616973|NCT00634634|DRUG|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
214616974|NCT03775954|DIAGNOSTIC_TEST|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
214616975|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
214616976|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
214616977|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214616978|NCT01199029|DRUG|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
214616979|NCT01199029|DRUG|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
214616980|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214616981|NCT01199029|DRUG|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214616982|NCT00885703|DRUG|Fluconazole|"Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
214616983|NCT00885703|DRUG|Amphotericin B|Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
214616984|NCT02761304|PROCEDURE|Ultrasound|
214616985|NCT01973777|DEVICE|IUB|intrauterine contraceptive device
214616986|NCT04870242|OTHER|Observational study, non-interventional|observational study for the ERAS protocols in pediatric surgery
214616987|NCT01183143|DRUG|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
214616988|NCT00689468|PROCEDURE|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
214616989|NCT00689468|DIETARY_SUPPLEMENT|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
214616990|NCT00689468|PROCEDURE|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
214716330|NCT05726955|OTHER|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
214616991|NCT00689468|DIETARY_SUPPLEMENT|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
214616992|NCT01188889|DRUG|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
214616993|NCT01188889|DRUG|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
214616994|NCT03045770|DRUG|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
214616995|NCT03045770|DRUG|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
214616996|NCT03045770|DRUG|Irinotecan|Irinotecan was used as first line treatment with AGC.
214616997|NCT03045770|DRUG|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
214616998|NCT03045770|DRUG|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
214616999|NCT05023356|DEVICE|Non-contact vital signs monitoring with camera|Monitor patients face image by non-contact vital signs monitoring with camera
214617000|NCT04096274|BEHAVIORAL|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
214617001|NCT04096274|BEHAVIORAL|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
214617002|NCT00001764|DRUG|Mycophenolate Mofetil|
214617003|NCT03638154|PROCEDURE|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
214617004|NCT03638154|PROCEDURE|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
214617005|NCT02756728|BIOLOGICAL|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
214617006|NCT02756728|OTHER|High dose melphalan|High dose melphalan (HDM)
214617007|NCT02756728|OTHER|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
214617008|NCT04739514|OTHER|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
214617009|NCT01365260|DEVICE|MM-II|Single intraarticular (knee) injection of MM-II
214617010|NCT01365260|DEVICE|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
214617011|NCT04584528|OTHER|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
214617012|NCT02270619|BIOLOGICAL|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
214617013|NCT02270619|BEHAVIORAL|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
214617014|NCT02270619|OTHER|Placebo|0.9% saline as IV bolus
214617015|NCT02270619|OTHER|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
214617016|NCT02726087|PROCEDURE|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
214617017|NCT02726087|PROCEDURE|Full sternotomy|Conventional full median sternotomy
214617018|NCT03223480|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
214617019|NCT05348512|OTHER|spectral imaging|non-contact, non-invasive hyperspectral and multispectral imaging without a diagnostic test
214617020|NCT05348512|OTHER|photoplethysmography|non-invasive pulse oximetry without a diagnostic test
214617021|NCT05343286|PROCEDURE|blood sample|blood sample before and after 12 weeks of physical activity
214617022|NCT05343286|OTHER|physical assessement|"physical assessement before and after 12 weeks of physical activity~* Standardized geriatric assessment (physician visit)~* ICOPE Monitor Assessment~* Sit-to-stand Test~* Quantified Gait Analysis (QAM)~* Bone densitometer measurement of body composition"
214716331|NCT01124513|PROCEDURE|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
214716332|NCT00948194|DRUG|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
214716333|NCT00233324|DRUG|Surfactant|Intubation and administration of surfactant by 1 hour of age.
214716334|NCT00233324|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
214716335|NCT00233324|DRUG|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
214716336|NCT00233324|DRUG|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
214617023|NCT05343286|BEHAVIORAL|psychometric assessment|"Psychometric questionnaires~* Cognitive tests (MMSE)~* The long questionnaire of personality traits: Big Five Inventory~* Perceived health and subjective age~* Age group identification~* Attitudes towards aging: French version of the Attitudes Toward Own Aging scale~* Physical self-perception: French version of the Physical Self-Perception Profile~* MOTIVATION SCALE FOR PA FOR HEALTH PURPOSES: Motivation Scale for Physical Activity in a Health Context~* Aging Stereotypes and Exercise Scale"
214617024|NCT05251714|DRUG|CFI-402257|Oral once daily in 28 day cycles
214617025|NCT05251714|DRUG|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
214617026|NCT03698942|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
214617027|NCT00209014|DRUG|Thalidomide|
214617028|NCT04818203|BIOLOGICAL|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10\^7 cells/1 mL/vial
214716337|NCT00829777|DRUG|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
214716338|NCT02929862|DRUG|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
214716339|NCT05633680|DIAGNOSTIC_TEST|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
214716340|NCT00753597|DRUG|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
214716341|NCT01626534|DRUG|Clopidogrel|600mg loading dose then 75mg/day
214716342|NCT01626534|DRUG|trigagrelor|180 mg loading dose then 90 mg Twice a day
214716343|NCT02556970|PROCEDURE|Single port VATS|Performing video-assisted thorascopic surgery through a single port
214617029|NCT04818203|OTHER|Placebo|The injection solution without clusters of autologous dermal fibroblasts
214716344|NCT02556970|DRUG|Paracetamol|1g intraoperatively
214716345|NCT02556970|DRUG|Diclofenac|75mg intraoperatively
214716346|NCT02556970|DEVICE|Camera (5mm diameter 30 degree videothoracoscope)|
214716347|NCT02556970|DEVICE|Forceps grasper|
214617030|NCT04737408|DRUG|Rosuvastatin 40mg|Rosuvastatin 40 mg
214617031|NCT06959680|OTHER|Exercise and Kinesiotaping|Exercise and Kinesiotaping
214617032|NCT06959680|OTHER|Exercise|only exercise will be performed without any band treatment
214617033|NCT06959680|OTHER|exercise and sham taping|exercise and sham banding (banding without tension with plaster)
214617034|NCT03874663|DEVICE|Directly assisted oral HIV self-testing (HIVST)|"1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
214617035|NCT00356083|DRUG|Methadone|
214617036|NCT05745662|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
214617037|NCT06838676|DRUG|ACT001|PO BID at 875 mg/m2 for 28 days
214617038|NCT00794495|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
214617039|NCT00794495|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
214716348|NCT02556970|DRUG|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
214716349|NCT04447924|DIETARY_SUPPLEMENT|Bif195|Daily intake of Bif195 dietary supplement
214716350|NCT04447924|OTHER|Placebo|Daily intake of Placebo
214716351|NCT03696446|BEHAVIORAL|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
214617040|NCT06788587|DRUG|LDX-01 plus TAU|"Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
214617041|NCT06788587|DRUG|Placebo plus TAU|"Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
214617042|NCT06104982|DEVICE|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
214617043|NCT06104982|OTHER|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
214617044|NCT05030454|DEVICE|ETHOS|Ring-gantry CT-guided radiotherapy unit, pairing a linear accelerator within a ring-gantry imaging unit.
214617045|NCT05030454|RADIATION|CT-guided stereotactic adaptive radiotherapy|All participants will be initially planned to at least 35 Gy in 5 fractions, subject to hard constraints based on the treatment site.
214617046|NCT04885868|OTHER|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.
214617047|NCT00504907|DRUG|BTA9881|Single oral escalating doses
214617048|NCT00504907|DRUG|Placebo|
214617049|NCT05508009|DRUG|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
214617050|NCT05508009|DRUG|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
214617051|NCT05508009|DRUG|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
214617052|NCT05508009|RADIATION|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
214617053|NCT05508009|DRUG|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
214617054|NCT05508009|DRUG|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
214617055|NCT05508009|DRUG|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
214617056|NCT05508009|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
214617057|NCT05508009|PROCEDURE|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with \> 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI \>18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
214617058|NCT06794164|PROCEDURE|skin to skin care|skin to skin care of preterm infants with their parents immediately after birth
214617059|NCT06794164|PROCEDURE|Standard Care (in control arm)|skin to skin care within 24 hours after birth
214617060|NCT00478465|DRUG|valganciclovir|
214617061|NCT06201897|DRUG|ACTH/Oral Steroids|Injection ACTH or Oral Steroids in children with West Syndrome
214617062|NCT06836232|DRUG|VTX2735|Oral tablet
214617063|NCT04989426|OTHER|the state of health of newly arrived migrant patients in the year following their arrival in France|the state of health of newly arrived migrant patients in the year following their arrival in France
214617064|NCT06401122|PROCEDURE|haemodialysis|process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
214617065|NCT02466867|DRUG|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
214617066|NCT02466867|DRUG|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
214617067|NCT03584828|BEHAVIORAL|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
214617068|NCT00099996|DRUG|SCH-58235|
214617069|NCT00099996|DRUG|Ezetimibe|
214617070|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
214617071|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
214617072|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
214617073|NCT00382239|DRUG|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
214617074|NCT05610904|DIAGNOSTIC_TEST|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
214617075|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
214617076|NCT00182195|PROCEDURE|Control Ventilation Strategy|
214617077|NCT04133532|DRUG|Metoprolol|metoprolol 50 mg daily for three months
214617078|NCT03947489|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
214617079|NCT03600142|BEHAVIORAL|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
214617080|NCT00842426|BEHAVIORAL|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
214617081|NCT00842426|BEHAVIORAL|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
214617082|NCT03210389|DRUG|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
214617083|NCT03662880|RADIATION|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
214617084|NCT03662880|RADIATION|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
214617085|NCT06243042|DIAGNOSTIC_TEST|serum vitamin D|blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.
214617086|NCT06243042|DIAGNOSTIC_TEST|urine osmolality|"nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg."
214617087|NCT06243042|OTHER|Frequency volume chart|volume and frequency from time of sleep till 8 am
214617088|NCT02956954|DRUG|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
214617089|NCT02956954|PROCEDURE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
214617090|NCT01086462|DRUG|GSK2239633|100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
214617091|NCT00516048|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214617092|NCT06470113|DEVICE|simultaneous cognitive training with transcranial magnetic stimulation|simultaneous cognitive training with transcranial magnetic stimulation can enhance the therapeutic effect and improve brain function non-invasively.
214617093|NCT02080247|DRUG|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
214617094|NCT02080247|DRUG|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
214617095|NCT00639691|BIOLOGICAL|omalizumab|sc
214617096|NCT04933331|DRUG|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
214617097|NCT04933331|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
214617098|NCT04933331|DEVICE|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
214617099|NCT04933331|DEVICE|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
214617100|NCT04933331|DRUG|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
214617101|NCT04620044|OTHER|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
214617102|NCT04620044|OTHER|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
214617103|NCT04620044|OTHER|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
214716352|NCT03696446|BEHAVIORAL|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
214716353|NCT00662389|DEVICE|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
214716354|NCT05526625|OTHER|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC \& IJV.
214716355|NCT06020768|OTHER|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
214716356|NCT01117805|BEHAVIORAL|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
214617104|NCT00916253|DRUG|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
214716357|NCT01333098|DRUG|Mifepristone|300mg per day, by mouth, for 21-28 days
214716358|NCT00398125|DRUG|GSK364735|
214716359|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
214716360|NCT02218762|DRUG|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
214716361|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
214716362|NCT02218762|DRUG|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
214617105|NCT00916253|DRUG|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
214617106|NCT01180478|DEVICE|White Light|White Light Cystoscopy
214617107|NCT01180478|DEVICE|Narrow Band Imaging|Narrow Band Imaging
214617108|NCT05328726|DRUG|GZR-18|As previously described in Arms
214617109|NCT05328726|OTHER|Placebo|Placebo will be dosed in an identical manner to active study drug.
214617110|NCT03012087|BEHAVIORAL|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
214617111|NCT03012087|OTHER|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
214617112|NCT02807480|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy
214617113|NCT02807480|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
214617114|NCT02807480|BEHAVIORAL|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
214617115|NCT02807480|BEHAVIORAL|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
214617116|NCT02807480|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
214617117|NCT02807480|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
214617118|NCT00054704|DRUG|Riluzole|Riluzole
214617119|NCT00054704|DRUG|Placebo|Placebo
214617120|NCT02163187|DEVICE|Implantation of the InterStimTM|
214617121|NCT02163187|BEHAVIORAL|MSK BFI questionnaires|
214617122|NCT02163187|BEHAVIORAL|The Low Anterior Resection Score (LARS) questionnaires|
214617123|NCT02163187|BEHAVIORAL|The EuroQOL5D questionnaires|
214716363|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes"
214617124|NCT02163187|BEHAVIORAL|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
214617125|NCT04415957|OTHER|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
214617126|NCT00362414|DRUG|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
214617127|NCT05414981|DRUG|ABI-H3733|25 mg or 100 mg tablets for oral administration
214617128|NCT05414981|DRUG|Placebo|25 mg or 100 mg tablets for oral administration
214617129|NCT05104645|OTHER|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
214617130|NCT05104645|OTHER|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
214617131|NCT05104645|OTHER|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
214617132|NCT02369848|DEVICE|Shockwave Lithoplasty System|
214617133|NCT02430142|OTHER|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
214617134|NCT01188200|OTHER|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
214617135|NCT01188200|OTHER|Standard food|Standard meal prior to test time
214617136|NCT04238975|BIOLOGICAL|GC3111 vaccine|0.5mL, Intramuscular
214617137|NCT04238975|BIOLOGICAL|Boostrix® vaccine|0.5mL, Intramuscular
214617138|NCT04594590|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
214617139|NCT05060822|DRUG|HEC585|HEC585 Tablets，once daily
214716364|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
214617140|NCT05060822|DRUG|Pirfenidone|Pirfenidone，three times a day
214617141|NCT05060822|DRUG|Placebo|Placebo，once daily
214617142|NCT00883662|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
214617143|NCT00007839|DRUG|beta alethine|
214617144|NCT05073497|OTHER|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
214617145|NCT01841502|DRUG|Paroxetine|paroxetine 20 mg once daily
214617146|NCT01841502|DRUG|telaprevir|telaprevir 1125 mg twice daily
214617147|NCT01262378|PROCEDURE|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
214617148|NCT04155255|OTHER|MyBFF@school|
214617149|NCT01505270|OTHER|Retrospective case study|Retrospective case study
214617150|NCT03527134|DRUG|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
214617151|NCT00019708|DRUG|tanespimycin|Given IV
214617152|NCT05755841|OTHER|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~* Twice weekly fetal cardiotocography.~* Complete blood count once a week.~* A weekly clinical and ultrasound examination."
214617153|NCT05755841|OTHER|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
214617154|NCT00000570|DRUG|pulmonary surfactant|
214617155|NCT03722342|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
214617156|NCT01511276|BEHAVIORAL|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
214617157|NCT01511276|BEHAVIORAL|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
214617158|NCT01451008|DEVICE|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
214617159|NCT05837156|DRUG|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
214617160|NCT05837156|DRUG|Heptaflurane|Heptaflurane only
214617161|NCT05837156|DRUG|Cyclophenol|Cyclophenol only
214617162|NCT04026698|BEHAVIORAL|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months."
214617163|NCT01806350|OTHER|questionnaire administration|Ancillary studies
214617164|NCT01806350|PROCEDURE|standard follow-up care|Receive usual care
214617165|NCT01806350|OTHER|educational intervention|Undergo PFMT
214617166|NCT02808754|PROCEDURE|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic \> 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
214617167|NCT00337909|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214617168|NCT00337909|OTHER|Educational DVDs|
214716365|NCT05480501|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
214716366|NCT05559073|PROCEDURE|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
214716367|NCT05989295|DIETARY_SUPPLEMENT|probiotic LRa05|treatment about 12 weeks
214716368|NCT03111342|DRUG|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
214617169|NCT04272671|OTHER|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
214617170|NCT06397755|PROCEDURE|Prostate Biopsy and/or Radical Prostatectomy|Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
214617171|NCT03118700|OTHER|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
214617172|NCT03118700|OTHER|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
214617173|NCT00575198|OTHER|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
214617174|NCT00575198|OTHER|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
214617175|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
214617176|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
214617177|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
214617178|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
214617179|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
214617180|NCT06323603|OTHER|Micro and nanoplastic|Biological samples will be obtained to evaluate the different biomarkers selected
214617181|NCT02053168|DEVICE|Resorbable Mesh|Phasix Mesh
214617182|NCT02853448|DEVICE|Novel Blood Drawing Apparatus|
214617183|NCT00636675|BEHAVIORAL|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets."
214716369|NCT03111342|PROCEDURE|Dry-needling|A placement of thin needle into the cervix without substance injection
214716370|NCT04410081|DRUG|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
214716371|NCT04409990|DIAGNOSTIC_TEST|Shear Wave Elastography|SWE value of rectal lesions
214716372|NCT01225120|OTHER|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
214716373|NCT05884281|DRUG|Roflumilast|0.5 mg once daily for treatment period
214716374|NCT05884281|DRUG|Placebo|Placebo for treatment period
214716375|NCT00601146|PROCEDURE|chest computed tomography scan|Once a year for three years
214716376|NCT01174888|DRUG|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
214716377|NCT01174888|DRUG|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
214716378|NCT01174888|DRUG|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
214716379|NCT01174888|DRUG|etoposide|Patients receive etoposide IV over 1 hour
214716380|NCT01174888|DRUG|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
214716381|NCT02268071|DRUG|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
214716382|NCT00054158|DRUG|dexamethasone|
214716383|NCT00054158|DRUG|doxorubicin hydrochloride|
214716384|NCT00054158|DRUG|thalidomide|
214716385|NCT00054158|DRUG|vincristine sulfate|
214716386|NCT05460572|DIETARY_SUPPLEMENT|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
214716387|NCT02923310|BIOLOGICAL|Platelets Rich Plasma|
214716388|NCT02923310|BIOLOGICAL|Leucocyte - Platelets Rich Plasma|
214716389|NCT02923310|DRUG|Hialuronic Acid|
214716390|NCT00048490|DEVICE|transcranial magnetic stimulation (TMS)|
214617184|NCT00636675|BEHAVIORAL|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
214617185|NCT00096785|DRUG|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
214617186|NCT00096785|DRUG|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
214617187|NCT04053868|OTHER|JUUL|Electronic Cigarette
214617188|NCT04053868|OTHER|Tobacco|Tobacco Cigarette
214617189|NCT00956774|PROCEDURE|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
214617190|NCT00956774|PROCEDURE|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
214617191|NCT00956774|PROCEDURE|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
214617192|NCT01912742|BEHAVIORAL|Very-low calorie diet (VLCD)|
214617193|NCT01912742|BEHAVIORAL|Low calorie diet (LCD)|
214716391|NCT01444508|DRUG|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
214716392|NCT01444508|DRUG|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
214716393|NCT02125630|PROCEDURE|Surgery|Surgery to primary tumor
214716394|NCT02125630|DRUG|Systemic therapy|Systemic therapy based on tumor phenotype
214716395|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214716396|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
214716397|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
214716398|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
214716399|NCT03177746|DRUG|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
214716400|NCT05463172|OTHER|abdominal strengthening exercises|abdominal strengthening exercises
214716401|NCT05463172|OTHER|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
214716402|NCT03512119|DRUG|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
214716403|NCT01858597|DIAGNOSTIC_TEST|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
214617194|NCT03023527|DRUG|Nivolumab|
214617195|NCT03023527|DRUG|Pomalidomide|
214617196|NCT03023527|DRUG|Dexamethasone|
214617197|NCT03023527|DRUG|Elotuzumab|
214617198|NCT01133899|DIETARY_SUPPLEMENT|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
214617199|NCT01133899|DIETARY_SUPPLEMENT|GAA-4|4.8 grams of guanidinoacetic acid
214617200|NCT01133899|DIETARY_SUPPLEMENT|GAA-1|1.2 grams of guanidinoacetic acid
214617201|NCT01133899|DIETARY_SUPPLEMENT|PLACEBO|celulose
214617202|NCT03545763|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
214617203|NCT02774512|DRUG|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
214617204|NCT02877693|RADIATION|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
214617205|NCT04729985|DEVICE|CGM device with diabetic education, CGM education and a follow up protocol.|Blind CGM placed and recorded for 14 days after discharge and data downloaded
214617206|NCT03677830|DRUG|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
214617207|NCT03677830|DRUG|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
214617208|NCT05313451|OTHER|Soluble fiber|15g/day during 2 months
214617209|NCT05313451|OTHER|Placebo|Maltodextrin 15g/day during 2 months
214617210|NCT02829307|DRUG|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
214617211|NCT02828553|OTHER|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
214617212|NCT00833053|DRUG|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
214617213|NCT00833053|DRUG|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
214716404|NCT05478057|DEVICE|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
214716405|NCT03218189|OTHER|Country characteristics|Observational study of country characteristics
214716406|NCT04827940|OTHER|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
214716407|NCT02116738|PROCEDURE|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
214716408|NCT04045574|PROCEDURE|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
214716409|NCT06507761|OTHER|Sham|An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.
214716410|NCT06507761|OTHER|Hot Pack|Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
214716411|NCT06507761|OTHER|Cold Pack|Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
214716412|NCT05579119|DRUG|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
214716413|NCT05579119|DRUG|Glargine|Glargine once daily.
214617214|NCT04483674|DRUG|50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide|"Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL"
214617215|NCT01408992|PROCEDURE|Audiometry|Standard hearing test performed by audiologists
214617216|NCT01408992|OTHER|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
214617217|NCT00522145|DRUG|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
214617218|NCT06496282|DRUG|Lemborexant|The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
214617219|NCT06496282|DRUG|Placebo|The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
214617220|NCT03707067|DEVICE|Compression garments|Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)
214716414|NCT05579119|DRUG|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
214716415|NCT05474755|DRUG|GP681 40mg|2X20mg tablets taken orally
214716416|NCT05474755|DRUG|Placebo|Placebo tablets matching GP681 40mg
214617221|NCT03707067|OTHER|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
214617222|NCT00637884|DRUG|Fexofenadine HCl|
214617223|NCT04064502|DIAGNOSTIC_TEST|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
214617224|NCT04082871|OTHER|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
214617225|NCT02187471|DRUG|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
214617226|NCT02187471|DRUG|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
214617227|NCT02187471|DRUG|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
214617228|NCT02187471|DRUG|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
214617229|NCT02651168|BIOLOGICAL|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
214617230|NCT02236520|DRUG|Spironolactone|
214617231|NCT02236520|DRUG|Chlorthalidone|
214617232|NCT02236520|DIETARY_SUPPLEMENT|Diet|
214617233|NCT02236520|DRUG|Placebo|
214617234|NCT06220539|OTHER|Casting and supervised rehabilitation|casting (8 weeks) followed by supervised rehabilitation
214617235|NCT01785160|DRUG|Raltegravir|low dose oral administration
214617236|NCT01785160|DRUG|Raltegravir|low dose oral administration
214617237|NCT01785160|DRUG|Faldaprevir|medium dose oral administration
214617238|NCT01539681|DRUG|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
214617239|NCT00820677|BEHAVIORAL|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
214617240|NCT04096209|DEVICE|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
214617241|NCT06022731|DIAGNOSTIC_TEST|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
214617242|NCT01370720|DIETARY_SUPPLEMENT|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
214617243|NCT01370720|OTHER|Placebo|tablets, 2tablets/day, 12 weeks
214716417|NCT01128881|BIOLOGICAL|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
214716418|NCT00724815|DRUG|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
214716419|NCT00724815|DRUG|Placebo|NP101 Placebo iontophoretic transdermal patch
214716420|NCT05892263|OTHER|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
214716421|NCT03950960|DRUG|BMS-986256|Specified dose on specified days
214617244|NCT05754385|BEHAVIORAL|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
214617245|NCT05754385|BEHAVIORAL|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
214716422|NCT03950960|DRUG|Itraconazole|Specified dose on specified days
214617246|NCT00957528|DRUG|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
214617247|NCT00957528|DRUG|Placebo|Weekly IM injections of sesame oil.
214617248|NCT06119867|PROCEDURE|Japanese pathological investigation|Japanese pathological investigation
214716423|NCT02137304|DEVICE|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
214716424|NCT04677023|OTHER|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
214716425|NCT04677023|OTHER|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
214716426|NCT06402968|DRUG|Clevidipine Injection|Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
214716427|NCT06402968|DRUG|Alternate IV Antihypertensive Regimen|"The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour."
214716428|NCT04880772|OTHER|Prehabilitation|exercise \& multivitamin (nutritional/dietary advice)
214716429|NCT00251017|PROCEDURE|Vancomycin|Two hour creatinine clearance before and after vancomycin
214716430|NCT00251017|PROCEDURE|DNA are extracted from the whole blood of subjects|
214617249|NCT06119867|PROCEDURE|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
214617250|NCT02154282|BEHAVIORAL|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
214617251|NCT05823415|PROCEDURE|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
214617252|NCT05823415|PROCEDURE|CAF with CTG|Gold standard surgical technique
214617253|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
214617254|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
214617255|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
214617256|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
214617257|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
214617258|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
214617259|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
214617260|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
214617261|NCT02440360|BEHAVIORAL|PSH|Please see arm description.
214617262|NCT02440360|BEHAVIORAL|Usual Care|Please see arm description.
214617263|NCT06361732|OTHER|No intervention|No intervention
214617264|NCT04776733|OTHER|prepackaged semisolid nutritional formulations|"The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast."
214617265|NCT04776733|OTHER|restricted diet|"The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast."
214617266|NCT02593162|DRUG|Faldaprevir|
214617267|NCT02593162|DRUG|TD-6450|
214617268|NCT02593162|DRUG|Ribavirin|
214617269|NCT03854864|OTHER|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
214617270|NCT06003114|DRUG|Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment.
214617271|NCT05141760|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
214617272|NCT05908682|OTHER|Non-interventional study|This is not an interventional study
214617273|NCT01021956|DRUG|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
214617274|NCT04090008|DRUG|PRP gel|The PRP gel is applied on the ulcer twice per week
214617275|NCT04090008|DRUG|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
214617276|NCT05793671|DEVICE|PPCI in heavy thrombus burden STEMI patients|minimally invasive procedures used to open clogged coronary arteries
214617277|NCT03027362|OTHER|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
214617278|NCT03027362|OTHER|Psychoeducation and medication|
214617279|NCT02116556|DRUG|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
214617280|NCT02116556|DRUG|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
214617281|NCT03553043|BEHAVIORAL|Intervention|Energy label condition.
214617282|NCT03553043|BEHAVIORAL|Control|No label
214617283|NCT02081534|DRUG|AZD1722|AZD1722, oral tablet
214617284|NCT02081534|DRUG|Placebo|Placebo bid, double dummy technique
214617285|NCT04911036|OTHER|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
214617286|NCT02345954|PROCEDURE|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
214617287|NCT02345954|PROCEDURE|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
214617288|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
214617289|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
214617290|NCT00670319|DRUG|Placebo|Placebo one tab orally per day
214617291|NCT00762892|DRUG|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
214617292|NCT00762892|DRUG|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
214617293|NCT03114176|DIETARY_SUPPLEMENT|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
214617294|NCT04182373|DRUG|Antithrombin gamma|Intravenous infusion, once a day, 7 days
214617295|NCT04182373|DRUG|physiological saline|Intravenous infusion, once a day, 7 days
214617296|NCT03269071|DRUG|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
214617297|NCT00837941|DRUG|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
214617298|NCT00837941|DRUG|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
214617299|NCT00837941|DRUG|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
214617300|NCT00483301|DRUG|Sorafenib (BAY 43-9006)|dosage
214617301|NCT00483301|DRUG|ABI-007(Abraxane)|dosage
214617302|NCT01378507|BEHAVIORAL|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
214722132|NCT03921606|BEHAVIORAL|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
214617303|NCT03611855|DEVICE|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
214617304|NCT03611855|OTHER|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
214617305|NCT00518037|BEHAVIORAL|surveys|anxiety surveys
214617306|NCT02250820|DRUG|Dexmedetomidine|Nasal administration
214617307|NCT02250820|DRUG|Pentobarbital|Oral administration
214617308|NCT02250820|OTHER|Oral Placebo|Oral placebo will be cherry syrup
214617309|NCT02250820|OTHER|Nasal Placebo|Nasal placebo will be nasally atomized saline
214617310|NCT04539340|BIOLOGICAL|GNR-055|Single intravenous administration
214617311|NCT05289635|PROCEDURE|different suture types|For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
214617312|NCT02234479|BIOLOGICAL|Hydrophor (Group A)|"* Rehydrates dry, chapped or chafed skin~* May be used alone as a skin lubricant or protectant"
214617313|NCT02234479|BIOLOGICAL|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~* Maintain a balanced environment for healing.~* Aids in reducing dermatitis.~* Reduce affected area pH.2-3"
214617314|NCT05040724|DRUG|Ivermectin|ivermectin placebo
214617315|NCT02318667|BIOLOGICAL|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
214617316|NCT01423409|DEVICE|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
214617317|NCT01423409|DEVICE|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
214716431|NCT01956266|BEHAVIORAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
214617318|NCT00343421|BIOLOGICAL|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
214716432|NCT05838209|DRUG|test|Ozone oil used as an adjunctive of scaling and root planing and control,
214617319|NCT00343421|BIOLOGICAL|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
214716433|NCT05838209|DRUG|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
214716434|NCT02516150|DRUG|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
214716435|NCT02516150|DRUG|Glucagon|injection of 50 micrograms of glucagon
214716436|NCT04391855|DRUG|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
214716437|NCT04391855|DRUG|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
214716438|NCT04391855|DRUG|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
214716439|NCT04391855|DRUG|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
214617320|NCT02177968|OTHER|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
214617321|NCT02151955|BEHAVIORAL|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
214617322|NCT04882592|DEVICE|SCiP|Noninvasive spinal cord neuromodulator
214617323|NCT06548919|DRUG|Endocrine therapy|All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
214617324|NCT06548919|DRUG|Chemotherapy Prednisone|All chemotherapy treatment regimens approved for advanced breast cancer
214617325|NCT02947672|DRUG|Intravenous Dexamethasone|
214617326|NCT02947672|DRUG|Intraperitoneal Dexamesathone|
214617327|NCT00820911|DRUG|cyclosporine (reduced exposure) / everolimus|twice daily
214617328|NCT00820911|DRUG|AEB071 300 mg b.i.d. / everolimus|twice daily
214617329|NCT00820911|DRUG|AEB071 200 mg b.i.d. / everolimus|twice daily
214617330|NCT05376865|DIETARY_SUPPLEMENT|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
214617331|NCT00309634|BIOLOGICAL|4 adjuvanted pandemic influenza candidate vaccines|
214617332|NCT00309634|BIOLOGICAL|4 non-adjuvanted pandemic influenza candidate vaccines|
214617333|NCT06116617|DRUG|SRSD107|SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
214617334|NCT06116617|DRUG|Placebo|Sodium chloride
214617335|NCT02672436|DRUG|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
214617336|NCT02672436|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
214617337|NCT04774731|OTHER|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
214617338|NCT02289742|DEVICE|Nelfilcon A multifocal contact lenses|
214617339|NCT02289742|DEVICE|Nelfilcon A toric contact lenses|
214617340|NCT02289742|DEVICE|Nelfilcon A sphere contact lenses|
214617341|NCT05802654|RADIATION|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
214617342|NCT03483909|DEVICE|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
214716440|NCT05856669|DEVICE|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
214716441|NCT00347477|DRUG|HyperHAES vs. RA-solution/NaCl|
214617343|NCT03483909|DEVICE|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
214617344|NCT03483909|DEVICE|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
214617345|NCT06037798|OTHER|cranio-cervical flexion test with NOD|testing the anterior neck muscles during a nodding movement and by using a dynamometer
214617346|NCT01365039|DEVICE|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
214617347|NCT01365039|DEVICE|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
214617348|NCT04871165|DIAGNOSTIC_TEST|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
214617349|NCT04871165|DIAGNOSTIC_TEST|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
214617350|NCT04871165|DIAGNOSTIC_TEST|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
214617351|NCT01203540|DRUG|NAABAK eyedrops|
214617352|NCT01203540|DRUG|Saline eyedrops|
214617353|NCT05379634|DRUG|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
214617354|NCT05379634|OTHER|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
214617355|NCT05379634|DRUG|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
214617356|NCT00159757|DRUG|ziprazidone|
214617357|NCT05354557|DRUG|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
214617358|NCT04396860|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
214617359|NCT04396860|BIOLOGICAL|Ipilimumab|Given IV
214617360|NCT04396860|BIOLOGICAL|Nivolumab|Given IV
214617361|NCT04396860|DEVICE|NovoTTF-100A Device|Wear Optune device
214617362|NCT04396860|OTHER|Quality-of-Life Assessment|Ancillary studies
214617363|NCT04396860|OTHER|Questionnaire Administration|Ancillary studies
214716442|NCT05572346|OTHER|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
214716443|NCT05307341|DRUG|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
214716444|NCT03230721|PROCEDURE|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
214716445|NCT03230721|PROCEDURE|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
214617364|NCT04396860|RADIATION|Radiation Therapy|Undergo radiation therapy
214716446|NCT03230721|PROCEDURE|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
214716447|NCT03902041|DRUG|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
214617365|NCT04396860|DRUG|Temozolomide|Given PO
214617366|NCT04557098|DRUG|Teclistamab|Teclistamab will be administered SC.
214716448|NCT01286701|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
214716449|NCT03350841|PROCEDURE|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
214716450|NCT03350841|PROCEDURE|root canal treatment|conventional root canal treatment and obturation with guttapercha
214716451|NCT05388955|OTHER|None, transplantation recipients|None, observational
214716452|NCT05703139|PROCEDURE|TRIANGLE procedure|The Triangle procedure aims to develop a novel method for patients with locally advanced pancreatic cancer after neoadjuvant therapy and was described in 2017. The basis of this operation is the notice that after neoadjuvant therapy conventional imaging fails to differentiate between actual tumor encasement and only fibrotic residual tissue mainly to the arterial structures
214617367|NCT04319575|DRUG|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
214617368|NCT05099341|OTHER|HDRS-17 depression scale|Measuring the severity of depression
214617369|NCT05099341|BIOLOGICAL|Blood sampling|3 tubes of 5 ml
214716453|NCT02186457|DRUG|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
214716454|NCT02186457|OTHER|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
214716455|NCT03168841|DRUG|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
214716456|NCT05381207|DRUG|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
214716457|NCT03975712|OTHER|Not applicable, no intervention|Not applicable, no intervention
214716458|NCT02198989|BEHAVIORAL|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
214716459|NCT01489267|OTHER|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
214716460|NCT00105183|BIOLOGICAL|Placebo|placebo infusion, single
214716461|NCT00105183|BIOLOGICAL|EZ-2053|single IV infusion, 9 mg/kg
214617370|NCT05939674|DRUG|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
214617371|NCT05939674|DRUG|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
214617372|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
214617373|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
214617374|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
214617375|NCT00853320|DRUG|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
214617376|NCT00853320|DRUG|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
214617377|NCT05726851|DRUG|E2025|E2025 IV infusion.
214617378|NCT05726851|DRUG|Placebo|E2025 matched placebo IV infusion.
214617379|NCT04223843|DRUG|Tiotropium + olodaterol|Oral Inhalation
214716462|NCT00105183|BIOLOGICAL|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
214716463|NCT06277583|BEHAVIORAL|Urban care farming|An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
214716464|NCT01988597|OTHER|Dry eyes|
214716465|NCT01999023|DIETARY_SUPPLEMENT|Low protein formula group|Low protein formula formula (28.5 g) twice a day
214716466|NCT04724681|DEVICE|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
214716467|NCT04623463|BEHAVIORAL|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
214716468|NCT05008133|BEHAVIORAL|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
214617380|NCT04223843|DRUG|Placebo|Oral Inhalation
214617381|NCT01473342|BEHAVIORAL|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
214716469|NCT01743885|DRUG|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
214716470|NCT01743885|DRUG|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
214716471|NCT02923908|OTHER|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
214716472|NCT02923908|OTHER|Voice Recording|A voice recording will be made for the duration of the tasting period.
214716473|NCT02923908|OTHER|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
214716474|NCT02923908|OTHER|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
214617382|NCT03707548|BEHAVIORAL|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
214716475|NCT01535768|DRUG|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
214617383|NCT03707548|BEHAVIORAL|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
214716476|NCT02641314|DRUG|metronomic therapy|"* Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
214617384|NCT03707548|BEHAVIORAL|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
214617385|NCT05470751|DEVICE|Intermittent self-catheterisation|Self-catheterising with GC Male and Glide Male with Feelclean technology
214617386|NCT04035070|COMBINATION_PRODUCT|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
214617387|NCT04035070|COMBINATION_PRODUCT|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
214617388|NCT04035070|COMBINATION_PRODUCT|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
214617389|NCT05926700|DRUG|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
214617390|NCT06959043|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants will follow the same strict vegetarian diet and regular physical exercise as in Intervention 1. Additionally, they will receive a probiotic supplement, taken twice daily for four weeks. This aims to evaluate the metabolic impact of probiotics in type 2 diabetes.
214617391|NCT06959043|DIETARY_SUPPLEMENT|Placebo Administration|Participants will follow a strictly plant-based diet rich in fiber and bioactive compounds, with controlled macronutrient distribution. Regular physical exercise includes supervised aerobic and resistance training sessions. The intervention lasts four weeks. Instead of probiotic supplementation, participants will receive a placebo, administered in the same manner as the probiotic group to maintain blinding.
214617392|NCT06836661|BEHAVIORAL|FDC and TLC and medication adherance|Level 1: Patient 1. Rational FDCs 2. NPHWs and PMs mediated therapeutic lifestyle changes 3. Texts/ WhatsApp reminders Level 2:Physician 1. Reinforcing task sharing 2. Providing evidence on FDCs 3. Theory based behavior modification Level 3: Health administrators 1. Pharmacy - Update drug formulary FDCs 2. CV health days 3. Facility strengthening
214617393|NCT06836661|BEHAVIORAL|Patients will Enhanced Usual Care (EUC)|Patients will Enhanced Usual Care (EUC) with periodic follow ups
214617394|NCT06493344|OTHER|Applying additional weight|Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
214617395|NCT01789762|BIOLOGICAL|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
214716477|NCT03990090|DRUG|TG103|Administered SC
214716478|NCT03990090|DRUG|Placebo|Administered SC
214716479|NCT03177785|BEHAVIORAL|EverydayMatters|
214617396|NCT01789762|BIOLOGICAL|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
214617397|NCT01789762|BIOLOGICAL|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
214617398|NCT01154244|OTHER|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
214617399|NCT01978782|DRUG|raltegravir|
214617400|NCT01978782|DRUG|citalopram|
214617401|NCT00383084|BEHAVIORAL|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
214617402|NCT00383084|BEHAVIORAL|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
214617403|NCT06848387|DIAGNOSTIC_TEST|Unbound cloxacillin concentration|Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
214617404|NCT02159729|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
214617405|NCT02159729|DRUG|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
214617406|NCT02159729|DRUG|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
214617407|NCT02159729|DRUG|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
214617408|NCT05454371|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
214617409|NCT06185829|DRUG|Neurloeptanalgesic treatment|Usual neuroleptanalgesic treatment
214617410|NCT06185829|OTHER|Hypnoanalgesia|Hypnoanalgesia
214617411|NCT04729036|PROCEDURE|open reduction and internal fixation|The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
214617412|NCT02106052|OTHER|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
214617413|NCT02106052|OTHER|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
214617414|NCT02636582|OTHER|Laboratory Biomarker Analysis|Correlative studies
214617415|NCT02636582|DRUG|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
214617416|NCT02636582|BIOLOGICAL|Sargramostim|Given ID
214617417|NCT02636582|PROCEDURE|Surgical Procedure|Undergo surgery
214617418|NCT03260504|BIOLOGICAL|Aldesleukin|Given SC or IV
214617419|NCT03260504|BIOLOGICAL|Pembrolizumab|Given IV
214617420|NCT04122014|OTHER|Progressive balance training|Progressive balance training program
214617421|NCT04122014|OTHER|Normal daily activities|Usual daily activities
214617422|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
214617423|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
214617424|NCT01263483|DRUG|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
214617425|NCT03799250|DRUG|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
214617426|NCT03799250|OTHER|standard care|standard care
214617427|NCT00326209|DRUG|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
214617428|NCT00714285|BIOLOGICAL|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
214617429|NCT00714285|BIOLOGICAL|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
214617430|NCT01372384|DRUG|erlotinib [Tarceva]|150 mg orally daily
214617431|NCT01621633|DRUG|LCZ696|
214617432|NCT01131676|DRUG|BI 10773 low dose|BI 10773 tablets once daily
214617433|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
214617434|NCT01131676|DRUG|BI 10773 high dose|BI 10773 tablets once daily
214617435|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
214617436|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
214617437|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
214617438|NCT01961349|DRUG|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
214617439|NCT01961349|DRUG|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
214617440|NCT01961349|DRUG|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
214617441|NCT03512795|BIOLOGICAL|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
214617442|NCT03889665|OTHER|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
214617443|NCT00896779|DRUG|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
214617444|NCT00771823|DRUG|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
214617445|NCT00771823|DRUG|Maraviroc|"* Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study."
214617446|NCT03953430|OTHER|Gait analysis|
214617447|NCT06476236|DIETARY_SUPPLEMENT|M4C|Nutraceutical designed to enhance novel metabolic pathway activity.
214617448|NCT04798937|OTHER|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
214716480|NCT04701749|DEVICE|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
214716481|NCT04701749|OTHER|No Percutaneous left atrial closure|No Percutaneous left atrial closure
214716482|NCT04328012|DRUG|Losartan|administered 14 days
214716483|NCT04328012|DRUG|Placebo|administered 14 days
214716484|NCT04042012|OTHER|Eccentric exercise|soleus eccentric exercise
214617449|NCT01239095|DRUG|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
214617450|NCT05354583|DRUG|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
214617451|NCT00829179|DRUG|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
214617452|NCT01541189|DRUG|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
214617453|NCT03098849|OTHER|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
214716485|NCT04042012|OTHER|PNE|the application of galvanic current
214716486|NCT04042012|OTHER|Combined|soleus eccentric exercise and PNE
214716487|NCT03853304|OTHER|+ Folic acid|Salt fortified with folic acid
214716488|NCT03853304|OTHER|+ Vitamin B12|Salt fortified with vitamin B12
214716489|NCT03853304|OTHER|DFS|Salt fortified with iron and iodine
214716490|NCT04876586|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
214716491|NCT03620253|DRUG|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
214716492|NCT03620253|DRUG|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
214716493|NCT03431909|DRUG|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
214716494|NCT03431909|DRUG|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
214716495|NCT00826488|DEVICE|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
214716496|NCT02135549|DIETARY_SUPPLEMENT|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
214716497|NCT02135549|DRUG|Placebo Oral Tablet|Placebo comparator
214716498|NCT03554304|DRUG|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
214716499|NCT03554304|DRUG|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
214716500|NCT03554304|DRUG|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
214617454|NCT06461975|DRUG|Benoxinate Hydrochloride|"The first group had the first examination done using the tear substitute Polyfresh ® eye drops and the second using the Benoxinate HCL drops Benox ® given just before the ROP screening."
214716501|NCT02716662|DIETARY_SUPPLEMENT|Axona|medical powder, supplement food
214617455|NCT06461975|DRUG|artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.|"The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening."
214617456|NCT03000179|DRUG|Avelumab|Avelumab through a vein once every 2 weeks
214716502|NCT04399057|DIAGNOSTIC_TEST|shear Wave Elastosonography|both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
214716503|NCT00453661|BEHAVIORAL|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
214716504|NCT00453661|BEHAVIORAL|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
214716505|NCT02321072|DRUG|Oxygen|
214716506|NCT01819506|BEHAVIORAL|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
214716507|NCT00436293|DRUG|Docetaxel|75 mg/m²
214617457|NCT00381199|DRUG|Amitriptyline Hydrochloride|
214617458|NCT00381199|DRUG|Nabilone|
214617459|NCT02410668|DIETARY_SUPPLEMENT|flaxseed|
214617460|NCT02410668|DIETARY_SUPPLEMENT|Placebo|
214617461|NCT02410668|BEHAVIORAL|Exercise recommendation|
214617462|NCT02738970|DRUG|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
214716508|NCT00436293|DRUG|Cisplatin|75 mg/m²
214716509|NCT03838003|PROCEDURE|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
214617463|NCT02738970|DRUG|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
214617464|NCT00217048|DRUG|Yohimbine, oral|
214617465|NCT05467514|DRUG|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
214617466|NCT05142475|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214716510|NCT01699295|BEHAVIORAL|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
214716511|NCT01699295|BEHAVIORAL|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
214716512|NCT04995614|DRUG|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
214716513|NCT04840368|OTHER|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
214716514|NCT01616784|OTHER|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
214716515|NCT01616784|OTHER|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
214716516|NCT02964988|DRUG|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
214716517|NCT02964988|DEVICE|PET/CT|Whole body PET/CT
214716518|NCT01039636|DRUG|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
214716519|NCT00129207|DRUG|bortezomib|
214716520|NCT03000686|BIOLOGICAL|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
214617467|NCT00002300|DRUG|Megestrol acetate|
214617468|NCT00914251|DRUG|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
214617469|NCT00914251|DRUG|Placebo|Administration of oral Placebo, 500 mg/daily
214617470|NCT00502814|PROCEDURE|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
214617471|NCT00502814|PROCEDURE|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
214617472|NCT00502814|PROCEDURE|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
214617473|NCT00502814|PROCEDURE|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
214617474|NCT01353027|DRUG|Placebo|Normal saline
214617475|NCT01353027|DRUG|AVI-6002|Single intravenous administration
214617476|NCT04168944|DRUG|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
214617477|NCT04168944|DRUG|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
214617478|NCT04168944|DRUG|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
214617479|NCT06417359|PROCEDURE|Mesh Fixation|That mesh will be fixation with three tackers.
214617480|NCT06417359|PROCEDURE|No Mesh Fixation|That mesh will not be fixation
214617481|NCT00258011|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
214617482|NCT03387436|BEHAVIORAL|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
214716521|NCT03000686|OTHER|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
214716522|NCT02822157|DRUG|Olaparib|
214716523|NCT02822157|DRUG|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
214716524|NCT00100646|BEHAVIORAL|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
214716525|NCT00100646|DRUG|Lamivudine|300 mg tablet taken orally daily
214716526|NCT00100646|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
214716527|NCT00100646|DRUG|Stavudine|Dosage dependent on weight
214716528|NCT00100646|BIOLOGICAL|Rabies de novo antigen|Vaccine injected intramuscularly
214716529|NCT02867722|DRUG|aminolevulinic acid HCl|Drug will be administered to consented patients
214716530|NCT05813613|OTHER|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
214617483|NCT03387436|BEHAVIORAL|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
214617484|NCT05479214|DRUG|Metformin|1gm tablet with the 2 main meals
214617485|NCT05479214|DRUG|Insulin|subcutaneous insulin daily administration
214617486|NCT01075412|DRUG|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
214617487|NCT00501371|DRUG|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
214617488|NCT00501371|DRUG|Placebo|soft-gel capsule, Qd, 12 weeks
214617489|NCT03959332|DRUG|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
214617490|NCT00554359|DRUG|I5NP (a small interfering RNA)|Single IV injection of experimental drug
214617491|NCT00554359|DRUG|placebo|Single IV injection of saline
214617492|NCT04278209|OTHER|Breakfast 1|Participant will receive Breakfast 1
214617493|NCT04278209|OTHER|Breakfast 2|Participant will receive Breakfast 2
214617494|NCT04278209|OTHER|Water|Participant will receive water
214617495|NCT02816307|OTHER|blood samples|
214617496|NCT02431091|OTHER|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
214716531|NCT00178698|OTHER|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
214617497|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
214617498|NCT01954186|DRUG|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
214617499|NCT01954186|PROCEDURE|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
214617500|NCT04619420|DRUG|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
214617501|NCT04619420|DRUG|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
214617502|NCT03394144|DRUG|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
214617503|NCT01179464|DRUG|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
214617504|NCT01179464|DRUG|Simvastatin|40 mg once daily
214716532|NCT00178698|DRUG|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
214716533|NCT00178698|OTHER|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
214716534|NCT02672618|OTHER||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
214716535|NCT02695576|PROCEDURE|Lumbar Fusion Surgery|Interbody fusion with fixation
214716536|NCT02695576|OTHER|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
214716537|NCT02695576|OTHER|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
214716538|NCT05512312|PROCEDURE|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
214716539|NCT05512312|PROCEDURE|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
214716540|NCT01763983|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
214716541|NCT01763983|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
214716542|NCT02336048|DRUG|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
214716543|NCT02336048|DRUG|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
214716544|NCT02336048|DRUG|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
214716545|NCT02336048|OTHER|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
214716546|NCT02336048|DRUG|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
214617505|NCT05239533|DRUG|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
214617506|NCT05239533|DRUG|Nivolumab|Nivolumab 240mg q2wk
214617507|NCT05239533|DIAGNOSTIC_TEST|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
214617508|NCT05239533|DIAGNOSTIC_TEST|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
214617509|NCT03506035|DIAGNOSTIC_TEST|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
214617510|NCT05993559|RADIATION|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
214617511|NCT05993559|RADIATION|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
214617512|NCT02772640|DRUG|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -\> evening evening -\> morning"
214617513|NCT04782011|BEHAVIORAL|ATC/DDD|The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
214617514|NCT04579562|OTHER|No intervention|This is observational, non-interventional study
214617515|NCT04961853|RADIATION|Ultrasound and MRI|Ultrasound examination and magnetic resonance imaging on the hand
214617516|NCT02692365|PROCEDURE|Magnetic Resonance + hemodynamic + infusion of gadolinium|
214617517|NCT00812799|DRUG|Oralgen|19.000 BU daily
214617518|NCT00812799|OTHER|placebo control|placebo control
214617519|NCT05837351|BEHAVIORAL|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
214617520|NCT03980834|BEHAVIORAL|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
214617521|NCT03980834|BEHAVIORAL|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
214617522|NCT03980834|BEHAVIORAL|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
214617523|NCT03980834|BEHAVIORAL|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
214617524|NCT05885438|BEHAVIORAL|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
214617525|NCT04042168|DIAGNOSTIC_TEST|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
214617526|NCT00870766|PROCEDURE|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
214617527|NCT06234150|OTHER|Aerobic dance|Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
214617528|NCT06234150|OTHER|Fast-walking|Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
214617529|NCT00237848|DRUG|D-serine|
214617530|NCT00237848|BEHAVIORAL|Cognitive retraining|
214617531|NCT02056054|OTHER|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
214617532|NCT02056054|OTHER|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
214617533|NCT02056054|OTHER|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
214617534|NCT02056054|OTHER|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
214617535|NCT02056054|OTHER|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
214716547|NCT04242459|RADIATION|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
214716548|NCT04140370|OTHER|There is no intervention|There is no intervention
214716549|NCT02532569|BIOLOGICAL|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
214716550|NCT02726334|DRUG|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
214716551|NCT02726334|DRUG|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
214716552|NCT00294684|DRUG|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
214617536|NCT02056054|OTHER|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
214617537|NCT02056054|OTHER|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
214617538|NCT01963429|PROCEDURE|radiofrequency ablation|"\* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min."
214716553|NCT00294684|DRUG|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
214617539|NCT01963429|RADIATION|Proton beam therapy|"\* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)"
214617540|NCT00865904|DRUG|VX-809|Capsules
214617541|NCT00865904|DRUG|Placebo|Placebo matched to VX-809 capsules.
214617542|NCT00517322|DRUG|ramipril|ramipril 2.5- 5 mg once daily
214617543|NCT00517322|DRUG|irbesartan|irbesartan 150-300 mg once daily
214617544|NCT00454038|DEVICE|HYPRO SORB F|resorbable, double layered, collagen membrane
214617545|NCT03625687|DRUG|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
214617546|NCT02372916|DRUG|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
214617547|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
214617548|NCT01431274|DRUG|tiotropium|low dose
214617549|NCT01431274|DRUG|olodaterol|one dose only
214617550|NCT01431274|DRUG|tiotropium|high dose
214617551|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
214617552|NCT01431274|DEVICE|Respimat|Respimat inhaler
214617553|NCT00941668|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
214617554|NCT00941668|DRUG|sodium monofluorophosphate toothpaste|Twice daily usage
214617555|NCT04593667|DEVICE|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
214617556|NCT01396226|DRUG|AZD2927|A single dose of AZD2927 administered as an iv infusion
214716554|NCT05729269|DIAGNOSTIC_TEST|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
214617557|NCT01396226|DRUG|Placebo|A single dose of placebo administered as an iv infusion
214617558|NCT05217121|OTHER|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
214617559|NCT05217121|OTHER|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
214617560|NCT00321750|DRUG|1% pimecrolimus cream|
214617561|NCT00711425|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
214617562|NCT01023867|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
214617563|NCT02485457|PROCEDURE|Volume loading|Volume loading with Ringer Lactate
214617564|NCT02485457|DRUG|Ringer solution|
214617565|NCT00916149|DRUG|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
214617566|NCT00916149|DRUG|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
214617567|NCT06428084|DRUG|Ondansetron|4 mg of ondansetron intravenously
214617568|NCT06428084|DRUG|Haloperidol|1 mg of Haloperidol intravenously
214617569|NCT06441045|DRUG|Double Dose of Third-generation EGFR-TKI|Double Dose of Third-generation EGFR-TKI
214617570|NCT06441045|DRUG|Intrathecal Pemetrexed|Intrathecal Pemetrexed
214617571|NCT05712148|BIOLOGICAL|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
214617572|NCT06119490|DRUG|Abrocitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks
214617573|NCT06119490|DRUG|Tofacitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
214617574|NCT00589420|DRUG|docetaxel|
214617575|NCT00589420|DRUG|sorafenib tosylate|
214617576|NCT03025230|OTHER|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
214617577|NCT03025230|OTHER|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
214617578|NCT06508918|DRUG|Betametasona|pressure pain threshold values of the most painful area will be recorded with a manual algometer
214617579|NCT02761395|PROCEDURE|Al-hijamah|"* Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
214617580|NCT02761395|DRUG|Deferasirox|20-40 mg/kg/day orally
214617581|NCT04475575|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
214617582|NCT06448702|PROCEDURE|wet wrap therapy|Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect
214617583|NCT06448702|DEVICE|External compression counter-pulsation (EECP)|External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
214617584|NCT01214928|DRUG|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
214617585|NCT03296085|PROCEDURE|Exam for quantity of edema|There is no intervention
214617586|NCT03216811|DRUG|nutraceutical|8-week administration of nutraceutical compound
214617587|NCT01846624|DRUG|Decitabine|Given IV
214617588|NCT01846624|DRUG|Midostaurin|Given PO
214617589|NCT03574753|DRUG|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
214617590|NCT00832520|DRUG|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None"
214617591|NCT05365555|PROCEDURE|Fascia Iliaca Compartment Block|Blind technique.
214617592|NCT05365555|PROCEDURE|Femoral Nerve Block|Ultrasound guided.
214617593|NCT05365555|DRUG|Ropivacaine|Ropivacaine dosed according to local guidelines.
214617594|NCT04930809|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
214617595|NCT03853720|PROCEDURE|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
214617596|NCT02218242|DEVICE|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
214617597|NCT04529681|DEVICE|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
214617598|NCT04529681|OTHER|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
214617599|NCT06165250|DRUG|BR1018A|One tablet administered alone
214617600|NCT06165250|DRUG|BR1018A-1|One tablet administered alone
214617601|NCT06165250|DRUG|BR1018B|One tablet administered alone
214617602|NCT06165250|DRUG|BR1018B-1|One tablet administered alone
214617603|NCT06165250|DRUG|BR1018C|One tablet administered alone
214617604|NCT06165250|DRUG|BR1018C-1|One tablet administered alone
214617605|NCT06148571|DEVICE|left bundle branch area pacing|left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
214617606|NCT02559297|DRUG|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
214617607|NCT02559297|DRUG|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
214617608|NCT05126108|PROCEDURE|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
214617609|NCT05126108|OTHER|Recurrent nerves monitoring|Recurrent nerves monitoring
214617610|NCT03762720|DEVICE|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
214617611|NCT00307151|DRUG|Lamivudine|4 mg/kg twice daily
214617612|NCT00307151|DRUG|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
214617613|NCT00307151|DRUG|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
214617614|NCT00307151|DRUG|Zidovudine|180 mg/m\^2 twice daily
214617615|NCT06439212|DRUG|Ginger powder capsule|Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
214617616|NCT06439212|DRUG|Placebo|Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
214617617|NCT00692484|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
214617618|NCT00692484|DRUG|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
214617619|NCT03926715|OTHER|Nutritional status|
214617620|NCT02520895|BIOLOGICAL|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
214617621|NCT01998620|DRUG|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
214617622|NCT01998620|DRUG|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
214617623|NCT01998620|DRUG|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
214617624|NCT01490450|BIOLOGICAL|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
214617625|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
214617626|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
214617627|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
214617628|NCT04363528|OTHER|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
214617629|NCT04316377|DRUG|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
214617630|NCT02800408|OTHER|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
214617631|NCT02800408|OTHER|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
214617632|NCT02800408|OTHER|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
214617633|NCT05542550|BEHAVIORAL|Voice Rest|Voice rest restricting patient phonation
214617634|NCT05542550|BEHAVIORAL|No Voice Rest|No Voice rest
214617635|NCT01814020|DRUG|MOB015B|
214617636|NCT03435848|DRUG|BST-236|1 to 4 courses
214617637|NCT03869359|OTHER|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
214617638|NCT03869359|OTHER|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
214617639|NCT01357096|BEHAVIORAL|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
214617640|NCT01357096|OTHER|Traditional group|CAD education fryers
214617641|NCT01833637|OTHER|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
214617642|NCT03887533|DRUG|VTS-270|Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
214617643|NCT04442295|DRUG|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
214617644|NCT04442295|DRUG|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
214617645|NCT05995288|DRUG|Homeopathic Globule|Homeopathic globules were administered after careful anamnesis
214617646|NCT00253643|DIETARY_SUPPLEMENT|green tea catechin extract|Given orally 2 times/day
214617647|NCT00253643|DIETARY_SUPPLEMENT|fish oil|Given orally 3 times/day
214617648|NCT00253643|OTHER|placebo|Given olive oil placebo orally 3 times/day
214617649|NCT00253643|OTHER|placebo|Given green tea placebo orally 2 times/day
214617650|NCT05798091|BEHAVIORAL|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
214617651|NCT05798091|OTHER|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
214617652|NCT01111851|DRUG|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
214617653|NCT01111851|DRUG|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
214617654|NCT01111851|DRUG|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
214716555|NCT03528824|OTHER|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
214617655|NCT01111851|DRUG|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
214617656|NCT01111851|DRUG|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
214617657|NCT01111851|DRUG|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
214617658|NCT01111851|DRUG|MK0999|I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
214617659|NCT05590143|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
214617660|NCT05590143|DRUG|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
214716556|NCT03528824|DRUG|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
214716557|NCT02025049|DRUG|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
214716558|NCT02025049|DRUG|Placebo|mannitol-based DP-b99 look-alike
214716559|NCT01085019|DIETARY_SUPPLEMENT|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
214617661|NCT05362968|DRUG|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
214617662|NCT05920616|OTHER|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
214617663|NCT05920616|OTHER|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
214617664|NCT04537494|DIETARY_SUPPLEMENT|L. reuteri|Probiotic
214617665|NCT03118986|DRUG|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
214617666|NCT03118986|DRUG|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
214617667|NCT04524702|DRUG|Gemcitabine|Given IV
214617668|NCT04524702|DRUG|Hydroxychloroquine|Given PO
214617669|NCT04524702|DRUG|Nab-paclitaxel|Given IV
214617670|NCT04524702|DRUG|Paricalcitol|Given IV
214617671|NCT03677050|OTHER|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
214716560|NCT01085019|DIETARY_SUPPLEMENT|Oregano|2.8g/day of oregano in capsules during 4 weeks.
214716561|NCT01085019|DIETARY_SUPPLEMENT|Ginger|2.8g/day of ginger in capsules during 4 weeks.
214716562|NCT01085019|DIETARY_SUPPLEMENT|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
214716563|NCT01085019|DIETARY_SUPPLEMENT|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
214716564|NCT01085019|DIETARY_SUPPLEMENT|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
214716565|NCT00968708|DRUG|Alogliptin|Alogliptin tablets
214716566|NCT00968708|DRUG|Placebo|Alogliptin placebo matching tablets
214716567|NCT03632304|PROCEDURE|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
214716568|NCT00389441|DRUG|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
214716569|NCT00704431|DRUG|SB-480848 (darapladib)|160 mg darapladib
214716570|NCT05191849|DIAGNOSTIC_TEST|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
214617672|NCT05916105|DRUG|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
214617673|NCT01471015|DRUG|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
214617674|NCT01471015|DRUG|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
214617675|NCT01471015|DRUG|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
214617676|NCT03668886|OTHER|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
214617677|NCT03606993|OTHER|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one \~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
214617678|NCT00507299|BEHAVIORAL|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
214716571|NCT04373707|DRUG|Enoxaparin|"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"
214716572|NCT04373707|DRUG|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
214716573|NCT03429764|PROCEDURE|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
214716574|NCT03429764|PROCEDURE|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
214716575|NCT01539213|DRUG|secukinumab (AIN457)|anti-IL-17 antibody
214716576|NCT04656288|DRUG|BI 764198 - Formula A|BI 764198
214716577|NCT04656288|DRUG|BI 764198 - Formula B|BI 764198
214617679|NCT00507299|BEHAVIORAL|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
214617680|NCT00112671|DRUG|sorafenib tosylate|Given orally 400mg orally twice daily
214617681|NCT00112671|OTHER|laboratory biomarker analysis|Correlative studies
214716578|NCT04656288|DRUG|BI 764198 - Formula C|BI 764198
214716579|NCT04656288|DRUG|BI 764198 - Formula D|BI 764198
214617682|NCT03007368|OTHER|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214617683|NCT03007368|OTHER|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
214617684|NCT03007368|OTHER|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214617685|NCT03007368|OTHER|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214716580|NCT01803113|DEVICE|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
214716581|NCT03891615|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
214716582|NCT03891615|DRUG|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
214716583|NCT02937688|DEVICE|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
214716584|NCT02357888|DRUG|V0018|Oromucosal - Single dose
214716585|NCT02357888|DRUG|Placebo|Oromucosal - Single dose
214716586|NCT04308954|DRUG|[18F]flumazenil|\[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
214617686|NCT03007368|OTHER|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214716587|NCT04466813|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
214716588|NCT04466813|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
214617687|NCT03007368|OTHER|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214617688|NCT03007368|OTHER|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214617689|NCT03007368|OTHER|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
214617690|NCT00464321|BIOLOGICAL|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
214617691|NCT00464321|BIOLOGICAL|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
214617692|NCT00464321|BIOLOGICAL|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
214617693|NCT00464321|BIOLOGICAL|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
214617694|NCT00612170|DRUG|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
214617695|NCT00612170|DRUG|Placebo|0 mg oral tablet once a day dosing
214617696|NCT00612170|DRUG|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
214617697|NCT00612170|DRUG|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
214617698|NCT02685423|BEHAVIORAL|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
214617699|NCT02685423|BEHAVIORAL|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
214617700|NCT04664361|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
214617701|NCT04664361|OTHER|Placebo|Daily supplementation with placebo for 38 days in total
214617702|NCT03413111|PROCEDURE|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
214617703|NCT01299376|DRUG|L50/H12.5/A5|
214617704|NCT01299376|DRUG|L50/H12.5|
214617705|NCT01299376|DRUG|Placebo to L50/H12.5/A5|
214617706|NCT01299376|DRUG|Placebo to L50/H12.5|
214617707|NCT02512471|DRUG|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
214617708|NCT00825279|DEVICE|Bare Metal Stent|Stainless steel stent
214617709|NCT00825279|DEVICE|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
214716589|NCT04530968|OTHER|No intervention|No intervention
214617710|NCT03076385|BIOLOGICAL|VAL-506440|Escalating dose levels
214617711|NCT03076385|OTHER|Placebo|
214617712|NCT00635479|DEVICE|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
214617713|NCT00635479|OTHER|Gauze dressing|Gauze dressing for surgical incision
214617714|NCT02300948|DRUG|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
214617715|NCT02300948|DRUG|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
214617716|NCT04490863|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
214617717|NCT01555047|PROCEDURE|IUI|intrauterine insemination
214617718|NCT01555047|PROCEDURE|IUI|intrauterine insemination
214617719|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
214617720|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
214617721|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
214617722|NCT00433680|BEHAVIORAL|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
214617723|NCT04315181|DRUG|Opioid Agonist|Abuse liability evaluation.
214617724|NCT04315181|DRUG|Sedatives|Abuse liability evaluation.
214617725|NCT05119608|BEHAVIORAL|CBT/ACT|10-session ACT-re-enforced CBT intervention.
214716590|NCT03466671|DRUG|TTA-121|A nove intranasal spray of oxytocin and placebo
214617726|NCT05879107|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
214716591|NCT01591811|RADIATION|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
214716592|NCT01591811|RADIATION|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
214617727|NCT05879107|BIOLOGICAL|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
214716593|NCT05678270|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 5mg, orally.
214716594|NCT01666860|PROCEDURE|Anterior Lumbar Interbody Fusion procedure|
214617728|NCT01473979|PROCEDURE|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
214617729|NCT02674542|OTHER|In-depth interviews|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
214617730|NCT02674542|OTHER|Focus Group|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
214716595|NCT00126672|DRUG|Rapamycin|
214716596|NCT01522768|DRUG|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
214716597|NCT01851863|DRUG|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
214716598|NCT01851863|DRUG|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
214716599|NCT01851863|DRUG|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
214716600|NCT01851863|DRUG|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
214716601|NCT04546867|DIAGNOSTIC_TEST|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
214716602|NCT00086294|DRUG|Intravenous Levodopa|
214716603|NCT00086294|DRUG|ACP-103|
214617731|NCT03120221|DIAGNOSTIC_TEST|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
214617732|NCT01811745|BEHAVIORAL|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
214617733|NCT01811745|BEHAVIORAL|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
214617734|NCT01421940|DRUG|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
214617735|NCT01421940|DRUG|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
214617736|NCT05786079|BEHAVIORAL|Footstrike modification|
214617737|NCT05786079|BEHAVIORAL|Control|
214617738|NCT03522051|OTHER|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
214617739|NCT03351790|OTHER|Questionniare only|A pre-procedure questionnaire will be completed by all participants
214617740|NCT04417179|PROCEDURE|transversus abdominis block|transversus abdominis block
214617741|NCT04417179|PROCEDURE|Erector spinae block|Erector spinae block
214617742|NCT04417179|DRUG|Bupivacaine 0.25% Injectable Solution|Local Anesthetic used in both blocks
214617743|NCT04417179|DEVICE|Siemens Acuson x300 3-5MHz Ultrasound|Ultrasound used to aid in the blocks
214617744|NCT00962442|DRUG|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
214617745|NCT00962442|DRUG|placebo|Glucosé 5% perfusion for 14 days, intravenously
214617746|NCT00681174|DRUG|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
214617747|NCT00681174|DRUG|oxycodone|20 mg p.o. 1 h before the start of anesthesia
214617748|NCT00681174|PROCEDURE|Paravertebral block|"* Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
214617749|NCT00681174|DRUG|Propofol|"* Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
214617750|NCT00681174|DRUG|Remifentanil|"* 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
214617751|NCT00681174|DRUG|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
214617752|NCT00681174|DRUG|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none"
214617753|NCT06466538|DRUG|Calcium hydroxide|intracanal medicament
214617754|NCT06466538|DRUG|Leddermix|Leddermix
214617755|NCT06466538|DRUG|Boswellia|Boswellia
214617756|NCT04071743|DEVICE|gammaCore Sapphire|non-invasive vagus nerve stimulator
214617757|NCT04071743|DEVICE|sham gammaCore Sapphire|sham gammaCore Sapphire
214617758|NCT00445484|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
214617759|NCT00445484|DRUG|lenalidomide|Given orally
214617760|NCT01772901|OTHER|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
214617761|NCT04607148|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
214617762|NCT01748942|DRUG|Dexamethasone|Given IV
214617763|NCT01748942|DRUG|Dexamethasone|Given PO
214617764|NCT01748942|OTHER|Placebo|Given PO
214617765|NCT01748942|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214617766|NCT01748942|OTHER|Questionnaire Administration|Ancillary studies
214617767|NCT01748942|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
214617768|NCT03366090|PROCEDURE|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
214617769|NCT00571844|BEHAVIORAL|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
214617770|NCT00571844|BEHAVIORAL|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
214617771|NCT02933099|DRUG|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
214617772|NCT02933099|DRUG|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
214617773|NCT02553122|DRUG|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
214617774|NCT02553122|DEVICE|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
214617775|NCT00998270|PROCEDURE|Autologous bone marrow transplantation|"Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
214617776|NCT00998270|PROCEDURE|Allogeneic bone marrow transplantation|"Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
214617777|NCT03574857|DRUG|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
214617778|NCT03574857|DRUG|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
214617779|NCT00912028|DEVICE|senofilcon A|contact lens
214617780|NCT00912028|DEVICE|lotrafilcon B|contact lens
214617781|NCT00912028|DEVICE|balafilcon A|contact lens
214617782|NCT00912028|DEVICE|methafilcon A|contact lens
214617783|NCT00912028|DEVICE|vifilcon A|contact lens
214617784|NCT04689581|OTHER|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
214617785|NCT04689581|OTHER|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
214617786|NCT05895682|DEVICE|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70\~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
214617787|NCT00585000|DRUG|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
214716604|NCT03358498|OTHER|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
214716605|NCT04083794|OTHER|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
214716606|NCT01605201|BIOLOGICAL|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
214716607|NCT03104985|DEVICE|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
214716608|NCT03104985|OTHER|Conventional therapy|"* An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment"
214716609|NCT02793089|OTHER|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
214716610|NCT04783285|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
214716611|NCT05713578|DRUG|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
214716612|NCT05713578|DRUG|apantamide+ADT treatment|apantamide+ADT treatment
214716613|NCT04248062|OTHER|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
214716614|NCT00108797|DRUG|eptacog alfa (activated)|
214716615|NCT00108797|DRUG|Feiba VH|
214716616|NCT04953065|OTHER|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
214716617|NCT05750420|OTHER|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
214716618|NCT02374034|OTHER|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
214716619|NCT02543502|PROCEDURE|periodontal treatment|treatment of periodontal cleaning
214716620|NCT01597011|PROCEDURE|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
214716621|NCT01597011|PROCEDURE|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
214617788|NCT04378530|BEHAVIORAL|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
214617789|NCT04378530|BEHAVIORAL|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
214617790|NCT04378530|BEHAVIORAL|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
214617791|NCT02123316|BIOLOGICAL|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
214716622|NCT03097029|DRUG|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
214617792|NCT02123316|BIOLOGICAL|Placebo|Placebo for subcutaneous injection
214617793|NCT00353834|DRUG|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
214617794|NCT00353834|DRUG|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
214617795|NCT00488722|DRUG|Zoladex|
214617796|NCT02973087|BIOLOGICAL|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
214617797|NCT02973087|BIOLOGICAL|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
214617798|NCT03675035|DEVICE|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
214617799|NCT05619302|DRUG|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
214617800|NCT04311216|OTHER|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
214617801|NCT04876755|DRUG|MBM-02|MBM-02 is an HIF-1 and HIF-2 inhibitor.
214617802|NCT01905163|PROCEDURE|Tumor Debulking Surgery by laparoscopy|
214617803|NCT02163083|PROCEDURE|ICG|Improvement of detection of positive lymphnodes
214617804|NCT01713751|OTHER|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
214617805|NCT01713751|OTHER|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\]
214716623|NCT06236230|DRUG|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
214716624|NCT00411086|BIOLOGICAL|Rituximab|375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
214617806|NCT05281796|DIAGNOSTIC_TEST|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
214617807|NCT05281796|DIAGNOSTIC_TEST|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
214716625|NCT00411086|BIOLOGICAL|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
214716626|NCT03323996|OTHER|Semi-Structured interviews|individual semi-structured interviews
214716627|NCT01669642|DRUG|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
214716628|NCT00516984|PROCEDURE|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
214716629|NCT00516984|PROCEDURE|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
214617808|NCT02047136|OTHER|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
214617809|NCT02047136|OTHER|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
214617810|NCT06034171|DEVICE|dental implant|Dental implant surgery in the lower jawbone.
214617811|NCT02660203|PROCEDURE|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
214617812|NCT03422419|DRUG|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
214617813|NCT03422419|DEVICE|TIPS|transjugular intrahepatic portosystemic shunt deployment
214617814|NCT01500122|DRUG|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
214617815|NCT00932360|DEVICE|TENS|Active TENS, Placebo TENS and No Treatment TENS
214617816|NCT04000789|DRUG|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
214617817|NCT06368167|DRUG|SHR2554|SHR2554
214617818|NCT06185621|DRUG|100mg aspirin|Patients received oral 100mg aspirin, one tablet daily for 2 years
214617819|NCT01753128|DRUG|imipramine|
214617820|NCT04417764|PROCEDURE|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
214617821|NCT04417764|BIOLOGICAL|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10\^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
214617822|NCT02034630|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
214617823|NCT04296214|DRUG|5-azacitidine|Cycles of 28 days
214617824|NCT02602912|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
214617825|NCT05653622|PROCEDURE|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
214617826|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
214617827|NCT01733979|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
214617828|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron|Heme-Iron (1g/day)
214617829|NCT01733979|DIETARY_SUPPLEMENT|Organic Iron|Organic Iron (1g/day)
214617830|NCT05381142|DRUG|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
214617831|NCT05381142|DRUG|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
214617832|NCT00542295|DRUG|alverine citrate and simeticone|
214617833|NCT00542295|DRUG|placebo|
214617834|NCT01924182|DEVICE|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
214617835|NCT01924182|OTHER|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
214617836|NCT00856960|DRUG|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
214617837|NCT00856960|DRUG|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
214617838|NCT00856960|DRUG|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
214617839|NCT00856960|DRUG|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
214617840|NCT00856960|DRUG|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
214617841|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression.
214617842|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression and perinatal extra support.|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression. Additionally, up to three supportive contacts with a midwife or perinatal mental health nurse to support ICBT treatment and adress general pregnancy related health problems.
214617843|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by chance|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation by chance.
214617844|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by choice|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation based on patient preference.
214617845|NCT00627653|DRUG|fenofibrate|148mg daily for 30 days
214617846|NCT00787462|DRUG|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
214617847|NCT00787462|DRUG|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
214617848|NCT04143009|BEHAVIORAL|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
214617849|NCT04143009|OTHER|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
214617850|NCT04143009|BEHAVIORAL|Adapted Friendship Bench|Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
214617851|NCT05945186|DEVICE|Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)|External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
214716630|NCT00516984|PROCEDURE|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
214716631|NCT03775590|PROCEDURE|Water|To evaluate using water in the treatment of atopic dermatitis
214716632|NCT03775590|PROCEDURE|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
214716633|NCT03775590|PROCEDURE|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
214716634|NCT00004685|DRUG|albuterol|
214617852|NCT05337787|OTHER|flipped classroom approach|The students in the experimental group were trained using the flipped learning model.
214617853|NCT00993265|DRUG|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
214617854|NCT00993265|DRUG|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
214617855|NCT06504537|OTHER|THERAGUN PERCUSSION THERAPY|In Group A, Patients will receive Theragun Percussion therapy along with routine Physical Therapy Treatment. The range of motion of lateral flexion and forward flexion will take by using a bubble inclinometer. Then the patient will place in a sitting position with the shoulder area exposed. Percussion therapy by using the Theragun device will give by a specific order. Treatment will start with the percussion head applied at the origin and insertion heads of the trapezius, Rhomboid and scalene muscle for 3-4 minutes each. Following this the percussive Theragun applicator will applied with circular strokes along the length of the muscle for 3 minutes. The pressure of application will adjust to the subject's tolerance.
214617856|NCT06504537|OTHER|COMPRESSION THERAPY|In Group B, Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks. The cap will store in a freezer (15-18°C). At the onset of the migraine attacks, patients wore the cap and used it. We will choose 25 minutes as the time for application of the gel cap based on the results of two published studies.(23) Headache severity will measured by Visual Analogue Scale and pain relief will measured on a similar scale. Analgesic treatment will not take within 25 minutes after the onset of cold therapy. If patients did not experience adequate relief from the headache, we will allow them to use analgesics 25 minutes after the onset of cold therapy. The routine physical treatment will be same as in group A.
214617857|NCT00846300|BEHAVIORAL|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
214617858|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
214617859|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
214617860|NCT02384902|OTHER|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
214617861|NCT00821080|DRUG|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
214617862|NCT00821080|DRUG|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
214617863|NCT04455763|PROCEDURE|SVF|Adipose-derived stromal vascular fraction
214617864|NCT04455763|OTHER|Splint|Thumb brace (Actimove® Rhizo Forte)
214716635|NCT03256071|DRUG|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
214617865|NCT01268358|DRUG|Lamazym|Lamazym, ERT, infusion weekly
214617866|NCT01744665|DRUG|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
214617867|NCT06148688|OTHER|Digital Story|"Digital storytelling; It is used in education and training, business marketing, non-profit organizations such as libraries, community centers and museums, and health sciences education. Digital storytelling in health sciences can be a tool for patients and health science professionals to share their experiences, cope with diseases, and add a human element to health problems.~In the study, digital stories were created to increase the self-management of pregnant women with gestational diabetes. In creating a digital story; Qualitative studies involving the self-management experiences of women with gestational diabetes have been examined in the literature. Using the results of the studies, scenarios were created that included factors that facilitate and complicate diabetes self-management. The created scenarios were used in the digital storytelling initiative. A total of four long and four short digital story videos were prepared."
214617868|NCT03755570|DIAGNOSTIC_TEST|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
214617869|NCT03755570|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
214617870|NCT03755570|DIAGNOSTIC_TEST|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
214617871|NCT03755570|DIAGNOSTIC_TEST|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
214617872|NCT03755570|DIAGNOSTIC_TEST|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
214617873|NCT03688399|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
214617874|NCT03688399|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
214617875|NCT01064674|OTHER|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
214617876|NCT01357655|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
214617877|NCT01357655|DRUG|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
214617878|NCT05003622|DRUG|Encorafenib|oral capsule
214617879|NCT04844684|OTHER|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
214716636|NCT03256071|DRUG|Modified BUCY|"1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
214716637|NCT04132648|DRUG|Curcumin|Oral supplement one time at 2,000 mg
214617880|NCT05193253|PROCEDURE|Radiofrequency ablation|Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
214716638|NCT04132648|OTHER|Placebo|Oral supplement one time at 2,000 mg
214617881|NCT05193253|PROCEDURE|Liver resection|Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
214617882|NCT05193253|PROCEDURE|Liver transplantation|Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
214617883|NCT04086082|DEVICE|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
214617884|NCT06241092|OTHER||
214617885|NCT02411162|DRUG|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
214617886|NCT02411162|DRUG|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
214617887|NCT00609986|DRUG|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
214617888|NCT00609986|DRUG|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
214716639|NCT02920606|PROCEDURE|Pulpotomy|
214716640|NCT02920606|PROCEDURE|Endodontic treatment|
214716641|NCT00036062|DRUG|Sivelestat|
214716642|NCT06202001|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
214617889|NCT02098512|DRUG|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
214716643|NCT00265967|DRUG|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
214716644|NCT05652972|OTHER|Ketogenic diet|1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
214716645|NCT05652972|OTHER|Control diet|1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
214716646|NCT00546234|DRUG|tiotropium|18 mcg daily via Handihaler
214716647|NCT00546234|DRUG|long acting beta agonist|Turbohaler, 6 \& 12 mcg
214716648|NCT05520918|DIAGNOSTIC_TEST|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
214617890|NCT02098512|PROCEDURE|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
214617891|NCT02098512|DRUG|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
214617892|NCT04986306|PROCEDURE|SLNB + ALND|Patients who received neoadjuvant chemotherapy will undergo SLNB+ALND to evaluate the feasibility of SLNB
214617893|NCT01271192|PROCEDURE|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
214617894|NCT01271192|PROCEDURE|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
214617895|NCT03173859|DRUG|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
214617896|NCT03173859|DRUG|Apalutamide|apalutamide 240mg qD orally
214617897|NCT05126186|OTHER|haplo-SCT with PTCy|"Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic."
214617898|NCT04355741|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
214617899|NCT03625050|PROCEDURE|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
214617900|NCT03625050|DRUG|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
214617901|NCT01590550|PROCEDURE|Use of citrate based dialysate|Use of heparin free citrate based dialysate
214617902|NCT03184077|PROCEDURE|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
214617903|NCT03184077|PROCEDURE|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
214716649|NCT02661464|BIOLOGICAL|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
214617904|NCT06265857|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214617905|NCT06265857|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214617906|NCT06265857|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214617907|NCT06040242|OTHER|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
214617908|NCT02921074|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214617909|NCT02921074|OTHER|Commercially available computerized training|
214617910|NCT05571228|BEHAVIORAL|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
214617911|NCT03998111|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
214617912|NCT02384668|DIETARY_SUPPLEMENT|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
214617913|NCT02384668|DIETARY_SUPPLEMENT|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
214617914|NCT00013208|BEHAVIORAL|Case Management|
214617915|NCT03062592|DIETARY_SUPPLEMENT|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
214617916|NCT04170439|DRUG|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
214617917|NCT04170439|DRUG|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
214617918|NCT04170439|DRUG|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
214617919|NCT03008850|DRUG|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
214617920|NCT03008850|DRUG|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
214617921|NCT02381405|DIETARY_SUPPLEMENT|Enterade beverage|
214617922|NCT00890032|BIOLOGICAL|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
214617923|NCT00478582|PROCEDURE|Estimation of Hb concentrations with the HemoHue card|
214617924|NCT04209751|DIAGNOSTIC_TEST|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
214617925|NCT02301182|DEVICE|ADM X3-MoP Cup|
214617926|NCT02301182|DEVICE|CoC Cup|
214617927|NCT00382746|DEVICE|EarlySense monitoring device|
214716650|NCT02661464|BIOLOGICAL|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
214716651|NCT06528808|OTHER|Simple reality simulator application|Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
214716652|NCT00860990|OTHER|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
214716653|NCT02073903|BEHAVIORAL|Patient Survey|
214716654|NCT02073903|BEHAVIORAL|Provider Survey|
214716655|NCT00737685|DRUG|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
214716656|NCT03069898|BEHAVIORAL|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
214716657|NCT03947567|DRUG|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
214716658|NCT05456412|OTHER|JAK inhibitor treatment|Standard care
214716659|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
214716660|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
214716661|NCT00334152|DRUG|casopitant|
214716662|NCT04864678|OTHER|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
214617928|NCT06430853|BEHAVIORAL|Step count goal|The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive weekly reminders that are tailored for their intervention arm. Intervention group participants will also receive a step count diary with motivational ideas of how to obtain step goals, which will be reviewed with a study team member every 2 weeks.
214617929|NCT06430853|DEVICE|Actigraph watch|Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
214617930|NCT05796570|DRUG|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
214617931|NCT05796570|DRUG|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
214617932|NCT06641999|DEVICE|Tinnitus Implant System|Implanted with Tinnitus Implant System: Active Implantable Medical Device
214617933|NCT06337357|BEHAVIORAL|Progressive Resistance Training|"Progressive resistance training includes face-to-face education on resistance training:~Resistance exercises with elastic bands include 9 exercises for 1 course. During the first 4 weeks, the patient exercises twice a week with a level of exertion according to Borg's category-ratio 10 (CR10) scale of 4-5 points. For the next 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 6-7 points. In the last 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 8-9 points.~The three-month intervention involves twelve weekly calls, with a focus on building rapport (e.g. providing feedback on the baseline assessment); education reinforcement on resistance training; and skill-building (e.g. self-monitoring and resistance training diary). The emphasis is on helping participants to gain the knowledge and skills necessary to achieve targeted intensity. Every 4 weeks, all patients are re-visited by investigators in the hospital."
214617934|NCT04917848|OTHER|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
214716663|NCT03148756|DRUG|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
214716664|NCT03148756|DRUG|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
214716665|NCT03412500|DRUG|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
214716666|NCT03412500|DRUG|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
214716667|NCT01867567|PROCEDURE|abdominal bandage|
214617935|NCT03318380|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
214617936|NCT06368921|BIOLOGICAL|VRT106|intratumoral injection
214617937|NCT03775330|RADIATION|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm"
214617938|NCT03775330|RADIATION|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
214617939|NCT05057949|DRUG|Larotinib|Larotinib Capsules
214617940|NCT05057949|DRUG|Rifampin|Rifampin Capsules
214617941|NCT05057949|DRUG|Itraconazole|Itraconazole Capsules
214617942|NCT06278935|BEHAVIORAL|Lifestyle-based intervention by an occupational therapist|Participants with diabetic foot ulcers will be offered lifestyle-based treatment sessions virtually for up to 8 sessions (\~8 weeks) with a licensed occupational therapist.
214617943|NCT01031550|DRUG|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
214617944|NCT01031550|DRUG|propofol|standard of care
214617945|NCT06424951|BEHAVIORAL|LKCM(Loving-kindness and Compassion Meditations)|Loving-kindness and Compassion Meditations
214617946|NCT00050154|DRUG|ZARNESTRA, tipifarnib, R115777|
214617947|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
214617948|NCT05510700|DEVICE|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
214617949|NCT05510700|DEVICE|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
214722133|NCT02619006|OTHER|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
214617950|NCT04354298|BEHAVIORAL|Improvisational Dance Class|Hour long movement classes that meet weekly for 12 weeks.
214617951|NCT03497806|BIOLOGICAL|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
214617952|NCT02258503|OTHER|pain in elderly patients|
214617953|NCT02247245|DRUG|Ivabradine|Ivabradine 7.5mg
214617954|NCT02247245|OTHER|Atrial fibrillation|Pacemaker base rate alteration
214617955|NCT02247245|DRUG|Placebo|Placebo
214617956|NCT03761875|OTHER|blood sample CHB patients|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 1 dry tube per patient"
214617957|NCT03761875|OTHER|boold sample Control group|"* 2 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 1 dry tube"
214617958|NCT02046096|DEVICE|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
214617959|NCT02046096|DEVICE|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
214617960|NCT01045798|DRUG|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
214716668|NCT05493540|DRUG|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
214716669|NCT05493540|DRUG|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
214716670|NCT02255643|DEVICE|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
214716671|NCT05386264|OTHER|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
214716672|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
214716673|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
214716674|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
214716675|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
214716676|NCT04021459|PROCEDURE|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
214716677|NCT06397742|OTHER|Physical activity|"Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches"
214722134|NCT02314598|OTHER|No treatment|
214722135|NCT05135429|OTHER|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
214617961|NCT01045798|DRUG|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
214617962|NCT02090413|DRUG|dimethyl fumarate|
214617963|NCT02090413|DRUG|acetylsalicylic acid|enteric-coated capsule
214617964|NCT02090413|DRUG|ASA-Placebo|matched placebo
214617965|NCT01693354|DEVICE|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
214617966|NCT01693354|DEVICE|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
214617967|NCT01529099|DEVICE|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
214617968|NCT06972225|DEVICE|DEB|Use of DEB to treat coronary lesions
214617969|NCT01608152|BEHAVIORAL|Focus Group|Attend a focus group
214617970|NCT01608152|OTHER|Internet-Based Intervention|Have access to the game
214716678|NCT06397742|OTHER|Physical therapy - myofascial techniques|"Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns."
214716679|NCT03755999|OTHER|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
214716680|NCT05832099|RADIATION|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
214716681|NCT02177175|DRUG|Carvedilol|
214716682|NCT02177175|OTHER|placebo|
214716683|NCT04154371|DEVICE|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
214716684|NCT01011218|BEHAVIORAL|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
214716685|NCT01011218|BEHAVIORAL|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
214716686|NCT01011218|DRUG|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
214716687|NCT03820726|DRUG|Nintedanib|Bid
214716688|NCT04110860|DRUG|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
214617971|NCT01608152|BEHAVIORAL|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
214617972|NCT05366933|DRUG|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
214617973|NCT05424484|DEVICE|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
214617974|NCT04898933|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
214617975|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
214617976|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
214617977|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
214617978|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
214617979|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
214617980|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
214617981|NCT00487396|DEVICE|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
214617982|NCT06464692|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214617983|NCT06966726|BEHAVIORAL|Positive Dental Imagery|Children were shown four A4-sized laminated color images depicting positive dental scenes (e.g., children interacting happily with the dentist, smiling after treatment) for 2 minutes prior to the procedure.
214617984|NCT06966726|BEHAVIORAL|Neutral Nature Imagery|Children were shown four A4-sized laminated color images depicting neutral nature scenes (e.g., a beach, sunset, flowers) for 2 minutes prior to the procedure.
214716689|NCT04110860|DRUG|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
214617985|NCT06968793|PROCEDURE|Pressure support 15|Pressure support of 15 cm H2O will be applied for 5 minutes.
214617986|NCT06968793|PROCEDURE|Pressure support 13|Pressure support of 13 cm H2O will be applied for 5 minutes.
214617987|NCT06968793|PROCEDURE|Pressure support 11|Pressure support of 11 cm H2O will be applied for 5 minutes.
214617988|NCT06968793|PROCEDURE|Pressure support 9|Pressure support of 9 cm H2O will be applied for 5 minutes.
214617989|NCT06968793|PROCEDURE|Pressure support 7|Pressure support of 7 cm H2O will be applied for 5 minutes.
214617990|NCT06968793|PROCEDURE|Pressure support 5|Pressure support of 5 cm H2O will be applied for 5 minutes.
214617991|NCT06344351|DRUG|TQB3006 tablets|TQB3006 is an inhibitor protein.
214617992|NCT06971484|DIETARY_SUPPLEMENT|Crystalline glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in a caplet.
214617993|NCT06971484|DIETARY_SUPPLEMENT|Regular glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in hard gel capsules.
214617994|NCT06973629|BIOLOGICAL|Debamestrocel - MSC-NTF (NurOwn)|MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).
214617995|NCT06973629|BIOLOGICAL|Placebo|Dulbecco Modified Eagle Medium (DMEM).
214617996|NCT06972979|BEHAVIORAL|Text Message Gamification and Remote Support|Participants in the intervention arm consists of several components: (I) medication check-ins with the ability to set the time(s) for daily medication reminders, (II) a gamification experience to drive behavior change, (III) ability to identify a support partner who receives weekly updates on the patient's game status; (IV) access to an RN team for clinical questions and care coordination, and (V) patients' providers can see real-time progress within an electronic health record (EHR) integrated application.
214617997|NCT02515383|OTHER|Interview|Complete cognitive debriefing interview
214617998|NCT02515383|OTHER|Quality-of-Life Assessment|Ancillary studies
214617999|NCT02515383|OTHER|Questionnaire Administration|Complete MDASI questionnaire
214618000|NCT00411359|BEHAVIORAL|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
214618001|NCT01651715|DRUG|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
214618002|NCT05680922|BIOLOGICAL|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
214618003|NCT04929210|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214618004|NCT04929210|DRUG|Placebo|Matching placebo will be administered as subcutaneous injection.
214618005|NCT06082635|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
214618006|NCT06082635|DRUG|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
214618007|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
214618008|NCT05425004|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
214618009|NCT05599672|BEHAVIORAL|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
214618010|NCT05599672|BEHAVIORAL|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
214618011|NCT05496543|DEVICE|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
214618012|NCT05496543|DEVICE|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
214618013|NCT05125601|OTHER|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
214618014|NCT04837001|DRUG|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
214618015|NCT04837001|OTHER|Placebo|Placebo will be administered as a single bolus injection.
214618016|NCT05321069|DRUG|BI 1015550|Participants received film-coated nerandomilast tablets orally twice daily at doses of either 9 mg or 18 mg, with each dose administered at least 12 hours apart and taken with 250 mL of water.
214618017|NCT05321069|DRUG|Placebo|Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally twice daily, with doses given at least 12 hours apart and each taken with 250 mL of water.
214618018|NCT06044935|OTHER|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
214716690|NCT04110860|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
214618019|NCT06044935|OTHER|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
214618020|NCT06044935|DIETARY_SUPPLEMENT|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
214618021|NCT06044935|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
214618022|NCT06317025|DIAGNOSTIC_TEST|Multi-modal Intelligent Anesthesia Monitoring System|To evaluate the sensitivity and specificity of self-developed anesthesia monitoring systems in diagnosing the depth of anesthesia (too deep or too shallow)
214618023|NCT05552222|DRUG|Teclistamab|Teclistamab will be administered as SC injection.
214618024|NCT05552222|DRUG|Daratumumab|Daratumumab will be administered as SC injection.
214618025|NCT05552222|DRUG|Lenalidomide|Lenalidomide will be administered orally.
214618026|NCT05552222|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
214618027|NCT05552222|DRUG|Talquetamab|Talquetamab will be administered as SC injection.
214618028|NCT06973668|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max: 1,000mg/dose) IV/PO three times daily
214618029|NCT06973668|DRUG|Ruxolitinib|5 mg PO every 12 hours
214618030|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
214716691|NCT05716594|COMBINATION_PRODUCT|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
214716692|NCT05716594|COMBINATION_PRODUCT|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
214716693|NCT03345992|DRUG|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
214716694|NCT03345992|DRUG|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
214716695|NCT00143962|BEHAVIORAL|Low Carbohydrate Diet|
214716696|NCT00206401|DRUG|Lantus and short acting analogs Vs NPH and short acting analogs|
214716697|NCT00345540|DRUG|NOV-002|60 mg / mL / day / 20-23 Days
214716698|NCT00345540|DRUG|Carboplatin|AUC 5 following IV bolus administration of NOV-002
214716699|NCT03164785|DRUG|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
214716700|NCT01406652|PROCEDURE|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
214716701|NCT01383187|PROCEDURE|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
214618031|NCT05820633|RADIATION|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
214618032|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
214618033|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
214618034|NCT05820633|RADIATION|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
214716702|NCT01383187|PROCEDURE|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
214716703|NCT02535637|OTHER|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
214716704|NCT05138237|PROCEDURE|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
214716705|NCT03255811|DRUG|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
214716706|NCT03965871|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
214716707|NCT03965871|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
214716708|NCT03965871|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
214716709|NCT03965871|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
214716710|NCT02629328|DEVICE|CardioCel|Treatment with CardioCel implant
214716711|NCT00861380|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
214716712|NCT00861380|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."
214618035|NCT05820633|RADIATION|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
214618036|NCT05820633|RADIATION|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
214618037|NCT05820633|RADIATION|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
214618038|NCT06316297|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: Liquid suspension for injection Route of administration: intramuscular
214618039|NCT06316297|OTHER|Placebo|Pharmaceutical form: Liquid solution for injection Route of administration: intramuscular
214618040|NCT06587243|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
214618041|NCT06587243|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
214716713|NCT00861380|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.
214716714|NCT02481063|OTHER|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
214716715|NCT02481063|OTHER|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
214716716|NCT03379896|OTHER|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
214618042|NCT06195488|PROCEDURE|Gastric ultrasound|performing gastric ultrasound to determine gastric contents
214618043|NCT06439082|BIOLOGICAL|Crizanlizumab|Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
214618044|NCT06439082|DRUG|Placebo|Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
214618045|NCT06602219|DRUG|LY4100511|Administered orally
214618046|NCT06602219|DRUG|Placebo|Administered orally
214618047|NCT06985407|DIETARY_SUPPLEMENT|Grape extract (VinteraTM Premium Red Grape)|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
214618048|NCT06985407|DIETARY_SUPPLEMENT|Control (placebo) group|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
214618049|NCT06985251|OTHER|gamified mHealth lifestyle app|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard.
214716717|NCT04041141|DIAGNOSTIC_TEST|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
214618050|NCT06985251|OTHER|Attention Control|Standard of care healthy lifestyle handouts were emailed monthly to control families.
214716718|NCT04041141|DEVICE|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
214618051|NCT06985251|OTHER|gamified mHealth app with financial incentives|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard. CommitFit$ adolescents received an extra $0.05 for each point they earned in the app.
214618052|NCT02489136|OTHER|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
214618053|NCT06984133|BEHAVIORAL|Structured education program|"A structured group educational program culturally adapted from a UK model for adolescents with type 1 diabetes. The program aims to empower adolescents by providing knowledge and tools needed for effective diabetes management.~It is delivered by dietitians, diabetes educators, and a pediatric endocrinologist in small groups. The curriculum targets both caregivers and adolescents: the first day is for parents and covers diabetes basics, management of hypoglycemia and hyperglycemia, insulin dosing, sick day management, and exercise considerations. The following three days focus on adolescents and include interactive sessions on the role of food in diabetes management, the effect of different nutrients on blood glucose levels, carbohydrate sources, reading food labels, advanced carbohydrate counting, and insulin dose adjustment."
214716719|NCT04559087|PROCEDURE|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
214618054|NCT04702451|PROCEDURE|Dispersion ablation + PVI|Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
214618055|NCT04702451|DEVICE|VX1|VX1-based dispersion mapping
214618056|NCT04702451|PROCEDURE|PVI|Pulmonary vein antrum isolation
214618057|NCT06051006|OTHER|ESR and ECAP measurements|"Measurement of electrically evoked stapedial reflexes (ESRT) by stimulation via the cochlear implant. Measurement of the Electric compound action potentials (ECAPs) on the electrodes where the ESRT were performed.~The measurements and tests will be performed during a routine visit to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
214716720|NCT04504461|OTHER|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
214716721|NCT00378976|DRUG|valacyclovir|500 mg twice-daily oral
214716722|NCT00378976|DRUG|matching placebo|twice daily as per experimental drug
214716723|NCT00637377|DRUG|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214716724|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214716725|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214618058|NCT06051006|OTHER|Device setting|"The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
214716726|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214716727|NCT02425280|BEHAVIORAL|Narrative Exposure Therapy|
214716728|NCT02425280|BEHAVIORAL|Treatment as Usual|
214618059|NCT06051006|OTHER|Speech audiometry|"This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
214618060|NCT06051006|OTHER|Intelligibility in noise test|"The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
214618061|NCT06051006|OTHER|Cochlear implant datalogging, speech audiometry test, FraSimat test|"The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR."
214618062|NCT06600542|DEVICE|Inari Medical Commercially Available Devices|Commercially approved Inari Medical devices
214618063|NCT06985550|BEHAVIORAL|Multicomponent Exercise|Participants in this group will engage in a 12-week supervised multicomponent exercise program, performed 3 times per week, 90 minutes per session. Each session includes a 10-minute warm-up, 40 minutes of Waltz dance (learning and practicing routines), 30 minutes of resistance band exercises (1-3 sets of 8-12 repetitions, using 10-20RM), and a 10-minute cool-down with stretching. Exercise intensity progresses from 50% to 75% of HRmax (RPE 10-13, 2.0-6.0 METs). The program is designed to improve lipid profile, body composition, cardiovascular fitness, balance, mental health, and cognitive function in postmenopausal women aged ≤65 years with dyslipidemia.
214618064|NCT06985550|OTHER|daily activity|Only daily activities are included.
214618065|NCT06481098|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
214618066|NCT06481098|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
214618067|NCT04276389|DEVICE|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
214618068|NCT04276389|DEVICE|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
214618071|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
214618072|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
214618073|NCT06984224|DEVICE|Neubie Direct Current Stimulation Device|Pulsed Direct Current Electrical Stimulation Device
214618074|NCT05816356|DRUG|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
214618075|NCT05816356|DRUG|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
214618076|NCT03350711|OTHER|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
214618077|NCT02724371|DEVICE|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
214618078|NCT05585983|BIOLOGICAL|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
214618081|NCT07001111|OTHER|kinesio taping|Kinesio taping at the level of the cubital tunnel on the elbow
214618082|NCT07001111|OTHER|Ulnar nerve mobilization exercise|All patients will be provided with information and an exercise sheet containing pictures on ulnar nerve gliding exercises. To monitor whether patients are performing the exercises correctly, they will be asked to come to the hospital once a week, where they will perform the exercises under the supervision of a physiotherapist. In the exercise program, different positions will be held for 30 seconds, with a 1-minute rest between them, and the exercises will be performed twice a day .
214618083|NCT07001111|OTHER|Sham (No Treatment)|It will be applied in the same way as kinesiological taping with adhesive tape.
214618084|NCT07001111|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Description: To demonstrate that kinesiological taping will result in a reduction of pain intensity associated with Cubital Tunnel Syndrome, as measured by the Numeric Rating Scale (NRS) ranging from 0 to 10.
214618085|NCT07001111|DIAGNOSTIC_TEST|the ulnar nerve cross-sectional area measured by ultrasound|The measurements will be taken with the patient in a supine position, the affected arm in shoulder abduction and external rotation, and the elbow flexed at 70°-90°. After applying a generous amount of gel, the lateral edge of the ultrasound probe will be placed on the medial epicondyle, and the medial edge of the probe will be positioned on the olecranon; the ulnar nerve will be directly examined in the retroepicondylar groove. Once the nerve is visualized, the widest point will be identified, and cross-sectional area (CSA) measurements will be taken with the probe perpendicular to the nerve at the center of the screen . The measurements will be repeated twice, and the average will be calculated.
214618086|NCT07001111|DIAGNOSTIC_TEST|Neuropathic pain scale (measured using the DN-4 scale)|"The DN4 questionnaire consists of two main sections and a total of ten questions. The first section includes seven questions related to pain characteristics and sensory information obtained through patient interview. These questions are about burning, electric shocks, coldness, tingling, pricking, numbness, and itching. The second section contains three statements related to physical examination (touch hypoesthesia, pinprick hypoesthesia, and allodynia). For each statement, yes or no responses are given. A score of 1 is assigned for yes answers and 0 for no answers, and the scores are summed. A total score of 4 or more out of 12 is interpreted as neuropathic pain."
214618087|NCT07001111|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale is a short form of the SF-36 Quality of Life Scale. While the SF-36 is used for chronic conditions (states), the SF-12 is used for short-term assessments (clinical findings). Similarly, it is also used to gather information about the patient's general health status. The SF-12 provides the same summary component scores as the SF-36, but with fewer items, making it a significant advantage due to its shorter application time. The scale asks the patient about their health opinions, how they feel, and how easily they can perform their usual activities. Scores range from 0 to 100, with higher scores indicating better quality of life.
214618088|NCT07001111|DIAGNOSTIC_TEST|QUICK-DASH|"QUICK-DASH (Shoulder, Arm, and Hand Problems Questionnaire):~This questionnaire assesses both the ability to perform certain physical activities as well as the symptoms of the disease. Each question is answered based on the condition of the past week, and the appropriate score is marked. The answer is given based solely on the ability to perform the physical activity, without considering which hand or arm is injured.~Scoring:~1. = No difficulty~2. = Mild difficulty~3. = Moderate difficulty~4. = Severe difficulty~5. = Unable to perform~QUICK DASH DISABILITY/SYMPTOM SCORE:~(\[(n total score\] - 1) x 25; where n represents the number of questions answered. If more than one question is unanswered, the Quick DASH score cannot be calculated.~SCORE FOR OPTIONAL MODELS:~For each model, divide the total score by 4, subtract 1, and multiply by 25. If more than one question is unanswered, the score for optional models cannot be calculated.~Based on the results of the questionnaire, a score b"
214618089|NCT07001111|DIAGNOSTIC_TEST|Grip strength measured with a hand dynamometer|Grip strength will be measured using a hand dynamometer, with the average of three measurements taken, each followed by a 30-second rest period.
214618090|NCT07001059|DIAGNOSTIC_TEST|orbital ultrasound|orbital ultrasound at the beginning of the participation, and at 6 months after the inclusion.
214618091|NCT04347226|DRUG|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
214618092|NCT06875128|DRUG|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
214618093|NCT06875128|DRUG|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
214618094|NCT05796427|BEHAVIORAL|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
214618095|NCT03979846|OTHER|Best Practice|Receive usual care
214618096|NCT03979846|OTHER|Computer Application|Use computer-based symptom reporting system
214618097|NCT03979846|OTHER|Questionnaire Administration|Ancillary studies
214618098|NCT03979846|OTHER|Quality-of-Life Assessment|Ancillary studies
214618099|NCT07010939|PROCEDURE|blood sampling|At baseline, participants will undergo peripheral blood collection using EDTA tubes. A total of 10 mL of venous blood will be collected and processed into plasma and peripheral blood mononuclear cells (PBMCs). Plasma samples will be stored at -80°C, and PBMCs will be cryopreserved in liquid nitrogen. These samples will be used for future biomarker discovery, multi-omics analysis, and studies of biological mechanisms underlying treatment-related toxicities.
214618100|NCT04090580|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks or 2000 mg metformin. Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
214618101|NCT07013006|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
214618102|NCT07016321|DRUG|Emetine Hydrochloride 6mg|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
214618103|NCT07016321|DRUG|Placebo|Participant take a placebo for 10 consecutive days.
214618104|NCT07016321|DRUG|Emetine Hydrochloride 12mg|To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
214618105|NCT02812290|PROCEDURE|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
214618106|NCT07023367|BEHAVIORAL|Parent Navigator Program|Participants in this group will be connected with a parent with lived experience to help get them obtain developmental follow up services and early intervention.
214618107|NCT07023367|BEHAVIORAL|Standard of Care|The families in the standard care group will have their connections to neurodevelopmental (ND) follow-up and support delivered in the standard fashion which consists of a referral to high-risk infant follow-up (HRIF) by discharge coordinator.
214618108|NCT07025044|DRUG|onabotulinum toxin type a|All subjects will be scheduled to undergo Onabotulinum toxin type A intradetrusor injection for management of OAB. On Day 0, subjects will undergo Onabotulinum toxin type A injection by a licensed clinical provider and receive a one-time dose of Nitrofurantoin for infection prevention per standard clinic protocol.
214618109|NCT07029204|DRUG|CycloSPORINE Injectable Product|Intralesional 0.5-2 mL injections of cyclosporine (2.5 mg/ml)
214618110|NCT07029204|DRUG|Saline Solution|Intralesional 0.5-2 mL injections of Saline Solution
214618111|NCT07025187|DRUG|Muscle relaxants tizanidine|All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day for one month .
214618112|NCT07025187|OTHER|integrated neuromuscular inhibition technique|Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month .
214618113|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
214618114|NCT07028697|DRUG|Daridorexant|Daridorexant will be taken orally, once daily in the evening as indicated by investigator.
214618115|NCT07028697|DRUG|Placebo|Placebo will be taken orally, once daily in the evening as indicated by investigator.
214618116|NCT06694402|DEVICE|focal muscle vibration combined with exercise|The treatment group will receive a 30-minute intervention in each session. Focal muscle vibration will be applied to the anterior and lateral parts of shoulder to give a sensory stimulation while participants are doing eaercise.
214618117|NCT06694402|OTHER|exercise|The control group will receive 30-minute exercise without focal muslce vibration.
214618118|NCT00597753|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
214618119|NCT00597753|DRUG|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
214618120|NCT05133271|OTHER|Clinical hemodynamic and echocardiographic evaluation|"Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~1. T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~2. T2: clinico-ultrasound evaluation after performing the PLR.~   Then, clinical hemodynamic evaluation during two periods T3 and T4:~3. T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~4. T4: period after performing spinal anesthesia until clamping of the umbilical cord."
214618121|NCT07030517|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
214716729|NCT05082402|DIAGNOSTIC_TEST|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
214716730|NCT04804280|GENETIC|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
214618122|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"Relaxing Acupressure entails applying pressure with either a finger, pencil, or similar object to acupressure points. For the relaxing protocol, there is a total of 9 acupoints (1 unilateral and 4 bilateral). Each point will be stimulated for 3 minutes, yielding a total treatment time of 27 minutes each day. The acupoints are:~1. Yin Tang (Unilaterally): Located on the forehead, between the eyebrows.~2. Anmian (Right and Left/bilaterally): Located on the posterior aspect of the neck, in a slight depression along the bone directly behind the ear.~3. Heart 7 (HT7) (Right and Left/bilaterally): Located on the palmer surface of the hands on the wrist crease; in line with the pinky.~4. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~5. Liver 3 (LIV3) (Right and Left/bilaterally): This point is located on the foot, near the big and second toes."
214716731|NCT04804280|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
214716732|NCT03254862|PROCEDURE|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
214618123|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"There is a total of 10 acupoints (2 unilateral and 4 bilateral). Each point is stimulated for 3 minutes, yielding a total treatment time of 30 minutes each day. The acupoints are:~1. Du 20 (Unilaterally): Located at the top of the head.~2. Large Intestine 4 (LI4) (Right and Left/bilaterally): Located on the back of the hand, between your thumb and index finger.~3. Conception Vessel 6 (CV6) (Unilaterally): Located two finger widths below the navel on the centerline.~4. Stomach 36 (ST36) (Right and Left/bilaterally): Located on the lower leg below the knee on the outside of the leg.~5. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~6. Kidney 3 (K3) (Right and Left/bilaterally): Located on the inside of the ankle."
214716733|NCT03254862|PROCEDURE|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
214716734|NCT04104373|OTHER|Observational Cohort|
214618124|NCT06710418|OTHER|Activity Tracking|Ancillary studies
214618125|NCT06710418|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214618126|NCT06710418|PROCEDURE|Cognitive Assessment|Ancillary studies
214618127|NCT06710418|OTHER|Electronic Health Record Review|Ancillary studies
214618128|NCT06710418|OTHER|Packed Red Blood Cell Transfusion|Undergo PRBC transfusion
214618129|NCT06710418|OTHER|Quality-of-Life Assessment|Ancillary studies
214618130|NCT05482516|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
214618131|NCT05482516|DRUG|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
214618132|NCT06881251|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
214618133|NCT06881251|DRUG|JNJ-95475939|JNJ-95475939 will be administered subcutaneously.
214618134|NCT06881251|DRUG|Placebo|Placebo will be administered subcutaneously.
214618135|NCT06717074|DRUG|RBD4059|RBD4059, active drug.
214618136|NCT06717074|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
214618137|NCT07045155|DRUG|The rHuEPO Monotherapy Group (Control Group)|The rHuEPO Monotherapy Group (Control Group) will be treated with rHuEPO for the first 16 weeks and then switch to Pegmolesatide treatment for the subsequent 8 weeks.
214618138|NCT07045155|DRUG|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group)|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group) will receive a combination of Pegmolesatide and roxadustat throughout the entire 24-week treatment period.
214618139|NCT07045155|DRUG|The Pegmolesatide Monotherapy Group (Experimental group)|The Pegmolesatide Monotherapy Group (Experimental Group) will receive Pegmolesatide treatment throughout the entire 24-week period.
214618140|NCT07047144|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
214618141|NCT07047144|DRUG|Nusinersen|Nusinersen is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered intrathecally per the prescribing information.
214618142|NCT07047144|DRUG|Risdiplam|Risdiplam is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered orally per the prescribing information.
214716735|NCT02992301|DRUG|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
214716736|NCT00755872|DRUG|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
214618143|NCT06926036|BEHAVIORAL|Wake training + TMR|"In this within-participant design, all participants will undergo the same intervention of waking training and TMR.~Waking training - waking training will associate an auditory cue with a specific learned behavioral response (a tongue protrusion and inhalation) during daily sessions for approximately one week, with home sleep monitoring.~TMR - Targeted memory reactivation (TMR) refers to the process of playing learning-associated audio cues quietly during sleep in order to reactivate memories associated with the cue. After completion of waking training, TMR occurs in a laboratory setting, with PSG recording, during a single night."
214618144|NCT06728904|BEHAVIORAL|Tai Chi intervention|40-90 minutes per session, 3-5 sessions per week. 6. Each practice mainly includes basic theoretical knowledge, warm-up exercises, standing exercises, Chen style Tai Chi, and relaxation techniques. This study expects to divide the Tai Chi intervention program into three stages: the first stage is the introductory learning of simple high-intensity Chen style Tai Chi, the second stage is the combination of strength training and Chen style Tai Chi courses, and the third stage uses optional high-intensity competitive Chen style Tai Chi or Tai Chi Sword as advanced content to consolidate learning outcomes, such as the 32 style Tai Chi Sword (HR of about 120 times/minute). The intervention plan will be combined with high-intensity interval training (HIIT) to adapt Chen style Tai Chi.
214618145|NCT06889012|DRUG|BR1018|One tablet administered alone
214618146|NCT06889012|DRUG|BR1018A|One tablet administered alone
214618147|NCT06889012|DRUG|BR1018B|One tablet administered alone
214618148|NCT06778057|DEVICE|Test Lens 1|Acuvue® Oasys MAX 1-Day daily disposable contact lenses
214618149|NCT06778057|DEVICE|Test Lens 2|Dailies Total 1 daily disposable contact lenses
214618150|NCT06778057|DEVICE|Test Lens 3|Clariti 1-Day daily disposable contact lenses
214618151|NCT06734585|DRUG|Gilteritinib|tablet, oral
214618152|NCT06737562|PROCEDURE|Immediatly sequential bilateral cataract surgery|Immediatly sequential bilateral cataract surgery
214618153|NCT06737562|PROCEDURE|Delayed sequential bilateral cataract surgery|Delayed sequential bilateral cataract surgery : 3 weeks +/-1 week between the two procedures
214618154|NCT06735404|OTHER|Hybrid care|"The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online"
214618155|NCT06737484|OTHER|APPLYING TOPICAL OLIVE OIL|"1. Preparation phase: Before the application, hand hygiene will be provided, materials will be prepared, and the application will be carried out wearing gloves. The patient bed will be prepared, a stretcher cover and a bed protector will be laid. A screen will be used for patient privacy and only the areas to be applied will be opened in order. Itchy areas will be identified. Before starting the application, olive oil will be tested by applying it to a small area on the inside of the patient's arm in case of any allergic reaction.~2. Application of olive oil: 3 drops of olive oil will be dropped on the itchy areas (excluding the scalp and private areas) for every 25 cm square area and gently spread over the area for 30-60 seconds. Since there is a 5-7 minute absorption period from the skin, the area will be kept open and then a VAS score will be taken.~3. After the application: The procedure will be marked on the patient follow-up form."
214618156|NCT05114876|OTHER|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses."
214618157|NCT06474793|OTHER|Aromatherapy Intervention Group-1|For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
214618158|NCT06474793|OTHER|Aromatherapy Intervention Group-2|For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
214716737|NCT00755872|DRUG|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
214716738|NCT00755872|DRUG|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
214716739|NCT00755872|DRUG|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
214716740|NCT04712799|DRUG|Otrivin|oxymetazoline nasal spray
214716741|NCT04501757|BIOLOGICAL|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
214716742|NCT00419367|DRUG|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
214716743|NCT02577367|DRUG|Levothyroxine|Administer Levothyroxine
214716744|NCT01822223|DEVICE|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
214618159|NCT06474793|OTHER|Aromatherapy Placebo Control Group|For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
214618160|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
214618161|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
214618162|NCT06773962|DRUG|TB006|IV infusion.
214618163|NCT06773962|DRUG|Placebo|IV infusion.
214618164|NCT04117620|OTHER|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
214618165|NCT01740076|OTHER|soy nuts|
214716745|NCT02439736|OTHER|Blood draw within 12 hours of head injury|
214716746|NCT01386892|OTHER|No intervention|There is no intervention for this study
214716747|NCT06042192|DRUG|TK-254RX|Two TK-254RX per day to predetermined application site
214716748|NCT05387798|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
214716749|NCT04888351|OTHER|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
214716750|NCT04888351|OTHER|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
214716751|NCT03001310|BIOLOGICAL|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
214716752|NCT00264446|DRUG|ADH300004|
214716753|NCT00631540|DEVICE|Formula Balloon-Expandable Stent|renal artery stenting
214716754|NCT05353868|OTHER|No intervention|No intervention
214716755|NCT00222248|BEHAVIORAL|Pelvic floor muscle training and bladder training|
214618166|NCT07088640|PROCEDURE|Single-step warming protocol by thawing solution only|Potentially eligible patients' vitrified blastocysts will be thawed by a single-step thawing protocol. For the warming phase, vitrified blastocysts are exposed to the thawing solution of a commercial embryo thawing kit (Irvine Scientific Inc., USA) at 37°C for one minute. Immediately following this, embryos will be rinsed in a 35mm diameter dish of 2ml of pre-equilibrated thawing solution before being placed in culture media in the incubator for at least 2 hours before transfer.
214618167|NCT07088640|PROCEDURE|Standard warming protocol|"For the MS protocol, thawing kits were equilibrated overnight in a 37°C incubator. Warming procedures utilized the kits (Cryotech RtU, Japan). To remove the cryoprotectants, blastocysts were warmed, and cryoprotectants were diluted in a three-step process.~The warming process starts with the exposure of blastocysts to thaw solution (TS) with 1M trehalose for one minute at 37°C. Subsequently, the blastocyst will be transferred to a second well containing a dilution solution (DS) of 0.5M trehalose for a two-minute rinse at room temperature. This is followed by two additional three-minute and 30-second rinses in the wash solution (WS) at room temperature. The timeline for standard warming of blastocysts requires a total of 6.5 min. After thawing, embryo will be placed in the incubator at least 2 hours before transfer."
214618168|NCT06905925|OTHER|The group receiving counseling|Patients in the experimental group will receive pre-operative stoma care education from the researcher. This training is expected to last approximately 15 minutes. After the training, a brochure will be provided to the patients, which they can use if they need additional information. During the training process, patients will be informed that the researcher will contact them by phone during the 1st, 2nd, 3rd, and 4th weeks after discharge. During these calls, patients will be asked weekly (during weeks 1, 2, 3, and 4) about the color, odor, texture of the wound area, the function of the colostomy, and any complications. Additionally, at the end of the 2nd week, if there are no issues around the wound or sutures, patients will be called to the hospital for suture removal and dressing changes. In other weeks, dietary habits and the condition of the wound will also be inquired. During this four-week period, patients or their relatives will be informed that they can contact the researcher
214618169|NCT05242471|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214618170|NCT05242471|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
214618171|NCT05242471|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
214618172|NCT05242471|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
214618173|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
214618174|NCT07089134|PROCEDURE|reabilitação fisioterapêutica tradicional|Active and passive exercises, and walking
214618175|NCT07089134|PROCEDURE|fisioterapia utilizando realidade virtual imersiva|Use of immersive virtual reality headset for rehabilitation sessions
214618176|NCT06461247|OTHER|Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals|Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
214618177|NCT06461247|OTHER|Standard Care Group|Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
214618178|NCT06764875|DRUG|Rilvegostomig|Q3W, intravenous infusion
214618179|NCT06764875|DRUG|Trastuzumab deruxtecan|Q3W, intravenous infusion
214618180|NCT06764875|DRUG|Trastuzumab|Q3W, intravenous infusion
214618181|NCT06764875|DRUG|Pembrolizumab|Q3W, intravenous infusion
214618182|NCT06764875|DRUG|5-fluorouracil|Q3W, intravenous infusion
214618183|NCT06764875|DRUG|Capecitabine|BID, oral administration
214618184|NCT06764875|DRUG|Cisplatin|Q3W, intravenous infusion
214618185|NCT06764875|DRUG|Oxaliplatin|Q3W, intravenous infusion
214618186|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
214618187|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
214618188|NCT06681324|DRUG|AZD7798|AZD7798
214618189|NCT06681324|OTHER|Placebo|Placebo
214618190|NCT04207892|PROCEDURE|Conservative (non-surgical) treatment|Cast Sling Splint Collar
214618191|NCT04207892|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
214618192|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
214618193|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
214716756|NCT03419910|DRUG|BMS-986165|Specified dose on specified days
214716757|NCT03419910|DRUG|Cyclosporine|Specified dose on specified days
214716758|NCT03437213|DRUG|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
214618194|NCT07099716|DEVICE|Wearing Hilo band, Ambulatory Blood Pressure Monitor, and Hydrostatic Pressure monitor|During study Visit 1, participants are equipped with tthree devices- the Device Under Test (Hilo band), the reference device (Ambulatory Blood Pressure Monitor), worn on the opposite arm, and a Hydrostatic pressure monitor on the chest. Subjects are instructed to wear the three devices for the next 24 hours to collect blood pressure (BP) and heart rate (HR) data as well as hydrostatic pressure measurements. After Visit 1, subjects return home with the devices in place. Visit 2 takes place at least 24.5 hours later, when participants return to the site to hand back the equipment.
214618195|NCT03777722|DEVICE|Tailored Lighting Intervention|Lighting Intervention - active or placebo
214618196|NCT06888050|DRUG|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ)|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention
214618197|NCT06888050|DRUG|Metformin|Metformin (500mg, twice a day) plus lifestyle intervention
214618198|NCT06760208|BIOLOGICAL|Pneumococcal 20-valent conjugate vaccine|For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be administered intramuscularly, preferably in the deltoid muscle, with care to avoid injection into or near nerves and blood vessels.
214618199|NCT06878404|DRUG|Icotrokinra|Icotrokinra will be administered.
214618200|NCT06878404|DRUG|Placebo|Placebo will be administered.
214618201|NCT06878404|DRUG|Active reference comparator|Active reference drug will be administered.
214618202|NCT06905119|OTHER|Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters|The application is offered to all patients at the time of PICC placement. If they accept, they go to the intervention group. If they do not accept, they go to the control group.
214722136|NCT03690674|BEHAVIORAL|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
214716759|NCT03437213|DRUG|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
214716760|NCT03984838|DRUG|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
214618203|NCT07097779|BEHAVIORAL|Visual Aids(Photos, Videos, and Pictograms)|Participants will be presented with three types of visual instructional aids: photographs, videos, and pictograms, via a laptop or tablet. Each participant will perform three motor tasks, each paired with a different visual aid, assigned in random order using a Latin Square design. Each task takes approximately 3 minutes, followed by 1 minute of rest. After completing all tasks, participants will complete a 5-minute survey about their understanding, preference, and perceived cognitive load. The total session lasts about 20 minutes.
214618204|NCT04481165|OTHER|Survey|Oral interview and written questions
214618205|NCT07107230|DRUG|JNJ-95437446|JNJ-95437446 will be administered.
214618206|NCT05384392|OTHER|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
214618207|NCT05384392|OTHER|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
214618208|NCT05384392|BIOLOGICAL|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
214618209|NCT04939610|DRUG|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
214618210|NCT04939610|DRUG|177Lu-FAP-2286|"Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose."
214618211|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
214618212|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
214618213|NCT06500884|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214618214|NCT06500884|DRUG|Prophylaxis A|Prophylaxis A will be administered orally.
214618215|NCT06500884|DRUG|Prophylaxis B|Prophylaxis B will be administered orally.
214618216|NCT06500884|DRUG|Prophylaxis C|Prophylaxis C will be administered orally.
214618217|NCT05251259|DRUG|Atuliflapon|Randomised participants will receive Atuliflapon
214716761|NCT03136367|OTHER|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
214618218|NCT05251259|DRUG|Placebo|Randomised participants will receive matching placebo to Atuliflapon.
214618219|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
214618220|NCT02500407|DRUG|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
214618221|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
214618222|NCT07109817|DRUG|Desloratodine|Desloratadine 5mg PO daily for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.
214618223|NCT07109817|DRUG|Placebo|Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.
214618224|NCT07109349|DEVICE|Sparrow Link|Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. Participants will self-administer daily active tAN sessions on Days 1 - 28.
214618225|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
214716762|NCT03136367|OTHER|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
214618226|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
214618227|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 1|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
214618228|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 2|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
214618229|NCT06430905|OTHER|Placebo|Administration of placebo to 5 participants.
214618230|NCT07102394|DRUG|Imlygic|intralesional administration of IMLYGIC administered on Days 1 and 21 of each cycle for 4 cycles (8 treatments).
214618231|NCT07106229|BIOLOGICAL|allogeneic human adipose-derived mesenchymal stem cells|The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs).
214618232|NCT07106229|OTHER|Placebo|Placebo is commercially available injectable normal saline (0.9% Sodium Chloride in Water for Injection)
214618233|NCT07108166|OTHER|Cigarette|COPD patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
214618234|NCT07108166|OTHER|THS|COPD patients will switch from cigarette smoking to ad libitum THS use, with no flavor variant restrictions.
214618235|NCT07112911|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20 sessions of robot-assisted upper limb training combined with central-to-peripheral electrical stimulation, delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of NMES and tsES-assisted robotic training. After a 10-minute break, the session will continue with an additional 20 minutes of robotic-assisted training combined with NMES alone, with tsES turned off during this phase. During the training, patients will perform repeated wrist and finger flexion-extension tasks. The training protocol is designed to activate wrist extension voluntarily (exceeding 10% of their initial MVC), which then triggers NMES and inflation of the robotic hand to assist finger opening.
214618236|NCT07112911|BEHAVIORAL|Occupational Therapy with Electrical Stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the OT training, the stroke participants will perform functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
214716763|NCT00034151|DRUG|S-8184 Paclitaxel Injectable Emulsion|
214716764|NCT00644124|DRUG|aflibercept|in combination with standard treatment R-CHOP
214722137|NCT04409626|OTHER|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
214722138|NCT03205189|OTHER|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
214716765|NCT05380960|DEVICE|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
214716766|NCT03854812|DRUG|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
214618237|NCT07112911|BEHAVIORAL|occupational therapy with sham electrical stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with sham trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with 0mA-intensity tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the training, the stroke participants will repeatedly practice functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
214618238|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
214618239|NCT06918834|OTHER|Immediate HSCT Group|Patients undergo direct allogeneic HSCT.
214618240|NCT06918834|OTHER|Bridging Therapy Group|"Patients receive one to two cycles of bridging therapy before undergoing allogeneic HSCT.~o Bridging Therapy Regimen: Hypomethylating agents (HMA) alone or HMA-based combination chemotherapy, e.g., azacitidine (AZA) 100 mg/day + venetoclax (VEN) 400 mg/day for 7 days. Targeted therapies (e.g., IDH1 inhibitors) will be used for eligible patients."
214618241|NCT07107659|DRUG|ONT01 is a small molecule CD11b modulator.|ONT01 will be administered orally twice daily (in the morning and in the evening at approximately 12 hours apart and approximately the same time each day) and should be taken as whole tablets (not crushed) under fasted conditions (2 hours before and 1 hour after each dose) with 8 oz/240 mL of water.
214618242|NCT04497844|DRUG|Niraparib|Participants will receive Niraparib 200 mg once daily.
214618243|NCT04497844|DRUG|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
214618244|NCT04497844|DRUG|Prednisone|Participants will receive prednisone 5 mg once daily.
214618245|NCT04497844|DRUG|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
214618246|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
214618247|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
214618248|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
214618249|NCT05765474|BEHAVIORAL|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
214618250|NCT05765474|BEHAVIORAL|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
214618251|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0.5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
214618252|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0.5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
214618253|NCT07147816|DEVICE|Transcutaneous electrical stimulation of the cervical spinal cord (tSCS)|All participants enrolled in this group will receive non-invasive transcutaneous electrical stimulation of the cervical spinal cord (tSCS) while performing strength, spasticity and motor control assessment tasks. Researchers will assess the immediate effects of tSCS (within the same experimental session) on arm and hand movements in individuals with motor impairments caused by traumatic brain injury.
214618254|NCT07149844|DRUG|tea tree oil ointment|Petrolatum (petroleum jelly) was sterilized in the oven at 160°C for 90 min, then The ointment was prepared as 10% .
214618255|NCT07157917|OTHER|Protocol based|Apply a thirst safety management protocol
214618256|NCT07157917|OTHER|Control|Room air water
214716767|NCT03854812|DRUG|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
214716768|NCT03854812|DRUG|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
214716769|NCT00935337|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
214618257|NCT07158229|OTHER|Questionnaires|Complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.
214618258|NCT07154992|DIETARY_SUPPLEMENT|Probiotic - Lacticaseibacillus rhamnosus CRL1505|The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU/g, with corn starch and maltodextrin as excipients.
214618259|NCT07154992|DIETARY_SUPPLEMENT|Placebo|The placebo product is provided in 2g sticks of corn starch and maltodextrin.
214618260|NCT07154784|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) will be performed at weeks 0 and 4 of study enrollment by administering approximately 250-300 cc of a multi-donor fecal suspension into the colon via sigmoidoscopy, colonoscopy, or by oral administration of an equivalent amount (4 capsules).
214716770|NCT00935337|BEHAVIORAL|Sleep Hygiene|treatment as usual
214716771|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
214716772|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
214618261|NCT07154979|DRUG|Oliceridine Injection|"Adult participants receive a single IV bolus of oliceridine (initial dose 45 µg/kg for ages 18-65 y or 40 µg/kg for ≥65 y). Two minutes later, propofol 2 mg/kg IV is administered. Upon loss of consciousness (MOAA/S ≤ 1), rocuronium 0.6 mg/kg IV is given. Direct laryngoscopic tracheal intubation is performed after full muscle relaxation. Blood pressure and heart rate are recorded at baseline, 2 min post-oliceridine, immediately pre-intubation, and for 3 min post-intubation. A positive hemodynamic response is defined as ≥ 20% increase in MAP or HR, HR ≥ 120 bpm, or SBP ≥ 180 mmHg. Subsequent oliceridine doses are adjusted ± 3 µg/kg based on the prior patient's response until seven response crossovers are observed, allowing estimation of ED₅₀ and ED₉₅."
214618262|NCT07153029|BEHAVIORAL|Smartphone based cognitive tasks|"15 days Smartphone/Cellphone tasks: Using NeuroUX smartphone testing software, Cognitive games/tasks lasting approximately 3-4 minutes each will be administered through the a smartphone application and will be prompted via text message twice per day across 15 consecutive days in the morning (8-11am) and evening (5-8). Tasks were chosen to measure aspects of diverse aspects of cognitive that are impaired among patients taking methadone, including N-back task (working memory), the Stroop Task (executive function/cognitive control), and the Variable Difficulty List Memory Test (learning and memory). The 15 days will include two types of task administration: a) Testing Phase: tasks administered at a consistent, fixed difficulty level (days 1-5) b) Remediation Phase: increasing task difficulty in response to participant performance (days 6-15). To encourage adherence, researchers will contact participants to remind them of task completion."
214716773|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
214716774|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
214618263|NCT07151105|DIETARY_SUPPLEMENT|Vitamin C|Participants will receive a vitamin C supplement while following a low vitamin C diet to achieve adequate vitamin C status in a blinded manner. This will be compared to participants receiving a placebo while following a low vitamin C diet that is expected to maintain inadequate vitamin C status.
214618264|NCT07151105|DIETARY_SUPPLEMENT|Placebo + Low Vitamin C Diet|Participants will receive a placebo while following a low vitamin C diet to achieve inadequate vitamin C status in a blinded manner. This will be compared to participants receiving a vitamin C supplement while following a low vitamin C diet that is expected to maintain adequate vitamin C status.
214618265|NCT07155967|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
214618266|NCT07155122|DRUG|Drug: Serplulimab|serplulimab Serplulimab , 300mg, D1, intravenous drip , Q3W.
214618267|NCT07155122|DRUG|Drug: Etoposide|Etoposide, 60-100 mg/m², D1-3 or D1-5, intravenous drip, Q3W
214618268|NCT07155122|DRUG|Drug: Chemotherapy|Cisplatin, 50-75 mg/m², D2, intravenous drip, Q3W. Or Carboplatin, AUC 5, D2, intravenous drip, Q3W.
214618269|NCT07159503|PROCEDURE|Vortex Intelligence Stone Optimized Removal|Vortex Intelligence Stone Optimized Removal integrates irrigation-suction, pressure monitoring-control, and lithotripsy-stone removal functions, aiming to improve stone clearance efficiency, stabilize intrapelvic pressure, and reduce complications.
214618270|NCT07159503|PROCEDURE|Percutaneous Nephrolithotomy (PCNL)|A standard PCNL technique will be performed according to institutional practice guidelines.
214618271|NCT07158476|DRUG|Meloxicam 15 mg|PO once/day for 1 week
214618272|NCT07158476|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|PO 6 day taper
214618273|NCT07158476|DRUG|Gabapentin 300 mg|PO every 8 hours for 1 week
214618274|NCT07158476|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|PO 1-2 tabs every 4 hours as needed (total of 28 pills)
214618275|NCT07158476|DRUG|Ketorolac 10 Mg Oral Tablet|PO every 6 hours for 5 days
214618276|NCT07161648|OTHER|neuromuscular electrical stimulation|The study participants will engage in 100-minutes of neuromuscular electrical stimulation (NMES). NMES pads are sticky pieces of plastic, similar in size to a 25-cent coin. The pads will be placed on the bellies of thigh muscles (the vastus lateralis, vastus medialis), and calf muscles (the long and short head of the gastrocnemius). These skeletal muscles are selected due to their size (thereby promoting a bigger increase for metabolic rate compared with a small muscle), because they are relatively superficial, and because previous published studies of NMES used these anatomical locations.
214618277|NCT07161063|BEHAVIORAL|Brief Family Therapy Program|The Lausanne Family Play - Brief is a video-feedback intervention adapted for families seeking support for a child two to nine years old with a mental health challenge. Feedback focuses on engagement, teamwork, conflict, and child-focused issues.
214618278|NCT07159789|DEVICE|Repetitive Transcranial Magnetic Stimulation|Treatment with the rTMS or sham rTMS will be scheduled daily 5x per week for a total of 6 consecutive weeks followed, after a 6 week pause, by another treatment session of 6 weeks where all patients will receive active rTMS treatment
214618279|NCT07161479|PROCEDURE|Argon Plasma Coagulation (APC)|Ablation of gastric adenoma using argon plasma coagulation.
214618280|NCT07161479|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic resection of gastric adenoma by mucosal resection technique.
214618281|NCT07159958|OTHER|Simulation-Based Vulvar Cancer and Self-Vulvar Examination Training|The topics covered include the definition of vulvar cancer, risk factors, symptoms, preventive measures to protect against cancer, the definition of KKVM, and the steps involved in performing an examination. The inspection phase of the examination was demonstrated using a light source and mirror on a simulated model of the external genitalia. In addition, the topic was reiterated by explaining on the model how palpation examination is performed, when it should be performed, what signs and symptoms to look for, and in which cases a doctor should be consulted.
214618282|NCT07161180|DRUG|PBK_M2301 (levodropropizine + Pelargonium sidoides extract)|A single oral tablet containing levodropropizine 60 mg and Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
214618283|NCT07161180|DRUG|R1_PBK_M2301 (levodropropizine)|A single oral tablet containing levodropropizine 60 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
214618284|NCT07161180|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|A single oral tablet containing Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
214618285|NCT07157852|DRUG|Mirogabalin|For the mirogabalin group, therapy will begin at 5mg twice daily. If the pain will remain inadequately controlled after one week without significant adverse effects, the dose will be escalated in 5 mg per day increments at weekly intervals, with a maximum allowable dose of 15mg twice daily.
214618286|NCT07157852|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
214618287|NCT07161336|DRUG|Methotrexate (MTX)|One group will receive MTX, starting with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated. another group will receive placebo
214618288|NCT07161336|DRUG|Placebo|The investigational drug and the placebo will be formulated to be identical in appearance, packaging, labeling. Blinded study medications will be prepared, packaged, and labeled by the sponsor according to Good Manufacturing Practice (GMP) standards. All packaging will use neutral labeling with unique subject numbers only.
214618289|NCT07160998|OTHER|Digital Lifestyle Therapeutic|Personalized real-time lifestyle recommendations delivered via smartphone/tablet, integrating CGM and wearable data.
214618290|NCT07160998|BEHAVIORAL|Standard Care|Participants receive standard diabetes management including medications and lifestyle recommendations based on guidelines.
214618291|NCT07146880|DRUG|Empagliflozin (EMPA)|Participants will take Empagliflozin once daily, starting at 10 mg. The dose will be increased to 25 mg at monthly follow-ups if participants are non-responders based on ECG ST-segment morphology. The total treatment period is three months.
214618292|NCT07165444|DRUG|Potassium-Competitive Acid Blocker|Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.
214618293|NCT07165444|DRUG|Proton Pump Inhibitor|Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.
214618294|NCT07161310|DIETARY_SUPPLEMENT|Urolithin A|Patients will receive urolithin A (UA) 1,000mg QD on from day -7 until day 60 (±7) of first-line ICI-based SACT.
214618295|NCT07161310|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo (PBO) on from day -7 until day 60 (±7) of first-line ICI-based SACT.
214618296|NCT07161310|OTHER|Bio specimens|Bio specimens (PBMC, plasma, stool) will be collected during screening and on days 1, 26 (±7) and 60 (±7) of ICI.
214618297|NCT07170020|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen has been shown in several case studies and retrospective studies to possibly improve mortality and morbidity in this patient population. One limitation of prior studies is many of them are retrospective. This study will be prospective.
214618298|NCT07171619|DRUG|Nirogacestat|oral dose of 150 mg nirogacestat
214618299|NCT07171619|DRUG|Nirogacestat and Famotidine|oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine
214618300|NCT07171619|DRUG|Nirogacestat and Rabeprazole|oral dose of 150 mg nirogacestat and oral dose of 20 mg rabeprazole
214618301|NCT07171021|DRUG|Theophylline 200 mg|taking theophylline (400 mg twice a day) and performing olfactory training for 6 months
214618302|NCT07171021|BEHAVIORAL|olfactory training|performing olfactory training for 6 months
214618303|NCT07169695|DIAGNOSTIC_TEST|Slit Lamp Examination|The participant will have a slit lamp examination
214618304|NCT07169695|DIAGNOSTIC_TEST|Far Best Corrected Visual Acuity (BCVA)|The participant 's BCVA will be evaluated.
214618305|NCT07169695|DRUG|T1695|The participant should instill T1695.
214618306|NCT07169695|DRUG|Ciclosporin|The participant should instill Ciclosporin.
214618307|NCT07169695|DIAGNOSTIC_TEST|Corneal fluorescein staining score on modified Oxford scale|One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
214618308|NCT07169903|PROCEDURE|Pulmonary segmentectomy|Segmentectomy is applied to lung adenocarcinomas with a diameter of 2-3 cm, in which intraoperative frozen pathology confirms a new pathological grade of 1-2.
214618309|NCT07171684|DRUG|Insulin glargine alone|Once daily dosing of insulin glargine
214618310|NCT07171684|DRUG|Insulin glargine + insulin lispro|Once daily dosing of insulin glargine + three times daily dosing of insulin lispro with meals
214618311|NCT07170475|DRUG|Febuxostat|Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
214618312|NCT07170475|DRUG|Inosine|Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
214618313|NCT07171463|PROCEDURE|Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation|Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter
214618314|NCT07171463|PROCEDURE|Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion|Targeted application of radiofrequency energy at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical location of the superior paraseptal parasympathetic ganglion.
214618315|NCT07170579|OTHER|Exercise|Participants engaged in High-Intensity Interval Training (HIIT) sessions three times per week, each lasting 60 minutes. Sessions included a 10-minute warm-up, a central HIIT block with cycles of aerobic exercises performed at high intensity (30-60 seconds) alternated with active recovery (60-90 seconds), followed by a 10-minute aerobic functional segment and a 10-minute cool-down with stretching. Exercises included modified jumping jacks, stationary marching, high knees, squats, and functional movements tailored to the participants' physical capacity. Training intensity was monitored using the Borg Rating of Perceived Exertion scale, targeting 13-17 during effort phases and 9-11 during recovery.
214618316|NCT07170644|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
214618317|NCT07170228|DIETARY_SUPPLEMENT|Micellar Casein|"Participants consumed 30 g of micellar casein powder dissolved in 300 mL of water.~Supplement timing varied by group:~Post-Exercise Casein Ingestion Group (PECIG): Taken 10-15 minutes after completing the standardized high-intensity resistance training session.~Pre-Sleep Casein Ingestion Group (PSCIG): Taken 30-60 minutes before bedtime on the same day as the training session.~The control group received no supplementation. All supplements were prepared and monitored by the research team to ensure dosage accuracy and participant compliance."
214618318|NCT07171593|DIETARY_SUPPLEMENT|HMB|EEN+HMB
214716775|NCT04541732|OTHER|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
214716776|NCT04541732|OTHER|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
214716777|NCT04541732|DRUG|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
214716778|NCT04541732|DRUG|Muscle Relaxant|Atracurium : 0.5mg/Kg.
214716779|NCT04541732|DRUG|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
214716780|NCT01810549|DRUG|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
214618319|NCT07170683|OTHER|MAIA Microperimetry|Microperimetry (MP) is not performed as part of the current NHS patient pathway. We plan testing 2 MP strategies ('standard' vrs 'fast') to determine whether the fast testing strategy is as robust as the standard test strategy. Adopting the fast strategy will reduce time spent on the MP machine to obtain relevant test results. Healthy volunteers (with no retinal disease) are necessary for comparison, and to establish validity of any new findings.
214618320|NCT07170683|DEVICE|Microperimetry|Two fully automatic MAIA MP (CenterVue, spa; Padova, Italy) examinations (to obtain retinal sensitivity) shall be performed over the 10° diameter central retinal area for the recruited study participants. The first one will be performed with a fast projection, and the second one with the standard full 4-2 staircase projection strategy. Identification of the PRL area will be automatically calculated at the end of each examination. All patient groups will have identical assessment, at all time points. Healthy volunteers will only have assessments at baseline (one examination only)..
214716781|NCT01810549|DRUG|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
214716783|NCT04446871|DRUG|0.9% sodium chloride|Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
214716784|NCT04446871|DRUG|Methylene Blue|Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
214716785|NCT02669199|BIOLOGICAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
214716786|NCT06098196|DRUG|Aminophyllin|Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
214716787|NCT04759313|BEHAVIORAL|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
214716788|NCT02899806|OTHER|Written Information|A written information on peridural anesthesia is delivered
214716789|NCT02899806|OTHER|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
214618321|NCT07170683|OTHER|Visual Acuity Measurement (logMAR)|Visual acuity will be measured with the ETDRS chart, and with the participant habitual distance correction, and recorded in logMAR notation
214618322|NCT07170683|DEVICE|OCT-A|OCT and OCT-A examination, as well FAF will be undertaken with the Topcon Triton Plus OCT
214618323|NCT07169916|DRUG|Yueju Pill + Standard Anti-tumor Therapy|Group A (Intervention): Standard therapy + Yueju Pill (6-9 g per dose, twice daily, orally until disease progression or intolerable toxicity).
214618324|NCT07169916|DRUG|Placebo + Standard anti-tumor therapy|Group B (Control): Standard therapy + placebo (identical in appearance, packaging, dosage, and administration frequency to Yueju Pill).
214618325|NCT07170774|DEVICE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
214716790|NCT05430672|DEVICE|The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. )|This is a objective performance criteria-controlled study, all subjects meet the criteria will receive the same treatment using the thoracic aortic stent graft system (Zylox-Tonbridge Medical Technology Co., Ltd. ).
214716791|NCT04034043|DEVICE|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
214716792|NCT04949555|OTHER|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
214716793|NCT01760187|DRUG|lomitapide|
214716794|NCT01794013|BEHAVIORAL|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
214716795|NCT01794013|BEHAVIORAL|Routine care|routine care
214716796|NCT05737407|OTHER|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
214716797|NCT05737407|OTHER|Standard choice of Peep|Choice of Peep according to standard practice
214716798|NCT01626053|BEHAVIORAL|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
214716799|NCT01626053|OTHER|Control Group|no intervention
214716800|NCT02401243|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
214618326|NCT07170774|DEVICE|Sham|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
214618327|NCT07171476|PROCEDURE|Guided bone regeneration|traditional guided bone regeneration will be done in which a flap will be raised under local anesthesia, followed by atraumatic extraction of the tooth, after which a 3D guided osteotomy will be done and the implant will be inserted, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing
214618328|NCT07171476|PROCEDURE|bone ring technique|bone ring technique will be applied in which the same procedure as group A will be followed till tooth extraction, after which a trephine bure will be inserted through a 3D guide to prepare the site to receive the bone ring. The osteotomy will be done through the bone ring and the implant will be inserted to fix the implant in place, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
214716801|NCT02853955|DEVICE|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
214716802|NCT05942729|OTHER|Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone|The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
214716803|NCT01930240|DRUG|TRIA-662|1-MNA Chloride
214716804|NCT01930240|DRUG|Placebo|Double-blind placebo
214716805|NCT06229587|PROCEDURE|furlow with buccinator flap|Assessment of speech and the middle ear function of patients between the age of 3 and 7 years surgically treated by ARC (Furlow z-palatoplasty with a buccinator myomucosal flap) was done
214716806|NCT06202209|PROCEDURE|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
214716807|NCT04876599|BEHAVIORAL|IN FOCUS|Adapted Resiliency Group Intervention
214716808|NCT04876599|BEHAVIORAL|Usual Care|Referral to Virtual Group Support
214716809|NCT04193670|OTHER|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
214722139|NCT00937326|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
214722140|NCT00937326|DRUG|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
214618329|NCT07171476|PROCEDURE|Tent pole technique|tent pole technique will be applied in which the same procedure same as group A will be followed till implant insertion. Two monocortical screws will then be inserted using 3D guide, mesial and distal to the implant and extending 3 mm outside the bone, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
214618330|NCT07171073|DEVICE|RecoveriX|RecoveriX is a brain-computer interface (BCI) system designed for motor rehabilitation after stroke. It records brain activity using EEG and provides real-time feedback through virtual reality and functional electrical stimulation (FES). Participants imagine hand movements, and the system activates corresponding virtual movements and stimulates the muscles to support motor recovery.
214722141|NCT03225560|OTHER|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
214618331|NCT07171073|DEVICE|Gloreha Aria|Gloreha Aria is a robotic therapy system for upper limb rehabilitation. It combines mechanical assistance with virtual reality tasks to restore hand and finger movements. The device can be used in passive, assistive, or active modes, depending on the patient's abilities, and provides interactive exercises to improve motor function and neuroplasticity.
214618332|NCT07171073|DEVICE|E-Link System|E-Link is an interactive computer-based system for hand and finger rehabilitation. It uses sensors to capture movements and provides individualized motor training through interactive tasks. The system allows both active motor practice and objective assessment of fine motor skills and functional abilities.
214618333|NCT07171073|OTHER|Standard Occupational Therapy|The control group will receive conventional occupational therapy as part of standard rehabilitation. Therapy will include individualized exercises to improve motor, cognitive, and functional abilities, consistent with usual clinical practice.
214618334|NCT07170358|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
214618335|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
214618336|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
214618337|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
214618338|NCT07170514|PROCEDURE|EIT-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O.~On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the EIT-GROUP optimal PEEP is considered as the intersect between the lower percentage of overdistension and collapse, based on the diagnostic tool of the EIT device."
214618339|NCT07170514|PROCEDURE|Cdyn-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O. On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the Cdyn-GROUP optimal PEEP is considered as the PEEP value resulting the highest possible Cdyn measured by the ventilator."
214618340|NCT07171190|OTHER|Lung Cancer Screening Invitation Intervention|Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message
214618341|NCT07171190|DIAGNOSTIC_TEST|Abdominal scan intervention|Receiving an abdominal CT scan at the same time as the lung scan.
214618342|NCT07171229|PROCEDURE|Pulpotomy|"* Local anesthesia will be administered, and the tooth will be isolated with a rubber dam.~* To minimize further bacterial contamination, carious tissues will be removed progressively, starting from the cavity periphery and then over the pulp chamber roof.~* Before managing the pulpal hemorrhage, a sterile cotton pellet will be placed over the pulp tissue for 30-45 s.~* A fresh sterile bur will be used to remove all coronal pulp tissue down to the root canal orifices, with copious water irrigation~* MTA will be used as medicament of choice for pulpotomy.~* The pulpotomy-treated tooth will be prepared to receive a full-coverage stainless steel crown (SSC) after the procedure."
214618343|NCT07171229|OTHER|Measuring Cytokines level|measuring cytokines level as an indicator for pulp inflammation
214618344|NCT07170449|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
214618345|NCT07170449|DIAGNOSTIC_TEST|Median nerve ultrasonography|Median nerve sonographic cross-sectional area and echogenicity measurements
214618346|NCT07170449|DIAGNOSTIC_TEST|Sensory testing|tactile sensory tests
214722142|NCT02578992|PROCEDURE|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
214618347|NCT07169864|PROCEDURE|Simple Surgical Glove Compression Technique|Patients will wear surgical gloves of smaller size than the patient's hand, on the dominant hand from 15 minutes before the start of each neoadjuvant chemotherapy infusion until 15 minutes after the end of infusion (total of 90 minutes). The non-dominant hand will serve as the untreated control.
214618348|NCT07169656|DRUG|ETV,TDF,TAF,TMF|treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)
214618349|NCT07169656|DRUG|Peginterferon α-2b injection|treated with Peginterferon α-2b injection
214618350|NCT07171060|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
214618351|NCT07170488|BEHAVIORAL|Yoga|The LoveYourBrain (LYB) Yoga program is a six-week, evidence-based, light intensity Yoga and meditation curriculum developed for individuals living with TBI. It is delivered online and synchronously, the program is led by experienced instructors with more than a decade of teaching experience in Yoga. Each weekly session is 75 minutes and combines gentle postures, guided breathing exercises (pranayama), Yoga nidra (deep relaxation), and meditation practices. Before each of the Yoga sessions, participants are e-mailed prerecorded tools that focused on a specific theme for the week (resilience, mindfulness etc.)
214618352|NCT07170488|BEHAVIORAL|Yoga for wait list control|After the active Yoga group received the intervention, the wait list control was then assigned to the intervention.
214618353|NCT07160452|DRUG|Levocarnitine Injection|1,000 mg levocarnitine IV (slow IV push or infusion per unit policy) post-hemodialysis, three times weekly for 6 months (\~72 doses). Administered in the dialysis unit in addition to usual ESA-based anemia care.
214618354|NCT07160452|OTHER|Usual ESA-Based Anemia Care|Standard-of-care anemia management using recombinant human erythropoietin (ESA) per unit protocol. Typical initial dosing: 50-100 U/kg/week if Hb \<10 g/dL (in 2-3 doses/week); 50 U/kg/week if Hb 10-11 g/dL; 25-50 U/kg/week as maintenance if Hb 11-12 g/dL. ESA dose adjusted monthly using ERI and Hb/Hct targets (generally Hb 10-12 g/dL).
214618355|NCT07158749|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
214618356|NCT07158749|BEHAVIORAL|Episodic Recent Thinking (ERT)|Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
214618357|NCT07158749|BEHAVIORAL|Domain-specific episodic thinking|Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).
214618358|NCT07158749|BEHAVIORAL|Generalized episodic thinking|Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).
214618359|NCT07160062|BEHAVIORAL|Mandala painting|Each mandala painting process took a total of 35 to 50 minutes, consisting of 30 to 40 minutes for mandala painting and drawing and 5 to 10 minutes for explaining the painted mandala.
214618360|NCT07165860|BEHAVIORAL|Doula Thrive|The intervention will be pairing intimate partner violence survivors with a trained doula
214618361|NCT07165860|BEHAVIORAL|Thrive|The active control arm will include pairing intimate partner violence survivors with IPV advocates
214618362|NCT07170371|OTHER|patient education|A culturally adapted patient education program designed for individuals with rheumatoid arthritis. The program was developed through a structured needs assessment and based on established health behavior theories. It includes five core modules delivered over six months: understanding rheumatoid arthritis, monitoring disease activity, treatment strategies, nutrition, and stress management. Sessions combine group workshops and individual support, with interactive materials and practical exercises. The program aims to strengthen patients' knowledge, self-management skills, and quality of life compared to usual care.
214618363|NCT07170371|OTHER|Usual Care|patients will receive usual care only
214716810|NCT04193670|PROCEDURE|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
214618364|NCT07171502|DEVICE|AI Annotation|Use the AI model to assist in annotating the target images.
214716811|NCT04193670|OTHER|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
214716812|NCT03175562|OTHER|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
214716813|NCT03175562|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
214716814|NCT04747522|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
214716815|NCT00006372|DRUG|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
214716816|NCT00006372|DRUG|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
214716817|NCT00006372|DRUG|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
214716818|NCT02937532|BEHAVIORAL|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
214716819|NCT02937532|BEHAVIORAL|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
214716820|NCT02146833|DRUG|Selinexor|Comparison of different dosages and dosing schedules of drug.
214716821|NCT01963754|DEVICE|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
214716822|NCT01963754|DRUG|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
214716823|NCT01963754|DRUG|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
214618365|NCT07171502|OTHER|manual annotation|Use the manual to annotate the target images.
214618366|NCT07170917|DRUG|Brivekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
214716824|NCT02823080|DRUG|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
214618367|NCT07170917|DRUG|Placebo|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
214618368|NCT07171541|DIAGNOSTIC_TEST|OCT ,mFERG,VA test|retinal photography by OCT, VA measurement, and mfERG test
214618369|NCT07170059|BIOLOGICAL|herpes zoster vaccine|Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
214618370|NCT07170696|BEHAVIORAL|nutrition education|dialogic reading-based nutrition education
214618371|NCT07171086|DEVICE|AI-POCUS (BabyChecker, Delft Imaging)|A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
214618372|NCT07171086|DEVICE|AI-POCUS (Edan, China)|An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
214618373|NCT07171138|DEVICE|Positioning and positioning devices|"Different positioning strategies and positional devices. Measurement of skin interface pressure at key anatomical pressure points (occiput, elbows, sacrum, heels) under different patient positioning strategies and positional devices.~The positions that produce the least amount of pressure are identified and will be implemented and compared with pre-intervention hospital acquired pressure injuries (HAPI)"
214716825|NCT07089927|PROCEDURE|Art Therapy|Complete virtual art therapy sessions. When complete the participant will receive a 3D printed replica of the avatar.
214618374|NCT07169968|DEVICE|clear aligners group|patients with lower anterior crowding, after randomization and allocation, will receive intraoral scanning to create a digital model. using computer software, teeth segmentation, setup and stagging of tooth movement will be carried out. models for each stage of tooth movement will be three-dimentionally printed and the aligners will be thermoformed over each model. patients are instructed to wear each aligner for a week then continue to the next aligner till treatment is finished
214618375|NCT07169968|DEVICE|micro-osteoperforations group|patients having lower anteriro crowding, after randomization and allocation, aligners will be produced for them. patients in this group will receive micro-osteoperforation using mini-implants before wearing the first aligner and after one month from starting treatment.
214716826|NCT07089927|OTHER|Interview|Ancillary studies
214716827|NCT07089927|OTHER|Survey Administration|Ancillary studies
214716828|NCT00522574|DRUG|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
214716829|NCT00676208|BEHAVIORAL|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
214716830|NCT00236522|DRUG|levofloxacin|
214716831|NCT05867199|BEHAVIORAL|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
214716832|NCT04370730|OTHER|clinical, neuroimaging and DNA assessments|Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
214716833|NCT04532918|DRUG|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
214716834|NCT04532918|DRUG|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
214716835|NCT04532918|DRUG|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
214618376|NCT07170280|PROCEDURE|Direct Infrapectineal Plating in Quadrilateral Plate Acetabular Fractures: A Prospective Cohort Study|This study aims to evaluate the outcomes of direct infrapectineal plate fixation in patients with quadrilateral plate acetabular fractures. A total of 25 adult patients with acute fractures were enrolled between 2021 and 2024 at a university-affiliated hospital. All patients underwent surgical fixation through the ilioinguinal approach. Radiological results were assessed using the Matta scoring system, and functional outcomes were evaluated using the Merle d'Aubigné and Postel scoring system. The study further assessed complication rates, operative time, intraoperative blood loss, and hospital stay.
214618377|NCT07170553|BEHAVIORAL|Digital Game|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will engage with a digital game prototype. The game involves brief relationship enhancing activities focused on different domains of attachment with the purpose of facilitating appropriate and healthy playful interaction between parents and children.
214618378|NCT07170553|BEHAVIORAL|Control|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will receive pamphlets with information regarding play based attachment activities and be given the chance to engage in said activities.
214618379|NCT07171554|DIAGNOSTIC_TEST|µCAN drug screen test|µCAN guided therapy is based on drug screening of patient-derived tumoroids. The patient might be treated with clinically relevant on-label or off-label drugs
214618380|NCT07171554|OTHER|Standard-of-Care Therapy|trifluridine/tipiracil/bevacizumab combination, 28 day cycles
214618381|NCT07169994|DRUG|YL202 for injection; Toripalimab injection|"Part 1: YL202 and Toripalimab will be administered intravenously.~Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined.~Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab"
214716836|NCT04532918|DRUG|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
214618382|NCT07169994|DRUG|YL202 for injection; Furmonertinib Mesilate Tablets|"Part 2: YL202 will be administered intravenously，Furmonertinib Mesilate Tablets will be administered orally.~Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined.~Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate."
214618383|NCT07159061|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
214618384|NCT07159061|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
214618385|NCT07161557|OTHER|No Intervention: Observational Cohort|No intervention involved, participants will fill out some questionnaires and blood samples will drawn for test and analysis.
214618386|NCT07171203|DRUG|Imatinib|Tyrosine kinase inhibitor. Imatinib will be dosed at 400 mg once a day. Dose can be reduced by 100 mg per dose reduction step if clinically indicated.
214618387|NCT07171203|DRUG|Fampridine|Voltage-gated potassium channel (VGKC) blocker. Fampridine will be dosed in a 3+3 design at 10 mg given either every 2 days, or every day, or twice a day.
214618388|NCT07170319|DRUG|IBI3032|IBI3032. Method of administration: oral, fasted administration.
214618389|NCT07170319|DRUG|placebo|Placebo (without active ingredients). Method of administration: oral, fasted administration.
214618390|NCT07169773|DEVICE|Rezum|Rezum procedure in Rezum group
214618391|NCT07169773|DRUG|Tamsulosin|Tamsulosin were given to Tamsulosin group
214618392|NCT07170215|DEVICE|antigravity treadmill (ALTERG VIA, Lifeward CA, Inc., Milmont Drive, Fremont, CA, U-SA)|Antigravity treadmill training in the experimental group (EG) involved walking in a straight line at a self-selected, com-fortable pace-without running, shortness of breath, or pain. The treadmill's chamber was set to reduce the participant's effective body weight to 20% of their actual body weight (slight unloading was applied to reduce the need for handrail support and to prevent the use of compensatory mechanisms).
214618393|NCT07171398|OTHER|Functional Performance Testing Battery|"Participants performed a standardized battery of sport-specific performance tests during a single laboratory session, including:~Countermovement Jump (height, power, flight time)~5-10-5 Pro-Agility Shuttle Test~Acceleration-Deceleration-Acceleration (ADA) Test~Side Jump Test~6-Meter Timed Hop Test~Single-Leg Hop Test~Triple Crossover Hop Test~Lateral Hop Test Performance was assessed using the Deepsport AI program and standard timing/distance protocols. Results compared between CAI and control cohorts."
214618394|NCT07171645|OTHER|Assessment regarding gender-affirming care|No comparison
214618395|NCT07169682|DRUG|interleukin 17 inhibitor|52 weeks
214618396|NCT07169682|DRUG|interleukin-23 inhibitor|52 weeks
214618397|NCT07169682|DRUG|conventional systemic agent or apremilast|52 weeks
214618398|NCT07171710|DRUG|0.05% Cyclosporine Eye Drops|Cyclosporin A 0.05% eye drops were administered twice daily to both eyes
214618399|NCT07171710|DEVICE|Smart plug absorbable lacrimal duct plugs|The lacrimal duct embolization implant is performed by partially sealing the tear discharge duct to increase the lubrication of natural tears on the eye surface.
214618400|NCT07171333|DEVICE|Colonoscopy with CADe system|Patients in the CADe+ arm underwent colonoscopy with CADe DISCOVERY™ (PENTAX Medical, Tokyo, Japan), an AI-driven tool highlighting suspected lesions in real-time, through a light-blue box. The final lesion characterization remained the endoscopist's responsibility.
214618401|NCT07170826|OTHER|Self questionnaire|Rosenberg Scale, SF36, MBRSQ
214618402|NCT07170826|OTHER|interview|Semi-structured individual interviews
214618403|NCT07171346|DEVICE|Zynex NexWave Electrotherapy Device|All participants will use the NMES device in addition to standard rehabilitation
214618404|NCT07171528|PROCEDURE|Secondary Cytoreductive Surgery|"Surgery will only be performed in patients assigned to the experimental arm of the study.~The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority."
214618405|NCT07171216|OTHER|Treat to target|"Participants will receive treatment from a toolbox depending on the situation to reach the PTH target. Available medication is mirroring what is used in the outpatient clinic setting already (native vitamin D, activated vitamin D, phosphate binders, calcimetics)."
214716837|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
214618406|NCT07169838|OTHER|Perinatal Tissue Collection|Collection of perinatal medical waste (amniotic fluid, amniotic membrane, umbilical cord, placenta) at the time of term delivery for laboratory-based mesenchymal stem cell isolation and analysis. No therapeutic or interventional procedure was performed on participants.
214618407|NCT07170982|DRUG|Fruquintinib|This study aims to confirm the safety and efficacy of fruquintinib combined with standard chemotherapy, further compare whether first-line standard chemotherapy has superiority, bring better survival benefits to patients with pMMR endometrial cancer, and provide more options for patients with late recurrent and metastatic endometrial cancer.
214716838|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
214716839|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
214716840|NCT01336166|BIOLOGICAL|Placebo control|120 adults were assigned to receive 1 dose of placebo.
214618408|NCT07171372|OTHER|Device&behavioral|The IoT-HFActive intervention is a 12-month personalized program delivered via a mobile app, integrating patient-centered goal setting, real-time monitoring, and behavioral support. Intervention group participants will first attend two structured education sessions on exercise in HF and the use of the app and smart wristbands. They will then complete 12 supervised group-based sessions (3×50 min/week for 4 weeks) including warm-up, moderate aerobic exercise, and cool-down. Personalized activity goals will be calculated using heart rate reserve (HRR) via the Karvonen formula and exponential weighted moving average (EWMA) based on wristband data. Continuous remote monitoring will display target HR, achieved minutes, calories, and steps, and include daily confirmation prompts. Behavioral support features of the app will provide personalized feedback, motivational messages, visualizations, and monthly goal re-planning to promote adherence and reduce sedentary behavior.
214618409|NCT07170397|DEVICE|Acupuncture Laser Therapy|Application of low-level laser therapy to patients with chronic kidney disease to evaluate its effects on pain, circulation, and functional outcomes
214618410|NCT07169942|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally Drug: placebo administered orally
214618411|NCT07169617|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214618412|NCT07169617|DRUG|Montanide ISA 51 VG|Given SC
214618413|NCT07169617|OTHER|Questionnaire Administration|Ancillary studies
214618414|NCT07169617|BIOLOGICAL|Sargramostim|Given SC
214618415|NCT07169617|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
214618416|NCT07169825|DRUG|Lu-177|Given by IV
214618417|NCT07169825|OTHER|SPECT|SPECT/CT
214618418|NCT07170787|BIOLOGICAL|IMM2510|IMM2510 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM2510 (e.g., 10 mg/kg, 20 mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
214618419|NCT07170787|BIOLOGICAL|IMM01|IMM01 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM01 (e.g., 1 mg/kg, 2 mg/kg, 3mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
214618420|NCT07170124|OTHER|Obstetric exercises|"The intervention will consist of a structured obstetric exercise program administered by a physiotherapist who is permanently employed at the hospital's prenatal education center, ensuring the reliability and standardization of the intervention. The program will be based on the Pregnancy and Exercise Guide (2012) published by the Turkish Ministry of Health and will be delivered in the pregnancy school of a public hospital in eastern Türkiye.~The exercises will be provided at weekly intervals and will include:~Active joint movements to improve mobility and maintain functional range of motion,~Stretching exercises to enhance flexibility and alleviate musculoskeletal discomfort,~Calisthenic bodyweight exercises to promote muscle strength and endurance,~Relaxation and breathing techniques to reduce stress and improve maternal well-being."
214618421|NCT07170384|BEHAVIORAL|Mediterranean Diet|"A structured Mediterranean diet program designed and supervised by a dietitian. The program emphasizes high consumption of olive oil, vegetables, fruits, legumes, whole grains, and fish; moderate intake of dairy and poultry; and low intake of red meat and processed foods. Adherence will be monitored through 10-day interval follow-up phone calls. Assessments will be conducted at baseline and 3 months"
214618422|NCT07170384|BEHAVIORAL|Healthy Eating Advice|Participants will continue their standard medical treatment and will receive general healthy eating advice, as routinely recommended in clinical practice. No additional structured dietary program will be provided. Assessments will be performed at baseline and at 3 months.
214618423|NCT07170306|PROCEDURE|transcatheter aortic valve replacement|Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).
214618424|NCT07171437|DEVICE|Doppler ultra sound|\- Doppler Ultrasound (DUS) To evaluate the abdominal aorta and the 3 main splanchnic vessels: Celiac Trunk (CT) Superior Mesenteric Artery (SMA) Inferior Mesenteric Artery (IMA) An ultrasound examination will be performed after a fasting period of at least 8 hours by a single operator blinded to clinical features. For abdominal vessels, the following parameters were measured: caliber, thickness, echogenicity, peak systolic velocity (PSV), end diastolic velocity (EDV), reverse velocity (RV), mean velocity (MV), resistive index (RI), and pulsatility index (PI).
214618425|NCT07170163|BEHAVIORAL|¡Iniciando! mHealth App|Participants will undergo 12 weekly, 1-hour virtual group sessions (separate for young adults and parents) and weekly, 30-minute individual virtual coaching sessions for young adults (which parents may attend as appropriate). Participants will also engage with the ¡Iniciando! app modules before and after their virtual group meetings. Throughout the approximately three-month study period, participants will complete (e.g., usability, satisfaction, adherence, app usage data).
214618426|NCT07171736|BEHAVIORAL|Virtual Reality chairwork exercise|A chairwork exercise from schema therapy, executed in Virtual Reality
214618427|NCT07171736|BEHAVIORAL|Imagination exercise|A regular schema therapy imagination exercise
214618430|NCT07171658|BEHAVIORAL|Sensitization to Cervical Cancer (CC) screening|Women will receive an awareness letter explaining the importance of cervical cancer screening, the Swiss recommendations and an invitation to schedule an appointment.
214618431|NCT07171658|BEHAVIORAL|Home-based HPV self-sampling|Women will receive a free-of-charge vaginal self-sampling kit for HPV infection.
214618432|NCT07170423|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive automated text messages instructing them to obtain hearing aids. The messages will also include basic information on the prevalence and negative effects of hearing loss.
214618433|NCT07171450|OTHER|Computerized Cognitive Remediation|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Importantly, NeuroFlex personalizes gameplay with adaptive algorithms that adjust difficulty on a trial-by-trial basis. Participants are prescribed a 30-hour dose distributed across 6 weeks. The treatment is completed remotely by the participant within their own home or other private location that is most convenient for the participant."
214618434|NCT07171450|OTHER|Alternative Computer Activities|The active control condition is carefully matched to the experimental condition in duration, computer tablet use, audiovisual stimulation, reward presentation, and interaction with study staff. It involves playing visuospatially-oriented computerized games that do not load on executive functions and watching stimulating educational videos.
214618435|NCT07169578|DRUG|Trontinemab|Participants will receive IV trontinemab.
214618436|NCT07169578|OTHER|Placebo|Participants will receive IV placebo.
214618437|NCT07165483|DRUG|Dexmedetomidine|Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
214618438|NCT07165483|DRUG|Dexmedetomidine|Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
214618439|NCT07165483|DRUG|Saline|Patients will receive saline before induction of anesthesia as a control group.
214618440|NCT07170852|DRUG|Bempedoic acid film coated tablet|1 tablet of 180 mg Bempedoic Acid
214618441|NCT07170852|DRUG|Nilemdo® Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
214618442|NCT05335941|DRUG|Pemetrexed|Given by vein (IV)
214618443|NCT05335941|DRUG|Zimberelimab|Given by vein (IV)
214618444|NCT05335941|DRUG|Etrumadenant|Given by PO
214722143|NCT02578992|DEVICE|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
214722144|NCT01782404|DEVICE|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
214722145|NCT00681291|DEVICE|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
214722146|NCT00681291|DEVICE|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
214618445|NCT05659576|DRUG|Sucralfate|"1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
214618446|NCT05659576|OTHER|Usual Care|Standard supportive care by using opioids.
214618447|NCT05659576|OTHER|One consent|Patient will sign one consent form.
214618448|NCT05659576|OTHER|Two consent|Patient will sign two consent forms.
214618449|NCT03218488|DRUG|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
214618450|NCT06104150|OTHER|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
214618451|NCT05611346|BEHAVIORAL|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
214618452|NCT05712278|DRUG|SAR445419|Cell suspension, by intraveneous (IV) injection
214618453|NCT05712278|DRUG|fludarabine|Solution for injection , by IV injection
214618454|NCT05712278|DRUG|cytarabine|Solution for injection, by IV injection
214618455|NCT05798221|BEHAVIORAL|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
214618456|NCT05798221|OTHER|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
214618457|NCT02516787|OTHER|Parabolic flight|
214618458|NCT02516787|OTHER|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
214618459|NCT02516787|OTHER|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
214618460|NCT05498350|PROCEDURE|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
214618461|NCT03820414|BIOLOGICAL|CRV 101|(Different formulations)
214618462|NCT03820414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
214618463|NCT03516526|DRUG|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
214618464|NCT03870438|DRUG|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
214618465|NCT03488173|DRUG|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
214618466|NCT02386436|DRUG|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
214716841|NCT03427138|BEHAVIORAL|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
214716842|NCT03427138|BEHAVIORAL|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
214618467|NCT02386436|DRUG|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
214618468|NCT03278184|DEVICE|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
214618469|NCT03278184|DEVICE|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
214618470|NCT03278184|DEVICE|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
214618471|NCT00822731|DRUG|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
214716843|NCT04639908|OTHER|Interview|interview with patient
214618472|NCT04481984|OTHER|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
214618473|NCT04481984|OTHER|Care advice|Patients received care advice including avoiding cold exposure and trauma.
214618474|NCT04617951|DIETARY_SUPPLEMENT|Ishige Okamurae extracts group|Ishige Okamurae extracts 300 mg/day for 12 weeks
214618475|NCT04617951|DIETARY_SUPPLEMENT|Placebo group|Placebo 300 mg/day for 12 weeks
214618476|NCT02455570|OTHER|No intervention|No intervention
214618477|NCT04012554|PROCEDURE|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
214618478|NCT04012554|PROCEDURE|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
214618479|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
214618480|NCT01141504|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
214618481|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
214618482|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
214618483|NCT03650842|DEVICE|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
214618484|NCT04171375|DEVICE|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
214716844|NCT05508399|OTHER|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~1. Blood cell samples;~2. Paraffin sample of residual tumor tissue of biopsy;~3. Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
214716845|NCT05435742|BIOLOGICAL|SON-080|Recombinant human interleukin-6 (rhIL-6)
214618485|NCT05988060|OTHER|Experimental Intervention|"Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week."
214618486|NCT04599777|DRUG|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
214618487|NCT02966509|BEHAVIORAL|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
214618488|NCT02170675|DRUG|Dabigatran etexilate|
214618489|NCT02170675|DRUG|Ketoconazole|
214618490|NCT04169087|OTHER|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
214618491|NCT06001996|PROCEDURE|Pericapsular nerve group (PENG) block|Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
214618492|NCT06001996|PROCEDURE|Suprainguinal fascia iliaca plane block|Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
214618493|NCT04327830|OTHER|Decisional needs assessment|Assessment of decision-making needs
214618494|NCT01717287|DRUG|Raltegravir Film-coated Tablet|
214618495|NCT01717287|DRUG|Raltegravir Chewable Tablet|
214618496|NCT01717287|DRUG|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
214618497|NCT03540225|DRUG|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
214618498|NCT03700281|BEHAVIORAL|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
214618499|NCT03700281|BEHAVIORAL|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
214618500|NCT05827159|DRUG|Naltrexone Pill|In the MAUD component, some participants will receive oral Naltrexone in the ED.
214618501|NCT05827159|DRUG|Naltrexone Injection|In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
214618502|NCT05827159|BEHAVIORAL|Brief Negotiation Interview|Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
214618503|NCT05827159|DRUG|Gabapentin Pill|In the MAUD component, ancillary treatment with gabapentin will be provided.
214618504|NCT00404820|DRUG|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
214618505|NCT00404820|DRUG|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
214618506|NCT00404820|DRUG|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
214618507|NCT04541290|DRUG|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
214618508|NCT01976520|BIOLOGICAL|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
214618509|NCT01310790|PROCEDURE|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was \>30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
214618510|NCT03960775|DRUG|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
214618511|NCT03960775|DRUG|saline|Saline infusion during same time period.
214618512|NCT05472467|DRUG|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
214618513|NCT05472467|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
214618514|NCT05472467|DRUG|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
214618515|NCT03870984|DIETARY_SUPPLEMENT|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
214618516|NCT03870984|OTHER|w/oNUTS, low-caloric diet without nuts|low caloric diet
214618517|NCT03095794|OTHER|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
214618518|NCT03095794|OTHER|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
214618519|NCT03095794|OTHER|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
214618520|NCT03095794|OTHER|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
214618521|NCT00351832|DRUG|Vildagliptin|
214618522|NCT02013947|OTHER|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
214618523|NCT02227628|DIETARY_SUPPLEMENT|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
214618524|NCT02227628|DIETARY_SUPPLEMENT|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
214618525|NCT02443363|OTHER|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
214618526|NCT02443363|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
214618527|NCT00907348|DRUG|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
214618528|NCT01993212|DRUG|Androxal 12.5 mg or 25 mg|
214618529|NCT01993212|DRUG|AndroGel 1.62%|
214618530|NCT01993212|DRUG|Placebo Capsules|
214618531|NCT01993212|DRUG|Placebo Gel|
214618532|NCT01018433|BEHAVIORAL|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
214618533|NCT01018433|OTHER|Treatment as usual|Can include other psychotherapy and pharmacotherapy
214618534|NCT02329964|DRUG|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
214618535|NCT02329964|DRUG|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
214618536|NCT00124059|DRUG|Seroquel|400mg/day quetiapine
214618537|NCT00124059|DRUG|Placebo|400mg/day placebo
214618538|NCT05137548|DRUG|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
214722147|NCT05258526|OTHER|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
214618539|NCT05137548|DRUG|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
214618540|NCT01469182|BIOLOGICAL|SCH 39641|Rapidly dissolving tablet sublingually once daily
214618541|NCT01469182|DRUG|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
214618542|NCT02613650|DRUG|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
214618543|NCT02114164|DEVICE|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
214618544|NCT02114164|DEVICE|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
214618545|NCT04798599|OTHER|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
214618546|NCT04798599|OTHER|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
214618547|NCT02687542|DRUG|Placebo|Placebo
214618548|NCT02687542|DRUG|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
214722148|NCT02002065|BIOLOGICAL|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
214618549|NCT02687542|DRUG|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
214618550|NCT02687542|DRUG|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
214618551|NCT02687542|DRUG|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
214618552|NCT01838616|DRUG|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
214618553|NCT01838616|DRUG|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
214618554|NCT02021084|DIETARY_SUPPLEMENT|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
214618555|NCT02021084|DIETARY_SUPPLEMENT|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
214618556|NCT00829075|DRUG|r-FSH|
214618557|NCT00829075|DRUG|HP-hMG|
214618558|NCT00829075|DRUG|r-FSH plus HP-hMG|
214618559|NCT05435651|BEHAVIORAL|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
214618560|NCT05435651|BEHAVIORAL|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
214618561|NCT02751203|BEHAVIORAL|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
214618562|NCT06243874|PROCEDURE|greater occipital nerve block|greater occipital nerve block
214618563|NCT06243874|PROCEDURE|transnasal sphenopalatine ganglion block|transnasal sphenopalatine ganglion block
214618564|NCT04411485|OTHER|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
214618565|NCT05778058|DEVICE|Unilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
214618566|NCT05778058|DEVICE|Bilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
214716846|NCT05243277|OTHER|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
214716847|NCT02564029|DRUG|PF-06372865|Single dose
214716848|NCT02564029|DRUG|Placebo|Placebo for PF-06372865 and placebo for lorazepam
214716849|NCT02564029|DRUG|Lorazepam|2 mg single oral dose
214716850|NCT02235402|DRUG|Lacidipine|
214716851|NCT02235402|DRUG|Bendrofluazide|
214716852|NCT02235402|DRUG|Placebo|
214716853|NCT04126031|DRUG|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
214716854|NCT04126031|DRUG|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
214716855|NCT03118076|DRUG|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
214716856|NCT03118076|DRUG|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
214716857|NCT00131664|DRUG|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
214716858|NCT00131664|DRUG|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
214716859|NCT00131664|DRUG|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
214618567|NCT05778058|DEVICE|Bilateral Sham Stimulation|Participants were shown that the device was working, but no current was given.
214716860|NCT00326157|DRUG|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
214618568|NCT05778058|DIAGNOSTIC_TEST|Bicycle Ergometer Test|Participants in this group were asked to perform bicycle exercise with maximum performance under 30 watts for 30 minutes.
214618569|NCT05778058|DIAGNOSTIC_TEST|Lactat Scout|For lactic acid analysis measurement, the middle fingertip of the athlete is disinfected with an alcohol swab and a blood sample is taken by puncturing the finger.The measuring range is 0.5 - 0.25 mmol/L.
214618570|NCT05778058|DIAGNOSTIC_TEST|Polar H10|RR times transferred to computer with Polar H10 are used in heart rate variability analysis. Heart rate data will be transferred to the Kubios program and heart rate variability parameters will be calculated and data on the autonomic nervous system (RMSSD, PNS index, Stress index, SNS index, pNN50, Power LF, Power HF and LF/HF ratio) will be obtained.
214618571|NCT05778058|DEVICE|Vagustim Device|Vagustim Health Technologies Vagus stimulator device is used for this experiment.
214716861|NCT01344252|DRUG|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
214716862|NCT00002511|RADIATION|low-LET photon therapy|
214716863|NCT00617656|DRUG|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
214716864|NCT00617656|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
214618572|NCT00103974|BIOLOGICAL|BHT-3009-01|
214618573|NCT01652183|DRUG|intravenous paracetamol|
214618574|NCT01652183|DRUG|Placebo|
214618575|NCT06004414|BEHAVIORAL|App-based Cognitive Behavioral Therapy (CBT)|SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
214618576|NCT06004414|BEHAVIORAL|Psychotherapy|Psychotherapy with a licensed clinician at one of the study sites.
214716865|NCT00617656|DRUG|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
214716866|NCT00617656|DRUG|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
214618577|NCT04638972|DEVICE|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
214618578|NCT01441830|DEVICE|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
214618579|NCT05760443|BEHAVIORAL|Learning to BREATHE|"Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
214618580|NCT04042779|OTHER|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
214716867|NCT05264558|DEVICE|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
214716868|NCT05264558|DRUG|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
214716869|NCT05264558|OTHER|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
214716870|NCT03789890|DRUG|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
214716871|NCT03789890|DRUG|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
214716872|NCT00176124|PROCEDURE|leukocyte depletion of whole blood|
214618581|NCT04042779|OTHER|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
214618582|NCT04042779|OTHER|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
214618583|NCT04042779|OTHER|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
214618584|NCT00003535|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214618585|NCT01607736|BEHAVIORAL|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
214618586|NCT05604495|DIAGNOSTIC_TEST|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
214618587|NCT06075589|BEHAVIORAL|Education for Intervention|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
214618588|NCT06075589|BEHAVIORAL|Best Practice|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
214618589|NCT06490588|OTHER|sevoflurane|No intervention
214618590|NCT05675943|BIOLOGICAL|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
214618591|NCT01868256|OTHER|early discharge (<72 h)|
214716873|NCT00176124|OTHER|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
214716874|NCT00554528|DEVICE|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
214716875|NCT00554528|PROCEDURE|arthrodesis - cervical disk surgery|discectomy and arthrodesis
214716876|NCT03397550|OTHER|salt restriction education|Salt intake target：\<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
214618592|NCT01868256|OTHER|Conventional discharge|
214618593|NCT01715753|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
214618594|NCT01715753|BEHAVIORAL|Diet counseling and group education lessons|Individual and group diet counseling to achieve a \>10% weight loss
214618595|NCT04266262|BEHAVIORAL|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
214618596|NCT04266262|BEHAVIORAL|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
214618597|NCT02181816|DRUG|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD \& HD
214618598|NCT04345289|BIOLOGICAL|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
214722149|NCT02002065|BIOLOGICAL|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
214722150|NCT04151446|DEVICE|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
214618599|NCT04345289|OTHER|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
214618600|NCT00867789|DRUG|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
214618601|NCT00867789|DRUG|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
214618602|NCT05650814|DEVICE|ButterfLife|On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.
214618603|NCT05650814|OTHER|Control|Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
214618604|NCT05843851|DIAGNOSTIC_TEST|Diagnostic test|Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
214618605|NCT02705521|DEVICE|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
214716877|NCT00612339|DRUG|Avastin and Temozolomide|This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
214716878|NCT01105936|DRUG|Paracetamol|665 mg sustained release paracetamol caplets
214716879|NCT01105936|DRUG|Placebo|Placebo caplets
214716880|NCT03062267|OTHER|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
214716881|NCT00951119|DEVICE|Resperate|device-guided breathing exercises
214716882|NCT00951119|DEVICE|Resperate|breathing device without slowing of breathing frequency
214716883|NCT04671095|DEVICE|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
214716884|NCT00836524|PROCEDURE|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
214716885|NCT02479386|OTHER|No intervention|No intervention was administered in this study.
214716886|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
214722151|NCT00040469|DRUG|Campath -1H|
214722152|NCT00040469|DRUG|Dilantin|
214722153|NCT00040469|DRUG|Busulfan|
214722154|NCT00040469|DRUG|Cyclophosphamide|
214618606|NCT05915689|OTHER|Myofascial arm pull technique|patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.
214618607|NCT05915689|OTHER|post isometric relaxation technique|The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
214618608|NCT03807349|DEVICE|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
214618609|NCT01399554|BEHAVIORAL|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
214618610|NCT00474396|BEHAVIORAL|Low fat dairy diet|
214618611|NCT01505348|OTHER|Overnight fast|Overnight fast from 21:00 h
214618612|NCT05666336|BIOLOGICAL|Telitacicept|It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
214618613|NCT05666336|DRUG|Hydroxychloroquine|It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
214618614|NCT05666336|DRUG|Prednisone|It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
214618615|NCT05666336|DRUG|Methylprednisolone|It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
214618616|NCT05666336|DRUG|Cyclophosphamide|It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
214618617|NCT05666336|DRUG|Mycophenolate Mofetil|It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
214618618|NCT05666336|DRUG|Tacrolimus|It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
214618619|NCT06475066|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|"After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline."
214618620|NCT06399887|OTHER|Exercise|All patients in these groups are taught diaphragmatic breathing, which is the basis for DNS, and are asked to maintain it throughout the exercises. The DNS protocol includes a 5-minute warm-up, 40 minutes of DNS exercises (10 minutes for each of the 4 different body parts) and breathing exercises. The DNS exercises included diaphragmatic breathing, Baby Rock, Roll Over, Lying on the Side, Sitting Down, Sitting Upright, Tripod, Kneeling, Squatting, Prone, and Pull Up (CGU). The focus of the first week is to teach and practice basic DNS exercises.
214618621|NCT06399887|OTHER|Biofeedback|Patients in Group II and Group III will be trained in animated CP using the Aymed Medical Locum Wireless System v.2.69.0.12 device. During CP, 10-second contraction and 30-second relaxation cycles are maintained throughout the animated game. Each session will last approximately 20 minutes. The training protocol will consist of a total of 12 sessions of 20 minutes per week for 3 months.
214716887|NCT03267407|OTHER|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
214716888|NCT03375970|OTHER|TCM|oral chinese herb, chinese topical ointment
214716889|NCT03375970|OTHER|Western medicine|oral steroid, oral antihistamine, topical steroid
214618622|NCT05138042|OTHER|Cryotherapy (frozen glove)|"In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes."
214716890|NCT01883219|DRUG|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
214716891|NCT01427114|DRUG|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
214716892|NCT02915289|PROCEDURE|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
214716893|NCT02915289|PROCEDURE|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
214716894|NCT03955497|OTHER|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
214716895|NCT03955497|DRUG|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
214716896|NCT03955497|PROCEDURE|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
214716897|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
214716898|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
214716899|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
214716900|NCT00116194|BEHAVIORAL|Physical Activity|
214716901|NCT02657434|DRUG|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
214716902|NCT02657434|DRUG|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
214716903|NCT02657434|DRUG|Cisplatin|Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
214618623|NCT01366547|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
214618624|NCT01366547|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
214618625|NCT01366547|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
214716904|NCT02657434|DRUG|Pemetrexed|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
214716905|NCT00608881|DRUG|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
214618626|NCT06210074|DEVICE|Daye Diagnostic Tampon|"The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746).~The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. The DDT needs to be worn for 20 minutes then when removed should be placed immediately in the sterile container."
214618627|NCT02538874|DRUG|BMS-986171|
214618628|NCT02538874|OTHER|Placebo|
214716906|NCT00608881|OTHER|placebo|an inactive substance
214716907|NCT00336661|DEVICE|PerioWave|
214716908|NCT00074542|DRUG|Epanova™ (Omega-3 Free Fatty Acids)|
214716909|NCT04279652|OTHER|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
214716910|NCT05247983|PROCEDURE|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
214716911|NCT01823757|OTHER|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
214716912|NCT01155791|DRUG|Docetaxel|IV 75 mg/m2
214716913|NCT01155791|DRUG|Biosyn|IV dosage varies
214716914|NCT01155791|DRUG|Prednisone|5mg, orally
214716915|NCT01998958|DRUG|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
214716916|NCT01998958|DRUG|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
214716917|NCT01998958|DRUG|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
214722155|NCT05193604|DRUG|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
214618629|NCT02861209|OTHER|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
214618630|NCT03549156|DIETARY_SUPPLEMENT|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
214618631|NCT03549156|DIETARY_SUPPLEMENT|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
214716918|NCT01998958|DRUG|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
214722156|NCT05193604|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214618632|NCT00603460|BIOLOGICAL|DCVax-L and T Cells|"Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit"
214618633|NCT01914380|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
214618634|NCT01360554|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
214618635|NCT01360554|DRUG|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
214618636|NCT01360554|DRUG|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
214618637|NCT01360554|DRUG|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
214716919|NCT01998958|DRUG|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
214716920|NCT04430946|DIAGNOSTIC_TEST|Standardized test meal|A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
214716921|NCT00484276|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
214716922|NCT01473303|BIOLOGICAL|ganitumab|Given IV
214716923|NCT01473303|DRUG|fluorouracil|Given IV
214716924|NCT01473303|DRUG|irinotecan hydrochloride|Given IV
214716925|NCT01473303|DRUG|leucovorin calcium|Given IV
214716926|NCT01473303|DRUG|oxaliplatin|Given IV
214716927|NCT01473303|OTHER|placebo|Given IV
214716928|NCT01473303|OTHER|questionnaire administration|Completed on paper
214618638|NCT02210065|BIOLOGICAL|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
214618639|NCT05258409|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
214618640|NCT05258409|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
214716929|NCT05428553|PROCEDURE|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
214716930|NCT05428553|PROCEDURE|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
214716931|NCT03808428|DEVICE|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
214716932|NCT05098418|DRUG|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
214716933|NCT04285710|DEVICE|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
214716934|NCT04285710|PROCEDURE|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
214716935|NCT03320889|OTHER|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
214722157|NCT05193604|DRUG|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
214618641|NCT06464107|DEVICE|PadKit™ from Preprogen|"The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval.~The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis."
214618642|NCT05954923|OTHER|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
214618643|NCT00187096|DRUG|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
214618644|NCT00187096|PROCEDURE|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
214618645|NCT00187096|DEVICE|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
214618646|NCT03958227|OTHER|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
214618647|NCT03958227|OTHER|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
214618648|NCT02170883|OTHER|Interactive SMS|
214618649|NCT02170883|OTHER|Usual care|
214618650|NCT01397370|DRUG|GLPG0492|Oral solution
214618651|NCT01397370|DRUG|Placebo|Oral solution
214618652|NCT02422420|BEHAVIORAL|Financial Incentives|Use of financial incentives to promote health behaviors.
214618653|NCT05726799|PROCEDURE|Cryo myectomy|Extended septal myecotmy using cryo energy
214618654|NCT05726799|PROCEDURE|Myectomy|Classic surgical myectomy
214618655|NCT01534247|DRUG|CAZ-AVI|Infusion
214618656|NCT01534247|DRUG|metronidazole|Infusion
214618657|NCT01534247|DRUG|CAZ-AVI + metronidazole|Infusion
214618658|NCT04663789|PROCEDURE|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
214618659|NCT04663789|PROCEDURE|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
214618660|NCT06136377|RADIATION|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
214618661|NCT00226109|DRUG|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
214618662|NCT02211729|DRUG|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
214618663|NCT02211729|DRUG|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
214618664|NCT00111800|DRUG|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618665|NCT00111800|DRUG|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618666|NCT00111800|DRUG|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618667|NCT00111800|DRUG|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618668|NCT00111800|DRUG|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618669|NCT00111800|DRUG|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
214618670|NCT02548325|OTHER|Not apply|None. Just registration epidemiology dates
214618671|NCT01273051|DRUG|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
214618672|NCT01273051|RADIATION|radiotherapy|radiation 25x2 Gy
214618673|NCT01273051|PROCEDURE|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
214722158|NCT05193604|DRUG|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
214618674|NCT01273051|PROCEDURE|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (\<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
214618675|NCT03609138|DEVICE|Spinal Hardware|Pedicle screws and patient specific rods
214618676|NCT04660461|DRUG|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
214618677|NCT04660461|DRUG|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
214618678|NCT04152577|DRUG|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
214618679|NCT04152577|DRUG|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
214618680|NCT00524602|PROCEDURE|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
214618681|NCT03448068|DRUG|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
214618682|NCT03448068|DRUG|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
214618683|NCT05645614|OTHER|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
214618684|NCT03651453|BEHAVIORAL|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
214618685|NCT03651453|BEHAVIORAL|Standard care|Standard harm reduction information
214618686|NCT01388660|DRUG|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)
214618687|NCT01388660|DRUG|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
214618688|NCT01704586|RADIATION|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
214618689|NCT01704586|RADIATION|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
214716936|NCT06145217|DRUG|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
214618690|NCT01989403|OTHER|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
214618691|NCT02113436|DRUG|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
214618692|NCT02113436|DRUG|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
214618693|NCT03844984|DRUG|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
214618694|NCT03844984|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
214618695|NCT03844984|DRUG|Normal saline|This group will receive normal saline 10 mL
214618696|NCT03844984|DRUG|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
214618697|NCT03844984|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
214716937|NCT04913480|DRUG|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
214716938|NCT04913480|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
214618698|NCT05645497|PROCEDURE|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
214618699|NCT05645497|PROCEDURE|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
214618700|NCT03283124|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
214618701|NCT03329911|DRUG|EU Avastin®|100 mg/4 mL
214618702|NCT03329911|DRUG|BAT1706|100 mg/4 mL
214618703|NCT03329911|DRUG|Paclitaxel|200 mg/m²
214618704|NCT03329911|DRUG|carboplatin|target area under the curve \[AUC\] 6 mg/mL•minute
214618705|NCT02969187|DRUG|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
214618706|NCT02969187|DRUG|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
214618707|NCT02969187|DRUG|Saline|
214618708|NCT05177120|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
214618709|NCT05177120|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients
214618710|NCT05177120|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
214618711|NCT05177120|OTHER|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
214618712|NCT05177120|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
214618713|NCT05177120|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
214618714|NCT05177120|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
214618715|NCT01486927|BIOLOGICAL|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
214618716|NCT01486927|BIOLOGICAL|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
214618717|NCT00365456|DRUG|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
214618718|NCT00365456|DRUG|Risedronate|Orally once weekly as one 35 mg tablet.
214618719|NCT03668600|DRUG|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
214618720|NCT03686436|DEVICE|ocular coherence tomography|imaging by ocular coherence tomography
214618721|NCT01735253|PROCEDURE|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
214618722|NCT03451786|DEVICE|IOL|Intraocular lens
214618723|NCT01476475|DRUG|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
214618724|NCT01476475|DRUG|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
214618725|NCT01476475|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
214618726|NCT01908764|DRUG|AL-60371 otic suspension|
214618727|NCT00873977|DEVICE|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
214618728|NCT02954367|DIETARY_SUPPLEMENT|PROTEIN|Immediately (\<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
214618729|NCT02954367|DIETARY_SUPPLEMENT|CARBOHYDRATE|Immediately (\<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
214618730|NCT01278745|BIOLOGICAL|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
214618731|NCT01278745|DRUG|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
214618732|NCT02560376|DRUG|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
214618733|NCT04608227|DEVICE|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
214618734|NCT00004340|DRUG|calcitriol|
214618735|NCT00004340|DRUG|growth hormone|
214618736|NCT03445871|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
214618737|NCT03445871|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
214618738|NCT00859378|DEVICE|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)
214618739|NCT00859378|DEVICE|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
214618740|NCT03353571|DEVICE|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
214618741|NCT05959395|DEVICE|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
214618742|NCT03627221|BEHAVIORAL|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
214618743|NCT04327583|BEHAVIORAL|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
214618744|NCT03458390|DEVICE|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
214618745|NCT03086733|DRUG|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
214618746|NCT02789904|OTHER|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
214618747|NCT01094769|DRUG|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
214618748|NCT01094769|DRUG|Placebo|lactose capsule taken once daily
214618749|NCT00777010|OTHER|Ketogenic diet|carbohydrate restricted diet
214618750|NCT00777010|OTHER|Healthy high carbohydrate diet|higher carbohydrate diet
214618751|NCT04044131|DRUG|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
214618752|NCT04044131|DRUG|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
214618753|NCT03121911|OTHER|Interval Training (IT)|"Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
214618754|NCT03121911|OTHER|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
214618755|NCT00272909|DRUG|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
214618756|NCT00272909|DRUG|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
214618757|NCT00272909|DRUG|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
214618758|NCT05100472|BIOLOGICAL|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
214618759|NCT05100472|RADIATION|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
214618760|NCT05100472|RADIATION|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
214618761|NCT06545968|BEHAVIORAL|A social media based intervention|WatsApp-based modules to influence retention in care behaviour
214618762|NCT04730258|DRUG|CFI-400945|The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
214618763|NCT04730258|DRUG|Azacitidine|Azacitidine will be given at its labeled dose and schedule
214716939|NCT04252248|DRUG|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
214716940|NCT05554718|BEHAVIORAL|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
214716941|NCT05554718|BEHAVIORAL|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
214716942|NCT00555282|DEVICE|central venous catheter|coated central venous catheter
214716943|NCT00555282|DEVICE|central venous catheter|standard central venous catheter
214716944|NCT03370198|BIOLOGICAL|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
214716945|NCT04612803|DRUG|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
214618764|NCT04821544|BEHAVIORAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
214618765|NCT04821544|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at 2,000 IU/day for 8 weeks.
214618766|NCT00390754|BEHAVIORAL|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
214618767|NCT04104243|OTHER|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
214618768|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
214618769|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
214618770|NCT05845645|DRUG|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
214618771|NCT05845645|OTHER|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
214618772|NCT05845645|OTHER|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
214618773|NCT03594630|DRUG|Chemotherapy|Receive chemotherapy
214618774|NCT03594630|OTHER|Patient Observation|Receive active surveillance
214618775|NCT03594630|OTHER|Questionnaire Administration|Ancillary studies
214618776|NCT03594630|PROCEDURE|Resection of Rectum|Undergo surgical resection
214618777|NCT02977650|PROCEDURE|Endoscopic ultrasonography-guided fine needle aspiration|
214618778|NCT05754528|DRUG|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
214618779|NCT05754528|DRUG|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
214618780|NCT06069934|DRUG|Pridopidine|Pridopidine 45 mg hard gelatin capsules once daily p.o. (or via feeding tube)
214618781|NCT05264545|DEVICE|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
214618782|NCT06048094|DRUG|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
214618783|NCT00843388|DRUG|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
214618784|NCT00843388|DRUG|placebo tablet|placebo tablet 25 mg OD
214618785|NCT00239616|DRUG|Iron Sucrose injection|Iron sucrose 100 mg dose
214618786|NCT02719392|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
214618787|NCT02719392|DRUG|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
214618788|NCT02719392|OTHER|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
214618789|NCT02263521|OTHER|No intervention employed. Study is based on a cross-sectional observational design.|
214618790|NCT01816061|BEHAVIORAL|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
214618791|NCT01816061|BEHAVIORAL|Control - COMPASS|Increased hours of patient-provider interactions Group.
214618792|NCT01265615|DRUG|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
214618793|NCT01265615|DRUG|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
214618794|NCT01265615|DRUG|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
214618795|NCT01265615|DIETARY_SUPPLEMENT|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
214618796|NCT00731055|DRUG|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
214618797|NCT00731055|DRUG|Placebo|1 dose of placebo
214618798|NCT04236063|OTHER|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
214618799|NCT02556996|BIOLOGICAL|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
214618800|NCT02556996|OTHER|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
214618801|NCT03243383|OTHER|DiaTOHC Program|"1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support"
214618802|NCT04427683|BEHAVIORAL|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
214618803|NCT03589495|DRUG|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
214618804|NCT03589495|OTHER|dextrose 5%|
214618805|NCT04654481|DEVICE|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
214618806|NCT04654481|OTHER|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
214618807|NCT00795249|BEHAVIORAL|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
214618808|NCT04506814|DEVICE|Endocardial PVI|Catheter based PVI
214618809|NCT04506814|DEVICE|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
214618810|NCT00338754|DRUG|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
214618811|NCT05212506|BIOLOGICAL|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
214618812|NCT03891290|OTHER|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
214618813|NCT05735808|BEHAVIORAL|Physician based education|Regular education provided by physician
214618814|NCT05735808|BEHAVIORAL|VR based education|VR based education
214618815|NCT02576444|DRUG|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
214618816|NCT02576444|DRUG|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
214618817|NCT02576444|DRUG|AZD1775|The recommended dose will be available no earlier than March 2016.
214618818|NCT02576444|DRUG|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
214618819|NCT04673591|DRUG|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
214618820|NCT04673591|OTHER|Placebo|Matched Placebo
214618821|NCT00988143|BIOLOGICAL|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
214618822|NCT00988143|BIOLOGICAL|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
214618823|NCT00988143|BIOLOGICAL|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
214618824|NCT00842231|OTHER|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
214618825|NCT02589899|OTHER|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
214618826|NCT04429165|OTHER|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
214618827|NCT04429165|OTHER|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
214618828|NCT04429165|OTHER|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
214618829|NCT01843842|DRUG|Ergoferon|Safety and Efficiency of liquid dosage form
214618830|NCT01843842|DRUG|Placebo|Safety and Efficiency of liquid dosage form
214618831|NCT06400173|BEHAVIORAL|Cognitive screening|The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
214618832|NCT06400173|BEHAVIORAL|Audiological Assessment|"Four audiological tests are included in the audiological assessment~1. Tympanometry to assss the middle ear status~2. Pure-tone audiometry with headphone to evaluate the hearing thresholds~3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise~4. The hAVICOP questionnaire to assess the hearing-related quality of life"
214618833|NCT00304200|DRUG|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
214618834|NCT02486978|OTHER|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
214618835|NCT02486978|DIETARY_SUPPLEMENT|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
214618836|NCT02486978|DIETARY_SUPPLEMENT|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
214618837|NCT03151642|RADIATION|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
214618838|NCT03151642|RADIATION|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
214618839|NCT03151642|PROCEDURE|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
214618840|NCT03151642|DEVICE|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
214618841|NCT03151642|OTHER|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
214618842|NCT02953340|DRUG|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
214618843|NCT02953340|DRUG|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
214618844|NCT02953340|DRUG|Docetaxel|75mg/m\^2 IV infusion administered on Day 1 of each cycle
214618845|NCT02953340|DRUG|Cyclophosphamide|600mg/m\^2 IV infusion administered on Day 1 of each cycle
214618846|NCT02512406|OTHER|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
214618847|NCT02512406|OTHER|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
214618848|NCT02512406|OTHER|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
214618849|NCT02512406|OTHER|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
214618850|NCT02512406|OTHER|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
214716946|NCT02021071|RADIATION|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
214618851|NCT02512406|OTHER|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
214716947|NCT02021071|RADIATION|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
214716948|NCT01977248|BEHAVIORAL|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
214716949|NCT01472991|DRUG|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
214716950|NCT01472991|DRUG|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
214716951|NCT01472991|DRUG|Placebo|Placebo capsules will be taken once daily for 4 weeks
214716952|NCT01661946|DRUG|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
214716953|NCT01661946|DRUG|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
214618852|NCT04526743|BEHAVIORAL|Questionnaire|Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
214618853|NCT01376778|DRUG|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
214618854|NCT01376778|OTHER|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
214618855|NCT04503304|OTHER|Exercises|already included in arm/group descriptions.
214618856|NCT00928889|DRUG|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
214618857|NCT00928889|DRUG|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
214618858|NCT01743924|OTHER|raw broccoli|To eat this plant material
214618859|NCT00061165|BEHAVIORAL|School + family changes promoting healthy eating + activity|
214618860|NCT03991000|DRUG|Ferric carboxymaltose|Intravenous iron
214618861|NCT03991000|DRUG|Saline|Saline application according to dosing rules of iron.
214618862|NCT02363348|DIETARY_SUPPLEMENT|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
214618863|NCT02363348|OTHER|Placebo|calcined magnesia
214618864|NCT02615483|OTHER|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
214618865|NCT03141554|DRUG|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
214618866|NCT03141554|DRUG|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
214618867|NCT03141554|DRUG|Normal saline gargle|Normal saline gargle
214618868|NCT03078075|DRUG|Naltrexone: Vivitrol®|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
214618869|NCT03078075|DRUG|Placebo (PLB) Injectable|Placebo: 4 intramuscular injections administered every 3 weeks
214618870|NCT03078075|DRUG|Bupropion: Wellbutrin XL®|Bupropion: 450 mg oral dose daily
214618871|NCT03078075|DRUG|Placebo (PLB) Oral|Placebo: once-daily oral placebo tablets
214618872|NCT04898270|DRUG|Flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."
214618873|NCT04898270|DRUG|Multi-acting receptor-targeted antipsychotics (MARTAs)|Multi-acting receptor-targeted antipsychotics (MARTAs)
214618874|NCT01989312|PROCEDURE|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
214618875|NCT01989312|PROCEDURE|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
214618876|NCT01989312|DEVICE|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
214618877|NCT01989312|DEVICE|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
214618878|NCT01989312|DRUG|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
214618879|NCT01989312|DRUG|Lidocaine|
214618880|NCT01989312|DRUG|Epinephrine|
214618881|NCT01989312|DRUG|Levobupivacaine|
214618882|NCT01547585|OTHER|Standardized soy containing muffin|Standardized muffin containing two levels of soy
214618883|NCT01676675|BIOLOGICAL|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
214618884|NCT01676675|BIOLOGICAL|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
214618885|NCT01676675|BIOLOGICAL|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
214618886|NCT01676675|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
214618887|NCT00820651|DIETARY_SUPPLEMENT|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
214618888|NCT00820651|OTHER|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
214618889|NCT03804333|RADIATION|standard treatment|3000 cGy in 10 daily fractions
214618890|NCT03804333|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
214618891|NCT04384562|DRUG|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
214618892|NCT04384562|DRUG|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
214618893|NCT04384562|DRUG|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
214618894|NCT04384562|DRUG|Placebo pill|A placebo pill is administered only once.
214618895|NCT04384562|DRUG|Placebo gum|A placebo gum is administered only once.
214618896|NCT04015453|PROCEDURE|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
214618897|NCT04142775|OTHER|complication versus no complication|development of ICH
214618898|NCT03351920|OTHER|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
214618899|NCT02343159|DRUG|dimethyl fumarate|120 mg and 240 mg delayed release capsules
214716954|NCT04946162|DRUG|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
214618900|NCT02343159|DEVICE|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
214716955|NCT01902004|DRUG|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
214716956|NCT01902004|DRUG|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
214618901|NCT02343159|BEHAVIORAL|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
214618902|NCT03769246|DEVICE|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
214618903|NCT03769246|OTHER|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
214618904|NCT02068742|OTHER|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
214618905|NCT02735395|PROCEDURE|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
214618906|NCT02735395|DRUG|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
214618907|NCT02735395|DRUG|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
214618908|NCT02735395|DRUG|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
214618909|NCT02735395|DRUG|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
214618910|NCT02735395|DRUG|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
214618911|NCT02735395|OTHER|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
214618912|NCT02735395|OTHER|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
214618913|NCT02735395|OTHER|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
214618914|NCT02735395|OTHER|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
214618915|NCT02058030|DEVICE|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
214618916|NCT02543463|DEVICE|Trident X3 Insert with Navigation system|
214618917|NCT02543463|DEVICE|Trident X3 Insert with conventional instrumentation|
214618918|NCT02375724|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
214618919|NCT02375724|DRUG|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
214618920|NCT03800784|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
214716957|NCT01902004|DRUG|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
214716958|NCT01831804|DRUG|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
214618921|NCT04712110|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
214618922|NCT04712110|BIOLOGICAL|Placebo|Placebo intramuscular injection
214618923|NCT04878003|DRUG|KRT-232|KRT-232, administration by mouth
214618924|NCT04878003|DRUG|TL-895|TL-895, administration by mouth
214618925|NCT03997435|DRUG|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
214618926|NCT03997435|DRUG|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
214618927|NCT05931237|DIETARY_SUPPLEMENT|Cranberry extract capsules|Cranberry extract capsules (Prebiocran(TM))
214716959|NCT01831804|DRUG|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
214716960|NCT05286996|DEVICE|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
214716961|NCT05286996|DRUG|Local anesthetic|Placebo - local anaesthesia
214716962|NCT04019457|OTHER|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
214722159|NCT06117904|DRUG|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
214618928|NCT01982032|PROCEDURE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
214618929|NCT01982032|DEVICE|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
214618930|NCT01982032|DEVICE|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
214618931|NCT02111161|DRUG|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
214618932|NCT02111161|DRUG|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
214618933|NCT04585464|DRUG|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
214618934|NCT04585464|DRUG|Placebo|Placebo is administered orally as a single dose or once daily
214618935|NCT04417036|DRUG|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
214618936|NCT04417036|OTHER|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
214618937|NCT04417036|DRUG|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
214618938|NCT03332823|BEHAVIORAL|SME Ambassadors training & program|"* Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
214618939|NCT04993235|BEHAVIORAL|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
214618940|NCT04993235|BEHAVIORAL|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
214618941|NCT04993235|BEHAVIORAL|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
214618942|NCT00562952|DRUG|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
214618943|NCT00562952|DRUG|placebo|no intervention
214618944|NCT01517893|DRUG|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
214618945|NCT01517893|DRUG|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
214618946|NCT06275763|DRUG|Phase C: Eplerenone|Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
214618947|NCT06275763|DRUG|Phase C: Spironolactone|Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
214618948|NCT06275763|DRUG|Phase C: Torasemide|Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
214618949|NCT06275763|DRUG|Phase B: Triplixam / Elestar HCT|Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
214618950|NCT06275763|DIAGNOSTIC_TEST|Phase A: Confirmation of uncontrolled hypertension|Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
214618951|NCT01309659|DRUG|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
214618952|NCT01309659|DRUG|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
214618953|NCT03462576|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
214618954|NCT03462576|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
214618955|NCT03462576|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
214618956|NCT04095650|BEHAVIORAL|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
214618957|NCT01921751|RADIATION|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
214618958|NCT01921751|DRUG|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
214618959|NCT01921751|DRUG|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]
214716963|NCT00398307|DRUG|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
214716964|NCT05214404|OTHER|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
214716965|NCT01767012|DEVICE|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
214716966|NCT01767012|DEVICE|Polylens EC-Y10-PAL (uncoated)|
214716967|NCT05752240|DEVICE|Transcranial direct current stimulation|Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
214716968|NCT04138212|DRUG|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
214716969|NCT04138212|RADIATION|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
214716970|NCT00055848|GENETIC|cytogenetic analysis|
214716971|NCT00055848|GENETIC|gene mapping|
214716972|NCT00055848|GENETIC|microarray analysis|
214716973|NCT02062242|OTHER|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
214716974|NCT02062242|OTHER|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
214716975|NCT02062242|OTHER|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
214618960|NCT01921751|RADIATION|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
214618961|NCT01921751|DRUG|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]
214618962|NCT01059669|OTHER|diagnostic test|
214618963|NCT02285777|BIOLOGICAL|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
214618964|NCT02285777|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
214716976|NCT02062242|OTHER|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
214716977|NCT02623491|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
214716978|NCT02623491|DRUG|Placebo|Participants will receive matching placebo.
214618965|NCT04502251|DRUG|Low-Dose Naltrexone|4.5mg daily dose, orally, during 26 days
214618966|NCT04502251|DEVICE|Transcranial Direct Current Stimulation|An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
214618967|NCT04502251|DRUG|Placebo|The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
214618968|NCT04502251|DEVICE|Sham Transcranial Direct Current Stimulation|Sham-tDCS stimulation consists of an active current during 30 seconds
214618969|NCT02667210|OTHER|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
214618970|NCT02092012|DRUG|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
214618971|NCT02092012|DRUG|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
214618972|NCT05627414|DRUG|Disitamab Vedotin|2.5mg/kg，IV，Q3W
214618973|NCT05627414|DRUG|Sintilimab|200 mg，IV，Q3W
214618974|NCT05627414|DRUG|S-1|40\~60mg / m2, bid, d1-14, repeated every 3 weeks.
214618975|NCT05627414|PROCEDURE|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
214618976|NCT05129059|OTHER|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
214618977|NCT06148376|OTHER|Personalized treatment|Discontinue prandial insulin treatment
214618978|NCT01083004|PROCEDURE|Indocyanine green|Using indocyanine green as intraoperative dye
214618979|NCT01083004|PROCEDURE|Brilliant blue arm|Using brilliant blue as intraoperative dye
214618980|NCT03269435|PROCEDURE|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
214618981|NCT03269435|DRUG|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
214618982|NCT05827939|OTHER|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
214618983|NCT00295711|DRUG|Bicifadine|
214618984|NCT00433108|DRUG|Mitoquinone mesylate (MitoQ)|
214618985|NCT05896085|OTHER|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
214618986|NCT01903707|OTHER|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
214618987|NCT01903707|OTHER|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
214618988|NCT04252053|OTHER|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
214618989|NCT04252053|OTHER|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
214618990|NCT04178759|PROCEDURE|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
214618991|NCT00300664|DRUG|Human Growth hormone|
214618992|NCT03962101|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
214618993|NCT01496131|RADIATION|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
214618994|NCT01496131|DRUG|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
214618995|NCT01496131|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
214618996|NCT01496131|DRUG|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
214716979|NCT04344704|OTHER|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
214618997|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
214618998|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
214618999|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
214619000|NCT00761007|DRUG|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
214619001|NCT05298891|OTHER|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~* energy equal to daily energy expenditure (estimated by indirect calorimetry \* physical activity factor)~* fats 28-35%~* carbohydrates 50-60%~* proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
214619002|NCT03199664|RADIATION|NB-UVB|NB-UVB given twice weekly for 6 months
214619003|NCT03199664|COMBINATION_PRODUCT|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
214619004|NCT00431340|DRUG|PXD101|
214619005|NCT03569709|BEHAVIORAL|Aerobic Exercise|Progressive sub-threshold aerobic exercise
214619006|NCT03569709|BEHAVIORAL|Rest|No structured exercise.
214619007|NCT03569709|BEHAVIORAL|Stretching|Gentle progressive upper and lower extremity stretching program
214619008|NCT00662402|OTHER|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
214619009|NCT00271596|DRUG|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
214619010|NCT00271596|DRUG|Placebo|a daily matching placebo administered over 16 weeks
214619011|NCT01956513|OTHER|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
214619012|NCT04533490|DRUG|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
214619013|NCT03535714|BEHAVIORAL|MANTR-a treatment|MANTR-a treatment
214619014|NCT05024799|DRUG|Fentanyl, propofol|The patients in this group will be administered with fentanyl and propofol
214619015|NCT05024799|DRUG|fentanyl and dexmedetomindine|The patients in this group will be administered with fentanyl and dexmedetomindine
214619016|NCT05024799|DRUG|Butorphanol and propofol|The patients in this group will be administered with butorphanol and propofol
214619017|NCT05024799|DRUG|Butorphanol and dexmedetomindine|The patients in this group will be administered with butorphanol and dexmedetomindine
214619018|NCT01329679|DIETARY_SUPPLEMENT|Energy Drink|Energy drink, 2oz twice daily for 7 days
214716980|NCT00834925|DRUG|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
214619019|NCT01329679|OTHER|Placebo|Water, lime juice and cherry flavoring
214619020|NCT04903925|PROCEDURE|Impacted tooth extraction|All patients will undergo a surgical tooth extraction
214619021|NCT02512809|DRUG|Isoflurane|
214619022|NCT02512809|DRUG|Dexmedetomidine|
214619023|NCT03353974|DEVICE|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
214619024|NCT03353974|DEVICE|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
214619025|NCT01069172|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
214619026|NCT01069172|PROCEDURE|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
214619027|NCT03429881|PROCEDURE|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
214619028|NCT05661227|DRUG|Dexmedetomidine|Whether apply DEX or not
214619029|NCT05661227|DRUG|0.9% Sodium chloride|Whether apply DEX or not
214619030|NCT05661227|DEVICE|Tourniquet(Early)|Timing of tourniquet application
214619031|NCT05661227|DEVICE|Tourniquet(Late)|Timing of tourniquet application
214619032|NCT00332254|DRUG|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
214619033|NCT04206605|OTHER|Placebo|Placebo-matching lanadelumab SC injection.
214619034|NCT04206605|DRUG|Lanadelumab|Lanadelumab solution in a PFS for injection.
214619035|NCT00679510|DRUG|rosuvastatin|tablet 10 mgs once daily
214619036|NCT00679510|DRUG|placebo|placebo
214716981|NCT00133185|DRUG|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
214716982|NCT00133185|DRUG|losartan 50 mg/hydrochlorothiazide 12.5 mg|
214716983|NCT03274245|BEHAVIORAL|Intervention Package|"* Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional."
214716984|NCT03274245|OTHER|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
214716985|NCT01744457|DEVICE|Measurement of tear film osmolarity with the TearLab® instrument|
214716986|NCT01744457|OTHER|Schirmer I test|
214619037|NCT03641872|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
214716987|NCT01744457|OTHER|Tear break up time|
214716988|NCT01744457|DEVICE|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
214716989|NCT01744457|OTHER|Ocular Surface Disease Index|
214716990|NCT03293186|COMBINATION_PRODUCT|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
214716991|NCT00117728|DRUG|nevirapine|
214716992|NCT06269588|DEVICE|Nexpowder|Endoscopic hemostasis
214716993|NCT00268463|DRUG|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
214716994|NCT00268463|DRUG|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
214716995|NCT00268463|DRUG|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
214716996|NCT01771367|BIOLOGICAL|Fluad|
214619038|NCT01944683|OTHER|Placebo|
214619039|NCT01944683|DRUG|GGF2|
214619040|NCT01944683|DRUG|Midazolam|
214619041|NCT06000995|OTHER|Survey Questions|Thirty questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure.
214619042|NCT02403336|OTHER|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
214619043|NCT02403336|BEHAVIORAL|Behavioral group intervention|Intervention on patients (educational workshop).
214716997|NCT01771367|BIOLOGICAL|Agrippal|
214716998|NCT01771367|BIOLOGICAL|Placebo|
214722160|NCT06117904|DRUG|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
214722161|NCT03491904|DRUG|Fasinumab AI|Self-administered with auto injector
214619044|NCT02403336|OTHER|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
214619045|NCT02964026|DEVICE|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
214619046|NCT03944226|DIETARY_SUPPLEMENT|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
214619047|NCT00003004|DRUG|alvocidib|
214619048|NCT00003004|DRUG|cisplatin|
214619049|NCT00003004|DRUG|paclitaxel|
214619050|NCT03890783|OTHER|Evaluation of phonation quality|"Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
214619051|NCT03890783|OTHER|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
214619052|NCT03890783|OTHER|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
214619053|NCT00113776|DRUG|ABX-EGF|
214619054|NCT00585611|DRUG|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
214619055|NCT00585611|OTHER|placebo|placebo
214619056|NCT01218464|DRUG|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
214619057|NCT01218464|DRUG|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
214619058|NCT04967560|DEVICE|deep brain stimulation|Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
214619059|NCT03948100|OTHER|Educational Intervention|Undergo dyadic education program
214619060|NCT03948100|OTHER|Quality-of-Life Assessment|Ancillary studies
214619061|NCT03948100|OTHER|Questionnaire Administration|Ancillary studies
214619062|NCT03948100|PROCEDURE|Yoga|Undergo dyadic yoga
214619063|NCT03388242|OTHER|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
214619064|NCT03901079|OTHER|single-arm study|single-arm study
214619065|NCT05800340|BIOLOGICAL|Toripalimab|240mg Q3W
214619066|NCT05800340|DRUG|Nab paclitaxel|135 mg/m2, d1, 8 Q3W
214619067|NCT05800340|DRUG|Pemetrexed|500mg/m2, d1 Q3W
214619068|NCT05800340|DRUG|Carboplatin|AUC 5, d1 Q3W
214619069|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks"
214619070|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks"
214619071|NCT02398708|OTHER|Questionnaires|Both groups will have questionnaires collected and compared.
214619072|NCT02398708|OTHER|Blood Sample|Both groups will have a blood sample collected and compared.
214619073|NCT02398708|OTHER|Stool Sample|Both groups will have a stool sample collected and compared.
214619074|NCT02398708|OTHER|Clinical data|Both groups will have clinical data collected and compared.
214619075|NCT03213964|BIOLOGICAL|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)"
214619076|NCT03213964|DRUG|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
214619077|NCT00376337|DRUG|Micafungin|IV
214619078|NCT00376337|DRUG|Systemic antifungal therapy|IV
214619079|NCT01217398|BIOLOGICAL|bevacizumab|
214619080|NCT01217398|DRUG|temozolomide|
214619081|NCT01217398|GENETIC|polymorphism analysis|
214619082|NCT01217398|OTHER|pharmacogenomic studies|
214619083|NCT05106673|BEHAVIORAL|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
214619084|NCT05106673|BEHAVIORAL|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
214619085|NCT05106673|BEHAVIORAL|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
214619086|NCT05106673|OTHER|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
214619087|NCT00708149|DRUG|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
214619088|NCT00708149|DRUG|placebo|takepron placebo
214619089|NCT02773030|DRUG|CC-220|Specified dose on specified days
214619090|NCT02773030|DRUG|Dexamethasone|Specified dose on specified days
214619091|NCT02773030|DRUG|Daratumumab|Specified dose on specified days
214619092|NCT02773030|DRUG|Bortezomib|Specified dose on specified days
214619093|NCT02773030|DRUG|Carfilzomib|Specified dose on specified days
214722162|NCT03491904|DRUG|Fasinumab PFS|Prefilled syringe administered by study staff
214722163|NCT02758925|DRUG|Rituximab|375mg/m2 IV day 1
214722164|NCT02758925|DRUG|Bendamustine|90mg/m2 IV day 1-2
214722165|NCT02758925|DRUG|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
214722166|NCT02001922|OTHER|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
214619094|NCT03764371|DIAGNOSTIC_TEST|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
214619095|NCT03975621|BEHAVIORAL|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
214619096|NCT00408395|BIOLOGICAL|Influenza vaccine|Seasonal Influenza Vaccine
214619097|NCT05956730|OTHER|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
214619098|NCT05956730|OTHER|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
214619099|NCT05259813|GENETIC|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
214619100|NCT01943513|BIOLOGICAL|BIIB023|Intravenous (IV) infusions
214619101|NCT01943513|BIOLOGICAL|Placebo|Matched placebo
214619102|NCT00602095|DRUG|misoprostol|0.025mg tablet vaginally every 4 hour until progress
214716999|NCT05897060|DEVICE|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
214619103|NCT00602095|DRUG|dinoprostone|2mg vaginal gel every 6 hours until progress
214619104|NCT00602095|DEVICE|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
214619105|NCT00843518|DRUG|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
214619106|NCT00843518|DRUG|Placebo|Placebo orally twice daily for 12 weeks
214619107|NCT05532449|DRUG|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
214619108|NCT00247741|DRUG|spinal administration of articaine|
214619109|NCT00247741|DRUG|spinal administration of lidocaine|
214619110|NCT00754351|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
214717000|NCT02920450|DRUG|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
214619111|NCT00754351|DRUG|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
214619112|NCT00754351|DRUG|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
214619113|NCT05146245|OTHER|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
214619114|NCT05146245|OTHER|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
214619115|NCT00827606|DRUG|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
214619116|NCT03636620|DEVICE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
214619117|NCT03636620|DEVICE|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
214619118|NCT00817882|OTHER|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
214619119|NCT00817882|OTHER|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
214619120|NCT00110292|BEHAVIORAL|Age-specific parenting newsletters and developmental toys|
214619121|NCT00110292|BEHAVIORAL|Parent-completed Ages & Stages Questionnaires|
214619122|NCT00110292|BEHAVIORAL|Clinic-based distribution of children's books|
214619123|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline and at follow up|Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
214619124|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline|Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
214619125|NCT03437564|DRUG|Vortioxetine|Vortioxetine tablet
214619126|NCT02098720|DRUG|Conbercept|
214619127|NCT05231499|OTHER|nasal irrigation|regular saline nasal rinse
214619128|NCT02748330|DRUG|Ticagrelor|Ticagrelor
214619129|NCT02748330|DRUG|Clopidogrel|Clopidogrel
214619130|NCT02748330|DRUG|Aspirin|Acetylsalicylic acid
214619131|NCT04037748|DRUG|Puran T4®|Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
214619132|NCT04037748|DRUG|Eutirox®|Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
214619133|NCT05454436|PROCEDURE|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
214619134|NCT00927654|DRUG|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
214619135|NCT00927654|DRUG|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
214619136|NCT02937025|DEVICE|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
214619137|NCT06159387|DRUG|Cannabis Extract Oil SR Capsule|"After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model"
214619138|NCT00163202|PROCEDURE|Blood samples|
214619139|NCT00163202|DRUG|Atorvastatin|
214619140|NCT02069470|BEHAVIORAL|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
214619141|NCT00573989|DRUG|erlotinib hydrochloride|
214619142|NCT00573989|DRUG|pemetrexed disodium|
214619143|NCT00573989|PROCEDURE|quality-of-life assessment|
214619144|NCT00573989|RADIATION|intensity-modulated radiation therapy|
214619145|NCT04544475|DEVICE|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
214619146|NCT04544475|DRUG|Estrace|Vaginal estrogen cream, estradiol: 100mcg
214619147|NCT04530942|DEVICE|Deep brain stimulation(Active)|DBS On with the optiomal parameters
214619148|NCT04530942|DEVICE|Deep brain stimulation(Sham)|DBS On with 0V Amplitude
214619149|NCT03507920|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
214619150|NCT03507920|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
214619151|NCT06158542|PROCEDURE|Spinal Anesthesia|After standard monitoring, the patient is placed in a sitting position for site marking and administration of anesthesia. The line connecting the upper border of the right and left iliac crests through conventional palpation of anatomical landmarks (Tuffier line) is identified as the entry point at the L3-L4 interspinous space or L2-L3 interspace. For patients in whom spinal entry is successful, spinal anesthesia is provided with the appropriate dose and types of local anesthetics (intrathecal 10-12 mg bupivacaine with the addition of 15-25 mcg fentanyl). After completing the procedure and placing the patient in the supine position, the block level is determined 10 minutes post-procedure using the ice test/pinprick test. Blocks reaching the T4-T6 level are considered successful.
214619152|NCT06158542|DIAGNOSTIC_TEST|Blood Sampling|Preoperatively, syndecan-1 serum levels will be investigated from the blood sample taken before cesarean section.
214619153|NCT03710174|RADIATION|Infrared LED photobiomodulation|Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
214619154|NCT03710174|DEVICE|Occlusal splint|After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
214619155|NCT03710174|RADIATION|Placebo LED photobiomodulation|The same procedure as LED group with the device turned off.
214619156|NCT03715699|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
214619157|NCT03715699|DRUG|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
214619158|NCT03089775|DRUG|BBI-2000|Experimental
214619159|NCT03089775|DRUG|Vehicle|Vehicle Comparator
214619160|NCT03089775|OTHER|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
214717001|NCT02920450|DRUG|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
214717002|NCT02920450|DRUG|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
214722167|NCT04442386|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
214619161|NCT05891925|OTHER|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~* older adult id,~* date, hour and time that the older adult listened to each poem,~* poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
214619162|NCT01826110|DRUG|[11C]PIB|Approximately 15 mCI \[11C\]PIB IV x1
214619163|NCT01378858|DRUG|Varenicline|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
214619164|NCT02431936|DRUG|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
214619165|NCT02431936|DRUG|Placebo|Sugar pill made to look identical to Prazosin intervention.
214619166|NCT00942175|DRUG|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
214619167|NCT00942175|DRUG|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
214619168|NCT00942175|DRUG|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
214619169|NCT00942175|DRUG|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
214619170|NCT00942175|DRUG|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
214619171|NCT04452474|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL
214619172|NCT04452474|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
214619173|NCT03581266|OTHER|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
214619174|NCT02664272|PROCEDURE|Total Hip Arthroplasty|
214619175|NCT02527525|BEHAVIORAL|Stepped Care|
214619176|NCT04534478|DRUG|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
214619177|NCT03436459|DEVICE|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
214619178|NCT03436459|DEVICE|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
214619179|NCT06044207|DIAGNOSTIC_TEST|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
214619180|NCT06044207|DIAGNOSTIC_TEST|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
214619181|NCT06044207|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
214619182|NCT04629820|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
214619183|NCT04001075|DRUG|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
214619184|NCT02173860|PROCEDURE|FFR-guided surgical revascularization|
214619185|NCT02173860|PROCEDURE|Angio-guided surgical revascularization|
214619186|NCT03991806|OTHER|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
214619187|NCT03263962|DRUG|Canrenone|Evaluation of canrenone therapy in patients with CHF
214619188|NCT02505503|DEVICE|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
214619189|NCT02505503|DEVICE|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
214619190|NCT05932940|PROCEDURE|Gonioscopy-Assisted Transluminal Trabeculotomy|Ab interno angle surgery one of MIGS to lower IOP
214619191|NCT02221531|DRUG|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
214619192|NCT02221531|DRUG|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
214619193|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
214619194|NCT05007951|BIOLOGICAL|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
214619195|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
214619196|NCT03073980|DRUG|IV Acetaminophen|IV Acetaminophen for pain control during procedure
214717003|NCT04206670|DEVICE|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
214717004|NCT04206670|DEVICE|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
214717005|NCT01543113|OTHER|sequencing|sequencing
214717006|NCT01732107|DRUG|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
214717007|NCT03789968|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
214717008|NCT00056836|DRUG|rhuFab V2 (ranibizumab)|
214717009|NCT01627223|DRUG|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
214717010|NCT01627223|DRUG|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
214717011|NCT00422890|DRUG|5-Azacytidin|in case of decreasing CD34 chimerism
214717012|NCT05134168|PROCEDURE|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
214717013|NCT05134168|PROCEDURE|LIFT|The fistula tract is ligated in the intersphincteric space
214717014|NCT04746209|DEVICE|Alpha/Beta T-cell and B-cell depleted HCT|Device: Alpha/Beta T-cell and B-cell depletion
214717015|NCT04746209|DRUG|Blinatumomab|28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
214717016|NCT02095990|DRUG|Hydroquinone|
214717017|NCT02095990|DRUG|Placebo|
214717018|NCT00971230|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
214717019|NCT00971230|DRUG|Placebo|Placebo
214717020|NCT06452368|DEVICE|facemask|Fixation of miniplates by four screws in the maxilla and protraction by using facemask
214717021|NCT00871936|DRUG|SLx-4090|SLx-4090
214717022|NCT00871936|OTHER|Placebo|matching tablets
214717023|NCT00871936|DRUG|Metformin|
214717024|NCT03407170|BIOLOGICAL|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
214717025|NCT00218361|DRUG|Hydromorphone|
214717026|NCT01998113|DRUG|Glyburide vs Insulin trials|Affecting groups 1 and 2
214717027|NCT01998113|DRUG|Metformin vs Insulin trials|Affecting groups 3 and 4
214717028|NCT01998113|DRUG|Metformin vs Glyburide trials|Affecting groups 5 and 6
214717029|NCT04144049|DRUG|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
214619197|NCT03073980|DRUG|PO Acetaminophen|PO Acetaminophen for pain control during procedure
214619198|NCT03073980|OTHER|Placebo IV Acetaminophen|Placebo IV Acetaminophen
214619199|NCT03073980|OTHER|Placebo PO Acetaminophen|Placebo PO Acetaminophen
214619200|NCT00812058|DRUG|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
214619201|NCT00812058|DRUG|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
214619202|NCT06338904|BEHAVIORAL|Problem-solving-based psychological intervention|The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).
214619203|NCT02895880|BEHAVIORAL|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
214619204|NCT02895880|BEHAVIORAL|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
214619205|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
214717030|NCT04144049|DRUG|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
214717031|NCT04913571|DRUG|Eribulin|Eribulin
214717032|NCT04913571|DRUG|Tislelizumab|Tislelizumab
214717033|NCT01153672|DRUG|vorinostat|Given PO
214619206|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
214619207|NCT00545064|DRUG|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
214619208|NCT03113656|OTHER|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
214619209|NCT03113656|OTHER|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
214619210|NCT00081237|DRUG|OSI-7904L|
214619211|NCT00081237|DRUG|oxaliplatin|
214619212|NCT04001621|DRUG|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
214619213|NCT03886051|PROCEDURE|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
214619214|NCT03886051|PROCEDURE|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
214717034|NCT01153672|OTHER|laboratory biomarker analysis|Correlative studies
214717035|NCT01153672|PROCEDURE|biopsy|Optional correlative studies
214717036|NCT01153672|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
214717037|NCT01153672|PROCEDURE|positron emission tomography|Correlative studies
214717038|NCT01153672|DRUG|anastrozole|Given PO
214717039|NCT01153672|DRUG|letrozole|Given PO
214717040|NCT01153672|DRUG|exemestane|Given PO
214717041|NCT01153672|GENETIC|gene expression analysis|Correlative studies
214717042|NCT05825313|BEHAVIORAL|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
214717043|NCT00374270|BEHAVIORAL|Lifestyle Counselling; Opinion Leader Influence Statements|
214717044|NCT03791268|PROCEDURE|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
214717045|NCT06054438|OTHER|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
214619215|NCT04342000|OTHER|Movement education workshop|"30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form."
214619216|NCT04342000|OTHER|Sham Education Workshop|"30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)"
214619217|NCT05953558|DEVICE|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
214619218|NCT03655808|BIOLOGICAL|Bronchial basal cells (BBCs)|Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
214717046|NCT00003408|BIOLOGICAL|aldesleukin|
214717047|NCT00003408|BIOLOGICAL|recombinant interferon alfa|
214717048|NCT00003408|BIOLOGICAL|sargramostim|
214619219|NCT03655808|PROCEDURE|Bronchoscopic airway clearance treatment （B-ACT）|The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
214619220|NCT02934308|DEVICE|Skin Conductance Monitor|
214619221|NCT01699854|DRUG|capsaicin patch (qutenza)|
214619222|NCT01699854|DRUG|Placebo|
214619223|NCT01345396|BEHAVIORAL|Health education about asthma|Three face-to-face appointments (\<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
214619224|NCT05520645|DRUG|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
214619225|NCT05520645|DRUG|propofol|use propofol for anesthesia induction in hysteroscopic surgery
214619226|NCT03880032|BEHAVIORAL|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
214619227|NCT01358760|DRUG|Placebo|Placebo vaginal suppository
214619228|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
214619229|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
214619230|NCT01506960|DEVICE|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
214619231|NCT00037011|BIOLOGICAL|beta-glucan|
214619232|NCT00037011|BIOLOGICAL|monoclonal antibody 3F8|
214619233|NCT02713165|OTHER|Raisins|Participants will consume 84g of raisins per day for 14 days.
214722168|NCT05047016|OTHER|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
214619234|NCT05896514|DEVICE|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
214619235|NCT05197348|BEHAVIORAL|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
214619236|NCT05197348|BEHAVIORAL|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
214619237|NCT03163589|DRUG|Erythropoietin|injection
214619238|NCT03163589|DRUG|normal saline|injection
214619239|NCT01439672|DIETARY_SUPPLEMENT|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \~100mg/dl at 1100.
214619240|NCT01251848|DRUG|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
214619241|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
214619242|NCT01251848|DRUG|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
214619243|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
214619244|NCT03350295|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
214619245|NCT00642395|DRUG|Bortezomib|bortezomib-Melphalan
214619246|NCT02458521|DEVICE|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
214619247|NCT02458521|DEVICE|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
214619248|NCT02779959|DRUG|Prochlorperazine|
214619249|NCT05771220|OTHER|radial extracorporeal shockwave therapy+ evidence-based physical therapy|The experimental group received six sessions of rESWT over six weeks in addition to an EBPT program. The rESWT procedure involved applying shockwaves to the affected area using a radial probe, with sessions lasting 10-15 minutes and consisting of up to 2000 impulses delivered at a frequency of 3-6 pulses per second and an energy intensity level of 1.8 bar, based on patient tolerance. Patients were seated or lying down during the rESWT procedure, with gel or oil applied to facilitate shockwave transmission through the skin. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
214619250|NCT05771220|OTHER|sham radial extracorporeal shockwave therapy+ evidence-based physical therapy|The participants in the control group received six weeks of sham rESWT (radial extracorporeal shock wave therapy) combined with the EBPT (evidence-based physical therapy) program. The sham rESWT involved six sessions with a maximum of 200 impulses delivered at a low intensity, with the applicator placed on the affected area for the same duration as the experimental group. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
214619251|NCT02836028|DRUG|Talazoparib|Talazoparib monotherapy 1mg/day orally
214619252|NCT02836028|DRUG|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
214619253|NCT04473690|BIOLOGICAL|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
214619254|NCT04473690|BIOLOGICAL|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
214619255|NCT04473690|BIOLOGICAL|Placebo|Buffered saline solution
214619256|NCT05555862|DRUG|Artesunate|artesunate formulated as intra-anal suppositories
214619257|NCT05555862|DRUG|Placebo|placebo intra-anal suppository
214619258|NCT05496868|DRUG|Reparixin 600mg|Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
214619259|NCT05496868|OTHER|Matching Placebo|"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
214619260|NCT06490731|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine
214619261|NCT06490731|DRUG|Ketamine|patients Will receive ketamine
214619262|NCT06805630|DIAGNOSTIC_TEST|Femto Human DNA Quantification Kit|Urine methylation biomarker test
214619263|NCT01591967|DEVICE|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
214619264|NCT05166629|BEHAVIORAL|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
214619265|NCT05166629|BEHAVIORAL|Usual Care|Please see above description of usual care.
214619266|NCT00625209|DRUG|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
214619267|NCT00625209|DRUG|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
214619268|NCT00625209|DRUG|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
214619269|NCT00625209|DRUG|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
214619270|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
214717049|NCT03561168|DIAGNOSTIC_TEST|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
214717050|NCT02899624|BIOLOGICAL|Extra blood draw samples|
214619271|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
214619272|NCT06975163|BEHAVIORAL|Mindfulness-Based Stigma Stress Reduction (MBSSR) program|The MBSSR program was developed by modifying elements from the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) programs to create a distinct mindfulness intervention targeted at alleviating stigma stress among parents of autistic children. This program consisted of four group sessions, each incorporating mindfulness practices, group discussions, and activities that helped participants apply mindfulness principles to their daily lives.
214619273|NCT02639572|BIOLOGICAL|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
214619274|NCT02639572|BIOLOGICAL|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
214619275|NCT02321930|DRUG|tofacitinib 5mg po bid|
214619276|NCT03129451|DIAGNOSTIC_TEST|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
214619277|NCT01530412|OTHER|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
214619278|NCT04422548|PROCEDURE|AI-assisted Colonoscopy|This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
214619279|NCT04422548|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
214619280|NCT01293968|DRUG|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
214619281|NCT01293968|DRUG|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
214619282|NCT01483742|DRUG|RO5024048|1000 mg orally bid, 24 weeks
214619283|NCT01483742|DRUG|danoprevir|100 mg orally bid, 24 weeks
214619284|NCT01483742|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
214619285|NCT01483742|DRUG|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
214619286|NCT01483742|DRUG|ritonavir|100 mg orally bid, 24 weeks
214619287|NCT01816412|DEVICE|MD02-LDCB Paclitaxel coated balloon catheter|
214619288|NCT01816412|PROCEDURE|Standard Uncoated Balloon Angioplasty Catheter|
214619289|NCT02806128|DRUG|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
214619290|NCT00956267|DRUG|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
214619291|NCT00956267|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
214619292|NCT00853749|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
214619293|NCT00853749|PROCEDURE|Blood draw|Collection of 10 mL of blood
214619294|NCT03352700|DRUG|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
214619295|NCT03352700|DRUG|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
214619296|NCT01392677|DRUG|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
214619297|NCT01392677|DRUG|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
214619298|NCT00000421|DRUG|Prednisone|
214619299|NCT00000421|DRUG|Placebo|
214619300|NCT03592966|DIETARY_SUPPLEMENT|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
214619301|NCT03592966|DIETARY_SUPPLEMENT|Placebo|Freeze-dried placebo powder
214619302|NCT03865212|DRUG|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
214619303|NCT06977919|BEHAVIORAL|NASM OPT Program|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included bench presses, chest flyes, and push-ups.
214619304|NCT06977919|BEHAVIORAL|General Exercise|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
214717051|NCT02899624|BIOLOGICAL|additional tissue samples|
214717052|NCT05210972|RADIATION|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
214619305|NCT06985667|BEHAVIORAL|Cognitive-Based Behavior Change Training Program|"Parents will be given an 8-session parent training program.~Session 1: Establishing a trusting relationship and informing them about the study Session 2: Informing parents about the cognitive development of 3-6 year old children Theme: Children learn with 'numbers/scales/amounts' Session 3: Parents being consistent in their approach to children Theme: Children learn with the all/or nothing rule Session 4: Reinforcing positive behaviors in children Theme: Children Learn Laterally Session 5: Parents being positive models Theme: Children Learn by Imitation Session 6: Guidance of parents on the principle of 'learning by doing and experiencing' Theme: Children Learn by Action Session 7: This is the last session. Session 8: Application of final tests and saying goodbye."
214619306|NCT06985173|DEVICE|Occlusal splints manufactured with fully digital workflow.|The intervention involves the fabrication of 3D printed occlusal splint with fully digitalization technique by the aid of Jaw Tracing Device. The acquisition and scanning of the patients are done by using an intra oral scanner and designing them using a designing software. This device will be printed with a 3D printer utilizing printable resin material
214619307|NCT06985173|DEVICE|Occlusal splints manufactured with Conventional workflow|For the comparator group, maxillary and mandibular impressions will be made with Cavex CA37 alginate impression material (Cavex Holland B.V, Holland), models will be poured with gypsum (Kimberlit, Type IV Dental Stone, Protechno Spain), facebow (Bio-art) record and interocclusal registrations will be recorded at centric by using bite registration material after patient deprogramming with Lucia jig. The models will be mounted in a semi-adjustable articulator (Bio-art, A7Plus, Brazil), wax pattern fabrication on surveyed and mounted casts to be invested finally to form a clear, heated-cured acrylic resin splint
214619308|NCT06984601|PROCEDURE|Lateral Internal Sphincterotomy (LIS)|This is a routinely performed surgical procedure for chronic anal fissure. The study is observational and does not assign this procedure to participants.
214619309|NCT02963545|OTHER|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
214619310|NCT02963545|BIOLOGICAL|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
214619311|NCT02963545|PROCEDURE|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
214619312|NCT02494258|DRUG|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
214619314|NCT06985134|DRUG|Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh|The present study included patients aged \>18 years with inflammatory low back pain fulfilling the Modified New York criteria \[12\], 2014 for moderate to severe ankylosing spondylitis. The criteria include radiographic sacroiliitis (at least grade II bilaterally or grade III unilaterally) along with clinical signs, such as inflammatory back pain for at least 3 months' duration, limitation of lumbar spine in sagittal and frontal planes, or chest expansion decreased relative to normal values for age and sex. Exclusion criteria were non-inflammatory back pain or back pain due to inflammatory causes other than AS, failure to confirm a washout period of four weeks, those who were on DMARDs, allergy to thalidomide, Sulfasalazine, and NSAIDs, known to have kidney diseases or cardiac disease, active peptic ulcer disease, and pregnancy.
214619315|NCT05767593|DEVICE|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
214619316|NCT00268489|BIOLOGICAL|bevacizumab|
214619317|NCT00268489|DRUG|pemetrexed disodium|
214619318|NCT00128479|DRUG|mifepristone|mifepristone 300 mg daily for 7 dats
214619319|NCT00128479|DRUG|mifepristone matched placebo|daily for 7 days
214619320|NCT00128479|DRUG|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
214619321|NCT00128479|DRUG|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
214717053|NCT00615459|DRUG|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
214717054|NCT00615459|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
214717055|NCT00615459|DRUG|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
214619322|NCT06365866|DEVICE|"BRAXX Esophageal Brachytherapy Applicator."|The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.
214619323|NCT06365866|RADIATION|Add-on of intraluminal brachytherapy|Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
214717056|NCT03373344|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
214717057|NCT03373344|BEHAVIORAL|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
214722169|NCT06437639|DRUG|Mexidol|Neurocytoprotector
214619324|NCT05377788|DRUG|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
214619325|NCT01329445|OTHER|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
214619326|NCT00736255|DRUG|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
214619327|NCT00736255|DRUG|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
214619328|NCT00736255|DRUG|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
214619329|NCT00960336|DRUG|pegylated liposomal doxorubicin hydrochloride|
214619330|NCT03427047|DEVICE|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
214619331|NCT03427047|DEVICE|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
214619332|NCT06320691|PROCEDURE|Total Hip Arthroplasty|Patients that underwent direct anterior approach total hip arthroplasty
214619333|NCT06320691|PROCEDURE|General Anesthesia|Patients that underwent general/systemic anesthesia before surgery
214619334|NCT06320691|PROCEDURE|Spinal Anesthesia|Patients that underwent spinal/neuraxial anesthesia before surgery
214619335|NCT02145286|RADIATION|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
214619336|NCT00764595|DRUG|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
214619337|NCT04046107|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
214619338|NCT05314608|COMBINATION_PRODUCT|IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee|Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
214619339|NCT00950508|PROCEDURE|High volume plasma exchange|3 high volume plasma exchanges over 3 days
214619340|NCT00950508|PROCEDURE|Standard medical treatment|Standard medical treatment
214619341|NCT00586261|DRUG|Pioglitazone|Pioglitazone 30 mg daily for 6 months
214619342|NCT00586261|DRUG|Placebo|Placebo 30 mg daily for 6 months
214619343|NCT00586261|DRUG|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
214619344|NCT02656095|DRUG|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
214619345|NCT03317041|OTHER|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
214619346|NCT05091463|DEVICE|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
214619347|NCT05807360|DEVICE|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
214619348|NCT04340375|DIETARY_SUPPLEMENT|AP green tea extracts|AP green tea extracts
214619349|NCT05449197|OTHER|HEMOPHAR e-learning program|training on professional practice by following HEMOPHAR e-learning program
214619350|NCT04609228|OTHER|Non-acceptance of blood-transfusions|Patients who do not accept blood products transfusions
214619351|NCT04609228|OTHER|Acceptance of blood-transfusions|Patients who accept blood products transfusions
214619352|NCT00983177|DRUG|Colchicine|0.5 mg twice daily for 4 months
214619353|NCT00983177|DRUG|lactose|lactose capsules twice daily
214619354|NCT01349868|DRUG|PT005 MDI|PT005 MDI taken as two inhalations
214619355|NCT01349868|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
214619356|NCT01349868|DRUG|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
214619357|NCT01349868|OTHER|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
214619358|NCT04272684|OTHER|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
214619359|NCT00309543|DRUG|Fluorouracil|
214619360|NCT00309543|DRUG|Leucovorin|
214619361|NCT00840086|DRUG|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
214619362|NCT01916837|OTHER|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
214619363|NCT01916837|OTHER|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
214619364|NCT01916837|PROCEDURE|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
214619365|NCT03332498|DRUG|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
214619366|NCT03332498|DRUG|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
214619367|NCT00379652|BEHAVIORAL|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
214619368|NCT00379652|BEHAVIORAL|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
214619369|NCT00379652|OTHER|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
214619370|NCT02970214|OTHER|no intervention, only observational|no intervention, only observational
214619371|NCT03033537|DRUG|Verapamil|Local treatment of erectile dysfunction
214619372|NCT01566773|DRUG|PT001 MDI|Administered as two puffs BID for 14 days
214619373|NCT01566773|DRUG|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
214619374|NCT01566773|DRUG|PT001 Placebo MDI|
214619375|NCT01750385|DRUG|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
214619376|NCT01750385|DRUG|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
214619377|NCT00003283|DRUG|octreotide acetate|
214619378|NCT00003283|DRUG|prednisone|
214619379|NCT00658476|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 fatty acid supplements.
214619380|NCT00658476|BEHAVIORAL|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
214619381|NCT00658476|OTHER|Placebo|
214619382|NCT04940104|DRUG|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
214619383|NCT04036708|BEHAVIORAL|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
214619384|NCT04036708|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
214619385|NCT05639127|DRUG|Prednisolone|Nebulization of prednisolone
214619386|NCT00136422|BIOLOGICAL|autologous tumor cells|
214619387|NCT01033734|DRUG|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
214619388|NCT00286273|DRUG|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
214619389|NCT00286273|DRUG|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
214619390|NCT04066582|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
214619391|NCT01577901|OTHER|Clearblue Advanced|Pregnancy test
214619392|NCT00236834|DRUG|levofloxacin; imipenem/cilastitin|
214619393|NCT04451915|OTHER|late management strategy|late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
214619394|NCT04451915|OTHER|early management strategy|early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
214619395|NCT02538016|DRUG|Tolvaptan|
214619396|NCT03089593|OTHER|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
214619397|NCT03089593|OTHER|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
214619398|NCT03351751|DRUG|Placebo|Placebo
214619399|NCT03351751|DRUG|PF-06372865|PF-06372865
214619400|NCT00657813|DRUG|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
214619401|NCT01347424|DRUG|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
214619402|NCT01347424|DRUG|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
214619403|NCT01110616|DRUG|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
214619404|NCT01110616|DRUG|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
214619405|NCT01110616|DRUG|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
214619406|NCT01417598|OTHER|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
214619407|NCT01417598|OTHER|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
214619408|NCT02889406|BEHAVIORAL|Motivational intervention|motivational interviewing schema
214619409|NCT05080023|DEVICE|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
214619410|NCT00000787|BEHAVIORAL|Pre- and post-test counseling|
214619411|NCT01409733|DEVICE|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
214619412|NCT03976011|DEVICE|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
214619413|NCT05800548|OTHER|survey application|In data collection; Socio-demographic and obstetric characteristics of puerperant women, descriptive information form including questions about current birth, Postpartum Family Planning Attitude Scale The Health Literacy Scale was used.
214619414|NCT03785990|OTHER|adipose tissue|taking a sample of the adipose tissue during operation
214619415|NCT03785990|OTHER|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
214619416|NCT03785990|DIAGNOSTIC_TEST|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
214619417|NCT06571279|OTHER|Plant-based diet|Standard plant-based meals will be provided directly to participants. The dietary intervention will begin with a one-week Western diet run-in; hereafter, participants will consume plant-based meals for approximately 5 weeks. Total energy provided will be equal to REE X 1.4 to account for light physical activity to support weight maintenance. High-inositol snacks will be provided to meet energy needs. Meals and snacks combined will provide a minimum of 20mg total inositol/kg body weight. For example, a 200lb participant will consume 1.8g daily, which is consistent with doses used in prior studies.
214619418|NCT03218098|PROCEDURE|Lobectomy via UVATS|lobectomy with small skin access 4 cm
214619419|NCT05941325|DRUG|fruquintinib|VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
214619420|NCT05941325|DRUG|Envafolimab|anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
214619421|NCT04184687|PROCEDURE|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
214619422|NCT04184687|PROCEDURE|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
214619423|NCT03974776|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
214619424|NCT03974776|OTHER|Placebo|Placebo administered subcutaneously
214619425|NCT04146779|BEHAVIORAL|Yoga Video|A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
214619426|NCT04146779|BEHAVIORAL|Posture and Strengthening Video|The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
214619427|NCT04146779|BEHAVIORAL|Relaxation Video|The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
214619428|NCT04146779|BEHAVIORAL|Breath Work Video|The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
214619429|NCT04146779|BEHAVIORAL|Satisfaction Survey|Participants will complete a questionnaire addressing satisfaction with the yoga program.
214619430|NCT04146779|BEHAVIORAL|Guided Yoga Session|Instructor guided yoga session twice a week
214619431|NCT04146779|BEHAVIORAL|Written Yoga Instructions|Introduction to Yoga and Yoga poses
214717058|NCT04523467|DRUG|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
214717059|NCT04523467|DRUG|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
214717060|NCT04523467|PROCEDURE|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
214717061|NCT02731976|OTHER|Dietary intervention|
214717062|NCT01408134|OTHER|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
214717063|NCT00051090|DRUG|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
214619432|NCT01865630|DRUG|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
214619433|NCT04311736|BEHAVIORAL|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
214619434|NCT04311736|BEHAVIORAL|Cycling|Cycling on a recumbent cycle ergometer
214619435|NCT04311736|BEHAVIORAL|Stretching|Stretching exercises
214619436|NCT02724254|DRUG|AP611074 5% gel|
214619437|NCT02724254|DRUG|AP611074 matching placebo|
214619438|NCT04203745|DEVICE|Nonablative Fractional Diode Laser|The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
214619439|NCT05246020|PROCEDURE|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
214619440|NCT05246020|PROCEDURE|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
214619441|NCT01764542|PROCEDURE|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
214619442|NCT05764382|BEHAVIORAL|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.
214619443|NCT05764382|OTHER|Usual care|Usual care as per primary care physican, physical therapist.
214717064|NCT00051090|DRUG|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
214717065|NCT00051090|DRUG|Efavirenz|Administered orally at a daily dose of 600 mg
214717066|NCT00051090|DRUG|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
214717067|NCT00051090|DRUG|Abacavir|Administered orally twice daily in doses of 300 mg
214619444|NCT03649282|OTHER|HFNC|HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
214619445|NCT03649282|OTHER|NCPAP|NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
214619446|NCT01444742|DRUG|Clofarabine|"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
214619447|NCT01444742|DRUG|Cytarabine|"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"
214619448|NCT04812431|BIOLOGICAL|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
214619449|NCT05187546|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
214619450|NCT02590120|DIETARY_SUPPLEMENT|Enteral nutrition|
214619451|NCT02366442|OTHER|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
214619452|NCT03858842|OTHER|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
214619453|NCT03151720|DRUG|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
214619454|NCT03151720|DRUG|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
214619455|NCT06159920|DIAGNOSTIC_TEST|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
214619456|NCT03494751|DEVICE|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
214619457|NCT03494751|DEVICE|No heart monitor|Standard monitoring by nurses.
214619458|NCT02535715|DRUG|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
214717068|NCT01150760|DRUG|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
214717069|NCT01126502|DRUG|alvespimycin hydrochloride|Given IV
214717070|NCT01126502|OTHER|diagnostic laboratory biomarker analysis|
214717071|NCT01126502|OTHER|pharmacogenomic studies|
214717072|NCT01126502|OTHER|pharmacological study|
214619459|NCT02535715|DRUG|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
214619460|NCT02535715|DRUG|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
214619461|NCT04022187|OTHER|Observational study : no intervention|Observational study : no intervention, only exporting data
214619462|NCT00909181|DRUG|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
214619463|NCT00909181|DRUG|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
214619464|NCT05601648|DRUG|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
214619465|NCT01227486|DEVICE|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
214619466|NCT05536310|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|TAVI with the JenaValve Trilogy Heart Valve System
214619467|NCT01030770|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
214619468|NCT01030770|DRUG|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
214619469|NCT05087290|OTHER|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
214619470|NCT05087290|OTHER|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
214717073|NCT04433156|DRUG|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214619471|NCT05950984|OTHER|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
214619472|NCT01767454|DRUG|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
214619473|NCT01767454|DRUG|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
214619474|NCT01767454|DRUG|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
214619475|NCT02933034|DRUG|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
214619476|NCT02933034|DRUG|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
214717074|NCT04433156|DRUG|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214717075|NCT04433156|DRUG|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214619477|NCT05241457|DEVICE|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
214619478|NCT05241457|PROCEDURE|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
214619479|NCT02506595|BEHAVIORAL|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
214619480|NCT02349048|DRUG|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
214619481|NCT02349048|DRUG|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
214619482|NCT02349048|DRUG|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
214619483|NCT03126942|DEVICE|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
214619484|NCT03126942|DEVICE|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
214619485|NCT01713842|DRUG|TCZ|Tocilizumab at week 0, 4 and 8.
214619486|NCT02219282|OTHER|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
214619487|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
214619488|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
214717076|NCT04433156|DRUG|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214619489|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
214619490|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
214619491|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
214619492|NCT00653614|DRUG|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
214619493|NCT00653614|DRUG|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
214619494|NCT00653614|DRUG|Placebo|Placebo administration in each arm
214619495|NCT04070027|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
214717077|NCT04433156|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
214717078|NCT02347852|DRUG|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
214717079|NCT03198104|DEVICE|MRI|
214722170|NCT00086385|DRUG|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
214722171|NCT00899600|DRUG|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
214619496|NCT04070027|OTHER|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
214619497|NCT02286414|DRUG|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
214619498|NCT02286414|DRUG|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
214619499|NCT01322464|DRUG|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
214619500|NCT01322464|DRUG|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
214619501|NCT01322464|DRUG|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
214619502|NCT01322464|DRUG|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
214619503|NCT03152903|BIOLOGICAL|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
214619504|NCT03152903|OTHER|Placebo|Single dose of Placebo is administered intradermally.
214619505|NCT06414811|OTHER|HYPOTENSİON|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
214619506|NCT00094770|DRUG|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
214619507|NCT00094770|DRUG|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
214619508|NCT00475683|OTHER|Mouth wash|Mouth wash with chlorehexidin, three times a day
214619509|NCT00475683|DIETARY_SUPPLEMENT|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
214619510|NCT05698082|DIAGNOSTIC_TEST|Immunohistochemical staining with anti-FOS|The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
214619511|NCT02771704|OTHER|Silver Diamine fluoride|
214619512|NCT02771704|OTHER|Potassium iodide|
214619513|NCT02771704|OTHER|Chlorhexidine|
214619514|NCT02771704|OTHER|Silver diamine fluoride and potassium iodide|
214619515|NCT02771704|OTHER|Physiological saline|
214619516|NCT04911803|BEHAVIORAL|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
214619517|NCT04911803|BEHAVIORAL|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
214619518|NCT05479942|OTHER|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~1. Left/right discrimination (Implicit motor imagery):~2. Explicit motor imagery~3. Mirror Therapy"
214619519|NCT05479942|OTHER|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
214619520|NCT06480916|PROCEDURE|Maternal-fetal transfers|Prospective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for.
214619521|NCT05244759|DRUG|[14C]-BLU-5937|Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
214619522|NCT03057236|BEHAVIORAL|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
214619523|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
214619524|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
214619525|NCT00914927|DRUG|Placebo|Placebo or inactive substance once a day for up to 7 days
214619526|NCT00822965|OTHER|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
214619527|NCT00822965|OTHER|Phone Interviews|2 follow-up phone interviews.
214619528|NCT00822965|BEHAVIORAL|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
214619529|NCT04347915|DRUG|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
214619530|NCT04347915|DRUG|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
214619531|NCT02877368|OTHER|Computed tomography|
214619532|NCT04335994|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
214619533|NCT04335994|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
214619534|NCT00053092|BIOLOGICAL|rituximab|
214619535|NCT00053092|DRUG|cyclophosphamide|
214619536|NCT00053092|DRUG|fludarabine phosphate|
214619537|NCT01274819|OTHER|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
214619538|NCT03081442|DRUG|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
214619539|NCT03081442|DEVICE|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
214619540|NCT06399523|DEVICE|VR therapy|Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.
214619541|NCT06399523|DEVICE|VR sham|Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
214619542|NCT00000270|DRUG|Cocaine|
214619543|NCT00025051|DRUG|celecoxib|
214619544|NCT00025051|PROCEDURE|anti-cytokine therapy|
214619545|NCT00025051|PROCEDURE|antiangiogenesis therapy|
214619546|NCT00025051|PROCEDURE|biological therapy|
214619547|NCT00025051|PROCEDURE|cancer prevention intervention|
214619548|NCT00025051|PROCEDURE|chemoprevention of cancer|
214619549|NCT00025051|PROCEDURE|growth factor antagonist therapy|
214619550|NCT04343625|BEHAVIORAL|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
214619551|NCT02571296|DRUG|micronized progesterone|Oral
214619552|NCT02571296|DRUG|Placebo|Oral
214619553|NCT02970604|DRUG|Aspirin|Non enteric coated aspirin
214619554|NCT04831489|RADIATION|Imaging|pre and postoperative CT scan of lung
214619555|NCT02835001|PROCEDURE|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
214619556|NCT02835001|DEVICE|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
214619557|NCT02604316|OTHER|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
214619558|NCT02604316|OTHER|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
214619559|NCT06073015|DRUG|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
214619560|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
214619561|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
214619562|NCT01648790|DRUG|Prasugrel ODT1 - Tablet|Administered orally as tablet.
214619563|NCT01648790|DRUG|Prasugrel ODT2 - Tablet|Administered orally as tablet.
214619564|NCT01648790|DRUG|Prasugrel ODT2 - Suspension|Administered orally as suspension.
214619565|NCT03002584|OTHER|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
214619566|NCT00527475|DRUG|ranibizumab|0.5 mg. given as an intraocular injection
214619567|NCT00527475|DRUG|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
214619568|NCT00004887|DRUG|carboplatin|
214619569|NCT00004887|DRUG|cisplatin|
214619570|NCT00004887|DRUG|ifosfamide|
214619571|NCT00004887|DRUG|mitomycin C|
214619572|NCT00004887|DRUG|paclitaxel|
214619573|NCT00004887|DRUG|vinblastine sulfate|
214619574|NCT01589471|DRUG|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
214619575|NCT01859832|OTHER|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
214619576|NCT05288738|DRUG|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
214619577|NCT05288738|DRUG|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
214619578|NCT03744351|OTHER|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
214619579|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
214619580|NCT03744351|OTHER|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
214619581|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
214619582|NCT04892264|BIOLOGICAL|Belantamab Mafodotin|Given IV
214619583|NCT04892264|BIOLOGICAL|Daratumumab|Given IV
214619584|NCT04892264|DRUG|Dexamethasone|Given PO
214619585|NCT04892264|DRUG|Lenalidomide|Given PO
214619586|NCT04892264|OTHER|Quality-of-Life Assessment|Ancillary studies
214619587|NCT04892264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214619588|NCT04892264|PROCEDURE|Skeletal Survey X-Ray|Undergo X-ray skeletal survey
214619589|NCT04892264|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo whole body low dose CT
214619590|NCT04892264|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214619591|NCT04892264|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214619592|NCT02214966|DRUG|Telmisartan/Ramipril, fixed dose combination tablet|
214619593|NCT02214966|OTHER|high fat, high caloric meal|
214619594|NCT05085951|DEVICE|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
214619595|NCT05085951|DIAGNOSTIC_TEST|OGD|OGD (No dilatation)
214619596|NCT01141036|DRUG|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
214619597|NCT01141036|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
214619598|NCT02562079|BIOLOGICAL|Blood samples|"* biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)"
214619599|NCT02562079|BIOLOGICAL|Biopsy|Skin biopsies
214619600|NCT03370120|DRUG|Padsevonil|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
214619601|NCT03434340|BIOLOGICAL|Peppermint essential oil|2 drops applied on a nasal strip
214619602|NCT03434340|DRUG|Granisetron|1mg intravenous injection
214717080|NCT01761994|DRUG|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
214717081|NCT02076334|OTHER|Far Infrared Fabric|
214717082|NCT02076334|OTHER|Spandex|
214717083|NCT01878240|PROCEDURE|EVAR without coils embolization/ Coils embolization during EVAR|
214717084|NCT02158455|PROCEDURE|NT SVG grafts|
214717085|NCT04119401|PROCEDURE|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
214717086|NCT04119401|PROCEDURE|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
214717087|NCT03238352|DEVICE|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
214717088|NCT03238352|DRUG|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
214717089|NCT03238352|OTHER|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
214717090|NCT02805062|PROCEDURE|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
214619603|NCT03434340|DRUG|Dexamethasone|4mg intravenous injection
214619604|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation|Oral, encapsulated FMT
214619605|NCT02801656|DRUG|Vancomycin|Vancomycin po 125 mg qid x 10 days
214619606|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
214619607|NCT02801656|DRUG|Vancomycin Placebo|Matching placebo to Vancomycin
214717091|NCT02805062|PROCEDURE|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
214717092|NCT06122753|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
214722172|NCT00899600|OTHER|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
214722173|NCT02428075|BEHAVIORAL|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
214619608|NCT00454857|OTHER|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
214619609|NCT00454857|OTHER|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
214619610|NCT00454857|OTHER|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
214619611|NCT03185364|DRUG|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
214619612|NCT03185364|DRUG|Placebo Oral Tablet|placebos treatment for 12 weeks
214619613|NCT01886573|DRUG|Azacitidine|Given SC
214619614|NCT01886573|DRUG|Entinostat|Given PO
214619615|NCT01886573|OTHER|Laboratory Biomarker Analysis|Correlative studies
214619616|NCT01886573|OTHER|Pharmacological Study|Correlative studies
214619617|NCT01886573|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214619618|NCT01977599|OTHER|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
214722174|NCT00767793|DRUG|Placebo|One drop in each eye every 12 hours for seven days
214619619|NCT03533647|OTHER|Observational|none (observational study)
214619620|NCT04206020|DRUG|SkQ1 Vehicle Solution|SkQ1 Ophthalmic Solution Vehicle
214619621|NCT04206020|DRUG|SkQ1 Ophthalmic Solution|SkQ1 Ophthalmic Solution
214619622|NCT04745039|DEVICE|Endopatch System|The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
214619623|NCT04278963|DRUG|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
214619624|NCT04278963|DRUG|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
214619625|NCT04278963|OTHER|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
214619626|NCT04278963|OTHER|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
214619627|NCT01835925|GENETIC|Tissue specimen|
214619628|NCT05780775|OTHER|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
214619629|NCT01722175|PROCEDURE|ALPPS surgery|
214619630|NCT01722175|PROCEDURE|PVO surgery|
214619631|NCT00080028|DRUG|Motexafin Gadolinium Injection|
214619632|NCT01550250|BEHAVIORAL|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
214619633|NCT01550250|BEHAVIORAL|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
214619634|NCT00962572|BEHAVIORAL|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
214619635|NCT03880487|DRUG|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
214619636|NCT03880487|DRUG|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
214619637|NCT03880487|DRUG|Oxycodone oral capsule|10 mg Oxycodone Capsules
214619638|NCT02011282|OTHER|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
214619639|NCT00127725|DEVICE|Pulsed electromagnetic field stimulation|
214717093|NCT06122753|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
214717094|NCT02732223|DIETARY_SUPPLEMENT|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
214619640|NCT06255704|DRUG|Zanubrutinib and RCHOP/RDHAP|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。"
214619641|NCT03483142|DRUG|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
214619642|NCT03483142|DRUG|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
214619643|NCT05415995|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
214619644|NCT02289170|DEVICE|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
214619645|NCT02289170|DEVICE|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
214619646|NCT00073216|BIOLOGICAL|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
214619647|NCT00073216|BIOLOGICAL|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
214619648|NCT02162836|DRUG|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
214619649|NCT05775185|RADIATION|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
214619650|NCT04217187|DEVICE|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
214619651|NCT04217187|DEVICE|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
214619652|NCT04512040|BEHAVIORAL|At-Home Yoga|At-home yoga practice over 12 weeks.
214619653|NCT05246436|PROCEDURE|warming saline media|use warm saline as a distention media in office hysteroscopy
214619654|NCT05246436|PROCEDURE|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
214619655|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily
214619656|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
214619657|NCT01197521|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
214619658|NCT01489566|DRUG|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
214619659|NCT01489566|DRUG|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
214619660|NCT00543075|DRUG|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
214619661|NCT00709982|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
214619662|NCT06098612|DRUG|C11-SY08|a PET imaging agent
214619663|NCT03481114|COMBINATION_PRODUCT|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
214619664|NCT03481114|COMBINATION_PRODUCT|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
214619665|NCT03155581|BEHAVIORAL|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
214619666|NCT03155581|BEHAVIORAL|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
214619667|NCT03899766|OTHER|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
214619668|NCT03899766|OTHER|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
214619669|NCT03899766|OTHER|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
214619670|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
214619671|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
214619672|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
214619673|NCT04746352|PROCEDURE|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
214717095|NCT02732223|DIETARY_SUPPLEMENT|Control treatment|placebo supplements
214619674|NCT04746352|PROCEDURE|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
214619675|NCT01830504|DRUG|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
214619676|NCT04971291|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks
214619677|NCT04971291|DRUG|Bupropion SR|Bupropion taken twice daily for 6 weeks
214619678|NCT04521036|BIOLOGICAL|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
214619679|NCT02053324|COMBINATION_PRODUCT|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
214619680|NCT04185753|DIAGNOSTIC_TEST|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
214619681|NCT00419146|DRUG|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
214619682|NCT00419146|DRUG|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
214619683|NCT00419146|OTHER|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
214619684|NCT00419146|OTHER|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
214619685|NCT05560282|DRUG|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
214619686|NCT00505596|BEHAVIORAL|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
214619687|NCT04807855|DEVICE|The cMLP device|There is only one medical device we are testing, so only one intervention.
214619688|NCT01072305|DEVICE|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
214619689|NCT01072305|DEVICE|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
214619690|NCT01651351|BIOLOGICAL|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
214619691|NCT01651351|BIOLOGICAL|Placebo: Human albumin 2.5%|Intravenous administration
214619692|NCT05111665|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|
214619693|NCT05111665|BEHAVIORAL|Relaxation Group Therapy (RGT)|
214619694|NCT05111665|BEHAVIORAL|Treatment as usual (TAU)|
214619695|NCT02746133|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
214619696|NCT03082105|OTHER|Breathing in snow|Breathing in snow with different physical properties
214619697|NCT05188820|PROCEDURE|PRP - platelet rich plasma injection|Facet block using PRP
214619698|NCT05188820|PROCEDURE|Cortisone injection|Facet block using cortisone
214619699|NCT04662944|DRUG|brolucizumab|There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
214619700|NCT04662944|DRUG|ranibizumab|There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
214619701|NCT04662944|DRUG|aflibercept|There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
214717096|NCT03477669|DIETARY_SUPPLEMENT|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
214717097|NCT03477669|DIETARY_SUPPLEMENT|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
214717098|NCT06071780|OTHER|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
214717099|NCT01296698|DRUG|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
214619702|NCT05104021|DEVICE|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
214619703|NCT00316251|DEVICE|Vibration Plate Therapy|
214619704|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
214619705|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
214619706|NCT00333398|BIOLOGICAL|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
214619707|NCT00707928|DRUG|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
214619708|NCT00707928|OTHER|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
214619709|NCT02529982|DIETARY_SUPPLEMENT|Curcumin|
214619710|NCT02529982|DIETARY_SUPPLEMENT|Placebo|
214619711|NCT02336659|DRUG|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
214619712|NCT02336659|DRUG|sitagliptin|DPP-4 Inhibition
214619713|NCT02336659|OTHER|Placebo|Saline
214619714|NCT04927286|BEHAVIORAL|Learning to Breathe|Learning to Breathe is an evidence-based mindfulness curriculum for adolescents
214619715|NCT04927286|BEHAVIORAL|Campus Connections|Campus Connections is a mentoring program for at-risk adolescents
214717100|NCT01296698|DRUG|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
214717101|NCT00251186|DRUG|Capecitabine and Cetuximab|
214619716|NCT03259750|OTHER|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
214619717|NCT01071538|DRUG|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
214619718|NCT04080570|OTHER|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
214619719|NCT04697238|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
214619720|NCT01784770|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
214619721|NCT05345535|OTHER|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
214619722|NCT05345535|OTHER|Walking|45 minutes of moderate tempo walking
214619723|NCT05606367|DEVICE|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
214619724|NCT05606367|DEVICE|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
214717102|NCT01975675|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
214717103|NCT01975675|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
214717104|NCT00224003|DRUG|Sodium Ferric Gluconate Complex in Sucrose.|
214619725|NCT00868062|OTHER|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
214619726|NCT05787873|DRUG|SIPS-2209-1|QD, PO
214619727|NCT05787873|DRUG|SIPS-2209-2, SIPS-2209-3|QD, PO
214717105|NCT00045812|DRUG|SCH-58235|
214717106|NCT00168909|DRUG|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
214717107|NCT00168909|DRUG|placebo|placebo once daily, oral, for 3 years
214619728|NCT01392911|DRUG|Rifampicin|High dose rifampicin
214619729|NCT00113828|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
214717108|NCT02012881|BEHAVIORAL|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
214717109|NCT02012881|BEHAVIORAL|Usual practice|Normal curriculum
214717110|NCT05124340|BIOLOGICAL|BCG vial vaccine|Intradermal injection
214717111|NCT05124340|BIOLOGICAL|BCG ampoule vaccine|Intradermal injection
214717112|NCT03520725|OTHER|No Intervention|This gruop did not have an intervention
214717113|NCT03520725|DIETARY_SUPPLEMENT|Pineapple snack bar|30 g daily of pineapple snack bar
214717114|NCT03520725|DIETARY_SUPPLEMENT|Mango snack bar|30 g daily of mango snack bar
214717115|NCT01202760|DRUG|LY2127399|
214619730|NCT00113828|PROCEDURE|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
214619731|NCT00258674|OTHER|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
214619732|NCT00258674|OTHER|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
214619733|NCT00258674|OTHER|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
214717116|NCT01202760|DRUG|Placebo|
214717117|NCT03018457|DEVICE|ISQ|Measured by Osstell.
214717118|NCT02483689|DRUG|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
214717119|NCT02483689|OTHER|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
214717120|NCT02483689|DRUG|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
214717121|NCT02483689|OTHER|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
214717122|NCT00871572|DRUG|LY2409021|4 capsules by mouth taken once daily for 12 weeks
214717123|NCT00871572|DRUG|Placebo|4 capsules by mouth once daily for 12 weeks
214717124|NCT00735670|DRUG|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
214717125|NCT00735670|OTHER|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
214717126|NCT02828007|DEVICE|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
214717127|NCT03679429|DEVICE|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
214619734|NCT01035554|OTHER|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
214619735|NCT01035554|OTHER|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
214619736|NCT01035554|OTHER|Usual Care|Standard care
214619737|NCT01035554|OTHER|Printed Materials|National Institutes of Health Printed Materials on hypertension
214619738|NCT00949546|DRUG|etanercept|etanercept 50 mg sc twice weekly
214619739|NCT00002117|DRUG|Zidovudine|
214619740|NCT00002117|DRUG|Zalcitabine|
214619741|NCT03715153|DRUG|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
214619742|NCT03715153|DRUG|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
214619743|NCT03715153|DRUG|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
214619744|NCT05223660|DRUG|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
214619745|NCT05223660|DRUG|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
214619746|NCT05223660|DRUG|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
214619747|NCT05223660|DRUG|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
214619748|NCT00150293|DRUG|Pregabalin|
214619749|NCT00075088|DEVICE|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
214619750|NCT00075088|OTHER|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
214619751|NCT05556278|DIAGNOSTIC_TEST|Ultrasound study|based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
214619752|NCT05556278|DIAGNOSTIC_TEST|Neurophysiological test|ultrasound protocol described by Chen et al. (2)
214619753|NCT00020579|DRUG|entinostat|
214619754|NCT01637909|DRUG|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
214717128|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone
214619755|NCT01637909|DIETARY_SUPPLEMENT|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
214619756|NCT01637909|OTHER|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
214619757|NCT02975427|OTHER|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
214619758|NCT02607683|DRUG|XAF5 (concentration A: 0.1%)|
214619759|NCT02607683|DRUG|XAF5 (concentration B: 0.035%)|
214619760|NCT02607683|DRUG|Matching placebo|
214619761|NCT01565915|DEVICE|Perlane-L|Perlane-L Injection in the midface
214619762|NCT01565915|OTHER|Non-treatment|Non-treatment Arm
214619763|NCT00904631|DEVICE|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
214619764|NCT05449990|OTHER|Participation in PFCC-IR|Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
214619765|NCT03093753|OTHER|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
214619766|NCT03093753|OTHER|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
214619767|NCT03093753|OTHER|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
214619768|NCT03093753|DIETARY_SUPPLEMENT|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
214619769|NCT03093753|OTHER|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
214619770|NCT03093753|DIETARY_SUPPLEMENT|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
214619771|NCT03093753|OTHER|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
214619772|NCT03093753|DIETARY_SUPPLEMENT|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
214619773|NCT03093753|OTHER|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
214619774|NCT03093753|OTHER|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
214619775|NCT03093753|OTHER|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
214619776|NCT03093753|OTHER|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
214619777|NCT03093753|OTHER|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
214619778|NCT03093753|OTHER|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
214717129|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
214619779|NCT00450723|DRUG|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
214619780|NCT00450723|PROCEDURE|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
214619781|NCT00450723|PROCEDURE|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
214619782|NCT00450723|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
214619783|NCT00450723|PROCEDURE|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
214619784|NCT00450723|RADIATION|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
214619785|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions|Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.
214619786|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions using intraoral scanners|Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
214619787|NCT00329667|DEVICE|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
214619788|NCT04572880|PROCEDURE|Trabeculectomy|Trabeculectomy is performed
214619789|NCT04572880|DEVICE|XEN®|Microinvasive Surgery with XEN® is performed
214619790|NCT04572880|DEVICE|Preserflo®|Microinvasive Surgery with Preserflo® is performed
214619791|NCT00078325|DRUG|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
214619792|NCT00078325|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
214619793|NCT00078325|DRUG|Placebo|Matching placebo tablets once daily in the morning
214619794|NCT04719494|OTHER|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
214619795|NCT00710736|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
214619796|NCT00710736|DRUG|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
214619797|NCT00578136|DRUG|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
214619798|NCT01677156|DIAGNOSTIC_TEST|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
214619799|NCT03700580|DRUG|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
214619800|NCT03700580|DRUG|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
214619801|NCT02680132|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
214619802|NCT02680132|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
214619803|NCT02047253|DRUG|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
214619804|NCT02047253|DRUG|Dexamethasone|Administered prior to administration of Study drug
214619805|NCT02047253|DRUG|Acyclovir|Administered orally twice daily
214619806|NCT01034592|DRUG|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
214619807|NCT01037660|DRUG|Metformin|Metformin 1 gram per day
214619808|NCT01987960|DRUG|Placebo|Once daily, tablets, orally
214717130|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with nivolumab combination
214619809|NCT01987960|DRUG|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
214619810|NCT00121433|DRUG|leptin|
214619811|NCT00445705|DRUG|placebo|Part A: Placebo every 12 hours for 4 weeks
214619812|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
214619813|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
214619814|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
214717131|NCT00036543|DRUG|Atrasentan|
214717132|NCT04572581|OTHER|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
214722175|NCT00767793|DRUG|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
214619815|NCT02575053|PROCEDURE|assessment of a new latex protocol|"1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol."
214619816|NCT00966420|DEVICE|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
214619817|NCT01582295|DRUG|Cabozantinib|Starting dose 40 mg daily
214619818|NCT02887014|PROCEDURE|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
214619819|NCT02065167|BIOLOGICAL|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
214619820|NCT02241382|DEVICE|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
214619821|NCT02241382|DEVICE|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
214619822|NCT01295476|GENETIC|gene expression analysis|
214619823|NCT01295476|GENETIC|microarray analysis|
214619824|NCT01295476|OTHER|laboratory biomarker analysis|
214619825|NCT02330822|DRUG|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
214619826|NCT04374760|BEHAVIORAL|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
214619827|NCT05731258|DRUG|Liposomal doxorubicin containing regimen|Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
214619828|NCT00527436|DIETARY_SUPPLEMENT|fish oil|Fish oil pills will be taken daily for 12 weeks
214619829|NCT00527436|DIETARY_SUPPLEMENT|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
214619830|NCT01499784|BEHAVIORAL|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
214619831|NCT04066036|OTHER|This is an observational study only.|This is an observational study only.
214619832|NCT02810847|DEVICE|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
214619833|NCT03371433|OTHER|Soft drinks|Caffeine and Caffeine free soft drinks
214619834|NCT04118270|DEVICE|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
214619835|NCT01304095|DRUG|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
214619836|NCT05627544|PROCEDURE|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
214619837|NCT05627544|PROCEDURE|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
214619838|NCT05627544|PROCEDURE|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
214619839|NCT05627544|PROCEDURE|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
214619840|NCT04586543|DRUG|Selegiline|10 mg selegiline tablet per day
214619841|NCT04586543|DRUG|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
214619842|NCT03223870|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
214619843|NCT00281645|DRUG|Bicifadine|
214619844|NCT00281645|DRUG|Standard of Care (pharmacological analgesic treatment)|
214619845|NCT02209298|DEVICE|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
214619846|NCT05273476|PROCEDURE|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
214619847|NCT04662658|DRUG|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
214619848|NCT01878942|DRUG|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
214619849|NCT01878942|DRUG|LSD|200µg per os, single dose
214619850|NCT04843215|PROCEDURE|Type of omentectomy|Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
214619851|NCT05602662|BEHAVIORAL|Music|Music therapy during mechanical ventilation
214619852|NCT01607424|BEHAVIORAL|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
214619853|NCT05824286|OTHER|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
214619854|NCT05586048|DRUG|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
214619855|NCT00480818|DRUG|SAM-531|
214619856|NCT01854320|BEHAVIORAL|Acceptance-based treatment|
214619857|NCT01854320|BEHAVIORAL|Standard behavioral treatment|
214619858|NCT04315194|DRUG|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
214619859|NCT05147467|DRUG|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
214619860|NCT01892163|DEVICE|Ozurdex|Dexamethasone implant (Ozurdex)
214717133|NCT04197986|DRUG|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
214717134|NCT04197986|DRUG|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
214717135|NCT02611700|DRUG|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
214619861|NCT04919291|DEVICE|Topoguided LASIK|Topoguided ablation profile on dominant eye
214619862|NCT04919291|DEVICE|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
214619863|NCT01058070|DEVICE|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
214619864|NCT03302975|DEVICE|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
214619865|NCT06089148|DIAGNOSTIC_TEST|contrast enhanced digital mammography, tomosyntheis and MRI|
214619866|NCT04018794|DEVICE|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
214619867|NCT06220370|OTHER|Observational|There is no clinical intervention as part of this study. Participants will receive treatment as per their clinical treating team.
214619868|NCT04007575|DIAGNOSTIC_TEST|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
214619869|NCT05636592|DRUG|immunotherapy|statin combined with immunotherapy
214619870|NCT01922687|DRUG|amlodipine plus atorvastatin (Caduet)|
214619871|NCT01922687|DRUG|amlodipine (Norvasc)|
214619872|NCT03497585|BEHAVIORAL|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
214717136|NCT02611700|DRUG|Paclitaxel|175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
214717137|NCT02611700|DRUG|Cisplatin|60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
214717138|NCT02611700|DRUG|Placebo|400mg,day1,weekly,until disease progression or toxicity
214717139|NCT04655053|BEHAVIORAL|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
214717140|NCT04655053|BEHAVIORAL|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
214717141|NCT04655053|BEHAVIORAL|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
214717142|NCT03920865|DRUG|Risdiplam|5 milligram (mg) oral dose administered in fasted state
214717143|NCT02557854|DRUG|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
214717144|NCT02557854|DEVICE|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
214717145|NCT01852929|OTHER|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
214717146|NCT01932658|BIOLOGICAL|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
214717147|NCT02389686|DEVICE|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
214717148|NCT04197141|RADIATION|Conventionally-fractionated WPRT|Total dose: 45 Gy in 25 fractions WPRT
214717149|NCT04197141|RADIATION|Hypofractionated WPRT|Total dose: 25 Gy in 5 fractions WPRT
214717150|NCT01042951|BIOLOGICAL|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
214717151|NCT01042951|OTHER|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
214717152|NCT04480931|BEHAVIORAL|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
214717153|NCT04480931|BEHAVIORAL|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
214717154|NCT03490435|DIAGNOSTIC_TEST|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
214717155|NCT02437552|DEVICE|ergometer cycle exercise|
214717156|NCT02437552|OTHER|routine physiotherapy|routine physiotherapy
214717157|NCT00108953|DRUG|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
214717158|NCT00108953|DRUG|Doxorubicin/Placebo|Chemotherapy plus Placebo
214717159|NCT05149612|OTHER|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
214717160|NCT03934424|BEHAVIORAL|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
214717161|NCT03934424|BEHAVIORAL|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
214717162|NCT01860963|PROCEDURE|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
214717163|NCT01154881|DRUG|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
214717164|NCT00347893|PROCEDURE|Selective laser trabeculoplasty|
214717165|NCT00476177|BIOLOGICAL|Infusion of donor dendritic cells|Given in the outpatient setting
214717166|NCT00476177|BIOLOGICAL|Infusion of donor lymphocytes|Given in outpatient setting
214717167|NCT01948869|DEVICE|Phoenix II (BAY81-2996)|
214717168|NCT01948869|DEVICE|Phoenix I (BAY81-2996)|
214717169|NCT00574444|PROCEDURE|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
214717170|NCT05706649|BEHAVIORAL|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
214717171|NCT05955079|OTHER|Whole blood|3 samples (before, after surgery and before chemotherapy)
214717172|NCT00554476|DRUG|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
214717173|NCT05666882|OTHER|Non-interventional|Non-interventional
214722176|NCT00767793|DRUG|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
214722177|NCT00767793|DRUG|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
214619873|NCT00219284|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
214619874|NCT04935099|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
214619875|NCT04935099|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
214619876|NCT01982474|BIOLOGICAL|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
214619877|NCT01982474|OTHER|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
214619878|NCT04076514|PROCEDURE|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
214619879|NCT03129490|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214619880|NCT03129490|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214619881|NCT03129490|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214619882|NCT03129490|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
214619883|NCT04643951|BEHAVIORAL|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
214619884|NCT05066789|DEVICE|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
214619885|NCT05066789|DRUG|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
214619886|NCT05375994|DRUG|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
214619887|NCT06321432|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
214619888|NCT06321432|BEHAVIORAL|Usual care|Usual care
214619889|NCT06552312|OTHER|Delphi Questionnaire|"Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion."
214619890|NCT06061250|DIETARY_SUPPLEMENT|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
214619891|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
214619892|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
214619893|NCT02943057|DRUG|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
214619894|NCT04722042|OTHER|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
214619895|NCT04722042|OTHER|default mapping|Default frequency filter assignments
214619896|NCT02289651|DEVICE|Venner|Video-laryngoscopy
214619897|NCT02289651|DEVICE|Miller|Direct-Laryngoscopy
214619898|NCT05803200|DRUG|No intervention|No intervention was given as this is an observational study.
214619899|NCT03067571|BIOLOGICAL|Daratumumab|Given IV
214619900|NCT06852274|DIETARY_SUPPLEMENT|Clostridium butyricum CBM588® (Butirrisan®)|Probiotic
214619901|NCT06852274|DRUG|Rifaximin 400 mg Oral Tablet|Antibiotic
214619902|NCT03598816|DRUG|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
214619903|NCT03598816|DRUG|Tremelimumab|-Tremelimumab will be administered first
214619904|NCT03598816|DEVICE|TDS-IM v1.0 System|-Integrated electroporation device
214619905|NCT03598816|BIOLOGICAL|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
214619906|NCT03598816|PROCEDURE|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
214619907|NCT05155202|DRUG|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
214619908|NCT02902250|PROCEDURE|Decompression|vertebral body decompression in compression fracture
214619909|NCT02902250|PROCEDURE|Conservative Treatment|Conservative Treatment in vertebral compression fracture
214619910|NCT06971705|DEVICE|repetitive transcranial magnetic stimulation, rTMS|Participants underwent rTMS intervention prior to daily ankle stability training. The interventional targets were the key cortical brain regions identified in preliminary studies, with stimulation applied to the contralateral cortical areas corresponding to the affected ankle joint. Parameters included a figure-of-8 coil, 10 Hz frequency, 2-second stimulation duration, 8-second inter-train intervals, 60 repetitions, totaling 1,200 pulses per session, with each session lasting 10 minutes. Ankle stability training commenced within 10 minutes post-rTMS, following the same duration and intensity as the Ankle Stability Training Group + Sham rTMS Group. The treatment was conducted three times per week for a total of 4 weeks.
214619911|NCT06971705|BEHAVIORAL|ankle stability training|The ankle stability training protocol comprised three modalities: neuromuscular training, balance training, and proprioceptive training. Specific exercises included single-leg stance, balance pad training, heel raises, resistive ankle inversion/eversion exercises, MOBO board balance exercises, alphabet tracing (toe-writing), lateral walking, heel walking, toe walking, and jump and landing control drills. The training progressed from stable to unstable surfaces, starting at low intensity and gradually increasing in difficulty and intensity. The training was conducted three times per week for a total of four weeks.
214619912|NCT06971705|DEVICE|Sham repetitive transcranial magnetic stimulation, SrTMS|Before each session of ankle stability training, participants received sham rTMS intervention. The sham stimulation mimicked the sensory experience of real rTMS but did not produce any physiological effects.
214619913|NCT06304805|DRUG|cycle 1: treatment drug|for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
214619914|NCT06304805|DRUG|cycle 1: reference drug|for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
214619915|NCT06304805|BEHAVIORAL|cycle 1: fasted|for cycle 1 treatment: participants are asked to take the drug fasted
214619916|NCT06304805|BEHAVIORAL|cycle 1: food|for cycle 1 treatment: participants are asked to take the drug after food intake
214717174|NCT04063072|PROCEDURE|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
214717175|NCT03803202|BIOLOGICAL|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
214717176|NCT03803202|BIOLOGICAL|PCV13|Participants received a single dose of PCV13 intramuscularly.
214717177|NCT03803202|BIOLOGICAL|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
214619917|NCT06304805|DRUG|cycle 2: treatment drug|for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
214619918|NCT06304805|DRUG|cycle 2: reference drug|for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
214619919|NCT06304805|BEHAVIORAL|cycle 2: fasted|for cycle 2 treatment: participants are asked to take the drug fasted
214619920|NCT06304805|BEHAVIORAL|cycle 2: food|for cycle 2 treatment: participants are asked to take the drug after food intake
214619921|NCT06304805|DRUG|cycle 3: treatment drug|for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
214717178|NCT04709718|PROCEDURE|hepatectomy|liver resection taking over the liver hemangioma
214717179|NCT04829266|BEHAVIORAL|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
214717180|NCT03751423|DRUG|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
214619922|NCT06304805|DRUG|cycle 3: reference drug|for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
214619923|NCT06304805|BEHAVIORAL|cycle 3: fasted|for cycle 3 treatment: participants are asked to take the drug fasted
214619924|NCT06304805|BEHAVIORAL|cycle 3: food|for cycle 3 treatment: participants are asked to take the drug after food intake
214619925|NCT00118391|BEHAVIORAL|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
214619926|NCT00118391|BEHAVIORAL|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
214619927|NCT06268444|DEVICE|7-day actimetry sleep recording|7-day actimetry sleep recording
214619928|NCT06268444|OTHER|Determination of environmental pollutants in breast milk|Determination of environmental pollutants in breast milk
214619929|NCT06268444|OTHER|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
214619930|NCT06268444|OTHER|Continuous recording of the child&#39;s temperature for 7 days|Continuous recording of the child\&#39;s temperature for 7 days
214619931|NCT06268444|OTHER|Use of a sleep diary for 7 days|Use of a sleep diary for 7 days
214619932|NCT06268444|OTHER|Parental questionnaire of environmental exposure|Parental questionnaire of environmental exposure
214619933|NCT06614465|OTHER|Multimodal Rehabilitation|The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
214619934|NCT06619522|DRUG|Ruxolitinib|Given orally
214619935|NCT06619522|DRUG|INCB57643|Given orally
214619936|NCT00761618|PROCEDURE|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
214619937|NCT00761618|PROCEDURE|IPC Placement|IPC placed in chest cavity to drain excess fluid
214619938|NCT00761618|RADIATION|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
214619939|NCT05399888|DRUG|BIIB080|Administered as specified in the treatment arm.
214619940|NCT05399888|DRUG|BIIB080-matching placebo|Administered as specified in the treatment arm.
214619941|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
214619944|NCT01739569|OTHER|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
214619945|NCT03779971|OTHER|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
214619946|NCT03779971|OTHER|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
214619947|NCT03779971|OTHER|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
214619948|NCT00498160|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
214619949|NCT01357421|DRUG|TT301|Single iv dose of TT301
214619950|NCT01357421|DRUG|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
214619951|NCT06026748|DRUG|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
214619952|NCT06026748|DRUG|Placebo|Placebo contains only excipients.
214619953|NCT05103878|DRUG|BT051 100mg|Single oral dose of 100mg BT051
214619954|NCT05103878|DRUG|BT051 300mg|Single oral dose of 300mg BT051
214717181|NCT03751423|DRUG|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
214717182|NCT03751423|DRUG|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
214619955|NCT05103878|DRUG|BT051 700mg|Single oral dose of 700mg BT051
214619956|NCT05103878|DRUG|BT051 1500mg|Single oral dose of 1500mg BT051
214619957|NCT05103878|DRUG|BT051 3500mg|Single oral dose of 3500mg BT051
214619958|NCT05103878|DRUG|Matching Placebo|Placebo Matching BT051
214619959|NCT03715894|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
214619960|NCT06144775|OTHER|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
214619961|NCT02988180|OTHER|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
214619962|NCT02988180|OTHER|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
214619963|NCT02652338|DIETARY_SUPPLEMENT|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
214619964|NCT02652338|DIETARY_SUPPLEMENT|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
214619965|NCT05445401|BEHAVIORAL|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
214619966|NCT05445401|BEHAVIORAL|Standard medical care|Traditional care
214619967|NCT00074321|DRUG|irinotecan hydrochloride|Given IV
214619968|NCT00074321|DRUG|oxaliplatin|Given IV
214619969|NCT00074321|DRUG|capecitabine|Given PO
214619970|NCT00074321|OTHER|laboratory biomarker analysis|Correlative studies
214619971|NCT00074321|OTHER|pharmacological study|Correlative studies
214619972|NCT05102370|DRUG|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
214619973|NCT03255252|DRUG|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
214619974|NCT03255252|COMBINATION_PRODUCT|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
214619975|NCT03392792|DRUG|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
214619976|NCT03392792|PROCEDURE|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
214619977|NCT00981513|BIOLOGICAL|Trivalent live attenuated seasonal influenza vaccine|One dose
214619978|NCT00981513|BIOLOGICAL|Monovalent live attenuated pandemic influenza vaccine|One dose
214619979|NCT00981513|BIOLOGICAL|Saline|One dose
214717183|NCT03751423|DRUG|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
214717184|NCT03751423|DRUG|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
214717185|NCT00457470|DRUG|AG-014699|
214717186|NCT05883085|DRUG|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
214717187|NCT03162393|PROCEDURE|nerve transfer|
214717188|NCT01585493|OTHER|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
214717189|NCT01585493|BEHAVIORAL|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
214717190|NCT01585493|BEHAVIORAL|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
214717191|NCT02715583|DRUG|11C-Acetate|
214717192|NCT01125293|DRUG|Everolimus|
214717193|NCT01125293|DRUG|Rituximab|
214717194|NCT01125293|DRUG|Bortezomib|
214717195|NCT04262622|DEVICE|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
214717196|NCT04262622|DEVICE|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
214717197|NCT03496727|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
214717198|NCT03496727|PROCEDURE|Patient controlled analgesia|Patient-controlled analgesia
214717199|NCT00738829|DRUG|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
214717200|NCT00738829|DRUG|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
214619980|NCT01839396|DEVICE|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
214619981|NCT04694664|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
214619982|NCT01519596|PROCEDURE|quality-of-life assessment|Ancillary studies
214619983|NCT01519596|OTHER|counseling intervention|Receive lifestyle-related counseling
214619984|NCT01519596|BEHAVIORAL|exercise intervention|Undergo physical activity intervention
214619985|NCT01519596|OTHER|educational intervention|Receive educational materials
214619986|NCT01519596|PROCEDURE|standard follow-up care|Undergo usual care
214619987|NCT05097144|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
214619988|NCT05097144|DEVICE|Lens B (asmofilcon A)|Daily wear for one month
214619989|NCT03100071|DRUG|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
214619990|NCT05071365|OTHER|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
214717201|NCT00738829|BIOLOGICAL|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
214717202|NCT02111512|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
214717203|NCT02407912|DRUG|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
214717204|NCT00357422|PROCEDURE|Operation|No drug needed
214619991|NCT02604953|DIAGNOSTIC_TEST|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
214619992|NCT02604953|DIAGNOSTIC_TEST|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
214619993|NCT02130739|PROCEDURE|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
214619994|NCT02130739|PROCEDURE|mastectomy|mastectomy with/without breast reconstruction
214619995|NCT02130739|DRUG|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
214619996|NCT02130739|DRUG|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
214619997|NCT02130739|DRUG|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
214619998|NCT03883594|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
214619999|NCT00664495|BEHAVIORAL|Diet Weight Loss|
214620000|NCT00664495|BEHAVIORAL|Exercise Weight Loss|
214620001|NCT00664495|BEHAVIORAL|Exercise Without Weight Loss|
214620002|NCT04196738|OTHER|ventilation strategy|Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
214620003|NCT03817554|DRUG|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
214620004|NCT03817554|OTHER|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
214620005|NCT02603471|OTHER|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
214620006|NCT02603471|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
214620007|NCT03999658|BIOLOGICAL|STI-3031|anti-PD-L1 antibody
214620008|NCT04224844|OTHER|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
214620009|NCT04224844|OTHER|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
214620010|NCT02449681|DRUG|TH-4000 (Tarloxotinib)|
214620011|NCT00199602|DRUG|warfarine - low molecular heparin|
214620012|NCT03480568|DRUG|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
214620013|NCT03276312|DEVICE|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
214620014|NCT00930839|DRUG|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
214620015|NCT02441413|RADIATION|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
214620016|NCT03275220|DIAGNOSTIC_TEST|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
214717205|NCT00357422|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
214620017|NCT00848133|PROCEDURE|mini-midvastus surgical approach for total knee arthroplasty|
214620018|NCT00848133|PROCEDURE|mini-subvastus surgical approach for total knee arthroplasty|
214620019|NCT04020939|DEVICE|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
214620020|NCT04020939|DRUG|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
214620021|NCT03294525|DRUG|Escitalopram Pill|escitalopram 10\~20mg/day
214620022|NCT03294525|DRUG|Duloxetine|duloxetine 30\~120mg/day
214620023|NCT03294525|DRUG|Mirtazapine Pill|Mirtazapine 15\~45mg/day
214620024|NCT03294525|DRUG|Other Antidepressants|
214620025|NCT06475313|BEHAVIORAL|plaque index assessment, periodontal probing, Bleeding on probing (BOP), Prosthetic adjacency check, initial occlusal contact, maximum occlusal contact, and filling of the cusps.|oral panoramic radiograph
214620026|NCT02401321|BEHAVIORAL|Telephone-Based Intervention|Complete Taking Care of Her program
214620027|NCT02401321|OTHER|Caregiver-Assisted Training|Complete Taking Care of Her program
214620028|NCT02401321|OTHER|Questionnaire Administration|Ancillary studies
214620029|NCT02401321|OTHER|Quality-of-Life Assessment|Ancillary studies
214620030|NCT03760341|PROCEDURE|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
214620031|NCT03760341|PROCEDURE|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
214620032|NCT05482074|DRUG|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
214620033|NCT00450242|DRUG|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
214620034|NCT00450242|DRUG|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
214717206|NCT03279341|DRUG|polyethylene glycol|osmotic laxative
214717207|NCT03279341|DRUG|Bisacodyl|stimulant laxative
214620035|NCT02113943|DRUG|Citalopram 30mg|
214620036|NCT02917681|OTHER|Two intrathecal MSC injections|
214620037|NCT04881071|DEVICE|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
214620038|NCT04881071|OTHER|Usual clinical practice|Participants will receive the usual clinical practice
214620039|NCT02269787|BEHAVIORAL|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
214620040|NCT04262635|DRUG|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
214620041|NCT04262635|DRUG|Cetuximab|Maintenance treatment ( ArmB )
214620042|NCT05407909|DRUG|SYHX2001|SYHX2001 tablets, oral
214620043|NCT06547658|OTHER|Mouth closure|Closing the mouth during sleep by applying pressure to the mentum until the teeth were in occlusion, without altering the head position.
214620044|NCT04170803|DEVICE|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
214620045|NCT04170803|OTHER|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
214620046|NCT04967079|DRUG|Trametinib|Trametinib 2 mg given orally, once daily
214620047|NCT04967079|DRUG|Anlotinib|Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle
214620048|NCT05899881|BEHAVIORAL|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
214620049|NCT00687440|DRUG|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
214620050|NCT00687440|DRUG|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
214620051|NCT00687440|DRUG|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
214717208|NCT03279341|DRUG|Prucalopride|prokinetic
214717209|NCT02080286|BEHAVIORAL|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
214620052|NCT02228720|DEVICE|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
214620053|NCT01892592|BEHAVIORAL|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
214620054|NCT03086395|DRUG|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
214620055|NCT00290199|DEVICE|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
214620056|NCT02829242|DEVICE|NIRS Monitoring (SenSmart Monitor)|
214620057|NCT04563273|BIOLOGICAL|BCG vaccine 1（0.025mg/0.1ml/person）|Intradermal injection of 0.025mg/0.1ml/person dose BCG.
214620058|NCT04563273|BIOLOGICAL|BCG vaccine 2 （0.05mg/0.1ml/person）|Intradermal injection of 0.05mg/0.1ml/person dose BCG.
214620059|NCT04563273|BIOLOGICAL|BCG vaccine 3（0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
214620060|NCT04563273|BIOLOGICAL|BCG vaccine 4 （0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
214620061|NCT04563273|BIOLOGICAL|Placebo of BCG vaccine （0.1ml/person）|Intradermal injection of 0.1ml/person dose Placebo.
214620062|NCT00254748|DRUG|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
214620063|NCT00254748|DRUG|Placebo|placebo
214620064|NCT00255970|OTHER|DFDBA|Demineralized Freeze Dried Allograft bone
214620065|NCT00255970|DEVICE|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
214620066|NCT03926689|BEHAVIORAL|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
214620067|NCT03926689|BEHAVIORAL|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
214620068|NCT03101774|DEVICE|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
214620069|NCT03101774|DEVICE|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
214620070|NCT03101774|OTHER|Control group|Conventional therapy without any inspiratory muscle training program
214620071|NCT02817971|BEHAVIORAL|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
214620072|NCT02817971|BEHAVIORAL|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
214620073|NCT00577109|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
214620074|NCT00577109|DRUG|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
214717210|NCT02080286|DEVICE|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
214717211|NCT02080286|DEVICE|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
214620075|NCT00577109|DRUG|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
214620076|NCT00577109|DRUG|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
214620077|NCT00577109|DRUG|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
214620078|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
214620079|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
214620080|NCT01837030|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
214620081|NCT01837030|DEVICE|Capsule Endoscopy|GIVEN capsule
214620082|NCT02726971|DRUG|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
214620083|NCT05206409|DIAGNOSTIC_TEST|Ultrasound|Fetal head position determination using ultrasound
214620084|NCT04127253|DEVICE|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
214620085|NCT04127253|DEVICE|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
214620086|NCT04127253|BEHAVIORAL|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
214620087|NCT03180099|DRUG|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
214620088|NCT03180099|DRUG|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
214620089|NCT02324075|BEHAVIORAL|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
214620090|NCT03321227|OTHER|Snack skipping|No snack provided
214620091|NCT03321227|OTHER|Whole eggs|2 whole large eggs scrambled, provided as a snack
214620092|NCT03321227|OTHER|Egg whites|2 egg whites scrambled, provided as a snack
214620093|NCT03321227|OTHER|Egg yolks|2 egg yolks scrambled, provided as a snack
214620094|NCT03321227|OTHER|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
214620095|NCT04623203|OTHER|No intervention|No intervention
214620096|NCT00474110|DRUG|Ketamine & hydromorphone|See Detailed Description
214620097|NCT03588988|DRUG|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
214620098|NCT03588988|DRUG|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
214620099|NCT01660360|BIOLOGICAL|Tanibirumab|
214620100|NCT04084067|DRUG|Indocyanine Green|IV
214620101|NCT02170402|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|"* Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen"
214620102|NCT04609735|OTHER|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
214620103|NCT04609735|OTHER|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
214620104|NCT04465721|BEHAVIORAL|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
214620105|NCT04465721|BEHAVIORAL|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
214620106|NCT05264740|BEHAVIORAL|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
214620107|NCT05264740|BEHAVIORAL|Educational materials|The control group will receive educational material only.
214620108|NCT06977165|DIAGNOSTIC_TEST|Antibiotic quantification|Piperacillin/tazobactam quantification using liquid chromatography-tandem mass spectrometry
214620109|NCT06978322|PROCEDURE|Immediate surgery|Patients will undergo upfront surgery, then adjuvant chemotherapy.
214620110|NCT06978322|PROCEDURE|Neoadjuvant chemotherapy|Patients will undergo neoadjuvant chemotherapy, then surgery.
214620111|NCT06979024|GENETIC|Triplet-primed PCR or Long-read sequencing|This study involves long-read sequencing in patients with Myotonic Dystrophy Type 1 (DM1) to identify specific motifs, determine the range of repeat numbers, and assess the presence of interruptions in the CTG repeat sequence. The aim is to gain insights into the genetic variability and its clinical implications in DM1.
214620112|NCT06977659|DRUG|Norepinephrine|Norepinephrine bitartrate (LEVOPHEDR, Pfizer inc.) 4 mg/4ml + 5% Dextrose in water 246 ml (total volume 250 ml, final concentration 16 mcg/ml) infuses intravenously via a central catheter or peripheral line with the rate of 10 ml/h (equivalent to 0.05 mcg/kg/min for a 50-kg patient). The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
214620113|NCT06977659|DRUG|Placebo|5% Dextrose in water 250 ml infused intravenously at a rate of 10 ml/h. The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
214717212|NCT02638870|DRUG|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
214620114|NCT06978075|DEVICE|Chest wall tumor resection by the artificial intelgent assistent|we plan to carry out of the research on the application of artificial intelligence (AI) assisted chest wall tumor research combined with a personalized 3D preformed chest wall defect reconstruction system in chest wall tumor surgery. Data will be imported into a computer to draw a 3D model of the tumor and construct an ideal resection range to ensuring sufficient surgical margins while avoiding damage to important nerve and vascular tissues in the chest. Preformed titanium plates will be prepared based on the calculated resection range and the titanium plates will be detachable assembly components through screws, which can be adjusted at any time according to the surgical situation.
214620115|NCT06978699|DRUG|XH-S003 Capsule|25mg \& 100mg
214620116|NCT06978933|DRUG|ABSK-011|"Drug: ABSK-011 RP2D according to the results of Phase I trial~Other Names:~• FGFR4 inhibitor Drug: ABSK043 RP2D according to the results of Phase I trial~Other Names:~• Oral PD-L1 inhibitor"
214620117|NCT06978777|DRUG|Caffeine (200 mg)|single dose of 200mg caffeine orally in study visit A
214620118|NCT06978777|DRUG|Placebo|single dose of 1 tablet Placebo in study visit B
214620119|NCT06978478|PROCEDURE|Unlabelled PET CT Scan|\[18F\]-FDG-PET CT
214620120|NCT06978478|PROCEDURE|Labelled PET CT Scan|\[18F\]-FBA-A20FMDV2 -PET CT
214620121|NCT06977217|PROCEDURE|CRT-D implantation|Cardiac resynchronization therapy with a defibrillator (CRT-D). This combination device uses a pacemaker and an implantable cardioverter-defibrillator (ICD). It may be recommended for people with heart failure who also have a risk of sudden cardiac death. It can find dangerous heart rhythms and correct them. It can pace the heartbeat or shock the heart out of a dangerous heart rhythm.
214620122|NCT06978023|COMBINATION_PRODUCT|JM-LD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix Lonicerae Japonicae Flos (CAL) plus low dose extract of Ophiopogonis Radix
214620123|NCT06978023|COMBINATION_PRODUCT|JM-HD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix, Lonicerae Japonicae Flos (CAL) plus high dose extract of Ophiopogonis Radix
214620124|NCT06978023|COMBINATION_PRODUCT|Placebo|Placebo consisting of excipients, coloring and food ingredients to provide a powder mixture of same weight with similar color, texture and odour
214620125|NCT06977906|PROCEDURE|conventional Robotic-assisted radical prostatectomy group|Robotic-assisted radical prostatectomy uses a standard anterior approach with transabdominal or extraperitoneal access. After establishing pneumoperitoneum, the Retzius space is dissected to expose the prostate. The deep dorsal venous complex is ligated to control bleeding, and the bladder neck is carefully dissected while preserving the ureters. Seminal vesicles, vas deferens, and neurovascular bundles are selectively preserved based on tumor characteristics. A tension-free anastomosis of the bladder and urethra is performed using absorbable sutures. Lymph node dissection is done if necessary. The robotic system ensures precise dissection, hemostasis, and suturing, optimizing oncological control while preserving urinary continence and sexual function with reduced bleeding and complications.
214717213|NCT06196918|DRUG|Rivaroxaban 10 MG|Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
214717214|NCT06196918|DRUG|Placebo|Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
214620126|NCT06977906|PROCEDURE|Improved Robotic-assisted radical prostatectomy group|The procedure is performed in a head-down, feet-up supine position with an abdominal or extraperitoneal approach. The right peritoneum is opened along the right external iliac vein to clear the obturator nerve, vessels, and lymph nodes. The external and internal iliac lymph nodes are also cleared. The right pelvic fascia is incised to remove prostate fat while preserving the bladder's anterior wall peritoneum. The same approach is used on the left side. The peritoneum is retracted to clear anterior prostate fat, and the deep venous complex is ligated to expose the prostate. Prostatectomy is performed, followed by urethra and bladder anastomosis, and peritoneal suturing with drainage tube placement.
214620127|NCT06977932|DRUG|Carbarmazepine|If patients were on carbamazepine (CBZ) prior to enrollment, the CBZ dose remained unchanged after enrollment; if patients were on oxcarbazepine (OXC) prior to enrollment, they received half of their pre-enrollment OXC dose as CBZ after enrollment. Orally administered for four consecutive weeks.
214620128|NCT06977932|PROCEDURE|Sham Electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent + GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent + ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
214620129|NCT06977932|DRUG|Carbarmazepine Placebo|CBZ placebo is a tablet with identical packaging and appearance to CBZ but lacks therapeutic effects. If patients were receiving CBZ prior to enrollment, they were transitioned to a CBZ placebo at an equivalent daily dose post-enrollment. For patients previously treated with oxcarbazepine, the post-enrollment regimen consisted of a CBZ placebo administered at half the pre-enrollment oxcarbazepine dose. Orally administered for four consecutive weeks.
214620130|NCT06977932|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
214620131|NCT06977412|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of breast cancer|The CT scan is part of the standard treatment protocol.
214620132|NCT06979115|DRUG|Indocyanine green (ICG)|Indocyanine green (ICG; National Drug Approval No. H20213567, Ruida Pharmaceuticals) is administered intravenously 24 hours preoperatively at a dose of 2 mg/kg. The drug is dissolved in 250 mL of normal saline using a light-protected infusion set and infused at a constant rate over 60 minutes. Alternatively, a 0.5 mg/kg dose may be administered via IV infusion 1-3 hours before surgery.
214620133|NCT06977087|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
214620134|NCT06977087|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
214620135|NCT06977087|BEHAVIORAL|Verbal Reasoning|Participants are asked to reflect on the pros and cons of facing the socially feared situation
214717215|NCT04780256|PROCEDURE|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~1. Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~2. Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~3. Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
214717216|NCT00314080|DRUG|Botulinum AntiToxin|
214717217|NCT00314080|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
214717218|NCT00314080|PROCEDURE|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
214717219|NCT03734562|PROCEDURE|Ablation|Substrate-based radiofrequency catheter ablation
214717220|NCT03734562|DRUG|Antiarrhythmic drug|Amiodarone or sotalol therapy
214717221|NCT01367860|PROCEDURE|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
214717222|NCT01367860|PROCEDURE|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
214717223|NCT02436044|PROCEDURE|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
214717224|NCT02436044|DRUG|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
214717225|NCT02436044|DRUG|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
214717226|NCT02436044|DRUG|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
214717227|NCT03928860|OTHER|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
214717228|NCT00037544|DRUG|ReFacto AF|
214717229|NCT02540772|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
214717230|NCT01125540|DEVICE|Acuvue (Standard Daily Disposable Contact Lens)|
214717231|NCT01125540|DEVICE|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
214717232|NCT01270958|DRUG|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
214717233|NCT01899586|OTHER|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
214717234|NCT01899586|OTHER|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
214717235|NCT02176304|DRUG|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
214717236|NCT02176304|DRUG|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
214717237|NCT02016222|PROCEDURE|tears sampling|
214717238|NCT02467855|OTHER|No Intervention|No intervention was administered in this study.
214620136|NCT06978205|DEVICE|Urethral Balloon Dilation|Urethral balloon dilation + conventional rehabilitation therapy. 1.A 14-Fr urethral catheter will be prefilled with sterile saline to check for balloon integrity. If intact, the saline will be completely withdrawn. 2.Ultrasound imaging will be used to precisely locate the external urethral sphincter. 3.The catheter will be fully lubricated and gently inserted into the urethra. 4.Under real-time ultrasound guidance, 2-4 mL of sterile saline will be gradually injected into the balloon to expand the external urethral sphincter. 5.Patients will be instructed to attempt urination during the procedure, and changes in voiding patterns will be observed. This procedure will be performed three times per participant. The expansion volume will increase by 0.5-1 mL per session, depending on urethral outlet resistance (urodynamic results) and degree of urethral narrowing (ultrasound assessment）Each session lasts 5 minutes. Strict aseptic techniques will be followed.
214620137|NCT06978205|DEVICE|intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine.
214620138|NCT06978205|DEVICE|Acupuncture treatment|Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints.
214620139|NCT06978205|BEHAVIORAL|Pelvic floor function training|The pelvic floor therapist assesses the patient's pelvic floor muscle condition and guides the patient to perform effective pelvic floor muscle contractions and relaxations.
214717239|NCT04688216|OTHER|risk factors of infection with multidrug-resistant organisms|"1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
214717240|NCT03073343|DIETARY_SUPPLEMENT|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
214717241|NCT01319279|DRUG|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
214717242|NCT00927264|BEHAVIORAL|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
214717243|NCT00927264|BEHAVIORAL|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
214717244|NCT03618602|DRUG|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
214717245|NCT01256203|DRUG|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
214717246|NCT01256203|PROCEDURE|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
214717247|NCT01730287|DRUG|Control|The teeth in this group restored only by filling material,without liner application.
214717248|NCT01730287|DRUG|Calcium Hydroxide|Calcium Hydroxide paste applied.
214717249|NCT01730287|DRUG|Mineral Trioxide Aggregate(MTA)|MTA applied .
214717250|NCT01730287|DRUG|CEM cement|CEM cement applied .
214717251|NCT00936299|DRUG|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
214717252|NCT00936299|OTHER|Placebo|
214717253|NCT04359342|DIETARY_SUPPLEMENT|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
214717254|NCT04359342|DIETARY_SUPPLEMENT|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
214717255|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
214717256|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
214620140|NCT06340451|DEVICE|iovera° system|subjects will receive ultrasound-guided iovera° system treatment
214620141|NCT06340451|DEVICE|sham iovera° system treatment|subjects will receive ultrasound-guided iovera° sham system treatment
214620142|NCT05229926|DEVICE|CareCube|modular, disposable, negative pressure, isolation patient care system
214620143|NCT01538628|DEVICE|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
214620144|NCT04086004|OTHER|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
214620145|NCT04086004|OTHER|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
214620146|NCT02410304|DEVICE|Xrays|Clinical evaluation
214620147|NCT02410304|DEVICE|Ultrasound (B mode )|
214620148|NCT02410304|DEVICE|Ultrasound (D mode)|
214620149|NCT06978569|DEVICE|Injectable Acellular dermal matrix hydrogel|An injectable, sterile acellular dermal matrix (ADM) gel derived from processed biological tissue, designed to promote healing in chronic wounds. The gel is injected directly onto the wound bed following standard debridement and serves as a biocompatible scaffold to support granulation tissue formation, epithelialization, and wound closure. After application, the wound is covered with a standard secondary dressing. Dressing changes are performed every 2 to 3 days or as clinically indicated.
214620150|NCT06978569|DEVICE|Alginate dressing|A sterile, absorbent alginate wound dressing composed of natural polysaccharide fibers derived from seaweed. Following standard debridement, the alginate dressing is applied directly to the wound bed to manage exudate and maintain a moist wound environment conducive to healing. The dressing is covered with a secondary dressing and changed according to the manufacturer's instructions and clinical protocol.
214620151|NCT06977789|DEVICE|S Patch3-Cardio/S-Patch Ex|S Patch3-Cardio/S-Patch Ex for 72 hours
214620152|NCT06977789|DEVICE|Holter|Holter for 24 hours
214717257|NCT03260907|PROCEDURE|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
214717258|NCT03260907|PROCEDURE|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
214620153|NCT06977776|BEHAVIORAL|Web-Based Osteoporosis Awareness Training Based on Health Belief Model|This study presents a web-based osteoporosis awareness training based on the health belief model. The training is designed to provide information about the risks of osteoporosis, ways of prevention and healthy lifestyle habits. Participants will be taught about the importance of calcium intake, the benefits of exercise and osteoporosis prevention methods. The training process will be supported by interactive content and individual counseling sessions offered through the website and participants will be provided with the opportunity to consolidate their knowledge.
214620154|NCT06977295|DEVICE|Diagnostic Software Application for CAD Assessment|A novel on-premises diagnostic software integrating automated coronary stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification for evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) datasets.
214620155|NCT06978790|OTHER|Generative Artificial Intelligence Nurse Staffing (GAINS) Intervention|The Generative Artificial Intelligence intervention is an industrial engineering and nursing-informed innovation developed to optimize team-based staffing of registered nurses and nursing assistants. We anticipate that the GAINS intervention will enhance staffing efficiency, reduces reliance on travel nurses, minimizes overtime costs, and supports nurse well-being by proactively managing workload distribution and reducing burnout. At the core of GAINS is a generative AI model that predicts future unit-level staffing needs using historical staffing patterns, patient turnover (admissions and discharges), and patient acuity scores (based on ICU versus medical/surgical status, physician orders, charge nurse input, and other clinical factors) reflective of workload. Based on the prediction, the intervention dynamically recommends float pool assignments by evaluating staffing gaps across units and optimally deploying available nurses and nursing assistants to where they are most needed.
214620156|NCT06813677|OTHER|In-person health promotion|The results from the initial pre-baseline examination are reviewed during the baseline visit to identify potential risk factors related to the Life's Essential 8 (LE8). Based on these findings, participants receive personalized recommendations to enhance their vascular health and information on local vascular health promotion resources. Additionally, participants receive bi-monthly motivational newsletters designed to support ongoing vascular health improvements.
214620157|NCT06977685|DRUG|Non-selective beta-blockers|Non-selective beta-blockers (NSBB) prescribed at discharge for patients hospitalized with hepatic complications. The study will analyze two types of NSBB: propranolol and carvedilol. The study will also examine potential dosage effects by categorizing NSBB use into low-dose and middle-high dose groups. NSBB use is defined as a prescription for at least 2 days at discharge.
214620158|NCT05567575|BEHAVIORAL|Cognitive Behavioral Therapy,|TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
214620159|NCT01147198|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
214717259|NCT04896307|OTHER|Survey|Survey
214717260|NCT05797688|DEVICE|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
214717261|NCT03095404|DRUG|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
214717262|NCT03095404|DRUG|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
214620160|NCT01147198|DIETARY_SUPPLEMENT|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
214717263|NCT05129787|PROCEDURE|Surgical resection|Resection of metastasis
214717264|NCT05129787|PROCEDURE|Thermal ablation|Ablation of metastasis
214620161|NCT04162821|DRUG|Hydronidone|Take hydroxynitone capsule
214717265|NCT05608330|OTHER|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
214717266|NCT05608330|OTHER|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
214620162|NCT01054742|DRUG|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
214620163|NCT01054742|DRUG|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
214620164|NCT04754698|BIOLOGICAL|CoronaVac|CoronaVac (Sinovac Biotech Ltd., Beijing, China)
214620165|NCT03366298|COMBINATION_PRODUCT|Epipen 0.3mg|Epipen 0.3mg auto-injector
214620166|NCT03366298|COMBINATION_PRODUCT|Emerade 300mcg|Emerade 300mcg auto-injector
214717267|NCT02348424|DRUG|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
214620167|NCT03366298|COMBINATION_PRODUCT|Emerade 500mcg|Emerade 500mcg auto-injector
214620168|NCT02481921|BEHAVIORAL|Group medical visits|Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
214620169|NCT04360551|DRUG|Telmisartan 40mg|Angiotensin Receptor Blocker (ARB)
214620170|NCT04360551|DRUG|Placebo|Placebo once daily
214620171|NCT01443520|DRUG|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
214620172|NCT01443520|DRUG|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
214620173|NCT01443520|DRUG|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
214620174|NCT04640337|OTHER|IPE applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
214722178|NCT04154397|DEVICE|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
214620175|NCT04640337|OTHER|IPE applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
214620176|NCT04640337|OTHER|IPE not applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
214620177|NCT04640337|OTHER|IPE not applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
214620178|NCT02916849|OTHER|Safe Step|Strength and balance exercise-digital version
214717268|NCT04977973|BEHAVIORAL|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
214620179|NCT02916849|OTHER|OEP|Strength and balance exercise -paper version
214620180|NCT02230059|OTHER|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
214620181|NCT01887236|BEHAVIORAL|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
214620182|NCT01887236|BEHAVIORAL|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
214620183|NCT00520884|DRUG|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
214620184|NCT00520884|DRUG|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
214620185|NCT00520884|OTHER|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
214620186|NCT00520884|OTHER|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
214620187|NCT02459327|BEHAVIORAL|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
214620188|NCT02459327|BEHAVIORAL|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
214620189|NCT05029206|PROCEDURE|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~1. In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~2. A minimum of 2 × 10\^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~3. Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~4. After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
214620190|NCT01149889|PROCEDURE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
214620191|NCT02894853|GENETIC|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
214620192|NCT03193697|DEVICE|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
214620193|NCT03193697|DEVICE|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
214620194|NCT02448602|OTHER|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
214620195|NCT02448602|OTHER|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
214620196|NCT02448602|OTHER|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
214620197|NCT00130585|BEHAVIORAL|Controlled diet|
214620198|NCT00130585|BEHAVIORAL|folic acid supplement|
214620199|NCT00130585|BEHAVIORAL|13C11-labelled folic acid supplement|
214620200|NCT02522702|OTHER|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
214620201|NCT00388973|DRUG|Quetiapine|
214620202|NCT01497470|DRUG|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
214620203|NCT03138538|DRUG|Part 1: M8891|Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
214620204|NCT03829930|DRUG|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
214722179|NCT03372447|DRUG|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
214722180|NCT03016039|DIETARY_SUPPLEMENT|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
214620205|NCT03829930|DRUG|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
214620206|NCT00000742|DRUG|Atevirdine mesylate|
214620207|NCT00000742|DRUG|Zidovudine|
214620208|NCT00000742|DRUG|Didanosine|
214620209|NCT02458755|DRUG|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
214620210|NCT02530528|DRUG|CHG|Varied application times
214620211|NCT00900458|BEHAVIORAL|Aerobic Exercise training|aerobic exercise training (cycling)
214620212|NCT01202331|DRUG|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
214620213|NCT01492608|DRUG|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
214620214|NCT06501404|DIETARY_SUPPLEMENT|High dose group|A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
214620215|NCT06501404|DIETARY_SUPPLEMENT|Low dose group|A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
214620216|NCT01263171|DRUG|Leucovorin|
214620217|NCT01263171|DRUG|fluorouracil|
214620218|NCT01263171|DRUG|leucovorin calcium|
214620219|NCT01263171|DRUG|oxaliplatin|
214620220|NCT01263171|PROCEDURE|adjuvant therapy|
214620221|NCT01263171|PROCEDURE|neoadjuvant therapy|
214620222|NCT01263171|PROCEDURE|therapeutic conventional surgery|
214620223|NCT01263171|RADIATION|radiation therapy|
214620224|NCT06536660|PROCEDURE|Magnesium bone plate and screw fixation in jaw surgery|Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.
214620225|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage survival cohort|consists of surviving patients
214620226|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage mortality cohort|consists of deceased patients
214620227|NCT02385981|DEVICE|Stivax|
214620228|NCT02690870|DRUG|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
214620229|NCT02690870|DRUG|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
214620230|NCT06008444|OTHER|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
214620231|NCT06008444|OTHER|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
214620232|NCT03739398|DEVICE|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1\. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
214620233|NCT03739398|DEVICE|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2\. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
214620234|NCT00177749|DRUG|Posaconazole|
214620235|NCT00086203|DRUG|Talabostat mesylate (PT-100) tablets|
214620236|NCT00086203|DRUG|Rituximab|
214620237|NCT03187938|DIAGNOSTIC_TEST|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
214620238|NCT02070029|PROCEDURE|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~\- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
214620239|NCT04282395|BEHAVIORAL|Resilience-Based Diabetes Self-Management Education|"During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~* the location in community-based church settings,~* recognition of cultural dietary preferences, and~* emphasis on cultural/historical significance of resilience in AAs."
214620240|NCT04282395|BEHAVIORAL|Standard Diabetes Self-Management Education|"Control group sessions, led by professional nurses, cover topics such as:~* causes and symptoms of type 2 diabetes,~* glucose self-monitoring,~* models for and principles of healthy eating, grocery shopping and dining out,~* physical activity,~* diabetes medications,~* managing sick days and stress, and~* community resources."
214620241|NCT03901105|DRUG|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
214620242|NCT03901105|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
214620243|NCT00779480|DRUG|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
214620244|NCT04773106|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally implanted during routine local intraocular pressure lowering procedures in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
214620245|NCT02700412|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
214620246|NCT05915520|BEHAVIORAL|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
214620247|NCT05915520|OTHER|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
214620248|NCT04302194|DIETARY_SUPPLEMENT|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
214620249|NCT06303284|DRUG|subcutaneous Teriparatide injection|20 µg subcutaneous (SC) Teriparatide injection
214620250|NCT06303284|OTHER|placebo|placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
214620251|NCT02462356|PROCEDURE|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
214620252|NCT02462356|PROCEDURE|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
214620253|NCT03924349|DEVICE|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
214620254|NCT01605279|DRUG|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
214620255|NCT01605279|DRUG|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
214717269|NCT04977973|BEHAVIORAL|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
214717270|NCT04355494|BIOLOGICAL|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
214620256|NCT04291443|PROCEDURE|Heavy Force (225g)|Orthodontic Force
214620257|NCT04291443|PROCEDURE|Light Force (25g)|Orthodontic Force
214620258|NCT00108394|DRUG|pamidronate|
214620259|NCT02330575|BEHAVIORAL|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
214620260|NCT02330575|BEHAVIORAL|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
214620261|NCT03399136|BEHAVIORAL|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
214620262|NCT02537886|DEVICE|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
214722398|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
214620263|NCT04416555|DEVICE|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
214620264|NCT04416555|DEVICE|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
214620265|NCT01568775|DRUG|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
214620266|NCT00159991|PROCEDURE|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
214620267|NCT00159991|PROCEDURE|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
214620268|NCT02006342|DRUG|Insulin Glargine|
214620269|NCT02006342|DRUG|Regular Insulin|
214620270|NCT00250250|DRUG|ZOMACTON|
214620271|NCT02840695|DRUG|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
214620272|NCT06466447|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
214620273|NCT04426877|BEHAVIORAL|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
214620274|NCT04426877|BEHAVIORAL|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
214620275|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
214620276|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
214620277|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
214620278|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
214620279|NCT01118273|DRUG|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
214620280|NCT01118273|DRUG|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
214620281|NCT03360097|PROCEDURE|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
214620282|NCT04989114|DEVICE|nasal continuous positive airway pressure|positive end expiratory pressure will be applied by nasal continuous positive airway pressure
214620283|NCT04592640|OTHER|Human amniotic mesenchymal stem cells|"1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
214620284|NCT05501561|BIOLOGICAL|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214620285|NCT05501561|BIOLOGICAL|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214620286|NCT05501561|BIOLOGICAL|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214620287|NCT05501561|BIOLOGICAL|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214620288|NCT06272474|OTHER|CAD-CAM zirconia crowns using buccal interocclusal record.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record.~First, scanning the buccal interocclusal record for each patient with the two arches in maximum intercuspation position (MIP) will be performed. The IOS will immediately reproduce the occlusal state of the digital casts; this method is called the buccal bite registration method (BBR)."
214620289|NCT06272474|OTHER|CAD-CAM zirconia crowns using lateral interocclusal records.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using lateral interocclusal record.~A second scan will be performed for each patient to record lateral mandibular excursion. Then, three STL files will be exported; maxillary arch, mandibular arch at MIP and lateral mandibular excursion"
214620290|NCT03374189|DEVICE|EZ close|EZ close used.
214620291|NCT03374189|DEVICE|Carter Thomason|Carter Thomason used.
214620292|NCT05401084|OTHER|Diet|Macronutrient diet changes.
214620293|NCT05067322|DEVICE|Minecraft|A game played within the videogame Minecraft
214620294|NCT01244555|OTHER|ultrasound|Twice weekly ultrasound sessions for 6 weeks
214620295|NCT01244555|OTHER|massage|Twice weekly massage sessions for 6 weeks
214620296|NCT03823066|DEVICE|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
214620297|NCT03489408|DEVICE|Conventus Cage™ PH|Proximal humeral fracture fixation
214620298|NCT03633175|DRUG|Vaginal progesterone|400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
214620299|NCT04334980|BIOLOGICAL|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
214620300|NCT00494611|DRUG|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
214620301|NCT02820792|PROCEDURE|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
214620302|NCT02820792|DEVICE|LMA ProtectorTM|
214620303|NCT02820792|DEVICE|Ambu AuraGainTM|
214620304|NCT00552175|DRUG|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
214620305|NCT00552175|DRUG|placebo|placebo taken orally every day
214620306|NCT00552175|DRUG|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
214620307|NCT05085639|BIOLOGICAL|GLS-5130|GLS-5310 DNA plasmid vaccine
214620308|NCT05085639|BIOLOGICAL|Placebo|Placebo
214620309|NCT03302715|GENETIC|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
214620310|NCT02713958|OTHER|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
214620311|NCT02713958|OTHER|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
214620312|NCT02921620|BIOLOGICAL|PRX-102|Intravenous
214620313|NCT02921620|OTHER|Placebo|Intravenous
214620314|NCT04338503|DIAGNOSTIC_TEST|Partial IVC occlusion|Partial balloon occlusion of the inferior vena cava.
214620315|NCT05874323|GENETIC|Detection of RAGE gene polymorphism (rs1800625)|Detection of RAGE gene polymorphism (rs1800625) By Molecular analysis (real time PCR)
214620316|NCT01779973|BEHAVIORAL|Remote Observed Dosing|
214620317|NCT01743755|DRUG|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
214620318|NCT01743755|DRUG|Placebo|Placebo tablet, once daily for four consecutive days
214620319|NCT04528862|BEHAVIORAL|Nature slides|participants will view a presentation of nature slides
214620320|NCT04528862|BEHAVIORAL|Urban slides|participants will view a presentation of urban slides
214620321|NCT05658016|DRUG|TK-112690|TK112690 treatment Pre \& Post Radiation
214620322|NCT05658016|DRUG|Placebo|TK112690 Placebo treatment Pre \& Post Radiation
214620323|NCT03789851|DEVICE|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
214620324|NCT03975920|DEVICE|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
214620325|NCT04824820|BEHAVIORAL|Vibrator|Clitoral stimulation
214620326|NCT00874445|DEVICE|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
214620327|NCT00228995|DRUG|epoetin alfa|
214620328|NCT03469765|OTHER|does not apply|biological sample taking: urine, blood
214620329|NCT00029692|DRUG|Ginseng|
214620330|NCT00029692|DRUG|Ginkgo|
214620331|NCT05279248|BIOLOGICAL|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
214620332|NCT05279248|BIOLOGICAL|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
214620333|NCT05279248|BIOLOGICAL|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
214620334|NCT04493021|DEVICE|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
214620335|NCT03046485|BEHAVIORAL|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
214620336|NCT02238873|DRUG|Pegfilgrastim|
214620337|NCT04597983|DIETARY_SUPPLEMENT|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
214620338|NCT04597983|DIETARY_SUPPLEMENT|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
214620339|NCT04441268|PROCEDURE|primary IOL implantation|implant IOL in capsular bag after cataract extraction
214620340|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
214620341|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
214620342|NCT00884273|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
214620343|NCT00884273|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
214620344|NCT00884273|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
214620345|NCT05032625|PROCEDURE|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
214620346|NCT02742753|OTHER|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
214620347|NCT02912416|DIETARY_SUPPLEMENT|Probiotics|
214620348|NCT02912416|DIETARY_SUPPLEMENT|Placebo|
214620349|NCT05693168|DEVICE|ANNE Limb Sensor|Pulse Oximeter
214620350|NCT03462420|OTHER|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
214620351|NCT04255446|DEVICE|Thora3DiTM|Not international
214620352|NCT02591381|PROCEDURE|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
214620353|NCT04502004|DEVICE|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
214620354|NCT04967781|BEHAVIORAL|autoimmunity|autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
214620355|NCT03216096|DRUG|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
214620356|NCT02512224|DEVICE|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
214620357|NCT02512224|DEVICE|Enteral nutrition|Participants are retrospectively selected with propensity score matching
214620358|NCT02699957|PROCEDURE|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
214620359|NCT04993534|BEHAVIORAL|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
214620360|NCT04993534|OTHER|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
214620361|NCT03492528|BIOLOGICAL|blood samples|blood samples
214620362|NCT05221801|BEHAVIORAL|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
214620363|NCT05221801|OTHER|food type|the swallowing was tested with 3 food types
214620364|NCT03961217|RADIATION|Radiotherapy|Radiotherapy as part of cancer treatment
214620365|NCT00482443|OTHER|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
214620366|NCT00482443|OTHER|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
214620367|NCT01195753|BIOLOGICAL|HHLivC|multiple infusion of liver cells
214620368|NCT05795686|OTHER|"Evaluation of program AVanCer"|Evaluation of program AVanCer with quantitative and qualitative approaches
214620369|NCT05530720|OTHER|Cross-sectional survey|No intervention.
214620370|NCT01050452|DRUG|albendazole|albendazole (400 mg on dose)
214620371|NCT01050452|DRUG|mebendazole|mebendazole (500 mg one dose)
214620372|NCT01050452|DRUG|ivermectin|ivermectin (200 microgram/kg body weight)
214620373|NCT01050452|DRUG|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
214620374|NCT01050452|DRUG|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
214620375|NCT04960020|OTHER|Retrospective Data Review|Retrospective Data Review
214620376|NCT01776736|DEVICE|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
214620377|NCT05198336|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214620378|NCT01535495|DRUG|Propranolol|Propranolol XL 120mg by mouth once daily
214620379|NCT03054922|DRUG|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
214620380|NCT03054922|DRUG|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
214620381|NCT03054922|DRUG|Normosol-R Inj|IV infusion of Normosol throughout surgery.
214620382|NCT02840110|OTHER|ACTR T Cell Product|
214620383|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
214620384|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
214620385|NCT01761045|DIETARY_SUPPLEMENT|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
214620386|NCT01761045|DIETARY_SUPPLEMENT|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
214620387|NCT01761045|DIETARY_SUPPLEMENT|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
214620388|NCT03762369|DRUG|CKD-351|twice a day
214620389|NCT03762369|DRUG|Latanoprost|once a day
214620390|NCT03762369|DRUG|D930|three times a day
214620391|NCT03762369|DRUG|Placebo of CKD-351|once a day
214620392|NCT03762369|DRUG|Placebo of CKD-351|twice a day
214620393|NCT03762369|DRUG|Placebo of D930|three times a day
214620394|NCT04515225|OTHER|Blood Sample|Blood Sample
214620395|NCT02372565|BEHAVIORAL|Facebook and text Message|Culturally-relevant physical activity promotion program
214620396|NCT02372565|BEHAVIORAL|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
214620397|NCT04960540|OTHER|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
214620398|NCT02293447|DRUG|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
214620399|NCT02293447|DRUG|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
214620400|NCT01147744|DRUG|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
214620401|NCT01147744|DRUG|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
214620402|NCT01147744|DRUG|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
214620403|NCT01147744|DRUG|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
214620404|NCT01147744|DRUG|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
214620405|NCT01147744|DRUG|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
214620406|NCT01147744|DRUG|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
214620407|NCT01147744|DRUG|Placebo montelukast|Placebo capsule once daily in the evening
214620408|NCT01147744|DRUG|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
214620409|NCT01147744|DRUG|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
214620410|NCT01788033|DRUG|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
214620411|NCT01788033|DRUG|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
214620412|NCT00089050|DRUG|cyclosporine|
214620413|NCT00089050|DRUG|gemtuzumab ozogamicin|
214620414|NCT05369104|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
214620415|NCT04879667|PROCEDURE|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
214620416|NCT04489251|DIAGNOSTIC_TEST|Protein Elisa analysis, microRNA analysis, whole exome sequencing|"ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing."
214620417|NCT02536313|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
214620418|NCT02536313|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214620419|NCT01555567|DEVICE|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
214620420|NCT01555567|OTHER|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
214620421|NCT03555513|PROCEDURE|living kidney transplantation|receiving kidney transplantation from living donor
214620422|NCT05672511|BEHAVIORAL|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
214620423|NCT02941705|BIOLOGICAL|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
214620424|NCT02941705|BIOLOGICAL|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
214620425|NCT01252745|DRUG|10.0 mg of Testosterone, 4.0% TID|
214620426|NCT01252745|DRUG|13.5 mg of Testosterone, 4.5% B.I.D|
214620427|NCT01252745|DRUG|11.25 mg of Testosterone, 4.5% T.I.D|
214620428|NCT03506737|OTHER|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
214620429|NCT03506737|OTHER|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
214620430|NCT02669966|PROCEDURE|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
214620431|NCT01208584|OTHER|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
214620432|NCT01460199|DRUG|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
214620433|NCT01460199|DRUG|placebo|tablets
214620434|NCT06460675|PROCEDURE|Autogenic Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
214620435|NCT06460675|PROCEDURE|Reciprocal Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
214717271|NCT04496557|DEVICE|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
214717272|NCT01477138|PROCEDURE|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
214717273|NCT06278129|DIAGNOSTIC_TEST|Vestibular myogenic potentials|observational study
214717274|NCT04530396|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
214717275|NCT04530396|OTHER|placebo|placebo comparator
214717276|NCT04505150|BEHAVIORAL|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
214717277|NCT04142515|OTHER|no intervention|no intervention
214717278|NCT01369407|OTHER|No Intervention|Not an interventional study
214717279|NCT04800471|DEVICE|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
214717280|NCT04800471|OTHER|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
214717281|NCT05419271|PROCEDURE|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
214717282|NCT06138028|DRUG|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
214717283|NCT03289871|DEVICE|Excilor|
214717284|NCT03289871|DRUG|Loceryl 5%|
214717285|NCT03779061|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
214717286|NCT03779061|DRUG|Propofol|Initial dose plus supplemental doses as necessary
214620436|NCT04754360|OTHER|Evaluation of functional impairment|Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test
214620437|NCT04754360|OTHER|Evaluation of pulmonary function|Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.
214620438|NCT04754360|OTHER|Evaluation of quality of life|Quality of life will be evaluated using Short Form-36 Questionnaire.
214717287|NCT03944083|OTHER|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
214717288|NCT03482128|DEVICE|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
214717289|NCT03482128|DEVICE|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
214717290|NCT01100645|DRUG|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
214717291|NCT01100645|DRUG|Placebo|Excipient
214717292|NCT00659126|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
214717293|NCT00659126|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
214717294|NCT00659126|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
214717295|NCT00659126|DRUG|Ferumoxytol|Given IV
214717296|NCT00659126|DRUG|Gadolinium|Given IV
214620439|NCT04754360|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form
214620440|NCT06186076|DRUG|TRX-221|TRX-221 oral dose as defined
214620441|NCT01457391|BEHAVIORAL|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
214620442|NCT01457391|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
214620443|NCT01457391|BEHAVIORAL|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
214620444|NCT02437864|DEVICE|Supplemental oxygen via nasal cannula|
214717297|NCT00659126|PROCEDURE|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
214717298|NCT00659126|PROCEDURE|Susceptibility Weighted Imaging|Undergo SWI
214717299|NCT05859360|OTHER|Physical performance and cardiovascular health measures|"* Retinal vessel analysis~* Muscle ultrasound~* Knee extension~* Voluntary activation~* spiroergometry"
214717300|NCT01837017|BEHAVIORAL|Home-based Exercise|This is a control group with no intervention
214620445|NCT01833442|BEHAVIORAL|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
214620446|NCT01833442|BEHAVIORAL|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
214620447|NCT05780255|DEVICE|VV-ECMO|veno-venous extracorporeal membrane oxygenation
214620448|NCT04350528|DRUG|Chlorpromazine or Pentobarbital|Sedation
214620449|NCT05410444|DEVICE|Clean Intermittent Catheterization|Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.
214620450|NCT05410444|DEVICE|Indwelling catheterization|A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
214620451|NCT01829971|DRUG|MRX34|micro RNA therapy
214620452|NCT01671540|DEVICE|intrapulmonary percussive ventilation|
214620453|NCT01671540|OTHER|standard treatment|breathing control exercises
214620454|NCT05787080|OTHER|Massage|In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
214620455|NCT02361541|PROCEDURE|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
214620456|NCT01289236|DRUG|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
214620457|NCT01289236|DRUG|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
214620458|NCT01289236|DRUG|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
214620459|NCT00262210|DRUG|Cyclophosphamide Epirubicin Etoposide Prednisolone|
214620460|NCT04651621|DEVICE|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
214620461|NCT04651621|DEVICE|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
214620462|NCT01014325|BIOLOGICAL|Allergen extract|sublingual application
214620463|NCT01014325|BIOLOGICAL|Placebo|sublingual application
214620464|NCT05842369|DEVICE|ADVOS|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
214620465|NCT05842369|DEVICE|CVVHD|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
214620466|NCT03493087|DIETARY_SUPPLEMENT|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
214620467|NCT03493087|DIETARY_SUPPLEMENT|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
214620468|NCT03939845|RADIATION|RT|external- beam radiotherapy (EBRT)
214620469|NCT03939845|PROCEDURE|TACE|transarterial chemoembolization (TACE)
214620470|NCT01552291|DIETARY_SUPPLEMENT|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
214620471|NCT01552291|DRUG|Placebo|30g oral maltodextrin / day for 5 days before surgery
214620472|NCT02754895|OTHER|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
214620473|NCT02754895|OTHER|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
214620474|NCT01080248|DRUG|Gemcitabine|
214620475|NCT01080248|DRUG|Pazopanib|
214620476|NCT00037570|DRUG|Pantoprazole|
214620477|NCT04191330|DEVICE|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
214620478|NCT04993040|DRUG|Oraxol|"* HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules"
214620479|NCT02287389|DEVICE|balloon dilation|
214620480|NCT02287389|PROCEDURE|cryotherapy|
214620481|NCT02287389|PROCEDURE|spiculiform electrosurgery|
214620482|NCT02287389|DRUG|mitomycin C|
214620483|NCT05606081|DEVICE|Logistic regression risk model|Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
214620484|NCT01824511|BEHAVIORAL|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
214620485|NCT05645874|DIAGNOSTIC_TEST|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
214717301|NCT06391658|OTHER|Functional Training|Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
214717302|NCT02481596|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
214717303|NCT02481596|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
214717304|NCT02481596|BEHAVIORAL|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
214717305|NCT01241955|BEHAVIORAL|video decision aid|video of CPR
214717306|NCT05315141|OTHER|No Intervention|No Intervention
214717307|NCT04447534|DRUG|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
214717308|NCT04447534|DRUG|zinc|Zinc tablets
214717309|NCT01619163|DRUG|Placebo|
214717310|NCT01619163|DRUG|Prednisolone|low dose, 7.5 mg/day
214717311|NCT01742533|BIOLOGICAL|human umbilical cord mesenchymal stem cells|
214717312|NCT01742533|BIOLOGICAL|hUCMSCs and hCBMNCs|
214717313|NCT01742533|BIOLOGICAL|human cord blood mononuclear cells|
214717314|NCT01742533|DRUG|Hormone Replacement Therapy|
214717315|NCT00870038|DEVICE|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
214717316|NCT00870038|DEVICE|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
214717317|NCT00870038|DEVICE|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
214717318|NCT06040307|PROCEDURE|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
214717319|NCT02379611|PROCEDURE|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
214717320|NCT05454397|OTHER|Observational study, no intervention|Observational study, no intervention
214620486|NCT05547880|DRUG|[11C]ER176|Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
214620487|NCT03454802|DIAGNOSTIC_TEST|Passive Leg Raising|See above
214620488|NCT02009436|DRUG|Azacitidine|Given via nebulizer
214717321|NCT01340391|DEVICE|Omnicast|dorsal splint 2-5 weeks
214717322|NCT05385627|PROCEDURE|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
214717323|NCT02722629|PROCEDURE|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
214620489|NCT02009436|OTHER|Laboratory Biomarker Analysis|Correlative studies
214620490|NCT02009436|OTHER|Pharmacological Study|Correlative studies
214620491|NCT02073175|DRUG|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
214620492|NCT01294202|DRUG|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
214620493|NCT06226350|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
214620494|NCT05883462|COMBINATION_PRODUCT|Airiver Nasal Drug Coated Balloon (DCB) Catheter.|The balloon is coated with a paclitaxel drug (3.5ug/mm2).
214620495|NCT01124903|PROCEDURE|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
214620496|NCT04979689|OTHER|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
214620497|NCT04979689|OTHER|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
214620498|NCT04945668|PROCEDURE|Modified technique for pericapsular nerve group block|with the patient in the supine position, ultrasound probe in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus. In this view, the ilio pubic eminence (IPE), the iliopsoas muscle and tendon will be observed. A spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip between the psoas tendon and the pubic ramus. Fluoroscopic image will be taken to confirm the needle tip position in the target site. Following negative aspiration, 15 ml dye will be injected in 5-mL increments while observing for adequate spread using fluoroscopy followed by 15ml local anesthetic
214620499|NCT01853995|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
214620500|NCT01043276|DRUG|Treatment A|PF-00258210 220 µg using inhaler A
214620501|NCT01043276|DRUG|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
214717324|NCT06059092|BEHAVIORAL|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
214717325|NCT06059092|BEHAVIORAL|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
214722399|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
214722400|NCT01784211|DRUG|LY2605541|
214620502|NCT01043276|DRUG|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
214620503|NCT01043276|DRUG|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
214620504|NCT01043276|DRUG|Treatment E|PF-00258210 220 µg using inhaler B
214620505|NCT01787682|DIETARY_SUPPLEMENT|BOOST High Protein|
214722401|NCT01784211|DRUG|Insulin Glargine|
214722402|NCT03022604|DIETARY_SUPPLEMENT|C4/Generation 4|12 grams of C4/Generation 4
214620506|NCT04918030|PROCEDURE|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
214717326|NCT06059092|BEHAVIORAL|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
214717327|NCT06059092|BEHAVIORAL|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
214620507|NCT04918030|PROCEDURE|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
214717328|NCT03514004|BEHAVIORAL|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
214717329|NCT03182842|DEVICE|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
214717330|NCT03182842|DEVICE|SMBG - Blinded Sensor|Insulin dosing based on SMBG
214717331|NCT03091699|DRUG|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
214717332|NCT03091699|BEHAVIORAL|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
214717333|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
214717334|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
214717335|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
214717336|NCT00648570|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
214620508|NCT00807742|DRUG|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
214620509|NCT00807742|BEHAVIORAL|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
214717337|NCT00648570|DRUG|Lexapro® Tablets (20 mg|20mg, single dose fasting
214717338|NCT02339857|PROCEDURE|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
214717339|NCT02633046|DRUG|Acthar Gel|Acthar Gel 80 U/mL solution for subcutaneous injection
214717340|NCT03998904|PROCEDURE|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
214717341|NCT03998904|PROCEDURE|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
214717342|NCT05953324|OTHER|Kiwifruit|2 kiwifruit for 6 weeks
214722403|NCT03022604|DIETARY_SUPPLEMENT|C450X|12 grams of C450X
214722404|NCT03022604|DIETARY_SUPPLEMENT|Placebo|12 grams of flavored dextrose
214620510|NCT00807742|BEHAVIORAL|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
214620511|NCT00807742|BEHAVIORAL|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
214620512|NCT02479100|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
214717343|NCT01676792|DRUG|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
214620513|NCT00492752|DRUG|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
214620514|NCT00492752|DRUG|Placebo|Matching placebo (orally) twice daily
214620515|NCT00004414|DRUG|sincalide|
214717344|NCT02925312|OTHER|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
214717345|NCT01779596|DRUG|Bosentan|
214717346|NCT01779596|DRUG|Placebo|
214620516|NCT02705924|BEHAVIORAL|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
214620517|NCT06262958|BEHAVIORAL|ASSIST|Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.
214620518|NCT06262958|OTHER|Treatment as usual|Psychotherapy and/or psychotropic drug treatment
214620519|NCT02258451|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
214620520|NCT02258451|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
214620521|NCT02258451|DRUG|Exemestane|One 25 mg tablet once daily after a meal.
214620522|NCT02258451|DRUG|Everolimus|"The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice."
214620523|NCT04738786|PROCEDURE|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
214620524|NCT04738786|PROCEDURE|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
214620525|NCT04991025|DRUG|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
214620526|NCT04991025|DRUG|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
214620527|NCT04991025|DRUG|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
214620528|NCT04991025|DRUG|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
214620529|NCT04991025|DRUG|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
214620530|NCT04991025|DRUG|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
214620531|NCT02390635|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
214620532|NCT02390635|PROCEDURE|Diffusion Weighted Imaging|Undergo whole body PET/MRI
214620533|NCT02390635|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
214620534|NCT02390635|DRUG|Gadolinium|Given IV
214620535|NCT02390635|PROCEDURE|Magnetic Resonance Imaging|Undergo whole body PET/MRI
214620536|NCT02390635|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
214620537|NCT02390635|PROCEDURE|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
214620538|NCT06216756|PROCEDURE|osteochondral transplant on the femoral condyle|Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
214620539|NCT05236556|BEHAVIORAL|Best practice advisory (BPA)|"For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider."
214620540|NCT05944926|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
214717347|NCT03449121|BEHAVIORAL|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
214620541|NCT05944926|DRUG|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
214620542|NCT05914766|BEHAVIORAL|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of four behavioral coaching sessions and a patient education guidebook.
214620543|NCT05914766|OTHER|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
214620544|NCT06850766|OTHER|Morning administration of TMZ|Administration of TMZ within 2 hours of waking
214717348|NCT00089102|DRUG|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
214620545|NCT06850766|OTHER|Evening administration of TMZ|Administration of TMZ within 2 hours of bedtime
214717349|NCT00089102|DRUG|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
214620546|NCT03674229|OTHER|Informational Intervention|Receive information about weight management programs
214620547|NCT03674229|OTHER|Questionnaire Administration|Ancillary studies
214620548|NCT03674229|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
214620549|NCT06383936|PROCEDURE|intensive rehabilitation after uncemented TKA|patients undergoing an intensive rehabilitation protocol after uncemented tka
214620550|NCT03514108|DRUG|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
214620551|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 3 daily
214620552|NCT03514108|DRUG|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
214620553|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
214620554|NCT04630587|PROCEDURE|Indirect restorations|see the Arm description
214620555|NCT03972787|DEVICE|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
214620556|NCT05742997|DEVICE|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
214717350|NCT03644108|DRUG|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
214717351|NCT00927719|BIOLOGICAL|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
214717352|NCT01990755|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
214717353|NCT01990755|OTHER|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
214717354|NCT01990755|DRUG|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
214620557|NCT05742997|DEVICE|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
214620558|NCT01992133|DIETARY_SUPPLEMENT|Vitamin D3|
214620559|NCT01992133|DIETARY_SUPPLEMENT|Placebo|
214620560|NCT06967142|DEVICE|Correcte Carotid flow measurement by USG Doppler|Aim of this study is to investigate the usability of changes in corrected carotid flow time induced by lung recruitment maneuvers during protective lung ventilation (6 ml/kg tidal volume) in patients undergoing elective Coronary Artery Bypass Graft Surgery (CABG) to evaluate fluid responsiveness. The secondary objective is to determine the correlation between measurements taken before and after sternotomy. This study aims to reduce invasive procedures used for assessing fluid responsiveness and develop an alternative method to the use of hard-to-access devices for measurements.
214620561|NCT03087188|OTHER|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
214620562|NCT03912142|DIAGNOSTIC_TEST|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
214620563|NCT04165226|DEVICE|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
214620564|NCT04165226|DEVICE|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
214620565|NCT04165226|DEVICE|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
214620566|NCT01440270|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
214620567|NCT02281032|OTHER|interRAI PC|"PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results"
214620568|NCT05467956|OTHER|Covid-19|Covid-19 disease
214620569|NCT03375398|DIETARY_SUPPLEMENT|Rice|Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water
214620570|NCT03375398|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
214620571|NCT05693636|PROCEDURE|Total wrist arthroplasty|Two different surgical interventions for treatment of end-stage arthritis are compared
214717355|NCT01990755|DIETARY_SUPPLEMENT|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
214717356|NCT01990755|DRUG|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
214717357|NCT00869219|DRUG|Nevanac|1 drop of NEVANAC at random eye
214620572|NCT05081479|DRUG|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.
214620573|NCT06228326|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
214717358|NCT00869219|DRUG|Acular LS|One drop of Acular LS
214620574|NCT06228326|DRUG|Pembrolizumab (KEYTRUDA®)|PD-1 immune checkpoint inhibitor
214620575|NCT06228326|DRUG|Chemotherapy|SOC chemotherapy
214620576|NCT04730622|DIAGNOSTIC_TEST|SARC-F questionnaire|Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
214620577|NCT04730622|DIAGNOSTIC_TEST|Bone tissue histology|Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
214717359|NCT02969538|OTHER|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
214717360|NCT02969538|OTHER|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
214717361|NCT04879784|OTHER|No intervention|No intervention
214722405|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
214620578|NCT04730622|DIAGNOSTIC_TEST|Muscle tissue histology|Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
214620579|NCT04730622|DIAGNOSTIC_TEST|Myostatin serum levels|Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
214620580|NCT04730622|DIAGNOSTIC_TEST|Insulin-like growth factor 1 (IGF-1) serum levels|Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
214620581|NCT04730622|OTHER|Frequency food questionnaire|Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
214620582|NCT04730622|OTHER|Gut microbiota profiling|Assessment of gut microbiome composition on stool samples.
214620583|NCT04001751|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
214620584|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
214620585|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
214620586|NCT05082285|COMBINATION_PRODUCT|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
214620587|NCT05082285|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
214620588|NCT05082285|COMBINATION_PRODUCT|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
214620589|NCT02920424|DRUG|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
214620590|NCT02920424|DRUG|Placebo|Subjects will receive matching placebo.
214620591|NCT06460064|BIOLOGICAL|fH1 2 ug|2 administrations at 3-week intervals.
214620592|NCT06460064|BIOLOGICAL|fH1 8 ug|2 administrations at 3-week intervals.
214620593|NCT06460064|BIOLOGICAL|DSP-0546LP 2.5 ug|2 administrations at 3-week intervals.
214717362|NCT06175442|DEVICE|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
214717363|NCT00830154|DRUG|pagoclone|0.30 mg BID, 0.60 mg BID
214620594|NCT06460064|BIOLOGICAL|DSP-0546LP 5 ug|2 administrations at 3-week intervals.
214620595|NCT06460064|BIOLOGICAL|DSP-0546LP 10 ug|2 administrations at 3-week intervals.
214620596|NCT06460064|BIOLOGICAL|Placebo|2 administrations at 3-week intervals.
214620597|NCT04415853|DRUG|Lerotinib|Specification: 50 mg/capsule and 150 mg/capsule
214620598|NCT04415853|DRUG|Irinotecan/Tegafur|Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule
214620599|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the PartnerCHESS app but not in ACHESS:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between identified patient and concerned significant other to follow key principles.~Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
214620600|NCT05419128|BEHAVIORAL|ACHESS|ACHESS offers the following, which are also available in PartnerCHESS: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
214620601|NCT04977791|DRUG|Anti-PD-1/PD-L1 monoclonal antibody|Observe a situation before and after immunotherapy
214620602|NCT03834519|BIOLOGICAL|Pembrolizumab|IV infusion
214620603|NCT03834519|DRUG|Olaparib|Oral tablets
214620604|NCT03834519|DRUG|Abiraterone acetate|Oral tablets
214620605|NCT03834519|DRUG|Prednisone|Oral tablets
214620606|NCT03834519|DRUG|Enzalutamide|Oral tablets or oral capsules
214620607|NCT03834519|DRUG|Prednisolone|Oral tablets
214620608|NCT06972485|PROCEDURE|spinal anesthesia|spinal anesthesia with hypobaric and hyperbaric bupivacaine
214620609|NCT06976411|DRUG|MTA|Perforation repair using MTA repair material
214620610|NCT06976411|DRUG|Bioceramic putty|Perforation repair using Bioceramic repair material
214620611|NCT06965569|DRUG|ALA-3000|Subcutaneous injection
214620612|NCT06965569|DRUG|Placebo|Subcutaneous injection
214717364|NCT00830154|OTHER|placebo|placebo
214717365|NCT03094819|BEHAVIORAL|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
214620613|NCT06965569|DRUG|escitalopram, sertraline, duloxetine or venlafaxine XR|Newly initiated oral AD selected from SSRI (escitalopram or sertraline) or SNRI (duloxetine or venlafaxine XR) will be given daily
214620614|NCT05696548|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
214620615|NCT05696548|DRUG|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
214620616|NCT00488111|OTHER|Ringer's Lactate|Ringer's Lactate was used 15min before operation
214620617|NCT00488111|OTHER|6% Starch|6% Starch was used 15min before operation
214620618|NCT04066491|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
214620619|NCT04066491|DRUG|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
214620620|NCT04066491|DRUG|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
214620621|NCT04066491|DRUG|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
214620622|NCT01641328|BEHAVIORAL|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
214620623|NCT01641328|BEHAVIORAL|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
214620624|NCT05957666|DRUG|Misoprostol Oral Tablet|oral misoprostol 50 microgram repeated after 6 hours if required
214620625|NCT05957666|DRUG|vaginal misoprostol|vaginal misoprostol 50 microgram repeated after 6 hours if required
214620626|NCT03650816|OTHER|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
214620627|NCT03650816|OTHER|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
214620628|NCT04506086|DRUG|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
214620629|NCT04506086|DEVICE|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
214620630|NCT01245504|OTHER|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
214620631|NCT04052451|BIOLOGICAL|MET-2|Subjects will take study medication once daily for the duration of the study
214620632|NCT04587167|OTHER|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
214620633|NCT04587167|OTHER|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
214620634|NCT04587167|OTHER|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
214620635|NCT06648980|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
214620636|NCT06648980|DIETARY_SUPPLEMENT|Phytoglycogen|Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
214620637|NCT06972134|DIETARY_SUPPLEMENT|Sesame Oil (SO) at 100 mg/mL in dissolving fluid.|Pure Sesamum indicum oil (cold-pressed, unrefined) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by homogenization (30 min, 37°C). Used as monotherapy.
214620638|NCT06972134|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO) at 100 mg/mL in dissolving fluid.|Pure Olea europaea oil (first cold-pressed, acidity ≤0.8%) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by vortex mixing (15 min, 25°C). Used as monotherapy.
214620639|NCT06972134|DIETARY_SUPPLEMENT|50% Sesame Oil (SO) + 50% Extra Virgin Olive Oil (EVOO).|A 1:1 (v/v) blend of Sesamum indicum oil (AIU-BC-618-1) and Olea europaea oil (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by mechanical stirring (1 hr, 40°C).
214620640|NCT06972134|DIETARY_SUPPLEMENT|50% Psyllium Extract (PE) + 50% Oil Blend (50% SO + 50% EVOO).|50% Plantago ovata mucilage extract (aqueous extraction, 65°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by sonication (20 min).
214620641|NCT06972134|DIETARY_SUPPLEMENT|Plantago ovata extract (AIU-BC-618-4) + AIU-BC-618-3|50% Taraxacum officinale root extract (ethanol-water extraction, 70°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by magnetic stirring (30 min, 50°C).
214717366|NCT03094819|BEHAVIORAL|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
214717367|NCT04774614|PROCEDURE|anterior laminate veneers|VITA ENAMIC multiColor
214620642|NCT06972134|DIETARY_SUPPLEMENT|50% Herbal Extract (25% PE + 25% DE) + 50% Oil Blend (25% SO + 25% EVOO).|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
214620643|NCT06972134|DRUG|Drug: Rowachol® (terpene extract) at 100 mg/mL in dissolving fluid.|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
214717368|NCT02681718|BEHAVIORAL|Community health worker education|Diabetes self-management education by community health workers
214717369|NCT02681718|BEHAVIORAL|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
214717370|NCT02766907|DEVICE|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
214717371|NCT02281344|DRUG|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
214717372|NCT02140892|PROCEDURE|respiratory physical therapy manual technique- Autogenic Drainage|
214717373|NCT02140892|DEVICE|respiratory physical therapy technique- IPV|
214717374|NCT00375960|DRUG|V3381|
214717375|NCT00375960|DRUG|Placebo|
214717376|NCT04454580|DRUG|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
214717377|NCT01360229|PROCEDURE|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
214717378|NCT01360229|OTHER|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
214717379|NCT04006080|BIOLOGICAL|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
214717380|NCT02017886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
214620644|NCT05570539|DRUG|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
214620645|NCT05570539|DRUG|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
214717381|NCT02017886|DIETARY_SUPPLEMENT|Placebo|Placebo tablet twice daily for three weeks
214717382|NCT05334550|OTHER|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
214717383|NCT06183736|DRUG|CVL237 tablets|CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
214717384|NCT05419414|DEVICE|Shear wave elastography|Both groups were examined with shear wave elastography.
214717385|NCT02640118|DRUG|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
214717386|NCT02640118|DRUG|Lixisenatide-Placebo|
214717387|NCT02640118|OTHER|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
214717388|NCT02829008|DRUG|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
214717389|NCT02829008|DRUG|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
214717390|NCT00259038|DRUG|Carperitide|
214717391|NCT00259038|DRUG|Placebo|
214717392|NCT04228887|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
214717393|NCT04228887|DEVICE|Balance Training|Balance training will provide with Biodex® Balance Training System
214717394|NCT04228887|DEVICE|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
214620646|NCT03524885|PROCEDURE|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
214620647|NCT03524885|PROCEDURE|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
214620648|NCT05827250|DEVICE|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
214717395|NCT04085042|DEVICE|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
214717396|NCT00818311|DEVICE|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
214717397|NCT00014547|DRUG|BBR 3464|
214717398|NCT01451151|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
214717399|NCT06216197|DRUG|FENT group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
214717400|NCT06216197|DRUG|DEX group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
214717401|NCT03205982|BEHAVIORAL|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
214717402|NCT03205982|BEHAVIORAL|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
214717403|NCT03355404|OTHER|standing patient|patient goes standing to the surgery room
214717404|NCT05153447|BEHAVIORAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
214717405|NCT05153447|OTHER|Usual Care|Participants randomized to the usual care arm will receive standard of care.
214717406|NCT01605383|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
214717407|NCT01605383|PROCEDURE|Standard treatment|Isolated core decompression
214717408|NCT05176860|DEVICE|CBCT Imaging|Two research CBCT images will be acquired per subject.
214717409|NCT06161857|OTHER|No intervention|There is no intervention this is an observational study to develop a diagnostic test
214717410|NCT00994162|DEVICE|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
214717411|NCT00660777|BEHAVIORAL|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
214620649|NCT00517751|DEVICE|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
214620650|NCT04687813|DRUG|Placebo|Placebo is a tablet with the same appearance as FTP-198
214620651|NCT01671423|DRUG|Prednisone|"See Prednisone arm description"
214717412|NCT00660777|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
214620652|NCT01671423|DRUG|Placebo|"See Placebo arm description"
214717413|NCT05765292|DIETARY_SUPPLEMENT|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
214717414|NCT05765292|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
214717415|NCT00655161|BIOLOGICAL|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
214717416|NCT03253133|DRUG|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"
214717417|NCT03253133|DRUG|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
214717418|NCT03253133|DRUG|Oxycodone|Oxycodone
214717419|NCT00185354|DRUG|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
214620653|NCT02237781|DRUG|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
214620654|NCT03600064|DRUG|Misoprostol|the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
214620655|NCT04201990|DRUG|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
214620656|NCT04173715|BEHAVIORAL|Older Adults Group.|Physical activity and energy expenditure quantification
214620657|NCT04173715|BEHAVIORAL|Low Physical Function Status Group|Physical activity and energy expenditure quantification
214620658|NCT04173715|BEHAVIORAL|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
214620659|NCT04173715|BEHAVIORAL|High Physical Function Status Group|Physical activity and energy expenditure quantification
214717420|NCT00185354|DRUG|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
214717421|NCT00976729|DRUG|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
214717422|NCT00976729|DRUG|NOX-E36|single SC doses, at safe and tolerable dose level
214717423|NCT00976729|DRUG|Placebo|
214717424|NCT02824848|BEHAVIORAL|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
214717425|NCT02824848|BEHAVIORAL|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
214620660|NCT02958007|BEHAVIORAL|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
214620661|NCT02958007|BEHAVIORAL|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
214620662|NCT02495155|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
214620663|NCT00545597|DRUG|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
214620664|NCT01441856|PROCEDURE|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
214620665|NCT01441856|PROCEDURE|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
214620666|NCT05896449|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
214620667|NCT06025890|OTHER|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
214620668|NCT06025890|OTHER|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
214620669|NCT02594969|OTHER|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
214620670|NCT02987179|OTHER|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
214620671|NCT05843682|DEVICE|Using the Avatr App|The patients will use the mobile application called Avatr, which will monitor their health data, as well as provide individualized care and early intervention through alerts generated for the multidisciplinary team.
214620672|NCT00668031|DRUG|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
214620673|NCT00668031|DRUG|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
214620674|NCT06048107|DRUG|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
214620675|NCT01484977|DRUG|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
214620676|NCT00361426|DEVICE|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
214620677|NCT01415011|DRUG|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
214620678|NCT01855451|DRUG|Cetuximab|
214620679|NCT01855451|RADIATION|RT (70 Gy in 35 fractions)|
214620680|NCT01855451|DRUG|Cisplatin|
214620681|NCT03019471|GENETIC|Isolation of tumor DNA|
214620682|NCT01081457|DEVICE|Deep brain stimulation|Comparison ON vs OFF
214620683|NCT02450604|GENETIC|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
214620684|NCT04097613|DRUG|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
214620685|NCT04097613|DRUG|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
214620686|NCT00041275|DRUG|megestrol acetate|
214620687|NCT03919929|DRUG|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
214620688|NCT03919929|OTHER|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
214620689|NCT02462213|OTHER|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
214620690|NCT02462213|OTHER|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
214620691|NCT04224675|DRUG|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
214620692|NCT04373681|OTHER|patient-administered questionnaires|patient-administered questionnaires
214620693|NCT01188720|BEHAVIORAL|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
214620694|NCT04858750|DEVICE|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
214620695|NCT01583933|DEVICE|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
214620696|NCT01583933|DEVICE|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
214620697|NCT05539768|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
214620698|NCT05691049|DEVICE|HCC_45|"Dosage form: HCC\_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
214620699|NCT01671813|DRUG|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
214620700|NCT04100681|DEVICE|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
214620701|NCT04100681|DEVICE|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
214620702|NCT00495820|DRUG|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
214620703|NCT00495820|OTHER|Placebo|Standard inactive pill.
214620704|NCT04857996|DRUG|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
214620705|NCT04857996|OTHER|Sham|Sham procedure
214620706|NCT01161290|BEHAVIORAL|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
214620707|NCT03236220|DRUG|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
214620708|NCT02470026|DRUG|yohimbine|single low dose treatment
214620709|NCT02470026|DRUG|placebo|single control treatment
214620710|NCT00741247|PROCEDURE|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
214620711|NCT05163470|OTHER|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
214620712|NCT05163470|OTHER|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
214620713|NCT06118151|BIOLOGICAL|Influenza Hemagglutinin mRNA vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
214620714|NCT06118151|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
214620715|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
214620716|NCT00820950|DRUG|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
214620717|NCT00820950|DRUG|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
214620718|NCT00820950|DRUG|Placebo cream|Cream applied once or twice daily for 56 days
214620719|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
214620720|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
214620721|NCT00798135|DRUG|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
214620722|NCT00447512|DRUG|ghrelin|acylated ghrelin
214620723|NCT03972579|BEHAVIORAL|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
214620724|NCT03972579|BEHAVIORAL|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
214620725|NCT04260412|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
214620726|NCT04260412|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
214620727|NCT04260412|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
214620728|NCT01803321|DRUG|rilonacept (IL-1 Trap)|
214620729|NCT01803321|OTHER|Placebo|
214620730|NCT03497481|BIOLOGICAL|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
214620731|NCT00777621|OTHER|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
214620732|NCT00777621|OTHER|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
214620733|NCT00777621|OTHER|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
214620734|NCT03314077|OTHER|GOLD 2017|Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
214620735|NCT04822051|OTHER|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
214620736|NCT04888299|DEVICE|Raman spectroscopy (SPECTRA IMDx)|The SPECTRA IMDx comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx probe is connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal for diagnostic classification.
214620737|NCT04169022|OTHER|Sample collection|Sample collection blood and/or bone marrow
214620738|NCT03778411|DEVICE|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
214620739|NCT06125912|OTHER|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
214620740|NCT06125912|OTHER|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
214620741|NCT05886712|OTHER|Naloxone|Naloxone
214620742|NCT05886712|OTHER|Usual intervention|usual administered drug for overdose
214620743|NCT04644939|OTHER|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
214620744|NCT04644939|OTHER|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
214620745|NCT04644939|OTHER|Colonoscopy|Patients will undergo colonoscopy
214620746|NCT02670070|DRUG|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
214620747|NCT06037642|BEHAVIORAL|ABC 0-2 years|Four 1 hour meetings and homework
214620748|NCT06037642|OTHER|waiting list|Will be put on hold for four weeks
214620749|NCT00538798|DRUG|[18F]SP203|
214620750|NCT04720781|DRUG|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
214620751|NCT04720781|DRUG|Esomeprazole|esomeprazole (20mg/day)
214620752|NCT04543058|DEVICE|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
214620753|NCT04543058|OTHER|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
214620754|NCT04543058|OTHER|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
214620755|NCT05192356|DRUG|CKD-348(3)|QD, PO
214620756|NCT05192356|DRUG|CKD-828, D097, D337|QD, PO
214717426|NCT05713825|PROCEDURE|Endovascular embolization or surgery|"* Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~* Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
214717427|NCT03447119|BEHAVIORAL|Living Well with a Disability|Implementation of an adapted health promotion program.
214620757|NCT03779308|DEVICE|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
214620758|NCT01969994|OTHER|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
214620759|NCT01969994|OTHER|(-)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.
214620760|NCT00278642|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214620761|NCT03072784|PROCEDURE|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
214620762|NCT01741675|BEHAVIORAL|Questionnaire and monetary incentive|
214620763|NCT01741675|BEHAVIORAL|Questionnaire only|
214620764|NCT04207450|OTHER|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
214620765|NCT04207450|OTHER|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
214620766|NCT04207450|OTHER|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
214620767|NCT05222256|DRUG|Levosimendan|Patients in this group will receive levosimendan
214620768|NCT05222256|DRUG|Adrenaline|Patients in this group will receive Adrenaline
214620769|NCT00503594|DRUG|Methotrexate and temozolomide|Methotrexate and temozolomide
214620770|NCT00503594|DRUG|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
214620771|NCT01326182|BEHAVIORAL|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
214620772|NCT01326182|BEHAVIORAL|MAAS|Group-based intervention including asthma education and education regarding general child health
214620773|NCT00199914|DEVICE|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
214620774|NCT06979271|DRUG|Telitacicept Tofacitinib|One group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment
214620775|NCT06977607|PROCEDURE|Platelets Rich Fibrin|Repair of facial nerve injury plus Platelets Rich Fibrin will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Nano-fat stem cells)
214620776|NCT06977607|PROCEDURE|Nano-fat stem cells (NFSCs)|Repair of facial nerve injury plus Nano fat derived stem cells will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Platelets Rich Fibrin).
214620777|NCT06977607|PROCEDURE|Repair only|facial nerve neurorrhaphy only (repair only) after acute facial nerve trauma and measure the out come in comparison with (Repair plus Nano- fat Stem Cells) and (Repair Plus Platelets Rich Fibrin).
214620778|NCT05351151|PROCEDURE|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
214620779|NCT05351151|PROCEDURE|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
214620780|NCT02681679|DRUG|0.1% bromfenac ophthalmic solution|
214620781|NCT02681679|PROCEDURE|femtosecond laser cataract surgery|
214620782|NCT00085956|DRUG|Arzoxifene|
214620783|NCT00085956|DRUG|Placebo|
214620784|NCT06979063|OTHER|Remote Infertility Education and Counseling|"Patients receive video call counseling covering infertility investigation, non-pharmacological fertility enhancement strategies, and healthcare navigation guidance.~Health professionals review patient records and request missing infertility-related exams according to local protocol.~Additional follow-ups occur approximately every 30 days to assist with pending investigations.~If significant findings arise, patients will receive an explanation and assistance in scheduling primary care consultations."
214620785|NCT06979063|OTHER|Standard Care Arm|Referrals from patients will be avaluated following local protocols in the electronic referral system. Incomplete data will be requested through this system. There will be no direct contact with patients.
214620786|NCT06985641|BEHAVIORAL|Khanya-Ekhaya|The Khanya Ekhaya intervention includes an integration of several evidence-based treatment components, including motivational interviewing (MI), problem solving therapy (PST), and behavioral activation (BA), previously tested and adapted for this context in clinic settings, as well as cognitive-behavioral and mindfulness strategies that target rumination and negative thinking patterns. Aims 1-2 will inform Khanya-Ekhaya adaptation, including intervention length, but it is likely to include 3-6 sessions of CHW home visits based on formative work with ongoing supervision and support for CHWs.
214620787|NCT00095355|DRUG|Lithium|
214620788|NCT00095355|DRUG|Divalproex|
214620789|NCT01169220|DRUG|Go-Lytely|Bowel cleansing agent
214620790|NCT01169220|DRUG|Go Lytely|Bowel cleansing agent
214620791|NCT06985264|PROCEDURE|Upper Eyelid Blepharoplasty surgery|Orbicularis oculi excision
214620792|NCT06984406|DIETARY_SUPPLEMENT|Beet-Derived Inorganic Nitrate-Based Food Product|This intervention consists of an orally administered food product enriched with inorganic nitrates derived from beetroot. Participants in the intervention group will consume a standardized dose of 12 mmol of nitrate per day for 5 days (starting 24 hours before PCI and continuing for 4 days post-procedure). The product is designed to enhance nitric oxide bioavailability, improve renal perfusion, reduce oxidative stress, and lower the risk of contrast-induced nephropathy (CIN).
214620793|NCT02524821|DEVICE|Gelesis100|3 capsules each containing 0.75 mg
214620794|NCT02524821|DRUG|Metformin|1 tablet of 850 mg
214620795|NCT04404998|OTHER|Lower Energy Density|Test meal with lower energy density
214620796|NCT04404998|OTHER|Higher Energy Density|Test meal with higher energy density
214620797|NCT04404998|OTHER|Lower Satiation|Information on lower satiation
214620798|NCT04404998|OTHER|Higher Satiation|Information on higher satiation
214620799|NCT01637220|BIOLOGICAL|Blood volume collected specifically for this study|"* case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection"
214620800|NCT01213420|OTHER|Nivea Cream for scar hydration|3 applications per day during 6 months
214620801|NCT01213420|OTHER|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
214620802|NCT01213420|OTHER|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
214620803|NCT01213420|OTHER|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
214620804|NCT06984835|DEVICE|Ellanse S|Ellanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe
214620805|NCT06984835|DEVICE|Calcium Hydroxylapatite-based filler|Calcium Hydroxylapatite and carboxymethylcellulose based filler
214620806|NCT06984250|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost
214620807|NCT06984731|PROCEDURE|left atrial appendage closure|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
214620808|NCT06984731|PROCEDURE|radiofrequency ablation|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
214620809|NCT06984289|OTHER|Radiomic Analysis of Ultrasound Images|Quantitative analysis of pre-treatment ultrasound images of the primary cervical tumor to extract radiomic features. These features will be used to develop and validate machine learning models for predicting treatment response and disease relapse in patients with locally advanced cervical cancer (LACC).
214620810|NCT06442865|DEVICE|AMNIODERM+|"A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC."
214620811|NCT05065931|OTHER|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
214620812|NCT04076254|DRUG|Albumins|albumin 5%
214620813|NCT04076254|DRUG|Fluid|Ringer Lactate
214620814|NCT05060120|DIAGNOSTIC_TEST|biomakers for ovarian torsion|Blood biomarkers analysis using multiplex ELISA: The Luminex system is a magnetic bead-based multiplex ELISA that enable to measure simultaneously multiple proteins within the same sample. Human magnetic Luminex assay will be used for the following analytes: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml). Plasma samples stored at -70°C will be sent to accredited lab at BioTest (Israel) for performing the multiplex ELISA readout assay test using MagPix system.
214717428|NCT00455936|DRUG|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
214717429|NCT00455936|PROCEDURE|chemotherapy|gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
214620815|NCT05060120|DIAGNOSTIC_TEST|peritoneal fluid proteins analysis|"Western blot for peritoneal fluid proteins analysis~We will look for the relative abundance of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS) using western blot. Superoxide dismutase 1 (SOD1, 16kDa) scavenges superoxides (O-2) within cells. Catalase (60kDa) is hydrogen peroxide (H2O2) scavenging enzyme regulate ROS concentrations within cells by reducing H202 into O2 and water. Thioredoxin (12kDa) facilitates the reduction of proteins via cysteine thiol-disulfide exchange. Alpha smooth muscle actin (42kDa) will be used as a loading control. These four proteins will be resolved by western blot given their different molecular weights using western blot cocktail antibodies (abcam # ab179843)."
214620816|NCT03602092|OTHER|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
214620817|NCT00940979|PROCEDURE|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
214620818|NCT00670436|DEVICE|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
214620819|NCT00670436|DEVICE|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
214620820|NCT05015920|GENETIC|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
214620821|NCT05440656|DRUG|Cohort|Participants with Severe Eosinophilic Asthma
214620822|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
214620823|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
214620824|NCT06676592|DIAGNOSTIC_TEST|Preoperative imaging|Preoperative imaging will be performed as part of the standard of care. Imaging data from US, CT, MRI, and/or PET performed for routine care will be used for this study.
214620825|NCT06676592|DIAGNOSTIC_TEST|3D framework|3D images of surface landmarks will be acquired by use of US and the Scaniverse app before surgery, in conjunction with the participant's standard-of-care US or US-guided biopsy procedure
214620826|NCT06984822|DRUG|Anti-VEGF treatment|Intravitreal anti-VEGF treatment
214717430|NCT01972594|PROCEDURE|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
214620827|NCT06984822|DEVICE|Dexamethasone implant|Intravitreal Dexamethasone implant
214620828|NCT06984822|OTHER|Anti-VEGF treatment or Dexamethasone implant|Intravitreal anti-VEGF treatment or Intravitreal Dexamethasone implant
214620829|NCT03332329|DRUG|Entecavir|Entecavir is used for 96 weeks
214620830|NCT03332329|DRUG|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
214717431|NCT01972594|DEVICE|Accelerometer(ActivPAL)|
214717432|NCT04490304|OTHER|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
214717433|NCT02790294|DEVICE|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
214717434|NCT06011980|DRUG|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
214717435|NCT01349296|DRUG|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
214620831|NCT03332329|DRUG|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
214620832|NCT03332329|DRUG|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
214620833|NCT03109379|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
214717436|NCT05165550|DRUG|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
214717437|NCT06388135|DRUG|Serplulimab Combined With Nab-paclitaxel and Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
214620834|NCT04178174|RADIATION|SABR boost and de-escalated chemoradiation|Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
214620835|NCT04178174|RADIATION|Standard chemoradiation|Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
214620836|NCT03739476|DRUG|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
214620837|NCT03739476|DRUG|Placebo oral capsule|Compare the incidence of postoperative delirium.
214620838|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
214620839|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
214620840|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
214717438|NCT06388135|DRUG|nab-paclitaxel，Cisplatin|nab-paclitaxel，Cisplatin
214620841|NCT06680934|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
214620842|NCT05672472|DRUG|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
214620843|NCT03246139|BEHAVIORAL|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
214620844|NCT03246139|BEHAVIORAL|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
214620845|NCT03246139|BEHAVIORAL|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
214620846|NCT03565575|BEHAVIORAL|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~1. Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~2. Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
214620847|NCT06324448|DEVICE|Transcranial direct current stimulation|tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).
214620848|NCT06869161|DEVICE|Stabilization splint|Measurements will be taken from the patients with intraoral scans, transferred to the design program and a stabilization splint will be digitally designed. The designed splint will be produced from 3D printers.
214620849|NCT06869161|OTHER|Muscle exercises|Muscle exercises prepared by physical therapists will be planned to relieve trigger points in the masticatory muscles.
214620850|NCT06042725|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood samples
214620851|NCT06042725|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214620852|NCT06042725|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214620853|NCT06042725|PROCEDURE|Chest Radiography|Undergo chest x-ray
214620854|NCT06042725|PROCEDURE|Computed Tomography|Undergo PET/CT
214620855|NCT06042725|BIOLOGICAL|Daratumumab|Given SC
214620856|NCT06042725|DRUG|Dexamethasone|Given PO
214620857|NCT06042725|DRUG|Lenalidomide|Given PO
214620858|NCT06042725|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
214620859|NCT06042725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214620860|NCT06042725|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214620861|NCT06042725|DRUG|Venetoclax|Given PO
214620862|NCT06042725|PROCEDURE|X-Ray Imaging|Undergo x-rays
214620863|NCT06042725|OTHER|Questionnaire Administration|Ancillary studies
214620864|NCT06872866|DRUG|ASP-001.1|Oral liquid suspension of sildenafil
214620865|NCT06872866|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
214620866|NCT00184236|BEHAVIORAL|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
214620867|NCT00184236|BEHAVIORAL|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
214620868|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice|Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.
214620869|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.
214620870|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
214620871|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
214620872|NCT06611540|PROCEDURE|Biospecimen Collection|Undergo collection of a cervical sample by clinician
214620873|NCT06611540|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy
214620874|NCT06611540|PROCEDURE|Colposcopy|Undergo colposcopy
214620875|NCT06611540|OTHER|Electronic Health Record Review|Ancillary studies
214620876|NCT06611540|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage
214620877|NCT06611540|PROCEDURE|Excision|Undergo cervical excisional procedure
214620878|NCT06611540|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
214620879|NCT06611540|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
214620880|NCT06611540|OTHER|Questionnaire Administration|Ancillary studies
214620881|NCT01383980|DIETARY_SUPPLEMENT|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
214620882|NCT04819256|OTHER|PACE-It mobile application|Care co-ordination platform
214620883|NCT06693856|DRUG|High-Dose Methylprednisolone|Methylprednisolone 500mg, administered intravenously once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
214620884|NCT06693856|DRUG|Low-Dose Methylprednisolone|Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
214620885|NCT06712602|DRUG|alcohol|During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.
214620886|NCT06712602|BEHAVIORAL|Stress-Induction|The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.
214620887|NCT06712602|DRUG|PT150|Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.
214620888|NCT06882642|PROCEDURE|Sensory integration therapy|Autistic patients will undergo sensory integration therapy
214620889|NCT05458050|DEVICE|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
214620890|NCT06708312|PROCEDURE|press needle acupuncture|Placement of press needle on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
214620891|NCT06708312|PROCEDURE|sham press needle acupuncture|Placement of adhesive plaster on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
214620892|NCT05472012|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
214620893|NCT06727331|DRUG|Tirzepatide|This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.
214620894|NCT06727331|OTHER|Saline Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
214620895|NCT06736509|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
214620896|NCT03298425|DEVICE|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
214620897|NCT03298425|DEVICE|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
214620898|NCT06889480|DEVICE|New Target DBS|Participants in this arm will receive active DBS targeting a novel brain region identified via electrophysiological brain mapping. A DBS electrode will be implanted at the new target, and stimulation parameters (including frequency, voltage, and pulse width) are individually optimized based on mapping and 24-hour testing. The procedure is performed using a robotic system for precise electrode placement, and the device is provided by Beijing PINS Medical Co., Ltd.
214620899|NCT06889480|DEVICE|CM-DBS|This intervention involves active DBS at the central medial thalamic nucleus (CM) -a widely used target in TS treatment. A DBS electrode is implanted at the CM target, with stimulation settings determined through electrophysiological brain mapping and subsequent 24-hour stimulation. This arm serves as an active comparator, with stimulation administered during a 1-month period in the crossover phase. The same device and robotic-assisted implantation are used to ensure consistency and precision.
214717439|NCT06402786|DEVICE|Kitea ICP Sensor|Kitea ICP Sensor placed in brain during shunt surgery.
214717440|NCT02194517|DEVICE|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
214717441|NCT05211258|DEVICE|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
214717442|NCT01955395|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
214620900|NCT06889480|DEVICE|Sham Stimulation|Participants assigned to the sham stimulation arm undergo the identical surgical procedure and electrode implantation as those in the active arms. However, during the stimulation periods, the device is programmed to deliver no active stimulation. This sham intervention is designed to control for placebo effects and ensure that any observed improvements in TS symptoms are attributable to the active DBS interventions.
214717443|NCT01170312|BIOLOGICAL|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
214717444|NCT01170312|OTHER|Normal saline|Normal saline injection
214717445|NCT04673955|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
214717446|NCT04673955|DRUG|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
214717447|NCT01425749|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
214717448|NCT01277913|DRUG|Vitamin D3|1000 IU once daily for 12 months
214717449|NCT01277913|DRUG|Vitamin D3|500 IU once daily for 12 months
214620901|NCT06747260|BIOLOGICAL|Intranasal breast milk|Neonates with hypoxic-ischemic encephalopathy receive their own-mother's fresh breast milk intranasally, starting from the first 48 hours of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart).
214620902|NCT05957861|BEHAVIORAL|web-based aerobic exercise|Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
214620903|NCT06733155|OTHER|Financial intervention|Participants completing the mammogram within the study end date will receive a $10 voucher.
214620904|NCT06733155|OTHER|Lottery intervention|Participants completing the mammogram within the study end date will receive achance to win a $5000 lottery.
214620905|NCT06733155|OTHER|Health Messages|Participants will receive a less than 5 minute long video from an influential person. The video will be available in four languages (English, Chinese, Malay, Tamil).
214620906|NCT06733155|OTHER|Personal Health Concierge|Participants will be able to call a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks of receive the the mailer.
214620907|NCT06733155|OTHER|Only reminder mailer|Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram.
214620908|NCT06763744|DRUG|P2Y12 antagonist monotherapy|CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.
214620909|NCT06763744|DRUG|clopidogrel + aspirin|In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
214620910|NCT06756581|OTHER|baked milk product diet|Elimination of none baked cow milk from diet . Baked cow milk containing diet.
214620911|NCT04192344|DRUG|ABSK021|ABSK021 oral capsule
214717450|NCT06117917|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
214717451|NCT06117917|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
214717452|NCT04110184|OTHER|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
214620912|NCT06891950|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Each 0.5 mL dose of the lyophilized formulation of Dengue 1,2,3,4 (attenuated) presents an approximate concentration of 103.0 PFU of each vaccine virus rDEN1Δ30-1545, rDEN2/4Δ30(ME)-1495,7163, rDEN3Δ30/31-7164, rDEN4Δ30-7132,7163,8308.
214620913|NCT06240624|OTHER|No intervention|No intervention will be given.
214620914|NCT03841097|DRUG|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
214620915|NCT03841097|DRUG|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
214620916|NCT01423851|DRUG|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
214620917|NCT06929195|DRUG|TQB2210 Injection|TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
214620918|NCT06930781|DEVICE|Ponto implantation|Ponto implantation is a surgical procedure to implant a bone-anchored hearing device, improving hearing by transmitting sound directly to the inner ear through bone conduction.
214620919|NCT06904339|BEHAVIORAL|Starting the Conversation|Starting the Conversation includes a 25-minute video with information about sexual health and gynecologic cancer and tips about how to talk to their cancer care team about sexual health concerns. Participants will also fill out a workbook with activities to help them practice communication skills.
214620920|NCT06904339|BEHAVIORAL|Sexual Health Resources|The sexual health resource guide includes institutional resources for patients with sexual concerns (for example, the Women's Survivorship Clinic) and links to reputable websites with information about sexual health after gynecologic cancer.
214717453|NCT03375138|DRUG|belatacept|Specified dose on specified days
214620921|NCT06903611|DRUG|CAM-101|fibrinogen depleted human platelet lysate
214717454|NCT00246064|DRUG|infliximab|
214717455|NCT02855138|DRUG|oral isotretinoin|
214717456|NCT01293084|DRUG|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
214620922|NCT06903611|OTHER|Vehicle Control|Plasmalyte-A
214620923|NCT03080883|DRUG|Apixaban|Given PO
214620924|NCT02984761|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
214717457|NCT01293084|DRUG|7% saline|5mL 7% saline inhaled once over 20 minutes
214717458|NCT02096042|DRUG|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
214717459|NCT02096042|DRUG|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
214717460|NCT06154499|PROCEDURE|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
214717461|NCT00006299|DRUG|Celebrex|
214717462|NCT02983799|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily
214717463|NCT00706615|BIOLOGICAL|Ad-sig-hMUC-1/ecdCD40L vaccine|
214717464|NCT00845507|DRUG|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
214717465|NCT00845507|DRUG|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
214620925|NCT02984761|PROCEDURE|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
214717466|NCT03406715|DRUG|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
214717467|NCT03406715|DRUG|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
214717468|NCT03406715|BIOLOGICAL|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
214620926|NCT05950360|DEVICE|Electromagnetic tracking system, surface electromyography|arm elevation in the scapular plane, overhead reaching to the target 15° backward to the frontal plane, pull-up with overhead reaching forward and backward.
214620927|NCT06928480|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders|"This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7).~In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows:~* Module 1 (session 1): Setting goals and maintaining motivation.~* Module 2 (sessions 2 and 3): Understanding your emotions.~* Module 3 (sessions 4 and 5): Mindful Emotions Awareness.~* Module 4 (sessions 6 and 7): Flexible thinking.~* Module 5 (session 8): Emotional baheviors.~* Module 6 (session 9): Facing physical sensations.~* Module 7 (sessions 10 and 11): Emotionl exposures.~* Module 8 (Session 12): Relapse prevention."
214620928|NCT06928480|OTHER|Treatment as Usual (TAU)|"This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19.~After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition."
214620929|NCT06939920|OTHER|Non-invasive ventilation mask with airway washout|Non-invasive ventilation mask with airway washout for dual limb ventilators
214717469|NCT04820153|DEVICE|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
214717470|NCT04820153|BEHAVIORAL|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
214717471|NCT03713606|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
214717472|NCT03578380|PROCEDURE|Surgery|Lymphovenous anastomosis
214717473|NCT03578380|OTHER|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
214717474|NCT06378060|DRUG|Modified transplantation system|Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
214717475|NCT02219217|DRUG|Dolutegravir, Elvitegravir and Cobicistat|
214717476|NCT03835013|DRUG|Saline 0.9%|Intravenous infusion of 0.9% saline
214717477|NCT03835013|DRUG|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
214717478|NCT03835013|DRUG|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
214717479|NCT03835013|DRUG|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
214717480|NCT03906175|DEVICE|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
214717481|NCT01998152|PROCEDURE|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
214717482|NCT00243685|OTHER|Laboratory Assay|Chemotherapy
214717483|NCT00243685|OTHER|Mick Assay|Chemotherapy doctor determined from results
214717484|NCT05235100|DRUG|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
214717485|NCT02783209|PROCEDURE|Cataract surgery|
214717486|NCT02195609|DIETARY_SUPPLEMENT|Omega-3|600 mg oral twice a day
214717487|NCT02195609|DIETARY_SUPPLEMENT|Soy Isoflavones|54.4 mg oral twice a day
214717488|NCT03380507|DRUG|Triple therapy group|Refer to arms description
214717489|NCT03558971|DRUG|Cortisol|Participants determine when to administer 5-day regimens of cortisol
214717490|NCT02313415|PROCEDURE|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
214717491|NCT04628611|DEVICE|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
214620930|NCT06939920|OTHER|non-invasive ventilation|standard state of the art non-invasive ventilation
214717492|NCT04628611|DEVICE|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
214717493|NCT01565811|PROCEDURE|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
214620931|NCT06936904|PROCEDURE|injection speed|Patients undergoing CT-guided lung nodule localization were selected for the study, and ultrasound-guided erector spinae plane block was performed before surgery with different injection speed.
214717494|NCT04938089|OTHER|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
214620932|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
214620933|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
214620934|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
214620935|NCT06947954|BEHAVIORAL|Nourish intervention then no intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 9 weeks, participants crossover into the No Intervention group.
214717495|NCT05340491|DRUG|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
214620936|NCT06947954|BEHAVIORAL|no intervention then Nourish intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
214620937|NCT00285129|DEVICE|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
214620938|NCT06275022|PROCEDURE|Inflow occlusion with perforation of septation and sclerotherapy|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
214620939|NCT06275022|PROCEDURE|Perforation of septation and sclerotherapy|Perforation of septation and sclerotherapy
214620940|NCT06275022|PROCEDURE|Indocyanine green-guided partial resection and sclerotherapy|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
214717496|NCT05340491|DRUG|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
214717497|NCT05340491|RADIATION|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
214717498|NCT00501462|DRUG|GSK189075|single 250 mg dose of drug
214717499|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
214717500|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
214620941|NCT06275022|PROCEDURE|Partial resection and sclerotherapy|Partial resection and sclerotherapy
214717501|NCT00537680|DRUG|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
214717502|NCT02476344|OTHER|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
214717503|NCT05739240|PROCEDURE|Osteosynthesis|Osteosynthesis of distal radius fractures
214717504|NCT01225172|DRUG|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
214717505|NCT01225172|DRUG|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
214717506|NCT01414517|DIETARY_SUPPLEMENT|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
214717507|NCT01414517|DIETARY_SUPPLEMENT|Maltodextrin|a non-prebiotic carbohydrate
214717508|NCT05581355|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
214717509|NCT02529670|PROCEDURE|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
214717510|NCT02529670|PROCEDURE|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
214717511|NCT02529670|PROCEDURE|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
214620942|NCT06176638|BEHAVIORAL|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
214620943|NCT00346073|BIOLOGICAL|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
214620944|NCT00346073|BIOLOGICAL|ADACEL®|Sanofi Pasteur
214620945|NCT00239798|DRUG|FTY720|
214620946|NCT01417715|DEVICE|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
214620947|NCT00515801|DRUG|glibenclamide|glibenclamide 15 mg single dose
214620948|NCT00515801|DRUG|placebo|placebo capsules, single dose
214620949|NCT00006476|DRUG|suramin|
214620950|NCT00006476|PROCEDURE|conventional surgery|
214717512|NCT05191732|COMBINATION_PRODUCT|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
214620951|NCT04551937|OTHER|Lactose Free 1% Milk|8 oz of study beverage daily
214620952|NCT04551937|OTHER|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
214620953|NCT00603109|DRUG|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
214620954|NCT00603109|DRUG|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
214620955|NCT04661709|DRUG|Wen Xin granule|one dose daily, two times per day.
214620956|NCT04661709|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
214620957|NCT04661709|DRUG|Atorvastatin Calcium|20 mg tablet, one tablet each night.
214620958|NCT04661709|DRUG|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
214717513|NCT05225480|BEHAVIORAL|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
214717514|NCT05225480|BEHAVIORAL|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
214717515|NCT00156013|DRUG|CLOFARABINE|4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
214717516|NCT03767998|OTHER|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
214620959|NCT04661709|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
214620960|NCT04661709|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
214620961|NCT04661709|DRUG|WXG placebo|one dose daily, two times per day.
214620962|NCT04661709|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
214620963|NCT04661709|DRUG|glyceryl trinitrate|be taken when angina pectoris attacks.
214620964|NCT02728193|PROCEDURE|RFA|
214620965|NCT02728193|PROCEDURE|MWV|
214620966|NCT02728193|PROCEDURE|PEI|Percutaneous ethanol injection
214620967|NCT03711656|DEVICE|isCGM (intermittently scanned Continuous Glucose Monitoring)|Data collection
214620968|NCT03711656|DEVICE|Physical exercise tracker|Data collection
214620969|NCT03053297|OTHER|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
214620970|NCT02079571|DIETARY_SUPPLEMENT|Coconut water|250 ml Coconut water for each subject
214620971|NCT02079571|DIETARY_SUPPLEMENT|ginger tea|250 ml for each subject
214620972|NCT04359303|OTHER|Systemic indirect endovenous ozone therapy|200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
214620973|NCT01006421|DIETARY_SUPPLEMENT|GINGKO BILOBA|MEMOREX 60 MG BID
214717517|NCT03767998|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
214620974|NCT02708953|PROCEDURE|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
214620975|NCT02708953|PROCEDURE|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
214620976|NCT06197828|OTHER|This study is an observational studie which have no intervention|This study is an observational studie which have no intervention
214620977|NCT00017862|DRUG|SCH55700|
214620978|NCT03762759|PROCEDURE|Computed Tomography|Undergo PET/CT
214620979|NCT03762759|DRUG|Fluciclovine F18|Given IV
214620980|NCT03762759|RADIATION|Gallium Ga68-labeled PSMA-11|Given IV
214620981|NCT03762759|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214717518|NCT03767998|OTHER|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
214620982|NCT03415295|OTHER|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
214717519|NCT04637191|DEVICE|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
214620983|NCT03773042|DRUG|HSK3486|For induction and maintenance of sedation.
214620984|NCT03773042|DRUG|Propofol|For induction and maintenance of sedation.
214717520|NCT04066530|DRUG|AD-203|AD-203 administered two times daily for two weeks
214717521|NCT04066530|DRUG|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
214717522|NCT02409758|BEHAVIORAL|Voice therapy|Voice therapy applied during 6 weeks.
214717523|NCT05726448|BEHAVIORAL|Telehealth solution|Mobile-friendly nutrition education platform
214620985|NCT02834468|DRUG|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
214620986|NCT00625833|DRUG|Placebo|Oral tablet once a day dosing for 10 weeks.
214620987|NCT00625833|DRUG|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
214620988|NCT04098770|BIOLOGICAL|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
214620989|NCT03339661|DRUG|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
214620990|NCT03339661|DRUG|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
214620991|NCT03339661|DRUG|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
214620992|NCT05716880|DRUG|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
214620993|NCT05716880|OTHER|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
214620994|NCT00355433|PROCEDURE|Urodymanics|
214717524|NCT00795509|DRUG|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
214620995|NCT03313427|OTHER|Physical Therapy Early Intervention|"At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
214620996|NCT03313427|OTHER|Usual Care|NICU usual care
214620997|NCT06355765|DIETARY_SUPPLEMENT|Citicoline blackcurrant supplement|Citicoline, Vitamins A, B, C and E, and Blackcurrant
214620998|NCT04795232|OTHER|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
214620999|NCT04795232|OTHER|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
214621000|NCT05453058|DIAGNOSTIC_TEST|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
214621001|NCT02275078|BEHAVIORAL|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
214621002|NCT02275078|DEVICE|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
214621003|NCT02275078|OTHER|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
214717525|NCT00800930|BIOLOGICAL|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
214621004|NCT04458142|OTHER|Single buccal infiltration|painless technique for palatal anesthesia,single injection,single puncture given
214621005|NCT00075023|DRUG|Thalidomide Gel|
214621006|NCT00075023|DRUG|Placebo Gel|
214621007|NCT04342871|BEHAVIORAL|FACT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
214621008|NCT03670953|DRUG|IR CD-LD|Active comparator - IR CD-LD
214621009|NCT03670953|DRUG|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
214621010|NCT03670953|OTHER|Placebo Matching IPX203|Double dummy placebo capsules
214621011|NCT03670953|OTHER|Placebo Matching IR CD-LD|Double dummy placebo tablets
214621012|NCT04268485|DIAGNOSTIC_TEST|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
214621013|NCT04179734|DRUG|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
214621014|NCT04179734|DRUG|Placebo|Placebo subcutaenous injection.
214621015|NCT06073496|OTHER|Electroacupuncture|Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator
214621016|NCT04438473|DIETARY_SUPPLEMENT|pectin-supplemented enteral nutrition feeding|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
214621017|NCT04438473|OTHER|enteral nutrition feeding|standard formula enteral nutrition feeding without pectin for 7 days
214621018|NCT04503954|OTHER|Chronic disease self-management program|The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
214621019|NCT04503954|OTHER|General psychiatric intervention|General psychiatric intervention contains the activities in psychiatric center.
214621020|NCT00899184|GENETIC|polymorphism analysis|
214621021|NCT00899184|OTHER|laboratory biomarker analysis|
214621022|NCT01078831|OTHER|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
214621023|NCT04395339|DRUG|Monosialotetrahexosyl ganglioside (GM1)|Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
214621024|NCT04395339|DRUG|Control|250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
214621025|NCT01683201|PROCEDURE|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
214621026|NCT01683201|PROCEDURE|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
214621027|NCT03740750|DEVICE|Thermacare heat wraps|low level continuous heat wrap
214621028|NCT03740750|DEVICE|TENS|electrical stimulation
214621029|NCT03740750|DEVICE|sham heat|expended heat wrap
214621030|NCT03740750|DEVICE|sham Tens|tens applied but unit not turned on
214621031|NCT00290615|BIOLOGICAL|bevacizumab|
214621032|NCT00290615|BIOLOGICAL|cetuximab|
214621033|NCT00290615|DRUG|capecitabine|
214621034|NCT00290615|DRUG|oxaliplatin|
214621035|NCT03471702|DEVICE|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
214621036|NCT04027114|BEHAVIORAL|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
214621037|NCT03105687|BEHAVIORAL|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
214621038|NCT01093274|DRUG|Sodium Picosulphate|2 Sachets
214621039|NCT01093274|DRUG|Polyethylene Glycol|3 Liters solution
214621040|NCT06407635|DRUG|Psilocybin|The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.
214621041|NCT06407635|OTHER|Trauma-focused psychotherapy|Components of trauma-focused psychotherapy will include Cognitive Processing Therapy and in vivo exposure. Such components of evidence-based psychotherapy may lower the safety risk profile for this vulnerable population and enhance the effect size and maintenance of psilocybin therapy.
214621042|NCT06407635|OTHER|Standard psychological support|Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.
214621043|NCT03366688|DRUG|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
214621044|NCT03366688|DRUG|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
214621045|NCT03691233|DRUG|Clinical audit on diagnosis and management of neonatal shock|intervenous
214621046|NCT01429584|DRUG|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
214621047|NCT01429584|DRUG|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
214621048|NCT04262687|DRUG|Capecitabine|2000 mg/m²/day, from day 1 to 14 of each cycle
214621049|NCT04262687|DRUG|Oxaliplatin|130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle
214621050|NCT04262687|DRUG|Bevacizumab|7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle
214717526|NCT00800930|BIOLOGICAL|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
214717527|NCT01752972|DIETARY_SUPPLEMENT|Spirulina|10 g/day orally for 12 weeks
214717528|NCT00909818|RADIATION|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
214621051|NCT04262687|DRUG|Pembrolizumab|200 mg by IV infusion over 30 minutes, on day 1 of each cycle
214621052|NCT02900079|DEVICE|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
214621053|NCT05058755|DRUG|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
214621054|NCT05058755|DRUG|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
214621055|NCT04715061|OTHER|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
214717529|NCT00909818|RADIATION|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
214717530|NCT03967275|OTHER|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
214717531|NCT01601470|DRUG|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
214717532|NCT01601470|DRUG|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
214717533|NCT03305601|OTHER|application on smarthphone|application on smarthphone
214717534|NCT04907318|DEVICE|Cataract surgery|
214717535|NCT05285436|DEVICE|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
214621056|NCT04715061|OTHER|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
214621057|NCT04715061|OTHER|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
214621058|NCT03522870|DEVICE|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
214621059|NCT03522870|DEVICE|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
214621060|NCT02452905|DRUG|Nitazoxanide|
214621061|NCT02452905|DRUG|Placebo (for Nitazoxanide)|
214621062|NCT04944511|DRUG|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
214621063|NCT05086328|BEHAVIORAL|Nonviolent Resistance|Six two weekly sessions of two hours, based on nonviolent resistance Questionnaires pre and post intervention
214621064|NCT02365220|BEHAVIORAL|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
214621065|NCT02365220|BEHAVIORAL|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
214621066|NCT02365220|BEHAVIORAL|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
214621067|NCT02365220|BEHAVIORAL|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
214621068|NCT06011148|DEVICE|Perceval S sutureless heart valve|Aortic Valve Replacement with Perceval S sutureless heart valve
214621069|NCT02263079|DRUG|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
214717536|NCT03907787|DIETARY_SUPPLEMENT|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
214717537|NCT03966495|OTHER|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
214621070|NCT02263079|DRUG|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
214621071|NCT02263079|DRUG|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
214621072|NCT03378804|PROCEDURE|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
214717538|NCT04905823|DIAGNOSTIC_TEST|blood test|assessment of humoral, immune cell response and glycemia
214621073|NCT03378804|PROCEDURE|Continous epidural analgesia|
214621074|NCT00199550|PROCEDURE|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
214621075|NCT00199550|PROCEDURE|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
214621076|NCT04216459|DRUG|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
214621077|NCT04216459|DRUG|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
214621078|NCT03343587|DRUG|LY3375880 IV|administered IV
214621079|NCT03343587|DRUG|LY3375880 SC|administered SC
214621080|NCT03343587|DRUG|Placebo IV|administered IV
214621081|NCT03343587|DRUG|Placebo SC|administered SC
214621082|NCT01157221|OTHER|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
214621083|NCT01157221|OTHER|EMSMTA|end-range mobilization/scapular mobilization treatment approach
214621084|NCT01467843|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
214621085|NCT01467843|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
214621086|NCT03970694|RADIATION|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
214621087|NCT03970694|DRUG|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
214621088|NCT02603120|DRUG|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
214621089|NCT02603120|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
214621090|NCT02603120|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
214621091|NCT02603120|DRUG|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
214621092|NCT01645189|BIOLOGICAL|Hunterase|once weekly, 0.5mg/kg IV infusion
214621093|NCT06156982|DRUG|Evusheld|Administration of Evusheld 600 mg
214621094|NCT04467424|DRUG|ketamine, propofol|anesthesia with ketofol in pediatric surgery
214621095|NCT04467424|DRUG|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
214621096|NCT01628445|DRUG|liraglutide|liraglutide titrated to 1.8 mg sc daily
214621097|NCT01628445|DRUG|placebo injection|placebo injected sc daily volume equal to active comparator
214621098|NCT01199042|DEVICE|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
214717539|NCT03494023|DIAGNOSTIC_TEST|Endoscopic ultrasound|Measurement of the common bile duct diameter
214717540|NCT00053638|DRUG|efavirenz|
214717541|NCT00053638|DRUG|tenofovir|
214621099|NCT06379737|BEHAVIORAL|Multi-systemic Rehabilitation|"Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit"
214621100|NCT04031911|DEVICE|Hydroposturotherapy|"Hydroposturotherapy combines:~* posturotherapy (patient placed upside down with water jets sent to the kidneys)~* lumbar percussion~* hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
214621101|NCT04031911|DEVICE|Standard support in urology|Dispensing of AFU plugs Dietary advice
214621102|NCT00677651|PROCEDURE|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
214621103|NCT00677651|PROCEDURE|Blood sample|Blood will be sampled from an IV line
214621104|NCT00677651|RADIATION|CT Scan|Single image at the level of the liver
214621105|NCT00677651|RADIATION|DEXA|Whole body scan
214621106|NCT01973374|BEHAVIORAL|Text Message Intervention|
214621107|NCT01432249|DRUG|Enbrel group|will be decided by treating physicians
214717542|NCT00053638|DRUG|abacavir/lamivudine|
214717543|NCT03822338|PROCEDURE|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
214717544|NCT03822338|PROCEDURE|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
214717545|NCT05895695|PROCEDURE|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
214717546|NCT05895695|PROCEDURE|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
214717547|NCT00825149|DRUG|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
214621108|NCT06434194|DEVICE|Serranator PTA Serration Catheter|The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
214621109|NCT06434194|DRUG|PTA (Standard of Care)|A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
214621110|NCT04639973|DIAGNOSTIC_TEST|Group 1 (First trimester ultrasound)|A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
214621111|NCT04639973|DIAGNOSTIC_TEST|Group 2 (Second trimester anatomy ultrasound)|Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
214621112|NCT01572116|DRUG|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
214621113|NCT01572116|DRUG|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
214621114|NCT03171220|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
214621115|NCT03171220|BIOLOGICAL|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
214717548|NCT00825149|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
214717549|NCT00825149|DRUG|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
214717550|NCT00825149|DRUG|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
214717551|NCT00825149|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
214717552|NCT00825149|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
214717553|NCT00825149|DRUG|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
214717554|NCT04213118|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
214717555|NCT04213118|PROCEDURE|TACE|TACE first, followed by anlotinib within day4（+/-1days）
214717556|NCT00301470|DEVICE|MR urography|undergoing both renal scintigraphy and MR within a month
214717557|NCT01871272|PROCEDURE|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
214717558|NCT05609851|OTHER|Short Physical Performance Batary|"The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function."
214717559|NCT05609851|OTHER|Occupational Balance Self-Assessment|"The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value."
214621116|NCT03171220|DRUG|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
214621117|NCT03171220|DRUG|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
214621118|NCT03171220|BIOLOGICAL|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
214717560|NCT03066297|PROCEDURE|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
214717561|NCT02468960|DEVICE|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
214621119|NCT00809666|DEVICE|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
214621120|NCT01867060|DEVICE|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
214621121|NCT01867060|DEVICE|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
214621122|NCT03328546|OTHER|Dietary intake|Dietary intake converted into dietary pattern scores.
214717562|NCT02468960|DEVICE|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
214717563|NCT02468960|DEVICE|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
214717564|NCT02468960|PROCEDURE|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
214717565|NCT02468960|OTHER|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
214717566|NCT03682406|BEHAVIORAL|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
214717567|NCT01909219|DRUG|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
214717568|NCT02045056|DRUG|Gemfibrozil|
214717569|NCT02045056|DRUG|Placebo|
214717570|NCT02603406|DRUG|erythropoietin|
214717571|NCT04916756|DRUG|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
214717572|NCT01728727|OTHER|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
214717573|NCT01728727|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
214621123|NCT01602770|DRUG|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
214621124|NCT00838773|BEHAVIORAL|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
214621125|NCT00838773|BEHAVIORAL|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
214621126|NCT00838773|BEHAVIORAL|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
214621127|NCT01748175|DRUG|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
214621128|NCT01035385|DRUG|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
214621129|NCT00529997|DEVICE|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
214621130|NCT04056572|DRUG|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
214621131|NCT05798442|OTHER|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
214717574|NCT01700881|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
214717575|NCT01700881|OTHER|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
214717576|NCT04848012|DEVICE|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
214717577|NCT02079519|DRUG|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
214717578|NCT05073913|DIAGNOSTIC_TEST|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
214717579|NCT01900756|BEHAVIORAL|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
214717580|NCT03769337|DIAGNOSTIC_TEST|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
214717581|NCT02580838|DRUG|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
214717582|NCT06239324|DRUG|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
214717583|NCT02171949|BIOLOGICAL|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
214717584|NCT00509652|PROCEDURE|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
214717585|NCT00509652|PROCEDURE|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
214717586|NCT04511936|DEVICE|i-Lumen AMD|Microcurrent stimulator
214717587|NCT04511936|DEVICE|i-Lumen AMD Sham|Sham microcurrent stimulator
214717588|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
214621132|NCT00176605|DRUG|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
214621133|NCT00176605|DRUG|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
214621134|NCT02288936|DRUG|Enzalutamide|Enzalutamide 160 mg/day
214621135|NCT04552275|DIAGNOSTIC_TEST|Proteomics Analysis|Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
214621136|NCT06050174|DRUG|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
214717589|NCT01225276|DRUG|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
214621137|NCT06050174|PROCEDURE|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
214621138|NCT01321710|BEHAVIORAL|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
214621139|NCT01321710|BEHAVIORAL|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
214621140|NCT01321710|DRUG|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
214621141|NCT03709238|BEHAVIORAL|Thermal stimulation|Thermal stimulation
214717590|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
214717591|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
214621142|NCT01423162|OTHER|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
214621143|NCT01423162|OTHER|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
214621144|NCT02157675|DIETARY_SUPPLEMENT|Polyherbal capsule|
214621145|NCT02157675|DIETARY_SUPPLEMENT|Placebo capsule|
214717592|NCT01522560|OTHER|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
214717593|NCT01522560|OTHER|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
214717594|NCT00399867|DRUG|Simvastatin|
214717595|NCT04821960|BEHAVIORAL|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
214717596|NCT04821960|BEHAVIORAL|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
214717597|NCT02720250|DIETARY_SUPPLEMENT|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
214621146|NCT01234974|DRUG|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
214717598|NCT02720250|DIETARY_SUPPLEMENT|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
214717599|NCT04787926|DEVICE|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
214717600|NCT01041404|DRUG|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
214621147|NCT01234974|DRUG|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
214621148|NCT01227187|DRUG|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
214621149|NCT01761292|DRUG|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
214621150|NCT05744089|DEVICE|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
214717601|NCT01041404|DRUG|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
214717602|NCT01041404|DRUG|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
214621151|NCT05913661|DRUG|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
214621152|NCT05913661|DRUG|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
214621153|NCT01880671|DEVICE|Inactive Migraine Medical Device|
214621154|NCT01880671|DEVICE|Migraine Medical Device|
214621155|NCT02180555|OTHER|Oral glucose tolerance test|
214621156|NCT01407770|GENETIC|DNA analysis|Genetic
214621157|NCT01407770|GENETIC|gene expression analysis|Genetic
214621158|NCT01407770|OTHER|enzyme-linked immunosorbent assay|Genetic
214621159|NCT01407770|OTHER|flow cytometry|Genetic
214621160|NCT01407770|OTHER|laboratory biomarker analysis|Genetic
214621161|NCT01407770|OTHER|questionnaire administration|Genetic
214621162|NCT01407770|PROCEDURE|adjuvant therapy|Genetic
214621163|NCT01407770|PROCEDURE|assessment of therapy complications|Genetic
214621164|NCT01407770|PROCEDURE|quality-of-life assessment|Genetic
214621165|NCT01407770|RADIATION|3-dimensional conformal radiation therapy|Genetic
214621166|NCT01407770|RADIATION|breast irradiation|Genetic
214621167|NCT01407770|RADIATION|external beam radiation therapy|Genetic
214621168|NCT01407770|RADIATION|hypofractionated radiation therapy|Genetic
214621169|NCT01407770|RADIATION|intensity-modulated radiation therapy|Genetic
214717603|NCT01041404|DRUG|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
214717604|NCT00092404|BIOLOGICAL|measles, mumps, and rubella virus vaccine live|
214621170|NCT01407770|RADIATION|whole breast irradiation|Genetic
214621171|NCT05311124|DEVICE|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
214621172|NCT02853942|BIOLOGICAL|Autologous adipose stem cell therapy|
214621173|NCT02853942|DRUG|Mecobalamin|
214621174|NCT03889314|DRUG|Rosuvastatin 20mg|Statin Therapy
214621175|NCT03889314|OTHER|Placebo|Placebo
214621176|NCT02791984|DEVICE|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
214621177|NCT05418400|OTHER|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
214717605|NCT00092404|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
214621178|NCT05953142|DRUG|Dobutamine|Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
214717606|NCT05308667|OTHER|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
214717607|NCT05308667|OTHER|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
214717608|NCT00768768|OTHER|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
214717609|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
214621179|NCT02361502|DRUG|mirabegron|
214717610|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
214621180|NCT02361502|DRUG|placebo|
214621181|NCT02029859|PROCEDURE|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
214621182|NCT02657395|DEVICE|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
214621183|NCT02554019|BIOLOGICAL|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
214621184|NCT02554019|BIOLOGICAL|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
214621185|NCT04639856|PROCEDURE|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
214621186|NCT03978455|BEHAVIORAL|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
214621187|NCT01908023|BEHAVIORAL|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
214621188|NCT04411264|DEVICE|virtual reality|Use of a virtual reality headset while caring for chronic wound dressings
214621189|NCT03603860|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
214621190|NCT02463409|DRUG|Theophylline|24 hour infusion of IV theophylline
214621191|NCT05627284|PROCEDURE|Stoma reversal with bio-mesh placement|Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.
214621192|NCT05285241|OTHER|Multidirectional stepping exercises|These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).
214621193|NCT05285241|OTHER|Conventional physiotherapy group|Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)
214621194|NCT02281370|DRUG|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
214717611|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
214717612|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
214621195|NCT02281370|DRUG|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
214621196|NCT04167046|PROCEDURE|Erector spinae block|Preoperative erector spinae block.
214717613|NCT00195481|DRUG|Rapamune|
214621197|NCT04170361|OTHER|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
214621198|NCT04170361|OTHER|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
214621199|NCT06450652|DRUG|Chinese Herbal Medicine granules|The intervention will be a 4 weeks of Chinese Herbal Medicine (CHM) granules, which will consist of six Chinese herbs. Subjects will take one sachet orally, twice daily after meals for 4 weeks. Way of taking CHM granules is as follow: Add 100ml boiling water into a cup, then pour one pack of granules into the cup and soap it for 2-3 mins. Stir until the granules completely dissolve before drinking.
214621200|NCT00772954|BIOLOGICAL|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
214621201|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
214621202|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
214621203|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
214621204|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
214621205|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
214621206|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
214621207|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
214621208|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
214621209|NCT02495844|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
214621210|NCT02325219|DRUG|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
214621211|NCT02325219|DRUG|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
214621212|NCT02325219|DRUG|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
214621213|NCT02325219|DRUG|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
214621214|NCT01433237|GENETIC|RNA analysis|
214621215|NCT01433237|GENETIC|gene expression analysis|
214621216|NCT01433237|OTHER|laboratory biomarker analysis|
214621217|NCT00798850|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.
214621218|NCT00798850|PROCEDURE|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
214621219|NCT00798850|PROCEDURE|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
214621220|NCT02603874|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
214621221|NCT03656679|PROCEDURE|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
214621222|NCT03656679|PROCEDURE|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
214621223|NCT03303950|DRUG|Busulfan|Given IV
214621224|NCT03303950|DRUG|Cyclophosphamide|Given IV
214621225|NCT03303950|DRUG|Fludarabine|Given IV
214621226|NCT03303950|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
214621227|NCT03303950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214621228|NCT05874973|OTHER|Time-controlled adaptative ventilation (TCAV)|Ventilation with TCAV set on the APRV mode on the ventilator.
214621229|NCT05874973|OTHER|Volume-controlled ventilation (VCV)|Ventilation with the VCV mode set on the ventilator.
214621230|NCT04782362|OTHER|Brace Treatment|Body image and quality of life of individuals who have used brace will be evaluated
214621231|NCT00880399|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
214621232|NCT00880399|OTHER|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
214621233|NCT04353284|DRUG|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
214621234|NCT04353284|OTHER|Placebo|Placebo taken orally, 4 times daily, for 7 days.
214621235|NCT02146508|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
214621236|NCT02146508|DEVICE|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
214621237|NCT02997527|DEVICE|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
214621238|NCT04715750|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
214621239|NCT01911442|DRUG|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
214621240|NCT01911442|DRUG|Lurasidone|Lurasidone 60 mg once daily
214621241|NCT01911442|DRUG|Placebo|Placebo
214621242|NCT00871845|BEHAVIORAL|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
214621243|NCT02094456|PROCEDURE|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
214621244|NCT02094456|PROCEDURE|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
214621245|NCT06152445|OTHER|Wheat bread|Different wheat breads
214621246|NCT04866693|OTHER|None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.|Qualitative study
214621247|NCT05175833|COMBINATION_PRODUCT|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
214621248|NCT05175833|OTHER|Oral placebo|Oral gel containing placebo
214621249|NCT01306448|DEVICE|Vibrant capsule|vibrating capsule
214621250|NCT00825500|DRUG|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
214621251|NCT00825500|DRUG|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
214621252|NCT00825500|DRUG|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
214621253|NCT00003437|DRUG|asparaginase|
214621254|NCT00003437|DRUG|cyclophosphamide|
214621255|NCT00003437|DRUG|cytarabine|
214621256|NCT00003437|DRUG|daunorubicin hydrochloride|
214621257|NCT00003437|DRUG|dexamethasone|
214621258|NCT00003437|DRUG|doxorubicin hydrochloride|
214621259|NCT00003437|DRUG|mercaptopurine|
214621260|NCT00003437|DRUG|methotrexate|
214621261|NCT00003437|DRUG|pegaspargase|
214621262|NCT00003437|DRUG|prednisolone|
214621263|NCT00003437|DRUG|thioguanine|
214621264|NCT00003437|DRUG|vincristine sulfate|
214621265|NCT00003437|RADIATION|radiation therapy|
214621266|NCT00122681|BIOLOGICAL|Cervarix™|Intramuscular injection, 3 doses
214621267|NCT00122681|BIOLOGICAL|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
214621268|NCT05312177|OTHER|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
214621269|NCT05312177|OTHER|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
214621270|NCT05312177|OTHER|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
214621271|NCT05312177|OTHER|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
214621272|NCT05312177|OTHER|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
214621273|NCT05312177|OTHER|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
214621274|NCT05312177|OTHER|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
214621275|NCT05312177|OTHER|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
214621276|NCT03211221|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
214621277|NCT02819635|DRUG|Placebo|Film-coated tablet for oral administration
214621278|NCT02819635|DRUG|Upadacitinib|Film-coated tablet for oral administration
214621279|NCT01035099|DRUG|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;"
214621280|NCT01035099|DRUG|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
214621281|NCT05018247|PROCEDURE|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
214621282|NCT00101751|DRUG|biphasic insulin aspart|
214621283|NCT00101751|BEHAVIORAL|dietary regimen|
214621284|NCT05988268|OTHER|Vibration Foam Rolling|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
214621285|NCT05988268|OTHER|Non-Vibration Foam Rolling|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
214621286|NCT03079206|DIAGNOSTIC_TEST|Food challenge|food challenge with hazelnut
214621287|NCT03079206|DIAGNOSTIC_TEST|skin testing|Skin testing with hazelnut extract
214621288|NCT03079206|DIAGNOSTIC_TEST|blood sampling|blood sampling to perform basophile activation tests
214621289|NCT04214379|PROCEDURE|Ptosis surgery|Frontalis sling surgery using pose-up and Wright's fascia-lata needle
214621290|NCT01795885|BEHAVIORAL|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
214621291|NCT03179891|DRUG|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
214621292|NCT02833922|BEHAVIORAL|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
214621293|NCT00530751|OTHER|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool \[GREAT\]) are explored.
214621294|NCT04058925|DEVICE|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
214621295|NCT05233020|DEVICE|robotic|fifteen patients undergo robotic operation
214621296|NCT05233020|DEVICE|hybrid|fifteen patients undergo hybrid operation
214621297|NCT02938884|DEVICE|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
214621298|NCT00018655|BEHAVIORAL|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
214621299|NCT00018655|BEHAVIORAL|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
214621300|NCT06372548|DEVICE|Find You! Cure My Animal Friends|Introduced cognitive evaluation theory combined with masking therapy to develop a gamified product that guides amblyopic children to develop habits for the purpose of rehabilitation training.
214621301|NCT06372548|DEVICE|DuoBao Vision Training System|This is a visual training app where participants are required to complete several training tasks.
214621302|NCT02771509|DRUG|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
214621303|NCT02771509|DRUG|Placebo|Normal saline
214621304|NCT04468542|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
214621305|NCT04468542|DRUG|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
214621306|NCT02456844|DRUG|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12."
214621307|NCT02456844|DRUG|Methotrexate, Leucovorin and BMS-986142|"1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10."
214621308|NCT04428463|PROCEDURE|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
214621309|NCT04428463|PROCEDURE|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
214621310|NCT03597230|OTHER|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
214621311|NCT03137589|OTHER|Telemedical support|Participating sites will be advised by telemedicine support.
214621312|NCT01349465|DRUG|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
214621313|NCT00073489|DRUG|OSI-461|
214621314|NCT03078374|DRUG|Warfarin|Reduced dosage to obtain lower INR range
214621315|NCT03677258|DEVICE|Collagen for injections 7%|Injection of medical device
214621316|NCT03677258|DEVICE|Hyaluronic acid for injections 2%|Injection of medical device
214621317|NCT00934570|DRUG|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
214621318|NCT00934570|DRUG|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
214621319|NCT00934570|BEHAVIORAL|Placebo Standard exercise|Standard exercise
214621320|NCT00934570|BEHAVIORAL|Intensive exercise|Placebo Intensive exercise
214621321|NCT00003073|DRUG|liposomal cytarabine|
214621322|NCT00621699|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
214621323|NCT00621699|DRUG|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
214621324|NCT00621699|DRUG|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
214621325|NCT04508400|DRUG|Fosaprepitant,ondansetron, dexamethasone|Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.
214621326|NCT04508400|DRUG|placebo ondansetron with dexamethasone|placebo plus ondansetron with dexamethasone
214621327|NCT01590940|PROCEDURE|Open inguinal hernia repair with mesh|
214621328|NCT04967300|PROCEDURE|Dental treatment|bilateral restorative treatment on the mandibular primary first molars
214621329|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
214621330|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
214621331|NCT00381342|DRUG|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
214621332|NCT01394042|DEVICE|Proxiscan device|All patients will be imaged with the device
214621333|NCT06414525|OTHER|abdominal massage|It will include patients that will receive abdominal massage; the frequency and duration of the massage will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
214621334|NCT06414525|OTHER|visceral manipulation|It will include patients that will receive visceral manipulation; the frequency and duration of the technique will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
214621335|NCT06414525|OTHER|instructions on daily, dietary , toilet , and physical activity habits|It will include patients that will receive behavioral therapy: defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advice (diet, water consumption, fiber food, etc.), teaching effective defecation posture, and timed toilet training.
214621336|NCT04026724|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
214621337|NCT00632099|DRUG|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
214621338|NCT00632099|DRUG|Placebo|matched placebo
214621339|NCT04349163|OTHER|Questionnaire|CD-RISC 25 questionnaire
214621340|NCT05141370|DEVICE|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
214621341|NCT06490835|BEHAVIORAL|High-quality palliative care through consultation-based palliative care services in the ICU|"Family Counseling: Social workers implement a supportive process for families, assessing the individualized psychosocial and decisional support needs of patients and families to provide foundational data for palliative care consultations.~Family Meeting Support: In cases of high medical complexity, uncertainty, value conflicts, or communication issues, the palliative care consultation team supports the facilitation of family meetings.~Consultation: The palliative care team provides consultations to the attending physician based on the palliative care needs assessed during family counseling. Topics include symptom management, understanding treatment options, decisional conflict, emotional and practical support, goal of care setting, resources, and bereavement support.~Palliative Care by attending Physician: The attending physician incorporates the consultations received from the palliative care consultation team to provide high-quality palliative care to patients and their families."
214621342|NCT00737191|DRUG|olanzapine|Given orally
214621343|NCT00737191|OTHER|placebo|Given orally
214621344|NCT04670614|PROCEDURE|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
214621345|NCT04670614|PROCEDURE|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
214621346|NCT04134182|DRUG|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
214621347|NCT04134182|DRUG|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
214621348|NCT04828070|OTHER|Observation|all participants followed for clinical data for one year, vital status check at 5 years
214621349|NCT02691975|DRUG|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
214621350|NCT03528343|DRUG|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
214621351|NCT06004843|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
214621352|NCT06004843|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
214621353|NCT05790382|DRUG|NM-101|"In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts)."
214621354|NCT05790382|DRUG|Placebo|Placebo solution for infusion
214621355|NCT03574675|DEVICE|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214621356|NCT03574675|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214621357|NCT01392534|DRUG|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
214621358|NCT03014778|DRUG|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
214621359|NCT03014778|DRUG|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
214621360|NCT00754832|DRUG|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
214621361|NCT00754832|DRUG|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
214621362|NCT05998421|PROCEDURE|acupuncture|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle. Seirin 0.2-×30-mm acupuncture needles were used. First, needles were inserted into Shenting (GV 24) and bilateral Benshen (G 13) to relieve uneasiness of mind. Then, they were inserted into Chung wan (cv 12), Qihai (CV6), Guan yuan, chung chi (cv 3), bilateral Guiai (S 29) and Zigong (Extra 16) to recuperate energy. Finally, bilateral Tsusanli (st 36), Yinlingch'uan (sp 9) and San yin chiao (sp 6) were used to soothe the liver and tonify the spleen and kidney. Each acupuncture treatment session lasted 30 minutes, with mostly bilateral needle retention over 20-30 minutes for evens techniques.
214717614|NCT01014949|OTHER|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia."
214717615|NCT00436267|DRUG|fluorouracil|
214717616|NCT00436267|RADIATION|selective external radiation therapy|
214717617|NCT00436267|RADIATION|tomotherapy|
214717618|NCT00436267|RADIATION|yttrium Y 90 glass microspheres|
214717619|NCT00436267|RADIATION|yttrium Y 90 resin microspheres|
214717620|NCT05410899|OTHER|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
214717621|NCT04212052|RADIATION|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
214717622|NCT04212052|DRUG|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
214717623|NCT04212052|DRUG|consolidation immunotherapy|Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
214717624|NCT02186756|OTHER|EMG-Biofeedback and Usual care|Please refer to arm description
214717625|NCT04437173|DEVICE|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
214717626|NCT04416945|OTHER|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
214717627|NCT04416945|OTHER|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
214717628|NCT04416945|OTHER|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
214621363|NCT05998421|DRUG|routine aspirin and heparin treatment|The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
214621364|NCT02004262|BIOLOGICAL|GVAX Pancreas Vaccine|
214621365|NCT02004262|BIOLOGICAL|CRS-207|
214621366|NCT02004262|DRUG|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
214621367|NCT02004262|DRUG|cyclophosphamide|
214717629|NCT05194787|DIAGNOSTIC_TEST|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
214621368|NCT04200053|OTHER|Reflexology massage|Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.
214621369|NCT04200053|OTHER|Reflexology massage and passive music|Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
214621370|NCT02888015|OTHER|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
214621371|NCT01923285|DEVICE|AXIUM Neurostimulator System|
214621372|NCT01923285|DEVICE|Control Spinal Cord Stimulation Device|
214621373|NCT00711984|DEVICE|Herkulink renal artery Stent|renal artery stent
214621374|NCT00711984|OTHER|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
214621375|NCT04945070|DRUG|IGlarLixi|Switching T2DM subjects from MDI to iGlarLixi
214621376|NCT04945070|DRUG|MDI - Multiple dose insulin injection|Continuing with established MDI regimen
214621377|NCT00039585|DRUG|imatinib mesylate|
214621378|NCT01209650|DRUG|BIBW 2992|tablets
214621379|NCT03978507|BEHAVIORAL|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
214621380|NCT03978507|BEHAVIORAL|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
214621381|NCT02583906|DEVICE|CPAP|Treatment with CPAP for six months in the CPAP arm.
214621382|NCT04863846|OTHER|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
214621383|NCT01041482|DRUG|sorafenib|sorafenib 400mg twice daily
214621384|NCT00428142|BIOLOGICAL|rituximab|375mg/m2 day 1
214621385|NCT00428142|DRUG|bortezomib|1.3mg/m2 days 1 \& 8
214621386|NCT00428142|DRUG|cyclophosphamide|750mg/m2 day 1
214621387|NCT00428142|DRUG|prednisone|40mg/m2 days 1-5
214621388|NCT00428142|DRUG|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
214621389|NCT00330382|DRUG|Bowman-Birk inhibitor concentrate|Given orally
214621390|NCT00330382|OTHER|placebo|Given orally
214621391|NCT00330382|OTHER|laboratory biomarker analysis|Correlative studies
214621392|NCT04188574|DRUG|BB2603-1|Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
214621393|NCT04188574|DRUG|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
214621394|NCT04188574|DRUG|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
214621395|NCT04188574|OTHER|Vehicle|Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
214621396|NCT05511272|BIOLOGICAL|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
214621397|NCT03045679|OTHER|RYGB|laparoscopic RYGB
214621398|NCT03045679|OTHER|OAGB/MGB|laparoscopic OAGB/MGB
214621399|NCT04542759|DRUG|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
214621400|NCT04542759|DRUG|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
214621401|NCT03172845|PROCEDURE|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
214621402|NCT03814486|OTHER|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
214621403|NCT03628053|BIOLOGICAL|Tisagenlecleucel|autologous cellular immunotherapy product
214621404|NCT03628053|DRUG|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
214621405|NCT03628053|DRUG|Inotuzumab|CD22-directed antibody-drug conjugate
214621406|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
214621407|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
214621408|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
214621409|NCT04603131|BIOLOGICAL|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
214621410|NCT02987036|DEVICE|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
214621411|NCT02987036|DEVICE|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
214621412|NCT01699477|DEVICE|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
214621413|NCT03544372|OTHER|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
214621414|NCT04331795|DRUG|Tocilizumab|"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
214621415|NCT04331795|DRUG|Tocilizumab|"Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
214621416|NCT00711620|DRUG|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
214621417|NCT03839173|OTHER|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
214621418|NCT02810756|DRUG|New Pazopanib formulation|
214621419|NCT02483663|DEVICE|Functional Magnetic Resonance Imaging|Measure brain activity.
214621420|NCT02483663|RADIATION|Dual Energy X-ray absorptiometry|Body composition measurements.
214621421|NCT02483663|OTHER|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
214621422|NCT02483663|OTHER|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
214621423|NCT02483663|OTHER|Test Meals|Breakfast, a snack, and lunch provided during study visit.
214621424|NCT02483663|OTHER|Computer Tests|Perform a series of computer tests to determine reaction time.
214621425|NCT02483663|PROCEDURE|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
214717630|NCT03900741|PROCEDURE|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
214621426|NCT01245582|DRUG|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
214621427|NCT01245582|DRUG|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
214621428|NCT01245582|DRUG|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
214621429|NCT03532594|PROCEDURE|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
214621430|NCT03532594|PROCEDURE|Standard Care|Protamine administered according to Standard Care
214621431|NCT02221453|DRUG|Triamcinolone Acetonide|
214621432|NCT03200366|BEHAVIORAL|Tailored DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
214621433|NCT03200366|BEHAVIORAL|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
214621434|NCT01732497|DEVICE|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
214621435|NCT04006886|DIETARY_SUPPLEMENT|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
214621436|NCT00871520|OTHER|no specific interventions|There are no specific interventions in this observational study
214621437|NCT04459182|DIAGNOSTIC_TEST|ENDOPAT|digital plethysmography
214621438|NCT01396174|BEHAVIORAL|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
214621439|NCT01396174|BEHAVIORAL|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
214621440|NCT04312035|PROCEDURE|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
214621441|NCT04312035|PROCEDURE|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
214621442|NCT04312035|PROCEDURE|Control|hands-on cutaneous technique
214621443|NCT05397626|BEHAVIORAL|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome
214621444|NCT05397626|DIETARY_SUPPLEMENT|Hydrogen Water|Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome
214621445|NCT05397626|COMBINATION_PRODUCT|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
214621446|NCT04004637|DRUG|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg."
214621447|NCT03590730|DEVICE|ICD implantation|ICD will be implanted according to current guidelines recommendations.
214621448|NCT02947035|PROCEDURE|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
214621449|NCT02947035|PROCEDURE|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
214621450|NCT03962374|DEVICE|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
214621451|NCT03962374|DEVICE|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
214621452|NCT03201458|DRUG|Atezolizumab|Given IV
214621453|NCT03201458|PROCEDURE|Biopsy|Undergo tumor biopsy
214621454|NCT03201458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214621455|NCT03201458|DRUG|Cobimetinib|Given PO
214621456|NCT03201458|PROCEDURE|Computed Tomography|Undergo CT
214621457|NCT03201458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214621458|NCT02963116|DRUG|AZD5718 IR tablet|
214621459|NCT02963116|DRUG|AZD5718 oral suspension|
214621460|NCT02963116|DRUG|Rosuvastatin tablet|
214621461|NCT05758519|DRUG|QLS1128|QLS1128
214621462|NCT05758519|DRUG|Placebo|Placebo
214621463|NCT01785459|DRUG|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
214621464|NCT01785459|DRUG|Standard Care|10 mg Intravenous injection of Prochlorperazine
214621465|NCT01263821|PROCEDURE|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
214621466|NCT01263821|PROCEDURE|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
214621467|NCT01263821|PROCEDURE|Functional magnetic resonance imaging|Undergo functional MRI
214621468|NCT01263821|PROCEDURE|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
214621469|NCT01263821|PROCEDURE|Therapeutic conventional surgery|Undergo maximal surgical resection
214621470|NCT01263821|PROCEDURE|Quality-of-life assessment|Ancillary studies
214621471|NCT01263821|PROCEDURE|Radiation therapy treatment planning/simulation|Undergo IMRT planning
214621472|NCT01263821|PROCEDURE|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
214621473|NCT01263821|OTHER|Questionnaire administration|Ancillary studies
214621474|NCT00442780|DRUG|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
214621475|NCT00442780|DRUG|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
214621476|NCT00750737|DRUG|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
214621477|NCT00750737|DRUG|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
214717631|NCT03900741|PROCEDURE|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
214717632|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
214621478|NCT05768451|OTHER|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
214621479|NCT03399877|BIOLOGICAL|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
214621480|NCT03399877|BIOLOGICAL|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
214621481|NCT03399877|BIOLOGICAL|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
214621482|NCT06493773|BEHAVIORAL|Offer of referral to specialized alcohol use disorder treatment|Patients are offered referral to specialized alcohol use disorder treatment.
214621483|NCT05479253|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
214621484|NCT03591640|DIAGNOSTIC_TEST|Blood test|Standard blood test
214621485|NCT05112536|DRUG|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
214621486|NCT05112536|DRUG|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
214621487|NCT05112536|DRUG|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
214621488|NCT05112536|DRUG|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
214621489|NCT05112536|DRUG|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
214621490|NCT05112536|BIOLOGICAL|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
214621491|NCT00522353|DIETARY_SUPPLEMENT|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
214717633|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
214717634|NCT00602511|DRUG|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
214717635|NCT00602511|DRUG|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
214717636|NCT06131229|BEHAVIORAL|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
214717637|NCT06131229|BEHAVIORAL|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
214621492|NCT00522353|DIETARY_SUPPLEMENT|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
214621493|NCT04739254|DIAGNOSTIC_TEST|CardioFlux|Magnetocardiography
214621494|NCT03694496|BEHAVIORAL|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
214621495|NCT04707157|DRUG|LY3556050|given orally
214621496|NCT04707157|DRUG|Placebo|given orally
214621497|NCT00502138|DRUG|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
214621498|NCT02069405|OTHER|Relaxation Music|
214621499|NCT01543828|DRUG|indacaterol|delivered via single-dose dry-powder inhaler
214621500|NCT01543828|DRUG|placebo|delivered via single-dose dry-powder inhaler
214621501|NCT03568591|PROCEDURE|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
214621502|NCT05338177|OTHER|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
214621503|NCT05338177|OTHER|No immunosuppression reduction|participants do not alter immunosuppresion
214621504|NCT05768945|DRUG|Semaglutide|Semaglutide claim is used as the exposure group.
214621505|NCT05768945|DRUG|DPP-4 inhibitor|DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
214621506|NCT06386965|OTHER|taking blood sample|A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
214621507|NCT00570973|PROCEDURE|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
214717638|NCT05595603|PROCEDURE|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
214717639|NCT05595603|PROCEDURE|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
214717640|NCT01607073|DRUG|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
214717641|NCT03468049|BIOLOGICAL|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
214717642|NCT03468049|BIOLOGICAL|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
214717643|NCT03468049|BIOLOGICAL|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
214717644|NCT03468049|OTHER|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
214717645|NCT05034458|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
214717646|NCT00284349|DEVICE|Use of a rehabilitation brace instead of a plaster|
214717647|NCT03716453|PROCEDURE|Standard protocol|Give narcotic according to vital signs
214717648|NCT03716453|PROCEDURE|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given."
214717649|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg lorlatinib
214717650|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
214717651|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg QD lorlatinib
214621508|NCT00570973|PROCEDURE|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
214621509|NCT04265716|OTHER|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
214621510|NCT04300699|OTHER|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
214621511|NCT00321347|DRUG|Lidocaine|
214621512|NCT01371136|PROCEDURE|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
214621513|NCT04277520|PROCEDURE|Root canal therapy|Different types of instrumentation motions during root canal therapy
214621514|NCT04035018|PROCEDURE|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
214621515|NCT04035018|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
214621516|NCT04340713|OTHER|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
214717652|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
214717653|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
214717654|NCT00881790|OTHER|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
214717655|NCT02881879|BIOLOGICAL|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
214621517|NCT03885791|DEVICE|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
214621518|NCT00738153|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214621519|NCT03436381|OTHER|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
214621520|NCT03702764|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
214621521|NCT06033742|DRUG|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
214621522|NCT06033742|DRUG|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
214717656|NCT03157921|RADIATION|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
214621523|NCT04519359|OTHER|Stop NAs therapy|Stop NAs therapy
214621524|NCT00804570|DRUG|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
214621525|NCT00804570|DRUG|placebo|once daily, orally, 16 weeks
214621526|NCT04312685|DEVICE|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
214621527|NCT05214612|COMBINATION_PRODUCT|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
214621528|NCT03870659|RADIATION|Breast MRI|Magnetic resonance imaging to the breast
214621529|NCT03837782|PROCEDURE|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
214621530|NCT06405711|DEVICE|frame lens|A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
214621531|NCT00290342|BIOLOGICAL|DTPa-IPV|3 intramuscular injections
214621532|NCT00290342|BIOLOGICAL|DTPa|3 intramuscular injections
214621533|NCT00290342|BIOLOGICAL|IMOVAX Polio®|3 intramuscular injections
214621534|NCT05171348|DRUG|CM326|a humanized monoclonal antibody
214621535|NCT05171348|DRUG|Placebo|Placebo
214621536|NCT03173729|DIAGNOSTIC_TEST|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
214717657|NCT03157921|DIAGNOSTIC_TEST|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
214717658|NCT01206790|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
214717659|NCT01946412|DRUG|Ivacaftor|
214621537|NCT06064942|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
214621538|NCT06064942|BEHAVIORAL|School services for families of children with ADHD|Selected school social personnel will deliver services as usual for the control group.
214621539|NCT03221491|DEVICE|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
214621540|NCT01045980|DRUG|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
214621541|NCT01045980|DRUG|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
214621542|NCT01045980|DRUG|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
214621543|NCT01045980|DEVICE|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
214621544|NCT03096951|BEHAVIORAL|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
214621545|NCT03096951|OTHER|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
214621546|NCT02535884|DEVICE|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
214621547|NCT01936636|DRUG|Fentanyl|
214621548|NCT05054647|OTHER|psychometric questionnaires|Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
214621549|NCT06474949|DRUG|Bupivacaine injection|Injection at end of Open Reduction Internal Fixation
214621550|NCT06474949|OTHER|Saline|Injection at end of Open Reduction Internal Fixation
214621551|NCT03341975|BEHAVIORAL|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
214621552|NCT01664988|BEHAVIORAL|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
214621553|NCT01664988|BEHAVIORAL|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
214621554|NCT01664988|OTHER|control (routine care)|received routine care of clinic or health center and use drugs if necessary
214621555|NCT01056510|DRUG|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
214621556|NCT01056510|DRUG|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
214621557|NCT01056510|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
214621558|NCT03275571|BEHAVIORAL|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
214621559|NCT01898871|DIETARY_SUPPLEMENT|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
214621560|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
214621561|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
214621562|NCT01034735|BIOLOGICAL|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
214621563|NCT01824992|DRUG|Yallaferon®|
214621564|NCT04137120|DRUG|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
214621565|NCT01269762|DRUG|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
214621566|NCT02798055|DRUG|Bosentan group|
214621567|NCT00927290|DRUG|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
214621568|NCT00927290|DRUG|Placebo|Placebo 45 mg QD (30 mg QD the first month)
214621569|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
214621570|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
214621571|NCT05148039|BEHAVIORAL|Dietician advice|Personalised dietetic advice
214621572|NCT05018039|OTHER|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
214621573|NCT04944654|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
214621574|NCT02285998|BIOLOGICAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
214621575|NCT02285998|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
214621576|NCT04006496|BEHAVIORAL|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
214621577|NCT04209036|OTHER|0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)|total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
214621578|NCT03271398|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing (intensive format)
214621579|NCT03271398|BEHAVIORAL|PC|Progressive counting (intensive format)
214621580|NCT00871182|DRUG|Inhaled PT001|single dose, inhaled
214621581|NCT00871182|DRUG|Inhaled Placebo|single dose, inhaled
214621582|NCT00871182|DRUG|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
214621583|NCT04796051|DEVICE|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
214621584|NCT04796051|OTHER|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
214621585|NCT04998838|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
214717660|NCT06063512|OTHER|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
214717661|NCT00030095|DRUG|2-methoxyestradiol|
214717662|NCT00428376|DEVICE|Building Blocks|
214717663|NCT04312789|DRUG|Avatrombopag|Given PO
214717664|NCT02088541|DRUG|Selinexor|Selinexor oral tablet.
214717665|NCT02088541|DRUG|Hydroxyurea|
214717666|NCT02088541|DRUG|Ara-C|Ara-C Subcutaneous Injection.
214717667|NCT05685719|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
214717668|NCT05685719|DRUG|Itraconazole|A strong CYP3A4 inhibitor
214717669|NCT05685719|DRUG|Rifampin|A strong CYP3A4 inducer
214717670|NCT01954810|BIOLOGICAL|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
214717671|NCT00439894|PROCEDURE|Blood draw|blood draw at baseline, week 12 and week 24
214717672|NCT06119555|DIETARY_SUPPLEMENT|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
214717673|NCT01877031|DEVICE|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
214717674|NCT01877031|DEVICE|Ultrasound|Standard of Care - Ultrasound guided intervention
214717675|NCT04573192|DRUG|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
214621586|NCT04998838|DRUG|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
214621587|NCT00545298|DRUG|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
214717676|NCT04573192|DRUG|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
214717677|NCT03700346|DEVICE|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
214717678|NCT02451189|DIETARY_SUPPLEMENT|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
214717679|NCT02451189|DIETARY_SUPPLEMENT|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
214717680|NCT02451189|DIETARY_SUPPLEMENT|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
214717681|NCT06450808|DIETARY_SUPPLEMENT|Dried Microalgae biomass|The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.
214621588|NCT00545298|DRUG|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
214621589|NCT00468520|DRUG|low dose oxytocin|
214621590|NCT05912777|RADIATION|Scanner|Scanner to be performed by patients
214621591|NCT00259155|DRUG|Rifaximin|
214717682|NCT02802956|OTHER|Daily Life Promotion Program|Daily Life Promotion Program
214717683|NCT02802956|OTHER|general rehabilitation treatment|general rehabilitation treatment
214717684|NCT01413828|DRUG|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
214717685|NCT01413828|DRUG|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
214621592|NCT01953575|DEVICE|Mucosal Impedance|A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
214621593|NCT01953575|PROCEDURE|Upper Endoscopy|Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
214621594|NCT01931657|DRUG|Mifepristone prior to Mirena|
214621595|NCT01931657|DRUG|Placebo prior to Mirena insertion|
214621596|NCT06470256|PROCEDURE|Palliative Hepatectomy|"Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection."
214621597|NCT06470256|DRUG|Durvalumab|Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
214621598|NCT06470256|DRUG|Lenvatinib|Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
214621599|NCT01450449|RADIATION|Radiotherapy|25 Gy in 5 daily fractions over 1 week
214621600|NCT01450449|RADIATION|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
214621601|NCT04080947|DRUG|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
214621602|NCT04080947|DRUG|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
214621603|NCT04669340|OTHER|E-learning patient education|"The intervention implies patient education through an e-learning program. The program consists of three learning modules covering knowledge of rheumatoid arthritis, medication, examinations, complications and daily living with RA. Module 1 consists of 'need to know' information about disease management, symptoms and medication. Thus, it is mandatory and must be completed before entering module 2 and 3. In module 2 and 3, patients can move around on the basis of their individual needs.~The duration of the full program is approximately two hours, but may vary dependent on the individual user needs. The program may be used as much as needed throughout the study period."
214621604|NCT04669340|OTHER|Standard face-to-face patient education|The intervention implies usual care, i.e. face-to-face patient education in a one-hour session with a nurse at the hospital. This form of patient education is based on the patients individual need for information and guidance in relation to rheumatoid arthritis and medication. Thus, aspects of daily life with the disease is discussed at the beginning and forms the conversation. However, as a standard, information of the disease, disease management, symptoms and medication must be discussed with the patient and relatives.
214621605|NCT02512133|DEVICE|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
214621606|NCT02512133|PROCEDURE|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
214621607|NCT03624933|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
214621608|NCT03624933|BEHAVIORAL|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
214621609|NCT00685880|DRUG|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
214621610|NCT00685880|DRUG|Betamethasone|CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
214621611|NCT02088970|DEVICE|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
214621612|NCT02088970|DRUG|antibiotic treatment|"If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone"
214621613|NCT02242578|DEVICE|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
214621614|NCT02242578|DEVICE|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
214621615|NCT00213187|BEHAVIORAL|Aerobic and Qi gong Exercise|
214621616|NCT01820364|DRUG|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
214621617|NCT01793142|DRUG|Viviant|Viviant (Bazedoxifene) 20mg once daily
214621618|NCT03451084|DRUG|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
214621619|NCT00966342|DRUG|Fluviral 2009/10|single dose given IM .05 mL
214621620|NCT01866384|PROCEDURE|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
214621621|NCT01866384|OTHER|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
214621622|NCT00326742|BEHAVIORAL|Trier Social Stress Test|
214621623|NCT03339206|BEHAVIORAL|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
214621624|NCT03339206|BEHAVIORAL|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
214621625|NCT03339206|BEHAVIORAL|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
214621626|NCT00836043|DRUG|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
214621627|NCT02662036|DRUG|Bupivicaine HCL|
214621628|NCT02662036|DRUG|Liposomal bupivacaine|
214621629|NCT04995055|DEVICE|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
214621630|NCT04995055|DEVICE|ACUVUE® OASYS Multifocal|CONTROL Lens
214621631|NCT02668874|DEVICE|Isolite System|
214621632|NCT02668874|OTHER|Cotton Roll Technique|
214621633|NCT01845922|DIETARY_SUPPLEMENT|Low sodium diet|Low sodium diet
214621634|NCT05421936|DRUG|Osimertinib|Treatment as the first EGFR-TKI
214621635|NCT00810004|DRUG|Ferinject|Intravenous infusion of iron
214621636|NCT01384227|DRUG|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
214621637|NCT03418129|DEVICE|Mindfulness|Neuromodulatory intervention for pain management
214621638|NCT03418129|DEVICE|Neurofeedback|Neuromodulatory intervention for pain management
214621639|NCT03418129|DEVICE|Relaxation|Neuromodulatory intervention for pain management
214621640|NCT00454103|DRUG|123I-Iodometomidate|
214621641|NCT04960982|DIAGNOSTIC_TEST|blood test|blood sample is taken in first, second and third trimester of pregnancy
214621642|NCT03230552|OTHER|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
214621643|NCT04267341|OTHER|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
214621644|NCT04267341|OTHER|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
214621645|NCT04267341|OTHER|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
214621646|NCT05326984|DRUG|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
214621647|NCT04532476|DEVICE|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
214621648|NCT01017003|DRUG|colchicine tablets|0.6mg colchicine tablet
214621649|NCT01017003|DRUG|colchicine tablets|0.6mg q12 hours for 10 days
214621650|NCT05014334|DRUG|Berberine|berberine 500 mg, twice daily for 14 days
214621651|NCT05014334|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
214621652|NCT05014334|DRUG|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
214621653|NCT05014334|DRUG|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
214621654|NCT05014334|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
214717686|NCT05837507|OTHER|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
214717687|NCT05837507|OTHER|Usual management including NIV.|Usual management including NIV.
214717688|NCT04942522|BIOLOGICAL|probiotics PS128|6×10\^10 CFU/capsule
214717689|NCT04942522|DRUG|placebo (Microcrystalline cellulose )|450 mg/capsule
214717690|NCT02866773|BEHAVIORAL|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
214717691|NCT02866773|BEHAVIORAL|PA2: Education sessions, Reminders|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
214717692|NCT02866773|BEHAVIORAL|PA3: Education sessions, Whataps group|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
214621655|NCT05014334|DRUG|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
214621656|NCT03300674|DRUG|Hydromorphone|Hydromorphone intravenous infusion
214621657|NCT03300674|DRUG|Lidocaine|Lidocaine intravenous infusion
214621658|NCT04521023|DRUG|Cantabell Tab|Patients assigned to experimental group are treated with Cantabell Tab
214621659|NCT04521023|DRUG|Candemore Plus Tab|Patients assigned to experimental group are treated with Candemore Plus Tab
214621660|NCT04146740|OTHER|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
214621661|NCT04146740|BEHAVIORAL|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
214621662|NCT02349594|DRUG|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
214621663|NCT02349594|DRUG|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
214621664|NCT03426956|DIETARY_SUPPLEMENT|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
214621665|NCT03426956|DIETARY_SUPPLEMENT|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
214621666|NCT04267419|DIAGNOSTIC_TEST|salivary biomarker|MDA and NO as salivary biomarkers
214621667|NCT04699019|OTHER|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
214621668|NCT04699019|OTHER|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
214621669|NCT01553188|DRUG|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
214621670|NCT01553188|DRUG|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
214621671|NCT01553188|DRUG|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
214621672|NCT02035085|DRUG|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
214621673|NCT00344721|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
214621674|NCT00344721|DIETARY_SUPPLEMENT|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
214621675|NCT03913052|PROCEDURE|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
214621676|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
214621677|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
214621678|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
214621679|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
214621680|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
214621681|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
214621682|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
214621683|NCT05843734|PROCEDURE|Equia forte HT|Restoration of anterior class III caries lesions
214621684|NCT03117075|DEVICE|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
214621685|NCT06264427|GENETIC|Whole genome sequencing|Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
214621686|NCT06264427|DIAGNOSTIC_TEST|VAGUS|To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
214621687|NCT06264427|DIAGNOSTIC_TEST|NightOwl|Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
214621688|NCT06264427|DEVICE|CPAP|Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
214621689|NCT00000475|BEHAVIORAL|health education|
214717693|NCT02866773|BEHAVIORAL|PA4: Education sessions|"The intervention includes one component only:~\- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
214621690|NCT01066585|DRUG|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
214621691|NCT01066585|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
214621692|NCT01444768|OTHER|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
214621693|NCT03495258|PROCEDURE|Clarion Evolve Laser Vaporization System|
214621694|NCT03495258|PROCEDURE|Olympus TURis Plasma Vaporization|
214621695|NCT01184222|DEVICE|great occipital nerve stimulation|"* Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
214621696|NCT02371239|BEHAVIORAL|Physical activity intervention|
214621697|NCT04275505|OTHER|shortwave diathermy treatment|shortwave diathermy is a deep heating physical therapy agent. It was found efficiaous in carpal tunnel syndrome which is an entrapment neuropathy like ulnar nerve entrapment so it was hypothesised that shortwave diathermy could be an effective treatment method in ulnar nerve entrapment.
214621698|NCT04275505|OTHER|placebo shortwave diathermy treatment|shortwave device was not turned on while participants were asked to put their elbow into the device
214621699|NCT04126083|DRUG|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
214621700|NCT03858036|DRUG|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
214621701|NCT03858036|DEVICE|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
214621702|NCT04133454|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
214621703|NCT05247814|GENETIC|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
214621704|NCT05247814|OTHER|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
214621705|NCT05247814|OTHER|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
214621706|NCT00959998|OTHER|Self-administered Acupressure|
214717694|NCT02866773|BEHAVIORAL|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~\- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
214621707|NCT02841098|OTHER|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
214621708|NCT02841098|DRUG|Optimal medical therapy alone|Optimal medical therapy alone
214621709|NCT01434589|BEHAVIORAL|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
214621710|NCT00020618|DRUG|morphine sulfate|
214621711|NCT00020618|PROCEDURE|quality-of-life assessment|
214621712|NCT04613154|DIETARY_SUPPLEMENT|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
214621713|NCT04613154|DIETARY_SUPPLEMENT|Placebo|Ester-c
214621714|NCT01279850|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
214621715|NCT01752660|BEHAVIORAL|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
214621716|NCT01752660|BEHAVIORAL|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
214621717|NCT01131520|BEHAVIORAL|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
214621718|NCT01131520|BEHAVIORAL|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
214621719|NCT03946137|OTHER|Chest Therapy|The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
214717695|NCT02866773|BEHAVIORAL|HD2: Education sessions, Reminders|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
214621720|NCT03946137|OTHER|Postural Hygiene|Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
214621721|NCT06131775|BIOLOGICAL|Blood sampling|One blood sample of 10mL is realized before initiation of immunotherapy
214621722|NCT06131775|BIOLOGICAL|Blood sampling|Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
214621723|NCT04405687|PROCEDURE|Severe head and face deformity reconstructive surgery|Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
214621724|NCT01485939|OTHER|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
214621725|NCT01485939|OTHER|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
214621726|NCT05903729|OTHER|Neurodevelopmental therapy treatment|The group will receive NDT therapy
214621727|NCT05903729|OTHER|conventional physiotherapy|conventional physiotherapy
214621728|NCT05901493|BEHAVIORAL|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
214621729|NCT02186847|RADIATION|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
214621730|NCT02186847|DRUG|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
214717696|NCT02866773|BEHAVIORAL|HD3:Education sessions, Whataps group|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
214717697|NCT02866773|BEHAVIORAL|HD4: Education sessions|"The intervention includes one component only:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
214717698|NCT04053218|COMBINATION_PRODUCT|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
214717699|NCT04053218|DIETARY_SUPPLEMENT|Placebo|Olive oil placebo
214717700|NCT01625611|DRUG|Naltrexone|Naltrexone 100 mg titrated over one week
214621731|NCT02186847|DRUG|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
214717701|NCT02941042|DRUG|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
214717702|NCT02941042|DRUG|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
214717703|NCT02455843|OTHER|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
214717704|NCT03875872|DRUG|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
214717705|NCT03875872|DRUG|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
214621732|NCT02186847|DRUG|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
214621733|NCT06977529|BEHAVIORAL|Algorithm; Algorithm-based maintenance created by researchers:such as falls training, early mobilization|"The Fall Prevention Algorithm prepared by the researchers was applied to the experimental group patients."
214621734|NCT06977126|DRUG|PORPHYSOMES|Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension
214621735|NCT06977126|DRUG|64Cu-PORPHYSOMES|Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension
214621736|NCT06978426|OTHER|Pain Group|Professional e-sports athletes who report wrist pain rated at 3 or higher on a 10-point Visual Analog Scale during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
214621737|NCT06978426|OTHER|No-Pain Group|Professional e-sports athletes who report minimal to no wrist pain (less than 3 on a 10-point Visual Analog Scale) during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
214621738|NCT06977945|DIAGNOSTIC_TEST|Specific positron imaging agents targeting NTRS-1(FL-091)|This study is diagnostic. Oncologists screen patients with malignant tumors such as head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma who are clinically suspected or confirmed; investigators talk to patients who meet the inclusion criteria, explain the study purpose and study process, sign informed consent forms, and patients can complete 68Ga-FL-091PET imaging and 111In-FL-091SPECT imaging respectively in outpatient or inpatient periods. General information, clinical data, blood routine, urine routine, liver and kidney function and other biochemical indicators, electrocardiogram, radionuclide imaging results and other imaging data of the patients participating in the study were collected and compared with histopathology to evaluate the value of both imaging in the diagnosis of head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma.
214621739|NCT06977893|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
214621740|NCT06977893|DRUG|Neoadjuvant Chemotherapy|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.
214621741|NCT06977464|DEVICE|Wearable Technology and Information Software-Based Psychological Stress Monitoring|The intervention group will additionally use a smartwatch for physiological monitoring and a mobile app for daily to weekly psychological assessments.
214621742|NCT06978387|DEVICE|Minimed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
214621743|NCT05016115|BEHAVIORAL|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
214621744|NCT04634396|BEHAVIORAL|ACT Acceptance and Commitment Therapy|6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
214621745|NCT03416153|DRUG|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
214621746|NCT03416153|RADIATION|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
214621747|NCT03416153|DRUG|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
214634569|NCT01358656|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
214634570|NCT03578120|BIOLOGICAL|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
214634571|NCT05823597|BEHAVIORAL|Sugar Intensive Treatment|see arm description
214634572|NCT05823597|BEHAVIORAL|General Health Control|see arm description
214634573|NCT00299832|DRUG|Aliskiren|
214634574|NCT04509921|OTHER|asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness|Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
214634575|NCT06164379|DRUG|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
214634576|NCT06164379|DRUG|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
214634577|NCT00661271|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
214634578|NCT00661271|BEHAVIORAL|Healthy topics|8 week health education program with one retreat session
214621748|NCT06410300|RADIATION|Curative Radiotherapy|Radiation dose of 45 Gy or higher
214621749|NCT06410300|DRUG|Immunotherapy|checkpoint inhibitor per PI discretion
214621750|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
214621751|NCT01605526|DRUG|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
214621752|NCT01605526|DRUG|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
214621753|NCT03849417|OTHER|ECT|ECT administered as part of normal clinical management
214621754|NCT00633906|BEHAVIORAL|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
214621755|NCT00633906|BEHAVIORAL|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
214621756|NCT04010500|DEVICE|no mouthguard|Control (not using mouthguard)
214621757|NCT04010500|DEVICE|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
214621758|NCT04010500|DEVICE|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
214621759|NCT00407095|DRUG|Pardoprunox|12-42 mg/day
214621760|NCT01497639|DEVICE|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
214621761|NCT01497639|DEVICE|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
214621762|NCT01116908|DEVICE|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
214621763|NCT01469338|DRUG|cabazitaxel|Given IV
214621764|NCT01469338|DRUG|prednisone|Given PO
214621765|NCT01469338|DRUG|octreotide pamoate|Given IM
214621766|NCT01469338|OTHER|questionnaire administration|Ancillary studies
214621767|NCT01469338|DRUG|octreotide acetate|Given SC
214621768|NCT00705211|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets,
214621769|NCT00705211|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
214621770|NCT03370783|DRUG|Ethanol|Moderate alcohol consumption
214621771|NCT03729674|DRUG|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
214621772|NCT03729674|DRUG|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
214621773|NCT04350853|PROCEDURE|Surgical extrusion|Surgically coronal reposition of the tooth
214621774|NCT02204150|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
214621775|NCT00001003|DRUG|Pentamidine isethionate|
214621776|NCT00001003|DRUG|Zidovudine|
214621777|NCT05914168|DEVICE|Breast Tomosynthesis|Three dimensional mammography
214621778|NCT00119535|BEHAVIORAL|Implementation of Proactive Diabetes Eye Care Program|
214621779|NCT06035900|DRUG|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
214621780|NCT01617460|DRUG|Aripiprazole|Flexibly dose administered orally once daily
214621781|NCT03703882|DRUG|Edasalonexent|100 mg/kg/day
214621782|NCT03703882|DRUG|Placebo|Placebo
214621783|NCT05183607|OTHER|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
214621784|NCT05936450|BIOLOGICAL|delivery of placentrex gel after open flap debridement|placentrex gel is placed after open flap debridement only in the test group
214621785|NCT05936450|PROCEDURE|Open Flap Debridement|Open Flap Debridement done in both test and control groups
214621786|NCT05280678|PROCEDURE|Orthodontic miniscrew insertion in the mandibular buccal shelf|"Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion."
214621787|NCT01140360|DRUG|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
214621788|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
214621789|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
214621790|NCT01535573|DRUG|Citalopram|20 mg once per day for 9 weeks
214621791|NCT01535573|DRUG|Citalopram|40 mg per day for 9 weeks
214621792|NCT01535573|DRUG|Placebo|0 mg per day for 9 weeks
214621793|NCT06081556|DIAGNOSTIC_TEST|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
214621794|NCT01123863|OTHER|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
214634579|NCT01243320|DRUG|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
214634580|NCT01243320|DRUG|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
214634581|NCT05244850|OTHER|Test|Measurements
214634582|NCT00136591|DRUG|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
214634583|NCT00136591|DRUG|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
214634584|NCT04779203|DEVICE|Osseodensification Densah Bur|Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
214634585|NCT03398577|DRUG|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
214634586|NCT03398577|DRUG|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
214621795|NCT01123863|OTHER|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
214621796|NCT06302907|PROCEDURE|Buffered Local anaesthesia|A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
214621797|NCT06302907|PROCEDURE|Unbuffered Local anaesthesia|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
214621798|NCT01388673|PROCEDURE|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
214717706|NCT02431793|BEHAVIORAL|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
214621799|NCT00466466|DRUG|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
214621800|NCT05378438|OTHER|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
214621801|NCT02229071|DRUG|Donafenib(200mg)|Donafenib 200mg,bid,po
214621802|NCT02229071|DRUG|Donafenib(300mg)|Donafenib 300mg,bid,po
214634587|NCT00683033|BEHAVIORAL|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
214634588|NCT00683033|BEHAVIORAL|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
214634589|NCT05758259|DRUG|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
214634590|NCT05758259|DRUG|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
214634591|NCT05758259|DRUG|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
214634592|NCT01899235|DEVICE|drug eluting balloon|
214634593|NCT01899235|DEVICE|drug eluting stent|
214621803|NCT03957837|DIAGNOSTIC_TEST|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
214621804|NCT04509310|DEVICE|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
214621805|NCT00666458|DRUG|saxagliptin|tablet, per oral, once daily
214621806|NCT00666458|DRUG|sitagliptin|capsule, per oral, once daily
214621807|NCT02222207|DRUG|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
214621808|NCT02222207|PROCEDURE|Sham IVT|Sham injections
214717707|NCT02431793|BEHAVIORAL|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
214621809|NCT02222207|DRUG|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
214621810|NCT02222207|DRUG|Placebo|Placebo eye drops
214621811|NCT01847482|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
214621812|NCT02878538|DRUG|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
214621813|NCT02878538|OTHER|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
214621814|NCT02982954|DRUG|Nivolumab|Specified dose on specified day
214621815|NCT02982954|DRUG|Ipilimumab|Specified Dose on Specified Day
214621816|NCT06114173|DRUG|Cardunilizumab|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
214621817|NCT01272310|BIOLOGICAL|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is \< 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is \>= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
214621818|NCT04772261|DIAGNOSTIC_TEST|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
214621819|NCT05194462|DEVICE|Pericoach® by Analytica|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback .
214621820|NCT05194462|OTHER|Pelvic Floor Physical Therapy|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of PFPT.
214634594|NCT04989101|DRUG|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
214634595|NCT06299254|OTHER|Placebo-Natural History|"Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts."
214634596|NCT01707693|BEHAVIORAL|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing \& follow-up
214621821|NCT05888727|BEHAVIORAL|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
214621822|NCT05888727|BEHAVIORAL|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
214621823|NCT03614754|DIAGNOSTIC_TEST|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
214621824|NCT04002037|DRUG|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
214621825|NCT04002037|DRUG|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
214621826|NCT04002037|DRUG|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
214621827|NCT00747643|DRUG|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
214621828|NCT00747643|DRUG|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
214621829|NCT04114292|DRUG|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
214621830|NCT01987687|BEHAVIORAL|Exercise|Exercise at 55% of maximum power output for 30 min.
214621831|NCT01987687|BEHAVIORAL|Rest|Rest for 30 min
214621832|NCT01987687|BEHAVIORAL|Delay|Delay between exercise and OGTT
214621833|NCT03588351|DRUG|chitosan nanoparticles gel|intracanal medicament
214621834|NCT03588351|DRUG|chitosan gel|intracanal medicament
214621835|NCT03588351|DRUG|chlorhexidine gluconate|intracanal medicament
214621836|NCT00750698|DRUG|Entinostat|Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
214621837|NCT00750698|DRUG|Erlotinib|Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
214621838|NCT01636973|PROCEDURE|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
214621839|NCT05947487|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"
214621840|NCT01426139|DEVICE|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
214621841|NCT05905120|DRUG|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
214621842|NCT00210392|DRUG|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
214621843|NCT01473238|OTHER|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
214621844|NCT05895942|DRUG|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
214621845|NCT02031562|OTHER|chiropractic|chiropractic
214621846|NCT02031562|OTHER|physical therapy|physical therapy
214621847|NCT05426889|PROCEDURE|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
214621848|NCT05426889|DRUG|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
214621849|NCT02004496|DEVICE|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
214621850|NCT04930055|BIOLOGICAL|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
214621851|NCT02665169|BEHAVIORAL|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
214621852|NCT02665169|OTHER|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
214621853|NCT03094234|DEVICE|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
214621854|NCT03094234|PROCEDURE|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
214621855|NCT03094234|DRUG|Propranolol|Appropriate dose of propranolol was administered to the patients.
214621856|NCT02281643|DRUG|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
214621857|NCT06232070|DEVICE|Lunit INSIGHT MMG|In the Lunit Assisted arm, the radiographers will also be seeing the Lunit INSIGHT MMG reports while reading the mammograms. The standard of care will be followed in all the cases
214621858|NCT06047340|DEVICE|G:DATA, dementia screen videogame|A videogame for screening
214621859|NCT02500680|BIOLOGICAL|MER4101|
214621860|NCT02500680|BIOLOGICAL|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
214621861|NCT01417195|DRUG|Bravelle|
214621862|NCT01417195|DRUG|Menopur|
214621863|NCT03357731|DRUG|HNO Donor|Infusion
214621864|NCT03357731|DRUG|Nitroglycerin (NTG)|Infusion
214621865|NCT03357731|OTHER|Placebo|Infusion
214621866|NCT01570504|DRUG|Ivermectin|oral formulation
214621867|NCT05196126|PROCEDURE|Permament pacemaker implantation|PM implantation
214621868|NCT05196126|PROCEDURE|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
214621869|NCT00535561|DRUG|Ferrous sulfate tablets 325 mg, po, TID|
214621870|NCT00535561|DRUG|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
214621871|NCT04155138|DEVICE|Naida Hearing Aid|hearing aid
214621872|NCT04155138|DEVICE|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
214621873|NCT01239342|DRUG|Akt Inhibitor MK2206|Given PO
214621874|NCT01239342|DRUG|Everolimus|Given PO
214621875|NCT01239342|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214621876|NCT03628014|OTHER|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities"
214621877|NCT00406510|DRUG|Optive, Systane|
214621878|NCT02892474|PROCEDURE|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
214621879|NCT02892474|PROCEDURE|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
214717708|NCT04838639|DRUG|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
214717709|NCT04838639|DRUG|Placebo|Two subjects per cohort will take a matched placebo.
214717710|NCT02827370|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary counseling
214621880|NCT04799392|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
214621881|NCT02011321|DRUG|clevidipine|clevidipine infusion x4 hours
214621882|NCT04156971|DIETARY_SUPPLEMENT|Omega 3|
214621883|NCT04156971|BEHAVIORAL|stage-based lifestyle modification intervention|
214621884|NCT00360594|DRUG|Acamprosate|3 pills (666 mg) for 1998mg/day
214621885|NCT00360594|DRUG|Placebo|3 pills (666mg) for 1998mg/day
214621886|NCT04956380|OTHER|Self-administered Triage|Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
214717711|NCT02286726|OTHER|Laboratory Biomarker Analysis|Correlative studies
214717712|NCT02286726|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214621887|NCT03118232|DRUG|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
214621888|NCT03118232|DRUG|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
214621889|NCT01136135|OTHER|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
214621890|NCT02655432|DEVICE|Spot photoscreener|Screening of vision problem through an automated device
214621891|NCT02655432|PROCEDURE|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
214621892|NCT02655432|PROCEDURE|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
214621893|NCT05705609|OTHER|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
214621894|NCT03986489|BEHAVIORAL|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
214621895|NCT03986489|BEHAVIORAL|Chronic pain social support group|"The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session."
214621896|NCT03426085|DRUG|Liraglutide 6 mg Solution for Injection|
214621897|NCT03426085|OTHER|Placebo|
214621898|NCT02918864|DRUG|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
214621899|NCT02918864|BEHAVIORAL|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
214621900|NCT02918864|BEHAVIORAL|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
214621901|NCT02268721|DEVICE|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
214621902|NCT03344315|DEVICE|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
214621903|NCT03344315|OTHER|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
214621904|NCT05198271|OTHER|Management of risk factors|"* For all patients:~  * Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~ * Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~ * Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~* Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
214621905|NCT05198271|BEHAVIORAL|Smoking cessation|"\- For active smoking patients:~* Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~* Nicotine substitutes +/- varenicline according to tobacco consumption~* Online notebook to record tobacco consumption and triggers"
214634597|NCT01707693|BEHAVIORAL|Information / Attention Comparison|Physical Activity information given \& follow-up, no behavioral counseling
214621906|NCT05198271|BEHAVIORAL|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
214621907|NCT05198271|OTHER|periodontal disease treatment|\- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
214621908|NCT05198271|BEHAVIORAL|increased physical activity|\- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
214621909|NCT05198271|BEHAVIORAL|Decreased anxiety|"\- For anxious patients:~* Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~* Delivery of connected equipment for the practice of cardiac coherence"
214621910|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621911|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621912|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621913|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621914|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621915|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
214621916|NCT00709215|DRUG|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
214621917|NCT00639483|DRUG|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
214621918|NCT00639483|DRUG|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
214621919|NCT02131558|PROCEDURE|ICG Dye|ICG Dye injections
214621920|NCT01677533|OTHER|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
214621921|NCT01677533|OTHER|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
214621922|NCT01677533|OTHER|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
214621923|NCT04134962|DIAGNOSTIC_TEST|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
214621924|NCT03289650|DRUG|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
214621925|NCT03289650|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
214621926|NCT02388438|DEVICE|Bongener|
214621927|NCT03842423|PROCEDURE|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
214621928|NCT02266992|BIOLOGICAL|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
214621929|NCT03577730|DRUG|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
214621930|NCT03577730|DRUG|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
214621931|NCT00079404|DRUG|tanespimycin|Given IV
214621932|NCT00733148|DRUG|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
214621933|NCT02634151|DRUG|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
214621934|NCT02634151|DRUG|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
214621935|NCT05940792|OTHER|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
214621936|NCT05940792|OTHER|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
214621937|NCT05143892|DRUG|Avatrombopag|Avatrombopag administered at the described frequency to achieve a target platelet count
214621938|NCT05143892|OTHER|Supportive care|Supportive care other than TPO-RAs or recombinant human thrombopoietin.
214621939|NCT02289430|DRUG|Crestor+Ezetrol|rosuvastatin+ezetimibe
214621940|NCT02289430|DRUG|Ezetrol|ezetimibe
214621941|NCT02289430|DRUG|Crestor|rosuvastatin
214621942|NCT00756145|PROCEDURE|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
214717713|NCT04705610|OTHER|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"* Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment"
214717714|NCT05948319|DIAGNOSTIC_TEST|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
214717715|NCT04112771|DRUG|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
214717716|NCT04112771|OTHER|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
214717717|NCT04479007|DEVICE|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
214621943|NCT00756145|PROCEDURE|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
214621944|NCT00756145|PROCEDURE|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
214621945|NCT00316680|BIOLOGICAL|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
214621946|NCT03156920|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214621947|NCT03156920|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214621948|NCT02089399|DRUG|Sevikar(amlodipne/olmesartan)|Treatment AB
214621949|NCT02089399|DRUG|crestor(Rosuvastatin)|Treatment AB/Treatment C
214621950|NCT04550091|DEVICE|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
214621951|NCT04640272|DRUG|RBM-007|Intravitreal injection
214621952|NCT04412850|DRUG|Magnesium Sulfate|"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge."
214621953|NCT01523496|DRUG|Vitamin D control dose|18,000 IU per month
214621954|NCT01523496|DRUG|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
214621955|NCT01792921|BEHAVIORAL|COG - FUN|
214621956|NCT01389375|DEVICE|FemoSeal®|Closure device for femoral artery access closure
214621957|NCT01389375|DEVICE|ExoSeal®|Closure device for femoral artery access closure
214621958|NCT01389375|OTHER|Manual compression|Conventional manual compression
214621959|NCT00521261|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
214621960|NCT04778098|OTHER|Received SMS reminder|telenursing
214621961|NCT00128856|DRUG|Gemcitabine|
214621962|NCT00128856|DRUG|Adriamycine|
214621963|NCT00128856|DRUG|Paclitaxel|
214621964|NCT05785156|OTHER|quick tests|"New quick tests are~* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
214621965|NCT03443076|DIETARY_SUPPLEMENT|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
214621966|NCT03443076|OTHER|Lovaza (active comparator; already FDA approved)|A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
214621967|NCT00351013|OTHER|Malaria Tropica Nosode D200|5 pellets every four months
214621968|NCT02464384|PROCEDURE|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
214621969|NCT05911542|BEHAVIORAL|Survey|Participants complete survey about pain management practices
214621970|NCT02203825|BIOLOGICAL|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
214621971|NCT04548726|DEVICE|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
214621972|NCT04548726|DEVICE|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
214621973|NCT05138016|DEVICE|Soft exosuit|Progressive cardiovascular exercise testing with soft exosuit assistance.
214621974|NCT05138016|BEHAVIORAL|No Soft exosuit|Progressive cardiovascular exercise testing.
214621975|NCT01647451|DRUG|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
214621976|NCT01647451|DRUG|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
214621977|NCT02568813|BEHAVIORAL|Multiscore Depression Inventory for Children scale|
214621978|NCT04636827|BIOLOGICAL|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
214621979|NCT04636827|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
214621980|NCT04636827|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
214621981|NCT04636827|BIOLOGICAL|HepA|HepA at the age of 18 month old
214717718|NCT03170258|DEVICE|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
214717719|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
214717720|NCT03464890|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
214621982|NCT06460402|OTHER|Ice packing|For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.
214717721|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
214717722|NCT03464890|OTHER|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
214717723|NCT00779363|DEVICE|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
214717724|NCT01496989|BIOLOGICAL|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
214717725|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
214717726|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
214717727|NCT01496989|BIOLOGICAL|Ad35-GRIN/ENV|(2x10\^10vp) Delivered intramuscularly by standard needle injection
214717728|NCT01563107|RADIATION|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
214717729|NCT01563107|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
214717730|NCT01563107|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
214717731|NCT04834050|PROCEDURE|Quadriceps femoris isometric home-based exercise|All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
214621983|NCT06460402|OTHER|Warm sitz bath|Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
214621984|NCT04777487|DIAGNOSTIC_TEST|GCF obtaining|4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
214621985|NCT00751400|DRUG|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
214621986|NCT00676676|DRUG|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
214621987|NCT00004998|DRUG|Lamivudine/Zidovudine|
214621988|NCT00004998|DRUG|Capravirine|
214621989|NCT00004998|DRUG|Nelfinavir mesylate|
214621990|NCT00643266|BEHAVIORAL|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
214621991|NCT00643266|BEHAVIORAL|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
214621992|NCT06171451|DIAGNOSTIC_TEST|PET with 11C-Fe-CIT|Use of the PET11C-Fe\_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
214621993|NCT01609946|DEVICE|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
214621994|NCT01609946|PROCEDURE|Cytology (FNAB) or Surgery|
214621995|NCT01334151|DRUG|Insulin LISPRO|Single doses of: 0.15 U/kg
214621996|NCT01334151|DRUG|recombinant human insulin|Single doses of: 0.15 U/kg
214621997|NCT01930136|BEHAVIORAL|Calorie restriction (25%)|
214621998|NCT01930136|BEHAVIORAL|Ad libitum health diet|
214621999|NCT06494852|DIAGNOSTIC_TEST|investigations|laboratory assesment Kidney function test, Urine analysis, Arterial blood gases ,Electrolytes (Na,K,Cl,Ca,phosphorus) and Calcium/creatinine ratio , Total serum IgE Radiological assessment Abdominal ultrasonography
214622000|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
214622001|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
214622002|NCT01222546|DRUG|CH5132799|
214622003|NCT01048762|OTHER|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
214622004|NCT01048762|OTHER|home training|one instruction in home based exercise training
214622005|NCT06247943|PROCEDURE|Lung Protective Ventilation Strategy|After 10 minutes of pneumoperitoneum, VT 7 ml/kg was used, PEEP 6 cmH2O, FiO2 was 40%, and plateau pressure \<30 cmH2O was maintained throughout.
214622006|NCT06247943|PROCEDURE|regular ventilation|VT 9ml /kg without PEEP, FiO2 of 60%
214622007|NCT03129321|DRUG|Econazole Nitrate Cream, 1%|
214622008|NCT03129321|DRUG|Placebo|
214622009|NCT04165707|DEVICE|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
214622010|NCT04165707|OTHER|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
214622011|NCT03559855|BEHAVIORAL|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
214622012|NCT05373654|OTHER|F-SUS Questionnaire|"This F-SUS questionnaire uses a Likert scale including 5 possible responses ranging from  I do not agree at all to  I completely agree  (Celenza A 2011, Croasmun JT 2011). The F-SUS is a short questionnaire with 10 questions (Brooke J 2013). In its original version half of the questions express strong agreement and the other half disagreement. Thus, all the even-numbered items (2, 4, 6, 8, 10) allow the participant to express a very negative opinion (disagreement). On the other hand, the odd-numbered items allow the participant to express a very positive opinion (strong agreement)."
214622013|NCT05373654|OTHER|Interview (only for dissatisfied patients)|"Patients that are dissatisfied with the recharge procedure (Score F-SUS \< 70/100) will be invited to a so-called complementary information interview (an interview after the questionnaire has been completed).~The corpus (the study group that will be interviewed) will naturally be diverse men/women, patients who were improved or not by stimulation, implanted with a rechargeable stimulator directly/replacing a stimulator, different brands of stimulator… The patient must agree to the interview and the way it will be performed (signature of consent form). The interview may be face-to -face at the site or by remote videoconference depending on the wishes and availability of the patient. There is no payment for these interviews but travelling or videoconference expenses are reimbursed All interviews will be audio- taped for further qualitative analysis."
214622014|NCT03219242|DEVICE|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
214622015|NCT00441974|DRUG|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
214622016|NCT02770547|DEVICE|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
214622017|NCT02770547|DEVICE|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
214622018|NCT01148537|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.
214622019|NCT01148537|DRUG|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
214622020|NCT01148537|DRUG|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
214622021|NCT03561909|OTHER|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
214622022|NCT03051555|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
214622023|NCT06171438|DIAGNOSTIC_TEST|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
214622024|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
214717732|NCT05211245|DEVICE|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
214622025|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
214622026|NCT01309074|DRUG|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
214622027|NCT01309074|DRUG|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
214622028|NCT01686620|DRUG|BIOD-123|
214622029|NCT01686620|DRUG|Lispro (Humalog)|
214622030|NCT05059496|OTHER|Hamstring stretching with Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
214622031|NCT05059496|OTHER|Hamstring stretching with out Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
214622032|NCT05325905|DIAGNOSTIC_TEST|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
214622033|NCT00060346|BIOLOGICAL|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
214622034|NCT00060346|DRUG|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
214622035|NCT00060346|DRUG|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
214622036|NCT00060346|DRUG|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
214622037|NCT00060346|DRUG|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
214622038|NCT03134599|DEVICE|etafilcon A|contact lens
214622039|NCT03134599|DEVICE|methafilcon A - Interozzo|contact lens
214622040|NCT03134599|DEVICE|methafilcon A - CVI (CooperVision)|contact lens
214622041|NCT03553342|DRUG|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
214622042|NCT03553342|OTHER|Placebo|Patients will receive placebo for seven days.
214622043|NCT02350556|OTHER|Dynamic Avoidance Task|
214622044|NCT02350556|PROCEDURE|physical therapy|
214622045|NCT02350556|DEVICE|3D motion on optoelectronic device|
214622046|NCT04001361|PROCEDURE|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
214622047|NCT03333083|DRUG|Raltegravir|Raltegravir (1200 mg once a day)
214622048|NCT03333083|DRUG|Lamivudine|Lamivudine (300 mg once a day)
214622049|NCT00393887|DEVICE|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
214622050|NCT00393887|DEVICE|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
214622051|NCT04417634|DIAGNOSTIC_TEST|RFR|Measurement of resting flow ratio
214622052|NCT04417634|DIAGNOSTIC_TEST|FFR|Measurement of fractional flow reserve
214622053|NCT05526690|DRUG|Metformin|1000 mg dose of immediate-release metformin
214717733|NCT01470365|PROCEDURE|quality-of-life assessment|Ancillary studies
214717734|NCT01470365|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214717735|NCT01470365|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
214622054|NCT05526690|DRUG|CIN-107|10 mg dose of CIN-107
214622055|NCT03016208|DRUG|Misoprostol vaginal insert|
214622056|NCT01966328|DRUG|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
214622057|NCT01966328|DRUG|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
214622058|NCT03385811|OTHER|no intervention, only questionnaires survey|questionnaires survey
214717736|NCT03006900|OTHER|Pilates|Pilates
214622059|NCT00224614|PROCEDURE|Allogenic transplantation|
214622060|NCT00492323|DRUG|placebo|twice daily for 4 weeks
214622061|NCT00492323|DRUG|carisbamate|200 mg tablet twice daily for 4 weeks
214622062|NCT02600104|DEVICE|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
214622063|NCT04513886|PROCEDURE|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
214622064|NCT02171962|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
214622065|NCT02887235|OTHER|Home Delivered, Medically Tailored Meals (HDTM)|
214622066|NCT04069195|DIETARY_SUPPLEMENT|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
214622067|NCT04069195|DIETARY_SUPPLEMENT|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
214622068|NCT02167750|OTHER|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
214622069|NCT03503877|DEVICE|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
214622070|NCT03503877|OTHER|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
214622071|NCT03503877|OTHER|SAGE MEDIA|Embryos will be cultured in SAGE media
214622072|NCT00002284|DRUG|Zidovudine|
214622073|NCT03840512|DRUG|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
214622074|NCT00609193|DRUG|lithium|standard clinical care
214622075|NCT00609193|DRUG|quetiapine|standard clinical care
214622076|NCT00865683|DIETARY_SUPPLEMENT|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
214622077|NCT00865683|DIETARY_SUPPLEMENT|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
214622078|NCT03546530|DRUG|Interferon|Interferon
214622079|NCT03546530|DRUG|Interferon+resveratrol|Interferon+resveratrol
214622080|NCT02723695|OTHER|Evaluation of postural performances|Postural tests
214622081|NCT01972620|DRUG|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
214622082|NCT02690857|DRUG|Docosahexaenoic acid|
214622083|NCT02690857|DRUG|Sunflower Oil|
214622084|NCT05704894|BIOLOGICAL|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between \<12g/dL
214622085|NCT04075474|DEVICE|silver diamine fluoride|38% SDF on primary upper anterior teeth
214622086|NCT04075474|DEVICE|sodium fluoride|5% NaF on primary upper anterior teeth
214717737|NCT03006900|OTHER|Massage|Massage
214622087|NCT04032600|PROCEDURE|Paracentesis|Full versus partial paracentesis (3 liters)
214622088|NCT06281470|DRUG|WS016 Single Dose(6g)|WS016 6g, to be administered orally as a single dose.
214622089|NCT06281470|DRUG|WS016 Single Dose(12g)|WS016 12g, to be administered orally as a single dose.
214622090|NCT06281470|DRUG|WS016 Single Dose(24g)|WS016 24g, to be administered orally as a single dose.
214622091|NCT06281470|DRUG|WS016 Single Dose(36g)|WS016 36g, to be administered orally as a single dose.
214622092|NCT06281470|DRUG|WS016 Single Dose(48g)|WS016 48g, to be administered orally as a single dose.
214622093|NCT06281470|DRUG|SAD matching placebo|Matching placebo, to be administered orally as a single dose.
214622094|NCT06281470|DRUG|WS016 Multiple Dose(12g)|WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
214622095|NCT06281470|DRUG|WS016 Multiple Dose(24g)|WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
214622096|NCT06281470|DRUG|WS016 Multiple Dose(48g)|WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
214622097|NCT06281470|DRUG|MAD matching placebo|Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
214622098|NCT02018822|DEVICE|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
214622099|NCT02018822|DEVICE|TPH3|light-cured resin composite for teeth
214622100|NCT02018822|DEVICE|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
214622101|NCT02107638|PROCEDURE|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
214622102|NCT02107638|OTHER|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
214622103|NCT04622332|DRUG|SIR1-365|Route of administration: oral
214622104|NCT04622332|DRUG|Matching Placebo|Route of administration: oral
214717738|NCT05702372|OTHER|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214717739|NCT05702372|OTHER|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214717740|NCT05702372|OTHER|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214622105|NCT02690155|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
214622106|NCT02690155|DRUG|VKA (Vitamin K antagonist)|As prescribed by treating physicians
214622107|NCT04428021|DRUG|Standard Therapy Protocol (STP)|Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee
214622108|NCT04428021|OTHER|STP + Standard Plasma (SP)|Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP
214622109|NCT04428021|OTHER|STP + COVID-19 Convalescent Plasma (CP)|Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
214622110|NCT05386901|PROCEDURE|Conventional positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.
214622111|NCT05386901|PROCEDURE|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
214622112|NCT00715026|DEVICE|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
214622113|NCT01106170|DRUG|Provex CV|dietary supplement, 2 capsules per day by mouth
214622114|NCT01106170|OTHER|placebo|corn starch, 2 capsules per day by mouth
214622115|NCT04624711|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
214622116|NCT04624711|DRUG|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
214622117|NCT03917173|PROCEDURE|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
214622118|NCT03917173|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
214622119|NCT01826253|DRUG|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
214622120|NCT03884738|OTHER|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
214622121|NCT03884738|OTHER|Nordic Eccentric exercise|"1. st week - 1 day - 2 sets of 5 repeats.~2. nd week - 2 days - 2 sets of 6 repeats.~3. rd week - 3 days - 3 sets of 6-8 repeats.~4. th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
214622122|NCT03884738|OTHER|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
214622123|NCT06116500|DEVICE|Modified twin block appliance with expander|These appliances are myofunctional appliance used for treating class II division growing adolescents.
214622124|NCT06116500|DEVICE|Conventional twin block appliance with expander|These appliances are myofunctional appliances used for treating class II division growing adolescents.
214622125|NCT00507390|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
214622126|NCT00507390|DIETARY_SUPPLEMENT|olive oil|1 capsule day
214622127|NCT00068744|DRUG|cisplatin|
214622128|NCT00068744|DRUG|fluorouracil|
214622129|NCT00068744|DRUG|mitomycin C|
214622130|NCT00068744|RADIATION|radiation therapy|
214622131|NCT00913900|BIOLOGICAL|autologous CD133+ cells|Intramuscular injection
214622132|NCT01161264|BIOLOGICAL|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
214622133|NCT05382975|BEHAVIORAL|CSPAP-T|"Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning"
214622134|NCT02820155|DRUG|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
214622135|NCT02820155|DRUG|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
214622136|NCT04346589|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
214622137|NCT02445625|DEVICE|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
214622138|NCT00061542|DRUG|BETOPTIC S (betaxolol HCl)|betaxolol HC)
214622139|NCT00061542|DRUG|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
214622140|NCT00547846|DRUG|PDC-748|
214622141|NCT03069885|DEVICE|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
214622142|NCT03069885|OTHER|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
214622143|NCT02087956|BEHAVIORAL|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
214717741|NCT05702372|OTHER|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214717742|NCT05833568|DEVICE|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
214622144|NCT02087956|BEHAVIORAL|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
214622145|NCT04536428|DEVICE|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops."
214622146|NCT04744207|DRUG|GS-248|120 mg, capsule, once daily for 4 weeks
214622147|NCT04744207|DRUG|Placebo|capsule, once daily for 4 weeks
214622148|NCT05973929|OTHER|Screen for movement disorder and correlates it with MRI findings.|"* To determine the prevalence of movement disorders in MS patients.~* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~* To find the correlation between the movement disorder and the different types of MS."
214622149|NCT00891982|DRUG|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
214622150|NCT00891982|DRUG|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
214622151|NCT02403570|OTHER|Brain MRI|
214622152|NCT01617070|DRUG|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
214622153|NCT01617070|DIETARY_SUPPLEMENT|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
214622154|NCT00077363|DRUG|tipifarnib|Given PO
214622155|NCT00077363|DRUG|capecitabine|Given PO
214622156|NCT03669432|RADIATION|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
214622157|NCT03669432|PROCEDURE|Surgery alone|This intervention is of no interest
214622158|NCT03096730|DRUG|Normal saline|Normal saline is intravenously administrated before anesthesia induction
214622159|NCT03096730|DRUG|Remifentanil|Remifentanil is intravenously administrated
214622160|NCT03096730|DRUG|Sufentanil|Sufentanil is intravenously administrated
214622161|NCT03096730|DRUG|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
214622162|NCT03096730|DRUG|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
214622163|NCT05289570|DRUG|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
214622164|NCT00974246|DRUG|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
214622165|NCT01336582|DRUG|taxotere|70 mg/m2 for age of ≥ 65
214622166|NCT04298775|PROCEDURE|spinal anesthesia with morphine|
214622167|NCT04298775|PROCEDURE|spinal anesthesia without morphine + peripheral nerve block|
214622168|NCT00058812|BIOLOGICAL|EBV specific T cells|One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
214622169|NCT03458221|DRUG|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
214622170|NCT03458221|DRUG|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
214622171|NCT03458221|DRUG|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
214622172|NCT03458221|DRUG|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
214622173|NCT01967355|OTHER|lipid apheresis|
214622174|NCT03906383|OTHER|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
214622175|NCT02111642|OTHER|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
214622176|NCT05125055|DRUG|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
214622177|NCT05125055|DRUG|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
214622178|NCT05125055|DRUG|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
214622179|NCT05125055|DRUG|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
214622180|NCT05125055|DRUG|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
214622181|NCT05675878|BEHAVIORAL|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
214622182|NCT00244387|DRUG|SPM 962|
214622183|NCT02797340|OTHER|Blood draws and urine samples for metformin concentration measurements|
214622184|NCT02797340|DRUG|Metformin|
214622185|NCT05462964|BEHAVIORAL|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
214622186|NCT05462964|BEHAVIORAL|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
214622187|NCT04638348|DEVICE|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
214717743|NCT05833568|DEVICE|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
214717744|NCT03907969|DRUG|AZD7648|Core: AZD7648 will be administered orally
214717745|NCT03907969|DRUG|PLD|The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
214717746|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
214717747|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
214717748|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
214717749|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
214717750|NCT00666536|DRUG|valsartan and amlodipine|
214622188|NCT05341362|PROCEDURE|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
214622189|NCT02718742|OTHER|Laboratory Biomarker Analysis|Correlative studies
214622190|NCT02718742|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214622191|NCT02718742|OTHER|Quality-of-Life Assessment|Ancillary studies
214622192|NCT00314184|DRUG|quetiapine fumarate|
214717751|NCT00666536|DRUG|valsartan and amlodipine|
214717752|NCT02122055|DRUG|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
214717753|NCT02122055|PROCEDURE|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
214717754|NCT02122055|PROCEDURE|Screen of weaning|1\. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
214622193|NCT03231046|DEVICE|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
214622194|NCT03231046|PROCEDURE|Hepatic Biopsy or Ablation|Standard of Care
214622195|NCT03166566|DEVICE|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
214622196|NCT03043716|OTHER|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
214622197|NCT02227602|DRUG|Mango polyphenolics|Frozen mango pack will be provided (200\~400g per day).
214622198|NCT00481286|BEHAVIORAL|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
214622199|NCT00481286|BEHAVIORAL|Standard of Care|Standard of care for diabetes patients
214622200|NCT05122884|DRUG|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
214622201|NCT01301443|DRUG|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
214622202|NCT02777268|DRUG|Infacort|Multi-particulate granules
214622203|NCT02777268|DRUG|Hydrocortisone|Tablet
214622204|NCT02348892|OTHER|Coordinator|Patients in complex situation taken care by coordinator
214622205|NCT02348892|OTHER|Classic plan|Patients in complex situation taken care by classic plan
214622206|NCT04279275|OTHER|SURVEY|QUESTIONAIRRE
214622207|NCT04159220|PROCEDURE|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
214622208|NCT04944212|DIAGNOSTIC_TEST|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
214622209|NCT02618655|OTHER|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
214622210|NCT02061670|BIOLOGICAL|Ragweed-SPIRE|Intradermal injection
214622211|NCT02061670|BIOLOGICAL|Placebo|
214622212|NCT02230384|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
214622213|NCT02230384|DRUG|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
214622214|NCT02582606|OTHER|Regular meal pattern|a 14-day period of eating 6 meal per day
214622215|NCT02582606|OTHER|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
214622216|NCT04928859|DRUG|Albumin|"At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group."
214622217|NCT00777101|DRUG|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
214622218|NCT00777101|DRUG|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
214622219|NCT00777101|DRUG|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
214622220|NCT00808236|DEVICE|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
214622221|NCT00808236|OTHER|Control|Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
214622222|NCT00961220|DRUG|Carmustine|Applied topically
214622223|NCT00961220|OTHER|Laboratory Biomarker Analysis|Correlative studies
214622224|NCT00961220|DRUG|O6-Benzylguanine|Given IV
214622225|NCT04732741|DIAGNOSTIC_TEST|Salivary Gamma-synuclein|Gamma-synuclein salivary levels measured using ELISA assay
214622226|NCT04732741|DIAGNOSTIC_TEST|Incisional biopsy|"A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region."
214622227|NCT04732741|DIAGNOSTIC_TEST|Conventional visual and tactile examination|Conventional visual and tactile examination using light and mirror
214622228|NCT03280875|OTHER|pedalling exercises|pedalling exercises on a bicycle ergometer
214717755|NCT02122055|DRUG|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
214622229|NCT06422975|DRUG|Vasopressin|Patients treated with vasopressin
214622230|NCT05752877|BIOLOGICAL|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
214622231|NCT05752877|BIOLOGICAL|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
214622232|NCT00881127|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
214622233|NCT00881127|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
214622234|NCT00888550|PROCEDURE|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
214622235|NCT00888550|PROCEDURE|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
214622236|NCT03379272|DEVICE|GOLDSTANDARD|RECORDING WITH EEG GOLDSTANDARD
214622237|NCT03379272|DEVICE|NEURONAUTE|RECORDING WITH NEURONAUTE
214622238|NCT05376215|DEVICE|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
214622239|NCT03666455|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
214622240|NCT02031770|DRUG|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
214622241|NCT02031770|OTHER|Control|subjects will receive no treatment
214622242|NCT00471705|DRUG|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
214622243|NCT00471705|DEVICE|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
214622244|NCT00471705|DRUG|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
214622245|NCT03666832|DRUG|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
214622246|NCT01301950|OTHER|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
214622247|NCT01301950|OTHER|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
214622248|NCT00593944|BIOLOGICAL|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
214622249|NCT01908270|BEHAVIORAL|Yoga|
214622250|NCT01908270|OTHER|Usual care|
214622251|NCT05023759|DIETARY_SUPPLEMENT|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
214622252|NCT02651584|DRUG|CAM2038 SC injection|
214622253|NCT02651584|DRUG|SL BPN/NX tabs|
214622254|NCT02651584|DRUG|placebo SC injections|
214622255|NCT02651584|DRUG|SL placebo tablets|
214622256|NCT02742428|DEVICE|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
214622257|NCT02742428|PROCEDURE|Acute paracentesis.|Evacuation of a large (\>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
214622258|NCT02742428|BEHAVIORAL|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
214622259|NCT02742428|BEHAVIORAL|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
214622260|NCT02742428|BEHAVIORAL|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
214622261|NCT01651624|OTHER|Invitation to screening|
214622262|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
214622263|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
214622264|NCT01592253|DRUG|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
214622265|NCT03621332|OTHER|Questionnaire|Online/paper questionnaires
214622266|NCT04802525|OTHER|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
214622267|NCT00007085|DEVICE|Tomography, X-ray Computed|
214622268|NCT00141024|BIOLOGICAL|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
214622269|NCT00141024|BIOLOGICAL|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
214622270|NCT03425214|OTHER|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
214622271|NCT03425214|OTHER|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
214622272|NCT03425214|OTHER|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
214622273|NCT03455491|DRUG|XC221 100 mg|once daily during 3 days.
214622274|NCT03455491|DRUG|XC221 200 mg|once daily during 3 days.
214622275|NCT03455491|DRUG|Placebo|once daily during 3 days.
214622276|NCT04219176|DIAGNOSTIC_TEST|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
214622277|NCT05505136|DEVICE|Arrhythmia Management System (AMS)|Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
214622278|NCT00236860|DRUG|topiramate|
214622279|NCT05815407|OTHER|No intervention|No intervention
214622280|NCT01391286|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
214622281|NCT01391286|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
214717756|NCT02122055|DRUG|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
214622282|NCT05790109|DEVICE|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
214622283|NCT06495034|DEVICE|airwave compression therapy|Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb
214622284|NCT06495034|OTHER|standard care: health education and routine functional exercise|standard care: health education and routine functional exercise
214622285|NCT04141332|DIAGNOSTIC_TEST|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
214622286|NCT01891500|DRUG|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
214622287|NCT01891500|DRUG|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
214622288|NCT01891500|DRUG|Crossover iNO|Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
214622289|NCT01141088|PROCEDURE|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
214622290|NCT01141088|PROCEDURE|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
214622291|NCT03821025|DEVICE|Biliary stent|Palliation of malignant biliary obstruction
214717757|NCT02122055|DRUG|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
214717758|NCT01055470|DRUG|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
214622292|NCT01732809|DRUG|AbobotulinumtoxinA (ABO)|Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
214622293|NCT01732809|DRUG|OnabotulinumtoxinA (ONA)|Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
214622294|NCT04247061|OTHER|Educational video|One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
214622295|NCT04247061|OTHER|Text-message program|A one-month text message program to motivate and facilitate contact with smoking cessation resources.
214622296|NCT02989831|DEVICE|Vibrating insoles 'on'|Duration: 30-60 seconds
214622297|NCT04509141|OTHER|acupuncture|acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
214622298|NCT01115530|OTHER|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
214622299|NCT01115530|DIETARY_SUPPLEMENT|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
214622300|NCT02752516|DRUG|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214622301|NCT06036251|OTHER|Questionnaires|Self-reported quality of life (QOL) measures completed online
214717759|NCT01055470|DRUG|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
214622302|NCT01120392|OTHER|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
214622303|NCT01120392|OTHER|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
214622304|NCT02048618|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
214622305|NCT02048618|DRUG|Placebo|placebo oral tablets, intake once daily for 20 weeks
214622306|NCT04570501|DRUG|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
214622307|NCT04570501|DRUG|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
214622308|NCT03186690|OTHER|Biodentine|
214622309|NCT03186690|OTHER|Mineral Trioxide Aggregate|
214717760|NCT01761136|BIOLOGICAL|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
214622310|NCT04714736|DEVICE|Coronary angiography using DyeVert system|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
214717761|NCT01761136|BIOLOGICAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
214622311|NCT04714736|PROCEDURE|Coronary angiography using conventional manual injection syringe.|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
214622312|NCT05875051|OTHER|Reduced-exertion high intensity training|The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
214622313|NCT05875051|OTHER|Short moderate intensity training|The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
214622314|NCT02126033|PROCEDURE|take blood samples|
214622315|NCT00492427|DRUG|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.
214622316|NCT00492427|DRUG|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
214622317|NCT05501145|PROCEDURE|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
214622318|NCT03463798|DEVICE|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
214622319|NCT03463798|DEVICE|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
214622320|NCT03610724|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel was infused once as an intravenous infustion at a dose of either 0.2 to 5 x 106 CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 108 CAR-positive viable T cells for subjects \> 50 kg.
214622321|NCT03610724|DRUG|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
214622322|NCT03610724|DRUG|Bridging Therapy|Pre-treatment phase could also include bridging therapy of investigator's choice
214622323|NCT01473563|DRUG|Pemetrexed|Administered intravenously
214622324|NCT01519765|DRUG|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
214622325|NCT01519765|DRUG|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
214622326|NCT05544188|DIAGNOSTIC_TEST|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
214622327|NCT00786565|DEVICE|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
214622328|NCT00786565|DEVICE|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
214622329|NCT01699542|DEVICE|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
214622330|NCT01699542|DEVICE|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
214622331|NCT00805272|OTHER|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
214622332|NCT05395611|OTHER|EBPcollected using the PExA device.|The PExA device is a non invasive device that collect particles in exhaled air
214622333|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
214622334|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
214622335|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
214622336|NCT04719650|DRUG|Placebo|Infusion normal saline once.
214622337|NCT00576017|DRUG|Fentanyl-TTS|
214622338|NCT04474665|DEVICE|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
214622339|NCT06648668|DRUG|TMP-301|Once daily \[QD\] × 14 days
214622340|NCT06648668|DRUG|Placebo|Once daily \[QD\] × 14 days
214622341|NCT02282150|DRUG|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
214622342|NCT02282150|DRUG|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
214622343|NCT03777540|PROCEDURE|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
214622344|NCT05302752|OTHER|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
214622345|NCT02067195|DRUG|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
214622346|NCT02067195|DRUG|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
214622347|NCT04171479|DEVICE|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
214622348|NCT04402970|DRUG|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
214622349|NCT03499509|OTHER|Low Glycemic Diet|Low Glycemic (LG) diet: The LG diet was made up of foods that do not stimulate insulin secretion and was composed of 20% CHO, 55% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
214622350|NCT03499509|OTHER|High Glycemic Diet|High Glycemic (HG) diet: The HG diet aligned with the United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/) and was composed of 55% CHO, 20% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
214622351|NCT01475175|DEVICE|CRT pacing at rest and during exercise|CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
214622352|NCT02171273|BEHAVIORAL|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
214622353|NCT02171273|BEHAVIORAL|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
214622354|NCT02171273|BEHAVIORAL|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
214622355|NCT05352126|OTHER|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
214622356|NCT02768090|DEVICE|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
214622357|NCT01889082|BEHAVIORAL|Behavioral Weight Loss Intervention for Young Adults|
214622358|NCT05560373|DRUG|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
214622359|NCT05560373|OTHER|operational treatment, the best basic treatment|other
214622360|NCT05560373|DRUG|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
214717762|NCT01391468|DIETARY_SUPPLEMENT|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
214622361|NCT05560373|OTHER|Interventional treatment, the best basic treatment|other
214622362|NCT05860842|OTHER|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
214717763|NCT01391468|DIETARY_SUPPLEMENT|Cornstarch|placebo will be given in 6 months
214717764|NCT01674985|BIOLOGICAL|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
214717765|NCT02977039|OTHER|NDPR diet|nutrient rich plant based diert
214717766|NCT02977039|OTHER|USDA healthy eating diet|DASH diet
214622363|NCT04288986|BEHAVIORAL|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
214622364|NCT00725881|DRUG|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
214622365|NCT00725881|DRUG|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
214622366|NCT03105167|PROCEDURE|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
214622367|NCT03105167|PROCEDURE|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
214622368|NCT05060653|OTHER|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
214622369|NCT02648802|PROCEDURE|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
214717767|NCT03515239|PROCEDURE|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
214717768|NCT03638336|DEVICE|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
214622370|NCT02648802|PROCEDURE|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
214622371|NCT05071976|DIAGNOSTIC_TEST|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
214622372|NCT06046872|BEHAVIORAL|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
214622373|NCT06965140|DEVICE|flat 1-piece open ostomy device|OCT scan and skin measurements of peristomal and abdominal skin
214622374|NCT05962138|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
214622375|NCT04963556|DIETARY_SUPPLEMENT|Red Bull|Drinking of Red Bull before exercise
214622376|NCT06968663|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
214622377|NCT06968663|BEHAVIORAL|Modified Constraint Induced Language Therapy (mCILT)|Constraint-induced language therapy (CILT) is a treatment approach for aphasia that focuses on forcing the patient to use their impaired language skills, while restricting the use of compensatory strategies like gestures or writing. All participants will receive mCILT.
214622378|NCT06526585|BEHAVIORAL|Cyclic Sighing Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes."
214622379|NCT06526585|BEHAVIORAL|Box Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes."
214717769|NCT04254445|OTHER|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
214622380|NCT06526585|BEHAVIORAL|Hypnosis|Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
214717770|NCT00000768|DRUG|Glutamic acid hydrochloride|
214717771|NCT00000768|DRUG|Ganciclovir|
214717772|NCT03408288|OTHER|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
214717773|NCT03408288|OTHER|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
214717774|NCT03408288|OTHER|Color description|Describe color of reference sample
214717775|NCT02756741|DRUG|ALBUMIN|Albumin in two different doses
214717776|NCT06367335|DRUG|Ribociclib, palbociclib, abemaciclib|evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
214717777|NCT01921699|PROCEDURE|taking blood samples from healthy people|
214717778|NCT04618549|PROCEDURE|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
214622381|NCT06526585|BEHAVIORAL|Audiobook|Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
214622382|NCT05918575|DEVICE|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
214622383|NCT05918575|DEVICE|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
214622384|NCT00887237|DEVICE|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
214622385|NCT00887237|DEVICE|Conventional cardiac resynchronization|Conventional cardiac resynchronization
214622386|NCT06543823|DEVICE|SupraTHEL 250|the membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures
214622387|NCT06543823|OTHER|Comparator|no membrane is placed onto the wound bed , left bare to heal
214622388|NCT05485155|DRUG|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.
214622389|NCT02389751|DRUG|Carboplatin|Given IV
214622390|NCT02389751|DRUG|Ganetespib|Given IV
214622391|NCT02389751|DRUG|Paclitaxel|Given IV
214622392|NCT02389751|RADIATION|Radiation Therapy|Undergo radiation therapy
214634598|NCT04223310|DRUG|Virtual AAD TEST group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design."
214634599|NCT04223310|DRUG|Empirical AAD group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design."
214717779|NCT04618549|PROCEDURE|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
214717780|NCT04618549|PROCEDURE|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
214622393|NCT06972173|OTHER|DEEP BREATHING AND PROGRESSIVE MUSCLE RELAXATION EXERCISES|"For deep breathing exercises, students were asked to place their dominant hand on their abdomen and non-dominant hand on their chest in the semi-fowler position. Afterwards, they were instructed to breath deeply through their nose for 4 seconds and exhale through their mouth for 8 seconds. These exercises were performed as 4 repetitions with 2 minutes rest time between the exercises. When the deep breathing exercises were finished, the students lay on their backs and rested for 1 minute and then progressive muscle relaxation exercise was started (10,11).~For the progressive muscle relaxation exercise, the students were asked to contract and then relax the right foot, left foot, right leg, left leg, hip, abdominal muscles, chest muscles and back muscles, right hand, left hand, right arm, left arm, neck and shoulders, and facial muscles respectively. Respectively, from bottom to top, all the major muscles are contracted while inhaling deeply and slowly, and relaxed and r"
214622394|NCT02306109|PROCEDURE|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
214634600|NCT00781716|DEVICE|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
214634601|NCT00973076|DRUG|AZD8055|Tablets, orally administered, twice daily
214634602|NCT02480127|PROCEDURE|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
214634603|NCT00302965|DRUG|Frozen Plasma|
214717781|NCT00994760|DRUG|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
214717782|NCT06171815|BEHAVIORAL|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
214622395|NCT02306109|PROCEDURE|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
214622396|NCT05020171|DEVICE|Group of strength training|2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
214622397|NCT05020171|OTHER|Group of physiotherapy not focus on strength training|2x a week during 5 weeks, active physical therapy treatment based on movement
214622398|NCT01018628|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
214622399|NCT01018628|DRUG|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
214622400|NCT05546125|OTHER|as per Physician's prescription|Participants need to take the Revatio as per Physician's prescription
214622401|NCT03558984|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
214622402|NCT03558984|OTHER|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
214622403|NCT05248295|BEHAVIORAL|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
214622404|NCT05248295|BEHAVIORAL|Metrical timing (vs. conversational)|This is the secondary contrast in the 2x2 design described above.
214622405|NCT01053871|DRUG|propofol|conscious sedation using propofol
214622406|NCT01053871|DRUG|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
214622407|NCT02874456|OTHER|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
214622408|NCT04543799|DEVICE|polysomnography, actigraphy, questionnaires|sleep quality recording
214622409|NCT03091075|DRUG|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
214622410|NCT03091075|DRUG|Placebo|Placebo group will receive placebo for 12 weeks postoperative
214622411|NCT05909397|DRUG|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
214622412|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
214622413|NCT05909397|DRUG|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
214622414|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
214622415|NCT03021499|DRUG|Voclosporin|calcineurin inhibitor
214622416|NCT03021499|DRUG|Placebo Oral Capsule|matching placebo capsule
214622417|NCT04410588|DRUG|Fentanyl + Topical Levobupivacaine|in nasal packing
214622418|NCT04410588|DRUG|levobupivacaine|in nasal packing
214622419|NCT04329481|DIETARY_SUPPLEMENT|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
214622420|NCT06350734|OTHER|Non-Interventional Study|Non-Interventional Study
214622421|NCT02959528|OTHER|Working memory training|n-back training program
214622422|NCT02959528|OTHER|perceptual training|visual-perceptual training program
214622423|NCT06135649|PROCEDURE|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
214622424|NCT01403818|DRUG|ASP1941|oral
214622425|NCT01403818|DRUG|Mitiglinide calcium hydrate|oral
214622426|NCT00025220|DRUG|Thalidomide|Given PO
214622427|NCT00025220|OTHER|Laboratory Biomarker Analysis|Correlative studies
214622428|NCT00470054|DRUG|dasatinib|Given PO
214622429|NCT04993794|DRUG|XueBiJing Injection|XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.
214622430|NCT04993794|DRUG|Normal saline|Same saline dose as XueBiJing injection is taken intravenously.
214622431|NCT00870220|DRUG|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
214622432|NCT03739905|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
214622433|NCT03459911|DRUG|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)
214622434|NCT03459911|DRUG|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
214622435|NCT04519411|DIAGNOSTIC_TEST|Transpulmonary pressure measurements|Transpulmonary pressure measurements
214622436|NCT04093843|DEVICE|TMS|NeuroStar TMS Therapy
214622437|NCT01666509|DEVICE|Rossoseq™|
214622438|NCT01666509|DEVICE|Placebo|
214622439|NCT02680925|PROCEDURE|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
214622440|NCT02680925|PROCEDURE|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
214622441|NCT01878526|DRUG|Alginic acid|Algycon 1 tab chew tid after meal
214622442|NCT01878526|DRUG|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
214622443|NCT01878526|DRUG|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
214622444|NCT01878526|DRUG|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
214622445|NCT02947152|DRUG|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
214622446|NCT01787942|DEVICE|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
214622447|NCT00754481|OTHER|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
214622448|NCT00754481|OTHER|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
214622449|NCT03639103|PROCEDURE|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
214622450|NCT03310450|OTHER|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
214622451|NCT05046847|DRUG|TQB3811|TQB3811 is a second-generation TrkA inhibitor.
214622452|NCT04869345|BEHAVIORAL|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
214622453|NCT03854136|PROCEDURE|Excision of tumor|Wide margin excision of tumors +/- limb preservation
214622454|NCT00359138|DRUG|desloratadine|5 mg tablet once daily
214622455|NCT00359138|DRUG|levocetirizine|5 mg capsule once daily
214622456|NCT00359138|DRUG|Desloratadine placebo tablet|once daily
214622457|NCT00359138|DRUG|Levocetirizine placebo capsule|once daily
214622458|NCT02716051|DEVICE|MRI|Whole body MRI with cardiac and pulmonary synchronization
214622459|NCT02716051|DEVICE|PET|
214622460|NCT04526236|DRUG|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
214622461|NCT05303116|DIAGNOSTIC_TEST|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
214622462|NCT02277015|DEVICE|Miller Laryngoscope|Direct Laryngoscopy
214622463|NCT02277015|DEVICE|The Berci-Kaplan DCI|Videolaryngoscope-1
214622464|NCT02277015|DEVICE|The AirTraq|Videolaryngoscope-2
214622465|NCT02277015|DEVICE|GlideScope GVL|Videolaryngoscope-3
214622466|NCT02277015|DEVICE|The Pentax AWS|Videolaryngoscope-4
214622467|NCT00626756|DEVICE|LiDCO technology|non invasive monitoring of cardiac output
214622468|NCT00001075|DRUG|Ritonavir|
214622469|NCT00001075|DRUG|Lamivudine|
214622470|NCT00001075|DRUG|Zidovudine|
214622471|NCT02781909|DRUG|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
214622472|NCT02781909|DRUG|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
214622473|NCT05970874|DEVICE|Hand grip strength measureme|Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).
214622474|NCT01128127|BEHAVIORAL|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
214622475|NCT01128127|BEHAVIORAL|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
214622476|NCT01128127|BEHAVIORAL|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
214622477|NCT05743738|DIAGNOSTIC_TEST|Doppler ultrasound|Control venous Doppler ultrasound
214622478|NCT00528021|DRUG|Placebo|Vehicle Only
214622479|NCT00528021|DRUG|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
214622480|NCT05094791|DEVICE|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
214622481|NCT05094791|DEVICE|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
214622482|NCT05094791|DEVICE|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
214622483|NCT04226690|DRUG|Active CBD/THC Dose 1|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
214622484|NCT04226690|DRUG|Active CBD/THC Dose 2|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
214622485|NCT04226690|DRUG|matched placebo comparator|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
214622486|NCT04050982|DEVICE|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
214622487|NCT04050982|BEHAVIORAL|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
214622488|NCT05144035|DRUG|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
214622489|NCT00449501|DRUG|Budesonide/formoterol pMDI|
214622490|NCT00449501|DRUG|Budesonide HFA pMDI|
214622491|NCT05054114|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
214622492|NCT06199609|PROCEDURE|Hemodialysis pathway|AVF and TCC are two different vascular pathways for hemodialysis
214622493|NCT06199609|PROCEDURE|AVF|Left atrial changes caused by AVF establishment
214622494|NCT06199609|PROCEDURE|AVF|New onset atrial fibrillation caused by AVF establishment
214622495|NCT00413647|DRUG|CardioPET|
214622496|NCT00751595|BIOLOGICAL|Tat protein|Biologically active recombinant Tat protein
214622497|NCT01791348|OTHER|d2 test of attention|
214622498|NCT06216431|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
214622499|NCT06978374|OTHER|Sonographic examination of thoracolumbar fascia, manual examination of MTrP|"Patients were positioned in the prone position, with a cushion placed under the abdomen to flatten the lumbar lordosis.~A 14-18 MHz linear transducer was used for ultrasonographic (USG) evaluation, performed with a GE Logiq P5 ultrasound device (Serial No: GE-114118SU3).~The USG probe was placed longitudinally at the L2-L3 intervertebral level, 2 cm lateral to the vertical line connecting the spinous processes on both sides, in order to assess the thoracolumbar fascia (TLF)."
214717783|NCT01196312|BEHAVIORAL|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
214717784|NCT00716989|BIOLOGICAL|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
214717785|NCT04909294|RADIATION|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
214717786|NCT06110104|OTHER|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
214717787|NCT06110104|OTHER|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
214717788|NCT06110104|OTHER|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
214717789|NCT03422016|DIAGNOSTIC_TEST|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
214717790|NCT00005675|DRUG|Oral bovine type I collagen|500 mcg of CI daily for 15 months
214622500|NCT06978504|OTHER|DASH diet|Prospective, single-arm, unblinded clinical trial lasting 90 days. The study population will consist of menopausal women aged between 40 and 60 years who are obese (BMI \> 30) and diagnosed with metabolic syndrome. Volunteers will have an in-person consultation with a nutritionist at t0 to assess their previous habitual food intake and will receive a DASH diet. To minimize losses during the study, in-person consultations with a nutritionist will be held at t0, t30, t60, t90 and online consultations (teleconsultation) at t15, t45 and t75 to answer a questionnaire to assess nutritional adherence that will be applied by the nutritionist. Saliva samples will be collected for genetic panel analysis only at t90. Serum samples for analysis of lipid profile, blood glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), follicle stimulating hormone (FSH), C-reactive protein (CRP) and tumor necrosis factor (TNF) and profile of medications used will be collected at t0 and t90.
214622501|NCT06977386|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of gastric cancer|CT scan of the abdomen outside of standard treatment options
214622502|NCT06978816|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|Intravenous infusion of 50 mg dexketoprofen trometamol injection
214622503|NCT06978816|OTHER|Auricular Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, verum auricular acupoint embedding was performed using disposable sterile press needles at three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), with needle retention for 60 minutes
214622504|NCT06978816|OTHER|Sham Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, sham auricular stimulation was administered using non-penetrating adhesive patches applied to three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), maintaining the application for 60 minutes.
214622505|NCT06977763|DRUG|succinylated gelatin injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
214622506|NCT06977763|DRUG|succinylated gelatin injection|Gelofusine
214622507|NCT06978517|PROCEDURE|Biodex balance system|Participants assigned to the Biodex balance training group underwent balance rehabilitation using the Biodex Balance System SD, a computerized platform designed to assess and train postural stability. Each participant engaged in training sessions three times per week, with each session lasting approximately 30 minutes, over a total period of six weeks. The intervention began with exercises conducted on a higher stability level (e.g., Level 8), gradually progressing to lower stability levels (e.g., Level 2) to increase the challenge as participants' balance improved. The training included both static and dynamic tasks aimed at enhancing weight shifting, center-of-gravity control, and response to instability. Real-time visual biofeedback was provided via the system's screen, enabling participants to monitor their performance and maintain motivation. All sessions were conducted under the supervision of a qualified physiotherapist to ensure proper technique and safety.
214622508|NCT06978517|PROCEDURE|nintendo Wii fit balance training|Participants in the Nintendo Wii Fit training group engaged in balance exercises using the Nintendo Wii console and Wii Fit balance board. This interactive system includes a variety of balance-focused activities and games that simulate real-life balance challenges in a virtual environment. The training was conducted three times per week, with each session lasting approximately 30 minutes, over a six-week period. Exercises included selected Wii Fit balance games (such as Ski Slalom, Table Tilt, and Tightrope Walk) and yoga-based poses (such as Tree Pose and Warrior), which encouraged participants to engage their core and lower limb muscles while maintaining postural alignment. The difficulty level was gradually increased by introducing more complex tasks and longer balance durations as participants progressed. The system provided immediate visual and auditory feedback, allowing users to track their scores and improvements in real time. All sessions were performed under supervision.
214622509|NCT06979284|PROCEDURE|IVUS-guided strategy|Percutaneous revascularization will be performed using intravascular ultrasound. The operators will follow instructions to modify arteries hardened by calcium and use IVUS to optimize the equipment (balloon and stents) used to unblock the artery.
214622510|NCT06977672|OTHER|Down Dog Yoga|In this study, a period of 10 weeks, commencing with a preliminary assessment during the first week, followed by an 8-week intervention phase, and concluding with a final assessment in the last week of the study period. The frequency-intensity-time-type principle will be implemented as follows: sessions will occur 4 times per week, consisting of 2 sessions led by experts and 2 sessions involving parents. The intensity will be 40 to 45 minutes for expert-led sessions and 20 to 25 minutes for parent-led sessions. These sessions will take place 3 or 4 times per week over an 8-week period, focusing on a type of intervention known as dog down yoga
214622511|NCT06977672|OTHER|Traditional|The children took part in group sessions four days a week over a span of 10 weeks, totaling 40 sessions. Each session, lasting around 20 minutes, involved small groups of four to seven children. The aim will be to evaluate the children's writing across four stages of development: pre-phonemic, semi-phonemic, phonemic, and conventional
214622512|NCT06977243|BEHAVIORAL|Online MedEd Intern Bootcamp|7 weeks, online training program
214622513|NCT06979167|DEVICE|midline catheter insertion during general anesthesia|This intervention involves the ultrasound-guided insertion of a midline catheter into a peripheral vein (basilic, cephalic, or brachial vein) during general anesthesia in pediatric patients.
214622514|NCT06978738|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
214622515|NCT03640598|PROCEDURE|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
214622516|NCT03640598|PROCEDURE|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
214622517|NCT01345747|DEVICE|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
214622518|NCT00592033|OTHER|oxygen from a portable concentrator|2 l/minute during exercise
214622519|NCT05367362|DRUG|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
214622520|NCT06872112|DRUG|Artesunate|Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
214622521|NCT00801645|BEHAVIORAL|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
214622522|NCT05118802|OTHER|Interview|Attends Interviews
214622523|NCT05118802|OTHER|Survey Administration|Complete Survey
214622524|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
214622525|NCT06927466|BIOLOGICAL|B019|B019： Intravenous infusion, 1.0×10\^6 CAR T cell/kg-10.0×10\^6 CAR T cell/kg
214622526|NCT00733954|DRUG|clobetasol propionate spray|Apply twice daily
214622527|NCT00733954|DRUG|clobetasol propionate ointment|Apply twice daily
214622528|NCT06438978|BIOLOGICAL|Tuberculosis Vaccine|"1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain~2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate~3. Lyophilized pellet in vials (10doses)~4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)"
214622529|NCT02663453|DRUG|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
214622530|NCT02663453|DRUG|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
214622531|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
214622532|NCT02085603|DRUG|Saracatinib|
214622533|NCT02085603|DRUG|Placebo|
214622534|NCT00985062|PROCEDURE|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
214717791|NCT00005675|DRUG|Placebo|CI placebo daily for 15 months
214622535|NCT00985062|PROCEDURE|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
214622536|NCT05407259|BEHAVIORAL|Resistance exercise|There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
214622537|NCT04858945|BEHAVIORAL|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
214622538|NCT02969057|OTHER|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
214622539|NCT02969057|OTHER|Breakfast with rice bran oil|25 grams of rice bran oil
214622540|NCT02969057|OTHER|Breakfast with palm oil gel|25 grams of palm oil gel
214622541|NCT02969057|OTHER|Breakfast with palm oil|25 grams of palm oil
214622542|NCT01568684|OTHER|Citalopram|Treatment
214622543|NCT06219265|BEHAVIORAL|Dance Therapy|"A single-centre prospective randomised controlled trial will be conducted with a minimum of 48 patients with severe mental disorder (SMD) who will be randomised into two groups, 1 intervention group receiving dance therapy (n=24) and 1 control group receiving no intervention or treatment (n=24).~In addition, there will be an intervention group of healthy people who will receive dance therapy (n=20).~All the tests, will be carried out with patients with SMD and only the EEG for healthy people, in order to determine their baseline state. The dance therapy program will last for 20 sessions over 10 weeks.~The 44 people in the two experimental groups will participate in a 10-week intervention program with 2 sessions per week in which they will work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.~The 24 people in the control group will not receive any type of intervention."
214622544|NCT03321136|DRUG|LSD|0.025 mg LSD per os, single dose
214622545|NCT03321136|DRUG|LSD|0.05 mg LSD per os, single dose
214622546|NCT03321136|DRUG|LSD|0.1 mg LSD per os, single dose
214622547|NCT03321136|DRUG|LSD|0.2 mg LSD per os, single dose
214622548|NCT03321136|DRUG|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
214622549|NCT03321136|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
214622550|NCT04964427|DRUG|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
214622551|NCT04964427|DEVICE|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
214622552|NCT04964427|DEVICE|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
214622553|NCT04298736|PROCEDURE|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
214622554|NCT04298736|BEHAVIORAL|Lifestyle modification|guided low-calorie diet and physical activity.
214622555|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with web-based support|Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
214622556|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with standard support|Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
214622557|NCT05823675|DRUG|Itolizumab|Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
214622558|NCT05823675|DRUG|Methylprednisolone|Methylprednisolone will be taperred as required
214622559|NCT02700724|OTHER|Immediate Surgery|
214622560|NCT02700724|OTHER|Observation|
214622561|NCT02700724|PROCEDURE|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
214622562|NCT04802993|OTHER|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
214622563|NCT03557281|DRUG|GSK3036656|GSK3036656 will be administered
214622564|NCT03557281|DRUG|Rifafour e-275|Rifafour e-275 will be administered
214622565|NCT00529074|DEVICE|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
214622566|NCT04216277|DIAGNOSTIC_TEST|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
214622567|NCT00402649|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
214622568|NCT01999465|DEVICE|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)"
214622569|NCT01999465|DEVICE|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)"
214622570|NCT01439464|DEVICE|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
214717792|NCT01600391|BEHAVIORAL|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
214622571|NCT01439464|DEVICE|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
214622572|NCT05030012|DEVICE|Automated Control|The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
214622573|NCT05030012|DEVICE|Manual Control|The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
214622574|NCT01114503|DRUG|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
214622575|NCT01114503|DRUG|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
214622576|NCT01114503|DRUG|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
214622577|NCT01114503|DRUG|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
214622578|NCT01114503|DRUG|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
214622579|NCT01114503|DRUG|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
214622580|NCT05365503|OTHER|Shamiri Intervention|The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
214622581|NCT02628236|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
214622582|NCT02628236|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
214622583|NCT02951715|DRUG|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
214622584|NCT01534312|DRUG|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
214622585|NCT01534312|DRUG|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
214622586|NCT00004231|BIOLOGICAL|aldesleukin|
214622587|NCT00004231|BIOLOGICAL|filgrastim|
214622588|NCT00004231|BIOLOGICAL|recombinant interferon alfa|
214622589|NCT00004231|DRUG|busulfan|
214622590|NCT00004231|DRUG|cyclophosphamide|
214622591|NCT00004231|DRUG|cytarabine|
214622592|NCT00004231|DRUG|doxorubicin hydrochloride|
214622593|NCT00004231|DRUG|leucovorin calcium|
214622594|NCT00004231|DRUG|methotrexate|
214622595|NCT00004231|DRUG|prednisone|
214622596|NCT00004231|DRUG|teniposide|
214622597|NCT00004231|DRUG|vincristine sulfate|
214622598|NCT00004231|PROCEDURE|allogeneic bone marrow transplantation|
214622599|NCT00004231|PROCEDURE|autologous bone marrow transplantation|
214622600|NCT00004231|PROCEDURE|peripheral blood stem cell transplantation|
214622601|NCT01308008|BEHAVIORAL|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
214622602|NCT01308008|BEHAVIORAL|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
214622603|NCT00000414|BEHAVIORAL|Arthritis Self-Management Program|
214622604|NCT00000414|BEHAVIORAL|SMART Program|
214622605|NCT01099852|OTHER|biological sample collection|blood sample collection urine sample cerebrospinal fluid sample
214622606|NCT01099852|OTHER|Quality of life Questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
214622607|NCT01099852|OTHER|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
214622608|NCT01099852|OTHER|Neuropathic Pain Questionnaire (DN4)|Questionnaire used during the follow up
214622609|NCT05447494|DRUG|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
214622610|NCT05447494|DRUG|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
214622611|NCT04667351|DRUG|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
214622612|NCT04667351|DRUG|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
214622613|NCT00198380|DRUG|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
214622614|NCT02645357|OTHER|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
214622615|NCT02645357|OTHER|Control group|control group
214622616|NCT01656031|DRUG|clofarabine|
214622617|NCT01656031|DRUG|cytarabine|
214622618|NCT05668624|OTHER|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
214622619|NCT04392115|BEHAVIORAL|The PREPARE program|"A home-based exercise program guided by paper materials, weekly phone calls, and a DVD.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
214622620|NCT01922817|DRUG|Saxagliptin|5mg saxagliptin
214622621|NCT06469996|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.
214622622|NCT06469996|OTHER|Self myofascial relaxation|Self myofascial relaxation will be practiced with foam roller in patients with Fibromyalgia.
214622623|NCT00145028|DRUG|Carboplatin|
214622624|NCT02185950|DEVICE|ultrasound|
214622625|NCT02185950|DEVICE|paraffin|
214622626|NCT02185950|DEVICE|endermotherapy|
214622627|NCT03687151|OTHER|non intervention / observationnal|non intervention / observationnal
214622628|NCT01875783|DEVICE|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
214622629|NCT05080465|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
214622630|NCT03877562|DRUG|Olanzapine|Olanzapine 10 mg oral tablet
214622631|NCT03877562|DRUG|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
214622632|NCT03877562|DRUG|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
214622633|NCT04172714|DEVICE|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
214622634|NCT00146315|BEHAVIORAL|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
214622635|NCT00146315|BEHAVIORAL|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
214622636|NCT05019898|DIAGNOSTIC_TEST|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~* The quantification of their anxiety~* An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
214622637|NCT05015075|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
214622638|NCT01512602|BEHAVIORAL|DBT|16 weeks DBT treatment
214622639|NCT01512602|BEHAVIORAL|CAMS|CAMS-informed psychotherapy
214622640|NCT01710384|DRUG|betamethasone|
214622641|NCT02572726|DEVICE|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
214622642|NCT02572726|DEVICE|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
214622643|NCT01170520|DEVICE|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
214717793|NCT01600391|BEHAVIORAL|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
214717794|NCT01600391|BEHAVIORAL|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
214717795|NCT00511108|DRUG|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
214717796|NCT00511108|DRUG|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
214622644|NCT01528111|DRUG|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
214622645|NCT01528111|DRUG|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
214622646|NCT01528111|DRUG|LX7101 Vehicle|Subjects will receive vehicle
214717797|NCT00511108|DRUG|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
214717798|NCT00511108|DRUG|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
214717799|NCT01234311|DRUG|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
214717800|NCT01234311|DRUG|Placebo|
214717801|NCT03186040|DRUG|Lacosamide|Sodium channel blocker
214717802|NCT02698566|DRUG|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
214717803|NCT05560919|DRUG|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
214717804|NCT05560919|OTHER|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
214717805|NCT05560919|OTHER|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
214717806|NCT00163163|PROCEDURE|Echographic measurements|
214717807|NCT00163163|PROCEDURE|Blood samples|
214717808|NCT02528799|BIOLOGICAL|Nexvax2|Nexvax2 intra-dermal injections twice weekly
214717809|NCT02528799|BIOLOGICAL|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
214717810|NCT02147691|DRUG|Azelaic acid 15%|Applied to the face each AM and PM
214717811|NCT02147691|DRUG|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
214717812|NCT02404584|GENETIC|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
214717813|NCT02404584|BIOLOGICAL|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
214717814|NCT02579902|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
214717815|NCT02579902|DIETARY_SUPPLEMENT|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
214717816|NCT02260674|DRUG|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
214717817|NCT02260674|DRUG|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
214717818|NCT02260674|DRUG|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
214717819|NCT06186492|DRUG|WVE-006|RNA editing oligonucleotide
214622647|NCT05917561|DRUG|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
214622648|NCT05917561|DRUG|Placebo|Placebo once a month, infusion for 36 weeks
214622649|NCT04164836|DIAGNOSTIC_TEST|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
214622650|NCT04790877|OTHER|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
214622651|NCT04790877|OTHER|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
214622652|NCT05352204|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
214717820|NCT02954952|DEVICE|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
214622653|NCT03923543|DIAGNOSTIC_TEST|Neutrophil to lymphosit ratio|
214622654|NCT01761084|BEHAVIORAL|Exercise and behaviour change strategies|"1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
214717821|NCT02954952|DEVICE|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
214717822|NCT02382770|PROCEDURE|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
214622655|NCT04659265|OTHER|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
214622656|NCT06477874|PROCEDURE|Dental implants placement|implants placed in consolidated bone grafts
214622657|NCT00940589|DRUG|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
214717823|NCT04866823|BEHAVIORAL|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
214717824|NCT04179032|COMBINATION_PRODUCT|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
214717825|NCT06183242|DRUG|Remaxa, enteric-coated tablets|enteric-coated tablets
214717826|NCT06183242|DRUG|Remaxol|solution for infusions
214622658|NCT00940589|DRUG|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
214622659|NCT00573430|DRUG|Candesartan Cilexetil|8 mg oral once daily dose
214622660|NCT00573430|DRUG|Candesartan Cilexetil|16 mg oral once daily dose
214622661|NCT00573430|DRUG|Candesartan Cilexetil 32mg|32 mg oral once daily dose
214622662|NCT00429403|DRUG|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
214622663|NCT03437382|DEVICE|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
214622664|NCT02194751|BIOLOGICAL|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
214622665|NCT00099970|DRUG|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
214622666|NCT01262521|DIETARY_SUPPLEMENT|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
214622667|NCT01262521|DIETARY_SUPPLEMENT|Water|150 ml Chapelle mineral water
214717827|NCT06183242|DRUG|Placebo|enteric-coated tablets
214717828|NCT06667674|BEHAVIORAL|iCBT for prolonged grief|Participants will undergo a 10-week internet-delivered, therapist-led cognitive behavioral therapy treatment (iCBT) for prolonged grief, which includes psychoeducation about grief and common grief reactions, exposure, cognitive restructuring and behavioral activation.
214717829|NCT06667674|BEHAVIORAL|Active control|Participants will undergo a 10-week internet-delivered, therapist-led treatment, which includes psychoeducation about grief and common grief reactions.
214622669|NCT05630079|DEVICE|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
214717830|NCT04703244|PROCEDURE|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
214622670|NCT05630079|DEVICE|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% \[-\] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
214622671|NCT06096402|PROCEDURE|no intervention, but surgical practice as usual is continued. Its a pragmatic study|no intervention
214622672|NCT02838498|DEVICE|ERCP Mechanical Simulator (EMS)|Hands on EMS training
214622673|NCT05266937|COMBINATION_PRODUCT|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
214717831|NCT03470857|DIAGNOSTIC_TEST|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
214622674|NCT03005795|DEVICE|Headphones|Music can be heard through headphones
214622675|NCT03005795|OTHER|No Headphones|No Headphones will be used.
214622676|NCT06033573|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
214622677|NCT00865059|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
214622678|NCT00865059|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
214622679|NCT04185090|COMBINATION_PRODUCT|ID1803|Amlodipine 10mg/Valsartan 160mg
214622680|NCT04185090|COMBINATION_PRODUCT|ID1801|Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
214622681|NCT04185090|COMBINATION_PRODUCT|ID1803+ID1801|Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
214622682|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
214622683|NCT04962022|DRUG|Itraconazole|Administered orally once daily for 8 days from Days 1 through 8
214622684|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
214622685|NCT05988775|BEHAVIORAL|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
214622686|NCT05988775|BEHAVIORAL|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
214622687|NCT05988775|OTHER|Nature movie watching|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
214717832|NCT03210220|PROCEDURE|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
214717833|NCT02268448|DRUG|Clonidine|
214717834|NCT02268448|DRUG|Naltrexone|
214717835|NCT00178061|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
214717836|NCT02911519|OTHER|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
214622688|NCT00006451|DRUG|anti-thymocyte globulin|
214622689|NCT00006451|DRUG|cyclophosphamide|
214622690|NCT00006451|DRUG|cyclosporine|
214622691|NCT00006451|DRUG|methotrexate|
214622692|NCT00006451|DRUG|methylprednisolone|
214622693|NCT00006451|PROCEDURE|allogeneic bone marrow transplantation|
214622694|NCT00006451|PROCEDURE|in vitro-treated bone marrow transplantation|
214622695|NCT00006451|PROCEDURE|radiation therapy|
214622696|NCT05914636|BIOLOGICAL|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
214622697|NCT02841397|DEVICE|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
214622698|NCT00071695|DRUG|Duloxetine Hydrochloride|
214622699|NCT00071695|DRUG|Venlafaxine Extended Release|
214622700|NCT00354770|DRUG|Placebo|daily
214622701|NCT00354770|DRUG|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
214622702|NCT02093806|OTHER|measurment|
214622703|NCT03782402|DRUG|Cannabinoids|Cannabinoids with THC and CBD versus placebo cannabinoids
214622704|NCT04240015|OTHER|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
214622705|NCT01146873|DRUG|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
214717837|NCT02911519|OTHER|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
214717838|NCT02667522|BEHAVIORAL|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
214622706|NCT01146873|DRUG|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
214622707|NCT01146873|DRUG|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
214622708|NCT01146873|DRUG|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
214622709|NCT06398548|OTHER|Control Group|Participants continue with their lifestyle as usual, with no modification to lifestyle, or exercise habits.
214717839|NCT06021847|OTHER|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
214717840|NCT06021847|OTHER|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
214717841|NCT00722098|BIOLOGICAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
214622710|NCT06398548|OTHER|Moderate Intensity Continuous Training|This group cycles at 70% of the resistance associated with their first lactate threshold.
214622711|NCT06398548|OTHER|Heavy Intensity Continuous Training|This group cycles at 10% of the difference between the resistance associated with their lactate threshold, and maximal achieved watts, added to the resistance associated with their lactate threshold.
214622712|NCT04647591|OTHER|Questionnaires|Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
214622713|NCT02616549|BEHAVIORAL|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
214622714|NCT01967628|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
214622715|NCT01967628|DIETARY_SUPPLEMENT|Placebo Sugar Pill|
214622716|NCT01545479|DRUG|captopril 25mg|renal blood oxygenation after captopril
214622717|NCT01356407|DRUG|PICOPREP|
214622718|NCT01356407|DRUG|PEG-ELS|
214622719|NCT04439604|OTHER|regional ventilation monitoring|regional ventilation monitoring
214622720|NCT01826279|DIETARY_SUPPLEMENT|Resveratrol|500mg 3 times daily for 1 month
214622721|NCT01826279|OTHER|Placebo|1 placebo tablet 3 times daily for 1 month
214622722|NCT04496622|OTHER|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
214622723|NCT04496622|OTHER|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
214622724|NCT00841802|DRUG|Prednisone|Prednisone 30mg once daily x 5 days
214622725|NCT03331055|DEVICE|PENS|percutaneous electrical nerve stimulation
214622726|NCT03331055|DEVICE|TENS|transcutaneous electrical nerve stimulation
214622727|NCT02970825|OTHER|Exercise|Moderate to high intensity physical training
214622728|NCT02970825|OTHER|Relaxation|Low intensity physical activity and relaxation
214622729|NCT05011929|BEHAVIORAL|Cognitive behavioral therapy|refer to the arm description
214622730|NCT00120991|PROCEDURE|Coronary artery bypass grafting|
214622731|NCT03827824|DEVICE|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
214622732|NCT03827824|DEVICE|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
214622733|NCT02820311|DRUG|TD-4208 175 mcg|via nebulizer
214622734|NCT02820311|DRUG|TD-4208 700 mcg|via nebulizer
214622735|NCT02820311|DRUG|Placebo for TD-4208|via nebulizer
214622736|NCT02820311|DRUG|Moxifloxacin 400 mg|oral
214622737|NCT02936583|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
214622738|NCT02317861|DRUG|RDEA3170|Oral Treatment
214622739|NCT02317861|DRUG|Febuxostat|Oral Treatment
214622740|NCT02317861|DRUG|Benzbromarone|Oral Treatment
214622741|NCT02192203|DRUG|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
214622742|NCT02192203|DRUG|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
214622743|NCT02192203|DRUG|Menthol Only Gel|3% menthol
214622744|NCT02192203|DRUG|Placebo Only Gel|0.09% menthol
214622745|NCT02055820|DRUG|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
214622746|NCT02055820|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
214622747|NCT02055820|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
214622748|NCT02055820|DRUG|Rituximab|Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
214622749|NCT02055820|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
214622750|NCT02055820|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
214622751|NCT02055820|DRUG|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
214622752|NCT04652323|DRUG|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
214622753|NCT02636088|DRUG|Cetuximab|
214622754|NCT02362958|DRUG|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
214622755|NCT04539561|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
214622756|NCT00877812|DIETARY_SUPPLEMENT|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
214622757|NCT00877812|DIETARY_SUPPLEMENT|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
214622758|NCT04784182|DIETARY_SUPPLEMENT|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
214622759|NCT04784182|DIETARY_SUPPLEMENT|placebo|Daily consumption of visually similar placebo pills
214622760|NCT03098823|DRUG|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
214622761|NCT03098823|DRUG|Prednisone|FDA approved corticosteroid frequently used for SLE.
214622762|NCT05583929|OTHER|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
214622763|NCT03007056|OTHER|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
214622764|NCT04193163|DEVICE|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
214622765|NCT01389752|DRUG|LY2216684|Administered orally
214622766|NCT01389752|DRUG|Activated Charcoal|Administered orally
214622767|NCT01401725|BEHAVIORAL|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
214622768|NCT01401725|BEHAVIORAL|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
214622769|NCT01401725|OTHER|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
214622770|NCT00315744|DRUG|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
214622771|NCT00315744|DRUG|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
214622772|NCT00315744|DRUG|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
214622773|NCT05142527|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
214622774|NCT05142527|OTHER|Placebo|Placebo
214622775|NCT04435509|DIETARY_SUPPLEMENT|1000+ Greek Mountain Tea|Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month
214622776|NCT04435509|OTHER|Mediterranean Diet|a Mediterranean dietary protocol
214622777|NCT04986462|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
214622778|NCT04153721|BEHAVIORAL|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
214717842|NCT00722098|BIOLOGICAL|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
214717843|NCT01707095|OTHER|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
214717844|NCT01707095|OTHER|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
214717845|NCT00839436|DRUG|CYT107|
214622779|NCT02949180|DEVICE|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
214622780|NCT03001050|DEVICE|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
214622781|NCT01063075|DRUG|Cetuximab|Administered Intravenously
214622782|NCT01063075|DRUG|Carboplatin|Administered Intravenously
214717846|NCT01578590|DIETARY_SUPPLEMENT|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
214717847|NCT05854797|OTHER|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
214622783|NCT01063075|DRUG|5 - FU|Administered Intravenously
214622784|NCT04243850|DRUG|Empagliflozin 10 MG|Jardiance
214622785|NCT04243850|DRUG|Placebo oral tablet|Placebo
214622786|NCT04243850|DIAGNOSTIC_TEST|Caffeine|caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
214622787|NCT03624699|DEVICE|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
214622788|NCT04643756|OTHER|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
214622789|NCT04643756|OTHER|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
214622790|NCT01157364|DRUG|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
214622791|NCT01157364|DRUG|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
214622792|NCT01157364|DRUG|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
214622793|NCT01157364|DRUG|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
214622794|NCT01157364|DRUG|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
214622795|NCT01157364|DRUG|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
214622796|NCT01157364|DRUG|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
214622797|NCT02243254|DRUG|high dose remifentanil|high dose remifentanil
214622798|NCT02243254|DRUG|Ibuprofen|intravenous ibuprofen
214622799|NCT02243254|DRUG|low dose remifentanil|low dose remifentanil
214622800|NCT03720431|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
214622801|NCT03716401|DIAGNOSTIC_TEST|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
214622802|NCT03716401|DIAGNOSTIC_TEST|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
214622803|NCT03716401|PROCEDURE|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
214622804|NCT03716401|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
214622805|NCT03716401|DIAGNOSTIC_TEST|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
214622806|NCT00482430|DRUG|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
214622807|NCT00482430|DRUG|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
214622808|NCT02410135|DRUG|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
214622809|NCT02891304|OTHER|Quarterly Feedback|Learning curves received quarterly vs. annually
214622810|NCT00541554|DRUG|Abilify (aripiprazole)|
214622811|NCT02529787|DRUG|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
214622812|NCT02529787|DRUG|Dexilant|1 capsule contains 60 mg Dexlansoprazole
214622813|NCT01594515|DRUG|BI 1015550|High dose powder for oral solution
214622814|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
214622815|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
214622816|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
214622817|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
214622818|NCT01594515|DRUG|Placebo|Solution for oral administration
214622819|NCT01594515|DRUG|BI 101550|High dose powder for oral solution
214622820|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
214622821|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
214622822|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
214622823|NCT02170285|DEVICE|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
214622824|NCT02170285|DEVICE|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
214622825|NCT01195129|DEVICE|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
214622826|NCT01195129|DEVICE|Non-hydrogel coils|Cerecyte or bare platinum coils
214622827|NCT04327687|DEVICE|Remote ischaemic conditioning|5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
214622828|NCT04327687|OTHER|conventional therapy|conventional therapy
214622829|NCT04362280|BEHAVIORAL|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
214622830|NCT04362280|BEHAVIORAL|TAU|PE class as usual led by PE teacher.
214622831|NCT04085679|OTHER|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
214622832|NCT01730508|DRUG|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
214622833|NCT04756700|DIAGNOSTIC_TEST|DigiCog (BCCAMS app)|Administered as specified in the treatment arm.
214622834|NCT04756700|DIAGNOSTIC_TEST|Konectom Application|Administered as specified in the treatment arm.
214622835|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
214622836|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
214622837|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
214622838|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
214622839|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
214622840|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
214622841|NCT03957265|PROCEDURE|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
214622842|NCT00643526|DEVICE|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
214622843|NCT06273007|OTHER|PartoMa intervention(Locally achievable intrapartum care guideline), in house LDHF trainings|We will implement PartoMa interventions: seminars, LDHF training, and supportive supervision
214622844|NCT03048539|PROCEDURE|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
214622845|NCT00303147|BEHAVIORAL|Expressive Writing|
214622846|NCT01079273|BIOLOGICAL|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
214622847|NCT01713621|DRUG|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
214622848|NCT04251910|DRUG|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
214622849|NCT04251910|DRUG|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
214622850|NCT03559036|PROCEDURE|Locomotor Training|Body-weight supported stepping on a treadmill.
214622851|NCT01722604|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
214622852|NCT01722604|DRUG|Azopt 1%|Azopt 1%, RLD
214622853|NCT00528515|DRUG|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
214622854|NCT00528515|DRUG|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
214622855|NCT06174844|OTHER|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
214717848|NCT05854797|OTHER|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
214622856|NCT03467464|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
214717849|NCT05466981|BEHAVIORAL|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
214717850|NCT01521572|DRUG|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
214717851|NCT04969367|OTHER|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
214717852|NCT04969367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214717853|NCT04969367|OTHER|Questionnaire Administration|Complete questionnaires
214622857|NCT03880942|OTHER|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
214622858|NCT03880942|OTHER|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
214717854|NCT04969367|OTHER|Quality-of-Life Assessment|Complete questionnaires
214717855|NCT03402282|PROCEDURE|embolization|upper rectal artery embolization with coils
214717856|NCT03402282|PROCEDURE|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
214622859|NCT04303130|DRUG|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
214622860|NCT03135275|PROCEDURE|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
214622861|NCT03135275|PROCEDURE|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
214622862|NCT03135275|DEVICE|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
214717857|NCT03460288|BEHAVIORAL|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
214622863|NCT00487136|DRUG|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
214717858|NCT04202978|DRUG|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
214622864|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
214622865|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
214717859|NCT04202978|DRUG|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
214622866|NCT00006047|DRUG|Oral Etoposide|
214622867|NCT00006047|DRUG|Oral 9-Nitrocamptothecin|
214717860|NCT04202978|DRUG|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
214717861|NCT04202978|DRUG|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
214717862|NCT04202978|RADIATION|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
214717863|NCT00364819|DRUG|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
214622868|NCT06466304|BEHAVIORAL|inspiratory muscle training|children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
214622869|NCT04776473|PROCEDURE|Open treatment|Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
214622870|NCT04776473|OTHER|Closed treatment|Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
214622871|NCT06385730|DRUG|neoadjuvant anti-PD-1|PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
214622872|NCT06385730|DRUG|neoadjuvant anti-PD-1 with LDRT|"Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators"
214622873|NCT00489814|BEHAVIORAL|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
214622874|NCT06490016|DEVICE|web based education|"The web page will be prepared with professional support in line with the guidelines of the Web Content Accessibility Guide (WCAG / WIEK 2.1) developed by W3C.~1. st meeting: online Informed Consent will be obtained. After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out online.~2. nd interview: Module 1-2.~3. rd interview: Module 3 -4.~4. th meeting: Module 5.They will be asked to fill out the System Usability Scale.~5. th interview: During the first menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online.~6. th interview: During the second menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online."
214622875|NCT06490016|BEHAVIORAL|Face to face|"In face-to-face training, female internal reproductive organ models, female external reproductive organ models, training content prepared with Braille alphabet, menstrual hygiene management kit (underwear, pads, napkins, calendar) materials will be used. Pictures and audio descriptions will be used in web-based training.~1. st interview: Informed Consent . After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out.~2. nd meeting: Module 1-2~3. rd meeting: Module 3- 4~4. th meeting: Module 5.~5. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed.~6. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed."
214622876|NCT05352152|DIAGNOSTIC_TEST|Next generation sequence|Next generation sequence will be used to detect the pathogens in ascites.
214622877|NCT02707380|OTHER|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
214622878|NCT02707380|OTHER|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
214622879|NCT01547169|DRUG|Placebo Comparator|saline, taken twice per day for a 3 week duration
214622880|NCT01547169|DRUG|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
214622881|NCT01547169|DRUG|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
214622882|NCT00724997|BIOLOGICAL|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
214622883|NCT00803699|DIETARY_SUPPLEMENT|placebo|daily placebo capsules for 12 months
214622884|NCT00803699|DIETARY_SUPPLEMENT|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
214622885|NCT00841568|DRUG|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
214622886|NCT00133991|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
214622887|NCT00133991|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
214622888|NCT00133991|DRUG|Cyclophosphamide|1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
214622889|NCT00133991|DRUG|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
214622890|NCT00133991|DRUG|Methotrexate|3 g/m\^2 on Day 8 of each cycle of R-CVP.
214622891|NCT00133991|DRUG|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
214622892|NCT00133991|DRUG|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
214622893|NCT00133991|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
214622894|NCT00133991|DRUG|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
214622895|NCT03002155|OTHER|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
214622896|NCT00763230|DEVICE|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
214622897|NCT03819348|OTHER|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
214622898|NCT01498198|PROCEDURE|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
214622899|NCT01498198|OTHER|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
214622900|NCT00978029|DRUG|Placebo|Placebo sublingual tablet, once daily
214622901|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
214622902|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
214622903|NCT01230281|OTHER|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
214622904|NCT01830751|OTHER|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
214622905|NCT04972474|OTHER|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
214622906|NCT04341220|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
214622907|NCT04341220|OTHER|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
214622908|NCT04178694|DEVICE|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
214622909|NCT01556139|DEVICE|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
214622910|NCT00002364|DRUG|Abacavir sulfate|
214622911|NCT01483716|BEHAVIORAL|Rehabilitation|
214622912|NCT05774379|DEVICE|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
214622913|NCT05774379|BEHAVIORAL|fatigue education|fatigue education for children
214622914|NCT06489496|DIAGNOSTIC_TEST|18F-1007 PSMA PSMA PET/CT|"Each patient will receive an IV injection 18F-PSMA-1007 PET/CT.~PET/CT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq/kg (max 400 MBq +/- 15%) 18F-PSMA-1007 in patients."
214622915|NCT01087775|BEHAVIORAL|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
214622916|NCT00454259|DRUG|Fentanyl/Placebo injection|Ultra low dose intravenous injection
214622917|NCT04562207|DIAGNOSTIC_TEST|Screening for respiratory virus infection|Nasopharyngeal swab for screening for respiratory virus infection before surgery
214622918|NCT06476210|DRUG|BDL regimen|"Drug:bedaquiline 100mg tablets~Other Names:~Bdq TMC-207 bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week~Drug:delamanid 50mg tablets~Other Names:~Dlm OPC-67683 delamanid 100mg 2 times daily~Drug:linezolid Scored 600mg tablets~Other Names:~Lzd linezolid 600mg once daily"
214622919|NCT05354011|OTHER|Kinesiotape|Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain
214622920|NCT05354011|OTHER|Active Release Technique|This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
214622921|NCT02153528|DRUG|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
214622922|NCT02153528|DRUG|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
214622923|NCT01068691|PROCEDURE|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"* Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~* Blood pressure~* Obstructive sleep apnea syndrome (OSAS)~* Carotid-to-femoral pulse wave velocity (PWV)~* Biological parameters"
214622924|NCT00426257|PROCEDURE|Secondary debulking|Secondary debulking
214622925|NCT00426257|PROCEDURE|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
214622926|NCT00272064|DRUG|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
214622927|NCT00272064|DRUG|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
214622928|NCT00272064|DRUG|Metformin|1000 mg b.i.d, since the qualification phase, oral
214622929|NCT04948775|OTHER|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
214622930|NCT05523037|DRUG|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
214622931|NCT05523037|DRUG|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
214622932|NCT06029621|PROCEDURE|RATS for Thymectomy|a minimally invasive surgical type for Thymoma: RATS
214622933|NCT06029621|PROCEDURE|VATS for Thymectomy|a minimally invasive surgical type for Thymoma: VATS
214622934|NCT01711411|DEVICE|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
214622935|NCT01024010|DRUG|Cyclophosphamide|Given IV
214622936|NCT01024010|OTHER|Laboratory Biomarker Analysis|Correlative studies
214622937|NCT01024010|BIOLOGICAL|Ofatumumab|Given IV
214622938|NCT01024010|DRUG|Pentostatin|Given IV
214622939|NCT00841789|DRUG|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
214622940|NCT00841789|DRUG|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
214622941|NCT03215420|DIAGNOSTIC_TEST|MRI 3T|
214622942|NCT05458765|DRUG|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
214622943|NCT05458765|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
214622944|NCT00784381|DEVICE|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
214622945|NCT03573427|DEVICE|Trans-atrial septal placement LV lead for CRT|
214622946|NCT01055600|DRUG|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
214622947|NCT01452763|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
214622948|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
214622949|NCT01452763|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
214622950|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
214622951|NCT01452763|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
214622952|NCT01452763|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
214622953|NCT03983577|OTHER|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
214622954|NCT03407638|OTHER|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
214622955|NCT04933175|DRUG|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
214622956|NCT04933175|DRUG|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
214622957|NCT05650801|OTHER|Music Therapy|Therapy using a traditional music originally from Indonesian culture
214622958|NCT05591118|DRUG|Anticoagulant Therapy|All subjects will receive anticoagulation for a minimum of 3 months.
214622959|NCT05591118|DEVICE|Catheter-Directed Therapy|The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
214622960|NCT00452751|PROCEDURE|laparoscopy-assisted distal gastrectomy|
214622961|NCT00452751|PROCEDURE|open distal gastrectomy|
214622962|NCT06282042|PROCEDURE|Early transcatheter edge-to-edge mitral valve repair (TEER).|TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.
214622963|NCT06282042|DEVICE|MitraClip|MitraClip
214622964|NCT06282042|OTHER|Optimal medical treatment|Optimal medical treatment
214622965|NCT05984342|DRUG|Tislelizumab|Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
214622966|NCT01803984|DEVICE|MRI|
214622967|NCT01803984|DEVICE|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
214622968|NCT01803984|OTHER|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
214622969|NCT02642445|DEVICE|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
214622970|NCT05809414|DEVICE|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
214622971|NCT05809414|DRUG|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
214622972|NCT02725723|DEVICE|Therm-AppTM TH, thermographic camera|
214622973|NCT02725723|DRUG|epidural injection|
214622974|NCT04075838|OTHER|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
214622975|NCT01748279|DRUG|Atorvastatin|
214622976|NCT01748279|DRUG|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
214622977|NCT01748279|DRUG|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
214622978|NCT03009032|DIETARY_SUPPLEMENT|PMT25341|
214622979|NCT03009032|DIETARY_SUPPLEMENT|Placebo|Lactose
214622980|NCT04294875|DRUG|MPT0B640|PO, every 3 days. dose escalation per MTD
214622981|NCT02026895|GENETIC|Genetic blood sample|
214622982|NCT04227509|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
214622983|NCT04227509|DRUG|Placebo|normal saline will be administered as a 30 minute IV infusion every 3 weeks.
214622984|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
214622985|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
214622986|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
214622987|NCT00534339|DEVICE|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
214622988|NCT01478035|DRUG|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
214622989|NCT01478035|DRUG|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
214622990|NCT02263898|DRUG|Raf kinase inhibitor LGX818|Given PO
214622991|NCT02263898|DRUG|binimetinib|Given PO
214622992|NCT02263898|OTHER|laboratory biomarker analysis|Correlative studies
214622993|NCT03454022|BEHAVIORAL|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
214622994|NCT03454022|BEHAVIORAL|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
214622995|NCT00563628|DEVICE|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
214622996|NCT06306521|GENETIC|BeginNGS Test|Genomic sequencing that screens for over 400 genetic diseases.
214622997|NCT04443543|DRUG|Capecitabine (Xeloda) Pharmacogenetic Test Reagents|CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
214622998|NCT04443543|DRUG|irinotecan|CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
214622999|NCT04443543|RADIATION|IMRT|Pelvic Radiation: 50Gy/25Fx
214623000|NCT04443543|DRUG|Oxaliplatin|FOLFIRINOX: 85mg/m2 d1
214623001|NCT04443543|DRUG|5Fluorouracil|FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
214623002|NCT04443543|DRUG|Tislelizumab|200mg iv
214623003|NCT03514342|PROCEDURE|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
214623004|NCT03514342|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
214623005|NCT00319774|DEVICE|Hemocontrol Biofeedback System|
214623006|NCT00878371|DRUG|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
214623007|NCT00964743|DRUG|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
214623008|NCT00964743|DRUG|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
214623009|NCT00277511|DRUG|Levofloxacin|
214623010|NCT03778619|DRUG|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
214623011|NCT03778619|DRUG|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
214623012|NCT03778619|DRUG|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
214623013|NCT03778619|BIOLOGICAL|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
214623014|NCT03778619|DRUG|Interleukin-2|1 x 10\^6 IU/m2, together with MG4101
214623015|NCT00781911|BIOLOGICAL|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
214623016|NCT00781911|DRUG|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
214623017|NCT04966546|DRUG|Memantine Hydrochloride|Active drug arm
214623018|NCT04966546|DRUG|Placebo|Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
214623019|NCT05650489|OTHER|assessment|correlation between Autistic features, motor function and quality of life
214623020|NCT06416904|DEVICE|archwire stopper mesial to the maxillary first molar group|canine retraction after the extraction of the maxillary first premolars with archwire stoppers is mesial to the maxillary first molars.
214623021|NCT06416904|DEVICE|inter-radicular mini-screw|canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
214623022|NCT05858021|DIAGNOSTIC_TEST|Physical examination|"Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA."
214717864|NCT04874844|BIOLOGICAL|Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)|"The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials."
214717865|NCT04227067|DEVICE|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
214717866|NCT04227067|DEVICE|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
214623023|NCT03212053|BIOLOGICAL|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
214623024|NCT03658265|OTHER|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
214623025|NCT03658265|OTHER|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
214623026|NCT03658265|OTHER|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
214623027|NCT03658265|OTHER|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
214623028|NCT03424785|OTHER|drug, stent, surgical treatment|drug, stent, surgical treatment
214623029|NCT02698670|DEVICE|Rhythmia mapping system|A 3-D Cardiac Mapping system
214623030|NCT02698670|DEVICE|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
214623031|NCT00651417|DIETARY_SUPPLEMENT|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
214623032|NCT00651417|DIETARY_SUPPLEMENT|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
214623033|NCT01274975|OTHER|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
214717867|NCT01901978|BEHAVIORAL|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
214717868|NCT00086216|DRUG|Atiprimod|Oral, once a day, 14 days on 14 days off
214717869|NCT01444898|DRUG|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
214717870|NCT02238782|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
214717871|NCT02238782|OTHER|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
214623034|NCT05981170|OTHER|Adapted physical activity at home|"The programme will take place over 6 months and will include :~1 consultation with the oncologist who will first assess the need for Adapted Physical Activity and then prescribe the APA with a certificate of no physical contraindication~1 consultation with the ICO's APA coach who will present the APA programme and assess the patient's physical capacity using the Short Physical Performance Battery (SPPB) test in order to adapt the programme to their needs.~13 home-based APA sessions (ideally one session per week) with the EAPA from Departmental Committee for Sport for All in 49~1 telephone call with the EAPA of the ICO to evaluate the programme 3 months after the last session.~Patients will also be asked to complete questionnaires at the first session (S1), halfway through the sessions (S6) and at the last session (S13).~These are FACIT-F 5Functional Assessment of Chronic Illness Therapy - Fatigue ; Ricci and L. Gagnon ; P-GIC (Patients' Global Impression of Change (PGIC) scale)"
214623035|NCT02086786|DRUG|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
214623036|NCT01530204|PROCEDURE|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
214623037|NCT01530204|BEHAVIORAL|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
214623038|NCT01530204|OTHER|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
214623039|NCT04049838|PROCEDURE|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
214623040|NCT03317795|DRUG|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
214623041|NCT03317795|DRUG|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
214717872|NCT06370949|DRUG|Bupivacain|Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
214623042|NCT02918383|DIAGNOSTIC_TEST|Indocyanin Green Dye (ICG)|
214623043|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg"
214623044|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg"
214623045|NCT03187431|BIOLOGICAL|autologous bone marrow mesenchymal stem cells|intravenous infusion
214623046|NCT00939783|DRUG|Dimebon|Tablet for oral administration
214623047|NCT02336490|OTHER|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
214623048|NCT02189161|DEVICE|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
214623049|NCT06174623|DEVICE|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
214623050|NCT02373059|OTHER|Diabetes Issue Cards Decision Aids|
214623051|NCT02373059|OTHER|Usual Pharmaceutical Care|
214623052|NCT01425827|DRUG|duloxetine HCL|60 mg/day duloxetine for 16 weeks
214623053|NCT01425827|DRUG|placebo|similar looking tablets to the active agent for 16 weeks
214623054|NCT06360991|DEVICE|Deep brain stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (vALIC, BNST, amSTN, VC/VS, or NAc) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
214623055|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
214623056|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
214623057|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
214623058|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
214623059|NCT00435838|DRUG|No Intervention -- Observational study|
214717873|NCT06370949|DRUG|bupivacain+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
214623060|NCT05939024|OTHER|Muscle Energy Technique plus Conventional Physical Therapy|Post-Isometric Relaxation of the Muscle Energy Techniques will be applied to Spinal Stabilizers and Mechanoreceptors. Hold time will be 7 seconds with 5 seconds rest between two performance x 3 times /session. Whereas, Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
214623061|NCT05939024|OTHER|Conventional Physical Therapy|Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
214623062|NCT01628471|DRUG|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
214623063|NCT04489745|RADIATION|SBRT|
214623064|NCT04489745|DRUG|Androgen deprivation therapy (ADT)|
214623065|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
214623066|NCT03015571|DEVICE|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
214623067|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
214623068|NCT03015571|DEVICE|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
214623069|NCT00479284|PROCEDURE|Average volume assured pressure support (AVAPS)|
214623070|NCT05754502|DRUG|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
214623071|NCT02718755|DRUG|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
214623072|NCT02718755|DRUG|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
214623073|NCT02718755|DRUG|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
214623074|NCT06183840|DEVICE|Glutack|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
214623075|NCT06183840|DEVICE|Conventional|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
214623076|NCT00905736|PROCEDURE|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
214623077|NCT00905736|PROCEDURE|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
214623078|NCT02386280|BEHAVIORAL|Motivational Interviewing for Change of Parenting Styles|
214623079|NCT02386280|BEHAVIORAL|Psicoeducation|
214623080|NCT06295939|OTHER|social support program|"Group 2, the experimental group, will receive routine nursing care from the assigned nurse and a social support program provided by the researcher, as follows:~Phase 1 (Before Pregnancy Termination)~Phase 2 (After Pregnancy Termination, Before Returning Home):"
214623081|NCT06295939|OTHER|Routine nursing care|The sample group will receive routine nursing care from the assigned nurse.
214623082|NCT04004650|PROCEDURE|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7\_vH2\_1ZZc
214623083|NCT04811456|OTHER|multisystem inflammatory syndrome in children (MIS-C)|as in group description
214623084|NCT00713427|DEVICE|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
214623085|NCT03672409|BEHAVIORAL|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
214623086|NCT00896207|DRUG|Akt inhibitor SR13668|Given orally as a single dose
214623087|NCT06022952|OTHER|Stone MD stent radar|Mobile app
214623088|NCT03297736|DEVICE|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
214623089|NCT03297736|DEVICE|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
214623090|NCT01298752|DRUG|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
214623091|NCT01298752|DRUG|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
214623092|NCT00455689|DRUG|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
214623093|NCT03969121|DRUG|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
214623094|NCT03969121|DRUG|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
214623095|NCT01824277|OTHER|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
214623096|NCT00638001|DEVICE|custom-molded insoles and custom-molded shoes|"* custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~* custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
214623097|NCT01549002|DRUG|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
214623098|NCT01549002|DRUG|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
214623099|NCT04655443|OTHER|Standard Care|Standard cardiovascular care
214623100|NCT06290206|BEHAVIORAL|PREVENT - BCT|"Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings)."
214623101|NCT05885100|DRUG|Eleveld Model|Target plasma propofol
214623102|NCT02438514|OTHER|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
214623103|NCT00663988|PROCEDURE|human transplantation|Allograft composite tissue transplantation. procedure. medication
214623104|NCT01664559|DRUG|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
214623105|NCT01664559|DRUG|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
214623106|NCT04113200|DIETARY_SUPPLEMENT|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
214623107|NCT04113200|DIETARY_SUPPLEMENT|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
214623108|NCT00864643|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
214623109|NCT00864643|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
214623110|NCT00111280|DRUG|TMC125|
214623111|NCT04168073|OTHER|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
214623112|NCT04168073|OTHER|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
214623113|NCT03569800|OTHER|self completed questionnaire|self completed questionnaire
214623114|NCT01509963|OTHER|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
214623115|NCT00083031|DRUG|bevacizumab|
214623116|NCT00083031|DRUG|cyclophosphamide|
214623117|NCT00083031|DRUG|methotrexate|
214623118|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
214717874|NCT01567423|DRUG|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
214717875|NCT01567423|DRUG|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
214623119|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
214623120|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
214623121|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
214623122|NCT03741114|PROCEDURE|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
214623123|NCT03741114|DRUG|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
214623124|NCT03741114|DRUG|Placebo|patients received 100 ml saline just before skin incision
214623125|NCT01918839|DEVICE|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
214623126|NCT01918839|DEVICE|Restylane-L|Restylane-L injected into wrinkle treatment area
214623127|NCT01880931|DRUG|Remifentanil|The effect site concentration of remifentanil
214623128|NCT01251367|BIOLOGICAL|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
214717876|NCT03029897|OTHER|My eReport France|"patients are educated to the use of My eReport France application"
214623129|NCT02255409|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
214623130|NCT02255409|BIOLOGICAL|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
214623131|NCT05872802|OTHER|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
214717877|NCT03261141|COMBINATION_PRODUCT|(PV-RQOL),(APA) ,Acoustic analysis|"1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
214623132|NCT05872802|OTHER|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
214623133|NCT04067570|RADIATION|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
214623134|NCT02114437|DEVICE|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
214623135|NCT02114437|DEVICE|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
214623136|NCT01353820|DIETARY_SUPPLEMENT|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( \>10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )
214623137|NCT01353820|DIETARY_SUPPLEMENT|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
214623138|NCT02189213|DRUG|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
214623139|NCT04457050|DRUG|Sofosbuvir 400 milligram|single daily dose of 400 milligrams
214623140|NCT04457050|DRUG|Daclatasvir 60 milligram|single daily dose of 60 milligrams for 12 weeks
214623141|NCT04457050|DRUG|Ribavirin 400 milligram|weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks
214623142|NCT04457050|DRUG|Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab|single daily dose for 12 weeks
214623143|NCT02016820|DRUG|Omeprazole (suspension)|1 mg/kg/day
214623144|NCT02016820|OTHER|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
214623145|NCT04474756|DEVICE|custom-made adjustable mandibular advancement device|a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
214623146|NCT00091104|BIOLOGICAL|MART-1:27-35 peptide vaccine|
214623147|NCT00091104|BIOLOGICAL|aldesleukin|
214623148|NCT00091104|BIOLOGICAL|filgrastim|
214623149|NCT00091104|BIOLOGICAL|incomplete Freund's adjuvant|
214717878|NCT02267369|BEHAVIORAL|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
214717879|NCT02267369|BEHAVIORAL|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
214623150|NCT00091104|BIOLOGICAL|therapeutic autologous lymphocytes|
214717880|NCT02267369|BEHAVIORAL|Basic fitness program|Participants can register workshops online and track program participation.
214623151|NCT00091104|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214623152|NCT00091104|DRUG|cyclophosphamide|
214623153|NCT00091104|DRUG|fludarabine phosphate|
214717881|NCT02580591|DRUG|Empagliflozin|
214717882|NCT02580591|DRUG|Placebo|For blinding purposes
214623154|NCT00091104|PROCEDURE|autologous hematopoietic stem cell transplantation|
214623155|NCT00091104|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214623156|NCT00091104|RADIATION|total-body irradiation|
214623157|NCT02134483|BIOLOGICAL|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
214623158|NCT02424253|DRUG|ZPL-3893787|ZPL-3893787
214623159|NCT02424253|DRUG|Placebo|Matched Placebo
214623160|NCT05773521|PROCEDURE|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
214623161|NCT00473343|DRUG|Metvix® cream|
214623162|NCT02261194|BEHAVIORAL|Self-Care Tools|
214623163|NCT00400673|BEHAVIORAL|Two-step remission induction and risk-oriented consolidation|
214717883|NCT00533169|DRUG|ZD6474|Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
214717884|NCT00533169|DRUG|Retinoic Acid|Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
214717885|NCT00696098|OTHER|sodium butyrate|1 enema (60 ml) once daily containing 100mM
214717886|NCT00696098|OTHER|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
214623164|NCT05782621|OTHER|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
214623165|NCT05782621|OTHER|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
214623166|NCT05782621|OTHER|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
214623167|NCT05107856|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
214623168|NCT05107856|DRUG|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
214623169|NCT05107856|DRUG|Venetoclax|Venetoclax will be administered orally
214623170|NCT00345176|DIETARY_SUPPLEMENT|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
214717887|NCT02582931|DEVICE|MRI-guided SBRT|
214717888|NCT02582931|BEHAVIORAL|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
214717889|NCT02582931|BEHAVIORAL|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
214623171|NCT00345176|DIETARY_SUPPLEMENT|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
214623172|NCT00345176|DRUG|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
214623173|NCT01886365|DEVICE|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
214623174|NCT01886365|OTHER|Conventional therapy with a fixed insulin dosing scheme|Routine care
214623175|NCT04452903|BEHAVIORAL|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
214717890|NCT03802240|DRUG|Sintilimab|200mg IV Q3W
214623176|NCT00935480|DRUG|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
214623177|NCT00935480|DRUG|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
214623178|NCT03359512|DEVICE|qCON monitor|supervision by qCON monitor of the depth of anesthesia
214717891|NCT03802240|DRUG|IBI305|15mg/kg IV Q3W
214717892|NCT03802240|DRUG|Pemetrexed|500mg/m2 IV Q3W
214717893|NCT03802240|DRUG|Cisplatin|75mg/m2 IV Q3W
214717894|NCT03802240|DRUG|Placebo1|Placebo1 IV Q3W
214717895|NCT03802240|DRUG|Placebo2|Placebo2 IV Q3W
214717896|NCT03304262|DEVICE|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
214717897|NCT03736668|DIAGNOSTIC_TEST|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
214623179|NCT03998046|BEHAVIORAL|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
214717898|NCT04127461|DEVICE|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
214623180|NCT03998046|BEHAVIORAL|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
214717899|NCT01937013|DRUG|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
214623181|NCT03998046|BEHAVIORAL|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
214623182|NCT02290873|DRUG|Remimazolam|For induction and maintenance of sedation
214623183|NCT02290873|DRUG|Midazolam|For induction of maintenance and sedation
214623184|NCT02290873|DRUG|Placebo|Inactive control arm
214623185|NCT00500630|DEVICE|Body fixed 3D sensors|
214623186|NCT02055105|PROCEDURE|miRNA in Sepsis|miRNA in Sepsis
214623187|NCT01136655|DRUG|80/2.25 μg Symbicort pMDI|inhalation
214623188|NCT01136655|DRUG|80/4.5 μg Symbicort pMDI|inhalation
214623189|NCT01136655|DRUG|Foradil Aerolizer 12 μg|inhalation
214623190|NCT01136655|DRUG|40 μg budesonide HFA pMDI|inhalation
214623191|NCT01136655|DRUG|placebo HFA pMDI|inhalation
214623192|NCT05435456|OTHER|Exercise|Strengthening and Relaxation Exercises
214623193|NCT02431572|OTHER|PBR PET|
214623194|NCT02431572|BIOLOGICAL|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
214623195|NCT02431572|RADIATION|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
214623196|NCT02031783|DIETARY_SUPPLEMENT|Mixture of glucose and fructose|
214623197|NCT02031783|DIETARY_SUPPLEMENT|glucose|
214623198|NCT04077450|BEHAVIORAL|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
214717900|NCT01937013|DRUG|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
214623199|NCT02633410|PROCEDURE|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
214623200|NCT00267033|PROCEDURE|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
214623201|NCT06036342|DIAGNOSTIC_TEST|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
214717901|NCT04572698|DRUG|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
214717902|NCT04572698|DRUG|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
214717903|NCT00655304|DEVICE|Prometheus (R) liver support dialysis|6-8 hours of dialysis
214717904|NCT00655304|DEVICE|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
214623202|NCT05880446|OTHER|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
214717905|NCT01402024|DRUG|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
214717906|NCT01402024|DRUG|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
214717907|NCT00561340|DIETARY_SUPPLEMENT|Pediasure|50% will be randomized to pediasure with nutritional counseling
214717908|NCT00561340|BEHAVIORAL|Nutritional counseling|50% randomized to nutritional counseling only
214717909|NCT00445341|DRUG|Flavopiridol|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
214717910|NCT02733471|DRUG|Lidocaine|
214717911|NCT02733471|DRUG|Placebo|Placebo
214717912|NCT00380406|DRUG|Leuprolide acetate|
214717913|NCT04880993|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
214717914|NCT04880993|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
214717915|NCT03879954|DEVICE|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
214717916|NCT04861311|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
214717917|NCT04397692|DEVICE|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
214717918|NCT04018157|DRUG|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
214717919|NCT00035568|DRUG|Glucovance (metformin HCl/glyburide)|
214717920|NCT00035568|DRUG|or Metformin HCl alone|
214717921|NCT00035568|DRUG|or Glyburide alone.|
214717922|NCT00134407|PROCEDURE|Normal diet|
214717923|NCT00134407|PROCEDURE|Nutrition via jejunal needle-catheter|
214717924|NCT03286296|BIOLOGICAL|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
214717925|NCT04240912|DEVICE|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
214717926|NCT06167772|DIETARY_SUPPLEMENT|BCAA|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days"
214717927|NCT06167772|OTHER|Standard nutrition|Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
214623203|NCT04455880|OTHER|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
214623204|NCT05761028|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
214623205|NCT05761028|OTHER|Placebo|Placebo
214623206|NCT03938779|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
214717928|NCT06167772|OTHER|Standard physiotherapy|A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
214717929|NCT01455506|DRUG|Decitabine plus Fludarabine and Busulfan|"* Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
214623207|NCT03938779|DIAGNOSTIC_TEST|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
214623208|NCT00685503|DRUG|Ranibizumab|
214623209|NCT02555943|DRUG|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
214717930|NCT02465255|DRUG|Ketorolac|
214717931|NCT02465255|DRUG|Tramadol|
214717932|NCT02465255|DRUG|Acetaminophen|
214717933|NCT00241449|DRUG|Fulvestrant|intramuscular injection 250 mg
214717934|NCT00241449|DRUG|Tamoxifen|20 mg oral tablet
214717935|NCT04752917|DEVICE|Noise Cancelling headphones|Use of headphones playing patients choice of music
214717936|NCT00137670|DEVICE|Video-based HIV/STD prevention intervention|
214717937|NCT01858896|DRUG|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
214623210|NCT02555943|DRUG|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
214623211|NCT02555943|DRUG|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
214623212|NCT02555943|DRUG|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
214623213|NCT02555943|DRUG|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
214623214|NCT03953066|OTHER|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
214623215|NCT00627887|PROCEDURE|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
214623216|NCT00627887|DRUG|venlafaxine|extended release target dose of 300mg/day duration of one year
214623217|NCT00627887|DRUG|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
214623218|NCT02278900|OTHER|Communication aids|Question Prompt list Audiofile
214623219|NCT02663388|PROCEDURE|gastric bypass, sleeve, gastric banding|
214717938|NCT01858896|OTHER|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
214717939|NCT03855241|BEHAVIORAL|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
214717940|NCT03855241|BEHAVIORAL|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
214717941|NCT02262338|DRUG|AGT-182|Recombinant HIRMAb-IDS
214717942|NCT04903704|DIAGNOSTIC_TEST|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
214717943|NCT00216268|DRUG|Ribavirin|
214717944|NCT02435862|DRUG|1.0mg Luminate®|
214717945|NCT02435862|DRUG|2.0mg Luminate®|
214717946|NCT02435862|DRUG|3.0mg Luminate®|
214717947|NCT02435862|OTHER|Balanced Salt Solution for intravitreal injection in 0.10cc|
214717948|NCT03199742|BEHAVIORAL|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
214717949|NCT03199742|BEHAVIORAL|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
214717950|NCT01476761|DEVICE|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
214623220|NCT04360759|DRUG|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
214717951|NCT00228410|DRUG|Tigecycline|
214717952|NCT00228410|DRUG|vancomycin with aztreonam|
214717953|NCT00047853|DEVICE|Shock device|A participant could receive a shock or not receive as shock
214717954|NCT00047853|DEVICE|Acoustic startle|Acoustic startle for MEG only
214717955|NCT00383877|DRUG|insulin detemir|
214717956|NCT00383877|DRUG|insulin NPH|
214717957|NCT02654470|DEVICE|Watchman FLX|Patients who are receiving the Watchman FLX device
214717958|NCT02090465|DRUG|Ingenol Mebutate|No intervention: observation of routine use of Picato®
214717959|NCT02229253|DRUG|degarelix|
214717960|NCT02443805|BIOLOGICAL|300 IR|300 IR tablet of HDM Allergen Extracts
214717961|NCT02443805|BIOLOGICAL|Placebo|Placebo tablet
214623221|NCT04496401|DRUG|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
214623222|NCT03045562|DRUG|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
214623223|NCT03045562|DRUG|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
214623224|NCT03080246|BEHAVIORAL|Strength Training Exercise|
214623225|NCT03518593|OTHER|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
214623226|NCT06476522|OTHER|Physiotherapy Program|In the first evaluation, 5 different exercises were shown and the patients were asked to do home exercises in accordance with the given program. The physiotherapist suggested starting with a 10-minute walk 5 times a week and then gradually increasing the walking time. The patients were given a program for balance and sensory training. They were asked to apply the physiotherapy program at least 3 days a week for 12 weeks. Weekly follow-up of the patients was carried out by the physiotherapist over the phone or face to face when they underwent routine treatment.
214623227|NCT06476522|OTHER|To Inform|The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.
214623228|NCT01378104|DRUG|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
214623229|NCT01378104|DRUG|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
214623230|NCT02287623|DRUG|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
214623231|NCT02287623|DRUG|bupivacaine|patients will receive a tap with bupivacaine
214623232|NCT03786562|DRUG|Intrathecal Morphine|Group 1
214623233|NCT03786562|DRUG|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
214717962|NCT00400556|DRUG|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
214717963|NCT03656666|DRUG|Apremilast|Apremilast oral tablets
214623234|NCT01189188|PROCEDURE|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
214623235|NCT01189188|PROCEDURE|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
214623236|NCT01303042|DRUG|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
214623237|NCT02847195|DEVICE|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
214717964|NCT03656666|DRUG|Placebo|Placebo oral tablets
214717965|NCT04595409|DRUG|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
214717966|NCT04595409|DRUG|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
214717967|NCT00419458|PROCEDURE|inspiratory muscle strength training|
214623238|NCT01102075|DEVICE|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
214623239|NCT01102075|DEVICE|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
214623240|NCT02755311|PROCEDURE|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
214623241|NCT02755311|PROCEDURE|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
214717968|NCT04362813|DRUG|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
214717969|NCT04362813|DRUG|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
214717970|NCT04824222|DRUG|Human fecal microbiota, MBiotix HBI|The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
214717971|NCT04824222|DRUG|Placebo|Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
214717972|NCT04824222|DRUG|SOC|The standard COVID 19 pharmacological treatment
214623242|NCT02755311|DRUG|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
214623243|NCT02755311|DRUG|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
214717973|NCT00961116|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
214717974|NCT00961116|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
214717975|NCT01787955|PROCEDURE|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
214623244|NCT02755311|DRUG|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
214623245|NCT02755311|OTHER|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
214717976|NCT01787955|PROCEDURE|conventional PPPD|
214717977|NCT00354952|DRUG|Macrolides (azithromycin or clarithromycin)|
214717978|NCT01082003|DRUG|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
214717979|NCT00007982|BIOLOGICAL|filgrastim|
214717980|NCT00007982|DRUG|carmustine|
214717981|NCT00007982|DRUG|cisplatin|
214717982|NCT00007982|DRUG|cyclophosphamide|
214717983|NCT00007982|DRUG|etoposide|
214717984|NCT00007982|DRUG|thiotepa|
214717985|NCT00007982|PROCEDURE|adjuvant therapy|
214717986|NCT00007982|PROCEDURE|autologous bone marrow transplantation|
214623246|NCT05796908|DEVICE|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
214623247|NCT04739085|DIAGNOSTIC_TEST|Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
214623248|NCT04739085|DIAGNOSTIC_TEST|wDDART - Monocular near visual acuity using the best correction for distance|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
214623249|NCT00885274|DRUG|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
214623250|NCT00885274|DRUG|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
214623251|NCT03645993|GENETIC|Genetic Testing|A one time blood sample will be taken.
214623252|NCT02700997|DEVICE|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
214623253|NCT00442052|DRUG|aspirin|
214623254|NCT00442052|DRUG|omeprazole|
214623255|NCT06471400|OTHER|interview|patient relatives or legal authorized representatives will be interviewed
214623256|NCT05929716|DRUG|Magrolimab|Given by IV (vein)
214623257|NCT05929716|DRUG|Rituximab|Given by IV (vein)
214623258|NCT05929716|DRUG|CAR T leukapheresis|Given by IV (vein)
214623259|NCT05929716|DRUG|Radiation|Given by IV (vein)
214623260|NCT06104852|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
214623261|NCT06104852|OTHER|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
214623262|NCT03563378|DRUG|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
214623263|NCT03563378|DRUG|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
214623264|NCT01505790|DRUG|PRASUGREL|60 mg the first day then 10 mg per day during one month
214717987|NCT00007982|PROCEDURE|bone marrow ablation with stem cell support|
214717988|NCT00007982|PROCEDURE|peripheral blood stem cell transplantation|
214623265|NCT01505790|DRUG|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
214623266|NCT02227680|OTHER|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
214623267|NCT02227680|OTHER|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
214623268|NCT05295004|BEHAVIORAL|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
214623269|NCT05161533|DRUG|Carboplatin|Given IV
214623270|NCT05161533|DRUG|Cisplatin|Given IV
214623271|NCT05161533|BIOLOGICAL|Durvalumab|Given IV
214623272|NCT05161533|DRUG|Etoposide|Given IV
214623273|NCT05161533|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214623274|NCT05161533|OTHER|Quality-of-Life Assessment|Ancillary studies
214623275|NCT05161533|OTHER|Questionnaire Administration|Ancillary studies
214623276|NCT03792815|DRUG|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
214717989|NCT02763241|DRUG|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
214623277|NCT03792815|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
214623278|NCT03792815|DRUG|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
214623279|NCT05382247|DEVICE|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
214623280|NCT02354222|DRUG|Canagliflozin|
214623281|NCT02354222|DRUG|Teneligliptin|
214623282|NCT02354222|DRUG|Placebo|
214717990|NCT02763241|DRUG|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
214717991|NCT05141734|DIAGNOSTIC_TEST|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
214717992|NCT04615780|OTHER|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
214717993|NCT04615780|OTHER|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
214717994|NCT04500067|DRUG|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
214717995|NCT00466661|DRUG|Acamprosate|666 mg po TID
214717996|NCT00466661|DRUG|Placebo|2 tabs po TID
214717997|NCT04566757|BIOLOGICAL|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
214717998|NCT05833555|BEHAVIORAL|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
214717999|NCT05833555|BEHAVIORAL|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
214718000|NCT05833555|BEHAVIORAL|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
214718001|NCT05833555|OTHER|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
214718002|NCT03242304|OTHER|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
214623283|NCT05301868|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
214718003|NCT02494219|PROCEDURE|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
214623284|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
214718004|NCT00490867|DRUG|Alpha lipoic acid|
214718005|NCT02987244|DRUG|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
214718006|NCT02987244|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
214718007|NCT02987244|DRUG|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
214718008|NCT02987244|DRUG|Vindesine|vindesine (4mg)was administered intravenously on d1;
214718009|NCT02987244|DRUG|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
214718010|NCT02987244|DRUG|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
214623285|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
214718011|NCT02801006|DEVICE|stenfilcon A|contact lens
214718012|NCT02801006|DEVICE|etafilcon A|contact lens
214718013|NCT03225937|DRUG|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
214623286|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
214623287|NCT03632590|DRUG|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
214623288|NCT01091584|DEVICE|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
214623289|NCT05289050|DRUG|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
214623290|NCT05289050|DRUG|S-ketamine|For patients in the s-ketamine group,anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
214623291|NCT06099899|OTHER|interview|conduct in-depth interviews
214623292|NCT05280028|DRUG|Tibolone 2.5 mg|Tibolone 2.5 mg per day
214623293|NCT05280028|DRUG|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
214623294|NCT06345521|OTHER|No intervention|No intervention
214623295|NCT06388044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
214623296|NCT00753831|PROCEDURE|Aurosling|Silicon rod to be used in frontalis suspension surgery
214623297|NCT01395875|DRUG|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
214623298|NCT01395875|DRUG|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
214718014|NCT03225937|DRUG|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
214718015|NCT00567957|DRUG|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
214718016|NCT00567957|DRUG|Saline|same volume iv bolus before induction followed by same volume infusion
214718017|NCT05189704|DRUG|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
214718018|NCT05189704|DRUG|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
214718019|NCT03538275|OTHER|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
214718020|NCT03340311|DEVICE|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
214718021|NCT02362542|DEVICE|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
214623299|NCT06443918|BEHAVIORAL|A Just-in-Time Adaptive Intervention for Child and Family Mental Health|Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
214623300|NCT04360980|DRUG|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
214623301|NCT04721470|PROCEDURE|Combined therapy|Patients undergoing combined therapy
214623302|NCT04721470|PROCEDURE|Microwave ablation|Patients undergoing Microwave ablation
214623303|NCT04721470|PROCEDURE|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
214718022|NCT01577199|DRUG|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
214718023|NCT01577199|DRUG|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
214718024|NCT01125878|DIETARY_SUPPLEMENT|Placebo|placebo
214718025|NCT01125878|DIETARY_SUPPLEMENT|Starch composite B|fiber mixture
214718026|NCT01125878|DIETARY_SUPPLEMENT|Starch composite C|fiber mixture
214718027|NCT01125878|DIETARY_SUPPLEMENT|Starch composite D|fiber mixture
214623304|NCT00248755|PROCEDURE|mucociliary clearance scan|
214623305|NCT02341638|DRUG|BMS-986141|
214623306|NCT02341638|DRUG|Placebo|
214623307|NCT02341638|DRUG|Aspirin|
214623308|NCT02341638|DRUG|Itraconazole|
214623309|NCT03471975|PROCEDURE|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
214623310|NCT03471975|PROCEDURE|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
214623311|NCT01342484|DRUG|placebo|comparison of different dosages of drug (low vs high) vs placebo
214623312|NCT01342484|DRUG|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
214623313|NCT01342484|DRUG|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
214623314|NCT01840579|BIOLOGICAL|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
214623315|NCT01840579|BIOLOGICAL|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
214623316|NCT01840579|BIOLOGICAL|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
214623317|NCT01840579|DRUG|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
214623318|NCT01840579|DRUG|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
214623319|NCT01840579|DRUG|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
214623320|NCT01840579|DRUG|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
214623321|NCT01840579|DRUG|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
214623322|NCT01840579|DRUG|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
214623323|NCT01840579|BIOLOGICAL|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
214623324|NCT01840579|DRUG|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
214623325|NCT01840579|DRUG|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
214623326|NCT00554567|BEHAVIORAL|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
214623327|NCT01446406|DEVICE|MONARCA|Monitoring affective symptoms entered by the patient every day.
214718028|NCT04354155|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
214718029|NCT06299813|DRUG|Bentelan|The experimental treatment group will be administered betamethasone 0.1 mg per kg.
214718030|NCT06299813|DRUG|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
214623328|NCT01446406|DEVICE|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
214623329|NCT00432042|BIOLOGICAL|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
214623330|NCT00432042|BIOLOGICAL|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
214623331|NCT00455390|PROCEDURE|Post-immediate Psychotherapeutic Intervention|
214623332|NCT01971021|DEVICE|PICC or subcutaneous venous port|
214623333|NCT00277186|OTHER|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
214623334|NCT06006234|OTHER|questionnaire survey|questionnaire survey
214623335|NCT02822885|RADIATION|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
214623336|NCT05517395|BEHAVIORAL|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
214623337|NCT05517395|BEHAVIORAL|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
214623338|NCT02710838|DEVICE|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
214623339|NCT01496729|PROCEDURE|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
214623340|NCT01496729|PROCEDURE|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
214623341|NCT04444999|PROCEDURE|Carbon Dioxide Angiography|• Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
214623342|NCT06977399|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of liver cancer|The CT scan is part of the standard treatment protocol.
214623343|NCT06978283|BEHAVIORAL|AI-assisted case analysis|Nursing students will perform visual case analyses of pressure injuries using an AI-based platform. The AI system will provide students with case-based feedback.
214623344|NCT06978283|BEHAVIORAL|Traditional case analysis|Participants will be present with written case scenarios and a case analysis will conduct with the instructor. The training process will be carried out with group discussions and the instructor's guidance. No technological or artificial intelligence support will be used.
214623345|NCT05847101|PROCEDURE|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
214623346|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
214623347|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
214623348|NCT04641455|DRUG|Water|Administration of water before upper endoscopy
214623349|NCT06809530|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every 2 weeks for 6 weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
214623350|NCT06809530|DRUG|Pemetrexed (Alimta)|Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
214623351|NCT06640491|DRUG|IO Administration of Cefazolin|Intraosseous injection of cefazolin to guard against infection.
214623352|NCT06640491|DRUG|IO Administration of Vancomycin|Intraosseous injection of vancomycin to guard against infection.
214623353|NCT06640491|DRUG|IV Administration of Cefazolin|Intravenous dose of cefazolin to guard against infection.
214623354|NCT06640491|DRUG|IV Administration of Vancomycin|Intravenous dose of vancomycin to guard against infection.
214623355|NCT04705168|DIAGNOSTIC_TEST|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter
214623356|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
214623357|NCT04342754|DEVICE|Deep Brain Stimulation (DBS)|The device will be ON
214623358|NCT04342754|DEVICE|Sham Stimulation|The device will be OFF
214623359|NCT02014350|DEVICE|DePuy Delta Xtend Reverse TSA|
214623360|NCT03832062|OTHER|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
214623361|NCT05406063|RADIATION|SBRT|Stereotactic multiple fraction radiotherapy
214623362|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
214623363|NCT03994939|BEHAVIORAL|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
214623364|NCT02113085|BEHAVIORAL|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
214623365|NCT01705600|BEHAVIORAL|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
214718031|NCT05693038|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
214623366|NCT01028664|DEVICE|SENSIMED Triggerfish|2-hour continuous IOP monitoring
214623367|NCT00641251|OTHER|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
214623368|NCT00641251|OTHER|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
214623369|NCT00897663|GENETIC|gene expression analysis|
214623370|NCT00897663|GENETIC|microarray analysis|
214623371|NCT00897663|GENETIC|protein expression analysis|
214623372|NCT00897663|OTHER|diagnostic laboratory biomarker analysis|
214623373|NCT00897663|OTHER|immunohistochemistry staining method|
214718032|NCT05693038|DIAGNOSTIC_TEST|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
214623374|NCT01556607|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
214623375|NCT01556607|DRUG|Placebo|
214623376|NCT05160259|RADIATION|Radial visualization of the foramen arcuale atlantis|In patients with diagnosed Kimmerle's anomaly, using transcranial Doppler sonography to determine the degree of changes in blood flow in the vertebral arteries
214623377|NCT05541809|OTHER|Aromatherapy|Peppermint aroma inhalation
214623378|NCT05541809|OTHER|Placebo|Water inhalation
214623379|NCT00980200|DRUG|Dose 4 QD|QD once daily
214623380|NCT00980200|DRUG|Dose 3 QD|QD once daily
214623381|NCT00980200|DRUG|placebo|placebo
214623382|NCT00980200|DRUG|Dose 2 QD|QD once daily
214623383|NCT00980200|DRUG|Dose 1 BD|BD twice daily
214623384|NCT04193007|DRUG|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
214623385|NCT04193007|RADIATION|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
214623386|NCT04106700|DRUG|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
214623387|NCT00457015|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
214718033|NCT02565615|OTHER|No intervention|Because this is a non-interventional study, there is no intervention here.
214718034|NCT05983835|PROCEDURE|Patients receive subsegmentectomy|Patients receive lobectomy
214718035|NCT01207817|OTHER|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
214718036|NCT03134924|BEHAVIORAL|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
214718037|NCT03134924|BEHAVIORAL|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
214718038|NCT03686696|DRUG|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
214718039|NCT03686696|DRUG|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
214718040|NCT03686696|DRUG|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
214623388|NCT00457015|DRUG|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
214623389|NCT00247754|BEHAVIORAL|Cognitive Behaviour Treatment|
214718041|NCT06100549|OTHER|No intervention|No intervention will be provided.
214623390|NCT00099190|DRUG|ARQ 501|
214623391|NCT03162770|BEHAVIORAL|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
214623392|NCT05461911|DIETARY_SUPPLEMENT|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
214718042|NCT03240718|PROCEDURE|Laser treatment|CORE fractional CO2 laser treatment
214718043|NCT00030355|DRUG|homoharringtonine|
214718044|NCT00030355|PROCEDURE|chemotherapy|
214623393|NCT01477385|PROCEDURE|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
214623394|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
214623395|NCT01477385|PROCEDURE|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
214623396|NCT01477385|PROCEDURE|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
214623397|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
214718045|NCT00158223|DRUG|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
214623398|NCT04711772|OTHER|whole-genome sequencing|Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
214623399|NCT02288585|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols
214623400|NCT02288585|DIETARY_SUPPLEMENT|Placebo product|Placebo product
214623401|NCT01243710|DEVICE|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
214623402|NCT05556499|DIAGNOSTIC_TEST|Biomarker assays|Circulating bone biomarkers assays
214623403|NCT05618665|OTHER|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
214623404|NCT05618665|OTHER|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
214623405|NCT05438316|DRUG|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
214623406|NCT05438316|DRUG|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
214623407|NCT00848861|DRUG|propofol (sedation for outpatient colonoscopy)|
214623408|NCT00848861|DRUG|midazolam plus meperidine (sedation for outpatient colonoscopy)|
214623409|NCT03031275|RADIATION|High-resolution computed tomography|HRCT of the thorax
214623410|NCT03031275|RADIATION|Magnetic resonance imaging|MRI of the brain
214623411|NCT03031275|BEHAVIORAL|Cognitive testing|Neuropsychological testing
214623412|NCT00143715|DRUG|Phytonadione (Vitamin K1)|1.25 mg given orally
214623413|NCT03446222|PROCEDURE|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
214623414|NCT03446222|PROCEDURE|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
214623415|NCT05120479|PROCEDURE|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
214623416|NCT05120479|PROCEDURE|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
214623417|NCT03872986|DEVICE|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
214623418|NCT03872986|DEVICE|Giomer|Beautifil II dental restorative material
214623419|NCT03872986|DEVICE|GIC|Equia forte dental restorative material
214623420|NCT03284684|OTHER|Blood test|plasma concentration of circulating DNA of specific genes
214623421|NCT01845012|OTHER|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
214623422|NCT06320561|OTHER|Longitudinal prospective cohort study|Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
214623423|NCT02140697|DIETARY_SUPPLEMENT|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
214623424|NCT02140697|DIETARY_SUPPLEMENT|Placebo (3g/day)|Placebo (3g/day), parallel design
214623425|NCT06082141|PROCEDURE|Transversus thoracis plane block combined with serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance
214623426|NCT06082141|PROCEDURE|Serratus anterior plan block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
214623427|NCT05073614|GENETIC|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
214623428|NCT01611974|DRUG|Maribavir|Tablet for oral administration
214623429|NCT05722119|DIAGNOSTIC_TEST|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
214623430|NCT01756534|DEVICE|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
214623431|NCT04185103|DRUG|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
214623432|NCT01351935|DRUG|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
214623433|NCT04040894|BIOLOGICAL|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
214623434|NCT00867373|BEHAVIORAL|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
214623435|NCT05745220|OTHER|Device: silicone hydrogel contact lens|Silicone hydrogel contact lens
214623436|NCT01465100|RADIATION|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
214623437|NCT01465100|PROCEDURE|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
214623438|NCT01465100|DRUG|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
214623439|NCT01465100|OTHER|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
214623440|NCT01465100|BEHAVIORAL|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
214623441|NCT01465100|DIAGNOSTIC_TEST|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
214623442|NCT01465100|PROCEDURE|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
214623443|NCT04749823|OTHER|Blended treatment program|A combined treatment program with specific active neck exercises and general aerobic training in counteractive amount will be executed during 12 weeks. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
214623444|NCT04749823|OTHER|Specific strength exercise program|This program includes an individual, patient-tailored exercise program with the aim of retraining the neck musculature. A detailed exercise programme will be constructed in which all exercises are listed with the amount of repetitions and series of each exercise. Strength exercises will be performed by means of dumbbells with different weights and elastic bands with different degrees of resistance. The amount of weight or resistance, and the amount of series and repetitions will be evaluated during the first session. This exercise programme will be re-evaluated repeatedly during the course of the program. Specific strength neck exercises will be performed for 30 minutes. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
214623445|NCT04749823|OTHER|General aerobic exercise program|This control group will receive a general aerobic exercise program. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
214623446|NCT02835183|DEVICE|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
214623447|NCT02835183|DEVICE|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
214623448|NCT00916357|DRUG|Humalog|
214623449|NCT00916357|DRUG|Humulin-R|
214623450|NCT00916357|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
214623451|NCT00350051|DRUG|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
214623452|NCT05382351|DRUG|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
214623453|NCT05382351|DRUG|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
214623454|NCT03069430|BEHAVIORAL|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
214623455|NCT04989283|BIOLOGICAL|Atezolizumab|Given IV
214718046|NCT00158223|DRUG|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
214623456|NCT04989283|PROCEDURE|Biopsy|Undergo tumor biopsy
214623457|NCT04989283|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214623458|NCT04989283|DRUG|Carboplatin|Given IV
214623459|NCT04989283|DRUG|Cisplatin|Given IV
214623460|NCT04989283|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214623461|NCT04989283|DRUG|Etoposide|Given IV
214623462|NCT04989283|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214623463|NCT04989283|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214623464|NCT04989283|DRUG|Paclitaxel|Given IV
214623465|NCT04989283|DRUG|Pemetrexed|Given IV
214623466|NCT04989283|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214623467|NCT04989283|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214623468|NCT01773109|DRUG|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
214623469|NCT01815307|DRUG|Gemcitabine|1000mg/m2, day 1 every 2 weeks
214718047|NCT03171311|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
214718048|NCT03171311|PROCEDURE|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
214718049|NCT00753688|DRUG|PAZOPANIB|800 mg once daily orally
214718050|NCT00753688|DRUG|Placebo|matching placebo 800 mg once daily orally
214718051|NCT05035095|DRUG|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
214623470|NCT01815307|DRUG|S-1|80mg/m2/day, day 1-28, every 6 weeks
214623471|NCT03067883|DRUG|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
214623472|NCT03258112|PROCEDURE|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
214623473|NCT05407584|DRUG|Orevogomab+PLD|"PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
214623474|NCT05407584|DRUG|Orevogomab+Paclitaxel|"paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
214623475|NCT03846752|PROCEDURE|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
214623476|NCT03846752|PROCEDURE|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
214623477|NCT06394713|DRUG|QLF31907|intravenous administration, once every 3 weeks
214623478|NCT06394713|DRUG|Irinotecan|intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
214718052|NCT05035095|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
214718053|NCT04503941|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
214718054|NCT04503941|DEVICE|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
214718055|NCT02986919|DRUG|CPI-0610|"* Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
214718056|NCT00889395|BEHAVIORAL|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
214718057|NCT00702910|DRUG|Placebo|comparator
214718058|NCT00702910|DRUG|GW642444|investigational drug or placebo
214718059|NCT00702910|DRUG|Magnesium Stearate|Magnesium Stearate
214623479|NCT06394713|DRUG|Docetaxel|intravenous administration, 75mg/m2, d1, every 3 weeks
214623480|NCT00084123|BEHAVIORAL|Healing Touch Therapy|
214623481|NCT00084123|BEHAVIORAL|Relaxation Therapy|
214623482|NCT00084123|BEHAVIORAL|Standard Care|Standard Care
214718060|NCT00210379|DRUG|rituximab|
214718061|NCT00210379|DRUG|CHOP|
214718062|NCT00210379|DRUG|intrathecal methotrexate|
214718063|NCT00210379|PROCEDURE|radiotherapy|
214718064|NCT06035588|OTHER|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
214718065|NCT06035588|OTHER|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
214718066|NCT01854593|DRUG|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
214718067|NCT01854593|PROCEDURE|Vitrectomy|vitrectomy of 25 gauge system.
214718068|NCT01854593|DEVICE|Sham injection|Sham injection one day before vitrectomy
214718069|NCT05400356|PROCEDURE|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
214718070|NCT03694054|OTHER|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
214718071|NCT05445882|DRUG|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
214718072|NCT05445882|DRUG|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
214718073|NCT05445882|BIOLOGICAL|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
214718074|NCT04695548|OTHER|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
214718075|NCT04695548|OTHER|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
214623483|NCT01500109|DRUG|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
214623484|NCT01500109|DRUG|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
214718076|NCT04695548|OTHER|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
214718077|NCT04695548|OTHER|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
214718078|NCT05738772|DIAGNOSTIC_TEST|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
214718079|NCT02522572|DRUG|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
214718080|NCT02522572|DRUG|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
214623485|NCT01500109|DRUG|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
214623486|NCT04704232|DRUG|ACD440|Double blind, parallel within subject comparison
214623487|NCT04704232|DRUG|PLAC|Double blind, parallel within subject comparison
214623488|NCT06188156|PROCEDURE|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
214623489|NCT02244216|DRUG|Berotec® N 100 µg Metered-dose Inhaler|
214623490|NCT05517642|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
214623491|NCT05517642|BIOLOGICAL|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
214623492|NCT02872740|PROCEDURE|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
214623493|NCT02872740|PROCEDURE|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
214623494|NCT06288087|OTHER|VR Based Training with Machine Guidance (MG Group)|The members of both groups will undertake a VR based basic training for ALS. Afterwards MG group were trained with VR based Advanced Training Module, which provides training with full machine guidance. The knowledge level will then be evaluated by the exam mode of the VR based training module
214623495|NCT06288087|OTHER|VR Based Training with Educator Guidance in Metaverse (EG Group)|The members of both groupswill undertake a VR based basic training for ALS. Afterwards EG group will attend at VR based Educator guided training in metaverse. The knowledge level will then be evaluated by the exam mode of the VR based training module
214623496|NCT06410560|OTHER|Training about storytelling and creative writing: 12 hours|Participants in training courses on creative writing and storytelling.
214623497|NCT06410560|OTHER|Training only about theoretical narrative medicine: 4 hours|Participants in training courses on only theoretical narrative medicine.
214623498|NCT03551444|DRUG|Administration of DAA-based treatment|"* Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered."
214623499|NCT03820622|DEVICE|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
214718081|NCT02522572|OTHER|plasmapheresis|Plasmapheresis will be administered based on group assignment.
214718082|NCT04237818|DIETARY_SUPPLEMENT|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
214623500|NCT03820622|DEVICE|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
214623501|NCT02732769|DEVICE|GammaKnifePerfexion®|neurosurgery
214623502|NCT02732769|DEVICE|GammaKnifeIcon®|neurosurgery
214623503|NCT02732769|DEVICE|Efficast®|Thermoformed mask
214623504|NCT02732769|DEVICE|MRI|
214623505|NCT04640688|PROCEDURE|Bariatric procedures|510(k) summary K081853 dated June 26, 2008, Endoscopic Sleeve Gastroplasty lecture, Methodist Dallas Medical Center Endobariatric Pathway \& Endoscopic Sleeve Gastroplasty Procedure Description
214718083|NCT04237818|DIETARY_SUPPLEMENT|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
214718084|NCT00855387|OTHER|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
214623506|NCT04022915|DRUG|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
214623507|NCT04022915|DIAGNOSTIC_TEST|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
214623508|NCT01958801|OTHER|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
214623509|NCT01958801|OTHER|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
214623510|NCT04870528|DEVICE|pulsed electromagnetic field device|the pulsed electromagnetic field device treatment parameters will be set as 15 Hz frequency, 20 gauss amplitude, and 20 minutes as total treatment duration.
214623511|NCT04870528|OTHER|Free weights for Strengthening Exercise|"• Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks"
214623512|NCT06145295|BEHAVIORAL|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
214623513|NCT06145295|BEHAVIORAL|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
214623514|NCT03841071|OTHER|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
214623515|NCT04766021|DRUG|Mirabegron|Dose-response effect on thermogenesis
214623516|NCT04766021|DRUG|Placebo|Placebo control condition
214623517|NCT02750540|DRUG|Tenofovir enema|
214623518|NCT02750540|OTHER|Saline enema|
214623519|NCT02979665|DRUG|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
214623520|NCT04464395|DRUG|CPI-006|Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
214623521|NCT04464395|OTHER|Standard of Care|Participants will receive standard of care treatment only.
214623522|NCT04595903|DEVICE|Hemopurifier|Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
214623523|NCT01032304|DRUG|Erdosteine|One 300 mg capsule twice a day
214623524|NCT01032304|DRUG|Placebo|One capsule twice a day
214623525|NCT03428893|DEVICE|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
214623526|NCT02872623|RADIATION|Enterography-MRI without enteroclysis|
214623527|NCT02872623|RADIATION|enteroCT with enteroclysis|
214623528|NCT06151171|DIETARY_SUPPLEMENT|CoQ10|"Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day."
214623529|NCT03116646|DIAGNOSTIC_TEST|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
214623530|NCT04824508|BEHAVIORAL|position|teamleaders are instructed to allocated position
214623531|NCT04187885|BEHAVIORAL|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
214623532|NCT04753073|PROCEDURE|Non-invasive physical plasma|Treatment with non invasive physical low-temperature plasma
214623533|NCT04479163|BIOLOGICAL|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
214623534|NCT04479163|OTHER|Placebo|Normal Saline 0.9%
214623535|NCT02034890|DRUG|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
214623536|NCT02257372|DRUG|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
214623537|NCT02257372|DRUG|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
214623538|NCT02257372|DRUG|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
214623539|NCT02257372|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
214623540|NCT05999188|OTHER|Observational|No interventions will be given to patients.
214623541|NCT00789529|DEVICE|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
214623542|NCT00789529|DEVICE|ReNu MultiPlus®|soft contact lens disinfecting solution
214623543|NCT01419951|BEHAVIORAL|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
214718085|NCT01787799|DEVICE|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
214623544|NCT01419951|OTHER|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
214623545|NCT01419951|BEHAVIORAL|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
214623546|NCT06318910|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
214623547|NCT06318910|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
214623548|NCT06465797|DIAGNOSTIC_TEST|Bronchoscopy|No intervention will take place in this study, only image material will be captured from the standard-of-care bronchoscopy
214623549|NCT04325542|DIAGNOSTIC_TEST|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
214623550|NCT06090942|OTHER|Smartphone-based cognitive training|Smartphone-based cognitive training
214623551|NCT02390011|PROCEDURE|MRI|
214623552|NCT00716105|OTHER|Standard infant formula|From 3 to 12 months of age. As per standard requirement
214623553|NCT00716105|OTHER|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
214623554|NCT03431155|OTHER|Nursing intervention|Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
214623555|NCT05660720|DRUG|Orelabrutinib and placebo (orelabrutinib tablet simulator)|Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
214623556|NCT05660720|DRUG|Orelabrutinib|Orelabrutinib will be administered as 8 tablets (400mg)
214623557|NCT05660720|DRUG|Placebo (orelabrutinib tablet simulator)|Placebo will be administered as 8 tablets (400mg).
214623558|NCT05660720|DRUG|Moxifloxacin hydrochloride|Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
214623559|NCT01725555|DRUG|Fasted treatment: AXL1717|
214623560|NCT01725555|DRUG|Fed treatment: AXL1717|
214623561|NCT04065555|DRUG|TAK-981|Intratumoral microdose injection by the CIVO device.
214623562|NCT04065555|BIOLOGICAL|Cetuximab|Intratumoral microdose injection by the CIVO device.
214623563|NCT04065555|BIOLOGICAL|Avelumab|Intratumoral microdose injection by the CIVO device.
214623564|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
214623565|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
214623566|NCT04734912|OTHER|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
214623567|NCT00928551|DRUG|vabicaserin|
214623568|NCT05008107|OTHER|Virtual reality|Using VR goggles to watch peri-operative instructional video.
214718086|NCT02999100|DRUG|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
214623569|NCT02618304|DRUG|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
214623570|NCT02471547|OTHER|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
214623571|NCT04136873|DRUG|CVL-231|CVL-231
214623572|NCT04136873|DRUG|Matching Placebo|Placebo matching CVL-231
214623573|NCT02363140|OTHER|Will undergo a single MRI assessment with intravenous dye|
214623574|NCT02363140|OTHER|pre and post surgery MRI scan|
214623575|NCT05710120|OTHER|Hepatitis C Screening Alerts in CHORUS™|"ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test."
214623576|NCT05710120|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
214623577|NCT03324906|DEVICE|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
214623578|NCT04096027|DRUG|Cabergoline Pill|0.5 mg cabergoline pill taken orally
214623579|NCT06475417|DRUG|Adebrelimab combined with DOS|After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR
214623580|NCT00823628|DRUG|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
214623581|NCT00823628|DRUG|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
214623582|NCT05427409|DIETARY_SUPPLEMENT|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
214623583|NCT01916876|OTHER|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice"
214623584|NCT02744443|DIETARY_SUPPLEMENT|Leucine|
214623585|NCT02744443|DIETARY_SUPPLEMENT|Placebo|
214623586|NCT06113900|DRUG|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
214623587|NCT04546477|DEVICE|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
214623588|NCT06036862|PROCEDURE|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
214623589|NCT02217605|DIETARY_SUPPLEMENT|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
214718087|NCT02999100|DRUG|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
214718088|NCT02999100|DRUG|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
214718089|NCT02999100|DEVICE|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
214718090|NCT02043184|BEHAVIORAL|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
214718091|NCT01385267|PROCEDURE|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
214718092|NCT01893684|BEHAVIORAL|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
214623590|NCT01671852|DRUG|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
214623591|NCT01671852|DRUG|Placebo|
214623592|NCT00019409|DRUG|asparaginase|
214623593|NCT00019409|DRUG|cyclophosphamide|
214623594|NCT00019409|DRUG|cytarabine|
214623595|NCT00019409|DRUG|daunorubicin hydrochloride|
214623596|NCT00019409|DRUG|mercaptopurine|
214718093|NCT01893684|BEHAVIORAL|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
214718094|NCT01893684|BEHAVIORAL|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
214718095|NCT01664858|OTHER|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
214718096|NCT01664858|OTHER|SPECT|SPECT: Single Photon Emission Computed Tomography
214718097|NCT01664858|OTHER|CT calcium score|CT calcium score
214718098|NCT01664858|OTHER|CT coronary angiography|CT coronary angiography
214718099|NCT01664858|OTHER|X-Ray coronary angiography|X-Ray coronary angiography
214718100|NCT03697486|BEHAVIORAL|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
214718101|NCT00293241|DEVICE|Managed Ventricular Pacing programmed ON/OFF|Device programming
214623597|NCT00019409|DRUG|methotrexate|
214623598|NCT00019409|DRUG|prednisone|
214623599|NCT00019409|DRUG|therapeutic hydrocortisone|
214623600|NCT00019409|DRUG|vincristine sulfate|
214623601|NCT00019409|RADIATION|radiation therapy|
214623602|NCT01972048|BEHAVIORAL|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
214623603|NCT01972048|OTHER|Print brochure|Mailed print brochure about breast cancer screening and community resources.
214623604|NCT00806936|DRUG|human insulin|Any kind of human insulin administered at the discretion of the physician
214623605|NCT00806936|DRUG|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
214623606|NCT04382170|DRUG|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
214623607|NCT04071821|DRUG|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
214623608|NCT04071821|DRUG|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
214623609|NCT02387359|DRUG|Plecanatide|
214623610|NCT02387359|DRUG|Placebo|
214623611|NCT02511652|DEVICE|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
214623612|NCT02511652|DEVICE|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
214623613|NCT02511652|PROCEDURE|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
214623614|NCT01323725|BEHAVIORAL|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
214623615|NCT00889148|DRUG|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
214623616|NCT00889148|OTHER|Placebo|Half the patients will be randomized to placebo
214623617|NCT05587855|OTHER|E-group|Participants with Hypertension will be assigned to eCulinary medicine
214718102|NCT03595384|BEHAVIORAL|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
214718103|NCT02181985|DRUG|Full dose TNK-tPA|
214718104|NCT02181985|DRUG|Half dose TNK-tPA|
214718105|NCT02181985|DRUG|Heparin|
214718106|NCT02181985|DRUG|Enoxaparin|
214718107|NCT02181985|DRUG|Abciximab|
214623618|NCT05440162|DIAGNOSTIC_TEST|electrolyte|follow up NA
214623619|NCT01439321|BIOLOGICAL|Eltrombopag|Switched to Eltrombopag
214623620|NCT01439321|BIOLOGICAL|Romiplostim|Switched to Romiplostim
214623621|NCT04082403|PROCEDURE|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
214623622|NCT04082403|PROCEDURE|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
214623623|NCT03144245|BIOLOGICAL|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
214623624|NCT03144245|COMBINATION_PRODUCT|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
214623625|NCT02328651|DRUG|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg,iv, Bid\~tid）"
214623626|NCT02328651|DRUG|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）"
214623627|NCT02332499|DRUG|Anlotinib|Anlotinib p.o. qd
214623628|NCT02332499|DRUG|Placebo|Placebo p.o. qd
214623629|NCT05513248|PROCEDURE|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
214623630|NCT01230242|DEVICE|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
214623631|NCT04315675|BEHAVIORAL|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
214623632|NCT04315675|BEHAVIORAL|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
214623633|NCT04315675|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
214623634|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with muscle stretching
214623635|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
214718108|NCT03368040|DEVICE|Tcore|Monitoring system to measure body temperature based on heat-flux technology
214718109|NCT03411668|OTHER|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
214718110|NCT02224638|DEVICE|TheraHoney HD|Honey
214718111|NCT02224638|DEVICE|SkinTegrity|Hydrogel
214718112|NCT05957588|OTHER|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
214718113|NCT05957588|OTHER|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
214623636|NCT04075721|DRUG|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
214623637|NCT04075721|DRUG|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
214623638|NCT01601028|DRUG|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
214623639|NCT01601028|DRUG|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
214623640|NCT00087828|DRUG|Cranberry juice cocktail|
214623641|NCT04329702|BEHAVIORAL|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
214623642|NCT04329702|BEHAVIORAL|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
214623643|NCT01630473|PROCEDURE|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
214623644|NCT01630473|PROCEDURE|Conventional orthodontics|Conventional orthodontic treatment
214623645|NCT01438489|BIOLOGICAL|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
214623646|NCT01438489|BIOLOGICAL|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
214718114|NCT05690971|BEHAVIORAL|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
214718115|NCT05690971|BEHAVIORAL|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
214718116|NCT02894528|DRUG|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
214718117|NCT02894528|DRUG|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
214718118|NCT05065307|DIAGNOSTIC_TEST|Venipuncture|Diagnostic venipuncture
214718119|NCT00383227|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
214623647|NCT01438489|OTHER|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
214718120|NCT03962712|OTHER|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
214718121|NCT03962712|OTHER|No Increase in Minimum Wage|No increase in minimum wage
214623648|NCT00597480|DRUG|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
214623649|NCT00597480|DRUG|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
214623650|NCT00766532|DRUG|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
214623651|NCT02907294|DRUG|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
214623652|NCT02907294|DRUG|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
214623653|NCT02907294|DRUG|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
214623654|NCT05927051|OTHER|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
214623655|NCT05927051|OTHER|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
214623656|NCT05927051|OTHER|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
214623657|NCT00533832|DEVICE|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
214718122|NCT06422429|DRUG|Traditional deep-fried Youtiao|45g 4 times a week for 4 months
214718123|NCT06422429|DRUG|PI Youtiao|45g 4 times a week for 4 months
214623658|NCT05099627|OTHER|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
214623659|NCT05099627|OTHER|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
214623660|NCT05099627|OTHER|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
214623661|NCT02291120|PROCEDURE|Pulpotomy|
214623662|NCT05699889|OTHER|Data collection|acute kidney injury and tubular dysfunction
214623663|NCT03915015|DIAGNOSTIC_TEST|MRI|MRI
214623664|NCT05491928|DRUG|Tempol|Tempol will be given as an adjunct to chemotherapy.
214623665|NCT02330159|PROCEDURE|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
214623666|NCT02749773|DEVICE|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
214623667|NCT00323232|DEVICE|2 Versus 4 Hole DHS|See Detailed Description.
214623668|NCT00129324|PROCEDURE|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
214623669|NCT00129324|PROCEDURE|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
214623670|NCT06155370|OTHER|construction of organoids from gynecological tumor|organoids construction
214623671|NCT02448030|OTHER|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
214623672|NCT02448030|OTHER|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
214623673|NCT03695575|DEVICE|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
214623674|NCT00159900|DRUG|Sildenafil Citrate|
214623675|NCT04066270|DIAGNOSTIC_TEST|video nystagmography|routine test battery applied to all cochlear implant candidates
214623676|NCT01191073|DEVICE|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
214623677|NCT01191073|DEVICE|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
214623678|NCT04565964|OTHER|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
214623679|NCT03298581|DRUG|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
214623680|NCT03420690|OTHER|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (\>1) and the death of patients (\> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
214718124|NCT06185894|PROCEDURE|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
214718125|NCT06185894|PROCEDURE|Conventional conservative surgery|Conventional conservative surgery
214718126|NCT00222417|PROCEDURE|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
214623681|NCT04808531|DRUG|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
214623682|NCT04808531|DRUG|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
214623683|NCT04808531|DRUG|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
214718127|NCT00222417|PROCEDURE|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
214623684|NCT04808531|DRUG|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
214623685|NCT04808531|DRUG|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
214623686|NCT04989920|BEHAVIORAL|Experimental group: CIMT group (Constraint-Induced Movement Therapy)|2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
214623687|NCT02037295|DRUG|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
214623688|NCT02037295|DRUG|Placebo oral tablet|Placebo pills orally four times per day for 12 days
214623689|NCT02037295|OTHER|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
214623690|NCT02037295|OTHER|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
214623691|NCT02466152|DRUG|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
214623692|NCT03688932|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
214623693|NCT03688932|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
214623694|NCT03688932|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
214623695|NCT04291950|PROCEDURE|Needle core biopsy|"Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab."
214623696|NCT02891655|OTHER|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
214623697|NCT03241914|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
214623698|NCT03241914|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
214623699|NCT06500143|DIAGNOSTIC_TEST|Gastric ultrasound|"Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create ring-down artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value."
214623700|NCT01499420|BIOLOGICAL|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
214718128|NCT04961086|OTHER|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
214718129|NCT01265342|DRUG|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
214718130|NCT01265342|DRUG|Placebo|Placebo nebulised suspension twice a day for 10 days
214623701|NCT01499420|BIOLOGICAL|Placebo|Single intravenous doses of normal saline (0.9%)
214623702|NCT01140451|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
214623703|NCT04575558|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
214623704|NCT05433506|DRUG|HU6 Tablet|Six subjects will receive a tablet formulation.
214623705|NCT05433506|DRUG|HU6 Capsule|Six subjects will receive the capsule formulation
214623706|NCT00556452|DRUG|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
214623707|NCT00556452|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
214623708|NCT00556452|RADIATION|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
214623709|NCT00695448|DRUG|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
214623710|NCT01255527|DRUG|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
214718131|NCT01216397|DRUG|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
214718132|NCT01216397|DRUG|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
214718133|NCT04219488|OTHER|Radial nerve mobilization|
214718134|NCT04219488|OTHER|Supervised home program|
214623711|NCT05666427|BEHAVIORAL|Pelvic floor muscle training combined with stabilization exercises|While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
214718135|NCT04153643|PROCEDURE|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
214718136|NCT00463879|DRUG|Galantamine|
214718137|NCT00592670|DRUG|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
214718138|NCT00592670|DRUG|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
214623712|NCT05666427|BEHAVIORAL|Pelvic floor muscle training|Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
214623713|NCT03629457|BEHAVIORAL|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
214718139|NCT02352103|PROCEDURE|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
214718140|NCT02352103|PROCEDURE|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
214718141|NCT02352103|DEVICE|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
214718142|NCT00482300|PROCEDURE|Systematic pelvic lymphadenectomy|
214718143|NCT00971633|DRUG|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
214623714|NCT01971073|DEVICE|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
214623715|NCT01971073|DEVICE|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
214623716|NCT00003362|BIOLOGICAL|QS21|
214623717|NCT00003362|BIOLOGICAL|gp100 antigen|
214718144|NCT00971633|DRUG|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
214718145|NCT00971633|DRUG|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
214718146|NCT04319406|PROCEDURE|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
214718147|NCT04319406|PROCEDURE|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
214718148|NCT03124901|DEVICE|DCI pulse oximeter sensor|
214718149|NCT02843919|OTHER|Electroencephalography and Electrocardiography|
214718150|NCT03366818|DEVICE|thrombectomy|mechanical thrombectomy
214718151|NCT00599235|DRUG|sildenafil|50mg 3 times daily for 7 days
214718152|NCT00599235|DRUG|hydralazine|25mg 3 times daily for 7 days
214718153|NCT00599235|DRUG|placebo|3 times daily for 7 days
214718154|NCT00686010|DRUG|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
214718155|NCT00686010|DRUG|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
214718156|NCT00686010|DRUG|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
214718157|NCT00686010|DRUG|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
214623718|NCT00003362|BIOLOGICAL|incomplete Freund's adjuvant|
214623719|NCT00003362|BIOLOGICAL|sargramostim|
214623720|NCT00003362|BIOLOGICAL|tyrosinase peptide|
214623721|NCT01505621|OTHER|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine
214623722|NCT02353156|OTHER|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
214623723|NCT02353156|OTHER|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
214623724|NCT02554123|DRUG|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
214623725|NCT02554123|DRUG|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
214623726|NCT00960661|DRUG|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
214623727|NCT00960661|DRUG|insulin lispro|titrated based on pre-meal glucose level; three times a day
214623728|NCT00960661|DRUG|Metformin|
214623729|NCT00960661|DRUG|Insulin/ Glargine|
214718158|NCT04420910|OTHER|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
214718159|NCT04420910|OTHER|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
214718160|NCT04420910|OTHER|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
214623730|NCT04091529|DEVICE|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
214623731|NCT00984971|DRUG|Tenofovir|Topical gel applied rectally
214623732|NCT00984971|DRUG|HEC Placebo|Placebo gel applied rectally
214623733|NCT00984971|DRUG|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
214623734|NCT05363475|DEVICE|ForeSite Intelligent Surface|The ForeSite IS is a continuous bedside pressure mapping system with machine learning and artificial intelligence (ML/AI). It consists of an overlay with over 1500 undetectable integrated sensors and a medical-grade bedside touchscreen monitor. The monitor displays a real-time coloured body pressure image, a turn timer, and a history of previous turns. The ML/AI software tracks 17 body locations and the patient's body position. The system has a centralized dashboard that shows the pressure injury risk and turn history, which can be transmitted to the nursing station. In addition, data is stored in an Amazon Web Services (AWS) secured cloud database, enabling access to individual reports on turn history and compliance and pressure exposure. Data is stored as both, raw pressure data files and real time event information on pressure exposure and turn data.
214623735|NCT02699892|DRUG|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
214623736|NCT00073723|DRUG|ABI-007|
214623737|NCT01981590|DEVICE|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
214623738|NCT02152085|DEVICE|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
214623739|NCT02152085|DEVICE|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
214623740|NCT03991351|OTHER|Exposure to images|Exposure to images
214623741|NCT00872105|PROCEDURE|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
214623742|NCT00872105|PROCEDURE|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
214623743|NCT00067028|DRUG|Clofarabine 40mg/m^2|40 mg/m\^2 by vein over 1 hour daily for 5 days.
214623744|NCT00067028|DRUG|Idarubicin 10mg/m^2|"10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
214623745|NCT00067028|DRUG|Ara-C 0.75 g/m^2|0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
214623746|NCT00067028|DRUG|Clofarabine 22.5mg/m^2|22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
214623747|NCT00067028|DRUG|Ara-C 1 g/m^2|1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
214623748|NCT00067028|DRUG|Idarubicin 6 mg/m^2|6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
214623749|NCT04608812|DRUG|OS2966|OS2966 is a humanized monoclonal antibody antagonizing CD29 (Beta 1 integrin)
214623750|NCT04608812|DRUG|Gadoteridol|Gadoteridol is a contrast agent which will be added to OS2966 to allow investigators to observe how OS2966 distributes within the brain tumor. Gadoteridol is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
214623751|NCT03391271|OTHER|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
214623752|NCT03391271|OTHER|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
214623753|NCT05178238|OTHER|Fecal sample|Fecal sample taken to investigate intestinal microbiota
214623754|NCT05279547|OTHER|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
214623755|NCT05279547|OTHER|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
214623756|NCT02534402|DRUG|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
214623757|NCT03303742|OTHER|deep chamfer|finish line marginal design of a full coverage crown preparation
214623758|NCT03303742|OTHER|feather edge|finish line marginal design of a full coverage crown preparation
214623759|NCT04245007|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
214623760|NCT05220527|DRUG|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
214623761|NCT05220527|DRUG|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
214623762|NCT05220527|DRUG|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
214623763|NCT05341271|OTHER|Experimental: digital reminiscence group (DRG)|Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
214623764|NCT05341271|OTHER|Experimental: general reminiscence group (GRG)|"Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences"
214623765|NCT01157312|DRUG|clomiphene citrate +highly purified uFSH|
214623766|NCT01157312|DRUG|clomiphene citrate|
214623767|NCT06392646|BEHAVIORAL|self-management education program|Intervention through a self-management education program constructed through evidence summarization and expert correspondence.
214623768|NCT05733871|DIETARY_SUPPLEMENT|meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
214623769|NCT05733871|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
214623770|NCT04003233|DEVICE|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
214623771|NCT04003233|DEVICE|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
214623772|NCT04485520|OTHER|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
214623773|NCT04485520|OTHER|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
214623774|NCT04563429|DIETARY_SUPPLEMENT|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
214623775|NCT02879565|OTHER|Semi structured interviews + EEG exams|
214623776|NCT02858674|OTHER|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
214623777|NCT02858674|OTHER|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
214623778|NCT00630266|DEVICE|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
214623779|NCT06413862|DRUG|Ciprofol|The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).
214623780|NCT06413862|DRUG|Propofol|The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
214623781|NCT05562375|DEVICE|GOCCLES|"Inspection using GOCCLES®. An UV light source will be administered, with polymerization lamp sdi radii xpert, with a potency of 1500 mW/cm2 and a wavelength of 440-480nm, applied at 20cm of the injury.~Notes will be taken on the location and size of the injury observed with the device.~Image register using the GOCCLES® photographic filter for mobile devices. The same light source will be used."
214623782|NCT05562375|DIAGNOSTIC_TEST|Toluidine blue stain|"To value the toluidine blue diagnosis capacity, the sequence described by Mashberg will be followed: The patient will realize a mouthwash with acetic acid at 1% for 20 seconds. Two using water for 20 seconds. Toluidine blue at 1% will be applied for 20 seconds. New mouthwash with acetic acid for 60 seconds and a final mouthwash with water.~Notes on the and pictures will be taken on the location and size of the injury."
214623783|NCT05562375|PROCEDURE|Biopsy|The area to biopsy will be chosen, and, using local anaesthesia, it will be resected. The specimens will be sent to the oral and maxillofacial pathology diagnostic service of the University of Basque Country for anatomopathological study
214623784|NCT03306732|DRUG|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
214623785|NCT03306732|DRUG|Normal saline (100ml)|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
214623786|NCT01324232|DRUG|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
214623787|NCT01324232|DRUG|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
214623788|NCT01324232|DRUG|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
214623789|NCT01324232|DRUG|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
214718161|NCT04420910|OTHER|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
214718162|NCT02876679|DRUG|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
214718163|NCT02876679|DRUG|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
214718164|NCT02876679|DRUG|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
214718165|NCT03310736|DIAGNOSTIC_TEST|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
214718166|NCT00987090|BIOLOGICAL|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
214718167|NCT00987090|RADIATION|MRI|intervention at the inclusion and 18 months after
214718168|NCT00987090|PROCEDURE|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
214718169|NCT00987090|BIOLOGICAL|Apolipoprotein E genotyping|genotyping at the inclusion
214718170|NCT00987090|BIOLOGICAL|Study of cerebrospinal fluid|intervention at the inclusion
214718171|NCT00003085|PROCEDURE|laparoscopy|
214718172|NCT00003085|PROCEDURE|ultrasound imaging|
214718173|NCT04957680|BEHAVIORAL|CCBT|computer-based treatment program for depressed adolescents
214718174|NCT01549457|OTHER|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
214718175|NCT02738762|OTHER|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
214718176|NCT03222440|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
214718177|NCT01462916|DIETARY_SUPPLEMENT|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
214718178|NCT00562016|DEVICE|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
214623790|NCT01168661|BEHAVIORAL|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) \>= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
214718179|NCT00562016|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
214718180|NCT02024841|DRUG|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
214718181|NCT04254055|OTHER|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
214718182|NCT00002908|DRUG|bryostatin 1|
214718183|NCT00002908|DRUG|vincristine sulfate|
214623791|NCT01168661|BEHAVIORAL|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
214623792|NCT01168661|BEHAVIORAL|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
214623793|NCT06377826|OTHER|aerobic exercises|group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
214623794|NCT06377826|OTHER|resistance training|this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
214623795|NCT06377826|DRUG|medication|This group will be just on medication and no exercise will be given to this group
214623796|NCT03047070|DRUG|Lidocaine|IV Lidocaine infusion
214623797|NCT03047070|DRUG|Normal saline|IV normal saline infusion
214623798|NCT01527474|DRUG|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
214623799|NCT00637260|DEVICE|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
214623800|NCT00637260|DEVICE|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
214623801|NCT01256073|DRUG|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
214623802|NCT04564586|BEHAVIORAL|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
214623803|NCT03490305|PROCEDURE|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
214623804|NCT03840538|DRUG|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
214623805|NCT03627845|DRUG|PHP-303|Investigational drug
214623806|NCT03627845|OTHER|Placebo|Matching placebo
214623807|NCT00661531|DRUG|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
214623808|NCT00661531|DRUG|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
214623809|NCT02869386|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
214623810|NCT02869386|PROCEDURE|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
214623811|NCT05493943|DEVICE|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
214623812|NCT05493943|OTHER|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
214623813|NCT04118816|DIAGNOSTIC_TEST|Polysomnography|overnight polysomnography recording at least six hours
214623814|NCT04118816|DIAGNOSTIC_TEST|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
214623815|NCT04118816|OTHER|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
214623816|NCT05469971|GENETIC|KIR genotyping|DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).
214718184|NCT06165523|OTHER|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
214718185|NCT06165523|OTHER|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
214718186|NCT06165523|OTHER|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
214718187|NCT01856842|PROCEDURE|Angiography and embolotherapy|
214623817|NCT00916188|DIETARY_SUPPLEMENT|Black Tea Extract|Amount/dose depends on Arm assignment.
214623818|NCT02021045|DEVICE|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
214623819|NCT06426355|DIETARY_SUPPLEMENT|NMN|NMN capsules (total of 600mg/day) for 2-5 months
214623820|NCT06426355|OTHER|Placebo|NMN-free placebo capsules for 2-5 months
214623821|NCT03645928|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.
214623822|NCT03645928|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
214623823|NCT03645928|DRUG|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
214623824|NCT03645928|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
214623825|NCT03645928|DRUG|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
214623826|NCT03645928|DRUG|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
214623827|NCT03645928|DRUG|Nivolumab-relatlimab|Nivolumab-relatlimab will be administered following tumor resection and will continue every 4 weeks thereafter for up to 2 years.
214623828|NCT03645928|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214623829|NCT03645928|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214623830|NCT03645928|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214623831|NCT03645928|DRUG|Nab-Paclitaxel|Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214623832|NCT03645928|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.
214623833|NCT05873881|DRUG|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
214623834|NCT05873881|DRUG|Colchicine placebo|Placebo colchicine daily
214623835|NCT05873881|DRUG|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
214623836|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
214623837|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
214623838|NCT06276283|DRUG|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
214623839|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
214623840|NCT00312624|PROCEDURE|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
214623841|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE NEO/TF|Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation
214718188|NCT04271670|OTHER|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
214623842|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro|Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
214623843|NCT01236690|DRUG|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
214623844|NCT06265675|DRUG|Phenol|Chemical neurolysis
214623845|NCT06265675|DRUG|Celestone|Chemical neurolysis with corticosteroid
214623846|NCT06265675|DRUG|Lidocain|Chemical neurolysis with local anesthetic
214623847|NCT02698267|DRUG|BIIB074|Administered as specified in the treatment arm
214623848|NCT02698267|DRUG|Itraconazole|200 mg twice daily \[BID\] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
214623849|NCT02031497|DIETARY_SUPPLEMENT|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
214623850|NCT02031497|DIETARY_SUPPLEMENT|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
214623851|NCT04531696|PROCEDURE|Blood draw|Blood draw at inclusion
214623852|NCT04531696|PROCEDURE|Post-mortem tissue collection|Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
214623853|NCT05307484|OTHER|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
214623854|NCT05307484|OTHER|Dengue prevention website|This is a website containing information regarding dengue prevention.
214623855|NCT04623684|DRUG|Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
214623856|NCT04623684|DRUG|Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]|1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
214623857|NCT03234387|OTHER|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
214623858|NCT01397799|DRUG|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
214623859|NCT02757599|OTHER|Ultrasound training|Training on the transvaginal ultrasound simulator.
214623860|NCT01152320|BEHAVIORAL|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
214623861|NCT06190067|DRUG|Azacitidine Plus PD-1 therapy|Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
214623862|NCT03433872|OTHER|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
214623863|NCT03851900|OTHER|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
214623864|NCT03851900|OTHER|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
214623865|NCT03851900|OTHER|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
214623866|NCT02614859|DRUG|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
214623867|NCT02614859|DRUG|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
214623868|NCT00001014|DRUG|Trimetrexate glucuronate|
214623869|NCT00001014|DRUG|Sulfamethoxazole-Trimethoprim|
214623870|NCT00001014|DRUG|Leucovorin calcium|
214718189|NCT04271670|OTHER|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
214718190|NCT04271670|OTHER|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
214718191|NCT01455415|DRUG|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
214718192|NCT01455415|DRUG|placebo|matching placebo 3 time a day
214718193|NCT04374578|DRUG|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
214718194|NCT00891761|DRUG|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
214718195|NCT00891761|DRUG|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
214623871|NCT02983682|DRUG|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
214623872|NCT02184195|DRUG|Olaparib|Tablet -100mg
214623873|NCT02184195|DRUG|Olaparib|Tablet-150mg
214623874|NCT02184195|DRUG|Placebo|Match Olaparib 100mg placebo
214623875|NCT02184195|DRUG|Placebo|Match Olaparib 150mg placebo
214623876|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - active|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
214623877|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - sham|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
214623878|NCT06512012|BEHAVIORAL|yoga and exercise|Technology-Assisted Yoga and Exercise Intervention during 6 months
214623879|NCT03070925|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
214623880|NCT04509375|DEVICE|Cranial Doppler Ultrasonography|Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.
214623881|NCT04509375|DEVICE|Near-Infrared Spectroscopy|Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
214623882|NCT04162184|BEHAVIORAL|Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention|a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
214623883|NCT02385149|OTHER|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
214623884|NCT02385149|OTHER|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
214623885|NCT00336219|DRUG|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
214623886|NCT02334449|DRUG|LML134|LML134 will be administered first as single doses and then as multiple doses
214623887|NCT02334449|DRUG|Placebo|All study cohorts (except food effect cohort) are placebo controlled
214623888|NCT00543426|DRUG|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
214623889|NCT00543426|DRUG|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
214623890|NCT05298189|BEHAVIORAL|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
214623891|NCT05298189|BEHAVIORAL|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
214623892|NCT05298189|BEHAVIORAL|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
214623893|NCT06294886|DIAGNOSTIC_TEST|Screening test to detect endometrial cancer and precancer|The device is designed to detect DNA biomarkers for cancer in cells shed from the lining of the uterus into vaginal fluid
214623894|NCT01857284|DRUG|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
214623895|NCT01857284|DRUG|Ursodeoxycholic Acid Capsules|250mg.tid.po
214623896|NCT00625469|DRUG|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
214623897|NCT01783275|BEHAVIORAL|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
214623898|NCT00409084|PROCEDURE|endoscopic variceal band ligation|endoscopic variceal band ligation
214623899|NCT04897477|DRUG|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
214623900|NCT05505162|DRUG|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
214623901|NCT05505162|DRUG|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
214623902|NCT04839731|DRUG|Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream|Apply twice per day for allotted time
214623903|NCT04839731|DRUG|Nourivan Base Cream|Apply twice per day for allotted time
214623904|NCT04320732|BEHAVIORAL|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
214623905|NCT05928195|DIETARY_SUPPLEMENT|Acute Moderate-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
214718196|NCT00891761|DRUG|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
214718197|NCT00891761|DRUG|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
214718198|NCT00891761|DRUG|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
214718199|NCT01601951|OTHER|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
214718200|NCT02334553|DRUG|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
214718201|NCT02334553|DRUG|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
214718202|NCT03670901|BIOLOGICAL|JHL1101|JHL1101, 100mg/10mL
214718203|NCT03670901|BIOLOGICAL|MabThera|Rituximab, 100mg/10mL
214718204|NCT00587301|DEVICE|Lap-Band|Obesity and adolescents
214718205|NCT02758613|DRUG|Baricitinib|Administered orally.
214718206|NCT02758613|DRUG|Placebo|Administered orally.
214718207|NCT01496274|BIOLOGICAL|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
214718208|NCT04128527|DEVICE|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
214718209|NCT00002941|DRUG|carmustine|
214718210|NCT00002941|DRUG|cyclophosphamide|
214623906|NCT05928195|DIETARY_SUPPLEMENT|Acute High-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
214623907|NCT05928195|DIETARY_SUPPLEMENT|Placebo|Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
214623908|NCT01227044|DRUG|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
214623909|NCT01227044|OTHER|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
214623910|NCT01342835|DRUG|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
214623911|NCT02343172|DRUG|HDM201|
214623912|NCT02343172|DRUG|LEE011|
214623913|NCT00583362|BIOLOGICAL|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
214623914|NCT06156956|PROCEDURE|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14"
214623915|NCT02982135|OTHER|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
214623916|NCT05858619|DRUG|Dupilumab|dupilumab 600 mg injection initially and then 300 mg every other week
214623917|NCT03961503|DRUG|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
214623918|NCT03961503|DRUG|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
214623919|NCT03621514|PROCEDURE|painless indwelling catheter|Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).
214623920|NCT03621514|PROCEDURE|indwelling catheter|The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
214718211|NCT00002941|DRUG|etoposide|
214718212|NCT00002941|DRUG|mesna|
214718213|NCT00002941|PROCEDURE|peripheral blood stem cell transplantation|
214718214|NCT00721617|OTHER|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
214718215|NCT00721617|OTHER|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
214623921|NCT02370615|DRUG|TAK-272|TAK-272 tablet.
214623922|NCT02370615|DRUG|Digoxin|Digoxin tablet.
214623923|NCT02370615|DRUG|Itraconazole|Itraconazole oral solution
214623924|NCT02370615|DRUG|Midazolam|Midazolam syrup.
214623925|NCT02491957|OTHER|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
214718216|NCT00721617|OTHER|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
214718217|NCT03364634|DIAGNOSTIC_TEST|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
214718218|NCT00351819|DRUG|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
214718219|NCT00351819|OTHER|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
214718220|NCT01213914|DEVICE|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
214623926|NCT02527369|DEVICE|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
214623927|NCT02268903|DRUG|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
214718221|NCT01213914|OTHER|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
214718222|NCT06204289|BEHAVIORAL|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
214718223|NCT01804114|PROCEDURE|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
214718224|NCT01804114|PROCEDURE|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
214718225|NCT02285517|PROCEDURE|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
214718226|NCT02285517|PROCEDURE|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
214718227|NCT01191632|RADIATION|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
214718228|NCT01191632|RADIATION|No Radiation|Control group with 0Gy
214718229|NCT00719537|DRUG|Aspirin|Aspirin 81 mg once a day
214718230|NCT00719537|DRUG|Placebo Oral Tablet|Placebo 1 tab Daily
214718231|NCT00719537|DRUG|Progesterone|Oral Progesterone 200 mg Twice Daily
214718232|NCT01018693|DRUG|VAK694; Alutard Avanz SQ|
214718233|NCT01018693|DRUG|VAK694 placebo infusion; Alutard Avanz SQ|
214718234|NCT01018693|DRUG|VAK694 placebo infusion; Saline|
214718235|NCT01360853|DRUG|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
214718236|NCT01360853|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
214718237|NCT01360853|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
214718238|NCT00158405|PROCEDURE|Structured Treatment Interruption|
214718239|NCT00158405|DRUG|Zidovudine (ZDV)|
214718240|NCT00158405|DRUG|Lamivudine (3TC)|
214718241|NCT00158405|DRUG|Efavirenz (EFV)|
214718242|NCT00158405|DRUG|Ritonavir (NRV)|
214718243|NCT00158405|DRUG|Indinavir (IDV)|
214718244|NCT05462405|PROCEDURE|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
214718245|NCT04397029|DEVICE|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
214623928|NCT02268903|DRUG|Placebo|Placebo in one single direct intra venous injection
214623929|NCT03852862|DRUG|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
214623930|NCT03852862|DRUG|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
214623931|NCT00645593|DRUG|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
214623932|NCT00645593|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
214623933|NCT00645593|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
214623934|NCT01585272|DRUG|ENA713|
214718246|NCT01459068|BEHAVIORAL|Common Elements Treatment Approach|"CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)"
214623935|NCT00404690|PROCEDURE|Bedside Silo|silo placed at bedside on admission
214623936|NCT00404690|PROCEDURE|Operative attempt at closure|go the operating room to attempt closure
214623937|NCT05217485|DEVICE|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
214623938|NCT03189823|DEVICE|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
214623939|NCT01579448|BIOLOGICAL|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
214623940|NCT01579448|BIOLOGICAL|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
214623941|NCT01579448|OTHER|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
214623942|NCT03650920|PROCEDURE|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
214623943|NCT03704142|DEVICE|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
214623944|NCT03704142|DEVICE|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
214623945|NCT03704142|DEVICE|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
214623946|NCT03704142|DEVICE|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
214623947|NCT00996268|DRUG|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
214623948|NCT00996268|DRUG|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
214623949|NCT00732277|DRUG|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
214623950|NCT01187186|DRUG|ASP1941|oral
214623951|NCT02905929|DEVICE|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
214623952|NCT02905929|BEHAVIORAL|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
214623953|NCT02905929|BEHAVIORAL|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
214718247|NCT00841269|DRUG|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
214718248|NCT00196196|DEVICE|Codman VPV System|Valve Positioning Verification (VPV) System
214718249|NCT01154595|DIETARY_SUPPLEMENT|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
214623954|NCT02905929|BEHAVIORAL|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
214623955|NCT02905929|OTHER|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
214623956|NCT02905929|BEHAVIORAL|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
214623957|NCT00427076|DRUG|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
214623958|NCT00427076|DRUG|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
214623959|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
214623960|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
214623961|NCT05270590|PROCEDURE|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
214623962|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
214623963|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.25mL dose for intramuscular injection
214623964|NCT03309085|PROCEDURE|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
214623965|NCT03309085|DEVICE|CT scan|CT scan
214623966|NCT06356298|OTHER|Airway Management: Flexible Reinforced Laryngeal Mask Airway|In the FLMA group, a FLMA was applied according to the manufacturer's recommendations. After lubrication of the posterior surface with oxybuprocaine hydrochloride gel, the FLMA was inserted after propping the shoulders. Its cuff was fully deflated before insertion, and the pressure was adjusted to 40 cm H2O with a manometer after insertion.
214623967|NCT06356298|OTHER|Airway Management: Endotracheal Tube|In the ETT group, guided by a visual laryngoscope, a ETT was intubated after lubrication of the surface with oxybuprocaine hydrochloride gel: endotracheal tube size = (16+ age) /4. The cuff pressure of ETT was adjusted to 20 cm H2O with a handheld manometer after inflation.
214623968|NCT04111640|OTHER|CoRe software|Computer-supported cognitive training (CT)
214623969|NCT04111640|OTHER|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
214623970|NCT01737476|PROCEDURE|Transcranial Magnetic Stimulation. PFC|
214623971|NCT01981655|DRUG|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
214623972|NCT01981655|DRUG|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
214623973|NCT00548015|BEHAVIORAL|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
214623974|NCT02908256|DRUG|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
214623975|NCT02908256|DRUG|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
214623976|NCT04400370|DEVICE|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~1. At the entrance of the operating room before induction of anesthesia~2. 1 hour after surgery~3. 24 hours after surgery"
214623977|NCT01718561|PROCEDURE|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
214623978|NCT03990064|OTHER|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
214623979|NCT06341530|DRUG|anlotinib combined with penpulimab|single arm
214623980|NCT02577146|DEVICE|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
214623981|NCT03765138|COMBINATION_PRODUCT|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
214623982|NCT00164112|DRUG|Cooperstown 5+1 alone|
214623983|NCT00164112|DRUG|Azithromycin plus Cooperstown 5+1|
214623984|NCT00164112|DRUG|Telithromycin plus Cooperstown 5+1|
214623985|NCT00164112|DRUG|Levofloxacin plus Cooperstown 5+1|
214623986|NCT05964374|DEVICE|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
214623987|NCT03034564|DRUG|Northera|
214623988|NCT03034564|DRUG|Placebo Oral Tablet|
214623989|NCT05798676|OTHER|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
214623990|NCT01159028|DRUG|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
214718250|NCT01154595|BEHAVIORAL|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
214623991|NCT01159028|DRUG|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
214623992|NCT00530985|BEHAVIORAL|Benefits Counseling|Help deciding whether to work
214623993|NCT00530985|BEHAVIORAL|VA Orientation|Orientation to services available at VA
214623994|NCT02428842|PROCEDURE|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
214623995|NCT02428842|PROCEDURE|Blood sampling|Blood sampling will be performed before and after treatment.
214623996|NCT01238016|DEVICE|experimental|
214623997|NCT02701452|OTHER|COAGO|blood samples for haemostasis and hormonal data
214623998|NCT04247633|DRUG|Palbociclib|Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
214623999|NCT01970501|DRUG|bucindolol hydrochloride|
214624000|NCT01970501|DRUG|metoprolol succinate|
214624001|NCT01970501|OTHER|Placebo oral capsule|
214624002|NCT03924752|DEVICE|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
214718251|NCT05106218|DEVICE|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
214718252|NCT05106218|DEVICE|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
214718253|NCT02910219|DRUG|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
214718254|NCT00708903|DRUG|neratinib|HKI-272
214718255|NCT00708903|OTHER|Placebo|Placebo
214624003|NCT04600245|PROCEDURE|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
214624004|NCT02745587|RADIATION|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
214624005|NCT01859728|DRUG|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
214624006|NCT01859728|DRUG|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
214624007|NCT01859728|DRUG|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
214718256|NCT00708903|DRUG|Moxifloxacin|
214624008|NCT01859728|DRUG|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
214624009|NCT02676089|DRUG|CHF 5993 200/6/12.5 µg|
214624010|NCT02676089|DRUG|CHF 1535 200/6 µg|
214624011|NCT02676089|DRUG|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
214624012|NCT06348485|OTHER|Patients without massive nasal bleeding|No event of massive nasal bleeding after curative radiotherapy
214624013|NCT06348485|OTHER|Patients with massive nasal bleeding|Any event of massive nasal bleeding after curative radiotherapy
214624014|NCT06497348|OTHER|manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder|They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
214624015|NCT03803059|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
214624016|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
214624017|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC)|See above in arm/group description
214624018|NCT05648994|BIOLOGICAL|TCR-T cells|patients will be administration of TCR-T cells
214624019|NCT05648994|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
214624020|NCT05648994|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
214624021|NCT05648994|DRUG|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
214624022|NCT05648994|DRUG|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
214624023|NCT05675540|DEVICE|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
214624024|NCT01231594|DRUG|GSK2118436|Study Drug
214624025|NCT01231594|DRUG|GSK1120212|Study Drug
214624026|NCT01231594|DRUG|Other approved anti-cancer agent|Study Drug
214624027|NCT05462015|BEHAVIORAL|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
214624028|NCT05462015|BEHAVIORAL|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
214624029|NCT01325922|PROCEDURE|DFT Testing with a 50/50% tilt|
214718257|NCT02659475|DRUG|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
214718258|NCT02055170|DRUG|finasteride 5mg oral daily|
214718259|NCT03810521|BIOLOGICAL|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
214624030|NCT04818736|BIOLOGICAL|COVID-19 Vaccination|Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28
214624031|NCT04818736|OTHER|Usual care|Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
214624032|NCT01027819|DEVICE|Mobile bearing|Mobile bearing in total knee arthroplasty
214624033|NCT01027819|DEVICE|Fixed bearing|Fixed bearing in total knee arthroplasty
214624034|NCT06170424|PROCEDURE|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
214624035|NCT06170424|PROCEDURE|Control group|The patients who used skin grafting.
214624036|NCT04013529|BEHAVIORAL|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
214624037|NCT04013529|BEHAVIORAL|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
214624038|NCT01763619|DEVICE|Freedom Cervical Disc|
214624039|NCT04398875|OTHER|Acupuncture and standard care (ASC)|A semi-standardized treatment protocol and standard care will be employed.
214624040|NCT04398875|OTHER|Sham acupuncture and standard care (SSC)|Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.
214624041|NCT04398875|OTHER|Standard care (SC)|Standard care will be employed.
214624042|NCT00554242|DIETARY_SUPPLEMENT|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
214624043|NCT04884321|OTHER|Complementary And Alternative Medicine|No intervention was done in the cross-sectional study
214718260|NCT01719679|BEHAVIORAL|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
214624044|NCT03019042|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
214624045|NCT03019042|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
214624046|NCT04020601|DRUG|Ropivacaine|Local anesthetic injection
214624047|NCT04020601|DRUG|Dextrose|Sham injection
214624048|NCT03116698|DRUG|Low dose DFD07 once daily|Low dose DFD07 once daily
214624049|NCT03116698|DRUG|High dose DFD07 once daily|High dose DFD07 once daily
214624050|NCT03116698|DRUG|High dose DFD07 twice daily|High dose DFD07 twice daily
214624051|NCT03116698|DRUG|Placebo twice daily|Placebo twice daily
214624052|NCT05041751|PROCEDURE|Acupuncture Point Injection|Receive trigger point injections
214624053|NCT05041751|PROCEDURE|Massage Therapy|Perform myofascial release
214624054|NCT05041751|OTHER|Quality-of-Life Assessment|Ancillary studies
214624055|NCT05041751|OTHER|Questionnaire Administration|Ancillary studies
214624056|NCT00788372|DRUG|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
214624057|NCT06317909|OTHER|allergen challenge|Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
214624058|NCT06494696|DIAGNOSTIC_TEST|Ga-68 PSMA PET/MRI|The participant will undergo a Ga-68 PSMA PET/MRI scan, and then be followed up for 2 years to see if prostate cancer is diagnosed.
214624059|NCT00817232|DEVICE|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
214624060|NCT04841421|DRUG|89Zr-CD147|The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
214624061|NCT05335174|DEVICE|Device: HemoSphere monitor and Acumen IQ sensor.|Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
214624062|NCT05815719|DRUG|Corifollitropin Alfa|150 micrograms per dose
214624063|NCT05815719|DRUG|Follitropin Alfa|Variable dose.
214624064|NCT05815719|DRUG|Follitropin Alfa Biosimilar|Variable dose.
214624065|NCT05815719|DRUG|Urinary Human follicle stimulating hormone|Variable dose.
214718261|NCT01797315|DRUG|Sirolimus|
214624066|NCT05402475|BEHAVIORAL|CBT + Mindfulness|Eight weeks of online CBT intervention combined with mindfulness
214624067|NCT05619510|BEHAVIORAL|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
214624068|NCT06025669|BEHAVIORAL|Nap restriction|There are 2 interventions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of nap intervention followed randomization.
214624069|NCT03988530|DRUG|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
214624070|NCT03988530|OTHER|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
214624071|NCT02589691|DRUG|Rocuronium|
214624072|NCT02589691|OTHER|Sodium chloride 0.9%|
214624073|NCT06977178|BEHAVIORAL|Trier Social Stress Test|Psychosocial stress procedure; 5 minutes of public speaking (preceded by 5 minutes of preparation) and 5 minutes of mental arithmetic.
214624074|NCT06977997|OTHER|KAP survey|33 questions to assess knowledge, attitude, and practice of dentists in Egypt regarding TMD
214718262|NCT02382653|DRUG|oral perixicam|Oral adminstration of buccal perixicam
214718263|NCT01513863|DRUG|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
214718264|NCT01513863|DRUG|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
214718265|NCT01513863|DRUG|Placebo|Placebo applied to affected area once a day for 70 days
214624075|NCT06977698|DIAGNOSTIC_TEST|OCT-Raman|a machine to detect positive margins in lumpectomy specimens
214624076|NCT05365035|DRUG|Cladribine|Given by Vein (IV)
214624077|NCT05365035|DRUG|Cytarabine|Given under the skin; subcutaneous injection (SQ)
214624078|NCT05365035|DRUG|Venetoclax|Given by PO
214624079|NCT05365035|DRUG|Azacitidine|Given by IV or subcutaneous injection (SQ)
214624080|NCT04070859|PROCEDURE|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes \& Screws, Tension bands. etc)
214624081|NCT02116777|OTHER|Laboratory Biomarker Analysis|Correlative studies
214624082|NCT02116777|OTHER|Pharmacological Study|Correlative studies
214624083|NCT02116777|DRUG|Talazoparib|Given PO
214624084|NCT02116777|DRUG|Temozolomide|Given PO
214624085|NCT02569814|DRUG|Fimasartan/Amlodipine/Rosuvastatin|
214624086|NCT02569814|DRUG|Fimasartan/Amlodipine|
214624087|NCT02569814|DRUG|Rosuvastatin|
214624088|NCT04558866|DRUG|Testosterone Cypionate|One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
214718266|NCT04009460|DRUG|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
214624089|NCT04558866|DRUG|Darolutamide|During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
214624090|NCT06978244|DRUG|BL1332 ophthalmic solution|Both arms taken four times a day for 1 day
214624091|NCT06978244|DRUG|BL1332 ophthalmic vehicle|Both arms taken four times a day for 1 day
214624092|NCT06978868|OTHER|Sauna Intervention in Clinically Stable Outpatients with HFpEF|Patients were accompanied by study physicians for two sessions weekly, each between 8-15 minutes. We started the first 2 weeks with 8 minutes. Week 3-4: 10 minutes, week 5-6: 12 minutes, week 7-10: 12-15 minutes. Patients were given the freedom to leave the sauna session at any time if they experienced discomfort or were unable to tolerate it. Sessions were done in groups of 5 patients of men or women. The temperature of the sauna was 60°C. After each session, patients were asked to shower with moderate temperature of water and then rest for 20 minutes. Blood pressure and heart rate were measured prior to each session as well as directly after the sauna session and at the end of the rest time.
214718267|NCT02794623|DEVICE|Tinnitus masking|Tinnitus masking via CI system
214718268|NCT01015820|PROCEDURE|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
214718269|NCT01015820|DEVICE|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
214718270|NCT05881512|DEVICE|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
214624093|NCT06978361|PROCEDURE|Microneedling with autologous Platelet Rich Plasma|Patients in group A will undergo Microneedling with autologous PRP
214624094|NCT06978361|PROCEDURE|Microneedling with topical insulin|Patients in group B will undergo Microneedling with Topical insulin ( regular).
214624095|NCT06978543|DEVICE|A Prototype Device Developed for Flat or Inverted Nipples (DFIN)|This is a non-commercial, researchers-developed prototype breastfeeding aid (DFIN) designed for mothers with flat or inverted nipples. Produced using 3D printing, the device is made of biocompatible material and is not commercially registered. Prior to its application in patients, official approval for use was obtained from the Turkish Medicines and Medical Devices Agency (TITCK). DFIN was developed based on clinical experience and literature. Previous studies showed that warming the breast increases nipple temperature and enhances milk production. DFIN contains a 150-200 mL reservoir of warm water (39-41°C) to apply heat directly. It is anatomically designed to fit the breast and is kept in place for 10 minutes. Then the piston in the DFIN is pulled, with the mother's maximum comfort.
214624096|NCT06978543|DEVICE|Modified injector|The syringe method used routinely in the unit was applied by the researcher to mothers immediately after delivery. In this method, the thin part to which the needle is attached is cut with a sharp knife, the plunger is placed in this area and the syringe is applied to the flat or inverted nipple to create a vacuum
214624097|NCT06977438|DRUG|Semaglutide|All participants in this study will receive treatment with Semaglutide
214624098|NCT06978712|PROCEDURE|Sub-gingival instrumentation|All patients will undergo dental biofilm control through patient motivation, oral hygiene instructions and supragingival professional mechanical plaque removal followed by sub-gingival instrumentation.
214718271|NCT02840513|OTHER|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
214718272|NCT03450993|OTHER|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
214718273|NCT04486989|BEHAVIORAL|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
214718274|NCT04486989|OTHER|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
214718275|NCT06052189|PROCEDURE|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
214718276|NCT01105780|DRUG|Placebo|Matching placebo
214718277|NCT01105780|DRUG|JNJ-41443532|250mg tablet once daily for 1 day
214718278|NCT02382757|DRUG|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
214718279|NCT00607126|DEVICE|Lokomat|locomotor training using body weight support on a treadmill
214718280|NCT00607126|PROCEDURE|resistive training|resistive training using theraband and/or weights
214718281|NCT06178757|DRUG|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
214718282|NCT06178757|DRUG|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
214718283|NCT03271957|PROCEDURE|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
214634604|NCT06076655|OTHER|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
214718284|NCT05102331|OTHER|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
214718285|NCT05102331|OTHER|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
214624099|NCT06601660|BEHAVIORAL|Morning Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 7 am to 10 am, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
214624100|NCT06601660|BEHAVIORAL|Night Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 6 pm to 9 pm, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
214624101|NCT06601660|OTHER|No intervention|Group of women who will not receive intervention with combined physical training, but will be evaluated before and after 8 weeks, and monitored, without any intervention with physical exercise.
214624102|NCT06978049|DRUG|Topical Lactic Acid Gel (BAYER)|Lactic acid gel, applied topically once daily to the episiotomy site, starting on postpartum day 7 for a total of seven consecutive days. Commercial product: BAYER (Bucharest, Romania).
214624103|NCT06977373|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer|The CT scan is part of the standard treatment protocol.
214624104|NCT06978101|OTHER|POAG group|Patients had intraocular pressure (IOP)\>21 mmHg.
214624105|NCT06978101|OTHER|Control group|Patients without family history of primary open-angle glaucoma (POAG), IOP ˂21mm Hg.
214624106|NCT06977308|DRUG|Methylphenidate (MPH)|Each participate will receive one oral dose of 60mg methylphenidate.
214624107|NCT06345963|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
214624108|NCT01810653|DRUG|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
214624109|NCT01810653|DRUG|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
214624110|NCT03401515|DRUG|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
214624111|NCT03401515|OTHER|Normal saline|Normal Saline 1 ml every 6 hrs
214624112|NCT01650961|DRUG|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
214624113|NCT01650961|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
214624114|NCT01352832|OTHER|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
214624115|NCT01352832|OTHER|Usual Care|Usual Care
214624116|NCT02682628|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214634605|NCT00375726|BIOLOGICAL|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
214634606|NCT00375726|BIOLOGICAL|Placebo|Placebo for rDEN3/4delta30(ME)
214634607|NCT01146106|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
214634608|NCT03638232|OTHER|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
214634609|NCT03638232|OTHER|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
214634610|NCT03638232|OTHER|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
214634611|NCT02895061|DRUG|Alfacalcidol|Alfacalcidol 1 microgram/capsule
214634612|NCT02575287|DEVICE|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
214634613|NCT02575287|DEVICE|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
214634614|NCT02575287|DEVICE|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
214634615|NCT02833103|DRUG|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
214634616|NCT02833103|DRUG|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
214634617|NCT03217838|DRUG|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
214718286|NCT05102331|PROCEDURE|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
214718287|NCT03255304|BEHAVIORAL|health mindest|groups be confronted with health aspects of food items
214718288|NCT03255304|BEHAVIORAL|palatability mindset|groups be confronted with palatability aspects of food items
214718289|NCT04163055|DEVICE|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
214718290|NCT02690168|BEHAVIORAL|Fasting|72 hour fasting
214718291|NCT00578604|DEVICE|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
214718292|NCT02249208|DEVICE|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
214718293|NCT02249208|DEVICE|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
214718294|NCT02249208|DEVICE|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
214718295|NCT00005808|DRUG|motexafin lutetium|Given IV
214718296|NCT00005808|DRUG|photodynamic therapy|Undergo laser therapy
214718297|NCT00005808|PROCEDURE|loop electrosurgical excision procedure|Undergo LEEP
214718298|NCT00005808|OTHER|laboratory biomarker analysis|Correlative studies
214718299|NCT00308321|DRUG|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
214718300|NCT00308321|DRUG|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
214718301|NCT04516733|OTHER|supportive care|visit with supportiv unit and neuropsychologue every 3 months
214718302|NCT05750888|BEHAVIORAL|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
214718303|NCT05750888|BEHAVIORAL|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
214718304|NCT01313078|DRUG|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
214718305|NCT05666661|OTHER|Sound and light therapy (BBT and FL group)|During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).
214718306|NCT05666661|OTHER|Sound therapy group (BBT)|Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.
214718307|NCT05666661|OTHER|Relaxing music group|Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
214718308|NCT01757587|DRUG|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
214718309|NCT01757587|DRUG|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
214718310|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
214718311|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
214718312|NCT01227720|DRUG|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
214718313|NCT01227720|DRUG|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
214718314|NCT01961089|DEVICE|Galilei Lens Professional|Measurement device
214718315|NCT01961089|DEVICE|IOLMaster|Measurement device
214718316|NCT01961089|DEVICE|Lenstar|Measurement device
214718317|NCT01155960|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
214718318|NCT04745468|DEVICE|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
214718319|NCT01774292|PROCEDURE|Endotracheal intubation with injection of liquid in the cuff|
214718320|NCT01559701|DRUG|PF-00345439|5-80 mg twice-a-day for 12 months
214718321|NCT01268904|DRUG|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
214718322|NCT00014001|DRUG|perphenazine|
214718323|NCT00014001|DRUG|olanzapine|
214718324|NCT00014001|DRUG|quetiapine|
214718325|NCT00014001|DRUG|risperidone|
214624117|NCT06977854|OTHER|Removal from study. In case of adverse event, subject treated for the AE.|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
214624118|NCT06977854|OTHER|removal from study|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
214718326|NCT00014001|DRUG|ziprasidone|
214718327|NCT00014001|DRUG|clozapine|
214718328|NCT00014001|DRUG|fluphenazine decanoate|
214718329|NCT05955430|OTHER|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
214718330|NCT05955430|OTHER|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
214718331|NCT05955430|OTHER|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
214718332|NCT05955430|OTHER|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
214718333|NCT05955430|OTHER|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
214718334|NCT01729104|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
214718335|NCT01729104|DRUG|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
214718336|NCT01729104|DRUG|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
214718337|NCT03990701|COMBINATION_PRODUCT|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
214718338|NCT05163834|BIOLOGICAL|Efgartigimod|intravenous infusion of efgartigimod
214718339|NCT05163834|OTHER|Placebo|intravenous infusion of placebo
214718340|NCT05163834|BIOLOGICAL|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
214718341|NCT03410134|DEVICE|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
214718342|NCT01692834|DRUG|Sandimmune® Injection|
214718343|NCT01692834|DRUG|NeuroSTAT®|
214624119|NCT06978764|PROCEDURE|Thalamic LIFUP|Patients will receive intervention in Thalamus region by LIFUP
214624120|NCT06985472|DRUG|ZO|Orelabrutinib 150mg, po, gd, D1-D28, every 28 days, cycle 1-12; Zuberitamab: intravenously administered on day 1 of the cycle at a dose of 375mg/m2 every 28 days, once every cycle for cycles 1-6 and once every 2 cycles for cycles 7-12.
214624121|NCT06984172|PROCEDURE|Remote cardiac rehabilitation|"The patient, following heart valve surgery, is undergoing home-based cardiovascular rehabilitation during the late recovery phase. The rehabilitation is remotely supervised by a therapist through the Open TeleRehab software and includes aerobic exercises, breathing exercises, and lower limb resistance training.~* Aerobic exercise: Performed 3 times per week, each session lasting 20-40 minutes. Activities include walking, stair climbing, or cycling. Exercise intensity is determined based on:~  1. Target heart rate: Set at the anaerobic threshold identified through Cardiopulmonary Exercise Testing (CPET) prior to hospital discharge; heart rate is monitored using a handheld pulse oximeter.~ 2. Borg Rating of Perceived Exertion (RPE) scale for dyspnea: maintained at 12-13 out of 20.~* Lower limb resistance training: Performed 3 times per week, each session lasting 30-40 minutes. Intensity is based on the one-repetition maximum (1RM).~* Breathing exercises: Performed 3 times per week"
214624122|NCT06984172|PROCEDURE|Facility-based cardiac rehabilitation|"After completing inpatient rehabilitation, patients are discharged and continue supervised outpatient rehabilitation three times per week. The program includes aerobic exercise, lower limb resistance training, and breathing exercises.~Aerobic exercise: Each session lasts 20-40 minutes, depending on the patient's condition, and is performed using a Cardiopulmonary Exercise Testing (CPET) device. Exercise intensity is determined based on the target heart rate and the Borg Rating of Perceived Exertion (RPE) scale for dyspnea and fatigue, in accordance with the 2021 guidelines of the Japanese Circulation Society.~Lower limb resistance training: Each session lasts 30-40 minutes.~Breathing exercises: Each session lasts 15-20 minutes"
214624123|NCT06986031|DRUG|Vaginal product|Intravaginal application of gel PKB171 with a single-use applicator (syringe)
214624124|NCT06655051|DEVICE|endoscopic retrograde biliary drainage (single plastic stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A single plastic stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
214624125|NCT06655051|DEVICE|endoscopic retrograde biliary drainage ( fully covered self-expanding metal stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A fully covered self-expanding metal stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
214624126|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
214624127|NCT02589496|DRUG|pembrolizumab|200 mg every 3 weeks
214624128|NCT01088776|DIETARY_SUPPLEMENT|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
214718344|NCT02679781|DRUG|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
214718345|NCT02679781|DRUG|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
214718346|NCT03490019|DRUG|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
214624129|NCT01088776|DIETARY_SUPPLEMENT|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
214624130|NCT01127685|DEVICE|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
214624131|NCT02544711|DEVICE|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
214624132|NCT02544711|PROCEDURE|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
214624133|NCT03066648|DRUG|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
214624134|NCT03066648|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
214624135|NCT03066648|DRUG|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
214624136|NCT03066648|DRUG|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
214624137|NCT04128488|OTHER|Abdominal MR Imaging|Imaging to evaluate visceral adipose tissue and hepatic lipid content
214624138|NCT04128488|OTHER|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
214624139|NCT04128488|OTHER|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
214624140|NCT04128488|OTHER|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
214624141|NCT06586528|OTHER|NGAGE tool|Access to NGAGE tool
214624142|NCT00102960|DRUG|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
214624143|NCT00102960|DRUG|Didanosine|Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
214624144|NCT00102960|DRUG|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
214624145|NCT00102960|DRUG|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
214624146|NCT00102960|DRUG|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
214624147|NCT00102960|DRUG|Nevirapine|Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
214624148|NCT00102960|DRUG|Zidovudine|First Line Regimen: 240 mg/m\^2 taken orally twice daily
214624149|NCT04375787|DRUG|Atorvastatin|Patients received 80 mg atorvastatin before elective coronary angiography
214624150|NCT05904977|PROCEDURE|Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)|The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
214624151|NCT06862557|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
214624152|NCT05039632|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
214624153|NCT05039632|RADIATION|Radiation Therapy|Undergo Abscopal radiation therapy
214624154|NCT05039632|RADIATION|Radiation Therapy|Undergo RadScopal radiation therapy
214624155|NCT03885427|DRUG|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
214624156|NCT04914325|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
214624157|NCT03789942|PROCEDURE|Oral surgery|Oral surgery procedures
214624158|NCT05307939|DIAGNOSTIC_TEST|HPV ctDNA Assay|HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
214624159|NCT05307939|DIAGNOSTIC_TEST|MRI Studies|Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
214718347|NCT03638115|DEVICE|VaSecure™|Drug Coated PTA Balloon Catheter
214718348|NCT04209400|BIOLOGICAL|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
214718349|NCT04209400|BIOLOGICAL|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
214718350|NCT01754285|DRUG|LF-PB and Placebo|
214718351|NCT01754285|DRUG|Placebo|
214624160|NCT05307939|BEHAVIORAL|EORTC QLQ H&N 35 and C30|The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
214624161|NCT05307939|BEHAVIORAL|MDADI-HN|The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
214624162|NCT05307939|BEHAVIORAL|COST-FACIT|Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
214624163|NCT05307939|RADIATION|Intensity-Modulated Radiation Therapy (Arm A)|59.4-60 Gy in 1.8-2 Gy fractions: CTV\_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
214624164|NCT05307939|COMBINATION_PRODUCT|Chemoradiation (Arm B)|30 Gy in 2 Gy fractions: CTV\_primary, CTV\_node-positive neck, CTV\_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
214624165|NCT04153773|DIAGNOSTIC_TEST|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
214624166|NCT06666621|DRUG|Normal saline infusion|"After assessment of response to lumbar medial branch block, 8 ml normal saline will be infused through IV over several minutes. 10 minutes will pass, and response to lumbar medial branch block procedure will be re-assessed.~After this step, naloxone infusion will occur (see next intervention)"
214718352|NCT01754285|DRUG|LF-PB|
214718353|NCT04644484|BIOLOGICAL|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
214718354|NCT04644484|BIOLOGICAL|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
214718355|NCT04644484|BIOLOGICAL|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
214718356|NCT00317876|DRUG|cyclophosphamide|
214718357|NCT00317876|DRUG|cyclosporine|
214718358|NCT00317876|DRUG|methotrexate|
214718359|NCT00317876|PROCEDURE|allogeneic bone marrow transplantation|
214718360|NCT00317876|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214718361|NCT02560480|DEVICE|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
214718362|NCT02152449|DIETARY_SUPPLEMENT|Oral nutritional supplementation|
214718363|NCT04128618|DEVICE|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
214718364|NCT03182153|DEVICE|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
214718365|NCT00209833|DRUG|Cytarabine|
214624167|NCT06666621|DRUG|Naloxone infusion|After infusion of normal saline and re-assessment of response to lumbar medial branch block procedure, 8 milligrams of naloxone will be infused over several minutes. Then after 10 minutes, response to lumbar medial branch block procedure will be re-reassessed for the final time.
214718366|NCT00209833|DRUG|Idarubicin|
214624168|NCT06911242|DRUG|ARN-75039|An oral therapy for the treatment of Lassa infection
214624169|NCT04532385|DIETARY_SUPPLEMENT|Green tea extract|400 mg capsule
214624170|NCT04532385|DIETARY_SUPPLEMENT|Placebo|400 mg capsule
214624171|NCT02523066|DEVICE|Magna Ease|This study is non-intervention
214624172|NCT06907849|DRUG|124I-evuzamitide|124I-evuzamitide is an iodine-124 (124I) labeled 45 L-amino acid peptide (also known as p5+14) suitable for single dose PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and with the ubiquitous amyloid-associated hypersulfated heparan sulfate proteoglycans.
214624173|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
214624174|NCT03581227|OTHER|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
214624175|NCT03563469|OTHER|Salivary bacterial and pH level|"1. Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~2. The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
214624176|NCT01849874|DRUG|MEK162, MEK inhibitor; oral|multiple dose, single schedule
214624177|NCT01849874|DRUG|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
214718367|NCT00209833|DRUG|Etoposide|
214718368|NCT00209833|DRUG|Fludarabine|
214718369|NCT00209833|DRUG|G-CSF|
214718370|NCT00209833|DRUG|Daunorubicine|
214624178|NCT02104583|DRUG|Eleclazine|Eleclazine tablets administered orally
214624179|NCT02104583|DRUG|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
214634618|NCT03217838|DRUG|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
214634619|NCT03217838|DRUG|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
214634620|NCT02956993|DRUG|vonapanitase|
214634621|NCT02956993|DRUG|Placebo|
214634622|NCT02758340|DRUG|Misoprostol|Women would be given misoprostol tablet by mouth
214634623|NCT02758340|DEVICE|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
214634624|NCT05268926|DRUG|Dapagliflozin 10Mg Tab|dapagliflozin 10 mg/d or matched placebo
214634625|NCT05268926|DRUG|Placebo|Placebo
214634626|NCT05972460|DRUG|IMM2510|IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
214634627|NCT05484960|OTHER|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
214634628|NCT00022529|DRUG|BMS-214662|Given IV
214634629|NCT00022529|BIOLOGICAL|trastuzumab|Given IV
214634630|NCT00022529|OTHER|pharmacological study|Correlative studies
214634631|NCT04509466|DRUG|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
214634632|NCT04509466|DRUG|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
214634633|NCT04509466|DRUG|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
214634634|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
214634635|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
214634636|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
214634637|NCT00985400|BEHAVIORAL|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
214634638|NCT00985400|BEHAVIORAL|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
214634639|NCT00985400|OTHER|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
214634640|NCT00985400|OTHER|Questionnaire administration|
214634641|NCT00985400|BEHAVIORAL|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
214634642|NCT01714986|BEHAVIORAL|Affect School|
214634643|NCT01714986|BEHAVIORAL|Body Awareness Therapy|
214624180|NCT02347098|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
214624181|NCT02347098|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
214624182|NCT02187172|DRUG|Ustekinumab|
214624183|NCT02187172|DRUG|Placebo|
214624184|NCT04673292|BEHAVIORAL|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
214624185|NCT04673292|BEHAVIORAL|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
214634644|NCT03017053|RADIATION|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
214634645|NCT03017053|PROCEDURE|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
214634646|NCT00066898|DRUG|AGI-1067|
214634647|NCT06420973|DRUG|RC48+carboplatin±bevacizumab|RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
214634648|NCT04437355|DIAGNOSTIC_TEST|Specific provocation test|To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (\<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
214634649|NCT05034965|DRUG|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
214634650|NCT05920876|DRUG|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
214634651|NCT01739179|PROCEDURE|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
214634652|NCT01739179|PROCEDURE|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
214634653|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using dehydrated corneas
214634654|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using standard organ culture stored corneas
214634655|NCT04593069|BEHAVIORAL|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
214634656|NCT05181527|DRUG|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
214634657|NCT05181527|DRUG|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
214634658|NCT05181527|DRUG|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
214634659|NCT04094220|PROCEDURE|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
214634660|NCT02889432|DRUG|Oral Melatonin 10mg|
214634661|NCT02889432|DRUG|Placebo|
214634662|NCT03198208|DRUG|Fentanyl dose administration|
214634663|NCT00248183|DRUG|PRX-00023|
214634664|NCT03847610|DRUG|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
214634665|NCT03847610|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
214634666|NCT05753956|DRUG|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
214634667|NCT05753956|DRUG|Placebo|GH002 placebo administered via i.v. bolus injection
214634668|NCT01074138|DRUG|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
214634669|NCT02421237|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|
214634670|NCT02421237|BEHAVIORAL|Supportive Group Therapy|
214634671|NCT04110665|DRUG|Tramadol|Tramadol 100 mg tablet
214634672|NCT04110665|DRUG|Nefopam 20 MG/ML|120 mg for 24 hours
214634673|NCT04110665|DRUG|Morphine Sulfate|Tablet 10mg
214634674|NCT04110665|DRUG|Oxycodone 20mg|release
214634675|NCT05988801|OTHER|Glass ionomer sealant|glass ionomer-based sealant material
214634676|NCT05988801|OTHER|Resin based sealant|resin-based sealant material
214634677|NCT06170398|DIAGNOSTIC_TEST|Wideband tympanometry|Wideband tympanometry
214624186|NCT04673292|BEHAVIORAL|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
214624187|NCT01160757|DEVICE|ultrasound|ultrasound exposure on acute acne lesions
214624188|NCT01427998|DIETARY_SUPPLEMENT|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
214624189|NCT01427998|OTHER|placebo|placebo
214624190|NCT04474769|OTHER|Educational intervention for preceptors|
214624191|NCT02678481|DEVICE|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
214624192|NCT02678481|DEVICE|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
214624193|NCT02409589|DEVICE|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
214634678|NCT06170398|DIAGNOSTIC_TEST|Electrocochleography|Electrocochleography
214634679|NCT06170398|DIAGNOSTIC_TEST|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
214634680|NCT02313779|BEHAVIORAL|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
214634681|NCT02313779|BEHAVIORAL|Mindfulness Meditation|
214634682|NCT05769179|OTHER|Massage group|Massage group will be applied classic massage and cervical stabilisation exercises 3 days a week for 4 weeks
214634683|NCT05769179|OTHER|Connective tissue massage group|Connective tissue massage group will be applied connective tissue massage and cervical stabilisation exercises 3 days a week for 4 weeks
214634684|NCT05769179|OTHER|Mobilization group|Mobilization group will be applied cervical mobilization techniques and cervical stabilisation exercises 3 days a week for 4 weeks
214634685|NCT00096863|DRUG|Ziprasidone|
214634686|NCT00096863|DRUG|Haloperidol|
214634687|NCT00096863|OTHER|Placebo|
214634688|NCT03056118|DRUG|6-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
214634689|NCT03056118|DRUG|12-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
214634690|NCT03056118|DEVICE|Zotarolimus eluting stent|Zotarolimus eluting stent is applied to coronary stenotic lesion
214634691|NCT03056118|DEVICE|Biolimus eluting stent|Biolimus eluting stent is applied to coronary stenotic lesion
214634692|NCT01552044|DRUG|Spironolactone|25mg tablet once a day for 1 month
214634693|NCT01552044|DRUG|Placebo|one tablet once a day for 1 month
214634694|NCT00016666|DRUG|Propranolol|
214634695|NCT00205478|DRUG|VX-702|
214634696|NCT01843855|DRUG|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
214634697|NCT01843855|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
214634698|NCT02624037|OTHER|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
214634699|NCT04534777|OTHER|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
214634700|NCT05167019|BEHAVIORAL|CODE intervention|The CODE intervention consists of 1) One interactive session of 2 to 3 hrs focusing on the concepts of medical-ethical decision-making, the psychological challenge of dealing with ethically sensitive medical topics, and empowering leadership. 2) Observation and debrief of the interdisciplinary meeting to enhance self-reflection on empowering leadership and managing group dynamics. 3) Individual coaching on the spot in self-reflective and empowering leadership and in managing groups dynamics with regard to ethical decision-making about patients who are perceived to receive excessive treatment during the intervention period, and in absence of such patients, every item with regard to ethical decision-making that is important for the coachee. 4) During the intervention coaches and doctors in charge will be informed of the presence of a patient potentially receiving excessive treatment in their ward by an electronic alert.
214634701|NCT05167019|OTHER|Usual care|The control group will receive usual care in which the quality of the ethical decision-making is determined by the clinical team according to their usual practice. Except from a treatment-limitation-decisions guideline which focuses on the legal and deontological framework, no other guideline with regard to ethical decision-making has been implemented at the Ghent University Hospital. In one ward (geriatrics), there is a ongoing project in which a clinical nurse specialist stimulates and performes advance care planning conversations with patient and/or relatives at request of the team and who organizes debriefings when needed based on the ethical concerns of the nurses.
214634702|NCT05220605|DRUG|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
214624194|NCT02409589|PROCEDURE|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
214624195|NCT02960828|PROCEDURE|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
214624196|NCT02960828|DRUG|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
214718371|NCT03532984|DIAGNOSTIC_TEST|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
214718372|NCT02191280|DRUG|Antistax®, low dose|
214718373|NCT02191280|DRUG|Antistax®, high dose|
214718374|NCT02191280|DRUG|Placebo|
214624197|NCT02960828|DEVICE|Subthreshold Laser|
214624198|NCT02831413|BEHAVIORAL|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
214624199|NCT02831413|BEHAVIORAL|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
214624200|NCT05097703|BEHAVIORAL|Sleep Resource|The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
214624201|NCT03024489|DRUG|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
214624202|NCT03024489|DRUG|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
214624203|NCT03024489|DRUG|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
214624204|NCT03024489|DRUG|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
214624205|NCT03024489|DRUG|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
214624206|NCT03024489|RADIATION|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
214624207|NCT01042860|DIETARY_SUPPLEMENT|Lutein|Lutein supplement, 10 mg daily
214624208|NCT01042860|DIETARY_SUPPLEMENT|Placebo|Placebo
214624209|NCT03914807|OTHER|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
214624210|NCT03914807|OTHER|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
214624211|NCT01082432|OTHER|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
214624212|NCT02531581|DRUG|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc
214624213|NCT02531581|DRUG|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
214624214|NCT02913937|DEVICE|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
214624215|NCT02913937|DEVICE|Endodontic needle|Endodontic irrigation
214624216|NCT02952157|DRUG|Lidocaine jelly application|
214624217|NCT02952157|DRUG|Normal saline application|
214624218|NCT02064530|DRUG|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
214624219|NCT02064530|DRUG|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
214624220|NCT02064530|DRUG|serum physiologic|21 ml serum physiologic is applied interfasially
214624221|NCT02830880|DRUG|FACBC PET-CT|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
214624222|NCT02830880|OTHER|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
214718375|NCT03744130|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|"1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station"
214624223|NCT04048915|BEHAVIORAL|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
214624224|NCT04048915|BEHAVIORAL|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
214624225|NCT00750958|PROCEDURE|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
214624226|NCT02646982|DRUG|Placebo|A matched placebo will be given once daily for 12 months.
214624227|NCT02646982|DRUG|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
214624228|NCT03045861|DRUG|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
214624229|NCT03045861|DRUG|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
214624230|NCT01077843|DRUG|Etoricoxib|Cox-2 inhibitor
214624231|NCT01077843|DRUG|Other Cox-2 inhibitors|Cox-2 inhibitor
214624232|NCT01077843|DRUG|Other Non-selective NSAIDs|Non-selective NSAID
214624233|NCT01077843|OTHER|No anti-inflammatory treatment|No anti-inflammatory prescription
214624234|NCT00527579|DRUG|[F-18]FBR|
214624235|NCT01412593|BIOLOGICAL|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
214624236|NCT01251809|DRUG|Oncaspar|2000 U/m2 BSA, single infusion
214624237|NCT01251809|DRUG|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
214718376|NCT01445964|DRUG|Atenolol|Atenolol oral administration
214718377|NCT01445964|DRUG|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
214624238|NCT00528762|BEHAVIORAL|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
214624239|NCT05400213|DEVICE|Vallos (DCP)|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
214624240|NCT05400213|DEVICE|Vallomix (DCF)|A combination of cow-derived xenograft and human-derived DFDBA particulate
214624241|NCT05400213|DEVICE|Vallos-F (DPX)|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
214624242|NCT05400213|DEVICE|Vallomix-F (DFX)|A combination of cow-derived xenograft and human-derived DFDBA fibers
214634703|NCT05725356|OTHER|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
214634704|NCT03945708|DEVICE|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
214634705|NCT01459705|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
214634706|NCT01459705|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
214634707|NCT01459705|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
214634708|NCT01090882|DRUG|Bupivocaine|20ml 0.25% at beginning of operation
214634709|NCT01090882|DRUG|0.9% normal saline solution|20ml 0.9% NaCl
214634710|NCT03658486|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
214634711|NCT03021902|DRUG|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
214634712|NCT03021902|DEVICE|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
214634713|NCT01428817|DRUG|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214634714|NCT01428817|DRUG|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214634715|NCT01428817|DRUG|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214634716|NCT01428817|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214634717|NCT01428817|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
214624243|NCT06047041|BEHAVIORAL|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation."
214624244|NCT06047041|BEHAVIORAL|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
214624245|NCT05571787|DRUG|HMPL-523|700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
214624246|NCT05571787|DRUG|Rabeprazole|40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
214624247|NCT01464476|DRUG|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
214624248|NCT01464476|DRUG|Placebo|Dose-matched placebo. Once daily, oral administration
214624249|NCT04096911|DRUG|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
214718378|NCT01445964|DRUG|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
214718379|NCT04409301|OTHER|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
214718380|NCT04409301|BEHAVIORAL|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
214718381|NCT05474989|DRUG|LSD|Moderate to high dose LSD
214718382|NCT05474989|DRUG|Active placebo|Low dose LSD
214624250|NCT04096911|DRUG|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
214718383|NCT01203787|DRUG|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
214624251|NCT05453331|PROCEDURE|bilateral STN deep brain stimulation|bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
214624252|NCT05580029|DEVICE|Triamcinolone Topical|The treatments will consist of fractional ablative CO2 laser therapies followed by topical application of triamcinolone dosed at 40 mg/ml.
214624253|NCT05580029|PROCEDURE|Fractional Ablative CO2 Therapy|1st pass: 30-40 mJ at 5% density. 2nd pass: 120 mJ at 1% density
214624254|NCT05580029|DRUG|EMLA 5% cream|2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
214624255|NCT02518009|OTHER|Genetic men treated with estrogen|Observational during estrogen treatment
214624256|NCT02518009|OTHER|Genetic women treated with androgen|Observational during androgen treatment
214624257|NCT06292936|BEHAVIORAL|Acceptance-Based Behavioral Intervention|"Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs)."
214624258|NCT03551509|PROCEDURE|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
214624259|NCT03551509|PROCEDURE|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
214624260|NCT03551509|BIOLOGICAL|Alternative Treatment Group|Patients who meet pre-op inclusion criteria where a repair cannot be accomplished due to intraoperative findings will remain in the study. This group will be analyzed separately and still follow study procedures.
214624261|NCT00253175|DRUG|topiramate|
214624262|NCT04461262|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
214624263|NCT04461262|DEVICE|Standard Care|Uncoated Foley catheter
214624264|NCT01337856|OTHER|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
214624265|NCT04697459|OTHER|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
214624266|NCT04697459|OTHER|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
214624267|NCT03966742|PROCEDURE|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
214624268|NCT04052685|PROCEDURE|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
214624269|NCT04052685|PROCEDURE|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
214624270|NCT03891940|PROCEDURE|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
214624271|NCT02874807|DRUG|Empagliflozin|
214624272|NCT02874807|OTHER|Placebo|
214624273|NCT03443908|DEVICE|CPAP|CPAP therapy 3-4 weeks
214624274|NCT04720482|DIAGNOSTIC_TEST|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
214624275|NCT04720482|DIAGNOSTIC_TEST|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
214624276|NCT04515693|OTHER|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
214624277|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
214718384|NCT01203787|DRUG|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
214718385|NCT03404518|DRUG|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
214718386|NCT03404518|DRUG|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
214624278|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
214718387|NCT01052181|DRUG|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
214718388|NCT01052181|DRUG|placebo|2 sachets monthly for an year
214718389|NCT05759546|DRUG|Fluzoparib|Parp inhibitor
214718390|NCT05759546|DRUG|Dalpiciclib|CDK4/6 inhibitor
214718391|NCT05759546|DRUG|Fulvestrant/AI|Endocrine therapy
214718392|NCT02288039|OTHER|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
214718393|NCT03765710|OTHER|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
214718394|NCT03765710|OTHER|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
214718395|NCT03006081|DRUG|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
214718396|NCT05911412|BEHAVIORAL|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
214718397|NCT05674604|PROCEDURE|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
214718398|NCT01090869|BEHAVIORAL|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
214718399|NCT02151968|PROCEDURE|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
214718400|NCT02151968|PROCEDURE|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
214718401|NCT00083629|PROCEDURE|PET|
214718402|NCT01745913|DEVICE|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
214624279|NCT01700556|OTHER|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
214624280|NCT01700556|OTHER|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
214718403|NCT01745913|DRUG|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
214718404|NCT01745913|DRUG|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
214718405|NCT01745913|DRUG|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
214718406|NCT01745913|PROCEDURE|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of \> 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
214624281|NCT01700556|OTHER|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
214624282|NCT01700556|OTHER|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
214718407|NCT01745913|PROCEDURE|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
214718408|NCT02569021|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)"
214718409|NCT02569021|OTHER|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
214624283|NCT04252846|DRUG|Perampanel|Perampanel oral tablets or oral suspension.
214624284|NCT00770614|DRUG|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
214624285|NCT00770614|DRUG|Isotonic saline|0.9% sodium chloride
214718410|NCT02569021|OTHER|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
214624286|NCT00770614|DRUG|Placebo|Placebo
214624287|NCT01040351|PROCEDURE|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
214624288|NCT04631575|DRUG|SHR6390|SHR6390, PO,single-dose
214624289|NCT01230307|DRUG|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
214624290|NCT01230307|DRUG|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
214624291|NCT02634853|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
214624292|NCT02634853|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
214624293|NCT04243590|BEHAVIORAL|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
214624294|NCT04243590|BEHAVIORAL|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
214718411|NCT02569021|DEVICE|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
214718412|NCT02569021|DEVICE|Trigno wireless system|The Trigno system measure muscle contractions.
214718413|NCT02569021|OTHER|GaitRite walking assessment.|GaitRite records a patients gait pattern.
214718414|NCT04961879|PROCEDURE|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~\- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
214718415|NCT04961879|PROCEDURE|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~\- this flap is harvested from the same finger ."
214718416|NCT02089503|OTHER|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
214718417|NCT03127579|BEHAVIORAL|Longer meal duration|Participants have 50% more time to eat than usual
214718418|NCT00279032|DRUG|GW406381|
214624295|NCT04243590|BEHAVIORAL|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study."
214624296|NCT00567970|PROCEDURE|quality-of-life assessment|
214624297|NCT00567970|RADIATION|stereotactic body radiation therapy|
214624298|NCT04527302|COMBINATION_PRODUCT|ERP combined with high-definition active tDCS|"The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4)."
214624299|NCT04527302|COMBINATION_PRODUCT|ERP combined with sham tDCS|Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
214718419|NCT00033982|DRUG|Posaconazole|
214718420|NCT04454138|DEVICE|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
214718421|NCT05830526|OTHER|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
214718422|NCT03693404|DRUG|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
214718423|NCT03693404|DRUG|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
214718424|NCT03693404|DRUG|General Anesthetics|Placebo group will only receive standard of care general anesthesia
214624300|NCT00577785|OTHER|tissue procurement|No intervention. Tissue procurement study.
214718425|NCT00223912|DEVICE|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
214718426|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
214718427|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
214718428|NCT00201760|DRUG|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
214718429|NCT00201760|DRUG|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
214718430|NCT00201760|DRUG|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
214718431|NCT06022172|DIAGNOSTIC_TEST|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
214624301|NCT06126432|DIETARY_SUPPLEMENT|Yugart|Yugart 2 bottles per day for 1 month
214624302|NCT02027142|OTHER|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality."
214624303|NCT02027142|OTHER|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
214624304|NCT02027142|OTHER|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
214624305|NCT02027142|OTHER|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
214624306|NCT00004262|PROCEDURE|conventional surgery|
214624307|NCT00004262|RADIATION|3-dimensional conformal radiation therapy|
214624308|NCT00004262|RADIATION|stereotactic radiosurgery|
214624309|NCT00004262|DRUG|motexafin gadolinium|Given IV
214624310|NCT00004262|PROCEDURE|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
214624311|NCT00004262|PROCEDURE|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
214624312|NCT01523379|DRUG|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
214624313|NCT01523379|DRUG|Placebo|NaCl i.v. two times a day, two days in an row
214624314|NCT03203044|OTHER|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
214624315|NCT00244270|DEVICE|totally implantable vascular access device|totally implantable vascular access device
214624316|NCT03411720|OTHER|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
214624317|NCT02774447|PROCEDURE|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
214624318|NCT00933673|DRUG|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
214624319|NCT01788384|DRUG|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
214624320|NCT01788384|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
214624321|NCT01788384|DRUG|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
214624322|NCT01077648|DRUG|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
214634718|NCT05199324|DRUG|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
214634719|NCT05199324|DRUG|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
214634720|NCT00035282|DRUG|aprepitant|
214634721|NCT00035282|DRUG|Comparator: placebo (unspecified)|
214634722|NCT05046405|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
214634723|NCT00130403|DRUG|risedronate sodium|
214634724|NCT02886416|OTHER|Non interventional study|
214634725|NCT04486092|DRUG|Valproic Acid|
214624323|NCT05319184|OTHER|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
214624324|NCT04776382|OTHER|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
214624325|NCT02859181|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
214624326|NCT03578471|DEVICE|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
214624327|NCT03578471|DEVICE|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
214624328|NCT03578471|DEVICE|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
214624329|NCT00114582|PROCEDURE|family style dinner|
214624330|NCT02605187|OTHER|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
214624331|NCT02605187|OTHER|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
214624332|NCT02605187|DRUG|Ibuprofen|Ibuprofen 600mg po q6h
214624333|NCT02605187|DRUG|Acetaminophen|Acetaminophen 650mg po q6h
214624334|NCT02605187|DRUG|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
214624335|NCT02605187|DRUG|Morphine (low)|Intrathecal morphine dose 50mcg
214624336|NCT02605187|DRUG|Morphine (med)|Intrathecal morphine dose 150mcg
214624337|NCT02605187|DRUG|Morphine (high)|Intrathecal morphine 300mcg
214624338|NCT05433571|DEVICE|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
214624339|NCT02562560|BEHAVIORAL|Neuropsychological tests|
214624340|NCT02562560|DEVICE|Cerebral imaging (MRI, PET-FDG)|
214624341|NCT01520935|OTHER|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
214624342|NCT02340585|DEVICE|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
214634726|NCT04425187|DRUG|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
214634727|NCT04425187|DRUG|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
214634728|NCT03821740|OTHER|Kinesiotaping|Mc Connel taping and another kinesiotaping technique
214634729|NCT06238167|DRUG|Tislelizumab|Tislelizumab, 200mg Q3W, max 16 cycles.
214634730|NCT06238167|DRUG|S-1 therapy|S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).
214634731|NCT06238167|DRUG|low dose SOX therapy|Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
214634732|NCT02302976|DRUG|cocaine hydrochloride|
214634733|NCT02302976|DRUG|exenatide|
214634734|NCT02302976|DRUG|placebo|
214634735|NCT00042887|DRUG|mitomycin C|
214634736|NCT00042887|PROCEDURE|conventional surgery|
214634737|NCT03222791|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
214634738|NCT03222791|OTHER|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
214634739|NCT02499861|DRUG|Decitabine and Genistein|intravenous Decitabine with oral genistein
214634740|NCT04891289|DRUG|Gemcitabine|See arm for details.
214634741|NCT04891289|DRUG|Oxaliplatin|See arm for details.
214634742|NCT04891289|DRUG|Dexamethasone|See arm for details.
214634743|NCT04891289|DRUG|Floxuridine (FUDR)|See arm for details.
214634744|NCT04891289|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
214634745|NCT01169155|OTHER|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
214634746|NCT02595476|DRUG|Remifentanil|
214634747|NCT02595476|DRUG|propofol|
214624343|NCT02431065|PROCEDURE|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
214624344|NCT02431065|DRUG|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
214624345|NCT02431065|OTHER|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
214624346|NCT06478069|DIAGNOSTIC_TEST|Group A|Group A was treated with Ibuprofen Dosage After breakfast and after dinner for 6 weeks.
214624347|NCT06478069|BEHAVIORAL|Group B|Group B was treated with physical therapy; (Upper limb: The stroke patient warmed up with some gentle stretches for the wrist and fingers to get the muscles ready. They subsequently engaged in resistance training using dumbbells or resistance bands to increase the strength of their upper limbs. Bicep curls, tricep extensions, and shoulder presses were some of these exercises. They tried to complete two to three sets of ten to fifteen repetitions for each exercise, progressively increasing the resistance as their strength increased. Then, to improve dexterity and coordination in daily tasks, functional exercises were included.
214624348|NCT02808000|DEVICE|BIP Foley (latex) or BIP Foley -silicone|
214624349|NCT02808000|DEVICE|Standard catheter|
214624350|NCT03586128|DRUG|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
214624351|NCT03586128|DRUG|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
214624352|NCT06359873|DIAGNOSTIC_TEST|CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)|"CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\].~C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\].~LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database."
214624353|NCT02238275|DRUG|Micardis® plus|
214624354|NCT04543071|DRUG|Motixafortide|1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
214624355|NCT04543071|DRUG|Cemiplimab|350 mg intravenous (IV) once every 21 days
214624356|NCT04543071|DRUG|Gemcitabine|1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
214624357|NCT04543071|DRUG|Nab paclitaxel|125 mg/m2 IV on days 1, 8, 14 (every 28 days)
214624358|NCT01918007|PROCEDURE|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
214634748|NCT02595476|DEVICE|TCI|
214634749|NCT02595476|PROCEDURE|Tetanic stimulation|
214634750|NCT02595476|DEVICE|Algiscan|Pupillometry
214634751|NCT04360070|DRUG|Ketamine Hydrochloride|Parenteral General Anesthetic
214634752|NCT02396186|DEVICE|PTCA Balloon Angioplasty|
214634753|NCT06084520|DIAGNOSTIC_TEST|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
214624359|NCT05778500|DEVICE|COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines
214624360|NCT00631774|DIETARY_SUPPLEMENT|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
214624361|NCT02150577|BEHAVIORAL|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
214624362|NCT02830100|OTHER|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
214624363|NCT02830100|DEVICE|MRI|
214624364|NCT04983407|DRUG|batiraxcept|Batiraxcept is experimental drug
214624365|NCT04983407|DRUG|Nab paclitaxel|Nab paclitaxel is active comparator
214624366|NCT04983407|DRUG|Gemcitabine|Gemcitabine is active comparator
214624367|NCT02085382|PROCEDURE|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
214634754|NCT06084520|DIAGNOSTIC_TEST|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
214634755|NCT06084520|DIAGNOSTIC_TEST|PETh|Alcohol use detection
214634756|NCT06084520|DIAGNOSTIC_TEST|ASI-SR|Cross-validation form
214634757|NCT06084520|DIAGNOSTIC_TEST|AUDIT|Cross-validation form
214634758|NCT06084520|DIAGNOSTIC_TEST|DUDIT|Cross-validation form
214624368|NCT02085382|PROCEDURE|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
214624369|NCT03623607|OTHER|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
214624370|NCT05710471|DRUG|Brolucizumab|Intravitreal injection
214624371|NCT05710471|DRUG|Aflibercept|Intravitreal injection
214624372|NCT04174781|DRUG|Sintilimab|Sintilimab: 200mg iv Q3W D1
214624373|NCT04174781|DRUG|DEB-TACE|DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
214624374|NCT05059314|OTHER|Brisk walking (moderate physical activity)|"1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6"
214624375|NCT05298007|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
214624376|NCT05298007|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214624377|NCT03410173|DRUG|Taurine|
214624378|NCT03410173|DRUG|Placebo|
214624379|NCT00952497|DRUG|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
214624380|NCT06548256|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|probiotics
214624381|NCT03958162|DIAGNOSTIC_TEST|lung biopsy|transbronchial lung cryobiopsy
214624382|NCT02701543|DEVICE|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
214624383|NCT02701543|DEVICE|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
214624384|NCT02666339|OTHER|Usual care|Usual care : drug therapy, nurse and physician consultations.
214624385|NCT02666339|BEHAVIORAL|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
214624386|NCT05389163|DEVICE|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
214624387|NCT05389163|DEVICE|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
214624388|NCT02442973|PROCEDURE|Control group (CG): standard practice|Standard practice group
214624389|NCT02442973|PROCEDURE|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
214624390|NCT02442973|DEVICE|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
214624391|NCT03551223|BIOLOGICAL|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
214624392|NCT04423809|OTHER|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
214624393|NCT03951623|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
214624394|NCT03951623|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
214624395|NCT01143753|DRUG|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
214624396|NCT00014456|BIOLOGICAL|filgrastim|
214624397|NCT00014456|DRUG|docetaxel|
214624398|NCT00014456|DRUG|gemcitabine hydrochloride|
214624399|NCT06544161|DEVICE|CPMX2|The CPMX2 is a point-of-care device for non-invasive, real-time, and intermittent monitoring of vascular occlusion pressure.
214624400|NCT01838109|DIETARY_SUPPLEMENT|oral nutritional supplement|
214624401|NCT00142350|DRUG|continuous infusion of 5-fluorouracil|
214624402|NCT00142350|DRUG|combination of irinotecan and cisplatin|
214624403|NCT00142350|DRUG|oral administration of S-1|
214624404|NCT00800293|DRUG|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
214624405|NCT03969849|DRUG|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
214624406|NCT03969849|DRUG|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
214624407|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
214624408|NCT01732796|DRUG|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
214624409|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
214624410|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
214624411|NCT01732796|DRUG|BI 201335 (Faldaprevir)|24 weeks of BI 201335
214624412|NCT01732796|DRUG|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
214624413|NCT01732796|DRUG|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
214624414|NCT01732796|DRUG|Faldaprevir (BI 201335)|24 weeks of 201335
214624415|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
214624416|NCT01422148|DRUG|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
214634759|NCT06084520|DIAGNOSTIC_TEST|Brief Pain Inventory - BPI|Cross-validation form
214624417|NCT01422148|DRUG|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
214624418|NCT05626270|DEVICE|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
214624419|NCT02441049|BEHAVIORAL|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
214624420|NCT03639870|DEVICE|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
214624421|NCT03147716|OTHER|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
214624422|NCT03147716|OTHER|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
214624423|NCT03147716|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
214624424|NCT03147716|OTHER|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
214624425|NCT01023633|DRUG|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
214624426|NCT01089348|DRUG|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
214624427|NCT01089348|DRUG|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
214624428|NCT02376270|DIETARY_SUPPLEMENT|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
214624429|NCT02376270|DIETARY_SUPPLEMENT|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
214624430|NCT05087550|PROCEDURE|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
214624431|NCT05774730|OTHER|Emphysema quantitative analysis software based on chest image AI technology|The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.
214624432|NCT05774730|OTHER|artificial analysis of chest image|The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.
214624433|NCT05774730|PROCEDURE|imported Chartis detection system|The participants would undergo imported Chartis detection system.
214624434|NCT06125769|PROCEDURE|Liver transplantation|Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
214624435|NCT02310776|DEVICE|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
214624436|NCT02310776|DEVICE|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
214624437|NCT03257670|DRUG|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
214624438|NCT03257670|DEVICE|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
214624439|NCT00280306|OTHER|No interventions|No intervention
214624440|NCT06211894|PROCEDURE|transobturator tape|transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
214634760|NCT06084520|DIAGNOSTIC_TEST|Patient Global Impression of Change PGIC|Cross-validation form
214634761|NCT06084520|DIAGNOSTIC_TEST|GAD-7|Cross-validation form
214634762|NCT06084520|DIAGNOSTIC_TEST|Patient Health questionnaire (PHQ9)|Cross-validation form
214634763|NCT06084520|DIAGNOSTIC_TEST|DBS - cannabis test|cross-validation form
214624441|NCT05267275|PROCEDURE|extended resection with splenic flexure mobilization|During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
214624442|NCT05144750|BEHAVIORAL|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
214624443|NCT00117429|BIOLOGICAL|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
214624444|NCT02854514|PROCEDURE|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
214624445|NCT02888093|DEVICE|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
214624446|NCT02389127|DEVICE|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
214624447|NCT05970198|RADIATION|Total Marrow irradiation，TMI|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min."
214624448|NCT05970198|PROCEDURE|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation;Porting method melphalan
214624449|NCT02104986|DRUG|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
214624450|NCT02104986|DRUG|Vepeside-ifosfamide-Cisplatin|
214624451|NCT00530270|DRUG|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
214624452|NCT00530270|DRUG|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
214624453|NCT01858077|DEVICE|ABSORB BVS™|Bioresorbable scaffold
214624454|NCT01858077|DEVICE|XIENCE™|Drug eluting metallic stent
214624455|NCT02975895|DEVICE|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
214624456|NCT02975895|DEVICE|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
214624457|NCT01169298|DRUG|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
214624458|NCT01823042|DRUG|azathioprine+enteral nutrition|
214624459|NCT01823042|DRUG|Azathioprine|
214624460|NCT02963389|DRUG|Tripegfilgrastim|
214624461|NCT02474212|DRUG|Enoxaparin|
214624462|NCT00283114|DRUG|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
214624463|NCT02324920|DEVICE|DDD-CLS|
214624464|NCT02324920|DEVICE|ODO|
214624465|NCT04240444|DEVICE|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
214624466|NCT05988476|OTHER|Exercise|5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
214624467|NCT05988476|DEVICE|Pulsed Electromagnetic Field Therapy|5 day/week, two week,two sessions consisting of 180 minutes
214624468|NCT01468584|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
214624469|NCT01468584|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
214624470|NCT01468584|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
214624471|NCT00892385|DRUG|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
214634764|NCT06084520|OTHER|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
214624472|NCT00892385|DRUG|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214624473|NCT04998435|PROCEDURE|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
214624474|NCT04998435|PROCEDURE|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
214624475|NCT00142467|DRUG|Gemcitabine|
214624476|NCT00142467|DRUG|Oxaliplatin|
214624477|NCT00142467|DRUG|Bevacizumab|
214624478|NCT00238251|DRUG|gefitinib|Once daily during days 1-28
214624479|NCT00238251|DRUG|temozolomide|Once daily on days 1-21
214624480|NCT00238251|RADIATION|radiation therapy|Whole brain radiotherapy
214624481|NCT03972969|BEHAVIORAL|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
214624482|NCT03972969|BEHAVIORAL|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
214624483|NCT03972969|BEHAVIORAL|Health education|Provision of general information about a variety of topics
214624484|NCT03927001|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
214634765|NCT03858673|PROCEDURE|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
214634766|NCT01951820|DRUG|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
214634767|NCT01951820|DRUG|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
214634768|NCT01951820|DRUG|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
214634769|NCT02829840|DRUG|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
214634770|NCT02829840|DRUG|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
214634771|NCT02829840|BEHAVIORAL|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
214634772|NCT05476159|DRUG|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
214634773|NCT05476159|DEVICE|Gastric bypass|Roux and Y Gastric bypass
214634774|NCT03290833|DEVICE|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
214634775|NCT03290833|OTHER|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
214624485|NCT05413382|DIETARY_SUPPLEMENT|Biofresh® 4plus|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
214624486|NCT05413382|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
214624487|NCT03024554|DEVICE|Implantation of the Bifurcated Multilayer Flow Modulator|
214624488|NCT01339806|BEHAVIORAL|Cognitive Rehab|APT-III, Other standard individual and group interventions.
214624489|NCT01339806|BEHAVIORAL|Brainworks|POSIT
214624490|NCT01339806|BEHAVIORAL|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
214624491|NCT01155804|BEHAVIORAL|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
214624492|NCT03971279|DRUG|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
214624493|NCT05882448|PROCEDURE|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
214624494|NCT05882448|PROCEDURE|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
214624495|NCT02734160|DRUG|Galunisertib|Administered orally
214624496|NCT02734160|DRUG|Durvalumab|Administered IV
214624497|NCT01381432|DRUG|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
214624498|NCT04066972|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
214624499|NCT00976222|DRUG|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
214624500|NCT00779649|OTHER|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
214624501|NCT00779649|OTHER|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
214624502|NCT01432873|DRUG|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
214624503|NCT01432873|DRUG|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
214624504|NCT03267121|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
214624505|NCT03267121|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
214624506|NCT06330389|PROCEDURE|Burn Injuries Graft Surgery|Burn Injuries Graft Surgery
214624507|NCT01628588|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
214624508|NCT00959868|DRUG|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
214634776|NCT01512303|BEHAVIORAL|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
214718432|NCT01999348|DRUG|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
214718433|NCT05820646|OTHER|Boswellia Sacra|"1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days"
214624509|NCT04568278|OTHER|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
214624510|NCT04778254|OTHER|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
214624511|NCT04778254|OTHER|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
214624512|NCT04778254|OTHER|conventional obturator|clasp retained obturator for management of hemi maxillectomy
214624513|NCT01399788|DRUG|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
214624514|NCT01399788|DRUG|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
214624515|NCT04944160|OTHER|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
214624516|NCT04944160|OTHER|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
214624517|NCT02919436|DRUG|Tamsulosin|Active drug
214624518|NCT02919436|DRUG|Placebo|Lactose-filled capsules identical to active drug
214624519|NCT00911352|DEVICE|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for \> 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
214634777|NCT01512303|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
214634778|NCT03506243|BIOLOGICAL|Follitrope PFS|Follitrope PFS
214634779|NCT03506243|BIOLOGICAL|Gonal-f pen|Gonal-f pen
214634780|NCT04349774|DRUG|Control Group - ESP block with SAP block|None - Control Group
214634781|NCT04349774|DRUG|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
214634782|NCT05243264|BEHAVIORAL|Empower@Home|The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
214634783|NCT03081520|BEHAVIORAL|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
214634784|NCT03081520|BEHAVIORAL|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
214634785|NCT03081520|BEHAVIORAL|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
214634786|NCT04543643|DRUG|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
214634787|NCT04543643|DRUG|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
214624520|NCT02383732|BEHAVIORAL|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
214624521|NCT02383732|BEHAVIORAL|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
214624522|NCT02383732|BEHAVIORAL|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
214624523|NCT01441037|DRUG|Danazol|Danazol, 800 mg daily by mouth for 2 years
214624524|NCT05076383|OTHER|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
214624525|NCT05076383|OTHER|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
214624526|NCT03362021|PROCEDURE|transvaginal oocyte retrieval|sedation for oocyte retrieval
214624527|NCT02854423|DEVICE|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
214624528|NCT03699007|BEHAVIORAL|Graded Exposure Therapy (GET Living)|The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
214624529|NCT03699007|BEHAVIORAL|Multidisciplinary Pain Management (MPM)|The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
214624530|NCT04990466|DRUG|IIBR-100|Administration of IIBR-100 vaccine
214624531|NCT04990466|DRUG|Active Comparator|Administration of a currently-approved vaccine for COVID-19
214624532|NCT00734799|BEHAVIORAL|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
214624533|NCT05808400|BIOLOGICAL|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.
214624534|NCT04599556|BIOLOGICAL|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
214624535|NCT00921232|BEHAVIORAL|Questionnaires|"During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data"
214624536|NCT04718974|OTHER|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
214718434|NCT04155125|DRUG|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
214718435|NCT04155125|DRUG|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
214718436|NCT02524067|BEHAVIORAL|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
214718437|NCT01240304|DRUG|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
214624537|NCT04643912|DIAGNOSTIC_TEST|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
214624538|NCT01923597|DRUG|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
214624539|NCT00002788|BIOLOGICAL|filgrastim|
214624540|NCT00002788|DRUG|cyclophosphamide|
214624541|NCT00002788|DRUG|dexamethasone|
214624542|NCT00002788|DRUG|etoposide|
214624543|NCT00002788|PROCEDURE|peripheral blood stem cell transplantation|
214624544|NCT00002788|RADIATION|radiation therapy|
214624545|NCT04220957|OTHER|Digital Impression Technique|Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
214624546|NCT04220957|OTHER|Conventional Impression Technique|Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
214624547|NCT03259074|BIOLOGICAL|Placebo|Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes
214624548|NCT03259074|BIOLOGICAL|GP2017 (adalimumab biosimilar)|40 mg in pre-filled syringes was administered subcutaneously
214624549|NCT03259074|BIOLOGICAL|AIN457 150 mg|150 mg in pre-filled syringes was administered subcutaneously
214624550|NCT01780662|DRUG|Brentuximab Vedotin|Given IV
214624551|NCT01780662|DRUG|Gemcitabine Hydrochloride|Given IV
214624552|NCT01653548|BEHAVIORAL|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
214624553|NCT01653548|BEHAVIORAL|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
214624554|NCT01653548|BEHAVIORAL|Habituation|Participants will habituate to personally-relevant stressor.
214624555|NCT01233973|OTHER|video decision aid|video
214624556|NCT03294785|PROCEDURE|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
214624557|NCT03294785|DRUG|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
214624558|NCT03294785|PROCEDURE|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
214624559|NCT05883891|DIAGNOSTIC_TEST|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
214624560|NCT01755715|PROCEDURE|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
214624561|NCT00097344|DRUG|Atamestane|
214624562|NCT00097344|DRUG|Toremifene|
214624563|NCT00097344|DRUG|Letrozole|
214624564|NCT00097344|DRUG|Aromatase inhibition|
214624565|NCT00097344|DRUG|Estrogen receptor blocker|
214624566|NCT00097344|PROCEDURE|Hormone therapy|
214624567|NCT00097344|PROCEDURE|Endocrine therapy|
214624568|NCT00097344|PROCEDURE|Antiestrogen therapy|
214624569|NCT05015088|OTHER|No interventions will be performed in this study|This study will not include any intervention
214624570|NCT03496246|DIAGNOSTIC_TEST|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
214624571|NCT03496246|DIAGNOSTIC_TEST|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
214624572|NCT03496246|DIAGNOSTIC_TEST|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
214624573|NCT03496246|DIAGNOSTIC_TEST|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
214624574|NCT03496246|DIAGNOSTIC_TEST|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
214624575|NCT03496246|DIAGNOSTIC_TEST|serum creatinine|for assessment of renal function
214624576|NCT03496246|DIAGNOSTIC_TEST|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
214624577|NCT03496246|DIAGNOSTIC_TEST|seum alanine aminotransferase|for assessment of liver function
214624578|NCT03496246|DIAGNOSTIC_TEST|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
214624579|NCT03496246|DIAGNOSTIC_TEST|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
214624580|NCT05329376|DEVICE|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine"
214624581|NCT05329376|OTHER|Usual Care|Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
214624582|NCT02779374|OTHER|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
214624583|NCT02723500|DEVICE|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
214624584|NCT03719274|DIETARY_SUPPLEMENT|vitamin c depigementation|locally injected vitamin c depigementation
214624585|NCT00868777|PROCEDURE|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
214718438|NCT01240304|RADIATION|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
214718439|NCT01240304|PROCEDURE|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
214624586|NCT00281398|BEHAVIORAL|Questionnaire|
214624587|NCT01741649|PROCEDURE|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
214624588|NCT01741649|PROCEDURE|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
214718440|NCT01157455|PROCEDURE|Everolimus Drug Eluting Stent|Implantation
214624589|NCT04780620|OTHER|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
214624590|NCT05741255|BEHAVIORAL|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
214624591|NCT00704782|DRUG|dimebon|
214624592|NCT03473496|BIOLOGICAL|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
214624593|NCT05069857|DRUG|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
214718441|NCT01157455|DRUG|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
214624594|NCT05069857|DRUG|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
214624595|NCT04950257|DEVICE|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
214624596|NCT04368156|DEVICE|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
214624597|NCT05032612|DEVICE|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
214624598|NCT05032612|DEVICE|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
214624599|NCT05217745|DIETARY_SUPPLEMENT|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
214624600|NCT05217745|DIETARY_SUPPLEMENT|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
214624601|NCT00575809|OTHER|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
214624602|NCT01538654|PROCEDURE|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
214624603|NCT00183274|DRUG|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
214624604|NCT00183274|DRUG|Placebo|six month intervention with placebo drug
214624605|NCT05848154|DIAGNOSTIC_TEST|ctDNA detection|Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
214624606|NCT04345744|PROCEDURE|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
214624607|NCT04345744|DEVICE|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
214624608|NCT04345744|DEVICE|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
214624609|NCT04111029|DIAGNOSTIC_TEST|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
214624610|NCT00188643|DRUG|Venlafaxine and Lamotrigine|
214624611|NCT02370875|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
214624612|NCT02370875|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
214624613|NCT04868721|PROCEDURE|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
214624614|NCT05598918|PROCEDURE|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
214624615|NCT05598918|PROCEDURE|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
214624616|NCT03048929|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
214624617|NCT03048929|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
214624618|NCT03847675|BEHAVIORAL|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
214718442|NCT01157455|DRUG|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
214718443|NCT01157455|DRUG|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
214718444|NCT01574937|DRUG|Cabozantinib|28 day cycle
214624619|NCT02597569|BEHAVIORAL|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
214718445|NCT01574937|DRUG|Abiraterone|28 day cycle
214624620|NCT00641589|DRUG|epoetin alfa|
214718446|NCT02795611|BEHAVIORAL|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
214718447|NCT02795611|BEHAVIORAL|regular occupational therapy|regular occupational therapy
214718448|NCT02795611|OTHER|intervention done outside our hospital|intervention done outside our hospital
214718449|NCT00005945|DRUG|cyclophosphamide|Given IV
214718450|NCT00005945|DRUG|cytarabine|Given IT
214624621|NCT05530226|DRUG|Traditional Chinese medicine|Traditional Chinese medicine, oral administration, twice daily
214624622|NCT04081363|DRUG|Centanafadine|Extended-release and immediate-release capsules.
214718451|NCT00005945|DRUG|daunorubicin hydrochloride|Given IV
214718452|NCT00005945|DRUG|dexamethasone|Given PO
214718453|NCT00005945|DRUG|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
214624623|NCT00015288|DRUG|Buprenorphine/naloxone|
214624624|NCT04712929|OTHER|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
214624625|NCT01805622|BEHAVIORAL|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
214718454|NCT00005945|DRUG|mercaptopurine|Given PO
214718455|NCT00005945|DRUG|methotrexate|Given PO and IT
214718456|NCT00005945|DRUG|pegaspargase|Given IM
214718457|NCT00005945|DRUG|thioguanine|Given PO
214718458|NCT00005945|DRUG|vincristine sulfate|Given IV
214718459|NCT00005945|RADIATION|radiation therapy|Undergo radiation therapy
214718460|NCT05060198|DRUG|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
214718461|NCT05060198|DRUG|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
214718462|NCT02655406|OTHER|Class 2 compression stockings|
214624626|NCT02409654|OTHER|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
214624627|NCT02409654|OTHER|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
214624628|NCT00077792|DRUG|Enoxaparin sodium (XRP4563)|
214624629|NCT03673774|DEVICE|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
214624630|NCT02409290|DRUG|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
214624631|NCT02409290|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
214624632|NCT02409290|DRUG|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
214624633|NCT02409290|DRUG|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
214624634|NCT02409290|DRUG|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
214624635|NCT02409290|DRUG|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
214624636|NCT02409290|DRUG|Prothionamide|Prothionamide has a bacteriostatic action.
214624637|NCT02409290|DRUG|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
214624638|NCT02409290|DRUG|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
214624639|NCT02409290|DRUG|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
214624640|NCT02389803|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
214624641|NCT02389803|DIETARY_SUPPLEMENT|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
214624642|NCT04971304|DRUG|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
214624643|NCT04026178|DRUG|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
214624644|NCT05021250|PROCEDURE|Lipiodol marking|HCC patients treated with TACE and the tumor marked with lipiodol.
214624645|NCT03401528|DRUG|AVB-S6-500|AVB-S6-500 is an investigational drug.
214624646|NCT03401528|OTHER|Placebo|Matching placebo
214624647|NCT00320008|BEHAVIORAL|Diet|
214624648|NCT00320008|BEHAVIORAL|Exercise|
214624649|NCT00320008|BEHAVIORAL|Stop smoking|
214624650|NCT00320008|DRUG|Glucose lowering therapy|
214624651|NCT00320008|DRUG|Blood pressure lowering therapy|
214624652|NCT00320008|DRUG|Lipid lowering therapy|
214624653|NCT05679336|DRUG|Rituximab, Cyclophosphamide, and Corticosteroids|"1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count \>5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7)."
214624654|NCT05494021|OTHER|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
214624655|NCT05494021|DEVICE|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
214624656|NCT05616936|BIOLOGICAL|injectable platelet rich fibrin|injectable platelet rich fibrin
214718463|NCT02143960|DEVICE|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
214718464|NCT02143960|DEVICE|CoolSculpt|Noninvasive Cryolipolysis
214718465|NCT01685203|DRUG|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
214718466|NCT01685203|DRUG|ABT-267|Tablet
214718467|NCT01685203|DRUG|Ribavirin (RBV)|Tablet
214718468|NCT04559412|DEVICE|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
214718469|NCT04559412|DRUG|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
214718470|NCT03191812|OTHER|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
214718471|NCT04555408|DEVICE|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
214718472|NCT04555408|DEVICE|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
214624657|NCT04363775|DEVICE|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
214718473|NCT04555408|DEVICE|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
214718474|NCT05428540|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
214624658|NCT04363775|DEVICE|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
214624659|NCT00708500|DRUG|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
214624660|NCT00708500|BIOLOGICAL|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
214624661|NCT00708500|DRUG|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
214624662|NCT00708500|DRUG|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
214624663|NCT05111444|DRUG|Camrelizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion
214718475|NCT05428540|OTHER|Placebo|Placebo
214718476|NCT02077491|OTHER|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
214718477|NCT01841294|DRUG|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
214718478|NCT01841294|DRUG|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
214718479|NCT00121680|DRUG|E7080|Oral.
214718480|NCT03125993|BEHAVIORAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
214624664|NCT05111444|DRUG|Pyrotinib|320mg as continuous oral once daily on every 21 days
214624665|NCT05111444|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
214624666|NCT05111444|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
214624667|NCT05111444|DRUG|Paclitaxel|80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
214624668|NCT05111444|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
214624669|NCT03440099|OTHER|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
214624670|NCT03583151|BIOLOGICAL|Amniotic fluid injection|Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
214624671|NCT03583151|BIOLOGICAL|Steroid injection|Solu-medrol
214624672|NCT01219010|BIOLOGICAL|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
214624673|NCT01242267|DRUG|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
214624674|NCT00896922|GENETIC|microarray analysis|
214624675|NCT00896922|OTHER|immunohistochemistry staining method|
214624676|NCT00896922|OTHER|laboratory biomarker analysis|
214624677|NCT00202735|PROCEDURE|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
214624678|NCT00202735|PROCEDURE|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
214624679|NCT00618410|DEVICE|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
214624680|NCT00618410|OTHER|Placebo|Nasal placebo
214624681|NCT05699161|GENETIC|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
214624682|NCT05068466|DRUG|INCB054707|Administered Orally
214624683|NCT05068466|DRUG|Placebo|Administered Orally
214624684|NCT01758796|PROCEDURE|Non-operative treatment|Below-the-knee cast for six weeks.
214624685|NCT01758796|PROCEDURE|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
214624686|NCT00403676|OTHER|Follow up bu a nurse|Follow up bu a nurse
214624687|NCT00403676|OTHER|Follow up by a medical doctor|Follow up by a medical doctor
214624688|NCT03525717|DIETARY_SUPPLEMENT|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
214624689|NCT03525717|DIETARY_SUPPLEMENT|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
214624690|NCT06360250|DRUG|Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation|Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.
214624691|NCT06360250|DRUG|Tetanus human immunoglobulin (HTIG)|Tetanus human immunoglobulin (HTIG)
214624692|NCT06360250|DRUG|Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo|There were no active ingredients, and other ingredients were the same
214624693|NCT06360250|BIOLOGICAL|Adsorbed tetanus vaccine (TT)|containing tetanus toxoid titer not less than 40 IU
214624694|NCT00595556|DRUG|zonisamide|flexible dosages of 100-500mg/day
214624695|NCT00595556|DRUG|Placebo|Placebo
214624696|NCT03747211|BEHAVIORAL|Aerobic exercise|High Intensity Interval Training (HIIT)
214624697|NCT00705783|DRUG|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
214624698|NCT00705783|DRUG|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
214718481|NCT04535505|DIAGNOSTIC_TEST|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
214718482|NCT03152396|OTHER|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
214718483|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
214718484|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
214718485|NCT02320214|DEVICE|Miami w/ frag Personal lubricant|
214718486|NCT06045143|DEVICE|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
214718487|NCT02398981|OTHER|Clinical decision support tool|
214718488|NCT03550742|OTHER|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
214624699|NCT02327052|OTHER|No intervention was performed.|No intervention was performed.
214624700|NCT05826756|OTHER|There are no interventions in this study. All participants complete online surveys.|There are no interventions in this study. All participants complete online surveys.
214624701|NCT02788097|PROCEDURE|Progesterone supplementation|artificial frozen embryo transfers
214624702|NCT00718276|DRUG|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
214624703|NCT00718276|DIETARY_SUPPLEMENT|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
214624704|NCT03849378|DIETARY_SUPPLEMENT|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
214624705|NCT03849378|DIETARY_SUPPLEMENT|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
214624706|NCT03300895|OTHER|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
214624707|NCT03300895|OTHER|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
214624708|NCT05891340|OTHER|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
214624709|NCT05891340|OTHER|Endurance exercise|walking exercise 5000 steps/day
214624710|NCT02997735|BEHAVIORAL|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
214624711|NCT02514616|PROCEDURE|Laparoscopic IPG and lead implant procedure|EST placement
214624712|NCT02514616|DEVICE|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
214624713|NCT02514616|DEVICE|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
214624714|NCT04213105|DRUG|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
214624715|NCT04213105|DRUG|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
214718489|NCT03717363|PROCEDURE|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
214718490|NCT03717363|BEHAVIORAL|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
214718491|NCT00663598|DRUG|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
214718492|NCT01957852|OTHER|FloSeal|
214718493|NCT00231855|DRUG|Topotecan and Taxotere|
214718494|NCT01684891|DRUG|RG1662|multiple doses of RG1662
214718495|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
214718496|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
214718497|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
214718498|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
214718499|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
214718500|NCT06528054|OTHER|Development of a model for predicting 90-day mortality and to compare various treatment strategies for anastomotic leakage|The prediction model and comparison of various treatment strategies will be studies when the data is available for analysis.
214718501|NCT00141856|BEHAVIORAL|Telephone care|
214718502|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-NA)|Root canal treatment procedures explained in arm descriptions.
214718503|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-EA)|Root canal treatment procedures explained in arm descriptions.
214718504|NCT06403293|PROCEDURE|Root canal treatment (BC-NA)|Root canal treatment procedures explained in arm descriptions.
214718505|NCT06403293|PROCEDURE|Root canal treatment (BC-EA)|Root canal treatment procedures explained in arm descriptions.
214718506|NCT06068296|DIAGNOSTIC_TEST|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
214718507|NCT06068296|DIAGNOSTIC_TEST|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
214718508|NCT06068296|DIAGNOSTIC_TEST|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
214718509|NCT06068296|DIAGNOSTIC_TEST|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
214718510|NCT04201938|COMBINATION_PRODUCT|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
214718511|NCT04201938|DIETARY_SUPPLEMENT|Placebo|Placebo
214718512|NCT03256838|DRUG|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
214718513|NCT05151367|BEHAVIORAL|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
214718514|NCT03655587|DEVICE|Solid ankle foot orthotic|
214718515|NCT03655587|DEVICE|Resting night splint|
214718516|NCT04939870|DIAGNOSTIC_TEST|Biochemical parameters evaluation|selected biochemical parameters
214718517|NCT02890732|DEVICE|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
214718518|NCT01962688|DEVICE|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
214718519|NCT01962688|DEVICE|Sham ultrasound|sham ultrasound to facilitate blinding
214718520|NCT02292498|DEVICE|FLIR ONE|
214718521|NCT04871685|DIAGNOSTIC_TEST|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
214718522|NCT03143868|BEHAVIORAL|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
214718523|NCT00439153|DEVICE|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
214718524|NCT04239547|PROCEDURE|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
214624716|NCT00670670|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
214624717|NCT00670670|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
214624718|NCT05170906|OTHER|Reflex locomotion stimulus|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
214624719|NCT05170906|OTHER|sham stimulus|The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
214624720|NCT03615196|DRUG|USB005 (aclerastide) Ophthalmic Solution|Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
214624721|NCT03615196|DRUG|USB005 Ophthalmic Solution Placebo|A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
214624722|NCT05464706|DIETARY_SUPPLEMENT|Synchrolevels|Supplement therapy to model the recovery after liver surgery
214624723|NCT03029143|DRUG|Vedolizumab IV|Vedolizumab intravenous infusion.
214624724|NCT04572984|PROCEDURE|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
214624725|NCT01662674|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
214624726|NCT01662674|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
214624727|NCT00851539|BEHAVIORAL|Video|Behavioral Intervention Video
214624728|NCT05738473|DRUG|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
214624729|NCT03203057|OTHER|coronary occlusion|percutaneous coronary intervention
214624730|NCT00974675|BIOLOGICAL|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
214624731|NCT00974675|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
214624732|NCT00974675|BIOLOGICAL|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
214624733|NCT00974675|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
214718525|NCT04239547|PROCEDURE|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
214718526|NCT03536650|DEVICE|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
214624734|NCT03752775|DEVICE|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
214624735|NCT00619255|BEHAVIORAL|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
214624736|NCT01669070|DRUG|FF, 50 mcg|Novel dry powder inhaler
214624737|NCT01669070|DRUG|FF, 100 mcg|Novel dry powder inhaler
214624738|NCT01669070|DRUG|FF, 200 mcg|Novel dry powder inhaler
214624739|NCT01669070|DRUG|FF, 250 mcg|Intravenous
214624740|NCT04123782|DEVICE|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
214624741|NCT04123782|DEVICE|Placebo F-ESW Treatment|Very low concentration of F-ESW.
214624742|NCT05227521|BEHAVIORAL|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
214624743|NCT02695992|DRUG|Metoprolol|Dosage 100 mg o.d.
214624744|NCT02695992|DRUG|Diltiazem|Dosage 360 mg o.d.
214624745|NCT01250340|DRUG|Aspirin|100 mg/day for 30 days
214624746|NCT01250340|DRUG|Placebo|1 cp day for 30 days
214624747|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
214624748|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
214624749|NCT02121262|DRUG|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
214624750|NCT02121262|PROCEDURE|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
214624751|NCT04422860|DRUG|Gum Arabic varnish|Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
214624752|NCT04422860|DRUG|Proflourid Varnish,VOCO|5% NaF varnish
214624753|NCT04422860|DRUG|MI Varnish,GC Japan Inc.|CPP-ACP with fluoride based varnish
214624754|NCT04160702|BEHAVIORAL|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
214718527|NCT03587818|OTHER|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
214624755|NCT01898572|OTHER|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
214718528|NCT06150989|BEHAVIORAL|Observational Group|"All participants will go through a series of lab-based assessments to evaluate their vascular health. These assessments include: heart rhythm/rate, blood pressure, large blood vessel flow, central aortic blood pressure and pulse wave velocity, brain blood flow, carbon dioxide concentration, flow mediated dilation/blood vessel responsiveness, breathing rate, and cerebral vasomotor reactivity. In addition, venous blood sample will be taken to identify biomarkers that are associated with elevating blood pressure and decreasing blood flow.~The 10-day monitoring period includes a wrist-worn activity tracker and a blood pressure monitor bracelet; a smartphone app that will prompt surveys up to 6 times a day to assess behaviors, social/physical context, mood/stress, and experience of racial discrimination/microaggression. Participants will also collect saliva samples on three consecutive days during the 10-day monitoring period."
214624756|NCT00851201|BEHAVIORAL|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
214624757|NCT00851201|BEHAVIORAL|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
214624758|NCT00033410|DRUG|carboplatin|
214624759|NCT00033410|DRUG|paclitaxel|
214718529|NCT05300971|OTHER|Heat therapy|36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
214718530|NCT05300971|OTHER|Thermoneutral water immersion|36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature \>0.2°C, and 12 weeks of follow-up.
214718531|NCT01375647|BIOLOGICAL|IPV (inactivated polio vaccine)|Administered per protocol
214718532|NCT01375647|BIOLOGICAL|Rotarix|Administered per protocol
214718533|NCT06195852|BEHAVIORAL|Usual Safe Touches|The in-person Safe Touches workshop is delivered in the classroom by 2 facilitators with live puppet skits, as designed.
214718534|NCT06195852|BEHAVIORAL|Modified Safe Touches|The modified Safe Touches workshop will be delivered by 1 facilitator in the classroom by utilizing prerecorded workshop skit videos.
214718535|NCT03322397|BEHAVIORAL|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
214718536|NCT03322397|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
214624760|NCT00033410|DRUG|tirapazamine|
214624761|NCT00033410|RADIATION|radiation therapy|
214624762|NCT02992340|DRUG|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
214624763|NCT02992340|DRUG|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
214624764|NCT02992340|DRUG|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
214718537|NCT03322397|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
214718538|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
214718539|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
214718540|NCT02244658|DRUG|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
214718541|NCT03140722|DRUG|vadadustat|vadadustat
214718542|NCT03140722|DRUG|epoetin alfa|epoetin alfa
214718543|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214718544|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214718545|NCT02564562|DRUG|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
214718546|NCT03185169|COMBINATION_PRODUCT|Replens and coconut oil|
214718547|NCT03705260|OTHER|Usual Care|Usual care from Primary Care Physician and dietitian.
214718548|NCT03705260|BEHAVIORAL|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
214718549|NCT03705260|OTHER|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
214718550|NCT03984812|DRUG|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
214718551|NCT03984812|DRUG|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
214718552|NCT04216706|DRUG|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
214718553|NCT06206707|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Capsule FMT
214718554|NCT06206707|PROCEDURE|Placebo|Placebo capsules
214718555|NCT00405236|DRUG|tiotropium|
214718556|NCT02283346|RADIATION|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~\+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
214718557|NCT02818270|DRUG|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
214718558|NCT02818270|DRUG|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
214718559|NCT04263493|OTHER|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
214718560|NCT05153863|DEVICE|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
214718561|NCT05370846|OTHER|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
214718562|NCT00067626|DIETARY_SUPPLEMENT|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
214718563|NCT04251741|DIAGNOSTIC_TEST|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
214718564|NCT04251741|OTHER|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
214718565|NCT04613271|DRUG|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
214718566|NCT04613271|DRUG|Azithromycin|Azithromycin 500 mg once a day for 5 days.
214718567|NCT05299645|BEHAVIORAL|Interview|Pilot study with digital browsers
214718568|NCT03869164|DEVICE|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
214624765|NCT05933369|BEHAVIORAL|Clincal pharmacist intervention|Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
214624766|NCT02601677|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
214624767|NCT02601677|DRUG|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
214624768|NCT06410365|DRUG|Dexmedetomidine injection|Comparison of intravenous and intrathecal route of dexmedetomidine
214624769|NCT04914689|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
214624770|NCT04914689|OTHER|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
214624771|NCT04914689|OTHER|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
214624772|NCT03602079|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
214624773|NCT00091715|DRUG|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
214624774|NCT00091715|DRUG|placebo|placebo for 6 months followed by an open-label period
214624775|NCT02588976|DEVICE|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
214624776|NCT01991990|DRUG|placebo|Single i.v. infusion
214624777|NCT01991990|DRUG|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
214624778|NCT06009003|DRUG|REL-1017|REL-1017 tablet
214624779|NCT00547170|DRUG|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
214624780|NCT00547170|DRUG|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
214624781|NCT03292809|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
214624782|NCT03292809|DRUG|Vehicle topical ocular, eye drops|Vehicle
214624783|NCT05598099|BEHAVIORAL|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
214624784|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
214624785|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
214624786|NCT03383445|PROCEDURE|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
214624787|NCT03383445|PROCEDURE|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
214624788|NCT03383445|PROCEDURE|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
214624789|NCT03383445|PROCEDURE|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
214624790|NCT04103684|DRUG|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
214624791|NCT04103684|DRUG|Dexamethasone|0.6mg per kg perday for 5 days
214624792|NCT03844165|BEHAVIORAL|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
214624793|NCT03844165|BEHAVIORAL|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
214624794|NCT02025907|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
214624795|NCT02025907|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
214624796|NCT02025907|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily.
214624797|NCT03424252|DRUG|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
214624798|NCT05514626|DEVICE|3D Holographic Display|3D holographic visualization of the anatomy during the planned interventional procedure. The HOLOSCOPE-i will be used in addition to and will not replace conventional displays that are currently being used during the procedure.
214624799|NCT01073332|DIETARY_SUPPLEMENT|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
214624800|NCT01073332|DIETARY_SUPPLEMENT|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
214624801|NCT04187638|DIETARY_SUPPLEMENT|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
214624802|NCT04187638|DIETARY_SUPPLEMENT|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
214624803|NCT02411539|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
214718569|NCT06198894|PROCEDURE|steroid-eluting sinus stent implant|In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
214624804|NCT02411539|BIOLOGICAL|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
214624805|NCT00282334|DEVICE|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
214624806|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
214624807|NCT02395926|DRUG|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
214624808|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
214624809|NCT03681119|BEHAVIORAL|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
214624810|NCT03681119|BEHAVIORAL|Education and Training|Education and training
214718570|NCT06198894|DRUG|Systemic glucocorticoids|Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
214718571|NCT06198894|DRUG|saline irrigations|Patients were routinely treated with saline irrigations (250ml) twice daily
214718572|NCT06198894|DRUG|Placebo|Groups were given systemic glucocorticoid placebo
214718573|NCT06198894|PROCEDURE|sham procedure|The sham procedure was performed in-office under local anesthesia
214624811|NCT01486849|DRUG|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
214624812|NCT01486849|DRUG|Placebo|Matching placebo tablets BID for 21 days
214624813|NCT01486849|DRUG|Riluzole 50 MG|
214624814|NCT03332563|BEHAVIORAL|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
214624815|NCT01704352|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
214624816|NCT03146000|DRUG|lidocaine-prilocaine cream|topical cream
214624817|NCT03146000|DRUG|meloxicam rectal suppository|suppository
214624818|NCT01236300|DEVICE|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
214624819|NCT06392568|OTHER|epidemiological records|Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
214624820|NCT02305095|DRUG|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
214624821|NCT03009214|DRUG|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
214624822|NCT02657161|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
214624823|NCT02657161|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
214624824|NCT02657161|BIOLOGICAL|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
214624825|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.
214624826|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
214624827|NCT05970900|DRUG|Imatinib Mesylate|"1. For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~2. For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd."
214624828|NCT05970900|PROCEDURE|Local resection|"According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach"
214624829|NCT01530984|DRUG|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
214624830|NCT01530984|DRUG|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
214624831|NCT02595671|OTHER|Digital Super Coach|Receive Digital Super Coach during 12 weeks
214624832|NCT02595671|OTHER|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
214624833|NCT02595671|OTHER|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
214624834|NCT02595671|OTHER|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
214624835|NCT06005727|DEVICE|Transanal ice pack|A condom is filled with 100ml of water and frozen to serve as a transanal ice pack. It is covered by sterile plastic dressing and applied to the hemorrhoidectomy wound for 1 minute after surgery is completed.
214624836|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
214624837|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
214624838|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
214624839|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
214624840|NCT00054067|DRUG|cisplatin|
214624841|NCT00054067|PROCEDURE|adjuvant therapy|
214624842|NCT00054067|PROCEDURE|conventional surgery|
214624843|NCT00054067|RADIATION|brachytherapy|
214624844|NCT00054067|RADIATION|radiation therapy|
214624845|NCT00882609|DEVICE|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
214624846|NCT03512600|DIETARY_SUPPLEMENT|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
214624847|NCT03512600|DIETARY_SUPPLEMENT|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
214624848|NCT03512600|DIETARY_SUPPLEMENT|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
214718574|NCT01245231|GENETIC|protein expression analysis|
214718575|NCT01245231|GENETIC|western blotting|
214718576|NCT01245231|OTHER|flow cytometry|
214718577|NCT01245231|OTHER|laboratory biomarker analysis|
214718578|NCT01245231|OTHER|medical chart review|
214624849|NCT03512600|DIETARY_SUPPLEMENT|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
214718579|NCT02225925|RADIATION|Brachytherapy|
214718580|NCT05698004|OTHER|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
214718581|NCT00626834|DRUG|Vigabatrin|Dose 1 BID
214718582|NCT00626834|DRUG|Vigabatrin|Dose 2 BID
214718583|NCT00626834|DRUG|Vigabatrin|Dose 3 BID
214718584|NCT00626834|DRUG|Matching placebo|Matching placebo BID
214718585|NCT04533516|OTHER|Manual therapy technics|Manual therapy technics
214718586|NCT04533516|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training
214718587|NCT03498989|OTHER|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
214718588|NCT03498989|OTHER|exclusive breast milk|exclusive breast milk
214718589|NCT03424044|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
214718590|NCT03424044|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
214718591|NCT03424044|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
214624850|NCT01923129|DRUG|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
214624851|NCT02477059|DRUG|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
214624852|NCT02477059|DRUG|saline solution|La saline solution is administered by intravenous infusion.
214718592|NCT03424044|DRUG|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
214718593|NCT02971007|DRUG|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
214718594|NCT02971007|DRUG|Fluconazole|
214718595|NCT01720693|PROCEDURE|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
214624853|NCT01166737|PROCEDURE|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
214718596|NCT00486512|DRUG|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
214718597|NCT00486512|DRUG|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
214718598|NCT00486512|DRUG|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
214718599|NCT00486512|DRUG|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
214624854|NCT03631732|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
214624855|NCT03631732|DRUG|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
214718600|NCT00486512|PROCEDURE|Colonoscopy|
214624856|NCT03631732|DRUG|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
214624857|NCT04827784|PROCEDURE|local anaesthetic injection|The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
214624858|NCT00330902|DRUG|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
214624859|NCT00330902|DRUG|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
214624860|NCT03334890|DIAGNOSTIC_TEST|plasma mSEPT9 level|the plasma level of methylated SEPT9
214624861|NCT00573573|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
214624862|NCT04046432|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
214624863|NCT04046432|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo.
214624864|NCT01457209|OTHER|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
214624865|NCT00005832|DRUG|R115777|300mg/dose BID, PO, Days 1-21, q 28days
214624866|NCT04288154|DEVICE|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
214624867|NCT04288154|OTHER|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
214624868|NCT02149940|OTHER|heart-failure related pharmaceutical intervention|
214624869|NCT03051360|DRUG|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
214624870|NCT03051360|DRUG|Placebos|Patients will receive Placebo by a biweekly injection
214624871|NCT03784976|OTHER|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
214624872|NCT01833286|PROCEDURE|TACE+RFA|TACE first, followed by RFA within 2 months
214624873|NCT01833286|PROCEDURE|re-resection|repeat hepatectomy for recurrent small HCC
214624874|NCT05944315|BEHAVIORAL|Education session|Classroom Education session appropriate for elementary school children
214624875|NCT04936295|DRUG|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
214624876|NCT02679898|OTHER|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
214624877|NCT02679898|OTHER|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
214624878|NCT03257007|BEHAVIORAL|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
214624879|NCT02445807|DRUG|DFD06-Cream|Twice daily topical application for 14 days.
214624880|NCT02445807|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
214624881|NCT01531309|DRUG|AGO178|AGO178 is administered as a sublingual tablet.
214624882|NCT06240832|OTHER|Physical therapy exercise|Endurance, strength and stretching training in Chronic liver disease children
214624883|NCT01455688|DRUG|early HAART|Initiation of HAART within 5 days of ICU admission
214624884|NCT01455688|DRUG|Late HAART|Initiation of HAART after ICU discharge
214624885|NCT04631146|DRUG|Camrelizumab|PD-1 inhibitors
214624886|NCT04650373|PROCEDURE|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
214624887|NCT00768521|DRUG|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
214624888|NCT00768521|DRUG|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
214624889|NCT03982004|DEVICE|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
214624890|NCT03982004|DRUG|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
214624891|NCT03982004|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
214718601|NCT02220530|DRUG|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
214624892|NCT03982004|OTHER|Dermatologic Quality of Life Index|"* 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
214624893|NCT03982004|OTHER|Functional Assessment of Cancer Therapy|"* 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
214718602|NCT01807611|RADIATION|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
214718603|NCT01807611|DRUG|Fludarabine|Given IV.
214718604|NCT01807611|DRUG|Cyclophosphamide|Given IV.
214718605|NCT01807611|DRUG|Thiotepa|Given IV.
214718606|NCT01807611|DRUG|Melphalan|Given IV.
214718607|NCT01807611|BIOLOGICAL|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
214718608|NCT01807611|BIOLOGICAL|TC-NK Infusion|Participants receive infusions of TC-NK.
214718609|NCT01807611|BIOLOGICAL|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
214718610|NCT01807611|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
214718611|NCT01807611|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214718612|NCT01807611|DRUG|Mycophenolate mofetil|Given intravenously or orally.
214718613|NCT05265936|PROCEDURE|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
214718614|NCT05265936|PROCEDURE|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
214718615|NCT03174769|OTHER|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
214718616|NCT03174769|OTHER|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
214718617|NCT04450004|BIOLOGICAL|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
214718618|NCT04352881|OTHER|Questionary patient|Assessing pain reduction using a 4-step questionary
214718619|NCT01680146|DIETARY_SUPPLEMENT|PRO+FAT|
214718620|NCT01680146|DIETARY_SUPPLEMENT|PRO|
214718621|NCT03588104|DEVICE|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
214718622|NCT03588104|OTHER|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
214718623|NCT02935595|DRUG|Ketamine|Ketamine Hydrochloride Injection
214718624|NCT06380036|PROCEDURE|video assisted fistula tract surgery|in one group pt recieved VAAFTS
214718625|NCT00402285|DIETARY_SUPPLEMENT|lycopene supplement|
214718626|NCT00402285|DIETARY_SUPPLEMENT|fish oil supplement|
214624894|NCT03982004|DRUG|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
214624895|NCT03982004|DEVICE|Cry-AC|-Device used to give the cryoimmunotherapy
214718627|NCT00402285|OTHER|Placebo|placebos for lycopene and fish oil.
214718628|NCT01287988|DRUG|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
214718629|NCT01287988|DRUG|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
214718630|NCT03309241|DRUG|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
214718631|NCT03309241|OTHER|Placebo|Placebo Single Dose
214718632|NCT04778644|DRUG|CBD|Oral gel capsule CBD
214718633|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
214624896|NCT03982004|PROCEDURE|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
214624897|NCT03982004|PROCEDURE|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
214624898|NCT01131377|DRUG|acetazolamide|"If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
214624899|NCT01131377|DRUG|Saline|They will receive saline 50ml via IV q 24h.
214624900|NCT06006793|DRUG|SY-5933|KRAS p.G12C inhibitor
214624901|NCT06150235|OTHER|Data collection|Data collection
214624902|NCT03182270|DIAGNOSTIC_TEST|nCLE|Procedure: EUS-FNA Device: nCLE
214624903|NCT03147729|RADIATION|Radiofrequency non ablation|Use of radiofrequency
214624904|NCT02870309|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
214624905|NCT00793260|BEHAVIORAL|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
214624906|NCT00793260|BEHAVIORAL|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
214624907|NCT05252364|DRUG|HP518 - Dose Escalation|"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."
214624908|NCT05252364|DRUG|HP518 - Dose expansion|"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."
214624909|NCT04041986|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
214624910|NCT04605302|DEVICE|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
214624911|NCT04605302|DEVICE|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
214624912|NCT05229302|BEHAVIORAL|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
214624913|NCT05229302|BEHAVIORAL|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
214624914|NCT01624662|DRUG|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
214624915|NCT04599322|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
214624916|NCT05818592|OTHER|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
214624917|NCT01361776|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 4 arms
214624918|NCT03115736|DRUG|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
214624919|NCT02354066|DEVICE|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
214624920|NCT02354066|DEVICE|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
214624921|NCT02354066|DEVICE|Retail Shoe|Brake response time measurement before surgery (control run)
214624922|NCT01972867|DEVICE|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
214624923|NCT02971462|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
214624924|NCT04938583|BIOLOGICAL|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
214624925|NCT04938583|DRUG|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
214624926|NCT04938583|DRUG|Paclitaxel|175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
214624927|NCT04938583|DRUG|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
214624928|NCT05512546|DRUG|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
214624929|NCT03853603|DIETARY_SUPPLEMENT|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
214624930|NCT03853603|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
214624931|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
214624932|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
214624933|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
214624934|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
214624935|NCT01285115|DRUG|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
214624936|NCT01285115|DRUG|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
214624937|NCT01285115|DRUG|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
214624938|NCT04171518|DEVICE|Catalys Precision Laser System|Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
214624939|NCT04071847|DEVICE|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
214624940|NCT01848184|DEVICE|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
214624941|NCT04206748|DEVICE|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
214624942|NCT04206748|DEVICE|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
214624943|NCT06972641|DRUG|Decitabine|Decitabine 3.5 mg/m2 1-5d for 28 days for 6 cycles of dosing
214624944|NCT06972641|DRUG|Sorafenib (BAY-43-9006)，giritinib|Sorafenib 0.2g 2/day or giritinib 40mg 2/day orally for 2 years
214624945|NCT06972641|DRUG|Avastinib|100 mg 1/day
214624946|NCT06972641|DRUG|Venetoclax;Selenisol|Vinaclat: 50-100mg 1/day orally, d1-14 1/day per month (adjust drug dosage based on blood levels), 28-day cycle; Selenisol: 20mg qw orally (weeks 1 and 2), 28-day cycle If the above treatment is not tolerated, adjust the regimen to decitabine 3.5 mg/m2 1-5 d; 28 days as a cycle of 6 cycles of medication; Vinaclat: 50-100 mg 1/day orally, d1-14 1/day per month orally (adjust the dose of the drug according to the blood concentration), 28 days as a cycle of medication
214624947|NCT05478798|OTHER|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
214624948|NCT05478798|OTHER|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
214624949|NCT05478798|OTHER|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
214624950|NCT04918277|DEVICE|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
214624951|NCT04326712|OTHER|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
214624952|NCT04326712|OTHER|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
214624953|NCT00134264|DRUG|torcetrapib/atorvastatin|
214624954|NCT00134264|DRUG|atorvastatin|
214624955|NCT00777777|DEVICE|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
214624956|NCT04609709|OTHER|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
214624957|NCT04609709|OTHER|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
214624958|NCT06978400|DRUG|mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy|Dabrafenib 150 mg twice orally daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks, Сalcium folinate 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks.
214624959|NCT06978725|DRUG|Oral Brepocitinib|Drug: Oral Brepocitinib
214624960|NCT06978725|DRUG|Oral Placebo|Drug: Oral Placebo
214624961|NCT00349856|DEVICE|Biofinity|Soft contact lens
214624962|NCT05791500|BEHAVIORAL|lifestyle intervention|dietary behavior interventions:through a couple of dietary health education lectures physical activity interventions:through at least an offline teaching and jump rope or jog regularly and quantitatively life schedule and habits intervention group: live in a regular and healthy life habit and last at least 4 months
214624963|NCT02193399|OTHER|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
214624964|NCT00870051|DEVICE|Endurant Stent Graft|Endurant Stent Graft implantation
214624965|NCT05376475|DEVICE|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
214624966|NCT05376475|DEVICE|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
214624967|NCT05376475|DEVICE|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
214624968|NCT05376475|DEVICE|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
214624969|NCT00139945|DRUG|Human acylated ghrelin|5 pmol/kg body weight per min
214624970|NCT02813551|DRUG|Torsemide|
214624971|NCT02813551|DRUG|Placebo|
214624972|NCT02017353|DIETARY_SUPPLEMENT|Curcuphyt|
214624973|NCT06141369|BIOLOGICAL|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
214624974|NCT06494670|OTHER|No intervention|This study was a cross-sectional study with no intervention for participants
214634788|NCT01967537|DRUG|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
214634789|NCT01967537|PROCEDURE|Radio-guided surgery|Using 68Gallium DOTATATE
214634790|NCT04985903|BEHAVIORAL|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
214634791|NCT04985903|OTHER|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
214634792|NCT02827864|BEHAVIORAL|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
214634793|NCT02827864|BEHAVIORAL|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
214634794|NCT02827864|BEHAVIORAL|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
214634795|NCT06411626|OTHER|PNH-relevant therapies|This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
214634796|NCT02517164|OTHER|Measurement of serum 25-hydroxyvitamin D|
214634797|NCT02517164|OTHER|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
214634798|NCT01783327|BEHAVIORAL|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
214634799|NCT01783327|BEHAVIORAL|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
214634800|NCT04829851|DEVICE|PROTEIN Mobile App|All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
214624975|NCT05378776|DIETARY_SUPPLEMENT|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
214624976|NCT05378776|DIETARY_SUPPLEMENT|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
214624977|NCT06214247|DEVICE|Wedge NC Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
214624978|NCT06214247|DEVICE|Scoreflex Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
214624979|NCT06776692|DRUG|Qdenga|Administration of Dengue vaccine and blood sample collection
214624980|NCT06870799|DEVICE|Surface guided radiation therapy|Radiation therapy will be delivered using no immobilization mask, but a surface guided system with infrared light
214624981|NCT06870799|DEVICE|Closed face mask|Radiotherapy with closed face mask for immobilization
214624982|NCT06949618|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)
214624983|NCT03900273|OTHER|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
214624984|NCT03900273|OTHER|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
214624985|NCT00115609|DRUG|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
214624986|NCT00115609|DRUG|tenofovir DF|300mg once a day
214624987|NCT00115609|DRUG|emtricitabine|one pill of 200mg once a day
214624988|NCT01183559|DRUG|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
214624989|NCT01183559|DRUG|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
214624990|NCT01183559|DRUG|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
214624991|NCT01183559|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
214624992|NCT01183559|RADIATION|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
214624993|NCT00113542|DRUG|Tetrathiomolybdate (TM)|
214624994|NCT04720235|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
214624995|NCT02474433|DRUG|Misoprostol (Cytotec)|
214718634|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
214718635|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
214624996|NCT00937300|BIOLOGICAL|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
214624997|NCT00290485|DRUG|Imatinib mesylate|
214624998|NCT06391671|OTHER|Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)|Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
214624999|NCT01050309|DRUG|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
214625000|NCT04864730|OTHER|No intervention|No intervention
214625001|NCT01700933|OTHER|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
214625002|NCT01700933|OTHER|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
214625003|NCT06457386|PROCEDURE|systematic echocardiography|"transthoracic echocardiography (TTE) will be performed as soon as possible within 14 days following the first blood sample collection for SAB diagnosis, completed, if required, by a transoesophageal (TEE) echocardiography based on the judgment of the echocardiographist.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
214625004|NCT06457386|PROCEDURE|no echocardiography arm|"no echocardiography will be performed unless occurrence of new events evocating IE (extra-cardiac events or positive Staphylococcus aureus blood culture), based on the clinical judgment of the investigator.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
214625005|NCT01084070|OTHER|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
214625006|NCT01084070|OTHER|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
214625007|NCT00234611|PROCEDURE|Echocardiogram guided left ventricular lead placement|
214625008|NCT05957289|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
214625009|NCT03238859|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
214625010|NCT03238859|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
214625011|NCT04535479|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
214625012|NCT02859935|BEHAVIORAL|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
214625013|NCT06177756|BEHAVIORAL|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
214718636|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
214718637|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
214718638|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
214718639|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
214625014|NCT05865678|OTHER|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
214625015|NCT04019132|DIAGNOSTIC_TEST|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
214625016|NCT05651295|BEHAVIORAL|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
214625017|NCT05651295|BEHAVIORAL|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
214625018|NCT05651295|BEHAVIORAL|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
214625019|NCT01733472|DRUG|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
214625020|NCT01733472|DRUG|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
214625021|NCT04490733|BEHAVIORAL|dual-task walking|Participants in the experimental group will receive 3 times interventions during chemotherapy and 12 weekly phone calls or via LINE to assess barriers of dual-task walking.
214625022|NCT02887391|OTHER|No intervention - observational study|No intervention - observational study
214625023|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
214718640|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
214718641|NCT00784459|DRUG|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
214718642|NCT00784459|DRUG|Placebo|Treatment with Placebo, IV
214718643|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
214718644|NCT04297345|DEVICE|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
214718645|NCT02398721|OTHER|Fine Needle Aspiration Cytology|
214718646|NCT01498770|DRUG|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
214718647|NCT01498770|DRUG|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
214718648|NCT01498770|DRUG|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
214718649|NCT01498770|DRUG|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
214625024|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
214625025|NCT06194890|OTHER|Distraction technique with comedy video|Women in the intervention group will watch an average of 6 minutes of comedy videos during the active phase, transition phase and latent phase of labor.
214625026|NCT00034372|DRUG|oregovomab|
214625027|NCT04192487|DRUG|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
214625028|NCT04176263|BEHAVIORAL|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
214625029|NCT04176263|BEHAVIORAL|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
214625030|NCT03724565|PROCEDURE|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
214625031|NCT01135498|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
214625032|NCT01135498|DRUG|eloxatin|Intravenous repeating dose
214718650|NCT01498770|DRUG|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
214718651|NCT01498770|DRUG|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
214718652|NCT01498770|DRUG|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
214718653|NCT01498770|DRUG|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
214718654|NCT01498770|DRUG|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
214718655|NCT01498770|DRUG|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
214718656|NCT01498770|DRUG|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
214718657|NCT01498770|DRUG|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
214718658|NCT01498770|DRUG|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
214718659|NCT04248686|BEHAVIORAL|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
214718660|NCT00002146|DRUG|Magnesium sulfate|
214718661|NCT00002146|DRUG|Foscarnet sodium|
214625033|NCT01135498|DRUG|capecitabine [Xeloda]|Oral repeating dose
214625034|NCT01135498|DRUG|erlotinib [Tarceva]|Oral repeating dose
214625035|NCT01726751|DEVICE|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
214625036|NCT01726751|DEVICE|Spinal cord nerve stimulation|
214718662|NCT05421091|OTHER|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
214718663|NCT02707601|DRUG|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
214718664|NCT02707601|DRUG|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
214718665|NCT02707601|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214625037|NCT02326870|DEVICE|AutoLap|
214625038|NCT03726645|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation
214718666|NCT03551184|BIOLOGICAL|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
214718667|NCT03551184|BIOLOGICAL|Placebo|Saline administered intravenously
214718668|NCT00001036|DRUG|Thymalfasin|
214625039|NCT00236015|DRUG|Gabitril|
214625040|NCT01385020|DRUG|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
214718669|NCT00001036|DRUG|Interleukin-2, Polyethylene Glycolated|
214718670|NCT00001036|DRUG|Zidovudine|
214718671|NCT05905770|DRUG|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
214718672|NCT00763607|GENETIC|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
214718673|NCT05826041|BEHAVIORAL|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
214625041|NCT03095742|DIAGNOSTIC_TEST|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
214625042|NCT03095742|DIAGNOSTIC_TEST|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
214625043|NCT02799407|OTHER|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
214718674|NCT05826041|BEHAVIORAL|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
214718675|NCT04269941|OTHER|total or subtotal gastrectomy|resection of the gastric tumor
214625044|NCT02693561|BEHAVIORAL|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
214625045|NCT02693561|BEHAVIORAL|Self-Help Book|Reading the self-help book.
214625046|NCT03784547|DRUG|Ocrelizumab|already described
214625047|NCT00933075|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
214625048|NCT05939310|PROCEDURE|Fluorescence guided detection of tumor positive margins.|Intraoperative fluorescence imaging detection of tumor positive margins using the targeted tracer bevacizumab-IRDye800CW.
214625049|NCT03865173|OTHER|Telephone Interview|Telephone Interview
214625050|NCT03239574|DEVICE|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
214625051|NCT00365521|PROCEDURE|Photodynamic Therapy|
214625052|NCT05231148|PROCEDURE|local debridement and local calcium sulfate loaded by antibiotics|debridement of infected non united fractures and placement of local calcium sulfate loaded by antibiotic then follow up at regular intervals
214718676|NCT00877760|DRUG|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
214718677|NCT00877760|DRUG|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
214718678|NCT01769612|OTHER|No Intervention|
214718679|NCT00704392|DRUG|XL647|Tablets supplied at 50-mg strength administered orally daily
214718680|NCT00704392|DRUG|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
214718681|NCT01063504|DRUG|teriparatide|
214718682|NCT04563572|DEVICE|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
214718683|NCT02561676|OTHER|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
214625053|NCT06076577|BEHAVIORAL|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
214625054|NCT06087653|DRUG|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
214625055|NCT06087653|DRUG|Lenalidomide 25 MG Oral Capsule|Oral lenalidomide for active control
214625056|NCT05815589|OTHER|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
214625057|NCT03500432|PROCEDURE|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
214625058|NCT00115154|DRUG|Aldara (imiquimod) cream, 5%|
214625059|NCT00185081|DRUG|Indium labeled IMP-205xm734|
214625060|NCT00291447|BIOLOGICAL|ch806|ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
214625061|NCT01361035|OTHER|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
214625062|NCT00530894|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|
214625063|NCT00530894|DEVICE|Surgical Valve Replacement|
214625064|NCT00530894|OTHER|medical management and/or balloon aortic valvuloplasty|
214625065|NCT02936427|DRUG|Dexamethasone|perineural infiltration of dexamethasone
214625066|NCT02256540|DRUG|Climara|
214625067|NCT02256540|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
214625068|NCT02256540|DIETARY_SUPPLEMENT|Resveratrol|
214625069|NCT02256540|DIETARY_SUPPLEMENT|Placebo|Placebo tablets designed to match active resveratrol tablets.
214625070|NCT05203497|DRUG|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
214625071|NCT04462562|DIAGNOSTIC_TEST|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
214625072|NCT01910259|DRUG|Amiloride|Comparison with placebo
214625073|NCT01910259|DRUG|Riluzole|Comparison with placebo
214625074|NCT01910259|DRUG|Fluoxetine|Comparison with placebo
214625075|NCT01910259|DRUG|Placebo|Placebo comparator
214625076|NCT03834467|OTHER|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
214625077|NCT03834467|OTHER|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
214625078|NCT03923426|OTHER|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
214625079|NCT00769002|BIOLOGICAL|FluShield|Flu vaccine
214625080|NCT00769002|BIOLOGICAL|FluShield - same arm|Flu vaccine
214625081|NCT00769002|BIOLOGICAL|FluShield - opposite arm|Flu vaccine
214625082|NCT00769002|PROCEDURE|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
214625083|NCT00769002|PROCEDURE|FDG PET-CT Scan|PET scan
214625084|NCT00769002|GENETIC|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
214625085|NCT02316535|DRUG|Capecitabine|adjuvant chemotherapy;
214625086|NCT06011343|DRUG|Oral tofacitinib|Association of tofacitinib and meglumine antimoniate
214625087|NCT06011343|DRUG|Parenteral meglumine antimoniate|Meglumine antimoniate
214625088|NCT05070975|OTHER|Epidemiology|Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
214625089|NCT04697875|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214625090|NCT04697875|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214625091|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
214625092|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
214625093|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
214625094|NCT01028092|DRUG|Thymoglobulin + Everolimus|"* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
214634801|NCT04829851|DEVICE|Expert Dashboard|Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
214718684|NCT02561676|OTHER|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
214718685|NCT02959970|DRUG|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
214718686|NCT02667028|PROCEDURE|PCI|percutaneous coronary intervention
214718687|NCT03486561|DRUG|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
214718688|NCT01255189|DEVICE|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
214718689|NCT01255189|DEVICE|invos 5100|near infrared spectroscopy: invos 5100
214625095|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine then Everolimus|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
214718690|NCT04846972|BEHAVIORAL|FASTRACS intervention|"Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
214718691|NCT00092391|BIOLOGICAL|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
214625096|NCT02191254|DRUG|Antistax®|
214625097|NCT02191254|DRUG|Placebo|
214718692|NCT00092391|BIOLOGICAL|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
214625098|NCT05779462|OTHER|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
214625099|NCT04006964|DEVICE|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
214625100|NCT01713023|DIETARY_SUPPLEMENT|Glucose|The same described in Arm description
214625101|NCT01713023|DIETARY_SUPPLEMENT|Fructose|The same described in Arm description
214718693|NCT01060722|DRUG|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
214718694|NCT01060722|DRUG|Placebo|Single subcutaneous dose of placebo material
214718695|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
214718696|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
214718697|NCT02821988|DEVICE|External fetal monitor for Nonstress test|
214625102|NCT00971451|OTHER|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
214625103|NCT00971451|OTHER|TENS|continuous use of TENS during the exercise session
214625104|NCT02005809|PROCEDURE|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
214625105|NCT00114049|DRUG|GW406381|
214625106|NCT05455853|OTHER|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
214625107|NCT01836432|DRUG|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
214625108|NCT01836432|BIOLOGICAL|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
214625109|NCT01836432|RADIATION|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
214625110|NCT01836432|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
214625111|NCT01836432|DRUG|Capecitabine|Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
214625112|NCT01836432|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
214625113|NCT03077347|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
214625114|NCT06077266|OTHER|Change of weight class to normal weight|The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
214625115|NCT02989558|DRUG|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
214625116|NCT02989558|DRUG|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
214625117|NCT02287974|DRUG|Stem cell infusion|Unique stem cell infusion of the randomized group
214625118|NCT04309240|DRUG|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
214625119|NCT00421668|DRUG|Zinc|zinc
214625120|NCT00421668|DRUG|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
214625121|NCT00421668|DRUG|Placebo|Placebo
214625122|NCT05396742|DRUG|Ravulizumab|Solution for infusion or injection, as applicable
214625123|NCT05396742|DRUG|rHuPH20|Solution for infusion
214625124|NCT02519933|PROCEDURE|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
214625125|NCT02519933|PROCEDURE|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
214625126|NCT02226107|BEHAVIORAL|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
214625127|NCT02226107|BEHAVIORAL|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
214625128|NCT05917574|OTHER|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
214625129|NCT03646851|DIAGNOSTIC_TEST|Questionnaries|patients will have to do a sputum and to complete some questionnaries
214625130|NCT03070470|DRUG|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
214625131|NCT03070470|DRUG|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
214625132|NCT03070470|DRUG|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
214625133|NCT03070470|DRUG|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
214718698|NCT02821988|DEVICE|Ultrasonography for Biophysical profile|
214625134|NCT03070470|DRUG|Placebo|Placebo (administered orally)
214625135|NCT03070470|DRUG|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
214625136|NCT02709499|DEVICE|0J LLLT|perform with the machine off
214625137|NCT02709499|DEVICE|6J LLLT|irradiation will be perform with 4J
214625138|NCT02371226|DRUG|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
214718699|NCT01332695|DRUG|ST101|tablets for oral administration
214718700|NCT01332695|DRUG|Placebo|placebo to match
214625139|NCT00630656|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
214625140|NCT00630656|DRUG|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
214625141|NCT02806089|DEVICE|Handheld dynamometer|Evaluation of muscle strength
214625142|NCT02806089|BIOLOGICAL|Creatinine index|Evaluation of muscle mass using plasma creatinine level
214625143|NCT02806089|DEVICE|Electrical bioimpedance analysis|Evaluation of lean body mass
214625144|NCT02806089|OTHER|"Voorrips score questionnaire"|Evaluation of physical activity
214625145|NCT02806089|BIOLOGICAL|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
214625146|NCT00932347|DRUG|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
214625147|NCT00932347|DRUG|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
214625148|NCT02443896|PROCEDURE|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
214625149|NCT02443896|PROCEDURE|No sealant of permanent molars|No sealant applied to permanent molars.
214625150|NCT06264895|BEHAVIORAL|Exercise|three times weekly exercise intervention with protein supplementation
214625151|NCT00861068|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
214625152|NCT00861068|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
214625153|NCT01757678|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
214625154|NCT01757678|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
214625155|NCT01757678|PROCEDURE|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
214625156|NCT01757678|OTHER|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
214625157|NCT01483391|BEHAVIORAL|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
214625158|NCT01483391|BEHAVIORAL|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
214625159|NCT01870102|DRUG|Pelubiprofen IR (Pelubiprofen 30mg) TID|
214625160|NCT01870102|DRUG|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
214625161|NCT00234689|DRUG|Naltrexone|
214625162|NCT04431570|DEVICE|rTMS|The device is made in London, United Kingdom
214625163|NCT04431570|DEVICE|sham stimulation|the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
214625164|NCT00838331|BIOLOGICAL|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
214634802|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
214634803|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
214634804|NCT02611388|DEVICE|fake stimulation|Patients were only attached electrodes without electric current
214634805|NCT03140137|DRUG|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
214634806|NCT04737655|DRUG|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
214634807|NCT05130463|DRUG|Empagliflozin/Linagliptin|Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.
214625165|NCT00838331|BIOLOGICAL|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions."
214625166|NCT03096964|OTHER|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
214625167|NCT03096964|OTHER|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
214625168|NCT02641145|RADIATION|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
214625169|NCT02641145|DEVICE|MRI|Cardiac MRI with gadolinium contrast.
214625170|NCT02641145|RADIATION|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
214625171|NCT01314677|PROCEDURE|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
214625172|NCT01314677|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
214625173|NCT02164175|DEVICE|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
214625174|NCT04071574|DRUG|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
214625175|NCT04071574|DRUG|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
214625176|NCT04071574|DRUG|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
214625177|NCT04071574|DRUG|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
214625178|NCT04484298|DIAGNOSTIC_TEST|Reference position patient is put in a 30 degree supine position during 5 minutes|Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
214625179|NCT04484298|DIAGNOSTIC_TEST|nitroglucerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
214625180|NCT01109875|OTHER|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
214625181|NCT00576459|DRUG|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
214718701|NCT05031806|DRUG|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
214625182|NCT00576459|DRUG|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
214625183|NCT00576459|PROCEDURE|standard of care laser photocoagulation|standard of care laser photocoagulation
214625184|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice1|Apple Juice1
214625185|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
214625186|NCT03846986|DIETARY_SUPPLEMENT|Raw Apple|Raw Apple
214625187|NCT04945603|OTHER|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
214625188|NCT03326076|DIAGNOSTIC_TEST|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
214625189|NCT03326076|OTHER|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
214625190|NCT03326076|DIAGNOSTIC_TEST|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
214625191|NCT03326076|DIAGNOSTIC_TEST|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
214625192|NCT06493968|DRUG|oxytocin|Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
214625193|NCT06493968|OTHER|placebo|IV bolus of normal saline immediately with the uterine incision
214625194|NCT01614314|OTHER|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
214625195|NCT01614314|OTHER|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
214634808|NCT03461757|DRUG|Rimegepant|75 mg ODT QD
214625196|NCT05632185|BEHAVIORAL|Equine-assisted Therapy|An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
214625197|NCT00264875|DRUG|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
214625198|NCT06460090|BEHAVIORAL|Happy Talk|A targeted selective speech language and communication programme embedded in the community, designed for people livling in social disadvantage.
214625199|NCT03488875|BEHAVIORAL|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
214625200|NCT01974544|DRUG|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
214625201|NCT01974544|PROCEDURE|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
214625202|NCT01974544|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
214634809|NCT03461757|DRUG|Placebo|Placebo ODT to match rimegepant dose QD
214634810|NCT02142777|DRUG|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
214634811|NCT02142777|DRUG|Placebo|The placebo has no active ingredients but is made to look like the study drug.
214634812|NCT03514628|OTHER|Standard Care|The Valsalva strain will be produced using Standard Care techniques
214634813|NCT03514628|DEVICE|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
214625203|NCT01974544|DRUG|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
214625204|NCT01974544|DRUG|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
214625205|NCT01974544|BEHAVIORAL|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
214625206|NCT05862181|PROCEDURE|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
214625207|NCT03600662|OTHER|TriRec|Trileaflet Reconstruction of the Aortic Valve
214625208|NCT03600662|OTHER|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
214625209|NCT01674101|OTHER|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
214625210|NCT01674101|OTHER|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
214625211|NCT01674101|OTHER|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
214625212|NCT01674101|OTHER|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
214718702|NCT05031806|DRUG|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
214718703|NCT05031806|DRUG|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
214718704|NCT05031806|DRUG|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
214718705|NCT02779530|DRUG|Diclofenac|50 mg po, b.i.d for 6 days
214718706|NCT02779530|OTHER|Placebo|Placebo po, b.i.d. for 6 days
214718707|NCT00693420|DRUG|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
214718708|NCT00693420|DRUG|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
214718709|NCT03300427|DRUG|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
214625213|NCT02766738|OTHER|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
214625214|NCT02766738|OTHER|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
214625215|NCT01500278|BIOLOGICAL|Certolizumab Pegol (CZP)|"* Active substance: an injectable volume of 1 ml solution for injection CZP~* Pharmaceutical form: prefilled syringes CZP~* Concentration: 200 mg/ml CZP~* Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
214625216|NCT01500278|BIOLOGICAL|Adalimumab (ADA)|"* Active substance: an injectable volume of 0.8 ml solution for injection ADA~* Pharmaceutical form: prefilled syringes ADA~* Concentration: 40 mg/0.8 ml ADA~* Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
214625217|NCT01500278|DRUG|Methotrexate (MTX)|"* Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally"
214625218|NCT05590260|DRUG|IV iron infusion|single-dose IV iron infusion
214625219|NCT05590260|DRUG|Oral iron tablets|60 mg of elemental iron
214625220|NCT02459795|DRUG|Ingenol Mebutate (Perrigo)|
214625221|NCT02459795|DRUG|Ingenol Mebutate (Reference)|
214625222|NCT02459795|DRUG|Placebo gel|
214625223|NCT04013035|PROCEDURE|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
214625224|NCT01709435|DRUG|Cabozantinib S-malate|Given PO
214625225|NCT01709435|OTHER|Laboratory Biomarker Analysis|Correlative studies
214625226|NCT01709435|OTHER|Pharmacological Study|Correlative studies
214625227|NCT02981875|OTHER|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
214625228|NCT02981875|OTHER|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
214625229|NCT00730938|DRUG|cefuroxime|intracameral cefuroxime 0.1 ml
214625230|NCT00730938|DRUG|Saline placebo|0.1 ml of Ringers lactate
214625231|NCT01319695|DRUG|corifollitropin alfa|100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg
214625232|NCT01319695|DRUG|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
214634814|NCT04754880|DIAGNOSTIC_TEST|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
214634815|NCT02984527|DEVICE|wet wipes|intimate hygiene with disposable wet wipes
214634816|NCT02984527|DEVICE|water and soap|Intimate hygiene with water and soap
214625233|NCT04452981|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
214625234|NCT01490437|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
214625235|NCT01490437|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
214625236|NCT01490437|DRUG|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
214625237|NCT01490437|DRUG|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
214625238|NCT00053417|DRUG|Placebo|Placebo for 15 weeks
214625239|NCT00053417|DRUG|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
214625240|NCT00053417|DRUG|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
214625241|NCT00053417|DRUG|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
214625242|NCT05914909|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
214625243|NCT05914909|OTHER|Placebo|Placebo
214634817|NCT06374823|DRUG|Multiple Electrolyte|Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
214718710|NCT03300427|DRUG|valsartan|Valsartan 80 or 160 mg BID
214718711|NCT03300427|DRUG|placebo to valsartan|placebo to valsartan 80 or 160 BID
214625244|NCT02360020|DEVICE|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
214625245|NCT03404011|OTHER|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
214625246|NCT03404011|DEVICE|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
214625247|NCT04881825|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
214625248|NCT02043535|DEVICE|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
214625249|NCT02043535|DEVICE|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
214625250|NCT06254365|BIOLOGICAL|Exogenous LEAP2 hormone|This intervention has never been examined in this type of study before.
214625251|NCT04196075|DRUG|Andrographis Paniculata|AP as palliative treatment
214625252|NCT00951847|DRUG|oxcarbazepine 300 mg/5 mL oral suspension|
214625253|NCT02988570|BEHAVIORAL|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
214625254|NCT00371293|BEHAVIORAL|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
214625255|NCT00371293|DEVICE|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
214625256|NCT01121133|DRUG|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
214625257|NCT01121133|DRUG|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
214625258|NCT02798536|DRUG|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
214625259|NCT02798536|DRUG|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
214718712|NCT03300427|DRUG|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
214625260|NCT02234154|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
214625261|NCT02182687|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
214625262|NCT02182687|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
214625263|NCT02182687|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
214625264|NCT01297270|DRUG|BI201335|QD BI 201335
214625265|NCT01297270|DRUG|PegIFN/RBV|
214625266|NCT01297270|DRUG|BI201335|QD (once daily) BI 201335
214625267|NCT01297270|DRUG|Placebo|
214625268|NCT01029132|DRUG|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
214625269|NCT06475014|PROCEDURE|Total knee replacement|Mechanical Alignment Using PSI Pre and post-operative CT Scan
214718713|NCT04246268|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
214718714|NCT02568852|PROCEDURE|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
214718715|NCT02568852|PROCEDURE|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
214718716|NCT04134377|OTHER|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
214718717|NCT01894555|DRUG|Aspirin|81 mg daily for 4 weeks
214718718|NCT03972605|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
214718719|NCT03756870|PROCEDURE|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
214625270|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
214625271|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
214718720|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
214718721|NCT00063986|PROCEDURE|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
214718722|NCT02359136|PROCEDURE|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
214718723|NCT02359136|PROCEDURE|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
214625272|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
214625273|NCT05468554|DRUG|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
214625274|NCT05468554|RADIATION|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
214625275|NCT04523506|BIOLOGICAL|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
214625276|NCT00121212|PROCEDURE|carbon-11 acetate PET scan|
214625277|NCT01384578|DRUG|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
214625278|NCT01384578|DRUG|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
214625279|NCT02060578|OTHER|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
214625280|NCT04793542|PROCEDURE|lower-limb hot water immersion|For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
214625281|NCT01707043|DRUG|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
214718724|NCT02359136|PROCEDURE|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
214718725|NCT01235338|DRUG|LDX + Venlafaxine XR|"* Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily."
214718726|NCT01235338|DRUG|Venlafaxine XR + LDX|"* Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg."
214718727|NCT01844791|DRUG|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
214625282|NCT02265770|DRUG|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
214718728|NCT01844791|DRUG|Platinum|Platinum is given as standard chemotherapy each cycle
214625283|NCT02265770|DRUG|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
214718729|NCT01844791|DRUG|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
214718730|NCT02027064|DRUG|Interferon-alpha|
214718731|NCT04185740|DEVICE|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
214625284|NCT02265770|DRUG|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
214625285|NCT02265770|RADIATION|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
214625286|NCT02265770|DRUG|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
214625287|NCT02265770|DRUG|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
214625288|NCT02265770|RADIATION|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
214625289|NCT00105248|BEHAVIORAL|patient-centered communication training|
214625290|NCT00019188|DRUG|interleukin-12|
214625291|NCT00006507|BEHAVIORAL|Occupational Therapy|
214625292|NCT03013673|OTHER|No intervention|No intervention
214625293|NCT03653273|OTHER|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
214625294|NCT03653273|DRUG|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
214625295|NCT02526342|DEVICE|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
214625296|NCT04861675|PROCEDURE|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
214634818|NCT06374823|DRUG|Normal Saline|Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
214634819|NCT03260959|BEHAVIORAL|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
214634820|NCT02864368|DRUG|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
214634821|NCT02864368|DRUG|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
214634822|NCT02864368|BIOLOGICAL|PEP-CMV: Component A|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
214634823|NCT02864368|DRUG|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
214634824|NCT02864368|DRUG|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
214634825|NCT02864368|BIOLOGICAL|PEP-CMV: Component B|500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
214625297|NCT03183193|OTHER|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
214718732|NCT05505539|DRUG|5-fluorouracil|Given intralesionally by injection
214625298|NCT03183193|OTHER|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
214634826|NCT03712397|DRUG|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
214634827|NCT03652662|DEVICE|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
214634828|NCT03652662|BEHAVIORAL|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
214634829|NCT00671021|OTHER|Platelet aggregation|Platelet aggregation TxA2 formation
214634830|NCT03861559|DRUG|mometasone furoate nasal spray|intranasal administration
214634831|NCT03861559|DRUG|placebo nasal spray|intranasal administration
214634832|NCT03841929|OTHER|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
214634833|NCT01725009|DRUG|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
214634834|NCT00861952|OTHER|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
214634835|NCT00861952|OTHER|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
214634836|NCT01988064|OTHER|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
214634837|NCT01988064|OTHER|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
214634838|NCT01394588|DEVICE|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
214634839|NCT05706389|DIETARY_SUPPLEMENT|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
214718733|NCT03669146|DEVICE|Glasses|Partial refractive correction in a pair of glasses.
214718734|NCT00509028|DRUG|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
214625299|NCT03540784|OTHER|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
214625300|NCT03540784|OTHER|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
214625301|NCT06489587|DIETARY_SUPPLEMENT|Placebo|Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
214625302|NCT06489587|DIETARY_SUPPLEMENT|Creatine|Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
214625303|NCT03643874|DRUG|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
214625304|NCT03643874|DRUG|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
214625305|NCT03724188|PROCEDURE|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
214625306|NCT05726344|DRUG|Lactulose|4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
214625307|NCT05726344|DRUG|Polyethylene Glycol 3350|4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
214625308|NCT02424032|BEHAVIORAL|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
214625309|NCT02424032|BEHAVIORAL|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
214625310|NCT02863809|DRUG|Riboflavin|Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
214625311|NCT02863809|DRUG|Dextran|Dextran is used to increase the viscosity of the solution.
214625312|NCT02863809|DEVICE|UVA Light Source|Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
214625313|NCT02829138|GENETIC|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
214625314|NCT02829138|BEHAVIORAL|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
214625315|NCT01394627|DRUG|Eplerenone|100mg x 2
214625316|NCT01394627|DRUG|Placebo|
214625317|NCT01765920|DRUG|Ergoferon|5 ml 3 times a day
214625318|NCT01765920|DRUG|Placebo|5 ml 3 times a day
214625319|NCT04335942|OTHER|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
214625320|NCT04335942|OTHER|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
214718735|NCT00509028|DRUG|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
214718736|NCT00948428|DRUG|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
214718737|NCT00948428|DRUG|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
214718738|NCT00948428|DRUG|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
214718739|NCT00004695|DRUG|PEG-interleukin-2|
214718740|NCT00904111|DRUG|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
214718741|NCT00904111|DRUG|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
214718742|NCT00132522|DRUG|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
214625321|NCT05114200|PROCEDURE|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
214625322|NCT01081249|DRUG|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
214718743|NCT06139939|PROCEDURE|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
214625323|NCT01081249|DRUG|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
214625324|NCT01544946|DRUG|88% sucrose po|88% sucrose solution (Syrup B.P.)
214625325|NCT01544946|DRUG|placebo po|sterile water
214718744|NCT05563259|RADIATION|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
214718745|NCT02918721|DEVICE|Restylane Lidocaine|Intradermal injection
214625326|NCT04891315|DIAGNOSTIC_TEST|Blood test for soluble VAP-1 (sVAP-1).|\~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
214625327|NCT00362934|DRUG|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
214625328|NCT00362934|DRUG|Atorvastatin|Atorvastatin 10 mg and 20mg
214718746|NCT02918721|DEVICE|Restylane|Intradermal injection
214718747|NCT04371185|DRUG|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
214718748|NCT04371185|DRUG|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
214625329|NCT02319421|OTHER|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
214625330|NCT00524342|DRUG|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
214718749|NCT04371185|DRUG|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
214718750|NCT03667794|DIAGNOSTIC_TEST|body plethysmography|measurement of conventional lung function parameters
214718751|NCT03667794|DIAGNOSTIC_TEST|impulse oscillometry|measurement of central and peripheral airway resistance
214625331|NCT04481542|DIAGNOSTIC_TEST|MRI|check MRI quality in aorta
214625332|NCT05676359|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
214625333|NCT05676359|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
214625334|NCT05676359|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
214625335|NCT05676359|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
214625336|NCT05676359|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
214625337|NCT05676359|OTHER|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
214625338|NCT05676359|OTHER|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
214625339|NCT05676359|OTHER|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
214625340|NCT04828395|BIOLOGICAL|Camrelizumab|200mg iv Q3W
214625341|NCT04828395|DRUG|Fluzoparib|150mg bid
214625342|NCT04828395|DRUG|Cisplatin，Pemetrexed|Cisplatin 75mg/m2 IV and Pemetrexed 500mg/m2 IV Q3W (Day 1 of each cycle of cycles 1-3) (non-squamous cell carcinoma only)
214625343|NCT04828395|DRUG|Cisplatin，Etoposide|Cisplatin 50mg/m2 IV (the 1st and 8th days of the 1st cycle and the 2nd cycle; the 8th and 15th days of the 3rd cycle); Etoposide 50mg/m2 IV (the 1st cycle And the 1st to the 5th day of the 2nd cycle; the 8th to the 12th day of the 3rd cycle).
214625344|NCT04828395|DRUG|Carboplatin, Albumin Paclitaxel|Carboplatin AUC=6, Albumin Paclitaxel 100mg/m2 IV; Days 1, 8 and 15 of cycles 1, 2, and 3.
214625345|NCT04828395|RADIATION|Radiotherapy|60 Gy (total 6 weeks)
214625346|NCT02794324|PROCEDURE|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v\_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
214625347|NCT02794324|PROCEDURE|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC\_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC\_DIBH, CT images will be obtained.
214625348|NCT02794324|PROCEDURE|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
214634840|NCT00847483|DRUG|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
214634841|NCT00847483|DRUG|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
214634842|NCT00847483|DRUG|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
214634843|NCT00005613|DRUG|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
214634844|NCT00005613|DRUG|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
214634845|NCT00005613|DRUG|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
214634846|NCT05235035|BEHAVIORAL|Night shift work|Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
214625349|NCT02794324|DEVICE|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
214625350|NCT06294457|DEVICE|Non-Invasive Neuromodulation NESA|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
214625351|NCT04245475|BEHAVIORAL|Virtual Reality psychological pain reduction|attention distraction
214625352|NCT06254729|OTHER|Observational study|Our study does not have any exposure factors.
214625353|NCT04474795|BEHAVIORAL|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
214625354|NCT06171321|DRUG|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
214625355|NCT00413426|DRUG|Darifenacin (DAR328)|
214625356|NCT04041284|DRUG|Fremanezumab|Monthly 225 mg subcutaneous
214625357|NCT04041284|DRUG|Placebo|Matching Placebo
214625358|NCT01148199|DEVICE|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
214625359|NCT01148199|DEVICE|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
214625360|NCT01576770|DEVICE|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
214625361|NCT01576770|DRUG|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
214625362|NCT00829907|DRUG|ORM-12741|Single dose as a capsule, oral administration
214625363|NCT00872651|DRUG|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
214625364|NCT00872651|DRUG|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
214625365|NCT01833611|DRUG|Entecavir|entecavir 0.5mg qd
214625366|NCT01833611|DRUG|placebo|placebo qd
214625367|NCT03478111|DRUG|CMAB008|the study drug
214625368|NCT03478111|DRUG|MTX|basic therapy drug
214625369|NCT03478111|DRUG|Remicade|active comparator
214625370|NCT04030923|DEVICE|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
214625371|NCT04253275|GENETIC|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
214625372|NCT04253275|DIAGNOSTIC_TEST|MRI without injection|MRI at inclusion for controls
214625373|NCT02331433|DRUG|APN1125|APN1125 orally at ascending doses
214625374|NCT02331433|DRUG|Placebo|Matching Placebo
214625375|NCT04009863|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
214634847|NCT01386359|DRUG|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
214718752|NCT03667794|DIAGNOSTIC_TEST|multiple breath washout|measurement of ventilation heterogeneity
214625376|NCT04009863|RADIATION|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
214625377|NCT04081636|PROCEDURE|Systematic Transrectal biopsy (TR-Bx)|Through the rectum
214718753|NCT02933372|DRUG|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
214625378|NCT04081636|PROCEDURE|Targeted Transrectal biopsy (TR-Bx)|Through the rectum
214625379|NCT04081636|PROCEDURE|Systematic Transperineal biopsy (TP-Bx)|Through the perineal skin
214718754|NCT01489228|DRUG|E1224|100 mg tablets
214718755|NCT01489228|DRUG|Benznidazole|100mg tablets
214718756|NCT01489228|DRUG|Placebo|tablets
214625380|NCT04081636|PROCEDURE|Targeted Transperineal biopsy (TP-Bx)|Through the perineal skin
214625381|NCT06395831|DIAGNOSTIC_TEST|BREF,ADL,AIS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
214625382|NCT00841594|DRUG|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
214718757|NCT03820557|OTHER|Educational Intervention|Undergo Decision Counseling Program
214718758|NCT04839393|DRUG|PF-06882961 followed by PF-06882961/PF-06865571|Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
214625383|NCT00841594|DRUG|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
214718759|NCT04839393|DRUG|PF-06882961/PF-06865571 followed by PF-06882961|Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
214625384|NCT03516682|BEHAVIORAL|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
214625385|NCT00563186|OTHER|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
214625386|NCT05618821|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
214625387|NCT04952298|PROCEDURE|Mesial temporal lobe epilepsy surgery|"Medial temporal lobe epilepsy surgery including~* selective Amygdalohippocempectomy (SAH) including anterior parahippocampal gyrus / entorhinal cortex~* anteromedial temporal lobe resection including amygdalohippocampectomy~* anterior temporal lobe resection"
214625388|NCT03812640|DEVICE|Vicryl suture|Corneal suture with Vicryl suture
214625389|NCT03812640|DEVICE|Nylon suture|Corneal suture with Nylon suture
214625390|NCT02776189|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
214625391|NCT02776189|DRUG|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
214625392|NCT02776189|DRUG|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
214625393|NCT01661907|PROCEDURE|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
214625394|NCT01661907|PROCEDURE|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
214625395|NCT03412175|BEHAVIORAL|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
214625396|NCT01087905|DRUG|Nicotine patch|"If \> 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day"
214625397|NCT01087905|DRUG|Nicotine gum|"If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
214625398|NCT01087905|BEHAVIORAL|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
214625399|NCT05561660|DEVICE|PFO device closure|Participants randomized into this group will take PFO device closure.
214625400|NCT05561660|DRUG|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
214625401|NCT01142102|RADIATION|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
214625402|NCT03620227|OTHER|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
214625403|NCT03620227|DIETARY_SUPPLEMENT|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
214625404|NCT03620227|DIETARY_SUPPLEMENT|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
214625405|NCT01347554|DEVICE|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
214625406|NCT01347554|DEVICE|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
214625407|NCT02567149|DRUG|Cidofovir|Cidofovir
214625408|NCT01865409|BEHAVIORAL|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
214625409|NCT00886600|DRUG|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
214625410|NCT00886600|DRUG|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
214625411|NCT00886600|DRUG|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
214625412|NCT03228355|DRUG|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
214625413|NCT03228355|DRUG|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
214625414|NCT01439204|BIOLOGICAL|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
214625415|NCT01358409|DRUG|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
214625416|NCT03027531|BEHAVIORAL|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
214718760|NCT04839393|DRUG|PF-06882961 + PF-06865571|Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
214625417|NCT02223260|DRUG|dabigatran|Experimental dose chosen based on age and weight
214625418|NCT01972750|DRUG|Dovitinib|daily oral intake of capsule
214625419|NCT00047060|OTHER|A matched peripheral donor stem cells|A matched peripheral donor stem cells
214625420|NCT00047060|DRUG|cyclosporine|cyclosporine
214625421|NCT00047060|DRUG|fludarabine|fludarabine
214625422|NCT00047060|DRUG|Campath|Campath
214625423|NCT00336973|DRUG|efalizumab|Subcutaneous repeating dose
214625424|NCT03115307|DRUG|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
214625425|NCT04045288|BEHAVIORAL|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
214625426|NCT04045288|BEHAVIORAL|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
214625427|NCT03917823|DEVICE|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
214625428|NCT03917823|DEVICE|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
214625429|NCT01246440|DRUG|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
214625430|NCT03775421|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
214625431|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
214625432|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
214625433|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
214625434|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
214625435|NCT04703556|DEVICE|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
214625436|NCT04304716|DRUG|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
214625437|NCT02199938|OTHER|Identification and characterization of molecular markers in musculoskeletal tumors|
214625438|NCT00094978|DRUG|Depsipeptide|
214625439|NCT00094978|DRUG|Flavopiridol (alvocidib)|
214625440|NCT02008682|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
214625441|NCT02008682|DRUG|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
214625442|NCT05234606|DRUG|SBT6290|Escalating doses by subcutaneous (SC) injection in 21-day cycles
214718761|NCT04039763|DEVICE|Dexcom G6|Realtime Continous Glucose Monitoring
214718762|NCT04039763|DEVICE|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
214625443|NCT05234606|DRUG|SBT6290|Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
214718763|NCT03379441|DRUG|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
214718764|NCT03507881|DEVICE|fusion|Internal fixation
214718765|NCT00956462|DRUG|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
214625444|NCT05234606|DRUG|pembrolizumab|200 mg via intravenous (IV) injection in 21-day cycles
214625445|NCT05266378|PROCEDURE|PECs block|The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
214625446|NCT05266378|OTHER|Not receiving PECs Block|In this group, the PECs block was not implemented.
214718766|NCT04194515|DRUG|YH1|YH1 treatment for one month
214718767|NCT04194515|DRUG|metformin|metformin treatment for one month
214718768|NCT04424004|OTHER|COVID-19 PCR and serology testing|"1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
214718769|NCT05272657|OTHER|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
214718770|NCT05272657|OTHER|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
214718771|NCT00470678|DRUG|ranibizumab|
214625447|NCT03685539|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
214625448|NCT03371615|OTHER|Anti-regurgitation infant formula|Anti regurgitation infant formula
214625449|NCT04377711|DRUG|Ciclesonide|160mcg Inhaler
214625450|NCT04377711|DRUG|Placebo|Matching Placebo Inhaler
214625451|NCT04599283|DEVICE|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
214625452|NCT02702765|PROCEDURE|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
214625453|NCT02702765|PROCEDURE|Ultrasound|Ultrasound is a non-invasive procedure
214625454|NCT02702765|DRUG|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
214625455|NCT02702765|PROCEDURE|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
214625456|NCT02702765|PROCEDURE|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
214625457|NCT02231554|OTHER|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
214625458|NCT02231554|OTHER|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
214625459|NCT03518788|PROCEDURE|Pleur-X|Permanent drainage
214625460|NCT03518788|PROCEDURE|Pleurodesis|Pleurodesis with talc in permanent VATS
214625461|NCT00205855|DEVICE|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
214625462|NCT00002278|DRUG|Diclazuril|
214625463|NCT06209554|DEVICE|ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser|diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
214625464|NCT03518879|OTHER|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
214625465|NCT03428178|DRUG|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
214625466|NCT03747250|DEVICE|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
214625467|NCT03747250|DEVICE|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
214625468|NCT00455013|DRUG|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
214625469|NCT00455013|DRUG|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
214625470|NCT00455013|DRUG|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
214625471|NCT00455013|DRUG|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
214718772|NCT00671970|DRUG|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
214718773|NCT00633893|DRUG|Apixaban|Tablets, Oral, twice daily, 12 months
214625472|NCT00455013|DRUG|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
214625473|NCT00263029|DRUG|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
214625474|NCT00263029|DRUG|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
214625475|NCT00263029|RADIATION|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
214625476|NCT06086093|DIETARY_SUPPLEMENT|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
214625477|NCT04901481|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
214625478|NCT00503646|OTHER|communication intervention|
214625479|NCT00503646|OTHER|counseling intervention|
214625480|NCT00503646|OTHER|questionnaire administration|
214625481|NCT00503646|PROCEDURE|psychosocial assessment and care|
214625482|NCT01271283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214625483|NCT01271283|DRUG|Lenalidomide|Given orally
214625484|NCT02739620|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
214625485|NCT03521050|DEVICE|defibrillator lead|observation of long-term performance of defibrillator leads
214625486|NCT06429267|DEVICE|Bioabsorbable Screw|Bioabsorbable screw that redissolves into the bone. Mineral fibers are composed of Silicon Dioxide (SiO2), Sodium Oxide, Calcium Oxide, Magnesium Oxide, Boron Trioxide, and Phosphorous Pentoxide
214625487|NCT06429267|DEVICE|Metal/Titanium Screw|Traditional metal screw used in fracture fixation that requires hardware removal
214625488|NCT03476941|DRUG|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
214625489|NCT03476941|DRUG|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
214625490|NCT03476941|OTHER|Placebo|The placebo group will receive drain irrigation twice/day
214625491|NCT05069883|DRUG|Steroid Drug|In this group Oral steroid medication after Direct Vision Internal Urethrotomy
214625492|NCT05069883|DRUG|No steroid|In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
214625493|NCT05246137|BIOLOGICAL|COVID-19 Vaccine 40 ug/dose|Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
214625494|NCT06358222|PROCEDURE|Blood ctDNA + methylation + PET-CT and Postoperative pathology|A highly sensitive tumor-naïve MRD panel of ctDNA will be employed to detect preoperative blood. Some patients will undergo methylation profiling to prospectively establish LNMs-specific ctDNA methylation signatures.
214625495|NCT06358222|PROCEDURE|MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA|A certain number (depending on the Results of Stage 1) of patients requiring invasive mediastinoscopy or EBUS-TBNA, based on the clinical guidelines, will be included for blood ctDNA mutation/methylation profile (or combined PET-CT), and the detection rate of LNMs will be assessed in patients with negative preoperative blood ctDNA mutation/methylation (or combined PET-CT). The accuracy of predicting LNMs will be compared with that of patients with negative or positive preoperative blood ctDNA mutation/methylation (or combined PET-CT).
214625496|NCT06358222|PROCEDURE|Intraoperative lymph node dissection|For patients with negative preoperative blood negative testing (ctDNA mutation/methylation profiles alone or in combination with PET-CT), systematic lymph node sampling/dissection and no lymph node dissection will be grouped and compared. Regular follow-up is performed to investigate the impact on long-term MRD negative duration and prognosis.
214625497|NCT02873936|DRUG|Filgotinib|Tablet(s) administered orally once daily
214625498|NCT02873936|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
214625499|NCT02873936|DRUG|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
214625500|NCT05772754|GENETIC|study of molecular and protein pathways|42 ml peripheral venous blood sample.
214625501|NCT05513625|DRUG|Pritelivir|oral administration
214625502|NCT05513625|DRUG|ESO and pritelivir|oral administration
214625503|NCT00754793|DRUG|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
214718774|NCT00633893|DRUG|Placebo|Tablets, Oral, twice daily, 12 months
214718775|NCT02741310|DRUG|Placebo|Administered by intravenous infusion
214625504|NCT00754793|DRUG|placebo|inactive comparator; titrated as per protocol over 12 weeks
214625505|NCT02860195|OTHER|oral dose of alcohol|
214625506|NCT02860195|DEVICE|alcotest|
214625507|NCT02860195|BIOLOGICAL|blood samples|
214625508|NCT02860195|DEVICE|Transdermal monitor|
214625509|NCT05563922|COMBINATION_PRODUCT|Total Neoadjuvant Chemoradiotherapy|"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"
214625510|NCT02166164|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
214625511|NCT02166164|OTHER|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
214718776|NCT02741310|DRUG|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
214718777|NCT02741310|DRUG|Erenumab|Administered by intravenous infusion
214718778|NCT05091918|DEVICE|MotionSense|MotionSense Wearable: Remote patient monitoring
214625512|NCT02166164|OTHER|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
214625513|NCT00018551|DRUG|Folic Acid|
214625514|NCT03517891|BEHAVIORAL|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
214625515|NCT05775640|BEHAVIORAL|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
214625516|NCT02461550|DEVICE|Irreversible Electroporation Ablation|
214625517|NCT04700839|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
214625518|NCT04700839|DRUG|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
214625519|NCT01225731|BIOLOGICAL|tildrakizumab|SC administration of tildrakizumab at assigned dose
214625520|NCT01225731|DRUG|Placebo|SC administration of Placebo
214625521|NCT00034710|DRUG|Capsaicin Patch|
214625522|NCT01943526|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
214625523|NCT04027699|PROCEDURE|Mini-bolus|"* First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)"
214625524|NCT00513110|GENETIC|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
214625525|NCT00513110|DRUG|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
214625526|NCT00513110|DRUG|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
214625527|NCT05080049|DRUG|Erythropoietin|"Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
214634848|NCT03506555|PROCEDURE|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
214634849|NCT06548984|OTHER|diaphragmatic exercises|Perform controlled and supervised diaphragmatic exercises
214634850|NCT06548984|OTHER|Respiratory muscle training|Perform respiratory muscle training with controlled and supervised devices
214634851|NCT00720109|DRUG|Asparaginase|Given IT
214634852|NCT00720109|DRUG|Cyclophosphamide|Given IV
214634853|NCT00720109|DRUG|Cytarabine|Given IT or IV
214634854|NCT00720109|DRUG|Dasatinib|Given PO
214634855|NCT00720109|DRUG|Daunorubicin Hydrochloride|Given IV
214634856|NCT00720109|DRUG|Dexamethasone|Given IV or PO
214634857|NCT00720109|DRUG|Etoposide|Given IV
214634858|NCT00720109|BIOLOGICAL|Filgrastim|Given IV or SC
214634859|NCT00720109|DRUG|Hydrocortisone Sodium Succinate|Given IT
214634860|NCT00720109|DRUG|Ifosfamide|Given IV
214634861|NCT00720109|OTHER|Laboratory Biomarker Analysis|Correlative studies
214634862|NCT00720109|DRUG|Leucovorin Calcium|Given IV or PO
214634863|NCT00720109|DRUG|Mercaptopurine|Given PO
214625528|NCT05080049|DRUG|Placebo|"In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
214625529|NCT01567657|DRUG|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
214625530|NCT01567657|DRUG|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
214625531|NCT05219942|DRUG|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
214625532|NCT05219942|OTHER|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
214634864|NCT00720109|DRUG|Methotrexate|Given IT, PO, or IV
214634865|NCT00720109|DRUG|Methylprednisolone|Given IV
214634866|NCT00720109|DRUG|Pegaspargase|Given IM
214634867|NCT00720109|DRUG|Prednisone|Given PO or IV
214634868|NCT00720109|RADIATION|Radiation Therapy|Some patients undergo cranial RT
214625533|NCT04341441|DRUG|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
214625534|NCT04341441|DRUG|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
214634869|NCT00720109|DRUG|Vincristine Sulfate|Given IV
214634870|NCT00299208|DRUG|Artesunate|
214625535|NCT04341441|OTHER|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
214625536|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
214625537|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
214625538|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
214625539|NCT04341441|OTHER|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 \&7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
214625540|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
214625541|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
214625542|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
214625543|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
214625544|NCT03300999|DIETARY_SUPPLEMENT|ginger tea|"1\. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
214625545|NCT00185952|DRUG|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
214625546|NCT05913570|DRUG|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
214625547|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
214625548|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
214625549|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
214625550|NCT00917150|DRUG|placebo|oral administration of placebo, once daily for 24months
214625551|NCT05873582|DEVICE|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
214625552|NCT05123833|PROCEDURE|Hypospadias repair|surgical repair of hypospadias
214625553|NCT00001545|DEVICE|Magstim Super Rapid Magnetic Stimulator|
214625554|NCT00001545|DEVICE|Cadwell MES-10|
214625555|NCT03737383|BEHAVIORAL|Narrative Exposure Therapy|brief, trauma-focused treatment.
214625556|NCT03978195|DEVICE|Non-invasive device for middle ear ventilation|Daily use of the device
214634871|NCT00299208|DRUG|Azithromycin|
214625557|NCT03184961|DIAGNOSTIC_TEST|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
214718779|NCT06169891|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
214718780|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
214625558|NCT01102647|DIETARY_SUPPLEMENT|phytosterol ester|1.6 g phytosterols/day for 29 days
214625559|NCT01747642|DIETARY_SUPPLEMENT|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
214625560|NCT01747642|DRUG|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
214625561|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 30|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
214625562|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 90|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
214625563|NCT01535456|PROCEDURE|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
214625564|NCT05520697|BEHAVIORAL|Nutritional intervention|Nutritional treatment with caloric restriction.
214625565|NCT05520697|BEHAVIORAL|Mental exercise.|Mental exercise.
214625566|NCT05520697|BEHAVIORAL|Physical training.|Exercise.
214625567|NCT03891264|DRUG|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
214625568|NCT04597736|BIOLOGICAL|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
214625569|NCT06210750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214625570|NCT06210750|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214718781|NCT06169891|DRUG|Compound Betamethasone Injection|1 mL i.m. once on Day 1
214718782|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
214718783|NCT02936336|OTHER|exercise|circuit exercise, aerobic dance and Tai Chi exercise
214718784|NCT00239356|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
214718785|NCT04616092|DRUG|FEFINJECT|FEFINJECT injection
214718786|NCT02176980|BEHAVIORAL|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
214718787|NCT02176980|BEHAVIORAL|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
214718788|NCT01378091|DRUG|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
214718789|NCT01378091|DRUG|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
214718790|NCT01378091|DRUG|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
214718791|NCT05843617|DIETARY_SUPPLEMENT|Liposomal Vitamin C|1000 mg of ascorbic acid in liposomal formulation
214718792|NCT05843617|DIETARY_SUPPLEMENT|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
214625571|NCT06210750|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214625572|NCT06210750|DRUG|Calaspargase Pegol|Given IV
214625573|NCT06210750|PROCEDURE|Computed Tomography|Undergo CT
214718793|NCT02596425|PROCEDURE|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
214625574|NCT06210750|DRUG|Cyclophosphamide|Given IV
214625575|NCT06210750|DRUG|Cytarabine|Given IT, IV or SC
214625576|NCT06210750|DRUG|Daunorubicin|Given IV
214625577|NCT06210750|DRUG|Dexamethasone|Given PO
214625578|NCT06210750|DRUG|Doxorubicin|Given IV
214625579|NCT06210750|PROCEDURE|Echocardiography|Undergo echocardiography
214625580|NCT06210750|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214625581|NCT06210750|DRUG|Mercaptopurine|Given PO
214625582|NCT06210750|DRUG|Methotrexate|Given IT
214625583|NCT06210750|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214625584|NCT06210750|BIOLOGICAL|Navitoclax|Given PO
214625585|NCT06210750|DRUG|Nelarabine|Given IV
214625586|NCT06210750|DRUG|Pegaspargase|Given IV
214625587|NCT06210750|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214625588|NCT06210750|DRUG|Thioguanine|Given PO
214718794|NCT02596425|PROCEDURE|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
214718795|NCT02596425|PROCEDURE|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
214718796|NCT04601181|BIOLOGICAL|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"
214718797|NCT02044822|DRUG|Idelalisib|150 mg tablets administered orally twice daily
214625589|NCT06210750|DRUG|Venetoclax|Given PO
214625590|NCT06210750|DRUG|Vincristine|Given IV
214625591|NCT06210750|PROCEDURE|X-Ray Imaging|Undergo X-ray
214625592|NCT00000299|DRUG|Buprenorphine|
214625593|NCT00002375|DRUG|Indinavir sulfate|
214625594|NCT00002375|DRUG|Nelfinavir mesylate|
214625595|NCT04808570|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
214625596|NCT00004138|PROCEDURE|positron emission tomography|
214625597|NCT00004138|PROCEDURE|radionuclide imaging|
214625598|NCT00004138|RADIATION|fludeoxyglucose F 18|
214625599|NCT03126695|DRUG|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
214625600|NCT03126695|DRUG|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
214625601|NCT03126695|DRUG|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
214625602|NCT03126695|DRUG|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
214625603|NCT01692275|OTHER|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
214625604|NCT01692275|OTHER|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
214625605|NCT04588779|OTHER|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
214625606|NCT04588779|OTHER|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
214625607|NCT02849561|OTHER|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
214625608|NCT02849561|DEVICE|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
214625609|NCT02849561|OTHER|Electroencephalography|
214718798|NCT02044822|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly x 8 weeks
214625610|NCT02849561|DEVICE|Pupillary light reflex surveillance|With Neurolight® device.
214625611|NCT02849561|DEVICE|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
214625612|NCT04338035|BEHAVIORAL|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
214625613|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
214625614|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
214625615|NCT01033825|DRUG|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
214625616|NCT01033825|DRUG|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
214625617|NCT01033825|DRUG|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
214625618|NCT01033825|DRUG|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
214625619|NCT01033825|DRUG|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
214625620|NCT02211027|BIOLOGICAL|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
214625621|NCT05088486|GENETIC|DNA analysis|GWAS
214625622|NCT01986413|DEVICE|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
214625623|NCT01986413|DEVICE|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
214625624|NCT01986413|DEVICE|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
214625625|NCT03270865|DEVICE|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
214625626|NCT03099187|DRUG|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
214625627|NCT03099187|DRUG|Placebo|Matching placebo capsules three times in a day.
214625628|NCT03001089|DRUG|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
214625629|NCT03001089|DRUG|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
214625630|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
214625631|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
214625632|NCT03542006|DRUG|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
214718799|NCT00164099|DRUG|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
214625633|NCT02899689|DEVICE|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
214625634|NCT02899689|DEVICE|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
214634872|NCT00299208|DRUG|Quinine|
214634873|NCT03462407|BEHAVIORAL|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
214625635|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
214718800|NCT02967172|DRUG|Ropivacaine|
214718801|NCT02967172|DRUG|Epinephrine|
214625636|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
214718802|NCT02967172|DRUG|Morphine|
214718803|NCT02967172|DRUG|0.9% sodium chloride solution|
214718804|NCT05207709|DRUG|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
214625637|NCT00217204|DRUG|Pancrelipase microtablets|
214625638|NCT00516542|DRUG|letrozole|A daily dose of 2.5 mg will be used throughout the study.
214625639|NCT00516542|DRUG|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
214625640|NCT00516542|OTHER|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
214625641|NCT00894556|DRUG|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
214625642|NCT00894556|DRUG|Comparator: Placebo|Placebo to Rizatriptan
214625643|NCT00894556|DRUG|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
214625644|NCT04264403|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
214718805|NCT05207709|DRUG|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
214718806|NCT05207709|DRUG|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
214718807|NCT03417505|DEVICE|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
214718808|NCT03417505|DEVICE|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
214718809|NCT04437316|DEVICE|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
214718810|NCT01650441|DRUG|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
214718811|NCT01650441|RADIATION|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
214625645|NCT02994433|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
214625646|NCT02994433|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
214625647|NCT02994433|DEVICE|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
214625648|NCT05617976|PROCEDURE|caudal block|caudal block
214625649|NCT01439555|DRUG|Simvastatin|Simvastatin, 40 mg per day orally
214625650|NCT01439555|DRUG|L-Arginine|L-Arginine, 2 Gm four times per day orally;
214625651|NCT01439555|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
214625652|NCT03209206|DRUG|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
214625653|NCT03209206|DRUG|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
214625654|NCT06369103|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
214625655|NCT06369103|DRUG|Propofol|Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
214625656|NCT00868348|DRUG|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
214625657|NCT00868348|DRUG|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
214625658|NCT02993874|DIETARY_SUPPLEMENT|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
214625659|NCT02993874|DIETARY_SUPPLEMENT|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
214625660|NCT03269370|BEHAVIORAL|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
214625661|NCT03269370|BEHAVIORAL|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
214625662|NCT03269370|BEHAVIORAL|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)"
214625663|NCT00150826|DRUG|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
214625664|NCT00150826|DRUG|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
214625665|NCT03402984|DRUG|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
214625666|NCT03402984|DRUG|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
214625667|NCT01884259|DRUG|Docetaxel|75 mg/m² on day 1 of 21-days cycle
214625668|NCT01884259|DRUG|Cisplatin|75 mg/m² on day 1 of 21-days cycle
214625669|NCT01884259|DRUG|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
214625670|NCT01884259|BIOLOGICAL|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
214718812|NCT05078307|PROCEDURE|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
214625671|NCT01884259|BIOLOGICAL|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
214625672|NCT01884259|RADIATION|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
214625673|NCT00003351|DRUG|irinotecan hydrochloride|
214625674|NCT06320587|OTHER|Kangaroo care practice by both mother and father|In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.
214625675|NCT06320587|OTHER|Kangaroo care practice only mother|In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
214625676|NCT00553709|DRUG|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
214625677|NCT03077685|DRUG|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
214625678|NCT03767023|OTHER|cross sectional|
214625679|NCT02594306|DEVICE|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
214625680|NCT02594306|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
214625681|NCT02594306|PROCEDURE|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
214625682|NCT02594306|PROCEDURE|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
214625683|NCT04227366|BIOLOGICAL|BCD-089|BCD-089 162 mg SC
214625684|NCT04227366|BIOLOGICAL|Placebo|Placebo
214625685|NCT04227366|DRUG|Methotrexat|15 to 25 mg/week
214625686|NCT02232373|BEHAVIORAL|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
214625687|NCT02232373|DIETARY_SUPPLEMENT|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
214625688|NCT02232373|DIETARY_SUPPLEMENT|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
214625689|NCT00058786|BIOLOGICAL|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
214625690|NCT02404623|DIETARY_SUPPLEMENT|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
214625691|NCT00616122|DRUG|cyclophosphamide|
214625692|NCT00616122|DRUG|methotrexate|
214625693|NCT00616122|DRUG|sunitinib malate|
214625694|NCT00616122|OTHER|laboratory biomarker analysis|
214625695|NCT03080844|BEHAVIORAL|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
214625696|NCT03080844|BEHAVIORAL|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
214625697|NCT00507949|DRUG|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
214625698|NCT00507949|DRUG|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
214625699|NCT05004636|DRUG|Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
214625700|NCT02159703|PROCEDURE|TORS|
214625701|NCT02159703|RADIATION|Adjuvant Radiation Therapy|
214625702|NCT04772495|GENETIC|miRNA|miRNA effect on Multiple sclerosis pathology
214625703|NCT05489731|DRUG|VIC-1911|VIC-1911 tablets for oral administration
214625704|NCT05489731|DRUG|Osimertinib Mesylate Tablets|Osimertinib tablets for oral administration
214625705|NCT04719143|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Subjects receive 6-8 CBT-I sessions in an individual format.
214625706|NCT05785468|DRUG|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
214625707|NCT01766960|OTHER|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
214625708|NCT01766960|DRUG|Morphine|Five milligrams of intravenous morphine will be administered.
214625709|NCT04141384|DEVICE|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
214625710|NCT06387407|DRUG|Dabigatran Etexilate 150mg|Oral dabigatran etexilate capsules, 150 mg twice a day.
214625711|NCT01246583|DRUG|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
214625712|NCT01246583|DRUG|Vehicle 1|Vehicle 1 twice daily for 4 weeks
214625713|NCT01246583|DRUG|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
214625714|NCT01246583|DRUG|Vehicle 2|Vehicle 2 twice daily for 4 weeks
214625715|NCT05169151|OTHER|Smartphone Application|Utilize smartphone application
214625716|NCT02132481|OTHER|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
214625717|NCT02132481|OTHER|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
214625718|NCT02132481|OTHER|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
214625719|NCT02132481|OTHER|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
214625720|NCT01473082|DEVICE|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
214625721|NCT01473082|DEVICE|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
214625722|NCT02488369|DEVICE|PET / CT|
214625723|NCT03707600|DEVICE|TMS|MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
214625724|NCT06403527|OTHER|Ultrasound guided venous access during AF ablation|Ultrasound guided venous access during AF ablation
214625725|NCT04030221|OTHER|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
214625726|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
214625727|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
214625728|NCT01076049|DEVICE|Standard of Care (SoC)|The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.
214625729|NCT01076049|DEVICE|Irrisept Delivery System|"Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression.~Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits."
214625730|NCT00621478|DRUG|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
214625731|NCT04894500|DIAGNOSTIC_TEST|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
214625732|NCT06248281|OTHER|combination of different rehabilitation strategies|"The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos."
214625733|NCT03412656|DEVICE|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
214625734|NCT01806779|DRUG|Chantix|
214625735|NCT01806779|DRUG|Zyban|
214625736|NCT01806779|DRUG|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
214625737|NCT01779024|DRUG|Ghrelin|
214625738|NCT01779024|DRUG|Placebo|
214625739|NCT01779024|PROCEDURE|fMRI|
214625740|NCT01779024|DRUG|Alcohol|
214625741|NCT05110703|DIETARY_SUPPLEMENT|Supergut|Meal replacement shake
214625742|NCT05110703|DIETARY_SUPPLEMENT|Placebo|Placebo
214625743|NCT05110703|OTHER|Dietary guidelines|Dietary guidelines
214625744|NCT06474442|GENETIC|BD111 Injection (investigational new drug)|BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.
214625745|NCT06474442|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
214625746|NCT06978829|DRUG|TP + Cetuximab + Tislelizumab|"Conversion therapy stage:~TP regimen: Albumin-bound paclitaxel+Platinum (Cisplatin or Carboplatin) Albumin-bound paclitaxel: 100 mg/m² by IV infusion, D1/D8, every 3 weeks (Q3W) Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W Cetuximab: The initial dose is 400 mg/m² by IV infusion for 1 week. Subsequently followed by 250 mg/m² IV infusion, D1/D8, Q3W.~Tislelizumab: 200 mg by IV infusion, Q3W. 3 weeks/cycle, 3 cycles in total.~Patients who have completed conversion therapy undergo efficacy evaluation.~Radical therapy stage:~Evaluated as operable: Undergo surgery, followed by one cycle of adjuvant chemotherapy according to the preoperative regimen.~Evaluated as inoperable: Receive radical radiotherapy.~Maintenance therapy stage:~Tislelizumab for 1 year or until disease progression, intolerable toxicity, or patient refusal to continue treatment."
214625747|NCT06979349|OTHER|Physical Evaluations in Players|Respiratory muscle strength, respiratory muscle endurance, cough strength or balance will be evaluated in adolescent volleyball players.
214625748|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
214625749|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
214625750|NCT06977542|DRUG|Ivonescimab|"a PD-1/ VEGF Bispecific Antibody, 20mg/kg, every 2 weeks;~Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide"
214625751|NCT06978192|DRUG|dexmedetomidine nasal spray group|Experimental group: Long duration high voltage pulse RF therapy plus dexmedetomidine nasal spray group
214625752|NCT06978192|OTHER|long duration high voltage pulse RF therapy group|Experimental group: long duration high voltage pulse RF therapy group
214625753|NCT06979258|OTHER|Cooling intervention|Infrastructure and/or equipment that cools the house in the hot season
214625754|NCT06978634|OTHER|SBAR training with cases|"The researcher will hold a face-to-face meeting with the students in the intervention group and provide information about the purpose of the study, the content of the training, the Student Guidelines for the SBAR Role Playing Application and the research process. Then, SBAR Training with Cases will be given. In addition, a group will be established via Whatsapp and communication during the process will be provided through this channel. The days and times of the training will be determined by looking at the students' course schedules. The training will be carried out in the Skills Laboratory of the Faculty of Health Sciences at Yüzüncü Yıl University."
214625755|NCT06977958|BEHAVIORAL|NASM OPT Group|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included hip thrusts, squats, and glute bridges.
214625756|NCT06977958|BEHAVIORAL|General Exercise Group|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
214634874|NCT03462407|BEHAVIORAL|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
214625757|NCT06979050|BEHAVIORAL|The Ronnie Gardiner Method|The intervention involves participants performing coordinated movements while saying specific cue words, synchronized to rhythmic music. The exercises are guided by a visual notation system consisting of 19 colored symbols that represent different body parts and movements. Red symbols indicate movements on the left side of the body, while blue symbols represent the right side. Each symbol corresponds to a specific movement and verbal cue. Exercises are typically performed standing to maximize balance effects and are accompanied by rhythmic, often popular, music to enhance engagement and motivation. Complexity can be increased by adjusting the tempo of the music or combining multiple symbols. Training sessions are conducted in groups, led by certified instructors, twice per week for 12 weeks (60 minutes per session), with an additional home-based practice session each week.
214625758|NCT06978985|DRUG|Risdiplam|Risdiplam
214625759|NCT06978985|DRUG|Nusinersen Injectable Product|Nusinersen
214625760|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
214625761|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
214625762|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
214625763|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
214625764|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
214625765|NCT04943575|DIETARY_SUPPLEMENT|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
214625766|NCT03194386|OTHER|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
214625767|NCT03194386|OTHER|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
214625768|NCT03040375|BEHAVIORAL|Peer counselling|
214625769|NCT02393638|OTHER|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
214625770|NCT02393638|OTHER|Lecture|Lecture
214625771|NCT06977347|DRUG|Piperacillin/Tazobactam|Piperacillin/tazobactam: 4.5g IV q6h (over 3h)
214625772|NCT06977347|DRUG|Piperacillin/tazobactam + Levofloxacin|"Piperacillin/tazobactam: 4.5g IV q6h (over 3h)~\+ Levofloxacin 750mg IV q24h (over 30min)"
214625773|NCT06979310|OTHER|text-based education messages only|Participants will receive text-based education messages
214625774|NCT06979310|OTHER|in-clinic tablet-based multimedia education|Participants will receive tablet-based multimedia education in clinic
214625775|NCT06979310|OTHER|standard of care provider led education|Participants will receive standard of care education from their provider
214625776|NCT02284126|DRUG|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
214625777|NCT06535841|BIOLOGICAL|MTX-474|MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
214625778|NCT06535841|OTHER|Placebo|Matching Placebo - Normal Saline
214625779|NCT04478292|DRUG|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
214625780|NCT04478292|PROCEDURE|Primary surgery resection|Resection of the primary tumor up-front
214625781|NCT04478292|DRUG|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
214625782|NCT04478292|DRUG|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
214625783|NCT04478292|PROCEDURE|Biopsy|Tumors are deemed unresectable at diagnosis.
214634875|NCT03595553|DRUG|Ridinilazole|ridinilazole (200 mg bid)
214634876|NCT03595553|DRUG|Vancomycin|vancomycin (125 mg qid)
214634877|NCT03910556|DRUG|Propofol|intraoperative factors
214625784|NCT04478292|PROCEDURE|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
214625785|NCT04478292|PROCEDURE|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
214625786|NCT04478292|DRUG|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
214625787|NCT04478292|DRUG|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
214625788|NCT04478292|DRUG|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
214625789|NCT04478292|DRUG|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
214625790|NCT06338553|DRUG|Semaglutide (Rybelsus®)|7 mg single dose of Rybelsus® by mouth once before each MMTT
214625791|NCT06338553|DRUG|Placebo|placebo capsule or tablet once before each MMTT.
214625792|NCT07004894|PROCEDURE|Neuromuscular re-education(experimental)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by neuromuscular reeducation technique (5-10 minutes duration) which includes for the 1st two weeks; cross friction massage with active movement and for the last two weeks longitudinal friction massage with active movement will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
214625793|NCT07004894|PROCEDURE|Friction massage(standard protocol)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by friction massage technique(5-10 minutes duration) which includes for the 1st two weeks; cross friction massage alone and for the last two weeks longitudinal friction massage alone will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
214625794|NCT02450175|DRUG|Everolimus|10 mg of Everolimus daily (by mouth)
214625795|NCT02450175|DRUG|Letrozole|2.5mg taken daily (by mouth)
214625796|NCT06869265|DRUG|Thiotepa ;busulfan;fludarabine|Eligible patients will receive the following conditioning regimen: thiotepa 5 mg/kg/day on Days -10 to -9; busulfan 3.2 mg/kg/day on Days -8 to -6; fludarabine 30 mg/m²/day on Days -6 to -2; and rabbit anti-thymocyte globulin (rATG) 1.5-2.5 mg/kg/day on Days -5 to -2. Hematopoietic stem cell infusion will be performed on Day 0. Graft-versus-host disease (GVHD) prophylaxis will include cyclosporine A (CsA), mycophenolate mofetil (MMF), and methotrexate (MTX).
214718813|NCT02708472|DEVICE|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
214718814|NCT06950073|RADIATION|Radiotherapy|Radiotherapy is offered in the same dose to all patients eligible to reirradiation no matter if they are enrolled in the study or not. Meaning no intervention is done. This is a registration study.
214718815|NCT04971993|DEVICE|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
214718816|NCT05767658|BEHAVIORAL|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents.
214718817|NCT05767658|BEHAVIORAL|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents.
214718818|NCT05767658|BEHAVIORAL|Early Brain Development and Parent-Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
214718819|NCT02983279|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo caloric restriction diet
214625797|NCT05106309|DRUG|10 mg CVL-231 as IR formulation|Tablets
214625798|NCT05106309|DRUG|30 mg CVL-231 as slow-release MR formulation|Capsules
214625799|NCT05106309|DRUG|30 mg CVL-231 as medium release MR formulation|Capsules
214625800|NCT05106309|DRUG|30 mg CVL-231 as fast release MR formulation|Capsules
214625801|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fasted|Capsules
214625802|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fed|Capsules
214625803|NCT05622344|BEHAVIORAL|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
214625804|NCT05622344|DEVICE|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
214718820|NCT02983279|OTHER|Counseling|Undergo counselor-led dietary counseling
214718821|NCT02983279|PROCEDURE|Therapeutic|Undergo standard of care surgery
214718822|NCT02432703|DRUG|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
214718823|NCT02432703|DRUG|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
214625805|NCT06872437|DRUG|Lidocaine Injectable Solution|Infiltration by injections of 6mL of lidocaine (10 mg/mL) per injection site (left ischioanal fossa, right ischioanal fossa right ischioanal fossa, coccyx),
214625806|NCT06872437|DRUG|Saline Solution for Block|Infiltration by injections of 6mL of saline solution per injection site (left ischio-anal fossa, right ischio-anal fossa right ischio-anal fossa, coccyx)
214625807|NCT03471065|DEVICE|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
214625808|NCT06874010|DRUG|DT-216P2|Active
214625809|NCT06695429|DIETARY_SUPPLEMENT|Beetroot juice|Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
214625810|NCT06869499|PROCEDURE|Blood sampling for dosage|4ml blood sample to measure acid sphingomyelinase enzyme activity and LysoSM, if required.
214625811|NCT07028112|OTHER|Cohort|Participants undergo one routine visit blood draw and non invasive liver stiffness measurement. Retrospective data are abstracted from medical records.
214634878|NCT02355561|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
214634879|NCT02355561|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
214634880|NCT02355561|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
214634881|NCT03318146|DEVICE|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
214634882|NCT03318146|DRUG|XALATAN®|one drop in the affected eye(s) once daily in the evening
214634883|NCT01596998|DRUG|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
214625812|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
214625813|NCT03085524|DIAGNOSTIC_TEST|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
214625814|NCT03085524|DIAGNOSTIC_TEST|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
214625815|NCT06894433|PROCEDURE|neuroendoscopic surgery|Subjects will receive Neuroendoscopic Surgery followed by standard medical management
214625816|NCT06894433|PROCEDURE|craniotomy|Subjects will receive Craniotomy followed by standard medical management
214625817|NCT03748446|DRUG|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
214625818|NCT03748446|DRUG|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
214625819|NCT02558673|OTHER|TMAO dietary precursors|
214625820|NCT02558673|OTHER|Control (or active comparator)|
214625821|NCT05213208|DRUG|Propofol|Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
214625822|NCT05695950|DRUG|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
214625823|NCT05695950|DRUG|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
214625824|NCT06829251|BEHAVIORAL|Effective Ear Massage|The intervention consists of a structured ear massage technique administered daily for 2 weeks. Parents will receive training on how to target specific pressure points on the ear to reduce stress and anxiety, and improve sleep quality. This training will be conducted via WhatsApp (What's up Application) for 20 minutes, followed by daily massage practice. The massage will be performed using varying pressure over a 3-minute period on the entire ear, focusing on stress and sleep points.
214625825|NCT06829251|BEHAVIORAL|Sham Ear Massage|The sham intervention involves a 1-minute ear massage on the outer helix rim, helix crest, and helix points 1, 2, and 3, without applying any pressure. The goal of the sham massage is to mimic the process of ear massage while ensuring no physiological effect on stress, anxiety, or sleep quality.
214625826|NCT06953388|DEVICE|transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Active stimulation will consist of direct electrical stimulation to the inner side of the left tragus (anode on the cymba concha, cathode on the surface of the tragus), thereby stimulating the ABVN. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
214718824|NCT06307444|PROCEDURE|Ultrasound-Guided Stellate Ganglion Block|high frequency (6 to 13 MHz) linear transducer will be placed perpendicular to the tracheal axis at the cricoid cartilage and will be moved inferiorly until the superior aspect of the thyroid gland is visualized. Later, the transducer should be relocated laterally to visualize the anterior aspect of the Chassaignac's tubercle on \[\]the C6 transverse process. The carotid artery, internal jugular vein, thyroid gland, trachea, Longus colli, and Longus capitis muscle, prevertebral fascia, the root of C6 spinal nerve, and transverse process of C6 can be identified. Color Doppler will be used to detect the position of the vessels. With an in-plane approach, 22 to 25 gauge echo-enhanced needle is placed beside the trachea with a lateral to medial direction.
214718825|NCT06307444|PROCEDURE|T2 T3 (High Thorathic) ESP Block|We will count the laminae in the cephaled-to-caudal direction, starting from the C7 using the US to determine the exact vertebral level where the needle will be inserted. A linear high-frequency ultrasound probe will be used to perform the blocks. After the determination of the needle insertion site, the US probe was placed over the spinous processes of the vertebrae at the midline in the longitudinal plane. The US probe will then slid laterally from the spinous processes to visualize the transverse process. The needle will be advanced posterior-to-anteriorly, in the caudal to cephalic direction using the in-plane orientation within paraspinal muscles, targeting the transverse process. When the tip of the needle reaches and contact the transverse process, the local anesthetic drugs(0.2-0.3ml/kg(11) of bupivacaine 0.25% 8mg Dexamethazone) will be administered
214625827|NCT06953388|DEVICE|sham transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Sham will be delivered to the ear lobe. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
214625828|NCT04218201|BEHAVIORAL|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
214625829|NCT04218201|BEHAVIORAL|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
214625830|NCT04218201|BEHAVIORAL|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
214625831|NCT04218201|BEHAVIORAL|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
214625832|NCT03631836|DRUG|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
214625833|NCT03631836|DRUG|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
214625834|NCT03631836|BIOLOGICAL|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
214625835|NCT03631836|DEVICE|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
214625836|NCT00218491|DRUG|N-Acetylcysteine|1200mg N-Acetylcysteine
214625837|NCT00218491|DRUG|N-Acetylcysteine|2400mg N-Acetylcysteine
214625838|NCT00218491|DRUG|Matching Placebo|Matching Placebo
214625839|NCT02562924|DEVICE|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
214625840|NCT02562924|DRUG|Budesonide|Topical steroid
214625841|NCT02562924|DRUG|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
214625842|NCT02562924|DRUG|Prednisone|Post-operatively, 40 mg daily for 7 days
214625843|NCT02562924|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
214625844|NCT02562924|DRUG|nasal saline spray|saline nasal mist every hour while awake
214625845|NCT01553630|PROCEDURE|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
214625846|NCT01553630|PROCEDURE|Surgery without bone graft|Plating of fracture without bone graft
214625847|NCT01834092|OTHER|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
214625848|NCT04523077|DIAGNOSTIC_TEST|determination of thyroid hormones and antibodies|TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
214625849|NCT00633659|DRUG|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
214718826|NCT02170350|PROCEDURE|Meditation therapy|Use brief mindful meditation practice
214625850|NCT00633659|DRUG|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
214625851|NCT01317342|DEVICE|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
214625852|NCT01579188|DRUG|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
214625853|NCT01579188|DRUG|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
214625854|NCT01860924|BEHAVIORAL|exercise|vigorous intensity exercise
214625855|NCT01860924|BEHAVIORAL|health education|education
214625856|NCT05266235|DEVICE|Validation of the Withings bodyscan scale WBS08|Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
214625857|NCT01677806|PROCEDURE|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
214625858|NCT01677806|OTHER|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
214625859|NCT03189875|OTHER|Standard of Care|Participants will be followed as per local routine clinical practice
214625860|NCT00991523|DIETARY_SUPPLEMENT|protein|protein
214625861|NCT00991523|DIETARY_SUPPLEMENT|placebo|placebo control
214625862|NCT01531920|DRUG|alcohol + placebo|Part A alcohol + placebo
214625863|NCT01531920|DRUG|alcohol + perampanel|Part A: alcohol + perampanel
214625864|NCT01531920|DRUG|perampanel + alcohol|Part B: perampanel + alcohol
214625865|NCT01531920|DRUG|placebo + alcohol|Part B: placebo + alcohol
214625866|NCT02195024|PROCEDURE|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
214625867|NCT00127907|DRUG|epinephrine (1 mg/1 mL)|
214625868|NCT00127907|DRUG|arginine-vasopressin (40 UI/2 mL)|
214625869|NCT01221064|PROCEDURE|Early drainage removal|Drainage will be removed in postoperative day 1
214625870|NCT01221064|PROCEDURE|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
214625871|NCT03723707|BEHAVIORAL|EQUIPED-ADRD Intervention|(10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
214625872|NCT03723707|BEHAVIORAL|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
214625873|NCT02019407|PROCEDURE|PVI, CTI block|"* PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
214625874|NCT02019407|PROCEDURE|PVI|PVI (pulmonary isolation)
214625875|NCT01409135|DRUG|AGS-22M6E|IV Infusion
214625876|NCT01409135|DRUG|ASG-22CE|IV Infusion
214625877|NCT01208350|BEHAVIORAL|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
214625878|NCT01208350|BEHAVIORAL|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
214625879|NCT01208350|BEHAVIORAL|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
214625880|NCT00037609|DRUG|Capecitabine|1000 mg/m\^2 taken by mouth twice daily.
214625881|NCT00037609|DRUG|Exisulind|125 mg taken by mouth twice daily.
214625882|NCT04027400|BEHAVIORAL|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
214625883|NCT05121480|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
214625884|NCT05121480|DRUG|Placebo|Placebo oral capsule
214625885|NCT02366611|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
214625886|NCT02658123|OTHER|Pre-operative education (standard of care)|
214625887|NCT02658123|OTHER|Home health care visits (standard of care)|
214625888|NCT02658123|OTHER|Follow-up post-operative visits|
214625889|NCT02658123|OTHER|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
214718827|NCT02170350|OTHER|Quality-of-life assessment|Ancillary studies
214625890|NCT02658123|OTHER|Healthcare Utilization Form|"* Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit"
214625891|NCT02658123|OTHER|The City of Hope QOL Survey for Ostomy Patients|"* Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
214625892|NCT02658123|OTHER|Phone call with CWOCN or PA|
214625893|NCT06205888|OTHER|18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT|Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
214625894|NCT02822066|PROCEDURE|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
214718828|NCT02170350|OTHER|Questionnaire administration|Ancillary studies
214718829|NCT04929678|DEVICE|Braive™ Growth Modulation System (Braive™ GMS)|"The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw."
214718830|NCT00653328|DRUG|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
214718831|NCT00653328|DRUG|doxil|50 mg/m2 intravenously every 28 days
214718832|NCT04261283|OTHER|Experimental|"The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment"
214718833|NCT04261283|OTHER|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
214718834|NCT00005061|BIOLOGICAL|bevacizumab|
214718835|NCT02592668|DEVICE|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
214625895|NCT04124146|RADIATION|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
214625896|NCT00001550|DRUG|IVIg|
214625897|NCT04851951|PROCEDURE|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
214625898|NCT02831673|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
214634884|NCT01596998|DRUG|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
214634885|NCT01596998|OTHER|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
214634886|NCT01596998|OTHER|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
214634887|NCT00001386|DRUG|PCLUS 3-18 MN|
214634888|NCT00001386|DRUG|PCLUS 6.1 MN|
214634889|NCT05543473|OTHER|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
214634890|NCT02678858|BEHAVIORAL|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
214634891|NCT02678858|BEHAVIORAL|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
214634892|NCT01594021|DRUG|Gelatin 500 mL|intravenous administration
214634893|NCT01594021|DRUG|Gelatin 50 mL|intravenous administration
214634894|NCT01776073|BEHAVIORAL|Patient Navigation|
214634895|NCT00710528|DRUG|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
214634896|NCT03881150|OTHER|Comprehensive assessment|Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
214634897|NCT03881150|OTHER|Counseling|Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
214634898|NCT03881150|OTHER|Group education|Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
214634899|NCT03881150|OTHER|Exercise sessions in hybrid program|"10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate."
214634900|NCT03881150|OTHER|Exercise sessions in standard program|"18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate."
214625899|NCT02831673|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
214625900|NCT02831673|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
214625901|NCT00919035|DRUG|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
214625902|NCT01411748|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
214625903|NCT01411748|DRUG|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
214625904|NCT02356562|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
214625905|NCT02356562|DRUG|Sofosbuvir|tablet
214625906|NCT02356562|DRUG|Ribavirin|tablet
214625907|NCT01469858|DEVICE|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
214625908|NCT03278132|BIOLOGICAL|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
214625909|NCT05453617|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
214625910|NCT05453617|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
214625911|NCT00126087|DRUG|dopamine|
214625912|NCT00294307|BEHAVIORAL|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];
214625913|NCT00294307|BEHAVIORAL|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.
214625914|NCT00294307|BEHAVIORAL|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
214625915|NCT03610061|DRUG|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
214625916|NCT03610061|RADIATION|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
214625917|NCT03610061|RADIATION|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
214625918|NCT04760665|BIOLOGICAL|Fecal microbiota transplantation|Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
214625919|NCT04760665|OTHER|Placebo|Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
214625920|NCT03772626|DEVICE|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
214625921|NCT04083482|PROCEDURE|continous venovenous hemofiltraion|CVVH
214625922|NCT03615183|DRUG|MK-8527|Single oral capsule
214625923|NCT01977781|DRUG|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
214625924|NCT01977781|DRUG|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
214625925|NCT02263183|DIETARY_SUPPLEMENT|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
214625926|NCT02263183|DIETARY_SUPPLEMENT|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
214625927|NCT03368651|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
214718836|NCT00885885|DRUG|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
214625928|NCT04706039|DIAGNOSTIC_TEST|Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process|"Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.~A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms."
214625929|NCT06407180|DRUG|Triamcinolone Acetonide|receive intraarticular triamcinolone injection
214625930|NCT06407180|DRUG|Normal saline|receive intraarticular normal saline injection
214625931|NCT03762070|DEVICE|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
214625932|NCT01526512|DRUG|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
214625933|NCT02611154|DRUG|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
214625934|NCT00089908|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
214625935|NCT00089908|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
214625936|NCT05208151|OTHER|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
214625937|NCT01490658|DRUG|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
214718837|NCT00885885|DRUG|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
214718838|NCT02521389|DRUG|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
214625938|NCT01490658|DRUG|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
214625939|NCT01490658|DRUG|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
214625940|NCT04135430|OTHER|Survey|practice of an updated questionnaire at D0, D2 and D7
214718839|NCT03273504|OTHER|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
214718840|NCT03273504|OTHER|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
214718841|NCT02928666|OTHER|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
214625941|NCT03139812|DRUG|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
214625942|NCT03139812|DEVICE|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
214625943|NCT00896675|OTHER|proteomic profiles|blood samples analysis
214625944|NCT00896675|OTHER|proteomic profiles|blood samples analysis
214625945|NCT06042400|BEHAVIORAL|Written Exposure Therapy|An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
214718842|NCT02077842|DEVICE|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
214718843|NCT02077842|DEVICE|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
214625946|NCT05069246|OTHER|Nigella Sativa oil|5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
214625947|NCT05069246|DRUG|Chlorhexidine mouthwash|10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
214625948|NCT06297746|PROCEDURE|Subvastus approach|Subvastus approach
214625949|NCT06297746|PROCEDURE|Medial Parapatellar approach|Medial Parapatellar approach
214625950|NCT01908647|BEHAVIORAL|RT fMRI|Real-time fMRI with neurofeedback.
214625951|NCT01908647|BEHAVIORAL|Cognitive Training|Computer based attention training.
214625952|NCT01908647|BEHAVIORAL|Control RT fMRI|Control condition for real-time fMRI.
214718844|NCT02361619|DRUG|Caffeine|probe
214718845|NCT02361619|DRUG|Diclofenac|probe
214625953|NCT01908647|BEHAVIORAL|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
214625954|NCT05265403|DRUG|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
214718846|NCT02361619|DRUG|Esomeprazole|probe
214718847|NCT02361619|DRUG|Metoprolol|probe
214625955|NCT05265403|DEVICE|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
214625956|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
214625957|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
214625958|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
214625959|NCT01351389|BEHAVIORAL|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
214625960|NCT01351389|BEHAVIORAL|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
214625961|NCT06490458|COMBINATION_PRODUCT|Balance Training|Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.
214625962|NCT03539744|DRUG|Pomalidomide|capsule, oral
214625963|NCT03539744|DRUG|Dexamethasone|oral, locally available form
214625964|NCT03539744|DRUG|Venetoclax|tablet; oral
214625965|NCT06312748|DRUG|L-Citrulline|100 mg tablet
214625966|NCT06312748|DRUG|Placebo for L-Citrulline|L-Citrulline-matched Placebo tablet
214625967|NCT06312748|DRUG|BH4|10mg/kg
214625968|NCT06312748|DRUG|Placebo for BH4|BH4-matched Placebo
214625969|NCT06312748|DRUG|Atorvastatin|10 mg tablet
214625970|NCT06312748|DRUG|Placebo for Atorvastatin|Atorvastatin-matched Placebo
214625971|NCT05950087|OTHER|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy
214625972|NCT05735691|PROCEDURE|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
214718848|NCT02361619|DRUG|Midazolam|probe
214718849|NCT02361619|DRUG|Dabigatran|probe
214718850|NCT02361619|DRUG|Clarithromycin|perpetrator
214625973|NCT05735691|PROCEDURE|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
214625974|NCT05735691|PROCEDURE|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
214625975|NCT04577950|PROCEDURE|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
214625976|NCT03113240|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
214625977|NCT03113240|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
214625978|NCT06153251|DRUG|BMS-986453|Specified dose on specified days
214625979|NCT06153251|DRUG|Fludarabine|Specified dose on specified days
214625980|NCT06153251|DRUG|Cyclophosphamide|Specified dose on specified days
214625981|NCT03487575|BEHAVIORAL|Open trial|Integrated electronic support and care support manager contact
214625982|NCT00252343|DRUG|SR58611A|
214625983|NCT02239276|DRUG|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
214625984|NCT00713700|DEVICE|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
214625985|NCT05336071|DRUG|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
214625986|NCT05336071|DRUG|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
214625987|NCT06137274|RADIATION|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
214625988|NCT06137274|OTHER|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
214625989|NCT05942027|DRUG|Placebo|Placebo match Coenzyme Q10 capsules once per day .
214625990|NCT05942027|DRUG|Co-Enzyme Q10|Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
214625991|NCT05001321|RADIATION|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
214625992|NCT05001321|OTHER|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
214625993|NCT01563770|DIETARY_SUPPLEMENT|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
214625994|NCT01563770|DIETARY_SUPPLEMENT|Placebo|3 placebo capsules, twice daily for four consecutive weeks
214625995|NCT03719690|DRUG|Tipifarnib|Tablet for oral administration
214625996|NCT03719690|DEVICE|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
214625997|NCT00847912|DRUG|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
214625998|NCT00847912|DRUG|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
214625999|NCT04596475|DRUG|glecaprevir/pibrentasvir (GLE/PIB)|The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
214626000|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
214626001|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
214626002|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
214626003|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
214626004|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
214626005|NCT02517775|DIETARY_SUPPLEMENT|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
214626006|NCT03589599|OTHER|Flavored tobacco|Effects of flavored tobacco
214626007|NCT03589599|OTHER|Non-flavored tobacco|Effects of non-flavored tobacco
214626008|NCT01487252|BEHAVIORAL|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
214626009|NCT05514379|BEHAVIORAL|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
214626010|NCT00150657|DRUG|bevacizumab|
214626011|NCT00150657|DRUG|carboplatin|
214626012|NCT00150657|DRUG|gemcitabine|
214626013|NCT06501651|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
214626014|NCT06501651|DRUG|Valsartan|Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
214626015|NCT02767440|BEHAVIORAL|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
214626016|NCT02458963|PROCEDURE|IVF|Women will undergo one IVF cycle
214626017|NCT02458963|DRUG|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
214626018|NCT02474732|DEVICE|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
214626019|NCT00397813|DRUG|Cyclosporine|Given PO
214626020|NCT00397813|DRUG|Fludarabine Phosphate|Given IV
214626021|NCT00397813|OTHER|Laboratory Biomarker Analysis|Correlative studies
214626022|NCT00397813|DRUG|Mycophenolate Mofetil|Given PO
214626023|NCT00397813|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
214626024|NCT00397813|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
214626025|NCT00397813|RADIATION|Total-Body Irradiation|Undergo TBI
214626026|NCT01074190|DRUG|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
214626027|NCT01074190|DRUG|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
214626028|NCT01074190|DRUG|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
214626029|NCT00732303|DRUG|Pemetrexed|Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
214626030|NCT00732303|RADIATION|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
214626031|NCT03445455|DEVICE|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
214626032|NCT05365542|OTHER|Hemodialyzer scanning|After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.
214626033|NCT05365542|OTHER|Bleeding Questionnaires|The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked
214626034|NCT05365542|OTHER|Quality of life questionnaire|The EQ5D questionnaire is asked.
214626035|NCT05365542|OTHER|Visual inspection of the limbs|Visual inspection is done of the patient's limbs in order to quantify bruising.
214626036|NCT01252212|BEHAVIORAL|SMS medication adherence|SMS messages to cell phones.
214626037|NCT01252212|BEHAVIORAL|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
214626038|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg once daily
214626039|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg bid
214626040|NCT03679533|DIETARY_SUPPLEMENT|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
214626041|NCT03679533|DIETARY_SUPPLEMENT|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
214626042|NCT01382797|DRUG|ALKS 37|Capsules for oral administration
214626043|NCT01382797|DRUG|Placebo|Capsules for oral administration
214626044|NCT05043571|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
214626045|NCT02477657|PROCEDURE|Paracentesis|Paracentesis
214626046|NCT02477657|DEVICE|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
214626047|NCT02477657|DEVICE|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
214626048|NCT05709964|OTHER|Self-reported|Self-reported height, weight, and neck circumference
214626049|NCT05709964|OTHER|Measured|Height, weight, and neck circumference measured by the investigator.
214626050|NCT03480100|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
214626051|NCT03480100|DEVICE|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
214626052|NCT03882970|DRUG|Tirzepatide|Administered SC
214626053|NCT03882970|DRUG|Insulin Degludec|Administered SC
214718851|NCT03498118|DRUG|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
214626054|NCT03831971|DRUG|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
214626055|NCT03820648|DEVICE|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
214626056|NCT03820648|DEVICE|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
214626057|NCT02567253|PROCEDURE|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
214718852|NCT00066508|DRUG|bortezomib|
214626058|NCT02567253|DRUG|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
214626059|NCT02567253|DRUG|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
214626060|NCT02567253|DRUG|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
214626061|NCT02567253|DRUG|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
214626062|NCT05284760|DRUG|Soticlestat|Soticlestat T4 tablets.
214626063|NCT05284760|DRUG|Soticlestat|Soticlestat T3 mini-tablets.
214626064|NCT05284760|DRUG|Soticlestat|Soticlestat commercial tablets.
214626065|NCT04555824|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
214626066|NCT04555824|OTHER|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
214626067|NCT05358756|DRUG|SACT-1|Single administartion of 150mg SACT-1
214626068|NCT05358756|DRUG|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
214626069|NCT05292105|DEVICE|NC Xperience|Coronary dilatation balloon catheter (non compliant)
214626070|NCT06268743|OTHER|High intensity|High intensity exercise
214626071|NCT06268743|OTHER|Moderate intensity|Moderate intensity exercise
214626072|NCT04707742|DRUG|Betadine© bucal 100 mg/ml|15 ml 2% povidone-iodine, one minute rinse.
214626073|NCT04707742|DRUG|Oximen® 3%|15 ml 1% hydrogen peroxide, one minute rinse.
214626074|NCT04707742|DRUG|Clorhexidine Dental PHB©|15 ml 0,12% clorhexidine, one minute rinse.
214626075|NCT04707742|DRUG|Vitis Xtra Forte©|15 ml 0,07% cetylpyridinium chloride, one minute rinse.
214626076|NCT04707742|DRUG|Distilled Water|15 ml distilled water, one minute rinse.
214626077|NCT05140538|OTHER|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
214626078|NCT05140538|OTHER|SRP + toothpaste|Use of domiciliary products twice a day
214626079|NCT00522587|DRUG|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
214626080|NCT00522587|DRUG|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
214626081|NCT00522587|DRUG|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
214626082|NCT00522587|DRUG|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
214626083|NCT00522587|DRUG|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
214626084|NCT00522587|DRUG|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
214626085|NCT00522587|DRUG|Fixed remifentanil dose 1|Dose 1 of remifentanil
214626086|NCT00522587|DRUG|Fixed remifentanil dose 2|Dose 2 of remifentanil
214626087|NCT00522587|DRUG|Fixed remifentanil dose 3|Dose 3 of remifentanil
214626088|NCT00522587|DRUG|Fixed remifentanil dose 4|Dose 4 of remifentanil
214626089|NCT00522587|DRUG|Fixed remifentanil dose 5|Dose 5 of remifentanil
214626090|NCT00522587|DRUG|Fixed remifentanil dose 6|Dose 6 of remifentanil
214626091|NCT01112046|PROCEDURE|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
214626092|NCT01112046|PROCEDURE|Laparoscopic resection|Surgical treatment performed under general anesthesia
214626093|NCT00634309|DRUG|Candesartan|
214626094|NCT00634309|DRUG|Placebo|
214626095|NCT02709564|DRUG|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
214626096|NCT02709564|DRUG|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
214626097|NCT00492167|BIOLOGICAL|beta-glucan|
214626098|NCT00492167|BIOLOGICAL|monoclonal antibody 3F8|
214626099|NCT00492167|OTHER|immunohistochemistry staining method|
214626100|NCT00492167|OTHER|laboratory biomarker analysis|
214626101|NCT02810665|BEHAVIORAL|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
214626102|NCT05106322|OTHER|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
214626103|NCT05429788|DRUG|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
214626104|NCT05429788|DRUG|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
214626105|NCT05429788|DRUG|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
214626106|NCT02830776|DRUG|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
214626107|NCT04558411|BEHAVIORAL|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
214626108|NCT00001990|DRUG|Atovaquone|
214626109|NCT05514314|DRUG|Icotinib|Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
214626110|NCT02103998|DRUG|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
214626111|NCT02103998|DRUG|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
214626112|NCT06308042|OTHER|30 second sit and stand test|The individual sits in the middle of the chair with his back upright, his feet on the ground, and his arms crossed in front of his chest. The individual starts the test with the start command while in this position and takes off as fully as he can for 30 seconds.
214626113|NCT03247270|BEHAVIORAL|Intervention I|Low intensive physical exercise
214626114|NCT03247270|BEHAVIORAL|Intervention II|High intensive physical exercise
214626115|NCT04848558|DRUG|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
214626116|NCT04848558|OTHER|Placebo|Participants will receive IV infusion or SC injection of placebo.
214718853|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
214718854|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
214718855|NCT01171014|DIETARY_SUPPLEMENT|Placebo|Placebo, once a day for 14 days
214626117|NCT04804787|DIAGNOSTIC_TEST|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
214626118|NCT04043325|DIAGNOSTIC_TEST|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
214626119|NCT00607386|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
214626120|NCT03459209|OTHER|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
214626121|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
214626122|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
214626123|NCT04938128|DEVICE|CPAP|Gold standard treatment for obstructive sleep apnea. In this group, patients will be prescribed CPAP treatment according to local policy.
214626124|NCT04860570|DEVICE|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
214626125|NCT06082388|DRUG|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
214626126|NCT02716987|DRUG|TAK-831|TAK-831 oral suspension.
214626127|NCT02716987|DRUG|[18F]PGM299|\[18F\]PGM299 injection
214626128|NCT02705651|DRUG|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
214626129|NCT05576389|DRUG|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
214626130|NCT04233697|DRUG|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
214626131|NCT04233697|DRUG|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
214626132|NCT03838302|PROCEDURE|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
214626133|NCT03838302|PROCEDURE|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
214626134|NCT05115838|DRUG|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
214626135|NCT05115838|DRUG|Placebo|Placebo implantable rod placed subdermally on the upper arm.
214626136|NCT03322189|GENETIC|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
214626137|NCT00153114|DRUG|polyethyleneglycol3350|
214626138|NCT02670863|OTHER|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
214626139|NCT02670863|OTHER|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
214626140|NCT00520364|OTHER|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
214626141|NCT03417908|PROCEDURE|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
214626142|NCT03417908|PROCEDURE|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
214626143|NCT02820285|OTHER|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
214626144|NCT02820285|OTHER|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
214626145|NCT02820285|OTHER|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
214626146|NCT01850485|DEVICE|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
214626147|NCT03622463|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
214626148|NCT03622463|OTHER|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
214626149|NCT04265885|OTHER|collection of testimonies from transgender people|guided interview
214626150|NCT05882955|BEHAVIORAL|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
214626151|NCT05882955|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
214626152|NCT02681172|DRUG|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
214626153|NCT02681172|PROCEDURE|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
214626154|NCT00436800|DRUG|Gemcitabine|1000mg/m² over 10mg/m²/min
214626155|NCT00436800|DRUG|Oxaliplatin|100 mg/m² over 2 hours.
214626156|NCT00767091|DRUG|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
214626157|NCT00767091|DRUG|placebo|transdermal patch of placebo
214626158|NCT04424654|DRUG|Testosterone cypionate|Testosterone cypionate 400 mg IM
214626159|NCT02988453|OTHER|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
214626160|NCT05151003|OTHER|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
214626161|NCT04615754|DIETARY_SUPPLEMENT|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
214626162|NCT04615754|DIETARY_SUPPLEMENT|Placebo - use of saline infusion|Saline is infused as an comparator
214626163|NCT03580252|OTHER|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
214626164|NCT05877482|OTHER|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
214626165|NCT05877482|OTHER|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
214626166|NCT01193855|DRUG|dutasteride|
214626167|NCT01193855|DRUG|gadolinium-chelate|
214626168|NCT01193855|OTHER|active surveillance|
214626169|NCT01193855|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214626170|NCT01193855|PROCEDURE|functional magnetic resonance imaging|
214626171|NCT01193855|PROCEDURE|prostate biopsy|
214626172|NCT01193855|PROCEDURE|ultrasound imaging|
214626173|NCT04510233|DRUG|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
214626174|NCT04510233|DRUG|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
214626175|NCT04510233|OTHER|standard care|oxygen via masks or ventilators
214626176|NCT05687331|PROCEDURE|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
214626177|NCT05687331|PROCEDURE|venipuncture|Peripheral venipuncture to gather a blood sample
214626178|NCT05687331|DIAGNOSTIC_TEST|MRI-scan|MRI-scan of the knee
214626179|NCT05687331|DIAGNOSTIC_TEST|Physical examination|Physical examination of the injured knee
214626180|NCT05687331|OTHER|KOOS questionnaire|KOOS questionnaire of the injured knee
214626181|NCT01963312|PROCEDURE|Transarterial Supraselective Embolization of the prostate|
214626182|NCT01963312|PROCEDURE|Transurethral Resection of the prostate|
214626183|NCT04317495|OTHER|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
214626184|NCT03569579|DRUG|Memantine Tab. 10mg|Memantine Tab. 10mg\* 2T/day, QD, PO
214626185|NCT03569579|DRUG|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
214626186|NCT03223428|DRUG|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
214626187|NCT02228291|DIETARY_SUPPLEMENT|Capsule containing citrus flavonoid|
214626188|NCT02228291|DIETARY_SUPPLEMENT|Placebo|
214626189|NCT01834274|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
214626190|NCT01834274|DRUG|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
214626191|NCT01834274|DRUG|Sitagliptin|Sitagliptin tablets
214626192|NCT01834274|DRUG|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
214626193|NCT01834274|DRUG|Metformin|Metformin tablets
214626194|NCT06012370|PROCEDURE|PRP injection|Injection of PRP and hyaluronic acid
214626195|NCT03119714|DRUG|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
214626196|NCT03119714|DRUG|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
214626197|NCT01142401|DRUG|Bortezomib|Given IV
214626198|NCT01142401|DRUG|Fulvestrant|Given IM
214626199|NCT01142401|OTHER|Laboratory Biomarker Analysis|Correlative studies
214626200|NCT02017327|DRUG|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
214626201|NCT02017327|DRUG|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
214626202|NCT02017327|DRUG|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
214626203|NCT05872750|DEVICE|theta burst stimulation|Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)
214626204|NCT05872750|DEVICE|sham stimulation|sham stimulation
214626205|NCT05973604|DIAGNOSTIC_TEST|Screening and Confirmatory diagnostic test for primary aldosteronism|Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is \>30, accompanied by elevated aldosterone values (\>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are \>5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are \>8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (\>6ng/dl) are found at the end of the test).
214626206|NCT06180200|DIAGNOSTIC_TEST|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
214626207|NCT02422212|OTHER|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
214626208|NCT01537562|OTHER|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
214626209|NCT03362970|DEVICE|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
214626210|NCT03362970|OTHER|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
214626211|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
214626212|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
214626213|NCT03880175|BEHAVIORAL|Anti Stigma Information|Adults in the households are provided anti-stigma information
214626214|NCT03880175|BEHAVIORAL|HIV/AIDS Information|The households receive information about HIV infection and AIDS
214626215|NCT03880175|BEHAVIORAL|ART Information|The households receive information about antiretroviral therapy.
214626216|NCT03880175|BEHAVIORAL|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
214626217|NCT03880175|BEHAVIORAL|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
214626218|NCT01956903|GENETIC|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
214626219|NCT03592940|DIETARY_SUPPLEMENT|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
214626220|NCT00106275|BEHAVIORAL|Mindfulness Based Stress Reduction|
214626221|NCT02739607|BEHAVIORAL|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
214626222|NCT00549172|PROCEDURE|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
214626223|NCT00549172|PROCEDURE|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
214626224|NCT02813694|DRUG|lefamulin|antibacterial agent
214626225|NCT02813694|DRUG|Moxifloxacin|antibacterial agent
214626226|NCT01529437|DRUG|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
214626227|NCT01529437|DRUG|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
214626228|NCT01265797|DEVICE|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
214626229|NCT01265797|DEVICE|Sham Device|participant wears sham device for 20 minutes daily for 28 days
214626230|NCT00491699|DRUG|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
214626231|NCT00731575|DRUG|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
214626232|NCT05711004|BEHAVIORAL|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
214626233|NCT06290375|DRUG|HSK21542 tablet|once-daily
214626234|NCT06290375|DRUG|Placebo|once-daily
214626235|NCT02980224|DRUG|OmegaD|OmegaD Softgels
214626236|NCT02980224|DRUG|Placebo|Placebo Softgels
214626237|NCT02942745|BEHAVIORAL|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
214626238|NCT02942745|BEHAVIORAL|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
214626239|NCT01428284|DRUG|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
214626240|NCT00606320|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
214626241|NCT03930719|DIAGNOSTIC_TEST|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
214626242|NCT03336021|OTHER|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
214626243|NCT04839380|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
214626244|NCT01179009|DRUG|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
214626245|NCT01179009|DRUG|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
214626246|NCT01179009|DRUG|placebo|IV saline (i.e. placebo ketamine)
214626247|NCT04325841|BIOLOGICAL|Murine autologous anti-CD19 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
214626248|NCT05780307|DRUG|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
214626249|NCT02937818|DRUG|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
214626250|NCT02937818|DRUG|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
214626251|NCT02937818|DRUG|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
214626252|NCT01748539|DRUG|KHK4827|
214626253|NCT01748539|DRUG|Placebo|
214626254|NCT02534701|DEVICE|ERIC® and SOFIA™|a self-expanding clot retrieval system
214626255|NCT02717884|DRUG|tranylcypromine|"TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
214626256|NCT02717884|DRUG|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
214626257|NCT02717884|DRUG|cytarabine|40mg s.c. (days 1-10)
214626258|NCT04568395|OTHER|TCIG|Use a TCIG
214626259|NCT04568395|OTHER|ECIG|Use an ECIG
214626260|NCT04568395|OTHER|sham control|Use a sham control (empty ECIG)
214626261|NCT00730964|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
214626262|NCT04596020|OTHER|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
214626263|NCT01015768|DEVICE|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
214626264|NCT01015768|DEVICE|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
214626265|NCT01561950|DRUG|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
214626266|NCT01561950|DRUG|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
214626267|NCT01561950|DRUG|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
214626268|NCT04234165|DEVICE|TURBT|different power sources ( bipolar vs monopolar)
214626269|NCT05164107|DEVICE|Globe Mapping and Pulsed Field Ablation System (Globe PF System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
214626270|NCT02079857|OTHER|Standard protocol|Subjects will receive a standard treatment
214626271|NCT02079857|OTHER|Individualized protocol|Subjects will receive an individualized treatment
214626272|NCT02079857|OTHER|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
214626273|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
214626274|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
214626275|NCT00456105|BEHAVIORAL|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
214626276|NCT00742248|DRUG|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
214626277|NCT00742248|DRUG|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
214626278|NCT00742248|DRUG|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
214626279|NCT04060420|OTHER|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
214626280|NCT01669161|DEVICE|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
214626281|NCT01669161|OTHER|Rehab Only|Rehabilitation without device implant and VNS
214626282|NCT00318214|DRUG|MRE0094|Gel, 500 mcg/g once each day
214626283|NCT00318214|DRUG|Vehicle gel|Gel administered once per day
214626284|NCT02943564|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
214626285|NCT02943564|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
214626286|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
214626287|NCT00063570|DRUG|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
214626288|NCT00063570|DRUG|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
214626289|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
214626290|NCT01367535|DRUG|SC Methylnaltrexone (MNTX)|
214626291|NCT01367535|DRUG|IV Methylnaltrexone (MNTX)|
214626292|NCT01367535|DRUG|Oral Paroxetine|
214626293|NCT01367535|DRUG|SC Placebo|
214626294|NCT01073267|RADIATION|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
214626295|NCT00977236|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
214626296|NCT00977236|DEVICE|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
214626297|NCT00577642|DRUG|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
214626298|NCT06017570|DIAGNOSTIC_TEST|Radiologic examination on orthopantomogram|Caries examination on the distal side of the adjacent second molar in the orthopantomogram of patients with an appointment for the extraction of mesioangular or horizontal partially impacted third molars
214626299|NCT06017570|DIAGNOSTIC_TEST|Clinical examination after surgery|İnspectional caries examination on the distal side of the adjacent second molar after surgery of patients with mesioangular or horizontal partially impacted third molars
214626300|NCT01587911|OTHER|Whey|Preload containing complete whey protein.
214626301|NCT01587911|OTHER|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
214626302|NCT01587911|OTHER|Control|Preload control matched for energy to the other 5 preloads.
214626303|NCT01587911|OTHER|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
214626304|NCT01587911|OTHER|MPI|Preload containing whole milk protein.
214626305|NCT01587911|OTHER|CPI|Preload containing sodium caseinate.
214626306|NCT00554502|DRUG|supportive therapy with: ACE-inhibitor / ARB / Statin|"* Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
214626307|NCT00554502|DRUG|supportive and immunosuppressive therapy|"* supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice"
214626308|NCT06427200|DRUG|oral Iron|oral iron once daily during or after meals as add-on therapy for 12 weeks.
214626309|NCT06427200|DRUG|Lactoferrin|lactoferrin twice daily before meals as add-on therapy for 12 weeks.
214626310|NCT06427200|DRUG|lactoferrin and oral iron|lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
214626311|NCT04973475|DRUG|Indocyanine Green|Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer
214626312|NCT01112540|DRUG|Morphine|0.1 mg/kg Intravenous bolus
214626313|NCT05105464|DRUG|SYHA1815|Subjects will receive SYHA1815 orally.
214626314|NCT02308982|DRUG|Immunoglobulins, Intravenous (Privigen)|
214626315|NCT02308982|DRUG|Placebo|
214626316|NCT01806363|DRUG|Telmisartan 80mg|
214626317|NCT01806363|DRUG|Chlorthalidone 25mg|
214626318|NCT00036075|DRUG|CP-461|
214626319|NCT04778436|DIETARY_SUPPLEMENT|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
214626320|NCT00923403|DIETARY_SUPPLEMENT|plant sterol enriched soymilk|plant sterol enriched soymilk
214626321|NCT00923403|DIETARY_SUPPLEMENT|control dairy milk|control dairy milk
214626322|NCT05248568|DEVICE|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
214626323|NCT00676390|OTHER|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
214626324|NCT01556425|DRUG|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
214626325|NCT01556425|BEHAVIORAL|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
214626326|NCT01556425|OTHER|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
214626327|NCT04518215|PROCEDURE|Erector Spinae Plain Block|Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.
214626328|NCT04518215|PROCEDURE|Intra-Venous Analgesia|Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.
214626329|NCT05649085|DEVICE|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
214626330|NCT01786096|DRUG|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
214626331|NCT05654597|OTHER|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
214626332|NCT05654597|OTHER|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
214626333|NCT04800562|DRUG|PCS499|PCS499 900mg twice a day with food
214626334|NCT04800562|OTHER|placebo|placebo comparator
214626335|NCT03344952|DRUG|Botulinum toxin type A|Repeated injections to hypertonic muscles
214626336|NCT03344952|OTHER|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
214626337|NCT05635799|OTHER|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
214626338|NCT05635799|OTHER|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
214626339|NCT05635799|OTHER|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
214626340|NCT05635799|OTHER|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
214626341|NCT01505634|DRUG|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
214626342|NCT01505634|DRUG|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
214626343|NCT01505634|DRUG|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
214626344|NCT01505634|DRUG|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
214626345|NCT01505634|DRUG|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
214626346|NCT02054897|DRUG|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
214626347|NCT02054897|DRUG|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
214626348|NCT00472264|PROCEDURE|PET imaging|Medical imaging assessment
214626349|NCT04261075|BIOLOGICAL|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
214626350|NCT04261075|BIOLOGICAL|durvalumab|Durvalumab Q3W for a maximum of 2 years
214626351|NCT04261075|BIOLOGICAL|oleclumab|Oleclumab Q3W for a maximum of 2 years
214626352|NCT01173224|DRUG|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
214626353|NCT01173224|DRUG|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
214626354|NCT04309942|OTHER|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
214626355|NCT06538948|PROCEDURE|Bariatric Surgery|The intervention is not assigned to the participant after recruitment in the study, rather the intervention is an inclusion criteria for participation in the study.
214626356|NCT03611192|OTHER|Multicomponent exercise|Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins
214626357|NCT03611192|OTHER|Home-program exercise|60 mins exercise
214626358|NCT00794157|DRUG|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214626359|NCT00794157|DRUG|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214626360|NCT00794157|DRUG|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214626361|NCT01673711|DRUG|deuterated phenanthrene tetraol|Given PO
214626362|NCT01673711|DRUG|pharmacological study|Correlative studies
214626363|NCT01673711|DRUG|laboratory biomarker analysis|Correlative studies
214626364|NCT02854644|OTHER|additional blood sample|
214626365|NCT02600832|BEHAVIORAL|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
214626366|NCT02600832|BEHAVIORAL|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
214626367|NCT01300169|BEHAVIORAL|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
214626368|NCT01300169|BEHAVIORAL|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
214626369|NCT02961621|BEHAVIORAL|Stress Reduction Training for 9-1-1 Telecommunicators|
214626370|NCT03734835|DIETARY_SUPPLEMENT|hesperidin|1000 mg hesperidin as two capsules
214626371|NCT03734835|DIETARY_SUPPLEMENT|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
214626372|NCT03734835|DIETARY_SUPPLEMENT|flaxseed|30 grams flaxseed
214626373|NCT03734835|OTHER|control|no supplementation
214626374|NCT03446950|PROCEDURE|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
214626375|NCT05602038|PROCEDURE|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
214626376|NCT05602038|DRUG|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
214626377|NCT05602038|DRUG|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
214626378|NCT02364089|PROCEDURE|Laparoscopic surgical removal of the adrenal tumor|
214626379|NCT02364089|DRUG|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day."
214626380|NCT00002152|DRUG|WF10|
214626381|NCT01888029|DEVICE|transcranial direct current stimulation|
214626382|NCT01888029|DEVICE|sham stimulation|
214626383|NCT05145907|BIOLOGICAL|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
214626384|NCT06087744|BEHAVIORAL|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
214626385|NCT06087744|BEHAVIORAL|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
214626386|NCT03439202|OTHER|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
214626387|NCT03816930|PROCEDURE|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
214626388|NCT03111784|OTHER|Fish consumption and lipid profiles|
214626389|NCT05160961|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
214626390|NCT05160961|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
214626391|NCT01632995|DRUG|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
214626392|NCT00385957|DRUG|AZT+3TC+IDV+RTV|
214626393|NCT00385957|DRUG|AZT+3TC+EFV|
214626394|NCT00401375|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
214626395|NCT00401375|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
214626396|NCT04540042|DRUG|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
214626397|NCT04540042|DRUG|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
214626398|NCT04540042|DRUG|SelK2 (Part 2)|I.V., single-dose (Day 1)
214626399|NCT04540042|DRUG|Placebo (Part 2)|I.V., single-dose (Day 1)
214626400|NCT01012375|DRUG|AZD1446|10 mg capsule, oral dose
214626401|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
214626402|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
214626403|NCT01012375|DRUG|Placebo|Matching capsule, oral dose
214626404|NCT03814070|PROCEDURE|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
214626405|NCT03814070|PROCEDURE|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
214626406|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
214626407|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
214626408|NCT03691129|BEHAVIORAL|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
214626409|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
214626410|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
214626411|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
214626412|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
214626413|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
214626414|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
214626415|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
214626416|NCT00361270|BEHAVIORAL|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
214626417|NCT05447468|OTHER|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
214626418|NCT05447468|OTHER|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
214626419|NCT05447468|OTHER|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
214626420|NCT05447468|OTHER|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
214626421|NCT05447468|OTHER|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
214626422|NCT05447468|OTHER|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
214626423|NCT00950664|DRUG|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
214626424|NCT00950664|DRUG|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
214626425|NCT04899700|DEVICE|Linked Color Imaging|Inspection of the postpolypectomy scar will be made with Linked Color Imaging
214626426|NCT04899700|OTHER|White light endoscopy|Inspection of the postpolypectomy scar will be made with White light Endoscopy
214626427|NCT02351505|DRUG|Selinexor|Given PO
214626428|NCT02351505|OTHER|Laboratory Biomarker Analysis|Correlative studies
214626429|NCT02351505|OTHER|Pharmacological Study|Correlative studies
214626430|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
214626431|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
214626432|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
214626433|NCT03761095|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
214626434|NCT03761095|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
214626435|NCT04116385|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214626436|NCT00669058|DRUG|Lactic acid (Dermacid)|
214626437|NCT02079103|DEVICE|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
214626438|NCT02079103|BEHAVIORAL|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
214626439|NCT02374099|DRUG|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
214626440|NCT02374099|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
214626441|NCT03898375|OTHER|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
214626442|NCT02913690|DIETARY_SUPPLEMENT|Placebo|2 x 150mg capsules daily
214626443|NCT02913690|DIETARY_SUPPLEMENT|TRF|2 x 150mg capsules daily
214626444|NCT04039893|DIAGNOSTIC_TEST|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
214626445|NCT04039893|DIAGNOSTIC_TEST|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
214626446|NCT04039893|PROCEDURE|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
214626447|NCT04039893|PROCEDURE|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
214626448|NCT00081159|DRUG|Doxorubicin hydrochloride|Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
214626449|NCT00081159|DRUG|Goserelin acetate|
214626450|NCT00081159|DRUG|Leuprolide acetate|
214626451|NCT00081159|DRUG|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
214626452|NCT00081159|PROCEDURE|orchiectomy|
214626453|NCT00081159|RADIATION|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
214626454|NCT02237521|OTHER|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
214626455|NCT02237521|OTHER|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
214626456|NCT01548339|PROCEDURE|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
214626457|NCT02731261|OTHER|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
214626458|NCT04124913|DRUG|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
214626459|NCT04124913|DRUG|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
214626460|NCT01553981|DRUG|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
214626461|NCT01553981|DRUG|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
214626462|NCT03449095|DRUG|Alcohol|Alcohol Target BAC .08%
214626463|NCT03063710|DRUG|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
214626464|NCT03921021|DRUG|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
214626465|NCT03578224|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
214626466|NCT03578224|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214626467|NCT03578224|PROCEDURE|Fine-Needle Aspiration|Undergo FNA
214626468|NCT03578224|DRUG|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
214626469|NCT05177653|OTHER|Intravenous infusion|GIP receptor antagonist (GIP(3-30)NH2)
214626470|NCT05177653|OTHER|Intravenous infusion|GLP-1 receptor antagonist (exendin(9-39)NH2)
214626471|NCT05177653|OTHER|Intravenous infusion|GIP(3-30)NH2 and exendin(9-39)NH2
214626472|NCT05177653|OTHER|Intravenous infusion|Saline
214626473|NCT01553136|DRUG|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
214626474|NCT04342286|GENETIC|Organoid culture|Organoid culture
214626475|NCT06047652|DEVICE|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
214626476|NCT06973031|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
214626477|NCT00214370|DRUG|Propofol-Fentanyl|
214626478|NCT00214370|DRUG|Propofol alone|
214626479|NCT01515761|PROCEDURE|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
214626480|NCT01515761|PROCEDURE|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
214626481|NCT03381716|DRUG|drug|Application bracket
214626482|NCT03381716|PROCEDURE|Surgery|Surgery
214626483|NCT01127568|DRUG|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
214626484|NCT04505618|DEVICE|Swept-Source (SS) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
214626485|NCT04505618|DEVICE|Spectral-Domain (SD) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
214626486|NCT04505618|DEVICE|Fundus Imaging|Non-invasive, minimal risk, ocular imaging study
214626487|NCT04505618|DEVICE|Axial Length Measurement Device|Non-invasive, minimal risk, ocular imaging study
214626488|NCT02632396|DRUG|Ixazomib|Given PO
214626489|NCT02632396|BIOLOGICAL|Rituximab|Given IV
214626490|NCT03926975|DEVICE|Scleral Lens|The contact lens will be worn on one eye.
214626491|NCT03926975|OTHER|No lens|No lens worn on the contralateral control eye
214626492|NCT01223170|BEHAVIORAL|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
214626493|NCT01223170|BEHAVIORAL|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
214626494|NCT01223170|BEHAVIORAL|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
214626495|NCT01223170|BEHAVIORAL|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
214626496|NCT00294359|DRUG|Mitomycin C; Capecitabine; Bevacizumab|
214626497|NCT04763642|PROCEDURE|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
214626498|NCT00573209|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
214626499|NCT00396201|DRUG|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
214626500|NCT03745274|BIOLOGICAL|GHB04L1|Solution
214626501|NCT03745274|OTHER|Placebo|Buffer solution
214626502|NCT01378234|BEHAVIORAL|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~1. Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~2. Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~3. Supporting caregivers to reduce stress and burden"
214626503|NCT03685266|OTHER|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
214626504|NCT05413486|OTHER|Observational|"Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups."
214626505|NCT00356850|DRUG|Azithromycin|
214626506|NCT06496815|DRUG|Donafenib|Donafenib will be taken orally twice a day, 0.2g each time.
214626507|NCT06496815|PROCEDURE|transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy|Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).
214626508|NCT06496815|DRUG|PD-1,PD-L1|PD-1/PD-L1 will be used as previous (if have).
214626509|NCT06137924|DRUG|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
214626510|NCT06137924|DRUG|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
214626511|NCT06137924|DRUG|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
214626512|NCT00867321|BIOLOGICAL|bevacizumab|Given IV
214626513|NCT00867321|DRUG|sorafenib tosylate|Given orally
214626514|NCT03921424|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
214626515|NCT03921424|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
214626516|NCT03921424|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
214626517|NCT03599128|OTHER|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
214626518|NCT03599128|OTHER|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
214626519|NCT03599128|OTHER|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
214626520|NCT03599128|OTHER|Placebo|Reconstituted in water and given to subjects
214626521|NCT02122198|DRUG|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
214626522|NCT02122198|DRUG|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
214626523|NCT02122198|DRUG|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
214626524|NCT02122198|DRUG|Placebo|placebo
214626525|NCT02883023|OTHER|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
214626526|NCT02883023|DRUG|Intralesional bleomycin injection|Local intralesional injections with bleomycin
214626527|NCT05063227|DIAGNOSTIC_TEST|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
214626528|NCT03853239|PROCEDURE|face mask ventilation crossover nasal ventilation|Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.
214626529|NCT03853239|PROCEDURE|nasal ventilation crossover face mask ventilation|Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
214626530|NCT02581202|DRUG|lopinavir/ritonavir|tablet
214626531|NCT02581202|DRUG|lamivudine|tablet
214626532|NCT00005039|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|Given IM
214626533|NCT00005039|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
214626534|NCT00005039|OTHER|laboratory biomarker analysis|Correlative studies
214626535|NCT01143727|DRUG|Santyl|Apply one 24-hr period sufficient to cover the wound.
214626536|NCT01143727|DRUG|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
214626537|NCT05884931|DEVICE|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
214626538|NCT05884931|PROCEDURE|Conventional Treatment|Standard hemostatic procedure
214626539|NCT03295162|DRUG|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
214626540|NCT03295162|COMBINATION_PRODUCT|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
214626541|NCT03205462|DRUG|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
214626542|NCT03205462|DRUG|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
214626543|NCT03205462|DRUG|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
214626544|NCT02587650|DRUG|Capmatinib|Given PO
214626545|NCT02587650|DRUG|Ceritinib|Given PO
214626546|NCT02587650|DRUG|Entrectinib|Given PO
214626547|NCT02587650|OTHER|Laboratory Biomarker Analysis|Correlative studies
214626548|NCT02587650|DRUG|Regorafenib|Given PO
214626549|NCT05062876|DRUG|AD-214|1 tablet administered before the breakfast during 7 days
214626550|NCT05062876|DRUG|AD-2141|1 tablet administered before the breakfast during 7 days
214626551|NCT05412056|DRUG|Metformin|as in arm/group description
214626552|NCT05412056|DRUG|Placebo oral tablet|as in arm/group description
214626553|NCT02898532|BEHAVIORAL|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
214626554|NCT03473574|BIOLOGICAL|Durvalumab|immune checkpoint inhibitor
214626555|NCT03473574|DRUG|Gemcitabine|standard chemotherapy
214626556|NCT03473574|DRUG|Cisplatin|standard chemotherapy
214626557|NCT03473574|BIOLOGICAL|Tremelimumab|immune checkpoint inhibitor
214626558|NCT04936360|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
214626559|NCT02595450|DRUG|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
214626560|NCT02613390|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
214626561|NCT02613390|BEHAVIORAL|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
214626562|NCT00391573|PROCEDURE|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
214626563|NCT00391573|PROCEDURE|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
214626564|NCT02330978|PROCEDURE|Intravitreal transplantation of mesenchymal stem cell|
214626565|NCT02330978|BIOLOGICAL|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
214626566|NCT05531175|OTHER|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
214626567|NCT06977425|DRUG|Magnesium sulphate|Patients received an initial intravenous loading dose of 30 mg/kg of 10% magnesium sulfate solution over 10 min. This will be followed by a continuous infusion of (10mg/kg/hr) for the entire duration of surgery.
214626568|NCT06977425|DRUG|Dexmedetomidine|Patients received dexmedetomidine infusion 0.5 μg/kg over 10 min as a bolus dose, followed by 0.2 μg/kg/h all over the operation.
214626569|NCT06978036|PROCEDURE|Flapless periodontal regeneration with EMD + EASD|Periodontal regneration with EMD in conjuction with Endoscope-assisted subgingival debridement
214626570|NCT06978036|PROCEDURE|Periodontal regeneration with EMD + PPT|Periodontal regneration with EMD in conjunction with periodontal surgery using Papilla Presevation Technique
214626571|NCT06978179|PROCEDURE|Ultrasound-Guided Quadratus Lumborum Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|"Group ( 1 ) QLB Type III: Patients will receive QLB performedwith20ml of diluted bupivacaine 0.25% on each side."
214626572|NCT06978179|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|Group ( 2 ) TAP: Patients will receive TAP block performed with 20ml of diluted bupivacaine 0.25% on each side.
214626573|NCT06978959|BEHAVIORAL|FN+ Intervention|Participants will attend 5 one-on-one sessions over the course of 5 weeks; they will meet with a family navigator over video conferencing software (e.g., Zoom). The purpose of each sessions are as follows: 1) Provide an overview of the program and help parents understand their perceptions of child behaviors, 2) Train parents to find, access, and overcome barriers to mental health services, 3) Build parent capacity in understanding how mental health treatment works and how to communicate with providers, 4) Help parents understand the common function of child behaviors, and 5) Train parents to find, evaluate, and use online mental health tools. Participants will complete measures of child symptoms, parent activation, barriers to treatment, and/or satisfaction with the program before the intervention, immediately after the intervention, and 3 months after completing the intervention.
214626574|NCT03501667|OTHER|Use of decision support tool|use of a decision support software during clinical assessment of a case
214626575|NCT03501667|OTHER|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
214626576|NCT02800889|DRUG|Pixantrone|Pixantrone
214626577|NCT06977477|OTHER|Remote Monitoring for Congestion Management in HFpEF Patients|All patients will undergo baseline tests, including echocardiography (left ventricular ejection fraction, E/e', left atrial volume index, left atrial strain analysis, left ventricular mass index, tricuspid annular plane systolic excursion, right ventricular strain, inferior vena cava index) and blood tests (NT-proBNP, creatinine, GFR, sST2, CA 125, bio-ADM, ALAT, ASAT, complete blood count, and hsCRP). Evaluation of extracellular and total body water volumes in the arms, legs, and trunk will be conducted using the Body Water Scale InBody (South Korea) and daily monitoring of pulmonary pressure through CardioMEMSTM. Bioelectrical impedance analysis (BIA) will be used to assess volume. Additional blood tests will be conducted at weeks 2, 6, 12, and at the final visit, with a focus on NT-proBNP, creatinine, GFR, ALAT, ASAT, hemoglobin, hematocrit, hsCRP, sST2, CA 125, and bio-ADM. At the final visit, a complete set of tests will be repeated to assess overall health and response to the int
214626578|NCT06978153|DRUG|benmelstobart combined with chemotherapy and anlotinib|Cohort 1: Neoadjuvant therapy (benmelstobart combined with chemotherapy and anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day 1. Anlotinib, 10 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Etoposide, 100mg/m2, day 1\~3. Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 10 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
214626579|NCT06978153|DRUG|benmelstobart combined with chemotherapy|Cohort 2: Neoadjuvant therapy (benmelstobart combined with chemotherapy, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; Etoposide, 100mg/m2, day 1\~3; Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
214626580|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
214626581|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection|Gelaspan
214626582|NCT03092102|DRUG|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
214626583|NCT03100045|DRUG|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
214626584|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 1|Soft gel capsule
214626585|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 2|Soft gel chewable
214626586|NCT01934556|DRUG|Ranibizumab 0.3 mg intravitreal injection|
214626587|NCT01934556|DEVICE|Guided Laser Photocoagulation|
214626588|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
214626589|NCT06659042|DRUG|Cisplatin|administered via IV infusion
214626590|NCT06659042|DRUG|Carboplatin|administered via IV infusion
214626591|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
214626592|NCT03845712|DRUG|doxecitine and doxribtimine|Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
214626593|NCT04769960|DIAGNOSTIC_TEST|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
214626594|NCT04769960|BEHAVIORAL|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
214626595|NCT06675617|DEVICE|Allay Aortic Stent|Endovascular treatment of an aortic dissection
214626596|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
214626597|NCT01260012|OTHER|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
214626598|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
214626599|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
214626600|NCT02922374|DRUG|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
214626601|NCT07006454|PROCEDURE|Ventro-Cephalic Translatoric Glide|"Participants of group A will receive ventro-cephalic translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's right side.~2. Therapist's stable hand: with the thumb and index finger of left hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her right hand on left side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in ventro-cranial direction in the right angle of the treatment plane of the facet joint."
214626602|NCT07006454|PROCEDURE|Dorso-Caudal Translatoric Glide|"Participants of group B will receive Dorso-caudal translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's left side.~2. Therapist's stable hand: with the thumb and index finger of right hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her left hand on right side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in dorso-caudal direction in the right angle of the treatment plane of the facet joint."
214626603|NCT06112067|DEVICE|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
214626604|NCT06099964|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
214626605|NCT06099964|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
214626606|NCT06692075|PROCEDURE|extracorporeal life support|ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA
214626607|NCT06692075|PROCEDURE|standard ACLS|Standard ACLS in cardioplumonary resuscitation of refractory OHCA
214626608|NCT05038020|DRUG|AKST4290|Oral AKST4290
214626609|NCT05038020|DRUG|Placebo|Oral Placebo
214626610|NCT06698939|DRUG|ORKA-001|ORKA-001 is supplied as sterile solution to be administered by SC injection
214626611|NCT06698939|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
214626612|NCT07028879|PROCEDURE|Fatigue management program|Combination of Occupational Therapy and Physiotherapy strategies and sessions.
214626613|NCT07029269|PROCEDURE|ERAS-tubeless group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; No abdominal drainage and nasojejunal feeding tubes were placed intraoperatively; None of these 3 tubes were present postoperatively.
214626614|NCT07029269|PROCEDURE|ERAS-tube group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; Nasojejunal feeding tube is not placed intraoperatively; 1 prophylactic abdominal drainage tube is placed at the duodenal stump for LDG and retained postoperatively.
214626615|NCT07029607|DIETARY_SUPPLEMENT|Placebo|Placebo
214626616|NCT07029607|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium
214626617|NCT07023315|DRUG|Cadonilimab|Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
214626618|NCT07023315|DRUG|SOX chemotherapy|A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium
214626619|NCT05309187|BIOLOGICAL|IO-202|IO-202 given as monotherapy
214626620|NCT05309187|BIOLOGICAL|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
214626621|NCT05309187|BIOLOGICAL|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
214626622|NCT07028437|PROCEDURE|Endoscopic-assisted transoral approach for parotid tumor resection|The buccal mucosa was incised in front of the mandibular ligament of the inner wing of the mouth, the submucosal tissue was separated, and important structures such as the buccal nerve, parotid duct, and facial nerve were protected. The tumor was completely resected while preserving the parotid gland.
214626623|NCT07028437|PROCEDURE|Blair S-shaped incision for parotid tumor|The Blair S-shaped incision was made through an anterior auricular incision. After cutting the skin, the flap was reflapped. The greater auricular nerve and facial nerve were separated and protected, and the tumor was completely resected.
214718856|NCT03336060|DIAGNOSTIC_TEST|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
214626624|NCT07027930|OTHER|Eye movement desensitization and reprocessing therapy integrative group treatment protocol for Ongoing traumatic stress|EMDR-IGTP-OTS is a group intervention based on EMDR 8-phased protocols with the integration of the Butterfly hug technique.
214626625|NCT07028450|BEHAVIORAL|Proactive call|The proactive call will be based on the principles of motivational interviewing. The content of the call comprises: 1) Asking the gambler/recipient to reflect on their gambling behavior, 2) providing to the gambler/recipient an overview of their gambling account and financial history, 3) offering to the gambler/recipient information about responsible gambling tools, such as setting lower limits, locking limits, taking a break, or self-exclusion, and 4) providing to the gambler/recipient information about relevant support services and the Gamban tool in cases where a need is expressed.
214626626|NCT06699342|PROCEDURE|Pacemaker implantation with Left bundle branch area pacing (LBBAP)|"Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients.~The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice."
214626627|NCT06699342|PROCEDURE|Atrioventricular node ablation (AVNA)|Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
214718857|NCT02152072|OTHER|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
214718858|NCT00493610|DRUG|N-acetylcysteine(Mucomyst)|
214626628|NCT06699342|DRUG|Pharmacologic therapy optimized for Atrial Fibrillation management|"Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy."
214626629|NCT06001333|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
214626630|NCT07027943|DIETARY_SUPPLEMENT|DAO supplement|Gastro-resistant DAO tablets of porcine kidney protein extract. Posology: 3 tablets per day (total 12.6mg of DAO extract/day).
214626631|NCT07027943|DIETARY_SUPPLEMENT|Placebo|Tablets containing microcrystalline cellulose and hydroxypropyl cellulose, with the same shape, size, and color as the DAO-containing tablets. Posology: 3 tablets per day.
214626632|NCT07028476|PROCEDURE|Automated Dynamic Laximetry|Patients are prescribed a Zimmer splint to immobilize the injured limb, and referred to a referring sports physician at the investigating center to perform the LDA as a confirmatory examination (complementary test). Patients arrange their appointment with the sports physician as soon as possible.
214626633|NCT07028476|PROCEDURE|MRI|In the control arm, and in line with standard practice, patients with a suspected ACL injury are prescribed a Zimmer splint to immobilize the injured limb, an MRI as a confirmatory examination, and a consultation with the doctor of their choice. Following the MRI, patients arrange their appointments according to the usual care pathway for their pathology.
214626634|NCT01125150|DRUG|Metformin|Dosage to be determined by Endocrinologist
214626635|NCT01125150|BEHAVIORAL|Dietary Modification|To be determined by Endocrinologist
214626636|NCT06718361|OTHER|Oxygen levels measurement (%)|Measuring levels of oxygen in the environment around the patient in %.
214626637|NCT06926010|OTHER|predictive approach to hemodynamic management|vasoactive drugs and fluids will be given based on the hypotension prediction index
214626638|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)|Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01
214626639|NCT06736379|DRUG|Pembrolizumab (KEYTRUDA®)|200mg twice 3 weeks apart IV
214626640|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)|Weekly IT injections of 3 x 10\^8 viral particles of VLPONC-01
214626641|NCT06744296|OTHER|Blood Draws and Tissue Sample(s)|All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.
214718859|NCT03842501|DIETARY_SUPPLEMENT|Release Supplement|Calorie reduced diet plus Release supplement
214718860|NCT03842501|DIETARY_SUPPLEMENT|Placebo|Calorie reduced diet plus Placebo
214626642|NCT06895993|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 2 mL: 100 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 1 min, with a speed of 2 mL/min.
214626643|NCT06895993|DRUG|Ferric Carboxymaltose Injection [Injectafer®]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Injectafer®) (R, 2 mL: 100 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 1 min, with a speed of 2 mL/min.
214626644|NCT02433652|BIOLOGICAL|Recombinant live attenuated trivalent dengue vaccine|Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.
214626645|NCT02433652|BIOLOGICAL|Placebo|
214626646|NCT02433652|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
214626647|NCT06862752|PROCEDURE|erector spine plane (ESP) block|Bilateral ultrasound guided erector spine plane (ESP) block will be performe preoperatively at T5 level. 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL serum physiologic % l) will be injected deep to the erector spinae muscle.
214626648|NCT06862752|PROCEDURE|Serratus Anterior Plane Block|Bilateral ultrasound guided serratus plane block with 20 ml %0,25 bupivacaine at the midaxillary 5. Rib
214626649|NCT06883747|DRUG|BMS-986504|MTA cooperative PRMT5 inhibitor
214626650|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
214626651|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
214626652|NCT06845423|DRUG|Low molecular weight heparin|"Pharmacological thromboprophylaxis using LMWH at preventive dosage. The choice of subcutaneous LMWH depends on the practice of each center:~* Enoxaparine 4000 UI (weight \> 90 kg 6000 UI)~* Tinzaparine 3500 UI (weight \> 90 kg 4500 UI)~* Dalteparine 5000 UI (weight \> 90 kg 7500 UI)~* Nadroparine 2850 UI (weight \> 90 kg 3800 UI)."
214626653|NCT03744390|DRUG|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
214626654|NCT00202787|DRUG|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
214626655|NCT00202787|DRUG|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
214626656|NCT00240409|DRUG|Pramipexole|
214626657|NCT00240409|DRUG|Bromocriptine|
214626658|NCT04044300|PROCEDURE|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
214626659|NCT04044300|OTHER|Conservative|Continued pain management and physical therapy.
214634901|NCT03881150|OTHER|Transition to unsupervised phase|After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
214718861|NCT04567953|OTHER|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
214626660|NCT03837639|OTHER|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
214626661|NCT03837639|OTHER|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
214626662|NCT03837639|OTHER|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
214718862|NCT05326074|OTHER|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
214626663|NCT04507685|OTHER|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
214626664|NCT06901882|BEHAVIORAL|CONECTEM, Communication based in BCS (basic communication skills) and AAC ( aumentative alternative communicatiton)|"It consists of applying basic and assisted communication techniques, already validated by experts (Happ, et al., 2008) to the critical patient admitted to the ICU. The intervention is divided into 3 strategies according to the level of patient awareness. Each strategy presents both verbal and non-verbal communication skills~Estratègia 3. Glasgow (≤8). Very ill patient, with indications for intubation, sedation and analgesia. We will basically use non-verbal communication, taking into account all external factors that may predispose to a change in the patient's condition.~Modulate your voice, speak softly and slowly, respecting an atmosphere of silence, without intense lights or loud noises. Adjust the temperature of the ICU according to the needs of the patient.~Achieve a relaxing atmosphere, playing calm music during the journey.Make comforting movements for the patient, avoiding abruptness and trying to establish non-verbal communication."
214626665|NCT06897501|DEVICE|bronchial blocker|Lung isolation for robot-assisted esophagectomy will be performed using bronchial blocker in this group.
214626666|NCT06897501|DEVICE|double-lumen endobronchial tube|Lung isolation for robot-assisted esophagectomy will be performed using double-lumen endobronchial tube in this group.
214626667|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
214626668|NCT06820671|OTHER|Recording voice samples|"Voice recording with~* reading the standard text~* repeating the test words~* vowel elicitation of 'a' and 'o' vowels for 5-10 seconds"
214626669|NCT06498713|DRUG|Acetaminophen 650 mg Oral Tablet|650 mg pills
214626670|NCT06498713|DRUG|Acetaminophen 650mg Liquid|650 mg liquid
214626671|NCT06498713|DEVICE|CADD pump|Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.
214626672|NCT06774859|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).
214626673|NCT06774859|DRUG|Oseltamivir|Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
214626674|NCT00377377|DRUG|EP1572 (ghrelin agonist) oral and duodenal application|
214626675|NCT04161833|DIETARY_SUPPLEMENT|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
214626676|NCT02209077|DEVICE|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
214626677|NCT00910793|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
214626678|NCT02821871|DRUG|SP2086|
214626679|NCT02821871|DIETARY_SUPPLEMENT|high fat diet|
214626680|NCT05982405|OTHER|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
214634902|NCT04865068|DIAGNOSTIC_TEST|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
214626681|NCT05982405|OTHER|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
214626682|NCT06766916|DRUG|Crisugabalin|"Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
214626683|NCT06766916|DRUG|Pregabalin|"Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
214626684|NCT06938607|DEVICE|Drain|Participants assigned to the drain group will have a surgical drain placed on the surface of the wound during closure. The drain will be removed within 24 hours.
214626685|NCT06938763|DRUG|J4|dry powder capsule
214626686|NCT06938763|DRUG|Placebo|Placebo dry powder capsule
214626687|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
214626688|NCT06944041|OTHER|STO3 sensor (Structure Inc., Boulder, CO)|The advent of Apple iPad based 3D scanner opens a new avenue for measuring limb volume. The latest ambient light scanner model was utilized for the current study. 3D scanning technology has gained broad industrial use, including the manufacturing of high-precision tools. A commercially available software package was used for limb volumetry.
214626689|NCT03087630|BEHAVIORAL|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
214626690|NCT03087630|BEHAVIORAL|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
214626691|NCT03087630|BEHAVIORAL|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
214626692|NCT03087630|BEHAVIORAL|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
214626693|NCT05598593|DRUG|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
214626694|NCT05870267|DEVICE|Power Knee with bone anchored suspension|Motor powered microprocessor controlled prosthetic knee joint
214626695|NCT05870267|DEVICE|C-Leg|Passive hydraulic microprocessor controlled prosthetic knee joint
214626696|NCT05870267|DEVICE|Rheo Knee XC|Passive magneto-rheologic microprocessor controlled knee joint
214626697|NCT06446440|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis
214626698|NCT06446440|PROCEDURE|Open adhesiolysis|Open adhesiolysis
214626699|NCT05645406|DRUG|Divigel 0.1% Topical Gel|estradiol topical products
214626700|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
214626701|NCT05626998|DRUG|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
214626702|NCT05626998|DRUG|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
214626703|NCT00006142|BEHAVIORAL|phenylalanine restricted diet|
214626704|NCT01689298|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214626705|NCT01689298|DRUG|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214626706|NCT00782951|DRUG|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
214626707|NCT00782951|DRUG|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
214626708|NCT00782951|DRUG|Placebo|single IV dose of placebo after dental impaction surgery
214626709|NCT02883946|OTHER|Data collection|
214626710|NCT03478514|DRUG|Palbociclib|Taken at 100 mg once daily for 21 days, followed by 7 days off
214626711|NCT03478514|DRUG|Ibrutinib|560 mg taken orally all patients throughout the study
214626712|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
214626713|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
214626714|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
214626715|NCT05233137|BEHAVIORAL|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
214634903|NCT00903175|DRUG|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
214626716|NCT05233137|OTHER|Exercise training|"Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
214626717|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
214626718|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
214626719|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
214626720|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
214626721|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
214626722|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
214626723|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
214626724|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
214626725|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
214626726|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
214626727|NCT06830499|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.
214626728|NCT06834451|DRUG|Revolade®|Tableta 50 mg Reference
214626729|NCT06834451|DRUG|Eltrombopag (EPAG)|Tableta 50 mg
214626730|NCT06192264|DRUG|ASC40|ASC 40 tablets orally once daily
214626731|NCT06039722|DEVICE|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
214626732|NCT04563078|DEVICE|Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
214626733|NCT04563078|PROCEDURE|Sham Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
214626734|NCT03770260|DRUG|Ixazomib Citrate|Given PO
214626735|NCT03770260|DRUG|Pevonedistat|Given IV
214626736|NCT05863572|OTHER|Primary care health worker training|Training primary care workers to detect and treat psychosis.
214626737|NCT05863572|OTHER|Community Health Workers Training|training community health workers in detection and referral
214626738|NCT05863572|OTHER|Home visits|home visits conducted by people with lived experience of psychosis
214626739|NCT05711446|OTHER|Double Voiding|Participant will be instructed to void twice.
214626740|NCT05711446|OTHER|Regular Voiding|Participant will void as usual
214626741|NCT05804318|DEVICE|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
214626742|NCT05368571|OTHER|CHOICES-TEEN|This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
214626743|NCT05368571|OTHER|Health and Life Skills Education|This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
214626744|NCT02432378|BIOLOGICAL|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
214626745|NCT02432378|BIOLOGICAL|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
214626746|NCT04138017|DEVICE|ViviGen|A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
214626747|NCT01292642|BEHAVIORAL|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
214626748|NCT01292642|DRUG|Nicotine Replacement Therapy|"1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
214626749|NCT05386992|DIAGNOSTIC_TEST|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
214626750|NCT04649255|DEVICE|Liquid Embolic|Lava Liquid Embolic System (LES)
214626751|NCT05682027|DIAGNOSTIC_TEST|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
214626752|NCT01851681|DRUG|Amoxicillin|
214626753|NCT00706251|DEVICE|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
214626754|NCT06534450|DEVICE|Sham|The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.
214626755|NCT06534450|DEVICE|Therapeutic Plasma Exchange|Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.
214626756|NCT06534450|DRUG|IVIG|Intravenous Immunoglobulin
214626757|NCT03529266|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
214626758|NCT03529266|PROCEDURE|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
214626759|NCT04185688|OTHER|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
214626760|NCT01316861|DRUG|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
214626761|NCT01316861|DRUG|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
214626762|NCT03312660|DIETARY_SUPPLEMENT|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
214626763|NCT03312660|DIETARY_SUPPLEMENT|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
214626764|NCT01225484|PROCEDURE|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
214626765|NCT01225484|PROCEDURE|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
214626766|NCT03008356|DIETARY_SUPPLEMENT|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
214626767|NCT03008356|BEHAVIORAL|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
214626768|NCT03008356|DIETARY_SUPPLEMENT|Placebo capsules|
214626769|NCT01040052|BIOLOGICAL|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
214626770|NCT04043546|BEHAVIORAL|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
214626771|NCT03801850|DEVICE|3D surface scan|measurement of inter fractional deformations by surface scanning
214626772|NCT05054972|PROCEDURE|Exclusion of the aortic aneurysm.|Surgical procedure in which an aortic aneurysm is excluded.
214626773|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
214626774|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
214626775|NCT05628220|OTHER|physiotherapy|rehabilitation through using session of virtual reality desensitization
214626776|NCT04071184|DRUG|Alofanib|Five dose cohorts and expanded cohort will be included
214626777|NCT05492929|OTHER|The deep breathing group|The deep breathing group
214626778|NCT05492929|OTHER|4-7-8 breathing technique|4-7-8 breathing technique Group
214626779|NCT01981915|PROCEDURE|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
214626780|NCT01981915|PROCEDURE|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
214626781|NCT00075400|DRUG|imatinib mesylate|Given PO
214626782|NCT00075400|OTHER|laboratory biomarker analysis|Correlative studies
214626783|NCT01652885|DRUG|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
214626784|NCT06130267|OTHER|Endocare|Virtual paradigm (calming environnement)
214626785|NCT00490568|DRUG|Rosiglitazone XR|Experimental drug
214626786|NCT01395394|DRUG|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
214626787|NCT01395394|OTHER|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
214626788|NCT01066364|DRUG|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
214626789|NCT04559958|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
214626790|NCT03574090|DRUG|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
214626791|NCT03574090|DRUG|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
214626792|NCT03451773|DRUG|M7824|1,200 or 500mg every 2 weeks by intravenous (IV) infusion
214626793|NCT03451773|DRUG|Gemcitabine|Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
214626794|NCT02316405|OTHER|Arm and Leg Cycling Exercise for Walking after Stroke|
214626795|NCT06053515|BEHAVIORAL|Rosie the Chatbot|"Participants in the intervention group will be using the chatbot to ask questions related to the mom and baby's health, provide feedback selecting thumbs up or thumbs down on the questions' response, and use the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus). In addition, participants will be taking a pre-test health survey, mid-test health survey, and post-test health survey."
214626796|NCT05558956|DRUG|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
214626797|NCT05073809|DIAGNOSTIC_TEST|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
214626798|NCT03468855|DRUG|ATI-50002 topical solution|Topical Solution administered twice daily
214626799|NCT02400788|DRUG|Resminostat|
214626800|NCT02400788|DRUG|Sorafenib|
214626801|NCT03283189|OTHER|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
214626802|NCT05097807|BEHAVIORAL|smartphone related behaviors|Participants are required to watch specific contents on their own smartphones.
214626803|NCT00371878|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (Prevnar)|
214626804|NCT01908101|DRUG|Eribulin Mesylate|Given IV
214626805|NCT01908101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214626806|NCT03838679|DIAGNOSTIC_TEST|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
214626807|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
214626808|NCT03838679|DIAGNOSTIC_TEST|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
214626809|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
214626810|NCT03838679|DIAGNOSTIC_TEST|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
214718863|NCT03051217|OTHER|Placebo|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"
214718864|NCT03051217|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
214718865|NCT04746989|DRUG|Probenecid|Probenecid claim is used as the exposure group.
214718866|NCT04746989|DRUG|Allopurinol|Allopurinol claim is used as the reference group.
214718867|NCT00591396|DRUG|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
214718868|NCT00109772|DRUG|lenalidomide|Two 5 mg capsules taken one time per day
214718869|NCT00109772|DRUG|Placebo|Two placebo capsules taken one time per day
214626811|NCT03838679|DIAGNOSTIC_TEST|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
214626812|NCT03838679|DIAGNOSTIC_TEST|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
214626813|NCT03838679|DIAGNOSTIC_TEST|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
214626814|NCT00464412|BEHAVIORAL|Education|
214626815|NCT04245020|OTHER|Text message follow up|A text message will be sent to the patient 6-8 weeks following discharge
214626816|NCT04245020|OTHER|Telephone follow up|The patient will be followed up at 6-8 weeks following discharge with a telephone call
214626817|NCT04245020|OTHER|In person follow up|The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
214626818|NCT04957771|OTHER|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
214626819|NCT03746704|DRUG|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
214626820|NCT01457742|DEVICE|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
214626821|NCT01457742|DEVICE|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
214626822|NCT03854708|DRUG|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
214626823|NCT03854708|DRUG|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
214626824|NCT03854708|DRUG|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
214626825|NCT06539013|DRUG|Remifentanil|remifentanil infusion
214626826|NCT06539013|DRUG|N2O|Use of N2O for analgesia
214626827|NCT06539013|DRUG|Fentanyl|Use of Fentanylfor analgesia
214626828|NCT00890565|DRUG|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
214626829|NCT04806607|PROCEDURE|19G FNB|Biopsy specimen adequacy using the 19G FNB
214626830|NCT04806607|PROCEDURE|22G FNB|Biopsy specimen adequacy using the 22G FNB.
214626831|NCT04090112|DRUG|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
214626832|NCT04090112|DRUG|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
214626833|NCT03269760|DRUG|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
214626834|NCT06543108|DIAGNOSTIC_TEST|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
214626835|NCT02146612|OTHER|Amino Acid Supplement Group|Group receiving nutritional supplement
214626836|NCT04489966|BEHAVIORAL|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
214626837|NCT00166205|DEVICE|Swedish Adjustable Gastric Band|Long term implantable device.
214626838|NCT05712044|DRUG|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
214626839|NCT02205749|BEHAVIORAL|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
214626840|NCT02205749|BEHAVIORAL|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
214626841|NCT02205749|BEHAVIORAL|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
214626842|NCT00412750|DRUG|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
214626843|NCT00412750|DRUG|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
214626844|NCT03496090|OTHER|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
214626845|NCT03496090|OTHER|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
214626846|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
214626847|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens2|TEST
214626848|NCT04609189|DRUG|Pearlium/EffectiCal|Oral administration of Pearlium/EffectiCal.
214626849|NCT04609189|DRUG|Calcium carbonate/vitamin D3|Oral administration of Calcium Carbonate/Vitamin D3
214626850|NCT04546685|OTHER|Usual Care|Participants who are randomized to the Usual Care group (waitlist for cross-over to ER) will be instructed to continue with their normal pain care. They will receive only study surveys (baseline, 2 weeks, and 1 month). Upon completion of the 1-month study, UC participants will be invited to cross-over and receive ER. Post-class treatment appraisal/satisfaction data only will be collected.
214626851|NCT04546685|BEHAVIORAL|Empowered Relief|The participants will attend an online Spanish Empowered Relief class. The two hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a Spanish binaural relaxation audio file for daily use.
214626852|NCT04223960|DRUG|EA1080|EA1080 Formulation A.
214626853|NCT04223960|DRUG|EA1080|EA1080 Formulation B.
214626854|NCT04223960|DRUG|EA1080|EA1080 Formulation C.
214626855|NCT04223960|DRUG|EA1080|EA1080 Formulation D.
214626856|NCT04223960|DRUG|EA1080-matching placebo|EA1080-matching placebo.
214626857|NCT04223960|DRUG|EA1080|EA1080 Formulation E.
214626858|NCT04223960|DRUG|EA1080|EA1080 Formulation F.
214626859|NCT01610765|DRUG|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
214626860|NCT01610765|DRUG|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
214626861|NCT03442543|DEVICE|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
214626862|NCT05640778|DRUG|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
214626863|NCT03044340|OTHER|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
214626864|NCT02148380|DRUG|pemetrexed plus carboplatin|
214626865|NCT02148380|DRUG|gefitinib|
214626866|NCT03381235|OTHER|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
214626867|NCT03655613|BIOLOGICAL|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
214626868|NCT03655613|DRUG|APL-101|Oral specific c-Met inhibitor
214626869|NCT03655613|BIOLOGICAL|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
214626870|NCT03413280|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
214626871|NCT03413280|DRUG|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
214626872|NCT05319171|DEVICE|TAVR|TAVR
214626873|NCT02598843|OTHER|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
214626874|NCT02598843|OTHER|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
214634904|NCT00903175|DRUG|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
214718870|NCT01517828|DRUG|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
214718871|NCT01517828|DRUG|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
214718872|NCT03437044|DRUG|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
214718873|NCT03437044|DRUG|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
214718874|NCT00345501|DRUG|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
214718875|NCT00345501|DRUG|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
214718876|NCT05690672|DIAGNOSTIC_TEST|Delirium Screening|Either 3D-CAM or 4AT
214718877|NCT01359046|DEVICE|silver SPC|subject randomized to receive silver alloy impregnated catheter
214718878|NCT01359046|DEVICE|standard SPC|subject randomized to receive standard catheter
214718879|NCT02574819|DRUG|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
214718880|NCT02574819|DRUG|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
214718881|NCT06353360|DEVICE|Tumor Treating Fields|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
214718882|NCT06353360|DRUG|Tislelizumab|Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
214718883|NCT06353360|DRUG|Temozolomide (TMZ)|The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
214626875|NCT04852107|OTHER|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
214718884|NCT00723268|DRUG|Prednisolone|5MG Prednisolone per day for 3 months
214718885|NCT00723268|DRUG|Colchicine|0.5 MG Colchicine per day for 3 months
214718886|NCT01213290|DEVICE|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
214626876|NCT04456179|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
214718887|NCT01213290|DEVICE|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
214718888|NCT04539262|DRUG|Remdesivir (RDV)|Administered as an aerosolized solution
214718889|NCT04539262|DRUG|Placebo|Administered as an aerosolized solution
214626877|NCT04456179|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
214626878|NCT04737577|PROCEDURE|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
214626879|NCT04737577|PROCEDURE|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
214626880|NCT02965495|DRUG|YYD302 2ml|YYD302 2ml
214626881|NCT02965495|DRUG|YYD302 3ml|YYD302 3ml
214626882|NCT02965495|DRUG|Placebo 3ml|phosphate buffered saline 3ml
214626883|NCT03669302|OTHER|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214718890|NCT05590104|PROCEDURE|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
214718891|NCT05169736|BEHAVIORAL|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
214718892|NCT04831268|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
214718893|NCT04831268|OTHER|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
214718894|NCT04831268|OTHER|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
214718895|NCT04831268|OTHER|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
214718896|NCT02270489|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
214718897|NCT02270489|BIOLOGICAL|AFFITOPE® PD03A + Adjuvant|s.c. injection
214626884|NCT03669302|DEVICE|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214718898|NCT02270489|BIOLOGICAL|Adjuvant without active component|s.c. injection
214718899|NCT03157336|OTHER|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
214718900|NCT03174561|DIETARY_SUPPLEMENT|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
214718901|NCT03174561|OTHER|diet restriction|diet restriction for 28 days
214718902|NCT04207008|OTHER|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
214718903|NCT04400227|OTHER|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
214718904|NCT02351739|DRUG|pembrolizumab|
214626885|NCT03669302|DEVICE|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214626886|NCT04091087|DRUG|crisaborole ointment|crisaborole ointment
214626887|NCT04091087|OTHER|vehicle ointment|vehicle ointment
214718905|NCT02351739|DRUG|ACP-196 in combination with pembrolizumab|
214718906|NCT02482740|DRUG|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
214626888|NCT03425032|DEVICE|CT scanner|Regular CT imaging of the abdomen and pelvis
214626889|NCT00186550|BEHAVIORAL|Supportive Expressive Group Psychotherapy|
214626890|NCT00186550|BEHAVIORAL|Education|
214626891|NCT00517595|DRUG|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
214626892|NCT06425575|BIOLOGICAL|Amniotic suspension allograft|the amniotic suspension allograft consists of fresh amniotic fluid into which micronized amniotic membrane has been added as a suspension.
214626893|NCT05217771|OTHER|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
214718907|NCT02482740|DRUG|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
214718908|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
214718909|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
214718910|NCT02773056|DEVICE|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
214718911|NCT02773056|DEVICE|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
214718912|NCT02773056|DEVICE|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
214718913|NCT02260895|DIETARY_SUPPLEMENT|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
214718914|NCT05471206|OTHER|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
214626894|NCT03872804|PROCEDURE|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
214718915|NCT03914534|DRUG|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
214718916|NCT03914534|DRUG|Valcote 500 mg|Administration of 500 mg of Valproic Acid
214718917|NCT03184116|BEHAVIORAL|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
214626895|NCT03872804|PROCEDURE|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
214626896|NCT03872804|PROCEDURE|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
214626897|NCT03872804|OTHER|Oral pulse steroid with narrow band|"* A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~* All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
214626898|NCT00041093|DRUG|Docetaxel|Given IV
214718918|NCT05452317|OTHER|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
214626899|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.
214626900|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.
214626901|NCT04507659|DRUG|Placebo|Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
214626902|NCT01019447|OTHER|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
214718919|NCT05452317|OTHER|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
214626903|NCT01019447|OTHER|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
214626904|NCT05043415|PROCEDURE|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
214718920|NCT02954302|PROCEDURE|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
214718921|NCT02954302|PROCEDURE|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
214718922|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenate
214718923|NCT00212212|DIETARY_SUPPLEMENT|selenium|400 µg selenium as selenate
214718924|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenomethionine
214626905|NCT05043415|PROCEDURE|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
214626906|NCT04277845|DRUG|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
214626907|NCT04869085|BEHAVIORAL|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
214626908|NCT02505399|DRUG|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:~* 180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 90 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 90 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
214626909|NCT02505399|DRUG|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:~* 300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 75 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 0 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
214626910|NCT06447610|PROCEDURE|Lateral arm free flap|In this study, we present a case series of 8 patients operated for a maxillo-facial defect with a lateral arm free flap.
214626911|NCT05150379|OTHER|Different exercises with their shoulders|"* Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test"
214626912|NCT05150379|BEHAVIORAL|SI-RSI questionnaire|French version of Shoulder Instability Return-to-Sport after Injury
214626913|NCT04997018|RADIATION|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
214718925|NCT00212212|DIETARY_SUPPLEMENT|placebo|placebo tablet
214718926|NCT03933124|DEVICE|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
214718927|NCT03725293|DEVICE|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
214718928|NCT03725293|DEVICE|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
214718929|NCT05477017|DRUG|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
214718930|NCT05499598|PROCEDURE|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
214718931|NCT05499598|PROCEDURE|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
214718932|NCT00602771|DRUG|tipifarnib|Given orally
214718933|NCT00602771|DRUG|etoposide|Given orally
214718934|NCT00292578|PROCEDURE|NAET Testing Modalities|
214718935|NCT00511121|DRUG|STI571 and PEG INTRON|
214718936|NCT00791804|DRUG|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
214718937|NCT06508970|BEHAVIORAL|Experimental RAM-based virtual reality glasses|"RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)"
214718938|NCT06508970|OTHER|pre-post test|Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
214626914|NCT05554614|BEHAVIORAL|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
214626915|NCT05554614|BEHAVIORAL|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
214626916|NCT05554614|BEHAVIORAL|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
214626917|NCT06149234|BEHAVIORAL|Fruit leather on the tongue|The patient holds a fruit leather strip on the tongue while being exposed.
214718939|NCT06097325|DIAGNOSTIC_TEST|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
214718940|NCT06097325|DIAGNOSTIC_TEST|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
214718941|NCT02665468|BEHAVIORAL|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
214718942|NCT02665468|BEHAVIORAL|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
214718943|NCT05430204|DEVICE|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
214626918|NCT06149234|BEHAVIORAL|Chewing gum strip|The patient holds a banana-tasting gum strip on the tongue while being exposed.
214626919|NCT06149234|BEHAVIORAL|Celluloid matrix group|The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
214626920|NCT00117468|DRUG|DR-2011|Administered vaginally from Day 14 to Day 31
214626921|NCT00117468|DRUG|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
214626922|NCT05251402|BEHAVIORAL|Group A - Patient Education|"If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice."
214718944|NCT05430204|DEVICE|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL"
214718945|NCT04045691|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
214718946|NCT04045691|DRUG|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
214718947|NCT02705443|OTHER|No Intervention|Standard of Care Only
214718948|NCT05829395|OTHER|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test."
214626923|NCT05251402|BEHAVIORAL|Group B - Patient Education with Nutrition Counseling|"If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term."
214626924|NCT04814251|OTHER|Observationnal cohort|data collection
214626925|NCT04527900|DRUG|carboplatin and paclitaxel|carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
214626926|NCT04527900|RADIATION|pelvic IMPT (Intensity Modulated Proton Therapy)|whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions
214626927|NCT00003345|DRUG|cisplatin|
214626928|NCT00003345|DRUG|irinotecan hydrochloride|
214626929|NCT05440539|OTHER|Written Handouts|The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
214626930|NCT05440539|OTHER|Interactive Workshop|Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
214626931|NCT03808077|DRUG|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.003 mg/kg/min or 0.18mg/kg/hr).
214626932|NCT03808077|DRUG|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.006mg/kg/min or 0.35mg/kg/hr).
214626933|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
214626934|NCT04152161|BIOLOGICAL|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
214626935|NCT04152161|BIOLOGICAL|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
214626936|NCT01409200|DRUG|Antiandrogen Therapy|Given per standard of care
214626937|NCT01409200|DRUG|Axitinib|Given PO
214626938|NCT01409200|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214626939|NCT01409200|PROCEDURE|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
214718949|NCT04485468|OTHER|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
214718950|NCT04397796|BIOLOGICAL|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
214718951|NCT04397796|BIOLOGICAL|Placebo|plasmalyte and human albumin
214718952|NCT05885048|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in blood
214718953|NCT05885048|DIAGNOSTIC_TEST|Sperm samples for analysis|Spermiogram
214718954|NCT05885048|OTHER|Satisfaction evaluation|Participant satisfaction assessment
214718955|NCT05885048|OTHER|Quality of Life questionnaire|The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
214626940|NCT05704933|DRUG|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
214718956|NCT03000634|DRUG|Elotuzumab|Administered through a small tube that goes directly into the vein
214626941|NCT05704933|DRUG|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.\[18-20\] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
214634905|NCT03770585|PROCEDURE|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
214634906|NCT03770585|PROCEDURE|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
214634907|NCT03826732|BEHAVIORAL|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
214634908|NCT03057925|DEVICE|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
214634909|NCT00987038|DRUG|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
214634910|NCT00987038|DRUG|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
214634911|NCT00964977|RADIATION|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
214626942|NCT05704933|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.\[6\] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
214626943|NCT05704933|PROCEDURE|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
214626944|NCT05701358|PROCEDURE|Physiology-guided NCL PCI|For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
214626945|NCT05701358|PROCEDURE|Angiography-guided NCL PCI|PCI will be performed as per local practice
214626946|NCT05937672|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
214718957|NCT03000634|DRUG|Bortezomib|Administered as a subcutaneous injection under the skin
214718958|NCT03000634|DRUG|Lenalidomide|Capsule taken by mouth
214718959|NCT03000634|DRUG|Dexamethasone|Taken by mouth
214718960|NCT01757977|DEVICE|double lumen endotracheal tube placement and use|
214626947|NCT06668714|COMBINATION_PRODUCT|Placebo + mixed meal|Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR
214626948|NCT06668714|COMBINATION_PRODUCT|Lactate + mixed meal|Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.
214626949|NCT06668714|RADIATION|PET-scan|Dynamic whole-body PET scan.
214626950|NCT06668714|COMBINATION_PRODUCT|Mixed meal with 18F-FTHA|Mixed meal test with the addition of 70 MBq 18F-FTHA
214626951|NCT00001379|BIOLOGICAL|Interferon|For lymphomatoid granulomatosis (LYG) Grade 1 and 2: Interferon starting at 7.5 million Units subcutaneous (subQ) 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond complete remission (CR).
214626952|NCT00001379|DRUG|Rituxan and EPOCH|For lymphomatoid granulomatosis (LYG) Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) every 3 weeks for 6 cycles.
214626953|NCT00001379|PROCEDURE|Tumor biopsy|Baseline (optional).
214626954|NCT00001379|PROCEDURE|Bone marrow biopsy|Baseline.
214626955|NCT00001379|BIOLOGICAL|Bone marrow aspirate|Baseline.
214626956|NCT00001379|PROCEDURE|Lumber puncture|Baseline.
214626957|NCT00001379|DIAGNOSTIC_TEST|CT|Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years. Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years.
214626958|NCT00001379|DIAGNOSTIC_TEST|Brain MRI|"Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with central nervous system (CNS) disease only).~Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with CNS disease only)."
214626959|NCT00001379|DIAGNOSTIC_TEST|Echocardiogram|For participants receiving \> 450 mg/m\^2 doxorubicin.
214626960|NCT00001379|DIAGNOSTIC_TEST|FDG-PET|Arm 1: Baseline and following completion of interferon. Arm 2: Baseline and following completion of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R).
214626961|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
214626962|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
214626963|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
214626964|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
214626965|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
214626966|NCT05070403|DRUG|Afatinib 40 MG|Participants will receive 40 mg Afatinib, once daily.
214626967|NCT06280209|DRUG|BMN 351|Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
214626968|NCT03945526|DRUG|Astaxanthine|
214626969|NCT03945526|DRUG|Placebo Oral Tablet|
214718961|NCT03487406|DRUG|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
214718962|NCT03487406|DRUG|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
214626970|NCT05841043|DRUG|SHR8028 eye drops|SHR8028 eye drops
214626971|NCT05841043|DRUG|Vehicle eye drops.|Vehicle eye drops.
214718963|NCT03487406|DRUG|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
214626972|NCT01527864|DRUG|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
214626973|NCT01527864|DRUG|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
214626974|NCT05569707|DEVICE|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with SPIO particles (Magtrace®).
214718964|NCT03487406|DRUG|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
214718965|NCT03067844|DRUG|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
214718966|NCT00802867|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
214718967|NCT03720301|PROCEDURE|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression"
214626975|NCT02510027|OTHER|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
214626976|NCT03703102|DRUG|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
214626977|NCT03703102|DRUG|Placebo|Matching placebo
214626978|NCT00808795|DRUG|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
214626979|NCT00808795|DRUG|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
214626980|NCT01220895|BIOLOGICAL|CMV-specific T-cells, single infusion following single positive CMV PCR result|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
214626981|NCT02311153|DEVICE|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
214626982|NCT02311153|DEVICE|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
214626983|NCT04882306|DEVICE|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
214626984|NCT04922840|BEHAVIORAL|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
214626985|NCT01186575|OTHER|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
214626986|NCT03465189|DEVICE|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
214626987|NCT06082700|DIAGNOSTIC_TEST|imaging|clinical examination to see missing posterior teeth \& vertical measurements by lateral cephalometric x-ray
214626988|NCT05392686|DRUG|PD-1 inhibitor|Tirelizumab
214626989|NCT05392686|DRUG|PARP inhibitor|Fluzopari capsule
214626990|NCT01379274|DRUG|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
214626991|NCT04503499|OTHER|Manuel Therapy|"The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times."
214626992|NCT06464250|OTHER|Bundla care group|A care package consisting of foot examination, correct foot care behaviours, and regular blood glucose monitoring was used.
214626993|NCT04086823|DRUG|RZL-012|Subcutaneous injection to the submental fat area
214626994|NCT04086823|DRUG|Placebo|Placebo
214626995|NCT05349929|DRUG|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
214626996|NCT05349929|DRUG|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
214626997|NCT05349929|PROCEDURE|Root Canal Therapy|all the participants go under RCT.
214626998|NCT06458803|DRUG|Eltrombopag|patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
214626999|NCT06535243|BEHAVIORAL|Lifespan Integration Therapy (LI)|same as above
214627000|NCT04219345|DEVICE|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
214627001|NCT03443674|DRUG|SCB-313|Lyophilized powder in a single-use vial
214627002|NCT00405067|DRUG|BMS-201038 (AEGR-733)|
214627003|NCT00405067|DRUG|Ezetimibe|
214627004|NCT05241730|OTHER|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
214627005|NCT05241730|OTHER|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
214627006|NCT05241730|OTHER|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
214627007|NCT05241730|OTHER|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
214634912|NCT03466177|DIAGNOSTIC_TEST|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
214634913|NCT00106171|DRUG|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
214627008|NCT06042218|BEHAVIORAL|Xiaxi intervention program|The Xiaxi sessions will follow the same structure in both intervention groups. First of all, 8-minute warm-up where the participants will work on: postural awareness; active static stretching of the pectoral, hamstring and psoas muscles; and mobility. The main part will include the following blocks of content during the 12 weeks of intervention (46 minutes will be spent on this part in each session): breathing; mobility; active and dynamic static stretching of the tonic muscles with effects on the spine dynamic; strength of the phasic muscles with effects on the spine dynamic, alternating upper limb, lower limb and core; postural awareness; and passive static stretching of the tonic muscles with effects on the spine dynamic. The cool down will be similar in each session (6 minutes) and will focus on: postural awareness and passive static stretching of the pectoral, hamstring and psoas muscles.
214627009|NCT00816426|DRUG|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
214627010|NCT00816426|DRUG|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
214627011|NCT00816426|DRUG|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
214627012|NCT00816426|DRUG|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
214627013|NCT00816426|DRUG|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
214627014|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
214627015|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
214627016|NCT02676492|OTHER|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
214627017|NCT02676492|OTHER|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
214627018|NCT01599403|PROCEDURE|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
214627019|NCT01599403|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
214627020|NCT01599403|PROCEDURE|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
214627021|NCT03767075|DRUG|Atezolizumab|1200 mg, administered IV, once every 3 weeks
214627022|NCT03767075|DRUG|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
214627023|NCT03767075|DRUG|Amivantamab|1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
214627024|NCT00004873|DRUG|cisplatin|
214627025|NCT00004873|DRUG|docetaxel|
214627026|NCT00004873|DRUG|epirubicin hydrochloride|
214627027|NCT00004873|DRUG|fluorouracil|
214627028|NCT01224626|DRUG|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
214627029|NCT01560780|DRUG|Prasugrel|one 10 mg tablet by mouth daily
214627030|NCT01560780|DRUG|Placebo|placebo similar in appearance to prasugrel
214627031|NCT03992976|OTHER|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
214627032|NCT05200078|DEVICE|Deep inspiration breath-hold technique|Selective application of deep inspiration breath-hold technique
214627033|NCT03798964|OTHER|Placental analysis|Analysis of placenta to determine expression of heparanase
214627034|NCT03363321|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous injection
214627035|NCT01577186|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
214627036|NCT06424782|OTHER|medicinal water|Medicinal water treatment in bath tub once daily.
214627037|NCT02783703|DIETARY_SUPPLEMENT|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
214627038|NCT05074251|DIAGNOSTIC_TEST|HIV self test|For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).
214627039|NCT05074251|BEHAVIORAL|Counseling and referral for partner testing|Counseling and refer participant's partner for facility based HIV testing
214627040|NCT01897285|DEVICE|AQUACEL® foam adhesive dressing|
214627041|NCT04352959|DEVICE|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
214627042|NCT04352959|DEVICE|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
214627043|NCT00957008|BEHAVIORAL|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
214627044|NCT00957008|OTHER|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
214627045|NCT00957008|DEVICE|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
214627046|NCT03147781|DEVICE|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
214627047|NCT03147781|DEVICE|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
214627048|NCT01515137|DRUG|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
214627049|NCT01515137|DRUG|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
214627050|NCT01515137|DRUG|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
214627051|NCT00631020|BEHAVIORAL|CBME|6 weeks of once a week one-on-one CBME
214627052|NCT00631020|DRUG|Optional NRT|NicoDerm CQ nicotine transdermal patch
214718968|NCT03720301|PROCEDURE|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
214718969|NCT01442701|OTHER|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
214718970|NCT00442182|DRUG|ITF2357|
214718971|NCT02808013|DRUG|NDS-446|
214718972|NCT02808013|DRUG|Placebo|
214627053|NCT01685463|DEVICE|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
214627054|NCT01685463|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
214627055|NCT03220542|DRUG|Probiotics|Saccharomyces boulardii
214627056|NCT03220542|DIETARY_SUPPLEMENT|Broccoli|Broccoli sprouts extract
214627057|NCT03220542|DRUG|Esomeprazole|Esomeprazole
214627058|NCT03220542|DRUG|Amoxicillin|Amoxicillin
214627059|NCT03220542|DRUG|Clarithromycin|Clarithromycin
214627060|NCT02409849|DRUG|Octreotide lar|
214627061|NCT04931784|DRUG|Nitrate|Administration of intra-coronary nitrate before percutaneous coronary intervention
214627062|NCT00518154|DRUG|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
214627063|NCT06168032|BIOLOGICAL|Any Chinese government-recommended COVID-19 booster vaccine|Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.
214627064|NCT06076421|OTHER|Fact box|Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
214627065|NCT00002000|DRUG|Valacyclovir hydrochloride|
214627066|NCT00002000|DRUG|Acyclovir|
214627067|NCT02317120|GENETIC|NGS BRCA 1 and BRCA 2 full sequencing|
214627068|NCT02317120|GENETIC|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
214627069|NCT02498015|DRUG|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
214627070|NCT02498015|DRUG|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
214627071|NCT03223064|DIAGNOSTIC_TEST|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
214718973|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
214718974|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
214627072|NCT03223064|DIAGNOSTIC_TEST|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
214627073|NCT02824705|PROCEDURE|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
214627074|NCT03949920|DRUG|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
214627075|NCT04070742|DRUG|FMX101|
214627076|NCT05160155|PROCEDURE|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
214627077|NCT05160155|PROCEDURE|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
214627078|NCT06495086|DEVICE|NIV|The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.
214627079|NCT06495086|DEVICE|HFNC-30|The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
214718975|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
214718976|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
214718977|NCT03023241|PROCEDURE|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
214634914|NCT01687712|DRUG|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
214634915|NCT01687712|DRUG|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
214634916|NCT04017260|PROCEDURE|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
214634917|NCT04017260|PROCEDURE|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
214634918|NCT04017260|PROCEDURE|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
214634919|NCT04017260|PROCEDURE|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
214634920|NCT01785134|PROCEDURE|Omentectomy|
214634921|NCT01785134|PROCEDURE|Gastric bypass operation|
214634922|NCT03074474|DEVICE|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
214634923|NCT00722150|DRUG|Artesunate|2 mg/kg/day x 7 days
214634924|NCT00722150|DRUG|Artesunate|4 mg/kg/day x 7 days
214634925|NCT00722150|DRUG|Artesunate|6 mg/kg/day x 7 days
214634926|NCT02987621|DEVICE|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
214634927|NCT00179582|DRUG|VSL#3|
214627080|NCT06495086|DEVICE|HFNC-50|The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
214627081|NCT02731209|DEVICE|urinary catheter|
214627082|NCT04523311|BEHAVIORAL|Hypnosis.|Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
214627083|NCT04523311|OTHER|Usual care|Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
214627084|NCT06279767|DRUG|6-mercaptopurine|6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
214627085|NCT02601521|BEHAVIORAL|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
214627086|NCT02601521|BEHAVIORAL|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
214718978|NCT05851794|PROCEDURE|endomanometric guided LNF|use of endomanometry during LNF
214718979|NCT05851794|PROCEDURE|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
214627087|NCT03853785|BIOLOGICAL|MMR vaccine|Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
214627088|NCT03853785|BIOLOGICAL|Candida antigen|Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
214627089|NCT03853785|DRUG|Topical Podophyllin|It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
214627090|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
214627091|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally(once daily) on Day 1
214718980|NCT03869671|BEHAVIORAL|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
214627092|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
214627093|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
214627094|NCT05345964|DRUG|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
214627095|NCT05345964|DRUG|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
214718981|NCT03869671|BEHAVIORAL|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
214718982|NCT01494415|DRUG|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
214718983|NCT01494415|DRUG|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
214718984|NCT01494415|RADIATION|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
214718985|NCT00654212|PROCEDURE|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
214627096|NCT03500900|DRUG|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
214627097|NCT03500900|DRUG|Placebo Oral Tablet|Acute administration of placebo tablet
214627098|NCT06308276|OTHER|Aerobic Training|Aerobic Training: Brisk walking, jogging, cycling, or low-impact aerobics
214627099|NCT06308276|OTHER|Resistance Training|Resistance Training: Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
214718986|NCT00654212|PROCEDURE|open approach|emergency open surgery
214627100|NCT03221751|DRUG|prazosin hydrochloride|Prazosin is an oral capsule. It is an alpha-1 antagonists.
214627101|NCT03221751|DRUG|placebo|Placebo is an inert oral capsule identical in appearance to prazosin capsules.
214627102|NCT03114514|BIOLOGICAL|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
214627103|NCT00721474|DRUG|Bosutinib|Bosutinib fasting
214627104|NCT00721474|DRUG|Bosutinib|Bosutinib fed
214627105|NCT04853784|PROCEDURE|intracorporeal anastomosis|intracorporeal anastomosis
214627106|NCT04517747|DRUG|Ramucirumab|chemotherapy i.v.
214627107|NCT04517747|DRUG|TAS 102|p.o. twice daily
214627108|NCT04131335|DRUG|AEONTM Repair|Lubricating eye drops
214627109|NCT04131335|OTHER|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
214627110|NCT03627260|BEHAVIORAL|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
214627111|NCT02757560|OTHER|SFA diet|SFA versus control diet
214627112|NCT02757560|OTHER|MUFA diet|MUFA versus control diet
214627113|NCT02757560|OTHER|CARB diet|CARB versus control diet
214627114|NCT04971876|DEVICE|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
214627115|NCT04971876|DEVICE|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
214627116|NCT04971876|DEVICE|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
214627117|NCT03571646|BEHAVIORAL|Capnostream 20 monitoring|Continuous monitoring on a general ward
214627118|NCT03571646|DEVICE|PM1000N-RR monitoring|Continuous monitoring on a general ward
214627119|NCT03548935|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
214627120|NCT03548935|DRUG|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
214627121|NCT00601068|OTHER|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
214627122|NCT03986385|DRUG|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
214627123|NCT03986385|DRUG|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
214627124|NCT04413253|DRUG|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
214627125|NCT04413253|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
214627126|NCT00801879|DRUG|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
214627127|NCT00801879|DRUG|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
214627128|NCT01324258|DRUG|GSK1120212|Part1 and Part2
214627129|NCT01324258|DRUG|Gemcitabine|Part2
214627130|NCT00649532|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fasting
214627131|NCT00649532|DRUG|Zofran® Tablets 24 mg|24mg, single dose fasting
214627132|NCT06098768|BEHAVIORAL|VR Social Skills|The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
214627133|NCT04925232|DEVICE|Transcranial Magnetic Stimulation device|Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
214627134|NCT03403114|BEHAVIORAL|Questionnaire|a 15min questionnaire
214627135|NCT02057315|DRUG|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
214627136|NCT02057315|DRUG|Placebo|One dose of matching placebo over 3 bilateral applications.
214627137|NCT01756131|DRUG|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
214627138|NCT01756131|OTHER|Placebo to match injectable suspension|placebo
214627139|NCT04774835|DIAGNOSTIC_TEST|HIVST|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
214627140|NCT04774835|DIAGNOSTIC_TEST|Standard aPS|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
214627141|NCT04921735|DRUG|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
214627142|NCT00166608|PROCEDURE|Blood sampling|
214627143|NCT06044688|DEVICE|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
214627144|NCT06044688|DEVICE|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
214627145|NCT00763815|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214627146|NCT00763815|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214627147|NCT00763815|DEVICE|Pen auto-injector|
214627148|NCT00763815|DRUG|Pioglitazone|Dose to be kept stable.
214627149|NCT00763815|DRUG|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
214627150|NCT03698435|DRUG|Ganciclovir|Intravenous ganciclovir + TDM
214627151|NCT03698435|DRUG|Valganciclovir|Oral valganciclovir + TDM
214627152|NCT00283595|DRUG|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
214627153|NCT00283595|DRUG|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
214627154|NCT04395664|DEVICE|C3+ Holter Monitor|ECG monitoring
214627155|NCT01362036|DRUG|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
214627156|NCT05559489|DRUG|Oral Rehydration Solution|Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
214627157|NCT05559489|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
214627158|NCT03535467|OTHER|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
214627159|NCT04309227|OTHER|Strength Training|"Strength training traditionally requires use of high intensity loads to stimulate muscle growth and strength improvements. Some participants will be randomized to a traditional strength training program.~Blood Flow Restriction (BFR) training is used to stimulate muscle hypertrophy and strength improvements in a variety of populations. Results of BFR training are comparable to traditional high intensity training (HIT) despite using weight that are at a low intensity (low percent of 1 repetition maximum). This intervention has not been extensively studies in the rheumatoid or osteoarthritis populations, nor the myositis populations despite idealogical benefit for each group of low-load strengthening."
214627160|NCT05224583|PROCEDURE|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
214627161|NCT00678405|BEHAVIORAL|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
214627162|NCT00678405|BEHAVIORAL|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
214627163|NCT06044480|DRUG|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
214627164|NCT06044480|OTHER|Placebo|Administration of the same amount of saline solution instead of dexamethasone
214627165|NCT02907385|DEVICE|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
214627166|NCT02206646|DRUG|Metalyse|
214627167|NCT01250600|BEHAVIORAL|Home exercise|Daily home exercise for 3 months
214627168|NCT02919878|DRUG|Gemcitabine|Nucleoside analog- Chemotherapy
214627169|NCT02919878|RADIATION|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
214627170|NCT02919878|DRUG|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
214627171|NCT04457804|BEHAVIORAL|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
214627172|NCT01263639|OTHER|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
214627173|NCT01263639|OTHER|Standard of care - No biosketch card|Standard of care
214627174|NCT06537960|PROCEDURE|18FDG PET-CT|"18FDG PET-CT will be performed in 2 phases:~1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer~2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection."
214627175|NCT05697601|DIAGNOSTIC_TEST|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
214627176|NCT05697601|DIAGNOSTIC_TEST|Pathology analysis|Pathology assessment of cells and tissues from respective organs
214627177|NCT01576549|DRUG|LY2127399|Administered subcutaneously
214627178|NCT00003715|BIOLOGICAL|BCG vaccine|
214627179|NCT00003715|BIOLOGICAL|autologous tumor cell vaccine|
214627180|NCT00003715|BIOLOGICAL|recombinant interferon alfa|
214627181|NCT00003715|DRUG|chemotherapy|
214627182|NCT00003715|DRUG|cyclophosphamide|
214627183|NCT00199563|DRUG|Viagra|Sildenafil 100mg daily for 12 weeks
214627184|NCT01485757|DRUG|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
214627185|NCT02419560|DRUG|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
214627186|NCT03166033|OTHER|the disease|Observation the patients and non-patients
214627187|NCT04646759|DRUG|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
214627188|NCT04646759|DRUG|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
214627189|NCT06359509|BIOLOGICAL|BCMA Targeted CAR T-cells|Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.
214627190|NCT02562456|PROCEDURE|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
214627191|NCT02562456|PROCEDURE|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
214627192|NCT03150771|DRUG|Aripiprazole|Injection
214627193|NCT05725616|PROCEDURE|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
214627194|NCT05012956|PROCEDURE|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
214627195|NCT05012956|PROCEDURE|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
214627196|NCT03594188|PROCEDURE|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
214627197|NCT01056627|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
214627198|NCT05969509|OTHER|progressive relaxation exercise|applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
214634928|NCT05334186|BEHAVIORAL|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
214634929|NCT02173743|OTHER|PRP|platelet enriched autologous blood plasma
214634930|NCT02173743|OTHER|Control|Regular barbotage/care as usual
214627199|NCT04951037|BEHAVIORAL|Fully Asynchronous Online Savvy Program|"The intervention is a fully online, self-administered psychoeducational program designed to enhance caregiver mastery for family and friends providing unpaid care for living with Alzheimer's and similar dementia disorders. Participants will be asked to engage with a fully online version of Tele-Savvy for 42 days.~Participants will receive a series of daily video lessons related to caregiving. These lessons are generally 8-15 minutes in length and are emailed to participants. Participants can watch the lessons whenever and as often as they wish over the course of the study. There will also be self-guided learning strategies and exercises to accomplish skill and mastery related to the caregiving role. The lessons cover a variety of topics including:~* Facts about dementing Illnesses~* Caregiving Strategies - guiding the person through days that are as safe, calm, and pleasant as possible~* Self-Care for the Caregiver"
214627200|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
214627201|NCT05949905|BEHAVIORAL|Stage-matched interventions|The intervention would be using the Processes of Change that match each Stage of Change.
214627202|NCT05561517|OTHER|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
214627203|NCT05137327|BEHAVIORAL|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
214627204|NCT05137327|BEHAVIORAL|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
214627205|NCT04677244|PROCEDURE|Blood sample in portal vein|A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
214627206|NCT04319978|DRUG|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
214627207|NCT02500524|DRUG|Cocamide diethanolamine|Topical lotion
214627208|NCT02500524|DRUG|Permethrin|Topical creme rinse
214627209|NCT03946709|OTHER|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
214627210|NCT01639677|PROCEDURE|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
214627211|NCT01639677|PROCEDURE|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
214627212|NCT04719182|OTHER|Adjunctive therapies|Determine and compare practice of adjunctive and supportive treatments for COVID-19
214627213|NCT03389035|BIOLOGICAL|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
214627214|NCT02214238|DEVICE|PAP device|
214627215|NCT05985031|DIAGNOSTIC_TEST|Tendon tap|While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
214627216|NCT05985031|DIAGNOSTIC_TEST|Tibial nerve stimulation|H-reflex responses were examined by tibial nerve stimulation
214718987|NCT04205695|PROCEDURE|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
214718988|NCT04205695|PROCEDURE|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
214718989|NCT04205695|PROCEDURE|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
214718990|NCT01362699|DRUG|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
214718991|NCT01362699|DRUG|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
214718992|NCT01765946|DRUG|Metformin|Metformin tablets 500 mg tris in die (tid)
214718993|NCT01765946|DRUG|placebo|
214718994|NCT05872256|DRUG|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
214718995|NCT01600001|DRUG|KWA-0711|
214718996|NCT01600001|DRUG|Placebo|
214718997|NCT05289856|DRUG|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
214718998|NCT00444080|PROCEDURE|Trabeculectomy|"Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged."
214718999|NCT00444080|DEVICE|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged."
214719000|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
214719001|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
214719002|NCT03979872|DIAGNOSTIC_TEST|MC1R Genetic Testing|\[See arm/group descriptions\]
214719003|NCT03979872|OTHER|Skin Cancer Education|\[See arm/group descriptions\]
214719004|NCT03979872|DEVICE|UV Photo|\[See arm/group descriptions\]
214719005|NCT03819270|DRUG|LY3372689|Administered orally
214719006|NCT03819270|DRUG|Placebo|Administered orally
214719007|NCT03684070|BEHAVIORAL|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
214719008|NCT03684070|BEHAVIORAL|Self-monitoring|Self-monitoring of data from wearable step count tracker
214719009|NCT04898127|DIAGNOSTIC_TEST|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
214719010|NCT03496441|OTHER|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
214719011|NCT03954990|DRUG|Metronidazole Oral|4 tablets (2 g of metronidazole)
214719012|NCT03954990|DRUG|Placebo Oral Tablet|4 tablets
214719013|NCT01391455|PROCEDURE|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
214719014|NCT00001669|DRUG|rhIGF-1 (CEP-151)|
214719015|NCT03024385|BEHAVIORAL|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
214719016|NCT01287598|DRUG|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
214719017|NCT01287598|DRUG|Warfarin|CYP 2C9 (warfarin) at Cycle 1
214719018|NCT01287598|DRUG|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
214719019|NCT01287598|DRUG|Midazolam|CYP 3A4 (midazolam) at Cycle 1
214719020|NCT01287598|DRUG|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
214719021|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
214719022|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
214719023|NCT05636904|DRUG|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
214719024|NCT05636904|DRUG|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
214719025|NCT02608372|OTHER|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
214719026|NCT02608372|OTHER|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
214719027|NCT02608372|OTHER|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
214627217|NCT03432078|OTHER|Hypnotherapy|Non-pharmacological treatment
214627218|NCT00273975|DRUG|Nevirapine|
214627219|NCT00273975|DRUG|Lamivudine|
214627220|NCT00273975|DRUG|Zidovudine|
214627221|NCT02833012|DRUG|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
214627222|NCT02833012|DRUG|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
214627223|NCT02833012|DRUG|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
214627224|NCT02833012|DRUG|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
214627225|NCT04583033|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
214627226|NCT05558878|DRUG|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
214627227|NCT01604265|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
214627228|NCT01604265|DRUG|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
214627229|NCT03807804|BIOLOGICAL|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
214627230|NCT06072521|DRUG|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
214627231|NCT05984238|DEVICE|ReCET|Investigational product.
214627232|NCT05984238|DRUG|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
214627233|NCT05984238|OTHER|Sham procedure|The sham control for the ReCET procedure.
214627234|NCT04492683|COMBINATION_PRODUCT|DBV1605|"Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation."
214627235|NCT01821651|DEVICE|HeartNavigator|Procedure with software
214627236|NCT01821651|DEVICE|EchoNav|Procedure with software
214627237|NCT01821651|OTHER|Control-Group EN|Procedure without software
214627238|NCT01821651|OTHER|Control-group HN|Procedure without software
214627239|NCT02706873|DRUG|Placebo to Upadacitinib|Tablet; Oral
214627240|NCT02706873|DRUG|Methotrexate|Capsule or Tablet; Oral
214627241|NCT02706873|DRUG|Placebo to Methotrexate|Capsule or Tablet; Oral
214627242|NCT02706873|DRUG|Upadacitinib|Tablet; Oral
214627243|NCT00657891|DRUG|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
214627244|NCT00657891|DRUG|Placebo|Placebo Injection
214627245|NCT05086536|OTHER|no intervention|This is a retrospective and observational study.
214627246|NCT03825770|BEHAVIORAL|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
214627247|NCT03825770|BEHAVIORAL|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
214627248|NCT02630758|BEHAVIORAL|Mindfulness-based Yoga|See study arm description.
214627249|NCT02630758|BEHAVIORAL|Walking Control Condition|See study arm description.
214627250|NCT00210093|DRUG|denufosol tetrasodium (INS37217)|
214627251|NCT04254068|BEHAVIORAL|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
214627252|NCT03167996|BEHAVIORAL|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
214627253|NCT03187665|DEVICE|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
214627254|NCT03187665|DEVICE|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
214627255|NCT05028400|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
214627256|NCT05395065|DEVICE|Silver Diamine Fluoride/Sodium Fluoride Varnish|Application of dental caries arresting topical medication
214627257|NCT03824808|DRUG|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
214627258|NCT03824808|DRUG|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
214627259|NCT04742088|DEVICE|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
214627260|NCT05461950|PROCEDURE|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
214627261|NCT05461950|PROCEDURE|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
214627262|NCT05461950|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
214627263|NCT05138081|OTHER|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
214627264|NCT05138081|OTHER|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
214627265|NCT00000848|DRUG|Indinavir sulfate|
214627266|NCT00000848|DRUG|Saquinavir|
214627267|NCT06310980|DEVICE|smartpen|use of a smartpen connected with glucose sensor by an digital application
214627268|NCT00586495|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
214627269|NCT02569762|DIETARY_SUPPLEMENT|Sucralose-Aspartame|Sucralose or aspartame
214627270|NCT02569762|DIETARY_SUPPLEMENT|Aspartame-Sucralose|Aspartame or sucralose
214627271|NCT02354937|DRUG|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
214627272|NCT03891173|DRUG|L-DOS47|L-DOS47 lyophilized powder reconstituted and diluted for iv injection
214627273|NCT03891173|DRUG|Cisplatin|Cisplatin concentrate for solution for iv infusion
214627274|NCT03891173|DRUG|Vinorelbine|Vinorelbine concentrate for solution for iv infusion
214627275|NCT00820495|BEHAVIORAL|Web + Phone|Web + Phone
214627276|NCT00820495|BEHAVIORAL|Web Only|Web Only
214627277|NCT00820495|BEHAVIORAL|Phone Only|Phone Only
214627278|NCT00820495|BEHAVIORAL|Usual Care|Usual Care
214627279|NCT04361591|OTHER|Observational only|Observational Study
214719028|NCT02062372|DEVICE|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
214719029|NCT02062372|PROCEDURE|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
214719030|NCT06009068|OTHER|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
214719031|NCT01150604|BEHAVIORAL|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
214719032|NCT00022893|DRUG|Iodine-131 Anti-B1 Antibody|
214719033|NCT04960462|PROCEDURE|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
214719034|NCT01336595|DEVICE|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
214719035|NCT01336595|DEVICE|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
214719036|NCT01706991|DEVICE|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
214719037|NCT03115125|OTHER|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
214719038|NCT04655768|DEVICE|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
214719039|NCT05024890|OTHER|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide"
214719040|NCT03015623|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
214719041|NCT03015623|DEVICE|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
214719042|NCT01994278|DEVICE|Peri Clean|
214719043|NCT03540641|DEVICE|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
214719044|NCT01937481|BEHAVIORAL|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
214719045|NCT02019017|DRUG|Botulinum Toxin Type A 25 IU|
214719046|NCT02019017|DRUG|Botulinum Toxin Type A 50 IU|
214719047|NCT00344760|DRUG|Enfuvirtide|subcutaneously twice a day
214719048|NCT00344760|DRUG|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
214719049|NCT02858284|DEVICE|TUG|Therapeutic Ultrasound for Glaucoma
214719050|NCT02858284|DEVICE|Sham|
214719051|NCT02522078|DRUG|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
214719052|NCT02522078|DRUG|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
214719053|NCT06431412|OTHER|no intervention|no intervention
214719054|NCT05385926|RADIATION|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
214719055|NCT02565277|BIOLOGICAL|Influenza Vaccine|
214719056|NCT02565277|DRUG|Placebo|
214719057|NCT03954379|DRUG|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
214719058|NCT03954379|DRUG|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery"
214719059|NCT03954379|PROCEDURE|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
214719060|NCT03954379|DRUG|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
214719061|NCT00152945|DRUG|Intravenous Intralipid|intravenous infusion
214719062|NCT00152945|DRUG|Intravenous leucine, glycerol|intravenous infusion
214719063|NCT02944734|DRUG|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
214719064|NCT02944734|DRUG|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
214719065|NCT02944734|DRUG|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
214719066|NCT02944734|DRUG|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
214719067|NCT00395213|DRUG|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
214719068|NCT01712503|DEVICE|Phacoemulsfication cataract surgery and intra-ocular lens implant|
214627280|NCT04082754|BIOLOGICAL|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
214627281|NCT04082754|DRUG|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
214627282|NCT02965807|DEVICE|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
214627283|NCT00356928|DRUG|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
214627284|NCT00356928|BIOLOGICAL|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
214627285|NCT03961815|DRUG|Brazikumab Induction Dose|Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
214627286|NCT03961815|DRUG|Brazikumab Maintenance Dose|Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
214627287|NCT06090370|DEVICE|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
214627288|NCT06090370|DEVICE|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
214627289|NCT06090370|OTHER|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
214627290|NCT06090370|OTHER|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
214627291|NCT06090370|OTHER|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
214627292|NCT04906174|OTHER|Electronic Health Record Review|Medical records are reviewed
214627293|NCT05752253|OTHER|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
214627294|NCT05213377|PROCEDURE|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
214627295|NCT05532774|DEVICE|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
214627296|NCT00823355|DRUG|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
214627297|NCT00823355|DRUG|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
214627298|NCT00823355|DRUG|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
214627299|NCT00823355|DRUG|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
214627300|NCT05937178|DRUG|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
214627301|NCT05937178|DRUG|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
214627302|NCT03237104|OTHER|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
214627303|NCT01311037|OTHER|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
214627304|NCT01774578|DRUG|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
214627305|NCT01774578|BIOLOGICAL|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
214627306|NCT01774578|DRUG|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
214627307|NCT01774578|DRUG|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
214634931|NCT02882659|BIOLOGICAL|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
214634932|NCT04755634|DEVICE|Hyaluronic Acid|Injectable
214634933|NCT03612986|DIETARY_SUPPLEMENT|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
214627308|NCT05259865|DIAGNOSTIC_TEST|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
214627309|NCT01100515|OTHER|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
214627310|NCT01100515|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
214627311|NCT01870427|DRUG|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
214627312|NCT01090466|DRUG|cisplatin|
214627313|NCT01090466|DRUG|gemcitabine hydrochloride|
214627314|NCT01090466|DRUG|temsirolimus|
214627315|NCT01090466|OTHER|pharmacological study|
214627316|NCT05422807|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
214627317|NCT00177333|DRUG|Doxycycline|
214627318|NCT03068442|DRUG|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
214627319|NCT02821507|DRUG|sirolimus and cyclophosphamide|
214627320|NCT01197404|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
214627321|NCT01197404|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
214627322|NCT02595723|DRUG|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
214627323|NCT02595723|DRUG|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
214627324|NCT02595723|DRUG|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
214627325|NCT02595723|DRUG|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
214627326|NCT02897700|DRUG|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
214627327|NCT02897700|DRUG|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
214627328|NCT02897700|DRUG|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
214627329|NCT06182982|DEVICE|auricolotherapy|Magnetic bal plasters are applied on the ear surface
214627330|NCT03570931|DRUG|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
214627331|NCT00096707|DRUG|2-deoxy-D-glucose (2DG)|
214627332|NCT00000522|BEHAVIORAL|diet, sodium-restricted|
214627333|NCT00000522|BEHAVIORAL|diet, reducing|
214627334|NCT00000522|BEHAVIORAL|exercise|
214627335|NCT00000522|BEHAVIORAL|alcohol restriction|
214627336|NCT00000522|DRUG|chlorthalidone|
214627337|NCT00000522|DRUG|acebutolol|
214627338|NCT00000522|DRUG|doxazosin|
214627339|NCT00000522|DRUG|amlodipine|
214627340|NCT00000522|DRUG|enalapril|
214627341|NCT04502485|PROCEDURE|Gastric water exchange|Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
214627342|NCT04502485|PROCEDURE|traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
214627343|NCT00004259|DRUG|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
214627344|NCT00004259|DRUG|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
214627345|NCT00004259|RADIATION|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
214627346|NCT00004259|DRUG|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
214627347|NCT00004259|DRUG|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
214627348|NCT00004259|DRUG|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
214627349|NCT00004259|DRUG|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
214627350|NCT00004259|DRUG|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
214634934|NCT03612986|DIETARY_SUPPLEMENT|Placebo|Placebo comparator. No chemical effect expected
214634935|NCT02058680|BIOLOGICAL|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
214634936|NCT00066079|PROCEDURE|massage|
214634937|NCT00066079|BEHAVIORAL|relaxation|
214634938|NCT01035905|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214634939|NCT01035905|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
214634940|NCT01227551|BIOLOGICAL|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
214627351|NCT05821764|OTHER|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~* Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~* The cord blood sample (10 mL) immediately after delivery.~Data collection :~* A data collection sheet for the attention of the investigator (doctor or midwife) ;~* Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
214627352|NCT00996944|DRUG|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
214627353|NCT00996944|DRUG|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
214627354|NCT01688154|DIETARY_SUPPLEMENT|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
214627355|NCT01688154|OTHER|2 empty capsules|
214627356|NCT03910907|DRUG|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
214627357|NCT00769184|DRUG|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
214627358|NCT00769184|OTHER|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
214627359|NCT00769184|DRUG|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
214627360|NCT01119300|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
214627361|NCT01119300|OTHER|Standard care|Standard care
214627362|NCT02381639|BEHAVIORAL|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
214627363|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 3 mg/kg
214627364|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 15 mg/kg
214627365|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 30 mg/kg
214627366|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 0.3 mg/kg
214627367|NCT04788121|DRUG|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
214627368|NCT04788121|OTHER|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
214627369|NCT00860210|DEVICE|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
214627370|NCT02337374|DEVICE|Midurethral sling mesh|
214627371|NCT02573363|DRUG|Cytarabine|Given per standard of care
214627372|NCT02573363|DRUG|Mitoxantrone Hydrochloride|Given per standard of care
214627373|NCT02573363|DRUG|Selinexor|Given PO
214634941|NCT04722172|DRUG|Acalabrutinib|Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
214634942|NCT04722172|DRUG|Obinutuzumab|Obinutuzumab will be administered during Cycles 2-7.
214634943|NCT05913232|DRUG|H-1337 0.6%|ophthalmic solution
214634944|NCT05913232|DRUG|H-1337 1.0%|ophthalmic solution
214634945|NCT05913232|DRUG|H-1337 Placebo|ophthalmic solution
214634946|NCT05913232|DRUG|Timolol 0.5%|ophthalmic solution
214634947|NCT00970853|BEHAVIORAL|MOM Program home visiting|Mixed professional home visiting program.
214634948|NCT00970853|OTHER|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
214719069|NCT05569616|OTHER|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
214719070|NCT05569616|OTHER|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
214719071|NCT05929638|BEHAVIORAL|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
214719072|NCT03854851|DRUG|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
214719073|NCT03854851|DRUG|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
214719074|NCT01484561|DRUG|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
214719075|NCT01484561|DRUG|Placebo|Placebo BID orally, approximately 72 days
214719076|NCT00162513|BIOLOGICAL|Allogeneic tumor cell vaccine|
214719077|NCT00220454|DRUG|Climara|
214719078|NCT00220454|DRUG|Hydrocortone|
214719079|NCT03882853|OTHER|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
214719080|NCT03882853|OTHER|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
214719081|NCT03371251|DRUG|BOS161721|SC administration
214719082|NCT03371251|DRUG|Placebo|SC administration
214719083|NCT02668172|DRUG|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
214719084|NCT02668172|DRUG|Pegvisomant|only in combination with pasireotide LAR
214719085|NCT00290524|BEHAVIORAL|Oral alimentation started 12 hours after colorectal surgery|
214719086|NCT04125875|DIAGNOSTIC_TEST|Electrogastrogram(EGG)|Heart Rate Variability
214719087|NCT04125875|DIAGNOSTIC_TEST|Heart Rate Variability(HRV)|Heart Rate Variability
214719088|NCT01233570|DRUG|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
214719089|NCT00430391|OTHER|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
214719090|NCT00430391|OTHER|Routine Control|Participants are assigned to the routine, standard consent.
214719091|NCT00114218|DRUG|Gemcitabine Hydrochloride|Given IV
214719092|NCT00114218|DRUG|Docetaxel|Given IV
214719093|NCT00291187|DRUG|20 mg VEC-162|20 mg VEC-162
214719094|NCT00291187|DRUG|50 mg VEC-162|50 mg VEC-162
214719095|NCT00291187|DRUG|100 mg VEC-162|100 mg VEC-162
214719096|NCT00291187|DRUG|Placebo|Placebo
214719097|NCT01927887|DRUG|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
214719098|NCT01927887|DEVICE|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
214719099|NCT01068613|DRUG|QAX028|QAX028 60 mcg via inhalation device
214719100|NCT01068613|DRUG|QAX028|QAX028 20 mcg via inhalation device
214719101|NCT01068613|DRUG|Tiotropium|Tiotropium via inhalation device
214719102|NCT01068613|DRUG|Placebo|Placebo to QAX028 via inhalation device
214719103|NCT00157170|BEHAVIORAL|supervised exercise|
214719104|NCT03168555|DRUG|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
214719105|NCT05666570|DEVICE|Avelle NPWT|wound management therapy
214627374|NCT03119792|OTHER|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
214627375|NCT03119792|OTHER|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
214627376|NCT03811457|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
214627377|NCT03729063|OTHER|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
214627378|NCT03729063|OTHER|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
214627379|NCT01724658|DRUG|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
214627380|NCT01724658|DRUG|placebo|placebo orally twice a week with progynova 1 mg oral daily
214627381|NCT00303914|PROCEDURE|assessment of therapy complications|
214627382|NCT00303914|PROCEDURE|cognitive assessment|
214627383|NCT00303914|PROCEDURE|psychosocial assessment and care|
214627384|NCT00775632|DRUG|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
214627385|NCT00775632|DRUG|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
214627386|NCT00663065|DRUG|PAZ-417|
214627387|NCT02911480|DRUG|Oxytocin|
214627388|NCT02757664|DEVICE|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
214627389|NCT02757664|OTHER|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
214627390|NCT02757664|DEVICE|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
214627391|NCT02940509|DRUG|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)"
214627392|NCT02940509|DRUG|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
214627393|NCT02626195|DIETARY_SUPPLEMENT|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse"
214627394|NCT04173676|DRUG|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
214627395|NCT03777150|OTHER|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
214627396|NCT03777150|OTHER|Postoperative care in standard ward|Postoperative care in standard ward
214627397|NCT03104894|PROCEDURE|Meibomian Glands Massage|Meibomian gland expression
214627398|NCT03104894|PROCEDURE|Sham Meibomian Glands Massage|Touching the eyelids gently
214627399|NCT03104894|DEVICE|Meibomian Massage device|Meibomian glands expression with applicator
214627400|NCT03999762|DEVICE|sample prep|Effectiveness of a sample preparation protocol
214719106|NCT01020032|OTHER|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
214719107|NCT02319408|RADIATION|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
214719108|NCT01782924|DRUG|KHK4827|
214719109|NCT04116216|COMBINATION_PRODUCT|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
214719110|NCT04116216|COMBINATION_PRODUCT|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
214719111|NCT04116216|COMBINATION_PRODUCT|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
214719112|NCT06274268|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
214719113|NCT01040845|DRUG|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
214719114|NCT01040845|DRUG|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
214719115|NCT01040845|DRUG|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
214719116|NCT02645461|DRUG|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
214719117|NCT02645461|DRUG|Riluzole|Riluzole 50 mg twice daily
214627401|NCT03857204|DEVICE|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
214627402|NCT06539572|PROCEDURE|Cleft lip repair; palatoplasty; alveolar bone grafting|cleft surgical treatment based on Chang Gung Craniofacial Center Protocol for cleft treatment
214627403|NCT06181942|DEVICE|SP|English name: da Vinci SP Surgical System Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
214627404|NCT03238105|DRUG|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
214627405|NCT03238105|DEVICE|Intense Pulsed Light|Monthly sessions for 3 months.
214627406|NCT00538395|DRUG|Adriamycin, Taxol and Cytoxan|Chemotherapy
214627407|NCT02923661|DEVICE|CM LOC|
214627408|NCT02923661|DEVICE|ball attachment|
214627409|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
214627410|NCT04735445|DIAGNOSTIC_TEST|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
214627411|NCT04735445|DIAGNOSTIC_TEST|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
214627412|NCT04735445|DIAGNOSTIC_TEST|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
214627413|NCT04735445|DIAGNOSTIC_TEST|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
214627414|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
214627415|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~* Asian male\> 40 years old~* Asian woman\> 50 years old~* African man or woman~* HCC family history"
214627416|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
214627417|NCT04735445|DIAGNOSTIC_TEST|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
214627418|NCT04735445|DIAGNOSTIC_TEST|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
214627419|NCT04735445|DIAGNOSTIC_TEST|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
214627420|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
214627421|NCT04735445|DIAGNOSTIC_TEST|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
214627422|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~* Age \> 40 years~* Active smoker or former smoker\<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~* No contraindications for thoracic surgery~* No lung infection in the last 2 months"
214627423|NCT04735445|DIAGNOSTIC_TEST|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
214627424|NCT06194513|OTHER|Intervention 1: Twice a day for 1 week PIOMI|Preterm babies will receive two sessions of treatment every day for a week, for a total of 14 sessions. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
214627425|NCT06194513|OTHER|Intervention 2: Once a day for 2 weeks PIOMI|Preterm babies will receive a total of 14 sessions of treatment, one every day for two weeks. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
214627426|NCT02663050|OTHER|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
214627427|NCT02663050|DRUG|NSAID's|twice a daily
214627428|NCT03803072|BEHAVIORAL|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
214627429|NCT03154814|DRUG|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
214627430|NCT03154814|DRUG|control|conventional CPB was applied without ulinastatin treatment
214719118|NCT01852916|DEVICE|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
214719119|NCT01852916|DEVICE|NHFOV|Nasal High Frequency Oscillatory Ventilation
214719120|NCT02645071|BEHAVIORAL|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
214719121|NCT00460681|DRUG|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
214719122|NCT05570799|OTHER|Augmented Reality and Kahoot game learning|"* An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
214719123|NCT04709913|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
214719124|NCT04965116|DRUG|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
214719125|NCT02708966|DRUG|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
214719126|NCT02708966|DRUG|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
214719127|NCT03377569|OTHER|Sleep, PD and DBS|Sleep, PD and DBS
214719128|NCT01515488|OTHER|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
214719129|NCT01515488|OTHER|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
214719130|NCT02714023|PROCEDURE|Normal Saline|Intra-operative irrigation with normal saline
214719131|NCT02714023|PROCEDURE|Sterile Water|Intra-operative irrigation with sterile water
214719132|NCT04571476|PROCEDURE|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
214719133|NCT04571476|PROCEDURE|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
214719134|NCT04571476|PROCEDURE|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
214719135|NCT04571476|PROCEDURE|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
214719136|NCT02687607|DEVICE|WEB Aneurysm Embolization System|
214719137|NCT04393909|BEHAVIORAL|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
214719138|NCT04393909|BEHAVIORAL|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
214719139|NCT04393909|BEHAVIORAL|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
214719140|NCT04393909|BEHAVIORAL|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
214719141|NCT04735809|DIETARY_SUPPLEMENT|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
214627431|NCT03112889|DRUG|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
214627432|NCT02076997|DRUG|Methotrexate|"Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
214627433|NCT02572674|OTHER|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
214627434|NCT02572674|GENETIC|Genetic sample|Blood samples
214627435|NCT03885310|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
214627436|NCT01811875|BIOLOGICAL|Optivate 500IU|
214627437|NCT03116074|BEHAVIORAL|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
214627438|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
214627439|NCT00531752|DRUG|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
214627440|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
214627441|NCT02427074|PROCEDURE|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
214627442|NCT02427074|PROCEDURE|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
214627443|NCT02526459|BEHAVIORAL|Birth plan|Patient will receive a birth plan
214627444|NCT02821715|DRUG|Active comparator: Modafinil + placebo|
214627445|NCT02821715|DRUG|THN102 300/3|
214627446|NCT02821715|DRUG|THN102 300/27|
214627447|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using locator attachment|
214627448|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using ball attachment|
214627449|NCT00640328|DRUG|Ofatumumab 100|100mg
214627450|NCT00640328|DRUG|Ofatumumab 300|300mg
214627451|NCT00640328|DRUG|Ofatumumab 700|700mg
214627452|NCT00640328|DRUG|Placebo|matching placebo
214627453|NCT03461328|DRUG|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
214627454|NCT00950768|PROCEDURE|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
214627455|NCT04686721|DIAGNOSTIC_TEST|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
214627456|NCT05417724|OTHER|Battlefield Acupuncture|Battlefield Acupuncture
214627457|NCT01433575|DRUG|RO4917838|10 mg single oral dose
214627458|NCT01433575|DRUG|RO4917838|20 mg single oral dose
214627459|NCT01326546|BIOLOGICAL|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
214627460|NCT01326546|DRUG|entecavir|0.5mg,per day,oral intake.
214627461|NCT01326546|OTHER|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
214627462|NCT01550146|DRUG|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
214627463|NCT01550146|DRUG|Placebo|iv. Normal Saline 0.1 ml/kg
214627464|NCT03152019|DRUG|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
214627465|NCT03152019|DRUG|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
214627466|NCT01057407|DRUG|ASP1585|oral
214627467|NCT01057407|DRUG|Sevelamer hydrochloride|oral
214634949|NCT06849440|BEHAVIORAL|Training|Participants will be divided into groups of ten and the training is planned in 4 sessions. Session contents are prepared as sharing general information on preparation for birth, explanation of frequently applied interventions in labor, explanation of non-drug pain relieving methods, teaching and practicing active birth positions that help the labor progress. The duration of the sessions is planned as 2 hours on average.
214627468|NCT04294719|OTHER|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
214627469|NCT03065907|OTHER|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
214627470|NCT03763071|OTHER|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
214627471|NCT04503239|DEVICE|G6|Wear 9 wear periods of the 10-day CGM
214627472|NCT05297942|OTHER|Expansion of Abbreviations and Acronyms|Expansion of Abbreviations and Acronyms
214627473|NCT03276000|PROCEDURE|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
214719142|NCT04735809|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
214719143|NCT02959190|DRUG|Galcanezumab|Administered SC
214627474|NCT00388700|DRUG|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
214627475|NCT00388700|DRUG|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
214627476|NCT01868880|DRUG|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
214627477|NCT01868880|DRUG|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
214627478|NCT01513421|PROCEDURE|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
214627479|NCT03757286|PROCEDURE|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
214627480|NCT03757286|PROCEDURE|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
214627481|NCT04286204|OTHER|Basic Life Support training based on ICTs|This intervention is defined as a self-training course consisting of a 5-minute educational video in basic life support and a Kit with the elements to build the home dummy and the home DEA allowing integrally students to develop the steps as the video. The Kit will be delivered at the beginning of the study and every month the necessary materials will be complemented. The strategy will be carried out by the students every month and supervised by their teachers. Students will have constant access to an educational platform based on ICTs.
214627482|NCT04286204|OTHER|Classic Basic Life Support training|It is defined as a module carried out by trained personnel in basic resuscitation (pre-hospital care program staff of the UdeA medical school), which includes two subcomponents of the conventional BLS course that are basic resuscitation and DEA in adults. The duration of the subcomponents is a theoretical part of 30 minutes and a practical part in a low fidelity simulator with 1.5 hours duration.
214719144|NCT02023268|DEVICE|T2762|1 drop in each eye 3 to 6 times daily during 84 days
214719145|NCT02023268|DEVICE|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
214719146|NCT01136213|RADIATION|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
214719147|NCT01136213|OTHER|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
214719148|NCT01136213|DRUG|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
214719149|NCT04445688|DRUG|AD036|Oral administration before bed
214719150|NCT04445688|DRUG|Atomoxetine|Oral administration before bed
214719151|NCT04445688|DRUG|Placebo|Oral administration before bed
214627483|NCT04322851|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
214627484|NCT01714687|DEVICE|balloon sinus dilation|
214719152|NCT00299416|DRUG|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
214719153|NCT00299416|PROCEDURE|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
214719154|NCT05812768|DEVICE|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
214719155|NCT02331641|PROCEDURE|Hepatectomy|Removal of a part of the liver
214719156|NCT01045928|DRUG|lenalidomide|Given orally
214719157|NCT01045928|BIOLOGICAL|rituximab|Given IV
214719158|NCT01045928|GENETIC|polymerase chain reaction|Correlative study
214719159|NCT01045928|GENETIC|nucleic acid sequencing|Correlative study
214719160|NCT01045928|GENETIC|polymorphism analysis|Correlative study
214719161|NCT01045928|OTHER|flow cytometry|Correlative study
214719162|NCT01045928|OTHER|laboratory biomarker analysis|Correlative study
214719163|NCT05768542|DRUG|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
214719164|NCT05768542|DRUG|Saline|5 ml given IV
214719165|NCT04732572|BEHAVIORAL|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
214719166|NCT04732572|OTHER|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
214719167|NCT04732572|PROCEDURE|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
214719168|NCT03919006|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
214719169|NCT03919006|OTHER|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
214719170|NCT06227806|PROCEDURE|Tibial Tubercle Transfer|Patients will receive the TTT surgery followed by a home exercise program.
214719171|NCT06227806|PROCEDURE|Home Exercise Program|Patients will receive an extensive home exercise program.
214719172|NCT02866929|PROCEDURE|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
214719173|NCT02866929|DEVICE|Orthodontics|Self-ligation brackets in upper and lower teeth
214719174|NCT02866929|DRUG|Mucograft|Porcine naturally cross-linked collagen matrix
214719175|NCT01023373|DRUG|Medical treatment|hypotensive drugs, statins and anti-platelets
214719176|NCT01023373|PROCEDURE|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
214719177|NCT01023373|DEVICE|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
214719178|NCT01023373|DEVICE|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
214719179|NCT01661504|BEHAVIORAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
214719180|NCT05118568|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
214719181|NCT01066169|BIOLOGICAL|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
214719182|NCT02032186|DRUG|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
214719183|NCT05915117|DIETARY_SUPPLEMENT|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
214719184|NCT05915117|DRUG|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
214719185|NCT01962389|DEVICE|Winsor Laser Catheter|
214719186|NCT02621645|PROCEDURE|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
214627485|NCT01714687|OTHER|medical therapy|
214627486|NCT00272142|DRUG|Zinc|
214627487|NCT00272142|DRUG|Placebo|
214627488|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
214627489|NCT04988412|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
214627490|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
214627491|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
214627492|NCT06402708|DRUG|Chemotherapy|paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
214627493|NCT06402708|RADIATION|Radiotherapy|IMRT, 50Gy/25f
214627494|NCT03177421|OTHER|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
214627495|NCT03177421|OTHER|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
214627496|NCT00203853|DEVICE|pillbox, wristwatch|
214627497|NCT02812277|OTHER||This is a Non-Interventional Study, so there are no drug or devices included.
214627498|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
214627499|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
214627500|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
214627501|NCT04594967|OTHER|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
214627502|NCT01964014|DRUG|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
214627503|NCT01070472|DRUG|Misoprostol|titrated oral misoprostol solution
214627504|NCT02704338|BIOLOGICAL|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
214627505|NCT04523636|DEVICE|Splinting|Pre-fabricated or custom resting hand splints
214627506|NCT04750876|OTHER|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
214627507|NCT04750876|OTHER|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~* consultations with a psychologist~* The patient will also be cared for on a daily basis by a physical therapist."
214627508|NCT00003936|DRUG|bryostatin 1|
214627509|NCT05543577|OTHER|Questionnaire|Questionnaire
214627510|NCT02284789|OTHER|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
214627511|NCT02094690|DEVICE|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
214627512|NCT02094690|DEVICE|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
214627513|NCT01979536|DRUG|Brentuximab Vedotin|Given IV
214627514|NCT01979536|DRUG|Crizotinib|Given PO
214627515|NCT01979536|DRUG|Cyclophosphamide|Given IV
214627516|NCT01979536|DRUG|Cytarabine|Given IT and IV
214627517|NCT01979536|DRUG|Dexamethasone|Given PO or IV
214627518|NCT01979536|DRUG|Doxorubicin Hydrochloride|Given IV
214627519|NCT01979536|DRUG|Etoposide|Given IV
214627520|NCT01979536|DRUG|Ifosfamide|Given IV
214627521|NCT01979536|DRUG|Methotrexate|Given IT and IV
214627522|NCT04926051|DRUG|BMS-986172|Specified dose on specified days
214627523|NCT04926051|OTHER|Placebo|Specified dose on specified days
214627524|NCT04885803|DIETARY_SUPPLEMENT|Softgel Vitamin D3|5000IU vitamin D3 taken as single oral softgel once daily for 30 days
214627525|NCT04885803|DIETARY_SUPPLEMENT|Nano Liquid Vitamin D3|5000IU vitamin D3 taken as liquid oral spray once daily for 30 days
214627526|NCT04885803|DIAGNOSTIC_TEST|25(OH)D Blood Serum Test|A sample of blood is drawn off and processed for 25(OH)D levels at baseline, after 15 days of supplementation, and after 30 days of supplementation
214719187|NCT02621645|PROCEDURE|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
214719188|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
214719189|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
214719190|NCT02621645|DEVICE|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
214719191|NCT05226767|DIETARY_SUPPLEMENT|NLC-V|NLC-V
214719192|NCT04761952|DRUG|azathioprine|daily orally
214719193|NCT04761952|DRUG|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
214719194|NCT04761952|DRUG|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
214719195|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
214719196|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
214719197|NCT00427167|DRUG|AMA1-C1/Alhydrogel + CPG 7909|
214719198|NCT01674738|DRUG|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
214719199|NCT01674738|DRUG|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
214719200|NCT01674738|DRUG|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
214719201|NCT02423460|OTHER|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
214719202|NCT05300893|OTHER|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
214719203|NCT06449846|DIAGNOSTIC_TEST|circulating tumor cell DNA detection|circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
214719204|NCT03701204|BEHAVIORAL|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule."
214719205|NCT02678728|DRUG|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
214719206|NCT02678728|DRUG|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
214719207|NCT05362331|OTHER|Web Application|Internet based application
214719208|NCT02878629|DEVICE|Mandibular Advancement Devices|
214719209|NCT00592917|DIETARY_SUPPLEMENT|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
214719210|NCT01262599|DEVICE|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
214719211|NCT01262599|DEVICE|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
214719212|NCT04294654|DRUG|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
214719213|NCT03760276|DRUG|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
214719214|NCT05401591|DIETARY_SUPPLEMENT|Protein shake|Participant will drink a protein shake made using each of the four protein types.
214719215|NCT00038272|DRUG|Mycophenolate mofetil|
214719216|NCT00038272|DRUG|Amdoxovir|
214719217|NCT01778270|DEVICE|Body Bioimpedance Sensor|
214719218|NCT05218577|OTHER|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
214719219|NCT05218577|DIETARY_SUPPLEMENT|selenium supplement|20 microgram/day selenium suppplement powder.
214719220|NCT05218577|OTHER|Placebo|the placebo mocaf powder
214719221|NCT03126578|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
214719222|NCT03126578|DRUG|Midazolam|Benzodiazepine
214719223|NCT01875510|DIETARY_SUPPLEMENT|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
214719224|NCT01875510|DIETARY_SUPPLEMENT|soybean-oil emulsion|soybean-oil emulsion
214719225|NCT04948814|BIOLOGICAL|Fecal microbiota transplantation|FMT utilizing stool from healthy children
214719226|NCT04948814|DRUG|Vancomycin|40mg/kg/day
214719227|NCT03224910|OTHER|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
214719228|NCT04911829|BEHAVIORAL|Psychotherapy|
214719229|NCT05630560|OTHER|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
214719230|NCT01711658|RADIATION|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
214719231|NCT01711658|DRUG|Cisplatin|100 mg/m\^2 administered intravenously on days 8 and 29
214719232|NCT01711658|DRUG|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
214719233|NCT01711658|DRUG|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
214719234|NCT03078959|OTHER|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
214719235|NCT03998761|DRUG|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
214719236|NCT03998761|DRUG|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
214719237|NCT01328197|DEVICE|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
214719238|NCT01699646|DEVICE|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
214719239|NCT01699646|PROCEDURE|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
214719240|NCT05276427|OTHER|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
214719241|NCT03846973|DRUG|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
214719242|NCT03846973|OTHER|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
214719243|NCT03620604|DEVICE|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
214719244|NCT01463020|BEHAVIORAL|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
214719245|NCT01463020|OTHER|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
214719246|NCT05848076|OTHER|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
214719247|NCT05848076|OTHER|core stability|McGill exercises for the low back.
214719248|NCT03483376|PROCEDURE|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
214634950|NCT06852872|OTHER|CRET Therapy|Diathermy therapy with a protocol to preheat the back extensor muscle
214634951|NCT06852872|OTHER|ILEX training|Isolated lumbar Extension Training
214634952|NCT06852872|OTHER|CRET therapy sham|Diathermy therapy withouth any radiofrequency as a sham intervention
214634953|NCT05176119|DRUG|Nalbuphine Injection|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
214634954|NCT05176119|DRUG|Ketamine|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
214634955|NCT05176119|DRUG|Saline|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
214634956|NCT01627899|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
214634957|NCT06412497|DRUG|Rituximab|For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.
214634958|NCT06412497|DRUG|Rabbit ATG|Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.
214634959|NCT06412497|DRUG|Cyclophosphamide|"Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines."
214634960|NCT06412497|DRUG|Fludarabine|For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.
214634961|NCT06412497|RADIATION|Total Body Irradiation|"For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.~Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus."
214634962|NCT06412497|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines.
214634963|NCT06412497|DRUG|Post-Transplant G-CSF|Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.
214634964|NCT06412497|DRUG|Tacrolimus|Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
214634965|NCT06412497|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
214634966|NCT01708109|OTHER|no measures taken to clear bile ductus|biliary calculus remain
214634967|NCT01708109|PROCEDURE|clearance of bile ductus|biliary calculus removed at surgery
214634968|NCT02051543|BEHAVIORAL|Brief Behavioral Treatment of Insomnia -Military Version|
214634969|NCT01489592|DRUG|curcuma longa|oral administration of 6 grams of curcumin
214634970|NCT04519801|OTHER|Blood Flow Restriction (BFR) therapy|BFR therapy beginning after first MD follow up appointment after ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion.
214634971|NCT04519801|OTHER|Standard REHAB|Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion
214634972|NCT05491226|DRUG|Pembrolizumab|Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
214719249|NCT03483376|DEVICE|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
214719250|NCT05941663|OTHER|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
214719251|NCT02445703|BIOLOGICAL|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
214719252|NCT02445703|BIOLOGICAL|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
214719253|NCT02867163|DRUG|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
214719254|NCT01763112|DEVICE|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
214719255|NCT05117749|DRUG|Saffron 100|to Mild and Moderate UC patients
214719256|NCT05117749|DRUG|Saffron 50|to Mild and Moderate UC patients
214719257|NCT05117749|DRUG|Placebo|to Mild and Moderate UC patients
214719258|NCT05369546|DIAGNOSTIC_TEST|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
214719259|NCT02294669|DEVICE|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
214719260|NCT04714723|BEHAVIORAL|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
214719261|NCT04714723|BEHAVIORAL|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
214719262|NCT00561587|DRUG|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
214719263|NCT06345599|RADIATION|Radiotherapy|This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
214627527|NCT04885803|OTHER|Placebo Control|Liquid oral spray once daily for 30 days. Solution identical in smell, taste, color, and production process to Nano Liquid D3, but containing no Vitamin D3.
214627528|NCT04158076|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
214627529|NCT04158076|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
214627530|NCT04158076|DRUG|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
214627531|NCT01933633|BEHAVIORAL|Exercise|
214627532|NCT01934686|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
214627533|NCT01353040|DRUG|AVI-6003|Single intravenous administration
214627534|NCT01353040|DRUG|Placebo|Single intravenous administration
214627535|NCT00476411|BIOLOGICAL|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
214627536|NCT06977880|DRUG|LY4292009|Administered orally
214627537|NCT06977880|DRUG|Placebo|Administered orally.
214627538|NCT05912842|BEHAVIORAL|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
214627539|NCT05912842|BEHAVIORAL|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
214627540|NCT05332158|BEHAVIORAL|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
214627541|NCT04758611|DEVICE|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
214627542|NCT05926830|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
214627543|NCT06047171|BIOLOGICAL|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
214627544|NCT06047171|DRUG|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
214627545|NCT06047171|DRUG|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
214627546|NCT06047171|DRUG|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
214627547|NCT06047171|DRUG|Placebo|Drug product that will contain no active ingredient
214627548|NCT06047171|DRUG|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
214627549|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
214627550|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
214627551|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
214627552|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
214627553|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
214627554|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
214627555|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
214627556|NCT06790602|DRUG|Cemiplimab Plus Gemcitabine|Cemiplimab Plus Gemcitabine
214634973|NCT05491226|RADIATION|Radiation Therapy|Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
214634974|NCT05491226|DRUG|Axatilimab|Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
214634975|NCT06329661|DRUG|Cyclosporine ophthalmic solution, 0.1%|Colorless and clear opthalmic solution containing 0.1% Cyclosporine
214634976|NCT06329661|DRUG|Saline solution, 0.6%|Colorless and clear sodium chloride solution (0.6%)
214719264|NCT06345599|DRUG|Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab|GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
214719265|NCT06345599|DRUG|Chemotherapy:Albumin-bound paclitaxel、Gemcitabine|Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
214719266|NCT00241878|BEHAVIORAL|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
214719267|NCT00241878|BEHAVIORAL|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
214719268|NCT06508853|OTHER|Qualitative research (no intervention)|Interviews are being conducted with support workers and managers.
214719269|NCT01142193|DRUG|USL255|
214719270|NCT01142193|DRUG|Placebo|
214719271|NCT02077504|OTHER|MEG and MRI|CONDUCTOME
214719272|NCT02381548|DRUG|Adavosertib|Given PO
214719273|NCT02381548|DRUG|Belinostat|Given IV
214719274|NCT02381548|OTHER|Laboratory Biomarker Analysis|Correlative studies
214719275|NCT02381548|OTHER|Pharmacological Study|Correlative studies
214719276|NCT04737980|DRUG|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
214719277|NCT04737980|DRUG|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
214719278|NCT04737980|DRUG|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
214719279|NCT04737980|DRUG|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
214719280|NCT01233180|OTHER|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
214719281|NCT01233180|DEVICE|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
214719282|NCT03347812|PROCEDURE|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
214719283|NCT03347812|PROCEDURE|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
214719284|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
214719285|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
214719286|NCT04249167|DRUG|Atezolizumab|Given IV
214719287|NCT04249167|PROCEDURE|Cryosurgery|Undergo cryoablation of the primary tumor
214719288|NCT04249167|DRUG|Nab-paclitaxel|Given IV
214719289|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
214719290|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
214719291|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
214719292|NCT01821404|DRUG|Atorvastatin|Capsules including 80 mg of atorvastatin
214719293|NCT01821404|DRUG|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
214719294|NCT06170281|BEHAVIORAL|Migraine Behavioral Treatment|Migraine Behavioral Treatment involving daily activities
214719295|NCT01753700|DIETARY_SUPPLEMENT|UHT treated milk|
214719296|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
214719297|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
214719298|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
214719299|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
214719300|NCT04641910|OTHER|No intervention|No intervention
214719301|NCT05376956|DIAGNOSTIC_TEST|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
214719302|NCT05376956|DIAGNOSTIC_TEST|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
214719303|NCT00846469|PROCEDURE|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
214719304|NCT00846469|OTHER|Control section|Normal emergency room treatment for symptoms of chest pain.
214719305|NCT00127088|DRUG|docetaxel|
214719306|NCT00127088|PROCEDURE|laparoscopic radical prostatectomy|
214719307|NCT00829660|DRUG|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
214719308|NCT00829660|DRUG|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
214719309|NCT05160662|PROCEDURE|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
214719310|NCT00273299|DRUG|valsartan plus hydrochlorothiazide|
214719311|NCT05239884|OTHER|ENDS Product A with 1.5% nicotine|P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719312|NCT05239884|OTHER|ENDS Product B with 1.5% nicotine|P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719313|NCT05239884|OTHER|ENDS Product C with 1.5% nicotine|P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719314|NCT05239884|OTHER|ENDS Product D with 1.5% nicotine|P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719315|NCT05239884|OTHER|ENDS Product E with 1.5% nicotine|P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719316|NCT05239884|OTHER|ENDS Product F with 1.5% nicotine|P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719317|NCT05239884|OTHER|ENDS Product G with 1.5% nicotine|P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719318|NCT05239884|OTHER|ENDS Product H with 1.5% nicotine|P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
214719319|NCT03212599|DRUG|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
214719320|NCT00383708|DRUG|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
214719321|NCT00383708|DRUG|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
214719322|NCT02945306|PROCEDURE|Adenotonsillectomy|
214719323|NCT02945306|DRUG|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
214719324|NCT00318370|DRUG|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
214719325|NCT00318370|DRUG|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
214719326|NCT06266871|DRUG|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
214719327|NCT00054184|DRUG|docetaxel|
214719328|NCT00054184|DRUG|paclitaxel poliglumex|
214719329|NCT06156904|DEVICE|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
214719330|NCT01750840|DEVICE|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
214719331|NCT01750840|DEVICE|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
214719332|NCT01750840|DEVICE|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
214719333|NCT03908580|DRUG|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
214719334|NCT00530491|PROCEDURE|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
214719335|NCT05460689|OTHER|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
214719336|NCT05460689|OTHER|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
214719337|NCT00936793|DRUG|Darunavir|
214719338|NCT00936793|DRUG|Ritonavir|
214719339|NCT00936793|DRUG|Beclomethasone Dipropionate HFA|
214719340|NCT02880462|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
214719341|NCT02880462|OTHER|placebo|Placebo is made of starch
214719342|NCT01094990|DRUG|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
214719343|NCT01109550|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
214719344|NCT01612442|BEHAVIORAL|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
214719345|NCT01612442|BEHAVIORAL|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
214719346|NCT06291467|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
214719347|NCT06291467|OTHER|questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)"
214719348|NCT00106821|DRUG|Tiotropium Bromide Inhalation Powder|
214719349|NCT02905903|DRUG|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
214719350|NCT03661372|OTHER|Robot|Use of a telesimulation robot using contextual interview format.
214719351|NCT03661372|OTHER|Face-to-face|Use of face-to-face patient interview using contextual interview format.
214719352|NCT05663242|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
214719353|NCT05663242|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
214719354|NCT03990259|OTHER|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
214719355|NCT06365372|DIAGNOSTIC_TEST|Western blot|Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
214719356|NCT05243719|BIOLOGICAL|ADP101|Active dry powder formulation at various volumes.
214719357|NCT00122304|DRUG|eculizumab|
214719358|NCT03655574|BEHAVIORAL|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
214719359|NCT03655574|OTHER|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
214719360|NCT06403748|DIETARY_SUPPLEMENT|Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.|The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
214719361|NCT06403748|OTHER|Placebo|Placebo
214719362|NCT03148587|BEHAVIORAL|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
214719363|NCT03148587|BEHAVIORAL|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
214719364|NCT03404271|DIETARY_SUPPLEMENT|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
214719365|NCT03404271|OTHER|Resistance Training|Performing supervised resistance training three times per week.
214719366|NCT03404271|DIETARY_SUPPLEMENT|Protein Supplementation|Consuming a protein supplement daily.
214719367|NCT03404271|BEHAVIORAL|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
214719368|NCT00141557|DRUG|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
214719369|NCT00141557|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
214719370|NCT04006535|GENETIC|genetic analysis|Saliva sample collection for genetic analysis
214719371|NCT00669032|DEVICE|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
214719372|NCT00669032|OTHER|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
214719373|NCT03627494|DRUG|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
214719374|NCT03627494|DRUG|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
214719375|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
214719376|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
214719377|NCT06783244|OTHER|Low intraabdominal pressure (8 mmHg)|Only difference in treatment is the lower level of intraabdominal pressure by which the procedure is performed. The intervention does not change the treatment. The surgical procedure is performed due to Danish national guidelines and remains the same in the two arms.
214719378|NCT05717166|RADIATION|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
214719379|NCT05717166|DRUG|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
214719380|NCT05717166|DRUG|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
214719381|NCT05717166|DRUG|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
214719382|NCT05717166|DRUG|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
214719383|NCT05717166|OTHER|Observation|Pre-specified based on the standard of care approach for that patient.
214719384|NCT05717166|RADIATION|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
214719385|NCT05717166|PROCEDURE|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
214719386|NCT05717166|OTHER|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
214719387|NCT05717166|RADIATION|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
214719388|NCT03906136|BIOLOGICAL|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab biosimilar 40 mg, s.c.
214719389|NCT03906136|OTHER|Standard-of-care|Treatment according to local practice standards by the rheumatologist following latest treatment recommendations with NSAIDs as the first-choice drug treatment and DMARDs for patients with active disease despite the use (or intolerance/contraindication) of NSAIDs.
214719390|NCT06088303|BEHAVIORAL|Adjunctive writing to amplify response and engagement (AWARE)|AWARE includes two components: 1) patients complete brief writing prompts asking about their experiences in treatment, and 2) therapists review patients' responses and facilitate guided discussion related to patients' experiences during check-ins at the beginning of each session.
214719391|NCT06088303|BEHAVIORAL|Cognitive processing therapy (CPT)|CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.
214719392|NCT06088303|BEHAVIORAL|Prolonged exposure (PE)|PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
214719393|NCT03374852|DRUG|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
214719394|NCT03374852|DRUG|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
214719395|NCT03162731|BIOLOGICAL|Nivolumab|Given IV
214719396|NCT03162731|BIOLOGICAL|Ipilimumab|Given IV
214719397|NCT03162731|RADIATION|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
214719398|NCT03162731|RADIATION|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
214719399|NCT04410835|DIAGNOSTIC_TEST|Online Survey|Psychological questionnaires
214719400|NCT06494501|DRUG|Inclisiran|Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
214719401|NCT06844396|OTHER|Music Therapy|"Music Therapy consisting of four types of protocol:~* Music combined with skin to skin~* Developmental multimodal technique~* Infant directed singing~* Parent/caregiver therapeutic support"
214719402|NCT00914719|BEHAVIORAL|Information only|
214719403|NCT00914719|BEHAVIORAL|Sexual risk reduction intervention|
214719404|NCT00914719|BEHAVIORAL|sexual risk reduction + alcohol risk reduction component|
214719405|NCT01786434|DRUG|Routine medication arm|50 micrograms of fentanyl given before the procedure
214719406|NCT01786434|DRUG|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
214719407|NCT02481791|DRUG|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
214719408|NCT02481791|DRUG|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
214719409|NCT02481791|DRUG|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
214719410|NCT03505957|DEVICE|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
214719411|NCT03386006|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
214719412|NCT01979328|DEVICE|geko|
214719413|NCT01979328|DEVICE|Plaster cast|
214719414|NCT02193854|DEVICE|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
214719415|NCT00150514|DRUG|Oralgen|
214719416|NCT00150514|PROCEDURE|Nasal biopsy|
214719417|NCT00150514|PROCEDURE|Nasal washing|
214719418|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
214719419|NCT04994275|OTHER|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or \<300 µg/L And TSAT\<20%) or no iron deficiency
214719420|NCT05988086|PROCEDURE|platelet rich fibrin|12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
214719421|NCT05988086|PROCEDURE|collagen membrane|12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
214719422|NCT03117699|DEVICE|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair"
214719423|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
214719424|NCT01208389|BIOLOGICAL|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
214719425|NCT03190317|OTHER|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
214719426|NCT03190317|OTHER|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
214719427|NCT03190317|OTHER|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
214719428|NCT04233957|DIETARY_SUPPLEMENT|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
214719429|NCT04233957|OTHER|Placebo|10 days of enteric capsules filled with dextrose.
214719430|NCT06410924|DRUG|DD01|Dual GLP-1 and glucagon receptor agonist
214719431|NCT06410924|DRUG|Placebo|Placebo matching DD01
214719432|NCT02559752|OTHER|NIH Toolbox Cognitive Battery|"* For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
214719433|NCT03499613|OTHER|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
214719434|NCT00516958|DRUG|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
214719435|NCT00516958|DRUG|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
214719436|NCT00516958|DRUG|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
214719437|NCT03892525|DRUG|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
214719438|NCT03892525|DRUG|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
214719439|NCT05523804|PROCEDURE|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
214719440|NCT05523804|PROCEDURE|delayed cytoreductive surgery|surgery after \>5 cycles of chemotherapy
214719441|NCT05523804|OTHER|no surgery|no cytoreductive surgery (\>5 cycles of chemotherapy alone)
214719442|NCT00323310|DRUG|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
214719443|NCT06257134|OTHER|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
214719444|NCT06257134|OTHER|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
214719445|NCT02929628|DEVICE|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
214719446|NCT00471783|PROCEDURE|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
214719447|NCT00446641|DRUG|Cilostazol|cilostazol 100mg twice a day for 4 weeks
214719448|NCT00446641|DRUG|placebo|placebo 1 tablet twice a day matching for cilostazol
214719449|NCT04143425|DIAGNOSTIC_TEST|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
214719450|NCT04143425|DIAGNOSTIC_TEST|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
214719451|NCT04143425|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
214719452|NCT04236219|DRUG|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
214719453|NCT04236219|DRUG|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
214719454|NCT03368352|DIETARY_SUPPLEMENT|Melatonin|Dietary supplement melatonin
214719455|NCT03368352|OTHER|Hypoxia|Sleep in a hypoxic tent simulating high altitude
214719456|NCT02736396|OTHER|fMRI|Functional MRI scan to be performed
214719457|NCT02736396|OTHER|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
214719458|NCT01689324|BIOLOGICAL|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
214719459|NCT00004300|DRUG|bromocriptine|
214627557|NCT05522608|PROCEDURE|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
214627558|NCT05376228|DRUG|Oral Vancomycin|As part of standard of care
214627559|NCT04017481|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
214627560|NCT04017481|OTHER|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
214627561|NCT01560000|DIETARY_SUPPLEMENT|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
214627562|NCT06785324|BEHAVIORAL|Nutrition Intervention|"The nutrition intervention will target a 10% caloric deficit calculated from each patient's Basal Metabolic Rate (WHO/Schofield) utilizing a high protein (\>25%), low fat (\<25%), low glycemic index/high fiber (45-55%) diet.~The study registered dietician (RD) will meet with the patient on day of enrollment to go over the menu of dietary options and will re-assess the patient every two days (excluding weekends) for adherence.~My Plate (USDA) will control portion size and eating habits."
214627563|NCT06785324|BEHAVIORAL|Exercise intervention|"The exercise intervention will target 200 minutes of moderate physical activity weekly, as defined by Metabolic Equivalents (METs) of 3-6, made up of aerobic and resistance training activities tailored to the patient's preference by working with the study physical therapist (PT).~Physical Therapist to evaluate patient every 48 hours, excluding weekends."
214627564|NCT02484911|DRUG|Olanzapine|5mg,twice a day orally on day 1 to day 4
214627565|NCT02484911|DRUG|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
214627566|NCT02484911|DRUG|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
214627567|NCT02484911|DRUG|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
214719460|NCT00004300|DRUG|sertraline hydrochloride|
214719461|NCT02049229|DEVICE|percutaneous coronary intervention|Optimax-stent implantation
214719462|NCT02049229|DEVICE|percutaneous coronary intervention|Synergy stent implantation
214719463|NCT03565991|DRUG|Avelumab|IV treatment
214719464|NCT03565991|DRUG|Talazoparib|Oral treatment
214719465|NCT03073382|OTHER|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
214719466|NCT04127240|OTHER|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
214719467|NCT05914740|PROCEDURE|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
214719468|NCT01826448|DRUG|PLX3397|
214719469|NCT01826448|DRUG|vemurafenib|
214719470|NCT02833818|DIETARY_SUPPLEMENT|CAKE-intervention|Increased protein and energy supplementation and conversations
214719471|NCT02833818|DIETARY_SUPPLEMENT|CAKE-control|nutrition according to established procedures
214719472|NCT05769907|BEHAVIORAL|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
214719473|NCT01038089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
214719474|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
214719475|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
214719476|NCT00381589|DRUG|ipratropium bromide 0.03% spray|
214719477|NCT04800094|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
214719478|NCT02490839|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
214719479|NCT02490839|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
214719480|NCT05339204|PROCEDURE|allo-HSCT|allo-HSCT from any type of donor
214719481|NCT05402904|DIAGNOSTIC_TEST|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
214719482|NCT00059319|PROCEDURE|single aorta clamp with retrograde cardioplegia|
214719483|NCT00059319|PROCEDURE|multiple aorta clamps with antegrade cardioplegia|
214719484|NCT04336007|DEVICE|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
214719485|NCT04336007|DEVICE|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
214719486|NCT04336007|OTHER|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
214719487|NCT05302804|DRUG|Menthol Gel|5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
214719488|NCT05302804|DRUG|Control Gel|Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
214719489|NCT00706758|BEHAVIORAL|IBS school|Structured patient group education
214719490|NCT00706758|BEHAVIORAL|IBS-guidebook|Written information - IBS-guidebook
214719491|NCT01086904|BIOLOGICAL|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
214719492|NCT00797810|DRUG|Rituximab|
214719493|NCT04672317|DRUG|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
214719494|NCT06120192|BEHAVIORAL|Piano|Receives the piano training
214719495|NCT03582839|BEHAVIORAL|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
214719496|NCT01017666|DRUG|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
214719497|NCT01017666|DRUG|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
214719498|NCT00442611|DRUG|Abatacept|
214719499|NCT00442611|DRUG|Placebo|
214719500|NCT02726607|BEHAVIORAL|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
214719501|NCT02726607|BEHAVIORAL|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
214719502|NCT02108223|DRUG|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
214719503|NCT02108223|DRUG|r-LH supplementation|recombinant luteinizing hormone
214719504|NCT02108223|DRUG|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
214719505|NCT02947490|OTHER|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
214719506|NCT02947490|OTHER|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
214719507|NCT02947490|OTHER|Standard BP management|GP to measure BP and manage BP control
214719508|NCT02947490|OTHER|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
214719509|NCT04695418|DIETARY_SUPPLEMENT|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
214719510|NCT04695418|COMBINATION_PRODUCT|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
214719511|NCT02252068|BEHAVIORAL|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
214719512|NCT02252068|BEHAVIORAL|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
214719513|NCT04944927|OTHER|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
214719514|NCT02352649|DRUG|Neovasculgen|
214719515|NCT03250624|DRUG|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
214719516|NCT03250624|DRUG|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
214627568|NCT02387255|DEVICE|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
214627569|NCT00274027|DRUG|tiotropium bromide|
214627570|NCT04226820|OTHER|examination: blood pressure assessment|blood pressure measurement for 30 minutes, dominant side
214627571|NCT04226820|OTHER|examination: Flow Mediated Dilatation (FMD)-test|Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality
214627572|NCT04226820|OTHER|examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring|participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation
214627573|NCT04226820|OTHER|examination: measurement of glucose by a finger prick|follow-up of blood sugar (glucose) during examinations by a finger prick
214627574|NCT04129528|DRUG|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
214627575|NCT04129528|OTHER|Placebo|Placebo for active drug
214627576|NCT01347151|DEVICE|The glidescope video laryngoscopy|
214627577|NCT01347151|DEVICE|The Pentax airwayscope|
214627578|NCT04194099|DEVICE|20 Hz rTMS (Brain)|Higher frequency (\>5 Hz) trains increase cortical excitability.
214627579|NCT04194099|DEVICE|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
214627580|NCT04194099|DEVICE|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
214627581|NCT04194099|DEVICE|20 Hz current square-wave pulses (Spinal)|Higher frequency (\>5 Hz) of current increase cortical excitability.
214627582|NCT04194099|DEVICE|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
214627583|NCT04194099|DEVICE|sham|with sham stimulation on brain and spinal.
214627584|NCT01156584|BIOLOGICAL|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
214627585|NCT01156584|DRUG|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
214627586|NCT04753827|OTHER|Drug eluting stent|Put a Drug eluting stent in the blood vessel
214627587|NCT04753827|OTHER|Durg coated balloon|Put a Durg coated balloon in the blood vessel
214627588|NCT03670875|DIETARY_SUPPLEMENT|Agave inulin|Will be provided in dehydrated apple cubes
214627589|NCT03670875|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
214627590|NCT03670875|DIETARY_SUPPLEMENT|O3FA|Will be provided in capsules
214627591|NCT03670875|BEHAVIORAL|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
214627592|NCT05149690|OTHER|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
214719517|NCT01597440|DRUG|N-carbamylglutamate|"Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
214719518|NCT01597440|OTHER|Standard of Care|Standard of Care
214719519|NCT01951911|DRUG|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
214719520|NCT01951911|DRUG|Placebo|
214719521|NCT05166486|OTHER|Calisthenic exercise|"Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks."
214719522|NCT04672031|OTHER|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
214719523|NCT04241120|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
214719524|NCT04241120|BEHAVIORAL|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
214719525|NCT02617706|DEVICE|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
214719526|NCT03945656|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
214719527|NCT03945656|DRUG|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
214719528|NCT01656018|DRUG|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
214719529|NCT01069809|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
214719530|NCT01069809|BIOLOGICAL|Placebo|Inactive Placebo Injection
214719531|NCT04395989|DRUG|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719532|NCT04395989|DRUG|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719533|NCT04395989|DRUG|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719534|NCT04395989|DRUG|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719535|NCT04395989|DRUG|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
214719536|NCT04395989|DRUG|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719537|NCT04395989|DRUG|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
214719538|NCT04395989|DRUG|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
214719539|NCT04395989|DRUG|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719540|NCT04395989|DRUG|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
214719541|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
214719542|NCT02515188|DRUG|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
214719543|NCT02515188|DRUG|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
214627593|NCT05149690|OTHER|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
214627594|NCT05182957|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
214627595|NCT05182957|DRUG|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
214627596|NCT05182957|DRUG|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
214627597|NCT05361772|DRUG|colchicine|colchicine 0.5mg per day for 24 months
214627598|NCT05361772|DRUG|Placebo|placebo 0.5mg per day for 24 months
214627599|NCT01258504|DRUG|St. Johns Wort|"* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
214627600|NCT01682135|BIOLOGICAL|Ramucirumab|Administered IV.
214719544|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
214627601|NCT02372474|BIOLOGICAL|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
214627602|NCT04315519|OTHER|Exercise|Aerobic Exercise
214627603|NCT03632421|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214627604|NCT03632421|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214627605|NCT05196659|BEHAVIORAL|Integrated comprehensive cardiovascular disease management|"1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   \- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team"
214627606|NCT04956159|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
214627607|NCT04956159|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
214627608|NCT06519786|DRUG|Metformin|Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
214719545|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
214719546|NCT06103591|DEVICE|The EmStop Embolic Protection System (EmStop System)|The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
214719547|NCT06441227|DRUG|HRS-5346 tablets|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
214719548|NCT06441227|DRUG|placebo|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
214719549|NCT02708992|DRUG|Azithromycin|
214719550|NCT02708992|DRUG|Cefixime|
214719551|NCT00798473|DRUG|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
214719552|NCT00798473|OTHER|IV saline infusion|
214627609|NCT03065348|DIETARY_SUPPLEMENT|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
214719553|NCT01591993|PROCEDURE|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
214719554|NCT01591993|PROCEDURE|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
214719555|NCT04484506|DRUG|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
214719556|NCT00794859|DRUG|Sorafenib|400mg twice daily
214719557|NCT02969694|OTHER|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
214719558|NCT02172846|RADIATION|Proton beam radiation therapy (PBT)|
214719559|NCT02172846|DRUG|Paclitaxel|
214719560|NCT02172846|DRUG|Carboplatin|
214719561|NCT01116310|DRUG|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
214719562|NCT01116310|DRUG|Placebo|Bottles containing 60 capsules.
214719563|NCT03556332|DRUG|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
214719564|NCT03556332|DRUG|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
214719565|NCT03556332|DRUG|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
214719566|NCT03556332|DRUG|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
214627610|NCT03065348|DIETARY_SUPPLEMENT|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
214627611|NCT03065348|DIETARY_SUPPLEMENT|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal"
214719567|NCT03556332|PROCEDURE|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
214719568|NCT02744560|DIETARY_SUPPLEMENT|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
214719569|NCT00185536|BEHAVIORAL|Packaging and identification of source|
214719570|NCT06148649|DRUG|HEC88473, Placebo, Dulaglutide|T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
214719571|NCT03008187|DRUG|MEN1703|MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
214719572|NCT00500838|DEVICE|Transthoracic Impedance|Impedance measures will be automatically collected via the device
214719573|NCT00715013|DRUG|Patupilone|Patupilone
214719574|NCT03613818|BEHAVIORAL|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
214719575|NCT04882358|DEVICE|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
214719576|NCT04882358|DRUG|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
214719577|NCT04128605|PROCEDURE|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
214719578|NCT04128605|PROCEDURE|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
214627612|NCT03065348|OTHER|Preoperative hydration|If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
214627613|NCT03065348|OTHER|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
214627614|NCT00187421|PROCEDURE|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
214627615|NCT00414102|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
214627616|NCT00414102|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
214627617|NCT02849795|OTHER|bone densitometry|
214627618|NCT02849795|OTHER|questionnaires|
214627619|NCT02849795|OTHER|biological analyses|
214627620|NCT05347888|OTHER|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
214627621|NCT01876407|DEVICE|Low intensity laser for oral mucositis|
214627622|NCT01876407|DEVICE|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
214627623|NCT00044577|DRUG|abacavir/lamivudine|
214627624|NCT00044577|DRUG|abacavir|
214627625|NCT00044577|DRUG|lamivudine|
214627626|NCT00044577|DRUG|tenofovir|
214627627|NCT06309459|DIAGNOSTIC_TEST|Carbonic anhydrase staining levels|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
214627628|NCT06519019|PROCEDURE|Dental Implant Surgery - Hydrophilic group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
214627629|NCT06519019|PROCEDURE|Dental Implant Surgery - Conventional group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
214627630|NCT01964352|DRUG|tiotropium|fixed dose combination
214627631|NCT01964352|DRUG|placebo|
214627632|NCT01964352|DRUG|olodaterol|fixed dose combination
214627633|NCT01964352|DRUG|tiotropium|fixed dose combination
214627634|NCT01964352|DRUG|tiotropium|
214627635|NCT01964352|DRUG|olodaterol|fixed dose combination
214627636|NCT04220996|DRUG|Vortioxetine|Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
214627637|NCT04278612|OTHER|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
214719579|NCT05543824|DRUG|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
214719580|NCT03012594|DRUG|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
214719581|NCT04890561|DRUG|Lemborexant|Lemborexant oral tablets.
214719582|NCT03381625|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
214719583|NCT03381625|DRUG|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
214719584|NCT04105322|OTHER|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
214719585|NCT03962634|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
214719586|NCT03962634|DRUG|Articaine Injection|Local anesthetic
214719587|NCT02264015|DRUG|Cilobradine, low, film-coated tablets|
214719588|NCT02264015|DRUG|Cilobradine, high, film-coated tablets|
214719589|NCT02264015|DRUG|Placebo, film-coated tablets|
214719590|NCT02264015|DRUG|Moxifloxacin, film-coated tablets|
214719591|NCT02542670|GENETIC|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
214719592|NCT02939313|DEVICE|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
214627638|NCT03616678|DEVICE|VenTouch System|"The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester."
214719593|NCT02939313|DEVICE|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
214719594|NCT02939313|DEVICE|sham|sham stimulation
214719595|NCT06156449|OTHER|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
214719596|NCT01510028|BIOLOGICAL|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
214719597|NCT00837239|DRUG|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
214719598|NCT00837239|DRUG|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
214719599|NCT00837239|DRUG|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
214719600|NCT06948331|DEVICE|PuraStat|Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.
214719601|NCT01349075|RADIATION|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
214719602|NCT01709214|DRUG|Cebranopadol (GRT6005) Low-Dose Range|Capsules
214719603|NCT01709214|DRUG|Cebranopadol (GRT6005) High-Dose Range|Capsules
214719604|NCT01709214|DRUG|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
214719605|NCT01709214|DRUG|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
214719606|NCT03235726|DRUG|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
214719607|NCT03235726|DRUG|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
214719608|NCT03528590|DEVICE|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
214719609|NCT03528590|DEVICE|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
214719610|NCT06272357|OTHER|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
214627639|NCT00477165|DRUG|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
214627640|NCT00477165|DRUG|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
214627641|NCT03159858|DEVICE|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
214627642|NCT00846014|DRUG|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
214627643|NCT05118256|DRUG|Pirfenidone Oral Tablet|Patients will be treated with pirfenidone (oral tablets) during 6 months
214627644|NCT03351257|OTHER|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
214627645|NCT00105443|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
214627646|NCT00105443|DRUG|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
214627647|NCT01864278|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
214627648|NCT02135692|BIOLOGICAL|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
214627649|NCT02135692|DRUG|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
214627650|NCT01056250|PROCEDURE|SILS cholangiography|intraoperative
214627651|NCT05842187|PROCEDURE|Biopsy of tumor tissue for organoid culture|By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
214627652|NCT00246532|DRUG|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
214627653|NCT00246532|DRUG|Placebo|Patients will receive placebo tablets.
214627654|NCT00144898|PROCEDURE|Sentinel Node Resection|Sentinel Node Resection
214627655|NCT00144898|PROCEDURE|Conventional Axillary Dissection|Conventional Axillary Dissection
214627656|NCT03976037|DRUG|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
214627657|NCT06367881|DRUG|Alveofact|Intratracheal High-dose Alveofact versus Low-dose Alveofact with or without Budesonide
214719611|NCT05325944|BEHAVIORAL|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
214719612|NCT05325944|BEHAVIORAL|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
214627658|NCT06367881|DRUG|Budesonide|Budesonide
214627659|NCT01099072|DRUG|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo
214627660|NCT01099072|DRUG|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
214627661|NCT01157078|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
214719613|NCT05325944|BEHAVIORAL|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
214719614|NCT04521920|DRUG|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
214627662|NCT01157078|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
214627663|NCT04448587|DRUG|Sitagliptin 100mg|Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
214627664|NCT05069987|OTHER|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax \& Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
214627665|NCT05689411|DEVICE|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
214627666|NCT03187769|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
214627667|NCT03187769|DRUG|Olanzapine|Daily oral dosing
214627668|NCT00250614|DRUG|Saredutant succinate (SR48968C)|
214627669|NCT01175785|PROCEDURE|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood transplant
214627670|NCT01175785|DRUG|fludarabine phosphate|Given IV
214627671|NCT01175785|DRUG|cyclophosphamide|Given IV
214627672|NCT01175785|BIOLOGICAL|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
214627673|NCT01175785|RADIATION|total-body irradiation|Undergo TBI
214627674|NCT01175785|DRUG|cyclosporine|Given IV
214627675|NCT01175785|DRUG|mycophenolate mofetil|Given IV and PO
214627676|NCT01175785|OTHER|laboratory biomarker analysis|Correlative studies
214627677|NCT04378283|DRUG|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)|The study is designed to evaluate topical anesthetics
214627678|NCT04378283|DRUG|EMLA plus infiltration as anesthetic for wound repair.|EMLA plus infiltration as anesthetic for wound repair.
214627679|NCT06364449|OTHER|No intervention|No intervention
214627680|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
214627681|NCT06167785|DRUG|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks
214627682|NCT06167785|DRUG|Zanubrutinib|Zanubrutinib 160 mg oral twice daily
214627683|NCT06167785|DRUG|Tislelizumab + Zanubrutinib|Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
214627684|NCT01793155|OTHER|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
214627685|NCT01793155|OTHER|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
214627686|NCT02597738|OTHER|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
214627687|NCT02597738|OTHER|Blood/Urine Sample Collection|A one time blood sample will be collected.
214719615|NCT04521920|DRUG|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
214719616|NCT03423563|DEVICE|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
214627688|NCT02198807|DRUG|Fosmidomycin-Piperaquine|
214627689|NCT05495893|DRUG|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
214627690|NCT05495893|DRUG|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
214627691|NCT04429061|BEHAVIORAL|SKILLZ-Girl curriculum|Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
214627692|NCT04314921|OTHER|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
214627693|NCT03103802|DEVICE|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
214627694|NCT05464303|DRUG|Intravenous Antibodies|Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
214627695|NCT00622648|DRUG|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
214627696|NCT00622648|DRUG|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
214627697|NCT03964961|OTHER|Functional massage|It's a massage combined with a stretching of the muscles.
214627698|NCT03964961|OTHER|Conventional massage|It's a regular massage made with the therapist's hands.
214627699|NCT04500977|BEHAVIORAL|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
214627700|NCT03186677|BIOLOGICAL|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous
214627701|NCT03186677|BIOLOGICAL|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
214627702|NCT03108313|DRUG|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
214627703|NCT03108313|DRUG|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
214627704|NCT03766048|PROCEDURE|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
214627705|NCT03766048|PROCEDURE|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
214627706|NCT05317520|PROCEDURE|Cold vapor|"The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated."
214627707|NCT00879229|DRUG|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
214627708|NCT00879229|DRUG|Placebo|Placebo to match ambrisentan administered orally once daily.
214627709|NCT02085889|OTHER|no intervention: observational study|observational
214627710|NCT05094700|OTHER|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
214627711|NCT01097746|BIOLOGICAL|Bevacizumab|Given IV
214627712|NCT01097746|DRUG|Carboplatin|Given IV
214627713|NCT01097746|DRUG|Paclitaxel|Given IV
214627714|NCT01227733|OTHER|Breast Tumor Blocks|
214719617|NCT03423563|DEVICE|Fexible intubation video endoscopy|Fexible intubation video endoscopy
214719618|NCT01307553|DEVICE|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
214719619|NCT03895918|OTHER|Educational Activity|Undergo parenting skills intervention
214627715|NCT05071950|OTHER|Control period|"* first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal"
214627716|NCT05071950|DIETARY_SUPPLEMENT|D-allulose period|"* \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose"
214627717|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
214627718|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
214627719|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
214627720|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
214627721|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
214627722|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
214627723|NCT04762537|OTHER|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
214627724|NCT04762537|OTHER|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
214627725|NCT00208221|DRUG|ramipril|
214627726|NCT00208221|DRUG|ramipril-telmisartan|
214627727|NCT00549458|BEHAVIORAL|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
214719620|NCT03895918|PROCEDURE|Patient Monitoring|Undergo medication adherence monitoring
214719621|NCT03895918|OTHER|Questionnaire Administration|Ancillary studies
214627728|NCT00549458|PROCEDURE|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
214627729|NCT00000859|DRUG|Indinavir sulfate|
214627730|NCT00000859|DRUG|Ritonavir|
214627731|NCT00000859|DRUG|Nelfinavir mesylate|
214627732|NCT04628637|OTHER|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
214627733|NCT03791788|DIAGNOSTIC_TEST|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
214627734|NCT03924609|DIAGNOSTIC_TEST|Intensive screening / routine screening|Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
214627735|NCT04179383|OTHER|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
214627736|NCT00390546|DRUG|Digoxin|
214627737|NCT00390546|DRUG|Propranolol|
214627738|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
214627739|NCT00631371|DRUG|Temsirolimus|Temsirolimus 25 mg IV weekly
214627740|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
214627741|NCT00631371|DRUG|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
214627742|NCT03670212|DRUG|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
214627743|NCT03670212|DRUG|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
214627744|NCT03670212|DRUG|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
214627745|NCT02241759|DRUG|TA-8995|
214627746|NCT02241759|DRUG|Moxifloxacin|
214627747|NCT02241759|DRUG|Placebo|
214627748|NCT04313127|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
214627749|NCT04893642|PROCEDURE|Suture rectopexy|
214627750|NCT04893642|PROCEDURE|resection rectopexy|
214627751|NCT04893642|PROCEDURE|Delorme's operation|
214627752|NCT04893642|PROCEDURE|Altemeier's operation|
214627753|NCT00489567|PROCEDURE|Blood sample collection|
214627754|NCT04117464|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
214627755|NCT04117464|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
214627756|NCT04117464|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
214627757|NCT04117464|OTHER|Wait List Group|No psychological intervention
214627758|NCT05007275|BIOLOGICAL|1x10^9 vp AZD1222|A single dose of 1x 10\^9 vp AZD1222
214627759|NCT05007275|BIOLOGICAL|5x10^9 vp AZD1222|A single dose of 5x 10\^9 vp AZD1222
214627760|NCT05007275|BIOLOGICAL|1x10^10 vp AZD1222|A single dose of 1x10\^10 vp AZD1222
214627761|NCT02836067|BEHAVIORAL|Counseling|Smoking cessation counseling
214627762|NCT02836067|OTHER|Smoking Cessation drugs|Medication to aid smoking cessation
214627763|NCT02836067|PROCEDURE|Bronchoscopy|Bronchoscopy
214627764|NCT02836067|PROCEDURE|Blood Draw|Screening and research blood draws
214627765|NCT02836067|BEHAVIORAL|Questionnaires|Behavioral questionnaires
214627766|NCT01093027|OTHER|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
214627767|NCT01093027|OTHER|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
214627768|NCT04286061|OTHER|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
214627769|NCT03992508|DEVICE|intermittent pneumatic compression|
214627770|NCT03992508|PROCEDURE|complex decongestive therapy|
214627771|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
214627772|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
214627773|NCT06073600|DRUG|Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
214627774|NCT06073600|DRUG|Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
214627775|NCT05088304|OTHER|no intervention|
214627776|NCT03962439|BEHAVIORAL|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
214627777|NCT03962439|BEHAVIORAL|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
214627778|NCT03962439|BEHAVIORAL|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
214627779|NCT02526706|OTHER|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
214627780|NCT05558839|BEHAVIORAL|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
214627781|NCT00665457|BIOLOGICAL|filgrastim|
214627782|NCT00665457|DRUG|capecitabine|
214627783|NCT00665457|DRUG|celecoxib|
214719622|NCT04897646|OTHER|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. \[Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal\]. Rev. Mal. Respir., 2020, 37: 550-560."
214719623|NCT05062551|PROCEDURE|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
214627784|NCT00665457|DRUG|cyclophosphamide|
214719624|NCT02556411|DRUG|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
214719625|NCT02556411|DRUG|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
214719626|NCT01721148|DRUG|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
214627785|NCT00665457|DRUG|docetaxel|
214627786|NCT00665457|DRUG|doxorubicin hydrochloride|
214627787|NCT00665457|GENETIC|gene expression analysis|
214627788|NCT00665457|GENETIC|polymorphism analysis|
214627789|NCT00665457|GENETIC|protein expression analysis|
214627790|NCT00665457|GENETIC|reverse transcriptase-polymerase chain reaction|
214627791|NCT00665457|OTHER|imaging biomarker analysis|
214627792|NCT00665457|OTHER|immunohistochemistry staining method|
214627793|NCT00665457|OTHER|laboratory biomarker analysis|
214627794|NCT00665457|OTHER|pharmacogenomic studies|
214627795|NCT00665457|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214627796|NCT00665457|PROCEDURE|needle biopsy|
214627797|NCT00665457|PROCEDURE|neoadjuvant therapy|
214627798|NCT00665457|PROCEDURE|radiomammography|
214627799|NCT00665457|PROCEDURE|ultrasound imaging|
214627800|NCT04195321|DRUG|Norepinephrine|infusion will be started after induction of spinal anesthesia
214627801|NCT04195321|DRUG|phenylephrine|infusion will be started after induction of spinal anesthesia
214719627|NCT03628495|DEVICE|compression|compression will be delivered using compression garment
214719628|NCT03628495|DEVICE|occlusion|occlusion will be delivered using silicone gel sheeting
214719629|NCT02680119|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
214719630|NCT02680119|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
214719631|NCT03432767|DEVICE|Non-invasive hemoglobin monitor|
214719632|NCT05539872|DRUG|I004|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
214719633|NCT05539872|DRUG|NovoLog|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
214719634|NCT02877316|OTHER|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
214719635|NCT02877316|OTHER|safety plan on paper|Standard treatment with safety plan on paper
214719636|NCT00510107|DRUG|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
214719637|NCT00510107|DRUG|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
214719638|NCT01952093|BEHAVIORAL|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
214719639|NCT01952093|BEHAVIORAL|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
214719640|NCT01544686|DEVICE|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
214719641|NCT02856906|OTHER|occlusal adjustment|
214719642|NCT04746560|DEVICE|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
214719643|NCT04430686|OTHER|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
214719644|NCT02314871|OTHER|Epidural analgesia|see Arm/group description
214719645|NCT02314871|DRUG|Piritramide|see Arm/group description
214719646|NCT02314871|DRUG|Morphine|see Arm/group description
214719647|NCT01263314|DRUG|MK-8266|Oral capsules, 0.1 mg potency
214719648|NCT01263314|DRUG|Placebo|Oral placebo capsules to match MK-8266 capsules
214719649|NCT00816283|DRUG|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
214719650|NCT00816283|DRUG|vorinostat|100 mg orally 2 times per day
214719651|NCT00816283|GENETIC|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
214719652|NCT00816283|GENETIC|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
214719653|NCT00816283|GENETIC|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
214719654|NCT00816283|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
214719655|NCT00816283|OTHER|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
214719656|NCT00816283|OTHER|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
214719657|NCT04071171|DRUG|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
214719658|NCT04071171|DRUG|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
214719659|NCT04071171|DRUG|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
214719660|NCT04071171|DRUG|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
214719661|NCT04331925|BEHAVIORAL|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
214719662|NCT04331925|BEHAVIORAL|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
214627802|NCT06307912|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
214627803|NCT06307912|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
214627804|NCT01554280|DEVICE|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
214627805|NCT01735487|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
214627806|NCT01735487|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
214627807|NCT01735487|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
214627808|NCT01735487|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
214627809|NCT01735487|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
214627810|NCT00291408|PROCEDURE|Skin Prick Test|
214627811|NCT00291408|PROCEDURE|Impulse Oscillometry|
214627812|NCT00291408|PROCEDURE|Exhaled Nitric Oxide|
214627813|NCT00291408|PROCEDURE|Spirometry|
214627814|NCT00291408|PROCEDURE|Reversibility|
214719663|NCT00995267|BEHAVIORAL|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
214719664|NCT00623285|DRUG|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
214627815|NCT00291408|PROCEDURE|Exhaled Breath Condensate|
214627816|NCT00291408|PROCEDURE|Sputum Induction|
214627817|NCT05348655|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease
214627818|NCT05348655|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
214627819|NCT01526902|DEVICE|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
214627820|NCT01526902|DEVICE|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
214627821|NCT04578795|DEVICE|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
214627822|NCT00812214|DRUG|eszopiclone|3 mg tablet every night at bedtime
214627823|NCT00812214|DRUG|placebo|1 tablet every night at bedtime
214627824|NCT01091701|BIOLOGICAL|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
214627825|NCT01091701|OTHER|Plasmalyte-A|Single IV dose of Plasmalyte-A
214627826|NCT01564355|DEVICE|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
214627827|NCT01564355|DRUG|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
214627828|NCT00046774|DRUG|MRA 003 US|
214627829|NCT02289222|DRUG|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
214627830|NCT02289222|DRUG|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
214627831|NCT02289222|DRUG|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
214627832|NCT04603573|DEVICE|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
214627833|NCT04603573|DEVICE|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
214627834|NCT06118684|DRUG|EP395 (Part A and B)|"EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg."
214627835|NCT06118684|DRUG|Verapamil (Part A)|Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
214627836|NCT06118684|DRUG|Midazolam (Part B)|Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
214627837|NCT06118684|DRUG|Digoxin (Part B)|Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
214627838|NCT04462952|DRUG|Adavosertib (AZD1775)|Adavosertib taken orally
214627839|NCT00636766|DRUG|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
214627840|NCT00636766|DRUG|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
214627841|NCT00636766|DRUG|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
214627842|NCT00636766|DRUG|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
214627843|NCT03080298|DRUG|BP101|
214627844|NCT03080298|DRUG|Placebo|
214627845|NCT02145741|DRUG|750 milligram Xentuzumab|750 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
214627846|NCT02145741|DRUG|1000 milligram Xentuzumab|1000 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
214627847|NCT02145741|DRUG|1400 milligram Xentuzumab|1400 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
214627848|NCT06406192|DIAGNOSTIC_TEST|Height, Weight, and Blood Pressure Measurement Procedures Improvement|"In the intervention group, the investigators improve the process of measuring blood pressure, height, and weight, requiring timely recording of these measurements. The intervention includes:~i. Enlisting the assistance of nurses and volunteers to improve the accessibility of measurement environments and provide guidance on instrument operation.~ii. Using paper reminders at check-in stations to prompt patients to complete blood pressure and weight recordings before entering examination rooms; providing paper for recording if patients forget their health insurance cards.~iii. Providing alcohol and hand wipes outside examination rooms for disinfecting measurement instruments.~iv. Promoting the recording mode outside the check-in station.~v. Ensuring that physicians or nurses in examination rooms accurately record measurements in the medical order system.~vi. Encouraging patients to ask physicians during consultations, Is my blood pressure and weight okay?"
214627849|NCT01192022|BIOLOGICAL|TachoSil®|Intraoperative application as secondary hemostatic treatment
214627850|NCT01192022|DEVICE|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
214627851|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
214627852|NCT06168292|PROCEDURE|ID-RFA and Radiotherapy|The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
214627853|NCT06246565|DRUG|HS-10383|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
214627854|NCT06246565|DRUG|HS-10383 Placebo|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
214627855|NCT06081803|DRUG|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
214627856|NCT06490913|DRUG|Capecitabine|1000mg/m2, bid, d1-d14，q3w，1cycle
214627857|NCT06490913|DRUG|oxaliplatin|130mg/m2, ivgtt, d1，q3w，1cycle
214627858|NCT06490913|DRUG|Cetuximab|cetuximab 500mg/m2, q2w
214627859|NCT06490913|DRUG|Oxaliplatin|85mg/m2, d1,q2w
214627860|NCT06490913|DRUG|Leucovorin|400mg/m2, d1,q2w
214627861|NCT06490913|DRUG|5-FU|400mg/m2，d1,q2w
214627862|NCT01692964|DEVICE|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
214627863|NCT00129766|BIOLOGICAL|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
214627864|NCT00129766|BIOLOGICAL|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
214627865|NCT02181829|RADIATION|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
214627866|NCT03865706|DRUG|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
214627867|NCT03865706|DRUG|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
214627868|NCT03865706|DRUG|Broad-spectrum antibiotics|Standard of care treatment for infections
214627869|NCT00278421|BIOLOGICAL|rituximab|
214627870|NCT00278421|DRUG|cyclophosphamide|
214627871|NCT00278421|DRUG|doxorubicin hydrochloride|
214627872|NCT00278421|DRUG|prednisone|
214627873|NCT00278421|DRUG|vincristine sulfate|
214627874|NCT03496909|BEHAVIORAL|Standard OT|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
214627875|NCT03496909|BEHAVIORAL|PhysioTouch|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
214627876|NCT04989582|OTHER|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
214627877|NCT02631330|OTHER|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
214627878|NCT06010966|DEVICE|rTMS|intermittent theta-burst stimulation (iTBS)
214627879|NCT05456477|OTHER|Beef|Beef entrees
214627880|NCT05456477|OTHER|Poultry|Poultry entrees
214627881|NCT04677348|PROCEDURE|Pericapsular nerve group (PENG) block|ultrasound-guided PENG block with 0.3% ropivacaine 20cc
214627882|NCT04677348|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
214627883|NCT06229795|DRUG|Green Tea Leaf Extract Decaffeinated|300 mg film coated tablet
214627884|NCT06229795|DRUG|Metformin Hydrochloride 500 MG|500 mg tablet
214627885|NCT04842084|BIOLOGICAL|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
214627886|NCT04986709|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
214627887|NCT01594853|BEHAVIORAL|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
214627888|NCT03628170|OTHER|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
214627889|NCT03628170|OTHER|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
214627890|NCT03709654|BIOLOGICAL|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
214627891|NCT03709654|OTHER|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
214627892|NCT01330238|DRUG|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
214627893|NCT03801668|DRUG|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
214627894|NCT03801668|DRUG|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
214627895|NCT02916355|DRUG|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
214627896|NCT02916355|DRUG|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
214627897|NCT02027103|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
214627898|NCT02027103|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
214627899|NCT00003625|DRUG|cyclosporine|
214627900|NCT00003625|DRUG|etoposide|
214627901|NCT00003625|DRUG|vincristine sulfate|
214627902|NCT00003625|RADIATION|radiation therapy|
214627903|NCT04835636|BEHAVIORAL|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
214627904|NCT03226145|PROCEDURE|MRI Motility|MRI sequence to assess colonic motility
214627905|NCT03226145|PROCEDURE|High Resolution Manometry|HRM of colon to assess motility
214719665|NCT00623285|DRUG|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
214627906|NCT03226145|DRUG|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
214627907|NCT03226145|DRUG|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
214627908|NCT05681507|DRUG|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
214627909|NCT05681507|PROCEDURE|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
214627910|NCT02642133|PROCEDURE|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
214627911|NCT01515787|DRUG|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
214627912|NCT01515787|OTHER|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
214627913|NCT01515787|PROCEDURE|surgery|low anterior resection with total mesorectal excision
214627914|NCT01515787|PROCEDURE|magnetic resonance imaging or endorectal ultrasound|
214627915|NCT03741998|DEVICE|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
214627916|NCT02631200|BEHAVIORAL|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
214627917|NCT03174132|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
214627918|NCT03174132|DEVICE|Restylane Perlane|Intradermal injection
214627919|NCT00948870|DRUG|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
214627920|NCT04583098|OTHER|fecal microbiota transplantation|frozen or capsulized stool from donors who had already finished recommended blood \& stool screening for stool donors
214627921|NCT05939843|BEHAVIORAL|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
214627922|NCT05939843|BEHAVIORAL|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
214627923|NCT05939843|BEHAVIORAL|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
214627924|NCT05939843|BEHAVIORAL|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
214719666|NCT04771546|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
214627925|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
214719667|NCT04250025|PROCEDURE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
214719668|NCT02551913|BEHAVIORAL|Control|the adolescents will not receive any specific intervention
214627926|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
214627927|NCT05974631|BEHAVIORAL|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
214627928|NCT05974631|BEHAVIORAL|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
214627929|NCT01081912|DRUG|Placebo|Capsules, no active substance, shells identical to active comparator capsules
214627930|NCT01081912|DRUG|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
214627931|NCT05374252|DRUG|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
214627932|NCT05374252|RADIATION|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
214627933|NCT02750033|DEVICE|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
214627934|NCT05564143|PROCEDURE|EUS-guided gastroenterostomy (EUS-GE)|Treatment
214627935|NCT05564143|PROCEDURE|Laparoscopic gastroenterostomy (LGE)|Treatment
214627936|NCT06849076|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
214627937|NCT06849076|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
214627938|NCT01166022|OTHER|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
214627939|NCT03175900|DRUG|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
214627940|NCT03175900|DRUG|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
214627941|NCT03875898|OTHER|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
214627942|NCT03875898|OTHER|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
214627943|NCT00920673|PROCEDURE|MRI|MRI during 35 to 65 minutes
214627944|NCT01920880|OTHER|Quantitative Sensory Testing analysis|
214627945|NCT02868242|DRUG|LDV/SOF|Tablet(s) administered orally once daily
214627946|NCT04639622|DIAGNOSTIC_TEST|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
214627947|NCT01457807|DRUG|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
214627948|NCT01457807|DRUG|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
214627949|NCT01457807|DRUG|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
214627950|NCT01493453|GENETIC|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10\*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
214627951|NCT01854619|DEVICE|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
214627952|NCT01854619|DEVICE|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
214627953|NCT03867578|DIAGNOSTIC_TEST|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
214627954|NCT03867578|DIAGNOSTIC_TEST|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
214627955|NCT03867578|DIAGNOSTIC_TEST|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
214719669|NCT02551913|BEHAVIORAL|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
214719670|NCT01142544|OTHER|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
214719671|NCT00519883|OTHER|Exercise|
214719672|NCT00519883|OTHER|Supportive Care|
214719673|NCT00366418|DRUG|Rituximab|
214719674|NCT01590667|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
214719675|NCT01590667|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
214719676|NCT04645004|DRUG|Aspirin 81Mg Non-enteric coated Tab|one tab daily
214719677|NCT04260529|DRUG|CyPep-1|Intratumoral injection
214719678|NCT04260529|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
214719679|NCT02201667|DRUG|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
214719680|NCT02201667|DRUG|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
214719681|NCT02201667|DRUG|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
214719682|NCT02201667|PROCEDURE|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
214719683|NCT05154357|OTHER|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
214719684|NCT05154357|OTHER|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
214719685|NCT02945839|DRUG|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
214719686|NCT02945839|BEHAVIORAL|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
214719687|NCT02945839|BEHAVIORAL|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
214627956|NCT04020250|DEVICE|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
214627957|NCT03124823|DEVICE|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
214627958|NCT03776175|DRUG|PF-05221304 Monotherapy|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
214627959|NCT03776175|DRUG|PF-06865571 Monotherapy|Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
214627960|NCT03776175|DRUG|Placebo|Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
214627961|NCT03776175|DRUG|PF-05221304 and PF-06865571 Combination|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
214719688|NCT05723874|DRUG|BI 425809|BI 425809
214719689|NCT05723874|DRUG|bosentan|bosentan
214719690|NCT00130468|DRUG|Hyalgan (sodium hyaluronate)|
214719691|NCT01083225|BEHAVIORAL|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
214719692|NCT01083225|BEHAVIORAL|Treatment as usual|Treatment as usual, consultations
214627962|NCT06849245|BEHAVIORAL|A digital social intervention by primary care clinicians|"* Signposting to the online health community by explaining different sections of the website.~* Introducing norms and values for passive (just reading) and active (writing posts) participation.~* Motivation for engagement with the online health community, emphasising that it could be used ad hoc (e.g. when feeling unwell, or when they need information or emotional support).~* Problem solving with respect to any difficulties/concerns.~* Signing patients up to the online health community, by explaining terms and conditions.~* Explaining the differences between posting publicly and privately (public posts are shared with third parties whereas private messages to other users are not shared).~* Collection of baseline measures. Data will be entered into the study's online database.~Patients will leave the consultation with a leaflet summarising all procedural matters in relation to signing up with the online health community and a reminder of their username and password."
214627963|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2 in orange juice|1000 IU dose
214627964|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3 in orange juice|1000 IU
214627965|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2|capsule, 1000 IU
214627966|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3|capsule, 1000 IU
214627967|NCT01778114|OTHER|Placebo|Placebo
214627968|NCT02344888|DRUG|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
214627969|NCT02344888|DRUG|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
214627970|NCT04105374|DRUG|Extended Release Flucytosine|Given PO
214627971|NCT04105374|DEVICE|NovoTTF-100A Device|Receive Optune device
214627972|NCT04105374|OTHER|Quality-of-Life Assessment|Ancillary studies
214627973|NCT04105374|OTHER|Questionnaire Administration|Ancillary studies
214627974|NCT04105374|RADIATION|Radiation Therapy|Undergo radiation
214627975|NCT04105374|DRUG|Temozolomide|Given PO
214627976|NCT04105374|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214627977|NCT04105374|BIOLOGICAL|Vocimagene Amiretrorepvec|Given via intracranial injection
214627978|NCT02098174|DRUG|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214627979|NCT02098174|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214627980|NCT05261022|BEHAVIORAL|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
214627981|NCT00773812|DRUG|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
214627982|NCT00773812|DRUG|placebo|One pill is taken once daily.
214627983|NCT04464161|DIETARY_SUPPLEMENT|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
214627984|NCT00715832|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
214627985|NCT01148446|DRUG|Cyclophosphamide|750 mg/mq IV, day 1
214627986|NCT01148446|DRUG|Cyclophosphamide|50 mg/mq IV, day 1
214627987|NCT01148446|DRUG|Doxorubicin|50 mg/mq IV, day1
214627988|NCT01148446|DRUG|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
214627989|NCT01148446|DRUG|Prednisone|75 mg/mq IV, days 1-5
214627990|NCT01148446|DRUG|Prednisone|60 mg/mq IV/PO, days 1-5
214627991|NCT01148446|DRUG|Epirubicin|50 mg/mq IV, day 1
214627992|NCT01148446|DRUG|Vinblastine|5 mg/mq IV, day 1
214627993|NCT01148446|DRUG|Rituximab|375 mg/mq IV, day 1
214627994|NCT01148446|DRUG|G-CSF|300 µg tot., SC; days 7-11
214627995|NCT01312597|OTHER|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
214627996|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 1|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
214627997|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 2|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
214627998|NCT04434274|DRUG|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
214627999|NCT02229500|DIETARY_SUPPLEMENT|Inulin|
214628000|NCT02229500|DIETARY_SUPPLEMENT|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
214628001|NCT02229500|DIETARY_SUPPLEMENT|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
214628002|NCT03608943|OTHER|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
214628003|NCT04677712|DRUG|CCH-aaes|Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
214628004|NCT04677712|OTHER|Compression|Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.
214628005|NCT04677712|OTHER|Cold Packs|Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.
214628006|NCT04677712|DRUG|Arnica Gel|Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
214628007|NCT04677712|DRUG|INhance®|Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
214628008|NCT04677712|OTHER|PDL|Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
214628009|NCT00711100|OTHER|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
214628010|NCT00711100|OTHER|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
214628011|NCT00711100|OTHER|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
214628012|NCT00711100|OTHER|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
214628013|NCT00711100|OTHER|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
214628014|NCT05815303|DRUG|Cadonilimab|10mg/kg iv on day 1, every 21 day
214628015|NCT05815303|DRUG|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
214628016|NCT05815303|DRUG|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
214628017|NCT01117636|DRUG|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
214628018|NCT01117636|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
214628019|NCT01117636|DRUG|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
214628020|NCT04519892|OTHER|PDRC|Personalized depression risk communication.
214628021|NCT04519892|OTHER|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
214628022|NCT01065688|PROCEDURE|Roux-en Y reconstruction|surgical procedure
214628023|NCT01065688|PROCEDURE|Billroth-I reconstruction|surgical procedure
214628024|NCT04479566|DRUG|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
214628025|NCT04479566|DRUG|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
214628026|NCT04322773|DRUG|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
214628027|NCT04322773|DRUG|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
214628028|NCT04322773|DRUG|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
214628029|NCT04322773|OTHER|Standard medical care|management as usual
214628030|NCT05241080|OTHER|Survey|It is a survey based on questionnaire
214628031|NCT01123252|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
214628032|NCT01123252|DIETARY_SUPPLEMENT|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
214628033|NCT02513329|DRUG|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
214628034|NCT02513329|DRUG|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
214628035|NCT03317756|OTHER|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
214628036|NCT03317756|OTHER|Patient Control|Patients will receive an attention control
214628037|NCT03962205|BEHAVIORAL|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
214628038|NCT03962205|BEHAVIORAL|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
214628039|NCT03962205|OTHER|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
214628040|NCT02121366|PROCEDURE|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
214628041|NCT05707091|OTHER|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
214628042|NCT05707091|PROCEDURE|Conventional therapy|Group B treated with ems and exercises
214719693|NCT03224104|DRUG|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
214719694|NCT03224104|RADIATION|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
214719695|NCT03224104|DRUG|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
214719696|NCT03612947|DRUG|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
214719697|NCT03612947|DRUG|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
214719698|NCT03436147|OTHER|POP-Q|Pelvic Organ Prolapse Quantification
214719699|NCT04211844|DRUG|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
214719700|NCT04211844|DRUG|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
214719701|NCT06212388|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
214719702|NCT06212388|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
214719703|NCT06212388|DRUG|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
214719704|NCT04642378|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
214719705|NCT04642378|DRUG|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
214719706|NCT01365013|BEHAVIORAL|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
214719707|NCT01365013|BEHAVIORAL|Control group|Standard advice for lifestyle change
214719708|NCT03395067|BEHAVIORAL|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
214628043|NCT01294670|DRUG|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
214628044|NCT02290795|OTHER|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
214628045|NCT03714529|BIOLOGICAL|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
214628046|NCT01871974|DRUG|FK949E|oral
214719709|NCT04419662|DRUG|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
214719710|NCT04419662|OTHER|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
214719711|NCT00678236|OTHER|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
214719712|NCT00678236|OTHER|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
214719713|NCT02169960|BEHAVIORAL|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
214719714|NCT02169960|BEHAVIORAL|Breaking Free|Online based intervention for Drug and Alcohol Use
214719715|NCT02169960|BEHAVIORAL|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
214719716|NCT02169960|BEHAVIORAL|Resiliency Training|Op Volle Kracht (OVK)
214719717|NCT00703430|DRUG|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
214628047|NCT04852848|BEHAVIORAL|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
214628048|NCT02042937|OTHER|Exercise|Exercise to improve gluteus maximus recruitment
214628049|NCT03981783|BEHAVIORAL|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
214628050|NCT03981783|BEHAVIORAL|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
214628051|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
214719718|NCT04314609|DEVICE|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
214719719|NCT00282568|DRUG|Tacrolimus Modified Release (MR)|Oral
214719720|NCT00282568|DRUG|tacrolimus|Oral
214719721|NCT00534924|DRUG|Vit C|
214719722|NCT00534924|PROCEDURE|Postconditioning|
214719723|NCT00534924|OTHER|no intervention|
214719724|NCT02645136|OTHER|Pilates|Pilates exercises
214719725|NCT02645136|OTHER|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
214719726|NCT02645136|OTHER|Control|
214719727|NCT03782844|DEVICE|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
214719728|NCT03782844|DEVICE|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
214719729|NCT03800433|DRUG|Trental 400 MG Extended Release Oral Tablet|oral tablets
214719730|NCT00032006|RADIATION|brachytherapy|
214719731|NCT00032006|RADIATION|radiation therapy|
214719732|NCT05375786|BIOLOGICAL|Vaccination completion status|the relation between vaccination completion status and the target population
214628052|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
214628053|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
214628054|NCT05677074|DIETARY_SUPPLEMENT|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
214628055|NCT05677074|DIETARY_SUPPLEMENT|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
214628056|NCT05677074|DIETARY_SUPPLEMENT|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
214628057|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
214628058|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
214628059|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
214628060|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
214628061|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
214628062|NCT01365663|DRUG|Saline 0.9%|3 Weekly SC injections
214628063|NCT05576402|PROCEDURE|colonoscopy|endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis
214628064|NCT06888830|DRUG|JS212 for Injection|JS212 for Injection is administered on the first day of the first cycle and every 3 weeks thereafter.
214628065|NCT02412787|DRUG|Idursulfase-IT|Participants received 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who were younger than 3 years of age received an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).
214628066|NCT02412787|DRUG|Elaprase|Participants received intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
214628067|NCT05836103|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
214628068|NCT02852031|OTHER|Collaborative Learning Network|
214628069|NCT05829135|DEVICE|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
214628070|NCT06223828|DRUG|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
214628071|NCT03113643|DRUG|Azacitidine|Chemotherapy
214628072|NCT03113643|DRUG|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
214628073|NCT03113643|DRUG|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
214628074|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
214719733|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
214719734|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
214719735|NCT02131389|DEVICE|Iconacy Hip System|
214719736|NCT02721446|BEHAVIORAL|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
214719737|NCT02721446|BEHAVIORAL|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
214719738|NCT02721446|BEHAVIORAL|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
214719739|NCT02721446|BEHAVIORAL|Incentive + Salience|Combined message of incentive plus salience.
214628075|NCT04278859|BIOLOGICAL|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
214628076|NCT06145724|BEHAVIORAL|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
214628077|NCT02339064|DRUG|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
214628078|NCT01303094|DRUG|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
214628079|NCT01303094|OTHER|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
214628080|NCT00945776|BEHAVIORAL|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
214628081|NCT00945776|BEHAVIORAL|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
214628082|NCT00945776|BEHAVIORAL|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
214628083|NCT00404014|DRUG|AL-208|1 dose of 300 mg
214628084|NCT00404014|DRUG|Placebo|1 dose of placebo
214628085|NCT00334022|DRUG|enfuvirtide|1ml BID
214628086|NCT06027359|OTHER|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~* Therapeutic play activities will not be performed with the children in the control group.~* One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
214628087|NCT03676621|DRUG|Misoprostol|buccal tablets
214628088|NCT03676621|DRUG|Oxytocin|intravenous drip
214628089|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
214628090|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
214719740|NCT03006926|DRUG|lenvatinib|4 mg capsules
214719741|NCT03006926|DRUG|pembrolizumab (200 mg)|30-minute intravenous infusion
214719742|NCT00332046|DRUG|GW679769|
214719743|NCT00423241|DEVICE|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
214719744|NCT00423241|DEVICE|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
214719745|NCT03234972|DRUG|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
214628091|NCT01032915|BIOLOGICAL|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
214628092|NCT01032915|DRUG|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
214628093|NCT05886790|BIOLOGICAL|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
214628094|NCT05886790|BIOLOGICAL|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
214628095|NCT05886790|BIOLOGICAL|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
214628096|NCT00883207|BEHAVIORAL|Psychotherapy|Narrative and dialogical approach for couples
214719746|NCT03234972|DRUG|Velcade|Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
214719747|NCT03234972|DRUG|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
214719748|NCT00611611|BIOLOGICAL|fluzone|once
214719749|NCT00611611|BIOLOGICAL|pneumovax|once
214719750|NCT00175071|BEHAVIORAL|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
214719751|NCT03554785|BEHAVIORAL|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
214719752|NCT01400074|DRUG|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
214719753|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg IV infusion.
214719754|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
214719755|NCT05287204|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
214628097|NCT02915523|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACi).
214628098|NCT02915523|DRUG|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
214628099|NCT02915523|DRUG|Placebo|A pill containing no active drug ingredient.
214628100|NCT03882814|DRUG|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
214628101|NCT03882814|DRUG|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
214628102|NCT01535170|DIETARY_SUPPLEMENT|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
214628103|NCT03742180|DRUG|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
214628104|NCT03742180|DRUG|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
214628105|NCT04010396|OTHER|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
214628106|NCT03940859|DEVICE|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
214628107|NCT05623579|BEHAVIORAL|Pain Neuroscience Education|8 Sessions of different pain education interventions
214628108|NCT05623579|BEHAVIORAL|Exercise|12 Sessions of Aerobic Exercise
214628109|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628110|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628111|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628112|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628113|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628114|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628115|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
214628116|NCT00848055|DRUG|AbGn168 subcutaneous injection|single dose subcutaneous injection
214628117|NCT02550886|OTHER|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
214628118|NCT00930761|BEHAVIORAL|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
214628119|NCT00915681|DRUG|Silibinin|20 mg/kg continuous IV is over 24 hours
214628120|NCT03141736|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
214628121|NCT03141736|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
214628122|NCT03141736|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
214628123|NCT03141736|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
214628124|NCT03255681|PROCEDURE|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
214628125|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
214628126|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
214628127|NCT00977951|DRUG|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
214628128|NCT00977951|DRUG|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
214628129|NCT01118351|DRUG|sunitinib malate|Given orally
214628130|NCT01118351|OTHER|immunohistochemistry staining method|Correlative studies
214628131|NCT01118351|OTHER|TdT-mediated dUTP nick end labeling assay|Correlative studies
214628132|NCT01118351|OTHER|light microscopy|Correlative studies
214628133|NCT01118351|OTHER|laboratory biomarker analysis|Correlative studies
214628134|NCT02738983|DRUG|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
214628135|NCT02738983|RADIATION|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
214628136|NCT00811135|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
214628137|NCT00811135|DRUG|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
214628138|NCT00811135|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
214628139|NCT04158622|PROCEDURE|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
214628140|NCT04158622|PROCEDURE|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
214628141|NCT02817321|PROCEDURE|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
214628142|NCT02817321|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
214628143|NCT02817321|DEVICE|PAJUNK Contiplex S Catheter|
214628144|NCT02817321|DRUG|single dose ropivacaine|"* 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed"
214628145|NCT02817321|DRUG|continuously infusion of ropivacaine|"* 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose"
214628146|NCT02817321|DRUG|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
214628147|NCT05372523|DIAGNOSTIC_TEST|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
214628148|NCT05372523|DIAGNOSTIC_TEST|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
214628149|NCT01226550|PROCEDURE|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
214628150|NCT00746980|DRUG|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
214628151|NCT04200261|DRUG|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
214628152|NCT04200261|DRUG|sodium chloride|sodium chloride
214628153|NCT04052659|DRUG|Sintilimab|200 mg IV, every 3 weeks, d1
214628154|NCT04052659|DRUG|Chidamide|30 mg PO, 2 times every week, d1 and d4
214628155|NCT04052659|DRUG|Azacidine|100 mg SC, every 3 weeks, d1 to d7
214628156|NCT00919503|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infused IV
214628157|NCT00919503|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214628158|NCT00919503|DRUG|Cyclosporine|Given IV or PO
214628159|NCT00919503|DRUG|Fludarabine Phosphate|Given IV
214628160|NCT00919503|OTHER|Laboratory Biomarker Analysis|Correlative studies
214628161|NCT00919503|DRUG|Methotrexate|Given IV
214628162|NCT00919503|DRUG|Mycophenolate Mofetil|Given IV or PO
214628163|NCT00919503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infused IV
214628164|NCT00919503|DRUG|Tacrolimus|Given IV or PO
214628165|NCT00919503|RADIATION|Total-Body Irradiation|Undergo total body irradiation
214628166|NCT00919503|DRUG|Treosulfan|Given IV
214628167|NCT00919503|PROCEDURE|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
214628168|NCT02086539|OTHER|Large Envelope|
214628169|NCT02086539|OTHER|Priority Mail|
214628170|NCT02086539|OTHER|Amazon|
214628171|NCT04833088|OTHER|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
214628172|NCT04677959|DRUG|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
214628173|NCT04677959|DRUG|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
214628174|NCT04677959|DRUG|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
214628175|NCT04677959|DRUG|Standard of Care Rescue Medication|Current rescue medication
214628176|NCT05945953|OTHER|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
214628177|NCT05945953|OTHER|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
214628178|NCT03227900|DRUG|Lidocaine|Intragastric infusion of lidocain
214628179|NCT03227900|DRUG|Placebos|Intragastric infusion of water for injections
214628180|NCT04654494|PROCEDURE|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
214628181|NCT04654494|PROCEDURE|Total colectomy|excision of the colon with preservation of the rectum
214628182|NCT04654494|PROCEDURE|Segmental colectomy|excision of a segment of colon
214628183|NCT01253655|DRUG|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
214628184|NCT04529759|OTHER|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
214628185|NCT04529759|OTHER|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
214628186|NCT01970995|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
214628187|NCT01970995|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
214628188|NCT01970995|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
214628189|NCT00886301|PROCEDURE|liver biopsy|liver biopsy
214628190|NCT02120014|PROCEDURE|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
214628191|NCT02120014|PROCEDURE|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
214628192|NCT05837637|DIAGNOSTIC_TEST|The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)|"* The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12"
214628193|NCT00845728|DRUG|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
214628194|NCT00845728|DRUG|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
214628195|NCT03934450|DRUG|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
214628196|NCT03934450|DRUG|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
214628197|NCT03934450|DRUG|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
214628198|NCT03934450|DRUG|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
214628199|NCT00500084|DRUG|Liprotamase|Administered orally
214628200|NCT01173991|BEHAVIORAL|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
214628201|NCT01717209|DRUG|Nitric Oxide|inhaled nitric oxide
214628202|NCT01717209|DRUG|Prostacyclin|inhaled prostacyclin
214628203|NCT04442230|BIOLOGICAL|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
214628204|NCT04442230|OTHER|Placebo|Normal saline
214628205|NCT05026307|PROCEDURE|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
214628206|NCT01578733|DIETARY_SUPPLEMENT|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
214628207|NCT02599961|DRUG|UX007|UX007 is a liquid intended for oral (PO) administration.
214628208|NCT05875675|DRUG|Drug: Pioglitazone Oral Tablet|Dietary Supplement: Pioglitazone 30 mg by mouth daily
214628209|NCT05875675|DIETARY_SUPPLEMENT|Placebo|Dietary: Supplement: Placebo
214628210|NCT00464334|BIOLOGICAL|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
214628211|NCT00464334|BIOLOGICAL|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
214628212|NCT00464334|BIOLOGICAL|Placebo to V950|
214628213|NCT00370279|PROCEDURE|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
214628214|NCT03341962|DRUG|IMU-838|IMU-838 tablet
214628215|NCT03341962|DRUG|Placebo|Tablets manufactured to mimic IMU-838 tablets
214628216|NCT03302845|DRUG|Omeprazole 40 MG|Omeprazole 40 mg capsule
214628217|NCT03302845|DRUG|Famotidine 40 mg|Famotidine 40 mg tablet
214628218|NCT03302845|DRUG|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
214628219|NCT04684446|BIOLOGICAL|AZD1222|Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
214628220|NCT04684446|BIOLOGICAL|rAd26-S|Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
214628221|NCT05377047|RADIATION|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
214628222|NCT04411355|DIETARY_SUPPLEMENT|control by dietitian|
214628223|NCT04411355|OTHER|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
214628224|NCT04411355|BEHAVIORAL|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
214628225|NCT02555670|OTHER|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
214628226|NCT03413189|OTHER|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
214628227|NCT03413189|OTHER|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
214628228|NCT03413189|OTHER|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
214628229|NCT00626691|BEHAVIORAL|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
214628230|NCT02662257|DRUG|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
214628231|NCT02662257|DRUG|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
214628232|NCT04241211|DRUG|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
214628233|NCT04241211|DRUG|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
214628234|NCT01422915|DRUG|Colestipol|2 grams morning and bedtime for 90 days.
214628235|NCT03761615|DEVICE|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
214628236|NCT04682886|DIAGNOSTIC_TEST|diagnosis|there is no intervention diagnosis or treatment for patients
214628237|NCT01152021|DRUG|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
214628238|NCT01152021|DRUG|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
214628239|NCT04586283|OTHER|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
214628240|NCT01982929|PROCEDURE|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
214628241|NCT01982929|PROCEDURE|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
214628242|NCT05013762|BEHAVIORAL|Fast intervention|This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.
214628243|NCT05013762|BEHAVIORAL|Active Monitoring|This is an observation-only group. The training received in this group will be dose equivalent to the active group.
214628244|NCT05209633|DRUG|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
214628245|NCT05209633|DRUG|Placebo|placebo
214628246|NCT02534688|DRUG|LNG-IUS|
214628247|NCT02534688|DRUG|DMPA|
214628248|NCT04893772|DIETARY_SUPPLEMENT|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
214628249|NCT00034658|DRUG|Posaconazole|
214628250|NCT04522089|BIOLOGICAL|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
214628251|NCT00517829|DRUG|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
214628252|NCT00517829|DRUG|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
214628253|NCT00517829|DRUG|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
214628254|NCT00251940|DRUG|Tesaglitazar 0.5 or 1 mg|
214628255|NCT00251940|DRUG|Glibenclamide 2.5, 5, 10 or 15 mg|
214628256|NCT03410888|PROCEDURE|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
214719756|NCT05287204|DIAGNOSTIC_TEST|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
214628257|NCT03410888|PROCEDURE|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
214628258|NCT00385255|BIOLOGICAL|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
214628259|NCT00385255|BIOLOGICAL|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
214628260|NCT02184078|DRUG|Nevirapine|
214628261|NCT02184078|DRUG|Rifabutin|
214628262|NCT04793425|BEHAVIORAL|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
214628263|NCT01825707|DRUG|[14C]-YH4808 200 mg|\[14C\]-YH4808 200 mg (oral) on day1
214628264|NCT02672670|BEHAVIORAL|Experimental: Intervention group---coping-oriented supportive programme|
214628265|NCT02672670|BEHAVIORAL|Active Comparator: Comparison group---a didactic talk (usual care)|
214628266|NCT02443883|DRUG|Ramucirumab|Administered IV
214628267|NCT02267694|DRUG|Freeze-dried black raspberry powder|
214628268|NCT02688595|DEVICE|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
214628269|NCT02688595|OTHER|General anesthesia|Scheduled operation under general anesthesia
214628270|NCT01643629|BIOLOGICAL|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
214628271|NCT01643629|OTHER|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
214628272|NCT04160130|PROCEDURE|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
214628273|NCT01885611|OTHER|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
214628274|NCT01885611|DIETARY_SUPPLEMENT|Virgin Coconut Oil|cold-processed VCO
214628275|NCT05979298|DRUG|Gemcitabine|Chemotherapeutics
214628276|NCT05979298|BIOLOGICAL|ELENAGEN|DNA plasmid
214628277|NCT01297335|DRUG|clonidine|Intrathecal Clonidine
214628278|NCT01329393|BEHAVIORAL|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
214628279|NCT01329393|BEHAVIORAL|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
214628280|NCT00674050|DRUG|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
214628281|NCT00674050|DRUG|Albuterol (Salbutamol)|2 puff= 200ug total dose
214628282|NCT00674050|DRUG|Fluticasone|2 puffs= 500ug total dose
214628283|NCT00006456|RADIATION|stereotactic radiosurgery|
214628284|NCT06373809|BIOLOGICAL|Transplantation of Placenta Derived Stem Cells|Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
214628285|NCT02970890|DEVICE|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
214628286|NCT01997411|DRUG|Nasal Glucagon|
214628287|NCT01997411|DRUG|Intramuscular Glucagon|
214628288|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
214628289|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
214628290|NCT03358888|DRUG|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
214628291|NCT03358888|DRUG|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
214628292|NCT03358888|DRUG|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
214628293|NCT02881632|DEVICE|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
214628294|NCT04793295|DRUG|MT-7117|MT-7117
214628295|NCT00091806|DRUG|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
214628296|NCT00091806|DRUG|Panitumumab|9 mg/kg once every 3 weeks
214628297|NCT04922476|DIETARY_SUPPLEMENT|Alflorex®|Each probiotic capsule contains 1 x 10\^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
214628298|NCT01868048|DRUG|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
214628299|NCT01868048|DRUG|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
214628300|NCT03604965|DRUG|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
214628301|NCT03604965|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
214628302|NCT00393107|DRUG|rituximab|
214628303|NCT00393107|DRUG|rituximab,fludarabine, cyclophosphamide|
214628304|NCT02079987|BEHAVIORAL|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
214628305|NCT02079987|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
214719757|NCT05287204|DIAGNOSTIC_TEST|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
214719758|NCT00432211|DRUG|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
214719759|NCT00096551|DRUG|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
214719760|NCT00096551|DRUG|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
214719761|NCT00096551|DRUG|Recombinant Fowlpox-GM-CSF|
214719762|NCT03547349|DEVICE|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
214719763|NCT03547349|DEVICE|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
214719764|NCT00324272|DRUG|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
214719765|NCT05137210|OTHER|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
214628306|NCT01617330|PROCEDURE|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
214628307|NCT01206205|DRUG|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
214628308|NCT00823290|DRUG|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
214628309|NCT00506883|DRUG|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
214628310|NCT00506883|DRUG|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
214719766|NCT05137210|OTHER|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
214719767|NCT05137210|OTHER|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
214719768|NCT02417064|DRUG|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
214719769|NCT02417064|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
214628311|NCT00506883|OTHER|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
214628312|NCT02224378|PROCEDURE|peep induced CVP|
214628313|NCT02224378|PROCEDURE|passive leg raising(PLR)|
214628314|NCT03429192|PROCEDURE|Surgery|Surgeries plus dissection of lymph nodes
214628315|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
214628316|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
214628317|NCT00399165|DRUG|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
214628318|NCT00399165|OTHER|placebo sesame oil|placebo sesame oil
214628319|NCT00399165|DRUG|Dutasteride|24.5 mg po once (Day 0)
214628320|NCT03636139|DEVICE|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
214628321|NCT03636139|DEVICE|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
214628322|NCT01445951|DRUG|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
214628323|NCT01445951|DRUG|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
214628324|NCT01445951|DRUG|Insulin Aspart in combination with a basal insulin|Injectable insulin
214628325|NCT05270070|OTHER|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
214628326|NCT04674475|DEVICE|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
214628327|NCT04442945|DRUG|ANAVEX3-71|Active oral dose of ANAVEX3-71
214628328|NCT04442945|DRUG|Placebo|Oral placebo
214628329|NCT04376320|DEVICE|customised ceramic sheets (Group 1)|guided bone regeneration
214628330|NCT04376320|COMBINATION_PRODUCT|modified sausage technique (Group 2)|guided bone regeneration
214628331|NCT02215876|DRUG|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
214628332|NCT02215876|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
214628333|NCT02215876|DRUG|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
214628334|NCT04055792|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
214628335|NCT03955302|BEHAVIORAL|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
214628336|NCT03817775|OTHER|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
214628337|NCT03804203|RADIATION|standard treatment|3000 cGy in 10 daily fractions
214628338|NCT03804203|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
214628339|NCT00350142|RADIATION|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
214628340|NCT00350142|DRUG|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
214628341|NCT00350142|OTHER|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
214628342|NCT00350142|RADIATION|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
214628343|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
214628344|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
214628345|NCT06220331|DEVICE|Intra Ocular Lens|Intensity SL Intra Ocular Lens
214628346|NCT02721680|OTHER|Internal Awareness Training Program|
214628347|NCT02721680|OTHER|External Awareness Training Program|
214628348|NCT00610987|DRUG|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
214628349|NCT00610987|DRUG|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
214628350|NCT01743911|OTHER|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
214628351|NCT01743911|DRUG|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
214628352|NCT00424424|DRUG|MK0719|
214628353|NCT00385502|DRUG|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
214628354|NCT00254501|BEHAVIORAL|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
214628355|NCT00254501|BEHAVIORAL|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
214628356|NCT03060135|BEHAVIORAL|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
214628357|NCT03060135|BEHAVIORAL|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
214628358|NCT03022695|DEVICE|High Intensity Focused Ultrasound|
214628359|NCT01509196|DRUG|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
214628360|NCT01317862|DEVICE|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
214628361|NCT06060964|OTHER|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
214628362|NCT00923130|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
214628363|NCT00923130|DRUG|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
214628364|NCT01402609|DEVICE|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
214628365|NCT01402609|DEVICE|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
214628366|NCT04919642|DRUG|TT-00420|TT-00420 tablet, administered orally once daily
214628367|NCT07020858|DIAGNOSTIC_TEST|FAPl lmaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPl) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPl imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
214628368|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
214628369|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） High Dose|
214628370|NCT01411254|DRUG|Sham|
214719770|NCT02417064|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
214628371|NCT06629753|BEHAVIORAL|Differentiated service delivery model|The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
214628372|NCT07027904|DEVICE|Implant|The immediate implant was placed, and the surrounding cavity was filled with xenograft bone material, along with the application of hyaluronic acid or platelet-rich fibrin (PRF) to enhance healing and bone integration.
214628373|NCT07028892|DEVICE|A gamified mobile learning|There will be a gamified environment in a mobile application with case scenarios on pressure injury prevention designed by researchers.
214628374|NCT07028892|OTHER|Booklet training|Nurses will receive training via a booklet about prevention of pressure injuries.
214628375|NCT07029867|DRUG|Yishen Daluo Yin granuls|The patient takes YSDLY granules or placebo twice a day.
214628376|NCT07029867|DRUG|Placebo|The patient takes placebo (YSDL mimetic granules) twice a day.
214628377|NCT07030023|OTHER|Non intervention|Non intervention
214628378|NCT07028970|OTHER|No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )|This study is observational study and all participants will be obsreved with no intervention.
214628379|NCT07029906|DRUG|Bisoprolol 2.5 mg|Active bisoprolol 2.5mg tablets
214628380|NCT07029906|DRUG|Placebo|Blinded placebo for a total of 3 weeks
214628381|NCT07029997|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|insertion of eartubes
214628382|NCT07029659|DIAGNOSTIC_TEST|Ovarian Cancer Score|Preoperatively, 5 ml blood samples were collected for OCS testing to determine the benign or malignant nature of ovarian endometriotic tissues. The OCS results were statistically analyzed against the gold standard of histopathological diagnosis.
214628383|NCT07028918|RADIATION|Low dose radiotherapy regimen|On the first and second day of chemotherapy and immunotherapy, low-dose radiotherapy of 1 Gy/1f was administered to the primary tumor lesion and metastatic lymph nodes, respectively, for a total of 4 Gy/4f.
214628384|NCT07028918|DRUG|New adjuvant immunotherapy regimen|Terriptylimab: fixed dose 240 mg, q30000, intravenous infusion, each infusion lasting 30 minutes (not less than 20 minutes, not more than 60 minutes); Chemotherapy regimen: Albumin bound paclitaxel: 175-260 mg/m2, d1, q3w; Platinum class: Cisplatin: 75mg/m2, d1-3, q3w; Carboplatin: AUC=5, d1, q3w (for patients with cisplatin allergy, intolerance, hearing impairment, creatinine clearance rate\<50ml/min, or grade 1 neuropathy that are not suitable for cisplatin use).
214628385|NCT07028918|PROCEDURE|Surgical treatment|Surgery begins around 4 weeks after the first day of the second cycle of neoadjuvant therapy. The surgical plan is developed and evaluated by oral surgeons with years of clinical surgical experience. The determination of surgical margins is mainly based on baseline standards before neoadjuvant therapy for tumors, and can be appropriately reduced by oral surgeons depending on the situation.
214628386|NCT07028918|DRUG|Postoperative adjuvant therapy plan|"* Patients with postoperative pathological progression of pCR were given maintenance treatment with Triprolizumab Q3W for 1 year.~  * Patients with postoperative pathology not reaching pCR should receive adjuvant radiotherapy (60-66Gy/30-33f) ③ Patients with high-risk recurrence factors in postoperative pathology (positive tumor margin or insufficient safe margin, presence of lymph node extracellular invasion) are given adjuvant radiotherapy and chemotherapy."
214628387|NCT07028918|RADIATION|Radical radiotherapy plan|"① Radical radiotherapy for the primary lesion and cervical lymphatic drainage area.~② Synchronous cisplatin during radiotherapy: 75mg/m2, d1-3, q3w."
214719771|NCT02417064|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
214719772|NCT02417064|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
214719773|NCT02417064|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
214628388|NCT07028736|OTHER|Dry eye assessment|Dry eye assessment was performed using the Mediworks Dry Eye Diagnostic System.
214628389|NCT07027917|DEVICE|Virtual Reality Goggles|VR
214628390|NCT07029893|BEHAVIORAL|Independent Life Skills Program (ILSP)|The ILSP runs for 14 weeks, covering six areas of independent living skills and 14 weekly sessions lasting 2 hours each. The program will run in a group format with 4 participants in each group. The ILSP will be run by occupational therapists who are trained in the program delivery.
214628391|NCT07029893|OTHER|Wait-list control|Participants do not receive the experimental treatment and will be put on a waiting list to receive the intervention after the active treatment group does.
214628392|NCT07029815|PROCEDURE|irradiation with Er:YAG laser|An Er:YAG laser (LightTouch, LightInstruments, Yokneam, Israel) was used with the following parameters: 400mJ (millijoules), 6W (Watt), 15Hz (Hertz), 5/8 water cooling, laser tip with a diameter of 800 microns. Tissue debridement continued until hard, healthy, lively bleeding bone was exposed, indicative of normal bone.
214628393|NCT07029815|PROCEDURE|Tissue preparation|Rose-shaped rotary drills (8 mm diameter) were used with water cooling at a speed not exceeding 40.000 rpm. Tissue preparation limits were consistent with those used for the Er:YAG laser group.
214628394|NCT07027878|DEVICE|JETi lower extremity venous thrombosis|The JETi System is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
214719774|NCT01541501|DEVICE|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
214719775|NCT03498547|PROCEDURE|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
214719776|NCT03498547|PROCEDURE|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
214719777|NCT02628951|DRUG|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
214719778|NCT02628951|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
214719779|NCT00371540|OTHER|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
214719780|NCT00990249|DRUG|Busulfan|Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
214719781|NCT00990249|DRUG|Clofarabine|40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
214719782|NCT00990249|DRUG|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
214719783|NCT00990249|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
214719784|NCT04624217|DRUG|SHR-1701|PDL1/TGFβ
214719785|NCT06527859|DRUG|Levothyroxin|The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
214719786|NCT05200884|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
214719787|NCT05200884|DRUG|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
214628395|NCT07028138|OTHER|electrical stimulation with mime therapy|"A total of 38 Bell's palsy patients will be randomly selected and divided into two equal groups at Shalamar Hospital.~Group A will receive mime therapy with electrical stimulation, including facial massage, relaxation, stretching, and facial movement exercises.~Group B will undergo electrical stimulation followed by proprioceptive neuromuscular facilitation (PNF) with resisted facial and tongue exercises.~Each group will receive 30-minute sessions, three times per week, for six weeks.~Outcomes will be assessed using the Facial Disability Index (FDI), Sunnybrook Facial Grading System, and SF-12 quality of life scale.~Evaluations will be conducted at baseline, after one month, and at a 2-3 month follow-up."
214628396|NCT07028229|BEHAVIORAL|Training Group|A structured educational and practical training program in gynecologic oncology ultrasound designed for residents. The intervention includes lectures, clinical case discussions, supervised and independent ultrasound examinations, and performance assessments to evaluate learning progression and diagnostic concordance with experts.
214628397|NCT07029243|BEHAVIORAL|HEAL-ME digital app|HEAL-ME is a digital prehabilitation app that provides semi-guided nutrition/exercise prehabilitation
214628398|NCT07029243|DIETARY_SUPPLEMENT|Creatine supplementation|Patients will take 5g creatine supplementation daily for 13 weeks
214628399|NCT07029243|DIETARY_SUPPLEMENT|Whey protein supplementation|Patients will take 35g whey protein supplementation daily
214628400|NCT07029243|DIETARY_SUPPLEMENT|Placebo|Patients will be administered daily placebo supplementation.
214628401|NCT07028203|DEVICE|Treatment with BTL-785 with the applicator BTL-785-7-11|The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes.
214628402|NCT07029074|DEVICE|Sham inspiratory muscle training (MIP 0%)|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
214628403|NCT07029074|DEVICE|MIP 30% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
214628404|NCT07029074|OTHER|MIP 70% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
214628405|NCT07029477|DEVICE|Incentive Spirometry|Participants received incentive spirometry therapy using a standard device beginning within 2 hours post-laparoscopic cholecystectomy. They were instructed to take 10 deep breaths every 2 hours for 12 hours.
214628406|NCT07029477|BEHAVIORAL|Massage Therapy|Participants received manual massage therapy at regular intervals of 4, 8, and 12 hours after laparoscopic cholecystectomy.
214628407|NCT07029282|DIETARY_SUPPLEMENT|MMS|Pregnant women in this arm will receive 6gms of MMS (UNIMAPP MMS) in a ready to use sachet form which includes 15 nutrients.
214628408|NCT07029282|DRUG|MMS Plus|Pregnant women in this arm will receive 6gms of MMS Plus in a ready to use sachet form which includes 18 nutrients.
214628409|NCT07029282|DIETARY_SUPPLEMENT|IFA|Pregnant women in this arm will receive 6gms of IFA (Iron/Folic Acid) in a ready to use sachet form which includes 2 nutrients.
214628410|NCT07028580|OTHER|Diet based on animal proteins|Ιntervention with a diet based on animal proteins.
214628411|NCT07028580|OTHER|Diet based on plant proteins.|Ιntervention with a diet based on animal proteins.
214628412|NCT07028580|OTHER|General instructions for patients with liver disease.|Α brochure with general instructions was designed for patients with liver disease.
214628413|NCT07028216|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
214628414|NCT07029880|OTHER|full veneered metal ceramic dental prosthesis cemented with resin cement|full veneered metal ceramic dental prosthesis cemented with resin cement
214628415|NCT07029958|DRUG|recombinant humanized anti-CD25 monoclonal antibody|"For children at high risk of GVHD, one of the following conditions must be met (haploidentical donors must meet one condition, while unrelated donors must meet two conditions):~1. The donor is ≥40 years old;~2. The donor is an unrelated donor with ≥1 locus mismatch, a haploidentical female donor, or collateral consanguinity (e.g., cousin, uncle/aunt);~3. Pre-transplant CD3 count ≥4 x 10\^8/kg;~4. The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase;~5. ATG (or biologically equivalent doses of ATLG \[1:2\] or ALG \[1:20\]) \<10mg/kg. Combining recombinant anti-CD25 humanized monoclonal antibody with conventional pretreatment regimen, before peripheral blood stem cell transfusion (i.e. 0d) and+3d, 1mg/kg，\<40kg the maximum dose should not exceed25mg/dose, ≥40kg 1mg/kg, and the maximum dose should not exceed 50mg/dose."
214628416|NCT07027852|BEHAVIORAL|My Lung Health Coach|Virtual education and self-management program with companion application
214628417|NCT07029256|OTHER|Non-Interventional Study|Non-interventional study
214628418|NCT07029386|DEVICE|tES|"his study employs a randomized controlled trial (RCT) design, randomly dividing eligible participants into a neuromodulation group and a sham neuromodulation group.~Neuromodulation Group:~Receive individualized transcranial electrical stimulation (tES) treatment Combined with cognitive training~Stimulation parameters:~Total current: approximately 2mA Duration: 21 minutes Electroencephalogram (EEG) and functional MRI (fMRI) monitoring before and after electrical stimulation"
214628419|NCT07029386|DEVICE|tES|Use the same device and procedure as the neuromodulation group Stimulation device automatically turns off after 30 seconds Maintain device connection Design creates similar initial sensations to actual stimulation Maintains the double-blind nature of the study
214628420|NCT07029191|OTHER|Progressive standing test|Progressive raising test in successive steps in a healthy subject
214628421|NCT07028814|OTHER|Risk-informed obesity care plan|A risk-informed obesity care plan, implemented through pediatric primary care provider training via a Virtual Learning Collaborative (VLC) will be deployed.
214628422|NCT07028255|DIETARY_SUPPLEMENT|Qualia Testosterone|Qualia Testosterone manufactured by Qualia Life Sciences
214628423|NCT07028255|DIETARY_SUPPLEMENT|Placebo|Rice Flour
214628424|NCT06706245|BEHAVIORAL|SET-VR (computer)|Low-immersive version of the SET-VR program
214628425|NCT06706245|BEHAVIORAL|SET-VR (headset)|High-immersive version of the SET-VR program
214628426|NCT07028931|BEHAVIORAL|Visualization technique|In GROUP A, i.e., visualization technique Athletes will be shown a video of stretching protocols and then will be asked to visualize those exercises, the total session time will be approximately 20 minutes which will be divided into three phases: pre-Session visualization (5-10 minutes) which will begin with 1-2 minutes of deep breathing and mental preparation to start visualization technique then players will be asked to visualize dynamic stretching (leg swings, arm circles, and lunges) and static stretching (hamstring and shoulder stretch) for 2-3 minutes each. Then begins the during session visualization phase (1-2 minutes per stretch) the players will be asked to pause before each stretch to visualize the movements, muscle engagement and the feeling of stretch and the transit between the stretches and then last comes the post session phase of visualization (5 minutes) this will involve visualization of cool down exercises like spinal twist, bicep stretch, triceps and hip stretch.
214628427|NCT07028931|OTHER|Combined Stretching Protocol|GROUP B will receive Combined stretching training protocol. The overall duration will be 20 minutes starting from warm up (5-7 minutes) which will include light jogging arm swings, leg swings and lunges, hamstring and shoulder stretches then followed by combined stretching movements (8-10 minutes) this will include hip flexor and hamstring combo, calf and Achilles stretch and spinal twist and arm extension movements and ending with a cool down protocol (5-7 minutes) which will include hip flexor stretch, quadriceps stretch and calf stretch, bicep and triceps stretch.
214628428|NCT07028060|DEVICE|PulseNmore MC™|novel mobile Self-scan ultrasound device, Pulsenmore MC™
214628429|NCT07029854|OTHER|Medical treatment|They will receive oral chemotherapy, based on the cancer stage, and will also undergo radiotherapy.
214628430|NCT07029854|OTHER|LASER acupoints therapy|LASER acupoints therapy will use the Pointer Pulse device (GMT2000 s.r.l., Italy), emitting 650 nm red light with an audio trimmer for acupoint detection. Treatment parameters include 5 mW power, 120 s irradiation per point over a 3.14 mm² area (fluence: 19.2 J/cm², power density: 0.16 W/cm², total dose: 0.6 J). Continuous red laser will be applied for effective stimulation. Sessions will occur once weekly for five weeks. Bilateral stimulation will follow this order: left hand, left face, trunk, right face, and right hand. Targeted acupoints: LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
214628431|NCT07029854|OTHER|Pseudo-LASER acupoints therapy|For the pseudo-LASER acupoints therapy, the same procedures and sequence of acupoint application will be followed as in the active treatment. However, the Pointer Pulse device (GMT2000 s.r.l., Italy) will be deactivated to emit no therapeutic laser light while maintaining visual and audio cues to mimic real stimulation. The device will appear active to ensure blinding. Sessions will be conducted once weekly for five weeks, applying the probe to the same bilateral acupoints in the following order: left hand, left face, trunk, right face, and right hand. The targeted points will be LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
214628432|NCT07027891|DEVICE|AI-ECG|The patients in AI-ECG group would be managed with the information of the myocardial infarction risk score in AI-ECG in addition to the usual care.
214628433|NCT07029165|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
214628434|NCT07029165|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
214719788|NCT00789295|OTHER|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
214719789|NCT01181310|DRUG|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
214628435|NCT07029165|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
214628436|NCT07028307|OTHER|Breathing Exercises|"Ujjai: While the mouth is closed, a hissing sound is made until the space between the throat and lungs is filled with breath, and a slow and deep inhalation is made. Then, without holding the breath, a long and full exhalation is made through a partially closed glottis and a slight laryngeal muscle contraction, and the same sound is made. In each session, two sets of ujjayi technique were applied, with an inhalation:exhalation ratio of 1:2 and 10 respiratory cycles, with a 1-minute rest period between sets.~Sukha Pranayama: Applied for 5 minutes with a 5:5 inhalation:exhalation ratio of 6 breaths per minute.~Nadi Shodhana: After closing the right nostril with the thumb of the right hand, a slow and deep inhalation is performed through the left nostril. After maximum inhalation, without holding the breath, the left nostril is closed with the fourth finger of the right hand and a full exhalation is performed through the right nostril. Maintaining the closed position of the left nostr"
214628437|NCT07028307|OTHER|Breathing Exercises + Kinesio Taping Group|The tape was not removed for 5 days from the day of the procedure, but was removed after the 5th day, allowing the skin to rest for 2 days, and then repeated for 4 weeks with a new kinesio tape application. The tapes of those who stated that there was wear or tear on the tape were renewed within a week. After the skin was cleaned with alcohol, the kinesio tape application was applied bilaterally as an I tape with 25-50% tension on the paraspinal muscles from the 7th cervical vertebra to the 12th thoracic vertebra. The I tape was applied horizontally with 50% tension to the point where the kyphotic area was clearly observed. All strips were rubbed to increase adhesion to the skin and activate the tape.
214628438|NCT06737627|OTHER|no intervention|no intervention
214628439|NCT06833502|OTHER|CT Scan|Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
214628440|NCT01307215|DRUG|Ropivacaine|20mLs of 0.5%
214628441|NCT01307215|DRUG|Ropivacaine|30mLs of 0.33%
214628442|NCT01307215|DRUG|Ropivacaine|40mLs of 0.25%
214628443|NCT06758362|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|A structured psychotherapy approach focused on reducing PTSD symptoms through guided eye movements and trauma processing.
214628444|NCT06758362|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A psychotherapy approach focused on identifying and modifying maladaptive thought patterns and behaviors to reduce PTSD symptoms.
214628445|NCT05696522|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
214628446|NCT06547840|DRUG|MOv18 IgE|MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
214628447|NCT06087926|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
214628448|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
214628449|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
214628450|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
214628451|NCT06443970|DEVICE|Exsalta Suction Device|Low flow endotracheal suction device
214628452|NCT06845163|DRUG|Dapagliflozin|Dapagliflozin 10 mg will be given orally once daily for three months.
214628453|NCT06845163|DRUG|Anti-VEGF drug|Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.
214628454|NCT02586675|DRUG|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
214719790|NCT01181310|DRUG|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
214719791|NCT01181310|DRUG|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
214719792|NCT01181310|DRUG|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
214719793|NCT01181310|DRUG|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
214719794|NCT01548417|DRUG|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
214719795|NCT01548417|DRUG|Sugar Pill|600 mg/day, oral pill, 7 days
214628455|NCT02586675|DRUG|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
214628456|NCT02586675|DRUG|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
214628457|NCT05736900|DIAGNOSTIC_TEST|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
214719796|NCT00139841|DRUG|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
214719797|NCT00179569|BEHAVIORAL|Relaxation response|8 weeks of relaxation response training
214719798|NCT04716478|OTHER|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
214719799|NCT02714608|DRUG|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
214628458|NCT00513409|BIOLOGICAL|Synflorix|Intramuscular injection, 1 or 2 doses
214628459|NCT00513409|BIOLOGICAL|Infanrix Hexa|1 Intramuscular injection
214628460|NCT00513409|BIOLOGICAL|Havrix|1 Intramuscular injection
214628461|NCT01088074|DEVICE|Histoacryl Tissue Adhesive|
214628462|NCT01088074|DEVICE|Dermabond|
214628463|NCT01088074|DEVICE|Staples|
214628464|NCT01088074|DEVICE|Monocryl 4-0|
214628465|NCT03066427|DRUG|Sunitinib|Sunitinib 50 mg/d
214628466|NCT03189446|RADIATION|Vaginal Cuff Brachytherapy|Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
214628467|NCT03189446|DRUG|Carboplatin|Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
214628468|NCT03189446|DRUG|Paclitaxel|Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
214628469|NCT05931809|BEHAVIORAL|Serqual tool|The SERVQUAL scale will be applied with the questionnaire of expectations in the first 24 hours after admission and perception questionnaire within the first 24 hours after discharge.
214719800|NCT02714608|DRUG|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
214628470|NCT06124482|DEVICE|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
214628471|NCT05634577|DRUG|Mitotane|Given by PO
214628472|NCT05634577|DRUG|Pembrolizumab|Given by vein (IV)
214628473|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drug free norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
214628474|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. Trainings and tools will be provided, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
214628475|NCT04459780|BIOLOGICAL|Skin biopsies|3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
214628476|NCT04459780|BIOLOGICAL|Blood sample|One blood sample for the group 1 only.
214628477|NCT05075356|DEVICE|The intelligent total body scanner (iToBoS)|"The intelligent total body scanner (iToBoS) device will be an AI diagnostic platform for early detection for melanoma, which includes a novel total-body high-resolution scanner and a Computer Aided Diagnostics (CAD) tool. The prototype iToBoS imaging device used in this study, will not have the integrated CAD system.~The device consists of a horizontal bed on which the participant would lie on. The bed will slide under a series of 5 arc shaped rails that have a total of 15 vision units mounted on rails (3 vision units per arc). The vision units incorporate high-resolution cameras and LED lighting system. When imaging is initiated by an operator, the vision units systematically move along the arch rails taking numerous images capturing majority of the skin surface. The imaging process will take approx. 10 minutes.~Purpose built software will be used to stitch images together to create a body avatar on which skin lesions can be viewed and monitored with."
214628478|NCT04522674|BIOLOGICAL|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
214628479|NCT00781456|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
214628480|NCT00781456|DRUG|Placebo|1 tablet daily to match experimental arm
214628481|NCT04803838|OTHER|No intervention|No intervention
214628482|NCT04229745|DEVICE|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
214628483|NCT02805777|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
214628484|NCT00658554|DRUG|ARQ 197|Treatment with ARQ 197
214628485|NCT01902966|DRUG|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
214628486|NCT01902966|BEHAVIORAL|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
214628487|NCT01902966|BEHAVIORAL|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
214628488|NCT01902966|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
214628489|NCT02321254|DEVICE|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
214628490|NCT02321254|BEHAVIORAL|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
214628491|NCT02486198|DRUG|placebo|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
214628492|NCT02486198|DRUG|GM|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
214628493|NCT02486198|DRUG|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
214628494|NCT00405197|BEHAVIORAL|Isocaloric diet high in MUFA or Mediterranean diet|
214628495|NCT02475798|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
214628496|NCT00783094|DRUG|Tadalafil 2.5 mg|oral, daily
214628497|NCT00783094|DRUG|Tadalafil 5 mg|oral, daily
214628498|NCT00783094|DRUG|Placebo|oral, daily
214628499|NCT06786936|DRUG|Secukinumab|Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.
214628500|NCT06786936|DRUG|Bimekizumab|Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.
214628501|NCT06786936|DRUG|Ixekizumab|Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.
214628502|NCT06786936|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
214628503|NCT03299348|BEHAVIORAL|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
214628504|NCT03299348|BEHAVIORAL|Active Control Group|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) four major health conditions that affect the lives of many middle-aged and older adults (e.g., cardiovascular disease, cancer, type 2 diabetes; clinical depression); and (b) how these conditions can be managed successfully.
214628505|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
214628506|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
214628507|NCT05930548|OTHER|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
214628508|NCT00622674|BIOLOGICAL|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
214719801|NCT02714608|DRUG|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
214719802|NCT00914238|BEHAVIORAL|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
214719803|NCT00914238|BEHAVIORAL|OPUS 5 years|
214719804|NCT00543868|DRUG|MK0782|
214628509|NCT00622674|DRUG|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
214628510|NCT03930654|BEHAVIORAL|iPrEP|"* iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women"
214628511|NCT03930654|BEHAVIORAL|Usual Care|"* Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies"
214628512|NCT00918034|DRUG|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
214628513|NCT00918034|DEVICE|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
214628514|NCT00918034|PROCEDURE|Placement|Placement of device in prostate urethra
214628515|NCT05427552|DEVICE|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 \* (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8\*6=16.8(%) were added to the normal intensity.
214628516|NCT00455234|DRUG|Intramuscular Olanzepine 10 mg|
214628517|NCT00455234|DRUG|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
214628518|NCT03405259|DEVICE|Super Seal® Desensitizer|Single dose professional application.
214628519|NCT03405259|DEVICE|Acclean® Fluoride Varnish|Single dose professional application.
214628520|NCT02788942|PROCEDURE|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
214628521|NCT05702528|DEVICE|Apollo Neuro|The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
214628522|NCT02730585|BIOLOGICAL|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
214628523|NCT05044208|DIAGNOSTIC_TEST|ECG monitoring|After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
214628524|NCT05033470|DEVICE|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
214719805|NCT02212080|DRUG|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
214719806|NCT02212080|DRUG|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
214628525|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
214628526|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
214628527|NCT05194085|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
214628528|NCT05194085|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
214628529|NCT00876187|BIOLOGICAL|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
214628530|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
214628531|NCT00876187|BIOLOGICAL|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
214628532|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
214628533|NCT00876187|BIOLOGICAL|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
214628534|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
214628535|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
214628536|NCT00876187|DRUG|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
214628537|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
214628538|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
214628539|NCT01068028|DRUG|ORM-12741|Ascending multiple doses to sequential panels
214628540|NCT01068028|DRUG|Placebo for ORM-12741|
214628541|NCT02742038|OTHER|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
214628542|NCT02855528|DEVICE|Tin Filter|
214628543|NCT00893724|DRUG|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
214628544|NCT00893724|DIETARY_SUPPLEMENT|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
214628545|NCT00893724|DRUG|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
214628546|NCT04351984|DEVICE|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
214628547|NCT02414386|OTHER|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
214628548|NCT02081040|OTHER|Not applicable (observational study with no active intervention)|
214628549|NCT04658901|DEVICE|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
214628550|NCT04658901|DEVICE|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
214628551|NCT00005648|DRUG|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
214628552|NCT00005648|DRUG|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
214628553|NCT03287219|DRUG|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
214628554|NCT06377787|OTHER|ELDOA and conventional therapy|hot pack and TENS for10 min, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4rep with 6 sec hold once a day) and ELDOA method C0-C1-C2, C2 \& C3 positions for cervical spine (2 sets of five repetitions with 45 sec hold and 15sec rest between each set once a day).
214628555|NCT06377787|OTHER|conventional therapy|include hot pack and TENS for 10 minutes, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4 reps with 6 seconds hold once a day).
214628556|NCT05910866|DEVICE|Left bundle branch area pacing (LBBAP)|Pacing of the conduction system of the heart to obtain physiological activation
214628557|NCT05910866|DEVICE|Right ventricular pacing (RVP)|Conventional ventricular pacing
214628558|NCT02413112|BEHAVIORAL|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
214628559|NCT04016480|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
214628560|NCT04016480|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
214628561|NCT05654389|OTHER|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
214628562|NCT00919100|DEVICE|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
214628563|NCT00919100|OTHER|vapocoolant|venipuncture with vapocoolant spray offered
214628564|NCT01536600|DRUG|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
214628565|NCT00823407|DRUG|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
214628566|NCT00823407|DRUG|Placebo|Subjects will receive a single oral dose of placebo
214628567|NCT01849302|DIETARY_SUPPLEMENT|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
214628568|NCT02785250|OTHER|DPX-Survivac|SubQ injection
214628569|NCT02785250|DRUG|Cyclophosphamide|PO BID
214628570|NCT02785250|DRUG|Epacadostat (INCB024360)|PO BID
214628571|NCT03724864|DIETARY_SUPPLEMENT|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
214628572|NCT03345108|DEVICE|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
214628573|NCT03345108|DEVICE|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
214628574|NCT03345108|OTHER|No Adhesive|No adhesive applied.
214628575|NCT02868697|DRUG|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
214628576|NCT02868697|DRUG|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
214628577|NCT01867281|DRUG|aspirin|
214628578|NCT05000385|OTHER|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
214628579|NCT05000385|DIAGNOSTIC_TEST|body mass index|as an indication of nutritional status
214719807|NCT04583969|BIOLOGICAL|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
214628580|NCT05879042|OTHER|Static Stretching|Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.
214628581|NCT05879042|OTHER|Dynamic Stretching|Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.
214719808|NCT04583969|OTHER|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
214719809|NCT04583969|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
214719810|NCT00383006|BEHAVIORAL|Skills for affect regulation (behavior)|
214719811|NCT05658419|PROCEDURE|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
214719812|NCT02562976|OTHER|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
214719813|NCT03086148|DRUG|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
214719814|NCT03086148|DRUG|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
214719815|NCT00718250|BIOLOGICAL|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
214719816|NCT00718250|BIOLOGICAL|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
214719817|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
214719818|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
214719819|NCT02697058|BIOLOGICAL|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
214628582|NCT05879042|OTHER|PNF Stretching|For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.
214628583|NCT05879042|OTHER|Sham stretching|Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
214628584|NCT05104580|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
214628585|NCT02712567|DRUG|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
214719820|NCT02697058|DRUG|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
214719821|NCT00289393|BEHAVIORAL|Perceived outcome by both patient and physician|
214719822|NCT04249284|DRUG|BMS-986165|Specified dose on specified days
214719823|NCT04249284|DRUG|BMS-986165 prototype 1|Specified dose on specified days
214719824|NCT04249284|DRUG|BMS-986165 prototype 2|Specified dose on specified days
214719825|NCT04418219|DRUG|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
214719826|NCT04418219|BIOLOGICAL|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
214719827|NCT04418219|BIOLOGICAL|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
214628586|NCT05284942|DRUG|Mycophenolate mofetil combined with oral prednisone|Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108
214628587|NCT05959135|DEVICE|Gastric ultrasonography|"It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies"
214628588|NCT01857661|DEVICE|sound generator|hearing aid with an integrated sound generator
214628589|NCT01857661|DEVICE|hearing aids with only amplification|
214628590|NCT01437852|BIOLOGICAL|StrataGraft Skin Tissue|
214628591|NCT04408690|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
214719828|NCT04418219|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
214719829|NCT04418219|OTHER|Questionnaire Administration|Ancillary studies
214719830|NCT04418219|OTHER|Quality of Life Assessment|Ancillary studies
214719831|NCT05228756|OTHER|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
214719832|NCT06238115|DRUG|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
214719833|NCT06238115|DRUG|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
214628592|NCT04408690|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
214628593|NCT04408690|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
214628594|NCT06378814|PROCEDURE|Selective Caries Removal (No Pulp Exposure)|Caries excavation technique where clinician leaves carious tissue so close to pulp
214628595|NCT06378814|PROCEDURE|Non-Selective Caries Removal (No Pulp exposure)|Complete caries removal even in areas so close to pulp
214628596|NCT06378814|PROCEDURE|Partial Pulpotomy (Pulp Exposed)|In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
214628597|NCT04648384|DIETARY_SUPPLEMENT|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
214628598|NCT04648384|DIETARY_SUPPLEMENT|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
214628599|NCT04648384|OTHER|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
214628600|NCT01816009|OTHER|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
214628601|NCT05234970|OTHER|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
214628602|NCT05234970|OTHER|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
214719834|NCT01228188|PROCEDURE|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
214628603|NCT00123006|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
214628604|NCT00123006|BEHAVIORAL|Control Diet|4 week feeding intervention
214628605|NCT04962360|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
214628606|NCT04962360|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
214628607|NCT02329769|DRUG|PRO044 SC 6 mg/kg|
214719835|NCT01057862|DRUG|Naltrexone|Targeted dosage of 50mg PO daily
214719836|NCT01057862|OTHER|Placebo|Sugar pills daily PO
214719837|NCT00330239|DRUG|Paroxetine CR|
214719838|NCT04255966|DEVICE|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
214628608|NCT02329769|DRUG|PRO044 IV 6 mg/kg|
214628609|NCT02329769|DRUG|PRO044 IV 9 mg/kg|
214628610|NCT05093738|OTHER|Cognitive Rehabilitation|In the content of the person-centered intervention program, attention, memory, orientation, praxis (motor planning) training; metacognition (metacognition) training; visual perception; There will be cognitive training for executive functions. The intervention will consist of play activities (games, computer-assisted games) for cognitive skills; The games will be applied in a way that suits the child from simple to complex. Visual perception applications (designing blocks, recognizing and sorting the shapes in the picture, matching opposite shapes etc.); attention practices, memory practices, strategy development, space-time orientation, motor planning, games and metacognitive strategies aimed at developing skills such as planning, organization, working memory, impulse control, time management and awareness, abstract thinking, cognitive flexibility will form our intervention program.
214628611|NCT04536688|DRUG|RGLS4326|Solution for subcutaneous injection
214628612|NCT00655031|DIETARY_SUPPLEMENT|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
214628613|NCT00655031|DIETARY_SUPPLEMENT|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
214628614|NCT03923569|DIAGNOSTIC_TEST|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
214628615|NCT03923569|DIAGNOSTIC_TEST|blood sample|blood sample for genetic testing of the Apolipoprotein E
214628616|NCT03923569|DIAGNOSTIC_TEST|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
214628617|NCT03923569|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
214628618|NCT03659682|DRUG|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
214628619|NCT00514865|DRUG|ONO-2333Ms Experimental 2|5-10 mg QD(once a day) for 8 weeks
214628620|NCT00514865|DRUG|Placebo|0 mg QD(once a day) for 8 weeks
214628621|NCT00514865|DRUG|ONO-2333Ms Experimental 1|1-2 mg QD(once a day) for 8 weeks
214628622|NCT02549768|DRUG|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
214628623|NCT02549768|DRUG|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
214628624|NCT00003460|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
214628625|NCT00331474|BIOLOGICAL|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
214628626|NCT05532410|DEVICE|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
214628627|NCT03245450|DRUG|Eribulin mesilate|IV infusion
214628628|NCT03245450|DRUG|Irinotecan hydrochloride|IV infusion
214628629|NCT02429414|DEVICE|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
214628630|NCT02429414|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
214628631|NCT02429414|DEVICE|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
214628632|NCT03616938|PROCEDURE|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
214628633|NCT03959280|OTHER|Tailored intervention|"* The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions."
214628634|NCT03959280|OTHER|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
214628635|NCT03155594|DEVICE|Freestyle Libre|Continuous glucose monitoring patch
214628636|NCT00849732|BIOLOGICAL|V520|Intentionally Blank
214628637|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26
214628638|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26
214628639|NCT00849732|BIOLOGICAL|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
214628640|NCT00969449|DRUG|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
214628641|NCT00969449|DRUG|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
214628642|NCT00000511|DIETARY_SUPPLEMENT|mineral supplements|
214628643|NCT00000511|DIETARY_SUPPLEMENT|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
214628644|NCT00000511|BEHAVIORAL|dietary supplements|
214628645|NCT00397826|DRUG|MK0733|Duration of Treatment: 12 Weeks
214628646|NCT04499261|PROCEDURE|laparoscopic surgery|Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
214628647|NCT04499261|PROCEDURE|Open surgery|Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
214628648|NCT01784861|DRUG|X-82|
214628649|NCT01784861|DRUG|Everolimus|
214628650|NCT05376826|BEHAVIORAL|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
214628651|NCT02122237|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
214628652|NCT04901143|DEVICE|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
214628653|NCT05300191|DIAGNOSTIC_TEST|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
214628654|NCT04242082|DIAGNOSTIC_TEST|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
214628655|NCT04232579|OTHER|Therapeutic strategy|Therapeutic strategy compatible with the guidelines and development of predictive biomarkers of the response to treatment.
214628656|NCT02467933|OTHER|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
214628657|NCT02467933|OTHER|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
214628658|NCT02467933|OTHER|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
214628659|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 without adjuvant
214628660|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 with adjuvant
214628661|NCT05903183|BIOLOGICAL|Placebo|Diluent
214628662|NCT02173574|DRUG|DEB025|
214628663|NCT02173574|DRUG|EDP239|
214628664|NCT04821037|BEHAVIORAL|ACT|Acceptance and Commitment Therapy
214628665|NCT04321759|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
214628666|NCT04321759|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
214628667|NCT04234711|PROCEDURE|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
214628668|NCT02432235|DRUG|Camidanlumab tesirine|Intravenous (IV) infusion.
214628669|NCT04019730|OTHER|diet|low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)
214628670|NCT03178227|BEHAVIORAL|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
214628671|NCT00855985|PROCEDURE|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
214628672|NCT03127371|DRUG|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
214628673|NCT03127371|DRUG|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
214628674|NCT02941016|DRUG|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
214628675|NCT04370080|DEVICE|Silver Diamine Fluoride 38%|Dental caries arrest medication
214628676|NCT02631525|DRUG|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
214628677|NCT02631525|DRUG|Propofol|Total intravenous anesthesia based on propofol
214628678|NCT03196076|DRUG|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
214628679|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
214628680|NCT01418183|PROCEDURE|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
214628681|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
214628682|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
214628683|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
214628684|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
214628685|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
214628686|NCT02424526|OTHER|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
214628687|NCT02424526|DEVICE|Treadmill|
214628688|NCT00794677|DRUG|ezetimibe|Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
214628689|NCT00794677|DRUG|placebo|Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
214628690|NCT02461992|DRUG|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
214628691|NCT06438484|BEHAVIORAL|multimodal prehabilitation program|"Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience). The physical exercise training consisted of high-intensity interval training (HIIT) three times a week and functional strengthening exercises. Patients visited the hospital two times a week and performed home exercise training five times a week on a stationary cycle ergometer (Corival Home+, Lode BV, Groningen, The Netherlands).~The dietary intervention consisted of optimization of energy and protein intake, optimization of timing of eating protein-rich products, and if necessary additional protein and vitamin supplements. Individual protein requirements were set at 1.5-1.9 g/kg fat free mass. Patients used the eiFIT-application or a food diary to track their protein intake."
214628692|NCT01699945|OTHER|This is an observational study being conducted as a substudy of antoher trial.|
214628693|NCT06443866|DIAGNOSTIC_TEST|Disease status detection|RAI dose determination
214719839|NCT05582551|OTHER|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
214628694|NCT06443866|DIAGNOSTIC_TEST|Theranostic dosimetry|Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer
214628695|NCT06443866|DRUG|I-124 PET/CT imaging|Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer
214628696|NCT03788720|PROCEDURE|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
214628697|NCT03788720|PROCEDURE|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
214628698|NCT06277895|DIAGNOSTIC_TEST|VOCs|test the end-expiratory gas
214628699|NCT05437003|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients
214628700|NCT05515250|DEVICE|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
214628701|NCT01305538|DRUG|BMS-954561|
214628702|NCT01305538|DRUG|BMS-954561|
214628703|NCT01305538|DRUG|Placebo|
214628704|NCT03015259|DRUG|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
214628705|NCT03015259|DRUG|Symbicort|Active Comparator: Treatment 2
214628706|NCT03015259|DRUG|Placebo|Placebo Comparator: Treatment 3
214628707|NCT00385645|DRUG|Combivir+Kaletra|
214628708|NCT00385645|DRUG|Combivir+Reyataz|
214628709|NCT04149067|DRUG|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
214628710|NCT04149067|DRUG|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
214719840|NCT00415584|DRUG|Cinacalcet HCl|
214719841|NCT05377827|BIOLOGICAL|WU-CART-007|Provided by Miltenyi Biotec
214628711|NCT03232086|OTHER|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214628712|NCT03232086|OTHER|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214628713|NCT02371447|DRUG|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
214628714|NCT06364085|DEVICE|Neuromodulation programming|"Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up."
214628715|NCT04400474|DRUG|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
214628716|NCT03173794|OTHER|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
214628717|NCT04499872|OTHER|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
214628718|NCT01965262|DEVICE|Hema-copolymer Lens|contact lens
214628719|NCT01965262|DEVICE|etafilcon A Lens|contact lens
214628720|NCT00362089|DIETARY_SUPPLEMENT|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
214628721|NCT00143312|DRUG|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
214628722|NCT03048903|DRUG|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
214628723|NCT03048903|DRUG|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
214628724|NCT02911532|PROCEDURE|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
214628725|NCT01029366|BIOLOGICAL|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
214628726|NCT03444285|OTHER|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
214628727|NCT03444285|OTHER|Hot Pack|20 minutes of hot-pack on both hamstring
214628728|NCT05210530|COMBINATION_PRODUCT|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
214628729|NCT02244567|DRUG|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
214628730|NCT02244567|PROCEDURE|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
214719842|NCT02640755|DRUG|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
214719843|NCT02640755|DRUG|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
214719844|NCT02640755|DRUG|Fulvestrant|Hormonal Agent
214719845|NCT02640755|DRUG|Paclitaxel|Taxane
214719846|NCT03434041|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
214719847|NCT03434041|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
214719848|NCT03434041|DRUG|Placebo|Participants will self-administer matching placebo as intranasal spray.
214719849|NCT03434041|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
214719850|NCT03434041|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
214628731|NCT02244567|OTHER|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
214628732|NCT05387811|COMBINATION_PRODUCT|Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy|Adherence to International Club of Ascites recommendations for the management of AKI
214628733|NCT05428787|PROCEDURE|Left Bundle Branch Area Pacing|The patients will be allocated by randomization to receive the intervention of Left Bundle Branch Area Pacing
214628734|NCT05428787|PROCEDURE|CRT|The patients will be allocated by randomization to receive the intervention of CRT.
214628735|NCT05428787|PROCEDURE|AV node ablation|AV node ablation after 4 weeks of CRT implant or LBBAP implant.
214628736|NCT01479543|OTHER|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
214628737|NCT01479543|OTHER|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
214628738|NCT01479543|OTHER|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
214719851|NCT03434041|DRUG|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
214719852|NCT03434041|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
214719853|NCT04075396|DRUG|Lazertinib|Participants will receive Lazertinib tablets once daily.
214628739|NCT01479543|OTHER|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
214628740|NCT01479543|OTHER|Placebo|Placebo capsule for 28 days.
214628741|NCT06212245|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg
214628742|NCT00906087|DRUG|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
214628743|NCT01109784|DRUG|prasugrel|prasugrel 10 mg/day
214628744|NCT01109784|DRUG|clopidogrel|clopidogrel per os 150mg/day
214628745|NCT01576692|BIOLOGICAL|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once"
214628746|NCT01576692|DRUG|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3"
214628747|NCT01576692|OTHER|Cytokines|"Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC \>2,000/mm\^3"
214628748|NCT01576692|BIOLOGICAL|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.
214628749|NCT01576692|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214628750|NCT02936700|BEHAVIORAL|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
214628751|NCT02936700|BEHAVIORAL|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions"
214628752|NCT00001133|DRUG|Indinavir sulfate|
214628753|NCT00001133|DRUG|Ritonavir|
214628754|NCT02151474|DRUG|INCB047986|
214628755|NCT02151474|DRUG|Placebo|
214628756|NCT00978315|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
214628757|NCT00978315|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
214628758|NCT00548496|DRUG|SB-751689|SB-751689
214719854|NCT04189991|DEVICE|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
214628759|NCT00548496|OTHER|Placebo|Placebo to match
214628760|NCT02432768|DRUG|Triheptanoin|Anaplerotic dietary oil
214628761|NCT02432768|OTHER|Placebo oil|Safflower oil
214628762|NCT02620696|DRUG|netazepide|
214628763|NCT00436371|DRUG|Amisulpride|Oral tablets
214628764|NCT02500628|DRUG|Metformin|500 mg orally after baseline testing of heart rate
214628765|NCT04212676|OTHER|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
214628766|NCT04212676|OTHER|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
214628767|NCT04640883|BEHAVIORAL|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (\>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.
214628768|NCT04640883|BEHAVIORAL|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (\>four hours per session), distance-matched to sprint group.
214628769|NCT04640883|BEHAVIORAL|Recovery for 10 days (low training load)|Habitual low-intensity cycling (\>0.5-2 hours per session)
214628770|NCT03934983|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214628771|NCT02381665|DEVICE|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
214628772|NCT02381665|DEVICE|Flexstim IF faked|Patient enrolled will receive a sham device.
214628773|NCT01710449|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
214628774|NCT05190003|OTHER|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
214628775|NCT00909558|BIOLOGICAL|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
214628776|NCT00641498|BEHAVIORAL|Psychotherapy|Individual supportive
214628777|NCT04858165|PROCEDURE|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
214628778|NCT06074874|OTHER|Intestinal tissue analysis|Intestinal tissue analysis
214719855|NCT03363165|DRUG|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
214719856|NCT03363165|OTHER|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
214719857|NCT02255760|DRUG|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
214719858|NCT02255760|DRUG|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
214719859|NCT02255760|DRUG|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
214719860|NCT02255760|DRUG|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
214719861|NCT02255760|OTHER|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
214719862|NCT00003838|PROCEDURE|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
214719863|NCT00003838|DRUG|Methotrexate|IV MTX on days +1, +3, and +6 will be given
214719864|NCT00003838|DRUG|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.
214719865|NCT00003838|DRUG|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
214719866|NCT00618813|OTHER|radiation therapy|Undergo radiation therapy
214719867|NCT00618813|OTHER|therapeutic conventional surgery|Undergo surgery
214719868|NCT00618813|DRUG|etoposide|Given IV
214628779|NCT02905565|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
214628780|NCT02905565|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
214628781|NCT03840655|PROCEDURE|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
214628782|NCT01441570|DRUG|Nebivolol|Subject will take nebivolol daily for 12 weeks.
214628783|NCT01441570|DRUG|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
214628784|NCT05318391|DIAGNOSTIC_TEST|Gene expression profile|"Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)"
214628785|NCT02958488|DEVICE|High Flow Nasal Cannula|
214628786|NCT05747911|OTHER||Groups will not be intervened. Only observational data will be used.
214628787|NCT03759626|BEHAVIORAL|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
214719869|NCT00618813|DRUG|ifosfamide|Given IV
214719870|NCT00618813|DRUG|doxorubicin hydrochloride|Given IV
214719871|NCT00618813|DRUG|cyclophosphamide|Given IV
214719872|NCT00618813|DRUG|vincristine sulfate|Given IV
214719873|NCT00618813|DRUG|topotecan hydrochloride|Given IV
214719874|NCT00618813|BIOLOGICAL|filgrastim|Given SC
214719875|NCT00397553|DRUG|Insulin glulisine|
214719876|NCT02208505|DRUG|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
214628788|NCT03759626|BEHAVIORAL|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
214719877|NCT02208505|DRUG|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
214719878|NCT03454724|DEVICE|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
214719879|NCT03454724|DEVICE|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
214719880|NCT00262327|DRUG|Antangiogenesis|
214719881|NCT00262327|GENETIC|endostatin gene|
214719882|NCT03722992|OTHER|MBSR|Guided yoga and meditation practices
214628789|NCT04027998|DIAGNOSTIC_TEST|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
214719883|NCT03151538|BEHAVIORAL|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
214628790|NCT00428532|DRUG|Licorice root extract or Pomegranate juice|
214628791|NCT04440995|PROCEDURE|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
214628792|NCT05472727|OTHER|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
214628793|NCT05472727|OTHER|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
214719884|NCT03151538|OTHER|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
214719885|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
214719886|NCT06470620|DIAGNOSTIC_TEST|pelvic floor muscle assessment|no intervention will be performed - several diagnostic assessments tools
214719887|NCT06643260|DRUG|piclidenoson|Piclidenoson is a selective A3AR agonist, supplied as tablets.
214719888|NCT06643260|DRUG|Placebo|Inactive control
214628794|NCT04847973|OTHER|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
214628795|NCT04847973|DIETARY_SUPPLEMENT|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
214628796|NCT02135718|DEVICE|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
214628797|NCT02135718|DEVICE|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
214628798|NCT05458076|DRUG|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
214628799|NCT05458076|DRUG|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
214628800|NCT05458076|DRUG|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
214628801|NCT04952064|DRUG|Monosialoganglioside GM1|Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
214628802|NCT02342002|DRUG|Mifepristone|Mifepristone for treatment of missed abortion
214628803|NCT02342002|DRUG|Misoprostol|Misoprostol for treatment of missed abortion
214628804|NCT00194545|BEHAVIORAL|Medication diaries|Caregivers expected to complete medication diaries daily
214628805|NCT00796315|DRUG|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
214628806|NCT04516928|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
214628807|NCT04516928|OTHER|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
214628808|NCT01975012|DRUG|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
214628809|NCT00802243|DRUG|leflunomide|
214628810|NCT04015154|DEVICE|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
214628811|NCT02223572|RADIATION|hip Xray|
214628812|NCT04017143|BEHAVIORAL|HPV app intervention|Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
214628813|NCT03937583|DRUG|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
214628814|NCT00782548|DRUG|KADIAN (morphine sulfate sustained-release) capsules|Capsules, 30 mg
214628815|NCT00782548|DRUG|Avinza (morphine sulfate sustained-release) capsules|Capsules, 30 mg
214628816|NCT01656863|OTHER|Questionnaire|
214628817|NCT06517134|DRUG|Antihypertensive Agents|use of antihypertensive drugs
214628818|NCT05634863|DEVICE|Implantable Doppler probe manufactured by COOK Medical Company.|The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
214628819|NCT04126382|PROCEDURE|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
214628820|NCT04126382|PROCEDURE|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
214628821|NCT02359630|DEVICE|EasyTube|Insertion for ventilation
214628822|NCT02359630|DEVICE|Endotracheal tube|Insertion for ventilation
214628823|NCT01638780|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
214628824|NCT01638780|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
214628825|NCT03663426|PROCEDURE|study group|"1. High dose corticoids pre-operative and 24h postoperative~2. Opioid free general anesthesia~3. Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
214628826|NCT03663426|PROCEDURE|control|"1. No corticoids pre-operative.~2. Opioid anesthesia~3. Opioids post-operative after NSAID and paracetamol."
214628827|NCT05508555|PROCEDURE|hyperthermic intrathoracic chemotherapy|application of chemotherapeutic agent intrathoracic under hyperthermic conditions
214628828|NCT02924662|OTHER|There is no intervention.|
214628829|NCT00604604|BEHAVIORAL|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
214628830|NCT03428165|OTHER|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
214628831|NCT05182554|BEHAVIORAL|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
214628832|NCT05182554|BEHAVIORAL|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
214628833|NCT05182554|BEHAVIORAL|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
214628834|NCT05182554|BEHAVIORAL|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
214628835|NCT05182554|BEHAVIORAL|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
214628836|NCT05182554|BEHAVIORAL|Video order|The order in which videos appear on the vaccine content website will be randomized.
214628837|NCT05195697|OTHER|Observational study of different treatments and time to treatment|Different treatment based on the clinical decision
214628838|NCT00259883|DRUG|paroxetine|1 or 2 tablets once a day
214628839|NCT06452966|OTHER|traditional Chinese medicine|"patients in the group will receive one of or a combination of the following interventions:~Oral Chinese medicine decoction:~The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs."
214719889|NCT03509623|DIAGNOSTIC_TEST|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
214628840|NCT06452966|OTHER|Routine ICU care|Patients will receive ICU care
214628841|NCT06452966|OTHER|historical Routine ICU care|Patients had received ICU care
214628842|NCT01627860|DRUG|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
214628843|NCT01627860|DRUG|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
214628844|NCT03385603|DEVICE|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
214628845|NCT03385603|BEHAVIORAL|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
214628846|NCT01230541|DRUG|Placebo|Daily, oral tablet
214628847|NCT01230541|DRUG|Udenafil|Daily tablet
214628848|NCT03672279|DIAGNOSTIC_TEST|CogCheck|Novel self-administered cognitive assessment tool
214628849|NCT03705585|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
214628850|NCT03705585|DRUG|Vaxchora|One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
214628851|NCT02524574|PROCEDURE|cardiac Rehabilitation|
214628852|NCT02524574|OTHER|Tomography Positron Emission|
214628853|NCT03260088|DIAGNOSTIC_TEST|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
214628854|NCT03215771|DEVICE|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
214719890|NCT01809197|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
214628855|NCT03215771|OTHER|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
214628856|NCT02039375|OTHER|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
214628857|NCT05530265|DEVICE|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
214628858|NCT00035022|DRUG|BCX-1777|
214628859|NCT01588795|PROCEDURE|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
214628860|NCT01588795|DRUG|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
214628861|NCT00453726|PROCEDURE|Non invasive mechanical ventilation|
214628862|NCT03134170|OTHER|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
214719891|NCT01809197|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
214719892|NCT01809197|DEVICE|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
214719893|NCT01809197|DEVICE|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
214628863|NCT01356082|DEVICE|CNAP|Non-invasive blood pressure monitor
214719894|NCT05438706|DRUG|chidamide|Chidamide, an HDAC inhibitor
214628864|NCT03234244|DRUG|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
214628865|NCT03234244|DRUG|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
214628866|NCT03234244|DRUG|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
214628867|NCT02462668|PROCEDURE|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
214628868|NCT02462668|PROCEDURE|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
214628869|NCT02462668|PROCEDURE|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
214628870|NCT00002106|DRUG|Ranitidine hydrochloride|
214628871|NCT01778439|DRUG|OMP-52M51|
214628872|NCT01794611|DEVICE|laryngoscopy|
214628873|NCT01962571|DRUG|Erythropoietin alfa|
214628874|NCT01962571|DRUG|Placebo|
214628875|NCT03278470|DRUG|HL237|Experimental
214628876|NCT03278470|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
214628877|NCT04296370|DRUG|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
214628878|NCT04296370|DRUG|Fluzoparib|Fluzoparib Orally twice daily
214628879|NCT04296370|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
214628880|NCT04770389|DRUG|Obicetrapib 5mg|tablet
214628881|NCT04770389|DRUG|Ezetimibe 10mg|tablet
214628882|NCT04770389|OTHER|Placebo|tablet
214628883|NCT01666431|DRUG|Lapatinib|
214628884|NCT02613936|DEVICE|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
214628885|NCT02613936|BEHAVIORAL|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
214628886|NCT01157975|DRUG|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
214628887|NCT01157975|DRUG|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
214628888|NCT00309309|DRUG|Rosiglitazone|
214628889|NCT02249143|DEVICE|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
214628890|NCT03831074|DEVICE|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
214628891|NCT03949933|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
214628892|NCT01555528|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
214628893|NCT05893407|DIAGNOSTIC_TEST|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
214628894|NCT00689871|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
214628895|NCT03388411|DIAGNOSTIC_TEST|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
214628896|NCT02084303|OTHER|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
214628897|NCT01783080|BEHAVIORAL|Behavioral Activation for return to work|See Arm Description
214628898|NCT06365203|PROCEDURE|Through knee amputation|Amputation Technique
214628899|NCT06365203|PROCEDURE|Above knee Amputation|Amputation Technique
214628900|NCT05273034|PROCEDURE|1-hour sepsis bundle|"The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate \> 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (\> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation."
214628901|NCT02185404|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
214628902|NCT04169880|DEVICE|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
214719895|NCT05438706|DRUG|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
214719896|NCT05438706|DRUG|carboplatin|Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
214719897|NCT05438706|DRUG|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
214719898|NCT06221436|BEHAVIORAL|Mental Imagery|"Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery."
214628903|NCT04169880|COMBINATION_PRODUCT|HILT & EXERCISE|HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
214628906|NCT00363948|DRUG|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
214628907|NCT00363948|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
214628908|NCT02533063|DEVICE|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
214628909|NCT02845570|OTHER|68Ga-DOTANOC PET/MRI|
214628910|NCT02845570|OTHER|18F-FDG PET/MRI|
214628911|NCT06051682|DEVICE|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
214628912|NCT06051682|PROCEDURE|Emergency physician|the emergency physician analyzes the x-rays
214719899|NCT06600425|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
214719900|NCT01016808|DRUG|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
214719901|NCT01016808|DRUG|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
214719902|NCT01016808|DRUG|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
214719903|NCT05952999|OTHER|Digital Care Solution as supportive personalized care|Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
214719904|NCT05952999|OTHER|Traditional Hospital Level Care|Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
214719905|NCT04883697|OTHER|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
214719906|NCT04516941|DRUG|Edoxaban Tablets|Treatment
214719907|NCT04516941|DRUG|Colchicine Tablets|Treatment
214719908|NCT01892241|DRUG|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
214719909|NCT01892241|DRUG|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
214719910|NCT00141206|DRUG|varenicline (CP-526,555)|
214719911|NCT02031510|DRUG|placebo|transversus abdominis plane block with saline 0.9%
214719912|NCT02031510|DRUG|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
214719913|NCT02031510|DRUG|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
214719914|NCT05148169|DRUG|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
214719915|NCT05148169|DIETARY_SUPPLEMENT|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
214719916|NCT02052141|BIOLOGICAL|CINRYZE 500|500 Units of CINRYZE administered by IV injection
214719917|NCT02052141|BIOLOGICAL|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
214719918|NCT02976545|DEVICE|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
214719919|NCT02976545|BEHAVIORAL|psychiatric evaluation|psychiatric evaluation
214719920|NCT03945201|OTHER|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
214719921|NCT03945201|OTHER|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
214719922|NCT04931550|DEVICE|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
214719923|NCT01599572|OTHER|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
214719924|NCT03481504|BEHAVIORAL|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
214628913|NCT00889265|DEVICE|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
214628914|NCT06364111|DEVICE|Vibrabot capsule|Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.
214628915|NCT06364111|DRUG|polyethylene glycol|Subjects in the control group received polyethylene glycol for 6 weeks
214628916|NCT04618159|OTHER|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
214628917|NCT02075099|OTHER|tensing exercises|Donors will do tensing exercises during blood donation
214628918|NCT02075099|OTHER|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
214628919|NCT01228370|DRUG|silodosin|silodosin 8mg once a day for 12 weeks
214628920|NCT01732302|OTHER|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
214719925|NCT00878891|DEVICE|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
214628921|NCT03357679|PROCEDURE|Tracheal intubation|Intubation of the trachea with endotracheal tube
214628922|NCT03357679|DEVICE|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
214628923|NCT03357679|DEVICE|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
214628924|NCT04455646|BEHAVIORAL|CBT-based, mobile-delivered, intervention platform|App of this platform have been shown to be associated with reduced psychopathology symptoms,including depressive symptoms, following treatment (i.e., relapse prevention). GGDE, which was specifically designed to address MDD related maladaptive beliefs and symptoms,includes different CBT-based intervention modules (nine active and one sham), as well as means for data collection and response monitoring. The active treatment modules will differ in the proportion of adaptive vs. maladaptive statements and the emphasis on particular content (e.g loneliness vs. hopelessness).
214628925|NCT04350775|OTHER|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
214628926|NCT04350775|OTHER|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
214628927|NCT02404259|DRUG|TDF (Tenofovir)|
214628928|NCT02404259|DRUG|Efavirenz|
214628929|NCT02404259|DRUG|lopinavir/ritonavir, atazanavir/ritonavir|
214628930|NCT02135211|BEHAVIORAL|Lifestyle counseling|
214719926|NCT00396305|DRUG|Placebo|Sterile phosphate buffered saline solution.
214719927|NCT00396305|BIOLOGICAL|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
214719928|NCT00758407|DRUG|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
214719929|NCT00758407|DRUG|Placebo|dosage according to an individual titration schedule
214628931|NCT00524407|DRUG|Epoetin alfa|
214628932|NCT05656677|BEHAVIORAL|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
214628933|NCT05656677|RADIATION|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
214628934|NCT00127738|PROCEDURE|Angiographic renal revascularization|
214628935|NCT06190652|DRUG|Chemotherapy combined with immunotherapy|chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
214628936|NCT06190652|RADIATION|radiotherapy|Intensity-modulated radiation therapy
214628937|NCT04648605|OTHER|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
214628938|NCT04514523|OTHER|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
214628939|NCT02690662|BEHAVIORAL|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
214628940|NCT02799823|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
214628941|NCT04777136|OTHER|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
214628942|NCT04777136|OTHER|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
214628943|NCT03275194|PROCEDURE|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
214628944|NCT04879043|DRUG|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
214628945|NCT05690529|PROCEDURE|Ablation|Radiofrequency AF ablatoon
214628946|NCT01422122|DRUG|Vitamin D3|4000 mg per day, one tablespoon syrup per day
214628947|NCT01422122|DRUG|Placebo|one table spoon Syrup per day
214628948|NCT03054376|OTHER|Immobilization|Full length cast of one leg R/L randomized
214628949|NCT03054376|OTHER|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
214628950|NCT03054376|OTHER|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
214628951|NCT03609307|DRUG|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
214628952|NCT03609307|DRUG|Intravitreal bevacizumab|these patients receive only Bevacizumab
214628953|NCT04967937|OTHER|Strengthening, resistance exercise, plyometric and dynamic movement training|(1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
214628954|NCT00250835|OTHER|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
214628955|NCT02302482|OTHER|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
214628956|NCT04155671|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
214628957|NCT04155671|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
214628958|NCT00256737|DRUG|Omeprazole|
214628959|NCT03793712|DRUG|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
214628960|NCT03793712|DRUG|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
214628961|NCT03793712|DRUG|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
214628962|NCT06123065|BEHAVIORAL|Yoga|8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
214628963|NCT06537713|DIAGNOSTIC_TEST|Testican-1|Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
214628964|NCT02955615|DRUG|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
214628965|NCT02955615|DRUG|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
214628966|NCT03937180|BEHAVIORAL|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
214719930|NCT02420990|BEHAVIORAL|Medication Integration Protocol (MIP)|
214719931|NCT02420990|BEHAVIORAL|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
214719932|NCT01402388|BEHAVIORAL|Group lifestyle programme|
214719933|NCT03275415|DRUG|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
214719934|NCT03275415|DRUG|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
214719935|NCT01154907|DRUG|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
214719936|NCT04602819|DEVICE|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
214719937|NCT04602819|DEVICE|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
214719938|NCT04602819|DEVICE|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
214719939|NCT04602819|DEVICE|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
214719940|NCT02788851|DRUG|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
214719941|NCT02788851|BEHAVIORAL|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
214719942|NCT04803890|PROCEDURE|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
214719943|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
214719944|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
214719945|NCT02955771|DEVICE|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
214719946|NCT02680392|PROCEDURE|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
214719947|NCT02680392|DRUG|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
214719948|NCT01913197|OTHER|An MRI-based technique to identify prostate cancer|
214719949|NCT01592006|DRUG|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
214719950|NCT01592006|DRUG|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
214628967|NCT03937180|BEHAVIORAL|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
214628968|NCT05182151|DRUG|Istradefylline 40 mg|adenosine A2A receptor antagonist
214628969|NCT01359709|DRUG|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
214628970|NCT05303545|OTHER|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
214628971|NCT06339528|PROCEDURE|Vojta's Reflex Locomotion|"Reflex locomotion according to Vojta's therapy is a neurorehabilitative concept originally used for diagnostics and treatment of infants who were at risk of non-physiological psychomotor development, especially spastic cerebral palsy. This concept utilizes stimulation of specific zones described by Vojta to evoke global motor and non-motor response.~Trigger zones are specific body zones that are stimulated with pressure during reflex locomotion stimulation. They are pressure stimulated in order to induce reflex response. Variations of stimulation of different trigger zones (spatial summation) causes multiplication of afferent impulses. Sufficiently long stimulation of trigger zones (temporal summation) induces isometric contraction in muscle groups described by Vojta."
214719951|NCT01592006|DRUG|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
214719952|NCT04740333|OTHER|No intervention- observational study|No intervention- observational study
214719953|NCT04282876|DRUG|Degarelix|Patients receiving Degarelix
214719954|NCT03107598|DRUG|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
214628972|NCT06339528|PROCEDURE|Sham stimulation|Control group received sham stimulation by physicians at zones outside of the pressure zones, specifically 4-5 cm above the patella and on the lateral malleolus.
214628973|NCT05022797|DRUG|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
214628974|NCT04797065|PROCEDURE|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
214628975|NCT04797065|PROCEDURE|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
214628976|NCT02463175|DRUG|Plasmalyte|Boluses of 5ml/kg of plasmalyte
214628977|NCT02463175|PROCEDURE|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
214628978|NCT00418353|DRUG|Betamethasone(Celestone soluspan) and Dexamethasone|
214628979|NCT05799456|DIAGNOSTIC_TEST|Free glycosaminoglycan profiling|Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
214628980|NCT05266066|OTHER|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.
214628981|NCT05266066|OTHER|7 day antibiotic course for VAT|Patients will receive standard care plus 7 day course of antibiotic.
214628982|NCT02735369|DRUG|2% OC-10X|2% OC-10X
214628983|NCT02735369|DRUG|Placebo Comparator|Placebo
214628984|NCT02319187|DRUG|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
214628985|NCT02319187|DRUG|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
214628986|NCT02319187|DRUG|irinotecan|irinotecan 160mg/m2 d1, every 14 days
214628987|NCT04319133|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
214628988|NCT02401828|DRUG|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
214628989|NCT03221738|BEHAVIORAL|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
214628990|NCT01650025|DIETARY_SUPPLEMENT|VSL#3 active probiotic|
214628991|NCT01650025|OTHER|VSL#3 placebo|
214628992|NCT05404464|OTHER|Different baseline characteristics and clinical management|Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
214628993|NCT02260115|DEVICE|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
214628994|NCT02260115|PROCEDURE|Surgical Control|Surgery only
214628995|NCT00823498|BEHAVIORAL|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
214628996|NCT00823498|BEHAVIORAL|Interview|Interview with a member of study staff at housing development site.
214628997|NCT00823498|OTHER|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
214628998|NCT00288756|PROCEDURE|lv injection of contrast|
214628999|NCT06632184|DRUG|Ondansetron Intraperitoneal Lavage|A single dose of 8 mg of ondansetron diluted in 500 mL of 0.9% saline solution will be administered as an intraperitoneal lavage at the end of elective laparoscopic cholecystectomy. The solution will remain in the abdominal cavity for 5 minutes and then be fully aspirated before surgical closure. This intervention aims to evaluate the local analgesic and antiemetic effects of ondansetron when used via the peritoneal route.
214629000|NCT06632184|DRUG|Saline Intraperitoneal Lavage|At the end of elective laparoscopic cholecystectomy, a peritoneal lavage will be performed using 500 mL of 0.9% saline solution (normal saline). The solution will be maintained in the peritoneal cavity for 5 minutes and then fully aspirated before surgical closure. This intervention serves as the comparator to assess the added effect of ondansetron in the experimental group.
214629001|NCT03885089|DRUG|Infliximab [infliximab biosimilar 3]|\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
214629002|NCT00802204|RADIATION|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
214629003|NCT00802204|PROCEDURE|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
214629004|NCT00802204|PROCEDURE|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
214629005|NCT00802204|BEHAVIORAL|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
214629006|NCT00802204|OTHER|Caloric Restriction|Obese participants only complete a short-term (\~10days) very low calorie diet
214629007|NCT04841707|DEVICE|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
214629008|NCT01744600|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
214629009|NCT04499443|DRUG|GST-HG131 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
214629010|NCT04499443|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
214629011|NCT05232838|DEVICE|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
214629012|NCT04489888|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
214629013|NCT04489888|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
214629014|NCT04489888|DRUG|Paclitaxel|At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
214629015|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators"
214629016|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
214629017|NCT06047600|OTHER|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
214629018|NCT03349099|DEVICE|Cook Flexor|ureteral access sheath
214629019|NCT03349099|DEVICE|Boston Scientific Navigator|ureteral access sheath
214629020|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
214629021|NCT02775396|DEVICE|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
214629022|NCT02727985|PROCEDURE|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
214629023|NCT01070732|DRUG|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
214629024|NCT01805531|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
214629025|NCT05422820|DIAGNOSTIC_TEST|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (\>150-400 or \>400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
214629026|NCT03641963|DEVICE|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
214629027|NCT05428891|PROCEDURE|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
214629028|NCT02967874|PROCEDURE|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
214629029|NCT02967874|DRUG|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
214629030|NCT02258828|DRUG|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
214629031|NCT02258828|DRUG|Placebo|Matched placebo
214629032|NCT01685827|DRUG|Fexinidazole|
214629033|NCT01685827|DRUG|Nifurtimox|
214629034|NCT01685827|DRUG|Eflornithine|
214629035|NCT01518218|BEHAVIORAL|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
214629036|NCT02285621|OTHER|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
214629037|NCT06493474|OTHER|Education|PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM
214629038|NCT06493474|OTHER|Routine Care|Non education program only routine care
214629039|NCT05941078|BEHAVIORAL|ICF-based post-stroke rehabilitation program|Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
214629040|NCT00872807|BEHAVIORAL|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
214629041|NCT00872807|BEHAVIORAL|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
214629042|NCT01750112|DEVICE|Macrolane VRF20|Injection treatment with Macrolane VRF20
214629043|NCT04080193|BEHAVIORAL|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
214629044|NCT02385630|OTHER|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
214629045|NCT03834415|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10\>8 CFU
214629046|NCT03834415|OTHER|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
214629047|NCT00278993|DRUG|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
214629048|NCT00986700|DIETARY_SUPPLEMENT|late night meal|Three different kinds of late night meal each for 2 days.
214629049|NCT04828057|DRUG|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
214629050|NCT01003275|DRUG|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
214629051|NCT01003275|DRUG|Placebo|Two soft gels by mouth daily for 8 weeks
214629052|NCT06539910|PROCEDURE|General Anesthesia|All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
214629053|NCT06539910|PROCEDURE|TIPS block|Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection. Distal adductor canal block via another needle puncture.Ten mL of a mixture of 0.25 % bupivacaine and 8 mg dexamethasone will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane lateral to medial approach just lateral to the superficial femoral artery
214719955|NCT02783417|OTHER|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
214629054|NCT06539910|PROCEDURE|Modified TIPS block|Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane.Both groups will receive a mixture of 0.25 % bupivacaine and 8 mg dexamethasone. Ten mL will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA anaesthetic mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane medial to lateral approach just lateral to the superficial femoral artery. Then, the needle will be redirected just underneath the ALM and 10 mL of the LA mixture will be injected in the plane between the ALM and the adductor magnus muscle (AMM).Total volume of LA will be 50 mL.
214629055|NCT06539910|PROCEDURE|Mutimodal analgesia|Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes
214629056|NCT02062788|DIETARY_SUPPLEMENT|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
214629057|NCT06333834|DRUG|Traditional scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)
214629058|NCT06333834|DRUG|Serial dose of scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
214629059|NCT06293469|PROCEDURE|Accelerated Flap Coverage Surgery|Timing of the flap surgery is with a goal of 72 hours from injury
214629060|NCT06293469|PROCEDURE|Standard of Care Flap Timing|Timing of the flap surgery is the standard of care flap timing for the participating institution.
214719956|NCT04414527|BEHAVIORAL|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
214629061|NCT02701387|DEVICE|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
214629062|NCT02701387|DEVICE|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
214629063|NCT02043548|DRUG|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
214629064|NCT02043548|DRUG|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
214629065|NCT05699265|DIAGNOSTIC_TEST|Measures of arterial stiffness and endothelial function|baseline cMRI, vascular reactivity studies, and CPET
214629066|NCT05699265|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).
214629067|NCT05699265|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.
214629068|NCT05699265|DIAGNOSTIC_TEST|Serum and urine biomarkers|Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
214629069|NCT03071614|OTHER|News items with spin|Interpretation of news items with spin
214629070|NCT03071614|OTHER|News items without spin|Interpretation of news items without spin
214629071|NCT04933604|PROCEDURE|laparoscopic partial nephrectomy|Nephron sparing minimally invasive surgery
214629072|NCT04933604|PROCEDURE|Laparoscopic radical nephrectomy|Completely removal of kidney by using laparoscopic surgery
214629073|NCT04703673|DRUG|Cineole|self administration according to directions for use
214629074|NCT04703673|DRUG|Nasal Decongestant|self administration according to directions for use
214629075|NCT00389428|DRUG|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
214629076|NCT05613764|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
214629077|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
214629078|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
214629079|NCT03871322|DIETARY_SUPPLEMENT|Placebo|Placebo control group
214629080|NCT05678036|DRUG|Opioid maintenance treatment|A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
214629081|NCT04674020|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
214629082|NCT06037733|RADIATION|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
214629083|NCT04010214|OTHER|No intervention|No intervention
214629084|NCT02136030|DRUG|Liposomal amphotericin B|4mg/kg/day, IV infusion
214629085|NCT02136030|DRUG|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
214629086|NCT02114320|DEVICE|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
214629087|NCT00456989|DRUG|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
214629088|NCT00456989|DRUG|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
214629089|NCT02100436|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
214629090|NCT04666779|OTHER|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
214629091|NCT04234906|DRUG|Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
214629092|NCT04234906|DRUG|Magnesium Sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
214629093|NCT04234906|DRUG|Amiodarone|I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
214629094|NCT04234906|DRUG|Procainamide|IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
214629095|NCT01290874|DRUG|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
214629096|NCT01290874|DRUG|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
214629097|NCT01290874|DRUG|Formoterol|Formoterol 12 mcg twice daily for one year
214629098|NCT01430455|DRUG|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
214629099|NCT05796102|PROCEDURE|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
214629100|NCT02598375|OTHER|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
214629101|NCT02386228|GENETIC|collection of CSF and blood|collection of CSF and blood
214629102|NCT05035615|DIAGNOSTIC_TEST|IUO Acute Leukemia Panel|This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
214629103|NCT02408471|DEVICE|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
214629104|NCT01481051|DRUG|Latanoprost-PPDS|Sustained delivery for 12 weeks
214629105|NCT05506176|DRUG|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
214629106|NCT05506176|DRUG|Placebo|Placebo (tablet)
214629107|NCT03829657|DRUG|ampreloxetine|Oral tablet, QD (Daily)
214629108|NCT03829657|DRUG|Placebo|Oral tablet, QD
214629109|NCT04501185|DEVICE|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
214629110|NCT04194528|DRUG|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
214629111|NCT04194528|DEVICE|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
214629112|NCT05216679|DEVICE|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
214629113|NCT05216679|DEVICE|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
214629114|NCT02121600|OTHER|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.
214629115|NCT02121600|RADIATION|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
214629116|NCT02121600|RADIATION|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
214629117|NCT00948363|OTHER|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
214629118|NCT00948363|OTHER|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
214629119|NCT04571411|OTHER|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
214629120|NCT02304107|DRUG|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
214629121|NCT02304107|DRUG|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
214629122|NCT06043232|BIOLOGICAL|DC vaccine|DC vaccine produced by the Team
214629123|NCT02325284|DEVICE|Pressure Algometer Testing|
214629124|NCT02188875|BEHAVIORAL|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
214629125|NCT02188875|BEHAVIORAL|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
214629126|NCT01255644|DRUG|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
214629127|NCT02589444|DIETARY_SUPPLEMENT|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
214629128|NCT02589444|OTHER|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
214629129|NCT02589444|OTHER|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
214629130|NCT02589444|OTHER|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
214629131|NCT02589444|PROCEDURE|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
214629132|NCT01195727|DRUG|Apixaban|
214629133|NCT01311050|DRUG|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
214629134|NCT05559190|OTHER|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
214629135|NCT05559190|OTHER|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
214629136|NCT00485602|PROCEDURE|"orthodontic treatment with Rafenalign appliance"|
214629137|NCT00116350|DRUG|Misoprostol|800 mcg sublingual misoprostol
214629138|NCT00116350|DRUG|Oxytocin|40 IU Oxytocin IV
214629139|NCT03587220|DRUG|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
214629140|NCT03587220|RADIATION|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
214629141|NCT03587220|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
214629142|NCT03587220|DRUG|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
214719957|NCT04414527|BEHAVIORAL|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
214719958|NCT00405717|DRUG|atorvastatin,pravastatin|
214719959|NCT02648243|BEHAVIORAL|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
214719960|NCT00228943|DIETARY_SUPPLEMENT|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
214719961|NCT00228943|DIETARY_SUPPLEMENT|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
214719962|NCT04368689|OTHER|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
214719963|NCT04685538|DRUG|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
214719964|NCT04685538|DRUG|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
214719965|NCT03518489|DRUG|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
214719966|NCT03518489|DRUG|standard care|Standard care will include mouth wash with antibiotics.
214719967|NCT03625089|DRUG|Atorvastatin|"Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
214629143|NCT04867473|BEHAVIORAL|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
214629144|NCT03200132|DIAGNOSTIC_TEST|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
214719968|NCT05480241|DRUG|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
214719969|NCT05480241|DRUG|Placebo|Placebo + Omeprazole 20mg once daily on fasting
214719970|NCT02638272|PROCEDURE|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
214719971|NCT02019745|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
214719972|NCT05267483|OTHER|No intervention|No intervention
214719973|NCT00493155|DRUG|RG1530|Administered po at escalating doses (10 cohorts)
214719974|NCT04815733|PROCEDURE|Mandatory ventilation|Use PCV-VG
214719975|NCT04815733|PROCEDURE|pressure support ventilation|Use PSVpro
214629145|NCT01014689|DRUG|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
214629146|NCT01014689|DRUG|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
214629147|NCT06020586|OTHER|hair lotion|ECOHAIR
214629148|NCT05422560|PROCEDURE|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
214629149|NCT03283826|BIOLOGICAL|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
214719976|NCT03809247|OTHER||have no any intervention
214719977|NCT03226548|OTHER|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
214719978|NCT04971369|DIAGNOSTIC_TEST|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
214719979|NCT00426933|DRUG|Daptomycin|
214719980|NCT00426933|DRUG|Vancomycin|
214719981|NCT03301233|DRUG|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
214719982|NCT01784614|DRUG|LY2624803 - Solution|Administered orally as reconstituted solution
214719983|NCT01784614|DRUG|LY2624803 - Capsule|Administered orally as a capsule
214629150|NCT03283826|DRUG|Placebo|Placebo matching to ATA188
214629151|NCT00432614|DRUG|SR58611A|oral administration
214629152|NCT00432614|DRUG|escitalopram|oral administration
214629153|NCT00432614|DRUG|placebo|oral administration
214629154|NCT00003462|DRUG|busulfan|
214629155|NCT01996475|DRUG|Escitalopram Oxalate Tablets|
214629156|NCT05468268|DEVICE|20 Hz rTMS|rTMS stimulation
214629157|NCT05468268|DEVICE|Sham rTMS|Sham stimulation
214629158|NCT01632462|DRUG|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
214629159|NCT05353699|OTHER|Implementation strategies|We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
214719984|NCT01784614|DRUG|Placebo - Solution|Administered orally as solution
214719985|NCT01784614|DRUG|Placebo - Capsule|Administered orally as a capsule
214719986|NCT05793424|OTHER|Cerebrospinal fluid (CSF) sample and additional blood samples|Lumbar puncture (Spinal Tap) and additional blood samples
214719987|NCT02361489|DEVICE|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
214719988|NCT03645915|OTHER|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
214719989|NCT05625815|DEVICE|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214719990|NCT05625815|DEVICE|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214629160|NCT01547455|DRUG|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
214629161|NCT01547455|DRUG|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
214629162|NCT00544609|DRUG|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
214629163|NCT00544609|PROCEDURE|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
214629164|NCT03565627|DEVICE|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
214629165|NCT03565627|DEVICE|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
214629166|NCT00718783|OTHER|Tissue samples taken from retinoblastoma|Tissue banking
214629167|NCT00718783|OTHER|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
214629168|NCT03813537|OTHER|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
214629169|NCT05075811|DRUG|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
214629170|NCT05075811|OTHER|Placebo|Normal Saline
214629171|NCT00362011|BEHAVIORAL|Salba diet|
214629172|NCT01696526|OTHER|vitamin D fortified fish|fish containing vitamin D3
214629173|NCT01696526|OTHER|conventional fish|fish containing low concentrations of vitamin D3
214629174|NCT02549209|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
214629175|NCT02549209|DRUG|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
214629176|NCT02549209|DRUG|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
214629177|NCT05686200|BEHAVIORAL|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
214629178|NCT00333359|DRUG|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
214629179|NCT00322283|DRUG|Oglemilast|Oglemilast, 15mg once per day, oral administration
214629180|NCT00322283|DRUG|Placebo|Dose-marched placebo, once per day, oral administration
214629181|NCT00584155|DRUG|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
214629182|NCT00584155|DRUG|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
214629183|NCT02282644|BIOLOGICAL|Bone marrow sampling|
214629184|NCT00941265|DRUG|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
214629185|NCT00941265|DRUG|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
214629186|NCT06285591|DRUG|Lactobacillus reuteri Tablets|Lactobacillus reuteri lozenges (NOW Foods, Sweden) contained 2×10\^8 CFU viable cells of Lactobacillus reuteri as the active ingredient.
214629187|NCT06285591|DRUG|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus reuteri.
214719991|NCT05625815|DEVICE|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214629188|NCT06285591|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
214629189|NCT02148965|BEHAVIORAL|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
214629190|NCT04793178|DEVICE|Oxygen Reserve Index, Masimo Corporation, USA.|The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
214629191|NCT01217671|BIOLOGICAL|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
214629192|NCT01217671|OTHER|Placebo|Placebo
214629193|NCT00826124|PROCEDURE|Epidural steroid injection|Injection based solely on history and physical exam
214629194|NCT00826124|PROCEDURE|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
214629195|NCT00826124|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
214629196|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
214629197|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
214629198|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
214629199|NCT04994119|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
214629200|NCT04994119|DRUG|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
214629201|NCT02030743|OTHER|Visual training|6 training sessions with computerised visual attention paradigm
214629202|NCT04197115|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
214629203|NCT04197115|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
214629204|NCT04197115|DRUG|Complex B|Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
214629205|NCT05462847|DRUG|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
214629206|NCT06512974|BEHAVIORAL|NeuroTrainer|Virtual reality based cognitive training
214629207|NCT06871462|BEHAVIORAL|BP monitor use training and app training|Patients will be taught how to use a BP monitor, along with the accompanying mobile app to view their readings.
214629208|NCT06871462|BEHAVIORAL|Online patient portal enrollment and training|Patients will receive training on how to use an online patient portal. If they are not yet enrolled in an online patient portal and would like to be, they will also be enrolled into one.
214629209|NCT06871462|BEHAVIORAL|SMS reminders to take blood pressure|Patients will receive reminders via SMS to take their blood pressure.
214629210|NCT06871462|BEHAVIORAL|Education about self-management of hypertension|One-time training with action planning, access to website with language concordant patient education, and educational text messages
214629211|NCT06871462|BEHAVIORAL|Educational text messages that encourage seeking support from a support person|Educational text messages about behavioral changes that explicitly encourage seeking support from a support person
214629212|NCT06871462|BEHAVIORAL|Involvement of caregiver or support person|Patients will be asked to involve a caregiver or support person for all activities above, including patient portal proxy access.
214629213|NCT06871462|BEHAVIORAL|Group classes|Patients will be asked to attend in-person or online group education classes on hypertension management
214629214|NCT03894670|OTHER|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
214629215|NCT03894670|OTHER|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
214629216|NCT05132101|DRUG|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
214629217|NCT07028047|BIOLOGICAL|WGc-043 Injection|WGc-043 Injection, intramuscular injection
214629218|NCT01920204|DRUG|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
214629219|NCT02091570|OTHER|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
214629220|NCT06116825|OTHER|1450ppm Fluoride toothpaste|1450ppm Fluoride toothpaste
214629221|NCT06116825|OTHER|1000Pppm Fluoride toothpaste|1000Pppm Fluoride toothpaste
214629222|NCT04201925|PROCEDURE|upper blepharoplasty|excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
214629223|NCT02098564|OTHER|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
214629224|NCT02098564|OTHER|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
214629225|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
214629226|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
214629227|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
214629228|NCT00938314|DRUG|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
214629229|NCT04652271|PROCEDURE|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
214629230|NCT01826552|DEVICE|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
214629231|NCT01826552|DEVICE|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
214629232|NCT04979507|OTHER|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
214629233|NCT01394939|BIOLOGICAL|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
214629234|NCT01394939|DRUG|Irinotecan|180 mg/m2 IV every 2 weeks.
214629235|NCT03379662|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
214629236|NCT03379662|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
214629237|NCT05928455|BIOLOGICAL|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
214629238|NCT05928455|BIOLOGICAL|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
214629239|NCT01871961|DRUG|Methotrexate (Metoject® prefilled pen)|
214629240|NCT02806323|OTHER|Yoga practice|
214629241|NCT00002350|BIOLOGICAL|APL 400-003|
214629242|NCT03955133|OTHER|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
214629243|NCT04395261|DIAGNOSTIC_TEST|Wideband Tympanometry|
214629244|NCT04590092|DEVICE|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
214629245|NCT01972893|DRUG|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
214629246|NCT01972893|DRUG|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
214629247|NCT02294513|DEVICE|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
214629248|NCT04513002|DIETARY_SUPPLEMENT|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
214629249|NCT00446602|DRUG|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
214629250|NCT05461612|DEVICE|Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device|Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
214629251|NCT05227638|OTHER|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
214629252|NCT03373305|DRUG|Brentuximab Vedotin|Given IV
214629253|NCT03373305|DRUG|Lenalidomide|Given PO
214629254|NCT03373305|OTHER|Laboratory Biomarker Analysis|Correlative studies
214629255|NCT05578729|BEHAVIORAL|Single surgical mask group, Double surgical mask group, N95 mask group|Masks were given to the resting pregnant women 30 minutes before the NST, and they were provided to wear masks. After 30 minutes, the vital signs of the pregnant women were measured just before and after the NST, and the images of the NST traces were taken.
214629256|NCT03637933|PROCEDURE|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
214629257|NCT01495442|DEVICE|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
214629258|NCT01495442|DEVICE|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
214629259|NCT04238390|DRUG|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
214629260|NCT04238390|DRUG|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
214629261|NCT05331014|DRUG|LivaloVA|For 8 weeks(PO, QD)
214629262|NCT05331014|DRUG|LivaloV|For 8 weeks(PO, QD)
214629263|NCT05331014|DRUG|VA|For 8 weeks(PO, QD)
214629264|NCT02342795|OTHER|e-cigarette|
214629265|NCT02342795|OTHER|cigarette substitute|
214629266|NCT04743102|PROCEDURE|multi-points and full-thickness Biopsy|Four points around the tumor site and center of the tumor site full-thickness Biopsy
214629267|NCT04743102|DIAGNOSTIC_TEST|traditional cCR|diginal examination, endoscopy test, rectal MRI, and serum CEA level
214629268|NCT01339559|DRUG|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
214629269|NCT02823691|DRUG|Lanreotide and Metformin|Lanreotide and Metformin
214629270|NCT00216411|BIOLOGICAL|Botulinum toxin type A|
214629271|NCT00216411|DRUG|Placebo|
214629272|NCT04690400|OTHER|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
214629273|NCT04690400|OTHER|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
214629274|NCT04842201|DRUG|CM326|subcutaneous injection
214629275|NCT04842201|DRUG|Placebo|subcutaneous injection
214629276|NCT00774462|DRUG|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
214629277|NCT06552169|DRUG|Arm 1: SOC (mTOR + CNI)|Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
214629278|NCT06552169|BIOLOGICAL|Arm 2A: TRACT/MONO mTOR|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
214629279|NCT06552169|BIOLOGICAL|Arm 2B: TRACT/MONO CNI|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
214629280|NCT03489382|OTHER|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
214629281|NCT01107678|OTHER|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
214629282|NCT04342221|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
214629283|NCT04342221|DRUG|Placebo|Placebo capsules
214629284|NCT06273332|OTHER|AI-assisted registration|We will use artificial intelligence to register 3d model on intra-oral scan
214629285|NCT06273332|OTHER|Point-based registration|We will use five references points or more to perform model registration
214629286|NCT00529256|BEHAVIORAL|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
214629287|NCT04716790|PROCEDURE|Ultrasound Debridement|Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
214629288|NCT04716790|PROCEDURE|Conventional Treatment|Conventional Treatment based on international guidelines for diabetic foot
214629289|NCT01133587|OTHER|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
214629290|NCT01133587|BEHAVIORAL|admissions contract|"contract regarding patient-guided admissions starting immediately"
214629291|NCT02368054|DRUG|Bupivacaine|Infiltration anesthesia
214629292|NCT02368054|DRUG|Adrenaline|Infiltration anesthesia
214629293|NCT03177772|BEHAVIORAL|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
214629294|NCT03094871|BEHAVIORAL|FACE-PC|
214629295|NCT01456676|DRUG|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
214629296|NCT01780025|BEHAVIORAL|Auditory evoked potentials and audiometry|
214629297|NCT01780025|BEHAVIORAL|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
214629298|NCT04889300|BEHAVIORAL|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
214719992|NCT05625815|DEVICE|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214719993|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
214719994|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
214629299|NCT04889300|BEHAVIORAL|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
214629300|NCT01018498|BEHAVIORAL|Restricted FODMAPs diet|Restricted fermentable substrate diet
214629301|NCT04674592|OTHER|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
214629302|NCT01950351|OTHER|Laboratory Biomarker Analysis|Correlative studies
214629303|NCT01950351|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214629304|NCT01950351|OTHER|Quality-of-Life Assessment|Ancillary studies
214629305|NCT05097456|DEVICE|carbon dioxide laser|carbon dioxide laser
214629306|NCT05097456|DEVICE|sham laser|sham laser
214629307|NCT04429178|OTHER|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
214719995|NCT03739736|OTHER|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
214719996|NCT05117593|DRUG|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
214719997|NCT05117593|DRUG|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
214629308|NCT06333509|BIOLOGICAL|CT071|a single CAR-T infusion of CT071
214629309|NCT02305355|DRUG|Omega-3-acids ethylesters 90 4g|
214629310|NCT02305355|DRUG|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
214629311|NCT00072735|PROCEDURE|Electrocardiogram|
214629312|NCT05070221|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
214629313|NCT05070221|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
214629314|NCT05070221|DRUG|Axitinib|5mg，bid，p.o.；
214629315|NCT05865236|PROCEDURE|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
214629316|NCT05865236|PROCEDURE|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
214629317|NCT03422315|DRUG|Propofol|injection;2mg/kg;single-dose
214629318|NCT00015977|BIOLOGICAL|PSA prostate cancer vaccine|
214629319|NCT00015977|BIOLOGICAL|recombinant interleukin-12|
214629320|NCT00414453|DRUG|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
214629321|NCT00414453|DRUG|Extended-release oxycodone|extended-release oxycodone titrating schedule
214629322|NCT00414453|DRUG|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
214629323|NCT00414453|DRUG|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
214629324|NCT01231100|OTHER|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
214629325|NCT01751308|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
214629326|NCT00813423|DRUG|Hydroxychloroquine|Given PO
214629327|NCT00813423|OTHER|Laboratory Biomarker Analysis|Correlative studies
214629328|NCT00813423|OTHER|Pharmacological Study|Correlative studies
214629329|NCT00813423|DRUG|Sunitinib Malate|Given PO
214629330|NCT00181181|DRUG|atorvastatin|Atorvastatin 80 mg daily for 3 months
214629331|NCT00181181|OTHER|placebo|placebo daily
214629332|NCT03938805|BEHAVIORAL|Internet-based cognitive behavioral therapy for insomnia|Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
214629333|NCT03938805|OTHER|Control group|Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
214629334|NCT06079450|OTHER|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
214629335|NCT04418700|DEVICE|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
214629336|NCT01803360|DRUG|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
214629337|NCT00290433|DRUG|Cyclophosphamide|Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
214629338|NCT00290433|DRUG|Mesna|Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
214629339|NCT00290433|DRUG|Vincristine|Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
214629340|NCT00290433|DRUG|Methotrexate|Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
214629341|NCT00290433|DRUG|Ara-C|Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
214629342|NCT00290433|DRUG|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
214629343|NCT00290433|DRUG|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
214629344|NCT00290433|DRUG|Doxil|Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
214719998|NCT04758741|BEHAVIORAL|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
214629345|NCT01829256|BEHAVIORAL|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
214629346|NCT03046875|OTHER|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
214629347|NCT03046875|OTHER|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
214629348|NCT00822757|BIOLOGICAL|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
214629349|NCT00822757|BIOLOGICAL|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
214629350|NCT00941876|BEHAVIORAL|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
214629351|NCT05990673|DRUG|Remimazolam|remimazolam is given intravenously
214719999|NCT04758741|OTHER|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
214720000|NCT06082375|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 in the form of cholecalciferol.
214720001|NCT06082375|DIETARY_SUPPLEMENT|Placebo|Vegetable oil.
214720002|NCT01496404|PROCEDURE|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
214629352|NCT05204966|DIAGNOSTIC_TEST|AI analysis|"1. Bottle feeding filming~   \- With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
214629353|NCT03285737|DIETARY_SUPPLEMENT|Whey|Supplement provided twice daily in 30g doses
214629354|NCT03285737|DIETARY_SUPPLEMENT|Collagen|Supplement provided twice daily in 30g doses
214629355|NCT04344587|OTHER|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
214720003|NCT01496404|PROCEDURE|Scalpel|Incising skin (epidermis and dermis) with scalpel.
214629356|NCT04344587|OTHER|Usual care|"The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
214629357|NCT05324046|DIAGNOSTIC_TEST|contrast-enhanced abdomen CT|"contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation).~* full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional)~* low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software.~* images are reconstructed using full dose (A- \& B- tubes) and smaller dose (A-tube only, B-tube only)"
214629358|NCT03919708|DEVICE|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
214629359|NCT02742285|DRUG|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
214720004|NCT02114398|OTHER|usual treatment|usual treatment
214629360|NCT03072056|DRUG|MIN-101|
214720005|NCT02114398|OTHER|usual treatment + sophrology|usual treatment + sophrology
214720006|NCT05615155|OTHER|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
214720007|NCT03152188|DRUG|FMT|Fifteen FMT Openbiome capsules administered at the same time
214629361|NCT00001287|DRUG|intravenous immunoglobulin (IVIg)|
214629362|NCT05101603|DEVICE|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
214629363|NCT05101603|DEVICE|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
214629364|NCT05101603|PROCEDURE|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
214629365|NCT03330886|DRUG|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
214629366|NCT04995393|PROCEDURE|Heating with a disposable glove containing water|Heating of the infants heel with a glove before blood sampling.
214629367|NCT04995393|PROCEDURE|Heating with a blanket|Heating of the infants heel with a blanket before blood sampling.
214629368|NCT04995393|PROCEDURE|Heating with a gel pack|Heating of the infants heel with a gel pack before blood sampling.
214629369|NCT02585011|DRUG|Ropivacaine|
214629370|NCT02585011|DRUG|Epinephrine|
214629371|NCT02585011|DRUG|Saline|
214629372|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|iPACK block + Adductor Canal Block
214629373|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|Erector Spinae Plane Block
214629374|NCT06302218|DRUG|control group|only spinal anesthesia
214629375|NCT04749459|DRUG|ChapStick Moisturizer, Strawberry Flavor|A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.
214629376|NCT04749459|DRUG|ChapStick Moisturizer, Classic Flavor|A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
214629377|NCT04749459|DRUG|ISO 24444:2010 P2 Standard Reference Sunscreen|A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
214629378|NCT00097760|DRUG|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
214629379|NCT00097760|DRUG|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
214629380|NCT00097760|DRUG|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
214629381|NCT02281695|OTHER|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
214720008|NCT03152188|OTHER|Placebo|Fifteen placebo capsules administered at the same time
214629382|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
214629383|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
214629384|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
214629385|NCT01356914|DRUG|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
214629386|NCT02991092|PROCEDURE|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
214629387|NCT06437678|DRUG|Liposomal Irinotecan Hydrochloride|Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
214629388|NCT05098041|DRUG|Soticlestat|Soticlestat tablets.
214629389|NCT05098041|DRUG|Rifampin|Rifampin capsules.
214629390|NCT00525395|GENETIC|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
214629391|NCT00525395|PROCEDURE|Continuous phototherapy|Group B: 6 months non-stop treatment.
214629392|NCT02037737|DRUG|Abatacept|
214629393|NCT03729388|OTHER|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
214629394|NCT01797900|DRUG|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
214629395|NCT01797900|DRUG|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
214629396|NCT01797900|RADIATION|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
214629397|NCT03948178|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
214629398|NCT05099861|OTHER|No intervention|this is an observational study
214629399|NCT03190200|DEVICE|MRI|No intervention - observational trial using MRI
214720009|NCT00856817|DRUG|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
214629400|NCT03597932|DEVICE|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
214629401|NCT05628714|OTHER|Patient decision aid for patients with superficial basal cell carcinoma|An online WebApp
214629402|NCT03177083|DRUG|peginterferon beta-1a|SC every 2 weeks
214629403|NCT03177083|DRUG|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
214629404|NCT03177083|DRUG|interferon beta-1b|Per SMPC
214629405|NCT00382993|DRUG|Placebo|Matching placebo tablet
214629406|NCT00382993|DRUG|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
214720010|NCT00856817|DRUG|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
214720011|NCT00202345|DRUG|Iron sucrose|
214629407|NCT01052311|DRUG|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
214629408|NCT01052311|DRUG|Placebo|Placebo tablets once daily
214629409|NCT01052311|DRUG|Tredaptive|Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
214629410|NCT02826109|DEVICE|PeriAcryl®90 HV|
214629411|NCT06131879|DEVICE|Laser acupuncture|Biostimulation of temporalis and masseter muscles
214629412|NCT06131879|BEHAVIORAL|Modified physical therapy|Progressive muscle relaxation of temporalis and masseter muscles
214629413|NCT03149081|DRUG|Boswellia|Boswellia is an extract from frankincense
214629414|NCT05134961|PROCEDURE|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
214629415|NCT01046877|DEVICE|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
214629416|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem \& Delta-TT cup with a polyethylene insert
214629417|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert
214629418|NCT03093038|DEVICE|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
214629419|NCT03869528|DRUG|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
214629420|NCT03869528|DRUG|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
214629421|NCT01108146|DRUG|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
214629422|NCT01108146|DRUG|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
214629423|NCT01888042|DRUG|Everolimus|10 mg (1 tablet of 10 mg)
214629424|NCT00712699|DRUG|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
214629425|NCT00712699|DRUG|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
214629426|NCT03831594|DEVICE|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
214629427|NCT03831594|OTHER|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
214629428|NCT02866474|DIETARY_SUPPLEMENT|population living at home with meals on wheels|
214629429|NCT02866474|DIETARY_SUPPLEMENT|population living in an EHPAD|
214629430|NCT03836391|BEHAVIORAL|Nudge|Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
214629431|NCT01515384|DRUG|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
214629432|NCT04280900|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
214629433|NCT04280900|BEHAVIORAL|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
214629434|NCT05020873|OTHER|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
214629435|NCT05209503|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
214629436|NCT05209503|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
214629437|NCT06466226|PROCEDURE|Multiple central venous lines in two sites separately|Patients with two central venous lines in two sites separately (two central venous sites).
214629438|NCT06466226|PROCEDURE|Multiple central venous lines in one site (internal jugular vein)|Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).
214629439|NCT05965284|DRUG|Azathioprine|All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
214629440|NCT05965284|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
214629441|NCT05828693|BEHAVIORAL|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
214629442|NCT05828693|BEHAVIORAL|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
214629443|NCT03350217|DRUG|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
214629444|NCT03350217|DRUG|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
214629445|NCT03027986|BEHAVIORAL|postural rehabilitation program|This program is based on sensory-motor control
214629446|NCT00800332|DRUG|CYT003-QbG10|subcutaneous injection
214629447|NCT00800332|DRUG|Placebo|subcutaneous injection
214629448|NCT04267874|PROCEDURE|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
214629449|NCT04267874|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given black raspberry nectar PO
214629450|NCT04267874|DRUG|Placebo Administration|Given PO
214720012|NCT02397967|OTHER|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
214629451|NCT04267874|OTHER|Questionnaire Administration|Ancillary studies
214629452|NCT02970292|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
214629453|NCT02970292|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
214629454|NCT05473403|OTHER|Corticosteroid therapy|Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
214629455|NCT04162574|OTHER|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
214629456|NCT00083993|DRUG|Temsirolimus (CCI-779) for 34 months|
214629457|NCT00083993|DRUG|Letrozole for 34 months|
214629458|NCT00947180|BEHAVIORAL|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
214629459|NCT00947180|OTHER|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
214629460|NCT00947180|BEHAVIORAL|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
214629461|NCT03757208|DIETARY_SUPPLEMENT|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
214720013|NCT05003141|DRUG|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
214720014|NCT03828500|BEHAVIORAL|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
214720015|NCT03591913|DRUG|Misoprostol|Oral tablets
214629462|NCT04096196|BEHAVIORAL|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
214629463|NCT04096196|OTHER|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
214629464|NCT03617991|OTHER|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
214629465|NCT03464656|DRUG|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)"
214629466|NCT03464656|DIAGNOSTIC_TEST|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
214629467|NCT03464656|DIAGNOSTIC_TEST|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
214720016|NCT05106439|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
214720017|NCT05106439|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
214720018|NCT05106439|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
214720019|NCT01635036|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
214629468|NCT03464656|DIAGNOSTIC_TEST|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
214629469|NCT00757250|DRUG|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
214629470|NCT00814775|DEVICE|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
214629471|NCT00814775|DEVICE|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
214629472|NCT04723121|DIAGNOSTIC_TEST|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
214629473|NCT04723121|DIAGNOSTIC_TEST|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
214629474|NCT02012985|BIOLOGICAL|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
214629475|NCT02012985|DRUG|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
214629476|NCT06549569|PROCEDURE|TFS|burn coverage with TFS
214629477|NCT06475833|DIAGNOSTIC_TEST|Prone plank test, Side plank test, The Awareness of Sports Injuries Scales|"Prone Plank Test: For the prone bridge test, athletes will position themselves in a plank position with their elbows shoulder-width apart and directly under their shoulders. Using a stopwatch, the duration for which they can maintain this position without breaking form will be recorded.~Side Plank Tests: For the side bridge test, athletes will position themselves in a side plank position, ensuring that the shoulder is directly above the elbow. The duration for which they can maintain this position will be recorded using a stopwatch.~The Injury Prevention Awareness Scale for Athletes will be used to evaluate athletes' awareness and attitudes towards preventing sports injuries. A high score indicates a good level of awareness of injury prevention in sports."
214629478|NCT01811251|DRUG|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
214629479|NCT04759651|OTHER|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
214629480|NCT04759651|OTHER|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
214629481|NCT04759651|OTHER|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
214629482|NCT04759651|OTHER|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
214629483|NCT04759651|OTHER|Insomnia Questionnaire|Subjective evaluation of insomnia.
214629484|NCT04759651|OTHER|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
214629485|NCT04759651|OTHER|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
214629486|NCT04759651|OTHER|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
214629487|NCT03353870|OTHER|qualitative interview|individual qualitative interview
214629488|NCT02820129|DEVICE|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
214629489|NCT02820129|DEVICE|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
214629490|NCT03579784|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
214629491|NCT03579784|DRUG|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
214629492|NCT03579784|DRUG|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
214629493|NCT02671136|DEVICE|Hyperbaric Oxygen therapy|
214629494|NCT02671136|OTHER|Conventional Wound Therapies|
214629495|NCT03643380|DEVICE|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
214629496|NCT04383860|PROCEDURE|5-0 suture|5-0 suture administration during surgery
214720020|NCT00821899|BIOLOGICAL|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
214629497|NCT04383860|PROCEDURE|4-0 suture|4-0 suture administration during surgery
214629498|NCT02327637|BEHAVIORAL|Moderate Activity|Ambulation 150 feet, two times per day
214629499|NCT02547350|DRUG|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
214629500|NCT00806559|OTHER|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
214720021|NCT00083876|DRUG|Thalidomide|
214722181|NCT01921283|DEVICE|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
214722182|NCT01921283|DRUG|no- BIS sensor attachment|
214629501|NCT00806559|OTHER|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
214629502|NCT04937556|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
214629503|NCT04937556|DIETARY_SUPPLEMENT|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
214629504|NCT05409261|BIOLOGICAL|Ad26.COV2.S|Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
214629505|NCT00599482|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
214722183|NCT02972736|RADIATION|Radiation dose expressed as DAP|
214722184|NCT00505518|DRUG|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
214629506|NCT01565070|DRUG|Biofreeze|Use of Biofreeze ointment
214629507|NCT01565070|OTHER|Placebo|Use of placebo ointment
214629508|NCT04572477|DRUG|[18F]THK-5351|F-18 THK PET Imaging
214629509|NCT04572477|DRUG|[18F]AV-45|F-18 AV45 PET Imaging
214629510|NCT02982343|BEHAVIORAL|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
214629511|NCT02982343|BEHAVIORAL|Falls management only|Participants will undergo a session of falls management and education.
214629512|NCT03766529|PROCEDURE|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
214722185|NCT00505518|BEHAVIORAL|Collaborative psychiatric and primary medical care|Regular care visits from health workers
214722186|NCT02668055|BIOLOGICAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
214722187|NCT03472768|DIAGNOSTIC_TEST|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
214722188|NCT04100044|OTHER|Exercise Counseling|Meet with physical therapist
214720022|NCT00646438|DRUG|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
214629513|NCT04251637|OTHER|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
214629514|NCT03730155|OTHER|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
214629515|NCT00279825|DRUG|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
214629516|NCT00279825|DRUG|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
214629517|NCT00279825|DRUG|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
214629518|NCT00279825|DRUG|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
214629519|NCT00279825|DRUG|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
214629520|NCT00279825|DRUG|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
214629521|NCT00279825|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
214629522|NCT00279825|DRUG|CD-LD CR Placebo|Placebo to match CD-LD CR
214629523|NCT03058042|OTHER|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
214629524|NCT03058042|OTHER|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
214629525|NCT00513500|DRUG|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
214629526|NCT00513500|DRUG|Coartem|Give Coartem without RDT and refer fast breathing
214629527|NCT06494137|OTHER|inulin|inulin from chicory root
214629528|NCT05852535|PROCEDURE|Exploration|abdominal exploration
214629529|NCT02248727|DEVICE|somofilcon A|somofilcon A lens
214629530|NCT02585505|PROCEDURE|stem cells|stem cell will be injected
214629531|NCT04326335|OTHER|Felt-tip marking|Marking the location of the future stoma with a felt pen
214629532|NCT04326335|OTHER|Felt-tip marking + 3D printed ostomy button|Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
214629533|NCT04639583|DEVICE|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
214629534|NCT03216356|BEHAVIORAL|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
214629535|NCT03216356|BEHAVIORAL|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
214629536|NCT03216356|DRUG|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
214629537|NCT03216356|DRUG|Placebo|polyethylene glycol 3350 powder
214629538|NCT03216356|DRUG|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
214720023|NCT03616847|OTHER|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
214629539|NCT00749996|DEVICE|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
214720024|NCT03616847|OTHER|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
214629540|NCT00749996|PROCEDURE|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
214629541|NCT04687579|OTHER|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
214720025|NCT00643097|BIOLOGICAL|PEP-3 vaccine|Given intradermally
214720026|NCT00643097|BIOLOGICAL|sargramostim|Given intradermally
214720027|NCT00643097|DRUG|Temozolomide|Standard of care chemotherapy
214720028|NCT05210621|DRUG|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
214722189|NCT04100044|BEHAVIORAL|Exercise Intervention|Receive personalized home exercise intervention
214722190|NCT04100044|OTHER|Questionnaire administration|Ancillary studies
214629542|NCT04687579|PROCEDURE|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
214629543|NCT04687579|PROCEDURE|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
214629544|NCT02613598|DRUG|Bortezomib|
214720029|NCT05778929|DIAGNOSTIC_TEST|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
214722191|NCT04100044|OTHER|Quality-of-Life Assessment|Ancillary studies
214629545|NCT02613598|DRUG|Ruxolitinib|
214629546|NCT06293612|OTHER|No intervention was administrated to the two cohorts.|
214629547|NCT03134872|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
214629548|NCT03134872|DRUG|Carboplatin|Carboplatin
214629549|NCT03134872|DRUG|Pemetrexed|Pemetrexed
214720030|NCT05720962|PROCEDURE|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
214629550|NCT00865826|OTHER|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
214629551|NCT02765568|BEHAVIORAL|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
214720031|NCT02754661|DEVICE|COLON Capsule endoscopy|
214720032|NCT02754661|DEVICE|Computed Tomographic Colonography|
214720033|NCT00002204|BIOLOGICAL|HIV p24/MF59 Vaccine|
214720034|NCT02969967|DEVICE|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
214720035|NCT04423757|DRUG|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
214720036|NCT04423757|DRUG|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
214720037|NCT02709109|DRUG|VX-371 + HS|
214720038|NCT02709109|DRUG|Hypertonic saline|
214629552|NCT02765568|BEHAVIORAL|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
214629553|NCT02765568|BEHAVIORAL|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
214629554|NCT04038788|DEVICE|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
214629555|NCT03061981|DRUG|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
214720039|NCT02709109|DRUG|Placebo|
214720040|NCT02709109|DRUG|Orkambi|
214629556|NCT03061981|DRUG|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
214629557|NCT03061981|DRUG|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
214629558|NCT02821702|DEVICE|Vaginal ultrasound|
214629559|NCT02821702|BIOLOGICAL|Blood sample|
214629560|NCT04356560|DIAGNOSTIC_TEST|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
214629561|NCT02171585|DRUG|Dabigatran etexilate|
214629562|NCT02171585|DRUG|Clarithromycin|
214629563|NCT02626897|DEVICE|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
214720041|NCT02709109|DRUG|VX-371|
214720042|NCT00000240|DRUG|Buprenorphine|
214720043|NCT03195504|DEVICE|HFNC|High flow nasal oxygen (60 l) under GA
214720044|NCT03195504|DEVICE|CON (control)|Standard oxygen (10-15 l) under GA
214720045|NCT05550896|DIAGNOSTIC_TEST|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
214720046|NCT05438810|DRUG|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
214720047|NCT05438810|DRUG|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
214629564|NCT02626897|DEVICE|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
214629565|NCT02905474|OTHER|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
214629566|NCT02905474|DEVICE|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
214629567|NCT02905474|DEVICE|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
214629568|NCT05211479|BEHAVIORAL|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
214629569|NCT03043248|DRUG|TRK-700|repeated oral administration
214629570|NCT03043248|DRUG|Digoxin|single oral administration with/without TRK-700
214629571|NCT03043248|DRUG|Midazolam|single oral administration with/without TRK-700
214720048|NCT01688440|OTHER|#1 Respiratory Care Solution|Respiratory care solution.
214629572|NCT04996121|DRUG|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
214629573|NCT01514227|DRUG|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
214629574|NCT01514227|DRUG|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
214629575|NCT02194127|DRUG|Anthocyan capsules|
214629576|NCT02194127|DRUG|Placebo|
214629577|NCT05595083|DRUG|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
214629578|NCT05595083|DRUG|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
214629579|NCT00223028|DRUG|sirolimus, mycophenolat mofetil, fluvastatin|
214629580|NCT00109707|DRUG|Nilotinib|
214629581|NCT00037180|DRUG|Celecoxib|
214720049|NCT02229110|OTHER|Signal|Automatic signal in the electronic medical record
214720050|NCT03511820|DRUG|Lipo-AB® (amphotericin B) liposome|"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
214629582|NCT00037180|DRUG|Irinotecan|
214629583|NCT00037180|DRUG|5-fluorouracil|
214629584|NCT00037180|DRUG|Leucovorin|
214629585|NCT04707898|DEVICE|Single Bond Universal|Adhesive system
214629586|NCT04707898|DEVICE|G-Premio Bond|Adhesive system
214629587|NCT00446511|DRUG|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
214629588|NCT00446511|DRUG|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
214629589|NCT00446511|DRUG|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
214629590|NCT00446511|DRUG|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
214629591|NCT04538794|DRUG|CDX-0159|Administered intravenously
214629592|NCT04538794|DRUG|Normal Saline|Administered intravenously
214629593|NCT04609852|DRUG|E8001|Intravenous infusion.
214629594|NCT04609852|DRUG|Placebo|Intravenous infusion.
214629595|NCT02243215|OTHER|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
214722192|NCT03130504|DRUG|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
214629596|NCT03245931|OTHER|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
214629597|NCT00796276|DRUG|IR OROS paliperidone and ER OROS paliperidone|
214629598|NCT00004420|DRUG|gamma-Linolenic acid|
214629599|NCT03339921|DRUG|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
214629600|NCT03339921|PROCEDURE|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
214629601|NCT01617980|OTHER|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
214629602|NCT03256500|DEVICE|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
214629603|NCT01178450|PROCEDURE|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
214629604|NCT01178450|DRUG|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
214629605|NCT05934500|DRUG|Cannabidiol Oil|Subjects will self administer CBD sublingually
214629606|NCT04683965|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
214629607|NCT04683965|DRUG|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
214629608|NCT04683965|DRUG|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
214629609|NCT01508728|DEVICE|ORTHOSENS orthosis|with active vibration
214629610|NCT01508728|DEVICE|ORTHOSENS orthosis|with placebo vibration
214629611|NCT00285727|DRUG|Ropinirole CR|
214629612|NCT00793481|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
214629613|NCT02204696|PROCEDURE|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
214629614|NCT03393767|DRUG|Ranibizumab|Intravitreal injection
214629615|NCT01109914|BIOLOGICAL|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
214629616|NCT01501305|DIETARY_SUPPLEMENT|Mineral solution|Rehydration mineral solution
214629617|NCT01501305|DIETARY_SUPPLEMENT|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
214629618|NCT02563847|DIETARY_SUPPLEMENT|0.52 g L-Tryptophan|
214629619|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
214629620|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
214629621|NCT02563847|DIETARY_SUPPLEMENT|50 g Xylitol|
214629622|NCT02563847|DIETARY_SUPPLEMENT|75 g Erythritol|
214629623|NCT02563847|DIETARY_SUPPLEMENT|75 g Glucose|
214629624|NCT02563847|DIETARY_SUPPLEMENT|300 mL tap water|
214629625|NCT02563847|OTHER|50 mg 13C-sodium acetate|
214629626|NCT02756507|BEHAVIORAL|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
214629627|NCT02756507|BEHAVIORAL|Wait list|Delayed intervention
214629628|NCT05940779|OTHER|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
214629629|NCT02971579|PROCEDURE|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
214629630|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
214629631|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
214629632|NCT03658382|OTHER|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
214629633|NCT05915572|OTHER|Mulligan Mobilization Technique|The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation
214720051|NCT05568056|BEHAVIORAL|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
214629634|NCT05915572|OTHER|Traditional Physical Therapy Program|Myofascial release and ROM ex. 3 sessions per week for 6 weeks.
214629635|NCT03743870|DRUG|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
214629636|NCT03743870|DRUG|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
214720052|NCT03557515|BEHAVIORAL|Stress Management and CBT|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention"
214629637|NCT04450121|DEVICE|Patients will be intubated using Air-Q airway|"Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)"
214629638|NCT01606111|DRUG|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
214629639|NCT01606111|DRUG|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
214629640|NCT03460782|BIOLOGICAL|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
214629641|NCT00606086|DRUG|GI-5005|40YU, subcutaneous
214629642|NCT00606086|DRUG|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
214629643|NCT00887393|OTHER|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (\< 15% of total kcaloric intake)
214629644|NCT00887393|OTHER|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
214720053|NCT03557515|BEHAVIORAL|Stress Management and Metta-Meditation|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future"
214720054|NCT02882737|DRUG|Glucagon before exercise|
214720055|NCT02882737|DRUG|Glucagon after exercise|
214720056|NCT02882737|DRUG|Glucagon after resting|
214629645|NCT01471457|DRUG|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
214629646|NCT00708578|DRUG|Glimepiride|Once a day before breakfast
214629647|NCT00708578|DRUG|Metformin|After breakfast and supper
214629648|NCT00708578|DRUG|Insulin Glargine|Injection in the morning
214629649|NCT03891511|DEVICE|MRI scann|MRI will be performed in the TMJ of participants affected with TMD
214629650|NCT05393466|DRUG|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
214629651|NCT06089642|DEVICE|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
214629652|NCT02997579|PROCEDURE|patellar resurfacing|patellar component insert with cement
214629653|NCT00092430|BIOLOGICAL|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
214629654|NCT05383027|BEHAVIORAL|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
214629655|NCT05383027|BEHAVIORAL|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
214629656|NCT04840680|OTHER|No Intervention|This is a non-interventional study.
214629657|NCT03106038|DRUG|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
214629658|NCT04476888|BIOLOGICAL|Convalescent Plasma (CP)|500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.
214629659|NCT04476888|OTHER|Drugs and supportive care|This will include drugs like steroids, tocilizumab, azithromycin and supportive care
214629660|NCT04689776|BEHAVIORAL|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
214629661|NCT01908660|DRUG|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
214629662|NCT04744337|PROCEDURE|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
214629663|NCT02072031|DRUG|Anlotinib|Anlotinib p.o. qd
214629664|NCT02072031|DRUG|Sunitinib maleate|Sunitinib 50 mg p.o. qd
214629665|NCT00037479|DRUG|ceftriaxone|
214629666|NCT00326807|DRUG|Naltrexone|
214629667|NCT00956670|OTHER|Quality-of-Life Assessment|Ancillary studies
214629668|NCT00956670|OTHER|Questionnaire Administration|Ancillary studies
214629669|NCT00956670|PROCEDURE|Study of High Risk Factors|Undergo lymphedema assessment
214629670|NCT00956670|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214629671|NCT00956670|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo surgery
214629672|NCT00956670|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
214629673|NCT01734577|PROCEDURE|Dry needling|Sterile monofilament needles
214629674|NCT01734577|PROCEDURE|Sham needling|Applicator tubes from the sterile monofilament needles
214629675|NCT00542269|DRUG|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
214629676|NCT00542269|DRUG|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
214629677|NCT00542269|DRUG|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
214629678|NCT00867399|DRUG|ABT-126|See arm for details
214629679|NCT03363750|BEHAVIORAL|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
214629680|NCT04450680|OTHER|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
214629681|NCT03873714|DEVICE|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
214629682|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
214629683|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
214629684|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
214629685|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
214629686|NCT00708123|DRUG|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
214629687|NCT00708123|DRUG|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
214629688|NCT01445821|BIOLOGICAL|Peripheral Blood Stem Cells|Mobilized leukapheresis product
214629689|NCT01445821|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
214629690|NCT01445821|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
214629691|NCT01445821|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
214629692|NCT01445821|DRUG|Methylprednisolone|Steroid
214629693|NCT01445821|DRUG|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
214629694|NCT01445821|DRUG|Fludarabine|Purine analog which inhibits DNA synthesis or repair
214629695|NCT00407524|DRUG|AKL 1|
214629696|NCT02813278|DIETARY_SUPPLEMENT|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
214629697|NCT02813278|OTHER|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
214629698|NCT03574870|DEVICE|wearable sensor|A commercially-available wearable fitness sensor
214629699|NCT04821466|DEVICE|Virtual Reality Headset to provide a Virtual Reality Experience|Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
214629700|NCT00814892|BIOLOGICAL|allogeneic tumor cell vaccine|Given intradermally
214720057|NCT05563714|BEHAVIORAL|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
214629701|NCT00814892|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
214629702|NCT00845650|BIOLOGICAL|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
214720058|NCT05563714|BEHAVIORAL|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
214629703|NCT00845650|BIOLOGICAL|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
214629704|NCT00845650|BIOLOGICAL|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
214629705|NCT00845650|BIOLOGICAL|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
214629706|NCT00845650|BIOLOGICAL|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
214629707|NCT00845650|BIOLOGICAL|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
214629708|NCT06264882|DRUG|Degarelix|After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.
214629709|NCT06264882|DRUG|Transdermal Estradiol Patch|Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
214629710|NCT06264882|DRUG|Transdermal Placebo Patch|Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
214629711|NCT05630248|DIAGNOSTIC_TEST|Recurrent Neural Network|it is to classify pulse types by using specialized pulse measuring instruments.
214629712|NCT00776607|DRUG|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
214720059|NCT05750316|OTHER|Cowpea leaves mixed with Jam|6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
214720060|NCT05750316|OTHER|Jam mixed with green food colour|Jam with green food colouring spread on bread
214720061|NCT01815580|DRUG|Atripla or Stribild|Antiretroviral therapy
214720062|NCT02228564|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
214720063|NCT02228564|DEVICE|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
214629713|NCT00776607|DRUG|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
214629714|NCT02550184|OTHER|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
214629715|NCT02350972|BIOLOGICAL|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
214629716|NCT01731379|PROCEDURE|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
214629717|NCT05277545|BEHAVIORAL|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
214629718|NCT04486950|DRUG|TAK-951|TAK-951 intravenous infusion.
214629719|NCT04486950|DRUG|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
214629720|NCT01541475|DRUG|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
214629721|NCT01541475|DRUG|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
214629722|NCT05339295|DRUG|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
214629723|NCT00710476|PROCEDURE|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
214629724|NCT01914874|BEHAVIORAL|Mindfulness Meditation|
214629725|NCT04772040|DIETARY_SUPPLEMENT|Fish oil supplementation|Fish oil capsules.
214629726|NCT03186170|OTHER|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
214629727|NCT00533442|DRUG|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
214629728|NCT00533442|DRUG|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
214629729|NCT00533442|DRUG|Tacrolimus|Part of standard maintenance.
214629730|NCT00533442|DRUG|Steroids|Part of standard maintenance
214629731|NCT06095661|OTHER|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
214629732|NCT02745275|BEHAVIORAL|Peer-led Health Education|Peer-led health education
214629733|NCT04403581|OTHER|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
214629734|NCT00606203|DRUG|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
214629735|NCT00606203|DRUG|placebo|placebo
214720064|NCT02879370|PROCEDURE|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
214720065|NCT02894489|DEVICE|corneal lenses|wear corneal lenses on daily basis
214629736|NCT03371446|GENETIC|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
214629737|NCT03319875|DEVICE|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
214720066|NCT02894489|DEVICE|large diameter lenses|
214720067|NCT00018629|OTHER||
214720068|NCT04432740|PROCEDURE|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
214720069|NCT03141892|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
214720070|NCT04562532|DEVICE|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
214629738|NCT00236808|DRUG|levofloxacin|
214629739|NCT02544685|DIETARY_SUPPLEMENT|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
214629740|NCT02544685|DIETARY_SUPPLEMENT|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
214629741|NCT02544685|OTHER|Placebo|Same dosage regimen as active drugs
214629742|NCT05941975|DEVICE|Visual Evoked Potential (VEP)|To assess the integrity of visual pathways through the optic nerves to the visual cortex, latencies and amplitudes of P100 will be measured after pattern-reversal stimuli.
214629743|NCT05941975|DEVICE|Somatosensory evoked potential (SSEP)|To assess the integrity of sensitive pathways through the peripheral nerves and dorsal spinal cord to the somatosensory cortex. For the upper limbs, latencies and amplitudes of N9, N13, P14, N20 and P25 will be measured after median nerve stimulation. For the lower limbs, latency and amplitude of P40 will be measured after tibial nerve stimulation.
214720071|NCT04562532|DEVICE|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"* Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)"
214720072|NCT00588887|DEVICE|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
214720073|NCT00588887|DEVICE|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
214720074|NCT03802656|DEVICE|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
214720075|NCT04975672|OTHER|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
214720076|NCT05291572|BEHAVIORAL|speech therapy only|fluency shaping technique
214629744|NCT05941975|DEVICE|Transcranial magnetic motor evoked potentials (TCmMEP)|To measure the integrity of motor pathways, the central conduction times will be measured for upper and lower limbs through magnetic stimulations of the primary motor cortex and the spinal cord, at cervical and lumbar levels.
214629745|NCT05941975|DEVICE|Tesla Brain MRI|All patients will undergo a single brain MRI on a 3T scanner. The acquisition protocol will include high-resolution three-dimensional (3D) T2\*-weighted echo-planar imaging and 3D T2-FLAIR images acquired, respectively, during or after intravenous injection of a single dose (0.1mmol/kg) of gadolinium-based contrast material.
214720077|NCT05291572|DEVICE|hyperbaric oxygen therapy|chamber system using oxygen with pressure
214720078|NCT05291572|DRUG|medical treatment|brain stimulant
214629746|NCT05941975|DIAGNOSTIC_TEST|Blood test - Neurofilament light chain (NfL)|\- Neurofilament light chain (NfL) will be tested (Quanterix's Simoa® Technology) in the serum of patients. To evaluate their variation over time, 3 time-point tests will be obtained at 6 months apart (at baseline, at 6- and 12-month follow-up).
214629747|NCT05941975|DIAGNOSTIC_TEST|Blood test - EBV serology|EBV serology will be assessed (VCA IgG) in the serum of patients to evaluate the variation of antibody titers over time (at baseline, at 6- and 12-month follow-up), and compare to titers at the time of diagnosis (when available in their medical record).
214629748|NCT00947336|DRUG|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
214629749|NCT00947336|DRUG|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
214629750|NCT04156880|OTHER|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
214629751|NCT00050609|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
214629752|NCT00050609|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
214629753|NCT00050609|DRUG|placebo|Placebo tablet taken by mouth once a day for 8 weeks
214629754|NCT03000907|OTHER|Intervention|Diet and physical exercises
214720079|NCT01998399|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
214720080|NCT01998399|DRUG|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
214629755|NCT02060682|DEVICE|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
214629756|NCT06066827|DRUG|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
214629757|NCT06066827|OTHER|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
214629758|NCT06066827|COMBINATION_PRODUCT|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
214629759|NCT00550680|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
214720081|NCT03235375|DRUG|MEDI0382|MEDI0382 administered subcutaneously
214629760|NCT03397407|OTHER|No intervention|
214720082|NCT01269047|DRUG|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
214720083|NCT01269047|DRUG|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
214720084|NCT01269047|DRUG|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
214720085|NCT04114539|DRUG|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
214720086|NCT06192667|DEVICE|GC Geanial Injectable (Tokyo,Japan)|Highly filled composite resin
214629761|NCT03098784|OTHER|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
214629762|NCT03098784|OTHER|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
214629763|NCT02757183|DEVICE|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
214629764|NCT01545856|DRUG|levodopa|levodopa use
214629765|NCT01119248|OTHER|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
214629766|NCT00138788|PROCEDURE|Radiotherapy, dose fractionation|
214629767|NCT05446545|OTHER|ND-EOC or platinum-sensitive rEOC|platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
214629768|NCT00505440|BEHAVIORAL|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
214629769|NCT00505440|BEHAVIORAL|Usual care|Usual care with mailed screening results
214629770|NCT01981642|OTHER|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
214629771|NCT01981642|OTHER|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
214720087|NCT06192667|DEVICE|3M Filtek Z250 Universal Restorative (Germany)|Conventional composite resin
214720088|NCT00617591|DRUG|Lenalidomide|25 mg orally on days 1-21
214720089|NCT00617591|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
214720090|NCT00617591|DRUG|Dexamethasone|40 mg orally on days on 1-4
214720091|NCT00376246|DRUG|Ezetimibe|
214720092|NCT03391076|DIAGNOSTIC_TEST|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
214720093|NCT04841694|DIETARY_SUPPLEMENT|Probiotic|Bacillus indicus
214720094|NCT04155658|OTHER|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
214720095|NCT04155658|OTHER|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
214629772|NCT03456752|DRUG|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
214629773|NCT03456752|DRUG|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
214629774|NCT00456352|PROCEDURE|duodenal exclusion|
214720096|NCT04155658|OTHER|Toothpaste with no fluoride|Toothpaste with no fluoride
214720097|NCT00044642|DRUG|Lorazepam|
214720098|NCT04671615|DRUG|palbociclib|As provided in real world practice
214720099|NCT02918656|OTHER|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
214720100|NCT02918656|OTHER|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
214720101|NCT02918656|OTHER|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
214720102|NCT00248105|BEHAVIORAL|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
214720103|NCT02585076|OTHER|Standard of care|As prescribed by treated physician
214720104|NCT01072448|DRUG|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214720105|NCT01072448|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214720106|NCT00003882|DRUG|anhydrovinblastine|
214720107|NCT05484427|OTHER|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
214720108|NCT01799304|PROCEDURE|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
214720109|NCT01799304|PROCEDURE|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
214720110|NCT01799304|PROCEDURE|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
214720111|NCT01799304|PROCEDURE|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
214720112|NCT00877604|DRUG|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
214629775|NCT05047757|DIETARY_SUPPLEMENT|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
214629776|NCT02247323|OTHER|Risk of malignancy index|Calculation of RMI before sugery.
214629777|NCT05017207|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
214720113|NCT00877604|DRUG|Placebo|identical placebo by oral route at the same dosing schedule
214629778|NCT00562354|BIOLOGICAL|13vPnC|13vPnC for both stratum
214629779|NCT04257825|DEVICE|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
214629780|NCT06002399|DEVICE|cataract surgery|cataract surgery
214629781|NCT00317109|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
214629782|NCT00317109|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
214629783|NCT00317109|BIOLOGICAL|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
214629784|NCT04687800|DRUG|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
214629785|NCT04687800|DRUG|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
214720114|NCT02358564|PROCEDURE|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
214720115|NCT02358564|PROCEDURE|Upper Endoscopy|
214629786|NCT04462094|DRUG|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
214629787|NCT04462094|DRUG|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
214629788|NCT03124771|DEVICE|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
214629789|NCT01315860|OTHER|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
214629790|NCT03693625|DRUG|GDC-0853|Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
214629791|NCT01508702|DRUG|lesinurad|Tablets, 400 mg QD
214629792|NCT01508702|DRUG|Placebo|Tablets, Placebo QD
214629793|NCT04632758|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, QD
214629794|NCT04632758|DRUG|crizotinib|Capsules, 250mg, BID
214629795|NCT05482685|BEHAVIORAL|Questionnaire|Conduct a 10-minute survey
214629796|NCT03991689|BEHAVIORAL|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
214629797|NCT01464502|PROCEDURE|Standard CRT Implant|
214629798|NCT01464502|PROCEDURE|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
214629799|NCT00684255|PROCEDURE|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
214629800|NCT00684255|DRUG|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
214629801|NCT00684255|DRUG|Busulfan|Busulfan 3.2 mg/kg Days \_8, -7, -6, -5
214629802|NCT00684255|DRUG|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
214629803|NCT01883635|BEHAVIORAL|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
214629804|NCT01883635|BEHAVIORAL|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
214720116|NCT02358564|PROCEDURE|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
214720117|NCT00418717|DRUG|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
214720118|NCT01400139|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
214720119|NCT04587596|OTHER|Pain education|70 minute lecture about chronic pain and one focus group afterwards
214720120|NCT02251158|DRUG|Tipranavir oral solution|
214629805|NCT04169360|DRUG|ANS-6637|White, oblong 300 mg tablet
214629806|NCT04169360|DRUG|Placebo oral tablet|White, oblong 300 mg tablet
214629807|NCT03402529|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammography|Pilot study
214629808|NCT03847129|OTHER|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
214629809|NCT03847129|OTHER|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
214629810|NCT04218253|DIETARY_SUPPLEMENT|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
214629811|NCT04218253|BEHAVIORAL|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
214629812|NCT03448250|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
214629813|NCT03448250|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
214629814|NCT02072811|DRUG|DAC|"* DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
214720121|NCT02251158|DRUG|Tipranavir capsules|
214720122|NCT02251158|DRUG|Ritonavir oral solution|
214720123|NCT02251158|DRUG|Ritonavir soft gel capsules|
214720124|NCT02251158|OTHER|High fat breakfast|
214720125|NCT00249795|DRUG|Irbesartan|oral administration (tablets) once daily
214720126|NCT00249795|DRUG|placebo|oral administration (tablets) once daily
214720127|NCT03134612|DRUG|Ondansetron 8 mg|
214720128|NCT03134612|DRUG|Lidocain 40 mg|
214720129|NCT03179410|DRUG|Avelumab|10 mg/kg intravenously every 2 weeks
214720130|NCT01535612|DEVICE|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
214720131|NCT04239170|DRUG|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
214720132|NCT05772442|DIAGNOSTIC_TEST|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
214720133|NCT02015806|BEHAVIORAL|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
214720134|NCT02015806|BEHAVIORAL|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
214720135|NCT02015806|BEHAVIORAL|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
214720136|NCT04661852|DRUG|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
214720137|NCT04661852|DRUG|Topotecan|IV, over 30 minutes (schedule based upon dose level)
214720138|NCT04661852|DRUG|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
214720139|NCT04661852|DRUG|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
214720140|NCT05236959|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
214720141|NCT05236959|OTHER|Treatment as Usual|Following an initial interview session, patients continue with their usual care
214720142|NCT02573337|DEVICE|Emervel Classic Lidocaine|Treatment of wrinkles and folds
214720143|NCT02573337|DEVICE|Emervel Deep Lidocaine|Treatment of wrinkles and folds
214720144|NCT00795171|DRUG|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
214720145|NCT00795171|DRUG|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
214629815|NCT02072811|DRUG|CLAG|"* G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
214629816|NCT02072811|DRUG|Consolidation, I HAM cycle|"* Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
214629817|NCT02072811|DRUG|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
214629818|NCT02072811|DRUG|Consolidation, III HiDAraC cycle|"* Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~* 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
214629819|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
214629820|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
214720146|NCT00795171|DRUG|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
214720147|NCT02460978|DRUG|Dapagliflozin|Tablets
214720148|NCT02460978|OTHER|Placebo for dapagliflozin|Tablets
214720149|NCT04347278|DRUG|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
214720150|NCT02301754|BIOLOGICAL|INVAC-1|intradermal injection combined with electroporation
214720151|NCT01800851|OTHER|Energy expenditure evaluation in calorimetric chamber|
214720152|NCT02091947|DEVICE|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
214629821|NCT03536988|PROCEDURE|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
214629822|NCT03536988|PROCEDURE|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
214629823|NCT01187953|DRUG|Prograf (tacrolimus)|Administered per current product labeling
214629824|NCT01187953|DRUG|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
214629825|NCT03826550|DRUG|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
214720153|NCT03380000|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
214720154|NCT03380000|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
214720155|NCT04724512|DEVICE|suture|a type of suture used in entropion surgery
214720156|NCT02182297|DRUG|BI 201335 NA in single rising doses|
214720157|NCT02182297|DRUG|Placebo|
214720158|NCT04263194|DEVICE|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
214720159|NCT04263194|DEVICE|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
214629826|NCT03826550|DRUG|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
214629827|NCT03826550|OTHER|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
214629828|NCT02572752|DRUG|Nintedanib|1 soft gelatine capsule, single dose, oral
214629829|NCT02572752|DRUG|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
214629830|NCT02572752|DRUG|Nintedanib|
214629831|NCT02105402|BEHAVIORAL|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
214629832|NCT01505842|PROCEDURE|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
214629833|NCT01505842|PROCEDURE|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
214720160|NCT05434104|OTHER|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
214720161|NCT05434104|DRUG|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
214722193|NCT05098808|OTHER|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
214722194|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
214629834|NCT05537597|PROCEDURE|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
214720162|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
214720163|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
214720164|NCT02021851|DRUG|Dexamethasone and aprepitant|
214720165|NCT02021851|DRUG|Dexamethasone and ondansetron|
214720166|NCT03549429|DEVICE|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
214720167|NCT06174883|DIETARY_SUPPLEMENT|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
214720168|NCT05982639|PROCEDURE|two lung ventilation|The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
214720169|NCT05982639|PROCEDURE|one lung ventilation|In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
214720170|NCT00531492|BEHAVIORAL|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
214720171|NCT00531492|OTHER|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
214720172|NCT00498225|DRUG|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
214629835|NCT05537597|PROCEDURE|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
214629836|NCT01464307|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
214629837|NCT01464307|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
214629838|NCT00964327|DRUG|TMC114|
214629839|NCT02714920|OTHER|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
214629840|NCT05480748|DEVICE|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
214629841|NCT04253795|OTHER|Laryngeal mask|After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
214629842|NCT04253795|OTHER|double lumen tube|After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
214629843|NCT05184608|OTHER|Cycling exercise|20 minutes of cycling (90 rpm).
214629844|NCT05184608|OTHER|Cognitive tasks|20 minutes of cognitive tasks based on the different domains of the UPDRS scale.
214629845|NCT01648127|DRUG|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
214629846|NCT01950000|DRUG|Fentanyl|
214629847|NCT01950000|OTHER|Placebo|
214629848|NCT02152852|BEHAVIORAL|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
214629849|NCT01335763|DRUG|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
214720173|NCT00498225|DRUG|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
214720174|NCT00498225|DRUG|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
214720175|NCT02562989|DRUG|[18F]MK-6240, ~185 MBq|IV dose of \~185 MBq \[18F\]MK-6240
214720176|NCT02562989|DRUG|[18F]MK-6240, ~160 MBq|IV dose of \~160 MBq \[18F\]MK-6240
214720177|NCT03420313|DRUG|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
214629850|NCT02911922|DEVICE|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
214629851|NCT02911922|DEVICE|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
214629852|NCT02911922|RADIATION|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
214629853|NCT03270735|DRUG|Snake venom thrombin (Treatment)|Snake venom thrombin
214629854|NCT03270735|DRUG|Placebo|No snake venom thrombin
214629855|NCT02997904|DEVICE|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
214629856|NCT01246570|BEHAVIORAL|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
214629857|NCT01246570|OTHER|Control|The patients will receive the usual care provided by the hospitals and the community health services
214629858|NCT00761514|DRUG|Humira (adalimumab)|40 mg eow
214720178|NCT00588523|DRUG|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
214629859|NCT02814630|BIOLOGICAL|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
214629860|NCT01217021|DRUG|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
214629861|NCT01040455|DRUG|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
214629862|NCT01040455|DRUG|placebo|placebo once daily for eight weeks
214629863|NCT00338871|PROCEDURE|home exercise|
214629864|NCT00916266|PROCEDURE|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
214720179|NCT00518843|BEHAVIORAL|FBT-BN|Mobilizing parents to curtail binge eating and purging
214629865|NCT05185271|BEHAVIORAL|Dyad-focused strategy training|"Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
214629866|NCT02457637|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
214629867|NCT00042861|DRUG|7-hydroxystaurosporine|
214629868|NCT00042861|DRUG|fluorouracil|
214629869|NCT00042861|DRUG|leucovorin calcium|
214629870|NCT04195152|OTHER|Observational|No intervention
214629871|NCT04916509|DRUG|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
214629872|NCT04916509|DRUG|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
214720180|NCT00518843|BEHAVIORAL|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
214629873|NCT01505569|DRUG|Ifosfamide|"* Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
214629874|NCT01505569|DRUG|Etoposide|"* Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age \>36 mos.) approx. hour 75 on days -5, -4, and -3"
214629875|NCT01505569|DRUG|Mesna|"* Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
214634977|NCT05432856|BEHAVIORAL|Time restricted eating, nutrition education, and sedentary time reduction strategies|"1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
214629876|NCT01505569|BIOLOGICAL|G-CSF|"* Arms A\&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (\>) 1,000/mm\^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3~* Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~* Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~* Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference"
214629877|NCT01505569|DRUG|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
214629878|NCT01505569|DRUG|Melphalan|Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
214629879|NCT01505569|DRUG|Thiotepa|Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age \>36 mos.) approx. hour 72 on days -5, -4, and -3
214629880|NCT01505569|BIOLOGICAL|Autologous stem cell infusion|"Arms A, B \& C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard."
214629881|NCT01505569|RADIATION|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
214629882|NCT01505569|DRUG|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
214629883|NCT01505569|DRUG|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
214629884|NCT01505569|PROCEDURE|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
214629885|NCT01505569|DRUG|Anti-seizure prophylaxis|"Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg."
214629886|NCT01505569|DRUG|Ursodiol|Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
214629887|NCT02902952|BEHAVIORAL|Physical Exercise|An eight week physical exercise intervention
214629888|NCT02902952|BEHAVIORAL|Control Intervention|An eight week sedentary control intervention
214629889|NCT00150254|DRUG|CP-526,555 (varenicline)|
214629890|NCT04840043|OTHER|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
214629891|NCT04840043|OTHER|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
214629892|NCT01588717|DRUG|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
214634978|NCT06142643|DEVICE|Dermal Filler Device|Injection of the device by investigators according to the IFU
214634979|NCT03485820|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
214634980|NCT03485820|BEHAVIORAL|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
214634981|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
214634982|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
214634983|NCT02959021|BEHAVIORAL|weight loss intervention - self directed|
214634984|NCT02959021|BEHAVIORAL|weight loss intervention - peer coach|
214629893|NCT01836783|OTHER|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
214720181|NCT01641718|DRUG|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
214629894|NCT01836783|OTHER|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
214720182|NCT01641718|DEVICE|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
214629895|NCT04011280|DRUG|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
214629896|NCT01966133|DRUG|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
214634985|NCT04868604|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
214634986|NCT04868604|DRUG|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
214720183|NCT02711605|DEVICE|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
214720184|NCT02020291|DRUG|Foxy-5|
214720185|NCT03879993|OTHER|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
214720186|NCT03958994|OTHER|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
214722195|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
214629897|NCT05558280|DRUG|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
214629898|NCT00934986|OTHER|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~* Stage A patient who does not require a treatment: one sample the day of enrollment.~* Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
214629899|NCT03027700|DEVICE|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
214629900|NCT02565979|DIETARY_SUPPLEMENT|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
214629901|NCT02565979|DIETARY_SUPPLEMENT|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
214629902|NCT04845828|PROCEDURE|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3\. Sentinel lymph node is excised"
214629903|NCT04845828|PROCEDURE|Routine lymph node dissection|"1. Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~2. Lymph node detection is performed."
214629904|NCT05805722|BEHAVIORAL|Behavioral counseling for tobacco cessation|"Participants can choose to receive behavioral counseling in group v. individual format:~Group Sessions: Participants will be offered the opportunity to attend 6 weekly 60-90 minute sessions Individual Sessions: Participants will be offered the opportunity to attend up to 12 30-45 minute sessions on a schedule mutually agreed upon between interventionist and participant"
214629905|NCT06168838|DRUG|Anticoagulant|Know the casuistry of spontaneous intracranial hemorrhages and secondary to the use of both oral and parenteral anticoagulants
214720187|NCT01709968|DRUG|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
214720188|NCT01709968|DRUG|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
214629906|NCT04942925|DEVICE|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
214629907|NCT04942925|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
214629908|NCT06584929|DRUG|Nicoderm CQ nicotine patch|Two week supply provided to participants on study.
214629909|NCT06584929|DRUG|Nicorette Nicotine Lozenges|Two week supply provided to participants on study.
214629910|NCT01273883|DIETARY_SUPPLEMENT|Magnesium|Magnesium 532 mg a day
214629911|NCT01273883|OTHER|Placebo|matching form/dosage
214629912|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
214722196|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
214722197|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
214629913|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
214629914|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
214629915|NCT01052298|DRUG|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
214629916|NCT02215720|DRUG|Cetuximab|
214629917|NCT02215720|DRUG|Temsirolimus|
214629918|NCT05170243|DRUG|9MW1911 Injection|Single dose intravenously on day 1
214629919|NCT05170243|DRUG|9MW1911 Injection Placebo|Single dose of matching placebo intravenously on day 1
214629920|NCT00005870|DRUG|fluorouracil|
214629921|NCT00005870|DRUG|gemcitabine hydrochloride|
214629922|NCT00005870|DRUG|mitomycin C|
214629923|NCT00005870|DRUG|rubitecan|
214634987|NCT06545084|PROCEDURE|Leukocyte and Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin (L-PRF) is a collection of growth factors rich in proinflammatory cells that promote healing after dental surgery. A L-PRF clot is obtained by collecting blood from the subject, similar to a phlebotomist drawing blood via venipuncture. The blood samples are spun in a centrifuge using the recommended settings by the manufacture(1). The resultant product has separated the red blood cells from the L-PRF clot which is placed back into the subject to promote healing of the surgical site.
214720189|NCT04742972|RADIATION|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
214629924|NCT02222259|PROCEDURE|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
214629925|NCT05021783|DIAGNOSTIC_TEST|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
214629926|NCT05021783|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
214629927|NCT05021783|OTHER|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
214629928|NCT05021783|DIAGNOSTIC_TEST|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
214629929|NCT05021783|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
214629930|NCT00159861|DRUG|Sildenafil citrate|
214629931|NCT05954442|DRUG|Everolimus|Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .
214720190|NCT04742972|OTHER|SOC|"Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment"
214720191|NCT00126854|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|
214720192|NCT00313755|PROCEDURE|Narrow Band Imaging|
214720193|NCT02226978|DRUG|Tipranavir|
214720194|NCT02226978|DRUG|Ritonavir|
214720195|NCT02226978|DRUG|Valaciclovir|
214720196|NCT03032510|DRUG|Eravacycline|
214720197|NCT03032510|DRUG|Ertapenem|
214629932|NCT05954442|DRUG|Investigator's Choice of Chemotherapy|Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
214629933|NCT01056146|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
214629934|NCT01056146|BEHAVIORAL|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
214629935|NCT02686515|DEVICE|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
214629936|NCT02686515|DEVICE|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
214629937|NCT01452399|PROCEDURE|Shave margins|Partial mastectomy with shave margins.
214629938|NCT01452399|PROCEDURE|No Shave Margins|Partial mastectomy without shave margins.
214629939|NCT06086132|COMBINATION_PRODUCT|Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy|Follow-up visits at baseline, 3-months, and 1-year
214629940|NCT05942300|DRUG|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
214629941|NCT05942300|DRUG|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
214629942|NCT04745559|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
214629943|NCT04745559|BIOLOGICAL|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
214629944|NCT05388461|OTHER|electroconvulsive therapy|electroconvulsive therapy
214629945|NCT00385632|DRUG|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
214629946|NCT01647971|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
214720198|NCT03032510|DRUG|Placebo|
214720199|NCT03032510|DRUG|Levofloxacin|
214722198|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
214629947|NCT00254462|DRUG|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
214629948|NCT00254462|DRUG|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
214629949|NCT00254462|BEHAVIORAL|Parent Training|All children will receive parent training for the duration of the study.
214629950|NCT01952561|DRUG|dapivirine ring|
214629951|NCT06503575|OTHER|Assesment|All assessments will be made
214629952|NCT02317211|DIETARY_SUPPLEMENT|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
214629953|NCT02317211|DIETARY_SUPPLEMENT|placebo|starch
214629954|NCT06068712|BEHAVIORAL|Attentional Cue Type|Positive cue (target), negative cue (distractor), or neutral cue (baseline)
214629955|NCT02346032|DRUG|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
214634991|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
214629956|NCT00631748|DRUG|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
214629957|NCT00631748|DRUG|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
214629958|NCT00631748|BEHAVIORAL|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
214629959|NCT05677555|DRUG|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
214629960|NCT05677555|DRUG|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
214629961|NCT05287945|DRUG|Orellanine|Orellanine administered intravenously
214629962|NCT02528903|DRUG|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
214629963|NCT02528903|DRUG|Matching placebo|Single intravenous dose
214629964|NCT02838966|DIETARY_SUPPLEMENT|Nestle IMPACT Advanced Recovery|
214629965|NCT02838966|DIETARY_SUPPLEMENT|Nestle Boost High Protein Drink|
214629966|NCT06363214|PROCEDURE|Patient blood management|Perioperative optimization of hemoglobin level, perioperative minimization of blood loss, increase of anemia tolerance
214629967|NCT01770132|DRUG|porfimer sodium|Given IV
214722199|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
214629968|NCT01770132|PROCEDURE|endoscopic ultrasonography|Undergo EUS-PDT
214629969|NCT01770132|PROCEDURE|photodynamic therapy|Undergo EUS-PDT
214629970|NCT01770132|DRUG|gemcitabine hydrochloride|Given IV
214629971|NCT04061421|DRUG|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
214629972|NCT04061421|DRUG|Itacitinib|Taken by mouth daily during each 28-day cycle
214629973|NCT02956603|OTHER|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
214629974|NCT00698243|DRUG|OSI-027|Administered orally
214629975|NCT00337870|BEHAVIORAL|PAT|Cognitive-Behavioral/Relaxation Intervention
214629976|NCT05571514|DIETARY_SUPPLEMENT|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
214629977|NCT05571514|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate is a source of calcium.
214629978|NCT06816017|DRUG|Eciskafusp Alfa|Participants will receive eciskafusp alfa via intravesical instillation.
214629979|NCT06816017|DRUG|BCG Medac Strain|Participants will receive BCG via intravesical instillation.
214629980|NCT06982469|RADIATION|Brachytherapy|HDR brachytherapy
214634992|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
214634993|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
214634994|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
214634995|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
214634996|NCT04685876|DRUG|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
214634997|NCT04685876|DRUG|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
214634998|NCT04685876|DRUG|Normal saline|placebo (normal saline).
214629981|NCT02072408|DRUG|aflibercept|"1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~   * Loss of five ETDRS letters or one Snellen line of vision from baseline~  * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~  * Presence of active polyp on indocyanine green angiography"
214629982|NCT00484653|PROCEDURE|cervical smear|biological analysis
214629983|NCT02380716|DEVICE|GORE® Ascending Stent Graft|
214629984|NCT02867995|DEVICE|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
214629985|NCT00502762|DRUG|topotecan|
214629986|NCT02548104|OTHER|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
214629987|NCT02548104|OTHER|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
214629988|NCT05618327|DRUG|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
214629989|NCT07001540|DRUG|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx)
214629990|NCT07008170|PROCEDURE|Laparoendoscopic rendezvous|"The main principles of LERV technique consists of~1. An antegrade trans cystic cannulation of the bile duct during laparoscopic cholecystectomy, with a guidewire that can be retrieved with a duodenoscope, thus facilitating retrograde bile duct cannulation.~2. An over-the-wire sphincterotome is then inserted and standard maneuvers of endoscopic common bile duct stones clearance are performed.~3. The procedure is then completed by cholecystectomy in one procedure"
214629991|NCT06868446|DEVICE|Digital Therapeutic (Version 1)|Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD
214629992|NCT06868446|DEVICE|Digital Therapeutic (Version 2)|Prescription digital therapeutic (increased dose) designed to overcome existing barriers and deliver evidence-based treatment for PTSD
214629993|NCT06868446|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual may include psychotherapy and/or pharmacological interventions.
214629994|NCT07014176|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
214629995|NCT07014176|PROCEDURE|Standard of Care (SOC)|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
214629996|NCT06691672|DIAGNOSTIC_TEST|Robotic Tomographic ultrasound imaging of the arm vasculature.|Semi-autonomous robotic tomographic ultrasound imaging of the arm vasculature for vascular access creation mapping in CKD patients.
214629997|NCT04994951|DRUG|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
214629998|NCT04994951|DRUG|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
214629999|NCT07019636|PROCEDURE|Weaning strategy with direct extubation (no spontaneous breathing trial)|Patients will be extubated within the 60 minutes following randomization
214630000|NCT07019636|PROCEDURE|Weaning strategy with extubation only after a successful spontaneous breathing|Patients will undergo a spontaneous breathing trial and will be extubated only in case of successful spontaneous breathing
214630001|NCT07021079|DEVICE|Focal muscle vibration|focal muscle vibration sessions, using small and portable vibrator devices.
214630002|NCT07021079|DEVICE|NO Focal muscle vibration|The control group will not receive any intervention.
214722200|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
214630003|NCT07029594|OTHER|balneotherapy|"Specific procedures performed during the 3-week spa therapy~Thermal Treatments (Number of sessions)~Individual nasal irrigation (18) Sonic aerosol therapy (18) Simple aerosol therapy (18) Individual inhalation therapy (18)~Administered by a licensed physiotherapist~Individual respiratory rehabilitation and bronchial drainage (18)~Administered by a spa physician Tubo-tympanic insufflation (9) Sinus lavage using the Proëtz displacement method 9"
214630004|NCT07028567|DRUG|Calcium hydroxylapatite filler|Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
214630005|NCT07028567|DRUG|Painting chemical reconstruction of skin scars trichloroacetic acid technique|Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
214630006|NCT07028502|PROCEDURE|J Wire|The movement of the puncture needle was monitored using intracardiac echocardiography rather than fluoroscopy. All other steps followed the conventional approach.
214630007|NCT07028502|PROCEDURE|3D mapping system|Guided by the ablation catheter image on the 3D mapping system, the long sheath was advanced to the puncture site and then exchanged for a puncture needle. The entire procedure was monitored with intracardiac echocardiography.
214630008|NCT07029802|OTHER|No intervention|This is an observational study
214630009|NCT07029984|OTHER|Baylor Continence Scale|This study may be one of the first to test the Turkish adaptation and validity of the scale in Turkish children with anorectal malformations.
214630010|NCT07027787|BEHAVIORAL|Standard Physical Therapy for Hand Dexterity in Stroke Patients|Standard physical therapy program for stroke patients targeting hand dexterity. Conducted 3 times/week for 8 weeks (60 min/session), exercises included wrist and forearm movements, object manipulation, ball gripping, and putty-based hand strengthening.
214630011|NCT07027787|BEHAVIORAL|Rehacom Attention Training + Physical Therapy|Combined intervention: 30 minutes of computerized attention training using the Rehacom system, followed by 30 minutes of standard hand dexterity physical therapy. Conducted 3 times/week for 8 weeks. Rehacom provided task-based cognitive training with visual, auditory, and performance feedback in a controlled lab setting.
214630012|NCT07029087|PROCEDURE|Pudendal Nerve Block|Pudendal nerve blocks are often preferred as an initial diagnostic and therapeutic method for chronic pelvic pain caused by pudendal neuralgia due to nerve entrapment. Additionally, the pudendal nerve block is a widely used regional anesthesia technique in gynecologic, obstetric, and anorectal procedures . It is particularly applied to provide perineal anesthesia during the second stage of vaginal delivery, vaginal repairs, and obstetric procedures including anorectal surgeries such as hemorrhoidectomy . Pudendal nerve blocks can effectively anesthetize the posterior perineum, anus, lower vagina, vulva/scrotum, and penis.
214630013|NCT07028242|PROCEDURE|Hysteroscopic fertility-sparing surgery and hormonal treatment|"Patients undergo hysteroscopic endometrial resection using the Mazzon three-step technique or tissue removal device (TRD), depending on the lesion type. Following surgery, hormonal treatment is administered either via intrauterine device (IUD) or oral progestin. Monitoring includes serial endometrial biopsies and transvaginal ultrasounds at 3, 6, and 12 months."
214630014|NCT07029100|OTHER|Ex-vivo organoid culture|ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection
214630015|NCT07029061|DEVICE|Air splints|Application of CPPS (Urias splints) + physiotherapy
214630016|NCT07028593|DRUG|Propofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in propofol group.
214630017|NCT07028593|DRUG|ciprofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in ciprofol group.
214630018|NCT07028827|DRUG|0.05% atropine eye drops|One drop of 0.05% atropine in each eye once a day before bedtime
214630019|NCT07028827|DRUG|0.025% atropine eye drops|One drop of 0.025% atropine in each eye once a day before bedtime
214630020|NCT07028827|DRUG|placebo eye drops|One drop of placebo in each eye once a day before bedtime
214630021|NCT06789601|OTHER|Informatics system for eligibility monitoring|A daily automated data query of eligible subjects will collect EHR data, and our informatics system will be run on these data behind our institution's secure firewall. The daily list of subjects identified by the informatics system as having a new irAE will be accessed by the Alliance irAE biorespository study team at Dana-Farber/Brigham Cancer Center for review.
214630022|NCT06789601|OTHER|Standard eligibility monitoring|Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.
214630023|NCT04068376|OTHER|Control excercise|Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).
214722201|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
214722202|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
214720200|NCT01291849|DRUG|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
214720201|NCT00259467|BEHAVIORAL|Home-Based Behavorial Intervention|
214720202|NCT03061812|DRUG|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
214720203|NCT03061812|DRUG|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
214720204|NCT03061812|DRUG|Dexamethasone|Oral tablet.
214720205|NCT05506696|DIETARY_SUPPLEMENT|Fultium|3200IU Fultium
214722203|NCT02884193|PROCEDURE|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
214722204|NCT02884193|PROCEDURE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
214722205|NCT02884193|PROCEDURE|Sham Ice Bag|"Placebo application through an ice bag empty."
214630024|NCT04068376|OTHER|"Mind and Movement for Cognitive Health in the Older Adult"|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).
214630025|NCT04068376|OTHER|Double-task exercise by older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
214630026|NCT00729456|OTHER|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
214630027|NCT04682405|DRUG|Uproleselan|Provided by study
214630028|NCT04682405|DRUG|Placebo|Provided by study
214630029|NCT04682405|DRUG|Melphalan|-Standard of care
214630030|NCT03536455|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214630031|NCT03536455|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214630032|NCT03777644|PROCEDURE|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
214630033|NCT03777644|PROCEDURE|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
214630034|NCT03777644|DRUG|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
214630035|NCT04987138|DEVICE|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
214630036|NCT04987138|DEVICE|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
214630037|NCT04349423|BEHAVIORAL|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
214720206|NCT05067712|PROCEDURE|Open Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
214720207|NCT05067712|PROCEDURE|Closed Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
214720208|NCT01613508|PROCEDURE|Direct Anterior Approach|
214720209|NCT01613508|PROCEDURE|Mini-Posterior Approach|
214720210|NCT04742036|DRUG|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
214720211|NCT04742036|DRUG|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
214720212|NCT00671619|DRUG|ESBA105|eye drops
214720213|NCT03032250|OTHER|Communication Intervention|Attend interventionist sessions
214720214|NCT03032250|OTHER|Watch video|Watch video on a DVD
214720215|NCT03032250|OTHER|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
214720216|NCT03032250|OTHER|Quality-of-Life Assessment|Ancillary studies
214720217|NCT03032250|OTHER|Survey Administration|Ancillary studies
214720218|NCT03032250|OTHER|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
214720219|NCT04057716|BEHAVIORAL|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
214720220|NCT04057716|BEHAVIORAL|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
214720221|NCT01352312|DRUG|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
214720222|NCT01352312|DRUG|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
214630038|NCT05186207|OTHER|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
214630039|NCT00659204|DRUG|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
214630040|NCT00659204|DRUG|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
214720223|NCT01352312|DRUG|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
214720224|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
214720225|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
214720226|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
214630041|NCT05619198|BEHAVIORAL|High Intensity Interval Exercise|"High Intensity Interval Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~* 5 minutes resting phase @ 0 watts."
214630042|NCT05619198|BEHAVIORAL|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of MICE 65% VO2max.~* 5 minutes resting phase @ 0 watts."
214630043|NCT03157427|DEVICE|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
214630044|NCT04210609|DEVICE|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
214720227|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
214630045|NCT00643695|BEHAVIORAL|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
214630046|NCT00643695|OTHER|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
214630047|NCT03378076|DRUG|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
214630048|NCT03378076|DRUG|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
214630049|NCT01049035|BIOLOGICAL|Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate|0.5 milliliter (mL), Intramuscular (IM) injection
214720228|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
214720229|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
214630050|NCT01049035|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)|0.5 mL, IM injection
214630051|NCT01049035|BIOLOGICAL|M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live|0.5 mL, Subcutaneous (SC) injection
214720230|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
214720231|NCT03903536|PROCEDURE|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
214630052|NCT01049035|BIOLOGICAL|Varicella Virus Vaccine Live|0.5 mL, SC injection
214630053|NCT01049035|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
214630054|NCT01049035|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
214630055|NCT01049035|BIOLOGICAL|Rotavirus Vaccine|oral
214630056|NCT01049035|BIOLOGICAL|Hepatitis B Vaccine|0.5 mL, IM injection
214630057|NCT04569721|DEVICE|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
214630058|NCT01312246|DEVICE|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
214630059|NCT03640039|PROCEDURE|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
214720232|NCT03903536|PROCEDURE|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
214720233|NCT01364857|GENETIC|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
214720234|NCT02690389|DRUG|Flumazenil|used alone or with acupuncture
214720235|NCT02690389|PROCEDURE|Acupuncture|used alone or with flumazenil
214630060|NCT00976066|DRUG|Part A Assessing GSK1521498|"Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
214630061|NCT00976066|DRUG|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
214720236|NCT02431702|DRUG|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
214720237|NCT02431702|DRUG|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
214720238|NCT02431702|DRUG|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
214720239|NCT02431702|DRUG|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
214720240|NCT02431702|DRUG|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
214720241|NCT02431702|DRUG|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
214720242|NCT02431702|DRUG|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
214630062|NCT00976066|DRUG|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
214630063|NCT02755857|DRUG|Lozanoc|65 mg
214630064|NCT06100341|OTHER|Virtual reality|A role-playing game set in a spaceship in outer space where a user will need to accomplish three activities to complete the game. These activities were designed based on typical therapy goals for children with cerebral palsy of improving balance, gross motor performance, walking speed, and functional mobility.
214720243|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
214720244|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
214720245|NCT00926991|OTHER|No intervention|No intervention; observation only
214720246|NCT02809118|DRUG|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
214720247|NCT02809118|DRUG|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
214720248|NCT02809118|OTHER|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
214720249|NCT04472819|DRUG|SHR2285 tablet|single dose or multi-dose
214630065|NCT04816812|BEHAVIORAL|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
214630066|NCT04816812|BEHAVIORAL|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
214630067|NCT00180310|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214630068|NCT00180310|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
214630069|NCT02289183|PROCEDURE|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
214630070|NCT02289183|PROCEDURE|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
214630071|NCT02491814|OTHER|1% M.F. Milk|
214630072|NCT02491814|OTHER|Yogurt Beverage|
214630073|NCT02491814|OTHER|Soy Beverage|
214630074|NCT02491814|OTHER|Almond Beverage|
214630075|NCT02491814|OTHER|Water|
214630076|NCT02491814|OTHER|Breakfast cereal|
214630077|NCT03315767|DIAGNOSTIC_TEST|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
214630078|NCT03315767|DIAGNOSTIC_TEST|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
214630079|NCT06046261|OTHER|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
214630080|NCT02095535|DRUG|Chlorhexidine gluconate|antiseptic
214720250|NCT04472819|DRUG|Placebo|single dose or multi-dose
214630081|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
214630082|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
214630083|NCT03538509|OTHER|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
214630084|NCT00288093|RADIATION|3-Dimensional Conformal Radiation Therapy|
214630085|NCT00288093|DRUG|Triapine|
214720251|NCT01801774|DRUG|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
214720252|NCT01801774|DRUG|Placebo|
214720253|NCT03477344|DRUG|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
214630086|NCT00568646|DRUG|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
214630087|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
214630088|NCT03714945|OTHER|No intervention|No intervention is required as this study is observational.
214630089|NCT06247709|OTHER|Immunohistochemical expression in pitNET cells of KLHL14|Lab essay evaluating the expression of KLHL 14
214630090|NCT02056483|OTHER|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
214720254|NCT03477344|DRUG|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
214720255|NCT03965806|BEHAVIORAL|SURVEY|SURVEY
214720256|NCT02186535|DIETARY_SUPPLEMENT|Vitamin D and Calcium|
214720257|NCT01557127|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
214720258|NCT02936362|OTHER|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
214720259|NCT02936362|OTHER|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
214720260|NCT05509491|BEHAVIORAL|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
214720261|NCT00649610|DRUG|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
214720262|NCT00649610|DRUG|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
214720263|NCT06118944|DEVICE|ICB00 IOL|Bilateral implantation of ICB00 IOL
214720264|NCT06118944|DEVICE|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
214720265|NCT06118944|DEVICE|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
214720266|NCT02408484|BIOLOGICAL|Octafibrin|Plasma-derived Fibrinogen concentrate
214720267|NCT03671642|DEVICE|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
214720268|NCT03671642|PROCEDURE|White light perfusion assessment|Traditional visual perfusion assessment in white light
214720269|NCT03671642|PROCEDURE|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
214720270|NCT05794880|DEVICE|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
214720271|NCT01114698|DRUG|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
214720272|NCT01114698|DRUG|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
214720273|NCT01114698|DRUG|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
214720274|NCT05201404|DRUG|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
214720275|NCT05201404|DRUG|Placebo|Control arm
214720276|NCT02925208|OTHER|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
214720277|NCT05229640|DEVICE|Fibroscan|Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
214720278|NCT00221663|DEVICE|surgery techniques (sternotomy for aortic valve replacement)|
214720279|NCT02389530|DRUG|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
214720280|NCT01461798|DIETARY_SUPPLEMENT|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
214720281|NCT01461798|DIETARY_SUPPLEMENT|Placebo Yogurt|Yogurt without the active principle
214720282|NCT01461798|DIETARY_SUPPLEMENT|yogurt|yogurt without plant stanols
214720283|NCT05145673|OTHER|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
214630091|NCT02823977|DRUG|Ketamine|Blinded study drug administered to experimental arm
214630092|NCT02823977|DRUG|Dexmedetomidine|Open-label study drug administered to both arms
214630093|NCT02823977|DRUG|Normal saline|Blinded comparator administered to control arm
214720284|NCT05145673|OTHER|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
214720285|NCT05092399|PROCEDURE|Bariatric Surgery|No study interventions
214720286|NCT03805971|DEVICE|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
214720287|NCT01197092|DIETARY_SUPPLEMENT|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
214720288|NCT01197092|DIETARY_SUPPLEMENT|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
214720289|NCT01197092|DEVICE|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
214720290|NCT01197092|BEHAVIORAL|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
214720291|NCT00676156|DRUG|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
214720292|NCT00676156|DRUG|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
214630094|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
214630095|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
214630096|NCT04543994|OTHER|Placebo|Normal saline
214630097|NCT05086471|DEVICE|NaviCam SB|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
214630098|NCT05086471|DEVICE|PillCam SB3|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
214630099|NCT06786520|DRUG|CAB LA|CAB LA injection will be administered
214630100|NCT06786520|DRUG|CAB ULA|CAB ULA injection will be administered
214630101|NCT00999414|DRUG|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
214630102|NCT01877187|DRUG|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
214630103|NCT04711707|OTHER|Community navigator|All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.
214630104|NCT04711707|OTHER|Self-Navigation|The control group will receive an electronic or paper copy of community resources that address the identified social needs.
214720293|NCT00676156|DRUG|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
214720294|NCT01063218|OTHER|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
214720295|NCT00517413|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
214720296|NCT05194605|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
214720297|NCT02866461|OTHER|No treatment|Observation
214720298|NCT06180733|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
214720299|NCT02768389|DRUG|Bevacizumab|Subjects receive Bevacizumab as standard of care
214720300|NCT02768389|BEHAVIORAL|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
214720301|NCT05263726|BEHAVIORAL|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
214720302|NCT05573568|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
214720303|NCT05528328|DEVICE|CACIPLIQ20®|CACIPLIQ20®
214720304|NCT05528328|DRUG|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
214720305|NCT00468611|DRUG|MBP8298|500mg MBP8298 IV every six months for a period of two years
214720306|NCT02321397|DRUG|Oxycodone|
214720307|NCT02321397|DRUG|Naloxone|Prolonged Release Tablets
214720308|NCT01355497|DRUG|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
214720309|NCT01355497|DRUG|placebo|subject will receive matching placebo for the duration of the trial
214720310|NCT01384188|DRUG|ONO-5334|150 mg for 5 days administered in the morning or in the evening
214720311|NCT01384188|DRUG|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
214720312|NCT04889690|DRUG|Danicopan|
214720313|NCT04889690|DRUG|Placebo|
214720314|NCT01502761|DRUG|Magnesium Sulfate|Intra-arterial
214720315|NCT05055037|OTHER|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
214720316|NCT01787045|OTHER|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
214720317|NCT01787045|OTHER|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
214720318|NCT05679440|BEHAVIORAL|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
214720319|NCT00911222|OTHER|non-interventional|non-interventional
214720320|NCT04230590|OTHER|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
214720321|NCT06393413|DRUG|Jiedu Yizhi Formula|Observation after 24 weeks of drug treatment
214720322|NCT06393413|DRUG|Donepezil Hydrochloride Tablets|Donepezil Hydrochloride Tablets
214720323|NCT00872781|DRUG|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
214720324|NCT02668952|DRUG|0.9% Normal Saline (0.9% Sodium Chloride) injection|
214720325|NCT02668952|DRUG|Isolyte S injection|
214720326|NCT02312011|DRUG|IONIS-DMPKRx|Drug
214720327|NCT02312011|DRUG|Placebo|Placebo
214720328|NCT06104891|DIETARY_SUPPLEMENT|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
214720329|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
214720330|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
214720331|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
214720332|NCT01958554|BEHAVIORAL|Intervention Group|
214720333|NCT03309904|OTHER|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
214720334|NCT02474914|DRUG|Octreotide|Octreotide will be given after PD
214720335|NCT02474914|DRUG|Placebo|Octreotide will NOT be given after PD
214720336|NCT03358004|DRUG|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
214720337|NCT03358004|DRUG|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
214720338|NCT05457400|DRUG|ENSO 16|30 g ENSO 16 dissolved in Water
214720339|NCT05457400|DRUG|Glucose Powder|30 g Glucose Powder dissolved in Water
214720340|NCT03809156|DRUG|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
214630105|NCT01489839|OTHER|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
214630106|NCT04141709|RADIATION|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~* Scheme A 3\*10 Gy (once a day, 2-3 days a week)~* Scheme B 25\*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3\*10 Gy or 25\*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
214630107|NCT06351995|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
214630108|NCT06351995|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
214630109|NCT04788355|DRUG|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
214630110|NCT04788355|DRUG|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
214630111|NCT04788355|DRUG|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
214720341|NCT02231489|DRUG|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
214720342|NCT02231489|DRUG|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
214720343|NCT02231489|DRUG|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
214720344|NCT00441727|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
214720345|NCT00441727|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
214720346|NCT00441727|DRUG|Placebo|Placebo once daily
214720347|NCT03998891|OTHER|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
214720348|NCT06392178|DEVICE|SugarVita|Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
214720349|NCT04218513|DRUG|Compound Edaravone Injection|30 min intravenous infusion
214720350|NCT04218513|DRUG|Edaravone Injection|30 min intravenous infusion
214720351|NCT04218513|DRUG|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
214720352|NCT01829867|DRUG|sNN0031|
214630112|NCT04788355|DRUG|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
214720353|NCT03042195|OTHER|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
214720354|NCT01877811|DRUG|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
214720355|NCT04931017|PROCEDURE|Biopsy|Undergo biopsy
214720356|NCT04931017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214630113|NCT04457427|DEVICE|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
214630114|NCT03232476|DEVICE|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
214630115|NCT05291494|BEHAVIORAL|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
214630116|NCT05291494|BEHAVIORAL|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
214630117|NCT04407559|OTHER|Serological analyses to be lead on a pre-existing biobank|"3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~* WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~* Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~* Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime."
214720357|NCT04931017|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
214720358|NCT04931017|DRUG|Extended Release Metformin Hydrochloride|Given PO
214720359|NCT04931017|OTHER|Questionnaire Administration|Ancillary studies
214720360|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
214720361|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
214720362|NCT04578119|PROCEDURE|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
214720363|NCT03058848|DIETARY_SUPPLEMENT|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
214720364|NCT00161811|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
214720365|NCT00161811|BIOLOGICAL|Egg cell-derived Influenza Vaccine|
214720366|NCT06109077|OTHER|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
214720367|NCT06109077|OTHER|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
214720368|NCT00220857|DRUG|Rabeprazole|
214720369|NCT06094114|DEVICE|pacemaker follow-up|Performance of an exercise test in patients previously implanted with Micra AV
214720370|NCT04770298|OTHER|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
214720371|NCT02100410|DEVICE|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
214720372|NCT02100410|DEVICE|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
214720373|NCT02100410|DEVICE|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
214720374|NCT02100410|DEVICE|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
214720375|NCT02100410|DEVICE|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
214720376|NCT02100410|DEVICE|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
214630118|NCT04682080|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
214630119|NCT04804254|DRUG|ABBV-623|Oral Tablets
214630120|NCT04804254|DRUG|ABBV-992|Oral Tablets
214630121|NCT06063109|DRUG|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
214630122|NCT06063109|DRUG|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
214630123|NCT04473456|PROCEDURE|Simultaneous EGD and colonoscopy|Patients are examined simultaneously by EGD and colonoscopy
214630124|NCT00003338|PROCEDURE|immunoscintigraphy|
214630125|NCT00003338|RADIATION|technetium Tc 99m epratuzumab|
214630126|NCT03372031|BEHAVIORAL|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
214630127|NCT03372031|BEHAVIORAL|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
214630128|NCT00589446|DEVICE|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
214630129|NCT06187376|DRUG|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
214630130|NCT06187376|DRUG|Placebo|Matching placebo tincture.
214630131|NCT03393273|DRUG|Elotuzumab|"* Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
214630132|NCT00923390|GENETIC|2G-1 TCR Retroviral Vector-Transduced lyn|
214630133|NCT00923390|DRUG|Aldesleukin|
214630134|NCT00923390|DRUG|Cyclophosphamide|
214630135|NCT00923390|DRUG|Fludarabine|
214630136|NCT00923390|DRUG|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
214630137|NCT01068171|OTHER|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
214630138|NCT01068171|OTHER|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
214630139|NCT05972811|OTHER|Cold application|In the experimental group, cold application will be made until the skin temperature of the drain exit area reaches 13.6 °C. And before drain removal, immediately after drain removal and 15 minutes later, pain levels will be measured with VAS and analgesic needs will be questioned
214630140|NCT00006130|PROCEDURE|Core decompression|
214630141|NCT05362409|DRUG|5 Aminolevulinic Acid|5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
214630142|NCT05362409|DEVICE|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
214720377|NCT02315105|PROCEDURE|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
214720378|NCT05423704|OTHER|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
214720379|NCT04751058|GENETIC|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~1. Automatic DNA extraction (ChemagicTM 360)~2. Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~3. Bioinformatic analysis:.~   * Identification of point mutations and small deletions or insertions~  * Analysis of CNVs using the BEDtools program package~  * Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF\> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
214720380|NCT01237223|DRUG|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
214720381|NCT01237223|DRUG|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
214720382|NCT01237223|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
214720383|NCT01237223|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
214720384|NCT01237223|DRUG|Placebo of Aliskiren|Aliskiren placebo tablet
214720385|NCT01237223|DRUG|Placebo of Amlodipine|Amlodipine placebo capsule
214630143|NCT06208020|OTHER|Functional near-infrared spectroscopy (fNIRS) detection|fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
214630144|NCT03102905|OTHER|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
214630145|NCT01641614|PROCEDURE|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
214630146|NCT01641614|PROCEDURE|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
214630147|NCT02368717|DRUG|Mesalazine Enema|
214630148|NCT02368717|DRUG|Placebo Enema|
214630149|NCT03548558|BEHAVIORAL|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
214720386|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
214720387|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
214720388|NCT04570228|DEVICE|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
214720389|NCT04570228|DEVICE|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
214720390|NCT02488356|DIETARY_SUPPLEMENT|Litramine|
214630150|NCT03548558|BEHAVIORAL|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
214630151|NCT03548558|BEHAVIORAL|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
214720391|NCT01222936|DRUG|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
214720392|NCT04112745|OTHER|Static magnet|Static magnet with 2,000 Gauss
214720393|NCT04112745|OTHER|Placebo|Polyvinyl chloride resin material black jewelry
214720394|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^9 vp
214720395|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^10 vp
214720396|NCT04586673|BIOLOGICAL|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10\^8 pfu
214720397|NCT04586673|BIOLOGICAL|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10\^8 pfu
214720398|NCT04675788|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
214720399|NCT04675788|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
214720400|NCT04675788|DRUG|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
214720401|NCT04675788|DRUG|Placebo|Lactose capsules
214720402|NCT03288818|DRUG|Mechlorethamine Hydrochloride Gel|Given topically
214720403|NCT03288818|PROCEDURE|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
214720404|NCT05179343|DEVICE|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
214720405|NCT05179343|DEVICE|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
214720406|NCT05686044|DRUG|Buntanetap/Posiphen|HPMC (vegetarian source) capsule shells
214720407|NCT05686044|DRUG|Placebo|HPMC (vegetarian source) capsule shells
214720408|NCT06851910|DRUG|Lacosamide|Patients will be included if they are prescribed intravenous lacosamide for their trigeminal neuralgia exacerbation
214720409|NCT00407550|DRUG|gemcitabine HCL|1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
214720410|NCT00407550|DRUG|pemetrexed disodium|500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
214720411|NCT00407550|DRUG|gemcitabine HCL|1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
214720412|NCT02183610|DRUG|[14C] BI 1356 as oral (p.o.) solution|
214720413|NCT02183610|DRUG|[14C] BI 1356 solution for i.v. infusion|
214720414|NCT02403713|DRUG|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
214720415|NCT02403713|DRUG|Formoterol|Formoterol
214720416|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
214720417|NCT02403713|DRUG|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
214720418|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
214720419|NCT00443846|BIOLOGICAL|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
214720420|NCT00443846|BIOLOGICAL|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
214720421|NCT02003118|DRUG|AKR 202|
214720422|NCT02003118|DRUG|Placebo|
214720423|NCT04280484|OTHER|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
214720424|NCT04280484|OTHER|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
214720425|NCT02477306|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
214720426|NCT02477306|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
214720427|NCT02812108|DEVICE|intracranial stent, flow diverter and coils|
214720428|NCT05539924|DRUG|Pregabalin 150mg gabapentin 400mg|oral administration
214720429|NCT00641706|DRUG|vorinostat|Given orally
214720430|NCT00641706|PROCEDURE|therapeutic conventional surgery|Patient undergoes surgery
214720431|NCT00641706|DRUG|bortezomib|Given IV
214720432|NCT05442125|OTHER|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
214630152|NCT03548558|BEHAVIORAL|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
214630153|NCT03584867|OTHER|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
214630154|NCT02350270|OTHER|gait and cognitive testing|
214630155|NCT01659645|DRUG|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
214630156|NCT04813471|DRUG|Endothelial Protocol|Endothelial Protocol
214630157|NCT03716869|OTHER|Universal Screening Arm|"Students with PHQ-9 score \>10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
214630158|NCT04491656|OTHER|WALANT Technique|A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
214630159|NCT03431571|PROCEDURE|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
214630160|NCT03756038|DRUG|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
214630161|NCT03756038|DRUG|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
214630162|NCT05449678|BEHAVIORAL|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
214630163|NCT00413361|DRUG|versus hydroxychloroquine|versus hydroxychloroquine
214630164|NCT03868683|OTHER|Glucose Reference 1|30 g of glucose dissolved in 250 ml of water
214630165|NCT03868683|OTHER|Glucose Reference 2|30 g of glucose dissolved in 250 ml of water
214630166|NCT03868683|OTHER|Glucose reference 3|30 g of glucose dissolved in 250 ml of water
214630167|NCT03868683|OTHER|Sucrose|30 g of Sucrose dissolved in 250 ml of water
214630168|NCT03868683|OTHER|Regular Bake beans in tomato sauce|Bake beans in tomato sauce containing 14 g of sugar
214630169|NCT03868683|OTHER|Bake beans in tomato sauce, reduced sugar|Bake beans in tomato sauce containing 12.2 g of sugar
214630170|NCT03868683|OTHER|Bake beans in tomato sauce, low GI|Bake beans in tomato sauce containing 7.2 g of sugar
214630171|NCT01789814|DRUG|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
214630172|NCT01789814|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
214630173|NCT05526833|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
214630174|NCT01090401|DEVICE|Linox smart S DX|ICD lead
214630175|NCT03273166|DEVICE|INVSENSOR00001|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
214630176|NCT03273166|DEVICE|Control SpHb sensor|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
214630177|NCT03273166|PROCEDURE|Hemodilution|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
214630178|NCT04329195|DRUG|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
214630179|NCT04329195|DRUG|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
214630180|NCT01317589|DRUG|fentanyl|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
214720433|NCT05442125|OTHER|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
214720434|NCT00810095|DEVICE|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
214720435|NCT03046160|OTHER|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
214720436|NCT03046160|OTHER|neck and scapular exercises.|A program of 12 neck and scapular exercises.
214720437|NCT03046160|OTHER|corrective tape|elastic tape used to correct the anterior tilt of the scapula
214720438|NCT05301803|DEVICE|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
214720439|NCT01599806|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
214720440|NCT01599806|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
214720441|NCT01599806|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
214720442|NCT01599806|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
214720443|NCT05599854|PROCEDURE|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
214630181|NCT01317589|DRUG|methadone|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
214630182|NCT01898182|OTHER|Kinetin, N6-furfuryladenine, 0.1%|
214630183|NCT02669017|DRUG|ADCT-402|intravenous infusion
214630184|NCT01289015|DRUG|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
214630185|NCT01289015|DRUG|Placebo|Topical; applied once daily for two weeks
214630186|NCT06001268|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
214630187|NCT06001268|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
214630188|NCT06001268|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
214720444|NCT02023918|DRUG|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
214720445|NCT03149926|OTHER|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
214720446|NCT00489034|BEHAVIORAL|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
214720447|NCT00489034|BEHAVIORAL|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
214720448|NCT00489034|BEHAVIORAL|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
214720449|NCT00391807|DRUG|Norethindrone acetate/ethinyl estradiol|one tablet per day
214720450|NCT04843969|BEHAVIORAL|Stress induction|Exposure to a psychosocial stressor
214630189|NCT05493475|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
214630190|NCT06639984|DRUG|Psyllium (0.7 g/year of age per day)|Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
214630191|NCT06639984|DRUG|Psyllium (0.5 g/year of age per day)|Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
214630192|NCT06639984|DRUG|Placebo|Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
214630193|NCT06639984|OTHER|fructans|Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
214630194|NCT02008656|DRUG|Oxaliplatin (OXAL)|
214630195|NCT02008656|DRUG|5-Fluorouracil (5-FU)|
214630196|NCT02008656|DRUG|Leucovorin|
214630197|NCT02008656|DRUG|Capecitabine (Xeloda®)|
214630198|NCT02008656|RADIATION|intensity modulated radiotherapy (IMRT)|
214630199|NCT02008656|BEHAVIORAL|Quality of Life Questionnaires|
214630200|NCT02008656|PROCEDURE|DRE-Endoscopy|
214630201|NCT00428974|DRUG|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
214630202|NCT00428974|DRUG|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
214630203|NCT00428974|DRUG|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
214630204|NCT00428974|DRUG|Placebo|Placebo tablets q12 hours for 12 weeks
214630205|NCT00343668|DRUG|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
214630206|NCT01266863|OTHER|E test method|E test strips directly applied to BAL
214630207|NCT01217632|DRUG|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
214630208|NCT01217632|DRUG|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
214630209|NCT01217632|DRUG|Entecavir|
214630210|NCT02797808|DRUG|Sertraline|Impact of sertraline on functional brain connectivity
214630211|NCT02797808|OTHER|No Intervention|Healthy control non-intervention
214630212|NCT04089007|DEVICE|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
214720451|NCT04843969|BEHAVIORAL|Control stress exposure|Exposure to a control task (no stress)
214720452|NCT04843969|BEHAVIORAL|Cue induction|Exposure to a smoking-related task
214720453|NCT04843969|BEHAVIORAL|Neutral cue exposure|Exposure to neutral cues
214630213|NCT04089007|OTHER|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
214630214|NCT01423799|DIETARY_SUPPLEMENT|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
214630215|NCT01423799|DIETARY_SUPPLEMENT|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
214630216|NCT05506189|OTHER|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
214630217|NCT06279156|DEVICE|Bioelectrical Impedance Analysis (BIA)|"Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition."
214720454|NCT02712281|BEHAVIORAL|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
214630218|NCT01175109|DRUG|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
214630219|NCT04807907|BEHAVIORAL|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
214630220|NCT03269123|DEVICE|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
214630221|NCT03509350|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
214630222|NCT03509350|DRUG|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
214630223|NCT03509350|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
214630224|NCT03509350|DRUG|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
214630225|NCT03509350|DRUG|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
214630226|NCT03509350|DRUG|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
214630227|NCT01425203|DRUG|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
214630228|NCT01425203|DRUG|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
214630229|NCT01425203|BIOLOGICAL|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
214720455|NCT02712281|BEHAVIORAL|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
214720456|NCT04694716|OTHER|No intervention|No intervention will be applied.
214630230|NCT01425203|DRUG|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
214630231|NCT05773196|OTHER|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~* 10 mL EDTA Vial (Box 1; Frozen)~  o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~* 10 mL EDTA Vial (Box 2; Ambient)~  * Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
214630232|NCT04338815|OTHER|Exoskeleton Optimization|Participants will walk 10-minute trials while an optimization algorithm changes the assistance profile of the exoskeleton.
214720457|NCT05968872|BEHAVIORAL|no intervation|it is observational, no intervention was taken
214630233|NCT04338815|OTHER|Endurance Evaluation|Participants will walk 2 trials at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes, which ever comes first.
214630234|NCT00535132|DRUG|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
214630235|NCT00535132|DRUG|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
214630236|NCT02878954|OTHER|No intervention (Observational study)|"160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed."
214630237|NCT02878954|OTHER|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
214720458|NCT04673188|PROCEDURE|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
214720459|NCT03683043|DRUG|Long GnRH agonist protocol|"8\. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9\. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
214630238|NCT02878954|OTHER|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
214630239|NCT01072214|DRUG|pazopanib|gw786034
214630240|NCT01072214|DRUG|pazopanib|gw786034
214630241|NCT01072214|DRUG|pazopanib|gw786034
214630242|NCT01072214|DRUG|Placebo|placebo
214630243|NCT04601948|BEHAVIORAL|mHealth Activity Intervention|Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
214630244|NCT03725748|OTHER|irrigation|irrigation the edges of the cs scar before closure
214630245|NCT03700307|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
214630246|NCT02590588|DRUG|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
214630247|NCT04840160|DIETARY_SUPPLEMENT|Cherry juice|A tart cherry juice intervention
214630248|NCT04840160|DIETARY_SUPPLEMENT|Placebo|A tart cherry juice placebo
214630249|NCT00261430|BEHAVIORAL|GAIN Acceptance Approach|
214630250|NCT02140814|DIETARY_SUPPLEMENT|Niacinamide|
214630251|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
214630252|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
214630253|NCT03641066|DEVICE|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
214630254|NCT01109888|DRUG|Cetrotide|
214720460|NCT03683043|PROCEDURE|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
214720461|NCT05911737|BEHAVIORAL|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
214720462|NCT02068950|BEHAVIORAL|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
214630255|NCT02567890|BEHAVIORAL|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
214630256|NCT02567890|BEHAVIORAL|Expressive writing|Participants will be asked to reflect upon issues related to body image.
214630257|NCT05269758|BEHAVIORAL|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
214630258|NCT01050270|DRUG|Ondansetron|4mgs iv bolus
214630259|NCT01050270|DRUG|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
214630260|NCT01050270|DRUG|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
214630261|NCT02918773|DEVICE|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
214630262|NCT02918773|DEVICE|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
214630263|NCT01960621|DRUG|cyclodextrin|intravenous
214630264|NCT03245073|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
214630265|NCT03245073|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
214630266|NCT01554137|OTHER|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
214630267|NCT01554137|OTHER|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
214630268|NCT05679635|DEVICE|Evone|The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
214630269|NCT05679635|DEVICE|Evita Infinity V500|Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
214630270|NCT02559687|BIOLOGICAL|pembrolizumab|IV Q3W
214630271|NCT03001674|DEVICE|Conductance catheterization|CD Leycom Conductance Catheter
214630272|NCT01702610|RADIATION|IMRT Technique|
214630273|NCT01702610|RADIATION|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
214630274|NCT01702610|RADIATION|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
214630275|NCT01702610|DRUG|Temozolomide and Accelerated Hypofractionation RT|
214630276|NCT03224273|OTHER|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
214630277|NCT03971201|PROCEDURE|hepatic resection|removal of portion of liver containing cancer
214630278|NCT03971201|DRUG|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
214720463|NCT04460040|BEHAVIORAL|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
214720464|NCT01464814|DIETARY_SUPPLEMENT|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
214720465|NCT01464814|DIETARY_SUPPLEMENT|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
214720466|NCT02011672|OTHER|nutrient-enriched milk|
214720467|NCT02011672|OTHER|regular milk|
214720468|NCT01266070|DRUG|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
214720469|NCT04231513|DRUG|E2814|E2814, intravenous infusion.
214720470|NCT04231513|DRUG|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
214720471|NCT03942146|BEHAVIORAL|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
214720472|NCT01585168|DRUG|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
214720473|NCT01585168|DRUG|Placebo|Identically appearing sugar pill, given orally
214720474|NCT01194414|DRUG|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
214720475|NCT01194414|DRUG|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
214720476|NCT01194414|DRUG|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
214720477|NCT01194414|DRUG|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
214720478|NCT01194414|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
214720479|NCT02256345|DRUG|KNO3|Active Comparator
214720480|NCT02256345|DRUG|KCl|Placebo Comparator
214720481|NCT02552667|DRUG|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
214720482|NCT02552667|DRUG|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
214720483|NCT03385408|DEVICE|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
214630279|NCT03760900|COMBINATION_PRODUCT|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
214630280|NCT04472585|DRUG|Ivermectin Injectable Solution|Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
214630281|NCT04472585|OTHER|Injectable Placebo|0.9% normal saline
214630282|NCT04472585|DRUG|Zinc|Zinc Sulphate 20mg 3 times a day
214630283|NCT04472585|DRUG|Placebo empty capsule|Placebo empty capsule
214630284|NCT04472585|DRUG|Oral Ivermectin|0.2mg/kg/day
214630285|NCT03534700|PROCEDURE|parasacral flap reconstruction|parasacral flap reconstruction
214630286|NCT03534700|PROCEDURE|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
214630287|NCT05564169|DRUG|Placebo|treatment per os
214630288|NCT05564169|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
214630289|NCT05564169|DRUG|Standard of care|Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
214720484|NCT03385408|DEVICE|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
214720485|NCT01495364|BIOLOGICAL|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
214720486|NCT01495364|OTHER|placebo|matching placebo
214720487|NCT03326583|DRUG|Patiromer|Patiromer will be orally self-administered by participants.
214720488|NCT03792802|PROCEDURE|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
214720489|NCT04159922|OTHER|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
214720490|NCT00747539|DRUG|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
214720491|NCT01317693|DEVICE|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
214720492|NCT04355026|DRUG|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
214720493|NCT03432117|OTHER|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
214720494|NCT03432117|OTHER|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
214720495|NCT01715272|DEVICE|TF037|
214720496|NCT01715272|DRUG|Fleet enema|
214720497|NCT01277471|BEHAVIORAL|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
214720498|NCT01277471|BEHAVIORAL|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
214720499|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - single-session
214720500|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - multi-session
214720501|NCT00682240|PROCEDURE|laser treatment with PASCAL®|grid / focal laser treatment
214720502|NCT00682240|PROCEDURE|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
214720503|NCT02938221|DEVICE|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
214720504|NCT02157103|DRUG|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
214720505|NCT00000608|BEHAVIORAL|diet, fat-restricted|
214720506|NCT00000608|BEHAVIORAL|diet, sodium-restricted|
214720507|NCT05704842|BEHAVIORAL|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
214720508|NCT06037512|DIAGNOSTIC_TEST|subject|blood glucose measurement by subject
214720509|NCT06037512|DIAGNOSTIC_TEST|reference|blood glucose measurement with reference
214720510|NCT01921452|DEVICE|Quantitative POC TSH Kit|A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
214720511|NCT01921452|DEVICE|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
214720512|NCT01921452|DEVICE|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
214720513|NCT01525667|BIOLOGICAL|150M PLX-PAD|Single course, multiple IM injections
214720514|NCT01525667|BIOLOGICAL|300M PLX-PAD|Single course, multiple IM injections
214720515|NCT01525667|BIOLOGICAL|Placebo|Single course, multiple IM injections
214720516|NCT00116987|DEVICE|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
214720517|NCT00116987|DEVICE|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
214720518|NCT00770224|BIOLOGICAL|rituximab|
214720519|NCT00770224|BIOLOGICAL|tositumomab|
214720520|NCT00770224|DRUG|cyclophosphamide|
214720521|NCT00770224|DRUG|doxorubicin|
214720522|NCT00770224|DRUG|prednisone|
214720523|NCT00770224|DRUG|vincristine|
214720524|NCT00770224|RADIATION|tositumomab|
214720525|NCT00517218|DRUG|Genasense® (, oblimersen sodium G3139)|
214720526|NCT02915640|OTHER|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
214720527|NCT04672902|PROCEDURE|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
214720528|NCT01505114|DRUG|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
214720529|NCT01505114|DRUG|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
214720530|NCT01505114|DRUG|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
214720531|NCT01505114|OTHER|Maraviroc placebo|Once daily from Week 0 through Week 48
214720532|NCT01505114|OTHER|Emtricitabine placebo|Once daily from Week 0 through Week 48
214720533|NCT01505114|OTHER|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
214720534|NCT04749160|DEVICE|Connected device|Connected device is a smart watch (with accelerometer without location data).
214720535|NCT06423170|DRUG|Camrelizumab plus GEMOX|"1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses."
214720536|NCT02746770|OTHER|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
214720537|NCT00454480|BIOLOGICAL|alemtuzumab|
214720538|NCT00454480|DRUG|arsenic trioxide|
214720539|NCT00454480|DRUG|azacitidine|
214720540|NCT00454480|DRUG|busulfan|
214720541|NCT00454480|DRUG|clofarabine|
214720542|NCT00454480|DRUG|cytarabine|
214720543|NCT00454480|DRUG|daunorubicin hydrochloride|
214720544|NCT00454480|DRUG|fludarabine phosphate|
214720545|NCT00454480|DRUG|gemtuzumab ozogamicin|
214720546|NCT00454480|DRUG|melphalan|
214720547|NCT00454480|DRUG|tipifarnib|
214720548|NCT00454480|GENETIC|DNA methylation analysis|
214720549|NCT00454480|GENETIC|cytogenetic analysis|
214720550|NCT00454480|GENETIC|gene expression analysis|
214720551|NCT00454480|GENETIC|mutation analysis|
214720552|NCT00454480|OTHER|diagnostic laboratory biomarker analysis|
214720553|NCT00454480|OTHER|immunologic technique|
214720554|NCT00454480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214720555|NCT00454480|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214720556|NCT00288041|DRUG|carboplatin|Given IV
214720557|NCT00288041|DRUG|paclitaxel|Given IV
214720558|NCT00288041|DRUG|bortezomib|Given IV
214720559|NCT00322751|DRUG|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
214720560|NCT01053403|DRUG|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
214720561|NCT02441192|OTHER|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
214720562|NCT02441192|OTHER|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
214720563|NCT02441192|OTHER|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
214720564|NCT05351190|DEVICE|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
214630290|NCT05152550|OTHER|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
214630291|NCT01936545|DRUG|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
214630292|NCT01936545|DRUG|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
214630293|NCT02956668|OTHER|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
214630294|NCT02956668|OTHER|Blindsight Training alone|The patient undergo visual rehabilitation
214630295|NCT01357486|DRUG|sorafenib|patients receiving sorafenib 400 mg - twice a day
214630296|NCT01357486|DRUG|Pravastatin|patients receiving pravastatin 40 mg - once a day
214630297|NCT01357486|DRUG|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
214630298|NCT01357486|OTHER|patients receiving best supportive care|palliative management
214630299|NCT03031301|DEVICE|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
214630300|NCT03031301|DEVICE|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
214630301|NCT02355782|BIOLOGICAL|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
214630302|NCT00209378|OTHER|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
214630303|NCT00209378|OTHER|HfCitPre|regional anticoagulation with citrate containing replacement solution
214630304|NCT01859442|PROCEDURE|Structured responsive interval exercise training programme|
214630305|NCT01859442|OTHER|Sham group|NO intervention in this group, only standard care (no exercise programme)
214630306|NCT06033820|DRUG|ZR2-ICE|"* Drug: zanubrutinib Oral Capsule~* Drug: lenalidomide Oral Capsule~* Drug: R-ICE chemotherapy"
214630307|NCT06260280|DIAGNOSTIC_TEST|Cerebral Nuclear Magnetic Resonance|Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
214630308|NCT01731652|DRUG|TMX-101|
214630309|NCT03283176|DIAGNOSTIC_TEST|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
214630310|NCT03729492|DIAGNOSTIC_TEST|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
214630311|NCT00983983|DIETARY_SUPPLEMENT|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
214630312|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
214630313|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
214630314|NCT04769011|DIAGNOSTIC_TEST|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
214630315|NCT04769011|DIAGNOSTIC_TEST|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
214630316|NCT04769011|DIAGNOSTIC_TEST|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
214630317|NCT04769011|DIAGNOSTIC_TEST|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
214630318|NCT01826682|OTHER|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
214630319|NCT01826682|OTHER|Medical treatment|Standard medical treatment without physiotherapy.
214630320|NCT06349395|OTHER|MBSR surgical nursing care|This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
214630321|NCT05009719|BIOLOGICAL|Prophylactic Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
214630322|NCT05009719|BIOLOGICAL|Preventive Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
214630323|NCT01120496|DRUG|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
214630324|NCT01120496|DRUG|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
214630325|NCT03504410|DRUG|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
214630326|NCT03504410|DRUG|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
214720565|NCT05810298|OTHER|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
214720566|NCT05810298|OTHER|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
214720567|NCT05810298|BEHAVIORAL|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
214720568|NCT01046968|DIETARY_SUPPLEMENT|Lepticore|300 mg twice daily
214630327|NCT03504410|DRUG|Mitoxantrone, Etoposide and Cytarabine|"Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6"
214630328|NCT03504410|DRUG|Fludarabine, Cytarabine, Filgrastim|"Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
214630329|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
214630330|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
214630331|NCT03375450|OTHER|Standard of Care|Participants will be followed as per local routine primary healthcare practice
214630332|NCT02661425|OTHER|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
214630333|NCT03784066|DRUG|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
214630334|NCT03784066|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
214630335|NCT04213612|DRUG|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
214630336|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
214630337|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 4) \& matching placebo administered orally once daily
214630338|NCT01241214|DRUG|Cetirizine|Ceterizine administered once daily
214630339|NCT01241214|DRUG|Placebo|Matching placebo administered twice daily.
214630340|NCT03759665|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
214630341|NCT00645983|DIETARY_SUPPLEMENT|Chamomile Extract|220 mg - 1100 mg daily
214630342|NCT00645983|OTHER|Placebo|1 to 5 capsules daily
214630343|NCT02114580|OTHER|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
214630344|NCT03665402|DRUG|Isoniazid|One of the first line anti-tubercolosis drug
214630345|NCT03413020|DRUG|esomeprazole|proton pump inhibitor
214630346|NCT03413020|DRUG|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
214720569|NCT02548741|DRUG|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
214630347|NCT03413020|DRUG|amoxicillin|antibiotic for H. pylori eradication
214630348|NCT03413020|DRUG|clarithromycin|antibiotic for H. pylori eradication
214630349|NCT03413020|DRUG|metronidazole|antibiotic for H. pylori eradication
214630350|NCT03413020|DRUG|levofloxacin|antibiotic for H. pylori eradication
214630351|NCT02776488|DRUG|Sodium Lactate|Infusion of exogenous sodium lactate
214630352|NCT02776488|DRUG|Placebo|Infusion of normal saline
214630353|NCT04429620|DIAGNOSTIC_TEST|Immunfluorescence|Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
214630354|NCT04064775|BEHAVIORAL|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
214630355|NCT03098329|OTHER|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
214630356|NCT02825095|PROCEDURE|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
214630357|NCT02825095|PROCEDURE|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
214630358|NCT02825095|PROCEDURE|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
214630359|NCT02825095|DRUG|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
214630360|NCT02825095|PROCEDURE|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
214630361|NCT03089073|DRUG|Desmopressin|60μg or 120μg once daily at bedtime
214630362|NCT00018265|BEHAVIORAL|Task specific endurance training|
214630363|NCT00018265|BEHAVIORAL|Tai Chi|
214630364|NCT04592783|DRUG|Antihypertensive Agents|Antihypertensive medications will be initialed once BP is at predetermined threshold
214630365|NCT01598038|OTHER|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
214630366|NCT04699487|DEVICE|Photobiomodulation|"Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session."
214630367|NCT00909311|DRUG|ABT-450|capsules, QD, 1 dose in each cross-over period
214630368|NCT00909311|DRUG|ritonavir|capsule, QD, 1 dose in each cross-over period
214630369|NCT03006510|OTHER|Hypoglycemia prediction alert|"In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is \>35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
214630370|NCT06106854|BEHAVIORAL|Behavioral: SystemCHANGE|six-month SystemCHANGE™ intervention
214630371|NCT06106854|OTHER|Education|Six patient education booklets
214630372|NCT03239717|OTHER|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
214630373|NCT03239717|OTHER|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
214630374|NCT04606459|DEVICE|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
214630375|NCT04606459|OTHER|Optimal medical therapy|Guideline-directed medical therapy
214630376|NCT00138736|DRUG|Mannan Binding Lectin (MBL)|
214630377|NCT00138736|DRUG|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
214630378|NCT02357498|PROCEDURE|transsphenoidal surgery|
214630379|NCT02009527|DRUG|N-hydroxy-nor-arginine|
214630380|NCT02009527|DRUG|NaCl|
214630381|NCT04992819|PROCEDURE|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
214630382|NCT05771298|DEVICE|532nm KTP|one to three treatment sessions
214630383|NCT05771298|DEVICE|585nm PDL|one to three treatment sessions
214630384|NCT03783390|BEHAVIORAL|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
214630385|NCT03783390|BEHAVIORAL|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
214630386|NCT01679210|BEHAVIORAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
214630387|NCT02148237|BEHAVIORAL|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
214720570|NCT02548741|DRUG|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
214720571|NCT02548741|OTHER|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
214720572|NCT02548741|OTHER|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
214720573|NCT01869803|DRUG|gemtuzumab ozogamicin|Given IV
214720574|NCT01869803|OTHER|laboratory biomarker analysis|Correlative studies
214720575|NCT03460613|OTHER|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
214720576|NCT01759355|PROCEDURE|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
214720577|NCT01235507|DRUG|methotrexate|stable dose as prescribed
214720578|NCT01235507|DRUG|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
214720579|NCT04725201|DRUG|Intravenous unfractionated heparin|See experimental arm description for intervention description.
214720580|NCT04725201|DRUG|Sham|See sham comparator arm description for intervention description.
214720581|NCT00442260|DRUG|DOXIL|
214720582|NCT00442260|DRUG|Abraxane|
214720583|NCT06212206|DEVICE|PillBot|The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
214720584|NCT00004852|DRUG|Efavirenz|
214720585|NCT00004852|DRUG|Lamivudine|
214720586|NCT00004852|DRUG|Zidovudine|
214720587|NCT04182906|BEHAVIORAL|Care Coordination|Screening and referral for basic needs and adult mental health
214720588|NCT04182906|BEHAVIORAL|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
214720589|NCT04182906|BEHAVIORAL|Usual Care|Usual Primary Pediatric Care
214720590|NCT00959881|DRUG|Donepezil plus placebo|5- and 10-mg tablets, single dose
214720591|NCT00959881|DRUG|Donepezil|5- and 10-mg tablets, single dose
214720592|NCT00959881|DRUG|Begacestat|6 x 50-mg capsules, single dose
214720593|NCT00617838|OTHER|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
214720594|NCT01980225|PROCEDURE|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
214720595|NCT02533076|OTHER|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
214720596|NCT02533076|OTHER|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
214720597|NCT02533076|DEVICE|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
214720598|NCT02533076|DEVICE|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
214630388|NCT03535259|RADIATION|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
214630389|NCT01399580|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
214630390|NCT01399580|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
214630391|NCT00282503|DRUG|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
214630392|NCT00282503|PROCEDURE|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
214630393|NCT00938756|OTHER|diagnostic laboratory biomarker analysis|
214630394|NCT00938756|OTHER|immunoenzyme technique|
214630395|NCT00938756|PROCEDURE|magnetic resonance imaging|
214630396|NCT02925130|DRUG|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
214630397|NCT02925130|DRUG|Placebo|Acute oral intake of a placebo drug
214630398|NCT03865693|DEVICE|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
214630399|NCT04746768|COMBINATION_PRODUCT|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
214630400|NCT05872776|DEVICE|Neuromodulation with RR2 device|non-invasive neuromodulation with RR2 device
214630401|NCT05872776|DEVICE|Mock sham neuromodulation with sham RR2 device|Mock sham stimulation with RR2 device
214630402|NCT01857869|BIOLOGICAL|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
214630403|NCT01857869|BIOLOGICAL|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
214630404|NCT01857869|PROCEDURE|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
214630405|NCT03988335|DRUG|RIST4721|RIST4721 oral solution
214630406|NCT03988335|DRUG|Placebo|Placebo oral solution
214630407|NCT00252707|DRUG|Gefitinib or Docetaxel|
214630408|NCT02971878|BIOLOGICAL|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
214630409|NCT00881777|PROCEDURE|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
214630410|NCT00881777|PROCEDURE|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
214630411|NCT05956106|DIETARY_SUPPLEMENT|Black Mulberry Fruit Powder|Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
214630412|NCT01785212|DEVICE|Stapler|stapler hepatectomy
214630413|NCT01785212|DEVICE|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
214630414|NCT03721094|OTHER|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
214720599|NCT05218304|BIOLOGICAL|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
214720600|NCT05031104|OTHER|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
214720601|NCT05031104|OTHER|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
214720602|NCT01363258|BEHAVIORAL|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
214720603|NCT01363258|PROCEDURE|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
214720604|NCT05170672|BIOLOGICAL|Abatacept|
214720605|NCT02428673|OTHER|Assisted Standing Treatment Program|
214720606|NCT04582604|DRUG|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
214720607|NCT04584931|PROCEDURE|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
214720608|NCT04584931|PROCEDURE|restorative intervention|colored composite restoration to camouflage the gingival recession defect
214720609|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
214720610|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
214720611|NCT01587274|DRUG|Naproxen|Naproxen 500mg twice/ day x 10 days
214720612|NCT01587274|DRUG|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
214720613|NCT01587274|DRUG|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
214720614|NCT04055025|OTHER|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
214720615|NCT04055025|OTHER|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
214720616|NCT01301417|DEVICE|ColonRing™|Creation of a circular Compression Anastomosis
214720617|NCT03896906|DEVICE|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
214720618|NCT03896906|DEVICE|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
214720619|NCT04753723|COMBINATION_PRODUCT|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
214720620|NCT03907813|DRUG|Exparel|liposomal bupivacaine wound infiltration
214720621|NCT03907813|OTHER|Saline infiltration|saline wound infiltration
214720622|NCT02475629|BIOLOGICAL|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
214720623|NCT02475629|DRUG|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
214720624|NCT04257604|DRUG|Perampanel|Perampanel tablets.
214720625|NCT02257125|BEHAVIORAL|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
214630415|NCT00491348|DRUG|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
214630416|NCT04283136|DRUG|Padsevonil type 1 Tablet 200 mg|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
214630417|NCT04283136|DRUG|Padsevonil type 2 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
214720626|NCT02257125|BEHAVIORAL|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
214630418|NCT04283136|DRUG|Padsevonil type 3 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
214630419|NCT04283136|DRUG|Padsevonil type 4 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
214630420|NCT04283136|DRUG|Padsevonil type 5 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
214720627|NCT02403960|DIETARY_SUPPLEMENT|probiotic|the patients used probiotic tablets in addition to scaling and root planning
214630421|NCT05601375|OTHER|Echocardiography|Fetal echocardiography (ultrasound)
214630422|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
214720628|NCT02403960|DIETARY_SUPPLEMENT|placebo|the patients used placebo tablets in addition to scaling and root planning
214720629|NCT02593461|DEVICE|Daifert|
214720630|NCT02593461|OTHER|Control Group|
214720631|NCT02242760|DRUG|SB204 2%|Applied topically twice daily
214720632|NCT02242760|DRUG|SB204 4%|Applied topically daily
214720633|NCT02242760|DRUG|Vehicle Gel|Applied topically twice and once daily
214720634|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
214630423|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
214630424|NCT03837470|DRUG|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
214630425|NCT03837470|DRUG|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
214630426|NCT02127190|DRUG|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
214630427|NCT02127190|DRUG|Placebo|
214630428|NCT03238820|PROCEDURE|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
214630429|NCT05892809|OTHER|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
214630430|NCT02482675|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
214630431|NCT02482675|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
214630432|NCT02482675|OTHER|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
214630433|NCT02482675|OTHER|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
214630434|NCT00331045|DRUG|alvimopan|0.25 mg/day
214630435|NCT00331045|DRUG|Placebo|
214630436|NCT00331045|DRUG|Alvimopan 0.5 mg/day|
214630437|NCT00331045|DRUG|Alvimopan 1 mg/day|
214630438|NCT01957358|BEHAVIORAL|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
214630439|NCT02898259|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
214630440|NCT02898259|DRUG|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~* Starting lenalidomide Dose (20mg)~* Calculated Creatinine Clearance: \>=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~* Calculated Creatinine Clearance: \>= 30 and \< 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
214630441|NCT02898259|DRUG|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
214630442|NCT01856881|DRUG|AMG 876|Ascending multiple doses of study drug administered SC
214630443|NCT03442634|OTHER|Early Hydration|this group will start oral hydration within 1 hour after cesarean section
214630444|NCT03442634|OTHER|Traditional Oral Hydration|this group will start oral hydration 6 hours after cesarean section
214630445|NCT01225679|DEVICE|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
214630446|NCT03099889|BEHAVIORAL|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
214630447|NCT01796327|DRUG|dacomitinib oral|Dacomitinib 45 mg oral tablet
214630448|NCT01796327|DRUG|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
214720635|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
214720636|NCT01641081|DRUG|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
214720637|NCT01641081|DRUG|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
214720638|NCT01641081|DRUG|Placebo|Placebo in the Pressair for 14 days
214720639|NCT01283893|PROCEDURE|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
214720640|NCT00112567|DRUG|fludarabine phosphate|
214720641|NCT00112567|DRUG|thiotepa|
214720642|NCT00112567|PROCEDURE|peripheral blood stem cell transplantation|
214720643|NCT00112567|RADIATION|radiation therapy|
214720644|NCT01042054|OTHER|Standard optimised recovery protocol.|"* Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
214720645|NCT01042054|OTHER|Wound catheter plus patient-controlled analgesia.|"* Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
214720646|NCT03011775|DRUG|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
214720647|NCT03011775|DRUG|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
214720648|NCT03011775|DRUG|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
214720649|NCT03011775|DRUG|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
214720650|NCT03011775|DRUG|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
214720651|NCT03011775|DRUG|Ramipril 5 MG|1 tablet per a day
214720652|NCT00674375|OTHER|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
214720653|NCT01502670|DRUG|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
214720654|NCT01505244|BEHAVIORAL|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
214720655|NCT00588380|DRUG|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
214720656|NCT00742040|DRUG|Captopril|A rapid 3-day up-titration protocol
214720657|NCT00742040|DRUG|Captopril|A slower 9-day up-titration protocol
214720658|NCT01781624|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
214720659|NCT00353990|DRUG|Insulin Aspart|
214720660|NCT01749800|DEVICE|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
214720661|NCT01749800|DEVICE|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
214720662|NCT01749800|DEVICE|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
214630449|NCT01272700|PROCEDURE|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
214630450|NCT01272700|PROCEDURE|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
214630451|NCT00084201|DRUG|Cranberry juice|
214630452|NCT00084201|DRUG|Amoxicillin|
214630453|NCT01040559|DRUG|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
214630454|NCT03016325|DRUG|HNO Donor|Infusion
214630455|NCT03016325|DRUG|Placebo|Infusion
214630456|NCT01323426|PROCEDURE|Periurethral injection|Periurethral injection of autologous muscle fibers
214630457|NCT01003496|BEHAVIORAL|Treatment as Usual (TAU)|Outpatient substance abuse treatment
214630458|NCT01003496|BEHAVIORAL|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
214630459|NCT03711500|DRUG|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
214720663|NCT05355181|OTHER|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
214630460|NCT03711500|DRUG|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
214630461|NCT01310894|DRUG|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
214630462|NCT00368511|PROCEDURE|Music Listening|Listen to music and posture measurements
214630463|NCT01902290|BIOLOGICAL|Placebo|Placebo administered subcutaneously
214630464|NCT01902290|BIOLOGICAL|Brodalumab|Brodalumab administered subcutaneously
214630465|NCT04434495|BIOLOGICAL|PRP|PRP injection into uterine cavity
214630466|NCT02883751|RADIATION|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
214630467|NCT02883751|PROCEDURE|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
214630468|NCT06199388|OTHER|Survival state|We recorded clinically relevant information and survival status of pediatric glioma patients
214630469|NCT02666573|DEVICE|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
214630470|NCT02666573|OTHER|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
214630471|NCT06518577|BIOLOGICAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4)
214630472|NCT06518577|BIOLOGICAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV)
214630473|NCT02486055|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
214630474|NCT03389854|DEVICE|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
214630475|NCT03389854|DEVICE|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
214630476|NCT00907101|DRUG|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
214630477|NCT00805831|DEVICE|HDH|sutureless vascular anastomosis
214630478|NCT00505999|BEHAVIORAL|Questionnaire|Questionnaire taking 30-40 minutes to complete.
214630479|NCT00576043|PROCEDURE|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
214630480|NCT00586209|DRUG|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
214630481|NCT00586209|DRUG|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
214630482|NCT03042715|BEHAVIORAL|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
214630483|NCT04807348|DRUG|Chiglitazar 32mg|Administrated once daily
214630484|NCT04807348|DRUG|Chiglitazar 48mg|Administrated once daily
214630485|NCT04807348|DRUG|Placebo|Placebo of Chiglitazar
214630486|NCT04807348|DRUG|Metformin Hydrochloride|most tolerable dose
214630487|NCT00001288|DRUG|15 O Water|
214630488|NCT00001288|DRUG|FDG|
214630489|NCT02199080|OTHER|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
214630490|NCT02250274|BIOLOGICAL|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
214630491|NCT02250274|BIOLOGICAL|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]"
214630492|NCT02556398|BEHAVIORAL|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
214630493|NCT01277549|DEVICE|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
214630494|NCT04395911|DEVICE|SCD|cytopheretic device
214630495|NCT00514956|BEHAVIORAL|Emotional Freedom Techniques (EFT)|
214630496|NCT03344302|DRUG|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
214630497|NCT03166293|BEHAVIORAL|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
214630498|NCT01365559|DRUG|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
214630499|NCT01365559|DRUG|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
214630500|NCT03030430|BIOLOGICAL|BAT1706 injection|1mg/kg, IV on day 1
214630501|NCT03030430|BIOLOGICAL|EU-sourced Avastin|1mg/kg, IV on day 1
214630502|NCT03030430|BIOLOGICAL|US-sourced Avastin|1mg/kg, IV on day 1
214630503|NCT01618214|DRUG|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
214630504|NCT00062335|RADIATION|radiation therapy|
214630505|NCT04394533|DRUG|Prilocaine (Hyperbaric 2%)|2 ml hyperbaric prilocaine
214630506|NCT04394533|DRUG|Bupivacaine (Hyperbaric 0.5%)|2 ml hyperbaric bupivacaine
214630507|NCT00599040|BEHAVIORAL|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
214630508|NCT00599040|BEHAVIORAL|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
214630509|NCT00599040|BEHAVIORAL|Dairy diet|participants are given a high dairy, reduced calorie diet
214630510|NCT01312935|DRUG|PMX-60056|investigational drug
214630511|NCT01758250|OTHER|Acoustic Radiation Force Impulse (ARFI)|
214630512|NCT01758250|OTHER|Laser Doppler Flowmetry (LDF)|
214630513|NCT01758250|OTHER|Laser Doppler Perfusion Imaging (LDI)|
214630514|NCT01758250|OTHER|Optical Coherence Tomography (OCT)|
214630515|NCT01758250|OTHER|Orthogonal Polarization Spectral Imaging (OPSI)|
214630516|NCT01758250|OTHER|Nail fold video capillaroscopy (NVC)|
214630517|NCT05468632|DRUG|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
214630518|NCT00571350|PROCEDURE|tvt-o operation|transvaginal tention free obturator tape
214630519|NCT00571350|PROCEDURE|tvt o operation|transobturator vaginal tape insertion
214630520|NCT01839864|BEHAVIORAL|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
214630521|NCT00391222|DRUG|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
214630522|NCT00391222|DRUG|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
214630523|NCT00391222|DRUG|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
214630524|NCT02504021|BEHAVIORAL|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
214630525|NCT02702037|DIETARY_SUPPLEMENT|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
214630526|NCT02702037|OTHER|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
214630527|NCT05700162|BEHAVIORAL|Photograph|As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.
214630528|NCT05700162|BEHAVIORAL|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
214630529|NCT05700162|BEHAVIORAL|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
214630530|NCT05700162|BEHAVIORAL|Control Group|She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
214630531|NCT00337064|PROCEDURE|Radiation Therapy|
214630532|NCT02996188|PROCEDURE|routine therapeutic paracentesis|
214630533|NCT03993366|COMBINATION_PRODUCT|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
214630534|NCT03993366|DEVICE|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
214720664|NCT05355181|OTHER|Core stabilization exercises|Core stabilization exercises
214630535|NCT05603715|DRUG|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
214630536|NCT03519763|DIAGNOSTIC_TEST|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
214630537|NCT00745563|DEVICE|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
214630538|NCT00574275|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
214630539|NCT00574275|DRUG|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
214630540|NCT00574275|DRUG|Gemcitabine|1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
214630541|NCT00870402|DRUG|Spironolactone|25 mg per day for 9 months
214630542|NCT00870402|DRUG|Placebo|Placebo 1 tablet per day for nine months
214630543|NCT05595824|DRUG|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
214630544|NCT05595824|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
214630545|NCT04170322|DEVICE|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
214630546|NCT04170322|DEVICE|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
214630547|NCT00652366|DRUG|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
214630548|NCT00652366|DRUG|Erlotinib, standard dose|100mg, PO, once daily
214630549|NCT00652366|DRUG|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
214630550|NCT03377530|DIAGNOSTIC_TEST|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
214630551|NCT01890642|DEVICE|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
214630552|NCT01890642|OTHER|Pain Ease Spray|Cold Spray used to anesthetize the skin
214720665|NCT04214041|OTHER|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
214630553|NCT01890642|DRUG|1% buffered lidocaine|Lidocaine placed using Jet Injection
214630554|NCT01890642|OTHER|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
214630555|NCT01890642|OTHER|Sucrose|Oral Sucrose used for children \< 1 year
214630556|NCT03383484|OTHER|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
214630557|NCT03383484|OTHER|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
214630558|NCT04905121|DRUG|Psilocybin|Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
214630559|NCT02599701|DRUG|Gabapentin|A single dose Gabapentin 300mg at bedtime.
214630560|NCT02599701|DRUG|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
214630561|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
214630562|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Hard Capsule-Route of administration:Oral
214630563|NCT03028870|DRUG|V120083|Capsules
214630564|NCT03028870|DRUG|Naproxen|Capsules
214630565|NCT03028870|DRUG|Placebo|Capsules to match V120083 and/or naproxen
214630566|NCT00012779|BEHAVIORAL|Health Education Program|
214630567|NCT04455529|OTHER|ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
214630568|NCT01618942|DEVICE|pressure algometer|
214630569|NCT03664999|DIAGNOSTIC_TEST|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
214630570|NCT04896554|BEHAVIORAL|Health literacy scale|"The Turkish version of The European Health Literacy Survey (HLS-EU) Health Literacy Questionnaire scale (ASOY-TR) was used to measure health literacy. This scale consists of 47 questions. Each item has 4 degrees such that 1 = Very difficult, 2 = Difficult, 3 = Easy, 4 = Very easy. Code 5 is used for the expression I don't know. The total score that can be obtained from the scale is between 47-188. For the sake of ease of calculation, the total score is standardized with the following formula to take a value between 0-50.~Formula = Index = (arithmetic mean-1) x \[50/3\] High score means better health literacy."
214630571|NCT01788254|DRUG|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
214630572|NCT01788254|DRUG|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
214630573|NCT01788254|DRUG|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
214630574|NCT01788254|DRUG|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
214630575|NCT01788254|DRUG|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
214630576|NCT03632733|DRUG|Tetracycline|Tetracycline cream
214630577|NCT03632733|DRUG|Clotrimazole|Clotrimazole cream
214630578|NCT03632733|DRUG|Tetracycline and Clotrimazole|Combination cream
214630579|NCT03632733|OTHER|Placebo|Placebo cream without active drug ingredients
214630580|NCT01411436|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
214630581|NCT02175732|BEHAVIORAL|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
214720666|NCT04214041|OTHER|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
214720667|NCT02180490|DRUG|UHAC 62 XX tablet|
214720668|NCT02180490|DRUG|UHAC 62 XX capsule|
214720669|NCT04046276|BEHAVIORAL|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
214720670|NCT04046276|OTHER|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
214720671|NCT04046276|BEHAVIORAL|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
214720672|NCT01339208|OTHER|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
214720673|NCT01040754|OTHER|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
214720674|NCT03758872|DIAGNOSTIC_TEST|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
214720675|NCT03077789|PROCEDURE|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
214720676|NCT00000281|BEHAVIORAL|Amantadine|
214720677|NCT03297944|DRUG|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
214720678|NCT03297944|DRUG|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
214720679|NCT03297944|DRUG|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
214720680|NCT03297944|DRUG|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
214720681|NCT03297944|DRUG|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
214720682|NCT03297944|DRUG|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
214720683|NCT02293590|DRUG|Certolizumab Pegol|
214720684|NCT03049085|DRUG|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
214720685|NCT03049085|DRUG|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
214720686|NCT00357786|DRUG|Replagal agalsidase alfa|
214720687|NCT00357786|DRUG|Replagal|
214720688|NCT00616291|BIOLOGICAL|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
214720689|NCT02703142|PROCEDURE|Patients after esophagectomy|postoperative endoscopic evaluation
214720690|NCT04390789|PROCEDURE|Non surgical Single visit Retreatment|Non-surgical endodontic retreatment will be carried out in single visit.
214720691|NCT04390789|PROCEDURE|Multi visit Retreatment with calcium hydroxide dressing|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
214720692|NCT00127699|PROCEDURE|Alcohol swab of umbilical cord|
214630582|NCT02175732|BEHAVIORAL|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
214630583|NCT03728075|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
214630584|NCT05193110|OTHER|Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis|Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
214630585|NCT02559440|DRUG|mometasone furoate|50μg, 1 puff in each nostril every evening
214630586|NCT02559440|DRUG|Placebo|1 puff in each nostril every evening
214630587|NCT02559440|DRUG|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
214630588|NCT02559440|DRUG|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
214630589|NCT02559440|DRUG|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
214630590|NCT02559440|DRUG|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
214630591|NCT03651284|BEHAVIORAL|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
214720693|NCT05983042|GENETIC|Ibuprofen|Ibuprofen 400mg three times a day for three days
214720694|NCT00002968|BIOLOGICAL|edrecolomab|Given IV
214720695|NCT00002968|OTHER|laboratory biomarker analysis|Correlative studies
214720696|NCT01564602|DEVICE|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
214720697|NCT04016987|BEHAVIORAL|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
214720698|NCT04107428|DRUG|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
214720699|NCT04107428|DRUG|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
214720700|NCT00661570|DEVICE|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
214720701|NCT03419845|DEVICE|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
214630592|NCT03651284|BEHAVIORAL|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
214720702|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"* 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214630593|NCT00579852|PROCEDURE|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
214630594|NCT06402266|DEVICE|tDCS|"The STM task will be combined with respectively two times active tDCS and one sham tDCS. The 3 conditions will be randomised, and both scientific staff and participants will be blinded.~Participants will perform the STM task on a tablet for 45 min. Headsets will deliver the tDCS. Two different placements will be used for the active stimulations: 1) F3 and PZ, and 2) F4 and PZ. The current output range will be 1.6mA and the stimulation will last for 30 min. The sham stimulation will function as a control condition. During the sham stimulation, the current density will be ramped up for 15 sec until the current reaches a density of 1.6mA for 60 sec and then again ramped down for 15 sec.~After the session, participants will fill out a brief questionnaire regarding their experience.~The time interval between sessions will be 1-3 weeks."
214630595|NCT03808727|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
214630596|NCT01251107|DRUG|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
214630597|NCT01251107|DRUG|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
214630598|NCT01251107|DRUG|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
214630599|NCT01251107|DRUG|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
214630600|NCT01251107|DRUG|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
214630601|NCT01251107|DRUG|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
214630602|NCT01251107|DRUG|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
214630603|NCT01251107|DRUG|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
214630604|NCT01251107|DRUG|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
214630605|NCT01251107|DRUG|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
214630606|NCT01251107|DRUG|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
214630607|NCT00137111|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
214630608|NCT00137111|DRUG|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
214630609|NCT00137111|DRUG|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
214630610|NCT00137111|DRUG|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
214630611|NCT00137111|PROCEDURE|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
214630612|NCT00137111|PROCEDURE|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
214630613|NCT01083303|BEHAVIORAL|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
214630614|NCT03115567|DRUG|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
214630615|NCT03362424|BIOLOGICAL|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
214630616|NCT03362424|PROCEDURE|Rotator cuff repair|Rotator cuff repair
214630617|NCT01582425|DRUG|Isavuconazole|oral
214630618|NCT01582425|DRUG|Methadone|oral
214630619|NCT02090322|PROCEDURE|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
214630620|NCT03269045|DRUG|ORL-1B|Oral ORL-1B
214630621|NCT04081350|DRUG|LY3471851|Administered SC
214630622|NCT04081350|DRUG|Placebo|Administered SC
214630623|NCT04577235|OTHER|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
214630624|NCT00232102|DRUG|Tegaserod|
214630625|NCT05065502|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.\[practice\]."
214720703|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"* 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214720704|NCT02562027|BEHAVIORAL|Modified Medical Research Council|"* Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214720705|NCT02562027|BEHAVIORAL|EQ-5D|"* 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214720706|NCT02562027|BEHAVIORAL|Center for Epidemiological Studies Depression Scale|"* 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214720707|NCT02562027|BEHAVIORAL|Medical Outcomes Study Social Support Survey|"* 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
214720708|NCT02134041|OTHER|traumatic brain injury|mild TBI, GCS \>/=13 after traumatic brain injury
214720709|NCT05011331|DEVICE|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
214630626|NCT05065502|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
214630627|NCT04703075|DRUG|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
214630628|NCT04703075|DRUG|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
214630629|NCT05061173|OTHER|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
214720710|NCT04083118|DIAGNOSTIC_TEST|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
214720711|NCT04083118|DIAGNOSTIC_TEST|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
214630630|NCT05061173|OTHER|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
214630631|NCT05061173|OTHER|Combined Exercise Training Group|"Combined Exercise training includes \[Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction\] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
214630632|NCT03325725|DEVICE|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
214630633|NCT02970448|PROCEDURE|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
214630634|NCT02970448|RADIATION|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
214630635|NCT02970448|DRUG|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
214630636|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5421|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
214630637|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5424|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
214630638|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5429|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
214630639|NCT06361875|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
214630640|NCT06361875|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
214630641|NCT06361875|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
214630642|NCT02312635|DRUG|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
214630643|NCT02312635|BEHAVIORAL|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
214630644|NCT05622526|DRUG|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
214630645|NCT05622526|OTHER|Group 2 or Control group|capsules of placebo
214630646|NCT01849471|OTHER|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
214630647|NCT04423497|OTHER|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
214630648|NCT03028571|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
214630649|NCT03028571|OTHER|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
214630650|NCT02054026|BEHAVIORAL|Reducing the Risk|
214630651|NCT02425826|DRUG|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
214630652|NCT02425826|DRUG|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
214630653|NCT02425826|DRUG|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
214630654|NCT04676997|BIOLOGICAL|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
214630655|NCT04676997|DRUG|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
214630656|NCT04676997|DRUG|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
214630657|NCT04676997|DRUG|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
214630658|NCT04554160|DEVICE|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
214630659|NCT04554160|DEVICE|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
214630660|NCT02202629|OTHER|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
214630661|NCT02337400|BEHAVIORAL|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
214630662|NCT02337400|BEHAVIORAL|15 minute counseling interview|
214630663|NCT04289844|OTHER|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
214630664|NCT04289844|OTHER|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
214630665|NCT02446431|DRUG|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
214630666|NCT02446431|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
214630667|NCT02446431|DRUG|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
214630668|NCT02446431|DRUG|Temsirolimus|Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
214630669|NCT04180293|BEHAVIORAL|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot virtual psychoeducation program and its evaluation. Two six-week sessions will be implemented over a virtual care platform (Zoom for healthcare) based out of OSI Clinic in Atlantic Canada - the first in January/February of 2021 and the second in the spring of 2021. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place virtually and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
214630670|NCT04180293|OTHER|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
214630671|NCT02690311|DEVICE|smartphone display|
214630672|NCT05260619|DRUG|lenalidomide|Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
214630673|NCT03380689|DRUG|S-1|\- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
214630674|NCT03380689|DRUG|Irinotecan|\- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
214630675|NCT03380689|DRUG|Bevacizumab|\- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
214630676|NCT02868008|PROCEDURE|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
214630677|NCT00853671|OTHER|Adenosine Stress Dual-source CTP|"Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure."
214630678|NCT01803243|OTHER|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
214630679|NCT01803243|OTHER|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
214630680|NCT01803243|OTHER|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
214630681|NCT02852512|PROCEDURE|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
214630682|NCT04978207|BEHAVIORAL|A Faithful Response to COVID-19|See previous description
214630683|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
214630684|NCT03441178|DEVICE|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
214630685|NCT02328430|DEVICE|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
214630686|NCT04358835|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio enteral ketogenic formula within 48 hours of intubation
214720712|NCT06283225|DEVICE|Pia-App|The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
214720713|NCT01000025|DRUG|PF-00299804|PF-804 45 mg PO, daily
214720714|NCT01000025|DRUG|Placebo|Placebo 45 mg PO, daily
214720715|NCT06197022|DEVICE|Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
214720716|NCT00422669|DEVICE|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
214720717|NCT00422669|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
214720718|NCT05869786|DEVICE|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
214720719|NCT05869786|OTHER|conventional rehabilitation program|conventional rehabilitation program
214720720|NCT05869786|BEHAVIORAL|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
214720721|NCT05681897|PROCEDURE|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
214720722|NCT00810589|DRUG|Levemir|0,4 IE per kg bodyweight
214720723|NCT00810589|DRUG|Humalog NPL Insulin|0,4 IE per kg bodyweight
214720724|NCT04123171|DIAGNOSTIC_TEST|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
214720725|NCT04307173|DRUG|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
214630687|NCT04358835|OTHER|standard of care|standard of care/supportive therapy
214630688|NCT01988610|DRUG|28 days treatment with Mifepristone.|
214630689|NCT02931058|OTHER|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
214630690|NCT02931058|OTHER|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
214720726|NCT04307173|DRUG|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
214720727|NCT01632072|DIETARY_SUPPLEMENT|Nutritional support|Nutritional support and counseling
214720728|NCT03886922|DRUG|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
214720729|NCT03886922|DRUG|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
214720730|NCT04360772|DIAGNOSTIC_TEST|mHLA-DR|"* Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~* At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~* At Month 24 : Collection from medical report of~* any infectious events that would have occured during the follow-up~* course of the disease with corticosteroids~* survival or death at 24 months of follow-up."
214720731|NCT03044080|DRUG|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
214720732|NCT03044080|DRUG|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
214720733|NCT05663476|OTHER|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
214720734|NCT03295591|DIAGNOSTIC_TEST|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
214720735|NCT03736811|DEVICE|Polyglactin 910 or polydioxanone|Vicryl or PDS II
214720736|NCT03736811|DEVICE|Polyester or polypropylene|Ethibond Excel or prolene
214630691|NCT02931058|OTHER|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
214630692|NCT00642915|DRUG|Lantus, Amaryl|
214630693|NCT01665183|DRUG|ADI-PEG 20|
214630694|NCT04875546|BEHAVIORAL|Standard treatment|Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
214630695|NCT04875546|BEHAVIORAL|Integrated Intervention|In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
214630696|NCT04875546|OTHER|Control|The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
214630697|NCT06241040|OTHER|Aerobic Exercises with core Muscle strengthening|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
214630698|NCT06241040|OTHER|Aerobic Exercise without Core Muscle Strengthening|Aerobic Exercise without Core Muscle Strengthening
214630699|NCT01107431|DIETARY_SUPPLEMENT|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
214630700|NCT01107431|DIETARY_SUPPLEMENT|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
214630701|NCT03070847|DRUG|Tranexamic Acid|Dose: 5mg/kg
214630702|NCT03070847|DRUG|Tranexamic Acid|Dose: 10mg/kg
214630703|NCT03070847|DRUG|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
214630704|NCT04756505|DRUG|Bintrafusp Alfa|Given IV
214630705|NCT04756505|BIOLOGICAL|Immunocytokine NHS-IL12|Given SC
214630706|NCT04756505|RADIATION|Radiation Therapy|Undergo radiation therapy
214630707|NCT05817877|OTHER|phone use|There is no intervention.
214630708|NCT05673551|OTHER|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
214630709|NCT01698164|DRUG|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
214630710|NCT01698164|DRUG|Ximingting Tablet|Participants are given phytoestrogen.
214630711|NCT01698164|DRUG|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
214720737|NCT00996593|BIOLOGICAL|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
214720738|NCT02791360|OTHER|Brain MRI|
214720739|NCT02738580|DRUG|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
214720740|NCT02738580|DRUG|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
214720741|NCT01000818|DRUG|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
214720742|NCT01000818|DRUG|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
214720743|NCT01000818|DRUG|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
214720744|NCT04657354|PROCEDURE|Assessment|Early surgical assessment
214720745|NCT02666690|DEVICE|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
214720746|NCT02491827|OTHER|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
214720747|NCT00708747|DRUG|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
214720748|NCT00708747|DRUG|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
214720749|NCT03483831|BEHAVIORAL|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
214720750|NCT04907162|DIAGNOSTIC_TEST|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
214720751|NCT04907162|DIAGNOSTIC_TEST|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
214720752|NCT04907162|DIAGNOSTIC_TEST|Brief Pain Inventory|Validated questionnaire for pain.
214720753|NCT04907162|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
214720754|NCT04907162|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
214630712|NCT02124564|DRUG|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
214630713|NCT01317433|DRUG|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
214630714|NCT01317433|DRUG|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
214630715|NCT04109820|DIETARY_SUPPLEMENT|MitoQ|Oral; 20mg once a day for 14 days
214630716|NCT05367817|OTHER|Neuromuscular exercise therapy|Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
214630717|NCT05367817|OTHER|Training program|Participants perform range of motion exercises for the wrist.
214630718|NCT06975891|DRUG|Systane PRO|Lubricating Eyedrops
214630719|NCT06975891|DRUG|Refresh Optive MEGA-3|Lubricating Eyedrops
214630720|NCT01383577|PROCEDURE|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
214630721|NCT01383577|PROCEDURE|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
214630722|NCT05062863|DEVICE|T3 dental implant system|This clinical study will evaluate patients being treated with the T3 dental implant to confirm its safety and performance (effect of treatment of edentulism). The patients treated will experience a benefit from treatment of edentulism with the T3 dental implant system. The patients will be followed prospectively from the time of exposure (dental implant placement surgery) to outcome (implant survival at 2 years).
214630723|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
214630724|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
214630725|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
214630726|NCT04571216|DRUG|NFL-101 dose 1|Subcutaneous injections
214630727|NCT04571216|DRUG|NFL-101 dose 2|Subcutaneous injections
214630728|NCT04571216|DRUG|Placebo|Subcutaneous injections
214630729|NCT04378816|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
214630730|NCT00507559|DEVICE|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
214630731|NCT03050242|DRUG|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
214630732|NCT05146921|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
214630733|NCT05146921|OTHER|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
214630734|NCT00247026|DRUG|curcumin; coenzyme q10|
214630735|NCT04986397|DEVICE|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
214630736|NCT04986397|OTHER|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
214630737|NCT04132791|OTHER|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
214630738|NCT04132791|OTHER|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
214630739|NCT05863104|DRUG|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
214630740|NCT05914142|DEVICE|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
214630741|NCT05685875|OTHER|diabetes|Diabetes and metabolic syndrome defined using criteria by IDF. Obesity defined as BMI\>=30
214630742|NCT00400881|OTHER|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
214630743|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
214630744|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
214630745|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
214630746|NCT02431351|DRUG|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
214630747|NCT02532894|DEVICE|Electronic cigarette|Inhaling e-cigarette vapor
214630748|NCT00863200|BEHAVIORAL|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
214630749|NCT00863200|BEHAVIORAL|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
214630750|NCT02292030|DRUG|HTEA|usually high thoracic epidural anesthesia
214630751|NCT01222455|DRUG|Fostamatinib|Oral tablets, single dose
214630752|NCT05437120|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
214630753|NCT04375202|DRUG|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
214630754|NCT03319485|DEVICE|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
214630755|NCT03319485|DEVICE|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
214630756|NCT00858858|DRUG|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
214630757|NCT03803462|OTHER|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
214630758|NCT02554097|PROCEDURE|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
214630759|NCT02554097|PROCEDURE|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
214630760|NCT02554097|PROCEDURE|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
214630761|NCT02554097|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
214630762|NCT06329037|DRUG|Vasopressin|Administration of Vasopressin (20 IU) (oral spray)
214630763|NCT06329037|DRUG|Placebo|Administration of Placebo (oral spray)
214630764|NCT03216473|DRUG|Neuronox|Clostridium Botulinum Toxin A 100 U
214630765|NCT03216473|DRUG|Botox|Clostridium Botulinum Toxin A 100 U
214630766|NCT04770051|PROCEDURE|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
214630767|NCT01425008|DRUG|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
214630768|NCT04314856|DRUG|18F-FTC-146|18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
214630769|NCT02097914|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
214630770|NCT05711290|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
214630771|NCT05711290|OTHER|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
214630772|NCT05536765|PROCEDURE|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
214630773|NCT00865072|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
214630774|NCT00865072|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
214630775|NCT05580133|PROCEDURE|anterior cruciate ligament reconstruction|Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
214630776|NCT05026398|DRUG|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
214630777|NCT05026398|OTHER|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
214630778|NCT03544827|DRUG|Atropine|Atropine 0.01% then atropine 0.1%
214630779|NCT03544827|DRUG|Atropine|Atropine 0.1% then atropine 0.01%
214630780|NCT02295527|OTHER|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
214630781|NCT02295527|OTHER|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
214630782|NCT01430039|PROCEDURE|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
214630783|NCT01430039|PROCEDURE|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
214630784|NCT04091997|DIAGNOSTIC_TEST|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
214630785|NCT03156088|DEVICE|"Sacral Neuromodulator InterStim"|
214630786|NCT00105651|BEHAVIORAL|Combined nursing invention|
214630787|NCT06682468|BEHAVIORAL|Population level patient portal based substance involvement screening|Participants 18 years or older, with an active patient portal account, who have attended an HIV care clinic visit in the HIV clinic in the last two years and have not completed the validated National Institute for Drug Abuse (NIDA) Quick Screen V1.0 in the previous year will be eligible for intervention randomization. Those randomized into the intervention group will receive the validated NIDA Quick Screen V1.0 over their patient portal account. Participants randomized to this group can complete the screener over the patient portal without a scheduled appointment with their HIV clinician.
214630788|NCT06682468|BEHAVIORAL|Usual Care Substance Use Involvement Screening|Participants randomized to the usual care group will receive the validated NIDA Quick Screen V1.0 during routine in-clinic visits if they attend their scheduled visit. The medical assistant will ask participants to complete the NIDA Quick Screen V1.0. Participants who endorse the use of illegal drugs or prescription drugs for non-medical reasons, tobacco use, or heavy drinking will be referred to SUD treatment.
214630789|NCT06654414|BEHAVIORAL|PRIDE QUIT|"This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will likely receive 6-10 weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session."
214630790|NCT06654414|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|Brief counseling, the option of nicotine replacement therapy, and referral to the Quit Line.
214630791|NCT00562588|DRUG|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
214630792|NCT00562588|DRUG|ASA 100 mg qd|
214630793|NCT06841913|BIOLOGICAL|LAIV nasal vaccine is chosen as a model viral infection|Inoculation with LAIV
214630794|NCT06841913|OTHER|Wood smoke|Wood smoke exposure concentrations at 500 ug/m3 for two hours.
214630795|NCT06841913|BIOLOGICAL|Placebo for LAIV nasal vaccine is chosen as a model viral infection|Placebo for LAIV inoculation. Nasal administration of normal saline.
214630796|NCT06841913|OTHER|Placebo for Wood Smoke (clean Air Exposure)|Clean Air Exposure for 2 hours
214630797|NCT06594354|OTHER|ICE|"The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent. During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later. The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive chemotherapy, and to record their applications on the "
214630798|NCT06568692|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
214630799|NCT06568692|DRUG|Capecitabine|Commercially available capecitabine is a commonly used oral fluoropyrimidine.
214630800|NCT00612638|DRUG|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
214630801|NCT07016022|OTHER|CardioPulmonary Variability Assessment|The Preoperative CardioPulmonary Variability Assessment (CPVA) will assess baseline HRV \& RRV and the ability to tolerate mild physiologic stress. The assessment will involve a a Philips MP50 monitor that will collect continuous ECG (Lead II) and CO2-based respiratory waveform data with intermittent blood pressure (BP) measurements over a test of less than 60 minutes. We will measure the response to mild physiological stress which reflects adaptability, autonomic function and functional mobility by having the participant perform certain tasks such as sitting, standing, deep breathing, valsalva manoeuvres, and marching.
214630802|NCT07030101|DRUG|TCA108|TCA108
214630803|NCT07030101|DRUG|Bramicar HCT|Bramicar HCT
214630804|NCT07028333|BEHAVIORAL|Motor-Motor Dual Task Exercise Group|Participants in this group will perform motor tasks (such as ball handling, throwing, holding) accompanied by physiotherapist. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
214630805|NCT07028333|BEHAVIORAL|Motor-Cognitive Dual Task Exercise Group|This group will also do walking and balance exercises with the physiotherapist, while simultaneously doing cognitive tasks (rhythmic counting, saying color names, finding words, etc.). The exercises will last approximately 40 minutes, 2 days a week, for 6 weeks.
214630806|NCT07028333|BEHAVIORAL|Control Group|Standard walking and balance exercises will be given to the control group at home and followed by parents. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
214720755|NCT04907162|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
214630807|NCT07028606|PROCEDURE|Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft.~Osteotomy for implant will be carried out with advanced kit of roott\_system Switzerland brand, sandwich osteotomy technique will be carried out with three full thickness cuts using the tungsten carbide disc were performed in the form of two vertical cuts away from the neighboring teeth by 3 mm and one horizontal bony cut on the labial surface of alveolar ridge. Bone splitting chisels were used in sequential width (2 mm, 3 mm) and lightweight mallet to complete splitting of the bony segment, the surgical sites will be irrigated with sterile saline. Surgical flaps will be sutured to the pre-surgical level."
214630808|NCT07028606|BIOLOGICAL|Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft with and with RGD.~Injectable RGD-bioconjugate Mussel Adhesive Proteins (RGD-MAPs) composite hydroxypropyl methylcellulose (HPMC) hydrogels . Previously we developed a novel type of injectable self-supported hydrogel (2 mg/ml of RGD-MAPs/HPMC) based porcine nano hydroxyapatite (MPH) for dental graft, which could good handling property, biodegradation or biocompatibility with the hydrogel disassembly and provided efficient cell adhesion activity and no inflammatory responses. Surgical flaps will be sutured to the pre-surgical level with 4-0 polyproline non resorbable suture utilizing a single interrupted suturing technique."
214720756|NCT04907162|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
214630809|NCT06877845|OTHER|Activity Tracker & Postural Corrector|"Use of Activity Tracker \& Postural Corrector along with following baseline treatment.~* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
214630810|NCT06877845|OTHER|Conventional Therapy|"* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
214630811|NCT06203561|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
214630812|NCT06203561|BEHAVIORAL|comprehensive rehabilitation therapy|including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.
214630813|NCT06203561|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214630814|NCT06203561|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214630815|NCT00481650|DRUG|Leios/Alesse|
214630816|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-V|Recombinant vaccinia virus vector antigen direct immunotherapy of the genus Orthopoxvirus. Administered by subcutaneous injection.
214630817|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-F|Recombinant fowlpox virus vector Antigen direct immunotherapy of the genus Avipoxvirus. Administered by subcutaneous injection.
214630818|NCT03315871|DRUG|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines immunoglobulin G1 (IgG1) anti-programmed death-ligand 1 (PD-L1) and Transforming growth factor, beta receptor II (TGFbetaRII) as a monoclonal antibody. Administered via intravenous (IV) infusion over 1 hour.
214630819|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: CV301|Recombinant vaccinia virus Antigen direct immunotherapy of the genus Avipoxvirus. Administered subcutaneously.
214630820|NCT03315871|DIAGNOSTIC_TEST|CT scan of chest|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
214720757|NCT04907162|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
214630821|NCT03315871|DIAGNOSTIC_TEST|CT scan of abdomen/pelvis|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
214630822|NCT03315871|DIAGNOSTIC_TEST|MRI|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
214630823|NCT03315871|DIAGNOSTIC_TEST|PSMA|Biochemical recurrence group only. Screening, prior to Antigen direct immunotherapy therapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
214630824|NCT03315871|DIAGNOSTIC_TEST|Bone scan|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
214630825|NCT06673277|DEVICE|Prolonged (2-hour) cryocompression therapy|The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.
214630826|NCT06067555|DEVICE|MicronJet|MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
214630827|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intradermal injections of 0.3mL
214630828|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intramuscular injection of 0.3mL
214630829|NCT06067555|OTHER|Bacteriostatic Saline|Intradermal injection of 0.3mL (control)
214630830|NCT05952557|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
214630831|NCT05952557|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered orally
214630832|NCT05952557|DRUG|Anastrozole|Anastrozole. Comparator. Administered orally
214630833|NCT05952557|DRUG|Letrozole|Letrozole. Comparator. Administered orally
214630834|NCT05952557|DRUG|Exemestane|Exemestane. Comparator. Administered orally
214630835|NCT05952557|DRUG|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
214630836|NCT06781814|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, specification: 3g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
214630837|NCT02907398|DEVICE|Inspire therapy|
214630838|NCT02907398|OTHER|No intervention|
214630839|NCT04305795|BIOLOGICAL|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
214630840|NCT04305795|BIOLOGICAL|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
214630841|NCT04305795|COMBINATION_PRODUCT|ASP-1929 PIT|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
214630842|NCT06298474|BEHAVIORAL|The BRAIN App|The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
214630843|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
214630844|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
214630845|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
214630846|NCT00085761|DRUG|Capsaicin Dermal Patch|
214630847|NCT03317938|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
214630848|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
214630849|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
214630850|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
214630851|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
214630852|NCT05388773|DRUG|Cisplatin|Given IV.
214630853|NCT05388773|DRUG|Carboplatin|Given IV
214630854|NCT05692037|COMBINATION_PRODUCT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
214720758|NCT04907162|DIAGNOSTIC_TEST|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
214630855|NCT06923761|DRUG|Module 1 (GRWD5769 on its own as monotherapy)|"Module 1 will initially be conducted in 4 study parts:~Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review committee)~Part B: (Optional) Monotherapy dose expansion part (to look at the effect of GRWD5769 on the body, and of the body on GRWD5769, at particular dose levels to include evaluation of biopsies of tumour tissue)~Part C: (Optional) Intra-patient dose escalation (where a patient may receive three different GRWD5769 doses so that blood levels at each dose can be measured in an individual)~Part D: Monotherapy dose expansion group(s) (where a dose of GRWD5769 may be chosen to be evaluated in specific types of cancer)"
214630856|NCT06923761|DRUG|Module 2 (GRWD5769 in combination with cemiplimab, administered IV)|"Module 2 will initially be conducted as 3 study parts, similar to those above, but looking at GRWD5769 when given in combination with cemiplimab:~Part A: Combination therapy dose escalation (like Module 1 Part A)~Part B: (Optional) Combination therapy dose expansion part (like Module 1 Part B)~Part C: Combination therapy dose expansion group(s) (where a dose of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer)"
214630857|NCT06931600|PROCEDURE|Sham adjustment|Two manual high velocity, low amplitude (HVLA) simulated/sham chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
214630858|NCT06931600|PROCEDURE|Chiropractic adjustment|Two manual high velocity, low amplitude (HVLA) genuine/real chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
214630859|NCT06945653|OTHER|Survey using a questionnaire.|The survey questions are aimed to assess the current state of diversity training in anesthesiology education. This survey serves as a needs assessment and will help gather information on the current state of DEI education within the specialty.
214630860|NCT06945900|OTHER|Telehealth|Paramedics will utilize Telehealth for STEMI patients during transport to determine appropriate care steps.
214630861|NCT00001498|DRUG|methotrexate|
214630862|NCT00001498|DRUG|leucovorin|
214630863|NCT00001498|DRUG|5-fluorouracil|
214630864|NCT00001498|DRUG|cyclophosphamide|
214630865|NCT00001498|PROCEDURE|peripheral blood progenitor cell|
214630866|NCT00001498|DRUG|paclitaxel|
214630867|NCT00001498|DRUG|doxorubicin|
214630868|NCT06213155|DEVICE|Cryoneurolysis|Cryoneurolysis
214630869|NCT06213155|DEVICE|Stimulation|Stimulation
214630870|NCT05032157|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
214630871|NCT05032157|DRUG|Placebo|Placebo
214630872|NCT05032157|DRUG|LOU064 (open-label)|LOU064 (open-label) active treatment
214630873|NCT06263569|PROCEDURE|Total hip arthroplasty|Unilateral primary total hip arthroplasty procedure.
214630874|NCT00150592|DRUG|SPD503 (Guanfacine HCl)|
214630875|NCT00150592|DRUG|Placebo|
214630876|NCT03047980|DRUG|Sirolimus|Low dose oral sirolimus
214630877|NCT02288507|DRUG|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
214630878|NCT02288507|RADIATION|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
214630879|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
214630880|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
214630881|NCT01281462|DRUG|Doripenem|500 mg doripenem IV q8h;
214630882|NCT01281462|DRUG|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
214630883|NCT05686174|DIETARY_SUPPLEMENT|MBS217|Soybean Fermented Extract (MBS217)
214630884|NCT05686174|DIETARY_SUPPLEMENT|Placebo|Without active ingredient
214630885|NCT02227693|DRUG|avatrombopag|E5501 (avatrombopag) 20-mg tablets
214630886|NCT02227693|DRUG|Placebo|Placebo matching 20-mg tablets
214630887|NCT00874120|DRUG|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
214720759|NCT04907162|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
214630888|NCT00874120|DRUG|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
214630889|NCT03504878|PROCEDURE|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
214630890|NCT03504878|PROCEDURE|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
214630891|NCT01096563|DRUG|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
214630892|NCT01096563|DRUG|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
214630893|NCT05299437|DRUG|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
214630894|NCT01823679|DRUG|Capecitabine|Given orally
214630895|NCT03706287|DRUG|anlotinib 8mg + AP/PC|anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
214630896|NCT03706287|DRUG|anlotinib 10mg + AP/PC|anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
214630897|NCT03706287|DRUG|anlotinib 12mg + AP/PC|anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
214630898|NCT03706287|DRUG|anlotinib + AP/PC|anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
214630899|NCT00225511|DRUG|Effexor XR|
214630900|NCT00225511|DRUG|Milnacipran|
214630901|NCT05185609|OTHER|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
214630902|NCT05185609|OTHER|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
214630903|NCT05230186|PROCEDURE|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
214630904|NCT01072370|BIOLOGICAL|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
214630905|NCT01072370|BIOLOGICAL|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
214630906|NCT02164981|DRUG|sodium nitroprusside|intravenous
214630907|NCT02164981|OTHER|Placebo|Placebo
214630908|NCT04710095|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
214720760|NCT04907162|DIAGNOSTIC_TEST|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
214720761|NCT00741260|DRUG|Neratinib|Neratinib orally once daily continually
214630909|NCT04710095|BEHAVIORAL|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
214630910|NCT00809770|BEHAVIORAL|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
214630911|NCT00809770|BEHAVIORAL|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
214720762|NCT00741260|DRUG|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
214720763|NCT04115527|PROCEDURE|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
214630912|NCT01465906|DRUG|tulobuterol|patch, 2mg, qN, 3 months
214630913|NCT01465906|DRUG|Tiotropium Bromide|18ug, inhale, qD, 3 months
214630914|NCT01465906|DRUG|tiotropium bromide|18ug, inhale, qD, 3 months
214630915|NCT04886687|PROCEDURE|mechanical thrombectomy|mechanical thrombectomy
214630916|NCT00651092|PROCEDURE|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
214630917|NCT00651092|PROCEDURE|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
214630918|NCT02469766|PROCEDURE|SWL|Patients in this arm will undergo SWL
214630919|NCT02469766|PROCEDURE|Semirigid URS|Patients in this arm will undergo semirigid URS
214630920|NCT02469766|PROCEDURE|Flexible URS|Patients in this arm will undergo Flexible URS
214630921|NCT00006388|DRUG|tamoxifen citrate|
214630922|NCT00006388|RADIATION|radiation therapy|
214720764|NCT04115527|PROCEDURE|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
214720765|NCT05533073|DRUG|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
214720766|NCT05533073|DRUG|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
214630923|NCT01039337|OTHER|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
214630924|NCT01039337|OTHER|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
214630925|NCT01039337|OTHER|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
214630926|NCT02404103|DRUG|Flunisolide HFA|
214630927|NCT05328037|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for dosage of vitamin C
214630928|NCT04275622|BEHAVIORAL|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
214630929|NCT01277094|DRUG|Placebo|Oral daily doses for 12 weeks
214630930|NCT01277094|DRUG|RO5093151|Oral daily doses for 12 weeks
214630931|NCT00650910|DRUG|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
214630932|NCT00650910|DRUG|Digoxin|0.5mg on Days 1 and 9
214630933|NCT00328627|DRUG|Alogliptin|Alogliptin tablets.
214630934|NCT00328627|DRUG|Alogliptin placebo|Alogliptin placebo-matching tablets.
214630935|NCT00328627|DRUG|Pioglitazone|Pioglitazone tablets.
214720767|NCT05533073|DRUG|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
214630936|NCT00328627|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
214630937|NCT05903287|DEVICE|Chang Gung Pleural Effusion Detection Software|"The Chang Gung Pleural Effusion Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pleural effusion. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pleural effusion.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
214630938|NCT02652897|PROCEDURE|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
214630939|NCT02652897|PROCEDURE|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
214630940|NCT03667066|DRUG|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
214630941|NCT03007173|PROCEDURE|umbilicus preserving surgery|excision of umbilical complex
214630942|NCT05771610|BEHAVIORAL|Activity pattern in CVD|Only individuals who have had a cardiac event within the past twelve months upon recruitment will be included in this study.
214630943|NCT02258360|OTHER|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
214630944|NCT05443841|OTHER|pleural lavage|pleural lavages before tumor resection and after tumor resecion, respectively
214630945|NCT01451710|DRUG|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
214630946|NCT01069822|DRUG|AZD6765|IV solution
214630947|NCT01069822|DRUG|midazolam|
214630948|NCT01178775|BEHAVIORAL|walking|use a pedometer for records steps.
214630949|NCT00522431|DRUG|Testosterone|2% gel
214630950|NCT02249650|DRUG|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
214630951|NCT03483480|PROCEDURE|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
214720768|NCT03175874|PROCEDURE|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
214630952|NCT03483480|PROCEDURE|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
214630953|NCT01137773|DRUG|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
214630954|NCT01137773|DRUG|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
214630955|NCT03891589|BEHAVIORAL|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
214630956|NCT03891589|DIETARY_SUPPLEMENT|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
214630957|NCT03548051|PROCEDURE|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
214630958|NCT03548051|DRUG|Saline|250 ml of saline delivered by retention enema
214720769|NCT02995473|DRUG|NP000888|270 µg/g topical (BID) for 24 weeks
214720770|NCT02995473|DRUG|Vehicle|Topical (BID) for 24 weeks
214720771|NCT03039933|BEHAVIORAL|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
214720772|NCT03039933|OTHER|Treatment As Usual|Treatment As Usual
214720773|NCT02950012|DIETARY_SUPPLEMENT|OPTI-BIOME™ Bacillus subtilis MB40|
214720774|NCT02950012|OTHER|Placebo|
214720775|NCT03026049|DEVICE|deep venous stenting|Deep venous stent
214720776|NCT02675179|DEVICE|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
214720777|NCT02675179|DEVICE|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
214720778|NCT02810951|GENETIC|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
214720779|NCT01250756|BIOLOGICAL|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
214720780|NCT01250756|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
214720781|NCT01250756|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
214720782|NCT05576610|PROCEDURE|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
214722206|NCT02468804|DEVICE|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
214720783|NCT05576610|PROCEDURE|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
214720784|NCT04146337|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
214720785|NCT02205398|DRUG|INC280|
214720786|NCT02205398|DRUG|cetuximab|
214720787|NCT01928082|DRUG|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
214720788|NCT00006063|DRUG|pancrelipase with bicarbonate|
214720789|NCT01664819|DIETARY_SUPPLEMENT|Antioxidant|
214720790|NCT01664819|DIETARY_SUPPLEMENT|Placebo|
214720791|NCT05560178|OTHER|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
214720792|NCT03890393|DEVICE|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
214722207|NCT02468804|DEVICE|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
214630959|NCT05581914|OTHER|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
214630960|NCT05581914|OTHER|Care as Usual|The care as usual the adolescents receives
214720793|NCT02533193|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem"
214630961|NCT03927105|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
214630962|NCT03927105|DRUG|cabiralizumab|Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
214630963|NCT03402607|PROCEDURE|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
214720794|NCT02533193|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed"
214630964|NCT03402607|RADIATION|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
214720795|NCT00248378|DRUG|Smoked Cannabis|
214720796|NCT00460837|DRUG|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
214720797|NCT00106288|DRUG|Micafungin|IV
214720798|NCT00106288|DRUG|Liposomal Amphotericin B|IV
214720799|NCT04893928|OTHER|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
214720800|NCT04893928|OTHER|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
214720801|NCT04893928|OTHER|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~* Frequency of use of ten different ICTs for personal purposes;~* Frequency of use of ten different ICTs for IBD-related purposes;~* A free question about others ICTs that the patient uses for IBD-related purposes;~* Eight specific IBD-related purposes ICTs are used to;~* Assessment of ICTs for eight IBD-related purposes;~* Eight Features an IBD-related App must comprehend."
214720802|NCT04893928|OTHER|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
214720803|NCT00583661|DEVICE|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
214720804|NCT05226897|DRUG|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
214630965|NCT02436850|PROCEDURE|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
214720805|NCT05226897|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
214630966|NCT04623476|PROCEDURE|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
214630967|NCT03470493|DIAGNOSTIC_TEST|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
214630968|NCT00820898|DRUG|Gemcitabine Hydrochloride|Given IV
214630969|NCT01000662|RADIATION|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
214720806|NCT05226897|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
214720807|NCT05226897|DRUG|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
214720808|NCT01679561|DRUG|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
214720809|NCT03129633|OTHER|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
214720810|NCT04077411|OTHER|Observational|This is an observational study with no interventions.
214720811|NCT04208646|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
214720812|NCT04208646|BIOLOGICAL|No mesenchymal progenitor cells|No mesenchymal progenitor cells for intra- articular use
214720813|NCT00339118|DRUG|doxorubicin, cytoxan|
214720814|NCT04087603|BEHAVIORAL|Weekend Morning Bright Light & Early Bedtime|
214720815|NCT02473835|OTHER|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
214720816|NCT02473835|OTHER|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
214720817|NCT02473835|OTHER|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
214720818|NCT02016729|DRUG|AMG 232|Given an an oral tablet in escalating doses.
214720819|NCT02016729|DRUG|Trametinib|Trametinib is an oral tablet given in a fixed dose.
214720820|NCT05610722|DEVICE|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
214720821|NCT00295737|PROCEDURE|bronchoscopy, allergen/endotoxin instillation|
214720822|NCT05584904|OTHER|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
214720823|NCT00184158|PROCEDURE|decompression|Conservative, simple decompression and nerve transfer
214720824|NCT03867110|DRUG|Placebo|
214720825|NCT03867110|DRUG|Ezetimibe 10 mg|
214720826|NCT03867110|DRUG|Atorvastatin 10 mg|
214720827|NCT03867110|DRUG|Atorvastatin 20 mg|
214720828|NCT03867110|DRUG|Atorvastatin 40 mg|
214720829|NCT03867110|DRUG|Atorvastatin 80 mg|
214720830|NCT04480541|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
214720831|NCT04480541|OTHER|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
214630970|NCT01000662|RADIATION|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
214630971|NCT04222595|OTHER|Fluenz Tetra nasal spray suspension|Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
214630972|NCT01858181|BIOLOGICAL|ocaratuzumab|
214630973|NCT00609479|PROCEDURE|Osteosynthesis|"1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
214630974|NCT00647556|DRUG|adapalene gel, 0.3%|applied topically once daily in the evening
214630975|NCT00647556|DRUG|tretinoin 0.05% emollient cream|applied topically once daily in the evening
214720832|NCT04480541|OTHER|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
214630976|NCT01120665|DRUG|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
214630977|NCT01120665|OTHER|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
214630978|NCT01120665|DRUG|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
214630979|NCT01120665|OTHER|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
214630980|NCT04170517|DIAGNOSTIC_TEST|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
214630981|NCT01652287|DRUG|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
214630982|NCT01652287|OTHER|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
214722208|NCT03932890|DEVICE|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
214630983|NCT00763139|DRUG|Pioglitazone|45 mg by mouth once a day for 8 weeks
214630984|NCT00763139|DRUG|Placebo|By mouth once a day for 8 weeks
214630985|NCT05855512|OTHER|Nursing Educational Intervention|Nursing Educational Intervention
214630986|NCT01334034|DRUG|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
214630987|NCT01334034|DRUG|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
214630988|NCT01334034|DRUG|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
214630989|NCT05744999|PROCEDURE|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
214630990|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
214630991|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
214630992|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD."
214630993|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD."
214630994|NCT06081907|DRUG|IBI363|The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
214630995|NCT00179309|DRUG|Docetaxel|35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
214630996|NCT00179309|BIOLOGICAL|PANVAC-V|2 x 10\^8 PFU
214630997|NCT00179309|BIOLOGICAL|PANVAC-F|1 x 10\^9 PFU
214630998|NCT00179309|BIOLOGICAL|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
214630999|NCT04947488|DIETARY_SUPPLEMENT|Bioarginina C|Dietary supplement vials
214631000|NCT04369365|DRUG|Azithromycin 500 milligram (mg) oral Tablet|weekly oral use
214631001|NCT04369365|DRUG|Placebo|weekly oral use
214631002|NCT01626898|BEHAVIORAL|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
214631003|NCT01626898|BEHAVIORAL|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
214631004|NCT05355142|BEHAVIORAL|PM+|"1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
214631005|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal powder
214631006|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intramuscular injection
214631007|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal spray
214631008|NCT02363686|PROCEDURE|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
214631009|NCT02363686|PROCEDURE|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
214631010|NCT00085371|DRUG|triapine|Given IV
214631011|NCT06477276|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
214631012|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
214631013|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
214631014|NCT06193486|BIOLOGICAL|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
214631015|NCT06193486|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
214631016|NCT06193486|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
214631017|NCT03621280|DRUG|Levoketoconazole|Levoketoconazole up to 1200 mg daily
214631018|NCT04621370|DRUG|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
214631019|NCT04621370|DRUG|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
214631020|NCT04621370|RADIATION|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
214631021|NCT04621370|RADIATION|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
214631022|NCT04621370|DRUG|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
214631023|NCT03757533|BEHAVIORAL|Health Coaching|10 phone calls with a trained health coach
214631024|NCT03757533|OTHER|Surveys|Surveys to assess Behavioural and Psychosocial measures
214631025|NCT01709149|DRUG|CK-2017357|CK-2017357 125 mg tablets twice daily
214631026|NCT01709149|OTHER|Placebo tablets|Tablets
214631027|NCT01709149|DRUG|Riluzole|Tablets
214631028|NCT03382795|DRUG|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
214631029|NCT03910829|BEHAVIORAL|Action Observation|Action observation training
214631030|NCT03910829|BEHAVIORAL|Motor Imagery|Motor imagery protocol
214631031|NCT03910829|BEHAVIORAL|Placebo Action Observation|Placebo Action Observation
214631032|NCT06179758|DEVICE|icompanion app|use of the icompanion app as a digital telemonitoring solution
214631033|NCT04622007|DRUG|Tomivosertib|Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
214631034|NCT04622007|BIOLOGICAL|Pembrolizumab|Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
214631035|NCT04622007|DRUG|Pemetrexed|Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
214631036|NCT02616289|OTHER|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
214631037|NCT04775329|DRUG|Rifaximin|Rifaximin 1000mg OM
214631038|NCT03279614|DRUG|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
214631039|NCT01714427|DRUG|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
214631040|NCT01714427|DRUG|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
214720833|NCT03481387|DEVICE|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
214720834|NCT05706961|OTHER|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
214720835|NCT05706961|OTHER|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
214720836|NCT02620709|BEHAVIORAL|Hula intervention|Hula and heart health education
214722209|NCT03932890|DEVICE|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
214631041|NCT03335332|BEHAVIORAL|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
214631042|NCT03335332|BEHAVIORAL|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
214631043|NCT02192827|DRUG|Dexamethasone Sodium Phosphate Injection|
214631044|NCT02277509|BEHAVIORAL|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
214631045|NCT02277509|BEHAVIORAL|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
214631046|NCT00006121|DRUG|oxaliplatin|
214631047|NCT00662103|BEHAVIORAL|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
214631048|NCT00662103|OTHER|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health \& Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
214631049|NCT00662103|OTHER|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
214631050|NCT00662103|OTHER|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
214631051|NCT00662103|PROCEDURE|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
214631052|NCT00662103|PROCEDURE|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
214631053|NCT00662103|PROCEDURE|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
214631054|NCT00662103|PROCEDURE|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
214631055|NCT05667714|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
214631056|NCT05667714|DRUG|Placebo|Placebo was provided by Sinovac Life Sciences Co. , Ltd.
214631057|NCT05797324|OTHER|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
214631058|NCT05797324|OTHER|Sham|Sham protocol (white light \<100 lux equivalent).
214631059|NCT05785312|DEVICE|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
214722210|NCT00564603|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
214631060|NCT05785312|OTHER|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
214722211|NCT00564603|OTHER|0.9% Saline|Saline, in same volume of 2mL
214631061|NCT02764827|BIOLOGICAL|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
214631062|NCT00620412|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.
214631063|NCT00620412|DIETARY_SUPPLEMENT|placebo control|2 capsules by mouth twice a day for 28 days
214631064|NCT00620412|BIOLOGICAL|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
214631065|NCT00881400|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
214631066|NCT00881400|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
214631067|NCT00940407|DEVICE|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
214631068|NCT05006469|DRUG|Bendamustine|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
214631069|NCT04025827|OTHER|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
214631070|NCT00222183|DRUG|Elidel (pimecrolimus)|
214631071|NCT03668483|OTHER|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
214631072|NCT02469285|DIETARY_SUPPLEMENT|Modified pork|Pork with modified fatty acid composition
214631073|NCT02469285|DIETARY_SUPPLEMENT|Pork|Pork with normal fat composition
214631074|NCT02469285|DIETARY_SUPPLEMENT|Pork and berries|Pork with normal fat composition and Finnish berries
214631075|NCT01968135|DRUG|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
214631076|NCT01968135|DRUG|Placebo Sugar Pill|Placebo Sugar Pill
214631077|NCT00793650|DRUG|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
214631078|NCT00793650|DRUG|Melphalan|"All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2."
214631079|NCT00793650|PROCEDURE|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
214631080|NCT04993365|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
214631081|NCT04993365|BIOLOGICAL|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
214631082|NCT06475144|OTHER|online escape room teaching|here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.
214631083|NCT06475144|OTHER|online video-based teaching|"The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay."
214631084|NCT04612010|DEVICE|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
214631085|NCT00723970|DRUG|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
214631086|NCT02128230|DEVICE|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
214631087|NCT02128230|DRUG|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, \& 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
214631088|NCT02128230|DRUG|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
214720837|NCT04751968|OTHER|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
214720838|NCT04751968|BEHAVIORAL|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
214720839|NCT00907972|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3
214720840|NCT00907972|OTHER|Placebo|Placebo
214720841|NCT01037972|BEHAVIORAL|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
214720842|NCT01037972|BEHAVIORAL|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
214720843|NCT05163067|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
214631089|NCT02128230|DRUG|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
214631090|NCT02128230|DRUG|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
214631091|NCT02128230|DRUG|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
214720844|NCT02657187|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
214720845|NCT02657187|DRUG|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
214720846|NCT01324687|OTHER|Telemedicine care|Availability of telemedicine
214720847|NCT04969432|OTHER|Client-centered|Rehabilitation
214720848|NCT03402269|OTHER|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
214720849|NCT02600494|DRUG|ITI-007 (Lumateperone)|
214720850|NCT02600494|DRUG|Placebo|
214631092|NCT02128230|DRUG|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
214631093|NCT03887897|PROCEDURE|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
214631094|NCT06339879|OTHER|High Whole Grain, Low Sugar|6 servings of whole grain and \<13% energy from added sugars.
214631095|NCT06339879|OTHER|Low Whole Grain, Low Sugar|3 servings of whole grain and \<13% energy from added sugars.
214631096|NCT06339879|OTHER|High Whole Grain, High Sugar|6 servings of whole grain and \>13% energy from added sugars.
214631097|NCT06339879|OTHER|Low Whole Grain, High Sugar|3 servings of whole grain and \>13% energy from added sugars.
214631098|NCT05913414|DRUG|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
214631099|NCT05913414|DRUG|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
214631100|NCT05913414|RADIATION|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
214631101|NCT06023979|OTHER|Full weight bearing|Full weight bearing monitored with a bio-feedback insole
214631102|NCT06023979|OTHER|Partial weight bearing|Partial weight bearing monitored with a bio-feedback insole
214631103|NCT01976598|OTHER|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
214631104|NCT04864665|DIETARY_SUPPLEMENT|a formula with prebiotics and milk fat|Provided in a formula added with prebiotics and milk fat for 1 month
214631105|NCT05337332|DRUG|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
214631106|NCT02326558|PROCEDURE|laparoscopic microwave ablation-assisted enucleation|
214631107|NCT02326558|PROCEDURE|conventional laparoscopic partial nephrectomy|
214631108|NCT05477290|PROCEDURE|Trigger Finger Release through Transverse Incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
214720851|NCT03509844|BEHAVIORAL|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
214720852|NCT03383627|DEVICE|Continuous Glucose Monitoring|"* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
214720853|NCT01195194|DRUG|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
214720854|NCT03032289|BEHAVIORAL|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
214631109|NCT05477290|PROCEDURE|Trigger Finger Release through Oblique Incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
214631110|NCT05477290|PROCEDURE|Trigger Finger Release through Vertical Incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
214720855|NCT00351091|DRUG|RISEDRONATE|
214631111|NCT00381771|BEHAVIORAL|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
214631112|NCT04381910|DRUG|LY01610( Irinotecan hydrochloride liposome injection )|LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
214631113|NCT00225472|DEVICE|Modified Viaspan|
214720856|NCT04853589|DEVICE|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
214631114|NCT03961087|DRUG|Coenzyme Q10|Coenzyme Q10 will be given twice
214631115|NCT03961087|DRUG|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
214631116|NCT02041377|DEVICE|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
214631117|NCT00864955|RADIATION|UVA and UVB irradiation|"* 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
214631118|NCT00000559|DRUG|estrogen replacement therapy|
214631119|NCT00000559|DRUG|hormone replacement therapy|
214631120|NCT00000559|DRUG|estradiol|
214631121|NCT00000559|DRUG|medroxyprogesterone|
214631122|NCT00000896|DRUG|Indinavir sulfate|
214631123|NCT00000896|DRUG|Lamivudine/Zidovudine|
214631124|NCT00000896|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
214631125|NCT00000896|DRUG|Interleukin-12|
214631126|NCT00000896|DRUG|Nevirapine|
214631127|NCT00000896|DRUG|Stavudine|
214631128|NCT00000896|DRUG|Sargramostim|
214631129|NCT05458414|DEVICE|Intra-operative Navigation System|In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
214631130|NCT00006366|DRUG|fluorouracil|
214631131|NCT00006366|DRUG|irinotecan hydrochloride|
214631132|NCT00006366|PROCEDURE|conventional surgery|
214631133|NCT00006366|RADIATION|radiation therapy|
214631134|NCT03246737|OTHER|monitoring|
214631135|NCT02973737|DRUG|pyrotinib|400 mg once daily
214631136|NCT02973737|DRUG|placebo|400 mg once daily
214631137|NCT02973737|DRUG|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
214631138|NCT05930262|DEVICE|TCM acupuncture therapy|TCM acupuncture therapy: Zusanli, Quchi, Hegu, Taichong, Feishu and Fenglong were selected as the main acupoints, and the auxiliary acupoints were selected according to the symptoms, including Fengchi, Dazhui, Lieque, Tiantu, Shenshu, Zhongfu, etc.
214631139|NCT05930262|DRUG|Conventional drug therapy|Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
214631140|NCT05930262|BEHAVIORAL|Rehabilitation therapy|Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.
214720857|NCT04853589|DEVICE|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
214720858|NCT03525626|BEHAVIORAL|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
214720859|NCT02673723|DRUG|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
214720860|NCT02673723|DRUG|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
214720861|NCT03972826|OTHER|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
214720862|NCT05793957|OTHER|Questionnaire Administration|Ancillary studies
214720863|NCT05793957|BEHAVIORAL|Telephone-Based Intervention|Use smartphone
214720864|NCT05793957|OTHER|Virtual Technology Intervention|Use VR headset
214720865|NCT02532426|PROCEDURE|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
214720866|NCT04003181|DRUG|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
214720867|NCT04003181|DRUG|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
214720868|NCT00346138|PROCEDURE|Corneal transplantation|
214720869|NCT01433120|DIETARY_SUPPLEMENT|Lactobacillus paracasei ssp paracasei F19|10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
214720870|NCT01433120|DIETARY_SUPPLEMENT|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
214720871|NCT01433120|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
214720872|NCT04539925|OTHER|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
214720873|NCT06202339|DEVICE|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
214720874|NCT04768530|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
214720875|NCT04768530|DRUG|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
214720876|NCT00819104|DRUG|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
214720877|NCT00819104|DRUG|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
214720878|NCT00819104|DRUG|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
214720879|NCT00819104|DRUG|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
214720880|NCT00819104|DRUG|Amlodipine 5mg|tablet,oral,OD,8 weeks
214720881|NCT03446989|BEHAVIORAL|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
214720882|NCT06090448|DEVICE|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
214720883|NCT05114148|DEVICE|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
214720884|NCT01939964|OTHER|Activation Mist|Activation Mist topical spray
214720885|NCT02142504|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
214720886|NCT02142504|DRUG|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
214720887|NCT05007223|DRUG|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
214720888|NCT02483455|DRUG|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
214720889|NCT02483455|DRUG|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
214720890|NCT01351064|OTHER|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
214720891|NCT02170038|DRUG|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
214720892|NCT02170038|DRUG|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
214720893|NCT01629979|PROCEDURE|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
214720894|NCT01629979|RADIATION|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
214720895|NCT01273987|PROCEDURE|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
214720896|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
214720897|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
214720898|NCT02120352|DRUG|CAB Oral Tablets|White to almost white oval shaped film coated 30 mg tablets for oral administration.
214720899|NCT02120352|DRUG|CAB LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
214720900|NCT02120352|DRUG|ABC/3TC Oral tablets|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
214720901|NCT02120352|DRUG|RPV Oral Tablets|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
214720902|NCT02120352|OTHER|HAART|Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
214720903|NCT02120352|DRUG|RPV|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
214631141|NCT05930262|BEHAVIORAL|Breathing training|Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.
214720904|NCT02322099|DRUG|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
214631142|NCT04283695|DRUG|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
214720905|NCT02322099|DRUG|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
214720906|NCT02322099|DIETARY_SUPPLEMENT|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
214720907|NCT02322099|DRUG|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
214720908|NCT05186987|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
214720909|NCT05186987|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
214720910|NCT01610206|DRUG|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
214720911|NCT01610206|DRUG|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
214720912|NCT01670136|DRUG|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
214720913|NCT06145087|DIETARY_SUPPLEMENT|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
214631143|NCT05304507|BEHAVIORAL|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
214631144|NCT05304507|BEHAVIORAL|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
214631145|NCT02905786|DEVICE|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
214631146|NCT02905786|OTHER|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
214631147|NCT02905786|OTHER|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
214720914|NCT06145087|DIETARY_SUPPLEMENT|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
214631148|NCT01515657|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
214631149|NCT01515657|DRUG|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
214631150|NCT01515657|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
214631151|NCT03236558|PROCEDURE|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
214631152|NCT05102643|BIOLOGICAL|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
214631153|NCT05102643|BIOLOGICAL|Matching placebo|Solution for intramuscular injection
214720915|NCT03895970|DRUG|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
214631154|NCT01763450|DRUG|bevacizumab plus chemotherapy|"1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
214631155|NCT02393729|BEHAVIORAL|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour"
214720916|NCT00055575|DRUG|Scopolamine Nasal Spray|
214631156|NCT02393729|OTHER|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
214631157|NCT04555122|BEHAVIORAL|Social Distancing Advertisements|Participants will receive 3 types of advertisements to increase social distancing/staying at home.
214631158|NCT01531114|DRUG|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
214631159|NCT01531114|DRUG|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
214631160|NCT05178732|DIETARY_SUPPLEMENT|Dose of protein|One of three protein doses provided
214631161|NCT05178732|OTHER|Menstrual cycle phase|Different phase of the menstrual cycle
214631162|NCT03995615|PROCEDURE|scaling and root planing|"* After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
214631163|NCT00785330|DRUG|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
214631164|NCT00785330|DRUG|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
214631165|NCT00731250|DRUG|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
214631166|NCT00731250|DRUG|Placebo|Subjects will be administered SB-705498 matching placebo tablets
214631167|NCT00731250|OTHER|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
214631168|NCT01472497|DRUG|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
214631169|NCT00181194|DEVICE|Asthma Control and Communication Instrument|
214631170|NCT01517477|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
214631171|NCT01517477|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
214720917|NCT01241656|BEHAVIORAL|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
214720918|NCT01241656|BEHAVIORAL|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
214631172|NCT01517477|DEVICE|iStent|Implantation of Three iStents through a small temporal clear corneal incision
214631173|NCT02150590|DRUG|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
214631174|NCT02150590|DRUG|sham oxygen (room air)|
214631175|NCT03420950|OTHER|Rapid sequence intubation: sedative first|Sedative first
214631176|NCT03420950|OTHER|Rapid sequence intubation: paralytic first|Paralytic first
214631177|NCT02560610|DRUG|OC000459|
214631178|NCT02560610|DRUG|Placebo|
214631179|NCT04517188|DRUG|Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP|Single topical administration
214631180|NCT04754100|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
214631181|NCT02230280|OTHER|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
214631182|NCT05429294|DRUG|Pyrotinib|Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
214631183|NCT00743379|DRUG|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
214631184|NCT00239876|DRUG|FTY720|
214631185|NCT01425151|DEVICE|i-Gel|Oropharyngeal leak pressure Insertion success
214631186|NCT01425151|DEVICE|ProSeal|Oropharyngeal leak pressure Insertion success
214720919|NCT01241656|BEHAVIORAL|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
214631187|NCT05411419|PROCEDURE|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
214631188|NCT04276714|OTHER|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
214631189|NCT04276714|OTHER|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
214631190|NCT00689572|DRUG|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
214631191|NCT00689572|DRUG|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
214631192|NCT03900403|OTHER|Walnut Intake|40g of daily walnut intake for 12 weeks
214631193|NCT00283075|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
214631194|NCT03053479|PROCEDURE|Laparoscopic sacrocolpopexy|see arm/group descriptions
214631195|NCT03053479|PROCEDURE|Transvaginal mesh procedure|see arm/group descriptions
214631196|NCT03053479|PROCEDURE|Amreich-Richter procedure|see arm/group descriptions
214720920|NCT00216515|DRUG|galantamine hydrobromide|
214631197|NCT03979157|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
214631198|NCT01127724|DRUG|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
214631199|NCT05726500|DIAGNOSTIC_TEST|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
214631200|NCT05726500|DIAGNOSTIC_TEST|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
214631201|NCT05726500|DIAGNOSTIC_TEST|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
214631202|NCT05726500|DIAGNOSTIC_TEST|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
214631203|NCT05726500|DIAGNOSTIC_TEST|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
214631204|NCT04307992|DEVICE|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
214631205|NCT01797575|DRUG|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
214631206|NCT01797575|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
214631207|NCT01797575|DRUG|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
214631208|NCT03603821|DIAGNOSTIC_TEST|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
214631209|NCT02826642|DRUG|IDH305|
214631210|NCT02941627|DEVICE|Neuro Zti|Cochlear implant
214720921|NCT05684588|DIAGNOSTIC_TEST|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
214720922|NCT01046656|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
214631211|NCT02941627|DEVICE|Neuro One|Sound processor
214631212|NCT06470269|BEHAVIORAL|Eye tracking|Recording the eye movement of participants while they read medical cases.
214631213|NCT01419912|DIETARY_SUPPLEMENT|soy milk|
214631214|NCT01419912|DIETARY_SUPPLEMENT|cow's milk|
214631215|NCT02237300|BEHAVIORAL|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
214631216|NCT02237300|BEHAVIORAL|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
214631217|NCT06320769|DEVICE|Plate Technique|Using Plates, non-absorbable sutures or cerclage wires to guide the distal femoral physis towards rotational growth to correct deformity
214631218|NCT05173064|DEVICE|Machine learning-based exercise training system|"The video-based exercise training system will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records."
214631219|NCT05173064|DEVICE|Video-based exercise training system|The video-based system will only include the exercise videos as those involved in the machine learning-based system. The features of real-time movement feedback and tracking of exercise progress will not be provided.
214631220|NCT03428971|PROCEDURE|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
214631221|NCT02286700|DRUG|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
214631222|NCT02286700|OTHER|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
214631223|NCT03132337|OTHER|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
214631224|NCT06479655|DRUG|Fentanyl|Intravenous fentanyl infusion with dilution of 10mcg/ml
214631225|NCT06479655|DRUG|Morphine|Intravenous morphine infusion with dilution 1mg/ml
214720923|NCT05563051|DEVICE|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
214720924|NCT00943254|OTHER|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
214720925|NCT00943254|OTHER|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
214720926|NCT04766983|DIAGNOSTIC_TEST|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
214720927|NCT01324427|BEHAVIORAL|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
214720928|NCT03274180|OTHER|Nursing consultation|travel preventive consultation was performed by nurse
214720929|NCT05468762|PROCEDURE|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
214720930|NCT02376491|DEVICE|Transcranial magnetic stimulation|
214720931|NCT01078519|DRUG|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
214720932|NCT02581124|DRUG|JTZ-951|
214720933|NCT02581124|DRUG|Lapatinib|
214720934|NCT02549963|DEVICE|WATCHMAN Left Atrial Appendage Occlusion Device|
214720935|NCT02549963|DRUG|Rivaroxaban|
214720936|NCT04749563|DRUG|IGC AD1|IGC AD1 oral Solution
214720937|NCT04749563|DRUG|Placebo|Placebo of IGC AD1 oral Solution
214720938|NCT04108819|DIETARY_SUPPLEMENT|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
214631226|NCT04888273|BEHAVIORAL|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
214631227|NCT02777671|DRUG|BIA 2-093|
214720939|NCT01454024|DEVICE|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
214720940|NCT01454024|DEVICE|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
214720941|NCT02796612|OTHER|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
214720942|NCT02796612|BEHAVIORAL|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
214720943|NCT02796612|BEHAVIORAL|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
214631228|NCT02777671|DRUG|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
214720944|NCT06530121|BEHAVIORAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
214720945|NCT00004910|PROCEDURE|bowel obstruction management|
214720946|NCT00004910|PROCEDURE|quality-of-life assessment|
214720947|NCT00373412|BIOLOGICAL|VCL CT02 pDNA vaccine|
214720948|NCT00373412|BIOLOGICAL|Towne CMV vaccine|
214720949|NCT02077946|DRUG|liraglutide|No treatment given.
214720950|NCT02077946|DRUG|sitagliptin|No treatment given.
214631229|NCT04640467|DIAGNOSTIC_TEST|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
214631230|NCT04640467|DIAGNOSTIC_TEST|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
214631231|NCT02763202|OTHER|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
214631232|NCT04319328|DRUG|Cefazolin|Non-interventional pharmacokinetic evaluation
214631233|NCT04319328|DRUG|Ceftazidime|Non-interventional pharmacokinetic evaluation
214631234|NCT01708642|DRUG|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
214631235|NCT01708642|DRUG|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
214631236|NCT04925609|DRUG|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
214631237|NCT06057779|OTHER|Slow and heavy exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
214720951|NCT02596685|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
214720952|NCT02596685|OTHER|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
214720953|NCT02596685|OTHER|Laboratory Biomarker Analysis|Correlative studies
214631238|NCT06057779|OTHER|Slow and light exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
214631239|NCT06057779|OTHER|Fast and heavy exercise therapy|6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
214631240|NCT02832973|DRUG|Spironolactone|Spironolactone 25 mg
214631241|NCT02832973|DRUG|Furosemide,|Furosemide 20-40 mg
214631242|NCT02832973|DRUG|Amiloride|Amiloride 5 mg
214631243|NCT02832973|DRUG|Ramipril|Ramipril 5-10 mg
214631244|NCT02832973|DRUG|Bisoprolol|Bisoprolol 5-10 mg
214631245|NCT00997100|DRUG|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
214631246|NCT05070767|DEVICE|Neurolens spectacle lens|spectacle lens
214631247|NCT05070767|DEVICE|Placebo spectacle lens|spectacle lens for refractive error correction
214631248|NCT04755361|BEHAVIORAL|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
214720954|NCT02596685|OTHER|Questionnaire Administration|Ancillary studies
214720955|NCT00444964|DRUG|Nutropin AQ|0.0125 mg/kg/day
214631249|NCT01696240|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
214631250|NCT01696240|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
214631251|NCT00689715|PROCEDURE|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
214631252|NCT05555537|DIAGNOSTIC_TEST|MiRNA223 and High mobility group box1(HMGB1)|Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
214631253|NCT03594227|DRUG|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
214631254|NCT03594227|DRUG|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
214631255|NCT03594227|DRUG|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
214720956|NCT04429321|DRUG|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
214720957|NCT04429321|DRUG|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
214631256|NCT03594227|DRUG|Placebo|Placebo - oral administration
214720958|NCT04429321|DEVICE|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
214720959|NCT04550936|DRUG|Isavuconazole|antifungal agent
214720960|NCT05201482|DEVICE|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
214720961|NCT05843591|BEHAVIORAL|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
214720962|NCT00868335|DEVICE|Activ C disc prosthesis|cervical disc prosthesis
214720963|NCT00868335|PROCEDURE|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
214720964|NCT03527316|DRUG|MDMA|125 mg MDMA per os, single dose
214720965|NCT03527316|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
214720966|NCT00897741|GENETIC|microarray analysis|
214720967|NCT00897741|OTHER|laboratory biomarker analysis|
214720968|NCT04976296|DIAGNOSTIC_TEST|MRD detection|The Geneplus OncoMRD lung assay is used to detect the MRD status.
214720969|NCT00991224|BIOLOGICAL|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
214720970|NCT00991224|BIOLOGICAL|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
214631257|NCT00790907|DRUG|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
214720971|NCT00991224|OTHER|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
214720972|NCT02209038|BEHAVIORAL|Expanded AD Choice|
214720973|NCT02209038|BEHAVIORAL|Expanded Life-sustaining Therapy Choice|
214720974|NCT03091595|DRUG|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
214720975|NCT03091595|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
214720976|NCT03014921|OTHER|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
214720977|NCT03014921|OTHER|saline solution injection|Injection of a 250mL saline solution
214720978|NCT01578538|PROCEDURE|inguinal hernia repair|strangulated hernias will be repaired surgically
214720979|NCT00166517|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
214720980|NCT00166517|BIOLOGICAL|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
214631258|NCT00790907|DRUG|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
214631259|NCT00790907|DRUG|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
214631260|NCT01801956|BEHAVIORAL|physical activity|free membership of a sport club
214631261|NCT01801956|OTHER|Motivational interview|Four motivational interviews by instructors of the local sport club
214631262|NCT01801956|OTHER|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
214631263|NCT01888640|DEVICE|TENS|"TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
214631264|NCT03669458|DEVICE|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
214631265|NCT03893968|BEHAVIORAL|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
214631266|NCT03893968|BEHAVIORAL|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
214631267|NCT00352651|DRUG|Pregabalin|
214631268|NCT01437020|DRUG|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
214631269|NCT01437020|DRUG|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
214631270|NCT05084911|DRUG|Pyramax|Pyronaridine-Artesunate(180/60mg) tablet for 3days.
214631271|NCT05084911|DRUG|Placebo|Placebo tablet for 3days.
214631272|NCT02018627|DRUG|Xeris glucagon|The subject is given an injection of xeris glucagon
214631273|NCT02018627|DRUG|Lilly glucagon|The subject is given an injection of lilly glucagon
214631274|NCT03732300|OTHER|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
214631275|NCT01595776|OTHER|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
214631276|NCT04051437|PROCEDURE|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
214631277|NCT04051437|DRUG|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
214631278|NCT00725400|OTHER|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
214631279|NCT00725400|PROCEDURE|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
214631280|NCT02875639|DRUG|Yiqi prescription|
214631281|NCT02875639|DRUG|Huoxue prescription|
214631282|NCT02875639|DRUG|Buyang huanwu decoction|
214631283|NCT02875639|DRUG|QISHEN YIQI DRIPPING PILLS|
214631284|NCT02875639|DRUG|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
214631285|NCT02875639|DRUG|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
214631286|NCT03017170|DRUG|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
214631287|NCT03017170|DRUG|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
214631288|NCT05151055|DIETARY_SUPPLEMENT|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
214631289|NCT05151055|DIETARY_SUPPLEMENT|Placebo|starch
214631290|NCT01600443|DEVICE|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
214631291|NCT01600443|DEVICE|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
214631292|NCT01600443|DEVICE|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
214631293|NCT04467307|DEVICE|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
214631294|NCT05574205|OTHER|Resistance Exercise|Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
214631295|NCT05574205|DIETARY_SUPPLEMENT|Protein supplementation|Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
214631296|NCT06542055|OTHER|Preoperative and postoperative pulmonary rehabilitation exercise|Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.
214631297|NCT06542055|OTHER|Preoperative education and postoperative exercise|Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises
214631298|NCT00736346|BEHAVIORAL|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
214631299|NCT00736346|BEHAVIORAL|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
214631300|NCT00736346|DRUG|paroxetine|40 mg die, for 6 months
214631301|NCT00092846|DRUG|MK0803, lovastatin|
214631302|NCT00092846|BEHAVIORAL|Self-Management System|
214631303|NCT06281860|DRUG|Cisplatine Teva®|PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C
214631304|NCT02102321|DRUG|albendazole|
214631305|NCT02102321|DRUG|placebo|
214631306|NCT00003737|DRUG|becatecarin|
214631307|NCT01438580|DRUG|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
214631308|NCT01438580|DRUG|aspirin|100mg aspirin was administrated every day
214631309|NCT06373289|DEVICE|higher oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the higher oxygen saturation target.
214631310|NCT06373289|DEVICE|lower oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the lower oxygen saturation target.
214631311|NCT03472157|OTHER|Lifestyle therapy|Lifestyle habits (caloric intake and exercise) + pedometer
214631312|NCT03472157|PROCEDURE|Bariatric surgery|Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
214631313|NCT02109900|OTHER|Serum Progesterone Levels|
214631314|NCT03436862|DRUG|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
214631315|NCT02733666|PROCEDURE|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
214631316|NCT04580381|DRUG|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
214631317|NCT04931004|DRUG|Mouthwash Product|Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
214631318|NCT04931004|OTHER|Water rinse|30-second water rinse will occur in the control group. Viral load will be measured prior to and after water rinse using serial face mask and saliva samples.
214631319|NCT04352439|DRUG|Aspirin|81 mg aspirin daily
214631320|NCT04732182|DEVICE|BrightGo cognitive training|Training on the BrightGo experimental device in the home
214631321|NCT04732182|DRUG|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
214631322|NCT04393922|BEHAVIORAL|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
214631323|NCT00278278|DRUG|cisplatin|Given IV
214631324|NCT00278278|DRUG|etoposide|Given IV
214631325|NCT00278278|DRUG|ifosfamide|Given IV
214631326|NCT00278278|DRUG|lomustine|Given IV
214631327|NCT00278278|DRUG|methotrexate|Given IV
214631328|NCT00278278|DRUG|prednisone|Given IV
214631329|NCT00278278|DRUG|vincristine sulfate|Given IV
214631330|NCT03386175|DEVICE|therapy with negative pression and instillation|therapy with negative pression and instillation
214631331|NCT00634829|DRUG|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
214631332|NCT00634829|DRUG|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
214631333|NCT00634829|DRUG|Placebo-HFA|Placebo containing HFA propellant without active drug substance
214631334|NCT02228590|DRUG|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
214631335|NCT04739046|DRUG|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
214631336|NCT05113836|BIOLOGICAL|Deep nasopharyngeal swab|On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
214631337|NCT05113836|BIOLOGICAL|Blood sample at D1, D3 and D7|"Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total)."
214631338|NCT00450476|DEVICE|Hi-Lo Evac Endotracheal Tube|
214631339|NCT04576598|OTHER|Self-management program to increase physical activity levels|Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.
214631340|NCT04576598|OTHER|Education information|Education on the importance of active lifestyle habits post-stroke.
214631341|NCT05279846|DRUG|MOB015B|Applied topically for 48 weeks
214631342|NCT05279846|DRUG|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
214631343|NCT03144466|COMBINATION_PRODUCT|Pembrolizumab|antiPD1 monoclonal antibody
214631344|NCT02447315|DRUG|Pilocarpine|oral
214631345|NCT02447315|DRUG|Placebo|oral
214631346|NCT01097863|DEVICE|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
214631347|NCT01097863|DEVICE|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
214631348|NCT01097863|DEVICE|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
214631349|NCT05458388|PROCEDURE|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
214631350|NCT05458388|PROCEDURE|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
214631351|NCT01214785|BEHAVIORAL|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
214631352|NCT03915873|DIAGNOSTIC_TEST|The von Willebrand Antigen level|blood sample
214631353|NCT01871584|DEVICE|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
214631354|NCT04568226|OTHER|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
214631355|NCT04568226|OTHER|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
214631356|NCT00005070|DRUG|irofulven|
214631357|NCT04307290|DRUG|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
214631358|NCT06350838|DRUG|BCG for Therapeutic Use|Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
214631359|NCT01063374|DIETARY_SUPPLEMENT|low glycemic diet instruction|
214631360|NCT01063374|DIETARY_SUPPLEMENT|high cereal fibre diet instruction|
214631361|NCT00763750|DRUG|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
214631362|NCT03692728|OTHER|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
214631363|NCT01959711|PROCEDURE|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
214631364|NCT01959711|PROCEDURE|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
214631365|NCT03278600|GENETIC|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
214631366|NCT01620242|DRUG|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
214631367|NCT00960843|DEVICE|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
214631368|NCT00960843|OTHER|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
214631369|NCT03233555|OTHER|Informational Intervention|Receive brochure
214720981|NCT03082417|OTHER|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture"
214720982|NCT04783870|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO QD
214631370|NCT03233555|OTHER|Internet-Based Intervention|Have access to EXCELS
214631371|NCT03233555|OTHER|Quality-of-Life Assessment|Ancillary studies
214631372|NCT03233555|OTHER|Questionnaire Administration|Ancillary studies
214631373|NCT03233555|BEHAVIORAL|Telephone-Based Intervention|Receive quarterly calls
214631374|NCT03957564|DRUG|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
214631375|NCT03957564|OTHER|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
214631376|NCT03957564|OTHER|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
214720983|NCT04783870|DRUG|Placebo|Placebo
214631377|NCT03957564|OTHER|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
214631378|NCT04276428|DRUG|LY3209590|Administered SC.
214631379|NCT04276428|DRUG|Insulin Degludec|Administered SC.
214631380|NCT03009266|DRUG|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
214631381|NCT04812132|PROCEDURE|One-anastomosis gastric bypass|One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)
214631382|NCT04812132|PROCEDURE|Long biliary limb Roux gastric bypass|Other group is planned to receive a long biliary limb Roux gastric bypass
214720984|NCT06527209|OTHER|Coffee and agave inulin-based beverage (A)|"Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g"
214720985|NCT06527209|OTHER|Control beverage (B)|"Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g."
214631383|NCT00558870|DRUG|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
214631384|NCT00558870|DRUG|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
214631385|NCT03609697|BEHAVIORAL|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
214631386|NCT03609697|BEHAVIORAL|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
214631387|NCT05949775|BIOLOGICAL|Neoantigen mRNA Personalised Cancer vaccine|Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection
214631388|NCT06417619|BEHAVIORAL|Mindfulness-Based Psychoeducation|The Effect of Mindfulness-Based Psychoeducation on Depression Level of Depression Patients
214631389|NCT04161430|DRUG|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
214631390|NCT04161430|DRUG|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
214631391|NCT04161430|DRUG|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
214631392|NCT02394873|BIOLOGICAL|ALLO-ASC-DFU|Dressing for second-degree burn wound.
214631393|NCT02331082|OTHER|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
214631394|NCT02331082|OTHER|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
214631395|NCT02331082|DEVICE|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
214631396|NCT02331082|DEVICE|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
214631397|NCT02331082|BEHAVIORAL|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
214631398|NCT02331082|OTHER|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
214631399|NCT04055714|DEVICE|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
214631400|NCT00153686|PROCEDURE|capsule endoscopy|capsule endoscopy of small intestine
214631401|NCT00153686|PROCEDURE|Mesenteric Angiogram|Mesenteric Angiogram
214631402|NCT00090194|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
214631403|NCT03456921|OTHER|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
214631404|NCT03413501|BEHAVIORAL|MUD-PI|
214631405|NCT00490451|DRUG|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
214631406|NCT01181011|DRUG|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
214631407|NCT05171257|DRUG|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
214631408|NCT05171257|DRUG|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
214631409|NCT03268044|OTHER|Hospital admission and surgery|Hospital admission and noncardiac surgery
214631410|NCT03997955|OTHER|Myofascial induction|Myofascial induction in plantar fascia
214631411|NCT03997955|OTHER|Sham myofascial induction|Sham myofascial induction in plantar fascia
214631412|NCT00892307|RADIATION|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
214631413|NCT03699176|DRUG|Vilaprisan (BAY1002670)|2 mg, once daily, oral
214631414|NCT03699176|DRUG|Placebo|Once daily, oral
214631415|NCT04186741|DRUG|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
214631416|NCT05486351|OTHER|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
214631417|NCT03682523|BEHAVIORAL|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
214631418|NCT02788747|DRUG|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
214631419|NCT02788747|DRUG|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
214631420|NCT02788747|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
214631421|NCT01967550|DRUG|diclofenac diethylamine, DDEA 2.32% gel|
214631422|NCT01967550|DRUG|Placebo|
214631423|NCT01223703|DRUG|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
214631424|NCT01223703|DRUG|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
214631425|NCT05309798|BEHAVIORAL|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
214631426|NCT05309798|BEHAVIORAL|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
214631427|NCT05309798|BEHAVIORAL|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
214631428|NCT04091633|BEHAVIORAL|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
214631429|NCT04091633|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
214631430|NCT00295984|DRUG|nicotine|
214631431|NCT00784654|DRUG|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
214631432|NCT00784654|DRUG|Placebo|Placebo capsule once per day (double-blind period)
214631433|NCT01640509|RADIATION|treated by synchrotron radiation|treated by synchrotron radiation
214631434|NCT04002635|DRUG|Letrozole|Letrozole ovulation induction
214631435|NCT04002635|DRUG|estradiol valerate|hormonal replacement therapy
214631436|NCT04163250|DIAGNOSTIC_TEST|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
214631437|NCT03458208|DRUG|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
214631438|NCT03458208|DRUG|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
214631439|NCT03458208|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
214631440|NCT03458208|DRUG|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
214631441|NCT00273104|PROCEDURE|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
214631442|NCT00273104|BEHAVIORAL|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
214631443|NCT03709173|BEHAVIORAL|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
214631444|NCT03740971|DEVICE|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
214631445|NCT03740971|DRUG|Guideline-based therapy|Guideline-based therapy
214631446|NCT06147479|BEHAVIORAL|CS-ADL (Cognitive stimulation in Activities of Daily Living)|CS-ADL sessions are delivered once weekly, for seven weeks. Sessions last approximately 2 hours. Sessions are themed around domains of everyday activities, for example 'Morning routine', ' Domestic Activities', 'Leisure'. Activities in each session follow this theme. A typical session begins with introductions, reality orientation, a group song and discussion of the news of the week. This is followed by a physical activity/game and ADL-focused cognitive stimulation activities. These activities include the identification and categorization of everyday items, discussion, reminiscence, planning and sequencing of ADLs and the completion of everyday writing/calculation tasks. This is followed by practice of an ADL. Examples of activities include making a breakfast, a simple gardening activity or sorting laundry. The session then ends with a summary and repeat of the group song, and a plan for the next session.
214631447|NCT03831841|BEHAVIORAL|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
214631448|NCT02989064|GENETIC|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
214631449|NCT05139186|DEVICE|Artificial Intelligence|Artificial intelligence
214631450|NCT01202929|PROCEDURE|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
214631451|NCT02698488|PROCEDURE|Morphology|
214631452|NCT02698488|PROCEDURE|Morphology and Mass Spectroscopy|
214631453|NCT04845100|OTHER|Animal Assisted Activity Program|"Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)"
214631454|NCT01180660|DRUG|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
214631455|NCT01180660|DRUG|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
214720986|NCT04835571|OTHER|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
214720987|NCT04310878|OTHER|Survey among perioperative nurses and surgeons|Online survey
214631456|NCT01962233|BIOLOGICAL|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
214631457|NCT04983914|DEVICE|Transcorneal Electrostimulation via OkuStim System|Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).
214631458|NCT06383273|DRUG|MELT-300 sublingual tablet|Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
214631459|NCT06383273|DRUG|Midalozam sublingual tablet|Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
214631460|NCT06383273|DRUG|Placebo sublingual tablet|Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
214631461|NCT03222206|DRUG|Salsalate|"1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
214631462|NCT03222206|OTHER|Placebo|"1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
214631463|NCT03505229|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
214631464|NCT03014401|PROCEDURE|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
214631465|NCT03014401|PROCEDURE|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
214631466|NCT00844753|DRUG|atomoxetine|atomoxetine
214631467|NCT00844753|DRUG|Placebo|Placebo + parent management treatment
214631468|NCT00844753|BEHAVIORAL|Parent Management Training|
214631469|NCT05909956|OTHER|KinesioTape|The kinesio tape technique, one of the physiotherapy techniques, is an elastic thin band, water-resistant, air-permeable framework to stimulate muscle movements, assist weak muscles (fascia and soft tissue), reduce discomfort and muscle cramps, facilitate proprioceptive input, boost lymph and blood flow, and relieve pain. Participants in the KT group will receive therapeutic tape on the sacral and suprapubic regions with the Star shape and ligament technique (From initial 4 h to 72 h of the menstruation cycle)
214631470|NCT05909956|OTHER|Sham Tape|This group will receive KT tapping without stretch on the sacral and suprapubic region.
214631471|NCT05909956|OTHER|General Physio session|General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck \& upper trapezius, arm \& shoulder girdle, triceps brachii, teres major \& minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
214631472|NCT03452696|DIETARY_SUPPLEMENT|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
214631473|NCT00549367|BEHAVIORAL|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
214631474|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
214631475|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
214631476|NCT00005071|PROCEDURE|biopsy|
214631477|NCT00005071|PROCEDURE|bronchoscopy|
214631478|NCT00005071|PROCEDURE|computed tomography|
214631479|NCT00005071|PROCEDURE|quality-of-life assessment|
214631480|NCT01852994|DRUG|Testosterone replacement|Application quarterly of Testosterone Undecylate
214631481|NCT01852994|OTHER|Exercise training|Aerobic and strength exercise training
214631482|NCT03143140|OTHER|PAFA|percutaneous ablation of tumor feeding artery
214631483|NCT03143140|OTHER|tumor ablation|ablation of tumor area directly
214631484|NCT05091398|OTHER|Regional analgesia of thoracic surgical patients|ultrasound-guided erector spinae block on T4 and T6 levels ,paravertebral block or intercostal nerve block after the anesthesia induction and turning the patient in the lateral position with 30 mL 0.5% bupivacaine +50 µ adrenaline will be injected by the surgeon through the thoracoscope .
214631485|NCT00510926|DRUG|Imatinib Mesilate (Glivec)|
214631486|NCT00525655|BEHAVIORAL|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
214631487|NCT00525655|BEHAVIORAL|Questionnaire|Questionnaires taking 10-15 minutes to complete.
214631488|NCT01550562|DEVICE|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
214631489|NCT04874987|OTHER|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
214631490|NCT04634500|DRUG|Dapagliflozin|Dapagliflozin Tablet
214631491|NCT03912675|PROCEDURE|Integra® dermal substitute and RigeneraTM protocol|Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
214631492|NCT01477242|DRUG|Ondansetron|2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
214631493|NCT02725983|BEHAVIORAL|SPT consultation|
214631494|NCT02725983|DEVICE|SOPROCARE®|
214631495|NCT02707783|DEVICE|Bioresorbable vascular scaffold (BVS) implantation|
214631496|NCT05667896|DRUG|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
214631497|NCT05637918|OTHER|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
214631498|NCT05637918|OTHER|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
214631499|NCT04724564|DIAGNOSTIC_TEST|THE SURGICAL PLETH INDEX|CORRELATION OF DIFFERENT TIME MEASUREMENTS OF THE SURGICAL PLETH INDEX WITH POSTOPERATIVE PAIN
214631500|NCT03171207|DEVICE|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
214631501|NCT03171207|DEVICE|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
214631502|NCT02813200|DRUG|Seretide® Diskus® 500/550 μg|Every day during 7 days
214631503|NCT02813200|DRUG|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
214631504|NCT02813200|DRUG|Spiriva® Respimat® 2,5 μg|Every day during 7 days
214631505|NCT01208714|DRUG|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%)."
214631506|NCT01208714|PROCEDURE|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
214631507|NCT02595151|DEVICE|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
214631508|NCT02282943|DEVICE|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
214631509|NCT02282943|DEVICE|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
214631510|NCT05500209|BEHAVIORAL|Personal resources' enhancement: self-efficacy|Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
214631511|NCT00852995|BIOLOGICAL|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
214631512|NCT00852995|BIOLOGICAL|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
214631513|NCT00445419|BIOLOGICAL|PEV2A PEV2B|
214631514|NCT04031651|DRUG|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
214631515|NCT02537171|DRUG|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
214631516|NCT03284736|PROCEDURE|Resorbable membrane|
214631517|NCT03284736|PROCEDURE|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
214631518|NCT02858414|OTHER|additional blood sample|
214631519|NCT00418197|DEVICE|Total Facet Arthroplasty System® (TFAS®)|
214631520|NCT06505109|BEHAVIORAL|RESST|Subjects randomized to the RESST intervention will receive on top of standard rehabilitation a behavioural group intervention focussing on improving sleep and stress. This intervention will consist of 5 till 6 meetings of 90 till 120 minutes in the local rehabilitation centre during a time period of 3 till 4 months.
214631521|NCT03615677|DRUG|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
214631522|NCT03615677|DRUG|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
214631523|NCT03649061|DRUG|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
214631524|NCT03649061|DRUG|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
214631525|NCT00579371|DRUG|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
214631526|NCT00247000|DEVICE|Routine Care in a HF clinic vs Home Telehealth Care for HF|
214720988|NCT01854671|OTHER|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
214631527|NCT05595187|DEVICE|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
214631528|NCT06394011|DRUG|venetoclax, azacitidine and HAAG regimen|Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
214720989|NCT02197598|DRUG|nalmefene|
214720990|NCT00934011|OTHER|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
214720991|NCT00934011|OTHER|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
214631529|NCT05163119|BEHAVIORAL|Commercial Cellphone-Blocking App (Active)|The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.
214631530|NCT05163119|BEHAVIORAL|Driving Mode|"Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider)."
214631531|NCT06460506|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
214631532|NCT06460506|DRUG|IVA|Granules for oral administration
214631533|NCT01441479|DEVICE|In Vitro Diagnostic Device aid in diagnosing|
214631534|NCT04818684|OTHER|questionnaire|a questionnaire consisting of a list of support practices
214631535|NCT02323269|DRUG|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
214631536|NCT04133467|OTHER|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
214631537|NCT04418076|DEVICE|Group A_No feedback|In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
214631538|NCT04418076|DEVICE|Group B_Automated feedback|For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
214631539|NCT04418076|DEVICE|Group C_Automated feedback + Clinician feedback|For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
214631540|NCT04418076|DEVICE|Group D_Automated feedback + Social Network feedback|For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
214631541|NCT06267196|OTHER|The use of a stress ball|The effect of the stress ball used during spinal anesthesia on pain and anxiety
214631542|NCT05424653|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
214631543|NCT04338750|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers|Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.
214631544|NCT04338750|BEHAVIORAL|minimally-Enhanced Usual Care|Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
214631545|NCT00978211|DRUG|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment."
214631546|NCT02844556|PROCEDURE|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
214631547|NCT02844556|OTHER|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
214631548|NCT00999531|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
214631549|NCT00999531|DRUG|Placebo|Inhaled Placebo, sterile saline
214631550|NCT04689529|DIAGNOSTIC_TEST|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
214631551|NCT03080909|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
214631552|NCT03080909|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
214631553|NCT05378451|PROCEDURE|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
214631554|NCT00429208|DRUG|Nicotine|
214631555|NCT04292509|DEVICE|SAP with stop before low|cross-over comparison from stop on low to stop before low
214631556|NCT04292509|DEVICE|SAP with stop on low|cross-over comparison from stop before low to stop on low
214631557|NCT04372277|DRUG|Enstilar|topical Enstilar foam
214631558|NCT00309231|PROCEDURE|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
214631559|NCT05288270|DEVICE|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~* 1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~* 5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
214631560|NCT05288270|OTHER|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
214631561|NCT01471782|BIOLOGICAL|Blinatumomab|Administered by continuous intravenous infusion
214631562|NCT01697735|DRUG|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
214631563|NCT01697735|DRUG|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
214631564|NCT01950871|DEVICE|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
214631565|NCT02164695|PROCEDURE|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
214631566|NCT02164695|PROCEDURE|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
214631567|NCT03363815|DRUG|CC-90001|CC-90001
214631568|NCT03363815|DRUG|Omeprazole|Omeprazole
214631569|NCT03363815|DRUG|Midazolam|Midazolam
214631570|NCT03363815|DRUG|Warfarin|Warfarin
214631571|NCT03363815|DIETARY_SUPPLEMENT|Vitamin K|Vitamin K
214631572|NCT03363815|DRUG|Rosuvastatin|Rosuvastatin
214631573|NCT03363815|DRUG|Metformin|Metformin
214631574|NCT03363815|DRUG|Digoxin|Digoxin
214631575|NCT03363815|DRUG|Nintedanib|Nintedanib
214631576|NCT03473288|BEHAVIORAL|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
214631577|NCT03473288|BEHAVIORAL|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
214631578|NCT02586168|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
214631579|NCT02586168|DRUG|Placebo|Placebo
214631580|NCT05269485|RADIATION|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
214720992|NCT03275428|DEVICE|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
214720993|NCT00149383|DRUG|Rosiglitazone|
214720994|NCT00149383|DRUG|Placebo|
214631581|NCT05269485|RADIATION|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
214631582|NCT04117971|OTHER|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
214631583|NCT03976973|DRUG|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
214631584|NCT03976973|DRUG|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
214631585|NCT03976973|PROCEDURE|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
214631586|NCT05779137|BEHAVIORAL|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
214631587|NCT00312988|DRUG|Hycamtin|
214631588|NCT00312988|DRUG|Gemcitabine|
214631589|NCT01403012|OTHER|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
214631590|NCT05567237|OTHER|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
214631591|NCT05567237|OTHER|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
214631592|NCT05567237|OTHER|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
214631593|NCT05567237|OTHER|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
214631594|NCT03718286|DRUG|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
214631595|NCT03718286|OTHER|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
214631596|NCT01808300|DRUG|Pregabalin 300mg, Thioctic acid 600mg|"* A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
214720995|NCT02186561|DEVICE|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
214631597|NCT03927274|DRUG|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
214631598|NCT00716651|DRUG|mepolizumab|750 mg mepolizumab iv q4wk until week 32
214631599|NCT02706808|DIETARY_SUPPLEMENT|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
214631600|NCT02706808|DIETARY_SUPPLEMENT|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
214631601|NCT06061549|BIOLOGICAL|AAV1/SERCA2a|3E13 viral genomes fixed dose
214631602|NCT04368728|BIOLOGICAL|BNT162b1|Intramuscular injection
214631603|NCT04368728|BIOLOGICAL|BNT162b2|Intramuscular injection
214631604|NCT04368728|OTHER|Placebo|Intramuscular injection
214631605|NCT04368728|BIOLOGICAL|BNT162b2SA|Intramuscular injection
214631606|NCT04468165|DRUG|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
214631607|NCT01314716|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
214631608|NCT01314716|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
214720996|NCT01758211|PROCEDURE|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
214720997|NCT01758211|PROCEDURE|conventional resection|conventional resection in AVM patients
214631609|NCT05314205|PROCEDURE|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
214631610|NCT04069065|DRUG|Conversion to Once-daily Tacrolimus|"* Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml."
214631611|NCT03713164|DIETARY_SUPPLEMENT|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
214720998|NCT04285853|DRUG|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
214720999|NCT04285853|DRUG|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
214721000|NCT01821547|DRUG|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
214721001|NCT03704805|BEHAVIORAL|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
214631612|NCT03713164|DIETARY_SUPPLEMENT|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
214631613|NCT03294031|OTHER|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
214631614|NCT03294031|OTHER|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
214631615|NCT00939900|DRUG|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
214631616|NCT02479009|DEVICE|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
214631617|NCT00805480|DRUG|AIN457|AIN457 was administered intravenously.
214631618|NCT00805480|DRUG|Placebo|Matching placebo to AIN457 was administered intravenously.
214631619|NCT06330038|DRUG|Propofol|Propofol will be used for the induction and maintenance of general anesthesia.
214631620|NCT06330038|DRUG|Inhaled anesthetics|Inhaled anesthetics will be used for the maintenance of general anesthesia.
214631621|NCT04290832|BEHAVIORAL|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
214631622|NCT03798158|OTHER|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
214631623|NCT02922062|OTHER|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
214721002|NCT03704805|OTHER|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
214721003|NCT04030897|BEHAVIORAL|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
214721004|NCT04030897|BEHAVIORAL|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
214721005|NCT04030897|BEHAVIORAL|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
214721006|NCT00790127|DRUG|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
214721007|NCT00790127|DRUG|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
214631624|NCT02922062|OTHER|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
214631625|NCT02922062|OTHER|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
214631626|NCT02191943|DEVICE|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
214721008|NCT00002004|DRUG|CD4 Antigens|
214721009|NCT01718964|DRUG|Cortisol 20 mg|
214721010|NCT01718964|DRUG|Mannitol|Mannitol used as placebo
214721011|NCT00294827|PROCEDURE|Liver transplantation and colo-rectal cancer|Liver transplantation
214721012|NCT00119236|DRUG|tanespimycin|
214721013|NCT00119236|DRUG|irinotecan hydrochloride|
214721014|NCT01009021|DRUG|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
214721015|NCT04606641|OTHER|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
214721016|NCT04606641|OTHER|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
214721017|NCT05565014|DRUG|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
214721018|NCT05565014|DRUG|Saline|The use of saline was the same as VAK group.
214721019|NCT02895412|BIOLOGICAL|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
214631627|NCT02191943|DEVICE|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
214631628|NCT04454190|DIAGNOSTIC_TEST|Collection of genetic material|Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
214631629|NCT01452152|DRUG|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
214631630|NCT01452152|DRUG|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
214631631|NCT06126237|BIOLOGICAL|CM313 injection|CM313, subcutaneous injection
214631632|NCT00313209|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
214721020|NCT03543670|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
214721021|NCT02455778|DIETARY_SUPPLEMENT|Cinnamon|
214721022|NCT02455778|DIETARY_SUPPLEMENT|Placebo|
214721023|NCT04714489|OTHER|NO.|NO.
214721024|NCT05245994|DRUG|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
214721025|NCT06413368|DRUG|Maralixibat 9.5 MG/ML [Livmarli]|Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
214721026|NCT01210755|DRUG|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
214721027|NCT01210755|DRUG|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
214721028|NCT00631618|DRUG|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
214631633|NCT00313209|DRUG|Placebo|once daily
214631634|NCT04434391|OTHER|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
214631635|NCT00163787|BEHAVIORAL|outcome measures and self report|
214631636|NCT03828591|PROCEDURE|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
214631637|NCT03828591|PROCEDURE|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
214631638|NCT06539923|OTHER|retrieving data|Data will be retrieved retrospectively
214631639|NCT01819051|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
214631640|NCT02997761|BIOLOGICAL|Blinatumomab|Given IV
214631641|NCT02997761|DRUG|Ibrutinib|Given PO
214631642|NCT02011659|DRUG|Ramosetron|
214631643|NCT04451356|DEVICE|Bioimpedance Spectroscopy|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device (BCM®Body Composition Monitor - Fresenius Medical Care D GmbH). The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. In addition, this analysis will provide the LTI and FTI for the included patients.
214631644|NCT04451356|DEVICE|Arterial Stiffness|Arterial stiffness assessment will be performed by applanation tonometry (SphygmoCorTM; PWV Inc., Westmead, Sydney, Australia) with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
214631645|NCT04451356|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic evaluations will be made in each patient at baseline. All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
214631646|NCT04451356|DIAGNOSTIC_TEST|Lung ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
214631647|NCT00406302|DRUG|Docetaxel|75mg/m², day 1,22
214631648|NCT00406302|DRUG|oxaliplatin|40mg/m², d1,2,22,23
214631649|NCT00406302|DRUG|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
214631650|NCT00406302|PROCEDURE|surgery|28 days after end of induction chemotherapy
214631651|NCT03701828|PROCEDURE|Weight loss surgery|All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
214631652|NCT04505098|DRUG|Icosapent ethyl|2 g by mouth twice daily for at least 6 months
214631653|NCT03784079|DRUG|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
214631654|NCT03784079|DRUG|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
214631655|NCT07003490|PROCEDURE|Radical Resection with Bilateral Lymph Node Dissection|The patient will be positioned in a contralateral decubitus position based on the location of the primary tumor, with the axillary region on the side of the primary tumor exposed. For example, if the patient is diagnosed with left-sided primary lung cancer with right-sided lymph node metastasis, investigators perform left axillary incision to resect the tumor. And then investigators change the patient's position to perform right axillary incision to resect the lymph nodes. Thoracoscopy surgery will be used to access and resect the primary lesion and lymph node metastasis.
214631656|NCT07009964|OTHER|ContextWell Educational Programme|ContextWell Educational Programme
214631657|NCT07028944|OTHER|Gravity assisted stress|Patients have a post 7-10 day ankle fracture x-ray taken under gravity assisted stress
214631658|NCT07028944|OTHER|Manual external rotation stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual external rotation stress
214631659|NCT07028944|OTHER|Weight-bearing stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual weigh-bearing stress
214631660|NCT07029841|DEVICE|catheter-based therapy|catheter-based therapy
214631661|NCT07029126|DRUG|Fremanezumab|subcutaneous injection 225 mg monthly or 675 mg quarterly
214631662|NCT07029685|OTHER|Physical|They will carry out a physical activity intervention based on the ecological model
214631663|NCT07028359|BEHAVIORAL|Printed Instructions with Phone Reminders|Participants received paper-based instructions for perioperative care, including medication, fasting, and follow-up logistics. Automated phone calls were sent before surgery to reinforce preparation. Participants used a printed checklist to self-report eye drop adherence.
214631664|NCT07028359|BEHAVIORAL|Sharp Health Companion App (CareKit)|The Sharp Health Companion App delivered interactive digital perioperative checklists, medication adherence prompts, COVID-19 protocol reminders, symptom tracking, and educational videos via iPhone. Participants logged their medication use in real time on the Sharp Health Companion App. Printed instructions were provided as a backup.
214631665|NCT05354505|DEVICE|Placement of the GOLDBAL2 balloon|The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
214631666|NCT06656936|BEHAVIORAL|PharmFIT|The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
214631667|NCT06900777|DRUG|Tacrolimus|Participants receive oral tacrolimus capsules at a dosage of 0.1 ± 0.05 mg/kg per day, divided into two administrations. The treatment duration is 24 weeks. Blood drug concentration is monitored to maintain trough levels between 7-15 ng/mL. Safety assessments include regular blood tests (hematology, liver/kidney function, blood glucose) and adverse event tracking.
214631668|NCT06900777|DRUG|Dexamethasone|Participants receive oral dexamethasone tablets at a dosage of 0.05 ± 0.025 mg/kg per day, administered as a single dose on weekends (Saturday and Sunday). The treatment duration is 24 weeks. Safety evaluations include monitoring of blood parameters (hematology, liver/kidney function, blood glucose), weight, and adrenal function (cortisol, ACTH levels).
214631669|NCT06926972|OTHER|NOURISH|Culinary medicine demonstrations and nutritional education focused on balanced eating.
214631670|NCT02956551|BIOLOGICAL|DC vaccine|subcutaneous administration
214631671|NCT04421248|DRUG|Methylphenidate|In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
214631672|NCT04421248|DRUG|Placebo|In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
214721029|NCT02685787|BEHAVIORAL|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
214721030|NCT02685787|BEHAVIORAL|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
214721031|NCT05070325|OTHER|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
214721032|NCT05070325|OTHER|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
214721033|NCT05070325|OTHER|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
214721034|NCT05307627|DRUG|low-dose naltrexone|LDN doses \<20 mg/day
214721035|NCT03499769|PROCEDURE|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
214721036|NCT03689881|DEVICE|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
214721037|NCT00642967|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
214721038|NCT03815812|DRUG|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
214721039|NCT03815812|DRUG|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
214721040|NCT03626480|OTHER|No treatment|No treatment
214721041|NCT04165005|BEHAVIORAL|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
214721042|NCT04165005|BEHAVIORAL|guided imagery|relaxing guided imagery including breathing exercises.
214721043|NCT03774368|OTHER|Emergency contraception website|Existing website with factual information about emergency contraception
214721044|NCT03774368|OTHER|Emergency contraception video|Existing video with factual information about emergency contraception
214721045|NCT02206321|PROCEDURE|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
214721046|NCT02206321|PROCEDURE|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
214721047|NCT00235664|PROCEDURE|Collection of stool and endotracheal aspirate samples|collection of samples
214721048|NCT02945995|PROCEDURE|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
214721049|NCT02087293|BEHAVIORAL|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
214721050|NCT01983878|DRUG|Ramucirumab|Administered IV
214721051|NCT05702398|DRUG|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
214721052|NCT05702398|DRUG|Nicotinamide|500 mg NAM twice a day for 6 months
214721053|NCT05702398|OTHER|Other: Placebo|Identical placebo pills twice a day
214721054|NCT03454945|DRUG|Vibramycin|Antibiotic
214721055|NCT03454945|DEVICE|Phototherapy|UVA+Psoralen
214721056|NCT01907776|DRUG|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
214721057|NCT01907776|DRUG|ME1100 placebo inhalation solution|Vehicle placebo
214721058|NCT03418064|DEVICE|Fanfilcon A toric lens|Contact lens
214721059|NCT03418064|DEVICE|Lotrafilcon B toric lens|Contact lens
214721060|NCT04447118|DRUG|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
214721061|NCT04447118|DRUG|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
214721062|NCT01802515|DRUG|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
214721063|NCT01802515|DRUG|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
214721064|NCT01802515|DRUG|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
214721065|NCT00410904|DRUG|cediranib maleate|
214721066|NCT00410904|DRUG|pemetrexed disodium|
214721067|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
214721068|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
214721069|NCT05443061|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
214721070|NCT05443061|DRUG|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
214721071|NCT06010472|DRUG|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
214721072|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
214721073|NCT01140464|OTHER|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
214721074|NCT01140464|OTHER|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
214721075|NCT00878644|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
214721076|NCT00878644|OTHER|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
214631673|NCT02023333|DRUG|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
214631674|NCT04274998|DRUG|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
214631675|NCT04274998|DRUG|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
214631676|NCT06568601|GENETIC|Pharmacogenetic and polygenic risk testing|The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
214631677|NCT06568601|OTHER|Active control|The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
214631678|NCT04099251|BIOLOGICAL|Nivolumab|Specified dose on specified days
214631679|NCT04099251|OTHER|Placebo|Specified dose on specified days
214631680|NCT03094026|BEHAVIORAL|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
214631681|NCT03094026|BEHAVIORAL|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
214631682|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
214631683|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
214631684|NCT03727971|DRUG|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
214631685|NCT03727971|DRUG|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
214631686|NCT06957405|BEHAVIORAL|MPPG (Mental and Physical Practice Group)|Participants in this group will undergo 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of: (1) two blocks of first-person kinesthetic MP, conducted while seated with eyes closed and guided using DNI principles; and (2) two blocks of corresponding PP, involving simulated gait components such as ankle mobility, postural weight shifts, and short-distance walking under real-time supervision. Each block lasts approximately 10 minutes. The MP emphasizes attentional focus, sensory detail, and task-specific goals. Sessions are conducted synchronously via video call by trained physiotherapists.
214631687|NCT06957405|BEHAVIORAL|PPG (Physical Practice Group)|Participants in the control group will receive 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of the same PP as the experimental group but replaces motor imagery with two 10-minute seated stretching block, focusing on the upper limbs and trunk. The PP follows the same structure and duration as in the experimental group. All sessions are delivered remotely via live video by physiotherapists trained in both protocols. Volume, frequency, and interaction levels are matched between groups to ensure equivalence.
214631688|NCT00006565|DEVICE|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
214631689|NCT00006565|DEVICE|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
214631690|NCT06246760|OTHER|Exercise|Incremental exercise test until volitional exhaustion
214631691|NCT02930993|BIOLOGICAL|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
214631692|NCT00913029|DEVICE|iStent|iStent
214631693|NCT00913029|DRUG|latanoprost/timolol|Combination latanoprost/timolol
214631694|NCT01783678|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214631695|NCT01783678|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214631696|NCT01995071|DRUG|ABT-493|Tablet
214631697|NCT01995071|DRUG|ABT-530|Tablet
214631698|NCT01995071|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214631699|NCT01995071|DRUG|Ribavirin (RBV)|Tablet
214631700|NCT05546892|PROCEDURE|Full bowel preparation prior to colon resection for cancer|Mechanical bowel preparation and oral antibiotics
214631701|NCT05546892|PROCEDURE|No bowel preparation|Omission of any bowel preparation
214631702|NCT01317680|DEVICE|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
214631703|NCT01317680|DEVICE|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
214631704|NCT05745935|DRUG|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
214631705|NCT06390085|OTHER|Soft tissue manipulation|The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
214631706|NCT02543528|DEVICE|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
214631707|NCT02543528|DEVICE|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
214631708|NCT02543528|DEVICE|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
214631709|NCT02543528|DEVICE|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
214631710|NCT02543528|DEVICE|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
214631711|NCT04437212|DRUG|Toripalimab|Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
214631712|NCT06277752|DRUG|dose-5 group|IBI128 300mg po. QD(Quaque Die)
214631713|NCT06277752|DRUG|dose-1 group|IBI128 25mg po. QD(Quaque Die)
214631714|NCT06277752|DRUG|dose-2 group|IBI128 50mg po. QD(Quaque Die)
214631715|NCT06277752|DRUG|dose-4 group|IBI128 200mg po. QD(Quaque Die)
214631716|NCT06277752|DRUG|dose-3 group|IBI128 100mg po. QD(Quaque Die)
214631717|NCT02049944|DRUG|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
214631718|NCT00916240|BEHAVIORAL|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
214721077|NCT00823186|DRUG|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
214631719|NCT00916240|BEHAVIORAL|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
214631720|NCT03678597|OTHER|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
214631721|NCT06391138|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
214631722|NCT01311947|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
214631723|NCT01272466|BIOLOGICAL|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
214631724|NCT05881187|DRUG|Riboflavin|topical application of riboflavin followed by cross linking
214631725|NCT05881187|DRUG|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
214631726|NCT05881187|DEVICE|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
214631727|NCT05273580|DEVICE|Garmin VivoSmart 4|Wearable sensor to record; sleep, stress, heart rate etc.
214631728|NCT05273580|DEVICE|mema - ilumivu|mEMA is the a self-service platform running on both iOS and Android that is specifically designed for the administration of mobile Ecological Momentary Assessment or Experience Sampling research studies.
214631729|NCT01765673|DEVICE|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
214631730|NCT01042600|DEVICE|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
214631731|NCT01042600|DEVICE|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
214631732|NCT06548204|DRUG|Fexofenadine Hydrochloride 60mg bid|Fexofenadine hydrochloride 60mg bid treatment for 6 months.
214631733|NCT06548204|OTHER|Placebo|Placebo administration for 6 months.
214631734|NCT06548204|DRUG|Fexofenadine Hydrochloride 120mg bid|Fexofenadine hydrochloride 120mg bid treatment for 6 months.
214631735|NCT00000873|DRUG|Infant Formula|
214631736|NCT02205684|OTHER|Computer game skills training|Playing Nintendo Wii Sports
214631737|NCT02205684|OTHER|Physical activity|Aerobic High Intensity Training (HIT)
214631738|NCT03678480|DRUG|HTD1801|HTD1801 capsules, 250mg
214631739|NCT03678480|DRUG|Ursodeoxycholic Acid|UDCA capsules, 125mg
214631740|NCT06473909|DRUG|CD25 antibody combined glucocorticoid as first-line treatment|CD25 antibody combined glucocorticoid as first-line treatment
214631741|NCT05568342|BEHAVIORAL|The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study|Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
214631742|NCT02643004|DEVICE|Senofilcon A|contact lens
214631743|NCT02643004|DEVICE|Stenfilcon A|contact lens
214631744|NCT01975922|BEHAVIORAL|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
214631745|NCT05392348|DIETARY_SUPPLEMENT|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
214631746|NCT05392348|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
214631747|NCT04771533|PROCEDURE|hand motor coordination in a sitting position|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
214631748|NCT04771533|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
214631749|NCT01932957|PROCEDURE|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
214631750|NCT01932957|PROCEDURE|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
214631751|NCT02485145|DRUG|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
214631752|NCT02485145|DRUG|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
214631753|NCT02485145|DRUG|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
214631754|NCT01082185|DEVICE|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
214631755|NCT06326242|OTHER|Solid Tumor|The study focuses on defining the problem of geographical accessibility of patients to the Phase 1 facility of the European Institute of Oncology, based on anonymized data extraction from the enrolled patient database, to evaluate national territorial disparities in access to innovative experimental therapies, in relation to various socioeconomic determinants. Finally, relevant information on psychological factors for participation in clinical trials will also be collected.
214631756|NCT04632355|OTHER|Interview|This interview will be conducted to collecting all outcomes about musculoskeletal pain in COVID-19 survivors
214631757|NCT04970004|OTHER|No intervention|No study intervention will be administered as part of this study.
214631758|NCT04917211|PROCEDURE|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
214631759|NCT04484532|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
214631760|NCT03536351|BEHAVIORAL|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
214631761|NCT01013987|DRUG|maraviroc|maraviroc: one 150 mg pill twice daily
214631762|NCT01013987|DRUG|Raltegravir|raltegravir : one 400 mg pill twice daily
214631763|NCT01013987|DRUG|Darunavir/ritonavir|"* darunavir : two 300 mg pills twice daily with meal~* ritonavir: one 100 mg pill twice daily with meal"
214631764|NCT00141765|PROCEDURE|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
214631765|NCT00141765|PROCEDURE|Stem Cell Rescue|autologous stem cell transplantation
214631766|NCT05396274|DEVICE|High Flow Nasal Cannula|high flow nasale cannula
214631767|NCT00190593|DRUG|raloxifene|
214721078|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
214721079|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
214631768|NCT00190593|DRUG|placebo|
214631769|NCT05054452|DEVICE|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
214631770|NCT00621504|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
214631771|NCT00621504|DRUG|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
214631772|NCT00621504|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
214631773|NCT00621504|DRUG|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
214631774|NCT00605085|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
214631775|NCT00605085|BIOLOGICAL|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
214631776|NCT01179074|PROCEDURE|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
214631777|NCT01179074|PROCEDURE|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
214631778|NCT02132104|PROCEDURE|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
214631779|NCT02132104|DEVICE|Foley balloon|Uterine application of Foley balloon
214631780|NCT02132104|DRUG|Femoston|Hormones treatment after surgery.
214631781|NCT05836298|OTHER|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
214631782|NCT02844387|DIETARY_SUPPLEMENT|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
214631783|NCT02844387|OTHER|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
214721080|NCT01549028|BEHAVIORAL|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
214721081|NCT01389076|DRUG|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
214721082|NCT01389076|DRUG|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
214721083|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
214721084|NCT04089228|OTHER|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
214721085|NCT04089228|OTHER|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
214721086|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
214721087|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
214721088|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
214721089|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
214721090|NCT05815004|DRUG|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
214721091|NCT05815004|DRUG|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
214721092|NCT00026195|DRUG|irinotecan hydrochloride|
214721093|NCT05225740|BEHAVIORAL|Standard Exposure|The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
214721094|NCT05225740|BEHAVIORAL|Stress Management Training|Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
214721095|NCT05225740|BEHAVIORAL|Enhanced Exposure|The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.
214721096|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
214721097|NCT05144542|PROCEDURE|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
214721098|NCT05144542|PROCEDURE|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
214721099|NCT05144542|DRUG|Nicotine Replacement|Smoke usual brand of cigarettes
214721100|NCT05144542|DRUG|Nicotine Replacement|Vape e-cigarettes
214721101|NCT05144542|OTHER|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
214721102|NCT01731990|DRUG|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
214721103|NCT01731990|DRUG|Placebo|Matching placebo of Canakinumab
214721104|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
214721105|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
214721106|NCT01280812|BEHAVIORAL|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
214721107|NCT04032197|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
214631784|NCT03980366|DEVICE|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
214631785|NCT05662267|OTHER|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
214631786|NCT00731874|DRUG|Tacrolimus|Dosed to achieve target trough concentrations.
214631787|NCT05130307|BEHAVIORAL|virtual reality game|participants interact with a computer generated world
214631788|NCT03206723|DEVICE|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
214631789|NCT03206723|DRUG|Eyedrop|Fluoroquinolone eyedrops 4x/day
214631790|NCT03206723|DRUG|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
214721108|NCT04032197|DRUG|Placebo (semaglutide)|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
214721109|NCT04483544|DRUG|pembrolizumab|PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
214721110|NCT04483544|DRUG|olaparib|PARP inhibitor olaparib 300 mg orally, twice daily (BID)
214721111|NCT04291079|BIOLOGICAL|SRK-181|anti-latent TGFβ1 monoclonal antibody
214721112|NCT04291079|BIOLOGICAL|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
214721113|NCT05569850|OTHER|Brushing|Brushing the teeth 2x a day for 4 weeks.
214721114|NCT06846528|DRUG|AZD2389|AZD2389 is administered orally
214721115|NCT06846528|DRUG|Itraconazole|Itraconazole is administered orally
214721116|NCT06843863|OTHER|No intervention.|Participants allocated to the groups were assessed only once. No intervention was applied, and they were not followed up.
214721117|NCT03147573|DIAGNOSTIC_TEST|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
214631791|NCT05898035|PROCEDURE|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
214631792|NCT06796309|OTHER|Trak Telerehabilitation Platform|The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.
214631793|NCT06796309|OTHER|Conventional Rehabilitation Program|Exercise protocol with the methodology of conventional clinical practice.
214631794|NCT06399276|BEHAVIORAL|Weight Loss|Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
214721118|NCT03147573|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
214721119|NCT03147573|DIAGNOSTIC_TEST|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
214721120|NCT03147573|DIAGNOSTIC_TEST|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
214721121|NCT01871415|DRUG|aleglitazar|150 mcg orally daily
214721122|NCT01871415|DRUG|metformin|pre-existing background regimen and dose
214721123|NCT01871415|DRUG|placebo|matching aleglitazar placebo orally daily
214721124|NCT05305053|OTHER|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
214721125|NCT03197948|OTHER|Internet-Based Intervention|Complete questionnaire via a smartphone application
214721126|NCT01131078|DRUG|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
214721127|NCT01131078|DRUG|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
214721128|NCT01131078|DRUG|Irinotecan|Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
214721129|NCT04683133|DIAGNOSTIC_TEST|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
214721130|NCT03675594|DEVICE|CAD/CAM titanium denture base|metallic denture base made of titanium
214721131|NCT03675594|DEVICE|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
214721132|NCT03731975|PROCEDURE|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
214721133|NCT03731975|PROCEDURE|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
214721134|NCT01636453|DEVICE|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
214721135|NCT03612544|OTHER|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214721136|NCT03612544|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214721137|NCT06280391|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
214721138|NCT06280391|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
214721139|NCT03600220|OTHER|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
214721140|NCT02579551|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical excision
214721141|NCT03687931|DRUG|Dexamethasone|Drop
214721142|NCT02094729|DRUG|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
214721143|NCT02094729|DRUG|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
214721144|NCT02094729|DRUG|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
214721145|NCT02094729|DRUG|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
214721146|NCT03981185|DEVICE|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
214721147|NCT03641794|DRUG|DN1406131|IDO1 and TDO2 inhibitor
214721148|NCT03641794|DRUG|Placebo|Placebo
214721149|NCT00790218|DRUG|CF102|CF102 capsules twice daily by mouth
214721150|NCT00880100|DRUG|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
214721151|NCT02764086|RADIATION|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
214721152|NCT02279160|DRUG|APD811|
214721153|NCT02279160|DRUG|Placebo|Placebo
214721154|NCT04012333|DRUG|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
214721155|NCT02628704|DRUG|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
214721156|NCT02628704|DRUG|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
214721157|NCT02628704|DRUG|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
214721158|NCT02628704|DRUG|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
214721159|NCT02853123|DRUG|Tiotropium|fixed dose combination once daily
214721160|NCT02853123|DRUG|Olodaterol|fixed dose combination once daily
214721161|NCT02853123|DRUG|Tiotropium|
214721162|NCT02054663|DRUG|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
214721163|NCT00776191|DRUG|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
214721164|NCT00776191|DRUG|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
214721165|NCT01644019|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
214721166|NCT00443625|DRUG|SK3530|
214721167|NCT06258265|DRUG|TAK-279|TAK-279 capsule.
214721168|NCT06258265|DRUG|TAK-279 Placebo|TAK-279 matching placebo capsule.
214721169|NCT06258265|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
214721170|NCT06258265|DRUG|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
214721171|NCT05668806|DEVICE|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
214721172|NCT00949949|DRUG|everolimus|Given PO
214721173|NCT00949949|DRUG|gemcitabine hydrochloride|Given IV
214721174|NCT00949949|DRUG|cisplatin|Given IV
214721175|NCT05283499|DRUG|OPIOID|Analgesic assignment
214721176|NCT05283499|DRUG|NON-OPIOID|Analgesic assignment
214721177|NCT01711476|BEHAVIORAL|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
214721178|NCT01711476|OTHER|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
214721179|NCT04387591|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
214721180|NCT04387591|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
214721181|NCT01464398|BEHAVIORAL|Stress reduction|8 weekly sessions
214721182|NCT01464398|BEHAVIORAL|Stress reduction with Health education|8 weekly sessions
214721183|NCT03021044|OTHER|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
214721184|NCT03021044|OTHER|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
214721185|NCT06139094|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
214721186|NCT03793894|BEHAVIORAL|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
214631795|NCT05490745|BEHAVIORAL|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
214631796|NCT05490745|OTHER|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
214631797|NCT06630793|RADIATION|IMPT (Intensity Modulated Proton Therapy)|Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.
214631798|NCT06630793|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
214631799|NCT03257267|DRUG|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
214631800|NCT03257267|DRUG|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
214631801|NCT01979523|OTHER|Laboratory Biomarker Analysis|Correlative studies
214631802|NCT01979523|OTHER|Pharmacological Study|Correlative studies
214631803|NCT01979523|DRUG|Trametinib|Given PO
214631804|NCT01979523|DRUG|Uprosertib|Given PO
214631805|NCT01508871|OTHER|Observational study, no intervention|No intervention
214631806|NCT02544308|DRUG|Lenalidomide|Experimental Arm
214631807|NCT02544308|DRUG|Dexamethasone|Experimental Arm
214631808|NCT02544308|OTHER|No further treatment|Comparator Arm
214631813|NCT04012047|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
214631814|NCT04012047|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
214631815|NCT03308656|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
214631816|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
214631817|NCT03311711|BEHAVIORAL|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
214631818|NCT03311711|BEHAVIORAL|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
214631819|NCT03311711|BEHAVIORAL|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
214631820|NCT01926483|OTHER|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
214631821|NCT01573715|DRUG|NIMBEX|
214631822|NCT01573715|DRUG|NIMBEX|
214631823|NCT01573715|OTHER|WITHOUT NIMBEX|
214631824|NCT00184678|DRUG|somatropin|
214721187|NCT03793894|BEHAVIORAL|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
214631825|NCT05896982|OTHER|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
214631826|NCT05896982|OTHER|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
214631827|NCT05896982|OTHER|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
214631828|NCT02077088|OTHER|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
214721188|NCT03793894|BEHAVIORAL|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
214631829|NCT02457871|BEHAVIORAL|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
214631830|NCT04231383|OTHER|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
214631831|NCT01442883|DEVICE|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
214721189|NCT03793894|BEHAVIORAL|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
214721190|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
214631832|NCT05298137|PROCEDURE|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
214631833|NCT03657368|PROCEDURE|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
214631834|NCT03657368|PROCEDURE|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
214631835|NCT03657368|PROCEDURE|Low PEEP|PEEP = 5 cm H2O
214631836|NCT03657368|PROCEDURE|High PEEP|PEEP = 8 cm H2O
214631837|NCT01623271|DRUG|Gabapentin|
214631838|NCT00706134|DRUG|Placebo|Placebo tablet taken once daily in the morning with a light meal.
214631839|NCT00706134|DRUG|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
214631840|NCT00706134|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
214631841|NCT00706134|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
214631842|NCT04188184|DRUG|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
214631843|NCT04188184|DRUG|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
214631844|NCT06537843|DRUG|Venetoclax|Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
214631845|NCT06537843|DRUG|Cytarabine Injection|Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
214631846|NCT06537843|DRUG|Metformin|Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
214631847|NCT03224897|DEVICE|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
214631848|NCT03224897|DEVICE|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
214631849|NCT03224897|DEVICE|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
214631850|NCT04747171|DRUG|intrathecal Magnesium|intrathecal adjuvants to bupivacaine
214631851|NCT04747171|DRUG|intrathecal dexamthasone|intrathecal adjuvants to bupivacaine
214631852|NCT04747171|DRUG|intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
214631853|NCT01614132|DRUG|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
214631854|NCT01614132|RADIATION|Radiotherapy|Radiotherapy of the partial brain
214631855|NCT03715283|OTHER|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
214631856|NCT03715283|OTHER|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
214631857|NCT02738658|DEVICE|Bioresorbable vascular scaffold|
214631858|NCT02738658|DEVICE|Everolimus-eluting stent|
214631859|NCT01982292|DRUG|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
214631860|NCT01982292|DRUG|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
214631861|NCT02195752|OTHER|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
214631862|NCT00720603|DRUG|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
214631863|NCT06375109|DRUG|Tislelizumab|administered via Intravenous (IV) injection
214721191|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
214631864|NCT06375109|DRUG|Carboplatin injection|administered via IV injection
214631865|NCT06375109|DRUG|Cisplatin injection|administered via IV injection
214631866|NCT06375109|DRUG|Etoposide injection|administered via IV injection
214631867|NCT01632514|DRUG|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
214631868|NCT00891605|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
214631869|NCT00891605|DRUG|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
214631870|NCT04320238|DRUG|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
214631871|NCT04320238|DRUG|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
214631872|NCT00011921|BIOLOGICAL|filgrastim|
214631873|NCT00011921|DRUG|carboplatin|
214631874|NCT00011921|DRUG|epirubicin hydrochloride|
214721192|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
214721193|NCT03036930|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214721194|NCT03036930|PROCEDURE|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
214721195|NCT03036930|OTHER|Questionnaire Administration|Ancillary studies
214631875|NCT00011921|DRUG|etoposide|
214631876|NCT00011921|DRUG|etoposide phosphate|
214631877|NCT00011921|DRUG|ifosfamide|
214631878|NCT00011921|DRUG|paclitaxel|
214631879|NCT00011921|PROCEDURE|autologous bone marrow transplantation|
214631880|NCT00011921|PROCEDURE|bone marrow ablation with stem cell support|
214631881|NCT00011921|PROCEDURE|peripheral blood stem cell transplantation|
214631882|NCT00011921|RADIATION|radiation therapy|
214631883|NCT02700490|BEHAVIORAL|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
214631884|NCT02730884|DRUG|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
214631885|NCT02730884|BEHAVIORAL|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
214631886|NCT05787262|PROCEDURE|upper endoscopy|Upper endoscopy , biopsy and histopathological examination of taken biopsies.
214631887|NCT03405623|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
214631888|NCT03405623|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
214631889|NCT05017740|PROCEDURE|ICSI|In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.
214631890|NCT05017740|PROCEDURE|PICSI|In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
214631891|NCT05729412|OTHER|Mentioned|If prescription is properly filled for specific details than it is compliance
214631892|NCT00963001|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
214631893|NCT00963001|OTHER|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
214631894|NCT03922009|DEVICE|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
214631895|NCT04821427|BEHAVIORAL|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
214631896|NCT04728685|PROCEDURE|Mechanical Traction|Mechanical Traction will be applied to the lumbar region using a traction unit.
214631897|NCT04584580|DRUG|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
214631898|NCT00554125|DRUG|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
214721196|NCT03036930|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214721197|NCT01978392|BEHAVIORAL|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
214721198|NCT05194397|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
214721199|NCT05194397|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
214631899|NCT03981237|DEVICE|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
214631900|NCT03981237|DEVICE|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).
214631901|NCT03981237|PROCEDURE|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
214631902|NCT01240642|DRUG|ASA404|
214631903|NCT01525004|DRUG|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
214631904|NCT01525004|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
214631905|NCT00935168|DRUG|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
214631906|NCT00935168|DRUG|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
214631907|NCT00157976|DRUG|Photrex (rostaporfin)|
214631908|NCT00082888|OTHER|Laboratory Biomarker Analysis|Correlative studies
214631909|NCT00082888|DRUG|Tipifarnib|Given PO
214631910|NCT01657409|DRUG|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
214631911|NCT01657409|DRUG|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
214631912|NCT01657409|DRUG|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
214721200|NCT05194397|OTHER|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
214721201|NCT01823016|DRUG|Placebo|Placebo tablet, taken once daily
214721202|NCT01823016|DRUG|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
214721203|NCT04349800|DRUG|KVD900|Active
214721204|NCT04349800|DRUG|Placebo to KVD900|Placebo
214721205|NCT06092086|DRUG|Loratinib|Continuous daily PO dosing of lorlatinib 100mg QD.
214721206|NCT05516134|BEHAVIORAL|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
214631913|NCT06268691|OTHER|Insecticide Coating INESFLY|The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
214631914|NCT05941598|DEVICE|Electroacupuncture|Participants in the electroacupuncture group will receive electroacupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
214631915|NCT05941598|DEVICE|Sham acupuncture|Participants in the sham acupuncture group will receive minimal acupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
214631916|NCT01378312|BIOLOGICAL|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
214631917|NCT01378312|BIOLOGICAL|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
214631918|NCT03874377|BEHAVIORAL|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
214631919|NCT03874377|BEHAVIORAL|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
214631920|NCT05748093|DRUG|Cobicistat|Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
214631921|NCT01549236|DRUG|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~\- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
214631922|NCT00317798|BIOLOGICAL|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
214631923|NCT00317798|DRUG|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
214721207|NCT03354572|DRUG|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
214721208|NCT03354572|DRUG|Placebos|saline 0.9% prior to surgery
214721209|NCT06005038|BEHAVIORAL|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
214721210|NCT06005038|BEHAVIORAL|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
214721211|NCT00632996|OTHER|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
214721212|NCT04262908|OTHER|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
214721213|NCT00442949|PROCEDURE|Catheterization immediate PCI|Catheterization immediate PCI
214721214|NCT00442949|PROCEDURE|delayed PCI|delayed PCI
214721215|NCT00784706|OTHER|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
214721216|NCT00784706|OTHER|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
214721217|NCT00784706|OTHER|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
214721218|NCT01838655|DRUG|Nitisinone|Oral dose of 2mg daily for 12 months.
214721219|NCT00650364|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
214721220|NCT00650364|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fasting
214721221|NCT02916199|DEVICE|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
214721222|NCT02970396|BEHAVIORAL|self-management|
214721223|NCT01094808|DRUG|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
214721224|NCT01094808|DRUG|Placebo|Placebo capsules
214721225|NCT01094808|OTHER|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
214721226|NCT02020928|DEVICE|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
214721227|NCT00646750|DRUG|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
214721228|NCT00369278|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
214721229|NCT01224106|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
214721230|NCT01224106|DRUG|Placebo|Participants received Placebo SC injection Q4W.
214721231|NCT00446797|DRUG|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
214721232|NCT00446797|DRUG|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
214721233|NCT02314169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214721234|NCT02314169|PROCEDURE|Computed Tomography|Undergo CT scan
214721235|NCT02314169|BIOLOGICAL|Ipilimumab|Given IV
214721236|NCT02314169|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214721237|NCT02314169|BIOLOGICAL|Nivolumab|Given IV
214721238|NCT02133001|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
214721239|NCT02133001|DRUG|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
214721240|NCT05168566|DRUG|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
214721241|NCT05935982|BEHAVIORAL|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
214721242|NCT03238365|BIOLOGICAL|Nivolumab|Given IV
214721243|NCT03238365|DRUG|Tadalafil|Given orally
214721244|NCT03238365|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214721245|NCT01349985|OTHER|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
214721246|NCT01349985|OTHER|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
214721247|NCT02061904|RADIATION|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
214721248|NCT02061904|OTHER|Short Form Health Survey 12|questionnaire for general health monitoring
214721249|NCT02061904|OTHER|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
214721250|NCT02061904|OTHER|VAS-pain|questionnaire for pain monitoring
214721251|NCT02061904|OTHER|Harris Hip Score|questionnaire for hip function monitoring
214721252|NCT03967847|DRUG|Ketorolac|Oral Ketorolac
214721253|NCT05661175|PROCEDURE|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
214721254|NCT02949687|PROCEDURE|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
214631924|NCT05931146|OTHER|MyNetDiary app group|MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
214631925|NCT05931146|OTHER|Paper diary group|Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
214631926|NCT01768455|DRUG|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
214631927|NCT01768455|DRUG|Glimepiride|Glimepiride 4mg (qd) on Day1
214631928|NCT01745146|BEHAVIORAL|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
214631929|NCT01745146|BEHAVIORAL|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
214631930|NCT04623242|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
214631931|NCT04623242|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
214631932|NCT04623242|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
214721255|NCT00549354|DEVICE|Endoluminal Graft|
214721256|NCT04067115|DRUG|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
214721257|NCT04067115|DRUG|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
214721258|NCT04067115|DIAGNOSTIC_TEST|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
214721259|NCT04067115|OTHER|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
214631933|NCT04623242|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
214631934|NCT01826747|DRUG|crinone (progesterone 8%, vaginal application)|
214631935|NCT02510768|DEVICE|ELAPR002f|Intradermal implant
214631936|NCT02510768|DEVICE|ELAPR002g|Intradermal implant
214631937|NCT02510768|DEVICE|Saline|Intradermal implant
214631938|NCT00316563|DRUG|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
214631939|NCT00316563|OTHER|Placebo|
214631940|NCT04660162|DEVICE|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
214631941|NCT04660162|OTHER|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
214631942|NCT05655338|DEVICE|antimicrobial photodynamic therapy|
214631943|NCT05655338|DRUG|systemic antibiotics|
214631944|NCT05493020|OTHER|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
214631945|NCT02454166|OTHER|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
214631946|NCT02454166|OTHER|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
214631947|NCT05594173|OTHER|Food texture modification|Food prepared in three different consistencies: minced and moist, soft and bite-sized and regular, as defined by the International Dysphagia Diet Standardisation Initiative
214631948|NCT02346760|DRUG|UB-621|100 mg/ml, subcutaneous injection
214631949|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
214631950|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
214631951|NCT00369187|DRUG|large protein molecule|
214631952|NCT03943212|OTHER|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
214631953|NCT03943212|OTHER|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
214631954|NCT05319392|DIAGNOSTIC_TEST|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
214631955|NCT05403983|BEHAVIORAL|Yoga movement intervention|Mixture of yoga, tai chi, pilates. Will be delivered in person (experimental) and online (active comparator)
214631956|NCT05403983|OTHER|Education booklet|Recently published postpartum physical activity guidebook through the Sport Information Resource Center of Canada
214721260|NCT03382197|DEVICE|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
214721261|NCT03382197|DEVICE|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
214721262|NCT03382197|DEVICE|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
214721263|NCT06105853|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors, representing the judging panel, and a faked exam situation (15 minutes duration).
214721264|NCT06105853|BEHAVIORAL|Barlab Cue-Exposure|Participants are exposed to a bar situation with their individual favorite alcohol presented. They handle their favorite alcoholic drink and water (9 minutes duration).
214721265|NCT06105853|BEHAVIORAL|Functional magnetic resonance imaging|Participants undergo a fMRI screening including three different behavioral tasks assessing alcohol cue reactivity, response inhibition, and emotion processing
214721266|NCT01290055|BIOLOGICAL|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
214721267|NCT01290055|OTHER|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
214631957|NCT03136315|OTHER|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
214631958|NCT04834531|DRUG|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
214631959|NCT04834531|DRUG|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
214631960|NCT04834531|OTHER|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
214631961|NCT01480297|DRUG|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
214631962|NCT03126760|DRUG|Acthar Gel|Acthar Gel 1 mL (80U) for subcutaneous injection
214631963|NCT03126760|DRUG|Placebo|Placebo for subcutaneous injection
214631964|NCT01481311|DEVICE|medical Body Composition Analyzer seca 514/515|Current of 100 µA
214631965|NCT01481311|PROCEDURE|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
214631966|NCT05466214|BEHAVIORAL|Conjoint Behavioral Consultation (CBC)|Within the treatment group, CBC will be integrated into how a school-based specialist works with families and teachers of children with or at risk of severe emotional disturbance.
214631967|NCT01748344|DRUG|Cetirizine|10mg tablets
214631968|NCT01748344|DRUG|High dose ONO-4053|Experimental
214631969|NCT01748344|DRUG|Low dose ONO-4053|Experimental
214721268|NCT02498392|DRUG|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
214631970|NCT01748344|DRUG|Placebo|None active
214631971|NCT04930575|OTHER|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
214631972|NCT04930575|OTHER|Mulligan Technique|"* The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~* Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
214631973|NCT06550154|OTHER|Data collection|Participants were identified by reviewing electronic medical records. Medical history information of thyroid disease and associated medication were collected in both groups, as well as a history of other comorbidities such as diabetes mellitus type 2, arterial hypertension, dyslipidemia, anxiety, and depression. Cases and controls were matched by age and sex.
214631974|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension/Tamiflu|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
214631975|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
214631976|NCT02490085|OTHER|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
214631977|NCT02490085|OTHER|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
214631978|NCT02490085|DRUG|Insulin|Subject's usual insulin analog will be used.
214631979|NCT02490085|DEVICE|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
214631980|NCT02490085|DEVICE|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
214631981|NCT01315379|BEHAVIORAL|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
214631982|NCT03340844|PROCEDURE|No Touch (NT)|Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.
214631983|NCT03340844|PROCEDURE|Superior Mesenteric Artery First (SMA)|Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
214631984|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
214631985|NCT01968460|DRUG|Placebo|placebo
214631986|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
214631987|NCT03177733|PROCEDURE|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
214631988|NCT01582438|DRUG|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
214631989|NCT00711633|DIETARY_SUPPLEMENT|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
214631990|NCT00711633|DIETARY_SUPPLEMENT|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
214631991|NCT04720820|OTHER|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
214631992|NCT04720820|OTHER|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
214631993|NCT00416962|DRUG|amantadine hydrochloride|
214631994|NCT00416962|DRUG|oseltamivir phosphate|
214631995|NCT03640923|OTHER|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
214721269|NCT02498392|OTHER|Placebo|Matching Placebo will be administered orally.
214631996|NCT05802719|OTHER|Blood sampling|"The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy"
214631997|NCT05151107|DIAGNOSTIC_TEST|"The radiographic images were collected through a software called PACS which combined with a viewer for image processing, that allows the calculation of the residual stomach area (RSA)."|Upper gastrointestinal radiographie
214721270|NCT06225284|DRUG|Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg|After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.
214721271|NCT01700647|OTHER|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
214721272|NCT01700647|OTHER|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
214721273|NCT04813302|PROCEDURE|Coronally advanced flap and connective tissue graft|CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
214721274|NCT00854438|OTHER|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
214631998|NCT02072473|PROCEDURE|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~1. coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~2. left-sided slow pathway ablation, using trans-septal approach."
214631999|NCT00488982|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days
214632000|NCT00488982|DRUG|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
214632001|NCT01678144|DEVICE|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
214632002|NCT02575521|DRUG|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
214632003|NCT02575521|DRUG|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
214632004|NCT05051774|BEHAVIORAL|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
214632005|NCT05051774|BEHAVIORAL|2. Exercise|"The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
214632006|NCT05051774|BEHAVIORAL|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
214632007|NCT00871312|DEVICE|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
214632008|NCT00871312|DEVICE|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
214632009|NCT01791907|BEHAVIORAL|Structured education in carbohydrate counting|
214632010|NCT01791907|BEHAVIORAL|Structured education in healthy food choices and low glycemic index|
214632011|NCT06276803|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.
214632012|NCT05133635|DRUG|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
214632013|NCT05133635|DRUG|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
214632014|NCT02917889|DRUG|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
214632015|NCT02917889|DRUG|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
214632016|NCT02917889|OTHER|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
214632017|NCT02917889|OTHER|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
214632018|NCT04377451|DRUG|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
214632019|NCT04481529|OTHER|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
214632020|NCT01780831|DRUG|Raltegravir|RAL was given as oral granules for suspension.
214632021|NCT02264990|DRUG|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
214632022|NCT02264990|DRUG|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
214632023|NCT02264990|DRUG|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
214632024|NCT02264990|DRUG|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
214632025|NCT02264990|DRUG|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
214721275|NCT03590093|PROCEDURE|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
214721276|NCT03590093|PROCEDURE|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
214721277|NCT00305734|DRUG|bortezomib|Given IV
214721278|NCT00305734|DRUG|gemcitabine hydrochloride|Given IV
214721279|NCT00305734|OTHER|laboratory biomarker analysis|Correlative studies
214632026|NCT03027583|DIETARY_SUPPLEMENT|Probiotic|6 weeks daily oral intake of a probiotic strain.
214632027|NCT03027583|DIETARY_SUPPLEMENT|Placebo|6 weeks daily oral intake of placebo.
214632028|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
214721280|NCT04436783|DEVICE|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
214721281|NCT04436783|OTHER|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
214632029|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
214632030|NCT04466800|OTHER|Intervention group_rehabilitation program|"Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate."
214632031|NCT06020456|DRUG|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
214632032|NCT00907400|DRUG|PN400|oral tablet
214632033|NCT00907400|DRUG|Naproxen|oral tablet
214632034|NCT00267748|DRUG|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
214632035|NCT00267748|DRUG|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
214632036|NCT00513032|DRUG|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
214632037|NCT04833283|DEVICE|ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)|Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
214632038|NCT04833283|DEVICE|ReOxy Cardio device|Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
214632039|NCT01134965|DRUG|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
214632040|NCT01134965|DRUG|Digoxin|Digoxin 0.5 mg as single dose
214632041|NCT02163018|DRUG|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
214632042|NCT02163018|DRUG|Placebo|Subcutaneous administration of increasing doses of placebo
214632043|NCT05179317|DRUG|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
214632044|NCT00958204|PROCEDURE|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
214632045|NCT00958204|PROCEDURE|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
214632046|NCT00958204|DRUG|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
214632047|NCT00958204|DRUG|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
214632048|NCT03130088|OTHER|no intervention planed|no intervention planed
214632049|NCT00896311|DRUG|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
214632050|NCT00896311|DRUG|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
214632051|NCT01294800|DRUG|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
214632052|NCT01294800|DRUG|Placebo tablet to match Preladenant|tablets taken orally BID
214721282|NCT05071443|OTHER|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
214721283|NCT05071443|OTHER|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
214721284|NCT05975372|DEVICE|Blossom tissue expander|Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
214721285|NCT05975372|DEVICE|Standard tissue expansion|Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
214721286|NCT03531606|DRUG|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
214721287|NCT03531606|DRUG|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
214721288|NCT02864706|DRUG|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
214721289|NCT02864706|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
214721290|NCT02864706|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
214632053|NCT01849172|OTHER|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
214721291|NCT02864706|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
214721292|NCT04415190|OTHER|early palliative care|early palliative care
214721293|NCT03135262|DRUG|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
214632054|NCT01849172|OTHER|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
214632055|NCT02491255|DEVICE|Lotus Valve System|Device: Lotus Valve System
214632056|NCT00014183|DRUG|gefitinib|
214632057|NCT00673166|PROCEDURE|Staff incentive & supervision|Control \& management of funds for incentive of staff; supervision
214632058|NCT00673166|BEHAVIORAL|Staff motivation|Supervision, control of funds
214632059|NCT00003683|DRUG|doxorubicin hydrochloride|
214632060|NCT00003683|DRUG|ifosfamide|
214632061|NCT01409720|OTHER|exercise|tailored isometric physical exercise
214632062|NCT01857713|DEVICE|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
214632063|NCT00244023|DRUG|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
214632064|NCT00244023|DRUG|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
214632065|NCT00244023|OTHER|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
214632066|NCT01662895|DRUG|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
214721294|NCT03135262|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
214721295|NCT03135262|DRUG|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
214632067|NCT01662895|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
214632068|NCT01595152|DRUG|solifenacin succinate|8 mg once daily for 60 days
214632069|NCT01595152|DRUG|fesoterodine|8 mg, once daily for 60 dyas
214632070|NCT03554915|OTHER|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
214632071|NCT03554915|OTHER|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
214632072|NCT02997995|DRUG|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
214632073|NCT02997995|DRUG|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
214632074|NCT02997995|PROCEDURE|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
214632075|NCT00961883|BIOLOGICAL|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU
214632076|NCT00961883|BIOLOGICAL|Placebo|Sodium Chloride for injection, delivered intramuscularly
214632077|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU
214632078|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU
214632079|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
214632080|NCT02373280|DRUG|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
214721296|NCT03135262|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
214632081|NCT02373280|DRUG|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]
214632082|NCT02373280|DRUG|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].
214632083|NCT02373280|DRUG|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
214632084|NCT05102955|OTHER|Observational questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
214721297|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
214632085|NCT00797732|DEVICE|Acupuncture|
214632086|NCT03958552|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
214632087|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg orally twice daily for three months
214632088|NCT00915200|DIETARY_SUPPLEMENT|silibin|480 mg orally twice daily for three months
214632089|NCT00915200|DIETARY_SUPPLEMENT|high-dose silibin|960 mg orally twice daily for three months
214632090|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine placebo|excipient orally twice daily for three months
214632091|NCT00915200|DIETARY_SUPPLEMENT|silibin placebo|excipient orally twice daily for three months
214632092|NCT02849132|DRUG|Entecavir|oral entecavir 0.5mg daily for 8 years
214632093|NCT03214484|OTHER|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
214632094|NCT03214484|OTHER|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
214632095|NCT00488384|DRUG|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
214632096|NCT06267833|BEHAVIORAL|exercise|In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
214632097|NCT00401752|DRUG|Esomeprazole|
214632098|NCT00401752|DRUG|Ranitidine|
214632099|NCT00689949|DIETARY_SUPPLEMENT|folic acid|0.4 mg of folic acid per day
214632100|NCT05836337|DEVICE|Tattoo- Black Eye|Device name: Black eye Manufacturer: The Standard Co., Ltd
214632101|NCT05836337|DEVICE|clip- HydroMARK|Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
214632102|NCT00087009|BIOLOGICAL|beta-glucan|Given orally
214632103|NCT00087009|BIOLOGICAL|rituximab|Given IV
214632104|NCT06282120|DRUG|Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy|The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
214632105|NCT01895322|DRUG|OPC-41061|
214632106|NCT03516760|DRUG|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
214632107|NCT00002279|DRUG|Zalcitabine|
214632108|NCT02275338|DRUG|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
214632109|NCT02870855|DRUG|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
214632110|NCT01612260|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
214632111|NCT01612260|DRUG|placebo Capsule|4 granules t.i.d. po for 12 weeks
214632112|NCT04136431|OTHER|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
214632113|NCT04136431|OTHER|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
214632114|NCT05148975|DIAGNOSTIC_TEST|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
214632115|NCT05146570|DIAGNOSTIC_TEST|D-lactate test|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
214632116|NCT05146570|DIAGNOSTIC_TEST|Standard diagnostic tests|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
214632117|NCT01061450|DRUG|Simvastatin|80 mg once a day
214632118|NCT01061450|DRUG|Placebo|1 pill once a day
214632119|NCT02154386|DEVICE|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
214632120|NCT04092127|OTHER|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
214632121|NCT00564811|DIETARY_SUPPLEMENT|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
214632122|NCT04505228|DRUG|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
214632123|NCT04505228|DRUG|Atropine Sulfate|The basic treatment for heart disease
214632124|NCT02882295|OTHER|Validation of a handwriting scale|
214632125|NCT03187600|PROCEDURE|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
214632126|NCT03187600|PROCEDURE|Standard of Care Pharyngeal Flap|Included in study arm description
214632127|NCT06170515|DIAGNOSTIC_TEST|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
214632128|NCT06170515|DIAGNOSTIC_TEST|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
214632129|NCT03527563|BEHAVIORAL|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
214632130|NCT02488395|OTHER|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
214632131|NCT02488395|OTHER|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
214632132|NCT02488395|OTHER|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
214632133|NCT02296398|DRUG|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
214632134|NCT03877887|DIAGNOSTIC_TEST|echo cardiogram|Assessment of left ventricular systolic and diastolic function
214632135|NCT06392880|OTHER|Floss Band|A floss band will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
214632136|NCT06392880|OTHER|Mulligan Mobilization|Mulligan mobilization will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
214632137|NCT06392880|OTHER|Control|Participants will practice various weight-bearing active ankle motions simultaneously.
214632138|NCT02465073|DEVICE|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
214632139|NCT02465073|DEVICE|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
214632140|NCT02465073|DEVICE|Standard of Care Group|Subjects will receive Standard of Care only.
214632141|NCT03473431|DRUG|Ketamine|single infusion of 0.5 mg / kg ketamine
214632142|NCT03473431|OTHER|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
214632143|NCT01914562|DRUG|OCA 10 mg|OCA 10 mg tablet oral
214632144|NCT01914562|DRUG|OCA 25 mg|OCA 25 mg tablet oral
214632145|NCT05037110|BEHAVIORAL|Physical activity|For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
214632146|NCT05037110|OTHER|Smell training|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
214722212|NCT01116349|PROCEDURE|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
214632147|NCT01999283|OTHER|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
214632148|NCT01999283|OTHER|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
214632149|NCT02215603|BEHAVIORAL|Breaking prolonged sitting with physical activity|
214632150|NCT00540878|DRUG|SB-751689 oral tablets (400 mg)|
214632151|NCT03936374|DRUG|BMS-986205|Participants will receive BMS-986205 on Days 1 and 15
214632152|NCT03936374|DRUG|omeprazole|Participants will receive omeprazole on Days 10 to 15
214632153|NCT00739414|DRUG|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
214632154|NCT02452580|OTHER|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
214632155|NCT04607733|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
214632156|NCT04607733|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
214632157|NCT05112783|DEVICE|Henan Tuoren Endotracheal Tube|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
214632158|NCT05112783|DEVICE|Smiths Portex Tracheal Tubes|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
214632159|NCT05847088|DRUG|Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:|Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
214632160|NCT00985205|DIETARY_SUPPLEMENT|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
214632161|NCT00985205|DIETARY_SUPPLEMENT|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
214632162|NCT01281566|DRUG|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
214632163|NCT01281566|DRUG|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
214632164|NCT00754910|DRUG|porfimer sodium|Given IV
214632165|NCT00754910|PROCEDURE|bronchoscopy|Patients undergo bronchoscopy
214632166|NCT03439709|RADIATION|Gamma knife radiosurgery|Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
214632167|NCT03439709|DRUG|Lanreotide 60Mg Solution for Injection|Lanreotide injection.
214632168|NCT05598892|DEVICE|Training with Robotic Hand Exoskeleton|The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
214632169|NCT02096341|DRUG|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
214632170|NCT05231382|PROCEDURE|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
214632171|NCT05231382|PROCEDURE|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
214632172|NCT02215356|DRUG|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
214632173|NCT02215356|DRUG|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
214632174|NCT02610595|DRUG|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
214632175|NCT04479579|DRUG|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
214632176|NCT01216436|BIOLOGICAL|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
214632177|NCT04856553|OTHER|Acute effects of handgrip exercise|The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
214632178|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
214632179|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
214632180|NCT06005870|DRUG|Zanubrutinib plus RCHOP|Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21
214632181|NCT01827670|DRUG|Stannous fluoride|Test dentifrice containing 0.454% SnF
214722213|NCT01116349|DEVICE|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
214632182|NCT01827670|DRUG|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
214632183|NCT04819152|BEHAVIORAL|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
214632184|NCT02298829|DRUG|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
214632185|NCT03303794|DRUG|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
214632186|NCT03303794|DRUG|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
214632187|NCT03070158|BEHAVIORAL|Attachment Promotion|"Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up."
214632188|NCT00080782|DRUG|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
214632189|NCT00080782|DRUG|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
214632190|NCT00080782|RADIATION|Strontium chloride Sr 89|IV on day 1
214632191|NCT05739786|DRUG|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
214632192|NCT05739786|DRUG|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
214632193|NCT00832559|BIOLOGICAL|CVA21|1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
214632194|NCT02365714|RADIATION|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
214632195|NCT00870961|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
214632196|NCT00870961|OTHER|placebo|Given orally
214632197|NCT05993624|DEVICE|virtual reality|The BeCure Balance Assessment System protocol used in this study; It was planned to determine the amount of change in the center of gravity in the x and y axes and the position of the center of gravity of the body with images during standing and balancing for 15 seconds on the board with eyes open. In order to support the balanced development of the participants with the Becure system; Balance surfing, balance adventure, balance bowling and traffic games were played. uBall, gates, smartclean and SmartBubblePop games with Kinect for the upper extremity; KneeUp game was played on the lower extremity.
214632198|NCT01443104|DEVICE|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
214632199|NCT01443104|DEVICE|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
214632200|NCT05030870|DEVICE|Capnography monitoring|Standard monitoring and capnographic monitoring.
214632201|NCT05030870|DEVICE|Standard monitoring|Standard monitoring but no capnographic monitoring
214632202|NCT03704870|DIAGNOSTIC_TEST|Chest Xray|Daily chest xray
214632203|NCT03704870|DIAGNOSTIC_TEST|No daily chest xray|Chest xray will be done post chest tube removal only
214632204|NCT05069181|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
214632205|NCT05069181|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
214632206|NCT05069181|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
214632207|NCT00707070|DRUG|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
214632208|NCT00707070|DRUG|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
214632209|NCT03490643|OTHER|Postural Analysis|posture and plantar pressure analysis
214632210|NCT03490643|OTHER|plantar pressure analysis|posture and plantar pressure analysis
214632211|NCT03413930|PROCEDURE|Transanal total mesorectal excision|Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
214632212|NCT03413930|PROCEDURE|Laparoscopic total mesorectal excision|Patients undergo Laparoscopic total mesorectal excision.
214632213|NCT03099486|DRUG|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
214632214|NCT03099486|DRUG|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
214632215|NCT03099486|DRUG|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
214632216|NCT05521230|DRUG|Placebo Mouthwash|Application of mouthwashes
214632217|NCT05521230|DRUG|Cymenol mouthwash|Application of mouthwashes
214722214|NCT03207724|DRUG|Xilonix plus Onivyde and 5FU|Xilonix by IV
214722215|NCT00050336|DRUG|Lonafarnib (SARASAR)|
214632218|NCT04312490|DIAGNOSTIC_TEST|endomyocardial biopsy|Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
214632219|NCT03603496|BEHAVIORAL|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
214632220|NCT03603496|BEHAVIORAL|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
214632221|NCT03603496|DRUG|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
214632222|NCT01764074|BEHAVIORAL|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
214632223|NCT05344521|DEVICE|Integra®|A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
214632224|NCT05344521|DEVICE|Integra®-SC|A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
214632225|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-experimental treatment
214632226|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-placebo
214632227|NCT00261872|DRUG|Methylphenidate|
214632228|NCT03419715|DRUG|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
214632229|NCT03419715|DRUG|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
214722216|NCT02074397|PROCEDURE|Distant extrafascial injection|
214722217|NCT02074397|PROCEDURE|Subfascial injection|
214722218|NCT03832816|DRUG|Placebo|Placebo vapor (distilled water)
214722219|NCT03832816|DRUG|Vaporized THC alone|Acute exposure to vaporized THC
214722220|NCT03832816|DRUG|Vaporized CBD alone|Acute exposure to vaporized CBD
214722221|NCT03832816|DRUG|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
214722222|NCT02928081|PROCEDURE|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
214632230|NCT02806297|PROCEDURE|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
214632231|NCT02806297|PROCEDURE|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
214632232|NCT02022488|DRUG|midazolam|Group M
214632233|NCT02022488|DRUG|alfentanil|Group MA
214632234|NCT02022488|DRUG|ketamine|Group MK
214632235|NCT04505241|BEHAVIORAL|Remotely-delivered physical activity promotion|Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
214632236|NCT00774345|DRUG|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
214632237|NCT00774345|DRUG|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
214632238|NCT00977821|OTHER|IVF|
214632239|NCT00977821|OTHER|Oocyte Vitrification|
214632240|NCT04933929|BEHAVIORAL|Post-hospitalization nutritional monitoring|Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
214632241|NCT05841823|BEHAVIORAL|Virtual reality exposure therapy (VRET)|The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
214632242|NCT05841823|BEHAVIORAL|Acceptance and commitment therapy (ACT)|The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
214632243|NCT01097278|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
214632244|NCT01097278|OTHER|placebo|Given orally
214632245|NCT00891579|DRUG|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
214632246|NCT00891579|DRUG|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
214722223|NCT02928081|PROCEDURE|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
214722224|NCT01314144|DRUG|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
214632247|NCT00484497|DRUG|cyclamax|
214632248|NCT00024115|DRUG|BL22 immunotoxin|
214632249|NCT00024115|PROCEDURE|antibody therapy|
214632250|NCT00024115|PROCEDURE|biological response modifier therapy|
214632251|NCT00024115|PROCEDURE|immunotoxin therapy|
214632252|NCT03889977|OTHER|Resistance exercise|2 major muscle groups (lower extremity, chest)
214632253|NCT04705194|PROCEDURE|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
214632254|NCT04705194|PROCEDURE|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
214632255|NCT00835237|BIOLOGICAL|Boostrix®|Intramuscular, single dose.
214632256|NCT00835237|BIOLOGICAL|Decavac™|Intramuscular, single dose.
214632257|NCT03108950|BEHAVIORAL|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
214632258|NCT05230888|OTHER|Questionnaires about symptoms|The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
214632259|NCT01926184|BEHAVIORAL|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
214632260|NCT01926184|BEHAVIORAL|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
214632261|NCT00193895|DRUG|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
214632262|NCT00193895|RADIATION|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
214632263|NCT01265550|DEVICE|Nissen fundoplication|laparoscopic antireflux surgery
214632264|NCT01265550|DRUG|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
214632265|NCT01265550|DRUG|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
214632266|NCT00684788|COMBINATION_PRODUCT|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
214632267|NCT03579355|BEHAVIORAL|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
214632268|NCT04558814|DIAGNOSTIC_TEST|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
214632269|NCT02639000|PROCEDURE|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
214632270|NCT04460976|BEHAVIORAL|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
214632271|NCT04460976|BEHAVIORAL|Treatment as usual/standard care|Standard care at disability/habilitation services.
214632272|NCT00623428|DRUG|peginterferon alfa-2a|
214632273|NCT00623428|DRUG|Ribavirin|
214722225|NCT02942693|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
214632274|NCT03948828|BIOLOGICAL|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
214632275|NCT03948828|DRUG|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
214632276|NCT03592095|DEVICE|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
214632277|NCT03592095|DEVICE|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
214632278|NCT05318456|DIETARY_SUPPLEMENT|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
214632279|NCT05318456|DIETARY_SUPPLEMENT|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
214632280|NCT05318456|OTHER|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
214632281|NCT00944164|BEHAVIORAL|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
214632282|NCT00944164|BEHAVIORAL|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
214632283|NCT04519385|DRUG|Tocilizumab|Tocilizumab therapy
214632284|NCT04519385|DRUG|Dexamethasone|dexamethsone pulse therapy
214721298|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
214632285|NCT06288620|PROCEDURE|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
214632286|NCT02961335|PROCEDURE|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
214632287|NCT02961335|PROCEDURE|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
214632288|NCT02961335|PROCEDURE|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
214632289|NCT04791774|DIETARY_SUPPLEMENT|Milk protein (food grade protein)|Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
214632290|NCT04791774|DIETARY_SUPPLEMENT|Fee amino acids (food grade amino acids)|Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
214632291|NCT02398591|DRUG|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
214632292|NCT02398591|DRUG|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
214632293|NCT01948843|DRUG|ADI-PEG 20|
214632294|NCT02640417|DRUG|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
214632295|NCT02640417|DRUG|B Vitamins|Oral treatment with vitamins B1, B6, and B12
214632296|NCT02686593|DRUG|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
214632297|NCT00343174|DRUG|Ancrod|
214632298|NCT00479791|BEHAVIORAL|Test meals rich in different fatty acids|
214632299|NCT03333031|DRUG|HS-196|HS-196 will be administered intravenously as a single dose
214632300|NCT00864435|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
214632301|NCT00864435|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
214632302|NCT04441229|BEHAVIORAL|ABMT mobile application|"After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required."
214632303|NCT01212302|DRUG|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
214632304|NCT02342015|DRUG|Atorvastatin|Atorvastatin 40mg/day for three months
214721299|NCT01675141|DRUG|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
214721300|NCT04002258|DRUG|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
214721301|NCT02057276|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
214721302|NCT02057276|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|
214721303|NCT02057276|OTHER|Occupational Therapy|
214632305|NCT01188083|DIETARY_SUPPLEMENT|Fructose Drink|Fructose Based beverage 8 oz
214632306|NCT01188083|DIETARY_SUPPLEMENT|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
214632307|NCT04336995|DIAGNOSTIC_TEST|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
214632308|NCT01692301|DRUG|LCZ696|200 mg tablet
214632309|NCT01692301|DRUG|Olmesartan|20 mg and 40 mg capsules
214632310|NCT01692301|DRUG|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
214632311|NCT01692301|DRUG|Olmesartan matching placebo|Olmesartan matching placebo capsule
214632312|NCT01692301|DRUG|amlodipine|amlodipine 2.5 mg or 5 mg tablets
214632313|NCT01692301|DRUG|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
214632314|NCT02274103|BEHAVIORAL|BFST|Family-based skills training.
214632315|NCT02789865|DRUG|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
214632316|NCT02789865|PROCEDURE|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
214632317|NCT02789865|PROCEDURE|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
214632318|NCT04073771|DEVICE|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
214632319|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
214632320|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
214632321|NCT01052584|DRUG|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
214632322|NCT01052584|DRUG|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
214632323|NCT01052584|DRUG|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
214632324|NCT06252064|OTHER|Rehabilitation + Drug therapy|Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.
214632325|NCT06252064|OTHER|Rehabilitation|Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.
214632326|NCT06252064|OTHER|Drug therapy|The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
214632327|NCT01227330|BEHAVIORAL|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
214632328|NCT01227330|BEHAVIORAL|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
214632329|NCT02318472|DEVICE|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
214632330|NCT02318472|DEVICE|Plaster cast|Lower limb plaster cast
214632331|NCT03501030|BEHAVIORAL|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
214632332|NCT00540189|PROCEDURE|Initial appendectomy|
214632333|NCT00540189|PROCEDURE|Interval appendectomy|
214632334|NCT06252272|DIAGNOSTIC_TEST|Biopsy from patients undergoing surgery abdominal.|A small portion (about 10 mm in diameter) of liver tissue was collected macroscopically free from alterations of the parenchyma obtained in the open at the site surgery for primary or secondary liver tumors, for the preparation of cultures of organotypic liver slices.
214632335|NCT00459992|DRUG|Betahistine Hydrochloride|
214632336|NCT01401634|OTHER|Oral water|2 Liters of water given orally
214632337|NCT01401634|OTHER|Intravenous normal saline|2 Liters Intravenous normal saline
214632338|NCT02592239|DEVICE|Functional brain MRI|Functional brain MRI before and after test meal ingestion
214632339|NCT02592239|DIETARY_SUPPLEMENT|A warm ham and cheese sandwich and a 200 ml fruit juice|
214722226|NCT02942693|RADIATION|Particle Therapy|Same total dose and fractionation will be used in both arms.
214632340|NCT01070264|DIETARY_SUPPLEMENT|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
214632341|NCT05143073|BEHAVIORAL|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
214632342|NCT05143073|BEHAVIORAL|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
214632343|NCT03212833|DIAGNOSTIC_TEST|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
214632344|NCT01727609|DIETARY_SUPPLEMENT|Milk feed (breast milk or formula milk)|
214632345|NCT04422249|PROCEDURE|laparoscopic middle hepatic vein guidance anatomic hemihepatectomy|95 patients with primary HCC were divided into the middle hepatic vein guidance group(n=45) and the traditional group(n=45) according to the odd and even Numbers, and sealed into envelopes.Outcomes were monitored and evaluated during the 3-year follow-up period
214632346|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 10mcg|10 mcg
214632347|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
214632348|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 60mcg|60 mcg
214632349|NCT02109484|OTHER|Placebo|
214632350|NCT00006112|DRUG|chemotherapy|
214632351|NCT00006112|DRUG|fluorouracil|
214632352|NCT00006112|DRUG|leucovorin calcium|
214632353|NCT00006112|DRUG|mitomycin C|
214632354|NCT00265538|BEHAVIORAL|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
214632355|NCT00265538|BEHAVIORAL|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
214632356|NCT00023374|DRUG|Rifampin|6mos REZ intermittent
214632357|NCT00023374|DRUG|Pyrazinamide|6mos REZ intermittent
214632358|NCT00023374|DRUG|Ethambutol|6mos REZ intermittent
214632359|NCT00023374|DRUG|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
214632360|NCT01242449|DRUG|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
214632361|NCT01242449|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
214632362|NCT03768947|OTHER|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of \~12-15 visits (45 min each) of immersion in to a hot tub.
214632363|NCT03801369|PROCEDURE|Biopsy|Undergo biopsy
214632364|NCT03801369|DRUG|Capivasertib|Given PO (orally)
214632365|NCT03801369|DRUG|Ceralasertib|Given PO (orally)
214632366|NCT03801369|BIOLOGICAL|Durvalumab|Given IV (infusion)
214632367|NCT03801369|DRUG|Olaparib|Given PO (orally)
214632368|NCT03801369|OTHER|Quality-of-Life Assessment|Ancillary studies
214632369|NCT03801369|DRUG|Selumetinib|Given PO (orally)
214632370|NCT04009044|DRUG|Afimoxifene|Apply topically
214632371|NCT04009044|PROCEDURE|Core Biopsy|Undergo core needle biopsy
214632372|NCT04009044|OTHER|Questionnaire Administration|Ancillary studies
214632373|NCT00847366|DRUG|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
214632374|NCT00847366|DRUG|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
214632375|NCT00847366|DRUG|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
214632376|NCT00293579|DRUG|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
214632377|NCT04196868|DRUG|Metformin treatment|1500 mg once a day, per os, during six months
214632378|NCT04196868|OTHER|Placebo|per os, during six months
214632379|NCT04196868|DRUG|Methotrexate treatment|per os
214632380|NCT02538068|BEHAVIORAL|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
214632381|NCT02538068|BEHAVIORAL|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
214632382|NCT00427609|DRUG|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
214632383|NCT03993184|BEHAVIORAL|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
214632384|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with hamstrings|Anatomical ACL reconstruction with quadruple-bundle hamstrings graft
214632385|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with patellar tendon|Anatomical single bundle ACL reconstruction with patellar tendon
214632386|NCT05088278|PROCEDURE|ACL reconstruction with over the top plus lateral plasty technique|Non-anatomical ACL reconstruction, the hamstrings' tibial insertion is preserved; a double-bundle hamstring graft is passed intra-articularly, fixed in over the top position on the lateral femoral condyle, and then passed extra-articularly deeply to ileo-tibial band up to the tibia, where it is fixed at the level of Gerdy's tubercle.
214632387|NCT01311700|DRUG|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
214632388|NCT04400812|OTHER|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
214632389|NCT00772486|BIOLOGICAL|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
214632390|NCT02023645|DIETARY_SUPPLEMENT|active supplement|tablet
214632391|NCT02023645|OTHER|placebo|tablet
214632392|NCT01701570|BEHAVIORAL|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
214632393|NCT01701570|OTHER|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
214632394|NCT03127384|DEVICE|Restylane Lidocaine|Hyaluronic acid based filler
214632395|NCT03127384|OTHER|No-treatment control|No-treatment control
214632396|NCT04966377|BEHAVIORAL|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS), increasing awareness of Syrian women under temporary protection against breast cancer, decreasing their perception of barriers to screening tests, developing early diagnosis behaviors (such as BSE, CBE and mammography), increasing their self-efficacy and breast cancer fears are expected to be reduced.
214632397|NCT02171611|DRUG|Dabigatran etexilate pellets|
214632398|NCT02171611|DRUG|Dabigatran etexilate powder|
214632399|NCT02171611|DRUG|Dabigatran etexilate capsule|
214632400|NCT02734836|DEVICE|Balloon Angioplasty|
214632401|NCT02734836|OTHER|Optical Coherence Tomography|
214632402|NCT00326352|DRUG|Sedation with propofol and remifentanil|
214632403|NCT05290025|DRUG|Nicotine patch|\> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
214632404|NCT05290025|DRUG|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
214632405|NCT05290025|DRUG|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
214632406|NCT05290025|BEHAVIORAL|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
214632407|NCT05290025|OTHER|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
214632408|NCT05290025|OTHER|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
214632409|NCT01026831|DRUG|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
214632410|NCT01026831|DRUG|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
214632411|NCT04249687|BIOLOGICAL|botulinum toxin|neuromodulator
214632412|NCT04249687|BIOLOGICAL|Placebo|placebo
214632413|NCT03916211|BIOLOGICAL|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
214632414|NCT03263507|DRUG|Placebo|Saline .9%
214632415|NCT03263507|DRUG|Donidalorsen|Donidalorsen administered subcutaneously
214632416|NCT03963635|DIAGNOSTIC_TEST|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
214632417|NCT04401176|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
214632418|NCT04401176|DRUG|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
214632419|NCT05543564|PROCEDURE|PRP|Single session prophylactic early Pan-retinal Photocoagulation
214632420|NCT03119909|OTHER|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
214632421|NCT03119909|OTHER|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
214632422|NCT03119909|OTHER|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
214632423|NCT03119909|OTHER|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
214721304|NCT02030665|BEHAVIORAL|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
214632424|NCT03119909|OTHER|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
214632425|NCT03119909|OTHER|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
214632426|NCT02683200|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
214632427|NCT02683200|RADIATION|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
214632428|NCT04036968|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
214632429|NCT04414800|DRUG|Placebo|Distilled water
214632430|NCT04414800|DRUG|Ketamine|1 mg/kg intranasal ketamine
214632431|NCT04414800|DRUG|Fentanyl|1μg/kg intranasal fentanyl
214632432|NCT00002689|DRUG|dexamethasone|
214632433|NCT00002689|DRUG|fluorouracil|
214632434|NCT00002689|RADIATION|brachytherapy|
214632435|NCT00002689|RADIATION|phosphorus P32|
214632436|NCT00002689|RADIATION|radiation therapy|
214632437|NCT04840108|BEHAVIORAL|Support Person Coaching Intervention|The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.
214632438|NCT04840108|BEHAVIORAL|Support Person Written Materials|Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
214632439|NCT03593252|DRUG|Senna|Laxative,used for bowel preparation
214632440|NCT03593252|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
214632441|NCT03593252|DRUG|Metronidazole Oral|Oral antibiotic
214632442|NCT03593252|DRUG|Neomycin|Oral non-absorbable antibiotic
214632443|NCT03593252|DRUG|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
214632444|NCT03593252|DRUG|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
214632445|NCT03593252|OTHER|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for \>=8 hours, no formula milk/full liquids \>= 4hours; no breast milk or clear fluids \>=2hours.
214632446|NCT03593252|OTHER|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
214632447|NCT02500121|OTHER|Placebo|Normal saline
214632448|NCT02500121|DRUG|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
214632449|NCT04647500|DRUG|Concerta|Evaluation of a treatment of Concerta over a period of 13 days.
214632450|NCT00366587|DEVICE|Cataract surgery and IOL implantation|
214632451|NCT03730116|DRUG|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
214632452|NCT03111446|PROCEDURE|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
214632453|NCT03111446|PROCEDURE|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
214632454|NCT02133989|DRUG|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
214632455|NCT02133989|DRUG|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
214632456|NCT00498173|DRUG|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
214632457|NCT00498173|DRUG|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
214632458|NCT00953368|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
214632459|NCT05256407|OTHER|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
214632460|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
214721305|NCT02030665|BEHAVIORAL|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
214632461|NCT04539639|DRUG|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
214632462|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
214721306|NCT02030665|BEHAVIORAL|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
214721307|NCT01949298|PROCEDURE|dental implant placement|
214721308|NCT04535206|DIAGNOSTIC_TEST|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
214721309|NCT01770093|OTHER|Questionnaire|
214721310|NCT01407848|DRUG|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
214721311|NCT01407848|DRUG|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
214721312|NCT02779881|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus LGG|
214721313|NCT00310349|BIOLOGICAL|23 valent pneumococcal polysaccharide vaccine|
214721314|NCT02919410|DEVICE|iodophor-impregnated adhesive drapes|
214721315|NCT02919410|OTHER|No adhesive drapes|
214721316|NCT03957746|OTHER|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
214721317|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
214721318|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
214721319|NCT01425320|DRUG|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
214721320|NCT01425320|DRUG|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
214721321|NCT00922519|OTHER|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
214721322|NCT02324868|DEVICE|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
214721323|NCT02324868|DEVICE|Conventional IV catheter protection|No Shower patch will be provided during study period
214721324|NCT00026585|DRUG|Tamoxifen|
214721325|NCT04776915|DIAGNOSTIC_TEST|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
214721326|NCT03097133|DRUG|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
214721327|NCT03097133|DRUG|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
214721328|NCT03097133|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
214721329|NCT06585202|DRUG|ATI-2138|ATI-2138 Oral Tablets BID
214721330|NCT02068586|DRUG|Sunitinib|Given PO
214721331|NCT02068586|DRUG|Valproic Acid|Given PO
214721332|NCT02068586|DRUG|Sunitinib Malate|Given PO
214721333|NCT02068586|DRUG|Sunitinib Malate + Valproic Acid|Given PO
214721334|NCT05249712|DRUG|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
214721335|NCT05249712|OTHER|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
214721336|NCT05444985|OTHER|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
214721337|NCT04309838|COMBINATION_PRODUCT|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
214721338|NCT00559416|DRUG|Cell Transfer|
214721339|NCT01691053|DRUG|Spironolactone|50mg once daily
214721340|NCT01691053|DRUG|Placebo|Placebo
214721341|NCT02575677|OTHER|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
214721342|NCT04451317|OTHER|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
214721343|NCT04727645|OTHER|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
214721344|NCT02873208|DRUG|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
214721345|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
214721346|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
214721347|NCT05263687|DIAGNOSTIC_TEST|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
214632463|NCT04539639|DRUG|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
214632464|NCT01681264|DRUG|Morphine|
214632465|NCT01681264|DRUG|Guanfacine 1mg|
214632466|NCT01681264|DRUG|Guanfacine 2mg|
214632467|NCT01681264|DRUG|Placebo|
214632468|NCT01110200|DRUG|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
214632469|NCT01110200|DRUG|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
214632470|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
214721348|NCT04411706|DRUG|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
214632471|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
214632472|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
214632473|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
214721349|NCT05126134|DIAGNOSTIC_TEST|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
214632474|NCT04011020|COMBINATION_PRODUCT|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
214632475|NCT00118014|DRUG|Sertraline|
214632476|NCT00118014|BEHAVIORAL|Habit Reversal Training|
214632477|NCT00661115|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
214632478|NCT00661115|DRUG|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
214632479|NCT03539250|RADIATION|IMRT|IMRT with and without chemotherapy
214632480|NCT02963532|OTHER|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
214632481|NCT04336631|BEHAVIORAL|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
214632482|NCT02565407|BEHAVIORAL|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
214632483|NCT02565407|BEHAVIORAL|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
214632484|NCT00245362|BIOLOGICAL|CG 8020 and CG 2505|
214632485|NCT00717171|DEVICE|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
214632486|NCT00717171|DEVICE|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
214632487|NCT02567487|DRUG|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
214632488|NCT03799393|BEHAVIORAL|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
214632489|NCT03799393|BEHAVIORAL|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
214632490|NCT05551832|DRUG|Arm I (Placebo),|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
214632491|NCT05551832|DRUG|Arm II (ESMESOL)|SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
214632492|NCT02615444|DIETARY_SUPPLEMENT|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
214632493|NCT02615444|DIETARY_SUPPLEMENT|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
214632494|NCT04986800|BEHAVIORAL|PROACTIVE Parent|PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
214632495|NCT00912249|BEHAVIORAL|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
214632496|NCT05346705|BEHAVIORAL|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
214632497|NCT05504733|DEVICE|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
214632498|NCT05504733|DEVICE|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
214632499|NCT04607200|DRUG|AGEN2034|Anti-PD-1 Monoclonal Antibody
214632500|NCT04607200|DRUG|AGEN1884|Anti-CTLA-4 Monoclonal Antibody
214632501|NCT03268928|BEHAVIORAL|Story Starters Intervention|Shared reading intervention
214632502|NCT03268928|BEHAVIORAL|Wait-list Control|Wait-list control
214632503|NCT03627403|DRUG|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
214632504|NCT04553120|BEHAVIORAL|Alternating single stimulus and multiple stimuli|"P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation)."
214632505|NCT01222676|DRUG|cisplatin|
214632506|NCT01222676|DRUG|gemcitabine hydrochloride|
214632507|NCT01222676|DRUG|sorafenib tosylate|
214632508|NCT01222676|OTHER|imaging biomarker analysis|
214632509|NCT01222676|OTHER|laboratory biomarker analysis|
214632510|NCT01222676|PROCEDURE|computed tomography|
214632511|NCT01222676|PROCEDURE|neoadjuvant therapy|
214632512|NCT01222676|RADIATION|fludeoxyglucose F 18|
214632513|NCT04518462|DRUG|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
214632514|NCT04518462|DRUG|Bupivacaine Hydrochloride|0.25% bupivacaine
214632515|NCT00376870|DRUG|Pioglitazone|pioglitazone 30 mg/d
214632516|NCT00376870|DRUG|Placebo|Placebo 30 mg/d
214632517|NCT02866279|DEVICE|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
214632518|NCT03919526|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
214632519|NCT03919526|DRUG|Fludarabine|30mg/m2/d
214721350|NCT04401410|BIOLOGICAL|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
214721351|NCT04401410|BIOLOGICAL|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
214632520|NCT03919526|DRUG|Cyclophosphamide|300mg/m2/d
214632521|NCT05723705|OTHER|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
214632522|NCT01234272|DRUG|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
214632523|NCT01234272|DRUG|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
214632524|NCT00893321|PROCEDURE|Inferior Oblique Muscle Recession and Myectomy|
214632525|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
214632526|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
214721352|NCT04401410|OTHER|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
214721353|NCT01240967|DRUG|TC-5214|Oral tablets, single dose
214721354|NCT04080752|DRUG|JNJ-61393215|JNJ-61393215 will be administrated orally.
214632527|NCT05898958|PROCEDURE|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
214632528|NCT05898958|PROCEDURE|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
214632529|NCT06459154|OTHER|Mixed Reality|The experimental group MR will use the mixed reality project involving activities in a supermarket. MR HoloLens2 glasses will be used to conduct the program. The technological equipment that will be used will allow the provision of visual and auditory stimuli. The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment. This program offers coordination activities, posture, cognitive activities and balance exercises. The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
214721355|NCT04080752|DRUG|Placebo|Matching placebo will be administered orally.
214632530|NCT06459154|OTHER|Traditional Physiotherapy|The group of traditional physiotherapy follows the guidelines of EPDA. Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks. The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
214632531|NCT07028658|OTHER|Speechreading training|The patient will undergo 16 lip reading training sessions. By developing functional lip reading skills, they will be able to fill in the gaps in auditory information they miss, especially in loud or noisy settings
214632532|NCT03424707|DRUG|DW340(pelubiprofen/eperisone)|DW340
214632533|NCT03424707|DRUG|Pelubi(pelubiprofen)|pelubiprofen
214632534|NCT03424707|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
214632535|NCT05276960|DRUG|Cholecalciferol Pill|Dose increments according to serum levels determined every 2 months
214632536|NCT04875884|DEVICE|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
214632537|NCT04151199|OTHER|EE Training|Participants randomized to EE training engage in three school-based or center-based (PERC) EE training sessions each week for approximately 12 weeks; each session lasting roughly 70 min with a 45-50 minutes of a stimulus phase and the remaining time being used to warm-up and cool down.
214632538|NCT05292781|OTHER|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
214632539|NCT05292781|OTHER|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
214632540|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
214632541|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
214632542|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
214632543|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
214632544|NCT02255383|DEVICE|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
214632545|NCT06407934|DRUG|Amlitelimab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection"
214632546|NCT06407934|DRUG|Placebo|"Pharmaceutical form: Injection solution~Route of administration: SC injection"
214632547|NCT05774600|BEHAVIORAL|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
214632548|NCT05774600|BEHAVIORAL|Minimal Information Control|Provision of online materials for skin cancer prevention.
214632549|NCT03624010|DRUG|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
214632550|NCT06454903|BEHAVIORAL|ACT to RECOVER|During Phase 3 (Stage 1b RCT), the treatment condition will employ ACT to RECOVER. ACT to RECOVER will be a smartphone app designed to act as a flexible, semi-structured, user-friendly adjunct to standard medication treatment for opioid use disorder. Content will include components appropriate for either self-management and/or use with providers. ACT to RECOVER will be designed to have major ACT-focused modules completable within 1 month.
214721356|NCT06265467|PROCEDURE|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
214632551|NCT06454903|BEHAVIORAL|Smartphone-based Symptom-Monitoring|During Phase 3 (Stage 1b RCT), the control condition will employ a smartphone-based symptom monitoring program in an effort to provide a balanced alternative to the treatment condition with respect to attention, time using a mobile application, and nonspecific intervention effects. This condition will not, however, include any content or components from the Prototype Digital Intervention hypothesized to produce active clinical effects.
214632552|NCT04311502|DRUG|Rifapentine|1200 mg once daily
214632553|NCT04311502|DRUG|Rifampicin|600 mg once daily
214632554|NCT04311502|DRUG|Isoniazid|300 mg once daily
214632555|NCT04311502|DRUG|Pyrazinamide|1000mg once daily if weight is 40 to \<55kg; 1500mg once daily if weight is 55 to \<71kg; 2000mg once if weight is ≥71kg
214632556|NCT04311502|DRUG|Ethambutol|800 mg once daily if weight is 40 to \<55kg; 1200 mg once daily if weight is 55 to \<71kg; 1600mg once if weight is ≥71kg
214632557|NCT04311502|DRUG|Clofazimine loading dose|300 mg once daily for 2 weeks (loading dose), then 100 mg once daily
214632558|NCT04311502|DRUG|Clofazimine 100 MG|100 mg once daily
214721357|NCT06265467|PROCEDURE|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
214721358|NCT00379886|DRUG|Propofol Thiopental|
214721359|NCT01192100|BEHAVIORAL|Breakfast Skipping|Participants will continue to skip breakfast each morning.
214721360|NCT01192100|BEHAVIORAL|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
214632559|NCT04707274|OTHER|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
214632560|NCT03833700|DRUG|E7386|E7386 doses.
214632561|NCT05279755|DRUG|prosetin|oral solution
214632562|NCT05279755|DRUG|placebo|oral solution
214632563|NCT03040999|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
214632564|NCT03040999|DRUG|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
214632565|NCT03040999|DRUG|Cisplatin|100 mg/m\^2 administered as an IV infusion Q3W
214632566|NCT03040999|RADIATION|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
214632567|NCT03040999|RADIATION|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
214632568|NCT05779774|BEHAVIORAL|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
214632569|NCT05779774|BEHAVIORAL|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
214632570|NCT06099769|DRUG|Enzalutamide|mouth once daily (160 mg/day)
214632571|NCT06099769|DRUG|Mifepristone|mouth once daily 300-mg tablet
214632572|NCT06099769|DRUG|TPC|"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
214632576|NCT03802851|PROCEDURE|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
214632577|NCT06776419|DIAGNOSTIC_TEST|Cardiac Magnetic Ressonance Imaging|CMR-protocol with gadolinium contrast
214632578|NCT06776419|DIAGNOSTIC_TEST|82Rubidium-positron emission tomography and computer-tomography|cardiac Rb-PET protocol
214632579|NCT02491164|OTHER|BAC TWO|BAC TWO administration
214632580|NCT02491164|DEVICE|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
214632581|NCT04766307|DRUG|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
214632582|NCT05269407|DEVICE|Peripheral perfusion index|"The study aimed to generate a model relating pre-spinal perfusion index to the likelihood and severity of the reduction in blood pressure in the first 20 min after spinal injection.~A correlation between the delta PI and the delta SBP (the difference between the baseline maternal systolic blood pressure and the lowest blood pressure)will be investigated to establish a predictive model to define cut-off values at which perfusion index variation indicated a low risk (no or mild hypotension groups) or a high risk (moderate, severe groups) of reduction in blood pressure.. The incremental change of a measure PI, the ΔPI will be calculated as the absolute change in PI between supine and sitting positions, ΔPI=PIsupine-sitting. The relative change in PI the rPI, will be expressed as the percentage of change in PI, rPI=ΔPI/PIsitting× 100."
214632583|NCT01047774|DIETARY_SUPPLEMENT|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
214632584|NCT01047774|DIETARY_SUPPLEMENT|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
214632585|NCT00276172|DRUG|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
214632586|NCT04901910|BEHAVIORAL|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
214632587|NCT04901910|BEHAVIORAL|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
214632588|NCT06461260|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
214632589|NCT03790254|OTHER|systematic review|
214632590|NCT04121442|BIOLOGICAL|Isunakinra|Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
214632591|NCT04121442|BIOLOGICAL|PD-(L)1 Inhibitor|Monoclonal antibody targeting PD-1 or PD-L1
214632592|NCT01583621|DIETARY_SUPPLEMENT|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
214632593|NCT05723614|BEHAVIORAL|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
214632594|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
214632595|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
214632596|NCT02579980|PROCEDURE|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
214632597|NCT02579980|PROCEDURE|Surgery|Standard of care procedure for sarcoma patients
214632598|NCT03368170|DRUG|Mesdopetam (IRL790)|Mesdopetam (IRL790) capsule
214721361|NCT01192100|BEHAVIORAL|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
214721362|NCT04409730|OTHER|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
214721363|NCT06812637|DRUG|WJ-MSC- Exosomes|warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC
214721364|NCT06812637|COMBINATION_PRODUCT|SOC (Standard of care)|Wound depridement for necrotic parts , local antibiotic , dressing , unloading
214721365|NCT06812637|OTHER|Vehicle (placebo)|Vehicle for the MSC-EXO
214721366|NCT00921427|BEHAVIORAL|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
214721367|NCT00921427|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
214721368|NCT01784003|DEVICE|Powered ankle-foot prosthesis|
214632599|NCT00193765|PROCEDURE|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
214632600|NCT00193765|PROCEDURE|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
214632601|NCT05672342|DRUG|Cannabidiol|Given PO
214632602|NCT05672342|DRUG|Delta-8-Tetrahydrocannabinol|Given PO
214632603|NCT05672342|DRUG|Placebo Administration|Given PO
214632604|NCT05672342|OTHER|Questionnaire Administration|Ancillary studies
214632605|NCT02587533|OTHER|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
214632606|NCT02587533|OTHER|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
214632607|NCT02587533|OTHER|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
214632608|NCT02587533|OTHER|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
214632609|NCT03143231|OTHER|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
214632610|NCT03143231|OTHER|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
214632611|NCT02589262|DRUG|AUT00206|
214632612|NCT02068547|BIOLOGICAL|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
214632613|NCT02068547|BIOLOGICAL|Bone Marrow Aspirate|
214632614|NCT01150539|OTHER|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
214632615|NCT01150539|OTHER|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
214632616|NCT02416284|OTHER|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
214632617|NCT03011346|DEVICE|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
214632618|NCT03011346|DEVICE|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
214632619|NCT03657043|DRUG|tisotumab vedotin|Intravenous (IV) infusion
214632620|NCT06425003|DRUG|[14C] ABBV-CLS-7262|Oral Solution
214632621|NCT04392518|OTHER|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
214632622|NCT04495738|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
214632623|NCT04495738|OTHER|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
214632624|NCT04495738|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
214632625|NCT04495738|OTHER|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
214632626|NCT04495738|OTHER|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
214632627|NCT04495738|OTHER|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
214632628|NCT00480610|DRUG|tacrolimus ointment|Topical application
214632629|NCT00480610|DRUG|Placebo ointment|Topical application
214632630|NCT01197326|DEVICE|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
214632631|NCT01497015|BEHAVIORAL|memory training|10 1-hour sessions over 6-8 weeks
214632632|NCT01497015|BEHAVIORAL|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
214632633|NCT01497015|BEHAVIORAL|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
214632634|NCT02627495|DEVICE|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
214632635|NCT05256498|DEVICE|Picostim Amber|Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
214632636|NCT02364128|BEHAVIORAL|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
214632637|NCT03314545|PROCEDURE|laminate veneer with coronal post|laminate veneer with coronal post
214632638|NCT03314545|PROCEDURE|post,core and crown|post,core and crown
214632639|NCT02187952|BEHAVIORAL|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
214632640|NCT00880893|BIOLOGICAL|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
214632641|NCT00880893|BIOLOGICAL|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
214632642|NCT04411550|DRUG|HLX11|healthy volunteers receive HLX11 (420mg) once
214632643|NCT04411550|DRUG|CN-Perjeta(Pertuzumab)|healthy volunteers receive CN-Perjeta (420mg) once
214632644|NCT04411550|DRUG|EU-Perjeta(Pertuzumab)|healthy volunteers receive EU-Perjeta (420mg) once
214632645|NCT04411550|DRUG|US-Perjeta(Pertuzumab)|healthy volunteers receive US-Perjeta (420mg) once
214632646|NCT03331809|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.
214632647|NCT03331809|PROCEDURE|Conventional intubation|The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
214632648|NCT01489514|OTHER|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~1. Histamine control purchased from Greer.~2. Saline control purchased from Greer.~3. Standard Peanut Extract purchased from Greer.~4. Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A \& T.~5. Sterile extract prepared from roasted \& blanched but untreated peanuts. This is prepared by North Carolina A \& T.~6. Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A \& T. This is not classified as a drug and is~7. Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~8. Sterile extracts containing peanuts that have been treated with alcalase"
214632649|NCT05738850|DRUG|ABBV-932|Oral Capsule
214632650|NCT05738850|DRUG|Placebo|Oral Capsule
214632651|NCT01612429|DIETARY_SUPPLEMENT|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
214632652|NCT03329235|DRUG|PRP|platelet rich plasma
214721369|NCT04611061|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
214721370|NCT04611061|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
214632653|NCT03329235|DRUG|HA|hyaluronic acid
214632654|NCT04864431|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
214632655|NCT04864431|OTHER|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
214632656|NCT04455555|DRUG|LY03003( the name of rotigotine)|LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
214632657|NCT04455555|OTHER|Placebo|Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
214632658|NCT02561091|OTHER|Placebo|
214632659|NCT02561091|DRUG|AM-111 0.4 mg/ml|
214632660|NCT02561091|DRUG|AM-111 0.8 mg/ml|
214632661|NCT01736579|DRUG|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
214632662|NCT05650983|BEHAVIORAL|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
214632663|NCT02542475|DEVICE|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
214632664|NCT00479154|DRUG|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
214721371|NCT04337723|BEHAVIORAL|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
214632665|NCT06045338|BEHAVIORAL|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
214632666|NCT05786625|DEVICE|Ablation|Bronchoscopy and microwave ablation of lung nodule
214632667|NCT04506697|PROCEDURE|Uroflowmetry|The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
214632668|NCT03754244|DRUG|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
214632669|NCT06541405|DRUG|NK520|The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.
214632670|NCT05088707|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214632671|NCT05088707|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
214632672|NCT01531283|DRUG|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
214632673|NCT01531283|DRUG|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
214632674|NCT01531283|DRUG|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
214632675|NCT01531283|DRUG|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
214632676|NCT04669834|OTHER|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
214632677|NCT04669834|OTHER|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
214632678|NCT00650754|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
214632679|NCT00650754|OTHER|Placebo|Placebo
214632680|NCT03090126|OTHER|Therapeutic education|Questionnaires
214632681|NCT05896020|DRUG|SHR- A1811|Subjects with gynaecological malignancies
214632682|NCT00364312|BEHAVIORAL|diet and physical activity|
214632683|NCT04710342|DEVICE|CapBuster|Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
214632684|NCT05808036|OTHER|Dietary intervention: DOMINO app|Life style intervention and diet low in FODMAPs.
214632685|NCT05808036|OTHER|Dietary intervention: low FODMAP diet|Strict low FODMAP diet.
214632686|NCT04943705|DEVICE|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
214632687|NCT06500832|OTHER|Survey-based Data Collection Tool|"The data collection tool to be presented to the participants is planned as a three-part survey. The first part of this form asked 9 questions about the demographic characteristics of the participants consisted of age, gender, marital status, duration in the profession, specialization in dentistry, type of workplace, and off-the-clock work.~The second part of the data collection tool consisted of the 'Defensive Dentistry Practice Survey,'(DDPS) DDPS which is the original language of which is Turkish, is a 5-point Likert-type scale. A total of 12 statements about DDPS which measure the opinions, attitudes, or behaviors of the participants in terms of DDP, the following options are used: strongly disagreed, disagreed, neither disagreed nor agreed, agreed and strongly agreed, each expressing groups of 20%.~The last part of the survey had 3 close-ended questions with yes-no options expressing 50% groups is used."
214632688|NCT00004941|DRUG|monoclonal antibody cA2|
214721372|NCT04493593|BEHAVIORAL|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
214721373|NCT01009736|DIETARY_SUPPLEMENT|tomato-soy juice|
214632689|NCT06220734|PROCEDURE|transurethral resection of the prostate|transurethral resection of the prostate for indicated patients then US was done for early detection of fluid accumulation in the lungs
214632690|NCT06373861|OTHER|no intervention|This study is an observational study without treatment intervention.
214632691|NCT01408147|BEHAVIORAL|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
214632692|NCT05926310|DEVICE|TWIICE Rise|"TWIICE Rise is a lower-limb overground robotic exoskeleton intended for patients with spinal cord injury (SCI).~TWIICE Rise is intended to perform ambulatory functions in rehabilitation institutions, home, or community environment under the supervision of a specially trained coach."
214632693|NCT06341673|DEVICE|Active Transcutaneous Electrical Nerve Stimulation (TENS)|For active group: TENS is to be used to stimulate tibial Nerve at medial aspect of the foot. The stimulation is proved by flexion of the big toe (motor response) and/or tingling sensation of ipsilateral sole of foot (sensory response) by raising the current amplitude, mA, intensity. Increasing the intensity above sensory threshold is recommended but should not be painful
214632694|NCT06341673|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|TENS on the lateral side of the foot, the negative electrode on the top of the foot just above the small toe for conduction and the positive electrode on the bottom of below the smallest toe to avoid the tibial nerve and relevant cutaneous nerves. Participants will be instructed to raise up the intensity until the first and slight tingling sensation on the sole of the foot or toe
214632695|NCT01564927|DEVICE|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
214632696|NCT01564927|DEVICE|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
214721374|NCT01009736|OTHER|laboratory biomarker analysis|
214632697|NCT01564927|DEVICE|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
214632698|NCT01662440|BIOLOGICAL|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
214632699|NCT01662440|BIOLOGICAL|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
214632700|NCT01662440|OTHER|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
214632701|NCT00112905|DRUG|sorafenib tosylate|Given PO
214632702|NCT00112905|OTHER|laboratory biomarker analysis|Optional correlative studies
214632703|NCT03999424|BIOLOGICAL|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
214632704|NCT05174000|DRUG|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
214632705|NCT05174000|DRUG|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
214632706|NCT04170595|BIOLOGICAL|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
214721375|NCT01009736|OTHER|pharmacological study|
214721376|NCT01009736|PROCEDURE|therapeutic conventional surgery|
214721377|NCT03121482|DEVICE|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
214632707|NCT04170595|BIOLOGICAL|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
214632708|NCT04170595|BIOLOGICAL|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
214632709|NCT04170595|BIOLOGICAL|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
214721378|NCT03121482|DEVICE|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
214632710|NCT04170595|BIOLOGICAL|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
214721379|NCT01655745|PROCEDURE|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
214721380|NCT04737759|BEHAVIORAL|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
214632711|NCT04170595|BIOLOGICAL|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
214632712|NCT04647955|DRUG|Itopride|Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
214632713|NCT04647955|DRUG|Placebo|Patients were treated for 8 weeks.
214632714|NCT02600507|DRUG|Lumateperone (ITI-007)|
214632715|NCT02600507|DRUG|Placebo|
214632716|NCT00742339|DRUG|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
214632717|NCT00742339|DRUG|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
214632718|NCT04541004|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
214632719|NCT05048719|DRUG|LY3502970|Administered orally
214632720|NCT05048719|DRUG|Dulaglutide|Administered subcutaneously
214632721|NCT05048719|DRUG|Placebo|Administered orally
214632722|NCT05048719|DRUG|Placebo|Administered subcutaneously
214632723|NCT01952587|BIOLOGICAL|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
214632724|NCT04818515|DRUG|Atogepant|Oral; Tablet
214632725|NCT04818515|DRUG|Ubrogepant|Oral; Tablet
214632726|NCT02514967|DRUG|Blisibimod|Administered via subcutaneous injection once per week
214632727|NCT02514967|DRUG|Placebo|Administered via subcutaneous injection once per week
214721381|NCT04737759|OTHER|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
214721382|NCT00633048|DRUG|NSA-789|
214721383|NCT00633048|DRUG|placebo|
214721384|NCT04420208|PROCEDURE|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
214721385|NCT02260388|DRUG|Nortriptyline|
214721386|NCT02260388|DRUG|Duloxetine|
214721387|NCT02260388|DRUG|Pregabalin|
214721388|NCT02260388|DRUG|Mexiletine|
214721389|NCT03882723|DEVICE|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
214721390|NCT03556865|OTHER|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
214721391|NCT00005883|DRUG|phenethyl isothiocyanate|
214632728|NCT00600015|DRUG|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
214632729|NCT00600015|DRUG|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
214632730|NCT00501982|DRUG|Poractant alfa (Curosurf®)|
214632731|NCT05332119|DEVICE|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
214632732|NCT05332119|OTHER|Control group|Patients will not receive distraction during chest drain removal
214632733|NCT04088344|DIETARY_SUPPLEMENT|isocaloric diet|a 7-day isocaloric diet
214632734|NCT04088344|DIETARY_SUPPLEMENT|Hypercaloric diet|A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
214632735|NCT04088344|OTHER|Liquid meal|
214632736|NCT04088344|RADIATION|PET imaging|
214632737|NCT04088344|OTHER|perfusions of stable tracers|
214632738|NCT04088344|DEVICE|Indirect calorimetry|
214632739|NCT06763913|DEVICE|taVNS|Set the pulse width to 200 microseconds, frequency to 30 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
214632740|NCT06763913|DEVICE|sham taVNS|Set the pulse width to 200 microseconds, frequency to 1 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
214632741|NCT00616109|DRUG|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
214632742|NCT05829525|OTHER|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
214721392|NCT02792283|BIOLOGICAL|whole blood collection|
214721393|NCT00137293|DRUG|GAP-486 (ZP-123)|
214721394|NCT00137293|DRUG|0.9% Sodium Chloride, USP|
214721395|NCT04163913|OTHER|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
214721396|NCT04163913|OTHER|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
214721397|NCT02074904|DRUG|Topiramate|
214721398|NCT02074904|DRUG|Placebo|
214721399|NCT01896661|DRUG|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
214721400|NCT01896661|DRUG|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
214722227|NCT05841641|DEVICE|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
214722228|NCT05841641|PROCEDURE|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
214722229|NCT03855761|BEHAVIORAL|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
214721401|NCT05221255|OTHER|spinal magnetic stimulation|"* Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
214721402|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
214632743|NCT04999189|OTHER|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
214632744|NCT00936624|DRUG|SOTB07|SOTB07 100mg
214632745|NCT00936624|DRUG|SOTB07|SOTB07 200mg
214721403|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
214632746|NCT00936624|DRUG|placebo|placebo
214632747|NCT00936624|DRUG|montelukast|montelukast 10mg po, bid, 12week
214632748|NCT02934009|DEVICE|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
214632749|NCT04480281|DRUG|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
214632750|NCT04480281|DRUG|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
214632751|NCT03110055|DRUG|Grazoprevir/Elbasvir|anti-viral treatment for HCV
214632752|NCT03110055|OTHER|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
214721404|NCT00663104|BEHAVIORAL|exercise|exercise: 3 joint sessions/week for 12 months
214721405|NCT00663104|BEHAVIORAL|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
214632753|NCT03110055|PROCEDURE|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
214632754|NCT05762328|BEHAVIORAL|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
214721406|NCT00663104|BEHAVIORAL|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
214721407|NCT02907281|OTHER|Observational|Observational
214721408|NCT01914783|OTHER|ultrafine particles|exposure to ultrafine particles
214721409|NCT01914783|OTHER|ultrafine particles and ozone|exposure to ultrafine particles and ozone
214721410|NCT01914783|OTHER|clean air|Exposure to clean air.
214722230|NCT03855761|BEHAVIORAL|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
214632755|NCT06840028|OTHER|mHealth/sFitRx|Experimental Group - Will receive a personalized mHealth application and fitness tracker. Specifically, Experimental Group participants will receive the sFitRx smartphone application that provides weekly personalized PA interventions informed by big data analysis. They will also receive a Fitbit Inspire 3 to track real-time PA, with PA data uploaded to Fitabase. Importantly, the PA data from the Fitbit Inspire 3 will inform the big data analyses used to generate the personalized PA intervention provided by the sFitRx application.
214632756|NCT06840028|OTHER|Fitness Tracker|Comparison Group - Will receive the Fitbit Inspire 3 only.
214632757|NCT06343194|DEVICE|Bruxoff ®|Bruxoff ® is a holter that measures the masseter muscle contraction and heart rate.
214632758|NCT00110773|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
214632759|NCT00110773|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
214632760|NCT00292825|DEVICE|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
214632761|NCT00292825|DEVICE|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
214632762|NCT01946607|DRUG|Citalopram|
214632763|NCT01946607|DRUG|Placebo|
214721411|NCT02819349|BEHAVIORAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
214632764|NCT03723382|OTHER|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
214632765|NCT04509778|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
214721412|NCT04176536|DRUG|BI 764198|Capsules
214721413|NCT02017704|RADIATION|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
214722231|NCT02126527|DRUG|auranofin|Given PO
214722232|NCT02126527|DRUG|sirolimus|Given PO
214632766|NCT05173454|BEHAVIORAL|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
214632767|NCT06022263|DRUG|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
214632768|NCT06022263|DRUG|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
214632769|NCT02229552|OTHER|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
214632770|NCT04872101|DRUG|Delgocitinib cream|Cream for topical application
214632771|NCT04872101|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214632772|NCT02915081|OTHER|Blue light|"Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
214632773|NCT05459831|DEVICE|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
214632774|NCT01372904|DRUG|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
214632775|NCT06471556|DRUG|IV Methylprednisolone pulses|Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
214632776|NCT03290235|DRUG|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
214632777|NCT02269527|OTHER|Live music|Providing 1-hour live music 5 days/ week.
214632778|NCT02029287|OTHER|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
214632779|NCT02029287|OTHER|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
214632780|NCT06265766|DEVICE|Active cTBS|10 sessions of active cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
214632781|NCT06265766|DEVICE|Sham cTBS|10 sessions of sham cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
214632782|NCT02115464|DRUG|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
214632783|NCT02115464|RADIATION|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
214632784|NCT03907332|OTHER|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
214632785|NCT04057625|DEVICE|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
214721414|NCT02017704|DRUG|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
214721415|NCT02017704|RADIATION|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
214721416|NCT02017704|DRUG|FOLFOX6|"* Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
214721417|NCT02017704|PROCEDURE|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
214721418|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
214721419|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
214721420|NCT01864317|DEVICE|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
214721421|NCT01864317|OTHER|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
214721422|NCT01864317|OTHER|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
214721423|NCT01864317|OTHER|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
214721424|NCT01864317|OTHER|Humphrey Perimetry|Visual Field Testing
214721425|NCT01864317|OTHER|Applanation Tonometry|Measurement of Intraocular Pressure
214722233|NCT02126527|OTHER|laboratory biomarker analysis|Correlative studies
214722234|NCT02126527|OTHER|pharmacological study|Correlative studies
214722235|NCT01784250|DRUG|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
214721426|NCT05260606|DIAGNOSTIC_TEST|F-18 FDG PET/CT|"1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan."
214721427|NCT02858102|BEHAVIORAL|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
214721428|NCT03381911|OTHER|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
214721429|NCT01121952|OTHER|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
214721430|NCT00232414|DRUG|Quetiapine|
214721431|NCT01553760|PROCEDURE|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
214721432|NCT01553760|PROCEDURE|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
214632786|NCT04349527|PROCEDURE|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
214632787|NCT04349527|PROCEDURE|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
214632788|NCT03807713|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
214632789|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
214632790|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
214632791|NCT03718507|DRUG|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
214632792|NCT03718507|DRUG|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
214632793|NCT00971945|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
214632794|NCT01998828|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
214632795|NCT03354663|DEVICE|TactiCath SE|Ablation to achieve pulmonary vein isolation.
214632796|NCT03691974|DRUG|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
214632797|NCT03691974|OTHER|Placebo|Subcutaneous (SC) every four weeks (Q4W)
214632798|NCT01482364|DEVICE|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
214632799|NCT01482364|DEVICE|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
214632800|NCT03354754|DRUG|LYS228|LYS228 IV infusion every 6 hours
214632801|NCT03354754|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
214632802|NCT02706821|DIETARY_SUPPLEMENT|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
214632803|NCT02706821|DIETARY_SUPPLEMENT|Placebo|Placebo, crossover design
214632804|NCT02670642|DRUG|Esomeprazole|Proton pump inhibitor
214632805|NCT05791656|DEVICE|Mectascrew-C|reconstruction of ACL or PCL rupture
214632806|NCT02837315|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
214632807|NCT02837315|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
214632808|NCT02837315|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
214721433|NCT04289194|DRUG|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
214721434|NCT04289194|DRUG|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
214721435|NCT04289194|DRUG|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
214721436|NCT05369780|DIETARY_SUPPLEMENT|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
214632809|NCT01661140|DRUG|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
214632810|NCT01661140|DRUG|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
214721437|NCT00918346|DRUG|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
214721438|NCT01089218|DRUG|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
214721439|NCT01089218|DRUG|control|no intervention with the same procedure of FB
214632811|NCT01661140|DRUG|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
214632812|NCT00176280|DRUG|Leukine|
214632813|NCT00176280|DRUG|Dexamethasone|
214632814|NCT00746252|DRUG|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
214632815|NCT00746252|DRUG|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
214632816|NCT02242955|DRUG|Diazepam|40 mg per day.
214632817|NCT04255056|DRUG|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
214632818|NCT06223282|OTHER|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
214632819|NCT06223282|OTHER|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
214721440|NCT01964729|DEVICE|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
214721441|NCT01964729|DEVICE|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
214721442|NCT03520205|PROCEDURE|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
214722236|NCT01784250|DRUG|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
214632820|NCT06223282|OTHER|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
214632821|NCT06223282|OTHER|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
214632822|NCT02279680|DEVICE|Electroencephalography|
214632823|NCT02279680|BEHAVIORAL|Neuropsychological assesments|
214632824|NCT02239939|BEHAVIORAL|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
214632825|NCT02239939|BEHAVIORAL|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
214632826|NCT05572762|DEVICE|Cannula plastic part while applying peribulbar block|Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
214632827|NCT05572762|PROCEDURE|traditional technique|the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
214632828|NCT00272974|BEHAVIORAL|Clinic-based counseling|
214632829|NCT02564315|DRUG|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
214632830|NCT02564315|BEHAVIORAL|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
214632831|NCT02564315|BEHAVIORAL|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
214632832|NCT02564315|BEHAVIORAL|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
214632833|NCT02564315|BEHAVIORAL|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
214632834|NCT02564315|BEHAVIORAL|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
214632835|NCT02564315|BEHAVIORAL|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
214721443|NCT03520205|PROCEDURE|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
214632836|NCT02564315|DRUG|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke \>10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke \<=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
214632837|NCT02716610|DRUG|INH 69 U (low)|inhaled human insulin
214632838|NCT02716610|DRUG|INH 69 U (high)|inhaled human insulin
214632839|NCT02716610|DRUG|INH 139 U|inhaled human insulin
214632840|NCT02716610|DRUG|INH 208 U|inhaled human insulin
214632841|NCT02716610|DRUG|LIS 18 U|subcutaneous insulin lispro
214632842|NCT04033835|OTHER|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
214632843|NCT04033835|OTHER|Treatment as usual|Treatment as usual
214632844|NCT06457581|OTHER|Dry Needling|Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.
214632845|NCT06457581|PROCEDURE|Trigger points injections|Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.
214632846|NCT06457581|DRUG|serotonin reuptake inhibitor (SSRI)|serotonin reuptake inhibitor (SSRI)
214632847|NCT00782457|PROCEDURE|RECTAL CANCER RESECTION|
214632848|NCT01759758|OTHER|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
214632849|NCT01759758|OTHER|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
214632850|NCT04582578|DEVICE|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
214632851|NCT01659320|DRUG|Minocycline|Minocycline 100 mg twice daily for 8 weeks
214632852|NCT05162482|BIOLOGICAL|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
214632853|NCT05162482|BIOLOGICAL|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
214632854|NCT05162482|BIOLOGICAL|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
214632855|NCT01514682|DRUG|Anti-inflammatory Combination Therapy|"1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
214632856|NCT01514682|DRUG|Placebo|Non-medication pills; To be taken in morning and evening intervals.
214632857|NCT00406770|DEVICE|Light therapy|
214632858|NCT01210339|DRUG|Clopidogrel|Clopidogrel
214632859|NCT01210339|DRUG|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
214632860|NCT06038786|BEHAVIORAL|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
214632861|NCT01870401|DEVICE|Lutonix DCB|
214632862|NCT01870401|DEVICE|Uncoated PTA Catheter|
214632863|NCT05381064|DEVICE|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
214632864|NCT05562986|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
214632865|NCT02684214|BEHAVIORAL|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
214632866|NCT02684214|BEHAVIORAL|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
214632867|NCT03023943|OTHER|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
214632868|NCT00992316|DRUG|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
214632869|NCT03826693|DRUG|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
214632870|NCT03826693|DRUG|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
214632871|NCT03878511|DIETARY_SUPPLEMENT|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
214632872|NCT03878511|DIETARY_SUPPLEMENT|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
214632873|NCT00951730|OTHER|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
214632874|NCT03506542|DEVICE|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
214632875|NCT03506542|PROCEDURE|Phacotrabeculectomy|Trabeculectomy with cataract extraction
214632876|NCT03506542|DRUG|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
214632877|NCT00699517|DRUG|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
214632878|NCT00699517|DRUG|Placebo|I.V. infusion followed by administration of cisplatin
214632879|NCT05096988|DIETARY_SUPPLEMENT|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
214721444|NCT01813968|PROCEDURE|Ischemic postconditioning|
214721445|NCT04115345|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
214721446|NCT06291545|DEVICE|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
214632880|NCT04651387|DIETARY_SUPPLEMENT|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
214632881|NCT00505466|BEHAVIORAL|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
214632882|NCT00625092|DRUG|fluorouracil|Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
214632883|NCT00625092|DRUG|leucovorin calcium|Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
214632884|NCT00625092|DRUG|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2
214632885|NCT00625092|PROCEDURE|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
214632886|NCT01602692|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
214632887|NCT01602692|DRUG|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
214632888|NCT02105454|DRUG|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
214632889|NCT02105454|DRUG|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
214632890|NCT02105454|DRUG|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
214632891|NCT01667471|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
214632892|NCT00753870|BIOLOGICAL|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
214632893|NCT02503904|PROCEDURE|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
214632894|NCT02503904|DEVICE|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
214632895|NCT02503904|DRUG|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
214632896|NCT01863511|DRUG|loop diuretic|
214632897|NCT01863511|DRUG|tolvaptan|
214632898|NCT01863511|PROCEDURE|ultrafiltration|
214632899|NCT00493870|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
214632900|NCT00493870|DRUG|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
214632901|NCT00493870|DRUG|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
214632902|NCT00272038|DRUG|Tarceva|150mg QD
214632903|NCT02211274|OTHER|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
214632904|NCT04940143|DRUG|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
214632905|NCT04940143|OTHER|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
214632906|NCT03368261|OTHER|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
214632907|NCT03294018|OTHER|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
214632908|NCT03605680|DRUG|Centanafadine SR|100 mg, BID, oral tablets
214632909|NCT03605680|OTHER|Placebo|BID, oral tablet.
214632910|NCT03605680|DRUG|Centanafadine SR|200 mg, BID, oral tablets
214632911|NCT02721355|DIETARY_SUPPLEMENT|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
214632912|NCT01002807|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
214721447|NCT06291545|DEVICE|ScoreFlex NC Coronary Dilatation Catheter|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
214721448|NCT02225236|BEHAVIORAL|Classroom Intervention|
214721449|NCT03676205|BIOLOGICAL|PRP|Platelet-Rich Plasma
214721450|NCT03676205|OTHER|Traumeel|Homeophatic Treatment
214721451|NCT01428440|RADIATION|18FML10|apoptosis imaging radio ligand
214721452|NCT06004193|BEHAVIORAL|Exercise|At least 150 minutes of exercise in a week
214721453|NCT01421069|DRUG|etanercept|"Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW."
214721454|NCT02491216|OTHER|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
214721455|NCT06224868|OTHER|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
214721456|NCT06224868|OTHER|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
214721457|NCT00781404|DRUG|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
214721458|NCT00565006|DRUG|MK0859|
214721459|NCT03850171|OTHER|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
214721460|NCT05181241|DRUG|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
214721461|NCT01335594|PROCEDURE|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
214632913|NCT01002807|DRUG|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
214632914|NCT01002807|DRUG|Glucophage|Tablets, Oral, 1000 mg, Single Dose
214632915|NCT02535182|OTHER|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
214632916|NCT05552911|PROCEDURE|Pretreatment strategies before drug balloon therapy|Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
214632917|NCT05552911|PROCEDURE|Different types of in-stent restenosis were treated with drug-coated balloons|A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
214632918|NCT00356278|DRUG|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
214632919|NCT00356278|DRUG|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
214632920|NCT00356278|BEHAVIORAL|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
214632921|NCT00356278|DRUG|Placebo|Placebo will be administered in the same manner as the active drugs.
214632922|NCT02341092|BEHAVIORAL|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
214632923|NCT05453643|BEHAVIORAL|sleep deprivation patterns|Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
214721462|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
214721463|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
214632924|NCT06344078|PROCEDURE|sigmoid resection and anastomosis / stoma|intestinal resection and recostruction or creation of stoma
214632925|NCT04395794|DIAGNOSTIC_TEST|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
214632926|NCT04395794|OTHER|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
214632927|NCT06538883|DRUG|Sedation with Ciprofol|During the drug administration period, ciprofol were IV infused at loading doses of 0.1 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
214721464|NCT01095666|DRUG|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
214721465|NCT01095666|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
214721466|NCT01095666|DRUG|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
214721467|NCT04677049|DRUG|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
214721468|NCT00853619|OTHER|Service based decision support intervention|Delivering CDS via services
214721469|NCT05152667|DEVICE|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
214721470|NCT00369044|DRUG|prednisone|
214721471|NCT04556448|OTHER|Aligners|Clear aligners
214721472|NCT04556448|OTHER|Clear braces|Clear braces
214721473|NCT04000022|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
214721474|NCT02447640|DRUG|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
214721475|NCT02447640|RADIATION|[18F]FPEB|radiotracer used for PET scanning
214721476|NCT03555071|BIOLOGICAL|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
214721477|NCT03555071|BIOLOGICAL|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
214721478|NCT03111589|BIOLOGICAL|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
214721479|NCT03111589|DIAGNOSTIC_TEST|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
214632928|NCT06538883|DRUG|Sedation with Propofol|During the drug administration period, propofol were IV infused at loading doses of 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Propofol were then immediately administered at an initial maintenance dose of 1.5 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
214632929|NCT00883337|DRUG|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
214632930|NCT00883337|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
214632931|NCT02230631|OTHER|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
214632932|NCT00242008|DRUG|Rotigotine|
214632933|NCT05284682|DIAGNOSTIC_TEST|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
214632934|NCT03253146|DIAGNOSTIC_TEST|VIM detection|VIM expression in serum and lymphocytes detection
214632935|NCT02106312|RADIATION|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
214632936|NCT00527605|DRUG|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
214632937|NCT00527605|DRUG|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
214632938|NCT03697187|DRUG|rhC1INH|Recombinant human C1 inhibitor
214632939|NCT03365466|DRUG|Low dose aspirin|LDA 25mg tid
214632940|NCT03365466|DRUG|Low molecular weight heparin|LMWH 5000u IH qd
214632941|NCT03365466|DRUG|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
214632942|NCT03365466|DRUG|no treatment|Patients who did not receive any treatment.
214721480|NCT04733872|DIETARY_SUPPLEMENT|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
214632943|NCT02838849|DIETARY_SUPPLEMENT|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
214632944|NCT02838849|DIETARY_SUPPLEMENT|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
214632945|NCT03556930|DEVICE|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
214632946|NCT03282760|BIOLOGICAL|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
214632947|NCT04789356|BIOLOGICAL|Adsorbed SARS-CoV-2 (inactivated) vaccine|600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.
214632948|NCT01592760|DEVICE|air-Q SP|air-Q SP placement for airway maintenance.
214721481|NCT04733872|DIETARY_SUPPLEMENT|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
214721482|NCT01511640|DRUG|Pregabalin|pregabalin 2x daily for duration of study
214721483|NCT01511640|DRUG|Placebo|placebo 2x daily for duration of study
214632949|NCT01592760|DEVICE|air-Q|air-Q placement for airway maintenance.
214632950|NCT01592760|DEVICE|i-gel|i-gel placement for airway maintenance.
214632951|NCT04312009|DRUG|Losartan|Losartan; 50 mg daily; oral administration
214632952|NCT04312009|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
214632953|NCT05216965|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
214632954|NCT01008280|DRUG|baclofen|baclofen 10 mg tid
214632955|NCT01008280|DRUG|placebo|placebo pill tid
214632956|NCT04469478|OTHER|Survey and interview|Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
214632957|NCT00280410|DRUG|E7337|
214632958|NCT01780610|DRUG|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5\~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
214632959|NCT01780610|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
214632960|NCT02177760|DRUG|Sirolimus|
214632961|NCT03146572|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
214632962|NCT03146572|OTHER|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
214632963|NCT01146678|DRUG|Insulin glargine HOE901|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214632964|NCT01146678|DRUG|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214632965|NCT03347877|PROCEDURE|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
214632966|NCT03347877|PROCEDURE|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
214632967|NCT03347877|DEVICE|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
214632968|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
214721484|NCT02489851|PROCEDURE|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
214721485|NCT02489851|PROCEDURE|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
214721486|NCT02997774|OTHER|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
214721487|NCT02997774|OTHER|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
214721488|NCT04418739|DRUG|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
214721489|NCT01459887|DRUG|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
214721490|NCT01459887|DRUG|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
214632969|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
214632970|NCT05768672|BEHAVIORAL|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
214632971|NCT05729373|DRUG|SEP-363856|once daily tablet
214632972|NCT05729373|DRUG|Placebo|once daily tablet
214632973|NCT05550311|OTHER|Robot-assisted rehabilitation|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program. Range of motion exercises will display on the monitor as a game form. There are 4 games available on the computer (airplane game, rabbit shooting game, ball game, and shopping game) and these games can provide exercises for three joints (shoulder, elbow wrist). There are also 3 different levels of resistance apparatus for each joint. People with a full range of motion can do these exercises with resistance. Before starting the rehabilitation, which joint and which movement to do is determined. To the person; After explaining the desired movement and how to play the game shown on the monitor, the exercises are started. The exercises last 45 minutes, during which exercises are performed for the shoulder, elbow, and wrist.
214632974|NCT05550311|OTHER|Conventional rehabilitation|The conventional Rehabilitation Program consists of; range of motion exercises, strengthening exercises, stretching exercises, balance, and walking exercises and Bobath based neurophysiological approaches.
214632975|NCT03825874|OTHER|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
214632976|NCT03825874|OTHER|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
214632977|NCT01892358|BEHAVIORAL|SKIN Intervention|
214632978|NCT01892358|OTHER|Treatment as Usual|
214632979|NCT05909202|DEVICE|Sham VR|Nature-based non-immersive VR program
214632980|NCT05909202|DEVICE|Active VR|Nature-based immersive VR program
214632981|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
214632982|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
214632983|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
214721491|NCT04063644|DEVICE|Vis Glyc Neo|1 drop in each eye, three times a day.
214721492|NCT04063644|DEVICE|Physiological saline solution|1 drop in each eye, three times a day.
214722237|NCT01784250|DRUG|Placebo|Sugar pill manufactured to mimic a drug
214632984|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
214632985|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
214632986|NCT00814229|BIOLOGICAL|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
214632987|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
214632988|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
214632989|NCT00814229|BIOLOGICAL|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
214632990|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
214632991|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
214632992|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
214632993|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
214632994|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
214632995|NCT03790683|DEVICE|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
214632996|NCT03790683|DEVICE|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
214721493|NCT05960136|PROCEDURE|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
214721494|NCT05960136|PROCEDURE|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
214632997|NCT06497569|BEHAVIORAL|Dietitian Consultation|"Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention."
214721495|NCT05591651|DRUG|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
214632998|NCT06497569|BEHAVIORAL|Survey|"Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention."
214632999|NCT06497569|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
214633000|NCT06497569|BEHAVIORAL|Referral to Dietitian|Usual Care condition referral to a dietitian based on physician discretion.
214633001|NCT06497569|BEHAVIORAL|Social Determinants of Health Survey (SDOH)|"Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy)."
214633002|NCT03907852|BIOLOGICAL|gavo-cel|gavo-cel
214633003|NCT03907852|DRUG|fludarabine|lymphodepletion chemotherapy
214633004|NCT03907852|DRUG|cyclophosphamide|lymphodepletion chemotherapy
214633005|NCT03907852|DRUG|Nivolumab|immuno-oncology agent
214633006|NCT03907852|DRUG|Ipilimumab|immuno-oncology agent
214633007|NCT06156579|DRUG|Decitabine|Decitabine 20 mg/m\^2, i.v., once daily, 10 days
214633008|NCT06156579|DRUG|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
214633009|NCT04671849|DRUG|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
214633010|NCT05779982|PROCEDURE|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
214633011|NCT05525117|BEHAVIORAL|covivio (additional to treatment as usual)|Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
214633012|NCT05525117|OTHER|treatment as usual|Participants may continue with any treatment that they require (treatment as usual)
214633013|NCT00057473|DRUG|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
214633014|NCT00057473|DRUG|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
214633015|NCT02750462|OTHER|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
214633016|NCT02750462|OTHER|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
214633017|NCT06422741|DIETARY_SUPPLEMENT|grape seed proanthocyanidin extract|250 mg of product presented in capsule form will be given.
214633018|NCT06422741|DIETARY_SUPPLEMENT|Placebo|165 mg of cellulose will be given presented in capsule form.
214633019|NCT01941407|DRUG|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
214633020|NCT02078076|DEVICE|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
214633021|NCT04378803|BEHAVIORAL|Mindfulness training (MT) Connect|MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.
214633022|NCT01070160|DRUG|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
214633023|NCT01070160|DRUG|Metformin|per clinical care guidelines
214633024|NCT00539695|BIOLOGICAL|IL-2|"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed \>grade I side effects to IL-2 and has not developed \>grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
214633025|NCT05215340|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214633026|NCT05215340|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214633027|NCT05468697|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
214633028|NCT05468697|DRUG|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
214633029|NCT06076408|OTHER|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
214633030|NCT06076408|OTHER|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
214633031|NCT06395324|OTHER|High arabinose diet|Participants will consume a high arabinose diet for 18 consecutive days.
214633032|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
214633033|NCT05879419|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
214633034|NCT05879419|OTHER|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
214633035|NCT05879419|OTHER|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
214633036|NCT05879419|OTHER|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
214633037|NCT05879419|OTHER|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
214633038|NCT05879419|OTHER|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
214633039|NCT06798597|BEHAVIORAL|Health4Life app|Health4Life is a program based on the anticipatory guidance approach aiming to support parents create healthy lifestyle behaviours starting in early infancy. The intervention consists of ten themes over a 16 month period and incorporates interactive features such as quizzes.
214633040|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
214633041|NCT05371886|OTHER|Dose-effect relationship of morphine +/- midazolam administration|Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
214721496|NCT05591651|DRUG|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
214633042|NCT06797869|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
214633043|NCT06797869|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
214633044|NCT05098197|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214633045|NCT05044065|OTHER|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
214633046|NCT06570304|PROCEDURE|iCount Device|"Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory."
214633047|NCT05010005|DRUG|Ruxolitinib|Ruxolitinib 20mg BID
214633048|NCT05010005|DRUG|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
214633049|NCT01485627|BEHAVIORAL|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
214633050|NCT02476721|OTHER|detection of pulmonary embolism|
214633051|NCT00152542|DRUG|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
214633052|NCT00152542|DRUG|Placebo|No iNO given for days 1-7
214633053|NCT06275503|BEHAVIORAL|Screening invitation mode|Cluster randomized study to compare mode of invitation
214633054|NCT06126302|OTHER|Birth year|we divided the patients according to patients' birth year
214633055|NCT04672759|DRUG|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
214633056|NCT04672759|DRUG|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
214633057|NCT02989415|OTHER|Mechanical Ventilation|Mechanical ventilation during robotic surgery
214633058|NCT03587454|DIAGNOSTIC_TEST|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
214633059|NCT05535348|BEHAVIORAL|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
214633060|NCT02335827|PROCEDURE|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
214633061|NCT04469413|DRUG|Paracetamol Infusion|Continuous and Standard Intermittent Boluses Paracetamol Infusion
214633062|NCT00003022|RADIATION|iodine I 131 monoclonal antibody 3F8|
214633063|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
214633064|NCT03239821|DRUG|Codeine Phosphate|58.8 mg codeïne phosphate
214633065|NCT03239821|DRUG|Placebo|Sirupus Simplex
214633066|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
214633067|NCT01687764|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
214633068|NCT01687764|OTHER|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
214633069|NCT01687764|BEHAVIORAL|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
214633070|NCT01687764|BEHAVIORAL|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
214633071|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
214721497|NCT05825586|DEVICE|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
214633072|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
214633073|NCT03798821|DIETARY_SUPPLEMENT|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
214633074|NCT00160459|DRUG|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
214633075|NCT00160459|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
214633076|NCT00160459|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
214633077|NCT00160459|DRUG|Placebo|Tablet, oral Daily for 12 weeks
214633078|NCT02246062|BEHAVIORAL|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
214633079|NCT02246062|BEHAVIORAL|smartphone|the child received smartphone application immediately before entering the operating room
214633080|NCT06239987|BEHAVIORAL|Care-oriented Practical Training|The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
214633081|NCT04388150|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
214633082|NCT05300178|PROCEDURE|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
214633083|NCT06221163|OTHER|collection of biographical and sociological data|collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
214633084|NCT03992937|DRUG|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
214633085|NCT03992937|DEVICE|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
214633086|NCT01452334|BIOLOGICAL|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
214633087|NCT02499068|DEVICE|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
214633088|NCT02302898|BEHAVIORAL|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
214633089|NCT02302898|OTHER|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
214633090|NCT02302898|OTHER|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
214633091|NCT02501265|BEHAVIORAL|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
214633092|NCT02501265|BEHAVIORAL|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
214633093|NCT02501265|DRUG|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
214633094|NCT02501265|DRUG|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
214633095|NCT06195722|OTHER|simulation|parenteral drug simulation
214633096|NCT03025958|DRUG|Nimotuzumab|Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.
214633097|NCT03025958|RADIATION|Radiation|Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
214633098|NCT01681420|BEHAVIORAL|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
214633099|NCT01681420|BEHAVIORAL|Blood Donation|Blood donation without HIV counseling
214721498|NCT03109444|DIAGNOSTIC_TEST|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
214721499|NCT00744692|BIOLOGICAL|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
214721500|NCT00744692|DRUG|Reduced Intensity Conditioning|
214721501|NCT01870791|DRUG|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
214721502|NCT03170908|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
214721503|NCT02253628|OTHER|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
214721504|NCT02253628|OTHER|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
214633100|NCT01441531|DRUG|gabapentin 600 mg po|Given one hour before surgery
214633101|NCT01441531|DRUG|Placebo pill given one hour before surgery|Placebo pill given
214633102|NCT02026609|OTHER|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
214633103|NCT02026609|OTHER|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
214633104|NCT05785143|PROCEDURE|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
214633105|NCT00841685|DEVICE|Goldlock|Insertion of Goldlock marker
214633106|NCT00841685|DEVICE|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
214633107|NCT00841685|DEVICE|Visicoil larger size|Insertion of Visicoil, larger size, marker
214633108|NCT00841685|DEVICE|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
214633109|NCT00841685|DEVICE|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
214633110|NCT02014064|DRUG|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)"
214721505|NCT02253628|OTHER|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
214633111|NCT02014064|OTHER|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
214633112|NCT03482414|OTHER|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
214633113|NCT03482414|OTHER|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
214633114|NCT03482414|OTHER|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
214633115|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the Turin group|Fracture classification annotations provided by the Turin group: fracture vs non-fracture, and, if fracture, the Arbeitsgemeinschaft für Osteosynthesefragen (AO, in English, Association for the Study of Internal Fixation)/Orthopedic Trauma Association (OTA) classification.
214633116|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the AO expert surgeon group|Fracture classification annotations provided by the AO expert surgeon group: fracture vs non-fracture, and, if fracture, the AO/OTA classification.
214633117|NCT01527214|RADIATION|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
214721506|NCT02253628|OTHER|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
214721507|NCT03480646|DRUG|CPI-1205|Administered orally
214721508|NCT03480646|DRUG|Enzalutamide|Administered orally
214721509|NCT03480646|DRUG|Abiraterone/Prednisone|Administered orally
214633118|NCT02202876|OTHER|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
214633119|NCT02202876|OTHER|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
214633120|NCT02202876|OTHER|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
214633121|NCT02202876|OTHER|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
214633122|NCT02202876|OTHER|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
214633123|NCT02497859|BEHAVIORAL|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
214633124|NCT02497859|BEHAVIORAL|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
214633125|NCT02497859|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
214633126|NCT02497859|BEHAVIORAL|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
214633127|NCT00416247|BEHAVIORAL|Hypnosis|Hypnosis
214633128|NCT00075504|DRUG|triapine|Given IV
214633129|NCT00075504|DRUG|gemcitabine|Given IV
214721510|NCT04894227|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214722238|NCT00910936|BEHAVIORAL|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
214633130|NCT03202966|OTHER|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
214633131|NCT02260843|OTHER|Generic Fitness|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
214633132|NCT02260843|OTHER|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
214633133|NCT03757910|DRUG|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
214633134|NCT03757910|DRUG|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
214633135|NCT03179332|DRUG|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
214633136|NCT03179332|DRUG|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
214633137|NCT03179332|DRUG|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
214633138|NCT05455112|BIOLOGICAL|RUTI® Vaccine|One subcutaneous injection of RUTI 25µg FCMtb
214633139|NCT05455112|BIOLOGICAL|Placebo|One subcutaneous injection of saline
214633140|NCT02474966|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
214633141|NCT01142726|DRUG|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
214633142|NCT01142726|DRUG|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
214633143|NCT01142726|DRUG|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
214633144|NCT01142726|DRUG|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
214633145|NCT03608176|OTHER|PASO diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
214633146|NCT03608176|OTHER|Low-fat diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
214633147|NCT03608176|OTHER|Waiting list group|This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
214633148|NCT04360902|OTHER|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
214633149|NCT01568593|DEVICE|T2750|1 drop in each eye 3 to 6 times daily during 84 days
214633150|NCT01568593|DEVICE|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
214633151|NCT03304015|BEHAVIORAL|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
214633152|NCT00865865|PROCEDURE|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
214633153|NCT00865865|PROCEDURE|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
214633154|NCT02138032|BEHAVIORAL|Gains Framed Message|
214633155|NCT02138032|BEHAVIORAL|Loss Framed Message|
214633156|NCT04755049|DIAGNOSTIC_TEST|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire
214633157|NCT05186142|OTHER|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
214633158|NCT04204733|BEHAVIORAL|Mobile application|Mobile application that incorporates biosensor feedback, teleconsultation, and online group physical activity classes
214633159|NCT03003208|OTHER|Pulmonary rehabilitation|An exercise and education program
214633160|NCT06428578|OTHER|FBM-In person|Participants will receive two home visits by a CHW. Each home visit will last about 30 minutes, during which the CHW will assist the woman with community resources and help with enrolling in any state or federal nutrition and medical programs. Furthermore, the participants will be given access to a private Facebook group for nutrition, health education, and social support. Home visits will occur during the second and fifth weeks of the study.
214633161|NCT06428578|OTHER|FBM-Virtual|Participants will receive access to a virtual platform which will have information on national, state, and local food and medical resources, as well as local community resources, and will have access to a private Facebook group for nutrition, health education, and social support.
214633162|NCT06428578|OTHER|home delivered food boxes|Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
214633163|NCT00892632|PROCEDURE|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
214633164|NCT05559229|PROCEDURE|laparoscopic whole-layer cholecystectomy|laparoscopic whole-layer cholecystectomy.
214633165|NCT05821803|OTHER|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
214633166|NCT05821803|OTHER|Foot Core Exercises|4 weeks including
214633167|NCT03445091|DEVICE|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
214633168|NCT03020732|PROCEDURE|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
214633169|NCT03020732|PROCEDURE|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
214633170|NCT04735094|DIAGNOSTIC_TEST|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
214633171|NCT03651596|BEHAVIORAL|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
214633172|NCT03651596|BEHAVIORAL|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
214633173|NCT02111993|DEVICE|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
214633174|NCT02111993|DEVICE|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
214633175|NCT03713944|DRUG|Carboplatin|Carboplatin, AUC 5
214633176|NCT03713944|DRUG|Pemetrexed|Pemetrexed 500mg/m2
214633177|NCT03713944|DRUG|Atezolizumab|Atezolizumab 1200mg
214633178|NCT03713944|DRUG|Bevacizumab|Bevacizumab 15mg/kg
214633179|NCT03671031|PROCEDURE|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
214633180|NCT03671031|PROCEDURE|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
214633181|NCT05797701|DRUG|SAR443820|Tablet by oral administration
214633182|NCT05797701|DRUG|SAR443820|Capsule by oral administration
214633183|NCT05987111|BEHAVIORAL|Pilates|Pilates exercises were applied twice a week for 4 weeks in both groups. The sessions were supervised by an Australian Physiotherapy and Pilates Institute (APPI) certified physiotherapist as 5 minutes of warm-up, 45 minutes of exercise and 5 minutes of cool-down periods.
214633184|NCT03730337|DRUG|ONO-7475|ONO-7475 specified dose on specified days
214633185|NCT03730337|DRUG|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
214633186|NCT03134352|DRUG|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
214633187|NCT03134352|DRUG|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
214633188|NCT00419380|DRUG|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
214633189|NCT03223545|BEHAVIORAL|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
214722239|NCT04146402|DRUG|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
214633190|NCT03223545|BEHAVIORAL|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
214633191|NCT01325012|PROCEDURE|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
214633192|NCT01325012|PROCEDURE|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
214633193|NCT02236052|BIOLOGICAL|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
214633194|NCT02236052|BIOLOGICAL|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
214633195|NCT02236052|BIOLOGICAL|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
214633196|NCT02236052|BIOLOGICAL|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
214633197|NCT02236052|BIOLOGICAL|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
214633198|NCT02236052|BIOLOGICAL|Placebo|A single dose of placebo
214633199|NCT00440505|DRUG|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
214633200|NCT00440505|DRUG|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
214633201|NCT00440505|DRUG|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
214633202|NCT04074928|BIOLOGICAL|QIVc|Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.
214633203|NCT04074928|BIOLOGICAL|Comparator QIV|Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
214633204|NCT01309178|DRUG|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
214633205|NCT01309178|DRUG|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
214633206|NCT00962832|DRUG|Placebo|Placebo was supplied as a sterile liquid solution.
214633207|NCT00962832|DRUG|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
214633208|NCT02014636|DRUG|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
214633209|NCT02014636|DRUG|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
214633210|NCT02525159|DIETARY_SUPPLEMENT|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
214633211|NCT02525159|OTHER|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
214633212|NCT00758745|DEVICE|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
214633213|NCT00758745|DEVICE|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
214633214|NCT01130571|PROCEDURE|Xenografts and cell cultures|
214633215|NCT02950220|DRUG|Ibrutinib|Given PO
214633216|NCT02950220|OTHER|Laboratory Biomarker Analysis|Correlative studies
214633217|NCT02950220|BIOLOGICAL|Pembrolizumab|Given IV
214633218|NCT02685709|DRUG|Octreotide capsules|
214633219|NCT00821639|BEHAVIORAL|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
214633220|NCT02656602|OTHER|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
214633221|NCT01903499|OTHER|Other: Bean patty|
214633222|NCT01903499|OTHER|Other: Beef patty|
214633223|NCT05218512|OTHER|WB-EMS|"The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS."
214633224|NCT00644774|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
214633225|NCT00644774|DRUG|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
214633226|NCT02703311|DEVICE|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
214633227|NCT04643028|OTHER|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
214633228|NCT04643028|OTHER|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
214633229|NCT04643028|OTHER|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
214633230|NCT00163774|DEVICE|Brain oxygenation and microdialysis catheters|
214633231|NCT02691442|DRUG|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
214633232|NCT02691442|DRUG|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
214633233|NCT02691442|DRUG|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
214633234|NCT00002753|RADIATION|iodine I 131 monoclonal antibody 81C6|
214633235|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
214633236|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
214633237|NCT02069899|DRUG|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
214633238|NCT06216639|DRUG|Bismuth Subcitrate|Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
214633239|NCT06216639|DRUG|Esomeprazole|Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
214633240|NCT06216639|DRUG|Metronidazole|Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
214633241|NCT06216639|DRUG|Amoxicillin|Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
214633242|NCT06216639|DRUG|Clarithromycin|Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
214633243|NCT06216639|DRUG|Levofloxacin|Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
214633244|NCT04344938|OTHER|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality|Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
214633245|NCT05223946|DIAGNOSTIC_TEST|Microwave Radiometry|The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
214633246|NCT05223946|DEVICE|SCENAR-CHENS-01|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
214633247|NCT05223946|COMBINATION_PRODUCT|Traditional Combination Therapy|ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
214633248|NCT02511730|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
214633249|NCT02511730|DEVICE|FFDM|FujiFilm Aspire Cristalle System
214633250|NCT06424028|OTHER|Right Ventricular Infarct|Consecutive patients presented with isolated inferior, infero-posterior and inferolateral wall MI with or without acute right ventricular infarction.
214633251|NCT05220826|PROCEDURE|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
214633252|NCT04199637|OTHER|TVG|Therapeutic video game
214633253|NCT04235556|BEHAVIORAL|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
214633254|NCT05607875|BEHAVIORAL|The Grow to Recovery Train-the-Trainer program|"Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training."
214633255|NCT05607875|OTHER|Control group|Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
214633256|NCT00332995|DRUG|dapivirine (TMC120) vaginal ring|
214633257|NCT04589273|DIETARY_SUPPLEMENT|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
214633258|NCT04589273|OTHER|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
214633259|NCT05284123|OTHER|Self-compassion workshop|The self-compassion workshop instructs participants to reflect on a source of shame, connect with their suffering related to it, and then direct feelings of support and understanding towards their suffering via a few brief writing tasks. This workshop also provides participants with basic information about mental health resources.
214722240|NCT04146402|DRUG|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
214633260|NCT05284123|OTHER|Mental health literacy workshop|The mental health literacy workshop provides participants with information about the symptoms and treatment of common mental disorders, and asks participants to reflect on what they learned through a couple brief writing tasks. This workshop also provides participants with basic information about mental health resources.
214633261|NCT05284123|OTHER|Control workshop|The control workshop provides participants with basic information about mental health resources.
214633262|NCT04417894|DRUG|dupilumab|Solution for subcutaneous (SC) injection administration
214633263|NCT04417894|DRUG|Placebo|Solution for SC injection administration
214633264|NCT01001000|PROCEDURE|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
214633265|NCT06106464|OTHER|Aerobic exercise+6.5 h of prolonged sitting|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
214633266|NCT06106464|OTHER|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
214633267|NCT06106464|OTHER|Aerobic exercise+4 minutes of walking breaks every 1-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
214722241|NCT06011785|DRUG|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
214722242|NCT01779895|DIETARY_SUPPLEMENT|Lactobacillus paracasei probiotic strain|
214721511|NCT05495191|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
214721512|NCT03592394|DEVICE|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
214721513|NCT01787851|DRUG|Triheptanoin oil|
214721514|NCT01577628|DRUG|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
214721515|NCT03250130|BEHAVIORAL|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
214721516|NCT00215228|DRUG|duloxetine vs. escitalopram|
214721517|NCT05078671|DRUG|Olaparib|olaparib treatment
214721518|NCT05078671|DRUG|Cobicistat|Pharmacokinetic booster
214721519|NCT01058057|DRUG|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
214721520|NCT05226572|DIAGNOSTIC_TEST|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
214721521|NCT06093945|DRUG|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
214721522|NCT06093945|DRUG|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
214721523|NCT00841672|DRUG|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
214722243|NCT01779895|DIETARY_SUPPLEMENT|Placebo|maltodextrin
214633268|NCT06106464|OTHER|Aerobic exercise+8 minutes of walking breaks every 2-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
214633269|NCT02790151|BEHAVIORAL|Standard Therapy|Learning and practicing Memory strategies
214633270|NCT02790151|BEHAVIORAL|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
214633271|NCT00262873|DRUG|bortezomib|
214633272|NCT04354714|DRUG|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
214633273|NCT04354714|PROCEDURE|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
214633274|NCT00634153|OTHER|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
214721524|NCT00841672|DRUG|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
214721525|NCT02932319|DEVICE|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
214721526|NCT02932319|OTHER|expectative|expectative until the next day befor starting the induction
214721527|NCT00356057|DEVICE|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
214633275|NCT06454253|DEVICE|Da Vinci Robot Surgical System|Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system
214633276|NCT06046144|DIAGNOSTIC_TEST|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
214633277|NCT06046144|DIAGNOSTIC_TEST|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
214633278|NCT06046144|DIAGNOSTIC_TEST|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
214633279|NCT02890810|OTHER|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
214633280|NCT02890810|OTHER|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
214633281|NCT03576937|DIAGNOSTIC_TEST|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
214633282|NCT01308970|BEHAVIORAL|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
214633283|NCT01308970|BEHAVIORAL|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
214633284|NCT01308970|BEHAVIORAL|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
214633285|NCT00449462|PROCEDURE|consumption of CLA enriched food|
214633286|NCT03477760|BIOLOGICAL|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
214633287|NCT03440814|DRUG|DCCR|Once daily oral administration
214633288|NCT03440814|DRUG|Placebo for DCCR|Once daily oral administration
214633289|NCT01926288|DRUG|Entecavir maleate tablets|
214633290|NCT01926288|DRUG|blank Baraclude tablets|
214633291|NCT01926288|DRUG|Blank maleate entecavir tablets|
214633292|NCT01926288|DRUG|Baraclude tablets|
214633293|NCT06421558|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
214633294|NCT06421558|DEVICE|Transcutaneous Electrical Stimulation|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
214722244|NCT06063837|BEHAVIORAL|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
214633295|NCT01201161|DRUG|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
214633296|NCT01201161|OTHER|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
214633297|NCT02678390|DIETARY_SUPPLEMENT|MCT|A 5 day consecutive MCT intake of 30 g/day.
214721528|NCT02755610|OTHER|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
214721529|NCT01180764|DRUG|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
214721530|NCT01180764|DRUG|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
214721531|NCT06276842|DRUG|Inferior Alveolar Nerve Block|Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
214722245|NCT04268706|DRUG|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
214633298|NCT02678390|DIETARY_SUPPLEMENT|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
214633299|NCT02678390|DIETARY_SUPPLEMENT|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
214633300|NCT02678390|DIETARY_SUPPLEMENT|Control day|No MCT or aerobic exercise
214633301|NCT00750633|DRUG|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
214633302|NCT00750633|DRUG|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
214633303|NCT00750633|DRUG|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
214633304|NCT00750633|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
214633305|NCT03268915|DIAGNOSTIC_TEST|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
214633306|NCT01616407|DRUG|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
214633307|NCT01616407|DRUG|Methylphenidate|40 mg per os, single dose
214633308|NCT01616407|DRUG|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
214633309|NCT01632566|DRUG|Placebo|Capsules administered orally
214633310|NCT01632566|DRUG|LY3031207|Administered orally
214633311|NCT01632566|DRUG|Celecoxib|Administered orally
214633312|NCT01632566|DRUG|Simvastatin|Administered orally
214633313|NCT05594043|DRUG|MK-6598|Oral tablet
214633314|NCT05594043|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
214721532|NCT06276842|DRUG|Buccal Infiltration|Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
214721533|NCT06276842|COMBINATION_PRODUCT|Inferior Alveolar Nerve Block and Buccal Infiltration|Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
214633315|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
214633316|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
214633317|NCT01318109|DRUG|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
214721534|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
214721535|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
214721536|NCT00750178|DRUG|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
214721537|NCT00274040|DRUG|Tiotropium|
214721538|NCT00274040|DRUG|Ipratropium|
214721539|NCT02854670|DRUG|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
214721540|NCT02233907|DRUG|Ventilat® - metered dose inhaler|
214721541|NCT05940441|DRUG|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
214721542|NCT01451398|DRUG|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
214721543|NCT01451398|DRUG|Technosphere Powder|Placebo Comparator
214634999|NCT04500782|OTHER|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
214721544|NCT00415545|BEHAVIORAL|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
214722246|NCT04268706|DRUG|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
214633318|NCT06127251|BEHAVIORAL|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
214635000|NCT00679705|DRUG|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
214635001|NCT00679705|DRUG|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
214635002|NCT00679705|DRUG|Placebo|Glucose 5%, IV
214633319|NCT06127251|BEHAVIORAL|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using ScanWatch. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
214633320|NCT06127251|DEVICE|Physical activity tracker|Participants will be asked to wear a ScanWatch tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
214633321|NCT06127251|BEHAVIORAL|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
214633322|NCT05656352|DEVICE|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
214633323|NCT05656352|DIAGNOSTIC_TEST|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
214633324|NCT05024864|DIAGNOSTIC_TEST|Urea breath test (UBT)|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection.~In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician.~During the period without H. pylori screening, the study´s UBT equipment will not be available."
214633325|NCT00089362|DRUG|alvespimycin hydrochloride|Given IV
214633326|NCT00089362|OTHER|laboratory biomarker analysis|Correlative studies
214633327|NCT00089362|OTHER|pharmacological study|Correlative studies
214633328|NCT01740375|PROCEDURE|esophagectomy|esophagectomy
214633329|NCT00017342|DRUG|bryostatin 1|
214633330|NCT00017342|DRUG|cytarabine|
214633331|NCT03711578|DRUG|Tenalisib,|BID, Orally
214633332|NCT03834428|BEHAVIORAL|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
214633333|NCT03834428|BEHAVIORAL|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
214633334|NCT03560856|DRUG|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
214633335|NCT00264238|DRUG|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
214633336|NCT00000879|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214633337|NCT00000879|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
214633338|NCT00000879|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214633339|NCT00862264|DRUG|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
214633340|NCT05416853|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
214633341|NCT01411085|DRUG|Risperidone + Desipramine|
214633342|NCT01547325|DRUG|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
214633343|NCT01547325|DRUG|placebo hydrogel|placebo hydrogel
214633344|NCT06654271|DEVICE|Robotic assisted bronchoscopy (RAB)|Participants allocated to the robotic assisted bronchoscopy arm will undergo robotic assisted bronchoscopy with integrated cone beam computed tomography
214633345|NCT06654271|DEVICE|Electromagnetic navigation bronchoscopy (ENB)|Participants allocated to the electromagnetic navigation bronchoscopy arm will undergo electromagnetic navigation bronchoscopy with integrated digital tomosynthesis
214633346|NCT01262690|DRUG|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
214633347|NCT01262690|DRUG|PF-05230901|Single dose SC
214633348|NCT06107062|DRUG|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
214633349|NCT06107062|DRUG|Placebo|Placebo arm
214633350|NCT06107062|DRUG|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
214721545|NCT00415545|BEHAVIORAL|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
214721546|NCT00784082|DRUG|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
214721547|NCT04049812|DEVICE|PEMF|
214721548|NCT04049812|DEVICE|Hot pack|
214721549|NCT04049812|DEVICE|TENS|
214721550|NCT04049812|DEVICE|Sham PEMF|
214721551|NCT03924648|OTHER|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
214721552|NCT05158530|OTHER|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
214721553|NCT05158530|OTHER|Pulmonary Exercises|"4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)"
214721554|NCT02606344|OTHER|Mico-finance based intervention|
214721555|NCT05518799|DRUG|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
214721556|NCT00503737|BEHAVIORAL|National Colorectal Cancer Roundtable Toolbox|
214721557|NCT02219997|DEVICE|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
214721558|NCT02219997|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
214721559|NCT02219997|DEVICE|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
214721560|NCT02219997|DEVICE|Clear IOL|Clear IOL, previously implanted
214721561|NCT04335708|DIETARY_SUPPLEMENT|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
214721562|NCT04335708|DIETARY_SUPPLEMENT|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
214721563|NCT02427100|BEHAVIORAL|Diet/Physical Activity|Diet/Physical Activity Intervention
214721564|NCT05993000|OTHER|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
214721565|NCT05993000|OTHER|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
214721566|NCT05993000|OTHER|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
214721567|NCT05993000|OTHER|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
214721568|NCT05993000|OTHER|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
214721569|NCT05322915|OTHER|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
214721570|NCT00842361|DRUG|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
214721571|NCT00842361|DRUG|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
214721572|NCT01966861|OTHER|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
214721573|NCT01432093|OTHER|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
214722247|NCT04268706|DRUG|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
214721574|NCT01432093|OTHER|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
214721575|NCT03293628|PROCEDURE|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
214721576|NCT03094611|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214722248|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
214721577|NCT02573233|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
214721578|NCT02573233|DRUG|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
214721579|NCT02573233|DRUG|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
214633351|NCT02193074|DRUG|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
214633352|NCT02193074|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
214633353|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
214633354|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
214633355|NCT07008989|BEHAVIORAL|Memory replay|"Within the HippoCamera application, half of all recorded events will be categorized as baseline memories, and half will be categorized as replay memories.~Baseline memories are recorded, but never viewed by the participant again until the Early HippoCamera test at the end of the 12-week intervention.~Replay memories are recorded, and then placed into a memory gallery. HippoCamera uses a research-based algorithm to select 5 memories from this gallery for participants to replay each day. Prior research has shown that this replay is associated with significant memory enhancements for replayed v. baseline memories for HippoCamera users from other populations."
214633356|NCT00004471|GENETIC|pGT-1 gene lipid complex|
214633357|NCT07011550|DRUG|Nivolumab|Given by IV
214633358|NCT07011550|DRUG|Bevacizumab|Given by IV
214633359|NCT07011550|DRUG|BMS-986340|Given by IV
214633360|NCT07011550|DRUG|Trifluridine + Tipiracil|Given by PO
214633361|NCT01534533|DIETARY_SUPPLEMENT|Placebo|one gelatine capsule containing starch per day, for 12 months
214633362|NCT01534533|DIETARY_SUPPLEMENT|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
214633363|NCT01534533|DIETARY_SUPPLEMENT|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
214633364|NCT01534533|DIETARY_SUPPLEMENT|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
214633365|NCT07015528|DRUG|Droperidol|Medication administered as a single intravenous dose.
214633366|NCT07015528|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration.
214633367|NCT07023211|BEHAVIORAL|Neo-Functional diaphragmatic breathing|This technique, rooted in the Neo-Functionalist orientation which actively utilizes body contact, involves direct manual assistance from the therapist during different respiratory movements. This hands-on guidance is specifically aimed at promoting and facilitating congruent movements across the thoracic, diaphragmatic, and abdominal regions throughout the breathing cycle, enhancing the targeted respiratory pattern. The intervention will be delivered by a psychotherapist specialized in Neo-Functional techniques.
214633368|NCT07023211|BEHAVIORAL|Social touch|Participants will receive occasional physical contact applied by the therapist specifically to the right arm. This contact is deliberately non-specific to the breathing process and contrasts with the targeted manual respiratory assistance provided to the experimental group. Participants in this group will not receive breathing instructions.
214633369|NCT07028099|DEVICE|Expandable OLIF cage with posterior bone grafting|This intervention involves the use of a novel expandable OLIF cage that allows intraoperative height adjustment and posterior bone grafting through a dedicated channel. The device is designed to restore intervertebral height and lumbar lordosis while minimizing endplate injury. Bone grafts (autologous or synthetic) are delivered after expansion to enhance fusion. This design aims to reduce cage subsidence, improve fusion rates, and simplify the surgical workflow compared to conventional OLIF cages with fixed heights.
214633370|NCT07028099|DEVICE|Conventional OLIF cage|Participants in the control group will undergo oblique lateral interbody fusion (OLIF) using a standard non-expandable interbody fusion cage. The cage has a fixed height and is inserted via the retroperitoneal approach. Bone grafts are packed into the cage prior to insertion through the anterior or lateral window. This represents the current standard practice for OLIF procedures and does not allow intraoperative height adjustment or posterior graft delivery. The procedure follows conventional OLIF surgical protocols without additional design modifications.
214633371|NCT07029698|DRUG|Vitamin B12, Vitamin B6, Folic acid|A solution for intramuscular injection of fixed vitamin combination (5 mg vitamin B6, 1 mg B12 and 1,05 mg folic acid )
214633372|NCT07029698|DRUG|Vitamin B12 (Cyanocobalamin)|oral tablets of 1mg Vitamin B12
214633373|NCT07029750|PROCEDURE|Lipoabdominoplasty|Combination of liposuction and abdominoplasty under general anesthesia. Klein solution used for tumescent liposuction. Muscle plication performed with 0 loop polydioxanone suture. Umbilicus preserved and repositioned. Postoperative compression corset used for 1 month.
214633374|NCT07027969|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
214633375|NCT07027969|DRUG|Anti-Obesity Medication (AOM) treatment|Implementation of obesity pharmacotherapy in the nonsurgical group includes initial assessment of side effects and response, followed by achieving a clinically meaningful weight loss (5% weight loss) after three months. Once this goal is reached, AOMs will be continued throughout the study. If a weight plateau is reached within the first AOM, then another AOM may be added in combination in a stepwise fashion. The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.
214721580|NCT02573233|DRUG|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
214721581|NCT02573233|DRUG|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
214721582|NCT06178094|BEHAVIORAL|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
214721583|NCT02119468|DRUG|ixazomib citrate|Given orally
214721584|NCT02119468|DRUG|dexamethasone|Given orally
214721585|NCT02119468|DRUG|pomalidomide|Given orally
214721586|NCT00003340|DRUG|cyclophosphamide|
214721587|NCT00003340|DRUG|topotecan hydrochloride|
214721588|NCT05073172|DRUG|Calendula Ointment|Applied topically
214721589|NCT05073172|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied topically
214633376|NCT07029620|DEVICE|Balance and postural rehabilitation using sensor-based stabilometric platform (GEAMASTER) under static and dynamic conditions|This intervention consists of a structured postural rehabilitation program supported by the GEAMASTER stabilometric platform. The device provides real-time feedback on center-of-pressure shifts and enables both static and dynamic balance training through interactive visual tasks. Exercises include multi-directional weight shifting, stability control, and task-specific balance strategies. The platform integrates sensor-based tracking and allows fine-grained analysis of postural parameters, distinguishing it from conventional physiotherapy by its precision, adaptability, and real-time feedback mechanisms.
214633377|NCT07029620|OTHER|Conventional balance and gait rehabilitation program|This intervention consists of a standardized physiotherapy program aimed at improving postural control and gait in patients with peripheral neuropathy. The rehabilitation protocol includes stretching, weight-shifting exercises, balance training on foam or unstable surfaces, and obstacle navigation. Unlike the experimental intervention, this program does not use any technological or sensor-based feedback systems. The content, frequency, and duration of the sessions are matched to those of the experimental arm to allow for comparative analysis of clinical outcomes.
214721590|NCT05073172|OTHER|Polyethylene Glycol Hydrogel|Applied topically
214721591|NCT05073172|DRUG|Silicone-based Film Forming Topical Gel|Applied topically
214721592|NCT05073172|DRUG|Silver Sulfadiazine|Applied topically
214721593|NCT05073172|DRUG|Topical Hydrocortisone|Applied topically
214721594|NCT02216890|DRUG|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
214721595|NCT03371927|OTHER|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
214721596|NCT01303458|BEHAVIORAL|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
214721597|NCT04369768|PROCEDURE|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
214721598|NCT01205919|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
214721599|NCT01205919|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
214721600|NCT02568163|OTHER|Non surgical periodontal treatment|
214721601|NCT01877941|DEVICE|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
214721602|NCT01877941|DEVICE|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
214721603|NCT01877941|DEVICE|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
214722249|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
214721604|NCT04233710|COMBINATION_PRODUCT|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
214721605|NCT04233710|BEHAVIORAL|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
214722250|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
214721606|NCT04690712|BEHAVIORAL|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
214721607|NCT01436695|DEVICE|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
214721608|NCT00204412|DIETARY_SUPPLEMENT|Flax lignan|543 mg SDG per day
214721609|NCT00204412|BEHAVIORAL|Exercise (walking)|walking 45 minutes per day 5 days per week
214721610|NCT00832481|DRUG|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
214721611|NCT00832481|DRUG|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
214721612|NCT04117412|OTHER|Exercise|Same participants will undergo different one bout of exercise protocols
214721613|NCT00789646|PROCEDURE|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
214721614|NCT00789646|PROCEDURE|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
214721615|NCT00004210|OTHER|loss of heterozygosity analysis|
214721616|NCT00004210|OTHER|microsatellite instability analysis|
214721617|NCT00004210|OTHER|mutation analysis|
214721618|NCT00004210|OTHER|counseling intervention|
214721619|NCT03986242|DEVICE|rolling|use non- vibration rolling and the total time is 20 minutes.
214633378|NCT07029620|OTHER|Stabilometric assessment in healthy volunteers|This intervention involves a non-interventional assessment of healthy adult volunteers using the GEAMASTER stabilometric platform. The objective is to generate normative data for stabilometric parameters and to assess test-retest reliability of the device under static and dynamic conditions. Participants do not undergo any rehabilitation program or therapeutic intervention. The data collected will serve as a reference for interpreting pathological findings in patients with peripheral neuropathy.
214633379|NCT07028073|DRUG|Group A (FIT): Avapritinib + IA regimen|Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)
214721620|NCT03986242|DEVICE|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
214721621|NCT03986242|OTHER|static stretching|static stretching and the total time is 20 minutes.
214721622|NCT00003852|BIOLOGICAL|filgrastim|
214721623|NCT00003852|DRUG|carboplatin|
214721624|NCT00003852|DRUG|cyclophosphamide|
214721625|NCT00003852|DRUG|epirubicin hydrochloride|
214721626|NCT00003852|DRUG|etoposide|
214721627|NCT00003852|DRUG|ifosfamide|
214721628|NCT00003852|DRUG|paclitaxel|
214721629|NCT00003852|DRUG|thiotepa|
214721630|NCT00003852|PROCEDURE|bone marrow ablation with stem cell support|
214721631|NCT00003852|PROCEDURE|peripheral blood stem cell transplantation|
214721632|NCT01536652|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
214721633|NCT05534152|OTHER|sumac|1% iranian brown sumac
214633380|NCT07028073|DRUG|Group B (UNFIT): Avapritinib + VA regimen|Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)
214633381|NCT06715124|DRUG|QTX3544|QTX3544 will be administered at protocol defined dose.
214633382|NCT06715124|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
214633383|NCT06744673|OTHER|No Intervention|This is a non-interventional study.
214633384|NCT06740435|OTHER|Enhanced Telemedicine for Type 2 Diabetes|Telemedicine-based endocrinology specialty care for type 2 diabetes with multidisciplinary diabetes care team support including pre-visit preparation, in-visit support and self-management education, and post-visit follow-up.
214633385|NCT06740435|OTHER|Usual Telemedicine Endocrinology Care for T2D|Routine telemedicine-based endocrinology specialty care for type 2 diabetes, generally consisting of synchronous virtual visit with an endocrinologist and additional support including self-management education on an individualized basis.
214633386|NCT06763328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214633387|NCT06763328|OTHER|Educational Intervention|Receive standard of care healthy diet and exercise handouts
214633388|NCT06763328|DRUG|Extended Release Metformin Hydrochloride|Given PO
214721634|NCT06508528|BEHAVIORAL|a 12-week growth mindset intervention|This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
214721635|NCT06508528|OTHER|Hospital mentoring|The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
214721636|NCT03471104|OTHER|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
214721637|NCT02855112|BIOLOGICAL|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
214721638|NCT03355768|DRUG|Romidepsin|Intravenous administration on a 28 day cycle
214721639|NCT03355768|DRUG|Pralatrexate|Intravenous administration on a 28 day cycle
214721640|NCT01469091|BEHAVIORAL|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
214721641|NCT00924729|DRUG|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
214721642|NCT00924729|DRUG|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
214721643|NCT05850013|DEVICE|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
214721644|NCT05222295|OTHER|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
214721645|NCT05222295|OTHER|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
214721646|NCT04322162|OTHER|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
214721647|NCT04381572|BEHAVIORAL|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
214721648|NCT02811796|OTHER|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
214721649|NCT02452710|OTHER|Placebo|Open-label placebo
214721650|NCT00193349|DRUG|Imatinib|
214721651|NCT00193349|DRUG|Irinotecan|
214721652|NCT00193349|DRUG|Carboplatin|
214633389|NCT06763328|OTHER|Questionnaire Administration|Ancillary studies
214721653|NCT01989819|OTHER|skin biopsy|
214721654|NCT05371938|PROCEDURE|Volar locking plate|Volar locking plate is the intervention
214721655|NCT05371938|PROCEDURE|external fixation|surgery with external fixation
214721656|NCT03148964|BIOLOGICAL|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
214633390|NCT02390297|GENETIC|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
214633391|NCT07102095|DRUG|Sevabertinib|Single oral dose of 20 mg sevabertinib administered as 2 x 10 mg film-coated tablets
214721657|NCT00050479|DRUG|Celecoxib (Celebrex)|
214721658|NCT02639403|RADIATION|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
214721659|NCT00214487|DEVICE|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
214721660|NCT00214487|DEVICE|Placebo Control|Single vision soft contact lenses
214721661|NCT05188599|DIAGNOSTIC_TEST|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
214633392|NCT03448237|OTHER|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
214633393|NCT03448237|OTHER|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~* Proprioceptive stimulation of oculomotor muscles (active prisms).~* Oral somatosensory stimulation (ALPH).~* Proprioceptive antigravity stimulation (proprioceptive sole).~* Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
214633394|NCT06934395|BEHAVIORAL|Healthy Choices|Healthy Choices is an adapted and developmentally tailored intervention designed to address self-management of risk behaviors and HIV from Motivational Enhancement Therapy, a brief alcohol intervention in SAMHSA's registry of evidenced-based programs. For the purposes of this project, this intervention will be delivered as a combination approach, with all participants receiving an initial session via CIAS, and randomized to either receiving a telehealth session with a trained interventionist at week 2, with additional randomizations for telehealth sessions at weeks 4 and 6. The goal is to test if delivering (vs. not delivering) a coaching session increases the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3
214633395|NCT06934395|BEHAVIORAL|Text Message Prompts|This within-participant micro-randomization will test whether, on average, delivering (vs. not delivering) a text messaged prompt focused on medication adherence or stress increases the likelihood of medication adherence by the end of the current day .
214633396|NCT06942741|DRUG|MK-1084 OCT|Oral tablet
214633397|NCT06942741|DRUG|MK-1084 FCT|Oral tablet
214633398|NCT06687746|DEVICE|Bili-ruler|The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.
214633399|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
214633400|NCT03711214|PROCEDURE|Periodontal scaling|Periodontal scaling and root planing
214633401|NCT06191185|BEHAVIORAL|BPB, No PIN|"Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
214721662|NCT02898142|OTHER|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
214721663|NCT03180242|BIOLOGICAL|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
214721664|NCT03180242|BIOLOGICAL|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
214721665|NCT03180242|BIOLOGICAL|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
214721666|NCT01646853|RADIATION|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
214721667|NCT01646853|DRUG|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
214721668|NCT00649051|DRUG|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
214721669|NCT00649051|DRUG|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
214721670|NCT00773851|PROCEDURE|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
214721671|NCT00773851|PROCEDURE|mesh fixation by staples|mesh fixation by staples
214721672|NCT00101153|DRUG|cytarabine|
214721673|NCT00101153|DRUG|daunorubicin hydrochloride|
214721674|NCT00101153|DRUG|tipifarnib|
214721675|NCT00981747|DRUG|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
214721676|NCT00981747|DRUG|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
214721677|NCT00981747|DRUG|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
214721678|NCT00981747|DRUG|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
214721679|NCT01606397|DRUG|Placebo|Administered orally (capsule)
214721680|NCT01606397|DRUG|LY2409021|Administered orally (capsule)
214721681|NCT01716026|DRUG|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
214721682|NCT00647946|DRUG|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
214721683|NCT00647946|DRUG|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
214721684|NCT02521857|DRUG|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
214721685|NCT01814826|DRUG|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
214721686|NCT01814826|DRUG|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~\- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
214721687|NCT03962946|OTHER|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
214721688|NCT03962946|OTHER|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
214633402|NCT06191185|BEHAVIORAL|BPB, PIN|"Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
214721689|NCT01960829|DRUG|Everolimus|
214721690|NCT02917629|OTHER|Laboratory Biomarker Analysis|Correlative studies
214721691|NCT02917629|DRUG|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
214721692|NCT02917629|OTHER|Pharmacological Study|Correlative studies
214721693|NCT02917629|OTHER|Placebo|Given PO
214721694|NCT00377104|DRUG|alvocidib|Given IV
214721695|NCT00377104|OTHER|pharmacological study|Correlative studies
214721696|NCT00377104|OTHER|laboratory biomarker analysis|Correlative studies
214721697|NCT04218604|PROCEDURE|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
214721698|NCT01320969|BEHAVIORAL|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
214721699|NCT03339401|OTHER|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
214721700|NCT03339401|DRUG|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
214721701|NCT00718523|DRUG|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
214721702|NCT00718523|DRUG|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
214721703|NCT02816437|BIOLOGICAL|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
214721704|NCT03271307|BEHAVIORAL|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
214721705|NCT03271307|DIAGNOSTIC_TEST|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
214721706|NCT03271307|DIAGNOSTIC_TEST|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
214721707|NCT00190645|DRUG|Duloxetine|
214721708|NCT01043783|OTHER|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
214721709|NCT03154177|BEHAVIORAL|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
214721710|NCT03154177|PROCEDURE|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
214721711|NCT03365947|DRUG|ARO-HBV|sc injection
214721712|NCT03365947|OTHER|Sterile Normal Saline (0.9% NaCl)|sc injection
214721713|NCT03365947|DRUG|JNJ-56136379|oral tablets
214721714|NCT03636880|BEHAVIORAL|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
214721715|NCT03636880|BEHAVIORAL|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
214721716|NCT04459494|PROCEDURE|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
214633403|NCT06191185|BEHAVIORAL|No BPB, PIN|Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.
214633404|NCT06191185|BEHAVIORAL|No BPB, No PIN|Patient-level: standard communication from their care team.
214633405|NCT06048835|DEVICE|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
214633406|NCT06202066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214633407|NCT06202066|PROCEDURE|Computed Tomography|Undergo CT scan
214633408|NCT06202066|BIOLOGICAL|Incomplete Freund''s Adjuvant|Given SC
214633409|NCT06202066|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214633410|NCT06202066|BIOLOGICAL|Sargramostim|Given SC
214633411|NCT06202066|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
214633412|NCT06202066|DRUG|Temozolomide|Given PO
214633413|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
214633414|NCT05380063|DRUG|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
214633415|NCT05380063|DRUG|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
214633416|NCT03596905|DRUG|Plecanatide|Taken orally daily for 4 weeks
214633417|NCT03596905|DRUG|Matching placebo|Taken orally daily for 4 weeks
214633418|NCT05980169|DEVICE|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
214633419|NCT04748094|DEVICE|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
214633420|NCT04748094|OTHER|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
214633421|NCT06963346|DRUG|Romidepsin|Administered as intravesical treatment.
214633422|NCT06963346|DRUG|Durvalumab|Administered as intravenous treatment.
214633423|NCT06963359|DEVICE|HD-sEMG|High definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair rises, depending on the patient's functional state
214633424|NCT06963359|DEVICE|Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed
214633425|NCT06963359|OTHER|IPAQ Physical Activity Questionnaire|Physical activity assessment questionnaire/adapted version for seniors
214633426|NCT06296329|OTHER|Rubber Hand Illusion|The traditional behavioural illusion of the Rubber Hand will be applied
214633427|NCT03232515|COMBINATION_PRODUCT|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
214633428|NCT06193785|OTHER|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
214633429|NCT05011188|BIOLOGICAL|FOR46|Given intravenously (IV)
214633430|NCT05011188|BIOLOGICAL|Enzalutamide|Given orally (PO)
214633431|NCT05011188|DRUG|Pegfilgrastim|Given subcutaneously (subQ)
214633432|NCT05011188|PROCEDURE|Blood Samples|Blood samples will be taken for correlative studies
214633433|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
214633434|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
214633435|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
214633436|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
214633437|NCT00465959|DRUG|trospium chloride inhalation powder (TrIP)|
214633438|NCT00465959|DRUG|Placebo|
214633439|NCT05955625|OTHER|TIMELY|The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
214633440|NCT02650037|PROCEDURE|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
214633441|NCT03036293|DRUG|Tenoten|Tablet for oral use.
214633442|NCT03036293|DRUG|Placebo|Tablet for oral use.
214633443|NCT01084187|DRUG|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
214633444|NCT06025266|DEVICE|Evaluation of Viscoelastic and mechanical properties with MyotonPRO|MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
214633445|NCT01535781|DRUG|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
214633446|NCT01535781|DRUG|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
214633447|NCT00691483|DRUG|placebo|placebo tablet taken orally twice daily for 12 weeks
214633448|NCT00691483|DRUG|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
214633449|NCT03639714|BIOLOGICAL|GRT-C901|a patient-specific neoantigen cancer vaccine prime
214633450|NCT03639714|BIOLOGICAL|GRT-R902|a patient-specific neoantigen cancer vaccine boost
214633451|NCT03639714|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
214633452|NCT03639714|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
214633453|NCT01891487|DRUG|Track A|Bimatoprost 0.03% solution applied to eyebrow
214633454|NCT01891487|DRUG|Track B|Refresh Tears applied to eyebrows
214633455|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
214633456|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
214633457|NCT06282003|PROCEDURE|The procedure of protective lung ventilation|The procedure of protective lung ventilation in the PV group of patients included preoxygenation with 60% oxygen in a mixture with air for 3 min, which maintained the target peripheral oxygen saturation at values above 94%, endotracheal intubation, volume-controlled mechanical ventilation, a tidal volume of 6 ml per kg of body weight. Normocarbia during the protective ventilation procedure was maintained by adjusting the minute ventilation, which is the product of the respiratory rate (12-14 breaths per minute) and the tidal volume set to 6 ml/kg of body weight. The most critical variable for the adjustment was the inhalation-exhalation ratio of 1:2, which ensured adequate oxygenation and removal of carbon dioxide during anesthesia. Identically as in the PV group, the target peripheral saturation was kept above 94% with an inspiratory oxygen concentration of 50% and peak airway pressure values of up to 40 kPa.
214633458|NCT01946321|OTHER|Post-amputation functional rehabilitation (normal clinical practice)|
214633459|NCT04295161|DRUG|Abiraterone Acetate|Abiraterone acetate immediate release formulations
214633460|NCT00439946|DRUG|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
214633461|NCT00439946|DEVICE|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
214633462|NCT05772260|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
214633463|NCT01391000|PROCEDURE|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
214633464|NCT01391000|PROCEDURE|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
214633465|NCT00049673|DRUG|prednisone|Given orally
214633466|NCT00049673|DRUG|thalidomide|Given orally
214633467|NCT01991782|OTHER|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
214633468|NCT03766880|PROCEDURE|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
214633469|NCT03766880|PROCEDURE|MR imaging|MR images for the post-processing analysis
214633470|NCT04783636|DRUG|leuprorelin acetate 3.75mg|PT105, PT105R
214633471|NCT04880200|DIAGNOSTIC_TEST|POC NAT & Adherence Intervention|The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
214633472|NCT00488891|DRUG|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
214633473|NCT00488891|DRUG|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
214633474|NCT04740047|DIAGNOSTIC_TEST|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
214633475|NCT03535753|DRUG|Decitabine and R-GDP|Decitabine and R-GDP
214633476|NCT02365168|OTHER|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
214633477|NCT02365168|OTHER|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
214633478|NCT02365168|OTHER|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
214633479|NCT02365168|OTHER|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
214633480|NCT01436539|DRUG|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
214633481|NCT01436539|DRUG|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
214633482|NCT04872114|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
214633483|NCT00817531|DRUG|Dasatinib|pill form, 100 mg daily
214633484|NCT05344456|DEVICE|Change in the device PVC algorithm to ''Off''|PVC algorithm change from Atrial Pace mode to Off
214633485|NCT02303379|OTHER|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
214633486|NCT02303379|OTHER|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
214633487|NCT02303379|OTHER|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
214633488|NCT02475681|DRUG|Acalabrutinib|
214633489|NCT02475681|DRUG|Obinutuzumab|
214633490|NCT02475681|DRUG|Chlorambucil|
214633491|NCT02896595|DEVICE|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
214633492|NCT02896595|DEVICE|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
214633493|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,"
214633494|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike"
214633495|NCT02103569|DRUG|FDC of Daclatasvir, Asunaprevir and BMS-791325|
214633496|NCT02103569|DRUG|FDC of Norethindrone and Ethinyl Estradiol|
214633497|NCT02103569|DRUG|BMS-791325|
214633498|NCT03678402|DEVICE|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
214633499|NCT04991766|DRUG|[¹⁴C]-LY3484356|Administered orally.
214633500|NCT04991766|DRUG|LY3484356|Administered orally.
214633501|NCT04991766|DRUG|[¹⁴C]-LY3484356 (IV)|Administered IV.
214633502|NCT03485833|DIAGNOSTIC_TEST|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
214721717|NCT04459494|PROCEDURE|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
214721718|NCT05477225|DEVICE|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
214633503|NCT04926974|BEHAVIORAL|Low Vision Rehabilitation|Smart phone App
214633504|NCT00251537|DRUG|LTB4|
214633505|NCT05661773|DEVICE|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
214633506|NCT01961700|OTHER|Physiotherapy|Physiotherapy treatment
214633507|NCT06445868|OTHER|Sedentary behaviour intervention|COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
214633508|NCT03206697|OTHER|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
214633509|NCT02872766|DEVICE|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
214633510|NCT03607864|DEVICE|coral bone graft and xenograft|"ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures."
214633511|NCT01450033|BEHAVIORAL|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
214633512|NCT01450033|BEHAVIORAL|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
214633513|NCT01536054|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
214633514|NCT01536054|DRUG|sirolimus|Given PO
214633515|NCT01536054|OTHER|laboratory biomarker analysis|Correlative studies
214633516|NCT01536054|BIOLOGICAL|sargramostim|Given SC
214633517|NCT04001816|OTHER|Orthodontic Brackets|Self ligating and Conventional brackets
214633518|NCT02323698|DRUG|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
214633519|NCT02323698|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
214633520|NCT02323698|OTHER|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
214633521|NCT02323698|OTHER|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
214633522|NCT02482454|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
214633523|NCT02482454|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
214633524|NCT01069562|OTHER|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
214633525|NCT01069562|OTHER|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
214633526|NCT06244238|OTHER|Observational study|Observational study
214633527|NCT03325673|DEVICE|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
214633528|NCT03325673|DEVICE|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
214633529|NCT03678805|PROCEDURE|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
214633530|NCT03678805|PROCEDURE|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
214633531|NCT04002011|DRUG|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
214633532|NCT04002011|DRUG|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
214633533|NCT04002011|DRUG|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
214633534|NCT04002011|DRUG|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
214633535|NCT04002011|DRUG|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
214633536|NCT05448872|DRUG|Sacubitril/Valsartan|HF patients treated with Sac/Val
214633537|NCT01751217|BEHAVIORAL|Functional Family Tx|
214633538|NCT01751217|BEHAVIORAL|Services as Usual|
214633539|NCT03652532|BEHAVIORAL|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
214633540|NCT03652532|BEHAVIORAL|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
214633541|NCT06299527|OTHER|Exercise Program|Exercise Program In our study, the telerehabilitation program was applied for both synchronous and asynchronous groups, 3 days a week, 1 session per day, for 8 weeks. The exercises were combined individually according to the person's capacity, and the intensity and duration of the exercise will gradually increase according to the patient's tolerance.
214633542|NCT04572269|OTHER|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
214633543|NCT03698006|DRUG|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
214633544|NCT03698006|DRUG|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
214633545|NCT03673683|BEHAVIORAL|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
214633546|NCT03673683|BEHAVIORAL|Usual care|Usual sedation and weaning management that is not protocol based
214633547|NCT01871454|RADIATION|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
214721719|NCT05477225|DEVICE|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
214721720|NCT02932644|OTHER|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
214721721|NCT02932644|OTHER|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
214633548|NCT01871454|DRUG|Pentoxifylline|pentoxifylline
214633549|NCT00590590|DRUG|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
214633550|NCT00590590|DRUG|lidocaine|semi solid, twice weekly for 4 months
214633551|NCT00590590|DRUG|placebo|semi solid, twice weekly for 4 months
214633552|NCT05766995|DEVICE|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
214633553|NCT05766995|DEVICE|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
214633554|NCT05766995|DEVICE|Waxed Dental Floss|Nylon string used to clean between the teeth manually
214633555|NCT02025426|DRUG|Phenylephrine|
214633556|NCT02025426|DRUG|Ephedrine|
214633557|NCT00132132|BEHAVIORAL|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
214633558|NCT04421274|BIOLOGICAL|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
214633559|NCT04421274|DRUG|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
214633560|NCT04421274|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
214633561|NCT02200315|OTHER|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
214633562|NCT05136937|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
214633563|NCT02235532|OTHER|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
214633564|NCT02235532|OTHER|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
214633565|NCT03889561|BEHAVIORAL|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
214633566|NCT01770925|DEVICE|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
214633567|NCT01770925|DEVICE|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
214633568|NCT01770925|DEVICE|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
214633569|NCT05875870|BEHAVIORAL|Daylight exposure combine walking|"1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
214633570|NCT05875870|BEHAVIORAL|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
214633571|NCT05500625|PROCEDURE|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
214721722|NCT03698422|DIAGNOSTIC_TEST|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
214721723|NCT04506944|OTHER|No intervention|No specific exposure is explored.
214721724|NCT01482468|DRUG|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
214721725|NCT01482468|DRUG|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
214721726|NCT04140539|BIOLOGICAL|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
214633572|NCT05500625|PROCEDURE|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
214633573|NCT04273178|DRUG|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
214633574|NCT05134272|DEVICE|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
214633575|NCT05134272|BEHAVIORAL|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
214633576|NCT05134272|BEHAVIORAL|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
214633577|NCT01916265|DRUG|Glucagon|
214721727|NCT02620735|DEVICE|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
214721728|NCT02620735|BEHAVIORAL|Exercise Only|12 week exercise program
214633578|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
214633579|NCT00737867|DRUG|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
214721729|NCT02620735|BEHAVIORAL|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
214721730|NCT02620735|BEHAVIORAL|Health Coaching|10 over the phone health coaching sessions.
214721731|NCT04042038|BEHAVIORAL|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
214633580|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
214633581|NCT00737867|DRUG|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
214633582|NCT03695003|DIETARY_SUPPLEMENT|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
214633583|NCT03695003|DIETARY_SUPPLEMENT|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
214633584|NCT00432978|DRUG|Bosentan administration|
214633585|NCT00494091|DRUG|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
214633586|NCT00494091|DRUG|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
214633587|NCT05796635|OTHER|Herpecin L|Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
214633588|NCT03300466|DEVICE|GP0045|Hyaluronic acid gel
214633589|NCT03300466|DEVICE|Comparator|Hyaluronic acid gel
214633590|NCT03343132|BEHAVIORAL|Standard locomotor therapy|Typical clinical therapy.
214633591|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine|
214633592|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine + adjuvant|
214633593|NCT02797236|BIOLOGICAL|Placebo|
214633594|NCT02797236|BIOLOGICAL|Placebo + adjuvant|
214633595|NCT00003385|DRUG|carboplatin|
214633596|NCT00003385|DRUG|paclitaxel|
214721732|NCT02853149|BEHAVIORAL|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
214633597|NCT00003385|DRUG|pegylated liposomal doxorubicin hydrochloride|
214633598|NCT04248413|DEVICE|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
214633599|NCT04248413|OTHER|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
214633600|NCT00452699|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
214633601|NCT00452699|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
214633602|NCT00807755|DRUG|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
214633603|NCT00807755|DRUG|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
214633604|NCT00807755|DRUG|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
214633605|NCT00326898|OTHER|Laboratory Biomarker Analysis|Correlative studies
214633606|NCT00326898|OTHER|Placebo|Given PO
214633607|NCT00326898|OTHER|Quality-of-Life Assessment|Ancillary studies
214633608|NCT00326898|DRUG|Sorafenib Tosylate|Given PO
214633609|NCT00326898|DRUG|Sunitinib Malate|Given PO
214633610|NCT00428649|DIETARY_SUPPLEMENT|20 µg selenium|20 µg selenium as selenomethionine
214633611|NCT00428649|DIETARY_SUPPLEMENT|40 µg selenium|40 µg selenium as selenomethionine
214633612|NCT00428649|DIETARY_SUPPLEMENT|60 µg selenium|60 µg selenium as selenomethionine
214633613|NCT00428649|DIETARY_SUPPLEMENT|80 µg selenium|80 µg selenium as selenomethionine
214633614|NCT00428649|DIETARY_SUPPLEMENT|100 µg selenium|100 µg selenium as selenomethionine
214633615|NCT00428649|DIETARY_SUPPLEMENT|120 µg selenium|120 µg selenium as selenomethionine
214633616|NCT00428649|DIETARY_SUPPLEMENT|placebo|placebo
214633617|NCT02953535|DRUG|Magicbuvir|1 tablet contains 400 mg sofosbuvir
214633618|NCT02953535|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
214633619|NCT02953535|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
214633620|NCT03847987|DRUG|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
214633621|NCT03847987|DRUG|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
214633622|NCT03847987|DRUG|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
214633623|NCT01265459|DEVICE|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
214633624|NCT04918329|OTHER|Observational study|Non interventional study
214633625|NCT04788979|DRUG|Melatonin 5Mg Oral Tablet|"1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
214633626|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
214721733|NCT02853149|BEHAVIORAL|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
214721734|NCT02853149|BEHAVIORAL|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
214721735|NCT01042938|DRUG|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
214721736|NCT01042938|DRUG|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
214721737|NCT01191281|BEHAVIORAL|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
214721738|NCT01191281|OTHER|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
214721739|NCT05400538|OTHER|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
214721740|NCT05400538|OTHER|Biorepair Toothpaste|Domiciliary application of the product twice a day.
214721741|NCT04867200|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
214721742|NCT04867200|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
214633627|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
214633628|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
214721743|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
214633629|NCT00648375|DRUG|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
214633630|NCT00648375|DRUG|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
214633631|NCT00648375|BEHAVIORAL|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
214633632|NCT03960281|OTHER|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
214633633|NCT02236455|BEHAVIORAL|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
214633634|NCT02236455|BEHAVIORAL|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
214633635|NCT02236455|BEHAVIORAL|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
214633636|NCT02236455|BEHAVIORAL|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
214633637|NCT01965132|DRUG|Biologic or targeted synthetic DMARD|
214633638|NCT00883714|OTHER|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
214633639|NCT00883714|OTHER|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
214633640|NCT01017393|DRUG|Ketamine|
214633641|NCT01017393|DRUG|ketamine free|
214633642|NCT03733392|DEVICE|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
214633643|NCT03824860|BEHAVIORAL|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~* guided breathing exercises,~* upper and lower extremity stretching~* structured postures and movements to improve balance and strength"
214633644|NCT03083340|BEHAVIORAL|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
214633645|NCT03638505|OTHER|PSP-QoL|"PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings."
214633646|NCT02012478|BEHAVIORAL|MI- informed SMS program|
214633647|NCT01578980|DEVICE|Outpatient Control-to-Range|Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
214633648|NCT03451188|DEVICE|Cerecare compression garments|all Cerecare compression garments
214633649|NCT01280136|BEHAVIORAL|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
214633650|NCT01535365|OTHER|Heat|Application of heat pack to the back or neck sprain.
214633651|NCT01535365|OTHER|Cold|Application of ice pack to the back or neck sprain.
214633652|NCT02615990|DEVICE|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
214633653|NCT02615990|OTHER|Standard Physical Therapy|Patients receive standard physical therapy.
214635003|NCT04263337|DRUG|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
214633654|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center);~Camrelizumab at a fixed dose of 200mg, administered via intravenous drip, with each infusion lasting no less than 30 min and no more than 60 min. Administered on day 1 of every 2-week cycle (d1, q2w).~Each treatment cycle is 14 days, and all drugs are administered on day 1."
214633655|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center); Each treatment cycle is 14 days, and all drugs are administered on day 1."
214633656|NCT00002553|DRUG|cyclophosphamide|
214633657|NCT00002553|PROCEDURE|allogeneic bone marrow transplantation|
214633658|NCT00002553|RADIATION|low-LET cobalt-60 gamma ray therapy|
214633659|NCT00036179|DRUG|FK463|
214633660|NCT05079503|DRUG|GEN-001|GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
214633661|NCT02397928|DEVICE|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
214633662|NCT02397928|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
214633663|NCT02397928|DRUG|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
214633664|NCT04135898|DRUG|SIBP-04|3mg/kg, infusion in 90 minutes
214633665|NCT04135898|DRUG|Bevacizumab|3mg/kg, infusion in 90 minutes
214633666|NCT01256437|DRUG|Threolone ointment|ointment once daily for 1 month
214633667|NCT01256437|DRUG|ointment Synthomycine|ointment once daily for 1 month
214633668|NCT01256437|DRUG|Aqua cream|ointment once daily for 1 month
214633669|NCT01363986|DRUG|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
214633670|NCT05572034|PROCEDURE|Electrophysiological study|Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.
214633671|NCT05572034|PROCEDURE|Electrophysiological study and Right side Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works (anatomic mapping):~In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and, the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
214633672|NCT05572034|PROCEDURE|Electrophysiological study and bi-atrial Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works(anatomic mapping):~In the LA: the inferior right GP (septal aspect of the right pulmonary veins \[PV\]) antra, and LA posterior wall. In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
214633673|NCT01637142|DRUG|LY2140023|Administered orally.
214633674|NCT01637142|DRUG|14C-LY2140023|Administered IV.
214633675|NCT01637142|DRUG|14C-LY404039|Administered IV.
214633676|NCT05087069|DRUG|BV100|Rifabutin for Infusion
214633677|NCT05087069|DRUG|Placebo|Saline intravenous infusion
214721744|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
214633680|NCT03582670|BEHAVIORAL|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
214633681|NCT03582670|BEHAVIORAL|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
214633682|NCT03582670|BEHAVIORAL|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
214633683|NCT02881268|OTHER|blood sample|
214633684|NCT01300182|OTHER|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
214633685|NCT01300182|OTHER|Control|Conventional post-operative physical therapy exercises and rehabilitation.
214633686|NCT03049904|BEHAVIORAL|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
214633687|NCT03767322|DRUG|Allopurinol|Eligible patients will receive allopurinol 300 mg before and after coronary intervention
214633688|NCT03767322|DRUG|Febuxostat|Eligible patients will receive febuxostat 80 mg before and after coronary intervention
214633689|NCT03767322|DRUG|Placebo|Eligible patients will receive before and after coronary intervention
214633690|NCT04813029|PROCEDURE|Straight leg raise maneuver|With the patient in supine position, one leg is raised to form an angle of at least 45 degrees with the bed. The patient will be asked to keep that position for at least 5 seconds. The maneuver will be repeated after 20-30 seconds. The first adequate maneuver will be considered for the study. Intra-esophageal and intra-abdominal pressure will be analyzed both during baseline and SLR maneuver. Intra-esophageal pressure is measured as peak and mean over 5 seconds, 1 cm and 5 cm above the proximal margin of the LES. Intra-abdominal pressure will be measured as peak and mean over 5 seconds 1 cm below the distal margin of the diaphragm notch.
214721745|NCT03083275|OTHER|Resistance Training|
214721746|NCT03136484|DRUG|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
214721747|NCT03136484|DRUG|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
214633691|NCT01531036|DEVICE|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
214633692|NCT02111564|DRUG|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
214633693|NCT02111564|DRUG|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
214633694|NCT02111564|DRUG|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
214633695|NCT00918814|DRUG|LIPO-102|Subcutaneous Injection
214633696|NCT00918814|DRUG|Placebo|Placebo
214633697|NCT02852382|DRUG|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
214633698|NCT02852382|DRUG|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
214633699|NCT00687362|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
214633700|NCT02950519|OTHER|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
214633701|NCT02354703|DRUG|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
214721748|NCT03136484|DRUG|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
214721749|NCT03136484|DRUG|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
214721750|NCT03465384|BEHAVIORAL|Comet|The intervention is a behaviorally based and manualized parent training program.
214633702|NCT02354703|DRUG|Placebo|Placebo + BBCET counseling
214633703|NCT01014845|BIOLOGICAL|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
214633704|NCT01014845|BIOLOGICAL|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
214633705|NCT02276092|OTHER|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
214633706|NCT04415073|DRUG|SNDX-6352|SNDX-6352
214633707|NCT04415073|DRUG|Placebo|Placebo comparator
214721751|NCT00360685|DRUG|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
214721752|NCT00360685|DRUG|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
214721753|NCT02352532|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
214633708|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
214633709|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
214633710|NCT06126991|DRUG|Cetirizine|Oral administration of cetirizine at 10mg once daily will be used.
214633711|NCT06126991|DRUG|Midazolam and Fentanyl|Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
214633712|NCT03468309|GENETIC|Genecept Assay and G-DIG decision tool|Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
214633713|NCT01004757|OTHER|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
214633714|NCT01004757|OTHER|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
214633715|NCT01864408|OTHER|"Usual practice counseling"|
214633716|NCT01864408|OTHER|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
214633717|NCT06137118|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
214633718|NCT05966298|OTHER|Core stabilization training|First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.
214633719|NCT05966298|OTHER|Standart Rehabilitation|This treatment includes shoulder exercises and conventional therapy (Infrared, TENS).
214633720|NCT01075061|OTHER|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
214721754|NCT02352532|OTHER|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
214633721|NCT01075061|OTHER|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
214633722|NCT01075061|OTHER|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
214633723|NCT03258567|BIOLOGICAL|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
214633724|NCT01707472|BIOLOGICAL|Simtuzumab|700 mg intravenously for a total of 12 infusions.
214633725|NCT06205121|DRUG|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
214633726|NCT06205121|DRUG|Placebo|Matching placebo tablets
214633727|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
214633728|NCT04188418|DRUG|Morphine|Given PO
214633729|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
214633730|NCT04188418|OTHER|Placebo Administration|Given PO
214633731|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
214633732|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
214721755|NCT05131529|OTHER|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
214633733|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
214633734|NCT06353451|BEHAVIORAL|Digital Detox|In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
214633735|NCT02396732|DRUG|Aspirin|Daily dose is 81 mg oral tablet
214633736|NCT02396732|DRUG|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
214633737|NCT04358679|OTHER|Conventional Treatment|"Conventional Treatment:~* Deep breathing: 10-15 reps, twice a day (BD)~* Assisted coughing 10-15 reps, BD~* range of motion (ROM)+ stretching 10 reps, BD~* Tilt table standing"
214633738|NCT04358679|OTHER|Upper Limb ergometer training|Conventional Treatment + upper limb (UL) ergometry exercise UL ergometry exercise 15 to 20 mints , 2 times ,five days per week for 6 weeks.
214633739|NCT05144607|OTHER|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
214633740|NCT01259609|PROCEDURE|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
214633741|NCT05195008|DRUG|BIIB113|Administered as specified in the treatment arm.
214633742|NCT05195008|DRUG|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
214633743|NCT05195008|DRUG|11^C]BIO-1819578|Administered as specified in the treatment arm.
214633744|NCT00646542|DRUG|Vildagliptin|
214633745|NCT00646542|DRUG|Placebo|
214633746|NCT02438709|DRUG|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
214633747|NCT04230174|DRUG|11C-PBR28|This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
214633748|NCT03185390|PROCEDURE|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
214633749|NCT00963274|DRUG|Bortezomib|Starting dose: 1.3 mg/sq m
214633750|NCT00963274|DRUG|Romidepsin|Starting dose: 8 mg/sq m
214633751|NCT03687216|PROCEDURE|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
214633752|NCT03687216|PROCEDURE|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
214633753|NCT02952222|DRUG|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
214633754|NCT02952222|DRUG|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
214633755|NCT02952222|DRUG|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
214633756|NCT00562549|DRUG|SLx-2101|
214633757|NCT05409339|DRUG|Caffeine|150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
214633758|NCT05409339|DRUG|Placebo|Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
214633759|NCT02981771|BEHAVIORAL|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
214633760|NCT02981771|BEHAVIORAL|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
214635004|NCT04263337|DRUG|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
214635005|NCT04263337|DRUG|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
214635006|NCT05442099|BEHAVIORAL|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
214635007|NCT05442099|BEHAVIORAL|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
214721756|NCT05131529|OTHER|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
214721757|NCT05131529|OTHER|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
214721758|NCT04629638|OTHER|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
214721759|NCT04253808|BEHAVIORAL|Carbohydrate-restricted, high-fat diet|"Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
214721760|NCT04253808|BEHAVIORAL|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
214721761|NCT02239367|BEHAVIORAL|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
214721762|NCT02463760|OTHER|Medical imaging|
214721763|NCT04399980|DRUG|Mavrilimumab|Treatment infusion
214721764|NCT04399980|DRUG|Placebos|Placebo infusion
214721765|NCT04334512|DRUG|Hydroxychloroquine|Treatment with hydroxychloroquine
214721766|NCT04334512|DRUG|Azithromycin|Treatment with azithromycin
214721767|NCT04334512|DIETARY_SUPPLEMENT|Vitamin C|Treatment with vitamin C
214721768|NCT04334512|DIETARY_SUPPLEMENT|Vitamin D|Treatment with vitamin D
214721769|NCT04334512|DIETARY_SUPPLEMENT|Zinc|Treatment with Zinc
214721770|NCT06350149|OTHER|Sugar Sweetened Beverages (SSB)|The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
214721771|NCT06350149|OTHER|Hi GI|The Glycemic Index of the high-GI meals will be at least 75
214721772|NCT06350149|OTHER|Lo GI|The Glycemic Index of the low- -GI meals will not be higher than 55.
214721773|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.
214721774|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
214721775|NCT01525303|BEHAVIORAL|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
214721776|NCT02452749|DIETARY_SUPPLEMENT|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
214721777|NCT03284021|DEVICE|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
214721778|NCT03747536|DRUG|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
214721779|NCT03747536|OTHER|Placebo|normal saline delivered via metered dose spray
214721780|NCT05444413|BIOLOGICAL|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
214721781|NCT03983213|PROCEDURE|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
214721782|NCT03949998|DEVICE|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
214721783|NCT03949998|OTHER|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
214721784|NCT03997760|DRUG|TAK-755|Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
214721785|NCT03997760|OTHER|Placebo|Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
214721786|NCT01854489|DRUG|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
214721787|NCT01854489|DRUG|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
214721788|NCT01854489|DRUG|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
214721789|NCT00856986|DRUG|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
214721790|NCT00856986|DRUG|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
214721791|NCT00856986|DRUG|metformin|Metformin tablets, at least 1500 mg/day
214721792|NCT04368104|DIAGNOSTIC_TEST|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
214721793|NCT04990375|DEVICE|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
214721794|NCT03345368|DEVICE|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
214721795|NCT03345368|DEVICE|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
214721796|NCT03345368|OTHER|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
214635008|NCT02860312|BEHAVIORAL|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
214635009|NCT02860312|BEHAVIORAL|Non-exercising group|Patients are having their usual physical activity
214635010|NCT03787498|DRUG|PLX2853|Tablets
214635011|NCT04186494|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
214635012|NCT04186494|DEVICE|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
214635013|NCT04186494|COMBINATION_PRODUCT|Liraglutide and CPAP|Combination of both treatments
214721797|NCT04580212|BEHAVIORAL|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
214721798|NCT01077869|PROCEDURE|endoscopic examination|on a weekly basis during 7 weeks
214721799|NCT01077869|PROCEDURE|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
214721800|NCT04883567|DIAGNOSTIC_TEST|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
214721801|NCT00259350|DRUG|Skin disinfection|
214721802|NCT05041062|DRUG|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
214721803|NCT05041062|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
214721804|NCT00004041|BIOLOGICAL|Ad5CMV-p53 gene|
214721805|NCT00004041|PROCEDURE|conventional surgery|
214721806|NCT01915095|DEVICE|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
214721807|NCT01915095|DEVICE|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
214721808|NCT01915095|OTHER|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
214721809|NCT01915095|OTHER|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
214721810|NCT04018612|DRUG|Acetaminophen|Acetaminophen is an analgesic and antipyretic
214721811|NCT04018612|OTHER|Placebo|Saline
214721812|NCT01651312|DRUG|14C-labeled YM178|oral solution (1.85 MBq)
214721813|NCT01911208|BEHAVIORAL|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
214721814|NCT01911208|BEHAVIORAL|Control|Non-intervention control.
214721815|NCT02537223|DRUG|BYL719|
214721816|NCT02537223|DRUG|Cisplatin|
214721817|NCT02537223|RADIATION|Intensity modulated radiation therapy (IMRT)|
214721818|NCT00044655|DRUG|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
214635014|NCT06354114|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
214635015|NCT03476499|DEVICE|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
214635016|NCT05348057|DRUG|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
214635017|NCT05404620|OTHER|Schroth exercises|9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.
214721819|NCT00044655|DRUG|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
214721820|NCT00044655|DRUG|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
214721821|NCT00044655|DRUG|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
214721822|NCT00044655|DRUG|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
214721823|NCT06396455|PROCEDURE|interscalene block group|The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
214721824|NCT06396455|PROCEDURE|Suprascapular nerve block group|After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
214721825|NCT04593836|DRUG|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
214721826|NCT04593836|DRUG|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
214721827|NCT03489070|COMBINATION_PRODUCT|Traumastem®|Intraoperative application as secondary hemostatic treatment
214721828|NCT03489070|COMBINATION_PRODUCT|Surgicel®|Intraoperative application as secondary hemostatic treatment
214721829|NCT05560152|DRUG|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
214721830|NCT02213549|DIETARY_SUPPLEMENT|Placebo|
214721831|NCT02213549|DIETARY_SUPPLEMENT|Ume paste and ginger powder|
214721832|NCT01693497|BEHAVIORAL|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
214721833|NCT01693497|BEHAVIORAL|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
214721834|NCT01873807|DRUG|IDA|Idarubicin: 15mg/m2/d: -8-\>-6d
214633761|NCT06296862|OTHER|Dietary Approaches to Stop Hypertension Diet|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
214633762|NCT00586573|DRUG|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
214633763|NCT06401161|OTHER|3T Pu'er tea|Two types of Pu-erh tea with different levels of theabrownin content.
214633764|NCT03657901|BEHAVIORAL|Music listening|Guided music listening for 30 minutes before sleep onset
214633765|NCT03657901|BEHAVIORAL|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
214633766|NCT01496885|OTHER|Observational study|This was an observational study and no study drug was administered.
214633767|NCT03434405|BEHAVIORAL|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
214633768|NCT03434405|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
214633769|NCT03434405|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
214633770|NCT05011708|DEVICE|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
214721835|NCT01873807|RADIATION|TBI|TBI: 4.5 Gy/d, -5d, -4d
214721836|NCT01873807|DRUG|CTX|CY:60mg/kg/d, -3d, -2d
214721837|NCT01873807|DRUG|VP-16|VP-16: 15mg/kg, -2d, -1d
214633771|NCT05011708|DEVICE|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
214633772|NCT00005012|DRUG|Peginterferon alfa-2b|
214633773|NCT01404299|DIETARY_SUPPLEMENT|Nutritional Supplementation|\- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
214633774|NCT01404299|OTHER|Control|\- No intervention, except monthly home visits
214633775|NCT03164382|DRUG|FOLFOX regimen|Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
214633776|NCT03164382|DRUG|Sorafenib 200Mg Tab|Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
214633777|NCT01406834|BEHAVIORAL|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
214633778|NCT05075538|BIOLOGICAL|Spikevax|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633779|NCT05075538|BIOLOGICAL|Comirnaty|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633780|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633781|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633782|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633783|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633784|NCT05075538|BIOLOGICAL|Comirnaty Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633785|NCT05075538|BIOLOGICAL|Spikevax Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
214633786|NCT05439499|DRUG|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
214633787|NCT05439499|DRUG|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
214633788|NCT03380910|BEHAVIORAL|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
214633789|NCT03380910|BEHAVIORAL|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
214633790|NCT05168358|PROCEDURE|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
214633791|NCT02652884|DRUG|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
214633792|NCT02652884|DRUG|saline 0.9% NaCl|single dose of intramuscular placebo
214633793|NCT03012074|BEHAVIORAL|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
214633794|NCT00554203|DRUG|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
214633795|NCT04882397|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
214721838|NCT04854577|PROCEDURE|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
214721839|NCT04854577|PROCEDURE|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
214721840|NCT02024945|DRUG|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
214721841|NCT03063398|DIAGNOSTIC_TEST|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
214721842|NCT00639496|DRUG|n-acetylcysteine|600 mg x 3, for 12 months
214721843|NCT00639496|DRUG|placebo|Placebo
214721844|NCT06134869|PROCEDURE|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
214721845|NCT05954260|DIAGNOSTIC_TEST|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
214633796|NCT04882397|OTHER|Sham|Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
214633797|NCT00170430|DRUG|Fluconazole|
214633798|NCT00170430|DRUG|Metronizadole|
214633799|NCT00845442|DEVICE|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
214633800|NCT05798260|DIAGNOSTIC_TEST|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
214633801|NCT03446885|DRUG|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
214633802|NCT03446885|DRUG|Placebo|Placebo capsule administered orally
214633803|NCT02801214|OTHER|fMRI|
214633804|NCT01124487|DIETARY_SUPPLEMENT|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
214721846|NCT04657445|DIAGNOSTIC_TEST|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
214633805|NCT05768659|BEHAVIORAL|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
214633806|NCT03988439|DRUG|IDP-118 Lotion|Topical
214633807|NCT04303858|DRUG|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
214633808|NCT04303858|DRUG|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
214633809|NCT05667753|BEHAVIORAL|MINISTOP 3.0|MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
214633810|NCT06472011|OTHER|lean steak and potatoes|Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633811|NCT06472011|OTHER|lentil and sweet potato chili|Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633812|NCT06472011|OTHER|macaroni and cheese|Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633813|NCT06472011|OTHER|fish tacos|Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633814|NCT06472011|OTHER|chicken and pea fried rice|Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633815|NCT06472011|OTHER|pita and hummus|Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633816|NCT06472011|OTHER|creamy pork pasta|Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
214633817|NCT04589988|BEHAVIORAL|Removing Environmental Barriers to Independent Living (REBIL)|REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.
214633818|NCT04589988|BEHAVIORAL|Waitlist Attentional Control|The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
214633819|NCT02498639|PROCEDURE|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
214633820|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
214633821|NCT03685786|BIOLOGICAL|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
214633822|NCT03760926|DEVICE|May Health Kit|The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
214721847|NCT01577004|DIETARY_SUPPLEMENT|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
214721848|NCT02081560|DRUG|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
214721849|NCT01670682|PROCEDURE|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
214721850|NCT01670682|PROCEDURE|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
214721851|NCT01670682|DEVICE|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
214721852|NCT05018169|BEHAVIORAL|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
214721853|NCT02333669|OTHER|no intervention|no intervention
214721854|NCT02671760|DRUG|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
214633823|NCT00274521|DRUG|Tiotropium|
214633824|NCT00832728|OTHER|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
214633825|NCT00832728|DEVICE|ELAD®|ELAD therapy
214633826|NCT04163445|DEVICE|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
214633827|NCT04163445|DEVICE|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
214633828|NCT03662425|DRUG|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
214633829|NCT03662425|DRUG|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
214633830|NCT05287009|PROCEDURE|ILM nonpeeling|ILM is not peeled after ERM removal
214633831|NCT05287009|PROCEDURE|ILM peeling|ILM is peeled after ERM removal
214721855|NCT02671760|DRUG|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
214721856|NCT02671760|DRUG|Placebo|Placebo
214721857|NCT02999191|DRUG|BI 1467335 (Treatment A)|
214721858|NCT02999191|DRUG|BI 1467335 (Treatment B)|
214721859|NCT02999191|DRUG|BI 1467335 (Treatment C)|
214633832|NCT06409312|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports the therapeutic training of people with musculoskeletal conditions. It provides two therapeutic training programs for patients, one for each specific indication. Patients have continuous access to these programs through Akina Cloud, allowing them to independently complete nine training sessions without supervision. A minimum of three sessions per week is recommended, but patients have the option to engage in daily sessions if preferred. These therapy programs are based on current treatment guidelines and supported by relevant scientific research. They include customizable physical exercises tailored to individual needs and difficulty levels. Patients receive audio-visual guidance during these exercise sessions to ensure proper execution. Exercise therapy has demonstrated its ability to reduce pain, improve physical function, and enhance the overall quality of life for patients suffering from back pain and hip osteoarthritis.
214633833|NCT02559466|DEVICE|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
214721860|NCT00138229|BIOLOGICAL|aldesleukin|
214721861|NCT00138229|BIOLOGICAL|filgrastim|
214721862|NCT00138229|BIOLOGICAL|therapeutic autologous lymphocytes|
214721863|NCT00138229|DRUG|cyclophosphamide|
214721864|NCT00138229|DRUG|fludarabine phosphate|
214721865|NCT03966729|OTHER|Time (outcome)|
214721866|NCT01611480|DRUG|Imiquimod (topical use)|
214633834|NCT02559466|DEVICE|Positon Emission Tomography (PET) - Discovery 710®|Class IB
214633835|NCT04057274|OTHER|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
214633836|NCT01200901|DRUG|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
214633837|NCT04901299|DRUG|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
214633838|NCT04901299|DRUG|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
214633839|NCT02995616|DEVICE|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
214633840|NCT02995616|DEVICE|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
214633841|NCT02995616|DEVICE|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
214633842|NCT03041285|DRUG|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
214633843|NCT03041285|RADIATION|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
214633844|NCT03524339|DRUG|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
214633845|NCT03524339|DRUG|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
214633846|NCT05066256|DIAGNOSTIC_TEST|Left ventricular diastolic function|Transthoracic echocardiography Mitral E/e'
214633847|NCT05066256|DIAGNOSTIC_TEST|Inferior vena cava variation|Inferior vena cava variation from ultrasound
214721867|NCT00200512|DRUG|apomorphine HCl injection|
214721868|NCT00136838|BEHAVIORAL|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
214721869|NCT02279979|DEVICE|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
214721870|NCT00594087|DRUG|eszopiclone|eszopiclone 2mg or 3mg at bedtime
214633848|NCT04687696|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
214633849|NCT04687696|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
214633850|NCT04687696|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
214633851|NCT03127033|OTHER|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
214633852|NCT02645175|DIETARY_SUPPLEMENT|TW1025|20ml, 3 times per day (daily dose: 60 ml)
214633853|NCT02645175|DIETARY_SUPPLEMENT|Placebo|20ml, 3 times per day (daily dose: 60 ml)
214633854|NCT00832507|DRUG|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
214633855|NCT00832507|DRUG|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
214633856|NCT05800249|DRUG|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
214633857|NCT06095765|DRUG|Colchicine 0.5 MG Oral Tablet|Oral intake of 0.5 mg colchicine once daily
214721871|NCT00594087|OTHER|placebo|2 mg or 3 mg at bedtime
214721872|NCT03865238|BIOLOGICAL|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
214633858|NCT06095765|DRUG|Placebo|Oral intake of matching placebo once daily
214633859|NCT02510287|DRUG|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
214633860|NCT02510287|DRUG|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
214633861|NCT02510287|DRUG|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
214633862|NCT02510287|DRUG|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
214633863|NCT02510287|DRUG|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
214633864|NCT04830670|PROCEDURE|sinus floor elevation with lateral approach|sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
214633865|NCT02112370|DRUG|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
214721873|NCT03865238|BIOLOGICAL|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
214721874|NCT06047106|RADIATION|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
214721875|NCT06047106|PROCEDURE|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
214721876|NCT06047106|BIOLOGICAL|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
214633866|NCT02112370|OTHER|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
214633867|NCT02962050|PROCEDURE|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
214633868|NCT02962050|DEVICE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
214633869|NCT02962050|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
214633870|NCT02962050|DRUG|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
214633871|NCT02962050|DEVICE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
214633872|NCT02962050|OTHER|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
214633873|NCT02962050|OTHER|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
214633874|NCT04951687|DIETARY_SUPPLEMENT|Ecologic Barrier©|5x10\^9 CFU/ 2g per day of Ecologic Barrier©
214633875|NCT04951687|DIETARY_SUPPLEMENT|Placebo powder|matched placebo
214633876|NCT04004884|DRUG|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
214633877|NCT02481973|OTHER|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
214633878|NCT01555203|BEHAVIORAL|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
214633879|NCT03249571|DIETARY_SUPPLEMENT|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
214633880|NCT03249571|DIETARY_SUPPLEMENT|Placebo|2-week ingestion of placebo supplement
214635018|NCT05404620|OTHER|PNF technique|9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
214635019|NCT03861754|BEHAVIORAL|Lifestyle modification|
214635020|NCT00601536|DRUG|Lithium|
214635021|NCT01302951|DRUG|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
214633881|NCT06118060|OTHER|Acupressure|In this study, the frequency of acupressure was twice a day (the interval between each acupressure was more than 6 hours, 6:00 to 9:00 in the morning and 1:00 to 4:00 in the afternoon); the acupressure was applied from the first day after surgery for a total of 5 days, that is, each patient received a total of 10 acupressure; the duration was 5 minutes, and the bilateral acupressure required 10 minutes.
214633882|NCT02433600|OTHER|Cow's milk-based infant formula|
214633883|NCT02433600|OTHER|Cow milk-based infant formula with enriched protein fractions|
214633884|NCT00271323|DRUG|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
214633885|NCT00271323|RADIATION|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
214633886|NCT02011165|PROCEDURE|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
214633887|NCT00388908|BEHAVIORAL|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
214633888|NCT00388908|OTHER|Usual Care|
214633889|NCT03723629|OTHER|No intercention|No intercention
214633890|NCT04370327|OTHER|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
214633891|NCT04370327|OTHER|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
214633892|NCT04370327|OTHER|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
214633893|NCT00453271|DRUG|NB-002|
214633894|NCT00453271|DRUG|Vehicle control|
214633895|NCT02164656|BEHAVIORAL|mindfulness for smokers|
214633896|NCT02491294|BEHAVIORAL|School|students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
214633897|NCT02491294|BEHAVIORAL|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
214633898|NCT02491294|BEHAVIORAL|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
214633899|NCT01378286|DRUG|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:~Route of administration:"
214633900|NCT01378286|DRUG|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
214721877|NCT06047106|BIOLOGICAL|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
214633901|NCT00300638|PROCEDURE|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
214633902|NCT00300638|BEHAVIORAL|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
214633903|NCT06076915|BEHAVIORAL|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
214633904|NCT02728830|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
214633905|NCT06398041|OTHER|Blood flow restriction training|standard physiotherapy 45 minutes per day, 5 day a week (GAPP) + 2 extra sessions of blood flow restriction training
214633906|NCT06398041|OTHER|Opinions|Healthcare workers in the geriatric rehabilitation ward and patients will be asked on their opinions on GAPP+Care concerning blood flow restriction training
214633907|NCT03242837|BEHAVIORAL|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
214633908|NCT03242837|OTHER|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
214633909|NCT04854837|DRUG|Remdesivir|Remdesivir treatment
214721878|NCT03777085|DRUG|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
214721879|NCT03777085|DRUG|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
214721880|NCT05525832|OTHER|Normal saline|Nasopharyngeal washes with NaCl 0.9%
214721881|NCT04864600|OTHER|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
214633910|NCT04659460|DEVICE|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
214633911|NCT06128460|DRUG|Zimberelimab|240mg, q3w，8 cycles
214633912|NCT06128460|DRUG|Platinum|cisplatin 40mg/m2 for 5-6 cycles
214633913|NCT06128460|RADIATION|radiotherapy|45-50Gy/1.8Gy/25-28f
214633914|NCT00123214|DRUG|Controlled Dietary Intervention|
214633915|NCT04760561|PROCEDURE|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
214633916|NCT00143455|DRUG|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
214633917|NCT00143455|DRUG|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
214633918|NCT00866138|DRUG|masitinib (AB1010)|masitinib 9 mg/kg/day per os
214633919|NCT04029012|DRUG|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
214633920|NCT01325428|DRUG|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
214633921|NCT01325428|DRUG|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
214633922|NCT03852394|OTHER|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
214633923|NCT03537027|DIETARY_SUPPLEMENT|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
214721882|NCT04864600|OTHER|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
214721883|NCT03358615|PROCEDURE|cesarean section|assessment of the indications of cesarean section according to Robson criteria
214721884|NCT04269837|OTHER|Counseling|Receive sexual health counseling
214721885|NCT04269837|OTHER|Quality-of-Life Assessment|Ancillary studies
214721886|NCT04269837|OTHER|Questionnaire Administration|Ancillary studies
214633924|NCT04593654|DRUG|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
214633925|NCT03665142|OTHER|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
214633926|NCT03665142|OTHER|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
214633927|NCT02141711|DRUG|TAK-438|TAK-438 tablets
214633928|NCT02141711|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
214633929|NCT02335996|BIOLOGICAL|Blood samples for measuring adiponectin, leptin and omentin plasma|
214721887|NCT01347632|DRUG|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
214721888|NCT02408185|DRUG|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
214633930|NCT02335996|DEVICE|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
214633931|NCT02184871|OTHER|exposure to different risk factors and molecular assessment|
214633932|NCT03557892|DEVICE|CGM+CSII|Animas Vibe Platinum insulin pump and Dexcom G4 CGM
214633933|NCT03557892|DEVICE|MDI with degludec|Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
214633934|NCT03657251|GENETIC|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
214633935|NCT05688878|DEVICE|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
214633936|NCT02577861|PROCEDURE|Biopsy from donor eye|Corneal biopsy from undamaged limbus
214633937|NCT02577861|PROCEDURE|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
214633938|NCT02577861|PROCEDURE|Ophtalmologic examination|"The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
214633939|NCT02577861|PROCEDURE|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
214633940|NCT02577861|PROCEDURE|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
214633941|NCT02577861|PROCEDURE|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
214633942|NCT02577861|BEHAVIORAL|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
214721889|NCT02408185|DRUG|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
214721890|NCT03189407|DIETARY_SUPPLEMENT|Moringa oleifera tea|
214721891|NCT05467488|PROCEDURE|photofunctionalization|UVA and UVC photofunctionalization of dental implants
214721892|NCT01090674|OTHER|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
214721893|NCT05054231|OTHER|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
214633943|NCT02577861|PROCEDURE|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
214633944|NCT01990287|DEVICE|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
214633945|NCT01990287|DEVICE|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
214633946|NCT04639180|DRUG|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
214633947|NCT04639180|DRUG|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
214633948|NCT02090400|DRUG|Bazedoxifene|20 mg Oral daily for 12 months
214633949|NCT02090400|DRUG|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
214633950|NCT01827033|BEHAVIORAL|meditation training|
214633951|NCT05533983|OTHER|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
214633952|NCT03298022|BIOLOGICAL|ALTB-168|monoclonal antibody
214633953|NCT03313245|OTHER|No Intervention/Observational Study|No Intervention/Observational Study
214633954|NCT01861405|BEHAVIORAL|neuropsychological testing and quality of life assessments|
214633955|NCT01861405|RADIATION|Standard of Care WBRT or SRS|
214633956|NCT01861405|DEVICE|Functional magnetic resonance imaging|
214633957|NCT01787916|DRUG|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
214633958|NCT01787916|DRUG|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
214633959|NCT01029067|BEHAVIORAL|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
214633960|NCT01029067|BEHAVIORAL|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
214633961|NCT01445769|DRUG|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
214633962|NCT03099707|BEHAVIORAL|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
214633963|NCT05926726|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
214721894|NCT02865265|PROCEDURE|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
214721895|NCT00689169|DRUG|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
214721896|NCT00689169|PROCEDURE|ASCT|ASCT : D0
214721897|NCT00689169|DRUG|Rituximab|Rituximab 250 mg/m² :D-21 D-14
214721898|NCT01883804|DRUG|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
214633964|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
214633965|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
214633966|NCT01024998|BIOLOGICAL|AAV2-sFLT01|6 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
214633967|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
214633968|NCT00144482|DRUG|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
214633969|NCT00144482|DRUG|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
214633970|NCT03721666|OTHER|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
214633971|NCT03039842|DRUG|Dextromethorphan|
214633972|NCT03039842|DRUG|Memantine|
214633973|NCT03039842|DRUG|dextromethorphan+memantine|
214633974|NCT03039842|DRUG|placebo+valproate|
214633975|NCT05957991|DRUG|Metformin Hydrochloride tablet|Treatment with metformin
214633976|NCT05957991|DRUG|Placebo|Treatment with placebo
214633977|NCT05957991|BEHAVIORAL|Lifestyle intervention|Changing behaviour on diet and excersise
214633978|NCT05957991|BEHAVIORAL|No lifestyle intervention|No changes in behaviou on diet and excersise
214633979|NCT03862352|DEVICE|Covered coronary stent|Insertion of covered coronary stent as part of standard care
214633980|NCT06287970|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.
214633981|NCT06287970|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
214633982|NCT00610831|DEVICE|DIRECTVIEW CR Mammography|4 views screening mammogram
214633983|NCT00129168|DRUG|Zosuquidar|
214633984|NCT00129168|DRUG|Daunorubicin|
214633985|NCT00129168|DRUG|Cytarabine|
214633986|NCT00355173|DEVICE|Lubo cervical collar|
214633987|NCT00715585|BEHAVIORAL|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
214633988|NCT00715585|BEHAVIORAL|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
214633989|NCT00715585|BEHAVIORAL|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
214633990|NCT02487420|BEHAVIORAL|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
214633991|NCT03926663|DRUG|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
214633992|NCT03926663|DRUG|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
214633993|NCT02340338|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
214721899|NCT00492414|DRUG|Paroxetine CR|
214633994|NCT04906980|DRUG|JNJ-64281802|JNJ-64281802 will be administered orally.
214633995|NCT04906980|DRUG|Placebo|Matching placebo (PEG400) will be administered orally.
214633996|NCT01168648|BEHAVIORAL|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
214633997|NCT01168648|OTHER|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
214721900|NCT01577355|RADIATION|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
214721901|NCT04957303|DEVICE|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
214721902|NCT03038672|BIOLOGICAL|Nivolumab|Given IV
214721903|NCT03038672|DRUG|Varlilumab|Given IV
214721904|NCT04694911|BEHAVIORAL|Focus Group|Participate in focus group
214721905|NCT04694911|OTHER|Interview|Complete cognitive interview
214633998|NCT02774382|DRUG|Vancomycin|Already incl. in arm description
214633999|NCT02774382|DRUG|Fecal microbiota transplantation|Already incl. in arm description
214634000|NCT02774382|DRUG|Rectal bacteriotherapy|Already incl. in arm description
214634001|NCT03496428|DEVICE|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
214721906|NCT04694911|OTHER|Research or Clinical Assessment Tool|Receive OOCAT
214721907|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
214721908|NCT04122118|OTHER|Medical Chart Review|Review of medical chart
214721909|NCT04122118|OTHER|Educational Intervention|Receive pharmacist-led education
214721910|NCT04122118|OTHER|Survey Administration|Ancillary studies
214721911|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
214721912|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
214721913|NCT01640080|DRUG|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
214721914|NCT00628316|DIETARY_SUPPLEMENT|caffeine|caffeine daily intake will be reduced form 150 ml per day
214721915|NCT03140488|DRUG|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
214721916|NCT01751204|DIETARY_SUPPLEMENT|Calcium tablet|
214721917|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (250mg)|
214721918|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (125mg)|
214721919|NCT04576260|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
214634002|NCT06218095|OTHER|Simulation application|Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
214634003|NCT01664728|DRUG|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
214634004|NCT01664728|DRUG|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
214634005|NCT00343889|BIOLOGICAL|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
214634006|NCT00343889|BIOLOGICAL|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
214634007|NCT00343889|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine
214634008|NCT05925296|DEVICE|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
214634009|NCT01294579|BIOLOGICAL|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
214634010|NCT01294579|DRUG|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
214634011|NCT04458298|DRUG|OP-101|OP-101 infusion will be administered intravenously.
214634012|NCT04458298|DRUG|Placebo|Matching placebo infusion will be administered intravenously.
214634013|NCT05517941|OTHER|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
214634014|NCT05517941|OTHER|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
214634015|NCT03957772|PROCEDURE|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
214634016|NCT03957772|PROCEDURE|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
214634017|NCT04324372|DRUG|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
214634018|NCT01659008|DRUG|Estradiol|
214634019|NCT01659008|DRUG|Lysteda|
214634020|NCT02505880|OTHER|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
214634021|NCT02505880|DRUG|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
214634022|NCT00487539|BIOLOGICAL|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
214634023|NCT00487539|BIOLOGICAL|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.
214634024|NCT00487539|BIOLOGICAL|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.
214634025|NCT00487539|BIOLOGICAL|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.
214634026|NCT00487539|BIOLOGICAL|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
214634027|NCT00879697|BEHAVIORAL|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
214634028|NCT00879697|BEHAVIORAL|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
214634029|NCT04885725|DEVICE|All group|All the participants performed the isokinetic proprioception and strength tests and the functional tests, on the same visit.
214634030|NCT02774837|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
214634031|NCT02774837|DRUG|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
214634032|NCT06241846|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
214634033|NCT00756873|DRUG|Administration of placebo|Placebo qd orally day 0-14
214634034|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
214634035|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
214634036|NCT01565733|DRUG|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
214634037|NCT00501787|DRUG|Metformin|
214634038|NCT04456309|OTHER|No intervention,|pure observational study
214634039|NCT01905280|PROCEDURE|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
214634040|NCT01905280|PROCEDURE|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
214634041|NCT03527121|OTHER|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
214634042|NCT03527121|OTHER|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
214634043|NCT02751502|DEVICE|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
214634044|NCT00301951|BIOLOGICAL|anti-thymocyte globulin|
214634045|NCT00301951|BIOLOGICAL|sargramostim|
214634046|NCT00301951|DRUG|busulfan|
214634047|NCT00301951|DRUG|fludarabine phosphate|
214634048|NCT00301951|DRUG|mycophenolate mofetil|
214634049|NCT00301951|DRUG|tacrolimus|
214634050|NCT00301951|PROCEDURE|umbilical cord blood transplantation|
214634051|NCT00088374|DRUG|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
214634052|NCT00088374|DRUG|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
214634053|NCT00088374|DRUG|[15-O] H2O|\[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
214634054|NCT00088374|DRUG|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
214634055|NCT02984046|DRUG|Protein CC16|
214634056|NCT03064737|OTHER|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
214634057|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
214634058|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
214634059|NCT02300701|DRUG|Xolair|According to manufacturer's instructions
214634060|NCT02300701|DRUG|Placebo|Placebo
214634061|NCT03499028|OTHER|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
214634062|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
214634063|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
214634064|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
214634065|NCT04194255|DIETARY_SUPPLEMENT|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
214634066|NCT02877342|OTHER|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
214634067|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
214634068|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
214634069|NCT01437397|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
214634070|NCT01437397|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
214634071|NCT01437397|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
214634072|NCT05903846|OTHER|Oketani massage|"The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless."
214634073|NCT02179229|DIETARY_SUPPLEMENT|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
214634074|NCT02179229|DIETARY_SUPPLEMENT|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
214634075|NCT02751840|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine capsule before RMR measurement
214634076|NCT02751840|DIETARY_SUPPLEMENT|Placebo|Placebo capsule (starch) before RMR measurement
214793813|NCT05508100|BIOLOGICAL|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
215030990|NCT02014987|BEHAVIORAL|Training programmes|"Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
214793814|NCT05508100|BIOLOGICAL|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
214793815|NCT02496026|DEVICE|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
214793816|NCT02496026|DEVICE|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
214793817|NCT04000009|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
215030991|NCT01828060|DIETARY_SUPPLEMENT|Jobelyn™|Sorghum bicolor leaf sheath extract
215030992|NCT01828060|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
214722406|NCT06171711|BEHAVIORAL|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
214722407|NCT04313101|OTHER|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
214722408|NCT06070636|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
214722409|NCT06070636|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214722410|NCT06070636|DRUG|Sintilimab|200mg intravenously every 32 weeks
214722411|NCT03713827|DEVICE|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
214722412|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
214722413|NCT04694820|OTHER|Survey Administration|Ancillary studies
214722414|NCT01001572|DRUG|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
214722415|NCT01001572|DRUG|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
214722416|NCT01001572|DRUG|Placebo|1 capsule or tablet taken orally once daily
214722417|NCT02772224|DEVICE|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
214722418|NCT02772224|DEVICE|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
214722419|NCT05265793|DRUG|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
214722420|NCT03652545|BIOLOGICAL|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
214722421|NCT02597192|OTHER|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
214722422|NCT02597192|OTHER|oral hygiene products without Bacillus|products without Bacillus
214722423|NCT00643799|DRUG|Celecoxib|200 mg oral capsule once daily for 6 months
214722424|NCT00643799|DRUG|Naproxen|500 mg oral capsule twice daily for 6 months
214722425|NCT00643799|DRUG|Placebo|Matched oral placebo for 6 months
214722426|NCT00964600|PROCEDURE|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
214722427|NCT03127436|DRUG|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
214722428|NCT01481506|PROCEDURE|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
214722429|NCT05104788|DRUG|Icotinib|Oral
214722430|NCT05104788|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
214722431|NCT05104788|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
214722432|NCT05104788|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
214722433|NCT03534791|OTHER|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
214722434|NCT05778357|OTHER|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
214722435|NCT06263790|DEVICE|Intubating laryngeal mask|Intubation through a laryngeal mask
214722436|NCT06263790|DEVICE|Direct laryngoscopy|Intubation by using a direct laryngoscope
214722437|NCT00943410|RADIATION|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
215030993|NCT05410314|DRUG|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
215030994|NCT03220633|DRUG|ATB-346|
215030995|NCT03220633|DRUG|Placebo|
215030996|NCT01678742|DIETARY_SUPPLEMENT|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
215030997|NCT01678742|DIETARY_SUPPLEMENT|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
214722438|NCT00943410|DRUG|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
214722439|NCT02019758|DRUG|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
214722440|NCT02019758|DRUG|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
214722441|NCT02019758|DRUG|Placebo slurry|Slurry of sucralose - 4 mL twice daily
214722442|NCT02019758|DRUG|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
214722443|NCT05994495|DIAGNOSTIC_TEST|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
214722444|NCT05994495|OTHER|Clinical Syndromic Approach|Physical examination
214722445|NCT04171167|DRUG|Fluticasone Propionate|three visits: 0, after washout, after FP usage
214722446|NCT03138291|DEVICE|Somnodent|Each pregnant women will be treat with a Somnodent
214722447|NCT02703649|DRUG|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
214722448|NCT05865756|OTHER|Acoustic cough features analysis|Acoustic cough features analysis
214722449|NCT05983679|DIAGNOSTIC_TEST|Blood sample|Blood sample
214722450|NCT03948594|DIETARY_SUPPLEMENT|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
214722451|NCT03948594|OTHER|plain water|250ml plain water
214722452|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners are blinded to each other and to the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
214722453|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners is now being informed of the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
214722454|NCT01548209|DRUG|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
214722455|NCT01548209|DRUG|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
214722456|NCT02025530|OTHER|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
214722457|NCT04464798|DRUG|CC-220|Oral
214722458|NCT04464798|DRUG|Rituximab|SC and IV infusion
214722459|NCT04464798|DRUG|Obinutuzumab|IV Infusion
214722460|NCT05746533|PROCEDURE|Hip Arthroscopy|Hip Preservation surgeries
214722461|NCT05947318|DEVICE|transcranial alternating current stimulation 70 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 70 Hz"
214722462|NCT05947318|BEHAVIORAL|Training|Training of the upper limb with specific kinematic and kinetic tasks plus functional training
214722463|NCT05947318|DEVICE|transcranial alternating current stimulation 7 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 7 Hz"
214722464|NCT05947318|DEVICE|transcranial alternating current stimulation Sham|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The stimulation will be turn on for 30 seconds (at 70 Hz)"
214722465|NCT04236479|BIOLOGICAL|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
214722466|NCT03551626|DRUG|Dabrafenib|Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration
214722467|NCT03551626|DRUG|Trametinib|Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
214722468|NCT05038553|OTHER|No intervention|No intervention
214722469|NCT05509933|DRUG|Budesonide|budesonide starting day 5 after transplant
214722470|NCT04307953|DRUG|AZD0530 Difumarate|AZD0530 for the duration of the trial
214722471|NCT04307953|DRUG|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
214722472|NCT04647695|DRUG|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
214722473|NCT04647695|DRUG|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
214722474|NCT05256992|OTHER|Standard Servies + Ray of Hope Curriculum|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.
215030998|NCT02296099|DRUG|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
215030999|NCT02296099|DRUG|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
215031000|NCT01085903|DRUG|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
214722475|NCT05256992|OTHER|Standard Services|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.
214722476|NCT00049140|DRUG|EF5|
214722477|NCT00049140|OTHER|bioluminescence|
214722478|NCT00049140|OTHER|flow cytometry|
214722479|NCT00049140|OTHER|immunohistochemistry staining method|
214722480|NCT00049140|PROCEDURE|biopsy|
214722481|NCT04223206|DIETARY_SUPPLEMENT|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
214722482|NCT05035823|DEVICE|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
214722483|NCT01620658|DEVICE|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
214722484|NCT01620658|DEVICE|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
214722485|NCT01620658|DEVICE|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
214722486|NCT03616262|DRUG|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
214722487|NCT03616262|DRUG|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
214722488|NCT01935570|DRUG|Magnesium chloride (ChronoMag Smart Tablet®)|
214722489|NCT01935570|DRUG|Magnesium carbonate (Mag2® Tablet)|
214722490|NCT05967208|BEHAVIORAL|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
214722491|NCT05967208|BEHAVIORAL|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
214722492|NCT05987475|PROCEDURE|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
214722493|NCT02868099|DRUG|Romiplostim|
214722494|NCT02868099|DRUG|Placebo|
214722495|NCT05068999|DEVICE|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
214722496|NCT05703113|BEHAVIORAL|Web 2.0 tools|Education with Web 2.0 tools
214722497|NCT04769336|DEVICE|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
214722498|NCT04769336|DEVICE|Point of Care CBC|lab samples will be analyzed at point of care
214722499|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
214722500|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
214722501|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
214722502|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
214722503|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
214722504|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
214722505|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
214722506|NCT05630898|DIAGNOSTIC_TEST|CMV PCR|Saliva CMV PCR
215031001|NCT01085903|DRUG|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
215031002|NCT01085903|BEHAVIORAL|Baseline|Observations made at baseline before any intervention
214722507|NCT03634878|OTHER|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
214722508|NCT04018586|DEVICE|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
214722509|NCT04018586|DEVICE|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
214722510|NCT04018586|DEVICE|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
214722511|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
215031003|NCT01085903|BEHAVIORAL|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
214722512|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
214793818|NCT05744609|OTHER|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
215031004|NCT01085903|BEHAVIORAL|Post CPS|20 minutes following the CPS condition.
215031005|NCT01085903|BEHAVIORAL|Follow up|Follow up testing occurred at 3 months
215031006|NCT04945837|OTHER|self administered questionnaire|longitunidal descriptive study
215031007|NCT02971839|DRUG|VX-561|
215031008|NCT02971839|DRUG|Placebo|
215031009|NCT02971839|DRUG|IVA|
214722513|NCT05735613|PROCEDURE|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
214722514|NCT05735613|PROCEDURE|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
214722515|NCT05735613|PROCEDURE|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
214722516|NCT01637818|PROCEDURE|Lichtenstein's operation|
214722517|NCT01637818|PROCEDURE|Mesh Plug Repair|
214722518|NCT01637818|DRUG|Opiate|Postoperative pain therapy
214722519|NCT01637818|DRUG|Paracetamol|Postoperative pain therapy
214722520|NCT01637818|DRUG|non-steroidal anti-inflammatory drug|Postoperative pain therapy
214722521|NCT03555968|DRUG|THC 0|THC dose = 0mg
214722522|NCT03555968|DRUG|THC 5|THC dose = 5mg
214722523|NCT03555968|DRUG|THC 10|THC dose = 10mg
214722524|NCT03555968|OTHER|BAC 0|Blood alcohol concentration = .000%
214722525|NCT03555968|OTHER|BAC .025|Blood alcohol concentration = .025%
214722526|NCT03555968|OTHER|BAC .049|Blood alcohol concentration = .049%
214722527|NCT03827980|OTHER|no intervention, only clinical examination|standardised interview and clinical examination
214722528|NCT00954824|BIOLOGICAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
214722529|NCT01007513|PROCEDURE|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
214722530|NCT01007513|PROCEDURE|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
214722531|NCT04334772|DEVICE|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
214722532|NCT04334772|DEVICE|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
214722533|NCT04334772|OTHER|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
214722534|NCT02017457|BIOLOGICAL|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6"
215031010|NCT06240286|BEHAVIORAL|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
214722535|NCT02017457|DRUG|Azacytidine|"* Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
214722536|NCT06405685|DRUG|Nimotuzumab|Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
214722537|NCT06405685|DRUG|AG|Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
215030455|NCT05920252|BEHAVIORAL|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
214722538|NCT06124885|DIAGNOSTIC_TEST|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
214722539|NCT01570608|DRUG|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
214722540|NCT01570608|DRUG|Verteporfin|Verteporfin photodynamic therapy standard fluence
214722541|NCT04443296|DRUG|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
214722542|NCT00263835|BEHAVIORAL|Empowerment|
214722543|NCT03608046|DRUG|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
214722544|NCT03608046|DRUG|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
214722545|NCT03608046|DRUG|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
214722546|NCT05103475|BEHAVIORAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
214722547|NCT05103475|BEHAVIORAL|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
214722548|NCT00045630|DRUG|carboplatin|
214722549|NCT00045630|DRUG|gemcitabine|
214722550|NCT00045630|DRUG|paclitaxel|
214722551|NCT00045630|PROCEDURE|surgery|
214722552|NCT02902822|PROCEDURE|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
214722553|NCT02902822|DEVICE|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
214722554|NCT00346255|DRUG|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
215030456|NCT05920252|BEHAVIORAL|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
214722555|NCT02685111|DRUG|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
214722556|NCT02685111|DRUG|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
214722557|NCT03027193|BIOLOGICAL|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
214722558|NCT03027193|BIOLOGICAL|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
214722559|NCT01566591|DEVICE|Deep TMS Treatment|24 TMS treatments over 6 weeks .
214722560|NCT01566591|DEVICE|Sham Treatment|24 TMS treatments over 6 weeks
214722561|NCT04401904|DRUG|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
214722562|NCT04401904|BEHAVIORAL|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
214722563|NCT00088972|DRUG|celecoxib|Given orally
214722564|NCT00088972|OTHER|placebo|Given orally
214722565|NCT04902768|OTHER|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
214722566|NCT02841592|OTHER|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
214722567|NCT02841592|OTHER|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
214722568|NCT02668744|BEHAVIORAL|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
214722569|NCT02023112|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
214722570|NCT02023112|DRUG|Ribavirin|Capsule
214722571|NCT03147599|DRUG|Coloverin|Mebeverine hydrochloride 135 mg
214722572|NCT03147599|DRUG|Placebo|Placebo
214722573|NCT03114098|OTHER|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
214722574|NCT03536923|DEVICE|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
214722575|NCT05317260|DRUG|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
214722576|NCT02228824|DRUG|Very low nicotine content cigarettes|0.07 mg nicotine delivery
214722577|NCT02228824|DRUG|Normal nicotine content cigarettes|0.8 mg nicotine delivery
214722578|NCT00309257|DRUG|ACE I, ATA II and Statins|
214722579|NCT00309257|DRUG|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
214722580|NCT05911113|OTHER|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
214722581|NCT05911113|OTHER|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
214722582|NCT00568607|DRUG|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
214722583|NCT00475371|DRUG|MKC253 Inhalation Powder|Inhalation powder
214722584|NCT04203940|PROCEDURE|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
214722585|NCT04203940|PROCEDURE|Suture|mesh fixation was done with polypropylene 2/0 sutures
214722586|NCT05944159|BEHAVIORAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
214722587|NCT05944159|OTHER|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
214722588|NCT02167724|OTHER|Bucco-dental examination|
214722589|NCT02167724|OTHER|Blood sample|
214722590|NCT02167724|OTHER|Clinical and social questionnaire|
214722591|NCT05483660|OTHER|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
214722592|NCT05483660|OTHER|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
214722593|NCT05483660|OTHER|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
214722594|NCT05483660|OTHER|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
214722595|NCT01906476|BEHAVIORAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
214722596|NCT01906476|BEHAVIORAL|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
214722597|NCT05057325|OTHER|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
214722598|NCT05057325|OTHER|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
214722599|NCT04287439|BEHAVIORAL|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
214722600|NCT04287439|BEHAVIORAL|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
214722601|NCT04287439|OTHER|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
214722602|NCT04307901|DEVICE|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
214722603|NCT00568204|DEVICE|Mexyn-A|Atomised topical self-chilled pressurised spray
214722604|NCT03037567|BEHAVIORAL|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
215030457|NCT05697224|DIAGNOSTIC_TEST|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis
215030458|NCT05846893|DEVICE|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
214722605|NCT06221072|DRUG|JMT103|120 mg by subcutaneous injection every 4 weeks
214722606|NCT06221072|DRUG|zoledronic acid|4 mg by intravenous drip (100mL:4mg) every 4 weeks
214722607|NCT01176240|DRUG|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
214722608|NCT01176240|OTHER|Placebo|Placebo
214722609|NCT01917240|OTHER|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
214722610|NCT01115517|DRUG|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
214722611|NCT01115517|DRUG|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
215030459|NCT05846893|DEVICE|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
214722612|NCT01053572|PROCEDURE|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
214722613|NCT02480504|OTHER|dietary intervention intermittent energy restriction|Randomized clinical trial
214722614|NCT02480504|OTHER|continuous energy restriction|
214722615|NCT00615212|DRUG|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
214722616|NCT00615212|DRUG|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
214722617|NCT00615212|DRUG|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
214722618|NCT00615212|DRUG|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
214722619|NCT04016103|DEVICE|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
214722620|NCT03119441|DEVICE|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
214722621|NCT03119441|DEVICE|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
214722622|NCT03889964|OTHER|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
214722623|NCT01786850|PROCEDURE|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
214722624|NCT01482455|OTHER|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
214722625|NCT01482455|OTHER|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
214722626|NCT01931150|DRUG|Topical Dapsone 5% Gel|
214722627|NCT01931150|OTHER|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
214722628|NCT01931150|DRUG|oral antibiotics|
214722629|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
214722630|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
215030460|NCT05838248|OTHER|antibiotic duration|Duration of antibiotic treatment post appendectomy
215030461|NCT06468176|OTHER|Cognitive Behavioral Therapy (CBT) neuropsychologist|"* CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week"
214722631|NCT06275997|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
214722632|NCT04816045|PROCEDURE|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
214722633|NCT04816045|PROCEDURE|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
214722634|NCT03647176|OTHER|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
214722635|NCT01500941|DIETARY_SUPPLEMENT|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
214722636|NCT01500941|OTHER|maltodextrin|sachets
214722637|NCT05826990|DRUG|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
214722638|NCT02597491|BEHAVIORAL|TLC monthly|Tobacco longitudinal care monthly
214722639|NCT02597491|BEHAVIORAL|TLC quarterly|Tobacco longitudinal care quarterly
214722640|NCT02597491|BEHAVIORAL|MTM|Medication management therapy
214722641|NCT02597491|BEHAVIORAL|4 week assessment|4 week assessment
214722642|NCT02597491|BEHAVIORAL|8 week assessment|8 week assessment
214722643|NCT03561246|OTHER|Incline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
214722644|NCT03561246|OTHER|Decline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
214722645|NCT03561246|OTHER|Level Treadmill (Control)|Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
214722646|NCT02896192|DRUG|Setmelanotide|Once daily SC injection
214722647|NCT02896192|DRUG|Placebo|Once daily SC injection
214722648|NCT00215592|DRUG|Zonegran|
214722649|NCT05537493|OTHER|Telerehabilitation|It will be followed by exercising on whatsapp
214722650|NCT05537493|OTHER|Face to face|It will be followed by face to face
214722651|NCT00464711|DRUG|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
214722652|NCT00544804|DRUG|lapatinib ditosylate|
214722653|NCT00544804|GENETIC|gene expression analysis|
214722654|NCT00544804|OTHER|diagnostic laboratory biomarker analysis|
214722655|NCT01308294|BIOLOGICAL|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
214722656|NCT01308294|BIOLOGICAL|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
214722657|NCT01308294|BIOLOGICAL|"2 vaccine injections in distinct limbs"|
214722658|NCT00535444|OTHER|Parish nurse visit|One visit with the parish nurse in 2 weeks
214722659|NCT05878691|DRUG|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
214722660|NCT05878691|DRUG|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
214722661|NCT05878691|DRUG|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
214722662|NCT03615989|BEHAVIORAL|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
214722663|NCT03615989|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
214722664|NCT03615989|DIETARY_SUPPLEMENT|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
214722665|NCT00479167|DRUG|Bortezomib and Tositumomab I-131|
214722666|NCT04488757|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
214722667|NCT04488757|OTHER|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
214722668|NCT04919772|OTHER|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
214722669|NCT03702140|DRUG|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
214722670|NCT01264068|DRUG|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
214722671|NCT02175303|BIOLOGICAL|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
214722672|NCT03230357|DEVICE|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
214722673|NCT02813863|DRUG|SP2086|
214722674|NCT02813863|DRUG|Metformin|
214722675|NCT00701246|DRUG|ferrous sulfate|
214722676|NCT00701246|DRUG|folic acid|
214722677|NCT00701246|DRUG|placebo (folic acid)|
214722678|NCT01603212|DRUG|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
214722679|NCT01603212|DRUG|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
214722680|NCT01603212|DRUG|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
214722681|NCT01390038|DEVICE|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
214722682|NCT04631614|OTHER|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
214722683|NCT04631614|OTHER|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
214722684|NCT04631614|OTHER|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
215031011|NCT06240286|BEHAVIORAL|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
215031012|NCT06240286|BEHAVIORAL|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
214722685|NCT04631614|OTHER|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
214722686|NCT04631614|OTHER|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
214722687|NCT04631614|OTHER|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
214722688|NCT04631614|OTHER|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
214722689|NCT04631614|OTHER|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
214722690|NCT01311895|DRUG|H2O|2 mg IV hydromorphone
214722691|NCT01311895|DRUG|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
215030462|NCT03763370|DRUG|Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)|"Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles"
215030463|NCT03763370|DRUG|Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)|"Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information"
214722692|NCT03571503|PROCEDURE|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
214722693|NCT03571503|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
214722694|NCT03571503|PROCEDURE|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
214722695|NCT03571503|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214722696|NCT03571503|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214722697|NCT03571503|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214722698|NCT03571503|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214722699|NCT03571503|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214635132|NCT07143175|OTHER|Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation|"The CARE-D-FOOT-Nav (Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation) program is a patient navigator intervention that aims to increase access to guideline-concordant multidisciplinary DFU care to improve DFU healing.~CARE-D-Foot-Nav is a diabetes educator who will serve as a dedicated Diabetic Foot Ulcer (DFU) patient navigator. The navigator will assist the subjects with diabetic foot ulcer care.~Based on community input, navigators will conduct 30-to 60-minute encounters, either by phone or in person, at least once a week during the 20-week program. Additional contact may be warranted to coordinate appointments and transportation. Participants can call the navigator with DFU-related concerns at any time during the navigator's working hours. The overarching goal of the navigator is to help patients access the four key pillars of DFU care, thereby optimizing the chances of DFU healing."
214722700|NCT03571503|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
214722701|NCT03049943|DEVICE|low level laser|
214722702|NCT02565953|DEVICE|Paclitaxel-releasing PTA balloon catheter|
214722703|NCT02565953|DEVICE|PTA balloon catheter|
214722704|NCT01269177|DEVICE|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability"
214722705|NCT05198427|OTHER|review of medical patient file|"The outcome measure is the evolution of HPV related lesions between :~* favourable evolution including partial or total regression~* unfavourable evolution including non-evolution or aggravation or recurrence."
214722706|NCT04773847|PROCEDURE|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
214722707|NCT01877824|OTHER|Fast-track training|
214722708|NCT05818072|PROCEDURE|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
214722709|NCT05818072|PROCEDURE|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
214722710|NCT05818072|PROCEDURE|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
214722711|NCT05818072|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
214722712|NCT00300716|DRUG|Memantine|
214722713|NCT02984891|PROCEDURE|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
215030464|NCT06548971|DRUG|Aspirin|Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
214635133|NCT07144358|BEHAVIORAL|Biological Feeding Position|Biological Feeding Position
214635134|NCT07143214|BEHAVIORAL|online dialectical behavior therapy|"Enrolled participants will be provided with credentials to access the mobile application for a 28-day therapist-supported DBT self-help intervention. Participants are required to engage with the application at least once daily throughout the 4-week intervention period, with each session requiring approximately 30 minutes of engagement. The application delivers automated daily reminders at user-configurable timepoints. Additionally, participants receive asynchronous text-based guidance via WeChat during the treatment phase, wherein therapists provide support, feedback, and clinical direction during predetermined response windows. Each participant's cumulative weekly guidance duration is capped at 15 minutes.~The application's therapeutic framework integrates core components from The Dialectical Behavior Therapy Skills for Emotional Eating and standardized DBT treatment manuals, structured across four evidence-based modules: (1) Mindfulness, (2) Distress Tolerance, (3) Interpersonal Eff"
214635135|NCT07143214|BEHAVIORAL|Waitlist and psychoeducation|The active control group serves as a rigorous placebo comparator condition. Participants allocated to this arm will receive daily psychoeducational communications regarding binge-eating pathology, encompassing epidemiological data, biopsychosocial determinants, clinical manifestations, and therapeutic approaches. Crucially, all disseminated content remains devoid of Dialectical Behavior Therapy (DBT)-related components or skill-building elements.
214635136|NCT05458284|PROCEDURE|Real Acupuncture|Real Acupuncture weekly till taxane completion
214635137|NCT05458284|OTHER|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
214635138|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
214635139|NCT05850598|DEVICE|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
214635140|NCT05850598|DEVICE|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
214635141|NCT05772832|DRUG|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
214635142|NCT05772832|DRUG|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
214635143|NCT06963411|DRUG|KP001|Epinephrine Inhalation Aerosol (0.125 mg per inhalation)
214635144|NCT06963411|DRUG|Placebo|Matched Placebo control (KP001 vehicle only)
214635145|NCT05763745|DIAGNOSTIC_TEST|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
214722714|NCT02984891|PROCEDURE|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of \< 40 microns and tissue penetration of 10 mm.
215030465|NCT06548971|DRUG|Placebo|Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
214635146|NCT06800014|OTHER|Telerehabilitation|Participants in the telerehabilitation group will receive weekly home exercise instructions through a mobile application installed on their or their caregivers' smartphones, in addition to their standard rehabilitation program. These instructions will include videos, reminders, and directives for the exercises, with compliance monitored through mini-surveys delivered via the app.
214635147|NCT06800014|OTHER|Conventional exercise|Participants in the conventional exercise group will continue their standard rehabilitation program supplemented with printed home exercise instructions, including visuals and text, similar to the content provided to the TG.
214635148|NCT03004378|BEHAVIORAL|Activity Tracker|Fitbit Alta
214635149|NCT01203384|DRUG|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
214635150|NCT01203384|DRUG|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
214635151|NCT01203384|DRUG|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
214635152|NCT01203384|DRUG|Placebo|oral tablet, placebo, once a day in the morning for 14 days
214635153|NCT04752995|PROCEDURE|osteotomy|osteotomy osteoclasis of upper tibia
214635154|NCT00107237|DRUG|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
214635155|NCT00107237|DRUG|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
214635156|NCT01850056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|
214635157|NCT01850056|DEVICE|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
214635158|NCT00959816|DRUG|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
214635159|NCT06356909|OTHER|Survey of sedo-analgesia practices before laryngoscopy|The survey will evaluate adequation to the French best practice guidelines to improve their dissemination and to identify current practices of premedication before laryngoscopy in neonates in French units (agents, dosing, efficacy, safety)
214635160|NCT04475055|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen (DIPS)|The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
214635161|NCT01055158|BEHAVIORAL|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
214635162|NCT01055158|BEHAVIORAL|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
214635163|NCT04365465|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
214635164|NCT04365465|DEVICE|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
215030466|NCT06548971|OTHER|Best medical management|Patients in both groups will receive the best medical management according to the guidelines.
215030467|NCT02954562|OTHER|fMRI|Participants will undergo two to three fMRI scans
215030468|NCT05189860|DEVICE|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
214635165|NCT04365465|OTHER|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
214635166|NCT03591081|OTHER|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
214635167|NCT02562742|DRUG|SOF|SOF 400 mg tablets administered orally once daily
214635168|NCT02562742|DRUG|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
214635169|NCT04032210|OTHER|dual Zinc plus Arginine based toothpaste (Colgate total)|Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
214635170|NCT04032210|OTHER|Zinc based toothpaste (Crest complete)|Regimen using Zinc based toothpaste (Crest complete)
214635171|NCT04032210|OTHER|Fluoride based toothpaste (Signal)|Fluoride based toothpaste (Signal)
214722715|NCT05458362|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
214722716|NCT05458362|BEHAVIORAL|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
214722717|NCT05305001|GENETIC|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
214722718|NCT01570062|DEVICE|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
214722719|NCT01570062|DEVICE|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
214722720|NCT04261881|DIETARY_SUPPLEMENT|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
214722721|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast
214722722|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
214722723|NCT01044056|DRUG|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
214722724|NCT01044056|DRUG|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
215030469|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
215030470|NCT02607722|DRUG|Nintedanib|
214722725|NCT01044056|DRUG|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
214722726|NCT03366597|DRUG|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
214722727|NCT04434105|DRUG|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
214722728|NCT04434105|DRUG|Triamcinolone Acetonide|40 mg triamcinolone acetonide
214722729|NCT04434105|DRUG|Saline|Saline
214722730|NCT03619837|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
214722731|NCT03619837|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
214722732|NCT00349037|BIOLOGICAL|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
214722733|NCT01680939|DRUG|Morphine|0.2-0.5 mg/kg PO q4h
214722734|NCT01680939|DRUG|Ibuprofen|10mg/kg PO q6hrs
214722735|NCT00118404|BEHAVIORAL|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
214635172|NCT04647292|OTHER|anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration|"A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly."
214635173|NCT04647292|OTHER|Standard of Care Blood Pressure Management with Antihypertensives|Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.
214722736|NCT00118404|DRUG|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
214722737|NCT00118404|OTHER|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
214722738|NCT00118404|BEHAVIORAL|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
214722739|NCT01960504|DEVICE|Percutaneous Coronary Intervention (DREAMS) stenting|
214722740|NCT01406158|DRUG|Solifenacin Succinate Formulation A|oral suspension
214722741|NCT01406158|DRUG|Solifenacin Succinate Formulation B|oral suspension
214722742|NCT01406158|DRUG|Solifenacin Succinate|oral tablet
214722743|NCT02654041|DRUG|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
214722744|NCT05270083|DIAGNOSTIC_TEST|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
214722745|NCT05268705|OTHER|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
214722746|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
214722747|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
215030471|NCT06036368|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
215030472|NCT06117540|DRUG|WX390|WX390 tablet, 1.1 mg once a day
214722748|NCT06507085|RADIATION|Radio-guided interventions to correct heart rhythm disorders|"All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate"
214722749|NCT03082807|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
214722750|NCT03082807|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
214722751|NCT02313922|DRUG|etanercept combined with methotrexate or etanercept combined with placebo|
214635174|NCT02977169|RADIATION|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
214635175|NCT02977169|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
214635176|NCT06407310|DRUG|Pembrolizumab|I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
214635177|NCT06407310|DRUG|Carboplatin|I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
214635178|NCT06407310|DRUG|Paclitaxel|I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
214722752|NCT00807014|DRUG|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
214635179|NCT05814289|OTHER|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
214635180|NCT03447158|PROCEDURE|15% Dextrose|inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
214635181|NCT03447158|PROCEDURE|Normal saline|inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
214635182|NCT01972230|DRUG|Sevoflurane|
214635183|NCT01972230|DRUG|Diprivan + Remifentanil TCI|
214722753|NCT00807014|DRUG|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
214635184|NCT05314244|PROCEDURE|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
214635185|NCT01540799|DEVICE|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
214635186|NCT02116010|DRUG|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
214635187|NCT02116010|DRUG|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
214635188|NCT02116010|DRUG|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
214635189|NCT02766829|PROCEDURE|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
214635190|NCT02766829|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
214635191|NCT02686229|OTHER|no interventions|
214635192|NCT03595540|OTHER|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
214635193|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
214722754|NCT03222622|DRUG|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
214722755|NCT03222622|DRUG|Placebo cream|Apply topically twice daily for 12 consecutive weeks
214722756|NCT06067932|RADIATION|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
214722757|NCT06067932|DIAGNOSTIC_TEST|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
214722758|NCT04339322|OTHER|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
214722759|NCT01769482|DRUG|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
214722760|NCT01769482|DRUG|placebo|
214722761|NCT01525524|DEVICE|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
214722762|NCT02210455|BEHAVIORAL|Strongest Families FASD intervention|
214722763|NCT02210455|OTHER|Psychoeducation|
214722764|NCT01792297|DIETARY_SUPPLEMENT|Bovine colostrum|
214722765|NCT01792297|DIETARY_SUPPLEMENT|Whey protein|
214722766|NCT02650895|BIOLOGICAL|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
214722767|NCT02650895|DRUG|Saline|0.9% sodium chloride
214722768|NCT05679609|DEVICE|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
214722769|NCT02509676|OTHER|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
214722770|NCT01223768|DRUG|Acetyl-l-Carnitine|2g per day
214722771|NCT01223768|DRUG|placebo|twice per day
214722772|NCT01628042|DRUG|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
214722773|NCT02747446|DIETARY_SUPPLEMENT|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
214722774|NCT03182127|RADIATION|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
214722775|NCT03182127|DEVICE|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
214722776|NCT00316654|BIOLOGICAL|Meningococcal C conjugate vaccine|
214722777|NCT05974007|DRUG|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
214722778|NCT05974007|DRUG|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
214722779|NCT01511991|DRUG|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
214722780|NCT01708538|DRUG|CXL|corneal crosslinking
215031013|NCT06240286|BEHAVIORAL|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
214722781|NCT02988401|DRUG|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
214722782|NCT02988401|DRUG|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
214722783|NCT02861053|OTHER|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
214722784|NCT02861053|OTHER|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
214722785|NCT04472637|DRUG|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
214722786|NCT04472637|DRUG|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
214722787|NCT05386849|DEVICE|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
215031014|NCT00375232|DRUG|Administration of montelukast or placebo|
215031015|NCT02194179|DRUG|NVP XR 400 mg (KCR 25%)|
214722788|NCT03307018|PROCEDURE|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
214722789|NCT04465461|PROCEDURE|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
214722790|NCT04465461|DEVICE|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
214722791|NCT05236192|BEHAVIORAL|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
214722792|NCT05236192|BEHAVIORAL|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
214722793|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
214722794|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
214722795|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
214722796|NCT04586166|DEVICE|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
214722797|NCT04586166|DEVICE|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
214722798|NCT06096259|DRUG|Metformin|Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
214722799|NCT06096259|DRUG|Placebo|The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
214722800|NCT04772469|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
214722801|NCT04772469|OTHER|Small monetary incentives|Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
214722802|NCT04772469|BEHAVIORAL|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
214722803|NCT06382207|DEVICE|Eko Duo electronic stethoscope|A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.
215031016|NCT02194179|DRUG|NVP XR 400 mg (KCR 20%)|
215031017|NCT02194179|DRUG|NVP XR 300 mg (KCR 25%)|
214635194|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
214635195|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
214635196|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
214635197|NCT01620541|PROCEDURE|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
215031018|NCT02194179|DRUG|NVP XR 300 mg (KCR 20%)|
215031019|NCT02194179|OTHER|high-fat breakfast|
214722804|NCT06382207|DEVICE|CORE 500 electronic stethoscope|The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
214722805|NCT06136494|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
214722806|NCT06136494|BEHAVIORAL|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
214722807|NCT03443180|OTHER|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
214722808|NCT02518568|DRUG|V0355|Oral administration (2 tablets)
214722809|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
214722810|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
214722811|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
214722812|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
214722813|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
214722814|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
214722815|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
214722816|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
214722817|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
214722818|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
214722819|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
214722820|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
214722821|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
214722822|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
214722823|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
214722824|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
214722825|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
214722826|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
214722827|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
214722828|NCT04139629|DIAGNOSTIC_TEST|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
214722829|NCT04139629|DRUG|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
214722830|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
214722831|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
214722832|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
214722833|NCT03719430|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
214722834|NCT03719430|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
214722835|NCT00858676|DRUG|acarbose|50mg acarbose 3 times a day PO. duration: one year
214722836|NCT04260672|BEHAVIORAL|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
215030473|NCT05442879|BEHAVIORAL|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
215030474|NCT05442879|BEHAVIORAL|Educational handout|Educational handout describing a commonly cited ACL-IPP.
214722837|NCT05841953|DEVICE|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
214722838|NCT05732493|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
214722839|NCT05732493|RADIATION|short-term radiotherapy|radiation: 25Gy/5Fx
214722840|NCT05732493|DRUG|Oxaliplatin|130mg/m2 d1 q3w
214722841|NCT05732493|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
214722842|NCT01161927|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
214722843|NCT01161927|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
214722844|NCT02335034|BEHAVIORAL|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
214722845|NCT02335034|BEHAVIORAL|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
214722846|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
214722847|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
214722848|NCT04790734|DRUG|Sedation drugs|Different sedation drugs
214722849|NCT02310724|OTHER|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
214722850|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
214722851|NCT05906368|DIAGNOSTIC_TEST|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
214722852|NCT05906368|DIAGNOSTIC_TEST|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
214722853|NCT05864534|DRUG|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
214722854|NCT05864534|DRUG|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
214722855|NCT05864534|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
214722856|NCT05864534|DEVICE|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
214722857|NCT06573814|DIETARY_SUPPLEMENT|Bio Gelee Royale Forte|Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
214722858|NCT06573814|OTHER|Placebo|Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
214722859|NCT04335656|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
214722860|NCT04335656|OTHER|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
214722861|NCT01976585|DRUG|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
214722862|NCT01976585|DRUG|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
214722863|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
214722864|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
214722865|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
215031020|NCT02194179|DRUG|NVP IR 200 mg (Viramune®)|
214635198|NCT01620541|PROCEDURE|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
214635199|NCT00264004|DRUG|AZD2171|30 mg \& 45 mg oral tablet
214722866|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose\_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 Group in Stage 2 (Africa).
214722867|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
214722868|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
214722869|NCT05480800|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
214635200|NCT06471868|DRUG|IY-HCR21|Betanechol 50mg
214635201|NCT06471868|DRUG|IY-MIC|Betanechol 25mg
214635202|NCT05244265|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).
214635203|NCT05244265|BEHAVIORAL|Treatment as usual (TAU)|Different interventions and support in outpatient and other services.
214722870|NCT05480800|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
214722871|NCT05480800|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
214722872|NCT05480800|DRUG|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo\_Step 1 and Placebo\_Step 2 in Stage 1 (Europe).
214722873|NCT05480800|OTHER|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo\_Step 1, iNTS-TCV full dose\_1, Placebo\_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 and Control\_Stage 2 groups in Stage 2 (Africa).
214635204|NCT01030510|DRUG|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
214635205|NCT04035317|DRUG|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
214635206|NCT04035317|DRUG|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
214635207|NCT04731935|DEVICE|Sparrow Therapy System|Transcutaneous auricular neurostimulation
214635208|NCT00595712|PROCEDURE|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
214635209|NCT00595712|PROCEDURE|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
214635210|NCT05415449|DEVICE|Gus gear protective wearable device|Gus gear protective wearable device for central line.
214635211|NCT01262365|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
214635212|NCT01262365|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
214635213|NCT01262365|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
214722874|NCT03649139|DRUG|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
214722875|NCT03649139|DRUG|Placebo drops|sublingual placebo drops
214722876|NCT00948714|BEHAVIORAL|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
214722877|NCT00948714|BEHAVIORAL|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
214722878|NCT00948714|OTHER|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
214722879|NCT03723408|DEVICE|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
214722880|NCT04476615|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
214722881|NCT04476615|DIETARY_SUPPLEMENT|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
214722882|NCT00075660|DRUG|triapine|
214722883|NCT05601050|OTHER|There is no intervention|There is no intervention
214722884|NCT02180568|PROCEDURE|Lipiodol|Lipiodol-guided lung localization technique
214722885|NCT02180568|PROCEDURE|Hookwire|Hookwire-guided lung localization technique
214722886|NCT02180568|DRUG|Lipiodol|
214722887|NCT02798445|OTHER|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
214722888|NCT02798445|OTHER|CONTROL|Multilayer bandages and wound care
214722889|NCT02706795|BIOLOGICAL|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
214722890|NCT00026039|DRUG|estrogen|
214722891|NCT05753202|DEVICE|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
214722892|NCT02306941|BEHAVIORAL|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
214722893|NCT04625088|OTHER|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
214722894|NCT04625088|DRUG|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
214722895|NCT00030160|BEHAVIORAL|Strength Training|
214722896|NCT01614275|BEHAVIORAL|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
214722897|NCT01614275|BEHAVIORAL|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
214793819|NCT05214807|DEVICE|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
214722898|NCT01614275|BEHAVIORAL|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
214722899|NCT01614275|BEHAVIORAL|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
214722900|NCT02668328|BEHAVIORAL|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
214722901|NCT04609215|OTHER|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
214722902|NCT02330445|DRUG|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
214722903|NCT05195424|DIAGNOSTIC_TEST|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
214722904|NCT05455307|DEVICE|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
214722905|NCT00012207|BIOLOGICAL|aldesleukin|
214722906|NCT00012207|BIOLOGICAL|therapeutic autologous lymphocytes|
214722907|NCT00012207|DRUG|cyclophosphamide|
214722908|NCT00012207|DRUG|prednisone|
214722909|NCT00012207|DRUG|vincristine sulfate|
214722910|NCT00012207|PROCEDURE|adjuvant therapy|
214722911|NCT00064623|DRUG|Capsaicin Dermal Patch|
214722912|NCT03527186|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
214722913|NCT00650897|DRUG|Escitalopram|10-20 mg once daily
214722914|NCT05298228|DRUG|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
214722915|NCT00992914|PROCEDURE|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
214722916|NCT00992914|PROCEDURE|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
214722917|NCT01670708|BEHAVIORAL|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
214722918|NCT01670708|BEHAVIORAL|Probation as Usual|Probation officer supervises following standard protocols.
214722919|NCT01442519|BIOLOGICAL|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0\_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
214722920|NCT01442519|DRUG|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
214722921|NCT01605890|DRUG|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
214722922|NCT02866318|DEVICE|Echocardiography|
214722923|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
214722924|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
214722925|NCT02117791|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
214722926|NCT04958525|PROCEDURE|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
214722927|NCT04958525|PROCEDURE|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
214722928|NCT00302055|BEHAVIORAL|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
214722929|NCT00302055|BEHAVIORAL|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
214722930|NCT03973749|OTHER|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
214722931|NCT05431036|DEVICE|transthoracic ultrasonography|"1. The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~2. The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
214722932|NCT02525809|DEVICE|Novae E®|
214722933|NCT02525809|DEVICE|Sunfit®|
214722934|NCT02525809|DEVICE|Quartz®|
214722935|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
214722936|NCT05728424|DRUG|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
214722937|NCT02259764|DRUG|KUC 7483 CL - single rising dose|
214722938|NCT02259764|DRUG|Placebo|
214722939|NCT02259764|OTHER|standardized high fat meal|
214722940|NCT01172561|BEHAVIORAL|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
214722941|NCT01172561|BEHAVIORAL|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
214722942|NCT05208346|DIETARY_SUPPLEMENT|Mixed meals|Mixed meals enriched with either 25 or 50 g of canola or coconut oil
214722943|NCT00088595|DRUG|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
214722944|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
214722945|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
214722946|NCT03149497|PROCEDURE|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
214722947|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
214722948|NCT00653406|DRUG|Risperidone long acting injectable|
214722949|NCT02900599|OTHER|Observationnal (no intervention)|
214722950|NCT01314456|DEVICE|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
214722951|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
214722952|NCT00792857|DRUG|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
214722953|NCT00792857|DRUG|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
214722954|NCT03245294|PROCEDURE|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
214722955|NCT03689699|DRUG|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
214722956|NCT03689699|DRUG|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
214722957|NCT03689699|DRUG|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
214722958|NCT04359121|OTHER|Questionnaires for specific phobia|Questionnaires will be used.
214722959|NCT05787366|OTHER|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
214722960|NCT05787366|OTHER|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
214722961|NCT03412162|BEHAVIORAL|Ethnic and Racial Identity Promotion|See arm description
214722962|NCT03412162|BEHAVIORAL|Academic Skills Promotion|See arm description
214722963|NCT03542149|DRUG|480 mg Piperaquine phosphate|480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
214722964|NCT03542149|DRUG|640 mg Piperaquine phosphate|640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
214722965|NCT03542149|DRUG|200 mg OZ 439|200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
214722966|NCT03542149|DRUG|400 mg OZ 439|400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
214722967|NCT03542149|DRUG|800 mg OZ 439|800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
214722968|NCT03542149|DRUG|960 mg PQP|960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
214722969|NCT03542149|DRUG|320 mg PQP|320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
214722970|NCT01789892|DRUG|methylprednisolone|Given IV
214722971|NCT01789892|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT scan
214722972|NCT01789892|PROCEDURE|positron emission tomography|Undergo FDG PET/CT scan
214722973|NCT01789892|PROCEDURE|computed tomography|Undergo FDG PET/CT scan
214722974|NCT04720690|DEVICE|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
214722975|NCT04720690|DEVICE|NICaS|Measurement of cardiac output
214722976|NCT04720690|DEVICE|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
214722977|NCT05991895|DRUG|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
214722978|NCT02434913|DEVICE|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
214722979|NCT01934868|DRUG|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
214722980|NCT01934868|DRUG|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
214722981|NCT00982748|BEHAVIORAL|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
214722982|NCT05587608|PROCEDURE|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
214722983|NCT03375762|OTHER|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
214722984|NCT03375762|OTHER|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
214722985|NCT03067480|DEVICE|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
214635214|NCT04864444|DRUG|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
214722986|NCT05117268|PROCEDURE|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
214722987|NCT05117268|PROCEDURE|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
214722988|NCT05117268|PROCEDURE|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
214722989|NCT03535090|DRUG|Methylprednisolone|
214722990|NCT00240929|DRUG|MEDI-493|Active Comparator
214722991|NCT05257629|COMBINATION_PRODUCT|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
214722992|NCT05257629|OTHER|Varenicline Plus Counseling|Varenicline plus counseling
214722993|NCT02673528|PROCEDURE|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
214722994|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
214722995|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
214722996|NCT00250367|DRUG|risperidone|
214635215|NCT04864444|DRUG|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
214635216|NCT02787850|DEVICE|CoolSculpting Treatment|The CoolSculpting device will be used to perform treatments.
214635217|NCT04018911|DEVICE|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
214635218|NCT04018911|DEVICE|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
214635219|NCT04018911|DEVICE|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
214635220|NCT04018911|DRUG|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
214635221|NCT01817309|OTHER|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
214635222|NCT00767377|DRUG|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
214635223|NCT03598166|DIAGNOSTIC_TEST|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
214635224|NCT02466061|BEHAVIORAL|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
214635225|NCT02466061|BEHAVIORAL|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
214635226|NCT02466061|BEHAVIORAL|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
214635227|NCT00917449|DRUG|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
214635228|NCT00917449|DRUG|Placebo|Oral Placebo BID for 18 months
214635229|NCT02921971|DRUG|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
214635230|NCT02921971|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
214635231|NCT00274131|DRUG|Pramipexole 0.125 mg tablets|
214635232|NCT00274131|DRUG|Pramipexole 0.5 mg tablets|
214635233|NCT02322710|DEVICE|Urgotul: Low-adherent dressing|
214635234|NCT02322710|DEVICE|TulleGras M.S.: Vaseline gauze|
214635235|NCT05576571|DIAGNOSTIC_TEST|Met-score|methylation analysis
214635236|NCT01708980|OTHER|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
214635237|NCT04619485|DEVICE|CO2 LASER|5 SESSIONS OF CO2 VAGINAL LASER
214635238|NCT04619485|DEVICE|CO2 SHAM LASER|5 SESSIONS OF CO2 VAGINAL SHAM LASER
214635239|NCT04161131|BEHAVIORAL|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
214635240|NCT00143585|PROCEDURE|intramyocardial delivery of either VEGF165 or placebo|
214722997|NCT05732597|PROCEDURE|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
214722998|NCT03912324|PROCEDURE|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
214635241|NCT06239129|DRUG|Initiation of specific medications|multiple therapies studied within this database
214635242|NCT06239129|PROCEDURE|Undertaking of specific procedures|multiple procedures/surgeries studied within this database
214635243|NCT06239129|DIAGNOSTIC_TEST|Abnormalities in specific laboratory tests|multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database
214635244|NCT02472132|DEVICE|POC US|Use of point of care ultrasound in insertion of CVC
214635245|NCT00703638|DRUG|cisplatin|Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
214635246|NCT00703638|DRUG|pemetrexed disodium|Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
214635247|NCT00703638|DRUG|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
214635248|NCT05119712|DRUG|Terbinafine Tablets|500mg oral terbinafine or placebo daily
214635249|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
214635250|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
214635251|NCT02816918|DEVICE|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
214635252|NCT02816918|DEVICE|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
214635253|NCT04536597|OTHER|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
214635254|NCT04536597|OTHER|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
214635255|NCT04536597|OTHER|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
214722999|NCT03912324|PROCEDURE|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214723000|NCT03912324|PROCEDURE|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214723001|NCT02676453|OTHER|Intervention|Dental hygienist support
214723002|NCT04942769|DRUG|Selenium|selenium 100ug ，take it orally twice daily
214723003|NCT04531397|DRUG|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
214723004|NCT04531397|DRUG|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
214723005|NCT02429349|PROCEDURE|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
214723006|NCT04829461|DEVICE|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
214723007|NCT04829461|DEVICE|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
214723008|NCT06185868|OTHER|No intervention measures|No intervention measures
214723009|NCT05392049|OTHER|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
214723010|NCT05392049|OTHER|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
214723011|NCT04176718|DRUG|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
214723012|NCT04176718|DRUG|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
214723013|NCT04176718|DRUG|Pomalidomide|predetermined dose, orally, daily per cycle
214723014|NCT04176718|DRUG|Dexamethasone|predetermined dose, orally, given 8 times per cycle
214723015|NCT02557334|DIETARY_SUPPLEMENT|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
214723016|NCT02557334|DIETARY_SUPPLEMENT|High Dose Strawberry Powder|40 g freeze dried strawberry powder
214723017|NCT02557334|DIETARY_SUPPLEMENT|Placebo Powder|40 g color and taste matched placebo powder
214723018|NCT00524043|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
214723019|NCT00524043|DRUG|Placebo|Once daily for 6 weeks
214723020|NCT00524043|DRUG|Paliperidone ER|6 mg tablet once daily for 6 weeks
214635256|NCT01185405|OTHER|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
214635257|NCT03165097|DRUG|ACT-709478|Hard gelatine capsules for oral administration
214635258|NCT03165097|DRUG|Placebo|Placebo capsules matching ACT-709478 capsules
214635259|NCT03165097|DRUG|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
214635260|NCT03165097|DRUG|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
214635261|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Psycho-educational group
214635262|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Spiritual-Existential Group
214635263|NCT06213727|DRUG|lowe-dose ZKY001 eye drops|eye drops
214635264|NCT06213727|DRUG|Medium-dose ZKY001 eye drops|eye drops
214635265|NCT06213727|DRUG|ZKY001 simulated eye drops|eye drops
214635266|NCT04209803|DRUG|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
214635267|NCT05058183|DIAGNOSTIC_TEST|ctDNA|Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
214635268|NCT05980715|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
214635269|NCT05980715|RADIATION|concurrent chemoradiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
214635270|NCT01592981|DRUG|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
214635271|NCT01592981|DRUG|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
214635272|NCT01592981|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
214635273|NCT01592981|DRUG|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
214635274|NCT05402644|PROCEDURE|hepatectomy|Liver resection
214635275|NCT00505258|DRUG|ceftobiprole medocaril|
214635276|NCT03936504|BEHAVIORAL|Control Group ：conventional exercise rehabilitation programs (CERP)|The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
214635277|NCT03936504|BEHAVIORAL|Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)|Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
214635278|NCT03883880|OTHER|Epigallocatechin gallate|Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
214635279|NCT03883880|OTHER|Epigallocatechin gallate control|Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
214635280|NCT03883880|OTHER|Linoleic acid|Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
214635281|NCT03883880|OTHER|Linoleic acid control|Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
214635282|NCT03883880|OTHER|Capsaicin solution|Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
214635283|NCT03883880|OTHER|Capsaicin control|Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
214635284|NCT02073773|DRUG|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
214635285|NCT02073773|OTHER|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
214635286|NCT04316585|DRUG|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
214635287|NCT04316585|DRUG|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
214635288|NCT01897246|PROCEDURE|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
214635289|NCT01897246|PROCEDURE|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
214635290|NCT00023530|DRUG|fluconazole|
214635291|NCT00023530|DRUG|voriconazole|
214635292|NCT00023530|PROCEDURE|bone marrow transplant|
214635293|NCT00023530|DRUG|thalidomide|
214635294|NCT00023530|DRUG|dexamethasone|
214635295|NCT02439125|DRUG|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
214635296|NCT02439125|DRUG|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
214635297|NCT02439125|DRUG|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
214635298|NCT02439125|DRUG|Placebo|b.i.d. orally for 3 weeks
214635299|NCT05350826|OTHER|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
214635300|NCT00130832|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
214635301|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
214635302|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
214635303|NCT04634175|BEHAVIORAL|Yoga intervention|The yoga intervention is composed of kundalini yoga techniques.
214635304|NCT04634175|BEHAVIORAL|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
214635305|NCT03905863|DEVICE|Natrox® Oxygen Wound Therapy|A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
214635306|NCT01207973|DRUG|BI 113823|5 dose-groups of multiple oral doses of BI 113823
214635307|NCT00532480|DRUG|Duloxetine|60 mg capsules
214635308|NCT02213601|BEHAVIORAL|Yoga|
214635309|NCT01471080|PROCEDURE|RFA|using RFA to treat cavernous hemangiomas
214635310|NCT01471080|PROCEDURE|hepatectomy|using hepatectomy to treat cavernous hemangiomas
214635311|NCT00477126|DRUG|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
214635312|NCT04176185|BIOLOGICAL|Sublingual allergy immunological tablet|For daily administration (1 tablet per day)
214635313|NCT04176185|OTHER|Placebo|For daily administration (1 tablet per day)
214635314|NCT03842930|PROCEDURE|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
214635315|NCT03408795|PROCEDURE|Laparoscopic distal gastrectomy|Longitudinal testing of The Japanese Operative Rating Scale for Laparoscopic Distal Gastrectomy
214635316|NCT01155115|PROCEDURE|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
214635317|NCT01155115|PROCEDURE|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
214635318|NCT01155115|PROCEDURE|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
214635319|NCT00794209|DRUG|i.v fentanyl, AeroLEF|"* i.v fentanyl~* 5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~* 5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~* 5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~* 3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
214635320|NCT05222217|DEVICE|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
214635321|NCT01675986|DRUG|hydroxyzine|75 mg
214635322|NCT01675986|DRUG|Pregabalin|150 mg
214635323|NCT01675986|DRUG|Lactose|4 g
214635324|NCT05026788|OTHER|type of treatment|pathway of management for conservative treatment, operative treatment and type of anaesthesia used
214635325|NCT04240977|BEHAVIORAL|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
214635326|NCT02584491|BEHAVIORAL|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
214635327|NCT04789733|OTHER|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
214635328|NCT04789733|OTHER|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
214723021|NCT04965285|BEHAVIORAL|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
214723022|NCT04545411|DRUG|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
214723023|NCT04545411|DRUG|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
214723024|NCT04545411|DRUG|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
214723025|NCT02124928|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
214723026|NCT04884997|DRUG|toripalimab|toripalimab 3mg/kg, Q2w;
214723027|NCT04884997|DRUG|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
214723028|NCT00003761|BIOLOGICAL|rV-DF3/MUC1|"\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
214723029|NCT01085773|BEHAVIORAL|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
214723030|NCT01085773|BEHAVIORAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
214723031|NCT00440141|DRUG|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
214723032|NCT00440141|DRUG|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
214723033|NCT05505149|OTHER|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
214723034|NCT00296166|PROCEDURE|Catheter ablation|
214723035|NCT00296166|PROCEDURE|Thoracoscopic epicardial ablation|
214723036|NCT03463213|BEHAVIORAL|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
214723037|NCT06213415|DRUG|Corticosteroid|Oral steroids plus intratympanic injection
214723038|NCT04371549|PROCEDURE|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
214723039|NCT04371549|PROCEDURE|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
214723040|NCT03642275|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
214723041|NCT03820206|DRUG|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
214723042|NCT03820206|PROCEDURE|Cesarean section|Lower segement transverse cesarean section
214723043|NCT03846622|OTHER|Calculation of scoring systems for bleeding|
214723044|NCT00269685|DRUG|vasopressin|
214723045|NCT05210413|DRUG|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
214723046|NCT05210413|DRUG|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
214635329|NCT05654844|RADIATION|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
214635330|NCT05654844|RADIATION|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
214635331|NCT04622176|DIAGNOSTIC_TEST|MMUS|MMUS will be used to perform diagnostics, we will compare with MRI and histology
214635332|NCT02996747|PROCEDURE|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
214635333|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
214635334|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
214635335|NCT05948280|OTHER|Virtual reality-supported mindfulness|A single mindful stretching exercise provides a conscious stretch of VR scenario. The implementation of VR exercises will be performed by the interventionist who have received training in the application of VR scenarios and have extensive experience in VR research.
214635336|NCT05948280|OTHER|Mindfulness|The interventionist will guide the participant to do a mindful stretching exercise in the first week. During the second week, the interventionist will send participants an audio recording on how to do mindful stretching exercise via WeChat/WhatsApp.
214635337|NCT05730179|OTHER|Mechanical Conditioning stimulus|Painful mechanical stimulus
214635338|NCT05439187|PROCEDURE|hernia repair|Open or laparoscopic hernia repair with mesh placement.
214635339|NCT02135731|OTHER|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
214723047|NCT05210413|DRUG|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
214723048|NCT05210413|DRUG|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
214723049|NCT05915104|DRUG|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
214723050|NCT05915104|DRUG|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
215030475|NCT05766254|DEVICE|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
214723051|NCT02935907|DRUG|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
214723052|NCT01238705|DRUG|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
214723053|NCT01238705|DRUG|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
214723054|NCT00565357|DEVICE|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
214723055|NCT00565357|OTHER|Control|Standard care in the neonatal intensive care unit
214723056|NCT03058302|BEHAVIORAL|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
214723057|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
214723058|NCT05472376|OTHER|Retrospective study|Retrospective study
214723059|NCT00711412|DRUG|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
214723060|NCT00711412|DRUG|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
214723061|NCT00711412|DRUG|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
214723062|NCT00711412|DRUG|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
214723063|NCT00711412|RADIATION|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
214723064|NCT00711412|PROCEDURE|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
214723065|NCT03455634|DEVICE|Twin Block|functional appliances for the stimulation of the mandibular growth
214723066|NCT03455634|DEVICE|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
214723067|NCT00728728|DRUG|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
214723068|NCT00728728|DIETARY_SUPPLEMENT|Placebo|Placebo
214723069|NCT05364437|DIETARY_SUPPLEMENT|Dietary Fibres Supplement|The dietary fibres supplement, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
214723070|NCT05364437|DIETARY_SUPPLEMENT|Cellulose Control|The control, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
214723071|NCT04211961|OTHER|Placebo / Saline|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
214723072|NCT04211961|DRUG|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
214723073|NCT02062827|BIOLOGICAL|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
214723074|NCT04906863|GENETIC|Blood draw|Blood draw for identification of genetic variants associated with the development of memory problems
214723075|NCT04906863|OTHER|Neurocognitive testing|Brief memory test
214723076|NCT04906863|OTHER|Medical questionnaire|Collection of medical history
214723077|NCT06633198|PROCEDURE|Passive Heating|The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
214723078|NCT06633198|DRUG|L-NAME|L-NAME will be used during measurement of cutaneous microvascular function to test the dependency upon NO to elicit vasodilation.
214723079|NCT00288522|DRUG|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
214723080|NCT05250518|PROCEDURE|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
214723081|NCT05250518|PROCEDURE|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
214723082|NCT05616845|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
214723083|NCT02649829|BIOLOGICAL|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
214723084|NCT02940028|BEHAVIORAL|Expressive writing|Brief expressive writing intervention
214723085|NCT02940028|BEHAVIORAL|Control writing|Brief fact-based writing exercise.
214723086|NCT04741295|DRUG|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
214723087|NCT05685186|DIAGNOSTIC_TEST|Spirometry|To assess lung function
214723088|NCT05685186|DIAGNOSTIC_TEST|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
214723089|NCT05685186|DIAGNOSTIC_TEST|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
214723090|NCT05685186|DIAGNOSTIC_TEST|CT of the chest|Low radiation to assess structural lung disease
214723091|NCT05685186|DIAGNOSTIC_TEST|MRI of the chest|To assess lung function and structural lung disease
214723092|NCT06400992|DEVICE|Cochlear implant processor Sky CITM M90 (CI-5295)|"The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
214723093|NCT06400992|DEVICE|Hearing Aid, including sound processor Phonak: Sky Link M90|"The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
214723094|NCT06400992|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
214635340|NCT04390087|OTHER|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
214635341|NCT01872728|DRUG|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
214635342|NCT00526682|DIETARY_SUPPLEMENT|Irvingia/cissus combo|
214635343|NCT02944448|DRUG|CR845 tablet 1 mg|CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
214635344|NCT02944448|DRUG|CR845 tablet 2.5 mg|CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
214635345|NCT02944448|DRUG|CR845 tablet 5 mg|CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
214635346|NCT02944448|DRUG|Placebo tablet|Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
214635347|NCT06334094|DRUG|Ozanimod|A hard capsule that is taken daily for one year.
214635348|NCT03871855|DRUG|SHR-1702|Administered IV
214635349|NCT03871855|DRUG|Camrelizumab|Administered IV
214635350|NCT01098890|DRUG|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
214635351|NCT01098890|DRUG|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
214635352|NCT00652353|OTHER|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
214635353|NCT00652353|OTHER|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
214635354|NCT04086251|OTHER|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
214635355|NCT00091910|DRUG|Epoetin alfa|
214635356|NCT02117726|DRUG|Dexmedetomidine,midazolam|
214635357|NCT02117726|DRUG|Propofol,midazolam|
214635358|NCT01135589|DRUG|Micafungin|i.v.
214635359|NCT06147557|PROCEDURE|Heat therapy|14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
214635360|NCT06068972|DEVICE|MolecuLight|Point-of-care fluorescence imaging of high bacterial loads
214635361|NCT02070107|OTHER|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
214635362|NCT04527198|DIAGNOSTIC_TEST|Brainstem Responses Assessment Sedation Score (BRASS)|"It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning."
214635363|NCT04527198|DIAGNOSTIC_TEST|Electroencephalogram with EKG lead|"A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity)."
214635364|NCT05627076|DEVICE|Blood Sampling|Blood samples will be collected for the PSP measurement using the abioSCOPE.
214635365|NCT03644433|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
214635366|NCT03644433|PROCEDURE|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
214635367|NCT04357106|BIOLOGICAL|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
214635368|NCT06064344|DRUG|Rituximab|Intralesional Rituximab Injection
214635369|NCT06064344|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
214635370|NCT01980472|BIOLOGICAL|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
214635371|NCT00521521|DRUG|docetaxel and cisplatin|
214635372|NCT00521521|DRUG|docetaxel|
214635373|NCT04858893|DIAGNOSTIC_TEST|CoMDA associated with Neural Net 91 classificator|
214635374|NCT02070861|OTHER|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
214635375|NCT03546855|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
214635376|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
214635377|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
214635378|NCT02392013|OTHER|Home Modification|Removal of home barriers or hazards.
214635379|NCT00639249|DRUG|placebo|Oral administration
214635380|NCT00639249|DRUG|SA4503 Low|Oral administration
214635381|NCT00639249|DRUG|SA4503 High|Oral administration
214635382|NCT04252430|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
214635383|NCT05499559|BEHAVIORAL|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
214635384|NCT05685433|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
214635385|NCT01931358|BIOLOGICAL|ALVAC-HIV|1 mL intramuscular injection containing 10\^6 CCID50/dose
214635386|NCT01931358|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
214635387|NCT01931358|BIOLOGICAL|ALVAC-HIV Placebo|1 mL per injection
214635388|NCT01931358|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
214635389|NCT05967663|DEVICE|PCI-immediate complete revascularisation|In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.
214635390|NCT05967663|DEVICE|PCI-staged complete revascularisation|In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.
214635391|NCT04681170|DRUG|Lomitapide|2mg,5mg, 10mg and 20mg capsules
214635392|NCT04986202|DRUG|AZD4831|AZD4831
214635393|NCT04986202|OTHER|Placebo|Placebo
214635394|NCT02468648|DRUG|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
214635395|NCT02468648|DRUG|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
214635396|NCT02118792|DRUG|AN2728 Topical Ointment, 2%|
214635397|NCT02118792|DRUG|Matching vehicle control|
214635398|NCT05131204|DRUG|Cemdisiran|Administered per protocol
214635399|NCT05131204|DRUG|Eculizumab|Administered per protocol
214635400|NCT05131204|DRUG|Pozelimab|Administered per protocol
214635401|NCT05131204|DRUG|Ravulizumab|Administered per protocol
214635402|NCT02493348|DEVICE|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
214635403|NCT05055180|DIAGNOSTIC_TEST|Invasive hemodynamics and myocardial biopsies|Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies
214635404|NCT06362239|OTHER|Study Surveys|Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
214635405|NCT06333015|DEVICE|enVista EY Beyond IOL|enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
214635406|NCT06333015|DEVICE|enVista MX60E monofocal IOL|enVista MX60E monofocal IOL
214635407|NCT05451849|BIOLOGICAL|TC-510|TC-510
214635408|NCT05451849|DRUG|Fludarabine|Fludarabine
214635409|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
214635410|NCT04656652|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
214635411|NCT04656652|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
214635412|NCT02787863|BIOLOGICAL|Prevenar-13|Conjugate 13 serotype pneumococcal vaccine
214635413|NCT02787863|BIOLOGICAL|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
214635414|NCT03802877|BEHAVIORAL|Resource bank|See intervention arm descriptions
214635415|NCT03802877|BEHAVIORAL|ePlatform|See intervention arm descriptions
214723095|NCT06400992|BEHAVIORAL|Audiologist Fitting Questionnaire|After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
214635416|NCT03802877|BEHAVIORAL|Health coach|See intervention arm descriptions
214635417|NCT03002415|OTHER|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
215030476|NCT05766254|DEVICE|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214723096|NCT06400992|BEHAVIORAL|Patient Satisfaction Questionnaire|The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
214723097|NCT06400992|BEHAVIORAL|AutoSens Feedback Discussion Form|6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
214723098|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
214723099|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
214723100|NCT00230295|PROCEDURE|IMR LAG|
214723101|NCT05856149|BEHAVIORAL|Mobile Diabetes Prevention Program|The intervention is a mobile, web-based diabetes prevention program that participants will have access to for a total of 12 weeks. The intervention is a behavioral intervention aimed at increasing the knowledge and skills of participants to reduce type 2 diabetes risk behaviors.
214723102|NCT06851871|DRUG|Deucravacitinib|Specified dose on specified days
214723103|NCT06851871|DRUG|Famotidine|Specified dose on specified days
214723104|NCT04836091|BEHAVIORAL|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
214723105|NCT04836091|BEHAVIORAL|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
214723106|NCT06280053|DEVICE|HealiAid Collagen Wound Dressing|HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
214723107|NCT02637648|DRUG|Sodium Oxybate|parallel Group administration
214723108|NCT02637648|DRUG|Placebo|parallel Group administration
214723109|NCT03793634|DRUG|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
214723110|NCT01686347|DRUG|ropivacaine|
214723111|NCT04368000|BEHAVIORAL|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
215030477|NCT03673072|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
215030478|NCT03673072|DRUG|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
214723112|NCT04368000|BEHAVIORAL|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
214723113|NCT04293042|BIOLOGICAL|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
214723114|NCT06397391|DEVICE|TREM-AB|Wearing medical device on site during 1 hour
214723115|NCT05212376|OTHER|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
214723116|NCT01301755|PROCEDURE|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
214723117|NCT05932394|BEHAVIORAL|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
214723118|NCT05932394|BEHAVIORAL|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
214723119|NCT03684525|PROCEDURE|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
214723120|NCT02103595|DEVICE|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
214723121|NCT02103595|DEVICE|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
214723122|NCT01456728|DIETARY_SUPPLEMENT|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
214723123|NCT01456728|DIETARY_SUPPLEMENT|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
215030479|NCT03673072|PROCEDURE|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
215030480|NCT03673072|DRUG|Adjuvant chemotherapy|Can be selected by Investigator's Choice
214635418|NCT03002415|OTHER|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
214635419|NCT02777216|DEVICE|ConfidenHT system|ConfidenHT Medical system
214635420|NCT01978093|BIOLOGICAL|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
214635421|NCT01978093|BIOLOGICAL|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
214635422|NCT01978093|BIOLOGICAL|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
214635423|NCT01978093|BIOLOGICAL|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
214635424|NCT01978093|BIOLOGICAL|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
214635425|NCT01978093|BIOLOGICAL|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
214635426|NCT06320483|DEVICE|Vibroacoustic device BARK VibroLUNG|"The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver."
214635427|NCT03305107|OTHER|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
214635428|NCT03305107|OTHER|Exercise and Water|High intensity interval exercise Water
214635429|NCT03305107|OTHER|Sitting and Chocolate Milk|Sitting Chocolate Milk
214635430|NCT03305107|OTHER|Sitting and Water|Sitting Water
214635431|NCT03424447|PROCEDURE|efferent limb stimulation|
214635432|NCT04110847|DRUG|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
214635433|NCT04079270|OTHER|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
214635434|NCT02458196|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
214635435|NCT02458196|DRUG|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
214635436|NCT04313829|BEHAVIORAL|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
214723124|NCT00135525|DRUG|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
214723125|NCT00135525|DRUG|Placebo|Placebo
214723126|NCT05240963|PROCEDURE|Temporal PEEK implant|Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
214723127|NCT03321890|DRUG|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
214723128|NCT03321890|DRUG|prednisone|oral, 20mg / day,after breakfast
214723129|NCT03321890|DRUG|Cyclophosphamide|oral, 50mg / day,after lunch
214723130|NCT03321890|DRUG|etoposide|oral, 50mg / day,after dinner
214723131|NCT03321890|DRUG|Methotrexate|oral, 10mg / times, once a week,after breakfast
214723132|NCT02989480|RADIATION|PET CT|PET CT scans
214723133|NCT02989480|OTHER|Cardiac MRI|Cardiac MRI
214723134|NCT01156363|PROCEDURE|Dialysis|regular haemodialysis or peritoneal dialysis
214723135|NCT01156363|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
214723136|NCT03484689|BEHAVIORAL|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
214723137|NCT00610077|DRUG|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
214723138|NCT00610077|DRUG|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
214723139|NCT01801124|DRUG|EXPAREL|single dose 266 mg of undiluted EXPAREL
214723140|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
214723141|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
214723142|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
214723143|NCT06840743|OTHER|Emotional intervention|The participant will wait for 2.20 minutes while simultaneously experience experimentally induced pain.
214723144|NCT03215745|BEHAVIORAL|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
214723145|NCT00004690|DRUG|monolaurin cream|
214723146|NCT00877734|DRUG|baclofen|10 mg Baclofen administered tid for 11 weeks
214723147|NCT00877734|DRUG|placebo|Placebo administered tid for 11 weeks
214723148|NCT00877734|BEHAVIORAL|BRENDA counseling|
214723149|NCT03363568|BEHAVIORAL|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
214723150|NCT03363568|BEHAVIORAL|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
214723151|NCT04383106|OTHER|no intervention|no intervention
214723152|NCT04383964|DEVICE|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
215030481|NCT05789290|DEVICE|Hilotherm cryocompression device|An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
215030482|NCT05422482|BIOLOGICAL|GC1123|ICV-administered Hunterase, Idursulfase-ß
215030483|NCT01969578|DRUG|bicalutamide + triptorelin|
214723153|NCT02394262|RADIATION|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
214723154|NCT02394262|OTHER|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
214723155|NCT02569333|OTHER|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
214723156|NCT02728206|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214723157|NCT02373306|PROCEDURE|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
214723158|NCT04989504|OTHER|Best Practice|Receive standard of care
214723159|NCT04989504|DEVICE|Wound Dressing Material|Apply Mepitel Film
214723160|NCT04989504|OTHER|Quality-of-Life Assessment|Ancillary studies
214723161|NCT04989504|OTHER|Questionnaire Administration|Ancillary studies
214723162|NCT01070706|DRUG|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
214723163|NCT06343454|OTHER|Digital Interocclusal Record In Different Head Positions|Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
214723164|NCT04176562|DEVICE|RTI Spine products|"* Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~* Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~* Bone graft substitute - is intended to aid in fusion."
214723165|NCT03167827|OTHER|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
214723166|NCT03167827|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
214723167|NCT03167827|OTHER|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
214723168|NCT01880879|DEVICE|helios stent|the group with helios stent implanted
214723169|NCT04307589|OTHER|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
214723170|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
214723171|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
214723172|NCT00821054|DRUG|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
214723173|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
214723174|NCT06305923|OTHER|colostrum cream|the intervention in our study is everyday using a cream with active ingridient
214723175|NCT06305923|OTHER|placebo cream|using a placebo cream
214723176|NCT01633528|DRUG|Asprin|100 mg
214723177|NCT01633528|DRUG|placebo|100mg
214723178|NCT05529134|DRUG|PTW-002 10 mg/g gel|poloxamer hydrogel for topical administration
214723179|NCT05529134|DRUG|Placebo|placebo poloxamer hydrogel for topical administration
215030484|NCT01969578|DRUG|Cisplatin + Doxorubicin|
214635437|NCT03096509|OTHER|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
214635438|NCT02085499|OTHER|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.~NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
214635439|NCT02085499|OTHER|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.~S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
214635440|NCT02469090|DRUG|APL-130277|"Use to treat up to 5 OFF episodes per day"
214635441|NCT02469090|DRUG|Placebo|placebo
214635442|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
214635443|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
214635444|NCT02163434|DRUG|Gabapentin|
214635445|NCT02163434|DRUG|Metoclopramide|
214635446|NCT04549701|OTHER|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
214635447|NCT04549701|OTHER|Standard of care|Standard of care will be provided.
214635448|NCT02350803|DEVICE|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
214635449|NCT05916404|OTHER|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (\<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
214635450|NCT05916404|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
214635451|NCT00000645|DRUG|Hypericin|
214635452|NCT06075095|DRUG|BGF MDI HFO 320/14.4/9.6μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
214635453|NCT06075095|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
214635454|NCT06075095|DRUG|Placebo MDI HFA|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
214635455|NCT04283669|DRUG|Crizotinib|Oral
214635456|NCT03987763|DRUG|IDP-122 Lotion|Topical
214635457|NCT04283123|BEHAVIORAL|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
214635458|NCT04283123|OTHER|No Intervention|Waitlist control
214635459|NCT04761055|OTHER|Clinical Breast exam (CBE)|The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.
214635460|NCT04761055|DEVICE|iBreastExam device|The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.
214635461|NCT04761055|DIAGNOSTIC_TEST|mammogram|All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
214635462|NCT06802380|DEVICE|Low-level tragus stimulation|Low-level tragus stimulation will recruit the fibers from the inner part of the tragus of the external ear and sent afferent signals through the greater auricular branch of the vagus nerve. Ultimately the stimulation is transmitted to the dorsal vagal complex and the brainstem thereby modulating the neuronal activity in the vehicle output. Sham stimulation will be performed by clipping the electrode to the ear lobule which will not relay any afferent signals through the greater auricular branch of the vagus nerve.
214635463|NCT06802380|DEVICE|Sham stimulation|In the sham stimulation the electrodes will be attached to the ear lobule which are devoid of any afferent nerves traveling to the greater auricular branch of the vagus nerve.
214635464|NCT03494881|DRUG|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
214635465|NCT05337423|DEVICE|Photobiomodulation|Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.
214635466|NCT05337423|OTHER|Moisturizer|Both groups will receive moisturizer.
214635467|NCT05625321|BEHAVIORAL|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
214635468|NCT05625321|BEHAVIORAL|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
214635469|NCT05466422|BIOLOGICAL|MK-2214|MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57
214723180|NCT03607292|PROCEDURE|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
214723181|NCT03607292|PROCEDURE|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
215030485|NCT01969578|DRUG|Carboplatin + Paclitaxel|
214635470|NCT05466422|DRUG|Placebo|Placebo as an IV infusion on Days 1, 29, and 57
214635471|NCT05313464|OTHER|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
214635472|NCT05313464|OTHER|syringe-push enteral feeding|skin to skin nutrition with syringe pump
214635473|NCT05838287|DRUG|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
214635474|NCT05838287|DRUG|Placebo|Placebo for Pioglitazone
214635475|NCT06381388|DEVICE|cTBS|A single cTBS session delivered to the contralesional primary motor cortex.
214635476|NCT05635968|RADIATION|Low-dose whole brain irradiation|In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
214635477|NCT04734106|DRUG|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
214635478|NCT04734106|OTHER|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
214635479|NCT06388187|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214635480|NCT06388187|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214635481|NCT06388187|DRUG|Placebo|Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
214723182|NCT04481724|DIETARY_SUPPLEMENT|gamma-linolenic acid|3 capsules per day of GLA for 24 months
214723183|NCT04481724|DIETARY_SUPPLEMENT|placebo|3 capsules per day of placebo for 24 months
214723184|NCT03908931|RADIATION|MRI|Follow up of osteochondral surgery by MRI and clinical examination
214723185|NCT04154761|PROCEDURE|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
214723186|NCT00000368|BEHAVIORAL|Cognitive behavior therapy|
214723187|NCT00000368|DRUG|Paroxetine or other medication - algorithm used|
214723188|NCT02901340|DIETARY_SUPPLEMENT|one to two liters of water daily|
214723189|NCT03599544|BEHAVIORAL|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
214723190|NCT03599544|BEHAVIORAL|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
214723191|NCT00429572|DRUG|Fludarabine|30 mg/m\^2 intravenously Daily for 5 Days
214723192|NCT00429572|DRUG|Melphalan|70 mg/m\^2 intravenously Daily for 2 Days
214723193|NCT00429572|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
214723194|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
214723195|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
214723196|NCT03312361|DRUG|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
214723197|NCT02773368|DRUG|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
214723198|NCT02773368|DRUG|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
214723199|NCT01665872|BEHAVIORAL|Cognitive-Behavioral Group Therapy|CBT Group
214723200|NCT05821036|BEHAVIORAL|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
214723201|NCT03960658|DRUG|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
214723202|NCT04030468|OTHER|Educational intervention addressed to general practitioners|"* feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course"
214723203|NCT04030468|OTHER|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
214723204|NCT01929018|BEHAVIORAL|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
214723205|NCT01929018|BEHAVIORAL|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
214723206|NCT01929018|BEHAVIORAL|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
214723207|NCT00748865|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
214723208|NCT00748865|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
214723209|NCT01366534|BIOLOGICAL|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
214723210|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
214723211|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
214723212|NCT01366534|OTHER|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
214723213|NCT02776852|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
214723214|NCT03349593|DIAGNOSTIC_TEST|Echocardiography|Preoperative transthoracic echocardiography
214723215|NCT00987727|DRUG|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
214723216|NCT00987727|DRUG|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
214723217|NCT04767776|DRUG|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
214723218|NCT04767776|DRUG|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
215030486|NCT04344912|OTHER|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
215030487|NCT04498767|RADIATION|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
214635482|NCT05857241|DIETARY_SUPPLEMENT|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
214635483|NCT01415752|BIOLOGICAL|rituximab|Given IV
214635484|NCT01415752|DRUG|Bendamustine|Given IV
214635485|NCT01415752|DRUG|bortezomib|Given IV or SC
214635486|NCT01415752|DRUG|lenalidomide|Given PO
214635487|NCT02736669|BEHAVIORAL|Energy Reduction|
214635488|NCT06117319|OTHER|Individual assistance Virtual reality training sessions|5 virtual reality training sessions where feedback will be provided to each individual by the research team
214635489|NCT06117319|OTHER|Collective assistance Virtual reality training sessions|4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual. No participant was ever assigned to this intervention.
214635490|NCT02705638|DRUG|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
214635491|NCT02705638|DRUG|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
214723219|NCT05784103|DEVICE|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
214723220|NCT05784103|DEVICE|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
214723221|NCT05784103|DEVICE|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
214723222|NCT05784103|DEVICE|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
214723223|NCT02769013|OTHER|Pre-treatment follow up|No active intervention; medical support provided if needed
214723224|NCT02769013|OTHER|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
214723225|NCT02769013|OTHER|Post treatment follow up|No active intervention; medical support provided if needed.
214723226|NCT02769013|OTHER|Olfactometer experiment|No active intervention; medical support provided if needed.
214723227|NCT06340776|OTHER|Acupressure|For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
214723228|NCT03710694|DEVICE|DAV132|"DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
214723229|NCT00591162|DRUG|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
214723230|NCT00591162|RADIATION|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
214723231|NCT00591162|PROCEDURE|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
214723232|NCT01789255|DRUG|vorinostat|Given PO
214723233|NCT01789255|DRUG|tacrolimus|Given IV or PO
214723234|NCT01789255|DRUG|cyclosporine|Given IV or PO
214723235|NCT01789255|DRUG|methotrexate|Given IV
214723236|NCT01789255|OTHER|laboratory biomarker analysis|Correlative studies
214723237|NCT01789255|OTHER|pharmacological study|Correlative studies
214723238|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
214723239|NCT02635867|PROCEDURE|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
214723240|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
214723241|NCT02635867|PROCEDURE|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
214635492|NCT02113735|DRUG|H.P. Acthar® Gel (repository corticotropin injection)|
214635493|NCT02113735|DRUG|Placebo|
214635494|NCT00252057|BEHAVIORAL|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
214635495|NCT00516347|GENETIC|comparative genomic hybridization|
214635496|NCT00516347|GENETIC|genetic linkage analysis|
214635497|NCT00516347|OTHER|laboratory biomarker analysis|
214635498|NCT00516347|OTHER|questionnaire administration|
214635499|NCT00516347|PROCEDURE|study of high risk factors|
214635500|NCT02490514|OTHER|No intervention|No intervention was administered in this study.
214635501|NCT04208477|PROCEDURE|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
214635502|NCT02092194|PROCEDURE|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
214635503|NCT02092194|PROCEDURE|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
214635504|NCT05648435|DIAGNOSTIC_TEST|Lithium measures|Measurements of lithium levels in blood and urine
214635505|NCT03248401|DRUG|Cilostazol|Cilostazol 200 mg/day
214635506|NCT03248401|DRUG|Aspirin|Aspirin 100 mg/day
214723242|NCT02635867|PROCEDURE|Direct Pulp capping-Calcium hydroxide - Dycal|\\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
214723243|NCT01866813|BEHAVIORAL|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
214723244|NCT02565576|DRUG|Placebo|
214723245|NCT02565576|DRUG|CFZ533|
214723246|NCT01496144|PROCEDURE|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
214723247|NCT01496144|PROCEDURE|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
214723248|NCT04693312|DRUG|Depo medrol|local injection
214723249|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
214723250|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
214723251|NCT01500265|BIOLOGICAL|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
214723252|NCT05067114|DEVICE|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
214723253|NCT00312741|PROCEDURE|empirical versus microbiological guided treatment|
214723254|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
214723255|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
214723256|NCT06950034|BIOLOGICAL|STX-0712|STX-0712 is IV administered every 21 days until the patient discontinues treatment.
214723257|NCT00045045|PROCEDURE|positron emission tomography|
214723258|NCT00045045|RADIATION|fludeoxyglucose F 18|
214723259|NCT00553761|DEVICE|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
214723260|NCT05904938|DEVICE|Lenodiar Pediatric|Medical Device made of natural substance
214723261|NCT05904938|OTHER|Placebo|Product appearance similar to verum without clinical efficacy
214723262|NCT04123444|DRUG|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
214723263|NCT04123444|DRUG|Isotonic saline|Continuously infusion for 72 hours.
214723264|NCT04569760|DRUG|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
214635507|NCT03066102|OTHER|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
214635508|NCT02926209|DEVICE|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
214635509|NCT02926209|PROCEDURE|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
214635510|NCT03449823|DIAGNOSTIC_TEST|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
214635511|NCT01660932|DRUG|placebo|
214635512|NCT01660932|DRUG|omega|
214635513|NCT00540254|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
214635514|NCT00540254|OTHER|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
214635515|NCT05412680|PROCEDURE|TOETVA|TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH
214635516|NCT05412680|PROCEDURE|conventional thyroidectomy|conventional open thyroidectomy by cervical approach
214635517|NCT02592850|OTHER|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
214635518|NCT02592850|OTHER|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
214635519|NCT00876993|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
214635520|NCT00876993|DRUG|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
214635521|NCT00876993|DRUG|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
214635522|NCT01240460|DRUG|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
214635523|NCT01240460|DRUG|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
214635524|NCT04884230|PROCEDURE|Oversewing|Oversewing of the gastric remnant
214635525|NCT05332483|DRUG|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
214635526|NCT02972255|DRUG|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
214635527|NCT02972255|DRUG|Meropenem|Meropenem will be administered as per schedule described in individual arm.
214635528|NCT02972255|OTHER|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
214635529|NCT02972255|OTHER|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
214635530|NCT01022190|DRUG|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
214635531|NCT01903837|DRUG|Samidorphan (Low Dose)|Tablets taken once daily
214635532|NCT01903837|DRUG|Samidorphan (Medium Dose)|Tablets taken once daily
214635533|NCT01903837|DRUG|Samidorphan (High Dose)|Tablets taken once daily
214635534|NCT01903837|DRUG|Placebo|Tablets taken once daily
214635535|NCT01903837|DRUG|Olanzapine|Tablets taken once daily
214635536|NCT02498626|OTHER|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
214635537|NCT00705939|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
214635538|NCT05048342|DRUG|LOU064|Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
214635539|NCT03440827|BEHAVIORAL|Focus Group|First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
214635540|NCT01937650|DRUG|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
214635541|NCT03313674|DEVICE|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
214723265|NCT04569760|DRUG|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
214635542|NCT03353727|OTHER|Orthoptic rehabilitation|Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
214635543|NCT02639780|OTHER|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
214635544|NCT02164422|DRUG|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
214635545|NCT02164422|DRUG|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
214635546|NCT02164422|DRUG|Placebo|
214723266|NCT03345342|DRUG|PP6M|Participants will receive intramuscular injection of PP6M.
214723267|NCT03345342|DRUG|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
214723268|NCT03345342|DRUG|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
214723269|NCT03345342|DRUG|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
214723270|NCT03345342|OTHER|Placebo|Participants will receive matching placebo.
214723271|NCT00414505|DEVICE|Intradermal Acupuncture Treatment|
214723272|NCT01268943|DRUG|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
214723273|NCT01268943|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
214723274|NCT01268943|DRUG|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
214723275|NCT01268943|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
214723276|NCT02782104|DRUG|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
214723277|NCT03185819|DRUG|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
214723278|NCT03185819|DRUG|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
214723279|NCT03185819|DRUG|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
214723280|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
214723281|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
214723282|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
214723283|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
214723284|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
214723285|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
214723286|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
214723287|NCT03375203|DRUG|Placebo|Matching placebo will be administered once daily based upon dosing group.
214723288|NCT03375203|DRUG|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
214723289|NCT03375203|DRUG|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
214723290|NCT03375203|DRUG|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
214723291|NCT03375203|DRUG|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
214723292|NCT03321526|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
214723293|NCT03321526|DRUG|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
214723294|NCT03321526|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
214723295|NCT03321526|DRUG|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
214723296|NCT03321526|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
214723297|NCT03321526|DRUG|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
214723298|NCT06685484|BEHAVIORAL|Modified Mindfulness Training Program (MMTP)|"The intervention, designed as a Modified Mindfulness Training Program (MMTP), aims to reduce antenatal depression and perceived stress among pregnant women, especially those with a preference for a male child. This program is adapted to address culturally specific stressors relevant to these women, promoting mental health and resilience during pregnancy.~The intervention is based on Nola Pender's Health Promotion Model and structured using the ADAPT-ITT framework, which includes Assessment, Decision, Adaptation, Production, Topical Experts, Integration, Training, and Testing phases. This phased approach ensures cultural relevance and feasibility within the target population of pregnant women in Pakistan.~Duration and Frequency: The intervention consists of six weekly sessions, each lasting two hours, held in a serene, controlled environment within a seminar room at Sindh Govt. Qatar Hospital, Karachi."
214723299|NCT06527196|BEHAVIORAL|Team Communication Training|Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
214723300|NCT06527196|BEHAVIORAL|Early Identification Universal Depression Screening|Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
214723301|NCT02907086|OTHER|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
214723302|NCT00220584|DRUG|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
214723303|NCT00064636|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
214723304|NCT00732641|DRUG|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
214723305|NCT00479349|DRUG|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
214723306|NCT02910089|BEHAVIORAL|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
214723307|NCT04883918|BIOLOGICAL|ASC930|4 intravenous doses of ASC930
214723308|NCT00467012|DRUG|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
214723309|NCT00467012|DRUG|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
214723310|NCT03246711|BEHAVIORAL|Fasting|Totally or partially fasting the holy month of ramadan for muslims
214723311|NCT02777164|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
214723312|NCT01455155|OTHER|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
214723313|NCT01455155|OTHER|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
214723314|NCT04449718|DIETARY_SUPPLEMENT|Vitamin D|200,000 IU on admission
214723315|NCT04449718|DIETARY_SUPPLEMENT|Placebo|200,000 IU on admission
214723316|NCT01386190|OTHER|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
214723317|NCT03718468|BIOLOGICAL|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
214723318|NCT03718468|BIOLOGICAL|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
214723319|NCT01880203|PROCEDURE|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
214723320|NCT06297798|OTHER|Telerehabilitation|"The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
214723321|NCT00821782|DRUG|Levofloxacin; Azithromycin|
214723322|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
214723323|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
214723324|NCT01148576|DRUG|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
214723325|NCT01148576|DRUG|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
214723326|NCT02058641|DRUG|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
214723327|NCT00120510|DRUG|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
214723328|NCT00120510|DRUG|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
214723329|NCT04254796|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
214723330|NCT05303025|OTHER|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
214723331|NCT05303025|OTHER|Semi-structured group discussion|Semi-structured group discussion.
214723332|NCT03371212|DEVICE|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
214723333|NCT03371212|DEVICE|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
214723334|NCT03288727|OTHER|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
214723335|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
214723336|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
214723337|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214723338|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214723339|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214723340|NCT02114060|BIOLOGICAL|Placebo|0.9% Normal Saline (NaCl)
214723341|NCT00024674|DRUG|SS1(dsFv)-PE38|
214723342|NCT04685369|OTHER|Medical Data extraction|Medical Data extraction
214723343|NCT02762136|DRUG|placebo|
214723344|NCT02762136|DRUG|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
214723345|NCT03900663|DEVICE|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
214723346|NCT03210064|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
214723347|NCT03210064|DRUG|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
214723348|NCT03431506|BEHAVIORAL|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
214723349|NCT02217683|DRUG|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
214723350|NCT04741087|DRUG|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
214723351|NCT04741087|DRUG|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
214723352|NCT01620593|DRUG|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
214723353|NCT01620593|DRUG|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
214723354|NCT04137562|BIOLOGICAL|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
214723355|NCT04137562|OTHER|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
214723356|NCT00079820|BIOLOGICAL|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
214723357|NCT04035538|DRUG|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
214635547|NCT01558661|DRUG|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
214635548|NCT03345472|DEVICE|Spinal Cord Stimulation System|Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
214635549|NCT05020600|DRUG|Duloxetine|First-line fibromyalgia treatment
214635550|NCT05020600|DRUG|Pregabalin|First-line fibromyalgia treatment
214635551|NCT05020600|DRUG|Amitriptyline|First-line fibromyalgia treatment
214723358|NCT03034057|DRUG|Sayana Press|Sayana Press in the Uniject injection system
214723359|NCT01633229|PROCEDURE|Bone Marrow Stromal Cell Infusion|
214723360|NCT01316029|PROCEDURE|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
214723361|NCT03838380|OTHER|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
214723362|NCT00655057|DRUG|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
214723363|NCT00655057|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
214723364|NCT00655057|PROCEDURE|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
214723365|NCT00701103|DRUG|Dalotuzumab|IV infusion
214723366|NCT03350867|OTHER|Personalized Insole Group|Personalized Insole Group
214723367|NCT03350867|OTHER|Placebo Group|Placebo Group
214793820|NCT05214807|DEVICE|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
214635552|NCT05148923|PROCEDURE|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
214635553|NCT01926782|DRUG|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
214635554|NCT01926782|DRUG|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
214635555|NCT01926782|DRUG|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
214635556|NCT02615743|BEHAVIORAL|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
214635557|NCT02615743|DEVICE|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
214635558|NCT00632801|OTHER|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
214635559|NCT02462473|DRUG|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
214793821|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
214793822|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
214793823|NCT02629549|DRUG|OTL38|Infusion of OTL38 prior to surgery
214723368|NCT03368599|PROCEDURE|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
214723369|NCT03368599|PROCEDURE|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
214723370|NCT05185817|BIOLOGICAL|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
214723371|NCT01929707|DRUG|LY3050258|
214723372|NCT01929707|DRUG|Placebo|
214723373|NCT00263315|DRUG|nebulised liposomal amphotericin B|
214723374|NCT03432611|OTHER|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
215030488|NCT04498767|RADIATION|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
214723375|NCT03432611|OTHER|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
214723376|NCT01976169|DRUG|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
214723377|NCT01804491|OTHER|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
214723378|NCT00179517|DRUG|Anastrozole 1mg|
214723379|NCT00179517|DRUG|Placebo Oral Tablet|
214723380|NCT01920438|PROCEDURE|Percutaneous Endoscopic Gastrostomy|PEG
214723381|NCT01920438|PROCEDURE|Radiologically-guided insertion of Gastrostomy|RIG
214723382|NCT00437203|DRUG|PF-00477736|"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
214723383|NCT00437203|DRUG|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
214723384|NCT06211452|DRUG|ARM A: Active Comparator Drug|Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
214723385|NCT06211452|DRUG|ARM B: Blocks Therapy Drug|"Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15."
214723386|NCT05048199|DEVICE|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
215030489|NCT05855993|OTHER|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
215030490|NCT05855993|OTHER|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
214635560|NCT02462473|DRUG|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
214635561|NCT02462473|DRUG|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
214635562|NCT02462473|DRUG|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
214635563|NCT02462473|DRUG|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
215030491|NCT03551119|BEHAVIORAL|Exercise|See previous description
215030492|NCT03551119|OTHER|Enhanced usual care|See previous description
215030493|NCT03377322|DRUG|Probiotic Capsule|Probiotic - one capsule a day for four weeks
215030494|NCT03377322|DRUG|Placebo Capsule|Placebo - one capsule a day for four weeks
214723387|NCT05048199|DEVICE|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
214723388|NCT01485432|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
214723389|NCT00084604|DRUG|irinotecan hydrochloride|Given IV
214723390|NCT00084604|BIOLOGICAL|bevacizumab|Given IV
214723391|NCT00084604|DRUG|cisplatin|Given IV
214723392|NCT00084604|PROCEDURE|computed tomography|Correlative studies
214723393|NCT00084604|OTHER|laboratory biomarker analysis|Correlative studies
214723394|NCT00003413|BIOLOGICAL|filgrastim|
214723395|NCT00003413|DRUG|carmustine|
214723396|NCT00003413|DRUG|cisplatin|
214723397|NCT00003413|DRUG|melphalan|
214723398|NCT00003413|DRUG|paclitaxel|
214723399|NCT00003413|PROCEDURE|peripheral blood stem cell transplantation|
214723400|NCT00003413|PROCEDURE|surgical procedure|
214723401|NCT03037606|DRUG|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
214723402|NCT03037606|DRUG|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
214723403|NCT01449955|DRUG|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
214723404|NCT01449955|DRUG|Placebo|Inactive
214723405|NCT03611049|DIETARY_SUPPLEMENT|High dose Vitamin D3|High dose arm- 5000IU given daily
214723406|NCT03611049|DIETARY_SUPPLEMENT|Low dose Vitamin D3|Low dose arm-800 IU given daily
214723407|NCT05849636|BEHAVIORAL|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
214635564|NCT01103674|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
214635565|NCT04211207|OTHER|non invasive monitoring value|heart's respiratory quotient as non invasive monitoring value
214635566|NCT03390062|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
214635567|NCT00868686|DEVICE|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
214635568|NCT00868686|DEVICE|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
214635569|NCT00868686|DEVICE|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
214723408|NCT05387213|BEHAVIORAL|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
214723409|NCT01332097|DRUG|BCT197|
214723410|NCT01332097|DRUG|Prednisone placebo|capsules
214723411|NCT01332097|DRUG|BCT197 placebo|capsules
214723412|NCT01332097|DRUG|Prednisone|capsules
214723413|NCT04734977|DEVICE|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
214723414|NCT04734977|DEVICE|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
214723415|NCT04734977|OTHER|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
214723416|NCT00003551|DRUG|aminocamptothecin colloidal dispersion|
214723417|NCT02661945|DEVICE|Near focus with narrow band imaging|
214723418|NCT00822562|OTHER|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
214723419|NCT00822562|PROCEDURE|surgery|only surgery
214723420|NCT00964262|DRUG|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
214723421|NCT00964262|DRUG|Placebo|Plcacebo of each doasage, single subcutanoeus injection
214723422|NCT06114030|PROCEDURE|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
214723423|NCT01674946|OTHER|saline|intraduodenal perfusion
214723424|NCT01674946|OTHER|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
214723425|NCT01674946|OTHER|oleanolic acid|intraduodenal perfusion
214723426|NCT01674946|DIETARY_SUPPLEMENT|oleic acid|intraduodenal perfusion
214723427|NCT01674192|DRUG|prucalopride|single dose of 2 mg prucalopride
214635570|NCT04854681|DRUG|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
214635571|NCT05946369|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient
214635572|NCT04099303|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
214635573|NCT04099303|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
214635574|NCT04099303|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
214635575|NCT04099303|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
214635576|NCT00001570|DRUG|PSC 833|
214635577|NCT00001570|DRUG|vinblastine|
214635578|NCT05599997|DRUG|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
214635579|NCT05599997|DRUG|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
214635580|NCT00257803|DRUG|Oxytocin|See detailed description
214635581|NCT00257803|DRUG|Saline solution|See detailed description
214723428|NCT01676441|DRUG|cellgram-spine|Mesenchymal stem cells transplantation
214723429|NCT02899260|DEVICE|Peanut Exercise Ball|A Peanut shaped exercise ball.
214723430|NCT02067533|PROCEDURE|soft tissue repair in flexion position|
214723431|NCT02067533|PROCEDURE|soft tissue repair in extension position|
214723432|NCT00004898|BIOLOGICAL|filgrastim|
214723433|NCT00004898|DRUG|cyclophosphamide|
214723434|NCT00004898|DRUG|etoposide|
214723435|NCT00004898|PROCEDURE|peripheral blood stem cell transplantation|
214723436|NCT00004898|RADIATION|radiation therapy|
214723437|NCT03343782|COMBINATION_PRODUCT|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
214723438|NCT05522296|DRUG|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
214723439|NCT00493194|DRUG|sirolimus|
214723440|NCT00493194|DRUG|cyclosporine|
214635582|NCT04375774|DEVICE|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
214635583|NCT04375774|DEVICE|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
214635584|NCT04375774|DEVICE|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
214635585|NCT04676737|DRUG|TTHX1114(NM141)|TTHX1114
214635586|NCT02723123|OTHER|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
214635587|NCT02693587|DRUG|Misodel and Angusta|
214635588|NCT01254279|DRUG|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
214635589|NCT01925690|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
214635590|NCT01925690|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
214635591|NCT01400451|DRUG|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
214635592|NCT01400451|DRUG|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
214635593|NCT04538391|DRUG|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
214635594|NCT03850912|OTHER|Stakeholder Survey (Control Period)|Before eSyM go-live, study team members from each site will solicit input via emailed survey, remote meetings and/or in-person meeting on the use of ePROs in oncology from stakeholders to obtain input regarding adaptation, anticipated challenges, and implementation.
214635595|NCT03850912|OTHER|Stakeholder Survey (Intervention Period)|After eSyM go-live and on an ongoing basis, we will evaluate the implementation process at each of the sites with a focus on adoption, appropriateness, acceptability, sustainability, penetration, and scalability. We will do so through emailed surveys and/or discussions with health system leadership, clinicians, clinic support staff, and informatics/IT staff.
214635596|NCT03850912|OTHER|Qualitative Interview|A small subset of patients and stakeholders were invited to take part in qualitative interviews after the eSyM trial rollout.
214635597|NCT03850912|OTHER|SASS Questionnaire|"A subset of control and intervention patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care."
214635598|NCT03850912|OTHER|eSyM|The electronic symptom management (eSyM) program is the EHR-integrated ePRO program being evaluated through this trial.
214723441|NCT00493194|DRUG|daclizumab|
214723442|NCT01280019|PROCEDURE|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
214723443|NCT04734769|OTHER|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
214723444|NCT04516031|PROCEDURE|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
214723445|NCT04516031|PROCEDURE|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
214723446|NCT00876486|DRUG|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
214723447|NCT00876486|DRUG|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
214723448|NCT03678818|OTHER|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
214723449|NCT01983618|PROCEDURE|Interscalene nerve block and catheter|
214723450|NCT01983618|PROCEDURE|Interscalene catheter|
214723451|NCT06034912|DEVICE|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
214723452|NCT02566109|DIAGNOSTIC_TEST|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
214723453|NCT05670249|PROCEDURE|suboccipital decompressive craniectomy|extensive bilateral suboccipital decompressive craniectomy with duraplasty
214723454|NCT01807767|DRUG|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
214723455|NCT01807767|DRUG|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
214723456|NCT01993667|DRUG|Low Dose Acetazolamide|Administration of low dose acetazolamide
214723457|NCT01993667|DRUG|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
214723458|NCT04220710|DIAGNOSTIC_TEST|DNA extraction and methylation detection|DNA extraction and methylation detection
214723459|NCT05933798|OTHER|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
214723460|NCT05933798|OTHER|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
214723461|NCT01022645|DEVICE|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
214723462|NCT01022645|DEVICE|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
214723463|NCT00805012|DRUG|docetaxel+CDDP|docetaxel+CDDP
214723464|NCT00805012|DRUG|docetaxel+S-1|docetaxel+S-1
214635599|NCT05671432|BIOLOGICAL|CM326|CM326 injection
214635600|NCT05671432|OTHER|Placebo|Placebo
214635601|NCT05499949|DIAGNOSTIC_TEST|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
214635602|NCT05499949|DIAGNOSTIC_TEST|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
214635603|NCT05499949|DIAGNOSTIC_TEST|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
214635604|NCT00619073|DRUG|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
214635605|NCT00619073|DRUG|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
214635606|NCT00619073|DRUG|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
214635607|NCT01539590|DRUG|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
214635608|NCT01539590|DRUG|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
214635609|NCT01258764|DRUG|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
214635610|NCT01258764|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
214635611|NCT04627272|DEVICE|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
214635612|NCT05789030|DRUG|Diprospan plus iguratimod|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
214635613|NCT05789030|DRUG|Diprospan plus leflunomide|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
214635614|NCT05789030|DRUG|Prednisone plus leflunomide|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
214635615|NCT00356941|DRUG|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
214635616|NCT00356941|DRUG|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
214635617|NCT00356941|PROCEDURE|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
214635618|NCT02590380|DEVICE|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
214635619|NCT02590380|DEVICE|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
214635620|NCT04326608|OTHER|physiotherapy|manual therapy and sef-care exercises
214635621|NCT03759535|DIAGNOSTIC_TEST|Acute rejection|Donor derived cell free DNA
214635622|NCT01440621|DRUG|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
214635623|NCT01440621|DRUG|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
214635624|NCT04397094|DRUG|Theracal LC|pulpotomy
214635625|NCT04397094|DRUG|Formocresol|Pulpotomy
214635626|NCT00903929|DRUG|Eltrombopag|dose escalation
214635627|NCT06383767|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
214635628|NCT06383767|DRUG|Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)|Eribulin, capecitabine, gemcitabine or vinorelbine
214635629|NCT02868346|OTHER|Anal swab|
214635630|NCT01487512|DRUG|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
214635631|NCT01487512|DRUG|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
214635632|NCT01487512|DRUG|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
214723465|NCT04121689|DIETARY_SUPPLEMENT|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
214723466|NCT05721196|BEHAVIORAL|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
214723467|NCT05721196|DRUG|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
214723468|NCT01297946|DEVICE|Conventional continuous subcutaneous insulin infusion therapy|
214723469|NCT01297946|DEVICE|Dual-hormone closed-loop|
214723470|NCT05793684|DRUG|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
214723471|NCT05793684|DRUG|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
214723472|NCT05793684|DRUG|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
214723473|NCT03930303|BEHAVIORAL|Multimedia- based patient education|Patients will receive a 5 minutes video education before D\&C
214723474|NCT01847079|OTHER|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
214635633|NCT01487512|DRUG|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
214635634|NCT00291005|DRUG|ARD6562, Docetaxel|
214635635|NCT01150266|DRUG|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
214635636|NCT02677155|RADIATION|Radiotherapy|Radiotherapy 8 Gy single dose
214635637|NCT02677155|BIOLOGICAL|Rituximab|Intranodal injection 5 mg
214635638|NCT02677155|BIOLOGICAL|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
214635639|NCT02677155|BIOLOGICAL|GM-CSF|Subcutaneous injection of 50 ug
214635640|NCT02677155|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
214635641|NCT05634395|DEVICE|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
214635642|NCT02158091|DRUG|IPI-145|oral PI3K delta/gamma inhibitor
214635643|NCT02158091|DRUG|Fludarabine|intravenous chemotherapy
214635644|NCT02158091|DRUG|Cyclophosphamide|intravenous chemotherapy
214635645|NCT02158091|DRUG|Rituximab|intravenous immunotherapy
214635646|NCT04404062|DIAGNOSTIC_TEST|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
214635647|NCT04404062|DIAGNOSTIC_TEST|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
214635648|NCT04404062|DIAGNOSTIC_TEST|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
214635649|NCT06558838|DRUG|acyclovir-penciclovir cream|Patients will treat their cold sore with active study drug based upon their randomization
214635650|NCT06558838|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
214635651|NCT04899687|DRUG|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
214635652|NCT04899687|DRUG|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
214635653|NCT02001233|BIOLOGICAL|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
214635654|NCT03977467|DRUG|Atezolizumab|Atezolizumab at a flat dose of 1200 mg IV every 3 weeks
214635655|NCT03977467|DRUG|Standard of Care Chemotherapy|Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
214635656|NCT03977467|DRUG|Tiragolumab|Tiragolumab at a flat dose of 600 mg IV every 3 weeks
214635657|NCT05513456|BEHAVIORAL|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
214723475|NCT05410808|OTHER|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
214635658|NCT05530798|DEVICE|Definity Perflutren Lipid Microsphere Ultrasound Contrast|"1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had."
214635659|NCT01696734|DRUG|Domperidone|Given PO
214635660|NCT01696734|OTHER|Questionnaire Administration|Ancillary studies
214635661|NCT05161377|PROCEDURE|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
214635662|NCT05161377|PROCEDURE|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
214635663|NCT06851312|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
214635664|NCT06504459|DRUG|Azacitidine|Given IV or SC
214635665|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214635666|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214635667|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214635668|NCT06504459|DRUG|Cladribine|Given IV
214635669|NCT06504459|DRUG|Cytarabine|Given SC
214635670|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
214635671|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
214635672|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214635673|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
214635674|NCT06504459|DRUG|Venetoclax|Given PO
214635675|NCT05693896|BEHAVIORAL|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
214723476|NCT05410808|OTHER|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
214635676|NCT06967519|DRUG|Artemether-lumefantrine (AL)|Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine
214635677|NCT06967519|DRUG|artesunate-amodiaquine (AS-AQ)|Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing
214635678|NCT02579070|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
214635679|NCT00039793|PROCEDURE|Moderate-intensity and low-intensity bodywork therapy|
214635680|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )|repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
214723477|NCT00220259|DRUG|Fluticasone or placebo|
214635681|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation|sham trans-spinal magnetic stimulation
214635682|NCT05024097|DRUG|Etrumadenant (AB928)|Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
214635683|NCT05024097|RADIATION|Radiation therapy|Patients will receive a radiation therapy dose of 25Gy in 5fx
214635684|NCT05024097|DRUG|FOLFOX regimen|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
214635685|NCT05024097|DRUG|Zimberelimab (AB122)|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
214723478|NCT03945448|DRUG|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
214635686|NCT06310499|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
214635687|NCT05700435|BEHAVIORAL|Stress Management and Resilience Training|The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
214635688|NCT04907760|OTHER|Personalized care program|It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
214635689|NCT04886089|DEVICE|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
214635690|NCT06576583|BIOLOGICAL|Engineered cartilage graft (N-TEC)|Nasal chondrocytes based tissue engineered cartilage
214635691|NCT06576583|PROCEDURE|Autologous Matrix Induced Chondrogenesis (AMIC)|Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells
214723479|NCT03945448|DRUG|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
214723480|NCT00292812|DRUG|Nutritional supplementation (nucleotides)|
214723481|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
214723482|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
214723483|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
214723484|NCT02533856|OTHER|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
214723485|NCT04703062|BEHAVIORAL|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
214723486|NCT04703062|BEHAVIORAL|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
214723487|NCT04570969|PROCEDURE|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
214723488|NCT03064269|BIOLOGICAL|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
214723489|NCT02650440|PROCEDURE|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
214723490|NCT02650440|PROCEDURE|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
214723491|NCT04125992|PROCEDURE|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
214723492|NCT04125992|PROCEDURE|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
214723493|NCT06089655|DEVICE|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
214723494|NCT06089655|BEHAVIORAL|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
214723495|NCT01997281|DIETARY_SUPPLEMENT|dietary fiber-enriched cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast"
214723496|NCT01997281|OTHER|conventional cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
214723497|NCT02448914|DRUG|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
214723498|NCT02448914|DRUG|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
214635692|NCT06576583|PROCEDURE|Patellofemoral Arthroplasty (PFA)|Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.
214635693|NCT04533659|BEHAVIORAL|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
214635694|NCT04533659|BEHAVIORAL|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
214635695|NCT06503172|BIOLOGICAL|Taiwanese whole grain job's tear (red job's tear)|300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
214635696|NCT06503172|BIOLOGICAL|White job's tear|300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
214635697|NCT01358864|DRUG|BI 201335|BI 201335 once a day (QD) for 24 weeks
214635698|NCT01358864|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
214635699|NCT01358864|DRUG|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
214635700|NCT01358864|DRUG|Placebo|Placebo to BI201335 for 24 weeks
214635701|NCT06640036|OTHER|Rapeseed oil|During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
214635702|NCT06640036|OTHER|Butter|During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
214635703|NCT06640036|OTHER|Coconut oil|During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
214635704|NCT04479111|PROCEDURE|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
214635705|NCT01986543|DRUG|drug administration|
214635706|NCT02656485|DRUG|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
214635707|NCT02656485|DRUG|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
214635708|NCT03194373|DRUG|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
214635709|NCT03194373|DRUG|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
214635710|NCT02386150|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
214635711|NCT02428257|PROCEDURE|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
214635712|NCT02428257|DRUG|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
214635713|NCT02428257|DRUG|isobaric bupivacaine|0.5% isobaric bupivacaine
214635714|NCT02428257|DRUG|ephedrine|
214635715|NCT01238458|DRUG|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
214635716|NCT01526161|DRUG|inhaled fluticasone propionate|100 micrograms
214723499|NCT01624610|OTHER|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
214723500|NCT02143323|DRUG|Augmentin tablet|
214635717|NCT01526161|DRUG|salmeterol|50 m
214635718|NCT01526161|DRUG|Montelukast|Double blind double dummy
214723501|NCT06450223|DRUG|Perampanel 12 MG|1 tablet of Perampanel Tablets 12 mg
214635719|NCT02177201|OTHER|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
214723502|NCT06450223|DRUG|Fycompa 12 mg film-coated tablets|1 tablet of Perampanel Tablets 12 mg
214635720|NCT02177201|OTHER|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
214635721|NCT05563506|BEHAVIORAL|Healthy Kids +|Three times a week for 30 weeks.
214635722|NCT02847130|OTHER|Informational Intervention|Participate in focus group
214635723|NCT02847130|OTHER|Interview|Undergo one-on-one interviews
214635724|NCT02847130|OTHER|Medical Chart Review|Review of medical chart
214635725|NCT02847130|OTHER|Questionnaire Administration|Ancillary studies
214635726|NCT06502171|DRUG|Cabozantinib Oral Tablet|"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."
214635727|NCT06502171|DRUG|Selumetinib Oral Capsule|"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."
214635728|NCT04261127|GENETIC|Genetic diagnosis (PMDA panel)|Blood samples for DNA study
214635729|NCT04261127|DIAGNOSTIC_TEST|Use of RADIAL algorithm|RADIAL card filling (contains clinical and biological data)
214635730|NCT04158648|DRUG|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
214635731|NCT04209855|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
214635732|NCT04209855|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
214635733|NCT04209855|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
214635734|NCT04209855|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
214635735|NCT04203615|DEVICE|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
214635736|NCT04203615|DEVICE|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
214723503|NCT02066545|DRUG|CLS001 Topical Gel|
214723504|NCT02066545|DRUG|CLS001 Topical Gel Vehicle|
214723505|NCT03012542|DIETARY_SUPPLEMENT|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
214723506|NCT03012542|DIETARY_SUPPLEMENT|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
214723507|NCT05725200|DRUG|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
214635737|NCT06479681|BEHAVIORAL|Peer recovery coaching (PRC)|The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.
214635738|NCT06479681|BEHAVIORAL|Brief Intervention (SBIRT)|The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
214635739|NCT03528694|BIOLOGICAL|Durvalumab (MEDI4736)|Investigational product
214635740|NCT03528694|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Standard of care
214635741|NCT02655965|DRUG|Ropivacaine|Ropivacaine 3.5 mg/ml
214635742|NCT02655965|DRUG|Clonidine|Clonidine 5µg/ml
214635743|NCT02655965|DRUG|Sodium Chloride|Sodium Chloride 0.9 %
214635744|NCT04338009|OTHER|Discontinuation of ARB/ACEI|The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
214635745|NCT04338009|OTHER|Continuation of ARB/ACEI|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
214635746|NCT01250379|DRUG|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
214635747|NCT01250379|DRUG|Chemotherapy|Standard chemotherapy (doublets not allowed)
214635748|NCT02358642|DRUG|Angiotensin converting enzyme inhibitor (Lisinopril)|
214635749|NCT02358642|DRUG|Placebo|
214635750|NCT05902364|OTHER|Systane Ultra PF lubricant eye drops|Commercially available preservative free eye drops
214635751|NCT03355300|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214635752|NCT02553512|OTHER|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
214635753|NCT00000625|DRUG|Zidovudine|
214635754|NCT00000625|DRUG|Zalcitabine|
214635755|NCT00000625|DRUG|Didanosine|
214635756|NCT01489527|BIOLOGICAL|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
214635757|NCT01489527|OTHER|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
214635758|NCT03042507|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
214635759|NCT01984268|DRUG|ACTHAR|
214635760|NCT04589104|BEHAVIORAL|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth"
214635761|NCT02566746|DEVICE|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
214635762|NCT02566746|DRUG|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
214635763|NCT04485312|BEHAVIORAL|preventive protocol|preventive protocol
214635764|NCT04485312|BEHAVIORAL|chlorhexidine added to the preventive protocol|chlorhexidine varnish added to the preventive protocol
214635765|NCT06222840|OTHER|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
214635766|NCT06222840|OTHER|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
214723508|NCT05725200|DRUG|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723509|NCT05725200|DRUG|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214635767|NCT06222840|OTHER|Clinical datas analysis|Clinical datas analysis
214635768|NCT06222840|OTHER|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
214635769|NCT05405283|BIOLOGICAL|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
214635770|NCT05405283|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
214635771|NCT02922140|BEHAVIORAL|pharmaceutical care service|
214635772|NCT04053738|DEVICE|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
214635773|NCT00800501|DRUG|sNN0029|Continuous ICV infusion at one of three dose levels
214635774|NCT00800501|DRUG|Placebo|Continuous ICV infusion
214635775|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
214723510|NCT05725200|DRUG|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723511|NCT05725200|DRUG|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
214635776|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
214635777|NCT01394146|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
214635778|NCT00485212|DEVICE|compression bandage|
214635779|NCT04899232|DRUG|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
214635780|NCT03312959|DRUG|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
214635781|NCT03312959|DRUG|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
214635782|NCT00898560|DRUG|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
214635783|NCT00898560|DRUG|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
214635784|NCT01327157|PROCEDURE|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
214635785|NCT01327157|BEHAVIORAL|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
214723512|NCT05725200|DRUG|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723513|NCT05725200|DRUG|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
214723514|NCT05725200|DRUG|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723515|NCT05725200|DRUG|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723516|NCT05725200|DRUG|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723517|NCT05725200|DRUG|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723518|NCT05725200|DRUG|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723519|NCT05725200|DRUG|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723520|NCT05725200|DRUG|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723521|NCT05725200|DRUG|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723522|NCT05725200|DRUG|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214723523|NCT05725200|DRUG|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
214635786|NCT04800536|OTHER|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
214635787|NCT04800536|OTHER|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
214635788|NCT04248439|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
214635789|NCT00248248|DRUG|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
214635790|NCT01380431|DRUG|Lisinopril|Tablets, 40 mg, single oral dose
214635791|NCT01380431|DRUG|lisinopril|Tablets, 40 mg, single, oral dose
214635792|NCT01380431|DRUG|Lisinopril|50% of subjects received the Par formulated product.
214635793|NCT05558540|DEVICE|spinal cord stimulator|By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
214635794|NCT02201407|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
214635795|NCT01344876|DRUG|OPB-51602|once daily during the treatment period
214635796|NCT05259982|PROCEDURE|Vital root resection|Vital resection of root with attachment loss exceeding 2/3 of the root with the use of calcium silicate cement in the pulpal wound
214635797|NCT04428424|DRUG|Enbrel|As provided in real world practice
214635798|NCT00381264|DRUG|Cesamet™ (nabilone)|
214635799|NCT01490619|BEHAVIORAL|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
214635800|NCT01490619|OTHER|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
214635801|NCT04797832|DRUG|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
214635802|NCT04760925|DEVICE|CascadeTM, Non-Occlusive Remodeling Net|Temporary assistance device for coil embolization of intracranial aneurysms
214635803|NCT01781494|PROCEDURE|Immobilization followed by protected range of motion|
214635804|NCT01781494|PROCEDURE|Immediate range of motion|
214635805|NCT02901288|DRUG|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
214635806|NCT02901288|DRUG|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
214635807|NCT02901288|DRUG|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
214635808|NCT02901288|DRUG|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
214723524|NCT00759083|DRUG|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
214723525|NCT03825497|OTHER|Promotion of activity during and after hospitalization|1\) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
214723526|NCT03326661|PROCEDURE|Aspiration|Needle aspiration of pus from the peritonsilar abscess
214723527|NCT03326661|PROCEDURE|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
214723528|NCT03326661|DRUG|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
214723529|NCT01570309|DRUG|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
214723530|NCT01570309|OTHER|Sugar pill|Oral capsule, once a week, 12 weeks
214723531|NCT01569997|OTHER|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
214723532|NCT00145197|BEHAVIORAL|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
214723533|NCT00560794|BIOLOGICAL|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
214723534|NCT00513994|DRUG|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
214723535|NCT01024062|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
214723536|NCT01024101|DRUG|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
214723537|NCT04857892|DRUG|GSK3640254|GSK3640254 will be administered via oral route.
214723538|NCT04857892|DRUG|DTG|DTG will be administered via oral route.
214723539|NCT04857892|DRUG|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
214723540|NCT00741806|BIOLOGICAL|GHB04L1|single dose intranasal administration of GHB04L1
214723541|NCT00741806|OTHER|Placebo|SPGN buffer
214723542|NCT04853199|DRUG|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
214723543|NCT04853199|DRUG|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
214723544|NCT05906667|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
214635809|NCT02901288|DRUG|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
214635810|NCT06287034|PROCEDURE|Primary suture|The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
214635811|NCT03922698|OTHER|No interventions|No interventions - observational study
214635812|NCT02796248|OTHER|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
214635813|NCT06235099|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
214635814|NCT02135887|DRUG|MB-6|6# TID with meal
214635815|NCT02135887|DRUG|Placebo|6# TID with meal
214635816|NCT04794712|DEVICE|Venous reflux tools (Ultrasound and Photo plethysmography (PPG))|Venous reflux tools Pain assessment tools
214635817|NCT00441597|DRUG|atorvastatin|atorvastatine 80mg, during 3 days
214635818|NCT02975544|BEHAVIORAL|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
214635819|NCT06269133|DRUG|REGN2810|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
214635820|NCT06269133|OTHER|Platinum-doublet chemotherapy|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
214635821|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
214635822|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
214635823|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
214635824|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
214635825|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
214635826|NCT04451421|BEHAVIORAL|Change of standing Angle|Change the patient's standing Angle by using an electric bed
214635827|NCT06989671|DRUG|JMT101|JMT101 Q2W or Q3W, intravenous injection
214635828|NCT06989671|DRUG|SYS6002|SYS6002 Q2W or Q3W, intravenous injection
214635829|NCT06989671|DRUG|SG001|SG001 Q2W or Q3W, intravenous injection
214635830|NCT06984744|DEVICE|MIIP-E2 containing gum|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit. MIIP-E2 is an ultrapure (\>99%) fully native and completely active form of bovine lactoferrin purified directly from raw milk.
214635831|NCT06984744|DEVICE|placebo gum without MIIP-E2|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit.
214635832|NCT07000149|DRUG|Volrustomig|Volrustomig will be administered as an intravenous (IV) infusion.
214635833|NCT07000149|DRUG|Casdatifan|Casdatifan will be administered orally.
214635834|NCT07000149|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion.
214635835|NCT07000149|DRUG|Ipilimumab|Ipilimumab will be administered as an IV infusion.
214635836|NCT06918561|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
214635837|NCT06918561|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214635838|NCT07006233|BEHAVIORAL|Whole Food Ketogenic Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This group will focus on the consumption of low-energy, nutrient dense whole foods with a targeted carbohydrate intake of 30-50g per day to achieve nutritional ketosis. The WFKD will adjust carbohydrate level for the individual participant to achieve average blood/urinary ketone levels of between 0.5 and 3.0 mmol/L (tested for objective feedback using a mix of urinary ketone sticks and finger prick blood measures).
214635839|NCT07006233|BEHAVIORAL|Whole Food Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This diet is high carbohydrate (45-65% of total energy coming from carbohydrate, 20-35% from fat and 15-25% from protein) based on the Australian dietary guidelines focusing on the consumption of low-energy, nutrient dense whole foods. The higher carbohydrate diet reflects current contemporary 'standard care' dietary recommendations as outlined by the National Health and Medical Research Council's Australian Dietary Guidelines, and therefore represents the most appropriate control diet to compare to the effects of the proposed intervention.
214635840|NCT07009483|BEHAVIORAL|Patient education modules providing information on the psychological aspects of atopic dermatitis treatment and management.|Provision of online patient educational modules (in addition to patients receiving regular clinical action/ appointments at the Kaye Edmonton Clinic, the Stollery Children's Hospital, and the Rao Dermatology Clinic for Atopic Dermatitis).
214635841|NCT07004205|OTHER|The ARCS Motivation Model Education|The ARCS Motivation Model Education-focused on Attention, Relevance, Confidence, and Satisfaction
214723545|NCT01766544|OTHER|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
214723546|NCT01766544|OTHER|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
214635842|NCT04586010|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
214635843|NCT04586010|DRUG|Teriflunomide|Participants will receive teriflunomide.
214635844|NCT04586010|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
214635845|NCT07018245|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
214635846|NCT07018245|DRUG|Placebo|Capsule, Once Daily
214635847|NCT07024966|DIETARY_SUPPLEMENT|Pterostilbene-silybin-nicotinamide riboside|Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.
214635848|NCT07024966|DIETARY_SUPPLEMENT|Control Group|Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.
214635849|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
214635850|NCT04647253|DEVICE|AGENT DCB|Drug coated PTCA balloon catheter
214635851|NCT04647253|DEVICE|PTCA balloon catheter|PTCA balloon catheter
214635852|NCT07029646|DEVICE|EndoScell™ intraoperative handheld microscope|The research instrument used is the EndoScell™ intraoperative handheld microscope, which employs the principle of epifluorescence. It is a miniaturized microscope that reduces the size of a traditional large optical microscope by approximately a thousand times. It is the world's first handheld micrometer-level intraoperative real-time cell imaging probe microscope. This microscope is equipped with high-definition, real-time, anti-shake, and full-coverage scanning features. It can rapidly investigate the structure and cell morphology of tissues in real-time.
214635853|NCT03895866|OTHER|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
214635854|NCT07029139|DRUG|JMT601 Injection|In accordance with the protocol
214635855|NCT07029139|DRUG|Rituximab|In accordance with the protocol
214635856|NCT07029139|DRUG|Cyclosporin Capsules|In accordance with the protocol
214635857|NCT07028411|BEHAVIORAL|Educational board game|The educational board game will be administered once for a duration of 90 minutes, consisting of a gameplay session followed by a debriefing.
214635858|NCT07028411|BEHAVIORAL|Lecture|The lecture will be administered once for a duration of 90 minutes, consisting of video lecture followed by question and answer (QnA) session.
214635859|NCT07028541|DEVICE|Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children|This is a first-in-child clinical investigation of a bioresorbable magnesium alloy DrillPin (RemeOs™) for fixation of distal radius fractures in children aged 5 to \<14 years. The implant is investigational, not CE-marked or FDA-approved, and represents a novel alternative to traditional metallic implants. It gradually degrades in vivo, eliminating the need for removal. The study focuses on safety and feasibility in a pediatric population, supported by preclinical data from a similar Mg-based RemeOs™ Screw. The DrillPin's material and design are intended to support bone healing without growth disturbances, offering a state-of-the-art, bioresorbable solution tailored for growing patients.
214635860|NCT06712407|DRUG|TARPEYO®|6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
214635861|NCT07046624|BEHAVIORAL|Infusion monitoring system developed for use by nurses in patient care|In the experimental group, the frequency of complications will first be determined and an infusion monitoring system will be developed and used by nurses in patient care.
214723547|NCT01394367|OTHER|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
214723548|NCT01279980|OTHER|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
214635862|NCT07061522|OTHER|Behavioral/Physical Assessment|This study will not include any therapeutic or clinical intervention. Instead, participants will undergo a series of structured physical and questionnaire-based assessments to evaluate lower extremity motor performance. These include the Fagerström Test for Nicotine Dependence and DSM-IV-TR criteria to classify smoking addiction. Anthropometric measurements such as Body Mass Index (BMI) and bimalleolar diameter/circumference will be recorded to assess potential confounding structural factors. Lower extremity coordination will be evaluated using the Lower Extremity Motor Coordination Test (LEMOCOT), and movement speed will be assessed with a 30-meter sprint test. All assessments will be conducted once in a controlled laboratory setting and are intended solely for comparative analysis between smokers and non-smokers.
214635863|NCT06898814|DRUG|Ferric Derisomaltose|The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%
214635864|NCT06898814|DRUG|Saline (NaCl 0,9 %) (placebo)|Single dose of 100 mL isotonic sodium chloride 0.9%
214635865|NCT06887218|DRUG|Regorafenib (BAY 73-4506)|Regorafenib will be administered a starting dose of 80 mg per day with weekly 40 mg per day increases to a maximum of 120 mg per day for 3 weeks on / 1 week off continued until disease progression or unacceptable toxic effects occurred or consent was withdrawn, up to 12 cycles of treatment.
214635866|NCT06887218|DRUG|5FU/LV|5FU/LV administered as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m² IV bolus then 2400 mg/m² IV infusion over 46 hours\] in 2-week cycles)
214635867|NCT06887218|DRUG|Bevacizumab|Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered intravenously on days 1 and 15.
214635868|NCT06887218|DRUG|Trifluridine-tipiracil|FTD-TPI, administered orally, BID, at a starting dose of 35 mg/m2 of body-surface area, on days 1 through 5 and on days 8 through 12 every 28 days.
214635869|NCT06768463|PROCEDURE|Cytoreductive Gastrectomy|The patients undergo gastrectomy after 4 cycles of systemic therapy
214635870|NCT07132073|RADIATION|Brachytherapy + SBRT|Brachytherapy + SBRT
214635871|NCT06902584|DEVICE|comfilcon A Sphere lens|2 hours of wear
214635872|NCT06902584|DEVICE|comfilcon A Toric lens|2 hours of wear
214635873|NCT06902584|DEVICE|comfilcon A Multifocal lens|2 hours of wear
214635874|NCT06902584|DEVICE|comfilcon A Multifocal Toric lens|2 hours of wear
214635875|NCT06902584|DEVICE|comfilcon A Energys lens|2 hours of wear
214635876|NCT07093580|DRUG|S-892216-LAI|S-892216-LAI injection will be administered per schedule specified in the arm description.
214635877|NCT07093580|DRUG|Placebo|Physiological saline will be administered per schedule specified in the arm description.
214635878|NCT06918548|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
214635879|NCT06918548|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214635880|NCT06916702|DRUG|BI 3031185|BI 3031185
214635881|NCT06916702|DRUG|Midazolam|Midazolam
214635882|NCT06916702|DRUG|Placebo|Placebo matching BI 3031185
214635883|NCT07110636|DIAGNOSTIC_TEST|Metagenomic plasma-based test for agnostic pathogen detection|Karius Spectrum metagenomic plasma-based test.
214635884|NCT06923527|DRUG|Elacestrant|"Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity. The pills shall be administered with food (to reduce nausea and vomiting) at approximately the same time each day, and the prescription will be provided with the standard Swallow tablets whole; do not chew, crush, or split warning label."
214635885|NCT06923462|OTHER|Communication Application|Participants will receive the VoiceLove intervention versus the standard care which does not utilize VoiceLove.
214723549|NCT01279980|OTHER|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
214635886|NCT06931301|DEVICE|Hyperbaric Oxygen Therapy|Sechrist Monoplace Hyperbaric Chamber Model 3600, Chamber will be used to supply patients with 100% oxygen to breathe at 2-2.4 ATA (the equivalent of diving to 33 - 45 feet of sea water) for two hours, 5 treatments per week
214635887|NCT07123285|DEVICE|Photobiomodulation plus Compression Therapy|This intervention uses a low-level laser device with 8 emitters, including 4 red emitters at 660 nm and 4 infrared emitters at 808 nm. Each emitter delivers 6 Joules of energy at 100 mW power, with a total power output of 800 mW. Treatment is administered twice weekly over 16 weeks, totaling 32 sessions per participant. The device is used in combination with standard compression therapy for venous leg ulcer management.
214635888|NCT07123285|DEVICE|Compression Therapy plus Sham Photobiomodulation|This intervention uses a sham photobiomodulation therapy with the same laser device used in the active group but without emission of therapeutic laser light (inactive device). The device appears identical and the treatment sessions are conducted twice weekly over 16 weeks, totaling 32 sessions per participant. Participants also receive standard compression therapy for venous leg ulcer management. This sham procedure is designed to mimic the active treatment without delivering any laser energy, serving as a placebo control.
214635889|NCT07126548|OTHER|Best Practice|Receive standard care
214635890|NCT07126548|OTHER|Discussion|Ancillary studies
214635891|NCT07126548|OTHER|Survey Administration|Ancillary studies
214635892|NCT07126548|PROCEDURE|Virtual Reality|Receive access to ViRA application
214635893|NCT07132060|RADIATION|MR-guided Irradiation|MR-guided Irradiation
214635894|NCT07132034|PROCEDURE|Acupuncture|8 sessions of acupuncture treatment (body and auricular acupuncture) will be given once a week after randomization.
214635895|NCT07132034|OTHER|Standard supportive care|Supportive care according to local standards will be given which may also include face-to-face psychosocial support or the participation of support groups
214635896|NCT07137273|BEHAVIORAL|Operant Conditioning Tasks with Reinforcement Manipulations|This behavioral intervention involves structured operant conditioning tasks. Reinforcement parameters (e.g., schedule arrangement, magnitude, and probability) are systematically manipulated to evaluate their effects on behavioral allocation. The primary objective is to assess how variations in reinforcement contingencies influence choice patterns. The procedures are designed to examine fundamental behavioral processes rather than to provide therapeutic benefit.
214635897|NCT06943573|DRUG|psilocybin (25 mg)|Single-dose psilocybin (25 mg)-assisted therapy (PAT)
214635898|NCT06943573|DRUG|psilocybin 1mg micro-dose|Single dose active placebo psilocybin-assisted therapy
214723550|NCT02390960|DRUG|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
214723551|NCT02390960|DRUG|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
214723552|NCT02390960|DEVICE|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
214723553|NCT01084330|DRUG|AUY922|70mg/m2
214723554|NCT01084330|DRUG|Docetaxel|Docetaxel 75mg/m2
214723555|NCT01084330|DRUG|Irinotecan|Iriniotecan 350mg/m2
214723556|NCT04006067|OTHER|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
214723557|NCT05154565|BEHAVIORAL|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
214723558|NCT00113412|DRUG|SP01A|
214723559|NCT05549414|DEVICE|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
214723560|NCT04379323|DIAGNOSTIC_TEST|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
214723561|NCT04541095|OTHER|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
214635899|NCT07142863|DRUG|Envafolimab and neoadjuvant chemotherapy|"\* PD-L1 inhibitor envafolimab Paediatric (\<18 years): 2.5 mg/kg (maximum 200 mg) by subcutaneous injection on Day 1 of every week (q1w).~Adult (≥18 years): 200 mg flat dose by subcutaneous injection on Day 1 of every week (q1w).~* Neoadjuvant chemotherapy--MAP regimen (paediatric patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Methotrexate 8-12 g/m² intravenously on Day 1 of weeks 3 and 4 of each 6-week cycle.~* Neoadjuvant chemotherapy--DIA regimen (adult patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Ifosfamide 12-15 g/m² total dose intravenously on Days 1-5 of week 3 of each 6-week cycle."
214723562|NCT04541095|OTHER|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
214723563|NCT00187850|PROCEDURE|PP|Partial pulpotomy
214723564|NCT00187850|PROCEDURE|DPC|Direct pulp capping
214723565|NCT06058884|DRUG|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
214723566|NCT01856803|DRUG|anti thymoglobulin|
214723567|NCT04125303|BEHAVIORAL|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
214723568|NCT05156333|DIETARY_SUPPLEMENT|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
214723569|NCT03634176|DIAGNOSTIC_TEST|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
214723570|NCT00194727|DRUG|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
214723571|NCT00194727|DRUG|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
214723572|NCT04713111|BEHAVIORAL|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
214723573|NCT04713111|BEHAVIORAL|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
214723574|NCT02050451|DIETARY_SUPPLEMENT|Ensure Plus®|
214723575|NCT02050451|DIETARY_SUPPLEMENT|Multivitamin|
214723576|NCT04486612|OTHER|spinal anesthesia|prospective observational study
214723577|NCT01350011|BEHAVIORAL|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
214723578|NCT01350011|BEHAVIORAL|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
214723579|NCT04437680|DEVICE|Votiva device|A retrospective chart review of the medical records
214723580|NCT01361880|BEHAVIORAL|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
214723581|NCT00655811|DRUG|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
214723582|NCT00655811|DRUG|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
214723583|NCT01237301|DEVICE|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
214723584|NCT01237301|DEVICE|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
214723585|NCT02468141|DRUG|SJDBT|Sipjeondaebo-tang
214723586|NCT02468141|DRUG|Placebo|Placebo
214723587|NCT01545414|BEHAVIORAL|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
214723588|NCT01545414|BEHAVIORAL|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
214723589|NCT03367611|DIAGNOSTIC_TEST|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
214723590|NCT00772811|DRUG|Flu-Mel|"* Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2."
214723591|NCT04888728|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
214723592|NCT04888728|DRUG|Nebivolol|Nebivolol
214723593|NCT04888728|DRUG|Paroxetine|Paroxetine
214723594|NCT01024660|DRUG|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
214723595|NCT01024660|DRUG|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
214723596|NCT01024660|DRUG|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
214723597|NCT04078529|OTHER|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
214723598|NCT04078529|OTHER|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
214723599|NCT04078529|OTHER|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
214723600|NCT03304912|BEHAVIORAL|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
214723601|NCT00185172|OTHER|placebo|Placebo oral tablets for 2 weeks
214723602|NCT00185172|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
214723603|NCT00185172|DRUG|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
214723604|NCT00368472|DRUG|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
214723605|NCT00728663|BIOLOGICAL|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
214723606|NCT00728663|DRUG|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
214723607|NCT01579149|DRUG|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
214723608|NCT01579149|DRUG|Placebo|Single subcutaneous (SC) dose of placebo
214723609|NCT01675206|DIETARY_SUPPLEMENT|Vitamin K2 supplementation|
214723610|NCT05481970|DRUG|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
214723611|NCT05481970|DRUG|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
214723612|NCT02224937|DRUG|Melatonin|
214723613|NCT02224937|DRUG|Placebo|
215030495|NCT06637566|OTHER|Brandt Daroff exercises along with Cawthorne Cooksey exercises|"Brandt Daroff exercises along with Cawthorne Cooksey exercises. The Cawthorne Cooksey exercises include eye and head movements, coordination of eye and head movements (visual-vestibular interaction), postural control exercises, and progressively more difficult balance tasks (eyes open, eyes closed, large base support, uneven base support, while walking, in high visual or noisy environments). Exercises should be done three times a day, with 5 repetitions of each. The exercises will be performed in three sessions per week with 60 minutes each session for eight weeks. The cawthorne Cooksey exercises includes the following:~A: Eye and head movement~B: Head and body movement, sitting down:~C: Standing up exercises:"
214723614|NCT00981682|DRUG|SER120|once a day treatment of nocturia
214723615|NCT02384993|BEHAVIORAL|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
214723616|NCT05580185|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
214723617|NCT01570205|DRUG|XG-102|single intravenous infusion
214723618|NCT04095793|DRUG|ampreloxetine|Oral tablet, QD
214723619|NCT02814136|PROCEDURE|Ablation|
214723620|NCT00651313|DRUG|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
214723621|NCT00651313|DRUG|Placebo|Placebo vaginal gel administered once daily for 4 days
214723622|NCT03942237|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
214723623|NCT03942237|PROCEDURE|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
214723624|NCT04213183|DIAGNOSTIC_TEST|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
214723625|NCT02992912|DRUG|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
214723626|NCT02992912|PROCEDURE|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
214723627|NCT00394277|DRUG|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
214723628|NCT00394277|DRUG|Ribavirin|1200 mg po daily for 48 weeks
214723629|NCT00394277|DRUG|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
214723630|NCT00394277|DRUG|Ribavirin|1400-1600 mg po daily for 48 weeks
214723631|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
214723632|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
214723633|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
214723634|NCT06275698|DIETARY_SUPPLEMENT|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
214723635|NCT06275698|DIETARY_SUPPLEMENT|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
214723636|NCT03076242|OTHER|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
214723637|NCT01955785|DEVICE|pressure controlled ventilator|
214723638|NCT01955785|DEVICE|Pressure Regulated Volume Controlled Ventilator|
214723639|NCT05010863|OTHER|Blood collection|The subject will be drawn a 5ml blood sample
214723640|NCT04576416|OTHER|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group."
214723641|NCT02591251|DRUG|Povidone-iodine solution|
214723642|NCT02591251|DRUG|Normal saline solution|
214723643|NCT01199198|DRUG|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
214723644|NCT01199198|DRUG|Placebo|Placebo by mouth once a day for 14 days.
214723645|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
214723646|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
214723647|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
214723648|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
214723649|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
214723650|NCT00922974|RADIATION|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
214723651|NCT00922974|RADIATION|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
214723652|NCT04062799|OTHER|no intervention|It is an observationa study. There is no intervention.
214723653|NCT01729676|DRUG|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
214723654|NCT02798640|DEVICE|Celliant|100% Celliant garment
214723655|NCT02798640|DEVICE|Control|Control Garment
214723656|NCT03458988|DEVICE|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
214723657|NCT03025516|DEVICE|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
214723658|NCT03025516|DEVICE|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
214723659|NCT00430027|DRUG|Capecitabine|Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
214723660|NCT00430027|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
214723661|NCT00430027|DRUG|Cetuximab|Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
214723662|NCT00004833|DRUG|Immune globulin|
214723663|NCT02451865|DRUG|Binimetinib|Given PO
214723664|NCT02451865|DRUG|Docetaxel|Given IV
214723665|NCT02451865|OTHER|Laboratory Biomarker Analysis|Correlative studies
214723666|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
214723667|NCT04908969|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
214723668|NCT02054936|DRUG|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
214723669|NCT02054936|DRUG|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
214723670|NCT01407406|DRUG|BIIB023 - low dose IV Dose|
214723671|NCT01407406|DRUG|BIIB023 - high dose IV Dose|
214723672|NCT03419507|DEVICE|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
214723673|NCT03419507|DEVICE|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
214723674|NCT02978170|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
214723675|NCT06507228|DIAGNOSTIC_TEST|NWL PEBBLE STT|At home testing for OSA with AcuPebble.
214723676|NCT00174928|DRUG|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
214723677|NCT00174928|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
214723678|NCT01149772|BEHAVIORAL|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
214723679|NCT04116190|BEHAVIORAL|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
214723680|NCT04116190|BEHAVIORAL|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
214723681|NCT02599857|DEVICE|CONCOR smartphone application|
214723682|NCT04673240|DRUG|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
214723683|NCT02348294|OTHER|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
214723684|NCT02652546|DRUG|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
214723685|NCT02652546|DRUG|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
214723686|NCT02652546|DRUG|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
214723687|NCT02652546|DRUG|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
214723688|NCT02111629|DRUG|Fluconazole and Secnidazole|
214723689|NCT04480515|OTHER|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
214723690|NCT02030093|BEHAVIORAL|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
214723691|NCT04986111|PROCEDURE|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
214723692|NCT04986111|PROCEDURE|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
214723693|NCT00003110|BIOLOGICAL|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
214723694|NCT02443155|DRUG|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
214723695|NCT02443155|DRUG|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
214723696|NCT02443155|DRUG|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
214723697|NCT06356415|DRUG|Bupivacaine injection|Group one will receive infraclavicular block using bupivacaine
214723698|NCT06356415|DRUG|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
214723699|NCT01643304|BEHAVIORAL|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
214723700|NCT01759693|PROCEDURE|Blood sampling|Blood sampling
214723701|NCT01936597|OTHER|Therapeutic and preventive strategies|Single set (control Arm)
214723702|NCT01936597|OTHER|Therapeutic and preventive strategies|Controller
214723703|NCT01936597|OTHER|Therapeutic and preventive strategies|Audio
214723704|NCT02389218|DEVICE|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
214723705|NCT02389218|DRUG|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
214723706|NCT02000219|BIOLOGICAL|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
214723707|NCT02936115|OTHER|TruSkin®|
214723708|NCT02936115|OTHER|Wound Cover|
214723709|NCT04063228|OTHER|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
214723710|NCT04063228|OTHER|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
214723711|NCT04347902|DRUG|Intravenous Lipid Emulsion|Various types of intravenous lipids
214723712|NCT05335252|DRUG|Dronabinol|5mg 2x daily for 7 days
214723713|NCT05335252|DRUG|Placebo|1 caplet 2x daily for 7 days
214723714|NCT05537272|DRUG|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
214723715|NCT05537272|DRUG|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
214723716|NCT05537272|OTHER|Placebo|Administration of placebo ( Vitamin C \[ascorbic acid\] 500mg tablet) once daily seven days before and seven days after prostate biopsy
214723717|NCT00923624|OTHER|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
214723718|NCT00923624|BEHAVIORAL|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
214723719|NCT01300000|OTHER|Human Milk|ad lib
214723720|NCT01300000|OTHER|Investigational infant formula|ad lib
214723721|NCT01300000|OTHER|Milk based standard infant formula|ad lib
214723722|NCT00634751|DRUG|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
214723723|NCT00634751|DRUG|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
214635900|NCT07143539|OTHER|Exercise-based rehabilitation program|Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.
214635901|NCT07143409|OTHER|epidemiology and medical treatment strategies|Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023
214635902|NCT07144384|PROCEDURE|Biopsy Procedure|Undergo SOC biopsy
214723724|NCT00634751|DRUG|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
214723725|NCT02249351|DRUG|Talsaclidine|
214723726|NCT02249351|DRUG|Placebo|
214723727|NCT05295836|OTHER|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
214723728|NCT05295836|DIETARY_SUPPLEMENT|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
214723729|NCT05538585|DRUG|Galicaftor|Oral
214723730|NCT05538585|DRUG|Navocaftor|Oral
214723731|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min."
214723732|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
214723733|NCT04017624|OTHER|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
214723734|NCT04017624|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
214723735|NCT05389306|DIAGNOSTIC_TEST|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
214723736|NCT05389306|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
215031021|NCT04744792|OTHER|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
214635903|NCT07144384|BIOLOGICAL|Natural Killer Cell Therapy|Given UD expanded NK cells intratumorally
214635904|NCT07144384|PROCEDURE|Surgical Procedure|Undergo SOC excision
214635905|NCT07144384|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given intratumorally
214635906|NCT07142694|DIETARY_SUPPLEMENT|Plant Based pudding|Will consume one high protein plant based pudding daily for 7-days per week for 12 weeks
214635907|NCT07144124|DIETARY_SUPPLEMENT|Biopro-max 8 Billion Probiotics (Bioserv Healthcare)|Participants in the intervention arm will receive Biopro-Max 8 Billion Probiotics (Bioserv Healthcare). The supplement will be administered as one bottle per day for 15 consecutive days in addition to standard ICU care. The intervention is intended to evaluate whether daily probiotic supplementation reduces the incidence of ICU-acquired infections and improves related clinical outcomes, including inflammatory and immune markers, feeding tolerance, muscle changes, and mortality.
214635908|NCT07143799|DRUG|Cisatracurium|Induction of general anesthesia will be done by IV propofol 2-2.5 mg / kg and IV fentanyl lug/kg. After IV Cis-atracurium 0.15mg/kg, endotracheal intubation will be done.
214635909|NCT07143799|OTHER|scalp block|The scalp block will target six pairs of sensory nerves that innervate the scalp: the supraorbital nerve, supratrochlear nerve, auriculotemporal nerve, zygomaticotemporal nerve, greater occipital nerve, and lesser occipital nerve. Local anesthetic (2% lidocaine and bupivacaine) will be infiltrated at specific anatomical landmarks corresponding to the course of each nerve.
214635910|NCT07144644|DEVICE|Adjusting intraocular pressure (IOP) settings|Investigating whether adjusting IOP settings near physiologic levels during cataract surgery could potentially lead to better surgical outcomes
214635911|NCT07144657|DRUG|Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole|"1. Frontline antibiotics treatment (two weeks of quadruple HPE regimens followed by 4 weeks of clarithromycin).~2. If no response to frontline antibiotics treatment, second line immune-modulator regimens (CAMC, clarithromycin (CAM) and low-dose cyclophosphamide) will be prescribed"
214635912|NCT07144774|DEVICE|Fitbit wrist-worn Inspire 2® activity tracker (Fitbit Inc., San Francisco, CA, USA)|Visual feedback of the physical activity level
214635913|NCT07142837|DRUG|ZG005|ZG005 20mg/kg; once every 3 weeks；IV infusion
214635914|NCT07142837|DRUG|Gecacitinib|Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
214635915|NCT07143032|PROCEDURE|Extropia squint surgery|patients with large angle exotropia will be treated by three different surgical techniques including: 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation ,to compare the surgical outcomes between them.
214635916|NCT07143682|DRUG|Letrozol step up dose|Tablet letrozole 2.5mg one, two, three, and four tablets once daily from 2nd/3rd day of the menstrual cycle for 4 days
214635917|NCT07143682|DRUG|Conventional fixed dose letrozole|Tab letrozole 5mg once daily for 5 days started from the 2nd/3rd day of the menstrual cycle
214635918|NCT07143188|DIETARY_SUPPLEMENT|elemental diet (ED)|mBIOTA is a palatable elemental diet formulation
214635919|NCT07143812|DRUG|MSC11FCD|Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery.
214635920|NCT07144488|DIETARY_SUPPLEMENT|Olive Oil Polyphenol Supplement (OOPs, OLEOPROTECT®, Thousand Olives®)|Participants receive two capsules daily (total 10 mg/day) of a standardized olive oil polyphenol extract. Each capsule contains 5 mg of aldehydic phenols: 75% oleocanthal/oleacein and 25% oleuropein aglycon/ligstroside aglycon. Formulated with PEG400, cellulose, silicon dioxide, and magnesium stearate. Duration: 12 weeks.
214635921|NCT07144488|DIETARY_SUPPLEMENT|Placebo capsules|Two capsules taken daily for 12 weeks. Identical in weight, appearance, and taste to the active OOPs capsules. Contain PEG400, cellulose, silicon dioxide, and magnesium stearate, but no active olive oil polyphenols.
214635922|NCT07143565|BEHAVIORAL|Online platform hub and mHealth Text Messaging|The treatment package includes both optional and mandatory treatments. The mandatory treatments consist of mHealth text messaging and an online platform hub. We have developed a game which educates teenagers about alcohol reduction and promotes awareness of alcohol-related harm. Designed to be both engaging and informative, the game uses real-life scenarios, interactive storytelling, and decision-based gameplay to help young people understand the risks of excessive drinking. Also, participants with Audit Score \> 7 will receive individualized chat-based instant text messages from WhatsApp for 8 weeks. They will have real-time and one-to-one interaction. The conversation intensity depends on the participants' need.
214635923|NCT07143565|BEHAVIORAL|Self-help material|Self-help material like leaflet is a common method used in preventing teenage Drinking.
214635924|NCT07143929|DRUG|CAR-T|autologous CD7-targeted CAR-T cells, single injection
214635925|NCT07144540|OTHER|NeuroBot|NeuroBot is an artificial intelligence online accessible chatbot that used machine learning and generative pretrained transformer model for supporting patients undergoing neurovascular surgery during perioperative period
214635926|NCT07144540|OTHER|Standard Care (in control arm)|Standard care include face-to-face consultation in preoperative nurse clinic and provision of leaflet
214635927|NCT07144371|OTHER|Virtual Reality Training Group|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
214635928|NCT07144371|OTHER|Standard Football Training|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
214635929|NCT07144566|OTHER|Nurse Led Sexual Health Clinical Program Intervention|In person visit with Advanced Practice Provider (APP) whom is an Advanced Practice Nurse Practitioner in Oncology. Visit will include a focused pelvic exam, sexual health treatment plan, sexual health education, and referrals that follow the current Sexual Health Survivorship NCCN guidelines. A post visit telephone will be provided by the APP 8 weeks after APP visit for follow up questions and further education if needed.
214635930|NCT07144475|BIOLOGICAL|Lactobacillus casei Shirota|Consumption of Lactobacillus casei Shirota three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
214723737|NCT05389306|DIAGNOSTIC_TEST|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
214635931|NCT07144475|BIOLOGICAL|Lactobacillus acidophilus|Consumption of Lactobacillus acidophilus three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
214635932|NCT07143201|DRUG|Standard Dose - Ibuprofen oral suspension|Standard dosing administers ibuprofen without adjustments, starting with an initial loading dose followed by two maintenance doses at 24-hour intervals: 10/5/5 mg/kg for infants aged ≤72 hours, and 20/10/10 mg/kg for those \>72 hours old.
214635933|NCT07143201|DRUG|Precision Dose - Ibuprofen oral suspension|Precision Dosing (Model-Informed Precision Dosing - MIPD): Begins with the same initial loading dose as the Standard Dosing arm, with subsequent doses adjusted based on a Bayesian forecasting model that integrates real-time PK and echocardiographic data.
214635934|NCT07143864|BIOLOGICAL|Stapokibart|A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha
214635935|NCT07143864|OTHER|Placebo drug|Placebo drugs without Stapokibart
214635936|NCT07142941|DIETARY_SUPPLEMENT|HMB|Participants were instructed to take active products including 3000 mg calcium-HMB per day
214635937|NCT07142941|BEHAVIORAL|Exercise|Participants allocated to the exercise programs were provided 45 min of supervised sessions on 2 nonconsecutive days per week
214635938|NCT07142941|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to take active products including equal in quality resistant dextrin per day
214635939|NCT07142941|OTHER|Education|Participants were given health education and educational manuals
214635940|NCT00380328|DRUG|neratinib|HKI-272
214635941|NCT06516913|DEVICE|Harvard Apparatus syringe pump|Used to administer buffer solution with hyaluronic acid SC.
214635942|NCT02396589|BEHAVIORAL|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
214635943|NCT02396589|BEHAVIORAL|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
214635944|NCT03899987|DRUG|EC Aspirin|Given PO
214635945|NCT03899987|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214635946|NCT03899987|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
214635947|NCT03899987|DRUG|Rintatolimod|Given IV
214635948|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
214635949|NCT05938673|OTHER|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
214635950|NCT05938673|OTHER|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
214635951|NCT06438432|OTHER|RAIT|The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
214635952|NCT04341948|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
214635953|NCT00836134|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
214635954|NCT00836134|PROCEDURE|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
214635955|NCT05570123|DIETARY_SUPPLEMENT|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
214635956|NCT05570123|DIETARY_SUPPLEMENT|Placebo|2 tablets a day, one in the morning, one in the evening
214635957|NCT00510627|DEVICE|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
214635958|NCT00510627|DRUG|Chemotherapy|Standard of care chemotherapy regimen
214635959|NCT01461174|DRUG|Modafinil|200 mg tablet, single dose
214635960|NCT01461174|DRUG|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
214635961|NCT01461174|DRUG|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
214635962|NCT04381442|RADIATION|Low Level Laser Therapy|
214635963|NCT04156555|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
214635964|NCT02381431|DEVICE|FLIR ONE|
214635965|NCT03508492|OTHER|Surgical tinted Chloraprep® applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
214635966|NCT03508492|OTHER|Surgical tinted Nex Clorex 2% applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
214723738|NCT02490241|DRUG|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
214723739|NCT03092622|OTHER|Exercise|Exercise training intervention as described earlier.
214723740|NCT03712670|DRUG|Aflibercept|monthly intravitreal injections
214723741|NCT03712670|DRUG|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
214723742|NCT03712670|DIETARY_SUPPLEMENT|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
214723743|NCT02738294|DEVICE|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
214723744|NCT02554201|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
214723745|NCT02554201|DEVICE|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
214723746|NCT03089008|OTHER|Eccentric exercises|
214723747|NCT03089008|OTHER|Stretching exercises|
214723748|NCT00608894|DRUG|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
214723749|NCT00608894|DRUG|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
214723750|NCT03105869|DIAGNOSTIC_TEST|fluorocholine PET/CT|standard diagnostic PET/CT procedure
214723751|NCT00562536|PROCEDURE|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
214723752|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
214723753|NCT03870893|BEHAVIORAL|hippotherapy|16weeks hippotherapy program
214723754|NCT05789706|BEHAVIORAL|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
214723755|NCT04468464|OTHER|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
214723756|NCT04468464|OTHER|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
214723757|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
214723758|NCT04503473|BEHAVIORAL|High Intensity Stepping Training|"The goals will be to maximize stepping activity at high intensities for 40 minutes per 1 hour session, with rest breaks as needed~Conventional Therapy: : Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions"
214723759|NCT04503473|BEHAVIORAL|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions
214723760|NCT02411877|PROCEDURE|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
214723761|NCT02411877|PROCEDURE|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
214723762|NCT02411877|DEVICE|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
214723763|NCT02411877|DEVICE|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
214723764|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
214723765|NCT05609305|OTHER|Discharge|observational study, not intervention
214723766|NCT06828302|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy|Parent management training delivered online where Internet-modules are combined with video sessions for live coaching.
214723767|NCT05920200|PROCEDURE|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
214723768|NCT05920200|PROCEDURE|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
214723769|NCT05920200|PROCEDURE|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
214723770|NCT03743298|DRUG|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
214723771|NCT05264636|OTHER|Sucrose|Sucrose Beverage
214723772|NCT05264636|OTHER|Steviol Glycosides|Steviol Glycoside Beverage
214723773|NCT01376388|DRUG|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
214723774|NCT03643016|OTHER|Surgical strategy based on a software|Surgical strategy décision based on a software
214723775|NCT05589012|BIOLOGICAL|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
214723776|NCT05589012|BIOLOGICAL|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
214635967|NCT03041558|BEHAVIORAL|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
214635968|NCT03041558|BEHAVIORAL|SafeCare (SC)|SafeCare intervention as usual
214635969|NCT01469910|DRUG|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
214635970|NCT01469910|DRUG|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
214635971|NCT05689931|BIOLOGICAL|Mepolizumab|"Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)"
214635972|NCT05689931|DRUG|Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)|Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
214635973|NCT01761266|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214635974|NCT01761266|DRUG|Sorafenib|400 mg twice daily (BID) oral dosing.
214635975|NCT05313997|DRUG|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
214635976|NCT02802605|DRUG|Bemiparin|Bemiparin subcutaneus administration
214635977|NCT03283631|BIOLOGICAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
214635978|NCT01284114|DRUG|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
214635979|NCT01984255|DRUG|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
214635980|NCT01984255|DRUG|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
214635981|NCT03936387|DRUG|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
214723777|NCT05589012|BIOLOGICAL|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
214723778|NCT04518020|PROCEDURE|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
214723779|NCT00054418|DIETARY_SUPPLEMENT|calcium carbonate|calcium 600 mg daily administered orally for one year
214723780|NCT00054418|DIETARY_SUPPLEMENT|vitamin D|vitamin D 400 U daily administered orally for one year
214723781|NCT00054418|DRUG|risedronate sodium|risedronate 35 mg weekly administered orally
214723782|NCT00054418|OTHER|placebo|placebo tablet weekly administered orally for one year
214723783|NCT01845519|BEHAVIORAL|Tailored Email|Participants will receive tailored emails.
214723784|NCT01845519|BEHAVIORAL|Targeted Email|Participants will receive targeted emails.
214723785|NCT02027974|DEVICE|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
214723786|NCT02027974|DEVICE|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
214723787|NCT05315024|DRUG|Fluarix Tetra|Fluarix Tetra
214723788|NCT05315024|DRUG|Imiquimod cream|Imiquimod cream
214723789|NCT00053014|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214723790|NCT00053014|DRUG|cyclosporine|
214723791|NCT00053014|DRUG|fludarabine|
214723792|NCT00053014|DRUG|mycophenolate mofetil|
214723793|NCT00053014|PROCEDURE|peripheral blood stem cell transplantation|
214723794|NCT00053014|RADIATION|radiation therapy|
214723795|NCT02126241|OTHER|NICaS guided CRT optimization|"1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay"
214723796|NCT01473355|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
214723797|NCT00644241|BIOLOGICAL|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
214723798|NCT00644241|PROCEDURE|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
214723799|NCT00106249|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
214723800|NCT00106249|DEVICE|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
214723801|NCT02325804|BEHAVIORAL|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
214635982|NCT01418547|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
214635983|NCT06840808|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
214635984|NCT06840808|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
214635985|NCT02007551|BEHAVIORAL|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
214635986|NCT03445000|DRUG|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
214635987|NCT03409744|DRUG|evinacumab|Intravenous (IV) administration
214635988|NCT02532231|OTHER|Laboratory Biomarker Analysis|Correlative studies
214635989|NCT02532231|BIOLOGICAL|Nivolumab|Given IV
214635990|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
214635991|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
214635992|NCT05819866|DRUG|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
214635993|NCT05819866|DRUG|Placebo|Placebo will match the study drug visually and by taste
214635994|NCT05951608|DRUG|AK127 in combination with AK112|AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years
214635995|NCT04693000|DRUG|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
214635996|NCT00748579|DRUG|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
214635997|NCT00748579|DRUG|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
214635998|NCT03707535|BIOLOGICAL|CT-P13|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
214635999|NCT03707535|BIOLOGICAL|Remicade|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
214636000|NCT02700737|OTHER|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
214636001|NCT02700737|OTHER|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
214636002|NCT00142883|DRUG|Pregabalin|pregabalin compared to placebo
214636003|NCT00142883|DRUG|placebo|sugar pill compared to pregabalin
214636004|NCT03591380|DRUG|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
214636005|NCT06109480|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
214723802|NCT01432704|DRUG|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
214723803|NCT04065815|OTHER|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
214723804|NCT04065815|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
214723805|NCT04065815|OTHER|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week"
214723806|NCT04065815|OTHER|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week"
214723807|NCT05081089|DRUG|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
214723808|NCT05081089|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
214723809|NCT05081089|DRUG|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
214723810|NCT05081089|DRUG|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
214723811|NCT06158854|DRUG|ABBV-383 (Etentamig)|Intravenous Infusion
214723812|NCT00149110|PROCEDURE|Sleep deprivation|3 days with a normal night between
214723813|NCT00149110|PROCEDURE|Light therapy|Daily light therapy for 29 weeks
214723814|NCT00149110|PROCEDURE|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
214723815|NCT00149110|BEHAVIORAL|Exercise|Moderate intensity daily exercise for 30 minutes at least
214723816|NCT00149110|DRUG|duloxetine|60 mg daily
214723817|NCT00149110|DRUG|duloxetine|60 mg daily
214723818|NCT00432263|DRUG|Genotropin (PN-180,307) Somatropin|
214723819|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
214723820|NCT03908268|BEHAVIORAL|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
214723821|NCT03908268|BEHAVIORAL|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
214723822|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
214723823|NCT03991624|DIAGNOSTIC_TEST|cognitive assessment|"* MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease"
214636006|NCT06109480|DEVICE|Sham High definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214636007|NCT06109480|DEVICE|electroconvulsive therapy device|ECT induces brief generalized epileptic seizures by electric current to stimulate the forehead under general anesthesia
214636008|NCT00145405|DRUG|Lanreotide Autogel and Octreotide LAR|
214636009|NCT03351777|DRUG|PR022|Topical Gel
214636010|NCT02158780|PROCEDURE|Scrotal Orchidopexy|Single incision
214636011|NCT02158780|PROCEDURE|Inguinal Orchidopexy|Double Incision (Standard)
214636012|NCT06501755|DEVICE|transcranial alternating current stimulation (tACS)|Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
214636013|NCT01935843|BIOLOGICAL|CART-HER-2|
214636014|NCT01014117|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
214636015|NCT01014117|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
214636016|NCT03412773|DRUG|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
214636017|NCT03412773|DRUG|Sorafenib|400 mg twice daily (BID), oral dosing
214723824|NCT03991624|OTHER|Inhibition evaluation|"* Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
214636018|NCT01243905|OTHER|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
214636019|NCT01243905|OTHER|Treatment as usual|Treatment as usual administered by physicians
214636020|NCT01348646|BEHAVIORAL|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
214636021|NCT01175746|DRUG|Nicardipine|
214636022|NCT01175746|DRUG|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
214636023|NCT04244929|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
214636024|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
214636025|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
214636026|NCT00545701|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
214636027|NCT01977235|DRUG|Irinotecan|
214636028|NCT01977235|DRUG|Cisplatin|
214636029|NCT01869647|RADIATION|Ultra low dose CT scan|Ultra low dose CT scan
214636030|NCT01869647|RADIATION|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
214636031|NCT01869647|RADIATION|No imaging|No imaging
214636032|NCT04922411|DEVICE|STN DBS|PD patients with DBS STN will be scanned and tested with DBS ON and OFF
214636033|NCT06268379|PROCEDURE|Surgery|Not an interventional study, it is an observational, longitudinal study.
214636034|NCT04775511|OTHER|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
214636035|NCT04775511|OTHER|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
214636036|NCT04775511|OTHER|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
214636037|NCT03828279|DIAGNOSTIC_TEST|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
214636038|NCT02601924|DRUG|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
214636039|NCT02601924|OTHER|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
214636040|NCT00775580|DRUG|Atenolol 100mg Tablets|
214636041|NCT01492998|OTHER|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
214636042|NCT02574533|BIOLOGICAL|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
214636043|NCT02574533|DRUG|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
214636044|NCT00397722|DRUG|GW876008|
214636045|NCT00397722|DRUG|paroxetine|
214636046|NCT04508660|DRUG|CGB-400|BID application
214636047|NCT01817738|BIOLOGICAL|CV9104|Intradermal injection of CV9104
214636048|NCT01817738|BIOLOGICAL|Placebo|Intradermal injection of placebo
214636049|NCT05684380|DRUG|MAZ-101association|Experimental drug
214636050|NCT05684380|DRUG|DYMISTA®|Active comparator
214636051|NCT03390413|PROCEDURE|Robot|Renal cancer treated with robotic surgery
214636052|NCT03390413|PROCEDURE|Cryoablation|Renal cancer treated with cryoablation
214723825|NCT03991624|OTHER|Assessment of mental flexibility|"* a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
214723826|NCT03991624|OTHER|Evaluation of the update|"* an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
214723827|NCT03991624|OTHER|working memory|"* the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
214723828|NCT03991624|OTHER|episodic memory|\- A recognition task with a Remember/Know paradigm
214723829|NCT04068038|OTHER|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
214723830|NCT03338881|DRUG|[14C]-TAK-659|\[14C\]-TAK-659 solution.
214723831|NCT03338881|DRUG|TAK-659|TAK-659 tablets.
214723832|NCT00062595|DRUG|phylloquinone (K1)|
214723833|NCT00062595|DRUG|menatetranone (MK4)|
214723834|NCT02305550|DEVICE|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
214723835|NCT05800613|OTHER|Survey|Questionnaire
214723836|NCT05791006|BEHAVIORAL|Neuropsychological tests|"Neuropsychological assessment with:~* NADL-F~* Frontal Assessment Battery (FAB)~* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
214723837|NCT04694157|DEVICE|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
214723838|NCT03249701|DEVICE|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
214723839|NCT03249701|DEVICE|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
214723840|NCT03249701|DEVICE|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
214723841|NCT04264494|PROCEDURE|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
214723842|NCT04264494|PROCEDURE|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
214723843|NCT01440504|OTHER|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
214723844|NCT02276794|OTHER|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
214723845|NCT02276794|OTHER|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
214723846|NCT00883649|DIETARY_SUPPLEMENT|Hydroeye|2 Capsules BID
214723847|NCT00883649|OTHER|Inactive Capsule|2 Capsules BID
214723848|NCT05829564|OTHER|virtual reality|The individuals participating in the study will experience virtual reality.
214723849|NCT05829564|OTHER|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
214723850|NCT05829564|OTHER|exercise|The individuals participating in the study will performed neck-specific exercises.
214723851|NCT01979380|DRUG|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
214723852|NCT01979380|DRUG|placebo|PO, once in the morning
214723853|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
214723854|NCT01126281|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
214723855|NCT01822015|DRUG|Sirolimus|Given PO
214723856|NCT01822015|DRUG|Idarubicin|Given IV
214723857|NCT01822015|DRUG|Cytarabine|Given IV
214723858|NCT06310785|DRUG|Esketamine|The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
214723859|NCT06310785|DRUG|Sufentanil|In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
214723860|NCT02977442|BEHAVIORAL|exercise|
214723861|NCT03765476|BEHAVIORAL|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
214723862|NCT03765476|BEHAVIORAL|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
214723863|NCT04796948|DRUG|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
214723864|NCT00602069|BEHAVIORAL|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
214723865|NCT00602069|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
214723866|NCT01119963|DRUG|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
214723867|NCT01119963|DRUG|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
214723868|NCT05373316|RADIATION|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
214723869|NCT01480232|DRUG|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
214723870|NCT01480232|DRUG|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
214723871|NCT01480232|DRUG|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
214723872|NCT01480232|DRUG|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
214723873|NCT01480232|BEHAVIORAL|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
214723874|NCT01512472|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
214636053|NCT03394560|DEVICE|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
214636054|NCT03394560|DEVICE|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
214636055|NCT01144585|PROCEDURE|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
214636056|NCT01144585|PROCEDURE|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
214636057|NCT03253263|DRUG|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
214636058|NCT04022382|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
214636059|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
214636060|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
214636061|NCT03660878|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
214636062|NCT01282073|DRUG|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
214636063|NCT01282073|DRUG|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
214636064|NCT06539598|OTHER|Respiratory Strength Training (RST)|Respiratory Strength training involves inhaling/exhaling against a fix resistant to potentially increase respiratory strength
214636065|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
214636066|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
214636067|NCT06492954|PROCEDURE|Surgical Resection|Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
214636068|NCT06492954|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
214636069|NCT06492954|DRUG|Atezolizumab|For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
214636070|NCT02524353|OTHER|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
214636071|NCT03491384|DRUG|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
214636072|NCT05565950|BIOLOGICAL|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
214636073|NCT05565950|BIOLOGICAL|Vehicle|Vehicle Formulation
214636074|NCT02375230|PROCEDURE|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
214636075|NCT02375230|PROCEDURE|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
214636076|NCT05743452|DEVICE|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
214636077|NCT06582745|DRUG|Trametinib|Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
214636078|NCT04381390|DIETARY_SUPPLEMENT|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
214636079|NCT04381390|DIETARY_SUPPLEMENT|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
214636080|NCT02386488|DRUG|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
214636081|NCT02386488|DRUG|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
214636082|NCT02386488|DRUG|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
214636083|NCT02386488|DRUG|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
214723875|NCT06245824|DRUG|Trastuzumab deruxtecan (T-DXd) with pyrotinib|T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
214636084|NCT02317666|PROCEDURE|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
214636085|NCT02800200|PROCEDURE|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
214636086|NCT02800200|DEVICE|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
214636087|NCT01931800|BIOLOGICAL|Sampling of blood|
214636088|NCT03389971|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
214636089|NCT02200380|DRUG|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
214636090|NCT02200380|DRUG|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
214636091|NCT05564065|PROCEDURE|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
214636092|NCT05564065|PROCEDURE|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
214636093|NCT04957134|DEVICE|Electro-acupuncture|The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
214723876|NCT01843205|DRUG|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
214723877|NCT01843205|DRUG|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
214723878|NCT00836303|BEHAVIORAL|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
214723879|NCT04876963|DEVICE|Holter-monitor|7-day holtermonitoring of each patient
214723880|NCT03938636|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214636094|NCT04957134|DEVICE|Sham electro-acupuncture|The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
214636095|NCT03118297|DRUG|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
214636096|NCT03118297|DRUG|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
214723881|NCT05515445|DRUG|Chiglitazar|Oral single dose 48 mg
214723882|NCT03835988|DEVICE|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
214723883|NCT03272971|DEVICE|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
214723884|NCT04737161|BIOLOGICAL|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
214723885|NCT03304652|DRUG|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
214723886|NCT03304652|OTHER|Natural Sleep|Natural Sleep without medication
214723887|NCT05194215|DEVICE|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
214723888|NCT02532413|DRUG|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
214636097|NCT03733223|DRUG|Ateptidase|Treatment of ischemic stroke with Ateptidase
214636098|NCT06186687|BEHAVIORAL|Myofunctional therapy exercise|Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
214636099|NCT02479802|BIOLOGICAL|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~* three weeks of intensive treatment with two plasma exchanges per week~* twenty-one weeks of maintenance treatment with one weekly plasma exchange"
214636100|NCT00358787|PROCEDURE|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
214636101|NCT00358787|PROCEDURE|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
214636102|NCT05313061|DRUG|MTX|MTX continuation
214636103|NCT03340610|DRUG|Alflibercept|Intravitreal Injection
214636104|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
214636105|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
214636106|NCT02101723|DIETARY_SUPPLEMENT|Placebo|Placebo powder without micronutrients
214636107|NCT01726348|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
214636108|NCT02343471|DIETARY_SUPPLEMENT|20 g whey protein|
214636109|NCT04580290|DEVICE|JewelACL|The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
214636110|NCT05359978|BEHAVIORAL|To with significance activities|activities with purpose with people who are diagnosed of dementia 2 days at week during 30 minutes
214636111|NCT04405375|DRUG|gemcitabin|1.25g/㎡ d1, repeated every 21 days
214636112|NCT04405375|DRUG|Pegaspargase|2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days
214636113|NCT04405375|DRUG|Etoposide|75mg/㎡ d1-3, repeated every 21 days
214636114|NCT04405375|DRUG|Dexamethasone|20mg d1-4
214636115|NCT04703894|DIETARY_SUPPLEMENT|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
214636116|NCT05001347|DRUG|TJ004309|Antibody to CD73
214636117|NCT06540950|DRUG|vinorelbine|Vinorelbine is administered orally at 60mg per square meter per week by body surface area before radiotherapy and continued to be administered at 30mg per square meter per week during radiotherapy until the end of radiotherapy. Within 6 weeks after the end of radiotherapy, there are no serious side effects, and immune checkpoint inhibitors monotherapy can be performed.
214636118|NCT02665429|BEHAVIORAL|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
214636119|NCT05854901|DIAGNOSTIC_TEST|Procalcitonin|blood test, measuring the concentration of PCT in ug/L
214636120|NCT05854901|OTHER|Physician's decision|The physician's decided whether the patient will receive antibiotic treatment or not
214636121|NCT02740088|OTHER|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
214636122|NCT01226238|OTHER|Online self-help|Provision of online self-help
214636123|NCT03725618|BIOLOGICAL|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
214636124|NCT02290314|PROCEDURE|minimally invasive MID-line Lumbar Fusion (MIDLF)|
214636125|NCT02290314|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|
214636126|NCT01716481|OTHER|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
214636127|NCT00483860|DRUG|Topotecan|once a day
214636128|NCT02498873|BEHAVIORAL|Linear Periodization|Linear Intensity Periodization Running
214636129|NCT02498873|BEHAVIORAL|Non Linear Periodization|Non Linear Periodization Running
214636130|NCT01833130|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
214636131|NCT01833130|DRUG|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
214636132|NCT04514029|DRUG|Simvastatin|Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
214636133|NCT04514029|DRUG|Dexamethasone|Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
214636134|NCT02118688|DRUG|Risperidone|
214636135|NCT02118688|DRUG|Trazodone|
214636136|NCT02118688|DRUG|Placebo|
214636137|NCT06963216|BIOLOGICAL|Coagadex(R)|Coagulation Factor X (Human)
214636138|NCT04520178|DRUG|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
214636139|NCT04520178|DRUG|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
214636140|NCT04520178|DRUG|Carbidopa|50mg
214636141|NCT04520178|DRUG|Placebo|Placebo
214636142|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
214636143|NCT05768633|BEHAVIORAL|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
214636144|NCT01996800|PROCEDURE|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
214636145|NCT01996800|PROCEDURE|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
214636146|NCT02072655|PROCEDURE|socio-aesthetic care|"* care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
214636147|NCT03286842|DRUG|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
214636148|NCT03530371|DRUG|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
214636149|NCT03036137|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
214636150|NCT03036137|DEVICE|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
214636151|NCT02261727|DRUG|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
214636152|NCT02261727|DRUG|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
214636153|NCT02261727|DRUG|Placebo (for prednisone)|"* Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
214636154|NCT02261727|DRUG|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
214723889|NCT02532413|DRUG|Entecavir|Entecavir can inhibit the replication of HBV.
214636155|NCT05272800|DEVICE|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
214636156|NCT05272800|OTHER|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
214636157|NCT05744739|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214636158|NCT05744739|DRUG|Tomivosertib|Given PO
214636159|NCT03783520|DEVICE|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
214636160|NCT03783520|OTHER|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
214636161|NCT02419287|DRUG|crizotinib|
214636162|NCT04293861|DEVICE|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
214636163|NCT01391507|DRUG|0.9 % sodium chloride|Monthly intravenous injection for 6 months
214636164|NCT01391507|DRUG|COR-1|Monthly intravenous injection for 6 months
214636165|NCT01391507|DRUG|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
214636166|NCT05398315|BEHAVIORAL|Empathic Statements/Reflections|Presence of Empathic Statements
214636167|NCT05398315|BEHAVIORAL|Narrator Backstory|Presence of a narrator backstory
214636168|NCT05398315|BEHAVIORAL|Male Narrator|Presence of a male narrator
214636169|NCT05398315|BEHAVIORAL|Female Narrator|Presence of a female narrator
214636170|NCT05398315|BEHAVIORAL|MI Techniques|Presence of MI techniques
214636171|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.003%|
214636172|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.004%|
214636173|NCT00857727|DRUG|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
214636174|NCT00857727|DRUG|Saline|Given by a continuous infusion
214636175|NCT02961556|DRUG|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
214636176|NCT01445028|DRUG|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
214636177|NCT01202656|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
214636178|NCT01202656|DRUG|Saline|intrauterine saline infusion 1 cc
214636179|NCT03915223|PROCEDURE|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
214636180|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
214636181|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
214636182|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
214636183|NCT01131000|OTHER|Normal Saline|Normal Saline, 100 ml, Single-dose
214636184|NCT04655664|DIAGNOSTIC_TEST|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
214636185|NCT04655664|DIAGNOSTIC_TEST|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
214636186|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
214636187|NCT02507011|DRUG|Carvedilol|Beta-adrenergic receptor blocker
214636188|NCT02507011|DRUG|Placebo|Placebo
214636189|NCT02070042|DRUG|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
214636190|NCT02070042|DRUG|Placebo|Placebo capsules (olive oil) twice a day
214636191|NCT04427215|OTHER|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
214636192|NCT05357300|DEVICE|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
214636193|NCT01562548|DRUG|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
214636194|NCT01562548|DRUG|Placebo|no active ingredient
214636195|NCT05459623|OTHER|Manual myofascial release|will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
214636196|NCT05459623|OTHER|Emmett intervention|"will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute."
214636197|NCT01355939|PROCEDURE|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
214636198|NCT01496066|DEVICE|LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|LAL implanted and adjusted with LDD
214636199|NCT01496066|DEVICE|Monofocal control IOL|Commercially available monofocal intraocular lens (IOL)
214636200|NCT06078969|DRUG|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
214636201|NCT01692548|OTHER|Neurofeedback|
214636202|NCT04612998|OTHER|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
214636203|NCT04612998|OTHER|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
214636204|NCT04612998|DRUG|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
214636205|NCT04612998|DRUG|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.
214636206|NCT04612998|DRUG|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
214636207|NCT01441063|DRUG|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
214636208|NCT01441063|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
214636209|NCT01441063|DRUG|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
214636210|NCT05055193|DRUG|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
214636211|NCT03639090|DIAGNOSTIC_TEST|mass spectrometry|mass spectrometry for bladder cancer cells
214636212|NCT02630238|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet \& exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
214636213|NCT02630238|OTHER|Placebo|All participants will partake in the same diet \& exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
214723890|NCT06329713|PROCEDURE|Group I: 30 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every 30 minutes, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minuts may be administered
214636214|NCT02630238|OTHER|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
214636215|NCT02630238|OTHER|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
214636216|NCT00010361|DRUG|cyclosporine|
214636217|NCT00010361|DRUG|fludarabine|
214636218|NCT00010361|DRUG|mycophenolate mofetil|
214636219|NCT03315832|DRUG|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
214636220|NCT03315832|DRUG|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
214636221|NCT06501417|OTHER|mainstreaming|mainstreaming in EC patients
214636222|NCT01014832|DRUG|Intensive insulin therapy|Intensive insulin therapy
214636223|NCT05248438|BEHAVIORAL|Questionnaire|Questionnaire
214636224|NCT00133380|DRUG|PPAR alpha|
214636225|NCT00133380|DRUG|atorvastatin|
214636226|NCT00133380|DRUG|placebo|
214636227|NCT01028807|OTHER|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
214636228|NCT01028807|OTHER|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
214636229|NCT04795557|DIETARY_SUPPLEMENT|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
214636230|NCT04795557|OTHER|Placebo oral solution|Excipients
214636231|NCT02955745|OTHER|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
214636232|NCT02948803|BEHAVIORAL|smartphone based intervention with Active Coach app|
214636233|NCT04814394|DIAGNOSTIC_TEST|flowcytometry|The study of CD4,CD25,FOXP3 and PD-1 on peripheral blood sample
214636234|NCT06501287|DIAGNOSTIC_TEST|Postprandial triglyceride|impact of postprandial triglyceride level on coronary atherosclerosis
214636235|NCT00733707|BEHAVIORAL|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
214636236|NCT00003426|DRUG|gemcitabine hydrochloride|
214636237|NCT00003426|RADIATION|radiation therapy|
214636238|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
214636239|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
214636240|NCT00685126|DRUG|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
214636241|NCT02254889|DRUG|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
214636242|NCT03138876|DEVICE|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
214636243|NCT03138876|DRUG|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
214636244|NCT03138876|PROCEDURE|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
214723891|NCT06329713|PROCEDURE|Group II: 60 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programme
214723892|NCT00236613|DRUG|topiramate|
214723893|NCT05038787|DRUG|LY3473329|Administered orally.
214723894|NCT05038787|DRUG|Placebo|Administered orally.
214636245|NCT06016426|OTHER|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
214636246|NCT03987854|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
214636247|NCT05559827|DRUG|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
214636248|NCT03682978|DRUG|Arbaclofen|Arbaclofen tablet.
214636249|NCT03682978|DRUG|Placebo|Placebo tablet.
214636250|NCT04577443|DRUG|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
214636251|NCT04577443|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
214636252|NCT04145401|DEVICE|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
214636253|NCT01570673|BEHAVIORAL|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
214636254|NCT01570673|BEHAVIORAL|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
214636255|NCT01487915|DRUG|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
214636256|NCT01487915|DRUG|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
214636257|NCT00803075|DEVICE|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
214636258|NCT02627820|DRUG|Isis 420915/GSK 299872|Open label study in comparison to historic control.
214636259|NCT05093400|OTHER|no intervention|saliva collection
214636260|NCT00102206|DRUG|Abacavir sulfate|
214636261|NCT00102206|DRUG|Emtricitabine|
214636262|NCT00102206|DRUG|Lamivudine|
214636263|NCT00102206|DRUG|Lopinavir/ritonavir|
214723895|NCT00131170|PROCEDURE|paravertebral block|
214723896|NCT04645576|DEVICE|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
214723897|NCT06086782|OTHER|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
214636264|NCT00102206|DRUG|Saquinavir|
214636265|NCT00102206|DRUG|Tenofovir disoproxil fumarate|
214636266|NCT00102206|DRUG|Zidovudine|
214636267|NCT03195907|OTHER|Pulmonary physiotherapy|
214636268|NCT02195388|OTHER|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
214636269|NCT05448911|PROCEDURE|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
214636270|NCT05448911|PROCEDURE|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
214636271|NCT05566756|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
214636272|NCT02085434|BEHAVIORAL|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
214636273|NCT01716572|DRUG|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
214636274|NCT01716572|PROCEDURE|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
214723898|NCT06086782|OTHER|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
214723899|NCT03537183|OTHER|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
214723900|NCT00252317|DRUG|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
214723901|NCT00252317|DRUG|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
214723902|NCT04113278|GENETIC|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
214723903|NCT04557007|DRUG|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
214723904|NCT01231828|DRUG|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
214723905|NCT01231828|DRUG|Lactulose|Lactulose (30-60 ml per day)
214636275|NCT03150225|OTHER|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
214636276|NCT03150225|DIETARY_SUPPLEMENT|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
214636277|NCT04082000|DRUG|BOL-DP-o-04|BOL-DP-o-04
214636278|NCT04082000|DRUG|Placebo|Placebo
214636279|NCT03933865|DRUG|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
214636280|NCT03933865|DRUG|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
214636281|NCT03933865|DRUG|Placebos|Placebo will be normal saline solution given via intramuscular injection.
214636282|NCT02820428|OTHER|Healthy participants|Semi-structured interview
214636283|NCT03183882|BEHAVIORAL|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
214636284|NCT03183882|BEHAVIORAL|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
214636285|NCT02147483|BEHAVIORAL|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
214636286|NCT02147483|BEHAVIORAL|Treatment as usual|Treatment usually provided by clinician
214636287|NCT06062862|DEVICE|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
214636288|NCT06062862|DEVICE|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
214636289|NCT04850209|OTHER|oral and written education|oral and written education
214636290|NCT04850209|OTHER|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
214636291|NCT03911765|BEHAVIORAL|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
214636292|NCT00971386|BEHAVIORAL|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
214636293|NCT03405948|DRUG|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
214636294|NCT00516737|DRUG|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
214636295|NCT00516737|DRUG|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
214636296|NCT02423915|DRUG|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
214636297|NCT02423915|DRUG|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
214636298|NCT02423915|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -8.
214636299|NCT02423915|RADIATION|Total Body Radiation|2 Gy delivered on Day -4.
214636300|NCT02423915|PROCEDURE|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Fucosylated T-reg cells on Day -1."
214636301|NCT02423915|PROCEDURE|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
214636302|NCT02423915|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
214636303|NCT02423915|DRUG|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
214723906|NCT04391153|PROCEDURE|ERCP with tissue sampling|Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
214723907|NCT02897154|DIAGNOSTIC_TEST|In-vitro|
214723908|NCT04629586|OTHER|No intervention|Observational research study
214723909|NCT04513041|PROCEDURE|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
214723910|NCT06015841|BIOLOGICAL|Placebo|The placebo is a solution matching the study vaccine formulation.
214723911|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
214723912|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
214723913|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
214723914|NCT00351390|OTHER|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
214723915|NCT00351390|OTHER|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
214723916|NCT03201484|OTHER|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
214723917|NCT03510403|DEVICE|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
214723918|NCT04507490|DEVICE|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
214723919|NCT02269904|DRUG|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
214723920|NCT02269904|DRUG|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
214723921|NCT02603172|DRUG|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
214723922|NCT06409104|DRUG|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
214636304|NCT02423915|PROCEDURE|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
214636305|NCT02423915|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
214636306|NCT02423915|PROCEDURE|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1."
214636307|NCT02173795|DRUG|Berodual® Respimat®|
214636308|NCT02173795|DRUG|Berodual® MA HFA|
214636309|NCT05578742|PROCEDURE|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
214636310|NCT05578742|PROCEDURE|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
214636311|NCT06107075|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
214636312|NCT06107075|DIETARY_SUPPLEMENT|Placebo|around 40g pea protein powder not containing phospholipids
214636313|NCT02448732|DRUG|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
214636314|NCT05565469|OTHER|Adjustment of neurostimulator settings|"This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation."
214723923|NCT06409104|DRUG|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
214636315|NCT05998629|DEVICE|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
214636316|NCT05998629|OTHER|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
214636317|NCT06667752|DEVICE|Advanced Antibacterial Wound Dressing|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
214636318|NCT06667752|DEVICE|Aquacel Ag+ Extra|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
214636319|NCT01844895|DRUG|Abatacept|
214723924|NCT01736163|DRUG|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
214723925|NCT01736163|DRUG|131I|28 mCi or ≥ 1.036 GBq.
214636320|NCT02471495|DEVICE|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
214723926|NCT01736163|OTHER|Thyroid Hormone Withdrawal|Stop taking hormone therapy
214723927|NCT04914195|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
214636321|NCT02122978|BEHAVIORAL|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
214636322|NCT02122978|BEHAVIORAL|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
214636323|NCT02122978|BEHAVIORAL|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
214636324|NCT01477931|DRUG|Bupropion extended release|300mg once a daily, PO, 8weeks
214636325|NCT05066490|OTHER|Endurance exercise|Treadmill training at moderate intensity.
214636326|NCT05066490|OTHER|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
214636327|NCT04595214|OTHER|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
214646915|NCT04529291|OTHER|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
214723928|NCT00492518|DRUG|Acetylcysteine|
214723929|NCT00492518|DRUG|Theophylline|
214723930|NCT00492518|DRUG|Placebo|
214723931|NCT03175952|DIAGNOSTIC_TEST|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
214723932|NCT03415672|BIOLOGICAL|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
214723933|NCT03415672|BIOLOGICAL|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
214723934|NCT00130494|DRUG|Zoledronic acid|
214723935|NCT03520894|RADIATION|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
214723936|NCT01964027|DRUG|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
214723937|NCT03928340|DRUG|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
214723938|NCT03928340|DRUG|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
214636328|NCT04938258|BEHAVIORAL|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
214636329|NCT00955630|DRUG|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
214636330|NCT00955630|DRUG|ranibizumab|prn injections of ranibizumab throughout the study
214636331|NCT04904458|OTHER|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
214636332|NCT04904458|OTHER|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
214636333|NCT01903512|PROCEDURE|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
214636334|NCT02757170|DEVICE|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
214723939|NCT01876472|BEHAVIORAL|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
214723940|NCT01660646|BEHAVIORAL|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
214723941|NCT05298163|DRUG|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
214636335|NCT05072132|OTHER|Personal information on genetic susceptibility to arsenic toxicity|The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
214636336|NCT05072132|OTHER|standard information on arsenic exposure reduction|In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
214636337|NCT03252483|OTHER|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
214636338|NCT03252483|OTHER|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
214636339|NCT01537757|DRUG|MK-8931|Single dose, administered as oral capsules
214636340|NCT01902550|DRUG|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
214636341|NCT01902550|DRUG|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
214723942|NCT05298163|DRUG|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
214723943|NCT03285490|DRUG|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
214723944|NCT03285490|DRUG|Placebo|Dosage form: Ointment; Route of administration: Topical
214723945|NCT03745989|DRUG|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
214723946|NCT03745989|DRUG|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
214636342|NCT01902550|DRUG|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
214636343|NCT04495309|RADIATION|Metastases-directed Radiotherapy|Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
214636344|NCT00394459|DEVICE|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
214636345|NCT00394459|DEVICE|Perifix Standard|Perifix Standard
214636346|NCT00394459|DEVICE|Perifix New|Perifix New
214636347|NCT00512798|DRUG|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2"
214636348|NCT00512798|DRUG|temozolomide|"Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2"
214636349|NCT00512798|OTHER|immunoenzyme technique|Not noted
214636350|NCT00512798|DRUG|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
214636351|NCT00512798|DRUG|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
214723947|NCT01687049|DRUG|Red yeast rice|
214636352|NCT03900871|DRUG|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
214723948|NCT02444806|OTHER|Full polysomnography|Full sleep and respiratory monitoring with EEG
214636353|NCT01387243|DRUG|Orlistat|60 mg
214636354|NCT04476238|DIETARY_SUPPLEMENT|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
214636355|NCT04476238|OTHER|Placebo|250 ml water taken by mouth
214636356|NCT04385654|DRUG|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
214636357|NCT04385654|DRUG|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
214636358|NCT06245551|DRUG|Budesonide/albuterol metered-dose inhaler 160/180 μg|Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
214723949|NCT02444806|OTHER|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
214636359|NCT06245551|DRUG|Placebo metered-dose inhaler|Placebo aerosol for inhalation, single dose (given as 2 actuations)
214636360|NCT03597048|BEHAVIORAL|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
214636361|NCT03597048|BEHAVIORAL|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
214636362|NCT03597048|BEHAVIORAL|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
214636363|NCT00968851|DRUG|EVP-6124|Arms: 1
214636364|NCT00968851|DRUG|Placebo|Arm: 3
214636365|NCT00968851|DRUG|EVP-6124|Arms: 2
214636366|NCT06194396|OTHER|chlorhexidine|chlorhexidine will be used as skin disinfectant before insertion of CVC, PICC line, and umbilical catheter
214636367|NCT06194396|OTHER|alcohol|alcohol will be used as skin disinfectant before insertion of CVC ,PICC line and umbilical catheter
214636368|NCT01061814|DRUG|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
214636369|NCT01061814|DRUG|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
214636370|NCT02508194|BIOLOGICAL|MEDI7510|RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
214636371|NCT02508194|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
214636372|NCT02508194|OTHER|Placebo|Sterile Saline
214723950|NCT03178175|PROCEDURE|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
214723951|NCT03178175|PROCEDURE|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
214723952|NCT01250301|OTHER|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
214723953|NCT01250301|OTHER|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
214723954|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
214723955|NCT05192044|OTHER|Conventional Care|Conventional Care
214723956|NCT03529929|DRUG|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
214723957|NCT02387450|DRUG|Sildenafil|100 mg per day
214723958|NCT02387450|DRUG|Placebo|Placebo with same presentation as the active drug
214723959|NCT01047436|DRUG|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
214723960|NCT01047436|DRUG|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
214723961|NCT06149741|PROCEDURE|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
214723962|NCT03938025|PROCEDURE|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
214723963|NCT05969262|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
214723964|NCT02837861|DRUG|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
214723965|NCT02837861|OTHER|Routine Nutritional Support|Enteral nutrition as tolerated.
214723966|NCT01900405|DRUG|Dexmedetomidine|
214723967|NCT05939076|DEVICE|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
214723968|NCT05939076|DRUG|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
214723969|NCT03885609|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
214723970|NCT03885609|DEVICE|powered toothbrush|regular powered toothbrush with no RF
214723971|NCT05440344|DRUG|Imlunestrant|Administered orally.
214723972|NCT00608803|DRUG|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
214723973|NCT00786461|PROCEDURE|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
214723974|NCT00786461|PROCEDURE|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
214723975|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
214723976|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
214723977|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
214723978|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
214723979|NCT04172376|PROCEDURE|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
214723980|NCT04172376|DRUG|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
214723981|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
214636373|NCT00393874|BEHAVIORAL|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
214636374|NCT00393874|DRUG|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
214636375|NCT00393874|DRUG|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
214636376|NCT00511355|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
214636377|NCT00511355|DRUG|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
214636378|NCT02235194|DIETARY_SUPPLEMENT|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
214636379|NCT02235194|DIETARY_SUPPLEMENT|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
214636380|NCT05820425|OTHER|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
214636381|NCT04405050|DEVICE|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
214636382|NCT04405050|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
214636383|NCT04067063|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
214636384|NCT02415738|PROCEDURE|Prone positioning|
214636385|NCT00713583|DRUG|levodopa|800mg levodopa and 200mg carbidopa per day
214636386|NCT00713583|DRUG|Placebo|Placebo
214636387|NCT00713583|BEHAVIORAL|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
214723982|NCT01890733|DEVICE|InSpace™ system|
214636388|NCT00713583|BEHAVIORAL|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
214636389|NCT03228966|DIAGNOSTIC_TEST|Echocardiogram|Screening echocardiogram
214636390|NCT01031914|DEVICE|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
214636391|NCT04654208|DRUG|palbociclib|patients on palbociclib combination treatment
214636392|NCT02803944|DRUG|Azithromycin|
214636393|NCT00454805|DRUG|AZD2171|Oral tablet
214636394|NCT00454805|DRUG|Fulvestrant|intramuscular injection
214636395|NCT03967548|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
214636396|NCT04870879|PROCEDURE|Liver Transplant|Liver Transplant from cadaveric donors
214636397|NCT04870879|DRUG|Chemotherapy|Chemotherapy
214723983|NCT04299256|BEHAVIORAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
214723984|NCT01834638|DRUG|ABT-126|capsule(s)
214723985|NCT05939700|DRUG|Mavacamten|Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
214723986|NCT00424099|DRUG|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
214723987|NCT00424099|BEHAVIORAL|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
214723988|NCT00424099|DRUG|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
214723989|NCT00424099|BEHAVIORAL|Non NTI|Non NTI are calls from research staff 3 times weekly.
214723990|NCT01665976|DRUG|RO4917838|film coated tablet, single dose
214723991|NCT01665976|DRUG|RO4917838|oral suspension, single dose
214723992|NCT01665976|DRUG|RO4927838|hard gelatin capsule, single dose
214723993|NCT04212403|DRUG|Levofloxacin|The control group receives AMP.
214723994|NCT05537961|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
214723995|NCT00632515|BEHAVIORAL|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
214723996|NCT00521118|OTHER|Laboratory Biomarker Analysis|Correlative studies
214723997|NCT00521118|PROCEDURE|Therapeutic Conventional Surgery|Undergo second curettage
214723998|NCT02280096|DRUG|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
214723999|NCT02280096|DRUG|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
214724000|NCT04427410|DIAGNOSTIC_TEST|Salivary test|Salivary test for measured of oxytocin levels
214724001|NCT05934890|BIOLOGICAL|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
214636398|NCT00767897|DRUG|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
214636399|NCT03742037|DRUG|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
214636400|NCT03742037|DRUG|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
214636401|NCT03742037|DRUG|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
214636402|NCT03742037|DRUG|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
214636403|NCT03742037|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
214636404|NCT03742037|DRUG|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
214724002|NCT05934890|BIOLOGICAL|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
214724003|NCT02296905|DRUG|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
214636405|NCT00802685|DRUG|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
214636406|NCT00802685|OTHER|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV."
214636407|NCT00040755|DRUG|rebimastat|Given orally
214724004|NCT02296905|DRUG|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
214636408|NCT00040755|OTHER|laboratory biomarker analysis|Correlative studies
214636409|NCT05199259|DIAGNOSTIC_TEST|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
214724005|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
214636410|NCT03800875|DRUG|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
214636411|NCT01479712|PROCEDURE|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
214636412|NCT03847701|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
214636413|NCT03847701|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
214636414|NCT02772432|BEHAVIORAL|Relaxation Response Resiliency Training for Parents of SPLD|
214636415|NCT04002544|DRUG|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
214636416|NCT04002544|OTHER|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
214636417|NCT00538720|DRUG|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
214636418|NCT00538720|DEVICE|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
214636419|NCT00476879|DRUG|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
214636420|NCT02126085|PROCEDURE|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
214636421|NCT06057363|OTHER|volumetric evaluation of gingival augmentation around dental implants|objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
214636422|NCT01450423|BEHAVIORAL|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
214636423|NCT02849366|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
214636424|NCT02849366|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
214636425|NCT05531669|BEHAVIORAL|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
214636426|NCT05531669|BEHAVIORAL|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
214636427|NCT03436186|OTHER||no intervention
214636428|NCT01545700|DRUG|Control-saline|Patients are randomized to receive saline 2 cc
214636429|NCT01545700|DRUG|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
214636430|NCT01545700|DRUG|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
214636431|NCT01545700|DRUG|Control saline|Patients are randomized to receive saline 2 cc
214636432|NCT01545700|DRUG|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
214636433|NCT01545700|DRUG|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
214636434|NCT00401063|DEVICE|Acupuncture|Acupuncture treatment twice a day for eight weeks
214636435|NCT03797469|DIETARY_SUPPLEMENT|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
214636436|NCT03797469|DIETARY_SUPPLEMENT|Pyruvate|2 tablets of 1500 mg each will be administered orally.
214636437|NCT03797469|DIETARY_SUPPLEMENT|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
214636438|NCT03208231|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered by subcutaneous injection.
214636439|NCT03208231|DRUG|Combination Antiretroviral Therapy (cART)|All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
214636440|NCT00691431|DEVICE|LASIK|
214636441|NCT03321097|DEVICE|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
214724006|NCT04946760|OTHER|Sham Manipulation|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
214724007|NCT04517916|DEVICE|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
214724008|NCT04084080|BIOLOGICAL|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.
214724009|NCT04084080|OTHER|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
214636442|NCT03321097|DEVICE|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
214636443|NCT01563887|BEHAVIORAL|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
214636444|NCT01563887|BEHAVIORAL|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
214636445|NCT03861143|DRUG|BT-11 (440 mg)|Oral, once daily tablet
214636446|NCT03861143|DRUG|BT-11 (880 mg)|Oral, once daily tablet
214636447|NCT03861143|DRUG|Placebo|Oral, once daily tablet
214636448|NCT00281879|BIOLOGICAL|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
214636449|NCT00281879|BIOLOGICAL|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
214636450|NCT00281879|DRUG|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
214636451|NCT00281879|DRUG|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
214636452|NCT00281879|DRUG|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
214636453|NCT00281879|DRUG|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
214636454|NCT00281879|DRUG|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
214636455|NCT00281879|DRUG|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
214636456|NCT00281879|DRUG|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
214636457|NCT00281879|DRUG|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
214636458|NCT00281879|DRUG|methotrexate|Administered on days +1, +3, and +7.
214636459|NCT00281879|DRUG|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
214636460|NCT00281879|DRUG|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
214636461|NCT00281879|DRUG|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
214636462|NCT00281879|PROCEDURE|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
214636463|NCT00281879|PROCEDURE|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
214636464|NCT00281879|RADIATION|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
214636465|NCT04442841|BIOLOGICAL|Hepatitis B vaccine|It may be GSk or MSD vaccine
214636466|NCT02228863|OTHER|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
214636467|NCT02228863|OTHER|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
214636468|NCT02228863|OTHER|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
214724010|NCT06154993|OTHER|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
214636469|NCT02228863|OTHER|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
214636470|NCT04679831|DIETARY_SUPPLEMENT|Ujiplus®|Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
214636471|NCT04679831|DRUG|Praziquantel 400mg|400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
214724011|NCT06154993|OTHER|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
214636472|NCT03188445|DRUG|Iron Isomaltoside 1000|Administered iv
214636473|NCT03188445|DRUG|ferrous fumarate with ascorbic acid|Oral administration
214724012|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol|Patients would begin taking myoinositol upon recruitment
214724013|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol placebo|Patients would begin taking placebo upon recruitment
214724014|NCT04066010|OTHER|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
214724015|NCT02939976|DEVICE|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
214724016|NCT02939976|PROCEDURE|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
214724017|NCT02939976|PROCEDURE|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
214724018|NCT02939976|DEVICE|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
214724019|NCT02939976|DEVICE|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
214724020|NCT02939976|DEVICE|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
214724021|NCT02939976|DEVICE|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
214724022|NCT02613091|DRUG|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
214724023|NCT03438513|BEHAVIORAL|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
214724024|NCT03438513|BEHAVIORAL|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
214724025|NCT03438513|BEHAVIORAL|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
214724026|NCT03438513|BEHAVIORAL|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
214724027|NCT03998241|OTHER|No intervention was provided|No intervention given
214724028|NCT01872897|DRUG|Sodium Alginate Double Action Chewable Tablets|4 tablets as a single dose
214724029|NCT01872897|DRUG|Placebo|4 tablets as a single dose
214724030|NCT06296472|OTHER|Rehabilitation|-the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.
214724031|NCT06296472|OTHER|Standard|-the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
214724032|NCT05310669|DEVICE|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose).
214724033|NCT06183554|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary aldosteronism will receive a CXCR4 PET imaging.
214724034|NCT03953040|DIAGNOSTIC_TEST|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
214724035|NCT01830322|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
214724036|NCT01830322|DRUG|Gemcitabine|
214724037|NCT01830322|DRUG|Any non-gemcitabine chemotherapies or best supportive care|
214724038|NCT05845411|BEHAVIORAL|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
214724039|NCT05845411|OTHER|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
214724040|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
214636474|NCT05043467|DRUG|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
214636475|NCT02080793|OTHER|Questionnaire|
214636476|NCT04024267|OTHER|Eurythmy therapy|Mind-body therapy
214636477|NCT04024267|OTHER|CoordiFit|Fitness training
214636478|NCT04666272|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
214636479|NCT04666272|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
214636480|NCT01865331|DRUG|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
214636481|NCT01865331|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
214636482|NCT01865331|DRUG|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
214636483|NCT04347239|DRUG|Placebo|Placebo
214636484|NCT04347239|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
214636485|NCT06390332|BEHAVIORAL|Giving Information for Trauma Support and Safety (GIFTSS) Training|Training for college health center staff and clinicians on GIFTSS intervention which is a universal education and brief counseling to address sexual violence prevention and intervention.
214636486|NCT06390332|BEHAVIORAL|Centering gender Affirming Resources in higher Education (CARE) Learning Modules|Training for college health center clinicians and staff on trans and gender diverse (TGD) affirming clinical practices in addition to sexual violence and alcohol abuse prevention that is inclusive of TGD service users
214636487|NCT04641442|BIOLOGICAL|MAS825|Experimental drug
214636488|NCT04641442|BIOLOGICAL|Placebo|matching placebo
214636489|NCT05142826|BEHAVIORAL|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
214636490|NCT05142826|OTHER|School as Usual|Interventions and supports as provided through usual care
214636491|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
214636492|NCT02065752|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
214636493|NCT02065752|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
214636494|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
214636495|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
214636496|NCT06384001|BEHAVIORAL|Active MBM|The MBM is designed to be applied for 20 minutes per session daily for two weeks. The recording will instruct participants to close their eyes, connect to the openness of one's minds, and mindfully maintain and deepen the connection through breathing with more openness and awareness. The MBM intervention will include three recordings that gradually take the participant into a more profound meditation practice. Participants will be instructed to listen to Meditation 1 for the first three days of the intervention, then switch to Meditation 2 for days 4-6 and Meditation 3 for the remainder of the 2-week intervention. The participants will be asked to practice meditation for eight weeks (6 weeks after the initial two weeks of MBM practice).
214636497|NCT06384001|BEHAVIORAL|Sham MBM|The sham MBM intervention was also recorded. The sham recording will instruct participants to relax and take deep breaths every 3 minutes without the specific mindfulness-based instructions (e.g., practicing mindful attention to the breath in a non-evaluative manner). All other aspects of the sham MBM intervention (e.g., body position, time spent listening to instructions, eyes closed) will match the active MBM.
214636498|NCT06403761|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214636499|NCT06403761|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214636500|NCT06403761|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
214636501|NCT06403761|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
214636502|NCT06492070|OTHER|Best Practice|Undergo standard of care
214636503|NCT06492070|DRUG|Cilostazol|Given PO
214636504|NCT06492070|DEVICE|Cryocompression Therapy|Undergo cryocompression therapy
214636505|NCT06492070|DRUG|Paclitaxel|Given by infusion
214636506|NCT06492070|OTHER|Quality-of-Life Assessment|Ancillary studies
214636507|NCT05099107|DRUG|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
214636508|NCT05099107|DRUG|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
214636509|NCT02626260|OTHER|adhesive strip|Adhesive strip with a standard adhesive base
214636510|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
214636511|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
214724041|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
214724042|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
214724043|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
214724044|NCT02418585|DRUG|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
214724045|NCT02418585|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
214724046|NCT02418585|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
214724047|NCT02418585|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
214724048|NCT02418585|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
214724049|NCT02418585|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
214724050|NCT02040857|DRUG|Palbociclib|CDK 4/6 inhibitor
214724051|NCT02040857|DRUG|Aromatase Inhibitor|Endocrine Therapy
214724052|NCT00671398|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
214724053|NCT00671398|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
214724054|NCT00671398|DRUG|Placebo|Ramelteon placebo-matching tablets, orally for one night only
214724055|NCT02621255|DRUG|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
214724056|NCT02621255|DRUG|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
214724057|NCT02957474|DRUG|GED-0301|
214724058|NCT02957474|DRUG|Omeprazole|
214724059|NCT04159701|DRUG|LY3454738|Administered IV
214724060|NCT04159701|DRUG|Placebo|Administered IV
214724061|NCT05342142|BEHAVIORAL|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
214724062|NCT04964804|PROCEDURE|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
214724063|NCT04964804|PROCEDURE|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
214724064|NCT05682768|PROCEDURE|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
214724065|NCT01137448|BEHAVIORAL|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
214724066|NCT01655641|DRUG|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
214724067|NCT01655641|OTHER|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
214724068|NCT00780104|DRUG|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
214636512|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
214724069|NCT00780104|DRUG|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
214724070|NCT02795065|DRUG|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
214724071|NCT02795065|DRUG|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
214724072|NCT05538429|PROCEDURE|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
214724073|NCT04563104|DIAGNOSTIC_TEST|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
214636513|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
214636514|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
214636515|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
214636516|NCT03705728|DRUG|Propofol|"Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
214636517|NCT03705728|DRUG|Sevoflurane|Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval
214724074|NCT06380972|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
214724075|NCT03605836|DRUG|Centanafadine SR|100 mg, BID, oral tablets
214724076|NCT03605836|OTHER|Placebo|BID, oral tablet
214724077|NCT03605836|DRUG|Centanafadine SR|200 mg, BID, oral tablets
214724078|NCT06186024|DEVICE|Bridge|Stent implantation
214724079|NCT00005065|DRUG|paclitaxel|Given IV
214724080|NCT00005065|DRUG|carboplatin|Given IV
214724081|NCT00005065|DRUG|motexafin gadolinium|Given IV
214724082|NCT00005065|PROCEDURE|conventional surgery|Undergo complete surgical resection
214724083|NCT00005065|RADIATION|radiation therapy|Undergo radiation therapy
214724084|NCT00260091|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
214724085|NCT00260091|PROCEDURE|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
214724086|NCT00964639|DRUG|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
214724087|NCT00964639|DRUG|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
214724088|NCT06315686|DRUG|pemetrexed|The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
214724089|NCT03968211|BIOLOGICAL|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
214724090|NCT02463227|BIOLOGICAL|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
214724091|NCT04696328|BIOLOGICAL|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
214724092|NCT02845440|OTHER|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
214724093|NCT02845440|OTHER|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
214724094|NCT02845440|OTHER|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
214724095|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
214724096|NCT03746340|DRUG|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
214724097|NCT03746340|DRUG|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
214724098|NCT00517725|DRUG|carvedilol|
214724099|NCT00517725|DRUG|bisoprolol|
214724100|NCT00517725|DRUG|Nebivolol|
214724101|NCT02894892|DRUG|(A)Bismuth|
214724102|NCT02894892|DRUG|(B)Bismuth|
214724103|NCT02894892|DRUG|(C)Bismuth|
214724104|NCT02894892|DRUG|(D)Esomeprazole and Bismuth|
214724105|NCT02894892|DRUG|(E)Esomeprazole and Bismuth|
214724106|NCT02894892|DRUG|(F)Esomeprazole and Bismuth|
214724107|NCT02894892|OTHER|(G)Control|
214724108|NCT03180021|PROCEDURE|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
214724109|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
214724110|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
214724111|NCT04428762|DEVICE|I-Port Advance use|participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
214724112|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
214724113|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
214724114|NCT03316742|COMBINATION_PRODUCT|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
214724115|NCT03316742|COMBINATION_PRODUCT|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
214724116|NCT06261411|DIAGNOSTIC_TEST|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
214724117|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
214724118|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
214724119|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
214724120|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
214724121|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
214724122|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
214724123|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
214636518|NCT03705728|DRUG|Remifentanil automatic|"Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
214636519|NCT03705728|DRUG|Remifentanil manual|Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
214636520|NCT03430921|DEVICE|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
214636521|NCT06240884|PROCEDURE|Infraspinatus-teres minor interfascial block|After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
214636522|NCT06240884|PROCEDURE|interscalene block|The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
214636523|NCT04892836|OTHER|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
214636524|NCT02224859|DEVICE|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
214636525|NCT02224859|OTHER|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
214636526|NCT05790265|DEVICE|ANNE One|Chest sensor for single lead ECG and finger sensor for pulse oximetry.
214636527|NCT06351527|DRUG|ICP-248|ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).
214636528|NCT06351527|DRUG|Obinutuzumab (G)|Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.
214636529|NCT06351527|DRUG|Rituximab (R)|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.
214636530|NCT06443606|DRUG|Bezafibrate 400 mg in addition to UDCA therapy|"* Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
214636531|NCT06443606|DRUG|Bezafibrate 200 mg in addition to UDCA therapy|"* Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
214636532|NCT06443606|DRUG|Placebo in addition to UDCA therapy|"* Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks placebo /UDCA = daily oral dose."
214724124|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
214724125|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
214724126|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
214724127|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
214724128|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
214724129|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
214724130|NCT02057068|BEHAVIORAL|SLEEP-E Dyads Intervention|Described in arm/group description
214724131|NCT02918422|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
214724132|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
214724133|NCT04802928|DRUG|Placebo|Placebo
214724134|NCT01944254|PROCEDURE|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
214724135|NCT01944254|PROCEDURE|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
214724136|NCT01944254|PROCEDURE|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
214724137|NCT05166551|PROCEDURE|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
214724138|NCT05166551|PROCEDURE|Placebo Acupressure|Placebo Acupressure
214724139|NCT03996889|DEVICE|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink"
214724140|NCT01782885|PROCEDURE|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
214724141|NCT01782885|DRUG|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
214724142|NCT04605185|DRUG|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
214724143|NCT04605185|BIOLOGICAL|Toripalimab Injection|240 mg, iv drip,q3w
214724144|NCT00881140|DRUG|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
214724145|NCT03447821|DRUG|400 mg Rifamycin SV dosage|
214724146|NCT03447821|DRUG|800 mg Rifamycin SV dosage|
214724147|NCT03447821|DRUG|1200 mg Rifamycin SV dosage|
214724148|NCT03929783|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEM
214724149|NCT04632745|OTHER|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
214724150|NCT04152746|OTHER|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
214724151|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
214636533|NCT03639025|DEVICE|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
214636534|NCT05653752|DRUG|YL202|"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."
214636535|NCT00069498|DRUG|5-aminosalicylic acid|
214636536|NCT02289950|DRUG|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
214636537|NCT02289950|DRUG|Placebo|Placebo will be administered intravenously (IV) weekly
214636538|NCT05326542|PROCEDURE|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
214636539|NCT05326542|PROCEDURE|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
214636540|NCT02270242|DRUG|Aspirin|
214636541|NCT02270242|DRUG|Placebo|
214636542|NCT02270242|DRUG|ticagrelor|
214636543|NCT02294240|DIETARY_SUPPLEMENT|Energy dense biscuits|Energy dense biscuits will be provided
214636544|NCT02294240|OTHER|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
214636545|NCT04800289|OTHER|questionnaires|questionnaires about disease and satisfaction of patient
214636546|NCT03963011|DIAGNOSTIC_TEST|Bowel Ultrasound|Ultrasound imaging of the bowel
214636547|NCT06062186|DIETARY_SUPPLEMENT|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
214636548|NCT06062186|DIETARY_SUPPLEMENT|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
214636549|NCT06062186|DIETARY_SUPPLEMENT|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
214636550|NCT04876014|OTHER|Guided Mobile-Based Perinatal Mindfulness Intervention|GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.
214636551|NCT02321436|BIOLOGICAL|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
214636552|NCT02321436|DRUG|Placebo|Placebo administered intramuscularly in the targeted upper limb.
214636553|NCT03801655|DIETARY_SUPPLEMENT|Bio-Kult|4 capsules/day
214724152|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
214724153|NCT04073641|OTHER|No intervention|No intervention
214724154|NCT05451602|DRUG|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
214724155|NCT02575989|OTHER|1: control group|Classic - current management of trauma patients by French medical teams
214724156|NCT02575989|OTHER|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
214724157|NCT06009198|DRUG|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
214724158|NCT03030391|OTHER|PET|
214724159|NCT03030391|OTHER|MRI|
214724160|NCT03662555|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
214724161|NCT00329784|BIOLOGICAL|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
214724162|NCT03749213|DRUG|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
214724163|NCT05467605|DIETARY_SUPPLEMENT|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
214724164|NCT05467605|OTHER|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
214724165|NCT00809510|DRUG|ABT-089|20 mg ABT-089 taken once-daily for 6 months
214724166|NCT06298760|COMBINATION_PRODUCT|Knee Massage With Black Cumin Oil Group:|The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
214724167|NCT06298760|COMBINATION_PRODUCT|Foot Reflexology Group With Black Cumin Oil|The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
214724168|NCT06298760|COMBINATION_PRODUCT|placebo group|Applications were made with vaseline
214724169|NCT05437913|OTHER|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
214724170|NCT04255992|DIETARY_SUPPLEMENT|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
214724171|NCT04255992|DIETARY_SUPPLEMENT|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
214724172|NCT03158090|PROCEDURE|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
214724173|NCT03158090|DRUG|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
214724174|NCT03158090|RADIATION|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
214724175|NCT04663542|PROCEDURE|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
214724176|NCT02884128|DRUG|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
214724177|NCT02884128|DRUG|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
214724178|NCT02884128|DRUG|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
214636554|NCT03801655|OTHER|Placebo|4 capsules/day
214636555|NCT04926272|DRUG|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
214636556|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
214636557|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
214636558|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
214636559|NCT00664833|OTHER|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
214636560|NCT02369614|OTHER|Active Comparator: 1 Hz rTMS|1 Hz rTMS
214636561|NCT02369614|OTHER|Active Comparator: 10 Hz rTMS|10 Hz rTMS
214636562|NCT02369614|OTHER|Sham Comparator:|Sham rTMS
214636563|NCT03225053|DEVICE|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
214636564|NCT00105937|DRUG|OraVescent fentanyl citrate|
214636565|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
214636566|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
214636567|NCT00644787|DRUG|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
214636568|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
214636569|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
214636570|NCT04901208|DRUG|Nicotine pod|Nicotine pods administered to individuals who use Juul
214636571|NCT04901208|DRUG|Placebo pod|Nicotine-free pods administered to individuals who use Juul
214636572|NCT05056532|DIAGNOSTIC_TEST|patient assessment|subjective and objective measurement will be performed in patients with PAH
214636573|NCT02097615|PROCEDURE|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
214636574|NCT02097615|OTHER|deionized water|application every 24 hours six weeks
214636575|NCT05517876|DEVICE|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
214636576|NCT01051427|DEVICE|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
214636577|NCT01051427|DEVICE|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
214724179|NCT03858569|PROCEDURE|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
214724180|NCT05887089|OTHER|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
214636578|NCT03048422|DRUG|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
214636579|NCT03048422|DRUG|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
214636580|NCT03048422|DRUG|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
214636581|NCT03048422|DRUG|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
214636582|NCT07115043|DRUG|AZD6750|AZD6750- CD8 guided IL-2
214636583|NCT07115043|DRUG|rilvegostomig|Rilvegostomig- PD1-TIGIT bispecific antibody
214636584|NCT03110224|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
214636585|NCT02180360|OTHER|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
215030496|NCT06637566|OTHER|Brandt Daroff exercises|brandt daroff exercises without cawthorne Cooksey exercises. To begin the Brandt-daroff exercise, the patient will sit and swivel the head 45 degrees to one side (left), then instantly lie down on the other shoulder (right). The patient should be instructed to maintain this posture for 30 seconds or until the vertigo subsides. The patient then gradually returns to the starting position, maintaining the left ear rotation until sat upright. Following the same 30 second time limits, the patient turns his head in the opposite way (right) and rests down on the opposite shoulder (left). These exercises will be instructed to perform at home for 3 sets (morning, afternoon and evening) with 5 repetitions approximately for 30 minutes in each session for five weeks
214724181|NCT01098032|DEVICE|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
214724182|NCT01098032|DRUG|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
214724183|NCT02353403|OTHER|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
214724184|NCT02353403|OTHER|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
214724185|NCT01229956|GENETIC|DNA methylation analysis|
214724186|NCT01229956|GENETIC|gene expression analysis|
214724187|NCT01229956|GENETIC|microarray analysis|
214724188|NCT01229956|GENETIC|reverse transcriptase-polymerase chain reaction|
214724189|NCT01229956|OTHER|laboratory biomarker analysis|
214724190|NCT00481988|DEVICE|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
214724191|NCT00481988|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
214724192|NCT00481988|DEVICE|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
214724193|NCT00481988|DEVICE|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
214724194|NCT05427175|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
214724195|NCT05427175|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
214724196|NCT03101449|OTHER|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
214724197|NCT03101449|OTHER|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
214724198|NCT04373213|DIAGNOSTIC_TEST|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
214724199|NCT00654420|DRUG|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
214724200|NCT00654420|DRUG|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
214724201|NCT01052636|OTHER|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
215030497|NCT00022854|PROCEDURE|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
215030498|NCT00022854|PROCEDURE|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
214724202|NCT02781415|PROCEDURE|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
214724203|NCT02781415|DRUG|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
214724204|NCT03080051|DRUG|[18F]MNI-952|Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
214724205|NCT03080051|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
214724206|NCT05821192|DRUG|Rituximab|375mg/m2 by IV infusion once every 3 weeks
214724207|NCT05821192|DRUG|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
214724208|NCT05821192|DRUG|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
214724209|NCT05821192|DRUG|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
214724210|NCT05821192|DRUG|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
214724211|NCT01525420|BEHAVIORAL|Acceptance Therapy (ACT)|ACT
214724212|NCT01525420|OTHER|Cognitive Behavioral Therapy (CBT)|CBT
214724213|NCT04682249|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
214724214|NCT04682249|DRUG|Sintilimab|Sintilimab
214724215|NCT04682249|DRUG|Apatinib|Apatinib
215030499|NCT00022854|PROCEDURE|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
214636586|NCT04818593|DEVICE|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
214636587|NCT04818593|OTHER|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
214636588|NCT04147104|DEVICE|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
214636589|NCT04147104|DEVICE|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
214636590|NCT04265183|OTHER|Placing preformed metal crowns using Hall technique.|Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
214636591|NCT01564862|DRUG|vortioxetine (Lu AA21004)|Lu AA21004 capsules
214636592|NCT01564862|DRUG|Duloxetine|Duloxetine capsules
214636593|NCT01564862|DRUG|Placebo|Placebo matching capsules
214636594|NCT06981780|DEVICE|Femoral artery Doppler|An experienced operator will conduct femoral artery examination for the change in Doppler indices namely pulsatility index, resisitive index, and waveform morphology
214724216|NCT02955368|DRUG|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
214724217|NCT02955368|DRUG|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
214724218|NCT02955368|DRUG|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
214724219|NCT02001506|DRUG|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
214724220|NCT00882830|PROCEDURE|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
214724221|NCT01816373|DEVICE|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
214724222|NCT00334698|DRUG|Cetirizine|
214724223|NCT00334698|DRUG|Pseudoephedrine|
214724224|NCT00334698|DRUG|Cetirizine with Pseudoephedrine|
214724225|NCT04477525|PROCEDURE|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
214724226|NCT04477525|DRUG|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
214724227|NCT06507332|DRUG|Letrozole 2.5mg|to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
214724228|NCT00838370|DRUG|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
214724229|NCT04179604|DRUG|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
214724230|NCT04179604|DRUG|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
214724231|NCT00264095|PROCEDURE|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
214724232|NCT00028795|DRUG|temozolomide|
214724233|NCT00028795|PROCEDURE|adjuvant therapy|
214724234|NCT00028795|RADIATION|radiation therapy|
214724235|NCT06047860|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
214724236|NCT06047860|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
214724237|NCT06047860|DRUG|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
214724238|NCT06047860|DRUG|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
214724239|NCT06047860|DRUG|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
214724240|NCT06434025|DRUG|Iron Carboxymaltose|Iron Carboxymaltose 500 mg. 2 vials administered IV.
214724241|NCT06434025|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab, PO, onde a day.
214724242|NCT06434025|DRUG|Placebo of Iron Carboxymaltose|Solution Sodium Chloride 0,9% 100 ml, IV, once.
214724243|NCT06434025|DRUG|Placebo of Dapagliflozin|Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
214724244|NCT00374036|DRUG|ECC|capecitabine
214724245|NCT00374036|DRUG|FOLFIRI|Irinotecan
214724246|NCT01407289|DRUG|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
214724247|NCT02287805|OTHER|qualitative survey|
214724248|NCT02287805|OTHER|quantitative survey|
214724249|NCT00471276|DRUG|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
214724250|NCT02174328|DRUG|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
214724251|NCT02174328|DRUG|Placebo|Placebo once a day until 36 week
214724252|NCT05923151|PROCEDURE|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
214724253|NCT01594411|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
214724254|NCT00838383|DRUG|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
214724255|NCT00838383|DRUG|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
214724256|NCT00838383|DRUG|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
214724257|NCT00650182|DRUG|fentanyl; naltrexone|
214724258|NCT03466112|OTHER|endurance training|endurance training with stationary bicycles
215030500|NCT06638970|DRUG|Secretome|3 ml Injection of secretome for 4 times two weeks apart
214636595|NCT02343354|BEHAVIORAL|Nutrition/physical activity intervention|Please see arm description
214636596|NCT01767675|PROCEDURE|Secondary Cytoreductive Surgery|
214636597|NCT01767675|DRUG|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
214636598|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|5 cycles
214636599|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|6 cycles
214636600|NCT06818734|OTHER|Clinical Decision Support Tool|The CDS in and AI algorithm that will alert clinicians only if patients have high risk of developing PPD, and provide clinicians with risk score, risk factors, and anticipatory actions with an order set to assist with ordering. Clinicians will make the ultimate clinical judgement after receiving CDS aid, including taking no actions towards PPD prevention. Clinicians will manage patients per usual care, including initiating PPD prevention such as conducting referrals to nutrition and behavioral health, suggest educational readings through patient portals, or no actions. Clinicians in the intervention arm will refer patients based on the CDS.
214636601|NCT05798338|DIAGNOSTIC_TEST|Blood sample|Analysis of plasma in order to quantify and characterize EVs
214636602|NCT06986993|DRUG|Semaglutide|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
214636603|NCT06986993|DRUG|Placebo|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
214636604|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
214636605|NCT02868073|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
214636606|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
214636607|NCT04526665|DRUG|Elafibranor 80mg|Elafibranor 80mg daily
214636608|NCT04526665|DRUG|Placebo|Placebo daily
214636609|NCT06607627|COMBINATION_PRODUCT|Gefurulimab|Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
214636610|NCT06588894|BEHAVIORAL|Questionnaire and Physical Exam|Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
214636611|NCT06588894|BEHAVIORAL|Motor Imagery Ability|Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
214636612|NCT06746831|DRUG|S-(+)-methamphetamine|15 mg
214636613|NCT06746831|DRUG|R-(-)-methamphetamine|15 mg
214636614|NCT06746831|DRUG|1:1 racemic mixture of two isomers|15 mg R-Meth + 15 mg S-Meth
214636615|NCT06538480|DRUG|PRGN-2012|PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
214636616|NCT06527391|DRUG|choline bitartrate|Daily supplementation for 9 months with 200 mg choline bitartrate
214636617|NCT06527391|OTHER|placebo drug|Daily supplementation for 9 months with identical placebo
214636618|NCT07000045|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy device used for calcium modification in coronary lesions, using either operator-determined or maximum pulsed numbers for lesion preparation prior to stenting.
214636619|NCT07000045|DEVICE|Rotational atherectomy|Rotational atherectomy device used to debulk calcified nodules before IVL and stent implantation.
214636620|NCT06547021|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
214636621|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
214636622|NCT06547021|DEVICE|Theta Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
214636623|NCT06547021|DEVICE|Sham|"Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
214636624|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)-Precuneus|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
214636625|NCT06679101|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214636626|NCT06679101|DRUG|Lenalidomide|Lenalidomide will be administered.
214636627|NCT06679101|DRUG|Dexamethasone|Dexamethasone will be administered.
214724259|NCT03466112|OTHER|balance and tone program|flexibility, core strength, balance, relaxation
214724260|NCT05426018|DRUG|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
214636628|NCT06679101|DRUG|Daratumumab|Daratumumab will be administered.
214636629|NCT07133880|DRUG|umeclidinium 62.5 µg and vilanterol 25 µg|DPI Treatment
214636630|NCT07133880|DRUG|Revefenacin 175 µg, Formoterol 20 µg|Nebulizer Treatment
214636631|NCT07133880|DRUG|Placebo ( Revefenacin and Formoterol )|Placebo Nebulizer Treatment
214636632|NCT07133880|DRUG|Placebo DPI|Placebo DPI Treatment
214636633|NCT07134114|PROCEDURE|Hall Technique|"Procedure: Hall Technique A preformed stainless-steel crown will be placed on a primary molar using the Hall Technique. This approach does not require local anesthesia, caries removal, or tooth preparation.~Digital Scan and Bite Registration Schedule:~* T0 (Baseline): Immediately before crown placement~* T1 (Immediate): Immediately after crown placement~* T2 (Two Weeks): Two weeks after crown placement~* T3 (One Month): One month after crown placement At each time point (T0-T3), digital scans of both the upper and lower arches will be obtained, and a bite registration will be recorded. These records will be used to generate three-dimensional digital models, which will be analyzed to assess occlusal relationships and monitor changes over time."
214636634|NCT07127380|PROCEDURE|Midline Lumbar Interbody Fusion (MIDLIF)|Midline Lumbar Interbody Fusion (MIDLIF) is a procedure utilizes a medial approach to the spine, involving the retraction of the segmental back muscles to expose the lamine and articular processes. Screw placement is medialized, with entry to a point along the pars intercularis or joint surface. It places the screw through potentially more cortical and stronger bone. Decompression is achieved by resecting the inferior articular process and lamina marginalis, followed by a discectomy. Subsequently, a transforaminal lumbar interbody fusion (TLIF) is performed to place an interbody cage and promote fusion.
214636635|NCT07127380|PROCEDURE|Minimally Invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF)|Minimally invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF) is a procedure that employs a percutaneous approach for pedicle screw placement through the pedicles. Decompression is performed using a lateral approach, with 2-3 cm lateral to the ipsilateral borders. This is followed by resection of the inferior articular process and removal of the ligamentum flavum, facilitating discectomy. An interbody cage is then inserted to achieve fusion.
214636636|NCT07128355|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Starting on Day 1 participants will have 2-4 treatments per week for about 2 weeks, with no more than 2 days in a row. This is expected to last about 2 weeks but could last up to 3 weeks.
214636637|NCT07128355|DRUG|Botensilimab|Administered once every 6 weeks by intravenous infusion over about 30 minutes, on Day 1 of Cycles 1-4 (six-week cycles). Administered 30 minutes after balstilimab.
214636638|NCT07128355|DRUG|Balstilimab|Administered once every 2 weeks by intravenous infusion over about 30 minutes, starting on Day 1 of Cycle 1 and continuing for 4 six-week cycles (with botensilimab) followed by up to 14 six-week cycles of balstilimab alone. Participants will receive balstilimab for a total of 18 six-week cycles.
214636639|NCT07005505|OTHER|Pressure Support Ventilation (PSV)|Spontaneous breathing trials will be conducted using the mode pressure support ventilation (PSV) with settings of a pressure support of 5 cmH2O and positive end expiratory pressure (PEEP) 5 cmH2O.
214636640|NCT07005505|OTHER|Automatic tube compensation (ATC)|Spontaneous breathing trials will be conducted using the mode automatic tube compensation (ATC) with settings of 100% tube compensation and a positive end expiratory pressure (PEEP) of 5 cmH2O.
214636641|NCT06310525|OTHER|Drowning incident|"Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid."
214636642|NCT07010315|BEHAVIORAL|Cognitive Testing|Given by Survey and one-on one interviews
214636643|NCT07010315|BEHAVIORAL|Usability Testing|Given by surveys and one-on-one interview.
214636644|NCT03377907|DRUG|ketamine in hematoma block|ketamine used in local hematoma block only
214636645|NCT03377907|DRUG|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
214636646|NCT03377907|DRUG|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
214636647|NCT07015853|DRUG|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
214636648|NCT07015853|RADIATION|Radiotherapy|RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2;
214636649|NCT07015853|DRUG|Axatilimab|Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
214636650|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
214636651|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
214636652|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
214636653|NCT07019376|OTHER|Visual biofeedback supported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be followed visually with the help of a laser.
214636654|NCT07019376|OTHER|visual biofeedback unsupported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be the same exercises as the group with laser support, but no visual support will be provided.
214636655|NCT06245603|DEVICE|Hydeal Cyst®|"BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation."
214636656|NCT07018661|DIAGNOSTIC_TEST|[18F]FAPI-74 PET/CT|Patients included in the study will undergo FAPI-PET/CT after initial staging with gastroscopy and a contrast-enhanced CT of thorax and abdomen, but before undergoing a staging laparoscopy. Based on the results of the FAPI-PET/CT, the MDT and/or treating physician will decide on the next step: confirming possible malignant lesions on PET/CT by biopsies (either percutaneous of by staging laparoscopy), or in case of negative PET/CT, diagnostic laparoscopy.
214636657|NCT07018661|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 will be administered intravenously 60 minutes before PET/CT-scanning to be able to detect (metastases of) gastric cancer
214636660|NCT06627517|DEVICE|Episodic overnight patch pump|Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.
214636661|NCT06631872|BEHAVIORAL|Tele-prehabilitation education session: Surgery School|Online telehealth education program using videos and a live clinician facilitator
214636662|NCT06631872|BEHAVIORAL|Individualised Inspiratory Muscle Training and Walking Program|An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.
214636663|NCT06631872|OTHER|Usual Care|Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
214636664|NCT07023003|DRUG|Enalapril 10mg QD|Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
214636665|NCT07023003|DRUG|Nifedipine 30mg XL BID|Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
214636666|NCT07023705|DIAGNOSTIC_TEST|Monocyte to Large Platelet Ratio (MLPR)|Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.
214636667|NCT07025720|DEVICE|TMS|"The protocol involves delivering sessions of intermittent theta burst stimulation (iTBS) of 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation sessions will be delivered hourly. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation will be delivered at 90% resting motor threshold (rMT) adjusted for cortical depth.~MR brain imaging will be used with the Localite Neuronavigation System (Localite GmbH, Sankt Augustin, Germany) to position the TMS coil over the individualized stimulation target."
214636668|NCT07023614|DRUG|Ninerafaxstat 200mg MR|Ninerafaxstat 200mg Modified Release tablet administered BID
214636669|NCT07023614|DRUG|Placebo|Matching placebo tablet administered BID
214636670|NCT07029295|OTHER|Sending a link to the video|Sending a link to the educational video (3 min, 34 sec.) prepared as part of the study, explaining the importance of proper preparation and the diet to follow.
214636671|NCT07029295|BEHAVIORAL|Compliance questionnaire|Patient completes a questionnaire on compliance with preparation instructions on the day of the imaging test.
214636672|NCT07029295|BIOLOGICAL|Determination of beta-hydroxybutyrate (BHB) in capillary blood|Determination of beta-hydroxybutyrate (BHB) in capillary blood prior to imaging examination.
214636675|NCT07029113|OTHER|Task-oriented trainig|In addition to MCP, PIP, DIP joint mobilisation and isometric exercises, the task-oriented training group will perform 30 repetitions of face washing, using a fork, drinking water with a glass, sitting and wearing a t-shirt exercises.
214636676|NCT07029113|OTHER|Mulligan mobilization|In patients included in the Mulligan mobilisation group, the therapist will apply a dorsal shift from the distal radius to the carpal bones and the patient simultaneously extends the wrist. It is essential that the movement is painless; if any pain occurs during mobilisation, the direction or technique is re-evaluated. This application is performed in 8-10 repetitions and the frequency of the session is planned according to the patient's symptoms.
214636677|NCT07029113|OTHER|Conventional treatment|Passive range of motion exercises, metacarpopalangeal, proximal interphalangeal and distal interphalangeal joint mobilisation and isometric exercises will be applied. Isometric exercises will be performed as 30 repetitions, while joint mobilisations will be performed by the therapist as moderate anteroposterior and mediolateral shifts.
214636678|NCT07028788|OTHER|Health Education Material|Weekly electronic health education handbooks covering nutrition, sleep, shift work, stress awareness, and digital device use.
214636679|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness|Guided mindfulness practice via mobile app using pre-recorded 360° natural environment video.
214636680|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness combined with Breathing|Mindfulness training combined with brief structured breathing exercises via mobile app using 360° nature video.
214636681|NCT07028788|BEHAVIORAL|VR-Based Mindfulness combined with Breathing|Virtual reality-delivered mindfulness and structured breathing training using immersive 360° natural environment video.
214724261|NCT00143988|BEHAVIORAL|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
214724262|NCT00143988|BEHAVIORAL|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
214724263|NCT02458677|DRUG|PRX003|
214724264|NCT02458677|OTHER|Placebo|
214724265|NCT00910728|DRUG|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
214724266|NCT05771506|OTHER|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
214724267|NCT05771506|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
214724268|NCT05771506|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
214724269|NCT05771506|OTHER|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
214724270|NCT05771506|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
214724271|NCT05771506|OTHER|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
214724272|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
214724273|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
214724274|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
214724275|NCT00292955|DRUG|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
214724276|NCT00004125|DRUG|cyclophosphamide|
214724277|NCT00004125|DRUG|docetaxel|
214724278|NCT00004125|DRUG|doxorubicin hydrochloride|
214724279|NCT00004125|DRUG|paclitaxel|
214724280|NCT00004125|DRUG|tamoxifen citrate|
214724281|NCT00004125|RADIATION|radiation therapy|
214724282|NCT00308243|DRUG|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
214724283|NCT02048358|DRUG|2B3-201|
214724284|NCT02048358|DRUG|Placebo|
214724285|NCT02048358|DRUG|Methylprednisolone hemisuccinate|
214724286|NCT05834101|OTHER|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
215030501|NCT06637670|OTHER|Kinesiology taping|'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
215030502|NCT06637670|OTHER|Placebo taping|A tape without tension was applied perpendicular on the quadriceps femoris muscle.
215030503|NCT06638775|OTHER|Fesia Grasp|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
215030504|NCT06638775|OTHER|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
214724287|NCT05834101|OTHER|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
214724288|NCT05300646|BEHAVIORAL|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
214724289|NCT00431496|DRUG|Cinacalcet|Cinacalcet tablets
214636682|NCT07028554|DEVICE|Cartridges of Disposable Endoscopic Linear Cutting Staplers, Disposable Powered|Investigational devices encompassing all models of the Cartridges for Disposable Endoscopic Linear Cutting Staplers, as well as Staplers utilized in conjunction with the Cartridges specified in the Study Plan (Plan number: WEKD-QS-PMCF).
214636683|NCT07028151|OTHER|manual therapy|"Participants who meet the inclusion criteria will be evaluated following the acquisition of written informed consent. Treatment will be administered with participants in the supine position. Initially, soft tissue mobilization will be applied to the cervical extensor muscle group, followed by gentle cervical vertebral traction. Subsequently, a classical facial massage will be performed. The massage will include the suprahyoid muscles and the medial pterygoid. Intramuscular stretching and friction massage techniques will be applied to the masseter and anterior temporalis muscles. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions."
214636684|NCT07028151|OTHER|Conventional Therapy|Participants who meet the inclusion criteria will be evaluated after providing written informed consent. Treatment will be administered with participants in the supine position. Protective goggles will be placed on the participants' eyes prior to the infrared therapy application. Following 20 minutes of infrared treatment, ultrasound (1 MHz) will be applied to the masseter muscle using the full-contact method for 3 minutes. Finally, transcutaneous electrical nerve stimulation (TENS) will be applied to the masseter and anterior temporalis muscles for 15 to 20 minutes. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions.
214636685|NCT06876935|OTHER|Daily avocado|Infants in the daily avocado group will receive a daily exposure amount of avocado ranging from 1/4 (\~37.5 g or 1.25 oz) to 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado. At 6-8 months, infants will be provided 1/4 (\~37.5 g or 1.25 oz) of a medium-sized avocado for daily consumption. Then from 9-12 months, they will begin receiving 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado for daily consumption.
214724290|NCT05037916|OTHER|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
214724291|NCT05795868|DEVICE|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
214724292|NCT05795868|OTHER|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
214724293|NCT00361218|DRUG|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
214724294|NCT03581682|OTHER|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
214724295|NCT02938507|DRUG|Formulation 1 solabegron|
214724296|NCT02938507|DRUG|Formulation 2 solabegron|
214724297|NCT01703104|DRUG|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
214724298|NCT01703104|DIETARY_SUPPLEMENT|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
214724299|NCT01505972|OTHER|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
214724300|NCT01505972|OTHER|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
214724301|NCT05024617|OTHER|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
214724302|NCT04777123|OTHER|sitting position|patients will be left seated for 2 minutes after subarachnoid injection
214724303|NCT05527106|DIETARY_SUPPLEMENT|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
214724304|NCT05527106|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
214724305|NCT05527106|DIETARY_SUPPLEMENT|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
214724306|NCT05527106|DIETARY_SUPPLEMENT|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
214724307|NCT01248585|DRUG|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
214724308|NCT01248585|DRUG|Placebo|2 placebo tablets taken once daily for 5 days
214724309|NCT06382961|DRUG|Dexmedetomidine injection|Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
214724310|NCT06382961|DRUG|Sufentanil injection|3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
214724311|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
214724312|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
214724313|NCT00820807|OTHER|Placebo|oral consumption in beverage
214636686|NCT04312113|DRUG|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
214636687|NCT07137143|OTHER|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.
214636688|NCT07027995|BEHAVIORAL|Exercise is Medicine (EIM)|During Phase 1 (Weeks 1-12), participants are enrolled in a comprehensive 12-week fitness education and training program.
214636689|NCT07027995|BEHAVIORAL|Culinary Education|During Phase 1 \& 2, participants receive monthly hybrid cooking demonstrations with culinary training.
214636690|NCT07027995|BEHAVIORAL|Food is Medicine|During Phase 1 (Weeks 1-12), participants receive bi-weekly medically tailored grocery vouchers.
214636691|NCT07027995|BEHAVIORAL|Nutrition Counseling|During Phase 1 (Weeks 1-12), participants engage in weekly behavioral nutrition counseling.
214636692|NCT07027995|BEHAVIORAL|Participant Website|During Phases 1 and 2, participants will receive digital behavioral reinforcers and access to a secure web portal that provides evidence-based resources.
214636693|NCT07032844|BEHAVIORAL|Digital Health Coaching|This program will be developed using existing, evidence-based curricula for chronic disease self-management, with emphasis on diabetes, hypertension, and obesity. Prior to initiating health coaching with participants, coaches will review data collected related to SDoH to further tailor the intervention as appropriate for housing stability, access to food and transportation, and interpersonal safety. All coaches will have access to participants' EMRs such that they can view medical information throughout the intervention. Coaches will be trained using a curriculum developed by Family and Community Medicine's inter-professional care team and our partners at NCHPAD, making the coaching inclusive of people with physical disabilities, such that the coaches are proficient in motivating behavior change related to resilience, physical activity, nutrition, mindfulness, and relationship-building, among others.
214636694|NCT07032844|BEHAVIORAL|Phone Based Coaching|Weekly coaching calls that address topics related to goal setting, creating supportive environments for behavior change, physical activity, and nutrition.
214636695|NCT07032844|BEHAVIORAL|Combination of Digital Health coaching + Remote Patient Monitoring|Combination of both digital health coaching and remote patient monitoring
214636696|NCT05907629|OTHER|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
214636697|NCT06728410|DRUG|Pemigatinib|Pemigatinib 13.5 mg
214636698|NCT06728410|DRUG|Durvalumab|Durvalumab 1500 mg IV
214636699|NCT06738303|DRUG|Cabazitaxel and carboplatin|Given IV
214636700|NCT06738303|DRUG|Lu-PSMA-617|Given IV
214636701|NCT06744374|DRUG|BGF|Budesonide/glycopyrrolate/formoterol fumarate
214636702|NCT06744374|DRUG|MITT|Multiple-inhaler triple therapy
214636703|NCT07127081|BEHAVIORAL|Stress ball|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
214636704|NCT07127081|BEHAVIORAL|Cartoons|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
214636705|NCT06774547|OTHER|Heavy-slow resistance training|Heavy-slow resistance training consists of a progressive protocol of dynamic exercises where the relative load increases over time from a weight that can only be lifted 15 times (i.e., 15 repetition maximum) during the first week to a relative load of 6 repetition maximum from Week 9 to 12. The exercises are performed unsupervised three days per week separated by a minimum of 48 hours. There are two exercises that are performed for four sets separated by a 2-minute rest. Participants with Achilles tendinopathy or plantar fasciopathy perform seated and standing weighted heel raises and participants with patellar tendinopathy perform a free-standing squat and a seated leg press. Tolerable pain during the exercises is allowed.
214636706|NCT06774547|OTHER|Plyometric exercise|The progressive plyometric programme consists of three different levels and is performed unsupervised three times per week separated by a minimum of 48 hours. Each level consists of several exercise sets that are separated by 2-minute rest intervals. Participants' self-evaluated readiness to progress to a higher level will guide the progression. Level 1 includes free-standing double-legged plyometric exercises where they push off the ground and lift their heels while maintaining contact with it. If the participant feels they can do more, they will progress to Level 2, where participants increase the relative load during the dynamic exercises and start performing plyometric double-legged jumps. At the highest level, Level 3, the relative load during the exercises is further increased, and the plyometric exercises are to be performed as single-legged hops. Tolerable pain during the exercises is allowed.
214636707|NCT07070076|PROCEDURE|Yttrium-90|Step 1: The MDT team conducts a routine preoperative assessment. Step 2: The interventional team performed tumor vascularity distribution and 99mTc simulation surgery. Step 3: Nuclear Medicine performs SPECT validation and yttrium-90 treatment activity calculation. Step 4: Infusion of yttrium-90 microspheres in the interventional department. Step 5: Nuclear Medicine uses PET/CT or SPECT to determine the distribution of nuclides. If the patient is unwell, he or she can be discharged after 24 hours without special protection. Follow-up examination 1 month after surgery, and then every 2 months, a total of 1 course of treatment. After yttrium-90 treatment, rest for 3-4 months, and arrange hepatectomy after excluding surgical contraindications. The patients in both groups were consulted and discussed by multidisciplinary experts in liver cancer, and elective hepatectomy was arranged after excluding surgical contraindications according to the standardized process.
214724314|NCT04822311|BEHAVIORAL|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
214636708|NCT07070076|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriography and hepatic arteriography are performed, and after the hepatic artery is cannulated to a predetermined position, the patient is returned to the ward with an indwelling catheter. In the ward, a catheter syringe pump is continuously pumped into the following chemotherapy drugs: oxaliplatin 135mg/m2 over 3hrs, leucovorin 400mg/m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs. After the chemotherapy is completed, the catheter is removed, and the patient can be discharged after 12 hours of compression bandaging to stop the bleeding. Repeat at intervals of 3\~4 weeks, a total of 2 or 4 strokes. For details, see 3.3.1.4 Grouping and Treatment Flow Chart. After the end of HAIC, rest for 3\~4 weeks for re-examination, and arrange liver resection after excluding surgical contraindications.
214636709|NCT07063251|GENETIC|HG005|Once subretinal injection; The duration of the study is about 52 weeks for each subject, including a 4 weeks screening period, enrollment visit, treatment visit, and 56 weeks follow-up period.
214636710|NCT06898905|OTHER|Bridging Radiation Therapy|Study seeks to compare the hypofractionated radiation therapy with hyperfractionated treatment within the same tumor. Each participant will be serving as their own control; half their tumor will receive once daily hypofractionated (QD) bridging radiotherapy, and the other half of their tumor will receive twice daily hyperfractionated (BID) bridging radiotherapy. Either schedule is considered standard of care and this study aims to determine which schedule may prove superior between the two standards.
214636711|NCT07072598|DEVICE|ClearPETRA suction access sheath|Ureteroscopy utilizing the ClearPETRA suction access sheath.
214636712|NCT07072598|DEVICE|ClearPETRA suction access sheath|Mini-PCNL utilizing the ClearPETRA suction access sheath
214636713|NCT02494869|BEHAVIORAL|Nonlinear Aerobic Training|
214636714|NCT02494869|OTHER|Height, Weight, BMI measure|
214636715|NCT02494869|OTHER|Blood draw|
214636716|NCT02494869|OTHER|Cardiopulmonary exercise test|
214636717|NCT06844500|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
214636718|NCT06844500|BIOLOGICAL|MVA-BN standard regimen (Administered as PEP)|"MVA-BN. Post Exposure Prophylaxis (PEP)~The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.~For Maternal Group 3, MVA-Bn will be administered as PEP as soon as possible after exposure, preferably within 4 days after exposure. However, as per WHO guidelines, PEP will be offered up to 14 days after exposure if the pregnant woman has not yet developed symptoms."
214636719|NCT01844986|DRUG|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
214636720|NCT05077137|BIOLOGICAL|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
214636721|NCT05077137|BIOLOGICAL|Polio Boost Immunization|trivalent inactivated polio vaccine
214724315|NCT02954445|BIOLOGICAL|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214636722|NCT06863480|DRUG|tocilizumab-aazg (TYENNE)|A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.
214636723|NCT05624268|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
214636724|NCT05043012|DEVICE|flexible AIR coil|mpMRI scan
214636725|NCT05043012|DEVICE|endorectal coi|mpMRI scan
214636726|NCT02028455|BIOLOGICAL|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
214636727|NCT00648635|BEHAVIORAL|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
214636728|NCT07078461|DEVICE|1927-nm Thulium Laser therapy|The investigators will use the LaseMD LEO Laser System (1927-nm Thulium laser) to create controlled, localized microscopic treatment zones (MTZs) of thermal injury to treatment area (unilateral upper arm). The investigators will utilize the random mode using the C1 tip (spot size 200 micrometers), which involves irradiation of the entire upper arm until diffuse erythema and edema appear. Additionally, the investigators may use the C5 tip (350 micrometers spot size) for focused treatment, up to five passes, until coagulation becomes evident. The maximum fluence for all C1 tip is 3-60 J/cm2 and 1-20 J/cm2 for C5 tips. The maximum pulse energy is 20 J with a pulse duration of 20 ms.
214636729|NCT07135427|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Administration of PCV20
214636730|NCT06909825|DRUG|FPI-2265|PSMA ligand radiolabeled with Ac225
214636731|NCT06909825|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor
214636732|NCT06911229|DEVICE|Deep Brain Stimulation (DBS)|Patients will receive DBS in the clinically-optimized setting.
214636733|NCT07131891|OTHER|Fatigue Severity Scale|"Individuals' fatigue severity will be assessed using the Fatigue Severity Scale (FSS). The scale consists of nine questions, and participants are asked about their fatigue level over the past week. Questions are scored from 1 to 7 using a Likert-type scale, where 1 corresponds to strongly disagree and 7 to strongly agree, with higher scores indicating greater agreement. The total score is calculated by taking the arithmetic mean of all items, with the highest possible score being 7. Scores of 4 and above indicate pathological fatigue. The validity and reliability of the FSS in Turkish have been previously established."
214636734|NCT07131891|OTHER|Depression, Anxiety and Stress Scale-21|"The 21-item Depression, Anxiety, and Stress Scale (DASS-21) will be administered to assess individuals' levels of depression, anxiety, and stress. The original scale was developed by Lovibond with 42 items. Subsequently, Brown et al. validated a shorter form for the same purpose and created the 21-item DASS-21. The Turkish adaptation of the DASS-21 was conducted by Yılmaz et al. The scale measures three subscales-depression, anxiety, and stress-consisting of seven items each. It is a 4-point Likert-type scale, with 0 indicating Does not apply to me, 1 Applies to me somewhat, 2 Generally applies to me, and 3 Applies to me completely. All items are scored positively, and each subscale is categorized as normal, mild, moderate, severe, or very severe."
214636735|NCT07131891|OTHER|Jenkins Sleep Scale|The Jenkins Sleep Scale consists of four questions that assess sleep problems over a four-week period. Each question is scored from 0 to 5, resulting in a total score ranging from 0 to 20, with higher scores indicating greater sleep disturbances.
214636736|NCT07131891|OTHER|Epworth Sleepiness Scale|The Epworth Sleepiness Scale (ESS) was developed to assess daytime sleepiness. It consists of eight items, each scored from 0 to 3, yielding a total score ranging from 0 to 24. Higher scores indicate greater daytime sleepiness. The Turkish version of the scale was validated for reliability and accuracy by İzci et al. in 2008..
214636737|NCT07131891|OTHER|Short Form-36|Quality of life will be assessed using the Turkish version of the Short Form-36 (SF-36). The SF-36 assesses quality of life under eight subscales: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for each subscale are calculated separately, ranging from 0 to 100, with higher scores indicating better health status. A total score is not calculated.
214636738|NCT06929143|DRUG|Aflibercept (Eylea, BAY86-5321)|8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).
214636739|NCT07130266|PROCEDURE|Procedure/Surgery: Hyaluronic acid gel application|After root surface cleaning and infected cement removal, 0.8% HA gel was applied to the root surface, bone, and inner surface of the flap and left for 2 minutes.
214636740|NCT07130266|PROCEDURE|giving an impression of the application|In the control group, instead of HA gel, the area was irrigated with physiological saline solution.
214636741|NCT03723083|DRUG|CC-2001|CC-2001 will be administered orally
214636742|NCT00376610|DEVICE|ASR/Re-cap|
214636743|NCT07143994|OTHER|eccentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
214636744|NCT07143994|OTHER|concentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
214636745|NCT07142824|PROCEDURE|burn dressing using Tilapia-Fish Skin|we use tilapia fish skin as a healing dressing in burn patients
214636746|NCT07142824|PROCEDURE|burn dressing using regular dressing|we use regular dressing in burn patients
214636747|NCT07143708|OTHER|Glaucoma Surgery with Amniotic Membrane|Arm 2: Glaucoma Surgery with Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. In this group, the implanted stent is covered with an amniotic membrane patch to reduce postoperative scarring and improve long-term outcomes. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
214636748|NCT07143708|OTHER|Glaucoma Surgery without Amniotic Membrane|Arm 1: Glaucoma Surgery without Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. No modifications are made to the procedure. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
214724316|NCT03718676|PROCEDURE|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
214724317|NCT03718676|PROCEDURE|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
214724318|NCT03718676|PROCEDURE|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
214636749|NCT07142876|PROCEDURE|Liver resection Cavitron Ultrasonic Surgical Aspirator (CUSA)|In-group A Cavitron Ultrasonic Surgical Settings Aspirator (CUSA) with standard tip was used for parenchymal transection with the following Settings; 23 kHz, 70 Watt, and continuous irrigation at rate of 4-6 ml/min with normal saline and the vessel coagulation was performed by the bipolar sealer (Valleylab force FX electrosurgical generator, Medtronic, Minneapolis, USA), the power was used at 50 Watt coagulation.
214636750|NCT07142876|PROCEDURE|Liver resection with the harmonic scalpel|In group B the harmonic scalpel (Ethicon EndoSurgery, Johnson \& Johnson, New Jersey, USA) was set at a high power, and blood vessels or bile ducts up to 3-4 mm in diameter were coagulated for 5-6 seconds.
214636751|NCT07144228|DEVICE|HeLP TM|lab test for prostate cancer
214636752|NCT07143045|DRUG|zorifertinib|Cohort A and B will receive zorifertinib as first line treatment
214636753|NCT07143916|PROCEDURE|bonded anterior bite turbos|Sixty patients with anterior deep bite malocclusion were treated with composite bite turbos bonded to the maxillary central incisors. A questionnaire form using the Likert scale with 5 responses (very unpleasant, unpleasant, acceptable, pleasant and very pleasant) was used by patients to document their satisfaction and feedback regarding the bite turbos after 1 week and 1 month.
214636754|NCT07142889|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
214636755|NCT07142889|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
214636756|NCT07142889|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
214636757|NCT07143253|PROCEDURE|Preventive pit and fissure sealant application|"Preventive pit and fissure sealant application is a preventive procedure involving the use of flowable resin-based or glass ionomer-based materials to physically cover the occlusal surfaces of teeth, particularly in pits and fissures at high risk of caries development. This barrier prevents plaque accumulation and protects the enamel surface.~In this study, no procedures beyond the routine clinical application of the materials will be performed. However, partially erupted permanent teeth with challenging isolation will be specifically selected. Both materials will be applied using a split-mouth design to the teeth of the same participant. This approach will allow for an effective and comparative evaluation of the clinical retention of the material."
214636758|NCT07142759|OTHER|Precision Bred Provitamin D-rich Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
214636759|NCT07142759|OTHER|Precision Bred Vitamin D-rich Tomato Soup|Participants will consume one tomato soup everyday for 21-days as part of their normal diet.
214636760|NCT07142759|OTHER|Wild-type (store-bought) Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
214636761|NCT07142759|OTHER|Wild-type (store-bought) Tomato with vitamin D supplementation Soup|Participants will consume one tomato soup everyday for 21 days as part of their normal diet.
214636762|NCT07143851|OTHER|Not applicable- observational study|There is no special intervention method
214636763|NCT07144501|DIAGNOSTIC_TEST|Ultrasonography|Ultrasound, also known as sonography or ultrasonography, is a medical imaging technique that uses high-frequency sound waves to create real-time images of internal body structures
214636764|NCT07144501|PROCEDURE|Blood Sampling|"To assess hepatic function in congenital heart disease (CHD) patients, blood samples will be collected from all patients in our study for:~* Alanine Transferase (ALT).~* Aspartate Aminotransferase (AST).~* Gamma Glutamyl Transferase (GGT).~* Alkaline Phosphatase (ALP).~* Total/direct bilirubin.~* Albumin.~* Prothrombin time.~* International Normalized Ratio (INR).~* Platelet count."
214636765|NCT07143890|OTHER|Meal A|Iron chlorophyllin + water
214636766|NCT07143890|OTHER|Meal B|Soy hemoglobin + water
214636767|NCT07143890|OTHER|Meal C|FeSO4 (negative control) + water
214636768|NCT07143890|OTHER|Meal D|Porcine hemoglobin (positive control) + water
214636769|NCT07143890|OTHER|Meal E|Iron chlorophyllin + maize porridge
214636770|NCT07143890|OTHER|Meal F|Soy hemoglobin + maize porridge
214636771|NCT07143890|OTHER|Meal G|FeSO4 (negative control) + maize porridge
214636772|NCT07143890|OTHER|Meal H|Porcine hemoglobin (positive control) + maize porridge
214636773|NCT07144254|DRUG|Tegavivint|Tegavivint will be administered second, IV over 4 hours, on days 1, 8, and 15 at the dose level assigned at study entry Cycle length will be 21 days. A cycle may be repeated for a total of 17 cycles, up to a total duration of therapy of approximately 12 months.
214636774|NCT07144254|DRUG|Gemcitabine|Gemcitabine will be administered first, intravenously (IV) over 60 minutes, on days 1 and 8 at a fixed dose of 1000 mg/m2
214636775|NCT07143097|DRUG|capecitabine|capecitabine 650 mg / m2 twice per day for one year
214636776|NCT07144709|DRUG|Phytotherapy|Phytotherapy or alphablockers
214636777|NCT07143500|OTHER|Selected physical therapy program|Passive stretching, active range of motion exercises, isometric strengthening, and functional gripping practice for the hand
214636778|NCT07143500|OTHER|Task Oriented Training for Upper limb|Seated in chair with arm and back support, with forearms resting on a table 73 cm high. Functional movements were trained through task-oriented exercises involving simple activities of daily living(ADL), such as eating (using a plate and spoon), personal hygiene (combing hair, brushing teeth), and tasks using household items (e.g., handling a cup and spoon, or opening a bottle and cap). Each task was repeated five times. Patients were allowed rest periods of five minutes as needed during the exercise sessions.
214636779|NCT07143500|OTHER|Action Observation Training Program|sat comfortably in a chair or wheelchair with both arms resting on a table (73 cm high) positioned 50 cm from a 15.6-inch colored laptop screen. They were instructed to attentively observe action videos displayed on the screen and then imitate the observed movements using their affected upper limb. A total of 30 action videos were used, each lasting approximately 50 seconds and demonstrating specific upper limb movements, such as wrist flexion/extension, abduction/adduction, pronation/supination, ulnar/radial deviation, and various grasping and manipulation tasks (e.g., handling coins, pens, a computer mouse, jar lids, bottle caps, typewriting, dialing a phone, and feeding).
214636780|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
214636781|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
214636782|NCT07143305|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|All participants engaged in a multicomponent physical exercise programme designed specifically for older adults. The programme was based on the latest evidence and international recommendations for sarcopenia and functional maintenance in ageing population
214636783|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy|The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.
214724319|NCT01369446|DEVICE|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
214724320|NCT05664555|DRUG|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
214724321|NCT01399840|DRUG|BMN 673|Oral capsule with multiple dosage forms given once daily
214724322|NCT04165304|DIETARY_SUPPLEMENT|sugar reduction|sugar reduction in the offered drinks
214724323|NCT06391567|OTHER|There was no intervention in this study.|There was no intervention in this study.
214724324|NCT01010269|DEVICE|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
214724325|NCT01010269|DEVICE|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
214724326|NCT02949713|BEHAVIORAL|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
214724327|NCT02820688|DRUG|Bupivacaine 0.25%|
214724328|NCT02820688|DRUG|Prilocaine 1%|
214724329|NCT02820688|PROCEDURE|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
214724330|NCT02820688|DRUG|Bupivacaine 0.167%|
214724331|NCT02820688|DRUG|Bupivacaine 0.125%|
214724332|NCT02820688|DRUG|Prilocaine 0.66%|
214724333|NCT02820688|DRUG|Prilocaine 0.5%|
214724334|NCT02820688|DEVICE|Ultrasound|All nerve blocks will be performed with ultrasound guidance
214724335|NCT00081744|DRUG|Tigecycline|
214724336|NCT01313468|BEHAVIORAL|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
214724337|NCT01313468|BEHAVIORAL|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
214724338|NCT01313468|BEHAVIORAL|Moderate continuous Training|47 minutes of Moderate continuous Training
214724339|NCT00272480|DRUG|Zidovudine/lamivudine|
214724340|NCT00272480|DRUG|Placebos|
214724341|NCT02788591|DRUG|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
214724342|NCT02788591|DRUG|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
214724343|NCT00757367|DRUG|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
214724344|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
214724345|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
214724346|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
214724347|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
214724348|NCT00750217|DRUG|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
214724349|NCT05817981|OTHER|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
214724350|NCT05817981|OTHER|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
214636784|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy|The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.
214636785|NCT07143240|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, clinical data relating to neuropathy, and tedizolid prescription modalities (dose, duration).
214636786|NCT07144345|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
214636787|NCT07144345|OTHER|Vehicle containing excipients only (VEH) without active ingredient|Solution for topical use
214636788|NCT07144345|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E|BLU-U® blue light Photodynamic Therapy (PDT) illuminator
214636789|NCT07143266|OTHER|This is an observational study. No drugs will be administered|Data from objective sleep evaluation (actigraphy, polisomnography and MLST), subjective sleep evaluation (questionnaires), neuroimaging (MRI and PET-CT), ophthalmological evaluation and hormone evaluation (urine and blood) will be collected in a cross-sectional manner, without performing any additional intervention.
214636790|NCT07142980|DRUG|HRS-7172 Tablets|HRS-7172 tablets.
214636791|NCT07142720|DIETARY_SUPPLEMENT|A seaweed extract from brown seaweed, containing fucoidan, laminarin, and the antioxidant phlorotannin.|Portions of the seaweed extract were dissolved in rice milk to help camouflage the strong algae-taste. Plain rice milk served as placebo.
214636792|NCT07143162|BEHAVIORAL|LoveYourBrain Yoga|The LoveYourBrain Yoga program consists of various techniques, including: breathing, Yoga postures, meditation, and psychoeducation as well as a group discussion.
214636793|NCT07142954|OTHER|P-tau217 Test|A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
214636794|NCT07143786|DRUG|iNSC-EV01|Intravenous induced neural stem cell-derived exosome
214636795|NCT07143786|DRUG|Placebo|iNSC-EV01 mimics
214636796|NCT07143357|BEHAVIORAL|Recovering Together after Cardiac Arrest 1|The intervention will teach resiliency skills (mindfulness and coping) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person until the survivor is discharged; remaining sessions will occur over Zoom.
214636797|NCT07143357|OTHER|Recovering Together after Cardiac Arrest 2|In this minimally enhanced usual care control, dyads will participate in one 30-minute session with a clinician at beside to review a pamphlet of available psychosocial resources for cardiac arrest survivors and their caregivers.
214636798|NCT07143773|DRUG|SGLT-2 inhibitor|The intervention in this clinical trial will be treatment with an SGLT2 inhibitor (Forxiga, 10 mg tablet once daily) compared with a matching placebo. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either Forxiga or placebo as an add-on to standard immunosuppressive therapy. This intervention differs from other studies by specifically targeting non-diabetic kidney transplant recipients, a population in which the efficacy and safety of SGLT2 inhibitors have not yet been established.
214636799|NCT07143773|DRUG|Placebo|The control intervention in this clinical trial will be a matching placebo tablet, identical in appearance to Forxiga (10 mg), administered once daily as an add-on to standard immunosuppressive therapy. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either placebo or Forxiga. This placebo intervention ensures blinding of both participants and investigators and allows a direct comparison of the safety and efficacy of SGLT2 inhibition versus no active treatment in this unique patient population.
214636800|NCT05406635|DIAGNOSTIC_TEST|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
214636801|NCT04370301|DRUG|Cyclophosphamide|Given IV
214636802|NCT04370301|DRUG|JAK Inhibitor|Given PO
214636803|NCT04370301|DRUG|Fludarabine|Given IV
214636804|NCT04370301|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
214636805|NCT04370301|DRUG|Melphalan|Given IV
214636806|NCT04370301|DRUG|Mycophenolate Mofetil|Given PO
214636807|NCT04370301|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
214636808|NCT04370301|DRUG|Tacrolimus|Given IV and PO
214636809|NCT04370301|RADIATION|Total-Body Irradiation|Undergo TBI
214636810|NCT04370301|PROCEDURE|Computed Tomography|Undergo CT
214636811|NCT04370301|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214636812|NCT04370301|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214636813|NCT04370301|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214636814|NCT04370301|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214636815|NCT04370301|PROCEDURE|Echocardiography|Undergo ECHO
214636816|NCT04370301|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214636817|NCT00004575|DRUG|Miconazole, L-NMMA, Bradykinin|
214636818|NCT01790503|DRUG|PLX3397|
214636819|NCT01790503|RADIATION|Radiation Therapy|
214636820|NCT01790503|DRUG|Temozolomide|
214636821|NCT01577485|DIETARY_SUPPLEMENT|Probiotics in an pastille|Test group
214636822|NCT01577485|DIETARY_SUPPLEMENT|Control pastille|Control group
214636823|NCT02944630|BEHAVIORAL|Psychotherapy|Individual psychotherapy
214636824|NCT04201483|OTHER|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
214636825|NCT04201483|OTHER|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
214636826|NCT04994106|DRUG|AZD5462|Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
214636827|NCT04994106|DRUG|Placebo|Participants will receive Placebo matched to AZD5462.
214636828|NCT04756375|DEVICE|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
214636829|NCT04756375|OTHER|Usual Care|Usual management of sickle cell patients with VOS
214636830|NCT02977195|DRUG|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
214636831|NCT03770065|DEVICE|VML-0001|Medical device
214636832|NCT02326805|OTHER|Laboratory Biomarker Analysis|Correlative studies
214636833|NCT02326805|OTHER|Placebo Administration|Given SC
214636834|NCT02326805|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
214636835|NCT05150366|PROCEDURE|Trans thoracic echocardiography|trans thoracic echocardiography at the beggining and at the end of the placement of the Saint Jude Medical AMULET type prosthesis
214636836|NCT01961479|BEHAVIORAL|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
214636837|NCT01961479|OTHER|Waiting list|During the waiting period, participants receive no treatment.
214636838|NCT03716089|PROCEDURE|Laparoscopic resection|Laparoscopic surgery under general anesthesia
214636839|NCT00388050|BEHAVIORAL|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
214724351|NCT05065268|DEVICE|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
214724352|NCT01372813|DRUG|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
214724353|NCT00044213|DRUG|EDTA|Participants will receive 40 infusions of standard chelation solution.
214724354|NCT00044213|DRUG|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
214724355|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin|
214724356|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin Placebo|
214724357|NCT03785470|OTHER|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
214724358|NCT05834699|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
214724359|NCT05097170|PROCEDURE|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
214724360|NCT03823430|DIAGNOSTIC_TEST|Pupillometry|Pupillar diameter variation measurement
214724361|NCT01985386|DIETARY_SUPPLEMENT|GDS capsule with meal|GDS capsule with meal
214724362|NCT01985386|DIETARY_SUPPLEMENT|Ferrous sulfate with meal|Ferrous sulfate with meal
214724363|NCT01927068|DEVICE|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
214724364|NCT01529619|DRUG|Rivastigmine transdermal patch|
214724365|NCT05240612|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
214724366|NCT05240612|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
214636840|NCT00388050|BEHAVIORAL|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
214636841|NCT02212132|OTHER|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
214636842|NCT00002800|BIOLOGICAL|filgrastim|
214636843|NCT00002800|BIOLOGICAL|lintuzumab|
214636844|NCT00002800|DRUG|cytarabine|
214636845|NCT00002800|DRUG|etoposide|
214636846|NCT00002800|DRUG|idarubicin|
214636847|NCT00865384|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
214636848|NCT00865384|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
214636849|NCT04295070|BIOLOGICAL|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
214636850|NCT04295070|BIOLOGICAL|Normal saline|Saline (0.9%) administered via dropper
214636851|NCT00859365|PROCEDURE|Real Acupuncture|Real acupuncture treatment in real acupuncture points
214636852|NCT00859365|PROCEDURE|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
214636853|NCT00859365|PROCEDURE|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
214636854|NCT01976923|DRUG|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
214636855|NCT01976923|PROCEDURE|Small-gauge pars plana vitrectomy|
214724367|NCT04907812|DRUG|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
214724368|NCT04907812|PROCEDURE|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
214724369|NCT01054612|OTHER|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
214724370|NCT02121314|DRUG|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
214724371|NCT00128752|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
214724372|NCT01507571|OTHER|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
214724373|NCT00735527|DRUG|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
214724374|NCT00735527|DRUG|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
214724375|NCT00880607|DRUG|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
214724376|NCT00880607|DRUG|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
214724377|NCT03704389|BEHAVIORAL|Clinical decision support|Clinical decision support nudges within the electronic health record
214724378|NCT05846269|OTHER|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
214724379|NCT03933072|PROCEDURE|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
214724380|NCT03933072|BIOLOGICAL|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
214724381|NCT03933072|PROCEDURE|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
214724382|NCT02104141|DEVICE|ROIA Interbody Cage with VerteBRIDGE plating|
214724383|NCT00331084|DRUG|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
214724384|NCT00331084|DRUG|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
214724385|NCT00433667|DRUG|RWJ-333369|
214724386|NCT04616794|BEHAVIORAL|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
214724387|NCT04616794|BEHAVIORAL|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
214724388|NCT04616794|BEHAVIORAL|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
214724389|NCT04616794|BEHAVIORAL|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
214724390|NCT00444418|DRUG|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
214724391|NCT00444418|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
214724392|NCT00444418|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
214724393|NCT02963766|DRUG|Dulaglutide|Administered SC
214724394|NCT02963766|DRUG|Placebo|Administered SC
214724395|NCT06135454|PROCEDURE|Open Wedge High Tibial Osteotomy|For OWHTO,The osteotomy plane, directed from 30 to 35 mm distal to the medial tibial plateau to 10-15 mm distal to the lateral tibial plateau in the coronal plane, was marked by two Kirschner wires with threaded tips. A transverse osteotomy was performed, leaving the lateral cortex intact as a hinge. After the ascending osteotomy and opening. The medial opening gap was filled with two β-TCP wedges and fixed with a TomoFix anatomical plate and locking screws .
214724396|NCT06135454|PROCEDURE|Double Level Osteotomy|The DLO was started from a lateral DFO. A 5-6-cm incision was made proximally at the distal femur from the lateral femoral epicondyle.Two Kirschner wires with threaded tips were inserted to make a length between the wires that was preoperatively planned as the lateral closed osteotomy. Transverse and ascending osteotomies were performed using a Precision Oscillating Tip Saw. The gap was closed and fixed using a TomoFix medial distal femur anatomical plate , which was bent for the lateral distal femur. The subsequent OWHTO was performed as described above.
214724397|NCT05695404|PROCEDURE|Segmentectomy|Lung resection
214724398|NCT00499460|DIETARY_SUPPLEMENT|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
214724399|NCT00499460|DRUG|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
214724400|NCT00662727|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
214724401|NCT00662727|DEVICE|Placebo|Placebo
214636856|NCT05410548|OTHER|Standard-of-Care|Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
214636857|NCT05410548|OTHER|Clinical Screening|Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
214636858|NCT03509220|DRUG|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
214636859|NCT03509220|DRUG|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
214636860|NCT02599584|BEHAVIORAL|precritical staff|free pre critical scenario team staff
214636861|NCT05233657|DRUG|JX11502MA|Oral capsule
214636862|NCT05233657|DRUG|Placebo|Oral capsule
214636863|NCT00135304|DRUG|Sensipar®|Cinacalcet hydrochloride
214724402|NCT06025084|DRUG|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
214724403|NCT05899894|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
214636864|NCT00135304|DRUG|Vitamin D|Vitamin D administered IV
214636865|NCT03269344|DRUG|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
214636866|NCT03269344|DRUG|Placebo Oral Capsule|Placebo
214636867|NCT06248957|COMBINATION_PRODUCT|Immunomodulation|Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
214724404|NCT03432572|DRUG|Pyridium|a urine discoloration agent
214724405|NCT03432572|DRUG|Riboflavin|a urine discoloration agent
214724406|NCT03432572|DRUG|Thiamine|active placebo not known to cause urine discoloration
214724407|NCT00546507|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
214724408|NCT00546507|DRUG|celecoxib|
214724409|NCT00546507|OTHER|placebo|
214724410|NCT04628273|PROCEDURE|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
214724411|NCT00814307|DRUG|CP-690,550|5mg CP-690,550 BID PO for 6 months
214724412|NCT00814307|DRUG|CP-690,550|10 mg CP-690,550 BID PO for 6 months
214636868|NCT02597855|DRUG|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
214636869|NCT02597855|DRUG|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
214636870|NCT00002944|DRUG|carboplatin|Given IV
214636871|NCT00002944|DRUG|lomustine|Given IV
214636872|NCT00002944|DRUG|procarbazine hydrochloride|Given PO
214636873|NCT00002944|DRUG|thioguanine|Given PO
214636874|NCT00002944|DRUG|vincristine sulfate|Given PO and IV
214636875|NCT01236456|DRUG|Cyclophosphamide|
214636876|NCT05995392|DRUG|Topical spironolactone ophthalmic solution, 0.005 mg/cc|Used four times a day in both eyes for 4 weeks.
214636877|NCT05995392|DRUG|Placebo|Used four times a day in both eyes for 4 weeks.
214636878|NCT05220592|BEHAVIORAL|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
214636879|NCT01449708|DRUG|TIVA NoNarc|"* patients in both groups receive antiemetic prophylaxis~* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~* postop management in both groups is similar in both groups"
214636880|NCT02977923|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
214724413|NCT00814307|DRUG|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
214724414|NCT00814307|DRUG|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
214724415|NCT04459923|PROCEDURE|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
214636881|NCT02977923|OTHER|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
214636882|NCT01231165|DRUG|Amiloride|5mg/daily for 12th months
214636883|NCT01231165|DRUG|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
214636884|NCT05982262|OTHER|Naturopathic-pharmacological consultation|The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
214636885|NCT01894204|OTHER|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
214636886|NCT00559507|DRUG|saracatinib|
214636887|NCT00559507|OTHER|laboratory biomarker analysis|Correlative studies
214636888|NCT01548001|DRUG|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
214636889|NCT01548001|DRUG|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
214636890|NCT02250014|PROCEDURE|cryotherapy|Undergo cryotherapy
214636891|NCT02250014|BIOLOGICAL|sargramostim|Given subcutaneously
214636892|NCT06335550|PROCEDURE|Robotic mastectomy|Robotic mastectomy with or without reconstruction
214636893|NCT02889796|DRUG|Filgotinib|200 mg or 100 mg tablet(s) administered orally once daily
214636894|NCT02889796|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
214636895|NCT02889796|DRUG|Adalimumab|40 mg administered via subcutaneous injection once every two weeks
214636896|NCT02889796|DRUG|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
214636897|NCT02889796|DRUG|MTX|Commercially sourced tablet(s) administered orally
214636898|NCT00360659|DEVICE|Continuous Positive Airway Pressure|
214636899|NCT04418687|DEVICE|Orthoglide|Knee rehabilitation device.
214636900|NCT04418687|OTHER|Physiotherapy only|Physiotherapy only.
214636901|NCT03346460|OTHER|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
214636902|NCT03346460|RADIATION|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
214636903|NCT03346460|RADIATION|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
214636904|NCT01629797|BEHAVIORAL|Educational script on Acne|An educational script on Acne will be presented by investigator
214636905|NCT00697671|OTHER|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
214636906|NCT00697671|BIOLOGICAL|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214636907|NCT00697671|DEVICE|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214636908|NCT00697671|DRUG|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214636909|NCT00697671|DRUG|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214724416|NCT04459923|PROCEDURE|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
214724417|NCT03871465|DRUG|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
214724418|NCT03871465|PROCEDURE|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
214724419|NCT03871465|DRUG|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
214724420|NCT04509362|DEVICE|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
214636910|NCT00697671|DRUG|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214636911|NCT00697671|DRUG|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
214636912|NCT06414512|DRUG|AMBITION trial control|Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
214636913|NCT06414512|DRUG|Flucytosine|Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
214636914|NCT01394081|OTHER|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
214636915|NCT01394081|OTHER|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
214636916|NCT03491332|DEVICE|conventional circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
214636917|NCT03491332|DEVICE|conventional humidification circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
214636918|NCT03491332|DEVICE|new humidifaction heat circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
214636919|NCT02831465|BEHAVIORAL|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
214636920|NCT01407926|OTHER|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
214636921|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
214636922|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
214636923|NCT04672161|OTHER|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
214636924|NCT02814565|DRUG|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
214636925|NCT02814565|DRUG|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
214724421|NCT05448508|DEVICE|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
214724422|NCT04313088|DRUG|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
214724423|NCT05625633|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
214636926|NCT06549452|DEVICE|mHealth Intervention|Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
214636927|NCT06549452|DEVICE|Usual Care|Routine medical care
214636928|NCT04747418|PROCEDURE|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
214636929|NCT04747418|PROCEDURE|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
214636930|NCT01414257|DRUG|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
214636931|NCT01411345|RADIATION|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
214636932|NCT01411345|RADIATION|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
214636933|NCT04607083|DIAGNOSTIC_TEST|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
214636934|NCT06961357|DRUG|Cyclophosphamide|Part of lymphodepletion regimen.
214636935|NCT06961357|DRUG|Fludarabine|Part of lymphodepletion regimen.
214636936|NCT06961357|DRUG|Interleukin-2|Standard of care.
214636937|NCT06961357|DRUG|TIL Product|Tumor-infiltrating lymphocytes are an investigational, personalized adoptive cell therapy.
214636938|NCT04631029|BIOLOGICAL|Atezolizumab|Given IV
214636939|NCT04631029|DRUG|Carboplatin|Given IV
214636940|NCT04631029|DRUG|Entinostat|Given PO
214636941|NCT04631029|DRUG|Etoposide|Given IV
214724424|NCT05625633|OTHER|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
214724425|NCT02740218|OTHER|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
214724426|NCT05797363|OTHER|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
214724427|NCT02693236|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
214724428|NCT05337150|BEHAVIORAL|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
214724429|NCT05337150|BEHAVIORAL|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
214724430|NCT05337150|BEHAVIORAL|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
214724431|NCT00118469|BEHAVIORAL|Psychoeducation|
214724432|NCT00118469|BEHAVIORAL|Cognitive behavior therapy|
214724433|NCT00002657|BIOLOGICAL|bleomycin sulfate|5 mg/m\^2
214724434|NCT00002657|BIOLOGICAL|recombinant interferon alfa|3.0 x 10\^6 IU/m\^2
214724435|NCT00002657|DRUG|cyclophosphamide|650 mg/m\^2
214724436|NCT00002657|DRUG|cytarabine|300 mg/m\^2
214636942|NCT05006885|DRUG|ALT-801|Injected subcutaneously (SC)
214636943|NCT05006885|OTHER|Placebo|Injected subcutaneously (SC)
214636944|NCT02516748|BEHAVIORAL|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
214636945|NCT01882907|DRUG|vildagliptin|vildagliptin 50mg bid for 16 weeks
214636946|NCT01882907|DRUG|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
214636947|NCT06242483|OTHER|Elfie Solution|"The Elfie solution was designed to improve knowledge, adherence, and the quality of care for patients with cardiovascular diseases. The Elfie solution comprises a mobile phone app with the following features related to hypertension:~1. Personalized monitoring plan based on health conditions to guide frequency of monitoring of blood pressure, weight, and step count~2. Digital pillbox with daily medication-taking reminders and refill reminders~3. Clinical measurements graphs for BP, weight, medical adherence and step count~4. Newsfeed with short videos and texts related to cardiovascular diseases~5. Digital coach - Artificial intelligence technology that provides information via a chatbox as well as feedback information via personalized videos. This feature does not provide medical advice.~6. Connection with a health app or wearable for step count~7. Possibility of family peer support~8. Gamification through the Elfie rewards scoring system"
214636948|NCT01248351|OTHER|autologous stored platelets|Administration of autologous stored platelets
214636949|NCT01248351|OTHER|administration of autologous stored platelets|administration of autologous stored platelets
214636950|NCT01248351|BIOLOGICAL|autologous stored platelets|transfusion of autologous stored platelets
214636951|NCT04623983|DEVICE|bonding tray|Orthodontic bonding tray
214636952|NCT00142701|BEHAVIORAL|diet|
214636953|NCT00142701|BEHAVIORAL|physical activity|
214636954|NCT00142701|BEHAVIORAL|stress management|
214636955|NCT00142701|BEHAVIORAL|smoking cessation|
214636956|NCT02499432|BEHAVIORAL|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
214636957|NCT01784965|DRUG|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
214636958|NCT01784965|DRUG|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
214636959|NCT02963805|BEHAVIORAL|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (\~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
214724437|NCT00002657|DRUG|doxorubicin hydrochloride|25 mg/m\^2
214724438|NCT00002657|DRUG|etoposide|120 mg/m\^2
214724439|NCT00002657|DRUG|methotrexate|120 mg/m\^2
214724440|NCT00002657|DRUG|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
214724441|NCT00002657|DRUG|vincristine sulfate|1.4 mg/m\^2
214724442|NCT00002657|PROCEDURE|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
214724443|NCT00002657|RADIATION|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
214724444|NCT00264667|DRUG|GW677954|
214724445|NCT06099353|BEHAVIORAL|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
214724446|NCT06099353|BEHAVIORAL|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
214724447|NCT06099353|BEHAVIORAL|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
214724448|NCT06326671|DRUG|Tiotropium Bromide Inhalation Powder|It's a generic product of Spiriva HandiHaler.
214724449|NCT06326671|DRUG|Spiriva HandiHaler|Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
214724450|NCT05463159|OTHER|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
214724451|NCT02290340|DRUG|Placebo|Participants will receive placebo intramuscularly.
214724452|NCT02290340|DRUG|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
214724453|NCT02290340|DRUG|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
214724454|NCT02290340|DRUG|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
214724455|NCT03046043|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
214724456|NCT03046043|PROCEDURE|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
214724457|NCT05366257|OTHER|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
214724458|NCT05366257|OTHER|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
214724459|NCT02840526|PROCEDURE|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
214724460|NCT02840526|DRUG|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
214724461|NCT02840526|DRUG|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
214724462|NCT02840526|DRUG|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
214724463|NCT02840526|DRUG|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
214724464|NCT02840526|DRUG|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
214724465|NCT02840526|DEVICE|Intubation|Intratracheal intubation with a single lumen endotracheal tube
214724466|NCT02840526|DRUG|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
214724467|NCT02840526|DRUG|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
214724468|NCT02840526|DRUG|Ketonal|100 mg ketoprofen intravenously every 12 hours
214724469|NCT02840526|DRUG|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
214724470|NCT03375723|OTHER|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
214724471|NCT03375723|OTHER|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
214724472|NCT04129086|DRUG|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
214724473|NCT04129086|DRUG|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
214636960|NCT02963805|BEHAVIORAL|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
214636961|NCT02963805|BEHAVIORAL|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
214636962|NCT02440815|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
214636963|NCT03622099|DRUG|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
214636964|NCT00670592|DRUG|HCD122|
214636965|NCT03109171|OTHER|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
214636966|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^7 CFU in 10 mL phosphate-buffered saline
214636967|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^8 CFU in 10 mL phosphate-buffered saline
214636968|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^9 CFU in 10 mL phosphate-buffered saline
214636969|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^10 CFU in 10 mL phosphate-buffered saline
214636970|NCT06201507|DRUG|Brentuximab vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
214636971|NCT06201507|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
214636972|NCT06201507|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
214636973|NCT06201507|DRUG|Vincristine|1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
214636974|NCT06201507|DRUG|Dacarbazine|375 mg/m2 will be administered on days 1 and 15
214636975|NCT02258880|DRUG|SUN13837|
214636976|NCT02258880|DRUG|placebo|
214636977|NCT03581851|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214636978|NCT03581851|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214636979|NCT04710329|DRUG|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
214636980|NCT01349166|BEHAVIORAL|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
214636981|NCT02571010|OTHER|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
214636982|NCT02571010|DEVICE|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
214636983|NCT02571010|DEVICE|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
214636984|NCT02710357|PROCEDURE|Mandibular Overdenture|Placement of an implant in the mandibular midline.
214636985|NCT02710357|PROCEDURE|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
214636986|NCT02981836|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
214636987|NCT02981836|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
214636988|NCT04385563|DRUG|TQ-B211|Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
214636989|NCT04385563|DRUG|Herceptin®|Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
214636990|NCT04385563|DRUG|docetaxel|Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
214636991|NCT03880500|OTHER|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
214636992|NCT05651035|OTHER|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
214636993|NCT03889041|OTHER|Quality of life assessment|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
214636994|NCT06221982|OTHER|No intervention, observational study|Observational study, no intervention
214636995|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
214636996|NCT03207672|DRUG|E7389-LF|intravenous infusion
214636997|NCT04175626|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
214636998|NCT03178487|DRUG|Upadacitinib|Tablet
214636999|NCT03178487|DRUG|Placebo|Tablet
214637000|NCT05373147|BIOLOGICAL|αPD1-MSLN-CAR T cells|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
214637001|NCT00004900|BIOLOGICAL|filgrastim|
214637002|NCT00004900|DRUG|anastrozole|
214637003|NCT00004900|DRUG|carboplatin|
214637004|NCT00004900|DRUG|cisplatin|
214637005|NCT00004900|DRUG|cyclophosphamide|
214637006|NCT00004900|DRUG|etoposide|
214637007|NCT00004900|DRUG|thiotepa|
214637008|NCT00004900|PROCEDURE|peripheral blood stem cell transplantation|
214724474|NCT04203017|BIOLOGICAL|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
214637009|NCT00004900|RADIATION|radiation therapy|
214637010|NCT04163068|OTHER|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
214637011|NCT04532060|DRUG|Nystatin|
214637012|NCT04532060|PROCEDURE|Antimicrobial Photodynamic Therapy|
214637013|NCT00634491|DRUG|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
214637014|NCT00634491|DRUG|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
214637015|NCT00634491|DRUG|normal salin|1 cc/kg/hr 6 hour before and after angiography
214637016|NCT03375190|OTHER|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
214637017|NCT03375190|OTHER|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
214637018|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
214637019|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
214637020|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
214637021|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
214637022|NCT06301880|DRUG|The topical application of a vasodilator on the LIMA graft|Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
214637023|NCT01797211|DIETARY_SUPPLEMENT|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
214637024|NCT04103437|DIAGNOSTIC_TEST|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
214637025|NCT04103437|DIAGNOSTIC_TEST|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
214637026|NCT04103437|OTHER|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
214637027|NCT02127437|DRUG|Lanreotide|120 mg, subcutaneously, once every 4 weeks
214637028|NCT02127437|DRUG|saline|0,5 ml, subcutaneously, once every 4 weeks
214637029|NCT01716910|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus NCFM and cellobiose|
214637030|NCT05511168|PROCEDURE|Craniostnostosis surgery|Surgery of craniosynostosis
214637031|NCT00153582|BIOLOGICAL|WT1 126-134 peptide|
214637032|NCT05979571|OTHER|Mobile health app|Breastfeeding knowledge and promotion information will be delivered through the AmiBreastfeed app platform
214637033|NCT04269226|PROCEDURE|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
214637034|NCT04269226|PROCEDURE|No recruitment maneuver|Usual ventilation procedures will be applied.
214637035|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
214637036|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
214637037|NCT05323435|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
214637038|NCT05323435|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
214637039|NCT02824744|DEVICE|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
214637040|NCT02824744|DEVICE|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
214637041|NCT01339546|OTHER|no intervention|
214637042|NCT00001193|PROCEDURE|high dose melphalan and autologous bone marrow transplantation|
214637043|NCT02268058|DRUG|Acetaminophen|routine administration of medication for a 72 hour period
214637044|NCT02268058|DRUG|Ibuprofen|routine administration of medication for a 72 hour period
214637045|NCT00493038|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
214637046|NCT00493038|DRUG|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
214637047|NCT02011009|OTHER|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
214637048|NCT00128869|PROCEDURE|spine mobilizations|
214637049|NCT00128869|PROCEDURE|spine manipulations|
214637050|NCT02741102|PROCEDURE|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
214637051|NCT06222125|DRUG|HB0025|HB0025 IV every 2 weeks (q2w)
214637052|NCT00104897|DRUG|tanespimycin|
214637053|NCT06446245|DRUG|Doxycycline|adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy
214637054|NCT06446245|DRUG|Placebo|Placebo
214637055|NCT06446245|DRUG|Anti Tuberculosis Drug|Standard anti-tuberculous therapy
214637056|NCT06446245|DRUG|Adjunctive corticosteroid|Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
214637057|NCT06311474|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a dyadic therapy that focuses on enhancing the parent-child relationship and improving child behavior through positive parenting and limit setting skills. All PCIT sessions are delivered remotely via Zoom once per week for up to 20 weeks. Session length is about 1 hour. There are two distinct phases of PCIT, the Child Directed Interaction and the Parent Directed Interaction. Each phase begins with a Teach session, where parents learn about the skills they will practice during that portion of PCIT, and is followed by Coach sessions, in which the PCIT therapist provides direct feedback and live coaching on the use of the skills. An additional component is Daily Play practice. Parents are instructed to spend five minutes per day playing with their child, during which they practice skills learned during sessions. Adaptations have been made to the standard approach to increase suitability for the TSC population.
214637058|NCT00803504|PROCEDURE|ocular blood flow measurement|
214637059|NCT01847885|DEVICE|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
214637060|NCT04358783|BIOLOGICAL|Plasma|The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.
214637061|NCT04358783|OTHER|Best Available Therapy|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
214637062|NCT02618447|DEVICE|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
214637063|NCT02618447|PROCEDURE|Portal vein embolization|
214637064|NCT04397705|DEVICE|Patient Status Engine|Wearable sensors
214724475|NCT05008458|DIAGNOSTIC_TEST|von willebrand factor and copeptin|biomarkers increase in children with febrile seizures
214724476|NCT00045487|DRUG|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
214637065|NCT06436885|DRUG|Iruplinalkib tablets|Iruplinalkib tablets should be administered orally at a roughly fixed time each day. Once daily, on an empty stomach or with food, 60mg per dose for days 1 to 7, 180 mg per dose from day 8 if tolerated. Swallow the tablet whole, do not crush, divide or chew the tablet
214637066|NCT04743947|OTHER|No intervention; observational study|no intervention
214637067|NCT00119158|DRUG|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
214637068|NCT00119158|DRUG|pimecrolimus|apply daily with fluticasone cream for flares
214637069|NCT03786549|OTHER|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients"
214637070|NCT02574637|DRUG|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
214637071|NCT02574637|DRUG|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
214637072|NCT02574637|DRUG|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
214724477|NCT03783338|COMBINATION_PRODUCT|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
214724478|NCT00001827|BIOLOGICAL|aldesleukin|
214724479|NCT00001827|BIOLOGICAL|incomplete Freund's adjuvant|
214724480|NCT00001827|BIOLOGICAL|p53 peptide vaccine|
214724481|NCT00001827|BIOLOGICAL|sargramostim|
214724482|NCT00001827|BIOLOGICAL|therapeutic autologous dendritic cells|
214724483|NCT00001827|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214637073|NCT05582642|DEVICE|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
214637074|NCT04714541|DRUG|Ketamine Hcl 50Mg/Ml Inj|Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
214637075|NCT00374309|DRUG|VRC-EBOADV018-00-VP|
214637076|NCT05997641|DRUG|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
214637077|NCT05997641|DRUG|Placebo|Visually matching 0 mg DF-003 capsules.
214637078|NCT05060588|DRUG|Sacubitril/Valsartan 49/51mg/Tab|patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
214637079|NCT05060588|DRUG|Valsartan 80mg/Tab|Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
214637080|NCT06437808|COMBINATION_PRODUCT|Training with Portable Force Plates Integration|This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.
214637081|NCT06437808|OTHER|Standard Training|This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
214637082|NCT01568606|DEVICE|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
214637083|NCT02889458|OTHER|Not Provided|
214637084|NCT00006479|DRUG|FOLFOX regimen|
214637085|NCT00006479|DRUG|fluorouracil|
214637086|NCT00006479|DRUG|leucovorin calcium|
214637087|NCT00006479|DRUG|oxaliplatin|
214637088|NCT00006479|PROCEDURE|adjuvant therapy|
214637089|NCT00006479|PROCEDURE|conventional surgery|
214637090|NCT00006479|PROCEDURE|neoadjuvant therapy|
214724484|NCT03209362|COMBINATION_PRODUCT|SI-613|SI-613 will be repeated intra-articularly administered.
214724485|NCT03209362|COMBINATION_PRODUCT|Placebo|Placebo will be repeated intra-articularly administered.
214724486|NCT02844673|DRUG|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
214724487|NCT02844673|DEVICE|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
214724488|NCT04819724|DIAGNOSTIC_TEST|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
214724489|NCT04819724|DIAGNOSTIC_TEST|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
214724490|NCT04819724|DIAGNOSTIC_TEST|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
214724491|NCT04819724|DIAGNOSTIC_TEST|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
214724492|NCT04819724|OTHER|data collection by health questionnaires|data collection by health questionnaires
214724493|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
214724494|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
214724495|NCT01594749|DRUG|Fosaprepitant dimeglumine|
214724496|NCT01594749|DRUG|Fosaprepitant Placebo|
214724497|NCT01594749|DRUG|Dexamethasone|
214724498|NCT01594749|DRUG|Ondansetron|
214724499|NCT01594749|DRUG|Dexamethasone Placebo|
214724500|NCT01594749|DRUG|Ondansetron Placebo|
214724501|NCT01594749|DRUG|Rescue Therapy|
214724502|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
214724503|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
214724504|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
214724505|NCT00054860|BIOLOGICAL|EP HIV-1090|
214724506|NCT01508793|BEHAVIORAL|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
214724507|NCT03401216|DEVICE|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
214724508|NCT03401216|PROCEDURE|PCI|Standard PCI procedure
214724509|NCT03401216|PROCEDURE|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
214724510|NCT03401216|PROCEDURE|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
214724511|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
214724512|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
214724513|NCT02177786|DRUG|Selonsertib|Tablets administered orally once daily
214724514|NCT02177786|DRUG|Placebo to match selonsertib|Tablets administered orally once daily
214724515|NCT02055729|BIOLOGICAL|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
214724516|NCT02055729|BIOLOGICAL|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
214724517|NCT02055729|BIOLOGICAL|Stool sample|Stool samples will be collected on days 0 and 28.
214724518|NCT02055729|BIOLOGICAL|Urine sample|Urine samples will be collected on days 0 and 28.
214724519|NCT01074840|OTHER|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
214724520|NCT01402323|OTHER|time point of tooth extraction|
214724521|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
214724522|NCT00439309|DEVICE|VascuSeal|VascuSeal
214724523|NCT02453139|BEHAVIORAL|Exercise|6 month supervised and home based aerobic exercise intervention
214637091|NCT05946408|OTHER|Supervised antenatal exercises|"Supervised antenatal exercises along with education twice a week. Protocol consists of warm up (10 min), Aerobic training (20 mins, 60-75% of max. HR), Strength training (25 minutes), followed by a cool down of 15 minutes.~The Interventions to be provided for a period of 12 weeks."
214637092|NCT05946408|OTHER|Antenatal Education|Antenatal education at 12th week of pregnancy. Which consists of education on Posture in pregnancy, Role of pelvic floor muscles, Labor and breathing and relaxation techniques.
214637093|NCT04311086|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
214637094|NCT00682266|BEHAVIORAL|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
214724524|NCT02233491|BEHAVIORAL|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
214724525|NCT02233491|OTHER|Control|No additional support other than lifestyle advice by clinician
214724526|NCT03857477|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
214724527|NCT03857477|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
214724528|NCT03857477|PROCEDURE|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
214724529|NCT03857477|PROCEDURE|Prostate biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
214724530|NCT04246346|OTHER|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
214724531|NCT04246346|OTHER|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
214724532|NCT03167125|OTHER|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
214724533|NCT03167125|OTHER|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
214724534|NCT00148525|BEHAVIORAL|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
214724535|NCT00148525|BEHAVIORAL|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
214724536|NCT05045105|OTHER|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
214724537|NCT00205946|DRUG|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
214724538|NCT00205946|DRUG|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
214724539|NCT05524558|DEVICE|Pulmonary artery catheter|PAC already in place
214724540|NCT05524558|DEVICE|Esophagal pressure|Esophagal pressure already in place
214724541|NCT01604434|PROCEDURE|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
214724542|NCT01604434|PROCEDURE|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
214724543|NCT04835688|PROCEDURE|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
214724544|NCT04835688|PROCEDURE|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
214724545|NCT03634293|DRUG|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
214724546|NCT03634293|DRUG|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
214724547|NCT02027272|DRUG|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
214724548|NCT04987424|DIAGNOSTIC_TEST|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
214724549|NCT00096824|BEHAVIORAL|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
214724550|NCT04036513|PROCEDURE|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
214724551|NCT04036513|PROCEDURE|Conventional SRP|Scaling and root planing with conventional instruments.
214724552|NCT01780324|DRUG|Lidocaine|Intervention - intraurethral lidocaine
214724553|NCT04574674|BEHAVIORAL|Flexibility exercise programme|Static passive flexibility exercises.
214724554|NCT04574674|BEHAVIORAL|Resistance exercise programme|Body weight and resistance bands exercises.
214724555|NCT04447625|DRUG|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
214724556|NCT04447625|DRUG|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
214724557|NCT04347252|DRUG|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
214724558|NCT04469556|DRUG|Folfirinox|Chemotherapy
214724559|NCT04469556|DRUG|Gemcitabine/nab-paclitaxel|Chemotherapy
214724560|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
214724561|NCT03180294|DRUG|Bupropion 150 mg XL|By mouth
214724562|NCT03180294|DRUG|Placebo|By mouth
214724563|NCT04325919|OTHER|No intervention|No intervention
214724564|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
214724565|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
214724566|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
214724567|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
214724568|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
214724569|NCT03887975|PROCEDURE|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
214724570|NCT03887975|PROCEDURE|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
214724571|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
214724572|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
214724573|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
214724574|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
214724575|NCT06118190|DRUG|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
214724576|NCT02204410|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|
214724577|NCT02204410|DRUG|ADHD Medication|
214724578|NCT06100107|OTHER|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
214724579|NCT00852423|DRUG|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
214724580|NCT00852423|DRUG|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
214724581|NCT00852423|DRUG|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
214724582|NCT00852423|DRUG|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
214724583|NCT02953067|PROCEDURE|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
214724584|NCT02953067|PROCEDURE|Primary arthrodesis|Primary arthrodesis versus ORIF
214724585|NCT02953067|PROCEDURE|Conservative treatment|Conservative treatment versus open reduction and internal fixation
214724586|NCT03654560|DEVICE|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
214724587|NCT03654560|DEVICE|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
214724588|NCT05648123|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
214724589|NCT02792036|DRUG|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
214724590|NCT02792036|DRUG|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
214724591|NCT02792036|PROCEDURE|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
214724592|NCT02792036|PROCEDURE|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
214724593|NCT00744731|DRUG|placebo|placebo for 1 week
214724594|NCT00744731|DRUG|carisbamate|400 mg/day to 1,200 mg per day
214724595|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
214724596|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
214724597|NCT00249912|DRUG|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
214724598|NCT01467089|OTHER|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
214724599|NCT03054025|DEVICE|Smart Phone Monitoring Device|Use activity tracker application
214724600|NCT02278224|BEHAVIORAL|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
214724601|NCT02278224|BEHAVIORAL|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
214724602|NCT01100658|DRUG|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
214724603|NCT01100658|DRUG|Placebo|1 capsule per day for 1 week.
214724604|NCT02790684|DRUG|DS-8500a|
214724605|NCT01902693|OTHER|No intervention for this study|No intervention
214724606|NCT02527564|DRUG|Suvorexant|
214724607|NCT02527564|DRUG|Placebo|
214724608|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
214724609|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
214724610|NCT00420342|DRUG|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
214724611|NCT01017549|RADIATION|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
214724612|NCT03076203|DRUG|Niraparib|Given orally
214724613|NCT03076203|RADIATION|Radium Ra 223 Dichloride|Given intravenously
214724614|NCT04062526|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
214724615|NCT05665738|RADIATION|High Dose Rate Monotherapy|High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
214724616|NCT03550092|BEHAVIORAL|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
214724617|NCT06061315|DIETARY_SUPPLEMENT|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
214724618|NCT06061315|DIETARY_SUPPLEMENT|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
214724619|NCT06403475|DEVICE|Transcutaneous Vagus Nerve Stimulation|"Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device."
214724620|NCT06403475|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.
214724621|NCT06403475|BEHAVIORAL|Computer Based Speech and Language Therapy (Step by Step)|Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
214724622|NCT05552755|DRUG|REC-4881|REC-4881 4mg capsules
214724623|NCT05552755|DRUG|Placebo|Placebo capsules
214724624|NCT04072575|DRUG|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
214724625|NCT04072575|DRUG|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
214724626|NCT02473289|DRUG|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
214724627|NCT02473289|DRUG|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
214724628|NCT04377126|DRUG|Ghrelin|Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.
214724629|NCT04377126|DRUG|Placebo|Placebo will consist of saline- no active ingredient.
214724630|NCT04290260|OTHER|Use of breast bra|Patients will use a breast from admission to hospital discharge
214724631|NCT04290260|OTHER|Usual care (not use of bra)|
214724632|NCT04575844|DRUG|Liraglutide|24 weeks of Liraglutide
214724633|NCT04575844|OTHER|Exercise training|24 weeks of Exercise training
214724634|NCT04575844|DRUG|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
214724635|NCT02912949|DRUG|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
214724636|NCT06061094|DRUG|Imatinib|Imatinib 600mg QD plus Chemotherapy
214724637|NCT06061094|DRUG|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
214724638|NCT06061094|DRUG|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
214724639|NCT06061094|OTHER|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
214724640|NCT04788758|OTHER|Educational Intervention|Receive G8 screening tool administration training
214724641|NCT04788758|OTHER|Screening Questionnaire Administration|Complete G8 screening tool
214724642|NCT04788758|OTHER|Referral|Receive referral
214724643|NCT04788758|OTHER|Questionnaire Administration|Ancillary studies
214724644|NCT05031520|PROCEDURE|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
214724645|NCT05031520|DRUG|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
214724646|NCT05031520|DRUG|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
214724647|NCT05031520|DRUG|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
214724648|NCT01478061|DEVICE|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
214724649|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
214724650|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
214724651|NCT02283541|BEHAVIORAL|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
214724652|NCT02244619|DRUG|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
214724653|NCT02244619|DRUG|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
214724654|NCT03134469|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
214724655|NCT03134469|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement
214724656|NCT02382289|PROCEDURE|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
214724657|NCT05320536|DRUG|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
214724658|NCT05320536|DRUG|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
214724659|NCT02282891|DRUG|Propofol|Induction of general anesthesia using propofol 2mg/kg
214724660|NCT02282891|DRUG|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
214724661|NCT04617106|PROCEDURE|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
214724662|NCT05837000|DRUG|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
214724663|NCT05837000|DRUG|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
214724664|NCT05837000|DRUG|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
214724665|NCT06034041|DRUG|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
214724666|NCT06034041|DRUG|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
214724667|NCT00383266|DRUG|Pemetrexed|
214724668|NCT00383266|DRUG|Carboplatin|
214637095|NCT00682266|BEHAVIORAL|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
214637096|NCT06492044|OTHER|Transthoracic echocardiography (TTE)|"In this pilot study, all included patients will undergo a TTE before (TTEt0) and after (TTEt1) the PLR maneuver, then before (TTEt2) and after the FC (TTEt3).~Passive leg raising is PLR. FC is fluid challenge. TTE, PLR and FC are routine care procedures in patient in septic shock. In this study the patient will undergo repeated image acquisition with TTE at different times as part of the study, resulting in a longer TTE procedure. The advantage of TTE is that it is a non-invasive, painless, non-irradiating procedure that can be easily performed at the patient's bedside and has no known side effects to date. TTE is a non-invasive procedure that poses no infectious or psychological risk to the patient. No additional follow-up or telephone contact will be necessary for the study. The study concludes once TTEt3 is completed."
214637097|NCT02011191|DIETARY_SUPPLEMENT|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
214637098|NCT02011191|DIETARY_SUPPLEMENT|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
214637099|NCT03669315|DEVICE|Transcranial Magnetic stimulation|Neuromodulation tool
214637100|NCT03591445|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
214637101|NCT00355394|DRUG|Metoclopramide|Intravenous bolus administration.
214637102|NCT00355394|OTHER|Placebo|Standard care including intravenous fluid, but no metoclopramide.
214637103|NCT05152797|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
214637104|NCT01389557|DRUG|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
214637105|NCT01912209|BEHAVIORAL|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
214637106|NCT05883098|PROCEDURE|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
214637107|NCT05883098|DEVICE|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
214637108|NCT00070941|DRUG|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
214637109|NCT00070941|DRUG|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
214637110|NCT00070941|DRUG|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
214637111|NCT01691469|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
214637112|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
214637113|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
214637114|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
214637115|NCT00094055|DRUG|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
214637116|NCT04851600|DEVICE|prosthesis|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
214637117|NCT01175902|DRUG|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
214637118|NCT01175902|DRUG|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
214637119|NCT04765280|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
214637120|NCT04765280|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
214637121|NCT04765280|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.
214724669|NCT03052465|OTHER|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
214637122|NCT04765280|OTHER|Disabilities of the Arm, Shoulder and Hand (DASH)|Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.
214637123|NCT04765280|OTHER|Neck Pain and Disability scale|Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.
214637124|NCT04765280|OTHER|Knee Injury and Osteoarthritis Outcome Score|Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.
214637125|NCT04765280|OTHER|Western Ontario and McMaster Universities Arthritis Index|Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.
214637126|NCT04765280|OTHER|Visual analogue scale|global pain score on a 0 to 10
214637127|NCT04861220|BEHAVIORAL|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
214637128|NCT02803021|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
214637129|NCT00226551|DRUG|Isoproterenol|
214637130|NCT01307475|OTHER|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
214637131|NCT01307475|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
214637132|NCT01307475|OTHER|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
214637133|NCT01307475|OTHER|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
214637134|NCT01307475|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
214637135|NCT01307475|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
214637136|NCT01307475|OTHER|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
214637137|NCT01307475|OTHER|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
214637138|NCT01307475|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
214637139|NCT04482335|OTHER|No intervention|No intervention
214637140|NCT01019382|DRUG|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
214637141|NCT04821804|DRUG|Hyaluronic Acid (HYADENT BG)|"the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures"
214637142|NCT01232829|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
214637143|NCT03453983|DEVICE|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
214637144|NCT06258070|OTHER|Abobotulinumtoxin A injection for bruxism|Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
214637145|NCT00411554|DRUG|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
214637146|NCT00411554|DRUG|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
214637147|NCT00080509|DRUG|KOS-862|
214637148|NCT03247894|OTHER|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
214637149|NCT03090594|PROCEDURE|Biopsy|Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
214637150|NCT00699907|DRUG|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
214637151|NCT02087787|BEHAVIORAL|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
214637152|NCT04015895|OTHER|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
214637153|NCT02680379|DRUG|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
214724670|NCT03486184|DIAGNOSTIC_TEST|Cystatin-C|"* Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~* Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
214724671|NCT02425969|PROCEDURE|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
214724672|NCT02425969|DRUG|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
214724673|NCT05386875|DIAGNOSTIC_TEST|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
214724674|NCT05364112|DEVICE|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
214724675|NCT03381703|DRUG|YH12852|YH12852 administration
214724676|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
214724677|NCT00287755|DRUG|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
214724678|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
214724679|NCT01291511|DRUG|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
214637154|NCT02680379|DRUG|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
214637155|NCT01934088|DRUG|Propofol|
214637156|NCT01934088|DRUG|Midazolam|
214637157|NCT01934088|DRUG|Fentanyl|
214637158|NCT02161211|BEHAVIORAL|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
214637159|NCT02161211|BEHAVIORAL|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
214637160|NCT02161211|BEHAVIORAL|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
214637161|NCT05430100|OTHER|The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
214637162|NCT05430100|OTHER|The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
214637163|NCT05430100|OTHER|The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
214637164|NCT00003580|DRUG|amifostine trihydrate|
214637165|NCT00003580|DRUG|cisplatin|
214637166|NCT00003580|RADIATION|radiation therapy|
214637167|NCT06319105|OTHER|Standard intervention: Offer PrEP choice|This hybrid observational-implementation study will observe the implementation of a choice of oral pre-exposure prophylaxis or long-acting injectable cabotegravir for pre-exposure prophylaxis for all participants.
214637168|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
214637169|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
214637170|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
214637171|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
214637172|NCT00703664|DRUG|Bortezomib|Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.
214637173|NCT00703664|OTHER|Laboratory Biomarker Analysis|Correlative studies
214637174|NCT00703664|DRUG|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
214637175|NCT01637233|DRUG|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
214637176|NCT01637233|DRUG|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
214637177|NCT01637233|DRUG|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
214637178|NCT03728309|DEVICE|JUVÉDERM VOLITE™ XC|Intradermal, needle in multiple microdepot injections across both cheeks.
214637179|NCT00397683|DRUG|MK0822|
214637180|NCT01889290|DRUG|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
214637181|NCT05529914|OTHER|Myofascial release|It is a type of physical therapy often used to treat myofascial pain syndrome with pressure.
214637182|NCT05529914|OTHER|Neuromuscular exercises|Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up \& down, Cool-down
214637183|NCT05529914|OTHER|Cold pack|Application of cold pack around the patient's body, and covered with dry towel
214637184|NCT00953758|DRUG|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
214637185|NCT04264247|DIAGNOSTIC_TEST|routine fetal ultrasonography at 11-14 weeks|routine fetal ultrasonography at 11-14 weeks
214637186|NCT01698346|BIOLOGICAL|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
214637187|NCT02076542|BEHAVIORAL|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
214724680|NCT01291511|DRUG|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
215030505|NCT06638723|BEHAVIORAL|Balance and fall recovery training|Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
214637188|NCT02702648|DRUG|AC-082|Hard gelatin capsules for oral administration
214637189|NCT02702648|DRUG|Placebo|Matched placebo capsules for oral administration
214637190|NCT00278681|DRUG|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
214637191|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
214637192|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
214637193|NCT01164722|OTHER|clinical observation|Patients undergo observation
214637194|NCT01164722|DEVICE|infrared photocoagulation therapy|Anal infrared coagulator ablation
214637195|NCT04444622|BIOLOGICAL|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
214637196|NCT00486408|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5x10\^10 Ad vg
215030506|NCT06638762|PROCEDURE|surgery|We recruited patients diagnosed with oral squamous cell carcinoma who had received surgical treatment, collected patient follow-up information and postoperative pathological images, enhanced and standardized pathological images, and extracted pathological features through visual transformation model.
214637197|NCT02981680|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
214637198|NCT02981680|PROCEDURE|sham-RIPC|
214637199|NCT00999908|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214637200|NCT00999908|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214637201|NCT00999908|DRUG|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214637202|NCT04302532|DRUG|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
214637203|NCT04302532|DRUG|clomiphene citrate|ovulation induction drug
214637204|NCT05044156|OTHER|salivary sample|salivary sample
214637205|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as two capsules
214637206|NCT06411275|DRUG|Placebo|Matching placebo administered orally BID as two to four capsules
214637207|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as four capsules
214637208|NCT00110565|DEVICE|Pulsed magnetic field pad|
214637209|NCT04951258|OTHER|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
214637210|NCT04951258|OTHER|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
214637211|NCT02121457|DIETARY_SUPPLEMENT|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
214637212|NCT02121457|DIETARY_SUPPLEMENT|selenium|
214637213|NCT04940910|DIETARY_SUPPLEMENT|Black rice bran extract|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
214637214|NCT04940910|DIETARY_SUPPLEMENT|Placebo|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
214637215|NCT01675960|DRUG|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
214637216|NCT01675960|DRUG|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
214637217|NCT05501353|OTHER|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
214637218|NCT05850221|OTHER|weight training|weight training
214637219|NCT03552341|OTHER|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
214637220|NCT05697328|DRUG|Pseudoephedrine Pill|One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
214637221|NCT05697328|DRUG|Placebo|One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
214637222|NCT00523588|PROCEDURE|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
214637223|NCT06471270|DIAGNOSTIC_TEST|histologic evaluation|histologic evaluation
214637224|NCT06471270|DIAGNOSTIC_TEST|biochemical analysis|IL-6, IL-8 and sCD44
214637225|NCT06471270|DIAGNOSTIC_TEST|clinical examination|clinical examination
214637226|NCT00006089|OTHER|Laboratory Biomarker Analysis|Correlative studies
214637227|NCT00006089|BIOLOGICAL|Trastuzumab|Given IV
214637228|NCT00290966|DRUG|XRP6976|
214637229|NCT03038425|DRUG|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
215030507|NCT06639880|OTHER|usual care exercise|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
214637230|NCT03038425|DRUG|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
214637231|NCT01703858|DRUG|BI 113608 PIB|powder for oral solution
214637232|NCT01703858|DRUG|BI 113608|conventional tablet formulation
214637233|NCT01703858|DRUG|BI 113608|conventional tablet formulation
214637234|NCT01703858|DRUG|BI 113608|conventional tablet formulation
214637235|NCT01703858|DRUG|pantoprazole 40 mg STADA|film-coated tablet
214637236|NCT01703858|DRUG|BI 113608|conventional tablet formulation
214637237|NCT01158521|DRUG|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
214637238|NCT01158521|PROCEDURE|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
214637239|NCT01382732|DRUG|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
214637240|NCT01382732|DRUG|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
214637241|NCT02501278|BIOLOGICAL|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~* VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~* INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
214637242|NCT02501278|RADIATION|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
214637243|NCT02501278|DRUG|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
214637244|NCT06202300|OTHER|Inflammation burden|Coronary artery disease patients undergone multimodality imaging with different level inflammation burden
214637245|NCT01290692|BIOLOGICAL|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
214637246|NCT02556255|DEVICE|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
214637247|NCT00467454|DRUG|Naltrexone|daily
214637248|NCT00467454|DRUG|Placebo|daily
214637249|NCT01849770|DRUG|Mexiletine|
214637250|NCT01849770|DRUG|Placebo|
214637251|NCT04799886|OTHER|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
214637252|NCT01511770|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
214637253|NCT01511770|DRUG|Fluconazole|Fluconazole 200 mg tablets
214637254|NCT00993031|DRUG|Lopinavir/ritonavir|LPV 200mg/r 50mg
214637255|NCT00993031|DRUG|Efavirenz|600mg
214637256|NCT00993031|DRUG|Zidovudine|Zidovudine 300 mg
214637257|NCT00993031|DRUG|Lamivudine|Lamivudine 150 mg
214637258|NCT04011865|PROCEDURE|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
214637259|NCT00598416|BEHAVIORAL|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
215030508|NCT06639880|OTHER|triple attack protocol|a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
214637260|NCT00270530|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
214637261|NCT00875355|DRUG|temozolomide|Given orally
214637262|NCT00875355|RADIATION|radiation therapy|Patients undergo radiotherapy
214637263|NCT03115151|DRUG|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
214637264|NCT03115151|DRUG|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
214637265|NCT03115151|DRUG|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
214637266|NCT00005059|DRUG|carboplatin|
214637267|NCT00005059|DRUG|paclitaxel|
214637268|NCT04515732|DRUG|Apremilast Oral Tablet|As in description
214637269|NCT00465595|DRUG|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
214637270|NCT00027339|DRUG|lopinavir/ritonavir|
214637271|NCT00027339|DRUG|indinavir sulfate|
214637272|NCT00027339|DRUG|tenofovir disoproxil fumarate|
214637273|NCT00027339|DRUG|ritonavir|
214637274|NCT00027339|DRUG|fosamprenavir|
214637275|NCT05547178|OTHER|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
214637276|NCT05547178|OTHER|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
214637277|NCT05547178|OTHER|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
214637278|NCT04534660|DEVICE|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
214637279|NCT01075555|DRUG|pravastatin sodium|
214637280|NCT01075555|DRUG|sorafenib tosylate|
214637281|NCT03279003|DEVICE|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
214637282|NCT04600895|DRUG|Favipiravir|Favipiravir
214637283|NCT04600895|DRUG|Placebo|Placebo
214637284|NCT02767648|OTHER|proteomic urine analysis|proteomic urine analysis
214637285|NCT03823469|BEHAVIORAL|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
214637286|NCT03823469|BEHAVIORAL|Nutritional counseling|Two 30-minute nutritional counseling sessions
214637287|NCT00868283|DRUG|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
214637288|NCT00868283|DRUG|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
214637289|NCT05779826|OTHER|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
214637290|NCT01622881|DRUG|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
214637291|NCT01622881|DRUG|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
214637292|NCT01787357|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
214637293|NCT01787357|DRUG|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
214637294|NCT01787357|DRUG|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
214637295|NCT01543087|PROCEDURE|blood sampling|Blood sample collection at different time points
214637296|NCT01543087|DRUG|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
214637297|NCT05722665|OTHER|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
214637298|NCT05764486|DEVICE|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
214637299|NCT02167932|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
214637300|NCT04467580|DIAGNOSTIC_TEST|abdominal [18F]FDG PET/CT|Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
214637301|NCT05536661|OTHER|Preservative free hyaluronic acid artificial tear|Ocular lubricant
214637302|NCT01938144|DRUG|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
214637303|NCT01938144|DRUG|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
214637304|NCT01938144|DRUG|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
214637305|NCT00706030|DRUG|neratinib|
214637306|NCT00706030|DRUG|vinorelbine|
214637307|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
214637308|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg single dose
214637309|NCT01244880|OTHER|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
214637310|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg tablet single dose
214637311|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
214637312|NCT01244880|OTHER|Placebo|Placebo tablet single dose
214637313|NCT01244880|OTHER|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
214637314|NCT01244880|OTHER|Placebo|Placebo tablet single dose
214637315|NCT01720537|BIOLOGICAL|PF-05335810 Dose A|Single SC Injection
214637316|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Subcutaneous Injection(s)
214637317|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
214637318|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Intravenous Infusion
214637319|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
214637320|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Subcutaneous Injection(s)
214724681|NCT04367649|OTHER|Hall technique|"* Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement"
214724682|NCT04367649|OTHER|Atraumatic restorative treatment|Caries removal using excavators, then restoration using glass ionomer (GIC)
214637321|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Intravenous Infusion
214637322|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Subcutaneous Injection(s)
214637323|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
214637324|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Intravenous Infusion
214637325|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
214637326|NCT01720537|BIOLOGICAL|PF-04950615|Single Subcutaneous Injection(s)
214724683|NCT04367649|OTHER|Conventional restorative treatment|Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
214724684|NCT02367859|DRUG|Dabrafenib|Given PO
214724685|NCT02367859|DRUG|Trametinib|Given PO
214724686|NCT00047008|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22
215030509|NCT06636760|OTHER|Placebo|The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
214637327|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Subcutaneous Injection(s)
214637328|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
214637329|NCT01720537|BIOLOGICAL|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
214637330|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Intravenous Infusion
214637331|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
214637332|NCT04481776|OTHER|Breakfast consumption|Standardised breakfast consumption across seven days
214637333|NCT04481776|OTHER|Breakfast omission|No breakfast consumed across seven days
214637334|NCT00884104|DRUG|Solifenacin|Oral
214637335|NCT04638569|PROCEDURE|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
214637336|NCT03188237|BEHAVIORAL|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
214637337|NCT06278909|DEVICE|Trigeminal Nerve Stimulation|Active trigeminal nerve stimulation
214637338|NCT02691780|DRUG|Sorafenib|
214637339|NCT02865330|OTHER|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
214637340|NCT02772861|DIETARY_SUPPLEMENT|Amino Acid Supplement - One dose|20gr
214637341|NCT02772861|DIETARY_SUPPLEMENT|3-Methylhistidine|120mgr
214637342|NCT02337088|PROCEDURE|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
214637343|NCT02337088|PROCEDURE|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
214637344|NCT04868084|BEHAVIORAL|Physical literacy in the early years|Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
214637345|NCT04776590|DRUG|Tislelizumab|neoadjuvant immunotherapy
214637346|NCT00373035|GENETIC|proteomic profiling|
214637347|NCT00373035|OTHER|immunological diagnostic method|
214637348|NCT00373035|OTHER|laboratory biomarker analysis|
214637349|NCT00373035|OTHER|mass spectrometry|
214637350|NCT00373035|PROCEDURE|biopsy|
214637351|NCT00373035|PROCEDURE|ultrasound imaging|
214637352|NCT04314960|DEVICE|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
214637353|NCT04280432|PROCEDURE|CESAREAN|Women hospitalized for cesarean section
214637354|NCT04673786|BIOLOGICAL|CT-P43|45mg or 90mg dose subcutaneous administration
214637355|NCT04673786|BIOLOGICAL|Stelara|45mg or 90mg dose subcutaneous administration
214637356|NCT04438174|DRUG|Processed Amniotic Fluid|Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
214637357|NCT04438174|OTHER|Standard of Care Wound Treatment Regimen|ointment-based dressing and non-ointment-based dressings
214637358|NCT03996915|DEVICE|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
214637359|NCT03996915|OTHER|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
214637360|NCT00005112|DRUG|Human recombinant growth hormone|
214637361|NCT03006939|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
214637362|NCT00791271|DRUG|Decitabine|Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
214637363|NCT00791271|DRUG|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
214637364|NCT03087006|OTHER|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
214637365|NCT03087006|OTHER|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
214637366|NCT02527980|OTHER|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
214637367|NCT04434144|DRUG|Ivermectin + Doxycycline|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
214637368|NCT04434144|DRUG|Hydroxychloroquine + Azithromycin|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
214637369|NCT02682901|DRUG|Cycloset|Cycloset 1.6 -3.2 mg/day
214637370|NCT02682901|DRUG|Placebo|Non-active placebo for cycloset
214637371|NCT01472887|DRUG|SAR3419|"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
214637372|NCT02097147|DRUG|Vilazodone 20 mg|Oral administration, once per day.
214637373|NCT02097147|DRUG|Vilazodone 40 mg|Oral administration, once per day.
214637374|NCT02097147|DRUG|Paroxetine 20 mg|Oral administration, once per day.
215030510|NCT06636760|DIETARY_SUPPLEMENT|herbal compound|The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
214637375|NCT02097147|DRUG|Placebo|Oral administration, once per day.
214637376|NCT01309035|PROCEDURE|Total Knee Arthroplasty|Surgery for OA knee pains
214637377|NCT03870555|DRUG|TAK-954|TAK-954 infusion administered intravenously.
214637378|NCT03870555|DRUG|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
215030511|NCT06642051|DEVICE|High Intensity focused ultrasound|Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
214637379|NCT03971110|DRUG|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
214637380|NCT02025387|BEHAVIORAL|Physical activity feedback|
214637381|NCT02025387|BEHAVIORAL|Usual care except physical activity measurement|
214637382|NCT05749380|DRUG|AmBisome|Reference, dose of 3 mg/kg.
214637383|NCT05749380|DRUG|DKF-5122|Test, dose of 3 mg/kg
214637384|NCT01924208|BIOLOGICAL|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
214637385|NCT01924208|BIOLOGICAL|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
214637386|NCT01924208|PROCEDURE|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
214637387|NCT04279015|PROCEDURE|Kinesio tape procedure|"Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application."
215030512|NCT06641453|BIOLOGICAL|GPC3-CART cells|"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."
214637388|NCT03112239|DEVICE|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
214637389|NCT04313907|COMBINATION_PRODUCT|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
214637390|NCT04313907|DRUG|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
214637391|NCT04313907|RADIATION|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
214637392|NCT03104725|DRUG|N-Acetylcysteine|Oral
215030513|NCT06641453|DRUG|Fludarabine Phosphate for Injection|Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
214724687|NCT00047008|RADIATION|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
214724688|NCT00047008|RADIATION|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
214724689|NCT00047008|PROCEDURE|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
214724690|NCT01769625|DRUG|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
214724691|NCT01528995|DEVICE|Medtronic Interstim II-3058|impulse generator
214724692|NCT01528995|PROCEDURE|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
214724693|NCT02971527|DEVICE|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
214724694|NCT02971527|DEVICE|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
214724695|NCT01762527|RADIATION|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
214724696|NCT00550992|BIOLOGICAL|anti-thymocyte globulin|
214724697|NCT00550992|DRUG|asparaginase|
214724698|NCT00550992|DRUG|busulfan|
214724699|NCT00550992|DRUG|cyclophosphamide|
214724700|NCT00550992|DRUG|cyclosporine|
214724701|NCT00550992|DRUG|cytarabine|
214724702|NCT00550992|DRUG|daunorubicin hydrochloride|
214724703|NCT00550992|DRUG|etoposide|
214724704|NCT00550992|DRUG|leucovorin calcium|
214724705|NCT00550992|DRUG|melphalan|
214724706|NCT00550992|DRUG|mercaptopurine|
214724707|NCT00550992|DRUG|methotrexate|
214724708|NCT00550992|DRUG|mitoxantrone hydrochloride|
214724709|NCT00550992|DRUG|pegaspargase|
214724710|NCT00550992|DRUG|prednisolone|
214724711|NCT00550992|DRUG|prednisone|
214724712|NCT00550992|DRUG|therapeutic hydrocortisone|
214724713|NCT00550992|DRUG|thioguanine|
214724714|NCT00550992|DRUG|vincristine sulfate|
214724715|NCT00550992|PROCEDURE|allogeneic bone marrow transplantation|
214724716|NCT00550992|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214724717|NCT00550992|PROCEDURE|umbilical cord blood transplantation|
214724718|NCT03959956|DIAGNOSTIC_TEST|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
214724719|NCT02837809|RADIATION|Low dose CT|annual CT vs biennial CT
215030514|NCT06641453|DRUG|Cyclophosphamide for Injection|Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
214637393|NCT03104725|PROCEDURE|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
214637394|NCT03104725|RADIATION|Fluoroscopy|If needed for lumbar puncture
214637395|NCT04632498|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
214637396|NCT00384020|DRUG|Paroxetine (Seroxat)|
214637397|NCT00384020|DRUG|Escitalopram (Lexapro)|
214724720|NCT03753386|OTHER|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test."
214724721|NCT05588713|PROCEDURE|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
214724722|NCT05588713|PROCEDURE|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
214724723|NCT02748525|OTHER|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
214724724|NCT02748525|BIOLOGICAL|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
214724725|NCT05462691|PROCEDURE|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
214724726|NCT00902512|DRUG|Treatment A|Viagra® 100 mg tablet, administered with water single dose
214724727|NCT00902512|DRUG|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
214637398|NCT01422239|BEHAVIORAL|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
214637399|NCT01422239|BEHAVIORAL|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
214637400|NCT01120119|DRUG|Calcitriol|
214637401|NCT01051141|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
214637402|NCT01051141|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
214637403|NCT01051141|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (\~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
214637404|NCT04511728|DRUG|HSK3486|The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h
214637405|NCT04511728|DRUG|Propofol|The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h
214637406|NCT00717600|DIETARY_SUPPLEMENT|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
214637407|NCT00423163|DRUG|micafungin|
214637408|NCT00423163|DRUG|voriconazole|
214637409|NCT01532531|DEVICE|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
214637410|NCT06419140|DRUG|Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation|Motivational counseling to perform nutritional, psychological, and exercise inventions
214637411|NCT02050269|DRUG|Iohexol|Iohexol, 300 mg/mL
214637412|NCT03227705|DRUG|Prometrium|Intravaginal use, off label, of Prometrium
214637413|NCT03227705|DEVICE|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
214724728|NCT00902512|DRUG|Treatment B|Sildenafil 100 mg CT administered with water single dose
214724729|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
214724730|NCT00902512|DRUG|Treatment C|Sildenafil 100 mg CT administered without water single dose
214724731|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
214724732|NCT04564690|DIETARY_SUPPLEMENT|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
214724733|NCT04564690|DIETARY_SUPPLEMENT|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
214724734|NCT02747329|DEVICE|BuMA Supreme™ stent|
214724735|NCT02747329|DEVICE|Xience V/Prime stent|
214724736|NCT01408732|DRUG|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
214724737|NCT01408732|OTHER|Standard Treatment|Normal standard of care followed by Drug interevention
214724738|NCT06391970|DEVICE|Cognitive screening|The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
214724739|NCT01524809|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
214724740|NCT01524809|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
214724741|NCT04904640|DEVICE|Hip stem|In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
214724742|NCT03880006|BEHAVIORAL|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
214724743|NCT00796003|DRUG|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
214637414|NCT06488157|OTHER|I-HoME|Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
214637415|NCT01732887|OTHER|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
214637416|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally three times a day
214637417|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally twice a day
214637418|NCT05818657|BIOLOGICAL|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
214637419|NCT05818657|BIOLOGICAL|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
214637420|NCT03959722|DIETARY_SUPPLEMENT|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
214637421|NCT03959722|DIETARY_SUPPLEMENT|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
214637422|NCT03167073|OTHER|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
214637423|NCT03167073|OTHER|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
214637424|NCT04082585|BEHAVIORAL|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
214637425|NCT03881397|BEHAVIORAL|Family Media Use Plan|A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
214637426|NCT03881397|BEHAVIORAL|Media Use Resources Awareness|Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
214637427|NCT01276236|DRUG|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
214637428|NCT05828511|DRUG|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
214637429|NCT00044512|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
214637430|NCT02673645|OTHER|SAGA Innovations|An intensive math tutoring program.
214637431|NCT01097304|DRUG|Ursodiol|Given PO
214637432|NCT01097304|OTHER|Laboratory Biomarker Analysis|Correlative studies
214637433|NCT01475201|BEHAVIORAL|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
214637434|NCT01475201|BEHAVIORAL|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
214637435|NCT01307969|DRUG|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
214637436|NCT06309056|DEVICE|VitalStim|VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
214637437|NCT01277640|DRUG|dapivirine|"* dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
214637438|NCT01277640|DRUG|matched placebo|"* dosage form: gel, no api~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
214637439|NCT01277640|DRUG|universal placebo|"* dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
214637440|NCT05207007|PROCEDURE|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
214637441|NCT03173833|OTHER|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
214637442|NCT02278172|DIETARY_SUPPLEMENT|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
214637443|NCT02278172|DIETARY_SUPPLEMENT|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
214637444|NCT03536871|DIETARY_SUPPLEMENT|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
214637445|NCT03536871|OTHER|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
214637446|NCT00820521|DRUG|active|
214637447|NCT00820521|DRUG|placebo|
214637448|NCT03569527|DIETARY_SUPPLEMENT|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
214637449|NCT03569527|DIETARY_SUPPLEMENT|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
214637450|NCT03569527|DIETARY_SUPPLEMENT|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
214637451|NCT04857255|BEHAVIORAL|Technology assisted language intervention|speech language therapy that has integrated technology delivered through specific software on an iPad
214637452|NCT04857255|BEHAVIORAL|Treatment as usual|No change will occur to the current ongoing speech-language therapy being delivered.
214637453|NCT06194591|DEVICE|NephrospecTM, low-intensity extracorporal shockwave therapy device|"Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter."
214637454|NCT06194591|DEVICE|Sham-Device|The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
214637455|NCT01290380|DRUG|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
214637456|NCT01112098|BEHAVIORAL|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
214637457|NCT02966691|OTHER|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
214637458|NCT06239311|DRUG|Methotrexate|Solution for injection in prefilled pen
214637459|NCT06239311|DRUG|Placebo|Solution for injection in prefilled pen
214637460|NCT03299920|OTHER|Standardized instructions|Specific instructions related to peripheral nerve block.
214637461|NCT03299920|OTHER|Conventional instructions|Usual post-operative instructions.
214637462|NCT04145011|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
214637463|NCT04145011|DEVICE|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
214637464|NCT00336947|DRUG|tegafur-gimeracil-oteracil potassium|
214637465|NCT00336947|DRUG|tegafur-uracil|
214637466|NCT00336947|PROCEDURE|adjuvant therapy|
214637467|NCT01666327|DRUG|MT-1303|
214637468|NCT05572775|PROCEDURE|Quadratus lumborum (QL) block|bilateral anterior subcostal quadratus lumborum block
214637469|NCT05572775|PROCEDURE|Erector Spinae Plane (ESP) Block|bilateral erector spinae plane block
214637470|NCT05347160|PROCEDURE|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
214637471|NCT02035995|OTHER|Pregnant volunteers with GDM|
214637472|NCT01520571|PROCEDURE|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
214637473|NCT01520571|PROCEDURE|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
214637474|NCT05024955|PROCEDURE|Discussion|Attend a focus group
214637475|NCT05024955|OTHER|Interview|Attend interview
214637476|NCT01383837|BEHAVIORAL|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
214637477|NCT01383837|BEHAVIORAL|Health Promotion|Health Promotion Intervention
214637478|NCT00470600|DRUG|Caldolor|800 milligrams intravenous
214637479|NCT00470600|OTHER|Normal Saline|Placebo comparator
214637480|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
214637481|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
214637482|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
214637483|NCT01962051|DEVICE|Amplatzer Cardiac Plug|
214637484|NCT00678873|PROCEDURE|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
214637485|NCT00270517|DRUG|EDP-420 / Duration of Treatment - 3 days|
214637486|NCT00270517|DRUG|Telithromycin / Duration of Treatment - 7 days|
214637487|NCT01432691|PROCEDURE|Hemi (hemialloplastik)|THA vs hemi
214637488|NCT01738334|BEHAVIORAL|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
214724744|NCT00796003|DRUG|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
214724745|NCT00776373|DRUG|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
214724746|NCT02727504|DEVICE|Electrocardiogram|ECG at inclusion and M12
214724747|NCT02727504|DEVICE|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
214724748|NCT02727504|DEVICE|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
214637489|NCT01738334|BEHAVIORAL|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
214637490|NCT02126709|DRUG|Repigel|Repigel will be used as the intervention in the treatment group
214637491|NCT00357500|DRUG|celecoxib|
214637492|NCT00357500|DRUG|cyclophosphamide|
214724749|NCT02727504|BIOLOGICAL|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
214724750|NCT02727504|DEVICE|Cardiac MRI|Cardiac MRI at inclusion
214637493|NCT00357500|DRUG|etoposide|
214637494|NCT00357500|DRUG|fenofibrate|
214637495|NCT00357500|DRUG|thalidomide|
214724751|NCT02727504|DEVICE|Cardiac scanner|Cardiac scanner at inclusion
214724752|NCT02727504|OTHER|6-minutes walking test|6-minutes walking test at inclusion and M12
214724753|NCT02727504|OTHER|Duke Activity Score|Duke Activity Score at inclusion and M12
214724754|NCT03687476|DRUG|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
214724755|NCT01929512|DRUG|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
214637496|NCT03550482|DIETARY_SUPPLEMENT|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
214637497|NCT00985335|OTHER|Neem Based External Application Cream|Apply externally 3-4 times per day
214637498|NCT01533376|DRUG|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
214637499|NCT01533376|DRUG|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
214637500|NCT02107586|PROCEDURE|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
214637501|NCT02107586|PROCEDURE|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
214637502|NCT03754426|DEVICE|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
214637503|NCT06017804|OTHER|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
214637504|NCT06017804|OTHER|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
214637505|NCT02841969|OTHER|Electrolysed water|Irrigation of wound using electrolysed water
214637506|NCT02841969|OTHER|Prontosan|Irrigation of wound using Prontosan
214637507|NCT00176995|DRUG|15% Eflornithine Hdyrochloride|
214637508|NCT00473707|PROCEDURE|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
214637509|NCT00473707|PROCEDURE|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
214637510|NCT00473707|DRUG|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
214637511|NCT00473707|DRUG|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
214724756|NCT01929512|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
214637512|NCT03132181|DRUG|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
214637513|NCT03132181|OTHER|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
214637514|NCT03739632|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
214637515|NCT03739632|OTHER|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
214637516|NCT03655964|DRUG|Olmesartan|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
214637517|NCT03655964|DRUG|Nebivolol|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
214637518|NCT03655964|OTHER|No antihypertensive treatment|Patients will be left without treatment
214637519|NCT02197676|DRUG|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
214637520|NCT05853614|BEHAVIORAL|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
214637521|NCT00746135|DEVICE|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
214637522|NCT04434521|BEHAVIORAL|Questionnaire|Questionnaire about habits in terms of near vision activities
214724757|NCT01929512|DRUG|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
214724758|NCT00657930|DRUG|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
214724759|NCT05179057|DRUG|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
214724760|NCT05179057|DRUG|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
214724761|NCT02155504|DRUG|ASP3700|oral
214724762|NCT02155504|DRUG|itraconazole|oral
214724763|NCT02155504|DRUG|Placebo|oral
214637523|NCT04434521|OTHER|Eye examination|"The eye examination involves the following measurements:~* Distant vision phoria with Thorington method~* Close vision with Thorington method~* Objective eye-to-eye refraction with self-refractometer~* Binocular objective refraction with autorefractometer~* Monocular/biocular/binocular refraction with Nidek TS610~* SiView automatic refraction~* Humphriss binocular refraction~* MOU Binocular refraction"
214637524|NCT02948621|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
214637525|NCT06146725|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
214637526|NCT06146725|PROCEDURE|Tumor biopsy|Biopsy of the tumor
214637527|NCT01730235|OTHER|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
214637528|NCT01816581|DRUG|Targin|
214637529|NCT01816581|DRUG|Oxynorm|
214637530|NCT01816581|DRUG|Morphine|
214637531|NCT02695628|DRUG|18F-Fluoromisonidazole|Undergo \[18F\] FMISO PET/CT
214637532|NCT02695628|PROCEDURE|Arterial Embolization|Undergo transcatheter arterial embolization
214637533|NCT02695628|DIAGNOSTIC_TEST|Computed Tomography|Undergo \[18F\] FMISO PET/CT
214637534|NCT02695628|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo \[18F\] FMISO PET/CT
214724764|NCT04409691|DRUG|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
214637535|NCT02175056|BIOLOGICAL|HL2351|Dose-escalation For 5 level dose groups A \~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
214637536|NCT02175056|BIOLOGICAL|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A\~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
214637537|NCT02520232|BEHAVIORAL|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
214637538|NCT02520232|BEHAVIORAL|Stretching and balance exercise program|Stretching and balance exercise program
214637539|NCT00679497|BIOLOGICAL|MVA-B|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
214637540|NCT00679497|BIOLOGICAL|Placebo|-3 immunisations at week 0, 4 and 16
214637541|NCT06017596|DEVICE|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
214724765|NCT04409691|DRUG|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
214724766|NCT03376776|PROCEDURE|Vitrectomy|
214724767|NCT04420065|DEVICE|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
214724768|NCT04420065|DEVICE|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
214724769|NCT03356795|BIOLOGICAL|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
214724770|NCT00644813|OTHER|Scapular with glenoid neck fractures|
214724771|NCT05092347|DRUG|Vonsetamig|Administered by intravenous (IV) infusion
214724772|NCT02437162|DRUG|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
214724773|NCT02437162|DRUG|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
214637542|NCT05068336|DIAGNOSTIC_TEST|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
214637543|NCT05068336|DIAGNOSTIC_TEST|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
214637544|NCT05089500|OTHER|Endoscopic injection sclerotherapy|Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
214637545|NCT05089500|OTHER|Endoscopic Band Ligation|Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
214637546|NCT04113772|DRUG|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
214637547|NCT04113772|DRUG|Orfadin|Orfadin
214637548|NCT00314600|DEVICE|above and below elbow cast|
214637549|NCT02681237|DRUG|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
214637550|NCT02681237|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
214637551|NCT04772729|DRUG|Insulin faster aspart (Fiasp, Novo Nordisk)|"Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent."
214637552|NCT02033564|DEVICE|Macintosh/Miller Laryngoscope|
214637553|NCT02033564|DEVICE|Glidescope Laryngoscope|
214637554|NCT01791192|DRUG|FTY720|Fingolimod
214637555|NCT01791192|DRUG|Oral Corticosteroid|Oral Corticosteroid
214724774|NCT02437162|DRUG|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
214724775|NCT02437162|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
214724776|NCT04338321|DRUG|Esketamine 28 mg|Esketamine will be self-administered at a dose of 28 mg as nasal spray.
214724777|NCT04338321|DRUG|Esketamine 56 mg|Esketamine will be self-administered at a dose of 56 mg as nasal spray.
214637556|NCT04914208|DEVICE|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
214637557|NCT04914208|DEVICE|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
214637558|NCT04914208|DEVICE|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
214637559|NCT04914208|OTHER|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
214637560|NCT04914208|OTHER|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
214637561|NCT04675866|OTHER|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
214637562|NCT03027739|BIOLOGICAL|CART-19|CART-19 cells treated
214637563|NCT02573155|DRUG|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637564|NCT02573155|DRUG|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637565|NCT02573155|DRUG|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637566|NCT02573155|DRUG|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637567|NCT02573155|DRUG|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637568|NCT02573155|DRUG|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637569|NCT02573155|DRUG|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214637570|NCT02573155|DRUG|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
214724778|NCT04338321|DRUG|Esketamine 84 mg|Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
214637571|NCT02573155|DRUG|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
214637572|NCT02573155|DRUG|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
214637573|NCT02573155|DRUG|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
214637574|NCT02179333|OTHER|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
214637575|NCT01681433|DRUG|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
214637576|NCT01681433|DRUG|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
214637577|NCT01681433|DRUG|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
214637578|NCT00896376|BIOLOGICAL|trastuzumab|
214637579|NCT00896376|OTHER|laboratory biomarker analysis|
214637580|NCT00896376|OTHER|pharmacological study|
214637581|NCT04963257|DRUG|sertraline fluvoxamine|the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
214637582|NCT04963257|DRUG|sertraline|The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
214637583|NCT02301403|DRUG|Nicotine patch|8 weeks of nicotine patch
214637584|NCT02301403|BEHAVIORAL|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
214637585|NCT02301403|DRUG|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
214637586|NCT02301403|DRUG|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
214637587|NCT02301403|BEHAVIORAL|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
214637588|NCT02301403|BEHAVIORAL|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
214637589|NCT02301403|BEHAVIORAL|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
214637590|NCT02884778|DIAGNOSTIC_TEST|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
214637591|NCT01148277|DRUG|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
214637592|NCT01148277|DRUG|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
214637593|NCT01148277|DRUG|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
214637594|NCT01421550|PROCEDURE|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
214637595|NCT01421550|PROCEDURE|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
214637596|NCT06463600|DEVICE|Magseed|Tumour localizer
214637597|NCT06463600|DEVICE|Metallic clip and guide wire|Tumour localizers
214637598|NCT05654831|DRUG|Placebo|Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
214637599|NCT05654831|DRUG|ECC5004|ECC5004 will be administered as oral tablet(s) during each dosing day.
214637600|NCT03958448|PROCEDURE|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
214637601|NCT03958448|PROCEDURE|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
214637602|NCT03958448|PROCEDURE|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
214637603|NCT02189850|DRUG|BLI800 - Dose 1|BLI800 oral solution
214637604|NCT02189850|DRUG|BLI800 - Dose 2|BLI800 oral solution
214637605|NCT01076582|DRUG|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
214637606|NCT01076582|DRUG|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
214637607|NCT01141595|DRUG|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
214637608|NCT03290495|DRUG|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
214637609|NCT03290495|DRUG|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
214637610|NCT00038350|BEHAVIORAL|Lingual Strengthening|8 week lingual strengthening exercise protocol
214637611|NCT06087354|OTHER|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
214637612|NCT05427266|OTHER|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
214637613|NCT04500327|OTHER|Drive app|The Drive app will be used to monitor sleep metrics for users of CPAP therapy.
214637614|NCT04500327|DEVICE|Non contact motion sensor|The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
214637615|NCT06317480|PROCEDURE|bone resection|patients underwent soft tissue sarcoma excision together with bone resection following either biological or endoprosthesis reconstruction
214637616|NCT06317480|PROCEDURE|subperiosteal excision|patients underwent sub-periosteal tumor excision combining bone and soft tissue ablation without bone excision
214637617|NCT04687501|DEVICE|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
214637618|NCT03347071|BEHAVIORAL|Prevention Course Group|The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
214637619|NCT05051007|DRUG|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
214637620|NCT05051007|DRUG|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
214637621|NCT03580421|PROCEDURE|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
214637622|NCT03580421|PROCEDURE|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
214637623|NCT04868812|DEVICE|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
214637624|NCT05079607|OTHER|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
214637625|NCT05079607|OTHER|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
214637626|NCT05701332|BIOLOGICAL|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
214637627|NCT03286855|DEVICE|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
214637628|NCT03286855|DEVICE|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
214637629|NCT00425386|DRUG|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily"
214637630|NCT00425386|DRUG|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
214637631|NCT00425386|PROCEDURE|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
214637632|NCT01708460|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
214637633|NCT04464980|DRUG|SL-BUP|Daily dosing of sublingual buprenorphine-naloxone
214637634|NCT04464980|DRUG|XR-BUP|Weekly/monthly dosing of extended-release injectable buprenorphine
214637635|NCT04464980|DRUG|XR-NTX|Monthly dosing of extended-release injectable naltrexone
214637636|NCT04464980|BEHAVIORAL|MM|MM consists of standard Medical Management and the usual counseling at the treatment program.
214637637|NCT04464980|BEHAVIORAL|MMR|MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
214637638|NCT04464980|BEHAVIORAL|MMD|MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
214637639|NCT03436615|DRUG|SB206 4%|Twice daily
214637640|NCT03436615|DRUG|SB206 8%|Twice daily
214637641|NCT03436615|DRUG|SB206 12%|Once or twice daily
214637642|NCT03436615|DRUG|Placebo|Once or twice daily
214637643|NCT02271412|DRUG|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
214637644|NCT02271412|DRUG|Placebo|Placebo
214637645|NCT03341169|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|:Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
214637646|NCT03341169|DRUG|placebo (0.9% NaCl (normal saline))|Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
214637647|NCT03505021|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
214637648|NCT03505021|DRUG|Placebo for levosimendan|Placebo capsule for oral administration
214637649|NCT02791061|OTHER|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
214637650|NCT02791061|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
214637651|NCT02791061|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
214637652|NCT03803098|DEVICE|reference measure|measure of a physiological parameter performed with the gold standard medical device
214637653|NCT03803098|DEVICE|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
214637654|NCT07089654|BEHAVIORAL|A PMT rehabilitation nursing plan|Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving 2 phases of relaxation and breathing exercises, face exercises, hand exercises and mind exercises to promote cognitive health. Phase 1 (Weeks 1-6): Includes relaxation and breathing exercises (10 minutes), facial exercises (10 minutes), bead maze activities (10 minutes), geometric shape puzzles (10 minutes), and finger exercises (20 minutes). Phase 2 (Weeks 7-12): Includes relaxation and breathing exercises (10 minutes), Tai Chi ball exercises (10 minutes), screw and nut assembly activities (10 minutes), tangram puzzles (10 minutes), and upper limb music exercises (20 minutes). The experimental group will be given interventions, twice a week every Tuesday and Thursday 9-10 am along with the study intervention.
214637655|NCT07089654|BEHAVIORAL|General rehabilitation nursing|The control group will be given a standard health education on cognitive health.
214724779|NCT04338321|DRUG|Quetiapine XR 50 mg|Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
214637656|NCT06917664|DRUG|sacubitril/valsartan|Sacubitril/valsartan therapy after isolated CABG
214637657|NCT07141745|PROCEDURE|Pulsed field ablation of reccurent atrial arrythmia|Substrate modification strategy based ablation of reccurent atrial arrythmia following pulmonary viens isolation employing pulsed field ablation with 3D guidance and high density mapping
214637658|NCT07141745|PROCEDURE|Radiofrequency ablation of reccurent atrial arrythmia (standard of care)|Standard radiofrequncy ablation of reccurent atrial arrythmia following pulmonary vien isolation employing substrate modification strategy
214637659|NCT07142902|OTHER|Data processing only, treatment is not part of the registry|Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.
214637660|NCT07143448|BIOLOGICAL|HS235|Subcutaneous Injection
214637661|NCT07143448|OTHER|Placebo|Subcutaneous Injection
214724780|NCT04338321|DRUG|Quetiapine XR 100 mg|Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
214724781|NCT04338321|DRUG|Quetiapine XR 150 mg|Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
214637662|NCT07142993|BEHAVIORAL|Social Media-Based Nursing Intervention|A structured nursing follow-up program delivered through a WeChat group. The program included regular sharing of educational content (articles, videos), personalized care advice, remote photo-based monitoring by medical staff, and peer support within the group. The intervention was managed by a dedicated team of dermatologists and nurses.
214637663|NCT07142993|BEHAVIORAL|Conventional Nursing Care|A standard care follow-up protocol involving verbal education at discharge, provision of printed health materials, and proactive weekly telephone calls to monitor the patient's condition, correct improper self-care actions, and encourage clinic visits if necessary.
214637664|NCT07143123|BEHAVIORAL|Cloud-based learning platform|"The SimCapture system is the technological backbone of the intervention, transforming the way clinical skills are taught and learned.~1. System Access and Structure:Both faculty and students are provided with individual accounts to access the SimCapture platform.~2. The system facilitates the organization of students into groups, enabling collaborative learning and peer feedback.~3. Digital Evaluation Tools:Faculty develop standardized, digital tools within SimCapture to assess student performance of clinical skills.These tools ensure consistent and objective evaluation.~4. Recording and Feedback:Students record their practice sessions using personal devices (e.g., smartphones).These recordings are uploaded to the SimCapture cloud, creating a repository of learning resources.~5. Faculty use tablets to provide specific, time-stamped feedback on student performance directly within the SimCapture system."
214637665|NCT07143058|PROCEDURE|Flaps reconstruction in head and neck in oral cance|Follow up and quality of life of reconstruction flaps in head and neck
214637666|NCT07143058|PROCEDURE|Flap of head and neck|All types of flaps in oral cancer reconstruction
214637667|NCT07144436|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
214637668|NCT07143149|DEVICE|the Intelligent Lipid Management Decision-support System|Doctor's Side: Long-term lipid management support based on guidelines/consensus• Provides lipid management pathways based on guidelines/consensus to ensure clinical decisions align with the latest standards.• Combines individualized patient data to offer intelligent lipid management and medication suggestions.• Provides medical education support to enhance doctors' awareness of guidelines, consensus, and management strategies.Patient's Side: Personalized lipid risk assessment and regular reminders• Based on the lipid test reports uploaded by patients via photos, provides lipid test reports tailored to the patient's risk stratification.• Uses digital tools to regularly remind patients, optimizing follow-up adherence and medication compliance.
214724782|NCT04338321|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
214724783|NCT03107793|DRUG|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
214637669|NCT07144423|PROCEDURE|Endoscope-assisted hematoma drainage|The procedure of endoscope-assisted hematoma drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as shown on CT scan. A bone flap measuring 2.0 cm × 2.0 cm is then created using a milling cutter. Under the guidance of a visualized neuroendoscope, the hematoma is thoroughly irrigated and evacuated. A subdural drainage tube is inserted, and postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
214637670|NCT07144423|PROCEDURE|Burr hole hematoma drainage|The procedure of burr hole drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as indicated by CT scan. A subdural drainage tube is then inserted. The hematoma cavity is irrigated intraoperatively until the drainage fluid becomes clear. Postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
214637671|NCT07144592|BEHAVIORAL|solution-oriented approach program|The solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment.
214724784|NCT06122909|DRUG|Group VTI|Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
214724785|NCT06122909|DRUG|Group IVC|Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
214637672|NCT07144722|OTHER|Exercise|What distinguishes this intervention from others is its hybrid delivery model, combining virtual more than in-person sessions to increase accessibility and adherence. Additionally, it incorporates specific inspiratory muscle training, which is often overlooked in standard prehabilitation programs, and emphasizes a personalized progression based on each participant's functional capacity and feedback. This tailored approach aims to optimize physical readiness before surgery while minimizing patient burden and travel requirements.
214637673|NCT05901818|DRUG|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
214637674|NCT05744921|DRUG|Pozelimab|Administered per the protocol
214637675|NCT05744921|DRUG|Cemdisiran|Administered per the protocol
214637676|NCT05752279|DRUG|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
214637677|NCT05752279|DRUG|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
214637678|NCT04319510|PROCEDURE|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
214637679|NCT04319510|PROCEDURE|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
214637680|NCT04319510|PROCEDURE|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered self-selection to 1:1 CST or participation in the CST self-help group training.
214637681|NCT04062318|DEVICE|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
214637682|NCT05861531|BEHAVIORAL|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
214637683|NCT05861531|BEHAVIORAL|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
214637684|NCT05861531|BEHAVIORAL|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
214637685|NCT05861531|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
214637686|NCT05861531|BEHAVIORAL|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
214637687|NCT04027972|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
214637688|NCT04027972|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
214637689|NCT01149265|BEHAVIORAL|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
214637690|NCT01149265|BEHAVIORAL|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
214637691|NCT04705051|DRUG|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
214637692|NCT04532710|DRUG|Eye Drops, Solution in Single-Dose Container|Application of eye drops
214724786|NCT02808507|OTHER|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
214637693|NCT06267027|BEHAVIORAL|Exercise|The aim of exercise therapy is to stretch and strengthen the wrist extensor and flexor muscles. All study groups were given a home exercise program including stretching and eccentric strengthening exercises. The patient was instructed to start with stretching, and the patient was informed to stretch for 30s by flexing the wrist with the other hand while the shoulder was flexed 90 degrees, the elbow was in extension and the forearm was pronated. When stretching exercises could be performed painlessly, the patient was instructed to move on to strengthening exercises. Eccentric strengthening exercises for wrist extensors and flexors were explained with a support under the forearm and each patient was given a written program supported with visuals. It was emphasized that the exercises should be performed within the pain limit and patients were told to stop if they had severe pain. The exercise program was told to be performed 2 times a day, in 3 sets, 10 repetitions.
214637694|NCT06267027|DEVICE|Kinesiotaping|Area where the tape would be applied was clean and dry. If there is excessive hair in the application area, patients were asked to shave this area. It was explained that cream and similar substances should not be used. Muscle inhibition technique and fascia correction technique were used as the application technique. An X strip of approximately 25 cm and a Y strip of 10 cm in length are prepared as long as the distance between the lateral epicondyle and the wrist. The short arms of the X strip are adhered to the dorsal side of the hand without stretching and the crossed part of the strip is placed on the wrist with maximal stretching. The long arms of the X strip are adhered along the extensor carpi ulnaris and extensor carpi radialis to the lateral epicondyle without stretching. The Y strip was applied using the fascia correction method. The tails of the Y band were applied using an oscillating motion. The taping procedure was applied 2 times a week for 3 weeks for a total of 6 times.
214637695|NCT06267027|DEVICE|High intensity laser therapy|The elbow area was marked and then the epicondylitis protocol was selected. The epicondylitis protocol consists of 3 phases. Phase 1 and 2 consist of analgesic treatment and phase 3 consists of anti-inflammatory treatment. In phase 1 and phase 2 treatment protocol, 8 W was applied to a circular area with a radius of 1.0 cm for 3 min. In Phase 3 protocol, a dose of 80 J/cm2 at 8 W power was applied and the patient's treatment was completed.
214637696|NCT04640623|DRUG|TAR-200|TAR-200 will be administered transuretherally.
214637697|NCT04640623|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
214637698|NCT01273545|DRUG|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
214637699|NCT06211231|BEHAVIORAL|Digitally delivered mindfulness- and acceptance-based psychological intervention|MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
214637700|NCT04906434|DRUG|ABSK-011|"During the escalation part, the administration of oral ABSK-011 will be guided by 3+3design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level."
214637701|NCT06425627|PROCEDURE|spinal anesthesia|An intrathecal anesthetic technique.
214637702|NCT06425627|PROCEDURE|general anesthesia|An intravenous (combined with inhalation) anesthetic technique.
214637703|NCT05101018|DRUG|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
214637704|NCT05101018|DRUG|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
214637705|NCT04835012|OTHER|Medical debt forgiveness|A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
214637706|NCT01772615|DRUG|Ciprofloxacin|Antibiotic
214637707|NCT01772615|DIETARY_SUPPLEMENT|E. coli Nissle|Probiotic
214637708|NCT03280004|DRUG|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
214637709|NCT04450485|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
214637710|NCT02244710|DRUG|Ticagrelor vs Clopidogrel|
214724787|NCT06667401|DEVICE|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia.We also aim to see of how it enhances teaching and training of residents by experienced regional anesthesia providers. We intend to use surveys/questionnaires of both resident and regional anesthesia provider as they utilize the device in real time.
214724788|NCT03198286|OTHER|Informational Intervention|Receive treatment summary and survivor care plan
214724789|NCT01989572|OTHER|Laboratory Biomarker Analysis|Correlative studies
214724790|NCT01989572|OTHER|Placebo|Given GM-CSF placebo SC
214724791|NCT01989572|OTHER|Placebo|Given peptide placebo SC
214724792|NCT01989572|BIOLOGICAL|Sargramostim|Given SC
214724793|NCT01989572|BIOLOGICAL|Tyrosinase Peptide|Given SC
214724794|NCT06322017|PROCEDURE|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|"The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner."
214724795|NCT06322017|DRUG|Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)|"Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations."
214724796|NCT03009149|OTHER|Aerobic exercise|Aerobic exercise will perform 3 days per week
214724797|NCT04689217|DRUG|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
214724798|NCT06009575|DIETARY_SUPPLEMENT|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
214724799|NCT00736606|DRUG|simvastatin|One single dose of 40mg
214724800|NCT00736606|DRUG|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
214724801|NCT02174809|BEHAVIORAL|Use of 5As to discuss gestational weight gain|
214724802|NCT02174809|BEHAVIORAL|Usual care|
214724803|NCT01129414|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
214724804|NCT01129414|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
214724805|NCT01129414|DRUG|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
214637711|NCT04109495|OTHER|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
214637712|NCT04109495|OTHER|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
214637713|NCT02270203|RADIATION|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
214637714|NCT04525716|OTHER|COVID-19 infection status|We will compare patients with/without confirmed COVID-19 infection
214637715|NCT00741156|DRUG|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
214637716|NCT01316172|BEHAVIORAL|5 Cs|education on consultation
214637717|NCT03879564|DRUG|Ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
214637718|NCT03879564|DRUG|Normal saline|NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
214637719|NCT03388463|DRUG|Omeprazole|Omeprazole 80 mg continues infusion
214637720|NCT03388463|DRUG|Placebo group|Omeprazole 40 mg single daily dose.
214637721|NCT01951469|DRUG|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
214637722|NCT01951469|DRUG|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
214637723|NCT02463955|DEVICE|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
214637724|NCT02463955|DEVICE|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
214637725|NCT00734669|DRUG|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
214637726|NCT02165384|DEVICE|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
214637727|NCT02762513|DRUG|Axitinib|
214637728|NCT01390909|DRUG|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
214637729|NCT03917602|PROCEDURE|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
214637730|NCT03459027|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g) acutely
214637731|NCT03459027|DIETARY_SUPPLEMENT|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
214637732|NCT00694057|DRUG|HE3286|HE3286 10 mg per day (5 mg BID)
214637733|NCT00694057|DRUG|Placebo|Placebo capsules BID
214637734|NCT04724161|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
214637735|NCT04357457|DRUG|Almitrine|Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
214637736|NCT04357457|DRUG|Placebo|Intravenous glucose 5% during 5 days
214637737|NCT06399497|OTHER|spinal manipulation|A high-velocity low-amplitude spinal manipulation at the L5 level will be performance by means of the lumbar roll technique, with the subject in right lateral decubitus.
214637738|NCT06399497|OTHER|simulated manipulation|Simulated manipulation intervention, in the same position as in the Intervention Group, performance in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
214637739|NCT03632395|DIAGNOSTIC_TEST|computed tomography|computed tomography
214637740|NCT03438045|BEHAVIORAL|Partnered intervention|CHWs will provide dental education and counseling, lead interactive demonstrations of brushing with fluoride toothpaste and flossing, and improve access to dental care through dental coverage enrollment and linkage to local dentists.
214637741|NCT05873348|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
214637742|NCT00984204|DEVICE|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
214637743|NCT03844906|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
214637744|NCT03844906|DRUG|Placebo|Placebo in combination with Ketamine
214637745|NCT04363372|DRUG|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
214637746|NCT04363372|DRUG|Placebo|Placebo capsules will be identical in appearance to active product.
214637747|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
214637748|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
214637749|NCT01294384|DRUG|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
214637750|NCT05850208|BIOLOGICAL|Transplantation of self BMSCs|Bone marrow was collected, cultured in vitro and injected back into the body
214637751|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
214637752|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
214637753|NCT01062360|DRUG|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
214637754|NCT01062360|DRUG|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
215030515|NCT06644950|OTHER|Efficacy and safety of administering 1 or two cartridges of anesthesia|"The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block."
214637755|NCT05129397|BEHAVIORAL|Mom Power|Virtual Mom Power is a manualized multi-family group intervention consisting of 10 virtual group + 2 individual sessions led by two masters-level co-facilitators. Virtual groups are 90 minutes, following a structured format via secure HIPAA compatible video platform. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice (4) Social Support; \& (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs.
214637756|NCT05129397|BEHAVIORAL|Mom Power Informational Mailing|This active comparison condition intervention includes two individual sessions along with 10 weeks of informational mailing with content related to Mom Power core concepts.
214637757|NCT02848079|DRUG|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
214637758|NCT02168686|GENETIC|ADVM-043|Gene transfer vector administration
214637759|NCT04290702|PROCEDURE|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
214637760|NCT02803164|DEVICE|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
214637761|NCT02803164|OTHER|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
214637762|NCT00786877|OTHER|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
214637763|NCT00786877|OTHER|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
214637764|NCT02828072|OTHER|SKY therapy|slow breathing
214637765|NCT02828072|DRUG|usual drug therapy|
214637766|NCT01076465|OTHER|Disease management program|1\. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
214637767|NCT01076465|BEHAVIORAL|Usual care|Usual care
214637768|NCT04313556|PROCEDURE|Lateral patellar release|Arthroscopic lateral patellar reticular release
214637769|NCT05093101|OTHER|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
214637770|NCT00004493|DRUG|sodium dichloroacetate|
214637771|NCT01268293|DRUG|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
214637772|NCT00699348|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
215030516|NCT04562090|DRUG|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
215030517|NCT06643247|DRUG|Drug|1\) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
214637773|NCT06173557|PROCEDURE|entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic i|technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports
214637774|NCT00618748|DRUG|Olanzapine|5-20 mg/day, oral, daily
214637775|NCT04788082|DIAGNOSTIC_TEST|3D Printed Heart Model|Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
214637776|NCT01099202|DRUG|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
214637777|NCT00883883|DRUG|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
214637778|NCT00883883|DRUG|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
214637779|NCT03870802|OTHER|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
214637780|NCT05273684|OTHER|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
214637781|NCT04390867|DEVICE|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
214637782|NCT04390867|DEVICE|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
214637783|NCT04390867|DEVICE|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
214637784|NCT04390867|DEVICE|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
214637785|NCT05446493|DRUG|Tadalafil 5mg|"* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~* Penile color Doppler ultrasound examination before and after treatment"
214637786|NCT03592979|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214637787|NCT03592979|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
214637788|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
214637789|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
214637790|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
214637791|NCT03812809|DRUG|BPI-7711|BPI-7711: 180mg, QD, oral
214637792|NCT05282823|DEVICE|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
214637793|NCT04505683|DRUG|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
214637794|NCT04505683|DRUG|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
214637795|NCT06164405|DEVICE|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
214637796|NCT05753722|BIOLOGICAL|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
214637797|NCT05753722|BIOLOGICAL|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
214637798|NCT04288570|PROCEDURE|suture anchor socket creation with punch|suture anchor socket creation with punch
214637799|NCT04288570|PROCEDURE|suture anchor socket creation with drill|suture anchor socket creation with drill
214637800|NCT06401018|PROCEDURE|No noise cancellation and no music playing|In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.
214637801|NCT06401018|PROCEDURE|Noise cancelled but not allowed to listen to music|In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.
214637802|NCT06401018|PROCEDURE|Music is played but noise is not cancelled|In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
214637803|NCT06175234|DEVICE|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
214637804|NCT04880577|DRUG|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
214637805|NCT04880577|DRUG|Placebo|Placebo arm
214637806|NCT05022641|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
214637807|NCT05022641|OTHER|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
214637808|NCT00223496|DRUG|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
214637809|NCT05000346|DRUG|Drug, inhalation|Solution administered by inhalation
214637810|NCT00435968|DRUG|CVT E002 (Cold-fX)|
214637811|NCT06032949|OTHER|Vialize|Any patients undergoing surgeries involving a groin incision (e.g., femoropopliteal bypass, aortofemoral bypass, loop thigh graft, femoral exposure for delivery of device) will receive Vialize subcutaneously.
214637812|NCT00360581|BEHAVIORAL|Yoga|
214637813|NCT00360581|BEHAVIORAL|Yoga and Cognitive Behavioral Therapy|
214637814|NCT05878652|DEVICE|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
214637815|NCT05878652|OTHER|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
214637816|NCT05882786|PROCEDURE|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
214637817|NCT05882786|PROCEDURE|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
214637818|NCT00428675|OTHER|ACI instrument|Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
214637819|NCT05702515|OTHER|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
214637820|NCT01635114|DIETARY_SUPPLEMENT|resveratrol|150 mg resVida per day for 12 weeks
214637821|NCT01635114|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214637822|NCT04697407|BIOLOGICAL|Blood sampling|In all groups, 80 ml of blood will be collected. For patients, this will be done during routine cares.
214637823|NCT04697407|BIOLOGICAL|CSF sampling|Only in both patients groups whom will have a CSF sampling in routine care, some CSF will be collected for the study in addition, with a limit of 5 ml for routine care and study.
214637824|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 500mg|Mitopure containing softgels
214637825|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 1000mg|Mitopure containing softgels
214637826|NCT03464500|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
214637827|NCT02698735|DRUG|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
214637828|NCT02698735|DRUG|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
214637829|NCT03027752|PROCEDURE|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
215030518|NCT06643247|PROCEDURE|Electroacupuncture|Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
214794237|NCT03744416|OTHER|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
214637830|NCT03027752|PROCEDURE|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
214637831|NCT02653768|BEHAVIORAL|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
214637832|NCT02653768|BEHAVIORAL|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
214637833|NCT04036409|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
214637834|NCT04036409|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
214637835|NCT04407767|BEHAVIORAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
214637836|NCT04407767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
214637837|NCT05904301|OTHER|Usual medical management of patients, additional blood and stool samples for biobanking|"For all systemic diseases the following data will be collected:~Clinical examination, Laboratory data, Current medications, Constitution of biobanking.~For each disease:~Pathology specific Activity score, Global subjective disease activity by patient and by physician."
214637838|NCT01345331|BEHAVIORAL|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
214637839|NCT00424827|DRUG|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
214637840|NCT00274365|PROCEDURE|videoconference|
214637841|NCT00777569|DRUG|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
214637842|NCT00777569|DRUG|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
214637843|NCT00777569|DRUG|Nicotine Lozenge|4 mg nicotine lozenge
214637844|NCT03264430|DRUG|Ketamine|an antagonist of the NMDA receptor
214637845|NCT03264430|DRUG|bupivacaine|local anaesthetic
214637846|NCT00053248|DRUG|arsenic trioxide|
214637847|NCT00053248|DRUG|imatinib mesylate|
214637848|NCT00159432|DRUG|Oxaliplatin|
214637849|NCT00159432|DRUG|Bevacizumab|
214637850|NCT00159432|DRUG|Capecitabine|
214637851|NCT03248726|DRUG|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
214637852|NCT03248726|DRUG|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
214637853|NCT01491178|DRUG|Prazaxa|Dabigatran etexilate
214637854|NCT05218499|DRUG|Brigimadlin|Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).
214637855|NCT05218499|DRUG|Doxorubicin|Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).
214637856|NCT02257047|DIETARY_SUPPLEMENT|Tea|
214637857|NCT02257047|DIETARY_SUPPLEMENT|RYR|red yeast rice
214637858|NCT05689047|DRUG|M5717 330 mg|Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
214637859|NCT05689047|DRUG|M5717 500 mg|Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
214637860|NCT05689047|DRUG|M5717 660 mg|Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
214637861|NCT05689047|DRUG|Pyronaridine 360 mg|Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
214637862|NCT05689047|DRUG|Pyronaridine 360 mg|Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
214637863|NCT05689047|DRUG|Pyronaridine 540 mg|Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
214637864|NCT05689047|DRUG|Pyronaridine 720 mg|Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
214637865|NCT06397833|DEVICE|Acorai ICPM system|Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
214637866|NCT06181240|DEVICE|Intravascular lithotripsy|Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
214794238|NCT04711525|BEHAVIORAL|Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
214794239|NCT04711525|BEHAVIORAL|Control Group: Standard health education|The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
214637867|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
214637868|NCT00612443|BEHAVIORAL|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
214637869|NCT00612443|BEHAVIORAL|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
214637870|NCT00517972|DRUG|Omacor (omega-3-acid ethyl esters)|
214637871|NCT06487624|DRUG|HCB301|HCB301 administered via. intravenous (IV) infusion.
214637872|NCT05607823|OTHER|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
214637873|NCT05607823|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
214637874|NCT05607823|OTHER|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
214637875|NCT05206838|PROCEDURE|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
214637876|NCT02174055|BEHAVIORAL|Patient Interviews|participate in a brief interview
214637877|NCT02174055|BEHAVIORAL|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
214637878|NCT02174055|BEHAVIORAL|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
214637879|NCT05206357|DRUG|Epcoritamab|Subcutaneous Injection (SC)
214637880|NCT05622110|PROCEDURE|Adhesive glue closure|Incision closure with adhesive glue
214637881|NCT05622110|PROCEDURE|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
214637882|NCT04481204|DRUG|Cisplatin|Given IV
214637883|NCT04481204|DRUG|Fluorouracil|Given IV
214637884|NCT04481204|DRUG|Gemcitabine|Given IV
214637885|NCT04481204|DRUG|Irinotecan|Given IV
214637886|NCT04481204|DRUG|Leucovorin|Given IV
214637887|NCT04481204|DRUG|Nab-paclitaxel|Given IV
214637888|NCT04481204|DRUG|Oxaliplatin|Given IV
214637889|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
214637890|NCT05944432|DEVICE|FreeStyle Libre 3 Continuous Glucose Monitoring System.|Subjects will be randomised to use the FreeStyle Libre 3 system
214637891|NCT05944432|DEVICE|Self monitoring of blood glucose|Subjects will be randomised to continue with their current glucose monitoring system
214637892|NCT05553704|DRUG|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
214637893|NCT04827355|DEVICE|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
214637894|NCT04827355|DEVICE|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
214637895|NCT05852704|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
214637896|NCT05852704|DRUG|Placebo Tab|Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
214637897|NCT05405179|PROCEDURE|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized bone flaps for jaw reconstruction using patient-specific surgical guides and titanium plates
214637898|NCT00083083|DRUG|carboplatin|
214637899|NCT00083083|DRUG|cisplatin|
214637900|NCT00083083|DRUG|docetaxel|
214637901|NCT00083083|DRUG|etoposide|
214637902|NCT00083083|DRUG|paclitaxel|
214637903|NCT00083083|DRUG|vinblastine sulfate|
214637904|NCT00083083|DRUG|vinorelbine tartrate|
214637905|NCT00083083|GENETIC|gene expression analysis|
214637906|NCT00083083|PROCEDURE|positron emission tomography|
214637907|NCT00083083|RADIATION|fludeoxyglucose F 18|
214637908|NCT00083083|RADIATION|radiation therapy|
214637909|NCT01018875|DRUG|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
214724806|NCT05756205|DEVICE|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
214637910|NCT01018875|DRUG|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
214637911|NCT01018875|DRUG|placebo|Subjects will take 4 capsules once daily for 12 weeks.
214637912|NCT06465589|OTHER|JOURNeY anonymous|"The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
214724807|NCT00410345|DRUG|Mifepristone|
214637913|NCT06465589|OTHER|JOURNeY standard|"The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
214637914|NCT03779113|DRUG|HMPL-523|Oral HMPL-523
214637915|NCT00211146|DRUG|epoetin alfa|
214637916|NCT03655756|BIOLOGICAL|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
214637917|NCT00798746|BEHAVIORAL|Telephone Questionnaire|Ten questions regarding symptoms of reflux
214637918|NCT02163473|PROCEDURE|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
214637919|NCT02163473|PROCEDURE|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
214637920|NCT05409547|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
214637921|NCT01476657|DRUG|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
214637922|NCT03406221|BEHAVIORAL|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
214637923|NCT03406221|OTHER|Control Condition|Standard of care
214637924|NCT04623450|OTHER|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
214637925|NCT03894930|BEHAVIORAL|Metta meditation|Administered 5 days per week for 8 weeks.
214637926|NCT04226404|OTHER|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
214637927|NCT04226404|OTHER|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
214637928|NCT04226404|OTHER|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
214637929|NCT04226404|OTHER|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
214637930|NCT04226404|OTHER|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
214637931|NCT04226404|OTHER|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
214637932|NCT04226404|OTHER|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
214637933|NCT02010164|DIETARY_SUPPLEMENT|Co-enzyme Q10|600mg for 3 months
214637934|NCT05364242|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
214637935|NCT00253630|OTHER|Laboratory Biomarker Analysis|Correlative studies
214637936|NCT00253630|DRUG|Vorinostat|Given PO
214637937|NCT03237065|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
214637938|NCT03237065|DRUG|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
214637939|NCT03771365|PROCEDURE|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
214637940|NCT03771365|PROCEDURE|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
214637941|NCT03771365|PROCEDURE|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
214637942|NCT00039988|DRUG|Glatiramer acetate|20 mg administered subcutaneously daily
214637943|NCT00039988|DRUG|Albuterol|2 mg or 4 mg oral capsules taken daily
214637944|NCT00039988|DRUG|Albuterol placebo|Oral placebo capsules will be taken daily
214637945|NCT00209339|DEVICE|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
214637946|NCT02188030|OTHER|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
214637947|NCT02188030|OTHER|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
214794240|NCT00419926|DRUG|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
214637948|NCT03589378|PROCEDURE|PEAF|PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
214637949|NCT05172739|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
214637950|NCT05172739|DRUG|Opioid-free Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
214637951|NCT00429858|DRUG|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
214794241|NCT00419926|DRUG|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
214794242|NCT00419926|DRUG|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
214637952|NCT00429858|DRUG|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
214637953|NCT02555423|DRUG|Local anaesthetic - chirocaine|
214637954|NCT00161629|DRUG|rhBMP-2/CPM|
214637955|NCT05449600|DEVICE|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
214637956|NCT05449600|DEVICE|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
214637957|NCT05449600|DEVICE|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
214637958|NCT01587079|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
214637959|NCT01587079|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
214637960|NCT01587079|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
214637961|NCT01587079|DRUG|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
214637962|NCT01184482|DRUG|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~1. 750 mg (3 tabs)~2. 1000 mg (4 tabs)~3. 1250 mg (5 tabs)"
214637963|NCT02796378|DRUG|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
214637964|NCT02796378|DRUG|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
214637965|NCT02796378|DRUG|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
214637966|NCT00555100|DRUG|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
214637967|NCT00555100|DRUG|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
214637968|NCT01654510|BEHAVIORAL|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
214637969|NCT01654510|OTHER|Vocational Services as Usual|
214637970|NCT02288338|DRUG|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637971|NCT02288338|DRUG|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637972|NCT02288338|DRUG|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637973|NCT02288338|DRUG|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637974|NCT02288338|DRUG|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637975|NCT02288338|DRUG|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637976|NCT02288338|DRUG|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637977|NCT02288338|DRUG|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637978|NCT02288338|DRUG|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637979|NCT02288338|DRUG|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637980|NCT02288338|DRUG|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637981|NCT02288338|DRUG|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637982|NCT02288338|DRUG|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637983|NCT02288338|DRUG|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637984|NCT02288338|DRUG|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637985|NCT02288338|DRUG|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637986|NCT02288338|DRUG|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
214637987|NCT02288338|DRUG|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
214637988|NCT03995264|PROCEDURE|Ultrasound -guided cannulation|radial artery cannulation using the ultrasound
214637989|NCT03995264|PROCEDURE|Palpation -guided cannulation|radial artery cannulation using the palpation
214637990|NCT04781816|DRUG|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
214637991|NCT04781816|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
214637992|NCT01882283|DIETARY_SUPPLEMENT|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
214637993|NCT01882283|DIETARY_SUPPLEMENT|Placebo|
214637994|NCT03322059|BEHAVIORAL|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
214637995|NCT03322059|BEHAVIORAL|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
214637996|NCT01065974|BEHAVIORAL|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
214637997|NCT01065974|DIETARY_SUPPLEMENT|Meal Replacements|Weight loss using CBT and meal replacements.
214637998|NCT01065974|BEHAVIORAL|Nutritrol|To make widespread nutritional changes to participants personal food environments.
214637999|NCT04904289|OTHER|All intervention of real world|We analyzed all data we can obtain from our databases
214638000|NCT01121393|DRUG|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
214638001|NCT01121393|DRUG|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
214638002|NCT01100944|DRUG|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
214638003|NCT00778037|DRUG|Cyclobenzaprine hydrochloride 10 mg tablet|
214638004|NCT05528627|OTHER|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
214638005|NCT02467530|OTHER|AGE|
214638006|NCT03736512|DEVICE|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
214638007|NCT00958139|OTHER|Permethrin|Permethrin 0.5% treatment of clothing one time
214638008|NCT00958139|OTHER|Placebo|water sprayed on clothing one time
214638009|NCT04741724|DEVICE|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
214638010|NCT01848535|DIETARY_SUPPLEMENT|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
214638011|NCT01848535|DIETARY_SUPPLEMENT|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
214638012|NCT03961282|OTHER|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
214638013|NCT03961282|OTHER|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
214638014|NCT05462210|OTHER|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
214638015|NCT00577993|DRUG|Fludarabine|Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
214638016|NCT00577993|DRUG|Novantrone|Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
214724808|NCT04308109|BEHAVIORAL|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
214724809|NCT05737485|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
214724810|NCT01733524|BEHAVIORAL|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
214724811|NCT01733524|BEHAVIORAL|Picture of a fish|Participants will receive a picture of a betta fish.
214638017|NCT00577993|DRUG|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
214638018|NCT00577993|DRUG|Rituximab|Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
214638019|NCT00577993|DRUG|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
214638020|NCT00577993|DRUG|Doxorubicin|25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
214638021|NCT00577993|DRUG|Vincristine|.7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
214638022|NCT00577993|DRUG|Bleomycin|5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
214638023|NCT00577993|DRUG|Cyclophosphamide|750 mg/m\^2 IV Day 2 of 1st Sequence.
214638024|NCT00577993|DRUG|Etoposide|40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
214638025|NCT00577993|DRUG|Cisplatin|25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
214638026|NCT00577993|DRUG|Ara-C|1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
214638027|NCT00577993|DRUG|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
214638028|NCT00577993|DRUG|Procarbazine|100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
214638029|NCT00577993|DRUG|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
214638030|NCT02217566|DRUG|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
214638031|NCT02217566|DRUG|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
214638032|NCT02217566|DRUG|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
214638033|NCT02296242|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
214638034|NCT01077973|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
214638035|NCT01077973|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
214638036|NCT01077973|DRUG|Placebo|Single-dose of placebo
214638037|NCT02679469|DRUG|nalmefene hydrochloride 10 mg|
214638038|NCT01515774|DRUG|Mirapex ER|Change Requip or Mirapex to Mirapex ER
214638039|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid|Readily available marketed open label ascorbic acid
214638040|NCT04342728|DIETARY_SUPPLEMENT|Zinc Gluconate|Readily available marketed open label zinc gluconate
214638041|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
214638042|NCT04342728|OTHER|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
214638043|NCT00415779|DRUG|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
214638044|NCT00415779|DRUG|zoledronic acid|2 mg IV every 2 weeks
214638045|NCT00328146|OTHER|Observation of sternal reentry|Observation of sternal reentry
214638046|NCT04453579|BEHAVIORAL|Telephonic interview during the Italian lockdown.|The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
214638047|NCT03541005|DIETARY_SUPPLEMENT|Obex|After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
214638048|NCT03541005|DIETARY_SUPPLEMENT|Placebo|After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
214638049|NCT00157612|PROCEDURE|a clinical pathway nursing home acquired pneumonia|treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
214638050|NCT00035594|DRUG|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
214638051|NCT00079859|DRUG|Implitapide|
214638052|NCT01999803|DRUG|sNN0029|
214638053|NCT01999803|DRUG|Placebo|
214638054|NCT04123899|DRUG|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
214638055|NCT04123899|DRUG|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
214638056|NCT03052452|OTHER|My Nutritional Health App|The My Nutritional Health app built in LifeData will be used as the data collection platform for this study. We will use the data collected in the app testing to develop population-level FAST scores.
214638057|NCT02424838|PROCEDURE|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
214638058|NCT02424838|DEVICE|22 gauge needle|
214638059|NCT02424838|DEVICE|25 gauge needle|
214638060|NCT01726946|DRUG|VX-135|12 weeks of VX-135
214638061|NCT01726946|DRUG|ribavirin|12 weeks of ribavirin
214638062|NCT04975061|DRUG|YY-20394|YY-20394 is a small molecule inhibitor.
214638063|NCT05156827|DRUG|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
214638064|NCT05156827|DRUG|Placebo|Normal saline administered through IV infusion over an hour
214638065|NCT04674566|DRUG|COR-101|Administered intravenously (IV) single dose
214638066|NCT04674566|DRUG|Placebo|Administered intravenously (IV) single dose
214638067|NCT04029519|DEVICE|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
214638068|NCT01055002|BIOLOGICAL|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
214638069|NCT02653222|PROCEDURE|Renal sympathicolysis|
214638070|NCT02653222|PROCEDURE|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
214638071|NCT02653222|RADIATION|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
214638072|NCT02653222|BIOLOGICAL|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
214638073|NCT03147469|PROCEDURE|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
214638074|NCT03147469|PROCEDURE|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
214638075|NCT03147469|PROCEDURE|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
214724812|NCT00047593|DRUG|IOP Lowering Medications|
214724813|NCT00558233|BEHAVIORAL|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
214638076|NCT05824429|OTHER|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
214638077|NCT05824429|OTHER|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
214638078|NCT05824429|OTHER|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
214638079|NCT05824429|OTHER|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
214638080|NCT02548026|BEHAVIORAL|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
214638081|NCT02548026|BEHAVIORAL|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
214638082|NCT05875259|DRUG|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
214638083|NCT05875259|DRUG|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
214638084|NCT05875259|DRUG|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
214638085|NCT02706730|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
214638086|NCT02064387|DRUG|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
214638087|NCT04429815|DIAGNOSTIC_TEST|Serological test for COVID-19.|Serological test for COVID-19 performed as part of standard of care.
214638088|NCT02499029|DRUG|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
214638089|NCT02499029|DRUG|Placebo|Identical looking placebo pills were administered each week.
214638090|NCT03369145|DIETARY_SUPPLEMENT|High-fat diet|The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
214638091|NCT02681016|DEVICE|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
214638092|NCT02681016|DEVICE|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
214638093|NCT02681016|PROCEDURE|Coronary angioplasty|
214638094|NCT03950973|BEHAVIORAL|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
214638095|NCT03950973|BEHAVIORAL|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
214638096|NCT03901950|DRUG|XNW7201 tablets|A wnt pathway inhibitor
214638097|NCT02115204|DRUG|Epirubicin|
214724814|NCT00558233|BEHAVIORAL|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
214724815|NCT02682576|PROCEDURE|Brachial artery ultrasound imaging|
214724816|NCT04018105|OTHER|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
214724817|NCT02474628|DIETARY_SUPPLEMENT|sodium bicarbonate|
214724818|NCT02474628|DIETARY_SUPPLEMENT|calcium carbonate|
214724819|NCT00194415|BEHAVIORAL|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
214724820|NCT00194415|PROCEDURE|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
214724821|NCT03127462|BEHAVIORAL|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
214724822|NCT00175838|DRUG|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
214724823|NCT00175838|DRUG|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
214724824|NCT04192318|BEHAVIORAL|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
214724825|NCT04192318|OTHER|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
214724826|NCT04192318|OTHER|Treatment as usual|Treat and release
214638098|NCT02115204|DRUG|Cyclophosphamide|
214638099|NCT02115204|DRUG|Docetaxel|
214724827|NCT01222897|DRUG|Valacyclovir hydrochloride|
214638100|NCT02115204|DRUG|Methotrexate|
214638101|NCT02115204|DRUG|5-fluorouracil|
214638102|NCT04453046|DEVICE|Hemopurifier|Two Hemopurifier treatments on Day 1 and Day 21
214638103|NCT04453046|DRUG|Pembrolizumab 200mg IV|Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
214638104|NCT05047276|BIOLOGICAL|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
214638105|NCT00810979|DRUG|SLx-4090|tablet
214638106|NCT00810979|DRUG|SLx-4090|tablet
214638107|NCT00810979|OTHER|Placebo|matching tablet
214638108|NCT00810979|DRUG|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
214638109|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
214638110|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
214638111|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
214638112|NCT00242827|DRUG|Oral CEP-701|
214638113|NCT06312475|DRUG|KN057|KN057 will be administered subcutaneously once a week.
214638114|NCT03889639|DRUG|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
214638115|NCT03889639|DRUG|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
214638116|NCT03889639|DRUG|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
214638117|NCT06345456|DEVICE|End-tidal capnography|The value of end-tidal capnography
214638118|NCT03060070|DRUG|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
214638119|NCT03060070|DRUG|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
214638120|NCT03060070|DRUG|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
214638121|NCT05792878|DRUG|Interferon|The naive treated patients with chronic hepatitis B were given antiviral treatment with interferon according to their condition.
214638122|NCT05792878|DRUG|nucleoside analogues|The naive treated patients with chronic hepatitis B were given antiviral treatment with nucleoside analogues according to their condition.
214724828|NCT00865046|OTHER|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
214724829|NCT00865046|OTHER|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
214724830|NCT00476398|PROCEDURE|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
214724831|NCT02366247|DRUG|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
214724832|NCT02366247|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
214724833|NCT02366247|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
214724834|NCT00235053|DRUG|fluticasone/salmeterol DISKUS 250/50|
214724835|NCT04587895|BEHAVIORAL|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
214724836|NCT04587895|BEHAVIORAL|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
214724837|NCT04587895|BEHAVIORAL|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
214724838|NCT05326568|OTHER|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
214724839|NCT04146038|DRUG|Azacitidine|Given IV
214638123|NCT05808244|BEHAVIORAL|tgCBFI|Six weekly sessions CBT-based family intervention programme
214638124|NCT05808244|BEHAVIORAL|Usual psychiatric care|Integrated community psychiatric care with medical follow-up
214638125|NCT03618511|BEHAVIORAL|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
214638126|NCT03618511|BEHAVIORAL|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
214638127|NCT03618511|BEHAVIORAL|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
214638128|NCT03618511|BEHAVIORAL|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
214638129|NCT03618511|BEHAVIORAL|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
214638130|NCT03618511|BEHAVIORAL|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
214638131|NCT01789450|PROCEDURE|Section of Periareolar Dermis in Breast Reduction.|
214638132|NCT04828408|PROCEDURE|Bariatric surgery|Patients with a body mass index (BMI) ˃35, age interval of 18-65, and ASA score II-III undergoing laparoscopic bariatric surgery were included in the study. Patients with neuromuscular, cardiopulmonary, and cerebrovascular diseases, phrenic nerve damage or diaphragm paralysis, those who have undergone thoracic surgery, who could not communicate, who did not want to participate in the study, who used alcohol, those who needed postoperative intensive care, those who had surgical complications during surgery, and those who were switched to open surgery were not included in the study.
214638133|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
214638134|NCT04080895|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
214638135|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
214638136|NCT04080895|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
214638137|NCT01993693|DEVICE|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
214638138|NCT01993693|DEVICE|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
214638139|NCT03158870|PROCEDURE|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
214638140|NCT00927095|DRUG|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
214638141|NCT00927095|DRUG|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
214638142|NCT00927095|DRUG|placebo|daily placebo
214638143|NCT04388995|DIAGNOSTIC_TEST|volume expansion|volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
214638144|NCT04894929|OTHER|multi component exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
214724840|NCT04146038|DRUG|Decitabine|Given IV
214724841|NCT04146038|DRUG|Salsalate|Given PO
214724842|NCT04146038|DRUG|Venetoclax|Given PO
214724843|NCT02839044|DIETARY_SUPPLEMENT|Menaquinone-7|
214724844|NCT02839044|DIETARY_SUPPLEMENT|Placebo|
214724845|NCT02680561|DRUG|Fluticasone Propionate MDPI|
214724846|NCT02680561|DRUG|Fluticasone Propionate/Salmeterol MDPI|
214724847|NCT02680561|DRUG|Fluticasone propionate/salmeterol|
214724848|NCT06387277|OTHER|RV1551P GB3224|"RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9)."
214724849|NCT00176878|PROCEDURE|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
214724850|NCT00176878|DRUG|Fludarabine monophosphate|fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
214724851|NCT00176878|PROCEDURE|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
214724852|NCT00176878|DRUG|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
214724853|NCT00176878|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
214724854|NCT01024920|DRUG|BIBF 1120|VEGF inhibitor
214724855|NCT01024920|DRUG|sunitinib|VEGF inhibitor
214724856|NCT06168890|DIAGNOSTIC_TEST|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
214724857|NCT06424392|OTHER|General Health Questionnaire (GHQ-12)|Anxiety and depression self-reported scales for both parents
214724858|NCT06424392|OTHER|State-Trait Anxiety Inventory (STAI-Y)|Anxiety and depression self-reported scales for both parents
214724859|NCT06424392|OTHER|Revised Children's Manifest Anxiety Scale (RCMAS)|Anxiety and depression self-reported scales for children
214724860|NCT06424392|OTHER|World Health Organization Quality of Life (WHOQOL-BREF)|Quality of life self-reported scales for parents
214724861|NCT06424392|OTHER|"Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)"|Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
214724862|NCT06424392|OTHER|Parental interview|The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
214724863|NCT06705842|DRUG|PVI|After removal of the appendix from the patient's abdomen and attainment of hemostasis, 10 mL/kg of 1% PVI (up to a maximum of 1,000 mL) will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned out
214724864|NCT06705842|DRUG|Usual Care|Surgeons may utilize local irrigation with saline if deemed necessary, defined as instillation of a small volume (\<100 mL) of liquid followed by aspiration, for the purpose of confirming hemostasis or suctioning thick fluid. Some surgeons may utilize large volume irrigation with saline solution, if that is consistent with their usual practice. Patients in the usual care arm will not receive PVI irrigation.
214724865|NCT06410469|PROCEDURE|rug weaving-like plication technique|anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
214724866|NCT06039969|OTHER||This is an obvertional study and there is no intervention
214724867|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
214724868|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
214724869|NCT05015322|DRUG|bupivacaine and methylprednisolone|suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
214724870|NCT01131845|DRUG|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
214724871|NCT02977507|OTHER|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
214724872|NCT02977507|DRUG|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
214724873|NCT02977507|OTHER|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
214724874|NCT02977507|OTHER|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
214724875|NCT02977507|OTHER|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
214724876|NCT06236763|DEVICE|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
214724877|NCT02785666|DRUG|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
214724878|NCT02785666|BEHAVIORAL|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
214724879|NCT00171002|DRUG|valsartan/amlodipine|
214724880|NCT06201923|DRUG|Honey Mouthwash|0.2% thyme honey mouth rinse
214724881|NCT06201923|DRUG|Normal saline|0.9% sodium chloride
214724882|NCT04252261|DRUG|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
214724883|NCT04252261|DRUG|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
214724884|NCT00949845|DRUG|Endotoxin|
214724885|NCT06180876|DRUG|remimazolam|continuous infusion
214724886|NCT06180876|DRUG|propofol|continuous infusion
214724887|NCT00004141|DRUG|Cisplatin|
214724888|NCT00004141|DRUG|dacarbazine|
214724889|NCT00004141|DRUG|Granulocyte-macrophage colony-stimulating factor|
214724890|NCT04630210|DRUG|Letrozole|Letrozole 2.5 mg/day oral until surgery
214724891|NCT04630210|DRUG|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
214638145|NCT04894929|OTHER|vestibular exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
214638146|NCT04894929|OTHER|vestibular exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
214638147|NCT04894929|OTHER|multi component exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
214724892|NCT01956058|RADIATION|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
214724893|NCT06087731|DRUG|Tocilizumab|Tocilizumab (8mg/kg) every 4 wekks
214724894|NCT00633360|DRUG|Drospirenone and ethinyl estradiol|Once daily by mouth
214724895|NCT00633360|DRUG|Placebo|Once daily by mouth
214724896|NCT01188460|BEHAVIORAL|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
214724897|NCT01188460|BEHAVIORAL|Sleep diary|
214724898|NCT01964287|DRUG|GEMBRAX|
214724899|NCT01964287|DRUG|FOLFIRINOX|
214724900|NCT05118750|DRUG|ALTO-300 oral (PO) tablet|One tablet daily
214724901|NCT06617949|DRUG|Regional Anesthesia|Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.
214724902|NCT06617949|DRUG|Hydromorphone Patient Controlled Analgelsic|This group will be administered epidural PCA as a modality for pain control post cesarian section
214724903|NCT06617949|PROCEDURE|Epidural local anesthetic infusion|Epidural group will receive pain control via a local anesthetic intermediate bolus infusion
214724904|NCT02036268|BEHAVIORAL|Standard|Standard ostomy education
214724905|NCT02036268|BEHAVIORAL|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
214724906|NCT02036268|BEHAVIORAL|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
214724907|NCT02200068|OTHER|SANOIA Website|
214724908|NCT04649190|DEVICE|TAVI|Coronary access for PCI after TAVI
214724909|NCT04655690|DRUG|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
214638148|NCT01662583|OTHER|Text Message|
214638149|NCT01662583|OTHER|Written reminder|
214638150|NCT04264533|DRUG|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
214638151|NCT04264533|DRUG|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
214638152|NCT04931992|OTHER|No intervention|Retrospective analysis
214638153|NCT03612271|BEHAVIORAL|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
214638154|NCT06101615|OTHER|IASTM (FAT)|Group-A participants would receive Facial Abrasion Technique (FAT) with an Instrument, FAT-Tool. Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm), to avoid possible confounding circadian effects. The FAT group will receive 2 min application on the quadriceps and hamstring muscles with a FAT-tool Pro Large model, which consists of a handle and 20cm treatment surface. The muscles will be treated in a pre-stretched position, meaning a knee flexion in a supine position for the quadriceps muscle and a hip flexion and knee extension in a side-lying position for the hamstring muscles.
214638155|NCT06101615|OTHER|Foam Rolling|Group-B participants would receive Foam Rolling (FR). Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm) to avoid possible confounding circadian effects. The Foam Roller group will receive 2x1 min of FR on the quadriceps and the hamstrings on the dominant leg with the opposite leg crossed over the dominant one. During each minute the muscle will be rolled out 4-5 times, with a break of 30s in between sets. They will be instructed to utilize short, kneading like movements in one direction and a quick motion in the other direction. A grid foam roller will be utilized with a length of 33cm, diameter of 14 cm and with a hard hollow core, wrapped in ethylene vinyl acetate foam.
214638156|NCT03055975|DIAGNOSTIC_TEST|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
214638157|NCT05462509|DEVICE|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
214724910|NCT04655690|DRUG|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
214724911|NCT05122013|BEHAVIORAL|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
214724912|NCT05122013|BEHAVIORAL|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
214724913|NCT01673425|DRUG|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
214638158|NCT02475811|RADIATION|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
214638159|NCT06352294|OTHER|Core stability training|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult
214638160|NCT06352294|OTHER|Core stability training and myofascial relase|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
214638161|NCT04087525|DRUG|HIP1701|Vildagliptin
214638162|NCT04087525|DRUG|HGP1809|Vildagliptin
214638163|NCT04471727|BIOLOGICAL|Gocatamig|IV infusion
214638164|NCT04471727|BIOLOGICAL|Atezolizumab|IV infusion
214638165|NCT04471727|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
214638166|NCT03506295|DEVICE|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
214638167|NCT03506295|DEVICE|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
214638168|NCT02762474|DRUG|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
214638169|NCT01251783|DIETARY_SUPPLEMENT|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
214638170|NCT01251783|DIETARY_SUPPLEMENT|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
214638171|NCT01251783|DIETARY_SUPPLEMENT|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
214638172|NCT01251783|DIETARY_SUPPLEMENT|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
214638173|NCT01251783|DIETARY_SUPPLEMENT|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
214638174|NCT01251783|DIETARY_SUPPLEMENT|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
214638175|NCT01402297|DRUG|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
214638176|NCT04451629|BEHAVIORAL|pelvıc base exercıse, core exercise|Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
214638177|NCT05730400|DRUG|BMAC loaded on bovine graft|Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
214638178|NCT05730400|DRUG|Bovine graft only|Bovine graft only for sinus floor augmentation
214638179|NCT02340663|DEVICE|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
214638180|NCT02340663|DEVICE|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
214724914|NCT02613988|DEVICE|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
214724915|NCT02613988|DEVICE|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
214724916|NCT02613988|DEVICE|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
214724917|NCT02613988|DEVICE|Dynamic susceptibility contrast MRI|dual echo EPI sequence
214724918|NCT06268509|DIAGNOSTIC_TEST|Nutritional panel laboratory examination|As stated in group description
214724919|NCT06268509|DIETARY_SUPPLEMENT|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
214724920|NCT06268509|DIAGNOSTIC_TEST|Fetomaternal ultrasound|As stated in group description
214724921|NCT03383068|DRUG|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
214724922|NCT03383068|DRUG|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
214724923|NCT03383068|DRUG|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
214724924|NCT03383068|DRUG|Metformin|metformin effective subjects,act as control group
214724925|NCT02572804|DEVICE|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
214724926|NCT02572804|DEVICE|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
214724927|NCT03476434|DEVICE|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
214724928|NCT05831514|OTHER|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
214724929|NCT03394118|DRUG|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
214724930|NCT00159380|DRUG|Aminoguanidine|500mg
214724931|NCT00159380|DRUG|Placebos|2ml
214724932|NCT01181297|OTHER|Extensively Hydrolyzed Formula with a Probiotic|
214724933|NCT01181297|OTHER|Extensively Hydrolyzed Formula without a Probiotic|
214724934|NCT01942304|PROCEDURE|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
214724935|NCT01942304|PROCEDURE|Anorganic bovine bone mineral in direct sinus augmentation|
214724936|NCT03923504|OTHER|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
214724937|NCT03923504|OTHER|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
214724938|NCT01259921|BEHAVIORAL|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
214724939|NCT01679340|DRUG|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
214724940|NCT01679340|DRUG|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
214724941|NCT01679340|DRUG|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
214724942|NCT00937508|BEHAVIORAL|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
214724943|NCT00937508|DRUG|varenicline|varenicline (an approved medication for smoking cessation)
214724944|NCT00937508|DRUG|placebo|sugar pill without any active medication
214724945|NCT02635685|OTHER|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
214724946|NCT05287269|DIAGNOSTIC_TEST|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
214724947|NCT00252876|DRUG|tesaglitazar|
214724948|NCT01209572|DEVICE|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
214724949|NCT01209572|DEVICE|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
214724950|NCT01987752|DRUG|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
214724951|NCT01359527|DEVICE|Hip Resurfacing|
214638181|NCT02171975|PROCEDURE|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
214638182|NCT02171975|PROCEDURE|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
214638183|NCT01656434|DRUG|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
214638184|NCT01656434|DRUG|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
214638185|NCT01656434|OTHER|Placebo|tablet
214638186|NCT01656434|DRUG|ethinylestradiol (EE)|EE 10 μg tablet
214638187|NCT01656434|DRUG|ferrous fumarate|ferrous fumarate 75 mg tablet
214638188|NCT06471764|DEVICE|FX+ and 12-Lead ECG Recording|While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.
214638189|NCT06549491|BEHAVIORAL|Sleep Wizard|First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.
214638190|NCT01828931|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
214638191|NCT01828931|OTHER|Usual Care|Care as usual
214638192|NCT04378608|DRUG|OBV/PTV/r) ± ribavirin (RBV)|
214638193|NCT00280007|DRUG|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
214638194|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
214638195|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
214638196|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
214638197|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
214638198|NCT01230957|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
214638199|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
214638200|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
214638201|NCT02989519|DRUG|dydrogesterone|
214638202|NCT02989519|DRUG|Micronized progesterone|
214638203|NCT01337076|DEVICE|cochlear implant|Cochlear implant surgery
214638204|NCT05042310|DRUG|LY3541860|Administered either IV or SC.
214638205|NCT05042310|DRUG|Placebo|Administered either IV or SC.
214638206|NCT00311467|DRUG|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
214638207|NCT00941460|DRUG|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
214638208|NCT00941460|DRUG|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
214638209|NCT00002655|PROCEDURE|cryosurgery|
214638210|NCT05239520|OTHER|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
214638211|NCT03694925|DIAGNOSTIC_TEST|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
214638212|NCT06500806|OTHER|Scroth and brace|Participants in this group will wear a brace and follow a 12-month Schroth exercise program three times a week. Sessions will be supervised by a physiotherapist and last 60 minutes, using equipment like foam blocks, exercise balls, and rods. Exercise intensity will gradually increase based on progress. The individualized Schroth exercises will aim to correct spinal deformity and include elongation, rotational correction, stretches, strengthening, and breathing exercises. These exercises will help patients maintain proper posture in daily activities and will be adapted to each participant's abilities, with varying difficulty and positions.
214638213|NCT06500806|DEVICE|Brace|Participants in this group will follow only the brace treatment
214638214|NCT01639872|DRUG|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
214638215|NCT01639872|DRUG|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
214638216|NCT06303934|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
214638217|NCT06303934|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
214724952|NCT01359527|DEVICE|Total Hip Arthroplasty|
214724953|NCT00621244|DRUG|LBH589|
214724954|NCT03188302|OTHER|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
214724955|NCT05655728|DRUG|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
214724956|NCT05655728|OTHER|Placebo|The participants will receive treatment of placebo.
214638218|NCT06303934|DEVICE|Persistent Nasogastric Tube Feeding|After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
214638219|NCT03954600|DRUG|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
214638220|NCT03954600|DRUG|Placebos (125 mg)|Placebo, 125 mg oral capsules
214638221|NCT02799069|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
214638222|NCT02799069|DRUG|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
214638223|NCT02799069|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
214638224|NCT01265680|DRUG|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
214638225|NCT05513989|DEVICE|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
214638226|NCT05513989|DEVICE|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
214638227|NCT00972673|DRUG|Placebo|comparator
214638228|NCT00972673|DRUG|GW685698X|Inhaled steroid
214638229|NCT00372502|PROCEDURE|Modified EGDT|Early goal directed therapy with lactate clearance
214638230|NCT00372502|PROCEDURE|Standard EGDT|Early goal directed therapy
214638231|NCT03659019|OTHER|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
214638232|NCT03677700|OTHER|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
214638233|NCT05479500|OTHER|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
214638234|NCT05479500|OTHER|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
214638235|NCT02092571|DRUG|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
214638236|NCT04406909|OTHER|Access to training facility|Access to training facility under national regulations for COVID control
214638237|NCT00301340|DRUG|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
214638238|NCT00653822|DRUG|alefacept|IC and SC
214638239|NCT00653822|DRUG|placebo|IV and SC
214724957|NCT00175318|BEHAVIORAL|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
214724958|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
214724959|NCT04078074|DEVICE|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
214724960|NCT04078074|DEVICE|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
214724961|NCT04078074|DEVICE|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
214724962|NCT03718273|DRUG|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
214724963|NCT03718273|DRUG|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
214724964|NCT05116111|DRUG|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
214724965|NCT05116111|DRUG|Placebo|Placebo, oral, twice daily
214724966|NCT04422197|BIOLOGICAL|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
214724967|NCT04422197|PROCEDURE|surgery without botox injection|surgery without botox injection
214724968|NCT05027776|BIOLOGICAL|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
214638240|NCT04993404|DRUG|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
214724969|NCT05027776|BIOLOGICAL|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
214638241|NCT04865328|OTHER|Overactive Bladder-Validated 8-question Screener (OAB-V8)|OAB-V8 is an eight-item, self-reported questionnaire that assesses the burden of OAB and the degree of bother caused by the symptoms. Since its development as a subscale of the overactive bladder questionnaire (OAB-q), the OAB-V8 questionnaire has been used to screen for OAB and to assess OAB symptom burden and severity.
214638242|NCT02178488|DRUG|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
214638243|NCT02178488|OTHER|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
214638244|NCT03033875|BEHAVIORAL|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
214638245|NCT03033875|BEHAVIORAL|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
214638246|NCT04000685|OTHER|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
214724970|NCT05027776|BIOLOGICAL|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
214638247|NCT04000685|OTHER|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
214638248|NCT04000685|OTHER|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
214638249|NCT02065154|DRUG|Cyclophosphamide|
214638250|NCT01972555|PROCEDURE|Minimally invasive aortic valve replacement|
214638251|NCT01972555|PROCEDURE|Conventional aortic valve replacement|
214638252|NCT02271503|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
214724971|NCT04716049|OTHER|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
214724972|NCT04716049|OTHER|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
214724973|NCT05238558|BIOLOGICAL|FMPV-1|Intradermal administration
214724974|NCT05238558|BIOLOGICAL|GM-CSF (as adjuvant)|Intradermal administration
214724975|NCT06505681|PROCEDURE|Pharmacopuncture|"The selection of acupoints, depth of insertion, and other parameters will be determined based on the clinical judgment of the Korean medicine practitioner, considering the patient's symptoms, imaging results, and degree of improvement. All acupoints where pharmacopuncture is administered will be recorded at the time of treatment.~The type and dosage of pharmacopuncture solution to be used during treatment will be determined entirely based on the clinical judgment of the Korean medicine practitioner performing the pharmacopuncture. Retrospective chart reviews will be conducted to record the type of pharmacopuncture solution used and the total amount administered (in ml).~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
214724976|NCT06505681|PROCEDURE|Physical therapy|"The selection of physical therapy methods, treatment areas, and treatment duration will be determined based on the clinical judgment of the physician, considering the patient's symptoms, imaging results, and degree of improvement. The type, frequency, and areas of prescribed and administered physical therapy will be recorded.~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
214724977|NCT01698073|BEHAVIORAL|mCOL|
214724978|NCT01698073|OTHER|AS+|
214724979|NCT04238689|BIOLOGICAL|TB31F|Monoclonal antibody
214638253|NCT02271503|DRUG|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
214638254|NCT02271503|DRUG|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
214638255|NCT02271503|DRUG|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
214638256|NCT02271503|DRUG|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
214724980|NCT04449276|BIOLOGICAL|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
214638257|NCT01431664|DRUG|multikinase inhibitor AT9283|
214724981|NCT04449276|DRUG|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
214724982|NCT01614795|BIOLOGICAL|Cixutumumab|Given IV
214724983|NCT01614795|OTHER|Laboratory Biomarker Analysis|Correlative studies
214724984|NCT01614795|DRUG|Temsirolimus|Given IV
214724985|NCT02970539|DRUG|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
214724986|NCT02970539|DRUG|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
214638258|NCT01431664|OTHER|laboratory biomarker analysis|
214638259|NCT01431664|OTHER|pharmacological study|
214638260|NCT04897464|OTHER|BGaze therapy Alzheimer|BGaze Therapy is an interactive eye tracking game
214638261|NCT04427631|DEVICE|Bone conduction headphones|Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
214638262|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
214638263|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
214638264|NCT02601339|PROCEDURE|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
214638265|NCT02519166|BIOLOGICAL|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
214638266|NCT02018731|DRUG|Metformin and Metformin & L-Citrulline|
214638267|NCT02018731|DRUG|L-Citrulline and Metformin & L-Citrulline|
214638268|NCT04086550|DEVICE|LIQOSEAL|Adjunctive bioresorbable patch
214638269|NCT04086550|DEVICE|DuraSeal, Adherus|synthetic absorbable sealants
214638270|NCT02108431|DEVICE|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
214638271|NCT02108431|DEVICE|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
214638272|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
214638273|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
214638274|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
214724987|NCT02384304|BEHAVIORAL|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
214724988|NCT02384304|BEHAVIORAL|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
214638275|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
214638276|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
214638277|NCT01819909|PROCEDURE|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
214638278|NCT01819909|PROCEDURE|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
214638279|NCT03308396|DRUG|Guadecitabine|Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2
214638280|NCT03308396|DRUG|Durvalumab|Day 8 Durvalumab (1500 mg IV)
214638281|NCT02665286|DRUG|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
214638282|NCT02665286|DRUG|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
214638283|NCT02665286|DRUG|Naproxen|Naproxen 500mg PO BID x 7 days
214638284|NCT02665286|DRUG|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
214638285|NCT06037330|DRUG|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.
214638286|NCT06037330|DRUG|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
214638287|NCT06488131|PROCEDURE|MTA Pulpotomy|Complete coronal MTA pulpotomy.
214638288|NCT06488131|PROCEDURE|Root Canal Treatment|Conventional root canal treatment.
214638289|NCT00361595|DRUG|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
214638290|NCT05654129|OTHER|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
214724989|NCT02384304|BEHAVIORAL|Self help|A self help program consisting of 8 modules
214724990|NCT05074862|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
214724991|NCT05074862|DIETARY_SUPPLEMENT|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
214724992|NCT02866604|PROCEDURE|Sterofundin|
214724993|NCT02866604|PROCEDURE|0.9% saline|
214638291|NCT05654129|OTHER|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
214638292|NCT03528512|DRUG|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
214638293|NCT03528512|DRUG|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
214638294|NCT00940264|PROCEDURE|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
214638295|NCT02611986|DEVICE|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
214638296|NCT02611986|DEVICE|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
214638297|NCT02689830|DEVICE|Bead Block|Prostate embolization
214638298|NCT00002356|DRUG|Fomivirsen sodium|
214638299|NCT03602872|BIOLOGICAL|Human allogeneic mesenchymal bone marrow derived stem cells|Intraarticular administration of 20x10\^6 MSCs
214638300|NCT04797845|OTHER|teleconsultation|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
214638301|NCT01047657|BEHAVIORAL|Low caloric diet plus orlistat and sibutramine|All subjetcs
214638302|NCT03790280|DIAGNOSTIC_TEST|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
214638303|NCT02797886|OTHER|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
214638304|NCT02797886|OTHER|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
214638305|NCT02797886|OTHER|VOL|The subject initiates and completes the movement without electrical stimulation.
214638306|NCT00164294|BEHAVIORAL|Brief intervention|
214638307|NCT01147146|DRUG|propofol, fentanyl, atracurium|general anesthesia
214638308|NCT01147146|DRUG|bupivacaine|spinal anesthesia
214638309|NCT01147146|DRUG|bupivacaine, Midazolam|spinal anesthesia \& sedation
214638310|NCT06420505|DEVICE|Percutaneous Coronary Intervention|The Vivo ISAR is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
214638311|NCT03186235|OTHER|Flow cytometry|Isolation of T regulatory cells from blood
214724994|NCT01857024|DRUG|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
214724995|NCT02918955|PROCEDURE|up-front neck dissection|
214638312|NCT04729777|PROCEDURE|Combined Cardiovascular Magnetic Resonance and Cardiopulmonary Exercise Testing|Clinical Cardiac MRI scan at rest with routine administration of gadolinium contrast agent. Participants then undergo the research component of the test which requires them to perform exercise, using a recumbent, MRI-compatible cycle ergometer, whilst their breathing is simultaneously analysed using a mask connected to a CPET machine, until they are limited by symptoms and they stop pedalling. Most participants will undergo only one scan. Some participants will be asked to have two or three such scans over 3 months to assess changes over time, and in response to standard treatment of pulmonary hypertension.
214638313|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
214638314|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
214638315|NCT00740350|PROCEDURE|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
214638316|NCT04979754|OTHER|standard of care|retrospective study : standard of care
214638317|NCT00897078|OTHER|laboratory biomarker analysis|
214638318|NCT00897078|OTHER|medical chart review|
214638319|NCT00897078|OTHER|metabolic assessment|
214638320|NCT00897078|OTHER|questionnaire administration|will be obtained at a single clinic visit
214638321|NCT00897078|PROCEDURE|assessment of therapy complications|
214638322|NCT01233778|DIETARY_SUPPLEMENT|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
214638323|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
214638324|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
214638325|NCT01233778|DIETARY_SUPPLEMENT|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
214638326|NCT01233778|DIETARY_SUPPLEMENT|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
214638327|NCT04565678|DRUG|Mitapivat tablets|Oral tablets
214638328|NCT04565678|DRUG|Mitapivat coated granules|Oral coated granules
214638329|NCT01918670|PROCEDURE|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
214638330|NCT01353742|DRUG|Lamivudine|100mg tablet
214638331|NCT01353742|DRUG|Adefovir dipivoxil|10mg tablet
214638332|NCT01353742|DRUG|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
214638333|NCT03711643|PROCEDURE|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
214638334|NCT03711643|DEVICE|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
214638335|NCT03064841|DRUG|No Treatment|No treatment
214638336|NCT03434977|DRUG|TAK-536|TAK-536 granule formulation
214638337|NCT02055066|DRUG|ARGX-111|
214638338|NCT06617520|OTHER|Cigarillo flavor type|Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor
214638339|NCT00217087|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
214638340|NCT00217087|PROCEDURE|Photodynamic Therapy|Porfimer sodium 2mg/kg
214638341|NCT03920670|DEVICE|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
214724996|NCT02918955|RADIATION|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
214724997|NCT02918955|DRUG|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
214724998|NCT02918955|PROCEDURE|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
214638342|NCT03920670|DEVICE|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
214638343|NCT06413511|BIOLOGICAL|Belantamab|Belantamab will be administered
214638344|NCT05574062|DEVICE|MiniMed 780G Auto Mode with G4S sensor|MiniMed™ 780G system in Auto Mode with G4S sensor.
214638345|NCT05574062|DEVICE|MiniMed 780G Manual Mode with G4S sensor|MiniMed™ 780G system in Manual Mode.
214638346|NCT05574062|DEVICE|MiniMed 780G Auto Mode with DS5 sensor|MiniMed 780G Auto Mode with DS5 sensor
214638347|NCT05752214|OTHER|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
214638348|NCT02611089|PROCEDURE|Tissue biopsy|Sampling of tissue as described.
214638349|NCT04417478|OTHER|Scaling and root planning|Periodontal debridement was performed in all patients.
214638350|NCT04621695|PROCEDURE|RBL|Both arms are standard care procedures in the Netherlands
214638351|NCT04621695|PROCEDURE|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
214638352|NCT01352806|PROCEDURE|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
214638353|NCT04312698|DRUG|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
214638354|NCT04312698|DRUG|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
214638355|NCT04312698|DRUG|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
214638356|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
214724999|NCT03020264|DEVICE|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
214638357|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
214638358|NCT05766059|DEVICE|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
214638359|NCT00223899|GENETIC|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
214638360|NCT04951778|DRUG|CC-91633|Administered orally according to the assigned treatment schedule
214725000|NCT02727517|PROCEDURE|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
214725001|NCT02727517|PROCEDURE|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
214725002|NCT06268483|DIETARY_SUPPLEMENT|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
214725003|NCT06268483|DIETARY_SUPPLEMENT|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
214638361|NCT06577116|DRUG|AK006 IV|Formulation for intravenous infusion
214638362|NCT01283165|BEHAVIORAL|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
214638363|NCT03271372|DRUG|Avelumab|Given IV
214638364|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
214725004|NCT00565812|DRUG|SD-6010|200 mg tablets once a day for 2 years
214725005|NCT00565812|DRUG|SD-6010|50 mg tablets once a day for 2 years
214725006|NCT00565812|DRUG|Placebo|Placebo tablets once a day for 2 years
214725007|NCT05246475|DIAGNOSTIC_TEST|PET-MRI|Simultaneous PET-MRI measurement
214725008|NCT01887756|DEVICE|Tele Rehabilitation|
214725009|NCT03926260|OTHER|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
214725010|NCT00317057|PROCEDURE|Patient education and disease management|
214725011|NCT03790540|DEVICE|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
214725012|NCT03790540|DRUG|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
214725013|NCT03403855|DEVICE|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
214638365|NCT03271372|OTHER|Placebo|Given IV
214725014|NCT03403855|DEVICE|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
214725015|NCT01128166|DEVICE|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
214725016|NCT01733836|DRUG|Metformin|
214725017|NCT01733836|DRUG|placebo|
214725018|NCT06071390|BEHAVIORAL|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
214638366|NCT05783596|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
214725019|NCT05693103|DEVICE|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
214638367|NCT05783596|DRUG|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
214638368|NCT06529120|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
214638369|NCT06211764|DRUG|TAR-200|Participants will receive TAR-200 intravesically.
214638370|NCT06211764|DRUG|Mitomycin C|Participants will receive MMC intravesically.
214725020|NCT02536157|DEVICE|Thermoplastic splinting|
214725021|NCT00006030|DRUG|tamoxifen citrate|
214725022|NCT00006030|PROCEDURE|conventional surgery|
214725023|NCT00006030|RADIATION|radiation therapy|
214725024|NCT02121444|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|
214638371|NCT06211764|DRUG|Gemcitabine|Participants will receive gemcitabine intravesically.
214725025|NCT02121444|DEVICE|BETACONNECT auto-injector.|
214725026|NCT06103019|OTHER|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
214725027|NCT06103019|OTHER|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
214725028|NCT04743271|OTHER|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
214638372|NCT03198052|BIOLOGICAL|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
214638373|NCT06388655|DEVICE|mobile neurofeedback|The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.
214638374|NCT06388655|DEVICE|sham mobile neurofeedback|The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
214638375|NCT01745770|DRUG|Mesalazine - TID 1000 mg|
214725029|NCT04743271|OTHER|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
214725030|NCT01398228|BEHAVIORAL|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
214725031|NCT04968353|DEVICE|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
214638376|NCT01745770|DRUG|Mesalazine - TID 2x 500 mg|
214638377|NCT01034007|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
214638378|NCT03864653|BEHAVIORAL|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
214638379|NCT04069845|DRUG|liposomal doxorubicin|intravenous liposomal doxorubicin
214638380|NCT00546052|DRUG|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
214638381|NCT06026332|DRUG|ADSTILADRIN|Non-interventional
214638382|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
214638383|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
214638384|NCT00015223|DRUG|Methylphenidate|
214725032|NCT04968353|DEVICE|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
214725033|NCT04968353|DEVICE|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
214638385|NCT05125237|DRUG|Amiloride|Amiloride claim is used as the exposure group.
214638386|NCT05125237|DRUG|Triamterene|Triamterene claim is used as the reference group.
214638387|NCT03583190|OTHER|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
214725034|NCT04968353|DEVICE|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
214638388|NCT03583190|OTHER|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
214638389|NCT03583190|OTHER|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
214638390|NCT03583190|OTHER|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
214638391|NCT03583190|OTHER|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
214638392|NCT01348997|BEHAVIORAL|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
214638393|NCT01348997|BEHAVIORAL|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
214638394|NCT01261156|DRUG|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
214725035|NCT01425645|OTHER|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
214725036|NCT00845845|DRUG|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
214725037|NCT00845845|DRUG|Placebo|Daily placebo with dietary counseling for 24 weeks.
214725038|NCT05606380|DRUG|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
214725039|NCT05013294|OTHER|Intervention|Text messages through a basic phone or smart phone
214638395|NCT01261156|DRUG|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
214638396|NCT06163612|BEHAVIORAL|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
214725040|NCT03455062|OTHER|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
214725041|NCT03472963|DRUG|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
214638397|NCT06163612|BEHAVIORAL|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
214725042|NCT02635529|PROCEDURE|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
214725043|NCT02635529|PROCEDURE|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
214725044|NCT05229419|OTHER|complete blood count|complete blood count will be done for corrosive cases
214725045|NCT02169713|DRUG|Mirabegron|Oral
214725046|NCT02169713|DRUG|Solifenacin succinate|Oral
214725047|NCT02169713|DRUG|Tamsulosin HCl|Oral
214725048|NCT02169713|DRUG|Placebo|Oral
214725049|NCT04266158|DEVICE|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
214725050|NCT03595449|DRUG|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
214725051|NCT03595449|DRUG|Surgilube|surgilube (placebo) applied during Mohs surgery
214725052|NCT03242590|DRUG|LPCN 1021|Oral testosterone undecanoate
214725053|NCT04212936|PROCEDURE|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
214725054|NCT04841213|PROCEDURE|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
214725055|NCT05845008|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
214725056|NCT00663338|DRUG|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
214725057|NCT03126279|PROCEDURE|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
214725058|NCT03999385|BEHAVIORAL|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
214725059|NCT01999712|PROCEDURE|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
214725060|NCT03412123|BEHAVIORAL|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
214725061|NCT02033850|BEHAVIORAL|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
214725062|NCT06179706|DIAGNOSTIC_TEST|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
214725063|NCT01920971|RADIATION|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
214725064|NCT01255293|PROCEDURE|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
214725065|NCT01255293|PROCEDURE|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
214725066|NCT04951180|OTHER|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
214725067|NCT02820038|BEHAVIORAL|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
214725068|NCT02820038|BEHAVIORAL|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
214725069|NCT02820038|BEHAVIORAL|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
214725070|NCT02998255|DRUG|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
214725071|NCT02998255|DRUG|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
214725072|NCT00260195|BEHAVIORAL|School-based cognitive behavioral support group|
214725073|NCT03702855|DRUG|Tetrabenazine Tablets 25 mg|
214725074|NCT03352128|DIETARY_SUPPLEMENT|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
214725075|NCT03352128|DIETARY_SUPPLEMENT|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
214725076|NCT02408926|BIOLOGICAL|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
214725077|NCT02408926|BIOLOGICAL|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
214725078|NCT02408926|BIOLOGICAL|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
214725079|NCT02408926|BIOLOGICAL|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
214725080|NCT00578422|OTHER|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
214638398|NCT06163612|OTHER|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
214638399|NCT06163612|BEHAVIORAL|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
214638400|NCT04955392|OTHER|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~1. Inhibition of the suboccipital muscles.~2. Parietal Lift.~3. Sutherland Technique of Sphenobasilar Synchondrosis.~4. Compression technique of the fourth ventricle (CV4)."
214638401|NCT04955392|OTHER|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
214638402|NCT02482129|DRUG|LME636 60 mg/mL ophthalmic solution|
214638403|NCT02482129|DRUG|Dexamethasone 0.1% ophthalmic solution|
214638404|NCT02482129|DRUG|LME636 Vehicle|Inactive ingredients used for masking purposes
214638405|NCT00602108|PROCEDURE|adjuvant therapy|
214638406|NCT00602108|PROCEDURE|conventional surgery|
214638407|NCT00602108|RADIATION|hypofractionated radiation therapy|
214638408|NCT00602108|RADIATION|intraoperative radiation therapy|
214638409|NCT05481372|OTHER|Imaging|Trans-perineal ultrasound and Magnetic resonance image acquisition
214638410|NCT05713097|DIAGNOSTIC_TEST|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
214638411|NCT01060358|PROCEDURE|method (non-surgical) to measure neuromuscular neutral zones|
214638412|NCT03413150|DRUG|Amiodarone|Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
214638413|NCT05855447|OTHER|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (\> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
214638414|NCT05855447|OTHER|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
214638415|NCT05855447|OTHER|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
214638416|NCT01928381|DRUG|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
214725081|NCT00578422|PROCEDURE|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
214638417|NCT01928381|DRUG|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
214638418|NCT01928381|DRUG|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
214638419|NCT05816980|RADIATION|Hyperfractionated external beam radiation|40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
214638420|NCT05583266|DRUG|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
214638421|NCT05583266|DRUG|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
214638422|NCT01209026|DRUG|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
214638423|NCT01209026|DRUG|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
214638424|NCT01209026|DRUG|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
214638425|NCT01209026|DRUG|Moxifloxacin 400mg|Film coated oral tablet
214638426|NCT01209026|DRUG|Moxifloxacin placebo|Film coated oral tablet
214638427|NCT00653003|DRUG|Leflunomide|tablets, 20mg, single-dose
214638428|NCT00653003|DRUG|ARAVA|Tablets, 20mg, single-dose
214638429|NCT04314440|BEHAVIORAL|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
214638430|NCT07121894|BEHAVIORAL|Ketogenic Diet|Participants will initiate a modified ketogenic diet under structured, intensive guidance. Simultaneously, participants will attend weekly behavioral support interviews with a psychiatrist to monitor mental health and mood stability.
214638431|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
214638432|NCT06649942|DRUG|KP-001|KP-001 400 mg
214638433|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
214638434|NCT06649942|DRUG|Placebo|Placebo
214638435|NCT06564207|DRUG|Placebo|Placebo to be given twice daily for 14 days
214638436|NCT06564207|DRUG|Fostamatinib|Fostamatinib 150mg to be given twice daily for 14 days
214638437|NCT06130293|DEVICE|VR game intervention|Using self-paced VR game to train.
214638438|NCT03676647|OTHER|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
214638439|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
214638440|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
214638441|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
214638442|NCT06814262|DEVICE|Corresponding treatment order in the prescription with Align Technology|Treating orthodontist placing the corresponding order in the prescription with Align Technology.
214638443|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Predicted model|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model will be superimposed with the predicted final model to establish the predicted movement of the maxillary lateral incisors
214638444|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x3mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x3mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
214638445|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x4mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x4mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
214638446|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x5mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x5mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
214638447|NCT06443060|BEHAVIORAL|Virtual Reality Group|Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
214638448|NCT06443060|BEHAVIORAL|Buzzy Application Group|Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
214638449|NCT06443060|OTHER|Control Group|Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
214638450|NCT05237128|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
214638451|NCT05237128|BEHAVIORAL|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
214638452|NCT03443154|DIAGNOSTIC_TEST|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
214638453|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
214638454|NCT06824363|DRUG|Tremelimumab|single dose, 300mg IV, day 1
214638455|NCT06824363|DRUG|Durvalumab|single dose, 1500 mg IV, day 1
214638456|NCT06989112|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
214638457|NCT06989112|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
214638458|NCT06989112|DRUG|Pembrolizumab|Immunotherapy by intravenous infusion
214638459|NCT06989112|DRUG|Carboplatin|Standard of Care (SoC) chemotherapy by intravenous infusion
214638460|NCT06989112|DRUG|Paclitaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
214638461|NCT06989112|DRUG|Docetaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
214638462|NCT06990841|DEVICE|sperm separation device|comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates
214638463|NCT06856473|OTHER|Traditional Physical Therapy|Traditional Physical Therapy based on neurodevelopmental technique
214638464|NCT06856473|OTHER|Dry Needling|Dry Needling in addition to the same traditional physical therapy program
214638465|NCT07006714|DRUG|Vitamin D3|Patients with a Vitamin D3 level of less than 30 nanograms per milliliter will receive a single oral (pill) dose of 300,000 international units of vitamin D3.
214638466|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
214638467|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
214638468|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
214638469|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
214638470|NCT06675799|BEHAVIORAL|Sleep Extension|Weekly educational material about sleep health and weekly brief phone coaching calls for a total of 6 weeks.
214638471|NCT06675799|BEHAVIORAL|Healthy Living Psychoeducation|Weekly educational materials about healthy habits and weekly brief phone calls to clarify terms or concepts.
214638472|NCT05049343|DRUG|SAGE-904|SAGE-904 oral solution.
214638473|NCT05049343|DRUG|Placebo|Placebo oral solution.
214638474|NCT05049343|DRUG|Ketamine|Ketamine intravenous (IV) infusion.
214638475|NCT07018466|OTHER|Tele-exercise|Exercise training 3x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
214638476|NCT07018466|OTHER|Standard of Care|Health education discussions and lectures 3x/week led remotely.
214638477|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22. Fenofibrate 160 mg tablets orally once daily during the period of the 6 cycles of the(VRd) regimen."
214638478|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22."
214638479|NCT07029633|OTHER|storytelling|to distract telling a story
214638480|NCT07029633|OTHER|cartoon|to distract watching a cartoon
214638481|NCT02956161|DEVICE|Stimulation of up-phase of sleep slow oscillation|
214638482|NCT02956161|DEVICE|Random stimulation of up phase of sleep slow oscillation|
214638483|NCT02956161|DEVICE|No stimulation|
214638484|NCT06716307|DRUG|CagriSema (cagrilintide B and semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.
214638485|NCT06716307|DRUG|CagriSema A|Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.
214725082|NCT03476967|PROCEDURE|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
214725083|NCT06216106|PROCEDURE|Prepectoral breast reconstruction with polyurethane implants|Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
214638486|NCT04049045|DRUG|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
214638487|NCT04049045|DRUG|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
214638488|NCT01355705|DRUG|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
214638489|NCT01355705|DRUG|Lenalidomide|15 mg daily by mouth
214638490|NCT01355705|DRUG|Dexamethasone|40 mg weekly by mouth
214638491|NCT01355705|DRUG|Aspirin|81 or 325 mg daily by mouth
214638492|NCT01355705|DRUG|Pegfilgrastim|6 mg subcutaneous on Day 2
214638493|NCT01934283|DEVICE|urine folly catheter|
214725084|NCT04202276|OTHER|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
214638494|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
214638495|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days.
214638496|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
214638497|NCT06026371|DRUG|Placebo|Given PO
214638498|NCT06736704|DRUG|SNV4818|SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
214638499|NCT06736704|DRUG|Fulvestrant|Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
214638500|NCT06746415|OTHER|Conventional Gait Training|onventional walking training group will be given 20 minutes of NMES, 20 minutes of weight transfer, stretching, mobilization, bobath exercises and 20 minutes of parallel bar walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks.
214725085|NCT03975530|BEHAVIORAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
214725086|NCT03975530|BEHAVIORAL|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
214638501|NCT06746415|OTHER|Robotic Gait Training|The robot-assisted walking group will receive 20 minutes of NMES, 20 minutes of weight transfer, stretching,mobilization, bobath exercises and 20 minutes of robot-assisted walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks
214638502|NCT06895941|DIAGNOSTIC_TEST|PET|Exploring the predictive value of PET/CT metabolic parameters for the efficacy of neoadjuvant immunotherapy in non-small cell lung cancer.
214638503|NCT03961945|DEVICE|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
214638504|NCT06742723|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
214638505|NCT06742723|DRUG|Placebo/dapagliflozin|"dapagliflozin tablet~placebo tablet"
214638506|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot A|Sterile liquid for injection
214638507|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot B|Sterile liquid for injection
214638508|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose B|Sterile liquid for injection
214638509|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose C|Sterile liquid for injection
214638510|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose A|Sterile liquid for injection
214638511|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose B|Sterile liquid for injection
214638512|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose A|Sterile liquid for injection
214638513|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose B|Sterile liquid for injection
214638514|NCT06864143|BIOLOGICAL|Influenza Vaccine|Sterile liquid for injection
214638515|NCT06864143|BIOLOGICAL|COVID-19 Vaccine|Sterile liquid for injection
214638516|NCT06864143|BIOLOGICAL|Investigational Influenza Vaccine|Sterile liquid for injection
214638517|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot A|Sterile liquid for injection
214638518|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot B|Sterile liquid for injection
214638519|NCT06333899|DRUG|Lorlatinib|Continue maintenance monotherapy for total 12 cycles
214638520|NCT06333899|DRUG|Lorlatinib with chemotherapy1|Continue lorlatinib with BABY-POG chemotherapy backbone for 72 weeks
214638521|NCT06333899|DRUG|Lorlatinib with chemotherapy 2|Continue lorlatinib with HIT-SKK chemotherapy backbone for 42 weeks
214638522|NCT06333899|DRUG|Lorlatinib post Radiation|Continue lorlatinib monotherapy 28 days post completion of radiation therapy for 12 cycles
214638523|NCT07062887|BEHAVIORAL|Mindfulness app|Mindfulness app called Calm Health. It has mindfulness guidance modules related to different aspects of physical and mental health, including type 1 diabetes. It also provides a final report to help you track the relationship between mindfulness and your blood sugar, stress, and sleep.
214638524|NCT06778135|PROCEDURE|Temporary implatation of large-scale intracranial electrode.|The Neuropixels probe (imec, Leuven, Belgium) is a new high resolution multi electrode technology that uses custom 130-nm complementary metal-oxide-semiconductor fabrication with high surface area but low-impedance titanium nitride recordings to produce high site count devices with extreme electrode density in a small package.
214638525|NCT06778135|DEVICE|brain electrode|Show that Neuropixels can safely and effectively record from large populations of neurons.
214638526|NCT01707849|DRUG|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
214638527|NCT01707849|DRUG|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
214638528|NCT03892447|DRUG|Alprostadil|Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d
214638529|NCT03892447|DRUG|Sodium Ferulate|Sodium Ferulate 2\~6mg/kg.d,iv,14d
214638530|NCT03892447|DRUG|Dopamine|Dopamine3～5 ug/kg·min,iv,3 h/d,14d
214638531|NCT05100641|BIOLOGICAL|AV-GBM-1|Therapeutic autologous dendritic cell vaccine
214638532|NCT05100641|BIOLOGICAL|Autologous monocytes|Autologous monocyte control
214638533|NCT06609005|DRUG|INV-9956|INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
214638534|NCT06844487|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
214725087|NCT05651984|DEVICE|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
214725088|NCT02302755|DRUG|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
214725089|NCT03148795|DRUG|Talazoparib|1 mg daily
214725090|NCT02949557|PROCEDURE|Decortication + bone grafts|
214725091|NCT06166290|PROCEDURE|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
214725092|NCT06166290|PROCEDURE|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
214725093|NCT01638169|DEVICE|adding a heel|walking with and without heels on the gaitrite system
214725094|NCT01238952|DRUG|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
214725095|NCT04297410|RADIATION|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
214725096|NCT02590640|DEVICE|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
214725097|NCT02590640|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
214725098|NCT05106335|DRUG|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
214725099|NCT05106335|DRUG|famitinib|famitinib malate capsules for oral administration
214725100|NCT05106335|DRUG|docetaxel|docetaxel for intravenous injection
214725101|NCT03527771|DEVICE|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
214725102|NCT03527771|DRUG|telephone-assisted CPR|Emergency call with telephone assistance in CPR
214725103|NCT04752943|OTHER|Tips By Text Messages|Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
214725104|NCT04262791|DEVICE|Wrist Actigraphy Device|Wrist Actigraphy Device
214725105|NCT04262791|DEVICE|Sleep Headband|Sleep Headband
214725106|NCT01734278|OTHER|No intervention|This is a non-interventional study.
214725107|NCT01176188|OTHER|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
214725108|NCT01176188|OTHER|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
214725109|NCT00740363|DRUG|sitagliptin|Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
214725110|NCT00740363|DRUG|placebo|No active sitagliptin treatment for 4 weeks
214725111|NCT06425263|BIOLOGICAL|adipose tissue fragmented|harvested from the case form buccal pad of fat
214725112|NCT03982745|DEVICE|bonfils|bonfils intubation
214638535|NCT06844487|BIOLOGICAL|MVA-BN half-dose regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as two half doses of the standard regimen; meaning infants/children allocated to Child Group 2 will receive 0.25 mL of the 0.5 mL. 1x10\^8 TCID50 Inf.U./0.5 mL standard regimen. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm. Only one vial will be used per infant/child.
214638536|NCT03226704|PROCEDURE|Leukapheresis|Leukapheresis
214638537|NCT07082686|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol
214638538|NCT07085442|PROCEDURE|Targeted Sentinel Node Biopsy (TSNB)|Targeted Sentinel Node Biopsy will be performed according to routine local practice. The procedure has been standardised for the post-NACT setting as part of the ongoing ATNEC trial. Sites are advised to follow the ATNEC protocol in the primary surgery setting, using either a dual- or single-tracer sentinel node biopsy technique, with localisation and removal of the marked biopsy proven positive node, and removal of at least 3 nodes.
214638539|NCT00931398|DRUG|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
214638540|NCT00931398|DRUG|Placebo|Matched placebo for all Concerta doses.
214638541|NCT07142967|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered with a prescription dose of 8 Gy x 5 fractions prescribed to the 95% isodose line encompassing the dominant recurrent intraprostatic lesion (DRIL) as seen on MRI and/or PET PSMA imaging plus 4mm (GTV+4mm=CTV\_40). Remainder of the prostate gland minus CTV\_40 (CTV\_25) will be prescribed to 5 Gy x 5 fractions at the 95% isodose line.
214638542|NCT07142967|DRUG|Androgen Deprivation Therapy (ADT)|ADT would be given 0-1 months prior to planned SBRT to the prostate for total of 4-6 months. ADT will be administered via Leuprolide or Degarelix monthly injections or daily Relugolix pills.
214725113|NCT00225888|BEHAVIORAL|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
214638543|NCT07144410|DRUG|fentanyl + morphine|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
214638544|NCT07144410|DRUG|fentanyl|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
214638545|NCT06942351|OTHER|Walnuts|Daily consumption of 1.5 ounces of plain walnuts for 12 weeks
214638546|NCT06942351|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
214638547|NCT07144007|DRUG|Dexmedetomidine|In rhinoplasty, 10 minute infusion of 0,5 mcg/kg dexmedetomidine will be administered after nasal packing
214638548|NCT07144007|DRUG|Propofol|In rhinoplasty, 0,5 mg/kg propofol IV bolus will be administered after nasal packing
214638549|NCT07144462|DRUG|Fludarabine|Specified dose on specified days
214638550|NCT07144462|DRUG|Cyclophosphamide (C)|Specified dose on specified days
214638551|NCT07144462|GENETIC|NEUK203-215 Injection|Specified dose on specified days
214638552|NCT06947083|DRUG|Elranatamab|Maintenance therapy
214638553|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-EDF+I Taping method: flex the knee 60° and apply two mesh Kinesio tape strips with natural tension to the painful area of the patellar tendon. Use a jellyfish-shaped Kinesio tape strip with natural tension to the center of the knee joint, aligning the center hole with the treatment area. Apply a thin KT strip clockwise around the tape strip. Then, stretch the center of an I-type tape strip to 50%-75% tension and apply it horizontally to the painful area of the patellar tendon, covering 1/3 to 1/2 the width of the inferior pole of the patella. Secure the ends without tension., and a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-EDF+I taping intervention was continued for 8 weeks."
214638554|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-I taping method: bend the knee joint 30°, use an I-shaped muscle tape to apply horizontally to the painful area of the patellar tendon (from the middle to the sides) with 50%-75% tension, and then use a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-I taping intervention was continued for 8 weeks."
214638555|NCT07143942|BEHAVIORAL|exercise therapy|"Phase 1 aims to control load and reduce pain. This includes quadriceps isometric exercises, double-legged squats with the knees bent 90 degrees against a wall, Spanish squats, vastus medialis exercises, single-leg hip bridges with the affected leg supported, and stretches for the quadriceps, hamstrings, and calf triceps.~Phase 2 aims to gradually increase load and strengthen the training. This includes eccentric and progressive loading exercises. This includes single-leg squats on a 25° incline, lunges, vastus medialis exercises, step-ups, and gluteus resistance exercises.~Phase 3 aims to strengthen function and gradually return to sports. Energy-conserving exercises such as jumping, box jumps, and interval running are performed, gradually increasing jump height, running distance, and speed. After completing all of these exercises and experiencing no knee discomfort for 24 hours, specific exercises can be gradually introduced."
214638556|NCT07135583|OTHER|Active Comparator: Single Intervention 1|Acute intermittent hypercapnic-hypoxia (15 episodes of 1.5 minute O2= 9%, CO2=4% and balance N2, interspaced with 1.5 min room air
214638557|NCT07135583|OTHER|Active Comparator: Single Intervention 2|An open-loop continuous tSCS stimulation \[30 min duration, low frequency (30 Hz), tolerable intensity (\~10-15 mA), 400 µsec pulse width, biphasic symmetric waveform\] will be delivered using 2 channels: Channel 1- C4-C5 spine; Channel 2- T4 spine; returning electrodes at ASIS.
214638558|NCT07135583|BEHAVIORAL|Respiratory Resistance Exercise|Respiratory strength training will be conducted using a standard, spring-loaded threshold device while the participant is receiving either tSCS or Sham tSCS. Participants will complete one warm-up set at a pressure threshold approximately 40% of their pre-test outcomes (obtained on day 1 of the corresponding intervention block) for maximal inspiratory and expiratory pressure generation. Following the warm-up, participants will train at a pressure threshold approximately 70% of their pre-test outcomes and will complete three sets of 6-12 repetitions for both inspiratory and expiratory strength training. A training breath will consist of a \~1-2-second sustained effort through the device, separated by 5-10 seconds of quiet breathing. The order of the three sets each of inspiratory or expiratory training will alternate for each of the five daily sessions; the order on day 1 of training will be randomly determined.
214725114|NCT03048357|DEVICE|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
214725115|NCT03048357|OTHER|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
214725116|NCT04184505|DRUG|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
214725117|NCT04184505|DRUG|Standard Chemotherapy|"1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
214725118|NCT04184505|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
214725119|NCT03043261|BEHAVIORAL|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
214725120|NCT01531361|DRUG|Crizotinib|Given PO
214725121|NCT01531361|OTHER|Laboratory Biomarker Analysis|Correlative studies
214725122|NCT01531361|OTHER|Pharmacological Study|Correlative studies
214725123|NCT01531361|DRUG|Sorafenib Tosylate|Given PO
214725124|NCT01531361|DRUG|Vemurafenib|Given PO
214725125|NCT02663180|BEHAVIORAL|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
214725126|NCT02663180|BEHAVIORAL|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
214725127|NCT06436820|PROCEDURE|Lumbar puncture|Lumbar puncture procedure performed within a clinical setting
214725128|NCT06189248|BEHAVIORAL|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
214725129|NCT06925802|OTHER|visceral manipulation|The procedure begins with the patient lying in a comfortable supine position to ensure relaxation and access to the abdominal region. Gentle palpation is used to assess tissue mobility and identify any restrictions or tension points. The practitioner applies light, rhythmic pressure to the gastroduodenal junction to stimulate movement and improve coordination between the stomach and duodenum. Attention is then given to the sphincter of Oddi, where soft, sustained pressure is employed to facilitate the release of bile and pancreatic juices, aiding digestive processes. Moving to the duodenojejunal flexure, the therapist uses gentle stretching and mobilization techniques to alleviate any obstructions, promoting smoother passage of intestinal contents. Finally, the sigmoid colon is manipulated with circular and oscillatory pressures to enhance peristalsis and relieve constipation.
214725130|NCT06728800|BEHAVIORAL|FBT 2.0|FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traﬃc Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The ﬁnal product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.
214725131|NCT06728800|BEHAVIORAL|Information-and-referral|Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
214725132|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
214725133|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
214725134|NCT04344262|DRUG|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
214725135|NCT04344262|DRUG|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
214725136|NCT03625804|GENETIC|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
214725137|NCT03625804|GENETIC|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
214725138|NCT03625804|GENETIC|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
214725139|NCT01186003|DRUG|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
214725140|NCT00550290|DRUG|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
214725141|NCT00550290|DRUG|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
214725142|NCT01802541|DIETARY_SUPPLEMENT|diacylglycerol oil|
214725143|NCT01802541|DIETARY_SUPPLEMENT|triacylglycerol oil|
214725144|NCT00251589|DRUG|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
214725145|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
214725146|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
214725147|NCT00251589|DRUG|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
214725148|NCT00251589|DRUG|erlotinib|erlotinib 150 mg once a day.
214725149|NCT02293941|DRUG|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
214725150|NCT02293941|DRUG|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
214725151|NCT02293941|DRUG|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
214725152|NCT02293941|DRUG|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
214725153|NCT01082341|BIOLOGICAL|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
214638559|NCT07144579|BEHAVIORAL|Mozart music group|The experimental group was played Mozart - Sonata for Two Pianos in D, K. 448 on the clinic computer.
214638560|NCT07144579|BEHAVIORAL|preferred music group|The experimental group was made to listen to their preferred music in the clinic.
214638561|NCT07144631|DEVICE|Peroneal Nerve Stimulation (PNS) Device|The TOMAC™ system is a non-invasive, wearable peroneal nerve stimulator that delivers high-frequency electrical stimulation to the common peroneal nerves at the fibular head. It is FDA-cleared for the treatment of moderate-to-severe Restless Legs Syndrome (RLS) in adults but has not been studied in pregnancy. In this trial, pregnant participants will undergo an in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation to determine comfortable therapeutic intensity. They will then use the device at home for 8 weeks, up to four 30-minute sessions daily, prioritizing periods of high symptom burden or before bedtime. Outcomes will assess feasibility, acceptability, adherence, symptom improvement, sleep quality, and maternal-fetal safety.
214638562|NCT07142811|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
214638563|NCT07142811|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
214638564|NCT07142811|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
214638565|NCT03087955|DRUG|Acoziborole|Acoziborole 3 x 320 mg tablets (fasted state)
214638566|NCT04496739|BEHAVIORAL|Cancer Educational Materials|Receive educational materials about breast cancer risk and chemoprevention via RealRisk
214638567|NCT04496739|OTHER|Decision Aid|Given patient-centered decision support via an action plan
214638568|NCT04496739|OTHER|Decision Aid|Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
214638569|NCT04496739|OTHER|Interview|Participate in audio-recorded interview via telephone or video conference
214638570|NCT04496739|OTHER|Questionnaire Administration|Ancillary studies
214638571|NCT06285097|DRUG|PF-07820435|immune agonist
214638572|NCT06285097|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
214638573|NCT05279456|BIOLOGICAL|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
214638574|NCT01061515|DRUG|Intraperitoneal Oxaliplatin|
214638575|NCT01061515|DRUG|Bevacizumab|
214638576|NCT01061515|DRUG|Capecitabine|
214638577|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
214638578|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
214638579|NCT06257966|DRUG|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
214638580|NCT06257966|DRUG|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
214638581|NCT01841723|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214638582|NCT01841723|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214638583|NCT01841723|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214638584|NCT01841723|PROCEDURE|Computed Tomography|Undergo CT
214638585|NCT01841723|DRUG|Ibrutinib|Given PO
214638586|NCT01841723|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214638587|NCT06420531|DIETARY_SUPPLEMENT|Human milk|maternal breastmilk or donor breastmilk
214638588|NCT06533579|GENETIC|Dose Level 1, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
214638589|NCT06533579|GENETIC|Dose Level 2, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
214638590|NCT06533579|GENETIC|Dose Level 3, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
214638591|NCT06533579|GENETIC|Dose Level 4, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
214638592|NCT02170181|RADIATION|SBRT|SBRT to Oligometastases
214638593|NCT06549478|PROCEDURE|Computed Tomography|Undergo PET/CT
214638594|NCT06549478|RADIATION|Image Guided Radiation Therapy|Undergo BgRT
214638595|NCT06549478|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214638596|NCT06549478|OTHER|Questionnaire Administration|Ancillary studies
214638597|NCT06604871|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
214638598|NCT05379946|DRUG|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
214638599|NCT05379946|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day
214638600|NCT02392429|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214638601|NCT02392429|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214638602|NCT02392429|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214638603|NCT02392429|DRUG|Chemotherapy|Given anthracycline IV
214638604|NCT02392429|PROCEDURE|Computed Tomography|Undergo FLT PET/CT
214638605|NCT02392429|DRUG|Cytarabine|Given IV
214638606|NCT02392429|OTHER|Fluorothymidine F-18|Undergo FLT PET/CT
214638607|NCT02392429|OTHER|Laboratory Biomarker Analysis|Correlative studies
214638608|NCT02392429|PROCEDURE|Positron Emission Tomography|Undergo FLT PET/CT
214638609|NCT06569108|DRUG|KN057|KN057 will be administered subcutaneously once a week.
214638610|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
214638611|NCT05392608|DRUG|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
214638612|NCT05392608|DRUG|Fulvestrant|Fulvestrant 300mg 1x/four weeks
214638613|NCT04880031|DRUG|Efimosfermin|Efimosfermin will be administered by subcutaneous injection
214638614|NCT04880031|DRUG|Placebo|Placebo will be administered by subcutaneous injection
214638615|NCT06467084|DRUG|KVD900 150 mg|KVD900 Tablet 150 mg (2 x 75 mg)
214638616|NCT06467084|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
214638617|NCT06467084|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
214638618|NCT03656562|DRUG|VAY736|150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
214638619|NCT03656562|DRUG|VAY736 Placebo|solution for injection; 0 mg/mL administered as 2 mL s.c. injection
214725154|NCT02450500|BEHAVIORAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
214725155|NCT00323427|BEHAVIORAL|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
214638620|NCT03656562|DRUG|CFZ533|150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
214638621|NCT03656562|DRUG|CFZ533 Placebo|Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
214725156|NCT00323427|DEVICE|hearing aid services|Standard VA audiological hearing aid dispensing services
214725157|NCT04829942|BEHAVIORAL|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
214638622|NCT04519489|DEVICE|PAP therapy with telemonitoring|This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
214725158|NCT05289154|OTHER|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
214725159|NCT05289154|BEHAVIORAL|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
214725160|NCT04963634|OTHER|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
214725161|NCT03723499|OTHER|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
214725162|NCT06794697|OTHER|Questionnaire including APAIS scale|Patients will complete a questionnaire in two stages : upon admission and just before leaving for the operating room
214725163|NCT04493463|DRUG|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
214725164|NCT04493463|DRUG|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
214725165|NCT02376478|DRUG|TNF-alpha inhibitors|therapy for at least 6 months
214725166|NCT02376478|DRUG|Alternative/no medication|therapy for at least 6 months or no therapy
214725167|NCT02376478|OTHER|Alternative/no medication|phototherapy for at least 6 months
214725168|NCT02376478|DRUG|Purine/folic acid analogues|therapy for at least 6 months
214725169|NCT02707679|OTHER|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
214638623|NCT04519489|OTHER|AF standard management and OSA general care|Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
214638624|NCT04101838|DRUG|Fluzone|inactivated seasonal influenza vaccine
214638625|NCT04101838|DRUG|Flucelvax|inactivated seasonal influenza vaccine
214638626|NCT04101838|DRUG|Fluzone High-Dose|inactivated seasonal influenza vaccine
214638627|NCT04101838|DRUG|Fluad|inactivated seasonal influenza vaccine
214638628|NCT02869282|OTHER|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
214638629|NCT02869282|OTHER|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
214638630|NCT00482014|DRUG|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
214638631|NCT00482014|DRUG|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
214638632|NCT00482014|DRUG|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles"
214638633|NCT00482014|RADIATION|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
214638634|NCT03213301|DRUG|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
214638635|NCT03343275|COMBINATION_PRODUCT|Lit control pHDown|Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
214638636|NCT06158165|DEVICE|Mostcare (Vytech, Vygon, Padua, Italy)|Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
214638637|NCT01178138|DRUG|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
214638638|NCT06763484|DRUG|Paroxetine|20 mg PO daily
214638639|NCT06763484|DIETARY_SUPPLEMENT|Placebo|1 capsule starch
214638640|NCT02381561|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214638641|NCT02381561|OTHER|Laboratory Biomarker Analysis|Correlative studies
214638642|NCT02381561|OTHER|Pharmacological Study|Correlative studies
214638643|NCT02381561|DRUG|Ropidoxuridine|Given PO
214725170|NCT02707679|OTHER|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
214725171|NCT02707679|OTHER|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
214638644|NCT05728866|PROCEDURE|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
214638645|NCT03225365|BIOLOGICAL|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
214638646|NCT01241708|DRUG|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
214725172|NCT02707679|OTHER|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
214638647|NCT06181162|OTHER|Social and/or physical environmental interventions|To be determined in the co-creation groups at the four sites (Denmark, the Netherlands, Nigeria, South Africa)
214725173|NCT04843943|DRUG|Sintilimab|Sintilimab: 200mg IV Q3W D1
214725174|NCT04843943|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
214725175|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
214725176|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
214725177|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
214725178|NCT01924741|PROCEDURE|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
214725179|NCT03954977|DIAGNOSTIC_TEST|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
214725180|NCT01070238|DIETARY_SUPPLEMENT|Isomaltulose|
214725181|NCT06020833|DRUG|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
214725182|NCT02571972|DRUG|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
214725183|NCT03137017|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
214725184|NCT03137017|DRUG|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
214725185|NCT02451033|DRUG|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
214638648|NCT04784221|RADIATION|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
214638649|NCT02968810|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214638650|NCT02968810|PROCEDURE|Computed Tomography|Undergo CT
214638651|NCT02968810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214638652|NCT02968810|OTHER|Placebo Administration|Given PO
214638653|NCT02968810|OTHER|Questionnaire Administration|Ancillary studies
214638654|NCT02968810|DRUG|Simvastatin|Given PO
214638655|NCT06846515|DRUG|AR882 50 mg|Solid Oral Capsule
214638656|NCT06846515|DRUG|AR882 75 mg|Solid Oral Capsule
214638657|NCT06846515|DRUG|Placebo|Matching Solid Oral Capsule Placebo
214638658|NCT04137887|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
214638659|NCT04137887|BIOLOGICAL|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
214638660|NCT02040298|DRUG|Clemastine|4mg tablet twice daily
214638661|NCT02040298|DRUG|Placebo|Placebo tablet twice daily
214638662|NCT00898222|DRUG|aspirin|81 mg orally daily for two weeks
214638663|NCT03787758|DRUG|SAGE-718|SAGE-718
214638664|NCT03735537|DRUG|Teriparatide Pen Injector|
214638665|NCT03735537|DRUG|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
214638666|NCT04183335|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214638667|NCT04183335|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214638668|NCT04183335|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
214638669|NCT04183335|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
214638670|NCT04183335|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
214638671|NCT03718143|DRUG|Combination AZD1775 with AraC|AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
214638672|NCT03718143|DRUG|AZD1775 only|AZD1775 days 1-5 \& 8-12
214638673|NCT00185393|BIOLOGICAL|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
214638674|NCT00185393|OTHER|no treatment|no treatment
214638675|NCT06569329|DEVICE|GentleWave System Root Canal Therapy|This device has 510k market approval for its intended use within this study.
214638676|NCT06569329|DEVICE|EdgePro Laser Root Canal Therapy|This device has 510k market approval for its intended use within this study.
214638677|NCT06569329|DEVICE|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|This device has 510k market approval for its intended use within this study.
214638678|NCT05064059|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
214638679|NCT05064059|DRUG|regorafenib|Oral
214638680|NCT05064059|DRUG|TAS-102|Oral
214725186|NCT02451033|DRUG|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
214725187|NCT02451033|DRUG|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
214725188|NCT03519399|DEVICE|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
214725189|NCT01085656|DRUG|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
214725190|NCT04298931|OTHER|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
214725191|NCT02078661|DRUG|PG101|A topical gel containing either 1% or 0.25% PG101 active.
214725192|NCT01770756|BEHAVIORAL|Self-Care Training|
214725193|NCT01146548|DRUG|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
214638681|NCT04424069|PROCEDURE|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
214638682|NCT02605642|DRUG|CT-P13|biosimilar infliximab
214638683|NCT02172157|DRUG|BI 1744 CL i.v.|
214638684|NCT02172157|DRUG|BI 1744 CL oral|
214638685|NCT00391404|DRUG|Alendronate|Alendronate 70 mg weekly (oral)
214638686|NCT00391404|DRUG|Placebo|Placebo
214638687|NCT06638892|BEHAVIORAL|Using PrEP, Doing it for Ourselves (UPDOs)|An e-Health intervention that considers women's lived experiences and uses three components: beauty salons and stylists as opinion leaders (trusted gatekeepers who share health information in the community), theory driven edutainment videos and blogs, and a secure online platform for accessing pre-exposure prophylaxis (PrEP).
214638688|NCT06638892|OTHER|Standard of Care|CDC standard of care, e.g., CDC videos and website.
214638689|NCT05111262|DRUG|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
214638690|NCT05116449|BEHAVIORAL|Quality of life questionnaires|Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
214638691|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
214638692|NCT00152425|DRUG|Certolizumab Pegol (CDP870)|
214638693|NCT05273827|DRUG|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
214638694|NCT05273827|DRUG|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
214638695|NCT06446739|DEVICE|Continuous Renal Replacement Therapy (CRRT)|Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
214638696|NCT03317860|DEVICE|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
214638697|NCT03317860|DEVICE|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
214638698|NCT04480450|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
214638699|NCT06180889|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
214638700|NCT06180889|DRUG|KN060 Low|Single dose of KN060 administered as intravenous infusion
214638701|NCT06180889|DRUG|KN060 Middle|Single dose of KN060 administered as intravenous infusion
214638702|NCT06180889|DRUG|KN060 Hight|Single dose of KN060 administered as intravenous infusion
214638703|NCT01693315|DRUG|AMA0076|
214638704|NCT01693315|DRUG|Placebo|
214638705|NCT02911766|DRUG|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
214638706|NCT02911766|DRUG|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
214638707|NCT02911766|DRUG|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
214638708|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
214638709|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
214638710|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
214638711|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
214638712|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
214638713|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
214638714|NCT06501274|DEVICE|capsule sponge|capsule sponge sampling device of the oesophagus
214638715|NCT05321836|OTHER|Glucosamine Chondroitin|control group
214638716|NCT05321836|COMBINATION_PRODUCT|glucosamine chondritin & Physiotherapy|experimental group
214638717|NCT06576427|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
214638718|NCT06959810|OTHER|Adapted Onco-Esthetics sessions|Patient will received three sessions of Adapted Onco-Esthetics
214725194|NCT01391338|DRUG|ASP3652|Oral
214725195|NCT01391338|DRUG|Placebo|Oral
214638719|NCT05422131|DEVICE|MyCare Insite Clozapine Test|The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
214638720|NCT00317148|DRUG|Placebos|Placebo capsule
214638721|NCT00317148|DRUG|DHEA capsule|One capsule of DHEA
214725196|NCT01359852|DRUG|[11C] JNJ-42491293|Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
214725197|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
214725198|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|"Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
214725199|NCT01359852|DRUG|[11C] JNJ-42491293|Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
214725200|NCT03529370|RADIATION|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
214638722|NCT06496178|DRUG|Petosemtamab|MCLA-158
214725201|NCT03039192|DRUG|Esketamine|Intranasal esketamine solution 84 milligram (mg)
214725202|NCT03039192|OTHER|Placebo|Intranasal Placebo solution
214725203|NCT03039192|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
214638723|NCT06496178|DRUG|Investigator's Choice|Cetuximab
214638724|NCT06496178|DRUG|Investigator's Choice|Methotrexate
214638725|NCT06496178|DRUG|Investigator's Choice|Docetaxel
214638726|NCT04040569|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
214638727|NCT06298071|DRUG|SIBP-R002|Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
214638728|NCT06298071|DRUG|SIBP-R002|Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
214638729|NCT06298071|DRUG|SIBP-R002|Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
214638730|NCT06298071|DRUG|Methotrexate|Combination drugs: Methotrexate, dose15 mg, oral.
214638731|NCT06845813|DRUG|AZD6234|Dose 1
214638732|NCT04970251|DRUG|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
214638733|NCT03279380|OTHER|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
214638734|NCT03279380|OTHER|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
214725204|NCT02493868|DRUG|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
214725205|NCT02493868|DRUG|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
214638735|NCT03279380|OTHER|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
214638736|NCT01396005|DRUG|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
214638737|NCT01396005|DRUG|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
214638738|NCT01396005|DRUG|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
214638739|NCT03156400|OTHER|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
214638740|NCT01178060|OTHER|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
214638741|NCT01178060|OTHER|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
214638742|NCT04593784|DRUG|Ciraparantag|Ciraparantag: 180 mg, intravenous
214638743|NCT04593784|DRUG|Placebo|Placebo: 0.9% sodium chloride, intravenous
214638744|NCT04593784|DEVICE|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
214638745|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
214638746|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
214638747|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 1 mg/kg IV on Day 1
214638748|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 5 mg/kg IV on Day 1
214638749|NCT00607308|DRUG|Placebo|Single dose of placebo IV on Day 1
214638750|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 10 mg/kg IV on Day 1
214638751|NCT02697383|DRUG|Ixazomib (MLN9708)|
214638752|NCT02697383|DRUG|Dexamethasone|
214638753|NCT03757988|BEHAVIORAL|Exercise Intervention- PACE-Life|Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
214725206|NCT02493868|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
214638754|NCT06286033|DRUG|AG-181|AG-181 tablets
214638755|NCT06286033|DRUG|Placebo|AG-181 matched-placebo tablets
214638756|NCT02093442|PROCEDURE|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
214638757|NCT03806127|DRUG|Vibegron|oral administration
214638758|NCT03806127|DRUG|Placebo|oral administration
214638759|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
214638760|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
214638761|NCT00133523|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
214638762|NCT00133523|OTHER|Placebo|Physiological saline administered as an intramuscular injection.
214638763|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
214638764|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
214638765|NCT00133523|OTHER|Placebo|Normal allantoic fluid administered annually as an internasal spray.
214638766|NCT02580500|PROCEDURE|epidural catheter|epidural anaesthesia application for spinal catheter will be used
214638767|NCT02580500|PROCEDURE|spinal catheter|spinal anesthesia application for spinal catheter will be used
214638768|NCT01467492|DRUG|Telaprevir|Tablet
214638769|NCT01467492|DRUG|Ribavirin|Tablet
214638770|NCT01467492|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
214638771|NCT04978558|OTHER|Continuous assessment of cerebrovascular autoregulation with NIRS and TCD|Continuous monitoring of MAP, cerebral oxygenation, and cerebral blood flow velocity before, during, and after surgery to calculate two cerebrovascular autoregulation indices Cox and Mx.
214638772|NCT02401737|DRUG|NVR 3-778|
214638773|NCT02401737|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
214638774|NCT02401737|DRUG|Pegasys|
214638775|NCT00769145|DRUG|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
214638776|NCT04436146|OTHER|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
214638777|NCT01627587|DRUG|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
214638778|NCT01627587|DRUG|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
214638779|NCT01627587|DRUG|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
214638780|NCT01627587|DRUG|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
214638781|NCT01627587|DRUG|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
214638782|NCT02829021|DEVICE|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
214638783|NCT06237517|BEHAVIORAL|Assessment of Vasomotion of People With Idiopathic Chilblains|Investigation of vasomotion of people with and without idiopathic chilblains
214638784|NCT00235079|DRUG|Colchicine|Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
214638785|NCT00235079|DRUG|Placebo|Placebo comparator
214638786|NCT01390259|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
214638787|NCT01390259|DEVICE|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
214638788|NCT04929171|OTHER|Physical Therapy|Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
214638789|NCT04408495|PROCEDURE|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
214638790|NCT04408495|PROCEDURE|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
214638791|NCT01164085|DRUG|Intravitreal Ketorolac|4mg of intravitreal ketorolac
214638792|NCT03489733|OTHER|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
214638793|NCT03489733|OTHER|Control formula|Infant formula with intact proteins and pre- and probiotics.
214638794|NCT00522795|DRUG|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
214638795|NCT02913157|DRUG|Hydroxychloroquine|Orally administered Hydroxychloroquine
214638796|NCT05159596|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
214638797|NCT05159596|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
214638798|NCT04500275|DRUG|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
214638799|NCT04500275|OTHER|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
214638800|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
214638801|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
214638802|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
214638803|NCT06674863|OTHER|Educational Intervention|Receive a low literacy educational supplement
214638804|NCT06674863|OTHER|Interview|Undergo a structured interview
214638805|NCT06674863|OTHER|Questionnaire Administration|Ancillary studies
214638806|NCT06674863|OTHER|Supportive Care|Receive standard SCP
214638807|NCT06674863|OTHER|Supportive Care|Receive a tailored SCP
214638808|NCT01804686|DRUG|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
214638809|NCT05487599|GENETIC|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
214638810|NCT06801275|OTHER|1 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering once with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
214638811|NCT06801275|OTHER|2 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering twice with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
214638812|NCT03508310|OTHER|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
214638813|NCT05851677|DRUG|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
214638814|NCT04468126|OTHER|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
214638815|NCT04468126|OTHER|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
214638816|NCT05286801|BIOLOGICAL|Atezolizumab|Given IV
214638817|NCT05286801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214638818|NCT05286801|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
214638819|NCT05286801|PROCEDURE|Echocardiography Test|Undergo ECHO
214638820|NCT05286801|OTHER|Fludeoxyglucose F-18|Given FDG
214638821|NCT05286801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214638822|NCT05286801|PROCEDURE|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
214638823|NCT05286801|BIOLOGICAL|Tiragolumab|Given IV
214638824|NCT05286801|PROCEDURE|X-Ray Imaging|Undergo x-rays
214638825|NCT03132636|DRUG|cemiplimab|Regimen as per protocol
214725207|NCT02493868|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
214638826|NCT02129751|DRUG|bupropion hydrobromide|study drug
214638827|NCT02129751|DRUG|Placebo|placebo arm
214638828|NCT03461445|DRUG|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
214638829|NCT03461445|DRUG|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
214638830|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
214638831|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638832|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638833|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638834|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638835|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638836|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
214638837|NCT05807035|BIOLOGICAL|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
214638838|NCT06323616|PROCEDURE|MAC adjustment to PSI between 25 and 50|According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
214638839|NCT06233656|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing.
214638840|NCT05105100|PROCEDURE|Biopsy|Tumor tissue collection
214638841|NCT05105100|PROCEDURE|Biospecimen Collection|Intravenously Blood draw
214638842|NCT06136234|BEHAVIORAL|Caring Contacts|Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern
214638843|NCT06136234|BEHAVIORAL|Best Available Resources Alone|Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
214638844|NCT04221542|DRUG|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
214725208|NCT02493868|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
214725209|NCT02493868|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
214725210|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
214725211|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
214725212|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
214725213|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
214725214|NCT03461185|DRUG|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
214725215|NCT03461185|DRUG|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
214725216|NCT02324738|DRUG|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
214725217|NCT02324738|OTHER|Wash-out period|
214725218|NCT02324738|DRUG|Mefloquine|2 tablets of Mefloquine single dose
214638845|NCT04221542|DRUG|Abiraterone|Abiraterone administered as oral tablets.
214638846|NCT04221542|DRUG|Enzalutamide|Enzalutamide administered as oral tablets.
214638847|NCT03142321|DRUG|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
214725219|NCT02299271|DRUG|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
214725220|NCT02299271|DRUG|Saline|Saline as a one-time, 60 milliliter injection.
214725221|NCT03725449|OTHER|Best Practice|Receive standard of care
214725222|NCT03725449|BEHAVIORAL|mySmartCheck|Receive access to mySmartcheck program
214725223|NCT03725449|OTHER|Survey Administration|Ancillary studies
214725224|NCT06460831|DEVICE|Microcatheter|The microcatheter group undergoes alcohol ablation using a microcatheter.
214725225|NCT06460831|DEVICE|OTW|The OTW group undergoes alcohol ablation using an OTW balloon.
214638848|NCT03042468|DRUG|177Lu-PSMA-617|177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
214725226|NCT03771989|BIOLOGICAL|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
214638849|NCT03042468|DRUG|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
214638850|NCT06278207|DRUG|Finerenone (BAY 94-8862)|10 mg or 20 mg daily
214638851|NCT05746767|BEHAVIORAL|Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
214638852|NCT05746767|BEHAVIORAL|Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
214638853|NCT05647226|COMBINATION_PRODUCT|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
214638854|NCT05647226|OTHER|Standard of care|Standard of care.
214638855|NCT06408077|OTHER|Water administration|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
214638856|NCT06408077|OTHER|NaCl-Administration|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
214638857|NCT06420245|DEVICE|Orion TM Amniotic Membrane Allograft|The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
214638858|NCT06420245|PROCEDURE|Standard of Care (SOC)|Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
214638859|NCT05140499|DRUG|Liposomal bupivacaine|Popliteal nerve block
214638860|NCT05140499|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
214638861|NCT05882058|DRUG|BI 764532, dose 1|BI 764532, dose 1
214638862|NCT05882058|DRUG|BI 764532, dose 2|BI 764532, dose 2
214638863|NCT05880368|OTHER|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
214638864|NCT05723653|BEHAVIORAL|Social Network Support Intervention|The Social Network Support Intervention is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV. The intervention consists of (1) selection and invitation of a Support Confidant, (2) a face-to-face intervention between the Intervention Case Manager and the Index and Support Confidant, and (3) quarterly interactive mini-booster sessions delivered to the Index and Support Confidant via text or telephone, based on participant preference.
214638865|NCT06414473|DRUG|Cannabidiol (CBD) Extract|Administered thrice daily (with food) using a sublingual route of administration
214638866|NCT06414473|DRUG|Placebo|Administered thrice daily (with food) using a sublingual route of administration
214638867|NCT04608110|DRUG|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
214638868|NCT06328686|DIETARY_SUPPLEMENT|Arginine|Given IV or PO
214638869|NCT06328686|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214638870|NCT06328686|PROCEDURE|Computed Tomography|Undergo CT
214638871|NCT06328686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214638872|NCT06328686|PROCEDURE|Spectroscopy|Undergo spectroscopy
214638873|NCT06328686|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214638874|NCT02453620|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214638875|NCT02453620|OTHER|Blood Sample|Undergo blood sample collection
214638876|NCT02453620|PROCEDURE|Bone Scan|Undergo bone scan
214638877|NCT02453620|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214638878|NCT02453620|DRUG|Entinostat|Given PO
214638879|NCT02453620|BIOLOGICAL|Ipilimumab|Given IV
214638880|NCT02453620|BIOLOGICAL|Nivolumab|Given IV
214638881|NCT02453620|OTHER|Pharmacogenomic Study|Correlative studies
214725227|NCT03771989|OTHER|Saline|The placebo is an injection with saline
214725228|NCT00868361|DRUG|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
214725229|NCT06429397|DRUG|Anlotinib and Benmelstobart|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
214725230|NCT06905483|DRUG|Budesonide/Glycopyrronium/Formoterol (BGF)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
214725231|NCT06905483|DRUG|Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
214638882|NCT02453620|OTHER|Pharmacological Study|Correlative studies
214638883|NCT02453620|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214638884|NCT05238714|DRUG|venglustat|Powder for Oral solution
214638885|NCT06431425|BEHAVIORAL|eCG Family Clinic|The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
214638886|NCT03212742|DRUG|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
214638887|NCT03212742|DRUG|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
214638888|NCT03212742|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
214638889|NCT05333341|BEHAVIORAL|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
214638890|NCT05333341|BEHAVIORAL|TCM plus COPES|The COPES program will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
214638891|NCT04161495|BIOLOGICAL|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV injection
214638892|NCT03656861|OTHER|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
214638893|NCT02117765|DRUG|Ustekinumab|
214638894|NCT01169077|DRUG|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
214638895|NCT01169077|BIOLOGICAL|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
214638896|NCT03005054|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
214638897|NCT03005054|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
214638898|NCT03257787|OTHER|new adhesive strip|This is a strip made of a newly developed adhesive
214638899|NCT03529292|DEVICE|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
214638900|NCT02213809|BEHAVIORAL|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
214638901|NCT02213809|BEHAVIORAL|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
214638902|NCT01239160|DEVICE|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
214638903|NCT01239160|DEVICE|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
214638904|NCT01764633|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214638905|NCT01764633|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214638906|NCT05339672|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
214638907|NCT01913392|PROCEDURE|laparoscopic sleeve gastrectomy|
214638908|NCT04567550|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
214638909|NCT04567550|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
214638910|NCT04567550|GENETIC|ABBV-RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
214638911|NCT04567550|DRUG|Topical Steroid|Topical Steroid
214638912|NCT04567550|GENETIC|ABBV-RGX-314 Dose 4|AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
214638913|NCT04567550|BIOLOGICAL|Aflibercept|Aflibercept
214638914|NCT02263833|DRUG|Mircera|Participants received Mircera according to individualized physician-prescribed regimen.
214638915|NCT04146610|DRUG|an antibody drug conjugate|Multiple dose grouping
214638916|NCT04421625|DIAGNOSTIC_TEST|Diagnostic test for SARS-Cov2 for patients and health staff|"Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)"
214638917|NCT01503255|BEHAVIORAL|cognitive behavioral group therapy|6 weekly 90-minute group sessions
214638918|NCT01503255|BEHAVIORAL|health education group|6 weekly 90-minute group sessions
214638919|NCT02929264|DRUG|ABX-1431|Capsules, 40 mg, single dose
214638920|NCT02929264|DRUG|Placebo|Capsules, single dose
214638921|NCT03355183|OTHER|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
214638922|NCT03302754|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
214638923|NCT00704964|BIOLOGICAL|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
214638924|NCT00704964|DRUG|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
214638925|NCT06303609|DEVICE|nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.
214638926|NCT06303609|DEVICE|Vaginal dilator|Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.
214638927|NCT06303609|DEVICE|Sham nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.
214638928|NCT00144183|DRUG|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
214638929|NCT00144183|DRUG|Zidovudine (ZCV)|
214638930|NCT00144183|DRUG|3TC|
214638931|NCT01571583|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
214638932|NCT01571583|DRUG|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
214638933|NCT01571583|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.
214638934|NCT04418765|DRUG|Eptinezumab|Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
214638935|NCT04418765|DRUG|Placebo|concentrate for solution for infusion, intravenously
214638936|NCT01789970|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
214725232|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE+HAIC."
214638937|NCT01789970|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
214638938|NCT00927771|DRUG|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
214638939|NCT00927771|DRUG|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
214638940|NCT02161562|DRUG|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
214638941|NCT02161562|DRUG|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
214638942|NCT00207415|BEHAVIORAL|ASHC and CDSMP|
214638943|NCT02668718|RADIATION|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
214638944|NCT02105532|OTHER|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
214725233|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE."
214725234|NCT03976518|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
214725235|NCT02345044|DRUG|CS-3150|
214725236|NCT02345044|DRUG|placebo|
214638945|NCT02105532|OTHER|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
214638946|NCT06195020|OTHER|Metaverse|"The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months."
214638947|NCT06195020|OTHER|Polyclinic information|This group will be informed only at the outpatient clinic. The intervention will last 3 months.
214638948|NCT02123485|DEVICE|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
214638949|NCT02123485|DEVICE|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
214638950|NCT04755946|DRUG|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
214638951|NCT04755946|DRUG|Placebo|Placebo
214638952|NCT03423342|DIETARY_SUPPLEMENT|nicotinamide riboside|nicotinamide riboside capsule
214638953|NCT03423342|DRUG|Placebo|matching placebo capsule
214638954|NCT01183273|PROCEDURE|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
214638955|NCT01183273|PROCEDURE|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
214638956|NCT04668352|DRUG|Dactolisib|TORC1 inhibitor
214638957|NCT04668352|OTHER|Placebo|Placebo
214638958|NCT00341250|DRUG|AMA1-C1/Alhydrogel Malaria Vaccine|
214638959|NCT02933697|DRUG|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
214638960|NCT02933697|DRUG|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
214725237|NCT02345044|DRUG|eplerenone|
214725238|NCT04010162|OTHER|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
214725239|NCT03074318|DRUG|Avelumab|Given IV
214725240|NCT03074318|DRUG|Trabectedin|Given IV
214725241|NCT02275520|DEVICE|NIO Adult device|IO access-1
214725242|NCT02275520|DEVICE|Bone Iniection Gun|IO access-2
214725243|NCT02275520|DEVICE|EZ-IO|IO access-3
214725244|NCT02275520|DEVICE|Jamshidi Intraosseous Needle|IO access-4
214725245|NCT02275520|DEVICE|Cook Intraosseous Needle|IO access-5
214725246|NCT00093756|RADIATION|3-dimensional conformal radiation therapy|
214725247|NCT00093756|DRUG|bortezomib|Given IV
214725248|NCT00093756|DRUG|paclitaxel|Given IV
214725249|NCT00093756|DRUG|carboplatin|Given IV
214725250|NCT00006968|BIOLOGICAL|filgrastim|
214725251|NCT00006968|DRUG|cyclosporine|
214638961|NCT01639833|DEVICE|Veriset Hemostatic Patch|Topical hemostat
214638962|NCT01639833|DEVICE|TachoSil®|Topical Hemostat
214638963|NCT00883246|DEVICE|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
214638964|NCT04976894|OTHER|open|open
214638965|NCT06182488|OTHER|ERAS protocols|ERAS protocols for emergency abdominal surgery
214638966|NCT06182488|OTHER|Conventional protocols|Conventional protocols for emergency abdominal surgery
214638967|NCT02450578|DRUG|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
214638968|NCT02450578|DRUG|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
214638969|NCT02450578|BIOLOGICAL|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
214638970|NCT02450578|DRUG|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
214725252|NCT00006968|DRUG|pentostatin|
214638971|NCT05450679|PROCEDURE|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at \> 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
214638972|NCT04291937|DRUG|Lurbinectedin|Powder for concentrate for solution for infusion in 4 mg vials
214638973|NCT01179958|BEHAVIORAL|aerobic training|24 weeks of aerobic training, 4X/week
214638974|NCT01179958|BEHAVIORAL|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
214725253|NCT00006968|PROCEDURE|allogeneic bone marrow transplantation|
214725254|NCT00006968|PROCEDURE|peripheral blood stem cell transplantation|
214638975|NCT04016311|BEHAVIORAL|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
214638976|NCT02656628|DEVICE|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
214638977|NCT00794560|BEHAVIORAL|patient education|"Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist"
214638978|NCT01584245|OTHER|Amino Acid formula|
214638979|NCT02266030|DRUG|Cilostazol|Pletaal as an active drug
214638980|NCT02266030|DRUG|Aspirin|Aspirin as an active comparator
214638981|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
214638982|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
214638983|NCT05082103|OTHER|Enzyme lozenge 1|Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
214638984|NCT05082103|OTHER|Enzyme lozenge 2|Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
214638985|NCT05082103|OTHER|Placebo lozenge|Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
214638986|NCT02237430|DEVICE|MynxGrip|Closure device for femoral artery access closure
214638987|NCT02237430|OTHER|Manual compression|Conventional manual compression
214638988|NCT02841215|DRUG|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
214638989|NCT02841215|DRUG|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
214638990|NCT02481388|OTHER|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
214638991|NCT03075566|BIOLOGICAL|Healthy subjects|\- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
214638992|NCT03075566|BIOLOGICAL|Patients|\- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
214638993|NCT03511131|BEHAVIORAL|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
214638994|NCT03511131|BEHAVIORAL|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
214638995|NCT03511131|BEHAVIORAL|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
214638996|NCT03511131|BEHAVIORAL|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
214638997|NCT03639844|BIOLOGICAL|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
214638998|NCT03639844|DRUG|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
214638999|NCT01887977|OTHER|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
214639000|NCT01014741|DRUG|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
214639001|NCT01014741|DRUG|Placebo|Placebo after PV isolation prior to CFE ablation.
214639002|NCT03326141|BEHAVIORAL|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
214639003|NCT03326141|DEVICE|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
214639004|NCT03326141|BEHAVIORAL|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
214639005|NCT03326141|BEHAVIORAL|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
214639006|NCT03326141|OTHER|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
214639007|NCT00180960|DRUG|Oxaliplatin and irinotecan|
214639008|NCT03489798|PROCEDURE|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
214639009|NCT03489798|PROCEDURE|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
214639010|NCT03607760|DEVICE|ECMO|the patients with severe respiratory failure were supported by ECMO
214639011|NCT03607760|DEVICE|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
214639012|NCT03153449|DEVICE|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
214725255|NCT00890669|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
214725256|NCT02881671|GENETIC|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
214639013|NCT03452566|DRUG|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
214639014|NCT05966285|OTHER|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
214639015|NCT05966285|OTHER|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
214639016|NCT00731172|DRUG|glatiramer acetate|20 mg daily subcutaneous injection through week 12
214639017|NCT00731172|DRUG|placebo|subcutaneous daiky injection through week 12
214639018|NCT03106623|DRUG|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
214639019|NCT03106623|DRUG|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
214639020|NCT03106623|DRUG|Placebo|Oral administration of Placebo once a daily for 4 weeks
214725257|NCT04813978|OTHER|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
214725258|NCT00360672|DRUG|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
214725259|NCT04359225|OTHER|3D Telemedicine|Telemedicine using 3D broadcast to clinician
214725260|NCT04359225|OTHER|2D Telemedicine|Standard care with 2D telemedicine
214725261|NCT06148350|OTHER|Stroke Rehabilitation|Both the groups received interventions three days/week for 30-60 minutes for four weeks
214725262|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
214725263|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
214725264|NCT00643448|DRUG|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
214725265|NCT04709874|OTHER|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
214639021|NCT02436876|DRUG|MBN-101|MBN-101 is a locally administered, anti-infective drug product
214639022|NCT02436876|OTHER|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
214639023|NCT03572556|BIOLOGICAL|Blood samples|"* 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
214639024|NCT03572556|OTHER|Epistaxis charts|Three monthly epistaxis charts to be completed
214639025|NCT04455373|PROCEDURE|pediatric vascular bypass grafting|pediatric vascular bypass grafting
214639026|NCT02776800|DEVICE|Allevyn Life|
214725266|NCT04709874|OTHER|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
214725267|NCT04340960|OTHER|Home Monitoring|Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
214725268|NCT05656391|DIETARY_SUPPLEMENT|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
214725269|NCT00888680|DRUG|BGC20-1531|BGC20-1531 administered orally
214725270|NCT00888680|DRUG|Lactose|Placebo administered orally
214725271|NCT06451276|DEVICE|Nasoalveolar molding in unilateral cleft lip and palate|compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
214725272|NCT03177967|BEHAVIORAL|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
214725273|NCT03177967|OTHER|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
214725274|NCT03177967|OTHER|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
214725275|NCT02177812|DRUG|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
214725276|NCT02177812|DRUG|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
214725277|NCT05979155|BIOLOGICAL|NWY001|Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
214725278|NCT05979155|BIOLOGICAL|NWY001|Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
214725279|NCT00089999|DRUG|Lapatinib|
214639027|NCT02776800|DEVICE|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
214639028|NCT05528510|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
214639029|NCT05528510|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
214639030|NCT05528510|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
214639031|NCT05528510|OTHER|Placebo|Placebo will be administered as SC injection.
214639032|NCT01113827|DIETARY_SUPPLEMENT|Olive Extract|Capsule form ingested 1x/day for 6 weeks
214639033|NCT01113827|DIETARY_SUPPLEMENT|Placebo|Placebo
214725280|NCT00453323|DRUG|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
214639034|NCT02809833|DRUG|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
214639035|NCT03285243|DEVICE|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
214639036|NCT03437239|DEVICE|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
214639037|NCT03166332|BEHAVIORAL|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
214639038|NCT03166332|BEHAVIORAL|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
214639039|NCT04459455|BEHAVIORAL|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
214639040|NCT04459455|BEHAVIORAL|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
214639041|NCT01665118|DEVICE|Trusculpt (Radio Frequency) Device|
214639042|NCT05779072|DEVICE|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
214639043|NCT02576743|DEVICE|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
214639044|NCT02844114|DRUG|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
214639045|NCT02844114|DRUG|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
214639046|NCT02844114|DRUG|Chemotherapy|iv.30 minutes
214725281|NCT00453323|DRUG|Capecitabine|capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
214725282|NCT02370550|DRUG|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
214639047|NCT03602287|DRUG|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
214639048|NCT03602287|DRUG|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
214639049|NCT03640871|DEVICE|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC\_019 dressing 10x10 cm (AWC=Advanced Wound Care)
214725283|NCT02370550|DRUG|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
214725284|NCT02370550|DRUG|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
214725285|NCT02370550|DRUG|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
214725286|NCT03091426|DRUG|Omiganan|Omiganan 1%
214725287|NCT03091426|DRUG|Omiganan|Omiganan 1.75%
214725288|NCT03091426|DRUG|Omiganan|Omiganan 2.5%
214725289|NCT03091426|DRUG|Placebo|Vehicle
214725290|NCT00588757|DEVICE|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
214639050|NCT02387580|DRUG|OZ439 + TPGS|
214639051|NCT02387580|DRUG|OZ439 Prototype 1|
214639052|NCT02387580|DRUG|OZ439 Prototype 3|
214639053|NCT02387580|DRUG|PQP|
214639054|NCT03353857|DRUG|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
214639055|NCT03353857|DRUG|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
214639056|NCT03353857|DRUG|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
214639057|NCT03353857|DRUG|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
214639058|NCT03353857|DRUG|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
214639059|NCT03353857|DRUG|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
214639060|NCT03353857|DRUG|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
214639061|NCT03201185|DRUG|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
214639062|NCT02397850|BEHAVIORAL|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
214639063|NCT02397850|BEHAVIORAL|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
214639064|NCT06099587|DIAGNOSTIC_TEST|high-resolution diffusion MRI|The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
214639065|NCT01765101|OTHER|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
214639066|NCT01765101|OTHER|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
214639067|NCT04961606|OTHER|interview|semi-structured individual interview
214639068|NCT03046355|PROCEDURE|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
214639069|NCT03046355|PROCEDURE|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
214639070|NCT05044052|BEHAVIORAL|Emphasis on the Choosing Wisely Viral Prescription Pad|We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
214725291|NCT00588757|DEVICE|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
214725292|NCT02846857|OTHER|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
214725293|NCT02846857|OTHER|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
214639071|NCT05514964|BEHAVIORAL|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
214639072|NCT03642678|DIETARY_SUPPLEMENT|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
214725294|NCT02846857|OTHER|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
214725295|NCT02846857|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
214725296|NCT02846857|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
214725297|NCT02846857|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
214725298|NCT02846857|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
214725299|NCT06932133|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound will be performed on symptomatic breast patients. The images will be analysed by AI
214725300|NCT06286267|DIAGNOSTIC_TEST|imaging|Patient medical imaging materials including ultrasound, mammography, CT, MRI
214725301|NCT01655940|DEVICE|Somanetics cerebral oximeter|Somanetics cerebral oximeter
214725302|NCT01655940|DEVICE|CASMED cerebral oximeter|CASMED cerebral oximeter
214725303|NCT05286268|DIAGNOSTIC_TEST|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
214725304|NCT00354939|DRUG|Insulin glargine|
214725305|NCT06506851|OTHER|AR-based Training with Microsoft HoloLens 2®|Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
214639073|NCT02695511|OTHER|Caloric restriction|25% caloric restriction below baseline energy requirement
214639074|NCT04461470|GENETIC|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
214639075|NCT01443533|BEHAVIORAL|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
214639076|NCT00725075|DRUG|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
214639077|NCT00725075|DRUG|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
214639078|NCT00725075|DRUG|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
214639079|NCT02686086|DEVICE|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
214639080|NCT02686086|DEVICE|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
214639081|NCT02686086|DRUG|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
214639082|NCT03680495|DRUG|Methylprednisolone|1\. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
214639083|NCT05175807|OTHER|Mindfulness|Mindfulness (e.g., body scan, gentle yoga, sitting, grounding, and walking meditation), relaxation techniques, and cognitive rehabilitation exercises.
214639084|NCT01178658|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
214725306|NCT06506851|OTHER|Traditional Guideline-based Self-Learning|Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
214639085|NCT02326779|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
214639086|NCT02219139|DEVICE|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
214639087|NCT00020540|BIOLOGICAL|recombinant CD40-ligand|
214639088|NCT00020540|BIOLOGICAL|recombinant flt3 ligand|
214639089|NCT00581295|DEVICE|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
214639090|NCT02972073|OTHER|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
214639091|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording."
214639092|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
214725307|NCT06944444|DRUG|SSS59|A humanized antibody targeting MUC17
214725308|NCT02072746|DIETARY_SUPPLEMENT|Zinc|
214725309|NCT02072746|DIETARY_SUPPLEMENT|Placebo|
214725310|NCT06350357|OTHER|punching closure|The hole clamping and the grooves hold the metal clips better
214725311|NCT06350357|OTHER|Conventional clipping|Metal lip closure is one of the most commonly used closure methods
214725312|NCT02794025|DRUG|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
214725313|NCT02794025|DRUG|natural saline|Control group also received natural saline via a micro pump,
214725314|NCT06948552|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Participants will receive a single oral dose of 5-aminolevulinic acid (20 mg/kg) approximately 2 to 4 hours prior to surgery. The goal is to evaluate the feasibility of using fluorescence cystoscopy with blue light to improve tumor detection and visualization during ureteroscopic resection of upper tract urothelial carcinoma.
214725315|NCT06949930|OTHER|Optimized package of child essential health and nutrition services|Optimized package of child essential health and nutrition services
214725316|NCT06949930|OTHER|Standard package of essential child and nutrition services|Standard package of essential child and nutrition services
214725317|NCT01570452|PROCEDURE|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
214725318|NCT06949761|DRUG|QLC1101+QL1203|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1203, developed by Qilu Pharmaceutical Co., Ltd., is a recombinant anti-EGFR fully human monoclonal antibody injection and a biosimilar to Vectibix®
214725319|NCT06949761|DRUG|QLC1101+QL2107|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL2107 developed by Qilu Pharmaceutical Co., Ltd. is a potential biosimilar to Pembrolizumab (Keytruda®)
214725320|NCT06949761|DRUG|QLC1101+QL1706|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1706 Injection (QL1706) is a combination antibody developed by Qilu Pharmaceutical Co., Ltd. It consists of two full-length immunoglobulin G (IgG) antibodies: anti-PD-1 monoclonal antibody (hereafter referred to as anti-PD-1) and anti-CTLA-4 monoclonal antibody (hereafter referred to as anti-CTLA-4)
214639093|NCT05838638|BEHAVIORAL|eSSET-CINV|Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
214639094|NCT00367042|DEVICE|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
214639095|NCT00367042|DEVICE|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
214639096|NCT02979431|BIOLOGICAL|ALX-0171 3.0 mg/kg|
214639097|NCT02979431|BIOLOGICAL|ALX-0171 6.0 mg/kg|
214639098|NCT02979431|BIOLOGICAL|ALX-0171 9.0 mg/kg|
214639099|NCT02979431|OTHER|Placebo|
214639100|NCT05167942|DEVICE|deep transcranial magnetic stimulation with H1 coil|Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
214639101|NCT05167942|DEVICE|High frequency deep transcranial magnetic stimulation with H1 coil|high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
214639102|NCT05167942|DEVICE|iTBS deep transcranial magnetic stimulation with H1 coil|iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
214639103|NCT05393609|PROCEDURE|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
214639104|NCT05393609|DIETARY_SUPPLEMENT|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
214639105|NCT02765360|OTHER|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~* Electrical impedance tomography~* EMGpara~* SpO2~* tcCO2~* Pneumotachography~* End-tidal CO2 monitoring"
214639106|NCT01646632|BEHAVIORAL|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
214639107|NCT01646632|BEHAVIORAL|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
214639108|NCT05853770|OTHER|TGfU volleyball intervention|"Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min)."
214639109|NCT05853770|OTHER|Regular physical education classes|Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
214639110|NCT02676687|PROCEDURE|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
214639111|NCT02676687|PROCEDURE|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
214639112|NCT06542315|PROCEDURE|Intraoperative parathyroid hormone (IOPTH) monitoring|Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.
214639113|NCT05788679|DRUG|Azacitidine|Azacitidine
214639114|NCT05788679|OTHER|Donor lymphocytes|Donor lymphocytes in patients without immune suppression
214639115|NCT05788679|OTHER|Tapering of immune suppression|Tapering of immune suppression in patients who are on immune suppressive drugs
214639116|NCT05519735|DIAGNOSTIC_TEST|Multimodality Imaging|Patients receive CXCR4-targeted PET/CT, CMR and Echo
214639117|NCT00457327|PROCEDURE|protective ileostomy|
214639118|NCT02137954|DRUG|Lidocaine|
214639119|NCT02137954|DRUG|Placebo|
214639120|NCT05103865|BEHAVIORAL|Animal-assisted therapy (AAT)|
214639121|NCT05103865|OTHER|usual treatment|
214639122|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
214639123|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
214639124|NCT02249910|DRUG|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
214639125|NCT02249910|DRUG|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
214639126|NCT02249910|DRUG|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
214639127|NCT02249910|DRUG|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
214639128|NCT04465682|DEVICE|Experimental: Dip Home-Based Dipstick Analyzer|Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
214639129|NCT05401305|BIOLOGICAL|Vaccine for the prevention of infections caused by Haemophilus influenza type b|The vaccine is administered into the region of the deltoid muscle
214639130|NCT05401305|BIOLOGICAL|Placebo|The placebo is administered into the region of the deltoid muscle
214639131|NCT02004873|DEVICE|Micra Pacemaker Implant|
214639132|NCT00481416|DEVICE|PillCam Eso|
214725321|NCT06949761|DRUG|QLC1101+docetaxel|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；Docetaxel is a tubulin binding agent that prevents cell division by stabilizing microtubule structure and leads to apoptosis
214725322|NCT06066853|DRUG|MDMA|MDMA-assisted psychotherapy
214725323|NCT06174961|DRUG|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
214725324|NCT06174961|BEHAVIORAL|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
214725325|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
214725326|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
214725327|NCT06174961|BEHAVIORAL|No exercise|No exercise
214639133|NCT03050580|BEHAVIORAL|self-esteem enhancement group|Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
214639134|NCT03050580|BEHAVIORAL|Standard care for abused women|The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
214639135|NCT05849870|OTHER|Frailty care pathway for older people in a rural primary care setting|This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
214639136|NCT00927836|BIOLOGICAL|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
214639137|NCT00927836|DRUG|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
214639138|NCT04269109|OTHER|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
214639139|NCT05358379|DRUG|CYC140|CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
214639140|NCT05416294|DEVICE|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
214639141|NCT05416294|DEVICE|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
214639142|NCT03395379|PROCEDURE|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
214639143|NCT05609890|DIETARY_SUPPLEMENT|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
214639144|NCT05609890|OTHER|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
214639145|NCT02715037|OTHER|Throat swabbing|
214639146|NCT03475459|DRUG|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
214639147|NCT02207933|PROCEDURE|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
214639148|NCT02207933|PROCEDURE|Gait training|Gait training only for 3 times a week for 6 weeks.
214639149|NCT06208592|DEVICE|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
214725328|NCT01167153|DRUG|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
214725329|NCT01167153|DRUG|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
214725330|NCT06949046|OTHER|nursing-led communication support|nursing-led communication support program using mobile health information
214725331|NCT06949046|OTHER|Nursing routine treatment|Nursing routine treatment
214725332|NCT03186261|DRUG|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
214725333|NCT03186261|DRUG|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
214725334|NCT00517205|PROCEDURE|Non-contrast helical computerized tomogram (NCHCT)|
214725335|NCT00633802|DRUG|Risperidone|1 mg/d risperidone for 10 weeks or placebo
214725336|NCT00797706|DRUG|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
214725337|NCT00048009|DRUG|Dual Integrin Antagonist|
214725338|NCT01039311|DEVICE|Optical Coherence Tomography|Obtain OCT images.
214725339|NCT04628598|BEHAVIORAL|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
214725340|NCT05628402|OTHER|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
214725341|NCT03529890|DRUG|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
214725342|NCT03529890|RADIATION|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
214725343|NCT03529890|PROCEDURE|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
214725344|NCT03396640|PROCEDURE|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
214725345|NCT03396640|PROCEDURE|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
214725346|NCT00435357|DEVICE|mobile-bearing TKA|
214725347|NCT00435357|DEVICE|fixed- bearing TKA|
214639150|NCT05057169|BIOLOGICAL|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
214639151|NCT05057169|BIOLOGICAL|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
214639152|NCT04937088|DRUG|ASA|Liquid aspirin formulation
214725348|NCT05166603|OTHER|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
214725349|NCT00024128|BIOLOGICAL|anti-thymocyte globulin|
214725350|NCT00024128|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214725351|NCT00024128|DRUG|cyclophosphamide|
214725352|NCT00024128|DRUG|cyclosporine|
214725353|NCT00024128|PROCEDURE|peripheral blood stem cell transplantation|
214725354|NCT00024128|RADIATION|radiation therapy|
214725355|NCT02778373|DIETARY_SUPPLEMENT|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
214725356|NCT02778373|DIETARY_SUPPLEMENT|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
214639153|NCT00630955|DRUG|memantine|Memantine 20 mg once per day for 7 days
214639154|NCT00630955|DRUG|Memantine|Memantine 40 mg once per day for 7 days
214639155|NCT00630955|DRUG|Placebo|Placebo once per day for 7 days
214639156|NCT02799680|BIOLOGICAL|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
214725357|NCT02778373|OTHER|Placebo: Water|
214725358|NCT04505878|DRUG|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
214725359|NCT06434090|DRUG|Liposomal irinotecan|Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
214725360|NCT06434090|DRUG|Bevacizumab|bevacizumab will be given biweekly at a dose of 5mg/m2
214639157|NCT04223934|OTHER|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
214639158|NCT02238444|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
214639159|NCT02238444|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
214639160|NCT02238444|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
214639161|NCT02238444|DRUG|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
214639162|NCT00373204|DRUG|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
214639163|NCT00921700|DRUG|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
214639164|NCT00921700|DRUG|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
214639165|NCT00921700|DRUG|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
214639166|NCT00921700|DRUG|Placebo|Single oral dose of lactose as placebo in gelatine capsules
214639167|NCT04824586|DRUG|Fast-acting human insulin|Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
214639168|NCT00866307|DRUG|Cyclophosphamide|Given IV
214639169|NCT00866307|DRUG|Cytarabine|Given IT and IV or SC
214639170|NCT00866307|DRUG|Daunorubicin Hydrochloride|Given IV
214639171|NCT00866307|DRUG|Dexamethasone|Given IV
214639172|NCT00866307|DRUG|Doxorubicin Hydrochloride|Given IV
214639173|NCT00866307|OTHER|Laboratory Biomarker Analysis|Correlative studies
214639174|NCT00866307|DRUG|Mercaptopurine|Given PO
214639175|NCT00866307|DRUG|Methotrexate|Given IT and PO
214639176|NCT00866307|DRUG|Pegaspargase|Given IV
214639177|NCT00866307|DRUG|Prednisone|Given IV or PO
214639178|NCT00866307|RADIATION|Prophylactic Cranial Irradiation|Undergo radiation
214639179|NCT00866307|DRUG|Thioguanine|Given PO
214639180|NCT00866307|DRUG|Vincristine Sulfate|Given IV
214725361|NCT01111721|BEHAVIORAL|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
214639181|NCT03726164|DEVICE|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
214639182|NCT03726164|DEVICE|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
214639183|NCT04353180|DRUG|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
214639184|NCT04353180|DRUG|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
214639185|NCT04353180|DRUG|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
214639186|NCT04353180|DRUG|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
214639187|NCT04353180|DRUG|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
214639188|NCT04793256|DEVICE|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).|5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces
214639189|NCT04793256|DEVICE|Resin based fissure sealant (3M Clinpro Sealant)|teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
214639190|NCT05373927|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
214639191|NCT01201239|DRUG|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
214725362|NCT01111721|BEHAVIORAL|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
214639192|NCT00500526|OTHER|Singing practice|
214639193|NCT00500526|OTHER|Singing classes|
214639194|NCT00500526|OTHER|Hand craft classes|
214639195|NCT02257983|DRUG|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
214639196|NCT02257983|DRUG|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
214725363|NCT03048409|OTHER|Enteral Formula|Enteral feeding with a peptide-based formula.
214725364|NCT01562145|PROCEDURE|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
214725365|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
214725366|NCT04602013|DRUG|Sintilimab|Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
214725367|NCT04602013|DRUG|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
214725368|NCT04602013|RADIATION|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
214639197|NCT04663958|DIAGNOSTIC_TEST|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
214639198|NCT02692066|BIOLOGICAL|varicella vaccine|
214639199|NCT04421495|DRUG|Delamanid|the eligible patients will be give damanid-containing regimen
214639200|NCT01060059|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214639201|NCT01060059|DRUG|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
214639202|NCT03824665|DRUG|Nalbuphine Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline"
214639203|NCT03824665|DRUG|Fentanyl Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline"
214639204|NCT03824665|DRUG|Control Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline."
214639205|NCT03575858|DEVICE|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
214639206|NCT03575858|DEVICE|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
214639207|NCT03269708|BEHAVIORAL|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
214639208|NCT05047809|OTHER|"Jingchuang Ointment(JCO)"|Applied once a day on the wounds
214639209|NCT05047809|OTHER|Regular Treatment|"Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual."
214639210|NCT01614093|DRUG|Oxytocin|Single dose intranasal oxytocin (24 IU)
214639211|NCT01614093|DRUG|Placebo|Placebo- Sugar pill
214639212|NCT06257030|DEVICE|Transarterial Radioembolization|(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
214725369|NCT00544505|DRUG|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
214725370|NCT04594668|DRUG|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
214725371|NCT04026646|PROCEDURE|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
214639213|NCT00848354|BIOLOGICAL|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
214725372|NCT04026646|PROCEDURE|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
214639214|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
214639215|NCT00848354|DRUG|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
214639216|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
214639217|NCT00848354|DRUG|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
214639218|NCT02216461|DRUG|Low dose of BIBW 2948 BS for oral inhalation|
214639219|NCT02216461|DRUG|Medium dose of BIBW 2948 BS for oral inhalation|
214639220|NCT02216461|DRUG|High dose of BIBW 2948 BS for oral inhalation|
214639221|NCT02216461|DRUG|Placebo|
214639222|NCT05066243|OTHER|questionnaire|this study is to develop a questionnaire for vulval conditions
214639223|NCT04354350|DRUG|Ramipril|Ramipril dispensing claim is used as the reference
214639224|NCT04354350|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
214639225|NCT05450146|OTHER|Partner in Balance|"The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals."
214639226|NCT02394977|DEVICE|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
214639227|NCT02394977|OTHER|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
214639228|NCT00002693|BIOLOGICAL|filgrastim|
214639229|NCT00002693|DRUG|carboplatin|
214639230|NCT00002693|DRUG|topotecan hydrochloride|
214639231|NCT05080010|DRUG|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
214639232|NCT04490837|DIAGNOSTIC_TEST|ELISA and Rapid test to detect antibodies against COVID-19|Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
214639233|NCT02067039|DEVICE|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home \& Sure Check HIV tests
214639234|NCT01972074|DRUG|Memantine|Capsule
214639235|NCT01972074|OTHER|Placebo|Capsule
214639236|NCT05595044|DRUG|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
214725373|NCT04037462|DRUG|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
214725374|NCT01962116|DRUG|Citrate 4%|
214725375|NCT01962116|DRUG|unfractionated heparin|
214725376|NCT02945943|OTHER|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
214725377|NCT02945943|OTHER|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
214639237|NCT05595044|OTHER|Habilitation|Habilitation
214639238|NCT04916405|OTHER|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
214639239|NCT06537115|BEHAVIORAL|exercise|progressive resistance exercise
214639240|NCT06537115|DIETARY_SUPPLEMENT|whey protein powder|The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
214639241|NCT06537115|DRUG|Eldecalcitol|Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
214639242|NCT02113631|DRUG|Telaprevir|
214639243|NCT02113631|DRUG|Boceprevir|
214639244|NCT02113631|DRUG|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
214639245|NCT02113631|DRUG|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
214639246|NCT04791046|DRUG|antihypertensive therapy|Personalized evidence-based antihypertensive therapy in patients with comorbidities
214639247|NCT00051155|DRUG|Travoprost (0.004%)|
214639248|NCT00051155|DRUG|Latanoprost (0.005%)/Timolol (0.5%)|
214639249|NCT03899662|OTHER|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
214639250|NCT03899662|OTHER|Physical Training|Physical training included aerobic, strength, flexibility and balance.
214639251|NCT04761211|DEVICE|smart bra|This is a patented infrared breast examination bra
214639252|NCT05537805|PROCEDURE|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
214725378|NCT05519124|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
214639253|NCT01522846|DRUG|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
214639254|NCT01009476|DRUG|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
214639255|NCT01009476|DRUG|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
214639256|NCT06355232|BIOLOGICAL|Covid-19 vaccine|Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant
214725379|NCT00189436|DRUG|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
214725380|NCT00189436|DRUG|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
214725381|NCT04402385|DRUG|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
214725382|NCT04402385|DRUG|Placebo|Participants randomized to placebo daily
214725383|NCT00655122|DRUG|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
214639257|NCT06355232|BIOLOGICAL|Influenza vaccine|Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
214639258|NCT04001868|PROCEDURE|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
214639259|NCT04001868|PROCEDURE|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
214639260|NCT01699555|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
214725384|NCT00655122|DRUG|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
214725385|NCT03731169|GENETIC|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
214725386|NCT03731169|DRUG|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
214639261|NCT01699555|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
214639262|NCT02734251|DIETARY_SUPPLEMENT|Relora|750 mg/day
214639263|NCT02734251|DIETARY_SUPPLEMENT|Placebo|
214639264|NCT06250322|DEVICE|Intervention|No study treatments will be administered during this study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
214639265|NCT04610528|DRUG|U3 1402|6.4 mg/kg dose
214639266|NCT04610528|DRUG|U3 1402|5.6 mg/kg dose
214639267|NCT05403125|DEVICE|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
214639268|NCT05403125|DEVICE|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
214639269|NCT05518604|BEHAVIORAL|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
214639270|NCT01502904|DEVICE|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639271|NCT01502904|DEVICE|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639272|NCT01502904|DRUG|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639273|NCT01502904|DRUG|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639274|NCT01502904|DRUG|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639275|NCT01502904|DRUG|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
214639276|NCT06529536|DIAGNOSTIC_TEST|Genotyping for CYP3A4 and CYP3A5 genes|"Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array). Pre-transplant genotyping will test for CYP3A5 \*3, \*6, \*7, \*8 and \*9 alleles, and will test for CYP3A4\*22 only (with CYP3A4\*1 reported if no variant corresponding to \*22 was present).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus. In addition, influence of CYP3A4 will be incorporated based on recent literature and interventional trials. Initial dose in BRUNO-PIC will use allometric size scaling from adult dose, with adjustment based on genotype (CYP3A4 \& CYP3A5)"
214639277|NCT06529536|DEVICE|Use of NextDose platform|NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.
214639278|NCT06529536|DRUG|Tacrolimus|Tacrolimus is administered to all patients post SOT at The Royal Children's Hospital (RCH)
214639279|NCT05986097|BEHAVIORAL|Breakfast|We will provide participants recipes and information to support this dietary change.
214639280|NCT06351852|DRUG|Combination of Neostigmine and Glycopyrrolate|Transcutaneous
214639281|NCT06351852|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
214639282|NCT06802393|OTHER|Intervention|The intervention incorporates a multifaceted pharmacist-led approach to addressing health-related social needs (HRSN) during transitions of care in the emergency department (ED) at Buffalo General Medical Center (BGMC). The intervention includes: 1) pharmacist-led medication reconciliation, and 2) HRSN screening using the Accountable Health Communities (AHC) HRSN tool. Based on the results, patients receive tailored referrals to community-based organizations using the 211 WNY database, which provides localized resources aligned with their social needs. Each patient is given a printed handout detailing the referral information. Within one month, a follow-up phone call is conducted to follow up with patients and assess additional needs as well as collect feedback through a patient satisfaction survey.
214725387|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
214725388|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
214639283|NCT06802393|OTHER|Control|The control arm of the study consists of a historical cohort of patients who were admitted to or discharged from the emergency department (ED) at Buffalo General Medical Center (BGMC) during the same timeframe as the intervention arm but did not receive the pharmacist-led health-related social needs (HRSN) screening or referral intervention. These patients are identified through the electronic health record (EHR) based on the same inclusion criteria as the intervention group, such as age, geographic location, and discharge disposition. Control participants are matched 1:1 with intervention participants using demographic and clinical characteristics, including age (within 5 years), zip code, insurance type, discharge status, and race. Data for the control arm include healthcare utilization metrics such as 30- and 90-day unplanned hospital readmissions and emergency department visits. The control arm serves as a comparator to evaluate the effectiveness of the intervention
214639284|NCT06323161|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214639285|NCT06323161|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214639286|NCT06323161|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
214639287|NCT04403165|PROCEDURE|Nocturnal polysomnography (NPSG)|Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
214639288|NCT04403165|PROCEDURE|Lumbar Puncture (LP)|Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
214639289|NCT04403165|OTHER|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
214639290|NCT04403165|BEHAVIORAL|Psychomotor Vigilance Task (PVT)|Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
214639291|NCT04278131|DRUG|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
214639292|NCT06434519|DRUG|Metronidazole cream|After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
214639293|NCT06434519|OTHER|Cetaphil moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
214639294|NCT06434519|OTHER|CeraVe moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
214639295|NCT06434519|OTHER|Eucerin Healing Lotion moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
214639296|NCT06434519|OTHER|Aveeno Calm and Restore Oat Gel moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
214639297|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
214639298|NCT06186141|DRUG|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
214639299|NCT06186141|DRUG|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
214639300|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
214639301|NCT06282575|DRUG|Zanidatamab|Administered intravenously (IV)
214639302|NCT06282575|DRUG|Cisplatin|Administered intravenously (IV)
214639303|NCT06282575|DRUG|Gemcitabine|Administered intravenously (IV)
214639304|NCT06282575|DRUG|Pembrolizumab|Administered intravenously (IV)
214639305|NCT06282575|DRUG|Durvalumab|Administered intravenously (IV)
214639306|NCT06839287|OTHER|Interpersonal psychotherapy-based counseling|The first data from the individuals in the experimental and control groups will be collected after the first interview. Data will be collected from the individuals to whom interpersonal relationship therapy techniques are applied after the 8th session by face-to-face interviews. In addition, if the individuals in the experimental group have questions about psychotherapy, they will be answered. The control group will be verbally informed with the data collection form and chronic disease adaptation and depression scales and will continue to receive routine care. Data will be collected by face-to-face interviews with the control group after the first interview and 8 weeks later when they come to the dialysis center. Follow-up data of the participants will be collected again at the 3rd month after the last interview.
214639307|NCT06263491|DRUG|Rituximab|Given by PO
214639308|NCT06263491|DRUG|Pirtobrutinib|Given by PO
214639309|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
214639310|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
214639311|NCT03320759|BEHAVIORAL|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
214639312|NCT04938661|OTHER|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
214639313|NCT04938661|OTHER|mHealth|Mobile Health Platform
214639314|NCT04938661|OTHER|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
214639315|NCT04253483|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR
214639316|NCT04253483|OTHER|Quality-of-Life Assessment|Ancillary studies
214639317|NCT04253483|OTHER|Questionnaire Administration|Ancillary studies
214639318|NCT04253483|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
214639319|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
214639320|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
214639321|NCT06152731|GENETIC|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
214639322|NCT04770779|DRUG|Placebo Matching Mitapivat|Tablets
214639323|NCT04770779|DRUG|Mitapivat|Tablets
214639324|NCT05560958|DEVICE|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
214639325|NCT01870154|BEHAVIORAL|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
214639326|NCT06179888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214639327|NCT06179888|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214639328|NCT06179888|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214725389|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
214725390|NCT02136316|DRUG|ASP7962|Oral
214725391|NCT02136316|DRUG|Placebo|Oral
214639329|NCT06179888|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
214639330|NCT06179888|DRUG|Iberdomide|Given PO
214639331|NCT06179888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214639332|NCT06179888|PROCEDURE|Patient Monitoring|Undergo disease monitoring
214639333|NCT06179888|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214639334|NCT06179888|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
214725392|NCT02058706|DRUG|enzalutamide|Given PO
214725393|NCT02058706|DRUG|bicalutamide|Given PO
214639335|NCT04820309|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
214725394|NCT02058706|PROCEDURE|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
214725395|NCT02058706|DRUG|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
214725396|NCT02058706|DRUG|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
214725397|NCT02058706|OTHER|laboratory biomarker analysis|Correlative studies
214639336|NCT06297291|DEVICE|Paradise Ultrasound Renal Denervation Treatment|"The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight."
214639337|NCT03692052|DRUG|AG-348|AG-348 tablet orally BID
214639338|NCT05632770|BEHAVIORAL|Stepped Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
214639339|NCT05632770|BEHAVIORAL|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
214639340|NCT06261294|DIAGNOSTIC_TEST|OncoSweep Lung Spotligh|This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
214639341|NCT04969081|BEHAVIORAL|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
214639342|NCT04969081|OTHER|treatment as usual|usual treatment
214639343|NCT06232317|OTHER|Virtual Reality Software|The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
214639344|NCT06232317|OTHER|Traditional Orientation Methods|Standard-of-care methods to orient patients after surgery
214639345|NCT05600309|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
214639346|NCT05600309|DRUG|regorafenib|Oral
214639347|NCT05600309|DRUG|TAS-102|Oral
214639348|NCT06195839|BEHAVIORAL|Remote Patient Monitoring|Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study. Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol. Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
214639349|NCT06195839|BEHAVIORAL|Self-monitoring of hypertension-related factors|As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity. Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
214639350|NCT06195839|BEHAVIORAL|Immediate financial incentives|Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)
214639351|NCT06195839|BEHAVIORAL|Delayed financial incentives|Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)
214639352|NCT02967289|DRUG|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
214639353|NCT02967289|DRUG|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
214639354|NCT06085963|DRUG|ITULAZAX 12 SQ-Bet|Active ingredients: Birch (Betula verrucosa) extracts Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Dose/strength: 12 SQ-Bet Excipients: Gelatine (fish source), mannitol and sodium hydroxide
214639355|NCT06085963|DRUG|Placebo tablet|Active ingredients: None Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Excipients: Gelatine (fish source), mannitol and sodium hydroxide
214639356|NCT06085963|DRUG|Nacl|Sodium chloride solution 9mg/ml
214639357|NCT04579588|BIOLOGICAL|Flu shot|All participants will receive a single shot of the flu vaccine
214639358|NCT05098210|BIOLOGICAL|Neoantigen Peptide Vaccine|Given IM
214639359|NCT05098210|BIOLOGICAL|Nivolumab|Given IV
214639360|NCT05098210|DRUG|Poly ICLC|Given IM
214639361|NCT05098210|PROCEDURE|Echocardiography|Undergo ECHO
214639362|NCT05098210|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214639363|NCT05098210|PROCEDURE|Biopsy|Undergo tumor biopsy
214639364|NCT05098210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214639365|NCT05098210|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214639366|NCT05098210|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
214639367|NCT05853497|BEHAVIORAL|Multi-Component Weight Loss Intervention|The intervention group will receive weekly 1-on-1 health coaching with a very-low calorie nutrition plan prior to total knee replacement and a conventional weight maintenance nutrition plan after surgery.
214639368|NCT05245500|DRUG|MRTX1719|"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
214639369|NCT03032601|DIETARY_SUPPLEMENT|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
214639370|NCT05165654|DEVICE|Transcranial Electrical Stimulation|Transcranial electrical stimulation
214639371|NCT06806852|DRUG|BI 770371|BI 770371
214639372|NCT06806852|DRUG|Pembrolizumab|Pembrolizumab
214639373|NCT06806852|DRUG|Cetuximab|Cetuximab
214639374|NCT05196035|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
214639375|NCT05196035|DRUG|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
214639376|NCT06033079|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
214639377|NCT03512418|BEHAVIORAL|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
214639378|NCT03512418|DEVICE|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
214639379|NCT03512418|DRUG|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
214639380|NCT05689983|DRUG|Maintenance ICS and Symptom Driven SABA|In this intervention, patients will be assigned to a standard therapy with a maintenance inhaled corticosteroid (Flovent) and an as needed short-acting beta-agonist and their adherence to this regimen will be assessed and compared to patients taking a regimen with an as needed inhaled corticosteroid and long-acting beta-agonist.
214639381|NCT05689983|DRUG|Symptom-driven budesonide/formoterol combination|In this intervention, patients will be assigned to a symptom-driven budesonide/formoterol combination therapy (Symbicort) and their adherence to this regimen will be assessed and compared to patients taking a standard therapy with a maintenance inhaled corticosteroid and as needed short-acting beta-agonist.
214639382|NCT05242484|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214639383|NCT05242484|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
214639384|NCT05242484|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
214639385|NCT05242484|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
214725398|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
214639386|NCT00980538|DRUG|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
214639387|NCT07120425|DRUG|IBI3032|"IBI3032:~Method of administration: oral, fasted administration."
214639388|NCT07120425|DRUG|placebo|Placebo (without active ingredients) Method of administration: oral, fasted administration.
214639389|NCT07120386|DEVICE|Negative Pressure Wound Therapy|NPWT creates a vacuum seal over your wound to promote healing
214639390|NCT07120386|DEVICE|Negative Pressure Wound Therapy with Instillation|NPWTi creates a vacuum seal over your wound and infuses the wound with hypochlorous acid (medical grade dilute bleach) to clean it.
214639391|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
214639392|NCT06269783|BEHAVIORAL|sipIT|Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
214639393|NCT06977503|PROCEDURE|Cranial Electrical Stimulation|Use Alpha-Stim® device
214639394|NCT06977503|OTHER|Discussion|Participate in discussions
214639395|NCT06977503|BEHAVIORAL|Health and Wellness Coach|Undergo coaching sessions
214639396|NCT06977503|OTHER|Informational Intervention|View video assignments
214639397|NCT06977503|PROCEDURE|Sham Intervention|Undergo sham intervention
214639398|NCT06977503|OTHER|Survey Administration|Ancillary studies
214639399|NCT05618158|BEHAVIORAL|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
214639400|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
214639401|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
214639402|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
214639403|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
214639404|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
214639405|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
214639406|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
214639407|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
214639408|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
214639409|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
214639410|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
214639411|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
214725399|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
214725400|NCT04285177|PROCEDURE|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
214725401|NCT03643198|DRUG|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
214725402|NCT03643198|OTHER|CONTROL|NO treatment
214725403|NCT05746000|BEHAVIORAL|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
214725404|NCT05746000|BEHAVIORAL|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
214725405|NCT00320632|DRUG|Desipramine|
214725406|NCT05863806|OTHER|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
214639412|NCT06612827|OTHER|organoid etablishment|"Prior to initiation of 1st-line therapy:~* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)~* A blood test blood a for tumoroid realization and :~* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo~* Analysis of correlation between in vivo and ex vivo tumor characteristics~* Analysis of first- and second-line survival rates and overall survival"
214639413|NCT06599762|DRUG|Tranexamic acid|Tranexamic acid 1000mg orally two or three times daily
214639414|NCT06599762|DRUG|Placebo|Placebo orally two or three times daily
214639415|NCT06670859|OTHER|Intervention-Control:|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the mobilization coverall they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the coverall-mobilization-sitting in the wheelchair and moving-taking off the coverall) with the overall.Than,will be asked to evaluate the indicator level that they think the coverall they wear protects physical privacy and the levels of comfort and satisfaction they feel about the coverall with the VAS.During the next mobilization,patients will be asked to perform the same application protocol with a traditional hospital gown.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.Than interview,participants will have completed the study by filling out the QUEST 2.0.
214639416|NCT06670859|OTHER|Control-Intervention|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the traditional hospital gown they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the gown-mobilization-sitting in the wheelchair and moving-taking off the gown) with the gown.Than,will be asked to evaluate the indicator level that they think the gown they wear protects physical privacy, and the levels of comfort and satisfaction they feel about the gown with the VAS.During the next mobilization, patients will be asked to perform the same application protocol with the mobilization coverall.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.At the end of the interview, participants will have completed the study by filling out the QUEST 2.0.
214639417|NCT06993844|DRUG|ETX-636 dose escalation|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.
214639418|NCT06993844|DRUG|ETX-636 dose escalation in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
214639419|NCT06993844|DRUG|ETX-636 dose expansion in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
214639420|NCT05527210|DIETARY_SUPPLEMENT|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
214639421|NCT05527210|DIETARY_SUPPLEMENT|Placebo Prebiotic|Placebo prebiotic mixed into water
214639422|NCT06204848|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
214639423|NCT05556525|OTHER|Fluorescein|Given IV
214639424|NCT05556525|DEVICE|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
214639425|NCT05556525|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
214639426|NCT06400537|BIOLOGICAL|A-319|A-319 will be dosed according to the assigned group.
214639427|NCT07010692|DRUG|Tirbanibulin ointment 1%|Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.
214639428|NCT07010692|DEVICE|non-ablative fractional laser|Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.
214639429|NCT06860724|OTHER|NG-nitro-L-arginine methyl ester (L-NAME)|Acute local perfusion of L-NAME (15 mM) directly to the microvasculature will be used to inhibit NO synthase.
214639430|NCT03532191|OTHER|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
214639431|NCT07013396|OTHER|TCD measurement|TCD measurement will be collected with TCD low frequency MHz probes. All TCD operations will be performed by a trained sonographer to assess bilateral MCA, ACA, PCA, Siph, and OA. TCD examinations will be performed as soon as possible after EVT, daily for 3 days and, when possible, as close to any reported neurological deterioration or CT brain scan performed within 72 hours of EVT.
214639432|NCT07013396|OTHER|TCD parameters|"TCD parameters are PSV, EDV, MFV, and PI. Sampling volume will be 5-10 mm, and the monitoring depth on transtemporal windows will be adjusted to gather appropriate vessel segment, e.g. 20-30 mm in the leptomeningeal flow, 40-50 mm in the distal MCA, 50-60 mm in the proximal MCA, 70-75 mm in the ACA, 62-70 mm in PCA, and transorbital, including 60-64 mm in the Siph and 50-60 mm in the OA. TAMMV and PI will be automatically derived from preset.~Additionally, flow diversion will be assessed as an indirect indicator of arterial occlusion or severe stenosis in the middle cerebral artery (M1). It will be identified by TCD based on the following criteria: (1) low-resistance flow pattern in the anterior or posterior cerebral artery, and (2) mean flow velocity in the ACA or PCA greater than or equal to that in the MCA."
214639433|NCT07013396|OTHER|Baseline characteristics|Baseline characteristics will be collected, including age, sex, ethnicity, history of HTN, DM, DLP, CHF, AF, CA, CKD, previous CAD, cirrhosis, mRS, previous stroke or TIA, current antiplatelet usage, current anticoagulant usage, smoking, and alcohol status. This data will be collected through a combination of verbal interviews with participants/LAR legally authorized representatives and a review of their medical history charts.
214639434|NCT07013396|OTHER|Clinical data will be collected|Clinical data will be collected, including blood pressure values before, during, and after TCD as well as, Door to needle, Door to groin, Groin to first pass, time from recanalization to TCD, baseline NIHSS, site of occlusion, infarct core volume, mismatch volume, mismatch ratio, and IVT treatment status. Classification of stroke etiologies will be collected based on widely accepted TOAST criteria categorized in large vessel atherosclerosis (LAA), cardio-embolism (CE), small vessel occlusion (SAO), Stroke of other determined etiology (SOC), and stroke of undetermined etiology (SUC) \[30\]. This data will be collected by reviewing medical charts from EHR coded as part of standard care.
214639435|NCT07013396|OTHER|All follow-up patients receive a phone call|All follow-up patients receive a phone call as part of standard post thrombectomy care from the stroke nurses to gather modified Rankin Scale at 7 days and 90 days since hospital discharge.
214639436|NCT06874699|BEHAVIORAL|Physical activity programme|"The physical activity programme will have the following features:~* 6-week programme~* 1-2 supervised physical activity sessions per week~* 60 minutes per session, including a mixture of physical activities (e.g. walking, other aerobic physical activity, resistance, balance and stretching exercises)~* Self-selected physical activity intensity~* Group-based (maximum of 10 students per session)~* Sessions supervised by a qualified exercise instructor. A member of the University's Wellbeing team will also be present to offer students mental health support, if needed.~* Physical activity behavioral strategies incorporated into the 6-week programme (e.g., goal setting, action planning, exploring barriers and enablers, setting cues or prompts for self-directed PA)~* Encouragement to be physically active away from the supervised sessions"
214639437|NCT06878248|BIOLOGICAL|Two Component Product CLBR001 + ABBV-461|Investigational switchable CAR-T cell therapy for breast cancer
214639438|NCT06701370|OTHER|Task Oriented Training|Task oriented training consists of opening the bottlecap, stacking cubes on different sizes, buttoning,screwing, wearing a coat.
214639439|NCT06701370|OTHER|Conventional Rehabilitation|Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.
214639440|NCT06701370|OTHER|Upper arm ergometer|The patients will be rode 5 minutes forwardly and 5 minutes backwardly
214725407|NCT05863806|OTHER|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
214725408|NCT06378606|BEHAVIORAL|cognitive therapy|"intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement .~group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only."
214639441|NCT06717919|PROCEDURE|Hypothermic oxygenated perfusion|All study centres will use either VitaSmart, Liver assist or Perlife devices for machine liver perfusion, with a pressure controlled hypothermic oxygenated liver perfusion through the portal vein (HOPE) or through the portal vein and the hepatic artery (DHOPE), targeting a flow rate between 200-250 ml/min at a pressure of 3 mmHg, and a perfusate temperature between 8-12°C. The perfusate consists of 3L re-circulating Belzer MPS® (Bridge to Life Ltd.) with an active oxygenation (70-110 kPa). The minimum perfusion duration is defined at 2 hours, while perfusion is generally continued until the recipient hepatectomy is completed. The perfusion will exclusively be performed in the recipient centre after initial cold storage and bench preparation of the liver for implantation. The perfusion devices are routinely used in all participating centres.
214639442|NCT06717919|PROCEDURE|Conventional cold storage|Conventional cold storage at 4°C will be performed with precooled preservation solution according to local standard of care. For cold storage at the Swiss centres, IGL-1 (Institute George Lopez) is used for cold storage. Liver transplant centres in other European countries, use mainly three other storage solutions (Histidine trypophan-ketoglutarat, HTK and University of Wisconsin, UW solution, Celsior) in accordance to their national guidelines.
214639443|NCT06889597|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
214639444|NCT06889597|OTHER|Experimental|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
214639445|NCT06730945|DRUG|Oral isosorbide mononitrate 4+ amlodipine|Oral isosorbide mononitrate 40mg (if unable to tolerate, 20mg) once daily + amlodipine 5mg (if unable to tolerate, 2.5mg) once daily for 24 weeks after CABG
214639446|NCT06888960|BIOLOGICAL|CC312|After a 28-day screening period, subjects who meet the inclusion and exclusion criteria will be enrolled for baseline assessments and biological sample collection prior to the guided administration period. The guided dose of CC312 will be administered via IV infusion on Day -3, followed by safety and tolerability assessments on the third day after the initial administration (i.e., Day -1). The therapeutic dose of CC312 will be administered via IV infusion on Day 1, with subsequent infusions scheduled on Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25. Comprehensive safety and tolerability assessments will be conducted at each of these time points.
214639447|NCT07042243|BEHAVIORAL|MyCarePulse and ASCENT PN|The combination of a digital platform and patient navigators assisting the process. Also, taking a multi-level approach engaging community members, patients, and providers in phase one through qualitative interviews. Then using the findings to adapt MyCarePulse for the clincial trial in phase two.
214639448|NCT06889298|DEVICE|Treatment with BTL-699|Four to six transcranial magnetic stimulation treatments with the BTL-699 device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 3 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
214639449|NCT07065721|DEVICE|Continuous glucose monitor|Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.
214639450|NCT06667908|DRUG|JNJ-90301900|JNJ-90301900 will be injected intratumorally and/or intranodally.
214639451|NCT06667908|BIOLOGICAL|Durvalumab|Durvalumab will be administered as intravenous (IV) infusion as cIT.
214639452|NCT06667908|RADIATION|Concurrent Chemo/Radiation Therapy (cCRT)|Radiation by intensity modulated radiation therapy (IMRT) will be administered.
214639453|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin|Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
214639454|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel|Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
214639455|NCT07071350|OTHER|HRV Coherence Ratio|Evaluates autonomic function and the intervention process's efficacy, specifically resonance frequency breathing. The HRV Coherence Ratio will be quantified using a non-invasive procedure during resonance frequency breathing conditions and a standardized definition.
214639456|NCT07071350|BEHAVIORAL|NSI|This inventory assesses the overall symptom burden, including post-concussion symptoms, on a 5-point scale. It is a well-established measure used by the Department of Defense (DoD) and VA and in mTBI outcome research at large, and includes 27 items that capture vestibular, somatosensory, cognitive, and affective symptoms.
214725409|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|\- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
214725410|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
214725411|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
214725412|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
214725413|NCT00935467|DRUG|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
214725414|NCT00469976|DRUG|bevacizumab|
214725415|NCT00469976|DRUG|carboplatin|
214725416|NCT00469976|DRUG|enzastaurin hydrochloride|
214725417|NCT00469976|DRUG|gemcitabine hydrochloride|
214725418|NCT00000995|DRUG|Zidovudine|
214725419|NCT00000995|DRUG|Ganciclovir|
214725420|NCT05490381|OTHER|Iodixanol|Given via injection
214725421|NCT05490381|PROCEDURE|Angiogram|Undergo diagnostic cerebral angiogram
214725422|NCT05490381|PROCEDURE|Arterial Embolization|Undergo tumor vessel embolization
214725423|NCT05490381|DRUG|Polyvinyl Alcohol|Given via catheter
214725424|NCT05490381|DRUG|Ethiodized Oil|Given via catheter
214725425|NCT05490381|PROCEDURE|Computed Tomography|Undergo head and neck CT scans
214725426|NCT05490381|OTHER|Chart Abstraction|Ancillary studies
214725427|NCT01125904|DRUG|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
214725428|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
214725429|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
214725430|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
214725431|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
214725432|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
214725433|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
214639457|NCT07071350|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|It includes seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Higher PSQI scores indicate poorer sleep quality.
214639458|NCT07071350|BEHAVIORAL|Quantitative Sleep Measures|Measured using wrist actigraphy, which provides objective data on sleep parameters such as sleep latency, duration, efficiency, fragmentation, and wake time after sleep onset (WASO). Participants will wear the actigraphy monitors at baseline, post-training, and follow-up assessments.
214639459|NCT07071350|BEHAVIORAL|Patient Global Impression of Change (PGIC)|It evaluates patients' perceptions of clinically meaningful changes in their condition following the intervention. It is considered the gold standard for such assessments.
214639460|NCT07071350|BEHAVIORAL|Cognitive Performance/NIH Toolbox Cognitive Battery|Assessed using the NIH Toolbox Cognitive Battery, which measures executive function, episodic memory, working memory, processing speed, language, attention, and reading through a brief, computer-based test
214639461|NCT07071350|OTHER|Pain Interference/TBI-QoL Pain Interference Short-Form|"Evaluated using the TBI-QoL Pain Interference Short-Form, a 10-item questionnaire that measures the extent to which pain interferes with daily activities and overall quality of life. Each BPI-I item is scored from 0=Does not interfere to 10=Completely interferes, and the scale score is the mean of the 7 items. Scores range from 0 to 10 with higher scores indicating greater pain interference."
214639462|NCT07071350|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|Assesses the severity of depressive symptoms over the past two weeks. Scores less than 5 almost always signified the absence of a depressive disorder; scores of 5 to 9 predominantly represented patients with either no depression or subthreshold (i.e., other) depression; scores of 10 to 14 represented a spectrum of patients; and scores of 15 or greater usually indicated major depression.
214639463|NCT07071350|BEHAVIORAL|PTSD Checklist for DSM-5 (PCL-5)|The PCL-5 (PTSD Checklist for DSM-5) is a screening tool that assesses the presence and severity of PTSD symptoms according to DSM-5 criteria. It's not a diagnostic tool itself but helps clinicians determine if further evaluation is needed. Scores range from 0 to 80, with higher scores indicating more severe symptoms.
214639464|NCT07071350|OTHER|HRV Biofeedback (HRV-B)|participants will receive weekly biofeedback training over a six-week period. Each session includes approximately 30-40 minutes of biofeedback training where participants are affixed with HRV monitoring equipment. They will be guided to synchronize their heart rate variability (HRV) through slow diaphragmatic breathing and focusing on positive emotions. This process involves viewing real-time HRV patterns on a computer monitor, with coaching to help participants achieve resonant frequency breathing.
214639465|NCT07071350|OTHER|Psychoeducational (Edu) Comparator Intervention|Six weekly meetings 30-40 minutes, viewing standardized educational content on concussion recovery. No information on breathing will be provided to participants in the Edu group.
214639466|NCT06896695|OTHER|Best Practice|Receive usual care
214639467|NCT06896695|OTHER|Discussion|Ancillary studies
214639468|NCT06896695|OTHER|Financial Navigation|Receive the Financial Compass intervention
214639469|NCT06896695|OTHER|Interview|Ancillary studies
214639470|NCT06896695|OTHER|Survey Administration|Ancillary studies
214639471|NCT07104383|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
214639472|NCT06922318|DRUG|ZEN-3694|One ZEN-3694 pill (48 mg) will be taken each day of each BATZEN cycle.
214639473|NCT06922318|DRUG|Testosterone cypionate|On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.
214725434|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablet
214725435|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablets
214639474|NCT06922318|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken daily by mouth on each ZENZA cycle.
214639475|NCT06922318|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.
214639476|NCT07121959|DRUG|Metformin|Oral Tablet
214639477|NCT07121959|DRUG|Belzutifan|Oral Tablet
214639478|NCT07124403|DIAGNOSTIC_TEST|blood sampling|DPD Activity wil be assessed from blood samples
214639479|NCT07124403|DIAGNOSTIC_TEST|Blood sampling|Measurement of uracilemia and assessment of renal function
214639480|NCT07140341|DRUG|ENO Lime|A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg
214639481|NCT07140016|DRUG|gilteritinib|Oral
214639482|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
214725436|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
214725437|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
214725438|NCT02899104|DRUG|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
214639483|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
214639484|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
214639485|NCT06937203|DRUG|ARO-ALK7|SC injection
214639486|NCT06937203|DRUG|Placebo|calculated volume to match active treatment by SC injection
214639487|NCT06943664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214639488|NCT06943664|BIOLOGICAL|Cemiplimab|Given IV
214639489|NCT06943664|BIOLOGICAL|Cetuximab Sarotalocan Sodium|Given IV
214639490|NCT06943664|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214639491|NCT06943664|OTHER|Electronic Health Record Review|Ancillary studies
214639492|NCT06943664|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
214639493|NCT06943664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214639494|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo EB-PIT
214639495|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo I-PIT
214725439|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
214725440|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
214639496|NCT06943664|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214639497|NCT06943664|PROCEDURE|Robotic Bronchoscopy|Undergo robotic bronchoscopy
214639498|NCT06943664|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
214639499|NCT06944340|OTHER|WHO Trauma Care Checklist|"A standardized checklist developed by the WHO for trauma care, designed to reduce errors and ensure compliance with critical steps in trauma management.~Implemented by trained clinicians during patient assessment and treatment phases. Components include verification of patient identity, assessment of airway/breathing/circulation, pain management, monitoring for missed injuries, and post-resuscitation care. Checklist use is documented in medical records."
214639500|NCT05133661|DIAGNOSTIC_TEST|HPV testing|Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.
214639501|NCT06942286|DIAGNOSTIC_TEST|HPV Self-Collection|Participants will perform HPV self-collection.
214639502|NCT06942234|DRUG|JSKN016|JSKN016 is administered via intravenous infusion at doses of 5mg/kg or 6mg/kg every 3 weeks, starting on Day 1 of each cycle. If the 5mg/kg dose is well tolerated during the safety lead-in phase, the dose may be increased to 6mg/kg for subsequent cycles.
214639503|NCT06942234|DRUG|Capecitabine|The drug is administered orally at a dose of 1000mg/m², twice daily for two weeks, followed by a one-week break. Treatment cycles repeat every three weeks.
214639504|NCT06942234|DRUG|Paclitaxel (albumin bound)|The drug is administered intravenously at a dose of 125mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
214639505|NCT06942234|DRUG|Eribulin|The drug is administered intravenously at a dose of 1.4mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
214639506|NCT06942234|DRUG|Pembrolizumab|The drug is administered intravenously at a fixed dose of 200mg, with infusions on Day 1 of each 3-week treatment cycle.
214639507|NCT06947473|DRUG|umbilical cord blood CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to umbilical cord blood CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
214639508|NCT07159828|BIOLOGICAL|AXN-2510|AXN-2510 is an antibody with PD-L1 blocking and VEGF inhibition activity in one drug. This is called a bispecific antibody, because it has 2 activities. This immuno-oncology treatment is in development for the treatment of solid tumors. AXN-2510 is differentiated from other PD-L1 and VEGF bispecific antibodies by its ability to inhibit multiple VEGF molecules and also increased antibody-dependent cellular cytotoxicity (ADCC) that can directly kill PD-L1-positive tumor cells.
214639509|NCT07166016|OTHER|Conservative|Patients with hammertoe deformities will undergo conservative treatments, including wearing proper shoes, insoles, and custom orthotics.
214639510|NCT07166016|PROCEDURE|Surgical|Patients with hammertoe deformities will undergo surgical treatments.
214725441|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
214639511|NCT07168291|DRUG|Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion|Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3. AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.
214639512|NCT07160478|OTHER|School Health Program|Health education interventions of approximately 60 minutes that include a conceptual presentation and a practical component.
214639513|NCT07166198|DEVICE|Wrist immobilization|The wrist immobilization will use a medical device (wrist cast) to immobilize the left, non-dominant wrist for 7 days.
214639514|NCT07166198|BEHAVIORAL|Resistance training|The cross-education intervention will consist of resistance training on the dominant, right hand.
214639515|NCT07166198|BEHAVIORAL|Resistance training rehabilitation|The resistance training rehabilitation will occur for the non-dominant, left hand following the immobilization phase for all participants.
214639516|NCT07166133|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Lesions in aortic arch in Zone 0 or Zone 1
214639517|NCT07166939|DRUG|Airsupra|1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period
214639518|NCT06776367|OTHER|Remote study participation and self-collection of specimens|Participants in Group B will complete all study procedures remotely and will not physically visit any clinical research site. This will include telehealth (videoconference) visits with study personnel, self-collection of specimens, shipping of specimens using pre-labeled packaging, and completion of electronic diaries for data collection.
214639519|NCT06776367|OTHER|Traditional clinical trial participation with clinician-collected specimens|Participants in Group A will attend study visits in person at a clinical research site and will have the majority of specimens collected by a clinician at the clinic. Group A participants will have some electronic diary usage.
214639520|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
214639521|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity and healthy eating|"Behavioural Experimental: guidelines-based physical activity:~Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.~Behavioural Experimental: guidelines-based healthy eating:~One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide."
214639522|NCT06345937|BEHAVIORAL|Behavioural: Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
214639523|NCT06362369|DRUG|Alintegimod|Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
214639524|NCT06362369|DRUG|Ipilimumab|Ipilimumab (Yervoy) will be administered via IV
214639525|NCT06362369|DRUG|Nivolumab|Nivolumab (Opdivo) will be administered via IV
214639526|NCT04441905|OTHER|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
214639527|NCT04441905|BIOLOGICAL|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
214725442|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
214639528|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
214725443|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
214639529|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
214639530|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
214639531|NCT04770753|DRUG|Placebo Matching Mitapivat|Tablets
214639532|NCT04770753|DRUG|Mitapivat|Tablets
214639533|NCT02775851|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214639534|NCT02775851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214639535|NCT02775851|PROCEDURE|Computed Tomography|Undergo CT scan
214639536|NCT02775851|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214639537|NCT02775851|BIOLOGICAL|Pembrolizumab|Given IV
214639538|NCT02775851|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214639539|NCT02775851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214639540|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention|Receive active EFT stimulus
214639541|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention (control)|Receive control EFT stimulus
214639542|NCT05825001|OTHER|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
214639543|NCT05643131|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
214639544|NCT06484322|BEHAVIORAL|Strategies Empowering Activities in Everyday life (SEE 2.0)|SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
214639545|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
214639546|NCT04862663|DRUG|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
214639547|NCT04862663|DRUG|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
214639548|NCT04862663|DRUG|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
214639549|NCT04862663|DRUG|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
214639550|NCT04862663|DRUG|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
214639551|NCT06416371|DIAGNOSTIC_TEST|Fundus fluorescein angiography, with ultrawide field retinal imaging|Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
214639552|NCT04570423|DRUG|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
214725444|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
214639553|NCT04570423|DRUG|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
214639554|NCT06487247|BEHAVIORAL|HEME-Hospice Program|A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.
214639555|NCT06952660|DRUG|TIVDAK|2 mg/kg once every 3 weeks (Q3W)
214639556|NCT06707090|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
214639557|NCT06707090|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
214639558|NCT03266016|OTHER|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
214639559|NCT03266016|DIAGNOSTIC_TEST|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
214639560|NCT03266016|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
214639561|NCT03266016|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
214639562|NCT03266016|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
214639563|NCT04229160|DEVICE|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
214639564|NCT04229160|DEVICE|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
214639565|NCT04229160|PROCEDURE|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
214639566|NCT06139523|DEVICE|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
214639567|NCT06139523|DEVICE|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
214639568|NCT03771586|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
214639569|NCT03771586|DRUG|Placebo|Placebo in combination with Ketamine
214639570|NCT06390592|DEVICE|PD cycler|"Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
214639571|NCT05099471|DRUG|Venetoclax; Rituximab|Combination of venetoclax and rituximab
214639572|NCT05099471|DRUG|DRC|Combination of Dexamethasone / Rituximab / Cyclophosphamide
214725445|NCT02550860|DRUG|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
214639573|NCT05553080|GENETIC|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
214639574|NCT04938973|PROCEDURE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
214639575|NCT04938973|PROCEDURE|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
214725446|NCT02550860|DRUG|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
214725447|NCT02894294|OTHER|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
214639576|NCT04938973|DEVICE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
214639577|NCT03686397|DRUG|SVT-15652|1 vial twice daily
214639578|NCT03686397|DRUG|Placebo|1 vial twice daily
214639579|NCT05181995|DRUG|NYX-783|NYX-783
214725448|NCT03990922|PROCEDURE|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
214639580|NCT05181995|DRUG|Placebo|Placebo for 50 mg NYX-783
214639581|NCT04310046|PROCEDURE|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
214725449|NCT03990922|PROCEDURE|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
214639582|NCT04310046|PROCEDURE|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
214639583|NCT03402776|DRUG|4th dose of hexavalent vaccine 1 month after the 3rd dose|4th dose of hexavalent vaccine 1 month after the 3rd dose
214725450|NCT03990922|DRUG|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
214725451|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
214725452|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
214725453|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214725454|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
214725455|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
214725456|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
214725457|NCT04984876|DRUG|ligelizumab|Subcutaneous injection once every 4 weeks
214639584|NCT02257580|DRUG|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
214639585|NCT05902169|DEVICE|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
214725458|NCT04984876|DRUG|Placebo|Subcutaneous injection once every 4 weeks
214639586|NCT05902169|DRUG|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\]."
214725459|NCT05109078|DRUG|[14C]- Rongliflozin|Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
214725460|NCT02444936|DRUG|ZOSTAVAX|Shingles vaccine
214725461|NCT01048255|DRUG|VX-765|300mg Oral Tablet, 900mg TID
214725462|NCT03793283|DEVICE|CSII|Currently receiving CSII therapy during 6 or more months.
214725463|NCT03793283|DRUG|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
214725464|NCT00003613|DRUG|O6-benzylguanine|Given IV
214725465|NCT00003613|DRUG|carmustine|Given topically
214725466|NCT00003613|OTHER|laboratory biomarker analysis|Correlative studies
214725467|NCT00395616|DRUG|Botox (drug)|
214725468|NCT04713670|DRUG|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
214725469|NCT04713670|DRUG|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
214725470|NCT04713670|DRUG|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
214725471|NCT04713670|DRUG|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
214725472|NCT04713670|DRUG|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
214725473|NCT04713670|DRUG|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
214725474|NCT04713670|DRUG|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
214725475|NCT04713670|DRUG|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
214725476|NCT00995813|BIOLOGICAL|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
214639587|NCT05902169|DRUG|Lomustine|Dosed and administered per labelling.
214639588|NCT05902169|DRUG|Temozolomide|Dosed and administered per labelling.
214639589|NCT03269214|DRUG|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
214639590|NCT05593029|DRUG|SEP-363856|Tablet
214639591|NCT05593029|OTHER|Placebo|Placebo
214639592|NCT05036681|DRUG|Futibatinib|tablets by mouth 1 time every day
214639593|NCT05036681|DRUG|Pembrolizumab|Given by vein over about 30-60 minutes on Day 1 of all cycles
214639594|NCT04292847|OTHER|Referrals Recommendations|All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
214639595|NCT05159557|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
214639596|NCT05159557|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
214639597|NCT05421663|BIOLOGICAL|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
214639598|NCT01934140|BIOLOGICAL|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
214639599|NCT00664248|DRUG|IDP-110|Topical application for 12 weeks
214725477|NCT00209092|DRUG|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1."
214725478|NCT00209092|DRUG|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
214639600|NCT00664248|DRUG|Clindamycin|Topical application for 12 weeks
214639601|NCT00664248|DRUG|Benzoyl peroxide|Topical application for 12 weeks
214639602|NCT00664248|DRUG|Vehicle|Topical application for 12 weeks
214639603|NCT00805740|DRUG|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
214639604|NCT00805740|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
214639605|NCT00200850|BIOLOGICAL|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
214639606|NCT00200850|BIOLOGICAL|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
214639607|NCT00200850|BIOLOGICAL|Placebo SLIT|Placebo SLIT daily
214639608|NCT02595879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214639609|NCT02595879|RADIATION|Brachytherapy|Undergo LDR brachytherapy
214639610|NCT02595879|DRUG|Cisplatin|Given IV
214639611|NCT02595879|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
214639612|NCT02595879|RADIATION|External Beam Radiation Therapy|Undergo pelvic EBRT
214639613|NCT02595879|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
214639614|NCT02595879|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
214639615|NCT02595879|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214639616|NCT02595879|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214639617|NCT02595879|OTHER|Pharmacological Study|Correlative studies
214639618|NCT02595879|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
214639619|NCT02595879|DRUG|Triapine|Given IV and PO
214639620|NCT06375135|BEHAVIORAL|TXTXT|Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.
214639621|NCT06375135|BEHAVIORAL|e-Navigation|"Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support."
214639622|NCT06375135|BEHAVIORAL|Ecological Momentary Assessment (EMA) supported e-Navigation.|Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
214639623|NCT03293563|PROCEDURE|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
215030519|NCT06639009|OTHER|940nm diode laser photobiomodulation|"The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes"
214725479|NCT06177015|DRUG|Darolutamide continuous|standard of care
214725480|NCT06177015|DRUG|Darolutamide intermittent|experimental group
214725481|NCT05399160|BEHAVIORAL|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
214725482|NCT02929368|DEVICE|PICC implantation under fluoroscopy|PICC Catheter implantation
214725483|NCT02929368|DEVICE|PICC Implantation under Sherlock System|PICC Catheter implantation
214725484|NCT00584779|DRUG|Gabapentin|CLcr:14-5 mL/min
214725485|NCT00584779|DRUG|Gabapentin|CLcr: 29-15 mL/min
214725486|NCT00584779|DRUG|Gabapentin|Hemodialysis
214639624|NCT05578690|BEHAVIORAL|Diet|An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
214639625|NCT05578690|BEHAVIORAL|Exercise|After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
214639626|NCT05578690|BEHAVIORAL|Mentorship|"Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups."
214725487|NCT00584779|DRUG|Gabapentin|CLcr: 29-30 mL/min
214725488|NCT01462045|BEHAVIORAL|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
214725489|NCT01193049|DRUG|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
214725490|NCT01193049|DRUG|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
214725491|NCT03726541|OTHER|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
214725492|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
214725493|NCT05187494|DRUG|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
214725494|NCT05187494|DRUG|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
214725495|NCT05187494|DRUG|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
214725496|NCT05187494|DRUG|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
214725497|NCT00076856|DRUG|Temozolomide|
214725498|NCT04737954|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
214725499|NCT04737954|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
214725500|NCT00053105|DRUG|cisplatin|
214725501|NCT00053105|DRUG|cytarabine|
214725502|NCT00053105|DRUG|methylprednisolone|
214725503|NCT00053105|DRUG|pixantrone dimaleate|
214725504|NCT03425851|OTHER|Diapers|Receive 600 diapers.
214725505|NCT03425851|OTHER|Resources of diaper banks|Caregivers will receive resources of diaper banks.
214725506|NCT04838795|BIOLOGICAL|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
214725507|NCT04459078|DRUG|Camrelizumab|Intravenous administration of (200mg/3weeks)
214725508|NCT04459078|DRUG|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
214725509|NCT04459078|DRUG|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
214725510|NCT04506385|DIETARY_SUPPLEMENT|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
214725511|NCT01711437|DEVICE|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
214725512|NCT01711437|DEVICE|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
214725513|NCT01711437|DEVICE|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
214725514|NCT01711437|DEVICE|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
214639627|NCT06580964|BEHAVIORAL|Heat therapy|Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 6d/wk (5 at-home and 1 in-lab).
214639628|NCT06580964|BEHAVIORAL|High-intensity interval training|High-intensity interval training will be performed 3 days per week for 12 weeks.
214639629|NCT06547775|DRUG|KN069|Solution for SC injection
214639630|NCT06636071|BIOLOGICAL|setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
214639631|NCT04669678|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
214639632|NCT04669678|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
214639633|NCT04669678|DRUG|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
214639634|NCT04669678|DEVICE|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
214639635|NCT05155579|BIOLOGICAL|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
214639636|NCT05155579|BIOLOGICAL|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
214725515|NCT03581565|OTHER|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
214725516|NCT04761575|OTHER|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
214725517|NCT04457661|DIETARY_SUPPLEMENT|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
214725518|NCT03793270|DIAGNOSTIC_TEST|for patients and healthy donors|"1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate"
214725519|NCT02462122|DRUG|IDP-118 Lotion|Lotion
214725520|NCT02462122|DRUG|IDP-118 Vehicle Lotion|Lotion
214725521|NCT05933993|OTHER|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
214725522|NCT00741741|DRUG|TMC278|
214725523|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
214639637|NCT05155579|BIOLOGICAL|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
214639638|NCT05155579|BIOLOGICAL|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
214639639|NCT05155579|BIOLOGICAL|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
214639640|NCT05155579|BIOLOGICAL|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
214639641|NCT05155579|BIOLOGICAL|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
214639642|NCT05155579|BIOLOGICAL|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
214639643|NCT05155579|BIOLOGICAL|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
214639644|NCT06429475|DRUG|Budesonide/formoterol|"The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years."
214725524|NCT01253967|PROCEDURE|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
214725525|NCT01253967|OTHER|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
214639645|NCT06429475|DRUG|standard of care|Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
214639646|NCT05227690|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
214639647|NCT05227690|DRUG|Emraclidine 10 mg|Emraclidine 10 mg, oral (tablet), once per day for 6 weeks
214639648|NCT05227690|DRUG|Emraclidine 30 mg|Emraclidine 30 mg, oral (tablet), once per day for 6 weeks
214639649|NCT06089603|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
214639650|NCT06089603|DRUG|Conventional pharmacological treatment|Usual treatment of the patient
214639651|NCT06089603|OTHER|Sleep ,diet and life style recomendations|Daily recomendatios
214725526|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
214639652|NCT05794061|BEHAVIORAL|Neuropsychological instruments|Cognitive and behavioral tests and questionnaires
214639653|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
214639654|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
214725527|NCT05894486|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
214793824|NCT03406130|PROCEDURE|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
214639655|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
214639656|NCT06799520|DRUG|VIS171|VIS171 will be administered as a SC injection.
214639657|NCT06461156|DRUG|HS-10504|HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
214639658|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
214639659|NCT01475123|DRUG|Nicorandil|15mg per day
214639660|NCT03631043|PROCEDURE|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
214639661|NCT03631043|DRUG|Lenalidomide|Given PO
214639662|NCT03631043|BIOLOGICAL|Vaccine Therapy|Given personalized vaccine SC
214639663|NCT06006806|RADIATION|Pencil Beam Scanning Proton Therapy|"Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called Spot Delete to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process."
214639664|NCT04033367|DRUG|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214639665|NCT04033367|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214639666|NCT05714202|DRUG|TAR-200|TAR-200 will be administered intravesically.
214639667|NCT05714202|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
214639668|NCT05714202|BIOLOGICAL|BCG Vesiculture|BCG will be administered intravesically.
214639669|NCT06169215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214639670|NCT06169215|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214639671|NCT06169215|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214639672|NCT06169215|DRUG|Bortezomib|Given SC
214639673|NCT06169215|PROCEDURE|Computed Tomography|Undergo CT
214639674|NCT06169215|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
214639675|NCT06169215|DRUG|Dexamethasone|Given PO
214639676|NCT06169215|DRUG|Lenalidomide|Given PO
214639677|NCT06169215|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214639678|NCT06169215|PROCEDURE|Positron Emission Tomography|Undergo PET
214639679|NCT06169215|DRUG|Selinexor|Given PO
214639680|NCT03799900|DRUG|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
214639681|NCT03799900|DRUG|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
214639682|NCT03799900|DRUG|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
214639683|NCT02908880|DEVICE|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
214639684|NCT04031079|DEVICE|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
214639685|NCT04031079|DEVICE|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
214639686|NCT04031079|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
214639687|NCT05559567|DEVICE|Orthokeratology|The use of a specialty GP contact lens to temporarily correct myopia
214639688|NCT02657135|BEHAVIORAL|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
214639689|NCT02657135|OTHER|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
214639690|NCT02657135|OTHER|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
214639691|NCT02657135|OTHER|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
214639692|NCT02657135|OTHER|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
214639693|NCT02657135|OTHER|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
214639694|NCT02657135|OTHER|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
214639695|NCT03341260|DRUG|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
214639696|NCT03341260|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
214639697|NCT03521505|DRUG|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration
214639698|NCT03521505|DRUG|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration."
214639699|NCT02789813|DRUG|Valproic Acid|Once oral administration of 500mg before exposure therapy.
214639700|NCT02789813|DRUG|Placebo|Once oral administration of 500mg before exposure therapy.
214639701|NCT02789813|BEHAVIORAL|Fear reactivation|Fear reactivation before exposure therapy.
214639702|NCT02789813|BEHAVIORAL|No fear reactivation|No fear reactivation before exposure therapy.
214639703|NCT00933049|DRUG|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
214639704|NCT00933049|DRUG|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
214639705|NCT00933049|DRUG|Amoxicillin placebo|
214639706|NCT00933049|DRUG|Cotrimoxazole placebo|
214639707|NCT02074852|OTHER|Foley urethral catheter|
214639708|NCT01266486|DRUG|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
214639709|NCT06127641|OTHER|Standard care plus pulmonary rehabilitation|A 12-week rehabilitation program, 3X/week. Each outpatient session will last 2 hours including: guidance on the care of inhalation techniques and/or oxygen therapy, when prescribed; aerobic training on a cycle ergometer supervised by a physiotherapist (30 min each: 5 min warm-up, 20 min training and 5 min cool-down) at constant load calculated with Hill's equation (HILL et al., 2008). Optional components of RP will include: inspiratory muscle conditioning using a threshold-loading device, inspiratory muscle training with powerbreathe, breathing exercises, airway clearance, psychological support, relaxation and nutritional counseling. Patients will participate in two group educational sessions, managed by a respiratory physiotherapist, on lifestyle, physical activity and maintenance programs (VISCA et al., 2019; FUGAZZARO et al., 2017; TENCONI et al., 2021).
214793825|NCT03406130|PROCEDURE|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
214639710|NCT06127641|OTHER|Standard Care|Participants will receive standard care (SC): a therapeutic education session upon admission, as well as pulmonary rehabilitation (PR) taught by a physical therapist. This therapeutic educational session will involve counseling and self-care management, emphasizing breathing exercises and sputum clearance and self-care techniques. It will consist of smoking cessation education (if this is the case, as tobacco is associated with TB), respiratory retraining (pursed lip breathing, diaphragmatic breathing and segmental breathing) and secretion removal training (coughing exercise, huffing , assisted cough and postural drainage).
214725528|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
214725529|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
214639711|NCT06849115|DRUG|L-Carnitine Injection，1000mg once daily|All patients were given L-carnitine therapy administered every 8 weeks, consisting of 1g L-carnitine diluted in 500 mL of 0.9% sodium chloride solution via intravenous infusion once daily. Each treatment cycle lasted 2 weeks, repeated at 8-week intervals for a total of 3 cycles, with L-carnitine 1g is administered orally once daily during the intervals between intravenous therapies.
214639712|NCT03193398|DRUG|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
214639713|NCT03193398|DRUG|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
214639714|NCT01394445|DRUG|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
214639715|NCT01394445|DRUG|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
214725530|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
214725531|NCT04722289|BEHAVIORAL|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
214725532|NCT01446549|OTHER|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
214725533|NCT01446549|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation implantation
214725534|NCT02828644|DEVICE|EVO|videogame-like digital therapy
214725535|NCT03928509|OTHER|No intervention|No intervention
214725536|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
214725537|NCT02461849|DRUG|Imatinib|Imatinib 400mg qd daily
214725538|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
214725539|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
214725540|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
214725541|NCT03517735|DEVICE|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
214725542|NCT03517735|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
214725543|NCT03517735|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
214639716|NCT01058343|BIOLOGICAL|IFN-K|3 to 4 IM injections over 3 months
214639717|NCT04461990|PROCEDURE|Multidisciplinary cooperative comprehensive treatment|Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
214639718|NCT00159289|PROCEDURE|Inhalation of LPS|
214725544|NCT02493335|DRUG|Budesonide 0.5mg orodispersible tablet twice daily|
214725545|NCT02493335|DRUG|Budesonide 1mg orodispersible tablet twice daily|
214725546|NCT02493335|DRUG|Placebo orodispersible tablet twice daily|
214725547|NCT03042585|RADIATION|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
214725548|NCT01392014|DRUG|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
214725549|NCT01392014|DRUG|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
214639719|NCT00159289|PROCEDURE|Placebo|
214639720|NCT06427460|RADIATION|Central-boost ablative dose delivered by stereotactic body radiation therapy|An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
214639721|NCT01820325|DRUG|Buparlisib|
214639722|NCT01820325|DRUG|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
214639723|NCT01820325|DRUG|Carboplatin|
214639724|NCT01820325|DRUG|Paclitaxel|
214639725|NCT01991132|OTHER|MediView 2.0 software|
214639726|NCT00003793|GENETIC|clonality analysis|
214639727|NCT00003793|GENETIC|microsatellite instability analysis|
214639728|NCT00003793|GENETIC|mutation analysis|
214639729|NCT02170662|DRUG|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
214639730|NCT02170662|DRUG|Placebo|
214639731|NCT06423079|PROCEDURE|Siepser knots|Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation
214639732|NCT00485641|DEVICE|SaeboFlex Dynamic Hand Orthosis|
214639733|NCT00485641|PROCEDURE|Saebo F.T.M. Arm Training Program|
214639734|NCT00167635|BEHAVIORAL|cognitive-behavioral|Cognitive-behavioral over 9 weeks
214639735|NCT05461079|DIAGNOSTIC_TEST|obtention of up to three semen samples|sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.
214639736|NCT03390179|DRUG|Steroid Drug|mesure of the glucose concentration
214639737|NCT03823391|DRUG|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
214639738|NCT03823391|DRUG|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
214725550|NCT01984359|OTHER|Obtaining Human tissue|
214725551|NCT00912496|BIOLOGICAL|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
214793826|NCT03935581|DEVICE|ExAblate|Auto Focusing (AF) echo imaging
214639739|NCT03823391|DRUG|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
214639740|NCT03823391|DRUG|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
214639741|NCT02770937|OTHER|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
214639742|NCT02770937|OTHER|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
214639743|NCT02770937|DEVICE|Simbionix|
214725552|NCT00912496|BIOLOGICAL|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
214725553|NCT00912496|DRUG|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
214725554|NCT01726504|DEVICE|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
214793827|NCT03772483|PROCEDURE|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
214639744|NCT02450487|DRUG|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
214639745|NCT06427551|DRUG|Ropivacaine|The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
214725555|NCT01726504|DEVICE|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
214639746|NCT04635306|DIAGNOSTIC_TEST|Approved GEBT test meal|FDA-approve GEBT test meal
214639747|NCT01790048|DIETARY_SUPPLEMENT|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
214725556|NCT02436915|OTHER|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
214725557|NCT02436915|OTHER|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
214725558|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
214639748|NCT01790048|DIETARY_SUPPLEMENT|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
214725559|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
214639749|NCT03609372|BEHAVIORAL|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
214639750|NCT05736588|BEHAVIORAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
214639751|NCT05366699|PROCEDURE|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
214639752|NCT05366699|PROCEDURE|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
214639753|NCT05366699|PROCEDURE|axillary lymphadenectomy with soft tissue reinforcement|axillary lymphadenectomy with soft tissue reinforcement(STR)
214639754|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
214639755|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
214639756|NCT05489237|DRUG|IDRX-42|Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
214725560|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
214725561|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
214725562|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
214639757|NCT06282458|DRUG|Enobosarm|Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
214639758|NCT06282458|DRUG|Semaglutide|Semaglutide for Chronic Weight Management
214639759|NCT06121401|DRUG|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
214639760|NCT06121401|DRUG|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
214639761|NCT00796471|DRUG|Paliperidone ER|
214639762|NCT06047561|RADIATION|PET-CT|PET combined with CT or MRI
214639763|NCT05754918|DEVICE|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
214639764|NCT05754918|DEVICE|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
214639765|NCT05035212|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
214725563|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
214725564|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
214725565|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
214639766|NCT05035212|BIOLOGICAL|Placebo|Placebo
214639767|NCT03403699|BIOLOGICAL|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
214639768|NCT05029921|DRUG|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
214639769|NCT06323174|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214639770|NCT06323174|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214639771|NCT06323174|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
214639772|NCT05072483|DEVICE|MRI|Research pulse sequences.
214639773|NCT06545786|DEVICE|Intraoperative electroencephalography|"EEG recording will be performed using the standard 16-electrode configuration according to the international 10-20 system. During the recording, electrode impedances will be maintained at a level not exceeding 5 kilo-ohms."
214639774|NCT06553612|OTHER|Multidisciplinary assessment|Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
214639775|NCT06553612|OTHER|Standard assesment|Delivery of a personalized post-cancer plan without a day hospital
214639776|NCT06553612|OTHER|Observational cohort|Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort
214639777|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
214639778|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
214725566|NCT05595213|DEVICE|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
214725567|NCT05595213|DEVICE|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
214725568|NCT05595213|OTHER|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
214725569|NCT02437968|BEHAVIORAL|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
214725570|NCT03889522|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition \[47, 49\]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
214725571|NCT03889522|DIAGNOSTIC_TEST|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
214725572|NCT03889522|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
214725573|NCT03856086|BEHAVIORAL|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
214725574|NCT03856086|BEHAVIORAL|NCCN Problem List|NCCN Distress Thermometer
214639779|NCT06482658|PROCEDURE|Transrectal perilesional/regional systematic biopsy (PB/RSB)|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
214639780|NCT06482658|PROCEDURE|Combination of transrectal systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
214639781|NCT06447922|OTHER|Metal ion level testing|Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
214639782|NCT06378346|OTHER|Observation|Participants will not receive glycyrrhizin
214639783|NCT06378346|DRUG|Glycyrrhizin - 75 mg|Participants will either receive 75 mg orally daily
214639784|NCT06378346|DRUG|Glycyrrhizin - 150 mg|Participants will receive 150 mg orally daily
214639785|NCT05542862|BIOLOGICAL|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
214639786|NCT05869773|DRUG|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
214639787|NCT05030311|DRUG|LOU064 25 mg (b.i.d)|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.
214639788|NCT05030311|DRUG|Placebo|Placebo
214639789|NCT05030311|DRUG|LOU064 25 mg (b.i.d) as a tablet.|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
214639790|NCT02484417|BIOLOGICAL|RSV A2|Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
214639791|NCT05309928|DRUG|Amoxicillin|medication administration
214639792|NCT06367920|DIAGNOSTIC_TEST|Magnetic Resonance Imaging, Behavioral assessments|Magnetic Resonance Imaging, Behavioral assessments
214639793|NCT04748874|PROCEDURE|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
214725575|NCT03856086|BEHAVIORAL|FACT-GP|Greater overall quality of life
214725576|NCT03856086|BEHAVIORAL|HADS|Lower anxiety and depression
214725577|NCT03856086|BEHAVIORAL|CSS-CG|web-based CSS-CG
214725578|NCT05572541|DIAGNOSTIC_TEST|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
214725579|NCT01117181|DRUG|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
214639794|NCT05132881|OTHER|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
214639795|NCT05132881|OTHER|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
214725580|NCT01117181|DRUG|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
214725581|NCT01117181|OTHER|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
214725582|NCT04078269|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
214725583|NCT04078269|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
214725584|NCT04078269|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
214725585|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~\- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
214725586|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
214725587|NCT05270967|DIAGNOSTIC_TEST|F-18 FDG PET/CT imaging|Oncological imaging
214639796|NCT05132881|OTHER|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
214639797|NCT05132881|OTHER|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
214639798|NCT04298658|DIAGNOSTIC_TEST|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
214639799|NCT04298658|DIAGNOSTIC_TEST|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
214639800|NCT04298658|OTHER|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
214639801|NCT04298658|DIAGNOSTIC_TEST|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
214639802|NCT04298658|DIAGNOSTIC_TEST|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
214639803|NCT03692897|OTHER|All approved therapies for the treatment of Chronic Hepatitis B (CHB)|All approved therapies for the treatment of Chronic Hepatitis B (CHB).
214639804|NCT05183568|BEHAVIORAL|Mindful Self-Compassion|Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
214639805|NCT06307106|DRUG|ketorolac and light marcaine|local injection at surgical site of 30 mg ketorolac and 7-1.5 mg\\kg\\dose light marcaine
214639806|NCT06307106|DRUG|light marcaine|local injection at surgical site of 7-1.5 mg\\kg\\dose light marcaine
214639807|NCT06307106|DRUG|Corticosteroids injection|local injection at surgical site of 40 mg\\ dose of dexamethasone
214639808|NCT06307106|DRUG|Diclofenac Sodium Gel|topical application of Diclofenac Sodium Gel
214639809|NCT06307106|OTHER|the standard analgesic protocol|the routine analgesia was given without local analgesia application
214639810|NCT06560021|OTHER|Biopsy strategy|Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
214639811|NCT04666155|DEVICE|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
214639812|NCT04666155|DEVICE|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
214639813|NCT04141657|OTHER|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
214639814|NCT02426177|DRUG|Labetalol|anti-hypertensive agents
214639815|NCT02426177|DRUG|Nifedipine|calcium channel blocker ,for lowering blood pressure
214639816|NCT03083886|OTHER|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
214639817|NCT03083886|OTHER|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
214639818|NCT03083886|OTHER|Usual PCP led care|Primary care provider will direct patients' care pathway.
214639819|NCT00006255|PROCEDURE|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
214639820|NCT00006255|PROCEDURE|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
214639821|NCT03912129|GENETIC|blood sample|"A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants."
214725588|NCT05270967|BIOLOGICAL|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
214725589|NCT02277236|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
214725590|NCT02277236|RADIATION|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
214725591|NCT00863317|DRUG|montelukast sodium|4mg granules daily for 14 days
214725592|NCT00863317|OTHER|sucrose|table sugar as placebo daily for 14 days
214725593|NCT00878813|PROCEDURE|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
214725594|NCT00878813|PROCEDURE|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
214725595|NCT05431738|DEVICE|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
214725596|NCT02283372|DRUG|nab-Paclitaxel|
214639822|NCT03174483|DRUG|Hypertonic saline|nasal spray
214639823|NCT03174483|DRUG|Fluticasone Nasal|nasal spray
214639824|NCT02062658|DRUG|Ketamine|0.5mg/kg IV
214639825|NCT02062658|BEHAVIORAL|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
214639826|NCT05090293|BEHAVIORAL|Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)|A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
214639827|NCT05090293|BEHAVIORAL|Lifestyle Intervention (LI)|A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
214725597|NCT02283372|DRUG|Gemcitabine|
214725598|NCT02283372|RADIATION|Intensity modulated radiation|
214639828|NCT06221020|DIAGNOSTIC_TEST|Malnutrition Universal Screening Tool|"The Malnutrition Universal Screening Tool (MUST) is a commonly used tool for assessing the nutritional status of adult patients. It is designed to identify early whether a patient is at risk of malnutrition or is already malnourished, enabling timely intervention and treatment. MUST includes three main assessment criteria:~Body Mass Index (BMI):~Degree of Weight Loss: This assesses the patient's weight change over the past three months, with grading based on the extent of weight loss.~Effect of Illness on Dietary Intake: This evaluates the impact of illness on the patient's dietary intake, with grading based on the reduction in dietary intake.~By combining the grades from these three assessment indicators, a final MUST score is obtained to determine the patient's nutritional status and level of risk. Based on the MUST score, patients can be categorized as low risk, medium risk, or high risk for malnutrition."
214725599|NCT06188728|DIETARY_SUPPLEMENT|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
214725600|NCT06188728|BEHAVIORAL|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
214725601|NCT06188728|COMBINATION_PRODUCT|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
214725602|NCT06188728|OTHER|Control|No intervention
214725603|NCT03878160|OTHER|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
214725604|NCT06379880|DEVICE|CONTINUUM+ CONNECT remote monitoring|"CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group."
214725605|NCT01737138|PROCEDURE|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
214725606|NCT01737138|DRUG|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
214725607|NCT06407336|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
214725608|NCT06407336|OTHER|Refraction|Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
214725609|NCT03531762|DRUG|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
214725610|NCT03531762|DRUG|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
214725611|NCT05759104|DRUG|Infliximab|Drug
214725612|NCT05759104|PROCEDURE|Stomy|Surgery
214725613|NCT00809614|BIOLOGICAL|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
214725614|NCT00809614|BIOLOGICAL|Placebo|Matching placebo to AIN457
214725615|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
214725616|NCT00779818|DEVICE|Laser|Treatment by laser
214725617|NCT03185325|OTHER|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
214725618|NCT03185325|OTHER|venous blood samples|venous blood samples are collected in healthy voulnteers
214725619|NCT04514406|DEVICE|APERTO OTW DCB|Drug Coated Balloon Angioplasty
214725620|NCT03482336|OTHER|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
214725621|NCT01080625|DRUG|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
214725622|NCT01080625|DRUG|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
214725623|NCT01080625|DRUG|placebo control|10ml of normal saline is administered at the time of reperfusion
214725624|NCT02368730|DRUG|desmopressin|
214639829|NCT06221020|DEVICE|TIB Olfactory Test Device|Olfactory testing is conducted on patients undergoing pituitary tumor surgery via nasal endoscopy using the TIB Olfactory Test Device (TIBSIT). This testing aims to compare olfactory (sense of smell) outcomes before and after the surgery. The olfactory tests are performed preoperatively and then again at the 3-month postoperative mark to assess any changes or impacts on the sense of smell due to the surgery.
214639830|NCT06221020|DIAGNOSTIC_TEST|Apfel Score for Postoperative nausea and vomiting|"Nausea and Vomiting Risk Scale: Apfel Score~Risk Factors: Female; Smoking habit; History of postoperative nausea and vomiting or motion sickness; Use of opioid painkillers post-surgery (Each risk factor scores 1 point; minimum score is 0; maximum score is 4)~Score Probability of Postoperative Nausea and Vomiting~0 - 10%~1. \- 21%~2. \- 39%~3. \- 61%~4. \- 79%"
214725625|NCT03563586|OTHER|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
214725626|NCT03563586|OTHER|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
214725627|NCT00740428|PROCEDURE|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
214725628|NCT05499689|DRUG|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
214725629|NCT05499689|OTHER|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
214725630|NCT04324268|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
214725631|NCT04324268|OTHER|Placebo|Placebo
214725632|NCT04225312|DRUG|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
214639831|NCT06221020|DIAGNOSTIC_TEST|The American Society of Anesthesiologists (ASA) Physical Status Classification|"ASA I: A normal, healthy patient with no systemic disease. ASA II: A patient with mild systemic disease. ASA III: A patient with severe systemic disease that limits activity but is not incapacitating.~ASA IV: A patient with severe systemic disease that is a constant threat to life.~ASA V: A moribund patient not expected to survive without the operation. This project involves collecting data from adult patients aged 20 to 75 years old who are classified as ASA I to III grade."
214639832|NCT06221020|BEHAVIORAL|Short Form-36|The Short Form-36 (SF-36) is a widely used health assessment tool, extensively applied in both research and clinical practice. It is a concise yet comprehensive questionnaire designed to evaluate individuals' health status and quality of life. The SF-36 covers eight different dimensions of health, including physical functioning, bodily pain, general health, vitality, social functioning, emotional health, mental health, and health change. Each dimension is assessed through a series of questions that address aspects such as an individual's capabilities in daily life, symptoms, and emotional states. The SF-36 allows healthcare professionals and researchers to gain insights into a person's health and quality of life across these varied aspects. Additionally, SF-36 has undergone extensive testing and validation, proving to have good reliability and validity.
214639833|NCT06221020|BEHAVIORAL|World Health Organization Quality of Life questionnaire (WHOQOL-BREF)|The World Health Organization Quality of Life questionnaire (WHOQOL-BREF) is a health-related quality of life assessment tool developed by the World Health Organization (WHO). It is designed to evaluate an individual's satisfaction with their life and overall health status. The WHOQOL-BREF is a condensed version of the original WHOQOL-100 questionnaire, intended to reduce the time required to complete it and enhance its applicability.
214639834|NCT06221020|BEHAVIORAL|BDI-II(Beck Depression Inventory-II)|"The BDI-II consists of 21 questions that assess the degree of depression by asking respondents about various depressive symptoms they have experienced. These symptoms include sadness, insomnia or oversleeping, changes in appetite, self-blame, self-disdain, loss of interest in daily activities, and more. Each question has four possible response options, allowing respondents to choose the answer that best fits their feelings.~Scoring on the BDI-II ranges from 0 to 63, with higher scores indicating more severe depression. Based on the scores, the severity of a respondent's depression can be classified into different levels, ranging from mild to severe. The purpose of using this scale is to help healthcare professionals assess a patient's depressive symptoms, monitor changes in condition, and evaluate the effectiveness of treatments."
214639835|NCT06221020|BEHAVIORAL|ERAS Patient Satisfaction Questionnaire(ERAS-PSQ)|The ERAS Patient Satisfaction Questionnaire (ERAS-PSQ) is a satisfaction survey specifically designed for patients who have undergone treatment following the Enhanced Recovery After Surgery (ERAS) protocols. This questionnaire aims to evaluate the patients' satisfaction and experience with the ERAS approach. Typically, it includes questions about various aspects of their treatment and care, such as pain management, the recovery process, the quality of nursing care, and communication with the medical team. The ERAS-PSQ is an important tool for assessing how well the ERAS protocols are received by patients and for identifying areas for improvement in patient care within the ERAS framework.
214639836|NCT06221020|BEHAVIORAL|Quality of Recovery-40(QoR-40)|The Quality of Recovery-40 (QoR-40) is a widely used questionnaire designed to assess the quality of recovery after surgery. It comprises 40 questions that cover both physical and psychological aspects of a patient's recovery, such as pain, nausea, anxiety, dietary habits, and social functioning. The QoR-40 provides a comprehensive view of a patient's postoperative recovery, encompassing a range of factors crucial to understanding the effectiveness of surgical procedures and the overall patient experience during the recovery phase. This tool is instrumental in evaluating and improving post-surgical care and patient outcomes.
214639837|NCT06437873|PROCEDURE|Total Thyroidectomy (TT)|TT:Surgical removal of the entire thyroid gland.
214639838|NCT06437873|RADIATION|Radioactive iodine treatment(RAIT)|RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
214639839|NCT01997879|DRUG|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
214639840|NCT04338958|DRUG|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
214639841|NCT04516473|PROCEDURE|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
214639842|NCT05125250|OTHER|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
214639843|NCT05125250|OTHER|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
214639844|NCT03368183|OTHER|Care delivery algorithim|SCAMP
214639845|NCT00131625|BEHAVIORAL|Health education according to WHO recommendations|
214639846|NCT00434564|PROCEDURE|Stress nuclear scan|
214639847|NCT03361397|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
214725633|NCT04225312|DRUG|Standard interval dosing|Standard interval dosing in control group and historic group
214725634|NCT04179760|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
214725635|NCT04179760|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
214725636|NCT06317441|DIETARY_SUPPLEMENT|Probiotic|The intervention consists of a probiotic either with a low or high dosage
214725637|NCT01092364|BEHAVIORAL|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
214725638|NCT02412527|OTHER|Patch III heart rate sensor|
214725639|NCT00364832|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
214725640|NCT03696849|OTHER|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
214725641|NCT00054756|DRUG|TRH (Thyrotropin Releasing Hormone)|
214725642|NCT05525065|DRUG|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
214725643|NCT00762528|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
214725644|NCT00762528|DRUG|Sodium monofluorophosphate toothpaste|Twice daily usage
214725645|NCT02148601|OTHER|Fecal Microbiota Transplantation|
214725646|NCT02148601|DRUG|Standard Antibiotic Therapy|
214725647|NCT02148601|DRUG|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
214725648|NCT05601765|OTHER|Standard communication pathways after discharge|Standard communication pathways after discharge
214725649|NCT05601765|OTHER|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
214725650|NCT03885076|PROCEDURE|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
214639848|NCT03361397|DRUG|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
214639849|NCT00419328|DRUG|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level"
214639850|NCT00726466|DRUG|Efalizumab, Ranibizumab|
214639851|NCT03064139|BEHAVIORAL|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
214639852|NCT03064139|BEHAVIORAL|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
214639853|NCT05872087|DRUG|Nebulised Dexmeditomidine|premedication by dexmeditomidine 3mcg/kg in children undergoing lower abdominal surgeries
214639854|NCT05872087|DRUG|Nebulised Midazolam|premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
214639855|NCT00608985|DRUG|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
214639856|NCT00608985|DRUG|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
214725651|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
214725652|NCT04634318|OTHER|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
214725653|NCT04634318|OTHER|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
214725654|NCT01174589|OTHER|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
214725655|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
214639857|NCT00608985|DRUG|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
214725656|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1\. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
214639858|NCT00608985|DRUG|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
214639859|NCT03033745|DRUG|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
214639860|NCT02562326|DRUG|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
214639861|NCT02562326|DRUG|Humalog®|Injection immediately before the start of the individualised standard meal
214639862|NCT03631823|OTHER|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
214639863|NCT01238939|DRUG|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
214639864|NCT04519723|DEVICE|Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .|
214639865|NCT05786092|DEVICE|Telemonitoring|Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
214639866|NCT00323557|DRUG|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
214639867|NCT00323557|BIOLOGICAL|Pneumococcal Vaccine|Subcutaneously on Day 0
214639868|NCT01175044|PROCEDURE|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
214639869|NCT01175044|PROCEDURE|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
214639870|NCT06403085|OTHER|Study group|Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.
214639871|NCT01743638|PROCEDURE|MR-Guided Laser Ablation|
214639872|NCT00584480|OTHER|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
214639873|NCT00662792|DRUG|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
214639874|NCT00662792|DRUG|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
214639875|NCT00662792|DRUG|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S\_DPI) twice daily (BID)
214639876|NCT00662792|DRUG|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S\_PE) inhalation powder
214639877|NCT05499962|BEHAVIORAL|Social Networking Strategies|Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
214639878|NCT00090545|DRUG|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
214639879|NCT05116800|DRUG|Gemcitabine|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
214639880|NCT05116800|DRUG|9-ING-41|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
214639881|NCT05116800|DRUG|Docetaxel|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
214639882|NCT00035880|DRUG|ABX-CBL|
214639883|NCT03161756|DRUG|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
214639884|NCT03161756|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
214639885|NCT03161756|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
214639886|NCT02347176|OTHER|Placebo|Subcutaneous injection with placebo
214639887|NCT02347176|BIOLOGICAL|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
214639888|NCT02347176|BIOLOGICAL|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
214639889|NCT02347176|BIOLOGICAL|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
214639890|NCT05404308|OTHER|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
214639891|NCT05404308|OTHER|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
214639892|NCT04282772|DIAGNOSTIC_TEST|Impacted|Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position
214725657|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2\. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
214639893|NCT04282772|DIAGNOSTIC_TEST|Self-corrected|The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
214639894|NCT03355508|DEVICE|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
214639895|NCT01679041|DRUG|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
214639896|NCT01679041|DRUG|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
214639897|NCT01679041|DRUG|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
214639898|NCT00236977|DRUG|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
214639899|NCT00236977|DRUG|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
214639900|NCT04031703|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
214639901|NCT04031703|DRUG|Carboplatin|Carboplatin chemotherapy (injection)
214639902|NCT04031703|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
214639903|NCT04031703|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
214639904|NCT04031703|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
214639905|NCT04031703|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
214639906|NCT05860062|DIETARY_SUPPLEMENT|Vitamin D|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
214639907|NCT05860062|OTHER|Calcium|3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
214639908|NCT03783260|OTHER|Mediterranean diet|During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
214639909|NCT05315921|DRUG|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214725658|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3\. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
214639910|NCT05315921|DRUG|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214639911|NCT05315921|DRUG|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214639912|NCT05315921|DRUG|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214639913|NCT05315921|DRUG|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214639914|NCT05315921|DRUG|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
214639915|NCT05810545|OTHER|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
214639916|NCT03119519|RADIATION|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
214639917|NCT03119519|DRUG|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
214639918|NCT01899170|PROCEDURE|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
214639919|NCT01899170|DEVICE|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
214639920|NCT01899170|DRUG|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
214639921|NCT03873155|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
214639922|NCT04758585|PROCEDURE|Arthroscopy|Shoulder Arthroscopy
214639923|NCT00062387|DRUG|perifosine|
214639924|NCT06241612|RADIATION|Individualized Elective Neck Irradiation|Individualized Elective Neck Irradiation
214725659|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
214725660|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
214725661|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
214725662|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
214639925|NCT04027933|BEHAVIORAL|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
214639926|NCT03403205|DRUG|ALXN1840|ALXN1840 administered orally in 15 mg tablets
214639927|NCT03403205|DRUG|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
214639928|NCT05018234|DEVICE|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
214639929|NCT01834729|DRUG|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
214639930|NCT01834729|OTHER|Placebo|placebo capsule identical to the study drug
214639931|NCT06533475|DRUG|Minzasolmin tablet formulation under fasting condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
214639932|NCT06533475|DRUG|Minzasolmin Granules in capsule under fasting condition|Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition
214639933|NCT06533475|DRUG|Minzasolmin tablet formulation under fed condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition
214639934|NCT02326415|OTHER|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
214639935|NCT02326415|OTHER|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
214639936|NCT03664414|DRUG|pentoxifylline|Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
214639937|NCT01258959|PROCEDURE|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
214639938|NCT03431987|DRUG|One day with a dose of placebo cannabis paired with alcohol|Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%
214639939|NCT03431987|DRUG|One day with a dose of active THC cannabis paired with alcohol|Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
214639940|NCT02971670|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
214639941|NCT00288080|DRUG|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
214639942|NCT00288080|DRUG|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
214639943|NCT00288080|DRUG|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
214639944|NCT00288080|DRUG|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
214639945|NCT00288080|RADIATION|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
214639946|NCT00288080|DRUG|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
214725663|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
214725664|NCT03986476|DIETARY_SUPPLEMENT|Probiotics|5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
214639947|NCT04206449|OTHER|Therapeutic decision PSG|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
214639948|NCT04206449|OTHER|Therapeutic decision Infrared thermgraphy system|Also randomizing for Infrared thermography system
214639949|NCT03524261|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214639950|NCT03524261|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214639951|NCT05813509|DEVICE|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
214639952|NCT05117359|DEVICE|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
214639953|NCT05275062|DRUG|IM92 CAR-T cells|2.5×10\^8 CAR-T cells
214639954|NCT00853697|OTHER|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
214639955|NCT01714271|BEHAVIORAL|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
214639956|NCT01714271|BEHAVIORAL|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
214639957|NCT01137383|DRUG|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
214639958|NCT03170674|OTHER|FT21039|an electronic cigarette product
214639959|NCT03170674|OTHER|FT21092|an electronic cigarette product
214639960|NCT03170674|OTHER|FT21018|an electronic cigarette product
214639961|NCT02392182|OTHER|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
214725665|NCT03986476|OTHER|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
214725666|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
214725667|NCT02658149|DRUG|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
214725668|NCT02658149|DRUG|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
214639962|NCT05868850|BEHAVIORAL|auricular point sticking|"1. Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~2. Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~3. Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
214639963|NCT01505907|DRUG|CXB909|CXB909
214725669|NCT02658149|DRUG|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
214725670|NCT02658149|DRUG|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
214725671|NCT02658149|DRUG|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
214725672|NCT03456414|OTHER|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
214639964|NCT04566575|OTHER|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
214639965|NCT04566575|OTHER|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
214639966|NCT04642339|BIOLOGICAL|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
214639967|NCT04642339|BIOLOGICAL|Placebo|Placebo
214639968|NCT03712579|DIETARY_SUPPLEMENT|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
214639969|NCT03712579|DIETARY_SUPPLEMENT|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
214725673|NCT04709250|PROCEDURE|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
214639970|NCT04315896|DRUG|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
214639971|NCT04315896|DRUG|Placebo oral tablet|Placebo oral tablet
214639972|NCT04128540|DRUG|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
214639973|NCT04128540|PROCEDURE|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
214639974|NCT00104546|PROCEDURE|Acupuncture point injection of vitamin K|
214639975|NCT05019105|DRUG|Placebo|Oral matching placebo
214639976|NCT05019105|DRUG|ALKS 1140|Active oral dose of ALKS 1140
214639977|NCT00065338|BEHAVIORAL|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
214639978|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
214639979|NCT00911131|PROCEDURE|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
214639980|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
214639981|NCT01235962|DRUG|pazopanib|Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
214639982|NCT01235962|DRUG|placebo|Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
214639983|NCT01235962|DRUG|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
214639984|NCT01235962|DRUG|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
214639985|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 72 weeks
214639986|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 48 weeks
214639987|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
214639988|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
214639989|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
214639990|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
214639991|NCT01308866|BEHAVIORAL|Share decision tool|
214639992|NCT03462056|DIETARY_SUPPLEMENT|Cystic Fibrosis Ready to Use Supplemental Food|Specially formulated for use by children with Cystic Fibrosis
214639993|NCT01331304|DRUG|Lithium|600-900mg per day over 6 months
214639994|NCT01331304|DRUG|Quetiapine|100-800mg a day over 6 months
214639995|NCT01580397|DRUG|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
214639996|NCT02303626|DRUG|BCX4161|
214639997|NCT02303626|DRUG|Placebo|
214639998|NCT04926779|DIAGNOSTIC_TEST|Biozek Covid-19 Antigen Rapid Test (Saliva)|Self-collection of nasopharyngeal and saliva samples and self test performance - Biozek Covid-19 Antigen Rapid Test (Saliva) and Biozek Covid-19 Antigen Rapid Test (Nasopharyngeal Swab). Both procedures are supervised by trained study personnel.
214639999|NCT02596412|OTHER|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
214640000|NCT05883189|DIAGNOSTIC_TEST|Draw blood|Draw blood from human body and make into serum to test
214640001|NCT04873479|DRUG|S-ketamine|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
214640002|NCT04873479|OTHER|saline|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
214640003|NCT05250661|OTHER|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
214640004|NCT05787847|BEHAVIORAL|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
214640005|NCT05787847|BEHAVIORAL|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
214640006|NCT06468059|DEVICE|Layered Low Profile Foot|The layered LPF is a novel low-profile prosthetic foot that provides compliant behavior while simultaneously exhibiting high mechanical strength.
214640007|NCT06468059|DEVICE|Prescribed Ankle|The prescribed ankle is the prosthetic ankle that the subject wears for daily use.
214640008|NCT02199197|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
214640009|NCT02199197|DRUG|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
214640010|NCT01881464|DEVICE|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
214640011|NCT01881464|DRUG|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
214640012|NCT04943328|DEVICE|Total Hip Arthroplasty|cemented hip arthroplasty
214640013|NCT06098729|BEHAVIORAL|Digital Exercise|A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
214640014|NCT04620460|DEVICE|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
214640015|NCT04662580|DRUG|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
214640016|NCT04662580|DRUG|Apalutamide|Oral tablet and will be given once daily by mouth.
214640017|NCT04662580|DRUG|Abiraterone acetate|Oral tablet and will be given once daily by mouth.
214640018|NCT04662580|DRUG|Prednisone|Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
214640019|NCT06822881|DRUG|CAR-T Therapy|CT1190B cells infusion
214640020|NCT02129660|DRUG|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
214640021|NCT02129660|DRUG|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
214640022|NCT02129660|DRUG|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
214640023|NCT02129660|DRUG|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
214640024|NCT02129660|OTHER|Vehicle|Vehicle Topical Wipes
214640025|NCT04179643|BIOLOGICAL|3 x 10e13vg AB-1002|There are 2 components to AB-1002. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
214640026|NCT03433222|DEVICE|HF-LED-RL Phototherapy|"The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
214725674|NCT04709250|PROCEDURE|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
214640027|NCT03433222|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
214640028|NCT04145414|DEVICE|MRI|Reproductibility test assessed with MRI for cerebrospinal fluid movements
214640029|NCT02555735|DRUG|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
214640030|NCT02103530|OTHER|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
214640031|NCT06072885|OTHER|Lung Ultrasound Scoring|Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
214640032|NCT04116112|DRUG|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
214640033|NCT04116112|DRUG|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
214640034|NCT04116112|DRUG|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
214640035|NCT02418416|OTHER|Oocyte double chemical activation|Oocyte double chemical activation
214640036|NCT03592446|DEVICE|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
214640037|NCT03592446|DEVICE|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
214640038|NCT00220012|PROCEDURE|Folate depletion and supplementation|
214640039|NCT03912077|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
214640040|NCT02448407|BIOLOGICAL|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
214640041|NCT02448407|DRUG|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
214640042|NCT00303251|DRUG|TKI258|
214640043|NCT04222166|BIOLOGICAL|CAM|Cryopreserved Amniotic Membrane
214640044|NCT03296046|BIOLOGICAL|Blood test|30 ml
214640045|NCT02189135|DEVICE|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
214640046|NCT06426069|OTHER|Masticatory efficiency assessment|Masticatory efficiency will be assessed for each group.
214640047|NCT04307108|DEVICE|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy \[29\] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
214640048|NCT02634723|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|
214640049|NCT04925752|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
214640050|NCT04925752|DRUG|F/TDF|Tablets administered orally
214640051|NCT04925752|DRUG|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
214640052|NCT04925752|DRUG|Placebo SC LEN|Administered via SC injections
214640053|NCT04925752|DRUG|PTM F/TDF|Tablets administered orally
214640054|NCT04925752|DRUG|PTM Oral LEN|Tablets administered orally
214640055|NCT04925752|DRUG|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
214640056|NCT06492096|DEVICE|Bibloc Mandibular Advancement device|Each patient received a CAD/CAM designed Bibloc Mandibular Advancement device
214640057|NCT04581980|OTHER|Exercise|Participants will exercise on a cycle ergometer
214640058|NCT02163174|DRUG|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
214640059|NCT02163174|DRUG|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
214640060|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 4mg|
214640061|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 6mg|
214640062|NCT06095856|DEVICE|Leaf Gauge|Occlusal device used to locate centric relation of the jaws
214640063|NCT06095856|DEVICE|Lucia Jig|Occlusal device used to locate centric relation of the jaws
214640064|NCT06095856|DEVICE|Kois Deprogrammer|Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
214640065|NCT03467958|DRUG|Ozanimod|Specified dose on specified days
214640066|NCT02692209|DEVICE|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
214640067|NCT02692209|DEVICE|FFDM Alone|FFDM Alone Images
214640068|NCT00868946|DRUG|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
214640069|NCT04515784|BEHAVIORAL|Safety Aid Reduction Treatment for PTSD|START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
214640070|NCT01109030|DRUG|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
214725675|NCT04709250|DRUG|bupivacaine|bupivacaine
214725676|NCT00478595|DRUG|Rimonabant|Tablet, oral administration
214725677|NCT00478595|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214725678|NCT00478595|DRUG|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
214725679|NCT04358991|DRUG|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
214725680|NCT01329068|BEHAVIORAL|individual consult|regular individual consultations
214725681|NCT01329068|BEHAVIORAL|group medical consult|group medical consult
214725682|NCT01397513|DRUG|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
214725683|NCT04481945|DRUG|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
214725684|NCT04331210|DRUG|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
214725685|NCT06179108|DRUG|LB-102|LB-102 is a dopamine D2/3 and 5HT7 antagonist.
214725686|NCT04228107|DEVICE|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
214725687|NCT03209011|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
214725688|NCT00668850|DRUG|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
214725689|NCT00668850|DRUG|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
214725690|NCT03053401|PROCEDURE|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
214640071|NCT01109030|DRUG|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
214640072|NCT05272033|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
214640073|NCT03183674|DRUG|Oxytocin|Single dose oxytocin 45 minutes before the test
214640074|NCT03183674|OTHER|placebo|saline solution 0,9% spray nasal
214640075|NCT06447467|DIAGNOSTIC_TEST|pro BNP|Test is mainly used to help diagnose or rule out heart failure in a person who is having symptoms
214640076|NCT00006465|DRUG|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
214640077|NCT00006465|DRUG|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
214640078|NCT00006465|DRUG|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
214640079|NCT04198857|BEHAVIORAL|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
214640080|NCT04172051|BEHAVIORAL|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
214640081|NCT00286676|DRUG|Nutropin|
214640082|NCT00286676|PROCEDURE|Oral Glucose Tolerance Test|
214640083|NCT00286676|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
214640084|NCT00286676|PROCEDURE|Computed Tomography (CT) Scan|
214640085|NCT06962839|DRUG|BI 1815368|BI 1815368
214640086|NCT06962839|DRUG|Placebo|Placebo matching BI 1815368
214640087|NCT05237895|DIAGNOSTIC_TEST|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
214640088|NCT03757104|BEHAVIORAL|micro-incentive|Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
214640089|NCT03757104|BEHAVIORAL|EPIC-HIV|Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
214640090|NCT03757104|BEHAVIORAL|micro-incentive and EPIC-HIV|"micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care."
214640091|NCT01211379|BEHAVIORAL|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
214640092|NCT02813772|DIETARY_SUPPLEMENT|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
214640093|NCT02813772|DIETARY_SUPPLEMENT|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
214640094|NCT05506059|DIAGNOSTIC_TEST|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
214640095|NCT06450197|DRUG|AZD7798|AZD7798
214640096|NCT06450197|OTHER|Placebo|Placebo
214640097|NCT00368576|DRUG|SB 480848, tablets|
214640098|NCT04999579|DEVICE|T scan|Occlusal load analysis
214640099|NCT05615636|DRUG|Mosunetuzumab|Given by IV (vein)
214640100|NCT05615636|DRUG|Polatuzumab vedotin|Given by IV (vein)
214640101|NCT05615636|DRUG|Tafasitamab|Given by IV (vein)
214725691|NCT03053401|PROCEDURE|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
214640102|NCT05615636|DRUG|Lenalidomide|Given by PO
214640103|NCT03356184|DEVICE|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214640104|NCT03356184|DEVICE|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214640105|NCT06282848|DRUG|Atropine 0.05%|Topical application
214640106|NCT06282848|DEVICE|DIMS lens|Spectacle wear
214640107|NCT06269679|DIAGNOSTIC_TEST|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
214640108|NCT04919512|DRUG|TAR-200|TAR-200 will be administered.
214640109|NCT04919512|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
214640110|NCT06567015|DRUG|STX-241|"Film-coated tablet~Route of administration: Oral"
214640111|NCT05708014|BEHAVIORAL|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
214640112|NCT05708014|BEHAVIORAL|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
214640113|NCT04663308|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
214640114|NCT04663308|DRUG|Placebo|Capsules matched to study drug minus active substance
214640115|NCT00455598|DRUG|ISIS 113715|doses of 100 and 200 mg per week
214640116|NCT05226624|BEHAVIORAL|Rooming-in care|Implementation of Rooming-in model of care
214640117|NCT05226624|BEHAVIORAL|Baseline standard of care|Baseline standard of care
214640118|NCT06428357|DIETARY_SUPPLEMENT|Recombinant Bovine Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
214640119|NCT06428357|DIETARY_SUPPLEMENT|Bovine Milk-Derived Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
214640120|NCT06428357|DIETARY_SUPPLEMENT|Placebo|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
214640121|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
214640122|NCT04507737|OTHER|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
214640123|NCT04906668|PROCEDURE|Cryoballoon pulmonary-vein isolation|Electrical isolation of the pulmonary-veins using cryoenergy
214640124|NCT04906668|PROCEDURE|Pacemaker implantation and ablation of atrioventricular-node|Pacemaker implantation and ablation of atrioventricular-node
214640125|NCT06386887|BEHAVIORAL|Intermittent Fasting|Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).
214640126|NCT06386887|DRUG|Neoadjuvant chemotherapy|Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
214640127|NCT06182579|DRUG|RiMO-401|• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
214640128|NCT06970405|DRUG|Garetosmab|Administered per the protocol
214640129|NCT06970405|DRUG|Matching Placebo|Administered per the protocol
214640130|NCT06289985|DEVICE|Endovascular thrombectomy with any FDA-approved category POL or NRY device|Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)
214640131|NCT06289985|OTHER|Medical Management|Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.
214640132|NCT06235151|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
214640133|NCT06541704|DRUG|Pozelimab|Subcutaneous (SC) injection
214640134|NCT06541704|DRUG|Cemdisiran|SC injection
214640135|NCT06541704|DRUG|Placebo|SC injection
214725692|NCT03053401|DEVICE|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
214725693|NCT03053401|DEVICE|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
214725694|NCT03053401|DRUG|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
214725695|NCT03053401|DRUG|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
214725696|NCT01973972|BEHAVIORAL|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
214725697|NCT01973972|BEHAVIORAL|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
214725698|NCT01519336|DRUG|danoprevir|100 mg q12h
214725699|NCT01519336|DRUG|darunavir|600 mg q12h
214725700|NCT01519336|DRUG|ritonavir|100 mg q12h
214725701|NCT01804842|DRUG|Met DR|metformin delayed-release tablets
214725702|NCT00862498|OTHER|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
214725703|NCT04248556|OTHER|Health care product|Health care product (gel) - to be applied on the participant's skin
214725704|NCT06234085|OTHER|VCA feedback report available|Access to feedback report described in the intervention
214725705|NCT03797885|OTHER|No treatment given|No treatment is administered to the participants for this study
214725706|NCT03734770|DRUG|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
214725707|NCT03734770|DRUG|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
214725708|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
214725709|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
214725710|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
214725711|NCT00728195|DRUG|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
214725712|NCT00728195|DRUG|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
214725713|NCT01738074|BIOLOGICAL|trivalent rotavirus genetic reassortment vaccine|
214725714|NCT01738074|BIOLOGICAL|Placebo|
214725715|NCT01440972|OTHER|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
214725716|NCT01440972|OTHER|low intensity resistance training|low intensity resistance training without partial blood flow restriction
214725717|NCT02811081|PROCEDURE|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
214725718|NCT02811081|PROCEDURE|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
214725719|NCT02811081|PROCEDURE|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
214725720|NCT03933215|DRUG|Cladribine|Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
214725721|NCT02964182|DRUG|Cigarette|Smoke usual brand of cigarettes
214725722|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
214725723|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
214725724|NCT02964182|OTHER|Questionnaire Administration|Ancillary studies
214725725|NCT02964182|OTHER|Survey Administration|Ancillary studies
214725726|NCT02964182|DRUG|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
214725727|NCT02964182|DEVICE|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
214725728|NCT02964182|DEVICE|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
214725729|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
214725730|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
214725731|NCT04821297|OTHER|Health Promotion and Education|Receive messages
214725732|NCT04821297|OTHER|Survey Administration|Complete survey
214725733|NCT04821297|OTHER|Interview|Participate in an interview
214725734|NCT04222673|BEHAVIORAL|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
214725735|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
214725736|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
214725737|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214725738|NCT04097028|DRUG|Oxaliplatin|Given IV
214725739|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
214725740|NCT05799755|DRUG|Placebo|Placebo comparator
214725741|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
214725742|NCT06071923|DEVICE|Fibroscan|Scan the liver for metabolic fatty changes
214725743|NCT05010395|BEHAVIORAL|Letter intervention|Letter intervention
214725744|NCT00954473|OTHER|laboratory biomarker analysis|Correlative studies
214725745|NCT02766049|BIOLOGICAL|DC|Autologous dendritic cells (3x10e7)
214725746|NCT02766049|BIOLOGICAL|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
214725747|NCT02766049|BIOLOGICAL|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
214725748|NCT00068822|DEVICE|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
214640136|NCT04867317|DRUG|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
214640137|NCT04867317|OTHER|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
214640138|NCT06102434|DRUG|Psilocybin|Five oral capsules containing 5 mg of psilocybin each
214640139|NCT06085352|DRUG|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
214640140|NCT06085352|DEVICE|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
214640141|NCT03933696|DEVICE|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
214640142|NCT04547504|DRUG|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
214640143|NCT04547504|DRUG|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
214640144|NCT02270359|DEVICE|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
214640145|NCT02270359|PROCEDURE|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
214640146|NCT02270359|DRUG|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
214640147|NCT06357247|DEVICE|Sensory Threshold|Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits
214640148|NCT06357247|BEHAVIORAL|Nine Hole Peg Test|The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.
214640149|NCT06357247|BEHAVIORAL|Semmes Weinstein Monofilament Assessment|A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
214640150|NCT03403686|BIOLOGICAL|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
214725749|NCT00068822|PROCEDURE|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
214725750|NCT04944758|DEVICE|Light therapy|Light therapy
214725751|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|DBS Active Treatment Group - implanted with investigational device and activated for stimulation
214725752|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
214725753|NCT03881644|DRUG|Imigran|All patients will undergo this intervention on one of two study days
214725754|NCT03881644|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
214725755|NCT03881644|OTHER|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
214725756|NCT00489502|BEHAVIORAL|Brief Counseling|
214725757|NCT00489502|DEVICE|REE Assessment|
214640151|NCT05072314|DRUG|lidocaine 2% and 10%|"Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
214640152|NCT05072314|DRUG|Placebo|"Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
214725758|NCT03073369|DRUG|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
214725759|NCT03073369|DRUG|Placebo|Oral Placebo - one capsule once daily for 6 weeks
214725760|NCT02837055|DEVICE|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
214725761|NCT02837055|DEVICE|conventional intubation|patients are intubated with a conventional endotracheal tube
214725762|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
214725763|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
214725764|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
214725765|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
214725766|NCT01960179|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
214725767|NCT03227094|DIAGNOSTIC_TEST|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage
214725768|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
214725769|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
214725770|NCT03638362|DIETARY_SUPPLEMENT|Placebo|Participants consumed placebo beverage for 4 weeks.
214725771|NCT03638362|DIETARY_SUPPLEMENT|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
214725772|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
214640153|NCT04342975|DRUG|Nicotinamide Riboside + Pterostilbene|It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
214725773|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
214725774|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
214725775|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
214725776|NCT04525560|OTHER|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
214725777|NCT04525560|OTHER|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
214725778|NCT00914095|DRUG|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
214725779|NCT00914095|DRUG|placebo|tablets of placebo 3 times a day
214725780|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
214725781|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
214725782|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
214725783|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
214725784|NCT04741204|DRUG|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
214725785|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
214725786|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
214725787|NCT05844774|DEVICE|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
214640154|NCT04342975|DRUG|Placebo|The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
214640155|NCT02886143|PROCEDURE|Active Voiding Trial|"Nursing protocol:~1. Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~2. Clamp the Foley~3. Deflate the catheter balloon and remove the catheter from the bladder.~4. Record the amount of saline that was instilled into the bladder.~5. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7\. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
214640156|NCT02886143|PROCEDURE|Passive Voiding Trial|"Nursing protocol:~1. Deflate the catheter balloon and remove the catheter from the bladder.~2. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~3. 5\. If the patient has not voided within 5 hours, assist the patient to try to void.~6\. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7\. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
214640157|NCT04202679|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214640158|NCT04202679|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214640159|NCT04202679|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
214640160|NCT04202679|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
214640161|NCT04202679|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
214640162|NCT04201119|DEVICE|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
214640163|NCT05505552|DIETARY_SUPPLEMENT|Vitamin K|1 mg/day phylloquinone (vitamin K1)
214640164|NCT05505552|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
214725788|NCT05844774|DEVICE|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
214725789|NCT03163940|BEHAVIORAL|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
214640165|NCT06027905|OTHER|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
214640166|NCT01680900|DRUG|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
214640167|NCT01680900|DRUG|placebo capsules|placebo capsules matched to drug capsules.
214640168|NCT06975046|DEVICE|Complete airflow interruption|Participants will produce a sustained vowel into a mouthpiece (with nose-clip) connected to a PVC tube, with a balloon valve
214640169|NCT06975046|DEVICE|Incomplete airflow interruption|Incomplete airflow interruption uses a Y-shaped device. The participant produces a sustained /a/ into a mouthpiece and air filter connected to the tube. The tube splits into two tubes distally.
214640170|NCT06975046|DEVICE|Airflow redirection|Participant phonates through a mouthpiece into a PVC tube that splits into two paths. One path is connected to an open balloon valve. When the balloon is inflated and blocks the path, air is redirected into the other path which is gated by a one-way valve.
214640171|NCT05434637|OTHER|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
214640172|NCT05434637|OTHER|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
214640173|NCT05434637|OTHER|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
214640174|NCT03939481|DRUG|Chemotherapy|Given chemotherapy regimen
214640175|NCT03939481|OTHER|Functional Assessment|Functional and sensory clinician assessments
214640176|NCT03939481|OTHER|Questionnaire Administration|Patient and physician reported responses
214640177|NCT06812260|DRUG|HLX10+chemo|Treatment arm
214640178|NCT06841575|DEVICE|Auto-aligned OCT|Swept Source OCT system with improved hand-held probe technology for auto-alignment to the patient's eye, as well as on-line detection of image quality and auto-saving at the proper time
214640179|NCT06995820|DRUG|AZD1613|AZD1613 will be administered as either SC injection or IV infusion on Day 1 in Part A and on Days 1, 29 and 57 in Part B of the study.
214640180|NCT06995820|DRUG|Placebo|Placebo will be administered as either SC injection or IV infusion on Day 1 in Part A and Days 1, 29 and 57 in Part B fo the study.
214640181|NCT06672224|PROCEDURE|Fluid Therapy|Given IV
214640182|NCT06672224|DRUG|Indocyanine Green|Given subcutaneously
214640183|NCT06672224|OTHER|Questionnaire Administration|Ancillary studies
214640184|NCT06672224|OTHER|Research or Clinical Assessment Tool|Undergo lymphedema assessment
214640185|NCT06672224|PROCEDURE|SPY Elite Fluorescence Imaging|Undergo SPY imaging
214640186|NCT06672224|OTHER|Survey Administration|Ancillary studies
214640187|NCT06807593|DRUG|Ustekinumab|Given by infusion
214640188|NCT07001891|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
214640189|NCT07001891|BEHAVIORAL|auto-questionnaires (PSQI, ISI, ESS and HADS)|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
214640190|NCT07001891|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administered per day during 14 days by a study-dedicated Android OS smartphone
214640191|NCT07001891|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
214640192|NCT07001891|BEHAVIORAL|auto-questionnaires (ASRS, PSAS, APS, MAIA-2)|Interoceptive awareness and accuracy estimation : Adult ADHD Self-Report Scale (ASRS), Pre-Sleep Arousal Scale (PSAS), Arousal Predisposition Scale (APS) et Multidimensional Assessment of Interoceptive Awareness version 2 (MAIA-2)
214640193|NCT07001891|DEVICE|MRI|Morning and evening functional brain imaging
214640194|NCT06615479|DRUG|BMS-986393|Specified dose on specified days
214640195|NCT06615479|DRUG|Cyclophosphamide|Specified dose on specified days
214640196|NCT06615479|DRUG|Fludarabine|Specified dose on specified days
214640197|NCT06615479|DRUG|Daratumumab|Specified dose on specified days
214640198|NCT06615479|DRUG|Pomalidomide|Specified dose on specified days
214640199|NCT06615479|DRUG|Dexamethasone|Specified dose on specified days
214640200|NCT06615479|DRUG|Carfilzomib|Specified dose on specified days
214640201|NCT06865781|OTHER|Forgone overnight vital signs|No vital signs (temp, heart rate, respiratory rate, blood pressure, oxygen saturation) taken at 0000 or 0400
214640202|NCT06258200|BEHAVIORAL|Gender and immunization activities|Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.
214640203|NCT06258200|OTHER|No intervention|Participants in the comparison group will not receive any intervention
214640204|NCT06869447|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214640205|NCT06869447|OTHER|Electronic Health Record Review|Ancillary studies
214640206|NCT06869447|OTHER|Medical Device Usage and Evaluation|Use Power Lung breathing device
214640207|NCT06869447|OTHER|Questionnaire Administration|Ancillary studies
214640208|NCT06869447|PROCEDURE|Respiratory Muscle Training|Participate in RMT sessions
214640209|NCT06869447|PROCEDURE|Sham Intervention|Participate in sham sessions
214640210|NCT07012863|BIOLOGICAL|Dry plasma|Patient that fulfil the inclusion criteria for this study and are randomized for active treatment will get dry plasma as intervention.
214640211|NCT05016245|COMBINATION_PRODUCT|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
214640212|NCT05016245|PROCEDURE|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
214640213|NCT03206060|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
214640214|NCT03206060|DRUG|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
214640215|NCT03206060|DRUG|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
214640216|NCT03206060|DRUG|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
214640217|NCT04372641|DRUG|p97 Inhibitor CB-5339 Tosylate|Given PO
214640218|NCT06880198|DIETARY_SUPPLEMENT|Oral Impact®|One Arm: 2 Impact brick/d for 21 days + 1 brick/d for 14 days, starting exactly one week before Anti PD-1 treatment in patients with inoperable locally advanced or metastatic melanoma Treatment duration: 35 days
214640219|NCT07137923|BEHAVIORAL|Clinical decision support + education (CDS+)|Intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
214640220|NCT07137923|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
214640221|NCT07037641|OTHER|Lumbar Spine Manipulation|Painful lumbar segments will be identified through palpation of the spinous and transverse processes. Patients will be positioned side-lying with head supported by a pillow. The lower arm will rest across the chest, and the lower leg will be extended while the upper leg will be flexed, with the foot placed in the popliteal space. The practitioner will assume a 45-degree angled stance, stabilizing the patient's pelvis between their thighs. The hypothenar eminence will contact the mammillary process of the dysfunctional vertebra, while the opposite hand stabilizes the upper shoulder. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction toward the patient's umbilicus. This technique will be performed twice per week for two weeks (4 sessions total), alongside conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
214725790|NCT06250504|DRUG|APRETUDE (cabotegravir) 600 mg\3 mL|choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
214640222|NCT07037641|OTHER|Sacroiliac Joint Manipulation|The side for sacroiliac joint manipulation will be determined using the Derifield leg length test. Based on functional leg length differences, a PI (posterior-inferior) ilium will be identified. Patients will be positioned side-lying with appropriate limb and trunk alignment. The practitioner's hypothenar eminence will be placed on the PSIS of the dysfunctional side. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction from the PSIS toward the patient's umbilicus to correct the joint dysfunction. The manipulation will be performed twice a week over two weeks (4 sessions in total), combined with conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
214640223|NCT07037641|OTHER|Conventional Physiotherapy|Conventional physiotherapy will consist of hot pack, TENS, therapeutic ultrasound, and supervised exercises applied over two weeks (6 sessions/week). Hot packs filled with silicate gel will be wrapped in four towel layers and applied for 20 minutes with the patient prone and a pillow under the abdomen. TENS will be delivered via Chattanooga Intelect device with a symmetrical biphasic program for 30 minutes using four electrodes placed on the treatment area. Ultrasound will be applied continuously for 3 minutes with the same device. Patients will be instructed on lumbar mobility and strengthening exercises, performed twice daily with 15 repetitions each. No spinal or sacroiliac manipulation will be performed in this group.
214640224|NCT07122895|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of negative symptoms
214640225|NCT07122895|DRUG|Placebo Cap|Use of placebo as a comparator
214640226|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive enhanced delivery half-price food boxes delivered by a community health worker
214640227|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive the standard half-price produce box delivery delivered by FreshFix staff
214640228|NCT07039630|OTHER|Health Promotion and Education|Receive nutritional education materials and resources
214640229|NCT07039630|OTHER|Questionnaire Administration|Ancillary studies
214640230|NCT07039630|OTHER|Survey Administration|Ancillary studies
214640231|NCT07039630|BEHAVIORAL|Telephone-Based Intervention|Receive a dietary recall phone call
214640232|NCT06921733|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
214640233|NCT06721416|OTHER|Traditional Aerobic Exercise|Traditional aerobic exercise will be continued with an arm ergometer, at moderate intensity, for 30 minutes.
214640234|NCT06721416|OTHER|VR Based Aerobic Exercise|"In the virtual reality-based aerobic exercise training, the game called Beat Saber will be played with Oculus Quest 2 virtual reality for 30 minutes."
214640235|NCT06721416|OTHER|Conventional Exercise|The conventional exercise program will be modified with stabilization, balance and strengthening exercises, taking into account the functional status of the participants.
214640236|NCT06733025|PROCEDURE|Tendon lengthening surgery|The participants will first receive BoNT injections, earliest three months after they will undergo tendon lengthening surgery
214640237|NCT06733025|DRUG|BoNT Injections|The dosage and number of injected muscles will vary depending on the degree and extent of spasticity. All patients had previous BoNT injections, one injection circle will be followed in this study.
214640238|NCT06892522|DRUG|Etentamig|Intravenous (IV) Infusion
214640239|NCT06892522|DRUG|Lenalidomide|Oral Capsule
214640240|NCT06892522|DRUG|Dexamethasone|IV Injection
214640241|NCT06892522|DRUG|Daratumumab|Subcutaneous Injection
214640242|NCT06892522|DRUG|Dexamethasone|Oral Tablet
214640243|NCT06892522|DRUG|Carfilzomib|IV Infusion
214640244|NCT06738394|BEHAVIORAL|High-Velocity Resistance Training|High-velocity resistance training for patients with non-dialysis dependent chronic kidney disease Stages 3-5 with mobility limitations.
214640245|NCT06738394|BEHAVIORAL|Attention|Dedicated contact, information, and motivation throughout the course of the study via weekly group sessions and informational handouts.
214640246|NCT05811351|DRUG|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
214640247|NCT05811351|DRUG|Prednisone|Prednisone will be administered as oral capsule.
214640248|NCT05811351|OTHER|Placebo|Prednisone matching placebo will be administered as oral capsule.
214640249|NCT05811351|DRUG|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
214640250|NCT05811351|OTHER|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
214640251|NCT07055607|DRUG|Semaglutide|Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.
214640252|NCT07060976|OTHER|18 Transdermal patches along with positive and negative controls 1)Capsaicin0.025% Topical Patch, 2)Diclofenac Diethylamine 100mg Transdermal Patch, 3)Diclofenac Diethylamine 200mg Transdermal Patch,|Dose: 1×1 cm of each Patch (1 cm2) Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 24 hours. At 24 hours post-application, patches will be removed and skin will be evaluated for irritation reactions at 30 mins,24 hours (Day 1)post patch removal and 168 hours (Day 7) post-patch removal (if needed). Frequency: single application
214640253|NCT07057141|DEVICE|Biorepair Total Protection Toothpaste|Application of Biorepair Total Protection toothpaste for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
214640254|NCT07057141|DEVICE|Biorepair High-Density Mouthwash|Application of Biorepair High-Density mouthwash for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
214640255|NCT06897618|BEHAVIORAL|Culturally tailored diabetes self-management education|Five weeks of culturally tailored diabetes self-management education modeled after Association of Diabetes Care and Education Seven-item Framework (ADCES7).
214640256|NCT06781749|DEVICE|Hearing aid use|Hearing aid use will be discussed with all eligible participants with hearing loss and will be encouraged to pursue hearing aid fitting through standard clinical indications via participants' insurance and audiologists.
214640257|NCT07063602|OTHER|Evaluation of the hypoesthesia of the thorax|In the recovery room, a member of the research team will come to assess the presence of hypoesthesia (loss of sensation) of the thorax using ice and a Von Frey filament applied at three different sections: midscapular, midaxillary and midclavicular.
214640258|NCT07073807|BEHAVIORAL|SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring|The SMART intervention uses TAPPT® smart labels and a web-based app for real-time monitoring of oral anticancer therapy adherence. It includes personalized text reminders, biweekly surveys for medication adherence and symptom burden, missed and extra dose management, symptom alerts to providers, monthly financial and health-related social needs screening with tailored resources, and educational texts for low health literacy. TAPPT® smart labels work with Android/iOS smartphones. All participants receive usual oncology care.
214640259|NCT06837870|DEVICE|percutaneous suture mediated closure|Vascular closure with a commercially available SMC device.
214640260|NCT06837870|DEVICE|Figure of Eight Suture|Manual Compression with Figure of Eight Suture (control).
214640261|NCT06901960|DEVICE|A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L)|A mobile AI-enhanced electrocardiogram device will be used to help patients monitor hyperkalemia. The device, shaped like a stick of chewing gum, collects time-series data of electrocardiogram lead I through two electrodes. Deep convolutional neural network algorithm can read the data and generated categories of plasma potassium (\<5 mmol/L, 5 - \<5.5 mmol/L, 5.5 - \<6.0 mmol/L and ≥ 6.0 mmol/L). Study participants receive the device after randomization. The staff establishes a WeChat group for each participant and reminds them to monitor plasma potassium every 3 days. When the detected plasma potassium category falls in 5 - \<5.5 mmol/L, they will be reminded to watch diet and to verify plasma potassium again. More intensive reminding (once daily) will be sent if plasma potassium category falls in 5.5 - \<6.0 mmol/L or ≥ 6.0 mmol/L. An extra outpatient appointment will also be made as soon as possible for the patients when their detected plasma potassium category is ≥ 6.0 mmol/L.
214640262|NCT07138027|BEHAVIORAL|Clinical decision support + education (CDS+) and population health management (PHM)|In Interval 1, intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+). In Interval 2, intervention clinics will have CDS+ and population health management (PHM) strategies, including an asthma community health worker and an asthma nurse care manager.
214640263|NCT07138027|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
214640264|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
214640265|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
214640266|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
214640267|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
214640268|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
214640269|NCT06925061|DRUG|After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks|Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).
214640270|NCT05321082|DRUG|BI 1015550|BI 1015550
214640271|NCT05321082|DRUG|Placebo|Placebo
214640272|NCT07102316|DRUG|TPIP F2|Inhalation using a capsule-based dry powder inhaler device.
214640273|NCT07102316|DRUG|TPIP F3|Inhalation using a capsule-based dry powder inhaler device.
214640274|NCT07101198|PROCEDURE|Ultrasound-guided erector spinae plane block|Patients in this group will receive an ultrasound-guided erector spinae plane block 30 minutes before surgery. A total volume of bupivacaine will be injected bilaterally into the fascial plane between the erector spinae muscle and the transverse process. All patients will also receive standard postoperative analgesia.
214640275|NCT05705219|DIAGNOSTIC_TEST|3D-MPUS|Participants will receive approximately \< 20 minutes ultrasound scan to locate the lesion followed by acquisition of 3D-MPUS acquisition.
214640276|NCT07104500|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
214640277|NCT05807139|OTHER|Placebo|Placebo
214640278|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
214640279|NCT07107204|DRUG|BT02|BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks
214640280|NCT07104279|DEVICE|Z1 Femoral Hip System|Subjects who will be implanted with the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty
214640281|NCT06828666|BIOLOGICAL|Cryopreserved Devitalized Adipose Tissue Allograft|BRC-OA is a Cryopreserved Devitalized Adipose Tissue Allograft that has demonstrated anti-inflammatory and antioxidant properties of adipose tissue.
214640282|NCT06828666|OTHER|Normal Saline (Placebo)|2 mL Normal Saline
214640283|NCT06560632|DRUG|RP-3467 at assigned dose and schedule|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
214640284|NCT06560632|DRUG|Olaparib 200-300 mg BID, daily|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
214640285|NCT02522611|DRUG|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
214640286|NCT07108621|DRUG|Choriongonadotropin alfa (hCG)|hCG 260 IU once daily for two menstrual cycles (aproximately 8 weeks) prior til standard IVF/ICSI.
214640287|NCT07108621|DRUG|Isotonic NaCl (Placebo)|Placebo priming (isotone NaCl) once daily for two menstrual cycles (approximately 8 weeks) prior to standard IVF/ICSI.
214640288|NCT07113561|OTHER|High-protein diet and resistance training|Participants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise.
214640289|NCT07113561|OTHER|Balanced control diet|Participants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention.
214640290|NCT07102082|BEHAVIORAL|Modified Risk - None|Participants view ads with no modified risk claim
214640291|NCT07102082|BEHAVIORAL|Modified Risk Claim|Participants view ads with a modified risk claim
214640292|NCT06408168|DRUG|Fulvestrant|Given by PO
214640293|NCT06408168|DRUG|Repotrectinib|Given by IV
214640294|NCT06915090|BEHAVIORAL|Health Coach/Fitbit|"Health coach visits (up to 6) will be conducted virtually and include:~Session 1:~* Assessment, wellness vision,~* Habits and goals (Stretching, strength training, cardiovascular PA/walking, Diet)~* Motivation, resources, and guidelines~* Online program orientation~* Set first week's goals~Sessions 2-5:~-Goal review, successes and challenges, new goal setting (i.e. Increase steps by 1,000/day if consistently meeting goal)45~Session 6~-Review of progress, maintenance plan, final assessment~Once baseline measures are completed, patients without a Fitbit device will be provided one for the duration of the study, which they get to keep. The same option will be available for patients who already have a Fitbit but would like one provided by the study team anyway. The participant will receive their Fitbit device at their baseline study visit. Participants will also be instructed to wear their Fitbit for a total of 12 weeks with a suggested step count."
214640295|NCT07104318|DRUG|Bismuth quadruple therapy with optimized PPI|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.
214725791|NCT06250504|DRUG|DAPIRING (Dapivirine) 25mg Vaginal Ring|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
214725792|NCT06250504|DRUG|tenofovir disoproxil and emtricitabine|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
214725793|NCT06250504|DRUG|Tenofovir Disoproxil, Lamuvidine and Dolutegravir|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
214725794|NCT03749668|OTHER|non applicable|no intervention in this observational study
214725795|NCT03745404|DRUG|Lidocaine 5% medicated Plaster|
214725796|NCT03745404|DRUG|Placebo Plaster|
214725797|NCT02374359|OTHER|follow-up|
214725798|NCT01897259|DRUG|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
214725799|NCT01897259|BEHAVIORAL|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
214725800|NCT01897259|DRUG|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
214725801|NCT01897259|DRUG|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
214725802|NCT00529646|DRUG|APD791|
214725803|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
214725804|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
214725805|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
214725806|NCT06002997|OTHER|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
214725807|NCT06002997|OTHER|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
214725808|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
214725809|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
214725810|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
214640296|NCT07104318|DRUG|Bismuth quadruple therapy with standard PPI|"Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days.~\*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding"
214640297|NCT07104318|DRUG|Clarithromycin triple therapy with optimized PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg QID for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
214640298|NCT07104318|DRUG|Clarithromycin triple therapy with standard PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
214640299|NCT07104318|DRUG|Standard bismuth quadruple therapy|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
214640300|NCT06943105|BEHAVIORAL|Nonviolent Communication Intervention|The intervention will be conducted by social workers who will be trained by professional NVC trainers through a train-the-trainer workshop, including six sessions. The interventions include an introduction to four fundamental principles of NVC, distinguishing observations from evaluations, identifying and expressing feelings, taking responsibility for feelings and needs, and using positive action language to make requests. Each session will feature a review of the previous session, a warm-up game and an exercise to consolidate the learning of the concepts. The intervention sessions will also include group discussions and debriefing sessions on parents' experiences of practising NVC.
214640301|NCT07146438|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered with the MagPro X100 system equipped with a Cool-DB80 coil and a Localite neuronavigation system. Neuronavigation will be performed for anatomical landmarking and co-registration of the brain to Talairach stereotaxic space, with the co-registered coil vertex coordinate (x0, y+60, z+60) as performed in previously published work on dmPFC-rTMS and which represents \~25% of the nasion-inion distance. Posterior coil handle orientation will be used with stimulation parameters of 20Hz repetition rate, 2 second stimulation duration, 20 second inter-train interval, and 50 trains, for a total of 2000 pulses per day. Stimulation will be delivered at 100% of extensor hallucis longus muscle resting motor threshold (MT), as determined by the PI. rTMS will be delivered 5 days per week (Monday through Friday) for 6 weeks for a total of 30 treatment sessions, in keeping with established protocols. Trained research staff will perform daily rTMS treatments and monitor participants.
214640302|NCT07146438|BEHAVIORAL|Supportive Therapy (ST)|"Supportive therapy (ST) is a nondirective talk therapy focused on enhancing coping skills, strengthening existing resources, and improving daily functioning. Core techniques will include active listening, encouragement, validation, reframing, clarification (summarizing and paraphrasing), and naming problems. Participants will receive two ST sessions per week during the 6-week rTMS course. General goals include using the therapeutic relationship to foster adaptation, improve self-esteem, and support overall well-being. Each session will last 53-60 minutes and take place concurrently with rTMS, with the participant remaining in the TMS treatment room throughout."
214640303|NCT07146438|BEHAVIORAL|Exposure and Response Prevention (ERP) Therapy|ERP is a form of cognitive-behavioral therapy designed to reduce obsessive-compulsive symptoms by weakening the association between feared stimuli and maladaptive responses. It promotes the formation and recall of non-threatening associations to counter fear-based learning. The participant and therapist will collaboratively create a hierarchy of OCD triggers, rated using the Subjective Units of Distress Scale (SUDS). ERP will begin with exposures rated 4-7 on the SUDS, while participants refrain from engaging in compulsions. Each trigger will be repeated until the SUDS rating decreases by at least 50% before progressing to the next item. Between-session ERP homework will be assigned, and participants will be provided self-monitoring homework rating forms to complete for subsequent review with the therapist. Each ERP session will last 53-60 minutes and will be conducted concurrently with rTMS, with the participant remaining in the TMS treatment room throughout.
214640304|NCT07158944|BEHAVIORAL|More and Less|Dose: 10 group sessions + 6 individual booster sessions Frequency: 10 weekly group sessions (10 weeks) 6 booster sessions every 6th week
214640305|NCT07162506|PROCEDURE|Surgery|Radical esophagectomy + mediastinal lymph node dissection
214640306|NCT07162506|RADIATION|Radiotherapy|Radiotherapy: 50.4 Gy/28f
214640307|NCT07162506|DRUG|Chemotherapy|Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles
214640308|NCT07169032|DEVICE|Er,Cr:YSGG laser irradiation|irradiation with a 2780 nm, 1.0 W Er,Cr:YSGG laser for 1 minute
214640309|NCT07169032|DRUG|Sham Laser irradiation|sham laser irradiation for 1 minute
214640310|NCT07169032|DRUG|Lidocaine|2% lidocaine gel
214640311|NCT07169032|DRUG|Vaseline|Vaseline
214640312|NCT07166770|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
214640313|NCT07168330|DEVICE|Ankle replacement|Total ankle arthroplasty
214725811|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
214640314|NCT07165158|DRUG|semaglutide combined with metformin|The initial dose of semaglutide is 0.25 mg once weekly. After 4 weeks, the dose is adjusted to 0.5 mg once weekly. After another 4 weeks, the dose is adjusted to 1 mg once weekly. During the same period, they will take metformin (500mg each time, three times a day) for treatment. The treatment course is 12 months.
214640315|NCT07164404|OTHER|EHR alert|EHR embedded alert into the admission note template, where it automatically inserts smoking history, prompts NRT prescribing in the hospital, and offers referral to outpatient follow up.
214640316|NCT07164677|PROCEDURE|Bilateral ultrasound guided Serratus Posterior Superior Plane Block|Bilateral ultrasound-guided Serratus Posterior Superior Plane Block (total of 60 ml, %0.25 bupivacaine) will be performed Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.
214640317|NCT07164677|DRUG|IV morphine patient-controlled analgesia|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
214640318|NCT07164677|PROCEDURE|Bilateral ultrasound guided Sham Block|"Bilateral ultrasound-guided needle placement will be performed in the same anatomical plane as in the SPSIP group, but instead of local anesthetic, an equivalent volume of normal saline (30 mL per side) will be injected.~Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis."
214640319|NCT07169084|OTHER|Manual Therapy|Manual mobilization techniques applied to the cervical and upper thoracic regions, 3 sessions/week for 4 weeks.
214640320|NCT07169084|OTHER|Instrument-Assisted Soft Tissue Mobilization (IASTM)|Mobilization applied with instruments to cervical and upper thoracic muscles, 3 sessions/week for 4 weeks.
214640321|NCT07178509|PROCEDURE|Stress Echocardiography with Contrast|Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
214640322|NCT07178418|OTHER|Muscle Architecture-Based Exercise Program|Participants in this arm will perform exercises specifically designed according to the architectural and functional properties of the triceps surae muscles. For example, knee-flexed positions will be used to target the soleus, while knee-extended positions will be emphasized for the gastrocnemii. Loading intensity and exercise progression will be tailored to optimize tendon and muscle remodeling.
214640323|NCT07178418|OTHER|Alfredson Protocol|This intervention involves the traditional eccentric heel-drop program, originally developed for mid-portion Achilles tendinopathy. Participants perform three sets of 15 repetitions, twice daily, throughout the intervention period. Exercises are carried out both with the knee extended and flexed to load different portions of the triceps surae. The protocol applies repetitive eccentric loading to the Achilles tendon with the aim of stimulating collagen synthesis, reducing symptoms, and promoting tendon adaptation.
214640324|NCT07178158|OTHER|Installing the Metacognium software app|Participants in the NIPA+TAU group will be sent two, URL's (one for iOS and one for Android) for installing the Metacognium software app, which hosts the four NIPA sessions. Participants will be provided with unique ID for registering and using the program on the Metacognium app. The NIPA sessions will be locked until participants have completed their baseline assessment. Once participants complete each NIPA session, they will receive an email and/or text notifying them that the next session is unlocked and that they can proceed to complete it.
214640325|NCT07178158|OTHER|Continue treatment as usual|Continue your treatment schedule as usual with the for 4 weeks.
214640326|NCT07178626|OTHER|Not applicable- observational study|This is a prospective observational study and does not involve any intervention measures
214640327|NCT07177625|PROCEDURE|Retrolaminar block|Ultrasound-guided retrolaminar block performed prior to prone-position ESWL. This intervention is applied only to participants in the RLB Group. Patients will be monitored for pain intensity (VAS), vital signs, procedural duration, and any adverse events during and after the procedure. Rescue analgesia will be administered if clinically indicated.
214640328|NCT07177625|DRUG|Sedoanalgesia|Standard sedoanalgesia administered during prone-position ESWL. This intervention is applied only to participants in the Sedation Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided as needed.
214640329|NCT07177625|OTHER|No Intervention / None|No additional regional block or sedoanalgesia; standard monitoring only. This applies only to participants in the Control Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided if clinically indicated.
214640330|NCT07178314|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|Participants will perform self-implemented at-home transcutaneous tibial nerve stimulation using a transcutaneous electrical nerve stimulation (TENS) unit. Participants will be instructed to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks upon receipt of the device. Intensity will be based on the participant's tolerance, just above the perception threshold but not painful.
214640331|NCT07177963|BEHAVIORAL|HIIT|Exercise sessions were conducted as telemedically supervised, home-based HIIT performed on electric resistance bikes, with protocols individually tailored. Each HIIT session comprised 8 cycles of alternating 30-second high-intensity intervals (HIT at 80% peakVO₂) and 60-second low-intensity recovery intervals (LIT at 50% peakVO₂). Warm-up and cool-down phases were performed with the bike's resistance set to 0 watts (unloaded pedaling). The total intervention duration was 8 weeks. Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
214640332|NCT07177963|BEHAVIORAL|No specific exercise intervention.|The control group will not receive any exercise intervention, and they will be instructed to not take any structured exercise regimens.Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
214640333|NCT07178899|BEHAVIORAL|typology-based intervention|The typology-based intervention includes: (1) typology-based counselling, (2) personalized E-message based on the counselling content discussed (3) a booklet introducing the typology of quit identity. All interventions and materials are delivered by smoking counselling.
214640334|NCT07178899|BEHAVIORAL|Routine Treatment|The routine smoking cessation intervention includes: (1) Routine counselling generic advice on preventing smoking relapse (2) Brief e-messages that consist of general quit advice for 4 weeks. Counsellors implement both routine practices.
214640335|NCT07178301|PROCEDURE|Computed Tomography|Undergo CT
214640336|NCT07178301|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo nasopharyngolaryngoscopy
214640337|NCT07178301|PROCEDURE|Positron Emission Tomography|Undergo PET
214640338|NCT07178301|OTHER|Questionnaire Administration|Ancillary studies
214640339|NCT07178301|RADIATION|Radiation Therapy|Undergo radiation therapy
214640340|NCT07179393|BEHAVIORAL|Ladies Gaelic Football-Specific Injury Prevention Programme|This intervention is an injury prevention programme designed with input from Ladies Gaelic football stakeholders (players and coaches) as well as experienced athletic therapy and physiotherapy practitioners and academics from the disciplines of injury prevention and coaching science.
214640341|NCT07178119|PROCEDURE|(Bridging) Horizontal Cannula Technique for Treatment of Nasolabial Folds using AILEENE Vol. 2|Participants will receive treatment to both NLF using the Bridging Technique. This involves injecting an HA dermal filler (AILEENE Vol. 2) in thin horizontal threads (less than 0.05 milliliters \[ml\] per retrograde placement) under the fold using a blunt cannula. The maximum total dose per participant is 1.0 ml across both folds. Each participant will receive one treatment at baseline (Day 0). An optional single top-up may be given at Week 2 (virtual or in-clinic) or Week 4 if clinically indicated, using only the remaining balance of the 1.0 ml total. Any top-up will be performed with a new, sterile syringe, not with filler left over from the initial treatment. This is a single-treatment course with follow-up for 6 months. Standardized photographs will be taken at Baseline, Week 4, Month 3, and Month 6 for blinded assessment.
214640342|NCT07178600|DRUG|Ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL.|Measurement of vital signs after ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL
214640343|NCT07178821|PROCEDURE|Conventional POEM|Standard posterior POEM with full-thickness myotomy, including both circular and gastric sling muscle fibers.
214640344|NCT07178821|PROCEDURE|Sling Fiber-Preserving POEM|Posterior POEM with selective preservation of gastric sling fibers by limiting myotomy to the right of the second penetrating vessel.
214640345|NCT07178015|COMBINATION_PRODUCT|ultrasound scanning|Ultrasound (US) is one of the most frequently utilized methods in carotid screening worldwide, because of its noninvasive and radiation-free nature and advantages of cost-effectiveness and convenience。
214640346|NCT07177638|BEHAVIORAL|Education Sessions to Improve Melanoma Knowledge and Awareness|Community based educational seminar led by a community health worker with follow-up questionnaires to assess knowledge retention and behavioral change.
214640347|NCT07177482|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
214725812|NCT04248192|BIOLOGICAL|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
214725813|NCT03644381|OTHER|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
214725814|NCT00732238|OTHER|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
214725815|NCT00732238|OTHER|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
214725816|NCT00826384|PROCEDURE|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
214725817|NCT02047708|DRUG|Zibotentan|Selective endothelin-A antagonist
214640348|NCT07177755|DIAGNOSTIC_TEST|High-field and very-low-field MRI acquisitions|MRI will be early acquired, as soon as possible after patient hospital admission and always in coma state for patients. For both patients and controls each MRI scanning session will encompass pairs of HF and VLF MRI acquisitions, that will be collected the same day. The main MRI sequences will be: T1, T2, FLAIR and DWI. The VLF spatial resolution recommended by the constructor for all these sequences correspond to voxel size is around 1.5mm/1.5mm/5mm. The total brain scanning time is estimated at 30 minutes.
214640349|NCT07177716|BIOLOGICAL|LB1410|LB1410 (IV, Q2W for up to 2 years)
214640350|NCT07177716|BIOLOGICAL|LB4330|LB4330 (IV, Q2W for 4 cycles)
214640351|NCT07177716|DRUG|Lenvatinib|lenvatinib (oral, once daily for up to 2 years)
214640352|NCT07179328|DEVICE|Focused Ultrasound Next Generation Dome Helmet|The Next Generation Dome Helmet (FUS NG) is a non-invasive, MRI-guided focused ultrasound system developed at Sunnybrook Research Institute. It is used to disrupt the blood-brain barrier (BBB) in patients with glioblastoma during the maintenance phase of temozolomide (TMZ) therapy. The device allows targeted BBB opening using a fixed transducer array and intravenous DEFINITY® contrast.
214640353|NCT07179328|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure.
214725818|NCT06181708|OTHER|N/A - Questionnaire based study|Questionnaire based study
214725819|NCT06642311|PROCEDURE|Empty bladder group|Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty. All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
214725820|NCT06642311|PROCEDURE|Bladder distension group|Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended . All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
214725821|NCT03892434|DRUG|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
214725822|NCT03892434|DEVICE|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
214725823|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
214725824|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
214725825|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
214725826|NCT05074394|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
214725827|NCT05074394|DRUG|Placebo|Diluent solution
214725828|NCT00979472|DRUG|Solifenacin|oral
214640354|NCT07177976|PROCEDURE|Pilates Breathing Technique along with standard pharmacological management|"Patients in this group will receive pilates breathing technique along with pharmacological management.~A total 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home.~Pilates breathing will be performed in sitting or supine position. The patient will place a hand over the Lower Posterior rib Cage and inhale through the nose.~While breathing they will actively contract the Transverse Abdominis (TrA) as if preparing for punch or holding in urine and engaging the pelvic floor muscles."
214640355|NCT07177976|PROCEDURE|Pursed-lip breathing along with pharmacological management|"Patient in this group will receive pursed-lip breathing along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days at home.~The patient will sit comfortably with straight back and relaxed shoulders. They will inhale slowly through the nose, with a deep relaxed breath, and then exhale slowly through the pursed lips, as if blowing out a candle. The exhalation should take 2-3 times longer than inhalation. This breathing cycle will be repeated with a focus on slow and relaxed breathing.~Pharmacological management: Patient will receive medications as per prescribed by pulmonologist"
214725829|NCT04826120|PROCEDURE|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
214725830|NCT04826120|PROCEDURE|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
214725831|NCT03525873|OTHER|Laboratory Biomarker Analysis|Correlative studies
214725832|NCT03525873|DRUG|Methylphenidate|Given PO
214725833|NCT03525873|OTHER|Physical Activity|Participate in physical activity
214725834|NCT03525873|OTHER|Placebo|Given PO
214725835|NCT03525873|OTHER|Quality-of-Life Assessment|Ancillary studies
214725836|NCT03525873|OTHER|Questionnaire Administration|Ancillary studies
214725837|NCT00246376|BEHAVIORAL|Diet|ATP-III diet
214725838|NCT00246376|BEHAVIORAL|Exercise|Supervised exercise in study gym
214725839|NCT00246376|DRUG|Niacin|Niaspan, titrated up to 2 grams per day
214725840|NCT00246376|DRUG|Fenofibrate|Tricor, 120 mg per day
214725841|NCT00246376|OTHER|Placebos|Placebos for Niaspan and Tricor
214725842|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
214640356|NCT07178184|DRUG|Modified Qing-Zao-Jiu-Fei Decoction (MQZJFD)|"MQZJFD is the core formula in this clinical study and consists of the 11 following herbs: Mori Folium 9g, Plaster stone 9g, Trichosanthis Fructus 9g, Ophiopogyonis Radix 6g, Armeniacae Semen Amarum 6g, Fritillariae Thunbergii Bulbus 6g, Eriobotryae Folium 6g, Ginseng Radix et Rhizoma 3g, Semen Sesami Nigrum 3g, Asini Corii Colla 3g, Glycyrrhizae Radix et Rhizoma 3g.~The formula will be prepared with single concentrated herbal granules (1 g of single concentrated herbal granule equates to 5 g of original dry herbs, except for Ophiopogyonis Radix whose ratio will be that 1 g of single concentrated herbal granule equals to 3 g of original dry herb, and Asini Corii Colla whose ratio will be that 1 g of single concentrated herbal granule equals to 1 g of original dry herb). The herbal granules will be provided by a Good Manufacturing Practice (GMP)-accredited supplier."
214640357|NCT07178184|DRUG|Placebo|The placebo granules consists of an inert substance made of starch filler, silica coating, flavor and coloring. Its appearance is unidentifiable to the real intervention drug. The placebo granules is also manufactured under GMP standards. To ensure blinding, the MQZJFD granules and placebo granules will be indistinguishable in appearance, smell and flavor.
214640358|NCT06409364|DRUG|Fludrocortisone|small white tablet containing 100mcg of fludrocortsone
214640359|NCT06409364|DRUG|Placebo|Matched placebo tablet,
214640360|NCT07178964|OTHER|Potassium-enriched salt-substitute|The patients in the experimental group will use potassium-enriched salt-substitutes for cooking and seasoning food in their home environment. Potassium-enriched salt-substitutes will contain 25% potassium chloride nad 75% sodium chloride.
214640361|NCT07178964|OTHER|Regular table salt|Patients in this arm will use regular table salt (100 % sodium chloride) for cooking and seasoning food in their home environment.
214640362|NCT07177677|BIOLOGICAL|hBMMSC|Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
214640363|NCT07179380|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
214640364|NCT07179380|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
214640365|NCT07177820|OTHER|Video-Guided Acupuncture Imagery Treatment (VGAIT)|Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them
214640366|NCT07178691|OTHER|Online psychological intervention|The HOPE-AF intervention is an online psychological intervention to prevent depression in patients with atrial fibrillation. The intervention combines verbal psychological sessions over phone or video with online text messages and a tailored 4-12 weeks online intervention with new modules each week including psychological exercises in writing and as sound exercises (e.g., breathing exercises and relaxations exercises etc.) and videos.
214640367|NCT07179146|DEVICE|Dental arch length anlysis|Arch length
214640368|NCT07179146|BEHAVIORAL|child satisfaction|Frankel rating scale
214640369|NCT07179146|DEVICE|Dental arch length anaylsis|Intermolar width
214640370|NCT07179146|DEVICE|Dental arch length analysis|Intercanine width
214640371|NCT07179146|DEVICE|Dental arch length anylsis|Arch depth
215030520|NCT06639009|OTHER|Conventional non -Invasive management in Oral Submucous fibrosis|"Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation"
214640372|NCT07178795|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214640373|NCT07178795|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
214640374|NCT07178795|DRUG|Pemetrexed|Administration by intravenous infusion for a cycle of 3 weeks.
214640375|NCT07178795|DRUG|Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
214640376|NCT07178795|DRUG|Cisplatin|Administration by intravenous infusion for a cycle of 3 weeks.
214640377|NCT07178067|OTHER|Mediterranean diet|The Mediterranean diet, characterised by a high intake of fruits, vegetables, whole grains, legumes, nuts, and olive oil, along with moderate consumption of fish and poultry, has been associated with anti-inflammatory and neuroprotective effects. Notably, this dietary pattern has the potential to enhance the production of short-chain fatty acids (SCFAs) and support gut microbial diversity, representing a promising strategy for nutritional intervention in patients with ALS.
214640378|NCT07177469|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
214640379|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
214640380|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
214640381|NCT07177469|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
214640382|NCT07178938|DRUG|Radiotracer targeting SSTR2 ([68Ga]Ga-DOTA-TOC)|Patients will receive a single infusion of the diagnostic agent \[68Ga\]Ga-DOTA-TOC will which will be detected by PET/CT imaging. The recommended activity for an adult weighing 70 kg is 100 to 200 MBq, administered by direct slow intravenous injection and for a single use only.
214640383|NCT07178249|BIOLOGICAL|EXG202 injection|EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration（wAMD） with a single intravitreal injection and administration.
214640384|NCT07178171|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706
214640385|NCT07178171|DRUG|Pirarubicin|pirarubicin
214640386|NCT07178171|DRUG|Nab-paclitaxel|nab-paclitaxel
214640387|NCT07178171|DRUG|Carboplatin (AUC 5)|carboplatin
214640388|NCT07178171|DRUG|Cyclophosphamide|cyclophosphamide
214640389|NCT07177547|OTHER|Mental health screening and referral practices in physiotherapy|Semi-structured interviews were conducted with 18 physiotherapists working in private settings to explore recognition, screening, and referral practices for anxiety and depression in patients with chronic musculoskeletal pain.
214640390|NCT07178496|OTHER|Sleep Hygiene Techniques|"Sleep Hygiene Techniques~The sleep hygiene program includes education and behavioral strategies to promote healthier sleep patterns, delivered alongside physiotherapy exercises. Key components are:~Regular Sleep-Wake Schedule~Encourage patients to maintain consistent bedtime and wake-up times, even on weekends.~Avoid excessive time in bed when not sleeping.~Optimizing the Sleep Environment~Ensure a quiet, dark, and cool bedroom (18-22°C).~Use supportive pillows to maintain neutral cervical alignment and reduce neck strain.~Remove distractions such as TVs, mobile phones, and bright lights.~Pre-Sleep Routine~Establish a relaxing wind-down routine (e.g., gentle stretching, breathing exercises, reading).~Avoid mentally stimulating activities or heavy problem-solving before bedtime.~Limiting Stimulants and Alcohol~Avoid caffeine, nicotine, and alcohol at least 4-6 hours before bedtime.~Avoid heavy meals close to bedtime; a light snack is acceptable if hungry.~Daytime Habits t"
214640391|NCT07178496|OTHER|conventional physiotherapy program|"Conventional Physiotherapy Program~1. Treatment Frequency and Duration~   Frequency: 3 sessions per week~   Duration: 8 weeks~   Session length: 45-60 minutes~2. Hot Pack Application (10-15 minutes)~   Purpose: Reduce pain, improve soft-tissue extensibility, and prepare muscles for exercise.~   Procedure:~   Moist hot pack applied to the cervical region.~   Temperature: 40-45°C (comfortable warmth, checked to avoid burns).~   Duration: 10-15 minutes with adequate towel layers.~3. Neck Endurance and Strength Training (30-40 minutes)"
214640392|NCT07178496|OTHER|Control arm|"only advices and home advices~Physiotherapy Advice for Patients with Neck Pain~Adhere to Your Exercise Program~Perform the prescribed neck strengthening and endurance exercises daily.~Focus on quality over quantity-slow, controlled movements are more effective.~Maintain Correct Posture During All Activities~Keep your neck in a neutral position whether sitting, standing, or walking.~Incorporate Frequent Micro-Breaks~Every 30-45 minutes, pause to gently move and stretch your neck and shoulders.~Small posture corrections throughout the day prevent stiffness.~Use Heat Before Exercise if Stiff or Painful~Apply a hot pack for 10-15 minutes before exercises to relax muscles.~Avoid prolonged or excessive heat application.~Stay Active - Avoid Prolonged Rest~Light physical activity (walking, cycling, gentle mobility work) helps recovery.~Bed rest should be avoided unless pain is severe.~Practice Relaxation and Breathing C"
214640393|NCT07178002|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
214640394|NCT07178002|DRUG|Placebo|Matching placebo
214640395|NCT07178834|BEHAVIORAL|Telerehab|Adverse events are observed during online rehabilitation with computer vision technology in patients with MS.
214640396|NCT07177456|BIOLOGICAL|UCB-MNCs|UCB-MNCs were administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
214640397|NCT07178587|DIAGNOSTIC_TEST|Single tracer PET/CT|Single tracer PET/CT for the HCC patients : one with \[18F\]FDG and one with \[18F\]F-choline Single tracer PET/CT for the GEP-NET patients : one with \[68Ga\]Ga-DOTATOC and one with \[18F\]FDG
215030521|NCT06253767|PROCEDURE|Endodontic Treatment|Conventional endodontic treatment will be performed equally on all participants.
214725843|NCT02611934|PROCEDURE|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
214725844|NCT01345825|OTHER|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
214725845|NCT01085162|DRUG|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
214725846|NCT01653756|DRUG|IPI-145, a PI3K Inhibitor|Active drug
214725847|NCT01653756|DRUG|Placebo to match IPI-145|Comparator
214725848|NCT00645515|DRUG|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
214725849|NCT00645515|DRUG|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
214725850|NCT01863706|DRUG|Misoprostol|400µg oral misoprostol
214725851|NCT01863706|DRUG|Oxytocin|20 IU Oxytocin
214725852|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
214725853|NCT05574712|DRUG|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
214725854|NCT03577522|DEVICE|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
214725855|NCT03577522|DEVICE|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
214725856|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
214725857|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
214725858|NCT00003304|DRUG|temozolomide|
214725859|NCT06248944|OTHER|observational-retrospective and prospective|observational-retrospective and prospective
214725860|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
214725861|NCT01886404|DRUG|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
214725862|NCT01581905|PROCEDURE|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
214725863|NCT01581905|PROCEDURE|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
214725864|NCT02329145|PROCEDURE|renal denervation|
214725865|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
214725866|NCT00077922|DRUG|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
214725867|NCT04917250|DRUG|Gemcitabine|1000mg/㎡，d1,4 ivdrip
214725868|NCT04917250|DRUG|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
214725869|NCT04917250|DRUG|Etoposide|100mg/㎡，d1-3 ivdrip
214725870|NCT04917250|DRUG|Dexamethasone|20mg/d d1-4 ivdrip
214725871|NCT04606407|DEVICE|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
214725872|NCT01608529|DEVICE|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
214725873|NCT01983449|DRUG|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
214725874|NCT06055049|OTHER|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
214725875|NCT02804373|DRUG|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
214725876|NCT02804373|DRUG|Placebo|Placebo daily during 28 days
214725877|NCT02804373|DRUG|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
214725878|NCT02804373|DRUG|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
214725879|NCT00626769|DIETARY_SUPPLEMENT|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
214725880|NCT00626769|DIETARY_SUPPLEMENT|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
214725881|NCT01547962|DEVICE|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
214725882|NCT01547962|OTHER|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
214725883|NCT04517110|DRUG|Pregabalin 300 mg|Pregabalin 300 mg, capsule
214725884|NCT04517110|DRUG|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
214725885|NCT04517110|DRUG|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
214725886|NCT04517110|DRUG|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
214725887|NCT04517110|OTHER|Usual Care|Usual Care
214725888|NCT00422357|DRUG|Urtica Dioica (Tea bag)|
214725889|NCT01789710|DRUG|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
214725890|NCT01789710|DRUG|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
214725891|NCT01789710|BEHAVIORAL|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
214725892|NCT05007262|DRUG|Tangningtongluo tablets|Four pills each time and three times a day after meals.
214725893|NCT05007262|DRUG|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
214725894|NCT01158638|BEHAVIORAL|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
214725895|NCT02236650|BEHAVIORAL|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
214725896|NCT02236650|OTHER|Treatment as Usual|Treatment as Usual for 4 weeks
214725897|NCT02098148|DRUG|Xenon|
214640398|NCT07178587|DIAGNOSTIC_TEST|Multiplexed PET-CT|Multiplexed PET-CT for HCC patients : \[18F\]FDG + \[18F\]F-choline. Multiplexed PET-CT for GEP-NET patients : \[18F\]FDG + \[68Ga\]Ga-DOTATOC. The PET scans must be performed in any order and at least 24 hours apart.
214640399|NCT07177911|DRUG|CC312|Subjects will initially receive a single intravenous dose of CC312. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
214640400|NCT07177911|DRUG|Placebo|Subjects will initially receive a single intravenous dose of Placebo. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
214640401|NCT07178925|OTHER|Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006|The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population.
214640402|NCT07179432|PROCEDURE|V-E facial mask ventilation maneuver|"The V-E maneuver is achieved by placing the thumbs and thenar eminence of each hand on the sides of the mask, creating a V shape, while the rest of the fingers perform a jaw thrust described as an E shape. This will be performed after anesthetic induction when the patient is unconscious and apneic. The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
214640403|NCT07179432|PROCEDURE|C-E facial mask ventilation maneuver|"The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
214640404|NCT07177924|PROCEDURE|Monarch RAB with CBCT-guided ICG Dye Marking|Under general anesthesia, the Monarch RAB platform is used to navigate to the target bronchus. With CBCT confirmation, 0.25 ml of ICG (0.2 mg/ml) mixed with 0.25 ml iodinated contrast is injected within 1 cm of the nodule. The dye marking is identified intraoperatively with near-infrared light to guide VATS sublobectomy.
214640405|NCT07177443|RADIATION|Radiotherapy|"Following induction therapy, eligible patients will receive radiotherapy alone or concurrent chemoradiotherapy per protocol. Photon or proton radiotherapy techniques were permitted. Prescribed doses were:~Primary tumor and metastatic lymph nodes: 70 Gy/33 fractions High-risk lymphatic drainage areas: 60 Gy/33 fractions Low-risk regions: 54 Gy/33 fractions~PTV dose specifications:~GTVnx: 70 Gy GTVnd: 66-70 Gy (reducible to 63 Gy for suspicious small nodes) CTV1: 60-62 Gy CTV2: 54-56 Gy All treatments will employ simultaneous integrated boost (SIB) intensity-modulated radiotherapy delivered once daily, 5 fractions per week."
214640406|NCT07177443|DRUG|Serplulimab|Serplulimab will be used in the induction phase for 3 cycles and the maintenance phase for 14 cycles.
214640407|NCT07177443|DRUG|Cisplatin|On days 64 and 85, patients will receive cisplatin chemotherapy at a dose of 100 mg/m² via intravenous infusion.
214640408|NCT07177950|DRUG|SHR-A1811|Systemic therapy: 4.8 mg/kg administered as an intravenous infusion on Day 1 of each cycle. 3 weeks a cycle. Continuous medication until study completion, occurrence of intolerable toxicity, disease progression, withdrawal from the study for any reason, or death, whichever occurs first, or until the investigator deems that the patient would no longer benefit from the treatment.
214640409|NCT07177950|DRUG|SHR-A1811|Intrathecal therapy: Administered intrathecally on Day 1 of each cycle. Dose escalation follows a Bayesian Optimal Interval (BOIN) design with three predefined dose levels-15 mg, 30 mg, and 40 mg. The starting dose level is 15 mg. Patients are enrolled in cohorts of three per dose level. If no dose-limiting toxicities (DLTs) are observed, escalation proceeds to the next higher dose level according to the BOIN algorithm. Treatment is administered for a minimum of two cycles and is continued until cerebrospinal fluid (CSF) cytology achieves negative conversion, completion of six cycles, or intolerable adverse events, whichever occurs first. Extension beyond six cycles may be permitted following investigator's discussion and must be documented with justification.
214640410|NCT07177950|RADIATION|radiotherapy|radiotherapy is determined by investigator's choice
214640411|NCT07178951|DEVICE|Neurotomy|Use of high intensity focused ultrasound to ablate the genicular nerve.
214640412|NCT07179068|BEHAVIORAL|Child Body Image Development Workshop|This is an online, single-session, modular intervention for parents of children that are two-to-six years old. It is designed to target and improve child body image development by providing psychoeducation and interactive activities to parents in each of the four modules. Modules include Body Image Development/Body Talk, Food Talk, Picky Eating and Mealtime Conversations, and Media Usage and Social Comparison. These modules were designed using the results of our previously completed Needs Assessment, as well as the current evidence-base regarding risk factors for the development of body image in young children.
214640413|NCT07179159|DRUG|14-day vonoprazan-amoxicillin dual therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid
214640414|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + levofloxacin 500mg qd + bismuth 220mg bid
214640415|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid + bismuth 220mg bid
214640416|NCT07178522|BIOLOGICAL|Envacgen®|Subjects are to receive a 0.5 mL IM injection of Envacgen®. Study drug is administered on Day 1 and Day 57 of the study.
214640417|NCT07178431|BIOLOGICAL|MB-CART2019.1|CAR T cell therapy
214640418|NCT07178561|OTHER|Exercises for lower back|"1. Physiotherapy Modalities (Preparation):~   Hot Pack Therapy: Applied to the lumbar region for 10-15 minutes before exercises to reduce muscle stiffness and pain.~   Interferential Therapy (IFT): Applied to the lower back for 10-15 minutes to decrease pain and improve circulation.~2. Exercise Program (30-40 minutes per session, 3 times/week):~A. Lumbar Stabilization Exercises:~B. Core Strengthening Exercises:"
214725898|NCT02098148|DRUG|Placebo|
214640419|NCT07178561|OTHER|Exercises and Physical Activity Program|"1. Frequency \& Duration:~   Frequency: 3 days per week~   Duration: 30 to 40minutes per session~   Intensity: Low to moderate (RPE 11-13 on Borg scale; light to somewhat hard)~2. Warm-Up (5 minutes):~   Gentle walking on treadmill at slow speed (1.5-2.5 km/h)~   Light dynamic stretches for lower back, hips, and legs~3. Main Activity~   A. Treadmill Walking:~   Speed: Comfortable pace for walking without pain~   Incline: Start flat, increase slightly (1-2%) if tolerated~   Goal: Promote cardiovascular endurance and safe weight-bearing activity~   B. Stationary Bicycle:~   Duration: 10-15 minutes~   Resistance: Low to moderate (enough to feel effort but no pain)~4. Cool-Down (5 minutes):~   Slow treadmill walking or easy pedaling on the bike~   Gentle stretches: hamstrings, hip flexors, lumbar rotation~5. Progression:~based on patient tolerance Gradually in"
214640420|NCT07178561|OTHER|Advices|Advices
214640421|NCT07177521|PROCEDURE|Insertion of implants in post-extraction tooth|"Two widely used approaches include:~1. Socket grafting with a fully resorbable synthetic biomaterial (β-tricalcium phosphate + calcium sulfate).~2. Socket grafting with a xenograft and a custom Sealing Socket Abutment (SSA) with a concave emergence profile.~No randomized controlled trials have yet compared these protocols with integrated outcomes including resonance frequency analysis, peri-implant health indices, radiographic bone level changes, and digital intraoral scanning (IOS)-based morphometric analysis."
214640422|NCT07178847|BIOLOGICAL|blood sampling|The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy
214640423|NCT07178106|OTHER|Fasting|Participants undergo the standardised Wilhelmi-Buchinger fasting intervention, which consists of two days of preparation with a dietary energy supply of \<1000 kcal, three days of fasting with a dietary energy supply of 300-500 kcal with tea, broth, fruit and vegetable juices, and two days of recovery.
214640424|NCT07179042|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 119-days.
214640425|NCT07179042|DRUG|Metformin|Metformin tablets will be dispensed to the participants for 119-days.
214640426|NCT07179341|PROCEDURE|Thymectomy for thymic carcinoma|Thymectomy for thymic cancer
214640427|NCT06351592|DRUG|ALN-SOD|Administered by intrathecal (IT) injection
214640428|NCT06351592|OTHER|Diluent|Administered by IT injection
214640429|NCT06351592|DRUG|Placebo (PB)|Administered by IT injection
214640430|NCT03406897|DRUG|Cholecalciferol|Oral Administration
214640431|NCT03406897|DRUG|Omega 3 fatty acid|Oral Administration
214640432|NCT05925049|DRUG|Natalizumab|Administered as specified in the treatment arm.
214640433|NCT06241586|PROCEDURE|The novel PMMI surgical strategy|"Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals."
214640434|NCT06241586|PROCEDURE|The conventional step-up strategy|Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
214725899|NCT04246424|BEHAVIORAL|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
214725900|NCT04246424|BEHAVIORAL|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
214725901|NCT04246424|BEHAVIORAL|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
214725902|NCT05526092|OTHER|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
214725903|NCT05344612|RADIATION|CT Coronary Angiography|Upfront ct-coronary angiography
214725904|NCT04346277|BIOLOGICAL|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
214725905|NCT00531895|DRUG|duloxetine|duloxetine 60 mg/d
214725906|NCT03849014|PROCEDURE|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
214640435|NCT00598975|DRUG|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
214640436|NCT00598975|DRUG|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
214640437|NCT00598975|DRUG|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
214640438|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
214640439|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
214640440|NCT06831162|OTHER|Multi-level HRSN initiative|The multi-level health-related social needs (HRSN) initiative includes multiple components aimed at assessing and addressing HRSN in clinical practice: HRSN screening, EHR tools for clinical decision support, training and tools for health care providers to address HRSN, care coordinator support for patient outreach, and community resources for referral and support.
214640441|NCT06833320|DRUG|Propranolol Hydrochloride|Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.
214640442|NCT06833320|DRUG|Placebo|Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle
214725907|NCT03849014|PROCEDURE|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
214725908|NCT00760890|DIETARY_SUPPLEMENT|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
214725909|NCT00760890|DIETARY_SUPPLEMENT|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
214725910|NCT05241288|COMBINATION_PRODUCT|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
214640443|NCT06163261|OTHER|Physical activity|The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
214640444|NCT06219174|DRUG|Pembrolizumab|200 mg IV Q3 weeks
214640445|NCT06219174|DRUG|Difluoromethylornithine|Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
214640446|NCT04392947|DEVICE|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
214640447|NCT04392947|DEVICE|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
214640448|NCT04415476|DRUG|Assigned Interventions|This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
214640449|NCT04892849|OTHER|Conventional Therapy acc. to prevailing clincal approved schemes|The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
214640450|NCT05450718|DRUG|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
214640451|NCT05450718|DRUG|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
214640452|NCT03875261|DRUG|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
214640453|NCT04594291|PROCEDURE|MRI scans|This study does not involve any intervention or new treatment. We will conduct MRI scans of the kidneys, muscles, abdomen and heart at baseline, 12 and 24 months after hospital discharge. The MRI scan will take 60-70 minutes in total.
214640454|NCT01354483|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|
214640455|NCT01354483|BIOLOGICAL|Methylprednisolone|30mg/kg i.v. methylprednisolone
214725911|NCT04027036|BIOLOGICAL|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
214725912|NCT00529412|OTHER|Seprafilm|two sheets per body
214640456|NCT01354483|DRUG|Lithium Carbonate Tablet|6 weeks
214640457|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^12 vg administered intramuscularly
214640458|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^13 vg administered intramuscularly
214725913|NCT04246489|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
214725914|NCT03428295|DEVICE|Dose Safety AP system|Device will be used to automatically dose insulin
214640459|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|8x10\^13 vg administered intramuscularly
214640460|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|1.2x10\^14 vg administered intramuscularly
214640461|NCT01158339|BEHAVIORAL|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
214640462|NCT01158339|BEHAVIORAL|Arm 1: CBGT|Intervention according to previously mentioned methods.
214725915|NCT04783714|DIETARY_SUPPLEMENT|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
214725916|NCT04783714|DIETARY_SUPPLEMENT|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
214725917|NCT05374291|DRUG|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
214725918|NCT05374291|DRUG|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
214725919|NCT03723785|DRUG|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
214725920|NCT04336111|PROCEDURE|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
214640463|NCT03159312|BEHAVIORAL|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
214640464|NCT00505453|BIOLOGICAL|Fluviral®|
214640465|NCT04337411|OTHER|Follow-up assessments|Longitudinal evaluation of recovery
214725921|NCT00964249|DRUG|GW642444|Long acting Beta 2 agonist
214725922|NCT00964249|DRUG|Placebo|Matching placebo
214725923|NCT05782348|BEHAVIORAL|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
214725924|NCT05782348|OTHER|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
214725925|NCT01619813|DRUG|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
214725926|NCT01619813|DRUG|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
214725927|NCT04328441|DRUG|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
214725928|NCT04328441|DRUG|Placebo|Intracutaneously 0.1ml NaCl 0,9%
214640466|NCT04654858|PROCEDURE|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
214640467|NCT03346408|BEHAVIORAL|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
214640468|NCT01516515|DRUG|Vehicle gel|placebo
214640469|NCT01516515|DRUG|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
214640470|NCT02553694|OTHER|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
214640471|NCT02553694|OTHER|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
214640472|NCT02553694|OTHER|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
214640473|NCT02553694|OTHER|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
214640474|NCT01931761|DRUG|[C14] selumetinib (oral)|Single oral administration \[C14\] 75mg
214640475|NCT05870904|OTHER|Dry Needling|"Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied"
214640476|NCT01324284|DRUG|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
214640477|NCT04573673|DEVICE|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
214640478|NCT04573673|DEVICE|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
214640479|NCT01206881|DRUG|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
214640480|NCT05134571|DRUG|Laronidase|Solution for injection; Intravenous
214640481|NCT02066792|DRUG|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
214640482|NCT02066792|DRUG|Placebo|Sugar pill
214725929|NCT05001568|DEVICE|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
214725930|NCT05001568|DEVICE|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
214725931|NCT05001568|DEVICE|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
214725932|NCT05001568|DEVICE|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
214725933|NCT01498536|BEHAVIORAL|aerobic exercise|3 times per week for 12-weeks
214725934|NCT02052323|DRUG|Artesunate/mefloquine (AS/MQ)|"* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
214640483|NCT02066792|BEHAVIORAL|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
214640484|NCT04544722|BEHAVIORAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
214640485|NCT04544722|BEHAVIORAL|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
214640486|NCT03790241|PROCEDURE|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
214640487|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
214640488|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
214640491|NCT05504109|PROCEDURE|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
214640492|NCT05504109|PROCEDURE|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
214640493|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
214640494|NCT05226260|BEHAVIORAL|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
214640495|NCT03868293|DEVICE|Focused ultrasound|Pulsed low intensity focused ultrasound
214640496|NCT02245828|DRUG|QCC374|Single and multiple ascending doses of QCC374
214640497|NCT02245828|DRUG|Placebo|Placebo comparator
214640498|NCT04788420|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
214725935|NCT03352869|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
214725936|NCT03352869|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
214725937|NCT06087094|DRUG|HRS-7450 ；Placebo|HRS-7450 or Placebo
214725938|NCT02531503|OTHER|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
214725939|NCT00776490|DRUG|Glimepiride 1mg Tablets|
214640499|NCT02723201|DRUG|TAK-020 Captisol Oral Solution|TAK-020 solution.
214640500|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet
214640501|NCT02723201|DRUG|TAK-020 SDT|TAK-020 Solid dispersion tablet.
214640502|NCT02723201|DRUG|TAK-020 IRT|TAK-020 immediate release tablet.
214640503|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet.
214640504|NCT02723201|DRUG|TAK-020 Solid Formulation|TAK-020 solid formulation
214640505|NCT03472560|DRUG|Avelumab (MSB0010718C)|IV treatment: Avelumab administered at 800 mg IV every two weeks
214640506|NCT03472560|DRUG|Axitinib (AG-013736)|Oral treatment: Axitinib given 5 mg PO BID
214640507|NCT01597063|DEVICE|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
214640508|NCT05374707|BEHAVIORAL|MOTIVATIONAL INTERVIEWING|Motivational interviewing is a form of interview conducted with a patient-centered approach in order to enable people to discover and solve the obstacles to behavior change.
214640509|NCT00485888|DRUG|Cipralex|10-20mg; one per day
214640510|NCT00485888|DRUG|Placebo|Matched to Cipralex
214640511|NCT06566456|PROCEDURE|The puncture site is 1.5-2.5 cm proximal to the radial styloid process|The ultrasound-guided radial artery puncture site is1.5-2.5 cm proximal to the radial styloid process
214640512|NCT06566456|PROCEDURE|traditional site|The ultrasound-guided radial artery puncture site is level with the radial styloid process and where the radial artery pulse is most prominent
214640513|NCT06010914|OTHER|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
214640514|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
214640515|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
214640516|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
214640517|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
214640518|NCT06355570|OTHER|Personal Pictures|Digital photos will be shown continuously at the patient's bedside for 12 hours a day (between 8 am to 8 pm).
214640519|NCT06355570|OTHER|Family Videos|Family-recorded videos will be played three times at specific hours of the day - 9 am, 2 pm and 7 pm - throughout patient stay in the ICU
214725940|NCT04825249|PROCEDURE|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
214725941|NCT04825249|PROCEDURE|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
214725942|NCT06347692|OTHER|antigravity treadmill|An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
214640520|NCT06355570|OTHER|Family Videos - Intervention as required|The last video shown will be re-played upon patient request and/or if patients develop ICU delirium.
214640521|NCT05350462|BEHAVIORAL|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
214640522|NCT01082315|DRUG|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
214640523|NCT03191149|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214640524|NCT03191149|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
214640525|NCT03191149|PROCEDURE|Echocardiography Test|Undergo ECHO
214640526|NCT03191149|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214640527|NCT03191149|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214640528|NCT03191149|DRUG|Osimertinib|Given PO
214725943|NCT06347692|OTHER|physical therapy exercise program|Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
214725944|NCT05110404|OTHER|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
214725945|NCT05110404|OTHER|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
214725946|NCT01960192|DRUG|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
214640534|NCT01534676|PROCEDURE|Transfusion|A routine medical procedure to transfuse packed red blood cells.
214640535|NCT01534676|BIOLOGICAL|Blood|"Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)"
214640536|NCT01534676|PROCEDURE|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
214640537|NCT04568668|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication."
214640538|NCT00880815|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
214640539|NCT00880815|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214640540|NCT00880815|DRUG|Bendamustine|Given IV
214640541|NCT00880815|BIOLOGICAL|Filgrastim|Given IV
214640542|NCT00880815|DRUG|Fludarabine|Given IV
214640543|NCT00880815|DRUG|Methotrexate|Given IV
214640544|NCT00880815|BIOLOGICAL|Rituximab|Given IV
214640545|NCT00880815|DRUG|Tacrolimus|Given IV and PO
214640546|NCT02460211|DIETARY_SUPPLEMENT|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
214640547|NCT02460211|DIETARY_SUPPLEMENT|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
214640548|NCT00610142|DRUG|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
214640549|NCT00610142|DRUG|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
214640550|NCT01197365|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
214640551|NCT01197365|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
214640552|NCT06211010|DIAGNOSTIC_TEST|the semiconductor metal oxide sensors.|The method of analyzing the VOCs was through analyzing the evaporated VOCs from the urine in the container when they evaporated into the sealed chamber. The VOCs in the chamber were then analyzed at the same time by the five different gas semiconductor sensors which were located on the top of the chamber.
214640553|NCT00540579|DRUG|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
214725947|NCT01960192|DRUG|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
214725948|NCT02826876|DRUG|Topical use|Topical use of Ropivacaine in laparoscopic surgery
214725949|NCT02826876|OTHER|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
214725950|NCT02826876|OTHER|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
214640554|NCT00540579|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
214640555|NCT00142896|DRUG|Tramadol|
214640556|NCT00142896|DRUG|Naloxone|
214640557|NCT00142896|DRUG|Morphine|
214640558|NCT01113203|BEHAVIORAL|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
214640559|NCT00280995|DRUG|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
214640560|NCT00280995|DRUG|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
214640561|NCT00280995|DRUG|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
214640562|NCT00280995|DRUG|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
214640563|NCT02268435|DRUG|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
214640564|NCT05639855|OTHER|Mental Health Literacy Programme|Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
214640565|NCT05313867|DIETARY_SUPPLEMENT|Nutri VX 1|1 sequence of 10 tablets (one intake)
214640566|NCT05313867|DIETARY_SUPPLEMENT|Placebo|1 sequence of 10 tablets (one intake)
214640567|NCT06486181|OTHER|Thrombolysis/Thrombectomy|"Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT."
214640568|NCT01976780|DRUG|Artesunate|
214640569|NCT01976780|DRUG|Artemether Lumefantrine|
214640570|NCT01976780|DRUG|Mefloquine|
214725951|NCT01986517|BEHAVIORAL|No feedback|Therapists will receive no feedback.
214640571|NCT02406807|OTHER|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
214640572|NCT02406807|OTHER|Sham Spinal lumbar manipulation|Sham manipulation
214640573|NCT03073135|BEHAVIORAL|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
214640574|NCT03073135|BEHAVIORAL|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
214640575|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
214640576|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
214640577|NCT02950233|DRUG|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).
214640578|NCT02950233|DRUG|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
214640579|NCT02950233|DRUG|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
214640580|NCT02950233|DRUG|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
214725952|NCT01986517|BEHAVIORAL|Feedback after every fourth session|
214725953|NCT00610207|DEVICE|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
214725954|NCT02117804|OTHER|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
214725955|NCT02558985|PROCEDURE|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
214725956|NCT02621372|OTHER|platelet count|Correlation of esophageal varices with platelet count
214725957|NCT00481741|DEVICE|SafeSeal(TM) Hemostasis Patch|
214725958|NCT06231030|OTHER|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
214725959|NCT02299804|DRUG|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
214725960|NCT02299804|DRUG|Placebo|No active ingredient
214725961|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
214725962|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
214725963|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
214640581|NCT06502093|OTHER|Observational Malnutrition Screening and Foodservice Satisfaction|Patients asked Acute Care Hospital Foodservice Patient Satisfaction Questionnaire and malnutrition risk assessed with NRS-2002 screening tool.
214640582|NCT05280977|OTHER|POST ISOMETRIC RELAXATION|Group A (Post Isometric Relaxation + Conventional Physiotherapy): This group will receive Muscle Energy Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session.
214640583|NCT05280977|OTHER|POST FACILITATION STRETCHING|"Group B (Post Facilitation Stretching + Conventional Physiotherapy):~This group will receive Post Facilitation Stretching Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session."
214640584|NCT02361645|DRUG|Ketorolac 0.5% eyedrops|
214640585|NCT02361645|DRUG|Indomethacin 0.5% eyedrops|
214640586|NCT02361645|DRUG|Bromfenac 0.09% eyedrops|
214640587|NCT02361645|DRUG|Nepafenac 0.1% eyedrops|
214640588|NCT04269395|DRUG|MAL Cream|No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
214725964|NCT03241589|OTHER|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
214725965|NCT04319770|DEVICE|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
214725966|NCT04319770|DEVICE|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
214640589|NCT04269395|DRUG|Vehicle cream|No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
214640590|NCT00584233|DEVICE|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
214640591|NCT00584233|DEVICE|MRI|Breast MRI
214640592|NCT02222714|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
214725967|NCT02465489|DRUG|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
214725968|NCT02465489|DRUG|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
214725969|NCT02950441|DIETARY_SUPPLEMENT|Nicotinamide Riboside|
214725970|NCT02950441|OTHER|Placebo|
214725971|NCT04776889|DRUG|Rosuvastatin 20mg|Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
214725972|NCT04776889|PROCEDURE|surgical castration|bilateral subcapsular orchiectomy
214725973|NCT02171039|DRUG|Dabigatran|
214725974|NCT02171039|DRUG|Atorvastatin|
214725975|NCT02972593|BIOLOGICAL|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
214725976|NCT00408291|PROCEDURE|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
214725977|NCT04599972|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
214725978|NCT04599972|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
214725979|NCT01951872|BEHAVIORAL|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
214725980|NCT02885272|PROCEDURE|Computed Tomography|Undergo PET/CT scans
214725981|NCT02885272|RADIATION|Fludeoxyglucose F-18|Given IV
214725982|NCT02885272|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
214725983|NCT02885272|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
214725984|NCT02500472|DIETARY_SUPPLEMENT|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
214725985|NCT01977157|DEVICE|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
214725986|NCT04306757|DEVICE|Evone|Airway ventilation device
214725987|NCT04306757|DEVICE|Primus|Airway ventilation device
214640593|NCT02222714|DRUG|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
214640594|NCT01779206|DRUG|Epirubicin|
214640595|NCT01779206|DRUG|Cyclophosphamide|
214640596|NCT01779206|DRUG|Docetaxel|
214640597|NCT01779206|DRUG|Paclitaxel|
214640598|NCT00524056|DRUG|Carisbamate|two 100 mg tablets twice per day
214640599|NCT00524056|DRUG|Placebo|two placebo tablets twice per day
214640600|NCT01677247|DRUG|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
214640601|NCT01677247|DRUG|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
214640602|NCT05079490|BEHAVIORAL|motor intervention|gross motor skill intervention combined with fitness training
214640603|NCT01200784|DRUG|Nicotinamide|dosage
214640604|NCT06222944|DRUG|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
214640605|NCT06222944|DRUG|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
214640606|NCT06222944|DRUG|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
214640607|NCT01842503|DRUG|GET 73|300 mg tid on 3 days cycle
214640608|NCT01842503|DRUG|inactive ingredients capsule|3 capsules tid on 3 days cycle
214640609|NCT02892266|OTHER|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
214640610|NCT05329532|BIOLOGICAL|Modi-1 Moditope|Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
214640611|NCT05329532|BIOLOGICAL|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
214640612|NCT05329532|DEVICE|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
214640613|NCT06803641|OTHER|Mindfulness practice with Tao Art (Calligraphy and Song Love Peace and Harmony).|During mindfulness practice with Tao Art (Calligraphy and Song Love Peace Harmony), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for three months.
214640614|NCT06064539|DRUG|Tolebrutinib|Tablet, taken orally
214640615|NCT06064539|DRUG|gemfibrozil|Tablet, taken orally
214640616|NCT06064539|DRUG|rifampicin|Tablet, taken orally
214640617|NCT04338893|PROCEDURE|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
214640618|NCT04338893|PROCEDURE|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
214640619|NCT04338893|PROCEDURE|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
214640620|NCT00887861|DRUG|Investigational new drug, company code: BGG492|
214725988|NCT00783549|DRUG|an undetermined dose of GSK1292263|GSK investigational product or placebo
214725989|NCT00783549|DRUG|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
214725990|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
214725991|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposures.
214725992|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
214725993|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
214640621|NCT00887861|DRUG|Placebo|
214640622|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
214640623|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214725994|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
214725995|NCT02597985|OTHER|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
214725996|NCT02597985|OTHER|Usual Care|
214725997|NCT03949621|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
214725998|NCT03889990|DEVICE|IQOS|"Smoke IQOS"
214725999|NCT05955872|DRUG|VX-147|Tablets for oral administration.
214726000|NCT05146037|OTHER|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
214726001|NCT05146037|OTHER|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
214726002|NCT06242093|DEVICE|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
214726003|NCT06242093|OTHER|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
214726004|NCT05305976|OTHER|Telerehabilitation|The 8 week exercise program with telerehabilitation
214726005|NCT06337994|DRUG|Memantine Hydrochloride|Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
214726006|NCT04443894|OTHER|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
214726007|NCT04443894|OTHER|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
214726008|NCT04189640|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
214726009|NCT06252740|OTHER|No intervention|Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
214726010|NCT01517906|BEHAVIORAL|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
214726011|NCT01517906|BEHAVIORAL|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
214726012|NCT00638690|DRUG|Placebo|Four tablets once daily until disease progression
214726013|NCT00638690|DRUG|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
214726014|NCT00638690|DRUG|Prednisone/prednisolone|5 mg twice daily until disease progression
214726015|NCT00115544|DRUG|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
214726016|NCT01147367|BEHAVIORAL|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
214640624|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214640625|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214640626|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214640627|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214640628|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214640629|NCT03529773|BIOLOGICAL|Formulation A|RSV vaccine
214640630|NCT03529773|BIOLOGICAL|Formulation B|RSV vaccine
214640631|NCT03529773|BIOLOGICAL|Placebo|Placebo
214640632|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
214640633|NCT01340209|DRUG|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
214640634|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
214640635|NCT05563792|BEHAVIORAL|Options for Pain Management using Non-medication Strategies|The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
214640636|NCT00835471|DRUG|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
214640637|NCT00835471|DRUG|erlotinib|erlotinib 150 mg/day continuously until disease progression
214640638|NCT02412293|BEHAVIORAL|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
214640639|NCT02412293|OTHER|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
214640640|NCT02412293|BEHAVIORAL|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
214640641|NCT01415427|DRUG|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
214640642|NCT01415427|DRUG|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
214640643|NCT05506761|PROCEDURE|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
214640644|NCT05506761|PROCEDURE|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
214640645|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
214640646|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
214640647|NCT05229107|DEVICE|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
214640648|NCT05370859|OTHER|There is no intervention for this study|There is no intervention or exposure for this study
214640649|NCT03530410|DEVICE|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
214640650|NCT00328770|DRUG|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
214640651|NCT05012293|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
214640652|NCT05012293|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
214640653|NCT02205060|OTHER|virtual reality exposure treatment|
214640654|NCT02205060|OTHER|cognitive and behavioral approaches therapy|
214640655|NCT06149858|PROCEDURE|hernioplasty|ventral hernia repair with mesh
214640656|NCT05206526|BEHAVIORAL|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
214640657|NCT05206526|BEHAVIORAL|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
214640658|NCT01381783|PROCEDURE|Phacoemulsification|Phacoemulsification under topical anesthesia
214640659|NCT04991298|DRUG|Oral premedication|Oral anesthesia premedication for congenital Cardiac surgery
214726017|NCT06353867|OTHER|Group Exercise|The children with special needs included in the study were included in group exercises for 45 minutes 2 days a week in groups of 10 children each. Group exercises were planned as balance and coordination exercises including warm-up and cool-down periods. In the warm-up and cool-down periods, counting in place and balance exercises were performed. The exercises included tasks such as side walking, tandem walking, walking on a balance board, walking in a figure 8, walking over obstacles, throwing a ball to the person next to him/her while passing through cones, and throwing a ball by jumping while passing through cones.The exercises were made more difficult by following a progressive method every 2 weeks. The exercises were performed in 3 sets of 5 repetitions under the supervision of a physiotherapist.
214640660|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
214640661|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
214640662|NCT02595190|PROCEDURE|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
214640663|NCT02595190|DRUG|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
214640664|NCT02595190|DEVICE|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
214640665|NCT00448188|PROCEDURE|central venous catheter application|
214640666|NCT00533078|DIETARY_SUPPLEMENT|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
214640667|NCT02007174|DRUG|Bevacizumab|
214640668|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
214640669|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
214640670|NCT02007174|PROCEDURE|Argon laser treatment|
214640671|NCT02642978|PROCEDURE|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
214640672|NCT02642978|PROCEDURE|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
214640673|NCT01625780|PROCEDURE|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
214640674|NCT01625780|PROCEDURE|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
214640675|NCT04456439|BIOLOGICAL|Remestemcel-L|Participants may receive up to 2 infusions of 2 x 10\^6 remestemcel-L within a 5-day period.
214640676|NCT04456439|DRUG|Hydrocortisone|Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
214640677|NCT04456439|DRUG|Diphenhydramine|Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
214640678|NCT02475655|DRUG|Ruxolitinib|10 mg orally twice daily for 5 weeks
214640679|NCT04293770|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
214640680|NCT03382847|COMBINATION_PRODUCT|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
214640681|NCT05946473|DIETARY_SUPPLEMENT|Gum base containing xylitol and essencial oils|Participants will be asked to chew 2 pieces of chewing gum containing additives for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
214640682|NCT05946473|DIETARY_SUPPLEMENT|Gum base with no additives|Participants will be asked to chew 2 pieces of pure gum base for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
214640683|NCT01936532|DRUG|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
214640684|NCT01936532|DRUG|Lenalidomide|
214640685|NCT01936532|DRUG|Dexamethasone|
214640686|NCT06463067|BEHAVIORAL|playing mobile game|Changes in anxiety levels were measured by playing a mobile game to children before dental examination.
214640687|NCT06463067|BEHAVIORAL|reading book|Changes in anxiety levels were measured by reading books to children before dental examination.
214640688|NCT06463067|BEHAVIORAL|watching video|Changes in anxiety levels were measured by showing a video to children before dental examination.
214640689|NCT06463067|BEHAVIORAL|tell-show-do group|Before the dental examination, the tell-show-do technique was applied to the children and the changes in their anxiety levels were measured.
214640690|NCT01877564|DRUG|Metformin|
214640691|NCT01573273|DRUG|Oxytocin|intranasal administration, 40 IUs
214640692|NCT01573273|DRUG|Saline|intranasal administration, 40 IUs
214640693|NCT04082195|OTHER|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
214640694|NCT04082195|OTHER|Uno board game|A popular board game which is not a mobile app.
214640695|NCT03973281|DEVICE|Materna Prep Device|Materna Prep Device
214640696|NCT03973281|OTHER|Standard of Care (SOC)|Standard of Care (SOC)
214640697|NCT03545906|OTHER|TEAM-UP Intervention Group|Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.
214640698|NCT03545906|OTHER|Enhanced Care Comparison|Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
214640699|NCT05625776|PROCEDURE|pain delivery with capsaicin and heat|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
214640700|NCT05625776|PROCEDURE|distractor delivery with sensory TENS|Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
214640701|NCT01017107|DRUG|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
214726018|NCT02607462|BIOLOGICAL|PRP|
214726019|NCT02607462|OTHER|Placebo|
214726020|NCT01720472|GENETIC|Biomarker studies|
214726021|NCT01452191|BEHAVIORAL|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
214726022|NCT01452191|BEHAVIORAL|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
214726023|NCT04703049|OTHER|Blood Viscosity Testing|we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
214726024|NCT00003549|DRUG|CMF regimen|
214726025|NCT00003549|DRUG|cyclophosphamide|
214726026|NCT00003549|DRUG|fluorouracil|
214726027|NCT00003549|DRUG|methotrexate|
214726028|NCT06479434|DRUG|Metformin|Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)
214726029|NCT04226144|DEVICE|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
214726030|NCT04226144|DEVICE|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
214726031|NCT00702936|DRUG|TELMISARTAN|80 mg daily
214726032|NCT00702936|DRUG|RAMIPRIL|5 mg daily
214726033|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
214726034|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
214726035|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
214726036|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
214726037|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
214726038|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
214726039|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
214726040|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
214726041|NCT01347073|DRUG|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
214726042|NCT02204059|DRUG|hMAb BIWA 4|
214726043|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
214726044|NCT02330601|PROCEDURE|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
214726045|NCT01478581|DRUG|PCI-32765|
214726046|NCT01478581|DRUG|Dexamethasone|
214726047|NCT06446895|DIAGNOSTIC_TEST|Coronariography|Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
214726048|NCT05941910|DRUG|Q10|240mg of Q10 orally, every day
214726049|NCT06323499|PROCEDURE|Induction of atypical atrial flutter|Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
214726050|NCT00338429|BEHAVIORAL|FHP Sleep Program|Cognitive-Behavioral Intervention
214726051|NCT02705352|DRUG|5-Fluorouracil|Treatment medication
214726052|NCT02705352|OTHER|Normal saline|Placebo
214726053|NCT00372489|DRUG|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
214726054|NCT03612674|PROCEDURE|Standard colonoscopy|Current standard of care colonoscopy.
214726055|NCT03612674|DEVICE|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
214726056|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
214726057|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
214726058|NCT05847556|OTHER|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
214726059|NCT05847556|OTHER|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
214726060|NCT05148429|OTHER|Ultrasound exam|Ultrasound exam
214726061|NCT05148429|OTHER|Fetal MRI|Fetal MRI
214726062|NCT05148429|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
214726063|NCT05148429|OTHER|Pediatric Follow up|Pediatric Follow up
214726064|NCT00389129|DRUG|acetylsalicylic acid|
214726065|NCT04494477|BEHAVIORAL|The IN•clued program|The INclued program as previously described.
214726066|NCT03634228|DRUG|Cytarabine|Given SC
214726067|NCT03634228|DRUG|Milademetan Tosylate|Given PO
214640702|NCT05201755|DEVICE|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
214640703|NCT03243994|DIAGNOSTIC_TEST|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
214640704|NCT01460823|PROCEDURE|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
214640705|NCT01976559|DEVICE|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
214640706|NCT01976559|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
214640707|NCT00353418|DRUG|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
214640708|NCT00353418|DRUG|Ribavirin|800 mg orally daily for 48 weeks
214640709|NCT00353418|DRUG|Ribavirin|1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
214640710|NCT01347034|PROCEDURE|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
214640711|NCT01347034|BIOLOGICAL|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
214640712|NCT03535623|OTHER|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
214640713|NCT03535623|OTHER|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.
214640714|NCT02828410|DIETARY_SUPPLEMENT|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
214640715|NCT00653237|DEVICE|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
214640716|NCT00257010|DRUG|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
214640717|NCT03618108|DRUG|Doxycycline Capsule|doxycycline capsule
214640718|NCT03618108|DRUG|Azithromycin Capsule|azithromycin capsule
214640719|NCT03618108|DRUG|Rifabutin Oral Capsule|rifabutin capsule
214640720|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
214640721|NCT03618108|DRUG|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
214640722|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
214640723|NCT03739073|OTHER|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
214640724|NCT03563937|DRUG|Phenprocoumon|Follow the physician's prescription.
214640725|NCT03563937|DRUG|Apixaban|2.5 mg or 5 mg, twice daily
214640726|NCT03563937|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
214640727|NCT03563937|DRUG|Edoxaban|30 mg or 60 mg, once daily
214640728|NCT01895127|DRUG|Eculizumab|
214640729|NCT01895127|BIOLOGICAL|Immunoglobulin|
214640730|NCT01895127|PROCEDURE|Plasmapheresis|
214726068|NCT03634228|DRUG|Venetoclax|Given PO
214640731|NCT03362775|DRUG|Propofol|Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
214640732|NCT02020486|DRUG|Perampanel|2 mg up to 4 mg
214640733|NCT02020486|DRUG|Perampanel|2 mg up to 6 mg
214640734|NCT03343015|PROCEDURE|complete dentures|therapy with maxilla and mandible dentures
214640735|NCT05019001|PROCEDURE|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
214640736|NCT05019001|PROCEDURE|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
214640737|NCT06156085|DRUG|Vonoprazan and Amoxicillin|vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days
214640738|NCT06156085|DRUG|Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole|lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
214640739|NCT03622697|BEHAVIORAL|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
214640740|NCT03877172|DEVICE|High-flow nasal cannula|To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
214640741|NCT03529877|BIOLOGICAL|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
214640742|NCT04232735|OTHER|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
214640743|NCT03244033|OTHER|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
214640744|NCT03244033|BEHAVIORAL|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
214640745|NCT00859703|DRUG|Risedronate|35mg oral risedronate once per week for 24 months
214726069|NCT01084473|DRUG|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
214640746|NCT00859703|DRUG|Placebo|Placebo 35 mg once a week for 24 months
214640747|NCT04464213|OTHER|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
214640748|NCT04464213|OTHER|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
214640749|NCT01699087|PROCEDURE|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
214640750|NCT01699087|DEVICE|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
214640751|NCT06455514|DRUG|Magnesium Sulfate|4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
214640752|NCT06455514|DRUG|Saline|Control subjects will receive an equivalent volume of normal saline intravenously.
214726070|NCT01084473|DRUG|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
214726071|NCT01084473|DRUG|Placebo|0.9 % NaCl will be infused.
214726072|NCT04281823|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
214726073|NCT03052699|PROCEDURE|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
214726074|NCT01901367|DIETARY_SUPPLEMENT|nutritional intervention|Receive nutritional intervention
214726075|NCT01901367|BEHAVIORAL|exercise intervention|Receive exercise intervention
214726076|NCT01901367|OTHER|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
214726077|NCT01901367|BEHAVIORAL|counseling intervention|Receive phone counseling with a trained health coach
214726078|NCT01901367|OTHER|quality-of-life assessment|Ancillary studies
214726079|NCT01901367|OTHER|laboratory biomarker analysis|Correlative studies
214726080|NCT01901367|OTHER|questionnaire administration|Ancillary studies
214726081|NCT00552344|BIOLOGICAL|Cimzia|"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
214726082|NCT03914872|BIOLOGICAL|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
214726083|NCT03914872|DEVICE|Integrated electroporation device|"* Ichor Medical Systems~* All study injections will be given intramuscularly using an integrated electroporation device"
214726084|NCT02407665|BEHAVIORAL|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
214726085|NCT03542292|DIAGNOSTIC_TEST|placental drainage|
214726086|NCT00717951|DRUG|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
214726087|NCT00997828|DEVICE|everolimus-eluting stent|Xience V stent
214726088|NCT00997828|PROCEDURE|coronary artery bypass graft surgery|coronary artery bypass graft surgery
214726089|NCT05234190|DRUG|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
214726090|NCT00659906|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
214726091|NCT00659906|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
214726092|NCT04023344|DRUG|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
214726093|NCT04023344|DRUG|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
214726094|NCT03803449|DRUG|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
214726095|NCT03803449|DRUG|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
214726096|NCT03803449|DRUG|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
214726097|NCT00314054|DRUG|HCV-796|HCV-796 1000mg single dose
214726098|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
214726099|NCT01531686|PROCEDURE|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
214726100|NCT03637894|DIETARY_SUPPLEMENT|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
214726101|NCT03637894|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
214726102|NCT03637894|OTHER|Breastfeeding infants|Reference group
214726103|NCT03317366|DRUG|ARQ 092|Open-label expanded access for ARQ 092 capsules
214726104|NCT00911066|DRUG|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
214726105|NCT00911066|DRUG|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
214726106|NCT04453605|OTHER|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
214726107|NCT05076552|DRUG|TACH101|Orally via capsules
214726108|NCT05321589|OTHER|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
214726109|NCT02144376|DIETARY_SUPPLEMENT|Ispaghula|
214640753|NCT04210466|BEHAVIORAL|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
214640754|NCT04210466|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q\&A 1 Session 4: Q\&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
214640755|NCT02582957|OTHER|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
214640756|NCT04902365|OTHER|neurofeedback|(based on real-time functional magnetic resonance signals)
214640757|NCT01217541|OTHER|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
214640758|NCT01217541|OTHER|Control|A control group of nursing home units that do not get any form of active intervention
214640759|NCT04168294|DRUG|Propofol|patients in sedation group will be intravenous injected propofol in bolus
214640760|NCT04168294|DEVICE|endoscopy|endoscopy system
214640761|NCT03021642|DRUG|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
214640762|NCT03021642|DRUG|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
214726110|NCT02144376|DIETARY_SUPPLEMENT|Maltodextrin|
214726111|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
214726112|NCT05859581|PROCEDURE|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
214726113|NCT03696628|OTHER|Electrocardiogram|heart testing
214726114|NCT03696628|OTHER|physical examination|done by the investigator
214726115|NCT03696628|OTHER|echocardiography|heart testing
214726116|NCT03696628|BIOLOGICAL|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
214726117|NCT00666055|DRUG|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
214726118|NCT04586296|OTHER|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
214640763|NCT03021642|DRUG|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
214640764|NCT03021642|DRUG|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
214726119|NCT02449772|OTHER|No intervention|No intervention
214640765|NCT01392820|DRUG|TC-5214|Tablet, Oral, twice daily
214640766|NCT01392820|DRUG|Placebo|Tablet, Oral, twice daily
214640767|NCT05412914|DRUG|Remimazolam infusion|Remimazolam infusion for anesthesia induction
214640768|NCT05412914|DRUG|Propofol infusion|Propofol infusion for anesthesia induction
214640769|NCT04438447|DIETARY_SUPPLEMENT|parenteral feeding|A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
214640770|NCT00441545|DRUG|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
214640771|NCT00441545|DRUG|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
214640772|NCT05074758|DIAGNOSTIC_TEST|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
214640773|NCT05074758|DIAGNOSTIC_TEST|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest"
214640774|NCT05074758|DIAGNOSTIC_TEST|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
214640775|NCT00882141|BEHAVIORAL|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
214640776|NCT00882141|BEHAVIORAL|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
214640777|NCT01724437|DEVICE|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
214640778|NCT02213874|OTHER|Questionnaire|A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
214640779|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Initial Check-up and Text Messages|Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.
214640780|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Flier and Text Messages|Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
214640781|NCT01783119|DIETARY_SUPPLEMENT|Aloe Barbadensis Miller|
214640782|NCT01783119|DIETARY_SUPPLEMENT|placebo water|
214726120|NCT01320813|PROCEDURE|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
214726121|NCT01320813|PROCEDURE|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
214640783|NCT05278182|DRUG|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
214640784|NCT05278182|DRUG|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
214640785|NCT01913080|OTHER|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
214640786|NCT02474082|BIOLOGICAL|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
214726122|NCT00023712|DRUG|bortezomib|Given IV
214640787|NCT02474082|DRUG|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
214640788|NCT03389282|DIAGNOSTIC_TEST|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
214640789|NCT00003100|DIETARY_SUPPLEMENT|soy isoflavones|
214640790|NCT00002147|DRUG|Doxorubicin hydrochloride (liposomal)|
214640791|NCT03452371|BEHAVIORAL|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
214640792|NCT03452371|BEHAVIORAL|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
214640793|NCT01034046|OTHER|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
214640794|NCT01034046|OTHER|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
214640795|NCT01792908|DEVICE|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
214640796|NCT04044755|OTHER|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
214640797|NCT04283903|DIAGNOSTIC_TEST|PICF|PICF collection from 4 sites
214640798|NCT00495651|DRUG|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
214640799|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
214640800|NCT00495651|DRUG|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
214640801|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
214640802|NCT04317274|BEHAVIORAL|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
214640803|NCT04317274|BEHAVIORAL|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
214640804|NCT04317274|BEHAVIORAL|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
214640805|NCT04317274|BEHAVIORAL|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
214640806|NCT05988151|OTHER|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
214640807|NCT05866198|DIAGNOSTIC_TEST|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
214640808|NCT03861637|OTHER|ESA for correction of PTA to 12-13g/dl|To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
214640809|NCT00266253|DRUG|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
214640810|NCT00266253|DRUG|Metformin|As prescribed, for 12 weeks
214726123|NCT00023712|OTHER|laboratory biomarker analysis|Correlative studies
214726124|NCT00023712|OTHER|pharmacological study|Correlative studies
214640811|NCT03970187|OTHER|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
214640812|NCT03067272|DEVICE|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
214640813|NCT03828929|DRUG|Vitamin C|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
214640814|NCT03828929|DRUG|Normal saline|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
214640815|NCT05320900|DIAGNOSTIC_TEST|Chest auscultation|Chest auscultation data
214640816|NCT04138485|BIOLOGICAL|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
214640817|NCT04138485|BIOLOGICAL|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
214640818|NCT02887131|OTHER|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
214640819|NCT02995109|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)"
214640820|NCT02995109|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214640821|NCT01387893|BEHAVIORAL|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
214640822|NCT04241614|OTHER|No interventions|No interventions
214640823|NCT00744874|PROCEDURE|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
214640824|NCT03396965|OTHER|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
214640825|NCT01681550|DRUG|Incretin-based therapy|
214640826|NCT04304027|OTHER|Tailored exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
214640827|NCT04304027|OTHER|Standard exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at \>70% heart rate reserve followed by 2 minutes working rest
214640828|NCT05743465|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
214640829|NCT05465356|OTHER|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
214640830|NCT05465356|OTHER|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
214640831|NCT03077568|BEHAVIORAL|My Stress Control|"The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.~The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.~Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals."
214640832|NCT01017952|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
214640833|NCT01017952|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
214640834|NCT01395992|DRUG|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
214640835|NCT01395992|DRUG|asenapine|asenapine 10 mg tablet, SL BID for 182 days
214640836|NCT02666014|DRUG|Sugammadex|Reversal of neuromuscular blockade
214640837|NCT02666014|DRUG|Neostigmine|Reversal of neuromuscular blockade
214640838|NCT05116124|OTHER|dosing of inflammatory parameters|View and register the dosing of inflammatory parameters
214640839|NCT04347083|DIAGNOSTIC_TEST|Electrodiagnostic test|Muscle spindle- based reflex latency will be measured
214640840|NCT00031161|DRUG|Nitisinone (NTBC)|
214640841|NCT00031161|DRUG|Dichloroacetate|
214640842|NCT00031161|BEHAVIORAL|Low-tyrosin diet|
214640843|NCT00264914|DRUG|SR121463B|
214640844|NCT05480813|DEVICE|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
214640845|NCT05480813|OTHER|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
214726125|NCT04866095|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
214726126|NCT04866095|DEVICE|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
214726127|NCT01378299|DRUG|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
214726128|NCT05920070|PROCEDURE|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
214726129|NCT05193877|PROCEDURE|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
214726130|NCT02702947|DIETARY_SUPPLEMENT|Prunus domestica extract|Prosman 1 capsule twice a day
214726131|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
214726132|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
214726133|NCT06430645|DRUG|Saline|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
214726134|NCT02046382|DRUG|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
214726135|NCT02046382|DRUG|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
214726136|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
214726137|NCT00901589|DIETARY_SUPPLEMENT|thistle oil|four capsules a day
214726138|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
214726139|NCT00901589|DIETARY_SUPPLEMENT|Thistle oil|Four capsules daily
214726140|NCT04425460|DRUG|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
214640846|NCT02443064|DRUG|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
214640847|NCT02949752|DRUG|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
214640848|NCT01064167|DRUG|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
214640849|NCT02339493|OTHER|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
214640850|NCT05076539|OTHER|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
214640851|NCT04702646|DRUG|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
214640852|NCT04702646|PROCEDURE|Colonoscopy|colonoscopy will be performed to every patient included in the study
214640853|NCT00433407|BIOLOGICAL|trastuzumab|
214640854|NCT03355989|OTHER|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
214640855|NCT03355989|OTHER|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
214640856|NCT01373983|DRUG|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
214640857|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
214726141|NCT04425460|OTHER|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
214726142|NCT01448707|DRUG|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
214726143|NCT01448707|DRUG|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
214640858|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
214640859|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is \>5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is \<5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
214640860|NCT00954278|DRUG|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
214640861|NCT03622827|COMBINATION_PRODUCT|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~* Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
214640862|NCT03965559|PROCEDURE|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]"
214640863|NCT03823612|DRUG|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
214640864|NCT03823612|DRUG|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
214640865|NCT04248738|BEHAVIORAL|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
214640866|NCT06270979|DEVICE|ISHA|Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).
214726144|NCT04306978|OTHER|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
214726145|NCT04306978|OTHER|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
214640867|NCT03032276|OTHER|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH\&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
214640868|NCT06481761|DEVICE|Double-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on double 0.016'' Stainless steel round wires in both slots of the double slot brackets.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
214640869|NCT06481761|DEVICE|Single-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on single 0.017x0.022'' Stainless steel wire. Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
214640870|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
214640871|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
214640872|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
214640873|NCT06437938|OTHER|Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold|To be taken according to the information in the study protocol/patient information leaflet.
214640874|NCT06437938|OTHER|Placebo group 2: Placebo powder corresponding to Wasabi leaf powder|To be taken according to the information in the study protocol/patient information leaflet.
214640875|NCT04475614|DIETARY_SUPPLEMENT|BioGaia Prodentis lozenges|oral probiotics
214640876|NCT04475614|PROCEDURE|low level laser treatment with Ga-Al-As laser|low level laser treatment
214640877|NCT04475614|DIETARY_SUPPLEMENT|B vitamin injections (Neurobion, Merck, Darmstadt, Germany)|intra muscular vitamin injections
214640878|NCT05953636|DIETARY_SUPPLEMENT|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
214640879|NCT00615615|DRUG|Levetiracetam|"* high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~* low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less"
214640880|NCT00615615|DRUG|Placebo|Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
214640881|NCT03504592|BEHAVIORAL|Completion of Glucose logs|Glucose logs will be assessed by provider for completeness and accuracy
214640882|NCT02429531|BIOLOGICAL|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
214640883|NCT02429531|BIOLOGICAL|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
214726146|NCT04853277|BEHAVIORAL|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
214726147|NCT06512831|DRUG|Isoniazid|Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
214640884|NCT03460431|DEVICE|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
214640885|NCT03460431|DEVICE|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
214640886|NCT02902120|DRUG|Post-transplant Grazoprevir and Elbasvir|Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
214640887|NCT04228185|PROCEDURE|sleeve gastrectomy|Comparison of banded and not-banded sleeve gastrectomy
214640888|NCT02936141|BEHAVIORAL|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
214640889|NCT01485692|DRUG|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
214640890|NCT01485692|DRUG|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
214640891|NCT01485692|DRUG|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
214640892|NCT01485692|DRUG|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
214640893|NCT06182592|DRUG|Liposomal cytarabine-daunorubicin for injection|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
214640894|NCT06182592|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2."
214640895|NCT01769092|DIETARY_SUPPLEMENT|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
214640896|NCT01769092|OTHER|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
214640897|NCT01758757|PROCEDURE|Vitrectomy|
214640898|NCT02435914|DRUG|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
214640899|NCT02435914|DRUG|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
214640900|NCT01278498|DRUG|Escitalopram|first week:5mg 2nd week\~12 week:10mg
214640901|NCT01278498|DRUG|sugar pill|first week:5mg 2nd week\~12 weeks:10mg
214640902|NCT01353703|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
214640903|NCT03814980|BEHAVIORAL|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
214640904|NCT03814980|DEVICE|application on a computer tablet|a computer tablet
214640905|NCT03867045|DEVICE|Usability of an electronic symptom management application|Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
214640906|NCT03667703|DRUG|Famotidine|Patients will be randomized to either receive a placebo or famotidine (study drug).
214640907|NCT03667703|DRUG|Placebo|Patients will be randomized to either receive a placebo or famotidine (study drug).
214640908|NCT06103032|PROCEDURE|Breast Conserving Surgery|Patients undergoing breast conserving surgery
214640909|NCT06103032|PROCEDURE|Mastectomy|Patients undergoing mastectomy
214640910|NCT00693160|DRUG|ketorolac|single intrathecal injection of ketorolac 2 mg
214640911|NCT00693160|DRUG|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
214640912|NCT00693160|DRUG|remifentanil|All subjects will receive a remifentanil infusion
214640913|NCT00693160|DRUG|Capsaicin|Topical capsaicin pain model utilized for each subject
214640914|NCT03522441|DRUG|Clindamycin 1% Gel|Topical gel
214640915|NCT03522441|DRUG|Placebo|Topical Placebo gel
214640916|NCT02281019|PROCEDURE|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
214640917|NCT02281019|DEVICE|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
214640918|NCT02444273|PROCEDURE|Exercise|Subjects will be given and individualized exercise program.
214640919|NCT01046500|DIETARY_SUPPLEMENT|myo-inositol|2 grams twice a day
214640920|NCT01046500|DRUG|Metformin|pill, 250 mg, twice a day
214640921|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
214640922|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
214640923|NCT00728221|DIETARY_SUPPLEMENT|Cornstarch|Placebo
214640924|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
214640925|NCT04172558|BIOLOGICAL|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
214640926|NCT04172558|DRUG|Trimix|on demand ICI of Trimix
214640927|NCT00868101|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
214640928|NCT03893149|BEHAVIORAL|Active-Start intervention|Supervised exercise training. The intervention is a physical activity intervention that consist of 5 times per week before starting the first school-class (8:00-8:30 a.m.), 5 times per week. Each session was previously planned and described in a manual dedicated to the study. These sessions were designed by the research team and delivered by a graduate in Sport The intervention program included sports games adapted to the age of the participants, playground games, dance and other recreational activities. The intensity of the main part of the sessions was moderate-to-vigorous according to a previous study and this intensity was confirmed by accelerometry. Also, different activities favoring social interactions were designed to facilitate the interactions between the participants at the end of the sessions (cold-down).
214640929|NCT03893149|BEHAVIORAL|No Intervention|No-exercise
214640930|NCT04218097|OTHER|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
214640931|NCT04617158|PROCEDURE|Adjustable strabismus surgery|Adjustable surgery will be done using sliding nose technique using fornix approach
214640932|NCT04063371|OTHER|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
214640933|NCT04063371|OTHER|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
214640934|NCT02642094|DRUG|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
214640935|NCT02284282|DRUG|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
214640936|NCT02284282|DRUG|subcutaneum injection lidocaine|placebo injection
214640937|NCT02882633|DRUG|30ml bolus of bupivacaine|Local anesthetic
214640938|NCT03283800|OTHER|Copper impregnated compression stocking|Copper impregnated compression stocking
214640939|NCT03283800|OTHER|Normal compression stocking|Normal compression stocking without copper
214640940|NCT06438315|OTHER|No intervention|No intervention
214640941|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
214640942|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
214640943|NCT03650192|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
214640944|NCT05335460|DRUG|Envafolimab|300mg,sc,d1,Q3W
214640945|NCT04405011|DRUG|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
214793828|NCT03772483|DEVICE|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
214640946|NCT04405011|DRUG|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
214640947|NCT04884048|DIAGNOSTIC_TEST|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
214640948|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
214640949|NCT06087055|DRUG|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
214640950|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
214640951|NCT04125355|OTHER|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
214640952|NCT04125355|OTHER|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
214640953|NCT05301946|OTHER|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
214640954|NCT06050044|DRUG|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
214793829|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
214793830|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
214640955|NCT06050044|DRUG|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
214640956|NCT02286947|DRUG|Eteplirsen|Eteplirsen solution for IV infusion
214640957|NCT04995146|OTHER|Clinical stroke extended management pathway|"1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS"
214640958|NCT03357627|DRUG|TAK-659|TAK-659 tablets.
214640959|NCT03357627|DRUG|Venetoclax|Venetoclax tablets.
214640960|NCT02175680|DRUG|PRO 140|CCR5 Antagonist
214640961|NCT02175680|OTHER|Historical data|Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
214640962|NCT03979274|DRUG|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
214640963|NCT03979274|DRUG|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
214640964|NCT00047138|BIOLOGICAL|dactinomycin|
214640965|NCT00047138|DRUG|carboplatin|
214640966|NCT00047138|DRUG|cyclophosphamide|
214640967|NCT00047138|DRUG|doxorubicin hydrochloride|
214640968|NCT00047138|DRUG|etoposide|
214640969|NCT00047138|DRUG|vincristine sulfate|
214640970|NCT00047138|PROCEDURE|adjuvant therapy|
214640971|NCT00047138|PROCEDURE|conventional surgery|
214640972|NCT00047138|PROCEDURE|neoadjuvant therapy|
214640973|NCT00047138|RADIATION|radiation therapy|
214640974|NCT04800198|PROCEDURE|non-invasive ventilation|none, measurements only
214640975|NCT01665144|DRUG|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
214640976|NCT01665144|DRUG|Placebo|Film-coated tablets
214640977|NCT01221428|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
214640978|NCT01128829|OTHER|Water|60 ml of water were drank 10 min before doing a OGTT
214640979|NCT01128829|OTHER|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
214640980|NCT03406065|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
214640981|NCT03406065|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
214793831|NCT04588428|DRUG|INO-4700|INO-4700 was administered ID.
214793832|NCT04588428|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
214640982|NCT04520113|BEHAVIORAL|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
214640983|NCT00501813|PROCEDURE|Hepatectomy|irregular Hepatectomy
214640984|NCT00501813|PROCEDURE|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
214640985|NCT01913483|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
214640986|NCT01913483|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
214640987|NCT05365763|BEHAVIORAL|Simulated telehealth serious illness conversation visit|"The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors."
214640988|NCT01459458|BEHAVIORAL|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
214640989|NCT01733030|DRUG|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
214640990|NCT01733030|DRUG|Seromycin|
214640991|NCT02302963|DEVICE|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
214640992|NCT02302963|DEVICE|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
214793833|NCT04588428|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device was administered following ID drug administration
214793834|NCT00679783|DRUG|AZD2281|PARP inhibitor Olaparib tablets, oral
214640993|NCT00368771|BEHAVIORAL|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
214640994|NCT00368771|BEHAVIORAL|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
214640995|NCT00368771|BEHAVIORAL|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
214640996|NCT00294112|DRUG|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
214640997|NCT00294112|DRUG|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
214640998|NCT00003887|BIOLOGICAL|peripheral blood lymphocyte therapy|
214640999|NCT00870753|BEHAVIORAL|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
214641000|NCT01816243|DRUG|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
214641001|NCT01816243|DRUG|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
214641002|NCT02916420|DRUG|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
214641003|NCT02916420|DRUG|Dexamethasone|≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
214641004|NCT05343065|DEVICE|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
214641005|NCT05893849|DRUG|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
214641006|NCT03515109|PROCEDURE|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
214641007|NCT03515109|PROCEDURE|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
214641008|NCT01459250|DRUG|AGO178C|
214641009|NCT05749614|DRUG|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
214641010|NCT05749614|DRUG|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
214641011|NCT00191594|DRUG|Duloxetine Hydrochloride|
214641012|NCT02972164|BEHAVIORAL|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
214641013|NCT02911428|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
214641014|NCT01049763|DRUG|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
214641015|NCT05718986|OTHER|No intervention|No intervention
214641016|NCT00915343|DRUG|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
214641017|NCT00915343|DRUG|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
214641018|NCT00630630|DRUG|Levetiracetam|
214641019|NCT00630630|OTHER|Placebo|
214641020|NCT02817412|BEHAVIORAL|Go/No-Training|
214641021|NCT02817412|BEHAVIORAL|Stop-Signal Training|
214641022|NCT02817412|BEHAVIORAL|Dot-Probe Paradigm|
214641023|NCT02817412|BEHAVIORAL|Generic Response Training|
214641024|NCT06251232|DRUG|Prednisone|Placebo
214641025|NCT01634438|DRUG|unfractionated heparin|unfractionated heparin
214641026|NCT02780882|DRUG|Pasireotide|
214641027|NCT03944239|BIOLOGICAL|Retinal pigment epitheliums transplantation|Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
214641028|NCT01920711|DRUG|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
214641029|NCT01920711|DRUG|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
214641030|NCT02170272|BEHAVIORAL|Home-based Lymphedema Care Program|Undergo HBLCP
214641031|NCT05294744|DRUG|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
214641032|NCT06507163|OTHER|The post-surgical breathing exercise group|Individuals in the Intervention-1 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.
214641033|NCT06507163|OTHER|The pre- and post- surgical breathing exercise group|Individuals in the Intervention-2 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
214641034|NCT04884555|OTHER|Standard neurorehabilitation|Routine post-stroke rehabilitation
214641035|NCT04884555|DIAGNOSTIC_TEST|Thiol-Disulphide Homeostasis|Monitoring the levels of thiol and disulphide in serum
214641036|NCT04884555|DIAGNOSTIC_TEST|Oxidized-reduced Glutathione Homeostasis|Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
214641037|NCT01318044|DRUG|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
214641038|NCT02396810|OTHER|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
214641039|NCT02396810|PROCEDURE|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
214641040|NCT03434379|DRUG|Atezolizumab|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
214641041|NCT03434379|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle
214641042|NCT03434379|DRUG|Sorafenib|Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle
214641043|NCT00005783|DRUG|Recombinant-methionyl human stem cell factor|
214641044|NCT01347736|OTHER|scrambler therapy|Undergo scrambler therapy
214641045|NCT01347736|OTHER|questionnaire administration|Ancillary studies
214641046|NCT01347736|PROCEDURE|dermatologic complications management/prevention|Undergo scrambler therapy
214641047|NCT06388473|BEHAVIORAL|Tailored implementation intervention|The tailored implementation intervention comprised of six implementation strategies: 1) Involve executive boards, 2) Mandate change, 3) Provide education and training, 4) Identify and prepare champions, 5) The use of information and communication technology and 6) Audit and provide feedback.
214641048|NCT03238287|DEVICE|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
214641049|NCT03238287|OTHER|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
214641050|NCT05744063|DRUG|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
214641051|NCT03068156|RADIATION|308-nm excimer laser|monochromator UVB laser (308nm)
214641052|NCT04405401|RADIATION|SABR|SABR to all oligoprogressive lesions + continuation of current systemic therapy
214641053|NCT04405401|OTHER|Standard of care|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
214641054|NCT06143748|DRUG|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
214641055|NCT06143748|DRUG|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
214641056|NCT06143748|RADIATION|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
214641057|NCT05110976|DRUG|AZD8630|Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
214641058|NCT05110976|DRUG|Placebo|Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
214641059|NCT02190851|DEVICE|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
214641060|NCT02190851|DEVICE|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
214641061|NCT05601557|OTHER|There is no intervention|The genotype of the patients was analyzed.
214641062|NCT02439658|DRUG|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
214641063|NCT01002079|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
214641064|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
214641065|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
214641066|NCT04997057|DIETARY_SUPPLEMENT|Probiotics mixture|"12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~* Bifidobacterium longum LA 101~* Lactobacillus helveticus La 102~* Lactococcus lactis LA 103~* Streptococcus thermophilus LA 104"
214641067|NCT03906500|BEHAVIORAL|High schools High on Life|"The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~* Online education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign competition~* Social norms campaign~Parent component~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website"
214641068|NCT05039359|DRUG|FlecIH-103|flecainide acetate inhalation solution
214641069|NCT03640429|DEVICE|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
214641070|NCT03640429|DEVICE|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
214641071|NCT03564626|OTHER|Health-IT +/- Scheduled Follow Up|"* Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4"
214641072|NCT01658657|DRUG|Hydrochlorothiazide|
214641073|NCT01658657|DRUG|Lisinopril|
214641074|NCT01658657|DRUG|Amlodipine|
214641075|NCT01658657|DRUG|metoprolol|
214641076|NCT01658657|DRUG|lisinopril/hydrochlorothiazide|This is a combination pill
214641077|NCT03687502|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast Enhanced Ultrasound of the appendix
214641078|NCT05449704|DRUG|DA-5218|single dose administration (DA-5218 one tablet once a day)
214641079|NCT05449704|DRUG|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
214641080|NCT00466310|DRUG|Aripiprazole|Aripiprazole for 4 weeks
214641081|NCT00466310|DRUG|Risperidone|Subjects will be randomized to risperidone for 4 weeks
214641082|NCT00466310|OTHER|Healthy volunteers|Healthy volunteers
214641083|NCT04949841|DRUG|Delgocitinib|Delgocitinib cream 20 mg/g
214726148|NCT02667392|PROCEDURE|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
214641084|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
214641085|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
214641086|NCT06149793|DRUG|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
214641087|NCT06149793|OTHER|Placebo Control|Placebo Control
214641088|NCT04211181|OTHER|The multifaceted interventions|"1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A newly developed mobile application (mini-program) will be employed to facilitate venous thromboembolism (VTE) risk assessment and prophylaxis. Patients will scan a QR code to enroll in the program and be linked with their physician. Through the application, patients will complete standardized self-assessments of VTE risk, and physicians will receive periodic reminders indicating whether the assessment and prophylaxis orders have been completed.The application also provides educational modules and targeted messages for both patients and physicians, and enables interactive communication.~4. A quality-control team will receive weekly feedback reports to verify whether all enrolled patients underwent appropriate prophylaxis."
214641089|NCT04211181|OTHER|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
214641090|NCT06084884|BIOLOGICAL|AZD5851|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
214641091|NCT06791122|DEVICE|Digital therapeutic (CT-155)|Digital therapeutic (CT-155) - in the form of a smartphone app
214641092|NCT05554367|DRUG|Binimetinib|Given PO
214641093|NCT05554367|PROCEDURE|Biopsy Procedure|Undergo biopsy
214641094|NCT05554367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214641095|NCT05554367|PROCEDURE|Bone Scan|Undergo bone scan
214641096|NCT05554367|PROCEDURE|Computed Tomography|Undergo CT
214641097|NCT05554367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214641098|NCT05554367|DRUG|Palbociclib|Given PO
214641099|NCT05839808|OTHER|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
214641100|NCT05401617|OTHER|additional information via the computerized tool|additional information delivered via the computerized tool
214641101|NCT03949972|OTHER|Biosampling|Biosampling at initial visit and follow-up visits
214641102|NCT03770780|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
214641103|NCT03770780|DRUG|Placebo|Placebo in combination with Ketamine
214726149|NCT02667392|PROCEDURE|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
214726150|NCT04439812|OTHER|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
214726151|NCT01250743|DIETARY_SUPPLEMENT|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
214726152|NCT03215667|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
214726153|NCT01886755|DIETARY_SUPPLEMENT|ORS rehydration solution|
214726154|NCT01886755|DIETARY_SUPPLEMENT|placebo|
214726155|NCT03374761|OTHER|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
214726156|NCT04208880|BEHAVIORAL|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
214726157|NCT04208880|BEHAVIORAL|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
214726158|NCT04208880|BEHAVIORAL|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
214726159|NCT04208880|BEHAVIORAL|TBH Memory 1.0|TBH Memory program with easy challenge activities.
214641104|NCT06965842|OTHER|Parent-centered developmental training|After discharge from the neonatal intensive care unit, 1:1 monitoring is conducted at home for 30 minutes twice a week using a video conferencing platform (Zoom) until the corrected age of 6 months to provide parent-centered early intervention. Parents film the developmental training process using a smartphone and send the video to the therapist, who analyzes the video data to provide new treatment goals and guidelines.
214641105|NCT05678491|OTHER|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
214641106|NCT06061861|OTHER|Financial support for healthy foods and free home delivery|Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
214641107|NCT06061861|OTHER|Free home delivery|Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
214641108|NCT01777581|DRUG|Milnacipran|
214641109|NCT01777581|DRUG|Placebo|
214641110|NCT01381159|BEHAVIORAL|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
214641111|NCT01381159|BEHAVIORAL|Control|Standard medical care
214641112|NCT01211600|OTHER|Staples|Interrupted Ethicon Staples
214726160|NCT04208880|BEHAVIORAL|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
214726161|NCT06118762|DRUG|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
214726162|NCT01810380|DRUG|Placebo|Once daily as tablets and capsules, orally
214726163|NCT01810380|DRUG|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
214726164|NCT01810380|DRUG|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
214726165|NCT00614991|DRUG|Raltegravir|400mg BID
214726166|NCT00614991|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
214726167|NCT00614991|DRUG|Ritonavir|100 mg BID or QD
214726168|NCT02918539|DRUG|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
214726169|NCT02253940|DRUG|BILR 355 - Treatment A (current tablet formulation)|
214726170|NCT02253940|DRUG|BILR 355 - Treatment B (new tablet formulation)|
214726171|NCT02253940|DRUG|BILR 355 - Treatment C (new capsule formulation)|
214726172|NCT02253940|DRUG|BILR 355 - Treatment D (current tablet formulation)|
214726173|NCT02253940|DRUG|BILR 355 - Treatment E (new capsule formulation)|
214726174|NCT02253940|DRUG|Ritonavir|
214726175|NCT01311739|DRUG|Cyanocobalamin|
214641113|NCT01211600|OTHER|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
214641114|NCT04032990|DEVICE|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
214641115|NCT01331356|DRUG|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
214641116|NCT04682470|OTHER|No intervention ; observational|No intervention; observational
214641117|NCT05408754|DEVICE|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
214641118|NCT04608695|PROCEDURE|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
214641119|NCT00003642|DRUG|cisplatin|
214641120|NCT00003642|DRUG|fluorouracil|
214641121|NCT00003642|RADIATION|radiation therapy|
214641122|NCT06430788|BIOLOGICAL|Emapalumab|Emapalumab is an interferon gamma (IFNγ) blocking antibody
214726176|NCT03029767|OTHER|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
214726177|NCT03029767|OTHER|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
214726178|NCT03029767|OTHER|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
214726179|NCT02067572|OTHER|Saline mouthwash|
214641123|NCT02403609|OTHER|BPT, Computerized Assessment|
214641124|NCT02670135|DRUG|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
214641125|NCT02670135|DRUG|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
214641126|NCT06141278|BEHAVIORAL|Care cascade intervention|Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
214641127|NCT01050400|GENETIC|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
214641128|NCT05754346|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
214641129|NCT05754346|OTHER|Upper extremity exercises combined with diaphragmatic breathing exercises|"Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises."
214641130|NCT03502993|DIAGNOSTIC_TEST|Validation of biomarker|
214641131|NCT04377737|DIAGNOSTIC_TEST|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
214641132|NCT00262431|PROCEDURE|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
214641133|NCT03512145|DEVICE|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
214641134|NCT05970263|DRUG|Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.|2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
214641135|NCT05970263|OTHER|External Comparator|Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
214641136|NCT06774040|DRUG|Etribnabdione 25 mg BID|The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.
214641137|NCT06774040|DRUG|Etribnabdione 50 mg BID|The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.
214641138|NCT05378763|DRUG|Poziotinib|Poziotinib tablets
214641139|NCT05378763|DRUG|Docetaxel|Docetaxel IV infusion
214641140|NCT06291909|BEHAVIORAL|Small Steps Program|Participants in the intervention group will be given access to the Small Steps website. Small Steps website provides a visual representation of the participant's current use of time and allows for manipulation to demonstrate how small lifestyle changes may improve sleep and physical activity needs. The personal outcome goals selected by the participant will also feature on participant's dashboard within the Small Steps website as a reminder. Participants will be prompted through the first 12 weeks to add a new behaviour change each week and will receive support phone calls weekly. During the 12-week Maintenance Phase participants will be guided to maintain their new behaviour, with supportive phone calls being progressively reduced from fortnightly to monthly. At the completion of the 12 weeks, investigator support will be withdrawn. Maintenance of the new behaviour without support will then be assessed over 12 additional weeks in the Follow-Up phase.
214641141|NCT06291909|BEHAVIORAL|Comparator Program|Participants will receive generic health advice only and it will not be individually tailored, nor will they receive weekly support phone calls during the first 12-weeks. Participants will receive no feedback or support in the Maintenance or Follow-Up phases.
214641142|NCT05994053|DEVICE|high definition transcranial alternating current stimulation|low intensity alternating current to OFC
214641143|NCT03798626|DRUG|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
214641144|NCT03798626|DRUG|Bevacizumab|25 mg/mL concentration; administered IV
214641145|NCT03798626|DRUG|Modified FOLFOX6|Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
214641146|NCT03798626|DRUG|FOLFIRI|Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
214641147|NCT03798626|DRUG|Ramucirumab|10 mg/mL concentration; administered IV
214641148|NCT03798626|DRUG|Paclitaxel|6 mg/mL concentration; administered IV
214641149|NCT03798626|DRUG|Cabozantinib|60 mg tablet; administered orally
214641150|NCT06521463|DEVICE|WATCHMAN FLX Pro LAAC Device|WATCHMAN FLX Pro LAAC Device Implantation
214641151|NCT05003960|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214641152|NCT05884684|OTHER|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
214641153|NCT06287580|DRUG|chlorthalidone|chlorthalidone, 12.5 mg or 25 mg orally once daily
214641154|NCT06287580|OTHER|Placebo|Placebo tablet taken orally once daily
214641155|NCT05898165|OTHER|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
214641156|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
214641157|NCT04892173|DRUG|JNJ-90301900 (NBTXR3)|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
214641158|NCT04892173|DRUG|Cetuximab|Solution for infusion
214641159|NCT04892173|RADIATION|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
214641160|NCT04001023|DEVICE|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
214641161|NCT00185003|DRUG|endotoxin|
214641162|NCT00185003|DRUG|Potassium channel blockers: TEA, Quinin, Tolbutamide|
214641163|NCT00185003|DRUG|L-NMMA|
214641164|NCT03224429|OTHER|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
214726180|NCT02067572|OTHER|Salvia mouthwash|
214726181|NCT02235168|PROCEDURE|six minute walking test|
214726182|NCT04585672|OTHER|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
214726183|NCT03771781|DRUG|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
214726184|NCT03771781|DRUG|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
214726185|NCT02371018|DIETARY_SUPPLEMENT|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
214726186|NCT02732249|DRUG|Esomeprazole|Given 30 min before morning and evening meals
214726187|NCT02732249|DRUG|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
214726188|NCT02732249|DRUG|Clarithromycin|Given 30 min after morning and evening meals
214641165|NCT03224429|OTHER|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
214641166|NCT01634555|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
214641167|NCT01634555|DRUG|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
214641168|NCT01634555|DRUG|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
214641169|NCT01634555|DRUG|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
214641170|NCT03977129|DEVICE|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.
214641171|NCT03977129|OTHER|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
214641172|NCT05235425|BEHAVIORAL|Standard NDPP|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
214641173|NCT05235425|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
214641174|NCT04769362|DRUG|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
214726189|NCT02732249|DRUG|Metronidazole|Given 30 min after meals or at bedtime
214726190|NCT02530099|PROCEDURE|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
214726191|NCT02530099|PROCEDURE|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
214726192|NCT02623699|DRUG|Tofersen|Administered as specified in the treatment arm.
214726193|NCT02623699|DRUG|Placebo|Administered as specified in the treatment arm.
214641175|NCT06591572|PROCEDURE|Single-port robotic transanal total mesorectal excision|Rectal resection by transanal TME with single-port robotic surgery
214641176|NCT04595747|PROCEDURE|Biopsy Procedure|Undergo biopsy
214726194|NCT06306352|OTHER|Vibrotactile feedback|The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
214726195|NCT05154071|OTHER|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
214726196|NCT02699671|DEVICE|Bioresorbable Vascular Scaffold|
214726197|NCT04295707|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
214726198|NCT04295707|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
214726199|NCT00510367|DRUG|5-Fluorouracil|500 mg/m\^2 By Vein Daily x 2 Days
214726200|NCT00510367|DRUG|Cyclophosphamide|500 mg/m\^2 By Vein On Day 1
214726201|NCT00510367|DRUG|Doxorubicin|50 mg/m\^2 By Vein Over 72 Hours
214726202|NCT02150460|PROCEDURE|One-site peribulbar injection|injection into the inferior medial orbital compartment
214726203|NCT02150460|PROCEDURE|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
214793835|NCT00996528|BEHAVIORAL|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
214726204|NCT01505660|BEHAVIORAL|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
214726205|NCT00253929|DRUG|Intra-arterial infusion of adenosine|
214726206|NCT00253929|DRUG|intra-arterial infusion of caffeine|
214726207|NCT00253929|DRUG|intra-arterial infusion of acetylcholine|
214726208|NCT00253929|DRUG|intra-arterial infusion of sodium nitroprusside|
214726209|NCT00253929|PROCEDURE|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
214726210|NCT02726048|DEVICE|Simplus/Eson|Released product Simplus and Eson masks
214726211|NCT02198560|DEVICE|RS-3000 Lite|
214726212|NCT03796195|DRUG|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
214726213|NCT01026350|DIETARY_SUPPLEMENT|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
214726214|NCT02894255|DEVICE|Coronary artery bypass grafting|
214726215|NCT02894255|PROCEDURE|Percutaneous coronary intervention|
214726216|NCT03874195|BEHAVIORAL|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
214641177|NCT04595747|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214641178|NCT04595747|PROCEDURE|Computed Tomography|Undergo CT scan and PET/CT scan
214726217|NCT03874195|BEHAVIORAL|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
214726218|NCT00464620|DRUG|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
214726219|NCT03286634|DRUG|Daunorubicin|Given IV
214726220|NCT03286634|DRUG|Prednisolone|Given PO or IV
214726221|NCT03286634|DRUG|Vincristine|Given IV
214726222|NCT03286634|DRUG|Epirubicin|Given IV
214726223|NCT03286634|DRUG|E-coli L-asparaginase|Given IM or IV
214641179|NCT04595747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214641180|NCT04595747|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214641181|NCT04595747|DRUG|Rogaratinib|Given PO
214641182|NCT06451068|DEVICE|Peripheral retina robotically aligned optical coherence tomography (OCT) system|To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
214641183|NCT06451068|OTHER|Likert Scales|Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
214641184|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
214726224|NCT03286634|DRUG|6-Mercaptopurine|Given PO
214726225|NCT03286634|DRUG|Methotrexate|Given IV, PO or IT
214726226|NCT03286634|DRUG|Hydrocortisone|Given IT
214726227|NCT03286634|DRUG|Cytarabine|Given IV, IT or SC
214726228|NCT03286634|DRUG|Cyclophosphamide|Given IV
214726229|NCT05326906|DRUG|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
214726230|NCT02465762|DEVICE|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
214726231|NCT00854984|BEHAVIORAL|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
214726232|NCT01879475|DEVICE|032-11|Topical haemostat
214726233|NCT01879475|DEVICE|Floseal (R)|Topical haemostat
214726234|NCT02796079|BIOLOGICAL|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
214726235|NCT02796079|BIOLOGICAL|saline|saline injections
214726236|NCT04262557|DIAGNOSTIC_TEST|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
214726237|NCT04262557|DIAGNOSTIC_TEST|Polysomnography|Gold standard method to diagnose SAS used as comparator
214726238|NCT04653727|OTHER|Cross-sectional survey|No intervention.
214726239|NCT00146224|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
214726240|NCT00146224|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
214726241|NCT04453618|DRUG|FE-SYHA1402 100mg|in either a fasted state or with a meal
214726242|NCT04453618|DRUG|SYHA1402-25mg|SYHA1402 25mg, oral tablets
214726243|NCT04453618|DRUG|Placebo-25mg|Matching placebo tablets
214726244|NCT04453618|DRUG|SYHA1402-50mg|SYHA1402 50mg, oral tablets
214726245|NCT04453618|DRUG|Placebo-50mg|Matching placebo tablets
214726246|NCT04453618|DRUG|SYHA1402-150mg|SYHA1402 150mg, oral tablets
214726247|NCT04453618|DRUG|Placebo-150mg|Matching placebo tablets
214726248|NCT03013426|DRUG|NVX-508|Administration of NVX-508 emulsion intravenously
214641185|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
214641186|NCT05832567|DEVICE|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
214641187|NCT05832567|DEVICE|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
214641188|NCT05832567|DIETARY_SUPPLEMENT|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
214641189|NCT06228586|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
214641190|NCT05572229|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
214641191|NCT05572229|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
214641192|NCT05572229|DRUG|Lenalidomide|Lenalidomide will be administered orally
214641193|NCT06444711|OTHER|NICE guidance|Patients will be assessed to determine whether their current treatment is in line with NICE guidelines. Changes will be made to their treatment plan in order for them to comply with NICE guidelines with the aim of reducing the number of serious adverse events in the group. They will be followed up until 6 months to identify improvements in their conditions
214641194|NCT05975476|BEHAVIORAL|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
214641195|NCT05975476|BEHAVIORAL|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
214641196|NCT03108495|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
214641197|NCT03108495|BIOLOGICAL|LN-145 + pembrolizumab|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
214641198|NCT06255990|OTHER|Standard of care|Standard of care
214726249|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
214726250|NCT00611416|DIETARY_SUPPLEMENT|green tea|different catechin combinations
214726251|NCT00611416|DIETARY_SUPPLEMENT|Mix of catechins and caffeine|3 tablet a day
214641199|NCT04166409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214641200|NCT04166409|DRUG|Carboplatin|Given IV
214641201|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214641202|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
214641203|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
214641204|NCT04166409|DRUG|Vincristine Sulfate|Given IV
214641205|NCT04971954|OTHER|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
214641206|NCT04971954|OTHER|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
214641207|NCT06229470|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation (SCS) system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
214641208|NCT06670105|DRUG|Glofitamab|Given by vein
214641209|NCT07017998|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
214641210|NCT07017998|DEVICE|Sham (No Treatment)|Sham headband-style device will be worn for 30 minutes. Participants will be told they are receiving therapy.
214641211|NCT05457634|OTHER|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214641212|NCT05457634|OTHER|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214641213|NCT05457634|OTHER|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214641214|NCT05457634|OTHER|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214641215|NCT05457634|OTHER|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214726252|NCT00611416|DIETARY_SUPPLEMENT|EGCG|3 tablets a day
214726253|NCT00611416|DIETARY_SUPPLEMENT|EGC|3 tablets a day
214726254|NCT00611416|DIETARY_SUPPLEMENT|Caffeine|3 tablets a day
214726255|NCT00611416|DIETARY_SUPPLEMENT|Placebo|3 tablets a day
214793836|NCT06014437|DRUG|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
214793837|NCT06014437|DRUG|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
214793838|NCT05248932|DRUG|Norepinephrine bolus|5 microgram bolus therapy
214793839|NCT05248932|DEVICE|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
214793840|NCT05248932|DRUG|Norepinephrine infusion|2.5 microgram/min infusion
214641216|NCT05457634|OTHER|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
214641217|NCT07024719|DEVICE|4D MIOCT integrated into a Zeiss Artevo 800|4D MIOCT integrated into a Zeiss Artevo 800 surgical microscope with an add-on investigational 3D OCT scanner
214641218|NCT06822712|DEVICE|Sirolimus-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
214641219|NCT06822712|DEVICE|Paclitaxel-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Paclitaxel-coated Balloon Dilatation Catheter in the control group, subsequently completing the remaining procedure
214641220|NCT07027293|OTHER|STANDART HEAD POSITION|STANDART HEAD POSITION
214641221|NCT07027293|OTHER|HEAD ROTATION POSITION|HEAD ROTATION POSITION
214641222|NCT07027293|DEVICE|Classic laryngeal mask airway (LMA)|Classic laryngeal mask airway (LMA)
214641223|NCT07027293|DEVICE|i-gel supraglottic airway device|i-gel supraglottic airway device
214641224|NCT06700538|DRUG|ARO-INHBE|SC injection
214641225|NCT06700538|DRUG|Placebo|calculated volume to match active treatment by SC injection
214641226|NCT06700538|DRUG|Tirzepatide|SC injection
214641227|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
214641228|NCT07053384|BIOLOGICAL|VH3810109|VH3810109 will be administered.
214641229|NCT07053384|DRUG|Fostemsavir (FTR)|Fostemsavir will be administered.
214641230|NCT07053384|DRUG|SOC INSTI-based ART|A SOC INSTI-based ART regimen will be administered.
214641231|NCT04034810|DEVICE|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
214641232|NCT06765317|DRUG|Glofitamab|C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
214641233|NCT06765317|DRUG|Polatuzumab|1.8 mg/kg iv C1D1 onwards, every 3 weeks
214641234|NCT06765317|DRUG|Rituximab|375 mg/m2 iv D1
214641235|NCT06765317|DRUG|Cyclophosphamide|400 mg/m2 iv D1
214641236|NCT06765317|DRUG|Doxorubicin|25 mg/m2 iv D1
214641237|NCT06765317|DRUG|Obinutuzumab:|1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
214641238|NCT07066254|DEVICE|Mepilex Ag Dressing|A silver-impregnated antimicrobial foam dressing (Mepilex Ag) will be placed over the cesarean incision immediately following skin closure in the operating room. Participants assigned to this intervention will be instructed to leave the dressing in place for 7 days, in accordance with manufacturer guidelines, unless earlier removal is necessary due to dressing saturation, displacement, or clinical concern. Mepilex Ag is FDA-cleared for use as a wound dressing and is designed to maintain a moist wound environment while providing sustained antimicrobial protection to help reduce the risk of surgical site infection.
214793841|NCT00494806|OTHER|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
214641239|NCT07066254|DEVICE|Standard Surgical Dressing (Telfa non-adhesive dressing, gauze, and Primapore adhesive bandage)|A standard postoperative dressing consisting of a sterile Telfa non-adhesive pad placed over the cesarean incision, covered with gauze, and secured with a Primapore adhesive bandage. The dressing is applied immediately following skin closure in the operating room as part of routine institutional care. It is typically removed within 24 to 48 hours postoperatively, depending on wound condition and provider discretion.
214793842|NCT02948322|DEVICE|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
214793843|NCT02948322|DRUG|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
214641240|NCT06899230|DRUG|iQ-007|Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid transporter-2 (EAAT2) and its rodent homologue (glutamate transporter-1\[GLT-1).
214641241|NCT06899230|DRUG|Placebo|Oral capsules identical in appearance to drug and containing vehicle only (Gelucire/Capmul-M).
214641242|NCT06578507|DRUG|Hydroxycarbamid|"Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide.~The IMP will be administered as half-strength twice daily, based on the body weight of the patient."
214641243|NCT06839235|DRUG|ABO-101|Intravenous (IV) infusion
214641244|NCT07073066|PROCEDURE|DC-LVA treatment plus usual care|Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
214641245|NCT07073066|OTHER|Usual care|The usual care group includes patients who were not using or were currently using medications for improving cognitive function.
214641246|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214641247|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
214641248|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
214641249|NCT04963153|PROCEDURE|Echocardiography Test|Undergo echocardiography
214641250|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
214641251|NCT04963153|DRUG|Erdafitinib|Given PO
214641252|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214641253|NCT06899217|DRUG|CIN-102 Dose 15mg|Twice daily for 12 weeks
214641254|NCT06899217|DRUG|Placebo|Twice daily for 12 weeks
214641255|NCT06899217|DRUG|CIN-102 Dose 10mg|Twice daily for 12 weeks
214641256|NCT07178340|DRUG|Perioperative treatment|perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab
214641257|NCT07179172|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) 8-Week Program|"The program consists of weekly 2.5-hour sessions over an eight-week period. The certified mindfulness instructor will follow a curriculum that includes in-class formal practice (2.5 hours) and assigned informal practice (30-40 minutes daily).~During the sessions, the instructor will guide participants through mindfulness meditation, pain awareness, mindful yoga, gratitude practice, loving-kindness meditation, and the sharing of daily life experiences. Additionally, a full-day, eight-hour silent retreat (9 a.m. to 5 p.m.) will be held between weeks six and seven to deepen inner awareness.~Following each weekly group session, participants will be instructed to perform and self-record daily home practice, which will be discussed and evaluated during the following week's class. The total course duration is approximately 26 hours, and participants will receive a certificate of completion upon graduation."
214641258|NCT07178262|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Bilateral Erector Spinae Block at T10 level using 30ml of 0.25% Bupivacaine will be administered under Ultrasound guidance before surgical incision.
214641259|NCT07178262|DRUG|Placebo|Bilateral Erector Spinae Block at T10 level using 30ml of Normal saline will be administered under Ultrasound guidance before surgical incision.
214641260|NCT07177794|DRUG|toripalimab|Patients will receive toripalimab with a maximum treatment duration of one year (240 mg, IV drip, Q3W, for 16 cycles).
214641261|NCT07177794|DRUG|capecitabine|Patients will receive metronomic capecitabine, with a maximum treatment duration of one year (500 mg, twice daily, orally).
214641262|NCT07177768|OTHER|Prolonged walking|walking on a treadmill for 60 minutes
214641263|NCT01636466|DRUG|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
214641264|NCT01966770|DEVICE|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
214641265|NCT01966770|DEVICE|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
214641266|NCT01966770|DEVICE|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
214641267|NCT01966770|DEVICE|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
214641268|NCT01966770|DEVICE|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
214641269|NCT01966770|DEVICE|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
214641270|NCT02377375|PROCEDURE|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
214641271|NCT02377375|PROCEDURE|Standard technique|Medtronic DBS lead 3391-28cm
214641272|NCT03123497|OTHER|completion of questionnaire|completion of questionnaire for patient and parent
214641273|NCT05253417|DRUG|50 mg Cannabidiol (CBD)|For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
214641274|NCT05253417|DRUG|Placebo|Participants take four (4) placebo capsules.
214641275|NCT05253417|DRUG|100 mg Cannabidiol (CBD)|For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
214641276|NCT01299766|BEHAVIORAL|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
214641277|NCT01299766|BEHAVIORAL|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
214641278|NCT03075085|BEHAVIORAL|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
214641279|NCT05236803|BEHAVIORAL|Testing of general motor skills, fine motor skills and occulomotricity|"Recording of participant's performance during eye, fine motor and gross motor tests; Children's gross motor skills will be assessed through a biomechanical analysis.~Eye movements will be recorded using the eye-tracking system (Tobii Pro TX300). The technique used is the corneal reflection technique."
214641280|NCT05236803|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires.
214641281|NCT05301387|PROCEDURE|Ganglion Sphenopalatine Block|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl
214641282|NCT05835947|OTHER|Dual Pathology|Women with both genital HSIL/SCC and Anal HSIL/SCC
214641283|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Ascending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the ascending limb
214641284|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Descending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the descending limb
214641285|NCT05701865|BEHAVIORAL|No Alcohol Control|Participants will be assigned to a no alcohol control condition
214641286|NCT03734757|PROCEDURE|imaging in trimodality|PET-CT and MRI
214641287|NCT02788500|OTHER|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
214793844|NCT02948322|PROCEDURE|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
214793845|NCT00497367|DEVICE|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
214793846|NCT00756964|DRUG|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
214726256|NCT05974891|OTHER|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
214726257|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
214726258|NCT00071604|BEHAVIORAL|Friendly Support Group|
214726259|NCT01518309|DRUG|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
214726260|NCT02647892|DRUG|lidocaine|local anesthesia
214726261|NCT02647892|DRUG|sodium bicarbonate|additional drug added to lidocaine
214726262|NCT04548479|DEVICE|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
214726263|NCT02579863|BIOLOGICAL|Pembrolizumab|IV infusion
214726264|NCT02579863|DRUG|Lenalidomide|oral capsules
214726265|NCT02579863|DRUG|Dexamethasone|oral tablets
214726266|NCT02855086|BIOLOGICAL|Cetuximab|Administered intravenously (IV)
214726267|NCT02855086|DRUG|Cetuximab-IRDye 800CW|Administered intravenously (IV)
214726268|NCT02855086|PROCEDURE|Tumor resection|Standard of care treatment
214726269|NCT04344015|OTHER|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
214726270|NCT02209259|OTHER|PROMIS Upper Extremity Function|
214726271|NCT02209259|OTHER|Pain intensity|
214726272|NCT02209259|OTHER|PROMIS depression|
214726273|NCT02209259|OTHER|Positive affect negative affect scale (PANAS)|
214726274|NCT02209259|OTHER|standard PCS|
214726275|NCT02209259|OTHER|positively-adjusted version of the PCS|
214726276|NCT05608200|DRUG|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
214726277|NCT05608200|DRUG|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
214726278|NCT02253394|DRUG|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
214726279|NCT02253394|DRUG|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
214726280|NCT02485067|DRUG|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
214726281|NCT02485067|DRUG|Placebo(For THVD-201)|
214726282|NCT02485067|DRUG|Detrusitol 2mg tablet|Tolterodine 2mg
214726283|NCT02485067|DRUG|Placebo(For Detrusitol 2mg tablet)|
214726284|NCT05363618|DIETARY_SUPPLEMENT|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
214726285|NCT05363618|OTHER|Placebo 1.4 ml|Placebo
214726286|NCT00038142|DRUG|Vincristine|2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
214726287|NCT00038142|DRUG|Doxorubicin|90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
214726288|NCT00038142|DRUG|Cyclophosphamide|2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
214726289|NCT00038142|DRUG|Dexrazoxane|900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
214726290|NCT00038142|BIOLOGICAL|ImmTher|900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
214726291|NCT04461613|OTHER|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
214726292|NCT04461613|OTHER|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
214726293|NCT00032110|DRUG|erlotinib hydrochloride|Given orally
214726294|NCT00032110|OTHER|pharmacological study|Correlative studies
214726295|NCT00032110|OTHER|laboratory biomarker analysis|Correlative studies
214726296|NCT01679704|DIETARY_SUPPLEMENT|Food products|
214726297|NCT05345704|OTHER|cardiopulmonary resuscitation (CPR)|Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
214726298|NCT01486940|DRUG|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
214726299|NCT01486940|DRUG|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
214726300|NCT01486940|DRUG|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
214726301|NCT01486940|DRUG|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
214726302|NCT03128255|OTHER|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
214726303|NCT01231672|BIOLOGICAL|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
214641288|NCT04802473|PROCEDURE|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
214641289|NCT03561584|DRUG|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
214641290|NCT03561584|DRUG|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
214641291|NCT02492438|BIOLOGICAL|PPV23 vaccination or PCV13 vaccination|
214641292|NCT00006519|DRUG|Capravirine|
214641293|NCT04133584|BIOLOGICAL|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
214641294|NCT04133584|BIOLOGICAL|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
214641295|NCT04133584|BIOLOGICAL|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
214641296|NCT03908619|DRUG|Omeprazole 20mg|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
214641297|NCT03908619|DRUG|Esomeprazole 20mg|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
214641298|NCT03908619|DRUG|Rabeprazole Sodium 20mg|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
214641299|NCT03908619|DRUG|Vonoprazan|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
214641300|NCT00744445|DRUG|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
214641301|NCT00606242|DRUG|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
214641302|NCT02399306|DRUG|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
214726304|NCT01571167|DRUG|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
214726305|NCT01571167|DRUG|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
214726306|NCT01571167|DRUG|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
214726307|NCT06099028|OTHER|no intervention|no intervention
214726308|NCT05386004|OTHER|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
214726309|NCT03946644|DEVICE|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
214726310|NCT03946644|DEVICE|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
214726311|NCT04024735|DIAGNOSTIC_TEST|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
214726312|NCT00589602|PROCEDURE|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
214726313|NCT00589602|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
214726314|NCT00589602|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
214726315|NCT00589602|RADIATION|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
214641303|NCT02399306|RADIATION|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
214641304|NCT03133845|PROCEDURE|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
214641305|NCT03133845|PROCEDURE|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
214641306|NCT03133845|PROCEDURE|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
214641307|NCT03133845|PROCEDURE|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
214641308|NCT03133845|PROCEDURE|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
214641309|NCT03133845|PROCEDURE|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
214641310|NCT03133845|PROCEDURE|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
214641311|NCT03133845|PROCEDURE|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
214641312|NCT03133845|PROCEDURE|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
214641313|NCT03133845|PROCEDURE|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
214641314|NCT04996355|OTHER|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~1. 5-FU~2. Oxaliplatin~3. Irinotecan~4. 5-FU+ Oxaliplatin~5. 5-FU+ Irinotecan~6. 5-FU+ Oxaliplatin+ Irinotecan~7. 5-FU+Cetuximab~8. Cetuximab~9. Regorafenib"
214641315|NCT05731804|DRUG|SIM0417 600 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
214641316|NCT05731804|DRUG|SIM0417 375 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
214641317|NCT05731804|DRUG|SIM0417 750 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
214641318|NCT03858959|DEVICE|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
214641319|NCT00683319|DRUG|carboplatin|
214641320|NCT00683319|DRUG|cisplatin|
214641321|NCT00683319|DRUG|cyclophosphamide|
214641322|NCT00683319|DRUG|methotrexate|
214641323|NCT00683319|DRUG|vincristine sulfate|
214726316|NCT04781725|DRUG|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
214641324|NCT00683319|PROCEDURE|adjuvant therapy|
214641325|NCT00683319|PROCEDURE|cognitive assessment|
214641326|NCT00683319|PROCEDURE|magnetic resonance imaging|
214641327|NCT00683319|PROCEDURE|magnetic resonance spectroscopic imaging|
214641328|NCT00683319|PROCEDURE|quality-of-life assessment|
214641329|NCT04897490|OTHER|Evaluation of first line treatment with ATO/ATRA outcome|Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.
214641330|NCT00843908|DEVICE|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
214641331|NCT00843908|DEVICE|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
214641332|NCT05282758|OTHER|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
214641333|NCT05282758|OTHER|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
214641334|NCT04041856|DRUG|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
214641335|NCT04878133|DIAGNOSTIC_TEST|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
214641336|NCT03064763|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
214641337|NCT02421341|DRUG|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
214641338|NCT02421341|PROCEDURE|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
214641339|NCT02421341|OTHER|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
214641340|NCT02421341|RADIATION|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
214641341|NCT02421341|OTHER|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
214641342|NCT02421341|OTHER|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
214641343|NCT02421341|OTHER|Chemosensitivity Test|Using a bag you breath in and out your own air.
214641344|NCT02421341|DRUG|Placebo|
214641345|NCT02440087|DIETARY_SUPPLEMENT|Refill Bypass|Dietary supplement
214641346|NCT03345056|PROCEDURE|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
214641347|NCT02113787|PROCEDURE|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
214641348|NCT01005160|DRUG|Metformin|CKD-501 0.5mg, metformin 1000mg
214641349|NCT01005160|DRUG|CKD-501|CKD-501 0.5mg, metformin 1000mg
214641350|NCT01009307|GENETIC|polymorphism analysis|
214641351|NCT01009307|OTHER|laboratory biomarker analysis|
214726317|NCT04781725|OTHER|Saline injection|Standard 0.9 % NaCl Normal Saline
214726318|NCT02734849|DRUG|AK001 low dose|25 mg AK001 will be administered as multiple doses
214641352|NCT01009307|OTHER|medical chart review|
214641353|NCT03118440|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
214641354|NCT03118440|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
214641355|NCT00403260|DRUG|Pyronaridine - artesunate|once a day for 3 days
214641356|NCT00403260|DRUG|Mefloquine plus artesunate|once a day for 3 days
214641357|NCT02487992|BIOLOGICAL|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
214641358|NCT01071187|DRUG|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
214641359|NCT01071187|DRUG|Placebo|Placebo
214726319|NCT02734849|DRUG|AK001 high dose|250 mg AK001 will be administered as multiple doses
214726320|NCT02734849|DRUG|Placebo|Placebo will be administered as multiple doses
214726321|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
214726322|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
214726323|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
214726324|NCT05032287|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily
214726325|NCT05032287|DRUG|Placebo|Placebo once daily
214726326|NCT05393544|BEHAVIORAL|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
214641360|NCT06018649|COMBINATION_PRODUCT|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
214641361|NCT06018649|COMBINATION_PRODUCT|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
214641362|NCT06018649|OTHER|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
214641363|NCT01431092|DRUG|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
214641364|NCT01431092|DRUG|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
214641365|NCT01354028|OTHER|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
214641366|NCT01936220|BEHAVIORAL|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
214641367|NCT01936220|BEHAVIORAL|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
214726327|NCT04210232|DEVICE|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
214726328|NCT01037751|BEHAVIORAL|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
214726329|NCT01037751|BEHAVIORAL|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
214726330|NCT02869685|RADIATION|radiotherapy|radiotherapy
214726331|NCT01525745|RADIATION|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
214726332|NCT01525745|RADIATION|External Beam Radiation Therapy|10 consecutive days of standard radiation
214726333|NCT02163668|OTHER|Yoga Group|8 months of Yoga training
214726334|NCT04258904|COMBINATION_PRODUCT|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
214726335|NCT04216511|DIAGNOSTIC_TEST|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
214641368|NCT01936220|BEHAVIORAL|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
214641369|NCT03886844|DIETARY_SUPPLEMENT|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
214641370|NCT03750188|DRUG|ProHance|0.1 mmol/kg ProHance intravenous injection
214641371|NCT04922866|OTHER|no intervention|no intervention
214641372|NCT03677193|BEHAVIORAL|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
214641373|NCT04489979|OTHER|Antibiotics|Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
214641374|NCT03334084|DRUG|ARGX-113|intravenous or subcutaneous administration
214641375|NCT00404521|DRUG|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
214641376|NCT00826813|DEVICE|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
214641377|NCT02109159|OTHER|A short online video with emotional content|
214641378|NCT02109159|OTHER|A short online video with less emotional content|
214641379|NCT06174350|BEHAVIORAL|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
214641380|NCT06174350|OTHER|Placebo|Intervention Description not
214641381|NCT00935883|DRUG|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
214726336|NCT00732706|PROCEDURE|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
214641382|NCT00935883|DRUG|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
214641383|NCT05482945|DRUG|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
214641384|NCT05897593|DEVICE|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
214641385|NCT01266577|OTHER|NSR MAGNETOM 7T|The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
214641386|NCT01266577|OTHER|1Tx x 32Rx Head Coil|Used to perform proton imaging and spectroscopy in the human heads.
214641387|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
214641388|NCT03731962|PROCEDURE|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
214641389|NCT00715988|DRUG|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
214641390|NCT00715988|DRUG|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
214641391|NCT00494897|DRUG|Asparaginase|
214641392|NCT00494897|DRUG|Cyclophosphamide|
214641393|NCT00494897|DRUG|Cytarabine|
214641394|NCT00494897|DRUG|Daunorubicin|
214641395|NCT00494897|DRUG|Mercaptopurine|
214641396|NCT00494897|DRUG|Prednisone|
214641397|NCT00494897|DRUG|Vincristine|
214641398|NCT00494897|DRUG|Methotrexate|
214641399|NCT00494897|PROCEDURE|Intrathecally treatment|
214641400|NCT03228160|OTHER|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
214641401|NCT06451432|PROCEDURE|Percutaneous Inguinal Ring Suturing (PIRS) technique|Percutaneous Inguinal Ring Suturing (PIRS) technique
214641402|NCT03546075|DIETARY_SUPPLEMENT|Resveratrol|
214641403|NCT03546075|OTHER|Placebo|
214641404|NCT05141305|DRUG|tenecteplase (0.25 mg/kg, Max 25 mg)|tenecteplase (0.25 mg/kg) is being used.
214641405|NCT05141305|DRUG|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
214641406|NCT06471881|DEVICE|Two mandibular implants|Rehabilitation with two mandibular implants and a mandibular implant overdenture supported by a computer-aided design bar
214641407|NCT03473093|DRUG|Pregabalin 150mg|One group will receive oral pregabalin with morphine infusion
214641408|NCT03473093|DRUG|Morphine|One group will receive morphine infusion 20 microgram/kg/h
214726337|NCT00732706|PROCEDURE|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
214641409|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
214641410|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
214641411|NCT04638491|DRUG|Lurbinectedin for injection|On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
214641412|NCT01874171|DRUG|Cisplatin|
214641413|NCT01874171|DRUG|Cetuximab|
214641414|NCT05242692|DRUG|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
214641415|NCT05242692|DRUG|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
214641416|NCT05242692|DRUG|Normal saline|Refer to either S-ketamine or Dexmedetomidine
214641417|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP|
214641418|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP + Stabilizer|
214641419|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4|
214641420|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4 + Stabilizer|
214641421|NCT05624008|OTHER|Bioceramic glass ionomer restoration|bioactive glass ionomer with unique biocompatibility and biological regenerative properties
214641422|NCT05624008|OTHER|Resin modified glass ionomer restoration|A hybrid of glass ionomer and composite resin with acid-base and polymerizable components
214641423|NCT06244797|PROCEDURE|L-PRF and H-PRF|Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.
214641424|NCT06244797|PROCEDURE|Impacted Tooth Removal|All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.
214641425|NCT05596019|PROCEDURE|specific neurodynamic exercises|Specific neurodynamic exercises in women older than 65 years with neck pain
214641426|NCT05596019|PROCEDURE|multimodal exercise|Multimodal and nonspecific exercises in women older than 65 years with neck pain
214641427|NCT04498845|OTHER|In-home assessment plan|The in-home family educational session provides participants with resources to identify and reduce exposures to metals in the home environment.
214641428|NCT04498845|BEHAVIORAL|Family educational session|The 1-hr in-home family educational session, administered during the first home visit to all participants, adapts a motivational interview model to reduce exposure to metals. this done by empowering families to make informed decisions regarding lead and metal exposures in their home environments that originate from different sources with an emphasis on sources from the workplace. The session will consist of both developing a plan tailored for the home and reviewing educational materials on strategies to reduce exposures in the home, focusing on barriers families experience when attempting to change their behaviors.
214641429|NCT04498845|BEHAVIORAL|Worker take home prevention training|The take home prevention 1-hour educational session guides the worker through 6 simple steps to identify and then prioritize change/s that can be made before leaving work to prevent take-home lead. It has been adapted from the AGILE model for prioritizing tasks. Participants will also be provided with a pamphlet about how to prevent lead from being taken home.
214641430|NCT04498845|OTHER|D-LEAD cleaner products|D-LEAD cleaner products include hand wipes, all surfaces cleaner and laundry detergent.
214641431|NCT05070884|OTHER|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
214641432|NCT01428401|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
214641433|NCT01428401|OTHER|Placebo|at a rate of 3 g three times per day
214641434|NCT01656720|DRUG|1R, 2S-methoxamine hydrochloride|
214641435|NCT01656720|DRUG|Placebo|
214641436|NCT04360356|COMBINATION_PRODUCT|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
214641437|NCT04360356|OTHER|Standard Care|Oxygen via Ventilators
214641438|NCT05638048|BEHAVIORAL|Precision grip training|First determine patients for holding the ball movement should reach the effective blood flow velocity and best duration - relaxation, and USES the electronic grips and color doppler ultrasonic diagnostic apparatus, for individual patients to choose the best grip the efforts and training, to form the best grip the training plan, and observe the scheme for Peripheral central venous catheter-associated thrombosis prevention effect.
214726338|NCT04323098|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
214726339|NCT02352090|DRUG|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
214726340|NCT02352090|DRUG|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
214726341|NCT02352090|DRUG|Dienogest|One tablet orally for 9 weeks, continuous use
214726342|NCT03208075|OTHER|normal diet|Diet containing 1500mg of phosphorus
214726343|NCT03208075|OTHER|low-phosphorus diet|Diet containing 500mg of phosphorus
214726344|NCT03208075|OTHER|high-phosphorus diet|Diet containing 2300mg of phosphorus
214726345|NCT00917137|PROCEDURE|TBNA + transbronchial lung biopsy + bronchial washing|
214726346|NCT01199497|DRUG|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
214726347|NCT01199497|DRUG|Group 2|placebo
214726348|NCT04520308|DRUG|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
214726349|NCT00279266|DRUG|Thiamine|
214726350|NCT05270265|BIOLOGICAL|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
214726351|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
214726352|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
214726353|NCT04366739|DRUG|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
214726354|NCT04366739|COMBINATION_PRODUCT|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
214726355|NCT04694794|OTHER|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
214793847|NCT00756964|DRUG|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
214793848|NCT04347590|DEVICE|Unblinded - CGM (Medtronic Guardian)|Data from device will be readable and alarms on
214793849|NCT04347590|DEVICE|Blinded - CGM (Medtronic Guardian)|Data from device will be blinded and alarms off
214726356|NCT05379764|OTHER|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
214726357|NCT05379764|OTHER|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
214726358|NCT02314286|DRUG|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
214726359|NCT02314286|DRUG|Placebo|
214726360|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
214726361|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
214726362|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
214793850|NCT01754259|DRUG|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
214641439|NCT05638048|BEHAVIORAL|Use maximum strength grip training|Patients were routinely implanted with PICC, and on the basis of health education in the control group, the best continuous-relaxation time, frequency and maximum grip strength of patients were used for grip strength training.
214641440|NCT05638048|BEHAVIORAL|Health education on routine grip strength training|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
214641441|NCT03381456|OTHER|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
214641442|NCT06496412|DRUG|fecal microbiota transplantation|Take fecal microbiota capsules.
214641443|NCT06496412|DRUG|Placebo|Take placebo capsules.
214641444|NCT03195517|OTHER|Physical exercise|
214641445|NCT06548867|DRUG|Cabozantinib|Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
214641446|NCT02211391|OTHER|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
214641447|NCT02211391|OTHER|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
214641448|NCT02160405|DIETARY_SUPPLEMENT|native potato|
214641449|NCT02668146|DRUG|Perampanel|Study drug will be administered to study subjects
214641450|NCT02668146|DRUG|Placebo|Placebo will be administered to study subjects
214641451|NCT03569995|DRUG|Rituximab|500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
214641452|NCT03569995|DRUG|Methotrexate|500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
214641453|NCT03569995|DRUG|Cytarabine Injection|3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
214641454|NCT00694291|DRUG|Sorafenib|400 mg orally twice daily
214641455|NCT00694291|DRUG|Placebo|Matching Placebo
214641456|NCT00235131|DEVICE|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
214641457|NCT00235131|DEVICE|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
214641458|NCT02495922|DRUG|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
214641459|NCT02495922|DRUG|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
214641460|NCT02495922|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
214641461|NCT02495922|DRUG|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
214641462|NCT00122330|DRUG|eculizumab|
214641463|NCT04428047|DRUG|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
214641464|NCT05148871|BIOLOGICAL|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
214641465|NCT06173999|DRUG|SHR2554/CHOP|SHR2554 with CHOP
214641466|NCT06173999|DRUG|SHR2554/CHOEP|SHR2554 with CHOEP
214641467|NCT05973136|OTHER|Telerehabilitation program based on cardiorespiratory principles|The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
214641468|NCT00427362|DRUG|Adalimumab|
214641469|NCT00267553|DRUG|Atamestane|
214641470|NCT00267553|DRUG|toremifene|
214641471|NCT00267553|DRUG|letrozole|
214641472|NCT01944085|DRUG|Acetaminophen|Syrup
214641473|NCT01944085|DRUG|Ibuprofen|Syrup
214641474|NCT01944085|OTHER|Vitamin C|Syrup
214641475|NCT05145621|DRUG|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
214641476|NCT01873755|BEHAVIORAL|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
214641477|NCT01846455|DRUG|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
214641478|NCT01846455|DRUG|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
214641479|NCT00282126|DIETARY_SUPPLEMENT|Potassium citrate|kcitrate
214641480|NCT03120169|OTHER|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
214793851|NCT01754259|DRUG|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
214641481|NCT03120169|OTHER|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
214641482|NCT03478618|DRUG|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
214641483|NCT05765903|OTHER|Standard of Care|"* Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment."
214641484|NCT05765903|OTHER|Enhanced Care|"* Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
214641485|NCT03414957|DIAGNOSTIC_TEST|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
214641486|NCT03462095|PROCEDURE|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
214641487|NCT06303661|DEVICE|Non-ablative Radiofrequency|There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
214641488|NCT06303661|DEVICE|Low-intensity Shock Wave Therapy|The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
214641489|NCT03777449|RADIATION|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
214641490|NCT06036966|DRUG|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
214641491|NCT02608632|DEVICE|Renal denervation guided by HFS|
214641492|NCT02608632|DEVICE|Renal denervation as standard procedure|
214641493|NCT01238003|OTHER|Interpretation of blood test results|Interpretation of blood test results
214641494|NCT05421000|PROCEDURE|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
214641495|NCT05421000|PROCEDURE|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
214641496|NCT03822013|DRUG|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
214641497|NCT06479980|BEHAVIORAL|Single Session Narrative Therapy|Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
214641498|NCT05750485|OTHER|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
214641499|NCT06111339|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
214641500|NCT06111339|OTHER|Saline Solution|The placebo will be a 0.9% saline solution administered over 40 minutes.
214641501|NCT05583773|DRUG|ShengXian-QuYu Decoction|Specification: 30ml/bag, given twice daily, per oral use.
214641502|NCT05583773|OTHER|Placebo|Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
214641503|NCT02314988|DRUG|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
214641504|NCT02314988|DRUG|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
214726363|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
214726364|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
214726365|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
214726366|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
214726367|NCT03066310|DIAGNOSTIC_TEST|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
214641505|NCT06355804|BEHAVIORAL|Physical activity condition|"Participants will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide behavioral strategies such as information on the benefits of physical activity, goal setting and monitoring, for increasing and maintaining physical activity levels.~  * Throughout the 16-week period, the investigators will ask participants to wear a Fitbit and record step count into a logbook daily for tracking physical activity.~ * The newsletter will be emailed to participants weekly throughout the program. The newsletters include knowledge, skills, and resources related to physical activity in the early stages of MS.~* The program also involves 7 1-on-1 coaching chats with a coach to guide participants through the program and navigate challenges. These chats are conducted over Zoom and generally last about 15 - 30 minutes each. These sessions will not be recorded."
214641506|NCT06355804|BEHAVIORAL|Waitlist condition|"Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide information on the benefits of physical activity, goal setting and monitoring, and other behavioral strategies for increasing and maintaining physical activity levels.~  * The newsletter will be emailed to participants weekly throughout the program.~ * Content on the newsletter includes knowledge and skills related to physical activity in the early stages of MS, text of individuals with MS discussing their experiences, web links, worksheets, and brochures.~* The program also involves 7 one-on-one video coaching chats with a behavioral coach to guide participants through the program and navigate challenges. These chats are conducted face- to-face over Zoom and generally last about 15 - 30 minutes each. The investigators do not record these sessions."
214726368|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
214726369|NCT00449995|PROCEDURE|confocal laser microscopy|
214726370|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
214726371|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
214726372|NCT00060151|DRUG|pazopanib hydrochloride|
214641507|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
214641508|NCT05663151|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
214641509|NCT00975156|OTHER|Physical Therapy|Conventional physical therapy
214726373|NCT03633513|DIAGNOSTIC_TEST|LBT-3627|Immunomodulatory agent
214726374|NCT03633513|DIAGNOSTIC_TEST|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
214726375|NCT04955509|OTHER|MRI|conventional MRI and diffusion MRI
214726376|NCT00978133|PROCEDURE|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
214726377|NCT00978133|PROCEDURE|Skin closure with skin staples|Skin closure with skin staples
214726378|NCT01849562|DRUG|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
214726379|NCT01849562|DRUG|ACH-3102|Nonstructural protein 5A inhibitor.
214726380|NCT01849562|DRUG|Ribavirin|
214726381|NCT01849562|DRUG|Placebo|
214726382|NCT05394207|DIETARY_SUPPLEMENT|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
214726383|NCT05394207|OTHER|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
214726384|NCT03146403|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
214726385|NCT03146403|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214726386|NCT03146403|OTHER|0.9% normal saline|Placebo
214726387|NCT02304419|DRUG|Galunisertib|Administered orally.
214726388|NCT00127816|PROCEDURE|Permanent prostate implant|
214793852|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
214726389|NCT04306666|OTHER|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
214641510|NCT00975156|DEVICE|Lokomat|Robotic-assisted walking device
214641511|NCT00305578|DRUG|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
214641512|NCT00305578|DRUG|Placebo|No active medication, only placebo
214641513|NCT03881007|OTHER|Mouthwash with LCM|Subjects will mouthwash daily with LCM and before/after sex
214641514|NCT03881007|OTHER|Mouthwash with placebo|Subjects will mouthwash daily with placebo and before/after sex
214641515|NCT03484468|DEVICE|anterior segment Ocular Coherence Tomography|anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
214641516|NCT05559723|DEVICE|electromagnetic field therapy|"Three times a week for four weeks, the study group got electromagnetic fields (EMFs) therapy and the selected physical therapy program. The EMFs therapy was applied using an electromagnetic field therapy device (Magner Plus Astar)~. From the prone lying position the device will be adjusted around the lumbar area at a low frequency (50 Hz), with the intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60), and the application time will be10 minutes"
214641517|NCT05559723|OTHER|selected physical therapy program|"in the form of~1. Hot packs will be placed paravertebral on the lumbar region for 5 minutes from a prone lying position~2. selected physical therapy exercises in form of Static exercise for back and abdominal muscles, stretching exercises for both lower limbs, 10 times each exercise"
214641518|NCT05559723|DEVICE|Therapeutic ultrasound therapy|Therapeutic ultrasound therapy using ultrasound device Chattanooga, model 2760, serial number T11238, 120-240V, 50/60Hz, made in Mexico . That will be applied paravertebral on the lumbar region from the prone lying position, with pulsed mode, frequency 1 MHz, intensity 0.5 W/cm2 and will be applied by circular moving technique at a rate of 4 cm/s for 10 minutes.
214641519|NCT05559723|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS): from the prone lying position, the electrodes will be placed on the course of pain detected by the patient, with an asymmetrical rectangular biphasic form, at a pulse repetition frequency of 100Hz and duty cycle of 250 microseconds; the intensity was set at a level that each patient could feel, for 15 minutes .
214641520|NCT03723681|DRUG|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
214641521|NCT02656927|BEHAVIORAL|Yoga Condition|
214641522|NCT02264587|DRUG|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
214641523|NCT02264587|DRUG|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
214641524|NCT00319969|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
214641525|NCT00319969|DRUG|Topotecan|Topotecan 1.5mg/m\<2\> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
214641526|NCT05434832|BEHAVIORAL|Virtual Reality|Distraction method
214641527|NCT05434832|BEHAVIORAL|Local cold-vibration|Distraction method
214641528|NCT02470455|DRUG|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
214641529|NCT02407093|BEHAVIORAL|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
214641530|NCT02407093|BEHAVIORAL|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
214641531|NCT00361738|DRUG|AVE2268|
214641532|NCT01946178|DEVICE|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
214641533|NCT02077933|DRUG|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
214641534|NCT02077933|DRUG|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
214726390|NCT04114045|DIETARY_SUPPLEMENT|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
214726391|NCT04114045|DIETARY_SUPPLEMENT|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
214726392|NCT04114045|OTHER|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
214726393|NCT01916187|DRUG|Imetelstat|
214726394|NCT01465451|PROCEDURE|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
214726395|NCT01465451|DRUG|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
214726396|NCT03954249|PROCEDURE|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
214726397|NCT03954249|PROCEDURE|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
214726398|NCT04816370|DIAGNOSTIC_TEST|FSFI|2 group and 2 subgroup
214726399|NCT03356808|BIOLOGICAL|Lung cancer-specific T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
214726400|NCT00549653|DRUG|GW856553|
214726401|NCT02262013|BEHAVIORAL|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
214726402|NCT02262013|BEHAVIORAL|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
214726403|NCT03003013|PROCEDURE|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
214726404|NCT01364142|PROCEDURE|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
214726405|NCT03136913|DEVICE|Cytoplast® TXT-200|Non-resorbable membrane
214641535|NCT02077933|DRUG|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
214641536|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
214641537|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
214641538|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
214641539|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
214641540|NCT05467891|DRUG|Exemestane|25 mg orally once daily
214641542|NCT04955275|OTHER|Cognitive Remediation Therapy Program (BrainHQ)|Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
214641543|NCT01193400|DRUG|Clofarabine|
214641544|NCT01193400|DRUG|Cytarabine|
214641545|NCT02821858|DRUG|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
214641546|NCT02821858|DRUG|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
214641547|NCT02821858|DRUG|Placebo|Matching placebo will be administered.
214641548|NCT03015805|BEHAVIORAL|Contingency Management|"Contingency Management (CM) utilizes behavior modification \& cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
214641549|NCT03015805|BEHAVIORAL|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
214641550|NCT03931356|OTHER|Pulmonary function tests|analysis of lung volume and diffusion capacity
214641551|NCT05489601|DRUG|Oxycodone|Oxycodone in 5mg increments up to a maximum of 10mg
214641552|NCT04868552|OTHER|Pre-hospital naloxone education|a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
214641553|NCT02623738|DRUG|Placebo ophthalmic solution|
214641554|NCT02623738|DRUG|DE-117 ophthalmic solution low|
214641555|NCT02623738|DRUG|DE-117 ophthalmic solution high|
214641556|NCT02623738|DRUG|Latanoprost ophthalmic solution 0.005%|
214641557|NCT04535219|OTHER|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
214641558|NCT04535219|OTHER|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
214641559|NCT01030692|DRUG|Placebo|The placebo groups will receive the same dosage throughout the study.
214641560|NCT01030692|DRUG|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
214641561|NCT01030692|DRUG|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
214726406|NCT03136913|DEVICE|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
214726407|NCT03136913|PROCEDURE|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
214726408|NCT03136913|PROCEDURE|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
214726409|NCT03562520|BEHAVIORAL|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
214726410|NCT00250497|BEHAVIORAL|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
214726411|NCT02182999|DEVICE|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
214726412|NCT02182999|DRUG|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
214726413|NCT02182999|DRUG|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
214726414|NCT01427127|DRUG|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
214726415|NCT05566327|BEHAVIORAL|De-implementation Bundle|"A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests."
214726416|NCT01197781|DRUG|FOSTAMATIN|Oral tablets - single dose
214726417|NCT01197781|DRUG|Verapamil|Oral tablets - administered 3 times daily over 4 days
214726418|NCT03216395|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
214726419|NCT03216395|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
214726420|NCT03216395|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 8 pulses
214726421|NCT03216395|DRUG|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
214726422|NCT06138392|DEVICE|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
214641562|NCT01030692|DRUG|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
214641563|NCT01030692|DRUG|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
214726423|NCT03228992|DRUG|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
214726424|NCT03228992|OTHER|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
214726425|NCT02252588|DRUG|Chlorhexidine|Oral Rinse
214726426|NCT02252588|OTHER|Placebo|Oral Rinse
214641564|NCT02421887|DRUG|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
214641565|NCT02421887|OTHER|Placebo|Placebo
214641566|NCT01742429|DRUG|Proton pump inhibitor|
214641567|NCT01742429|DRUG|Bismuth subsalicylate|
214641568|NCT01742429|DRUG|Metronidazole|antibiotic
214726427|NCT02521168|DRUG|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
214726428|NCT02521168|DRUG|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
214726429|NCT04993755|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
214726430|NCT04993755|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
214726431|NCT02616536|OTHER|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
214726432|NCT02396004|DEVICE|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
214726433|NCT02219672|DRUG|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
214726434|NCT02219672|DRUG|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
214726435|NCT03039790|BIOLOGICAL|NoV Vaccine|NoV vaccine injection administered.
214726436|NCT00058188|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
214726437|NCT00058188|DRUG|calcium gluconate|Given orally
214726438|NCT00058188|DRUG|zoledronic acid|Given IV
214726439|NCT04912661|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
214726440|NCT01520688|DRUG|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
214726441|NCT01520688|DRUG|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
214726442|NCT01520688|DRUG|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
214726443|NCT01520688|DRUG|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
214726444|NCT01520688|DRUG|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
214726445|NCT01520688|DRUG|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
214726446|NCT02266004|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
214726447|NCT02266004|OTHER|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
214726448|NCT05642065|OTHER|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
214726449|NCT01791465|DRUG|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
214726450|NCT02909582|PROCEDURE|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
214726451|NCT03289052|DEVICE|Restylane Volyme|Subcutis injection
214726452|NCT00537771|DRUG|Anastrozole|1 mg once daily oral dose
214726453|NCT00537771|DRUG|Tamoxifen|20 mg once daily oral dose
214726454|NCT04246541|DRUG|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
214726455|NCT04246541|DRUG|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
214726456|NCT02323308|OTHER|blood sampling|
214793853|NCT04403100|DRUG|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
214641569|NCT01742429|DRUG|Tetracycline|antibiotic
214641570|NCT01742429|DRUG|Amoxicillin|antibiotic
214641571|NCT01742429|DRUG|Levofloxacin|antibiotic
214641572|NCT03029013|DRUG|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
214641573|NCT03450928|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
214641574|NCT03201055|DEVICE|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
214641575|NCT05708742|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
214641576|NCT05708742|DRUG|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
214641577|NCT05708742|DRUG|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
214641578|NCT05708742|DEVICE|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
214641579|NCT06445205|DIAGNOSTIC_TEST|Mitra® device with VAMS® (volumetric absorptive microsampling) technology|Capillary blood sample
214641580|NCT03590509|OTHER|Telemedicine Program|"A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits\* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
214641581|NCT03590509|OTHER|Usual Comprehensive Care|Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
214641582|NCT01610635|OTHER|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
214641583|NCT04773405|DRUG|a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance."
214726457|NCT02575300|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
214726458|NCT03034109|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
214726459|NCT00026975|PROCEDURE|Hyperbaric Oxygen|
214726460|NCT05190757|OTHER|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
214726461|NCT04847739|PROCEDURE|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
214726462|NCT04847739|DRUG|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
214726463|NCT00063388|BIOLOGICAL|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
214726464|NCT04346004|DRUG|Normal saline|"Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery."
214726465|NCT04346004|DRUG|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery."
214726466|NCT03068052|BEHAVIORAL|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
214726467|NCT03068052|BEHAVIORAL|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
214726468|NCT00873704|OTHER|supplemental postoperative oxygen|
214726469|NCT03099798|OTHER|Questionnaires|"All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment"
214726470|NCT03099798|DIAGNOSTIC_TEST|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
214726471|NCT02736929|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
214726472|NCT06417398|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
214726473|NCT04130880|DIAGNOSTIC_TEST|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
214726474|NCT01681290|DRUG|CBX129801|
214726475|NCT04125381|OTHER|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
214726476|NCT04253470|OTHER|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
214726477|NCT01105949|DEVICE|Marketed nasal strip|Marketed nasal strip
214726478|NCT01105949|DEVICE|NexGen AB 2R11|Nasal strip prototype
214726479|NCT01105949|DEVICE|NexGen JB Organic PET/PE|Nasal strip
214726480|NCT00823160|PROCEDURE|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
214726481|NCT00823160|PROCEDURE|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
214726482|NCT00926185|DRUG|Lifitegrast|Ophthalmic Solution
214726483|NCT00926185|DRUG|Placebo|Ophthalmic Solution
214726484|NCT06031376|DRUG|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
214726485|NCT06031376|DRUG|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
214726486|NCT06031376|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
214726487|NCT06031376|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
214726488|NCT02454452|PROCEDURE|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
214726489|NCT02454452|PROCEDURE|Saphenous vein stripping|Saphenous vein stripping
214726490|NCT02454452|PROCEDURE|CHIVA|conservative hemodynamic treatment venous insufficiency
214726491|NCT00141401|DRUG|Pregabalin|
214641584|NCT02078687|DIETARY_SUPPLEMENT|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
214641585|NCT02078687|DIETARY_SUPPLEMENT|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
214641586|NCT02078687|DIETARY_SUPPLEMENT|Mothers own milk|Group 1 received mothers own milk without fortification
214641587|NCT01956812|DRUG|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
214641588|NCT01956812|DRUG|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
214641589|NCT01956812|DRUG|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
214641590|NCT00098917|DRUG|autologous tumor cell vaccine|
214641591|NCT00098917|DRUG|therapeutic autologous dendritic cells|
214641592|NCT00098917|PROCEDURE|adjuvant therapy|
214641593|NCT00098917|PROCEDURE|biological therapy|
214641594|NCT00098917|PROCEDURE|conventional surgery|
214641595|NCT00098917|PROCEDURE|surgery|
214641596|NCT00098917|PROCEDURE|tumor cell derivative vaccine|
214641597|NCT00098917|PROCEDURE|vaccine therapy|
214726492|NCT02069704|DRUG|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
214641598|NCT04010669|DRUG|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
214641599|NCT04010669|DRUG|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
214641600|NCT05307315|OTHER|listening to music|The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
214641601|NCT06068387|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
214641602|NCT01622569|DRUG|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
214641603|NCT01505894|DRUG|BI 409306|Film-coated tablet
214641604|NCT01505894|DRUG|Placebo|Film-coated tablet
214641605|NCT01001702|DRUG|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
214641606|NCT04248205|DRUG|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
214641607|NCT06526936|BEHAVIORAL|Education|Information about diabetic foot care
214641608|NCT00569894|BIOLOGICAL|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
214641609|NCT00569894|BIOLOGICAL|TIV (Injection)|One or two injections of TIV depending on previous status.
214641610|NCT00569894|OTHER|Unvaccinated Control|no vaccine
214641611|NCT03685773|DRUG|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
214641612|NCT03685773|DRUG|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
214641613|NCT03685773|DRUG|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
214641614|NCT03665363|OTHER|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
214641615|NCT03665363|OTHER|Self-study|Active control consisting of directed self-studies on internet.
214641616|NCT00424060|DRUG|sagopilone|
214641617|NCT00424060|GENETIC|fluorescence in situ hybridization|
214641618|NCT00424060|GENETIC|gene expression analysis|
214641619|NCT00424060|OTHER|immunohistochemistry staining method|
214641620|NCT00424060|OTHER|laboratory biomarker analysis|
214641621|NCT00424060|OTHER|pharmacological study|
214641622|NCT00997516|PROCEDURE|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
214641623|NCT00997516|PROCEDURE|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
214641624|NCT02083458|PROCEDURE|Catheterization of the axillary vein.|
214641625|NCT04217265|DRUG|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
214641626|NCT04217265|DRUG|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
214641627|NCT02975830|RADIATION|Three dimensional CT based images|Right bronchial angle, left bronchial angle
214641628|NCT06545487|OTHER|BLOOD SAMPLE|BLOOD ANALYTICS IN SEVERAL PARAMETERS
214641629|NCT01940484|DRUG|Methoxy polyethylene glycol epoetin beta|
214641630|NCT01894126|BEHAVIORAL|Two-way SMS Dialogue|
214641631|NCT01894126|BEHAVIORAL|One-way SMS Messaging|
214641632|NCT01007214|PROCEDURE|Prostatectomy|Elective prostatectomy
214641633|NCT04361201|PROCEDURE|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
214641634|NCT04361201|DIAGNOSTIC_TEST|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
214641635|NCT03646084|OTHER|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
214641636|NCT03646084|OTHER|Rehabilitation program|Rehabilitation program current clinical practice
214641637|NCT01970176|DRUG|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
214641638|NCT01970176|DRUG|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
214641639|NCT05813197|BEHAVIORAL|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
214641640|NCT05813197|BEHAVIORAL|Usual services|Usual services
214641641|NCT05904314|BEHAVIORAL|Simulation training in electronic fetal monitor management|Simulation training in electronic fetal monitor management
214641642|NCT03315923|DRUG|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
214641643|NCT03315923|DRUG|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
214641644|NCT01285908|DRUG|Intravenous Norepinephrine Infusion|
214641645|NCT01866007|DRUG|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
214641646|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
214641647|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
214641648|NCT01866007|DRUG|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
214641649|NCT06219577|DRUG|Systane Complete Multi-Dose PF|Eyedrop
214641650|NCT06219577|DRUG|Walgreen's Lubricant Balance|Eyedrop
214641651|NCT00445133|DEVICE|Magnetic Sleep Pad|
214641652|NCT02570633|OTHER|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
214641653|NCT02570633|OTHER|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
214641654|NCT03011658|PROCEDURE|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
214641655|NCT04847661|DRUG|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
214641656|NCT03054610|DRUG|Betamethason Sodium Phosphate|
214641657|NCT03054610|DRUG|Ropivacaine|
214641658|NCT03054610|DRUG|Botulinum Toxins, Type A|
214641659|NCT02988583|DEVICE|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
214641660|NCT02988583|DEVICE|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
214641661|NCT02257190|BEHAVIORAL|Control|One hour of rest.
214641662|NCT02257190|BEHAVIORAL|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
214641663|NCT02257190|BEHAVIORAL|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
214641664|NCT01236430|DRUG|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
214641665|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
214641666|NCT01236430|DRUG|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
214641667|NCT01236430|DRUG|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
214641668|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
214726493|NCT02069704|DRUG|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
214726494|NCT03986567|BEHAVIORAL|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
214726495|NCT01236768|DRUG|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
214726496|NCT01236768|DRUG|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
214726497|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
214726498|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
214726499|NCT01855425|RADIATION|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
214726500|NCT03046563|OTHER|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
214726501|NCT03046563|OTHER|Pressing the Sham points|Pressing the sham points for eight minutes
214726502|NCT04066699|PROCEDURE|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
214726503|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
214726504|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
214726505|NCT00813267|BIOLOGICAL|mesenchymal stem cell infusion|
214726506|NCT00813267|BIOLOGICAL|bone marrow mononuclear cell infusion|
214726507|NCT01522118|DEVICE|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
214726508|NCT01909986|DRUG|[14C]ONO-4053|Single dose \[14C\]ONO-4053
214726509|NCT04313504|DRUG|Niraparib|Niraparib \& Dostarlimab combination
214726510|NCT04313504|DRUG|Dostarlimab|Niraparib \& Dostarlimab combination
214726511|NCT00605358|BEHAVIORAL|Open Door intervention|"Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
214726512|NCT03456180|DEVICE|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
214726513|NCT00111891|DRUG|niacin (+) laropiprant|
214726514|NCT00111891|DRUG|Comparator: placebo (unspecified)|
214726515|NCT06598163|DEVICE|Five Lives MED|"Five Lives MED is a mobile application that can be installed on smartphones and tablets using the Android and/or iOS operating systems for use at home.~The app offers structured sessions that can be completed once per day. Once the session is completed, the app also offers optional access to additional cognitive training exercises and educational articles.~The intervention sessions begins with a Habit Quest, a physical activity habit building tool delivered through a chat bot. Following the Habit Quest, the participant is guided through a series of gamified cognitive training exercises aimed at improving attention, memory, language and executive function."
214726516|NCT03859804|PROCEDURE|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
214726517|NCT03859804|PROCEDURE|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
214726518|NCT00725829|DRUG|simvastatin|Simvastatin 40mg/d
214726519|NCT00725829|DRUG|ezetimibe|ezetimibe 10mg/d
214726520|NCT00725829|DRUG|placebo|placebo
214726521|NCT05243147|DEVICE|nasal stents|using nasal stents after septoplasty
214726522|NCT05243147|DEVICE|merocel|using merocel after septoplasty
214726523|NCT02861118|OTHER|No Intervention|
214726524|NCT02454894|DRUG|lidocaine|surface anesthesia with lidocaine
214726525|NCT02454894|PROCEDURE|postoperative management|lying without the pillow for half an hour after lumbar puncture
214726526|NCT04949828|DRUG|CREON|Oral Capsules
214726527|NCT05589740|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
214726528|NCT05589740|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
214726529|NCT00625014|DRUG|Haloperidol|Haloperidol 3 mg/day for 8 days
214726530|NCT03674294|DRUG|Aprepitant|Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
214726531|NCT03674294|DRUG|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
214726532|NCT03674294|DRUG|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
214726533|NCT03674294|DRUG|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
214726534|NCT05743725|DRUG|Dexmedetomidine|dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
214726535|NCT05743725|DRUG|Magnesium sulfate|2 gm magnesium infusion for 30 minutes
214726536|NCT03486249|OTHER|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
214726537|NCT04064944|DEVICE|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
214726538|NCT02625467|PROCEDURE|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
214726539|NCT02625467|PROCEDURE|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
214726540|NCT02625467|DRUG|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
214726541|NCT03378973|DRUG|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
214726542|NCT00302770|DRUG|quetiapine|
214726543|NCT01706120|DRUG|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
214726544|NCT01706120|DRUG|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
214726545|NCT01706120|DRUG|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
214726546|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
214726547|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
214726548|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
214726549|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
214726550|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
214793854|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
214641669|NCT04219150|DEVICE|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
214641670|NCT04219150|DRUG|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
214641671|NCT01484782|BEHAVIORAL|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
214641672|NCT04142983|BIOLOGICAL|Adacel|0.5 mL, Intramuscular
214641673|NCT02893449|BEHAVIORAL|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
214641674|NCT02893449|BEHAVIORAL|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
214641675|NCT02893449|PROCEDURE|Deep brain stimulation|
214641676|NCT04221880|DRUG|Bupivacaine Hcl 0.25% Inj|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
214641677|NCT04221880|DRUG|Saline Solution for Block|Ultrasound-guided erector spinae plane block with 20 ml saline
214641678|NCT04221880|DRUG|Saline Solution intravenously|Same volume saline solution bolus and infusion as Group Lidocaine
214641679|NCT04221880|DRUG|Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
214641680|NCT03445078|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
214641681|NCT03445078|DIETARY_SUPPLEMENT|ordinary corn powder|ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
214641682|NCT04561154|OTHER|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
214641683|NCT03414580|PROCEDURE|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
214641684|NCT00857870|DRUG|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
214641685|NCT00857870|DRUG|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
214641686|NCT02776163|DRUG|Nedaplatin|nedaplatin 35mg/m\^2，D1-2，2 cycles
214641687|NCT02776163|DRUG|Docetaxel|Docetaxel 70mg/m\^2，D1，2 cycles
214641688|NCT02776163|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks
214641689|NCT03567070|OTHER|qualitative study based on an individual clinical interview|qualitative study based on an individual clinical interview
214641690|NCT02872454|BEHAVIORAL|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
214641691|NCT04809610|BEHAVIORAL|Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
214641692|NCT03537391|DIAGNOSTIC_TEST|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
214793855|NCT04403100|DRUG|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
214793856|NCT05268978|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
214793857|NCT04318652|DRUG|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
214726551|NCT06367049|DIAGNOSTIC_TEST|Methylation-specific PCR|"Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly."
214641693|NCT03537391|DIAGNOSTIC_TEST|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
214641694|NCT03537391|DIAGNOSTIC_TEST|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index \~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
214641695|NCT03537391|DIAGNOSTIC_TEST|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
214641696|NCT03537391|DIAGNOSTIC_TEST|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (\<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is \< 6 mm.
214641697|NCT04867798|DRUG|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels \<1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
214641698|NCT00419471|DRUG|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
214641699|NCT00419471|DRUG|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
214641700|NCT00450931|OTHER|counseling intervention|
214641701|NCT00450931|OTHER|educational intervention|
214641702|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6|Vitamin B-6 50 mg/d
214641703|NCT01964001|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg
214641704|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
214641705|NCT01964001|OTHER|Placebo|starch
214641706|NCT03937856|BEHAVIORAL|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
214726552|NCT02740894|DRUG|Gefitinib|
214726553|NCT04282460|BEHAVIORAL|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
214726554|NCT04282460|BEHAVIORAL|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
214726555|NCT05711511|PROCEDURE|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
214641707|NCT02655250|OTHER|Microbiome|
214793858|NCT04579874|DIAGNOSTIC_TEST|LIVERFASt|blood draw
214726556|NCT05711511|DEVICE|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
214726557|NCT05813860|DRUG|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
214726558|NCT05813860|DRUG|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
214726559|NCT01690988|DRUG|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
214726560|NCT01690988|DRUG|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
214726561|NCT01690988|DRUG|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
214726562|NCT00638274|PROCEDURE|Air|3 mls used for identifying epidural space
214726563|NCT00638274|PROCEDURE|Saline|3 mls of saline used to identify epidural space
214726564|NCT01465373|DRUG|Endometrin|100 mg per vagina TID
214726565|NCT01465373|DRUG|Progesterone in Oil|50 mg IM injection daily
214726566|NCT03878043|OTHER|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
214726567|NCT01251991|DRUG|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
214726568|NCT01251991|DIETARY_SUPPLEMENT|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
214726569|NCT01251991|DIETARY_SUPPLEMENT|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
214726570|NCT01251991|OTHER|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
214726571|NCT02927535|DRUG|TNF blockers monotherapy|
214726572|NCT03978286|DRUG|Vortioxetine|10 mg per day
214726573|NCT03978286|DRUG|Sertraline|75 mg per day
214726574|NCT01634100|DRUG|Probenecid|Probenecid
214726575|NCT01634100|DRUG|Rifampicin|Rifampicin
214726576|NCT01634100|DRUG|Empagliflozin|BI Drug
214726577|NCT01634100|DRUG|Empagliflozin|BI Drug
214726578|NCT01634100|DRUG|Rifampicin|Rifampicin
214726579|NCT01634100|DRUG|Probenecid|Probenecid
214726580|NCT01634100|DRUG|Empagliflozin (BI 10773)|BI Drug
214726581|NCT04330456|RADIATION|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
214726582|NCT04330456|PROCEDURE|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
214726583|NCT04330456|RADIATION|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
214726584|NCT02331316|OTHER|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
214726585|NCT03645811|BEHAVIORAL|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
214726586|NCT03645811|BEHAVIORAL|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
214726587|NCT01934608|BEHAVIORAL|Refill synch|
214726588|NCT01662986|DRUG|tiotropium bromide|18 mcg once a day (QD)
214726589|NCT01662986|DRUG|Placebo|Once a day (QD)
214726590|NCT00482365|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
214726591|NCT00482365|OTHER|medical chart review|review of patients' medical records at study entry and every 6 months
214726592|NCT00482365|OTHER|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
214726593|NCT03774706|DRUG|Misoprostol|two tablets misoprostol 400 μg sublingual
214726594|NCT03774706|DRUG|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
214641708|NCT05315466|PROCEDURE|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
214641709|NCT05315466|PROCEDURE|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
214641710|NCT00969215|DEVICE|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
214641711|NCT04369898|OTHER|Image analysis/ Central vein detection|Image analysis/ Central vein detection will be performed using a fully automated approach based on an ensemble of 3D convolutional neural Networks. The method is applied to T1w, T2w and T2\*w data . Results will be manually reviewed by 2 experts in CVs detection. MRI data must have been collected at 3 Tesla (3T) between 1990 and 2020 and must include T1 w, T2 w, T2-star based sequence (CVs detection).
214641712|NCT04369898|OTHER|Image analysis/ Automatic cortical lesion detection|Image analysis/ Automatic cortical lesion detection will be performed by using a convolutional neural network-based method. MRI data must have been collected at 3T between 1990 and 2020 and must include Double inversion recovery (DIR)/Phase-Sensitive Inversion Recovery (PSIR)/Magnetization Prepared - 2- RApid Gradient Echo Gradient Echo (MP2RAGE) (eventually also high spatial resolution Magnetization Prepared - RApid Gradient Echo (MPRAGE)) for cortical lesion detection.
214641713|NCT01394705|DEVICE|BodyMedia|Accelerometer
214641714|NCT03516344|PROCEDURE|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
214641715|NCT01411969|DRUG|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
214641716|NCT00643994|RADIATION|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
214641717|NCT01284699|PROCEDURE|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
214641718|NCT02904980|BEHAVIORAL|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
214641719|NCT02904980|BEHAVIORAL|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
214641720|NCT02061254|DEVICE|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
214641721|NCT02061254|DEVICE|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
214641722|NCT02061254|DEVICE|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
214641723|NCT02061254|PROCEDURE|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
214641724|NCT02646527|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
214641725|NCT00197054|BIOLOGICAL|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
214641726|NCT00197054|BIOLOGICAL|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
214726595|NCT03774706|DRUG|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
214726596|NCT00553618|DRUG|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
214726597|NCT02252328|DRUG|Simvastatin|Simvastatin 80mg once daily
214726598|NCT02252328|DRUG|Placebo|Placebo tablets once daily
214641727|NCT00197054|BIOLOGICAL|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
214641728|NCT02494531|RADIATION|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
214641729|NCT02494531|RADIATION|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
214641730|NCT03728946|DRUG|Liposomal Bupivacaine|Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
214726599|NCT03007628|DEVICE|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214726600|NCT03007628|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214726601|NCT03007628|OTHER|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
214726602|NCT03700086|DEVICE|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
214726603|NCT03700086|DEVICE|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
214726604|NCT05875012|OTHER|action observation physical training|Action observation training 3 sessions per week for 3 successive months
214726605|NCT05875012|OTHER|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
214641731|NCT06300853|OTHER|Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses|"Whole blood and serum samples will be longitudinally collected at the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1). Possible further time points will be collected within 2 years, based on the National recommended future vaccination regimens.~Biological samples will be used for the following exams:~* Cellular immunity characterization~  * T- and B-cells Immunophenotype.~ * Specific T-cell response.~ * In vitro specific B-cells characterization.~ * Antibody-dependent cellular cytotoxicity.~* Humoral response characterization~  * Serology assays.~ * Avidity assay.~ * Neutralization assays with different SARS-CoV-2 variants.~ * Presence of specific or cross-reactive antibodies for common hCoV.~* Genetic and epigenetic analysis"
214641732|NCT06519591|DRUG|Cadonilimab, LM-302, S-1, paclitaxel|Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
214641733|NCT02272686|DRUG|Ibrutinib|560 mg by mouth daily.
214641734|NCT03317951|OTHER|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
214641735|NCT03317951|OTHER|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
214641736|NCT05340985|DIETARY_SUPPLEMENT|25(OH)D3|calcifediol
214641737|NCT05340985|DIETARY_SUPPLEMENT|vitamin D3|Cholecalciferol
214641738|NCT00003209|BIOLOGICAL|bleomycin sulfate|
214641739|NCT00003209|DRUG|cisplatin|
214641740|NCT00003209|DRUG|fluorouracil|
214641741|NCT00003209|DRUG|ifosfamide|
214641742|NCT00003209|DRUG|methotrexate|
214641743|NCT00003209|DRUG|mitomycin C|
214641744|NCT00003209|DRUG|vinblastine sulfate|
214641745|NCT00003209|DRUG|vindesine|
214641746|NCT00003209|RADIATION|radiation therapy|
214641747|NCT00781157|DRUG|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
214641748|NCT02100605|DEVICE|Phytosun, decongestant, nasal spray|one time application of the nasal spray
214641749|NCT02800655|DEVICE|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
214641750|NCT02639663|DEVICE|dental device|"Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
214641751|NCT06485154|DRUG|TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir|Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
214641752|NCT04823949|DEVICE|Home blood pressure monitoring|See arm description
214641753|NCT03461133|OTHER|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
214641754|NCT03797105|BEHAVIORAL|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
214641755|NCT06548659|BEHAVIORAL|screen-based simulation|Randomization took place among 198 people. The intervention group was given training on pediatric medication administration through screen-based simulation.
214641756|NCT01846286|BEHAVIORAL|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
214641757|NCT01846286|OTHER|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
214641758|NCT05922748|OTHER|imaging|Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
214641759|NCT05922748|OTHER|Evoked Potentials|EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
214641760|NCT05922748|OTHER|MEG|MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
214641761|NCT05922748|BEHAVIORAL|Behavioural tests|Behavioural tests will be evaluated.
214641762|NCT03145298|BIOLOGICAL|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
214641763|NCT03145298|BIOLOGICAL|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
214726606|NCT02809846|DEVICE|Quell|
214726607|NCT02809846|DEVICE|Sham Quell|
214641764|NCT05483530|BIOLOGICAL|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
214641765|NCT00470080|PROCEDURE|venepuncture|venepuncture
214641766|NCT05381246|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
214726608|NCT05221489|OTHER|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
214793859|NCT02235233|DRUG|Technetium Tc 99M Mebrofenin|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
214726609|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
214641767|NCT05381246|OTHER|Reiki|In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
214641768|NCT04189679|OTHER|Immune signature in serum associated to the metabolic signature|Immune signature in serum associated to the metabolic signature
214641769|NCT04189679|GENETIC|Meta-genomic signature of intestinal flora|Meta-genomic signature of intestinal flora
214641770|NCT00598299|PROCEDURE|venous puncture|venous puncture
214641771|NCT00598299|OTHER|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
214641772|NCT00374738|BEHAVIORAL|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
214641773|NCT04697485|DRUG|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
214641774|NCT06287320|RADIATION|concurrent or sequential chemoradiotherapy|Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.
214641775|NCT06287320|DRUG|Immunotherapy|anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
214641776|NCT01442259|DRUG|AFQ056|
214641777|NCT04480177|DEVICE|foot insole|the subject was instructed to wear foot insole for 8 hours.
214641778|NCT04480177|OTHER|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
214641779|NCT04536883|PROCEDURE|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
214641780|NCT02369276|OTHER|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
214641781|NCT05358847|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214641782|NCT04634266|DEVICE|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
214641783|NCT00289263|DRUG|Paclitaxel|
214641784|NCT00264706|DRUG|Nona-L-arginine|
214641785|NCT04567212|GENETIC|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
214641786|NCT04567212|OTHER|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
214641787|NCT03524248|RADIATION|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
214641788|NCT04557852|PROCEDURE|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
214641789|NCT06148558|OTHER|Sunscreen Moisturizer|A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
214641790|NCT06148558|OTHER|Gentle Cleansing Lotion|A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
214641791|NCT06148558|OTHER|Facial Moisturizer|A provided facial moisturizer (Goodier) was used 1x daily (PM).
214641792|NCT03534427|OTHER|Jump rope exercise intervention|12-week jump rope exercise program
214641793|NCT02914262|DRUG|AKB-4924|Comparison of different dosages of AKB-4924
214641794|NCT02914262|OTHER|Placebo|Placebo comparator
214641795|NCT03592160|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
214641796|NCT06409676|PROCEDURE|ERAS protocols|Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
214641797|NCT03796767|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214641798|NCT03796767|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214641799|NCT03796767|PROCEDURE|Metastasectomy|Undergo salvage oligometastasectomy
214641800|NCT03796767|OTHER|Quality-of-Life Assessment|Ancillary studies
214641801|NCT03796767|OTHER|Questionnaire Administration|Ancillary studies
214641802|NCT03796767|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214641803|NCT05771727|OTHER|survey|The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).
214641804|NCT04989855|DRUG|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
214641805|NCT02482155|DRUG|Ibuprofen|ibuprofen 400 mg single dose oral solution
214641806|NCT06400888|OTHER|needle-free subcutaneous injector for Mecbl|needle-free subcutaneous injector for Mecbl
214641807|NCT06400888|OTHER|intramuscular injection of Mecbl|intramuscular injection of Mecbl
214641808|NCT00006023|DRUG|capecitabine|
214641809|NCT01307930|DRUG|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
214641810|NCT03259945|OTHER|Data collection|demographic and clinical data
214641811|NCT03259945|OTHER|Review of ECGs|nature and frequency of proven conduction disorders
214641812|NCT03754309|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
214641813|NCT03754309|DRUG|Placebo|Matched placebo
214641814|NCT06388486|BEHAVIORAL|Psychotherapy|Subject receive psychotherapy during hospital treatment.
214641815|NCT00784966|DRUG|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
214641816|NCT00784966|DRUG|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
214641817|NCT00958672|OTHER|Endoscopic capsule|Endoscopic capsule
214726610|NCT04827173|PROCEDURE|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
214726611|NCT02940197|BEHAVIORAL|MediterrAsian diet|no other description
214726612|NCT01751789|BEHAVIORAL|Linkage|
214726613|NCT01751789|OTHER|Treatment as Usual|
214726614|NCT01512693|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
214641818|NCT00797823|DRUG|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
214641819|NCT00797823|DRUG|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
214641820|NCT00797823|DRUG|Placebo|Saline solution 0.9%
214641821|NCT03926221|BEHAVIORAL|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
214641822|NCT01640457|DRUG|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
214641823|NCT01640457|DEVICE|NOVOCART® Disc basic|ADCT (Media with no active cell component)
214641824|NCT06131619|OTHER|assesment of cognitive parameters with DLOTCA-G|All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
214641825|NCT06489717|OTHER|SDB assessment|SDB will be assessed by respiratory polygraphy according to clinical standards
214641826|NCT04492436|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
214641827|NCT04492436|DRUG|Placebo|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
214641828|NCT02568046|DRUG|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
214641829|NCT02568046|DRUG|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
214641830|NCT06221475|DRUG|BAY2927088 coated tablet 10 mg|4 coated tablets (10 mg) per single dose 30 min after a light meal
214641831|NCT06221475|DRUG|[14C]-BAY2927088 solution for infusion|IV infusion 15 min ending at 2 hours oral post-dose
214641832|NCT06221475|DRUG|[14C]-BAY2927088 oral solution|After a light meal
214641833|NCT01367522|DRUG|SC Methylnaltrexone (MNTX)|
214641834|NCT03543514|OTHER|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~* Control with the 6-minute walking test and podometer of physical activity~* Dietary advice to be able to perform a hyperproteic diet~* Mindfullnes to improve the emotional level."
214641835|NCT02931721|DIAGNOSTIC_TEST|MRI|Pelvis MRI
214641836|NCT03014856|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
214641837|NCT00004979|DRUG|paclitaxel|
214641838|NCT00004979|DRUG|topotecan hydrochloride|
214641839|NCT01181414|PROCEDURE|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
214641840|NCT01181414|DRUG|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
214641841|NCT00387114|DRUG|Vitamin C|
214641842|NCT00523991|DRUG|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
214641843|NCT00523991|DRUG|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
214641844|NCT00193063|DRUG|Trastuzumab|Trastuzumab
214641845|NCT00193063|DRUG|Gemcitabine|Gemcitabine
214641846|NCT03439033|DRUG|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
214641847|NCT03439033|DRUG|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
214641848|NCT03439033|DRUG|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
214641849|NCT01418976|BEHAVIORAL|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
214641850|NCT00149578|DRUG|Gemcitabine Oxaliplatin 5FU and Leucovorin|
214641851|NCT00920660|DRUG|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
214641852|NCT00920660|DRUG|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
214641853|NCT00920660|DRUG|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
214641854|NCT00920660|DRUG|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
214641855|NCT00920660|DRUG|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
214641856|NCT00920660|DRUG|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
214641857|NCT06247891|PROCEDURE|ECS Group|Patients underwent endoscopic and endocytoscopic evaluations.
214641858|NCT00009971|DRUG|fenretinide|
214641859|NCT01197287|DRUG|QAK423A|
214641860|NCT01197287|DRUG|QAK423A|
214641861|NCT01197287|DRUG|QAK423A|
214641862|NCT02899039|BIOLOGICAL|extra blood draw samples|
214726615|NCT05013099|BIOLOGICAL|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
214726616|NCT04326881|DRUG|SHR-1314|single dosing
214726617|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
214726618|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
214726619|NCT01975376|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
214726620|NCT01975376|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
214726621|NCT01816542|OTHER|patch tests on healthy skin|Patches will be placed on healthy skin.
214726622|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
214726623|NCT01442090|DRUG|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
214726624|NCT01442090|DRUG|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
214726625|NCT00596895|DIETARY_SUPPLEMENT|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
214726626|NCT00000199|DRUG|Piracetam|
214726627|NCT04731922|DRUG|TAK-510|TAK-510 solution.
214726628|NCT04731922|DRUG|TAK-510 Placebo|TAK-510 placebo-matching solution.
214726629|NCT03225651|BIOLOGICAL|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
214726630|NCT03225651|BEHAVIORAL|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
214726631|NCT05345938|DRUG|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
214726632|NCT02738346|DRUG|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
214726633|NCT02738346|DRUG|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
214726634|NCT02738346|DRUG|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
214726635|NCT02738346|DEVICE|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
214726636|NCT02339441|DRUG|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
214726637|NCT02339441|DRUG|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
214726638|NCT02339441|DRUG|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
214726639|NCT02564068|DRUG|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
214726640|NCT05018468|DEVICE|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
214726641|NCT06949995|DEVICE|Active Recovery with Blood Flow Restriction|10-minute active recovery protocol performed with blood flow restriction using a pneumatic cuff set at 60% of the participant's total occlusion pressure.
214726642|NCT06949995|OTHER|Active Recovery|10-minute active recovery protocol.
214726643|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Prophylaxis|a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
214726644|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Treatment|a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
214726645|NCT04603274|PROCEDURE|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
214726646|NCT01819194|DEVICE|senofilcon A|
214726647|NCT06869577|OTHER|Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma|A 12-week supportive group intervention targeted caregivers to patients with glioblastoma.
214726648|NCT01875705|DRUG|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
214726649|NCT01875705|DRUG|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
214726650|NCT00247572|DRUG|NRP104|
214726651|NCT06263244|DRUG|Ziltivekimab|Monoclonal antibody targeting IL-6
214726652|NCT06263244|DRUG|Placebo|Placebo
214726653|NCT01962857|BEHAVIORAL|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
214726654|NCT02562950|DRUG|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
214726655|NCT02562950|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
214726656|NCT02562950|DRUG|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
214726657|NCT00005969|DRUG|Chemotherapy|
214726658|NCT00005969|DRUG|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
214726659|NCT03442504|DIAGNOSTIC_TEST|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
214726660|NCT03054740|DRUG|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
214726661|NCT03054740|DRUG|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
214726662|NCT05059704|OTHER|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
214726663|NCT05059704|OTHER|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
214726664|NCT00331955|DRUG|doxorubicin hydrochloride|Given IV
214726665|NCT00331955|DRUG|vorinostat|Given orally
214726666|NCT00331955|OTHER|pharmacological study|Correlative studies
214726667|NCT00331955|OTHER|laboratory biomarker analysis|Correlative studies
214726668|NCT03156855|DRUG|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
214726669|NCT03156855|DRUG|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
214726670|NCT00110123|DRUG|fotemustine|
214726671|NCT00110123|DRUG|isolated perfusion|
214726672|NCT01586650|OTHER|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
214726673|NCT01586650|OTHER|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
214726674|NCT06220552|DRUG|Sintilimab|Sintilimab 200mg D1, Q3W
214726675|NCT06220552|RADIATION|Low-dose Radiotherapy|Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W
214726676|NCT04683172|DEVICE|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
214726677|NCT04683172|DEVICE|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
214726678|NCT05946707|DRUG|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
214726679|NCT05946707|DRUG|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
214726680|NCT03043209|GENETIC|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
214726681|NCT03489850|DRUG|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
214726682|NCT03489850|OTHER|Placebo|Placebo is matched to ibudilast active medication.
214726683|NCT03374813|DEVICE|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
214726684|NCT03374813|DEVICE|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
214726685|NCT01832857|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
214726686|NCT02343952|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
214726687|NCT06053970|OTHER|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
214726688|NCT00829218|OTHER|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
214726689|NCT00829218|OTHER|Placebo diet|Juice with nothing added.
214726690|NCT04589338|OTHER|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
214726691|NCT04589338|OTHER|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
214726692|NCT00456885|DRUG|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
214726693|NCT00456885|DRUG|Placebo|Twice daily injection of placebo
214726694|NCT00254878|DRUG|Methylphenidate hydrochloride|
214726695|NCT01690819|PROCEDURE|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
214726696|NCT01690819|PROCEDURE|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
214726697|NCT00044993|BIOLOGICAL|Ad5CMV-p53 gene|
214726698|NCT00044993|DRUG|docetaxel|
214726699|NCT00044993|DRUG|doxorubicin hydrochloride|
214726700|NCT00044993|PROCEDURE|conventional surgery|
214726701|NCT00044993|PROCEDURE|neoadjuvant therapy|
214726702|NCT05825092|DRUG|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
214726703|NCT05825092|DRUG|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
214726704|NCT05825092|DIAGNOSTIC_TEST|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
214726705|NCT05825092|DIAGNOSTIC_TEST|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
214726706|NCT05825092|DIAGNOSTIC_TEST|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
214726707|NCT05825092|DIAGNOSTIC_TEST|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
214726708|NCT05825092|DIAGNOSTIC_TEST|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
214726709|NCT00650312|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
214726710|NCT00650312|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
214726711|NCT05094804|DRUG|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
214726712|NCT05094804|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
214726713|NCT05094804|DRUG|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
214726714|NCT04746781|BEHAVIORAL|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
214726715|NCT04746781|BEHAVIORAL|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
214726716|NCT04746781|BEHAVIORAL|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
214726717|NCT04679714|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
214726718|NCT00946023|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
214726719|NCT00946023|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
214726720|NCT00946023|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
214726721|NCT00946023|DRUG|Tacrolimus|Start on Day 5 through Day 180
214726722|NCT00946023|DRUG|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
214726723|NCT00946023|DRUG|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
214726724|NCT00946023|BIOLOGICAL|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
214726725|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
214726726|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
214726727|NCT01944488|DRUG|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
214726728|NCT03771495|OTHER|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
214726729|NCT03771495|OTHER|Laying on of Hands|Sham Hip Joint Mobilization
214726730|NCT01956994|DIETARY_SUPPLEMENT|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
214726731|NCT01956994|DIETARY_SUPPLEMENT|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
214726732|NCT05823792|DIAGNOSTIC_TEST|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
214726733|NCT00133172|DRUG|Tacrolimus|IV
214726734|NCT00133172|DRUG|mycophenolate mofetil|IV
214726735|NCT00133172|DRUG|Prednisone|IV
214641863|NCT04173429|DRUG|Nadroparin calcium, warfarin|Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
214641864|NCT00566930|OTHER|spinal manipulation|Monthly cervical spinal manipulation
214641865|NCT00566930|OTHER|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
214641866|NCT05827029|PROCEDURE|Preopertive drink|"* Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
214641867|NCT00732095|BEHAVIORAL|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
214641868|NCT00379795|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
214641869|NCT02475642|OTHER|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
214641870|NCT02475642|OTHER|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
214641871|NCT03250403|DRUG|PRP injection|peri-neural injection of platelet rich plasma
214641872|NCT03250403|OTHER|traditional medical treatment|traditional medical treatment
214641873|NCT02435849|BIOLOGICAL|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
214641874|NCT04717674|DRUG|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|\[18F\]FPIA radiotracer administration
214641875|NCT04717674|PROCEDURE|PET/CT|PET/CT scan
214641876|NCT05836792|OTHER|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
214641877|NCT05836792|DEVICE|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
214641878|NCT05836792|DEVICE|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
214641879|NCT05836792|OTHER|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
214641880|NCT02507362|RADIATION|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
214641881|NCT02507362|RADIATION|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
214641882|NCT02507362|DRUG|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
214641883|NCT02507362|PROCEDURE|epithelial debridement|corneal epithelium will be removed by a cottons swab
214641884|NCT04849780|DEVICE|ACUVUE Oasys 1-Day|TEST
214641885|NCT04849780|DEVICE|Habitual Lens|Subjects' own Habitual Lenses
214726736|NCT00004604|BIOLOGICAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
214726737|NCT04930952|DRUG|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
214726738|NCT00033371|DRUG|Celecoxib|Given 400 mg PO twice a day
214726739|NCT00033371|OTHER|Placebo|Given PO to match DFMO
214641886|NCT01613755|DRUG|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
214641887|NCT01613755|DRUG|Metformin|Metformin 500 mg twice daily for four days
214641888|NCT05408520|PROCEDURE|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
214641889|NCT03598855|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
214641890|NCT04293679|DRUG|STP705|Investigational Product
214641891|NCT04680611|OTHER|no study intervention. Patients receive standard clinical care|no intervention. observational study
214641892|NCT00876135|DRUG|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
214641893|NCT01306227|DRUG|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
214641894|NCT01306227|DRUG|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
214641895|NCT02372487|DRUG|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
214726740|NCT00033371|DRUG|eflornithine|Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).
214726741|NCT00033371|OTHER|Laboratory biomarker analysis|Correlative studies
214726742|NCT00033371|OTHER|Questionnaire administration|Ancillary studies
214641896|NCT02372487|DIETARY_SUPPLEMENT|fluid therapy|2 liters of fluid per day
214641897|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
214641898|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
214641899|NCT03276611|OTHER|echocardiograghy|transthoracic echocardiograghy
214641900|NCT04388306|OTHER|Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)|Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
214641901|NCT02990442|DEVICE|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R\_DLPFC)
214641902|NCT01664780|DEVICE|ARFI imaging|
214726743|NCT03577951|PROCEDURE|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
214726744|NCT03577951|PROCEDURE|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
214726745|NCT00899678|DRUG|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
214641903|NCT04598373|BEHAVIORAL|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
214641904|NCT06084130|DRUG|Zolpidem|10 milligrams zolpidem contained in white-color opaque medicine capsule
214641905|NCT06084130|DRUG|Placebo|corn-starch contained in identical white-color opaque medicine capsule
214641906|NCT02319044|DRUG|MEDI4736|MEDI4736 monotherapy
214641907|NCT02319044|DRUG|Tremelimumab|Tremelimumab monotherapy
214641908|NCT02319044|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
214641909|NCT00176111|PROCEDURE|peripheral nerve stimulation (procedure)|
214641910|NCT04041882|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
214641911|NCT04563065|OTHER|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
214641912|NCT04563065|OTHER|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
214641913|NCT00758472|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
214641914|NCT05157815|DIETARY_SUPPLEMENT|Soluble Fibre|10g soluble corn fibre to be consumed twice per day
214641915|NCT05157815|DIETARY_SUPPLEMENT|Calorie Matched Control|2g maltodextrin consumed twice per day
214641916|NCT02937714|OTHER|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
214641917|NCT01145066|DRUG|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
214641918|NCT01145066|DIETARY_SUPPLEMENT|fish oil|1.6g/day EPA and 1.08g/day DHA
214641919|NCT01145066|DIETARY_SUPPLEMENT|corn oil|contains 4.5 g/day linoleic acid
214641920|NCT02864472|PROCEDURE|PDT|PDT and ranibizumab
214641921|NCT02864472|DRUG|Ranibizumab|Ranibizumab
214641922|NCT02864472|DRUG|ranibizumab PRN|ranibizumab PRN
214641923|NCT00449709|DRUG|GSK221149|
214726746|NCT00899678|DRUG|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
214726747|NCT02699125|DRUG|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
214641924|NCT00723788|DEVICE|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
214641925|NCT00434135|DRUG|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
214641926|NCT02584192|BEHAVIORAL|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
214641927|NCT02584192|OTHER|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
214641928|NCT03721926|OTHER|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
214641929|NCT03721926|OTHER|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
214726748|NCT02699125|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
214726749|NCT02923050|BEHAVIORAL|Simple Suppers|Theory-based 10-week family meals program
214726750|NCT03123484|DRUG|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
214726751|NCT03123484|DRUG|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
214726752|NCT00601679|OTHER|NT-proBNP guided care|knowledge of NT-proBNP results
214641930|NCT01724528|DRUG|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
214641931|NCT01724528|DRUG|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
214641932|NCT04275115|DRUG|Drug Cocktail|Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)
214641933|NCT04275115|DRUG|Foliglurax|Foliglurax
214641934|NCT04275115|DRUG|midazolam iv|Single intravenous (iv) dose of midazolam 0.025 mg/kg
214641935|NCT01864616|DIETARY_SUPPLEMENT|Vitamin D3|
214641936|NCT05329077|DEVICE|Pulsenmore ES home ultrasound device|Pregnant participants will use Pulsenmore ES device to assess the safety and the efficacy of the device in monitoring fetal parameters
214641937|NCT06134492|DRUG|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
214641938|NCT05731180|OTHER|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
214641939|NCT04247425|OTHER|Exercise Counseling|Receive instructional guidance
214641940|NCT04247425|OTHER|Quality-of-Life Assessment|Ancillary studies
214641941|NCT04247425|OTHER|Questionnaire Administration|Ancillary studies
214641942|NCT04247425|OTHER|Resistance Training|Complete progressive resistance training
214641943|NCT05548205|DEVICE|Continuous Glucose Monitor|Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.
214641944|NCT05548205|DEVICE|Blood Glucose Monitor|Self-administered according to investigator instruction.
214641945|NCT06856044|PROCEDURE|ileocolic resection with extended mesenteric resection|The resection limits will be in healthy mesenteric areas. The restoration of continuity in one stage should be preferred. The choice of laparoscopy versus laparotomy is at the surgeon's discretion.
214641946|NCT06492785|BIOLOGICAL|High Hyaluronic Acid concentrations (0.5 mg/ml)|Hyaluronic Acid(EmbryoGlue®)
214641947|NCT06492785|BIOLOGICAL|Low Hyaluronic Acid concentrations (0.125 mg/ml)|Hyaluronic Acid (G2 medium)
214641948|NCT06350006|DRUG|SHR-A1904; Adebrelimab|SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
214641949|NCT06350006|DRUG|SHR-A1904; CAPOX; Adebrelimab|SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
214641950|NCT05597904|GENETIC|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
214641951|NCT05565599|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
214641952|NCT07025096|OTHER|Artifical Intelligence-Generated Treatment Recommendations|The clinical vignette will contain treatment recommendations which were generated by an artificial intelligence-based clinical decision support system.
214641953|NCT07028125|DRUG|cabozantinib and nivolumab|"cabozantinib and nivolumab according to the labelling indication, namely:~* CABOZANTINIB 40 mg per oral route once daily~* NIVOLUMAB 240 mg per intravenous route every 2 weeks~During this combined treatment, the digital monitoring system is used to collect weekly data on treatment tolerance by patient self-report."
214641954|NCT06546670|DRUG|ITU512|ITU512 is an investigational, oral, low molecular weight (LMW) compound.
214641955|NCT06546670|DRUG|Placebo|An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
214641956|NCT06926283|DRUG|DXC008|Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.
214726753|NCT00333047|DRUG|Letrozole|
214726754|NCT02914197|OTHER|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
214726755|NCT03799627|DRUG|Vadadustat|Vadadustat Tablets 150 mg
214726756|NCT03799627|DRUG|Epoetin Alfa|Epoetin Alfa
214726757|NCT03799627|DRUG|Vadadustat TIW|Oral Vadadustat
214726758|NCT00776698|DRUG|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
214726759|NCT00776698|DRUG|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
214726760|NCT00776698|DRUG|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
214726761|NCT02883426|BIOLOGICAL|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
214726762|NCT02883426|BIOLOGICAL|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
214641957|NCT07076238|BIOLOGICAL|Bacteriophage Treatment|Participants who have a positive match for their NTM isolate will start on mycobacteriophage treatment per prescribed treatment regimen.
214641958|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
214641959|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
214641960|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
214641961|NCT07078994|OTHER|Placebo|injection
214641962|NCT04409236|BEHAVIORAL|Quit2Heal|Use Quit2Heal app
214641963|NCT04409236|BEHAVIORAL|QuitGuide|Use QuitGuide app
214641964|NCT04409236|OTHER|Survey Administration|Ancillary studies
214641965|NCT06814119|DRUG|MK-1084|Oral tablet
214641966|NCT06843213|BEHAVIORAL|Peer Intervention|Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.
214641967|NCT06843213|OTHER|Enhanced Usual Care|Participants will receive a handout that includes harm reduction education and resources in their local area as part of enhanced usual care.
214641968|NCT05571839|DRUG|PF-08046049|Given into the vein (IV; intravenous)
214641969|NCT07082920|DRUG|JNJ-78278343|JNJ-78278343 will be administered intravenously.
214641970|NCT07082920|DRUG|JNJ-95298177|JNJ-95298177 will be administered intravenously.
214641971|NCT07081958|DRUG|RO7795081|RO7795081 will be administered orally once daily, according to the randomized dosing regimen, during the 38-week treatment period.
214641972|NCT07081958|DRUG|Placebo|Placebo matching each RO7795081 dosing regimen arm will be administered orally once daily during the 38-week treatment period.
214641973|NCT06902519|DRUG|GS-0151|Administered for 12 weeks
214641974|NCT06902519|DRUG|Placebo|Administered for 12 weeks
214641975|NCT06903533|OTHER|Puzzle Activity|After assigning the students to the intervention and control groups, a puzzle activity will be conducted with the intervention group following a lecture. In preparing the puzzles, the researchers will use free online puzzle-making tools (e.g., https://crosswordlabs.com/). The puzzles will include questions related to basic knowledge and concepts concerning gerontological nursing competence. During the puzzle-solving process, the researcher will be present in the classroom and provide guidance to students when needed. After students complete the puzzles, the researcher will project the puzzle on the presentation screen and evaluate the answers through interactive discussion with the students. Upon completion of each puzzle, the researcher will collect the puzzles from the students to prevent contamination between the intervention and control groups. A post-test will be administered to students at the end of the puzzle activity.
214641976|NCT04644770|DRUG|JNJ-69086420|Participants will receive JNJ-69086420.
214641977|NCT04644770|DRUG|JNJ-78278343|Participants will receive JNJ-78278343.
214641978|NCT04644770|RADIATION|Stereotactic body radiation therapy|Participants will receive stereotactic body radiaition therapy.
214641979|NCT06929260|DRUG|Ceralasertib|Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.
214641980|NCT06929260|DRUG|Drug X|Participants will receive a single dose of Drug X on Day 5 and Day 22.
214641981|NCT06929260|DRUG|Drug Y|Participants will receive a single dose of Drug Y on Day 7 and Day 28.
214641982|NCT06929260|DRUG|Drug Z|Participants will receive a single dose of Drug Z on Day 7 and Day 28.
214641983|NCT07085390|OTHER|Use of a Balloon Guide Catheter|Use of a balloon guide catheter in stroke thrombectomy.
214641984|NCT07085390|OTHER|Use of a Conventional (non-balloon) Guide Catheter|Use of a conventional (non-balloon) guide catheter in stroke thrombectomy.
214641985|NCT07086976|DRUG|rilzabrutinib|Pharmaceutical form:tablet-Route of administration:oral
214641986|NCT07086976|DRUG|placebo|Pharmaceutical form:tablet-Route of administration:oral
214641987|NCT06015893|BEHAVIORAL|Take Control|A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.
214726763|NCT02883426|BIOLOGICAL|Placebo|Administered by nasal spray
214726764|NCT02666040|DEVICE|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
214726765|NCT02666040|DEVICE|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
214726766|NCT02666040|PROCEDURE|Detecting the mode of admission to hospital|Ordinary admission or day surgery
214726767|NCT02666040|PROCEDURE|Duration of surgery|Time operating room
214641988|NCT06015893|DRUG|Semaglutide|Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
214641989|NCT06894615|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
214641990|NCT04925479|DRUG|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: 1 mg film-coated granules in a size 0 capsule will be supplied, taken orally (capsules are a container for the granules and are not ingested):~10 mg (10x 1 mg film-coated granules in capsule) 15 mg (15x 1 mg film-coated granules in capsule) 20 mg (20x 1 mg film-coated granules in capsule) 30 mg (30x 1 mg film-coated granules in capsule)"
214641991|NCT04925479|DRUG|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
214641992|NCT06320431|DRUG|Tenecteplase|Thrombolytic
214641993|NCT06906627|OTHER|(IRIS-CKD Screening Program): Home Kit|"All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results.~Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline."
214641994|NCT06906627|OTHER|(IRIS-CKD Screening Program): Standard Lab Order|ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab
214641995|NCT06906640|OTHER|(IRIS-CKD Management Program): Education|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
214641996|NCT06906640|OTHER|(IRIS-CKD Management Program): GDMT|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.
214641997|NCT07084675|BEHAVIORAL|Hydration-Dehydration-Rehydration Protocol (HDR)|"The HDR Protocol is a 12-day, sequential fluid manipulation intervention designed to assess the physiological effects of controlled changes in hydration status. The protocol consists of three consecutive 4-day phases:~Hydration Phase (Days 1-4): Participants follow a standardized fluid intake protocol designed to promote and maintain a euhydrated state. Hydration status is monitored using objective measures such as urine specific gravity and body mass.~Dehydration Phase (Days 5-8): Participants adhere to a fluid-restriction regimen to induce a hypohydrated state. The level of dehydration is verified through the same hydration status measures to ensure consistent and safe hypohydration.~Rehydration Phase (Days 9-12): Participants resume the standardized fluid intake protocol used during the Hydration Phase to restore euhydration. Rehydration effectiveness is confirmed through repeated hydration assessments."
214641998|NCT06723236|BIOLOGICAL|MGC028|MGC028 is an antibody-drug conjugate targeted against ADAM9.
214641999|NCT07096687|DEVICE|Targeted Temperature Management with CB240_Aurora|The proposed experimental treatment with the CB240\_Aurora device will serve as a complementary approach to standard therapies, aiming to enhance their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.
214642000|NCT07096687|DEVICE|Standard of care Temperature treatment|In the control group, patients will receive treatment according to the latest guidelines for the management of ischemic stroke, including standard body temperature management. The CB240\_Aurora device will be used exclusively in monitoring mode, without delivering any active treatment, and will be maintained for 72 consecutive hours from the time of enrollment
214642001|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
214642002|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
214642003|NCT06910631|OTHER|Capillary CRP|CRP measured semi-quantitatively using ACTIM-CRP device
214726768|NCT02666040|PROCEDURE|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
214726769|NCT02154334|DRUG|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
214642004|NCT06910592|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
214642005|NCT06910384|BIOLOGICAL|STR04|autologous bone-marrow-derived mesenchymal stem cells
214642006|NCT06919965|DRUG|TAR-210|TAR-210 will be administered intravesically.
214642007|NCT06919965|DRUG|Mitomycin C|MMC will be administered intravesically.
214642008|NCT06919965|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
214642009|NCT06933368|DRUG|Crest Cavity Protection Toothpaste|Toothpaste containing 0.243% w/w NaF.
214642010|NCT06933368|DRUG|Experimental Mouthwash|Mouthwash containing 0.085% w/w CPC.
214642011|NCT06937320|DIETARY_SUPPLEMENT|Exogenous Ketone Drink|"(R)-1,3-butanediol (BD, commercially available as KetoneIQ) initially dosed 300 mg/kg BID (target dose 400 mg/kg grams BID if tolerated) for 8 weeks"
214642012|NCT06937320|DIETARY_SUPPLEMENT|Placebo|equi-volume placebo administered for 8 weeks
214642013|NCT06935838|DRUG|Tirzepatide|Tirzepatide is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, obesity and overweight with at least one weight-related medical condition, and moderate to severe obstructive sleep apnea. An initial dose of TZP 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg.
214642014|NCT07141004|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214642015|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MRSA|Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
214642016|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MSSA|Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
214642017|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MRSA|Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.
214642018|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MSSA|Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.
214642019|NCT07149142|DIAGNOSTIC_TEST|Non-mydriatic fundus camera photography|Non-mydriatic fundus camera photography assessed by artificial intelligence software
214642020|NCT07149142|DIAGNOSTIC_TEST|Fundus ophtalmoscopy|Fundus opthalmoscopy assessed by an experienced ophtalmologist
214642021|NCT07149142|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography assessed by an experienced ophtalmologist
214642022|NCT07149142|DIAGNOSTIC_TEST|Confocal microscopy of the retina|In a subset of participants over 18 years of age, confocal microscopy of the retina will be performed to assess the presence of diabetic neuropathy
214642023|NCT07142525|PROCEDURE|Hybrid Osteoplasty|Open rhinoplasty with dorsal hump reduction performed using a powered surgical burr under irrigation and direct visualization. Bone is contoured gradually to achieve a smooth dorsum while preserving the keystone area. No dorsal osteotomy is performed in this arm. Cartilaginous work and adjunctive steps (e.g., septoplasty or tip refinement) are performed as clinically indicated but are not part of the intervention being tested.
214642024|NCT07142525|PROCEDURE|Traditional Osteotomy and Rasping|Open rhinoplasty using the conventional technique for dorsal hump reduction. The bony hump is resected with a straight osteotome, followed by manual rasping to refine the nasal dorsum, with preservation of the keystone area. Powered burrs are not used for primary dorsal contouring in this arm. Cartilaginous work and adjunctive procedures may be performed as clinically indicated but are not part of the tested intervention.
214642025|NCT07150845|DRUG|EVO756|Dose 1
214642026|NCT07150845|DRUG|EVO756|Dose 2
214642027|NCT07150845|DRUG|EVO756|Dose 3
214642028|NCT07150845|DRUG|Placebo control|Placebo control
214642029|NCT07120945|DEVICE|Robotic Assisted-Surgery (RAS) Hysterectomy|Patients indicated for Robotic Assisted-Surgery (RAS) hysterectomy procedures will have the RAS surgery using the Medtronic Hugo™ RAS system.
214642030|NCT07160127|DRUG|TJAOA103|Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.
214642031|NCT07153562|OTHER|liuzijue qigong exercises|Liuzijue qigong exercise for 20 minutes, 5 times per week, for 12 successive weeks.
214642032|NCT07153562|OTHER|conventional rehabilitation treatment|conventional rehabilitation exercises, 3 sessions per week, 45-60 minutes per session, for 12 successive weeks.
214642033|NCT07163819|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
214642034|NCT07163819|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
214726770|NCT02154334|DRUG|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
214726771|NCT02154334|DRUG|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
214642035|NCT07165977|DIETARY_SUPPLEMENT|Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo|"Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
214642036|NCT07165977|DIETARY_SUPPLEMENT|Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)|"Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
214642037|NCT07167953|DEVICE|Brain MRI|90 participants will undergo a 60 minute SOC brain MRI followed by 15 minute spiral MRI
214642038|NCT07167953|DEVICE|Brain MRI - SOC and spiral|6 participants will be scanned using 2 versions (SOC and spiral) pf 6 sequences (12 scans total).
214642039|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 sequences, 3 times (9 total scans per participants)
214642040|NCT07167953|DEVICE|Brain MRI - SOC and spiral|10 participants will be scanned using 2 versions (SOC and spiral) of 6 sequences (12 scans total).
214642041|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 spiral sequences to achieve desired signal to noise ratio (SNR).
214642042|NCT07167953|DEVICE|Brain MRI - spiral|5 participants will be scanned with 2 pairs of 6 spiral sequences.
214642043|NCT07167836|OTHER|Electronic medical record-based care pathway|Participants will undergo initial automated risk stratification to direct tailored follow-up intervals. If exceeding the maximum time interval, participants in the intervention arm will be contacted by scheduling personnel using a standardized protocol to schedule a follow-up visit. In contrast, patients in the control arm who are overdue will not be made known to any staff and will not be proactively contacted, instead continuing to be managed according to standard of care. To maximize generalizability and understanding among staff and patients, risk stratification will be based on inflammatory bowel disease medication use.
214642044|NCT07168824|DIETARY_SUPPLEMENT|Lacticaseibacillus paracasei|one capsule daily for 12 weeks
214642045|NCT07178379|PROCEDURE|Local paracervical Anesthesia|"1\. Intervention Group (Local Anesthesia) Name: Mepivacaine 3% uterosacral ligament block Type: Pharmacological (local anesthetic).~Dose/Administration:~Drug: Mepivacaine hydrochloride 3% (4 vials of 1.7 mL each, total 6.8 mL). Route: Bilateral injection into uterosacral ligaments (2 injections per ligament, 3.4 mL per side).~Technique:~Patient in lithotomy position. Uterosacral ligaments identified posteriorly to the cervix. Injection with a 27G Carpule needle (25 mm length) at 2-3 mm depth. Slow infusion (to minimize dispersion). Timing: Administered ≥1 minute before hysteroscopy."
214642046|NCT07178379|OTHER|Placebo|"Procedure:~Vaginal and cervical irrigation with 0.9% saline solution (4 irrigations, mimicking anesthesia administration).~Mimicry:~Same equipment (syringe, speculum) as intervention group. Identical patient positioning and timing"
214642047|NCT07179081|DRUG|AL58805|Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）
214642048|NCT07178756|PROCEDURE|Acupuncture|"Both groups A and B will undergo standard postoperative management program. This includes conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge, post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery.~In addition, acupuncture treatment will be delivered for the treatment group. Acupuncture will be performed 2x/week from postoperative week (POW) 5 to POW 8, a total of 8 acupuncture treatments will be administered. From the 2nd to 8th treatment, electroacupuncture and infrared therapeutic lamp will be used. The acupuncture needles to be used for this study are Kinhong/MAC sterile acupuncture needles for single use. The needles will be left in situ for 20 minutes. Electrical stimulation will be delivered at 2Hz for 20 min, at an intensity below individual patient's pain threshold. 4 acupuncture points will be stimulated in pairs."
214642049|NCT07178756|OTHER|Post-operative standard care|Standard postoperative management program includes: conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge. Post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery. No acupuncture given
214642052|NCT07179315|DRUG|cemiplimab+fianlimab|Fianlimab 1600 mg + Cemiplimab 350 mg FDC
214642053|NCT07179315|DRUG|Cemiplimab|350 mg
214642054|NCT07178769|DIETARY_SUPPLEMENT|ARKOSTEROL|After 2 and 4 months from the start of treatment, a follow-up will be carried out in which anthropometric data will be measured (weight, BMI, waist circumference), vital signs (blood pressure and pulse) and a sample will be taken for analysis to measure the following parameters: CT, LDL, HDL, triglycerides, VLDL, Apo A, Apo B, liver function (GOT, GPT) and kidney function (creatinine) and Liposcale ® (in case of treatment group).
214642055|NCT07177859|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
214726772|NCT00259519|PROCEDURE|Induction of delivery|Induction of delivery
214642056|NCT07177859|DRUG|Eculizumab Injection|Eculizumab
214642057|NCT07178236|DEVICE|MARIE|Portable capnoghraphy
214642058|NCT07178444|BEHAVIORAL|"New care pathway"|"Initially, the patient will have an interdisciplinary consultation aimed at identifying personalized goals for the patient and providing educational/preventive care using tools that will be provided to all centers. This consultation will bring together a cardiologist, an advanced practice nurse (APN), a dietitian and a pharmacist. This consultation will take place approximately 4 weeks after the hospitalization for acute coronary syndrome (ACS).~Secondly, the patient will have 3 follow-up consultations with the APN (at 3, 6 and 12 months after discharge from hospitalization for an ACS). During these consultations, the APN will perform a clinical assessment, a personalized educational support, a coaching based on the patient's personalized goals, an adjustment of therapies and, depending on needs, referral to other health professionals."
214642059|NCT07178444|OTHER|"Standard care pathway"|The French National Health Authority recommends two medical visits (at 6 and 12 month) and, if necessary, a third one (between the first and third month post-ACS) for the monitoring of the left ventricular. - The European Society of Cardiology recommends a reassessment of the lipid profile within 4-6 weeks post-ACS.
214642060|NCT07177781|DIETARY_SUPPLEMENT|Wild blueberry powder|Study volunteers will consume daily 26 grams of wild blueberry powder for 16 weeks, which has to be dissolved in a glass of water.
214642061|NCT07177651|PROCEDURE|Laminoplasty|Is a posterior approach that involves the surgical widening of the spinal canal by reshaping or repositioning the lamina. However, some patients with cervical stenosis
214642062|NCT07177651|PROCEDURE|Laminectomy with lateral mass fixation|Posterior cervical decompression with lateral mass screw insertion
214642063|NCT07178470|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) Dyspnea scale , , point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS) and physical examination|After obtaining informed consent, the Modified Medical Research Council (mMRC) Dyspnea scale will be administered to patients, and their responses will be recorded on a scale of 0 to +4. During the same clinical visit, a physical examination will be performed by the primary nephrologist, who will categorize the patient's volume status as hypovolemic, euvolemic, mild, moderate, or severe volume overloaded. Finally, point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), will be performed. Patients will be assigned a score based on the number of B-lines observed. We will measure discordance and concordance between the LUS and physical exam, the LUS and mMRC dyspnea scale, and between the physical exam and mMRc dyspnea scale.
214642064|NCT07178327|DRUG|LYN101|"In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection.~In Part B, participants will receive multiple doses of LYN101 administered as a SC injection."
214642065|NCT07178327|DRUG|Placebo|"In Part A, participants will receive single dose of the matched placebo administered as a subcutaneous (SC) injection (4 cohorts).~In Part B, participants will receive multiple doses of the matched placebo administered as a SC injection."
214642066|NCT07179263|OTHER|50% glycolic acid|Subjects use 3 drops about 0.2g of 50% Glycolic Acid product on half face under instruction, then wait for 3 minutes and wash face by tap water. Wait for 10 minutes before measuring.
214642067|NCT07179263|OTHER|Tape Stripping|Technician use the D100 to paste on the center of the test area and make it fit the skin more completely and evenly by pump fully cover the D100 patch for 10 seconds. Stripping on each test area until the skin change into redness. The number of stripping will be recorded.
214642068|NCT07178548|OTHER|Online Survey|Participants will complete a structured online survey designed to assess their knowledge, attitudes, and application of evidence-based guidelines (clinical practice guidelines - CPGs) in managing low back pain (LBP).
214642069|NCT07177495|PROCEDURE|maxillary sinus floor elevation using Open Maxillary sinus floor elevation and Augmentation using Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml~  \+ adrenaline0.017 mg), full-thickness mucoperiosteal flap originating from the mid-crestal area or slightly toward the palate side would be opened.~* lateral window will be created in the maxillary bone to allow for adequate access to the sinus membrane.~* The membrane will be carefully elevated using a sinus elevator.~* bone graft will be placed into the sinus cavity using Autogenous Bone with Deproteinized Bovine Bone Particulate.~* collagen membrane will be secured in place using resorbable sutures or tacks if necessary.~Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~* full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened.~* core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
214642070|NCT07177495|PROCEDURE|Open Maxillary sinus floor elevation and Augmentation using A Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* After maxillary sinus floor elevation, Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate will be placed in the sinus cavity and secured in place using resorbable sutures or tacks if necessary.~* Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~  * full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened. • core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
214642071|NCT07178808|PROCEDURE|Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy|CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use of heated and high dose chemotherapy to address microscopic residual disease.
214726773|NCT03395041|DIAGNOSTIC_TEST|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
214726774|NCT02092324|OTHER|Laboratory Biomarker Analysis|Correlative studies
214726775|NCT02092324|OTHER|Quality-of-Life Assessment|Ancillary studies
214726776|NCT02092324|OTHER|Questionnaire Administration|Ancillary studies
214726777|NCT02092324|DRUG|Ruxolitinib Phosphate|Given PO
214726778|NCT01211119|OTHER|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
214726779|NCT02758041|DEVICE|Sebacia Microparticles|
214642072|NCT07177989|OTHER|Experimental Group|The interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise heart rate will be calculated using the Karvonen formula for the base line week and the following weeks.Following each aerobic session, they'll practice Alternate Nostril Breathing (ANB), beginning with 5 minutes in the first week and progressing to 10 minutes thereafter. ANB involves specific hand positioning and breathing techniques to promote relaxation and balance. All sessions will be supervised by a physiotherapist.
214642073|NCT07177989|OTHER|interventional group A|In interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down phase lasting 5-7 minutes, allowing the heart rate to gradually return to baseline and preventing post-exercise hypotension. From the second week onwards, the aerobic training session will begin with a 5-minute warm-up to prepare the body and gradually increase heart rate. The main workout involves a cycle ergometer, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes. The session ends with a 5-7 min
214642074|NCT07177586|DEVICE|GMA Laryngeal Mask Airway|The GMA-Tulip is a new single-use supraglottic airway device (SAD). Device size is selected based on the patient's weight and height, following manufacturer guidelines.
214642075|NCT07177586|DEVICE|Inflatable Laryngeal Mask Airway|The comparator is a conventional inflatable Laryngeal Mask Airway (LMA) of appropriate size (selected by weight/height), inserted using standard clinical protocols.
214642076|NCT07178730|DRUG|Sacituzumab govitecan|"SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle.~The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines.~SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC."
214642077|NCT07178730|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.
214642078|NCT07178730|DRUG|SoC Chemotherapy|Standard of care chemotherapy as per common treatment guidelines and recommendations
214726780|NCT06153914|PROCEDURE|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
214726781|NCT03224260|DRUG|BMS-986177|Oral Suspension
214726782|NCT03224260|OTHER|Matched Placebo|Oral Suspension
214726783|NCT06056401|BEHAVIORAL|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
214726784|NCT02139267|BIOLOGICAL|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
214726785|NCT06454162|OTHER|Modified Ketogenic Diet|the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
214726786|NCT06454162|OTHER|exercise program|the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
214726787|NCT01339780|RADIATION|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
214726788|NCT05051176|DIAGNOSTIC_TEST|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
214726789|NCT00861094|DRUG|cisplatin|
214726790|NCT00861094|DRUG|5-FU|
214726791|NCT00861094|DRUG|oxaliplatin|
214726792|NCT00861094|RADIATION|radiation therapy|
214726793|NCT00861094|DRUG|Folinic Acid|
214726794|NCT02512276|BEHAVIORAL|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
214726795|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
214726796|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
214726797|NCT04019392|DEVICE|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
214726798|NCT04019392|OTHER|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
214726799|NCT02287662|OTHER|Vancouver 3M Clinical Pathway|
214726800|NCT02637804|DEVICE|stenfilcon A|contact lens
214726801|NCT02637804|DEVICE|narafilcon A|contact lens
214726802|NCT02637804|DEVICE|delefilcon A|contact lens
214726803|NCT03065725|PROCEDURE|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
214726804|NCT02393222|OTHER|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
214726805|NCT06115057|DIETARY_SUPPLEMENT|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
214726806|NCT03587922|DEVICE|Fantom|Treatment of den ovo coronary lesions
214726807|NCT03175016|PROCEDURE|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
214726808|NCT03175016|DRUG|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
214726809|NCT03175016|DEVICE|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
214726810|NCT06101316|DRUG|CB06-036|CB06-036 Capsule
214726811|NCT01599819|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
214726812|NCT01599819|BIOLOGICAL|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
214726813|NCT04151719|DRUG|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
214726814|NCT04212546|OTHER|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
214726815|NCT04212546|OTHER|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
214726816|NCT02983513|BEHAVIORAL|Early Intervention|
214726817|NCT04479449|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
214726818|NCT04479449|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
214726819|NCT00669513|BEHAVIORAL|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
214726820|NCT03430336|OTHER|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
214726821|NCT03430336|OTHER|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
214726822|NCT03430336|OTHER|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
214726823|NCT03430336|OTHER|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
214726824|NCT03430336|OTHER|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
214726825|NCT03600870|DRUG|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
214726826|NCT02417675|OTHER|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
214726827|NCT02417675|OTHER|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
214726828|NCT02417675|OTHER|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
214726829|NCT05300854|PROCEDURE|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
214726830|NCT05300854|PROCEDURE|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
214726831|NCT02091193|DIETARY_SUPPLEMENT|Krill Oil (Supplement A)|
214726832|NCT02091193|DIETARY_SUPPLEMENT|Placebo (Supplement B)|
214726833|NCT02959697|DRUG|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
214726834|NCT02959697|DRUG|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
214726835|NCT02959697|PROCEDURE|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
214726836|NCT05625880|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
214726837|NCT00320294|DRUG|irinotecan|
214726838|NCT00320294|DRUG|cisplatin|
214726839|NCT01922739|DRUG|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
214726840|NCT01922739|DRUG|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
214726841|NCT06453863|OTHER|Greater plantar feedback shoes|Shoes providing enhanced plantar feedback
214726842|NCT06453863|OTHER|Neutral gym shoes|Regular gym shoes
214726843|NCT06453863|OTHER|Barefoot|For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
214726844|NCT01526317|DRUG|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
214726845|NCT02619058|BIOLOGICAL|NKT cells|autologous natural killer T cell
214726846|NCT01352013|DIETARY_SUPPLEMENT|Omega-3 (oil)|5ml daily with breakfast for 56 days.
214726847|NCT01352013|DIETARY_SUPPLEMENT|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
214726848|NCT00481221|PROCEDURE|Observation of results from laboratory tests|Laboratory data summary only
214726849|NCT01176890|DRUG|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
214726850|NCT01176890|OTHER|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
214726851|NCT06228443|DRUG|Leflunomide 20 mg Film-coated Tablet|Leflunomide 20 mg Film-coated Tablet (Test Drug)
214726852|NCT06228443|DRUG|ARAVA® 20 mg Film-coated Tablet|ARAVA® 20 mg Tablets (Reference Drug)
214726853|NCT04762264|DEVICE|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
214726854|NCT00910013|DRUG|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
214726855|NCT02288442|OTHER|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
214726856|NCT03150199|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
214726857|NCT03150199|BEHAVIORAL|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
214726858|NCT01494025|BEHAVIORAL|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
214726859|NCT02377908|OTHER|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
214726860|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of darifenacin
214726861|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
214726862|NCT01616069|DRUG|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
214726863|NCT01898962|PROCEDURE|Complete Surgical Removal|
214726864|NCT01898962|RADIATION|Stereotactic Radiosurgery|
214726865|NCT01898962|RADIATION|Ablative external beam radiation dose|
214726866|NCT01898962|PROCEDURE|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
214726867|NCT01898962|RADIATION|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
214726868|NCT04021576|OTHER|preventative training program|complementary training of leg-, hip- and core-strength/stability
214726869|NCT01995422|OTHER|Physical activity program|One hour sessions of active walking occurring three times a week during three months
214726870|NCT03647748|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
214726871|NCT03237429|DIAGNOSTIC_TEST|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
214726872|NCT03536273|OTHER|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
214726873|NCT04185662|DIETARY_SUPPLEMENT|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
214726874|NCT02725268|DRUG|Paclitaxel|Paclitaxel intravenous solution.
214726875|NCT02725268|DRUG|Sapanisertib|Sapanisertib capsules.
214726876|NCT02725268|DRUG|MLN1117|MLN1117 capsules.
214726877|NCT05936372|BEHAVIORAL|Acute intense aerobic exercise|The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
214726878|NCT04498468|DRUG|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
214726879|NCT04498468|OTHER|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
214726880|NCT03694067|OTHER|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
214726881|NCT03365440|DEVICE|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
214726882|NCT03696004|DRUG|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
214726883|NCT05882123|OTHER|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
214726884|NCT00074620|DRUG|PEG-hirudin|
214726885|NCT04601844|DRUG|Pozelimab|Single dose administered subcutaneously
214726886|NCT04601844|DRUG|Cemdisiran|Single dose administered SC
214726887|NCT05177289|DEVICE|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
214726888|NCT05177289|DEVICE|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
214726889|NCT06086457|RADIATION|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
214726890|NCT06086457|DRUG|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
214726891|NCT06086457|BIOLOGICAL|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
214726892|NCT04024449|OTHER|Group A|ovarian function test in control group
214726893|NCT04862741|DRUG|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
214726894|NCT04862741|DRUG|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
214726895|NCT04862741|DRUG|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
214726896|NCT04862741|DRUG|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
214726897|NCT00863941|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
214726898|NCT00863941|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
214726899|NCT05892536|PROCEDURE|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
214726900|NCT03135639|OTHER|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
214726901|NCT03135639|OTHER|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
214726902|NCT04826029|OTHER|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
214793860|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
214726903|NCT04826029|OTHER|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
214726904|NCT01154322|DEVICE|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
214726905|NCT00722475|DRUG|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
214726906|NCT00722475|DRUG|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
214726907|NCT02224274|DRUG|Clopidogrel|
214726908|NCT02224274|DRUG|Ticagrelor|
214726909|NCT04556201|DEVICE|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
214726910|NCT02745041|DRUG|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
214726911|NCT02745041|OTHER|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
214726912|NCT03199131|PROCEDURE|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
214726913|NCT00187044|BIOLOGICAL|PolyEnv1 vaccine|administered subcutaneously as 10\*7 pfu in 0.8 mL
214726914|NCT02422394|DRUG|Eltrombopag|
214726915|NCT01976624|DRUG|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
214726916|NCT00020449|BIOLOGICAL|recombinant interleukin-12|
214726917|NCT00020449|DRUG|paclitaxel|
214726918|NCT00020449|DRUG|pegylated liposomal doxorubicin hydrochloride|
214726919|NCT03931980|PROCEDURE|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
214726920|NCT04350372|DEVICE|MitraClip Procedure|MitraClip procedure with MitraClip NT System
214726921|NCT06401252|BEHAVIORAL|Mindfulness-based intervention|"• The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting)"
214726922|NCT02628899|DEVICE|Transfemoral TAVR|
214726923|NCT02628899|DEVICE|SAVR|
214726924|NCT00411970|DEVICE|20- and 23 gauge vitreoretinal surgery systems|
214726925|NCT03079518|DRUG|Ferric Carboxymaltose|single shot infusion
214726926|NCT03079518|OTHER|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
214726927|NCT03944551|DEVICE|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
214642079|NCT07178665|RADIATION|Radiation: Accelerated Partial Breast Irradiation (APBI)|"Radiation: Accelerated Partial Breast Irradiation (APBI) - 5 fractions delivered every other day before surgery.~Procedure: Surgery - lumpectomy or mastectomy scheduled 1-3 weeks after RT; additional whole-breast/lymph node RT if indicated."
214642080|NCT07178639|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
214642081|NCT07178639|DRUG|Nepafenac 0.3% Oph Susp|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
214642082|NCT07178639|DRUG|diclofenac 0.1% ophthalmic susp.|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
214642083|NCT07177534|OTHER|No intervention|This study is a retrospective observational study without intervention.
214642084|NCT07177391|OTHER|Discontinuous subcostal echocardiographic cardiac output assessment|Right Ventricular Outflow Chamber Diameter (RVOD) and Left Ventricular Outflow Chamber Diameter (LVOD) assessments via subcostal approach
214642085|NCT07178912|DRUG|Blinatumomab|Given by Iv
214642086|NCT07178912|DRUG|olverembatinib|Given by PO
214642087|NCT07177352|OTHER|No Intervention|Participants will have their blood drawn and cognitive score measured by the ISLT.
214642088|NCT07179107|OTHER|Baseline - week 1|Habitual fluid intake during week 1
214642089|NCT07179107|OTHER|Low Water Intake - week 2|Low water intake as described by the protocol
214642090|NCT07179107|OTHER|Moderate Water Intake - week 3|Moderate Water Intake - Week 3
214642091|NCT07179107|OTHER|Adequate Water Intake - week 4|Adequate Water Intake - week 4
214642092|NCT07179107|OTHER|Washout - week 5|Washout - week 5
214642093|NCT07179107|OTHER|Low fluid intake with non caloric sweeteners - Week 6|Low fluid intake with non caloric sweeteners - Week 6
214642094|NCT07179107|OTHER|Moderate fluid intake with non caloric sweeteners - Week 7|Moderate fluid intake with non caloric sweeteners - Week 7
214642095|NCT07179107|OTHER|Adequate fluid intake with non caloric sweeteners - Week 8|Adequate fluid intake with non caloric sweeteners - Week 8
214642096|NCT07177833|DEVICE|Fractional CO2 laser|Fractional CO2 Laser Therapy is an extra-dermal (applied to the surface of the skin) and non-invasive treatment that involves the use of lasers to destroy and reduce abnormal collagen in scarred tissue.
214642097|NCT07177833|OTHER|Sham (No Treatment)|Patients will undergo a treatment with a vibratory device capable of mimicking fractional CO2 laser therapy
214642098|NCT07177417|BIOLOGICAL|FluMist|intranasal administered live attenuated influenza vaccine
214642099|NCT07177417|BIOLOGICAL|inactivated influenza vaccine|intramuscular administered inactivated influenza vaccine
214642100|NCT07177417|PROCEDURE|bronchoscopy|bronchoscopy with bronchoalveolar lavage and endobronchial biopsy sampling
214642101|NCT05463991|DEVICE|Bioengineered collagen implant|Urethral stricture repair
214642102|NCT05513027|DEVICE|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.
214642103|NCT05513027|DEVICE|PET/CT|-Standard of care
214642104|NCT04658862|BIOLOGICAL|Cetrelimab|Participants will receive intravenous Cetrelimab.
214642105|NCT04658862|DRUG|TAR-200|Participants will receive intravesical TAR-200.
214642106|NCT04658862|DRUG|Cisplatin|Participants will receive cisplatin intravenously.
214642107|NCT04658862|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously.
214642108|NCT04658862|RADIATION|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
214726928|NCT03944551|OTHER|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
214726929|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
214726930|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
214726931|NCT01025297|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
214726932|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 5 mg
214726933|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
214726934|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 10 mg
214726935|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
214726936|NCT02058251|DRUG|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
214726937|NCT02058251|DRUG|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
214726938|NCT06882408|DEVICE|Photorefraction device under investigation|Objective refraction measurement with and without cyclopegia
214726939|NCT06882408|DEVICE|Comparator device, Tabletop auto-refractometer|Objective refraction measurement with and without cyclopegia
214726940|NCT06882408|DEVICE|Comparator device, portable photorefraction device|Objective refraction measurement with and without cyclopegia
214726941|NCT06882408|OTHER|Distance visual acuity assessments|Distance visual acuity is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
214726942|NCT06882408|OTHER|Subjective refraction and far visual acuity|Subjective refraction is assessed and far visual acuity is assessed with the found refraction measures
214726943|NCT06882408|OTHER|Strabismus assessment|Strabismus is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
214726944|NCT05730127|OTHER|Conditioning stimulus|Pain stimulus on non-dominant side
214726945|NCT00278551|BIOLOGICAL|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
214726946|NCT03513250|DRUG|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
214726947|NCT03513250|DRUG|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
214726948|NCT04961827|BEHAVIORAL|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
214726949|NCT04961827|BEHAVIORAL|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
214726950|NCT01948349|OTHER|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
214726951|NCT01948349|OTHER|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
214726952|NCT02859987|PROCEDURE|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
214726953|NCT02859987|PROCEDURE|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
214726954|NCT02859987|DEVICE|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
214793861|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
214726955|NCT01190020|DRUG|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
214726956|NCT01190020|DRUG|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
214726957|NCT05597241|DRUG|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
214726958|NCT05597241|DRUG|Placebo|Placebo
214726959|NCT03878225|DIETARY_SUPPLEMENT|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
214726960|NCT03878225|OTHER|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
214726961|NCT02511275|PROCEDURE|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
214642109|NCT04658862|RADIATION|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
214642110|NCT05634408|DEVICE|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
214642111|NCT06452797|BEHAVIORAL|ProVent-14 score|A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
214642112|NCT02192931|DRUG|Creatine monohydrate|
214642113|NCT06074640|OTHER|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
214642114|NCT06074640|OTHER|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
214642115|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally|coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine
214642116|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously|coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
214642117|NCT04445857|OTHER|Normal Saline (NS)|coadministration of normal saline and a single-shot hyperbaric bupivacaine
214642118|NCT01227902|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
214642119|NCT06008574|OTHER|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
214642120|NCT06008574|OTHER|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
214642121|NCT06008574|OTHER|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
214642122|NCT05366283|BIOLOGICAL|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
214642123|NCT02939157|OTHER|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
214642124|NCT02527707|DRUG|lonafarnib|antiviral farnesyltransferase inhibitor
214642125|NCT02527707|DRUG|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
214642126|NCT06217315|OTHER|No Intervention|There is no intervention.
214642127|NCT00234312|DRUG|escitalopram and sertraline|
214642128|NCT00060255|DRUG|busulfan|iv
214642129|NCT00060255|DRUG|carboplatin|iv
214642130|NCT00060255|DRUG|carmustine|iv
214642131|NCT00060255|DRUG|cyclophosphamide|iv
214642132|NCT00060255|DRUG|etoposide|iv
214642133|NCT00060255|DRUG|melphalan|oral
214642134|NCT00060255|DRUG|thiotepa|iv
214642135|NCT00060255|PROCEDURE|autologous bone marrow transplantation|iv
214642136|NCT00060255|PROCEDURE|bone marrow ablation with stem cell support|iv
214642137|NCT00060255|PROCEDURE|peripheral blood stem cell transplantation|iv
214642138|NCT00060255|RADIATION|radiation therapy|body x-ray
214642139|NCT00930059|DRUG|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
214642140|NCT00930059|DRUG|Placebo|matching placebo tablets, every 12 hours for 12 wks
214642141|NCT04002310|DRUG|BI 754132|One single injection
214642142|NCT00542997|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
214642143|NCT04788940|PROCEDURE|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
214642144|NCT04857099|OTHER|Data extraction from medical files|Data extraction from medical files
214642145|NCT06538506|DEVICE|RehUp BCI Intervention|Participants will be seated wearing a cap on their head containing surface electrodes connected to a computer/laptop. The laptop employs machine learning algorithms and uses the scalp electroencephalogram (EEG) signals from the scalp's surface to control a robotic arm which supports the patient's stroke-affected arm. The machine learning algorithms rapidly interpret EEG signals and adjust the outgoing movement commands to the robot based on an individual's responses to stimuli. The participant will be wearing a VR headset. The VR displays visual stimulus in time with the robotic arm. Based on information from the EEG, the participant is able to animate their robotic arm and receive visual task-based feedback in the VR.
214642146|NCT06538506|OTHER|Control Therapy|The study therapist will focus on 3 activities (\~15 minutes each/session): passive range of motion exercises, motor imagery, and mirror therapy. These activities were chosen as they are all passive activities that are commonly used in a patient with severe impairment of the post-stroke arm and hand. Each session will last \~1hour including set up and switching between activities.
214642147|NCT00001357|DRUG|Interleukin-2|
214642148|NCT01746771|DRUG|HM781-36B(Poziotinib)|QD\*2weeks/3weeks
214642149|NCT01746771|DRUG|Paclitaxel|175mg/m2
214642150|NCT01746771|DRUG|Trastuzumab|8mg/kg
214726962|NCT00125437|DRUG|spironolactone|
214726963|NCT06725264|DRUG|Deucravacitinib|6 mg twice daily
214726964|NCT03385525|DRUG|BIIB074|Administered as specified in the treatment arm
214726965|NCT03385525|DRUG|Valproic Acid|Administered as specified in the treatment arm
214726966|NCT03044470|OTHER|cryotherapy|Role of cryotherapy in reduction of post operative pain
214793862|NCT00491504|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
214642151|NCT03303911|DRUG|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
214642152|NCT02949128|BIOLOGICAL|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
214642153|NCT02050412|OTHER|Cat fur scratch test|
214642154|NCT05340920|DIAGNOSTIC_TEST|Oral Food Challenge|diagnostic values of skin prick test and specific IgE for allergy confirmed by oral food challenge (routine, not an intervention)
214642155|NCT04271098|PROCEDURE|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
214642156|NCT04271098|OTHER|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
214642157|NCT04271098|OTHER|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
214642158|NCT04799041|DRUG|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
214642159|NCT04799041|DRUG|Placebo|There were 15 patients in this group. Each one received only one treatment.
214642160|NCT02388568|DRUG|Lorcaserin|Lorcaserin plus Lifestyle Modification
214642161|NCT02388568|DRUG|Placebo|Placebo plus Lifestyle Modification
214642162|NCT03897738|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
214642163|NCT03897738|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
214642164|NCT03897738|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
214642165|NCT05812677|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214642166|NCT04271332|DRUG|Arbaclofen|Arbaclofen tablet
214642167|NCT04271332|DRUG|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
214642168|NCT01641120|DRUG|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
214642169|NCT02583334|DEVICE|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
214642170|NCT02583334|DEVICE|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
214642171|NCT01694004|DRUG|Benzocaine Infusion into Duodenum|
214642172|NCT00294541|DRUG|ICA-17043|
214642173|NCT03624257|DEVICE|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
214642174|NCT03624257|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
214642175|NCT04158063|BEHAVIORAL|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross"
214642176|NCT04158063|OTHER|Single Mobility Training|standard routine training
214642177|NCT05524064|RADIATION|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (\>40 Gy/s).
214642178|NCT05105763|OTHER|Sequential switched feedback training on the knee and the hip (Condition A)|Condition A will include four 6-mins training blocks: 2-mins knee joint feedback-on, 2-mins hip joint feedback-on, and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
214642179|NCT05105763|OTHER|Feedback training on the knee alone (Condition B)|Condition B will include four 6-mins training blocks: 4-mins knee joint feedback-on and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
214642180|NCT03313960|DRUG|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
214793863|NCT00491504|OTHER|Placebo|Placebo: 2 sprays in each nostril
214793864|NCT04228341|OTHER|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
214642181|NCT03313960|OTHER|"One Drop | Premium"|"Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
214642182|NCT01698957|OTHER|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
214642183|NCT05087615|DRUG|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
214642184|NCT05087615|DRUG|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
214642185|NCT05087615|DRUG|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
214642186|NCT05087615|DRUG|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
214642187|NCT01027533|OTHER|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
214642188|NCT02664155|DRUG|Apixaban|Direct Oral Anticoagulant
214642189|NCT02664155|DRUG|Rivaroxaban|Direct Oral Anticoagulant
214642190|NCT02664155|DRUG|Heparin|Standard Of Care
214642191|NCT02664155|DRUG|VKA|Standard Of Care
214642192|NCT03599700|DIAGNOSTIC_TEST|myeloproliferative neoplasms|BLOOD SAMPLING
214642193|NCT02594644|DEVICE|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
214642194|NCT02594644|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
214642195|NCT02594644|RADIATION|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
214642196|NCT03160560|DRUG|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
214642197|NCT03160560|DRUG|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
214642198|NCT03160560|OTHER|Placebo|Subjects in Placebo group will receive Placebo Rinse.
214642199|NCT04314050|DRUG|Tramadol|tramadol and paracetamol will perform
214642200|NCT04314050|DRUG|Dexmedetomidine|dexmedetomidine and paracetamol will perform
214642201|NCT04314050|OTHER|control|paracetamol will perform
214642202|NCT04153084|DRUG|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
214642203|NCT04153084|DRUG|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
214642204|NCT04153084|DRUG|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
214642205|NCT03018132|OTHER|mental health screening, education and referral program|"I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
214642206|NCT01769937|DRUG|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
214642207|NCT05205590|OTHER|Non|Non
214642208|NCT01151683|DIETARY_SUPPLEMENT|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
214642209|NCT01151683|DIETARY_SUPPLEMENT|placebo|Two capsules of placebo per oral twice a day
214642210|NCT05974982|BIOLOGICAL|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
214642211|NCT05974982|OTHER|Conventional therapy|Conventional therapy
214793865|NCT04228341|OTHER|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
214793866|NCT04228341|OTHER|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
214793867|NCT04228341|OTHER|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
214793868|NCT04228341|OTHER|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
214642212|NCT03667001|DRUG|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
214642213|NCT03667001|DRUG|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
214642214|NCT06320444|PROCEDURE|232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)|"Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)"
214642215|NCT05852639|DEVICE|Ultrasound|Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
214642216|NCT01664793|BEHAVIORAL|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
214642217|NCT02280850|DRUG|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
214642218|NCT02280850|DRUG|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
214642219|NCT02280850|DRUG|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
214642220|NCT06543615|DEVICE|Ultrasonography|Ultrasound assessment of residual gastric volume
214642221|NCT05363176|BEHAVIORAL|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, \~45 minute sessions delivered via telehealth.
214642222|NCT05363176|BEHAVIORAL|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, \~45 minute session delivered via telehealth
214642223|NCT03007212|PROCEDURE|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
214642224|NCT05629325|DRUG|Buspirone Hydrochloride 10 MG|4 weeks of treatment with buspirone
214642225|NCT05629325|DRUG|Placebo|4 weeks of treatment with placebo
214642226|NCT02659592|PROCEDURE|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
214642227|NCT05018819|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214642228|NCT00993811|DEVICE|Shang Ring circumcision|novel device for adult male circumcision
214642229|NCT02743260|DRUG|pitavastatin|
214642230|NCT02743260|DRUG|Metformin|
214642231|NCT02743260|DRUG|digoxin|
214642232|NCT02743260|DRUG|Adefovir|
214642233|NCT02743260|DRUG|sitagliptin|
214793869|NCT04228341|OTHER|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
214793870|NCT04228341|OTHER|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
214793871|NCT04228341|OTHER|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
214642234|NCT06342674|OTHER|Giving breast milk to the newborn according to the circadian rhythm|It is the delivery of milk expressed by the newborn's mother during the neonatal intensive care unit, in accordance with the time of expression. Breast milk follows the circadian rhythm, that is, the milk the mother expresses at night will be given to her infant at night, and the milk she expresses during the day will be given to her infant during the day
214642235|NCT06342674|OTHER|Usual care|Newborns in the control group will be given expressed milk first, in line with the routine practice of the clinic
214642236|NCT02611635|DRUG|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642237|NCT02611635|DRUG|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642238|NCT02611635|DRUG|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642239|NCT02611635|DRUG|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642240|NCT02611635|DRUG|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642241|NCT02611635|DRUG|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214642242|NCT03424759|DRUG|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
214642243|NCT06549205|DEVICE|device that stimulates the dorsal surface of the tongue|the device will be placed on the dorsal surface of the tongue. this instrument has two electrodes in turn connected to the TENS, so ultra low frequency stimulation (\<0.66 Hz) will be administered
214642244|NCT06549205|DEVICE|device that stimulates the tragus|two electrodes will be placed at tragus level for the administration of dental ULFTENS
214642245|NCT05811403|OTHER|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
214642246|NCT05811403|OTHER|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
214642247|NCT05811403|OTHER|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
214642248|NCT05811403|OTHER|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
214642249|NCT05806801|BEHAVIORAL|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
214642250|NCT05806801|BEHAVIORAL|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
214642251|NCT01745640|DRUG|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
214642252|NCT01745640|DRUG|Dexamethasone|40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
214642253|NCT03597425|PROCEDURE|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation (CPR) is an emergency treatment for patients with respiratory arrest and cardiac arrest in an attempt to restore the patient to spontaneous breathing and heartbeat through cardiopulmonary resuscitation
214642254|NCT03312517|DRUG|Suvorexant 10 mg|Subject will receive suvorexant 10mg
214642255|NCT03312517|DRUG|Suvorexant 20 mg|Subject will receive suvorexant 20mg
214642256|NCT03312517|DRUG|Placebo oral capsule|Subject will receive placebo.
214642257|NCT01977885|BEHAVIORAL|High Protein Diet|All participants will be individually counseled by an RD for \~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
214793872|NCT02529059|DRUG|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
214642258|NCT01977885|BEHAVIORAL|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or \~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
214642259|NCT01137240|PROCEDURE|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
214793873|NCT03197402|DIETARY_SUPPLEMENT|Leucine-enriched protein gel delivery system|Leucine enriched
214793874|NCT03197402|DIETARY_SUPPLEMENT|Milk protein gel delivery system|Non-leucine enriched
214793875|NCT04971057|OTHER|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
214642260|NCT00808444|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
214642261|NCT00808444|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
214642262|NCT00808444|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
214642263|NCT00808444|BIOLOGICAL|Rotarix|Oral, 2 doses
214642264|NCT02770326|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|
214642265|NCT03479632|BEHAVIORAL|Aerobic walking program|Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
214642266|NCT03479632|BEHAVIORAL|Standard physical therapy|Participants will receive standard care they normally would after a stroke.
214642267|NCT02971202|DRUG|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
214642268|NCT02971202|DRUG|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
214642269|NCT05374473|BEHAVIORAL|Lifestyle modification|Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.
214642270|NCT05374473|BEHAVIORAL|Standard-care|Content in standard-care arm was adapted from MS-related websites
214793876|NCT01323881|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
214793877|NCT03561506|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
214642271|NCT00993707|DRUG|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
214642272|NCT04702009|DRUG|Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy|Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
214642273|NCT04702009|DEVICE|Bronchoscopy-assisted Interventional Therapy|Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
214642274|NCT03581331|DIAGNOSTIC_TEST|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
214642275|NCT02953808|DRUG|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
214642276|NCT02953808|DRUG|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
214642277|NCT06195202|DRUG|AIs|Patients with AIs
214642278|NCT06195202|DRUG|OFS+AIs|Patients with OFS+AIs
214642279|NCT06195202|DRUG|FUL|Patients with FUL
214642280|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
214793878|NCT03561506|DRUG|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
214793879|NCT00306748|DRUG|MD-1100 Acetate|
214642281|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
214642282|NCT01047202|BIOLOGICAL|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
214642283|NCT05107167|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
214642284|NCT02521701|DRUG|NFL101|"Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
214642285|NCT02634580|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214642286|NCT02634580|DRUG|Ezetimibe|Tablet for oral administration
214642287|NCT02634580|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
214642288|NCT02634580|DRUG|Placebo Ezetimibe|Tablet for oral administration
214642289|NCT01412970|OTHER|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
214642290|NCT01673321|OTHER|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
214642291|NCT02619500|OTHER|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
214642292|NCT02619500|OTHER|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
214642293|NCT02619500|OTHER|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
214642294|NCT02619500|OTHER|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
214642295|NCT00519740|OTHER|inhalative specific bronchial provocation with grass-pollen|
214642296|NCT02409511|OTHER|non intervention|
214642297|NCT00381407|BEHAVIORAL|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
214642298|NCT00381407|BEHAVIORAL|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
214642299|NCT01533675|OTHER|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
214642300|NCT01533675|OTHER|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
214642301|NCT01380808|DRUG|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
214642302|NCT01275209|DRUG|HCD122|
214642303|NCT03222427|DRUG|LY3314814|Administered orally
214642304|NCT03222427|DRUG|[13C415N3] LY3314814|Administered as an IV infusion
214642305|NCT04184817|OTHER|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
214642306|NCT02922387|DRUG|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
214642307|NCT02922387|BEHAVIORAL|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
214642308|NCT05336084|BEHAVIORAL|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
214642309|NCT06231758|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
214642310|NCT06231758|DRUG|Metformin|Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
214642311|NCT04931134|DEVICE|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
214642312|NCT04931134|DEVICE|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
214642313|NCT03106779|DRUG|Asciminib|40 mg tablets was taken orally twice a day (BID)
214642314|NCT03106779|DRUG|Bosutinib|500 mg tablets was taken orally once daily (QD)
214642315|NCT05867667|OTHER|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
214642316|NCT03737370|DRUG|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
214642317|NCT03737370|RADIATION|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
214642318|NCT04001647|DRUG|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
214642319|NCT04001647|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
214642320|NCT04001647|DRUG|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
214726967|NCT02109068|BEHAVIORAL|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
214726968|NCT02109068|BEHAVIORAL|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
214726969|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
214726970|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
214726971|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
214726972|NCT01915017|BEHAVIORAL|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
214726973|NCT01915017|BEHAVIORAL|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
214726974|NCT01915017|BEHAVIORAL|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
214726975|NCT01915017|OTHER|Treatment as Usual|Standard medication follow up and limited case management
214726976|NCT00695500|DRUG|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
214726977|NCT00695500|DRUG|Placebo|Placebo tablets, 0 mg per day for 3 weeks
214726978|NCT00355329|PROCEDURE|Tongue Acupuncture (Procedure)|
214726979|NCT00108836|DRUG|XBD173|
214726980|NCT06926647|DRUG|Nucleos(t)ide Analogues|Administer NAs \[LAM, ETV, TDF, TAF (TAF preferred for those aged 6 years and older)\] continuously for 48 weeks based on age.
214726981|NCT06926647|DRUG|Interferon alfa|IFNα monotherapy for 48 weeks (select conventional IFNα for ages ≥1 and \<3 years, select PEG-IFNα-2b for ages ≥3 years)
214726982|NCT06926647|DRUG|NAs combined with IFNα|Receive NAs combined with IFNα treatment for 48 weeks.
214726983|NCT06926647|OTHER|comparative observation|Blank control observation for 48 weeks.
214726984|NCT06926647|OTHER|drug withdrawal observation|This group is the drug withdrawal observation group, which will strictly monitor virological indicators and biochemical results, and will reinitiate antiviral treatment if necessary based on antiviral treatment standards and the willingness of the child (or family members)
214726985|NCT01627782|DRUG|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
214726986|NCT01627782|DRUG|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
214726987|NCT03573401|COMBINATION_PRODUCT|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
214642321|NCT05188703|BEHAVIORAL|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
214642322|NCT04971824|PROCEDURE|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
214642323|NCT05622097|OTHER|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
214642324|NCT05622097|OTHER|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
214642325|NCT06507566|DEVICE|Tasso+™|The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.
214642326|NCT05003934|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214642327|NCT05682443|DRUG|ONC-392 low|ONC-392 will be given as IV infusion, Q4W for up to 13 doses.
214642328|NCT05682443|DRUG|ONC-392 high|ONC-392 will be given as IV infusion, Q6W for up to 9 doses.
214642329|NCT05682443|DRUG|lutetium Lu 177 vipivotide tetraxetan|lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
214642330|NCT06420960|DEVICE|Wearing the connected watch|"All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance."
214642331|NCT02288247|DRUG|Enzalutamide|Oral
214642332|NCT02288247|DRUG|Docetaxel|intravenous infusion
214642333|NCT02288247|DRUG|Prednisolone|Oral
214642334|NCT02288247|DRUG|Placebo|Oral
214642335|NCT06395090|BIOLOGICAL|Pembrolizumab|IV infusion
214642336|NCT06395090|BIOLOGICAL|Favezelimab|IV infusion
214642337|NCT06395090|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
214642338|NCT06395090|BIOLOGICAL|Vibostolimab|IV infusion
214642339|NCT06395090|BIOLOGICAL|Pembrolizumab/Vibostolimab|IV infusion
214642340|NCT04133961|DRUG|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
214642341|NCT04133961|DRUG|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
214642342|NCT03792841|DRUG|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
214642343|NCT03792841|DRUG|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
214642344|NCT03792841|DRUG|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
214642345|NCT03792841|DRUG|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
214642346|NCT05269290|DRUG|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
214642347|NCT05269290|DRUG|Placebo|Placebo will be administered once a day on top of standard therapy.
214642348|NCT05120310|BEHAVIORAL|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
214642349|NCT04093531|DRUG|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
214642350|NCT04911946|OTHER|Questionnaire|After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
214642351|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
214793880|NCT03708861|DRUG|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
214642352|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
214642353|NCT01281410|PROCEDURE|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
214642354|NCT01281410|OTHER|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
214642355|NCT02771132|BEHAVIORAL|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
214642356|NCT02771132|BEHAVIORAL|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
214793881|NCT00306384|DRUG|Alogliptin|Alogliptin tablets.
214726988|NCT03573401|COMBINATION_PRODUCT|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
214726989|NCT05218538|DIAGNOSTIC_TEST|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
214726990|NCT01969305|BEHAVIORAL|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
214726991|NCT01969305|BEHAVIORAL|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
214726992|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
214726993|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
214726994|NCT06916338|RADIATION|18F-FAPI-04 PET scan|FAPI-04, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-FAPI-04 PET scan.
214726995|NCT06032572|PROCEDURE|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
214726996|NCT06032572|PROCEDURE|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
214726997|NCT00616772|DRUG|ABT-335|Capsule
214726998|NCT00616772|DRUG|Placebo|Capsule
214726999|NCT00616772|OTHER|Atorvastatin|Capsule
214727000|NCT03389269|OTHER|Meal test|240 min mixed meal test with aspiration using AspireAssist.
214727001|NCT01186094|DEVICE|Cypher|Sirolimus-eluting stent
214727002|NCT01186094|DEVICE|Endeavor Resolute|Zotarolimus-eluting Stent
214727003|NCT06234072|DRUG|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
214727004|NCT06234072|DRUG|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
214727005|NCT05316519|OTHER|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
214727006|NCT06939465|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The participants will undergo a 6-week cognitive behavioral therapy (CBT) guided by a psychologist, with one session per week, each lasting 1 hour.
214727007|NCT06939465|BEHAVIORAL|Lifestyle management (sham control)|The participants will undergo a 6-week lifestyle management (sham control) guided by a psychologist, with one session per week, each lasting 1 hour.
214727008|NCT03688893|DEVICE|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
214793882|NCT05709106|DRUG|Rimegepant 75 MG|Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
214793883|NCT06190847|OTHER|regular chemoradiotherapy|regular chemoradiotherapy
214727009|NCT03872557|DIETARY_SUPPLEMENT|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
214727010|NCT06949358|DRUG|Olipudase alfa|Pharmaceutical form:Powder for concentrate for solution for infusion-Route of administration:intravenous infusion
214642357|NCT02771132|BEHAVIORAL|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
214642358|NCT06501781|BEHAVIORAL|Peer Activate-LAI|Peer Activate-LAI is a Peer Recovery Specialist-delivered behavioral activation and problem solving intervention, based on our team's formative work. The intervention focuses on problem-solving skills to improve adherence to ART and/or PrEP both at the individual level and environmental barriers to care (i.e., transportation, housing).
214642359|NCT06501781|OTHER|Standard of Care HIV treatment or prevention with LAI-PrEP/ART|Standard of care HIV treatment or prevention with LAI-PrEP/ART
214642360|NCT02988765|PROCEDURE|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
214642361|NCT03730805|BEHAVIORAL|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller \& Rollnick, 1991).
214642362|NCT03730805|BEHAVIORAL|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
214727011|NCT06948188|DIAGNOSTIC_TEST|Infrared exposure test|"Patients will undergo a standardized infrared exposure test (this test is specifically for research purposes) to evaluate the occurrence of cholinergic urticaria reaction.~IR exposure test with non-invasive core body temperature measurements, evaluate the occurrence of cholinergic urticaria up to 10 minutes after the end of the test, stop the test at the first clinical signs of urticaria.~Desk lamp with infrared bulb, switched on 20cm vertically from the forearm posteriorly for 3 minutes. Reading up to 10 minutes after end of exposure test: diagnosis of cholinergic urticaria flare-up if presence of pruritic micropapules on erythematous background of trunk +/- limbs. Stop the test as soon as urticarial lesions appear."
214727012|NCT06949293|OTHER|Hand massage with lavender oil|Each hand of the patient will be massaged with lavender oil for 5 minutes before and during cystoscopy. Before the application, 5% lavender oil will be applied to a small part of the hand and this area will be monitored for signs of allergic reaction such as swelling and redness. If no allergic reaction is observed, the study will continue.
214727013|NCT06949293|OTHER|Classic hand massage|Each hand of the patient will be massaged with baby oil for 5 minutes before and during the cystoscopy procedure.
214727014|NCT06949293|OTHER|Lavender inhalation|Before and during the cystoscopy procedure, 2-3 drops of 5% lavender oil will be poured onto a 5x5 cm sterile gauze. It will be placed 10 cm away from the patient's nose and sniffed for 10 minutes.
214727015|NCT06949891|DIETARY_SUPPLEMENT|Ketogenic diet|A eucaloric ketogenic diet (30-40 g carbohydrate per day) for 3 months, followed by a less strict ketogenic diet (50-60 g carbohydrate per day) for another 3 months.
214727016|NCT06949891|DIETARY_SUPPLEMENT|Mediterranean diet|The control group will receive a eucaloric diet according to the national healthy food guidelines/Mediterranean diet.
214727017|NCT06948734|DIAGNOSTIC_TEST|Clinical and radiographic examination|In order to evaluate the pulpal and periapical health of natural teeth adjacent to dental implants at specific time intervals, percussion, palpation, and pulpal diagnostic tests were performed, and the presence of any pathological changes was monitored using radiographic examinations.
214727018|NCT06949059|DRUG|Hydromorphone|Hydromorphone 1mg was given intravenously and conventional treatment was performed at the same time.
214727019|NCT06240793|PROCEDURE|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
214727020|NCT06240793|PROCEDURE|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
214727021|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
214727022|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
214727023|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
214727024|NCT06949020|DRUG|JMKX003142 placebo|JMKX003142 placebo for placebo groups once daily for five days.
214727025|NCT06949540|DIETARY_SUPPLEMENT|Blue Burn Tincture|Participants will complete self-assessments and provide weight and blood measurements during the study.
214727026|NCT06948305|BEHAVIORAL|instant messaging software|instant messaging software
214727027|NCT01203124|DRUG|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
214727028|NCT01203124|DRUG|Placebo|Placebo
214727029|NCT06948877|BEHAVIORAL|ARMOR Online|"The online version of ARMOR comprised three core components. The first was an MI-based relationship check-up with a brief relationship assessment. In the second component, SMs chose relationship improvement domains from a list of 10 topic areas or modules and watched a short (5-7 minute) video on their chosen area providing (a) evidence-based or evidence-informed psychoeducation, (b) modeling of skills, and (c) practice of the skills. For the third component, SMs were asked MI's key question (i.e., What's the next step? Miller \& Rollnick, 2023) and, if desired, completed a planning module where they were given the opportunity to create a personalized action plan (specifying how they might test any planned changes to see if they had the desired impact)."
214727030|NCT03619083|OTHER|SAE battery|The SAE battery yields 12 variables.
214642363|NCT03730805|BEHAVIORAL|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
214642364|NCT03129659|DIAGNOSTIC_TEST|Coronary CT Angiography|Coronary CT angiography
214642365|NCT04894656|DIAGNOSTIC_TEST|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
214642366|NCT06584045|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
214642367|NCT05312034|BEHAVIORAL|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
214642368|NCT04102033|DRUG|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
214642369|NCT02798796|DEVICE|MRI|All patients will be submitted to MRI
214642370|NCT02341378|BIOLOGICAL|TissueGene-C(Low dose)|TissueGene-C at 6.0x10\^6 cells
214642371|NCT02341378|BIOLOGICAL|TissueGene-C(High dose)|TissueGene-C at 1.8x10\^7 cells
214642372|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial.
214727031|NCT03619083|BEHAVIORAL|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
214793884|NCT05263219|PROCEDURE|dTACE-HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination."
214642373|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
214642374|NCT03692858|DRUG|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
214642375|NCT03692858|DRUG|Adductor Canal Block|Adductor Canal Block using Ropivacaine
214642376|NCT00852293|OTHER|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
214642377|NCT02183090|DRUG|Meloxicam ampoule|
214642378|NCT02183090|DRUG|Meloxicam tablet|
214642379|NCT04396509|BEHAVIORAL|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
214642380|NCT05464784|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
214642381|NCT05464784|DRUG|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
214727032|NCT06569160|DEVICE|Upper-room UVGI (Ultra-Violet Germicidal Irradiation)|"Nursing homes are equipped with UVGI devices in all common living places. UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team. The centers included will be randomized into two arms. In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2. In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.~The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI equipments will be switched off in both arms."
214642382|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
214642383|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
214642384|NCT03344666|BEHAVIORAL|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
214642385|NCT03344666|BEHAVIORAL|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
214642386|NCT06444672|OTHER|Home-based Rehabilitation program|Home-based rehabilitation program The investigators used the ASIA scale to evaluate the sensory function and voluntary movement7. The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-minute duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises. Participants who could stand with assistive devices (such as knee-ankle-foot orthoses, KAFO) performed walking exercises.
214642387|NCT06444672|DEVICE|Knee-Ankle-Foot-Orthosis|It is used to assist the participant in holding his /her body weight on the lower limb through standing and walking
214642388|NCT01415635|DIETARY_SUPPLEMENT|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
214642389|NCT04389242|OTHER|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
214642390|NCT02678715|DEVICE|Solubrux®|prefabricated device adaptable by temperature
214642391|NCT02678715|DEVICE|Customized Appliance|customized device fabricated in the dental laboratory
214642392|NCT02678715|DEVICE|Somatics®|standard device
214642393|NCT04575701|OTHER|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
214642394|NCT02918019|DRUG|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
214642395|NCT02918019|DRUG|Placebo|Placebo matched with MSTT1041A.
214642396|NCT02784938|BEHAVIORAL|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
214642397|NCT01743482|DRUG|Pazopanib|
214642398|NCT01212185|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
214642399|NCT01212185|OTHER|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
214642400|NCT03222349|DRUG|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
214642401|NCT01744288|DRUG|Ticagrelor|Oral single loading dose 180ng
214642402|NCT01744288|DRUG|Clopidogrel|Oral single loading dose 600mg
214642403|NCT01744288|DRUG|ASA|81mg once daily from day -2 up to platelet transfusion
214727033|NCT00027404|DRUG|Fluoxetine|
214727034|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
214727035|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
214727036|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
214727037|NCT05444829|DEVICE|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
214727038|NCT05444829|DEVICE|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
214727039|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
214727040|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
214727041|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
214727042|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
214727043|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
214727044|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
214727045|NCT01807676|DEVICE|ET View Double Lumen Tube|
214727046|NCT01807676|DEVICE|conventional Double Lumen Tube|
214727047|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
214727048|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
214727049|NCT06262646|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Trained FACT interventionists will be guided by manualized FACT intervention to identify how many psychopathological processes need support and which ACT process(es) need to work on first, then offer parents process-matched ACT intervention strategies following the principles of FACT. The intervention strategies include ACT metaphors, experiential exercises, audio-guided mindfulness exercises, guided imagery exercises and value clarification exercises. The FACT steps in each session depend on the client's situation/stage.
214727050|NCT06262646|OTHER|Control Group|Both study groups will receive standard family support from collaborating NGOs.
214727051|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
214727052|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
214793885|NCT05263219|PROCEDURE|HAIC|"HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles."
214642404|NCT06541873|OTHER|Clinical and gait evaluation|The dual-task conditions to be assessed during gait performance will include: counting backwards by 3 (executive simple task); counting backwards by 7 (executive complex task); mnemonic recall of the Rey's Auditory Verbal Learning Test (RAVLT). Performance scores will be correlated with cognitive status and clinical features. Data will be collected at the baseline (i.e., only) visit within the enrollment timeframe of 3 years from study initiation.
214642405|NCT00510809|DRUG|Policosanol|Policosanol 20 mg daily
214642406|NCT00510809|OTHER|Placebo|Placebo daily
214642407|NCT00510809|DRUG|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
214642408|NCT00191841|DRUG|gemcitabine|
214642409|NCT00191841|DRUG|Cisplatin|
214642410|NCT02021409|DRUG|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
214642411|NCT02021409|BIOLOGICAL|Darbepoetin alfa|
214642412|NCT04389177|DRUG|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
214642413|NCT00094757|DRUG|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
214642414|NCT00094757|DRUG|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
214642415|NCT00094757|DRUG|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
214642416|NCT00094757|DRUG|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
214642417|NCT05120739|DRUG|2% CHX cloths|skin preparation in 2% CHX cloths
214642418|NCT05600595|PROCEDURE|Operation for snoring in children|Tonsillectomy and/or adenoidectomy
214642419|NCT02061852|DEVICE|Simeox|
214642420|NCT02061852|PROCEDURE|Physiotherapy|
214642421|NCT03317769|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
214642422|NCT03317769|OTHER|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
214642423|NCT03317769|OTHER|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
214642424|NCT03317769|OTHER|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
214642425|NCT02758457|DEVICE|dental crowns|
214642426|NCT01808612|DRUG|Fluoxetine|
214642427|NCT01808612|DRUG|Placebo|
214642428|NCT00756938|DRUG|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
214642429|NCT01437774|DEVICE|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
214642430|NCT02900703|BIOLOGICAL|stool samples|
214642431|NCT01765894|OTHER|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
214642432|NCT03078465|DRUG|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
214642433|NCT03078465|DRUG|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
214642434|NCT00356642|DRUG|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
214642435|NCT00356642|DRUG|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
214642436|NCT03838224|OTHER|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
214642437|NCT03838224|OTHER|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
214642438|NCT01127165|DRUG|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.
214642439|NCT01127165|DRUG|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
214642440|NCT05649293|OTHER|measure vitamin b6 in serum|"* Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results ."
214642441|NCT01290965|DRUG|Placebo|Oral tablet given once or three times daily for 15 consecutive days
214642442|NCT01290965|DRUG|SCY-635|oral capsule
214793886|NCT05263219|DRUG|dTACE-HAIC protocol|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h."
214642443|NCT03175549|DRUG|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
214642444|NCT03175549|DRUG|Placebo|Identical placebo pills taken orally for 14 days
214642445|NCT00613457|DRUG|dexamethasone|10 mg/sqm/day from for 21 days
214642446|NCT00613457|DRUG|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
214642447|NCT00613457|DRUG|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
214642448|NCT00613457|DRUG|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
214642449|NCT00613457|DRUG|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
214642450|NCT00613457|DRUG|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
214642451|NCT00613457|DRUG|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
214642452|NCT00613457|DRUG|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
214642453|NCT00613457|DRUG|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
214642454|NCT00613457|DRUG|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
214642455|NCT00613457|DRUG|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
214642456|NCT00613457|DRUG|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
214642457|NCT00613457|DRUG|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
214642458|NCT00613457|DRUG|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
214642459|NCT00613457|DRUG|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
214642460|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 12 mg|Capsule with 12 mg cafestol
214642461|NCT04911582|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
214642462|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 6 mg|Capsule with 6 mg cafestol
214642463|NCT00763321|DRUG|ABT-712|ABT-712 extended-release tablet
214642464|NCT00763321|DRUG|Placebo|Placebo tablet
214642465|NCT01302873|DRUG|BGG492A|
214642466|NCT01302873|DRUG|BGG492A|
214642467|NCT02486757|DRUG|micronized progesterone|
214642468|NCT02486757|DRUG|transdermal estradiol|
214642469|NCT04069052|DRUG|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
214642470|NCT04069052|DRUG|Placebo|Room air (placebo) flowed into a mask and breathed in.
214642471|NCT02793232|DRUG|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
214642472|NCT02793232|DRUG|Placebo single dose|Matched Placebo suspension administered as single dose
214642473|NCT02793232|DRUG|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
214642474|NCT02793232|DRUG|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
214642475|NCT02793232|DRUG|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
214642476|NCT02793232|DRUG|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
214642477|NCT01615848|OTHER|mediterranean diet restricted calorie|1500 k/cal 30% fat
214642478|NCT01615848|OTHER|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
214642479|NCT01615848|OTHER|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
214642480|NCT06449768|BEHAVIORAL|Diabetic Macular Edema|observing the eye behavior in Diabetic Macular Edema
214642481|NCT01868100|OTHER|self-completion questionnaire|
214642482|NCT06421220|PROCEDURE|Preoperative injection of indocyanine green|Submucosal injection of indocyanine green into the gastric mucosa prior to surgery， indocyanine green，25mg，powder，once
214642483|NCT01219231|BEHAVIORAL|Exercise|6 months of aerobic exercise
214642484|NCT04792710|DRUG|Metronidazole|Metronidazole 500 mg intravenous stat dose prior to skin incision
214642485|NCT03254966|DRUG|SHR0302|Oral tablets
214642486|NCT03254966|DRUG|Placebo|Oral tablets
214642487|NCT00496314|DEVICE|e2TM Cervical Cell Collector|
214642488|NCT01298492|DRUG|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
214642489|NCT04192409|BEHAVIORAL|Smartphone Application|Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
214642490|NCT04600908|OTHER|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
214642491|NCT05644366|OTHER|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
214642492|NCT00264433|DRUG|ADH -1 (Exherin™)|
214642493|NCT00352105|DRUG|cisplatin|20mg/m2/d IV continuous infusion x4 days
214642494|NCT00352105|DRUG|fluorouracil|1000mg.m2/d IV continuous x 4 days
214642495|NCT00352105|DRUG|Iressa|250mg/PO qd x 2 years
214642496|NCT00352105|RADIATION|hyperfractionated radiation therapy|120cGy bid
214642497|NCT01882946|BIOLOGICAL|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
214642498|NCT02713568|OTHER|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
214642499|NCT02713568|OTHER|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031\*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
214642500|NCT02997592|DEVICE|SpinCare|The burn wound is treated using the SpinCare Systen
214642501|NCT00801866|DRUG|Bevacizumab|Intravitreal administration
214642502|NCT00801866|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation
214642503|NCT01430650|DRUG|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
214642504|NCT01430650|DRUG|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
214642505|NCT04001855|OTHER|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
214642506|NCT04001855|OTHER|Dilute bleach|Dilute bleach baths or gauze soaks
214642507|NCT05405647|DEVICE|Shock wave Therapy|a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
214642508|NCT05405647|DEVICE|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
214642509|NCT04537689|BIOLOGICAL|Ixekizumab|Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
214642510|NCT04537689|DRUG|Methotrexate|Oral tablet up to 15mg per week
214642511|NCT04537689|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
214642512|NCT04537689|DRUG|Acitretin|Oral capsule up to 25mg per day
214642513|NCT00878839|DEVICE|Toric|AcrySof Toric IOL
214642514|NCT03517631|BIOLOGICAL|shRNA-modified CD34+ cells|Infusion of CD34+ cells transduced with shRNAs.
214642515|NCT03517631|DRUG|Low dose busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
214642516|NCT03517631|DRUG|Busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
214642517|NCT06436456|BEHAVIORAL|Online psychological intervention|The online intervention constitutes a psychological intervention rooted in therapeutic principals of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Comprising 7 obligatory modules and 4 optional modules, the intervention is facilitated through an online platform, offering a text-based self-help program. Patients receive written guidance from a psychologist at Steno Diabetes Center Odense (SDCO). While undergoing intervention, patients have the option to seek clarification or assistance from the psychologist if encountered with queries or difficulties. It is anticipated that patients will progress through approximately one module per week. Following completion of the intervention, patients retain access to the online intervention for a duration of 3 months.
214642518|NCT06436456|BEHAVIORAL|Individual psychological intervention|In the individual intervention, patients undergo personalized therapy administered by the assigned psychologist from SDCO. This treatment approach is grounded in the principles of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Delivery of treatment can occur through various modalities, including telephone, video conferencing, or in-person sessions, tailored to accommodate the preferences and requirements of the patient. A maximum of 10 treatment sessions are available for each patient.
214642519|NCT01819779|DRUG|Exforge tab. 10/160mg|
214642520|NCT01819779|DRUG|Lodivixx tab. 5/160mg|
214642521|NCT02112500|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
214642522|NCT00749333|DRUG|AZD8566|solution. Specific dose will be selected by the safety review committee
214642523|NCT00749333|DRUG|Placebo|Single 10ml oral solution.
214642524|NCT00876083|DRUG|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
214642525|NCT04642742|DIETARY_SUPPLEMENT|Chewable plant sterol|Chewable plant sterol (gummy)
214642526|NCT01618292|PROCEDURE|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
214642527|NCT05376085|DRUG|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
214642528|NCT05376085|DRUG|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
214642529|NCT00727207|DRUG|everolimus|
214642530|NCT05914701|DRUG|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
214642531|NCT03032952|OTHER|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
214642532|NCT01405053|DRUG|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
214642533|NCT01405053|DRUG|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
214642534|NCT03654846|DEVICE|EmergencyEye|EmergencyEye Smartphone App
214642535|NCT00273819|PROCEDURE|CT angiography|
214642536|NCT02551159|BIOLOGICAL|MEDI4736|Anti-PD-L1 antibody
214642537|NCT02551159|BIOLOGICAL|Tremelimumab|Anti-CTLA-4 Antibody
214642538|NCT02551159|BIOLOGICAL|MEDI4736+Tremelimumab|
214642539|NCT02551159|BIOLOGICAL|Cetuximab|Monoclonal Antibody
214642540|NCT02551159|DRUG|5-fluorouracil (5FU)|Chemotherapy Agent
214642541|NCT02551159|DRUG|Cisplatin|Chemotherapy agent
214642542|NCT02551159|DRUG|Carboplatin|Chemotherapy Agent
214642543|NCT00359775|BEHAVIORAL|Coping Skills Training|6 session behavioral program
214642544|NCT05204264|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
214642545|NCT05204264|BEHAVIORAL|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
214642546|NCT00120458|DIETARY_SUPPLEMENT|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
214642547|NCT00779376|DRUG|Zidovudine 300mg tablets|
214642548|NCT06474559|DEVICE|LMA Protector|LMA Protector will be inserted by a researcher after standard anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale.Mini bronchoalveolar lavage will be collected before the end of the procedure
214642549|NCT06474559|DEVICE|Endotracheal tube|tracheal intubation will be perform after standard anaesthetic induction. Cormack Lehane will be recorded. Mini bronchoalveolar lavage will be collected before the end of the procedure
214642550|NCT02639585|DRUG|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
214642551|NCT00156312|DRUG|Docetaxel|
214642552|NCT00156312|DRUG|Capecitabine|
214642553|NCT02851004|DRUG|Napabucasin|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
214642554|NCT02851004|DRUG|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
214642555|NCT05691855|DRUG|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
214642556|NCT00268242|DRUG|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
214642557|NCT00268242|DRUG|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
214642558|NCT00993928|BEHAVIORAL|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
214642559|NCT03225300|RADIATION|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
214642560|NCT01359475|PROCEDURE|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
214642561|NCT05040594|DEVICE|PavéDerm J-Fill Soft Dermal Filler|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
214642562|NCT05040594|DEVICE|Restylane® Lyft Lidocaine|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
214642563|NCT03970902|OTHER|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
214642564|NCT03970902|OTHER|Care As Usual|No intervention Patients receive care as usual from their family physician
214642565|NCT00217815|DRUG|Mycograb, Docetaxel|
214642566|NCT00723164|DRUG|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
214642567|NCT00723164|DRUG|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
214642568|NCT04871711|DRUG|Delgocitinib cream|Cream for topical application
214642569|NCT04871711|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.
214642570|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|20 minutes exposure
214642571|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|40 minutes exposure
214642572|NCT03467646|PROCEDURE|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
214642573|NCT03467646|PROCEDURE|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
214642574|NCT03467646|PROCEDURE|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
214642575|NCT04547205|DRUG|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
214642576|NCT04513431|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
214727053|NCT03157999|BEHAVIORAL|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy."
214727054|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
214727055|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
214727056|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
214727057|NCT06819189|DRUG|Ethanol|IV Ethanol
214727058|NCT04623931|OTHER|Quality-of-Life Assessment|Ancillary studies
214727059|NCT04623931|OTHER|Questionnaire Administration|Ancillary studies
214727060|NCT04623931|RADIATION|Radiation Therapy|Undergo radiation therapy
214727061|NCT04623931|DRUG|Temozolomide|Given PO
214727062|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
214727063|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
214727064|NCT03024151|DRUG|Synthroid|T4 mono replacement
214727065|NCT01415973|DIETARY_SUPPLEMENT|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
214727066|NCT01415973|DIETARY_SUPPLEMENT|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
214727067|NCT00777257|BIOLOGICAL|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
214727068|NCT00777257|BIOLOGICAL|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
214727069|NCT00777257|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
214727070|NCT00854867|DRUG|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
214727071|NCT00854867|DRUG|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
214727072|NCT02267902|DRUG|DA-1229|
214642577|NCT04887493|DRUG|Misoprostol|Misoprostol 25µg will be used for both the study arms
214642578|NCT00028912|DRUG|bortezomib|
214642579|NCT00028912|DRUG|carboplatin|
214642580|NCT02052271|DEVICE|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
214642581|NCT04219423|BEHAVIORAL|Multimodal physical therapy|see description in arm/group description
214642582|NCT02468791|DRUG|Rituximab|
214642583|NCT00671255|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
214642584|NCT00671255|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
214642585|NCT00671255|DRUG|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
214727073|NCT03023319|DRUG|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
214727074|NCT03023319|DRUG|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
214727075|NCT04841681|BEHAVIORAL|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
214727076|NCT04315298|DRUG|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
214642586|NCT02285725|PROCEDURE|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
214642587|NCT02285725|PROCEDURE|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
214727077|NCT04315298|DRUG|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
214727078|NCT00364468|DRUG|pegfilgrastim|
214727079|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
214727080|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
214727081|NCT02411994|DRUG|Pyronaridine-artesunate|
214727082|NCT02411994|DRUG|Artemether-lumefantrine combination|
214727083|NCT00131131|BEHAVIORAL|Exercise|
214793887|NCT05263219|DRUG|HAIC protocol|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
214642588|NCT00935558|BIOLOGICAL|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
214642589|NCT00935558|DRUG|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
214642590|NCT06424093|PROCEDURE|Virtual Reality Technology|To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
214642591|NCT03719157|PROCEDURE|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
214642592|NCT03719157|PROCEDURE|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
214642593|NCT03719157|PROCEDURE|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
214642594|NCT03719157|DRUG|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
214642595|NCT03995290|OTHER|3D Hip Model from Pre-operative CT scan|A printed 3D model will be created based off of the patient's standard of care preoperative CT scan.
214642596|NCT02579655|BEHAVIORAL|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
214642597|NCT02579655|BEHAVIORAL|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
214642598|NCT06233526|OTHER|Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test|"1. Leukemia cells from newly diagnosed and relapsed children with AML were tested for high throughput in vitro drug sensitivity and resistance.~2. Combined with multi-omics sequencing technology such as whole exome and transcriptome, the data of drug sensitivity, drug resistance and genomic characteristics of children AML patients were integrated, and the internal rules between drug sensitivity or drug resistance and molecular characteristics such as gene fusion, gene mutation and abnormal gene expression of children AML patients were deeply analyzed, and the molecular characteristics of drug sensitivity in children AML were mapped"
214793888|NCT06102967|BEHAVIORAL|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
214642599|NCT01315262|DRUG|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
214642600|NCT00535925|DRUG|SoC therapy|the patients have to be treated according the standard good medical practice by any center
214642601|NCT00535925|DRUG|irbesartan|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
214642602|NCT00535925|DRUG|ramipril|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
214642603|NCT00535925|DRUG|hydrochlorothiazide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
214727084|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
214727085|NCT02150785|DRUG|Streptokinase|
214727086|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
214727087|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
214727088|NCT00098865|DRUG|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
214727089|NCT00098865|DRUG|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
214727090|NCT02113644|OTHER|Lifestyle intervention|
214793889|NCT04125004|DEVICE|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
214642604|NCT00535925|DRUG|furosemide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
214642605|NCT00535925|DRUG|amlodipine|"Therapy for hypertension~\- Step 3: amlodipine up to 10 mg/die"
214642606|NCT00535925|DRUG|atenolol|"Therapy for hypertension~\- Step 4: atenolol up to 100 mg/die"
214642607|NCT00535925|DRUG|doxazosin|"Therapy for hypertension~\- Step 5: doxazosin up to 4 mg/die"
214642608|NCT00535925|DRUG|clonidine|"Therapy for hypertension~\- Step 6: clonidine"
214642609|NCT00535925|DRUG|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c \<7):~\- insulin"
214642610|NCT00535925|DRUG|simvastatin|"Therapy for hypercholesterolemia:~\- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die"
214642611|NCT00535925|DRUG|fibrate|"Therapy for hypertriglyceridemia~\- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate"
214642612|NCT00535925|DRUG|erythropoietin|"Treatment of anaemia:~\- erythropoietin"
214642613|NCT00535925|DRUG|aspirin|"Antiplatelet therapy (in all patients without contraindications):~\- aspirin up to 160 mg/die"
214642614|NCT05664165|OTHER|dry needling|The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed
214642615|NCT05664165|OTHER|cold spray and stretching|The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied.
214642616|NCT00321230|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
214642617|NCT05498688|DIETARY_SUPPLEMENT|Low carbohydrate|Participants will have a low carbohydrate meal
214642618|NCT04336761|DIAGNOSTIC_TEST|nasopharyngeal swab|Data collection and nasopharyngeal swab
214642619|NCT01403337|OTHER|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP \> 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
214642620|NCT01403337|OTHER|Control|A Blood Pressure cuff inflated to 40-50 mmHg
214642621|NCT04741269|DIAGNOSTIC_TEST|Find a link between lack of knee flexion and meniscal posterior luxation fixed|"Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift."
214642622|NCT05117775|OTHER|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
214642623|NCT02420873|DRUG|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
214642624|NCT03594890|BIOLOGICAL|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
214642625|NCT03594890|BIOLOGICAL|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
214642626|NCT03594890|BIOLOGICAL|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
214642627|NCT03594890|BIOLOGICAL|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
214642628|NCT02349698|BIOLOGICAL|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
214642629|NCT06296732|PROCEDURE|Duration of surgery intervention|Intraoperative- duration from the beginning of the skin incision to skin suture (min)
214642630|NCT05467722|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
214642631|NCT05223361|DRUG|Six percent hydroxy ethyl starch 130/0.4|6% HES 130/0.4 additive to ringer lactate as prime solution
214642632|NCT05223361|DRUG|Ringer lactate|Ringer lactate as prime solution
214642633|NCT03949270|BEHAVIORAL|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
214642634|NCT02180893|OTHER|Paravertebral Block|Paravertebral nerve block injection
214642635|NCT02180893|OTHER|Placebo Comparator|"No block~Patients who did not receive PVB"
214727091|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
214642636|NCT04751162|DEVICE|Actigraphy device (wearable) and mobile application|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
214642637|NCT02448511|OTHER|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
214642638|NCT02448511|DEVICE|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
214642639|NCT02448511|OTHER|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
214642640|NCT05713643|PROCEDURE|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
214727092|NCT00010244|RADIATION|radiation therapy|
214642641|NCT05713643|PROCEDURE|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
214642642|NCT05713643|PROCEDURE|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
214642643|NCT02838407|OTHER|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
214642644|NCT02838407|OTHER|Nasopharyngeal swab sampling|1 swab, Day 0
214642645|NCT05634759|DRUG|Azithromycin for Routine Community-wide MDA|"Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan."
214642646|NCT05634759|DRUG|Two Additional Rounds of Azithromycin for Children|An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
214727093|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
214727094|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
214727095|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
214727096|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
214727097|NCT01183104|DRUG|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
214727098|NCT01183104|DRUG|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
214727099|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
214793890|NCT05359432|DRUG|Empagliflozin|Receiving allocated drug dosage as per clinical needs
214642647|NCT05634759|DRUG|Azithromycin for Second Community-wide MDA|A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
214642648|NCT03551743|COMBINATION_PRODUCT|PRT064445/Edoxaban|
214642649|NCT03551743|COMBINATION_PRODUCT|Placebo/Edoxaban|
214642650|NCT03551743|DRUG|Placebo|
214642651|NCT06312072|OTHER|No intervention; observational study|No intervention; observational study
214642652|NCT02059590|DRUG|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
214642653|NCT03708055|BEHAVIORAL|Exercise Intervention|Undergo weight bearing exercise program
214727100|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
214727101|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
214727102|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
214727103|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
214727104|NCT00297284|DRUG|Modafinil|
214727105|NCT02292615|OTHER|Medical Imaging|
214727106|NCT05441124|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
214642654|NCT03779022|GENETIC|microRNA|The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
214642655|NCT05841095|DRUG|ISA104|SLP vaccine
214642656|NCT05841095|DRUG|Placebo|Saline solution (0.9% NaCl)
214642657|NCT03803644|DRUG|CC-92480|Part 1 dose escalation
214642658|NCT03803644|DRUG|CC-92480|CC-92480
214642659|NCT04041895|OTHER|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
214727107|NCT00364351|DRUG|Vandetanib|once daily oral tablet
214727108|NCT00364351|DRUG|Erlotinib|oral dose
214642660|NCT01069497|OTHER|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
214642661|NCT00911989|DEVICE|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
214642662|NCT02237287|OTHER|wound dressing with VAC and sNAG without antiaggregation|
214642663|NCT02237287|PROCEDURE|wound dressing with VAC|
214642664|NCT02237287|DRUG|wound dressing with VAC and sNAG under Antiaggregation|
214642665|NCT00563342|DRUG|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
214642666|NCT05321979|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
214642667|NCT04525105|GENETIC|SMAD2|a family of structurally related cytokines
214642668|NCT04696588|OTHER|Complex set of kinesiotherapy of cervical spine and delicate massage|"Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~1. Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~2. Massage of cervical interspinales muscles performed by therapist 3 minutes.~3. Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~4. Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes."
214642669|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
214642670|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
214642671|NCT00817011|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
214642672|NCT00817011|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
214727109|NCT03812198|DRUG|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
214727110|NCT03812198|DRUG|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
214727111|NCT03812198|DRUG|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
214727112|NCT03812198|DRUG|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
214727113|NCT03812198|DRUG|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
214727114|NCT03812198|DRUG|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
214727115|NCT03812198|OTHER|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
214727116|NCT06424041|OTHER|Fecal Microbiome Transplantation|Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
214727117|NCT06424041|OTHER|Sham Fecal Microbiome Transplantation|Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
214727118|NCT05375656|OTHER|Cross-over study|Traditional Inuit Diet and Western Diet.
214727119|NCT04872504|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
214727120|NCT04008667|OTHER|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
214727121|NCT04008667|OTHER|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
214727122|NCT05977374|OTHER|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
214727123|NCT04120350|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
214727124|NCT04120350|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
214727125|NCT04120350|DRUG|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
214727126|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
214727127|NCT03613168|DRUG|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
214727128|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
214727129|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
214727130|NCT00858975|PROCEDURE|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
214727131|NCT02145754|OTHER|MKP media|one half of skin specimen was put in MKP media
214727132|NCT02145754|OTHER|BSK-H media|one half of skin specimen was put in BSK-H media
214727133|NCT05799911|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
214727134|NCT05799911|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
214727135|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
214727136|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
214727137|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
214727138|NCT02282774|DRUG|Sham subtenon block|
214727139|NCT03020797|DRUG|Perampanel|
214727140|NCT03020797|DRUG|Placebo Oral Tablet|
214727141|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
214727142|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
214793891|NCT05359432|DRUG|Vildagliptin|Receiving allocated drug dosage as per clinical needs
214793892|NCT00745251|DRUG|VI-0521|15 mg Phentermine and 92 mg Topiramate
214727143|NCT05424744|BEHAVIORAL|Telemedicine Management of Hypertension|Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
214727144|NCT05992935|BIOLOGICAL|mRNA-1403|Sterile liquid for injection
214727145|NCT05992935|BIOLOGICAL|mRNA-1405|Sterile liquid for injection
214727146|NCT05992935|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214727147|NCT01594086|DIETARY_SUPPLEMENT|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
214727148|NCT02958085|DRUG|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
214727149|NCT02958085|DRUG|Placebo|Dosed either once daily or once weekly
214727150|NCT00688623|DRUG|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
214727151|NCT02667236|DRUG|A-101 Solution|Active Drug
214727152|NCT02667236|OTHER|Vehicle Solution|Placebo
214727153|NCT00645190|DRUG|Galantamine HBr|
214727154|NCT00032305|DRUG|Visilizumab|
214727155|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
214727156|NCT01945190|DEVICE|Electroacupuncture|
214727157|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
214727158|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
214727159|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
214727160|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
214727161|NCT05120375|DRUG|BAT6021|Ⅳ infusions
214727162|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
214727163|NCT00004580|DRUG|Lopinavir/Ritonavir|
214727164|NCT00004580|DRUG|Nevirapine|
214727165|NCT04976309|DRUG|Lu AG09222|Single dose
214727166|NCT04976309|DRUG|Placebo|Single dose
214727167|NCT02000544|DEVICE|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
214727168|NCT00171613|DRUG|Octreotide|
214727169|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
214727170|NCT02672150|BEHAVIORAL|Core|
214727171|NCT02672150|BEHAVIORAL|Enhanced|
214727172|NCT01942408|PROCEDURE|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
214727173|NCT02870244|BIOLOGICAL|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells."
214727174|NCT03432208|PROCEDURE|GI consult|
214727175|NCT04974944|DRUG|Camrelizumab|IV injection
214727176|NCT04974944|DRUG|Apatinib|Oral
214727177|NCT04974944|DRUG|Paclitaxel|IV injection
214727178|NCT04974944|DRUG|Cisplatin|IV infusion
214727179|NCT04974944|DRUG|Carboplatin|IV infusion
214727180|NCT04974944|DRUG|Bevacizumab|IV infusion
214727181|NCT00438724|BEHAVIORAL|Information, counseling and support|
214727182|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
214727183|NCT00794469|OTHER|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
214727184|NCT02458352|DEVICE|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
214727185|NCT02458352|DEVICE|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
214727186|NCT05181215|DRUG|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
214727187|NCT05181215|DRUG|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
214727188|NCT04935567|OTHER|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
214727189|NCT03887052|DEVICE|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
214727190|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
214727191|NCT03766113|OTHER|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
214727192|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
214727193|NCT00921570|DRUG|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
214793893|NCT00745251|DRUG|placebo|placebo
214642673|NCT02260518|BEHAVIORAL|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
214642674|NCT02260518|BEHAVIORAL|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
214642675|NCT05697458|OTHER|computerized tomography scanning|In all patients the investigators will perform CT for determination of iliac arteries calcifications
214642676|NCT04798287|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
214642677|NCT04798287|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
214642678|NCT04665830|DRUG|Evolocumab|treated patients with evolocumab for high cholesterol
214642679|NCT03079479|DIAGNOSTIC_TEST|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
214642680|NCT03079479|DIAGNOSTIC_TEST|2D Kinematics Analysis|2D Kinematics Analysis of the gait
214642681|NCT03354182|PROCEDURE|Open flap surgery|Elevation of a flap in order to access the treated furcation
214642682|NCT03354182|DEVICE|Bio-oss collagen|Biomaterial for periodontal surgery
214642683|NCT03354182|DEVICE|Bio-gide|Biomaterial for periodontal surgery
214642684|NCT01407094|DRUG|Sertraline|50-200mg/day
214642685|NCT01407094|DRUG|Placebo|1-4 pills per day
214642686|NCT01407094|DRUG|BupropionXL|150-450 mg/day
214642687|NCT04416880|DEVICE|Press Tack Needle Acupuncture|Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
214642688|NCT03463590|DEVICE|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
214642689|NCT03423498|OTHER|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
214642690|NCT05768490|RADIATION|brain radiotherapy|Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.
214642691|NCT05768490|DRUG|Almonertinib|almonertinib po 110mg QD
214642692|NCT01493180|DRUG|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
214642693|NCT01493180|DRUG|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
214642694|NCT01431404|BIOLOGICAL|Etanercept (Enbrel)|prefilled syringe, SC
214642695|NCT01431404|BIOLOGICAL|HD203|HD203, prefilled syringe, SC injection
214642696|NCT04945798|OTHER|OMT|OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds
214642697|NCT05153057|OTHER|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
214642698|NCT02598765|PROCEDURE|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
214642699|NCT02598765|PROCEDURE|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
214642700|NCT00135122|DRUG|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
214642701|NCT04556617|DRUG|PLX2853 20 mg|PLX2853 tablets
214642702|NCT04556617|DRUG|Olaparib|Olaparib tablets
214642703|NCT04556617|DRUG|Abiraterone acetate|Abiraterone acetate tablets
214642704|NCT04556617|DRUG|Prednisone|Prednisone (or equivalent) tablets
214642705|NCT04556617|DRUG|PLX2853 40 mg|PLX2853 tablets
214642706|NCT04556617|DRUG|PLX2853 80 mg|PLX2853 tablets
214642707|NCT06194123|OTHER|Crest Daily Whitening Serum|one week's use of Crest Daily Whitening Serum as described on the label.
214642708|NCT03179436|BIOLOGICAL|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
214642709|NCT03179436|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
214642710|NCT03179436|DRUG|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
214642711|NCT02809287|PROCEDURE|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
214727194|NCT00921570|DRUG|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
214642712|NCT05013255|DRUG|Pioglitazone 15mg|PIO 15mg orally once daily for 2 weeks
214642713|NCT05013255|DRUG|Pioglitazone 30 mg|PIO 30mg orally once daily for 2 weeks
214642714|NCT02407678|GENETIC|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
214642715|NCT01733017|BEHAVIORAL|Sodium reduction|Teaching and skill building to reduce dietary sodium
214642716|NCT01733017|DIETARY_SUPPLEMENT|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
214642717|NCT01733017|DIETARY_SUPPLEMENT|rice bran oil capsules|placebo capsules
214642718|NCT01733017|BEHAVIORAL|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
214642719|NCT06084377|GENETIC|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
214642720|NCT03382574|BIOLOGICAL|Denosumab|Given SC
214642721|NCT03382574|PROCEDURE|Salpingo-Oophorectomy|Undergo risk-reducing salpingo-oophorectomy
214642722|NCT02434848|DRUG|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
214642723|NCT02434848|DRUG|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
214642724|NCT04695964|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
214642725|NCT05591664|DIAGNOSTIC_TEST|eicosapentaenoic acid|eicosapentaenoic acid levels of the groups will be monitored
214642726|NCT03837080|OTHER|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
214642727|NCT04856709|PROCEDURE|Abdominal Pectopexy|Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.
214642728|NCT04856709|PROCEDURE|Abdominal Sacral Hysteropexy|Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
214642729|NCT02001376|OTHER|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
214642730|NCT02001376|OTHER|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
214642731|NCT02001376|OTHER|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
214642732|NCT00130897|DRUG|Sutent|Sutent, 25, 37.5. or 50 mg daily
214642733|NCT02247193|DRUG|Botulinum Toxin Type A|Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
214727195|NCT03224156|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
214727196|NCT00257322|DRUG|GM-CSF|250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
214642734|NCT02247193|DRUG|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
214642735|NCT02586792|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
214642736|NCT02298764|OTHER|Standard back pain treatment|Standard back pain treatment
214642737|NCT02298764|OTHER|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
214642738|NCT02544932|DRUG|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
214642739|NCT02544932|DRUG|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
214642740|NCT02544932|DRUG|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
214642741|NCT01877083|DRUG|Lenvatinib|Starting dose of 24 mg orally, once per day
214793894|NCT04995978|DRUG|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
214642742|NCT04173897|OTHER|LIBERATE website|The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services \& support and support for family \& loved ones.
214642743|NCT01487759|DIETARY_SUPPLEMENT|Oligofructose enriched inulin|
214642744|NCT01487759|DIETARY_SUPPLEMENT|Maltodextrin|
214642745|NCT05083637|DRUG|L- carnitine oral solution|The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
214793895|NCT04995978|DRUG|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
214642746|NCT05083637|OTHER|Placebo|The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
214642747|NCT04953312|BIOLOGICAL|Blood samples|blood
214642748|NCT00762515|DRUG|Fluoride|Brush teeth two times daily for 6 weeks
214642749|NCT00762515|DRUG|Triclosan|Brush two times daily for 6 weeks
214642750|NCT00762515|DRUG|Fluoride|Brush two times daily for 6 weeks
214642751|NCT02960620|DEVICE|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
214642752|NCT05522166|OTHER|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
214642753|NCT03751865|BEHAVIORAL|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
214642754|NCT03751865|BEHAVIORAL|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
214642755|NCT06050538|PROCEDURE|Transabdominal preperitoneal (TAPP) using polyprolene mesh|Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
214642756|NCT06050538|PROCEDURE|Total extraperitoneal (TEP) hernioplasty using polyprolene mesh|Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
214642757|NCT01258907|DRUG|MLDL1278A|Single intravenous dose
214642758|NCT01258907|DRUG|MLDL1278A|Repeating intravenous dose
214642759|NCT01258907|DRUG|placebo|Repeating intravenous dose
214642760|NCT01258907|DRUG|statin, stable dose|Repeating oral dose
214642761|NCT05879783|DIAGNOSTIC_TEST|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
214642762|NCT00500682|DRUG|Placebo|9g /day (3 times a day)
214642763|NCT00500682|DRUG|AST-120|9g /day (3 times a day)
214642764|NCT06549959|DRUG|Telitacicept Pre-filled Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
214642765|NCT06549959|DRUG|Telitacicept Freeze-dried powder Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
214642766|NCT04154501|DRUG|CNTX-6016|Oral Dose CNTX-6016
214642767|NCT04154501|OTHER|Other: Placebo|Oral Dose Placebo
214642768|NCT01910675|DRUG|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
214642769|NCT01910675|DRUG|FFP|4 units Octaplas. Additional fibrinogen if needed.
214793896|NCT00042497|BIOLOGICAL|autologous dexosomes loaded with tumor-specific peptides|
214793897|NCT05660057|DEVICE|New computer monitor|The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.
214642770|NCT05649995|OTHER|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
214642771|NCT05649995|OTHER|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
214793898|NCT04083339|DRUG|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
214793899|NCT04083339|DRUG|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
214793900|NCT04485247|PROCEDURE|Transumbilical Laparoscopic-Assisted Appendectomy|appendectomy performed extracorporeally through umbilical port
214642772|NCT05160935|BEHAVIORAL|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
214642773|NCT05576974|DRUG|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
214642774|NCT00996099|DEVICE|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
214642775|NCT00996099|OTHER|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
214642776|NCT02851173|DEVICE|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
214642777|NCT02851173|DEVICE|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
214642778|NCT02670265|DIETARY_SUPPLEMENT|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
214642779|NCT02670265|DIETARY_SUPPLEMENT|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
214642780|NCT00429585|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
214642781|NCT00429585|DEVICE|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
214642782|NCT03781648|DIAGNOSTIC_TEST|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
214642783|NCT01582308|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
214642784|NCT01582308|DRUG|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
214642785|NCT01582308|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
214642786|NCT01582308|DRUG|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
214793901|NCT04485247|PROCEDURE|3-port laparoscopic appendectomy|appendectomy performed intracorporeally with 3-port
214642787|NCT01582308|DRUG|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
214642788|NCT01762566|DIETARY_SUPPLEMENT|wheat|wheat is administered blindly versus placebo in capsules once
214642789|NCT01762566|DIETARY_SUPPLEMENT|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
214642790|NCT01080885|BEHAVIORAL|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
214642791|NCT01080885|BEHAVIORAL|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
214642792|NCT05061303|OTHER|Assessment of the drug concentration in the blood|The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
214642793|NCT00371930|PROCEDURE|application of a dye suspension followed by a laser intervention|
214642794|NCT05840744|DIAGNOSTIC_TEST|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
214642795|NCT06548906|DRUG|GZR4 Injection|GZR4 Injection administered sc, once weekly.
214642796|NCT03502720|DEVICE|Scaphoid fixation using 3D device|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide
214642797|NCT03502720|PROCEDURE|Scaphoid fixation using standard procedure|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
214642798|NCT00441857|BEHAVIORAL|plant stanol consumption|
214642799|NCT03778164|OTHER|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
214642800|NCT03778164|OTHER|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
214642801|NCT04639323|DIAGNOSTIC_TEST|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
214642802|NCT00458731|BIOLOGICAL|bevacizumab|Given IV
214642803|NCT00458731|DRUG|cediranib maleate|Given orally
214642804|NCT03222466|OTHER|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
214642805|NCT02861040|OTHER|Laboratory Biomarker Analysis|Correlative studies
214642806|NCT02861040|OTHER|Pharmacological Study|Correlative studies
214642807|NCT02861040|DRUG|Vincristine Sulfate Liposome|Given IV
214642808|NCT02861040|DRUG|Volasertib|Given IV
214642809|NCT02709278|BIOLOGICAL|BCG|BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
214642810|NCT02709278|OTHER|Saline placebo|Saline placebo
214642811|NCT02709278|BIOLOGICAL|BCG|BCG Bulgaria (InterVax)
214642812|NCT03796468|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
214642813|NCT03796468|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
214642814|NCT02017574|BEHAVIORAL|Reaching Task|Learn a reaching task that requires coordination of the arm segments
214642815|NCT00332540|DRUG|bimatoprost/timolol fixed combination|
214642816|NCT01386333|DRUG|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
214642817|NCT01386333|DRUG|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
214642818|NCT04764760|DEVICE|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
214642819|NCT05541614|OTHER|Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative|Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
214642820|NCT05541614|OTHER|Emdogain® - Enamel Matrix Derivative|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.
214642821|NCT00389025|DRUG|Olopatadine (generic name)|
214642822|NCT02320487|DRUG|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
214642823|NCT02320487|DRUG|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
214642824|NCT01230879|OTHER|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
214642825|NCT03220828|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets)
214642826|NCT02392273|DRUG|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
214642827|NCT05122234|BIOLOGICAL|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
214642828|NCT05122234|OTHER|Placebo|Normal saline
214642829|NCT05122234|DRUG|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
214642830|NCT03099720|DRUG|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
214642831|NCT03099720|DRUG|Placebo|placebo fluid will be given at the site of operation locally
214642832|NCT05832294|DEVICE|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
214642833|NCT05832294|DEVICE|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
214642834|NCT00002778|BIOLOGICAL|sargramostim|
214642835|NCT00002778|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214642836|NCT00002778|PROCEDURE|allogeneic bone marrow transplantation|
214642837|NCT00002778|PROCEDURE|in vitro-treated bone marrow transplantation|
214642838|NCT06237231|DRUG|DIT112|DIT112 tablet
214642839|NCT06237231|DRUG|DIPYRONE|Dipyrone tablet 1.000mg
214642840|NCT06237231|DRUG|TRAMADOL|Tramadol tablet 50mg
214642841|NCT06237231|DRUG|DIT112 Placebo|DIT112 placebo tablet
214642842|NCT06237231|DRUG|Dipyrone Placebo|Dipyrone placebo tablet
214642843|NCT06237231|DRUG|Tramadol Placebo|Tramadol placebo capsule
214642844|NCT05242783|DRUG|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
214642845|NCT04993378|DEVICE|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
214642846|NCT03938493|OTHER|monitoring of the endotracheal tube cuff|We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
214642847|NCT04004598|BEHAVIORAL|golf training|12 weeks of training by Professional Golf Association professional
214642848|NCT06658600|OTHER|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
214642849|NCT06658600|OTHER|Physician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease|Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.
214642850|NCT02161679|DRUG|IMMU-132 infusion is administered to participants in one arm for the study|
214642851|NCT02161679|DRUG|IMMU-132 plus Carboplatin infusion|
214642852|NCT01182428|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
214642853|NCT01182428|DEVICE|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
214642854|NCT02007707|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
214642855|NCT02007707|BEHAVIORAL|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
214642856|NCT05121532|DIAGNOSTIC_TEST|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
214642857|NCT06729489|PROCEDURE|Upper Endoscopy|Endoscopy in children with refractory iron deficiency anemia
214642858|NCT00472524|PROCEDURE|Mydriasis/cycloplegia via different modes of administration|
214642859|NCT02705989|DRUG|BMS-986195|Specified dose on specified day
214642860|NCT02705989|OTHER|Placebo|Specified dose on specified day
214642861|NCT00366522|DRUG|LXR-623|
214642862|NCT01841333|DRUG|PF-04449913|100mg given orally
214642863|NCT05442853|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
214642864|NCT05442853|DEVICE|Point of care glucose monitoring|Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
214642865|NCT06915441|DRUG|SOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
214642866|NCT06915441|DRUG|MOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
214727197|NCT03409575|OTHER|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
214793902|NCT02277314|PROCEDURE|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
214642867|NCT06916546|COMBINATION_PRODUCT|SIRT-L-P|Patients received 1-2 session of SIRT. Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
214642868|NCT06916546|COMBINATION_PRODUCT|TACE-L-P|Patients received TACE. TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications (on-demand TACE). Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
214642869|NCT06915272|OTHER|Head and Neck Cooling Intervention|Participants received a head and neck cooling intervention involving the daily use (≥2 hours/day) of cooling devices consisting of a cooling cap and cooling towel specifically designed for localized head and neck cooling. Devices were activated by immersing them in cold water maintained at approximately 10°C.
214642870|NCT06916000|DRUG|Pericapsular nerve group (PENG) block|"As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.~All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points."
214642871|NCT06916000|OTHER|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.
214793903|NCT03743428|DRUG|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
214727198|NCT03409575|OTHER|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
214727199|NCT00628134|DRUG|calfactant|single inhaled dose by nebulizer
214727200|NCT00628134|DRUG|isotonic saline|single inhaled dose by nebulizer
214727201|NCT05591430|PROCEDURE|Ganglion Impar Neurolysis|block of Ganglion Impar by neurolytic drug
214727202|NCT05591430|PROCEDURE|Bilateral S2, S3 and S4 Pulsed radiofrequency|Bilateral S2, S3 and S4 Pulsed radiofrequency
214727203|NCT03541590|PROCEDURE|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
214727204|NCT03237390|DRUG|Gemcitabine Hydrochloride|Given IV
214642872|NCT06913699|PROCEDURE|Ultrasonund-guided percutaneous liver biopsy|All patients completed blood routine, coagulation function and liver biochemical indexes before surgery, and informed the patients and their families about the purpose and risks of surgery, and signed an informed consent. During the procedure, the patient was placed in the left lateral decubitus position. After locating by ultrasound and routine disinfection, 0.5% lidocaine was used for local anesthesia. Under the guidance of ultrasound, a 16G disposable biopsy needle (SC1620) was inserted into the liver parenchyma, and the biopsy gun was started and fired for sampling. The removed liver tissue was fixed in 4% formaldehyde solution and sent to the pathology department. The patient's puncture site was disinfected and covered with sterile dressing, and the abdominal band was bandaged. The patients were instructed to stay in bed for 24 hours after operation, closely observe whether there was pain and bleeding after operation, and monitor electrocardiogram for 24 hours.
214642873|NCT06916325|DEVICE|dual hypothermic oxygenated perfusion (DHOPE)|Clinically, end-ischemic DHOPE has been shown to restore hepatic ATP, reduce reperfusion injury, and improve outcomes after deceased donor liver transplantation. Recent prospective and retrospective clinical studies detail the safety and feasibility of prolonged preservation of donor livers with DHOPE for up to 20 hours; prolonged perfusion has shown similarly low rates of serious adverse events, a potential protective effect in mitigating acute kidney injury and may facilitate decreased frequency of discarded and nonuse of donor livers.
214642874|NCT00525538|RADIATION|conformal radiotherapy|
214642875|NCT00466648|PROCEDURE|Tissue adhesive|
214642876|NCT07155239|DEVICE|AviClear Lase Treatment|Three laser sessions at Weeks 0, 4, 8; follow-ups at Weeks 12, 16, 24.
214642877|NCT07155239|DEVICE|Sham (No Treatment)|No active laser treatment
214642878|NCT07160231|DRUG|JAKi dose reduction strategy|JAKi dose reduction strategy
214642879|NCT07160231|DRUG|JAKi disease activity guided continuation of same dose strategy|JAKi disease activity guided continuation of same dose strategy
214642880|NCT07171866|PROCEDURE|Immediate Implant Placement with SST|Participants underwent extraction and socket shield preparation, followed by immediate implant placement in the esthetic maxillary zone. The implant was inserted at the same surgical session using a flapless or minimally invasive approach. CBCT was used to guide planning and assess ridge dimensions. Healing and follow-up assessments were conducted at 1 year and 6 years post-placement.
214642881|NCT07171866|PROCEDURE|Delayed Implant Placement with SST|Participants underwent extraction and socket shield preparation. Implant placement was delayed for 6 months to allow soft and hard tissue healing. The implant was placed after verifying shield stability and ridge preservation via CBCT. Follow-up assessments were conducted at 1 year and 6 years post-placement.
214642882|NCT07171879|PROCEDURE|Tooth Extraction only|Conventional atraumatic extraction of the non-restorable maxillary tooth in the esthetic zone without socket preservation procedures.
214642883|NCT07171879|PROCEDURE|Extraction + MPM|Tooth extraction followed by socket grafting using MPM, prepared from autologous blood combined with xenograft bone particles.
214642884|NCT07171879|PROCEDURE|Pontic Shield Only|Partial extraction therapy using the pontic shield technique, in which the buccal root fragment is preserved to maintain ridge contour, without additional grafting.
214642885|NCT07171879|PROCEDURE|Pontic Shield + MPM|Pontic shield technique combined with grafting using mineralized plasmatic matrix (MPM) for enhanced ridge preservation and healing.
214642886|NCT07178041|PROCEDURE|Remote Ischaemic Conditioning|Brief episodes of reversible ischaemia are applied to a particular tissue or organ by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg). This procedure is performed for periods that avoid physical injury to the limbs, but induce neurohormonal, systemic or vascular changes in the body. In this study, the treatment will be delivered on the upper arm or unaffected leg.
214727205|NCT03237390|OTHER|Laboratory Biomarker Analysis|Correlative studies
214727206|NCT03237390|OTHER|Pharmacological Study|Correlative studies
214727207|NCT03237390|DRUG|Ribociclib|Given PO
214727208|NCT04124406|DEVICE|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
214727209|NCT00865995|PROCEDURE|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
214727210|NCT01271595|OTHER|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
214642888|NCT07178093|DIETARY_SUPPLEMENT|Antrodia cinnamomea|The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
214642889|NCT07178093|DIETARY_SUPPLEMENT|placebo|The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
214642890|NCT07177378|DEVICE|management of medication related osteonecrosis of the jaw|after buccal flap reflection, the bone osteonecrosis was debrided using piezosurgery. the buccal mucoperiosteal flap was dissected to two layers first, the periosteal layer was based superiorly and the mucosal flap to achieve double layers closure.
214642891|NCT07179198|DEVICE|KIO021|KIO021 is used as a device product for dry skin and dull complexion
214642892|NCT07179289|OTHER|Provision of the MSProgress quality approach support tool|"The MSProgress tool is composed of 43 quantitative indicators identified by field teams and queried in health insurance databases. It is presented in a 20-page document organized by theme, allowing simplified access to the team's data, easily understandable by all. It allows the MSP to choose the indicators that make sense at the level of their patient base. Updated annually, the results make it possible to observe the team's progress and to position itself in relation to the regional average of MSPs in the Auvergne-Rhône-Alpes region, promoting collective reflection on the implementation of corrective actions.~The MSProgress tool will be made available for 12, 24 or 36 months depending on the randomization group."
214642893|NCT07177599|BIOLOGICAL|Natural history|Natural history of pancreatic diseases
214642894|NCT07178873|BEHAVIORAL|Psychosocial teleassistance intervention|The teleassistance psychosocial intervention involves 10 weekly 90-minute group sessions, with each group comprising 6 to 7 participants. These sessions are designed to enhance self-concept, self-esteem and social skills, reduce symptoms, and improve overall psychological well-being. Two follow-up sessions will be provided three months after the main program concludes.
214642895|NCT07178990|BEHAVIORAL|Digital Contingency Management Intervention Arm|Participants will use a version of the app for 6-months. Participants in this group may earn rewards for completing recovery-related activities and for abstinence from drugs and alcohol. During the 6 months this will include: random saliva drug tests, breathalyzer tests, and video selfies, completing surveys and questionnaires through the app, and receiving rewards on a debit card for abstinent tests, surveys, and activities. Additionally, participants will complete follow-up at approximately 9 months after randomization.
214642896|NCT07178990|BEHAVIORAL|Digital Wellness Arm|Participants will use a version of the app for 6-months focussed on wellness. During the 6 months this will include: random requests to do saliva drug tests, breathalyzer tests, and video selfies, complete surveys and questionnaires through the app, and receive rewards on a debit card for completing tests, surveys, and activities. Participants in this group may also earn rewards for completing study activities like tests and surveys. Additionally, participants will complete follow-up at approximately 9 months after randomization.
214642897|NCT07179055|DRUG|VSJ-110|ophthalmic solution
214642898|NCT07179055|DRUG|Placebo|ophthalmic solution
214642899|NCT07178145|DRUG|GLP-1RA|Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of 0.5, 1.0, 1.7, and 2.4 mg until a target dose of 2.4mg is reached after 16 weeks.
214642900|NCT07177664|OTHER|Breastfeeding Consultation Provided through the Nurse Navigation Program|The navigator nurse will meet with the pregnant woman/mother starting at 28-32 weeks of gestation and continuing until the sixth month postpartum. During these meetings, planned breastfeeding education will be provided, women's questions about breastfeeding will be answered, and counseling will be provided to address any concerns.
214642901|NCT07178210|DEVICE|Symani Surgical System|Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.
214642902|NCT07178613|DRUG|Serine（Oral）|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
214642903|NCT07178613|DRUG|Fluoropyrimidine Drugs|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
214642904|NCT07178405|OTHER|Meal low in energy density, low in ultra-processed food|Meal low in energy density, low in ultra-processed food
214642905|NCT07178405|OTHER|Meal low in energy density, high in ultra-processed food|Meal low in energy density, high in ultra-processed food
214642906|NCT07178405|OTHER|Meal high in energy density, low in ultra-processed food|Meal high in energy density, low in ultra-processed food
214642907|NCT07178405|OTHER|Meal high in energy density, high in ultra-processed food|Meal high in energy density, high in ultra-processed food
214642908|NCT07178275|BEHAVIORAL|Baduanjin Qigong|A standardized 60-minute Baduanjin Qigong protocol (15 minutes of breathing-focused warm-up, eight movements each lasting 5 minutes, and 10 minutes of breathing-focused closing). The sessions will be conducted by a licensed occupational therapist certified in Qigong.
214642909|NCT07178275|BEHAVIORAL|Passive Rest|Passive rest refers to a condition in which participants remain seated or lying quietly in a calm environment for a specified period of time, without engaging in any structured physical activity, therapeutic exercise, or cognitive tasks. During this period, external stimuli such as phone use, electronic devices, or reading materials are restricted in order to minimize distraction. The purpose of the passive rest condition is to provide a neutral control state that accounts for the passage of time and environmental factors, allowing valid comparison with the active intervention
214642910|NCT07179445|OTHER|Not applicable- observational study|Not applicable- observational study
214642911|NCT07178080|DEVICE|PIUR tUS Infinity Ultrasound|PIUR imaging technology, cleared by the U.S. Food and Drug Administration under 510(k) (K240036), is designed to provide advanced volumetric imaging capabilities to improve accuracy in assessing nodule size and volume reduction.
214642912|NCT07179237|DIETARY_SUPPLEMENT|Carminal Oral solution|Carminal is an oral dietary supplement presented in 30 ml vials, administered once daily (1 vial BID). It contains Aloe vera extract, olive extract, glutamic acid, zinc, and other components with potential antioxidant, anti-inflammatory, and immunomodulatory effects on gastric mucosa. In this study, Carminal is administered for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued treatment post-eradication to support mucosal recovery and improve dyspeptic symptoms.
214642913|NCT07179237|OTHER|Placebo|Placebo is an oral solution presented in 30 ml vials, identical in appearance, taste, color, and smell to Carminal, but without any active ingredients. It is administered once daily (1 vial BID) for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued placebo treatment post-eradication. This comparator is used to evaluate the efficacy of Carminal in mucosal recovery and symptom improvement in patients with H. pylori positive gastritis.
214642914|NCT07179406|OTHER|H-Reflex|H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes.
214642915|NCT07179406|OTHER|Somatosensory evoked potential (SSEP)|A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes.
214642916|NCT07179406|OTHER|Vibratory Electrophysiological Response Potential (ERP)|stimulation is provided to the ankle with vibration sensations using a device like a buzzer and the recording of the body's responses using the EEG and/or EMG electrodes.
214642917|NCT07179406|OTHER|Transcranial Magnetic Stimulation (TMS)|A small magnetic pulse is used to provide a small amount of electrical stimulation to the nervous system. The EEG and/or EMG electrodes will be used to measure the body's reaction.
214642918|NCT07179406|OTHER|Spinal Cord Stimulator (SCS) manipulation|Spinal cord stimulator will be turned on/off
214642919|NCT07179094|OTHER|Routine Protective Oral Care|In the control group, this group will perform oral care according to the routine clinical oral care procedures applied in the oncology clinic.
214642920|NCT07179094|OTHER|Protective Oral Care Using Peppermint Oil Mouthwash|Patients in the intervention group will perform a mouth rinse three times daily using 1 mL of peppermint oil diluted in 50 mL of water. The first application will be initiated on the day of chemotherapy, and patients will continue the peppermint oil oral care for six consecutive days (Day 0, Day 1, Day 2, Day 3, Day 4, and Day 5). The peppermint oil oral care protocol is scheduled to be administered at 07:00-08:00, 15:00-16:00, and 22:00-23:00, taking into account the routine timing of antiemetic medication administration in the clinic. The detailed description of the oral care protocol is presented below.
214642921|NCT07178743|DRUG|Initiation of palbociclib plus letrozole|Initiation of palbociclib plus letrozole described in electronic health records is used as the exposure.
214642922|NCT07178743|DRUG|Initiation of letrozole|Initiation of letrozole described in electronic health records is used as the reference.
214727211|NCT01006694|OTHER|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
214727212|NCT01006694|DRUG|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
214727213|NCT03687827|DRUG|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
214727214|NCT03687827|DRUG|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
214727215|NCT04819867|DRUG|Propolis|propolis is an extract derived from bee hives
214727216|NCT04819867|DRUG|Gluma Desensitizer|Gluma is a desensitizer agent
214727217|NCT04044313|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
214727218|NCT04044313|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214727219|NCT04044313|DRUG|Toripalimab|240mg intravenously every 3 weeks
214727220|NCT03209986|PROCEDURE|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
214727221|NCT03209986|OTHER|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
214727222|NCT06205680|DEVICE|NAA for topical anaesthesia of the nasal cavity|NAA for topical anaesthesia of the nasal cavity
214727223|NCT00269958|DRUG|epoetin alfa|
214642923|NCT07177898|DRUG|Allopurinol|Group A received allopurinol with lisinopril, and Group B received lisinopril alone
214642924|NCT07179120|DRUG|Semaglutide (Rybelsus®)|Participants receive once-weekly subcutaneous injections of Semaglutide. The dose is titrated every 4 weeks: 0.25 mg (Weeks 1-4), 0.5 mg (Weeks 5-8), and maintained at 1.0 mg from Week 9 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
214642925|NCT07179120|DRUG|Tirzepatide|Participants receive once-weekly subcutaneous injections of Tirzepatide. The dose is titrated every 4 weeks: 2.5 mg (Weeks 1-4), 5 mg (Weeks 5-8), 10 mg (Weeks 9-12), and maintained at 15 mg from Week 13 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
214727224|NCT01191957|DRUG|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
214727225|NCT01191957|DRUG|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
214642926|NCT07179120|BEHAVIORAL|Standardized Lifestyle Intervention|Participants receive individualized intensive lifestyle management, including a calorie-restricted Mediterranean diet (daily deficit of 500 kcal), structured aerobic and resistance exercise (150 mins/week), and behavioral coaching. Delivered through weekly face-to-face sessions for the first 12 weeks, followed by bi-weekly sessions for the remaining 20 weeks. No pharmacotherapy is administered.
214727226|NCT00498641|PROCEDURE|computer program and patching|
214727227|NCT02111707|DRUG|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
214727228|NCT01678313|DRUG|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
214727229|NCT01678313|DRUG|Doxazosin 4 mg every day (QD)|Control group
214727230|NCT00164788|DRUG|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
214727231|NCT00164788|DRUG|Oral esomeprazole|40mg every 12 hours for 24 hours
214727232|NCT02128958|DRUG|CF102|orally q12h
214727233|NCT02128958|DRUG|Placebo|orally q12 hours
214727234|NCT00981292|DIETARY_SUPPLEMENT|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
214727235|NCT00981292|DIETARY_SUPPLEMENT|Placebo|Pharmaceutical grade silica was utilized as placebo
214727236|NCT06242106|DEVICE|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
214727237|NCT05565066|DEVICE|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
214727238|NCT05565066|DEVICE|FNA group|Fine-needle-aspiration (Echotip Needle)
214727239|NCT04691349|DRUG|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
214642927|NCT07178717|DRUG|Rechalange with bevacizumab + encorafenib|Patients will receive encorafenib 300mg once daily plus cetuximab 500mg/m2 every 2 weeks until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy or death.
214642928|NCT07177872|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
214642929|NCT07178457|DRUG|Brentuximab Vedotin (Bv)|1.8 mg/kg in 100 mlof NaCl 0.9%, Q3W with a maximum of 16 cycles
214642930|NCT07178457|DRUG|Placebo|NaCl 0.9% 100 ml IV Q3W with a maximum of 16 cycles
214642931|NCT07177703|DRUG|Treprostinil|Treprostinil is initiated at a dose of 1.25 ng/kg/min. The dose is then titrated upwards based on individual patient tolerability and clinical response. The planned titration schedule is an increase of 1.25 ng/kg/min weekly for the first four weeks of treatment, followed by weekly increases of 2.5 ng/kg/min thereafter, as tolerated.
214642932|NCT07178678|DRUG|NeuroEPO|0.5 mg of NeuroEPO will be administered intranasally three times a week for 52 weeks.
214642933|NCT07178678|DRUG|Placebo|250 µL of placebo will be administered to intranasally to each nostril three times a week for 52 weeks.
214642934|NCT06785168|OTHER|Machine-based Resistance Training|The participants will receive HF treatment as prescribed by cardiologists. If participants have any additional medical conditions, their existing medications or treatments should continue. They are also asked to maintain their usual physical activity, exercise routines, and dietary habits, without making changes outside of the study intervention. At the beginning, patients participating in resistance training should complete a pretest of one-repetition maximum (1-RM) to assess muscle strength, which will be used by a professional physical therapist to develop an individualized prescription. The specific movements are as follows: (1) leg press and (2) calf raise by Proxomed Compass 540 (Germany); (3) leg curl, (4) chest press, (5) push up, (6) seated row by HUR machine (US). During the 8 weeks, subjects will train 3 non-consecutive days/week with intensity 30%1-RM to 60% 1-RM, 3 sets/one excercise with 8-12 repetitions.
214727240|NCT01131130|DEVICE|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
214727241|NCT01131130|DEVICE|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
214727242|NCT01131130|DEVICE|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
214642935|NCT01473797|DRUG|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
214727243|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
214642936|NCT05280756|DEVICE|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
214642937|NCT05280756|DEVICE|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
214642938|NCT04787965|DRUG|Opicapone|Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
214642939|NCT05724550|DRUG|Sugammadex|"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
214642940|NCT05724550|DRUG|Neostigmine|"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
214642941|NCT00836355|DRUG|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
214642942|NCT00836355|DRUG|Minocycline|200 mg orally once daily for 5 days
214642943|NCT04473417|DRUG|Forxiga|single dose administration after 10hr fasting
214642944|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
214642945|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
214642946|NCT04473417|DRUG|DA-2811|single dose administration after high fat and calorie fed diet
214642947|NCT03972631|BEHAVIORAL|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
214642948|NCT03972631|BEHAVIORAL|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
214642949|NCT03972631|BEHAVIORAL|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
214642950|NCT02913248|PROCEDURE|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
214642951|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
214642952|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
214642953|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
214642954|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
214642955|NCT03179085|BEHAVIORAL|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
214642956|NCT06183164|OTHER|Mindfulness: Awareness-Based Stress Reduction Program|The mindfulness-based stress reduction program was applied to the patients in the experimental group once a week, for 150 minutes, for 8 weeks and 8 times in total. Then, an intermediate test is applied to the patients. After the interim test, patients are asked to repeat the mindfulness-based stress reduction program individually for 8 weeks (between weeks 8-16). In addition, after the conscious awareness-based stress reduction program is applied to the patients in the experimental group by the researcher, the 'Conscious Awareness-Based Stress Reduction Program' booklet prepared by the researcher is given to the patients as a guide. experimental group.
214642957|NCT03851783|DEVICE|Solar-powered oxygen|Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
214642958|NCT00784797|DRUG|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
214642959|NCT00784797|DRUG|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
214642960|NCT05348798|OTHER|Web based survey|Web-based survey on exercise addiction and personality traits
214642961|NCT00121628|DRUG|AMG 706|
214642962|NCT06674577|DRUG|Atacicept 150 mg|"The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½ 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec"
214642963|NCT02002975|DRUG|Pioglitazone|Pioglitazone tablets
214642964|NCT01762280|DRUG|Famitinib Malate Capsule|
214642965|NCT04391959|DRUG|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
214642966|NCT04391959|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
214642967|NCT06108362|DRUG|Terlipressin|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
214642968|NCT06108362|DRUG|normal saline|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
214642969|NCT01350856|DRUG|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
214642970|NCT01350856|DRUG|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
214642971|NCT05554627|DRUG|Esketamine|Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
214642972|NCT05554627|DRUG|Aripiprazole|Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
214642973|NCT04306432|OTHER|Cognitive tests and Patient Reported Outcomes|Each patient will undergo cognitive tests and questionnaires
214642974|NCT06036589|DRUG|CA and BAM8-22|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
214642975|NCT06036589|DRUG|Vehicle and BAM8-22 application|Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
214642976|NCT06036589|DRUG|CA|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
214642977|NCT06036589|DRUG|vehicle|Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
214642978|NCT06040983|DEVICE|FR-101 Chest Dressing|"Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent Build-up effect. If the application time is longer than the recommendation, discomfort may happen depending on subject's condition."
214642979|NCT00101257|BIOLOGICAL|therapeutic autologous lymphocytes|
214642980|NCT01935050|BEHAVIORAL|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
214727244|NCT05267145|COMBINATION_PRODUCT|blood preservation solution III|Blood bag added blood preservation solution III
214727245|NCT03464136|BIOLOGICAL|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
214642981|NCT05666713|DEVICE|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
214642982|NCT01430442|DRUG|Rimegepant|Rimegepant capsules
214727246|NCT03464136|BIOLOGICAL|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
214727247|NCT03464136|BIOLOGICAL|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
214642983|NCT01430442|DRUG|Placebo|Rimegepant placebo-matching capsules
214642984|NCT01430442|DRUG|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
214642985|NCT01641939|DRUG|Taxane|Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.
214642986|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
214642987|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
214642988|NCT05665270|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
214727248|NCT03464136|BIOLOGICAL|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
214727249|NCT03464136|BIOLOGICAL|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
214727250|NCT03412565|DRUG|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
214727251|NCT03412565|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
214727252|NCT03412565|DRUG|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
214642989|NCT05665270|DRUG|Prednisolone Acetate 1%|"Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen."
214642990|NCT01231997|DRUG|Udenafil|100mg Single Oral Dose of
214642991|NCT04886934|DEVICE|CS1 System|Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
214642992|NCT02160392|PROCEDURE|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
214642993|NCT02007603|DRUG|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
214642994|NCT02007603|DRUG|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
214642995|NCT02007603|PROCEDURE|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
214642996|NCT02173119|OTHER|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
214642997|NCT01356550|DRUG|RO4917838|single oral dose
214642998|NCT01960322|BEHAVIORAL|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
214642999|NCT05458336|DEVICE|Nasal lavages with Tonimer Panthexyl®|At the moment of diagnosis, patients were asked to fill out an ad hoc questionnaire to subjectively evaluate symptoms and comorbidities at the moment of diagnosis and of negativization. Subjects performed a daily nasal swab. When the subjects tested negative for the first time, they had to complete the questionnaire once again. Patients were given nasal washes (Tonimer Panthexyl®) to be performed three times a day, and in any case after nasal swab.
214643000|NCT02841059|PROCEDURE|LSH|laparoscopic subtotal hysterectomy: LSH
214727253|NCT03412565|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
214643001|NCT02841059|PROCEDURE|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
214643002|NCT02841059|PROCEDURE|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
214643003|NCT02496949|DRUG|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
214643004|NCT04512833|RADIATION|Cyberknife stereotactic body radiation therapy|A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
214643005|NCT03932071|DRUG|Zoledronic Acid|
214643006|NCT02926326|DRUG|BCT197|A single dose of BCT197
214643007|NCT02926326|DRUG|Azithromycin|3 daily doses of Azithromycin
214727254|NCT03412565|DRUG|Melphalan|Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
214727255|NCT03412565|DRUG|Prednisone|Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
214793904|NCT03743428|DRUG|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
214727256|NCT03412565|DRUG|Carfilzomib|Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
214727257|NCT03277105|DRUG|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
214727258|NCT03277105|DRUG|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
214727259|NCT06243315|DEVICE|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
214727260|NCT05566574|DRUG|RP-3500|RP-3500 on Days 1-5.
214727261|NCT05566574|RADIATION|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
214727262|NCT01769638|DRUG|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
214727263|NCT01769638|DRUG|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
214727264|NCT00262639|DRUG|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
214727265|NCT00262639|DRUG|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
214727266|NCT06478550|DRUG|Semaglutide|Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
214727267|NCT04026945|DRUG|Lidocaine|Sustained-release lidocaine injection
214727268|NCT02656524|DRUG|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
214643008|NCT00716976|DRUG|sodium thiosulfate|Given IV
214643009|NCT00716976|PROCEDURE|examination|Patients undergo audiological assessments periodically
214643010|NCT01340521|DRUG|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
214643011|NCT00122135|OTHER|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
214727269|NCT03846089|PROCEDURE|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
214727270|NCT01530373|DRUG|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
214727271|NCT01530373|DRUG|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
214727272|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
214727273|NCT06587802|DRUG|Triprolizumab|At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
214727274|NCT06587802|DEVICE|rodiotherapy|SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)
214727275|NCT02622048|BEHAVIORAL|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
214727276|NCT04031924|OTHER|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
214727277|NCT00029341|BEHAVIORAL|Treatment Interruption|
214727278|NCT00996541|BEHAVIORAL|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
214727279|NCT02295436|DRUG|minodronic acid|comparison of different doses, ages and medication conditions
214643012|NCT06547476|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib|Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w
214643013|NCT00003632|BIOLOGICAL|filgrastim|
214643014|NCT00003632|DRUG|carmustine|
214643015|NCT00003632|DRUG|cytarabine|
214643016|NCT00003632|DRUG|etoposide|
214643017|NCT00003632|DRUG|melphalan|
214643018|NCT00003632|DRUG|methotrexate|
214643019|NCT00003632|PROCEDURE|peripheral blood stem cell transplantation|
214643020|NCT04879797|OTHER|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
214727280|NCT01766245|DRUG|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
214793905|NCT03336983|DRUG|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
214793906|NCT03336983|DRUG|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
214793907|NCT06542042|DIAGNOSTIC_TEST|NAS, NGS and Laboratory tests|Using three diffrent detection methods and comparing their efficiency
214793908|NCT01204320|PROCEDURE|Paclitaxel-coated Balloon|POBA
214793909|NCT01204320|DEVICE|Paclitaxel-eluting Stent|Stenting
214643021|NCT04879797|OTHER|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
214643022|NCT03068325|OTHER|EAT-PTSD|
214643023|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
214643024|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
214643025|NCT02723825|PROCEDURE|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
214643026|NCT02723825|PROCEDURE|Open reduction|Open reduction and internal fixation
214643027|NCT02088385|DEVICE|Hemospray|
214643028|NCT02088385|DEVICE|Combined Conventional Technique|
214643029|NCT00847587|DRUG|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
214643030|NCT00847587|DRUG|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
214643031|NCT02718378|DRUG|estetrol|
214643032|NCT02718378|DRUG|placebo|
214643033|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214643034|NCT05839795|OTHER|Assessment study|Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
214643035|NCT06917599|DEVICE|Low-level laser|Effect of Low-level laser therapy in wound healing after primary molar extraction
214643036|NCT06917599|OTHER|Saline Solution (NaCl 0,9%)|Following the extraction, a piece of gauze soaked in normal saline solution (NSS) will be placed over the socket. Both parents and children will be instructed to keep the gauze in place for 45 minutes
214643037|NCT00305656|DRUG|cediranib maleate|Given orally
214643038|NCT02684721|OTHER|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
214643039|NCT01575795|DRUG|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
214643040|NCT01575795|DRUG|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
214643041|NCT03882307|DRUG|sofosbuvir and daclatasvir|oral tablets
214643042|NCT03630731|DRUG|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
214643043|NCT03705182|DEVICE|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
214643044|NCT01418001|DRUG|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
214643045|NCT01316250|DRUG|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
214643046|NCT00690885|DRUG|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
214643047|NCT00690885|DRUG|placebo lozenges|matching placebo lozenges
214643048|NCT01237366|BEHAVIORAL|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
214643049|NCT03412409|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
214643050|NCT01175941|DRUG|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
214643051|NCT01175941|DRUG|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
214643052|NCT04224805|DEVICE|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
214643053|NCT04224805|DEVICE|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
214643054|NCT00083577|DRUG|Thalidomide|
214643055|NCT03196128|OTHER|Digital communication|Communicating with patients via email and text message.
214643056|NCT03196128|OTHER|Non digital|Communicating with patients via telephone and written appointment letters.
214643057|NCT02027740|DIETARY_SUPPLEMENT|almond|
214643058|NCT01136499|DRUG|LBH589 (Panobinostat®)|"40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity."
214643059|NCT02480933|PROCEDURE|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
214643060|NCT02480933|OTHER|Biopsy|Biopsy of BI-RADS 3 and superior lesions
214643061|NCT05753826|DRUG|Adebrelimab|20mg/kg，D1，q3W
214643062|NCT05753826|DRUG|Fuzuloparib|100 mg bid
214643063|NCT02194153|DRUG|Metalyse weight-adjusted|
214643064|NCT00374803|DRUG|Mycophenolic Acid (Myfortic)|"* Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
214643065|NCT02413437|OTHER|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
214643066|NCT02413437|OTHER|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
214643067|NCT02413437|DEVICE|Ultrasound|
214643068|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
214643069|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
214643070|NCT03731286|DIETARY_SUPPLEMENT|Microcellulose crystalline|2 capsules
214643071|NCT00809380|BEHAVIORAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
214643072|NCT00809380|BEHAVIORAL|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
214643073|NCT00005956|BIOLOGICAL|HER-2/neu intracellular domain protein|
214643074|NCT00005956|BIOLOGICAL|therapeutic autologous dendritic cells|
214643075|NCT04280354|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
214643076|NCT04280354|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
214643077|NCT04036279|PROCEDURE|Total Hip Arthroplasty|
214643078|NCT01345500|OTHER|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
214643079|NCT01345500|OTHER|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
214643080|NCT01345500|OTHER|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
214643081|NCT05425563|BEHAVIORAL|Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming somatic pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
214643082|NCT05425563|BEHAVIORAL|Vicarious Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming vicarious pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
214643083|NCT05425563|BEHAVIORAL|Cognitive Effort Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming cognitive effort stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
214643084|NCT00446914|BEHAVIORAL|Systems Change (High Blood Pressure Strategy)|
214643085|NCT01069445|DIETARY_SUPPLEMENT|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
214643086|NCT01069445|DIETARY_SUPPLEMENT|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
214643087|NCT01069445|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
214643088|NCT01069445|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
214643089|NCT05445973|PROCEDURE|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
214643090|NCT01722838|BEHAVIORAL|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
214643091|NCT02246257|OTHER|Simvastatin|LDL \> 2.5 is treated with 40 mg
214643092|NCT02246257|OTHER|Losartan|BT \> 140/90 mmHg treated with 50 mg OD
214643093|NCT02246257|OTHER|Losartan|DM BT \> 130/80 mmHg treated with 50 mg OD
214643094|NCT02246257|OTHER|Losartan|Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD
214643095|NCT02246257|OTHER|Metformin|HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
214643096|NCT02246257|OTHER|Outpatient rheumatology department|(4 times yearly)
214643097|NCT02246257|OTHER|Refered to general practice|
214643098|NCT02298933|DRUG|Eculizumab|300 mg single-use vials
214643099|NCT01410279|OTHER|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
214643100|NCT01087541|BEHAVIORAL|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
214643101|NCT00168831|DRUG|Tiotropium Inhalation Solution|
214643102|NCT00168831|OTHER|Placebo|
214643103|NCT00684190|DRUG|AZD3355|150 mg bid, oral, 7 days
214643104|NCT00684190|DRUG|Esomeprazole|40 mg od, oral, 7 days
214643105|NCT02146287|OTHER|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
214643106|NCT05646108|DEVICE|Endovascular treatment|Endovascular treatment
214643107|NCT00394849|PROCEDURE|suture one tonsillar fossa|one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
214643108|NCT05801237|DRUG|PE0116&PE0105|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
214643109|NCT02009878|DRUG|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
214643110|NCT01964066|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
214643111|NCT01964066|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
214643112|NCT01964066|PROCEDURE|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
214643113|NCT06340009|OTHER|mime therapy|"1. Facial Massage~2. Frowning~3. Close eyes~4. Smile~5. Fish Face~6. Eyebrow raising~7. Breathing exercise~8. Blow cheeks~9. Mouth opening and closing.~10. Moving lips side to side~11. Blow a candle.~12. Nasal flaring~13. Chewing exercise~14. Rinse mouth~15. Speaking vowels~16. Fill mouth with water~17. Fill rubber balloon~18. Sucking water with straw"
214643114|NCT06340009|OTHER|motor imagery|"1. Raising your eyebrows~2. Showing angry face~3. Closing and opening eyes~4. Pouting~5. Blowing cheeks~6. Smiling~7. Nasal flaring~8. Blowing candle~9. Deviating lips side to side~10. Chewing something~11. Speaking vowels"
214643115|NCT02690623|OTHER|Pediatric hospitalist program|In-house hospitalists available at all hours
214643116|NCT02690623|OTHER|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
214643117|NCT06528470|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when direct motor stimulation ceases and sensory stimulation is comfortable. Continuous stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
214643118|NCT06528470|DEVICE|Sham Stimulation|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when no stimulation is delivered. No stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
214643119|NCT00814957|DRUG|GSK618334|D3 receptor antagonist
214643120|NCT00001387|DRUG|paclitaxel|
214643121|NCT03094000|BEHAVIORAL|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
214643122|NCT03094000|BEHAVIORAL|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
214643123|NCT05370573|OTHER|No intervention|Observational - no interventions
214643124|NCT05210504|DRUG|L-Lysine|5g L-lysine in 50ml water, administered orally
214643125|NCT05210504|DRUG|Normal Saline|Normal (0.9%) Saline
214643126|NCT01471665|DRUG|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
214643127|NCT01471665|DRUG|Placebo|Placebo will be administered once daily for up to 16 days.
214643128|NCT02504788|RADIATION|hippocampal-sparing WBRT|
214643129|NCT00127751|BEHAVIORAL|Enhance health lifestyle changes and medication compliance|
214643130|NCT04026984|DRUG|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
214643131|NCT04026984|DRUG|Placebo|Matching Placebo tablets
214793910|NCT06002295|DRUG|Chlorhexidine Topical Cream|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
214643132|NCT03015467|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
214643133|NCT03015467|OTHER|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
214643134|NCT05310214|OTHER|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
214643135|NCT05310214|OTHER|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
214643136|NCT03567148|PROCEDURE|PRF|Applying to the palatal wounds
214643137|NCT03567148|PROCEDURE|Essix retainer|Applying to the palatal wounds
214643138|NCT03567148|PROCEDURE|Ozone therapy|Applying to the palatal wounds
214643139|NCT03567148|PROCEDURE|LLLT|Applying to the palatal wounds
214643140|NCT03567148|PROCEDURE|Collagen fleece|Applying to the palatal wounds
214643141|NCT01044966|DRUG|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
214643142|NCT05773677|DIETARY_SUPPLEMENT|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
214643143|NCT03762304|OTHER|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
214643144|NCT05029557|BEHAVIORAL|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
214643145|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
214643146|NCT03345186|OTHER|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
214643147|NCT05506397|OTHER|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
214643148|NCT04623645|DEVICE|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
214643149|NCT05566002|DIAGNOSTIC_TEST|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
214643150|NCT04652804|BEHAVIORAL|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
214643151|NCT04652804|BEHAVIORAL|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
214643152|NCT04652804|BEHAVIORAL|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
214643153|NCT00584194|BIOLOGICAL|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to \< 1:40.
214643154|NCT01397864|DRUG|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
214643155|NCT01571115|BEHAVIORAL|Physical Exercise|
214643156|NCT02238457|DRUG|Low dose losartan|25 mg losartan bid for 10 weeks
214643157|NCT02238457|DRUG|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
214643158|NCT01180933|DIETARY_SUPPLEMENT|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
214643159|NCT01180933|DIETARY_SUPPLEMENT|folate|400 µg per day
214643160|NCT01180933|DIETARY_SUPPLEMENT|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
214643161|NCT01180933|DIETARY_SUPPLEMENT|placebo|only vitamins and minerals as recommended, but no fish oil or folate
214643162|NCT03634800|DRUG|Nivolumab 240mg|Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.
214643163|NCT03634800|RADIATION|Radiation therapy|Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
214643164|NCT03118596|DEVICE|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
214643165|NCT03118596|DEVICE|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
214643166|NCT06067880|OTHER|Cancer-related Unilateral|This group included patients who have used only contraction type LVs.
214643167|NCT06067880|OTHER|Normal + Ectasis LVs|This group included patients who had only non- contraction type LVs.
214643168|NCT04831333|OTHER||
214643169|NCT03714490|RADIATION|SCPRT|Short-course preoperative radiotherapy(SCPRT), which consists of 5 Gy x 5f and 4Gy for boost on the GTV with MRI-simulation alone.
214643170|NCT03714490|RADIATION|CRT|Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.
214643171|NCT03714490|DRUG|CAPOX|Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
214643172|NCT03690310|BIOLOGICAL|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
214643173|NCT05210179|BIOLOGICAL|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
214643174|NCT05210179|BIOLOGICAL|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
214643175|NCT00197197|DRUG|GW873140|
214643176|NCT02776241|OTHER|water|
214643177|NCT05086445|DRUG|LY3502970|Administered orally
214643178|NCT05086445|DRUG|Placebo|Administered orally
214643179|NCT03884400|PROCEDURE|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
214643180|NCT00984750|DRUG|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
214643181|NCT00984750|DRUG|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
214643182|NCT05325775|DRUG|ACER-801 50 mg BID|50 mg BID (twice daily)
214643183|NCT05325775|DRUG|ACER-801 100 mg BID|100 mg BID (twice daily)
214643184|NCT05325775|DRUG|ACER-801 200 mg BID|200 mg BID (twice daily)
214643185|NCT05325775|DRUG|Placebo|Placebo
214643186|NCT03676127|OTHER|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
214643187|NCT00343512|DRUG|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
214643188|NCT00343512|GENETIC|protein expression analysis|protein expression analysis
214643189|NCT00343512|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214643190|NCT00343512|PROCEDURE|biopsy|biopsy
214643191|NCT00343512|PROCEDURE|conventional surgery|conventional surgery
214643192|NCT00343512|PROCEDURE|neoadjuvant therapy|neoadjuvant therapy
214643193|NCT01819519|BEHAVIORAL|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q\&A.
214643194|NCT04143269|DEVICE|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
214643195|NCT04143269|DEVICE|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
214643196|NCT00276575|BIOLOGICAL|bevacizumab|
214643197|NCT00276575|DRUG|erlotinib hydrochloride|
214643198|NCT00276575|DRUG|everolimus|
214643199|NCT04043000|DIETARY_SUPPLEMENT|Super 13 Pro & Prebiotics|"Super 13 Pro \& Prebiotics was given three times a day for four weeks."
214643200|NCT01637545|DRUG|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
214643201|NCT03887299|COMBINATION_PRODUCT|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
214643202|NCT03887299|OTHER|Standard Wound Care|Wound care will be administered as standard protocol in our institution
214643203|NCT02760082|OTHER|Qualitative evaluation|
214643204|NCT00858429|DRUG|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
214643205|NCT00858429|RADIATION|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
214643206|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed under transabdominal ultrasound guidance|The placement of an ultrasound probe on the lower abdomen while a Pipelle® endometrial biopsy is obtained.
214643207|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed without ultrasound guidance|A Pipelle® endometrial biopsy is performed by using touch alone.
214643208|NCT00684515|DRUG|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
214643209|NCT00684515|DRUG|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
214643210|NCT00684515|DRUG|Placebo|oral tablets; once daily for 60 days
214643211|NCT00684515|DRUG|Aspirin 75-150 mg|oral tablets; once daily for 60 days
214643212|NCT06213922|BEHAVIORAL|Food intake|Fast food
214643213|NCT03373565|PROCEDURE|Radial|Coronary angiography using radial approach
214643214|NCT03373565|PROCEDURE|Palmar|Coronary angiography using radial approach
214643215|NCT00634569|BIOLOGICAL|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
214643216|NCT02346188|DIETARY_SUPPLEMENT|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
214643217|NCT02346188|DIETARY_SUPPLEMENT|Zinc oxide|Tablet formulated from 30 mg zinc oxide
214643218|NCT02346188|DIETARY_SUPPLEMENT|Placebo|
214643219|NCT00063401|BIOLOGICAL|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
214643220|NCT00063401|DRUG|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
214643221|NCT00063401|DRUG|Carboplatin|AUC = 6 Day1, six 21-day cycles
214643222|NCT02655081|DIETARY_SUPPLEMENT|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
214643223|NCT04146142|PROCEDURE|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
214643224|NCT04733690|DIETARY_SUPPLEMENT|Common bean product|"Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected"
214643225|NCT03369964|DRUG|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
214643226|NCT03369964|DRUG|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
214643227|NCT03369964|DRUG|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
214643228|NCT03509324|DRUG|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
214643229|NCT04127448|OTHER|Exergaming Training Group|"Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down."
214643230|NCT04127448|OTHER|Aerobic Exercise Group|Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
214643231|NCT03669783|DRUG|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
214643232|NCT03669783|DRUG|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
214643233|NCT03669783|DRUG|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
214643234|NCT03669783|DRUG|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
214643235|NCT03669783|DRUG|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
214643236|NCT01171846|OTHER|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
214643237|NCT00788346|BEHAVIORAL|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
214643238|NCT00788346|BEHAVIORAL|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
214643239|NCT03568019|OTHER|Retrospective study|No subjects will be contacted or recruited. All data will be acquired retrospectively.
214643240|NCT01791608|DIETARY_SUPPLEMENT|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
214643241|NCT01791608|DIETARY_SUPPLEMENT|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
214643242|NCT01791608|DIETARY_SUPPLEMENT|Milk without fortification without zinc|Milk without fortification
214727281|NCT04085692|BEHAVIORAL|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
214727282|NCT04403841|OTHER|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
214727283|NCT04403841|OTHER|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
214727284|NCT04031157|DEVICE|Predictix Antidepressant|Predictix Antidepressant guided treatment
214727285|NCT03489538|PROCEDURE|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
214727286|NCT02480062|OTHER|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
214727287|NCT02480062|OTHER|Usual Care|Usual care at the community health centers
214727288|NCT00113711|BEHAVIORAL|smoking cessation|
214727289|NCT00113711|BEHAVIORAL|reducing diet|
214727290|NCT01554189|DRUG|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
214727291|NCT01554189|DRUG|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
214727292|NCT02456454|DRUG|Risperidone|Liquid risperidone
214727293|NCT02456454|DRUG|Valproic Acid|Liquid valproic acid
214727294|NCT02456454|DRUG|Placebo|
214727295|NCT02219737|DRUG|Carboplatin|Given IVPB
214727296|NCT02219737|DRUG|Etoposide|Given IVPB
214727297|NCT02219737|DRUG|Ibrutinib|Given PO
214727298|NCT02219737|DRUG|Ifosfamide|Given IV
214727299|NCT02219737|OTHER|Laboratory Biomarker Analysis|Correlative studies
214727300|NCT02219737|OTHER|Pharmacological Study|Correlative studies
214727301|NCT02219737|BIOLOGICAL|Rituximab|Given IV
214727302|NCT03121807|OTHER|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
214727303|NCT03121807|DRUG|Oxaliplatin|
214727304|NCT03121807|DRUG|5Fluorouracil|
214727305|NCT03121807|DRUG|Leucovorin|
214727306|NCT05551910|DRUG|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
214727307|NCT05551910|DRUG|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
214727308|NCT05551910|DRUG|propofol|propofol
214643243|NCT01076257|BEHAVIORAL|Modified Constraint-induced Movement Therapy|"Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)"
214643244|NCT02024516|OTHER|50 gr concentrated pomegranate juice|
214643245|NCT04447885|DEVICE|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
214643246|NCT01004302|PROCEDURE|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
214643247|NCT04663178|OTHER|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
214643248|NCT00503204|DRUG|Cediranib|oral tablet
214643249|NCT00503204|DRUG|Lomustine|oral capsule
214643250|NCT06344845|DIAGNOSTIC_TEST|18F-PBB3 PET/CT scan|Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
214643251|NCT02815839|DRUG|SHR4640|
214643252|NCT02815839|DRUG|Placebo|
214643253|NCT03029975|BEHAVIORAL|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
214643254|NCT03029975|BEHAVIORAL|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
214643255|NCT00401271|DRUG|OPC-67683|
214643256|NCT00401271|DRUG|Rifafour e-275|
214643257|NCT02609360|OTHER|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
214643258|NCT02609360|OTHER|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
214643259|NCT02609360|OTHER|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
214643260|NCT01700192|BIOLOGICAL|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
214643261|NCT01700192|BIOLOGICAL|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
214643262|NCT01700192|DRUG|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
214643263|NCT01700192|DRUG|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
214643264|NCT01700192|DRUG|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
214643265|NCT01700192|DRUG|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
214643266|NCT05697510|DRUG|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
214643267|NCT00416988|OTHER|educational intervention|
214643268|NCT05699720|DRUG|Nebulized Magnesium Sulphate|Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
214643269|NCT01157039|DIETARY_SUPPLEMENT|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
214643270|NCT01727895|DIETARY_SUPPLEMENT|Beta-glucan (Glucan #300®)|
214643271|NCT03884582|DEVICE|Cova Monitoring System 3|Healthy Volunteers
214643272|NCT03403192|DEVICE|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
214643273|NCT03403192|DEVICE|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
214643274|NCT04479800|DRUG|ASTX660|Form: capsule; Route of administration: oral
214643275|NCT03543410|DRUG|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
214643276|NCT03543410|DRUG|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
214643277|NCT03543410|DRUG|Placebo|Placebo (supplied in two tablets/day)
214727309|NCT00333424|BIOLOGICAL|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
214727310|NCT01091142|DRUG|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
214727311|NCT01091142|DRUG|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
214727312|NCT00504192|DRUG|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
214727313|NCT00365742|DRUG|simvastatin|
214727314|NCT00365742|DRUG|red yeast rice|
214727315|NCT00365742|DRUG|pharmaceutical grade fish oil|
214727316|NCT00365742|BEHAVIORAL|therapeutic lifestyle changes|
214727317|NCT02762123|DRUG|BMS-986142 200mg|
214727318|NCT02762123|DRUG|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
214727319|NCT02762123|DRUG|BMS-986142 350mg|
214727320|NCT06386536|DEVICE|Intelligent stationary bike|A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
214727321|NCT06386536|DEVICE|Conventional stationary bilke|A conventional stationary bike that can be found in gyms or rehab centers.
214727322|NCT01716949|RADIATION|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
214727323|NCT01716949|PROCEDURE|Hyperthermia|10 sessions, therapeutic time 60 min
214727324|NCT01716949|DRUG|5-Fluorouracil|250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
214727325|NCT01716949|DRUG|Capecitabine|1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
214727326|NCT01716949|DRUG|Oxaliplatin|50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
214727327|NCT00498368|DRUG|Intravenous Rituximab|"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
214727328|NCT00498368|DRUG|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
214727329|NCT00498368|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
214727330|NCT05367713|OTHER|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
214727331|NCT00964769|BIOLOGICAL|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
214727332|NCT03935490|PROCEDURE|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
214727333|NCT02373566|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
214727334|NCT03174808|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
214727335|NCT05312268|DRUG|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
214727336|NCT03423615|BEHAVIORAL|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
214727337|NCT00934713|DRUG|montelukast|montelukast 4mg once per day for 8 weeks period
214727338|NCT00802724|BEHAVIORAL|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
214727339|NCT00802724|BEHAVIORAL|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
214727340|NCT03431792|DEVICE|Long Tail Balloon|s. description of experimental Arm
214727341|NCT03144830|DEVICE|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
214727342|NCT02078089|DRUG|Morphine|Morphine will be given to patients as part of their standard care
214727343|NCT02078089|DRUG|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
214727344|NCT03521401|BEHAVIORAL|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
214727345|NCT01744041|BEHAVIORAL|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
214727346|NCT01744041|OTHER|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
214727347|NCT01351857|OTHER|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
214727348|NCT01438775|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
214727349|NCT01614041|DRUG|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
214727350|NCT01614041|DRUG|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
214727351|NCT05221593|DRUG|Lithium Carbonate|400 mg tablet in controlled released formula
214727352|NCT00432185|DRUG|PEP005|0.25% PEP005 Gel
214727353|NCT01936272|DEVICE|Chhabra Shunt Placement|
214727354|NCT01936272|PROCEDURE|ETV/CPC|
214727355|NCT02447068|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
214727356|NCT02447068|DEVICE|Luma Light|NBUVB light
214727357|NCT02447068|DEVICE|Occlusive Dressing|Off-the-shelf occlusive dressing
214727358|NCT00285649|OTHER|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
214727359|NCT00285649|OTHER|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
214727360|NCT00285649|OTHER|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
214727361|NCT04364906|OTHER|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
214727362|NCT02541500|DRUG|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
214727363|NCT02382965|DEVICE|transcranial focused ultrasound|
214727364|NCT04837781|PROCEDURE|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
214727365|NCT05861557|DRUG|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
214727366|NCT05861557|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
214727367|NCT04501172|BEHAVIORAL|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
214727368|NCT03342404|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
214727369|NCT03342404|OTHER|Placebo|Placebo, Subcutaneous, every 21 days
214727370|NCT03342404|OTHER|Best Supportive Care (BSC)|Best Supportive Care (BSC)
214727371|NCT01968304|OTHER|Iron status follow up|
214643278|NCT05481866|OTHER|Oropharyngeal administration of colostrum|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.
214643279|NCT05481866|OTHER|Oropharyngeal administration of sterile water|The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
214643280|NCT02883244|DEVICE|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
214643281|NCT02883244|DEVICE|Floss|Floss will be used once a day to clean interdental sites at home.
214643282|NCT00983190|DEVICE|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
214643283|NCT04586829|OTHER|Diet|\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
214643284|NCT00402441|DRUG|Risedronate (HMR4003)|
214643285|NCT03840330|OTHER|Experimental: High-intensity interval training group|16 weeks of High-intensity interval training
214727372|NCT00052832|DIETARY_SUPPLEMENT|doxercalciferol|
214643286|NCT03840330|OTHER|Experimental: Moderate-intensity interval training group|16 weeks of Moderate-intensity interval training
214727373|NCT00927329|BIOLOGICAL|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
214727374|NCT01961102|PROCEDURE|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
214727375|NCT02527902|DEVICE|Holter|measure of ANS in IgAN patients
214727376|NCT00002675|BIOLOGICAL|filgrastim|
214727377|NCT00002675|DRUG|carboplatin|
214727378|NCT00002675|DRUG|cisplatin|
214727379|NCT00002675|DRUG|cyclophosphamide|
214727380|NCT00002675|DRUG|etoposide|
214727381|NCT00002675|DRUG|mesna|
214727382|NCT00002675|DRUG|vincristine sulfate|
214727383|NCT04723004|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
214727384|NCT04723004|DRUG|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
214727385|NCT03156413|DEVICE|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
214727386|NCT02128204|DEVICE|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
214727387|NCT02128204|DEVICE|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
214727388|NCT00023205|BEHAVIORAL|11th grade reading level arthritis materials|
214727389|NCT00023205|BEHAVIORAL|Interactive in-person arthritis education|
214727390|NCT04559997|OTHER|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
214727391|NCT04559997|OTHER|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
214727392|NCT05799547|OTHER|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
214727393|NCT01957085|OTHER|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
214727394|NCT00244777|DRUG|Hypo-osmolar ORS|
214727395|NCT01966276|DRUG|Methyl-P plus Nutrient Formula|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula"
214727396|NCT01966276|DRUG|Methyl-P plus Nutrient matched placebos|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo"
214727397|NCT02650167|BIOLOGICAL|Colostrum feeding|
214727398|NCT02650167|BIOLOGICAL|formula for preterm infants|
214727399|NCT04247321|DEVICE|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
214727400|NCT04247321|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
214643287|NCT00820755|DRUG|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
214727401|NCT01168375|DRUG|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
214727402|NCT01168375|DRUG|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
214727403|NCT02108522|BIOLOGICAL|Multivirus Specific T cells|
214727404|NCT00349024|DRUG|polyvinylpyrrolidone-sodium hyaluronate gel|
214727405|NCT05553262|BEHAVIORAL|Behavioral support|Behavioral support as described under 'Arm description'.
214727406|NCT05001776|PROCEDURE|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
214727407|NCT05001776|DRUG|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
214727408|NCT02844140|PROCEDURE|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
214727409|NCT03748420|OTHER|Adherence Intervention|The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
214727410|NCT00373880|DRUG|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
214727411|NCT00373880|DRUG|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
214727412|NCT03987867|BIOLOGICAL|CIK cell|CIK cell injection
214727413|NCT03987867|BIOLOGICAL|Sintilimab Injection|IBI308 injection
214727414|NCT03987867|DRUG|Pemetrexed|Pemetrexed injection
214727415|NCT03987867|DRUG|Liposome paclitaxel|Liposome paclitaxel injection
214727416|NCT03987867|DRUG|Carboplatin|Carboplatin injection
214643288|NCT00820755|DRUG|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
214643289|NCT00820755|DRUG|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
214727417|NCT05155839|DRUG|MRG001|Administrated intravenously
214727418|NCT00515944|DRUG|Botulinum neurotoxin type A, free of complexing proteins|
214727419|NCT05770739|BEHAVIORAL|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
214643290|NCT04148261|DRUG|Hydrocortisone Acetate (CORT)|Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
214727420|NCT05770739|BEHAVIORAL|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
214727421|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
214727422|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
214727423|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
214727424|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
214727425|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
214727426|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
214727427|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
214727428|NCT00312728|DRUG|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
214727429|NCT00312728|DRUG|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
214643291|NCT04148261|DRUG|Epinephrine Sulfate (EPI)|Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
214643292|NCT04148261|DRUG|Placebo (PLB)|Participants will receive a placebo
214643293|NCT02153567|DRUG|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
214643294|NCT02153567|OTHER|Placebo|Placebo will be given for the next 10 weeks.
214727430|NCT00312728|DRUG|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
214727431|NCT03304392|BEHAVIORAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
214727432|NCT03304392|BEHAVIORAL|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
214727433|NCT03045640|OTHER|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
214727434|NCT00298285|DRUG|enoxaparin|
214727435|NCT00311090|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
214727436|NCT00311090|DRUG|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
214727437|NCT00311090|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
214727438|NCT00311090|DRUG|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
214727439|NCT01307228|OTHER|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
214727440|NCT05299151|OTHER|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
214727441|NCT05299151|OTHER|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
214727442|NCT01215786|DRUG|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
214643295|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
214643296|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
214643297|NCT03315351|PROCEDURE|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
214643298|NCT03315351|OTHER|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy"
214643299|NCT01155700|DRUG|omalizumab|
214727443|NCT01215786|DRUG|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
214727444|NCT01215786|DRUG|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
214727445|NCT02868151|DRUG|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
214727446|NCT02868151|DRUG|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
214643300|NCT05728294|PROCEDURE|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
214643301|NCT05728294|PROCEDURE|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
214727447|NCT03058263|DRUG|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
214727448|NCT05265390|OTHER|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
214727449|NCT04085991|DRUG|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
214727450|NCT03593564|BEHAVIORAL|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
214727451|NCT03518775|DEVICE|Biometry|Measurement of Cornea
214727452|NCT06316687|OTHER|questionnaire for food consumption frequency|questionnaire about Food consumption frequency, Screen time , Dental neglect scale
214727453|NCT05008549|DIETARY_SUPPLEMENT|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
214727454|NCT06033690|BEHAVIORAL|multidisciplinary guide|use of the food guide for education, clarification of doubts
214643302|NCT04992416|PROCEDURE|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
214643303|NCT04992416|PROCEDURE|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
214643304|NCT05659446|PROCEDURE|endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
214643305|NCT06061198|DEVICE|a virtual reality device|the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
214643306|NCT04177719|DRUG|Oxytocin|oxytocin will be given intranasally. The order of administration will be counterbalanced
214643307|NCT04177719|DRUG|Placebo|Saline placebo will be given intranasally. The order of administration will be counterbalanced
214727455|NCT01335490|OTHER|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
214727456|NCT02426112|DRUG|Azithromycin|
214727457|NCT02426112|DRUG|Placebo|
214727458|NCT00124332|DRUG|Rimonabant (SR141716)|
214727459|NCT00124332|DRUG|Placebo|
214727460|NCT02251067|DRUG|VPI-2690B low dose|Comparison of different doses of study drug
214727461|NCT02251067|DRUG|VPI-2690B medium dose|Comparison of different doses of study drug
214727462|NCT02251067|DRUG|Placebo to match VPI-2690B|
214643308|NCT03978559|DRUG|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
214643309|NCT03978559|DRUG|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
214727463|NCT02251067|DRUG|VPI-2690B high dose|Comparison of different doses of study drug
214727464|NCT02989311|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
214727465|NCT02989311|DIETARY_SUPPLEMENT|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
214727466|NCT04321278|DRUG|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
214643310|NCT03978559|DRUG|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
214643311|NCT02282592|OTHER|Observation about the presence of metabolic syndrome|
214643312|NCT05031741|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
214643313|NCT04072757|BEHAVIORAL|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~* connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~* seasonal fruits \& vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~* quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~* choose healthier foods Session Five: Taste Bud Rehab~* reduce foods high in sugar and salt.Mind-body connection Session Six: Batch \& One Ingredient Cooking~* making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~* prepare healthier desserts Session Eight: Family Meal Practices~* healthy eating habits in children Session Nine: Snacks as Mini Meals~* make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~* healthy up favorite recipes"
214643314|NCT04072757|BEHAVIORAL|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
214643315|NCT04927728|OTHER|Mental Practice|MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.
214643316|NCT04927728|OTHER|Repetitive-Task Practice|Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.
214643317|NCT04927728|OTHER|Traditional Therapy|Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
214643318|NCT05989906|BEHAVIORAL|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
214643319|NCT05989906|BEHAVIORAL|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
214643320|NCT05989906|BEHAVIORAL|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
214643321|NCT05989906|BEHAVIORAL|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
214643322|NCT03811509|DRUG|bisphosphonate|antiresorptives
214643323|NCT03881995|DRUG|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
214643324|NCT03881995|DRUG|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
214643325|NCT00836212|DRUG|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
214643326|NCT00836212|DRUG|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
214643327|NCT05133011|PROCEDURE|Tongue base reduction surgery|Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
214643328|NCT06290050|DRUG|Midazolam|Midazolam syrup.
214643329|NCT06290050|DRUG|Repaglinide|Repaglinide tablets.
214643330|NCT06290050|DRUG|TAK-279|TAK-279 capsules.
214643331|NCT03146533|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
214643332|NCT03146533|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
214643333|NCT03146533|BIOLOGICAL|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
214643334|NCT02704533|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
214727467|NCT04321278|DRUG|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
214727468|NCT05730101|OTHER|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
214643335|NCT02704533|BIOLOGICAL|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
214643336|NCT02704533|BIOLOGICAL|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
214643337|NCT02704533|OTHER|Normal saline|0.9% sodium chloride
214643338|NCT04159038|OTHER|Intervention Group|The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.
214643339|NCT04159038|OTHER|Control group|The control group will continue usual WIC care.
214643340|NCT04728490|OTHER|Allogenic transplantation transplantation|Haplo-identical transplantation with the use of Treosulfan, Thiotepa and Fludarabine in conditioning regimen.
214643341|NCT06304454|OTHER|Board game intervention|5 weeks / 2 sessions each week / 1 hour each session
214643342|NCT03396380|DRUG|Vitamin D with calcium and clomiphene citrate|"1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days ."
214643343|NCT03396380|DRUG|Placebo Oral Tablet with calcium and clomiphene citrate|"1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days"
214643344|NCT01767883|OTHER|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation~* Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
214643345|NCT01767883|OTHER|Clinical Decision Support Only|"* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms"
214727469|NCT05730101|OTHER|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
214727470|NCT01458795|PROCEDURE|Endovenous laser ablation|
214727471|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
214727472|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
214727473|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
214727474|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
214727475|NCT02280486|DRUG|Saxagliptin|5 mg/d
214727476|NCT02280486|DRUG|Glimepiride|1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
214727477|NCT04348786|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
214727478|NCT04348786|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
214727479|NCT02882022|DEVICE|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
214727480|NCT01292525|DRUG|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
214727481|NCT01292525|DRUG|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
214727482|NCT04134169|OTHER|Not applicable(observational study)|Not applicable(observational study)
214727483|NCT00423592|DRUG|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
214727484|NCT03446612|DRUG|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
214727485|NCT03446612|DRUG|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
214727486|NCT03446612|DRUG|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
214727487|NCT03446612|DRUG|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
214727488|NCT03446612|DRUG|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
214727489|NCT02082028|DEVICE|BGStar|
214727490|NCT02082028|DEVICE|glucose meter|
214727491|NCT03023605|BEHAVIORAL|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day"
214727492|NCT04039789|BEHAVIORAL|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
214643346|NCT01407783|BEHAVIORAL|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
214643347|NCT02841371|RADIATION|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
214643348|NCT05789017|DRUG|Prednisone and Mycophenolate Mofetil|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.
214643349|NCT05789017|DRUG|Mycophenolate Mofetil|Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
214643350|NCT05789017|DRUG|Leflunomide|Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
214643351|NCT00023387|DRUG|Rifapentine|
214643352|NCT00023387|DRUG|25-desacetyl Rifapentine|
214643353|NCT00023387|DRUG|Isoniazid|
214643354|NCT01478854|RADIATION|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
214643355|NCT01478854|DRUG|Chemotherapy|Temozolomide
214643356|NCT00874250|DEVICE|GORE CTAG Device|Endovascular aortic stent-graft
214643357|NCT01625273|OTHER|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10\^8 CFU per day from 28 days to 6 months of infant age
214643358|NCT02317562|DRUG|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
214643359|NCT03319862|PROCEDURE|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
214643360|NCT01889979|DRUG|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
214643361|NCT01889979|DRUG|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
214643362|NCT00603915|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) day 1 and day 8
214643363|NCT00603915|DRUG|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
214643364|NCT00603915|DRUG|erlotinib|150mg daily (post GC therapy)
214643365|NCT03891901|DRUG|Imatinib|Tablets, administered orally
214643366|NCT03891901|DRUG|Isoniazid|300 mg tablets, administered orally
214643367|NCT03891901|DRUG|Rifabutin|300 mg capsules, administered orally
214643368|NCT01569685|DRUG|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
214643369|NCT01569685|DRUG|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
214643370|NCT01182831|PROCEDURE|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
214643371|NCT01182831|PROCEDURE|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
214643372|NCT01407549|BEHAVIORAL|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
214643373|NCT02547480|DEVICE|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
214727493|NCT04039789|PROCEDURE|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
214727494|NCT00228189|BIOLOGICAL|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
214727495|NCT04199546|OTHER|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
214727496|NCT03314012|DEVICE|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
214727497|NCT04191213|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
214727498|NCT04191213|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
214727499|NCT03261570|DRUG|Pyridostigmine|60mg by mouth
214727500|NCT03261570|DRUG|Digoxin|0.5 (500mcg) by mouth
214727501|NCT03261570|DRUG|Placebo|Lactulose 50mg by mouth
214727502|NCT01671891|RADIATION|radiation therapy|45-55Gy
214727503|NCT01671891|DRUG|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
214727504|NCT05185284|DRUG|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
214727505|NCT05185284|DRUG|Favipiravir|200 mg coated tablets
214643374|NCT00864266|DRUG|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
214643375|NCT03686501|DRUG|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections
214643376|NCT03757832|DEVICE|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
214727506|NCT05185284|DRUG|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
214727507|NCT02251171|DRUG|Tipranavir|
214727508|NCT02251171|DRUG|Ritonavir|
214727509|NCT02251171|DRUG|Rifabutin|
214727510|NCT04904315|OTHER|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
214727511|NCT00205751|DRUG|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
214727512|NCT01526005|DRUG|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
214727513|NCT01526005|DRUG|Transdermal Placebo Patch|1 patch per day; 8 weeks total
214643377|NCT02129946|OTHER|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
214643378|NCT03473132|DRUG|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
214643379|NCT00911846|OTHER|interview|interview using questionnaires
214643380|NCT04186026|OTHER|Saline + saline|Double saline infusion followed by an ad libitum meal
214643381|NCT04186026|OTHER|Neurotensin + saline|Neurotensin + saline infusion followed by an ad libitum meal
214643382|NCT04186026|OTHER|GLP-1 + saline|GLP-1 + saline infusion followed by an ad libitum meal
214643383|NCT04186026|OTHER|GLP-1 + Neurotensin|GLP-1 + Neurotensin infusion followed by an ad libitum meal
214643384|NCT01314300|DRUG|Lidocaine|Lidocaine 5% plaster
214643385|NCT05350059|DEVICE|High Intensity Focused Ultrasound (HIFU) to the Breast Cancer|Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
214727514|NCT03658798|PROCEDURE|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
214727515|NCT01882192|BEHAVIORAL|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
214643386|NCT02903537|DRUG|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
214643387|NCT02903537|DRUG|Interferon-beta|Subcutaneous administration interferon-beta
214643388|NCT02105415|DRUG|Ketamine / Propofol Admixture|
214643389|NCT02105415|DRUG|Etomidate|
214643390|NCT03140904|OTHER|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
214643391|NCT03140904|OTHER|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
214643392|NCT03370497|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
214643393|NCT03370497|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
214643394|NCT05156541|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
214643395|NCT03589404|DEVICE|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
214643396|NCT00742469|DRUG|Rifaximin|
214643397|NCT00742469|DRUG|Placebo|
214643398|NCT04033419|DRUG|Memantine|"memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
214643399|NCT01055535|DRUG|Microplasmin|125 µg intravitreal injection
214643400|NCT02662647|DRUG|Decitabine 20 mg/m²/day for 5 days|
214643401|NCT01132209|PROCEDURE|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
214643402|NCT05227339|DEVICE|RAE|Subjects in the interventional group will have access to the RAE Health mobile app which receives continuous physiologic data from a wearable device. Algorithms embedded in the RAE app detect stress and craving events, and trigger mobile phone notifications when detected. Notifications are paired to real-time mindfulness based interventions.
214643403|NCT05365165|DRUG|Sevoflurane|Sevoflurane will be applied during aortic cross- clamping in cardiac surgery
214643404|NCT03778086|PROCEDURE|gonioscopy|gonioscopic observation and grading of iridocorneal angle
214643405|NCT02999490|RADIATION|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
214643406|NCT00573794|BIOLOGICAL|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
214643407|NCT02558374|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
214643408|NCT02558374|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
214643409|NCT02558374|OTHER|Placebo|1 drop QD, AM, OU
214643410|NCT02095743|DEVICE|implanted port for chemo administration (X-port isp)|
214643411|NCT02095743|DEVICE|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
214727516|NCT02019498|BEHAVIORAL|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
214643412|NCT00347828|DRUG|Moxifloxacin ophthalmic solution 0.5%|
214643413|NCT00347828|DRUG|Gatifloxacin ophthalmic solution 0.3%|
214643414|NCT03663088|OTHER|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
214643415|NCT03663088|OTHER|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
214643416|NCT06548802|DRUG|Baricitinib|Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.
214643417|NCT06196086|DIAGNOSTIC_TEST|Echocardiography examination|Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
214643418|NCT06500247|DRUG|Dalpicilib|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
214643419|NCT06500247|DRUG|Abiraterone Acetate (II)|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
214643420|NCT06500247|DRUG|Androgen Deprivation Therapy|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
214643421|NCT06500247|DRUG|Prednisone|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
214643422|NCT02026063|DRUG|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
214643423|NCT03116945|DRUG|68Gallium Citrate|Procedure: PET/CT Imaging
214727517|NCT02019498|OTHER|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
214727518|NCT02327312|DEVICE|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
214727519|NCT02327312|PROCEDURE|Laser|Laser Trabeculoplasty
214727520|NCT02327312|DEVICE|Laser Trabeculoplasty|
214727521|NCT03348566|OTHER|fish|fish intkae
214727522|NCT04553367|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
214727523|NCT04553367|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
214727524|NCT04553367|DEVICE|ventilator|ventilator
214727525|NCT01437267|BIOLOGICAL|Vi-CRM197 vaccine|
214727526|NCT01437267|BIOLOGICAL|Pneumococcal conjugate vaccine|
214727527|NCT01437267|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
214727528|NCT00838695|DRUG|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
214727529|NCT03934203|DRUG|BI 409306|Film-coated tablet
214727530|NCT03934203|DRUG|Moxifloxacin|Film-coated tablet
214727531|NCT03934203|DRUG|Placebo matching to BI 409306|Film-coated tablet
214727532|NCT02457299|PROCEDURE|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
214727533|NCT02457299|PROCEDURE|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
214727534|NCT03898388|PROCEDURE|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
214727535|NCT04319445|BEHAVIORAL|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
214727536|NCT00735098|OTHER|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
214727537|NCT00735098|OTHER|strength training exercise|strength training exercise, 3 times per week for 8 weeks
214727538|NCT00735098|OTHER|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
214727539|NCT00735098|OTHER|Control group|8 week control group
214727540|NCT04379947|PROCEDURE|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
214727541|NCT04925947|DRUG|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
214727542|NCT03785444|OTHER|WHODAS 2.0|WHO Disability Score
214727543|NCT03785444|OTHER|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
214727544|NCT03785444|OTHER|IADL|The Lawton Instrumental Activities of Daily Living
214643424|NCT00052195|BIOLOGICAL|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
214643425|NCT05170711|PROCEDURE|hypotensive anesthesia|hypotensive anesthesia
214643426|NCT05170711|PROCEDURE|normotensive anesthesia|normotensive anesthesia group
214643427|NCT05218616|DRUG|Aviga, capsules 50 mg / Sutent®, capsules 50 mg|Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
214643428|NCT05218616|DRUG|Sutent®, capsules 50 mg / Aviga, capsules 50 mg|Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
214643429|NCT00639938|DRUG|Nevirapine|200 mg Nevirapine tablet
214643430|NCT00639938|DRUG|HIV immune globulin solution|5% intravenous HIV immune globulin solution
214643431|NCT01154647|DRUG|citalopram|intravenous
214643432|NCT01154647|DRUG|1 ml 0.9 % NaCl|intravenous
214643433|NCT02810028|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
214643434|NCT03695068|BEHAVIORAL|RISE Intervention|Described in Arms description.
214643435|NCT04208854|DRUG|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
214643436|NCT01044186|DRUG|ICL670|
214727545|NCT03785444|OTHER|Barthel-Score|Barthel Score of the patient
214727546|NCT03785444|OTHER|SF-36|Short Form Health 36
214727547|NCT03785444|OTHER|MoCA Blind|Montreal Cognitive Assessment
214727548|NCT00351806|DRUG|Erigeron breviscapus injection|
214727549|NCT00351806|DRUG|hua tuo zai zao wan (a herbal medicine pill)|
214727550|NCT00351806|DRUG|Compound stroke herbal medicine (8 herbal)|
214643437|NCT00604968|DRUG|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).
214727551|NCT00608842|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
214727552|NCT00608842|DRUG|Placebo|Matching vehicle placebo administered via intralipomal injection.
214727553|NCT03787095|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
214727554|NCT03787095|BIOLOGICAL|Placebo|Diluent for REGN2810, administered as an IV infusion
214727555|NCT06328855|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214727556|NCT06328855|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214727557|NCT06328855|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214727558|NCT02394223|PROCEDURE|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
214727559|NCT03944304|DRUG|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
214727560|NCT00000314|DRUG|M-CPP|
214727561|NCT01039428|DIETARY_SUPPLEMENT|HS219|Chewing for 30 min three time a day far after meal
214727562|NCT01039428|DIETARY_SUPPLEMENT|Placebo|Chewing for 30 min three times a day far after meal
214727563|NCT03594461|DRUG|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
214727564|NCT01617928|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
214727565|NCT01617928|DRUG|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
214727566|NCT01617928|DRUG|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
214727567|NCT02262676|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
214727568|NCT00053222|DRUG|arsenic trioxide|
214727569|NCT05793112|DRUG|INF108F probiotic|Oral suspension
214727570|NCT05793112|DRUG|Placebo|Oral suspension
214727571|NCT04841850|OTHER|Clinical and biological characteristics|"* Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose"
214727572|NCT01468038|DRUG|Trazodone|active trazodone and sentra pm-like placebo
214727573|NCT01468038|OTHER|Sentra PM|Active Sentra PM and trazodone-like placebo
214727574|NCT01468038|DRUG|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
214727575|NCT01468038|DRUG|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
214727576|NCT01424319|DRUG|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
214727577|NCT01424319|DRUG|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
214727578|NCT01424319|DRUG|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
214727579|NCT01789749|OTHER|Snare Tip Soft Coagulation|
214727580|NCT01789749|OTHER|No Snare Tip Soft Coagulation|
214727581|NCT00766064|DRUG|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
214727582|NCT01553721|DRUG|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
214727583|NCT01553721|DRUG|placebo|Phase IIa - placebo Phase IIb - placebo
214727584|NCT03013959|DRUG|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
214727585|NCT01562678|DRUG|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
214727586|NCT01562678|DRUG|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
214727587|NCT04668547|DEVICE|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
214727588|NCT03907592|DIETARY_SUPPLEMENT|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
214727589|NCT03907592|DIETARY_SUPPLEMENT|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
214727590|NCT03907592|PROCEDURE|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
214727591|NCT04672070|OTHER|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
214727592|NCT04672070|OTHER|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
214727593|NCT02418728|OTHER|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
214727594|NCT05757024|DEVICE|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
214727595|NCT02395289|BEHAVIORAL|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
214727596|NCT02395289|BEHAVIORAL|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
214727597|NCT00303576|DRUG|dapivirine (TMC120) vaginal gel|
214727598|NCT05076331|DIAGNOSTIC_TEST|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
214727599|NCT01793090|DRUG|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
214727600|NCT01793090|OTHER|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
214727601|NCT04460365|DIETARY_SUPPLEMENT|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
214727602|NCT04460365|OTHER|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
214727603|NCT00321360|DRUG|Propofol|
214727604|NCT00321360|DEVICE|Patient maintained sedation|
214727605|NCT04892680|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
214727606|NCT05944029|DIETARY_SUPPLEMENT|Pomegranate seed powder|10 g powder / day
214727607|NCT00422240|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
214727608|NCT00422240|DRUG|Adapalene Gel, 0.1%|0.1% of adapalene gel topically daily in the evening for 12 Weeks.
214727609|NCT00422240|DRUG|Benzoyl Peroxide Gel 2.5%|2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
214727610|NCT00422240|DRUG|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
214727611|NCT00625040|OTHER|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
214727612|NCT00287846|DRUG|imatinib mesylate|
214727613|NCT02341404|DRUG|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
214727614|NCT02957110|BEHAVIORAL|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
214727615|NCT05328414|DRUG|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
214727616|NCT05950555|OTHER|Saline|We used 0.9% isotonic sodium chloride.
214727617|NCT05950555|OTHER|Dexmedetomidine|We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
214727618|NCT05950555|OTHER|Ketamine|We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
214727619|NCT04822441|OTHER|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
214727620|NCT00159614|DRUG|KW-3902IV|
214727621|NCT04771481|DRUG|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
214727622|NCT04771481|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
214727623|NCT04831593|OTHER|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
214727624|NCT04831593|OTHER|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
214727625|NCT03627000|OTHER|failure after reimplantation|description of cinical and microbiological failure
214727626|NCT01041391|PROCEDURE|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
214727627|NCT04489940|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
214727628|NCT04843072|DEVICE|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
214727629|NCT04843072|DEVICE|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
214727630|NCT02349204|BEHAVIORAL|Music - Mozart's sonata for 2 pianos in D-440|
214727631|NCT00668772|DRUG|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
214727632|NCT00668772|DRUG|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
214727633|NCT00668772|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
214727634|NCT00668772|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
214727635|NCT00668772|DRUG|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
214727636|NCT01624467|BIOLOGICAL|Necitumumab|800 mg necitumumab, administered once per week IV
214727637|NCT04705350|DRUG|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
214727638|NCT04705350|DRUG|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
214727639|NCT00744640|DRUG|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
214727640|NCT03186872|BEHAVIORAL|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
214643438|NCT01116544|DEVICE|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
214727641|NCT01838304|DEVICE|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
214727642|NCT01838304|DEVICE|Monitoring|Manual recording of drug doses determined by CRNA
214727643|NCT05706818|OTHER|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
214727644|NCT03169114|DRUG|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
214727645|NCT03169114|PROCEDURE|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
214727646|NCT06482255|OTHER|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
214727647|NCT06482255|OTHER|manual therapy and therapeutic exercise and virtual reality|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality"
214727648|NCT05258981|DIAGNOSTIC_TEST|MRI|Brain MRI
214727649|NCT05560295|PROCEDURE|Naser Al-Husban|uterine surgery
214727650|NCT05225506|BEHAVIORAL|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
214727651|NCT06373536|DIAGNOSTIC_TEST|Thermoacoustic imaging, MRI and Ultrasound imaging|This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
214727652|NCT02360449|BEHAVIORAL|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
214727653|NCT04884906|BIOLOGICAL|Camrelizumab|200mg/m2, iv, d1, Q3W, a total of 6 cycles
214727654|NCT04884906|RADIATION|radiotherapy|1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
214727655|NCT04884906|DRUG|Albumin Paclitaxel|260mg/m2, iv, d1, Q3W, a total of 6 cycles
214727656|NCT04884906|DRUG|Cisplatin|80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
214727657|NCT04130100|BIOLOGICAL|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
214727658|NCT04130100|BIOLOGICAL|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
214727659|NCT04130100|DRUG|Sodium Hyaluronate|Sodium Hyaluronate injection
214727660|NCT03557736|BEHAVIORAL|Training mode|type of exercise training completed for 12 weeks
214727661|NCT03961893|DEVICE|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
214727662|NCT03961893|DEVICE|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
214727663|NCT03964493|DRUG|TNP-2092|TNP-2092 100mg/vial
214727664|NCT03964493|DRUG|Vancomycin|Vancomycin 1g/vial
214727665|NCT06506292|DRUG|Adebrelimab|Adebrelimab:1200 mg, iv, d1
214727666|NCT06506292|DRUG|XELOX|oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
214727667|NCT02915692|DEVICE|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
214727668|NCT02915692|DEVICE|Comparator Silver Coated Catheter|Foley catheter coated with silver
214727669|NCT05740891|DRUG|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
214727670|NCT02470429|DEVICE|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
214727671|NCT02470429|DEVICE|Hyabak 0.15% eye drops|Preservative-free
214727672|NCT02470429|DRUG|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
214727673|NCT00966680|OTHER|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
214727674|NCT04247789|OTHER|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
214727675|NCT02244008|OTHER|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
214643439|NCT03378063|DRUG|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
214727676|NCT02244008|OTHER|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
214727677|NCT00006190|DRUG|Nelfinavir mesylate|
214727678|NCT00006190|DRUG|Stavudine|
214727679|NCT00006190|DRUG|Lamivudine|
214727680|NCT00006190|DRUG|Efavirenz|
214727681|NCT00398138|BIOLOGICAL|WT-1 analog peptide vaccine|
214727682|NCT00398138|BIOLOGICAL|incomplete Freund's adjuvant|
214727683|NCT00398138|BIOLOGICAL|sargramostim|
214727684|NCT00398138|GENETIC|polymerase chain reaction|
214727685|NCT00398138|OTHER|flow cytometry|
214727686|NCT00398138|OTHER|immunoenzyme technique|
214727687|NCT01947647|BEHAVIORAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
214727688|NCT01947647|BEHAVIORAL|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
214727689|NCT03844139|DEVICE|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
214727690|NCT03903913|DRUG|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
214727691|NCT02048852|OTHER|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
214727692|NCT02048852|OTHER|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
214727693|NCT02048852|OTHER|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
214727694|NCT02048852|OTHER|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
214727695|NCT00029289|DRUG|Lutein (10 or 30 mg/day) capsules|
214727696|NCT06287931|DRUG|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
214727697|NCT06287931|DRUG|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
214727698|NCT00071214|BIOLOGICAL|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
214727699|NCT03534713|DRUG|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
214727700|NCT03534713|DRUG|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
214727701|NCT03534713|DRUG|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
214727702|NCT03534713|RADIATION|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
214727703|NCT01333462|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
214727704|NCT01333462|OTHER|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
214727705|NCT00903994|DRUG|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
214727706|NCT05310760|DRUG|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
214727707|NCT01456520|DRUG|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
214727708|NCT01456520|DRUG|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
214727709|NCT01503892|DIETARY_SUPPLEMENT|Metanx|Metanx- one tablet twice daily for twelve months
214727710|NCT01503892|DRUG|Placebo|Placebo- one tablet twice daily for twelve months.
214727711|NCT03021590|DRUG|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
214727712|NCT03021590|DRUG|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
214727713|NCT06059833|DIAGNOSTIC_TEST|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
214727714|NCT01188811|DRUG|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
214727715|NCT01188811|DRUG|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
214727716|NCT05944445|DRUG|Linezolid 600 mg|Linezolid 600mg injection
214727717|NCT04426292|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
214727718|NCT01602744|OTHER|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
214727719|NCT02766972|PROCEDURE|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
214727720|NCT05455840|DEVICE|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
214727721|NCT04019236|OTHER|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
214727722|NCT03148184|DIAGNOSTIC_TEST|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
214727723|NCT02363855|DRUG|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
214727724|NCT01159821|DRUG|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
214727725|NCT03966352|OTHER|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
214727726|NCT04459442|PROCEDURE|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
214727727|NCT00003000|DRUG|fentanyl citrate|
214727728|NCT00003000|DRUG|morphine sulfate|
214727729|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
214727730|NCT03625960|DRUG|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
214727731|NCT03625960|DRUG|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
214727732|NCT03418376|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
214727733|NCT03418376|OTHER|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
214727734|NCT01751360|DRUG|SYR-472|
214727735|NCT03975517|BEHAVIORAL|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
214727736|NCT03028467|DRUG|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
214727737|NCT03028467|DRUG|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
214727738|NCT03028467|DRUG|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
214727739|NCT03028467|DRUG|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
214727740|NCT03028467|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
214727741|NCT03028467|DRUG|Folic acid|Folic acid tablet 5 mg per week is given orally.
214727742|NCT00281567|DRUG|Tiotropium|
214727743|NCT00281567|DEVICE|Respimat SMI|
214727744|NCT00281567|DEVICE|HandiHaler|
214727745|NCT05889169|OTHER|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
214727746|NCT03506113|DRUG|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
214727747|NCT03506113|DRUG|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
214727748|NCT01387594|PROCEDURE|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
214727749|NCT01387594|DRUG|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
214727750|NCT02845999|BIOLOGICAL|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
214727751|NCT02845999|BIOLOGICAL|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
214727752|NCT02845999|DRUG|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
214727753|NCT02845999|DRUG|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
214727754|NCT02845999|DRUG|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
214727755|NCT00925691|DEVICE|RV lead|The RV lead is implanted at the apex or at the interventricular septum
214727756|NCT06916624|RADIATION|18F-NY104 PET/CT|The radionuclide ¹⁸F will serve as the tracer in this study. NY104 will be labeled with \[¹⁸F\]AlF to form the ¹⁸F-NY104 injection for use in this research.All participants will undergo ¹⁸F-NY104 PET scan.
214727757|NCT05676801|DRUG|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
214727758|NCT03441555|DRUG|Venetoclax|tablet, oral
214727759|NCT03441555|DRUG|Alvocidib|Intravenous
214727760|NCT01820767|DRUG|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
214727761|NCT01820767|DRUG|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
214727762|NCT01820767|DRUG|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
214727763|NCT03991468|DIAGNOSTIC_TEST|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
214727764|NCT03991468|DIAGNOSTIC_TEST|Light Microscopy|Use of traditional light microscopy per institutional standard practice
214727765|NCT05412836|DEVICE|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
214727766|NCT05401903|OTHER|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
214727767|NCT02813434|BIOLOGICAL|florbetapir|18F-AV-45 or 18F-Florbetapir
214727768|NCT05394012|BIOLOGICAL|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
214727769|NCT05394012|BIOLOGICAL|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
214643440|NCT03378063|DRUG|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
214643441|NCT05519345|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response during stimulation.
214643442|NCT05519345|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
214643443|NCT03704129|OTHER|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
214643444|NCT03805893|PROCEDURE|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
214643445|NCT06269250|OTHER|Policy Change|There will be a change with the digitalization in the health care system with the beginning of the year 2024 and between Wave 1 and Wave 2
214643446|NCT02137967|PROCEDURE|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
214643447|NCT02137967|PROCEDURE|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
214643448|NCT02137967|DRUG|2.5% NaOCl|
214643449|NCT02137967|DRUG|20% Formocresol|
214643450|NCT05420389|OTHER|breast massage|Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
214643451|NCT05420389|OTHER|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
214643452|NCT05420389|OTHER|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
214643453|NCT04947176|DIETARY_SUPPLEMENT|Supplement|200mg C15:0 once daily
214643454|NCT04947176|OTHER|Placebo|Matching placebo once daily
214643455|NCT00930215|DRUG|D961H|Oral gelatin capsule
214643456|NCT00930215|DRUG|D961H|Oral HPMC capsule
214643457|NCT02183519|DRUG|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
214643458|NCT02183519|OTHER|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
214643459|NCT01612715|OTHER|Segmental Allergen Challenge|segmental allergen challenge
214643460|NCT00982904|DRUG|Fexinidazole/Placebo|
214643461|NCT02542072|DEVICE|comfilcon A|contact lens
214643462|NCT02542072|DEVICE|samfilcon A|contact lens
214727770|NCT01433692|BEHAVIORAL|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
214727771|NCT04421612|BEHAVIORAL|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
214727772|NCT06939582|DRUG|Hydroxychloroquine Sulfate Tablets|the trial group use the hydroxychloroquine sulfate tablets (200mg/time, bid)
214727773|NCT06939582|OTHER|Placebo|the control group use the Placebo
214727774|NCT06942702|DRUG|Genicular blocks (bupivakain)|Genicular block is a regional analgesic technique performed with USG
214727775|NCT06942702|DRUG|Patient Control Analgesia (PCA) Morphine group|this group consists of the patients no any intervention preoperatively and they will be given morfin with PCA (Patient controlled analgesia) and paracetamol 3x1000 mg intravenous and diclofenac 75 mg intramuscular (if needed)
214727776|NCT06942702|DRUG|Paracetamol (acetaminophen) + Diclofenac Sodium|All patients are given paracetamol (3x1000 mg) and diclofenac (if needed)
214727777|NCT06942871|DEVICE|Remote Dielectric Sensing|The lung fluid monitor Remote Dielectric Sensing (ReDS™) is the world's first non-invasive device for heart failure monitoring and management. It directly reflects lung fluid content by measuring changes in thoracic dielectric constants, with a detection range of 15% \~ 60%. The device can sensitively identify pathological states ranging from mild compensation to severe pulmonary edema. ReDS™ technology cannot directly measure pulmonary artery pressure, but changes in lung fluid content may indirectly reflect disease progression in certain types of pulmonary hypertension.
214727778|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
214727779|NCT01780207|DEVICE|PFO Closure|
214727780|NCT06940258|PROCEDURE|ultrasound measurement of caval aorta index|ultrasound measurement of caval aorta index
214727781|NCT06940258|OTHER|control group|fixed fluid prescription
214793911|NCT06002295|DRUG|Methylated Spirit|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
214643463|NCT03863626|OTHER|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
214643464|NCT03863626|OTHER|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
214643465|NCT03754907|PROCEDURE|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson \& Johnson K.K., Tokyo, Japan)
214643466|NCT03754907|PROCEDURE|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
214643467|NCT06056752|BIOLOGICAL|QH103 Cell Injection|dose escalation (3+3) : dose 1 (3×10\^8CAR+cells) ,dose 2 (1 × 10\^9 CAR+cells）,dose 3 (3 × 10\^9CAR+cells)
214643468|NCT06056752|DRUG|Fludarabine|Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition
214643469|NCT06056752|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
214643470|NCT01653041|DRUG|Everolimus|
214643471|NCT01401504|DRUG|ASP3026|oral
214643472|NCT04804592|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
214643473|NCT04804592|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
214643474|NCT04804592|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
214643475|NCT02752100|PROCEDURE|Percutaneous transluminal angioplasty|
214643476|NCT06233695|DRUG|Potassium sparing diuretic|Starting Spironolactone or Eplerenone at the time of enrollment.
214643477|NCT06066892|PROCEDURE|Impression techniques|3 types of impression techniques for all on four
214643478|NCT02338102|OTHER|Saline mixture|premeasured salt packets mixed with distilled water
214727782|NCT06943547|BEHAVIORAL|Arm 2: Patient Navigator|The patient navigation model used in the study is aligned with the conceptual model for cervical cancer screening proposed by the Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium. The initial contact, as well as most navigation activities, will occur mostly over the phone. In our study, the roles of the patient navigator (Arms 2 and 4) will include: exploring individual barriers to screening, use of motivational interviewing to educate and encourage patients to perform screening, performing reminder calls, and coordinating of referral and clinical services if needed. Also, providing other services to identify and overcome access barriers encountered during the cancer care process, including linkage to community resources. In arm 4, the patient navigator will also facilitate the explanation of the use of the self-collection kits by study participants.
214727783|NCT06943547|BEHAVIORAL|HPV self-collection kit|Each HPV testing kit will include an invitation letter, information sheet, one FLOQSwabs552C® and one sealable plastic bag to put the swab. Because home high risk (HR) HPV self-screening is not standard of care in the US, the kit will also include a letter advising women to receive routine Pap tests, regardless of their HR-HPV self-sampling results. Detailed instructions on how to collect the cervical sample and how to mail the kit back to the study site or bring it to the clinical visit (depending on their preference) will be included.
214727784|NCT05514925|DRUG|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
214727785|NCT05514925|PROCEDURE|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
214727786|NCT04347616|BIOLOGICAL|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
214727787|NCT04347616|DRUG|IL-2|In vivo cytokine support
214727788|NCT01455233|DRUG|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
214727789|NCT01455233|DRUG|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
214727790|NCT02793804|DEVICE|Oraquick (made in Thailand)|
214727791|NCT03573804|OTHER|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
214727792|NCT04553978|DRUG|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
214727793|NCT01425307|DRUG|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
214727794|NCT02578095|DRUG|VK5211|Capsule
214727795|NCT02578095|DRUG|Placebo|Capsule
214727796|NCT02741089|PROCEDURE|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
214727797|NCT06942676|BEHAVIORAL|Core Exercise Program|This intervention consists of a 4-week core training program including exercises like planks, side planks, bird-dogs, bridges, and dead bugs, performed 3 days per week alongside regular soccer training. Each session lasted approximately 25-30 minutes.
214727798|NCT06949852|DRUG|Nalbuphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
214643479|NCT00289107|DEVICE|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
214727799|NCT06949852|DRUG|Morphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
214727800|NCT06948357|DRUG|BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo|BRIMOCHOL PF eye drops, CARBACHOL PF eye drops, Brimonidine eye drops and Placebo were administered in 7 treatment sequences in various combinations and doses
214643480|NCT00289107|DEVICE|Total knee replacement|Fixed Cruciate Substituting Knee System
214643481|NCT04751812|PROCEDURE|High-pain multimodal anesthesia with opioids|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
214727801|NCT06949917|DIETARY_SUPPLEMENT|body mass index for age|different body mass index according to age (normal weight,overweight,obeiece)
214727802|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active|The study will utilize the H7 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
214727803|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham|The study will utilize an identical protocol using the H7 coil to administer a sham condition.
214793912|NCT00717977|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
214727804|NCT06948370|BEHAVIORAL|Intervention Name: PARADIGM-Q Diabetes Self-Management Education Program|PARADIGM-Q Diabetes Self-Management Education Program This is a culturally sensitive, structured education intervention tailored for adults with Type 2 Diabetes in Qatar. Developed using the PARADIGM model and delivered through a Case-Based Learning (CBL) approach, the program comprises three weekly group sessions of 3.5 hours each. Each session targets key self-management attributes: problem-solving, decision-making, taking action, resource utilization, and patient-provider relationships. The program emphasizes real-life applicability, cultural relevance, and skill-building to support sustainable diabetes self-care.
214727805|NCT06948370|BEHAVIORAL|Control Arm (DESMOND): DESMOND Diabetes Self-Management Education Program|The DESMOND Diabetes Self-Management Education Program is the standard diabetes education intervention currently offered to newly diagnosed patients with Type 2 Diabetes in Qatar. It is a UK-developed, theory-driven program delivered over two group sessions, each lasting approximately four hours. The program provides structured education on diabetes, lifestyle management, and risk reduction strategies. It does not incorporate case-based learning or cultural tailoring, distinguishing it from the experimental PARADIGM-Q intervention. DESMOND is used here as an active comparator to evaluate the added value of culturally sensitive, problem-based education.
214727806|NCT06949189|PROCEDURE|Nail Bed Repair with Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be replaced and secured with a figure-of-eight suture using Prolene. A low-adherent dressing will be applied. If the fingernail is unavailable (e.g., due to damage or loss), a substitute material (such as foil) will be chosen by the operating surgeon
214727807|NCT06949189|PROCEDURE|Nail Bed Repair without Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be discarded. A low-adherent dressing will be applied without any covering of the nail bed
214727808|NCT06949267|BIOLOGICAL|iMSC|1× 10\^6/kg each time, twice a week
214727809|NCT06949267|COMBINATION_PRODUCT|conventional aGVHD prophylaxis|Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）
214727810|NCT06949904|DRUG|Melatonin|1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days
214727811|NCT06950086|DRUG|TYK-00540|Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +Fulvestrant)
214727812|NCT06948383|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|administer 30 mL %0.25 bupivacain between third costa and serratus posterior superior muscle
214727813|NCT06948383|PROCEDURE|Serratus Anterior Plane Block|administer 30 mL %0.25 bupivacain between 5th costa and serratus anterior muscle in midaxiller line
214727814|NCT01766765|PROCEDURE|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
214727815|NCT01766765|OTHER|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
214727816|NCT00373906|DRUG|Bortezomib (Velcade)|
214727817|NCT06949670|DIAGNOSTIC_TEST|18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06|Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET/CT or MRI imaging within the specificed time.
214727818|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
214727819|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
214727820|NCT01177826|PROCEDURE|Sample collection|Stool sample
214727821|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
214727822|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
214727823|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
214727824|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
214727825|NCT00863434|DRUG|clofarabine|Given IV
214727826|NCT00863434|DRUG|cytarabine|Given IV
214727827|NCT00863434|BIOLOGICAL|filgrastim|Given SC
214727828|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
214727829|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
214727830|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
214727831|NCT04058990|DEVICE|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
214727832|NCT04058990|DEVICE|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
214727833|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
214727834|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
214727835|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
214727836|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
214727837|NCT06793566|DEVICE|Repeated Muscle Vibration (rMV)|rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (impaired upper limb), interspersed with a 1-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
214727838|NCT06840756|BIOLOGICAL|Sex-mismatched red blood cell transfusions|Sex-mismatched red blood cell transfusions
214727839|NCT06840756|BIOLOGICAL|Sex-matched red blood cell transfusions|Sex-matched red blood cell transfusions
214727840|NCT06834789|DRUG|AGN-151586|Intramuscular injection
214727841|NCT06834789|DRUG|OnabotulinumtoxinA|Intramuscular injection
214727842|NCT06834789|DRUG|Placebo|Intramuscular injection
214727843|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
214727844|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
214727845|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
214727846|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
214727847|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
214727848|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
214727849|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
214727850|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
214727851|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
214727852|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
214727853|NCT04772651|OTHER|dietary coaching|dietary coaching
214727854|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
214727855|NCT06334354|OTHER|Assessments|Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
214727856|NCT06334354|OTHER|Assessment (Survivors Only)|\*Tumor/Treatment Variables (Survivors Only)
214727857|NCT06334354|OTHER|APOE and DNA Isolation|Biospecimens procurement and processing
214727858|NCT02014545|DRUG|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
214727859|NCT02014545|OTHER|Placebo|Only standard treatment of whole brain radiation therapy is done.
214727860|NCT00654394|DRUG|Rosuvastatin|
214727861|NCT04718402|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
214727862|NCT03050307|DRUG|TAK-438|TAK-438 tablets
214727863|NCT03050307|DRUG|Lansoprazole|Lansoprazole capsules
214727864|NCT03050307|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
214727865|NCT03050307|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214727866|NCT03050307|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
214727867|NCT04949633|DRUG|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
214727868|NCT04949633|DRUG|Oxytocin|Induction of labor with oxytocin.
214727869|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
214727870|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
214727871|NCT02422160|OTHER|No interventions are planned|No interventions are planned
214727872|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
214727873|NCT01048164|PROCEDURE|Massage|Chair Massage
214727874|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
214727875|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
214727876|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
214727877|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
214727878|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
214727879|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
214727880|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
214727881|NCT05385913|OTHER|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
214727882|NCT03737396|PROCEDURE|Self-administered electronic health screening|Health assessment using an electronic device
214727883|NCT05493436|DIAGNOSTIC_TEST|MII pH-meter|using multichannel impedance pH-meter
214727884|NCT04295668|BEHAVIORAL|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
214793913|NCT03542136|DEVICE|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
214793914|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
214793915|NCT00386672|BEHAVIORAL|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
214793916|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
214727885|NCT04295668|BEHAVIORAL|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
214727886|NCT00912639|DRUG|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
214727887|NCT03380169|OTHER|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
214727888|NCT03380169|OTHER|Prophylactic conventional wound dressing|Conventional gauze dressing
214727889|NCT02230787|DEVICE|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
214727890|NCT02230787|DEVICE|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
214727891|NCT04527536|DIAGNOSTIC_TEST|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
214727892|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
214727893|NCT02308553|DRUG|Nintedanib|Nintedanib (150 mg or 200 mg BID)
214727894|NCT02308553|DRUG|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
214727895|NCT02308553|DRUG|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
214727896|NCT01902654|OTHER|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
214727897|NCT01902654|OTHER|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
214727898|NCT01902654|OTHER|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
214727899|NCT05126654|DIETARY_SUPPLEMENT|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
214727900|NCT06139445|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)
214727901|NCT06139445|OTHER|Plasebo Group|random superficial touches not involved in any manual technique
214727902|NCT01998906|DRUG|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
214727903|NCT01998906|DRUG|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
214727904|NCT01998906|DRUG|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
214727905|NCT01998906|DRUG|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
214727906|NCT05148559|BEHAVIORAL|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
214727907|NCT05148559|BEHAVIORAL|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
214727908|NCT04115891|OTHER|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
214727909|NCT04115891|OTHER|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
214727910|NCT04115891|OTHER|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
214727911|NCT04115891|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
214727912|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
214727913|NCT00230373|DRUG|imiquimod 5% cream (Aldara)|
214727914|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
214727915|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
214727916|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
214727917|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
214727918|NCT04830657|OTHER|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
214727919|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
214727920|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
214727921|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
214727922|NCT05091073|DRUG|NNC0385-0434|All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
214727923|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
214727924|NCT00004256|BIOLOGICAL|sargramostim|
214727925|NCT00004256|PROCEDURE|quality-of-life assessment|
214727926|NCT00004256|RADIATION|radiation therapy|
214727927|NCT02996110|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
214727928|NCT02996110|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
214727929|NCT02996110|BIOLOGICAL|Relatlimab|Specified Dose on Specified Days
214727930|NCT02996110|DRUG|BMS-986205|Specified Dose on Specified Days
214727931|NCT02996110|DRUG|BMS-813160|Specified Dose on Specified Days
214727932|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
214727933|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
214727934|NCT03357328|OTHER|Therapy light room|See group description
214643482|NCT04751812|PROCEDURE|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
214643483|NCT04751812|PROCEDURE|Standard of care|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
214727935|NCT03357328|OTHER|Standard light|See group description
214643484|NCT06539312|OTHER|APP assessment and management of asthma|APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
214727936|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
214727937|NCT05191381|BIOLOGICAL|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
214643485|NCT05495126|DIAGNOSTIC_TEST|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
214727938|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
214727939|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
214793917|NCT00929708|DRUG|AZD3199|Dry powder for inhalation, o.d., 4 weeks
214793918|NCT00929708|DRUG|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
214793919|NCT00929708|DRUG|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
214793920|NCT01094444|OTHER|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
214793921|NCT01893138|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
214793922|NCT01893138|BIOLOGICAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
214793923|NCT03449043|OTHER|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
214643486|NCT05495126|DIAGNOSTIC_TEST|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
214793924|NCT02154529|DRUG|Tesevatinib|
214793925|NCT02154529|DRUG|Trastuzumab|
214643487|NCT05491993|DIAGNOSTIC_TEST|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
214643488|NCT00273377|OTHER|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
214643489|NCT00273377|OTHER|Supplemental oxygen (80% vs. 30%)|
214643490|NCT00273377|DRUG|Dexamethasone|4 mg
214643491|NCT00273377|DRUG|Placebo|placebo
214643492|NCT02811692|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
214643493|NCT06560164|OTHER|Red Blood Cell transfusion|When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
214643494|NCT05168267|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
214643495|NCT00284037|DEVICE|continuous positive airway pressure therapy|
214643496|NCT01184937|BEHAVIORAL|Patient education program|"All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs."
214643497|NCT03090685|PROCEDURE|True auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
214643498|NCT03090685|PROCEDURE|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
214643499|NCT01900093|DRUG|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
214643500|NCT04722211|DIETARY_SUPPLEMENT|PS128|daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
214793926|NCT00824460|DRUG|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
214643501|NCT04722211|DIETARY_SUPPLEMENT|placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
214643502|NCT05083871|OTHER|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
214643503|NCT05702736|BEHAVIORAL|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
214643504|NCT01172652|DRUG|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
214643505|NCT01172652|DRUG|Placebo|Inactive control
214643506|NCT04230863|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
214643507|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
214643508|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
214643509|NCT05911646|OTHER|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe \>81."
214643510|NCT05911646|OTHER|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
214643511|NCT04102969|BEHAVIORAL|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
214643512|NCT04102969|OTHER|Nutrition Package Session|A nutrition package session will be given to the control group.
214643513|NCT00695565|DRUG|Placebo Gel|TID x 12 weeks
214643514|NCT00695565|DRUG|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
214643515|NCT02937350|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
214643516|NCT01462266|DRUG|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
214643517|NCT01462266|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
214643518|NCT01462266|BIOLOGICAL|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
214643519|NCT01462266|DRUG|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
214643520|NCT03391947|PROCEDURE|semilunar coronally positioned flap|The description of this intervention has been already given before
214643521|NCT03391947|PROCEDURE|coronally advanced flap|The description of this intervention has been already given before
214643522|NCT01106846|DRUG|Group A: Saline Group|Saline continuous infusion
214643523|NCT01106846|DRUG|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
214643524|NCT00042380|DRUG|Novasoy|
214643525|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 5mg, with additional doses of 2.5mg as necessary
214643526|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 10mg, with additional doses of 2.5mg as necessary
214643527|NCT00561197|DRUG|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
214643528|NCT01119456|BIOLOGICAL|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
214643529|NCT01119456|BIOLOGICAL|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
214643530|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
214643531|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
214643532|NCT01119456|BIOLOGICAL|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
214643533|NCT01119456|BIOLOGICAL|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
214643534|NCT01119456|BIOLOGICAL|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
214643535|NCT01119456|BIOLOGICAL|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
214643536|NCT02312492|OTHER|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
214643537|NCT02312492|OTHER|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
214643538|NCT02312492|OTHER|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
214643539|NCT03396094|DEVICE|High-flow nasal cannulae (HFNC) oxygenation|Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher \& Paykel Healthcare, Auckland, New Zealand)
214643540|NCT03396094|DEVICE|Non-rebreather mask and standard nasal cannula|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
214643541|NCT02288273|DRUG|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
214643542|NCT02288273|DRUG|Placebo|Placebo
214793927|NCT00824460|DRUG|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
214643543|NCT00803179|DRUG|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
214643544|NCT00931216|PROCEDURE|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
214643545|NCT05604599|DRUG|Intranasal dexmedetomidine|45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
214643546|NCT05604599|DRUG|Intravenous dexmedetomidine|patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
214643547|NCT03084640|DRUG|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
214643548|NCT03084640|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
214643549|NCT03084640|DRUG|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
214643550|NCT05866055|DRUG|VX-973|Suspension for oral administration.
214643551|NCT05866055|DRUG|Placebo|Suspension for oral administration.
214643552|NCT05866055|DRUG|Midazolam|Syrup for oral administration.
214643553|NCT00146263|BEHAVIORAL|Savyon|Computerized cognitive training
214643554|NCT00146263|BEHAVIORAL|Control|Usual activity
214643555|NCT02419508|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
214643556|NCT02419508|DRUG|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
214643557|NCT02419508|DRUG|Prostaglandin analogue|
214643558|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
214643559|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
214643560|NCT06456983|DEVICE|maintenance electroconvulsive therapy (mECT)|see Arms
214643561|NCT04811716|DRUG|Pozelimab|Administered Sub-cutaneous (SC) per protocol
214643562|NCT04811716|DRUG|Cemdisiran|Administered SC per protocol
214643563|NCT05223192|BEHAVIORAL|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
214643564|NCT03110900|DRUG|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
214643565|NCT03110900|DRUG|Loxapine|loxapine + placebo
214643566|NCT05968859|BEHAVIORAL|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
214643567|NCT05968859|BEHAVIORAL|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
214643568|NCT00163332|DRUG|Ciclesonide|
214643569|NCT02877173|DRUG|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
214643570|NCT02877173|DRUG|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
214643571|NCT01897636|PROCEDURE|EUS-guided fine-needle injection of DCs vaccinations|
214643572|NCT06501664|DRUG|liposomal irinotecan|Liposomal irinotecan 70 mg/m²
214643573|NCT06501664|DRUG|5-FU|5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
214643574|NCT06501664|DRUG|LV|LV 400 mg/m²
214643575|NCT06501664|DRUG|Irinotecan|Irinotecan 180 mg/m²
214643576|NCT01528514|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
214643577|NCT01528514|OTHER|Placebo|Placebo in capsule form, 4 capsules 4 times/day
214643578|NCT04961788|DRUG|Gemox combimed PD1 antibody|"1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
214643579|NCT04583397|OTHER|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
214643580|NCT04103801|DIETARY_SUPPLEMENT|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
214793928|NCT00824460|DRUG|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
214793929|NCT00824460|DRUG|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
214643581|NCT02674438|OTHER|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
214643582|NCT04348409|DRUG|Nitazoxanide Tablets|Patients will receive nitazoxanide 600 mg BID for 7 days
214643583|NCT04348409|DRUG|Placebo|Patients will receive placebo BID for 7 days
214643584|NCT01568814|DRUG|Low volume PEG|low volume polyethylene glycol 2 liter one time
214643585|NCT01568814|DRUG|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
214643586|NCT04545346|OTHER|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
214643587|NCT01016639|OTHER|oxaliplatin, capecitabine, radiotherapy|
214643588|NCT05683444|DRUG|Octreotide infusion|Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
214643589|NCT05683444|DRUG|Saline infusion|Saline Infusion
214643590|NCT01380457|DRUG|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
214643591|NCT01380457|DRUG|Marinol|Capsules, 10 mg, single-dose, fasting conditions
214643592|NCT01007578|DEVICE|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
214793930|NCT00824460|DRUG|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
214793931|NCT00824460|DRUG|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
214793932|NCT00468533|DRUG|Aripiprazole|
214643593|NCT00398463|DRUG|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
214643594|NCT00398463|DRUG|Placebo|Saline infusion will be administered for 14-24 hours
214643595|NCT04124588|DEVICE|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
214643596|NCT04124588|DEVICE|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
214643597|NCT05397990|BEHAVIORAL|Exercise|12 weeks of moderate intensity exercise, three times a week.
214643598|NCT06499987|PROCEDURE|resection anastomosis|resection of stenotic part of trachea and reanastmosis
214643599|NCT02945631|RADIATION|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
214643600|NCT02945631|RADIATION|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
214643601|NCT05099692|BEHAVIORAL|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
214643602|NCT00318760|DRUG|Clonidine|0.1 or 0.2 mg oral, one dose
214643603|NCT00318760|DRUG|Placebo|oral capsule 1 dose
214643604|NCT03782935|DIETARY_SUPPLEMENT|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
214643605|NCT04890210|DIETARY_SUPPLEMENT|Early Diet Group|Initiation of clear fluid diet 1 hour after esophageal variceal ligation
214643606|NCT04890210|DIETARY_SUPPLEMENT|Late Diet Group|Initiation of clear fluid diet 6 hours after esophageal variceal ligation
214793933|NCT01412671|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
214643607|NCT00751868|DRUG|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
214727940|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
214727941|NCT05574478|BEHAVIORAL|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
214727942|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
214727943|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
214727944|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
214727945|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
214727946|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
214727947|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
214727948|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
214643608|NCT06144983|DRUG|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
214643609|NCT06144983|DRUG|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
214643610|NCT03887754|DRUG|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
214727949|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
214727950|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
214727951|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
214727952|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
214727953|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
214727954|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
214727955|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
214727956|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
214727957|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
214727958|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
214727959|NCT06048809|OTHER|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
214727960|NCT06048809|OTHER|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
214727961|NCT06370338|OTHER|Delphi Questionnaire|Experts will be approached to participate in the research via email. If the experts agree to participate they will check 'yes' in the email with the informed consent and will be directed to the Qualtrics survey. If the expert decides to decline consent they will check 'no' in the email and will not be enrolled. Subjects who agree to participate will undergo 2 phases of questions with three rounds of the same questions in each phase. This Delphi survey research involves Phase 1 and Phase 2 of questioning, each phase involves up to 3 rounds of questions to determine agreement or disagreement. Each round will take approximately 20 minutes to complete, and your responses will remain completely confidential. For both phases, the questions will either be 7-point Likert or multiple choices. For both phases, the group of questions will be sent up to three times until we obtain agreement (up to 80% of agreement consensus). Questions that have obtained agreement will be removed in each round.
214727962|NCT06476795|OTHER|Chardonnay Marc|Food product made from Chardonnay wine grapes
214727963|NCT05450445|DEVICE|myHealthHub|myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
214727964|NCT05450445|DEVICE|TV-only|myHealthHub device equipped with the TV-only entertainment option.
214727965|NCT03775603|DEVICE|TOFscan|comparison of TOFscan over TOF-Watch SX
214727966|NCT02325089|DEVICE|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
214727967|NCT02325089|DEVICE|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
214727968|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4|
214727969|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, before cooking|
214727970|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, after cooking|
214643611|NCT03887754|DEVICE|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
214643612|NCT03887754|DRUG|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
214643613|NCT00643643|DRUG|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
214643614|NCT00643643|DRUG|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
214643615|NCT00643643|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
214643616|NCT00643643|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
214643617|NCT00643643|OTHER|Placebo|Matching placebo oral tablet twice daily for 10 days
214643618|NCT01849861|DRUG|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity"
214727971|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4 + ascorbic acid|
214727972|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, before cooking|
214727973|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, after cooking|
214727974|NCT05715840|DRUG|SG001 injection|360 mg，Q3W，IV infusion
214643619|NCT05586633|PROCEDURE|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
214643620|NCT05586633|PROCEDURE|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
214727975|NCT05715840|DRUG|Paclitaxel|175 mg/m\^2，Q3W，IV infusion
214727976|NCT05715840|DRUG|Cisplatin|50 mg/m\^2，Q3W，IV infusion
214727977|NCT05715840|DRUG|Carboplatin|AUC=5，Q3W，IV infusion
214727978|NCT05715840|DRUG|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
214727979|NCT05715840|DRUG|SG001 placebo|Q3W，IV infusion
214793934|NCT03248856|DRUG|Triamcinolone Acetonide|Intratympanic administration
214793935|NCT03571308|DRUG|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
214643621|NCT04065529|COMBINATION_PRODUCT|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
214727980|NCT02840734|OTHER|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
214643622|NCT04065529|COMBINATION_PRODUCT|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
214643623|NCT00494143|DEVICE|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
214643624|NCT00494143|DEVICE|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
214643625|NCT00494143|DEVICE|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
214643626|NCT02542761|DEVICE|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
214643627|NCT02542761|DEVICE|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
214643628|NCT03439150|DIAGNOSTIC_TEST|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
214643629|NCT04057339|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
214643630|NCT04057339|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
214643631|NCT05976191|BEHAVIORAL|Patients whose blood glucose is measured intravenously and from the fingertip|A satisfaction survey will be conducted after these patients have previously examined their blood glucose via intravenous route, then fingertip blood glucose will be measured and a satisfaction survey will be applied.
214643632|NCT00993746|DRUG|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
214643633|NCT00993746|DRUG|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
214643634|NCT02037659|PROCEDURE|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
214643635|NCT04693962|DIAGNOSTIC_TEST|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
214643636|NCT05309863|BEHAVIORAL|Lifestyle management|Increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
214643637|NCT02447848|DRUG|sufentanil sublingual 30 mcg tablet|
214643638|NCT03598387|OTHER|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~* The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~* The minimal target weekly Kt/V is 2.1-3.5/W."
214643639|NCT03598387|OTHER|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
214643640|NCT03302273|OTHER|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
214643641|NCT05562154|PROCEDURE|Total Ankle Replacement|Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
214643642|NCT01332539|OTHER|no intervention|non-interventional study
214727981|NCT04510155|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
214727982|NCT00225667|DRUG|Irbesartan|
214793936|NCT06234800|PROCEDURE|Removal of failed dental implants|Removal (with various techniques) of failed dental implants.
214793937|NCT03741413|OTHER|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
214643643|NCT01501058|BEHAVIORAL|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
214643644|NCT01501058|BEHAVIORAL|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
214643645|NCT01505998|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
214643646|NCT04199325|DIETARY_SUPPLEMENT|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
214643647|NCT04199325|DRUG|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
214643648|NCT05949229|DRUG|Duloxetine 60 MG|Patients will recieve 2-hour preoperative duloxetine
214643649|NCT00326365|DRUG|Kali bichromicum 10-60 (C30)|
214643650|NCT03219866|DEVICE|Nebulizers|Patients treated and discharged on nebulized bronchodilators
214643651|NCT03219866|DEVICE|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
214643652|NCT03219866|DRUG|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
214643653|NCT03219866|DRUG|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
214643654|NCT03219866|DRUG|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
214643655|NCT03219866|DRUG|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
214643656|NCT03219866|DRUG|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
214643657|NCT04345445|DRUG|Tocilizumab|IV infusion
214727983|NCT06442085|OTHER|Teaching of trauma resuscitation by using virtual reality simulation|"The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator."
214727984|NCT06442085|OTHER|Teaching of trauma resuscitation by using mannequin based simulation|Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
214643658|NCT04345445|DRUG|Methylprednisolone|IV infusion
214643659|NCT04642014|BIOLOGICAL|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
214643660|NCT03834532|OTHER|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
214643661|NCT03834532|OTHER|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
214643662|NCT03509519|OTHER|NMES-Millicurrent|Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
214643663|NCT01796405|DRUG|Clofarabine|
214643664|NCT00578305|BIOLOGICAL|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
214643665|NCT00578305|DRUG|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
214643666|NCT00578305|DRUG|Methylprednisolone|
214643667|NCT00578305|DRUG|Methotrexate|
214643668|NCT00578305|DRUG|Folic acid or folate|
214643669|NCT03682497|DRUG|AZD9977|AZD9977 capsules taken orally for 28 days.
214643670|NCT03682497|DRUG|Spironolactone|Spironolactone tablets taken orally for 28 days.
214643671|NCT00129155|DRUG|treosulfan|
214643672|NCT05081284|DEVICE|Volume-stable collagen matrix Geistlich Fibro-Gide®|"After tooth extraction and implant insertion the Test group will receive a soft tissue augmentation on the buccal side oh the implant. an envelop flap will be raised and a volume-stable collagen graft will be stabilized with sutures.~Control group will not receive soft tissue augmentation."
214643673|NCT02613728|BEHAVIORAL|Accelerated Recovery Plan|
214643674|NCT02613728|BEHAVIORAL|Early Discharge|
214643675|NCT02613728|OTHER|Telemedicine|
214643676|NCT02613728|BEHAVIORAL|Standard Enhanced Care|
214643677|NCT06902896|BIOLOGICAL|FAP immunosuppressive CAR-DC|Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion
214643678|NCT05007353|BEHAVIORAL|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
214643679|NCT05007353|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
214643680|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
214643681|NCT06357832|DEVICE|Brainsway Deep TMS System|The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.
214643682|NCT05448326|OTHER|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
214643683|NCT05448326|OTHER|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
214643684|NCT05448326|BIOLOGICAL|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
214643685|NCT06909318|BEHAVIORAL|Asthma Education - Animated Video|"This intervention consists of a 7-minute and 39-second animated video titled Living with Asthma, specifically designed for children aged 7 to 11. The video features two characters, Mert and Robo, who explain asthma, its symptoms, triggers, and correct inhaler techniques in a child-friendly manner. The content is based on the latest GINA (2020) and NHLBI (2020) guidelines. The video is first watched in the clinic setting using a tablet device and then shared with parents via WhatsApp, email, or CD for home viewing. Parents are asked to watch the video with their child at least twice per week for two months and record viewing frequency using a structured observation form. This visual and engaging format distinguishes the intervention from conventional text-based education."
214643686|NCT06909318|BEHAVIORAL|Booklet Group|"This intervention involves the distribution of a 12-page, full-color, illustrated educational booklet titled Living with Asthma, developed for children aged 7 to 11. The booklet covers topics such as asthma symptoms, triggers, medication use, and device techniques using simple language and visual aids. Its content was developed in line with GINA (2020) and National Heart, Lung, and Blood Institute (2020) recommendations. During the initial clinic visit, children and parents are introduced to the booklet and instructed to review it together at least twice per week over two months. Parents are also asked to log reading sessions using a structured observation form. This printed, interactive material offers a visually supported, age-appropriate alternative to standard asthma education methods."
214727985|NCT02763267|OTHER|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
214643687|NCT06908005|OTHER|CT radiomic analysis|Radiomic features of tumor tissue
214643688|NCT06908005|OTHER|Fibrosis assessment|Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software (v1.5)
214643689|NCT06914752|DEVICE|TENS|transcutaneous electrical nerve stimulation
214643690|NCT02508805|DRUG|Neuromultivit|
214643691|NCT02508805|DRUG|Voltaren|
214643692|NCT02508805|DRUG|Sirdalud|
214643693|NCT06916520|DRUG|Prasugrel 5 mg|Prasugrel 5 mg once daily (monotherapy)
214643694|NCT06916520|DRUG|Dual Antiplatelet (DAPT) Therapy|Dual antiplatelet therapy according to guidelines
214643695|NCT06917495|DRUG|Rifampin|Rifampin: once daily, 600 mg.
214643696|NCT06917495|DRUG|Isoniazid|Isoniazid: once daily, 300 mg.
214643697|NCT06917495|DRUG|Rifapentine (RPT)|Rifapentine: once daily with dosage adjusted based on body weight: 750 mg for ≤41.2 kg, 900 mg for \>41.3-48.7 kg, 1050 mg for \> 48.8-56.2 kg, 1200 mg for ≥ 56.3 kg.
214643698|NCT06917495|DRUG|Moxifloxacin|Moxifloxacin: once daily, 400 mg.
214793938|NCT03741413|OTHER|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
214643699|NCT06917495|DRUG|Pyrazinamide|Pyrazinamide: once daily with dosage adjusted based on body weight: 1000 mg for \< 55 kg, 1500 mg for ≥ 55-75 kg, and 2000 mg for \>75 kg.
214643700|NCT06917495|DRUG|Ethambutol|Ethambutol: once daily with dosage adjusted based on body weight: 800 mg for \< 55 kg, 1200 mg for ≥ 55-75 kg, and 1600 mg for \> 75 kg.
214643701|NCT06915922|DEVICE|Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy|Nd:YAG laser treatment(s) for Vision Degrading Myodesopsia (clinically significant vitreous floaters) in eyes with vitreous opacities due to myopic vitreopathy and posterior vitreous detachment (PVD).
214643702|NCT06917339|DEVICE|NeuroStar Advanced TMS Therapy System|non-invasive brain stimulation device
214643703|NCT06917066|PROCEDURE|TAVR|TAVR procedure using Myval Transcatheter Heart Valve
214643704|NCT06915181|DRUG|Pyridostigmine|"Subjects will participate in a double-blind randomized controlled cross-over trial. All patients will receive the study drug and placebo. Subjects and investigators will remain blinded to whether the subject receives active treatment during the first or second treatment period.~Participation in the study will last 10 weeks, with 4 weeks on active treatment and 4 weeks on placebo, with a 2-week wash-out period in between."
214643705|NCT06915818|DEVICE|Ileo-colic and colo-colonic Anastomosis with Flexagon SFM and OTOLoc|This study will investigate two types of intervention: ileo-colic and colo-colonic anastomosis creation in subjects undergoing colon surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into a portion of either the ileum or the colon that are intended to be anastomosed. An OTOLoc device will be deployed into the ileum/colon wall to provide access for the deployment of a Flexagon SFM into the bowel. The process is repeated at an intended section of colon. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
214643706|NCT06910449|RADIATION|hemithoracic Volumetric Arc Radiotherapy post Pleural decortication|post operative delivery of hemithoracic Volumetric Arc Radiotherapy
214643707|NCT06917183|OTHER|Training using the Immersive Multi- player Virtual Surgical Safety Checklist Training Simulator|Training for performing surgical safety checklist for a period of 4 weeks.
214643708|NCT06914089|DEVICE|The BioMime is an ultra-thin strut (65 µm) SES that uses a cobalt-chromium platform with a unique hybrid design of open cells in the mid segment and closed cells at the edges|testing its safety and efficacy at long term follow up after primary percutaneous intervention
214643709|NCT06913062|PROCEDURE|conventional rehabilitation|For control group, the conventional rehabilitation protocol aimed to alleviate muscular and neuropathic pain in the short term, improve cervical mobility, reduce muscle tension, and increase muscle strength in the medium term, and promote a healthy lifestyle along with socio-professional reintegration in the long term. The principles included educating patients about their condition, respecting pain thresholds, and considering fatigue levels. Each patient received treatment for two months, with three sessions per week, each lasting about one hour. The protocol consisted of three phases: the first week focused on relaxation through massage and low-frequency electrotherapy; the second week introduced passive joint mobilizations; and from the third week, muscle stretching and strengthening exercises were incorporated. Additionally, functional exercises targeting daily activities and body awareness techniques are included to maintain proper posture.
214643710|NCT06913062|PROCEDURE|neural mobilisation|The protocol was structured around three main axes: treatment of interfaces (joint mobilizations and traction), direct treatment (using neurodynamic techniques), and indirect treatment (neural self-mobilization and lifestyle advice). The treatment included various stages for each ULNT technique. ULNT1 targeted the median nerve and involved shoulder abduction, elbow extension, and head inclination. ULNT2 focused on scapular depression and targeted cervical roots. ULNT3 emphasized radial nerve tension with internal rotation of the shoulder, while ULNT4 addressed ulnar nerve tension through elbow flexion and shoulder abduction. Each technique was executed with specific movements, maintained for 20 to 30 seconds, and repeated 15 times, followed by gentle scapular mobilizations until pain resolution.
214643711|NCT06916676|DEVICE|Low-Dose High-Intensity Laser Therapy (10 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 10 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
214643712|NCT06916676|DEVICE|Medium-Dose High-Intensity Laser Therapy (15 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 15 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
214727986|NCT04193605|BEHAVIORAL|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
214727987|NCT02144090|DEVICE|Fractional flow reserve measurement|Fractional flow reserve measurement
214727988|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
214727989|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
214793939|NCT03741413|OTHER|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
214727990|NCT02416765|OTHER|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
214727991|NCT02416765|DRUG|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
214727992|NCT02416765|DRUG|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
214727993|NCT02416765|OTHER|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
214727994|NCT03262064|COMBINATION_PRODUCT|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
214727995|NCT04765657|DRUG|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
214727996|NCT04765657|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
214727997|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~\+ 3 extra exercise sessions led by a caregiver (+Care)"
214727998|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
214727999|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
214728000|NCT05452187|DRUG|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
214728001|NCT05452187|DRUG|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
214728002|NCT05452187|OTHER|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
214728003|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
214728004|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
214728005|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
214728006|NCT04443257|OTHER|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
214728007|NCT05129124|DEVICE|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
214728008|NCT05129124|DEVICE|Commercially available Ultra for Astigmatism Contact Lenses|Commercially available Ultra for Astigmatism Contact Lenses at different fittings
214728009|NCT04744883|OTHER|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
214728010|NCT04744883|DRUG|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
214728011|NCT04744883|DRUG|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
214793940|NCT03879213|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
214643713|NCT06916676|DEVICE|High-Dose High-Intensity Laser Therapy (20 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 20 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
214643714|NCT06916676|DEVICE|Sham High-Intensity Laser Therapy|Sham procedure mimicking active HILT using the same Nd:YAG laser device (BTL-6000). Same setup, patient positioning, scanning technique over identical zones, and session duration/frequency (3x/week, 4 weeks, 15-20 min). Device powered on with visual/auditory cues active, but no laser energy emitted. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
214643715|NCT06915948|PROCEDURE|Macular Hole Surgery|Pars Plana Vitrectomy with ILM peeling with silicone oil tamponade
214643716|NCT00684957|DRUG|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
214643717|NCT00684957|DRUG|Recombinant Human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
214643718|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
214643719|NCT03576417|DRUG|Cisplatin|Intravenous
214643720|NCT03576417|DRUG|Nivolumab|Intravenous
214643721|NCT03576417|RADIATION|RT|IMRT 66 Gy / 6.5 weeks
214643722|NCT05847322|BIOLOGICAL|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
214643723|NCT05847322|DRUG|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
214643724|NCT03793062|OTHER|No Interventions|Not applicable - No Interventions
214643725|NCT03842696|DRUG|Vorinostat|"* HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
214643726|NCT03842696|PROCEDURE|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
214643727|NCT03842696|DRUG|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
214643728|NCT03842696|DRUG|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
214643729|NCT03842696|DRUG|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
214643730|NCT03842696|DRUG|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
214643731|NCT03099434|BEHAVIORAL|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
214643732|NCT03099434|BEHAVIORAL|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
214643733|NCT05942144|OTHER|Exercise-snacks program|"Subjects in the exercise-snacks group will perform 4 exercise-snacks sessions per working day for 4 weeks. These sessions will consist of 80 one-to-one walks to be completed as quickly as possible. They will also receive information about their attitudes to physical activity."
214793941|NCT03879213|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
214793942|NCT03150251|OTHER|Cereal - oats|Consumption of one cereal in the beginning of each visit
214793943|NCT03150251|OTHER|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
214793944|NCT01502345|BIOLOGICAL|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
214793945|NCT06324136|DIAGNOSTIC_TEST|Implementation of the diagnostic algorithm|Patients will be selected based on specific clinical criteria and referred to the tertiary center for genetic testing. All selected patients will undergo genetic testing by whole-exome sequencing (WES), followed by in silico analysis for an extended panel of genes associated with kidney diseases. The results of genetic testing will be evaluated by a multidisciplinary team of experts to establish conclusive diagnosis.
214643734|NCT06960694|DRUG|L-carnitine|This group will be treated with tablet L-carnitine 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
214643735|NCT06960694|DRUG|Placebo|This group will be treated with tablet Placebo 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
214643736|NCT03196180|DRUG|Imiquimod|Given intravaginally
214643737|NCT03196180|DRUG|Topical Fluorouracil|Given intravaginally
214643738|NCT04439175|DRUG|Taselisib|Given PO
214643739|NCT04654728|PROCEDURE|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
214643742|NCT00152867|DRUG|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
214643743|NCT05246332|DEVICE|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
214643744|NCT06312332|BEHAVIORAL|Pulmonary Embolism (PE) Care in Emergency Department (ED)|Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
214643745|NCT02262494|PROCEDURE|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
214643746|NCT02262494|PROCEDURE|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
214643747|NCT02262494|PROCEDURE|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
214643748|NCT00003267|PROCEDURE|infection prophylaxis and management|
214643749|NCT00003267|PROCEDURE|management of therapy complications|
214643750|NCT00003267|PROCEDURE|surgical procedure|
214643751|NCT06467812|DIETARY_SUPPLEMENT|Salt Tablets|Three doses of 4 Salt Tablets (1gm) will be taken with 400mL of water on day 2 (1200ml total) between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm.
214643752|NCT06467812|DIETARY_SUPPLEMENT|Electrolyte Solution|"Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day.~The ingredients are included below for the two flavors offered.~Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole).~Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA."
214643753|NCT05197231|PROCEDURE|Resisted knee extension exercise|Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
214643754|NCT05197231|DRUG|IV amino acids|IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
214643755|NCT01138956|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
214643756|NCT01138956|DRUG|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
214643757|NCT01504282|DRUG|mitomycin-C|
214643758|NCT01504282|DRUG|Placebo|balanced salt solution (BSS)
214643759|NCT00939198|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
214643760|NCT03050983|DEVICE|IPI|Enable the IPI algorithm and IPI alarm algorithm
214643761|NCT05006014|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
214643762|NCT04864873|DIAGNOSTIC_TEST|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
214643763|NCT04864873|DIAGNOSTIC_TEST|Standard microbiological diagnostic pathway|See previous.
214643764|NCT05620355|DRUG|BG2109|BG2109 100mg film coated tablet for oral administration once daily.
214643765|NCT05620355|DRUG|Placebo for BG2109|Placebo for BG2109 100mg tablet for oral administration once daily.
214643766|NCT05620355|DRUG|Placebo for add-back therapy|Placebo for add-back therapy tablet for oral administration once daily.
214643767|NCT05620355|DRUG|Add-back therapy|Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.
214793946|NCT00675649|BIOLOGICAL|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
214793947|NCT00675649|BIOLOGICAL|placebo|placebo sc injection every 4 weeks from week 0 to week 20
214793948|NCT02565420|OTHER|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
214643768|NCT02363478|DRUG|buspirone|buspirone 10 mg X2 for 4 weeks
214643769|NCT06103747|DRUG|Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of test drug
214643770|NCT06103747|DRUG|Galvumet® Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of reference drug
214643771|NCT00953693|PROCEDURE|Biopsy|Skin biopsy
214643772|NCT01020760|BEHAVIORAL|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
214643773|NCT00768898|OTHER|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
214643774|NCT03597165|OTHER|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
214643775|NCT03597165|OTHER|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
214643776|NCT01436721|DEVICE|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
214643777|NCT06107556|DIAGNOSTIC_TEST|Gait analysis|3D gait analysis with electromyographic measurements
214643778|NCT00008112|DRUG|cisplatin|
214643779|NCT00008112|PROCEDURE|hyperthermia treatment|
214643780|NCT00008112|RADIATION|brachytherapy|
214643781|NCT00008112|RADIATION|radiation therapy|
214643782|NCT06140979|BEHAVIORAL|Playing the game|The intervention is based on a parkour game in which the player runs forward as a cartoon character, avoiding obstacles in front of him/her while collecting gold coins and various props. In this process, players need to stay focused and operate in time to avoid obstacles or collect rewards, and as time goes on, the difficulty of the game increases until eventually they cannot avoid obstacles. As time goes on, the difficulty of the game will increase until the end of the game when you can't avoid the obstacles.
214643783|NCT06140979|BEHAVIORAL|Watching the gameplay video|"The intervention consists of a 30-minute non-therapeutic video of a parkour game, which is paused every 10 minutes and requires the patient to click continue until the end of the video. No other action is required."
214643784|NCT03262363|COMBINATION_PRODUCT|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
214643785|NCT03262363|COMBINATION_PRODUCT|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
214643786|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
214643787|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
214643788|NCT00576238|DRUG|urea|Topical application twice daily for up to 6 months
214793949|NCT02565420|OTHER|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
214793950|NCT01368523|DRUG|nilotinib|
214728012|NCT04744883|BEHAVIORAL|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
214728013|NCT05896423|BEHAVIORAL|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
214728014|NCT03482362|DRUG|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
214728015|NCT04428788|DRUG|CC-94676|Specified dose on specified days
214728016|NCT04428788|DRUG|CC1083611|Specified dose on specified days
214728017|NCT04428788|DRUG|CC1083610|Specified dose on specified days
214728018|NCT04574869|DRUG|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
214728019|NCT04574869|DRUG|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
214728020|NCT04574869|DRUG|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
214728021|NCT04574869|DRUG|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
214728022|NCT04574869|DRUG|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
214728023|NCT04692896|DRUG|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
214728024|NCT00766181|BEHAVIORAL|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
214728025|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
214728026|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
214728027|NCT04712643|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
214643789|NCT02554929|BEHAVIORAL|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
214643790|NCT02554929|BEHAVIORAL|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
214643791|NCT03623724|BEHAVIORAL|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
214643792|NCT03623724|OTHER|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
214643793|NCT00001398|DRUG|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
214643794|NCT05836649|BEHAVIORAL|Oculus Go headset without active intervention|VR software with non-interactive content.
214643795|NCT05836649|BEHAVIORAL|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
214643796|NCT00546364|DRUG|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
214643797|NCT00546364|DRUG|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
214643798|NCT00546364|DRUG|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
214643799|NCT01608425|PROCEDURE|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
214643800|NCT02077790|DEVICE|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
214728028|NCT04712643|DRUG|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
214728029|NCT04712643|DEVICE|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
214728030|NCT05554055|BIOLOGICAL|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
214728031|NCT04369222|OTHER|Observational|Maternal consumption of mild analgesics
214643801|NCT00667576|DRUG|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
214643802|NCT00667576|DRUG|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
214643803|NCT06224114|DEVICE|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
214643804|NCT06224114|DEVICE|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
214643805|NCT06305741|OTHER|Managing Anxiety from Cancer (MAC)|"The intervention, MAC, is a seven-session (45-60 minutes per session) psychotherapy intervention delivered via videoconference.~and/or telephone by licensed social workers"
214643806|NCT01390389|DRUG|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
214643807|NCT04110041|BEHAVIORAL|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
214643808|NCT02897895|BIOLOGICAL|levels of CNI in whole blood|
214643809|NCT02897895|BIOLOGICAL|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
214643810|NCT02545725|OTHER|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
214643811|NCT00416338|DEVICE|film dressing by adhesive|
214643812|NCT01160939|OTHER|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
214643813|NCT06548893|OTHER|Group acceptance and commitment therapy (ACT)|Group psychotherapy based on ACT + EPR
214643814|NCT02669472|OTHER|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F\&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
214643815|NCT02669472|BEHAVIORAL|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F\&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F\&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
214643816|NCT02669472|BEHAVIORAL|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
214643817|NCT02641509|DEVICE|NBI during polypectomy|NBI to perform the polipectomy
214643818|NCT02641509|DEVICE|no NBI during polypectomy|no NBI to perform the polypectomy
214643819|NCT05077696|OTHER|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
214728032|NCT05740293|PROCEDURE|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
214728033|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
214728034|NCT00561301|DRUG|GemDOx|gemcitabine oxliplatin
214728035|NCT01578525|OTHER|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
214728036|NCT05211492|OTHER|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
214728037|NCT02986165|DIETARY_SUPPLEMENT|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
214728038|NCT02986165|DIETARY_SUPPLEMENT|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
214728039|NCT02986165|DIETARY_SUPPLEMENT|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
214728040|NCT06186622|DRUG|Orforglipron|Administered orally.
214728041|NCT06186622|DRUG|Simvastatin|Administered orally.
214728042|NCT06186622|DRUG|Digoxin|Administered orally.
214728043|NCT06186622|DRUG|Rosuvastatin|Administered orally.
214728044|NCT06186622|DRUG|Acetaminophen|Administered orally.
214728045|NCT06186622|DRUG|Midazolam|Administered orally.
214728046|NCT06186622|DRUG|Sodium Bicarbonate|Administered orally.
214728047|NCT05668325|OTHER|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
214728048|NCT05668325|OTHER|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
214728049|NCT05848336|BEHAVIORAL|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
214728050|NCT02985489|DIETARY_SUPPLEMENT|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
214728051|NCT05089188|OTHER|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
214728052|NCT06590207|DRUG|plasma rich with WNV neutralizing antibodies|200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
214728053|NCT06590207|DRUG|Saline|Placebo
214728054|NCT05267938|DRUG|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
214728055|NCT05267938|DRUG|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
214728056|NCT02762045|BIOLOGICAL|Ad5-gag|Ad5-gag is used as vaccine in all arms.
214643820|NCT00624455|DRUG|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
214728057|NCT02762045|BIOLOGICAL|Placebo|Preservation Solution is used as control in all arms.
214728058|NCT05401604|DIETARY_SUPPLEMENT|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
214728059|NCT05401604|DIETARY_SUPPLEMENT|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
214728060|NCT00554853|DRUG|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
214643821|NCT00624455|DRUG|Placebo|Placebo
214643822|NCT02602730|BEHAVIORAL|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
214728061|NCT00554853|DRUG|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
214728062|NCT00948285|PROCEDURE|MRI|magnetic resonance imaging (MRI)
214728063|NCT05247060|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
214728064|NCT02128919|DEVICE|tDCS|Transcranial Direct Current Stimulation
214643823|NCT02602730|BEHAVIORAL|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
214643824|NCT00292500|DEVICE|Automated distal anastomotic device|CABG
214728065|NCT03906201|DIETARY_SUPPLEMENT|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
214728066|NCT03906201|OTHER|Placebo|no pharmacologic effect
214728067|NCT01556789|BIOLOGICAL|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
214728068|NCT03966092|PROCEDURE|Quadratus lumborum block|"* Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
214728069|NCT03660280|DIETARY_SUPPLEMENT|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
214728070|NCT03660280|OTHER|Placebo|Placebo
214728071|NCT02681640|OTHER|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
214728072|NCT02681640|DEVICE|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
214728073|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214728074|NCT03812783|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
214728075|NCT03812783|DRUG|Sorafenib|administration of Sorafenib
214728076|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214728077|NCT03812783|DRUG|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
214728078|NCT01116804|PROCEDURE|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
214728079|NCT01116804|PROCEDURE|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
214728080|NCT01116804|PROCEDURE|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
214728081|NCT01116804|PROCEDURE|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
214728082|NCT02325440|DRUG|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
214728083|NCT02325440|DRUG|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
214728084|NCT00674024|DRUG|Pazopanib|
214728085|NCT00674024|DRUG|Pazopanib (GW786034)(GW786034)|
214728086|NCT02384785|DEVICE|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
214793951|NCT05789277|OTHER|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging"
214728087|NCT02148952|BEHAVIORAL|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
214728088|NCT01160224|DRUG|GW766944|Drug: GW766944 (Active Drug Treatment)
214728089|NCT01160224|OTHER|Placebo|This is placebo to match.
214728090|NCT01600105|DRUG|Perfusion MRI|1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
214728091|NCT00407641|DRUG|Tinzaparin administration|Patients will receive tinzaparin during the HD session
214728092|NCT00407641|DRUG|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
214728093|NCT04629365|OTHER|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
214728094|NCT04629365|OTHER|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
214728095|NCT04708340|DRUG|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
214728096|NCT04708340|DRUG|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
214728097|NCT02021149|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
214728098|NCT02021149|BEHAVIORAL|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
214728099|NCT02021149|OTHER|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
214728100|NCT02021149|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
214728101|NCT01699776|DRUG|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
214728102|NCT01699776|DRUG|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
214728103|NCT04343391|BEHAVIORAL|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
214728104|NCT04343391|DRUG|Pharmacological treatment|Treatment as usual in PC
214728105|NCT02891252|PROCEDURE|outpatient procedure|
214728106|NCT00197340|DRUG|Epidural ropivacaine|
214728107|NCT05148689|DRUG|Oxymetazoline hydrochloride Cream, 1%|Cream
214728108|NCT05148689|DRUG|Rhofade™ (oxymetazoline) cream, 1%|cream
214728109|NCT05148689|DRUG|Placebo|cream
214728110|NCT02233608|BEHAVIORAL|Advanced Pelvic Floor Muscle Exercise (APFX)|
214728111|NCT01066650|DEVICE|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
214728112|NCT01066650|DEVICE|Xience V (Everolimus-eluting stent)|Drug eluting stent
214728113|NCT05689749|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
214728114|NCT04007367|DRUG|SAGE-217|SAGE-217 capsule
214728115|NCT04007367|DRUG|Placebo|SAGE-217 matching placebo capsule
214728116|NCT01561040|DIETARY_SUPPLEMENT|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
214728117|NCT03774836|DRUG|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
214728118|NCT03774836|DRUG|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
214728119|NCT03774836|OTHER|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
214728120|NCT03647462|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
214728121|NCT02056756|DRUG|Carfilzomib|
214728122|NCT03795636|OTHER|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
214728123|NCT03795636|OTHER|NaOCl (COLTENE®)|Sodium hypochlorite
214728124|NCT01207804|DEVICE|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
214728125|NCT00474006|DRUG|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
214728126|NCT01764022|DRUG|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
214728127|NCT01764022|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
214728128|NCT00862524|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
214728129|NCT00862524|DRUG|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
214728130|NCT04722380|PROCEDURE|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
214643825|NCT02098954|DRUG|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
214728131|NCT00291746|DRUG|Esomeprazole|
214728132|NCT00291746|PROCEDURE|Bravo technique|
214728133|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
214728134|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
214728135|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
214728136|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
214728137|NCT02092506|DRUG|10 day triple therapy|10 day triple therapy
214643826|NCT03750851|OTHER|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
214643827|NCT03750851|OTHER|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
214728138|NCT02092506|DRUG|10 day sequential therapy|10 day sequential therapy
214728139|NCT02092506|DRUG|10 day concomitant therapy|10 day concomitant therapy
214728140|NCT04247529|OTHER|Exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
214728141|NCT04247529|OTHER|No exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
214728142|NCT00626340|DRUG|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
214728143|NCT00626340|DRUG|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
214728144|NCT00626340|DRUG|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
214728145|NCT00626340|DRUG|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
214728146|NCT02245880|DEVICE|Glidescope|videolaryngoscope
214728147|NCT02245880|DEVICE|ILMA|handling of the device till the optimal ventilation achieved
214728148|NCT01899768|DRUG|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
214728149|NCT01899768|DRUG|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
214728150|NCT04028024|DRUG|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
214728151|NCT01728649|OTHER|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
214728152|NCT05355324|OTHER|no intervention|no intervention
214728153|NCT04933253|PROCEDURE|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
214728154|NCT00432640|PROCEDURE|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
214728155|NCT00432640|PROCEDURE|Surgical staging|Surgical staging
214728156|NCT04626570|OTHER|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
214728157|NCT02158962|BEHAVIORAL|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
214728158|NCT02921906|OTHER|High protein meal|Breakfast with high protein / low carbohydrate content
214728159|NCT02921906|OTHER|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
214728160|NCT02921906|DRUG|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
214643828|NCT03750851|OTHER|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
214643829|NCT03750851|OTHER|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
214643830|NCT04009941|DRUG|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
214643831|NCT00599807|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
214643832|NCT02256930|DRUG|M518101|
214643833|NCT02256930|DRUG|M518101 Vehicle|
214728161|NCT02921906|OTHER|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
214728162|NCT04142840|DRUG|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
214728163|NCT04142840|DRUG|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
214728164|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
214728165|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
214643834|NCT02256930|OTHER|Sodium lauryl sulfate|
214643835|NCT02256930|OTHER|Saline|
214643836|NCT00962026|DRUG|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
214643837|NCT05147480|OTHER|internet-based mother-baby yoga|Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
214643838|NCT04439955|DRUG|CBD|300 mg CBD
214643839|NCT00483886|DRUG|Prucalopride|2 mg o.d.
214643840|NCT00483886|OTHER|Placebo|Placebo o.d.
214643841|NCT00483886|DRUG|Prucalopride|4 mg o.d.
214728166|NCT04098016|BEHAVIORAL|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
214793952|NCT05789277|OTHER|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
214643842|NCT02917967|DRUG|Botulinum toxin injection|"1. BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~2. Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
214643843|NCT03018886|OTHER|GHRH plus arginine test|One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
214643844|NCT00975247|OTHER|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
214643845|NCT05756725|OTHER|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
214643846|NCT04861337|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
214643847|NCT04861337|DRUG|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
214643848|NCT03793400|DRUG|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
214643849|NCT01344967|DRUG|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
214728167|NCT01245127|DRUG|Ilaris|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
214728168|NCT04043416|OTHER|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
214728169|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
214728170|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
214728171|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
214728172|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
214728173|NCT03616470|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
214728174|NCT03616470|DRUG|Placebo|Saline, 0.9% Sodium Chloride
214728175|NCT01832844|PROCEDURE|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
214728176|NCT01832844|PROCEDURE|"Group  without scan "|
214728177|NCT03827967|BIOLOGICAL|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
214728178|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
214728179|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
214728180|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
214728181|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
214728182|NCT01606332|PROCEDURE|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
214728183|NCT03808844|DRUG|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
214728184|NCT03808844|DRUG|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
214728185|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
214728186|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
214728187|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
214728188|NCT05575583|DEVICE|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
214728189|NCT05575583|DEVICE|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
214728190|NCT00822640|DEVICE|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
214728191|NCT01599949|DRUG|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
214728192|NCT04739995|DRUG|Low-dose naltrexone|4.5 mg LDN/day for 1 year
214728193|NCT01869452|BEHAVIORAL|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
214728194|NCT01541540|BEHAVIORAL|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
214728195|NCT01541540|BEHAVIORAL|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
214728196|NCT06313749|DEVICE|Minimally Invasive Micro Sclerostomy Device|During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
214728197|NCT03080701|BEHAVIORAL|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
214728198|NCT03080701|BEHAVIORAL|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
214728199|NCT02017067|PROCEDURE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
214728200|NCT03842761|DRUG|BI 685509|Tablet
214728201|NCT03842761|DRUG|Placebo|Tablet
214728202|NCT03930927|DRUG|Self Assembling peptide|enamel regeneration
214728203|NCT03930927|DRUG|remineralizing agent|enamel regeneration
214728204|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
214728205|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
214728206|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
214728207|NCT03887325|DRUG|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
214728208|NCT03887325|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
214728209|NCT06408987|PROCEDURE|arthroscopically assisted|Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
214728210|NCT06408987|PROCEDURE|open surgical reduction|Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
214728211|NCT04837690|PROCEDURE|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
214728212|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
214728213|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
214728214|NCT00676728|DRUG|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
214728215|NCT00865202|DRUG|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
214728216|NCT00865202|DRUG|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
214728217|NCT03531710|BIOLOGICAL|UB-311|Intramuscular injection
214728218|NCT03531710|DRUG|Placebo|Intramuscular injection
214728219|NCT03609710|DEVICE|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
214728220|NCT03609710|PROCEDURE|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
214728221|NCT03609710|PROCEDURE|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
214728222|NCT03609710|DEVICE|Robotic surgery|Robotic low anterior resection for rectal cancer
214728223|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
214728224|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
214728225|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
214728226|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
214728227|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
214728228|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
214728229|NCT04743869|DEVICE|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
214728230|NCT04743869|DEVICE|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
214728231|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
214728232|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
214728233|NCT05987514|DIAGNOSTIC_TEST|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
214728234|NCT05762965|DIETARY_SUPPLEMENT|GOS 1|1 sachet each morning
214728235|NCT05762965|DIETARY_SUPPLEMENT|GOS 2|1 sachet each morning
214728236|NCT05580237|PROCEDURE|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
214728237|NCT03813199|DRUG|ABX464 50mg|ABX464 is a new anti-inflammatory drug
214728238|NCT03813199|DRUG|Matching Placebo|placebo matching with ABX464
214728239|NCT03813199|DRUG|ABX464 100mg|ABX464 is a new anti-inflammatory drug
214728240|NCT03813199|DRUG|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
214728241|NCT02044315|DEVICE|ICD programming|
214728242|NCT02950311|DRUG|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
214728243|NCT02950311|OTHER|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
214728244|NCT01191138|PROCEDURE|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
214728245|NCT01191138|PROCEDURE|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
214728246|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
214728247|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
214728248|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
214728249|NCT03961139|OTHER|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
214728250|NCT02269982|DEVICE|AR-v7 assays|
214728251|NCT03067064|OTHER|no intervention|Clinical examination
214728252|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
214728253|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
214728254|NCT04630444|DRUG|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
214728255|NCT02237144|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
214728256|NCT02237144|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
214728257|NCT02237144|OTHER|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
214728258|NCT02237144|BEHAVIORAL|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
214728259|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
214728260|NCT02022891|BEHAVIORAL|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
214728261|NCT04265092|DRUG|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
214728262|NCT04281108|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
214728263|NCT04281108|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet.
214728264|NCT04281108|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
214728265|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
214728266|NCT04407286|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3 capsules
214728267|NCT00744991|DRUG|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
214728268|NCT03644589|BIOLOGICAL|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
214728269|NCT03644589|DRUG|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
214728270|NCT01487863|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
214728271|NCT01487863|DRUG|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
214728272|NCT01718366|DRUG|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
214728273|NCT06177223|BEHAVIORAL|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
214728274|NCT06059274|OTHER|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
214728275|NCT05249803|COMBINATION_PRODUCT|Patients with COVID-19 Pneumonia|Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
214728276|NCT00000895|DRUG|Nelfinavir mesylate|
214728277|NCT00000895|DRUG|Nevirapine|
214728278|NCT00000895|DRUG|Azithromycin|
214728279|NCT02251028|BEHAVIORAL|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
214728280|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
214728281|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
214728282|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
214728283|NCT02139280|DRUG|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
214728284|NCT02044367|DRUG|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
214728285|NCT02044367|DRUG|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
214728286|NCT02044367|DRUG|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
214728287|NCT00899366|GENETIC|microarray analysis|
214728288|NCT00899366|GENETIC|mutation analysis|
214728289|NCT00899366|OTHER|immunologic technique|
214728290|NCT05257915|DRUG|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
214728291|NCT00491751|DRUG|atorvastatin|atorvastatin 40 or 80 mg/day
214728292|NCT00491751|DRUG|ascorbic acid|ascorbic acid 500 mg/day
214728293|NCT00491751|DRUG|Placebo|matching placebo
214728294|NCT02291328|OTHER|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
214728295|NCT02291328|OTHER|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
214728296|NCT06949280|DIETARY_SUPPLEMENT|Peanut Snack Experimental|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
214728297|NCT06949280|DIETARY_SUPPLEMENT|Nut-free Snack|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
214728298|NCT01395966|DRUG|DF289|Ear drops
214728299|NCT01395966|DRUG|DF277|Ear drops
214728300|NCT01395966|DRUG|DF289 plus DF277|Ear drops
214728301|NCT03012282|DIAGNOSTIC_TEST|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
214728302|NCT00422903|DRUG|lapatinib|1500 mg administered orally daily
214728303|NCT00422903|DRUG|letrozole|2.5 mg administered orally daily
214728304|NCT00422903|OTHER|placebo|1500 mg administered orally daily
214728305|NCT06394076|DEVICE|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
214728306|NCT05965531|DRUG|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
214728307|NCT05965531|RADIATION|intensity-modulated radiotherapy|intensity-modulated radiotherapy
214643850|NCT03720899|DRUG|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
214643851|NCT03720899|DRUG|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
214728308|NCT01302691|DRUG|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
214728309|NCT01302691|DRUG|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
214728310|NCT01302691|DRUG|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
214728311|NCT01302691|DRUG|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
214728312|NCT01302691|DRUG|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
214728313|NCT01302691|DRUG|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
214728314|NCT06158282|OTHER|Voluntary apnoea|Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
214728315|NCT04309357|DRUG|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
214728316|NCT04858503|OTHER|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
214643852|NCT06265844|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214728317|NCT03582969|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
214728318|NCT03582969|OTHER|Placebo|Placebo capsules
214728319|NCT01462968|DEVICE|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
214728320|NCT04720339|GENETIC|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
214728321|NCT00428883|DRUG|N-acetylcysteine (NAC)|
214728322|NCT04315597|DRUG|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
214728323|NCT04315597|DRUG|Placebo|1 x daily, 1 tablet, 900 mg
214728324|NCT05022043|DIAGNOSTIC_TEST|Serum Presepsin|Estimation of Serum Presepsin at time of admission
214728325|NCT05765552|OTHER|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
214728326|NCT05765552|OTHER|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
214728327|NCT05698108|DEVICE|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
214728328|NCT05698108|OTHER|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
214643853|NCT06265844|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214643854|NCT06265844|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214643855|NCT03725410|DEVICE|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
214643856|NCT03725410|DEVICE|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
214643857|NCT00748748|BIOLOGICAL|Culturelle|10\^10 Lactobacillus rhamnosus GG per capsule
214643858|NCT01886521|PROCEDURE|Lumbar drain|
214643859|NCT01886521|PROCEDURE|Ventricular drain|
214643860|NCT05073055|PROCEDURE|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
214643861|NCT02408692|DRUG|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
214643862|NCT02408692|DRUG|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
214643863|NCT03569202|DEVICE|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
214643864|NCT03569202|DEVICE|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
214643865|NCT00727363|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
214643866|NCT00727363|DIETARY_SUPPLEMENT|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
214643867|NCT01283932|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
214643868|NCT01145937|PROCEDURE|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
214643869|NCT01145937|PROCEDURE|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
214643870|NCT00420511|DRUG|Sitagliptin|sitagliptin 100 mg once a day
214643871|NCT00420511|DRUG|Placebo|placebo once a day
214643872|NCT00420511|DRUG|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
214643873|NCT02415712|DRUG|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
214643874|NCT01668654|DRUG|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
214643875|NCT01526668|BEHAVIORAL|Follow-up strategy|Comparison of different follow-up strategies
214643876|NCT01526668|BEHAVIORAL|No contact after discharge|
214643877|NCT04557384|DRUG|Ramucirumab|Administered SC
214643878|NCT00454779|DRUG|Cisplatin|chemotherapy arm
214643879|NCT00454779|DRUG|Panitumumab|experimental arm
214643880|NCT00454779|DRUG|Docetaxel|chemotherapy arm
214643881|NCT00454779|DRUG|Cisplatin|experimental arm
214643882|NCT00454779|DRUG|Docetaxel|experimental arm
214643883|NCT05590598|COMBINATION_PRODUCT|Azelastine + Mometazone, nasal spray|140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
214728329|NCT03423862|OTHER|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
214728330|NCT02324712|DEVICE|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
214728331|NCT02324712|DEVICE|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
214728332|NCT02561780|BEHAVIORAL|Curriculum|A mental health educational resource delivered in the classroom by trained educators
214728333|NCT02561780|BEHAVIORAL|eLearning Follow-up|An online mental health education module that students access individually
214728334|NCT00441480|DIETARY_SUPPLEMENT|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
214728335|NCT00441480|DIETARY_SUPPLEMENT|placebo|4 gr of corn oil
214728336|NCT02705222|PROCEDURE|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
214728337|NCT02705222|PROCEDURE|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
214728338|NCT02411513|DEVICE|CEFALY|
214728339|NCT03708757|OTHER|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
214728340|NCT03708757|OTHER|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
214728341|NCT03385434|DEVICE|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
214728342|NCT04833790|BEHAVIORAL|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
214728343|NCT04833790|BEHAVIORAL|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
214728344|NCT04833790|BEHAVIORAL|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
214728345|NCT04833790|BEHAVIORAL|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
214728346|NCT04833790|BEHAVIORAL|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
214728347|NCT02680106|DEVICE|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
214728348|NCT02680106|DEVICE|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
214728349|NCT06508398|DIAGNOSTIC_TEST|Microbiological Diagnostic Testing|"This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs."
214728350|NCT03681834|OTHER|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
214728351|NCT03623906|PROCEDURE|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
214728352|NCT03623906|PROCEDURE|Air insufflation colonoscopy|Room air insufflation colonoscopy
214728353|NCT01374191|DRUG|onabotulinum toxin type-A|1 injection of Btx-A
214728354|NCT01374191|OTHER|placebo|1 injection of saline solution
214728355|NCT01374191|DRUG|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
214728356|NCT05461157|DEVICE|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
214728357|NCT05461157|OTHER|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
214728358|NCT05783492|DRUG|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
214728359|NCT01637857|DIETARY_SUPPLEMENT|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
214728360|NCT01637857|DIETARY_SUPPLEMENT|oligoantigenic diet|oligoantigenic diet associated to life style counseling
214643884|NCT05590598|COMBINATION_PRODUCT|Momat Rhino Advance|140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
214643885|NCT01039857|BEHAVIORAL|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
214643886|NCT01039857|BEHAVIORAL|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
214643887|NCT00662844|DIETARY_SUPPLEMENT|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
214643888|NCT06098859|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia was started preoperatively and rest posoperative 48 hours
214643889|NCT06098859|PROCEDURE|Erector spinae plane block|Erector spinae plane block was applied preoperatively using local anesthetic
214643890|NCT02456350|DRUG|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
214643891|NCT02456350|DRUG|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
214643892|NCT02456350|BIOLOGICAL|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
214643893|NCT02617810|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
214643894|NCT02617810|DRUG|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
214643895|NCT02617810|DRUG|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
214643896|NCT02137408|DIETARY_SUPPLEMENT|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
214643897|NCT02137408|DRUG|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
214643898|NCT02397473|DRUG|Galcanezumab|Administered SC
214643899|NCT02397473|DRUG|Placebo|Administered SC
214643900|NCT00019760|DRUG|floxuridine|
214643901|NCT00019760|DRUG|leucovorin calcium|
214643902|NCT00019760|DRUG|melphalan|
214643903|NCT00827697|OTHER|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
214643904|NCT03256045|DRUG|Carfilzomib|Given IV
214643905|NCT03256045|OTHER|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
214643906|NCT03256045|DRUG|Dexamethasone|Given PO
214643907|NCT03256045|OTHER|Laboratory Biomarker Analysis|Correlative studies
214643908|NCT03256045|DRUG|Panobinostat|Given PO
214643909|NCT03047499|DRUG|Botulinum toxin type A|Botulinum toxin type-A injection
214643910|NCT01786317|DEVICE|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
214643911|NCT05207228|BEHAVIORAL|CBT4CBT|Cognitive behavioral treatment through the web CBT4CBT
214728361|NCT05896410|DEVICE|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
214728362|NCT04437810|BIOLOGICAL|Albumin|\- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
214728363|NCT04437810|OTHER|Standard Medical Treatment|standard medical therapy
214728364|NCT04836923|BEHAVIORAL|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
214728365|NCT04836923|BEHAVIORAL|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
214643912|NCT00769288|DRUG|2'-F-ara-deoxyuridine|Given IV
214643913|NCT00769288|OTHER|positron emission tomography|Correlative studies
214643914|NCT00769288|OTHER|laboratory biomarker analysis|Correlative studies
214643915|NCT00769288|OTHER|pharmacological study|Correlative studies
214643916|NCT00769288|OTHER|pharmacogenomic studies|Correlative studies
214643917|NCT01526109|BEHAVIORAL|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
214643918|NCT01526109|BEHAVIORAL|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
214643919|NCT01526109|BEHAVIORAL|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
214643920|NCT01491256|DRUG|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
214643921|NCT01491256|DRUG|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
214643922|NCT00138697|DRUG|IVIG-L|
214643923|NCT01131195|BIOLOGICAL|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
214643924|NCT01131195|BIOLOGICAL|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
214643925|NCT02750787|OTHER|Nutritional Study Product|Two 220 ml servings per day
214643926|NCT00049088|DRUG|docetaxel|Given IV
214643927|NCT00049088|BIOLOGICAL|bevacizumab|Given IV
214643928|NCT00049088|OTHER|laboratory biomarker analysis|Correlative studies
214643929|NCT00049088|OTHER|pharmacological study|Correlative studies
214643930|NCT00553046|OTHER|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
214728366|NCT00441012|BIOLOGICAL|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
214728367|NCT00441012|BIOLOGICAL|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
214728368|NCT00196807|BEHAVIORAL|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
214728369|NCT05768893|DEVICE|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
214728370|NCT05768893|DEVICE|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
214728371|NCT04737967|DRUG|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
214728372|NCT04737967|DRUG|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
214728373|NCT01953367|DRUG|Vantobra (tobramycin)|Inhalation
214728374|NCT01953367|DRUG|TOBI (tobramycin)|Inhalation
214728375|NCT02201472|DEVICE|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
214728376|NCT00003519|DRUG|cyclophosphamide|
214728377|NCT00003519|DRUG|docetaxel|
214728378|NCT00003519|DRUG|doxorubicin hydrochloride|
214728379|NCT02035241|DIETARY_SUPPLEMENT|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214728380|NCT02035241|DIETARY_SUPPLEMENT|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214728381|NCT02035241|DIETARY_SUPPLEMENT|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214728382|NCT02035241|DIETARY_SUPPLEMENT|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214728383|NCT02035241|DIETARY_SUPPLEMENT|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214643931|NCT02373111|DIETARY_SUPPLEMENT|Isoflavone|
214643932|NCT02373111|DIETARY_SUPPLEMENT|Astaxanthin|
214643933|NCT02373111|DIETARY_SUPPLEMENT|Placebo|
214643934|NCT03856255|DEVICE|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
214643935|NCT01207271|BEHAVIORAL|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
214643936|NCT01207271|BEHAVIORAL|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
214643937|NCT00929071|DEVICE|Evolence|Injectable collagen
214643938|NCT00929071|DEVICE|Lidocaine|admix anesthetic
214643939|NCT00929071|DRUG|topical anesthetic|
214643940|NCT02995304|DRUG|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
214643941|NCT02995304|DRUG|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
214643942|NCT02995304|DRUG|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
214643943|NCT03130790|DRUG|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
214728384|NCT02035241|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
214728385|NCT03674541|DRUG|Pyridostigmine Bromide|Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
214728386|NCT03674541|DRUG|Placebo|Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
214728387|NCT05482555|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
214728388|NCT05482555|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
214728389|NCT05579795|PROCEDURE|Detethering of the spinal cord|Release of the tethered spinal cord
214728390|NCT04072536|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
214728391|NCT04072536|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
214728392|NCT03870906|BEHAVIORAL|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
214728393|NCT03870906|BEHAVIORAL|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
214728394|NCT03870906|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
214643944|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
214643945|NCT03130790|DRUG|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
214643946|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
214643947|NCT04206878|DIAGNOSTIC_TEST|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
214643948|NCT01325103|PROCEDURE|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
214643949|NCT01793415|DRUG|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
214643950|NCT01793415|OTHER|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
214643951|NCT04845412|DIAGNOSTIC_TEST|Hearing screening tests|"Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device."
214643952|NCT03616431|DIAGNOSTIC_TEST|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
214643953|NCT03017560|BEHAVIORAL|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
214643954|NCT01757717|RADIATION|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
214643955|NCT03008395|BEHAVIORAL|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
214643956|NCT03008395|OTHER|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
214643957|NCT02597621|OTHER|no intervention|no intervention
214643958|NCT05301075|DRUG|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
214643959|NCT05254028|PROCEDURE|filiform needle|Manual acupuncture using filiform needles
214643960|NCT03612687|DEVICE|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
214643961|NCT03061266|BEHAVIORAL|E-health Education|E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.
214643962|NCT03061266|OTHER|Routine care|Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
214643963|NCT01361997|BIOLOGICAL|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
214643964|NCT01361997|BIOLOGICAL|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
214643965|NCT03426020|OTHER|Oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before induction
214643966|NCT03426020|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
214643967|NCT03426020|OTHER|Play game (PC fishing game)|Patients will be played a simple PC game (a fishing game) 20 minutes before induction
214643968|NCT02685917|PROCEDURE|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
214643969|NCT02685917|PROCEDURE|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
214643970|NCT05410782|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
214643971|NCT01521273|OTHER|Bean varieties|10 x 50 g/ arm
214643972|NCT04835285|DIAGNOSTIC_TEST|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
214643973|NCT01851408|DRUG|sorafenib tosylate|Given orally
214643974|NCT01851408|DRUG|temsirolimus|Given IV
214643975|NCT00927368|PROCEDURE|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
214643976|NCT00927368|PROCEDURE|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
214643977|NCT00927368|PROCEDURE|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
214643978|NCT01079481|DRUG|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
214643979|NCT02624492|DRUG|BI 836826|
214643980|NCT02624492|DRUG|GemOx|
214643981|NCT02624492|DRUG|Rituximab|
214643982|NCT02624492|DRUG|GemOx|
214643983|NCT00883675|DRUG|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
214643984|NCT03321448|DRUG|TMTP1-ICG|Detection of SLN
214643985|NCT03321448|DRUG|ICG|Detection of SLN
214643986|NCT06548763|DRUG|Topotecan|1.4mg/㎡, orally administered, d1-5
214643987|NCT06548763|DRUG|Toripalimab|240mg, intravenous drip, d1, q3w
214643988|NCT03333070|DIETARY_SUPPLEMENT|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
214643989|NCT03333070|OTHER|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
214643990|NCT04743557|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
214643991|NCT00841737|OTHER|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
214728395|NCT03870906|BIOLOGICAL|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
214728396|NCT05104749|DRUG|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
214728397|NCT05104749|OTHER|Placebo|Inert lactose pellets
214728398|NCT02980549|OTHER|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
214643992|NCT00841737|OTHER|Control Group|In the control group the depression is treated as usual with the conventional treatment.
214643993|NCT00364689|DRUG|Rifaximin|
214643994|NCT00364689|DRUG|Lactulose|
214643995|NCT00364689|OTHER|Placebo|
214643996|NCT04545905|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
214643997|NCT04553211|BEHAVIORAL|EPT|Expedited Partner Therapy (EPT) involves provision of empiric oral antibiotic therapy to the recent sexual partners of an individual diagnosed with gonorrhea and/or chlamydia infection.
214643998|NCT05611957|DRUG|LY3437943|Administered SC.
214643999|NCT01019018|DEVICE|subtenon block|subtenon block with stevens cannula
214644000|NCT01019018|DEVICE|subtenon block|subtenon block with Olive tip cannula cannula
214644001|NCT03909360|PROCEDURE|drainage tube|sub-hepatic drainage tube for laparoscopic cholecystectomy
214644002|NCT04075929|OTHER|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
214644003|NCT03429946|DRUG|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
214644004|NCT03429946|DRUG|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
214644005|NCT03429946|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
214644006|NCT03429946|OTHER|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
214644007|NCT01043757|BEHAVIORAL|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
214644008|NCT01750515|DEVICE|Acupuncture|
214644009|NCT00924937|BEHAVIORAL|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).
214644010|NCT00924937|BEHAVIORAL|Low Fat Diet|Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
214728399|NCT01639300|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
214728400|NCT01639300|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
214728401|NCT03632551|OTHER|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
214728402|NCT02799628|BEHAVIORAL|intervention|intervention with recommendation and therapist introduction
214728403|NCT02799628|OTHER|placebo|low back pain education, and physical therapy 3 times per week
214728404|NCT02748278|PROCEDURE|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
214728405|NCT02748278|PROCEDURE|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
214728406|NCT03195686|DEVICE|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
214728407|NCT04998292|DEVICE|Piezo-surgery with low level laser therapy|Low level laser therapy
214728408|NCT04998292|DEVICE|Piezo-surgery only|Piezo-surgery only
214728409|NCT00182013|DRUG|Risperidone|Open treatment with Risperidone
214728410|NCT00182013|DRUG|Olanzapine|Open treatment with Olanzapine
214728411|NCT00182013|DRUG|Quetiapine|Open treatment with Quetiapine
214728412|NCT00850265|DEVICE|Volumatic spacer|A spacer is a plastic device to inhaler medication
214728413|NCT03094494|OTHER|none intervention|none intervention
214728414|NCT03401476|DRUG|Morphine Sulfate|Morphine Sulfate Tablets
214728415|NCT00675662|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
214728416|NCT00675662|BEHAVIORAL|waiting list control|waiting list control
214728417|NCT01300767|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
214728418|NCT01300767|DEVICE|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
214728419|NCT01300767|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
214728420|NCT02498327|OTHER|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
214728421|NCT02498327|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
214728422|NCT05280236|DRUG|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
214728423|NCT05280236|DRUG|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
214728424|NCT00963313|DRUG|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
214728425|NCT00528008|OTHER|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
214728426|NCT00528008|OTHER|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
214728427|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Probiotics|6 Billion CFU
214728428|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|0 CFU per day
214728429|NCT03366974|DRUG|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
214728430|NCT03366974|DRUG|Clarithromycin|Clarithromycin 500 mg bid
214728431|NCT03366974|DIETARY_SUPPLEMENT|Grapefruit juice|Grapefruit juice 500 mL
214728432|NCT00117572|DRUG|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
214728433|NCT00117572|DRUG|cisplatin|75 mg/m2 on day 1
214728434|NCT00117572|DRUG|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
214728435|NCT00117572|DRUG|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
214728436|NCT00117572|PROCEDURE|chemotherapy|See protocol for details
214728437|NCT00117572|PROCEDURE|radiotherapy|See protocol for details
214728438|NCT03619850|DRUG|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
214728439|NCT03619850|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
214728440|NCT01755338|DRUG|Methylprednisolone|Methylprednisolone 15mg/kg
214728441|NCT01755338|DRUG|Placebo|Placebo
214728442|NCT03256136|DRUG|Carboplatin|Chemotherapy
214728443|NCT03256136|DRUG|Nivolumab|will allow the body's immune system to work against tumor cells
214728444|NCT03256136|DRUG|pemetrexed|Chemo therapy
214728445|NCT03256136|DRUG|Ipilimumab|will allow the body's immune system to work against tumor cells
214728446|NCT04973085|DEVICE|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
214728447|NCT04973085|DEVICE|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
214728448|NCT03929406|DEVICE|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
214644011|NCT03473561|DRUG|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to \< 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
214644012|NCT02876887|DRUG|Cocoa|
214728449|NCT04011306|DEVICE|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
214728450|NCT04818489|DRUG|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
214728451|NCT04818489|OTHER|the standard protocol only|the local standard protocol for COVID19
214728452|NCT02947334|BIOLOGICAL|Bococizumab|Bococizumab PFS
214728453|NCT02947334|DRUG|Placebo|Placebo
214728454|NCT04483752|OTHER|CHEST CT SCAN|Chest CTscan at 3 and 12 months
214728455|NCT00887068|DRUG|Azacitidine|32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
214728456|NCT04333992|DRUG|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
214728457|NCT04333992|DRUG|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
214644013|NCT02876887|DRUG|Placebo|
214644014|NCT04095169|DIAGNOSTIC_TEST|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
214644015|NCT00191451|DRUG|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
214644016|NCT00191451|DRUG|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
214728458|NCT04681365|OTHER|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
214728459|NCT02090673|DRUG|Exenatide|
214728460|NCT03190967|DRUG|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
214728461|NCT03190967|DRUG|TMZ|Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
214728462|NCT04104841|BEHAVIORAL|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
214728463|NCT04104841|BEHAVIORAL|Usual Care|Referral to school mental health provider, social worker, or community care.
214728464|NCT04739241|DRUG|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
214728465|NCT04739241|DRUG|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
214728466|NCT03893851|BEHAVIORAL|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
214728467|NCT03418220|OTHER|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
214644017|NCT00191451|DRUG|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
214644018|NCT03569852|BEHAVIORAL|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
214644019|NCT03569852|BEHAVIORAL|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
214644020|NCT00670410|PROCEDURE|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
214644021|NCT00670410|PROCEDURE|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
214644022|NCT00670410|DRUG|Busulfan|Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients \> 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration \> 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
214644023|NCT00670410|DRUG|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
214644024|NCT00670410|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
214644025|NCT03972722|DRUG|GLS-010|Patients will be given 240mg GLS-010 every treatment.
214644026|NCT01499017|DRUG|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
214644027|NCT01499017|DRUG|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
214644028|NCT02755194|OTHER|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
214644029|NCT00003160|DRUG|paclitaxel|
214644030|NCT05565963|OTHER|Virtual reality exercise intervention|The experimental group received VR exercise sessions for 75-90 minutes, twice a week for a duration of 12 weeks.
214644031|NCT02441504|OTHER|Low intensity Exercise|aerobic exercise training using walking and running
214644032|NCT03650998|DRUG|Ropivacaine|See arm description
214644033|NCT03650998|DRUG|Saline|See arm description
214644034|NCT00592475|DRUG|conivaptan|IV
214644035|NCT00592475|DRUG|Placebo|IV
214644036|NCT06240910|OTHER|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise.
214644037|NCT06240910|OTHER|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
214644038|NCT01114529|DRUG|Everolimus|Early CNI to everolimus conversion
214644039|NCT01114529|DRUG|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
214728468|NCT02891772|PROCEDURE|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
214728469|NCT03299452|DRUG|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
214728470|NCT03299452|DRUG|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
214728471|NCT03299452|DRUG|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
214728472|NCT00085358|DRUG|carboplatin|Given intraperitoneally
214728473|NCT00085358|DRUG|paclitaxel|Given IV or intraperitoneally
214728474|NCT00085358|DRUG|docetaxel|Given IV
214728475|NCT00085358|BIOLOGICAL|bevacizumab|Given IV
214728476|NCT04129190|BIOLOGICAL|Glucose|Oral Intake of Glucose
214728477|NCT05319223|BEHAVIORAL|patient blood management|three pillars of patient blood management will be applied
214728478|NCT03348813|BEHAVIORAL|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
214728479|NCT03348813|BEHAVIORAL|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
214728480|NCT03491280|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
214728481|NCT00031135|DRUG|Choline Chloride|
214728482|NCT03422055|DRUG|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
214728483|NCT03959345|DRUG|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
214728484|NCT03959345|DRUG|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
214728485|NCT04996524|DRUG|epidural analgesia|Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
214728486|NCT01886352|DRUG|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
214728487|NCT01886352|DRUG|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
214728488|NCT01886352|DRUG|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
214728489|NCT03054298|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
214728490|NCT05488925|DRUG|Vitamin E|Evion, 400 mg
214728491|NCT05488925|DRUG|Diclofenac Sodium|Voltral SR100, 100 mg
214728492|NCT05488925|DRUG|Piroxicam|Feldene, 20 mg
214728493|NCT05488925|DRUG|Tramadol|Tramal, 50 mg
214728494|NCT02544204|BIOLOGICAL|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
214728495|NCT02544204|BIOLOGICAL|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
214728496|NCT06409507|GENETIC|FKBP12 expression|The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
214728497|NCT05627791|DRUG|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
214728498|NCT05627791|DRUG|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
214728499|NCT00832689|DRUG|Irinotecan and Gemcitabine|
214728500|NCT04929691|DEVICE|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
214728501|NCT04929691|OTHER|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
214728502|NCT04534049|OTHER|Intensive Strength Training (IST)|
214728503|NCT04534049|OTHER|Strength Endurance Training (SET)|
214728504|NCT04534049|OTHER|Flexibility Training (FT)|
214728505|NCT00801710|DEVICE|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
214728506|NCT03607149|DRUG|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
214728507|NCT00024206|DRUG|orantinib|Given orally
214728508|NCT00024206|OTHER|laboratory biomarker analysis|Correlative studies
214728509|NCT00024206|OTHER|pharmacological study|Correlative studies
214728510|NCT05097976|DRUG|Methylprednisolone|21 x 4mg tablets beginning on POD 1
214728511|NCT05097976|DRUG|Placebo|21 sugar tablets beginning on POD 1 with standard management
214728512|NCT03144089|DEVICE|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
214728513|NCT03144089|DEVICE|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
214728514|NCT04808492|DEVICE|CureWave High Intensity Laser|"* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
214728515|NCT04808492|OTHER|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
214728516|NCT02023541|RADIATION|Proton beam therapy|
214728517|NCT00802880|DRUG|Dacarbazine|
214728518|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
214728519|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
214728520|NCT02147106|OTHER|Videoconsultation|
215030522|NCT06253767|DEVICE|Low Level Laser Therapy|Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
215030523|NCT06253767|DEVICE|Simulation Low Level Laser therapy|A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
215030524|NCT04782180|DRUG|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
214644040|NCT00783393|DRUG|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
214644041|NCT00272987|DRUG|lapatinib|(GW572016) 1000 mg QD
214644042|NCT00272987|DRUG|paclitaxel|80 mg/m2 IV weekly for three weeks
214644043|NCT00272987|DRUG|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
214644044|NCT04992143|PROCEDURE|TACE|TACE first ,and more TACE could be performed when it is necessary.
214644045|NCT04992143|DRUG|Tilelizumab|Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
214644046|NCT04992143|DRUG|Sorafenib|Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
214644047|NCT00449514|DRUG|tamoxifen|
214644048|NCT00449514|DRUG|clomiphene citrate|
214644049|NCT00331409|DRUG|Everolimus|2.5 mg by mouth daily
214644050|NCT00331409|DRUG|imatinib mesylate|600 mg by mouth daily
214644051|NCT06205108|DEVICE|taVNS stimulation|Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
214728521|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
214728522|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
214728523|NCT01006213|BEHAVIORAL|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
214728524|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
214728525|NCT03182621|BEHAVIORAL|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
214728526|NCT03182621|BEHAVIORAL|SPARK|traditional YMCA program
214728527|NCT00782301|DRUG|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
214728528|NCT00782301|DRUG|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
214728529|NCT00864123|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
214728530|NCT00864123|DRUG|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
214728531|NCT00864123|DRUG|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
214728532|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
214728533|NCT05941676|DIAGNOSTIC_TEST|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
214728534|NCT02737176|OTHER|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
214728535|NCT04633031|DEVICE|Boston|
214728536|NCT04633031|DEVICE|Cheneau|
214728537|NCT02882165|OTHER|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
214728538|NCT06887803|DRUG|Roginolisib|IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD
214644052|NCT06205108|DEVICE|sham stimulation|Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
214644053|NCT04428411|DRUG|Enbrel|As provided in real world practice
214644054|NCT00356031|DRUG|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
214644055|NCT00356031|RADIATION|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
214644056|NCT00356031|PROCEDURE|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
214644057|NCT02574104|OTHER|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
214644058|NCT01163786|DRUG|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
214644059|NCT00311857|DRUG|Cetuximab|
214644060|NCT00311857|DRUG|Temozolomide|
214644061|NCT00311857|PROCEDURE|Radiation therapy|
214644062|NCT05361629|PROCEDURE|Intralesional steroid administration|Treatment by administering steroids into the lesion
214644063|NCT05361629|PROCEDURE|Intraoperative cavity steroid administration|Treatment by administering steroids into the surgical cavity
214644064|NCT05637554|PROCEDURE|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
214644065|NCT05637554|PROCEDURE|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
214644066|NCT06520189|DEVICE|F-18 FDGPET/CT|F-18 FDGPET/CT oncology protocol for lung cancer patients
214644067|NCT04507984|DIAGNOSTIC_TEST|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
214644068|NCT04507984|DIAGNOSTIC_TEST|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
214644069|NCT04615637|DEVICE|MEG recordings|"1. Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~2. MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
214644070|NCT06193941|DIAGNOSTIC_TEST|RT-qPCR|RT-qPCR
214644071|NCT00813397|DEVICE|Sepraspray|Max. 10g of Sepraspray
214644072|NCT03942315|OTHER|Data collection from standard follow-up after liver transplant|All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
214644073|NCT06217120|DRUG|Colchicine|Colchicine 0.5 mg daily
214644074|NCT06217120|DRUG|Placebo|Placebo once daily
214644075|NCT06001944|OTHER|Blood flow restriction|The BFR training group will be given detailed information about the technique and discussed possible side effects.The American Association of Sports Physicians (ACSM) recommends that at least 65% of 1 maximum repetition, similar to high-intensity exercise, 8-12 repetitions of resistant weight lifting strength training, can be used with low loads such as 20% to 30% of the maximum 1 repetition in therapy to caste hypertrophy and strength.
214644076|NCT06001944|OTHER|Multimodal rehabilitation|"Patients with LDT will be informed that the condition will be gradually resolved with adequate rest and time.~Exercise Training will consist of 3 phases.The goal is to protect the injured tissue from stress during the first phase of rehabilitation during the protective phase but not to restrict its function. In this phase, the use of counterforce breys, cold application, cyriax physiotherapy, Mill's manipulation, elbow mobilization and stretching to the wrist extensors will be applied. The program will be created taking into account the principle of proximal stability for distal mobility during the reinforcement phase. The rotator manchet will be added to the program. It will be active first in the exercise and then progresses resistantly according to the condition of the patient. After distal strengthening, the dress will be transferred to stabilization exercises where flexion and extension reveal simultaneous contraction."
214644077|NCT06549751|BIOLOGICAL|MT-601|Cellular Therapy
214644078|NCT04137783|OTHER|no intervention|there is no intervention in this study, only observation.
215030525|NCT04782180|BEHAVIORAL|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
215030526|NCT05949385|DRUG|ZX-7101A|Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
215030527|NCT06125405|DRUG|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
214644079|NCT02965079|DEVICE|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
214644080|NCT02305693|DRUG|Letrozole|
214728539|NCT05134597|GENETIC|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
214728540|NCT00796224|DRUG|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
214728541|NCT00796224|DRUG|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
214793953|NCT04326777|PROCEDURE|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
215030528|NCT06320782|BEHAVIORAL|Calorie restriction and balanced distribution of macronutrients|Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats
214644081|NCT02305693|PROCEDURE|Laparoscopic ovarian drilling|
214644082|NCT03792074|DRUG|SCT510|SCT510 Injection
214644083|NCT03792074|DRUG|Bevacizumab|Bevacizumab Injection
214644084|NCT03792074|DRUG|Paclitaxel|Paclitaxel Injection
214644085|NCT03792074|DRUG|Carboplatin|Carboplatin injection
214644086|NCT02103868|BEHAVIORAL|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
214644087|NCT02101970|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
214644088|NCT02101970|OTHER|Placebo Capsule|
214644089|NCT02101970|OTHER|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
214644090|NCT02312947|DEVICE|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
214644091|NCT02312947|DEVICE|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
214644092|NCT04668859|DRUG|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
214644093|NCT04668859|DRUG|Methylcellulose|Placebo will consist of inert methylcellulose
214644094|NCT06503445|OTHER|education video|"the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video."
214644095|NCT00576173|DRUG|tramadol hydrochloride; acetaminophen|
214644096|NCT06528886|PROCEDURE|hysterectomy by V-NOTES|V-notes is like laparoscopy via the vaginal route.
214644097|NCT01166451|DIETARY_SUPPLEMENT|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
214644098|NCT01166451|DIETARY_SUPPLEMENT|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
214644099|NCT00065728|DRUG|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
214644100|NCT03555266|DEVICE|NSS-2 Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
214644101|NCT03555266|DEVICE|Sham NSS-2 BRIDGE|NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
214644102|NCT04067947|DRUG|XG005|XG005 Tablet
214644103|NCT04067947|DRUG|Placebos|Placebo Tablet
214644104|NCT03544073|DRUG|Saline Solution for Injection|Placebo arm will receive a saline injection
214644105|NCT03544073|DRUG|Leuprolide Acetate|Treatment arm will receive a Leuprolide injection
214644106|NCT00137917|BIOLOGICAL|Meningococcal serogroup B vaccine|
214644107|NCT00372437|DRUG|MGCD0103|MGCD0103 as an oral dose three times per week.
214644108|NCT00372437|DRUG|Gemcitabine|Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle.
214644109|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BNT162b2 subjects
214644110|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BNT162b2 subjects
214644111|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
214644112|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
214644113|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
214644114|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
214644115|NCT02167945|DRUG|ABT-450/r/ABT-267|Tablet for oral use
214644116|NCT02167945|DRUG|ABT-333|Tablet for oral use
214644117|NCT02167945|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
214644118|NCT05299385|BEHAVIORAL|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~* method of the conventional rehabilitation treatment~* intensity for aerobic exercise and anaerobic exercise"
214644119|NCT05299385|DEVICE|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
214644120|NCT00132730|DRUG|MK-0873 2.5 mg|
214644121|NCT00132730|DRUG|MK-0873 1.25 mg|
214644122|NCT00132730|DRUG|MK-0873 0.75 mg|
214644123|NCT00132730|DRUG|Placebo to MK-0873|
214644124|NCT00132730|DRUG|Usual Care|
214644125|NCT05215366|DIAGNOSTIC_TEST|copeptin biomarker in children with febrile seizures|biomarkers increase in children with febrile seizures
214644126|NCT04318405|DRUG|Iron isomaltoside 1000|Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000
214644127|NCT04196660|BEHAVIORAL|Labor Dance|The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
214644128|NCT06547970|OTHER|Educational intervension|an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
214644129|NCT05957172|DEVICE|ZOLL Arrhythmia Management System|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)
214644130|NCT01554579|DRUG|Gefapixant|BID
214644131|NCT01554579|DRUG|Sugar Pill|Placebo
214644132|NCT02303717|DEVICE|Percutaneous coronary intervention|Percutaneous coronary stent implantation
214644133|NCT02303717|DRUG|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
214644134|NCT05211557|BIOLOGICAL|fhB7H3.CAR-Ts|"Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan"
214644135|NCT02976870|RADIATION|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
214644136|NCT01308411|OTHER|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
214644137|NCT05319236|DEVICE|Gabi System|See arm description
214644138|NCT01420146|DRUG|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
214644139|NCT01665963|DEVICE|TopClosure(c) System|
214644140|NCT01665963|DEVICE|Pressure Bandage|
214644141|NCT06070948|DRUG|Venetoclax|Oral; Tablet
214644142|NCT05941819|DEVICE|ARC-IM Thoracic System implantation|Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
214644143|NCT04982081|BIOLOGICAL|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
214644144|NCT02945956|DRUG|Entecavir|The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
214644145|NCT02945956|DRUG|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
214644146|NCT05275569|PROCEDURE|True acupuncture + standard antiemetic treatment|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy."
214644147|NCT05275569|PROCEDURE|Sham acupuncture + standard antiemetic treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group)."
214644148|NCT01046695|DEVICE|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
214644149|NCT01788007|DRUG|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
214644150|NCT01788007|DRUG|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
214644151|NCT01788007|DRUG|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
214644152|NCT01171456|DRUG|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
214644153|NCT01171456|DRUG|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
214644154|NCT02280213|DEVICE|MIL|Direct laryngoscopy 1
214644155|NCT02280213|DEVICE|MAC|Direct laryngoscopy 2
214644156|NCT02280213|DEVICE|WIS|Direct laryngoscopy 3
214644157|NCT02280213|DEVICE|PHIL|Direct laryngoscopy 4
214644158|NCT00788645|BEHAVIORAL|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
214644159|NCT00788645|BEHAVIORAL|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
214644160|NCT01450982|DRUG|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
214644161|NCT02648126|PROCEDURE|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
214644162|NCT02338687|DIETARY_SUPPLEMENT|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
214644163|NCT02338687|BEHAVIORAL|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
214644164|NCT00005979|DRUG|FOLFIRI regimen|
214644165|NCT00005979|DRUG|fluorouracil|
214644166|NCT00005979|DRUG|irinotecan hydrochloride|
214644167|NCT00005979|DRUG|leucovorin calcium|
214644168|NCT04756713|PROCEDURE|Uterine curettage|Manual or electric vacuum aspiration under ultrasound guidance.
214644169|NCT04756713|DRUG|Chemotherapy|conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
214644170|NCT02028195|OTHER|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
214644171|NCT06549387|PROCEDURE|Corneal cross linking|Applying UVA irradiation to the cornea after soaking with riboflavin
214644172|NCT03176082|OTHER|Mailed Reminders with Fecal Immunochemical Testing kits|
214644173|NCT03176082|OTHER|Reminder letter only|
214644174|NCT01535079|DRUG|Placebo|Single administration
214728542|NCT03953885|OTHER|Fire needle|"1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
214728543|NCT03953885|OTHER|Fire needle Placebo|"1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
214728544|NCT03940014|OTHER|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
214728545|NCT00661167|DRUG|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
214728546|NCT01285336|GENETIC||
214728547|NCT05103241|DRUG|[14C] GP681|40 mg suspension containing 100μCi of \[14C\]GP681
214728548|NCT02232724|DEVICE|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
214728549|NCT06743620|OTHER|iltamiocel|This is an observational study with no intervention.
214728551|NCT06743165|BEHAVIORAL|Pelvic floor muscle training with ultrasound biofeedback|Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.
214728552|NCT06743165|BEHAVIORAL|Dynamic neuromuscular stabilization exercise|Dynamic neuromuscular exercises (DNS) involve the joint activation of the intrinsic muscle group of the spine, which includes the cervical flexors and extensors, diaphragm, transversus abdominis, multifidus and pelvic floor, which form the integrated spinal stabilization system. The application principles are joint centering, core stabilization - Integrated spinal stabilization system and stabilization function of the diaphragm. DNS training will be applied in three stages. Preparation for exercises, IAB regulation and application of exercises according to developmental kinesiology positions. Exercises will start with preparatory training. In preparatory training, stroking, brushing and tapping techniques will be taught and self-facilitation will be demonstrated in order to increase proprioceptive input to the lower extremity, upper extremity, trunk and pelvic region. Fascial mobilizations will be performed to the foot and hand regions.
214728553|NCT00418899|BEHAVIORAL|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
214728554|NCT00033111|DRUG|Cabergoline|
214644175|NCT01535079|DRUG|Ibuprofen 35 mg|Single administration
214644176|NCT01535079|DRUG|Ibuprofen 25 mg|Single administration
214644177|NCT01535079|DRUG|Ibuprofen 15 mg|Single administration
214644178|NCT01535079|DRUG|Strefen|Single administration
214644179|NCT06498934|DEVICE|deep brain stimulation|Stimulation of the dentate nucleus that is paired with upper limb rehabilitation movements.
214644180|NCT06498934|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
214644181|NCT06194357|OTHER|Mindfulness-based Health Qigong Intervention|Participants are introduced the practice of the most essential skills, particularly mindfulness, the basic movements of Qigong and the use of the resources package. Following the initial session, participants will kick off 8 bi-weekly online sessions of Mindfulness-based interventions approximately two hours each via the Mobile App. Afterwards, participants will be asked to practice Qigong for 30 minutes per day with five days weekly for another 8 weeks. Follow-up sessions will be conducted by an experienced coach via the Mobile App. After the first 16-week intervention, booster sessions will be provided every 3 months to revise the interventions and follow-up assessments will be completed every 6 months for 2 years.
214644182|NCT02998723|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
214644183|NCT02998723|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
214644184|NCT00939692|DRUG|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
214644185|NCT02502760|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
214644186|NCT02502760|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
214728555|NCT00033111|DRUG|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
214728556|NCT06861829|DRUG|BI 3731579|BI 3731579
214728557|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
214728558|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
214728559|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
214728560|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
214728561|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
214644187|NCT02502760|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
214644188|NCT02849756|OTHER|older in intensive care unit|It is an observational study with no intervention.
214644189|NCT00002953|DRUG|cyclophosphamide|
214644190|NCT00002953|DRUG|epirubicin hydrochloride|
214644191|NCT00002953|DRUG|paclitaxel|
214644192|NCT01392807|DRUG|NKTR-118|25 mg Oral tablets, single dose
214644193|NCT03163381|DRUG|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
214644194|NCT06086847|OTHER|progressive resistant exercises|"Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3\. Progressive Resistance exercises:~1. Leg press :( dual leg press): Leg press target the~   Quadriceps or quads .but they also work your Hamstrings.~2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4\. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
214644195|NCT02416557|PROCEDURE|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
214644196|NCT00259480|BEHAVIORAL|Home Based Intervention|occupational therapy
214644197|NCT04528121|OTHER|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
214644198|NCT04528121|OTHER|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
214644199|NCT04409873|DRUG|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
214644200|NCT04409873|DRUG|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
214644201|NCT04409873|DRUG|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
214644202|NCT04409873|DRUG|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
214644203|NCT04409873|DRUG|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
214644204|NCT02856165|DEVICE|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F\&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 \> 94%.
214644205|NCT02856165|DEVICE|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 \> 94% (up to a maximum of 2l/min).
214644206|NCT03433781|DRUG|Vitamin C|All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).
214644207|NCT03359135|OTHER|Rehabilitation|Rehabilitation during 4 weeks
214644208|NCT03359135|DEVICE|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
214644209|NCT06228222|PROCEDURE|renal biopsy|"Renal biopsy will be performed for all patients fulfilling the American College of Rheumatology (ACR) criteria to confirm the diagnosis of lupus nephritis (LN) and to classify the glomerular disease by the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 histopathological classification system"
214644210|NCT04351139|OTHER|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
215030529|NCT06320782|BEHAVIORAL|Calorie restriction and low-carbohydrate diet|Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate
214644211|NCT05264220|BEHAVIORAL|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
214644212|NCT04244344|OTHER|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
214644213|NCT06286865|OTHER|Easy-ICD|Easy-ICD is an AI-based computer-assisted clinical coding (CAC) system that helps clinical coder assign ICD-10 codes to clinical notes such as discharge summaries.
214644214|NCT01286246|DRUG|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
214644215|NCT01286246|DRUG|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
214644216|NCT04503876|OTHER|Increasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
214644217|NCT04503876|OTHER|Decreasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
214644218|NCT01953744|DRUG|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
214644219|NCT01953744|DRUG|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
214644220|NCT05369819|DRUG|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
214644221|NCT05369819|DRUG|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
214644222|NCT03404999|OTHER|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
214644223|NCT03709381|DRUG|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
214644224|NCT03709381|DRUG|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
214644225|NCT04539093|OTHER|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
214644226|NCT05939895|DEVICE|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
214644227|NCT06047704|OTHER|No intervention|No intervention
214644228|NCT00408694|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214644229|NCT00408694|BIOLOGICAL|Bevacizumab|Given IV
214644230|NCT00408694|DRUG|Cisplatin|Given IV
214644231|NCT00408694|DRUG|Fluorouracil|Given IV
214644232|NCT00408694|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214644233|NCT01985672|PROCEDURE|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
214644234|NCT00492973|DRUG|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
214644235|NCT00492973|DRUG|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
214644236|NCT01988389|DIETARY_SUPPLEMENT|whole apples (WA)|
214644237|NCT01988389|DIETARY_SUPPLEMENT|apple juice (AJ)|
214644238|NCT02984592|BEHAVIORAL|physical exercise|regular exercise programs in the previous 6 months.
214644239|NCT02427048|BEHAVIORAL|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
214644240|NCT03261531|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
214728562|NCT02428933|DRUG|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
214728563|NCT02116361|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
214728564|NCT02116361|DRUG|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
214728565|NCT06805162|OTHER|Normal training|Athletes should continue their normal training
214728566|NCT06805162|OTHER|Specific training|Athletes should consider i) watching the educational videos on injury prevention, ii) perform the neuro-muscular exercises, iii) practice the techniques against stress and anxiety, and iv) consider the injury prognostic feedback.
214728567|NCT06833047|BEHAVIORAL|Emotional intervention|Participants will receive different emotional interventions such as boredom, positive valence, mind-wandering.
214728568|NCT03227224|DRUG|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
214728569|NCT03227224|DRUG|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
214728570|NCT04195750|DRUG|Belzutifan|Oral tablets
214728571|NCT04195750|DRUG|Everolimus|Oral tablets
214728572|NCT06927154|OTHER|Mobilization with movement|Group A will receive Mobilization with movement in which therapist manually applies a gentle mobilizing force to the joint while the patient actively performs a movement (2 to 3 sets) 6 to 10 repetitions per set in sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.
214728573|NCT06927154|OTHER|Facet joint oscillatory mobilization|Group B will receive Facet joint oscillatory mobilization on the cervical spine C2-C7 (6 to 10 repetitions in each session) in the sitting position.Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.
214728574|NCT02406027|DRUG|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
214728575|NCT02406027|DRUG|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
214644241|NCT00363038|DRUG|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
214644242|NCT00363038|DRUG|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
214644243|NCT00363038|DRUG|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
214644244|NCT00363038|DRUG|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
214644245|NCT01265771|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
214728576|NCT02406027|DRUG|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
214728577|NCT02406027|DRUG|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
214728578|NCT02497287|DRUG|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.
214728579|NCT02497287|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
214728580|NCT02497287|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
214728581|NCT02497287|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
214728582|NCT02497287|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
214728583|NCT03238079|BIOLOGICAL|10% IGIV|300-900 mg/kg
214644246|NCT01265771|DEVICE|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
214644247|NCT05455957|OTHER|exercise|neuromuscular and vestibulo-ocular training
214728584|NCT03782376|DRUG|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
214728585|NCT03782376|DRUG|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
214728586|NCT03782376|DRUG|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
214728587|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
214728588|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
214728589|NCT03559192|DRUG|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
214728590|NCT03559192|DRUG|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
214728591|NCT03517722|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
214728592|NCT03517722|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
214728593|NCT03517722|DRUG|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
214728594|NCT02863705|DRUG|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
214728595|NCT02863705|DRUG|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
214728596|NCT06930170|DEVICE|Cochlear implantation|During surgery at 8 weeks after inclusion, cochlear implant is implanted
214728597|NCT06930170|DEVICE|CROS or BiCROS device fitting|At 8 weeks after inclusion, CROS or BICROS (depending on the type of hearing loss) is fitting
214728598|NCT06930170|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat is an adaptive test that measures speech intelligibility in noise. It consists of 14 sentences of 3 words each, recorded in the presence of background noise. The FraSimat will be performed in two different configurations in relation to the source of the signal and noise before implantation or fitting, and 1, 2, 3 and 4 months after.
214728599|NCT06930170|DIAGNOSTIC_TEST|Sound localization test (ERKI)|"ERKI for German Erfassung des Richtungshörens für Kinder is an automated test that assesses spatial localization skills. The test is performed with the child seated facing a semi-circular table, surrounded by a set of 5 loudspeakers arranged 1 meter apart.~The test consists of 5 stimuli, followed by 42 trials. Following the presentation of each stimulus, the child must turn a control knob and direct the LED light to the point where he or she has perceived it. The child validates his or her response by pressing the button.~ERKI is evaluated before implantation or fitting, and 1, 2 and 3 months after."
214728600|NCT06930170|DIAGNOSTIC_TEST|Cortical Auditory Evoked Potentials (PEAc)|"The recording of Auditory Cortical Evoked Potentials provides an objective means of assessing the maturation of the auditory system and its ability to process auditory signals. AEPs consist of a series of cortical responses to an auditory stimulus.~PEAc are assessed using a non-invasive EEG recording, made under quiet wakefulness. Four surface electrodes are glued to the patient's skull: one on the vertex, one on the forehead, and one on each mastoid. The latency (msec) and amplitude (mV) values of each of the four component waves will be analyzed.~PEAc is evaluated before implantation or fitting, and 3 and 4 months after."
214728601|NCT06930170|OTHER|Speech, Spatial and Qualities of Hearing Scale (SSQ)|"The Speech, Spatial and Qualities of Hearing Scale is a questionnaire for subjective evaluation of listening performance in everyday listening situations. The parent version is adapted for parents of hearing-impaired children.~SSQ is evaluated before implantation or fitting, and 4 months after."
214728602|NCT06930170|OTHER|Peabody Picture Vocabulary Scale (PPVT or EVIP in french)|"Peabody Picture Vocabulary Scale assesses the extent of French listening vocabulary acquired by the child.~The PPVT is designed for patients aged from 2 years and 6 months to 18 years. The raw score is the number of images correctly identified.~Peabody Picture Vocabulary Scale is evaluated before implantation or fitting, and 4 months after."
214644248|NCT00004914|BIOLOGICAL|epoetin alfa|
214644249|NCT00004914|PROCEDURE|physical therapy|
214644250|NCT03895125|BEHAVIORAL|[year1] dual-task training with task priority strategy|postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
214644251|NCT03895125|BEHAVIORAL|[year2-3] dual-task training with internal and external focus|internal focus: focus mainly on body movements external focus: focus mainly on object in the environment
214644252|NCT06536400|DRUG|HSK42360|Oral administration, QD
214644253|NCT04428177|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
214644254|NCT04428177|DEVICE|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
214644255|NCT05008094|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole-exome sequencing with the focus on Parkinson's disease loci.
214644256|NCT05008094|DIAGNOSTIC_TEST|Microbiota sequencing|Next generation sequencing of microbiota from stool and saliva samples.
214644257|NCT05008094|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.
214644258|NCT05008094|DIAGNOSTIC_TEST|Transcranial ultrasound and Electroencephalography|Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
214644259|NCT05008094|DIAGNOSTIC_TEST|ELISA (Enzyme-Linked Immunosorbent Assay)|ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples
214644260|NCT05008094|DIAGNOSTIC_TEST|Fluorescent correlation spectroscopy (FCS)|Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
214644261|NCT02063035|DRUG|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
214644262|NCT02063035|DRUG|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
214644263|NCT06114979|DRUG|Silodosin|Each patient will receive 8 mg of silodosin tablet once daily.
214644264|NCT06114979|DRUG|Placebo|Each patient will receive placebo tablet.
214644265|NCT05983289|DRUG|HSK7653|HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
214644266|NCT05983289|DRUG|Placebo|Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
214644267|NCT00006093|DRUG|cilengitide|
214644268|NCT02640963|OTHER|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
214644269|NCT02640963|OTHER|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
214644270|NCT04244565|BEHAVIORAL|Self-directed model of clinical learning for nurses|the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources \& decide whether learning method can be used, and engaging in self-reflection \& evaluation.
214644271|NCT04213859|BEHAVIORAL|VRET - Virtual Reality Exposure Therapy|VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
214644272|NCT03649295|OTHER|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
214644273|NCT03649295|OTHER|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
214644274|NCT01916629|DRUG|Photocil for Psoriasis|Photocil for Psoriasis
214644275|NCT01916629|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
214644276|NCT04000802|BEHAVIORAL|response to questionnary|No intervention. Observational study
214644277|NCT02082678|DRUG|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
214644278|NCT02082678|DRUG|Placebo|Inactive ingredient matching the active medication in appearance
214644279|NCT03034395|PROCEDURE|Wide Local Excision|Surgery
214644280|NCT03301181|DRUG|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
214644281|NCT03301181|DRUG|Rifampin|600 mg rifampin once daily
214644282|NCT03301181|DRUG|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
214644283|NCT03301181|DRUG|Itraconazole|200 mg itraconazole once daily
214644284|NCT04202731|BEHAVIORAL|PBS Study|Sleep extension intervention
214644285|NCT04336098|DRUG|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
214644286|NCT04336098|DRUG|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
214644287|NCT04336098|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
214644288|NCT04336098|DRUG|Pembrolizumab|Pembrolizumab as an IV infusion .
214644289|NCT04182867|OTHER|Dietary intervention|Dietary modification (provision of diet).
214644290|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
214644291|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
214644292|NCT01463813|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
214644293|NCT03543085|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
214644294|NCT04428606|DIETARY_SUPPLEMENT|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
214644295|NCT04428606|DIETARY_SUPPLEMENT|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
214644296|NCT04428606|DIETARY_SUPPLEMENT|Placebo|Placebo
214728603|NCT06930170|OTHER|NEPSY-II (A Developmental Neuropsychological Assessment)|"The NEPSY-II (A Developmental Neuropsychological Assessment) is a battery of neuropsychological tests designed to assess children's skills in 6 major neuropsychological domains. The various tests are validated for the age range indicated in brackets, and will be used for patients aged 5 and over.~NEPSY-II is evaluated before implantation or fitting, and 4 months after."
214728604|NCT06930170|OTHER|Pediatric Quality of Life Inventory™ Multidimensional Fatigue Scale (PedsQL MFS)|PedsQL MFS is a questionnaire used to assess subjective experiences of fatigue. The questionnaire consists of 18 items The parent version is adapted for parents of hearing-impaired children. PedsQL MFS is evaluated before implantation or fitting, and 4 months after.
214728605|NCT06904196|COMBINATION_PRODUCT|Lenvatinib plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD will be started at 3-7 days after the first SIRT.
214728606|NCT06904196|DRUG|Lenvatinib|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD.
214728607|NCT01990703|DRUG|Levonorgestrel IUD|Timing of IUD insertion
214728608|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
214728609|NCT03971292|GENETIC|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
214728610|NCT03277794|BEHAVIORAL|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
214728611|NCT03277794|BEHAVIORAL|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
214728612|NCT02168660|DRUG|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
214728613|NCT06719102|BEHAVIORAL|MAGIC-FEED|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.
214728614|NCT06719102|BEHAVIORAL|MAGIC-SAFE|Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
214728615|NCT05258513|DIETARY_SUPPLEMENT|Placebo Supplementation|8 weeks of placebo supplementation
215030530|NCT06320782|BEHAVIORAL|Calorie restriction and low-fat diet|Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate
214728616|NCT05258513|DIETARY_SUPPLEMENT|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
214728617|NCT05274594|RADIATION|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
214728618|NCT00004360|DRUG|chlorothiazide|
214728619|NCT00611988|BEHAVIORAL|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
214728620|NCT00611988|OTHER|Control group|Attention control group will receive routine follow-up phone calls
214793954|NCT00682305|PROCEDURE|Hematopoietic stem cell transplantation|"conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT"
214793955|NCT03164395|PROCEDURE|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
214793956|NCT03164395|PROCEDURE|External Cardioversion|External Cardioversion per institutional protocol
214793957|NCT00003908|DRUG|carboplatin|
214793958|NCT00003908|DRUG|docetaxel|
214644297|NCT01099969|DEVICE|Glidescope videolaryngoscope|
214644298|NCT01099969|DEVICE|McGrath videolaryngoscope|
214644299|NCT01099969|DEVICE|Non-styletted Endotrol endotracheal tube (ETT)|
214644300|NCT01099969|DEVICE|Regular endotracheal tube (ETT) with Gliderite stylet|
214644301|NCT04478825|DRUG|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
214644302|NCT00015600|BEHAVIORAL|Behavior modification through social marketing|
214644303|NCT04908839|OTHER|spot-25 questionnaire|spot-25 questionnaire
214644304|NCT00956254|DRUG|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
214644305|NCT00091832|BIOLOGICAL|Denosumab|Denosumab administered by subcutaneous injection
214644306|NCT00091832|DRUG|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
214644307|NCT06778018|DIETARY_SUPPLEMENT|Lotus Seed|Regimen supplemented with 200 mg/kg of Lotus Seed capsules for 12-month randomized controlled trial.
214644308|NCT06778018|DIETARY_SUPPLEMENT|Placebo|Regimen supplemented with 200 mg/kg of Starch capsules for 12-month randomized controlled trial.
214644309|NCT03400722|DRUG|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
214644310|NCT03400722|DRUG|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
214644311|NCT05707780|PROCEDURE|Resin-matrix|posterior crowns
214644312|NCT05707780|PROCEDURE|Monolithic zirconia|posterior crowns
214644313|NCT05707780|PROCEDURE|Metal-ceramic|posterior crowns
214644314|NCT02934438|DIETARY_SUPPLEMENT|Neo40|
214644315|NCT02934438|DIETARY_SUPPLEMENT|Placebo|
214644316|NCT03899454|DRUG|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
214644317|NCT03899454|DRUG|Placebo Control|Placebo Control
214644318|NCT00946309|DRUG|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
214644319|NCT00946309|DRUG|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
214644320|NCT01162330|OTHER|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
214644321|NCT05300516|PROCEDURE|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
214644322|NCT01929304|OTHER|Survey|
214644323|NCT00987363|OTHER|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
214644324|NCT00626093|DEVICE|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"* Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~* Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
214644325|NCT00003955|BIOLOGICAL|dactinomycin|
214644326|NCT00003955|BIOLOGICAL|filgrastim|
214644327|NCT00003955|BIOLOGICAL|pegfilgrastim|
214644328|NCT00003955|BIOLOGICAL|sargramostim|
214644329|NCT00003955|DRUG|cyclophosphamide|
214644330|NCT00003955|DRUG|irinotecan hydrochloride|
214644331|NCT00003955|DRUG|vincristine sulfate|
214644332|NCT00003955|RADIATION|radiation therapy|
214644333|NCT03793387|PROCEDURE|AF-guided endobronchial marking|Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
214644334|NCT03793387|DEVICE|ENB-guided endobronchial marking|Bronchoscopic dye marking with ENB system
214644335|NCT04834869|BIOLOGICAL|BNT162b2|Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
214644336|NCT04834869|BIOLOGICAL|mRNA-1273|Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
214644337|NCT04834869|BIOLOGICAL|AZD1222|Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
214644338|NCT04834869|BIOLOGICAL|CoronaVac|Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
214644339|NCT04834869|BIOLOGICAL|Sinopharm|Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
214644340|NCT04834869|BIOLOGICAL|Gam-COVID-Vac|Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
214644341|NCT04834869|BIOLOGICAL|JNJ-78436735|Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
214644342|NCT04834869|BIOLOGICAL|CVnCoV|Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
214644343|NCT04834869|BIOLOGICAL|NVX-CoV2373|Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
214644344|NCT04834869|BIOLOGICAL|BBV152|Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
214644345|NCT03682315|DEVICE|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
214644346|NCT03682315|DEVICE|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
214644347|NCT02031705|PROCEDURE|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
214644348|NCT02031705|PROCEDURE|control group|Control group was performed no additional cavotricuspid isthmus ablation.
214644349|NCT05241327|DIETARY_SUPPLEMENT|Beetroot Juice|Inorganic Nitrate
214644350|NCT06501560|GENETIC|GWAS|In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.
214644351|NCT03491410|DRUG|Aspirin Low Dose|Low-Dose Aspirin is to be added in the standard patient´s treatment
214644352|NCT03491410|DRUG|Placebo Oral Tablet|Placebo is to be added in the standard patient´s treatment
214644353|NCT01284166|DRUG|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
214644354|NCT00983047|DRUG|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
214644355|NCT03607331|DEVICE|Auricular vagus nerve stimulation|Auricular vagus nerve stimulation is a typical representative of TCM modernization.
214728621|NCT05455255|OTHER|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
214728622|NCT06124092|OTHER|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
214728623|NCT03408886|DRUG|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
214728624|NCT03408886|DRUG|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
214728625|NCT03408886|BIOLOGICAL|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
214728626|NCT06031181|PROCEDURE|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
214728627|NCT02814799|OTHER|bone removal|
214728628|NCT06943456|PROCEDURE|Transversus Abdominis Plane (TAP) Block for Postoperative Pain Management|The intervention involves the administration of a Transversus Abdominis Plane (TAP) block performed at the end of an open appendectomy surgery. A mixture of 10 ml of 1% lignocaine and 10 ml of 0.5% bupivacaine is injected into the transversus abdominis plane, located between the transversus abdominis and internal oblique muscles, under direct vision. This procedure aims to provide localized pain relief by blocking the sensory nerves of the anterior abdominal wall, reducing the need for systemic opioid analgesics during post-operative recovery
214728629|NCT06943456|PROCEDURE|Standard Open Appendectomy with Postoperative Pain Management|The intervention involves the standard open appendectomy surgical procedure without the addition of a Transversus Abdominis Plane (TAP) block. Postoperative pain management in this group is managed using standard opioid analgesics. No local anesthetic block is performed, and pain management is entirely reliant on systemic medications, including opioids, for post-operative recovery
214728630|NCT06944717|BIOLOGICAL|VXA-G1.1-NN|Legacy vaccine, administered orally.
214728631|NCT06944717|BIOLOGICAL|VXA-G2.4-NS|Legacy vaccine, administered orally.
214728632|NCT06944717|BIOLOGICAL|VXA G1.1 NN-T|Next generation vaccine, administered orally.
214728633|NCT06944717|BIOLOGICAL|VXA G2.4 NS-T|Next generation vaccine, administered orally.
214728634|NCT01226472|BIOLOGICAL|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
214728635|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
214728636|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
214728637|NCT00952419|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
214728638|NCT06948539|DRUG|TQB2101 for injection|TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.
214728639|NCT06948240|OTHER|AF related coronary embolism|AF related coronary embolism
214728640|NCT06949839|DEVICE|Therapeutic exercise program combined with RMT|"For the RMT protocol, the Orygen-dual valve® device will be used. Each participant will start with a load of 30% of the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Once every 10 days, the performance will be reviewed and the resistance will be increased by 10cmH2O of the initial MIP/MEP of each patient. Each session will consist of breathing through the device for 20 minutes (10 minutes dedicated to each muscle group). This process will be repeated once a day, five days a week, for eight weeks.~The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down."
214793959|NCT02619123|OTHER|Tailored screening according to breast density|Different interval of mammography screening according to breast density
215030531|NCT06320782|BEHAVIORAL|Collective nutritional guidance|Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
214644356|NCT03607331|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
214644357|NCT05192811|DIETARY_SUPPLEMENT|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10\^9cfu) ,for 60days
214644358|NCT05192811|DIETARY_SUPPLEMENT|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
214644359|NCT00330473|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
214644360|NCT00330473|DRUG|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
214644361|NCT03923205|OTHER|Dietary Intervention|The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
214644362|NCT02916654|DIETARY_SUPPLEMENT|sucrosomial iron|administration of sucrosomial iron
214644363|NCT02916654|DRUG|Sulphate iron|administration of sulphate iron
214644364|NCT04479904|DRUG|Famitinib|po
214644365|NCT05296577|DRUG|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
214644366|NCT05296577|DRUG|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
214644367|NCT05406856|RADIATION|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
214644368|NCT05406856|RADIATION|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
214644369|NCT05406856|DRUG|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
214644370|NCT05406856|RADIATION|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2\_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
214644371|NCT03122431|DRUG|Thalidomide|Thalidomide 100 mg/day
214644372|NCT03122431|DRUG|Hydroxychloroquine reduced|Hydroxychloroquine 2.5 mg/kg/day
214644373|NCT03122431|DRUG|standard dose of HCQ|Hydroxychloroquine 5.0 mg/kg/day
214644374|NCT04323904|OTHER|Retrospective data collection|Retrospective data collection from patients with hantavirus infection and matching control group patients.
214644375|NCT05751356|DRUG|TR128|TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
214728641|NCT06949839|DEVICE|Therapeutic exercise program combined with sham RMT|The sham RMT protocol will have the same frequency as in the intervention group. The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down.
214728642|NCT06949488|PROCEDURE|Group A (DT): Dexmedetomidine group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 100 µg Dexmeditomidine and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
214728643|NCT06949488|PROCEDURE|Group B (MG): Magnesium group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 150 mg of magnesium sulfate and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
214793960|NCT02619123|OTHER|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
214793961|NCT00003390|DRUG|irofulven|
214793962|NCT03940313|PROCEDURE|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
214793963|NCT02398318|DEVICE|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
214793964|NCT02398318|DEVICE|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
214644376|NCT02154087|BIOLOGICAL|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
214644377|NCT06046703|OTHER|Daily nutritional intake|Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
214644378|NCT04763070|DRUG|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
214644379|NCT02182349|DRUG|BI 201335 NA soft gelatin capsule|
214644380|NCT02182349|DRUG|[14C]-BI 201335 NA radiolabelled drug|
214644381|NCT01715584|OTHER|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
214644382|NCT03961711|PROCEDURE|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
214644383|NCT03961711|PROCEDURE|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
214644384|NCT00486278|DRUG|eptacog alfa (activated)|90 mcg/kg, injected i.v.
214644385|NCT00486278|DRUG|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
214644386|NCT00486278|DRUG|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
214644387|NCT00486278|DRUG|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
214644388|NCT00486278|DRUG|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
214644389|NCT00486278|DRUG|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
214644390|NCT04164303|OTHER|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
214644391|NCT00003378|DRUG|carboplatin|
214644392|NCT00003378|DRUG|gemcitabine hydrochloride|
214644393|NCT00003378|DRUG|paclitaxel|
214644394|NCT04168424|OTHER|no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people
214644395|NCT05501119|BEHAVIORAL|A Program of SUPPORT-D (dementia)|The SUPPORT-D intervention consists educational materials will be presented in a format with enhanced content (face-to-face virtually delivered by nurse interventionist via telehealth (e.g., MS Teams), with printed booklet, and identical digital content (electronic pdf and recorded videos of printed content). The SUPPORT-D intervention will be addressed in four sequential sections including: 1) understanding the disease 2) caring for myself; 3) information for the caregiver; and 4) planning for the future. Within the four sections of the intervention seven topics are addressed included symptom management, understanding your disease, putting safety first, ongoing conversations, respite care, palliative care, and alternative treatments. Participants will attend a total of 4 study visits across 8 weeks (approximately every 2 weeks).
214644396|NCT01831960|DRUG|cortexolone 17α-propionate|
214644397|NCT03542201|OTHER|PLS|Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)
214644398|NCT03542201|OTHER|Blogshot|Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
214644399|NCT02795078|DRUG|conservative treatment|
214644400|NCT02795078|PROCEDURE|Aneurysms clipping|
214644401|NCT02795078|PROCEDURE|Interventional embolization forAneurysms|
214644402|NCT02795078|PROCEDURE|stenting for stenosis|
214644403|NCT02004002|BEHAVIORAL|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
214644404|NCT02004002|BEHAVIORAL|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
214644405|NCT00168610|DRUG|Vitamin A|
214644406|NCT02058602|OTHER|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
214728644|NCT06949488|PROCEDURE|Group C (DM): Dexamethasone group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 8 mg dexamethasone and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
214728645|NCT06948253|OTHER|Erector Spinae Plane Block|The correct location of the needle tip in the fascial plane deep to the erector spinae muscle will be conﬁrmed by injecting 0.5-1 ml of saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process while avoiding muscle distension (hydro dissection)
214728646|NCT06948253|OTHER|Caudal Block Anesthesia|"The needle will be advanced at a 20-degree angle with needle tip and length visualization. A pop can be appreciated as the needle passes through the sacrococcygeal ligament.~Once the needle will be confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood."
214728647|NCT06948253|OTHER|External Oblique Intercostal Plane Block|the needle will be advanced until the tip lay in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs
214728648|NCT06948461|BIOLOGICAL|ORAL-LYO-FMT|An oral capsule formulation of lyophilized fecal microbiota. Participants receive 7 capsules, three times per week (Monday, Wednesday, Friday), for either 4 or 7 weeks depending on treatment allocation. The product aims to restore healthy gut microbiota for treatment of IBS-D or prevention of rCDI.
214728649|NCT06948461|OTHER|Placebo|Double-coated oral capsules visually identical to ORAL-LYO-FMT but containing no active material. Participants receive 7 capsules, three times per week, for either 3 or 7 weeks depending on treatment allocation.
214728650|NCT06948123|OTHER|Educational intervention|The experimental group was trained with educational material prepared by the researcher using a computer at home for 15 days after hospital discharge.
214728651|NCT06948123|OTHER|control group|The control group was visited at home 15 days after discharge and the scales were applied. The final scales were applied to the patient who came to the hospital for 3 months. The patient was told that the study was over and given educational materials.
214728652|NCT06949527|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|A custom-made acrylic open bite activator was fabricated for each participant, with the bite registered 3-4 mm above freeway space. Miniscrews were placed between the lateral and canine teeth in both jaws. Vertical elastics (150g force) were applied bilaterally between miniscrews and the appliance. The intervention aimed to reduce vertical growth in posterior regions and stimulate anterior dentoalveolar development while improving masseter muscle morphology.
214728653|NCT03399786|DRUG|evinacumab|IV administration of evinacumab
214728654|NCT03399786|DRUG|Placebo|IV administration of placebo
214728655|NCT06439485|DRUG|Pemigatinib|Given by PO
214728656|NCT06439485|DRUG|Atezolizumab|Given by PO and IV
214728657|NCT06439485|DRUG|Bevacizumab|Given by PO and IV
214728658|NCT04507360|BEHAVIORAL|Study 1, Demographics Survey|Participants will be shown a demographics survey (e.g., age range, gender, income).
214644407|NCT03042936|BEHAVIORAL|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
214644408|NCT01032148|DRUG|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
214644409|NCT01397578|DRUG|MABT5102A|Repeating subcutaneous injection
214644410|NCT01397578|DRUG|MABT5102A|Repeating intravenous infusion
214644411|NCT01397578|DRUG|placebo|Repeating subcutaneous injection
214644412|NCT01397578|DRUG|placebo|Repeating intravenous infusion
214644413|NCT02528240|PROCEDURE|EMS|
214644414|NCT02528240|DEVICE|+ occlusive membrane|
214644415|NCT02528240|DEVICE|conebeam CT|
214644416|NCT04044833|BEHAVIORAL|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
214644417|NCT00935389|DRUG|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
214644418|NCT05003388|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214644419|NCT06145893|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
214644420|NCT06145893|DRUG|Hemay005|Hemay005 tables 45mg bid p.o;
214644421|NCT06145893|DRUG|Placebo|placebo to Hemay005 tables bid p.o
214644422|NCT05016804|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214644423|NCT05536349|DRUG|Pirtobrutinib|Given by PO
214644424|NCT05536349|DRUG|Obinutuzumab|Given by (IV) vein
214644425|NCT05536349|DRUG|Venetoclax|Given by PO
214644426|NCT05536349|DRUG|Valacyclovir|Given by PO
214644427|NCT05536349|DRUG|Allopurinol|Given by PO
214644428|NCT05243628|BIOLOGICAL|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
214644429|NCT05243628|BIOLOGICAL|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214644430|NCT05243628|DEVICE|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
214728659|NCT04507360|BEHAVIORAL|Study 1, Next Steps Survey|Participants will be shown the Next Steps Survey, which includes 2 items assessing intended next steps on the Mental Health America (MHA) website (e.g., take another mental health test, find a treatment provider near you) and perceived need (yes, no, or I don't know) in addition to the Demographics Survey items.
214728660|NCT04507360|BEHAVIORAL|Study 1, Generic Response|Participants will be provided with the generic/current response to screening.
214728661|NCT04507360|BEHAVIORAL|Study 1, Generic Resources|Participants will be provided with links to a list of 4 generic Mental Health America (MHA) resources.
214728662|NCT04507360|BEHAVIORAL|Study 1, Tailored Response|Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes, no, or I don't know).
214728663|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Demographics|Participants will be provided with links to Mental Health America (MHA) resources tailored to sexuality (Lesbian, Gay, Bisexual, Transgender, or Queer) status and age range.
214728664|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Desired Resources|Participants will be provided with links to Mental Health America (MHA) resources aligned with their expressed interest (e.g., additional screening, self help tools).
214728665|NCT04507360|BEHAVIORAL|Study 2, Control|Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY).
214728666|NCT04507360|BEHAVIORAL|Study 2, DIY tool without AI|Participants in the Do-It-Yourself (DIY) tool without Artificial Intelligence (AI) group will be instructed to use the DIY tool 3 times a week.
214728667|NCT04507360|BEHAVIORAL|Study 2, DIY tool with AI|Participants in the Do-It-Yourself (DIY) tool with Artificial Intelligence (AI) group will be instructed to use the DIY tool with AI 3 times a week.
214728668|NCT05844254|PROCEDURE|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
214728669|NCT00636155|DRUG|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
214728670|NCT00636155|DRUG|Rituximab|375 mg/m2 on day 2
214728671|NCT00636155|DRUG|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
214728672|NCT00636155|DRUG|Fludarabine|25 mg/m2 on days 2, 3, and 4
214728673|NCT01922518|PROCEDURE|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
214728674|NCT01922518|PROCEDURE|Apex pacing|Put RV lead around the apex
214728675|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
214728676|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
214644431|NCT05948956|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-ketone Powder ™ and electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
214644432|NCT05948956|DIETARY_SUPPLEMENT|Electrolyte Beverage|Participants will consume an electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
214644433|NCT05948956|BEHAVIORAL|Cycling Intervention|"Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down."
214728677|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
214728678|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
214728679|NCT02624661|DRUG|Glycerol|
214728680|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
214728681|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
214728682|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
214728683|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
214728684|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
214728685|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
214728686|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
214728687|NCT00779181|DRUG|Placebo|Placebo taken three times a day
214728688|NCT02845284|BEHAVIORAL|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
214728689|NCT02845284|BEHAVIORAL|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
214728690|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
214728691|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
214728692|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
214728693|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
214728694|NCT00534664|DEVICE|TheraBionic device|Daily outpatient treatment with theraBionic device
214728695|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
214728696|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
214728697|NCT00352404|DEVICE|Endomicroscope|
214728698|NCT04334044|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
214728699|NCT00470977|DRUG|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
214728700|NCT02064829|DRUG|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
214728701|NCT02064829|DRUG|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
214728702|NCT04849195|OTHER|No intervention|No intervention
214728703|NCT02158000|OTHER|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
214728704|NCT02094196|OTHER|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
214728705|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
214728706|NCT01144091|DRUG|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
214728707|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
214728708|NCT01144091|DRUG|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
214728709|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
214728710|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
214728711|NCT02973997|DRUG|Lenvatinib|Given PO
214728712|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
214728713|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
214728714|NCT03638518|OTHER|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
214728715|NCT03638518|OTHER|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
214728716|NCT02620124|DRUG|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
214728717|NCT02620124|DRUG|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
214728718|NCT02165644|DRUG|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
214728719|NCT02165644|DRUG|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
214728720|NCT00131534|BEHAVIORAL|Individual therapy|Stage-based individual therapy for trauma survivors
214728721|NCT00131534|BEHAVIORAL|Group therapy|Stage-based group therapy for trauma survivors
214728722|NCT06433024|DIAGNOSTIC_TEST|PPG Diagnostic|The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
214728723|NCT01326390|DEVICE|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
214728724|NCT01326390|PROCEDURE|DSA arteriogram- hepatic arteries|Standard of care
214728725|NCT01326390|PROCEDURE|CO2 aortogram|Standard of care
214728726|NCT01481766|DIETARY_SUPPLEMENT|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
214728727|NCT01481766|DIETARY_SUPPLEMENT|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
214728728|NCT01481766|BEHAVIORAL|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
214728729|NCT02138162|DRUG|enzalutamide|oral
214728730|NCT00684463|DRUG|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
214728731|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
214728732|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
214728733|NCT00325949|DRUG|placebo|2 tablets BID
214728734|NCT00673218|DRUG|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
214728735|NCT00673218|DRUG|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
214728736|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
214728737|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
214728738|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
214728739|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
214728740|NCT02737605|DRUG|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
214728741|NCT02737605|DRUG|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
214728742|NCT02737605|DRUG|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
214728743|NCT02737605|DRUG|Oral Placebo|Participants will receive matching placebo orally.
214728744|NCT02737605|DRUG|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
214728745|NCT02737605|DRUG|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
214728746|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
214728747|NCT00444951|BIOLOGICAL|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
214728748|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
214728749|NCT05802290|DRUG|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
214728750|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
214728751|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
214728752|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
214728753|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
214728754|NCT01731275|DRUG|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
214728755|NCT01731275|DRUG|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
214728756|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
214728757|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
214728758|NCT01462422|DRUG|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
214728759|NCT01462422|DRUG|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
214728760|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
214728761|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
214728762|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
214728763|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
214728764|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
214728765|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
214728766|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
214728767|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
214728768|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
214728769|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
214728770|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
214728771|NCT00366444|DRUG|Placebo|Placebo every 6 hours
214728772|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
214728773|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
214728774|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
214728775|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
214728776|NCT06300437|PROCEDURE|jaw thrust|children who will receive jaw thrusting during fiberoptic intubation
214728777|NCT06300437|PROCEDURE|control (sub laxed jaw)|children who will not receive jaw thrusting (just sub laxed open mouth)
214728778|NCT06058351|BEHAVIORAL|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
214728779|NCT05724069|DRUG|Velusetrag 15 mg once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
214728780|NCT05724069|DRUG|Placebo once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
214644434|NCT05618366|DRUG|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
214644435|NCT05618366|DRUG|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
214644436|NCT01509352|PROCEDURE|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
214644437|NCT01509352|PROCEDURE|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
214644438|NCT00324285|DRUG|Amylase resistant starch added ORS|
214644439|NCT01032551|BEHAVIORAL|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
214644440|NCT04925895|OTHER|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
214644441|NCT04925895|OTHER|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
214644442|NCT04925895|OTHER|Cryotherapy|application of cold pack on knee joint for 10 minutes
214644443|NCT04925895|OTHER|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
214644444|NCT01251328|PROCEDURE|General anaesthesia|general anaesthesia is performed according to the hospitals standard
214644445|NCT01251328|PROCEDURE|Sedation|Sedation is performed according to the hospitals standard
214644446|NCT04121247|OTHER|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
214644447|NCT00502216|DRUG|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
214644448|NCT00502216|DRUG|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
214644449|NCT06372132|PROCEDURE|G-POEM|Gastric Per-Oral Endoscopic Pyloromyotomy
214644450|NCT02549482|OTHER|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
214644451|NCT02549755|DRUG|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
214644452|NCT06269445|DRUG|Icaritin Combined With Bevacizumab and FOLFIRI|Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
214728781|NCT06343558|OTHER|Questionnaires, clinical scales and instrumental tests|Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
214644453|NCT02381119|BEHAVIORAL|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
214644454|NCT02381119|BEHAVIORAL|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
214644455|NCT03285997|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
214644456|NCT03285997|BIOLOGICAL|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
214644457|NCT05070377|OTHER|Physical activity|"1. structured physical activity sessions by physical education (school), twice a week, with twenty-minute each lesson;~2. self-monitoring plus goal setting by pedometer (out-of-school), progressive goals to achieve weekly;~3. healthy lifestyle guidance ( parents social support)."
214644458|NCT02280278|PROCEDURE|Radical surgery|
214644459|NCT02280278|DRUG|Adjuvant chemotherapy|
214644460|NCT02280278|BIOLOGICAL|Cytokine-induced killer cell immunotherapy|
214644461|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
214644462|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
214644463|NCT03644238|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|75g of glucose is consumed
214644464|NCT03644238|BEHAVIORAL|Inactivity|Lying or sitting down.
214644465|NCT03644238|BEHAVIORAL|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
214644466|NCT01625754|BEHAVIORAL|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
214644467|NCT05010356|DRUG|Insulin|Hyperinsulinemic euglycemic clamp
214644468|NCT01738971|OTHER|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
214644469|NCT01738971|OTHER|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
214644470|NCT01088035|DRUG|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
214644471|NCT01031446|DRUG|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
214644472|NCT01031446|DRUG|everolimus|Taken daily by mouth.
214644473|NCT01031446|DRUG|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
214644474|NCT01031446|OTHER|laboratory biomarker analysis|Blood collection
214644475|NCT01447108|DEVICE|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
214644476|NCT05932550|DRUG|Maraviroc 300 mg|10 week treatment as add-on therapy to anti-depressants
214644477|NCT05033496|DIAGNOSTIC_TEST|Thyroid function test|Thyroid function test
214644478|NCT03320122|OTHER|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
214644479|NCT03320122|OTHER|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
214644480|NCT03320122|OTHER|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
214644481|NCT02109341|DRUG|Paclitaxel bound albumine|
214644482|NCT00692211|OTHER|Mailed fecal occult blood tests|Stool blood test
214644483|NCT00692211|OTHER|Mailed fecal immunochemical tests|Stool blood test
214644484|NCT03737773|OTHER|glasses (prismatic lenses)|
214644485|NCT03737773|OTHER|glasses (neutral)|
214644486|NCT00782366|GENETIC|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
214644487|NCT04320407|DEVICE|Osia 2 System|The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
214644488|NCT06152822|DRUG|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
214644489|NCT06335615|BEHAVIORAL|Brief Acceptance Intervention|The intervention consist of explanations and exercises about acceptance of stress. The intervention starts with a welcome, after which participants do jumping jacks and then breath through a straw to induce an uncomfortable experience. Next, a Chinese finger trap is used to show the automatic, but often not useful, reaction to avoid stress. Participants then watch a short video that introduces the concept of acceptance, and they do a short, guided meditation. Afterwards, they do the straw exercise again, but this time with instruction to examine and allow uncomfortable experiences. The session ends with a recap and the introduction of the home exercise. Participants install an app that reminds them every hour to do a three-second meditation in which they pay attention to their breathing and body in an accepting way.
214644490|NCT06335615|BEHAVIORAL|Psychoeducation|In the psychoeducation, participants learn about the stress response, mindfulness, and acceptance. For this, they are guided through a vignette about a student who struggles with stress and then develops a more accepting stance towards it. The psychoeducation explains how acceptance can help to deal with stress but does not instruct participants to apply this in their own life.
214644491|NCT02531646|RADIATION|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
214644492|NCT00054977|DRUG|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
214644493|NCT00054977|DRUG|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
214644494|NCT00114062|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
214644495|NCT05079997|DEVICE|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
214644496|NCT01617941|DRUG|BGG492|
214644497|NCT01617941|DRUG|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
214644498|NCT04957381|BEHAVIORAL|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
214644499|NCT03914976|PROCEDURE|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
214644500|NCT00726687|DRUG|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
214644501|NCT00726687|DRUG|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
214644502|NCT06473038|OTHER|Reduction in Salt and Sugar|150 participants who are grouped under interventions, their data will be collected according to the alterations of sodium and sugar intake and then compared with the control group. Instruments include urine analysis, providing two spot urine samples - first-morning void and last void in the evening before leaving campus, at three-time points - at the start of the study, after 3 months, and after 6 months. This will yield a total of 300 × 2 × 3 = 1800 samples. Urine electrolytes (sodium, potassium, chloride) and creatinine will be measured using the potentiometry method (Alinity Abbott) at the laboratory department of Sunway Medical Centre, Bandar Sunway.
214644503|NCT06473038|DEVICE|The potentiometer|The potentiometer is utilized for the quantitative analysis of electrolytes present in urine samples. The potentiometer used for urine electrolytes analysis is a specialized device equipped with electrodes and sensors designed to detect and measure the concentration of specific electrolytes in urine samples. It employs potentiometric principles to generate electrical signals proportional to the concentration of ions present in the sample.
214644504|NCT06473038|DEVICE|Dry Ashing Method Followed by Flame Atomic Absorption Spectrometry (FAAS)|"Dry ashing method involves heating the food samples in a controlled environment to remove organic matter and moisture, leaving behind inorganic residues (ashes) containing the salts and minerals present in the food. Flame Atomic Absorption Spectrometryis utilized to measure the levels of sodium and potassium (components of salt) as well as carbon and hydrogen (components of sugar) in the ashed food samples.~By determining the concentrations of these elements, the salt and sugar content of the food samples can be quantified accurately."
214644505|NCT06419764|DRUG|Spleen Invigorating and Weight Reducing Decoction|"Composition: Raw Astragalus (Huang Qi) 5g, Cang Zhu 5g, Fructus Aurantii Immaturus (Zhi Shi) 3g, Prepared Rhubarb (Shu Jun) 3g, Red Peony Root (Chi Shao Yao) 3g, Crataegus (Shan Zha) 3g, Tribulus (Bai Jie Li) 2g, Cimicifuga (Sheng Ma) 1g.~Granule form, for oral administration. Take 1 dose daily (2 bags, once in the morning and once in the evening, dissolved in water), for a course of 1 month."
214644506|NCT06419764|OTHER|Diet and meal replacements|The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
214644507|NCT00002508|DRUG|carboplatin|
214644508|NCT00002508|DRUG|etoposide|
214644509|NCT00002508|PROCEDURE|autologous bone marrow transplantation|
214644510|NCT00002508|PROCEDURE|peripheral blood stem cell transplantation|
214644511|NCT05544890|PROCEDURE|Exercise|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Therapeutic exercise"
214644512|NCT05544890|PROCEDURE|Manual Therapy|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Manipulation"
214728782|NCT04829734|DEVICE|Active PBMT-sMF|The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
214728783|NCT04829734|DEVICE|Placebo PBMT-sMF|The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
214728784|NCT03552289|DEVICE|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
214728785|NCT03552289|DEVICE|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
214728786|NCT02791477|DEVICE|Attune FB PS knee arthroplasty|
214728787|NCT00273806|BEHAVIORAL|Intervention for 4 behavioral risks by medical assistants.|
214728788|NCT02749786|OTHER|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
214728789|NCT01609491|DRUG|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
214728790|NCT01609491|DRUG|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
214728791|NCT04594889|PROCEDURE|angioplasty|Balloon releasing a drug inflated in the target vessel
214728792|NCT00062972|DRUG|donepezil|
214728793|NCT00062972|DRUG|glucose|
214728794|NCT00264628|DRUG|GW679769|
214728795|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
214728796|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
214728797|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
214728798|NCT04825106|OTHER|Diagnostic context|A life-threatening situation occurs in 3 different contexts
214728799|NCT00242944|DRUG|Pitavastatin|Pitavastatin 4mg per day
214728800|NCT00242944|DRUG|Atorvastatin|Atorvastatin 20mg per day
214728801|NCT04409340|DEVICE|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
214728802|NCT04409340|DEVICE|QUS|QUS
214728803|NCT00397449|BIOLOGICAL|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
214728804|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
214728805|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
214728806|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
214728807|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
214728808|NCT03979495|OTHER|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
214728809|NCT01008436|DRUG|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
214728810|NCT01008436|DRUG|Control|Traditional surgical Hemostasis
214728811|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
214728812|NCT04403802|DEVICE|Voxx Human Performance Technology Socks|"Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
214728813|NCT04403802|DEVICE|Placebo Socks|"Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
214728814|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
214728815|NCT00965744|DEVICE|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
214728816|NCT01938391|DEVICE|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
214728817|NCT05547594|BEHAVIORAL|Multimodal surgical prehabilitation|Participants will be encouraged to engage in regular physical activity (endurance and resistance exercise), eat healthily and undergo cognitive behavioural therapy (the latter only if required) during the weeks prior to surgery.
214728818|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
214728819|NCT02337075|DEVICE|Activity Mentor|
214728820|NCT05857215|DRUG|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
214728821|NCT01250899|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
214728822|NCT02026934|DEVICE|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
214728823|NCT00246285|DRUG|risperidone|
214728824|NCT06411106|DRUG|IMIQUIMOD cream 50mg/g|5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber
214728825|NCT00469040|DRUG|GW642444M for 14 days|M salt
214728826|NCT00673816|DRUG|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
214728827|NCT05479136|DRUG|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
214728828|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
214728829|NCT04829006|DEVICE|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
214728830|NCT05042570|OTHER|Instrument Assisted Soft Tissue Mobilization|"* This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
214793965|NCT00649025|DRUG|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
214793966|NCT00649025|DRUG|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
214793967|NCT00649025|DRUG|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
214793968|NCT03621800|OTHER|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
214728831|NCT05042570|OTHER|Stretching Exercises|"* The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
214728832|NCT05042570|OTHER|Control Group / NDT program|"* Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance."
214728833|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
214728834|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
214728835|NCT02401776|DIETARY_SUPPLEMENT|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
214728836|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
214728837|NCT02401776|DIETARY_SUPPLEMENT|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
214728838|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
214728839|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
214728840|NCT00533780|PROCEDURE|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
214728841|NCT05017987|DRUG|ATB-101, ATB-1011, ATB-1012|"1. Test drug~   \- Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin"
214728842|NCT04300842|DEVICE|smart bracelet|to measure the stress, fatigue, and activity.
214728843|NCT03500536|BEHAVIORAL|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
214728844|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
214728845|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
214728846|NCT00343395|DRUG|AVANDAMET|2/500 mg
214728847|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
214728848|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
214728849|NCT03437993|OTHER|Recollect, the game|"Recollect is a working memory training game"
214728850|NCT03437993|OTHER|Tetris|App-based video game where shapes are rotated and placed to fit a grid
214728851|NCT06118008|DRUG|HS-20094 5mg|Administrated by subcutaneous injection
214728852|NCT06118008|DRUG|HS-20094 10mg|Administrated by subcutaneous injection
214728853|NCT06118008|DRUG|HS-20094 15mg|Administrated by subcutaneous injection
214728854|NCT06118008|DRUG|HS-20094 20mg|Administrated by subcutaneous injection
214728855|NCT06085703|DRUG|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214728856|NCT06085703|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214728857|NCT06212466|DEVICE|CardioFlux|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.
214728858|NCT02401685|OTHER|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
214728859|NCT02401685|PROCEDURE|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
214728860|NCT06520345|DRUG|177Lu-TLX591|Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
214728861|NCT06520345|DRUG|Enzalutamide|Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
214728862|NCT06520345|DRUG|Abiraterone|Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
214728863|NCT06520345|DRUG|Docetaxel|Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
214728864|NCT06415656|DEVICE|TempTraq|TempTraq (Blue Spark Technologies, Westlake, OH) is an FDA 510K cleared wearable, wireless temperature monitoring patch designed to continuously monitor and track body temperature.
214728865|NCT06415656|DEVICE|VitalTraq|VitalTraq (Blue Spark Technologies, Westlake, OH) is an experimental and novel multi-vital sign monitoring platform that allows for interval measurements of heart rate, heart rate variability, and blood pressure.
214728866|NCT05480306|DRUG|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
214728867|NCT05480306|DRUG|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
214728868|NCT05480306|DRUG|Bevacizumab|90-min IV infusion (5mg)
214728869|NCT05480306|DRUG|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
214728870|NCT02234050|DRUG|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
214728871|NCT02234050|OTHER|Local standard of care|Left to the discretion of the investigator
214728872|NCT02365506|DRUG|Eleclazine|Tablets administered orally in a single dose
214728873|NCT02365506|DRUG|Placebo|Placebo to match tablets administered orally in a single dose
214728874|NCT00592176|DRUG|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
214728875|NCT04252391|PROCEDURE|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
214728876|NCT04252391|PROCEDURE|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
214728877|NCT01680991|DRUG|Obinutuzumab|Multiple doses of obinutuzumab.
214728878|NCT01335438|DEVICE|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
214728879|NCT01335438|DEVICE|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
214728880|NCT06179355|PROCEDURE|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
214728881|NCT06179355|PROCEDURE|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
214728882|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
214728883|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
214728884|NCT00599222|BIOLOGICAL|ranibizumab|0.5 mg intravitreal injection
214728885|NCT00599222|PROCEDURE|TTT|Transpupillary thermotherapy (TTT)
214728886|NCT00599222|PROCEDURE|Sham TTT|Sham Transpupillary thermotherapy (TTT)
214728887|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
214728888|NCT01852591|BIOLOGICAL|PCV 13|
214728889|NCT02375880|DRUG|DKN-01|Administration by intravenous (IV) infusion.
214728890|NCT02375880|DRUG|gemcitabine|Administered by IV infusion.
214728891|NCT02375880|DRUG|cisplatin|Administered by IV infusion
214728892|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
214728893|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
214728894|NCT04300946|DEVICE|TMS targeted on the cerebellum|Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
214728895|NCT05628194|OTHER|Observational/Survery|MSM participants will complete a one-time survey, delivered in an e-format. Survey will be accessible via Meta-based social media platforms (Facebook, Instagram).
214728896|NCT05547620|DEVICE|LIFUS Online Real|Stimulation using NeuroFUS device while standing
214728897|NCT05547620|DEVICE|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
214728898|NCT05547620|DEVICE|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
214728899|NCT06073054|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
214728900|NCT06448585|DRUG|Specific immunotherapy (SIT) treatment|Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
214728901|NCT06448585|DIETARY_SUPPLEMENT|Dietary Supplement: ABB C1|"Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams"
214728902|NCT06448585|DIETARY_SUPPLEMENT|Mini-tablets with pork extract|Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
214728903|NCT06629233|PROCEDURE|Tumor resection|As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
214728904|NCT06499857|DRUG|Semaglutide|3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
214728905|NCT06499857|DRUG|Placebo|3ml pen-injector containing placebo solution for subcutaneous use.
214728906|NCT04657432|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
214728907|NCT06553898|BIOLOGICAL|anti-BCMA/CD70 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
214728908|NCT04307277|DRUG|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
214728909|NCT04307277|OTHER|Standard of care|Surgical excision with external radiotherapy (if applicable)
214728910|NCT04574570|DEVICE|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
214728911|NCT06420193|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
214728912|NCT05563272|DIAGNOSTIC_TEST|89Zr-girentuximab for PET/CT imaging of CAIX positive tumors|On Day 0, participants will receive a single administration of 89Zr-girentuximab (37 Megabecquerel (MBq) \[1mCi\] ± 10%, containing a mass dose of 10 mg of girentuximab).
214728913|NCT03601078|BIOLOGICAL|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
214728914|NCT03601078|DRUG|Lenalomide|Specified dose on specified days
214728915|NCT03601078|DRUG|Talquetamab|Specified dose on specified days
214728916|NCT05738603|DEVICE|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
214728917|NCT04270565|BEHAVIORAL|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
214728918|NCT04270565|BEHAVIORAL|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
214728919|NCT03630185|DEVICE|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
214728920|NCT03630185|DEVICE|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
214728921|NCT02079415|OTHER|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
214728922|NCT00141167|DRUG|varenicline|
214728923|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
214728924|NCT02186340|PROCEDURE|Inspiratory muscle training|
214728925|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
214728926|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
214728927|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
214728928|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
214728929|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
214728930|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
214728931|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
214728932|NCT00002852|DRUG|paclitaxel|Given IV
214728933|NCT00002852|DRUG|carboplatin|Given IV
214728934|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214728935|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
214728936|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
214728937|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
214728938|NCT03278925|PROCEDURE|Biopsy|Undergo biopsy
214728939|NCT03278925|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214728940|NCT03278925|PROCEDURE|Computed Tomography|Undergo CT
214728941|NCT03278925|DRUG|Defined Green Tea Catechin Extract|Given PO
214728942|NCT03278925|OTHER|Laboratory Biomarker Analysis|Correlative studies
214728943|NCT03278925|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214728944|NCT03278925|OTHER|Pharmacological Study|Correlative studies
214728945|NCT03278925|OTHER|Questionnaire Administration|Ancillary studies
214728946|NCT03278925|PROCEDURE|Ultrasound|Undergo ultrasound
214728947|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
214728948|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
214728949|NCT01712191|DEVICE|NUsurface Meniscus Implant|
214728950|NCT05685849|DEVICE|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
214728951|NCT01490333|DIETARY_SUPPLEMENT|Vitamin D3|The vitamin D3 will be taken daily.
214728952|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
214728953|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
214728954|NCT01172054|BIOLOGICAL|VAX128|one IM injection
214728955|NCT01172054|BIOLOGICAL|Placebo|One IM injection
214728956|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
214728957|NCT02548091|PROCEDURE|Non invasive ventilation|
214728958|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
214728959|NCT02548091|PROCEDURE|Computed tomography (CT)|
214728960|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
214728961|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
214728962|NCT05505734|DRUG|BDA MDI|Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
214728963|NCT05505734|DRUG|AS MDI|Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
214728964|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
214728965|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
214728966|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
214728967|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
214728968|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
214728969|NCT00435929|DRUG|Ritonavir|100mg po bid
214728970|NCT00435929|DRUG|saquinavir [Invirase]|1000mg po bid
214728971|NCT00564265|OTHER|Observation|Not applied
214728972|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
214728973|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
214728974|NCT02253680|PROCEDURE|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
214728975|NCT06027541|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
214728976|NCT06331325|PROCEDURE|Frenotomy|Partial thickness procedure aiming to relocate high frenum attachment to a more apical level.
214728977|NCT06331325|PROCEDURE|Frenectomy|Full-thickness excision of the frenum down to the bone level and suturing by achieving primary closure.
214728978|NCT05553587|DRUG|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
214728979|NCT00976963|DRUG|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
214728980|NCT00976963|DRUG|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
214728981|NCT00757081|DRUG|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
214728982|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
214728983|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
214728984|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
214728985|NCT02583828|DRUG|Cyclophosphamide 50mg|
214728986|NCT02583828|DRUG|Letrozole 2.5 mg|
214728987|NCT01775800|OTHER|Treatment modification|
214728988|NCT00085345|DRUG|arsenic trioxide|
214728989|NCT00085345|DRUG|ascorbic acid|
214728990|NCT00085345|DRUG|melphalan|
214728991|NCT00085345|PROCEDURE|chemosensitization/potentiation|
214728992|NCT00085345|PROCEDURE|chemotherapy|
214728993|NCT03234270|DEVICE|Core temperature measurements|Core temperature measurements with coretemp pill
214728994|NCT01328769|DRUG|Febuxostat|
214728995|NCT01328769|DRUG|Placebo|
214728996|NCT00394693|GENETIC|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
214728997|NCT02768103|BEHAVIORAL|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
214728998|NCT04574141|DIETARY_SUPPLEMENT|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
214728999|NCT04024241|DEVICE|Flow Cytometer|high dose
214729000|NCT04024241|DRUG|Mitoxantrone|high dose
214729001|NCT04024241|DRUG|Cytarabine|high dose
214729002|NCT01666990|DRUG|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
214729003|NCT01666990|DRUG|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
214644513|NCT05544890|PROCEDURE|Kinesiotape|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Kinesiotaping"
214644514|NCT05352581|DIAGNOSTIC_TEST|BD Veritor At-Home|BD Veritor At-Home rapid self testing
214644515|NCT05352581|DIAGNOSTIC_TEST|BD Veritor Professional|BD Veritor Professional rapid test
214644516|NCT01382693|BEHAVIORAL|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
214644517|NCT01382693|BEHAVIORAL|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
214644518|NCT04588324|DRUG|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
214644519|NCT04588324|DRUG|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
214644520|NCT04588324|DRUG|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
214644521|NCT01337128|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
214644522|NCT01337128|PROCEDURE|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
214644523|NCT01337128|PROCEDURE|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
214644524|NCT01337128|PROCEDURE|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
214644525|NCT01337128|PROCEDURE|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
214644526|NCT01337128|PROCEDURE|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
214644527|NCT05275907|DRUG|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
214644528|NCT05275907|DRUG|Chlorthalidone|25mg capsule once daily for 6 weeks
214644529|NCT05656209|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
214644530|NCT04319900|DRUG|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
214644531|NCT04319900|DRUG|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
214644532|NCT04319900|DRUG|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
214644533|NCT01240161|DRUG|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
214644534|NCT06818396|OTHER|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia
214644535|NCT06818396|DRUG|Intrathecal nalbuphine and spinal anesthesia|intrathecal nalbuphine and spinal anesthesia
214644536|NCT06818396|OTHER|Spinal anesthesia|Spinal anesthesia
214644537|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.
214644538|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy+Transbronchial cryobiopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
214644539|NCT06222151|OTHER|Intervention 1: Mobilization during hospitalization|Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
214644540|NCT06222151|OTHER|Intervention 2: Mobilization the first 4 postoperative weeks|Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
214644541|NCT06222151|OTHER|Control group|"The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge."
214729004|NCT04348188|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
214729005|NCT01048047|DRUG|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
214729006|NCT04724772|DRUG|Tranexamic acid injection|Injection of tranexamic acid preoperatively
214729007|NCT01962467|DRUG|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
214729008|NCT01962467|DRUG|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
214729009|NCT01962467|DRUG|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
214729010|NCT05224752|OTHER|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
214729011|NCT02433691|OTHER|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
214729012|NCT02433691|OTHER|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
214729013|NCT02433691|OTHER|stretching and toning|anaerobic stretching and toning followed by memory training.
214729014|NCT01045876|DRUG|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
214729015|NCT01045876|OTHER|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
214729016|NCT02283840|DRUG|BIA 2-093|
214729017|NCT03369704|DRUG|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
214729018|NCT03369704|DRUG|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
214729019|NCT05471024|PROCEDURE|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
214729020|NCT05471024|PROCEDURE|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
214729021|NCT05471024|PROCEDURE|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
214729022|NCT01855490|DRUG|Exenatide|
214729023|NCT02348840|DEVICE|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
214729024|NCT02505802|DRUG|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
214729025|NCT01263444|DRUG|Brinzolamide 1% / timolol 0.5% Fixed Combination|
214729026|NCT01263444|DRUG|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
214729027|NCT01611662|DRUG|gemcitabine hydrochloride|Given IV
214729028|NCT01611662|DRUG|cisplatin|Given IV
214729029|NCT01611662|PROCEDURE|therapeutic conventional surgery|Undergo radical cystectomy
214729030|NCT01611662|OTHER|laboratory biomarker analysis|Correlative studies
214729031|NCT02233894|DRUG|Atrovent® - inhalets|
214729032|NCT06092840|DIETARY_SUPPLEMENT|Transform Burn|Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
214729033|NCT03236506|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
214729034|NCT03236506|BEHAVIORAL|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
214729035|NCT03236506|DRUG|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
214729036|NCT03621124|PROCEDURE|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
214729037|NCT03621124|OTHER|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
214729038|NCT04327895|BEHAVIORAL|evaluation of the need for training|analyse of results of survey
214729039|NCT01037140|DRUG|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
214729040|NCT01037140|DRUG|placebo|oral placebo tablets similar to active comparator
214729041|NCT01466062|DRUG|Palivizumab|
214729042|NCT02865928|DRUG|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
214729043|NCT02865928|DRUG|Normal Saline|Same injection technique as intervention arm with normal saline
214729044|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
214729045|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
214729046|NCT03152110|OTHER|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
214729047|NCT04584944|RADIATION|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
214729048|NCT02082665|DRUG|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
214729049|NCT02082665|DRUG|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
214729050|NCT02082665|DRUG|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
214729051|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
214729052|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
214729053|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
214729054|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
214729055|NCT02264652|DEVICE|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
214729056|NCT05726643|OTHER|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
214729057|NCT05726643|OTHER|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
214729058|NCT03278444|OTHER|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
214729059|NCT03278444|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
214729060|NCT03278444|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
214729061|NCT05909462|DRUG|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine|ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
214729062|NCT00481689|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
214729063|NCT04493944|BEHAVIORAL|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
214729064|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
214729065|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
214729066|NCT01807494|DEVICE|Total hip replacement components|All patients will receive the same implants
214729067|NCT02458742|DRUG|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
214729068|NCT02458742|DRUG|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
214729069|NCT02711410|DRUG|Clopidogrel|
214729070|NCT01922986|DEVICE|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
214729071|NCT01922986|DEVICE|sham rTMS|20 minutes of sham rTMS stimulation
214729072|NCT01922986|BEHAVIORAL|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
214729073|NCT04857606|DRUG|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
214729074|NCT04857606|DRUG|Placebo|Single dose of placebo administered as a subcutaneous injection.
214729075|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
214729076|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
214729077|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
214729078|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
214729079|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
214729080|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
214729081|NCT00671476|DRUG|pegylated liposomal doxorubicin hydrochloride|
214729082|NCT00671476|GENETIC|DNA methylation analysis|
214729083|NCT00671476|GENETIC|TdT-mediated dUTP nick end labeling assay|
214729084|NCT00671476|GENETIC|fluorescence in situ hybridization|
214729085|NCT00671476|GENETIC|loss of heterozygosity analysis|
214729086|NCT00671476|GENETIC|polymerase chain reaction|
214729087|NCT00671476|OTHER|immunoenzyme technique|
214729088|NCT00671476|OTHER|immunohistochemistry staining method|
214729089|NCT00671476|OTHER|laboratory biomarker analysis|
214729090|NCT00671476|PROCEDURE|breast duct lavage|
214729091|NCT00671476|PROCEDURE|neoadjuvant therapy|
214729092|NCT00671476|PROCEDURE|therapeutic conventional surgery|
214729093|NCT05382806|DRUG|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
214729094|NCT05153564|DRUG|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
214729095|NCT05153564|DRUG|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
214729096|NCT05153564|DRUG|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
214729097|NCT05153564|DRUG|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
214729098|NCT05153564|DRUG|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
214729099|NCT00723086|DRUG|docetaxel (XRP6976)|combined treatment with prednisolone
214729100|NCT00662285|DIETARY_SUPPLEMENT|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
214729101|NCT00125697|PROCEDURE|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
214729102|NCT01401985|DRUG|TD-1211|Capsules
214729103|NCT01401985|DRUG|Placebo|Capsules
214729104|NCT00113906|DRUG|melatonin|
214729105|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
214729106|NCT01674972|OTHER|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
214729107|NCT02213081|DRUG|Ulipristal|Patient will take 15mg every other day, or every 4 days per week.
214729108|NCT00658866|PROCEDURE|Microdialysis|PK measurements with microdialysis
214729109|NCT05098249|DRUG|Verum|The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
214729110|NCT05098249|DRUG|Placebo|The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
214729111|NCT00836316|DRUG|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
214729112|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
214729113|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
214729114|NCT03284151|RADIATION|Cyberknife|
214729115|NCT02640430|DEVICE|standard treatment|20 minutes, twice a day for 10 sessions
214729116|NCT02640430|DEVICE|Free Aspire|20 minutes, twice a day for 10 sessions
214729117|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
214729118|NCT00438490|DRUG|Recombinant Human Prolactin|
214729119|NCT02327728|PROCEDURE|Botulinum toxin A injection (5 sites: 12.5U)|
214729120|NCT02327728|PROCEDURE|Botulinum toxin A injection (4 sites: 10U)|
214729121|NCT02327728|DRUG|Botulinum toxin A 12.5U|
214729122|NCT02327728|DRUG|Botulinum toxin A 10U|
214729123|NCT05953103|DRUG|Synbixin/Placebo|Synbixin/Placebo
214729124|NCT04135391|BEHAVIORAL|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
214729125|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
214729126|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
214729127|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
214729128|NCT00665691|OTHER|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
214729129|NCT02644694|DRUG|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
214729130|NCT01858506|PROCEDURE|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
214729131|NCT01858506|PROCEDURE|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
214729132|NCT02515851|DRUG|Exparel|
214729133|NCT02515851|DRUG|Placebo|
214729134|NCT01501162|DRUG|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
214729135|NCT01501162|DRUG|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
214729136|NCT01919086|DRUG|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
214729137|NCT01919086|DRUG|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
214729138|NCT01919086|DRUG|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
214729139|NCT00028964|DIETARY_SUPPLEMENT|Chinese herbs|
214729140|NCT00028964|DRUG|cyclophosphamide|
214729141|NCT00028964|DRUG|doxorubicin hydrochloride|
214729142|NCT00028964|PROCEDURE|adjuvant therapy|
214729143|NCT05346861|DRUG|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
214729144|NCT05346861|DRUG|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
214729145|NCT06026423|OTHER|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
214729146|NCT06026423|OTHER|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
214729147|NCT04259346|DRUG|Ixekizumab|Administered SC.
214729148|NCT03021928|OTHER|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
214793969|NCT03404076|DIAGNOSTIC_TEST|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
214793970|NCT03544320|DEVICE|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
214793971|NCT03544320|DEVICE|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
214729149|NCT00572065|DRUG|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
214729150|NCT00572065|DRUG|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
214729151|NCT00085644|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
214729152|NCT00085644|BIOLOGICAL|placebo|Placebo every other week, subcutaneous
214729153|NCT02805894|DRUG|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
214729154|NCT02805894|DRUG|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
214729155|NCT03685929|PROCEDURE|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
214729156|NCT06019091|DEVICE|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
214729157|NCT03330106|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
214729158|NCT03330106|DRUG|Docetaxel|Docetaxel intravenous infusion.
214729159|NCT03330106|DRUG|Carboplatin|Carboplatin intravenous infusion.
214729160|NCT03330106|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
214729161|NCT01404806|DRUG|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
214729162|NCT05071911|PROCEDURE|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
214729163|NCT00623766|DRUG|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
214729164|NCT00623766|DRUG|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
214729165|NCT00623766|DRUG|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
214729166|NCT00623766|DRUG|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
214729167|NCT00623766|DRUG|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
214729168|NCT00623766|DRUG|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
214729169|NCT00623766|DRUG|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
214729170|NCT00623766|DRUG|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
214729171|NCT00623766|DRUG|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
214729172|NCT00623766|DRUG|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
214729173|NCT02958033|RADIATION|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
214729174|NCT04555811|DRUG|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
214729175|NCT04555811|DRUG|Rituximab|Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
214729176|NCT05714254|DRUG|MEDI0618|Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
214729177|NCT05714254|DRUG|Placebo|Four doses of IV placebo or SC placebo administered once every two weeks.
214729178|NCT04202432|DIAGNOSTIC_TEST|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
214729179|NCT00486889|BIOLOGICAL|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
214729180|NCT00036946|BIOLOGICAL|ziv-aflibercept|
214729181|NCT00421590|DRUG|SMC021|
214729182|NCT01283178|RADIATION|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
214729183|NCT01283178|DRUG|cisplatin|Given IV
214729184|NCT01283178|RADIATION|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
214729185|NCT01283178|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
214729186|NCT01283178|PROCEDURE|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
214729187|NCT01283178|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
214729188|NCT02772991|OTHER|troponin measurement|Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
214729189|NCT05513092|DIAGNOSTIC_TEST|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
214729190|NCT00893763|PROCEDURE|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
214729191|NCT00893763|PROCEDURE|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
214729192|NCT02387073|OTHER|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
214729193|NCT06283303|BIOLOGICAL|T3011 hepatic artery infusion|The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
214729194|NCT06283303|DRUG|toripalimab|The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
214729195|NCT06283303|DRUG|regorafenib|The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
214729196|NCT00033449|DRUG|gefitinib|Given orally
214729197|NCT00033449|RADIATION|radiation therapy|Undergo radiation therapy
214729198|NCT00033449|DRUG|cisplatin|Given IV
214729199|NCT00033449|OTHER|laboratory biomarker analysis|Correlative studies
214729200|NCT03884127|DRUG|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
214729201|NCT03884127|DRUG|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
214729202|NCT06229808|DEVICE|Multifunctional Birthing ball|"In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
214729203|NCT04804111|DRUG|arm 0|placebo group
214729204|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
214729205|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
214729206|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
214729207|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
214729208|NCT04729595|DRUG|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
214644542|NCT06824870|OTHER|RV5026B - ET1732 - Period 1|Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area.
214644543|NCT06824870|DRUG|reference topical product - Period 2|Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face.
214644544|NCT06824870|OTHER|RV5026B - ET1732 - Period 2|Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products.
214644545|NCT06183268|RADIATION|Spot Delete|"The treatments plans will utilize the scripted spot delete method to remove spots from the skin rind. To ensure all relevant skin spots are removed, the SkinSpots structure will be a 0.5 cm rind extending inward from the skin contour within 5 cm of the CTV. Spots will be removed from this structure and optimization will continue. Optimization objectives will be utilized to spare the skin rind structure during treatment planning, in addition to deleting spots."
214644546|NCT02490293|DRUG|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
214644547|NCT02490293|DRUG|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
214644548|NCT03746912|DRUG|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
214644549|NCT01879345|DRUG|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
214644550|NCT01879345|DRUG|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
214644551|NCT01879345|DRUG|Placebo|placebo tablets
214644552|NCT03655418|OTHER|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
214644553|NCT06878833|DRUG|LYN-005 (risperidone)|long-acting oral (LAO) capsule
214644554|NCT06878833|DRUG|Placebo for LYN-005|capsule
214644555|NCT06878833|DRUG|IR Risperidone|tablets
214644556|NCT06878833|DRUG|Placebo for IR Risperidone|tablets
214644557|NCT06888154|OTHER|compress application with heated saline|Covering intestines with sterile gauze soaked in 36°C heated saline during surgery to prevent drying and reduce infection risk
214644558|NCT03548441|PROCEDURE|Surgery|Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
214644559|NCT03548441|OTHER|Non-surgical management|Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
214644560|NCT04484285|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
214644561|NCT05877742|OTHER|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
214644562|NCT05877742|OTHER|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
214644563|NCT05888103|DRUG|Inclisiran|Inclisiran s.c
214644564|NCT05888103|DRUG|Matching Placebo for Inclisiran|Matching s.c. placebo
214644565|NCT05180786|OTHER|Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned on.
214644566|NCT05180786|OTHER|No Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned off.
214644567|NCT00962273|BEHAVIORAL|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
214729209|NCT04729595|OTHER|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
214729210|NCT02324049|DRUG|SBC-103|
214729211|NCT06377436|BEHAVIORAL|Experimental training|Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
214729212|NCT01537289|DEVICE|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
214729213|NCT01537289|DEVICE|chest tube (28-French)|inserting chest tube to decompress pneumothorax
214729214|NCT03640728|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
214729215|NCT03640728|DRUG|Entecavir|Entecavir 0.5 mg/day orally
214729216|NCT03640728|DRUG|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
214729217|NCT01358006|DRUG|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
214729218|NCT01358006|DRUG|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
214729219|NCT03862586|DRUG|N-acetyl cysteine|
214729220|NCT03862586|DRUG|Placebos|
214729221|NCT00995189|DEVICE|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
214729222|NCT00995189|DEVICE|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
214729223|NCT00995189|DEVICE|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
214729224|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
214729225|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
214729226|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
214729227|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
214729228|NCT02809391|DEVICE|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
214729229|NCT02809391|DEVICE|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
214729230|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
214729231|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
214729232|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
214729233|NCT01836029|DRUG|VTX-2337|TLR8 Agonist
214729234|NCT01836029|DRUG|Carboplatin|
214729235|NCT01836029|DRUG|Cisplatin|
214729236|NCT01836029|DRUG|5-fluorouracil|
214729237|NCT01836029|DRUG|Placebo|
214729238|NCT04476706|DRUG|canakinumab|canakinumab
214729239|NCT02776306|OTHER|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
214729240|NCT00004205|DRUG|letrozole|Letrozole 2.5 mg daily oral administration.
214729241|NCT00004205|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
214729242|NCT03388554|DEVICE|tDCS|
214729243|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
214729244|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
214729245|NCT01396031|BEHAVIORAL|Physical Therapy|Standard of care
214729246|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
214729247|NCT04224909|DIAGNOSTIC_TEST|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
214729248|NCT02384928|PROCEDURE|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
214729249|NCT02384928|DEVICE|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
214729250|NCT02384928|DRUG|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
214729251|NCT02384928|PROCEDURE|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
214729252|NCT02384928|BEHAVIORAL|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
214729253|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
214729254|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
214729255|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
214729256|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
214729257|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
214729258|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
214729259|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
214729260|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
214729261|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
214729262|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
214729263|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
214729264|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
214729265|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
214729266|NCT05071794|DRUG|saline 0.9%|Placebo
214729267|NCT03477864|BIOLOGICAL|Ipilimumab|Given via intraprostatic injection
214729268|NCT03477864|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
214729269|NCT03477864|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214729270|NCT03477864|BIOLOGICAL|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
214729271|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
214729272|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
214729273|NCT04157751|DRUG|Empagliflozin|Film-coated tablet
214729274|NCT04157751|DRUG|Placebo to Empagliflozin|Film-coated tablet
214729275|NCT00524667|DRUG|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
214729276|NCT00427791|DRUG|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
214729277|NCT00427791|RADIATION|Total Body Irradiation|3 Gy Daily for 4 Days
214729278|NCT00427791|DRUG|Rituximab|375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
214729279|NCT03420157|OTHER|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
214644568|NCT00962273|BEHAVIORAL|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
214644569|NCT01569984|RADIATION|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
214644570|NCT00270608|PROCEDURE|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
214644571|NCT00270608|PROCEDURE|MRI of the spine and the right knee|a single time 45 minutes procedure
214644572|NCT00270608|PROCEDURE|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
214644573|NCT03968419|DRUG|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
214644574|NCT03968419|DRUG|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
214729280|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
214729281|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
214729282|NCT04282369|DEVICE|HHHFNC|noninvasive ventilation modality
214729283|NCT04282369|DEVICE|NCPAP|noninvasive ventilation modality
214729284|NCT04282369|DEVICE|NIPPV|noninvasive ventilation modality
214729285|NCT04282369|DEVICE|NHFO|noninvasive ventilation modality
214729286|NCT06106308|DRUG|Onvansertib|Oral capsule
214729287|NCT06106308|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
214729288|NCT06106308|DRUG|Bevacizumab|IV Infusion
214729289|NCT06106308|DRUG|FOLFOX|FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
214729290|NCT03960372|BEHAVIORAL|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
214729291|NCT04629976|DRUG|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
214729292|NCT04629976|DRUG|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
214729293|NCT04629976|DRUG|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
214729294|NCT02664389|GENETIC|Genetic analysis|Sequencing of 200 selected genes in the different study populations
214729295|NCT05514106|DRUG|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
214729296|NCT05514106|DIAGNOSTIC_TEST|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
214729297|NCT06015568|DRUG|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
214729298|NCT06015568|DRUG|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
214729299|NCT05186012|DRUG|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
214729300|NCT05186012|DRUG|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
214729301|NCT01425853|DRUG|Chondroitin/Glucosamine (Droglican)|Experimental
214729302|NCT01425853|DRUG|Celecoxib|Active comparator
214729303|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
214729304|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
214729305|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
214729306|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
214729307|NCT02688725|DEVICE|post mastectomy ultrasound|post mastectomy ultrasound
214729308|NCT00801138|DRUG|saline|2 ml 0.9% saline (placebo)
214729309|NCT00801138|DRUG|Dexamethasone|dexamethasone 8 mg (2 ml)
214729310|NCT00801138|DRUG|ropivacaine|30 ml 0.5% ropivacaine
214729311|NCT00801138|DRUG|Bupivacaine|30 ml 0.5% bupivacaine
214729312|NCT02959112|DRUG|Epinephrine|
214729313|NCT02959112|OTHER|Sterile water|
214729314|NCT02959112|DRUG|Indomethacin Rectal Suppository|
214729315|NCT01686100|PROCEDURE|No touch technique|The vein graft is harvested with its surronding tissues.
214729316|NCT01686100|PROCEDURE|Conventional technique|The vein graft is stripped from its surrounding tissues.
214729317|NCT02901080|DEVICE|Alpha Stim AID cranial electrotherapy stimulation|\- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
214729318|NCT02901080|BEHAVIORAL|Pregnancy test|\- Pregnancy test x 1 (day 1)
214729319|NCT02901080|OTHER|Anxiety questionnaire|\- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
214729320|NCT02901080|OTHER|Quality of life questionnaire|\- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
214729321|NCT02901080|OTHER|Work and social questionnaire|\- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
214729322|NCT02901080|OTHER|Sleep questionnaire|\- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
214729323|NCT02901080|OTHER|Depression questionnaire|\- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
214729324|NCT02901080|OTHER|Quality of life and financial questionnaire|\- CSRI questionnaire x 3 (day 1, week 12 and week 24)
214729325|NCT06142968|DIAGNOSTIC_TEST|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
214729326|NCT05226143|OTHER|Gel Cream|Gel Cream
214729327|NCT03766542|DEVICE|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
214729328|NCT03766542|DEVICE|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
214729329|NCT03290794|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
214729330|NCT05838794|OTHER|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
214729331|NCT05838794|OTHER|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
214644575|NCT04886271|DRUG|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
214644576|NCT02151513|DEVICE|Intrathecal Pump Placement|
214644577|NCT02953717|RADIATION|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
214644578|NCT02953717|RADIATION|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
214644579|NCT01052025|DRUG|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
214644580|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214644581|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214644582|NCT02167178|OTHER|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
214644583|NCT02167178|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
214644584|NCT02167178|OTHER|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
214644585|NCT02167178|OTHER|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
214644586|NCT02894840|BIOLOGICAL|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
214644587|NCT02894840|OTHER|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
214729332|NCT02836080|BEHAVIORAL|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
214729333|NCT02836080|OTHER|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
214729334|NCT05241665|DEVICE|SpectraWAVE Imaging System|Coronary imaging
214729335|NCT04884529|BEHAVIORAL|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
214729336|NCT05021172|OTHER|Best Practice|Receive usual care
214729337|NCT05021172|OTHER|Informational Intervention|Receive Passport to Health booklet
214729338|NCT05021172|OTHER|Questionnaire Administration|Complete ePrognosis
214729339|NCT05021172|OTHER|Survey Administration|Ancillary studies
214729340|NCT03814681|OTHER|Colorectal Surgery|elective Colorectal Surgery
214729341|NCT02829775|DRUG|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
214729342|NCT02829775|DRUG|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
214729343|NCT04231032|OTHER|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
214729344|NCT04231032|OTHER|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
214729345|NCT04804904|DRUG|TQ-B3101|TQ-B3101 oral capsule
214729346|NCT06261476|DIETARY_SUPPLEMENT|Ashwagandha (Withnia somnifera)|Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
214729347|NCT06301594|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week"
214729348|NCT02608125|DRUG|PRN1371|
214729349|NCT01249157|DEVICE|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
214729350|NCT00396825|BEHAVIORAL|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
214729351|NCT00087048|DRUG|topotecan hydrochloride|
214729352|NCT02406339|DEVICE|NMES|Neuromuscular Electrical Stimulation
214729353|NCT02406339|DEVICE|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
214729354|NCT02734095|DEVICE|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
214729355|NCT00062647|DRUG|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
214729356|NCT00062647|DRUG|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
214729357|NCT04445051|DEVICE|SpeediCath® Standard male or female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
214729358|NCT04445051|DEVICE|New intermittent Variant 1 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
215031022|NCT04744792|OTHER|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
215031023|NCT00002035|DRUG|Zidovudine|
214729359|NCT04445051|DEVICE|New intermittent Variant 2 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
214729360|NCT03949127|OTHER|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
214729361|NCT02939651|DRUG|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
214729362|NCT01844427|DRUG|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
214729363|NCT01844427|DRUG|Placebo|
214729364|NCT00904176|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
214729365|NCT00904176|DRUG|Warfarin|Tablets, Oral, 25 mg, Single Dose
214729366|NCT00904176|DRUG|Digoxin|Tablets, Oral, 0.25, Single Dose
214729367|NCT01067651|DEVICE|Plaster of Paris (POP) casting using the Ponseti Method|
214729368|NCT01067651|DEVICE|Semi-Rigid Fiberglass softcast using the Ponseti Method|
214729369|NCT05321693|DEVICE|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
214729370|NCT05376189|DIETARY_SUPPLEMENT|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
214729371|NCT05376189|DIETARY_SUPPLEMENT|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
214729372|NCT05376189|DIETARY_SUPPLEMENT|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
214729373|NCT05376189|DRUG|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
214729374|NCT02353689|DIETARY_SUPPLEMENT|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
214729375|NCT02353689|DIETARY_SUPPLEMENT|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
214729376|NCT02353689|DIETARY_SUPPLEMENT|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
214729377|NCT00390429|DRUG|docetaxel|Given IV
214729378|NCT00390429|DRUG|erlotinib hydrochloride|Given orally
214729379|NCT01711580|OTHER|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
215031024|NCT00002035|DRUG|Didanosine|
214729380|NCT01711580|OTHER|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
214729381|NCT01711580|OTHER|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
214729382|NCT01711580|OTHER|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
214729383|NCT01711580|OTHER|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
214729384|NCT01711580|OTHER|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
214729385|NCT01711580|OTHER|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
214729386|NCT01711580|OTHER|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
214729387|NCT02106104|DRUG|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
214644588|NCT04704479|DEVICE|Russian current|For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration
214644589|NCT04704479|DEVICE|EMT|patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
214644590|NCT04041336|DIAGNOSTIC_TEST|Optical coherence tomography|Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
214644591|NCT04866290|DEVICE|HepaSphere Microspheres|
214644592|NCT03686787|DRUG|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
214644593|NCT00678145|DRUG|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
214644594|NCT00678145|DIETARY_SUPPLEMENT|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
214644595|NCT00678145|BEHAVIORAL|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
214644596|NCT00678145|DRUG|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
214644597|NCT00678145|DRUG|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
214644598|NCT02000804|DRUG|darapladib 160mg|drug
214644599|NCT05722379|PROCEDURE|left bundle branch pacing (LBBP)|After recording the His potential, the 3830-69 lead (Medtronic Inc., Minneapolis, MN USA) was sent 1-2 cm forward and downward to find the insertion point of the right side of intra-ventricular septum combined with the pre-rotation impedance and ECG changes. Ultimately, the tip was perpendicularly straightforward posited against the septum to the left septal side .
214644600|NCT05722379|PROCEDURE|Right ventricular pacing (RVP)|Right ventricular pacing (RVP) is the standard treatment for patients with continuous ventricular pacing needs.
214644601|NCT06197061|PROCEDURE|RAMS|The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
214729388|NCT02106104|DRUG|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
214729389|NCT02392468|DRUG|Placebo matching BI 409306 25 mg|Film-coated tablet
214729390|NCT02392468|DRUG|Placebo matching BI 409306 50 mg|Film-coated tablet
214729391|NCT02392468|DRUG|BI 409306 25 mg|Film-coated tablet
214729392|NCT02392468|DRUG|BI 409306 50 mg|Film-coated tablet
214729393|NCT06225804|DRUG|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
214729394|NCT03699904|DRUG|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
214729395|NCT03699904|DRUG|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
214729396|NCT01012804|GENETIC|western blotting|
214729397|NCT01012804|OTHER|immunohistochemistry staining method|
214729398|NCT01012804|OTHER|laboratory biomarker analysis|
214729399|NCT06244719|DEVICE|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
214729400|NCT03024710|BEHAVIORAL|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
214729401|NCT02070341|DRUG|Polyethylene Glycol|
214729402|NCT02070341|DRUG|Picosalax|
214729403|NCT02820558|DRUG|Substance P|
214729404|NCT04803019|COMBINATION_PRODUCT|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
214729405|NCT04803019|DEVICE|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
214729406|NCT04594018|DRUG|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
214729407|NCT04594018|DRUG|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
214729408|NCT00647907|DRUG|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
214729409|NCT02259946|DRUG|BI 1744 CL|
214729410|NCT02259946|DRUG|Placebo|
214729411|NCT02259946|DRUG|Tiotropium bromide|
214729412|NCT04157075|DRUG|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
214729413|NCT05009238|OTHER|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
214729414|NCT03338036|DEVICE|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
214729415|NCT03338036|DEVICE|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
214729416|NCT06076239|OTHER|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
214729417|NCT06076239|OTHER|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
214729418|NCT06248242|DRUG|Edaravone dexborneol|edaravone 10 mg and dexborneol 2.5 mg twice daily
214729419|NCT04389268|DIAGNOSTIC_TEST|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
214729420|NCT00997555|PROCEDURE|bronchoscopy|Scheduled bronchoscopy.
214729421|NCT01378845|DRUG|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
214729422|NCT01378845|DRUG|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
214729423|NCT02782247|DEVICE|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal \< 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis \>11.5kPa. It cannot be used in patients with ascites."
214729424|NCT02782247|DEVICE|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
214729425|NCT01431469|DIETARY_SUPPLEMENT|Cow's milk|Powdered Whole Cow's Milk
214729426|NCT01431469|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
214729427|NCT00940849|DIETARY_SUPPLEMENT|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
214729428|NCT00940849|DIETARY_SUPPLEMENT|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
214729429|NCT04487418|PROCEDURE|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
214729430|NCT04487418|PROCEDURE|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
214729431|NCT04488549|OTHER|Survey|International E-survey
214729432|NCT00002394|DRUG|Terbinafine hydrochloride|
214729433|NCT01905904|DRUG|sevorane|Sevorane 4% Sevorane 7%
214729434|NCT02702167|DEVICE|High-frequency rTMS|10 Hz active stimulation, once daily
214729435|NCT02702167|DEVICE|Low-frequency rTMS|1 Hz active stimulation, once daily
214729436|NCT02702167|DEVICE|Sham rTMS|Sham stimulation, once daily
214729437|NCT03669107|DRUG|Gum|no gum
214729438|NCT05942677|PROCEDURE|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
214729439|NCT06437548|DEVICE|Percutaneous spinal cord stimulation|The parameters of percutaneous cervical spinal cord stimulation leads will be adjusted for optimal upper extremity motor function.
214729440|NCT04363463|OTHER|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
214729441|NCT04865224|DIAGNOSTIC_TEST|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
214729442|NCT00901394|DRUG|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
214729443|NCT00901394|DRUG|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
214729444|NCT00901394|OTHER|Placebo|Saline
214729445|NCT00901394|OTHER|oxygen nitrogen|60% air and oxygen mix.
214729446|NCT04306302|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
214729447|NCT04306302|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo.
214729448|NCT04480346|BEHAVIORAL|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
214729449|NCT06039280|DRUG|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
214729450|NCT06039280|DRUG|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
214729451|NCT06039280|OTHER|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
214729452|NCT04142944|DEVICE|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
214729453|NCT04142944|DEVICE|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
214729454|NCT05309395|COMBINATION_PRODUCT|FoodRx|Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
214729455|NCT06759233|PROCEDURE|endoscopic cryoballoon ablation treatment(ECAT)+PD-1|"ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice.~PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions."
214729456|NCT06747390|DRUG|Lidocaine 1% Injectable Solution|1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
214729457|NCT03485963|BIOLOGICAL|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
214729458|NCT06781593|DEVICE|Light therapy|The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.
214729459|NCT00509938|DRUG|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
214729460|NCT06369038|BEHAVIORAL|observation of level of dental anxiety in children|analysis of children's drawings using CD:H index
214729461|NCT04614467|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34+ cells
214729462|NCT04614467|BIOLOGICAL|Placebo|isotonic solution (no CD34+ cells)
214729463|NCT05620069|OTHER|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
214729464|NCT04220567|OTHER|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
214729465|NCT04220567|OTHER|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
214729466|NCT01961128|BEHAVIORAL|Exercise Intervention|
214729467|NCT02625389|DRUG|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
214729468|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
214729469|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
214729470|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
214729471|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
214729472|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
214729473|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
214729474|NCT00321009|DRUG|Enoxaparin|
214729475|NCT06903988|PROCEDURE|laparoscopic lateral suspension|Laparoscopic lateral suspension: Place a 1/2 T4 mesh in the vesicovaginal space. The two lateral slings are passed out from the outer upper side of the bilateral anterior superior iliac spine, and the prolapsed organs are suspended to the abdominal wall.
214729476|NCT06903988|PROCEDURE|Transvaginal sacrospinous ligament fixation|Transvaginal sacrospinous ligament fixation: Dissect the rectovaginal space to expose the right sacrospinous ligament, and fix the cervix or vaginal cuff to the right sacrospinous ligament.
214729477|NCT03140657|DRUG|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
214729478|NCT03140657|DRUG|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
214729479|NCT02912741|DRUG|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
214729480|NCT02912741|DRUG|resin infiltration|low viscous light cure resin applied in layers and cured
214729481|NCT04661267|DIETARY_SUPPLEMENT|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
214729482|NCT04661267|DIETARY_SUPPLEMENT|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
214729483|NCT05671237|OTHER|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
214729484|NCT00545467|DRUG|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
214729485|NCT00458367|DRUG|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
214729486|NCT04459104|OTHER|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
214729487|NCT04459104|OTHER|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
214729488|NCT03039569|BEHAVIORAL|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
214729489|NCT00002413|DRUG|Emivirine|
214729490|NCT00074867|DRUG|CP-547,632|
214729491|NCT02254304|DRUG|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
214729492|NCT02762760|BIOLOGICAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
214729493|NCT02762760|BIOLOGICAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
214729494|NCT05182541|OTHER|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
214729495|NCT05182541|OTHER|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
214729496|NCT05182541|OTHER|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
214729497|NCT05182541|OTHER|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
214729498|NCT05016440|DRUG|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
214729499|NCT06937047|PROCEDURE|cold snare polypectomy|Cold snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
214729500|NCT06937047|PROCEDURE|hot snare polypectomy|Hot snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
214729501|NCT06935630|DIETARY_SUPPLEMENT|Folic Acid|Participants in this group will receive a daily oral dose of 600 mcg (1.35 μmol) of folic acid in film-coated tablet form for a duration of three months. This synthetic form of folate will be administered to assess its impact on red blood cell folate levels compared to 5-MTHF.
214729502|NCT06935630|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|Participants in this group will receive a daily oral dose of 1100 mcg (1.35 μmol) of 5-methyltetrahydrofolate (5-MTHF) glucosamine salt, specifically HY-FOLIC®, in film-coated tablet form for a duration of three months. This active form of folate will be administered to assess its impact on red blood cell folate levels compared to folic acid
214729503|NCT06939608|DIETARY_SUPPLEMENT|Yohimbine|A single oral dose of 50 µg yohimbine, administered as 2 x 1 tablets of Yohimbinum hydrochloricum D4® will be co-administered with 25 mg of ¹³C₃-caffeine as drinking solution with 240mL of still water under overnight fasting conditions. A total of 19 blood samples will be collected at defined time points (baseline; 10; 20; 30; 40; 50; 60; 70; 80; 90; 100; 110 min; 2; 3; 4; 6; 8; 10; 24 h). At each time point, 4.9 mL of blood will be drawn for plasma separation to determine yohimbine, the primary metabolite 11-OH-yohimbine and ¹³C₃-caffeine with associated CYP1A2 dependent metabolites.
214729504|NCT06939608|OTHER|¹³C₃-caffeine|A single oral dose of 25 mg of ¹³C₃-caffeine as a drinking solution will be co-administered with yohimbine with 240 mL of still water under overnight fasting conditions. ¹³C₃-caffeine is a stable isotope-labeled standard probe for phenotyping CYP1A2 activity and assessing potential interactions between CYP2D6 and CYP1A2. Plasma concentrations of ¹³C₃-caffeine with associated CYP1A2 dependent metabolites will be measured at predefined time points, following the sampling schedule outlined for yohimbine.
214729505|NCT03084432|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
214729506|NCT01831011|DRUG|mildronate injection|
214729507|NCT01831011|DRUG|cinepazide maleate injection|
214729508|NCT01831011|DRUG|aspirin|
214729509|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
214729510|NCT06062810|DRUG|Raloxifene - Usual|"* Generic-1 - raloxifene hydrochloride tablet~* Raloxifene 60 mg taken orally daily"
214729511|NCT06062810|DRUG|Raloxifene - Study|"* Generic-2 - Raloxifene tablet~* Raloxifene 60 mg taken orally daily"
214729512|NCT00277823|DRUG|DVS-SR 50 mg|
214729513|NCT00277823|DRUG|DVS-SR 100 mg|
214729514|NCT00277823|DRUG|Placebo|
214729515|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
214729516|NCT04888507|DRUG|Cemdisiran|SC administration
214729517|NCT06449612|DEVICE|TeleRehaStroke: Training programme using the 'Blended Clinic' mobile application|Primary end users (patients after stroke) will be familiarised with the application and the 'TeleRehaStroke' programme in two to three sessions during their last two to three weeks prior to discharge from the inpatient rehabilitation centre. This includes performing daily exercises, wearing an activity tracker and measuring blood pressure daily. Following discharge from rehabilitation, they will continue to use the application for 12 weeks.
214729518|NCT05921552|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
214729519|NCT05921552|BEHAVIORAL|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
214729520|NCT06309563|DIETARY_SUPPLEMENT|Aminoacid supplementation|Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
214729521|NCT06309563|DIETARY_SUPPLEMENT|Placebo|Low-calorie and low-protein diet + placebo for 2 weeks
214729522|NCT06097468|DRUG|NisinZ® P|NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
214729523|NCT06097468|PROCEDURE|Surgery (non-interventional, standard of care)|Surgical removal of tumor as part of standard of care treatment
214729524|NCT00400946|DRUG|asparaginase|
214729525|NCT00400946|DRUG|cyclophosphamide|
214729526|NCT00400946|DRUG|cytarabine|
214729527|NCT00400946|DRUG|dexamethasone|
214729528|NCT00400946|DRUG|dexrazoxane hydrochloride|
214729529|NCT00400946|DRUG|doxorubicin hydrochloride|
214729530|NCT00400946|DRUG|etoposide|Given IV
214729531|NCT00400946|DRUG|leucovorin calcium|
214729532|NCT00400946|DRUG|mercaptopurine|Given orally
214729533|NCT00400946|DRUG|methotrexate|
214729534|NCT00400946|DRUG|methylprednisolone|
214729535|NCT00400946|DRUG|pegaspargase|Given IV
214729536|NCT00400946|DRUG|prednisolone|
214729537|NCT00400946|DRUG|therapeutic hydrocortisone|
214729538|NCT00400946|DRUG|vincristine sulfate|
214729539|NCT00400946|RADIATION|radiation therapy|
214729540|NCT03932903|BEHAVIORAL|ADAPTS (ADherence Assessments and Personalized Timely Support).|ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.
214729541|NCT06955910|OTHER|questionnaires|"Anamnestic and socio-demographic information will be collected through a generic self-designed questionnaire including the following data: age, sex, residence (within or outside the Veneto region), marital status (married, divorced, cohabiting, single, widowed), employment status (employed, unemployed, retired), presence of dependents (yes/no), level of education (defined as primary, middle or high school, university degree), concomitant pathologies.~Additional data on the oncological history are also reported: histology and staging of the disease, presence or absence of metastatic disease, additional treatments before or after surgery (e.g. neoadjuvant treatments, adjuvant treatments, radiotherapy)."
214729542|NCT06834217|DEVICE|Active transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning and end of a 20-minute stimulation period.
214729543|NCT06834217|DEVICE|Sham transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning of a 20-minute period.
214729544|NCT06431334|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d
214729545|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
214729546|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
214729547|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
214729548|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
214729549|NCT02306291|DRUG|Etoposide|induction chemotherapy
214729550|NCT02306291|DRUG|Cytarabine|induction chemotherapy
214729551|NCT02306291|DRUG|Idarubicin|induction chemotherapy
214729552|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
214729553|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
214729554|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
214729555|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
214729556|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
214729557|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
214729558|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
214729559|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
214729560|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
214729561|NCT06745479|BEHAVIORAL|Positive Emotion Upregulation|Participants will identify personal goals or activities that they would like to engage in more and describe these goals/activities in a written format with research staff. Participants will then complete a gambling task during functional MRI scanning. Prior to making some gambling decisions, participants are instructed to mentally imagine achieving a goal or engaging in an enjoyable activity. Prior to the other decisions participants are instructed to respond naturally (i.e., not use the cognitive strategy).
214729562|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
214729563|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
214729564|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
214729565|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
214729566|NCT06102330|OTHER|HomeVENT decision support tool|Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation
214729567|NCT04884633|PROCEDURE|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
214729568|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
214729569|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214729570|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214729571|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
214729572|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
214729573|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214729574|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
214729575|NCT01786499|BEHAVIORAL|Relaxation Response Training|
214729576|NCT00312390|PROCEDURE|Flicker|
214729577|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
214729578|NCT00312390|PROCEDURE|Retinal Blood Flow|
214729579|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
214729580|NCT03978793|DEVICE|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
214729581|NCT04640012|DRUG|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
214729582|NCT04640012|DRUG|Placebo|Placebo orally administered
214729583|NCT04959474|OTHER|Best Practice|Given standard dietary recommendations
214729584|NCT04959474|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
214729585|NCT04959474|PROCEDURE|Resection|Undergo surgical resection
214729586|NCT04959474|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
214729587|NCT04959474|OTHER|Dietary Intervention|Undergo a caloric restriction diet
214729588|NCT04959474|OTHER|Questionnaire Administration|Ancillary studies
214729589|NCT04959474|OTHER|Quality-of-Life Assessment|Ancillary studies
214729590|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
214729591|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
214729592|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
214729593|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
214729594|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
214729595|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
214729596|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
214729597|NCT00483431|DIETARY_SUPPLEMENT|MK7|
214729598|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
214729599|NCT05620160|DRUG|Placebo|placebo （tablet）
214729600|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
214729601|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
214729602|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
214729603|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
214729604|NCT06787248|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 4.2 software (Brain Innovation, Maastricht, The Netherlands)
214729605|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
214729606|NCT06379087|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
214729607|NCT06379087|DRUG|Tislelizumab Injection|Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
214729608|NCT06379087|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
214729609|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
214729610|NCT00278044|PROCEDURE|blood sampling and medical records|
214729611|NCT04687475|OTHER|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
214729612|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
214729613|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
214729614|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
214729615|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
214729616|NCT04413344|DRUG|Bromocriptine Mesilate|Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
214729617|NCT04413344|DRUG|Placebos|Identical tablets which contain no active ingredient
214729618|NCT04340141|DRUG|Oxaliplatin|Given IV
214729619|NCT04340141|DRUG|Irinotecan Hydrochloride|Given IV
214729620|NCT04340141|DRUG|Leucovorin Calcium|Given IV
214729621|NCT04340141|DRUG|Fluorouracil|Given IV
214729622|NCT04340141|PROCEDURE|Resection|Undergo surgical resection
214729623|NCT04340141|OTHER|Questionnaire Administration|Ancillary studies
214729624|NCT04963296|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
214729625|NCT04963296|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
214729626|NCT04963296|DRUG|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
214729627|NCT04963296|DRUG|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
214729628|NCT04963296|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
214729629|NCT06516965|DRUG|Povorcitinib|Oral Tablet
214729630|NCT06516965|DRUG|Placebo|Oral Tablet
214729631|NCT01748149|DRUG|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
214729632|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
214729633|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
214729634|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 600 mg on Day1 to Day673
214729635|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673
214729636|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589
214729637|NCT05426460|BEHAVIORAL|Approach/Avoidance Task|The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.
214729638|NCT05426460|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
214729639|NCT05426460|BEHAVIORAL|AC|During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
214729640|NCT05426460|DEVICE|Sham tDCS|Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
214729641|NCT04607590|OTHER|Best Practice|Receive usual care
214729642|NCT04607590|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214729643|NCT04607590|OTHER|Questionnaire Administration|Ancillary studies
214729644|NCT04607590|PROCEDURE|Yoga|Participate in yoga sessions
214729645|NCT04250259|DRUG|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
214729646|NCT04250259|DRUG|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
214729647|NCT06030193|DRUG|QLS-111 ophthalmic solution (0.015%)|QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
214729648|NCT06030193|DRUG|Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)|Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
214729649|NCT05001269|DRUG|nedosiran|Monthly subcutaneous dosing throughout study period
214729650|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
214729651|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
214729652|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
214729653|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
214729654|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
214729655|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
214729656|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
214729657|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
214729658|NCT00564915|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
214729659|NCT02514213|BIOLOGICAL|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
214729660|NCT02514213|BIOLOGICAL|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
214729661|NCT02514213|BIOLOGICAL|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
214729662|NCT02514213|BIOLOGICAL|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
214729663|NCT02514213|DEVICE|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
214729664|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
214729665|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
214729666|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
214729667|NCT02916628|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
214729668|NCT02916628|DEVICE|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
214729669|NCT02916628|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
214729670|NCT04770090|OTHER|Blood samples|Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.
214729671|NCT05897424|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
214729672|NCT04464668|BEHAVIORAL|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
214729673|NCT04464668|BEHAVIORAL|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
214729674|NCT03539614|DRUG|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
214729675|NCT03539614|DRUG|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
214729676|NCT04997850|DRUG|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
214729677|NCT04997850|PROCEDURE|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
214729678|NCT02996305|DRUG|OV101 Regimen 1|
214729679|NCT02996305|DRUG|OV101 regimen 2|
214729680|NCT02996305|OTHER|Placebo|
214729681|NCT05230511|DRUG|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
214729682|NCT05230511|DRUG|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
214729683|NCT01712776|DEVICE|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
214729684|NCT01712776|DEVICE|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
214729685|NCT05924178|BEHAVIORAL|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
214729686|NCT05924178|BEHAVIORAL|routine treatment|The control group receives conventional treatment preoperative.
214729687|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
214729688|NCT04891757|DRUG|FHD-286|FHD-286 administered orally
214729689|NCT04891757|DRUG|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
214729690|NCT04891757|DRUG|Decitabine|Decitabine administered intravenously
214729691|NCT04807530|DEVICE|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
214729692|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
214729693|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
214729694|NCT02718664|OTHER|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
214729695|NCT03956745|BEHAVIORAL|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep \~12h opposite their usual sleep time.
214729696|NCT03956745|BEHAVIORAL|constant routine|Study participants will spend \~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
214729697|NCT01285752|DRUG|AK106-001616|
214729698|NCT01285752|DRUG|AK106-001616|
214729699|NCT01285752|DRUG|Active comparator|
214729700|NCT01431521|DRUG|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
214729701|NCT01431521|DRUG|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
214729702|NCT01431521|DRUG|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
214729703|NCT01431521|DRUG|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
214729704|NCT05907772|OTHER|No intervention|No intervention
214729705|NCT06631989|DRUG|WSD0922-FU|"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
214729706|NCT02896751|DEVICE|3D printed NIV mask|use of 3D printed mask
214729707|NCT01996228|DEVICE|Stem Cell Educator|
214729708|NCT04482621|DRUG|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)"
214729709|NCT04482621|OTHER|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
214729710|NCT00223613|DRUG|daily intranasal administration of insulin|
214729711|NCT04011137|OTHER|Exercise|Arm-cranking exercise
214729712|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
214729713|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
214729714|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
214729715|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
214729716|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
214729717|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
214729718|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
214729719|NCT06305000|PROCEDURE|Non-surgical treatment|Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.
214729720|NCT06305000|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
214729721|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
214729722|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
214729723|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
214729724|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
214729725|NCT02444689|BEHAVIORAL|Standard of care education|
214729726|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
214729727|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
214729728|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
214729729|NCT06382012|DRUG|Fosaprepitant 150 mg|Fosaprepitant 150mg IV administered over 15 minutes
214729730|NCT06382012|DRUG|Ondansetron 4 mg|Ondansetron 4mg IV administered over 15 minutes
214729731|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
214729732|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
214729733|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
214729734|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
214729735|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
214729736|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
214729737|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
214729738|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
214729739|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
214729740|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
214729741|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
214729742|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
214729743|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
214729744|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
214729745|NCT05452876|OTHER|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
214729746|NCT05452876|OTHER|Usual Care|Standard of care treatment
214729747|NCT05171816|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
214729748|NCT05171816|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
214729749|NCT06514105|OTHER|Physiotherapy program|All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
214729750|NCT06514105|OTHER|High intensity laser|High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.
214729751|NCT06514105|OTHER|Sham high intensity laser|In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
214729752|NCT06793709|OTHER|No Intervention|This is a non-interventional study.
214729753|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
214729754|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
214729755|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
214729756|NCT06636669|DRUG|Probiotic|Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.
214729757|NCT06636669|OTHER|Standard of care|Standard of care (SOC) treatment includes surgery and antimicrobials.
214729758|NCT04667949|DRUG|Fingolimod 0.5mg|Subjects received fingolimod 0.5mg capsule QD up to month 24
214729759|NCT05053139|DRUG|NNC0365-3769 (Mim8)|Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
214729760|NCT06432569|DIETARY_SUPPLEMENT|ButirBioma + PeaBioma|randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.
214729761|NCT06432569|DIETARY_SUPPLEMENT|Placebo|Placebo( 3+3 cps/die)
214729762|NCT06639997|DRUG|AZD5148|Participants will receive AZD5148 as IM injection or IV bolus
214729763|NCT06639997|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
214729764|NCT04518228|DRUG|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729765|NCT04518228|DRUG|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729766|NCT04518228|DRUG|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729767|NCT04518228|DRUG|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729768|NCT04518228|DRUG|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729769|NCT04518228|DRUG|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729770|NCT04518228|DRUG|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729771|NCT04518228|DRUG|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729772|NCT04518228|DRUG|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729773|NCT04518228|DRUG|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
214729774|NCT04518228|DRUG|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
214729775|NCT04518228|DRUG|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
214729776|NCT05406583|DRUG|Dolutegravir 0.5 mg/kg oral suspension|DTG 0.5 mg/kg liquid suspension administered orally
214729777|NCT05406583|DRUG|Dolutegravir 5 mg Dispersible Tablets|DTG 5 mg DT administered orally
214729778|NCT04357704|OTHER|S0N0|(no ITD)
214729779|NCT04357704|OTHER|S0N500|(ITD +500µs on noise)
214729780|NCT04357704|OTHER|S-500N500|(ITD -500µs on signal and +500 µs on noise)
214729781|NCT04357704|OTHER|S0N1000|(ITD + 1000 µs on noise)
214729782|NCT04357704|OTHER|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
214729783|NCT05275868|DRUG|MGY825|investigational drug
214729784|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
214729785|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
214729786|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
214729787|NCT06699849|BIOLOGICAL|CSL889|CSL889 is a solution for infusion to be administered by the IV route.
214729788|NCT06699849|DRUG|Placebo|Volume and regimen matched to CSL899 will be administered.
214729789|NCT02000622|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
214729790|NCT02000622|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
214729791|NCT00424840|DRUG|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
214729792|NCT00424840|DRUG|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
214729793|NCT00424840|DRUG|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
214729794|NCT00424840|DRUG|Carboplatin AUC 6|Carboplatin AUC6
214729795|NCT00424840|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
214729796|NCT00424840|DRUG|Taxotere|Taxotere 70 + G-CSF
214729797|NCT01405027|PROCEDURE|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
214729798|NCT01405027|OTHER|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
214729799|NCT04825704|DRUG|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
214729800|NCT04825704|DRUG|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
214729801|NCT05085327|DRUG|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
214729802|NCT05085327|DRUG|ChapStick Lip Moisturizer Mint|Sunscreen lip balm.
215031025|NCT04622930|DEVICE|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
214729803|NCT05085327|DRUG|ChapStick Lip Moisturizer Black Cherry|Sunscreen lip balm.
214729804|NCT05085327|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
214729805|NCT01786278|RADIATION|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
214729806|NCT01786278|PROCEDURE|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
214729807|NCT05727631|OTHER|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
214729808|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
214729809|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
214729810|NCT01989936|DRUG|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
214729811|NCT01989936|DRUG|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
214729812|NCT01989936|DRUG|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
214729813|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
214729814|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
214729815|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
214729816|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
214729817|NCT00519571|DEVICE|ImplantLock device|dental implant
214729818|NCT04949139|DRUG|Dextrose 5% in water|Reducing the sodium concentration
214729819|NCT00212667|DRUG|ONO-5920|
214729820|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
214729821|NCT02334813|DRUG|Prednisone|Continuous daily therapy
214729822|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
214729823|NCT01652222|OTHER|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
214729824|NCT01652222|OTHER|Socio-educational training only|4 socio-educative training sessions during 8 weeks
214729825|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
215031026|NCT04225767|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
214729826|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
214729827|NCT02365805|DRUG|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
214729828|NCT02365805|DRUG|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
214729829|NCT02365805|DRUG|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
214729830|NCT05064085|DRUG|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
214729831|NCT05064085|DRUG|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
214729832|NCT02597686|BEHAVIORAL|SD-PB training|
214729833|NCT03968107|OTHER|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
214729834|NCT04036045|OTHER|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
214729835|NCT04036045|OTHER|Echocardiogram|Patients will have an echocardiogram at four time points during the study
214729836|NCT04036045|OTHER|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
214729837|NCT05405842|DEVICE|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
214729838|NCT03728881|BIOLOGICAL|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Given IM
214729839|NCT03728881|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
214729840|NCT04962867|DRUG|E7090|140 mg of E7090 is orally administered once daily.
214729841|NCT03145506|DEVICE|Multimodal Spectroscopy|optical measurement of excised tissue
214729842|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
214729843|NCT04833140|DRUG|Estradiol patch|The patch will provide 100mcg of estradiol daily.
214729844|NCT04833140|DRUG|Placebo|Placebo patch will contain no estradiol.
214729845|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
214729846|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
214729847|NCT04088331|DEVICE|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
214729848|NCT01451567|BEHAVIORAL|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
214729849|NCT05942872|OTHER|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
214729850|NCT04582539|DRUG|INCB000928|INCB000928 will be administered once daily.
214729851|NCT01511549|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
214729852|NCT01511549|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
214729853|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
214729854|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
214729855|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
214729856|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
214729857|NCT01994109|DRUG|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
214729858|NCT01994109|OTHER|PLACEBO|
214729859|NCT01265173|DRUG|Cefotaxime|3 g
214729860|NCT01265173|DRUG|Ceftriaxone|2 g
214729861|NCT01265173|DRUG|Ciprofloxacin|400 mg
214729862|NCT03491852|BEHAVIORAL|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
214729863|NCT03491852|BEHAVIORAL|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
214729864|NCT01165294|DRUG|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
214729865|NCT01165294|DRUG|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
214729866|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
214729867|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
214729868|NCT02931955|OTHER|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
214729869|NCT00506740|DEVICE|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
214729870|NCT00506740|DEVICE|monopolar electrosurgery generator and tip|
214729871|NCT00576147|DEVICE|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
214729872|NCT06645834|DEVICE|Smart MDI System|"The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal"
214729873|NCT04642274|OTHER|Preoperative Strategies|Patient Education Preoperative Oral Carbohydrate Loading Nutritional Optimization Glycemic Control Anemia Correction Preoperative Hair Removal
214729874|NCT04642274|OTHER|Intraoperative Strategies|Anesthetic Technique (Multimodal Analgesia) Antibiotics Glycemic Control Blood Transfusion Blood Conservation Optimization of Hemodynamics Protective Lung Ventilation Strategy Optimization of Anesthetic Depth Optimization of CPB Management
214729875|NCT04642274|OTHER|Postoperative Strategies|Postoperative Analgesia Temperature Management Renal Protection Glycemic Control Early Extubation Early Oral Intake Maintain Drain Patency and Early Removal Early Ambulation Thromboprophylaxis
214729877|NCT03137888|RADIATION|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
214729878|NCT03137888|PROCEDURE|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
214729879|NCT03137888|DRUG|Temozolomide|Given PO
214729880|NCT04693806|OTHER|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
214729881|NCT05776355|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
214729882|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
214729883|NCT02155712|DEVICE|Triathlon Knee|Cemented
214729884|NCT02394860|OTHER|echo Doppler lower limbs|
214729885|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214729886|NCT04527991|DRUG|Paclitaxel|Administered intravenously
214729887|NCT04527991|DRUG|Docetaxel|Administered intravenously
214729888|NCT04527991|DRUG|Vinflunine|Administered intravenously
214729889|NCT01095939|DRUG|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
214729890|NCT01095939|DRUG|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
214729891|NCT06039384|DRUG|INCB099280|Administered as specified in the treatment arm description
214729892|NCT06039384|DRUG|adagrasib|Administered as specified in the treatment arm description
214729893|NCT05630118|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
214729894|NCT05630118|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
214729895|NCT00852098|PROCEDURE|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
214729896|NCT00852098|PROCEDURE|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
214729897|NCT04313673|DIAGNOSTIC_TEST|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
214729898|NCT04587973|PROCEDURE|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
214729899|NCT04587973|PROCEDURE|Group Ropivacaine|Plain ropivacaine group
214729900|NCT04587973|PROCEDURE|Group Control|Control group
214729901|NCT03669744|OTHER|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
214729902|NCT04684849|OTHER|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
214729903|NCT04684849|OTHER|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
214729904|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
214729905|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
214729906|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
214729907|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
214729908|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
214729909|NCT00926562|DRUG|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
214729910|NCT00926562|DRUG|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
214729911|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
214729912|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
214729913|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
214729914|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
214729915|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
214729916|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
214729917|NCT04124224|OTHER|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
214729918|NCT01755260|OTHER|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
214729919|NCT06408519|OTHER|Placebo (open-label)|P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
214729920|NCT06408519|DRUG|Ibuprofen 400 mg|Ibuprofen pills 3x/day
214729921|NCT00622570|DRUG|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
214729922|NCT00622570|DRUG|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
214729923|NCT06384300|OTHER|Financial Incentives|In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
214729924|NCT06384300|OTHER|Motivational Intervention|For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
214729925|NCT06384300|OTHER|Mixed Intervention|Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
214729926|NCT02756845|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
214729927|NCT02331654|OTHER|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
214729928|NCT02331654|OTHER|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
214729929|NCT03030014|BEHAVIORAL|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
214729930|NCT03030014|OTHER|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
214729931|NCT01878227|DRUG|Coenzyme A|Coenzyme A 400mg per day
214729932|NCT01878227|DRUG|Fenofibrate 200mg|Fenofibrate 200mg per day
214729933|NCT00255996|DRUG|linezolid|
214729934|NCT00134953|DRUG|Rivastigmine|
214729935|NCT04967911|OTHER|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
214729936|NCT04967911|OTHER|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
214729937|NCT01688999|DRUG|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
214729938|NCT00534560|DRUG|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
214729939|NCT00534560|DRUG|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
214729940|NCT00534560|DRUG|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
214729941|NCT02951455|BEHAVIORAL|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
215030532|NCT04672681|BEHAVIORAL|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
215030533|NCT04662879|OTHER|Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score|ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
214729942|NCT02951455|BEHAVIORAL|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
214729943|NCT02951455|BEHAVIORAL|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
214729944|NCT02951455|BEHAVIORAL|PF|Whether the intervention is delivered by a peer facilitator.
214729945|NCT02951455|BEHAVIORAL|LC|Whether the intervention is delivered by a licensed clinician.
214729946|NCT05849545|DEVICE|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
214729947|NCT05849545|PROCEDURE|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
214729948|NCT06358976|OTHER|Vibration plus anti-spastic hand splint|vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
214729949|NCT06358976|OTHER|Anti-spastic hand splint|the use of anti-spastic hand splint alone.
214729950|NCT06358976|OTHER|Vibration|The use of hand vibrator alone
214729951|NCT05336019|BEHAVIORAL|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
214729952|NCT05336019|OTHER|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
214729953|NCT04543630|PROCEDURE|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
214729954|NCT04104204|DRUG|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
214729955|NCT04104204|DRUG|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
214729956|NCT00381108|DRUG|Placebo Tablet|Two tablets, twice daily.
214729957|NCT00381108|DRUG|Pomegranate Tablet|Two tablets, twice daily.
214729958|NCT06595576|DRUG|Cannabis - Placebo Dose (0 mg)|Participants will consume placebo cannabis edibles.
214729959|NCT06595576|DRUG|Cannabis - Low Dose (2 mg)|Participants will consume a low dose (2 mg) of cannabis edibles.
214729960|NCT06595576|DRUG|Cannabis - Medium Dose (10 mg)|Participants will consume a medium dose (10 mg) of cannabis edibles.
214729961|NCT06595576|DRUG|Cannabis - High Dose (20 mg)|Participants will consume a high dose (20 mg) of cannabis edibles.
214729962|NCT03778580|DIETARY_SUPPLEMENT|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
214729963|NCT03778580|DRUG|placebo|placebo
214729964|NCT01603706|PROCEDURE|Echo guided implantation group|Lead placement according echo strain imaging result
214729965|NCT01505140|OTHER|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
214729966|NCT01025232|DRUG|Ranibizumab|Intravitreal Injection of 2.0mg formulation
214729967|NCT05535270|DIAGNOSTIC_TEST|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
214729968|NCT03928444|PROCEDURE|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
214729969|NCT03928444|PROCEDURE|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
214729970|NCT00467948|DRUG|cefazolin|
214729971|NCT05789914|PROCEDURE|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
214729972|NCT04682795|DEVICE|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
214729973|NCT04682795|DEVICE|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
214729974|NCT00039091|BIOLOGICAL|ipilimumab|Given IV
214729975|NCT00777686|PROCEDURE|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
214729976|NCT02039128|DIETARY_SUPPLEMENT|Krill oil or Fish oil|
214729977|NCT02039128|DIETARY_SUPPLEMENT|Placebo|
214729978|NCT02618512|DRUG|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
214729979|NCT04132128|OTHER|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
214729980|NCT01946568|DRUG|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
214729981|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
214729982|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
214729983|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
214729984|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
214729985|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
214729986|NCT01785290|DRUG|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
214729987|NCT01785290|DRUG|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
214729988|NCT01785290|DRUG|Placebo|Sodium Chloride 0.9%
214729989|NCT03250819|OTHER|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
214729990|NCT00736450|BIOLOGICAL|oblimersen sodium|Given IV
214729991|NCT00736450|BIOLOGICAL|rituximab|Given IV
214729992|NCT00736450|DRUG|cyclophosphamide|Given IV
214729993|NCT00736450|DRUG|doxorubicin hydrochloride|Given IV
214729994|NCT00736450|DRUG|vincristine sulfate|Given IV
214729995|NCT00736450|DRUG|prednisone|Given orally
214729996|NCT00736450|PROCEDURE|biopsy|Correlative studies
214729997|NCT00736450|GENETIC|microarray analysis|Correlative studies
214729998|NCT00736450|OTHER|immunohistochemistry staining method|Correlative studies
214729999|NCT00736450|GENETIC|gene expression analysis|Correlative studies
214730000|NCT00736450|GENETIC|cytogenetic analysis|Correlative studies
214730001|NCT06543121|OTHER|Translating the Stroke Knowledge Test into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the test and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
214730002|NCT06543121|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of 10 expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Stroke Knowledge Test. For face validity, the final version of the form will be provided with opinions from 3 stroke patients.
214730003|NCT06543121|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
214730004|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
214730005|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
214730006|NCT05957328|DRUG|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
214730007|NCT05957328|DRUG|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
214730008|NCT05124067|DRUG|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
214730009|NCT05124067|DRUG|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
214730010|NCT05124067|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
215030534|NCT04662879|OTHER|Abdominal imaging|Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
215030535|NCT06161493|DRUG|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
215030536|NCT06161493|DRUG|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
214730011|NCT05124067|DRUG|normal Saline|patients will receive normal saline.
214730012|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
214730013|NCT06859632|OTHER|3-hour educational intervention|"A 3-hour educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
214730014|NCT06859632|OTHER|45-minute educational intervention|"A 45-minute educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
214730015|NCT05376995|DIAGNOSTIC_TEST|Graston technique|Graston technique among patient of knee osteoarthritis
214730016|NCT05376995|DIAGNOSTIC_TEST|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
214730017|NCT00829062|DEVICE|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
214730018|NCT06195904|OTHER|NA (No intervention)|NA (No intervention)
214730019|NCT04516824|PROCEDURE|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
214730020|NCT02353676|DRUG|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
214730021|NCT02353676|OTHER|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
214730022|NCT03081572|DIAGNOSTIC_TEST|Platelet aggregation|Platelet aggregation
214730023|NCT01313039|DRUG|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
214730024|NCT04509401|DRUG|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
214730025|NCT04509401|DRUG|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
214730026|NCT03185312|DIAGNOSTIC_TEST|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
214730027|NCT05083949|DRUG|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
214730028|NCT05083949|DRUG|Empagliflozin|empagliflozin 10mg (R1)
214730029|NCT05083949|DRUG|Glifage®|Glifage® 850mg (R2)
214730030|NCT00261794|BEHAVIORAL|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
214730031|NCT00261794|BEHAVIORAL|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
214730032|NCT01160263|DRUG|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
214730033|NCT05578313|DRUG|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
214730034|NCT02410590|DRUG|Rocuronium|
214730035|NCT02410590|DRUG|Sugammadex|
214730036|NCT02410590|DRUG|Cisatracurium|
214730037|NCT02410590|DRUG|Neostigmine/Atropine|
214730038|NCT02410590|DRUG|Succinylcholine|
214730039|NCT03638713|BEHAVIORAL|colonoscopy first|Received water exchange colonoscopy followed by EGD
214730040|NCT03638713|BEHAVIORAL|EGD first|Received EGD followed by water exchange colonoscopy
214730041|NCT04434261|DIAGNOSTIC_TEST|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
214730042|NCT00674687|DRUG|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
214730043|NCT00674687|DRUG|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
214730044|NCT06262672|OTHER|Evaluation form|This form is a form of demographic information, questions that question the habits of COVİD-19 era, and evaluation scales.
214730045|NCT03930667|PROCEDURE|clips|
214730046|NCT03930667|PROCEDURE|knotting|
214730047|NCT04673461|DRUG|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
214730048|NCT04673461|DRUG|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
214730049|NCT04673461|DRUG|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
214730050|NCT00000345|DRUG|Lofexidine|
214730051|NCT04745247|PROCEDURE|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
214730052|NCT02031757|OTHER|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
214730053|NCT02031757|OTHER|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
214730054|NCT04304404|BEHAVIORAL|Breast Cancer Risk Reduction Program (BrCaRRP)|Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
214730055|NCT02340572|DRUG|PRS-080#022-DP|hepcidin antagonist
214730056|NCT02340572|DRUG|PRS-080-Placebo#001|Placebo treatment
214730057|NCT00815776|DEVICE|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
214730058|NCT00815776|DEVICE|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
214730059|NCT00815776|OTHER|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
214730060|NCT04878276|DEVICE|Dimet 5|The application is carried out according to the enclosed instructions for use.
214730061|NCT02233582|DRUG|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
214730062|NCT02233582|DRUG|Sugar pill|
214730063|NCT05333536|OTHER|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
214730064|NCT05333536|OTHER|No Intervention: Control group|control only participates in their yearly swimming trainings.
214730065|NCT04962490|PROCEDURE|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
214730066|NCT00559013|DEVICE|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
214730067|NCT04500223|OTHER|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
214730068|NCT04500223|OTHER|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
214730069|NCT03606655|DRUG|Kava|Kava: 75 mg three times daily (3 capsules)
214730070|NCT01059890|DRUG|cefotaxime|
214730071|NCT01059890|DRUG|Metronidazole|
214730072|NCT01059890|DRUG|Ciprofloxacin|
214730073|NCT01059890|DRUG|Fosfocine|
214730074|NCT05666206|PROCEDURE|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
214730075|NCT02583360|DIAGNOSTIC_TEST|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
214730076|NCT04228445|DRUG|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
214730077|NCT04228445|DRUG|Saline spray|Placebo
214730078|NCT05490498|OTHER|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
214730079|NCT02296294|DRUG|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
214730080|NCT02296294|DEVICE|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
214730081|NCT05108961|PROCEDURE|Acupuncture|one session with precise acupunture points
214730082|NCT05108961|BEHAVIORAL|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
214730083|NCT05108961|BEHAVIORAL|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
214730084|NCT05108961|DIAGNOSTIC_TEST|Bispectral Index|BIS is based on an EEG analysis algorithm
214730085|NCT02823613|DIETARY_SUPPLEMENT|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
214730086|NCT02823613|DIETARY_SUPPLEMENT|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
214730087|NCT04969627|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
214730088|NCT04969627|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
214730089|NCT00002097|DRUG|Nystatin|
214730090|NCT00835276|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
214730091|NCT00835276|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
214730092|NCT05068076|DRUG|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
214730093|NCT00019214|BIOLOGICAL|MART-1 antigen|
214730094|NCT00019214|BIOLOGICAL|aldesleukin|
214730095|NCT00019214|BIOLOGICAL|gp100 antigen|
214730096|NCT03411434|DRUG|Methylphenidate Oral Tablet|cf arm group description
214730097|NCT06244524|OTHER|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
214730098|NCT01574261|DRUG|Placebo|Placebo for four months
214730099|NCT01574261|DRUG|Inositol|Inositol 4g/die for four months
214730100|NCT00663689|DRUG|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
214730101|NCT06360497|OTHER|mindfulness meditation intervention and loving-kindness and compassion meditation intervention|Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
215030537|NCT03886636|OTHER|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
214730102|NCT01405378|DEVICE|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
214730103|NCT04443036|DRUG|Albumin-Bound Paclitaxel|"* 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity"
214730104|NCT04443036|DRUG|Toripalimab|"* 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
214730105|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
214730106|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
214730107|NCT03966664|DIAGNOSTIC_TEST|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
214730108|NCT02982642|DRUG|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
214730109|NCT02982642|DRUG|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
214730110|NCT05859906|OTHER|mechanical power measurement|"Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]"
214730111|NCT03156725|DRUG|Ferrous Sulfate|
214730112|NCT03156725|DIETARY_SUPPLEMENT|Aspiron|
214730113|NCT05905861|PROCEDURE|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
214730114|NCT05905861|PROCEDURE|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
214730115|NCT06004089|PROCEDURE|V NOTES Sacrocolpopexy|The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
214730116|NCT02702284|BEHAVIORAL|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
214730117|NCT02702284|BEHAVIORAL|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
214730118|NCT01392768|DRUG|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
214730119|NCT01392768|DRUG|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
214730120|NCT02253160|DEVICE|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
214730121|NCT02253160|DEVICE|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
214730122|NCT02253160|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
214730123|NCT00651768|DRUG|budesonide/formoterol|
214730124|NCT00651768|DRUG|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
214730125|NCT02556580|DRUG|Albumin 20%|Intervention: intravenious infusion Drug: albumin
214730126|NCT01589692|PROCEDURE|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
214730127|NCT01589692|PROCEDURE|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
214730128|NCT01589692|PROCEDURE|Percutaneous Pinning|Pinning with any number of Kirschner wires
214730129|NCT01589692|PROCEDURE|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
214730130|NCT01316380|DRUG|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
214730131|NCT01316380|DRUG|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
214730132|NCT01316380|DRUG|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
214730133|NCT03965546|COMBINATION_PRODUCT|Sorafenib combined with ET140202-T cell|"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
214730134|NCT03965546|COMBINATION_PRODUCT|TAE combined with ET140202-T cell|"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
214730135|NCT03965546|BIOLOGICAL|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
214730136|NCT02240992|BIOLOGICAL|PBSC|
214730137|NCT02240992|BIOLOGICAL|MSCs|
214730138|NCT04594304|BEHAVIORAL|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
214730139|NCT03258944|OTHER|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
214730140|NCT05838820|DIAGNOSTIC_TEST|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
214730141|NCT05838820|DIAGNOSTIC_TEST|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
214730142|NCT05447260|DRUG|Ruxolitinib|Dosage based on platelet count
214730143|NCT00988377|OTHER|dietary intervention|whey protein 10-40 g
214730144|NCT00988377|OTHER|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
214730145|NCT01894776|DRUG|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
214730146|NCT01894776|DRUG|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
214730147|NCT04917731|DRUG|Botulinum toxin type A|Botox injected at digital artery
214730148|NCT03395860|DRUG|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
214730149|NCT01695460|DRUG|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
214730150|NCT01695460|DRUG|Placebo|
214730151|NCT04171063|DEVICE|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
214730152|NCT02853786|BEHAVIORAL|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
214730153|NCT02853786|OTHER|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
214730154|NCT01848795|DEVICE|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
214730155|NCT01848795|DEVICE|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
214730156|NCT02089867|OTHER|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
214730157|NCT02089867|DRUG|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
214730158|NCT02089867|DIETARY_SUPPLEMENT|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
214730159|NCT00036231|DRUG|RG1068 (Synthetic Human Secretin)|
214730160|NCT00200889|DEVICE|active TEAS|non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
214730161|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
214730162|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
214730163|NCT04556929|DIAGNOSTIC_TEST|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
214730164|NCT05399602|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)
214730165|NCT05399602|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement
214730166|NCT05399602|DIAGNOSTIC_TEST|Lumbar infusion test|Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
214730167|NCT05399602|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
214730168|NCT05399602|PROCEDURE|General Anesthesia|Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.
214730169|NCT05399602|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)
214730170|NCT05399602|PROCEDURE|Blood sampling #1|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
214730171|NCT05399602|PROCEDURE|Blood sampling #2|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery
214730172|NCT05399602|PROCEDURE|Blood sampling #3|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery
214730173|NCT05399602|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
214730174|NCT05094882|PROCEDURE|pulmonary lobectomy|resection of lung lobe
214730175|NCT00241657|BIOLOGICAL|BCG|
214730176|NCT04197206|OTHER|costotransverse block|patient controlled analgesia devices with tramadol
214730177|NCT00510575|DEVICE|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
214730178|NCT03512275|DRUG|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
214730179|NCT04984070|DRUG|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
214730180|NCT04984070|DRUG|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
214730181|NCT04984070|OTHER|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
214730182|NCT00641459|OTHER|Observational BPSD treatment study|Observational BPSD treatment study
214730183|NCT03104959|DIETARY_SUPPLEMENT|N-acetyl cysteine|
214730184|NCT03104959|OTHER|placebo|
214730185|NCT02333136|DEVICE|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
214730186|NCT01144741|OTHER|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
214730187|NCT01144741|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
214730188|NCT01144741|OTHER|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
214730189|NCT01144741|OTHER|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
214730190|NCT01144741|OTHER|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
214730191|NCT01144741|OTHER|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
214730192|NCT01144741|OTHER|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
214730193|NCT01307046|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
214730194|NCT01307046|DRUG|Losartan|Tablet containing losartan potassium (100 mg), once daily
214730195|NCT01307046|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
214730196|NCT01307046|DRUG|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
214730197|NCT01307046|DRUG|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
214730198|NCT00096304|DRUG|docetaxel|
214730199|NCT00096304|DRUG|epirubicin hydrochloride|
214730200|NCT00609167|DRUG|bortezomib|"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"
214730201|NCT00609167|DRUG|cyclophosphamide|300mg/m\^2 PO days 1, 8, 15 \& 22
214730202|NCT00609167|DRUG|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
214730203|NCT00374101|DRUG|omeprazole|
214730204|NCT00374101|DRUG|pantoprazole|
214730205|NCT00428103|PROCEDURE|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
214730206|NCT01997138|DRUG|Anakinra 100 mg in 2 ml saline IA|
214730207|NCT00367705|DIETARY_SUPPLEMENT|VSL#3®|1-2 sachets/day per os, 6 months
214730208|NCT00367705|DIETARY_SUPPLEMENT|Placebo|1-2 sachets/day per os, 6 months
214730209|NCT03801798|DRUG|GC1102|NAs antivirals+GC1102 180,000 IU
214730210|NCT03801798|OTHER|GC1102 Placebo|NAs antivirals+GC1102 Placebo
214730211|NCT04288297|PROCEDURE|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
214730212|NCT04746313|BIOLOGICAL|blood test|"* to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin"
214730213|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
214730214|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
214730215|NCT00713557|DEVICE|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
214730216|NCT00713557|DRUG|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
214730217|NCT02574520|DRUG|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
214730218|NCT02574520|DRUG|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
214730219|NCT02574520|DRUG|Saline Placebo|5 ml once at end of surgery
214730220|NCT02574520|DRUG|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
214730221|NCT04573491|GENETIC|Pharmacogenetic test|genotyping for genes that affect drug metabolism
214730222|NCT04573491|OTHER|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
214730223|NCT02550093|PROCEDURE|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
214730224|NCT02550093|BEHAVIORAL|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
214730225|NCT02550093|PROCEDURE|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
214730226|NCT02903745|OTHER|observational|
214730227|NCT00740194|DRUG|Aromatase inhibition|Letrozole
214730228|NCT00740194|DRUG|Estradiol|Dermestril
214730229|NCT00128362|PROCEDURE|Radio-guided sentinel node biopsy|
214730230|NCT00128362|PROCEDURE|Axillary sampling|
214730231|NCT04684160|DEVICE|Fixed-bearing TKA|
214730232|NCT04684160|DEVICE|Mobile-bearing TKA|
214730233|NCT00224497|DRUG|SB-742457|
214730234|NCT02467660|BEHAVIORAL|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
214730235|NCT02467660|BEHAVIORAL|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
214730236|NCT04941976|DRUG|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
214730237|NCT04941976|DRUG|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
214730238|NCT02003768|DRUG|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
214730239|NCT02003768|DRUG|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
214730240|NCT03426644|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
214730241|NCT00993980|PROCEDURE|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
214730242|NCT00993980|PROCEDURE|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
214730243|NCT03822780|DRUG|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
214730244|NCT02250391|DRUG|NPB-06|5 days continuous-infusion
214730245|NCT02250391|DRUG|Placebo|5 days continuous-infusion
214730246|NCT01365091|DRUG|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
214730247|NCT01365091|DRUG|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
214730248|NCT01365091|DRUG|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
214730249|NCT01365091|DRUG|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
214730250|NCT01365091|DRUG|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
214730251|NCT05724381|DIAGNOSTIC_TEST|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
214730252|NCT01739374|OTHER|reduced mesh implants|mesh for pelvic floor reinforcement
214730253|NCT01375439|OTHER|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
214730254|NCT00583830|BIOLOGICAL|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
214730255|NCT00583830|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
214730256|NCT00583830|DRUG|Paclitaxel|200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
214730257|NCT00583830|DRUG|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
214730258|NCT04052412|DRUG|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
214730259|NCT02583464|DRUG|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
214730260|NCT01238276|DRUG|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
214730261|NCT01238276|DEVICE|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
214730262|NCT05116683|DRUG|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
214730263|NCT00392951|DRUG|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
214730264|NCT06694233|OTHER|Aspirin prescription on outpatient basis|Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
214730265|NCT01474889|DEVICE|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
214730266|NCT04245657|OTHER|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
214730267|NCT04245657|OTHER|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
214730268|NCT04245657|OTHER|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
214730269|NCT04245657|OTHER|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
214730270|NCT04245657|OTHER|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
214730271|NCT04245657|OTHER|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
214730272|NCT04245657|OTHER|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
214730273|NCT04245657|OTHER|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
214730274|NCT04245657|OTHER|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
214730275|NCT03298048|BIOLOGICAL|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
214730276|NCT03298048|BIOLOGICAL|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
214730277|NCT03298048|BIOLOGICAL|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
214730278|NCT01492816|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
214730279|NCT00726310|DEVICE|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
214730280|NCT05056636|DIAGNOSTIC_TEST|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
214730281|NCT03935594|BIOLOGICAL|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
214730282|NCT03935594|DRUG|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
214730283|NCT04229082|OTHER|observational|
214730284|NCT01435122|DRUG|Axitinib|Axitinib Administration as outlined in Arm description
214730285|NCT03993301|OTHER|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
214730286|NCT03993301|OTHER|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
214730287|NCT03993301|OTHER|Regular formula|Feeding baby two meals a day with regular formula at least.
214730288|NCT04412668|DRUG|Efzofitimod 1 mg/kg|Concentrate for solution for infusion
214730289|NCT04412668|DRUG|Efzofitimod 3 mg/kg|Concentrate for solution for infusion
214730290|NCT04412668|DRUG|Placebo|Concentrate for solution for infusion
214730291|NCT05187572|BEHAVIORAL|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
214730292|NCT01804647|OTHER|No study treatments administered - blood draws only|
214730293|NCT05203744|DRUG|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
214730294|NCT02132689|DRUG|Actilyse (Thrombolytic therapy)|
214730295|NCT02132689|DRUG|Heparine (Standard anticoagulation therapy)|
214730296|NCT02159989|DRUG|Sapanisertib|Given PO
214730297|NCT02159989|BIOLOGICAL|Ziv-Aflibercept|Given IV
214730298|NCT03557229|DRUG|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
214730299|NCT03557229|DRUG|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
214730300|NCT03557229|DRUG|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
214730301|NCT03557229|DRUG|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
214730302|NCT02482389|RADIATION|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
214730303|NCT01808365|PROCEDURE|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
214730304|NCT01808365|OTHER|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
214730305|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
214730306|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
214730307|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
214730308|NCT02834494|PROCEDURE|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
214730309|NCT02834494|BIOLOGICAL|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
214730310|NCT02371694|OTHER|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
214730311|NCT03864627|DRUG|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
214730312|NCT03864627|DRUG|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
214730313|NCT01388491|DRUG|desogestrel/ethinyl estradiol and ethinyl estradiol|
214730314|NCT01388491|DRUG|desogestrel/ethinyl estradiol|
214730315|NCT05135182|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
214730316|NCT05135182|DRUG|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
214730317|NCT02758561|BEHAVIORAL|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
214730318|NCT03960385|BIOLOGICAL|CYD-TDV|Dengue vaccine
214730319|NCT04188210|OTHER|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
214730320|NCT03699527|BEHAVIORAL|Multiple questionnaires administered|This is an observational trial
214730321|NCT03631394|OTHER|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
214730322|NCT03631394|OTHER|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
214730323|NCT01153568|DIETARY_SUPPLEMENT|Vitamin D 3|Patients will bew given a single capsule to take once daily
214730324|NCT01153568|OTHER|placebo|placebo tablets
214730325|NCT00198367|DRUG|Cisplatin-Gemzar|
214730326|NCT00198367|DRUG|Cisplatin-Navelbine-Radiotherapy|
214730327|NCT00198367|DRUG|Carboplatin-Taxol-Radiotherapy|
214730328|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
214730329|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
214730330|NCT03333512|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
214730331|NCT05455645|OTHER|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
214730332|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
214730333|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
214730334|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
214730335|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
214730336|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
214730337|NCT05021666|DRUG|Placebo|matching placebo
214730338|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
214730339|NCT00965549|DRUG|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
214730340|NCT00965549|DRUG|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
214730341|NCT00965549|DRUG|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
214730342|NCT06113172|OTHER|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
214730343|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
214730344|NCT02050672|OTHER|untreated|
214730345|NCT02451254|PROCEDURE|circumferential ablation|circumferential ablation of the pulmonary veins
214730346|NCT02451254|DEVICE|SVT ablation|SVT ablation
214730347|NCT02456571|DEVICE|CTC biomarker expression prevalence|
214730348|NCT04964557|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
214730349|NCT04964557|DRUG|Placebo|Placebo solution
214730350|NCT06074718|OTHER|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
214730351|NCT04756349|OTHER|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
214730352|NCT06722664|DRUG|Recombinant Human Chymotrypsin(OsrhCT) 4000U|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder
214730353|NCT06722664|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder
214730354|NCT06722664|DRUG|Dimethicone emulsion 4ml|Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.
214730355|NCT03476928|DRUG|Vilaprisan (BAY1002670)|2mg, once daily, oral
214730356|NCT03607604|GENETIC|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
214730357|NCT00962468|OTHER|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
215031027|NCT02399293|BEHAVIORAL|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
214730358|NCT00826709|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
214730359|NCT04511338|DEVICE|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
214730360|NCT06926491|DRUG|KK8398|KK8398 will be administered.
214730361|NCT05884268|DRUG|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
214730362|NCT05884268|DRUG|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
214730363|NCT00000405|PROCEDURE|Exercise intervention|
214730364|NCT02369211|DRUG|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
214730365|NCT02369211|OTHER|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
214730366|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
214730367|NCT02150291|DRUG|Neurobion|
214730368|NCT02150291|DRUG|placebo|
214730369|NCT05956262|DEVICE|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
214730370|NCT05956262|BEHAVIORAL|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
214730371|NCT06942793|DRUG|CsA-PG Ophthalmic Gel|Administer to eyes
214730372|NCT06942793|DRUG|CsA Ophthalmic Gel|Administer to eyes
214730373|NCT06942572|GENETIC|SB-007|Subretinal Administration of SB-007
214730374|NCT04339725|OTHER|DNA extraction|Extraction fecal DNA and compare disease group to normal group
214730375|NCT05104086|DEVICE|ultrasound elastography|strain ratio and resistivity index
214730376|NCT03649815|COMBINATION_PRODUCT|App4Independence|"The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations"
214730377|NCT00874224|PROCEDURE|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
214730378|NCT00874224|PROCEDURE|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
214730379|NCT01251822|DRUG|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
214730380|NCT01251822|DRUG|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
214730381|NCT06949332|DEVICE|electromyography|In this study, surface Electromyography (EMG) was employed to assess the electrical activity of the masseter muscles. Surface EMG is a physiological measurement technique that allows for the recording of electrical potentials generated by muscle fiber depolarization through non-invasive electrodes placed on the skin. This method is widely accepted for objectively determining muscle activation levels and timing, enabling the quantitative analysis of changes in masseter muscle activity during the performance of various Rocabado exercises in this study. The validity and reliability of the EMG device utilized (Noraxon USA Inc., Scottsdale, AZ, USA) have been established in the literature.
214730382|NCT06949306|OTHER|"Bracelet, assistant, APP: the golden triangle of smart life"|The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.
214730383|NCT06949501|OTHER|virtual patient simulation|Students in this group are expected to provide sexual counseling to a virtual patient model following theoretical training. In this context, a virtual patient model has been developed with whom the students will engage for the counseling process.
214730384|NCT06949501|OTHER|peer simulation conducted in a virtual environment|Students in this group are expected to provide sexual counseling to their peers in a virtual environment following theoretical training. In the virtual peer simulation, students will see the same background displayed in the virtual patient simulation; however, instead of interacting with a virtual patient, they will connect with a peer via an online platform to conduct the counseling session.
214730385|NCT06949501|OTHER|face-to-face peer simulation|Students in this group are expected to provide sexual counseling to their peers following theoretical training. In the peer simulation, students will conduct their sessions in a communication skills laboratory designed to resemble a clinical consultation room.
214730386|NCT06948058|OTHER|Electronic Cigarettes (EC)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to EC for 8 weeks, with EC provided.
214730387|NCT06948058|OTHER|Nicotine replacement therapy (NRT)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to combination NRT (transdermal + oral) for 8 weeks, with NRT provided.
214730388|NCT06948071|OTHER|Discharge on oral antibiotics|Patients will be discharged to home on an oral antibiotic regimen for 3 days instead of being admitted for intravenous antibiotics.
214730389|NCT06949137|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal stem cell|Intravenous infusion of hMSC100 at 20-25 drops per minute
214730390|NCT06949878|DRUG|Antivet|"Complete stain removal from the Enamel-Use a compact cotton swab (3 mm) to apply Antivet solution (Dental Continental, México)to the stained dental piece according to manufacturer's instructions.-Replace the swab as it becomes stained and continue until the stain is removed.  This may take 1-5 minutes per tooth, but do not exceed 15 minutes in total.  - We will keep the tooth moist during the process for effective results and avoid reusing stained cotton swab.-Then we will apply the neutralizing solution to the tooth with a brush or micro brush, ensuring it reaches the gingival margin. Leave it on for 2 minutes.-Once the antivet solution is neutralized, rinse the area and remove the rubber dam."
214730391|NCT06949878|DRUG|opalustre|Complete stain removal from the Enamel. Product will be applied to the surface with a 1 mm thick layer; ten applications of 60s to help penetration of the gel into the enamel.- Using an abrasive rubber cup (OpalCup™ Ultradent) in contra-angle low-speed handpiece at low revolution.- Then will be rinsed with injectable water for 30 seconds between each application.
214730392|NCT06949943|BEHAVIORAL|Behavioral Intervention|Listen to guided meditation
214730393|NCT06949943|BEHAVIORAL|Behavioral Intervention|Wear noise cancelling headphones
214730394|NCT06949943|OTHER|Electronic Health Record Review|Ancillary studies
214730395|NCT06949943|OTHER|Survey Administration|Ancillary studies
214730396|NCT06948162|DEVICE|dental-dedicated MRI (ddMRI)|This descriptive observational research is comparative in design, that is comparing existing standard clinical dental images, not obtained in this study, to test (i.e., ddMRI) images.
214730397|NCT06948201|DIETARY_SUPPLEMENT|70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice)|70mL Nitrate Rich Beetroot Juice for 14 days followed by placebo (Nitrate depleted beetroot juice) for 14 days
214730398|NCT06948201|DIETARY_SUPPLEMENT|Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice|Placebo (70 mL Nitrate depleted beetroot juice) for 14 days followed by 70mL Nitrate Rich Beetroot Juice for 14 days
214730399|NCT06949397|OTHER|Change in VAS voice performance score following the characteristics of the menstrual cycle of two women|application of menstrual belt and stress ball to women in the research group
214730400|NCT06948474|DRUG|Dachengqi decoction|experimental Participants received Dachengqi decoction (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
214730401|NCT06948474|PROCEDURE|modified gastrointestinal dual-lumen feeding tube|experimental and control group participants underwent intraoperative placement of modified gastrointestinal dual-lumen feeding tubes with distal ends positioned 15-20 cm distal to the gastrojejunostomy anastomosis (all devices were uniformly procured by China-Japan Friendship Hospital).
214730402|NCT06948474|DRUG|Normal Saline (0.9% NaCl)|control group participants were administered glucose and sodium chloride injection (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
215030538|NCT03886636|OTHER|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
214730403|NCT06948526|DRUG|Moringa Oleifera Leaf Extract|A plant-based extract derived from Moringa Oleifera leaves, used as an intracanal irrigant during pulpectomy procedures in primary molars. It is administered using a 3 ml syringe with a side-vented needle following canal preparation and working length determination. This intervention aims to evaluate the clinical and radiographic efficacy of a natural, biocompatible alternative to conventional chemical irrigants.
214730404|NCT06948526|DRUG|Sodium Hypochlorite 1%|A 1% concentration of Sodium Hypochlorite solution used as a standard intracanal irrigant in pediatric endodontics. It is administered using a 3 ml syringe with a side-vented needle after canal instrumentation. Known for its strong antimicrobial and tissue-dissolving properties, Sodium Hypochlorite serves as the active comparator in this study.
214730405|NCT04901104|DRUG|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
214730406|NCT00479934|DRUG|imatinib mesylate|6 month treatment with 400mg/day (per os)
214730407|NCT04541654|GENETIC|Data and Specimen Collection|"* Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional)."
214730408|NCT00177606|BEHAVIORAL|withdrawal of life sustaining treatments|
214730409|NCT00171067|DRUG|valsartan|
214730410|NCT00171067|DRUG|lisinopril|
214730411|NCT02894788|OTHER|ICU admission|
214730412|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
214730413|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
214730414|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
214730415|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
214730416|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
214730417|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
214730418|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
214730419|NCT00585104|DRUG|levosimendan|10-minute infusion
214730420|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
214730421|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
214730422|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
214730423|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
214730424|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
214730425|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
214730426|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
214730427|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
214730428|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
214730429|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
214730430|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
214730431|NCT02726204|OTHER|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
214730432|NCT02726204|OTHER|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
214730433|NCT02726204|OTHER|Path Assistance and Gravity Elimination|
214730434|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
214730435|NCT01485185|DRUG|Donepezil|Repeat, oral dose
214730436|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
214730437|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
214730438|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
214730439|NCT00544193|DRUG|gemcitabine hydrochloride|
214730440|NCT00544193|GENETIC|polymerase chain reaction|
214730441|NCT00544193|OTHER|immunohistochemistry staining method|
214730442|NCT00544193|PROCEDURE|conventional surgery|
214730443|NCT00544193|RADIATION|intraoperative radiation therapy|
214730444|NCT00544193|RADIATION|radiation therapy|
214730445|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214730446|NCT05955274|BEHAVIORAL|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
214730447|NCT05955274|BEHAVIORAL|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
214730448|NCT05080673|PROCEDURE|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
214730449|NCT05789862|BEHAVIORAL|Counseling Sessions|Virtual sessions
214730450|NCT05789862|BEHAVIORAL|Quality of Life Questionnaires|Self administered questionnaires
214730451|NCT02784496|OTHER|Long-term Follow-up|Undergo follow-up assessment
214730452|NCT02784496|OTHER|Quality-of-Life Assessment|Ancillary studies
214730453|NCT02784496|DRUG|Ruxolitinib|Given PO
214730454|NCT05201547|DRUG|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
214730455|NCT05201547|DRUG|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
214730456|NCT04924114|DRUG|MK-6194|Subcutaneous injection
214730457|NCT04924114|DRUG|MK-6194-matching placebo|Subcutaneous injection
214730458|NCT04327609|DEVICE|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
214730459|NCT04327609|DEVICE|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
214730460|NCT05611671|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
214730461|NCT05611671|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
214730462|NCT06568497|OTHER|Food|Food
214730463|NCT05330611|DEVICE|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
214730464|NCT05330611|OTHER|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
214730465|NCT03728972|DRUG|Pembrolizumab|200mg IVPB every 3 weeks
214730466|NCT04960202|DRUG|PF-07321332|PF-07321332 (tablet)
214730467|NCT04960202|DRUG|Ritonavir|Ritonavir (capsule)
214730468|NCT04960202|DRUG|Placebo|Placebo (tablet or capsule)
214730469|NCT05220358|DRUG|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
214730470|NCT05113251|DRUG|Trastuzumab Deruxtecan|administered by intravenous infusion
214730471|NCT05113251|DRUG|Paclitaxel|administered by intravenous infusion
214730472|NCT05113251|DRUG|Trastuzumab|administered by intravenous infusion
214730473|NCT05113251|DRUG|Pertuzumab|administered by intravenous infusion
214730474|NCT05113251|DRUG|Doxorubicin|administered by intravenous infusion
214730475|NCT05113251|DRUG|cyclophosphamide|administered by intravenous infusion
214730476|NCT05396001|BEHAVIORAL|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
214730477|NCT05396001|BEHAVIORAL|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
214730478|NCT05626907|OTHER|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
214730479|NCT05626907|OTHER|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
214730480|NCT05626907|OTHER|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
214730481|NCT06465953|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
214730482|NCT06465953|DRUG|Azacitidine|Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
214730483|NCT05242627|BEHAVIORAL|Clinical Firearm Safety Counseling Module|"The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program."
214730484|NCT02346409|DEVICE|tACS of the cerebellum|tACS of the cerebellum
214730485|NCT02552823|OTHER|Group1|
214730486|NCT02552823|OTHER|Group2|
214730487|NCT01518673|PROCEDURE|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
214730488|NCT04021628|OTHER|No intervention- not applicable|No intervention - not applicable
214730489|NCT04835051|BEHAVIORAL|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
214730490|NCT05127356|DEVICE|DIAGNOdent|Laser fluorescence device
214730491|NCT05127356|DIAGNOSTIC_TEST|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
214730492|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
214730493|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
214730494|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
214730495|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
214730496|NCT00692393|PROCEDURE|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
214730497|NCT00692393|PROCEDURE|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
214730498|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
214730499|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
214730500|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
214730501|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
214730502|NCT05861050|PROCEDURE|Biopsy|Undergo tumor biopsy
214730503|NCT05861050|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214730504|NCT05861050|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214730505|NCT05861050|PROCEDURE|Computed Tomography|Undergo CT scan
214730506|NCT05861050|BIOLOGICAL|Glofitamab|Given IV
214730507|NCT05861050|DRUG|Lenalidomide|Given PO
214730508|NCT05861050|BIOLOGICAL|Obinutuzumab|Given IV
214730509|NCT05861050|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214730510|NCT05861050|DRUG|Venetoclax|Given PO
214730511|NCT06430840|BEHAVIORAL|CostCOM (Cost Communication, Financial navigation and counseling)|"Patients will receive two 1-hour, phone or video sessions with a remote financial counselor, each session will cover each of these 3 components of CostCOM.~Out-of-pocket cost communication (OOPC): A review of insurance benefits and education of the patient-specific OOPC for anticipated treatment regimen if any (i.e., medication). The OOPC is provided as a total estimate and will be updated at 3-month session in case of changes in treatment or insurance.~Financial navigation: Real-time professional guidance to identify financial assistance programs (e.g., co-pay, living expenses) that alleviate costs of care and discuss information to improve insurance coverage.~Financial counseling: To address the range of patients' financial concerns and enroll patients in financial assistance programs."
214730512|NCT06430840|BEHAVIORAL|Provision of local and national resources to address financial and social needs|Patients will be provided with a comprehensive list of local resources (in patients' preferred language) in Orange County that can help with food insecurity, ir transportation, as well as contact information for national non-profit organization where patients can self-refer for financial navigation (e.g., Patient Advocate Foundation (PAF)
214730513|NCT06430840|BEHAVIORAL|Financial Education|Patient will receive online and paper educational materials on topics such as health insurance and health insurance literacy, navigating hospitals' price estimator tool.
214730514|NCT06430840|OTHER|Usual care|Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.
214730515|NCT06430840|OTHER|Screening for financial and social needs|Patients will be screened for financial hardship and health-related social risks.
214730516|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
214730517|NCT03935828|DRUG|Oral versus topical antibioitics|Previously described in two arms
214730518|NCT01794546|BEHAVIORAL|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
214730519|NCT00354484|DRUG|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
214730520|NCT00354484|DRUG|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
214730521|NCT04161313|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
214730522|NCT04161313|OTHER|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
214730523|NCT04161313|OTHER|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
214730524|NCT04161313|OTHER|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
214730525|NCT04161313|OTHER|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
214730526|NCT06491368|PROCEDURE|Cesarean Delivery|A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
214730527|NCT05683483|OTHER|WEsleep Interventions|1\) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
214730528|NCT02508363|BEHAVIORAL|questionnaires|
214730529|NCT06043271|BEHAVIORAL|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
214730530|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
214730531|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
214730532|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
215030539|NCT03886636|OTHER|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
214730533|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
214730534|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
214730535|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
214730536|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
214730537|NCT00378534|DEVICE|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
214730538|NCT00378534|DRUG|Fludarabine|Therapeutic
214730539|NCT00378534|DRUG|Cyclosporine|Therapeutic
214730540|NCT00378534|DRUG|Cyclophosphamide|Therapeutic
214730541|NCT00378534|OTHER|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
214730542|NCT04969900|OTHER|Placebo oil|The placebo group will receive placebo oil.
214730543|NCT04969900|OTHER|Lavender oil.|Investigational Product. This group will receive Lavender oil.
214730544|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
214730545|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
214730546|NCT03537937|OTHER|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
214730547|NCT03537937|OTHER|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
214730548|NCT03537937|OTHER|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
214730549|NCT03733106|DIAGNOSTIC_TEST|digital breast tomosynthesis|pseudo three dimension mammography
214730550|NCT03733106|DIAGNOSTIC_TEST|standard two dimension digital mammogram|standard two dimension mammogram
214730551|NCT06632769|DEVICE|No intervention|No intervention
214730552|NCT03671148|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
214730553|NCT03671148|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
214730554|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
214730555|NCT01620801|BIOLOGICAL|AAV8-hFIX19|One-time IV vector administration.
214730556|NCT05788978|OTHER|Scale development|Scale development
214730557|NCT05065866|DRUG|BMS-986345|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
215031028|NCT02399293|BEHAVIORAL|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
214730558|NCT05065866|DRUG|Duvelisib|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
214730559|NCT04423718|DRUG|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
214730560|NCT04423718|DRUG|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
214730561|NCT06114511|DRUG|BL-M07D1|Administration by intravenous infusion
214730562|NCT06961786|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
214730563|NCT06961786|BIOLOGICAL|TIL|Adoptive T cell therapy with TILs
214730564|NCT06961786|DRUG|Cyclophosphamide|Lymphocyte-depleting chemotherapy
214730565|NCT06961786|DRUG|Fludarabine|Lymphocyte-depleting chemotherapy
214730566|NCT00425945|DRUG|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
214730567|NCT02743975|DRUG|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
214730568|NCT06098794|DIETARY_SUPPLEMENT|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
214730569|NCT06098794|DIETARY_SUPPLEMENT|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
214730570|NCT05411224|OTHER|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
214730571|NCT03783013|OTHER|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
214730572|NCT03783013|OTHER|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
214730573|NCT02095249|DRUG|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
214730574|NCT05516940|OTHER||
214730575|NCT02233140|DEVICE|Extra-corporeal pulsed-activated therapy or shockwave therapy|
214730576|NCT02462811|DRUG|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
214730577|NCT02462811|DRUG|Placebo|
214730578|NCT02462811|DRUG|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
214730579|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
214730580|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
214730581|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
214730582|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
214730583|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
214730584|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
214730585|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
214730586|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
214730587|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
214730588|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
214730589|NCT01430910|DRUG|CAZ104|IV infusion
214730590|NCT01430910|DRUG|Avibactam|IV infusion
214730591|NCT01430910|DRUG|Ceftazidime|IV infusion
214730592|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
214730593|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
214730594|NCT05614700|RADIATION|Brachytherapy|High Dose-Rate Brachytherapy
214730595|NCT05614700|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
214730596|NCT02098655|OTHER|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
214730597|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
214730598|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
214730599|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
214730600|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
214730601|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
214730602|NCT01594463|OTHER|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
214730603|NCT01594463|OTHER|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
214730604|NCT01731808|BEHAVIORAL|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
214730605|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
214730606|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
214730607|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
214730608|NCT02875353|DEVICE|Doppler Endoscopic Probe|A colon length catheter (probe).
214730609|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
214730610|NCT03880123|DRUG|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
214730611|NCT03880123|DRUG|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
214730612|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
214730613|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
214730614|NCT02138734|BIOLOGICAL|BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
214730615|NCT02138734|BIOLOGICAL|BCG( 50mg/Instillation)|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
214730616|NCT04502095|DRUG|Clindamycin|Given PO
214730617|NCT04502095|OTHER|Diary|Complete drug diary
214730618|NCT04502095|DRUG|Ertapenem|Given PO
214730619|NCT04502095|DRUG|Levofloxacin|Given PO
214730620|NCT04502095|DRUG|Nitrofurantoin|Given PO
214730621|NCT04502095|DRUG|Trimethoprim-Sulfamethoxazole|Given PO
214730622|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
214730623|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
214730624|NCT06083857|DRUG|Amivantamab|Given by IV (vein)
214730625|NCT06083857|DRUG|Tepotinib|Given by PO
214730626|NCT00945269|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214730627|NCT00945269|BIOLOGICAL|aldesleukin|Given SC
214730628|NCT00945269|BIOLOGICAL|denileukin diftitox|Given IV
214730629|NCT00945269|PROCEDURE|biopsy|Optional correlative studies
214730630|NCT00945269|OTHER|immunohistochemistry staining method|Correlative studies
214730631|NCT00945269|OTHER|laboratory biomarker analysis|Correlative studies
214730632|NCT00945269|GENETIC|polymerase chain reaction|Correlative studies
214730633|NCT03922334|BEHAVIORAL|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
214730634|NCT04217447|DRUG|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
214730635|NCT04217447|DRUG|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
214730636|NCT05032755|OTHER|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
214730637|NCT05032755|OTHER|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
214730638|NCT04944420|BEHAVIORAL|Health enSuite Caregivers|"Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access."
214730639|NCT02330926|OTHER|standard care|Routine oncology and palliative care
214730640|NCT02330926|DIETARY_SUPPLEMENT|nutritional supplements and advice|n-3 PUFA enriched supplements, dietary advice
214730641|NCT02330926|BEHAVIORAL|home-based self-assisted exercise program|Strength and aerobic
214730642|NCT02330926|DRUG|Ibuprofen|400mgx3
214730643|NCT05031390|PROCEDURE|Physiotherapist-led training|Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
214730644|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
214730645|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
214730646|NCT00814905|DRUG|saline|A saline infusion after delivery (one dose)
214730647|NCT00814905|DRUG|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
214730648|NCT00814905|DRUG|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
214730649|NCT00814905|DRUG|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
214730650|NCT05618808|DRUG|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
214730651|NCT05618808|DRUG|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
214730652|NCT05618808|DRUG|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
214730653|NCT06509568|RADIATION|Neoadjuvant chemoradiotherapy followed by immunotherapy|Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose tislelizumab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.
214730654|NCT06509568|DRUG|Neoadjuvant chemoimmunotherapy|Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and tislelizumab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
214730655|NCT02566122|OTHER|measurements|
214730656|NCT04284787|DRUG|Azacitidine|Given IV or SC
214730657|NCT04284787|PROCEDURE|Biopsy Procedure|Undergo biopsy
214730658|NCT04284787|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214730659|NCT04284787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214730660|NCT04284787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214730661|NCT04284787|PROCEDURE|Echocardiography Test|Undergo ECHO
214730662|NCT04284787|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214730663|NCT04284787|BIOLOGICAL|Pembrolizumab|Given IV
214730664|NCT04284787|DRUG|Venetoclax|Given PO
214730665|NCT03613532|DRUG|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
214730666|NCT03613532|DRUG|Fludarabine|Given once daily for 4 days
214730667|NCT03613532|DRUG|Busulfan|Given twice daily for 4 days
214730668|NCT03613532|DRUG|Venetoclax|Part 2, Part 3, and Part 4: 14 doses for 8-12 cycles depending on dose level assigned
214730669|NCT03613532|DRUG|Azacitidine|Part 2 and Part 4: 5 doses for 8-12 cycles depending on dose level assigned
214730670|NCT03613532|DRUG|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
214730671|NCT05805839|DRUG|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
214730672|NCT05805839|DRUG|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
214730673|NCT05805839|DIAGNOSTIC_TEST|PET/CT scan|Imaging of entire brain
214730674|NCT05805839|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging of the Brain
214730675|NCT06097832|BIOLOGICAL|NXC-201 CAR-T|NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
214730676|NCT06798337|OTHER|Conventional Physiotherapy group|Participants in the regular physical therapy group performed balance and coordination exercises three times a week without the use of rewards. These subjects completed only physical exercises, without engaging in game-like interactive tasks using virtual reality (VR) glasses. Each session was conducted at the same time for each subject, with a potential variation of ±1 hour.
214730677|NCT06798337|OTHER|Reward based physiotherapy group|Subjects in the reward group performed balance and coordination exercises three times a week, with the inclusion of rewards. At the end of each exercise session, participants engaged in game-like interactive tasks using virtual reality (VR) glasses. Exercise sessions were conducted at the same time for each subject, with a permissible variation of ±1 hour.
214730678|NCT06016738|DRUG|Palazestrant|Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
214730679|NCT06016738|DRUG|Fulvestrant|Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
214730680|NCT06016738|DRUG|Anastrozole|Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
214730681|NCT06016738|DRUG|Letrozole|Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
214730682|NCT06016738|DRUG|Exemestane|Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
214730683|NCT01874353|DRUG|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
214730684|NCT01874353|DRUG|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
214730685|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
214730686|NCT03059823|DRUG|retifanlimab|Anti-PD-1 monoclonal antibody
214730687|NCT05240300|BIOLOGICAL|BX005-A|phage gel
214730688|NCT05240300|OTHER|Placebo|vehicle gel
214730689|NCT06628869|DIETARY_SUPPLEMENT|Fructanase|Participants will consume one capsule containing 400 INU inulinase (325 mg, includes maltodextrin) with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The fructanase was obtained from Aspergillus tubingensis.
214730690|NCT06628869|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing 300 mg maltodextrin with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The maltodextrin was obtained from tapioca.
214730691|NCT06085495|PROCEDURE|mechanical thrombectomy (PMT)|After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
214730692|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
214730693|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
214730694|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
214730695|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
214730696|NCT04195945|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214730697|NCT04195945|DRUG|Cladribine|Given IV
214730698|NCT04195945|DRUG|Cytarabine|Given IV
214730699|NCT04195945|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
214730700|NCT04195945|DRUG|Mitoxantrone|Given IV
214730701|NCT04195945|OTHER|Questionnaire Administration|Ancillary studies
214730702|NCT04195945|OTHER|Quality-of-Life Assessment|Ancillary studies
214730703|NCT04413994|DIETARY_SUPPLEMENT|Humavant|"Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
214730704|NCT04919369|BIOLOGICAL|Atezolizumab|Given IV
214730705|NCT04919369|DRUG|Tretinoin|Given PO
214730706|NCT03567733|DEVICE|XIENCE Sierra|Percutaneous coronary intervention
214730707|NCT04561453|DIAGNOSTIC_TEST|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
214730708|NCT05187611|DEVICE|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
214730709|NCT05187611|DEVICE|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
214730710|NCT05879926|DRUG|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
214730711|NCT05879926|DRUG|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
214730712|NCT01797055|DRUG|Human apotransferrin|intravenous infusion
214730713|NCT06803602|DEVICE|EMSELLA®|Subjects will receive 100% intensity of the EMSELLA® (BTL Industries, Marlborough, MA) High-Intensity Focused Electromagnetic (HIFEM) treatment, in a single 30-minute session, twice per week for 3 weeks.
214730714|NCT06803602|DEVICE|Sham Comparator Device|Subjects will be asked to sit on the EMSELLA® (BTL Industries, Marlborough, MA) treatment head which will be powered off and instead have a small remote control vibration device that will simulate active treatment, in a single 30-minute session, twice per week for 3 weeks.
214730715|NCT05848895|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
214730716|NCT05848895|BEHAVIORAL|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
214730717|NCT06085443|OTHER|Ear Hygiene|2 sprays in each ear, every 3 days at home
214730718|NCT03502785|BIOLOGICAL|INO-5401|INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
214730719|NCT03502785|BIOLOGICAL|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
214730720|NCT03502785|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
214730721|NCT03502785|DEVICE|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
214730722|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
214730723|NCT05243875|BEHAVIORAL|LEAP Education + Navigation|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE; and (2) navigation, which involves individual tailoring of information about where and how to get tested, and where to get vaccinated, and when appropriate, guiding participants in scheduling testing and vaccination appointments.
214730724|NCT05243875|BEHAVIORAL|LEAP Education|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE.
214730725|NCT05426083|OTHER|Physiological Assessment|Observational only
214730726|NCT04992507|PROCEDURE|Anesthesia Procedure|Given TIVA
214730727|NCT04992507|DRUG|General Anesthesia Procedure|Given inhaled volatile anesthetics
214730728|NCT04992507|PROCEDURE|Resection|Undergo surgical resection
214730729|NCT04168905|DEVICE|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
214730730|NCT02945852|DRUG|apatinib|apatinib 500mg/d until progressive Disease
214730731|NCT04572685|DRUG|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
214730732|NCT06305819|BEHAVIORAL|self-management support program|The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.
214730733|NCT06305819|OTHER|Control group|Treatment as usual
214730734|NCT04893395|OTHER|Pharmacogenomic Screening|"First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations"
214730735|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
214730736|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
214730737|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
214730738|NCT03774875|DRUG|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
214730739|NCT03774875|DRUG|Placebo|Placebo tablets taken orally twice a day
214730740|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide
214730741|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
214730742|NCT05222373|BEHAVIORAL|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
214730743|NCT02013154|DRUG|DKN-01 150 mg|Administered by IV infusion
214730744|NCT02013154|DRUG|Paclitaxel|Administered by IV infusion
214730745|NCT02013154|DRUG|Pembrolizumab|Administered by IV infusion
214730746|NCT02013154|DRUG|DKN-01 300 mg|Administered by IV infusion
214730747|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
214730748|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
214730749|NCT03348293|PROCEDURE|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
214730750|NCT04170894|OTHER|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
214730751|NCT04170894|OTHER|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
214730752|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
214730753|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
214730754|NCT05624710|DRUG|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
214730755|NCT05718557|DRUG|PYX-106|Intravenous (IV) infusion
214730756|NCT04090710|DRUG|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
214730757|NCT04090710|RADIATION|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
214730758|NCT05705401|RADIATION|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
214730759|NCT05705401|DRUG|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
214730760|NCT05645692|DRUG|Atezolizumab|Participants will receive 1200 mg IV atezolizumab Q3W.
214730761|NCT05645692|DRUG|Tobemstomig|Participants will receive 600 mg IV tobemstomig Q3W.
214730762|NCT05645692|DRUG|Tiragolumab|Participants will receive 600 mg IV tiragolumab Q3W.
214730763|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
214730764|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
214730765|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
214730766|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
214730767|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
214730768|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
214730769|NCT03250247|DEVICE|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices \> 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
214730770|NCT01239134|BIOLOGICAL|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
214730771|NCT05507541|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214730772|NCT05507541|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
214730773|NCT05507541|DRUG|Ontorpacept|Given IV
214730774|NCT05507541|BIOLOGICAL|Pembrolizumab|Given IV
214730775|NCT05507541|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
214730776|NCT05507541|DRUG|Maplirpacept|Given IV
214730777|NCT05507541|PROCEDURE|Biopsy|Undergo tumor biopsy
214730778|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
214730779|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
214730780|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
214730781|NCT06245044|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
214730782|NCT06245044|BEHAVIORAL|Scenario #1|Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
214730783|NCT06245044|BEHAVIORAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
214730784|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
214730785|NCT04250155|DRUG|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
214730786|NCT04250155|DRUG|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
214730787|NCT04250155|DRUG|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
214730788|NCT06792461|BEHAVIORAL|Physical activity and nutritional behavioural intervention|"The ePro-Schools intervention includes two digital platforms designed to promote physical activity and healthy nutrition among adolescents:~1. The Intervention Platform, which provides interactive content for both students and PE teachers.~2. The Information Platform, which offers educational resources for students, teachers, and families.~The intervention content-currently being refined through a co-creation process-will feature engaging modules focused on physical activity and healthy eating. Adolescents will have access to more than 15 interactive modules, while PE teachers will benefit from 8 targeted pedagogical modules aimed at enhancing their lessons and encouraging greater student participation in physical activity.~Control group will have access to the information platform"
214730789|NCT06225141|OTHER|Clinical Data reuse|Clinical Data reuse
214730790|NCT05371795|DEVICE|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
214730791|NCT05371795|DEVICE|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
214730792|NCT05412693|DEVICE|Functional orthosis|See arm descriptions
214730793|NCT05412693|DEVICE|Cast immobilization|See arm descriptions
214730794|NCT03908463|DEVICE|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
214730795|NCT03995121|DRUG|[11C]APP311|It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
214730796|NCT04440085|DRUG|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
214730797|NCT04440085|DRUG|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
214730798|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
214730799|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
214730800|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
214730801|NCT05400811|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
214730802|NCT05400811|BIOLOGICAL|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
214730803|NCT00166244|DRUG|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
214730804|NCT06357429|OTHER|Cold Application|Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
214730805|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
214730806|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
214730807|NCT06488014|PROCEDURE|Erector spina plan block (ESP)|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
214730808|NCT06488014|PROCEDURE|Paravertebral block|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
214730809|NCT02844322|DRUG|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
214730810|NCT02844322|DRUG|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
214730811|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
214730812|NCT03659708|PROCEDURE|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
214730813|NCT03659708|PROCEDURE|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
214730814|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
214730815|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
214730816|NCT06970665|DRUG|avacincaptad pegol|intravitreal injection
214730817|NCT03736590|BEHAVIORAL|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
214730818|NCT06012097|DRUG|Diclofenac gel|using diclofenac as a comparator
214730819|NCT06012097|DRUG|Aromatherapy gel|using Aromatherapy gel as an experimetnal treatment
214730820|NCT04920539|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
214730821|NCT02974621|BIOLOGICAL|Bevacizumab|Given IV
214730822|NCT02974621|DRUG|Cediranib|Given PO
214730823|NCT02974621|DRUG|Cediranib Maleate|Given PO
214730824|NCT02974621|DRUG|Olaparib|Given PO
214730825|NCT02549521|DIETARY_SUPPLEMENT|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
214730826|NCT02549521|DIETARY_SUPPLEMENT|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
214730827|NCT06103565|OTHER|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
214730828|NCT06576661|DEVICE|INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™.
214730829|NCT04852887|OTHER|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
214730830|NCT04852887|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
214730831|NCT05476380|DRUG|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
214730832|NCT01172990|PROCEDURE|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
214730833|NCT01172990|PROCEDURE|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
214730834|NCT06570603|BEHAVIORAL|Self-Efficacy|Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.
214730835|NCT06570603|BEHAVIORAL|Willingness|Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.
214730836|NCT06570603|BEHAVIORAL|Psychoeducation|Psychoeducation about the components and functions of emotion.
214730837|NCT01641224|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
214730838|NCT01641224|DEVICE|Atractylodes|Atractylodes (\~10-15g)
214730839|NCT01641224|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
214730840|NCT01641224|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
214730841|NCT01641224|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
214730842|NCT01641224|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
214730843|NCT01641224|DRUG|Radix curcumae|Radix curcumae (\~10g)
214730844|NCT01641224|DRUG|Fingered citron|Fingered citron (\~10g)
214730845|NCT01641224|DRUG|Tuckahoe|Tuckahoe (15g)
214730846|NCT01641224|DRUG|Placebo|Placebo is blindly given to patients.
214730847|NCT04432324|BIOLOGICAL|Intravenous Immune Globulin|IVIG Intravenous infusion
214730848|NCT04432324|DRUG|Standard Medical Treatment|SMT
214730849|NCT01805674|DIETARY_SUPPLEMENT|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
214730850|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
214730851|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
214730852|NCT04097080|DRUG|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
214730853|NCT04097080|DRUG|Standard of Care|Placebo group will receive reconstituted air given three times a week.
214730854|NCT02972281|BIOLOGICAL|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
214730855|NCT04955301|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
214730856|NCT03037112|BEHAVIORAL|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
214730857|NCT03037112|BEHAVIORAL|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
214730858|NCT05126550|BIOLOGICAL|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
214730859|NCT01856855|RADIATION|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
214730860|NCT05103995|OTHER|no intervention|no intervention, just observation
214730861|NCT00557323|DRUG|Lanthanum carbonate|
214730862|NCT03003130|DEVICE|Restylane Defyne|Intradermal injection
214730863|NCT03003130|DEVICE|Restylane|Intradermal injection
214730864|NCT02415504|BEHAVIORAL|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
214730865|NCT02415504|BEHAVIORAL|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
214730866|NCT05724147|BEHAVIORAL|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
214730867|NCT01863901|DEVICE|Treatment with Cryo-Touch III device|
214730868|NCT04783376|DRUG|: Insulin, lispro and regular insulin|"* A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
214730869|NCT05324956|OTHER|No intervention|Individuals will not receive any interventions
214730870|NCT02876484|DRUG|Colesevelam|
214730871|NCT02876484|DRUG|Chenodeoxycholic Acid|
214730872|NCT02876484|OTHER|Water|
214730873|NCT04099836|DRUG|Atezolizumab|1200 mg IV every 3 weeks
214730874|NCT04099836|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks
214730875|NCT02455440|DRUG|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
214730876|NCT02455440|DRUG|Placebo|
214730877|NCT02455440|DRUG|Propofol and sevoflurane|
214730878|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
214730879|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
214730880|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
214730881|NCT01196091|DRUG|Standard of Care|
214644602|NCT06197061|PROCEDURE|LAMS|The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line. After the laparoscopy was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the laparoscopic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
214644603|NCT05196945|DRUG|vonoprazan fumarate + amoxicillin|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
214644604|NCT05196945|DRUG|Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate|Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
214644605|NCT02452372|DRUG|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
214644606|NCT02452372|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
214644607|NCT01815229|PROCEDURE|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
214644608|NCT02672085|PROCEDURE|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
214644609|NCT02672085|PROCEDURE|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
214644610|NCT06202573|PROCEDURE|rhinoplasty|patients who have a step counter and we do not motivate them to walk
214644611|NCT02794220|DEVICE|CN electronic cigarette 10 mg|Inhalation
214644612|NCT02794220|DEVICE|CN electronic cigarette 15 mg|Inhalation
214644613|NCT02794220|DEVICE|Nicorette Inhalator 15 mg|Inhalation
214644614|NCT02794220|OTHER|Cigarette|Inhalation
214644615|NCT05162066|DRUG|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
214644616|NCT01072344|DRUG|Chamomile (Matricaria recutita)|500 mg 3 times daily
214644617|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
214644618|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
214644619|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
214644620|NCT04147468|OTHER|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
214730882|NCT00593775|PROCEDURE|assisted hatching|assisted hatching with laser
214644621|NCT04147468|OTHER|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
214730883|NCT03797144|DEVICE|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
214730884|NCT00004194|DRUG|fludarabine phosphate|
214730885|NCT05823428|PROCEDURE|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
214730886|NCT05823428|PROCEDURE|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
214730887|NCT02573506|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
214730888|NCT02573506|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
214730889|NCT00827125|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
214730890|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
214730891|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
214730892|NCT00345956|BIOLOGICAL|Human rotavirus liquid vaccine|
214730893|NCT00955344|BEHAVIORAL|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
214730894|NCT00955344|BEHAVIORAL|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
214730895|NCT04502199|OTHER|non interventional study|observational study
214730896|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
214730897|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
214730898|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
214730900|NCT04688827|OTHER|Exercise therapy|15 weeks of resistance training (additional to endurance training)
214730901|NCT00298311|BEHAVIORAL|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
214730902|NCT03077711|DRUG|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
214730903|NCT03077711|DRUG|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
214730904|NCT01110928|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
214730905|NCT03052634|DRUG|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
214730906|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
214730907|NCT03052634|DRUG|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
214730908|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
214730909|NCT04249791|PROCEDURE|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
214730910|NCT00376675|DRUG|methylphenidate hydrochloride|Given orally
214730911|NCT00376675|OTHER|placebo|Given orally
214730912|NCT03570190|OTHER|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect"
214730913|NCT00995215|PROCEDURE|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
214730914|NCT00995215|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
214730915|NCT03317912|DRUG|Lidocaïne 2%|Continuous infusion during per and postoperative periods
214730916|NCT03317912|DRUG|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
214730917|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
214730918|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
214730919|NCT04787263|BIOLOGICAL|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR\_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
214730920|NCT05480631|PROCEDURE|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
214730921|NCT05480631|PROCEDURE|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
214730922|NCT05480631|PROCEDURE|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
214730923|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
214730924|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
214730925|NCT04771104|DIETARY_SUPPLEMENT|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
214730926|NCT02943668|DRUG|Deferasirox|Given PO
214730927|NCT02943668|OTHER|Laboratory Biomarker Analysis|Correlative studies
214730928|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
214730929|NCT01487694|DRUG|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
214730930|NCT01487694|DRUG|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
214730931|NCT05822960|DEVICE|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
214730932|NCT02201251|DRUG|Topiramate|Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
214730933|NCT02201251|DRUG|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
214730934|NCT03595189|DRUG|Cilastatin|Dose escalation 3-hour single intravenous administration
214730935|NCT03595189|DRUG|Placebo|3-hour single intravenous administration
214730936|NCT01332851|BEHAVIORAL|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
214730937|NCT01332851|BEHAVIORAL|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
214730938|NCT04205474|DIAGNOSTIC_TEST|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
214730939|NCT07005986|DIAGNOSTIC_TEST|Plasmatic PPi level|Plasmatic PPi level dosage at visit 1
214730940|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
214730941|NCT03865849|DEVICE|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
214730942|NCT03865849|DEVICE|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
214730943|NCT05292573|DRUG|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
214730944|NCT06623409|BIOLOGICAL|GARDASIL®9 (G9)|Suspension administered via intramuscular (IM) injection
214730945|NCT06623409|BIOLOGICAL|V540B|Experimental vaccine and adjuvant administered via IM injection
214730946|NCT06625905|DIAGNOSTIC_TEST|Ultrasound imaging|Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).
214730947|NCT02521740|OTHER|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
214730948|NCT06685679|DRUG|Melatonin|oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
214730949|NCT06685679|OTHER|Placebo|Equivalent amount of distilled water will be given every hours as combined therapy to milrinone
214730950|NCT06095544|PROCEDURE|Enhanced recovery for SPK recipients|Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
214730951|NCT00552994|DEVICE|Cypher Select plus|Drug eluting stent
214730952|NCT00552994|DEVICE|Xience V stent|Drug eluting stent
214730953|NCT01937624|DEVICE|Diagnostic Ultrasound|
214730954|NCT01937624|RADIATION|X-ray imaging|
214730955|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
214730956|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
214730957|NCT03585465|DRUG|Vinblastine|"* Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
214730958|NCT03585465|DRUG|Cyclophosphamide|"* Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
214730959|NCT03585465|DRUG|Capecitabine|"* Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
214730960|NCT03585465|DRUG|Nivolumab|"* Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle"
214730961|NCT03885674|OTHER|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
214730962|NCT03885674|OTHER|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
214730963|NCT00546936|DRUG|ranibizumab|0.5mg ranibizumab
214730964|NCT00546936|DRUG|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
214730965|NCT03051269|DRUG|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
214730966|NCT03051269|DEVICE|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
214730967|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
214730968|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
214730969|NCT00788918|DRUG|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
214730970|NCT06081699|DRUG|TNP-2198|Oral
214730971|NCT06081699|DRUG|TNP-2198 Placebo|The placebo for TNP-2198 active drug
214730972|NCT01947894|OTHER|Non Interventional Study|Non Interventional Study
214730973|NCT01817660|PROCEDURE|Open repair of popliteal artery|
214730974|NCT01817660|PROCEDURE|Endovascular repair of popliteal artery|
214730975|NCT01231126|DRUG|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
214730976|NCT04666025|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
214730977|NCT04666025|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214730978|NCT04666025|OTHER|Electronic Health Record Review|Medical charts are reviewed
214730979|NCT04666025|OTHER|Questionnaire Administration|Complete questionnaire
214730980|NCT00005806|DRUG|carboplatin|
214730981|NCT00005806|DRUG|gefitinib|
214730982|NCT00005806|DRUG|paclitaxel|
214730983|NCT03672357|PROCEDURE|Laparoscopic liver resection|Laparoscopic hepatectomy
214730984|NCT03672357|PROCEDURE|Open liver resection|Traditional open hepatectomy
214730985|NCT00987610|DEVICE|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
214730986|NCT07018635|DRUG|INCB161734|Oral; Tablet
214730987|NCT07018635|DRUG|Itraconazole|Oral; Tablet
214730988|NCT07018635|DRUG|Rifampin|Oral; Tablet
214730989|NCT07018635|DRUG|Esomeprazole|Oral; Tablet
214730990|NCT07018635|DRUG|Famotidine|Oral; Tablet
214730991|NCT04084405|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
214730992|NCT00035477|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
214730993|NCT00035477|DRUG|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
214730994|NCT04134299|DIETARY_SUPPLEMENT|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
214730995|NCT01779804|PROCEDURE|OFAR|OFAR
214730996|NCT00333970|BEHAVIORAL|cognitive remediation|individual cognitive training
214730997|NCT03260283|DRUG|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
214730998|NCT03260283|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
214730999|NCT03260283|DRUG|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
214731000|NCT05337345|DRUG|Cendakimab|Specified Dose on Specified Days
214731001|NCT05076994|OTHER|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
214731002|NCT05076994|OTHER|Standard Care|An exercise prescription and verbal instructions in clinic
214731003|NCT00901862|DEVICE|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
214731004|NCT00901862|DEVICE|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
214731005|NCT02380482|OTHER|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
214731006|NCT02380482|OTHER|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
214731007|NCT02005510|BEHAVIORAL|Mailed in-home high-risk HPV testing kit|
214731008|NCT02005510|OTHER|Usual care|
214731009|NCT01300949|DIAGNOSTIC_TEST|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
214731010|NCT01300949|DIAGNOSTIC_TEST|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
214731011|NCT02049788|BEHAVIORAL|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
214731012|NCT02049788|BEHAVIORAL|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
214731013|NCT00776334|DRUG|Fosinopril 40mg Tablets|
214731014|NCT00087386|DRUG|tanespimycin|Given IV
214731015|NCT00087386|OTHER|laboratory biomarker analysis|Correlative studies
214731016|NCT01678560|DEVICE|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
214731017|NCT01678560|DEVICE|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
214731018|NCT03437629|PROCEDURE|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
214731019|NCT03437629|PROCEDURE|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
214731020|NCT00925067|PROCEDURE|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
214731021|NCT00925067|DEVICE|lightweight TiMesh|
214731022|NCT00925067|DEVICE|lightweight VyproII|
214731023|NCT00925067|DEVICE|Heavyweight Marlex|
214731024|NCT04180917|OTHER|Survey|survey
214731025|NCT04904341|DRUG|Cerebrolysin|neuroprotection treatment
214731026|NCT03675919|DEVICE|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
214731027|NCT03675919|DEVICE|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
214731028|NCT03675919|DEVICE|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
214731029|NCT03675919|OTHER|Access to the online portal|self-monitoring of health parameters
214731030|NCT03675919|OTHER|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
214731031|NCT02685618|DRUG|Iloprost|
214731032|NCT02685618|DRUG|Saline|
214731033|NCT02685618|DEVICE|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
214731034|NCT02685618|DEVICE|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
214731035|NCT05540210|DEVICE|measurement of PSP|one or two blood samples
214731036|NCT03189810|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
214731037|NCT03189810|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
214731038|NCT03189810|BEHAVIORAL|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
214731039|NCT01835314|DRUG|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
214731040|NCT01429155|GENETIC|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
214731041|NCT05840523|OTHER|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
214731042|NCT05840523|OTHER|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
214731043|NCT02545452|DRUG|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
214731044|NCT02545452|DRUG|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
214731045|NCT02545452|DRUG|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
214731046|NCT02545452|DRUG|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
214731047|NCT02545452|OTHER|Tampon|
214731048|NCT03122652|DRUG|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
214731049|NCT03122652|DRUG|Placebo Oral Tablet|1 tablet once a day
214731050|NCT03108300|DRUG|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
214731051|NCT03108300|DRUG|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
214731052|NCT00533351|DRUG|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
214731053|NCT00533351|DRUG|placebo|placebo 50 mg capsules three-times daily for 2 weeks
214731054|NCT01126294|DIETARY_SUPPLEMENT|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
214731055|NCT01126294|DIETARY_SUPPLEMENT|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
214731056|NCT01126294|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
214731057|NCT00628342|DRUG|Esomeprazole|20mg Oral tablet once daily
214731058|NCT00628342|DRUG|Esomeprazole|40mg Oral tablet once daily
214731059|NCT00628342|DRUG|Placebo|Oral once daily
214731060|NCT04509557|DRUG|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
214731061|NCT06427148|OTHER|"The biofeedback-assisted VR game Golden Breath"|"The biofeedback-assisted VR game Golden Breath that we presented in this study was designed to meet children's healthcare needs quickly and efficiently while reducing pain and fear during medical procedures in the pediatric population. Golden Breath u"
214731062|NCT03362489|PROCEDURE|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
214731063|NCT03362489|PROCEDURE|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
214731064|NCT04298749|DRUG|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
214731065|NCT04298749|DRUG|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
214731066|NCT04298749|DRUG|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
214731067|NCT02823236|DRUG|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
214731068|NCT02823236|DRUG|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
214731069|NCT02823236|DRUG|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
214731070|NCT01963936|DEVICE|Supreme LMA|
214731071|NCT01963936|DEVICE|Facial mask|
214731072|NCT05798819|DRUG|GLS-010|IV infusion
214731073|NCT05798819|DRUG|Placebo|IV infusion
214731074|NCT05798819|DRUG|paclitaxel|IV infusion
214731075|NCT05798819|DRUG|cisplatin|IV infusion
214731076|NCT05798819|DRUG|carboplatin|IV infusion
214731077|NCT05798819|DRUG|bevacizumab|IV infusion
214731078|NCT06455384|BEHAVIORAL|Genetics Navigator|The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
214731079|NCT06455384|BEHAVIORAL|Standard Care with Genetics Professionals|Standard care for the delivery of genetic services, including receiving genetic counselling and test results
214731080|NCT03382327|PROCEDURE|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
214731081|NCT00691977|RADIATION|Radiation Therapy followed by prostatectomy|Radiation Therapy
214731082|NCT02773472|DEVICE|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
214731083|NCT02773472|DRUG|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
214731084|NCT05688540|OTHER|e book|e book
214731085|NCT05688540|OTHER|traditional education booklet|traditional education booklet
214731086|NCT02826655|DEVICE|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
214731087|NCT00056550|BIOLOGICAL|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
214731088|NCT02636738|DEVICE|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
214731089|NCT03243955|DEVICE|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
214731090|NCT03243955|DEVICE|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
214731091|NCT01715090|DEVICE|Web-based insulin titration|
214731092|NCT05977803|RADIATION|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~* The CEST sequence~* The ASL infusion sequence~* The IVIM sequence"
214731093|NCT01555736|DRUG|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
214731094|NCT03650036|DRUG|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
214731095|NCT03650036|DRUG|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
214731096|NCT04781049|PROCEDURE|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
214731097|NCT04781049|PROCEDURE|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
214731098|NCT01609738|DEVICE|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
214731099|NCT00767299|DRUG|arzoxifene|20 mg, QD, PO,24 weeks
214731100|NCT00767299|DRUG|Placebo|QD, PO, 24 weeks
214731101|NCT05628987|OTHER|no intervention|Observational studies, no intervention
214731102|NCT00322387|DRUG|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
214731103|NCT02518542|PROCEDURE|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
214731104|NCT02518542|PROCEDURE|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
214731105|NCT02518542|PROCEDURE|Endoscopic intervention C|Endoscopic balloon dilatation
214731106|NCT02518542|PROCEDURE|Laparoscopic Surgery|Laparoscopic Heller myotomy
214731107|NCT03229304|OTHER||
214731108|NCT01086449|BIOLOGICAL|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
214731109|NCT01151176|DRUG|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
214731110|NCT01151176|DRUG|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U"
214731111|NCT05021380|OTHER|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
214731112|NCT05433974|BIOLOGICAL|Blood sample collection|Blood sample collection : 2 X 6 mL
214731113|NCT05832060|DEVICE|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
214731114|NCT05832060|DEVICE|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
214731115|NCT05832060|DEVICE|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
214731116|NCT02092168|DRUG|BIA 9-1067|
214731117|NCT04110444|DRUG|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
214731118|NCT05620173|DEVICE|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
214731119|NCT05620173|DEVICE|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
214731120|NCT01828567|BEHAVIORAL|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
214731121|NCT05125991|PROCEDURE|Prepectoral reconstruction|Prepectoral breast reconstruction
214731122|NCT05125991|PROCEDURE|Submuscolar reconstruction|Submuscolar breast reconstruction
214731123|NCT02803814|PROCEDURE|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
214731124|NCT02803814|PROCEDURE|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
214731125|NCT00195624|BIOLOGICAL|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
214731126|NCT00195624|DRUG|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
214731127|NCT00345514|BEHAVIORAL|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
214731128|NCT00345514|BEHAVIORAL|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
214731129|NCT00723853|BEHAVIORAL|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
214731130|NCT00723853|BEHAVIORAL|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
214731131|NCT01353183|PROCEDURE|colonoscopy or rectosigmoidoscopy|Usual procedure
214731132|NCT02195947|DRUG|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
214731133|NCT01210976|DRUG|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
214731134|NCT01210976|DRUG|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
214731135|NCT02746445|OTHER|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
214731136|NCT01427660|BEHAVIORAL|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
214731137|NCT01427660|BEHAVIORAL|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
214731138|NCT00920946|DRUG|Dimebon|20 mg Dimebon orally TID
214731139|NCT00920946|OTHER|Placebo|Orally TID
214731140|NCT00707486|DEVICE|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
214731141|NCT00707486|DEVICE|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
214731142|NCT02048657|DEVICE|Foley Airway Stylet Tool|
214731143|NCT02048657|DEVICE|introducer-tool|
214731144|NCT00944957|DRUG|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
214731145|NCT00944957|DRUG|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
214731146|NCT00944957|DRUG|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
214731147|NCT00944957|DRUG|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
214731148|NCT00034892|DRUG|Olanzapine, risperidone|
214731149|NCT02482792|OTHER|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
214731150|NCT02482792|OTHER|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
214731151|NCT00090766|DRUG|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
214731152|NCT04552626|BEHAVIORAL|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
214731153|NCT04552626|BEHAVIORAL|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
214731154|NCT04552626|BEHAVIORAL|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
214731155|NCT06152692|DEVICE|SHAM Continuous positive airway pressure|Placebo treatment
214731156|NCT06152692|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
214731157|NCT00831857|OTHER|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
214731158|NCT02278380|OTHER|Low GI Standard Breakfast|Low GI Standard Breakfast
214731159|NCT02278380|OTHER|Medium GI Standard Breakfast|Medium GI Standard Breakfast
214731160|NCT02278380|OTHER|Enfamama A+|Nutritional pregnant milk supplement
214731161|NCT02278380|OTHER|Glucerna Triple Care|Nutritional product for diabetics
214731162|NCT02278380|OTHER|Dumex Precima|Pregnant and lactation women milk powder
214731163|NCT02278380|OTHER|Diasip|Nutritional drinks for diabetics
214731164|NCT02278380|OTHER|Test product|Test product not patented yet
214731165|NCT00396422|DRUG|RWJ-445380|
214731166|NCT00804986|DRUG|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
214731167|NCT00804986|DRUG|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
214731168|NCT00654368|BIOLOGICAL|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
214731169|NCT00654368|DRUG|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
214731170|NCT00014586|DRUG|bicalutamide|
214731171|NCT00014586|DRUG|goserelin acetate|
214731172|NCT00014586|PROCEDURE|orchiectomy|
214731173|NCT02797769|DRUG|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
214731174|NCT02797769|DRUG|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
214731175|NCT04403620|RADIATION|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
214731176|NCT02708004|DRUG|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
214731177|NCT02708004|OTHER|Placebo|Matching active drug
214731178|NCT03296072|DRUG|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
214731179|NCT03296072|DRUG|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
214731180|NCT03296072|DRUG|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
214731181|NCT03327363|DEVICE|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
214731182|NCT01204424|DEVICE|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
214731183|NCT01204424|DEVICE|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
214731184|NCT02927184|DRUG|VK2809|
214731185|NCT02927184|DRUG|Placebo|
214731186|NCT05177224|OTHER|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
214731187|NCT01816386|OTHER|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
214731188|NCT01816386|OTHER|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
214731189|NCT04259034|OTHER|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
214731190|NCT04259034|OTHER|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
214731191|NCT02584023|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
214731192|NCT06082349|PROCEDURE|Lymphaticovenous anastomosis|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
214731193|NCT06082349|PROCEDURE|Sham surgery|Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.
214731194|NCT05609136|OTHER|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
214731195|NCT00959699|DRUG|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
214731196|NCT00959699|DRUG|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
214731197|NCT00959699|DRUG|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
214731198|NCT00959699|DRUG|Boceprevir|Boceprevir (800 mg, orally, three times per day)
214731199|NCT05891470|DEVICE|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
214731200|NCT05891470|DEVICE|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
214731201|NCT04583345|BEHAVIORAL|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
214731202|NCT01061645|DRUG|MOC31-PE|Immunotoxines
214731203|NCT05925400|DEVICE|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
214731204|NCT00606294|RADIATION|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
214731205|NCT00606294|DEVICE|18F-FMISO PET scan|
214731206|NCT00606294|DEVICE|MRI|
214731207|NCT00606294|DEVICE|FDG PET/CT scan|
214731208|NCT02421146|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
214731209|NCT02421146|DEVICE|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
214731210|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)"
214731211|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)"
214731212|NCT00871676|BEHAVIORAL|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
214731213|NCT00871676|BEHAVIORAL|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
214731214|NCT03924427|DRUG|BMS-986165|Oral tablet administration
214731215|NCT04922710|BEHAVIORAL|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
214731216|NCT02565862|DRUG|Daclatasvir|
214731217|NCT02565862|DRUG|Metformin|
214731218|NCT01063946|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
214731219|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
214731220|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
214731221|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
214731222|NCT00003991|BIOLOGICAL|aldesleukin|
214731223|NCT00003991|DRUG|histamine dihydrochloride|
214731224|NCT01651234|DRUG|GCC-4401|"* Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C"
214731225|NCT01651234|DRUG|GCC-4401C|"* Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo"
214731226|NCT00069017|BIOLOGICAL|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
214731227|NCT00069017|OTHER|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
214731228|NCT03797157|DIETARY_SUPPLEMENT|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
214731229|NCT03797157|DIETARY_SUPPLEMENT|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
214731230|NCT02832817|DEVICE|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
214731231|NCT04308408|BEHAVIORAL|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
214731232|NCT04308408|BEHAVIORAL|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
214731233|NCT04308408|BEHAVIORAL|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
214731234|NCT04308408|BEHAVIORAL|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
214731235|NCT06016335|DIAGNOSTIC_TEST|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
214731236|NCT06016335|DIAGNOSTIC_TEST|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
214731237|NCT06016335|OTHER|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
214731238|NCT04985513|PROCEDURE|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
214731239|NCT05990166|OTHER|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
214731240|NCT05990166|OTHER|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
214731241|NCT00700349|OTHER|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
214731242|NCT01902836|BIOLOGICAL|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
214731243|NCT01902836|BIOLOGICAL|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
214731244|NCT02858713|DRUG|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
214731245|NCT02858713|DEVICE|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
214731246|NCT06003452|PROCEDURE|surface treatment with Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
214731247|NCT00998036|DRUG|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
214731248|NCT00998036|DRUG|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
214731249|NCT00998036|DRUG|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
214731250|NCT00510770|DEVICE|CPAP application|
214731251|NCT00126425|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single dose
214731252|NCT01891604|DIETARY_SUPPLEMENT|breast milk with Bifidobacterium Longum subp. Infantis R0033|
214731253|NCT01891604|DIETARY_SUPPLEMENT|breast milk|
214731254|NCT02774291|BIOLOGICAL|Aldesleukin|Given IV
214731255|NCT02774291|BIOLOGICAL|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
214731256|NCT02774291|DRUG|Cyclophosphamide|Given IV
214731257|NCT02774291|BIOLOGICAL|Filgrastim|Given SC
214731258|NCT02774291|DRUG|Fludarabine Phosphate|Given IVPB
214731259|NCT02774291|OTHER|Laboratory Biomarker Analysis|Correlative studies
214731260|NCT05375825|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
214731261|NCT05375825|DRUG|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
214731262|NCT05375825|DIAGNOSTIC_TEST|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
214731263|NCT01833390|DRUG|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
215030540|NCT05706740|OTHER|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
214731264|NCT03834480|OTHER|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
214731265|NCT00565240|DRUG|Marvelon|oral contraceptive
214731266|NCT00565240|DRUG|Nuvaring|contraceptive vaginal ring
214731267|NCT00565240|DRUG|Letrozole|Aromatase Inhibitors
214731268|NCT02756546|DRUG|Cyclophosphamide|
214731269|NCT02756546|DRUG|Hydroxychloroquine|
214731270|NCT02756546|DRUG|Hydrocortisone|
214731271|NCT00000767|BIOLOGICAL|TBC-3B Vaccine|
214731272|NCT00000767|BIOLOGICAL|Smallpox Vaccine|
214731273|NCT05295940|DRUG|LY3841136|Administered SC.
214731274|NCT05295940|DRUG|Placebo|Administered SC.
214731275|NCT05180604|BEHAVIORAL|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
214731276|NCT00149890|DRUG|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
214731277|NCT00149890|DRUG|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
214731278|NCT00149890|DRUG|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
214731279|NCT04929847|OTHER|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
214731280|NCT00236405|DRUG|epoetin alfa|
214731281|NCT04117594|DIAGNOSTIC_TEST|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
214731282|NCT02332876|BEHAVIORAL|Exercise|
214731283|NCT02332876|BEHAVIORAL|Control|
214731284|NCT01895634|DEVICE|Rev-01|Treatment arm patients have used Rev-01 at least once
214731285|NCT00493714|BEHAVIORAL|Questionnaire|Surveys lasting 30 minutes or more.
214731286|NCT00962481|DRUG|Bimosiamose|
214731287|NCT00962481|DRUG|Placebo|
214731288|NCT02415595|DRUG|BMS-955176|HIV Maturation Inhibitor
214731289|NCT02415595|DRUG|EFV|EFV
214731290|NCT02415595|DRUG|TDF/FTC|TDF/FTC
214731291|NCT02382614|DEVICE|Spiration Valve System|
214731292|NCT02614261|DRUG|Galcanezumab|Administered SC
214731293|NCT02614261|DRUG|Placebo|Administered SC
214731294|NCT00938093|BEHAVIORAL|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
215030541|NCT00684580|OTHER|Data Collection|Continuing review of outcomes and late toxicities
214731295|NCT00938093|BEHAVIORAL|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
214731296|NCT00471315|DRUG|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
214731297|NCT01462591|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
214731298|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
214731299|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
214731300|NCT00926263|BIOLOGICAL|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
214731301|NCT05793372|OTHER|Retrospective study of clinical features|Retrospective study of clinical features
214731302|NCT00125892|DRUG|duloxetine|
214731303|NCT02835235|DRUG|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
214731304|NCT02835235|DRUG|placebo|Administered daily subcutaneously (s.c., under the skin)
214731305|NCT05570136|BEHAVIORAL|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
214731306|NCT05570136|BEHAVIORAL|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
214731307|NCT03026205|DRUG|ARMS-I|
214731308|NCT06249880|OTHER|Observation|This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
214731309|NCT04856215|DRUG|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
214731310|NCT00372294|DRUG|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
214731311|NCT00372294|DRUG|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
214731312|NCT01803529|OTHER|heat-pack with massage|
214731313|NCT01803529|OTHER|heat-pack only|
214731314|NCT06335160|DRUG|Mebendazole|mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
214731315|NCT00005629|BIOLOGICAL|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
214731316|NCT01614522|DRUG|ASLAN001|ASLAN001 500mg BID
214731317|NCT04394013|BEHAVIORAL|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
214731318|NCT04394013|BEHAVIORAL|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
214731319|NCT06067295|OTHER|Non-Interventional Study|Non-interventional study
214731320|NCT06486805|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
214731321|NCT06486805|OTHER|normal saline|the same volume of normal saline
214731322|NCT03695471|BIOLOGICAL|Pembrolizumab|Given IV
214731323|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
214731324|NCT02859558|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
214731325|NCT05176223|PROCEDURE|Computed Tomography|Undergo 68Ga PSMA PET/CT
214731326|NCT05176223|DRUG|Gallium Ga 68 Gozetotide|Undergo 68Ga PSMA PET/CT
214731327|NCT05176223|PROCEDURE|Positron Emission Tomography|Undergo 68Ga PSMA PET/CT
214731328|NCT05665595|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
214731329|NCT05665595|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
214731330|NCT02342964|OTHER|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
214731331|NCT04645602|DRUG|Lenvatinib|Pill taken by mouth, once daily.
214731332|NCT04645602|DRUG|Pembrolizumab|Intravenous injection through a vein (IV).
214731333|NCT06423352|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
214731334|NCT06423352|DRUG|Placebo|Placebo administered by SC injection
214731336|NCT05651282|DRUG|Provera|Progesterone Challenge Test
214731337|NCT05485961|DRUG|CSL300|IV administration
214731338|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
214731339|NCT05485961|DRUG|Placebo|Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
214731340|NCT04962087|BEHAVIORAL|Experimental: Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioral treatments for insomnia (2,5,6) and adapted to fit an automated interactive platform available via an internet enabled device. Previous research has found that CBT for insomnia can be delivered via a web-based platform (15,16). The program is divided into a series of treatment modules or levels that will be delivered over the course of 8 weeks. The content of these 8 levels includes the following components, a sleep diary, Introduction to Health EnSuite Insomnia, Sleep restriction clock, Medications, Herbal Remedies \& Sleep, Chronobiology \& Sleep Timing, Sleep hygiene, Relaxation techniques, Changing Negative Thoughts Related to Sleep, Light and Sleep.
214731341|NCT05339022|OTHER|Best Practice|Receive standard of care
214731342|NCT05339022|OTHER|Exercise Intervention|Undergo exercise intervention
214731343|NCT05339022|PROCEDURE|Physical Therapy|Undergo physical therapy
214731344|NCT05339022|OTHER|Quality-of-Life Assessment|Ancillary studies
214731345|NCT05339022|OTHER|Questionnaire Administration|Ancillary studies
214731346|NCT05339022|PROCEDURE|Relaxation Therapy|Undergo progressive muscles relaxation exercises
214731347|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
214731348|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
214731349|NCT05581810|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
214731350|NCT05581810|BEHAVIORAL|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
214731351|NCT05193825|DEVICE|Remote Programming|Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
214731352|NCT05193825|DEVICE|Standard Programming|Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
214731353|NCT00766142|BIOLOGICAL|cetuximab|
214731354|NCT00766142|DRUG|fluorouracil|
214731355|NCT00766142|DRUG|leucovorin calcium|
214731356|NCT00766142|DRUG|oxaliplatin|
214731357|NCT00766142|PROCEDURE|adjuvant therapy|
214731358|NCT00766142|PROCEDURE|therapeutic conventional surgery|
214731359|NCT06033365|BEHAVIORAL|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
214731360|NCT05756829|OTHER|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
214731361|NCT05365685|BEHAVIORAL|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
214731362|NCT04567732|COMBINATION_PRODUCT|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
214731363|NCT04567732|DRUG|Placebo|Single injection of Placebo
214731364|NCT06207162|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
214731365|NCT06617390|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
214731366|NCT06458998|BEHAVIORAL|Patient Navigation|Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.
214731367|NCT06458998|BEHAVIORAL|Implementation Facilitation|Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
214731368|NCT05744713|OTHER|Observational|Observational
214731369|NCT05755269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214731370|NCT05755269|PROCEDURE|Genotyping|Undergo genotyping
214731371|NCT05755269|OTHER|Survey Administration|Complete surveys
214731372|NCT05761899|COMBINATION_PRODUCT|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
214731373|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
214731374|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
214731375|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
214731376|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
214731377|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
214731378|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
214731379|NCT00142818|DRUG|Modafinil|400 mg daily
214731380|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
214731381|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
214731382|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
214731383|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
214731384|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
214731385|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
214731386|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
214731387|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
214731388|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
214731389|NCT03782467|BIOLOGICAL|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
214731390|NCT00311012|DRUG|Aliskiren|
214731391|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
214731392|NCT02940353|DEVICE|TREFOIL concept|
214731393|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
214731394|NCT02241356|DEVICE|single vision glasses|single vision glasses
214731395|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
214731396|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
214731397|NCT04978727|BIOLOGICAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
214731398|NCT06203002|DRUG|Placebo (blinded)|LX9211 matching placebo tablets
214731399|NCT06203002|DRUG|LX9211 (blinded)|LX9211 (blinded) tablets
214731400|NCT06963840|DIETARY_SUPPLEMENT|Theronomic Ova-All Care|Two capsules of Theronomic Ova-All Care, one a day, for 12 weeks. Ova-All Care is a tribiotic, a health product that includes prebiotics, probiotics, and postbiotics. Ova-All Care affects ovarian health by regulating the gut microbiome, which affects oestrogen production and other factors.
214731401|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
214731402|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
214731403|NCT01670487|DEVICE|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
214731404|NCT01670487|DEVICE|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
214731405|NCT04902833|PROCEDURE|Blood Draw|Blood specimen 2-4 teaspoons
214731406|NCT04675333|DRUG|evorpacept|IV Q3W
214731407|NCT04675333|DRUG|pembrolizumab|IV Q3W
214731408|NCT04675333|DRUG|Cisplatin/Carboplatin; 5FU|IV Q3W
214731409|NCT04275557|OTHER|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
214731410|NCT04275557|OTHER|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
214731411|NCT04275557|OTHER|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
214731412|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
214731413|NCT06384352|DRUG|YL211|Patients will be treated with YL211 intravenous (IV) infusion.
214731414|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
214731415|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
214731416|NCT02425813|DRUG|Budesonide|Given PO
214731417|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
214731418|NCT00003899|BIOLOGICAL|filgrastim|
214731419|NCT00003899|DRUG|cyclophosphamide|
214731420|NCT00003899|DRUG|melphalan|
214731421|NCT00003899|DRUG|paclitaxel|
214731422|NCT00003899|DRUG|thiotepa|
214731423|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
214731424|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
214731425|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
214731426|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
214731427|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
214731428|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
214731429|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
214731430|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
214731431|NCT06436300|BEHAVIORAL|Motivational text messaging|Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
214731432|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
214731433|NCT04362696|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
214793972|NCT01259427|BEHAVIORAL|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
214731434|NCT06740708|BEHAVIORAL|SCALE-NCD|"1. FCHV home visits every three months, including~   * For hypertension i. Blood pressure measurement with digital BP devices ii. Lifestyle counseling iii. Referral if uncontrolled BP (≥140/90 mmHg) for 3 months~  * For type 2 diabetes i. Fasting blood glucose measurement with glucometer ii. Lifestyle counseling focusing on diabetes management iii. Referral if uncontrolled diabetes (≥126mg/dl) for 3 months~  * For current smokers i. Smoking cessation counseling ii. Referral for nicotine replacement therapy if request by participants~2. Mobile phone messages, including~   * Lifestyle modification~  * Conveyed as voice or text messages, depending on participant preference"
214731435|NCT05769153|DRUG|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
214731436|NCT05769153|DRUG|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
214731437|NCT05769153|DRUG|AR-14034 SR implant|AR-14034 SR administered as an intravitreal implant
214731438|NCT05769153|DRUG|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
214731439|NCT05769153|DRUG|Sham procedure|Needleless syringe used to simulate an intravitreal injection
214731440|NCT02670213|DRUG|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
214731441|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
214731442|NCT06031584|DRUG|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
214731443|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
214731444|NCT00003309|BIOLOGICAL|filgrastim|
214731445|NCT00003309|DRUG|cisplatin|
214731446|NCT00003309|DRUG|cyclophosphamide|
214731447|NCT00003309|DRUG|etoposide|
214731448|NCT00003309|DRUG|vincristine sulfate|
214731449|NCT00003309|PROCEDURE|adjuvant therapy|
214731450|NCT00003309|RADIATION|radiation therapy|
214731451|NCT06150560|DRUG|Losartan|50mg administered orally once daily for 52 weeks.
214731452|NCT06150560|DRUG|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
214731453|NCT06150560|DRUG|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
214731456|NCT04681248|DRUG|DKN-01|Administered by IV infusion
214731457|NCT06496854|DRUG|Lorazepam 1 mg|1 mg oral lorazepam, a sedative used to relieve anxiety
214731458|NCT06496854|DRUG|Ibuprofen 800 mg|800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
214731459|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
214731460|NCT04481997|OTHER|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
214731461|NCT05673928|DRUG|Trastuzumab emtansine|Given by IV (vein)
214731462|NCT05673928|DRUG|Tucatinib|Given by PO
214731463|NCT03793010|DRUG|FX006|Single Intra-articular injection
214731464|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
214731465|NCT02804685|OTHER|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
214731466|NCT05247398|OTHER|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
214731467|NCT06042933|OTHER|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
214731468|NCT06042933|OTHER|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
214731469|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
214731470|NCT06481241|DRUG|Venetoclax|VEN
214731471|NCT05661916|DRUG|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
214731472|NCT05661916|DRUG|Placebo|Placebo will be administered by SC injection.
214731473|NCT00638768|OTHER|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
214731474|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
214731475|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
214731476|NCT03807765|DRUG|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
214731477|NCT03807765|RADIATION|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
214731478|NCT05087641|DEVICE|IAB System|Bronchoscopic implantation of one or multiple IABs
214731479|NCT02230072|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
214731480|NCT05405114|DRUG|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
214731481|NCT05405114|DRUG|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
214731482|NCT05405114|DRUG|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
214731483|NCT00867464|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214731484|NCT00867464|OTHER|Laboratory Biomarker Analysis|Correlative studies
214731485|NCT00867464|OTHER|Long-term Follow-up|Undergo extended follow-up
214731486|NCT00867464|OTHER|Questionnaire Administration|Ancillary studies
214731487|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
214731488|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
214731489|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
214731490|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
214731491|NCT05334316|DRUG|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm
214731492|NCT03692195|DEVICE|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
214731493|NCT03692195|OTHER|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
214731494|NCT05980611|DIAGNOSTIC_TEST|IL B,IL 3 in nasal swap and serum|Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
214731495|NCT06231654|DEVICE|Remote photoplethysmography for physiological parameters|"Patients participating in the study will be recruited from our emergency department.~The child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient. The whole device is connected to our standard device. Once the child is immobile and ready, the Caducy® application is launched. At the same time, our standard device is activated. After 30 seconds, we will collect the HR and FR values revealed by the Caducy® application via the non-contact plethysmography method. On the other hand, it will collect the HR and FR values revealed by our standard device (Mindray® scope)."
214731496|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
214731497|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
214731498|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
214731499|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
214731500|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
214731501|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
214731502|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
214731503|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
214731504|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
214731505|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
214731506|NCT06366503|PROCEDURE|Fractional Ablative CO2 Laser|A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
214731507|NCT06366503|OTHER|Facial Cleanser|Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
214731508|NCT06366503|OTHER|Facial Moisturizer|A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
214731509|NCT06366503|OTHER|Sunscreen|During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
214731510|NCT06366503|OTHER|Basic Ointment|The basic ointment was used only on the comparator side for three days (72 hours) post-procedure. This was a requirement of the comparator anhydrous formulation.
214731511|NCT05836324|DRUG|INCA33890|INCA33890 will be administered at protocol defined dose.
214731512|NCT05836324|DRUG|bevacizumab|Bevacizumab will be administered at protocol defined dose.
214731513|NCT05836324|DRUG|FOLFIRI|FOLFIRI will be administered at protocol defined dose.
214731514|NCT05836324|DRUG|FOLFOX|FOLFOX will be administered at protocol defined dose.
214731515|NCT05836324|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
214731516|NCT05874635|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
214731517|NCT06246552|BIOLOGICAL|JTM201|"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
214731518|NCT06246552|BIOLOGICAL|Placebo|"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
214731519|NCT05914311|DEVICE|Suture|secures SCS trial leads with a suture
214731520|NCT05914311|DEVICE|Dermabond|secures SCS trial leads with dermabond
214731521|NCT04934748|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
214731522|NCT04934748|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
214731523|NCT04934748|DRUG|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
214731524|NCT04934748|DRUG|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
214731525|NCT06483698|OTHER|Sublobar resection|Sublobar resection is a series of surgical approaches for lung cancer.
214731526|NCT06483698|OTHER|Lobectomy|Lobectomy is the surgical approach for lung cancer.
214731527|NCT06144229|DIAGNOSTIC_TEST|Self-Collection HPV testing kit from Abbott|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
214731528|NCT04488991|OTHER|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
214731529|NCT06442514|BEHAVIORAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
214731530|NCT06442514|OTHER|Treatment as Usual|Referral to the local smoking cessation VA clinic.
214731531|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
214731532|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
214731533|NCT05010564|GENETIC|Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy|"Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10\^6 cells/m2~DL1: 1×10\^7 cells/m2~DL2: 3×10\^7 cells/m2~DL3: 1×10\^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells."
214731534|NCT05965713|DEVICE|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline and at 12 weeks completion of IpsiHand use.
214731535|NCT05965713|OTHER|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized standard of care home exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks.
214731536|NCT05951439|DIETARY_SUPPLEMENT|CRE + HMB|3 g/day of CRE and 3 g/day of HMB
214731537|NCT05951439|DIETARY_SUPPLEMENT|Placebo|6 g/day of inulin
214731538|NCT03218137|DRUG|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
214731539|NCT05016037|BEHAVIORAL|Lexically based speech recast|"A child's spontaneous or elicited word production containing phonological errors is immediately followed with a clinician verbal model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as \[be\] would be the whole lexeme bake \[bek\] rather than production drill on \[k\] in isolation."
214731540|NCT04685486|OTHER|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
214731541|NCT03580785|GENETIC|genetic analysis|saliva is collected for DNA extraction
214731542|NCT03580785|RADIATION|panoramic radiography|panoramic radiography
214731543|NCT03580785|RADIATION|teleradiography|teleradiography
214731544|NCT03580785|RADIATION|intraoral X-rays|intraoral X-rays
214731545|NCT03580785|RADIATION|CT scan of maxillary and mandible|CT scan of maxillary and mandible
214731546|NCT06253065|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model (developed)|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
214731547|NCT03936335|DRUG|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
214731548|NCT06976554|PROCEDURE|weaning|gradual weaning from the mechanical ventilator
214731549|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
214731550|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
214731551|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
214731552|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
214731553|NCT02219516|DRUG|RDEA3170|
214731554|NCT04685356|OTHER|IBAIP : Infant Behaviour Assessment and Intervention Program|The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
214731555|NCT04685356|OTHER|Standard Support|One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
214731556|NCT04685356|OTHER|Ages and Stages Questionnaire (ASQ)|Global development screening tool
214731557|NCT04685356|OTHER|Parenting Stress Index (PSI)|Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
214731558|NCT04685356|OTHER|Bayley Scales of Infant and Toddler Development (BSID-IV)|This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
214731559|NCT03786354|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
214731560|NCT03786354|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214731561|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214731562|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214731563|NCT06198829|OTHER|Physical examination tests and surveys|Patients'hip joint range of motion range of motion, pain levels, pressure-pain threshold levels, kinesiophobia levels, and hip dysfunction levels will be measured, and the alpha angle will be evaluated on hip radiographs.
214731564|NCT04774419|RADIATION|Intensity modulated radiation therapy (IMRT)|To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
214731565|NCT04774419|DRUG|Dostarlimab|IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
214731566|NCT04774419|RADIATION|Hypofractionated IMRT|Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
214731567|NCT03554174|DRUG|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
214731568|NCT03554174|DRUG|Placebo|microcrystalline cellulose capsule
214731569|NCT03554174|DRUG|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
214731570|NCT06618911|OTHER|5 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 5 Hz"
214731571|NCT06618911|OTHER|Sham electroacupuncture|Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce \&#34;deqi.\&#34; A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm serves as a placebo control to evaluate the true effect of electroacupuncture.
214793973|NCT01259427|BEHAVIORAL|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
214731572|NCT06618911|OTHER|100 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 100 Hz"
214731573|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
214731574|NCT03413228|OTHER|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
214731575|NCT00236574|DRUG|Galantamine hydrobromide|
214731576|NCT00129376|DRUG|Doxorubicin|
214731577|NCT00129376|DRUG|Cyclophosphamide|
214731578|NCT00129376|DRUG|Docetaxel|
214731579|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
214731580|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
214731581|NCT00000515|BEHAVIORAL|diet, reducing|
214731582|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
214731583|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
214731584|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
214731585|NCT06975293|COMBINATION_PRODUCT|STC-15 in combination with toripalimab|STC-15 in combination with toripalimab in 21-day cycles
214731586|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
214731587|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
214731588|NCT05174169|DEVICE|Signatera test|Central ctDNA testing for all patients
214731589|NCT05174169|DRUG|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
214731590|NCT05174169|DRUG|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
214731591|NCT05174169|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
214731592|NCT05174169|DRUG|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
214731593|NCT05174169|DRUG|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
214731594|NCT03218826|DRUG|Docetaxel|Given IV
214731595|NCT03218826|OTHER|Laboratory Biomarker Analysis|Correlative studies
214731596|NCT03218826|OTHER|Pharmacological Study|Correlative studies
214731597|NCT03218826|DRUG|PI3Kbeta Inhibitor AZD8186|Given PO
214731598|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
214731599|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
214793974|NCT01628120|BIOLOGICAL|Epoetin Hospira|Subcutaneous(SC) injection
214731600|NCT04996277|PROCEDURE|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
214731601|NCT04996277|PROCEDURE|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
214731602|NCT04996277|PROCEDURE|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
214731603|NCT04996277|BEHAVIORAL|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
214731604|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
214731605|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
214731606|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
214731607|NCT01426009|DRUG|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
214731608|NCT01426009|DRUG|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
214731609|NCT01426009|DRUG|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
214731610|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
214731611|NCT06312046|OTHER|HiBalance-MS|See arm description for intervention group.
214731612|NCT01478178|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
214731613|NCT02283333|BEHAVIORAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
214731614|NCT02283333|BEHAVIORAL|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
214731615|NCT02049294|BIOLOGICAL|Omalizumab (Xolair)|
214731616|NCT02049294|DRUG|Placebo|
214731617|NCT05422222|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
214731618|NCT04462978|OTHER|Non IgE-mediated food allergy|
214731619|NCT02192619|OTHER|observational|
214731620|NCT04063540|DRUG|Amiloride|Treatment by Amiloride vs placebo in crossover
214731621|NCT04063540|DRUG|Placebos|Treatment by Amiloride vs placebo in crossover
214731622|NCT03438760|BEHAVIORAL|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
214731623|NCT03438760|BEHAVIORAL|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
214731624|NCT03438760|BEHAVIORAL|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
214731625|NCT01938560|OTHER|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
214731626|NCT04164849|DRUG|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
214731627|NCT04164849|PROCEDURE|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
214731628|NCT04164849|PROCEDURE|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
214731629|NCT04164849|PROCEDURE|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
214731630|NCT00748306|DRUG|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
214731631|NCT00748306|DRUG|Placebo|Matching Intervention Drug
214731632|NCT01821885|BEHAVIORAL|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
214731633|NCT01821885|BEHAVIORAL|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
214731634|NCT00776581|PROCEDURE|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
214731635|NCT00776581|PROCEDURE|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
214731636|NCT00776581|PROCEDURE|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
214731637|NCT00776581|PROCEDURE|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
214731638|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
214731639|NCT01814449|OTHER|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
214731640|NCT01814449|DRUG|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
214731641|NCT03607240|PROCEDURE|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
214731642|NCT03607240|PROCEDURE|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
214731643|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
214731644|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
214731645|NCT03219554|DRUG|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
214731646|NCT00149006|PROCEDURE|Cell therapy|
214731647|NCT02812329|BEHAVIORAL|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
214731648|NCT01866306|BIOLOGICAL|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
214731649|NCT01866306|DRUG|LABA|Asthmatic participants were treated with LABA as part of their standard of care
214731650|NCT05155410|DIETARY_SUPPLEMENT|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
214731651|NCT05155410|DIETARY_SUPPLEMENT|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
214731652|NCT00820963|DRUG|temozolomide|Given orally
214731653|NCT00820963|RADIATION|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
214731654|NCT00820963|RADIATION|radiation therapy|Patients undergo standard radiotherapy
214731655|NCT06396130|DEVICE|Photobiomodulation by low level diode laser|Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
214731656|NCT06396130|OTHER|Mock Laser Application|Placebo for control group
214731657|NCT06432491|BEHAVIORAL|Drinking cold water|Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
215030542|NCT05253131|DRUG|Selumetinib|"* Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
215030543|NCT06064318|PROCEDURE|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
214731658|NCT03988790|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
214731659|NCT05141565|OTHER|No intervention|No intervention
214731660|NCT02460094|DRUG|BIIB092|See Arm Descriptions for dosing information.
214731661|NCT02460094|DRUG|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
214731662|NCT01095328|OTHER|screening|screening for Q-fever with a single blood sampling
214731663|NCT00796549|DRUG|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
214731664|NCT04311437|PROCEDURE|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
214731665|NCT04311437|PROCEDURE|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
214731666|NCT00245349|PROCEDURE|F-18 Fluorothymidine|
214731667|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
214731668|NCT01102946|DRUG|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
214731669|NCT01102946|PROCEDURE|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
214731670|NCT02966899|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
214731671|NCT02719210|BIOLOGICAL|High Volume Plasma Exchange|
214731672|NCT02719210|DRUG|Hypertonic 3% saline|
214731673|NCT02719210|DRUG|Mannitol|
214731674|NCT02719210|DEVICE|Elective positive pressure ventilation|
214731675|NCT00474773|DRUG|Celecoxib|
214731676|NCT02661256|DEVICE|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
214731677|NCT02661256|DIETARY_SUPPLEMENT|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
214731678|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
214731679|NCT03426761|DRUG|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
214731680|NCT03426761|DRUG|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
214731681|NCT00747708|DRUG|Granulocyte-colony stimulating factor|5 days subcutaneous injection
214731682|NCT00747708|PROCEDURE|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
214731683|NCT00747708|PROCEDURE|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
214731684|NCT04143490|OTHER|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
214731685|NCT03868475|PROCEDURE|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
214731686|NCT03868475|PROCEDURE|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
214731687|NCT01878175|BEHAVIORAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
214731688|NCT04591873|OTHER|telemedicine|Using telemedicine system to communicate
214731689|NCT04591873|OTHER|traditional communication tools|Use telephone or direct verbal communication
214731690|NCT03102463|DIETARY_SUPPLEMENT|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
214731691|NCT03102463|DIETARY_SUPPLEMENT|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
214731692|NCT03102463|DIETARY_SUPPLEMENT|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
214731693|NCT03102463|OTHER|Lipid Load|100mL oral lipid load
214731694|NCT04611204|OTHER|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
214731695|NCT01498497|DRUG|EUR-1100|
214731696|NCT01498497|DRUG|Placebo|
214731697|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
214731698|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
214731699|NCT04728880|DRUG|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
214731700|NCT05049642|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
214731701|NCT03083470|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
214731702|NCT03083470|OTHER|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
214731703|NCT05399589|COMBINATION_PRODUCT|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
214731704|NCT05399589|COMBINATION_PRODUCT|use healing cap in control group|use healing cap in control group
214731705|NCT06984263|PROCEDURE|Circumcision|Circumcision performed as part of standard clinical care in patients with phimosis, which may be caused by lichen sclerosus. The procedure is not assigned by the study but observed as part of routine treatment
214731706|NCT00041535|DRUG|OGT 918|
214731707|NCT02670187|BIOLOGICAL|GLS-5300|
214731708|NCT00606229|DRUG|Aripiprazole|oral, 24mg/day
214731709|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
214731710|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
214731711|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
214731712|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
214731713|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
214731714|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
214731715|NCT04519476|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
214731716|NCT04519476|DRUG|Lenalidomide|Immunomodulatory drug
214731717|NCT04519476|DRUG|Methylprednisolone|Glucocorticoid, steroid
214731718|NCT05299216|OTHER|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
214731719|NCT05299216|OTHER|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
214731720|NCT05299216|OTHER|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
214731721|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
214731722|NCT05474924|DRUG|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
214731723|NCT05474924|DRUG|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
214731724|NCT05474924|DRUG|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
214731725|NCT00836953|BIOLOGICAL|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
214731726|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
214731727|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
214731728|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
214731729|NCT01833026|DEVICE|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
214731730|NCT01833026|DRUG|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
214731731|NCT00419237|DRUG|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
214731732|NCT06066190|OTHER|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
214731733|NCT03583112|DRUG|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
214731734|NCT03583112|DRUG|Placebo Tablet|oral one placebo tablet before MRI scan.
214731735|NCT04955574|OTHER|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
214731736|NCT04955574|DRUG|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
214793975|NCT02924857|DEVICE|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
214731737|NCT04955574|OTHER|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
214731738|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
214731739|NCT06612268|DRUG|Etavopivat|Etavopivat will be administered orally.
214731740|NCT06612268|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
214731741|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
214731742|NCT03592589|DEVICE|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
214731743|NCT05393570|BEHAVIORAL|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
214731744|NCT06614361|BEHAVIORAL|Health education on COVID and flu vaccination|1 session (30 min) with a health educator on vaccination
214731745|NCT06614361|BEHAVIORAL|Nurse-led shared decision-making|1 session and FU calls with a trained nurse
214731746|NCT06614361|BEHAVIORAL|Text messages|Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)
214731747|NCT06614361|BEHAVIORAL|Lottery prize for vaccination|Modest lottery prize for COVID vaccination
214731748|NCT06614361|BEHAVIORAL|Peer navigation|Peer navigation (4 months duration, contact as needed).
214793976|NCT02924857|DEVICE|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
214793977|NCT00108420|DRUG|Prazosin|
214793978|NCT04612920|DRUG|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
214731749|NCT06341569|OTHER|Respiratory breathing techniques group|"Target group: subjects in the respiratory breathing techniques group. Program duration: the program lasts for 14 weeks.~Breathing techniques: the program includes various breathing exercises, including:~Diaphragmatic breathing teaches participants to breathe deeply, engaging the diaphragm muscle, which can improve lung capacity and relaxation.~Pursed-lips breathing: this technique involves inhaling through the nose and exhaling slowly through pursed lips, which can help slow down breathing and manage shortness of breath.~Alternate nostril breathing: this technique involves closing one nostril while inhaling and exhaling through the other nostril alternately.~Relaxation techniques: the program incorporates progressive muscle relaxation techniques. This involves progressively tensing and relaxing different muscle groups.~Medical education: topics like the anatomy of the respiratory system, the importance of proper breathing, potential benefits of specific breathing exercises."
214731750|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed.
214731751|NCT06997393|BEHAVIORAL|Prevention programme|The prevention programme consists of a validated educational video and training in the basic recognition and prevention of hand eczema.
214731752|NCT06996444|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
214731753|NCT01914939|DRUG|Oxytocin|
214731754|NCT01914939|BEHAVIORAL|Social Skills focused CBT|
214731755|NCT01914939|BEHAVIORAL|Stress management/relaxation training|
214731756|NCT01914939|DRUG|placebo drug|
214731757|NCT06993675|DRUG|Talquetamab|Talquetamab is a GPRC5DxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
214731758|NCT06993675|DRUG|Teclistamab|Teclistamab is a BCMAxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
214731759|NCT06541990|BEHAVIORAL|HARMONY|A psychoeducational intervention for patients with HCC
214731760|NCT06541990|OTHER|Enhanced usual care|A supportive care resource guide
214731761|NCT06427967|BEHAVIORAL|Project Dream Team|Five total sessions, 60-minutes each, with one session every 7 days (+/- 21 days between sessions), Session activities include discussion prompts, interactive learning methods, skill rehearsals, mindfulness / somatic exercises and lecture slides facilitated by a trained facilitator.
214731762|NCT06538064|OTHER|No Intervention|This is a non-interventional study.
214731763|NCT06541678|DRUG|Danuglipron|MR Tablet
214731764|NCT06541678|DRUG|Cyclosporine|Capsule
214731765|NCT06541678|DRUG|Itraconazole|Oral solution
214731766|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
214731767|NCT03313752|OTHER|Placebo|placebo
214731768|NCT02877134|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
214731769|NCT02877134|DRUG|Placebo|Participants will receive placebo Subcutaneously.
214731770|NCT02877134|DRUG|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
214731771|NCT06591598|DRUG|Aflibercept (BAY86-5321, Eylea)|8 mg, intravitreal injection
214731772|NCT07007806|DRUG|Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting|On day 1 single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions.
214731773|NCT07007806|DRUG|Treatment B-Omeprazole 20 mg dose administered fasting|On Day 4 to Day 13, a 20 mg dose omeprazole (1 × 20 mg) will be administered QD under fasting conditions.
214731774|NCT07007806|DRUG|Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting|On Day 8, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions simultaneously with a 20 mg dose omeprazole (1 × 20 mg).
214731775|NCT07007806|DRUG|Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole|On Day 13, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 0.5 hour before the administration of a 20 mg dose omeprazole (1 × 20 mg).
214731776|NCT07007806|DRUG|Treatment E-Omeprazole 40 mg administered fasting|On Day 14 to Day 22, a 40 mg dose omeprazole (2 × 20 mg) will be administered QD under fasting conditions.
214731777|NCT07007806|DRUG|Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole|On Day 18, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 2 hours after the administration of a 40 mg dose omeprazole (2 × 20 mg).
214731778|NCT00255606|DRUG|docetaxel|Given in 3- or 4- week courses
214731779|NCT00255606|DRUG|prednisone|Given in 3- or 4- week courses
214731780|NCT06373978|DRUG|Diclofenac|50mg every 8hours as needed for pain
214731781|NCT06373978|DRUG|Tramadol|50mg every 8hours as needed for pain
214731782|NCT06373978|OTHER|Acetaminophen|1000mg every 8hours as needed for pain
214731783|NCT07011667|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.
214731784|NCT07011667|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
214731785|NCT06867575|OTHER|Progressive Relaxation Exercise|Progressive Relaxation Exercise Steps
214731786|NCT03049930|DRUG|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
214731787|NCT03049930|DRUG|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
214731788|NCT03511300|BEHAVIORAL|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
214731789|NCT03511300|BEHAVIORAL|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
214731790|NCT00778310|DRUG|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
214731791|NCT00778310|DRUG|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
214731792|NCT00995605|DRUG|AMAP102|AMAP102 or Placebo
214731793|NCT03163173|DRUG|GC4419|30 mg (\~100 μCi) dose of \[14C\]GC4419
214731794|NCT00698776|DRUG|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
214731795|NCT00698776|BIOLOGICAL|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
214731796|NCT01197794|DRUG|AZD1981|AZD1981 twice daily
214731797|NCT01197794|DRUG|AZD1981|AZD1981 once daily
214731798|NCT01197794|DRUG|Placebo|Placebo to match AZD1981
214731799|NCT01055457|DEVICE|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
214731800|NCT01055457|DEVICE|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
214731801|NCT04055844|DRUG|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
214731802|NCT04055844|DRUG|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.
214731803|NCT04055844|DRUG|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
214731804|NCT04598841|DIETARY_SUPPLEMENT|supplement nutritional supporting|Special medical formula for the purpose of formula food
214731805|NCT04716010|OTHER|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
214731806|NCT04716010|OTHER|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
214731807|NCT04716010|OTHER|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
214731808|NCT04716010|OTHER|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
214731809|NCT02732184|DRUG|Co-ArgI-PEG modified human arginase I|
214731810|NCT03777397|OTHER|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
214731811|NCT04356872|DRUG|Sintilimab|immune check point inhibitor, 200mg, iv, d1
214731812|NCT04356872|DRUG|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
214731813|NCT04356872|DRUG|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
214731814|NCT00679380|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
214731815|NCT00679380|DRUG|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
214731816|NCT00679380|DRUG|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
214731817|NCT00679380|DRUG|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
214731818|NCT00679380|DRUG|Placebo|Placebo
214731819|NCT00656760|OTHER|PET/CT|PET/CT is being performed on all patients in the study.
214731820|NCT03630016|DIAGNOSTIC_TEST|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
214731821|NCT02715596|DIETARY_SUPPLEMENT|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
214731822|NCT02715596|OTHER|Placebo|placebo in 15 cc emulsion stick-pack
214731823|NCT00502619|PROCEDURE|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
214731824|NCT00502619|OTHER|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
214731825|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
214731826|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
214731827|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
214731828|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
214731829|NCT01833806|DEVICE|ExAblate MRgFUS|Focused Ultrasound Ablation
214731830|NCT00881699|BEHAVIORAL|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
214731831|NCT00881699|BEHAVIORAL|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
214731832|NCT02724111|DRUG|sufficient dose of rocuronium|
214731833|NCT02724111|DRUG|sugammadex 10 min after position change|
214731834|NCT00319683|DRUG|ADH300004|
214731835|NCT00971360|OTHER|conversion disorder|Proinflammatory cytokine levels in conversion disorder
214731836|NCT04710992|PROCEDURE|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
214731837|NCT04710992|PROCEDURE|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
214731838|NCT04710992|PROCEDURE|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
214731839|NCT02136550|BEHAVIORAL|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
214731840|NCT05369793|DRUG|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
214731841|NCT05369793|DRUG|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
214731842|NCT04450641|OTHER|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
214731843|NCT01722357|BEHAVIORAL|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
214731844|NCT01722357|BEHAVIORAL|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
214731845|NCT05475444|DEVICE|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
214731846|NCT05475444|DEVICE|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
214731847|NCT04010812|OTHER|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
214731848|NCT02996500|DRUG|PF-06650833|Investigational
214731849|NCT02996500|DRUG|Placebo|Placebo
214731850|NCT02996500|DRUG|Tofacitinib|Investigational
214731851|NCT05639829|BEHAVIORAL|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
214731852|NCT03978572|BEHAVIORAL|Resistance Training|Exercise intervention designed to improve muscular strength and power
214731853|NCT03978572|BEHAVIORAL|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
214731854|NCT03978572|BEHAVIORAL|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
214731855|NCT00004772|DRUG|Immune globulin|
214731856|NCT01770886|DRUG|UE2343|Oral capsule
214731857|NCT01770886|DRUG|Placebo|Oral capsule
214731858|NCT00068484|DRUG|topotecan hydrochloride|Given IV
214731859|NCT00068484|DRUG|bortezomib|Given IV
214731860|NCT00068484|OTHER|pharmacological study|Correlative studies
214731861|NCT00068484|OTHER|laboratory biomarker analysis|Correlative studies
214731862|NCT04173390|DRUG|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
214731863|NCT04173390|DRUG|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
214731864|NCT05522855|DEVICE|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
214731865|NCT02892175|PROCEDURE|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
214731866|NCT01853852|DRUG|GR181413A/AT1001 solution|Powder for reconstitution
214731867|NCT01853852|DRUG|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
214731868|NCT01853852|OTHER|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
214731869|NCT01853852|DRUG|Placebo capsule|Solution matched
214731870|NCT03322085|PROCEDURE|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
214731871|NCT03821480|DRUG|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
214731872|NCT03821480|DRUG|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
214731873|NCT01977807|DEVICE|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
214731874|NCT02863861|DRUG|Dexmedetomidine-ketamine|
214731875|NCT02863861|DRUG|propofol-ketamine|
214731876|NCT01611922|OTHER|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
214731877|NCT01611922|DEVICE|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
214731878|NCT01376895|BEHAVIORAL|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
214731879|NCT01376895|BEHAVIORAL|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
214731880|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
214731881|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
214731882|NCT00645203|DRUG|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
214731883|NCT02725736|DRUG|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
214731884|NCT02725736|DRUG|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
214731885|NCT01659359|DEVICE|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
214731886|NCT01659359|DRUG|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
214731887|NCT01171742|PROCEDURE|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
214731888|NCT05579223|DRUG|Intrathecal Hydromorphone Mono Injection|Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s
214731889|NCT05579223|DRUG|Intrathecal Placebo Mono Injection|Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
214731890|NCT05928104|OTHER|Medication review|Pharmacist-led medication review in primary care using a co-designed document
214731891|NCT01924195|DRUG|Anlotinib|Anlotinib QD po.
214731892|NCT01924195|DRUG|Placebo capsule|Placebo QD po.
214731893|NCT00348491|DRUG|Lumiracoxib|
214731894|NCT05255627|OTHER|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
214731895|NCT05255627|OTHER|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
214731896|NCT00774969|DRUG|Metronidazole|Metronidazole 10% ointment three times a day 7 days
214731897|NCT06039657|OTHER|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
214731898|NCT06039657|OTHER|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
214731899|NCT04528394|RADIATION|Photon|Photon combined with Carbon ion in Arm 1
214731900|NCT04528394|RADIATION|Proton|Proton combined with Carbon ion in Arm 2
214731901|NCT04528394|RADIATION|Carbon ion|Same dose and fractionation will be used in both arms.
214731902|NCT03105245|OTHER|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
214731903|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
214731904|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
214731905|NCT02566876|DRUG|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
214731906|NCT05213676|DRUG|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
214731907|NCT05213676|OTHER|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
214731908|NCT06309498|PROCEDURE|blood test|11 DOC levels will be measured in enrolled patients
214731909|NCT02887365|DRUG|tegafur-uracil|
214731910|NCT06153394|DRUG|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
214731911|NCT06153394|DRUG|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
214731912|NCT03879460|DRUG|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
214731913|NCT04189380|OTHER|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
214731914|NCT04189380|OTHER|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
214731915|NCT01574417|DIETARY_SUPPLEMENT|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
214731916|NCT01574417|DIETARY_SUPPLEMENT|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
214731917|NCT03581799|OTHER|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
214731918|NCT03336476|DEVICE|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
214731919|NCT03336476|DEVICE|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
214731920|NCT02485860|DEVICE|Melectis G|
214731921|NCT05142176|OTHER|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
214731922|NCT05142176|DRUG|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
214731923|NCT04871386|BEHAVIORAL|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
214731924|NCT04871386|BEHAVIORAL|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
214731925|NCT02419586|OTHER|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
214731926|NCT01381224|OTHER|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
214731927|NCT00017524|DRUG|pelitrexol|
214731928|NCT00895908|BEHAVIORAL|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
214731929|NCT00895908|BEHAVIORAL|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
214731930|NCT06204510|OTHER|complex decongestive therapy|This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
214731931|NCT02402881|BEHAVIORAL|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
214731932|NCT03325010|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214731933|NCT03325010|DRUG|Placebo oral capsule|non-active dosage form
214731934|NCT03942549|DEVICE|Retropubic midurethral sling|Midurethral sling
214731935|NCT05855213|DEVICE|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
214731936|NCT05855213|DEVICE|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
214731937|NCT04915105|DIAGNOSTIC_TEST|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
214731938|NCT05764811|DRUG|Canagliflozin 100mg|100 mg daily for a month
214731939|NCT05642793|DRUG|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
214731940|NCT05642793|DRUG|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
214731941|NCT00275041|BIOLOGICAL|cetuximab|
214731942|NCT00275041|DRUG|irinotecan hydrochloride|
214731943|NCT00108277|BEHAVIORAL|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
214731944|NCT00108277|BEHAVIORAL|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
214731945|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
214731946|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
215030544|NCT04625660|DEVICE|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
215030545|NCT03633058|DRUG|Ketamine|oral ketamine dosed twice daily for 5 days
215030546|NCT04859075|OTHER|Bifidobacterium longum 35624|1 capsule daily
215030547|NCT05474859|DRUG|XT-0528|Once Daily
214731947|NCT03479658|BEHAVIORAL|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
214731948|NCT03479658|BEHAVIORAL|Nutritional education|School-based nutritional education on healthy dietary habits
214731949|NCT05265104|DRUG|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
214731950|NCT05265104|DEVICE|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
214731951|NCT05265104|OTHER|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
214731952|NCT02315833|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
214731953|NCT02315833|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
214731954|NCT01426724|DRUG|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
214731955|NCT03050606|OTHER|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
214731956|NCT03050606|OTHER|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
214731957|NCT03824457|DRUG|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
214731958|NCT03824457|DRUG|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
214731959|NCT05791773|PROCEDURE|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
214731960|NCT05791773|PROCEDURE|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
214731961|NCT00460525|BIOLOGICAL|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
214731962|NCT00460525|BIOLOGICAL|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
214731963|NCT03440892|DRUG|methotrexate|folate antagonist
214731964|NCT03440892|DRUG|sulfasalazine|Immunomodulatory
214731965|NCT03440892|DRUG|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
214731966|NCT03440892|DRUG|tocilizumab|IL-6 receptor antagonist
214731967|NCT03440892|DRUG|tofacitinib/baricitinib|JAK inhibitor
214731968|NCT04631367|BEHAVIORAL|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
214731969|NCT04631367|DEVICE|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
214731970|NCT06417268|PROCEDURE|Caudal epidural analgesia|"patient will be placed in the left lateral position with flexed hips.After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture is performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, the needle is inserted immediately below the spinous process S4.~After perforating the membrane, the needle will be advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection, The confirmation of the correct position of the caudal needle before injection by performing the modified 'swoosh' test performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of saline. Bupivacaine 0.25% at a dose of 1 ml/kg will be injected, with care taken not to exceed the maximum recommended dose (2 mg/kg)."
215030548|NCT03312543|DEVICE|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
214731971|NCT06417268|PROCEDURE|Ultrasound-guided Combined Pericapsular Nerve Group Block|"With supine position, the probe will be put in a transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral nerve, and femoral artery (FA).~Then the probe will be rotated counter clockwise to align with the pubic ramus to visualize the AIIS, iliopsoas prominence (IPE), FA, iliopsoas, and iliopsoas notch.~Under direct vision, a 22-gauge, 50-mm echo needle will be advanced in the lateral-medial plane between the psoas tendon and the pubic ramus until the needle tip touches the IPE. The needle will be withdrawn, and after negative aspiration, 1 ml/kg (Bupivacaine 0.25%) is injected"
214731972|NCT06417268|PROCEDURE|Ultrasound-guided Lateral Femoral Cutaneous Nerve Block|patient remains supine, and the transducer is parallel to the inguinal ligament. With the femoral artery and vein as guidance, the lateral part of the sartorius muscle and fascia lata is visualized. Approximately 3 cm inferior from this point, the branches of the lateral femoral cutaneous nerve are visualized in the hypoechoic fat-filled subfascial space between the sartorius muscle medially and the tensor fascia lata muscle laterally. A 22-gauge, 50-mm needle is inserted with in plane approach at a shallow angle to reach the area of the nerve and after negative aspiration, 0.1 ml/kg (Bupivacaine 0.25%) is injected.
214731973|NCT06417268|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
214731974|NCT06417268|DRUG|Morphine|If a FLACC pain Score is ≥ 4/10, the patient in the PACU will receive morphine (intravenous, 0.03 mg/kg), and the maximum allowed dose is 0.1mg/kg every 4 hours.
214731975|NCT06417268|DRUG|Acetaminophen|P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
214731976|NCT02460172|DEVICE|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
214731977|NCT02460172|DEVICE|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
214731978|NCT06078306|DRUG|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
214731979|NCT06078306|DRUG|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
214731980|NCT06078306|DRUG|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
214731981|NCT03073200|DRUG|Ixekizumab|Administered SC
214731982|NCT03073200|DRUG|Placebo|Administered SC
214731983|NCT03073200|DRUG|Etanercept|Administered SC
214731984|NCT02194452|RADIATION|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
214731985|NCT02194452|PROCEDURE|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
214731986|NCT02194452|PROCEDURE|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
214731987|NCT02194452|OTHER|laboratory biomarker analysis|Correlative studies
214731988|NCT02421640|DRUG|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
214731989|NCT02421640|DRUG|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
214731990|NCT00067444|DRUG|Paroxetine CR|
214731991|NCT00427375|PROCEDURE|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
214731992|NCT00427375|PROCEDURE|total mesorectal excision|standard surgery
214731993|NCT06014021|BEHAVIORAL|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
214731994|NCT06014021|BEHAVIORAL|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
214731995|NCT06014021|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
214731996|NCT04757376|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
214731997|NCT04757376|BIOLOGICAL|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
214731998|NCT03253185|DRUG|SC-007|intravenous
214731999|NCT04474366|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
214732000|NCT04474366|OTHER|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
214732001|NCT00720720|DIETARY_SUPPLEMENT|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
214732002|NCT00720720|DIETARY_SUPPLEMENT|placebo margarine|
214732003|NCT05810376|BEHAVIORAL|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
214732004|NCT05810376|OTHER|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
214732005|NCT03053973|DEVICE|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
214732006|NCT03053973|OTHER|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
214732007|NCT03364062|PROCEDURE|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
214732008|NCT04063865|DRUG|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
214732009|NCT04063865|DRUG|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
214732010|NCT04064372|BEHAVIORAL|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
214732011|NCT04064372|BEHAVIORAL|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
214732012|NCT05409092|DIETARY_SUPPLEMENT|Astaxanthin|8 mg/day in one capsule for 4 weeks
214732013|NCT05409092|DIETARY_SUPPLEMENT|Placebo|8 mg/day in one capsule for 4 weeks
214732014|NCT03659240|OTHER|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
214732015|NCT03659240|OTHER|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
214732016|NCT03288623|DIETARY_SUPPLEMENT|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
214732017|NCT03288623|DIETARY_SUPPLEMENT|White/Milk chocolate (<35% cocoa)|white or milk chocolate (\<35% cocoa) in tablet
214732018|NCT03175250|BEHAVIORAL|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
214732019|NCT03175250|BEHAVIORAL|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
214732020|NCT03175250|BEHAVIORAL|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
214732021|NCT01948323|BEHAVIORAL|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
214732022|NCT03898323|DEVICE|Alcohol Approach Bias Modification|Computerized training
214732023|NCT03258450|BEHAVIORAL|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
214732024|NCT06455423|PROCEDURE|Thoracic Manipulation|Thoracic manipulation will be administered at hypomobile or stiff segments.
214732025|NCT06455423|PROCEDURE|Chin tuck in exercises|Chin tuck in exercises
214732026|NCT06455423|PROCEDURE|Thoracic Extension Exercise|Thoracic Extension Exercise
214732027|NCT06455423|PROCEDURE|Scapular Retraction Exercises|Scapular Retraction Exercises
214732028|NCT06455423|DEVICE|Hot Pack|Hot Pack
214732029|NCT06455423|DEVICE|TENS|Trans Cutaneous Electric Nerve Stimulation (TENS)
214732030|NCT06455423|PROCEDURE|ELDOA|ELDOA exercises
214732031|NCT06503133|OTHER|Birth preparation training|Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).
214732032|NCT06503133|OTHER|Prenatal yoga practice|Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
214732033|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
214732034|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|"1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
214732035|NCT00620737|BIOLOGICAL|Autologous Human Fibroblasts (Isolagen TherapyTM)|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
214732036|NCT00620737|BIOLOGICAL|Placebo|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
214732037|NCT01547806|DRUG|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
214732038|NCT01547806|DRUG|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
214732039|NCT01547806|PROCEDURE|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
214732040|NCT00320190|DRUG|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
214732041|NCT00320190|DRUG|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
214732042|NCT00515554|DRUG|Rituximab|addition of Rituximab to BEACOPP escalated
214732043|NCT00515554|DRUG|BEACOPP escalated|chemotherapy with BEACOPP escalated
214732044|NCT05129683|OTHER|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
214732045|NCT05129683|OTHER|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
214732046|NCT05129683|OTHER|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
214732047|NCT02448797|DRUG|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
214732048|NCT02448797|DRUG|Chemotherapy|Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
214732049|NCT06247449|DIAGNOSTIC_TEST|Brain imaging|Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
214732050|NCT06247449|DIAGNOSTIC_TEST|Analysis of circulating tumor DNA|One single blood draw for analysis of circulating tumor DNA
214732051|NCT06247449|BEHAVIORAL|Testing Morbidities Index|Questionnaire regarding the participant's perception of brain imaging.
214732052|NCT04915872|PROCEDURE|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
214732053|NCT04915872|PROCEDURE|other samplings (T1)|"\- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
214732054|NCT00712270|DRUG|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
214732055|NCT00712270|DRUG|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
214732056|NCT02852291|BEHAVIORAL|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
214732057|NCT02852291|BEHAVIORAL|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
214732058|NCT02828995|OTHER|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
214732059|NCT01041040|DRUG|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
214732060|NCT00005640|PROCEDURE|Preoperative Endoscopy|
214732061|NCT00005640|RADIATION|Technetium Tc 99m Sulfur Colloid|
214732062|NCT00005640|PROCEDURE|Gamma Probe|
214732063|NCT00005640|PROCEDURE|Biopsy of Sentinel Lymph Nodes|
214732064|NCT04429074|PROCEDURE|Minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy
214732065|NCT01755104|DIETARY_SUPPLEMENT|Stablor|
214732066|NCT01755104|DIETARY_SUPPLEMENT|Placebo|
214732067|NCT04443868|DRUG|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
214732068|NCT05885906|DRUG|Aloevera|Mouthwash
214732069|NCT05885906|DRUG|Thyme honey|Mouthwash
214732070|NCT05885906|DRUG|Saline|Mouthwash
214732071|NCT01611311|DRUG|BI 409306|Film-coated tablet
214732072|NCT01611311|DRUG|Placebo|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
214732073|NCT03119922|OTHER|No intervention|
214732074|NCT00433927|DRUG|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
214732075|NCT00433927|DRUG|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
214732076|NCT00433927|DRUG|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
214732077|NCT00433927|DRUG|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
214732078|NCT00433927|DRUG|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
214732079|NCT00886691|BIOLOGICAL|Bevacizumab|Given IV
214732080|NCT00886691|DRUG|Everolimus|Given PO
214732081|NCT00886691|OTHER|Laboratory Biomarker Analysis|Correlative studies
214732082|NCT00886691|OTHER|Placebo|Given PO
214732083|NCT05908929|PROCEDURE|SRP and concomitant insertion of PRF membrane|The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane. Blood samples were drawn without anticoagulants in 10 mL tubes, which were immediately centrifuged at 4000 rpm for 8 minutes. Upon centrifugation, the blood showed three distinct layers: the uppermost layer contained platelet poor plasma, the middle layer consisted of a fibrin clot, and the lowermost band appeared bright red due to the presence of red blood cells. The fibrin clot polymerized in a diffuse manner within the tube, which was then cut with sharp scissors and squeezed between two glass slides to obtain a thick membrane. The PRF membrane was carefully handled using a carrier and isolated with a periodontal pack dressing (Coe-Pak). All patients were followed up at one week and six weeks after the treatment.
214732084|NCT05908929|PROCEDURE|SRP|The pockets were treated using the conventional procedure of scaling and root planing (SRP) utilizing curettes and an ultrasonic device. All patients were followed up at one week and six weeks after the treatment.
214732085|NCT04341025|BEHAVIORAL|Mindfulness based psychosexual therapy ( MBPST)|The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
214732086|NCT05478967|PROCEDURE|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
214732087|NCT01428986|DRUG|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
214732088|NCT01636167|DEVICE|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
214732089|NCT00655239|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
214732090|NCT00655239|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
214732091|NCT01864486|DEVICE|Intelligent Retinal Implant System|
214732092|NCT03875833|DEVICE|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
214732093|NCT01992328|DRUG|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
214732094|NCT01660997|DRUG|MLN9708|
214732095|NCT01660997|DRUG|Dexamethasone|
214732096|NCT05255497|DEVICE|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
214732097|NCT04927351|BEHAVIORAL|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
214732098|NCT01269827|DRUG|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
214732099|NCT01269827|DRUG|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
214732100|NCT00216229|BIOLOGICAL|Combined vaccine against hepatitis A and B (Twinrix)|
214732101|NCT06690255|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
214732102|NCT05746689|DRUG|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
214732103|NCT06902246|DRUG|Regorafenib|"Participants will orally self-administer Regorafenib tablets for the first 21 days of each 28-day cycle as follows. Dose-escalation will occur only if there are no significant drug-related adverse events:~* Safety Run-in Phase: For the first six (6) participants enrolled. The starting dose is 80 mg/day during Cycles 1 and 2. In Cycle 3, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose of 160 mg/day on Days 15 to 21. Participants will continue to receive the maximum tolerated dose determined at the end of Cycle 3.~* Phase 2: For participants enrolled after the Safety Run-in phase. In Cycle 1, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose 160 mg/day on Days 15 to 21. From Cycle 2 onward, participants will take 160 mg/day (or maximum tolerated dose from Cycle 1), on Days 1 to 21."
214732104|NCT06902246|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Y-90 absorbed glass microspheres will be administered standard of care once via the percutaneous trans-arterial approach after the first 3 weeks of Regorafenib treatment but before Day 28. Additional Y-90 absorbed glass microsphere administration is allowed for treatment of baseline disease in the absence of disease progression within 6 months of the initial Y-90 TARE treatment.
214732105|NCT03551106|OTHER|Web based learning module|Web based learning module available on a especially designed website
214732106|NCT03028532|DRUG|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
214732107|NCT02282488|OTHER|Low protein formula|
214732108|NCT02282488|OTHER|High protein formula|
214732109|NCT03137056|DEVICE|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
214732110|NCT03137056|DEVICE|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
214732111|NCT03137056|DEVICE|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
214732112|NCT02672644|DEVICE|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
214732113|NCT02672644|DEVICE|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
214732114|NCT06216769|DRUG|Rivaroxaban|"Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours."
214732115|NCT03455504|DRUG|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
214732116|NCT00909194|BEHAVIORAL|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
214732117|NCT03828565|PROCEDURE|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
214732118|NCT00721357|BEHAVIORAL|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
214732119|NCT00721357|OTHER|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
214732120|NCT00438776|DRUG|olanzapine|2.5mg to 15mg daily
214732121|NCT00438776|DRUG|sugar pill|matching placebo to olanzapine
214732122|NCT00916396|DRUG|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
214732123|NCT00916396|DRUG|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
214732124|NCT03017040|DEVICE|CT scan|A CT scan of the wrist
214732125|NCT03017040|DEVICE|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
214732126|NCT01001143|DRUG|Decitabine|
214732127|NCT01001143|DRUG|Bexarotene|
214732128|NCT01428414|DRUG|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
214732129|NCT01428414|DRUG|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
214732130|NCT01428414|DRUG|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
214732131|NCT01428414|DRUG|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
214732132|NCT04137055|DRUG|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
214732133|NCT04137055|DRUG|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
214732134|NCT04137055|DRUG|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
214732135|NCT04137055|DRUG|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
214732136|NCT04137055|DRUG|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
214732137|NCT04137055|DRUG|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
214732138|NCT04137055|DRUG|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
214732139|NCT04137055|DRUG|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
214732140|NCT04137055|DRUG|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
214732141|NCT04137055|DRUG|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
214732142|NCT04137055|DRUG|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
214732143|NCT04137055|DRUG|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
214732144|NCT03327246|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
214732145|NCT00985140|RADIATION|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
214793979|NCT01886274|DEVICE|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
214732146|NCT04120480|DIAGNOSTIC_TEST|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
214732147|NCT03371589|DRUG|Dexamethasone|Solution for otic injection
214732148|NCT02021474|DRUG|AGX-201|Subcutaneous injection
214732149|NCT02021474|DRUG|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
214732150|NCT02626299|DRUG|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
214732151|NCT02626299|DRUG|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
214732152|NCT02626299|OTHER|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
214732153|NCT04501965|COMBINATION_PRODUCT|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
214732154|NCT04501965|COMBINATION_PRODUCT|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
214732155|NCT04501965|COMBINATION_PRODUCT|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
214732156|NCT05307081|DRUG|Artificial Tears|Artificial Tears are an FDA approved intervention
214732157|NCT04105595|DEVICE|Septal defect closure|Device closure of atrial septal defect
214732158|NCT00166621|DRUG|Buspirone|
214732159|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
214732160|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
214732161|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
214732162|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
214732163|NCT02033291|PROCEDURE|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
214732164|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
214732165|NCT02875366|DRUG|LUM/IVA|
214732166|NCT02875366|DRUG|Placebo|
214732167|NCT03623204|OTHER|Dyspnea evaluation|
214732168|NCT00001302|DRUG|PSC 833|
214732169|NCT04033380|DEVICE|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
214732170|NCT04033380|DEVICE|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
214732171|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
214732172|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
214732173|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
214732174|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
214732175|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
214732176|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
214732177|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
214793980|NCT04118231|OTHER|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
214732178|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
214732179|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
214732180|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
214732181|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
214732182|NCT02659098|DRUG|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
214732183|NCT02659098|DEVICE|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
214793981|NCT04741035|OTHER|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
214732184|NCT04363944|DEVICE|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
214732185|NCT03083106|DEVICE|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
214732186|NCT03219476|DRUG|Anastrozole|1 mg once daily.
214732187|NCT03219476|DRUG|Letrozole|2.5mg once daily.
214732188|NCT03219476|DRUG|Exemestane|25 mg once daily.
214732189|NCT03219476|DRUG|Tamoxifen|20 mg once daily.
214732190|NCT01105468|DEVICE|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
214732191|NCT01105468|DEVICE|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
214732192|NCT06917651|DRUG|sufentanil sublingual 30 mcg tablet|"patient randomized in the SST 30mcg arm will receive a 30-microgram sublingual sufentanil tablet"
214732193|NCT06917651|OTHER|Standard of Care (SOC)|"patients randomized in the SOC arm will receive analgesic treatment according to the department's internal pain management protocol."
214732194|NCT06932380|PROCEDURE|Talus prosthesis|The Episealer Talus is an individualised resurfacing implant intended for use on either the medial or lateral talus. It aims to treat patients suffering from pain and reduced mobility due to focal osteochondral lesions in the talus.
214732195|NCT06932822|OTHER|Mental Imagery|Placement of a peripheral venous catheter on a simulation mannequin after a mental visualization session
214732196|NCT05434936|PROCEDURE|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
214732197|NCT04341311|DRUG|Marizomib|\- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
214732198|NCT04341311|DRUG|Panobinostat|\- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
214732199|NCT05136040|DRUG|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
214732200|NCT02112461|BEHAVIORAL|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
214732201|NCT06949787|PROCEDURE|Membrane sweeping|Participants in the membranes sweeping group will receive membrane sweeping. If labor will not initiate within 48 hours, the procedure will be repeated up to a maximum of three times at 48-hour intervals.
214732202|NCT06948838|BEHAVIORAL|RBPM|Standardized blood pressure measurement and treatment protocols in clinical practice.
214732203|NCT06948838|OTHER|MII|Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.
214732204|NCT06949384|OTHER|observational study|This observational study focuses on the measurement of self-esteem in medical students using the Rosenberg Self-Esteem Scale. There is no intervention or treatment applied, and participants are only assessed for their self-esteem levels based on their demographic information.
215030549|NCT03312543|DEVICE|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
214732205|NCT04776252|DRUG|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
214732206|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
214732207|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
214732208|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
214732209|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
214732210|NCT05909488|BIOLOGICAL|1.5 x 10^6 UC-MSC + CM|1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
214732211|NCT05909488|BIOLOGICAL|5 x 10^6 UC-MSC + CM|5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
215030550|NCT05407766|BIOLOGICAL|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
215030551|NCT05407766|OTHER|Placebo|Single injection of placebo (saline)
215030552|NCT05535972|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
214732212|NCT06447220|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
214732213|NCT01711671|DRUG|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
214732214|NCT01711671|DRUG|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
214732215|NCT01711671|DRUG|Standard of Care|Current approved standard of care
214732216|NCT05974202|DEVICE|Active H7-coil repetitive transcranial magnetic stimulation (rTMS)|A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.
214732217|NCT05974202|DEVICE|Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)|A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
214732218|NCT06464276|OTHER|No intervention|No intervention
214732219|NCT05076617|DRUG|Staccato alprazolam|"* Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
214732220|NCT06794073|DEVICE|Multimodal Thermal Therapy|The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
214732221|NCT06479811|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.
214732222|NCT06479811|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET will be given IV 7 days prior to \[212Pb\]VMT-alpha-NET.
214732223|NCT06479811|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
214732224|NCT06518473|DIAGNOSTIC_TEST|Skin prick test|"Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold.~Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)"
214732225|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
214732226|NCT03872947|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
214732227|NCT03872947|BIOLOGICAL|TRK-950|5 mg/kg administered intravenously over 60 minutes (weekly)
214732228|NCT03872947|BIOLOGICAL|TRK-950|Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)
214732229|NCT03872947|DRUG|Irinotecan|Intravenously over 30 - 90 minutes
214732230|NCT03872947|DRUG|Leucovorin|Intravenously over 30 - 90 minutes
214732231|NCT03872947|DRUG|5-FU|Intravenously bolus and intravenously for two days
214732232|NCT03872947|DRUG|Gemcitabine|Intravenously over 30 minutes
214732233|NCT03872947|DRUG|Cisplatin|Intravenously over 60 minutes
214732234|NCT03872947|DRUG|Carboplatin|Intravenously per package insert
214732235|NCT03872947|DRUG|Ramucirumab|Intravenously over 60 minutes
214732236|NCT03872947|DRUG|Paclitaxel|Intravenously
214732237|NCT03872947|DRUG|Nivolumab|Intravenously over 30 minutes
214732238|NCT03872947|DRUG|Pembrolizumab|Intravenously over 30 minutes
214732239|NCT03872947|DRUG|Imiquimod Cream|Topically
214732240|NCT03872947|DRUG|Bevacizumab|Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
214732241|NCT03872947|DRUG|PLD|Intravenously over 60 minutes
214732242|NCT03144206|DRUG|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
214732243|NCT05110963|BEHAVIORAL|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
214732244|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
214732245|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
214732246|NCT06319534|BEHAVIORAL|Comprehensive rehabilitation|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
214732247|NCT06319534|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
214732248|NCT06319534|DRUG|Lidocaine Hydrochloride|the patients are provided with Stellate ganglion block, using 2.8ml of 0.8% Lidocaine hydrochloride and 0.2 ml of 0.5% vitamin B12. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
214732249|NCT06319534|BEHAVIORAL|placebo injection|2.8 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
214732250|NCT04923659|DRUG|Carbamazepine|600 mg reconstituted as one table. Administered once
214732251|NCT04923659|DRUG|Lorazepam|2.5 mg mg reconstituted as one table. Administered once
214732252|NCT04923659|DRUG|Dextromethorphan|150 mgmg reconstituted as one table. Administered once
214732253|NCT04923659|DRUG|Nimodipine|30 mg reconstituted as one table. Administered once
214732254|NCT04923659|DRUG|Placebo|Administered once
214732255|NCT03724994|DRUG|Gemcitabine|Adjuvant or palliative chemotherapy according to national guidelines
214732256|NCT02918734|DEVICE|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
214732257|NCT02918734|DEVICE|Metal interference screw|ACL reconstruction with metal interference screw
214732258|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
214732259|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
214732260|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
214732261|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
214732262|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
214732263|NCT05487092|OTHER|Placebo|Placebo
214732264|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
214732265|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
214732266|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
214732267|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|participants performed moderate intensity soleus push-ups with ankle weights, calculated as 30-40% of individuals 1RM of soleus muscle's strength. The single set of MSPU was performed 15 minutes after the meal for time till the point where the muscle started to fatigue. The participants were in sitting position with legs positioned at 90 degree angle relative to floor and feet flat on ground performed continuous planter flexion against the ankle weight. Three sets of MSPU was performed at every 15 and Session lasted in 60 minutes.
214732268|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
214732269|NCT01351714|PROCEDURE|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
214732270|NCT04970433|PROCEDURE|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
214732271|NCT04970433|PROCEDURE|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
214732272|NCT04970433|PROCEDURE|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
214732273|NCT02903966|DRUG|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
214732274|NCT02903966|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
214732275|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
214732276|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
214732277|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
214732278|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
214732279|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
214732280|NCT03289494|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
214732281|NCT03289494|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
214732282|NCT04974411|OTHER|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
214732283|NCT04974411|OTHER|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
214732284|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
214732285|NCT02119611|DEVICE|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
214732286|NCT05220098|DRUG|TAK-280|Participants will receive TAK-280 as IV infusion.
214732287|NCT06003387|GENETIC|CSL222 (AAV5-hFIXco-Padua)|Administered as a single IV infusion.
214793982|NCT04741035|OTHER|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
214793983|NCT00767117|DRUG|Etravirine; Lopinavir; Ritonavir|
214732288|NCT06849310|BEHAVIORAL|Group that will receive emotional regulation training|The content of the program is based on the current literature (Dennison, 2024; Holmqvist Larsson et al., 2020; Kara \& Yüksel, 2022; Kılıçarslan \& Varol, 2023; Siegel \& Brayson, 2021; Vafaei et al., 2021) for four weeks, once a week (average 50 minutes/week). The module on noticing emotions, which will be applied in the first week, is aimed at adolescents to think about and notice emotions. The content of the training will include determining the beliefs and effects of the group members about emotions, teaching the nature of all emotions and the function of adaptation, distinguishing between emotions and thoughts, teaching similar and opposite emotions, and situations that contribute to the positivity of the emotional state.
214732289|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
214732290|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
214732291|NCT06128629|BIOLOGICAL|NTLA-2001|NTLA-2001 (55mg) by IV infusion
214732292|NCT06128629|DRUG|Placebo|Normal saline (0.9% NaCl) by IV infusion
214732293|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
214732294|NCT01377324|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
214732295|NCT02090218|DEVICE|I-Gel|I-Gel supraglottic airway device
214732296|NCT02090218|DEVICE|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
214732297|NCT04950933|DRUG|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
214732298|NCT04950933|DRUG|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
214732299|NCT01128452|DRUG|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
214732300|NCT01128452|DRUG|Placebo|HPMC Placebo capsules, once daily for 28 days
214732301|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
214732302|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
214732303|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
214732304|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214732305|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
214732306|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
214732307|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
214732308|NCT06624475|DRUG|Nivolumab|Nivolumab is a fully humanized monoclonal antibody that binds to the PD-1 receptor, blocking its interactions with PD-L1 and PD-L2, and thus additionally inhibiting PD1-driven immune suppression. Nivolumab 490 mg via IV administration 28 day cycle
214732309|NCT06624475|DRUG|Opdualag|Opdualag (Opdualag) is supplied as a single dose vial containing 240 mg of Nivolumab and 80 mg. Relatlimab per 20 mL for intravenous administration ; 28 day cycle.
214732310|NCT05763693|DRUG|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
214732311|NCT05763693|DRUG|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
214732312|NCT05763693|OTHER|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
214732313|NCT05763693|OTHER|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
214732314|NCT04574076|DRUG|Turoctocog alfa pegol (N8-GP)|Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
214732315|NCT04224350|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
214732316|NCT04224350|DRUG|Tacrolimus cap.|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
214732317|NCT05673148|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
214732318|NCT05673148|PROCEDURE|Resection|undergo surgical resection
214732319|NCT05673148|PROCEDURE|Microwave Ablation|undergo microwave ablation
214732320|NCT05673148|DRUG|Chemotherapy|Receive SOC chemotherapy
214732321|NCT05673148|PROCEDURE|Computed Tomography|Undergo CT scan
214732322|NCT05673148|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214732323|NCT05673148|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214732324|NCT06471608|OTHER|Ambulatory management|"* Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home."
214732325|NCT06471608|OTHER|Standard Care|"Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
214732326|NCT04334057|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
214732327|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
214732328|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
214732329|NCT03596268|DIAGNOSTIC_TEST|Imaging|3T Prisma MRI
214732330|NCT03596268|DIAGNOSTIC_TEST|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
214732331|NCT03596268|DIAGNOSTIC_TEST|Lumbar Puncture|CSF will be collected
214732332|NCT03381274|BIOLOGICAL|Oleclumab|Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
214732333|NCT03381274|DRUG|Osimertinib|Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
214732334|NCT03381274|DRUG|AZD4635|Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
214732335|NCT03874052|DRUG|Azacitidine|Given IV or SC
214732336|NCT03874052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214732337|NCT03874052|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214732338|NCT03874052|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214732339|NCT03874052|PROCEDURE|Echocardiography Test|Undergo ECHO
214732340|NCT03874052|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
214732341|NCT03874052|OTHER|Questionnaire Administration|Ancillary studies
214732342|NCT03874052|DRUG|Ruxolitinib|Given PO
214732343|NCT03874052|DRUG|Venetoclax|Given PO
214732344|NCT06799286|DRUG|BMS-986489|Specified dose on specified days
214732345|NCT04526938|DEVICE|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
214732346|NCT05298774|DEVICE|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
214732347|NCT01492036|OTHER|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
214732348|NCT01492036|BEHAVIORAL|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
214732349|NCT04428580|OTHER|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
214732350|NCT04428580|OTHER|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
214732351|NCT06083077|OTHER|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
214732352|NCT05302986|DRUG|Tranexamic acid injection|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes during the shoulder surgery.
214732353|NCT05302986|DRUG|Placebo|Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
214732354|NCT06048367|DRUG|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
214732355|NCT06048367|DRUG|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
214732356|NCT06048367|DRUG|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
214732357|NCT06048367|DRUG|CNSI-Fe(II) 120 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
214732358|NCT06048367|DRUG|CNSI-Fe(II) 150 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
214732359|NCT05374564|DRUG|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
215030553|NCT05790031|DEVICE|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
214732360|NCT02906098|BEHAVIORAL|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
214732361|NCT02906098|BEHAVIORAL|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
214732362|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
214732363|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
214732364|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
214732365|NCT05124912|PROCEDURE|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
214732366|NCT05124912|DRUG|Steroid Therapy|Best medical management with steroid therapy
214732367|NCT05124912|PROCEDURE|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
214732368|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
214732369|NCT06422507|DRUG|8 mg aflibercept (BAY 86-5321) (High Dose)|High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
214732370|NCT06422507|DRUG|2 mg aflibercept (EYLEA, BAY 86-5321)|"Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye."
214732371|NCT06422507|OTHER|Sham|"To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM)."
214732372|NCT03894657|DIAGNOSTIC_TEST|Nasal brushing|Nasal scrapping at visit V0
214732373|NCT03894657|OTHER|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study"
214732374|NCT03894657|OTHER|blood sample|"Visit V0 : Additional 14 mL~* 5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~* 3 mL in Dry tube for Serum biobank~* 6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~* 2x3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~* 3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank"
214732375|NCT03894657|DRUG|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
214732376|NCT05815862|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
214732377|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
214732378|NCT01364948|OTHER|No oil application|Oil application was not done
214732379|NCT03927820|OTHER|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
214732380|NCT04053114|OTHER|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
215030554|NCT05362305|BEHAVIORAL|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
214732381|NCT02136134|DRUG|Daratumumab|Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
214732382|NCT02136134|DRUG|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
214732383|NCT02136134|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
214732384|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
214732385|NCT06821425|DRUG|Melatonin gel mixed with xenograft|This study will be conducted to evaluate the effect of melatonin (5% gel) when used as an adjunct to xenograft for the surgical management of intrabony periodontal defects.
214732386|NCT06821425|OTHER|Xenograft|Application of Xenograft alone for the surgical management of intrabony periodontal defects.
214732387|NCT05196867|BEHAVIORAL|Intervention Group|Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.
214732388|NCT05196867|BEHAVIORAL|Control Group|Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
214732389|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
214732390|NCT06030505|OTHER|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
214732391|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
214732392|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
214732393|NCT04042701|DRUG|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
214732394|NCT04255693|BEHAVIORAL|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
214732395|NCT04255693|BEHAVIORAL|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
214732396|NCT04255693|BEHAVIORAL|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
214732397|NCT04255693|BEHAVIORAL|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
214732398|NCT04255693|BEHAVIORAL|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
214732399|NCT04255693|BEHAVIORAL|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
214732400|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
214732401|NCT02381886|DRUG|IDH305|
214732402|NCT05879653|DRUG|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
214732403|NCT05879653|DRUG|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
214732404|NCT05879653|PROCEDURE|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
214732405|NCT05879653|RADIATION|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
214732406|NCT06038578|BIOLOGICAL|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
214732407|NCT06038578|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
214732408|NCT06038578|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
214732409|NCT05977686|DEVICE|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
214732410|NCT05977686|DEVICE|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
214732411|NCT05232929|DRUG|Risdiplam|Risdiplam taken by participants as prescribed by their physician.
214732412|NCT05232929|DEVICE|SMA-DAT Application and ADAM Sensor|Participants will perform a programmed selection of SMA-DAT tasks while wearing the ADAM Sensor.
214732413|NCT03070119|DRUG|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
214732420|NCT03217318|DEVICE|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
214732421|NCT00732472|DRUG|GSK573719|7 day repeat dose
214732422|NCT02502955|PROCEDURE|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
214732423|NCT02159768|DEVICE|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
214732424|NCT00255983|DRUG|Faropenem medoxomil|600 mg BID for 5 days
214732425|NCT00255983|DRUG|placebo|placebo tablets BID for 5 days
214732426|NCT00554346|DRUG|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
214732427|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
214732428|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
214732429|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
214732430|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
214732431|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
214732432|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
214732433|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
214732434|NCT06967675|PROCEDURE|Low-Flow Anesthesia (LFA)|General anesthesia with a fresh gas flow rate of 1 L/min (50% oxygen + 50% air).
214732435|NCT05180721|BEHAVIORAL|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
214732436|NCT05846282|BEHAVIORAL|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
214732437|NCT05846282|BEHAVIORAL|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
214732438|NCT04870099|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
214732439|NCT01996865|DRUG|Lenalidomide|
214732440|NCT01996865|DRUG|Rituximab|
214732441|NCT05058859|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
214732442|NCT06342843|PROCEDURE|Total Hip Arthroplasty|a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.
214732443|NCT06217575|BEHAVIORAL|Alpha neurofeedback training|Alpha neurofeedback training affords the participant the ability to monitor cortical EEG waves and entrain to a specific rhythm using visual feedback. Alpha is measured between 8-12Hz and is associated with cortical inhibition. Aging related changes in alpha have been associated with loss of modulation ability. However, alpha training may afford increased perception of visual details.
214732444|NCT06217575|BEHAVIORAL|Visual Attention Training|"Visual attention training involves repeated testing on the location and identity of objects in the visual field. Also called the Dual Decision task training, objects are briefly presented in a radial field of view surrounding a gaze fixation point. The participant is asked to remember the location and object presented within the field. The test progressively increases in difficulty by limiting the amount of time the object is presented on screen. Accuracy is measured by either a correct or incorrect response (binary response)."
214732445|NCT05667623|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
214732446|NCT05667623|OTHER|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
214732447|NCT05455294|DRUG|Navitoclax|See Arm Description
214732448|NCT05455294|DRUG|Venetoclax|See Arm Description
214732449|NCT05455294|DRUG|Decitabine|See Arm Description
214732450|NCT04934956|OTHER|Split-belt walking|These will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.
214732451|NCT04934956|OTHER|Multiple transitions between split-belt and tied-belt walking|This intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018).
214732452|NCT03044210|OTHER|Metabolic evaluation|"* diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)"
214732453|NCT06206746|DEVICE|May Health System|The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
214732454|NCT04783506|OTHER|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
214732455|NCT03575351|DRUG|Standard of Care|Standard of Care
214732456|NCT03575351|GENETIC|JCAR017|JCAR017
214732457|NCT04288089|DRUG|Palbociclib (75, 100, 125 milligram [mg])|Palbociclib orally, once daily (QD).
214732458|NCT04288089|DRUG|H3B-6545 (150, 300, 450 mg)|H3B-6545 orally, QD.
214732459|NCT06519682|DRUG|Nivolumab|All patients will be administered Nivolumab with or without radiation
214732460|NCT06519682|RADIATION|Radiation|Radiation
214732461|NCT06322238|DIAGNOSTIC_TEST|PGx panel test|In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mayo Clinic Health System), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
214732462|NCT03715205|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
214732463|NCT06435806|OTHER|Medical Illustration design|We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
214732464|NCT05273996|DRUG|Sertraline, bupropion, desvenlafaxine|Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
214732465|NCT03288311|OTHER|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
214732466|NCT03288311|OTHER|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
214732467|NCT02110550|OTHER|IPS.emmax endocrown|
214732468|NCT06190717|DEVICE|EchoMark/EchoSure|Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
214732469|NCT06190717|PROCEDURE|Standard of Care|Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
214732470|NCT02286089|BIOLOGICAL|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
214732471|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
214732472|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
214732473|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
214732474|NCT07126600|OTHER|No investigational intervention administered|No investigational intervention administered
214732475|NCT06648655|DRUG|TMP-301|Daily (QD) x 14 weeks.
214732476|NCT06648655|DRUG|Placebo|Daily (QD) x 14 weeks.
214732477|NCT06479278|BEHAVIORAL|Talk with Me Baby|Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
214732478|NCT06813365|DRUG|DZD6008|Daily dose of DZD6008
214732479|NCT05941052|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
214732480|NCT04112992|PROCEDURE|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
214732481|NCT01081028|OTHER|First-line therapy|As prescribed by treating physician
214732482|NCT01081028|DRUG|Second-line Multiple Myeloma treatments|As prescribed by the treating physician
214732483|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
214732484|NCT03426449|PROCEDURE|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
214732485|NCT03426449|PROCEDURE|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
214732486|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
214732487|NCT04955652|BEHAVIORAL|Health Maintenance Topic|Alert
214732488|NCT04955652|BEHAVIORAL|Actionable Sidebar Item|Alert
214732489|NCT04955652|BEHAVIORAL|Best Practice Alert|Alert
214732490|NCT04883099|DEVICE|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
214732491|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
214732492|NCT01378676|DRUG|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
214732493|NCT01378676|DRUG|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
214732494|NCT01378676|DRUG|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
214732495|NCT01378676|DRUG|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
214732496|NCT01378676|DRUG|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
214732497|NCT01378676|DRUG|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
214732498|NCT01378676|DRUG|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
214732499|NCT01378676|DRUG|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
214732500|NCT01378676|DRUG|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
214732501|NCT02482415|OTHER|Psycho-educational|
214732502|NCT03629483|DRUG|Dexmedetomidine|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
214732503|NCT03629483|DRUG|Placebo|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
214793984|NCT05118321|DEVICE|Custom-made upper limb exosuit and hand exoskeleton|Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
214793985|NCT05304637|DEVICE|iTEAR100 treatment|Vibratory energy to the external nasal nerve
214732504|NCT01501734|DEVICE|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
214732505|NCT03598660|GENETIC|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
214732506|NCT03598660|OTHER|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
214732507|NCT03872336|DRUG|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
214732508|NCT03872336|OTHER|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
214732509|NCT03239262|PROCEDURE|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
214732510|NCT03239262|PROCEDURE|No intervention|No intervention was performed in patients without ganglionated plexi.
214732511|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
214732512|NCT03733249|DRUG|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
214732513|NCT03733249|BIOLOGICAL|rivogenlecleucel|donor T-cells modified with iCasp safety switch
214732514|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
214732515|NCT01637844|DRUG|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
214732516|NCT00011375|DRUG|Rolipram|
214732517|NCT02516891|DEVICE|Drug-Eluting Stents implantation in bifurcation lesions|
214732518|NCT05560074|DEVICE|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
214732519|NCT05560074|OTHER|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
214732520|NCT01936428|OTHER|interview|
214732521|NCT04247828|DEVICE|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
214732522|NCT04247828|DEVICE|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
214732523|NCT02789189|DRUG|nedaplatin and gemcitabine|
214732524|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
214732525|NCT04196049|PROCEDURE|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
214732526|NCT04752631|DRUG|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
214732527|NCT01751373|BEHAVIORAL|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
214732528|NCT01751373|BEHAVIORAL|Standard Therapy|
214732529|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
214732530|NCT02347202|OTHER|Telephone support as needed|
214732531|NCT03712995|PROCEDURE|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
214732532|NCT05467072|DEVICE|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
214732533|NCT05801172|PROCEDURE|ketoprofen for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
214732534|NCT05801172|PROCEDURE|ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
214732535|NCT05801172|PROCEDURE|ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
214732536|NCT03814460|DIAGNOSTIC_TEST|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
214732537|NCT04272814|OTHER|Compression therapy|Compression application
214732538|NCT04272814|DIAGNOSTIC_TEST|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
214732539|NCT03299166|DRUG|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
214732540|NCT03299166|DRUG|Placebo|Matching capsule once daily (QD)
214732541|NCT05277116|OTHER|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
214732542|NCT05464498|DEVICE|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
214732543|NCT05464498|OTHER|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
214732544|NCT07012148|DEVICE|UNEEG SubQ device|Subjects will be implanted with the UNEEG SubQ device in the neurosurgical operating suite under general anesthesia. Electrodes will be placed over the temporal lobe of the hemisphere established as the origin of seizures by previous EEG monitoring. Only one UNEEG device will be placed, and only the seizure onset hemisphere will be covered.
214732545|NCT04111653|OTHER|Mud therapy|Application of sludge poultice
214732546|NCT02455362|DRUG|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
214732547|NCT02455362|DRUG|Placebo|
214732548|NCT05964712|PROCEDURE|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
214732549|NCT05263544|OTHER|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
214732550|NCT00043004|BIOLOGICAL|bevacizumab|
214732551|NCT00043004|DRUG|FOLFOX regimen|
214732552|NCT00043004|DRUG|fluorouracil|
214732553|NCT00043004|DRUG|leucovorin calcium|
214732554|NCT00043004|DRUG|oxaliplatin|
214732555|NCT00043004|PROCEDURE|conventional surgery|
214732556|NCT00043004|PROCEDURE|radiofrequency ablation|
214732557|NCT03538990|OTHER|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
214732558|NCT06013319|DRUG|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
214732559|NCT03732521|OTHER|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
214732560|NCT00307814|DRUG|Epoetin Alfa|
214732561|NCT00572728|PROCEDURE|CT|Undergo 18F-FLT PET/CT
214732562|NCT00572728|DRUG|18F-FLT|Undergo 18F-FLT PET/CT
214732563|NCT00572728|PROCEDURE|PET|Undergo 18F-FLT PET/CT
214732564|NCT02615262|DRUG|Dexamethasone|
214732565|NCT02615262|DRUG|Placebo|0.9% Sodium Chloride
214732566|NCT06435962|DEVICE|sonography|measurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
214732567|NCT02719457|OTHER|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
214732568|NCT02719457|OTHER|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
214732569|NCT04113512|OTHER|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
214732570|NCT00002981|PROCEDURE|positron emission tomography|
214732571|NCT00002981|RADIATION|fludeoxyglucose F 18|
214732572|NCT00002981|RADIATION|methionine C 11|
214732573|NCT01529450|DRUG|LDE225|800-mg (4 200-mg capsules/day) capsule
214732574|NCT02142855|BEHAVIORAL|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
214732575|NCT02142855|BEHAVIORAL|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
214732576|NCT03457636|DRUG|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
214732577|NCT03457636|DRUG|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
214732578|NCT00358709|BEHAVIORAL|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
214732579|NCT01487707|BEHAVIORAL|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
214732580|NCT01487707|BEHAVIORAL|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
214732581|NCT01487707|BEHAVIORAL|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
214732582|NCT04431804|OTHER|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
215030555|NCT06265415|DRUG|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
215030556|NCT06265415|DRUG|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
214732583|NCT04823741|GENETIC|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
214732584|NCT03465046|COMBINATION_PRODUCT|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
214732585|NCT00540527|DRUG|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
214732586|NCT00540527|DRUG|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
214732587|NCT00731952|DRUG|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
214732588|NCT04001660|PROCEDURE|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
214732589|NCT04369586|DRUG|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
214732590|NCT04369586|DRUG|Placebo|placebo
214732591|NCT04046601|DEVICE|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
214732592|NCT05437692|DRUG|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
215030557|NCT06265415|DRUG|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
214732593|NCT04925830|BEHAVIORAL|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
214732594|NCT04152668|PROCEDURE|Titanium curette.|Implant debridement.
214732595|NCT04152668|PROCEDURE|Ultrasonic|Implant debridement.
214732596|NCT04152668|PROCEDURE|Air-polishing|Implant debridement and polishing.
214732597|NCT04426240|DRUG|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
214732598|NCT01376505|BIOLOGICAL|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
214732599|NCT01376505|BIOLOGICAL|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
214732600|NCT03780088|BEHAVIORAL|mTranS-C|mobile health
214732601|NCT02391298|BEHAVIORAL|Mindfulness Meditation|
214732602|NCT03421262|DIAGNOSTIC_TEST|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
214732603|NCT03421262|DIAGNOSTIC_TEST|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
214732604|NCT03336203|DRUG|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
214732605|NCT01228838|DRUG|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
214732606|NCT01228838|DRUG|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
214732607|NCT02244125|DRUG|PCD|"STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~\- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]"
214732608|NCT02244125|PROCEDURE|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
214732609|NCT05637567|DRUG|Acetylsalicylic acid|100 mg per os once daily
214732610|NCT05637567|DRUG|Placebo|Placebo pill per os once daily
214732611|NCT02725749|RADIATION|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
214732612|NCT02725749|OTHER|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
214732613|NCT02725749|RADIATION|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
214732614|NCT06507215|DIAGNOSTIC_TEST|Protein analysis|The investigator enrolled 149 healthy volunteers and collected peripheral blood samples for protein analysis. While 18 of these individuals with protein levels in the range of 40%-64% were predicted to be carriers by the monocyte assay, subsequent DYSF sequencing analysis in 14 of 18 detected missense variants in only four. Analysis of DNA methylation patterns at the DYSF locus showed no changes in methylation levels at CpG islands and shores between samples.
214732615|NCT01963962|DRUG|Copper IUD|
214732616|NCT01963962|DRUG|Levonorgestrel IUD|
214732617|NCT01343576|DIETARY_SUPPLEMENT|milk fat|45 g milk fat per day in 4 weeks
214732618|NCT00003992|BIOLOGICAL|trastuzumab|
214732619|NCT00003992|DRUG|cyclophosphamide|
214732620|NCT00003992|DRUG|doxorubicin hydrochloride|
214732621|NCT00003992|DRUG|paclitaxel|
214732622|NCT00003992|DRUG|tamoxifen citrate|
214732623|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
214732624|NCT03954704|DRUG|mFOLFOX6 Regimen|Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
214732625|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
214732626|NCT02669446|DEVICE|Medical devices|
214732627|NCT02669446|DEVICE|traditional household remedy|
214732628|NCT04273568|OTHER|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
215030558|NCT02614248|OTHER|Organic, Unrefined Coconut Oil|
214732629|NCT04273568|OTHER|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
214732630|NCT03628040|DRUG|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
214732631|NCT03628040|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane
214732632|NCT04552067|DRUG|Lovenox|patients given curative dose of Lovenox
214732633|NCT04552067|DRUG|Enoxaparin|patients given curative dose of Enoxa
214732634|NCT00102804|DRUG|Pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
214732635|NCT00102804|DRUG|Placebo|IV administration, q 21 days
214732636|NCT00102804|OTHER|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
214732637|NCT03233672|RADIATION|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
214732638|NCT02507050|DRUG|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
214732639|NCT00058773|DRUG|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
214732640|NCT01896414|DIETARY_SUPPLEMENT|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
214732641|NCT01896414|DIETARY_SUPPLEMENT|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
214732642|NCT01722214|BIOLOGICAL|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
214732643|NCT01722214|OTHER|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
214732644|NCT02094664|DEVICE|Heated and humidified oxygen|
214732645|NCT01886495|OTHER|nutrition intervention|
214732646|NCT05202002|BEHAVIORAL|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
214732647|NCT05202002|BEHAVIORAL|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
215030559|NCT02614248|OTHER|Medline Remedy Phytoplex Z-Guard Skin Protectant|
215030560|NCT02694263|DRUG|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
214732648|NCT03377829|PROCEDURE|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
214732649|NCT03377829|PROCEDURE|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
214732650|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
214732651|NCT03253029|DIETARY_SUPPLEMENT|Pure Encapsulations Branched Chain Amino Acid powder|
214732652|NCT03253029|DIETARY_SUPPLEMENT|control group (no BCAAs provided)|
214732653|NCT00755391|BEHAVIORAL|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
214732654|NCT00755391|BEHAVIORAL|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
214732655|NCT00833612|DEVICE|Counterpulsation with IAB|IABC pre-reperfusion PCI
214732656|NCT03729908|BEHAVIORAL|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
214732657|NCT03729908|BEHAVIORAL|Anti-stress program|A mindfulness based intervention with no reference to animals
214732658|NCT00658450|BEHAVIORAL|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
214732659|NCT05405569|OTHER|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
214732660|NCT05405569|OTHER|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
214732661|NCT00000703|DRUG|Bleomycin sulfate|
214732662|NCT00000703|DRUG|Vincristine sulfate|
214732663|NCT00000703|DRUG|Doxorubicin hydrochloride|
214732664|NCT00000703|DRUG|Cyclophosphamide|
214732665|NCT00000703|DRUG|Allopurinol|
214732666|NCT00000703|DRUG|Methotrexate|
214732667|NCT00000703|DRUG|Cytarabine|
214732668|NCT00000703|DRUG|Leucovorin calcium|
214732669|NCT00000703|DRUG|Zidovudine|
214732670|NCT00000703|DRUG|Dexamethasone|
214732671|NCT03256006|OTHER|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
214732672|NCT06870019|BEHAVIORAL|GPS tracker device|GPS tracker device
214732673|NCT03882866|PROCEDURE|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
214732674|NCT03882866|PROCEDURE|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
214732675|NCT02307604|GENETIC|Tumour markers testing|
214732676|NCT02159001|DEVICE|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
214732677|NCT03677544|OTHER|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
214732678|NCT04844567|DEVICE|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
214732679|NCT04844567|DEVICE|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
214732680|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
214732681|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
214732682|NCT06388356|OTHER|Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care|"Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive."
214732683|NCT01312285|DEVICE|Resonator device|low level magnetic fields
214732684|NCT00139633|DRUG|carboplatin, 5FU, Taxol and radiation|
214732685|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
214732686|NCT04060433|BEHAVIORAL|Family Therapy|Swedish version of the evidence based manualized Family Therapy
214732687|NCT06220188|DRUG|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
214732688|NCT03061227|DRUG|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
214732689|NCT03061227|DRUG|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
214732690|NCT05758974|PROCEDURE|dental treatment|Extraction, pulp therapy or both
214732691|NCT00877227|DRUG|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
214732692|NCT00374127|DRUG|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
214732693|NCT00374127|DRUG|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
214732694|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
214732695|NCT03769389|DIETARY_SUPPLEMENT|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
214732696|NCT03769389|DIETARY_SUPPLEMENT|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
214732697|NCT03769389|DIETARY_SUPPLEMENT|placebo|50g of pure glucose dissolved in 100ml of water
214732698|NCT04330989|BEHAVIORAL|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
214732699|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
214732700|NCT05616572|BEHAVIORAL|OncoWhiz|OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
214732701|NCT00112840|DRUG|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
214732702|NCT00112840|DRUG|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
214732703|NCT02299206|DRUG|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
214732704|NCT02299206|DRUG|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
214732705|NCT05736042|DEVICE|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
214732706|NCT00407251|DRUG|Patupilone|
214732707|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
214732708|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
214732709|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
214732710|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
214732711|NCT05254925|DRUG|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
214732712|NCT05254925|OTHER|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
214732713|NCT05254925|DRUG|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
214732714|NCT05254925|OTHER|Petrolatum vehicle|Petrolatum vehicle
214732715|NCT03566498|DIETARY_SUPPLEMENT|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
214732716|NCT03566498|DIETARY_SUPPLEMENT|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
214732717|NCT03419351|DIAGNOSTIC_TEST|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
214732718|NCT03419351|DIAGNOSTIC_TEST|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
214732719|NCT03419351|DIAGNOSTIC_TEST|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
214732720|NCT00683774|DRUG|diazoxide|100mg orally three times per day for 10 days
214732721|NCT01145404|DRUG|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
214732722|NCT01145404|DRUG|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
214732723|NCT02484040|RADIATION|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
214732724|NCT02484040|DRUG|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
214732725|NCT03249441|BEHAVIORAL|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
214732726|NCT01453686|DRUG|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
214732727|NCT01453686|DRUG|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
214732728|NCT03053713|BEHAVIORAL|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
214732729|NCT03053713|BEHAVIORAL|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
214732730|NCT06697353|DRUG|vericiguat (BAY 1021189)|2.5 mg initiating dose
214732731|NCT00691054|DRUG|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
214732732|NCT01531933|DRUG|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
214732733|NCT01531933|DRUG|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
214732734|NCT02551328|DRUG|sevofluorane|Continuous infusion of sevofluorane
214732735|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
214732736|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
214732737|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
214732738|NCT01250392|BEHAVIORAL|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
214732739|NCT02308904|OTHER|Blood Draw/Semen Exam|"Females:~1\. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
214732740|NCT02308904|OTHER|Retrospective data/Chart Review/Relevant Clinical Results|"1. 1\. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1\. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1\. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
214732741|NCT02308904|OTHER|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
214732742|NCT00781183|OTHER|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
214732743|NCT03148249|OTHER|interview|control group: interview, study group: explanation and exploration
214732744|NCT06166251|BEHAVIORAL|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
214732745|NCT06166251|BEHAVIORAL|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
214732746|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
214732747|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
214732748|NCT07025382|OTHER|Home-based pulmonary rehabilitation|"An eight-week (three sessions per week) telerehabilitation home-based program, including:~Twenty-four PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations. Participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application (TELEREHAPP) for guidance throughout the program, remote monitoring, and communication. Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Physical activity coaching, including a daily step goal."
214732749|NCT07025382|OTHER|Center-based pulmonary rehabilitation|"An eight-week (three sessions per week) center-based pulmonary rehabilitation program, including:~Twenty-four center-based PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations."
214732750|NCT03592173|DIAGNOSTIC_TEST|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
214732751|NCT06700291|PROCEDURE|Surgery|Patient undergoing Anesthesia and Surgery
214732752|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
214732753|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
214732754|NCT00441194|DEVICE|Visual Field (Octopus 311 and the HFA 700 series)|
214732755|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
214732756|NCT02735044|DRUG|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
214732757|NCT02735044|DRUG|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
214732758|NCT02735044|DRUG|Background therapy|Fast-acting mealtime insulin analogs
214732759|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
214732760|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
214732761|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
214732762|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
214732763|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
214732764|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
214732765|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
214732766|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
215030561|NCT02694263|DRUG|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
214732767|NCT04669509|DIAGNOSTIC_TEST|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
214732768|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
214732769|NCT01682759|DRUG|Omarigliptin|
214732770|NCT01682759|DRUG|Placebo to Omarigliptin|
214732771|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
214732772|NCT01682759|DRUG|Glimepiride Placebo|
214732773|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
214732774|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
214732775|NCT00685828|DRUG|imatinib mesylate|By mouth
214732776|NCT00004728|DRUG|Warfarin|
214732777|NCT00004728|DRUG|Aspirin|
214732778|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
214732779|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
214732780|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
214732781|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
214732782|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
214732783|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
214732784|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
214732785|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
214732786|NCT02462200|OTHER|Indocyanine green|
214732787|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
214732788|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
214732789|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
214732790|NCT06873789|DRUG|INCB177054|INCB177054 will be administered at protocol defined dose.
214732791|NCT06873789|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
214732792|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
214732793|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
215030562|NCT02694263|DRUG|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
214644622|NCT05836233|DRUG|Pulmonary Vasodilators|"Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose."
214644623|NCT01288560|OTHER|Advanced cardiac imaging|
214644624|NCT01288560|OTHER|Standard Cardiac Imaging|
214732794|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
214732795|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
214732796|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
214732797|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
214732798|NCT05625659|DIAGNOSTIC_TEST|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
214732799|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 5-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 5 ounces.
214732800|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 1-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the control group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 1 ounce.
214732801|NCT03374891|OTHER|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
214732802|NCT01868594|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
214732803|NCT01868594|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
214732804|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
214732805|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
214732806|NCT07032272|DRUG|remibrutinib|Tablet with oral route of administration
214732807|NCT06878131|BEHAVIORAL|Colorectal Cancer|Participants that take part in this research, will be responsible for following study directions and allowing blood samples to be collected every 3 months for correlative studies.
214732808|NCT06186895|DRUG|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
214732809|NCT06186895|DRUG|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
214732810|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|Tested positive
214732811|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|tested negative
214732812|NCT07102355|OTHER|Experimental: Group A = Dry Cupping|Dry cupping, originating in Middle Eastern and Asian countries, gained popularity in the United States after the 2016 Summer Olympics. It has two main forms: wet and dry cupping. Wet cupping involves laceration of the skin, while dry cupping uses negative pressure to pull the skin into the cup. Cupping is used to reduce musculoskeletal or myofascial pain, with the most accepted mechanism being localized hyperemia, which improves microcirculation and promotes healing
215030563|NCT02694263|DRUG|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
215030564|NCT02694263|DRUG|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
214732813|NCT07102355|OTHER|Experimental: Group B = Graston Technique|Instrument-assisted soft tissue mobilization (IASTM), derived from Cyriax cross-friction massage, is a popular alternative to traditional manual therapy techniques, with its first controlled study published in 1997 (Seffrin \&amp; Gardiner-Shires, 2019) .The Graston Technique(GT), also known as instrument-assisted soft tissue mobilization (IASTM), is used by chiropractors, doctors, and therapists to alleviate pain and range-of-motion restrictions caused by musculoskeletal injuries and scar tissue. (McKivigan, J. M., \&amp; Tulimero, G. et al. , 2020) . The Graston technique, is also used to alleviate upper cervical pain.
214732814|NCT05976685|PROCEDURE|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
214732815|NCT05976685|DRUG|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
214732816|NCT01201967|OTHER|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
214732817|NCT01201967|OTHER|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
214732818|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
214732819|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
214732820|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
214732821|NCT05412667|DIETARY_SUPPLEMENT|TWK10|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
214732822|NCT05412667|OTHER|Placebo|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
214732823|NCT06706869|DRUG|PF-07258669|Tablet
214732824|NCT06706869|DRUG|Itraconazole|Solution
214732825|NCT07135388|DIETARY_SUPPLEMENT|Food for special medical purposes|Oral supplementation with a protein supplement high in branched-chain amino acids and β-hydroxy-β-methyl-butyrate (HMB)
214732826|NCT06706778|BEHAVIORAL|Music intervention|Based on the NIH toolkit and MBIs reporting guidelines, the engagement in this pilot study will be receptive by providing participants with prerecorded, preselected playlists. Participants will also receive a guided video on maximizing music's therapeutic benefits. The playlists will be purely instrumental, with a 60-80 bpm tempo, and feature melodies and harmonies designed for stress relief, including soothing, grounding, meditation, emotional release, etc. This approach is resource-efficient and easily accessible, allowing participants to integrate it into daily pain self-management strategies. Participants will be asked to engage in the MBI in the morning and at night for 30 minutes each, wearing the abdominal belt and smartwatch.
214732827|NCT05844657|OTHER|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
214732828|NCT05844657|OTHER|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
214732829|NCT05844657|OTHER|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
214732830|NCT05844657|OTHER|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
214732831|NCT05844657|OTHER|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
214732832|NCT05844657|OTHER|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
214732833|NCT05844657|OTHER|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
214732834|NCT05844657|OTHER|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
214732835|NCT05844657|OTHER|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
214732836|NCT05844657|OTHER|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
214732837|NCT05844657|OTHER|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
214732838|NCT05844657|OTHER|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
214732839|NCT05844657|OTHER|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
214732840|NCT05844657|OTHER|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
214732841|NCT05844657|OTHER|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
214732842|NCT05844657|OTHER|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
214732843|NCT05844657|OTHER|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
214732844|NCT05844657|OTHER|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
214732845|NCT05844657|OTHER|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
214732846|NCT05844657|OTHER|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
214732847|NCT05844657|OTHER|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
214732848|NCT05844657|OTHER|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
214732849|NCT05844657|OTHER|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
214732850|NCT03709940|DRUG|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
214732851|NCT06880393|BIOLOGICAL|anti-BCMA-CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg
214732852|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 5|The number of family skills training sessions administered: 5 sessions
214732853|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: In-person|The mode of administration of family skills training sessions: in person or online
214732854|NCT06724406|BEHAVIORAL|Family Skills Training Content: Communication|The content of family skills training sessions administered focused on communication and conflict resolution : communication and conflict resolution
214732855|NCT06724406|BEHAVIORAL|Family Skills Training Content: Cohesion|The content of family skills training sessions administered focused on cohesion: cohesion or no cohesion
214732856|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 10|The number of family skills training sessions administered: 10 sessions
214732857|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: Online|The mode of administration of family skills training sessions: online
214732858|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Communication|The content of family skills training sessions administered focused on communication and conflict resolution : no communication and conflict resolution
214732859|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Cohesion|The content of family skills training sessions administered focused on cohesion: no cohesion
214732860|NCT03796871|DEVICE|Dermapol|Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
214732861|NCT06727032|DEVICE|Brain Metastasis AI|There will be no intervention
214732862|NCT06885827|DIETARY_SUPPLEMENT|Vitamin B-mix|"Daily oral supplementation with:~Vitamin B6 (pyridoxine, 25 mg), 1 capsule Vitamin B9 (folic acid, 400 µg) + Vitamin B12 (cyanocobalamin, 1 mg), 2 capsules.~Choline (choline bitartrate, 500 mg), 2 capsules Administered alongside standard glaucoma care."
214732863|NCT06885827|OTHER|Standard Care|Usual glaucoma management (e.g., monitoring and/or IOP-lowering treatments) without additional supplementation.
214732864|NCT07045519|DEVICE|Local Vibration Therapy|Local vibration (LV) will be applied using the Vibrasens© device (Techno Concept, Mane, France). Vibrasens© is a non-invasive therapeutic mechanical vibrator used for transcutaneous vibratory stimulation in sensorimotor rehabilitation. The system includes one pilot unit, one manual vibrator (VB200), four flat skin contactors for tendon applications, four round skin contactors for surface applications, a power supply, a user manual, and a protocol guide.
214732865|NCT07045519|DEVICE|Sham Vibration|Participants will receive sham stimulation by placing the Vibrasens© device on the same area as the treatment group for 10 minutes, without activating the vibration function. They will be informed that they will only feel the contact of the device.
214732866|NCT06731075|DRUG|ORMD-0801 8 mg|1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
214732867|NCT06731075|OTHER|Placebo capsule|Placebo capsule
214732868|NCT06731075|DRUG|ORMD-0801 16 mg|2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
214732869|NCT06926530|OTHER|No intervention|Participants will complete a one-time 33-question survey. The survey is comprised of three sections: (1) Section A includes 12 questions related to demographic information, (2) Section B consists of 2 questions addressing treatment characteristics, \& (3) Section C contains 19 questions focusing on supplement usage.
214732870|NCT06925321|DRUG|Fosmanogepix IV infusion|Fosmanogepix will be administered IV
214732871|NCT06925321|DRUG|Standard of care antifungal therapy|Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines
214732872|NCT06925321|DRUG|Fosmanogepix oral tablet|Fosmanogepix will be administered orally.
214732873|NCT06922656|DRUG|Dapagliflozin (DAPA)|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
214732874|NCT06922656|DRUG|Pioglitazone 45 mg|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
214732875|NCT06922656|DRUG|Placebo|Placebo
214732876|NCT06725004|DRUG|Oxytocin|Injection Oxytocin 10 mg intramuscular as trigger for ovulation induction
214732877|NCT06725004|DRUG|Human Chorionic Gonadotropin|Injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
214732878|NCT07041723|BEHAVIORAL|Visual-acoustic biofeedback for Sibilants|Participants will view a real-time FFT spectrum and will be cued to match a visual target for /s/ where the spectral energy is concentrated to the right side of the display, primarily in the 5000-10,000 Hz region of the spectrum. Practice will occur in blocks of 10 consecutive trials on the same item (e.g., 10 /sa/), after which a new item will be addressed (e.g., 10 /se/). Within each block, the clinician will provide qualitative (knowledge of performance) feedback as prompted by the research team's custom open-source software, Challenge Point Program (CPP). The CPP software prompts clinician actions such as delivery of knowledge of performance (KP) feedback. Following each block of ten trials, the software automatically tallies the scores entered by the clinician and uses the summed scores to make adaptive changes in practice difficulty.
214732879|NCT06732362|OTHER|Different DPN ratings|According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
214732880|NCT06724913|OTHER|specialized food product based on ice cream|Day 1: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 3: standard ice cream (12% fat)
214732881|NCT06724913|OTHER|specialized food product based on ice cream 2|Day 1: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: standard ice cream (12% fat)
214732882|NCT06724913|OTHER|specialized food product based on ice cream 3|Day 1: standard ice cream (12% fat) Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin
214732883|NCT06733506|DRUG|Chlorhexidine gluconate|"Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml)."
214732884|NCT06733506|DRUG|Isopropyl Alcohol 70% Topical Application Solution|Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
214732885|NCT06733506|BEHAVIORAL|Skin Prep Before Injecting Recreational/Street Drugs|During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
214732886|NCT06738485|BIOLOGICAL|Recombinant single-chain factor VIII (rVIII-SingleChain)|Lyophilized powder for solution for intravenous injection
214732887|NCT07048808|COMBINATION_PRODUCT|XC001|XC001 administered by percutaneous catheter delivery using the Extroducer® Infusion Catheter System.
214732888|NCT07048808|COMBINATION_PRODUCT|Sham (No Treatment)|Subjects randomized to the sham catheterization procedure group will receive the same procedure as the treatment group (with introduction of an iliofemoral or radial sheath, positioning of the pigtail catheter in the left ventricle, generation of ventriculograms, and mimicking of the injection procedure by the interventional team following a Cath Lab script), except they will not have the delivery catheter inserted and will not receive any endocardial injections
214732889|NCT07050589|BEHAVIORAL|Exercise and art|Weekly SMARTfit dual-task exergaming and group art-making
214732890|NCT07047300|DIAGNOSTIC_TEST|Record EMG maximum amplitude from bilateral erector spinae, rectus femoris, and medial and lateral gastrocnemius muscles.|"Conduct measurements under two conditions:~Condition 1: Standing with standardized flat shoes. Perform three trials for each participant. Calculate and record the mean as baseline data. Condition 2: Standing with a standardized heel lift insole inside the flat shoes.~Conduct three trials. Record the mean for comparative analysis."
214732891|NCT07047300|DIAGNOSTIC_TEST|Photograph participants from anterior and lateral views to assess knee valgus angle and lumbosacral angle.|"Capture two sets of photographs for each participant:~Set 1: Wearing flat shoes. Set 2: Wearing the heel lift insole inside the flat shoes. Compare knee valgus angle and lumbosacral angle under both conditions. Ensure consistency and reliability by following standardized protocols and performing repeated measurements.~Analyze the effects of heel lift insoles on muscle activity and postural alignment."
214732892|NCT07044388|BEHAVIORAL|Coping with asthma through life management program|Participants will complete surveys, learn stress coping strategies, receive asthma education information, and obtain access local community financial resources.
214732893|NCT07044388|BEHAVIORAL|Waitlist Control (CALM)|Participants in this group will complete surveys but will not receive the CALM intervention. Upon completing the study after 12 weeks they will be able to complete the program if they would like the resources/materials to learn healthy stress coping strategies, asthma health education, and access to financial resources.
214732894|NCT07048262|BIOLOGICAL|CSL787|CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of \>= 6 months but not exceeding 12 months.
214732895|NCT07048262|DRUG|Placebo|Participants will receive a matching volume of placebo QD over a period of \>= 6 months but not exceeding 12 months.
214732896|NCT07048262|DEVICE|Nebulizer|The nebulizer is a CE-marked device.
214732897|NCT06745882|DRUG|Cisplatin|Given on day 1 of every 21-day cycle.
214732898|NCT06745882|DRUG|Carboplatin|Given on day 1 of every 21-day cycle.
214732899|NCT06745882|DRUG|Pemetrexed|Given on day 1 of every 21-day cycle.
214732900|NCT06745882|DRUG|Pembrolizumab|Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.
214732901|NCT06745882|DRUG|Abraxane|Given on days 1, 8, and 15 of each 21-day cycle.
214732902|NCT06745882|DRUG|Paclitaxel|Given on day 1 of every 21-day cycle.
214732903|NCT04737707|OTHER|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
214732904|NCT07052552|OTHER|osteopathic manipulative tratment only|focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome
214732905|NCT07052552|OTHER|ujjayi pranayama and osteopathic manipulative treatment|"Ujjayi pranayama, often called ocean breath, can be a helpful practice for individuals with Upper Cross Syndrome (UCS) by promoting relaxation and improving breath control. While not a direct cure, it can alleviate some symptoms and improve overall posture and body awareness.~Osteopathic manipulative treatment focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome"
214732906|NCT02466204|DRUG|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
214732907|NCT02466204|DRUG|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
214732908|NCT07054684|DRUG|BHV-1400|BHV-1400 is delivered subcutaneously (SC)
214732909|NCT06853210|DEVICE|Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
214732910|NCT06853210|DEVICE|Human Amnion/Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
214732911|NCT06860815|PROCEDURE|Biopsy|Undergo tumor biopsy
214732912|NCT06860815|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214732913|NCT06860815|BIOLOGICAL|Cemiplimab|Given IV
214732914|NCT06860815|PROCEDURE|Computed Tomography|Undergo CT
214732915|NCT06860815|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214732916|NCT06860815|RADIATION|Transarterial Radioembolization|Undergo TARE
215030565|NCT02402647|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
214732917|NCT06860815|RADIATION|Yttrium Y 90 Resin Microspheres|Given intratumorally
214732918|NCT07057817|DEVICE|Cerament G|Partial Calcanectomy plus cerament G
214732919|NCT07057817|OTHER|Standard Surgical Managment|Partial Calcanectomy as standard of care
214732920|NCT07060456|DRUG|HRS953|HRS953-low dose
214732921|NCT07060456|DRUG|HRS953|HRS953-high dose
214732922|NCT07060456|DRUG|Placebo|Placebo
214732923|NCT07054983|OTHER|Qualitative Research Interview|Qualitative research interview of parents of pediatric patients seen in an interdisciplinary feeding clinic who underwent a tube weaning program
214732924|NCT07061691|DEVICE|WIM Robotic Exoskeleton|Wearable hip-powered exoskeleton
214732925|NCT06898450|DRUG|NDI-219216|NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
214732926|NCT06841055|DRUG|BNT327|Intravenous infusion
214732927|NCT06841055|DRUG|Docetaxel|Intravenous infusion
214732928|NCT07057531|PROCEDURE|Tubeless thoracic surgery|Tubeless thoracic surgery is a minimally invasive procedure performed without tracheal intubation or mechanical ventilation, allowing for spontaneous breathing. Anesthesia combines conscious sedation with local nerve blocks to ensure pain relief while preserving diaphragmatic movement. The surgical approach is similar to conventional video-assisted thoracic surgery (VATS), used for procedures like lung resections and mediastinal mass excisions. Post-operative care focuses on early mobilization and quick discharge.
214732929|NCT06369285|DRUG|Alisertib|Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
214732930|NCT06369285|DRUG|Endocrine therapy|"Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter"
214732931|NCT05768347|BIOLOGICAL|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
214732932|NCT06763627|OTHER|Gamification ( Board game )|"A three- or four-player board game will be designed to teach acute cholecystitis and pancreatitis. The game has two stages: educational (houses 1-9) and reinforcement (houses 10-30). Players roll dice and move their pieces to answer various questions such as multiple-choice, true/false, matching, puzzles, and scenario-based problem-solving. Each player starts with three hearts, and if they land on one of the three red trap spaces and answer incorrectly, they lose one heart. Yellow spaces introduce random events like gaining or losing hearts. One space features a general knowledge question for variety. Players must achieve a point threshold in the educational section to move to the reinforcement section, and the highest scorer at the end of the hour wins. Groups of 3 or 4 students will play for one hour under the supervision of the investigator."
214732933|NCT06763627|OTHER|Traditional lecture-based teaching|Students will attend a standard one-hour lecture delivered by a general surgery faculty member, covering the same topics. PowerPoint presentations prepared by the research team will ensure consistency with the game content.
214732934|NCT06784791|DRUG|Amivantamab Intravenous|Stage 1: Pre-operative amivantamab monotherapy Stage 2: Pre-operative amivantamab treatment plus chemotherapy (carboplatin/pemetrexed)
214732935|NCT06784791|DRUG|Carboplatin/Pemetrexed|Stage 2: Pre-operative amivantamab plus chemotherapy (carboplatin/pemetrexed)
214732936|NCT02978638|DEVICE|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
214732937|NCT07063069|OTHER|Abdominal ultrasound|All patients included will have an abdominal ultrasound scan to mesure anterior/posterior external diameter of gastric antrum upstream of pyloru and external diameter upper/lower of gastric antrum upstream of pylorus
214732938|NCT07069179|BEHAVIORAL|Choose to Move Replacement Ready|As described under study arm description.
214732939|NCT07069309|BIOLOGICAL|BNT162b2 (Omi LP.8.1)|BNT162b2 monovalent (Omicron LP.8.1)
214732941|NCT05977322|DRUG|68Ga-FF58|Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection
214732942|NCT05977322|DRUG|177Lu-FF58|Solution for injection/infusion
214732943|NCT07136883|DEVICE|POBA|The intervention consists of preparing the artery with a traditional/regular angioplasty balloon before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
214732944|NCT07136883|DEVICE|Scoring Balloon|The intervention consists of preparing the artery with a scoring balloon (Angiosculpt™; Manufacturer: Spectranetics Corporation, Fremont, California, USA) before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
214732945|NCT07077213|COMBINATION_PRODUCT|18F-FAPI-74|10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan, performed during the first 6 weeks of treatment and a second dose of 10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan within 6 weeks after tuberculosis treatment completion.
214732946|NCT06823193|BEHAVIORAL|Mental Time Travel task|"A psychophysical task (D'Angelo et al., 2023) will be adopted. In this task, a projection in time will be induced by faces of different ages. Face stimuli will be presented with a short sentence describing a particular life event, commonly occurring around 60. Participants will perform a two-alternative forced-choice task under two experimental conditions. In the past projection condition, they will indicate whether it is likely or unlikely that the person of the face shown could have experienced the indicated event 10 years earlier. In the future projection, they will indicate whether it is likely or unlikely that the person depicted will experience the indicated event in 10 years."
214732947|NCT06823193|BEHAVIORAL|Age Estimation control task|In this task participants will estimate the age of the faces adopted as stimuli.
214732948|NCT06823193|BEHAVIORAL|Lifeline task|In this task participants will be instructed to associated each event with the age at which they believe it typically occurred.
214732949|NCT06748144|DRUG|Intraosseous Vancomycin|The intervention is specific to the method of administration that will be used when giving the dose of antibiotic vancomycin which is done to prevent infection following surgery.
214732950|NCT06748144|DRUG|Intravenous Vancomycin|This is the standard method of giving the antibiotic vancomycin to patients undergoing surgery across many specialties in order to prevent infection.
214732951|NCT06889571|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session.
214732952|NCT07084467|OTHER|EF1 guided CRT optimisation|In the EF1-guided optimisation group, the settings of the CRT device are adjusted to maximise early heart pumping efficiency, measured by a parameter called first-phase ejection fraction (EF1). Depending on the patient's heart rhythm, either the timing between heart chambers (AV or VV delay) is adjusted in small steps. The device setting that gives the best EF1 reading is chosen to help improve the heart's response to CRT.
214732953|NCT07084467|OTHER|Standard of Care (SOC)|This group will receive standard of care for their health condition and CRT management.
214732954|NCT06102382|DRUG|Norepinephrine (0.1)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
214732955|NCT06102382|DRUG|Norepinephrine (0.075)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
214732956|NCT07125534|DRUG|Alcohol beverage|This intervention involves the administration of an alcohol beverage (vodka mixed with juice or soda) in a controlled laboratory setting, targeting a blood alcohol concentration (BAC) of 0.08%. The alcohol is consumed over a 36-minute period in three equal parts.
214732957|NCT07125534|OTHER|Control - non alcoholic beverage|This intervention involves the administration of a non-alcoholic control beverage in a controlled laboratory setting. The beverage is matched in volume and palatability to the alcohol condition but co
214732958|NCT07085975|DRUG|Adenosine 5'-triphosphate|Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
214732959|NCT00353327|PROCEDURE|Plasma infusion|
214732960|NCT06466876|BEHAVIORAL|retrieval-based word learning|Word learning intervention that compares two strategies for teaching novel words
214732961|NCT07087743|BEHAVIORAL|VR-Based Gait Training with End-Effector Robot|A single-session gait training protocol using the Morning Walk® end-effector robot with real-time virtual reality visual feedback to encourage paretic limb propulsion and symmetrical gait. This intervention is intended to study participants' behavioral and biomechanical responses to the VR feedback, not to evaluate the robot as a device.
214732962|NCT07089797|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app (i.e., WeChat mini program) delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session (up to 20 minutes each) across a 6 week intervention period.
214732963|NCT07089797|BEHAVIORAL|Sleep hygiene education|The participants in the control group will receive only sleep hygiene (one-page handout) via WeChat. Access to the CBT-I WeChat mini program will be offered to these participants after the completion of the 3-month follow-up assessment.
214732964|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
214732965|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214732966|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214732967|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214732968|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
214732969|NCT06343376|DRUG|Cyclophosphamide|Given IV
214732970|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
214732971|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
214732972|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
214732973|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
214732974|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214732975|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
214732976|NCT07085468|DRUG|LY3549492|Administered orally
214732977|NCT07085468|DRUG|Placebo|Administered orally
214732978|NCT07094087|BIOLOGICAL|BE1116|A single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.
214732979|NCT07094087|BIOLOGICAL|FFP|A single dose of FFP will be administered as investigational product (IP) by IV infusion intraoperatively.
214732980|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
214732981|NCT06910813|GENETIC|DFT383|DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.
214732982|NCT07137741|BEHAVIORAL|FICare nursing method guided by Swanson's caring theory|"encompasses the following five dimensions: Understanding: A neonatologist provided a comprehensive explanation regarding the developmental progress of premature infants, potential complications, and essential aspects of nursing care to ensure the family gained a thorough understanding of the care requirements for premature infants.~Accompaniment: Two nursing guides provided essential support to parents of newborns in the NICU, helping to alleviate the anxiety and sense of helplessness among family members and fostering a relationship of trust between the medical staff and the families.~Help: A neonatal nurse played a guiding role in facilitating parental involvement in the daily care of premature infants, which encompassed feeding guidance, introduction of complementary foods, skin care, and related aspects.~Empowerment: A psychological counselor was assigned to provide psychological counseling and guidance to new parents, offering appropriate emotional support and assisting them in ac"
214732983|NCT07137611|BEHAVIORAL|Low Exercise|• Low-Intensity Continuous Training (LICT): Participants will run continuously for 24 minutes at 50-60% of their MAS without breaks.
214732984|NCT07137611|BEHAVIORAL|Moderate-Intensity Exercise|Moderate-Intensity Continuous Training (MICT): Participants will run at a speed corresponding to 70-80% of their MAS. The protocol consists of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants performed light jogging. This pattern totaled 24 minutes of exercise.
214732985|NCT07137611|BEHAVIORAL|HIIT Exercise|High-Intensity Interval Training (HIIT): Participants will run at 110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they will rest passively for 15 seconds and returned to their starting point. This will be repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets will be completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
214732986|NCT07088718|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
214732987|NCT07088718|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the reference.
214732988|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
214732989|NCT06794554|DRUG|Rezafungin Acetate|IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
214732990|NCT07070323|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
214732991|NCT07070323|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
214732992|NCT07070323|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
214732993|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
214732994|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
214732995|NCT06481228|DRUG|Olverembatinib|TKI
214732996|NCT06831734|DRUG|Concizumab|Participants will be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Alhemo is made at the physician's discretion before and independently from this study.
214732997|NCT07096167|BEHAVIORAL|Voucher for Afterschool Care|Intervention includes a voucher for afterschool care and enrollment assistance
214732998|NCT07099274|DRUG|lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib|lparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, q3w; Lenvatinib: 8 mg once daily for patients weighing \<60 kg, or 12 mg once daily for those weighing ≥60 kg, administered orally, continuous daily dosing； TACE: Administered 4-6 times, using a combination of anthracyclines, lipiodol, and microspheres. The procedure should be performed within one week before or after QL1706 administration.
214732999|NCT01394211|DRUG|anastrozole|Given PO
214733000|NCT01394211|DRUG|pazopanib hydrochloride|Given PO
214733001|NCT01394211|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
214733002|NCT07096063|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
214733003|NCT07096063|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the comparator.
214733004|NCT07096063|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure/comparator.
214733005|NCT07096063|DRUG|Sitagliptin|New use of sitagliptin dispensing claim is used as the comparator.
214733006|NCT07102446|OTHER|Opioid Stewardship Program|The Opioid Stewardship Program (OSP) includes pain and functional assessments, opioid prescription review and coordination, patient education, and counseling provided by trained pharmacists.
214733007|NCT07101627|DRUG|Hetrombopag Tablets|"Stage 1: After screening and enrollment, patients will receive oral administration of hetrombopag, 7.5 mg/day, for 14 days from the first day after the end of chemotherapy in this cycle.~Stage 2: Patients who met the inclusion criteria were randomized 1:1 to the experimental group and the control group after enrollment. Patients in the experimental group began to orally take hetrombopag 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle; patients in the control group began to orally take hetrombopag simulated tablets 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle. Randomization was stratified by concomitant immunotherapy (yes versus no) and chemotherapy with gemcitabine plus platinum (yes versus no)."
214733008|NCT07101796|DEVICE|continous positive airway pressure (CPAP)|using CPAP to treat OSA
214733009|NCT07101822|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
214733010|NCT07100899|OTHER|Dual task training|Dual motor task training for 30 minutes. The dual motor training was divided into two phases. The first part involved a single task condition in which the stroke patient was instructed to stand up from a seated position at a self-selected speed without the use of upper limb assistance. Cognitive and physical tasks, is the second part of training. In addition to a 30-minute selected physiotherapy program.
214733011|NCT07100899|OTHER|Task-specific training|Began with a highchair before switching to a low one. In addition to a 30-minute selected physiotherapy program.
214733012|NCT07100899|OTHER|Selected physiotherapy program|Consisting of trunk control, trunk stabilization, balance training and lower extremity strengthening exercises (primarily for the hip adductors and abductors) for 60 minutes.
214733013|NCT07101913|BIOLOGICAL|Incidence of acute kidney injury|"* Creatinine measurement before lymphodepletion chemotherapy, before CAR-T cells injection (day 0) and at day 1, day 3, day 5, day 7, day 10, day 14, day 21 and day 28.~* AKI according to 2012 KDIGO."
214733014|NCT07101913|OTHER|Describe risk factors in AKI occurrence.|"Comparison of caracteristics between participants with AKI and participants without AKI :~* Baseline caracteristics of participants : age, gender, BMI (Body mass index), medical history…~* Caracteristics of hematology disease : severity of lymphoma, previous treatments (chemotherapy, autologous/allogenic stem cell transplant), type of CAR-T cells (axi-cel, tisa-cel)~* Other adverse affects : cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS)~* Use of nephrotoxic medications Informations found in medical field."
214733015|NCT07101913|OTHER|Focus on patient with chronic kidney disease at baseline|Looking at the subgroup with chronic kidney disease at baseline : are the outcomes different in this population ? Efficacity of CAR-T ? More adverse effects ?
214733016|NCT07101913|OTHER|Long term evolution after treatment by CAR-T cells|Creatinine measurement 1 year after CAR-T treatment. Informations found in medical field.
214733017|NCT07101991|OTHER|Standard monitoring|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
214733018|NCT07101991|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
214733019|NCT07100626|DEVICE|BlueCheck|Caries Detection and Monitoring
214733020|NCT07100262|OTHER|Effortful swallow exercise|"The participants will be practiced effortful swallow exercises as follows:~When you are ready to swallow your saliva, squeeze your tongue against the roof of your mouth.~B) As you swallow squeeze all the muscles in your throat. Imagine you are trying to swallow a large tablet or a golf ball.~C) If it has been recommended by your speech and language therapist, this exercise may be repeated when eating and drinking.~Frequency of exercise:~Exercises will be two 30-minutes sessions of effortful swallow practice daily, 5 days/week.~For every patient: 4 sets (1 set = 8-12 repetitions) 5 days/week, for 18 weeks."
214733021|NCT07100262|DEVICE|Pulsed electromagnetic therapy|"The participants will receive pulsed electromagnetic therapy as the following:~Position of patient: supine lying position with head supported by pillow. Sleeve of device: above anterior neck area.~Parameters of application of device: according to programs for sarcopenia and muscular pain as the following:~Power: 30 GAUSS. Frequency: in first 6weeks: 5Hz - second 6weeks: 10Hz - last 6weeks: 15Hz. Time of session: 30 min. Sessions frequency: 3 sessions per week. Time of treatment course: 18 weeks."
214733022|NCT07101315|PROCEDURE|Laparoscopic Cholecystectomy|Standard four-port laparoscopic cholecystectomy was performed by a specialist or resident surgeon.
214733023|NCT07101497|DRUG|BN104 monotherapy|BN104 will be started at 200 mg or 300mg, to a target dose of 400mg, twice daily, orally, 28 days a cycle, for a total of 24 to 36 cycles . When used in combination with posaconazoles and voriconazole, the dose of BN104 should be reduced by 50%.
214733024|NCT07100561|OTHER|Extensive post discharge counselling and phone-based follow up|Counselling by their attending physicians plus Extensive post-discharge counselling from a study doctor/pharmacist/a trained nurse and telephone follow-ups in addition to their normal outpatient reviews. The telephone follow-ups will be weekly for the first 30 days and then 4 weekly till day 90.
214733025|NCT07100509|OTHER|Major Vascular Injury During Elective Thoracic Surgery|This exposure refers to patients who experienced major vascular injuries during elective thoracic surgery. Injuries involved central vessels such as the subclavian artery, brachiocephalic vein, superior vena cava, and innominate vein. No experimental intervention was applied. The study retrospectively evaluated the surgical management, transfusion requirements, preoperative planning, and clinical outcomes associated with these intraoperative events.
214733026|NCT06909422|BEHAVIORAL|Mobile Intervention for Biased Thinking|This intervention will be delivered via a mobile application.
214733027|NCT07101549|DRUG|R-Star001|"Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (R-Star001).~The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase."
214733028|NCT00024544|DRUG|anti-IL-4 monoclonal antibody (pascolizumab)|
214733029|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
214733030|NCT06535932|DEVICE|Amara View Minimal Contact Full Face Mask|The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
214733031|NCT06535932|DEVICE|F40 Minimal Contact Full Face Mask|The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
214733032|NCT06911723|BEHAVIORAL|Brief Activities|The activities will be completed online.
214733033|NCT07101081|DIAGNOSTIC_TEST|HER-2 Test|Samples from patients with gynecological tumors eligible to the study will be retrospectively identified and the paraffin slides will be sent to central laboratory to perform HER2 IHC testing using the automated protocols (Dako and Ventana). Expert pathologists will select primary tumor samples from surgery or excisional biopsies with enough material to perform HER2 testing using both antibodies without exhausting the cancer tissue. The entire cohort will be tested with both Dako HercepTest and Roche Ventana 4B5 antibody using gastric cancer and breast cancer criteria for positivity (3+, 2+ and 1+, 0).
214733034|NCT06756685|OTHER|Core Strengthening Exercises|The Core Strengthening Program participants will have supervised gym-based sessions for 8 weeks. In the first 4 weeks , participants will attend two 1 hour training sessions, followed by self-selected one or two sessions per week. The session will begin with 20min of aerobic conditioning of walking or running on a treadmill, starting at 65% and moving to 85% of HR max. The 5 key elements of focus are i. Centering ii. Breathing iii. Head and neck placement iv. Shoulder placement v. Chest wall placement
214733035|NCT06756685|OTHER|Motor Control Training|"Participants in Motor Control group will receive two physiotherapy sessions of 1hour / week in the first 4 weeks, during stage 1. i. Abdominal drawing-in maneuver (ADIM) : isometric contraction of the local stability muscles (e.g., lumbar multifidus, transversus abdominis) in minimally loading positions (supine lying, quadruped, sitting, and standing) by maintaining a neutral spine while maintaining normal breathing. During Phase 2, One 1 hour session / week in the second 4 weeks.~Activation and facilitation of transversus abdominis, lumbar multifidus and pelvic floor motor control(36).Exercises target the transversus abdominis, multifidus and pelvic floor muscles plus postural correction to restore optimal motor control during non-weight-bearing activities. Exercises and progressions will follow previous protocols of motor control exercise."
214733036|NCT07102186|DRUG|use of adapalene gel 0.1% and hyaluronic acid at bedtime|in this intervention a combination of adapalene gel 0.1% and hyaluronic acid will be used
214733037|NCT07102186|DRUG|use of adapalene gel 0.1% once daily at bedtime|in this intervention involves the use of adapalene gel 0.1% once daily only topically at bedtime
214733038|NCT07100808|PROCEDURE|Using the tunnel technique in the treatment of gingival recession|Microsurgical periodontal instruments were used during surgical procedures. In this study, specially developed tunnel instruments (Helmunt Zepf, Seitingen-Oberflacht, Germany) were used to mobilize the gingivo-papillary unit and prepare the supraperiosteal tunnel bed. After passing the coronal edge of the alveolar bone with the tunnel instrument placed in the soft tissue, it was advanced towards the apical mucogingival junction with small, circular movements. This procedure was repeated by entering from the sulcus of each tooth. Care was taken to ensure that the prepared flaps were in the same layer and opened towards each other. In the interdental areas, the papillary complex was carefully separated from the periosteum and mobilized in the buccal direction. Thus, mobilization of the entire buccal soft tissue complex was achieved in the coronal direction. After these procedures, it was checked whether the flap covered the recession areas without tension.
214733039|NCT06287047|PROCEDURE|Epidural analgesia|Epidural analgesia alone or with dural puncture with different sizes of spinal needles
214733040|NCT04443842|BEHAVIORAL|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
214733041|NCT01171313|DRUG|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
214733042|NCT01171313|DRUG|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
214733043|NCT01171313|DRUG|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
214733044|NCT01171313|DRUG|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
214733045|NCT00404638|DRUG|Desmopresin|
214733046|NCT00404638|BEHAVIORAL|Paula Method of Circular Muscle Exercise|
214733047|NCT00683501|DRUG|DNB-001|four dosages of DNB-001, one placebo dosage
214733048|NCT07140861|OTHER|Conventional|"patients will receive conventional therapy that include~1. Short foot exercises~2. Towel-curl exercise~3. Heel raise exercise~4. Calf stretch"
214733049|NCT07140861|OTHER|Experimental|"Core stability exercises:~The training programs will last 6 weeks and comprise 3 training sessions per week. Each training session lasted 30 min, starting with a brief, standardized warm-up program mainly consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, research group will conduct the big 3 exercises as described by McGill (Mcgill, 2001). These include the curl-up, side bridge, and quadruped position. In other words, every single training session consisted of frontal, dorsal, and lateral core exercises. Training intensity will be progressed and individually increased over the 6-week training program by modulating lever lengths, movement velocity"
214733050|NCT03285061|DEVICE|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
214733051|NCT07138651|OTHER|Aspiration care bundle|Evidence-based aspiration care protocol
214733052|NCT06949150|DIAGNOSTIC_TEST|coronary angiography|Invasive coronary angiography (ICA), with or without percutaneous coronary intervention (PCI), intravascular ultrasound (IVUS), optical coherence tomography (OCT), or fractional flow reserve (FFR).
214733053|NCT06949150|OTHER|Medical therapy|Patients do not undergo invasive coronary angiography (ICA), recieving medical treatment, lifestyle intervention or further test
214733054|NCT05829811|DEVICE|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
214733055|NCT03128307|DEVICE|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
214733056|NCT06950021|DEVICE|Magnetic seed|All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.
214733057|NCT06948890|OTHER|Music intervention|"Subjects will listen to two songs of their choosing. They will be prompted: Please choose two songs that you really enjoy and that make you feel relaxed or take away stress."
214733058|NCT06948890|OTHER|Silence|Subjects will listen to 10 minutes of silence through high quality noise canceling headphones
214733059|NCT07149103|OTHER|Percutaneous Tibial Nerve Stimulation|By wearing the Confidanz Smart Patch, the Tibial Nerve will be stimulated
214733060|NCT07149103|OTHER|Placebo|No active stimulation will be provided
214733061|NCT07147959|DRUG|[89Zr]Zr-CIT|radiolabelled CIT-013
214733062|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training is an adaptive N-back task in which participants respond to colors and/or shapes.
214733063|NCT07147894|BEHAVIORAL|Gamified N-back training|Participants train on a gamified version of the N-back task, specifically, players control an astronaut that collects resources (target stimuli) needed to feed a colony and keep the technology working, while avoiding non-targets and other obstacles.
214733064|NCT07147894|BEHAVIORAL|Multiple Domain Training|Participants train on a gamified versions of the N-back task, Complex span, Set-shifting and Inhibitory control task.
214733065|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training trains a visual, adaptive N-back task in which participants respond to colors and/or shapes.
214733066|NCT07147894|BEHAVIORAL|Coaching Session|Participants in coaching conditions receive weekly, motivational coaching sessions via videoconference to (i) provide encouragement taking into account individual training performance and self-reported engagement (strength-based feedback), (ii) set realistic goals for training (time management, scheduling, and session completion plan, performance goals) while emphasizing autonomy and choice, and (iii) re-explain task and provide corrective feedback as needed.
214733067|NCT07148141|OTHER|Ovarian stimulation|Ovarian stimulation before oocytes retrieval
214733068|NCT06948409|DRUG|Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])|The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.
214733069|NCT06949579|BIOLOGICAL|blood sampling for DNA|Blood sampling for DNA and serum and plasma colection and PBMC
214733070|NCT07147712|BEHAVIORAL|Psychological Group Intervention|6-session psychological group intervention, delivered once per week over six weeks. The intervention is designed to promote well-being and improve the quality of social relationships. It includes psychoeducational content, experiential exercises, and guided group discussions focused on emotional expression, social connection, and mutual support. A follow-up session will be offered after 4 weeks. Sessions will be led by trained psychologists and conducted in a university setting.
214733071|NCT07147257|BIOLOGICAL|CHS-1420|Dose of 40 mg will be subcutaneously administered to participants in
214733072|NCT07147257|BIOLOGICAL|HUMIRA®|Dose of 40 mg will be subcutaneously administered to participants in
214733073|NCT06132529|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
214733074|NCT06132529|OTHER|Speech Sample|Recorded reading aloud of pre-written words and sentences
214733075|NCT06132529|OTHER|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
214733076|NCT02621021|BIOLOGICAL|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
214733077|NCT02621021|DRUG|Pembrolizumab|(Cohort 1, Arm 2 ,Cohort 2 and Cohort 3, Arm 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes.
215030566|NCT02402647|BEHAVIORAL|Exposure Therapy (ET)|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
215030567|NCT05724771|DRUG|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
214733078|NCT02621021|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
214733079|NCT02621021|DRUG|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
214733080|NCT02621021|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
214733081|NCT04685408|BEHAVIORAL|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
214733082|NCT04685408|BEHAVIORAL|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
214733083|NCT02051088|PROCEDURE|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
214733084|NCT02051088|PROCEDURE|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
214733085|NCT02051088|DEVICE|drug-coated balloons and/or drug-eluting stents|
214733086|NCT06366425|DIAGNOSTIC_TEST|Blood sample then fibroscan|"The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan."
214733087|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
214733088|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
214733089|NCT05501405|OTHER|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
214733090|NCT06771869|DIAGNOSTIC_TEST|Sodium balance|cumulative sodium balance and cumulative fluid balance will be estimated in the first three days after admission
215030568|NCT06258382|OTHER|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
215030569|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
215030570|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
214733091|NCT06797076|BEHAVIORAL|Health enSuite Headache|"The program consists of treatment modules delivered over 8 weeks. Modules include topics such as Headaches and Triggers, Relaxation, Breathing, Changing Thoughts, Imagery, Problem Solving, Nutrition, Sleep, Exercise, Medication, and more. Each module features sections like Goals, Getting Started, Let's Talk, and a Quiz, with Let's Practice in four modules. Intervention participants track headaches using a structured tracker to log impacts, daily events (e.g., exposure, strategies, medication), and notes. Control group participants track headaches only at baseline, two months, and five months post-randomization. Weekly reminders (nudges) encourage app usage, with the same frequency for all users. Reports summarizing daily headache data are available to participants."
214733092|NCT05442060|BIOLOGICAL|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
214733093|NCT05442060|DRUG|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
214733094|NCT06793449|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
214733095|NCT06793449|BIOLOGICAL|ASCT|Autologous stem cell infusion
214733096|NCT06959160|OTHER|Atlanto-occipital manipulation|Participants in the first group received atlanto-occipital manipulation. The patient was positioned in a supine position, with the head rotated to one side. The therapist placed the middle and ring fingers of one hand on the patient's mastoid process, while the palm of the other hand made contact with the patient's jawline and cheek. A gentle traction force was applied to the cranial region using both hands. When the therapist sensed joint tension, a high-velocity, low-amplitude thrust was delivered in the direction of the traction with a slight rotational force. The procedure was performed bilaterally and lasted approximately 5 minutes.
214733097|NCT06959160|OTHER|Cervical mobilization|Participants in the second group underwent Grade II-III cervical mobilization techniques, administered over a period of 10 minutes. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
214733098|NCT06959160|OTHER|Trigger point therapy|Participants in the third group received trigger point therapy, which included ischemic compression followed by myofascial stretching on the upper trapezius muscle. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
214733099|NCT06114043|OTHER|Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus|60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.
214733100|NCT06114043|OTHER|Operation for mild to moderate hallux valgus|60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
214733101|NCT05157685|DRUG|Azithromycin Oral Tablet|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
214733102|NCT05157685|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
214733103|NCT04547816|PROCEDURE|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
214733104|NCT04547816|PROCEDURE|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
214733105|NCT04547816|BEHAVIORAL|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
214733106|NCT04547816|BEHAVIORAL|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
214733107|NCT03662685|OTHER|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
214733108|NCT03662685|DRUG|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
214733109|NCT03662685|DEVICE|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
214733110|NCT03738878|DRUG|Valsartan|oral valsartan
214733111|NCT03738878|DRUG|LCZ696|oral LCZ696
214733112|NCT03738878|DRUG|Bradykinin|Intra-arterial bradykinin at three graded doses
214733113|NCT03738878|DRUG|Substance P|Intra-arterial substance P at three graded doses
214733114|NCT03738878|DRUG|BNP|Intra-arterial BNP at three graded doses
214733115|NCT03738878|DRUG|Sitagliptin|oral sitagliptin
214733116|NCT06198959|DEVICE|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
214733117|NCT06198959|DEVICE|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
214733118|NCT06198959|DEVICE|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
214733119|NCT06198959|DEVICE|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
214733120|NCT06198959|DEVICE|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
214733121|NCT05810402|BIOLOGICAL|Liquid Biopsy|"30mL blood sample:~* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
214733122|NCT05611242|PROCEDURE|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
214733123|NCT05611242|PROCEDURE|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
214733124|NCT05611242|PROCEDURE|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
214733125|NCT06845345|OTHER|early time restricted Mediterranean diet|Participants will start with a calorie restricted Mediterranean diet, with an eating window between 8AM till 6PM (early time-restricted eating) for a period of six months. Participants are asked to stop eating at 6PM. This results in a daily fasting window of approximately 14 hours. A daily caloric intake of 500 kcal compared to the calculated energy requirement is assumed to stimulate weight loss.
214733126|NCT06845345|DRUG|Mysimba|Participants will take Mysimba twice daily at a total dose of 32 mg/360 mg naltrexone/bupropion per day for a duration of six months. The dosage will be built up in the first month following the stepped care approach used in the SmPC. Participants receive usual care, including the advice of 60 minutes of exercise per day and standard dietary recommendations according to the guidelines for the Dutch population.
214733127|NCT02632344|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
214733128|NCT02171104|BIOLOGICAL|Stem Cell Transplantation|Infusion given on Day 0
214733129|NCT02171104|DRUG|IMD Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan"
214733130|NCT02171104|DRUG|Osteopetrosis Only Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa"
214733131|NCT02171104|DRUG|Osteopetrosis Haploidentical Only Preparative Regimen|"* Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine"
214733132|NCT02171104|DRUG|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
214733133|NCT02171104|DRUG|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
214733134|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
214733135|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
214733136|NCT04065295|DRUG|BI 1356225|Oral Dose
214733137|NCT04065295|DRUG|Placebo|Oral dose
214733138|NCT05509699|DRUG|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
214733139|NCT05509699|DRUG|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
214733140|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
214733141|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
214733142|NCT04248127|OTHER|Honey sweetened yogurt|2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
214733143|NCT04248127|OTHER|Sugar sweetened yogurt|sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
214733144|NCT01980381|OTHER|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
214733145|NCT05957549|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
214733146|NCT05706909|DEVICE|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
214733147|NCT06525389|DRUG|Liposomal Amphotericin B (LAmB)|Antifungal dosed at 10 mg/kg/day IV x one single dose.
214733148|NCT06525389|DRUG|Flucytosine (5FC)|Antifungal dosed at 25mg/kg oral 3x daily.
214733149|NCT06525389|DRUG|Flucytosine (5FC) placebo pill|Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
214733150|NCT06525389|DRUG|Deoxycholate Amphotericin B (DAmB)|Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
214733151|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
214733152|NCT02474368|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|
214733153|NCT02474368|DRUG|Cisplatin|
214733154|NCT02474368|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
214733155|NCT06057207|DIAGNOSTIC_TEST|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
214733156|NCT06057207|DIAGNOSTIC_TEST|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
214733157|NCT06057207|OTHER|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.
214733158|NCT06057207|OTHER|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic or laparotomic dehiscence, wound/local infection, postoperative bleeding, reoperation and nonsurgical site complications: sepsis, pneumonia, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure, postoperative delirium. Length of ICU and overall hospital stay with after discharge from hospital will be documented.
214733159|NCT04076579|DRUG|Olaparib|Olaparib taken by mouth twice daily
214733160|NCT04076579|DRUG|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
214733161|NCT05067764|PROCEDURE|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
214733162|NCT05067764|PROCEDURE|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
214733163|NCT03871075|DEVICE|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
214733164|NCT03871075|BEHAVIORAL|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
214733165|NCT03871075|DEVICE|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
214733166|NCT03871075|BEHAVIORAL|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
214733167|NCT06309550|DIAGNOSTIC_TEST|exercise test|exercise test
214733168|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
214733169|NCT06481150|OTHER|Placebo|Placebo
214733170|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
214733171|NCT04809467|DRUG|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
214733172|NCT04809467|DRUG|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
214733173|NCT04884802|PROCEDURE|Tight blood pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
214733174|NCT04884802|PROCEDURE|Routine blood pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
214733175|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
214733176|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
214733177|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
214733178|NCT05031182|PROCEDURE|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
214733179|NCT05031182|PROCEDURE|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
214733180|NCT05890599|BEHAVIORAL|Yoga Therapy|"The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume."
214733181|NCT05890599|BEHAVIORAL|Health Education|Health education courses are conducted on-site once a week for 90 minutes over a 12-week period by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
214733182|NCT06464679|BIOLOGICAL|anti-CD19 CAR NK cells|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
215030571|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
214733183|NCT06013449|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|Pulsed Electromagnetic Field (PEMF) Device BEMER Device consist of a total body mat (B. BODY) plus a targeted pelvic mat (B.PAD), and a Control Unit which powers the device and logs usage. Both B.BODY and B.PAD must be plugged into the Control Unit simultaneously and activated individually. B. Body must be placed on a flat surface (i.e. bed, floor, reclining chair etc.) for best results.
214733184|NCT06013449|DEVICE|Sham Pulsed Electromagnetic Feild (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
214733185|NCT06397131|COMBINATION_PRODUCT|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.
214733186|NCT05534126|PROCEDURE|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
214733187|NCT05534126|PROCEDURE|Placebo|Sham
214733188|NCT06631820|DIETARY_SUPPLEMENT|Epicatechin extract|In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
214733189|NCT02170558|DEVICE|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
214733190|NCT02911337|DIETARY_SUPPLEMENT|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
214733191|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
214733192|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
214733193|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
215030572|NCT01374854|BIOLOGICAL|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
215030573|NCT01374854|DRUG|traditional therapy|exogenous insulin injection daily
214733194|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
214733195|NCT00050570|BEHAVIORAL|Web-based intervention to reduce eating disorder risk factors|
214733196|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
214733197|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
214733198|NCT02125812|OTHER|scaling and root planing|scaling and root planing
214733199|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
214733200|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
214733201|NCT02966106|DEVICE|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
214733202|NCT02966106|OTHER|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
214733203|NCT02362256|DRUG|Naltrexone|
214733204|NCT02362256|DRUG|Clonidine|
214733205|NCT02362256|DRUG|Lorazepam|
214733206|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
214733207|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
214733208|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
214733209|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
214733210|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
214733211|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
214733212|NCT02890940|BEHAVIORAL|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
214733213|NCT06097299|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214733214|NCT06097299|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214733215|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
215030574|NCT04197583|DEVICE|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
214733216|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
214733217|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
214733218|NCT06548074|BEHAVIORAL|H-PACE Behavioral Intervention|Participate in the H-PACE program
214733219|NCT06548074|OTHER|Accelerometer|Wear an accelerometer
214733220|NCT06548074|OTHER|Questionnaire Administration|Ancillary studies
214733221|NCT06548074|OTHER|Supportive Care|Parents may participate in an optional virtual peer support group
214733222|NCT00236210|BEHAVIORAL|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
214733223|NCT00236210|BEHAVIORAL|VIP program|Risk assessment, lifestyle counselling, exercise program
214733224|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
214733225|NCT03898752|DIETARY_SUPPLEMENT|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
214733226|NCT00949806|DRUG|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
214733227|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
214733228|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
214733229|NCT05815758|DRUG|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
214733230|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
214733231|NCT03837301|PROCEDURE|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
214733232|NCT01924260|DRUG|alisertib|Given PO
214733233|NCT01924260|DRUG|gemcitabine|Given IV
214733234|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
214733235|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
214733236|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
214733237|NCT03682042|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
215030575|NCT06355297|BEHAVIORAL|Education about pelvic floor|The three educational sessions will last 60 minutes, as follows: session1, anatomy of pelvic floor; session2, function and dysfunction of pelvic floor; session3, risk factor for pelvic floor dysfunctions.
214733238|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
214733239|NCT02987205|DEVICE|Restylane|NLF Correction
214733240|NCT04803006|BIOLOGICAL|TCD601|Investigational Product
214733241|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
214733242|NCT06388200|GENETIC|Sub-Retinal Administration of OCU400-301|Sub-Retinal Administration of OCU400-301
214733243|NCT03057106|DRUG|Durvalumab|MEDI4736
214733244|NCT03057106|DRUG|Tremelimumab|Tremelimumab
214733245|NCT03057106|DRUG|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
214733246|NCT04675632|PROCEDURE|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
214733247|NCT06113471|DRUG|Povorcitinib|Oral, Tablet
214733248|NCT06113471|DRUG|Placebo|Oral, Tablet
214733249|NCT06436599|OTHER|plane block with %0.25 30 ml bupivacaine|evaluation of the efficacy of two different plan blocks for postoperative analgesia
214733250|NCT03292835|DEVICE|LeiProtect®|Filmogenic dressing gel
214733251|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
214733252|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
214733253|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
214733254|NCT02627196|DEVICE|BAROSTIM NEO® System|
214733255|NCT02627196|DRUG|Medical Management|
214733256|NCT02088736|DEVICE|Intraosseous|
214733257|NCT02088736|DEVICE|Intravenous|
214733258|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
214733259|NCT00633425|DRUG|GLIMEPIRIDE|
214733260|NCT05623059|DRUG|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
214733261|NCT02362594|BIOLOGICAL|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
214733262|NCT02362594|DRUG|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
214733263|NCT04167514|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
214733264|NCT04167514|DRUG|Placebo|Albumin solution administered intravenously
214733265|NCT05711693|DEVICE|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
214733266|NCT05711693|PROCEDURE|Blood pressure and heart rate measurement|"To all patients:~\- blood pressure and heart rate will be measured"
214733267|NCT05711693|DEVICE|carotid to femoral PWW measurement|"To all patients:~\- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
214733268|NCT05711693|PROCEDURE|Questionnaire completion|All patients will complete a questionnaire of acceptability
214733269|NCT06528496|BIOLOGICAL|DANYELZA|DANYELZA is a humanized monoclonal antibody of the IgG1 subclass
214733270|NCT06528496|BIOLOGICAL|Sargramostim|Yeast derived recombinant human Sargramostim (GM-CSF)
214733271|NCT06528496|DRUG|Cytoxan|Cyclophosphamide is an alkylating agent related to nitrogen mustard
214733272|NCT06528496|DRUG|Topotecan|Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
214733273|NCT06528496|DRUG|Vincristine|Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
214733274|NCT06528496|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic
214733275|NCT06528496|DRUG|Ifosfamide|Ifosfamide is a structural analogue of cyclophosphamide
214733276|NCT06528496|DRUG|Etoposide|Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
214733277|NCT06528496|DRUG|Carboplatin|Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
214733278|NCT06528496|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
214733279|NCT06528496|DRUG|Temozolomide|Temozolomide is administered intravenously
214733280|NCT04305041|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214733281|NCT04305041|BIOLOGICAL|Quavonlimab|Administered via IV infusion at a specified dose on specified days
214733282|NCT04305041|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
214733283|NCT04305041|DRUG|Lenvatinib|Administered via oral capsules at a specified dose on specified days
214733284|NCT04305041|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
214733285|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
214733286|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
214733287|NCT04319835|DEVICE|OnZurf Probe|
214733288|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
214733289|NCT06156306|BEHAVIORAL|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
214733290|NCT06156306|BEHAVIORAL|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
214733291|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 1|single infusion of rapcabtagene autoleucel
214733292|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 2|single infusion of rapcabtagene autoleucel
214733293|NCT06581198|OTHER|Standard of Care|The treatment regimen must be in line with KDIGO guidelines for treatment of class III/IV LN.
214733294|NCT00741767|DRUG|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
214733295|NCT03991936|DRUG|Placebos|Normal saline intralesional injection
214733296|NCT03991936|DRUG|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
214733297|NCT03991936|DRUG|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
214733298|NCT03991936|DRUG|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
214733299|NCT03991936|DRUG|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
214733300|NCT04905810|DRUG|Azacitidine|Given IV
214733301|NCT04905810|DRUG|Decitabine|Given IV
214733302|NCT04905810|DRUG|Venetoclax|Given PO
214733303|NCT00551967|PROCEDURE|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
214733304|NCT00939055|DEVICE|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
214733305|NCT00939055|PROCEDURE|Sham procedure|False procedure
214733306|NCT03139435|PROCEDURE|Biopsy|Undergo skin biopsy
214733307|NCT03139435|OTHER|Questionnaire Administration|Ancillary studies
214733308|NCT03139435|DIAGNOSTIC_TEST|Ultrasound Tomography|Undergo peripheral nerve ultrasound
214733309|NCT00584987|DRUG|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
214733310|NCT00584987|DRUG|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
214733311|NCT00584987|DRUG|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
214733312|NCT00584987|DRUG|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
214733313|NCT05997173|OTHER|Control|Investigation of scale of control
214733314|NCT05997173|OTHER|Non erosive OLP|Investigation of cale of non erosive OLP patients
214733315|NCT05997173|OTHER|Erosive OLP|Investigation of cale of erosive OLP patients
214733316|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
214733317|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
214733318|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
214733319|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
214733320|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
214733321|NCT02542566|PROCEDURE|Physiotherapy rehabilitation|Physiotherapy rehabilitation
214733322|NCT03258593|DRUG|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
214733323|NCT03258593|DRUG|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
214733324|NCT03258593|DRUG|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
214733325|NCT03258593|DRUG|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
214733326|NCT03258593|PROCEDURE|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
214733327|NCT03258593|PROCEDURE|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
214733328|NCT03258593|PROCEDURE|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
214733329|NCT03258593|DIAGNOSTIC_TEST|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
214733330|NCT03258593|DIAGNOSTIC_TEST|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
214733331|NCT03258593|DIAGNOSTIC_TEST|CT|Computed tomography (CT) at screening and every 12 months while on study.
214733332|NCT03258593|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
214733333|NCT06136195|DRUG|Mavoglurant|The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
214733334|NCT04076904|DIAGNOSTIC_TEST|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
214733335|NCT03857464|DIAGNOSTIC_TEST|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
214733336|NCT03857464|DIAGNOSTIC_TEST|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
214733337|NCT05318183|OTHER|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
214733338|NCT05318183|OTHER|White Bread (control)|Standardized white bread (128 g daily)
214733339|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
214733340|NCT06643988|BEHAVIORAL|MemFlex|MemFlex employs cognitive training exercises in self-led sessions to improve 1) switching between specific and general AMs, 2) access to positive AMs, and 3) vividness of positive AMs.
214733341|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
214733342|NCT05812807|BIOLOGICAL|Pembrolizumab|Given IV
214733343|NCT05812807|OTHER|Patient Observation|Undergo observation
214733344|NCT05812807|PROCEDURE|Biopsy|Undergo biopsy
214733345|NCT05812807|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214733346|NCT05812807|OTHER|Questionnaire Administration|Ancillary studies
214733347|NCT05812807|OTHER|Quality-of-Life Assessment|Ancillary studies
214733348|NCT06801639|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
214733349|NCT06801639|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
214733350|NCT04228276|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
214733351|NCT06431126|OTHER|Nature and animal-assisted activities|Supervised activities on a farm, 2 half day/week for 12 weeks
214733352|NCT03527472|DRUG|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
214733353|NCT03527472|DRUG|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
214733354|NCT06803771|DEVICE|Avantect Pancreatic Cancer Test|Avantect test
214733355|NCT03825536|DRUG|Oral Methamphetamine|An initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
214733356|NCT03825536|OTHER|Placebo oral capsule|One placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
214733357|NCT02498600|BIOLOGICAL|Ipilimumab|Given IV
214733358|NCT02498600|BIOLOGICAL|Nivolumab|Given IV
214733359|NCT05602363|DRUG|Docirbrutinib|oral tablet, twice daily
214733360|NCT04269239|BEHAVIORAL|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
214733361|NCT04269239|BEHAVIORAL|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
214733362|NCT06563596|DRUG|Zanubrutinib|Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
214733363|NCT06563596|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
214733364|NCT06563596|DRUG|Epcoritamab|Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
214733365|NCT06285071|DRUG|Concizumab|Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
214733366|NCT06217822|DRUG|225Ac-PSMA-Trillium (BAY3563254)|Intravenous slow injection on Day 1 of a 6 week treatment cycle.
214733367|NCT05999435|DRUG|LAU-7b for 3 cycles|Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.
214733368|NCT05999435|DRUG|LAU-7b for 1 cycle, then placebo|One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.
214733369|NCT05999435|OTHER|Placebo for 3 cycles|Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of14 days
214733370|NCT05085275|DRUG|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
214733371|NCT05085275|DRUG|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
214733372|NCT06441643|DRUG|AR-17043 Ophthalmic Solution|Investigational monotherapy supplied in three concentration levels: low, medium, high
214733373|NCT06441643|DRUG|PG043 Ophthalmic Solution|Investigational fixed dose combination supplied in two concentration levels: low and high
214733374|NCT06441643|DRUG|Latanoprost 0.005% Ophthalmic Solution|Marketed monotherapy
214733375|NCT06441643|DRUG|Netarsudil 0.02% Ophthalmic Solution|Marketed monotherapy
214733376|NCT06441643|DRUG|Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution|Marketed fixed dose combination
214733377|NCT06441643|DRUG|AR-17043 Vehicle|Placebo comparator
214733378|NCT04134598|RADIATION|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
214733379|NCT04134598|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
214733380|NCT04039243|BEHAVIORAL|Being Brave|Up to 12 weekly sessions
214733381|NCT04039243|OTHER|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
214733382|NCT03713151|OTHER|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
214733383|NCT00058006|DRUG|celecoxib|
214733384|NCT00058006|PROCEDURE|adjuvant therapy|
214733385|NCT01081262|BIOLOGICAL|Bevacizumab|Given IV
214733386|NCT01081262|DRUG|Capecitabine|Given PO
214733387|NCT01081262|DRUG|Carboplatin|Given IV
214733388|NCT01081262|OTHER|Laboratory Biomarker Analysis|Correlative studies
214733389|NCT01081262|DRUG|Oxaliplatin|Given IV
214733390|NCT01081262|DRUG|Paclitaxel|Given IV
214733391|NCT01081262|OTHER|Quality-of-Life Assessment|Ancillary studies
214733392|NCT04331522|DIAGNOSTIC_TEST|Oral provocation test|Titrated provocation with allergen
214733393|NCT06575387|PROCEDURE|Partogram|to evaluate the utility of partogram in management and progress of active labor in Primigravidae.
214733394|NCT06247384|DEVICE|Hypotension Prediction Index Hemodynamic Monitoring|The application of the perioperative hemodynamic management according to the hypotension prediction index algorithm.
214733395|NCT04979429|BEHAVIORAL|Perioperative Pain Self-management (PePS)|4 sessions of telephone CBT-based pain self-management.
214733396|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
214733397|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
214733398|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
214733399|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
214733400|NCT05841355|OTHER|Educate|Education sessions
214733401|NCT05841355|OTHER|Empower|Empowerment sessions
214733402|NCT03493048|DRUG|Irinotecan|Irinotecan 130 mg/m²
214733403|NCT03493048|DRUG|Cetuximab|Cetuximab, iv, 500mg/m2
214733404|NCT03493048|DRUG|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
214733405|NCT03493048|DRUG|Oxaliplatin|oxaliplatin 85 mg/m²
214733406|NCT03493048|DRUG|Leucovorin|leucovorin 200 mg/m²
214733407|NCT04972825|BEHAVIORAL|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
214733408|NCT05664113|DRUG|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
214733409|NCT06206421|DRUG|Fezolinetant|oral
214733410|NCT06206421|DRUG|Placebo|oral
214733411|NCT00949104|DRUG|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
214733412|NCT00949104|DRUG|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
214733413|NCT06128733|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
214733414|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
214733415|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
214733416|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
214733417|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
214733418|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
214733419|NCT06128733|BIOLOGICAL|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
214733420|NCT06128733|BIOLOGICAL|MenABCYW conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
214733421|NCT04453722|DEVICE|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
214733422|NCT04453722|DEVICE|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
214733423|NCT02691923|DRUG|Fluorescein|
214733424|NCT02691923|DRUG|Fluorescein + ALA|
214733425|NCT05403385|DRUG|inupadenant|Adenosine 2a receptor antagonist
214733426|NCT05403385|DRUG|Placebo|matched placebo capsule to inupadenant
214733427|NCT05403385|DRUG|Carboplatin|standard of care chemotherapeutic, alkylating agent
214733428|NCT05403385|DRUG|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
214733429|NCT03947099|DRUG|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
214733430|NCT04849676|OTHER|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
214733431|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
214733432|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
214733433|NCT01263470|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
214733434|NCT01263470|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
214733435|NCT01263470|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
214733436|NCT01263470|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
214733437|NCT01263470|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
214733438|NCT01263470|DRUG|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
214733439|NCT00610714|DRUG|AZD0530|oral once daily dose
214733440|NCT00610714|DRUG|Carboplatin|intravenous injection
214733441|NCT00610714|DRUG|Paclitaxel|intravenous infusion
214733442|NCT05275127|OTHER|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
214733443|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
214733444|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
214733445|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
214733446|NCT04303169|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214733447|NCT04303169|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
214733448|NCT04303169|BIOLOGICAL|Gebasaxturev|Administered via IT injection at a specified dose on specified days
214733449|NCT04303169|BIOLOGICAL|MK-4830|Administered via IV infusion at a specified dose on specified days
214733450|NCT04303169|BIOLOGICAL|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214733451|NCT04303169|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
214733452|NCT01327573|DRUG|eculizumab|"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
214733453|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
214733454|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
214733455|NCT01748006|OTHER|Standard of care therapy for severe decompensated heart failure|
214733456|NCT03923829|DRUG|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
214733457|NCT03923829|PROCEDURE|scaling and root planing|scaling and root planing
214733458|NCT00712712|DRUG|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
214733459|NCT00712712|DRUG|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
214733460|NCT00712712|OTHER|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~* The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~* the background morphine analgesic treatment during the last 24 hours,~* the morphine analgesic treatment taken during painful attacks,~* the possible undesirable effects of morphine treatment.~* the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
214733461|NCT00712712|PROCEDURE|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
214733462|NCT00712712|PROCEDURE|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
214733463|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
214733464|NCT05609500|BEHAVIORAL|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
214733465|NCT05490043|DRUG|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
214733466|NCT05848557|BEHAVIORAL|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
214733467|NCT06527456|OTHER|participation of the general practitioner|participation of the general practitioner in encouraging cervical cancer screening
214733468|NCT03698214|OTHER|reversed shock index < 1|Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
214733469|NCT03698214|OTHER|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
214733470|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
214733471|NCT05722288|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214733472|NCT05722288|OTHER|Informational Intervention|Receive nutritional counseling
214733473|NCT05722288|OTHER|Quality-of-Life Assessment|Ancillary studies
214733474|NCT05722288|OTHER|Questionnaire Administration|Ancillary studies
214733475|NCT05722288|BEHAVIORAL|Short-Term Fasting|Undergo time-restricted eating
214733476|NCT05674838|OTHER|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
214733477|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214733478|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
214733479|NCT06639958|BEHAVIORAL|Compliance Monitoring|Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits
214733480|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
214733481|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
214733482|NCT06639958|OTHER|Media Intervention|View MIPE program videos
214733483|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
214733484|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
214733485|NCT06639958|DRUG|Mercaptopurine|Given PO
214733486|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
214733487|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
214733488|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminders
214733489|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Manually activate daily smartphone reminders with successive alerts (using the snooze function)"
214733490|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
214733491|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
214733492|NCT06364943|OTHER|with/without dry eye syndrome|compare tear ferning structure between dry eye and non-dry eye patients
214733493|NCT06821802|DIETARY_SUPPLEMENT|Moltein PURE Protein Powder|80 g protein supplementation per day (two bottles, each containing 40 g protein)
214733494|NCT06821802|BEHAVIORAL|Fluid restriction|total daily fluid intake to a maximum of 1000 ml
215030576|NCT01568879|OTHER|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
214733495|NCT06177535|DIETARY_SUPPLEMENT|Kavalactones|Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
214733496|NCT06177535|DRUG|Placebo|Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
215030577|NCT01568879|OTHER|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
215030578|NCT03637348|DEVICE|TrueTear|Ues of TrueTear neurostimulator
214733497|NCT06378099|OTHER|Patient guided and followed by the pharmacist|"The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~This training will cover both pharmacological and non-pharmacological aspects of MA management. The pharmacological component will emphasize the appropriate selection and safe use of nonprescription drugs, with a focus on identifying potential drug interactions, contraindications, and moderate and serious ADRs. Pharmacy staff will also be equipped with tools to apply proper criteria for referral to a GP when necessary.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Consensus-based Protocols."
214733498|NCT05081245|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
214733499|NCT05081245|DRUG|ML-004 Placebo|Participants will receive matching placebo once daily.
214733500|NCT05978557|OTHER|Biospecimen collection|Biospecimen will be collected during surgery.
214733501|NCT06053281|DRUG|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
214733502|NCT06053281|OTHER|Placebo|Placebo
214733503|NCT05044351|DEVICE|Fluobeam LX|See arm description
214733504|NCT05044351|OTHER|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
214733505|NCT03833349|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
214733506|NCT03833349|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
214733507|NCT03833349|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
214733508|NCT02432690|DRUG|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
214733509|NCT04691531|DEVICE|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
214733510|NCT04691531|DEVICE|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
214733511|NCT05544214|DRUG|CKD-371|PO
214733512|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
214733513|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
214733514|NCT00099840|PROCEDURE|Procalcitonin guided antibiotic therapy|
214733515|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
214733516|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
214733517|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
214733518|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
214733519|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
214733520|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
215030579|NCT06564597|OTHER|Patient education|Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
214733521|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
214733522|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
214733523|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
214733524|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
214733525|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
214733526|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
214733527|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
214733528|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
214733529|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
214733530|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
214733531|NCT04081558|DEVICE|Electronic patient reported outcomes tool|Electronic patient reported outcomes
214733532|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
214733533|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
214733534|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
214733535|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
214733536|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
214733537|NCT06399952|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Participants will undergo a 5-10 minute non-anesthesia brain MRI in order to evaluate for changes in brain structure. A 20 to 30 minutes 20 channel surface electroencephalography will be performed in the wake and sleep states.
214733538|NCT06399952|GENETIC|Whole Genome Sequencing|15 milliliters of blood will be collected at the initial visit. Blood samples will be centrifuged, and plasma stored in the University of Missouri Next Gen Precision Health building. Next generation whole genome sequencing and proteomics will be performed on plasma samples. Additional blood will be collected for the DNA biobank.
214733539|NCT06399952|OTHER|Induced Pluripotential Stem Cells|A 3 mm skin punch biopsy will be collected for developing induced pluripotential stem cells.
214733540|NCT06630585|DRUG|Tirzepatide|"Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks."
214794243|NCT06141915|OTHER|Aerobic training|"patients will be engaged in aerobic training using treadmill three times per week, for 12 weeks. The exercise intensity will be 50-70% of each patient's maximum heart rate. Each exercise session will consist of three phases; five-minutes warming up phase in form of stretching exercises and walking on the treadmill at the slowest speed, 20-minutes conditioning phase in form of walking on the treadmill at 50% of participants' maximum heart rate in the first two weeks then progressed gradually to reach the 70% of maximum heart rate by the 12th weeks, and five-minutes cool down phase that will be constant as warming up phase. During the training, the patient's blood pressure, heart rate, and breathing pattern will be frequently monitored"
214794244|NCT06141915|OTHER|diet protocol|diet protocol
214733541|NCT04083781|DRUG|Concizumab|Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
214733542|NCT03501979|DRUG|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
214733543|NCT03501979|DRUG|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
214733544|NCT03501979|DRUG|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
214733545|NCT04571684|OTHER|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
214733546|NCT05240898|DRUG|RO7623066|Administered orally in capsule
214733547|NCT05240898|DRUG|Olaparib|"Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts."
214733548|NCT05240898|DRUG|Carboplatin|Administered intravenously.
214733549|NCT06295991|DEVICE|Lycra garment|Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
214733550|NCT06976437|DRUG|RN1101 injection|RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.
214733551|NCT06804811|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
214733552|NCT06804811|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
214733553|NCT03733132|DRUG|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
214733554|NCT03733132|DRUG|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
214733555|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
214733556|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
214733557|NCT02968277|DEVICE|Standard Rollator|A control rollator device
214733558|NCT05879484|DRUG|pembrolizumab|"Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks."
214733559|NCT05879484|DRUG|valemetostat|"Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose."
214733560|NCT05027789|BEHAVIORAL|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
214733561|NCT05027789|BEHAVIORAL|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
214733562|NCT06807957|DEVICE|Group with IMT|Group with IMT + CrossFit training
214733563|NCT06807957|BEHAVIORAL|CrossFit® Training|The training routine will occur seven days a week, with participants encouraged and motivated to attend at least five training sessions. CrossFit® classes will include: warm-up exercises, strength training (with a focus on Olympic weightlifting and free weights), strength endurance (body weight and external loads), aerobic capacity (across multiple domains), maximal aerobic power (across multiple domains), anaerobic capacity (across multiple domains), cool-down activities, and mobility exercises. Each training session will be designed and supervised by a team of certified physical educators.
214733564|NCT02836548|DRUG|Vorinostat|vorinostat 360 milligram once daily
214733565|NCT01602822|DRUG|Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
214733566|NCT03739892|BEHAVIORAL|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
214733567|NCT05322083|DRUG|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
214733568|NCT05492877|DRUG|Mitiperstat (AZD4831)|Oral dosage, once daily.
215030580|NCT03754361|PROCEDURE|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
215030581|NCT03754361|PROCEDURE|IHD|HD 4hour 2-3times per week
215030582|NCT05852470|DEVICE|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
214733569|NCT05492877|OTHER|Placebo|Oral dosage, once daily.
214733570|NCT05835167|PROCEDURE|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
214733571|NCT05835167|PROCEDURE|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
214733572|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
214733573|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
214733574|NCT00536094|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
214733575|NCT00536094|BEHAVIORAL|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
214733576|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
214733577|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
214733578|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
214733579|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
214733580|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
214733581|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
214733582|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
214733583|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
214733584|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
214733585|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
214733586|NCT06338631|OTHER|Diet|Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
215030583|NCT05852470|DEVICE|Clareon Monofocal/Clareon Toric IOL|Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
214733587|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
214733588|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
214733589|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
214733590|NCT04372979|DRUG|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
214733591|NCT04372979|DRUG|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
214733592|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
214733593|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
214733594|NCT00809055|DRUG|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
214733595|NCT02353338|PROCEDURE|Surgical intervention|Surgical management of radial fracture
214733596|NCT02353338|PROCEDURE|Conservative management|Immobilized/cast for 6 weeks
214733597|NCT02353338|DEVICE|cast|
214733598|NCT05105529|BEHAVIORAL|Exercise|Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
214733599|NCT05105529|OTHER|Ozone|Breathing 170ppb ozone
214733600|NCT05105529|OTHER|Filtere Air|Breathing filtered air
214733601|NCT01149525|DRUG|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
214733602|NCT01149525|DRUG|Placebo|oral solution, twice per day (morning/evening), during 3 months
214733603|NCT05678504|DEVICE|The phlebotomy procedure|The process of blood collection with a vascular imaging device
214733604|NCT05394181|OTHER|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
214733605|NCT05402111|DRUG|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
214733606|NCT05402111|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
214733607|NCT05333289|BIOLOGICAL|mRNA-1030|Sterile liquid for injection
214733608|NCT05333289|BIOLOGICAL|mRNA-1020|Sterile liquid for injection
214733609|NCT05333289|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214733610|NCT05333289|BIOLOGICAL|Active Comparator|Sterile liquid for injection
214733611|NCT05274009|OTHER|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
214733612|NCT05274009|OTHER|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
214733613|NCT05274009|OTHER|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
214733614|NCT00221689|DRUG|baclofen (drug)|
214733615|NCT00218569|DRUG|Naltrexone|Naltrexone
214733616|NCT00218569|DRUG|Placebo|Placebo
214733617|NCT05431335|OTHER|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
214733618|NCT05431335|OTHER|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
214733619|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
214733620|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
214733621|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
214733622|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
214733623|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
214733624|NCT01905514|DEVICE|internet mobile application|
214733625|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
214733626|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
214733627|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
214733628|NCT00806650|GENETIC|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
214733629|NCT00806650|GENETIC|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
214733630|NCT00806650|DIAGNOSTIC_TEST|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
214733631|NCT00806650|OTHER|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
215030584|NCT04134936|DRUG|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
214733632|NCT00806650|OTHER|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
214733633|NCT04476108|DRUG|LY3016859|Administered IV
214733634|NCT04476108|DRUG|Placebo|Administered IV
214733635|NCT00883792|PROCEDURE|Colonoscopy|Once-only colonoscopy screening
214733636|NCT05009836|DRUG|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
214733637|NCT05009836|DRUG|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
214733638|NCT02253992|BIOLOGICAL|Urelumab|
214733639|NCT02253992|BIOLOGICAL|Nivolumab|
214733640|NCT03683095|PROCEDURE|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
214733641|NCT06141889|DRUG|Azelaprag|oral, apelin receptor (APJ) agonist
214733642|NCT02968966|OTHER|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
214733643|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
214733644|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
215030585|NCT04134936|DRUG|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
215030586|NCT06124313|DIETARY_SUPPLEMENT|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
214733645|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
214733646|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
214733647|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
214733648|NCT03206983|DEVICE|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
214733649|NCT03323086|BEHAVIORAL|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
214733650|NCT03323086|OTHER|Brochure|Brochures provided one time
214733651|NCT02911051|DEVICE|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
214733652|NCT01537523|PROCEDURE|community-care program|community nurse care, physiotherapy
214733653|NCT03283891|OTHER|Educational intervention - humanistic nursing practice|"Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
214733654|NCT00355615|DRUG|Rosuvastatin|oral
214733655|NCT00355615|DRUG|Placebo|oral
214733656|NCT03873428|OTHER|FES PET|FES injection
214733657|NCT03676465|OTHER|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
214733658|NCT03676465|OTHER|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
214733659|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
214733660|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
214733661|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
214733662|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
214733663|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
214733664|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
214733665|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
214733666|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
214733667|NCT02980263|DRUG|Canakinumab|
214733668|NCT06218628|DRUG|Talazoparib|pacritinib in combination with talazoparib
214733669|NCT06218628|DRUG|pacritinib|pacritinib in combination with talazoparib
214733670|NCT04797494|DEVICE|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
214733671|NCT05634837|BEHAVIORAL|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
214733672|NCT05634837|BEHAVIORAL|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
214733673|NCT03140046|PROCEDURE|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
214733674|NCT03685643|BEHAVIORAL|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
214733675|NCT03685643|BEHAVIORAL|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
214733676|NCT04916301|BEHAVIORAL|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
214733677|NCT00718991|DEVICE|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
214733678|NCT02159365|DRUG|Elotuzumab|
214733679|NCT02159365|DRUG|Lenalidomide|
214733680|NCT02159365|DRUG|Dexamethasone|
214733681|NCT02608294|DEVICE|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
214733682|NCT02608294|DEVICE|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
214733683|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
214733684|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
214733685|NCT02081911|PROCEDURE|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
214733686|NCT02081911|PROCEDURE|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
214733687|NCT02081911|PROCEDURE|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
214733688|NCT02617199|DRUG|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
214733689|NCT02617199|DRUG|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
214733690|NCT06659744|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
214733691|NCT06659744|DRUG|New initiation of sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
214733692|NCT03931889|DIETARY_SUPPLEMENT|Vitamin D3|Cap. Cholecalciferol 40,000 IU
214733693|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
214733694|NCT01941212|BEHAVIORAL|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
214733695|NCT04760691|DRUG|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
214733696|NCT04760691|DRUG|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
214733697|NCT04760691|DRUG|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
214733698|NCT04760691|DRUG|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
214733699|NCT04760691|DRUG|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
214733700|NCT00428285|PROCEDURE|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
214733701|NCT04686929|DRUG|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
214733702|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
214733703|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
214733704|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
214733705|NCT00605228|DRUG|MOVIPREP|2L Drug
214733706|NCT00605228|DRUG|COLOPEG|4L Drug
215030587|NCT06446648|DRUG|ICG|Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
215030588|NCT01381887|DRUG|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
214733707|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
214733708|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
214733709|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
214733710|NCT03523715|DIETARY_SUPPLEMENT|Prunes|12 oz of prunes daily
214733711|NCT03523715|DRUG|Docusate Sodium|Oral docusate sodium twice daily
215030589|NCT01381887|DRUG|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
215030590|NCT01381887|DRUG|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
215030591|NCT01381887|DRUG|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
215030592|NCT03345225|DEVICE|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
215030593|NCT03345225|DEVICE|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
215030594|NCT01717274|PROCEDURE|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
214733712|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
214733713|NCT00151528|DRUG|Pregabalin|
214733714|NCT01654328|DRUG|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
214733715|NCT01654328|DRUG|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
214733716|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
214733717|NCT01369667|OTHER|Placebo|
214733718|NCT06009406|OTHER|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
214733719|NCT03830463|DRUG|CTP-692|Single oral dose
214733720|NCT03830463|DRUG|Placebo|Single oral dose
214733721|NCT03698929|OTHER|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
214733722|NCT03698929|OTHER|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
214733723|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
214733724|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
214733725|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
214733726|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
214733727|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
214733728|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
214733729|NCT00645736|OTHER|No intervention|No intervention
214733730|NCT05017727|DEVICE|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
214733731|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
214733732|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
214733733|NCT00276224|DRUG|ferrous sulphate (drug)|
214733734|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
214733735|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
214733736|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
214733737|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
215030595|NCT01040026|OTHER|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
215030596|NCT00242892|PROCEDURE|Intra coronary measures of pressure|Intra coronary measures of pressure
215030597|NCT02170519|DRUG|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
214733738|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
214733739|NCT05790902|DRUG|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
214733740|NCT05790902|DRUG|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
214733741|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
214733742|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
214733743|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
214733744|NCT05581927|DEVICE|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
214733745|NCT05581927|DEVICE|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
214733746|NCT06612008|DEVICE|Mandibular Advancement Device|MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
214733747|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
214733748|NCT06989463|OTHER|12 Week Exercise Intervention|Participants will be provided with the results of their physical functioning and fitness assessments and will receive an individually tailored exercise prescription, written by an exercise specialist and approved by the study physician. The prescription will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity and twice weekly strengthening106 over 12 weeks.
214733749|NCT06989463|OTHER|Cognitive Training Intervention|"Participants will complete cognitive training with Lumosity (Lumos Labs, Inc.; San Francisco, California; cognitive training program). This computer-based training consists of games focused on specific executive function skills (shifting attention, working memory, verbal fluency, problem solving). Each 20-minute session includes five games focused specifically on these executive functioning skills.~Participants will be prescribed three 20-minute sessions each week for 12-weeks."
214733750|NCT06989463|OTHER|Mindfulness practice intervention|"The mindfulness practice intervention is a modified version of the University of California at Los Angeles Mindfulness Awareness Research Center's Mindful Awareness Practices designated to be remotely delivered.~during odd weeks, participants will watch the educational lecture video once and practice meditation daily. During even weeks, they will review the educational video as needed and continue daily meditation practice."
214733751|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
214733752|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
214733753|NCT06594185|DEVICE|enVista Aspire EA or Aspire Toric ETA IOLs|enVista Aspire EA or Aspire Toric ETA IOLs
214733754|NCT06864650|OTHER|Ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
214733755|NCT06864650|OTHER|exercise program|stretching exercises strengthening exercises waist exercises core exercises relaxation exercises
214733756|NCT05248529|OTHER|Education booklet|Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
214733757|NCT03531918|DRUG|Cladribine|Given IV
214733758|NCT03531918|DRUG|Cytarabine|Given IV
214733759|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
214733760|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
214733761|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
214733762|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
214733763|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
214733764|NCT04655963|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
214733765|NCT06687278|BEHAVIORAL|Interpersonal Relationship Psychotherapy-Based Intervention Program|The Interpersonal Relationship Psychotherapy-Based Intervention Program is based on IPR and developed with reference to relevant literature and a previously published study (Cort et all., 2014). Subsequent to the development of the program, a series of expert opinions were obtained from seven specialists in the field. The Interpersonal Relationship Psychotherapy-Based Intervention Program is a 2.5-3 month program comprising eight individual sessions. The program is designed to be administered on a weekly basis, with each session lasting approximately 45-60 minutes. The participants in this group will receive an Interpersonal Relationship Psychotherapy Based Intervention Programme, which consists of eight individual sessions.
214733766|NCT04407624|OTHER|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
214733767|NCT04407624|OTHER|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
214733768|NCT02230839|BEHAVIORAL|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
214733769|NCT02230839|BEHAVIORAL|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
214733770|NCT03815760|DEVICE|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
214733771|NCT02683460|PROCEDURE|Patella resurfacing|
214733772|NCT02683460|PROCEDURE|Patella retention|
214733773|NCT01885104|DRUG|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
214733774|NCT01885104|DRUG|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
214733775|NCT01885104|DRUG|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
214733776|NCT06144567|DRUG|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
214733777|NCT00654576|DRUG|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
214733778|NCT00654576|BEHAVIORAL|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
214733779|NCT00906334|DRUG|ON 01910.Na|The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
214733780|NCT00906334|DRUG|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
214733781|NCT03622216|DRUG|Bradanicline|Three different doses over the course of the study
214733782|NCT03622216|DRUG|Placebo|Matching placebo for Bradanicline
214733783|NCT03131011|OTHER|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
214733784|NCT05622656|DRUG|Dexmedetomidine|Dexmedetomidine 0.0005%
214733785|NCT05622656|DRUG|Placebo|0.9% Sodium Chloride Solution
214733786|NCT03304093|DRUG|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
214733787|NCT05859867|OTHER|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
214733788|NCT06041191|DIAGNOSTIC_TEST|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
214733789|NCT03580525|DRUG|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
214733790|NCT03580525|DRUG|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
214733791|NCT03580525|DRUG|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
214733792|NCT03580525|DRUG|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
214733793|NCT03580525|DRUG|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
214733794|NCT02545972|DRUG|tacrolimus extended release|daily dosing of tacrolimus
214733795|NCT01761942|DIETARY_SUPPLEMENT|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
214733796|NCT00113555|DEVICE|ACT (Adjustable Continence Therapy)|surgically implanted device
214733797|NCT02469584|PROCEDURE|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
214733798|NCT03202368|DRUG|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
214733799|NCT02374073|OTHER|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
214733800|NCT02374073|OTHER|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
214733801|NCT01512329|BEHAVIORAL|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
214733802|NCT01512329|BEHAVIORAL|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
214733803|NCT03749850|DRUG|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
214733804|NCT03749850|PROCEDURE|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~\- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
214733805|NCT03749850|DRUG|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~\- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
214733806|NCT01638676|DRUG|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
214733807|NCT01638676|DRUG|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
214733808|NCT01223690|DRUG|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
214733809|NCT01223690|DRUG|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
214733810|NCT01703715|DEVICE|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
214733813|NCT01576224|DEVICE|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
214733814|NCT01060124|DRUG|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
214733815|NCT03398824|DRUG|metformin HCl|Receive metformin HCl
214733816|NCT06168981|OTHER|Chewing Gum|The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
214733817|NCT06302608|GENETIC|NGGT001|Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
214733818|NCT06156462|DEVICE|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
214733819|NCT00174889|DRUG|Pregnenolone|
214733820|NCT05708729|DEVICE|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
214733821|NCT05708729|DEVICE|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
214733822|NCT06691698|OTHER|The Cognitive Orientation to Daily Occupational Performance Approach|CO-OP is a client-centred, performance-based, problem-solving focused, occupation-focused and occupation-based intervention. In CO-OP the person is guided to use a meta-cognitive strategy to find his or her own strategies for specific activities. The main purpose is to enable meta-cognitive thinking in every day activities, leading to enhanced self-efficacy, occupational performance and independency.
214733823|NCT05937490|DRUG|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
214733824|NCT05937490|DRUG|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
214733825|NCT05937490|DRUG|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
214733826|NCT05937490|DRUG|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
214733827|NCT03044743|DRUG|Fludarabine|To modify immune micro-environment
214733828|NCT03044743|DRUG|Cyclophosphamide|To modify immune micro-environment
214733829|NCT03044743|DRUG|Interleukin-2|To sustain the survival of infused T cells
214733830|NCT04071808|DIAGNOSTIC_TEST|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
214733831|NCT01251315|DRUG|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
214733832|NCT01251315|DRUG|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
214733833|NCT01251315|DRUG|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
214733834|NCT01251315|DRUG|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
214733835|NCT01251315|DRUG|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
214733836|NCT01251315|DRUG|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
214733837|NCT05086094|DRUG|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
214733838|NCT06146140|DIETARY_SUPPLEMENT|Oral herbal supplement|Take one capsule daily
214733839|NCT06146140|DIETARY_SUPPLEMENT|Oral placebo supplement|Take one capsule daily
214733840|NCT06412640|DRUG|Keverprazan|Potassium-competitive acid blocker
214733841|NCT06412640|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214733842|NCT03858686|DRUG|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
214733843|NCT03858686|DRUG|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
214733844|NCT00290680|DRUG|bortezomib|
214733845|NCT00290680|DRUG|celecoxib|
214733846|NCT02415829|DRUG|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
214733847|NCT03832023|OTHER|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
214733848|NCT01626755|PROCEDURE|Sciatic name block|Ultrasound-guided sciatic nerve block.
214733849|NCT01432938|BIOLOGICAL|dulaglutide|Administered subcutaneously
214733850|NCT01432938|DRUG|Warfarin|Administered orally
214733851|NCT04951817|DRUG|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
214733852|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
214733853|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
214733854|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
214733855|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
214733856|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
214733857|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
214733858|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
214733859|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
214733860|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
214733861|NCT02336880|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|
214733862|NCT06709430|OTHER|Classical education group|Students will be divided into standardized patient and Classical education group. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.
214733863|NCT06709430|OTHER|Standardized Patient Group|Students will be divided into standardized patient group and control groups. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the
214733864|NCT06720896|DRUG|APT-001 topical ophthalmic ointment (spinosad)|APT-001 topical ophthalmic ointment, administered once daily
214733865|NCT06720896|DRUG|Vehicle control for APT-001 topical ophthalmic ointment|Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
214733866|NCT06727279|OTHER|Specialized food - Plant-Based Meat Analog|Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.
214733867|NCT06727279|OTHER|standard isocalorie diet|Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
214733868|NCT07047014|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
214733869|NCT07047014|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
214733870|NCT06728540|OTHER|Investigation of Physical Activity Levels, Respiratory and Pelvic Floor Muscle Function|The sociodemographic and clinical characteristics of the children participating in the study will be evaluated with an evaluation form, respiratory muscle strength with an RP Check brand electronic pressure measurement device, and body composition with a Tanita MC-580 brand bioelectrical impedance analyzer. Pelvic floor muscle functions of children with LUTD will be evaluated with a 632 Myomed biofeedback device. The survey questions and the evaluation form will be filled out by the parents.
214733871|NCT06372327|BEHAVIORAL|Daily Exercise Snacks|Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
214733872|NCT06075498|PROCEDURE|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
214733873|NCT07047820|DRUG|Zuranolone|Administered as specified in the treatment arm
214733874|NCT07052279|OTHER|water based burpee exercises|water based burpee exercises ( Aquatic exercise ) is one method that has previously been shown to improve muscle strength, balance, and coordination in those of advancing age Although the evidence supports the effectiveness of both water-based burpee exercise in middle-aged and elderly individuals, has, to our knowledge, never been investigated. Thus, the objective of this study was to assess the long-term effect of water-based burpee exercises
214733875|NCT07052279|OTHER|aerobic exercises|Traditional aerobic exercises for post-menopause include activities like brisk walking, jogging and cycling. These exercises help improve cardiovascular health, boost metabolism, and enhance mood. They can also be beneficial for maintaining bone density, especially weight-bearing exercises like walking and jogging.
214733876|NCT06564051|OTHER|Non-Interventional Study|Non-interventional study
214733877|NCT06795009|DRUG|Zanzalintinib|Taken by mouth.
214733878|NCT06795009|DRUG|Paclitaxel|175 mg\^m2 intravenous over 3 hours.
214733879|NCT06751589|DRUG|Tirzepatide|2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
214733880|NCT07124117|DRUG|OBI-902|OBI-902 is an antibody-drug conjugate study drug
214733881|NCT06853860|OTHER|reflexology massage|classic hand massage
214733882|NCT06853860|OTHER|classic hand massage|classic hand massage
214733883|NCT07089459|DEVICE|Low-Level Laser Therapy (LLLT)|Low-Level Laser Therapy (LLLT) will be administered using an 830 nm wavelength and 150 mW power output with 5 W/cm² power density. The laser probe will be applied 2-3 times per week for 6 weeks over the affected knee. Treatment is performed using a direct skin contact method with 3-4 minutes of exposure per point around the knee joint. The goal is to reduce inflammation, enhance collagen synthesis, and support ligament healing in patients with partial anterior cruciate ligament (ACL) tears. This intervention is provided in addition to standard physiotherapy and shortwave diathermy.
214733884|NCT07089459|BEHAVIORAL|Shortwave therapy|Participants in this group will receive standard physiotherapy exercises combined with shortwave diathermy (SWD), without the application of Low-Level Laser Therapy (LLLT). The exercise protocol includes heel slides, supported partial knee bends, quadriceps sets, and step-ups, performed in 2 sets of 10 repetitions with 3-5 second rest intervals. SWD will be delivered 2-3 times, using a 27.12 MHz frequency for 20-30 minutes per session, targeting pain relief and enhanced soft tissue healing. This group functions as an active comparator to assess the additional therapeutic value of LLLT used in the intervention group.
214733885|NCT06360718|BEHAVIORAL|"Who is Luke Eemia? Storybook"|"Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later)."
214733886|NCT06893341|DEVICE|The Sensing Device|Children diagnosed with diabetes that wear a continuous glucose monitor will be given the Sensing Device. The subjects will provide breath samples into the device during euglycemia, hypoglycemia, and hyperglycemia, and the breath data will be analyzed to draw correlations with blood glucose levels.
214733887|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were given orally as a single dose
214733888|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were taken orally multiple times
214733889|NCT07100210|BIOLOGICAL|IL-22BP mRNA vaccine injection|During the injection of IL-22BP/LNP compound, there were three dose groups, namely 25 μg, 50 μg, and 100 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP/LNP compound formulation. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL-22BP/LNP compound injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be administered 1 month after the 4th dose.The entire treatment period lasts for 2 months.
214733890|NCT07101068|DEVICE|Dental Anesthesia Injector|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using Dental Anesthesia Injector.
214733891|NCT07101068|OTHER|conventional syringe|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using conventional syringe
214733892|NCT06911970|OTHER|Exercise|"Moderate-Intensity Continuous Exercise (MOD):~The MOD condition will consist of a 37-minute continuous aerobic exercise session on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 32-minute period at moderate intensity at a power corresponding to 50% of the last stop completed in the modified YMCA test completed in the preliminary visit.~High-Intensity Interval Exercise (HIIE):~The HIIE condition will consist of a 35-minute high-intensity aerobic exercise session on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (110% of power highest poweroutput reached during the submaximal test) and 2 minutes of active rest (25% of highest power output)."
214733893|NCT07102290|BEHAVIORAL|Free Help|Text message offering free quitline coaching. FREE HELP: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. A Quit Coach can double your chances of quitting. For more info call 1-844-XXXXXXX.
214733894|NCT07102290|BEHAVIORAL|Free NRT|Text message for free nicotine patches with free quitline counseling. FREE NRT: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. You may be able to get nicotine patches mailed to your home at no cost. For more info call 1-844-XXXXXXX.
214733895|NCT07102511|BIOLOGICAL|lerodalcibep 300 mg Monthly SC|lerodalcibep or placebo
214733896|NCT07101952|OTHER|Braded Suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
214733897|NCT07101952|OTHER|Multifilament vicryl suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
214733898|NCT06832982|DRUG|FS-8002 injection|Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first
214733899|NCT04867616|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
214733900|NCT04867616|BIOLOGICAL|Bepranemab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
214733903|NCT04191096|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
214733904|NCT04191096|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
214733905|NCT04191096|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
214733906|NCT04191096|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
214733907|NCT07100704|DRUG|Nivolumab|240 mg will be administered on Day 1 and Day 15 of each cycle, or 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and the site principal investigator or site co-investigator.
214733908|NCT05954065|DEVICE|Erchonia CFL Laser|405nm violet and 520nm green laser light therapy.
214733909|NCT07102251|DRUG|HEC-007 injection|Single dose escalation of HEC-007 injection in healthy subjects
214733910|NCT07102251|DRUG|Placebo|Single dose of placebo in healthy adults
214733911|NCT07102251|DRUG|HEC-007 injection|Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects
214733912|NCT07102251|DRUG|Placebo|Multiple dose of placebo in Overweight or Obese Subjects
214733913|NCT06364709|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
214733914|NCT07115732|DEVICE|Total Hip Replacement|Primary elective total hip replacement
214733915|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
214733916|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
214733917|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
214733918|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
214733919|NCT07149285|OTHER|Mandala coloring|"Intervention Group:~The content of the study and the mandala application will be explained to women diagnosed with menopause, and after obtaining consent, a personal information form and scales regarding menopause symptoms and quality of life will be applied. Participants will be given a sample and blank mandala, 12 colored crayons and a follow-up form. The mandala application will be done for 20-30 minutes every day for 15 days, and will be monitored by phone every other day. At the end of the process, the scales will be re-applied and the follow-up forms will be collected. Their routine treatments will continue."
214733920|NCT07148648|PROCEDURE|Chest Wall Reconstruction|there are many methods described in literature for reconstruction of chest wall after chest wall resection. The investigators are focusing on chest wall reconstruction using steel wires in this study.
214733921|NCT07148622|DRUG|Antibiotic regimen 1: sulbactam + ampicillin + azithromycin|For the first 48 hours, 4×2 g IV sulbactam + ampicillin, 1 g oral azithromycin on day 1, and from days 3-7, 3×500 mg oral amoxicillin
214733922|NCT07148622|DRUG|Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin|For the first 48 hours, 1×1 g IV ceftriaxone + 2×500 mg oral clarithromycin, and from day 3 onwards, 3×500 mg oral amoxicillin + 2×500 mg oral clarithromycin.
214733923|NCT07148154|DEVICE|Cytology|Two cervical samples are collected using a cervical brush or swab, following the standard procedure for cervical cytology. Cells are taken from the cervix using a brush/spatula during a gynecological exam. (1) The first sample is kept in the clinical center's pathology department for examination. (2) The second sample is sent to MiMARK's facilities for the investigational project, where it will be processed and stored for future cohort selection and analysis.
214733924|NCT07147517|OTHER|Component A0|It will be implemented as a recruitment strategy. This strategy will enable members of the community to access no cost testing for respiratory infections. If a participant feels sick or thinks they have been exposed to a respiratory infection and wants to be tested, they can complete a symptoms and exposure survey in the PREVENT APP, retrieve a PCR test kit from a vending machine using a unique code received through the PREVENT APP, self-collect an anterior nares nasal swab following instructions provided, and return the test kit at one of the vending machines or drop off locations for the EXCITE lab to pick up and process. The anterior nares nasal swab will be tested for SARS-CoV-2, influenza, Respiratory Syncytial Virus, and other germs (viruses or bacteria) that cause respiratory infections. At the time of consent and registration for the Community Testing Component, participants will be used to screen for Cohorts A/B.
214733925|NCT07147517|OTHER|Component A1|Participants will be invited to 'test' out the PREVENT App and a provide a 'baseline' sample to ensure competency for requesting a nasal swab, retrieving the test kit from a vending machine, self-collecting a sample, and returning the test for PCR testing, with the assistance of study staff. Weekly Symptom Surveys, Annual Surveys, and immunization status.
214733926|NCT07147517|OTHER|Component A2|Investigators will collect immunologic specimens from a subset of participants in Component A (the subset herein referred to as Component A immunologic sub-study). Investigators will combine testing data from these immunologic specimens with multiple data elements already captured in Component A (such as data from pathogen testing and sequencing, survey data, medical records, or immunization services) and Component B (serum obtained at enrollment and 28 post-enrollment) to meet sub-study objectives. Overall, the Component A sub-study will provide critical insight into the immune response to respiratory pathogen infections and immunizations.
214733927|NCT07147517|OTHER|Component B|"Participants will be asked to complete the enrollment survey after enrolling in Component B if the survey has not already been completed as part of Component A. They will also be asked to complete:~1. Daily anterior nares nasal swab collection~2. All household participants, including the index case, will be asked to self-collect an enrollment swab and daily nasal swab specimens for 14 days and return them for testing.~3. Mucosal specimen collection~4. Survey data collection"
214733928|NCT07147738|BEHAVIORAL|Kapot Sterk (translate as Incredibly Strong)|The program consists of five lessons of approximately 60 minutes long, delivered over a period of four to eight weeks. The lessons are facilitated by trained pedagogical staff (e.g., youth workers), while the school's own teachers are always present during the sessions. Lessons include active learning strategies such as role-playing, group discussions, and reflection exercises, often based on realistic and recognizable scenarios. The program focuses on strengthening key social-emotional skills, such as self-esteem, self-control, and resistance to peer pressure.
214733929|NCT07148193|OTHER|No intervention (observational study)|No intervention (observational study)
214733930|NCT07148037|GENETIC|Atorvastatin|10mg once a day for 2 months
214733931|NCT07147335|DIAGNOSTIC_TEST|serum AKR1B10 levels|Investigators collected blood from the patients every three months to test their serum AKR1B10 levels.
214733932|NCT07149064|DIETARY_SUPPLEMENT|Nextida GC-B|One liquid shot contains 5 g of collagen hydrolysate.
214733933|NCT07149064|OTHER|Placebo|One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).
214733934|NCT07148804|DRUG|Fermented Deglycyrrhizinated Licorice|Oral capsules containing 500 mg of fermented deglycyrrhizinated licorice root extract standardized to 2500 IU/gm of α-amylase enzyme and naturally occurring flavonoids and acid-lipase. Administered twice daily (1000 mg/day).
214733935|NCT07148804|DIETARY_SUPPLEMENT|Non-fermented Deglycyrrhizinated Licorice|500 mg non-fermented deglycyrrhizinated licorice root extract capsules, matching FDGL in appearance, color, weight, and excipients. Administered twice daily.
214733936|NCT07148050|BIOLOGICAL|SC-CAR.GPC3xIL15.21 CAR T cells|Autologous SC-CAR.GPC3xIL15.21 T cell products infusion
215030598|NCT01430715|OTHER|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
215030599|NCT02793050|DRUG|Trabectedin|Collection of data on the clinical use of Trabectedin
215030600|NCT05498909|OTHER|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
215030601|NCT04600089|DRUG|Saline|Saline infusion
214733937|NCT07148479|OTHER|Telerehabilitation group|The telerehabilitation group participated in balance training sessions delivered through secure virtual platforms such as WhatsApp video calls. Participants completed 3 sessions per week, each lasting 45-60 minutes, over a total of 6 weeks (18 sessions). The program target static, dynamic, anticipatory, and reactive balance. participants will use households items.session began with warm-up exercises such as gentle marching, arm circles, and hamstring stretches, followed by balance training targeting static, dynamic, anticipatory, and reactive components. Exercises included heel-to-toe standing, single-leg stance, tandem stance, obstacle walking, heel-to-toe walking, side stepping, functional reach, weight shifting, caregiver-assisted perturbations, and foam surface standing. All exercises were performed in 3 sets with specified holds or repetitions. Sessions concluded with cool-down activities including tricep stretches, forward bends, and deep breathing.
214733938|NCT07148479|OTHER|Traditional balance training group|Same as telerehabilitation group but it will concluded in a clinical setting.
214733939|NCT06949696|OTHER|Dual Task Training|In dual task training, patients will be given cognitive exercises such as counting backwards from 100 by 3, counting the names of cities, girls and boys while walking.
214733940|NCT06949696|OTHER|Cognitive Rehabilitation|In cognitive rehabilitation, patients will be given paper-and-pencil activities and exercises to find the difference between two pictures.
214733941|NCT06949696|OTHER|Conventionel Physiotherapy|In conventionel physiotherapy, patients will be given posture exercises for balance and strengthening.
214733942|NCT06948448|DRUG|ONO-4578|ONO-4578 tablets once a day
214733943|NCT06948448|DRUG|Opdivo®|Specified dose on specified days
214733944|NCT06948448|DRUG|Oxaliplatin|Specified dose on specified days
214733945|NCT06948448|DRUG|5-Fluorouracil|Specified dose on specified days
214733946|NCT06948448|DRUG|Bevacizumab|Specified dose on specified days
214733947|NCT06948448|DRUG|Leucovorin|Specified dose on specified days
214733948|NCT06949215|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration."
214733949|NCT06948513|DRUG|Naproxen|Naproxen given immediately post-operatively following Mohs surgery reconstruction
214733950|NCT06948513|DRUG|Acetaminophen (Standard of Care)|Acetaminophen alternated with ibuprofen on an as needed, patient directed basis
214733951|NCT06948513|DRUG|ibuprofen|Ibuprofen alternated with acetaminophen in a patient directed manner for as needed pain control
214733952|NCT06950112|DEVICE|lung ultrasound|The lung ultrasound score between 0 and 3 (0 = normal A lines, 1 = multiple separated B lines, 2 = coalescing B lines or light beam, 3 = consolidation). The aeration score will be built by the sum of the scores of the 12 segments, with a minimum of 0 and a maximum of 36 according to the aeration loss.
214733953|NCT06949826|DRUG|Buprenorphine Transdermal System|The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
214733954|NCT06949826|DRUG|Placebo Patch|The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
214733955|NCT06948994|COMBINATION_PRODUCT|autologous NK cell plus GD2 antibody|Combination of autologous NK cells and GD2 monoclonal antibody
214733956|NCT06949865|OTHER|video recording|The patient's motor symptoms were recorded via video for assessment purposes.
214733957|NCT07148830|PROCEDURE|Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)|"* All patients undergo pancreaticoduodenectomy with total mesopancreatic excision (TMpE) and Adjuvant chemotherapy.~* Meticulous dissection and en bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels (superior mesenteric artery and portal vein) and the celiac axis, performed during pancreaticoduodenectomy."
214733958|NCT07147543|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
214733959|NCT07147322|OTHER|Medical education, basic life support training|One basic life support training session / participant. Duration of educational session aprox. 30min.
214733960|NCT07147244|OTHER|Treatment 1: Full GRIN course (Lessons 1-8)|multi module online training
214733961|NCT07147244|OTHER|Treatment 2: Part 1 of GRIN (Lessons 1-4)|multi module online training
214733962|NCT07147244|OTHER|Treatment 3: Part 2 of GRIN (Lesson 1, 5-8)|multi module online training
215030602|NCT04600089|DRUG|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
214733963|NCT07148596|OTHER|It is an observational study without any intervention measures.|All patients will fast for 6 hours and will abstain from drinking for 2 hours preoperatively, with no premedication. Preoxygenation will be performed with an oxygen flow rate of 6 L/min. Ciprofol will be continuously infused via a micropump at a rate of 12 mg/kg/h. During preoxygenation with a facemask, if respiratory depression occurs during ciprofol infusion, assisted ventilation via facemask will be initiated. After LOC and completion of observation indices, the anesthesiologist may administer midazolam (1-3 mg), sufentanil (0.2-0.5 μg/kg), and rocuronium (0.3-0.6 mg/kg) sequentially based on the patient's age, physical condition, and BIS values to complete anesthesia induction. If hypotension (systolic blood pressure \<90 mmHg or \<80% of baseline) or bradycardia (heart rate \<50 beats/min) occurs during induction, vasoactive agents such as ephedrine or atropine will be administered for management.
214733964|NCT07149129|DEVICE|Electromyographic Biofeedback|"This intervention phase will last 30 minutes of training, during which the participant will be encouraged to actively and voluntarily relax their spastic muscles and will receive visual feedback through the software when this occurs. Two modes will be used in the software: the first, called Recovery, which consists of a game in which the participant is encouraged to contract and relax their muscles in order to guide a rocket in a specific direction to earn points. The second, called Maestro, in which the participant's objective is to keep the rocket below the specified line while maintaining their muscles relaxed. The participant will perform each mode for 15 minutes, totaling the proposed 30 minutes. There may be a break between each mode if the participant experiences fatigue. Afterward, they will receive standard occupational therapy."
214733965|NCT07149129|DEVICE|Sham (No Treatment)|The intervention with the placebo group will have an identical structure to that of the intervention group, but during the biofeedback phase, the software screen will be a simulation, not corresponding to the patient's muscle activity. The patient will receive occupational therapy as usual, in a manner identical to that of the intervention group after the placebo biofeedback therapy.
214733966|NCT07148219|BEHAVIORAL|Embrace Your Power: A VR Journey to Overcome Negative Emotions|"EYP-VR represents a virtual reality (VR) educational tool to combat bullying. Using Meta Quest 3 passthrough technology, the app combines real-world classroom elements with immersive virtual scenarios, enabling safe and interactive experiences that simulate bullying situations but that do not place students in the roles of victims or aggressors but heroes or protectors.~The app guides participants through narrative episodes focused on building empathy, practicing assertiveness, and learning conflict resolution techniques. AI-driven characters dynamically respond to students' actions as they engage in puzzles, and sensory feedback (visual, auditory, and haptic) reinforces key socio-emotional learning outcomes.~The program will take place in classrooms during instructional hours. Each session will end with a feedback phase so that the school counselor can manage any issues that interest them."
214733967|NCT07148973|PROCEDURE|Transcatheter Aortic Valve Replacement|The TAVR surgery mainly involves attaching an artificially-made aortic valve to a special catheter, and then using the catheter to deliver the valve to the affected area and release it. This surgery replaces the original aortic valve with an artificial one, thereby restoring the valve function. Compared with traditional open-chest surgery, it causes less trauma, has lower risks, and enables faster recovery. It is particularly suitable for patients who cannot tolerate open-chest surgery, have poor cardiac function, or are older.
214733968|NCT07139223|BEHAVIORAL|laughter yoga|Intervention arm: Laughter yoga group sessions will be implemented twice a week for 4 weeks (8 sessions in total); the first session will be \~45 min, the subsequent sessions \~30 min. Sessions will be conducted face-to-face in a suitable room within the institution. Following the interim measurement in week 4, the intervention arm will continue structured individual laughter practices daily for 4 weeks.
214733969|NCT07149259|DEVICE|At Home Use|Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.
214733970|NCT07147998|OTHER|Oral hygiene instruction|Oral hygiene and gingival health of all patients were assessed using the Turesky Modification of the Quigley-Hein Plaque Index and the Gingival Index. Tooth brushing frequency was recorded. The 2D:4D ratio was calculated by dividing the second digit length by the fourth, with three measurements taken per finger to ensure reliability. A cut-off value of 1 was used to evaluate prenatal androgen influence, and participants were grouped by 2D:4D ratio (≥1 or \<1). All participants received standardized oral hygiene instructions from the same instructor, including Modified Bass brushing and interdental cleaning. A second clinical exam was performed one week later by the same examiner, and both indices were re-scored.
214733971|NCT06948149|DIETARY_SUPPLEMENT|Creatine monohydrate|Participants will consume one serving of creatine daily (0.10g of creatine/kg of body weight). This relative dosing approach ensures that smaller participants do not receive excessive doses, while larger participants receive an adequate amount. There is currently limited evidence to conclude the effectiveness of timing daily creatine intake, but it is recommended that creatine be consumed at mealtime for optimal absorption. Participants will choose what meal they will take the supplement and will be asked to keep timing consistent throughout the study. This daily low dose method was chosen because other methods (high-dose loading) may have negative side effects (e.g., water retention, cramping).
215030603|NCT05938946|DRUG|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
214733972|NCT06948149|BEHAVIORAL|Resistance training|Participants will use the programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. The investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
214733973|NCT07148609|BEHAVIORAL|Video game-facilitated group activity|The intervention is a 12-week group activity program for each participant in the intervention group, and the program consists of three 50-minute video game facilitated group activity sessions per week. Participants in the intervention group will engage in those group activity session which will be mediated by the game of Super Mario Party on Nintendo Switch.
214733974|NCT07149311|BEHAVIORAL|Intervention|The intervention group will receive the usual consultation from their doctor and referral to a diabetes educator for individualised structured DSME training. A clinical sheet will be used while delivering the education to ensure that all core topics are covered. For this study, 2 diabetes educators will offer the individualised DSME sessions using the American Association of Diabetes Education (AADE) 7 self-care behaviour model. The participants are scheduled to attend a 1-hour individualised session at the hospital every 3 months as well as telephone consultations lasting up to 15 minutes every 2 weeks at the convenience of the participant to reinforce DSME for 6 months. The first session is arranged on the first day after consultation with the doctor. At the end of the sessions, the participants will receive a patient guide to diabetes booklet and graphic material illustrating several self-care activities such as foot care
214733975|NCT07147972|DRUG|Propranolol 80 mg|Propranolol 40-80 mg/day
214733976|NCT07147972|DRUG|Magnesium 400Mg|Magnesium 400 mg daily
214733977|NCT07148882|DRUG|fentanyl|"Intra nasal fentanyl group: will receive intranasal fentanyl using nasal dose of INF is 1.5µg/kg/dose, and typically one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment (maximum two doses per procedure).~Intravenous fentanyl group: will receive intravenous fentanyl 1 µg/kg/dose and typically, one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment maximum two doses per procedure.~Measure MDA Malondialdehyde level as oxidative stress marker in pain response , venous blood sample 0.5 ml will be collected twice, just before and 30 minutes after the procedure.~Monitor adverse events after fentanyl use as apnea cessation of breathing for \>20 s, bradycardia heart rate \< 100 beats/minute, desaturation oxygen saturation \< 80%"
214733978|NCT07148180|DRUG|Tagraxofusp|A CD123-directed cytotoxin, Single-use vial, via intravenous (into the vein) infusion per protocol.
214733979|NCT07148180|DRUG|Azacitidine (AZA)|A cytidine nucleoside analog, single-use vial, via intravenous infusion or subcutaneous (under the skin) injection per standard of care.
214733980|NCT07148180|DRUG|Venetoclax|A BCL-2 inhibitor, tablet, via orally per standard of care.
214733981|NCT07149077|DRUG|Echo-guided scalp blocks|Classic anesthetic strategy in association with echo-guided scalp blocks
214733982|NCT07149077|DRUG|Classic anesthetic strategy|classic anesthetic strategy with postoperative analgesia associating Paracetamol and Morphine with standardized dose.
214733983|NCT03757260|DEVICE|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
214733984|NCT03757260|DEVICE|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
214733985|NCT01820494|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
214733986|NCT00168168|DRUG|G-CSF/Filgrastim|
214733987|NCT06156293|BEHAVIORAL|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
214733988|NCT05119231|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
214733989|NCT05119231|OTHER|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
214733990|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
214733991|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
214733992|NCT05374512|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
214733993|NCT05374512|DRUG|Paclitaxel|IV Infusion. Active comparator
214733994|NCT05374512|DRUG|Nab-paclitaxel|IV infusion. Active comparator
214733995|NCT05374512|DRUG|Carboplatin|IV infusion. Active comparator
214733996|NCT05374512|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
214733997|NCT05374512|DRUG|Eribulin mesylate|IV infusion. Active comparator
214733998|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
214733999|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
214734000|NCT04370574|DIAGNOSTIC_TEST|Soluble Biomarkers dosage|"1. CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~2. Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
214734001|NCT04422847|DEVICE|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
214734002|NCT03787355|COMBINATION_PRODUCT|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
214734003|NCT04085406|DEVICE|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
214734004|NCT04418427|BIOLOGICAL|6E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
214734005|NCT04418427|BIOLOGICAL|2E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
214734006|NCT04418427|BIOLOGICAL|Aflibercept|Commercially available Active Comparator
214734007|NCT04495673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
214734008|NCT04495673|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
214734009|NCT04495673|BEHAVIORAL|Cognitive Training|Executive functioning tasks
214734010|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
214734011|NCT05560009|DRUG|Fluorodopa F 18|Given IV
214734012|NCT05560009|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214734013|NCT05560009|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214734014|NCT05560009|RADIATION|Radiation Therapy|Receive standard of care radiation therapy
214734015|NCT05560009|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
214734016|NCT05110157|DRUG|Placebo|Oral capsules
214734017|NCT05110157|DRUG|Valbenazine|Oral capsules
214734018|NCT05248789|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
214734019|NCT06799377|BEHAVIORAL|Restricted Activity Reccomendations|"Patients in this respective group will be given restricted activity recommendations over the casting period. They will be told Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the restricted activity group. We ask that you limit sprinting, jumping, and organized sports during the time of cast immobilization. As a rule of thumb, we recommend feet on the floor activities while playing and avoiding playgrounds and gym class if possible. While it is not realistic to restrict a young child entirely, do your best to avoid strenuous or intense exercise until cleared by your physician or nurse practitioner"
214734020|NCT06799377|BEHAVIORAL|Full Activity/Limited Activity Reccomendations|"Patients in this respective group will be allowed to engage in most activities. They will be read Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the activity as tolerated group. Your child may participate in all desired activities except contact sports. Your child does not need to increase his/her activity level but should participate in activities as they feel comfortable doing so. Sprinting, jumping, and organized sports are acceptable as long as your child is not experiencing pain. Your child may use playgrounds and participate in gym class as desired. Do your best to avoid restricting your child from activities unless they are experiencing pain or you have concerns about their safety."
214734021|NCT05471609|DRUG|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
214734022|NCT05471609|DRUG|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
214734023|NCT05230355|DEVICE|standard technique|The probe was moved over each hemisphere for 120 seconds (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
214734024|NCT05230355|DEVICE|modified pattern|The probe was moved over 3 quadrants for 80 seconds for each quadrant (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
214734025|NCT00189059|DRUG|amitriptyline|
214734026|NCT06296667|OTHER|core muscles training exercises|The sessions will be conducted three times per week for four weeks and each exercise will be performed two sets of 10 repetitions. For the static exercises, the final position will be held for 6 second. There will be a pause of 3 second between repetitions, and a 60 sec rest between each exercise. The exercise will be performed in three forms: abdominal bracing, dynamic stabilization, and advanced core strengthening.
214734027|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
214734028|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
214734029|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
214734030|NCT00002624|PROCEDURE|adjuvant therapy|
214734031|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
214734032|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
214734033|NCT00002624|PROCEDURE|video-assisted surgery|
214734034|NCT00002624|RADIATION|radiation therapy|
214734035|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
214734036|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
214734037|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
214734038|NCT05359991|OTHER|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
214734039|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
214734040|NCT01030757|RADIATION|Tomotherapy treatment|"* A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%"
214734041|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 326.3 µg RE of vitamin A/day. This would fulfill \~59.3% of the RNI of vitamin A for children aged 7-12 years old.
214734042|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
214734043|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
214734044|NCT04124952|DEVICE|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
214734045|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
214734046|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
214734047|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
214734048|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
214734049|NCT05719064|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
214734050|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
214734051|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
214734052|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
214734053|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
214734054|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
214734055|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
214734056|NCT00397644|BEHAVIORAL|Prompting (survey instrument/resources list) (behavior)|
214734057|NCT03261037|OTHER|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
214734058|NCT03261037|OTHER|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
214734059|NCT03261037|OTHER|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
214734060|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
214734061|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
214734062|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
214734063|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
214734064|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
214734065|NCT04708769|BEHAVIORAL|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
214734066|NCT04708769|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
214734067|NCT01355224|GENETIC|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
214734068|NCT01355224|BEHAVIORAL|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
214734069|NCT04576663|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
214734070|NCT04576663|DRUG|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
214734071|NCT05422690|DRUG|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
214734072|NCT05422690|RADIATION|Concurrent Y-90 treatment|Patients will undergo a Y-90 treatment planning consultation by the treating interventional radiologist during cycle 1. One or two cycles (depending on tumor size) of cisplatin, 25 mg/m2 and gemcitabine 300 mg/m2 given on day 1 and day 8 in combination with Yttrium-90 (Y-90) microspheres which will be given on day 3-7 or day 10-21 at the discretion of the interventional radiologist, separated in time by at least 2 days from a chemo infusion during that cycle
214734073|NCT05422690|DRUG|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
214734074|NCT02483351|OTHER|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
214734075|NCT02483351|OTHER|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
214734076|NCT05465668|DRUG|DWP16001 Drug A|DWP16001 Drug A
214734077|NCT05465668|DRUG|DWP16001 Drug C|DWP16001 Drug C
214734078|NCT01370772|DRUG|Rituximab|"* Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
214734079|NCT01370772|DRUG|Rituximab|"* Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
214734080|NCT01370772|DRUG|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
214734081|NCT01370772|DRUG|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
214734082|NCT03537001|OTHER|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
214734083|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
214734084|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
214734085|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
214734086|NCT06491992|DRUG|Chitosan Phonophresis|Chitosan Phonophresis, three times per week for four weeks.
214734087|NCT06491992|OTHER|selected physical therapy exercise|selected neck exercise and electrotherapy on cervical region
214734088|NCT06282302|OTHER|Group control|Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
215030604|NCT05938946|DRUG|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
215030605|NCT05294523|PROCEDURE|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
215030606|NCT00323622|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
215030607|NCT00323622|BIOLOGICAL|Engerix™-B|IM injection in the deltoid muscle
215030608|NCT00323622|BIOLOGICAL|Hiberix®|IM injection in the deltoid muscle
214734089|NCT06282302|OTHER|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
214734090|NCT06282302|OTHER|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
214734091|NCT04547491|DEVICE|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
214734092|NCT04547491|DEVICE|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
214734093|NCT05522543|OTHER|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
214734094|NCT05522543|OTHER|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
214734095|NCT02373891|DRUG|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
214734096|NCT02373891|DRUG|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
214734097|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
214734098|NCT04725604|DEVICE|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
214734099|NCT00470873|DRUG|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
214734100|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
214734101|NCT02085486|OTHER|Standard|Standard inspection, palpation.
214734102|NCT05211973|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
214734103|NCT05211973|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
214734104|NCT05211973|DEVICE|Chair Scale|a wheel-chair compatible scale to measure body weight
214734105|NCT05211973|DEVICE|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
214734106|NCT05211973|DEVICE|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
214734107|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
214734108|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
214734109|NCT01873196|BEHAVIORAL|Receive extra oil|
214734110|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
214734111|NCT03942640|OTHER|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
214734112|NCT03942640|OTHER|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
214734113|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
214734114|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
214734115|NCT04400669|OTHER|Mechanical Bowel Preparation|oral sodium phosphate (NaP) enema
214734116|NCT04400669|DIETARY_SUPPLEMENT|Low fibre diet|3 days
214734117|NCT04400669|OTHER|MBP plus low-fibre diet|3 days low fibre diet preoperative mechanical bowel preparation
214734118|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
214734119|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
215030609|NCT00323622|BIOLOGICAL|Prevnar™|IM injection in the deltoid muscle
215030610|NCT00323622|DRUG|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
214734120|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
214734121|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
214734122|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
214734123|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
214734124|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
214734125|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
214734126|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
214734127|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
214734128|NCT02110472|DEVICE|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
214734129|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
214734130|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
214734131|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
214734132|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
214734133|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
214734134|NCT01633372|DRUG|itacitinib|
214734135|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
214734136|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
214734137|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
214734138|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
214734139|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
214734140|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
214734141|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
214734142|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
214734143|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
214734144|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
214734145|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
214734146|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
214734147|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
214734148|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
214734149|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
214734150|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
214734151|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
214734152|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
214734153|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
214734154|NCT02023892|DRUG|atorvastatin|
214734155|NCT02023892|DRUG|placebo|
214734156|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
214734157|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
215030611|NCT00323622|DRUG|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
214734158|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
214734159|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
214734160|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
214734161|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
214734162|NCT01207921|DRUG|Lenalidomide|
214734163|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
214734164|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
214734165|NCT02696590|DIETARY_SUPPLEMENT|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
214734166|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
214734167|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
214734168|NCT05736302|OTHER|Doubly-Labeled Water|All eligible participants will receive a dose of doubly-labeled water.
214734169|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
214734170|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
214734171|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
214734172|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
214734173|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
214734174|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214734175|NCT06538389|DRUG|BRC-001|Given PO
214734176|NCT06538389|DRUG|Placebo Administration|Given PO
214734177|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
214734178|NCT04437511|DRUG|Donanemab|Given IV
214734179|NCT04437511|DRUG|Placebo|Given IV
214734180|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
214734181|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
214734182|NCT06377605|PROCEDURE|ESPB|the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
214734183|NCT06377605|PROCEDURE|local anaesthetic infiltration|the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
214734184|NCT06377605|DRUG|midazolam and lidocaine|midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
214734185|NCT06377605|DRUG|Bupivacain|bupivacaine infiltration
214734186|NCT00911183|BIOLOGICAL|filgrastim|Given subcutaneously
214734187|NCT00911183|BIOLOGICAL|pegfilgrastim|Given subcutaneously
215030612|NCT00622206|DRUG|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
215030613|NCT04954989|BIOLOGICAL|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
214734188|NCT00911183|BIOLOGICAL|rituximab|Given IV
214734189|NCT00911183|DRUG|cyclophosphamide|Given IV
214734190|NCT00911183|DRUG|liposome-encapsulated doxorubicin citrate|Given IV
214734191|NCT00911183|DRUG|prednisone|Given orally
214734192|NCT00911183|DRUG|vincristine sulfate|Given IV
214734193|NCT04654468|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight between 40 and 100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100 kg) or 1020 mg SC (for participants with body weight ≥ 100 kg). Dosing schedule will be as described above.
214734196|NCT05088460|DRUG|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
214734197|NCT05088460|DRUG|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
214734198|NCT05879822|DRUG|INCB099280|Administered as specified in the treatment arm description
214734199|NCT04146285|DRUG|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
214734200|NCT04601233|DRUG|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
214734201|NCT02073604|OTHER|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
214734202|NCT02073604|OTHER|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
214734203|NCT05741346|DRUG|BCX9930|Taken orally at 400 mg twice daily (BID)
214734204|NCT06530927|DIAGNOSTIC_TEST|3D rotational digital tomography|DHTM is label-free and records the phase shift of low-energy light passing through the specimen on a transparent surface with minimal perturbation. DHTM measures the refractive index (RI) and computes the refractive index gradient (RIG), unveiling optical heterogeneity in cells. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots.
214734205|NCT06530927|DIAGNOSTIC_TEST|Atomic Force Microscopy|The atomic force microscope (AFM) is widely used in materials science and has found many applications in biological sciences but has been limited in use in vision science. The AFM can be used to image the topography of soft biological materials in their native environments. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots
214734206|NCT06530927|DIAGNOSTIC_TEST|Micro-Computertomography|"Micro-CT is a 3D imaging technique utilizing X-rays to see inside an object, slice by slice. Micro-CT, also called microtomography or micro computed tomography, is similar to hospital CT or CAT scan imaging but on a small scale with greatly increased resolution. Samples can be imaged with pixel sizes as small as 100 nanometers and objects can be scanned as large as 200 millimeters in diameter. We will use micro-CT to analyze blood clots from patients with large vessel occlusion."
214734207|NCT05422573|BEHAVIORAL|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
214734208|NCT05422573|BEHAVIORAL|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
214734209|NCT05422573|BEHAVIORAL|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
214734210|NCT06109935|DRUG|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
214734211|NCT03093350|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
214734212|NCT05994482|OTHER|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
214734213|NCT05994482|OTHER|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
214734214|NCT05994482|OTHER|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
214734215|NCT04934683|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
214734216|NCT04934683|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
214734217|NCT04934683|DRUG|Etomidate Induction|Anesthetic induction with etomidate.
214734218|NCT04934683|DRUG|Propofol Induction|Anesthetic induction with propofol.
214734219|NCT05165160|DIAGNOSTIC_TEST|Blood sample|Pre- and postoperative blood sample
214734220|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
214734221|NCT05898802|DIETARY_SUPPLEMENT|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
214734222|NCT05898802|DIETARY_SUPPLEMENT|Placebo|Lactose with kimchi flavor
214734223|NCT05798247|OTHER|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
214734224|NCT01319045|DRUG|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
214734225|NCT06239675|DEVICE|tDCS|tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.
214734226|NCT06239675|BEHAVIORAL|CIMT|CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
214734227|NCT06239675|DEVICE|sham tDCS|sham tDCS
214734228|NCT03537378|PROCEDURE|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
214734229|NCT06254950|DRUG|TAK-279|TAK-279 capsules.
214734230|NCT06254950|DRUG|Placebo|TAK-279 placebo-matching capsules.
214734231|NCT02912572|DRUG|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
214734232|NCT02912572|DRUG|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
214734233|NCT02912572|DRUG|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
214734234|NCT05381818|BEHAVIORAL|Daily Inspiratory Muscle Training (dIMT)|Daily IMT training sessions for 2-4 weeks prior to surgery
214734235|NCT05381818|BEHAVIORAL|Acute Inspiratory Muscle Training (aIMT)|A single session of IMT provided within 30 minutes prior to anesthesia induction.
214734236|NCT05381818|OTHER|Standard of Care (SOC)|Standard of care only pre and post-operatively.
214734237|NCT06246513|BIOLOGICAL|SRP-9003|Solution for single IV infusion
214734238|NCT06246513|DRUG|Glucocorticoid|Oral tablet (prophylactic)
214734239|NCT05485948|DRUG|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
214734240|NCT05370911|DRUG|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
214734241|NCT05451524|BEHAVIORAL|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
214734242|NCT05451524|BEHAVIORAL|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
214734243|NCT06216964|DIAGNOSTIC_TEST|Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)|Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
214734244|NCT04596644|DRUG|Active Cannabis|6.58% THC + \<0.01% CBD cannabis (in one cigarette)
214734245|NCT04596644|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
214734246|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
214734247|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
214734248|NCT01368055|RADIATION|70 Gy/CGE|Low Risk
214734249|NCT01368055|RADIATION|72.5 Gy/CGE|Intermediate Risk
214734250|NCT05018208|OTHER|Computer-Assisted Intervention|Use smartphone app
214734251|NCT05018208|PROCEDURE|Patient Monitoring|Wear Biofourmis wearable device(s)
214734252|NCT05018208|OTHER|Questionnaire Administration|Complete questionnaires
214734253|NCT03467516|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
214734254|NCT05306964|PROCEDURE|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
214734255|NCT05306964|PROCEDURE|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
214734256|NCT06549400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
214734257|NCT05219955|BEHAVIORAL|Morning Action Plan Execution|Each day, participants are asked to track if they do the morning activity plan.
214734258|NCT05219955|BEHAVIORAL|Activity Strategy-based Session with Therapist|Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
214734259|NCT05219955|BEHAVIORAL|Attention-based Session with Therapist|Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
214734260|NCT05219955|BEHAVIORAL|Advance sleep-wake time|Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
214734261|NCT04757220|OTHER|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
214734262|NCT06060561|OTHER|Non-Interventional Study|Non-interventional study
214734263|NCT04931251|BEHAVIORAL|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
214734264|NCT05690256|BEHAVIORAL|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
214734265|NCT05690256|BEHAVIORAL|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
214734266|NCT06171945|BEHAVIORAL|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
214734267|NCT06171945|BEHAVIORAL|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
214734268|NCT06171945|BEHAVIORAL|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
214734269|NCT01381731|DRUG|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
214734270|NCT01381731|DRUG|placebo|opthalmic solution 2 drops in each eye QID
214734271|NCT04564027|DRUG|Ceralasertib|Tablets will be administered orally
215030614|NCT04954989|BIOLOGICAL|Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
215030615|NCT06016244|OTHER|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
215030616|NCT06567392|DRUG|[14C] HRS-5965|Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
215030617|NCT05280145|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
215030618|NCT05280145|DEVICE|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
214734272|NCT05292521|OTHER|Best Practice|Receive usual care
214734273|NCT05292521|OTHER|Informational Intervention|Receive QOL fact sheet
214734274|NCT05292521|OTHER|Questionnaire Administration|Ancillary studies
214734275|NCT06578819|BEHAVIORAL|doll therapy|Doll therapy applied to the experimental group 4 days a week.
214734276|NCT00777036|DRUG|Dasatinib|
214734277|NCT04632589|DRUG|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
214734278|NCT04632589|DRUG|Placebo|subjects ingest placebo tablet daily for 6 weeks
214734279|NCT06388759|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
214734280|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
214734281|NCT06436534|DRUG|Ganciclovir Oral Capsule|2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
214734282|NCT06436534|DRUG|Ganciclovir Simulant Oral Capsule|2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
214734283|NCT06436534|DRUG|Mometasone Nasal|From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
214734284|NCT06648486|DEVICE|With the assistance of wearable isokinetic training robot （ 7 children with SMA type II）|A child with SMA will use a wearable isokinetic training robot to train the knee joint for three stages. ( Stage 1: 1.5 months=30 sessions; Stage 2 (follow up): 1.5 months=18 sessions, Stage 3(follow up) = 0 session)
214734285|NCT05346536|OTHER|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
214734286|NCT01267955|OTHER|Laboratory Biomarker Analysis|Correlative studies
214734287|NCT01267955|OTHER|Pharmacogenomic Study|Correlative studies
214734288|NCT01267955|DRUG|Vismodegib|Given PO
214734289|NCT04334109|BEHAVIORAL|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
214734290|NCT04334109|BEHAVIORAL|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
214734291|NCT04168866|PROCEDURE|Operative management|Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
214734292|NCT04168866|OTHER|Drainage or antibiotics|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
214734293|NCT06272942|OTHER|An ICU admission and a temporally related ARDS diagnosis|"This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome."
214734294|NCT05857150|DIAGNOSTIC_TEST|Treadmill Test|Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
214734295|NCT05857150|DIAGNOSTIC_TEST|Strength Test|Measure the strength of leg muscles by kicking against a machine with resistance.
214734296|NCT05857150|DIAGNOSTIC_TEST|Dual-Energy X-Ray Absorptiometry|Body composition measurement.
214734297|NCT05857150|PROCEDURE|Muscle Biopsy|Obtain a small piece of muscles from the upper part of the legs
214734298|NCT05857150|PROCEDURE|Fat Biopsy|Fat sample taken from abdomen
214734299|NCT05857150|DIAGNOSTIC_TEST|Resting Energy Expenditure|Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
214734300|NCT05857150|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI on upper leg to look at fat and muscle
214734301|NCT05852600|BEHAVIORAL|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
215030619|NCT05280145|PROCEDURE|Ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
214734302|NCT05852600|BEHAVIORAL|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
214734303|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
214734304|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
214734305|NCT05465538|DRUG|[11C]UCB-J PET|Single PET scan using the radioligand \[11C\]UCB-J
214734306|NCT02422381|DRUG|MK-3475|Investigational drug.
214734307|NCT02422381|DRUG|Gemcitabine|Standard care drug.
214734308|NCT06390371|OTHER|Spotlight AQ Survey platform|A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
214734309|NCT05868668|DEVICE|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
214734310|NCT05868668|DEVICE|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
214734311|NCT05868668|DEVICE|Sham treatment|Handheld sham probe
214734312|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 1
214734313|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 3
214734314|NCT05379686|DRUG|GlucaGen|150 ug glucagon will be administered to the participants before exercise.
214734315|NCT03811535|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
214734316|NCT03811535|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
214734317|NCT00271180|DEVICE|Device|
214734318|NCT05564039|DRUG|Tirzepatide|Administered SC
214734319|NCT05564039|DRUG|Dulaglutide|Administered SC
214734320|NCT06524908|BEHAVIORAL|Exercise and dietary calorie restriction|The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
214734321|NCT06065449|DRUG|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
214734322|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
214734323|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
214734324|NCT04651777|DRUG|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
215030620|NCT04977349|OTHER|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
214734325|NCT04566445|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
214734326|NCT02421939|DRUG|gilteritinib|tablet, oral
214734327|NCT02421939|DRUG|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
214734328|NCT02421939|DRUG|Azacitidine|SC or IV injection
214734329|NCT02421939|DRUG|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
214734330|NCT02421939|DRUG|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
214734331|NCT04785144|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
214734332|NCT04785144|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
214734333|NCT05614102|DRUG|BAY2965501|Daily oral application
214734334|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
214734335|NCT05614102|DRUG|Platinum-based Chemotherapy|Standard of care doses per tumor type will be administered.
214734336|NCT04683952|DEVICE|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
214734337|NCT04683952|OTHER|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
214734338|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
214734339|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
214734340|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
214734341|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
214734342|NCT01197872|OTHER|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
214734345|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
214734346|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
214734347|NCT03606707|DRUG|Steroids|intra-articular steroid injection for atlantoaxial joint
214734348|NCT02966236|DRUG|Tranexamic Acid|
214734349|NCT02966236|DRUG|Placebos|
214734350|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
214734351|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
214734352|NCT03072368|OTHER|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
214734353|NCT06022432|OTHER|Video of a patients testimonial|The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.
214734354|NCT06022432|OTHER|Writing Task|Participants write freely about their current treatment expectations / apprehensions to seek treatment
214734355|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
214734356|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
214734357|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
214734358|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
214734359|NCT04331028|DEVICE|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
214734360|NCT02446028|DRUG|BIOD-531|
214734361|NCT02446028|DRUG|Humalog® Mix 75/25|
214734362|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
214734363|NCT02106845|DRUG|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
214734364|NCT02106845|DRUG|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
214734365|NCT02106845|DRUG|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
214734366|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
214734367|NCT03617471|PROCEDURE|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
214734368|NCT00667940|BEHAVIORAL|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
214734369|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
214734370|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
214734371|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
214734372|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
214734373|NCT04084795|BEHAVIORAL|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
214734374|NCT04084795|OTHER|transcranial Direct Current Stimulation|tDCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; Fp1, F7, Fc5, AF3, Fc1, Fz, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 2mA tDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
214734375|NCT06445400|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214734376|NCT06445400|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
214734377|NCT06445400|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
214734378|NCT05438004|OTHER|Ambulatory nice birth|discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
214734379|NCT03445962|DIAGNOSTIC_TEST|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity"
214734380|NCT06105970|OTHER|No intervention|cross sectional study#no intervention
214734381|NCT05103501|DRUG|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
215030621|NCT04977349|OTHER|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
214734382|NCT05120284|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
214734383|NCT05120284|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
214734384|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
214734385|NCT05448807|DRUG|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
214734386|NCT06624150|DEVICE|Active tDCS sessions, StarStim device|10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
214734387|NCT06624150|DEVICE|Sham (fake) tDCS sessions|10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
214734388|NCT05674955|DIAGNOSTIC_TEST|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
214734389|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
214734390|NCT00807443|DRUG|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
214734391|NCT04106180|DRUG|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
214734392|NCT04106180|DRUG|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
214734393|NCT04106180|RADIATION|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
214734394|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
214734395|NCT06358430|DRUG|Cyclophosphamide|Given by IV
214734396|NCT06358430|DRUG|Cetuximab|Given by IV
214734397|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
214734398|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
214734399|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
214734400|NCT04617639|BEHAVIORAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
214734401|NCT04617639|BEHAVIORAL|Standard care|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
214734402|NCT04617639|BEHAVIORAL|Observation group|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
214734403|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|Administered one time via subcutaneous route.
214734404|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Administered one time via intravenous route.
214734405|NCT05304611|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
214734406|NCT06281314|DEVICE|Vespa software|The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
214734407|NCT01165463|BEHAVIORAL|SOPT basic training|10 hours of basic training
214734408|NCT01165463|BEHAVIORAL|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
214734409|NCT01165463|BEHAVIORAL|SOPT booster training|4 hours of subsequent booster-training
214734410|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
214734411|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
214734412|NCT03239769|PROCEDURE|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
214734413|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
214734414|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
214734415|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
214734416|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
214734417|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
214734418|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
214734419|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
214734420|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
214734421|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
214734422|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
214734423|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
214734424|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
215030622|NCT05430321|OTHER|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
214734425|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
214734426|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
214734427|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
214734428|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
214734429|NCT04796012|DRUG|Atezolizumab|Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle
214734430|NCT04796012|DRUG|Vincristine|Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle
214734431|NCT04796012|DRUG|Irinotecan|Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle
214734432|NCT04796012|DRUG|Temozolomide|Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
214734433|NCT06299111|DRUG|REGN9933|Intravenous (IV) single dose administered
214734434|NCT06299111|DRUG|REGN7508|IV single dose administered
214734435|NCT06299111|DRUG|Placebo|IV single dose administered
214734436|NCT05064007|BEHAVIORAL|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
214734437|NCT05064007|BEHAVIORAL|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
214734438|NCT05064007|BEHAVIORAL|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
214734439|NCT06563479|DIAGNOSTIC_TEST|FMISO-PET Scan|Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
214734440|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
214734441|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
214734442|NCT06563479|OTHER|Assessments|EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
214734443|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
214734444|NCT05164341|DRUG|Placebo|Placebo
214734445|NCT04577313|BEHAVIORAL|Behavioral Self-Regulation Adherence Counseling|Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
214734446|NCT06287814|BIOLOGICAL|Blood sample/lliquid biopsy|ctDNA analysis
214734447|NCT05393362|PROCEDURE|Cardiac Rehabilitation Program (CR)|"Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end."
215030623|NCT05430321|OTHER|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
215030624|NCT05430321|OTHER|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
214734448|NCT05393362|BEHAVIORAL|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
214734449|NCT02682511|DRUG|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
214734450|NCT02682511|DRUG|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
214734451|NCT04316117|PROCEDURE|Computed Tomography|Undergo PET/CT
214734452|NCT04316117|OTHER|Fludeoxyglucose F-18|Given IV
214734453|NCT04316117|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214734454|NCT04556175|BEHAVIORAL|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
214734455|NCT04556175|BEHAVIORAL|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
214734456|NCT04430894|DRUG|Carfilzomib|"* Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
214734457|NCT04430894|DRUG|Isatuximab|"* Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  \-- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
214734458|NCT04430894|DRUG|Lenalidomide|\- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
214734459|NCT04430894|DRUG|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
214734460|NCT05549505|DRUG|ARV-471|100 mg tablet
214734461|NCT05549505|DRUG|Anastrozole|1 mg tablet
214734462|NCT05549505|PROCEDURE|Surgical resection of breast tumor|Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
214734463|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
214734464|NCT06408818|BEHAVIORAL|Media Aware Parent - Tween|Media Aware Parent - Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
214734465|NCT06408818|BEHAVIORAL|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
214734466|NCT02960308|RADIATION|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
214734467|NCT00854061|DRUG|T-Pred|sterile ophthalmic solution
214734468|NCT00854061|DRUG|Pred Forte|sterile ophthalmic solution
214734469|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
214734470|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
214734471|NCT05022706|OTHER|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
214734472|NCT05022706|BEHAVIORAL|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
214734473|NCT05022706|BEHAVIORAL|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
214734474|NCT04711915|DRUG|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
214734475|NCT04711915|DRUG|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
214734476|NCT02871791|DRUG|Palbociclib|
214734477|NCT02871791|DRUG|Everolimus|
214734478|NCT02871791|DRUG|Exemestane|
214734479|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
214734480|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
214734481|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
214734482|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
214734483|NCT00136461|DRUG|All-trans retinoic acid|
214734484|NCT00136461|DRUG|Bryostatin 1|
214734485|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
214734486|NCT00984919|OTHER|high performance liquid chromatography|
214734487|NCT00984919|OTHER|laboratory biomarker analysis|
214734488|NCT00984919|OTHER|mass spectrometry|
214734489|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
214734490|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
214734491|NCT02404909|OTHER|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
214734492|NCT06827275|PROCEDURE|Feeding process|Nutritional therapy is administered according to the feeding procedure
214734493|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
214734494|NCT04917328|OTHER|compression ultrasound|performing a compression ultrasound
214734495|NCT00585507|DRUG|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
214734496|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
214734497|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
214734498|NCT06647485|PROCEDURE|PF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only PF energy for ablation
214734499|NCT06647485|PROCEDURE|Hybrid PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing both PF and RF energy for ablation. Specifically, PF energy is used for the posterior segments and RF energy for the anterior segments of the pulmonary veins
214734500|NCT06647485|PROCEDURE|RF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only RF energy for ablation
214734501|NCT06842147|DEVICE|7-day single-lead long-term ECG monitoring device.|Participants in the long-term screening group will undergo baseline data collection and a 12-lead ECG at baseline, followed using a 7-day single-lead long-term ECG monitoring device. This device continuously collects dynamic ECG data for seven days and allows participants to view and store ECGs through the accompanying software (registration number: 20192070163).
214734502|NCT06842147|DEVICE|Standard Screening Group|Patients in the standard screening group will undergo baseline data collection and a standard 12-lead ECG at the start of the study, with follow-up including opportunistic ECG checks as needed. Those diagnosed with AF will receive anticoagulation and antiarrhythmic therapy according to clinical guidelines.
215030625|NCT06265441|PROCEDURE|Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected|The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
214734503|NCT04921865|DEVICE|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
214734504|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
214734505|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
214734506|NCT04173481|OTHER|Rood's Group|"ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
215030626|NCT06265441|PROCEDURE|Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%|The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
215030627|NCT02420717|DRUG|Cyclophosphamide|Given IV
215030628|NCT02420717|DRUG|Cytarabine|Given IV
215030629|NCT02420717|DRUG|Dasatinib|Given PO
215030630|NCT02420717|DRUG|Dexamethasone|Given PO or IV
215030631|NCT02420717|DRUG|Doxorubicin|Given IV
215030632|NCT02420717|OTHER|Laboratory Biomarker Analysis|Correlative studies
215030633|NCT02420717|DRUG|Leucovorin|Given IV or PO
214734507|NCT04173481|OTHER|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
214734508|NCT06981741|BIOLOGICAL|BP CC 001|10-20 x 10\^6 UC-MSC in 1 ml suspension, applied to a collagen carrier structure (Chondro-Gide®)
214734509|NCT06806657|BIOLOGICAL|Garadacimab|Participants will receive a loading dose of garadacimab, followed by once monthly garadacimab administration for 2 months. Garadacimab will be given as a subcutaneous injection. The timing for the administration of the loading dose (first administration of garadacimab) is determined by the dosing schedule of the current HAE prophylactic treatment. No washout necessary.
214734510|NCT03307473|BEHAVIORAL|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
214734511|NCT00367627|DRUG|Albendazole|
214734512|NCT01756365|PROCEDURE|Surgical transplantation of ACCE|The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
214734513|NCT05999240|DRUG|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
214734514|NCT05999240|DRUG|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
215030634|NCT02420717|DRUG|Mercaptopurine|Given PO
215030635|NCT02420717|DRUG|Methotrexate|Given IV and PO
215030636|NCT02420717|DRUG|Prednisone|Given PO
215030637|NCT02420717|BIOLOGICAL|Rituximab|Given IV
214734515|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
214734516|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
214734517|NCT06421415|DRUG|Allergen Immunotherapy Extract|Patients will be treated as usual. The study is an observation of the long term effect of the treatment
214734518|NCT02204111|OTHER|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
214734519|NCT02497053|DRUG|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
214734520|NCT02497053|DRUG|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
214734521|NCT06654336|RADIATION|Recurrence-directed therapy (RDT)|RDT options include radiotherapy or surgical resection.
214734522|NCT06654336|DRUG|ELIGARD 22.5mg|ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
214734523|NCT02974660|DRUG|Protamine sulfate|
214734524|NCT02974660|DRUG|0.9% NaCl|
214734525|NCT05529862|GENETIC|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
214734526|NCT05529862|GENETIC|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
214734527|NCT05529862|GENETIC|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
214734528|NCT05529862|GENETIC|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
214734529|NCT04005755|DRUG|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
214734530|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
214734531|NCT00681902|DRUG|Placebo|Jet saline
214734532|NCT06594627|DEVICE|Smart pillow|Utilize a smart pillow that is designed to reduce snoring issues and OSA symptoms during sleep
214734533|NCT00909883|DRUG|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
214734534|NCT00909883|DRUG|Placebo|Placebo injection
214734535|NCT06816368|DEVICE|Catheter ablation using sequential radiofrequency and pulsed field ablation|We are using sequential application of radiofrequency and pulsed field ablation to increase lesion depth and better treat ventricular arrhythmias.
214734536|NCT06986317|OTHER|Positional release techniques|Positional release techniques apply for 90 second with the frequency of 3. This protocol will given 2 times in a week.
214734537|NCT06986317|OTHER|Graston technique|Graston technique will apply at 45 degree to muscle fiber for 60 sec with the frequency of three. 2 session will be given per week
214734538|NCT06085937|DRUG|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
214734539|NCT06662994|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
214734540|NCT02723019|BEHAVIORAL|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
214734541|NCT06490536|DRUG|Oxaliplatin|"Oxaliplatin is used as part of the chemotherapy regimens for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Oxaliplatin 130 mg/m² is given intravenously on day 1, in combination with capecitabine 1000 mg/m² taken orally twice daily on days 1-14 of each 21-day cycle.~FOLFOX Regimen: Oxaliplatin 85 mg/m² is administered intravenously on day 1, alongside folinic acid 400 mg/m² and fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~Dosages are standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
215030638|NCT02420717|DRUG|Ruxolitinib Phosphate|Given PO
215030639|NCT02420717|DRUG|Vincristine|Given IV
215030640|NCT00009542|DRUG|kava (Piper methysticum)|
215030641|NCT01123187|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
215030642|NCT06644963|DEVICE|Impella (5, 5.5 or CP)|Impella (5, 5.5 or CP) as an isolated circulatory support or combined with others Temporary Mechanical Circulatory Support
215030643|NCT03133377|BEHAVIORAL|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
214734542|NCT06490536|DRUG|Capecitabine|"Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months."
214734543|NCT06490536|DRUG|Folinic acid|"Folinic acid is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1, in combination with oxaliplatin 85 mg/m² IV on day 1 and fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of folinic acid is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
214734544|NCT06490536|DRUG|Fluorouracil|"Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results."
214734545|NCT06490536|DRUG|Temozolomide|"Temozolomide is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial, specifically for those with MGMT-negative tumors. It is administered in the following way:~TEMIRI Regimen: Temozolomide 150-200 mg/m² is taken orally once daily on days 1-5 of each 28-day cycle, in combination with irinotecan 250 mg/m² administered intravenously on day 1 of each cycle.~The dosage of temozolomide is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734546|NCT06490536|DRUG|Irinotecan|"Irinotecan is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~TEMIRI Regimen: Irinotecan 250 mg/m² is administered intravenously on day 1 of each 28-day cycle, in combination with temozolomide 150-200 mg/m² taken orally once daily on days 1-5.~FOLFIRI Regimen: Irinotecan 180 mg/m² is given intravenously on day 1, in combination with folinic acid (leucovorin) 400 mg/m² IV, fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of irinotecan is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734547|NCT06490536|DRUG|Nivolumab|"Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734548|NCT06490536|DRUG|Ipilimumab|"Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734549|NCT06490536|DRUG|Trastuzumab|"Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734550|NCT06490536|DRUG|Pertuzumab|"Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734551|NCT06490536|DRUG|Panitumumab|"Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
214734552|NCT01453933|DRUG|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
214734553|NCT04461145|BEHAVIORAL|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
214734554|NCT04639505|DIAGNOSTIC_TEST|ELISA|ELISA kit detecting the serum AMH level
214734555|NCT04639505|DIAGNOSTIC_TEST|Chemiluminescence|CLIA method detecting the serum AMH level
214734556|NCT01952613|DEVICE|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
214734557|NCT05633160|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
214734558|NCT05633160|DRUG|67Cu-SAR-BBN|67Cu-SAR-BBN
214734559|NCT02324036|DEVICE|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
214734560|NCT02324036|BEHAVIORAL|Coached Care|Community health worker provides participation training to patient
215030644|NCT05328167|DRUG|Perflutren Protein-Type A Microspheres|Given IV
215030645|NCT05328167|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
215030646|NCT06238856|DRUG|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
214734561|NCT00513370|BIOLOGICAL|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
214734562|NCT01492166|DRUG|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
214734563|NCT05448937|PROCEDURE|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
214734564|NCT05448937|PROCEDURE|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
214734565|NCT04103203|DIAGNOSTIC_TEST|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
214734566|NCT05379192|OTHER|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
214734567|NCT00941707|DRUG|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
214734568|NCT00941707|DRUG|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
214734569|NCT01122823|BEHAVIORAL|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
214734570|NCT04717050|BEHAVIORAL|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
214734571|NCT04717050|BEHAVIORAL|Attention Control (AC)|12 month stretching program
214734572|NCT02394990|BEHAVIORAL|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
214734573|NCT02394990|BEHAVIORAL|ABI|
214734574|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
214734575|NCT02576093|DRUG|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
214734576|NCT02576093|DRUG|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
214734577|NCT02576093|DRUG|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
214734578|NCT02576093|DRUG|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
214734579|NCT00515099|DRUG|Antithymocyte globulin|Daily 4-day escalating dose
214734580|NCT00515099|DRUG|Placebo|Daily 4-day saline solution
214734581|NCT05837234|DEVICE|ULF SCS|Ultra low frequency spinal cord stimulation
214734582|NCT03648411|GENETIC|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
214734583|NCT03639688|PROCEDURE|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
214734584|NCT03639688|PROCEDURE|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
214734585|NCT01905306|PROCEDURE|computer guided implant planning|
214734586|NCT01905306|PROCEDURE|free hand implants placement|
214734587|NCT00592072|DIETARY_SUPPLEMENT|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
214734588|NCT00592072|OTHER|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
214734589|NCT05002036|DEVICE|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
214734590|NCT01071291|DRUG|Niaspan|Niaspan™
214734591|NCT01071291|DRUG|Comparator: Placebo|Placebo
214734592|NCT06587490|RADIATION|stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
214734593|NCT00475072|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
214734594|NCT00475072|DRUG|ribavirin|1000/1200mg po daily for 48 weeks
214734595|NCT00004147|DRUG|incyclinide|
214734596|NCT02630394|DRUG|Azithromycin|
214734597|NCT04732780|OTHER|No intervention|No intervention
214734598|NCT03035422|DRUG|Sequential Packaging (SET)|"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
214734599|NCT03035422|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at D0
214734600|NCT03035422|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
214734601|NCT03035422|DRUG|Care supports|According to the protocols of each center
214734602|NCT03035422|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
214734603|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
214734604|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
214734605|NCT03888976|PROCEDURE|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
214734606|NCT01047462|PROCEDURE|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
214734607|NCT06108440|OTHER|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
214734608|NCT06108440|OTHER|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
214734609|NCT02381262|BEHAVIORAL|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
214734610|NCT01228149|DRUG|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
214734611|NCT01228149|DRUG|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
214734612|NCT03148899|DRUG|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
214734613|NCT03148899|DRUG|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
214734614|NCT00979862|DRUG|Cediranib Maleate|Given PO
214734615|NCT00979862|DRUG|Cilengitide|Given IV
214734616|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
214734617|NCT06119568|DEVICE|Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).|Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
214734618|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
214734619|NCT01859884|BEHAVIORAL|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
214734620|NCT04340687|DEVICE|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
215030647|NCT06238856|DRUG|Placebo|Nebulized saline.
215030648|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
214734621|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
214734622|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
214734623|NCT01680562|OTHER|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
214734624|NCT03714789|OTHER|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
214734625|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
214734626|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
214734627|NCT03644316|DEVICE|BandGrip skin closure device|topical skin closure device
214734628|NCT03678506|DRUG|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
214734629|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
214734630|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
214734631|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
214734632|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
214734633|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
214734634|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
214734635|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
214734636|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
214734637|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
214734638|NCT05825365|DRUG|Selumetinib|Selumetinib
214734639|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
214734640|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
214734641|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
214734642|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
214734643|NCT02952430|PROCEDURE|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
214734644|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
214734645|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
214734646|NCT03160066|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
214734647|NCT03160066|DIETARY_SUPPLEMENT|Placebo|Placebo
214734648|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
214734649|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
214734650|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
214734651|NCT02750501|DEVICE|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
214734652|NCT02750501|OTHER|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
214734653|NCT01738594|DRUG|carfilzomib|Given IV
214734654|NCT01738594|DRUG|romidepsin|Given IV
214734655|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
214734656|NCT01481428|BEHAVIORAL|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
214734657|NCT01481428|BEHAVIORAL|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
214734658|NCT03510728|BEHAVIORAL|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
214734659|NCT03510728|BEHAVIORAL|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
214734660|NCT03510728|BEHAVIORAL|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
214734661|NCT00403390|DRUG|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
214734662|NCT00403390|DRUG|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
214734663|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
214734664|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
214734665|NCT05130229|BEHAVIORAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
214734666|NCT01393665|DRUG|PENNEL capsule|"hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
214734667|NCT01393665|DRUG|Placebo|Placebo
214734668|NCT05620485|PROCEDURE|laparoscopic-assisted CDC excision and hepaticojejunostomy|After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
214734669|NCT06666764|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
214734670|NCT06666764|OTHER|Control|Best medical care
214734671|NCT06675188|DRUG|PF-07275315|PF-07275315 solution for injection (single use only)
214734672|NCT06675188|OTHER|Placebo|Placebo solution for injection (single use only)
214734673|NCT07000162|RADIATION|Lattice radiation therapy|"A total dose will be 20 Gy, with a simultaneous boost to selected tumor regions (hot spots) reaching a minimum median dose of 50 Gy.~Peripheral blood (PB) samples for the immune cell characterization and quantification of immune-related circulating factors will be collected at baseline (pre-therapy) and within 7 -14 days after the end of the treatment (post-therapy)."
214734674|NCT03820479|OTHER|Protocol|Best practice of protocol
214734675|NCT07001852|OTHER|Endovascular Therapy (Mechanical Thrombectomy)|Endovascular therapy performed with CE-approved thrombectomy devices, initiated within 6 to 72 hours after stroke onset in patients with anterior circulation large vessel occlusion. The procedure is guided by an automated non-contrast CT detection tool and follows standard device-specific instructions for use.
214734676|NCT07001852|OTHER|Standard Medical Management|Standard medical management including therapies such as antiplatelet agents, anticoagulants, blood pressure control, and general supportive care. Delivered in accordance with institutional guidelines for acute ischemic stroke.
214734677|NCT06204926|DIAGNOSTIC_TEST|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
214734678|NCT06001892|BEHAVIORAL|Tennessee Youth Prepared for Success|both 5 day classroom interventions.
214734679|NCT01563406|OTHER|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
214734680|NCT01563406|OTHER|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
214734681|NCT01563406|DRUG|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
214734682|NCT01563406|DRUG|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
214734683|NCT06390150|DEVICE|Spinal Cord Stimulator|The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
214734684|NCT07009119|PROCEDURE|laparoscopic Pancreaticoduodenectomy|The patient is positioned in French position (right arm in, left arm abducted 90°), with a suprapubic area reserved for Pfannenstiel incision. A 6-port technique is used: sub-umbilical (12 mm), four semi-circular trocars (two 12 mm, two 5 mm), and a sub-xiphoid trocar for liver retraction. Laparoscopic pancreaticoduodenectomy (LPD) proceeds if no vascular invasion/metastasis is found. Key steps include Kocher's maneuver, vessel ligation (gastroepiploic, gastric, gastroduodenal), lymphadenectomy (stations 5-17), pancreatic neck transection, and jejunal division. Reconstruction involves duct-to-mucosa pancreaticojejunostomy (or invaginating if duct unfound), hepaticojejunostomy, and stapled gastrojejunostomy. Margins are examined post-resection. Harmonic scalpel/Ligasure and staplers are used.
214734685|NCT05259800|OTHER|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
214734686|NCT05259800|OTHER|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
214734687|NCT04815876|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
214734688|NCT04815876|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
214734689|NCT04815876|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
214734690|NCT02758912|DRUG|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
214734691|NCT06338852|OTHER|Socio demographic and evaluation questionnaires|Socio demographic and evaluation questionnaires Used to measure the awareness of gynaecologists about role of physical therapy in genital prolapse
214734692|NCT00329459|DRUG|sumatriptan succinate/naproxen sodium|
214734693|NCT00329459|DRUG|placebo|placebo to match
214734694|NCT02315417|DRUG|gevokizumab|
214734695|NCT02315417|DRUG|Placebo|
214734696|NCT02315417|DRUG|gevokizumab open-label|
214734697|NCT06245304|DEVICE|Dual chamber Medtronic pacemaker implantation.|"All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830."
214734698|NCT06245304|OTHER|DDD-50 pacing program|This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
214734699|NCT06245304|OTHER|AAI-DDD 50 pacing program|This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
214734700|NCT04236531|OTHER|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
214734701|NCT00991367|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
214734702|NCT00991367|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
214734703|NCT05375240|DRUG|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
214734704|NCT05375240|DRUG|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
214734705|NCT00944580|BIOLOGICAL|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
214734706|NCT00004889|BIOLOGICAL|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
214734707|NCT02602704|DRUG|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
214734708|NCT02602704|DRUG|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
214734709|NCT02825940|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
214734710|NCT02825940|DRUG|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.
214734711|NCT02825940|DRUG|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
214734712|NCT00576368|DRUG|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
214734713|NCT05959915|DEVICE|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
214734714|NCT03942172|DEVICE|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
214734715|NCT02812615|DIETARY_SUPPLEMENT|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
214734716|NCT02812615|DIETARY_SUPPLEMENT|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
214734717|NCT02812615|DRUG|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
214734718|NCT02812615|BEHAVIORAL|Nutritional counselling|Parents/caregivers will be given nutritional counselling
214734719|NCT02812615|DIETARY_SUPPLEMENT|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
214734720|NCT02237898|BEHAVIORAL|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
214734721|NCT02237898|BEHAVIORAL|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
214734722|NCT02237898|DEVICE|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
214734723|NCT02237898|DEVICE|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
214734724|NCT06330766|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
214734725|NCT00442130|BIOLOGICAL|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
214734726|NCT00442130|PROCEDURE|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
214734727|NCT04884386|DEVICE|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
214734728|NCT04884386|BEHAVIORAL|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
214734729|NCT04432181|OTHER|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
214734730|NCT00417833|DRUG|Intravitreal Bevacizumab|
214734731|NCT01359111|DEVICE|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
214734732|NCT01562197|DRUG|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
214734733|NCT01562197|DRUG|Axitinib plus Lomustine|Lomustine 90mg/m²
214734734|NCT04063397|DIAGNOSTIC_TEST|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
214734735|NCT04063397|DIAGNOSTIC_TEST|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
214734736|NCT04864327|BEHAVIORAL|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
214734737|NCT03846076|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
214734738|NCT00275106|DRUG|asparaginase|
214734739|NCT00275106|DRUG|cyclophosphamide|
214734740|NCT00275106|DRUG|cytarabine|
214734741|NCT00275106|DRUG|daunorubicin hydrochloride|
214734742|NCT00275106|DRUG|dexamethasone|
214734743|NCT00275106|DRUG|doxorubicin hydrochloride|
214734744|NCT00275106|DRUG|leucovorin calcium|
214734745|NCT00275106|DRUG|mercaptopurine|
214734746|NCT00275106|DRUG|methotrexate|
214734747|NCT00275106|DRUG|prednisolone|
214734748|NCT00275106|DRUG|thioguanine|
214734749|NCT00275106|DRUG|vincristine sulfate|
214734750|NCT00275106|PROCEDURE|radiation therapy|
214734751|NCT01708915|DRUG|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
214734752|NCT01708915|DRUG|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
214734753|NCT01708915|DRUG|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
214734754|NCT01708915|DRUG|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
214734755|NCT01666015|OTHER|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
214734756|NCT01666015|OTHER|Standard Care|This group will be under standard care without any EX intervention.
214734757|NCT02907411|OTHER|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
214734758|NCT02072733|OTHER|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
214734759|NCT02171156|DRUG|nintedanib|soft gelatin capsule
214734760|NCT00108615|DRUG|Metformin|
214734761|NCT00108615|DRUG|Pioglitazone|
214734762|NCT00108615|DRUG|Metformin|
214734763|NCT00108615|DRUG|Pioglitazone|
214734764|NCT00108615|RADIATION|CT scans|To measure changes in adipose tissue volumes
214734765|NCT00108615|PROCEDURE|Oral glucose tolerance test|To detect a change in glucose tolerance
214734766|NCT05242809|BEHAVIORAL|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
214734767|NCT05651074|DRUG|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
214734768|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
214734769|NCT02802657|PROCEDURE|Treat-and-Extend regimen|For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
214734770|NCT02802657|PROCEDURE|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
214734771|NCT02802657|DRUG|Conbercept|
214734772|NCT03414268|OTHER|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
214734773|NCT03414268|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
214734774|NCT04856969|DRUG|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
214734775|NCT04856969|DRUG|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
214734776|NCT04272762|PROCEDURE|Cryoablation|Pulmonary vein isolation with cryoablation
214734777|NCT04272762|PROCEDURE|Placebo|Placebo procedure
214734778|NCT00353340|DRUG|n acetylcysteine|
214734779|NCT00353340|DRUG|sodium bicarbonate|
214734780|NCT00353340|DRUG|sodium chloride|
214734781|NCT04738240|DIAGNOSTIC_TEST|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
214734782|NCT05699044|DIAGNOSTIC_TEST|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
214734783|NCT04453891|DEVICE|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
214734784|NCT03231228|DRUG|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
214734785|NCT03231228|DRUG|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
214734786|NCT07028385|DRUG|Bariticinib 2 mg|Commercially available tablets containing 2 mg of barticiinib will be used. The tablets will be re-capsulated to keep the study blind.
214734787|NCT07028385|OTHER|Placebo|Maltodextrin capsules with identical weight and appearance (shape, size, colour and flavour) as the bariticinib-containing capsules.
214734788|NCT06720597|DRUG|Daily low-dose PDE5 inhibitor therapy|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
214734789|NCT06720597|DRUG|Testosterone therapy as per clinical guidelines.|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
214734790|NCT07063277|DEVICE|Preoperative Evaluation with ORI and Spirometry|"All participants in this single-arm diagnostic study will undergo preoperative evaluation involving two non-invasive respiratory assessment methods: the Oxygen Reserve Index (ORI) and spirometry. ORI will be measured using a multi-wavelength pulse co-oximetry sensor placed on the patient's fingertip. This sensor provides a continuous, real-time index (ranging from 0.00 to 1.00) that reflects the patient's oxygen reserve within a PaO₂ range of approximately 100-200 mmHg.~Spirometry will be performed using standard pulmonary function testing protocols. Each patient will be instructed to perform forced expiratory maneuvers to obtain parameters including forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and the FEV₁/FVC ratio. These values will be recorded prior to surgery and interpreted according to internationally accepted reference ranges."
214734791|NCT06853470|DEVICE|VA-ECMO circulatory support|Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a percutaneous mechanical circulatory support device that can provide short-term hemodynamic support during high-risk PCI.
214734792|NCT06853470|DEVICE|SynFlow 3.0 circulatory support|The SynFlow 3.0 is a novel percutaneous left ventricular-assist device that can provide temporary hemodynamic support during high-risk procedure.
214734793|NCT06853470|PROCEDURE|percutaneous coronary intervention|The percutaneous coronary intervention is a percutaneous endovascular intervention technique that can restore coronary blood flow by various intervention methods such as angioplasty and stent implantation.
214734794|NCT07137845|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
214734795|NCT07137845|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
214734796|NCT07137845|PROCEDURE|Sham CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
214734797|NCT07077460|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
214734798|NCT07077460|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is applied in Mirror therapy.
214734799|NCT07077460|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
214734800|NCT07077460|DEVICE|Graded-Pressure Haptic Device (Passive press-feedback cushion)|A passive press-feedback cushion (Graded-Pressure Haptic Device) would deliver force pulses to the subjects' non-dominant fingertips in synchrony with the TiPR game's force output (matched amplitude)
214734801|NCT05681442|DRUG|continuous pivotal βL-AB|continuous pivotal βL-AB
214734802|NCT05681442|DRUG|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
214734803|NCT05681442|DRUG|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
214734804|NCT05681442|DRUG|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
214734805|NCT07076342|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)
214734806|NCT07076342|DRUG|PET Scan with [11C]ABP688|Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \[11C\]ABP688) to quantify hippocampal mGluR5 density.
214734807|NCT06931080|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 6 weeks
214734808|NCT06931080|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 6 weeks
214734809|NCT06931080|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
214734810|NCT07086560|DRUG|IV adenosine|Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment
214734811|NCT07086560|DRUG|IV diltiazem|Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment
214734812|NCT01412762|BEHAVIORAL|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
214734813|NCT01412762|BEHAVIORAL|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
214734814|NCT07094971|DEVICE|Pure Impact|Pure Impact is an EMS module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.
214734818|NCT07102342|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain
214734819|NCT07101848|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. Patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
214734820|NCT07102537|DEVICE|Hyaluronic acid combined with calcium hydroxyapatite injection|The filler was injected in nasolabial folds in a before-after setting
214734821|NCT07101432|DRUG|Fludarabine|Given by infusion
214734822|NCT07101432|DRUG|Cyclophosphamide|Given by infusion
214734823|NCT07100977|DIETARY_SUPPLEMENT|Bragg ACV Supplement|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
214734824|NCT07100977|OTHER|Placebo|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
214734825|NCT07100483|PROCEDURE|Atrial Fibrillation Ablation|Ablation of the heart to reduce Afib Occurrence
214734826|NCT07095972|DEVICE|Abbot Freestyle Libre CGM|Participants assigned to the CGM group will receive the Libre 2+ systems (Abbott Diabetes Care, Alameda, CA) upon randomization. This will include comprehensive training provided by a qualified healthcare professional. The training will cover detailed instructions on sensor placement, how to download and use the associated smartphone application, and guidance on interpreting the glucose data effectively. To ensure continuous and accurate monitoring, the CGM sensor will be routinely replaced every 14 days following randomization. Additionally, in the event of sensor detachment or loss, immediate replacement will be arranged to maintain uninterrupted glucose tracking. Regular sessions are conducted to analyze glucose trends, refine management strategies, and provide additional support or education on device usage.
214734827|NCT07102017|DEVICE|Passive Robotic Support for Enhanced Well-Being|Previous research primarily compared scenarios with robots versus without robots, while this study examines how differences in robot activity levels and interaction levels affect older adults' well-being. In this study, this intervention includes a passive robot that would not initiate any interactions with older adults. In this arm, we employed LOVOT as a passive comfort object that only reacts to older adults when being triggered. Besides, this robot has no voice (i.e. the device was muted).
214734828|NCT07102017|DEVICE|Proactive Robotic Support for Enhanced Well-Being|This intervention differs significantly from the Passove Robotic Support for Enhanced Well-Being primarily through its proactive social engagement capabilities and autonomous agency. This intervention actively seeks interaction by enabling free movement, approaching individuals, and following them. Furthermore, the robot in this intervention responds dynamically to auditory stimuli with sounds and head tilts, offering a richer, reciprocal interaction compared to Arm 1's limited reactive purring and eye blinks. This shift transforms the LOVOT's role from a passive comfort object into an active social catalyst designed to stimulate engagement and reciprocity.
214734829|NCT07101120|DRUG|KH607 tablets|oral 30mg , once daily for 14 days
214734830|NCT07101120|DRUG|placebo|oral, once daily for 21 days
214734831|NCT07101120|DRUG|KH607 tablets|oral 20mg, once daily for 21 days
214734832|NCT07101120|DRUG|KH607 tablets|oral 30mg, once daily for 21 days
214734833|NCT07102056|DIAGNOSTIC_TEST|18F-AlF-NOTA-Octreotide PET-CT or PET-MR|18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging
214734834|NCT07100197|DEVICE|continuous Theta-burst stimulation|Treatment parameters: each cTBS session consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 s, totaling 600 pulses, and every set simulation includes 3 sessions. Electrodes are attached to designated head regions (right dorsolateral prefrontal cortex).
214734835|NCT07100197|DEVICE|Sham|the treatment mode was with sham coil.
214734836|NCT07101185|DEVICE|VIRTUAL REALITY|"The interventional part of the study is limited to 3 centers. It explores SOCIAL COGNITION throught a newly developed paradigm in Virtual Reality.~In detail: an adapted version of the Virtual Reality Social Prediction Improvement and Rehabilitation Intensive Training (VR-SPIRIT) using a VR Head Mounted Display (HMD) will be implemented on a portable HMD, the Oculus Quest, equipped with two controllers with motion sensors that are used to track hand position.~In a VR-SPIRIT session, participants are immersed in the playground scenario and engaged in a competition with four avatars. Each avatar has a pre-established probability to move toward one of the three described games.~Different indices about a partecipant's performance are recorded automatically by the system during the session, such as the duration of each trial and the prediction score (percentage of trials in which the participant correctly predicted an avatar's intention)."
214734837|NCT06921837|DRUG|BDC-4182|Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
214734838|NCT07120477|DRUG|Intravenous Esketamine|Single-session intravenous esketamine infusion (0.5 mg/kg) administered over 40 minutes in a medical setting with continuous monitoring of vital signs, blood pressure, ECG, and oxygen saturation for 4 hours post-infusion. Administration supervised by trained medical staff with emergency protocols available. Participants will be discharged 24 hours post-infusion if no clinical complications arise, with ambulatory evaluations at 48 hours, 72 hours, and 7 days post-infusion.
214734839|NCT07120477|OTHER|Crisis Response Planning intervention (structures safety planning)|Collaborative safety planning intervention delivered by trained clinical psychologists in 20-45 minute sessions. Participants create personalized, written crisis response plans identifying warning signs of emotional distress, internal coping strategies, social support contacts, professional resources, and means restriction methods. The intervention follows a structured format focusing on practical crisis management tools that participants can implement during suicidal crises.
214734840|NCT07122219|BEHAVIORAL|NIATx|The Network for the Improvement of Addiction Treatment (NIATx) model uses a bundle of implementation tools that include expert facilitation (coaching) and quality process improvement specifically for behavioural healthcare settings to improve access and retention in treatment.
214734841|NCT07134101|DRUG|Serplulimab|Serplulimab 300 mg IV on Day 1
214734842|NCT07134101|DRUG|Bevacizumab|Bevacizumab 5 mg/kg IV on Day 1
214734843|NCT07134101|RADIATION|Short-Course Radioterapy|25 Gy in 5 fractions over 1 week
214734844|NCT07134101|DRUG|Chemotherapy (CAPOX or capecitabine)|Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle
214734845|NCT07132489|DIAGNOSTIC_TEST|HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio|"1. To investigate whether the HbA1c to C-peptide ratio can serve as a predictive marker for no-reflow, reflecting the impact of chronic glycemic control and pancreatic beta-cell function.~2. To evaluate the neutrophil-to-HDL ratio as a potential indicator of no-reflow, representing the balance between systemic inflammation and endogenous vascular protection.~3. To examine the prognostic value of the albumin-bilirubin (ALBI) score in identifying patients at higher risk for no-reflow, considering the systemic influence of hepatic function and inflammation."
214734846|NCT07139886|DRUG|Stillen® Tab|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
214734847|NCT07139886|DRUG|Stillen® Tab Placebo|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
214734848|NCT07137767|DEVICE|Quantitative refractive crosslinking|Non-invasive corneal crosslinking device delivering controlled UV light through a contact lens platform for refractive reshaping of the cornea.
214734849|NCT07142486|DRUG|Omeprazole 20 mg|"Omeprazole 20mg capsule~1 dose = 1 capsule~Participants will consume one dose per day for 5 days prior to their study visit. They will also consume one dose the day of the study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
214734850|NCT07142486|OTHER|Placebo|"Placebo~1 dose of placebo = 1 capsule filled with maltodextrin~Participants will consume 1 dose per day for 5 days prior to their study visit. They will then consume 1 dose the day of their study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
214734851|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
214734852|NCT07149051|BEHAVIORAL|Gamified Sensory Integration Exercise Program|This study implemented a gamified physical activity intervention aimed at improving sensory integration abilities among first-grade students with sensory processing difficulties. The intervention program incorporated game narratives, mechanisms, and components into physical education activities, guided by the Octalysis Framework to strategically engage both extrinsic (e.g., rewards, rankings) and intrinsic (e.g., creativity, social interaction, meaning) motivational drives.
214734853|NCT07147803|OTHER|Pittsburgh Sleep Quality Index|PSQI (Arabic validated version) - main sleep measure; global score 0-21; PSQI \>5 = poor sleep quality.
214734854|NCT07147491|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
214734855|NCT07147699|DEVICE|cardiostory|measure the pressure of remplissage
214734856|NCT07147413|BEHAVIORAL|Behavioral/Digital Health Intervention|Participants in this group will utilize an AI-powered digital health management platform designed to optimize blood pressure control. The platform provides personalized medication and blood pressure measurement reminders, tailored health education, and interactive quizzes to improve hypertension awareness and engagement. Data from blood pressure monitors will be scanned and uploaded, and the system will alert participants and case managers to abnormal readings, enabling timely interventions.
214734857|NCT07148427|DRUG|Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy|Iparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX
214734858|NCT06109363|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I intervention will be provided to participants once their districts are exposed.
214734859|NCT03853252|OTHER|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
214734860|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
214734861|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
214734862|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
214734863|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
214734864|NCT05238324|BIOLOGICAL|Genetic HMI-203|HMI-203 delivered intravenously
214734865|NCT04826640|OTHER|Observational|Observational
214734866|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
214734867|NCT02554721|DRUG|Cilostazol|
214734868|NCT02554721|DRUG|Acetylsalicylic acid|
214734869|NCT02554721|DRUG|Clopidogrel|
214734870|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
214734871|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
214734872|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
214734873|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
214734874|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
214734875|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
214734876|NCT04814355|DRUG|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
214734877|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
214734878|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
214734879|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
214734880|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
214734881|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
214734882|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
214734883|NCT05846919|PROCEDURE|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
214734884|NCT05846919|PROCEDURE|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
214734885|NCT05846919|PROCEDURE|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
214734886|NCT06455800|DIAGNOSTIC_TEST|lung function measurements|Patients will once a year be monitored with different lung function methods
214734887|NCT00232050|DRUG|Omalizumab|
214734888|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
214734889|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
214734890|NCT02829606|OTHER|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
214734891|NCT02829606|OTHER|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
214734892|NCT02432911|DRUG|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
214734893|NCT02432911|DRUG|low dose cytarabine|cytarabine 20mg bid for 10 days.
214734894|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
214734895|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
214734896|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
214734897|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
214734898|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
214734899|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
214734900|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
214734901|NCT06447935|OTHER|No intervention|not applicable - no intervention required
214734902|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
214734903|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
214734904|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
214734905|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
214734906|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
214734907|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
214734908|NCT00421616|BEHAVIORAL|High protein diet study|
214734909|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
214734910|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
214734911|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
214734912|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
214734913|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
214734914|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
214734915|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
214734916|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
214734917|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
214734918|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
214734919|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
214734920|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
214734921|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
214734922|NCT05587439|GENETIC|Data and Specimen Collection|"* Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members"
214734923|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
214734924|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 0|10 (8-12) x 10\^6 MSCs
214734925|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 1|20 (16-24) x 10\^6
214734926|NCT03750344|DEVICE|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
214734927|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
214734928|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
214734929|NCT02094612|DEVICE|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
214734930|NCT02094612|BEHAVIORAL|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
214734931|NCT05929937|DRUG|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
214734932|NCT05929937|OTHER|No opioids|Standard of care, patients will not receive a prescription for opioids.
214734933|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
214734934|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
214734935|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
214734936|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
214734937|NCT03416517|DRUG|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
214734938|NCT03416517|DRUG|Irinotecan|Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
214734939|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
214734940|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
214734941|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
214734942|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
214734943|NCT04768920|BEHAVIORAL|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
214734944|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
214734945|NCT00723489|DRUG|YFV-17D Placebo|
214734946|NCT04838340|OTHER|Standart care|This group will leave in the hospital's usual care and no intervention will be applied.
214734947|NCT04838340|BEHAVIORAL|Hypnobirthig training|"Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor."
214734948|NCT02171806|DRUG|BI 1744 CL|
214734949|NCT02171806|DRUG|Placebo|
214734950|NCT03033992|DEVICE|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
214734951|NCT03033992|COMBINATION_PRODUCT|Concurrent Optune and RT followed by Optune System alone|In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
214734952|NCT05852925|OTHER|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
214734953|NCT05852925|DEVICE|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
214734954|NCT03803553|DRUG|FOLFIRI Protocol|FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
214734955|NCT03803553|OTHER|ACTIVE SURVEILLANCE|Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
214734956|NCT03803553|DRUG|Nivolumab Protocol|Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.
214734957|NCT03803553|DRUG|Encorafenib/Binimetinib/Cetuximab Protocol|Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.
214734958|NCT03803553|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
214734959|NCT03900026|DRUG|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
214734960|NCT03900026|OTHER|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
214734961|NCT06127173|OTHER|Positive End Expiratory Pressure PEEP|children will receive different levels of PEEP during induction of anesthesia
214734962|NCT00081263|DRUG|Celecoxib|Given orally
214734963|NCT00081263|OTHER|Laboratory Biomarker Analysis|Correlative studies
214734964|NCT00081263|OTHER|Placebo|Given orally
214734965|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
214734966|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
214734967|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
214734968|NCT06249386|BEHAVIORAL|Behavioral Activation (BA)|BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.
214734969|NCT06249386|BEHAVIORAL|Relapse Prevention (RP)|RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
214734970|NCT05920343|DRUG|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
214734971|NCT05920343|OTHER|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
214734972|NCT04517253|DRUG|Baricitinib|Administered orally
214734973|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
214734974|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
214734975|NCT05681780|BIOLOGICAL|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
214734976|NCT05681780|DRUG|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
214734977|NCT05681780|DRUG|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
214734978|NCT05681780|DRUG|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
214734979|NCT05681780|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
214734980|NCT05681780|DRUG|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
214734981|NCT03140033|DRUG|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
214734982|NCT03140033|DRUG|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
214734983|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
214734984|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
214734985|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
214734986|NCT06380556|DEVICE|ShotBlocker|The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
214734987|NCT06380556|DEVICE|Mechanical vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
214734988|NCT00486590|PROCEDURE|Prolact-Plus Human Milk Fortifier|
214734989|NCT03353441|DIETARY_SUPPLEMENT|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
214734990|NCT03353441|DIETARY_SUPPLEMENT|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
214734991|NCT05415865|COMBINATION_PRODUCT|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
214734992|NCT05415865|DRUG|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
214734993|NCT02559115|RADIATION|68Ga-RM2 (RM2)|
214734994|NCT02559115|DEVICE|PET/CT Scan|
214734995|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
214734996|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
214734997|NCT05841277|DRUG|LY3819469|Administered SC.
214734998|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
214734999|NCT02954861|OTHER|No intervention|No intervention
214735000|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
214735001|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
214735002|NCT00693563|BEHAVIORAL|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
214735003|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
214735004|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
214735005|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
214735006|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
214735007|NCT02060903|DRUG|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
214735008|NCT02060903|DRUG|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
214735009|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
214735010|NCT06574555|DRUG|Norepinephrine|"The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30."
214735011|NCT04332848|DRUG|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
214735012|NCT04332848|DRUG|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
214735013|NCT05501457|DEVICE|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
214735014|NCT01003340|BEHAVIORAL|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
214735015|NCT03727633|DRUG|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
214735016|NCT03993119|DRUG|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
214735017|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
214735018|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
214735019|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
214735020|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
214735021|NCT05029193|BEHAVIORAL|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
214735022|NCT06069999|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
214735023|NCT06202027|DRUG|FGF23-related hypophosphataemic rickets and osteomalacia|FGF23-related hypophosphataemic rickets and osteomalacia
214735024|NCT05308966|OTHER|Data collection|Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
214735025|NCT05664126|DRUG|VST infusion|single intravenous (IV) infusion.
214735026|NCT05664126|DEVICE|CliniMACS|Cells infusions are prepared using the ClinMACS
214735027|NCT05889273|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
214735028|NCT05550857|OTHER|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
214735029|NCT05550857|OTHER|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
214735030|NCT05379933|OTHER|Remote health coaching to improve self-care behaviors|Participants will be asked to wear an activity tracker, complete brief surveys, and participate in weekly health coaching sessions remotely for 8 weeks
214735031|NCT00141622|DRUG|Slow sodium|
214735032|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
214735033|NCT06549699|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
214735034|NCT06549699|OTHER|Usual Care|Usual care plus healthy recipes provided
214735035|NCT05898659|DEVICE|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
214735036|NCT05898659|DEVICE|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
214735037|NCT06371404|DRUG|Bavarostat|Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
214735038|NCT06810544|DRUG|TNG456|A selective PRMT5 inhibitor
214735039|NCT06810544|DRUG|abemaciclib|A kinase inhibitor
214735040|NCT00879047|DRUG|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
214735041|NCT00879047|DRUG|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
214735042|NCT02788825|PROCEDURE|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
214735043|NCT05439304|OTHER|No intervention|No intervention
214735044|NCT00537459|DRUG|16448|
214735045|NCT01770119|BIOLOGICAL|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
214735046|NCT04660006|PROCEDURE|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
214735047|NCT02329860|DRUG|Apatinib|
214735048|NCT02329860|DRUG|Placebo|
214735049|NCT05306262|PROCEDURE|Hypnosis session|Comfort hypnosis: accompaniment of a pleasant memory.
214735050|NCT05306262|OTHER|Catalepsy|Catalepsy of the hand.
214735051|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
214735052|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
214735053|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
214735054|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
214735055|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
214735056|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
214735057|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
214735058|NCT06977321|OTHER|Kinesiotaping|Kinesiotaping, unlike wrist splints, which are frequently used in the treatment of carpal tunnel syndrome, does not restrict daily living activities. Space correction technique will be applied while performing kinesio taping.
214735059|NCT06977321|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
214735060|NCT06977321|OTHER|Home exercise|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
214735061|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
214735062|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
214735063|NCT06980181|OTHER|Graded Motor Imagery|Graded Motor Imagery typically 1 to 3 times per day for 5 to 10 minutes for each phase. No physical movement at first only cognitive task, mental rehearsal and visual motor.
214735064|NCT06980181|OTHER|Mirror Therapy|Mirror Therapy typically involves 1 to 3 sessions per day for 10 to 15 minutes gradually increases as tolerated.Visual and motor training using a mirror placed at the midline.
214735065|NCT06599073|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest
214644625|NCT04482946|DIAGNOSTIC_TEST|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
214644626|NCT00498745|DRUG|neratinib|HKI-272
214644627|NCT00167245|DRUG|Topiramate|300mg/day for 13 weeks
214644628|NCT00167245|DRUG|placebo|placebo pills
214644629|NCT06113874|OTHER|Hurriseal desensitizer|"Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
214644630|NCT06113874|OTHER|Gluma desensitizer|"Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
214644631|NCT04753398|DEVICE|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
214644632|NCT02307916|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
214644633|NCT02307916|OTHER|Placebo|Placebo comparator using a sterile saline solution.
214644634|NCT00746967|DRUG|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
214644635|NCT04273048|OTHER|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
214644636|NCT04273048|OTHER|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
214644637|NCT02641535|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
214735066|NCT06599073|DEVICE|Rescue|RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
214735067|NCT05182294|DEVICE|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
214644638|NCT02641535|DEVICE|BC membrane protective garment|
214644639|NCT02641535|DEVICE|NBC mask|
214644640|NCT02790866|BEHAVIORAL|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
214644641|NCT02790866|BEHAVIORAL|NCI Website|NCI Website on Lung Cancer Screening
214644642|NCT00855660|DRUG|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
214644643|NCT00855660|DRUG|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
214644644|NCT03285932|RADIATION|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
214735068|NCT06983782|OTHER|Exercise and education programme|Participants will complete 8-week online exercise programme consisting of an online exercise class once per week. The exercises will target improving strength, balance and range of movement. In addition, participants will receive educational materials on exercise, nutrition, walking changes, fatigue, optimizing bone health, pain management, mental health, sleep and physical activity maintenance.
214735069|NCT06983782|OTHER|control group|The control group will receive educational materials over 8 weeks
214735070|NCT00705380|BEHAVIORAL|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
214735071|NCT00705380|BEHAVIORAL|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
214735072|NCT02789072|OTHER|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
214735073|NCT00169338|PROCEDURE|Deep brain stimulation|internal pallidal deep brain stimulation
214735074|NCT03012360|DRUG|ceftriaxone|2 g iv every 24h
214735075|NCT03012360|DRUG|ciprofloxacin|400 mg iv every 8h
214735076|NCT03012360|DRUG|imipenem|1 g iv every 8h
214735077|NCT03012360|DRUG|linezolid|600 mg iv every 12h
214735078|NCT03012360|DRUG|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
214735079|NCT05017168|DRUG|CT-P63|CT-P63 will be administered
214735080|NCT05017168|DRUG|Placebo|Placebo-matching CT-P63
214735081|NCT00608491|DRUG|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
214735082|NCT00608491|DEVICE|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
214735083|NCT00958191|DEVICE|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
214735084|NCT01184339|DEVICE|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
214735085|NCT05929677|DRUG|Placebo|Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.
214735086|NCT05929677|DRUG|Alcohol|Participants receive alcohol intravenously, clamped at BrACs of 20mg%, 40mg%, and 60mg%. They will also have the opportunity to self-administer alcohol (up to 120mg% BrAC) during the 60-minute free-access IV self-administration period in session 3.
214735087|NCT05728749|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
214735088|NCT03216668|DRUG|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
214735089|NCT03216668|DRUG|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
214735090|NCT04128072|DRUG|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
214735091|NCT04128072|RADIATION|Total Skin Electron Beam Therapy (TSEB)|"* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration."
214735092|NCT04128072|DRUG|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
214735093|NCT00611767|DRUG|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
214735094|NCT00611767|DRUG|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
214735095|NCT00135993|DRUG|Rotigotine|
214735096|NCT04940741|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
214735097|NCT04940741|OTHER|Placebo|comparator without active ingredient
214735098|NCT03272880|BEHAVIORAL|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
214735099|NCT05185219|DRUG|Valerian|A natural plant
214735100|NCT02010567|DRUG|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
214735101|NCT02010567|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
214735102|NCT02010567|RADIATION|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
214735103|NCT02010567|PROCEDURE|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
214735104|NCT00118040|DRUG|Genistein|Given orally
214735105|NCT00118040|OTHER|Laboratory Biomarker Analysis|Correlative studies
214735106|NCT00118040|OTHER|Pharmacological Study|Correlative studies
214735107|NCT00118040|OTHER|Placebo Administration|Given orally
214735108|NCT00118040|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
214735109|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
214735110|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
214735111|NCT05018091|DRUG|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
214735112|NCT05018091|DRUG|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
214735113|NCT05018091|DRUG|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
214735114|NCT00485121|DRUG|Ezetimibe|
214735115|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
214735116|NCT06246864|OTHER|Hydrocolloid dressing|After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
214735117|NCT06246864|OTHER|Hypoallergenic Flexible|After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
214735118|NCT00152841|DRUG|Iron supplement 300-600 mg/day|
214735119|NCT00152841|DRUG|Vitamin E 800IU|
214735120|NCT06992934|DRUG|Gilteritinib|Administration of Gilteritinib
214735121|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks
214735122|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
214735123|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
214735124|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
214735125|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
214735126|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
214735127|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
214735128|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
214735129|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
214735130|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
214735131|NCT03100006|DRUG|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
214735132|NCT03100006|DRUG|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
214735133|NCT06861647|OTHER|sample collection|sample collection of surplus samples not needed for diagnostic or pathological requirements
214735134|NCT06861647|OTHER|Discussing study/seeking consent|An NHS or CRN staff member will inform patients of the nature and objectives of the study, go through the participant information sheet, highlighting possible risks associated with their participation and reiterate the voluntary nature of this study. Patients will be given opportunities to ask questions pertaining to the study. If the potential participant is still interested in taking part, written informed consent for the study will then be received and a copy of the informed consent will be given to the participant to keep.
214735135|NCT06861647|OTHER|Completion of Study Questionnaire|Patient will complete in own time. To take place in a routine outpatient clinic appointment
214735136|NCT06861647|OTHER|Blood Sample|To take place in an outpatient clinic.
214735137|NCT06308653|DRUG|Psilocybin 25 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
214735138|NCT06308653|DRUG|Inactive Placebo|The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
214735139|NCT06308653|DRUG|Psilocybin 5 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
214735140|NCT06308653|BEHAVIORAL|Psychosocial Support|Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
214735141|NCT05605041|DEVICE|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
214735142|NCT04272801|DRUG|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
214735143|NCT04272801|BEHAVIORAL|Patient reported outcomes|"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
214735144|NCT06617858|DRUG|AMB-05X|Given by IV
214735145|NCT06998784|DEVICE|taVNS|"Patients will receive taVNS at left tragus (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows:~* Duty circle: 30s on periods alternating with 30s off periods;~* Frequency: 25 Hz;~* Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient);~* Pulse width: 0.5 ms."
214735146|NCT06998784|DEVICE|Sham-taVNS|"Patients will receive taVNS at left earlobe (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows: \*Duty circle: 30s on periods alternating with 30s off periods; \*Frequency: 25 Hz; \*Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient); \*Pulse width: 0.5 ms."
214735147|NCT04060706|RADIATION|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
214735148|NCT06625073|DRUG|Empagliflozin|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
214735149|NCT06625073|DRUG|Placebo|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
214735150|NCT07009886|OTHER|Communication|Participants meet with clinician
214735151|NCT07012915|DIAGNOSTIC_TEST|Blood testing|Blood sample will be collected twice for each participants procedding and following dental implant removal. Cone Beam Computed Tomography will be applied to evaluate the shape, severity of bone defect in direct viscinity of the implant.
214735152|NCT03117309|DRUG|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
214735153|NCT03117309|DRUG|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
214735154|NCT03117309|DRUG|Nivolumab 3mg/kg|In combination with Ipilimumab
214735155|NCT03117309|DRUG|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
214735156|NCT04048876|DRUG|CC-90001|oral
214735157|NCT04048876|DRUG|Placebo|oral
214735158|NCT01089075|DRUG|Hydrocortisone|20 mg po for 7 days (2 tablets)
214735159|NCT01089075|DRUG|Placebo|2 tablets po
214735160|NCT05046236|OTHER|Interactive POWER rehabilitation|Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
214735161|NCT05046236|OTHER|Conventical physical training|Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
214735162|NCT02227901|DRUG|Tipifarnib|Given PO
214735163|NCT02227901|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214735164|NCT02227901|DRUG|Temozolomide|Given PO
214735165|NCT02227901|OTHER|Laboratory Biomarker Analysis|Correlative studies
214735166|NCT05007301|DEVICE|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
214735167|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
214735168|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
214735169|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
214735170|NCT06145763|OTHER|Survey Administration|Ancillary studies
214735171|NCT01368952|DEVICE|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
214735172|NCT04192760|PROCEDURE|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
214735173|NCT06043934|OTHER|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
214735174|NCT06043934|OTHER|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
214735175|NCT02685124|DIETARY_SUPPLEMENT|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
214735176|NCT04720560|DIAGNOSTIC_TEST|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
214735177|NCT02120560|PROCEDURE|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
214735178|NCT03374436|BEHAVIORAL|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
214735179|NCT03374436|BEHAVIORAL|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
214735180|NCT03374436|BEHAVIORAL|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
214735181|NCT07020702|DEVICE|Implantation of an ICD|Implantation of an ICD
214735182|NCT03103776|OTHER|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
214735183|NCT03764462|DRUG|AD-101 45mg|Raloxifene 45mg tablet
214735184|NCT03764462|DRUG|Raloxifene 60mg|Raloxifene 60mg tablet
214735185|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
214735186|NCT01297023|DIETARY_SUPPLEMENT|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
214735187|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
214735188|NCT01297023|OTHER|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
214735189|NCT03435276|DRUG|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
214735190|NCT03435276|OTHER|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
214735191|NCT05381389|DRUG|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
214735192|NCT05381389|DRUG|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
214735193|NCT04568876|DIETARY_SUPPLEMENT|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
214735194|NCT04568876|COMBINATION_PRODUCT|Standard Therapy|Standard therapy established for individual patients
214735195|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
214735196|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
214735197|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
214735198|NCT01159886|PROCEDURE|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
214735199|NCT00366938|DRUG|Lumiracoxib|
214735200|NCT03228849|PROCEDURE|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
214735201|NCT03228849|PROCEDURE|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
214735202|NCT04173403|DRUG|450mg AK102|AK102 Q4W
214735203|NCT04173403|DRUG|300mg AK102|AK102 Q4W
214735204|NCT04173403|DRUG|150mg AK102|AK102 Q2W
214735205|NCT04173403|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
214735206|NCT04101370|DRUG|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
214735207|NCT04101370|DRUG|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
214735208|NCT05823649|DIETARY_SUPPLEMENT|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
214735209|NCT02031627|DEVICE|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
214735210|NCT02031627|DEVICE|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM \& PM (2 hours)
214735211|NCT02031627|DEVICE|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
214735212|NCT01925482|DRUG|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
214735213|NCT01925482|DRUG|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
214735214|NCT01925482|DRUG|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
214735215|NCT01925482|DRUG|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
214735216|NCT01925482|DRUG|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
214735217|NCT01925482|DRUG|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
214735218|NCT02094625|DRUG|N-Acetylcysteine|"NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
214735219|NCT01099761|BIOLOGICAL|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
214735220|NCT01099761|BIOLOGICAL|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
214735221|NCT01099761|OTHER|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
214735222|NCT01804660|OTHER|No study treatments administered|
214735223|NCT00484367|BEHAVIORAL|Adolescent group therapy|Adolescent group therapy
214735224|NCT00484367|BEHAVIORAL|Transitional family therapy|Transitional family therapy
214735225|NCT03193944|DRUG|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
214735226|NCT03193944|DRUG|Placebo vitamin D3|vitamin D as a placebo
214735227|NCT05007340|OTHER|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
214735228|NCT05007340|OTHER|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
214735229|NCT05007340|OTHER|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
214735230|NCT05007340|OTHER|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
214735231|NCT00928304|DRUG|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
214735232|NCT04162912|BEHAVIORAL|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
214735233|NCT01010776|DRUG|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
214735234|NCT03402360|OTHER|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
214735235|NCT03402360|OTHER|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
214735236|NCT03286881|OTHER|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
214735237|NCT03286881|OTHER|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
214735238|NCT03286881|OTHER|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
214735239|NCT03286881|OTHER|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
214735240|NCT03286881|OTHER|Usual treatment|Medication provided by a general practitioner.
214735241|NCT06331273|PROCEDURE|"Liver transplantation with No-touch technique"|"The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues."
214735242|NCT04222257|DRUG|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
214735243|NCT04222257|DRUG|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
214735244|NCT04446767|RADIATION|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
214735245|NCT04446767|OTHER|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
214735246|NCT00824967|OTHER|Training and valuation of the treating personnel|Training and valuation of the treating personnel
214735247|NCT00169767|OTHER|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
214735248|NCT03019172|COMBINATION_PRODUCT|Lactobacillus reuteri|Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
214735249|NCT03019172|DIETARY_SUPPLEMENT|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
214735250|NCT01637090|DRUG|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
214735251|NCT02822352|OTHER|Chromoendoscopy|High definition virtual chromoendoscopy
214735252|NCT00198731|BEHAVIORAL|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
214735253|NCT02913833|OTHER|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
214735254|NCT03832166|OTHER|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
214735255|NCT03832166|OTHER|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
214735256|NCT05354973|DEVICE|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
214735257|NCT03903276|OTHER|rehabilitation|Tens
214735258|NCT03746145|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
214735259|NCT03746145|DIETARY_SUPPLEMENT|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
214735260|NCT03890497|BIOLOGICAL|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
214735261|NCT04537572|DIAGNOSTIC_TEST|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
214735262|NCT04853056|DEVICE|virtual reality|wearing virtual reality glasses
214735263|NCT04853056|DEVICE|Cold vibration|Buzzy
214735264|NCT01012037|DRUG|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
214735265|NCT01012037|DRUG|placebo|patient to receive placebo tablet(s) matching linagliptin
214735266|NCT01012037|DRUG|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
214735267|NCT02583711|DEVICE|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
214735268|NCT05675475|OTHER|Exposure|Higher education students from health technologies field exposed to digital devices.
214735269|NCT05675475|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
214735270|NCT05675475|DIAGNOSTIC_TEST|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
214735271|NCT02282930|DRUG|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
214735272|NCT01832389|DEVICE|PiCCO|
214735273|NCT06343129|BEHAVIORAL|Dietary education program|"Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/"
214735274|NCT03876704|DRUG|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
214735275|NCT03876704|DRUG|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
214735276|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with investigational device
214735277|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with reference device
214735278|NCT02149186|DEVICE|iCTuS-L|
214735279|NCT00164567|BEHAVIORAL|Onsite IPV specialist|
214735280|NCT00164567|BEHAVIORAL|Empowerment focused intervention|
214735281|NCT00419835|DRUG|enalapril|
214735282|NCT00419835|DRUG|losartan|
214735283|NCT03248817|DRUG|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
214735284|NCT03248817|DRUG|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
214735285|NCT03248817|DRUG|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
214735286|NCT03248817|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
214735287|NCT00177008|DRUG|Aripiprazole|
214735288|NCT00415623|DRUG|Amlodipine|Amlodipine 5mg/ day
214735289|NCT00415623|DRUG|Amlodipine|Amlodipine 10mg/ day
214735290|NCT00233181|BEHAVIORAL|Home-based adherence monitoring|
214735291|NCT04261218|DRUG|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
214735292|NCT04261218|DRUG|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
214735293|NCT05557136|DEVICE|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
214735294|NCT05557136|DEVICE|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
214735295|NCT05307523|DEVICE|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
214735296|NCT05307523|OTHER|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
214735297|NCT00057928|DRUG|cisplatin|
214735298|NCT00057928|DRUG|gemcitabine hydrochloride|
214735299|NCT00057928|DRUG|paclitaxel|
214735300|NCT01186315|BEHAVIORAL|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
214735301|NCT01186315|BEHAVIORAL|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
214735302|NCT01855867|DRUG|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
214735303|NCT00182234|BEHAVIORAL|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
214735304|NCT01572636|DRUG|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
214735305|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
214735306|NCT00678249|PROCEDURE|PTA|Percutaneous Transluminal Angioplasty
214735307|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
214735308|NCT00957190|DRUG|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
214735309|NCT03828864|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
214735310|NCT03828864|DEVICE|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
214735311|NCT03458403|PROCEDURE|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
214735312|NCT02052908|OTHER|Laboratory Biomarker Analysis|Correlative studies
214735313|NCT02052908|DRUG|Naproxen|Given PO
214735314|NCT02052908|OTHER|Placebo Administration|Given PO
214735315|NCT02920879|PROCEDURE|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
214735316|NCT04135664|PROCEDURE|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
214735317|NCT04135664|COMBINATION_PRODUCT|chemoradiation|concurrent chemotherapy and radiotherapy
214735318|NCT04135664|OTHER|active surveillance|No further adjuvant therapy
214735319|NCT02111070|BIOLOGICAL|IL-YANG FLU Vaccine|0.5mL
214735320|NCT03273699|DEVICE|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
214735321|NCT04662645|OTHER|Palliative Therapy|Undergo embedded palliative care
214735322|NCT04662645|OTHER|Questionnaire Administration|Ancillary studies
214735323|NCT00906828|DRUG|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
214735324|NCT00906828|DRUG|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
214735325|NCT00906828|DRUG|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
214735326|NCT04742140|DRUG|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
214735327|NCT04742140|DRUG|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
214735328|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
214735329|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
214735330|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
214735331|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
214735332|NCT04892394|OTHER|Information Types Before Endodontic Treatment|The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
214735333|NCT02002624|DEVICE|PSI|
214735334|NCT02002624|DEVICE|Conventional instrumentation|
214735335|NCT04697108|OTHER|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
214735336|NCT03651128|BIOLOGICAL|bb2121|bb2121
214735337|NCT03651128|DRUG|Daratumumab|Daratumumab
214735338|NCT03651128|DRUG|Pomalidomide|Pomalidomide
214735339|NCT03651128|DRUG|Dexamethasone|Dexamethasone
214735340|NCT03651128|DRUG|Bortezomib|Bortezomib
214735341|NCT03651128|DRUG|Ixazomib|Ixazomib
214735342|NCT03651128|DRUG|Lenalidomide|Lenalidomide
214735343|NCT03651128|DRUG|Carfilzomib|Carfilzomib
214735344|NCT03651128|DRUG|Elotuzumab|Elotuzumab
214735345|NCT01045551|DRUG|Apremilast|20mg taken orally twice per day for 12 weeks
214735346|NCT02663245|OTHER|Intervention 1|"* Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
214735347|NCT02663245|OTHER|Intervention 2|"* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
214735348|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
214735349|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
214735350|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
214735351|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
214735352|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
214735353|NCT03943940|BIOLOGICAL|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg"
214735354|NCT03943940|OTHER|Control|Standard medicine
214735355|NCT01563952|DEVICE|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
214735356|NCT01563952|DEVICE|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
214735357|NCT01563952|DEVICE|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
214735358|NCT01563952|DEVICE|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
214735359|NCT00566332|DRUG|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
214735360|NCT00566332|DRUG|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
214735361|NCT04602299|OTHER|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
214735362|NCT02098928|BEHAVIORAL|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
214735363|NCT02098928|DEVICE|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
214735364|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
214735365|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
214735366|NCT01510561|DRUG|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
214735367|NCT01510561|DRUG|90Y-hPAM4|
214735368|NCT01510561|DRUG|90Y-hPAM4 + gemcitabine|
214735369|NCT02930811|DRUG|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
214735370|NCT02930811|DRUG|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
214735371|NCT00268476|DRUG|Celecoxib|
214735372|NCT00268476|DRUG|Docetaxel|
214735373|NCT00268476|DRUG|Prednisolone|
214735374|NCT00268476|DRUG|ADT|
214735375|NCT00268476|DRUG|Zoledronic Acid|
214735376|NCT00268476|DRUG|Abiraterone|
214735377|NCT00268476|RADIATION|Radiotherapy to the prostate|
214735378|NCT00268476|DRUG|Enzalutamide|
214735379|NCT00268476|DRUG|Metformin|
214735380|NCT00268476|DRUG|Transdermal Oestradiol|
214735381|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
214735382|NCT03727776|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
214735383|NCT00269620|DRUG|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
214735384|NCT00269620|DRUG|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
214735385|NCT01847872|DRUG|IPV IM Needle|
214735386|NCT01847872|DRUG|IPV ID Needle|
214735387|NCT01847872|DRUG|IPV IM Device|
214735388|NCT01847872|DRUG|IPV ID Device|
214735389|NCT05399836|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
214735390|NCT02096471|DRUG|PD-0325901|
214735391|NCT03324867|DRUG|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
214735392|NCT03324867|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
214735393|NCT04317898|PROCEDURE|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
214735394|NCT04317898|PROCEDURE|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
214735395|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
214735396|NCT03508973|OTHER|Sculpta|
214735397|NCT01281774|BIOLOGICAL|CSL112|reconstituted high density lipoprotein
214735398|NCT01281774|BIOLOGICAL|Placebo|Normal saline (0.9%)
214735399|NCT01337791|DRUG|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
214735400|NCT05469880|OTHER|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
214735401|NCT05469880|OTHER|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
214735402|NCT04570982|BIOLOGICAL|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
214735403|NCT04574765|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
214735404|NCT04574765|OTHER|Questionnaire collection (CITF)|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
214735405|NCT04574765|OTHER|Optional blood collection|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
214735406|NCT04574765|OTHER|Optional questionnaire completion (mental health)|Fill out an optional mental health questionnaire.
214735407|NCT04574765|DIAGNOSTIC_TEST|Optional saliva sample (for validation)|Provide saliva sample anonymously.
214735408|NCT04574765|DIAGNOSTIC_TEST|Nasal Swab (rapid antigen test)|Panbio nasal swab rapid antigen test
214644645|NCT03285932|RADIATION|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
214644646|NCT01796951|DRUG|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
214644647|NCT01796951|DRUG|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
214644648|NCT03504826|DEVICE|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
214644649|NCT06549075|OTHER|Therapeutic support|The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
214644650|NCT06549075|OTHER|Standard Specialized Palliative Consultation Service|According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
214644651|NCT04988100|PROCEDURE|splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
214644652|NCT04988100|PROCEDURE|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
214644653|NCT03246828|OTHER|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
214644654|NCT02813122|DEVICE|x-ray|x-ray for the detection of leaks and bleeding
214644655|NCT01871090|DEVICE|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
214644656|NCT04995874|DIETARY_SUPPLEMENT|KOKOPlus protein and micronutrient powder|KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
214644657|NCT04507087|BEHAVIORAL|Documentary|A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products
214644658|NCT04507087|BEHAVIORAL|Control|"A 20-minute unrelated video (a motivational talk entitled Listening to shame)"
214644659|NCT02488304|RADIATION|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
214644660|NCT02761083|DEVICE|Novosyn® Quick|Eye surgery
214644661|NCT02761083|DEVICE|Vicryl® Rapid|Eye surgery
214644662|NCT00570648|DRUG|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
214644663|NCT03595696|OTHER|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
214644664|NCT05136625|DRUG|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
214644665|NCT05136625|DRUG|Standard Preparation|Troncular scalp blockade. Local site infiltration
214644666|NCT03006809|BIOLOGICAL|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
214644667|NCT03006809|OTHER|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
214644668|NCT02144272|DRUG|LY3114062 SC|LY3114062 administered SC.
214644669|NCT02144272|DRUG|Placebo|Placebo administered SC.
214644670|NCT02144272|DRUG|LY3114062 IV|LY3114062 administered IV.
214644671|NCT05112887|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
214644672|NCT04226794|DEVICE|a-tDCS|Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).
214644673|NCT04226794|BEHAVIORAL|Nutritional Counseling|Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions
214644674|NCT04226794|COMBINATION_PRODUCT|a-tDCS and nutritional counseling|a-tDCS + Nutritional Counseling
214644675|NCT04226794|COMBINATION_PRODUCT|s-tDCS and nutritional counseling|s-tDCS + Nutritional Counseling
214644676|NCT06530784|PROCEDURE|Cryoablation|After the completion of screening, the subjects received cryoablation treatment
214644677|NCT06530784|DRUG|PD-1 antibody and bevacizumab|Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
214735409|NCT03603574|DEVICE|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
214735410|NCT03603574|DEVICE|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
214735411|NCT03520426|DEVICE|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
214735412|NCT01339104|DRUG|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
214735413|NCT04272372|DRUG|Ketoprofen|PO and local therapy
214735414|NCT03663972|BEHAVIORAL|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
214735415|NCT03663972|BEHAVIORAL|phonologic treatment|children receive instruction in producing new sounds at the word level
214735416|NCT00409396|PROCEDURE|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
214735417|NCT00409396|PROCEDURE|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
214735418|NCT00073034|DRUG|EAA-090|
214735419|NCT00803296|OTHER|Oral glucose tolerance test (OGTT)|
214735420|NCT00803296|OTHER|Isoglycemic intravenous glucose infusion|
214735421|NCT01321658|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
214735422|NCT05388734|OTHER|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
214735423|NCT01610414|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
214735424|NCT01610414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
214735425|NCT03305913|DRUG|TAS 102|TAS-102 tablet
214735426|NCT03305913|DRUG|Regorafenib|Regorafenib tablet
214735427|NCT03973632|DRUG|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
214735428|NCT02074761|DEVICE|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
214735429|NCT02736474|DRUG|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
214735430|NCT02736474|DRUG|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
214735431|NCT02736474|DRUG|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
214735432|NCT02736474|DRUG|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
214735433|NCT04432168|PROCEDURE|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
214735434|NCT04432168|OTHER|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
214735435|NCT05947695|BEHAVIORAL|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
214735436|NCT02540655|BIOLOGICAL|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
214735437|NCT02540655|PROCEDURE|Excipients|Patients will receive excipients through intravenous infusion
214735438|NCT06245395|DEVICE|Virtual Reality|Meta Quest 2 Headset
214644678|NCT01172756|DRUG|Riociguat (BAY63-2521)|0.5 mg single oral dose
214644679|NCT01172756|DRUG|Riociguat (BAY63-2521)|1 mg single oral dose
214644680|NCT01172756|DRUG|Riociguat (BAY63-2521)|2 mg single oral dose
214644681|NCT01172756|DRUG|Placebo|single oral dose
214644682|NCT02647151|DRUG|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
214735439|NCT02649075|OTHER|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
214735440|NCT02649075|OTHER|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
214735441|NCT01550770|DRUG|propofol|peripheral IV of propofol at increasing dose levels
214735442|NCT02587975|DRUG|Evogliptin|10 mg
214735443|NCT01172704|BEHAVIORAL|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
214735444|NCT01079208|OTHER|test starter infant formula|infants are fed for 6 months with this starter formula
214735445|NCT01079208|OTHER|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
214735446|NCT01079208|OTHER|control standard formula|infant are fed 6 months with this formula
214735447|NCT02483611|DRUG|Magnesium Sulfate|
214735448|NCT02483611|DRUG|Lidocaine|
214735449|NCT02483611|DRUG|Isotonic Solution|
214735450|NCT02483611|DRUG|Cisatracurium|
214735451|NCT01353066|DRUG|Intensive Medical Treatment|
214735452|NCT01353066|OTHER|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
214735453|NCT05830240|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214735454|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
214735455|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
214735456|NCT02382276|DRUG|Nalmefene hydrochloride|
214735457|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
214735458|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
214735459|NCT05661838|PROCEDURE|transfusion|transfusion
214735460|NCT03008928|BEHAVIORAL|Alcooquizz|
214735461|NCT05391412|DRUG|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
214735462|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
214735463|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
214735464|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
214735465|NCT06700551|OTHER|Psychoeducation|Each week, the investigator will send participants one topic through the chat function on the Zalo app. Before receiving the topic, participants will vote on which topic they would like to learn about. The topics will be presented as videos and will cover the following seven areas: providing everyday care, being a caregiver, self-care, knowledge about dementia, fall prevention, pressure injury prevention and care, and managing behavior changes.They may ask questions related to providing dementia care or share their feelings via the chat on the Zalo app.
214735466|NCT07138430|OTHER|İntervention|Patients participating in the study will be informed about the purpose of the study. Participants will be included in the study after verbally and in writing confirming the informed consent form. Patients will receive training and information about the virtual reality headset before the procedure. Patients will complete a personal information form 1 hour before the coronary angiography procedure. Pain and anxiety levels will be measured using the Visual Analog Scale (VAS) and the State Anxiety Scale 10 minutes before the procedure. Patients in the intervention group will wear virtual reality headsets during coronary angiography. Local anesthesia will not be administered to the femoral intervention site in these patients. Pain and anxiety will be assessed after the coronary angiography procedure (10 minutes later). Patients will also be questioned about their satisfaction with the virtual reality application after the procedure. One week after discharge, the patient will be re-evaluate
214735467|NCT07138430|OTHER|Control|Ten minutes before the coronary angiography procedure, patients will be assessed for pain and anxiety using the Visual Analog Scale (VAS) and the State Anxiety Scale. During the coronary angiography, control group patients will undergo routine interventional procedures. Following the coronary angiography procedure (10 minutes later), patients will be assessed for pain and anxiety. One week after discharge, the patient will be re-evaluated at the hospital for an interventional site examination. The femoral area will be examined for edema, hematoma, pain, and difficulty walking. These assessments will be recorded on forms.
214735468|NCT05979363|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
214735469|NCT05979363|DRUG|VRD-based regimen|Bortezomib, Lenalidomide and Dexamethasone
214735470|NCT06723405|BIOLOGICAL|EVO301|Intravenous EVO301
214735471|NCT06723405|BIOLOGICAL|Placebo|Placebo
214735472|NCT05439876|DRUG|Melatonin|Melatonin 2 mg daily for 4 weeks
214735473|NCT05439876|DRUG|Placebo|Placebo daily for 4 weeks
214735474|NCT07060716|DIAGNOSTIC_TEST|donor-derived cell-free DNA test|A donor-derived cell-free DNA (dd-cfDNA) test used to measure the concentration of total cell-free DNA and the fractional abundance of the dd-cfDNA.
214735475|NCT07058584|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is administered using a figure-of-eight coil from MagVenture positioned over the left primary motor cortex (M1) in an anteroposterior direction. High-frequency rTMS is delivered at 10 Hz, consisting of 100 trains of 10-second duration (3000 pulses), with 20-second inter-train intervals, at \~90% of resting motor threshold (RMT) depending on participant tolerance and TMS-EEG brain response.
214735476|NCT07058584|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|This intervention involves high-frequency repetitive transcranial magnetic stimulation (rTMS) applied over the primary motor cortex (M1), using a figure-of-eight coil. In the sham condition, the same coil is used, but it is oriented away from the scalp at an angle that prevents effective magnetic stimulation of the brain, while still producing similar auditory and tactile sensations. This allows participants to remain blinded to the intervention type, maintaining the single-blind nature of the study. The active stimulation is delivered at 10 Hz, comprising 30 trains of 10 seconds (9900 milliseconds)(3000 pulses in total), with 20-second inter-train intervals, at \~110% of the individual's resting motor threshold (rMT). Stimulation is delivered while the participant is seated at rest, and the full rTMS protocol takes approximately 15 minutes to complete.
214735477|NCT06771648|DEVICE|Daxxin Psoriasis Shampoo|Daxxin Psoriasis Shampoo at least 3 times a week and at most once a day as per instructions for use
214735478|NCT06760156|DRUG|Tafasitamab|The recommended dose of tafasitamab is 12 mg/kg.
214735479|NCT06760156|DRUG|Lenalidomide|The starting dose for lenalidomide will be 25 mg PO daily.
214735480|NCT02717962|DRUG|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
214735481|NCT06814041|OTHER|Chatbot as an informational coach|"The chatbot acts as an empathic informational coach, performing three main functions: (1) offering short conversation sessions about key topics on living with HIV; (2) responding to users' ad-hoc questions on HIV; (3) reminding users of medical appointments and drug taking.~The chatbot comprises a conversational system, utilizing WhatsApp for user interaction, with messages routed through the backend Voiceflow. User can access the chatbot system via WhatsApp. That means that they access the chatbot like any other contact in their WhatsApp chat list. The bot incorporates mostly text-based input- and output modalities, and a few images, which are more protective of users' privacy than speech. Concretely, chatbot users interact with the chatbot on WhatsApp by selecting from pre-defined options (buttons) or, in some parts, writing text."
214735482|NCT06790784|PROCEDURE|Vitrectomy|The vitrectomy must occur within 4 weeks of randomization. A single injection of faricimab is allowed at any point before the vitrectomy. It is recommended that this injection is within 1 week of the vitrectomy. Requirement of triamcinolone staining to assist in complete elevation and removal of the posterior hyaloid and in removal of as much peripheral vitreous as is safely possible, 20 gauge not permitted. Allows subconjunctival steroid at investigator discretion; however, sub-tenon's triamcinolone or other long-acting steroid will not be permitted.
214735483|NCT06790784|DEVICE|Endolaser|Complete panretinal photocoagulation (PRP) during vitrectomy
214735484|NCT06790784|DRUG|Faricimab|Treatment must be initiated on the day of randomization with one faricumab injection. The remainder of the randomized treatment includes 2 additional injections every 4-weeks. Injections must be completed within 90 days of randomization.
214735485|NCT06790784|DEVICE|Panretinal Photocoagulation (PRP)|Complete PRP. PRP may be completed in 1-3 sessions, with the timing at the investigator's discretion. All PRP sessions must be completed within 90 days of randomization.
214735486|NCT07074184|OTHER|Radiofrequency 448khz with manual therapy|The intervention in consisted of a total of 12 sessions (twice a week) of treatment. The set duration for each session was 45 minutes, except for those sessions where variable measurements were required, which lasted 60 minutes. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
214735487|NCT07074184|OTHER|Turn off radiofrequency 448khz|Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
214735488|NCT07074184|OTHER|Manual therapy|Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
214735489|NCT06812286|OTHER|Less-volume|In the first 10-week cycle, the less-volume group will perform around 1500 repetitions per intervention. Participants will perform 1-3 sets of 4-7 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
214735490|NCT06812286|OTHER|More-volume|In the first 10-week cycle, the more-volume group will perform around 2000 repetitions per intervention. Participants will perform 1-3 sets of 6-10 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
214735491|NCT06812286|OTHER|Control|Participants in the control group will undergo sham training twice weekly for 30 weeks, consisting of stretching exercises supervised by two exercise physiologists.
214735492|NCT07081360|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (mFOLFIRINOX) followed by pancreaticoduodenectomy
214735493|NCT07081360|PROCEDURE|Upfront Surgery Group|Pancreaticoduodenectomy followed by adjuvant chemotherapy
214735494|NCT07083817|DRUG|[14C]Xeruborbactam|Carbon Radiolabeled Xeruborbactam
214735495|NCT07123597|OTHER|5mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 5mm bioceramic putty coronal plug.
214735496|NCT07123597|OTHER|3mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 3mm bioceramic putty coronal plug.
214735497|NCT07125183|DRUG|Doxorubicin|Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium. It has widespread use as a chemotherapeutic agent since the 1960s. Doxorubicin is part of the anthracycline group of chemotherapeutic agents. Doxorubicin may be used to treat soft tissue and bone sarcomas and cancers of the breast, ovary, bladder, and thyroid. It is also used to treat acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and small cell lung cancer.
214735498|NCT06853847|OTHER|The bed levels of the patients in the experimental group changed the patient's position|The bed levels of the patients in the experimental group changed the patient's position
214735499|NCT06779994|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
214735500|NCT06779994|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
214735501|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
214735502|NCT05083546|OTHER|Placebo|sugar pill
214735503|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
214735504|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
214735505|NCT05076760|DRUG|Docetaxel|75 mg/m2 intravenous administration every 3 weeks
214735506|NCT06313593|DRUG|INCB160058|Oral; Tablet
214735507|NCT06060613|BIOLOGICAL|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide."
214735508|NCT07091565|OTHER|Qualitative interview/Focus group|Participants will take part in a 1:1 interview or focus group
214735509|NCT07091344|BEHAVIORAL|VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments|"VR-Based Avatar Therapy is a 12-week intervention designed to help patients with psychosis manage distressing auditory hallucinations. The therapy consists of 7 individual sessions using virtual reality (VR) technology to externalize the auditory hallucinations, allowing patients to interact with a computer-generated avatar representing their dominant voice.~In addition to standard therapy, participants will undergo assessments of cognition, metacognition, and social cognition to explore their impact on treatment outcomes. These assessments include measures of emotion recognition, attributional style, theory of mind, cognitive flexibility, and trauma history. Sessions are conducted using VR headsets and noise-canceling headphones to enhance immersion, and patients receive ongoing therapeutic guidance throughout the process."
214735510|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
214735511|NCT07101770|OTHER|A combined retrospective and prospective observational follow-up|A combined retrospective and prospective observational follow-up
214735512|NCT07101718|OTHER|No intervention|No intervention
214735513|NCT07101666|RADIATION|Short course radiation therapy|25 Gy in 5 fractions
214735514|NCT07101666|DRUG|Standard of care neoadjuvant chemotherapy|Recommended options are CAPOX, FOLFOX, or FLOT but other standard of care chemotherapy may be given given at the discretion of the treating medical oncologist after consultation with the study Principal Investigator.
214735515|NCT07102498|BEHAVIORAL|BG mmol/L|BG presented in mmol/L (the standard presentation in Canada)
214735516|NCT07102498|BEHAVIORAL|BG mg/dl|BG presented in mg/dl
214735517|NCT07102498|BEHAVIORAL|A1c percent|HbA1c presented in percent (the standard presentation in Canada)
214735518|NCT07102498|BEHAVIORAL|A1c mmol/mol|HbA1c presented in mmol/mol
214735519|NCT07101354|DRUG|0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
214735520|NCT07101354|DRUG|0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
214735521|NCT07101354|DRUG|0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
214735522|NCT07101354|DRUG|0.08mg/kg DGPR1008 Injection Dose Group 4 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
214735523|NCT07101354|DRUG|Dose Group 0 (n=8)|Within the specified time frame, dose escalation will be conducted. Intravenous infusions will be administered according to randomization, with subjects receiving either the corresponding dose or placebo.
214735524|NCT07099742|DRUG|Tirzepatide|Exposure
214735525|NCT07099742|BEHAVIORAL|Life Style Modification|Referent group - Lifestyle interventions, exercise, and diet control
214735526|NCT07100860|PROCEDURE|One-Lung ventilation|In this observational study, the naturally occurring duration of intraoperative single-lung ventilation (SLV) during thoracic surgery will be recorded. No intervention is applied or modified for research purposes. The exposure of interest is the total duration (in minutes) of SLV, which will be timed from initiation to termination during surgery. This variable will be analyzed in relation to postoperative pulmonary complications.
214735527|NCT07100613|DRUG|Clobetasol Patch|A mucoadhesive patch containing clobetasol propionate 0.05%. Applied once daily for 30 days to the oral lesion.
214735528|NCT07100613|DRUG|Clobetasol + Resveratrol Patch|A mucoadhesive patch containing clobetasol propionate 0.05% and resveratrol. Applied once daily for 30 days to the oral lesion.
214735529|NCT07100613|DRUG|Clobetasol in Orabase|Clobetasol propionate 0.05% in orabase-type adhesive paste. Applied once daily for 30 days to the oral lesion.
214735530|NCT07100717|BEHAVIORAL|2-days workshop and self-mindfulness practices|Participants will attend 2-days face-to-face workshop on mindfulness-based self-care (MBSC) program. After the completion of the 2-days workshop, the participants will be required to complete self-mindfulness practices within a period of 4 weeks
214735531|NCT07100431|PROCEDURE|Articulating (experimental group)|1\. Surgical procedure On the day of surgery, random allocation to either the experimental or the control group will be perfored just before the start of the procedure. All of the surgery will be conducted laparoscopically. The control group will undergo surgery using a conventional straight laparoscopic instrument, while the experimental group will use an articulating instrument. The surgical procedure will be the same for both groups. The total time of surgery and the time spent on the supra-pancreatic lymph node dissection will be recorded during the procedure. The estimated blood loss during surgery will be also measured.
214735532|NCT07100431|PROCEDURE|Control (control group)|"2\. Postoperative follow-up Patients participating in this study will have the same postoperative care as those not participating in this study. To compare the degree of pancreatic injury, amylase and lipase levels will be measured in the serum and the peritoneal fluid frome the drainage on postoperative days 1 and 3.~Postoperative complications will be classified and recorded according to the Clavien-Dindo classification for all complications occurring within 30 days after surgery. The dissected lymph nodes will be categorized by region, and the number of dissected lymph nodes will also be confirmed."
214735533|NCT07100548|BEHAVIORAL|"ich bin alles (English: I am everything)"|"The web-based information platform ich bin alles (www.ich-bin-alles.de) on depression and mental health in youth as well as its social media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the Ludwig-Maximilians-University Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e., short videos with overlays of text and music; https://www.instagram.com/ich.bin.alles/). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
214735534|NCT07100184|DRUG|Disitamab Vedotin combined with Radiotherapy|Disitamab Vedotin (RC-48) injection 2mg/kg, Q2w for 4 circles before radiotherapy and 2mg/kg, Q3w for 8 circles after radiotherapy; Radiotherapy (Whole bladder dose: 25 Gy in 5 doses, QD)
214735535|NCT07102550|BIOLOGICAL|MiMedx AmnioFix|MiMedx Amniofix to be placed on biliary anastomosis of the recipient during living donor liver transplant.
214735536|NCT07100795|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
214735537|NCT07100652|PROCEDURE|Threshold FiO₂|"Group 1 (Intervention Group) received the initial dose of pulmonary surfactant immediately upon reaching an inhaled oxygen concentration (FiO₂) \>0.25.~Group 2 (Control Group) received the initial dose of pulmonary surfactant as early as possible within 48 hours, but only when FiO₂ was titrated to \>0.3 based on the infant's clinical condition."
214735538|NCT07100925|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection
214735539|NCT07100457|DIAGNOSTIC_TEST|Blood Biomarker Profiling and Prognostic Follow-up|Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.
214735540|NCT07101614|DRUG|JS004 in combination with toripalimab and chemotherapy|"BTLA inhibitor (JS004):200mg, IV infusion , d1, Q3W;(1-24 week)~Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
214735541|NCT07101614|DRUG|Toripalimab and chemotherapy|"Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
214735542|NCT07101614|DRUG|Chemotherapy|"Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
214735543|NCT07114276|OTHER|Machine learning models predictions of acute kidney injury and acute kidney disease|Comparison of the performances of machine learning models and clinicians in predicting AKI within 14 days and AKD within 89 days
214644683|NCT02647151|DRUG|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
214644684|NCT04304131|DIAGNOSTIC_TEST|Earlytect Colon Cancer|A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
214644685|NCT02020044|OTHER|Endothelial Keratoplasty|
214735544|NCT06921941|DRUG|Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR|"Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions.~Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions.~Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions."
214644686|NCT05302323|OTHER|Disposable Drape|Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
214644687|NCT05302323|OTHER|Reusable Drape|Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
214644688|NCT06101576|PROCEDURE|TUIP|Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.
214644689|NCT06101576|PROCEDURE|TURP|Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.
214644690|NCT06101576|PROCEDURE|Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
214735545|NCT06921941|DRUG|Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR|"Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions.~Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions.~Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions."
214735546|NCT05964413|DRUG|vilobelimab|vilobelimab infusion
214735547|NCT05964413|DRUG|Placebo|Placebo Infusion
214735548|NCT06932146|DRUG|LLX-424|Tablets for oral administration
214735549|NCT07124832|BEHAVIORAL|Socratic Questioning Method|"Socratic questioning is a method in which behaviour is examined through questions such as what, where, which, who, when, how, and why. It consists of four stages: defining the problem, evaluating and identifying alternatives, redefining, and discussing feasible outcomes. Through this process, individuals develop their critical thinking skills and make self-evaluations."
214735550|NCT07136402|OTHER|Educating participants about healthcare resources|MA-CEAL team members, including the community health ambassador (CHA), will assist in connecting residents with healthcare resources.
214735551|NCT07136402|OTHER|Healthcare appointments|MA-CEAL team members, including the community health ambassador (CHA), will assist residents in making physician appointments.
214735552|NCT07136402|OTHER|Workshops|Trained CHAs will provide workshops with information about diabetes and hypertension and how to be screened and get care.
214735553|NCT06932731|BEHAVIORAL|Mind-body Intervention|The Mind-Body Intervention group designed to included several elements with mind and body involvement such as mindful breathing, body scan, stretching, mindful movement as well as adapting mindful practice in their routine. Mind-Body Intervention group will join the activities in a group setting for 5 sessions. Each session 45 to 60 minutes. Intervention is led by a registered nurse. Each session (except for the first session) will start by sharing of practice from the past week. Followed by mind-body practices. Before the end of session, a group discussion on the practice of that day and reflection will be done.
214735554|NCT06932731|BEHAVIORAL|Befriending Intervention|In this group, volunteer will spend time with the participants, engaging in conversation and join their routine activities by the time of visit or other scheduled activities in the institution (such as arts and crafts, playing board games or reminiscing activities).
214735555|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
214735556|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
214735557|NCT05505669|OTHER|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
214644691|NCT06101576|PROCEDURE|AEEP|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
214644692|NCT00332956|BIOLOGICAL|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
214644693|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
214644694|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
214644695|NCT00332956|BIOLOGICAL|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
214644696|NCT03125278|OTHER|Medication knowledge|Participants will be asked questions over the phone about their medications
214644697|NCT04749394|DRUG|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
214644698|NCT04749394|DRUG|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
214644699|NCT02550028|DRUG|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
214644700|NCT02550028|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
214644701|NCT00135603|DRUG|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
214644702|NCT00135603|PROCEDURE|appendectomy|ablation of the appendix by laparotomy or laparoscopy
214644703|NCT00721487|DRUG|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
214644704|NCT03562663|DEVICE|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
214644705|NCT03562663|DEVICE|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
214644706|NCT05869006|BEHAVIORAL|Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice|Group Practice
214644707|NCT05869006|BEHAVIORAL|Placebo group practice|The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
214735558|NCT07140224|OTHER|Korfball-Based Movement Training|"The weekly training content was structured as follows:~* Week 1: Chest pass, overhead pass, right-left hand pass, moving pass, cool-down (15 repetitions).~* Week 2: One-handed pass, penalty shot, defensive follow-up run, lay-up shot, cool-down (20 repetitions).~* Week 3: One-handed pass, diagonal passing, penalty shot, lay-up shot, short and long-distance shooting (25 repetitions).~* Week 4: Lay-up shot, V-cut shot, stationary short-distance shot, defensive follow-up run,penalty shot, cool-down (20 repetitions).~* Week 5: V-cut shot, stationary short-distance shot, front-of-the-basket shot, behind-the-basket short-distance shot (15 repetitions).~* Week 6: V-cut shot, lay-up shot, stationary shot, defensive follow-up run, penalty shot (20 repetitions).~* Week 7: One-handed pass, penalty shot, lay-up shot (right-left), shooting, V-cut shot (10 repetitions).~* Week 8: One-handed pass penalty shot, lay-up shot (right-left), stationary shot, V-cut shot (10 repetitions)."
214735559|NCT01287767|BEHAVIORAL|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
214735560|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
214735561|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
214735562|NCT06939946|DEVICE|Parathyroid auto-fluorescence imaging|All enrolled patients for thyroid surgery, once the thyroid gland is removed the device will be used to identify the parathyroid glands.
214735563|NCT06939946|DRUG|Indocyanine green|For a select group of patients when deemed necessary by the surgeon, and when one or more parathyroid gland appear to be de vascularized ICG will be administered, A dosage of 5 mg will be injected into a peripheral IV line, followed by fluorescence imaging to determine the perfusion status of the gland.
214735564|NCT07148661|PROCEDURE|Removal of PPcT|Iatrogenic Pulmonary Parenchymal Chest Tube is removed as a staged procedure in which gradual retraction of 2cm of chest tube is done from lung parenchyma keeping an eye on the hemodynamic status of Patient.
214735565|NCT07147933|OTHER|phusical therapy program|physical therapy program including stretching of the hamstrings and strengthening of the quadriceps only. The program will be delivered 3 times per week for 8 weeks under therapist supervisio
214735566|NCT07147933|OTHER|physical therapy program|A targeted physical therapy program including correction of anterior pelvic tilt, strengthening of the soleus, core strengthening, stretching of the hamstrings, and strengthening of the quadriceps. The program will be delivered 3 times per week for 8 weeks under therapist supervision.
214735567|NCT07148843|DRUG|Cannabidiol (CBD)|Cannabidiol
214735568|NCT07148843|DRUG|Placebo|placebo
214735569|NCT07148466|OTHER|Scapular PNF|scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment . It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
214644708|NCT05035680|BIOLOGICAL|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
214644709|NCT05035680|BIOLOGICAL|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
214644710|NCT05035680|BIOLOGICAL|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
214644711|NCT03658226|BEHAVIORAL|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
214644712|NCT03926676|OTHER|grandio blocks|nano hybrid composite blocks
214644713|NCT03926676|OTHER|emax|ceramic blocks
214644714|NCT02224235|DRUG|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
214644715|NCT02224235|DEVICE|Resolute Integrity DES|Resolute Integrity DES
214644716|NCT02224235|DEVICE|COBRA PzF|
214644717|NCT02224235|DRUG|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
214644718|NCT01831128|DEVICE|ASV Treatment|
214644719|NCT03436355|BEHAVIORAL|Physical activity|"The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework."
214644720|NCT00334503|DRUG|Miglitol|
214644721|NCT00804687|OTHER|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
214644722|NCT00804687|DRUG|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
214644723|NCT00804687|DRUG|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
214644724|NCT02435602|PROCEDURE|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
214644725|NCT02435602|PROCEDURE|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions \>= 5 mm diameter Pathologic examination of all biopsy tissue specimens
214644726|NCT02550158|PROCEDURE|Educational program EDU-MICI|
214644727|NCT03288246|DIAGNOSTIC_TEST|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
214644728|NCT01002092|DRUG|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
214644729|NCT01002092|DRUG|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
214644730|NCT04822532|GENETIC|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
214735570|NCT07148466|OTHER|Conventional treatment|Conventional treatment. It includes closed kinematic chain exercises of upper limb, upper and lower extremity range of motion exercises, stretching and strengthening exercises for upper limb, trunk and lower limb, balance \& coordination, manual dexterity exercises (e.g., grasp release), and teaching of ADLs.. It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
214735571|NCT07147452|PROCEDURE|Dual tracer: The infiltration of the Supermagnetic Iron Oxide (SPIO) and Methylene Blue|"Participation in the study did not alter the indications or standard surgical technique. The only additional intervention consisted of intraoperative administration of SPIO, performed either laparoscopically or conventionally, as appropriate.~Immediately after removal of the surgical specimen : Submucosal instillation of methylene blue was then performed at the tumour periphery"
214735572|NCT07147452|DIAGNOSTIC_TEST|OSNA AND H-E|Analysed the performance of one-step nucleic acid amplification (OSNA) versus conventional histology and applied pooling analysis with OSNA in non-sentinel nodes
214735573|NCT07147179|RADIATION|Short Course Radiotherapy|Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions).
214644731|NCT05042427|OTHER|Pregnancy Weight Management Health Literacy Questionnaire|Give questionnaires to check the weight management health literacy level of primigravida women.
214644732|NCT01050114|DRUG|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
214644733|NCT01050114|DRUG|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
214644734|NCT02012556|DRUG|Tesamorelin|
214644735|NCT05886062|OTHER|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
214644736|NCT05886062|OTHER|Control Group|They will only continue their routine basketball technical-tactical training.
214644737|NCT04157387|OTHER|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
214644738|NCT04157387|OTHER|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
214644739|NCT03037281|DIAGNOSTIC_TEST|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
214644740|NCT02118376|DRUG|Exenatide|5ug bid,Subcutaneous injection
214644741|NCT02393391|DEVICE|Neuroelectrics STARSTIM|
214644742|NCT01864785|PROCEDURE|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
214644743|NCT01864785|PROCEDURE|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
214644744|NCT04460755|OTHER|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214735574|NCT07148258|OTHER|Project ImPACT Training As Usual|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The typical training model for Project ImPACT includes a 6-hour, interactive online tutorial that walks providers through the core Project ImPACT intervention strategies. After completing the online tutorial, providers attend a live interactive workshop virtually that is spread across 4, 3.5-hour days (14 hours total). Providers receive 1 hour of consultation once every other week for an hour from a trained Project ImPACT consultant (research staff member) following training."
214735575|NCT07148258|OTHER|Project ImPACT Training Plus Co-Production|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The second cohort for Project ImPACT training is a model in which providers receive the same typical Project ImPACT training activities, in addition to three supplemental modules on other common areas of concern for families and how best to integrate other topics within Project ImPACT to meet the diverse needs of families."
214735576|NCT07148258|BEHAVIORAL|Routine Project ImPACT|Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills. Project ImPACT is delivered with parents meeting once or twice each week for one hour over 12- 16 weeks. In each session, parents receive: 1) didactic instruction in intervention strategies; 2) modeling of the intervention techniques by the therapist; 3) live coaching from the therapist while practicing the strategies with their child; and 4) homework to practice the strategies at home with their child, 20 minutes each day across meaningful home routines.
214735577|NCT07147686|BEHAVIORAL|Slow tempo basic motor skills exercises with music (30 BPM)|Participants performed basic motor skills exercises synchronized with slow-tempo music at 30 beats per minute (BPM). The slow tempo was intended to enhance internal timing, cognitive inhibition, controlled movement coordination, and sustained attention. Each session lasted 10-15 minutes per exercise, using traditional Turkish music (e.g., Erik Dali, Horon, Sari Zeybek) to provide culturally relevant rhythmic patterns.
214735578|NCT07147686|BEHAVIORAL|Fast tempo basic motor skills exercises with music (60 BPM)|Participants performed basic motor skills exercises synchronized with fast-tempo music at 60 BPM. The faster tempo aimed to increase reaction speed, attention demand, processing speed, decision-making, and cognitive flexibility. Each session lasted 10-15 minutes per exercise, using traditional Turkish music with asymmetric rhythms to challenge timing and planning skills.
214735579|NCT07148089|DRUG|SGT-501|IV for infusion
214735580|NCT07147647|DEVICE|Direct Selective Laser Trabeculoplasty|DSLT using the Belkin Vision Eagle Device
214735581|NCT07147387|BEHAVIORAL|Lion Hearts Family-Based Physical Activity Program|The Lion Hearts Family-Based Physical Activity Program is a 12-week, community-based intervention designed to improve cardiovascular health and physical activity behaviors among mother-child dyads. The program consists of twice-weekly, 60-minute group exercise sessions delivered at local CrossFit affiliates. Each session includes scalable functional movement exercises, strength training, cardiovascular conditioning, and flexibility activities appropriate for both adults and children. In addition to physical activity, sessions incorporate goal-setting, family teamwork activities, and health education components to promote sustainable behavior change. The program was co-designed with community members during earlier study phases and is tailored to support engagement, feasibility, and family bonding.
214735582|NCT07148453|OTHER|Experimental Group|The experimental group will receive training through a smartphone-based brain training program using the Lumosity app, as well as aerobic exercise on a bicycle ergometer for 18 sessions other days for 6 weeks, 3 times per week, every session for 40 minutes (20 minutes aerobic training on a stationary bicycle ergometer followed by 20 minutes for Lumosity training application on the smartphone).
214735583|NCT07148453|OTHER|Control Group|The control group will participate in aerobic training on a bicycle ergometer as well as mental exercises for 18 sessions every other day for 6 weeks, 3 sessions/week, each for 40 minutes
214735584|NCT07148817|BEHAVIORAL|Noise canceling earplugs|Modifiable noise cancelling earplugs will be used to attempt to limit individual noise exposure in those with high levels of exposure or high levels of annoyance related to noise
214735585|NCT07148817|BEHAVIORAL|Usual care|No behavioral changes to limit noise exposure
214735586|NCT07147400|BIOLOGICAL|10µg of R21 with 50µg Matrix-M1|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
214735587|NCT07147400|BIOLOGICAL|6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation|"R21 Malaria antigen is expressed in a recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.~Recombinant CRM197 is a recombinant protein, and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India.~Recombinant Pfs230D1M drug substance lots/batches of cGMP were manufactured using Hansenula Polymorpha and manufactured at the SIIPL.~A single vial coformulation containing 10µg R21 and 6µg Pfs230D1-CRM197 conjugate mixed with 50µg Matrix-M1 has been developed and is manufactured by SIIPL."
214735588|NCT07147400|BIOLOGICAL|RABIVAX-S|Sterile, purified inactivated rabies vaccine prepared on vero cells, indicated for the prevention of rabies in children and adults.
214644745|NCT04460755|OTHER|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214644746|NCT04460755|OTHER|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214644747|NCT04460755|OTHER|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214735589|NCT07147400|BIOLOGICAL|Conjugated Pfs230D1 Vaccine (Pfs230D1-CRM197) For Bedside Mixing|"Recombinant Pfs230D1M drug substance lots/batches cGMP manufactured using Pichia pastoris manufactured at the Pilot Bioproduction Facility, Walter Reed Army Institute of Research (Silver Spring, Maryland), and at SIIPL respectively.~Recombinant CRM197 is a recombinant protein and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India."
214735590|NCT07147400|BIOLOGICAL|R21 Malaria Vaccine (Recombinant) For Bedside Mixing|R21 is a fusion protein of hepatitis B surface antigen (HBsAg) to the C-terminus and central repeats of the circumsporozoite (CS) protein of Plasmodium falciparum. R21 VLP, recombinant HBsAg spontaneously self-assembled \& formed a virus-like particle, wherein circumsporozoite protein (CSP) from Plasmodium falciparum is presented on the VLP of recombinant HBsAg particles. R21 Malaria antigen expressed in recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.
214735591|NCT07147400|BIOLOGICAL|MATRIX-M1 (Adjuvant) For Bedside Mixing|active ingredient in Matrix-M1 are saponin-based fractions. Matrix-M1 has a ratio of Matrix-A and Matrix-C of 85:15 (by weight). Both Matrix-A and Matrix-C are individual fractions (separated by chromatography) derived from extracts from the Quillaja saponaria tree. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
214735592|NCT07147283|BEHAVIORAL|Educational film and volitional help sheet|The intervention consists of a bespoke online gynaecological cancer awareness educational film and a volitional help sheet to plan future gynaecological help seeking and monitoring based on implementation intention principles \[24\]. The intervention will be delivered online using Qualtrics™.
214735593|NCT07147270|OTHER|side to side and front to back rotation 30 minutes each|side to side and front to back rotation 30 minutes each after pleurodesis
214735594|NCT07148687|BEHAVIORAL|Conventional Exercise Program|Exercise protocol targeting subacromial pain syndrome, including shoulder mobility, strengthening, and posture correction exercises based on established clinical guidelines.
214735595|NCT07148687|BEHAVIORAL|ChatGPT-Guided Rehabilitation|AI-generated exercise recommendations from ChatGPT-4 tailored to the patient's profile and applied under physiotherapist supervision.
214735596|NCT07148687|BEHAVIORAL|DeepSeek-Guided Rehabilitation|Personalized rehabilitation exercises generated by DeepSeek-R1 and implemented under physiotherapist guidance.
214735597|NCT07147764|OTHER|Physiotherapy|Physiotherapy treatment programs include therapeutic ultrasound, muscle relaxation techniques, range of motion exercises, and joint and soft tissue mobilization.
214735598|NCT07147764|BEHAVIORAL|Pain Neuroscience Education|"PNE sessions will be conducted in addition to physiotherapy programs for intervention groups. PNE sessions will occupy half of each session during the first two weeks. Physiotherapists trained in PNE will deliver sessions using a combination of metaphors, animated videos, and scientifically accurate descriptions. The same physiotherapist will lead both sessions with the same patient.~Active learning techniques will include:~Connecting new information with prior knowledge. Operationalizing key pain concepts into individual contexts. Facilitated problem-solving and critical reflection."
214735599|NCT07149272|DEVICE|Virtual Reality Exercise (VRE) using VRAGMENT software|Adjuvant Virtual Reality Exercise (VRE) delivered via Oculus Quest 2 headset with VRAGMENT software, a culturally adapted VR program simulating daily activities (e.g., grocery shopping, phone calls) to induce physical movement. Participants received VRE alongside conventional multimodal exercise (breathing, resistance, aerobic) during hospitalization. Sessions were tailored to individual clinical conditions and aimed to improve fatigue and mobility through gamified rehabilitation
214735600|NCT07147218|DEVICE|TMS|transcranial magnetic stimulation - DASH 36 treatment delivered in 5 days
214735601|NCT07148388|DEVICE|Repetitive transcranial magnetic stimulation|Patients in the AiTBS group received 5 consecutive days of AiTBS treatment, with 6 sessions of iTBS interventions per day (1800 pulses per trial, with a 50-minute interval between trials). Patients in the 10Hz rTMS group received 10 consecutive days of 10Hz rTMS treatment within 10 days, with 1500 pulses per day, totaling 15 minutes.
214735602|NCT07149220|DRUG|Mucoadhesive fenretinide-releasing system (FMS)|All persons with premalignant oral epithelial lesions will receive active intervention. The intervention consists of b.i.d. application of the FMS to the premalignant lesion for a total of six weeks. Please note that the intervention title Drug and intervention titled Other are the same entity.
214735603|NCT07149012|OTHER|Artificial Intelligence Awareness and Feasibility Assessment|"A sequential explanatory mixed-methods assessment of surgeons' awareness, readiness, and perceived barriers to adopting artificial intelligence in surgical care during the ongoing Sudan conflict. The intervention consisted of:~A validated, structured online questionnaire adapted from established AI awareness tools, assessing familiarity, perceived benefits, barriers, and ethical concerns.~Semi-structured interviews with senior surgical residents and consultants to explore contextual and ethical perspectives in greater depth.~The study did not implement AI tools in practice but focused on measuring feasibility and identifying requirements for future AI deployment in conflict-affected surgical systems."
214735604|NCT07148778|BEHAVIORAL|Educational intervention|"In this study, a web-based postpartum care package program supported by a chatbot will be administered to the intervention group.~A pre-test will be administered to participants in the intervention group within 24-48 hours after birth.~Participants in this group will be informed that they must watch the videos in the educational modules until the sixth week postpartum. Reminder messages will also be sent to participants via the website, email, and phone calls (between days 7 and 14 postpartum and week 3 postpartum). Participants who have completed the module training will be eligible for post-tests at 6 weeks postpartum and 3 months postpartum."
214735605|NCT07148557|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (400 mg/dose) was SC
214735606|NCT07148557|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (600 mg/dose) was SC
214735607|NCT07148102|DEVICE|Diaphragmatic US|Diaphragmatic thickening fraction (DTF) and diaphragmatic excursion (DE) were measured by ultrasound within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
214735608|NCT07148102|DEVICE|EC|TFC was assessed using electrical cardiometry (EC). Measurements were obtained within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
214735609|NCT07148739|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.
214735610|NCT07148739|OTHER|therapeutic drug monitoring|Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.
214735611|NCT07147920|DEVICE|Chest-Worn ECG Monitoring Device|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor electrocardiogram (ECG) signals using dry conductive adhesive electrodes. In this validation study, the device will be evaluated for its ability to accurately measure ECG parameters including heart rate, QT interval, QRS duration, and R-R intervals compared to FDA-cleared Holter monitors.~The study intervention involves three components: (1) simultaneous ECG recording with the patch and reference Holter monitor for 15 minutes while participants remain seated, (2) placement tolerance testing where the patch is positioned at various locations (±20mm from optimal placement) to assess performance under suboptimal positioning, and (3) long-term wear evaluation where participants wear the patch continuously for 15 days with periodic assessments. The intervention is limited to device application and ECG data collection under controlled conditions, with no therapeutic treatment provided."
214735612|NCT07147608|OTHER|actimeter wearing|actimeter wearing during 7 days : recording of physical activity over 7 days using a non-invasive external sensor
214735613|NCT07147608|OTHER|physical activities questionnaires|IPAQ and SAPHIR questionnaires
214735614|NCT07149155|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|The intervention was a 2-hour, in-person SFA/HRW training followed by 30-minute monthly learning collaboratives to address occupational stress of harm reduction workers.
214735615|NCT07149038|DEVICE|Cerogrin|Participants in this arm will receive transcutaneous auricular vagus nerve stimulation using the Cerogrin device. This device non-invasively delivers electrical stimulation to the vagus nerve located on the outer ear, aiming to improve cognitive function.
214735616|NCT07149038|DEVICE|Sham Device|Participants in this arm will use a sham device. This device is identical in appearance to the active Cerogrin device but delivers no electrical stimulation or therapeutic effect. The sham device serves as a control to compare outcomes with the active treatment group.
214735617|NCT07148323|DEVICE|HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor|Subjects with planned monitoring with a pulmonary artery catheter in the operating room, will be monitored with the above listed devices.
214735618|NCT07148856|OTHER|Conventional Physiotherapy|A standard physiotherapy program provided after Achilles tendon surgery, including stretching, strengthening, mobility, and functional training exercises
214735619|NCT07148856|OTHER|Myofascial Release Technique|A manual therapy technique applied to the lower limb and ankle region, aiming to release fascial restrictions, improve soft tissue flexibility, and enhance ankle range of motion.
214735620|NCT07148492|PROCEDURE|Antireflux suture|Antireflux suture will be taken in this intervention group
214735621|NCT07148492|PROCEDURE|No Antireflux suture|Antireflux suture will not be taken in this intervention group
214735622|NCT07148869|BEHAVIORAL|LAUGHTER YOGA|Patients will be divided into groups of at least 5 people according to the sample size. Laughter yoga sessions will be conducted under the leadership of the researcher in a suitable room / hall determined within the hospital. A total of 8 sessions will be applied, 2 sessions per week for 4 weeks, with each session lasting an average of 40 minutes.
214735623|NCT07148869|OTHER|control group|there will be no application to this group
214735624|NCT07149233|DEVICE|Inspiratory Muscle Training|Inspiratory muscle training (IMT) was performed for 4 weeks in patients with moderate to severe OSA. The intervention group used a threshold device with resistance: training occurred twice daily, 7 days per week, with 3 sets of 30 fast inspiratory efforts and 1-minute rest between sets. Load started at 50% of maximal inspiratory pressure (MIP), increased to 60% in week 3, and 75% in week 4. Weekly visits were held for load adjustment. The sham group followed the same schedule using the same device without resistance (spring removed). Both groups recorded adherence in training diaries and received daily follow-up calls from the principal investigator
214735627|NCT07149168|DRUG|Dexmedetomidin|The PENG block will be performed using a mixture of 0.25% bupivacaine (1.25 to 2.5 mg/kg.) combined with dexmedetomidine at a dose of 1.25 mcg/kg
214735628|NCT07149168|DRUG|Bupivacain|a typical dose of 0.5% hyperbaric bupivacaine ranges from 0.1 to 0.15 mg/kg (2 to 3 mL), depending on the patient's height and clinical condition. Lower doses are used for shorter or elderly patients, while taller patients may require higher doses
214735629|NCT07149116|DEVICE|Tracheostomy sealing|A non-classified silicone-based prototype device designed to temporarily seal the tracheostomy tract from within the airway for up to 7 days after decannulation.
214735630|NCT07148635|PROCEDURE|Electrical Dry Needling (EDN)|Electrical dry needling will be performed at active myofascial trigger points in lumbar muscles (quadratus lumborum, multifidus, iliocostalis lumborum). Fine monofilament needles are inserted into trigger points and connected to a low-frequency stimulator (2-10 Hz) for 10-15 minutes per session. Treatment is delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program.
214735631|NCT07148635|PROCEDURE|Sham Dry Needling (SDN)|Sham dry needling will be administered at the same anatomical sites as the experimental group, using superficial or blunt needle placement without penetration into muscle tissue and without electrical stimulation. Sessions are delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive the same standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program to maintain consistency with the experimental arm.
214735632|NCT07149090|DRUG|Lenvatinib|"Description: Lenvatinib: 12 mg (for body weight ≥ 60 kg) or 8 mg (for body weight \< 60 kg) per oral once daily~* Dose level 1: 8mg per oral once daily (for \<60kg) 12mg per oral once daily (for ≥ 60kg)~* Dose level 2: 4mg per oral once daily (for \<60kg) 8mg per oral once daily (for ≥ 60kg) Nivolumab: 360 mg administered intravenously every 3 weeks Chemotherapy(Oxaliplatin+Capecitabine) every 3 weeks~* Capecitabine 1000 mg/m² per oral twice daily on Days 1-14~* Oxaliplatin 130 mg/m² administered intravenously on Day 1"
214735633|NCT07149025|PROCEDURE|Osteopathic Manipulative Therapy|1 session of OMT
214735634|NCT07148284|OTHER|Isolation of EVs + RNA sequencing|Isolation of EVs + RNA sequencing
214735635|NCT07147985|BEHAVIORAL|162 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 162 steps per minute crossover to 180 steps per minute and 198 steps per minute.
214735636|NCT07147985|BEHAVIORAL|180 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 180 steps per minute crossover to 162 steps per minute and 198 steps per minute.
214735637|NCT07147985|BEHAVIORAL|198 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 198 steps per minute crossover to 162 steps per minute and 180 steps per minute.
214735638|NCT07147595|PROCEDURE|Isometric handgrip exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with a handgrip device for each arm, with 1-minute rest intervals between sets and between arms.
214735639|NCT07147595|PROCEDURE|Isometric knee extension exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with adjustable ankle weights for each leg, with 1-minute rest intervals between sets and between legs.
214735640|NCT07148531|BEHAVIORAL|Seeds for Attachment (translated version)|"Developed by, and base at Universidad de los Andes, this is a community-based psychosocial model for caregivers of young children in conflict-affected settings.~The program is implemented through a 15-week group-based model with approximately 15 caregivers per group, and led by community facilitators (non-professionals).~The program follows four sequential goals: (1) promoting awareness of and tools for emotional regulation of the psychological consequences of conflict and forced displacement; (2) understanding children's emotional needs and the caregiver-child relationship; (3) developing responsive caregiving practices that foster secure attachment; and (4) strengthening social support networks. The approach integrates psychosocial support with attention to the social determinants of caregiving and mental health."
214735641|NCT07148570|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Delivery Room Nursing Care Based on Kolcaba's Comfort Theory
214644748|NCT04460755|OTHER|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214644749|NCT04460755|OTHER|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
214644750|NCT02847754|OTHER|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
214644751|NCT00688909|DRUG|letrozole|2.5 mg daily by mouth for 6 months
214644752|NCT02008825|DEVICE|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
214644753|NCT02008825|DEVICE|Usual non suction Bougie|Usual non suction Bougie
214644754|NCT01220414|DRUG|Naltrexone, then placebo|50 mg of naltrexone
214644755|NCT01220414|DRUG|Placebo, then Naltrexone|sugar pill
214644756|NCT01936389|DRUG|AR-12286|
214644757|NCT05431257|DRUG|Venetoclax|"Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia."
214644758|NCT04227756|DRUG|LSD|LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
214644759|NCT04227756|DRUG|Psilocybin|Psilocybin 20 mg per os, single dose
214644760|NCT04227756|DRUG|Mescaline|Mescaline 300 mg or 500 mg per os, single dose
214644761|NCT04227756|OTHER|Placebo|Placebo (Mannitol)
214644762|NCT02969902|DEVICE|Buzzy® device|
214644763|NCT02969902|DEVICE|Hand-held computer|
214644764|NCT03190187|OTHER|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
214644765|NCT03190187|OTHER|Sham manipulation|Patients will receive simulated spinal manipulation without force application
214644766|NCT03329456|DRUG|Ropivacaine|Minimum effective volume
214735642|NCT07100223|OTHER|EDUCATION|"Assignment to the intervention and control groups will be made by randomization method.~Before training is given to the intervention and control groups, Parental Introduction Form, Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~After parents attend a 1-week birth preparation training at Kayseri City Hospital Pregnancy School, they will participate in a 9-week Awareness-Based Parenting and Birth Preparation Training.~After the training is completed; Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~Wijma Birth Expectation/Experience Scale Version B will be administered to mothers on the 1st postpartum day."
214735643|NCT07147569|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|The target patients are those who were attempted to implant the AC during the enrollment period of this surveillance. Patients will also be targeted even if all components of the TAMBE device (devices that can be used in combination with AC specified in IFU) were not used, or if a device other than the component of the TAMBE device was used.
214735644|NCT07147881|DEVICE|IpsiHand|IpsiHand is a therapeutic device that uses a brain-computer interface system which detects neural signals associated with motor intent and translates them into assisted hand movements in individuals with upper extremity impairment following a stroke.
214735645|NCT07148674|DEVICE|Positive Expiratory Pressure (10cmH2O) in hypobaric hypoxia|The intervention under investigation will be the application of positive expiratory pressure (PEP) at 10 cmH₂O using an Ambu mask. The mask will allow participants to inspire freely while generating a controlled expiratory pressure. The PEP device is a non-pharmacological medical device whose uses in both hospital and pre-hospital settings are part of everyday medical practice.
214735646|NCT07148921|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a psychophysical test procedure. With the help of calibrated stimuli and subjective sensory information, the functional state of the somatosensory system of a subject or patient is examined with regard to the expression of clinical signs.~The test includes:~* Cold detection threshold~* Warm detection threshold~* Paradoxical heat sensation~* Cold pain threshold~* Heat pain threshold~* Mechanical detection threshold~* Mechanical pain threshold~* Mechanical pain sensitivity~* Dynamic mechanical allodynia~* Wind-up phenomena~* Vibration threshold~* Pressure pain threshold"
214735647|NCT07148921|DIAGNOSTIC_TEST|Patient Health Questionnaire 9|The Patient Health Questionnaire 9 (PHQ-9), a validated and internationally used health questionnaire, will also be completed twice at the first study day before the sex hormone therapy is initiated and during the last study day in month 6. The questionnaire consists of 9 items on the topic of mental well-being.
214735648|NCT07148921|DIAGNOSTIC_TEST|Hormone concentrations|"Blood concentrations of the following laboratory parameters will be determined:~* Follicle stimulating hormone (FSH)~* Luteotropic hormone (LH)~* Prolactin (PRL)~* Oestradiol (E2)~* Sex hormone-binding globulin (SHBG)~* Testosterone"
214735649|NCT07148167|OTHER|Magnetic resonance imaging|use Magnetic Resonance Imaging (MRI) to evaluate the cervical muscle planes in AS patients in more detailed and objective ways. In this study, in addition to cervical muscle volumes in AS patients, we also aimed to evaluate cervical fat infiltration and cervical alignment, which have not been previously evaluated in AS patients.
214735650|NCT07148947|DRUG|Pacritinib|Given PO
214735651|NCT07148947|DRUG|Decitabine|Given IV
214735652|NCT07148947|DRUG|Decitabine and Cedazuridine|Given PO
214735653|NCT07148947|DRUG|Azacitidine|Given IV or SC
214735654|NCT07148947|OTHER|Survey Administration|Ancillary studies
214735655|NCT07148947|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214735656|NCT07148947|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214735657|NCT07148947|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214735658|NCT07147660|OTHER|Compensatory scanning training|Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
214735659|NCT07147660|OTHER|Delayed Compensatory scanning training|Delayed track start. Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
214735660|NCT07148401|DEVICE|Hall technique|Hall technique for placement of crowns on carious primary molars
214735661|NCT07147582|OTHER|Transcranial alternating current stimulation with two electrodes placed on scalp|Transcranial alternating current stimulation with anode and cathode electrodes and frequency ranged from 8 to 13 HZ
214735662|NCT04223778|DRUG|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
214735663|NCT04223778|DRUG|ART|Baseline ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
214735664|NCT06547112|DRUG|Motixafortide|Dose = 1.25 mg/kg via subcutaneous injection
214735665|NCT06547112|DRUG|G-CSF|Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
214735666|NCT03893630|DRUG|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
214735667|NCT03893630|DRUG|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
214735668|NCT03893630|OTHER|Control|Standard of Care
214735669|NCT06956508|OTHER|Targeted Brain Rehabilitation|"Patients will be given a virtual reality headset that is pre-loaded with the targeted brain rehabilitation (TBR) software at the time of their major amputation.~The Virtual Reality (VR) environment will consist of a high-fidelity virtual representation of the participant's phantom limb. Participants will use a mounted head display (MHD) to interact with a virtual avatar, with the phantom limb represented as a realistic 3D limb model matching the remaining anatomy and skin tone. The VR system will be set up either in the clinic or at the participant's home, depending on individual circumstances and preferences.~The VR protocol will be standardized and include exercises designed to mimic typical occupational therapy session."
214735670|NCT06536101|DRUG|GIM-407|GIM-407 oral dose
214735671|NCT06536101|DRUG|Placebo|Matching placebo oral dose
214735672|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
214735673|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
214735674|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
214735675|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
214735676|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
214735677|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
214735678|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
214735679|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
214735680|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
214735681|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
214735682|NCT01370499|DRUG|LY2216684|
214735683|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
214735684|NCT00532233|DRUG|QAX576|
214735685|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
214735686|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
214735687|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
214735688|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
214735689|NCT04427228|RADIATION|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
214735690|NCT04427228|RADIATION|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
214735691|NCT02949414|PROCEDURE|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
214735692|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
214735693|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
214735694|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
214735695|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
214735696|NCT03501615|DRUG|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
214735697|NCT06485661|DRUG|Captopril Tablets|Patients will be given captopril to see effect on global longitudinal strain
214735698|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
214735699|NCT01913652|DRUG|Cabazitaxel|
214735700|NCT03363789|BIOLOGICAL|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
214735701|NCT03363789|PROCEDURE|Physical Therapy|Patients will receive a prescription for physical therapy.
214735702|NCT01449344|DRUG|Rituximab|Rituximab 375mg/m² IV , day 1
214735703|NCT01449344|DRUG|High dose Ara-C|Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
214735704|NCT01449344|DRUG|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
214735705|NCT01449344|DRUG|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
214735706|NCT04576273|DIAGNOSTIC_TEST|Pathology examination|Gross and microscopic evaluation
214735707|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
214735708|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
214735709|NCT00865358|BEHAVIORAL|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
214735710|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
214735711|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
214735712|NCT00017225|BIOLOGICAL|filgrastim|
214735713|NCT00017225|DRUG|carboplatin|
214735714|NCT00017225|DRUG|cisplatin|
214735715|NCT00017225|DRUG|cyclophosphamide|
214735716|NCT00017225|DRUG|dacarbazine|
214735717|NCT00017225|DRUG|doxorubicin hydrochloride|
214735718|NCT00017225|DRUG|etoposide|
214735719|NCT00017225|DRUG|ifosfamide|
214735720|NCT00017225|DRUG|melphalan|
214735721|NCT00017225|DRUG|tretinoin|
214735722|NCT00017225|DRUG|vincristine sulfate|
214735723|NCT00017225|DRUG|vindesine|
214735724|NCT00017225|PROCEDURE|autologous bone marrow transplantation|
214735725|NCT00017225|PROCEDURE|conventional surgery|
214735726|NCT00017225|PROCEDURE|peripheral blood stem cell transplantation|
214735727|NCT00017225|RADIATION|radiation therapy|
214735728|NCT00069251|DRUG|Bupropion|
214735729|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
214735730|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
214735731|NCT03934515|OTHER|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values."
214735732|NCT03934515|OTHER|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values."
214735733|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
214735734|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
214735735|NCT00118924|BIOLOGICAL|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
214735736|NCT00118924|BIOLOGICAL|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
214735737|NCT00765830|DRUG|vildagliptin|50mg qd
214735738|NCT00765830|DRUG|Placebo|qd
214735739|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
214735740|NCT02045979|DRUG|BI 695501|BI 695501 single s.c. injection
214735741|NCT02045979|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
214735742|NCT02045979|DRUG|adalimumab-US source|adalimumab-US source single s.c. injection.
214735743|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
214735744|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
214735745|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
214735746|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
214735747|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
214735748|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
214735749|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
214735750|NCT03196206|DRUG|BMS-986177|Oral Suspension
214735751|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
214735752|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
214735753|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
214735754|NCT02086760|RADIATION|Scintigraphy|
214735755|NCT02447393|DRUG|levocetirizine|levocetirizine
214735756|NCT02447393|DRUG|cetirizine|cetiridine
214735757|NCT02447393|DRUG|placebo|placebo
214735758|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
214735759|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
214735760|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
214735761|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
214735762|NCT00039546|DRUG|cyclophosphamide|
214735763|NCT00039546|DRUG|epirubicin hydrochloride|
214735764|NCT00039546|DRUG|gemcitabine hydrochloride|
214735765|NCT00039546|DRUG|paclitaxel|
214735766|NCT00039546|PROCEDURE|adjuvant therapy|
214735767|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
214735768|NCT06379672|OTHER|Resonance breathing|Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
214735769|NCT02306928|OTHER|Blood draw|
214735770|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
214735771|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
214735772|NCT00120029|BEHAVIORAL|weight loss counseling|
214735773|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
214735774|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
214735775|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
214735776|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
214735777|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
214735778|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
214735779|NCT03686462|DEVICE|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
214735780|NCT03686462|DEVICE|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
214735781|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
214735782|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
214735783|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
214735784|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
214735785|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
214735786|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
214735787|NCT05053867|DRUG|tranexamic acid|Inhaled
214735788|NCT05053867|OTHER|Usual Care|Standard of Care
214735789|NCT03062670|OTHER|Retreat|Full day off-site training session
214735790|NCT05481944|DIAGNOSTIC_TEST|MRI in patients|Injected MRI
214735791|NCT05481944|DIAGNOSTIC_TEST|MRI in healthy volunteers|non injected MRI
214735792|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
214735793|NCT04888182|DIETARY_SUPPLEMENT|intervention|a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
214735794|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
214735795|NCT04918069|DRUG|Capsaicin|Topical capsaicin ointment
214735796|NCT04918069|DRUG|Placebo|Topical placebo ointment
214735797|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
214735798|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
214735799|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
214735800|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
214735801|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
214735802|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
214735803|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
214735804|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
214735805|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
214735806|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
214735807|NCT05836428|OTHER|no intervention|no intervention
214735808|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
214735809|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
214735810|NCT05427058|PROCEDURE|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
214735811|NCT05427058|PROCEDURE|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
214735812|NCT03760302|OTHER|analgesics|analgesics given to a patient treated from HEMS
214735813|NCT03760302|OTHER|hypnotics|hypnotics given to a patient treated from HEMS
214735814|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
214735815|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
214735816|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
214735817|NCT02749552|BEHAVIORAL|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
214735818|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
214735819|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
214735820|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
214735821|NCT03801083|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
214735822|NCT06037954|OTHER|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
214735823|NCT06037954|OTHER|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
214735824|NCT06037954|OTHER|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care"
214735825|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214735826|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214735827|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214735828|NCT03534453|DRUG|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
214735829|NCT06194929|DRUG|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
214735830|NCT06194929|DRUG|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
214735831|NCT06194929|DRUG|Encorafenib|Encorafinib administered orally per arm description.
214735832|NCT04003649|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
214735833|NCT04003649|BIOLOGICAL|Ipilimumab|Given IV
214735834|NCT04003649|BIOLOGICAL|Nivolumab|Given IV
214735835|NCT04003649|OTHER|Quality-of-Life Assessment|Ancillary studies
214735836|NCT04003649|OTHER|Questionnaire Administration|Ancillary studies
214735837|NCT04278235|DRUG|Elezanumab|Solution for intravenous (IV) infusion
214735838|NCT05814042|DRUG|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
214735839|NCT05814042|DRUG|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
214735840|NCT05827978|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214735841|NCT05827978|BIOLOGICAL|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
214735842|NCT03336606|DRUG|MEDI0562|Surgical resection of tumor
214735843|NCT04752228|OTHER|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
214735844|NCT04752228|OTHER|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
214735845|NCT00579462|OTHER|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
214735846|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
214735847|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
214735848|NCT00729560|DRUG|Flutamide|250 mg twice daily for 4 weeks
214735849|NCT00729560|DRUG|Placebo|Placebo twice daily for 4 weeks
214735850|NCT04709094|DRUG|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
214735851|NCT04709094|DRUG|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
214735852|NCT04709094|DRUG|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
214735853|NCT04709094|DRUG|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
214735854|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
214735855|NCT00249522|BEHAVIORAL|Contingency management|
214735856|NCT01732133|DEVICE|Nexfin|
214735857|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
214735858|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
214735859|NCT01256957|DEVICE|HEPA filter|
214735860|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
214735861|NCT02940158|OTHER|1/4 cup- Small red lentil|
214735862|NCT02940158|OTHER|1/4 cup- Small green lentil|
214735863|NCT02940158|OTHER|1/4 cup- corn|
214735864|NCT02940158|OTHER|1/4 cup- macaroni|
214735865|NCT02940158|OTHER|1/4 cup- white potato|
214735866|NCT02940158|OTHER|1/4 cup- white rice|
214735867|NCT02940158|OTHER|1/2 cup- small red lentil|
214735868|NCT02940158|OTHER|1/2 cup- small green lentil|
214735869|NCT02940158|OTHER|1/2 cup- corn|
214735870|NCT02940158|OTHER|1/2 cup- macaroni|
214735871|NCT02940158|OTHER|1/2 cup- white potato|
214735872|NCT02940158|OTHER|1/2 cup- white rice|
214735873|NCT00172003|DRUG|Zoledronic acid|
214735874|NCT00103207|BIOLOGICAL|cetuximab|
214735875|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
214735876|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
214735877|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
214735878|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
214735879|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
214735880|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
214735881|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
214735882|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
214735883|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
214735884|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
214735885|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
214735886|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
214735887|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
214735888|NCT03662789|DRUG|Iron Isomaltoside 1000|Intravenous infusion
214735889|NCT03662789|OTHER|Placebo: NaCl 0,9%|Intravenous infusion
214735890|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
214735891|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
214735892|NCT05103631|GENETIC|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214735893|NCT06647433|OTHER|Observation|case study will be observed participants, methods will include observation, interview and video reflexive ethnography
214735894|NCT03602235|OTHER|Ascorbate|Ascorbate is in the vitamin drug class
214735895|NCT03602235|DRUG|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
214735896|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
214735897|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
214735898|NCT04771390|DRUG|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
214735899|NCT04771390|DRUG|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
214735900|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
214735901|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
214735902|NCT03447067|PROCEDURE|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
214735903|NCT03447067|PROCEDURE|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
214735904|NCT03447067|DEVICE|CBCT|For measuring the bone removeal
214735905|NCT03447067|DEVICE|CBCT|for identifed the nerve
214735906|NCT05655416|PROCEDURE|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
214735907|NCT01023516|DRUG|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
214735908|NCT01023516|DRUG|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
214735909|NCT05060081|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
214735910|NCT05060081|OTHER|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
214735911|NCT03330093|BEHAVIORAL|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
214735912|NCT03330093|BEHAVIORAL|Health and Safety Intervention|In-person, family-based behavioral intervention
214735913|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
214735914|NCT00369564|OTHER|placebo|Given orally 3 times daily
214735915|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
214735916|NCT04507516|OTHER|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
214735917|NCT06138704|PROCEDURE|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
214735918|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
214735919|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
214735920|NCT00002274|DRUG|Didanosine|
214735921|NCT05576415|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
214735922|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
214735923|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
214735924|NCT02400840|PROCEDURE|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
214735925|NCT02400840|DRUG|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
214735926|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
214735927|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
214735928|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
214735929|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
214735930|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
214735931|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
214735932|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
214735933|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
214735934|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
214735935|NCT05398068|OTHER|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
214735936|NCT05398068|OTHER|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
214735937|NCT02126384|DRUG|pneumovax vaccination|vaccination
214735938|NCT02955940|DRUG|Ruxolitinib|5 mg BID
214735939|NCT02955940|DRUG|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
214735940|NCT02955940|DRUG|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
214735941|NCT03805789|BIOLOGICAL|AAT|AAT is a lyophilized product for IV administration.
214735942|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
214735943|NCT03980340|BEHAVIORAL|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
214735944|NCT03980340|BEHAVIORAL|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
214735945|NCT04717414|DRUG|ACE-536|Subcutaneous Injection
214735946|NCT04717414|OTHER|Placebo|Subcutaneous Injection
214735947|NCT00986804|DRUG|Decitabine|
214735948|NCT00853112|DRUG|PF-00489791|tablet form, 1 mg, single dose (Day 1)
214735949|NCT00853112|DRUG|PF-00489791|tablet form, 2 mg, single dose (Day 1)
214735950|NCT00853112|DRUG|PF-00489791|tablet form, 4 mg, single dose (Day 1)
214735951|NCT00853112|DRUG|PF-00489791|tablet form, 10 mg, single dose (Day 1)
214735952|NCT00853112|DRUG|PF-00489791|tablet form, 20 mg, single dose (Day 1)
214735953|NCT00853112|DRUG|placebo|tablet form, single dose (Day 1)
214735954|NCT00853112|DRUG|sildenafil|tablet form, 20 mg, single dose (Day 1)
214735955|NCT01762592|DRUG|Iodine (124I) Girentuximab|i.v.
214735956|NCT05535790|OTHER|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
214735957|NCT05535790|OTHER|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
214735958|NCT01553591|DRUG|Eluxadoline|Oral tablets twice daily
214735959|NCT01553591|DRUG|Placebo|Oral tablets twice daily
214735960|NCT04951219|DRUG|Resmetirom|Tablet
215030649|NCT06658249|OTHER|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
214735961|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
214735962|NCT06593379|BEHAVIORAL|Safety planning|Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.
214735963|NCT06593379|BEHAVIORAL|Treatment as usual|This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans
214735964|NCT06593379|BEHAVIORAL|MIST Intervention|This is a mobile intervention designed to target and modify suicidal cognitions. Veteran in this condition will be asked to use the intervention 5 times a week for 4 weeks.
214735965|NCT02881086|DRUG|Rituximab|
214735966|NCT02881086|DRUG|Nelarabine|
214735967|NCT02881086|DRUG|PEG-Asparaginase|
214735968|NCT02881086|PROCEDURE|Cranial irradiation|
214735969|NCT02881086|DRUG|Imatinib|
214735970|NCT02881086|DRUG|Idarubicin|
214735971|NCT02881086|DRUG|Dexamethasone|
214735972|NCT02881086|DRUG|Cyclophosphamide|
214735973|NCT02881086|DRUG|Fludarabine|
214735974|NCT02881086|DRUG|Vincristine|
214735975|NCT02881086|DRUG|Mercaptopurine|
214735976|NCT02881086|DRUG|VP16|
214735977|NCT02881086|DRUG|Daunorubicin (DNR)|
214735978|NCT02881086|DRUG|Methotrexate|
214735979|NCT02881086|PROCEDURE|Stem cell transplantation|
214735980|NCT02881086|DRUG|Cytarabine|
214735981|NCT02881086|DRUG|Vindesine|
214735982|NCT02881086|DRUG|Adriamycin|
214735983|NCT02881086|DRUG|Prednisolone|
214735984|NCT04419597|DEVICE|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
214735985|NCT04419597|DEVICE|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
214735986|NCT04255368|OTHER|Water-soluble choline|600 mg choline as choline bitartrate
214735987|NCT04255368|OTHER|Fat-soluble choline|600 mg choline as phosphatidylcholine
214735988|NCT04255368|OTHER|No choline control|No choline
214735989|NCT01818765|PROCEDURE|Trans-ventricular-septal placement of LV pacing lead|
214735990|NCT01818765|OTHER|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
214735991|NCT01818765|OTHER|Acute response assessment|Cardiac output monitoring
214735992|NCT05935475|PROCEDURE|Anatomical landmark guided dialysis catheter insertion|.: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
214735993|NCT05935475|PROCEDURE|ECG guided dialysis catheter insertion|after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
214735994|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
214735995|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
214735996|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
214735997|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
214735998|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
214735999|NCT02005211|DRUG|AZD3293|Oral solution
214736000|NCT02005211|DRUG|Placebo|Oral solution
214736001|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
214736002|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
214736003|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
214736004|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
214736005|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
214736006|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
214736007|NCT04214106|DRUG|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
214736008|NCT03177954|BEHAVIORAL|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
214736009|NCT00397631|DRUG|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
214736010|NCT00397631|DRUG|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
214736011|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
214736012|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
214736013|NCT05319886|DRUG|Anlotinib and Penpulimab|Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
214736014|NCT01666353|RADIATION|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
214736015|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
214736016|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
214736017|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
214736018|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
214736019|NCT00003716|BIOLOGICAL|rituximab|
214736020|NCT03245944|PROCEDURE|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
214736021|NCT03245944|PROCEDURE|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
214736022|NCT04022291|BIOLOGICAL|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
214736023|NCT04022291|BIOLOGICAL|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
214736024|NCT04211857|DEVICE|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
214736025|NCT00832091|DRUG|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
214736026|NCT00832091|DRUG|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
214736027|NCT01782612|PROCEDURE|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
214736028|NCT01782612|PROCEDURE|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
214736029|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
214736030|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
214736031|NCT04759612|OTHER|Action Observation|Participants will watch an upper extremity functionality test.
214736032|NCT03667573|DEVICE|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
214736033|NCT03667573|DEVICE|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
214736034|NCT03667573|OTHER|textured shoe insoles|textured shoe insoles
214736035|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
214736036|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
214736037|NCT02508506|DRUG|ALKS 5461|Single dose, given orally
214736038|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
214736039|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
214736040|NCT04145505|PROCEDURE|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
214736041|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
214736042|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
214736043|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|Given via injection
214736044|NCT06661902|DRUG|Lidocaine|Given via injection
214736045|NCT06661902|PROCEDURE|Biopsy of Prostate|Undergo SOC prostate biopsy
214736046|NCT06661902|OTHER|Questionnaire Administration|Ancillary studies
214736047|NCT04146870|OTHER|not have|not have
214736048|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
214736049|NCT06859281|DRUG|Grammidin neo|Grammidin neo, lozenges, 1 lozenge to be taken once under fed conditions.
214736050|NCT06859281|DRUG|Grammidin, a metered dose topical spray|Grammidin, a metered dose topical spray, 4 sprays to be taken once under fed conditions.
214736051|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
214736052|NCT02180464|DRUG|LAS41004|
214736053|NCT02180464|DRUG|control|
214736054|NCT04829864|BEHAVIORAL|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
214736055|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
214736056|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214736057|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
214736058|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
214736059|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
214736060|NCT05246007|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
214736061|NCT05246007|DRUG|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
214736062|NCT04237610|BEHAVIORAL|behavioral assessment|Probabilistic learning task
214736063|NCT06602869|OTHER|Scheduled visit (V1)|During the scheduled visit (V1), as part of routine care, a blood draw will be performed. On this occasion, an additional 7 ml tube will be collected to perform serology and culture. This will help define the group (NTM+ Cases/NTM- Controls) and measure cellular biomarkers.
214736064|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
214736065|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
214736066|NCT06996730|DRUG|Donanemab|IV Infusion
214736067|NCT06996730|DRUG|RG6289|Oral tablet
214736068|NCT06996730|DRUG|Donanemab placebo|IV placebo
214736069|NCT06996730|DRUG|RG6289 placebo|Oral tablet placebo
214736070|NCT05442515|BIOLOGICAL|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
214736071|NCT05442515|DRUG|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
214736072|NCT05442515|DRUG|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
214736073|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
214736074|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
214736075|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
214736076|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
214736077|NCT06997627|BIOLOGICAL|GC3111B|0.5 mL, Intramuscular injection
214736078|NCT06997627|BIOLOGICAL|Boostrix®|0.5 mL, Intramuscular injection
214736079|NCT06865014|OTHER|Intermittent Ramadan Fasting|Intermittent fasting during the month Ramadan
214736080|NCT06517732|OTHER|Secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
214736081|NCT06300788|OTHER|PPI and T50 dosing|Sampling for PPI determination and T50 in blood and urine.
214736082|NCT02711553|DRUG|Ramucirumab|Administered IV
214736083|NCT02711553|DRUG|Merestinib|Administered orally
214736084|NCT02711553|DRUG|Cisplatin|Administered IV
214736085|NCT02711553|DRUG|Gemcitabine|Administered IV
214736086|NCT02711553|DRUG|Placebo Oral|Administered orally
214736087|NCT02711553|DRUG|Placebo IV|Administered IV
214736088|NCT06996574|OTHER|Randomization|The all-in-one (NTG) procedure versus the established two-phase closed-loop SCS procedure with at-home screening trials (TG) under everyday clinical practice, that can be used for clinical decision-making and to inform health policy decisions.
214736089|NCT03678389|OTHER|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
214736090|NCT01771718|DEVICE|Multiphoton microscopy-based tomograph.|non-invasive optical biopsy
214736091|NCT00648492|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
214736092|NCT00648492|DRUG|Glucophage® XR 500 mg|500mg, single dose fed
214736093|NCT07004751|DIAGNOSTIC_TEST|Additional laboratory analysis|Additional lab tests will be done to establish the diagnosis of Murine typhus, Bartonellosis, Q-fever, Chikungunya, Zika, Japanese B encephalitis, West Nile virus
214736094|NCT07004751|DIAGNOSTIC_TEST|Standard of Care (SOC)|Standard of care evaluation of a febrile patient is done by the treating medical team as Standard of care evaluation of a febrile patient is done by the treating medical team which includes clinical, basic laboratory, radiological and microbiological evaluations
214736095|NCT07006064|DEVICE|SUPERNOVA|In the intervention group, oxygen is delivered using the SuperNO2VA™ nasal positive airway pressure mask (Vyaire Medical, USA), which differs from conventional nasal oxygen delivery systems by providing continuous positive airway pressure (CPAP) through a sealed nasal interface. This mask also includes an integrated sampling port for accurate end tidal carbon dioxide (EtCO2) monitoring. The aim is to reduce the incidence of hypoxia and allow for better detection and prevention of hypo/hypercapnia during sedation in elderly patients undergoing TAVI without intubation. The use of positive pressure is intended to prevent upper airway collapse, maintain functional residual capacity, and improve gas exchange during sedation.
214736096|NCT07006064|DEVICE|NASAL MASK|Traditional nasal cannulas only provide passive oxygen flow. End-tidal CO2 measurement is being conducted with Capnostream™ 35 Portable Respiratory Monitor.
214736097|NCT01742663|DRUG|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
214736098|NCT01742663|DRUG|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
214736099|NCT01742663|DRUG|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
214736100|NCT05559203|BEHAVIORAL|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
214736101|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
214736102|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
214736103|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
214736104|NCT01818128|DEVICE|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
214736105|NCT01818128|DEVICE|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
214736106|NCT01573286|DRUG|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
214736107|NCT01573286|DRUG|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
214736108|NCT06627816|DRUG|Nefopam|efficacy of 3 drugs in preventing post-spinal anesthesia shivering
214736109|NCT06624358|BEHAVIORAL|Increase Physical Activity|Behavioral interventions to improve physical activity
214736110|NCT00961558|PROCEDURE|Varicocelectomy|Varicocelectomy
214736111|NCT02177214|PROCEDURE|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
214736112|NCT01861613|BIOLOGICAL|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
214736113|NCT00215189|BEHAVIORAL|In SHAPE (Pilot Health Promotion Intervention)|
214736114|NCT01503619|OTHER|laboratory biomarker analysis|Correlative studies
214736115|NCT05856279|PROCEDURE|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
214736116|NCT00810251|DEVICE|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
214736117|NCT03949010|OTHER|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
214736118|NCT03949010|OTHER|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
214736119|NCT03949010|OTHER|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
214736120|NCT01524926|DRUG|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
214736121|NCT03874104|DIETARY_SUPPLEMENT|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
214736122|NCT02187224|DRUG|Progesterone|
214736123|NCT02187224|DRUG|Placebo (for Progesterone)|
214736124|NCT00006062|DRUG|oxaliplatin|
214736125|NCT01039038|RADIATION|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
214736126|NCT01208818|DRUG|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
214736127|NCT01208818|DRUG|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
214736128|NCT01208818|DEVICE|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
214736129|NCT01208818|DEVICE|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
214736130|NCT03527303|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
214736131|NCT05748236|DRUG|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
214736132|NCT05748236|DRUG|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
214736133|NCT00373464|DRUG|etoricoxib|
214736134|NCT00388375|PROCEDURE|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
214736135|NCT00044694|DRUG|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
214736136|NCT00044694|DRUG|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
214736137|NCT00044694|DRUG|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
214736138|NCT00044694|DRUG|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
214736139|NCT00044694|DRUG|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
214736140|NCT00044694|DRUG|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
214736141|NCT00044694|DRUG|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
214736142|NCT00044694|DRUG|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
214736143|NCT02237365|DRUG|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
214736144|NCT02237365|DRUG|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
214736145|NCT02237365|DRUG|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
214736146|NCT02377076|DIETARY_SUPPLEMENT|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
214736147|NCT02377076|DIETARY_SUPPLEMENT|Control|Control (Whey protein, vitamin D, sugar and salt)
214736148|NCT01386229|DRUG|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
214736149|NCT01386229|DRUG|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
214736150|NCT06687876|DRUG|Metformin|Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
214736151|NCT06693726|DRUG|Angiotensin II Infusion|Angiotensin II continuous infusion
214736152|NCT01229410|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
214736153|NCT01229410|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
214736154|NCT04655846|BEHAVIORAL|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
214736155|NCT04655846|BEHAVIORAL|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
214736156|NCT04485936|DEVICE|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
214736157|NCT03334656|BIOLOGICAL|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
214736158|NCT03334656|OTHER|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
214736159|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
214736160|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 3mcg
214736161|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 15mcg
214736162|NCT00902057|DRUG|placebo|saline subcutaneous
214736163|NCT05232292|BIOLOGICAL|Ultrix Quadri|vaccination by Ultrix Quadri against flu
214736164|NCT04140682|DEVICE|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
214736165|NCT04140682|DEVICE|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
214736166|NCT02929381|DEVICE|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
214736167|NCT02929381|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
214736168|NCT03294772|OTHER|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
214736169|NCT03294772|OTHER|liquid soap|DCCs received liquid soap and a program educational.
214736170|NCT00952952|DRUG|Mesalamine|
214736171|NCT04600453|OTHER|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
214736172|NCT01665898|PROCEDURE|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
214736173|NCT01665898|PROCEDURE|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
214736174|NCT02931747|DIETARY_SUPPLEMENT|Placebo|Subjects are received Placebo once daily for 16 weeks.
214736175|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
214736176|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
214736177|NCT01815905|OTHER|Mobile program for occupational and speech therapy|
214736178|NCT01815905|OTHER|Traditional rehabilitation therapy|
214736179|NCT04386473|DEVICE|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
214736180|NCT02280525|DRUG|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
214736181|NCT02280525|DRUG|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
214736182|NCT02280525|DRUG|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
214736183|NCT02280525|DRUG|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
214736184|NCT02280525|PROCEDURE|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
214736185|NCT02280525|DRUG|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
214736186|NCT00333931|DRUG|Phenytoin|
214736187|NCT00333931|BEHAVIORAL|Cognitive Behavioral Therapy|
214736188|NCT00922038|BEHAVIORAL|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
214736189|NCT04277052|DEVICE|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
214736190|NCT01542294|DRUG|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
214736191|NCT01542294|DRUG|Oxaliplatin|130mg/m2 d1 repeated every 21 days
214736192|NCT04520867|OTHER|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
214736193|NCT04050475|DIETARY_SUPPLEMENT|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
214736194|NCT01318928|DRUG|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
214736195|NCT05469152|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
214736196|NCT00155467|PROCEDURE|CT|
214736197|NCT03566992|PROCEDURE|Gastric|Placement of a nasoenteric tube
214736198|NCT02152540|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
214736199|NCT02152540|DEVICE|Sham rTMS|Placebo Device that simulates active rTMS treatment
214736200|NCT06107790|DRUG|HS022|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
214736201|NCT06107790|DRUG|Trastuzumab|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
214736202|NCT06107790|DRUG|Vinorelbine Bitartrate|"Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first."
214736203|NCT02793206|DEVICE|Imaging|
214736204|NCT01480791|DRUG|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
214736205|NCT01480791|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
214736206|NCT07022457|BIOLOGICAL|Encorafenib + Binimetinib|Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics
214736207|NCT05740267|PROCEDURE|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
214736208|NCT01700140|DRUG|SyB D-0701|Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
214736209|NCT01700140|DRUG|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
214736210|NCT04969458|OTHER|survey application|"Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)"
214736211|NCT00896350|DRUG|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
214736212|NCT02663947|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
214736213|NCT06695858|DRUG|ESPB|Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
214736214|NCT05474768|OTHER|no intervention|no intervention
214736215|NCT01899001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
214736216|NCT01899001|BEHAVIORAL|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
214736217|NCT04251195|BEHAVIORAL|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
214736218|NCT04251195|BEHAVIORAL|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
214736219|NCT04174872|DRUG|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
214736220|NCT04174872|DRUG|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
214736221|NCT02573012|DRUG|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
214736222|NCT02573012|DRUG|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
214736223|NCT02573012|BIOLOGICAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
214736224|NCT04019197|DRUG|Semaglutide Injectable Product|semaglutide subcutaneous injection
214736225|NCT04019197|DRUG|Placebo|placebo injection
214736226|NCT03518580|OTHER|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
214736227|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
214736228|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
214736229|NCT05315973|DEVICE|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
214736230|NCT04862650|DRUG|Carboplatin|Given IV
214736231|NCT04862650|BIOLOGICAL|Cemiplimab|Given IV
214736232|NCT04862650|DRUG|Paclitaxel|Given IV
214736233|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
214736234|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
214736235|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
214736236|NCT04961502|BIOLOGICAL|Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly|3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers): the first carried out before the anti-Coronavirus Disease 2019 (COVID-19) vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
214736237|NCT02587104|OTHER|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
214736238|NCT03773601|OTHER|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
214736239|NCT03773601|OTHER|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
214736240|NCT03773601|OTHER|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
214736241|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
214736242|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
214736243|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
214736244|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
214736245|NCT02268760|DRUG|BILN 2061 ZW single rising doses|
214736246|NCT02268760|DRUG|Placebo|
214736247|NCT02268760|DRUG|BILN 2061 ZW fixed dose|
214736248|NCT02268760|OTHER|Standardized breakfast|
214736249|NCT00369889|DRUG|bevacizumab|iv every 21 days
214736250|NCT00369889|DRUG|Erlotinib|oral daily
214736251|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
214736252|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
214736253|NCT04520295|GENETIC|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
214736254|NCT02409264|OTHER|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
214736255|NCT03227601|DEVICE|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
214736256|NCT00454350|DRUG|Hectorol (doxercalciferol injection)|
214736257|NCT00454350|DRUG|Zemplar (Paricalcitol injection)|
214736258|NCT01222416|RADIATION|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
214736259|NCT01222416|RADIATION|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
214736260|NCT01748903|DEVICE|Target 360°, 2D Coils, Nano Coils|
214736261|NCT02685449|DRUG|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
214736262|NCT02685449|DRUG|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
214736263|NCT02685449|DRUG|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
214736264|NCT03784326|DRUG|Atezolizumab|Given IV (vein)
214736265|NCT03784326|PROCEDURE|Conventional Surgery|Undergo surgical resection
214736266|NCT03784326|DRUG|Fluorouracil|Given IV (vein)
214736267|NCT03784326|DRUG|Oxaliplatin|Given IV (vein)
214736268|NCT03784326|DRUG|Tiragolumab|Given IV (vein)
214736269|NCT01758367|DRUG|Deciatbine(DAC)|
214736270|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
214736271|NCT05569356|OTHER|Retrospective|None (only data collection)
214736273|NCT00518336|PROCEDURE|Blood sampling|Blood sampling at Visit 3, 5 and 7.
214736274|NCT00518336|PROCEDURE|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
214736275|NCT00518336|BIOLOGICAL|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
214736276|NCT00238160|DRUG|cisplatin|
214736277|NCT00238160|DRUG|fluorouracil|
214736278|NCT00238160|PROCEDURE|adjuvant therapy|
214736279|NCT00238160|PROCEDURE|chemotherapy|
214736280|NCT00238160|PROCEDURE|conventional surgery|
214736281|NCT00238160|PROCEDURE|hepatic arterial infusion|
214736282|NCT00238160|PROCEDURE|surgery|
214736283|NCT04479306|DRUG|Alisertib|Given PO
214736284|NCT04479306|DRUG|Osimertinib|Given PO
214736285|NCT04479306|DRUG|Sapanisertib|Given PO
214736286|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
214736287|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
214736288|NCT03628391|DRUG|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
214736289|NCT03628391|DRUG|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
214736290|NCT04166955|BEHAVIORAL|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
214736291|NCT07030608|BEHAVIORAL|Exercise|Pelvic Floor Muscle Exercise Program Week 1: Contract the pelvic floor muscles for 6 seconds, then relax for 6 seconds. Repeat 25 times. Perform 3 sessions per day (total of 75 contractions per day). Week 2: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day). Week 3: Contract for 6 seconds, relax for 6 seconds. Repeat 75 times. Perform 3 sessions per day (total of 225 contractions per day). Weeks 4-24: Contract for 6 seconds, relax for 6 seconds. Repeat 100 times. Perform 3 sessions per day (total of 300 contractions per day). After Week 24: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day).
214736292|NCT00879788|DRUG|Ramipril 10mg capsules|
214736293|NCT01723176|PROCEDURE|Echocardiography|
214736294|NCT00000231|DRUG|Buprenorphine|
214736295|NCT06713499|DRUG|SHR-1819 injection|SHR-1819 injection.
214736296|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
214736297|NCT00716040|BEHAVIORAL|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
214736298|NCT00716040|OTHER|Usual care|The control group will be submitted to the usual care of the health service
214736299|NCT06721975|DEVICE|Thulio pulsed Thulium:YAG (p-Tm:YAG)|A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG.
214736300|NCT06721975|DEVICE|Thulium Laser Fiber (TFL)|The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
214736301|NCT05282186|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
214736302|NCT05282186|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
214736303|NCT06925776|OTHER|CHOOSE Home Intervention|Integration of a CHW (Community Health Worker) in the CKD (Chronic Kidney Disease) care process to augment patient engagement and address HRSNs (Health-Related Social Needs) within the context of an IDC (Interdisciplinary Care) CKD clinic. The multifaceted components of the intervention are tailored to address key care delivery and social barriers to home dialysis utilization before implementation.
214736304|NCT06925776|OTHER|Usual Care|This is the usual interdisciplinary care that patients would typically receive for their chronic kidney disease. A key missing factor here is the lack of a community health worker. Patients in this group will be screened for health-related social needs and receive general information on ways to access social services from a study coordinator. Patients will not receive facilitated peer support and social care navigation from the Community Health Worker.
214736305|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
214736306|NCT01718119|DRUG|r-hCG|r-hCG(250mcg) injection subcutaneously
214736307|NCT06534164|DEVICE|Full/High Tech Telerehabilitation decision support system|"The TeleRehaB DSS intervention includes balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
214736308|NCT06534164|DEVICE|Basic/Low Tech Telerehabilitation decision support system|"The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
214736309|NCT06534164|PROCEDURE|OTAGO Home exercise program|balance rehabilitation program
214736310|NCT06534164|PROCEDURE|Vestibular rehabilitation program|vestibular rehabilitation and dizziness program
214736311|NCT07048587|DIAGNOSTIC_TEST|Beta-hCG levels in the uterine cavity lavage for differential diagnosis in pregnancy of unknown locations and ectopic pregnancy|The intervention in this study centers on utilizing beta-hCG levels in uterine cavity lavage as a diagnostic tool to differentiate between ectopic pregnancy and early pregnancy loss.The procedure includes females aged 18-45 with positive serum beta-hCG, inconclusive clinical findings, and transvaginal ultrasound results, focusing on beta-hCG levels below 1500-2000 mIU/mL and abnormal progression.The intervention performed before probe curettage (P/C). Before the intervention beta-hCG is measured in venous blood. Patients undergo uterine cavity lavage with 5 ml of saline solution administered and 3 ml of aspirated liquid collected for beta-hCG measurement. Data collection involves beta-hCG levels from lavage fluid and venous blood, pathology results.After the samples were collected, each one was frozen at -80 ºC. All uterine lavage samples were then analyzed later on the same day.
214736312|NCT06890559|BEHAVIORAL|financial incentive intervention based on a digital platform|The intervention will span a duration of 12 months. All residents in the 8 intervention subdistricts/townships are available for participation; each participant household needs to register a household account on the digital platform. Each family member who completes targeted vaccine uptake or related health behaviors can earn points through two point-recording routes. Reward points will be accumulated on a household basis to encourage family members' engagement. Points can be redeemed for gifts on the digital platform and are only valid once.
214736313|NCT05911945|PROCEDURE|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
214736314|NCT05911945|PROCEDURE|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
214736315|NCT07052942|DRUG|Inhaled corticosteroid (ICS)|Participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy.
214736316|NCT07052942|DRUG|Azithromycin|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects.
214736317|NCT07052942|OTHER|Asthma Symptom Monitoring Web-based Application|All participants will be provided access to the Asthma Symptom Monitoring (ASM) tools. ASM can be integrated with electronic health records (EHR) or used as a stand alone application. Participants will answer 5 questions about their asthma each week. If symptoms are problematic, participants can request a call back from a person on their care team. Participants can view a graph of their data, watch videos, and record peak flows. Clinicians and members of the care team can view data in the EHR (not for stand alone web app).
214736318|NCT07057674|DRUG|HS-20094 AI pen;|Arm 1: Administered SC The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
214736319|NCT07057674|DRUG|HS-20094 MDV pen|The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
214736320|NCT07057895|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM) Criteria Assessment|Malnutrition was diagnosed according to the GLIM consensus criteria. This required at least one phenotypic criterion (non-volitional weight loss, low BMI, or reduced muscle mass) and one etiologic criterion (reduced food intake/assimilation or inflammation/disease burden). Reduced muscle mass was assessed by bioelectrical impedance analysis (BIA). The assessment was performed once for each patient within 24 hours of hospital admission.
214736321|NCT07057895|DIAGNOSTIC_TEST|Patient-Generated Subjective Global Assessment (PG-SGA)|A comprehensive nutritional assessment administered by trained clinical staff. The tool comprises patient-reported sections (weight history, food intake, symptoms, activities/function) and clinician-assessed sections (disease, metabolic demand, physical exam). For this study, a total score of ≥2 was considered indicative of malnutrition. The assessment was performed once for each patient within 24 hours of hospital admission.
214736322|NCT07057518|BEHAVIORAL|emotional freedom technique|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
214736323|NCT07058636|DRUG|2% Lidocaine HCl + saline|The intervention consists of injecting a mixture of 1 ml 2% lidocaine and 1 ml normal saline into trigger points located in the upper trapezius muscle.
214736324|NCT07058636|DRUG|Steroid+lidocaine|The GON block involves injecting a mixture of 1 ml 2% lidocaine and 1 ml betamethasone.
214736325|NCT07059247|BIOLOGICAL|Application of Enamel Matrix Derivatives|After the extraction of the impacted lower third molar, EMD will be applied on the distal site of the second molar
214736326|NCT07059247|PROCEDURE|Extraction of the impacted third molar|Extraction of the impacted third molar
214736327|NCT07059286|BEHAVIORAL|Maternal Frailty Inventory (MaFra) Questionnaire|A validated psychometric inventory designed to assess maternal clinical, psychological, and lifestyle risk factors during pregnancy. The composite risk score is used to stratify participants into low- or medium/high-risk categories. Administered during pregnancy, the inventory informs classification and predictive modeling of fetal and child neurodevelopmental outcomes.
214736328|NCT07059286|DIAGNOSTIC_TEST|Fetal Resting-State Functional MRI|Non-invasive resting-state functional MRI scans performed during gestation (fetal) life to assess functional connectivity across sensorimotor, auditory, visual, language, and attention networks. Imaging data are analyzed to derive local and global connectivity measures and indices of segregation and integration among functional brain systems. Structural MRI is used to confirm normal brain morphology.
214736329|NCT07059286|BEHAVIORAL|Maternal Emotional Reactivity|During fetal rs-fMRI acquisition, mothers listen to emotionally evocative musical excerpts while rating their emotional responses. These self-reported ratings (valence and arousal) are later correlated with fetal brain connectivity responses.
214736330|NCT07059286|DIAGNOSTIC_TEST|Neonatal Resting-State Functional MRI|Non-invasive MRI scanning protocol conducted during the neonatal period to acquire resting-state functional MRI (rs-fMRI) data. The scan is performed while the newborn is in a natural sleep state, using motion-optimized sequences to assess functional connectivity between brain regions. The focus is on sensorimotor, auditory, visual, language, and attention networks. Structural MRI is also acquired to verify normative brain morphology. Imaging outcomes are used in longitudinal analyses to link early brain connectivity with cognitive and behavioral development.
214736331|NCT07059286|BEHAVIORAL|Longitudinal Neurodevelopmental Testing Battery|Standardized neuropsychological and behavioral assessments are administered at multiple timepoints between birth and 72 months of age. Domains evaluated include sensorimotor skills, cognitive abilities, language development, executive function, social-emotional regulation, and adaptive behaviors. Data are used to compute specific and composite scores that reflect neurocognitive and behavioral profiles. These are later integrated with prenatal and neonatal brain imaging and maternal risk data to model individual neurodevelopmental trajectories.
214736332|NCT07058025|BIOLOGICAL|Human Allogenic Umbilical Cord Mesenchymal Stromal Cells|IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded
214736333|NCT07058025|OTHER|Sham procedure control|Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks
214736334|NCT07059468|DIAGNOSTIC_TEST|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA)|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method
214736335|NCT07058246|OTHER|Mime therapy with Conventional therapy|"Experimental group was given mime therapy along with conventional therapy. Mirror therapy, Raising eyebrows as if surprised, Widening eyes in shock, blinking rapidly, Extreme smiling, Eye closure with dramatic expressions, exaggeration nose wrinkling. pouting and mouth opening, expression transitions.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
214736336|NCT07058246|OTHER|Conventional therapy|"Raising and lowering eyebrows, Wrinkling nose, smiling, frowning, massage.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
214736337|NCT07059494|DRUG|Atezolizumab|Atezolizumab is an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. It is indicated for usage in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS).
214736338|NCT07059494|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It is also indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in participants who have progressed on a first-line bevacizumab product-containing regimen.
214736339|NCT07059494|RADIATION|Y^90 Radioembolization|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat cancers in the liver. Tiny beads filled with a radioactive isotope are placed inside the blood vessels that supply a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. It can help extend the lives of participants with inoperable tumors and improve their quality of life.
214736340|NCT07059156|DRUG|Induction Therapy Regimen|"VICP+VEN regimen:~* Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22.~* Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.~* Cyclophosphamide (CTX): 500 mg/m², days 7, 21.~* Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28~* Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day"
214736341|NCT07059156|DRUG|Pre-Treatment Regimen|"Indications for pre-treatment:~* WBC ≥30×10⁹/L, or significant hepatosplenomegaly/lymphadenopathy.~* Laboratory signs of tumor lysis syndrome (e.g., electrolyte abnormalities).~Pre-treatment protocol:~* Glucocorticoids (e.g., prednisone or dexamethasone): Prednisone 1 mg/kg/day (PO/IV) for 3-5 days.~* Optional addition of CTX: 200 mg/m²/day IV for 3-5 days."
214736342|NCT07059156|OTHER|Post-CR Treatment|"Principles:~1. MRD-positive or rising: Administer blinatumomab (CD19/CD3 bispecific antibody) for residual disease clearance, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).~2. MRD-negative/unknown: Continue multi-agent chemotherapy ± blinatumomab consolidation. Allo-HSCT for patients with high-risk clinical/genetic features."
214736343|NCT07059156|DRUG|Post-CR Consolidation Regimens|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO)."
214736344|NCT07059156|OTHER|Transplant-Eligible Subsequent Therapy|"* Allo-HSCT for eligible patients after induction.~* Conditioning regimen: TBI-VP16-CY.~* Donor priority: HLA-matched sibling donor (MSD), Matched unrelated donor (MUD), Haploidentical donor (Haplo).(Consider age/donor health status)."
214736345|NCT07059156|OTHER|Allo-HSCT Protocol|"1.6.1 Conditioning Regimen (TBI-VP16-Cy/ATG):~* TBI: 5 Gy (Days -7 to -6).~* VP16: 10 mg/kg/day (Days -5 to -4).~* CTX: 30 mg/kg/day (Days -3 to -2).~* ATG: 7.5 mg/kg/day (Days -5 to -2). 1.6.2 GVHD Prophylaxis:~* Basiliximab (anti-CD25 mAb): 50 mg (Days +1, +4).~* Standard regimen: Cyclosporine (CsA): IV: 2 mg/kg/day (start Day -9; target level 150-250 μg/L). PO: 3-5 mg/kg/day BID (switch delayed until Day +10 if no aGVHD); Mycophenolate mofetil (MMF) + short-course methotrexate."
214736346|NCT07059156|OTHER|Non-Transplant Maintenance Therapy Options|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO).~  * Maintenance (6-MP/MTX alternating with V-Dex): 6-MP: 75 mg/m²/day at bedtime (Days 1-21); MTX: 20 mg/m² IM weekly × 3 weeks.\*Adjust doses to maintain WBC \~3×10⁹/L, ANC 1.0-1.5×10⁹/L.\*"
214736347|NCT07058337|PROCEDURE|parsplana vitrectomy|23 gauge parsplana vitrectomy
214736348|NCT07058337|PROCEDURE|adjunctive use of Methotrexate|intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively
214736349|NCT07058415|OTHER|Stool sample 1|Stool sampling at D0 for having baseline reference
214736350|NCT07058415|OTHER|Stool sample 2|Stool sampling at D5 to study the impact of antibiotics on microbiota
214736351|NCT07058415|OTHER|Stool sample 3|Stool sampling at DX+28 to study the impact of antibiotics on microbiota
214736352|NCT07058688|DRUG|NTRX-07|Orally administered CB2 agonist
214736353|NCT07058688|DRUG|Placebo|Inactive matched comparator
214736354|NCT07057856|BIOLOGICAL|Ustekinumab (UST)|The first sufficient dose of UST (6mg/kg) was administered intravenously at weeks 0
214736355|NCT07058805|RADIATION|Compartmentalized Postoperative Radiotherapy|Pathology- and imaging-guided compartmentalized postoperative radiotherapy (PORT), with or without concurrent systemic treatment. Based on a predefined algorithm, PORT or specific anatomical volumes may be omitted. Dose prescription and volumes are risk-adapted.
214736356|NCT07058571|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participating Veterans will engage in bi-weekly, telehealth mediated resistance exercise session. Aerobic exercise will be monitored passively through FitBit data collection. Telehealth exercise sessions will last approximately 45-90 minutes pending the individual Veteran's progress. Participants will also undergo a one-time dietary consultation and recommendations by a Leukemia and Lymphoma Society (LLS) member.
214736357|NCT07058285|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. o ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
214736358|NCT07058285|OTHER|SDTT+ anteroposterior perturbations|The SDTT+ anteroposterior perturbations program will trigger reactive gait adaptations by accelerations and decelerations of one of the belts of a split-belt treadmill.
214736359|NCT07057700|DEVICE|welwalk training|welwalk training group 30 min of welwalk robot-assisted training + 15 min of walking training + 15 min of other training per session.The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
214736360|NCT07057700|OTHER|physical therapy|45 min of walking training + 15 min of other training per session. The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
214736361|NCT07058545|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
214736362|NCT07058545|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
214736363|NCT02422563|PROCEDURE|hysterectomy|radical hysterectomy
214736364|NCT02422563|RADIATION|Radiation|
214736365|NCT02422563|DRUG|Cisplatin|
214736366|NCT02422563|DRUG|Paclitaxel|
214736367|NCT02422563|DRUG|Carboplatin|
214736368|NCT02422563|DRUG|Ifosfamide|
214736369|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
214736370|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
214736371|NCT04873843|BEHAVIORAL|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
214736372|NCT04873843|BEHAVIORAL|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
214736373|NCT07054866|BEHAVIORAL|Speech-Gesture combinations|this is a pretest, test, posttest evaluation of language comprehension with and without gestures, to see if gestures can improve language comprehension
214736374|NCT07054801|DRUG|Lidocaine hydrochloride|A total of 20 mg injected in 10 mg doses will be administered over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 40 mg per MMA. The injection will be performed bilaterally, yielding a total dose of 80 mg per patient.
214736375|NCT07054801|DRUG|Methylprednisolone sodium succinate|A total of 10 mg were injected over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 20 mg per MMA, yielding a total dose of 40 mg per patient.
214736376|NCT07054632|GENETIC|LX101|Subretinal administration of LX101 to the study eye
214736377|NCT07059143|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
214736378|NCT07058779|DRUG|SSS55|SSS55 is an injection targeting complement C3b
214736379|NCT07058896|BEHAVIORAL|High intensity task oriented circuit training + Telerehabilitation|"Participants will receive 12 sessions of high-intensity, task-oriented circuit training, three times a week for four weeks. Each session will last 180 minutes, with 108 minutes of active training. Each session will include three rounds, each lasting 51 minutes. During each round, participants will rotate between stations working for six minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including sit-to-stand transitions, walking, standing, bed mobility and transfers, stepping, and wheelchair use. If participants are unable to walk, the walking station will be replaced by upper limb function station.~After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. Including monthly televisits with the physiotherapist. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring."
214736380|NCT07058090|DRUG|Silymarin 420 mg|silymarin group received silymarin 140mg thrice daily along with antituberculous drugs for 14 days
214736381|NCT07058090|DRUG|N Acetyl Cysteine|N- acetylcysteine group will receive N-acetylcysteine 900mg once daily with antituberculous drugs for 14 days
214736382|NCT07058090|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|Antituberculous drugs only
214736383|NCT06751251|DIAGNOSTIC_TEST|IHC: Immunohistochemistry|Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.
214736384|NCT06751251|GENETIC|RNA-seq|RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.
214736385|NCT02449915|DRUG|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
214736386|NCT02449915|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
214736387|NCT07058116|DRUG|L-Boronophenylalanine intravenous administration|L-BPA will be complexed with fructose to form L-BPA-fructose (L-BPA-F) to increase solubility, and 400 mg/kg of L-BFA as complexed with fructose (L-BPA-F) will then be administered intravenously at a concentration of L-BPA 30 g/L over 2 hours before neutron irradiation.
214736388|NCT07058831|DEVICE|Home ECG monitoring|The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.
214736389|NCT07059260|DIAGNOSTIC_TEST|Early referral|The intervention involves early referral, allowing patients to be assessed by a cardiologist prior to the standard referral process. During this visit, the cardiologist will perform a comprehensive medical history and a detailed physical examination to assess signs of central and peripheral congestion. A standardized echocardiogram will also be conducted, including a series of objective measurements.
214736390|NCT06843967|DRUG|Mirdametinib|Mirdametinib (PD-0325901) is a highly selective non-ATP-competitive inhibitor of MEK1 and MEK2. It significantly inhibits the phosphorylation of the MAP kinases ERK1 and ERK2, leading to impaired tumor cell growth in vitro and in vivo in a broad spectrum of human tumors
214736391|NCT06843967|DRUG|Palbociclib|Palbociclib (IBRANCE®) is a kinase inhibitor FDA approved for the following indications: treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men or fulvestrant in patients with disease progression following endocrine therapy.
214736392|NCT07058233|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Oral Nutritional Supplement (ONS) in the form of a soy-based drink (235 kcal/200mL: 10.34 g protein, 7.9 g fat, 30.61 g carbohydrate; Protein)
214736393|NCT07057739|DRUG|Superficial cervical plexus block|Patients received superficial cervical plexus block with 1 ml of normal saline with 7ml bupivacaine 0.25% per side without adjuvants.
214736394|NCT07057739|DRUG|Superficial cervical plexus block + Fentanyl|Patients received superficial cervical plexus block with fentanyl 1 ml (50 microgram) as an adjuvant to 7ml bupivacaine 0.25% per side.
214736395|NCT07057739|DRUG|Superficial cervical plexus block + Dexmedetomidine|Patients received superficial cervical plexus block with dexmedetomidine 0.5mcg/kg in 1 ml of normal saline as an adjuvant to 7ml bupivacaine 0.25% per side.
214736396|NCT06757218|OTHER|empty socket|Patients will be left socket empty without any graft materials for spontaneous healing process after tooth extraction
214736397|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and platelet rich fibrin in the socket after extraction.
214736398|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Albumin Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and Albumin Platelet Rich Fibrin in the socket after extraction.
214736399|NCT07063446|DEVICE|sTMS|Single pulses of TMS will be delivered over the motor cortex to quantify and map the motor evoked potentials
214736400|NCT07063446|DEVICE|taVNS|taVNS will be used to stimulate the auricular branch of the vagus nerve and paired with CIMT for a total of 40hours of CIMT
214736401|NCT06769633|DRUG|Givinostat Hydrochloride|Cohort 1 - from 4 to 6 years old
214736402|NCT06769633|DRUG|Givinostat Hydrochloride - Cohort 2|Cohort 2 - from 2 to 4 years old
214736403|NCT07058532|OTHER|Therapeutic Writing Intervention in Pain Rehabilitation|The therapeutic writing intervention is designed to support emotional processing and regulation in individuals with chronic pain and comorbid mental health disorders. It has been developed specifically for use in a clinical rehabilitation setting and is delivered in two phases over a four-week period at the Pain Clinic of Satasairaala Hospital. Sessions are conducted in person, with clinical staff available to support participants. The intervention is non-pharmacological, low-risk, and integrated into the broader multidisciplinary care pathway.
214736404|NCT07058766|BEHAVIORAL|positively affects the physical and psychological health of pregnant women in the disaster area.|As time passes after the earthquake, psychological first aid services are not sufficient. Developing a care protocol to provide physical and psychosocial support to pregnant women who are earthquake victims, especially those in the vulnerable group, during the post-disaster disappointment period (months 2-36), is an important unique value of this project.
214736405|NCT02407691|OTHER|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
214736406|NCT02407691|OTHER|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
214736407|NCT07058870|BEHAVIORAL|High Intensity Task Oriented Circuit Training + Telerehabilitation|Participants will receive 10 sessions of high-intensity, task-oriented circuit training, three times a week. Each session will last 60 minutes, with minutes of active training. Each session will include three rounds, each lasting 55 minutes. During each round, participants will rotate between stations working for four minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including supine to stand transitions, walking speed and functional capacity, walking adaptability and stepping. After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring.
214736408|NCT07058259|BEHAVIORAL|Acupuncture|Acupuncture will be administered twice weekly for 5 weeks (10 sessions total) at predefined bilateral acupoints: LU1, LU9, LI18, ST36, GB12, BL13, BL20, and BL23. Single-use, sterile 25 mm × 0.25 mm needles will be inserted at each point for 20 minutes per session.
214736409|NCT07058259|DRUG|Standard COPD Pharmacological Therapy (LAMA + LABA or LAMA + LABA + ICS)|"Patients in this group receive standard pharmacological treatment for COPD according to current clinical guidelines. Treatment includes either dual or triple inhaler therapy:~Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a long-acting muscarinic antagonist (LAMA) such as Tiotropium bromide, Umeclidinium, or Glycopyrronium.~Triple Therapy (LABA + LAMA + ICS): Patients receive the above combination of LABA and LAMA plus an inhaled corticosteroid (ICS) such as Budesonide, Fluticasone, or Beclometasone.~These medications may be administered either as fixed-dose combination inhalers or as separate inhalers, depending on patient needs and physician discretion. The treatment regimen is individualized based on clinical condition, prior therapy, and symptom severity."
214736410|NCT07058818|BEHAVIORAL|Resistance training|Full-body physical therapy and resistance training intervention
214736411|NCT07059299|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
214736412|NCT07059299|DRUG|FLOT Chemotherapy|docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W
214736413|NCT07058675|DRUG|Metformin Hydrochloride 500 MG|metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.
214736414|NCT07058675|DRUG|Myoinositol|myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily
214736415|NCT07070440|DRUG|DZD6008|DZD6008 was administered orally at 40/60/90 mg QD.
214736416|NCT07070440|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.
214736417|NCT07070440|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.
214736418|NCT07070440|DRUG|Docetaxel|Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.
214736419|NCT05227612|DRUG|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg).
214736420|NCT05227612|BEHAVIORAL|Cognitive behavioral therapy|Twelve total sessions of therapy, including manualized cognitive behavioral therapy for major depressive disorder, including psychoeducation about depression, cognitive skills, and behavioral skills as well as preparation for psilocybin.
214736421|NCT05227612|BEHAVIORAL|Minimal therapeutic support|Six total therapy sessions. Preparation for psilocybin in the first three sessions plus supportive, nondirective psychotherapy in the final three sessions.
214736422|NCT06899945|DEVICE|a percussion massage gun (Hypervolt device (Hyperice, CA, USA))|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the deltoid, supraspinatus, infraspinatus, and teres minor muscles with a percussion massage gun (Hypervolt device (Hyperice, CA, USA)) along the origo-insertio line for 3 minutes for each muscle group. Vibration application will be performed using the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
214736423|NCT06899945|OTHER|conventional physiotherapy program|"Participants in the conventional physiotherapy program will follow a 3-week exercise plan, with sessions 5 days per week, each lasting 30 minutes under physiotherapist supervision.~Treatment includes:~TENS therapy (20 min, 100 Hz) on the painful area. Wand exercises for flexion, abduction, extension, internal, and external rotation (10 reps/set).~Codman exercises for flexion, abduction, and circular movements (10 reps/set). Active \& passive stretching for flexion, abduction, internal, and external rotation (10 reps/set).~Finger ladder exercises for flexion and abduction (10 reps/set). Strengthening with a theraband for flexion, abduction, external/internal rotation, and extension, adjusted based on progress (10 reps/set).~This exercise program will be applied to all study groups."
214736424|NCT01846689|DRUG|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
214736425|NCT04305054|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214736426|NCT04305054|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
214736427|NCT04305054|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
214736428|NCT04305054|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
214736429|NCT04305054|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
214736430|NCT04305054|DRUG|ATRA|Administered via oral capsule at a specified dose on specified days
214736431|NCT07137182|OTHER|8-week physical activity program|Individuals in the experimental group will be administered an eight-week physical activity program. The researcher who will administer the activity is a specialist in Sports Sciences and holds the necessary certifications. The activity program includes cardio exercises, jumping, stretching, and stretching exercises.
214736432|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
214736433|NCT04975997|DRUG|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
214736434|NCT04975997|DRUG|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
214736435|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
214736436|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
214736437|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
214736438|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
214736439|NCT04975997|DRUG|Daratumumab|Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
214736440|NCT06692673|DRUG|Use of Linaclotide as a single agent Colonoscopy prep|We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
214736441|NCT06924164|OTHER|Progressive resistance training|The progressive resistance program consist of a five-minute aerobic warm-up on either an ergometer bike, treadmill or rowing machine followed by six resistance training exercises: landmine twist, walking lunges, leg press, hip abduction, hip adduction and hip flexion. All training sessions (three per week) will be supervised for the first two weeks. After that, there will be one weekly supervised training session and two self-directed sessions. The subjects will be scheduled for 36 training sessions over 12 weeks, of which 16 will be supervised. Each training session is designed based on the findings from the feasibility study and is expected to last approximately one hour. If a subject cannot perform all scheduled sessions in a week, additional sessions will be planned for the following week to obtain the 16 supervised sessions.
214736442|NCT06924164|BEHAVIORAL|Waiting time|12 weeks of waiting time
214736443|NCT06924164|BEHAVIORAL|Self guided exercise|12 weeks of self guided exercise
214736444|NCT06929403|BEHAVIORAL|Diet|Low-fat, low-cholesterol heart-protective diet
214736445|NCT06929403|DIETARY_SUPPLEMENT|Diet supplementation|2 tablets/daily bergamot and plant sterol/stanol supplement (375 mg bergamot fruit extract, 800 mg plant sterols and 150 mg flavonoids) for 12 weeks
214736446|NCT05172973|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
214736447|NCT06858332|DRUG|Atorvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
214736448|NCT06858332|DRUG|Simvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
214736449|NCT06858332|DRUG|Rozuvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
214736450|NCT06858332|DRUG|Ezetimibe|Ezetimibe
214736451|NCT06858332|DRUG|Niacin|Niacin
214736452|NCT06858332|DRUG|Ciprofibrate|Fibrates
214736453|NCT06858332|DRUG|Fenofibrate|Fibrates
214736454|NCT06858332|DRUG|Bezafibrate|Fibrates
214736455|NCT06858332|DRUG|Evolocumab|PCSK9 inhibitor
214736456|NCT06858332|DRUG|Alirocumab|PCSK9 inhibitor
214736457|NCT06858332|DRUG|Inclisiran|Small interfering RNA
214736458|NCT07093619|DEVICE|FERTILE Plus|The FERTILE PLUS™ method is a standardized method with an easy-to-follow protocol that is far less dependent on the skill or experience of the embryologist than other methods, such as density gradients. The FERTILE PLUS™ (850 µL) Sperm Sorting Chip is a single-use, flow-free, dual chambered, microfluidic-based sperm sorting device. FERTILE PLUS™ was previously known as Zymot, prior to a name change by the manufacturer. The lower chamber contains a sample inlet and fluid channel separated from the upper collection chamber by a microporous membrane with 8-μm pores, demonstrated as the optimal size for selection of sperm with higher motility and normal morphology \[18\].
214736459|NCT07093684|OTHER|Kidney disease|This is a registry-based observational study investigating the association between kidney disease and dementia-related outcomes. Kidney disease is not assigned or manipulated by the researchers but is classified as an exposure based on diagnostic codes (e.g., ICD codes), and related laboratory test recorded in health registers.
214736460|NCT07093437|DEVICE|GRIP-LOK FOLEY SECUREMENT DEVICE ®|"* Used device: adhesive~* Specific Skin protection: with non alcohol barrier film"
214736461|NCT07093437|DEVICE|CONVEEN, ELASTIC LEG WRISTBAND FOR URINARY CATHETER|The elastic wristband will be adjusted appropriately to minimize catheter movement while allowing normal blood circulation in the limb.
214736462|NCT06909214|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
214736463|NCT07095543|BEHAVIORAL|Low-fat, vegan diet|All participants will be asked to follow a low-fat vegan diet for the duration of the study. Participants will attend weekly classes where they we receive education and support.
214736464|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
214736465|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
214736466|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
214736467|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
214736468|NCT07096739|DIETARY_SUPPLEMENT|High protein shake|Subjects in this study will consume the study product for 1 week. Participants will record GI symptoms over the past 24h on 3 days during the week prior to the intervention, and on days 3, 5, and 7 during the intervention. On the first day, overnight fasted participants will be given the product and symptoms will be followed for 2h. 24h dietary recalls will be collected at the beginning and end of the 7-day treatment period.
214736469|NCT04960397|OTHER|Placebo|Physiological saline, i.e., 0.9% sodium chloride.
214736470|NCT04960397|BIOLOGICAL|Sing2016 M2SR H3N2|Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.
214736471|NCT03579446|DRUG|Hydrocodone|Given by PO
214736472|NCT03579446|DRUG|Hydromorphone|Given by PO
214736473|NCT03579446|DRUG|Levorphanol|Given PO
214736474|NCT03579446|DRUG|Morphine|Given by PO
214736475|NCT03579446|DRUG|Oxycodone|Given by PO
214736476|NCT03579446|DRUG|Oxymorphone|Given by PO
214736477|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
214736478|NCT07101380|DEVICE|Tablet-based Physical SuperBrain BOOM|"This intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI).~Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function.~Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting.~The app also helps track progress and encourage adherence to the exercise regimen."
214736479|NCT07101380|DEVICE|Smartphone-based SuperBrain BOOM|This intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen.
214736480|NCT07100470|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI is used to detect early metabolic alterations in neurodegenerative diseases
214736481|NCT07101341|PROCEDURE|Traditional aerobic training|5 minutes of warm-up at increasing intensity up to 60% of maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cool-down at decreasing intensity (30-60% HRmax)
214736482|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT)|5 minutes warm-up at increasing intensity up to 60% maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax)
214736483|NCT07101341|PROCEDURE|Aerobic training performed with a immersive virtual reality application|5 minutes of warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cooling at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses and an immersive virtual reality application
214736484|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT) performed with a immersive virtual reality application|5 minutes warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses for an immersive virtual reality application
214736485|NCT07101237|DIAGNOSTIC_TEST|Multi-modal ultrasonic imaging system for liver cancer|Conventional ultrasound, SMI, shear wave /strain elastography, and CEUS will be conducted for HCC/ICC patients. All above the imaging examinations will be conducted at 1/2/3/4/5/6, 9/12/15/18/21/24, and 30/36/42/48/54/60 months after the postoperative/post-conversion therapy.
214736486|NCT07102485|OTHER|disease-induced immunity|"Using a different label for natural immunity, specifically, disease-induced immunity"
214736487|NCT07102485|OTHER|natural immunity|"Using standard label natural immunity"
214736488|NCT07102004|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).
214736489|NCT07101601|DRUG|DM5167|Once daily for 28 days
214736490|NCT07100067|BIOLOGICAL|LCAR- F33S cells intravenous infusion|Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214736491|NCT07100301|OTHER|Proximal/distal protocol|Proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
214736492|NCT07100301|OTHER|Distal protocol|Distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
214736493|NCT07102472|BEHAVIORAL|"Using the term community immunity instead of herd immunity"|"In the intervention arm, participants are shown the less traditional term community immunity in place of the more traditional herd immunity"
214736494|NCT07102472|BEHAVIORAL|Herd immunity|"Using the traditional term herd immunity"
214736495|NCT07101731|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|Participants in the control group will receive an individualized home-based pelvic floor muscle exercise program. Exercises will be performed once daily for 8 weeks, focusing on voluntary pelvic floor contractions in various positions (supine, sitting, standing). Participants will receive initial training and written instructions from a physiotherapist, and will be contacted weekly to monitor adherence.
214736496|NCT07101731|BEHAVIORAL|Hypopressive Exercises|Participants in the experimental group will attend supervised hypopressive exercise sessions twice per week for 8 weeks. These sessions involve specific postural sequences combined with breathing and apnea techniques aimed at reducing intra-abdominal pressure while activating pelvic floor and abdominal muscles. Sessions will be led by a physiotherapist and adapted based on individual performance and posture tolerance.
214736497|NCT07101055|DRUG|Letermovir 480 mg [PREVYMIS]|A single 480 mg oral dose of letermovir (2 x 240 mg tablets).
214736498|NCT07100756|DEVICE|AI vertebral fracture diagnostics (Flamingo)|The AI (name: Flamingo from Image Biopsy Lab, IBL, Vienna, Austria) screens thoracic and abdominal CT scans for vertebral fractures.
214736499|NCT07101887|PROCEDURE|Implantation of thumb prosthesis|Replacing the articular surface of the trapezo-metacarpal joint with a socked-ball prosthesis.
214736500|NCT07101887|PROCEDURE|Burton-Pellegrini technique|Remove the trapezium bone and perform a suspensionplasty using a hemi-slip of the flexor carpi radialis tendon
214736501|NCT07101939|DRUG|(S)-pindolol benzoate|(S)-pindolol benzoate (ACM-001.1) immediate release tablet containing (S)-pindolol benzoate administered BID.
214736502|NCT07101939|DRUG|Semaglutide|Semaglutide, solution for injection in pre-filled pen
214736503|NCT07101939|DRUG|Placebo to (S)-pindolol benzoate|Placebo to ACM-001.1 immediate release tablet administered BID
214736504|NCT07101146|OTHER|Quality of life questionnaire|The NEI-RQL-42 (National Eye Institute Refractive Quality of Life) questionnaire will be self-administered via a secure online platform to assess the impact of pathological myopia on quality of life.
214736505|NCT07101146|OTHER|Performance Outcomes (PerfO)|"Three tests are planned to assess the impact of high myopia on critical aspects of mobility and safety, with the possibility of adjusting their scope based on pilot data.~* The first test involves an assessment of driving on a simulator, designed to evaluate the performance of detecting pedestrians in peripheral vision, with and without glare.~* The second test focuses on assessing mobility and obstacle avoidance under six levels of brightness.~* The third test evaluates visual search ability. It consists of finding spheres in everyday scenes in an apartment with six levels of contrast tested."
214736506|NCT07101146|OTHER|Semi-structured interviews|Semi-structured interviews will only be offered to patients recruited in Phase 1 Qualitative and aim to further explore the information gathered from the NEI-RQL-42 questionnaire responses and the difficulties encountered during the performance tasks in the laboratory, by exploring in more detail the limitations encountered by patients with pathological myopia in their daily activities. These interviews will help identify the specific causes of the difficulties encountered, as well as the environmental conditions that may create discomfort or increased hardship.
214736507|NCT07102173|PROCEDURE|Intercostal nerve block|Before final lung re-expansion, involving the administration of 20 mL of 0.5% levobupivacaine using a 27G needle into the subpleural space of the thoracotomy access site and adjacent intercostal spaces.
214736508|NCT07102173|PROCEDURE|Ultrasound-guided ESPB|After identifying the target transverse process, a linear ultrasound probe is placed sagittally approximately 2 cm from the midline. The needle (22G, 50 mm) is inserted in-plane in a cranio-caudal direction until contacting the transverse process. After confirming proper injection by observing anesthetic spread between the erector spinae muscle and transverse process, a total of 30 mL of 0.375% ropivacaine is administered.
214736509|NCT07100873|DRUG|ADI-001|Anti-CD20 CAR-T
214736510|NCT07100873|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
214736511|NCT07100873|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
214736512|NCT07100574|OTHER|atheroma plaque|During the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
214736513|NCT07100574|OTHER|dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
214736514|NCT07100327|PROCEDURE|Band|Laparoscopic sleeve gastrectomy with the placement of a 1.5 x 5.5 cm polypropylene band around the proximal gastric pouch to enhance restriction.
214736515|NCT07100327|PROCEDURE|Non-Band|Standard laparoscopic sleeve gastrectomy where approximately 75-80% of the stomach is resected to form a tubular structure
214736516|NCT07101133|DIETARY_SUPPLEMENT|Control group: Energy-limited balanced diet group|"Based on clinical phenotype + energy-restricted diet group：Based on the baseline dietary quality assessment of the subjects and baseline clinical data , a dietary plan was formulated, and the types and proportions of food were adjusted specifically .~Intervention group based on genetic susceptibility：Integrate deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimpose obesity nutrition gene data and nutrient metabolism genes, and customize the macronutrient ratio.~Based on genetic susceptibility + intestinal flora intervention group: Integrating deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimposing obesity nutrition gene + intestinal flora genomic data, including 33 obesity nutrition-related genes and 170 intestinal obesity nutrient metabolic bacterial genera/species test results, to customize the proportion of macronutrients."
214736517|NCT07100275|BEHAVIORAL|Patient education|In addition to the procedures in the control group, the patient will be informed about the surgery while he/she is at home the day before the surgery. Information will be provided about the hospital and surgical process. If there are any questions, the patient will be asked and their concerns will be resolved. T0-T1-T2 procedures will be performed on patients in the intervention group, respectively.
214736518|NCT07100275|BEHAVIORAL|Follow-up via Mobile Health Application|The researcher will create a video depicting the process of transferring patients from the ward to surgery. The video will be created with a volunteer mannequin. It will not be created with a real patient. This video will be recorded during a non-busy Sunday at the hospital. This video will be shown to patients the evening before surgery, following online education, and their questions will be answered.
214736519|NCT07101003|PROCEDURE|single visit instrumentation|root canal instrumentation will be done on single visit treatment
214736520|NCT07101003|PROCEDURE|multiple visit instrumentation|root canal treatment will be done on two visits
214736521|NCT05543252|DRUG|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
214736522|NCT05337137|DRUG|Relatlimab|Specified dose on specified days
214736523|NCT05337137|DRUG|Nivolumab|Specified dose on specified days
214736524|NCT05337137|DRUG|Bevacizumab|Specified dose on specified days
214736525|NCT05337137|OTHER|Placebo|Specified dose on specified days
214736526|NCT07101562|DEVICE|Tissue-engineered bone|Tissue-engineered bone with autologous bone marrow mesenchymal stem cells
214736527|NCT07100834|DEVICE|Single-Shot Pulsed Field Ablation (FARAPULSE™ Pulsed Field Ablation System)|The FARAPULSE™ Pulsed Field Ablation System (Boston Scientific, Inc.) is a CE-marked system consisting of the FARASTAR™ Pulsed Field Ablation Generator that is used with the FARAWAVE™ Pulsed Field Ablation Catheter for cardiac tissue ablation
214736528|NCT07100834|DEVICE|Single-Shot Cryoballoon Devices (Arctic Front Advance PRO, Medtronic Inc., Minneapolis, MN, USA; POLARx and POLARx FIT Balloon Catheter, Marlborough, MA, USA)|The Arctic Front Advance PRO, POLARx and FIT Balloon Catheters are CE-marked cryoablation systems consisting of a cryoballoon device, which is used in conjunction with a CryoConsole, a steerable sheath, and a circular mapping catheter
214736529|NCT07100535|BEHAVIORAL|Education and Literacy for an Active Life|This study will assess the effectiveness of a school-based health literacy intervention on the four dimensions of health literacy (i.e., access, understanding, evaluation, and application) on diet, sedentary behaviour, physical activity, sleep, and mental health in 5th and 6th graders (aged 9-12), and explored its implementation feasibility.
214736530|NCT07101211|BEHAVIORAL|Video-Based Educational Animation|A short, Turkish-dubbed educational animation video explaining the cystoscopy procedure, including steps of the procedure, expected sensations, and post-procedure care. The video is viewed by patients via QR code on their mobile devices before the cystoscopy to enhance patient understanding and reduce anxiety, stress, and depression.
214644767|NCT04214847|PROCEDURE|Ahmed Glaucoma Valve surgery|The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
214644768|NCT00445302|DRUG|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
214736531|NCT07101211|OTHER|Standard Written Informed Consent|A standard written informed consent form describing the cystoscopy procedure, including the purpose, steps, possible sensations, and post-procedure care, provided to all participants before the procedure.
214736532|NCT07100743|DIETARY_SUPPLEMENT|Probiotic Agent|HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg
214736533|NCT07100743|DIETARY_SUPPLEMENT|Placebo|The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.
214644769|NCT00188630|DRUG|N-acetylcysteine|
214644770|NCT00188630|OTHER|5% dextrose solution|
214644771|NCT02055625|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
214644772|NCT00496392|DRUG|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
214644773|NCT03646448|BEHAVIORAL|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
214644774|NCT01029730|DRUG|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
214644775|NCT01029730|DRUG|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
214644776|NCT01029730|DRUG|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
214644777|NCT02988102|OTHER|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
214644778|NCT00578123|BEHAVIORAL|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
214644779|NCT02668614|DEVICE|WR-22 model microwave sensor|
214644780|NCT03242330|DEVICE|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
214644781|NCT06031077|PROCEDURE|cardiac catheterization|An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
214736534|NCT07101653|OTHER|Exercise|According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minute sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period
214736535|NCT01877005|DRUG|Ruxolitinib|
214736536|NCT07102420|OTHER|Questionnaire and Physical Exam|Artificial Intelligence Anxiety Scale, Exercise Benefits/Barriers Scale
214736537|NCT07101861|BEHAVIORAL|Survivors RESET|16-session adaptation of the Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training
214736538|NCT06933095|DIETARY_SUPPLEMENT|LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)|apsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
214736539|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 4 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
214736540|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 2 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 2 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
214736541|NCT07148128|DRUG|WEF-001|Starting dose of 0.3 mg/m2 q4wks IV, dose escalation
214736542|NCT07148544|OTHER|Sedo analgesia protocol|Nurse-Controlled Sedo-Analgesia Protocol
214736543|NCT07148544|OTHER|control group|The clinic's routine sedation analgesia management plan will be implemented.
214736544|NCT07147205|OTHER|Therapy|MCGP will be delivered in 8 weekly sessions for 90 minutes over Zoom by a licensed doctoral level psychologist.
214736545|NCT07147907|DEVICE|Chest Worn Respiratory Rate Monitor|The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including respiratory rate and other health metrics. In this study, the device will be evaluated for its ability to accurately measure respiratory rate during controlled breathing exercises in healthy adult volunteers. The respiratory rate values recorded by the Perin Health Patch will be compared against respiratory rate measurements obtained via manually scored end tidal carbon dioxide (EtCO2) waveforms from a GE Datex-Ohmeda monitor, following Element Laboratory protocols aligned with clinical validation standards. The intervention in this study is limited to the application and use of the device for data collection during controlled respiratory rate conditions, where participants perform paced breathing exercises at various rates (5-50 breaths per minute) using a breathing app while positioned sitting or lying supine.
214736546|NCT07149207|DRUG|Indocyanine Green (ICG)|Dose: 5 mg/kg IV injection prior to surgery
214736547|NCT06949514|OTHER|guided imagery|Participants in this group will receive the guided imagery intervention. They will be approached after being hospitalized for at least 24 hours. The guided imagery audio recording will be played for the pregnant women every evening before sleep for three consecutive days.
214736548|NCT06948955|DRUG|Bezuclastinib|Drug: Bezuclastinib
214736549|NCT06948955|DRUG|Sunitinib|Drug: Sunitinib (locally sourced)
214736550|NCT06951165|BEHAVIORAL|Parent Supported Psychosocial Development Programme|A six-module online program was developed for parents of children ages 1 to 3. The program was provided to parents as a PDF, one module per week, and each module was discussed online.
214736551|NCT07149194|OTHER|CBC derived markers|CBC derived markers against CRP and ESR in detecting active Rheumatoid arthritis
214736552|NCT07148908|DIETARY_SUPPLEMENT|Yeast Protein Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
214736553|NCT07148908|DIETARY_SUPPLEMENT|Whey Protein Isolate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
214736554|NCT07148908|DIETARY_SUPPLEMENT|Collagen Hydrolysate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
214736555|NCT07147842|DRUG|Rutin 500 MG|Rutin 500 mg capsules twice daily for 30 days
214736556|NCT07147842|OTHER|Placebo|Placebo Tablets
214736557|NCT07147842|DIAGNOSTIC_TEST|fecal calprotectin|Fecal calprotectin level was measured using an ELISA kit .
214736558|NCT07148375|PROCEDURE|Anterograde screws for medial Malleolus fractures|Fixation of medial Malleolus fracures by anterograde headless screws
214736559|NCT07147530|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
214736560|NCT07149181|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
214736561|NCT07149181|DRUG|SOX Chemotherapy|SOX or XELOX
214736562|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
214736563|NCT04716920|DEVICE|FitBit|Wear FitBit
214736564|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
214736565|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
214736566|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
214736567|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
214736568|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
214736569|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
214736570|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
214736571|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Expanding retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. This practice schedule is repeated the next day (Day 2).
214736572|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).
214736573|NCT05726747|DIAGNOSTIC_TEST|Quality of Life surveys|QoL and sarcopenia assessments
214736574|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
214736575|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
214736576|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
214736577|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
214736578|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
214736579|NCT05953961|DEVICE|Therasphere 90Y|Transarterial Radioembolization
214736580|NCT05953961|DEVICE|Microwave Ablation|Microwave Ablation
214736581|NCT05910320|DEVICE|Wearable Vital Signs Monitoring Device|The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
214736582|NCT05493982|BEHAVIORAL|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
214736583|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
214736584|NCT01747447|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214736585|NCT01747447|DIETARY_SUPPLEMENT|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214736586|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
214736587|NCT06213649|DRUG|Polyhexamethylene biguanide (PHMB)|PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
214736588|NCT06213649|DRUG|Topical corticosteroid|Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
214736589|NCT06213649|OTHER|Topical placebo|An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
214736590|NCT05200715|OTHER|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
214736591|NCT03093116|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
214736592|NCT06835842|OTHER|rib mobilization technique|"rib mobilization technique The patient in experimental group will be relaxed in semi- fowler position while connected to mechanical ventilator, therapist will seat at the patient side, his fingers pads are placed at the position of the patient's rib angles , pulling upward and the lateral position the position is held while wait for the soft tissues to release this take from 15 seconds .Release of the diaphragm through manual contact with hypothenar region of therapist thumb inferior laterally xiphoid process and rest along Antero lateral costal margin below rib7 during exhalation the therapist thumb give pressure posteriorly repeat this steps for 3 to5 respiratory cycle • routine chest physiotherapy percussion on chest wall its frequency should be 3-7 beats per sec. vibration applying a light pressure with hand on affected segment for about 5 min modified postural drainage R. and L. side. U\&L limb passive ex. for R.10 x3 set~.this program for 30 minutes once daily for ten days"
214736593|NCT06835842|OTHER|routine chest physiotherapy|"routine chest physiotherapy the patient will be laid in half supine position connected to a ventilator applying~* percussion on chest wall its frequency should be 3-7 beats per second or 180-420 beats per minute~* vibration applying a light pressure with flattened hand on affected segment for about 5 minutes~* modified postural drainage (right and left sidling 10 min for each side~* upper and lower limb exercise for 4 limbs (3 sets and each set has 10 repetition~* this program for 30 minutes once daily~* for 10 consecutive days"
214736594|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
214736595|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
214736596|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
214736597|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
214736598|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
214736599|NCT01842282|DRUG|Amlexanox|
214736600|NCT03930225|BEHAVIORAL|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
214736601|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
214736602|NCT06229093|DEVICE|Gamma|For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
214736603|NCT06229093|DEVICE|Synchrony|For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
214736604|NCT00122824|DRUG|duloxetine hydrochloride|
214736605|NCT00122824|DRUG|placebo|
214736606|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
214736607|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
214736608|NCT02411669|OTHER|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
214736609|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
214736610|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
214736611|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
214736612|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
214736613|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
214736614|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
214736615|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
214736616|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
214736617|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
214736618|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
214736619|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
214736620|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214736621|NCT00025194|DRUG|estramustine phosphate sodium|
214736622|NCT00025194|DRUG|ixabepilone|
214736623|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736624|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
214736625|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
214736626|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
214736627|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736628|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736629|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
214736630|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736631|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
214736632|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736633|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
214736634|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
214736635|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
214736636|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736637|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736638|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
214736639|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
214736640|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
214736641|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
214736642|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
214736643|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
214736644|NCT02306148|OTHER|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
214736645|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
214736646|NCT01901809|DRUG|Furosemide|
214736647|NCT01901809|DRUG|Dopamine|
214736648|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
214736649|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
214736650|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
214736651|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
214736652|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
214736653|NCT06292429|OTHER|Control Group|No intervention given
214736654|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
214736655|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
214736656|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
214736657|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
214736658|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
214736659|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
214736660|NCT01768624|PROCEDURE|dialysis, kidney transplant|
214736661|NCT01952041|BEHAVIORAL|Device: Smartphone|
214736662|NCT01952041|BEHAVIORAL|Treatment as usual|
214736663|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
214736664|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1\) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
214736665|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
214736666|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
214736667|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
214736668|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
214736669|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
214736670|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
214736671|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
214736672|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
214736673|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
214736674|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
214736675|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
214736676|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
214736677|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
214736678|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
214736679|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
214736680|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
214736681|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
214736682|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
214736683|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
214736684|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
214736685|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
214736686|NCT01118585|PROCEDURE|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
214736687|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
214736688|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
214736689|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
214736690|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
214736691|NCT04770259|OTHER|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
214736692|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
214736693|NCT00162799|DRUG|Triflusal (DCI)|
214736694|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
214736695|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
214736696|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
214736697|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
214736698|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
214736699|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
214736700|NCT01741584|BEHAVIORAL|stationary bike exercise|
214736701|NCT01741584|BEHAVIORAL|aerobic|
214736702|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
214736703|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
214736704|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
214736705|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
214736706|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
214736707|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
214736708|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
214736709|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
214736710|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
214736711|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
214736712|NCT02299128|OTHER|Physical Therapy Treatment|
214736713|NCT00499161|BEHAVIORAL|New model of nursing care|
214736714|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
214736715|NCT01886144|DEVICE|Knee OA Brace|
214736716|NCT06241937|BEHAVIORAL|Expanded Clinical Firearm Safety Counseling Training|Members of the DGSOM class of 2027 will participate in a mandatory 3.5 hour training session as a part of the regular curriculum that will include: (1) didactic information on firearm violence epidemiology; (2) suicide epidemiology and introduction to lethal means restriction; (3) firearm safety counseling techniques; (4) a panel of firearm violence survivors / trauma interventionists; and (5) a small group session with discussions of the aforementioned topics and a demonstration of a patient encounter using a standardized patient actor depicting a clinical scenario warranting firearm safety counseling. The training will be taught by faculty members, invited subject matter experts, senior medical students, and the DGSOM Standardized Patient Program.
214736717|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
214736718|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
214736719|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
214736720|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
214736721|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
214736722|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
214736723|NCT06333535|OTHER|foot massage|foot massage
214736724|NCT06333535|OTHER|abdominal massage|abdominal massage
214736725|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
214736726|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
214736727|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
214736728|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
214736729|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
214736730|NCT04835389|DRUG|Placebo|0.9% normal saline
214736731|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
214736732|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
214736733|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
214736734|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
214736735|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
214736736|NCT01087151|DRUG|ABT-263|Oral repeating dose
214736737|NCT01087151|DRUG|rituximab|Intravenous repeating dose
214736738|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
214736739|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
214736740|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
214736741|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
214736742|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
214736743|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
214736744|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
214736745|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
214736746|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
214736747|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
214736748|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
214736749|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
214736750|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
214736751|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
214736752|NCT00784680|DRUG|Anastrozole|1mg, orally, once daily
214736753|NCT00784680|DRUG|Tamoxifen|20mg, orally, once daily
214736754|NCT00270010|DRUG|epoetin alfa|
214736755|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
214644782|NCT02477345|DRUG|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
214644783|NCT00445887|OTHER|Laboratory Biomarker Analysis|Correlative studies
214644784|NCT00445887|DRUG|Levonorgestrel|Given orally
214644785|NCT00445887|OTHER|Placebo|Given orally
214644786|NCT00860158|DRUG|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
214644787|NCT00860158|DRUG|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
214644788|NCT00860158|PROCEDURE|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
214644789|NCT06014944|DRUG|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
214644790|NCT01860560|DEVICE|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
214644791|NCT01860560|DEVICE|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
214644792|NCT03065179|DRUG|Nivolumab/Ipilimumab|IV immunotherapy
214644793|NCT03065179|RADIATION|SBRT|SBRT will be delivered in conjunction with immunotherapy
214644794|NCT05971966|OTHER|Virtual Reality technique|"They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
214644795|NCT05971966|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
214644796|NCT02799862|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
214644797|NCT02799862|DRUG|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
214644798|NCT00669617|DRUG|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
214644799|NCT00669617|DRUG|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
214644800|NCT00669617|DRUG|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
214644801|NCT00669617|DRUG|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
214644802|NCT00669617|DRUG|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
214644803|NCT00669617|DRUG|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
214644804|NCT05499520|OTHER|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
214736756|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
214736757|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
214736758|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
214736759|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
214736760|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
214736761|NCT01967082|OTHER|Survey Administration|Complete survey
214736762|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
214736763|NCT02015858|PROCEDURE|Chest drain withdrawal|
214736764|NCT02015858|DEVICE|Pain Monitor|
214736765|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
214736766|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
214736767|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
214736768|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
214736769|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
214736770|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
214736771|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
214736772|NCT01108224|BEHAVIORAL|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
214736773|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
214736774|NCT02473016|DRUG|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
214644805|NCT05719480|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
214644806|NCT01613326|DRUG|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
214644807|NCT01613326|DRUG|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
214644808|NCT01613326|DRUG|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
214644809|NCT01613326|DRUG|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
214644810|NCT01613326|DRUG|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
214736775|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
214736776|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
214736777|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
214736778|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
214736779|NCT04443205|OTHER|Data record|Data record
214736780|NCT05754372|DIAGNOSTIC_TEST|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
214736781|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
214736782|NCT02008461|PROCEDURE|radiofrequency ablation|
214736783|NCT02008461|DRUG|botulinum toxin injection|
214736784|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
214736785|NCT00495508|DRUG|Quinine|
214736786|NCT00495508|DRUG|artemether / lumefantrine|
214736787|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
214736788|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
214736789|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
214736790|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
214736791|NCT05248646|DRUG|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
214736792|NCT05248646|DRUG|Placebo|Placebo s.c. q 4 weeks
214736793|NCT01776372|DEVICE|Medela Thopaz Thoracic Drainage System|
214736794|NCT01776372|DEVICE|Atrium Express Dry Seal Chest Drain|
214736795|NCT03896087|DIAGNOSTIC_TEST|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
214736796|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
214736797|NCT03896087|DIAGNOSTIC_TEST|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
214736798|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
214644811|NCT02201160|DIETARY_SUPPLEMENT|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
214644812|NCT03370159|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
214644813|NCT03370159|DRUG|Docetaxel|Given IV
214644814|NCT03370159|OTHER|Pharmacological Study|Correlative studies
214644815|NCT05205408|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection as single agent.
214644816|NCT02977104|OTHER|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
214644817|NCT04737473|DRUG|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
214644818|NCT04181879|BEHAVIORAL|Intervention|"* GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
214644819|NCT05331911|DRUG|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
214644820|NCT05331911|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
214644821|NCT06499818|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
214644822|NCT06499818|PROCEDURE|STABLE-AF|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during Atrial Fibrillation
214644823|NCT06499818|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
214644824|NCT03980938|DRUG|neflamapimod|40 mg neflamapimod capsule
214644825|NCT03980938|OTHER|Placebo|matching placebo capsule
214644826|NCT02266173|DRUG|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
214644827|NCT02485080|DRUG|Simeprevir|
214644828|NCT02485080|DRUG|Sofosbuvir|
214644829|NCT00230347|PROCEDURE|Stereotactic radiosurgery|
214644830|NCT04724148|DRUG|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
214644831|NCT00840827|DRUG|lenalidomide|Lenalidomide 10mg po daily
214644832|NCT00840827|DRUG|cyclosporine A|CSA 250mg orally twice daily
214644833|NCT02314793|DRUG|ASP2205|oral
214644834|NCT02314793|DRUG|Placebo|oral
214644835|NCT01445535|BIOLOGICAL|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
214644836|NCT01445535|DRUG|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
214644837|NCT01445535|BIOLOGICAL|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
214644838|NCT01445535|DRUG|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
214644839|NCT01445535|DRUG|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
214644840|NCT01445535|DRUG|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
214644841|NCT01445535|DRUG|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
214644842|NCT01183624|OTHER|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
214644843|NCT01183624|OTHER|Placebo Patch|Control patch with no herbal ingredients
214644844|NCT03216382|BEHAVIORAL|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
214644845|NCT03216382|BEHAVIORAL|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
214644846|NCT02687399|OTHER|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
214644847|NCT02687399|BIOLOGICAL|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
214644848|NCT00264056|DEVICE|hyperthermia|
214644849|NCT02636777|OTHER|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
214644850|NCT01681329|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
214644851|NCT01681329|OTHER|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
214736799|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
214736800|NCT00065221|DRUG|Ginger|
214644852|NCT05025566|DIAGNOSTIC_TEST|Cognitive (behavioural and neurophysiological) screening|"Cognitive disorders are attested at the behavioral level by the psychologist specialized in neuropsychology who makes the patient take a standardized battery of specific psychometric tests. This assessment thus makes it possible to obtain behavioral data such as reaction time, error rates and modeling parameters.~The electroencephalogram (EEG) consists of collecting the signal of the brain's bioelectrical activity by means of electrodes placed on the scalp. The EEG is used to determine the cerebral functioning underlying cognitive functions by performing it simultaneously with the behavioral tasks of the neuropsychological assessment, thus obtaining a neurophysiological phenotyping of cognitive disorders."
214644853|NCT03934788|DEVICE|oxysoft (olifilcon C)|subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
214644854|NCT03934788|DEVICE|Si-Hy (olifilcon B)|subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
214644855|NCT06154967|RADIATION|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
214644856|NCT04598490|DEVICE|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
214644857|NCT04598490|DEVICE|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
214644858|NCT02439580|DIETARY_SUPPLEMENT|Annona muricata extract|ethanol-soluble fraction of water extract
214644859|NCT02439580|DIETARY_SUPPLEMENT|Placebo|maltose
214644860|NCT00337233|PROCEDURE|yoga therapy|10 week yoga class
214644861|NCT00890838|DIETARY_SUPPLEMENT|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
214644862|NCT01646099|BEHAVIORAL|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
214644863|NCT03335085|DRUG|Oxytocin|
214644864|NCT03335085|OTHER|Placebo|
214644865|NCT02487186|DRUG|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
214644866|NCT02487186|PROCEDURE|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
214736801|NCT02274311|DRUG|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
214736802|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
214736803|NCT06258161|PROCEDURE|Spinal Fusion|Realignment and fusion of adult spinal deformity
214736804|NCT06258161|OTHER|No intervention|No intervention for control group.
214736805|NCT05840393|OTHER|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
214736806|NCT05260190|DEVICE|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
214736807|NCT05260190|DEVICE|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
214736808|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
214736809|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
214736810|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
214736811|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
214736812|NCT05727891|DRUG|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
214736813|NCT05727891|OTHER|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
214736814|NCT06972004|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|"Preventing Loss of Independence through Exercise (PLIÉ) is a multi-domain, mind-body, group movement program for people with dementia that improves quality of life.~Classes begins and ends with fully body tapping/massaging and breathing exercises that bring participants into awareness of their bodies in the present moment and create a calming ritual. Participants are invited to share appreciations of things in their lives that make them feel happy or grateful. Instructors lead participants through progressive, functional movement sequences that are designed to be repetitive (to build procedural or muscle memory) and to build slowly in functional complexity over time. Movements are tailored to the ability levels of the group. Resting, breathing and mindful body awareness exercises are incorporated throughout each class to provide breaks and to improve focus and attention. A non-judgmental errorless learning process is used, and all movements are performed slowly and purposefully."
214736815|NCT01985204|DIETARY_SUPPLEMENT|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
214736816|NCT01985204|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet without iodine
214736817|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
214736818|NCT01110486|DRUG|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
214736819|NCT01110486|DRUG|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
214736820|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
214736821|NCT01110486|DRUG|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
214736822|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
214736823|NCT02098915|DRUG|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
214736824|NCT02098915|OTHER|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
214736825|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
214736826|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
214736827|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
214736828|NCT05458492|DRUG|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
214736829|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
214736830|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
214736831|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
214736832|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
214736833|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
214736834|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
214736835|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
214736836|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
214736837|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
214736838|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
214736839|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
214736840|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
214736841|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
214736842|NCT03109288|DRUG|Pioglitazone|15-45 mg po qd
214736843|NCT03109288|DRUG|clemastine fumarate|8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
214736844|NCT03109288|DRUG|Dantrolene|Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
214736845|NCT03109288|DRUG|Pirfenidone|"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid"
214736846|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
214736847|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
214736848|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
214736849|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
214736850|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
214736851|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
214736852|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
214736853|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
214736854|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
214736855|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
214736856|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
214736857|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
214736858|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
214736859|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
214736860|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
214736861|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
214736862|NCT00232531|DRUG|Niaspan|
214736863|NCT03211546|PROCEDURE|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
214736864|NCT03211546|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
214736865|NCT04981860|DRUG|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
214736866|NCT04981860|DRUG|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
214736867|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
214736868|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
214736869|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
214736870|NCT02319564|DRUG|Beclomethasone|
214736871|NCT02319564|DRUG|Beclomethasone and Salbutamol|
214736872|NCT02319564|DRUG|Placebo|
214736873|NCT02319564|DEVICE|Aerochamber Max®|
214736874|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
214736875|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
214736876|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
214736877|NCT03720067|DRUG|Rosuvastatin|20mg / day
214736878|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
214736879|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
214736880|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
214736881|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
214736882|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
214736883|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
214736884|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
214736885|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
214736886|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
214736887|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
214736888|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
214736889|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
214736890|NCT05925829|BIOLOGICAL|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
214736891|NCT03350802|DIAGNOSTIC_TEST|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
214736892|NCT03809195|BEHAVIORAL|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
214736893|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
214736894|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
214736895|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
214736896|NCT02477800|DRUG|Placebo|Placebo
214736897|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
214736898|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
214736899|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
214736900|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
214736901|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
214736902|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
214644867|NCT05340205|DRUG|Tranexamic acid|Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
214644868|NCT05340205|DRUG|Misoprostol|"Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~."
214644869|NCT05340205|DRUG|Oxytocin|Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
214644870|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
214644871|NCT02274285|BIOLOGICAL|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
214644872|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
214644873|NCT03932994|BEHAVIORAL|ACT on Health|This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
214644874|NCT06342869|PROCEDURE|Anesthesia|application of different anesthesia techniques
214644875|NCT01337973|BEHAVIORAL|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
214644876|NCT01337973|BEHAVIORAL|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
214644877|NCT01337973|BEHAVIORAL|E-TAU|Enhanced Treatment as Usual
214644878|NCT04456452|BIOLOGICAL|Ampion|Ampion, administered by intravenous infusion
214644879|NCT04456452|OTHER|Standard of Care|Standard of Care
214644880|NCT00248703|DRUG|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
214644881|NCT05422872|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to expert consensus.
214644882|NCT02529579|OTHER|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
214644883|NCT02529579|DRUG|Gemcitabine|standard Gemcitabine therapy
214644884|NCT01990157|DRUG|TAB08|Weekly intravenous administration in escalating doses.
214644885|NCT03372239|DRUG|Indoximod base formulation|Specified dose on specified days
214644886|NCT03372239|DRUG|Indoximod HCL (salt) formulation|Specified dose on specified days
214644887|NCT03372239|OTHER|Placebo|Specified dose on specified days
214644888|NCT00055380|PROCEDURE|Oral cytobrushing|
214644889|NCT01448395|DRUG|[14C]NXL104|500mg/100mL intravenous solution
214644890|NCT01244256|DRUG|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
214644891|NCT01244256|DRUG|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
214644892|NCT05202457|PROCEDURE|Elective surgery|Patient undergoing elective or urgent surgery
214644893|NCT02765282|DEVICE|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
214644894|NCT01255774|DRUG|ranibizumab|An open-label, study of intravitreally administered ranibizumab
214644895|NCT02494596|DRUG|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
214644896|NCT02494596|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
214644897|NCT00002550|DRUG|cisplatin|
214644898|NCT00002550|DRUG|etoposide|
214644899|NCT00002550|PROCEDURE|conventional surgery|
214644900|NCT00002550|RADIATION|radiation therapy|
214644901|NCT00254566|OTHER|Moxifloxacin Placebo|1 capsule once daily for 5 days
214644902|NCT00254566|DRUG|Moxifloxacin|1 X 400mg capsule once daily for 5 days
214644903|NCT00254566|OTHER|Azithromycin SR Placebo|single dose, oral.
214644904|NCT00254566|DRUG|Azithromycin SR|single dose 2.0 g oral
214644905|NCT00059202|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
214644906|NCT00059202|DRUG|Placebo|Placebo for Urso
214644907|NCT03378479|DRUG|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)
214644908|NCT03378479|OTHER|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
214644909|NCT00358657|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
214644910|NCT00358657|DRUG|Cyclophosphamide|Given IV
214644911|NCT00358657|DRUG|Fludarabine Phosphate|Given IV
214644912|NCT00358657|OTHER|Laboratory Biomarker Analysis|Correlative studies
214644913|NCT00358657|DRUG|Mycophenolate Mofetil|Given PO
214644914|NCT00358657|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
214644915|NCT00358657|DRUG|Sirolimus|Given PO
214644916|NCT00358657|DRUG|Tacrolimus|Given IV or PO
214644917|NCT00358657|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
214644918|NCT00079378|DRUG|decitabine|Given IV
214644919|NCT00079378|DRUG|valproic acid|Given orally
214644920|NCT00079378|OTHER|pharmacological study|Correlative studies
214644921|NCT00079378|OTHER|laboratory biomarker analysis|Correlative studies
214644922|NCT00348621|PROCEDURE|Visual impairment intervention program|enhanced access to eye care services
214736903|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
214736904|NCT05939219|BIOLOGICAL|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
215030650|NCT06658249|OTHER|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
214736905|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
214736906|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
214736907|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
214736908|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
214736909|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
214736910|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
214736911|NCT02709239|DIETARY_SUPPLEMENT|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
214736912|NCT02709239|DIETARY_SUPPLEMENT|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
214736913|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
214736914|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
214736915|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
214736916|NCT02258191|DEVICE|telemonitoring|
214736917|NCT02258191|DEVICE|sham telemonitoring|
214736918|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
214736919|NCT05594667|DRUG|Psilocybin|25mg of psilocybin provided by Filament Health
214736920|NCT00263406|DRUG|Administration of an ACE-inhibitor or not|
214736921|NCT05482594|DIAGNOSTIC_TEST|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
214736922|NCT05482594|DIAGNOSTIC_TEST|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
214736923|NCT01076270|DRUG|plerixafor|Given SC
214736924|NCT01076270|BIOLOGICAL|filgrastim|Given SC
214736925|NCT01076270|PROCEDURE|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
214736926|NCT01076270|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
214736927|NCT00675311|BEHAVIORAL|DM-Standard|Device/t+ Medical Diabetes Management System
214736928|NCT00675311|BEHAVIORAL|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
215030651|NCT05248009|DEVICE|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
215030652|NCT06665555|DRUG|ledaborbactam etzadroxil|Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours
215030653|NCT06665555|DRUG|ceftibuten|Five doses of ceftibuten will be administered orally every 12 hours
215030654|NCT05319197|OTHER|No Interventions|No Interventions
214736929|NCT05477251|PROCEDURE|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
214736930|NCT05477251|PROCEDURE|lobectomy|lobectomy for GGOs located in hilar regions
214736931|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
214736932|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
214736933|NCT01948518|DRUG|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
214736934|NCT03793790|BEHAVIORAL|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
214736935|NCT03793790|BEHAVIORAL|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
214736936|NCT03793790|BEHAVIORAL|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
214736937|NCT03793790|BEHAVIORAL|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
214736938|NCT03793790|BEHAVIORAL|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
214736939|NCT03975049|RADIATION|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
214736940|NCT03975049|DRUG|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
214736941|NCT03975049|DRUG|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
214736942|NCT04473495|DEVICE|educational video|educational video before intervention
214736943|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
214736944|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
214736945|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
214736946|NCT02196090|BEHAVIORAL|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
214736947|NCT02196090|DEVICE|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
214736948|NCT05518136|BEHAVIORAL|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
214736949|NCT04600427|PROCEDURE|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
214736950|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
214736951|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
214736952|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
215030655|NCT07003841|DEVICE|Surgical navigation system with stereotactic guidance|This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery
214736953|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
214736954|NCT00034697|DRUG|temozolomide|
214736955|NCT04801355|PROCEDURE|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
214736956|NCT04801355|PROCEDURE|laparoscopic colon resection|Standard laparoscopic colon resection
214736957|NCT04062006|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
214736958|NCT02111954|DIAGNOSTIC_TEST|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
214736959|NCT00170846|DRUG|Everolimus (RAD001)|
214736960|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
214736961|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
214736962|NCT00170846|DRUG|Steroids|
214736963|NCT01550614|GENETIC|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
214736964|NCT01968915|DRUG|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
214736965|NCT01968915|DRUG|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
214736966|NCT00532064|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214736967|NCT00532064|OTHER|Questionnaire Administration|Ancillary studies
214736968|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
214736969|NCT04814706|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
214736970|NCT04589832|DRUG|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
214736971|NCT04589832|DRUG|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
214736972|NCT06359886|PROCEDURE|B-Lynch Transverse Compression Suture|closure of uterine and utero ovarian arteries bilaterally with one suture
214736973|NCT01416506|OTHER|No Drug|It's a surveillance
214736974|NCT01756833|DRUG|Doxycycline|100 mg po bid
214736975|NCT01756833|DRUG|Placebo|capsule identical to the doxycycline capsule
214736976|NCT06135142|OTHER|Connective Tissue Massage|It involves manipulating the soft and deep tissues of the body.
214736977|NCT06135142|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
214736978|NCT06135142|OTHER|Classical Massage|It involves manipulating the soft tissues of the body.
214736979|NCT06135142|DEVICE|Therapatic Ultrasound|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
214736980|NCT06135142|OTHER|Heat Treatment|Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
214736981|NCT01522196|DRUG|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
214736982|NCT01522196|OTHER|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
214736983|NCT05747664|DRUG|DWP16001|0.3mg
214736984|NCT05162833|DEVICE|TheraNova Neuromodulation Device|TENS device
214736985|NCT02061163|DEVICE|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
214736986|NCT02061163|DRUG|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
214736987|NCT00006463|DRUG|ECTEINASCIDIN 743|
214736988|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
214736989|NCT00124384|BEHAVIORAL|CBT-I|
214736990|NCT00124384|DRUG|modafinil|
214736991|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
214736992|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
214736993|NCT03602521|OTHER|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1\) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2\) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
214736994|NCT05398341|DEVICE|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy \[BSE\] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
214736995|NCT06256575|COMBINATION_PRODUCT|Diosmin|A medical food of diosmin and alka4-complex
214736996|NCT06256575|OTHER|Placebo|Corn starch one (1) capsule twice daily
214736997|NCT06615349|BEHAVIORAL|DigiPall|DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.
214736998|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
214736999|NCT05919511|OTHER|Non-Interventional|This is an observational study
214737000|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
214737001|NCT04346368|BIOLOGICAL|Placebo|Placebo
214737002|NCT04368741|DIETARY_SUPPLEMENT|SANZ®KINGWILL|20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
214737003|NCT04368741|DIETARY_SUPPLEMENT|GLUCERNA SR®|17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
214737004|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
214737005|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
214737006|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
214737007|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
214737008|NCT01662128|DRUG|Xeloda|Xeloda as Adjuvant Therapy
214737009|NCT02724280|DEVICE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
214737010|NCT02724280|DEVICE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
214737011|NCT01028040|DRUG|AZD3043|Intravenous, single dose
214737012|NCT01028040|DRUG|AZD3043|Infusion, single dose
214737013|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
214737014|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
214737015|NCT01546090|DRUG|Alprazolam|preoperative administration of an orally 0.50 mg single dose
214737016|NCT01546090|DRUG|placebo|placebo capsules were filled with starch
214737017|NCT01438359|DRUG|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
214737018|NCT01438359|DRUG|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
214737019|NCT01438359|DRUG|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
214737020|NCT04623255|DRUG|OCTAPLAS|plasma exchange
214737021|NCT02211950|DRUG|BI 44847|
214737022|NCT02211950|DRUG|Acarbose|
214737023|NCT02211950|OTHER|Japanese diet|
214737024|NCT06507098|OTHER|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.
214737025|NCT06507098|OTHER|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
214737026|NCT06090929|DEVICE|STN-DBS|STN-DBS was implanted according normal process
214737027|NCT01518634|DRUG|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
214737028|NCT01518634|DRUG|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
214737029|NCT01092949|DEVICE|MRI|MRI, 45 minutes
214737030|NCT06063525|OTHER|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
214737031|NCT00184067|BIOLOGICAL|Montanide ISA 51|
214737032|NCT04921410|DEVICE|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
214737033|NCT04921410|DEVICE|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
214737034|NCT02257112|DEVICE|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
214737035|NCT00384449|DRUG|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
214737036|NCT03976193|BEHAVIORAL|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
214737037|NCT03976193|BEHAVIORAL|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
214737038|NCT04976478|DRUG|Nimotuzumab|Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
214737039|NCT04976478|RADIATION|EBRT combined with brachytherapy|"IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy.~Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80\~85Gy (EQD2); If the tumor diameter is ≥4cm, HR-CTV D90 cumulative dose is ≥87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks."
214737040|NCT05839236|COMBINATION_PRODUCT|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
214737041|NCT01836367|DRUG|Ingenol Mebutate 0.015%|Picato
214737042|NCT03616249|OTHER|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
214737043|NCT03616249|OTHER|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
214737044|NCT00998985|DRUG|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
214737045|NCT00998985|DRUG|Placebo|Placebo tablet, orally, once a day for 7 days
214737046|NCT00382551|BEHAVIORAL|Moderate daily consumption of Red wine|
214737047|NCT00382551|BEHAVIORAL|Moderate daily consumption of beer|
214737048|NCT00382551|BEHAVIORAL|Moderate consumption of fruit juice rich in polyphenolics|
214737049|NCT00253799|DEVICE|Hylan GF-20|
214737050|NCT01271127|RADIATION|CT coronary angiography|patient will undergo one CT coronary angiography
214737051|NCT00017927|DRUG|Pegvisomant|
214737052|NCT02637167|DRUG|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
214644923|NCT05661201|DRUG|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
214644924|NCT05661201|DRUG|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
214644925|NCT04878367|BEHAVIORAL|Five active practices of living rules for responding to fine dust.|"1. Check the fine dust weather forecast~2. Check the operation time and filter of the air purifier~3. Window ventilation~4. Inhalant is used or not~5. Bad fine dust: Refrain from going out"
214644926|NCT02658448|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
214644927|NCT03177161|OTHER|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
214644928|NCT06496594|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
214644929|NCT06496594|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
214644930|NCT01590147|PROCEDURE|Yoga therapy|receive YST
214644931|NCT01590147|OTHER|questionnaire administration|Ancillary studies
214644932|NCT01590147|PROCEDURE|quality-of-life assessment|Ancillary studies
214644933|NCT01590147|OTHER|laboratory biomarker analysis|Correlative studies
214644934|NCT01590147|OTHER|assessment of therapy complications|Ancillary studies
214644935|NCT01590147|PROCEDURE|management of therapy complications|Receive YST or CE
214644936|NCT01590147|OTHER|educational intervention|Receive CE
214644937|NCT04545489|BEHAVIORAL|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
214644938|NCT04545489|BEHAVIORAL|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
214644939|NCT06097897|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
214644940|NCT04270929|DRUG|FOLFIRI|During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
214644941|NCT04270929|DRUG|FOLFIRINOX|During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
214644942|NCT04270929|DEVICE|TriSalus Infusion System|The TriSalus Infusion System administers therapeutics using PEDD technology.
214644943|NCT02172859|DIETARY_SUPPLEMENT|lumiVida™|
214644944|NCT02172859|DIETARY_SUPPLEMENT|Placebo|
214644945|NCT00471432|DRUG|custirsen sodium|
214644946|NCT00471432|DRUG|docetaxel|
214644947|NCT00471432|OTHER|pharmacological study|
214644948|NCT04543214|OTHER|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
214644949|NCT06073392|OTHER|Educational video|Educational video in animation mode
214737053|NCT02637167|DRUG|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
214737054|NCT01995786|DEVICE|Goal Directed Fluid Therapy FloTrac/Vigileo|
214737055|NCT03649386|DEVICE|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
214737056|NCT03649386|DEVICE|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
214737057|NCT01595308|DIETARY_SUPPLEMENT|Pomegranate juice|Pomegranate juice
214737058|NCT01701856|DRUG|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
214737059|NCT02062970|BIOLOGICAL|blood draw|
214737060|NCT01623856|OTHER|laboratory biomarker analysis|Correlative studies
214737061|NCT03824964|BIOLOGICAL|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
214737062|NCT00549406|PROCEDURE|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
214737063|NCT00549406|PROCEDURE|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
214737064|NCT00549406|PROCEDURE|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
214737065|NCT01167088|DRUG|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
214737066|NCT01167088|DRUG|Placebo|Placebo
214737067|NCT01040728|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
214737068|NCT01040728|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
214737069|NCT01040728|DRUG|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
214737070|NCT01040728|DRUG|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
214737071|NCT01040728|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
214737072|NCT01958268|PROCEDURE|Pretest and validation of a translated questionnaire|
214737073|NCT02141529|PROCEDURE|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
214737074|NCT02141529|PROCEDURE|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
214737075|NCT04930172|DEVICE|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
214737076|NCT03445611|DRUG|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
214737077|NCT03445611|DRUG|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
214737078|NCT05362461|DIAGNOSTIC_TEST|Near Infrared Transillumination|Caries imaging detection technology.
214737079|NCT03345173|DRUG|CI-581-a|Two infusions in the context of naltrexone induction protocol.
214737080|NCT03345173|DRUG|CI-581-b|Two infusions in the context of naltrexone induction protocol.
214737081|NCT03276260|DEVICE|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
214737082|NCT04717167|OTHER|Dry Needling|
214737083|NCT04717167|OTHER|Sham Needling|
214737084|NCT07022002|DRUG|SSGJ-705|anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody
214737085|NCT07022002|DRUG|PD-1/L1 inhibitor combined with chemotherapy|Immune checkpoint inhibitors
214737086|NCT07022002|DRUG|SSGJ-705 combined with chemotherapy|anti-PD-1 and anti-HER2 bispecifc antibody
214737087|NCT00432289|PROCEDURE|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
214737088|NCT02029391|OTHER|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
214737089|NCT02029391|OTHER|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
214737090|NCT04207125|BEHAVIORAL|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
214737091|NCT03605225|DEVICE|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
215030656|NCT07003841|DEVICE|General ultrasound imaging system|A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.
214737092|NCT06198504|PROCEDURE|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
214737093|NCT00456924|DRUG|VA2914|
214737094|NCT01759628|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
214737095|NCT04851327|BEHAVIORAL|High Energy preload|Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
214737096|NCT04851327|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
214737097|NCT04851327|BEHAVIORAL|Test meal|Test meal to follow low or high energy preload
214737098|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
214737099|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
214737100|NCT04396327|DRUG|SM-1|diphenhydramine, zolpidem and lorazepam
214737101|NCT04396327|DRUG|Active Comparator|diphenhydramine and lorazepam
214737102|NCT04162262|OTHER|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
214737103|NCT04162262|OTHER|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
214737104|NCT04162262|OTHER|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
214737105|NCT04114773|OTHER|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
214737106|NCT03973567|DRUG|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
214737107|NCT03973567|OTHER|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
214737108|NCT02388672|DIETARY_SUPPLEMENT|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
214737109|NCT02388672|DIETARY_SUPPLEMENT|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
214737110|NCT02388672|DIETARY_SUPPLEMENT|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
214737111|NCT02388672|DIETARY_SUPPLEMENT|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
214737112|NCT04520919|OTHER|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
214737113|NCT03116841|DRUG|Vonoprazan|Vonoprazan 20 mg
214737114|NCT04363723|OTHER|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
214737115|NCT06070727|OTHER|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
214737116|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
214737117|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
214737118|NCT05069389|OTHER|Data collection|"Some data will be collected for all patients included :~* specific treatment administered in COVID unit~* dosages of treatment~* inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
214737119|NCT02249260|BEHAVIORAL|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
214737120|NCT05589623|OTHER|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
214737121|NCT05589623|OTHER|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
214737122|NCT03234075|OTHER|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator"
214737123|NCT04484038|RADIATION|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
214737124|NCT01961999|PROCEDURE|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
214737125|NCT01961999|PROCEDURE|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)"
214737126|NCT01601873|DEVICE|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
214737127|NCT01601873|DEVICE|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
214737128|NCT00487994|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
214737129|NCT00487994|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
214737130|NCT00487994|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
214737131|NCT01875874|BIOLOGICAL|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
214737132|NCT04126460|DRUG|Toripalimab|Toripalimab is a type of PD-1 antibody
214737133|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
214737134|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
214737135|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
214737136|NCT04583267|DRUG|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
215030657|NCT03646357|OTHER|Non-betablocker|No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
214737137|NCT03201744|PROCEDURE|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
214737138|NCT00572312|DRUG|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
214737139|NCT01528436|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
214737140|NCT01528436|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
214737141|NCT01528436|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
214737142|NCT04220658|OTHER|Biomarker study|Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation
214737143|NCT03270618|DEVICE|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
214737144|NCT00002749|DRUG|carboplatin|
214737145|NCT02663115|OTHER|Biopsy of the diaphragmatic muscle|
214737146|NCT02663115|OTHER|Skeletal muscle biopsy|
214737147|NCT01635244|DEVICE|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
214737148|NCT02772835|DEVICE|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
214737149|NCT00002041|DRUG|Amphotericin B|
214737150|NCT06376435|DRUG|Herombopag Olamine Tablets|Herombopag Olamine；combined rhTPO;combined IL-11
214737151|NCT01607749|BEHAVIORAL|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
214737152|NCT01607749|OTHER|Usual Asthma Information for teachers|Common asthma information for teachers
214737153|NCT03827070|DRUG|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%
214737154|NCT03827070|DRUG|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
214737155|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
214737156|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
214737157|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
214737158|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
214737159|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
214737160|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
214737161|NCT01018615|DRUG|silymarin|capsules, 700 mg, twice daily, 12 days
214737162|NCT01018615|DIETARY_SUPPLEMENT|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
214737163|NCT01965028|DEVICE|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
214737164|NCT02176005|DEVICE|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
214737165|NCT02176005|DRUG|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
214737166|NCT02176005|OTHER|Negative Control|Moxifloxacin is used alone
214737167|NCT04913792|DEVICE|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
214737168|NCT04880460|DIETARY_SUPPLEMENT|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
214737169|NCT04880460|DIETARY_SUPPLEMENT|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
214737170|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
214737171|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
214737172|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
214737173|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
214737174|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
214737175|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
214737176|NCT00481377|PROCEDURE|ablation|
214737177|NCT00603876|DIETARY_SUPPLEMENT|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
214737178|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
214737179|NCT00374062|BEHAVIORAL|relaxation therapy 1|relaxation therapy 1
214737180|NCT00374062|BEHAVIORAL|relaxation therapy 2|relaxation therapy 2
214737181|NCT00374062|BEHAVIORAL|relaxation therapy 3|relaxation therapy 3
214737182|NCT01935167|DRUG|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
214737183|NCT01935167|DRUG|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
214737184|NCT01935167|DRUG|Placebo|Placebo 2 tablets b.i.d.
214737185|NCT01728766|OTHER|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
214737186|NCT01728766|OTHER|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
214737187|NCT01740765|OTHER|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
214737188|NCT03932591|PROCEDURE|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
214737189|NCT03932591|PROCEDURE|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
214737190|NCT05774574|DIETARY_SUPPLEMENT|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
214737191|NCT05774574|DIETARY_SUPPLEMENT|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
214737192|NCT00826540|DRUG|sorafenib tosylate|Given orally
214737193|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
214737194|NCT00542217|BIOLOGICAL|Imprime PGG|
214737195|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
214737196|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
214737197|NCT04225936|DRUG|BMS-986263|Single Dose
214737198|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
214737199|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
214737200|NCT04993430|DEVICE|HRS8807、SHR6390|HRS8807 in combination with SHR6390
214737201|NCT04993430|DRUG|HRS8807、SHR6390|HRS8807 in combination with SHR6390
214737202|NCT05528562|OTHER|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
214737203|NCT05528562|OTHER|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
214737204|NCT05528562|OTHER|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
214737205|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
214737206|NCT03631849|PROCEDURE|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
214737207|NCT03631849|OTHER|Care|descaling and maintenance of implants
214737208|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
214737209|NCT06332183|GENETIC|Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
214737210|NCT02071329|DRUG|Vaccine FP-01.1|
214737211|NCT02071329|DRUG|Placebo|
214737212|NCT02071329|OTHER|Virus Challenge|
214737213|NCT03851224|PROCEDURE|control group|immediate implant with immediate loading using no graft
214737214|NCT03851224|PROCEDURE|study group|immediate implant with immediate loading using autogenous bone graft
214737215|NCT03851224|PROCEDURE|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
214737216|NCT02871570|DRUG|Rivipansel|A single dose of IV Rivipansel over 20 minutes
214737217|NCT06386367|BEHAVIORAL|Monastery-based health education by Buddhist monks|During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
214737218|NCT02178592|DRUG|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
214737219|NCT02178592|DRUG|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
214737220|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
214737221|NCT06227416|OTHER|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
214737222|NCT01476553|PROCEDURE|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
214737223|NCT03390127|OTHER|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
214737224|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
214737225|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
214737226|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
214737227|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
214737228|NCT02045225|BEHAVIORAL|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
214737229|NCT01628458|PROCEDURE|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
214737230|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
214737231|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
214737232|NCT02520141|OTHER|Laboratory Biomarker Analysis|Correlative studies
214737233|NCT02520141|BIOLOGICAL|Ramucirumab|Given IV
214737234|NCT01640067|BIOLOGICAL|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
214737235|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
214737236|NCT00703781|DRUG|placebo|sterile ophthalmic solution
214737237|NCT01228695|OTHER|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
214737238|NCT00192712|DRUG|irinotecan, gemcitabine|
214737239|NCT00112554|DRUG|cytarabine|Given IV
214737240|NCT00112554|DRUG|laromustine|Given IV
214737241|NCT00112554|OTHER|placebo|Given IV
214737242|NCT03797794|DEVICE|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
214737243|NCT03797794|DEVICE|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
214737244|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
214737245|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
214737246|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
214737247|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
214737248|NCT03756142|DIAGNOSTIC_TEST|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
214737249|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
214737250|NCT02901106|DRUG|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
214737251|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
214737252|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
214737253|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
214737254|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
214737255|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
214737256|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
214737257|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
214737258|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
214737259|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
214737260|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
214737261|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
214737262|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
214737263|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
214737264|NCT05335993|BIOLOGICAL|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
214737265|NCT05335993|DRUG|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
214737266|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
214737267|NCT04937127|OTHER|usual care|usual care
214737268|NCT03357770|DRUG|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
214737269|NCT05742789|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
214737270|NCT05742789|DRUG|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
214737271|NCT05742789|DRUG|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
214737272|NCT04227119|DEVICE|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
214737273|NCT04227119|DEVICE|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
214737274|NCT01917591|DEVICE|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
214737275|NCT01917591|DEVICE|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
214737276|NCT06875973|DRUG|Pelacarsen (TQJ230)|pelacarsen 80mg s.c. monthly
214737277|NCT07102134|PROCEDURE|Suturing-LIFT procedure|This group received conventional ligation with absorbable sutures
214737278|NCT07102134|PROCEDURE|Clipped-LIFT procedure|This group was treated with absorbable clips commonly used for vascular or biliary duct occlusion
214737279|NCT06711302|DEVICE|Sham RIC|Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
214737280|NCT06711302|DEVICE|Remote Ischemic Conditioning treatment instrument|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
214737281|NCT07030868|DRUG|LY6249492|Administered orally
214737282|NCT07030868|DRUG|Placebo|Administered orally
214737283|NCT05874336|DRUG|Aramchol|Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
214737284|NCT07044518|DEVICE|Over-the-Counter Hearing Aid|This intervention involves a self-fit, over-the-counter (OTC) hearing aid that is set up by the user with limited to no help from a hearing professional. Amplification is personalized through an app-based hearing test on a smartphone. The device is used during a single study visit (90 minutes) to assess hearing and provide amplification.
214737285|NCT07044518|DEVICE|Hearing aid, air conduction|This intervention uses a prescription hearing aid that is programmed and fitted based on results from a standard hearing test. The device is also used during a single study visit (90 min) for comparison purposes.
214737286|NCT07046468|DEVICE|Ingestion of sensor capsule (twice)|Ingestion of the GISMO GEN1 System, an ingestible sensor capsule which measures pH, temperature and oxidation reduction potential (ORP) in the intestines.
214737287|NCT07046468|BEHAVIORAL|Device evaluation questionnaire|A 16-item online questionnaire to assess participant's experiences with the ingestible sensor capsule after the study measurements.
214737288|NCT07046468|DEVICE|Wearing device|Participants will wear a small device on a soft belt around their waist during study measurements with the sensor capsules.
214737289|NCT07046468|BEHAVIORAL|Monitoring sensor capsule exit|Participants are instructed to press a button on the wearable device when they use the toilet for defaecation and wait with flushing to toilet until the wearable device indicates (using colored LEDs) that the toilet can be flushed and 1) that the sensor capsule is still in the body and study measurements continue or 2) that the sensor capsule has likely been excreted via the feces and the participant has to contact the research team to confirm exit.
214737290|NCT07046468|DEVICE|Placement of devices at home|Participants do not have to wear the device around the waist during sleeping. For optimal monitoring of sensor capsule exit during the nights, a second device will be placed on the participant's bedside table/close to the bed and a third device will be placed close to the toilet that the participant usually uses during the night.
214737291|NCT07046468|DIAGNOSTIC_TEST|Follow-up intestinal ultrasound|At 3 months after treatment initiation, participants with ulcerative colitis will undergo a follow-up intestinal ultrasound (IUS) (non-endoscopic) outside of routine care to assess treatment response.
214737292|NCT06334055|DEVICE|Masimo INVSENSOR00073|Noninvasive blood pressure monitor
214737293|NCT06196905|DRUG|MT-2990|i.v. infusion
214737294|NCT02545049|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
214737295|NCT02545049|DRUG|Placebo|Matching placebo to be taken orally, once daily.
214737296|NCT07057973|DRUG|Ferric carboxymaltose|The experimental group was treated with 1000 mg of ferric carboxymaltose
214737297|NCT07059364|BEHAVIORAL|CAST Treatment|Activity completion will be evaluated based the number of consecutive and total activities completed, duration of sustained activity engagement, prompts or redirection, and adult proximity at baseline and post-trial.
214737298|NCT07059481|OTHER|Root Canal Treatment and Sample Collection|Single session root canal treatment procedure will be performed with VDW Gold Reciproc device and reciprocal files (Endo T-Must, Dentac, Turkey). Endodontium Samples will be collected from each patient's root canal, with 15 Hedström files (Dentsplay).
214737299|NCT07059481|DIAGNOSTIC_TEST|PAI Score Comparasion|PAI scores of the patients will be determined with periapical films taken before treatment and compared with oxidative stress markers before and after treatment for the epoxyamine group and bioceramic group.
214737300|NCT07057687|OTHER|Conventional Physical Therapy Group|Conventional physical therapy applied to patients consists of Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound (US) and Hot Pack. TENS will be applied for 20 minutes at a frequency of 100 hertz. US will be applied for 5 minutes at an intensity of 1.2-1.5 W/cm2. Hot Pack will be applied for 20 minutes. Treatment will be applied to the lumbar region. Application will be made 3 days a week for 4 weeks.
214737301|NCT07057687|OTHER|Relaxation Techniques Group|The individual will be in a sitting or lying position without muscle tension, and progressive relaxation will be provided with verbal commands given for each body part in order. The patient is asked to place their hand on their abdomen and by applying light resistance, they are provided with the direction in which the breath will go. During diaphragmatic breathing, the person breathes deeply and slowly through the nose and out through the mouth for 5-7 seconds, holds it for 2 seconds and exhales for 6-8 seconds. During this time, the abdomen is inflated in 4 directions and care is taken to ensure that there is no auxiliary muscle activity. First, after taking a deep breath, the muscles are tensed, this tension is maintained for 5-7 seconds and then the muscles are relaxed (8-10 seconds). This application will be applied in 3 sets, with 5/6 repetitions and then returning to calm/normal breathing. The treatment will be applied 3 days a week and will last for 4 weeks.
214737302|NCT07057687|OTHER|Mulligan Treatment Group|Application of the Technique: The direction of the technique will be shaped according to the direction of movement of the patient's pain. If the patient's pain occurs during flexion, flexion will be applied, if it occurs during extension, extension SNAGS will be applied. In the flexion SNAGS application, the physiotherapist places the mobilization belt at the patient's spina iliaca anterior superior (SIAS) level while the patient is sitting or standing. The physiotherapist places his hand, thumbs or the hypothenar part of the hand parallel to the spinous processes one level above the relevant segment. Then, he asks the patient to flex until he feels pain. The physiotherapist continues the flexion by applying force towards the cranium with his hand. After waiting for a while at the end point, the starting position is returned. During this time, the physiotherapist maintains the natural shift in the facet joint. If the pain does not disappear, the application is applied unilaterally.
214737303|NCT07058701|OTHER|Investigational Serum, Standard Cleanser|"Mode of Group Serum application : On-site single use~Standard cleanser + Investigational Serum (random half-face) \[FLA #2039128 50\]~\- subjects should wash face with standard cleanser \[FLA #730457 36\] on site before measurements.~The technician will apply the Investigational Serum \[FLA #2039128 50\] on the subject's half face (according to the Annex 11.6) at the test site, keep another half face as blank control."
214737304|NCT07058701|DEVICE|Infrared Light for Redness Induction on Face|"Infrared light has high radiation frequency, its permeability is strong, the wavelength of infrared light can penetrate the human dermis to promote blood circulation and induce skin redness.The redness induction process will be done after baseline measurements for each subject.The subject's face was exposed at a distance of 20cm from infrared lamp for minimum 5 - 10 minutes at a temperature of 30-40°C and a wavelength of 760-5000 nm. In general, the skin will not be burned during the induction process. Due to individual differences, if the subjects cannot tolerate or feel uncomfortable during the process, the investigators will stop the process according to the situation; If there is any burn during the process, the on-site dermatologist will treat it in time, and the subject needs to follow the dermatologist's advice for follow-up treatment.~Infrared light type: PHILIPS, IR250 RH IR2, 230-250V, 250W, wave length 760-5000nm, T 30\~40°C"
214737305|NCT07057869|PROCEDURE|5-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 5 minutes per session, 4 weeks duration.
214737306|NCT07057869|PROCEDURE|10-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 10 minutes per session, 4 weeks duration.
214737307|NCT07057869|PROCEDURE|15-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 15 minutes per session, 4 weeks duration.
214737308|NCT07059195|PROCEDURE|cervical collar or cervical-thoracic orthosis.|postoperative cervical spine flexion maintained using non-invasive techniques, such as a cervical collar or cervical-thoracic orthosis.
214737309|NCT07059195|DEVICE|chin-to-chest (Grillo) suturing|cervical spine flexion maintained using traditional chin-to-chest (Grillo) suturing
214737310|NCT07058129|PROCEDURE|Deep cervical lymphatic venous anastomosis|The intervention requires to perform bilateral deep cervical lymphatic venous anastomosis (DC-LVA). Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
214737311|NCT07057778|DRUG|Iguratimod|oral iguratimod at 25mg twice daily for 26 weeks
214737312|NCT07057778|DRUG|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
214737313|NCT07057752|OTHER|Virtual Reality|Virtual reality (VR) will be applied to patients in this group in addition to painkillers. VR is a non-pharmacological method that uses special glasses to create an immersive visual and auditory experience. It helps distract patients from the procedure and may reduce pain and anxiety.
214737314|NCT07057752|DRUG|dexketoprofen + midazolam|Patients in this group will be treated with dexketoprofen as a painkiller and midazolam as an anxiolytic, if needed. This combination aims to reduce both pain and anxiety during the procedure.
214737315|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
214737316|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
214737317|NCT07059442|DIAGNOSTIC_TEST|anal HPV screening|From all included women samples will be collected at the out-patient HIV departments including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA.
214737318|NCT01154738|DRUG|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
214737319|NCT01154738|DRUG|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
214737320|NCT06899620|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 60 days.
214737321|NCT06899620|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 60 days.
214737322|NCT06856057|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|CAARE is a technology-enhanced stepped model of care that is designed to deliver education at the bedside to caregivers of children under age 12 years hospitalized for pediatric injury about mental health recovery after pediatric injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and reinforcement of coping skills via mHealth tools (Step 2), screen for caregivers' and children's PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm hand-off to mental health services if needed (Step 4).
214737323|NCT06879327|BIOLOGICAL|R21 Matrix-M (R21/MM) Malaria Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
214737324|NCT06879327|BIOLOGICAL|Placebo|Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
214737325|NCT06879327|BIOLOGICAL|Hexavalent Vaccine|"Administered by intramuscular injection. Each dose of 0.5 mL contains:~* Diphtheria Toxoid \> 30 IU~* Tetanus Toxoid \> 40 IU~* B. pertussis (whole cell) \> 4 IU~* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg~* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU~* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]"
214737326|NCT06879327|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
214737327|NCT06879327|BIOLOGICAL|Rotavirus, Live Attenuated (Oral) Vaccine|Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
214737328|NCT06879327|BIOLOGICAL|Measles and Rubella Vaccine|Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
214737329|NCT06879327|BIOLOGICAL|Meningococcal A conjugate vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
214737330|NCT06879327|BIOLOGICAL|Yellow Fever vaccine|Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
214737331|NCT06879327|BIOLOGICAL|Typhoid Conjugate vaccine|Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
214737332|NCT02364661|BEHAVIORAL|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
214737333|NCT06107452|OTHER|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
214737334|NCT06107452|OTHER|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
214737335|NCT06587932|OTHER|brain gym exercises|It is comprised very easy body movements which have been designed to coax the two hemispheres of the brain.
214737336|NCT06587932|OTHER|Traditional treatments|traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other
214737337|NCT06843577|DEVICE|Zona Plus Device|Use of the Zona Plus device involves performing isometric handgrip exercise therapy. Isometric exercise is the type of exercise in which you tense or tighten your muscle without seeing it change in length.
214737338|NCT06843577|OTHER|Relaxing Music App|Relaxing music will be made available through a mobile app that users access via their smart phone or tablet. Subjects will have the option to listen to 5 different music genres that support relaxation (Classical, Nature, Movie Soundtracks, Jazz, Reggae).
214737339|NCT06740214|DRUG|0.5% standard bupivacaine only|20ml 0.5% standard bupivacaine only
214737340|NCT06740214|DRUG|1.33% liposomal bupivacaine with 0.5% standard bupivacaine|10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
214737341|NCT06740214|DRUG|1.33% liposomal bupivacaine only|20ml 1.33% liposomal bupivacaine (266mg)
214737342|NCT06443463|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
214737343|NCT06443463|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
214737344|NCT00502398|PROCEDURE|Blood test|
214737345|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Live Online|"Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes daily and increasing to 20 minutes daily using guided meditations. Attendance in the group sessions and home practice will be tracked to determine dose of the intervention received."
214737346|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Digital App|"The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine dose of the intervention received."
214737347|NCT06748222|BEHAVIORAL|Meditation Only Control Group|"Use of the meditations will be tracked to determine dose of the intervention received."
214737348|NCT05690906|DEVICE|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
214737349|NCT05690906|DEVICE|gauze packing|The subjects of both groups will be given gauze packing
214737350|NCT06925477|DEVICE|DSLT treatment for Open-Angle Glaucoma|This intervention aims to determine the efficacy and safety of Direct Selective Laser Trabeculoplasty (DSLT) in reducing intraocular pressure in patients with open-angle glaucoma.
214737351|NCT06925477|DEVICE|SLT treatment for Open-Angle Glaucoma|To determine the efficacy and safety of using Selective Laser Trabeculoplasty for treatment of open-angle glaucoma.
214737352|NCT04267887|DRUG|Abiraterone Acetate|Given PO
214737353|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
214737354|NCT04267887|DRUG|Apalutamide|Given PO
214737355|NCT04267887|DRUG|Prednisone|Given PO
214737356|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
214737357|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
214737358|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214737359|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
214737360|NCT05118789|DRUG|Zidesamtinib (NVL-520)|Oral tablet of zidesamtinib (NVL-520)
214737361|NCT07095855|DRUG|ZM-H1505R 100mg|ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.
214737362|NCT07095855|OTHER|ZM-H1505R Placebo|ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.
214737363|NCT07095855|COMBINATION_PRODUCT|"NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments"|"All eligible subjects will be use NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments during the study for 148 weeks, including Part A and Part B.~Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions."
214737364|NCT07096401|DEVICE|Reverse Curve of Spee Archwire|Orthodontic treatment using a 0.016 × 0.022 NiTi reverse curve of Spee archwire to correct deep bite through posterior extrusion and anterior intrusion.
214737365|NCT07096401|DEVICE|Anterior Bite Turbos|Orthodontic treatment using anterior bite turbos bonded to the palatal surfaces of the upper central incisors to promote posterior extrusion and correct deep bite.
214737366|NCT07096401|DEVICE|Clear Aligners|Orthodontic treatment using clear aligner therapy designed for anterior intrusion and leveling of the curve of Spee to correct deep bite.
214737367|NCT07093983|OTHER|Constraint-Induced Movement Therapy (CIMT)|Participants in this group will receive modified CIMT in combination with conventional physical therapy. The unaffected arm will be restrained to encourage use of the affected upper limb. Task-specific exercises will include fine motor tasks, strengthening, reaching, and functional movement training. Each session will last approximately 45-60 minutes and will be conducted three times per week for 12 weeks.
214737368|NCT07093983|OTHER|Coupling Rehabilitation|Participants in this group will receive Coupling Rehabilitation in addition to conventional physical therapy. This method involves bilateral arm training and functional tasks designed to improve coordination between both upper limbs, using the unaffected limb to guide movement in the affected one. Exercises will include trunk-supported reaching, object retrieval, and posture-supported task practice. Sessions will occur three times per week for 12 weeks, each lasting approximately 45-60 minutes.
214737369|NCT07100769|PROCEDURE|Real-time ultrasound-guided thoracic epidural placement|"Real-time ultrasound-guided thoracic epidural catheter placement is performed by an attending anesthesiologist using paramedian-cross view to approach thoracic epidural space.~The patient is placed in the prone position with a pillow under the upper abdomen. The probe is placed to identify the rib, then moved medially to identify key anatomical structures: costotransverse joint, transverse process, lamina, superior articular process. The probe is rotated clockwise toward the midline to visualize the lamina and base of the spinal process.~A 18G Tuohy needle is advanced under ultrasound guidance from inferior to superior aiming for the interspace between the lamina and base of the upper spinal process.~After the tip of Tuohy needle approaches the interspace, the anesthesiologist will perform a loss-of-resistance test to identify the epidural space. Then a catheter will be inserted into epidural space."
214737370|NCT07101276|OTHER|No intervention|No intervention will be performed in this study.
214737371|NCT07100730|COMBINATION_PRODUCT|TLX-101-Tx + Lomustine|Combination therapy with TLX-101-Tx + Lomustine
214737372|NCT07100730|RADIATION|TLX101-Tx|TLX101-Tx
214737373|NCT07101016|DRUG|Diclofenac Sodium Gel|I1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity
214737374|NCT07101692|BEHAVIORAL|Virtual Reality-Based NGT Training|Participants will be given nasogastric catheter application training accompanied by a PowerPoint presentation and then they will be provided with three individual applications on the model.
214737375|NCT07102160|DEVICE|Aspiration thrombectomy system|The Cleaner Vac® Thrombectomy System is a percutaneous mechanical aspiration thrombectomy device designed for the removal of fresh, soft thrombi and emboli from the peripheral venous vasculature. The system includes an aspiration canister with integrated pump, an 18F aspiration catheter, a handpiece with aspiration control lever, a dilator, and an optional flushing adapter. The device operates via controlled suction to extract thrombus and restore venous patency.
214737376|NCT07100886|OTHER|long-term follow up visit|Phone call questionnaire- retrospective treatment arm Phone call questionnaire- retrospective control arm
214737377|NCT07100951|BEHAVIORAL|Brief Psychoanalytic Couple Therapy|Brief Psychoanalytic Couple Therapy (BPCT) consists of 12 weekly online sessions (50 minutes each) focused on uncovering unconscious relational dynamics, symbolic conflict meanings, and early attachment schemas. Techniques include relational interpretations, exploration of projective identification and transference, and analysis of emotional defenses. Therapists maintain a neutral, reflective stance to promote insight and self-awareness within the couple dynamic.
214737378|NCT07100951|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Therapy (EFT) involves 12 weekly online sessions (50 minutes each) focusing on repairing emotional bonds and enhancing attachment security. The intervention targets maladaptive emotional interaction cycles and promotes the expression of primary emotions and attachment needs. Therapists actively guide couples through restructuring emotional responses and rebuilding secure, responsive communication patterns.
214737379|NCT07101588|COMBINATION_PRODUCT|Ruxolitinib, Decitabine|"1. Decitabine: 20 mg/m²/day, administered from Day -15 to Day -10.~2. Ruxolitinib:~   * 10 mg twice daily (bid), Day -15 to Day -5~  * 5 mg twice daily (bid), Day -4 to Day -3~  * 5 mg once daily (Qd), Day -2"
214737380|NCT00175422|BEHAVIORAL|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
214737381|NCT06940596|OTHER|FODMAP Diet|The intervention is an online diet program. The diet is the low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet. It is a 3-phase diet which involves: 1.Phase 1 FODMAP restriction: restrict foods high or moderate in FODMAPs and swap these for low FODMAP alternatives; 2. Phase 2 FODMAP reintroduction: continue to follow a low FODMAP diet and complete a series of food challenges to understand which foods and FODMAPs are tolerated and which trigger symptoms; 3. Phase 3 FODMAP personalization: include well-tolerated foods and FODMAPs back into the diet, and restrict poorly tolerated foods and FODMAPs to a level needed to maintain symptom relief. The online FODMAP program is a self-directed diet program with support from an online clinician (Accredited Practicing Dietitian \[APD\]). The content is delivered over 12 weeks. After each module participants will complete homework activities and questions and submit them to the dietitian for feedback.
214737382|NCT06940596|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|The intervention is an online behavioral therapy program. The behavioral therapy is Exposure-based Cognitive Behavioral Therapy (E-CBT) Program. The E-CBT program is organised into six steps to be completed over 12 weekly modules with support from an online clinician (Psychologist). The first step contains a rationale for the treatment and instructions on self-observation. Steps 2, 3 and 4 contain a presentation of a psychological model of IBS and continued self-observation exercises. The fifth step covers exposure exercises, divided into three categories; (1) exercises that provoke symptoms, (2) abolishment of behaviors that serve to control symptoms, (3) exposure to situations where symptoms were unwanted. The final step (Step 6) includes how to handle relapses into avoidance behaviors and how to maintain a widened behavioral repertoire. After each module participants will be directed to complete homework activities and questions and submit them to the psychologist for feedback.
214737383|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
214737384|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
214737385|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
214737386|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
214737387|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
214737388|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
214737389|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
214737390|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
214737391|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
214737392|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
214737393|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
214737394|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
214737395|NCT01855919|DRUG|Duloxetine|Administered orally
214737396|NCT01855919|DRUG|Placebo|Administered orally
214737397|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
214737398|NCT04459416|OTHER|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
214737399|NCT04459416|DRUG|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
214737400|NCT04459416|OTHER|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
214737401|NCT05680545|OTHER|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
214737402|NCT04083963|DRUG|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
214737403|NCT04083963|DRUG|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
214737404|NCT04083963|DRUG|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
214737405|NCT04083963|DRUG|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
214737406|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
214737407|NCT04898153|DEVICE|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
214737408|NCT06506097|BEHAVIORAL|Family-school Partnership Intervention (FSPI)|"FSPI includes implementation activities across multiple levels.~FSPI Planning Team Meetings will be held monthly to plan project activities, practice staff and parent coaching strategies, and troubleshoot implementation challenges.~FSPI Staff Training (3 hours) will be provided during a single professional development day (3 hours), and attended by members of the FSPI Planning Team and teachers.~FSPI Playgroups. Over the course of the school year, each parent-child dyad will be invited to participate in three FSPI Playgroup events. Typically, teachers from two classrooms will collaborate in hosting playgroup events, and each playgroup will be attended by four parent-child dyads (i.e., two per classroom). Teachers will be provided with a curriculum and learning outcomes to target.~FSPI Debrief Meetings are held after each FSPI Playgroup to debrief, reflect, and improve FSPI implementation."
214737409|NCT04713657|OTHER|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
214737410|NCT04713657|OTHER|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
214737411|NCT04713657|PROCEDURE|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in Tetrology of Fallot/ Pulmonary Stenosis (ToF/PS) and is non-invasive.
214737412|NCT04713657|PROCEDURE|Cardiac MRI (CMR)|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
214737413|NCT04713657|DRUG|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
214737414|NCT04713657|DRUG|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.
214737415|NCT04713657|PROCEDURE|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
214737416|NCT04713657|OTHER|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
214737417|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
214737418|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
214737419|NCT06318481|DRUG|Ticagrelor 90 MG|Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
214737420|NCT06318481|DRUG|Clopidogrel|Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
214737421|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
214737422|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
214737423|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
214737424|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
214737425|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
214737426|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
214737427|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
214737428|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
214737429|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
214737430|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
214737431|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
214737432|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
214737433|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
214737434|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
215030658|NCT03646357|DRUG|Betablocker|"A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care."
214737435|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
214737436|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
214737437|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
214737438|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
214737439|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
214737440|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
214737441|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
214737442|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
214737443|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
214737444|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
214737445|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
214737446|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
214737447|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
214737448|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
214737449|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
214737450|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
214737451|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
214737452|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
214737453|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
214737454|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
214737455|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
214737456|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
214737457|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
214737458|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
214737459|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
214737460|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
214737461|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
214737462|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
214737463|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
214737464|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
214737465|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
214737466|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
214737467|NCT02274987|OTHER|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
214737468|NCT02274987|RADIATION|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
214737469|NCT03031327|DEVICE|Lubricin 20µg/ml|Lubricin 20µg/ml eye drops
214737470|NCT03031327|DEVICE|Lubricin 50µg/ml|Lubricin 50µg/ml eye drops
214737471|NCT03031327|DEVICE|Sodium hyaluronate 0.18%|Sodium hyaluronate (HA) 0.18% eye drops
214737472|NCT00526760|DRUG|Dexmedetomidine|
214737473|NCT01226758|BIOLOGICAL|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
214737474|NCT01226758|BIOLOGICAL|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
214737475|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
214737476|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
214737477|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
214737478|NCT01226602|DRUG|Placebo|
214737479|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
214737480|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
214737481|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
214737482|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
214737483|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
214737484|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
214737485|NCT03942029|DRUG|Placebo|Administered orally as tablet
214737486|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
214737487|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
214737488|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
214737489|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
214737490|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
214737491|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
214737492|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
214737493|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
214737494|NCT04177940|DRUG|DMAB Discontinuation and Switching|"Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
214737495|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
214737496|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
214737497|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
214737498|NCT04361695|DRUG|Placebo|Placebo
214737499|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
214737500|NCT00003389|DRUG|Doxorubicin|given IV
214737501|NCT00003389|DRUG|Bleomycin|given IV
214737502|NCT00003389|DRUG|Vinblastine|given IV
214737503|NCT00003389|DRUG|Dacarbazine|given IV
214737504|NCT00003389|DRUG|Vincristine|given IV
214737505|NCT00003389|DRUG|Mechlorethamine|given IV
214737506|NCT00003389|DRUG|Etoposide|given IV
214737507|NCT00003389|DRUG|Prednisone|taken orally
214737508|NCT00003389|DRUG|Cyclophosphamide|given IV
214737509|NCT00003389|RADIATION|Radiotherapy|
214737510|NCT01678469|OTHER|blood sample|
214737511|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
214737512|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
214737513|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
214737514|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
214737515|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
214737516|NCT03790267|OTHER|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
214737517|NCT04605068|PROCEDURE|Transverse preputial island flap (Duckett's technique)|
214737518|NCT04605068|PROCEDURE|Double-faced preputial flap (DFPF)|
214737519|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
214737520|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
214737521|NCT00686699|DRUG|Preladenant|capsules
214737522|NCT00686699|DRUG|Placebo|capsules
214737523|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
214737524|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
214737525|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
214737526|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
214737527|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
214737528|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
214737529|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
214737530|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
214737531|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214737532|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214737533|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214737534|NCT01662752|DRUG|Indocyanine green|Please see arm description
214737535|NCT06028906|DIAGNOSTIC_TEST|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
214737536|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
214737537|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
214737538|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
214737539|NCT05765721|BEHAVIORAL|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
214737540|NCT05214365|DEVICE|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
214737541|NCT05214365|DEVICE|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
214737542|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
214737543|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
214737544|NCT01855139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
214737545|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
214737546|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
214737547|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
214737548|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
214737549|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
214737550|NCT01935622|DRUG|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
214737551|NCT01935622|DRUG|placebo|Placebo 1 tablet every 12 hours for 14 days
214737552|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
214737553|NCT05753124|OTHER|Observational|This is an observational study
214737554|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
214737555|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
214737556|NCT00601510|DRUG|capecitabine|
214737557|NCT00601510|DRUG|cisplatin|
214737558|NCT00601510|DRUG|imatinib mesylate|
214737559|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
214737560|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
214737561|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
214737562|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
214737563|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
214737564|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
214737565|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
214737566|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
214737567|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
214737568|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
214737569|NCT03968523|PROCEDURE|TAP block|TAP block technique
214737570|NCT03040479|DRUG|lasmiditan 200 mg|single dose
214737571|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
214737572|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
214737573|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
214737574|NCT05320640|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
214737575|NCT05320640|DRUG|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
214737576|NCT05320640|DRUG|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
214737577|NCT04657003|DRUG|Tirzepatide|Administered SC
214737578|NCT04657003|OTHER|Placebo|Administered SC
214737579|NCT04044625|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
214737580|NCT04044625|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
214737581|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
214737582|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
214737583|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
214737584|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
214737585|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
214737586|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
214737587|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
214737588|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
214737589|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
214737590|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
214737591|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
214737592|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
214737593|NCT00935766|DRUG|Placebo|
214737594|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
214737595|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
214737596|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
214737597|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
214737598|NCT00768040|DRUG|Aliskiren|300 mg once daily
214737599|NCT00768040|DRUG|Placebo|Matching placebo once daily
214737600|NCT01790451|PROCEDURE|Irreversible Electroporation|
214737601|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
214737602|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
214737603|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
214737604|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
214737605|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
214737606|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
214737607|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
214737608|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
214737609|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
214737610|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
214737611|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
214737612|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
214737613|NCT02763605|OTHER|no intervention|
214737614|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
214737615|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
214737616|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
214737617|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
214737618|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
214737619|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
214737620|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
214737621|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
214737622|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
214737623|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
214737624|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
214737625|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
214737626|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
214737627|NCT04874129|DRUG|YYC506 (phase 1)|Test
214737628|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
214737629|NCT04874129|DRUG|YYC506 (phase 2)|Test
214737630|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
214737631|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
214737632|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
214737633|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
214737634|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
214737635|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
214737636|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
214737637|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
214737638|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
214737639|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
214737640|NCT00537251|DRUG|Insulin glargine|
214737641|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
214737642|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
214737643|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
214737644|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
214737645|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
214737646|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
214737647|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
214737648|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
214737649|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
214737650|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
214737651|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
214737652|NCT02185040|DRUG|Placebo|Matching oral placebo daily
214737653|NCT01713257|DIETARY_SUPPLEMENT|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
214737654|NCT01713257|DIETARY_SUPPLEMENT|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
214737655|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
214737656|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
214737657|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
214737658|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
214737659|NCT05427864|DIAGNOSTIC_TEST|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
214737660|NCT02543606|DRUG|Esomelone|powder for injection/ infusion Esomeprazole 40mg
214737661|NCT02543606|DRUG|Nexium|powder for injection/ infusion Esomeprazole 40mg
214737662|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
214737663|NCT06425406|DEVICE|high-flow nasal cannula|In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
214737664|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
214737665|NCT04506879|PROCEDURE|Popliteal Sciatic nerve block|Patients schedule for lower limb surgery under regional anesthesia will receive ultrasound guided subparaneural popliteal sciatic nerve block. After identification of the common peroneal nerve and tibial nerve, local anesthetic agents will be injected close to each nerve below the point of divergence at the popliteal fossa. The spread of the drug and the sensory and motor function of that limb will be assessed regularly till it is ready for surgery.
214737666|NCT05804071|DRUG|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
214737667|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
214737668|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
214737669|NCT05392101|DRUG|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
214737670|NCT01646151|DRUG|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
214737671|NCT00944476|PROCEDURE|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
214737672|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
214737673|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
214737674|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
214737675|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
214737676|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
214737677|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
214737678|NCT06232187|BEHAVIORAL|Artificial Intelligence feedback for ultrasound EFW standard plane images|AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
214737679|NCT03787901|OTHER|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
214737680|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
214737681|NCT02029365|OTHER|semi-structured interview|phone interview
214737682|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
214737683|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
214737684|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
214737685|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
214737686|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
214737687|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
214737688|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
214737689|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
214737690|NCT00003684|DRUG|theophylline|
214737691|NCT00003684|PROCEDURE|quality-of-life assessment|
214737692|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
214737693|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
214737694|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
214737695|NCT01930396|DRUG|Tinzaparin|
214737696|NCT01930396|DRUG|Unfractionated Heparin|
214737697|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
214737698|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
214737699|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
214737700|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
214737701|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
214737702|NCT02198313|DRUG|BIIX 1 XX - D1|
214737703|NCT02198313|DRUG|BIIX 1 XX - D2|
214737704|NCT02198313|DRUG|BIIX 1 XX - D3|
214737705|NCT02198313|DRUG|Placebo|
214737706|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
214737707|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
214737708|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
214737709|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
214737710|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
214737711|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
214737712|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
214737713|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
214737714|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
214737715|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
214737716|NCT01921959|BEHAVIORAL|Intervention|Postpartum women are randomized to intervention or control group
214737717|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
214737718|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
214737719|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
214737720|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
214737721|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
214737722|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
214737723|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
214737724|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
214737725|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
214737726|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
214737727|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
214737728|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
214737729|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
214737730|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
214737731|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
214737732|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
214737733|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
214737734|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
214737735|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
214737736|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
214737737|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
214737738|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
214737739|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
214737740|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
214737741|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
214737742|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
214737743|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
214737744|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
214737745|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
214737746|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
214737747|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
214737748|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
214737749|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
214737750|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
214737751|NCT02491593|DEVICE|fecal occult blood test|
214737752|NCT05465967|PROCEDURE|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
214737753|NCT04290767|DIAGNOSTIC_TEST|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
214737754|NCT00290355|BIOLOGICAL|GSK 249553 vaccine|Intramuscular injection, 13 doses
214737755|NCT00290355|BIOLOGICAL|Placebo|Intramuscular administration, 13 doses
214737756|NCT00381524|BEHAVIORAL|Increase condom use|Voluntary increase in condom use
214737757|NCT01173822|OTHER|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
214737758|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
214737759|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
214737760|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
214737761|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
214737762|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
214737763|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
214737764|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
214737765|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
214737766|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
214737767|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
214737768|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
214737769|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
214737770|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
214737771|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
214737772|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
214737773|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
214737774|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
215030659|NCT04420923|OTHER|Observe and Plan|First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.
214737775|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
214737776|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
214737777|NCT02827487|DRUG|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
214737778|NCT02827487|DRUG|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
214737779|NCT02827487|DRUG|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
214737780|NCT02827487|DRUG|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
214737781|NCT02827487|PROCEDURE|IUD|IUD insertion
214737782|NCT00809575|OTHER|questionnaire administration|
214737783|NCT00809575|OTHER|fatigue assessment and management|
214737784|NCT00809575|OTHER|observation|
214737785|NCT00809575|OTHER|quality-of-life assessment|
214737786|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
214737787|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
214737788|NCT03502941|DIETARY_SUPPLEMENT|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
214737789|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
214737790|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
214737791|NCT01814189|DRUG|Sumatriptan+Promethazine (SPr)|
214737792|NCT00218452|BEHAVIORAL|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
214737793|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
214737794|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
214737795|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
214737796|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
214737797|NCT00057265|DRUG|telbivudine or lamivudine|
214737798|NCT00618865|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
215030660|NCT04420923|OTHER|Treat-and-Extend|"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."
215030661|NCT02323620|PROCEDURE|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
214737799|NCT05617248|BEHAVIORAL|Self-efficacy App|The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
214737800|NCT00881686|DRUG|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
214737801|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
214737802|NCT00040911|PROCEDURE|electroacupuncture therapy|
214737803|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
214737804|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
214737805|NCT00161746|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
214737806|NCT01914991|PROCEDURE|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
214737807|NCT01914991|PROCEDURE|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
214737808|NCT04444323|OTHER|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
214737809|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
214737810|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
214737811|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
214737812|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
214737813|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
214737814|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
214737815|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
214737816|NCT06041230|DEVICE|Ozone Generator|Ultrasound guided ozone therapy
214737817|NCT06041230|DEVICE|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
214737818|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
214737819|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
214737820|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
214737821|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
214737822|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
214737823|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
214737824|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
214737825|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
214737826|NCT04018716|DEVICE|MTA|Indirect capping with MTA
214737827|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
214737828|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
214737829|NCT02146885|OTHER|Weight Control|Weight Control
214737830|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
214737831|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
214737832|NCT01032057|DRUG|capecitabine|
214737833|NCT01032057|DRUG|gemcitabine hydrochloride|
214737834|NCT01032057|PROCEDURE|quality-of-life assessment|
214737835|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
214737836|NCT05334329|BIOLOGICAL|Antineoplastic Immune Cell|Given COH06 IV
214737837|NCT05334329|BIOLOGICAL|Atezolizumab|Given IV
214737838|NCT05334329|PROCEDURE|Biospecimen Collection|Correlative studies
214737839|NCT05334329|DRUG|Cyclophosphamide|Given IV
214737840|NCT05334329|DRUG|Fludarabine|Given IV
214737841|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
214737842|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
214737843|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
214737844|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
214737845|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
214737846|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
214737847|NCT01685372|BIOLOGICAL|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
214737848|NCT01685372|BIOLOGICAL|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
214737849|NCT04828850|PROCEDURE|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
214737850|NCT05790967|OTHER|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
214737851|NCT00267657|DRUG|Reserpine|
214737852|NCT03224832|PROCEDURE|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
214737853|NCT03224832|PROCEDURE|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
214737854|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
214737855|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
214737856|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
214737857|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
214737858|NCT04966806|PROCEDURE|LASIK refractive surgery|laser vision correction for myopic eyes
214737859|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
214737860|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
214737861|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
214737862|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
214737863|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
214737864|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
214737865|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
214737866|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
214737867|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
214737868|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
214737869|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
214737870|NCT05488977|BEHAVIORAL|Exercise training|8 weeks of supervised high-intensity interval training (HIIT).
214737871|NCT06350682|BEHAVIORAL|HealthMPowerment (HMP)|Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.
214737872|NCT02689544|OTHER|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
214737873|NCT02689544|OTHER|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
214737874|NCT02689544|OTHER|Control|The control group volunteers no received intervention
214737875|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
214737876|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
214737877|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
214737878|NCT06976775|BIOLOGICAL|"Rush regimen"|"The rush regimen consists of the administration of several incremental doses daily, every day, over the first week of the Induction Phase (Part 1)"
214737879|NCT06976775|BIOLOGICAL|"Conventional regimen"|"The conventional regimen consists of the administration of only one incremental dose every 2 weeks, throughout all the Induction Phase (Part 1)"
214737880|NCT02061540|DRUG|LUM001|LUM001 oral dose
214737881|NCT00004064|BIOLOGICAL|oregovomab|
214737882|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
214737883|NCT00068549|DRUG|Cisplatin|Given IV
214737884|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
214737885|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
214737886|NCT03955120|BEHAVIORAL|Dayzz mobile sleep training|"1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
214737887|NCT03955120|OTHER|Treatment as usual|Standard medical care for specific sleep condition
214737888|NCT03526692|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
214737889|NCT02289833|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
214737890|NCT03501381|DRUG|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
214737891|NCT03501381|DRUG|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
214737892|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
214737893|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
214737894|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
214737895|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
214737896|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
214737897|NCT00262353|DEVICE|Dialysis with different artificial devices|
214737898|NCT01608555|DRUG|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
214737899|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
214737900|NCT01642004|BIOLOGICAL|Nivolumab|
214737901|NCT01642004|DRUG|Docetaxel|
214737902|NCT04705428|OTHER|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
214737903|NCT03817749|DIETARY_SUPPLEMENT|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
214737904|NCT02077972|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
214737905|NCT01898000|BEHAVIORAL|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
214737906|NCT01898000|BEHAVIORAL|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
214737907|NCT04743401|OTHER|Tele-exergaming Tablet|"The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program."
214737908|NCT03166657|PROCEDURE|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
214737909|NCT06593626|DRUG|[18F]Florbetazine|Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
214737910|NCT00598806|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
214737911|NCT00598806|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
214737912|NCT00598806|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
214737913|NCT05001581|PROCEDURE|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
214737914|NCT05001581|PROCEDURE|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
214737915|NCT04099225|DIAGNOSTIC_TEST|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
214737916|NCT01126567|OTHER|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
214737917|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
214737918|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
214737919|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
214737920|NCT01908049|DIETARY_SUPPLEMENT|Probiotic.|
214737921|NCT01908049|DIETARY_SUPPLEMENT|Placebo|
214737922|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
214737923|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
214737924|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
214737925|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
214737926|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
214737927|NCT02238236|DRUG|Alesion®|Dry Syrup
214737928|NCT01253941|OTHER|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
214737929|NCT03031990|BEHAVIORAL|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
214737930|NCT03031990|BEHAVIORAL|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
214737931|NCT03031990|BEHAVIORAL|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
214737932|NCT01730001|PROCEDURE|Early Intubation|
214737933|NCT01730001|PROCEDURE|Late intubation|
214737934|NCT03249480|BIOLOGICAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
214737935|NCT05412160|DRUG|Arginine|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
214737936|NCT05412160|DRUG|Placebo|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
214737937|NCT02114918|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
214737938|NCT02114918|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
214737939|NCT00896662|OTHER|immunologic technique|immunologic technique
214737940|NCT00896662|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214737941|NCT00896662|OTHER|pharmacological study|pharmacological study
214737942|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
214737943|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
214737944|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
214737945|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
214737946|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
214737947|NCT03371394|OTHER|no intervention|no intervention
214737948|NCT02240524|PROCEDURE|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
214737949|NCT02240524|PROCEDURE|Systemic chemotherapy|
214737950|NCT02240524|PROCEDURE|HIPEC|
214737951|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
214737952|NCT05346380|DEVICE|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
214737953|NCT05346380|DRUG|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
214737954|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
214737955|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
214737956|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
214737957|NCT06348862|BEHAVIORAL|Listening to either Quran, Music, and or Natural sound|Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
214737958|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
214737959|NCT03839056|DEVICE|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
214737960|NCT03839056|DEVICE|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
214737961|NCT03839056|DEVICE|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
214737962|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
214737963|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
214737964|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
214737965|NCT05843344|DRUG|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
214737966|NCT00706264|DEVICE|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
214737967|NCT05749874|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
214737968|NCT05749874|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
214737969|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
214737970|NCT02607865|DRUG|semaglutide|Oral administration once-daily
214737971|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
214737972|NCT02607865|DRUG|placebo|Oral administration once-daily
214737973|NCT00528840|BIOLOGICAL|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
214737974|NCT02447952|DEVICE|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
214737975|NCT02447952|DEVICE|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
214737976|NCT02447952|PROCEDURE|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
214737977|NCT02448095|DRUG|Ponatinib|Observation of tolerability and safety profiles
214737978|NCT03720106|OTHER|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
214737979|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
214737980|NCT00126386|DRUG|Zoledronic acid (Zometa)|
214737981|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
214737982|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
214737983|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
214737984|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
214737985|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
214737986|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
214737987|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
214737988|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
214737989|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
214737990|NCT00058448|DRUG|docetaxel|
214737991|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
214737992|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
214737993|NCT02664740|DRUG|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
214737994|NCT02664740|DRUG|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
214737995|NCT01960764|DRUG|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
214737996|NCT01960764|OTHER|Control|
214737997|NCT01697189|BEHAVIORAL|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
214737998|NCT01087073|BEHAVIORAL|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
214737999|NCT01087073|BEHAVIORAL|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
214738000|NCT01087073|BEHAVIORAL|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
214738001|NCT01087073|BEHAVIORAL|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
214738002|NCT00000642|DRUG|CD4-IgG|
214738003|NCT01766401|DRUG|Placebo|
214738004|NCT01766401|DRUG|Vilazadone|Viibryd
214738005|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
214738006|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
214738007|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
214738008|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
214738009|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
214738010|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
214738011|NCT00398086|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
214738012|NCT00398086|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
214738013|NCT01432665|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
214738014|NCT01432665|DRUG|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
214738015|NCT01432665|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
214738016|NCT05384990|DEVICE|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
214738017|NCT01950364|DRUG|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
214738018|NCT01950364|DRUG|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
214738019|NCT02118402|DIETARY_SUPPLEMENT|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
214738020|NCT02657109|OTHER|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
214644950|NCT06017154|OTHER|Motor-Cognitive Training Program|The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
214644951|NCT01654900|OTHER|No intervention in this study|
214644952|NCT03440359|DRUG|Progesterone Vaginal Gel 8%|progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
214644953|NCT03440359|DRUG|Letrozole Oral Tablet|letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
214738021|NCT03529175|DRUG|Abraxane (nab-paclitaxel)|
214738022|NCT03529175|DRUG|Gemcitabine|
214738023|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
214738024|NCT03944811|PROCEDURE|Summers technique|Summers technique
214738025|NCT01006915|PROCEDURE|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
214738026|NCT00614042|DRUG|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
214738027|NCT06315322|DRUG|Brivaracetam Film-coated tablet|Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
214738028|NCT06315322|DRUG|Brivaracetam oral solution|Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
214738029|NCT00003804|BIOLOGICAL|dactinomycin|
214738030|NCT00003804|DRUG|vincristine sulfate|
214738031|NCT00003804|PROCEDURE|conventional surgery|
214738032|NCT07007091|DRUG|Risankizumab|Subcutaneous (SC) Injection
214644954|NCT03440359|DIAGNOSTIC_TEST|pelvic ultrasound|pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is \>17 mm in diameter
214738033|NCT07007091|DRUG|Risankizumab|On-Body Injector (OBI)
214738034|NCT06868173|DEVICE|Electro-acupuncture|Electroacupuncture at Trigger Points is electroacupuncture at predetermined trigger points. Electroacupuncture at traditional acupoints is electroacupuncture at the following points: Jiaji (L2-L5), Yaoyangguan (GV3), Shendu (BL23), Dachangdu (BL25), and Weizhong (BL40).
214738035|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
214738036|NCT03208504|DEVICE|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
214738037|NCT05068427|DRUG|Chidamide|20mg or 30mg orally twice per week(BIW)
214738038|NCT05068427|DRUG|Envafolimab|400mg subcutaneous infusions every 4 weeks
214738039|NCT00878306|DRUG|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
214738040|NCT00878306|DRUG|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
214738041|NCT00878306|DRUG|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
214738042|NCT00878306|DRUG|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
214738043|NCT02946151|DEVICE|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
214738044|NCT03850704|DRUG|Selinexor|
214738045|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
214738046|NCT00186472|BEHAVIORAL|Brief Cognitive Behavioral Treatment|
214738047|NCT04369872|PROCEDURE|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
214738048|NCT04869189|DEVICE|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
214738049|NCT04974957|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
214738050|NCT03338452|BEHAVIORAL|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
214644955|NCT03440359|DRUG|Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe|ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter
214644956|NCT03440359|OTHER|Intrauterine insemination or timed intercourse|Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
214644957|NCT03675880|DRUG|TAB014|TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
214644958|NCT03850184|DIAGNOSTIC_TEST|The Exercise in Mental Illness Questionnaire (EMIQ)|Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
214644959|NCT04873466|DIETARY_SUPPLEMENT|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
214644960|NCT05068609|BIOLOGICAL|Nivolumab|Participants in this study are being treated with nivolumab for SCCHN
214644961|NCT04882176|DRUG|LM-061|The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
214644962|NCT03979326|PROCEDURE|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
214644963|NCT02623335|OTHER|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
214644964|NCT04871503|DEVICE|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
214644965|NCT03683394|BEHAVIORAL|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
214644966|NCT03683394|BEHAVIORAL|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
214738051|NCT06382740|PROCEDURE|Liver transplantation|Liver transplantation
214738052|NCT05093569|DEVICE|K'watch|Patients
214738053|NCT01100762|DEVICE|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
214738054|NCT01100762|DEVICE|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
214738055|NCT01100762|DEVICE|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
214738056|NCT01736930|DEVICE|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
214738057|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
214738058|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
214738059|NCT00431223|BEHAVIORAL|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
214738060|NCT03024229|DEVICE|LifePort® perfusion machine|Renal perfusion on LifePort® machine
214738061|NCT03398174|BEHAVIORAL|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
214738062|NCT03398174|BEHAVIORAL|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
214738063|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
214738064|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
214738065|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
214738066|NCT01693289|DRUG|metformin plus letrozole|
214738067|NCT01693289|PROCEDURE|ovarian drilling|
214738068|NCT03371303|OTHER|collection of prescription data|collection of prescription data before and after a hospitalization
214738069|NCT01166386|BEHAVIORAL|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
214738070|NCT01166386|BEHAVIORAL|FANCI|Watching DVDs chosen by participants on various topics.
214738071|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
214738072|NCT02239029|DRUG|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
214738073|NCT02239029|DRUG|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
214738074|NCT00675129|BEHAVIORAL|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
214738075|NCT00675129|BEHAVIORAL|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
214738076|NCT02640924|RADIATION|Proton radiotherapy|
214738077|NCT02640924|PROCEDURE|Radiofrequency Ablation|
214738078|NCT01341236|OTHER|different nutrional regimen|compare bolus versus intermittent nutrition
214738079|NCT01341236|OTHER|comparison of different feeding regimens|compare intermittent versus bolus nutrition
214738080|NCT00975442|OTHER|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
214738081|NCT00975442|DEVICE|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
214738082|NCT00975442|DEVICE|Forearm band|All patients were instructed to use a forearm band during all daily activities.
214738083|NCT01138462|OTHER|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
214738084|NCT03714256|DEVICE|Device, patient mobility, powered|Pediatric mobility device
214738085|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
214738086|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
214738087|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
214738088|NCT07022639|PROCEDURE|Total pancreatectomy|Total pancreatectomy for any kind of disease
214738089|NCT07022639|PROCEDURE|Proximal pancreatectomy|Proximal pancreatectomy for any kind of disease
214738090|NCT07022639|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy for any kind of disease
214738091|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
214738092|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
214738093|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
214738094|NCT01943695|BEHAVIORAL|Aerobic Training|
214738095|NCT01943695|BEHAVIORAL|Educational Information|Subjects will be given material regarding cancer and it's impact.
214738096|NCT01943695|BEHAVIORAL|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
214738097|NCT02691468|DEVICE|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
214738098|NCT02691468|DEVICE|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
214738099|NCT02052154|BIOLOGICAL|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
214738100|NCT04839328|DRUG|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
214738101|NCT04839328|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
214738102|NCT00256646|DRUG|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
214738103|NCT06881290|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab combined with glucocorticoid therapy: Vunakizumab is administered subcutaneously at 240 mg at weeks 0, 2, and 4, followed by maintenance dosing every 4 weeks at 240 mg per dose.
214738104|NCT07047482|BIOLOGICAL|Immunohistochemical staining|Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
214738105|NCT07051642|BEHAVIORAL|Incredible Years Dinosaur Child Program|The Incredible Years Dinosaur Child Program is a structured, manualized group intervention designed for children aged 4 to 8 years with elevated or (sub)clinical conduct problems. The program consists of 18 weekly group sessions lasting approximately two hours each. Sessions are delivered in small groups (5-6 children per group) by certified trainers and follow a developmentally appropriate, play-based curriculum. Intervention components include storytelling with puppets, role-play, video modeling, and group discussions. The program aims to enhance emotional regulation, social competence, and problem-solving skills. The Dutch version of the program is used in this study and implemented in both clinical and preventive settings.
214738106|NCT07059338|DRUG|Trastuzumab +Cetuximab β+Irinotecan|Trastuzumab 4 mg/kg , Cetuximab β: 500 mg/m² ,Irinotecan 180 mg/m², repeat once every 2 weeks
214738107|NCT06747858|BIOLOGICAL|ARCT-032|CFTR mRNA formulated in lipid nanoparticles
214738108|NCT07057843|BEHAVIORAL|Sequential Nutrition Intervention|"Participants received a structured, sequential nutrition intervention guided by nutritional risk screening (NRS2002). A multidisciplinary team provided the intervention, which included:~* Pre-CyberKnife phase: Calculation of energy requirements using the Harris-Benedict formula, dietary guidance, and initiation of oral nutritional supplements (ONS). If oral intake was less than 60% of target, partial enteral (PEN) or parenteral nutrition (PPN) was administered for 7-10 days.~* Post-CyberKnife phase: Phased re-introduction of feeding, starting with enteral nutrition via nasojejunal tube (Day 1-2) and transitioning to an oral diet (Day 3 onwards).~* Post-discharge phase: Home energy targets were recalculated, with telephone/WeChat follow-up to ensure adherence. ONS prescribed if intake fell below 60% of targets."
214738109|NCT07057843|DRUG|Enteral Nutrition Emulsion|Fresubin (500 mL/bottle) administered at 30 mL/kg/day during the initial post-CyberKnife phase if required.
214738110|NCT07057843|BEHAVIORAL|Routine Nutritional Intervention|Participants received routine nutritional intervention, which consisted of dietary education focused on balanced, soft, and easily digestible meals rich in protein and other nutrients (e.g., high-protein soups).
214738111|NCT07059169|DRUG|JY231 (JY231 injection)|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.
214738112|NCT07058493|DRUG|Dexmedetomidine|dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
214738113|NCT07058493|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%.
214738114|NCT07057622|DRUG|177Lu-DOTATATE injection|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the test group are treated with 177Lu-DOTATATE injection, 7.4GBq±0.74GBq (200mCi±20mCi)/cycle, once every 8 to 12 weeks, 4 times in total.
214738115|NCT07057622|DRUG|Octreotide LAR (Long-acting release)|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the treatment group are treated with 60mg of long-acting octreotide once every 4 weeks±3 days.
214738116|NCT04561284|DIETARY_SUPPLEMENT|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
214738117|NCT04561284|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
214738118|NCT01801189|DRUG|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
214738119|NCT01801189|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
214738120|NCT01731756|OTHER|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
214738121|NCT01731756|DRUG|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
214738122|NCT01731756|OTHER|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
214738123|NCT03300557|DRUG|Exemestane|Given PO
214738124|NCT03300557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214738125|NCT03300557|OTHER|Pharmacokinetic Study|Correlative studies
214738126|NCT03300557|OTHER|Questionnaire Administration|Ancillary studies
214738127|NCT07072325|DRUG|CD-001|CD-001 administered as an intravenous (lV)infusion.
214738128|NCT04470024|DRUG|INCAGN01876|agonistic antihuman GITR mAb
214738129|NCT04470024|DRUG|INCMGA00012|humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
214738130|NCT04470024|BIOLOGICAL|DPV-001|autophagosome cancer vaccine
214738131|NCT06926829|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 52 weeks
214738132|NCT06926829|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 52 weeks
214738133|NCT04581109|BIOLOGICAL|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
214738134|NCT04929288|DRUG|Alcohol|Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.
214738135|NCT07086222|BIOLOGICAL|NVX-CoV2705|NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant
214738136|NCT07086222|BIOLOGICAL|Placebo|Placebo (normal saline) in a 0.5 mL injection volume.
214738137|NCT07099209|BEHAVIORAL|Delta-Wave Hypnoanalgesia|Binaural beat audio tracks at delta frequencies (1-4 Hz) to induce deep relaxation and reduce perioperative anxiety.
214738138|NCT01365169|BEHAVIORAL|Exercise Intervention|Participate in walking and/or strengthening program
214738139|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
214738140|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
214738141|NCT01365169|OTHER|Health Telemonitoring|Use smart phone
214738142|NCT01365169|OTHER|Health Telemonitoring|Use CO monitor and smart phone
214738143|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
214738144|NCT01365169|OTHER|Quality-of-Life Assessment|Ancillary studies
214738145|NCT01365169|OTHER|Questionnaire Administration|Ancillary studies
214738146|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit and Actigraph
214738147|NCT07095751|DEVICE|AI Uro-Cam|As stated in AI Uro-Cam arm description
214738148|NCT07096908|DRUG|Tirzepatide|weekly injections
214738149|NCT07096908|DRUG|Placebo|weekly injections
214738150|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and atropine infusion|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Atropine infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
214738151|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Saline infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
214738152|NCT07102225|DRUG|prolotherapy solution of 20% dextrose|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
214738153|NCT07102225|DRUG|Hyaluronic Acid (HA)|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
214738154|NCT07101029|DRUG|Bio-C Temp Intracanal Medication|Bio-C Temp Bioceramic intracanal dressing in the form of injectable premixed paste
214738155|NCT07101029|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide intracanal dressing in the form of injectable premixed paste
214738156|NCT07100379|PROCEDURE|Endoscopic Balloon Dilation|Endoscopic balloon dilation is a routine procedure in which a catheter with a balloon is introduced into the esophagus to help treat esophageal strictures via endoscope. The catheter is placed directly across the span of the esophageal stricture and the balloon is inflated to pre-determined volume in order to dilate the esophageal stricture. Balloon will remain inflated for either 30 or 180 seconds based on patient's randomization.
214738157|NCT07102303|BEHAVIORAL|Online Group Cognitive-Behavioral Therapy (CBT)|"12-session group online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and in a group format. The program consists of twelve sessions of approximately 2,5 hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
214738158|NCT07102303|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
214738159|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 100 mg orally, daily on days 1-21 of a 28-day cycle, for 3 years.
214738160|NCT07101159|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitor), as per physician's choice.
214738161|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 125 mg orally, daily on days 1-21 of a 28-day cycle, for 2 years.
214738162|NCT07102576|DRUG|MDMA Hydrochloride|Initial dose of 120 mg MDMA HCl in a therapeutic setting, followed 1.5 to 2 hours later by a supplemental dose of 40 mg MDMA HCl. Supplemental doses may be withheld if tolerability issues emerge or it is declined by the participant.
214738163|NCT07100288|OTHER|resection of infundibulopelvic ligament|Therefore, this study also aims to perform bilateral infundibulopelvic ligament resection (at least 8 cm in length) during surgery for ovarian cancer patients
214738164|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
214738165|NCT05013788|OTHER|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
214738166|NCT05013788|OTHER|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
214738167|NCT06935331|DRUG|Opioid-Free/Opioid-Avoidant|"Managed post-operatively with an opioid-free pain regimen which will include:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Aromatherapy, Music therapy, Pet therapy, Early mobilization and PT"
214738168|NCT06935331|DRUG|Opioid-Containing|"Managed post-operatively with a traditional opioid containing pain regimen including:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Post-operative morphine IV for breakthrough pain~Oral narcotic (hydrocodone/acetaminophen)~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Early mobilization and PT"
214738169|NCT06939075|DIAGNOSTIC_TEST|ROLE OF Cross sectional imaging modalities in the diagnosis and characterization of colonic masses|"Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):~* CT Scan: To evaluate mass morphology, size, and lymph node involvement.~* MRI: To assess tissue composition, characterization and diffusion restriction.~* Colonoscopy and Biopsy: Gold standard reference to assess the diagnostic accuracy for different"
214738170|NCT05996809|DEVICE|Coseal|Adhesion reduction
214738171|NCT03030157|DRUG|pirarubicin(THP)|
214738172|NCT05931068|OTHER|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
214738173|NCT07101978|BEHAVIORAL|serial whole body hyperthermia|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermiatreatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
214738174|NCT07100340|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
214738175|NCT07101393|PROCEDURE|Intraoperative Epiaortic Ultrasound (EAU)|Intraoperative epiaortic ultrasound (EAU) is a real-time imaging technique used during coronary artery bypass grafting (CABG) to evaluate the presence, location, and severity of atherosclerotic plaques in the ascending and arch aorta. In this study, EAU was performed after median sternotomy but prior to aortic manipulation, using a high-frequency linear transducer directly applied to the exposed aorta. Plaques were classified by thickness, and findings were used to guide surgical strategy, including modification of cannulation site, avoidance of cross-clamping, or alteration of grafting technique. This intervention differs from conventional CABG, in which such imaging is not routinely employed.
214738176|NCT07101536|BIOLOGICAL|EBV mRNA vaccine|EBV mRNA vaccine
214738177|NCT07101536|BIOLOGICAL|Immune Checkpoint Inhibitors, ICIs|Immune Checkpoint Inhibitors, ICIs
214738178|NCT03649581|OTHER|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
214738179|NCT03649581|OTHER|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
214738180|NCT06169488|PROCEDURE|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
214738181|NCT06169488|BEHAVIORAL|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training, but the protocol is somewhat compressed in terms of time and additionally updated in line with recent years' research in cognitive functional rehabilitation.
214738182|NCT04901273|PROCEDURE|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
214738183|NCT04901273|PROCEDURE|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
214738184|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
214738185|NCT02803437|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
214738186|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
214738187|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
214738188|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
214738189|NCT02972658|DRUG|Lanabecestat|Administered orally
214738190|NCT02638285|DRUG|LH|
214738191|NCT02638285|DRUG|HCG|
214738192|NCT02638285|DRUG|Clomiphene|
214738193|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
214738194|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
214738195|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
214738196|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
214738197|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
214738198|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
214738199|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
214738200|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
214738201|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
214738202|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
214738203|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
214738204|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
214738205|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
214738206|NCT02499172|BIOLOGICAL|Shanchol|
214738207|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
214738208|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
214738209|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
214738210|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
214738211|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
214738212|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
214738213|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
214738214|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
214738215|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
214738216|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
214738217|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
214738218|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
214738219|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
214738220|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
214738221|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
214738222|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
214738223|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
214738224|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
214738225|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
214738226|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
214738227|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
214738228|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
214738229|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
214738230|NCT02735876|DRUG|acalabrutinib|
214738231|NCT02735876|DRUG|ibrutinib|
214738232|NCT02735876|DRUG|rituximab|
214738233|NCT01234558|DRUG|GLYX-13|single IV dose
214738234|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
214738235|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
214738236|NCT05385172|OTHER|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
214738237|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
214738238|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
214738239|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
214738240|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
214738241|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
214738242|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
214738243|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
214738244|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
214738245|NCT03247712|DRUG|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
214738246|NCT03247712|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
214738247|NCT03247712|RADIATION|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
214738248|NCT03247712|RADIATION|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
214738249|NCT00908050|DRUG|Botulinum toxin type A|Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
214738250|NCT00908050|DRUG|Placebo arm|Placebo comparator
214738251|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
214738252|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
214738253|NCT05195619|BIOLOGICAL|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
214738254|NCT05195619|DRUG|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
214738255|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
214738256|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
214738257|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
214738258|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
214738259|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
214738260|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
214738261|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
214738262|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
214738263|NCT01381289|DRUG|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
214738264|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
214738265|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
214738266|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
214738267|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
214738268|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
214738269|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
214738270|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
214738271|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
214738272|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
214738273|NCT00012870|BEHAVIORAL|Behavioral Management|
214738274|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
214738275|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
214738276|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
214738277|NCT00000529|DRUG|tamoxifen|
214738278|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
214738279|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
214738280|NCT00036816|BIOLOGICAL|MART-1 antigen|
214738281|NCT00036816|BIOLOGICAL|NA17-A antigen|
214738282|NCT00036816|BIOLOGICAL|gp100 antigen|
214738283|NCT00036816|BIOLOGICAL|tyrosinase peptide|
214738284|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
214738285|NCT02196389|DEVICE|Nasal dilator Nozovent|
214738286|NCT02196389|DEVICE|Nasal dilator Breath Right|
214738287|NCT02196389|DEVICE|Nasal dilator Airmax|
214738288|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
214738289|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
214738290|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
214738291|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
214738292|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
214738293|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
214738294|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
214738295|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
214738296|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
214738297|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
214738298|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
214738299|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
214738300|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
214738301|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
214738302|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
214738303|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
214738304|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
214738305|NCT06054594|OTHER|Resistance exercise|After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
214738306|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
214738307|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
214738308|NCT02055872|DRUG|Intravenous albumin|
214738309|NCT02055872|DRUG|Normal saline|
214738310|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
214738311|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
214738312|NCT02136264|OTHER|PCFA interventional dietary counselling|
214738313|NCT02136264|OTHER|conventional DASH diet counselling|
214738314|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
214738315|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
214738316|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
214738317|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
214738318|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
214738319|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
214738320|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
214738321|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
214738322|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
214738323|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
214738324|NCT02089191|DEVICE|Nelfilcon A contact lenses|
214738325|NCT02089191|DEVICE|Stenfilcon A contact lenses|
214738326|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound and neurostimulator|
214738327|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound|
214738328|NCT02721290|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
214738329|NCT02789800|BEHAVIORAL|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
214738330|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
214738331|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
214738332|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
214738333|NCT06234891|DRUG|Nsaid|Medical treatment
214738334|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
214738335|NCT00005066|DRUG|O6-benzylguanine|
214738336|NCT00005066|DRUG|carmustine|
214738337|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
214738338|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
214738339|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
214738340|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
214738341|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
214738342|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
214738343|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
214738344|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
214738345|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
214738346|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
214738347|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
214738348|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
214738349|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
214738350|NCT04198311|BEHAVIORAL|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
214738351|NCT03042494|DIETARY_SUPPLEMENT|Control|Isocaloric food without the test prebiotic.
214738352|NCT03042494|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
214738353|NCT05562700|OTHER|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~* Socio-demographic questions: age, height, weight, smoking status, etc.~* Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~* Functional results"
214738354|NCT01227252|DRUG|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
214738355|NCT01227252|DRUG|Placebo|Administered orally as capsules, daily for 14 days
214738356|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
214738357|NCT00005555|BEHAVIORAL|Exercise|
214738358|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
214738359|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
214738360|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
214738361|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
214738362|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
214738363|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
214738364|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
214738365|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
214738366|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
214738367|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
214738368|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
214738369|NCT02561273|DRUG|Cyclophosphamide|Given IV
214738370|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
214738371|NCT02561273|DRUG|Etoposide|Given IV
214738372|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
214738373|NCT02561273|DRUG|Lenalidomide|Given PO
214738374|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
214738375|NCT02561273|DRUG|Prednisone|Given PO
214738376|NCT02561273|DRUG|Vincristine Sulfate|Given IV
214738377|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
214738378|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
214738379|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
214738380|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
214738381|NCT03017833|OTHER|Laboratory Biomarker Analysis|Correlative studies
214738382|NCT03017833|DRUG|Metformin|Given PO
214738383|NCT03017833|OTHER|Pharmacological Study|Ancillary studies
214738384|NCT03017833|DRUG|Sapanisertib|Given PO
214738385|NCT01071369|DRUG|Xylocaine|0.5% Xylocaine
214738386|NCT01071369|DRUG|Xylocaine and Celestone|non-particulate Celestone
214738387|NCT00724646|OTHER|Survey|3 individual surveys
214738388|NCT00724646|OTHER|Focus group|Focus group discussions facilitated by a psychologist
214738389|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
214738390|NCT03527836|DRUG|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
214738391|NCT03527836|DRUG|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
214738392|NCT03527836|DRUG|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
214738393|NCT01619527|DRUG|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
214738394|NCT01619527|DRUG|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
214738395|NCT03442595|OTHER|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
214738396|NCT06302868|BEHAVIORAL|Telemedicine Exposure Therapy Using Photos and Videos|Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
214738397|NCT06302868|BEHAVIORAL|Telemedicine-Based Virtual Reality Exposure Therapy|Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
214738398|NCT04739917|BIOLOGICAL|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
214738399|NCT04739917|OTHER|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
214738400|NCT05165004|BEHAVIORAL|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
214738401|NCT05165004|BEHAVIORAL|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
214738402|NCT05165004|BEHAVIORAL|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
214738403|NCT05135468|DRUG|CU-40102 Spray|topical application, 1\~4 sprays each time, once daily
214738404|NCT04233840|DRUG|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
214738405|NCT04233840|DRUG|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
214738406|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
214738407|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
214738408|NCT06336447|OTHER|Experimental: Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
214738409|NCT06336447|OTHER|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
214738410|NCT04324476|DRUG|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
214738411|NCT00102336|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
214738412|NCT00102336|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
214738413|NCT04509297|DIETARY_SUPPLEMENT|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
214738414|NCT04509297|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
214738415|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
214738416|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
214738417|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
214738418|NCT05008367|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
214738419|NCT05008367|DRUG|Isotonic saline|6 ml of isotonic saline
214738420|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
214738421|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
214738422|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
214738423|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
214738424|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
214738425|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
214738426|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
214738427|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
214738428|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
214738429|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
214738430|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
214738431|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
214738432|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
214738433|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
214738434|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
214738435|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
214738436|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
214738437|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
214738438|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
214738439|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
214738440|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
214738441|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
214738442|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
214738443|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
214738444|NCT01128855|OTHER|Placebo|Weekly Placebo
214738445|NCT01832051|DRUG|89Zr-trastuzumab injection|
214738446|NCT03075930|DEVICE|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
214738447|NCT03075930|DEVICE|Body surface potential map|ECG with 184 leads and a 5 minute recording
214738448|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
214738449|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
214738450|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
214738451|NCT05714852|BEHAVIORAL|Healthy eating|Promotion of healthy eating
214738452|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
214738453|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
214738454|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
214738455|NCT05592444|DIAGNOSTIC_TEST|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
214738456|NCT04583228|DRUG|HLX71|Single-dose, intravenous infusion
214738457|NCT04583228|OTHER|Placebo|Single-dose, intravenous infusion
214738458|NCT03232502|DIAGNOSTIC_TEST|Pharmacogenetic testing|Basic pharmacogenetic panel
214738459|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
214738460|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
214738461|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
214738462|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
214738463|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
214738464|NCT02192190|OTHER|Placebo- oral|Administered orally
214738465|NCT02192190|OTHER|Placebo - SC|Administered SC
214738466|NCT02192190|DRUG|Celecoxib|Administered orally
214738467|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
214738468|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
214738469|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
214738470|NCT03227692|DEVICE|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
214738471|NCT03227692|PROCEDURE|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
214738472|NCT03227692|DEVICE|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
214738473|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
214738474|NCT00005623|DRUG|cyproterone acetate|
214738475|NCT00005623|PROCEDURE|quality-of-life assessment|
214738476|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
214738477|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
214738478|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
214738479|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
214738480|NCT02108795|DRUG|Placebo|
214738481|NCT05064943|DIAGNOSTIC_TEST|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
214738482|NCT05143736|DIAGNOSTIC_TEST|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
214738483|NCT03247010|OTHER|Blood sampling|Blood samples are taken before each cycle of Radium 223
214738484|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
214738485|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
214738486|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
214738487|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
214738488|NCT01138293|DEVICE|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
214738489|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
214738490|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
214738491|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
214738492|NCT04809649|DRUG|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
214738493|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
214738494|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
214738495|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
214738496|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
214738497|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
214738498|NCT04323917|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
214738499|NCT03710291|DRUG|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
214738500|NCT03710291|DRUG|Placebo|Placebo comparator
214644967|NCT03739528|DRUG|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
214644968|NCT03739528|DRUG|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
214644969|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
214644970|NCT01642745|DRUG|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
214644971|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
214644972|NCT03038646|DRUG|MIN-101|
214738501|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
214738502|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
214738503|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
214738504|NCT04456803|DRUG|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
214738505|NCT04456803|DRUG|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
214738506|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
214644973|NCT04355598|DRUG|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
214644974|NCT04355598|DRUG|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
214644975|NCT04355598|DRUG|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
214644976|NCT06112041|DRUG|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
214644977|NCT05885581|OTHER|Arm A Grow Well|"1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data."
214644978|NCT05885581|OTHER|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
214738507|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
214738508|NCT06084065|DEVICE|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
214738509|NCT01808911|DRUG|Steroid + cyclophosphamide|
214738510|NCT01808911|DRUG|Steroid + rituximab|
214738511|NCT04958551|OTHER|No intervention|No intervention
214644979|NCT05091320|DRUG|Mechanical thrombectomy|Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
214644980|NCT05091320|DRUG|medical treatment|medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
214644981|NCT02710409|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
214738512|NCT06355206|COMBINATION_PRODUCT|endoscopic intervention, surgery or conservative treatment|Personal information and treatment of the enrolled subjects will be collected.
214738513|NCT04731194|BEHAVIORAL|Performance-based financial incentive program|"1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
214738514|NCT06610474|BEHAVIORAL|"Use of the online Talk to Nathan about Prostate Cancer decision aid"|This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html
214738515|NCT06610474|BEHAVIORAL|Use of a standard prostate cancer screening decision aid|The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html
214738516|NCT06610474|BEHAVIORAL|Use of standard prostate cancer education materials|The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
214738517|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
214738518|NCT00952588|DRUG|AZD1152|1200 mg, iv, 7 day infusion
214738519|NCT00952588|DRUG|LDAC|20 mg, sc, bd, 10 days
214738520|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
214738521|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
214738522|NCT03596320|PROCEDURE|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
214738523|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
214738524|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
214738525|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
214738526|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214738527|NCT00515866|DRUG|Gemcitabine|intravenous injection
214738528|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
214738529|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
214738530|NCT05972122|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214738531|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
214738532|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
214738533|NCT04025749|OTHER|Care as usual|Care as usual
214738534|NCT00348075|DEVICE|Neurovision|
214738535|NCT00000175|DRUG|Estrogen|
214738536|NCT00000175|DRUG|Testosterone|
214738537|NCT03439722|OTHER|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
214738538|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
214738539|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
214738540|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
214738541|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
214738542|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
214738543|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
214738544|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
214738545|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
214738546|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
214738547|NCT05647928|OTHER|no intervention|no intervention
214738548|NCT02795182|DRUG|Zanubrutinib|
214738549|NCT02795182|DRUG|Tislelizumab|
214738550|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
214738551|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
214738552|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
214738553|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
214738554|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
214738555|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
214738556|NCT02280109|DRUG|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
214738557|NCT02280109|DRUG|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
214738558|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
214738559|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
214738560|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
214738561|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
214738562|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
214738563|NCT02846766|DRUG|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
214738564|NCT00348192|DRUG|SB-742457|
214738565|NCT00348192|DRUG|donepezil|
214738566|NCT02737371|DRUG|F901318 Dose level A oral|Adverse events days 1-10
214738567|NCT02737371|DRUG|Placebo dose level A oral|Placebo adverse events days 1-10
214738568|NCT02737371|DRUG|F901318 Dose level B oral|F901318 adverse events days 1-10
214738569|NCT02737371|DRUG|Placebo dose level B oral|Placebo adverse events days 1-10
214738570|NCT02737371|DRUG|F901318 Dose level C oral|F901318 adverse events days 1-10
214738571|NCT02737371|DRUG|Placebo Dose level C oral|Placebo adverse events days 1-10
214738572|NCT00261378|DEVICE|Transarterialchemoembolisation (TACE)|
214738573|NCT00261378|DEVICE|DC Bead with Doxorubicin|
214738574|NCT01406366|BEHAVIORAL|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
214738575|NCT01406366|BEHAVIORAL|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
214738576|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
214738577|NCT00095134|DRUG|risperidone|
214738578|NCT06980168|OTHER|kabat technique|kabat technique include diagonal movements to activate weak muscles through resistance . 3-5 repetetion per muscle for 2-3 sets .session conducted 5 days per week for three weeks each lasting 30 minutes .
214738579|NCT06980168|OTHER|facial nerve mobilization|neural mobilization involves manual traction and circular movement around ear to enhance nerve mobility and function .5-10 repetetions .Session conduted 5 days per week for 3 weeks lasting 30 minutes facial exercises include raising eyebrows-eye closure-lip raising-smiling-snarling flaring of nose-forehead wrinkling-lipspuckering-pouting. 5-10 repetetions 3 times a day .7 days for 3 weeks
214738580|NCT01021553|DRUG|GSK557296|50 mg GSK557296
214738581|NCT01021553|DRUG|GSK557296|150 mg GSK557296
214738582|NCT01021553|DRUG|placebo|placebo
214738583|NCT00006493|DRUG|Rosiglitazone|
214738584|NCT00997607|BIOLOGICAL|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
214738585|NCT00997607|BIOLOGICAL|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
214738586|NCT00997607|OTHER|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
214738587|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
214738588|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
214738589|NCT01579526|DRUG|FP01|comparison of different dosages
214738590|NCT02744781|DEVICE|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
214738591|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
214738592|NCT00033293|OTHER|Clinical Observation|Undergo observation
214738593|NCT00033293|DRUG|Cyclophosphamide|Given IV
214738594|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
214738595|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
214738596|NCT00033293|DRUG|Prednisone|Given orally
214738597|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
214738598|NCT00396344|OTHER|Çontrol|Intravenous saline
214738599|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
214738600|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
214738601|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
214738602|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
214738603|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
214738604|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
214738605|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
214738606|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
214738607|NCT01592942|DEVICE|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
214738608|NCT01592942|DEVICE|Progrip|self-gripping mesh
214738609|NCT01592942|DEVICE|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
214738610|NCT04488601|DRUG|Rapamycin|Rapamycin in 2 different dosage forms.
214738611|NCT04488601|DRUG|Placebo|Placebo capsules
214738612|NCT04853264|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
214738613|NCT04853264|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
214738614|NCT03938558|OTHER|MS-Dance|The experimental group will perform 10 weeks of dance training
214738615|NCT03938558|OTHER|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, …)
214738616|NCT02411006|BEHAVIORAL|Prediction mailing|Ask people to predict their upcoming medication adherence
214738617|NCT02411006|BEHAVIORAL|Commitment mailing|Ask people to commit to their upcoming medication adherence
214738618|NCT02411006|BEHAVIORAL|Reminder|Remind people to take their medicine
214738619|NCT02411006|BEHAVIORAL|Anonymity|Keep patient predictions and commitment anonymous
214738620|NCT02411006|BEHAVIORAL|Identification|Ask patients to report their predictions and commitments
214738621|NCT02087241|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
214738622|NCT02087241|DRUG|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
214738623|NCT02087241|DRUG|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
214738624|NCT02087241|DRUG|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
214738625|NCT00004127|DRUG|FOLFOX regimen|
214738626|NCT00004127|DRUG|fluorouracil|
214738627|NCT00004127|DRUG|leucovorin calcium|
214738628|NCT00004127|DRUG|oxaliplatin|
214738629|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
214738630|NCT01725919|BEHAVIORAL|CI therapy|constraint induced movement therapy
214738631|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
214738632|NCT01296464|DRUG|Carbidopa|Capsules
214738633|NCT06990828|OTHER|Frenkel Stabilization Exercises|Participants included in the study will undergo a program of Frenkel Stabilization Exercises.
214738634|NCT02181504|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
214738635|NCT02181504|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
214738636|NCT02181504|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
214738637|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
214738638|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
214738639|NCT03068182|OTHER|Exercise|
214738640|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
214738641|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
214738642|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
214738643|NCT04849260|BIOLOGICAL|Pexa-Vec combined with ZKAB001|"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."
214738644|NCT04849260|BIOLOGICAL|ZKAB001 monotherapy|ZKAB001 monotherapy
214738645|NCT02897011|DRUG|Methotrexate|
214738646|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
214738647|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
214738648|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
214738649|NCT02303470|BEHAVIORAL|Moderate Exercise|
214738650|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
214738651|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
214738652|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
214738653|NCT01825759|DRUG|danshen dripping pill|
214738654|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
214738655|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
214738656|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
214738657|NCT00169273|BEHAVIORAL|Structured behavioral weight loss group|Structured group weight loss program
214738658|NCT00169273|BEHAVIORAL|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
214738659|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
214738660|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
214738661|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
214738662|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
214738663|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
214738664|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
214738665|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
214738666|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
214738667|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
214738668|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
214738669|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
214738670|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
214738671|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
214738672|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
214738673|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
214738674|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
214738675|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
214738676|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
214644982|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
214644983|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
214644984|NCT05049603|DRUG|Atorvastatin 20mg|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
214644985|NCT05049603|OTHER|Placebo|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
214644986|NCT01906125|DRUG|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
214644987|NCT01906125|DRUG|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
214644988|NCT01906125|DRUG|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
214644989|NCT03437551|OTHER|cross-sectional observation|cross-sectional ophthalmic examination
214644990|NCT02239263|DEVICE|Nucleus 6 Sound Processor|
214644991|NCT02328898|DEVICE|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
214644992|NCT02328898|DEVICE|Resolute Integrity stent|
214644993|NCT03072160|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
214644994|NCT04926935|DIAGNOSTIC_TEST|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
214644995|NCT01717469|DEVICE|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
214644996|NCT01717469|DEVICE|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
214644997|NCT01091571|DRUG|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
214644998|NCT01091571|DRUG|Placebo|Placebo twice daily during seven consecutive days
214644999|NCT01091571|OTHER|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
214645000|NCT02287727|OTHER|Laboratory Biomarker Analysis|Correlative studies
214645001|NCT02287727|DRUG|Regorafenib|Given PO
214645002|NCT02866825|BIOLOGICAL|IFX-1|
214645003|NCT02866825|BIOLOGICAL|Placebo|
214645004|NCT03992625|DEVICE|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
214645005|NCT00822107|DRUG|Hydrochlorothiazide|50 mg one time
214738677|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
214738678|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
214738679|NCT00002102|DRUG|Trimetrexate glucuronate|
214738680|NCT00002102|DRUG|Leucovorin calcium|
214738681|NCT05327309|DRUG|Bleomycin|
214738682|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
214738683|NCT01322711|DRUG|Placebo|Diet
214738684|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
214738685|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
214738686|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
214738687|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
214738688|NCT02960802|PROCEDURE|kidney transplantation|
214738689|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
214738690|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
214738691|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
214738692|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
214738693|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
214738694|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
214738695|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
214738696|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
214738697|NCT05992051|BEHAVIORAL|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
214738698|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
214738699|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
214738700|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
214738701|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
214738702|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
214738703|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
214738704|NCT02528461|PROCEDURE|Gastroscopy|
214738705|NCT02528461|PROCEDURE|Liver biopsy|
214738706|NCT02528461|PROCEDURE|Fibroscan|
214738707|NCT02528461|PROCEDURE|Liver vein catheterization|
214738708|NCT02528461|DRUG|Sofosbuvir|
214738709|NCT03006952|DRUG|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
214738710|NCT03006952|DRUG|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
214738711|NCT00004795|DRUG|dehydroepiandrosterone|
214738712|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
214738713|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
214738714|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
214738715|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
214738716|NCT02325128|BEHAVIORAL|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
214738717|NCT05233319|OTHER|There is no intervention|There is no intervention
214738718|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
214738719|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
214738720|NCT06990776|DRUG|TQA3605 tablets Placebo|Placebo contains no active substance.
214738721|NCT06990776|DRUG|TQA3605 Tablets|TQA3605 tablets is core protein allosteric modulators
214738722|NCT06990776|DRUG|Entecavir dispersible tablets|Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.
214738723|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
214738724|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
214738725|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
214738726|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
214738727|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
214738728|NCT03200418|OTHER|P-4|This patch is made of new adhesive
214738729|NCT03200418|OTHER|P-15|This patch is made of new adhesive
214738730|NCT03200418|OTHER|P-16|This patch is made of new adhesive
214738731|NCT02223949|DEVICE|Cook double balloon catheter|
214738732|NCT02223949|DRUG|PGE1 tablet|
214738733|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
214738734|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
214738735|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
214738736|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
214738737|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
214738738|NCT04533360|DIAGNOSTIC_TEST|VITROS Anti-SARS-CoV-2 IgG test|The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
214738739|NCT01071941|BIOLOGICAL|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
214738740|NCT00389805|DRUG|bortezomib|
214738741|NCT00389805|DRUG|pemetrexed disodium|
214738742|NCT00389805|GENETIC|gene expression analysis|
214738743|NCT00389805|GENETIC|mutation analysis|
214738744|NCT00389805|GENETIC|protein expression analysis|
214738745|NCT00389805|GENETIC|reverse transcriptase-polymerase chain reaction|
214738746|NCT00389805|OTHER|flow cytometry|
214738747|NCT00389805|OTHER|immunoenzyme technique|
214738748|NCT00389805|OTHER|immunohistochemistry staining method|
214738749|NCT02558452|DRUG|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
214738750|NCT01677676|BIOLOGICAL|FP-01.1|IM injection
214738751|NCT01677676|BIOLOGICAL|FP-01.1-Adjuvant|IM injection
214738752|NCT05111184|BEHAVIORAL|Education groupe|Education
214738753|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
214738754|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
214738755|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
214738756|NCT01289028|DRUG|Nilotinib|
214738757|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
214738758|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
214738759|NCT01657214|DRUG|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
214738760|NCT06321640|GENETIC|Cohort A: primarily operable disease, candidate to adjuvant|This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint
214738761|NCT06321640|GENETIC|Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.
214738762|NCT06321640|GENETIC|Cohort C: metastatic disease|In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.
214738763|NCT06321640|GENETIC|Cohort D: Progressive disease|In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.
214738764|NCT06321640|GENETIC|Cohort E: Hematological neoplasms|Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.
214738765|NCT06321640|GENETIC|Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
214738766|NCT01709604|PROCEDURE|CVVH|Ultrafiltration at 35ml/h/Kg
214738767|NCT01709604|PROCEDURE|Standardized therapy regimens|"Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care"
214738768|NCT00382655|PROCEDURE|Education and referral|
214738769|NCT02980991|DRUG|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
214738770|NCT02980991|DRUG|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
214738771|NCT02120469|DRUG|everolimus|Given PO
214738772|NCT02120469|DRUG|eribulin mesylate|Given IV
214738773|NCT02120469|OTHER|pharmacological study|Correlative studies
214738774|NCT02120469|OTHER|laboratory biomarker analysis|Optional correlative studies
214738775|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
214738776|NCT04469257|BEHAVIORAL|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
214738777|NCT05391620|OTHER|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
214738778|NCT05391620|OTHER|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
214738779|NCT05570357|DIETARY_SUPPLEMENT|Berberine+Cinnamon (TDS)|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
214738780|NCT05570357|OTHER|Placebo (TDS)|Placebo contains Maltodexterin
214738781|NCT02597972|PROCEDURE|Fracture repair|
214738782|NCT02597972|PROCEDURE|Fracture repair with joint replacement|
214738783|NCT06124352|DIAGNOSTIC_TEST|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
214738784|NCT06124352|DIAGNOSTIC_TEST|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
214738785|NCT06124352|DIAGNOSTIC_TEST|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 \[24, 25\].
214738786|NCT00250029|DRUG|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
214738787|NCT01183481|DRUG|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
214738788|NCT01183481|RADIATION|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
214738789|NCT01183481|DRUG|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
214738790|NCT01725295|OTHER|NST|A form of physical therapy
214738791|NCT01725295|OTHER|Hydrotherapy|
214738792|NCT04454749|DIAGNOSTIC_TEST|Blood test|Mesurement of E2, P4, LH, FSH hormones
214738793|NCT04454749|DIAGNOSTIC_TEST|Ultrasound|Follicular measurement and endometrium measurement
214738794|NCT00122070|DRUG|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
214738795|NCT02591836|DRUG|Gemcabene|Gemcabene
214738796|NCT02591836|DRUG|Atorvastatin|Atorvastatin
214738797|NCT02591836|DRUG|Placebo|
214738798|NCT04168151|OTHER|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
214738799|NCT03952689|DEVICE|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
214738800|NCT00411840|PROCEDURE|intraarterial and intramuscular injection of BMCs|
214645006|NCT01243736|DRUG|Combination Prep|"combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
214738801|NCT01942395|BEHAVIORAL|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
214738802|NCT01942395|BEHAVIORAL|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
214738803|NCT01846208|DRUG|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
214645007|NCT03671928|OTHER|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
214645008|NCT03671928|OTHER|additional blood sample|for le group control, another blood sample is taken outside the usual care.
214645009|NCT01827631|DRUG|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
214645010|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
214645011|NCT04282031|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
214645012|NCT04282031|DRUG|Letrozole|Letrozole 2.5 mg once daily of a 28-day cycle
214738804|NCT01846208|DRUG|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
214738805|NCT05233423|DEVICE|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
214738806|NCT01424306|OTHER|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
214738807|NCT01424306|OTHER|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
214738808|NCT01424306|OTHER|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
214738809|NCT00369928|DRUG|PG-760564|100 mg BID, of oral PG-760564
214738810|NCT00369928|DRUG|Placebo dose|placebo, BID, oral for 12 weeks
214738811|NCT00369928|DRUG|PG-760564|25 mg BID, of oral PG-760564
214738812|NCT00193128|DRUG|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
214738813|NCT00193128|DRUG|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
214738814|NCT00193128|DRUG|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
214645013|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily of a 28-day cycle
214645014|NCT01835119|DRUG|gum|gum
214645015|NCT04808856|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic Hormone Injection 25u qd iv \*3d
214645016|NCT04808856|DRUG|Methylprednisolone Injection|Methylprednisolone Injection 40mg qd iv \*3d
214645017|NCT01058096|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
214645018|NCT01058096|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
214645019|NCT01500356|BEHAVIORAL|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
214645020|NCT01500356|BEHAVIORAL|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
214645021|NCT01500356|BEHAVIORAL|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
214645022|NCT00828282|DRUG|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
214645023|NCT05781828|DIAGNOSTIC_TEST|Detailed abdominal ultrasound|size of the liver and architecture, size of the spleen, presence or absence of ascites
214645024|NCT04658394|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
214645025|NCT01207557|BEHAVIORAL|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
214645026|NCT01207557|BEHAVIORAL|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
214645027|NCT03253588|PROCEDURE|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
214645028|NCT00309322|DRUG|Phentolamine Mesylate (NV-101)|
214645029|NCT04276207|DRUG|LY900014|Administered by CSII
214645030|NCT04276207|DRUG|Insulin Lispro|Administered by CSII
214645031|NCT02916940|DRUG|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
214645032|NCT01328795|OTHER|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
214645033|NCT06318845|DRUG|DHP2302R1|75 mg per dose, once daily
214645034|NCT06318845|DRUG|DHP2302R2|50 mg per dose, once daily
214645035|NCT04282005|PROCEDURE|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
214645036|NCT04282005|OTHER|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
214645037|NCT03067909|OTHER|CIED surgery|
214645038|NCT01949363|DRUG|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
214645039|NCT01463098|DRUG|E2006 1.0 mg|E2006 1.0 mg capsule.
214645040|NCT01463098|DRUG|E2006 2.5 mg|E2006 2.5 mg capsule.
214645041|NCT01463098|DRUG|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
214645042|NCT01463098|DRUG|E2006 10.0 mg|E2006 10.0 mg capsule.
214645043|NCT01463098|DRUG|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
214645044|NCT01463098|DRUG|E2006 50.0 mg|E2006 50.0 mg capsule.
214645045|NCT01463098|DRUG|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
214645046|NCT01463098|DRUG|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
214645047|NCT01463098|DRUG|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
214645048|NCT01463098|DRUG|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
214645049|NCT01463098|DRUG|E2006 Matched Placebo|E2006-matched placebo capsule.
214645050|NCT05812664|OTHER|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
214645051|NCT05812664|PROCEDURE|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
214738815|NCT00193128|RADIATION|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
214738816|NCT02812394|DRUG|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
214738817|NCT02812394|DRUG|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
214738818|NCT02812394|DRUG|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
214738819|NCT04460300|OTHER|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
214738820|NCT04460300|OTHER|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
214738821|NCT00004056|BIOLOGICAL|filgrastim|
214738822|NCT00004056|DRUG|asparaginase|
214645052|NCT05812664|PROCEDURE|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
214645053|NCT02870361|DRUG|intranasal insulin|
214645054|NCT02870361|DRUG|Placebo|
214645055|NCT01417845|BEHAVIORAL|High Intensity Exercise Training|"* High intensity resistance and aerobic training~* Resistance training is performed 2 days per week for 3 months~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
214645056|NCT01417845|BEHAVIORAL|Moderate Intensity Exercise Training|"* Moderate intensity resistance and aerobic training~* Resistance training is performed on 2 days per week for 3 months.~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
214645057|NCT01891331|DRUG|VT-1161|
214645058|NCT01891331|DRUG|Fluconazole|
214645059|NCT03648632|RADIATION|Stereotactic Radiotherapy|Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
214645060|NCT04451330|DRUG|Trifarotene cream|Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
214645061|NCT04451330|DRUG|Doxycycline hyclate|Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
214645062|NCT04451330|DRUG|Trifarotene Vehicle|Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
214645063|NCT04451330|DRUG|Doxycycline Placebo|Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
214645064|NCT02769624|DRUG|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
214645065|NCT02769624|DRUG|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
214645066|NCT05135832|DEVICE|Electronic patient-reported outcomes regarding symptoms and health-related quality of life|"Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.~The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes."
214645067|NCT05099640|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
214645068|NCT05099640|DRUG|Placebo|Placebo matching to PTC923
214645069|NCT02218918|BEHAVIORAL|Ground walk training|3 times a week and 6 weeks
214645070|NCT02218918|BEHAVIORAL|Supervised Treadmill Walk training|3 times a week and 6 weeks
214645071|NCT04844255|DIETARY_SUPPLEMENT|dietary salt|2 grams of dietary salt
214645072|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
214738823|NCT00004056|DRUG|cytarabine|
214645073|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
214645074|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
214645075|NCT00097357|DRUG|Apixaban|Tablets, Oral, 12 +/- 2 days
214645076|NCT00097357|DRUG|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
214645077|NCT00097357|DRUG|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
214645078|NCT00097357|DRUG|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
214645079|NCT00097357|DRUG|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
214645080|NCT03342950|DRUG|Topical Solution|Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
214645081|NCT03342950|DRUG|Placebos|Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
214645082|NCT00000704|DRUG|Zalcitabine|
214645083|NCT00179959|DRUG|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
214645084|NCT00179959|DRUG|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
214645085|NCT00179959|DRUG|Water|Water baths twice weekly for three months
214645086|NCT00179959|DRUG|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
214645087|NCT02287987|PROCEDURE|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
214645088|NCT02287987|PROCEDURE|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
214645089|NCT00135460|DRUG|nucleoside analogue sparing HAART regimen|
214645090|NCT05590520|PROCEDURE|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
214645091|NCT05590520|DRUG|GTN OINTMENT|0.2%GTN applied on anal canal.
214645092|NCT01592201|DRUG|Paliperdidone ER|Form = osmotic release oral system, route = oral
214645093|NCT01592201|DRUG|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
214645094|NCT04123158|DIAGNOSTIC_TEST|Ultrasound|"Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]"
214645095|NCT04123158|DIAGNOSTIC_TEST|MRI|"Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity \[relative to myometrium\] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI \[SItumour - SImyometrium / SImyometrium\]"
214645096|NCT06528275|OTHER|Health promotion intervention|Health promotion intervention with activites linked to nutrition, and distribution of baskets of fresh fruits and vegetables
214645097|NCT03942432|OTHER|Oral Glucose Tolerance Test (OGTT)|Blood samples at T0, T30min, T120min
214645098|NCT03942432|OTHER|Clinical exam|weight, length, waist measurement, cardiac frequency, blood pressure
214645099|NCT03942432|BIOLOGICAL|Blood sample|Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
214645100|NCT03942432|DEVICE|MRI|3 Tesla abdominal MRI
214645101|NCT03942432|DEVICE|Bioimpedance|Measurement of body composition
214645102|NCT03942432|BEHAVIORAL|Questionnaires|Quality of life, physical activity, alcohol consumption and eating habits
214645103|NCT05169528|OTHER|Colorectal Cancer Prehabilitation Programme|Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
214645104|NCT04075331|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection
214645105|NCT04075331|DRUG|Placebo|Saline solution for subcutaneous injection
214645106|NCT05417854|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
214645107|NCT06356233|OTHER|No intervention will be performed|No intervention will be performed
214645108|NCT03220672|BEHAVIORAL|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
214645109|NCT06351930|BEHAVIORAL|CBT-I + UC group|Refer to the arm description
214645110|NCT00448708|DEVICE|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm\^2 paclitaxel
214645111|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
214645112|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
214645113|NCT05883280|OTHER|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
214645114|NCT00928421|DRUG|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
214645115|NCT03288909|OTHER|MRI|
214645116|NCT05152940|DRUG|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
214645117|NCT05152940|DRUG|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
214645118|NCT01356004|DRUG|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
214645119|NCT01356004|DRUG|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
214645120|NCT03932552|OTHER|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
214645121|NCT03932552|OTHER|nutritional therapy|individualised nutritional intervention
214645122|NCT00236080|DRUG|PROVIGIL 200 mg|PROVIGIL 200 mg/day
214645123|NCT00236080|DRUG|Armodafinil 250 mg|Armodafinil 250 mg/day
214645124|NCT00236080|DRUG|Armodafinil 200 mg|Armodafinil 200 mg/day
214645125|NCT00236080|DRUG|Armodafinil 150 mg|Armodafinil 150 mg/day
214645126|NCT00236080|DRUG|Placebo|Matching placebo tablets
214645127|NCT02400255|DRUG|Crenolanib besylate|
214738824|NCT00004056|DRUG|daunorubicin hydrochloride|
214738825|NCT00004056|DRUG|melphalan|
214738826|NCT00004056|DRUG|thioguanine|
214738827|NCT00004056|PROCEDURE|peripheral blood stem cell transplantation|
214738828|NCT03344562|DEVICE|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
214738829|NCT03344562|DEVICE|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
214645128|NCT02881034|DRUG|Triple therapy|
214645129|NCT00599417|DRUG|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
214645130|NCT00599417|DRUG|placebo|placebo controlled
214645131|NCT06076668|DRUG|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
214738830|NCT02717429|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
214738831|NCT02717429|BEHAVIORAL|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
214738832|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
214738833|NCT01329172|OTHER|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
214738834|NCT01329172|OTHER|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
214645132|NCT06076668|DRUG|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
214645133|NCT06076668|DRUG|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
214645134|NCT05709808|OTHER|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
214645135|NCT05709808|OTHER|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
214645136|NCT05709808|OTHER|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
214645137|NCT02697942|OTHER|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
214645138|NCT02697942|OTHER|exercise training|The investigators will provide participants with foot peddlers.
214645139|NCT01423539|DRUG|bendamustine|Intravenous repeating dose\\n
214645140|NCT01423539|DRUG|navitoclax|Oral repeating dose\\n
214645141|NCT01423539|DRUG|rituximab|Intravenous repeating dose\\n
214645142|NCT00602355|DRUG|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
214645143|NCT00602355|DRUG|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
214645144|NCT00602355|BEHAVIORAL|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
214645145|NCT00602355|BEHAVIORAL|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
214738835|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
214738836|NCT01555541|DRUG|Ofatumumab|1000 mg IV days 0, 7, 14, 21
214738837|NCT01555541|DRUG|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
214738838|NCT01555541|DRUG|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
214738839|NCT03381352|RADIATION|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
214738840|NCT03381352|DRUG|Capecitabine|Capecitabine 825mg/m2 PO BID
214738841|NCT03381352|DRUG|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
214738842|NCT05813405|OTHER|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
214738843|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
214738844|NCT03894267|DEVICE|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
214738845|NCT01755390|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
214738846|NCT02463331|DRUG|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
214738847|NCT02463331|DRUG|prednisone|Prednisone 5-15 mg/day until the end of the study
214738848|NCT02463331|DRUG|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
214738849|NCT06259604|OTHER|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
214738850|NCT06259604|OTHER|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
214738851|NCT05976906|BIOLOGICAL|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
214738852|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
214738853|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
214738854|NCT00086242|BEHAVIORAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
214738855|NCT01437059|DRUG|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
214738856|NCT01437059|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214738857|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
214738858|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
214738859|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
214738860|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
214738861|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
214738862|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
214738863|NCT02227433|DRUG|Brentuximab Vedotin|
214738864|NCT02339454|DEVICE|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
214738865|NCT02339454|DEVICE|Placebo group|Placebo Applicator
214738866|NCT04770428|DRUG|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
214738867|NCT04770428|DRUG|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
214738868|NCT03184766|DRUG|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
214738869|NCT03184766|DRUG|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
214738870|NCT03184766|DRUG|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
214738871|NCT02274766|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
214738872|NCT02274766|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
214738873|NCT03817931|DRUG|Anticholinergic|Tablet taken once daily.
214738874|NCT03817931|DRUG|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
214738875|NCT03817931|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
214738876|NCT03817931|DIAGNOSTIC_TEST|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
214738877|NCT02902692|OTHER|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
214738878|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
214738879|NCT04526444|OTHER|Online training|Les Mills On Demand
214738880|NCT04526444|OTHER|Peer support via social media|Facebook group
214738881|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
214738882|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
214738883|NCT04807244|PROCEDURE|Selective Caries Removal with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
214738884|NCT04807244|PROCEDURE|Partial Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
214738885|NCT04807244|PROCEDURE|Full Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
214645146|NCT00602355|BEHAVIORAL|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
214645147|NCT01653119|DRUG|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
214645148|NCT02159027|DRUG|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
214645149|NCT02159027|DRUG|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
214645150|NCT03604445|DRUG|BI 905677|Solution for infusion
214645151|NCT01815645|BEHAVIORAL|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
214645152|NCT01815645|BEHAVIORAL|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
214645153|NCT00130286|DRUG|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
214645154|NCT00130286|DRUG|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
214645155|NCT02468336|DEVICE|AngioDefender|
214645156|NCT02468336|DEVICE|Ultrasound|
214645157|NCT06386848|DRUG|Botulinum toxin|Botulinum toxin doses injected in dystonia
214645158|NCT04059744|DEVICE|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
214645159|NCT00055666|DRUG|beclomethasone dipropionate|
214645160|NCT04278911|DIAGNOSTIC_TEST|MMSE and MoCA|This is an observational study. All the patients evaluate with MMSE (Mini-mental State Examination) and MoCA (Montreal Cognitive Assessment), and investigate the incidence and characteristics of cognitive and MACE
214645161|NCT02580331|DRUG|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
214645162|NCT02580331|DRUG|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
214645163|NCT01558063|DRUG|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
214645164|NCT01558063|DRUG|Saline|Single infusion of saline given intravenously over 40 minutes.
214645165|NCT01558063|PROCEDURE|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
214645166|NCT05953792|PROCEDURE|Select the vertebra above sagittal stable vertebra as the distal fusion level|The surgeries were performed by the same surgical team. Multi-level Ponte osteotomies were performed across the apex of the kyphosis after complete exposure of the spine, with resection of supra- and inter-spinous ligaments, ligamentum flavum, and the whole facet joints. After placement of the pedicle screws at the expected fusion levels, pre-contoured rods were attached to the screws followed by segmental compression. During rod placement, two to three rounds of compression in the area with Ponte osteotomies were employed to enhance kyphosis correction. Satellite rods were routinely added to long rods and implanted with duet screws. The final tightening was performed, and the posterior fusion was completed with a mixture of local and allogeneic bone. Due attention was given to preserving the posterior ligamentous structures at the upper and lower junctional areas.
214645167|NCT01154933|DRUG|exenatide 5 mcg|exenatide 5 mcg
214645168|NCT01154933|DRUG|exenatide 10 mcg|exenatide 10 mcg
214645169|NCT01154933|DRUG|placebo|saline sq
214645170|NCT03777683|DIETARY_SUPPLEMENT|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
214645171|NCT03777683|OTHER|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
214645172|NCT00191516|DRUG|Atomoxetine|
214645173|NCT03365778|OTHER|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
214645174|NCT03365778|OTHER|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
214645175|NCT03365778|OTHER|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
214645176|NCT01753908|DRUG|Broccoli Sprout Extract|Given PO
214645177|NCT01753908|OTHER|Laboratory Biomarker Analysis|Correlative studies
214645178|NCT01753908|OTHER|Pharmacological Study|Urinary ITCs and metabolites measured
214645179|NCT01753908|OTHER|Placebo|Given PO
214645180|NCT00308607|DRUG|Bevacizumab (Avastin)|
214645181|NCT00308607|DRUG|dacarbazine|
214645182|NCT00308607|DRUG|interferon-alfa-2a (Roferon-A)|
214645183|NCT00713219|RADIATION|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
214738886|NCT04807244|PROCEDURE|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
214738887|NCT06178458|OTHER|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
214738888|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
214738889|NCT04905836|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
214738890|NCT04905836|DRUG|Placebo|Excipient solution
214738891|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
214738892|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
214738893|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
214738894|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
214645184|NCT02012530|PROCEDURE|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
214645185|NCT02012530|PROCEDURE|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
214645186|NCT03867630|PROCEDURE|Transforaminal Block|Epidural block via neural foramen of lumbar spine
214645187|NCT01769755|BIOLOGICAL|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
214645188|NCT01769755|DRUG|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
214645189|NCT05410288|DEVICE|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
214645190|NCT05410288|OTHER|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
214645191|NCT05410288|OTHER|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
214645192|NCT05410288|OTHER|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
214645193|NCT01580930|BEHAVIORAL|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
214645194|NCT01580930|BEHAVIORAL|sedentary time reduction|participants provided with strategies to decrease sitting
214738895|NCT01620437|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
214738896|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
214738897|NCT02334137|BEHAVIORAL|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
214738898|NCT02334137|BEHAVIORAL|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
214738899|NCT02334137|BEHAVIORAL|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
214738900|NCT02378610|OTHER|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
214738901|NCT06423001|DIETARY_SUPPLEMENT|PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.|Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).
214738902|NCT04959786|DRUG|Ivermectin,ribavirin ,nitazoxanide and zinc|oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
214738903|NCT04582162|OTHER|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
214738904|NCT04582162|OTHER|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
214738905|NCT01212120|BIOLOGICAL|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
214738906|NCT06375694|DIETARY_SUPPLEMENT|Herbiotics Oral + Ent Probiotic|Chewable Tablets containing Lactobacillus species.
214738907|NCT06375694|DIETARY_SUPPLEMENT|Placebo|Honest Placebo Pills by Zeebo
214738908|NCT04051489|OTHER|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
214738909|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
214738910|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
214738911|NCT02590406|PROCEDURE|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
214738912|NCT02590406|PROCEDURE|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
214738913|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
214738914|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
214738915|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
214738916|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
214738917|NCT02907801|BEHAVIORAL|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
214738918|NCT02349776|OTHER|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
214738919|NCT00302575|BEHAVIORAL|Collaborative Behavioral Management|
214738920|NCT00302575|PROCEDURE|Integrated parole and outpatient addiction treatment|
214738921|NCT06064552|DIAGNOSTIC_TEST|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
214738922|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
214738923|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
214738924|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
214738925|NCT06117956|DIAGNOSTIC_TEST|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
214738926|NCT05129111|DEVICE|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
214738927|NCT03821350|OTHER|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
214738928|NCT01758640|DRUG|Warfarin|Low dose warfarin of 5mg or less per day
214738929|NCT01758640|DRUG|phenindione|Phenindione of 100mg or less per day
214738930|NCT04812665|BEHAVIORAL|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
214738931|NCT02652572|DRUG|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
214738932|NCT03486769|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
214738933|NCT03486769|DEVICE|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
214738934|NCT03486769|DEVICE|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
214738935|NCT03486769|BEHAVIORAL|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
214738936|NCT05057884|BEHAVIORAL|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
214645195|NCT01580930|BEHAVIORAL|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
214645196|NCT00215605|DRUG|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
214645197|NCT00132067|DRUG|vorinostat|Given orally
214645198|NCT02899858|OTHER|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
214645199|NCT02899858|OTHER|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
214645200|NCT02899858|PROCEDURE|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
214645201|NCT02899858|OTHER|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
214645202|NCT02899858|OTHER|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
214645203|NCT02899858|OTHER|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
214645204|NCT01295060|DRUG|Octreotide|84 mg Octreotide Implant
214738937|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
214738938|NCT01930669|OTHER|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
214738939|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
214738940|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
214738941|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
214738942|NCT06220240|OTHER|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
214738943|NCT06220240|OTHER|Routine Training Programme|A routine training program will be used.
214738944|NCT00859716|BIOLOGICAL|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
214738945|NCT00859716|BIOLOGICAL|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
214738946|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
214738947|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
214738948|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
214738949|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
214645205|NCT02185378|PROCEDURE|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
214645206|NCT02185378|PROCEDURE|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
214645207|NCT00880256|BEHAVIORAL|mindfulness-based stress reduction|An 8-week course in mindfulness training
214645208|NCT02218229|DEVICE|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
214645209|NCT01820715|DRUG|600㎍ of DA-3030 Injection|
214645210|NCT01820715|DRUG|Placebo|
214645211|NCT04405219|OTHER|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
214645212|NCT05963763|BEHAVIORAL|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs."
214645213|NCT05825872|PROCEDURE|internal superior laryngeal nerve block|"A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly"
214645214|NCT05825872|DRUG|Lidocaine 2% Injectable Solution|0.5 ml will be injected
214645215|NCT05825872|DRUG|Bupivacaine 0.5% Injectable Solution|1.5 ml will be injected
214645216|NCT05836376|PROCEDURE|Mitral valve annuloplasty|implantation of a prosthetic ring to treat mitral valve regurgitation
214645217|NCT03285256|BEHAVIORAL|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
214645218|NCT03285256|BEHAVIORAL|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
214645219|NCT03285256|BEHAVIORAL|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
214645220|NCT05644171|DEVICE|RESToration Of Rehabilitative function with Epidural spinal Stimulation|Three patients with chronic motor SCI will be recruited in total for this study. The recruited patients will not be randomized nor blinded due to the nature of this study. Pre-op rehabilitation session will take place over 4 weeks. 1 month post-surgical implants, patients will undergo 24 weeks of rehabilitation. The training sessions may continue to take place after the stipulated 24 weeks as long the electrode remains implanted, and the patient is available.
214645221|NCT05443204|OTHER|Fortimel energy|Standard nutritional oral supplement
214645222|NCT05443204|OTHER|Nutrision Advanced Diason Energy HP|Specifc nutritional oral supplement in diabetics patients
214645223|NCT03488160|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
214645224|NCT04669990|DRUG|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
214645225|NCT01549548|DRUG|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
214645226|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~* The American Cancer Society~* The American Academy of Dermatology~* The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~* Sun protection practices~* Risk factors for melanoma~* Information about what melanoma looks like~* How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
214738950|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
214738951|NCT00921908|OTHER|2 mBq radioactive technetium diluted in 20 mL saline|
214738952|NCT04448340|DIAGNOSTIC_TEST|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
214738953|NCT02036476|DRUG|Cabozantinib|oral administration
214738954|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
214738955|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
214738956|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
214738957|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
214738958|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
214738959|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
214738960|NCT05956990|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
214738961|NCT02034539|DEVICE|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
214738962|NCT02227290|DRUG|Naftin Cream|
214738963|NCT02227290|DRUG|Placebo Cream|
214738964|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
214738965|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
214738966|NCT02523742|DEVICE|IMRf|
214738967|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
214738968|NCT03113799|DEVICE|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
214738969|NCT00688389|OTHER|case/control|case: infected dengue fever people control:healthy people
214738970|NCT01660529|BIOLOGICAL|hTERT|
214738971|NCT03708029|OTHER|Revita Allograft|Human placental allograft
214738972|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
214738973|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
214738974|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
214738975|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
214738976|NCT00005054|DRUG|temozolomide|
214738977|NCT02985684|DEVICE|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
214738978|NCT07052591|BEHAVIORAL|Zumba Exercise|Participants in the Zumba Exercise group engaged in supervised aerobic dance sessions lasting 60 minutes, twice per week, over an 8-week period. The exercise intensity was set to match aerobic-level activity suitable for improving body composition, muscle strength, and balance. Sessions included warm-up, main Zumba dance routines, and cool-down phases, all conducted by certified instructors.
214738979|NCT07052591|OTHER|Control Group|Participants in this arm did not receive any structured exercise intervention. They continued their usual daily activities throughout the 8-week study period. No physical training or behavioral program was applied.
214738980|NCT07052656|OTHER|Observational study, participants are not assigned an intervention as part of the study.|Observational study, participants are not assigned an intervention as part of the study.
214738981|NCT07052656|OTHER|Transport modality|Transfer modality to tertiary centers
214738982|NCT07053397|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs).~It has a wide range of use for postoperative pain management in trauma surgery, cardiac surgery, thoracic surgery and breast surgery."
214738983|NCT07053397|PROCEDURE|DSAPB|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs). Following hydrodissection between the serratus anterior and intercostal muscles, a single-shot injection is administered. Subsequently, a peripheral nerve block catheter is placed in the same region under ultrasound guidance."
214738984|NCT07058610|DEVICE|Amplifi Vein Dilation System|An investigational extracorporeal blood pump and catheter system designed to promote vein dilation prior to AVF creation.
214738985|NCT07058181|BEHAVIORAL|Meaning-centered intervention for individuals who tend to feel down or anxious|"Meaning-centered intervention for internalizing symptoms adapted from the intervention Meaning-centered intervention for youth worrying about their weight and shape.~* Six 1-hour individual online sessions, approximately every 4 days~* Sessions led by a certified trainer based on intervention manual~* Four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* Participants follow intervention using intervention workbook~* Homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
214738986|NCT07059416|BEHAVIORAL|Oncology nurses carried out hand hygiene awareness activities with positive affirmation words and breathing exercises while washing hands or providing hand hygiene with hand antiseptic.|positive affirmation, focus on the moment
214738987|NCT07059390|BEHAVIORAL|Nature Immersion Therapy|During the length of inpatient stay at Changi General Hospital (CGH), which ranges from 5 to 10 days, the patients and caregivers will be enrolled for a set of 3 nature-based sessions. Each session will be conducted in groups of 4 to 6 patients incorporating a relational multi-sensory experience as well as mind-body connectedness while spending time in nature. Each of the 3 sessions will be 45 minutes each. The nature-based therapy/green social prescription plan will be conducted in groups guided by a trained CGH staff (Allied Health Professionals/Nurse). This Green social prescribing plan (Playbook) will be integrated into inpatient's care plan. Caregivers of the enrolled patients will also be part of the therapy group following the necessary consent.
214738988|NCT01749865|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
214738989|NCT06105541|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
214738990|NCT01436357|BIOLOGICAL|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
214738991|NCT01436357|BIOLOGICAL|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
214738992|NCT01436357|OTHER|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
214738993|NCT04626050|BEHAVIORAL|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
214738994|NCT04626050|BEHAVIORAL|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
214738995|NCT04626050|BEHAVIORAL|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
214738996|NCT04626050|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
214738997|NCT06287749|BIOLOGICAL|Blood sample/Liquid Biopsy|ctDNA analysis
214645227|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~* Melanoma and skin cancer protection guidelines~* The benefits of skin screening practices~* Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
214645228|NCT00816374|OTHER|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment"
214645229|NCT00055952|DRUG|exatecan mesylate|
214645230|NCT04267211|OTHER|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
214645231|NCT04267211|OTHER|Standard Prenatal Consult|Standard prenatal consult
214645232|NCT00760981|DRUG|Imatinib|The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
214645233|NCT04434352|DEVICE|Storz Duolith Low-Intensity Shockwave Therapy|"A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete."
214645234|NCT00903279|DRUG|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
214738998|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
214738999|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
214645235|NCT00903279|DRUG|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
214645236|NCT06381661|DRUG|Tocilizumab|8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
214645237|NCT06381661|DRUG|Baricitinib|4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
214645238|NCT06381661|DRUG|Anakinra|100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
214645239|NCT06381661|DRUG|Hydrocortisone|50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
214645240|NCT06381661|DRUG|Hydrocortisone and fludrocortisone|Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
214739000|NCT04936529|DIETARY_SUPPLEMENT|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
214739001|NCT04936529|DRUG|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
214739002|NCT04936529|BIOLOGICAL|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
214739003|NCT07087769|BEHAVIORAL|Treadmill Walking with Split-Belt and/or Tied-Belt Conditions|Participants will walk on an instrumented treadmill under split-belt and/or tied-belt conditions depending on their walking capacity. The belt speeds will be adjusted to facilitate locomotor adaptation and evaluate propulsion symmetry.
214739004|NCT07087769|BEHAVIORAL|Mechanical Resistance (Pelvis and/or Ankle) depending on participant's walking capacity|Participants will walk on a treadmill (Split-belt and/or Tied-belt) with backward-directed resistance applied at the pelvis, ankle, or both. The resistance is used to challenge paretic leg propulsion and assess adaptive gait responses.
214739005|NCT07087769|BEHAVIORAL|Sensory Feedback Training|Real-time feedback-visual, auditory, or combined-will be provided based on the propulsive force generated during split-belt and/or tied-belt treadmill walking, with or without mechanical resistance.
214739006|NCT01841086|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
214739007|NCT01841086|DRUG|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
214739008|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
214739009|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
214739010|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
214739011|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
214739012|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214739013|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
214739014|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
214739015|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214739016|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
214739017|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
214739018|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
214739019|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
214739020|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
214739021|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
214739022|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
214739023|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
214739024|NCT06443177|DEVICE|Sham|No electrode is placed.
214739025|NCT04794075|OTHER|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
214739026|NCT05315297|DEVICE|PEMF device|PEMF device wear overnight daily for four weeks
214739027|NCT05315297|DEVICE|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
214739028|NCT05949632|DRUG|INCB099280|Administered as specified in the treatment arm description
214739029|NCT05949632|DRUG|axitinib|Administered as specified in the treatment arm description
214739030|NCT05524584|DRUG|Fulvestrant|Given intramuscularly
214739031|NCT05524584|DRUG|Anastrozole|Given orally
214739032|NCT05524584|DRUG|Abemaciclib|Given orally
214739033|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
214739034|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
214739035|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
214739036|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
214739037|NCT00396968|DRUG|AMD3100|
214739038|NCT00396968|PROCEDURE|Allogeneic Stem Cell Transplantation|
214739039|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
214739040|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
214739041|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
214739042|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
214739043|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
214739044|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
214739045|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
214739046|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
214739047|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
214739048|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
214739049|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
214739050|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
214739051|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
214739052|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
214739053|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
214739054|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
214739055|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
214739056|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
214645241|NCT06381661|DRUG|Heparin|Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
214645242|NCT06381661|DRUG|Low molecular weight heparin|Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
214645243|NCT06381661|DRUG|Recombinant humanThrombomodulin( rhTM)|Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
214645244|NCT06381661|DRUG|Sivelestat|0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)
214645245|NCT06381661|BIOLOGICAL|Fresh frozen plasma|12 ml/kg/day as long as INR remains \>1.4
214645246|NCT06381661|OTHER|Usual care|Usual care
214645247|NCT05436548|OTHER|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
214645248|NCT05436548|OTHER|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
214645249|NCT00603135|DRUG|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
214645250|NCT03183544|COMBINATION_PRODUCT|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
214645251|NCT05057455|PROCEDURE|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
214645252|NCT05772897|BEHAVIORAL|Circle of Security Parenting program|The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
214645253|NCT03504202|DRUG|Trimetazidine|After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
214645254|NCT03336502|DRUG|Posaconazole|Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
214645255|NCT04326634|OTHER|controlled exercises|controlled exercises
214645256|NCT04326634|OTHER|non controlled exercises group|non controlled exercises
214739057|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
214739058|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
214739059|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
214739060|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
214739061|NCT03607461|DEVICE|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
214739062|NCT03607461|COMBINATION_PRODUCT|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
214739063|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
214739064|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
214739065|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
214739066|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
214739067|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
214739068|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
214739069|NCT04607291|OTHER|Survey Administration|Ancillary studies
214739070|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
214739071|NCT04547127|DRUG|Standard Medical Treatment|SMT
214739072|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
214739073|NCT04330794|OTHER|NMFACT|caries index
214739074|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
214739075|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
214645257|NCT03409874|OTHER|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
214645258|NCT03409874|OTHER|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
214645259|NCT03409874|OTHER|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
214645260|NCT03409874|DRUG|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
214645261|NCT03409874|OTHER|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
214645262|NCT04497519|DRUG|inhaled hydroxychloroquine|ascending dose of iHCQ
214645263|NCT04568564|OTHER|Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.
214645264|NCT04568564|OTHER|Exercise booklet|Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.
214645265|NCT03746561|DIAGNOSTIC_TEST|deep learning|detect and classify spinal stenosis by deep learning
214739076|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
214739077|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
214739078|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
214739079|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
214739080|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
214739081|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
214739082|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
214739083|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
214739084|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
214739085|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
214739086|NCT02134912|DRUG|crizotinib|Given PO
214739087|NCT02134912|DRUG|pemetrexed disodium|Given IV
214739088|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
214739089|NCT02134912|OTHER|pharmacological study|Correlative studies
214739090|NCT00184366|DRUG|efalizumab|efalizumab
214739091|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
214739092|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
214739093|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
214739094|NCT00561067|DRUG|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
214739095|NCT00561067|DRUG|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
214739096|NCT00478530|PROCEDURE|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
214739097|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
214739098|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
214739099|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
214739100|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
214739101|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
214739102|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
214739103|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
214739104|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
214739105|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
214739106|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
214739107|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
214739108|NCT04829591|OTHER|observational|Heart failure, non interventional
214739109|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
214739110|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
214739111|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
214739112|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
214739113|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2\. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
214739114|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
214739115|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
214739116|NCT03272009|DRUG|Entecavir|Tablets administered orally
214739117|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
214739118|NCT03309722|OTHER|biomarker study|
214739119|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
214739120|NCT06292026|OTHER|standard of care|apply non adherent dressing
214739121|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
214739122|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
214739123|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
214739124|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
214739125|NCT02033252|DEVICE|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
214739126|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
214739127|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
214739128|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
214739129|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
214739130|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
214739131|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
214739132|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
214739133|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
214739134|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
214739135|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
214739136|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
214739137|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
214739138|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
214739139|NCT01228084|OTHER|Pharmacological study|Correlative studies
214739140|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
214739141|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
214739142|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
214739143|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
214739144|NCT02367157|PROCEDURE|Kenzo Kase Method|
214739145|NCT02367157|DEVICE|Kinesio Taping|
214739146|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
214739147|NCT00340938|PROCEDURE|Blood testing|
214739148|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
214739149|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
214739150|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
214739151|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
214739152|NCT01520727|DRUG|Placebo|single-dose
214739153|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
214739154|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
214739155|NCT02182505|DRUG|Berodual® Respimat®, low dose|
214739156|NCT02182505|DRUG|Berodual® Respimat®, high dose|
214739157|NCT02182505|DRUG|Berodual® MDI|
214739158|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
214739159|NCT04844970|DRUG|Placebo|Anamorelin placebo
214739160|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
214739161|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
214739162|NCT03597789|BEHAVIORAL|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
214739163|NCT04145193|DRUG|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
214739164|NCT04145193|DRUG|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
214739165|NCT04145193|DRUG|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
214739166|NCT04145193|DRUG|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
214739167|NCT04989140|DRUG|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
214739168|NCT03061149|OTHER|Low-level laser therapy|
214739169|NCT03061149|OTHER|Ultrasound treatment|
214739170|NCT05352321|DRUG|Gemcitabine|for induction chemotherapy
214739171|NCT05352321|DRUG|Cisplatin|for induction and concurrent chemotherapy
214739172|NCT05352321|RADIATION|regular intensity-modulated radiotherapy|in active comparator arm
214739173|NCT05352321|PROCEDURE|surgery|in experimental arm
214739174|NCT05352321|RADIATION|Target-reduction intensity-modulated radiotherapy|in experimental arm
214739175|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
214739176|NCT00440102|DRUG|Ketamine|Ketamine
214739177|NCT00440102|DRUG|Etomidate|Etomidate
214739178|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
214739179|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
214739180|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
214739181|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
214739182|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
214739183|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
214739184|NCT05847387|DIAGNOSTIC_TEST|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
214739185|NCT05613491|DRUG|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
214739186|NCT05613491|DRUG|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
214739187|NCT02777034|OTHER|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
214739188|NCT02777034|OTHER|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
214739189|NCT01430364|DEVICE|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
214739190|NCT01430364|DEVICE|BIOSS Lim|
214739191|NCT01430364|DEVICE|CarloS|
214739192|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
214739193|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
214739194|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
214739195|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
214739196|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
214739197|NCT03442933|OTHER|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
214739198|NCT03442933|OTHER|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
214739199|NCT03011424|DEVICE|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
214739200|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
214739201|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
214739202|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
214739203|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
214739204|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
214739205|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
214739206|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
214739207|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
214739208|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
214739209|NCT04220645|OTHER|Standard of care|Referral at discharge
214739210|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
214739211|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
214739212|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
214739213|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
214739214|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
214739215|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
214739216|NCT02169466|DRUG|Placebo|PLC, Placebo
214739217|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
214739218|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
214739219|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
214739220|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
214739221|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
214739222|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
214739223|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
214739224|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
214739225|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
214739226|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
214739227|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
214739228|NCT00171327|DRUG|valsartan, fluvastatin|
214739229|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
214739230|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
214739231|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
214739232|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
214739233|NCT03564210|BEHAVIORAL|Screen time permitted|Cohort will not be directed to abstain from screen time
214739234|NCT03564210|BEHAVIORAL|Screen Time Abstain|Cohort will be directed to abstain from screen time
214739235|NCT05143645|OTHER|Plasma vancoymcin measurements|
214739236|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
214739237|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
214739238|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
214739239|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
214739240|NCT00436722|DRUG|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
214739241|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
214739242|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
214739243|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
214739244|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
214739245|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
214739246|NCT00006037|DRUG|fluorouracil|
214739247|NCT00006037|DRUG|irinotecan hydrochloride|
214739248|NCT00006037|DRUG|oglufanide disodium|
214739249|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
214739250|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
214739251|NCT04241536|PROCEDURE|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
214739252|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
214739253|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
214739254|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
214739255|NCT00003958|DRUG|vincristine sulfate|Given IV
214739256|NCT00003958|DRUG|cyclophosphamide|Given IV
214739257|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214739258|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
214739259|NCT00003958|DRUG|topotecan hydrochloride|Given IV
214739260|NCT00003958|BIOLOGICAL|filgrastim|Given SC
214739261|NCT00003958|BIOLOGICAL|sargramostim|Given SC
214739262|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
214739263|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
214739264|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
214739265|NCT00688194|DRUG|fulvestrant|Given intramuscularly
214739266|NCT00688194|DRUG|lapatinib ditosylate|Given orally
214739267|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
214739268|NCT00688194|OTHER|placebo|Given orally
214739269|NCT02442765|DRUG|AVP-786|
214739270|NCT02442765|DRUG|Placebo|
214739271|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
214739272|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
214739273|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
214739274|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
214739275|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
214739276|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
214739277|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
214739278|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
214739279|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
214739280|NCT03033290|DRUG|placebo|placebo control
214739281|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
214739282|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
214739283|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
214739284|NCT00003159|DRUG|carboplatin|
214739285|NCT00003159|DRUG|cisplatin|
214739286|NCT00003159|DRUG|docetaxel|
214739287|NCT00003159|DRUG|gemcitabine hydrochloride|
214739288|NCT00003159|DRUG|ifosfamide|
214739289|NCT00003159|DRUG|mitomycin C|
214739290|NCT00003159|DRUG|paclitaxel|
214739291|NCT00003159|DRUG|vinblastine sulfate|
214739292|NCT00003159|DRUG|vinorelbine tartrate|
214739293|NCT00003159|PROCEDURE|conventional surgery|
214739294|NCT00003159|PROCEDURE|neoadjuvant therapy|
214739295|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
214739296|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
214739297|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
214739298|NCT05353881|OTHER|No intervention|No intervention
214739299|NCT06594406|DIETARY_SUPPLEMENT|Creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks, and administration of a placebo.
214739300|NCT06594406|DIETARY_SUPPLEMENT|Bifidobacterium and creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks. In parallel, the dosing schedule of bifidobacterium administration is 200 million colony-forming units (CFU) /day for 4 weeks.
214739301|NCT06594406|DIETARY_SUPPLEMENT|Placebo|Administration of creatine placebo and bifidobacterium placebo for 4 weeks,
214739302|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
214739303|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
214739304|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
214739305|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
214739306|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
214739307|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
214739308|NCT01563224|DRUG|placebo|placebo
214739309|NCT06989242|DEVICE|Yoga-Based Therapeutic Device (incorporating guided breathing and movement)|The Fluere™ Therapeutic Device is a computer-guided, electro-mechanical system designed to simulate yoga-inspired spinal movement and rhythmic breathing. Resembling a dental chair, the device dynamically adjusts spinal curvature to replicate motion patterns associated with deep abdominal breathing, similar to Kundalini or Qi Gong breathwork. The device operates automatically, with optional manual adjustments by the researcher.
214739310|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
214739311|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
214739312|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
214739313|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
214739314|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
214739315|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
214739316|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
214739317|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
214739318|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
214739319|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
214739320|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
214739321|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
214739322|NCT06617689|OTHER|Various levels of patient education|"The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them."
214739323|NCT07002008|OTHER|Scapular Stabilization Exercise|"Intervention Description:~The intervention consists of a structured, physiotherapist-supervised scapular stabilization exercise program developed specifically for athletes engaged in traditional archery. The program is designed to enhance scapular alignment, motor control, and dynamic stability by targeting key stabilizing muscles such as the serratus anterior and lower trapezius.~Participants in the intervention group will continue their standard traditional archery training and will additionally perform the scapular stabilization protocol three times per week for 8 consecutive weeks, with each session lasting approximately 40 minutes.~The exercise regimen includes:~Scapular Retraction Exercise (prone position with arm elevation)~Push-Up Plus Exercise (with scapular protraction emphasis)~Scapular Retraction and Depression with Elastic Band Resistance~Dipping Exercise (shoulder elevation and scapular control in seated position)~Forward Lean Exercise on Therapy Ball (scapular pro"
214739324|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
214739325|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
214739326|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
214739327|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
214739328|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
214739329|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
214739330|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
214739331|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
214739332|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
214739333|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
214739334|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
214739335|NCT04669106|OTHER|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
214739336|NCT05254587|DEVICE|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
214739337|NCT03515616|DIAGNOSTIC_TEST|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
214739338|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
214739339|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
214739340|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
214739341|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
214739342|NCT04143789|DRUG|AP-002|Dose escalation
214739343|NCT04235088|OTHER|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
214739344|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
214739345|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
214739346|NCT06231004|PROCEDURE|glucocorticosteroid and surgery|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
214739347|NCT06102928|DRUG|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
214739348|NCT05609162|PROCEDURE|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
214739349|NCT03104829|BEHAVIORAL|Motivational interviewing|
214739350|NCT03104829|DRUG|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
214739351|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device|
214739352|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device in placebo mode|
214739353|NCT02076243|DRUG|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
214739354|NCT05384795|OTHER|Lung ultrasound|Lung atelectasis score
214739355|NCT06022224|BIOLOGICAL|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.
214739356|NCT06022224|BIOLOGICAL|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
214739357|NCT02828189|OTHER|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
214739358|NCT02828189|BEHAVIORAL|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
214739359|NCT02828189|OTHER|Therapeutic exercise-Physiotherapy|"1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises"
214739360|NCT03905525|DRUG|CFZ533|Biological
214739361|NCT03905525|OTHER|Placebo|liquid placebo for injections
214739362|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
214739363|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
214739364|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
214739365|NCT01369069|DRUG|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
214739366|NCT01369069|DRUG|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
214739367|NCT02820480|DEVICE|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
214739368|NCT00882362|DRUG|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
214739369|NCT04451694|OTHER|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
214739370|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
214739371|NCT03105375|DRUG|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
214739372|NCT03105375|DRUG|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
214739373|NCT03105375|DRUG|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
214739374|NCT03739099|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
214739375|NCT02203942|OTHER|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
214739376|NCT02530827|DRUG|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
214739377|NCT04868331|BEHAVIORAL|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
214739378|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
214739379|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
214739380|NCT04527666|DRUG|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
214739381|NCT04090515|BEHAVIORAL|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
214739382|NCT04090515|OTHER|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
214739383|NCT03196973|DRUG|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
214739384|NCT03196973|DRUG|DF289|1 vial into the affected ear twice daily for 7 days
214739385|NCT03196973|DRUG|DF277|1 vial into the affected ear twice daily for 7 days
214739386|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
214739387|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
214739388|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
214739389|NCT01802294|BEHAVIORAL|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
214739390|NCT03602638|DRUG|Sitagliptin|Sitagliptin 100mg QD
214739391|NCT03602638|DRUG|Acarbose|Acarbose
214739392|NCT02039089|DRUG|E2006 2.5 mg|
214739393|NCT02039089|DRUG|E2006 10 mg|
214739394|NCT02039089|DRUG|E2006 25 mg|
214739395|NCT02039089|DRUG|Placebo|
214739396|NCT05990140|OTHER|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
214739397|NCT00408772|BIOLOGICAL|bevacizumab|
214739398|NCT00408772|DRUG|capecitabine|
214739399|NCT00408772|DRUG|oxaliplatin|
214739400|NCT00408772|PROCEDURE|conventional surgery|
214739401|NCT00408772|PROCEDURE|neoadjuvant therapy|
214739402|NCT00408772|PROCEDURE|radiofrequency ablation|
214739403|NCT02647372|PROCEDURE|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
214739404|NCT02647372|PROCEDURE|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
214739405|NCT05488106|DIETARY_SUPPLEMENT|Placebo|Placebo
214739406|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
214739407|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 5mg/d|Riboflavin 5mg/d
214739408|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 20mg/d|Riboflavin 20mg/d
214739409|NCT00236106|DRUG|tacrolimus ointment 0.1%|
214739410|NCT00236106|DRUG|mometasone furoate 0.1%|
214739411|NCT04383171|DEVICE|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
214739412|NCT04474392|OTHER|N/A (Observational Study)|Observational study, no intervention will be administered.
214739413|NCT02728310|DRUG|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
214739414|NCT02728310|DRUG|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
214739415|NCT02437721|OTHER|infant formula containing folic acid|
214739416|NCT02437721|OTHER|infant formula containing MTHF|
214739417|NCT03726749|DRUG|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
214739418|NCT03726749|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
214739419|NCT04957745|BEHAVIORAL|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
214739420|NCT04957745|BEHAVIORAL|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
214739421|NCT04957745|BEHAVIORAL|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
214739422|NCT03906591|PROCEDURE|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
214739423|NCT03906591|PROCEDURE|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
214739424|NCT01646346|RADIATION|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
214739425|NCT01315340|PROCEDURE|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
214739426|NCT02698852|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
214739427|NCT02630485|BEHAVIORAL|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
214739428|NCT02630485|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
214739429|NCT02630485|DRUG|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
214739430|NCT01564485|DIAGNOSTIC_TEST|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
214739431|NCT01564485|BEHAVIORAL|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
214739432|NCT05677854|OTHER|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
214739433|NCT05677854|OTHER|Health literacy based health education|Health education based on health literacy was used.
214739434|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
214739435|NCT05664828|DRUG|SN132D|Manganese-based macromolecular MRI contrast agent
214739436|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
214739437|NCT02462889|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection
214739438|NCT02462889|DRUG|Placebo|Sham injection
214739439|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
214739440|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
214739441|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
214739442|NCT02311140|OTHER|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
214739443|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
214739444|NCT04009824|BIOLOGICAL|AGS-v PLUS Vaccine|Administered by subcutaneous injection
214739445|NCT04009824|BIOLOGICAL|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
214739446|NCT04009824|BIOLOGICAL|Alhydrogel® Adjuvant|Administered by subcutaneous injection
214739447|NCT04009824|BIOLOGICAL|Saline Placebo|Administered by subcutaneous injection
214739448|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
214739449|NCT01855204|RADIATION|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
214739450|NCT03238040|OTHER|None, observational study|Observational study, no interventions
214739451|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
214739452|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
214739453|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
214739454|NCT06096012|DRUG|Anti-MRSA therapy|chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
214739455|NCT03452995|PROCEDURE|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
214739456|NCT00391495|PROCEDURE|Blood drawing|
214739457|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
214739458|NCT03731910|DIAGNOSTIC_TEST|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
214739459|NCT06019390|DEVICE|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
214739460|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
214739461|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
214739462|NCT04176328|DRUG|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
214739463|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
214739464|NCT01381809|DRUG|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
214739465|NCT01381809|DRUG|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
214739466|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
214739467|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
214739468|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
214739469|NCT00976261|DRUG|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
214739470|NCT00976261|DRUG|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
214739471|NCT00976261|OTHER|Placebo|Comparator
214739472|NCT03988894|DEVICE|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
214739473|NCT02180191|OTHER|Comparison of the gut microbiota composition|
214739474|NCT01142791|DEVICE|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
214739475|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
214739476|NCT03450824|OTHER|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
214739477|NCT04840849|BIOLOGICAL|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
214739478|NCT04840849|OTHER|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
214739479|NCT03032523|DIAGNOSTIC_TEST|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
214739480|NCT01982669|OTHER|No Intervention|
214739481|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
214739482|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
214739483|NCT01243203|DRUG|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
214739484|NCT01163695|BEHAVIORAL|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
214739485|NCT00935662|DRUG|AZD8329|Oral solution, single ascending doses
214739486|NCT00935662|DRUG|Placebo|Oral solution, placebo
214739487|NCT02292888|OTHER|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
214739488|NCT06193837|DRUG|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
214739489|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
214739490|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
214739491|NCT00281528|DRUG|bevacizumab|infusions
214739492|NCT04081051|OTHER|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
214739493|NCT00291460|DEVICE|inspiratory muscle training|
214739494|NCT02133144|BEHAVIORAL|overeating fat|
214739495|NCT02133144|BEHAVIORAL|overeating carbohydrate|
214739496|NCT04396106|DRUG|AT-527|One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
214739497|NCT04396106|OTHER|Placebo|One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
214739498|NCT04396106|DRUG|AT-527|Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
214739499|NCT04396106|OTHER|Placebo|Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
214739500|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
214739501|NCT02783651|OTHER|Other|No intervention other than routine medical care
214739502|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
214739503|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
214739504|NCT05592145|DEVICE|ViOptix|ViOptix machine
214739505|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
214739506|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
214739507|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
214739508|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
214739509|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
214739510|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
214739511|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
214739512|NCT00381836|DRUG|Darbepoetin Alfa|
214739513|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
214739514|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
214739515|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
214739516|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
214739517|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
214739518|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
214739519|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
214739520|NCT00003687|DRUG|dextromethorphan hydrobromide|
214739521|NCT00003687|DRUG|morphine sulfate|
214739522|NCT01768702|BIOLOGICAL|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
214739523|NCT01768702|BIOLOGICAL|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
214739524|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
214739525|NCT03035058|DRUG|Vedolizumab|Vedolizumab intravenous infusion
214739526|NCT03035058|DRUG|Placebo|Placebo
214739527|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
214739528|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
214739529|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
214739530|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214739531|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
214739532|NCT06256094|DIETARY_SUPPLEMENT|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
214739533|NCT06256094|DIETARY_SUPPLEMENT|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
214739534|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
214739535|NCT01814228|PROCEDURE|transcatheter ablation of ganglionated plexi in right atrium|
214739536|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
214739537|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
214739538|NCT01371799|DRUG|Drug|Placebo
214739539|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
214739540|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
214739541|NCT01393561|DRUG|Group 2|Placebo
214739542|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
214739543|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
214739544|NCT01987609|DRUG|Hylenex|
214739545|NCT01987609|DRUG|Normal Saline|
214739546|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
214739547|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
214739548|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
214739549|NCT01774838|DRUG|Prasugrel|3 months treatment
214739550|NCT01774838|DRUG|Clopidogrel|3 months treatment
214739551|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
214739552|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
214739553|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
214739554|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
214739555|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
214739556|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
214739557|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
214739558|NCT04737551|OTHER|Follow-up only|Only routine follow-up but no treatment
214739559|NCT04737551|DRUG|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
214739560|NCT04737551|RADIATION|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
214739561|NCT04737551|RADIATION|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
214739562|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
214739563|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
214739564|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
214739565|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
214739566|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
214739567|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
214739568|NCT02709889|DRUG|Rovalpituzumab tesirine|
214739569|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
214739570|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
214739571|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
214739572|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
214739573|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
214739574|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
214739575|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
214739576|NCT00537810|DRUG|Sibutramine|15 mg daily
214739577|NCT00537810|DRUG|Placebo|Daily
214739578|NCT00537810|BEHAVIORAL|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
214739579|NCT00537810|BEHAVIORAL|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
214739580|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
214739581|NCT01729481|DRUG|Erlotinib|100mg, once per day
214739582|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
214739583|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
214739584|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
214739585|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
214739586|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
214739587|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
214739588|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
214739589|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
214739590|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
214739591|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
214739592|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
214739593|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
214739594|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
214739595|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
214739596|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
214739597|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
214739598|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
214739599|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
214739600|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
214739601|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
214739602|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
214739603|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
214739604|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
214739605|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
214739606|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
214739607|NCT01711359|DRUG|Baricitinib|Administered orally
214739608|NCT01711359|DRUG|Methotrexate|Administered orally
214739609|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
214739610|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
214739611|NCT01711359|DRUG|Folic Acid|Administered orally every day
214739612|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
214739613|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
214739614|NCT00026819|DRUG|Rofecoxib|
214739615|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
214739616|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
214739617|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
214739618|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
214739619|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
214739620|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
214739621|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
214739622|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
214739623|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
214739624|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
214739625|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
214739626|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
214739627|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
214739628|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
214739629|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
214739630|NCT02253173|DRUG|Estradiol|
214739631|NCT02253173|DRUG|Placebo|
214739632|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
214739633|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
214739634|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
214739635|NCT00795717|DRUG|Placebo|2 capsules given twice daily
214739636|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
214739637|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
214739638|NCT01477073|DRUG|FSH-GEX™|
214739639|NCT01477073|DRUG|recombinant FSH|
214739640|NCT01477073|DRUG|urinary FSH|
214739641|NCT01477073|DRUG|Placebo|
214739642|NCT05312385|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
214739643|NCT05312385|DRUG|Propofol|Intravenous infusion of propofol
214739644|NCT01661231|DEVICE|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
214739645|NCT01800162|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
214739646|NCT01800162|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
214739647|NCT01800162|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
214739648|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
214739649|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
214739650|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
214739651|NCT04481711|PROCEDURE|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
214739652|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
214739653|NCT06722781|BEHAVIORAL|Unified Protocol|The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.
214739654|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
214739655|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
214739656|NCT07043868|DEVICE|Low Level Laser Therapy|Painless, non-invasive treatment
214739657|NCT06720545|DEVICE|No HGNS therapy (HGNS-off)|Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
214739658|NCT07045870|DRUG|group L : will receive lidocaine|group L : will receive 1.5 mg/kg bolus of iv lidocaine 10 minutes before anaesthesia induction then continuous iv infusion rate 1.5 mg / kg / h
214739659|NCT07045870|DRUG|group k : will receive Ketamine|patients will receive .25 mg / kg bolus of iv ketamine 10 minutes before anaesthesia induction then continuous iv infusion of ketamine at .25 mg /kg /h
214739660|NCT07045870|DRUG|group c: will recieve .9% saline|group c will be injected with equivalent volumes and rates of .9% saline using the same application scheme as the lidocaine and ketamine as a control group
214739661|NCT07046676|DRUG|sodium valproate|All three groups are administered twice a day via oral administration. Patients are given different doses based on their body weight and the therapeutic effect in controlling epilepsy.
214739662|NCT06719362|DRUG|M3T01|Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.
214739663|NCT06719362|DRUG|Pembrolizumab|Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.
214739664|NCT06719362|RADIATION|Chemoradiation|Subjects will be treated with standard of care chemoradiation therapy consisting of TMZ 75 mg/m2 daily with concurrent radiation therapy (60 Gy administered over 6 weeks). Following chemoradiation therapy, subjects will have a 4-week break from TMZ before starting standard adjuvant TMZ 150-200 mg/m2 days 1-5 of 28-day cycles for 6 cycles. Subjects will be treated with M3T01 at the RP2D through an IV infusion every 3 weeks that will begin concurrently with chemoradiation therapy.
214739665|NCT06719362|DRUG|FOLFOX regimen|FOLFOX will be given as standard of care on 14 day cycles. Subjects will receive oxaliplatin 85 mg/m2 IV on Day 1, leucovorin 400 mg/m2 IV on Day 1, fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles.
214739666|NCT00362141|DRUG|levetiracetam (add-on)|
214739667|NCT03378128|PROCEDURE|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
214739668|NCT05228704|BEHAVIORAL|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
214739669|NCT07047378|BEHAVIORAL|ACT Intervention Group|"For Parent ACT Group, parents will participate in a six-week, group-based ACT program integrated with behavioral parenting training based on positive parenting principles. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of parenting education and/or behavioral skills training.~For Children ACT Group, children (aged 6-11) will also receive a child-focused ACT intervention to help them manage emotional challenges. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of behavioral skills training."
214739670|NCT07047378|OTHER|control group|"Participants allocated to the Control Group will not receive the ACT intervention but will continue to receive the standard services originally provided by Harmony House. These services constitute usual care and include initial assessments, individual counselling, group counselling, the provision of community resource information, and referrals. Control group participants will receive these supports as usual. This study will not alter their existing service arrangements in any way, nor will it add to or reduce the support they receive.~Aside from not participating in the ACT program, the control group's experience will be identical to that of clients receiving regular services. After the intervention group completes the program, the control group will be offered the same course content (i.e., a waitlist intervention arrangement)."
214739671|NCT06099808|OTHER|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
214739672|NCT06099808|OTHER|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
214739673|NCT06099808|OTHER|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
214739674|NCT04140474|DEVICE|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
214739675|NCT06444997|DRUG|Oxycodone Hydrochloride|Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
214739676|NCT06444997|DRUG|Remifentanil|Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
214739677|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
214739678|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
214739679|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
214739680|NCT01875666|DRUG|Trastuzumab|8 mg/kg IV, single dose
214739681|NCT01875666|DRUG|pertuzumab|840 mg IV single dose
214739682|NCT01875666|DRUG|lapatinib|1000 mg daily for 7 days
214739683|NCT07050771|OTHER|Comprehensive multimodal prehabilitation (CMMP)|Components of the CMMP intervention (which will be administered for at least 3 weeks from study registration to the Preoperative Reassessment) will include: 1) Motivational interviewing: 2 sessions, 10-15 minutes each. 2) Nutritional prehabilitation (a supplement containing 18-22g high quality protein consumed 2 times/day, 7 days/week). 3) Inspiratory muscle training using a hand-held inspiratory muscle device, 5 minutes of respiratory muscle training twice/day, 5 days per week. 4) Physical prehabilitation a) aerobic exercise (20 minutes of moderate-intensity exercise at least 3 days/week) and b) strength resistance training using resistance bands (3 sets of 10 repetitions at moderate intensity at least 3 days/week).
214645266|NCT04760002|DEVICE|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
214645267|NCT04301427|OTHER|Bone mineral density|Bone mineral density will be measured twice in all included patients.
214645268|NCT03514927|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214645269|NCT03514927|DEVICE|High-Intensity Focused Ultrasound|Under go HIFU
214645270|NCT03514927|OTHER|Laboratory Biomarker Analysis|Correlative studies
214645271|NCT03514927|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214645272|NCT03514927|PROCEDURE|Radical Prostatectomy|Undergo prostatectomy
214645273|NCT01133340|RADIATION|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
214645274|NCT00480857|DRUG|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
214645275|NCT06244953|OTHER|TIER-HF-PC|The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
214739684|NCT07052331|DEVICE|Birth Mobility System|Participants receive standard obstetric care and have access to a birth mobility system installed on the birthing bed. Use of the system is voluntary and guided by medical professionals. Participants view a video explaining the system's operation. Birth mobility data is collected passively.
214739685|NCT07052240|BEHAVIORAL|Gatekeeper Training Program (GTK)|"Behavioral: Gatekeeper Training Program (GTK)~The GTK program is a suicide prevention intervention for university students. It includes two sessions of 3 hours each (total: 6 hours), delivered over one week, either face-to-face or online. Content is organized into six modules:~1. Introduction to suicidal behavior.~2. Warning signs and risk/protective factors.~3. Crisis intervention and suicide first aid.~4. Safety planning and community resources.~5. Ethics and gatekeeper self-care.~6. Practical simulations and skill application.~The program includes interactive exercises, role-plays, take-home materials, and a booster session plus a focus group at the 2-month follow-up."
214739686|NCT07051707|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD)Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
214739687|NCT07051707|DRUG|Standard medical care|Continuing standard of care COPD maintenance medication that minimally includes LABA/ICS, LAMA/LABA or LABA/LAMA/ICS.
214739688|NCT07052981|DRUG|Telitacicept|The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.
214739689|NCT01041001|BIOLOGICAL|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
214739690|NCT01041001|PROCEDURE|Microfracture treatment|
214739691|NCT01586962|DRUG|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
214739692|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Patients with Rheumatoid Arthritis|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. Both the prevalence of osteosarcopenia and the subgroups of sarcopenia will be compared with the healthy control group. Through this comparison, we will explain the relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the changes in fall and fracture risk using various questionnaires and tests.
214739693|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Healthy Control Group|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. The relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the risk of falls and fractures will be evaluated using various questionnaires and tests.
214739694|NCT07058220|OTHER|Cervical proprioceptive training|Study group will receive proprioceptive training through use of a laser pointer in a similar way to the testing. From sitting position, patients were asked to flex, extend and rotate their head and then return to the neutral position . This training was commenced with open eyes. Each direction was repeated 8 times for two sets, 30 seconds rest between sets. Progression of exercise was achieved by closing eyes, and altering the duration (trace shapes for 5 minutes and progress by increasing 2-3 minutes weekly as tolerated), repetitions (2-3 repetitions weekly), sets (1 set weekly) and the degree of difficulty of the task (different shapes and positions as standing and walking)
214739695|NCT07058220|OTHER|Advices|Patients of control group were allowed to stay active, avoid poor cervical ergonomics (poor sleeping habits, improper use of mobile/telephone),hot/cold packs, some range of motion exercises, and local medicines as prescribed by their general practitioner.
214739696|NCT07058857|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
214739697|NCT07058857|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
214739698|NCT07059130|BIOLOGICAL|Mirikizumab|Mirikizumab will be administered to participants according to FDA-approved dosing guidelines for moderate-to-severe Crohn's Disease and Ulcerative Colitis. Participants will receive scheduled doses throughout the study period at predefined intervals. Clinical assessments, patient-reported outcomes, biomarker analyses, and safety monitoring will occur at baseline and at Weeks 12, 24, and 48.
214739699|NCT07057934|PROCEDURE|ESPB Block|Under sterile conditions and ultrasound guidance, 20 mL of local anesthetic solution (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected bilaterally into the erector spinae plane at the T7-T8 level before incision. The block was performed after induction of general anesthesia but before the start of laparoscopic cholecystectomy.
214645276|NCT06244953|OTHER|Usual Care|Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
214645277|NCT03761329|PROCEDURE|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
214645278|NCT03761329|PROCEDURE|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
214645279|NCT04620330|DRUG|avutometinib (VS-6766)|Monotherapy
214739700|NCT07057934|PROCEDURE|EOPB Block|Under ultrasound guidance, 20 mL of local anesthetic mixture (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected into the fascial plane between the external oblique and internal intercostal muscles at the level of the 6th rib. The procedure was done after anesthesia induction but prior to laparoscopic cholecystectomy.
214645280|NCT04620330|DRUG|avutometinib (VS-6766) and Defactinib|Combination therapy
214739701|NCT07057934|DRUG|Standard Systemic Analgesia|No regional anesthesia technique was applied. Postoperative pain was managed using systemic rescue analgesia: 50 mg dexketoprofen trometamol IV when VAS ≥4, followed by 50 mg tramadol IV if pain persisted.
214645281|NCT00939835|DRUG|Citalopram Hydrobromide|
214739702|NCT07057765|DRUG|Observational Assessment of Standard R-CHOP Treatment|Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.
214739703|NCT07058844|BEHAVIORAL|High-BPM Line Dance|A structured aerobic dance program set to music with tempos of 130-140 BPM, designed to improve cognitive and physical function in older adults with MCI.
214739704|NCT07058844|BEHAVIORAL|Low-BPM Line Dance|A structured aerobic dance program set to music with tempos of 90-100 BPM, using the same choreography but slower rhythm and reduced rest intervals.
214739705|NCT07058844|OTHER|Usual Daily Activity|No structured intervention will be provided. Participants will continue their routine lifestyle.
214645282|NCT04113915|DRUG|triple therapy|Effect of treatment on immunity to obtain infection with hepatitis B\&C
214645283|NCT04113915|DRUG|Steroids|Oral or parenteral steroid therapy for ITP
214645284|NCT00640471|BIOLOGICAL|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
214645285|NCT00640471|DRUG|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
214645286|NCT01890421|DRUG|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
214645287|NCT00207051|DRUG|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
214645288|NCT04823351|BEHAVIORAL|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
214645289|NCT01760161|DRUG|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
214645290|NCT01760161|DRUG|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
214645291|NCT00244595|DRUG|candsartan cilexetil|
214645292|NCT02990260|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
214645293|NCT02990260|DIETARY_SUPPLEMENT|Lynside Wall Basic|yeast cell walls
214645294|NCT02990260|DIETARY_SUPPLEMENT|Placebo|Maize starch and magnesium stearate
214645295|NCT01465659|DRUG|temozolomide|Given PO
214645296|NCT01465659|DRUG|pazopanib hydrochloride|Given PO
214645297|NCT00374244|DRUG|Pimozide|half of the subjects are randomized to the active drug group
214645298|NCT00374244|DRUG|placebo|half of the subjects are randomized to placebo group
214645299|NCT05688787|PROCEDURE|Perineural Injection|".injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1\_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest\&amp; T10 cross over iliac crest at a distance 8-10cm"
214645300|NCT01698528|DEVICE|Tablet Computer|
214645301|NCT03044860|PROCEDURE|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine
214645302|NCT03550066|BEHAVIORAL|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
214645303|NCT03550066|BEHAVIORAL|No affirmation|A health message alone
214645304|NCT00685594|DRUG|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
214645305|NCT00685594|DRUG|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
214645306|NCT02181166|OTHER|Kinesiotherapy|
214645307|NCT02181166|OTHER|Isquemic compression|
214645308|NCT02181166|OTHER|High voltage electrical stimulation|
214645309|NCT03657719|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
214645310|NCT03657719|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
214645311|NCT05797077|PROCEDURE|Colorectal resection surgery.|Colorectal cancer radical resection combined with liver metastasis resection or ablation.
214739706|NCT07058389|OTHER|8-week outdoor physical activity program|"EXT group will perform aerobic and resistance exercises with a coach in adapted physical activities on a green environment in a parc.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) EXR group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
214739707|NCT07058389|OTHER|8-week indoor physical activity program|"INT group will perform aerobic and resistance exercises with a coach in adapted physical activities, inside a conventional gym.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) INT group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
214739708|NCT07058012|DRUG|Cemiplimab|Cemiplimab 350mg intravenously
214739709|NCT07058012|DRUG|cemiplimab plus fianlimab|Cemiplimab 350mg + Fianlimab 1600mg intravenously
214739710|NCT07058012|DRUG|cemiplimab + REGN7075|Cemiplimab 350mg + REGN7075 2700mg intravenously
214739711|NCT07058012|OTHER|ctDNA testing|Eligible patients using results for ctDNA-positivity as obtained from a commercial assay run in any CLIA-certified lab will proceed to enrollment and begin treatment. All patients will have confirmation of ctDNA-positivity via the Signatera\^TM assay (Clinical Trial Assay), but treatment may proceed while awaiting confirmatory results.
214739712|NCT07057804|DIAGNOSTIC_TEST|Lung Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Lung ultrasound was conducted across 12 zones (anterior and posterior) to evaluate aeration and calculate the lung ultrasound score (LUS).
214739713|NCT07057804|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Diaphragmatic excursion and thickening fraction were measured on the right hemidiaphragm.
214739714|NCT07058103|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
214739715|NCT07058142|BEHAVIORAL|Interaction Standard Theory-Based Multi-Care Program|A comprehensive nursing program based on King's Theory of Goal Attainment and Satir's model, focusing on structured nurse-patient communication, shared goal-setting, and multi-dimensional care addressing cognitive, psychological, behavioral, and dietary aspects. Delivered daily during hospitalization (30-45 min sessions) with post-discharge follow-up.
214739716|NCT07058142|BEHAVIORAL|Conventional Nursing Intervention|Standard hospital protocol for postpartum hemorrhage management including physiological monitoring, emergency measures as needed, and basic postpartum care education.
214739717|NCT07058506|DEVICE|Comparison of 5 interfaces used to capture user intent to operate a neuroprosthesis|No intervention
214739718|NCT07057713|PROCEDURE|Total Arterial Grafting|Coronary artery bypass grafting using only arterial conduits in the left coronary artery system. The left internal thoracic artery (LITA) is grafted to the LAD, and the radial artery is anastomosed to the obtuse marginal or diagonal branches. This approach avoids the use of saphenous vein grafts for the left coronary system.
214739719|NCT07057713|PROCEDURE|Conventional Mixed Grafting|A standard coronary artery bypass grafting (CABG) procedure where the left internal thoracic artery (LITA) is grafted to the LAD, and saphenous vein grafts are used for the obtuse marginal or diagonal branches of the left coronary system. This approach represents the conventional mixed arterial-venous strategy.
214739720|NCT07058480|BEHAVIORAL|Combined MET and MFC-Based Pelvic Stabilization Training|This intervention consisted of a combination of Muscle Energy Technique (MET) for iliac and sacral dysfunctions (20 minutes per session) and myofascial chain-based pelvic stabilization training (including curl-ups, planks, and anti-rotation exercises; 30 minutes per session), targeting pelvic alignment and neuromuscular control. Sessions were conducted 3 times per week, 50 minutes per session, for 4 consecutive weeks.
214739721|NCT07058480|DEVICE|Interferential current therapy (ICT)|Interferential current therapy (ICT) was applied to the lumbar (lower back), sacroiliac, and iliac crest regions, 3 sessions per week, 20 minutes per session, for 4 weeks.
214739722|NCT07058480|BEHAVIORAL|Deep Friction Massage (DFM)|Deep friction massage was administered to the lumbar, sacroiliac, and iliac crest regions for 30 minutes per session, 3 sessions per week, for 4 weeks.
214739723|NCT07059533|OTHER|Verum|anodal transcranial direct current stimulation: 20 minutes of stimulation with 1 mA (ramp-up/ramp-down times of 8 seconds)
214739724|NCT07059533|OTHER|Placebo|anodal transcranial direct current stimulation with 40 seconds of stimulation delivered at the beginning of training (with 8 seconds ramp-up and 5 seconds ramp-down times)
214794245|NCT02946164|BEHAVIORAL|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
214645312|NCT05797077|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
214645313|NCT05797077|DRUG|Capecitabine|Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
214645314|NCT03976622|BIOLOGICAL|Blood samples|Blood samples: serum and PBMC
214645315|NCT03976622|BIOLOGICAL|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
214645316|NCT00428597|DRUG|sunitinib malate|"* sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
214645317|NCT00428597|DRUG|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
214645318|NCT05149170|DRUG|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
214645319|NCT01425112|PROCEDURE|Phacoemulsification|Surgery for complications of trabeculectomy
214645320|NCT03760497|PROCEDURE|Restorative treatment|For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
214645321|NCT01465308|DIETARY_SUPPLEMENT|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
214645322|NCT01465308|OTHER|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
214645323|NCT03668509|DRUG|SHR1459|oral adminstration, single dose
214645324|NCT01469000|DRUG|Gefitinib|250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
214645325|NCT01469000|DRUG|Pemetrexed|500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
214645326|NCT00504764|DRUG|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
214645327|NCT00504764|PROCEDURE|Autologous Transplantation|Autologous Transplantation
214645328|NCT00504764|PROCEDURE|Allogenic Transplantation|Allogenic Transplantation
214645329|NCT00504764|DRUG|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
214645330|NCT00686647|DEVICE|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
214645331|NCT00686647|DEVICE|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
214645332|NCT00632853|RADIATION|Standard Radiation Dose Therapy|45 Gy
214645333|NCT00632853|DRUG|cisplatin|IV
214645334|NCT00632853|DRUG|etoposide|IV
214645335|NCT00632853|RADIATION|High Radiation Dose Therapy|70 Gy
214645336|NCT00632853|DRUG|carboplatin|IV
214645337|NCT03752645|DEVICE|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
214794246|NCT03515395|BEHAVIORAL|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
214645338|NCT04161287|PROCEDURE|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
214645339|NCT05268406|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
214645340|NCT00931489|DRUG|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
214645341|NCT00955994|DRUG|asimadoline|
214794247|NCT01081561|DRUG|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
214794248|NCT03106870|DRUG|Insulin Mixtard|"Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
214645342|NCT01725750|DEVICE|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
214645343|NCT01725750|DEVICE|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
214645344|NCT04291755|DRUG|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
214645345|NCT04983160|DRUG|Allopurinol|Allopurinol
214645346|NCT04983160|DRUG|Placebo|Placebo
214645347|NCT06162208|OTHER|Standard exercise program based on telerehabilitation|Exercises included in a standard exercise program based on telerehabilitation; Week 0-3 Patellar mobilization Isometric quadriceps femoris exercise Terminal extension exercise Active assisted knee flexion Straight leg lift Active hip abduction Active assisted knee flexion in sitting SAFTE Cold pack application Week 3-6 Straight leg raises with weights Hip abduction in weighted side lying Knee flexion in the prone position Knee extension in weight-bearing sitting Sliding forward in the chair to increase the knee flexion angle Standing weighted hip abduction Standing knee flexion with weight Squat Walking Climbing stairs Action observation therapy will be practiced by watching videos of all exercises with a focus on close-up action.
214645348|NCT02541773|DEVICE|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
214645349|NCT03961360|DRUG|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
214645350|NCT03961360|DRUG|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
214645351|NCT00006247|DRUG|semaxanib|
214645352|NCT00426894|PROCEDURE|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
214645353|NCT04241965|DRUG|OPC-214870|Tablet(s)
214645354|NCT04241965|OTHER|Placebo|Tablet(s)
214739725|NCT07058272|OTHER|Comprehensive corrective exercise protocol|"Initial phase exercises include lying supine on a foam roll with the arms in 3 different abduction angles, side-lying external rotation, side-lying forward flexion, standing diagonal flexion , and military press .Initial phase lasts for 2 weeks, with exercises progressing from 7 Reps of 10-second holds to 10 Reps of 15-second hold.~Improvement phase consist of exercises including side-lying external rotation with a dumbbell , side-lying forward flexion with a dumbbell , standing diagonal flexion with a dumbbell, standing external rotation with Thera-Band, standing diagonal flexion with Thera-Band, abduction while sitting on a training ball, prone lying V, T, and W exercises, and standing abduction on a balance board. The improvement phase lasts for 2 weeks, with exercises progressing from seven sets of 10-seconds hold to 10 sets of 15 secs hold.~The exercises in the maintenance phase are the same as those in the improvement phase, with no increase in intensity and frequency"
214794249|NCT03106870|DRUG|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
214794250|NCT05713500|OTHER|TCI|Temperament and character inventory
214794251|NCT05713500|OTHER|BPI|Brief Pain Inventory
214794252|NCT05713500|OTHER|CPAQ-8|Chronic Pain Acceptance Questionnaire-8
214739726|NCT07058272|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) Techniques|"In this study following PNF Stretching techniques are used~* Hold-relax or Contract-relax~* Hold-relax with agonist contraction In the Hold-Relax or Contract-Relax technique, stretching is performed 4sessions per week for each muscle group, with each session lasting 40 min. The protocol includes a 10-sec hold phase followed by a 10-sec contraction phase, repeated for 7 reps . The total duration of this program is 8weeks including 6 weeks of treatment phase and last 2 weeks of detraining.~In Hold-Relax with Agonist contract, the same procedure is followed as in Hold-Relax method, with 4sessions per week for each muscle group. The patient is asked to hold the initial stretch for 10 sec, followed by a relaxation phase. Afterward, the agonist muscle is contracted to actively move further into the stretch, which is then held for 10 sec. This protocol is performed for 7 reps per session, and the total duration of study is 8 weeks including 6 weeks of treatment program with last 2 weeks"
214739727|NCT07058753|PROCEDURE|Prehabilitation. An intensive prehabilitation for NACT patients|Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided.
214739728|NCT05263401|DIETARY_SUPPLEMENT|3-hydroxybutyrate|Orally administered pre-meal drinks.
214739729|NCT04714554|DRUG|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
214739730|NCT04714554|DRUG|Relugolix|Relugolix 120-mg tablets; oral administration.
214739731|NCT04714554|DRUG|Erythromycin|Erythromycin 500-mg tablets; oral administration.
214739732|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
214739733|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
214739734|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
214739735|NCT07058402|PROCEDURE|Retrograde Intrarenal Surgery (RIRS) with Tip-Flexible Suction Access Sheath|Participants undergo retrograde intrarenal surgery (RIRS) using a tip-flexible suction access sheath. The procedure involves the insertion of a flexible ureteroscope through the urethra and ureter into the kidney. A novel access sheath with tip-flexible and suction capabilities is used to facilitate stone fragmentation and removal. The goal is to improve stone clearance and reduce intrarenal pressure during the procedure.
214739736|NCT07058402|PROCEDURE|Standard Percutaneous Nephrolithotomy (PCNL)|Participants undergo standard percutaneous nephrolithotomy (PCNL). The procedure involves creating a percutaneous tract into the renal collecting system under imaging guidance, followed by nephroscope insertion to fragment and extract 2-3 cm renal stones. This represents the current standard of care for large renal calculi.
214739737|NCT06843018|DRUG|Grammidin with anesthetic|Grammidin with anesthetic, a metered dose topical spray
214739738|NCT06843018|DRUG|Septolete Total|Septolete Total, lozenges 3 mg + 1 mg
214794253|NCT05713500|OTHER|SF-MPQ|short-form McGill Pain Questionnaire
214794254|NCT05713500|OTHER|King's Parkinson's Disease Pain Scale (KPPS)|King's Parkinson's Disease Pain Scale
214645355|NCT04448990|DEVICE|TENS eco 2 Transauricular vagal nerve stimulation|"Auricular electrical stimulation will be applied bilaterally using Transcutaneous Electrical Nerve Stimulation device TENS eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany).~tVNS will be applied bilaterally using electrical square impulses delivered in blocks of 9 impulses with a frequency of 100 Hz and a pulse width of 200 μs emitted twice per second resulting in mixed frequency pattern of 100 Hz/2 Hz with the current intensity, that will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved."
214645356|NCT04448990|DEVICE|Sham TENS eco 2|Sham
214645357|NCT00654498|DRUG|Pramipexole|
214645358|NCT00654498|DRUG|Placebo|
214739739|NCT07058363|OTHER|Progressive Relaxation Exercises|"Progressive Relaxation Exercises are defined as a method that provides relaxation throughout the body by voluntary, regular relaxation of large muscle groups in the human body. The main purpose of relaxation exercises is for individuals to feel the difference between tension and relaxation in the muscles and to learn to relax on their own in cases of tension."
214645359|NCT04830267|DRUG|Camrelizumab|Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
214645360|NCT04830267|RADIATION|Stereotactic body radiotherapy|Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).
214645361|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection before vitrectomy
214645362|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection after vitrectomy
214645363|NCT00375102|PROCEDURE|Acupuncture|
214645364|NCT00375102|BEHAVIORAL|Relaxation Response|
214645365|NCT04251377|DEVICE|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
214739740|NCT06099678|BEHAVIORAL|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
214739741|NCT06099678|BEHAVIORAL|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
214739742|NCT01960556|OTHER|Simulation Training|Simulation training provided to one group
214739743|NCT03039907|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty
214739744|NCT06892925|DRUG|QL1706|Eligible participants will receive QL1706 at 5.0 mg/kg intravenously every 3 weeks, lenvatinib at 8 mg orally once daily every 3 weeks, oxaliplatin at 85 mg/m², and gemcitabine at 1000 mg/m² (on days 1 and 8 of each cycle) for up to 8 cycles. Then, they will continue with QL1706 and lenvatinib until clinical progression, imaging progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met.
214739745|NCT06899815|DRUG|F230 tablets|"SAD： A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg .~MAD： B1: F230 tablets 6mg; B2: F230 tablets 12mg; B3: F230 tablets 20mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach."
214739746|NCT06349473|DRUG|SR604|SR604 will be administered as SC injection.
214739747|NCT06349473|DRUG|Placebo|Placebo will be administered as single SC injection.
214739748|NCT01657227|BEHAVIORAL|Intervention to patients|"Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
214739749|NCT01657227|BEHAVIORAL|Intervention to professionals|"Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
214739750|NCT01657227|OTHER|Usual care|Usual care for T2DM received in primary health care
214739751|NCT03786276|BEHAVIORAL|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
214739752|NCT03786276|BEHAVIORAL|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
214739753|NCT03786276|BEHAVIORAL|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
214739754|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
214739755|NCT01271049|OTHER|Control Food Product|Control food product
214739756|NCT05954845|OTHER|biopsies|Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
214739757|NCT07078838|DRUG|Tirzepatide|Patients will receive a subcutaneous dose of 5 mg weekly for the 4 weeks prior to surgical staging.
214739758|NCT02729402|OTHER|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
214739759|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
214739760|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
214739761|NCT07102199|OTHER|Internal focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
214739762|NCT07102199|OTHER|External focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
214739763|NCT07102199|OTHER|Home exercises|Participants' home exercise program includes cervical and scapulothoracic stabilization exercises and self-mobilization exercises with the self-sustained natural apophyseal glide (SNAG) method.
214739764|NCT07101042|OTHER|Cold Stimulation|Ice massage using circular movements over the suprapubic and inner thigh areas to stimulate sensory afferents. Each session lasted 20 minutes, delivered 3 times per week for 4 weeks.
214739765|NCT07101042|OTHER|Paraspinal Electrical Stimulation|Surface electrodes applied bilaterally to the T12-L2 region. Parameters: 20 Hz frequency, 200 µs pulse width, intensity set below motor threshold. Sessions were administered 3 times per week for 4 weeks.
214739766|NCT02020304|DRUG|combined spinal epidural|Combined Spinal Epidural
214794255|NCT05713500|OTHER|Hospital Anxiety and Depression scale (HAD) questionary|Hospital Anxiety and Depression scale
214794256|NCT05713500|OTHER|PCS|Pain Catastrophism Scale
214739767|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
214739768|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
214739769|NCT02814812|PROCEDURE|CT scan|
214739770|NCT06442176|DIAGNOSTIC_TEST|OCT|Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
214739771|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
214739772|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
214739773|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing (PIRS) with peritoneal cauterization|Percutaneous Internal Ring Suturing with peritoneal cauterization at the internal ring.
214739774|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing|Percutaneous Internal Ring Suturing (PIRS) without peritoneal cauterization.
214739775|NCT07101484|DRUG|GD007 Low-dose drug group|"o Eligible patients who provide informed consent will receive:~* First exosome perfusion: 24 hours post-operatively~* Subsequent perfusions: Every 3 days (total 3 perfusions)"
214794257|NCT05713500|OTHER|ORT|Opioid Risk Tool
214794258|NCT05713500|OTHER|Social Support Questionnaire (SSQ6)|Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)
214739776|NCT07101484|DRUG|GD007 Mid-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
214739777|NCT07101484|DRUG|GD007 High-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
214739778|NCT07101484|DRUG|GD007 Blank Control drug Group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
214739779|NCT07100171|OTHER|Biological: GM101|Neurosurgical delivery of GM101 to the putamen
214739780|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
214739781|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
214739782|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
214739783|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
214739784|NCT06910254|DEVICE|Overground Robot-Assisted Gait Training (o-RAGT)|This group receives a combination of overground robot-assisted gait training (o-RAGT) and recumbent bicycle training. The o-RAGT is delivered using the Angel Legs M20 wearable exoskeleton with the MW10 suspension system for safety and gait assistance. Each o-RAGT session lasts 30 minutes and is performed overground, with support gradually reduced based on patient tolerance. Recumbent bicycle training uses the TBR9000 device (DRAX, Korea) for 30 minutes per session, focusing on lower limb strength and aerobic conditioning. Resistance is progressively increased based on patient tolerance using an RPE scale (11-14). Training is provided 5 times per week for 4 weeks. The combined program aims to improve muscle mass, physical function, and cardiopulmonary endurance in subacute stroke patients with pre-sarcopenia.
214739785|NCT06910254|DEVICE|Recumbent Bicycle Training|This group receives 30-minute recumbent bicycle training sessions using the TBR9000 device (DRAX, Korea), 5 times per week for 4 weeks. Resistance is gradually increased based on patient tolerance and monitored using an RPE scale (11-14). The intervention targets lower limb muscle strengthening and aerobic conditioning to promote physical recovery. No robotic gait training is provided in this group.
214739786|NCT06857890|DRUG|Grammidin with anesthetic neo|Grammidin with anesthetic neo, lozenges, 1 lozenge to be taken once under fed conditions.
214739787|NCT06857890|DRUG|Grammidin with anesthetic, a metered dose topical spray|Grammidin with anesthetic, a metered dose topical spray, 4 sprays to be taken once under fed conditions
214739788|NCT06522438|COMBINATION_PRODUCT|Hyaluronic Acid (HA) and Octenidine gel|A thermosensitive gel with Hyaluronic Acid (HA) and Octenidine (Pocket-X®, Geistlich, Wolhusen, Switzerland) will be applied in the periodontal pockets ≥5mm immediately after the subgingival PMPR, by means of a pre-filled syringe bearing a thin plastic tip and following manufacturer's instructions.
214739789|NCT06522438|PROCEDURE|Non-surgical periodontal treatment (NSPT)|Full mouth supragingival professional mechanical plaque removal (PMPR) and subgingival PMPR at sites with PPD ≥4mm will be performed with the aid of manual and power-driven instruments under local anaesthesia.
214739790|NCT05234463|OTHER|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
214739791|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
214739792|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
214739793|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
214739794|NCT02951728|DRUG|Rituximab|
214739795|NCT02951728|DRUG|Cyclophosphamide|
214739796|NCT02951728|DRUG|Doxorubicin|
214739797|NCT02951728|DRUG|Vincristine|
214739798|NCT02951728|DRUG|Prednisone|
214739799|NCT02951728|DRUG|Decitabine|
214739800|NCT01247012|DIETARY_SUPPLEMENT|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
214739801|NCT01247012|DIETARY_SUPPLEMENT|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
214739802|NCT06935500|PROCEDURE|endoscopic ureteric lithotripsy|2 different sizes of ureteroscopes, 4.5/65f and 7.5/9.5f, will be used in the study.
214739803|NCT02912962|BEHAVIORAL|Self-Regulation Intervention adapted from the Alert Program ®|
214739804|NCT04728815|BEHAVIORAL|TAU - Phase 1|4-8 weeks of TAU treatment
214739805|NCT04728815|BEHAVIORAL|CAMS - Phase 1|4-8 weeks of CAMS treatment
214739806|NCT04728815|BEHAVIORAL|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
214739807|NCT04728815|BEHAVIORAL|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
214739808|NCT04728815|BEHAVIORAL|DBT - Phase 2|Up to 8 weeks of DBT treatment
214739809|NCT06953752|OTHER|Music intervention|Music group patients select preferred genres (classical/pop/rock/jazz; classical default) delivered at 50-60 dB during the procedure.
214739810|NCT06953752|OTHER|Control|Controls receive no music.
214794259|NCT05713500|OTHER|IPQ-R|Illness Perception Questionnaire Revised
214794260|NCT05713500|OTHER|WCC-R|Ways of Coping Checklist Revised
214739811|NCT05421546|DIETARY_SUPPLEMENT|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
214739812|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
214739813|NCT06953479|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|Individuals will receive a full course (i.e., 84 tablets) of Sofosbuvir / Velpatasvir 400/100mg tablets.
214739814|NCT06953479|OTHER|Community Health Worker|Participants will receive support from a Community Health Worker which may include assistance with basic needs (transportation, housing, employment, vital documents, insurance re-activation) as well as medication adherence, patient navigation, and peer recovery support.
214739815|NCT06954857|DEVICE|Cuff pressure monitor|"Participants were allocated to the experimental group and the control group using block randomization.~Experimental group: A pressure monitor was used to continuously monitor and promptly adjust the cuff pressure, seal pressure, and leakage pressure of the laryngeal mask."
214739816|NCT06949033|DRUG|Neoadjuvant cadonilimab combined with perioperative SOX|Cadonilimab: 10 mg/kg, iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
214739817|NCT06949033|DRUG|Neoadjuvant placebo plus perioperative SOX|Placebo: iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
214739818|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
214739819|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
214739820|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
214739821|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
214739822|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
214739823|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
214739824|NCT00284726|DEVICE|Celsior Cold Storage Solution|
214739825|NCT05186363|DRUG|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
214739826|NCT05186363|DRUG|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
214739827|NCT00957034|DRUG|placebo|placebo patch
214739828|NCT00957034|DRUG|testosterone|300 or 450 micrograms/day transdermal testosterone patch
214739829|NCT05670132|OTHER|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
214739830|NCT05670132|OTHER|Standard of care|No intervention during the neurocardiac rehabilitation program
214739831|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739832|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739833|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739834|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739835|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739836|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214739837|NCT00308568|BEHAVIORAL|Mailed educational brochure|
214739838|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
214739839|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
214739840|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
214739841|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
214739842|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
214739843|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
214739844|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
214739845|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
214739846|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
214739847|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
214739848|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
214739849|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
214739850|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
214739851|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
214739852|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
214739853|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
214739854|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
214739855|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
214739856|NCT06722313|DIAGNOSTIC_TEST|Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband|"1. Targeted deep sequencing for mosaicism detection for patients with suspected gonadal mosaicism, eg. Repeated similar abortion due to the same variant while the couple were tested negative for the variant in the peripheral blood.~2. Ovarian stimulation, embryo culture, biopsy and vitrification as routinely used in the IVF clinical practice.~3. Gametes and arrested embryo preservation by the embryo laboratory during embryo culture.~4. Genetic testing, including multiple displacement amplification for WGA, variant sequencing in WGA products and Infinium Chip protocol for amplified DNA and haplotype analysis"
214739857|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
214739858|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
214739859|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
214739860|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
214739861|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
214739862|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
214739863|NCT01986166|DRUG|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
214739864|NCT01986166|DRUG|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
214739865|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
214739866|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
214739867|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
214739868|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
214739869|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
214739870|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
214739871|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
214739872|NCT00247052|DRUG|matching placebo|
214739873|NCT02132169|DRUG|Drug: AC-170 0.24%|
214739874|NCT02132169|DRUG|AC-170 0%|
214739875|NCT03724799|DEVICE|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
214739876|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
214739877|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
214739878|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
214739879|NCT01773616|DRUG|Oral prednisolone|
214739880|NCT01773616|DRUG|Rituximab|
214739881|NCT01773616|DRUG|Mycophenolate mofetil|
214739882|NCT01773616|DRUG|Methyl prednisolone|
214739883|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
214739884|NCT04765176|DEVICE|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
214739885|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
214739886|NCT02450240|BEHAVIORAL|standardized diagnostic assessment|
214739887|NCT02450240|BEHAVIORAL|self-report questionnaires|
214739888|NCT02450240|BEHAVIORAL|behavioral tasks|
214739889|NCT02450240|OTHER|physiological measurements|
214739890|NCT02450240|OTHER|structural and functional magnetic resonance imaging and EEG|
214739891|NCT02450240|OTHER|biomarker and microbiome assessments|
214739892|NCT02450240|OTHER|blood to derive induced pluripotent stem cells|
214739893|NCT02450240|OTHER|genetic and epigenetic assessments|
214739894|NCT03748875|BEHAVIORAL|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
214739895|NCT06399068|DRUG|CKD-387|1 Tablet
214739896|NCT06399068|DRUG|D484|1 Tablet
214739897|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
214739898|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
214739899|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
214739900|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
214739901|NCT01813630|DRUG|DA-3002|
214739902|NCT01813630|DRUG|Genotropin®|
214739903|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
214739904|NCT05993585|OTHER|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
214739905|NCT05993585|OTHER|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
214739906|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
214739907|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
214739908|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
214739909|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
214739910|NCT02143336|PROCEDURE|subcuticular suture|
214739911|NCT02143336|PROCEDURE|Skin staples|
214739912|NCT02355860|BEHAVIORAL|assessment|assessment
214739913|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
214739914|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
214739915|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
214739916|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
214739917|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
214739918|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
214739919|NCT00025090|DRUG|cisplatin|
214739920|NCT00025090|DRUG|fluorouracil|
214739921|NCT00025090|DRUG|mitomycin C|
214739922|NCT00025090|RADIATION|radiation therapy|
214739923|NCT02959736|BEHAVIORAL|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
214739924|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
214739925|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
214739926|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
214739927|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
214739928|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
214739929|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
214739930|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
214739931|NCT03095157|DIETARY_SUPPLEMENT|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
214739932|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
214739933|NCT03313440|OTHER|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
214739934|NCT03313440|OTHER|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
214739935|NCT00501930|DRUG|GSK189075|
214739936|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
214739937|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
214739938|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
214739939|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
214739940|NCT04598100|BEHAVIORAL|FOCUS-EC|
214739941|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
214739942|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
214739943|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
214739944|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
214739945|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
214739946|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
214739947|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
214739948|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
214739949|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
214739950|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
214739951|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
214739952|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
214739953|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
214739954|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
214739955|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
214739956|NCT00712764|DRUG|Adenosine|
214739957|NCT00712764|DRUG|Placebo|
214739958|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
214739959|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
214739960|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
214739961|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
214739962|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
214739963|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
214739964|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
214739965|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
214739966|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
214739967|NCT00134199|DRUG|CP-945,598|
214739968|NCT00134199|DRUG|sibutramine|
214739969|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
214739970|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
214739971|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
214739972|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
214739973|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
214739974|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
214739975|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
214739976|NCT01868126|DRUG|DE-117 ophthalmic solution|
214739977|NCT01868126|DRUG|latanoprost ophthalmic solution|
214739978|NCT01868126|OTHER|Placebo|
214739979|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
214739980|NCT03466528|DRUG|Pabrinex|standard treatment
214739981|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
214739982|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
214739983|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
214739984|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
214739985|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
214739986|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
214739987|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
214739988|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
214739989|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
214739990|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
214739991|NCT04802395|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
214739992|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
214739993|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
214739994|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
214739995|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
214739996|NCT04921111|DRUG|placebo|aluminium phosphate
214739997|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
214739998|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
214739999|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
214740000|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
214740001|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
214740002|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
214740003|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
214740004|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
214740005|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
214740006|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
214740007|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
214740008|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
214740009|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
214740010|NCT03858855|OTHER|Subject Diary|Complete journal
214740011|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
214740012|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
214740013|NCT00846027|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
214740014|NCT00846027|DRUG|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
214740015|NCT00846027|DRUG|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
214740016|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
214740017|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
214740018|NCT05833061|OTHER|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
214740019|NCT05833061|OTHER|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
214740020|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
214740021|NCT02278159|PROCEDURE|Peritoneal dialysis|
214740022|NCT02278159|PROCEDURE|Home hemodialysis|
214740023|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
214740024|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
214740025|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
214740026|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
214740027|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
214740028|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
214740029|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
214740030|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
214740031|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
214740032|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
214740033|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
214740034|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
214740035|NCT05516316|DRUG|EP395|Capsule for oral use
214740036|NCT05516316|DRUG|Placebo|Capsule for oral use
214740037|NCT02058186|DRUG|oral vitamin D|
214740038|NCT02058186|DRUG|Placebo|
214740039|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
214740040|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
214740041|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
214740042|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
214740043|NCT00327834|DRUG|atomoxetine|
214740044|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
214740045|NCT00848172|DRUG|Octanoic Acid|4mg/kg
214740046|NCT00848172|DRUG|Placebo|identical capsules
214740047|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
214740048|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
214740049|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
214740050|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
214740051|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
214740052|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
214740053|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
214645366|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
214645367|NCT02353533|DEVICE|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
214645368|NCT02353533|DEVICE|EMR|Standard endoscopic mucosal resection using a resection snare
214645369|NCT06508580|BEHAVIORAL|Component 1: Calorie Goal Attainment|On weeks that participants are randomized to receive this component, they will be provided with feedback on the number of days that they met their calorie goal.
214645370|NCT06508580|BEHAVIORAL|Component 2: Diet Quality|On weeks that participants are randomized to receive this component, they will receive three comments regarding specific dietary choices that may impact weight loss success, including reinforcing comments for behaviors consistent with weight loss and potential areas for change.
214645371|NCT06508580|BEHAVIORAL|Component 3: Physical Activity Goal Attainment|On weeks that participants are randomized to receive this component, they will receive feedback related to attainment of that week's physical activity goal.
214645372|NCT06508580|BEHAVIORAL|Component 4: Goal Setting|On weeks that participants are randomized to receive the goal setting component, they will be asked to complete an open-text prompt encouraging them to set a specific weight-related behavior change goal for the next week.
214740054|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
214740055|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
214740056|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
214740057|NCT02908841|DEVICE|Surgicel Snow|
214740058|NCT02908841|OTHER|Standard of Care|
214740059|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
214740060|NCT01611558|BIOLOGICAL|Ipilimumab|
214740061|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
214740062|NCT00044811|DRUG|Fexofenadine|
214740063|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
214740064|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
214740065|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
214740066|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
214740067|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
214740068|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
214740069|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
214740070|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
214740071|NCT04005885|DEVICE|comfilcon A|Contact Lens
214740072|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
214740073|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
214740074|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
214740075|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
214740076|NCT01427855|OTHER|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
214740077|NCT01427855|OTHER|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
214740078|NCT01427855|OTHER|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
214740079|NCT01427855|OTHER|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
214740080|NCT01427855|OTHER|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
214740081|NCT01427855|OTHER|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
214740082|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
214740083|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
214740084|NCT00826787|DRUG|Levetiracetam|750 mg tablet
214740085|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
214740086|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
214740087|NCT00031824|DRUG|cyclosporine|
214740088|NCT00031824|DRUG|hydroxychloroquine|
214740089|NCT00031824|DRUG|prednisone|
214740090|NCT00031824|DRUG|tacrolimus|
214740091|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
214740092|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
214740093|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
214740094|NCT02413086|PROCEDURE|Early-stage amputation|Individuals with DFU were given early-stage amputation.
214740095|NCT02413086|PROCEDURE|Amputation|Individuals with DFU were given amputation.
214740096|NCT02413086|OTHER|External herbs chitosan|Wound was given external herbs chitosan after amputation.
214740097|NCT02413086|OTHER|Traditional gauze|Wound was given traditional gauze after amputation.
214740098|NCT05291741|DIETARY_SUPPLEMENT|VLCD|Advice regarding VLCD
214740099|NCT05291741|DIETARY_SUPPLEMENT|Standard care|Standard dietary advice for weight loss before bariatric surgery
214740100|NCT02718625|BIOLOGICAL|Santyl|Collagenase ointment applied topically
214740101|NCT02718625|BIOLOGICAL|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
214740102|NCT03971019|DRUG|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
214740103|NCT03971019|BEHAVIORAL|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
214740104|NCT02681068|OTHER|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
214740105|NCT02828462|OTHER|CAPRI|
214740106|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
214740107|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
214740108|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
214740109|NCT00984152|DRUG|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
214740110|NCT00984152|DRUG|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
214740111|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
214740112|NCT00000641|DRUG|Ethambutol hydrochloride|
214740113|NCT00000641|DRUG|Amikacin sulfate|
214740114|NCT00000641|DRUG|Azithromycin|
214740115|NCT00000641|DRUG|Rifampin|
214740116|NCT00000641|DRUG|Clofazimine|
214740117|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
214740118|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
214740119|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
214740120|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
214740121|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
214740122|NCT01836549|DRUG|imetelstat sodium|Given IV
214740123|NCT00003465|DRUG|temozolomide|
214740124|NCT01500421|DEVICE|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
214740125|NCT01500421|DEVICE|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
214740126|NCT01500421|DEVICE|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
214740127|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
214740128|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
214740129|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
214740130|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
214740131|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
214645373|NCT05869825|PROCEDURE|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
214645374|NCT05869825|PROCEDURE|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
214645375|NCT04263831|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
214645376|NCT01657578|DRUG|Omeprazole|administration of Omeprazole
214645377|NCT06485219|DRUG|11.2 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
214645378|NCT06485219|DRUG|15 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
214645379|NCT01314950|BEHAVIORAL|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
214740132|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
214740133|NCT02516306|DRUG|EV06 Ophthalmic Solution|
214740134|NCT02516306|DRUG|Placebo Ophthalmic Solution|
214740135|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
214740136|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
214740137|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
214740138|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
214740139|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
214740140|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
214740141|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
214740142|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
214740143|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
214740144|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
214740145|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
214740146|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
214740147|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
214740148|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
214740149|NCT00000970|DRUG|Foscarnet sodium|
214740150|NCT00000970|DRUG|Ganciclovir|
214740151|NCT00642122|DRUG|Budesonide|0.5mg once daily
214740152|NCT00642122|DRUG|Budesonide|1mg once daily
214740153|NCT00642122|DRUG|Budesonide|1mg twice daily
214740154|NCT00642122|DRUG|Budesonide|2mg once daily
214740155|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
214740156|NCT02749643|DEVICE|Vibrotactile feedback system|
214740157|NCT06137989|PROCEDURE|Fill-Up Class ӀӀ restoration|Bulk-fill technique
214740158|NCT06137989|PROCEDURE|QuiXfil Class ӀӀ restoration|Bulk-fill technique
214740159|NCT06137989|PROCEDURE|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
214740160|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
214740161|NCT02736149|DRUG|ubenimex|
214740162|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
214740163|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
214740164|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
214740165|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
214740166|NCT01022918|DRUG|Temodal/radiotherapy|
214740167|NCT05949463|OTHER|Intermittent teaching unit|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
214740168|NCT05949463|OTHER|No intervention group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
214740169|NCT02234024|DIETARY_SUPPLEMENT|Supplementation of dairy-derived concentrated gangliosides.|
214740170|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
214740171|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
214740172|NCT00242710|DRUG|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
214740173|NCT00242710|OTHER|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
214740174|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
214645380|NCT01314950|BEHAVIORAL|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
214645381|NCT03664375|OTHER|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
214645382|NCT03664375|OTHER|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
214645383|NCT02532270|DRUG|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
214645384|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
214645385|NCT00573001|DRUG|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
214645386|NCT00573001|DRUG|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
214645387|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
214740175|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
214740176|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
214740177|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
214740178|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
214740179|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
214740180|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
214740181|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
214645388|NCT06148038|DRUG|CBD Oral|CBD Oral 350mg twice daily for 28 days
214645389|NCT06148038|OTHER|Control|Placebo Control
214645390|NCT06023732|BEHAVIORAL|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
214645391|NCT06127524|DEVICE|SEM Scanner|Implementation of the SEM Scanner as part of weekly standard skin assessments of sacrum and heels
214645392|NCT06000293|OTHER|Oral health education|Anticipatory Guidance (AG) provided to the primary caregivers-infant pairs in the intervention group
214645393|NCT04100330|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
214645394|NCT04100330|DRUG|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
214740182|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
214740183|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
214740184|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
214740185|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
214740186|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
214740187|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
214740188|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
214740189|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
214740190|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
214740191|NCT00362440|DRUG|Leptin|
214740192|NCT00362440|DRUG|Pioglitazone or metformin|
214740193|NCT00362440|DRUG|Placebo|
214740194|NCT03644173|BEHAVIORAL|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
214740195|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
214740196|NCT00381706|BIOLOGICAL|cetuximab|given IV
214740197|NCT00381706|DRUG|ECF|epirubicin and 5-fluorouracil given IV
214740198|NCT00381706|DRUG|IC|cisplatin and irinotecan given IV
214740199|NCT00381706|DRUG|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
214740200|NCT00051194|DRUG|Combination IOP Lowering Therapy|
214740201|NCT02113891|DRUG|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
214740202|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
214740203|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
214740204|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
214740205|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
214740206|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
214740207|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
214740208|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
214740209|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
214740210|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
214740211|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
214740212|NCT01551485|DRUG|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
214740213|NCT01551485|DRUG|Placebo|Pacebo tablet, blinded given on the first night after surgery
214740214|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
214740215|NCT03279146|DRUG|Tenofovir exalidex (TXL)|Oral formulations
214740216|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
214740217|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
214740218|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
214740219|NCT00636038|DIETARY_SUPPLEMENT|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
214740220|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
214740221|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
214740222|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
214740223|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
214740224|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
214740225|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
214740226|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
214740227|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
214740228|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
214740229|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
214740230|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
214740231|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
214740232|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
214740233|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
214740234|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
214740235|NCT02411266|OTHER|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
214740236|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
214740237|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
214740238|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
214740239|NCT03087474|OTHER|Non-Interventional|Non-Interventional
214740240|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
214740241|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
214740242|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
214740243|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
214740244|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
214740245|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
214740246|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
214740247|NCT04576390|DRUG|Ondansetron 4 mg|Antiemetic drug
214740248|NCT04576390|DRUG|Palonosetron 75 mcg|Antiemetic drug
214740249|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
214740250|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
214740251|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
214740252|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
214740253|NCT01881724|BEHAVIORAL|Sleep education|
214740254|NCT00372580|PROCEDURE|blood test|
214740255|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
214740256|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
214740257|NCT02983851|PROCEDURE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
214740258|NCT02983851|PROCEDURE|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
214740259|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
214740260|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
214740261|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
214740262|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
214740263|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
214740264|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
214740265|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
214740266|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
214740267|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
214740268|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
214740269|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
214740270|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
214645395|NCT05441774|DEVICE|Active transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the active condition, stimulator electrodes deliver a mild electrical current to the tragus. Stimulation parameters: stimulation of left tragus via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
214645396|NCT05441774|BEHAVIORAL|Active self-compassion imagery|Self-compassion imagery is both a meditative technique and a component of compassion-focused cognitive therapy. Here, self-compassionate imagery is delivered as standardized audio-recorded instructions.
214645397|NCT05441774|DEVICE|Sham transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the sham condition, stimulator electrodes deliver a mild electrical current to the earlobe. Stimulation parameters: stimulation of left earlobe via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
214645398|NCT05441774|BEHAVIORAL|Sham mental imagery|Draw-a-face-in-imagination is the sham/ control imagery condition. Here, control imagery instructions are delivered as a standardized audio-recording, well-matched to self-compassion imagery for number of words, complexity of language, and duration of the audio instructions.
214645399|NCT00574574|DIETARY_SUPPLEMENT|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
214645400|NCT04663945|BEHAVIORAL|Biobehavioral Tele-rehabilitation Sessions|Biobehavioral tele-rehabilitation sessions
214645401|NCT02286531|DRUG|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
214645402|NCT04405960|DRUG|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
214645403|NCT04405960|DRUG|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
214645404|NCT00396175|DRUG|MK0906, finasteride / Duration of Treatment : 48 Weeks|
214645405|NCT00396175|DRUG|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
214740271|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
214740272|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
214740273|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
214740274|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
214740275|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
214740276|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
214740277|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
214740278|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
214740279|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
214740280|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
214740281|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
214740282|NCT04539665|PROCEDURE|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
214740283|NCT00152789|PROCEDURE|Oxygen measurement - Eppendorf machine|
214740284|NCT00005577|DRUG|gemcitabine hydrochloride|
214740285|NCT05458869|PROCEDURE|HPV Self-Collection|Use HPV self-collection kit
214740286|NCT05458869|OTHER|Interview|Attend interview
214740287|NCT05458869|OTHER|Survey Administration|Complete surveys
214740288|NCT01336257|OTHER|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
214740289|NCT01003067|DEVICE|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
214740290|NCT03099304|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214740291|NCT03099304|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
214740292|NCT00002590|BIOLOGICAL|filgrastim|
214740293|NCT00002590|DRUG|cyclophosphamide|
214740294|NCT00002590|DRUG|cytarabine|
214740295|NCT00002590|DRUG|daunorubicin hydrochloride|
214740296|NCT00002590|DRUG|doxorubicin hydrochloride|
214740297|NCT00002590|DRUG|etoposide|
214740298|NCT00002590|DRUG|leucovorin calcium|
214740299|NCT00002590|DRUG|methotrexate|
214740300|NCT00002590|DRUG|pegaspargase|
214740301|NCT00002590|DRUG|prednisone|
214740302|NCT00002590|DRUG|thioguanine|
214740303|NCT00002590|DRUG|vincristine sulfate|
214740304|NCT00002590|RADIATION|radiation therapy|
214740305|NCT00947089|DEVICE|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
214740306|NCT00947089|DEVICE|iodoform gauze|one iodoform gauze
214740307|NCT03248960|DIAGNOSTIC_TEST|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
214740308|NCT03248960|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
214740309|NCT03248960|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
214740310|NCT03248960|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
214740311|NCT06189625|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
214740312|NCT06189625|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
214645406|NCT03652142|OTHER|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
214645407|NCT03652142|DRUG|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
214645408|NCT02486315|DEVICE|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
214645409|NCT06099938|DRUG|sufentanil, ropivacaine|The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
214645410|NCT00772668|DRUG|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
214645411|NCT00772668|DRUG|Bortezomib|Administered intravenously per protocol.
214645412|NCT00772668|DRUG|Cyclophosphamide|Administered intravenously per protocol.
214645413|NCT00772668|DRUG|Prednisone|Administered orally (PO) per protocol.
214645414|NCT05591586|BEHAVIORAL|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
214740313|NCT06154759|OTHER|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
214740314|NCT04966611|DRUG|Anlotinib|This is an observational study
214740315|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
214740316|NCT03194204|DRUG|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
214740317|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
214740318|NCT01401101|OTHER|PCM|Care Manager (CM) intervention
214740319|NCT01401101|OTHER|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
214740320|NCT04096404|GENETIC|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
214740321|NCT04096404|BEHAVIORAL|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
214740322|NCT01661725|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
214740323|NCT05680090|DIAGNOSTIC_TEST|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
214740324|NCT02822924|PROCEDURE|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
214740325|NCT00715949|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
214740326|NCT02676050|OTHER|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
214740327|NCT02676050|DEVICE|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
214740328|NCT02676050|DEVICE|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
214740329|NCT00789659|OTHER|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
214740330|NCT03665987|BEHAVIORAL|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
214740331|NCT01841164|DRUG|Montelukast|
214740332|NCT01841164|DRUG|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
214740333|NCT01841164|OTHER|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
214645415|NCT05591586|BEHAVIORAL|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
214645416|NCT01493336|DRUG|capecitabine RTD|single oral dose
214740334|NCT03998995|DEVICE|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
214740335|NCT00885729|PROCEDURE|stem cells|Stem cells or chondrocytes under a commercial available membrane
214740336|NCT00885729|PROCEDURE|Chondrocytes|Implantation of chondrocytes
214645417|NCT01493336|DRUG|capecitabine [Xeloda]|single oral dose
214645418|NCT01493336|DRUG|capecitabine [Xeloda]|standard treatment
214645419|NCT03014414|BEHAVIORAL|Fun First|Learn key enjoyable maintenance skills before losing weight
214645420|NCT03014414|BEHAVIORAL|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
214645421|NCT02065453|DEVICE|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
214645422|NCT02065453|DEVICE|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
214645423|NCT00529971|BEHAVIORAL|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
214645424|NCT00529971|OTHER|Control|Treatment as usual, which could include medications or psychotherapy
214645425|NCT05876052|DEVICE|Hypothermic oxygenated Perfusion - HOPE|HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
214645426|NCT06915909|DEVICE|surgery|40 patients randomised to two arms will undergo robotic prostatectomies using either the control AirSeal® Insufflation System (AIS) or the intervention Stryker PneumoClear Insufflator. Intra-operative and post-operative pain will be compared between the two arms of the trial.
214645427|NCT06916390|DRUG|Guselkumab|"All patients will receive guselkumab 400 mg intravenous at week 0, week 4, and week 8, followed by subcutaneous guselkumab 200 mg at week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 40, week 44, and week 48.~All subjects will receive concomitant antibiotic treatment with ciprofloxacin 500mg twice daily from randomization through week 4."
214645428|NCT06916390|OTHER|Diet|Subjects randomized to the group with the dietary intervention will be advised to follow a low-UPF, high-fruit diet. Patients will be instructed to restrict the intake of NOVA 4 food products during the first 16 weeks of the trial, and to increase the intake of fruits (minimum 3 servings per day) during the full trial. Dietary education will be provided by certified IBD dietitians, lists of products to avoid, and week menu's will also be provided to increase dietary adherence. Dietary information will be collected with food records and food frequency questionnaires.
214740337|NCT00885729|OTHER|Rehabilitation program|Strength exercises, neuromuscular exercises
214740338|NCT05206682|DRUG|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
214740339|NCT00294229|PROCEDURE|manipulative therapy|
214740340|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
214740341|NCT03450486|OTHER|exercise|one 30 minute bout of mild exercise
214740342|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
214740343|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
214740344|NCT01528618|DRUG|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
214740345|NCT01528618|DRUG|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
214740346|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
214740347|NCT00656994|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
214740348|NCT00656994|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
214740349|NCT02839655|DEVICE|Da Vinci Xi|
214740350|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
214740351|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
214740352|NCT04562038|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
214740353|NCT04992000|OTHER|4-free app + PHN intervention|same mentioned in groups
214740354|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
214740355|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
214740356|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
214740357|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214740358|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214740359|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214740360|NCT03307213|DEVICE|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
214740361|NCT03307213|DEVICE|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
214740362|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
214740363|NCT00740818|OTHER|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
214740364|NCT00740818|PROCEDURE|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
214740365|NCT00740818|PROCEDURE|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
214740366|NCT02375464|DRUG|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
214740367|NCT03170492|OTHER|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
214740368|NCT03170492|OTHER|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
214740369|NCT01170468|DRUG|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
214740370|NCT01170468|DRUG|Placebo|Placebo orally, daily for 2 years
214740371|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
214740372|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
214740373|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
214740374|NCT02385591|BEHAVIORAL|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
214740375|NCT02385591|BEHAVIORAL|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
214740376|NCT05512195|RADIATION|New delineation approach|New delineation approach
214740377|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
214740378|NCT03781154|BEHAVIORAL|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
214740379|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
214740380|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
214740381|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
214740382|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214740383|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
214740384|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
214740385|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
214740386|NCT05391295|OTHER|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
214740387|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
214740388|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
214740389|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
214740390|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
214740391|NCT06352502|DRUG|Furmonertinib|Patients treated with Furmonertinib mesilate tablets orally
214740392|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
214740393|NCT04337528|OTHER|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
214740394|NCT04337528|OTHER|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
214740395|NCT04337528|OTHER|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
214740396|NCT02149628|DRUG|propofol|
214740397|NCT02149628|DRUG|Desflurane|
214740398|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
214740399|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
214740400|NCT02005718|DRUG|Cholecalciferol|
214740401|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
214740402|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
214740403|NCT03431623|BIOLOGICAL|CKD-11101(Darbepoetin alfa)|
214740404|NCT03431623|BIOLOGICAL|NESP(Darbepoetin alfa)|
214740405|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
214740406|NCT03686579|RADIATION|chest trauma|clinical and radiological study
214740407|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
214740408|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
214740409|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
214740410|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
214740411|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
214740412|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
214740413|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
214740414|NCT02685839|OTHER|general physical therapy|
214740415|NCT02161224|DRUG|FG-4592|Oral
214740416|NCT02438670|DEVICE|PID control algorithm|
214740417|NCT02438670|DEVICE|MPC control algorithm|
214740418|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
214740419|NCT02845115|DEVICE|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
214740420|NCT02845115|DEVICE|optimized implantation with laser velocimetry|
214740421|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
214740422|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
214740423|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
214740424|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
214740425|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
214740426|NCT02993783|DRUG|Vedolizumab|Vedolizumab IV infusion
214740427|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
214740428|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
214740429|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
214740430|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
214740431|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
214740432|NCT02117492|PROCEDURE|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
214740433|NCT02335567|OTHER|there is no intervention|
214740434|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
214740435|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
214740436|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
214740437|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
214740438|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
214740439|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
214740440|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
214740441|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
214740442|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
214740443|NCT05822284|DIAGNOSTIC_TEST|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
214740444|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
214740445|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
214740446|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
214740447|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
214740448|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
214740449|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
214740450|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
214740451|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
214740452|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
214740453|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
214740454|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
214740455|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
214740456|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
214740457|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
214740458|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
214740459|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
214740460|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
214740461|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
214740462|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
214740463|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
214740464|NCT06305169|DIAGNOSTIC_TEST|Gastropanel|Gastropanel is a commercially available blood test which given serum levels of pepsinogen I and II and gastrin 17 along with helicobacter pylori infection status
214740465|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
214740466|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
214740467|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
214740468|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
214740469|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
214740470|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1\. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
214740471|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
214740472|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
214740473|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
214740474|NCT02396264|OTHER|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
214740475|NCT02396264|OTHER|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
214740476|NCT05237414|DEVICE|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
214740477|NCT05237414|DEVICE|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
214740478|NCT05237414|BEHAVIORAL|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
214740479|NCT05237414|BEHAVIORAL|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
214740480|NCT04691011|OTHER|Muscular MRI|MRI (1.5T)
214740481|NCT04691011|OTHER|Electrophysiological exam|MUNIX
214740482|NCT04691011|OTHER|Brain MRI|MRI (7T)
214740483|NCT04691011|OTHER|Spinal cord MRI|7T and 3T MRI
214740484|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
214740485|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
214740486|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
214740487|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
214740488|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
214740489|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
214740490|NCT00304681|DRUG|OROS*-Methylphenidate|
214740491|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
214740492|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
214740493|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
214740494|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
214740495|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
214740496|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
214740497|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
214740498|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
214740499|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
214740500|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
214740501|NCT01512849|DRUG|TA-7284 Low|Low
214740502|NCT01512849|DRUG|TA-7284 High|High
214740503|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
214740504|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
214740505|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
214740506|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
214740507|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
214740508|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
214740509|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
214740510|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
214740511|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
214740512|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
214740513|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
214740514|NCT02006394|OTHER|Market variety bread products|placebo bread products
214740515|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
214740516|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
214740517|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
214740518|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
214740519|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
214740520|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
214740521|NCT00404326|DRUG|Hydralazine and magnesium valproate|
214740522|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
214740523|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
214740524|NCT00006242|DRUG|BMS-214662|Given IV
214740525|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
214740526|NCT00006242|OTHER|pharmacological study|Correlative studies
214740527|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
214740528|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
214740529|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
214740530|NCT00267267|DRUG|torcetrapib/atorvastatin|
214740531|NCT00267267|DRUG|ezetimibe/simvastatin|
214740532|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
214740533|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
214740534|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
214740535|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
214740536|NCT00517673|DRUG|GSK945237|
214740537|NCT00517673|DRUG|Sugar Pill|Placebo
214740538|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
214740539|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
214740540|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
214740541|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
214740542|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
214740543|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
214740544|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
214740545|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
214740546|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
214740547|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
214740548|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
214740549|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
214740550|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
214740551|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
214740552|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
214740553|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
214740554|NCT01709240|DEVICE|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
214740555|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
214740556|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
214740557|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
214740558|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
214740559|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
214740560|NCT00410514|DRUG|Mirabegron|oral
214740561|NCT00410514|DRUG|Placebo|oral
214740562|NCT03351062|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
214740563|NCT03351062|DRUG|Toremifene|Patients will be given 60mg Toremifene once a day.
214740564|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
214740565|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
214740566|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
214740567|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
214740568|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
214740569|NCT00881023|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
214740570|NCT00881023|DEVICE|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
214740571|NCT05743413|PROCEDURE|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
214740572|NCT05743413|PROCEDURE|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
214740573|NCT02289521|DEVICE|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
214740574|NCT02481323|DRUG|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
214740575|NCT02481323|DRUG|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
214740576|NCT07050056|DRUG|Tislelizumab|200mg, iv, Q3W, 3-4 cycle
214740577|NCT07050056|RADIATION|3D-CRT/IMRT|40Gy in 20 fractions
214740578|NCT07058597|DEVICE|Twinfork plate|Twinfork plate
214740579|NCT07058597|DEVICE|3D-interlocking plate|3D-interlocking plate
214740580|NCT07058597|DEVICE|Miniplate|Miniplate
214740581|NCT06731894|PROCEDURE|Biospecimen Collection|Undergo urine sample collection
214740582|NCT06731894|DRUG|Cannabidiol|Given PO
214740583|NCT06731894|DRUG|Dronabinol|Given PO
214740584|NCT06731894|DRUG|Placebo Administration|Given PO
214740585|NCT06731894|OTHER|Survey Administration|Ancillary studies
214740586|NCT02074475|OTHER|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
214740587|NCT05880160|OTHER|Phased withdrawal of heart failure medications|As per arm/group description
214740588|NCT07072962|DEVICE|home-based self-administered interactive exercise|The Tele-Exergame system delivers a structured foot and ankle exercise program tailored for individuals with cognitive impairment or mild dementia to support balance and cognitive function. Exercises such as leg raising and foot flexion are guided through audio, visual, and text prompts on a tablet. A foot-mounted motion sensor provides real-time feedback to ensure proper range of motion, while exercise data are securely streamed to the cloud for remote monitoring of adherence. The system also includes a telemedicine interface to enable remote support and education when needed.
214740589|NCT06049706|DEVICE|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
214740590|NCT06049706|DEVICE|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
214740591|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
214740592|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
214740593|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
214740594|NCT00468624|DRUG|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
214740595|NCT00468624|PROCEDURE|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
214740596|NCT00468624|PROCEDURE|blood sampling before and after pegvisomant/placebo|
214740597|NCT00468624|PROCEDURE|arginine stimulation test after each limb|
214740598|NCT03080532|OTHER|dietary habits|
214740599|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
214740600|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
214740601|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
214740602|NCT06911008|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
214740603|NCT06911008|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214740604|NCT06911008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214740605|NCT06911008|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214740606|NCT06911008|OTHER|Questionnaire Administration|Ancillary studies
214740607|NCT06911008|BIOLOGICAL|SCD1 Inhibitor MTI-301|Given PO
214740608|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
214740609|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
214740610|NCT06908395|OTHER|10-day ambulatory assessment in everyday life combined with two laboratory office days|Participants undergo a 10-day ambulatory assessment period wearing a continuous glucose monitor and a light logger as a necklace as well as completing short questionnaires through a smartphone app at regular intervals every day. On the first day, participants also undergo an extensive eye examination. Day 11 and 12 are spent in either dim or bright office lighting in randomized order.
214794261|NCT01480531|DRUG|Clevidipine|"Clevidipine administration begins in the ER or ICU~* Clevidipine is again administered post op when blood pressure control is required.~* Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~* Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~* Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~* Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
214740611|NCT07100236|OTHER|Observational study of 29 - gene - defined HCC subtypes and immunotherapy responsiveness correlation|This is a non - interventional observational study. We will stratify patients with hepatocellular carcinoma (HCC) based on transcriptome sequencing of their tumor samples, specifically using a 29 - gene signature to classify them into different subtypes. Without interfering with patients' existing immunotherapy regimens (which are determined by clinical practice), we will retrospectively collect and analyze data on treatment responses. The goal is to explore the correlation between the 29 - gene - based HCC subtypes and responsiveness to immunotherapy, focusing on differences in outcomes like objective response rate (ORR) and progression - free survival (PFS) across subtypes. This study distinguishes itself by emphasizing observational analysis of pre - existing treatment patterns rather than implementing active interventions, aiming to provide insights into personalized immunotherapy for HCC through genetic subtyping.
214740612|NCT05281549|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
214740613|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
214740614|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
214740615|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo posterior spinal tumor resection
214740616|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
214740617|NCT01308489|PROCEDURE|quality-of-life assessment|Ancillary studies
214740618|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
214740619|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
214740620|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
214740621|NCT00477867|PROCEDURE|quality-of-life assessment|
214740622|NCT06909578|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
214740623|NCT06412198|DRUG|Cetuximab|Given by IV
214740624|NCT06412198|DRUG|Cemiplimab|Given by IV
214740625|NCT06412198|DRUG|Adagrasib|Given by PO
214740626|NCT07101744|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab combined with Nimotuzumab , administered on Day 1 every 3 weeks (D1 Q3W), until disease progression or unacceptable toxicity.
214740627|NCT07102238|PROCEDURE|muscoloskeletal ultrasound and synovial biopsy|Use of a standardized US evaluation according with OMERACT definition and scoring system; Synovial biopsy; To identify systemic and synovial disease biomarkers in SLE patients that can predict different joint patterns, systemic manifestations and response to therapy through multi-omics technologies.
214740628|NCT07100093|PROCEDURE|Drug serum levels|Ustekinumab trough levels (prior to administration of the next dose of the drug) will be determined by enzyme-linked immunoadsorption assay (ELISA) methodology.
214740629|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
214740630|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
214740631|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
214740632|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
214740633|NCT02897076|DRUG|betamethasone 24 mg|
214740634|NCT02897076|DRUG|12mg betamethasone +placebo|
214740635|NCT06928142|BIOLOGICAL|Sibeprenlimab|400 mg administered SC Q4 weeks
214740636|NCT06928142|OTHER|Placebo|Administered SC Q4 weeks
214740637|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
214740638|NCT01289561|DRUG|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
214740639|NCT01289561|DRUG|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
214740640|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
214740641|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
214740642|NCT00938197|DRUG|Fimasartan|Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
214740643|NCT00938197|DRUG|Amlodipine|Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
214740644|NCT00508469|DRUG|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
214740645|NCT00508469|DRUG|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
214740646|NCT00508469|DRUG|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
214740647|NCT00508469|DEVICE|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
214740648|NCT06766604|OTHER|Super-GDF9 supplementation during CAPA-IVM|Group 1: donated COCs will be exposed to Super-GDF9 at 50 ng/ml in both the CAPACITATION and MATURATION culture steps.
214740649|NCT06766604|OTHER|Conventional CAPA-IVM|Group 2: The subject's remaining COCs will be cultured in the CAPA step and the IVM step without the addition of Super-GDF9 during CAPA-IVM.
214740650|NCT05573022|OTHER|Pre-consultation electronic patient decision aid|This group is invited to access an electronic version before the consultation. The group of colorectal cancer patients is also introduced to a paper-based version by the clinician in the consultation.
214740651|NCT05573022|OTHER|In-consultation paper-based patient decision aid|This group is introduced to a paper-based version by the clinician in the consultation
214740652|NCT06419790|DEVICE|EIT electrode belt, spirometry|Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
214740653|NCT03109535|BEHAVIORAL|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
214740654|NCT03109535|BEHAVIORAL|Fitbit only|Users receive a Fitbit Zip to wear daily.
214740655|NCT05700994|BEHAVIORAL|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
214740656|NCT05700994|BEHAVIORAL|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
214740657|NCT05244733|BEHAVIORAL|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
214740658|NCT05244733|BEHAVIORAL|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
214740659|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
214740660|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
214740661|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
214740662|NCT04362514|BEHAVIORAL|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
214740663|NCT04362514|OTHER|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
214740664|NCT01150149|BEHAVIORAL|No face touch|
214740665|NCT01150149|DEVICE|Surgical face mask|
214740666|NCT01150149|DEVICE|Surgical face mask + no face touch|
214740667|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
214740668|NCT01376115|DRUG|Nelarabine|
214740669|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
214740670|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
214740671|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
214740672|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
214740673|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
214740674|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
214740675|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
214740676|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
214740677|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
214740678|NCT00491062|PROCEDURE|Biopsies|
214740679|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
214740680|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
214740681|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
214740682|NCT01240629|OTHER|questionnaire administration|Correlative study
214740683|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
214740684|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
214740685|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
214740686|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
214740687|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
214740688|NCT02879968|OTHER|Non-interventional study|
214740689|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
214740690|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
214740691|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
214740692|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
214740693|NCT04408105|BEHAVIORAL|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
214740694|NCT04408105|BEHAVIORAL|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
214740695|NCT04408105|BEHAVIORAL|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
214740696|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
214740697|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
214740698|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
214740699|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
214740700|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
214740701|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
214740702|NCT00452166|DRUG|rosiglitazone|
214740703|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
214740704|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
214740705|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
214740706|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
214740707|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
214740708|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
214740709|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
214740710|NCT06199193|DIETARY_SUPPLEMENT|Personalized diet|Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets
214740711|NCT06199193|DIETARY_SUPPLEMENT|Dietary counseling|Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
214740712|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
214740713|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
214740714|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
214740715|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
214740716|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
214740717|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
214740718|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
214740719|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
214740720|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
214740721|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
214740722|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
214794262|NCT01205607|DEVICE|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
214740723|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
214740724|NCT00003855|PROCEDURE|axillary lymph node dissection|
214740725|NCT00003855|RADIATION|whole breast irradiation|
214740726|NCT06037863|OTHER|Best Practice|Undergo bladder filling prior to CT
214740727|NCT06037863|PROCEDURE|Computed Tomography|Undergo CT
214740728|NCT06037863|OTHER|Electronic Health Record Review|Ancillary studies
214740729|NCT06037863|PROCEDURE|Imaging Procedure|Undergo bladder emptying prior to CT
214740730|NCT06037863|OTHER|Questionnaire Administration|Ancillary studies
214740731|NCT06037863|RADIATION|Radiation Therapy|Undergo radiation therapy
214740732|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
214740733|NCT05366686|BEHAVIORAL|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
214740734|NCT02841254|OTHER|Non interventional study|
214740735|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
214740736|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
214740737|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
214740738|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
214740739|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
214740740|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
214740741|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
214740742|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
214740743|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
214740744|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
214740745|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
214740746|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
214740747|NCT02267460|BIOLOGICAL|AA4500|
214740748|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
214740749|NCT02267460|PROCEDURE|Investigator Modeling|
214740750|NCT01621581|GENETIC|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
214740751|NCT02318082|DRUG|Interleukin-2|
214740752|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
214740753|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
214740754|NCT03231592|OTHER|CSA Group|Already included in the arm descriptions.
214740755|NCT03231592|OTHER|Enhanced Usual Care Group|Already included in the arm descriptions.
214740756|NCT00336466|DRUG|Human recombinant erythropoietin|
214740757|NCT05637073|DRUG|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
214740758|NCT05637073|PROCEDURE|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
214740759|NCT05637073|OTHER|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
214740760|NCT00278967|DRUG|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
214740761|NCT00278967|DRUG|HalfLytely - Reformulation|
214740762|NCT00443534|DRUG|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
214740763|NCT02531919|DRUG|Sodium Bicarbonate|Given PO
214740764|NCT03362216|DRUG|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
214740765|NCT03362216|DRUG|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
214740766|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
214740767|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
214740768|NCT00364611|DRUG|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
214740769|NCT00364611|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
214740770|NCT00364611|DRUG|Trastuzumab|"* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
214740771|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
214740772|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
214740773|NCT04191252|DIAGNOSTIC_TEST|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
214740774|NCT04471532|BEHAVIORAL|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
214740775|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
214740776|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
214740777|NCT05466240|DRUG|AT-752|AT-752 for 5 days
214740778|NCT05466240|DRUG|Placebo|Placebo for 5 days
214740779|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
214740780|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
214740781|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
214740782|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
214740783|NCT00154895|DRUG|intrapleural minocycline instillation|
214740784|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
214740785|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
214740786|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
214740787|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
214740788|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
214740789|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
214740790|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
214740791|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
214740792|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
214740793|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
214740794|NCT00305773|DRUG|vorinostat|Given orally once daily
214740795|NCT00305773|DRUG|vorinostat|Given orally three times daily
214740796|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
214740797|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
214740798|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
214740799|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
214740800|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
214740801|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
214740802|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
214740803|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
214740804|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
214740805|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
214740806|NCT00073541|DRUG|EMD 72000|
214740807|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
214740808|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
214740809|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
214740810|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
214740811|NCT00409149|BEHAVIORAL|CALM Approache|
214740812|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
214740813|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
214740814|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
214740815|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
214740816|NCT00958230|DEVICE|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
214740817|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
214740818|NCT00002494|DRUG|cyclophosphamide|
214740819|NCT00002494|DRUG|cytarabine|
214740820|NCT00002494|DRUG|dexamethasone|
214740821|NCT00002494|DRUG|doxorubicin hydrochloride|
214740822|NCT00002494|DRUG|etoposide|
214740823|NCT00002494|DRUG|ifosfamide|
214740824|NCT00002494|DRUG|leucovorin calcium|
214740825|NCT00002494|DRUG|mesna|
214740826|NCT00002494|DRUG|methotrexate|
214740827|NCT00002494|DRUG|prednisone|
214740828|NCT00002494|DRUG|therapeutic hydrocortisone|
214740829|NCT00002494|DRUG|vincristine sulfate|
214740830|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
214740831|NCT00002494|RADIATION|low-LET photon therapy|
214740832|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
214740833|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
214740834|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
214740835|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
214740836|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
214740837|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
214740838|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
214740839|NCT04984252|BEHAVIORAL|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
214740840|NCT04984252|BEHAVIORAL|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
214740841|NCT04984252|BEHAVIORAL|Distraction group|Participants will be asked to listen recording on irrelevant topic.
214740842|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
214740843|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
214740844|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
214740845|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
214740846|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
214740847|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
214740848|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
214740849|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
214794263|NCT01205607|DEVICE|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
214740850|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
214740851|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
214740852|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
214740853|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
214740854|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
214740855|NCT03178591|DRUG|vildagliptin|
214740856|NCT03178591|DRUG|Dapagliflozin|
214740857|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
214740858|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
214740859|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
214740860|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
214740861|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
214740862|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
214740863|NCT04686539|DRUG|Placebo|Placebo Oil
214740864|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214740865|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
214740866|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
214740867|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
214740868|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
214740869|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
214740870|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
214740871|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
214740872|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
214740873|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
214740874|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
214740875|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
214740876|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
214740877|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
214740878|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
214740879|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
214740880|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
214740881|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
214740882|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
214740883|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
214740884|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
214740885|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
214740886|NCT02249858|PROCEDURE|Cranial Vault Hold|
214740887|NCT02249858|PROCEDURE|Cervical HVLA|
214740888|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
214740889|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
214740890|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
214740891|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
214740892|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
214740893|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
214740894|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
214740895|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
214740896|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
214740897|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
214740898|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
214740899|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
214740900|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
214740901|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
214740902|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
214740903|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
214740904|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
214740905|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
214740906|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
214740907|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
214740908|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
214740909|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
214740910|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
214740911|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
214740912|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
214740913|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
214740914|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
214740915|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
214740916|NCT05482958|DEVICE|HOP watch|Prospective observational study
214740917|NCT02712892|GENETIC|Non Interventional Study|
214740918|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
214740919|NCT02184520|DEVICE|TRANSITION|
214740920|NCT02184520|DEVICE|REVERE|
214740921|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
214740922|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
214740923|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
214740924|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
214740925|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
214740926|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
214740927|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
214740928|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
214740929|NCT00003016|DRUG|tamoxifen citrate|
214740930|NCT00003016|PROCEDURE|adjuvant therapy|
214740931|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
214740932|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
214740933|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
214740934|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
214740935|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
214740936|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
214740937|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
214740938|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
214740939|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
214740940|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
214740941|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
214740942|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
214740943|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
214740944|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
214740945|NCT05249504|OTHER|Community resources|Learn about community resources
214740946|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
214740947|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
214740948|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
214740949|NCT02397772|DRUG|albendazole|Single dose of albendazole (400 mg)
214740950|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
214740951|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
214740952|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
214740953|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
214740954|NCT03595982|DRUG|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
214740955|NCT03595982|DRUG|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
214740956|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
214740957|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
214740958|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
214740959|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
214740960|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
214740961|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
214740962|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
214740963|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
214740964|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
214740965|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
214740966|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
214740967|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
214740968|NCT02773849|BIOLOGICAL|ADSTILADRIN|
214740969|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
214740970|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
214740971|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
214740972|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
214740973|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
214740974|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
214740975|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
214740976|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
214740977|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
214740978|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
214740979|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
214740980|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
214740981|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
214740982|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
214740983|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
214740984|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
214740985|NCT03331393|OTHER|Non-interventional|Non-interventional
214740986|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
214740987|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
214740988|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
214740989|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
214740990|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
214740991|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
214740992|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
214740993|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
214740994|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
214740995|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
214794264|NCT01699581|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
214740996|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
214740997|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
214740998|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
214740999|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
214741000|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
214741001|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
214741002|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
214741003|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
214741004|NCT02418000|DRUG|E6201|Single Group Assignment
214741005|NCT02772042|OTHER|Intervention Group|
214741006|NCT02772042|OTHER|Control Group|
214741007|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
214741008|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
214741009|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
214741010|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
214741011|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
214741012|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
214741013|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
214741014|NCT03261739|BIOLOGICAL|Placebo|Placebo
214741015|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
214741016|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
214741017|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
214741018|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
214741019|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
214741020|NCT01845766|OTHER|exercise rehabilitation|
214741021|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
214741022|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
214741023|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
214741024|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
214741025|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
214741026|NCT00946829|DRUG|telmisartan|
214741027|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
214741028|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
214741029|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
214741030|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
214741031|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
214741032|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
214741033|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
214741034|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
214741035|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
214741036|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
214741037|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
214741038|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
214741039|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
214741040|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
214741041|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
214741042|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
214741043|NCT00114400|DRUG|folic acid|
214741044|NCT00114400|DRUG|vitamin B12|
214741045|NCT00114400|DRUG|vitamin B6|
214794265|NCT02294656|DRUG|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
214741046|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
214741047|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
214741048|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
214741049|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
214741050|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
214741051|NCT04522986|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
214741052|NCT05908162|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
214741053|NCT03530059|OTHER|Home-based rehabilitation|Observational study
214741054|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
214741055|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
214741056|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
214741057|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
214741058|NCT02709941|OTHER|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
214741059|NCT02709941|OTHER|Placebo|
214741060|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
214741061|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
214741062|NCT00282607|DRUG|DA-8159|
214741063|NCT01424865|GENETIC|fluorescence in situ hybridization|
214741064|NCT01424865|OTHER|immunohistochemistry staining method|
214741065|NCT01424865|OTHER|immunologic technique|
214741066|NCT01424865|OTHER|laboratory biomarker analysis|
214741067|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
214741068|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
214741069|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
214741070|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
214741071|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
214741072|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
214741073|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
214741074|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
214741075|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
214741076|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
214741077|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
214741078|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
214741079|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
214741080|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214741081|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
214741082|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
214741083|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
214741084|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1\) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
214741085|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
214741086|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
214741087|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
214741088|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
214741089|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
214741090|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
214741091|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
214741092|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
214741093|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
214741094|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
214741095|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
214741096|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
214741097|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
214741098|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
214741099|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
214741100|NCT01986049|DRUG|Bupivicaine|
214741101|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
214741102|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
214741103|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
214741104|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
214741105|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
214741106|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
214741107|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
214741108|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
214741109|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
214741110|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
214741111|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
214741112|NCT03880162|OTHER|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
214741113|NCT03880162|OTHER|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
214741114|NCT04560127|DRUG|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
214741115|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
214741116|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
214741117|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
214741118|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
214741119|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
214741120|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
214741121|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
214741122|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
214741123|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
214741124|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
214741125|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
214741126|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
214741127|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
214741128|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
214741129|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
214741130|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
214741131|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
214741132|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
214741133|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
214741134|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
214741135|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
214741136|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
214741137|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
214741138|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
214741139|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
214741140|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
214741141|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
214741142|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
214741143|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
214741144|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
214741145|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
214741146|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
214794266|NCT02294656|DRUG|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
214794267|NCT03291509|BEHAVIORAL|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
214794268|NCT03291509|BEHAVIORAL|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
214741147|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
214741148|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
214741149|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
214741150|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
214741151|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
214741152|NCT01676649|DRUG|Carboplatin|AUC = 6
214741153|NCT01676649|DRUG|Paclitaxel|175 mg/m2
214741154|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
214741155|NCT01051856|DEVICE|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
214741156|NCT01051856|PROCEDURE|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
214741157|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
214741158|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
214741159|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
214741160|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
214741161|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
214741162|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
214741163|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
214741164|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
214741165|NCT02381795|DRUG|Nasal Carbon Dioxide|
214741166|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
214741167|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
214741168|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
214741169|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
214741170|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
214741171|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
214741172|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
214741173|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
214741174|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
214741175|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
214741176|NCT01245972|PROCEDURE|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
214741177|NCT01412333|DRUG|Interferon beta-1a|
214741178|NCT01412333|DRUG|Ocrelizumab-matching placebo|
214741179|NCT01412333|DRUG|Ocrelizumab|
214741180|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
214741181|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
214741182|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
214794269|NCT03291509|BEHAVIORAL|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
214741183|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
214741184|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
214741185|NCT02079701|BIOLOGICAL|Placebo|
214741186|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
214741187|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
214741188|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
214741189|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
214741190|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
214741191|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
214741192|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
214741193|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
214741194|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
214741195|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
214741196|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
214741197|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
214741198|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
214741199|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
214741200|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
214741201|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
214741202|NCT00000244|DRUG|Dynorphin 1 - 13|
214741203|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
214741204|NCT00003572|DRUG|mycophenolate mofetil|
214741205|NCT00003572|DRUG|tacrolimus|
214741206|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
214741207|NCT00003572|RADIATION|radiation therapy|
214741208|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
214741209|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
214741210|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
214741211|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
214741212|NCT00462657|GENETIC|polymerase chain reaction|
214741213|NCT00462657|OTHER|bronchoalveolar lavage|
214741214|NCT00462657|OTHER|immunoenzyme technique|
214741215|NCT00462657|OTHER|laboratory biomarker analysis|
214741216|NCT00462657|PROCEDURE|bronchoscopy|
214741217|NCT00462657|PROCEDURE|management of therapy complications|
214741218|NCT01430949|PROCEDURE|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
214741219|NCT00860704|DRUG|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
214741220|NCT03704090|BEHAVIORAL|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
214741221|NCT03704090|BEHAVIORAL|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
214741222|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
214741223|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
214741224|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
214741225|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
214741226|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
214741227|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
214741228|NCT00001343|DRUG|Humatrope|
214741229|NCT00001343|DRUG|Oxandrolone|
214741230|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
214741231|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
214741232|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
214741233|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
214741234|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
214741235|NCT04075955|DRUG|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
214741236|NCT04075955|DRUG|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
214794270|NCT03291509|BEHAVIORAL|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
214794271|NCT00148915|DRUG|ibandronate|
214794272|NCT00148915|DRUG|Placebo|matching placebo
214794273|NCT00533403|DRUG|MK0686|
214741237|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
214741238|NCT00271076|PROCEDURE|IVUS|
214741239|NCT00271076|DEVICE|CAS|
214741240|NCT00271076|PROCEDURE|CEA|
214741241|NCT01943136|DRUG|papaya 1% extract ointment|
214741242|NCT01943136|DRUG|mupirocin 2% ointment|
214741243|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
214741244|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
214741245|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
214741246|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
214741247|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
214741248|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
214741249|NCT01969565|DRUG|Carfilzomib|
214741250|NCT01969565|DRUG|Dexamethasone|
214741251|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
214741252|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
214741253|NCT01910649|DRUG|Drisapersen|Subcutaneous and Intravenous
214741254|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
214741255|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
214741256|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
214741257|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
214741258|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
214741259|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
214741260|NCT04212611|DRUG|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
214741261|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
214741262|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
214741263|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
214741264|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
214741265|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
214741266|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
214741267|NCT03257306|PROCEDURE|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
214741268|NCT03257306|PROCEDURE|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
214741269|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
214741270|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
214741271|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
214741272|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
214741273|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
214741274|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
214741275|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
214741276|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
214741277|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
214741278|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
214741279|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
214741280|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
214741281|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
214741282|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
214741283|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
214741284|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
214741285|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
214741286|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
214741287|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
214741288|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
214741289|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
214741290|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
214741291|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
214741292|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
214741293|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
214741294|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
214741295|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
214741296|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
214741297|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
214741298|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
214741299|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
214741300|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
214741301|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
214741302|NCT01784900|DRUG|Catumaxomab 100µg|
214741303|NCT01784900|DRUG|Catumaxomab 140µg|
214741304|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
214741305|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
214741306|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
214741307|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
214741308|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
214741309|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
214741310|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
214741311|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
214741312|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
214741313|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
214741314|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
214741315|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
214741316|NCT02136329|DRUG|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
214741317|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
214741318|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
214741319|NCT03266367|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
214741320|NCT01585909|PROCEDURE|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
214741321|NCT04111926|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
214741322|NCT04111926|DRUG|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
214741323|NCT03062605|DRUG|Iodine (Betadine)|
214741324|NCT03062605|BIOLOGICAL|NaOCL|
214741325|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
214741326|NCT01742182|OTHER|Light exposure|
214741327|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
214741328|NCT00151723|PROCEDURE|treatment with 131I|
214741329|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
214741330|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
214741331|NCT03424616|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
214741332|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
214741333|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
214741334|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
214741335|NCT01768039|DRUG|Vitamin D|
214741336|NCT01768039|DRUG|Placebo|
214741337|NCT02522091|DEVICE|functional brain MRI|
214741338|NCT02522091|OTHER|Neuropsychology tests|
214741339|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
214741340|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
214741341|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
214741342|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
214741343|NCT03481634|DRUG|Aflibercept|Intravitreal injection
214741344|NCT00994890|DRUG|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
214741345|NCT00994890|DRUG|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
214741346|NCT00994890|DRUG|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
214741347|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
214741348|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
214741349|NCT00089206|BIOLOGICAL|sargramostim|
214741350|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
214741351|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
214741352|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
214741353|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
214741354|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
214741355|NCT01469637|DRUG|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
214741356|NCT01469637|DRUG|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
214741357|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
214741358|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
214741359|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
214741360|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
214741361|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
214741362|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
214741363|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
214741364|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
214741365|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
214741366|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
214741367|NCT00834392|BEHAVIORAL|Exercise|Walking exercise
214741368|NCT04275492|DRUG|Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)|Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
214741369|NCT04275492|DRUG|Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)|Siforl® is produced by Boehringer Ingelheim International Gmbh
214741370|NCT00597532|DIETARY_SUPPLEMENT|Soy|soy (soy protein supplementation 50 grams/day)
214741371|NCT00597532|DIETARY_SUPPLEMENT|Milk|placebo (milk protein supplementation 50 grams/day)
214741372|NCT05687253|DRUG|BX1000|IV BX1000
214741373|NCT05687253|DRUG|Rocuronium Bromide|IV Rocuronium
214741374|NCT03398252|DRUG|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
214741375|NCT03398252|DRUG|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
214741376|NCT01525108|BEHAVIORAL|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
214741377|NCT01525108|OTHER|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
214741378|NCT05961397|DRUG|baxdrostat|single oral dose of baxdrostat 10 mg
214741379|NCT06404229|DIAGNOSTIC_TEST|CardioPulmonary Exercise Testing|CardioPulmonary Exercise Testing using an arm ergometer prior to surgery
214741380|NCT00604357|DRUG|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
214741381|NCT03727386|OTHER|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
214741382|NCT03727386|OTHER|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
214741383|NCT00310063|PROCEDURE|acupressure therapy|Acupressure wristband
214741384|NCT00310063|PROCEDURE|sham intervention|Sham wristband
214741385|NCT00472043|DRUG|PDT with Metvix 160 mg/g cream|
214741386|NCT00472043|DRUG|Placebo|
214741387|NCT04995731|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
214741388|NCT04995731|PROCEDURE|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
214741389|NCT02802735|DRUG|Apremilast|Tablet for oral administration
214741390|NCT02802735|DRUG|Placebo|Tablet for oral administration
214741391|NCT04542395|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
214741392|NCT03686527|PROCEDURE|stenosis aortic valve|"The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial"
214741393|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
214741394|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
214741395|NCT06106685|DRUG|High-dose washed microbiota suspension|The high-dose group will be administered a high dose of washed microbiota suspension。
214741396|NCT06106685|DRUG|Low-dose washed microbiota suspension|The low-dose group will be administered a low dose of washed microbiota suspension.
214741397|NCT06106685|DRUG|Placebo|The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
214741398|NCT04733664|DEVICE|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
214741399|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
214741400|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
214741401|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
214741402|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
214741403|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
214741404|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
214741405|NCT03973502|DRUG|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
214741406|NCT04690556|DRUG|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
214741407|NCT04690556|DRUG|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
214741408|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
214741409|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
214741410|NCT03166228|DRUG|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
214741411|NCT03166228|DRUG|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
214741412|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
214741413|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
214741414|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
214741415|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
214741416|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
214741417|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
214741418|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
214741419|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
214741420|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
214741421|NCT04335357|DRUG|Placebo|Placebo
214741422|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
214741423|NCT00761033|BEHAVIORAL|music|
214741424|NCT00439699|DRUG|Memantine|Mematine administration
214741425|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
214741426|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
214741427|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
214741428|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
214741429|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
214741430|NCT01902927|OTHER|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
214741431|NCT02582151|DEVICE|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
214741432|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
214741433|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
214741434|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
214741435|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
214741436|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
214741437|NCT02570581|OTHER|Jelly with Furosemide|
214741438|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
214741439|NCT02570581|OTHER|Jelly with Memantine|
214741440|NCT02570581|OTHER|Jelly with Zopiclone|
214741441|NCT02570581|OTHER|Jelly with Alprazolam|
214741442|NCT02570581|OTHER|Jelly with Oxazepam|
214741443|NCT02570581|OTHER|Jelly with Donepezil|
214741444|NCT02570581|OTHER|Jelly with Clopidogrel|
214741445|NCT02570581|OTHER|Jelly with Ramipril|
214741446|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
214741447|NCT02570581|OTHER|Plain jelly control|
214741448|NCT02570581|OTHER|Apple compote Paracetamol|
214741449|NCT02570581|OTHER|Apple compote Furosemide|
214741450|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
214741451|NCT02570581|OTHER|Apple compote Memantine|
214741452|NCT02570581|OTHER|Apple compote Zopiclone|
214741453|NCT02570581|OTHER|Apple compote Alprazolam|
214741454|NCT02570581|OTHER|Apple compote Oxazepam|
214741455|NCT02570581|OTHER|Apple compote Donepezil|
214741456|NCT02570581|OTHER|Apple compote Clopidogrel|
214741457|NCT02570581|OTHER|Apple compote Ramipril|
214741458|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
214741459|NCT02570581|OTHER|Plain apple compote control|
214741460|NCT02217449|OTHER|Prediction of histology|
214741461|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
214741462|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
214741463|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
214741464|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
214741465|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
214741466|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
214741467|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
214741468|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
214741469|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
214741470|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
214741471|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
214741472|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
214741473|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
214741474|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
214741475|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
214741476|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
214741477|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
214741478|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
214741479|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
214741480|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
214741481|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
214741482|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
214741483|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
214741484|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
214741485|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
214741486|NCT03220620|OTHER|GDT|individualized fluid therapy
214741487|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
214741488|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
214741489|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
214741490|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
214741491|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
214741492|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
214741493|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
214741494|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
214741495|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
214741496|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
214741497|NCT03102541|OTHER|None intervention|
214741498|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
214741499|NCT00205010|PROCEDURE|Lymphoscintigraphy|
214741500|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
214741501|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
214741502|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
214741503|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
214741504|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
214741505|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
214741506|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
214741507|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
214741508|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
214741509|NCT06369402|DIAGNOSTIC_TEST|Cerebral haemodynamic testing using transcranial Doppler|Measurement of cerebral haemodynamics using transcranial Doppler to insonate the middle cerebral arteries bilaterally testing neurovascular coupling with selected domains from the Addenbrooks cognitive examination III and the digit span forward and backwards.
214741510|NCT06369402|DIAGNOSTIC_TEST|Ankle-brachial pressure index|Ratio of ankle to brachial blood pressure measured using handheld Doppler at rest and after exercise (six-minute walk test).
214741511|NCT06369402|DIAGNOSTIC_TEST|Six-minute walk test|Supervised brisk walk for six minutes. Time and distance to onset of claudication pain and total distance walked (and total time walked if did not complete the full six minutes).
214741512|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
214741513|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
214741514|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
214741515|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
214741516|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
214741517|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
214741518|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
214741519|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
214741520|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
214741521|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
214741522|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
214741523|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
214741524|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
214741525|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
214794274|NCT01632787|OTHER|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
214741526|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
214741527|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
214741528|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
214741529|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
214741530|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
214741531|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
214741532|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
214741533|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
214741534|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
214794275|NCT02764008|DRUG|Bupivacaine|20 ml %0,25 bupivacaine
214741535|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
214741536|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
214741537|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
214741538|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
214741539|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
214741540|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
214741541|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
214741542|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
214741543|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
214741544|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
214741545|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
214741546|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
214741547|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
214741548|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
214741549|NCT03539666|OTHER|diet|dietary patterns
214741550|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
214741551|NCT00275704|DRUG|Flaxseed|
214741552|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
214741553|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
214741554|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
214741555|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
214741556|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
214741557|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
214741558|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
214741559|NCT00983944|BIOLOGICAL|rituximab|Given IV
214741560|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
214741561|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
214741562|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
214741563|NCT00983944|DRUG|etoposide|Given IV or orally
214741564|NCT00983944|DRUG|prednisone|Given IV or orally
214741565|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
214741566|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
214741567|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
214741568|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
214741569|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
214741570|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
214741571|NCT00075634|DRUG|decitabine|Given IV
214741572|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
214741573|NCT00075634|DRUG|cyclophosphamide|Given IV
214741574|NCT00075634|BIOLOGICAL|filgrastim|Given SC
214741575|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
214741576|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
214741577|NCT00075634|OTHER|pharmacological study|Correlative studies
214741578|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
214741579|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
214741580|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
214741581|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
214741582|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
214741583|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
214741584|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
214741585|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
214741586|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR\_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
214741587|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
214741588|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
214741589|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
214741590|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
214794276|NCT02764008|DEVICE|Ultrasound|
214741591|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
214741592|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
214741593|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
214741594|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
214741595|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
214741596|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
214741597|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
214794277|NCT00004381|DRUG|tin mesoporphyrin|
214741598|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
214741599|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
214741600|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
214741601|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
214741602|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
214741603|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
214741604|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
214741605|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
214741606|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
214741607|NCT01888380|PROCEDURE|Conventional autopsy|
214741608|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
214741609|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
214741610|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
214741611|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
214741612|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
214741613|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
214741614|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
214741615|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
214741616|NCT02327182|DRUG|MT-4666|
214741617|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
214741618|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
214741619|NCT02408016|DRUG|Cyclophosphamide|Given IV
214741620|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
214741621|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214741622|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
214741623|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
214741624|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
214741625|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
214741626|NCT00216346|DRUG|Paromomycin sulfate|
214741627|NCT00216346|DRUG|Amphotericin B|
214741628|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
214741629|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
214741630|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
214741631|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
214794278|NCT06460974|OTHER|stress ball|A stress ball was applied to the patients in the during chemotherapy treatment.
214741632|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
214741633|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
214741634|NCT00003410|DRUG|motexafin gadolinium|
214741635|NCT00003410|PROCEDURE|magnetic resonance imaging|
214741636|NCT00003410|PROCEDURE|surgical procedure|
214741637|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
214741638|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
214741639|NCT00284167|BEHAVIORAL|tailored web-based weight management intervention|
214741640|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
214741641|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
214741642|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
214741643|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
214741644|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
214741645|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
214741646|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
214741647|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
214741648|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
214741649|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
214741650|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
214741651|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
214741652|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
214741653|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
214741654|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
214741655|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
214741656|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
214741657|NCT01722552|BEHAVIORAL|adherence feedback|
214741658|NCT01722552|BEHAVIORAL|standard of care|
214741659|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
214741660|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
214741661|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
214741662|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
214741663|NCT00045565|DRUG|arsenic trioxide|Given IV
214741664|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
214741665|NCT02581098|OTHER|No interventions|No interventions
214741666|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
214741667|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
214741668|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
214741669|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
214741670|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
214741671|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
214741672|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
214741673|NCT02967562|OTHER|Inflation Breaths|
214741674|NCT02967562|OTHER|Sustained Inflation|
214741675|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
214741676|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
214741677|NCT03260062|BEHAVIORAL|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
214741678|NCT03260062|OTHER|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
214741679|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
214741680|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
214741681|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
214741682|NCT04335552|OTHER|Standard of care|Standard of care
214741683|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
214741684|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
214741685|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
214741686|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
214741687|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
214741688|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
214741689|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
214741690|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
214741691|NCT02004457|BEHAVIORAL|ABBT|
214741692|NCT02004457|OTHER|TAU|
214741693|NCT04563624|DRUG|composite blocks|cad cam composite blocks
214741694|NCT04563624|DRUG|ceramic cad cam blocks|ceramic cad cam blocks
214741695|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
214741696|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
214741697|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
214741698|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
214741699|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
214741700|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
214741701|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
214741702|NCT02870348|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
214741703|NCT06366854|PROCEDURE|Personalised fluid and haemodynamic resuscitation|individualised resuscitation
214741704|NCT00672139|DRUG|Methylnaltrexone bromide|
214741705|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
214741706|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
214741707|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
214741708|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
214741709|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
214741710|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
214741711|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
214741712|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
214741713|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
214741714|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
214741715|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
214741716|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
214741717|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
214741718|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
214741719|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
214741720|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214741721|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
214741722|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
214741723|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
214741724|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
214741725|NCT00420823|DRUG|Taurine 4g|
214741726|NCT05302102|OTHER|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
214794279|NCT03936400|BEHAVIORAL|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
214741727|NCT05302102|OTHER|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
214741728|NCT05302102|OTHER|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
214741729|NCT05272306|OTHER|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
214741730|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
214741731|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
214741732|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
214741733|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
214741734|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
214794280|NCT01695109|DRUG|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
214794281|NCT01695109|DRUG|Placebo|0.9% NaCl, 0.2 ml
214741735|NCT05807191|OTHER|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
214741736|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
214741737|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
214741738|NCT00107536|DRUG|lapatinib ditosylate|
214741739|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
214741740|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
214741741|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
214741742|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
214741743|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
214741744|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
214741745|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
214741746|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
214741747|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
214741748|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
214741749|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
214741750|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
214741751|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
214741752|NCT05278611|DRUG|placebo|placebo
214741753|NCT02002637|DEVICE|Latella Knee Implant System|
214741754|NCT02393612|DRUG|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
214741755|NCT02393612|DRUG|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
214741756|NCT00159653|DRUG|Xalacom|
214741757|NCT00159653|DRUG|Xalatan|
214741758|NCT00159653|DRUG|Timolol|
214741759|NCT03344874|DEVICE|Stethee®|Stethee® is a new wireless digital stethoscope.
214741760|NCT03344874|DEVICE|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
214741761|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
214741762|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
214741763|NCT04048057|OTHER|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
214741764|NCT00597857|DRUG|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
214741765|NCT00597857|DRUG|placebo|receipt of a placebo pill for 16 days
214741766|NCT04054219|DEVICE|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
214741767|NCT00213967|DEVICE|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
214741768|NCT02355925|DRUG|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
214741769|NCT02355925|DRUG|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
214741770|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
214741771|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
214741772|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
214741773|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
214741774|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
214741775|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
214741776|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
214741777|NCT05648006|BIOLOGICAL|OH2|Oncolytic Type 2 Herpes Simplex Virus
214741778|NCT05648006|DRUG|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
214741779|NCT05648006|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
214741780|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
214741781|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
214741782|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
214741783|NCT05914233|DEVICE|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
214741784|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
214741785|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
214741786|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
214741787|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
214741788|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
214741789|NCT00001925|DRUG|Alcohol|
214741790|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
214741791|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
214794282|NCT00240682|DRUG|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
214741792|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
214741793|NCT04454840|BIOLOGICAL|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
214741794|NCT04454840|DRUG|Riluzole|The basic treatment is Riluzole 25\~50mg twice daily
214741795|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
214741796|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
214741797|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
214741798|NCT04451395|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
214741799|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
214741800|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
214741801|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
214741802|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
214741803|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
214741804|NCT00857116|DRUG|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
214741805|NCT00857116|DRUG|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
214741806|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
214741807|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
214741808|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
214741809|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
214741810|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
214741811|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
214741812|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
214741813|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
214741814|NCT05119790|DRUG|[14C] BIIB122 ([14C] DNL151)|Oral dose
214741815|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
214741816|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
214741817|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
214741818|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
214741819|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
214794283|NCT01617577|DRUG|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
214741820|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
214741821|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
214741822|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
214741823|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
214741824|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
214741825|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
214741826|NCT02429076|DRUG|Placebo|normal saline
214741827|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
214741828|NCT02429076|DRUG|Propofol|IV anesthetic
214741829|NCT00242814|DRUG|Micardis|
214741830|NCT00242814|DRUG|Amlodipine|
214741831|NCT00242814|PROCEDURE|Abdominal biopsy|
214741832|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
214794284|NCT01617577|DRUG|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
214741833|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
214741834|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
214741835|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
214741836|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
214741837|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
214741838|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
214741839|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
214741840|NCT00372944|DRUG|AZD6244|oral capsule
214741841|NCT00372944|DRUG|capecitabine|oral tablet
214741842|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
214741843|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
214741844|NCT01741285|DRUG|Fluticasone|Course particle treatment
214741845|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
214741846|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
214741847|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
214741848|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
214741849|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
214741850|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
214741851|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
214741852|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
214741853|NCT00544154|DRUG|CDP870|
214741854|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
214741855|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
214741856|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
214741857|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
214741858|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
214741859|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
214741860|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
214741861|NCT06277609|DRUG|Lu AF28996|Capsule
214741862|NCT06277609|DRUG|Acetylsalicylic Acid|Tablet
214741863|NCT06277609|DRUG|Mefenamic Acid|Tablet
214741864|NCT06277609|DRUG|Amoxicillin/clavulanic acid|Tablet
214741865|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
214741866|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
214741867|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
214741868|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
214741869|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
214741870|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
214741871|NCT00256204|OTHER|Placebo|Placebo
214741872|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
214741873|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
214741874|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
214741875|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
214741876|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
214741877|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
214741878|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
214741879|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
214741880|NCT03427528|BEHAVIORAL|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
214741881|NCT03427528|BEHAVIORAL|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
214741882|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
214741883|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
214741884|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
214741885|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
214741886|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
214741887|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
214741888|NCT06201585|DEVICE|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
214741889|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
214741890|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
214741891|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
214741892|NCT00474136|DRUG|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
214741893|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
214741894|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
214741895|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
214741896|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
214741897|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
214741898|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
214741899|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
214741900|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
214741901|NCT04144933|DRUG|Dexamethasone, Ondansetron|6 mg, 4 mg
214741902|NCT04144933|DRUG|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
214741903|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
214741904|NCT04144933|DRUG|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
214741905|NCT02405091|DRUG|NBI-98854|
214741906|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
214741907|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
214741908|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
214741909|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
214741910|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
214741911|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
214741912|NCT01644812|BEHAVIORAL|Aerobic exercise|
214741913|NCT01644812|BEHAVIORAL|Stretching|
214741914|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
214741915|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
214741916|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
214741917|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
214741918|NCT00002024|DRUG|Ganciclovir|
214741919|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
214741920|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
214741921|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
214741922|NCT00191438|DRUG|gemcitabine|
214741923|NCT00191438|DRUG|capecitabine|
214741924|NCT00191438|DRUG|docetaxel|
214741925|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
214741926|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
214741927|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
214741928|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
214741929|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
214741930|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
214741931|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
214741932|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
214741933|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
214741934|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
214741935|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
214741936|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
214741937|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
214741938|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
214741939|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
214741940|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
214741941|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
214741942|NCT02074436|DRUG|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
214741943|NCT02074436|OTHER|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
214741944|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
214741945|NCT02401945|DRUG|DE-120|
214741946|NCT02401945|DRUG|Aflibercept|
214741947|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
214741948|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
214741949|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
214741950|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
214741951|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
214741952|NCT01694966|DRUG|Methylene Blue MMX®|
214741953|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
214741954|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
214741955|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
214741956|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
214741957|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
214741958|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
214741959|NCT04068220|OTHER|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
214741960|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
214741961|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
214741962|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
214741963|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
214741964|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
214741965|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
214741966|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
214741967|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
214741968|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
214741969|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
214741970|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
214741971|NCT00247962|DRUG|etanercept|50 mg
214741972|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
214741973|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
214741974|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
214741975|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
214741976|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
214741977|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
214741978|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
214741979|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
214741980|NCT02924922|DRUG|Mannitol|
214741981|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
214741982|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
214741983|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
214741984|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
214741985|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
214741986|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
214741987|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
214741988|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
214741989|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
214741990|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
214741991|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
214741992|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
214741993|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
214741994|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
214741995|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
214741996|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
214741997|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
214741998|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
214741999|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
214742000|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
214742001|NCT00155246|DRUG|pentoxifylline (drug)|
214742002|NCT00702949|DRUG|pregabalin|Given orally
214742003|NCT00702949|OTHER|placebo|Given orally
214742004|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
214742005|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
214742006|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
214742007|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
214742008|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
214742009|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
214742010|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
214742011|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
214742012|NCT02690506|DRUG|Placebo|
214742013|NCT02690506|DRUG|Pregabalin|
214742014|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
214742015|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
214742016|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
214742017|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
214742018|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
214742019|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
214742020|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
214742021|NCT00052494|DRUG|cisplatin|
214742022|NCT00052494|DRUG|imatinib mesylate|
214742023|NCT00052494|DRUG|irinotecan hydrochloride|
214742024|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
214742025|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
214742026|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
214742027|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
214742028|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
214742029|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
214742030|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
214742031|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
214742032|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
214742033|NCT04989660|DRUG|6% aqueous phenol|1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
214742034|NCT04989660|DRUG|Isotonic saline|1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
214742035|NCT00923962|DRUG|Glucagon like peptide-1|0,1 pmol/kg/min
214742036|NCT00923962|DRUG|Adenosine|20-40 microgram/minute
214742037|NCT02505269|DRUG|Brentuximab Vedotin|
214742038|NCT02505269|DRUG|Adriamycin|
214742039|NCT02505269|DRUG|Dacarbazine|
214742040|NCT03904004|PROCEDURE|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
214742041|NCT03904004|PROCEDURE|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
214742042|NCT03904004|PROCEDURE|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
214742043|NCT03904004|PROCEDURE|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
214742044|NCT01451957|OTHER|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
214742045|NCT01451957|OTHER|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
214742046|NCT01451957|OTHER|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
214742047|NCT01983046|DRUG|Three different mixture of acetate, butyrate and propionate and palcebo|
214742048|NCT00307892|DRUG|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
214742049|NCT00307892|DRUG|Placebo|placebo remedy
214742050|NCT04012762|DEVICE|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
214742051|NCT01135004|PROCEDURE|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
214742052|NCT00199368|DRUG|Istradefylline ( KW-6002)|
214742053|NCT00150150|PROCEDURE|Interstitial laser photocoagulation|
214742054|NCT03542890|DEVICE|Baska Mask|used in adult low risk females undergoing elective gynecological operations
214742055|NCT03542890|DEVICE|I-gel|used in adult low risk females undergoing elective gynecological operations
214742056|NCT00578890|PROCEDURE|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
214742057|NCT01339676|DRUG|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
214742058|NCT01339676|DRUG|Placebo capsules|Identically appearing once weekly peroral placebo capsules
214742059|NCT01344304|DRUG|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
214742060|NCT03304769|DEVICE|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
214742061|NCT03822546|OTHER|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
214742062|NCT03822546|OTHER|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
214742063|NCT03822546|OTHER|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
214742064|NCT03822546|OTHER|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
214742065|NCT03822546|OTHER|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
214742066|NCT03822546|OTHER|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
214742067|NCT03518463|COMBINATION_PRODUCT|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
214794285|NCT02287532|DEVICE|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
214794286|NCT02605109|OTHER|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
214742068|NCT05692986|DIAGNOSTIC_TEST|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of \>5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
214742069|NCT02162264|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
214742070|NCT00190606|DRUG|Duloxetine|
214742071|NCT00190606|PROCEDURE|Pelvic Floor Muscle Training (PFMT)|
214742072|NCT00190606|PROCEDURE|Imitation PFMT|
214742073|NCT00190606|DRUG|placebo|
214742074|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
214742075|NCT06279052|BEHAVIORAL|Phone interview|Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
214742076|NCT00804128|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
214742077|NCT00804128|DRUG|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
214742078|NCT03922711|DRUG|Pridopidine|Oral capsule
214742079|NCT03922711|DRUG|Placebo|Oral capsule
214742080|NCT00852761|DRUG|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
214742081|NCT00852761|DRUG|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
214742082|NCT01499212|PROCEDURE|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
214742083|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
214742084|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
214742085|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
214742086|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
214742087|NCT00000756|DRUG|Lymphocytes, Activated|
214742088|NCT04111185|DEVICE|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
214742089|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
214742090|NCT05063760|BEHAVIORAL|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
214742091|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
214742092|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
214742093|NCT02807155|BEHAVIORAL|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
214742094|NCT02807155|BEHAVIORAL|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
214742095|NCT02807155|BEHAVIORAL|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
214742096|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
214742097|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
214742098|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
214742099|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
214742100|NCT06296043|PROCEDURE|Progressive Muscle Relaxation Exercise Group|Exercise Group
214742101|NCT06296043|PROCEDURE|Su-Jok Intervention|Hand massage with seeds
214742102|NCT05616052|DRUG|Semaglutide|treatment with different dosage regimes
214742103|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
214742104|NCT00742391|DRUG|Vehicle gel|two day treatment
214742105|NCT06049628|BEHAVIORAL|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
214742106|NCT06049628|BEHAVIORAL|routine program|This program consists of jogging, and stretching exercises.
214742107|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
214742108|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
214742109|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
214742110|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
214742111|NCT01706744|OTHER|Intermediate care unit|
214742112|NCT01706744|OTHER|Local health care 1|
214742113|NCT01706744|OTHER|Local health care 2|
214742114|NCT02324413|DRUG|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
214742115|NCT02324413|DRUG|Placebo|
214742116|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
214742117|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
214742118|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
214742119|NCT04383535|OTHER|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
214742120|NCT04383535|OTHER|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
214742121|NCT00381472|DRUG|Ropinirole|
214742122|NCT05557240|DRUG|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
214742123|NCT05557240|DRUG|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
214742124|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
214742125|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
214742126|NCT01160042|DRUG|Metformin|Metformin Tablets 1000 mg
214742127|NCT01160042|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
214742128|NCT03271411|BEHAVIORAL|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
214742129|NCT03271411|BEHAVIORAL|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
214742130|NCT05874947|DEVICE|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
214742131|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
214742132|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
214742133|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
214742134|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
214742135|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
214742136|NCT01646736|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
214742137|NCT01646736|DRUG|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
214742138|NCT01646736|DRUG|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
214742139|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
214742140|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
214742141|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
214742142|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
214742143|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
214742144|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
214742145|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
214742146|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742147|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742148|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742149|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742150|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742151|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
214742152|NCT00933387|DRUG|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
214742153|NCT02599324|DRUG|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
214742154|NCT02599324|DRUG|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
214742155|NCT02599324|DRUG|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
214742156|NCT02599324|DRUG|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
214742157|NCT02599324|DRUG|cetuximab|Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
214742158|NCT02599324|DRUG|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
214742159|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
214742160|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
214742161|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
214742162|NCT04352049|PROCEDURE|Preoxygenation|
214742163|NCT00003606|DRUG|cisplatin|
214742164|NCT00003606|DRUG|cyclophosphamide|
214742165|NCT00003606|DRUG|epirubicin hydrochloride|
214742166|NCT00003606|DRUG|etoposide|
214742167|NCT00003606|RADIATION|radiation therapy|
214742168|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
214742169|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
214742170|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
214742171|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
214742172|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
214742173|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
214742174|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
214742175|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
214742176|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
214742177|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
214742178|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
214742179|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
214742180|NCT05219006|DIETARY_SUPPLEMENT|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
214742181|NCT05219006|DIETARY_SUPPLEMENT|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
214742182|NCT00266149|DRUG|Oral contraception|
214742183|NCT00266149|DRUG|Lamotrigine|
214742184|NCT04585113|RADIATION|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
214742185|NCT01901679|DRUG|Celebrex|200 mg PO BID
214742186|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
214742187|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
214742188|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
214742189|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
214742190|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
214742191|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
214742192|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
214742193|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
214742194|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
214742195|NCT01914510|DRUG|ENMD-2076|
214742196|NCT03453346|DRUG|Sofosbuvir|Generic sofosbuvir tablet 400 mg
214742197|NCT03453346|DRUG|Ribavirin|Ribavirin was provided in 100-mg tablets.
214742198|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
214742199|NCT05910983|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Bipolar enucleation of the prostate (BipolEP)
214742200|NCT05910983|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
214742201|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
214742202|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
214742203|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
214742204|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
214742205|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
214742206|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
214742207|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
214742208|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
214742209|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
214742210|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
214742211|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
214742212|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
214742213|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
214742214|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
214742215|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
214742216|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
214742217|NCT05539742|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
214742218|NCT05539742|DIETARY_SUPPLEMENT|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
214742219|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
214742220|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
214742221|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
214742222|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
214742223|NCT00417898|DRUG|Aspirin|
214742224|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
214742225|NCT05034029|DRUG|Placebo|Placebo
214742226|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
214742227|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
214742228|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
214742229|NCT02563886|OTHER|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
214742230|NCT02563886|OTHER|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
214742231|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214742232|NCT05061758|DRUG|LY3056480|LY3056480 is an inhibitor of gamma-secretase
214742233|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
214742234|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
214742235|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
214742236|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
214794287|NCT03344367|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
214794288|NCT04226911|BEHAVIORAL|S&SEs|"S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned."
214742237|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
214742238|NCT02741336|BEHAVIORAL|Self-Monitoring|
214742239|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
214742240|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
214742241|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
214742242|NCT04805606|DRUG|CKD-843 A|Single Dose
214742243|NCT04805606|DRUG|CKD-843 B|Single Dose
214742244|NCT04805606|DRUG|CKD-843-R|QD, PO
214742245|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
214742246|NCT04884009|DRUG|SHR-1701|SHR-1701
214742247|NCT00060333|RADIATION|radiation therapy|
214742248|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
214742249|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
214742250|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
214742251|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
214742252|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
214742253|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
214742254|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
214742255|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
214742256|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
214794289|NCT04226911|BEHAVIORAL|Sugar|"Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products."
214794290|NCT02563509|BIOLOGICAL|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
214742257|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
214742258|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
214742259|NCT04097106|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic dietary supplement in capsule form
214742260|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
214742261|NCT02886338|DEVICE|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
214742262|NCT00284336|DRUG|Caelyx|
214742263|NCT00284336|DRUG|endoxan|
214742264|NCT00394654|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
214742265|NCT00394654|OTHER|Placebo|Placebo administered as a single intravenous infusion
214742266|NCT00122317|DRUG|eculizumab|
214742267|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
214742268|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
214742269|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
214742270|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
214742271|NCT06263400|BEHAVIORAL|psychoeducation and follow-up study|In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
214742272|NCT02184390|OTHER|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
214742273|NCT04095962|OTHER|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
214742274|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
214742275|NCT02393989|PROCEDURE|posterior restoration|restorations for caries effected teeth
214742276|NCT03739060|DEVICE|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
214742277|NCT04250610|OTHER|Survey|On-line survey.
214742278|NCT01518140|DEVICE|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
214742279|NCT01518140|BEHAVIORAL|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
214742280|NCT00262561|DRUG|Aspirin|The effect of Aspirin on platelet function was assessed.
214742281|NCT05597111|DIAGNOSTIC_TEST|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
214742282|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
214742283|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
214742284|NCT07050212|DRUG|remimazolam group|remimazolam is administered intravenously at a dose of 0.3 mg/kg
214742285|NCT07050212|DRUG|dexmedetomidine group|dexmedetomidine is administered intravenously at a dose of 1 μg/kg
214742286|NCT07050212|DRUG|esketamine group|esketamine is administered intravenously at a dose of 0.5 mg/kg
214742287|NCT00600249|DRUG|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
214742288|NCT00600249|DRUG|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
214742289|NCT02705755|DRUG|TD-9855|Administered orally.
214742290|NCT02705755|DRUG|Placebo|Administered orally.
214742291|NCT07058168|DIETARY_SUPPLEMENT|Other: experimental group (labor diet)|"The data collection tools Personal Information Form, Women's Perception of Supportive Care Provided at Birth Scale, and Pregnant and Infant Monitoring Form (VAS pain, anxiety, fatigue and thirst scales) were applied. The VAS scales contains numbers evenly spaced (0-10) on a line. It's an evaluation scale filled out by pregnants stating their current levels by givig a number. The cut off point of the VAS anxiety and thirst scales were found to be four.In VAS anxiety, scores above this cut-off point indicate deviation from normal and individuals must be handled by professionals. In VAS thirst, patients who score above this score are considered to be experiencing dehydration symptoms. The time of the last meal was learnt according to the information given by the pregnant woman. Spontaneous blood glucose measurement was performed. The labor diet was administered after 6 hours of fasting. Post-prandial blood glucose and tools were measured after the labor diet (at the 2nd hours)"
214742292|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
214742293|NCT05453006|DEVICE|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview non-intervention clinics.
214742294|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
214742295|NCT02216292|OTHER|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
214742296|NCT02216292|OTHER|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
214742297|NCT06517446|OTHER|Optokinetic Virtual Reality Stimulation|"The optokinetic stimulation protocol is defined as follows:~* Optokinetic stimulation sessions are planned with a balloon rotation speed of 20°/s (degrees per second) during the first four weeks. In the fifth and sixth weeks, the speed will be increased to 25°/s, and in the seventh and eighth weeks, it will be raised to 30°/s.~* The background screen will be set to rotate in the same direction as the balloons, with a rotation speed equal to 30-50% of the balloon rotation speed.~* Session duration will start at 30 seconds and will increase to 150 seconds depending on patient tolerance as the sessions progress.~* Participants will be instructed to focus on the red balloon in a moving visual scene.~Optokinetic stimuli will be applied to participants in various postures: sitting, upright posture (feet together), semi-tandem stance, or tandem stance positions."
214742298|NCT06517446|OTHER|Conventional rehabilitation program based on Cawthorne Cooksey exercises|The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
214742299|NCT06517446|OTHER|VR+OKS|"The optokinetic stimulation protocol is defined as follows:~Optokinetic stimulation will be applied over 8 weeks with gradually increasing balloon rotation speeds: 20°/s (weeks 1-4), 25°/s (weeks 5-6), and 30°/s (weeks 7-8). The background will rotate in the same direction at 30-50% of the balloon speed. Sessions will start at 30 seconds and increase to 150 seconds based on tolerance. Participants will focus on a red balloon in a rotating visual scene, and the stimulation will be performed in various postures including sitting, feet together, semi-tandem, and tandem stance.~The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used."
214742300|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
214742301|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
214742302|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
214742303|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
214742304|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
214742305|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
214742306|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
214742307|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
214742308|NCT06471686|DRUG|Acamprosate|2 pills three times a day
214742309|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
214742310|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
214742311|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
214742312|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
214742313|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
214742314|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
214742315|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
214742316|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
214742317|NCT00027846|PROCEDURE|therapeutic conventional surgery|
214794291|NCT05899790|OTHER|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
214742318|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
214742319|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
214742320|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
214742321|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
214742322|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
214742323|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
214742324|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
214742325|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
214742326|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
214742327|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
214742328|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
214794292|NCT01968798|DRUG|Aspirin|100mg enteric-coated aspirin, taken daily
214742329|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
214742330|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
214742331|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
214742332|NCT01354964|DRUG|Vitamin D|
214742333|NCT01354964|DRUG|Placebo|
214742334|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
214742335|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
214742336|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
214742337|NCT03345927|OTHER|no intervention|no intervention
214742338|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
214742339|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
214742340|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
214742341|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
214742342|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
214742343|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
214742344|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
214742345|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
214742346|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
214742347|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
214742348|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
214742349|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
214742350|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
214742351|NCT05846659|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
214742352|NCT05846659|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
214742353|NCT05846659|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
214742354|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
214742355|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
214742356|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
214742357|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
214742358|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
214742359|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
214794293|NCT01968798|DRUG|Placebo|100mg enteric-coated placebo, taken daily
214742360|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
214742361|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
214742362|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
214742363|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
214742364|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
214742365|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
214742366|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
214742367|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
214742368|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
214742369|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
214742370|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
214742371|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
214742372|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
214742373|NCT01005966|DRUG|Placebo|placebo and washout treatment
214742374|NCT01005966|DRUG|675 ppmf toothpaste|dose response
214742375|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
214742376|NCT00863564|DIETARY_SUPPLEMENT|Cod|
214742377|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
214742378|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
214742379|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
214742380|NCT01451203|DRUG|CZP|SC
214742381|NCT01451203|DRUG|methotrexate (MTX)|oral
214742382|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
214742383|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
214794294|NCT04026464|DRUG|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
214742384|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
214742385|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
214742386|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
214742387|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
214742388|NCT02553486|OTHER|quality of life evaluation|
214742389|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
214742390|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
214742391|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
214742392|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
214742393|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
214742394|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
214742395|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
214742396|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
214742397|NCT02430064|OTHER|Low PAMP diet|
214742398|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
214742399|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
214742400|NCT03308799|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
214742401|NCT03308799|DRUG|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
214742402|NCT03308799|DRUG|Cream vehicle|Vehicle Cream
214742403|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
214742404|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
214742405|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
214742406|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
214742407|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
214742408|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
214742409|NCT04084444|DRUG|Placebo|Blank control.
214742410|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
214742411|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
214742412|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
214742413|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
214742414|NCT06304493|DEVICE|Alarms|"The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
214742415|NCT05534412|OTHER|Academic Detailing|"1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
214742416|NCT05534412|OTHER|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
214794295|NCT04026464|DRUG|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
214794296|NCT03342495|OTHER|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
214794297|NCT03342495|OTHER|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
214742417|NCT05534412|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
214742418|NCT05534412|OTHER|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
214742419|NCT01403415|DRUG|Dexamethasone|Given PO or IV
214742420|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
214742421|NCT01403415|DRUG|Methotrexate|Given IT
214742422|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
214742423|NCT01403415|DRUG|Pegaspargase|Given IV
214742424|NCT01403415|OTHER|Pharmacological Study|Correlative studies
214742425|NCT01403415|DRUG|Temsirolimus|Given IV
214742426|NCT01403415|DRUG|Vincristine Sulfate|Given IV
214742427|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
214742428|NCT00000980|DRUG|Spiramycin|
214742429|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
214742430|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
214742431|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
214742432|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
214742433|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
214742434|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
214742435|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
214742436|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
214742437|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
214742438|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
214742439|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
214742440|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
214742441|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
214742442|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
214742443|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
214742444|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
214742445|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
214742446|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
214742447|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
214742448|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
214742449|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
214742450|NCT00027027|DRUG|rhuMAb 2C4|
214794298|NCT05751070|OTHER|Bowen Technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Bowen treatment will be 15 to 20 Bowen moves with 2 mins gap between each set for total of 20 mins."
214742451|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
214742452|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
214742453|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
214742454|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
214742455|NCT01809158|DRUG|minocycline|
214742456|NCT01809158|DRUG|placebo|
214742457|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
214742458|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
214742459|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
214742460|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
214742461|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
214742462|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
214742463|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
214742464|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
214742465|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
214742466|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
214742467|NCT01829529|DRUG|Amoxicillin|Amoxicillin
214742468|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
214742469|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
214742470|NCT04115020|DRUG|Placebo|Placebo oral suspension
214742471|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
214742472|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
214742473|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
214742474|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
214742475|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
214742476|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
214742477|NCT02039687|OTHER|Placebo|Formulation buffer
214742478|NCT05959278|OTHER|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
214742479|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
214742480|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
214742481|NCT00343161|DRUG|esomeprazole|
214742482|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
214742483|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
214742484|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
214742485|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
214742486|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
214742487|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
214742488|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
214742489|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
214742490|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
214742491|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
214742492|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
214742493|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
214742494|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
214742495|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
214742496|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
214742497|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
214742498|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
214742499|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
214742500|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
214742501|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
214742502|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
214742503|NCT00570089|DRUG|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
214742504|NCT00570089|DRUG|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
214742505|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
214742506|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
214742507|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
214742508|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
214742509|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
214742510|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
214742511|NCT00510406|DRUG|Placebo|Placebo
214742512|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
214742513|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
214742514|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
214742515|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
214742516|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
214742517|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
214742518|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
214742519|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
214742520|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
214742521|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
214742522|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
214742523|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
214742524|NCT00124696|DRUG|Cocaethylene|
214742525|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
214742526|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
214742527|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
214742528|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
214742529|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
214742530|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
214742531|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
214742532|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
214742533|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
214742534|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
214742535|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
214742536|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
214742537|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
214742538|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
214742539|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
214742540|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
214742541|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
214742542|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
214742543|NCT02502994|DRUG|GEN0101|
214742544|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
214742545|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
214742546|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
214742547|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
214742548|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
214742549|NCT00072085|BIOLOGICAL|aldesleukin|
214742550|NCT00072085|BIOLOGICAL|gp100 antigen|
214742551|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
214742552|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
214742553|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
214742554|NCT00034801|DRUG|olanzapine|
214742555|NCT00034801|DRUG|ziprasidone|
214742556|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
214742557|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
214742558|NCT02758106|DEVICE|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
214742559|NCT02758106|DEVICE|placebo intervention|CCPT for 15 minutes then sputum suction.
214742560|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
214742561|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
214742562|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
214742563|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
214742564|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
214742565|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
214742566|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
214742567|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
214742568|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
214742569|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
214742570|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
214742571|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
214742572|NCT00689611|DRUG|Placebo|Placebo
214742573|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
214742574|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
214742575|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
214794299|NCT05751070|OTHER|Graston technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Graston treatment will be by using lubricant on the skin then a stainless steel instrument to relax the fascia and muscles. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute for total of 20 mins."
214742576|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
214742577|NCT03676712|DEVICE|scoliosis brace|Wear at least 18 hours a day
214742578|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
214742579|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
214742580|NCT05959876|OTHER|Training group|Face-to-face perineal care training
214742581|NCT05959876|OTHER|Control group|No intervention
214742582|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
214742583|NCT06065371|DRUG|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
214742584|NCT06065371|DRUG|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
214742585|NCT05949177|BEHAVIORAL|Graded Exposure and Mindfulness Meditation|Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
214742586|NCT05949177|BEHAVIORAL|Waitlist Control|Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
214742587|NCT05989815|OTHER|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
214742588|NCT05989815|DEVICE|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
214742589|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
214742590|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
214742591|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
214742592|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
214742593|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
214742594|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
214742595|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
214742596|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
214742597|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
214742598|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
214742599|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
214742600|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
214742601|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
214742602|NCT03018028|DRUG|Semaglutide|Oral administration once daily
214742603|NCT03018028|DRUG|Placebo|Oral administration once daily
214742604|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
214742605|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
214742606|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
214794300|NCT04842487|DRUG|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
214742607|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
214742608|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
214742609|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
214742610|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
214742611|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
214742612|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
214742613|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
214742614|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
214742615|NCT02543801|DRUG|Ropivacaine|Periarticular injection
214742616|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
214742617|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
214742618|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
214742619|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
214742620|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
214742621|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
214742622|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
214742623|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
214742624|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
214742625|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
214742626|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
214742627|NCT00682760|DRUG|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
214742628|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
214742629|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
214742630|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
214742631|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
214742632|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
214742633|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
214742634|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
214742635|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
214742636|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
214742637|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
214742638|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
214742639|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
214742640|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
214742641|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
214742642|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
214742643|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
214742644|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
214742645|NCT00352833|DRUG|catumaxomab|
214742646|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
214742647|NCT01020994|DRUG|LAS41003|Once daily, topically
214742648|NCT01020994|DRUG|LAS189962|Once daily, topically
214742649|NCT01020994|DRUG|LAS189961|Once daily, topically
214742650|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
214742651|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
214742652|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
214742653|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
214742654|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
214742655|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
214742656|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
214742657|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
214742658|NCT04139603|OTHER|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
214742659|NCT04139603|OTHER|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
214742660|NCT04139603|OTHER|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
214742661|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
214742662|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
214742663|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
214742664|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
214742665|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
214742666|NCT02084316|BEHAVIORAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
214742667|NCT02084316|BEHAVIORAL|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
214742668|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
214742669|NCT02736487|DEVICE|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
214742670|NCT02736487|DEVICE|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
214742671|NCT00580827|DRUG|Placebo|Matched placebo.
214742672|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
214742673|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
214742674|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
214742675|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
214742676|NCT01634087|DRUG|Placebo|Placebo administered orally
214742677|NCT00424736|PROCEDURE|whole body CT scan|
214742678|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
214742679|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
214742680|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
214742681|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
214742682|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
214742683|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
214742684|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
214742685|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
214742686|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
214742687|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
214742688|NCT03323385|DRUG|N1539|Once Daily
214742689|NCT03323385|DRUG|Placebo|Once Daily
214742690|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
214742691|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
214742692|NCT02963194|DRUG|Oxytocin|
214742693|NCT02963194|DRUG|Placebo|
214742694|NCT01087229|DRUG|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
214742695|NCT01087229|DRUG|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
214742696|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
214742697|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
214742698|NCT02538705|DRUG|Neovasculgen|
214742699|NCT02142075|DRUG|Daptomycin|
214742700|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
214742701|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
214742702|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
214742703|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
214742704|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
214742705|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
214742706|NCT02872090|DRUG|Indacaterol|inhalation
214742707|NCT02872090|DRUG|Glycopyrronium|inhalation
214742708|NCT02872090|DRUG|Tiotropium|inhalation
214742709|NCT02872090|DRUG|Placebo|
214742710|NCT02872090|PROCEDURE|photoplethysmography|inhalation
214742711|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
214742712|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
214742713|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
214742714|NCT06514170|OTHER|No intervention|No intervention
214742715|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
214742716|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
214742717|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
214742718|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
214742719|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
214742720|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
214742721|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
214742722|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
214742723|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
214742724|NCT00846352|PROCEDURE|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
214742725|NCT05476757|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
214742726|NCT02692560|BEHAVIORAL|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
214742727|NCT02692560|OTHER|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
214742728|NCT05004389|DIAGNOSTIC_TEST|MRI|white matter integrity and brain structural connectivity metrics
214742729|NCT05004389|DIAGNOSTIC_TEST|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
214742730|NCT05004389|OTHER|Clinical assessments|measures of strength, balance, and mobility
214742731|NCT01641341|DRUG|Bifidobacterium infantis|once a day for seven to eight weeks
214742732|NCT01641341|DRUG|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
214742733|NCT01641341|DRUG|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
214742734|NCT01641341|DRUG|Placebo|Placebo capsule will not contain active treatment ingredients.
214742735|NCT05917392|DIETARY_SUPPLEMENT|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
214742736|NCT05917392|DIETARY_SUPPLEMENT|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
214742737|NCT05917392|DIETARY_SUPPLEMENT|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
214742738|NCT00641745|DRUG|Lurasidone HCl|40 - 120mg per day
214742739|NCT00641745|DRUG|Risperidone|Risperidone
214742740|NCT03494946|PROCEDURE|Liver transplantation|
214742741|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
214742742|NCT02490904|DRUG|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
214742743|NCT02490904|DRUG|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
214742744|NCT01875068|BEHAVIORAL|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
214742745|NCT01875068|BEHAVIORAL|versus NPs and PAs who are not required to discuss patient referrals (control group).|
214742746|NCT05212467|BEHAVIORAL|AIR-program|This is a guided self management program that is added on the treatment as usual.
214742747|NCT05212467|BEHAVIORAL|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
214742748|NCT05212467|BEHAVIORAL|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
214742749|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
214742750|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
214742751|NCT02825238|OTHER|Supervised exercise program|
214742752|NCT01701349|DRUG|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
214742753|NCT01701349|DRUG|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
214742754|NCT03088332|PROCEDURE|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
214742755|NCT01675856|OTHER|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
214742756|NCT01675856|OTHER|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
214742757|NCT04700228|DRUG|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
214742758|NCT04700228|DRUG|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
214742759|NCT05422833|OTHER|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
214742760|NCT05554744|PROCEDURE|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
214742761|NCT00420212|DRUG|BG00012|
214742762|NCT00420212|DRUG|Placebo|
214742763|NCT02943044|DEVICE|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
214742764|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
214742765|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
214742766|NCT00417391|DRUG|RR110 (Tamibarotene)|1 mg RR110
214742767|NCT00417391|DRUG|RR110 (Tamibarotene)|4 mg RR110
214742768|NCT05141344|DRUG|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
214742769|NCT05141344|DRUG|Placebo|sugar-coated tablets will be given one hour preoperatively
214742770|NCT00854568|DRUG|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
214742771|NCT00854568|DRUG|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
214742772|NCT03934489|BEHAVIORAL|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
214742773|NCT03934489|BEHAVIORAL|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
214742774|NCT05178680|OTHER|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
214742775|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
214742776|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
214742777|NCT01326910|DRUG|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
214742778|NCT01326910|DEVICE|Topical Cream|Topical cream applied twice daily (or as needed)
214742779|NCT03449186|OTHER|Saliva collection|
214742780|NCT03449186|OTHER|GCF collection|
214742781|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
214742782|NCT01590446|DRUG|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
214742783|NCT01590446|DRUG|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
214742784|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
214742785|NCT05202184|PROCEDURE|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
214742786|NCT05405855|BEHAVIORAL|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
214742787|NCT01270113|BEHAVIORAL|contingency management|
214742788|NCT06446050|BIOLOGICAL|MSC-L|Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
214742789|NCT00001685|BIOLOGICAL|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
214742790|NCT06410729|OTHER|Observational study, no intervention|
214742791|NCT01261494|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
214742792|NCT01261494|DRUG|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
214742793|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
214742794|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
214742795|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
214742796|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
214742797|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
214742798|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
214742799|NCT04080349|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
214742800|NCT04080349|DRUG|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
214742801|NCT04080349|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
214742802|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
214742803|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
214742804|NCT00493844|OTHER|Exercise testing|Exercise testing
214742805|NCT00493844|OTHER|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
214742806|NCT04299750|PROCEDURE|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
214742807|NCT04299750|PROCEDURE|Tooth extraction|Tooth extraction and socket natural healing
214742808|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742809|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742810|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742811|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742812|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742813|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
214742814|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742815|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742816|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742817|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742818|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742819|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
214742820|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
214742821|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
214742822|NCT05790915|COMBINATION_PRODUCT|Standardized interventions|Standardized interventions according organ dysfunction
214742823|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
214742824|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
214742825|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
214742826|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
214742827|NCT03610867|DRUG|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
214742828|NCT03610867|DRUG|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
214742829|NCT03610867|DRUG|Placebo (SAD)|Each subject will receive the sample once by oral administration.
214742830|NCT03610867|DRUG|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
214742831|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
214742832|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
214742833|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
214742834|NCT00198289|DRUG|Aurexis® (tefibazumab)|
214742835|NCT02105168|PROCEDURE|Blood sample|Optional
214742836|NCT02105168|PROCEDURE|Tumorous biopsy|Optional
214742837|NCT02105168|PROCEDURE|Healthy material sample|Optional
214742838|NCT02981173|DRUG|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
214742839|NCT02981173|DRUG|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
214742840|NCT02981173|DRUG|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
214742841|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
214742842|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
214742843|NCT00415246|DRUG|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
214742844|NCT00205374|DRUG|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
214742845|NCT00205374|DRUG|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
214742846|NCT01251081|OTHER|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
214742847|NCT01251081|OTHER|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
214742848|NCT02142712|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
214742849|NCT02142712|DRUG|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
214742850|NCT02142712|DRUG|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
214742851|NCT02142712|DRUG|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
214742852|NCT03795545|PROCEDURE|SWL|Shock wave lithotripsy
214742853|NCT02239562|DRUG|sPIF|
214742854|NCT02239562|DRUG|Placebo|
214742855|NCT01834469|DRUG|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
214742856|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
214742857|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
214742858|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
214742859|NCT00021281|DRUG|FOLFIRI regimen|
214742860|NCT00021281|DRUG|fluorouracil|
214742861|NCT00021281|DRUG|irinotecan hydrochloride|
214742862|NCT00021281|DRUG|leucovorin calcium|
214742863|NCT00021281|DRUG|semaxanib|
214742864|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
214742865|NCT00600236|PROCEDURE|blood sample|
214742866|NCT00497159|OTHER|Placebo|Placebo TID x 90 days
214742867|NCT00497159|DRUG|Dimebon|Dimebon 20 mg TID x 90 days
214742868|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
214742869|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
214742870|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
214742871|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
214742872|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
214742873|NCT02633917|BEHAVIORAL|Motor control exercises|exercises to strength the lumbar musculature and control the posture
214742874|NCT02633917|BEHAVIORAL|Standard exercises|general exercises
214742875|NCT01981096|BEHAVIORAL|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
214742876|NCT01981096|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
214742877|NCT00293319|BIOLOGICAL|filgrastim|
214742878|NCT00293319|RADIATION|iobenguane I 131|
214742879|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
214742880|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
214742881|NCT04322266|DRUG|HGP0904|Amlodipine
214742882|NCT04322266|DRUG|HGP0608|Losartan potassium
214742883|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
214742884|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
214742885|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
214742886|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
214742887|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
214742888|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
214742889|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
214742890|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
214742891|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
214742892|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
214742893|NCT01225211|DRUG|Lumacaftor|Tablet
214742894|NCT01225211|DRUG|Ivacaftor|Tablet.
214742895|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
214742896|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
214742897|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
214742898|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
214742899|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
215030662|NCT07010874|OTHER|REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL|"The duration of the intervention is determined as 10 weeks. Distance nursing interventions based on the model will be carried out through a web page called Take Care of Yourself. Each participant will have a unique username and password while using the website, so that login information and the frequency of visiting the website will be recorded. During the 10-week intervention period, caregivers will be provided with 8 modules of training content. In the first session of the intervention, the website will be introduced, personal goals will be set and the session will be completed with the planning of the next week. personal goals will be set, and in the last session of the intervention, feedback will be given to the individuals by the researcher regarding the achievement of their personal goals and their ability to cope with future difficulties."
214742900|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
214742901|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
214742902|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
214742903|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
214742904|NCT00807989|DRUG|Carbamazepine|
214742905|NCT00807989|DRUG|Lamotrigine/Valproate|
214742906|NCT02619929|DRUG|Vinorelbine oral|
215030663|NCT07010042|OTHER|The Beck Anxiety Inventory (BAI) of adult patients|Postoperative 0,5,10,15 minutes , RSAS and NRS values
215030664|NCT06675214|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
214742907|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
214742908|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
214742909|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
214742910|NCT02067546|DEVICE|Experimental toilet seat|
214742911|NCT02067546|DEVICE|Standard toilet seat|
214742912|NCT03700931|BEHAVIORAL|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
214742913|NCT03700931|BEHAVIORAL|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
214742914|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
214742915|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
214742916|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
214742917|NCT00002336|DRUG|Clarithromycin|
214742918|NCT02476903|DRUG|Monovisc|
214742919|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
214742920|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
214742921|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
214742922|NCT01893879|DRUG|placebo for study drug|Given PO
214742923|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
214742924|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
214742925|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
214742926|NCT00075413|DRUG|arsenic trioxide|
214742927|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
214742928|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
214742929|NCT00106366|DRUG|insulin detemir|
214742930|NCT00106366|DRUG|insulin glargine|
214742931|NCT00106366|DRUG|insulin aspart|
214742932|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
214742933|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
214742934|NCT01520675|PROCEDURE|surgery|Drainage procedure
214742935|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
214742936|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
214742937|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
214742938|NCT04904991|PROCEDURE|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
214742939|NCT02355665|DRUG|Nicotine Spray|Nicotine Spray
214742940|NCT02355665|DRUG|Placebo|Placebo to match nicotine spray
214742941|NCT01579162|DEVICE|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
214742942|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
214742943|NCT01209117|DRUG|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
214742944|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
214742945|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
214742946|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
214742947|NCT01209117|DRUG|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
214742948|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
214742949|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
214742950|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
214742951|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
214742952|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
214742953|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
214742954|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
214742955|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
214742956|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
214742957|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
214742958|NCT05312099|OTHER|Case control|Case control study
214742959|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
214742960|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
214742961|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
214742962|NCT05413356|DRUG|Ruxolitinib|Oral ruxolitinib twice daily
214742963|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
214742964|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
214742965|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
214742966|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
214742967|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
214742968|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
214742969|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
214742970|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
214742971|NCT02604628|BEHAVIORAL|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
214742972|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
214742973|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
214742974|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
214742975|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
214742976|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
214742977|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
214742978|NCT02746991|DRUG|Sham Injection|Placebo
214742979|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
214742980|NCT01774227|PROCEDURE|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
214742981|NCT01774227|PROCEDURE|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
214742982|NCT00653198|OTHER|No intervention|
214742983|NCT00669591|DRUG|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
214742984|NCT05546957|DRUG|Aspirin|Administered orally once per day (QD)
214742985|NCT05546957|DRUG|rivaroxaban low dose|Administered orally twice per day (BID)
214742986|NCT05546957|DRUG|rivaroxaban high dose|Administered orally QD
214742987|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
214742988|NCT01389895|DRUG|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
214742989|NCT01389895|DRUG|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
214742990|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
214742991|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
214742992|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
214742993|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
214742994|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
214742995|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
214742996|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
214742997|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
214742998|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
214742999|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
214743000|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
214743001|NCT04851522|DRUG|Di-Dak-Sol|Topical solution applied externally.
214743002|NCT04851522|OTHER|White Petrolatum|Topical ointment applied externally
214743003|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
214743004|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
214743005|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
214743006|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
214743007|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
214743008|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
214743009|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
214743010|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
214743011|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
214743012|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
214794301|NCT05713409|DIAGNOSTIC_TEST|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
215030665|NCT06675214|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
215030666|NCT06675214|RADIATION|Standard-dose IMRT|GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy
214743013|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
214743014|NCT01078779|DRUG|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
214743015|NCT01078779|DRUG|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
214743016|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
214743017|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
214743018|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
214743019|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
214743020|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
214743021|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
214743022|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
214743023|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
214743024|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
214743025|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
214743026|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
214743027|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
214743028|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
214743029|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
214743030|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
214743031|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
214743032|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
215030667|NCT06675214|RADIATION|Gradient Fractionated IMRT|GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy
215030668|NCT06675214|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
214743033|NCT04034069|DEVICE|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
214743034|NCT04034069|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
214743035|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
214743036|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
214743037|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
214743038|NCT04052594|DRUG|LY3475766 - IV|Administered IV
214743039|NCT04052594|DRUG|LY3475766 - SC|Administered SC
214743040|NCT04052594|DRUG|Placebo - IV|Administered IV
214743041|NCT04052594|DRUG|Placebo - SC|Administered SC
214743042|NCT01808040|DRUG|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
214743043|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
214743044|NCT02485431|DRUG|Deflazacort|
214743045|NCT02993289|OTHER|Different well-known treatments|
214743046|NCT04559867|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
214743047|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
214743048|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
214743049|NCT00519558|DRUG|somatropin|
214743050|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
214743051|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
214743052|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
214743053|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
214743054|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
214743055|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
214743056|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
214743057|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
214743058|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
215030669|NCT07009925|DRUG|Ivonescimab 20mg/kg intravenous every 3 weeks|Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.If patient assessment is of clinical benefit, maintenance therapy with ivonescimab or plus polymeric micelles paclitaxel(≤230mg/m\^2) can be continued based on investigator's evaluation and patient's own choice until disease progression or unacceptable toxicity. Ivonescimab is administered first, followed by paclitaxel polymeric micelles and platinum.The maximum treatment duration of ivonescimab and polymeric micelles paclitaxel is 24 months.
214743059|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
214743060|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
214743061|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
214743062|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
214743063|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
214743064|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
214743065|NCT01654406|DEVICE|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4\_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
214743066|NCT01654406|DEVICE|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
214743067|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
214743068|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
214743069|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
214743070|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
214743071|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
214743072|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
215030670|NCT07010263|DRUG|AK112|AK112 20mg/kg, intravenous \[IV\]),Q3W
215030671|NCT07010263|OTHER|Placebo|Placebo, intravenous \[IV\]),Q3W
214743073|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
214743074|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
214743075|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
214743076|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
214743077|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
214743078|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
214743079|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
214743080|NCT00779233|DRUG|Zidovudine tablets 300 mg|
214743081|NCT01110889|DRUG|Agomelatine (AGO178C)|
214743082|NCT01110889|DRUG|Agomelatine (AGO178C)|
214743083|NCT01110889|DRUG|Placebo|
214743084|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
214743085|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
214743086|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
214743087|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
214743088|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
214743089|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
214743090|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
214743091|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
214743092|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
214743093|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
214743094|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
214743095|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
214743096|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
214743097|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
214743098|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
214743099|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
214743100|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
214743101|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
214743102|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
214743103|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
214743104|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
214743105|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
214743106|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
214743107|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
214743108|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
214743109|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
214743110|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
214743111|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214743112|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
214743113|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
214743114|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
214743115|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
214743116|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
214743117|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
214743118|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
214743119|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
214743120|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
214743121|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
214743122|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
214743123|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
214743124|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
214743125|NCT00337740|PROCEDURE|endoscopic variceal banding|
214743126|NCT00337740|DRUG|propranolol|
214743127|NCT05265585|DIAGNOSTIC_TEST|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
215030672|NCT07010991|OTHER|AI based clinical problem solving education|This direct involvement of AI and educators aims to improve learning outcomes by leveraging the scalability of AI and the expertise of educators. The question sets created by students and the answers obtained from ChatGPT are discussed within the group and prepared for class presentation, and the instructor provides feedback on accuracy, timeliness, and scientific relevance. This process aims to support students' participation as active questioners and analyzers, rather than passive consumers of information. Intervention will last for 2 weeks, 2 hours of courses each week, in total 4 hours of education will be given. First 2 hours will be the usage parameters and the knowledge about the ChatGPT system and the 2nd week's 2 hours of education will include the presentations and interactive discussion about the case.
214743128|NCT00490126|OTHER|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
214743129|NCT07052708|BEHAVIORAL|No adherence group|Patients with poor adherence was defined as medication possession ratio(MPR) \<50%.
214743130|NCT07052708|BEHAVIORAL|Adherence group|Patients with good adherence was defined as medication possession ratio(MPR) ≥50%.
214743131|NCT07058428|DRUG|Bevacizumab|Bevacizumab starts on day 1 (one week before FSRT treatment), q3w，a total of 4 treatment courses, intravenous injection, with a dose of 7.5mg/kg.
214743132|NCT07058428|RADIATION|FSRT|The FSRT group received simple FSRT radiotherapy; FSRT is targeted at visible intracranial lesions, with a total dose of 30Gy, administered once a day for a total of 5 days, with a fraction dose of 6Gy.
214743133|NCT07058428|RADIATION|Whole brain radiotherapy|The WBRT group received whole brain radiotherapy and locally increased dose radiotherapy for visible intracranial lesions, with a total dose of 40Gy for local lesions and 30Gy for the whole brain, once a day for a total of 10 days.
214743134|NCT03458234|DEVICE|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
214743135|NCT02651376|COMBINATION_PRODUCT|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
214743136|NCT01565460|OTHER|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
214743137|NCT04773964|DRUG|MET642|MET642 active treatment
214743138|NCT04773964|DRUG|Placebo|Placebo comparator
214743139|NCT03567590|PROCEDURE|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
214743140|NCT03567590|PROCEDURE|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
214743141|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
214743142|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
214743143|NCT00432354|DRUG|atorvastatin|
214743144|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
214743145|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
214743146|NCT03164122|DRUG|injection of microfat and plasma rich platelet PRP|intra-articular injections
214743147|NCT03164122|DEVICE|MRI|MRI 3T
214743148|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
214743149|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
214743150|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
214743151|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
214743152|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
214743153|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
214743154|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
214743155|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
214743156|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
214743157|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
214743158|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
214743159|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
214743160|NCT02049385|DRUG|Placebo|Placebo
214743161|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
214743162|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
214743163|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
214743164|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
214743165|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
214743166|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
214743167|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
214743168|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
214743169|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
214743170|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
214743171|NCT03758612|DRUG|TBI-223 oral suspension|TBI-223 oral suspension, orally administered.
214743172|NCT03758612|DRUG|TBI-223 enteric capsule|TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.
214743173|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 1|TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.
214743174|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 2|TBI-223 600 mg SR tablet Prototype 2, orally administered.
214743175|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 3|TBI-223 900 mg SR tablet Prototype 3, orally administered.
214743176|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet, orally administered
214743177|NCT03758612|DRUG|Placebo suspension|Placebo for TBI-223 oral Suspension; orally administered.
214743178|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
214743179|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
214743180|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
214743181|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
214743182|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
214743183|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
214743184|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
214743185|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
214743186|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
214743187|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
214743188|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
214743189|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
214743190|NCT01603615|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
214743191|NCT02967965|OTHER|Imagery|MRI at year 3
214743192|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
214743193|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
214743194|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
214743195|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
214743196|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
214743197|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
214743198|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
214743199|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
214743200|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
214743201|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
214743202|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
214743203|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
214743204|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
214743205|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
214743206|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
214743207|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
214743208|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
214743209|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
214743210|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
214743211|NCT01970124|DRUG|KPS-0373, High dose|
214743212|NCT01970124|DRUG|KPS-0373, Low dose|
214743213|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
214743214|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
214743215|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
214743216|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
214743217|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
214743218|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
214743219|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
214743220|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
214743221|NCT00188162|DEVICE|CT|
214743222|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
214743223|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
214743224|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
214743225|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
214743226|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
214743227|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
214743228|NCT00085189|DRUG|agatolimod sodium|Given SC
214743229|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
214743230|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
214743231|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
214743232|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
214743233|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
214794302|NCT01180244|DEVICE|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
214743234|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
214743235|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
214743236|NCT04450394|DRUG|LY3209590|Administered SC
214743237|NCT04450394|DRUG|Insulin Degludec|Administered SC
214794303|NCT01180244|DEVICE|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
214743238|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
214743239|NCT04252872|DRUG|HCP0605|
214743240|NCT04252872|DRUG|HGP1405|
214743241|NCT04252872|DRUG|HCP1401|
214743242|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
214743243|NCT01730768|DRUG|AQW051|
214743244|NCT01730768|DRUG|Placebo|
214743245|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
214743246|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
214743247|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
214743248|NCT00104429|DRUG|GW873140|
214743249|NCT00104429|DRUG|Combivir|
214743250|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
214743251|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
214743252|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
214743253|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
214743254|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
214743255|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
214743256|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
214743257|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
214743258|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
214743259|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
214743260|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
214743261|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
214743262|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
214743263|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
214743264|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
214743265|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
214743266|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
214743267|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
214743268|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
214743269|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
214743270|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
214743271|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
214743272|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
214743273|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
214743274|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
214743275|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
214743276|NCT00374764|DRUG|Risperidone|
214743277|NCT00374764|BEHAVIORAL|ABA|
214743278|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
214743279|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
214743280|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
214794013|NCT05819008|DIAGNOSTIC_TEST|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995)."
214743281|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
214743282|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
214743283|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
214743284|NCT01434498|DRUG|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
214743285|NCT01434498|DRUG|GS-9451 tablet|GS-9451 tablet, 200 mg QD
214743286|NCT01434498|DRUG|tegobuvir capsule|tegobuvir capsule, 30 mg BID
214743287|NCT01434498|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
214743288|NCT01434498|DRUG|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
214743289|NCT01434498|DEVICE|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
214743290|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
214743291|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
214743292|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
214743293|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214743294|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214743295|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214743296|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214743297|NCT00002176|DRUG|Hydroxyurea|
214743298|NCT00002176|DRUG|Nelfinavir mesylate|
214743299|NCT00002176|DRUG|Stavudine|
214743300|NCT00002176|DRUG|Didanosine|
214743301|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
214743302|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
214743303|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
214743304|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
214743305|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
214743306|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
214743307|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
214743308|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
214743309|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
214743310|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
214743311|NCT00153699|DRUG|Topiramate|
214743312|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214743313|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214743314|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214743315|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214743316|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
214743317|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
214743318|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
214743319|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
214743320|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
214743321|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
214743322|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
214743323|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
214743324|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
214743325|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
214743326|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
214743327|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
214743328|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
214743329|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
214743330|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
214743331|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
214743332|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
214743333|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
214743334|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
214743335|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
214743336|NCT03934333|DRUG|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
214743337|NCT03934333|DRUG|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
214743338|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
214743339|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
214743340|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
214743341|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
214743342|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
214743343|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
214743344|NCT00133640|DRUG|cholecalciferol|
214743345|NCT00133640|BEHAVIORAL|Physiotherapy|
214743346|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
214743347|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
214743348|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
214743349|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
214743350|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
214743351|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
214743352|NCT02050256|OTHER|continuing medical education and electronic decision support|
214743353|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
214743354|NCT01745159|DRUG|tacrolimus|
214743355|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
214743356|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
214743357|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
214743358|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
214743359|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
214743360|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
214743361|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
214743362|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
214743363|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
214743364|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
214794014|NCT05304299|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
214743365|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
214743366|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
214743367|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
214743368|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
214743369|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
214743370|NCT00759993|DRUG|chromium piccolinate|1000mg tab
214743371|NCT00759993|DRUG|placebo for chromium piccolinate|
214743372|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
214743373|NCT00493909|PROCEDURE|thoracic epidural analgesia|
214743374|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
214743375|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
214743376|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
214743377|NCT02073292|PROCEDURE|c-RFA|
214743378|NCT02073292|PROCEDURE|tRFA|
214743379|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1\) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
214743380|NCT04853368|DRUG|ABBV-576|Oral capsules
214743381|NCT04853368|DRUG|Galicaftor|Oral capsules
214743382|NCT04853368|DRUG|Placebo|Oral capsules
214743383|NCT04853368|DRUG|Navocaftor|Oral capsules
214743384|NCT04853368|DRUG|ABBV-119|Oral capsules
214743385|NCT00266331|DRUG|Reduced glutathione|
214743386|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
214743387|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
214743388|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
214743389|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
214743390|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
214743391|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
214743392|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
214743393|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
214743394|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
214743395|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
214743396|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
214743397|NCT01880320|DRUG|Topical Gel Vehicle|
214743398|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
214743399|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
214743400|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
214743401|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
214743402|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
214743403|NCT03511222|DRUG|Nivolumab|Standard of care
214743404|NCT03511222|DRUG|Pembrolizumab|Standard of care
214743405|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
214743406|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
214743407|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
214743408|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
214743409|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
214794304|NCT01697722|DRUG|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
214794015|NCT02110771|BEHAVIORAL|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
214794016|NCT02110771|BEHAVIORAL|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
214743410|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
214743411|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
214743412|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
214743413|NCT02176031|DRUG|Natalizumab|
214743414|NCT02176031|DRUG|Methylprednisolone|
214743415|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
214743416|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
214743417|NCT00055939|DRUG|exatecan mesylate|
214743418|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
214743419|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
214743420|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
214743421|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
214743422|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
214743423|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
214743424|NCT00167713|DRUG|Ibuprofen|
214743425|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
214743426|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
214743427|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
214743428|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
214743429|NCT02643420|DRUG|Docetaxel|Standard therapy
214743430|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
214743431|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
214743432|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
214743433|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
214743434|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
214743435|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
214743436|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
214743437|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
214743438|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
214743439|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
214743440|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
214743441|NCT02895477|DEVICE|hearing aid|
214743442|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
214743443|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
214743444|NCT04446039|DRUG|Escitalopram|Treatment for depression
214743445|NCT04446039|DRUG|Paroxetine|Treatment for depression
214743446|NCT04446039|DRUG|Fluoxetine|Treatment for depression
214743447|NCT04446039|DRUG|Mirtazapine|Treatment for depression
214743448|NCT04446039|DRUG|Duloxetine|Treatment for depression
214743449|NCT04446039|DRUG|Sertraline|Treatment for depression
214743450|NCT04446039|DRUG|Venlafaxine|Treatment for depression
214743451|NCT04446039|DRUG|Tianeptine|Treatment for depression
214743452|NCT04446039|DRUG|Vortioxetine|Treatment for depression
214743453|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
214743454|NCT04446039|DRUG|Bupropion|Treatment for depression
214743455|NCT02298790|BEHAVIORAL|Meal schedule|
214743456|NCT00472628|PROCEDURE|Blood samples collected|
214743457|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
214794017|NCT01296932|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
214743458|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
214743459|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
214743460|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
214743461|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
214743462|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
214743463|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
214743464|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
214743465|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
214743466|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
214743467|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
214743468|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
214743469|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
214743470|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
214743471|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
214743472|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
214743473|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
214743474|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
214743475|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
214743476|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
214743477|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
214743478|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
214743479|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
214743480|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
214743481|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
214743482|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
214743483|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
214743484|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
214743485|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
214743486|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
214743487|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
214743488|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
214743489|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
214743490|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
214743491|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
214743492|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
214743493|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
214743494|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
214743495|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
214743496|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
214743497|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
214743498|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
214743499|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
214743500|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
214743501|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
214743502|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
214743503|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
214743504|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
214743505|NCT06525337|BEHAVIORAL|STANDARDCARE (STAND) group|Will receive a device and health coaching
214743506|NCT06525337|OTHER|CONTROL (CON) group|Will not use any devices or receive health coaching
214743507|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
214743508|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
214743509|NCT03055806|DRUG|Placebo|Placebo caplet(s)
214743510|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
214743511|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
214743512|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
214743513|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
214743514|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
214743515|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
214743516|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
214743517|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
214743518|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
214743519|NCT00125138|DRUG|Placebo|Syrup formulation
214743520|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
214743521|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
214743522|NCT00041119|DRUG|AC regimen|Given IV
214743523|NCT00041119|DRUG|cyclophosphamide|Given IV
214743524|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
214743525|NCT00041119|DRUG|paclitaxel|Given IV
214743526|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
214794018|NCT00974493|DRUG|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
214794019|NCT01468051|BIOLOGICAL|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
214794020|NCT01468051|BIOLOGICAL|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
214743527|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214743528|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214743529|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
214743530|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
214743531|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
214743532|NCT03820518|DRUG|Calcitriol|
214743533|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
214743534|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
214743535|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
214743536|NCT00005838|OTHER|placebo|Given orally
214743537|NCT00005838|DRUG|cisplatin|Given IV
214743538|NCT00005838|DRUG|vinorelbine tartrate|Given IV
214743539|NCT00005838|DRUG|carboplatin|Given IV
214743540|NCT00005838|DRUG|paclitaxel|Given IV
214743541|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
214743542|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
214743543|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
214743544|NCT00000576|DRUG|beclomethasone|
214743545|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
214743546|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
214743547|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
214743548|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
214743549|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
214743550|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
214743551|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
214743552|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
214743553|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
214743554|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
214743555|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
214743556|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
214743557|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
214743558|NCT03708926|DRUG|Placebo|placebo injection pen
214743559|NCT04672200|OTHER|Group exercise|Weekly group exercises delivered online and face to face
214743560|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
214743561|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
214743562|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
214743563|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
214743564|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
214743565|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
214743566|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
214794021|NCT06543654|OTHER|Omnichroma|Each participants had two kinds of veneers
214794022|NCT06543654|OTHER|Ceram. X Spectra|Ceram. X Spectra
214743567|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
214743568|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
214743569|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
214743570|NCT03673150|OTHER|non intervention|Observational study / non intervention
214743571|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
214743572|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
214794023|NCT04884659|OTHER|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
214794024|NCT04884659|OTHER|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
214743573|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
214743574|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
214743575|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
214743576|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
214743577|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
214743578|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
214743579|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
214743580|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
214743581|NCT00939861|PROCEDURE|laparotomy|colorectal resection
214743582|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
214743583|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
214743584|NCT04056325|DRUG|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
214743585|NCT04056325|DRUG|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
214743586|NCT04056325|DRUG|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
214743587|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
214743588|NCT05731726|DRUG|Serplilumab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits."
214743589|NCT05731726|DRUG|Capecitabine|Given PO
214743590|NCT05731726|DRUG|Oxaliplatin|Given IV
214743591|NCT05731726|DRUG|Celecoxib|celebrex
214743592|NCT05642884|OTHER|Multi-modal Exercise Regimen|Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.
214743593|NCT05642884|BEHAVIORAL|Dietary Guidelines|Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
214743594|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
214743595|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
214743596|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
214743597|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
214743598|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
214743599|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
214743600|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
214743601|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
214743602|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
214743603|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
214743604|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
214743605|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
214743606|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
214743607|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
214743608|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
214743609|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
214743610|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
214743611|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
214743612|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
214743613|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
214743614|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
214743615|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
214743616|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
214743617|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
214743618|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
214743619|NCT00001961|PROCEDURE|MRI|
214743620|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
214743621|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
214743622|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
214743623|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
214743624|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
214743625|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
214743626|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
214794025|NCT02796027|OTHER|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
214794026|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
214743627|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
214794027|NCT01579474|DRUG|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
214794028|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
214794029|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
214794030|NCT01066494|DRUG|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
214743628|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
214743629|NCT04629105|OTHER|Placebo|Placebo
214743630|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
214743631|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
214743632|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
214743633|NCT00089505|DRUG|Nevirapine|200 mg taken orally
214743634|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
214743635|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
214743636|NCT02868801|DRUG|Placebo|same intervention as the experimental group
214743637|NCT02868801|DRUG|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
214743638|NCT02868801|DRUG|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
214743639|NCT02868801|DRUG|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
214794031|NCT04464694|DRUG|Ranibizumab|Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3\~7 days before vitrectomy.
214794032|NCT04464694|OTHER|Sham injection|Patients will receive single sham injection 3\~7 days before vitrectomy.
214794033|NCT04464694|PROCEDURE|Pars plana vitrectomy|Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
214794034|NCT05945394|OTHER|No intervention|This is an obvertional study, and there is no intervention.
214794035|NCT00130520|DRUG|bevacizumab|10mg/kg every two weeks IV-bevacizumab
214743640|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
214743641|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
214743642|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
214743643|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
214743644|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
214743645|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
214743646|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
214743647|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
214743648|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
214743649|NCT00611351|DRUG|busulfan|
214743650|NCT00611351|DRUG|cyclophosphamide|
214743651|NCT00611351|DRUG|mycophenolate mofetil|
214743652|NCT00611351|DRUG|tacrolimus|
214743653|NCT00611351|GENETIC|polymerase chain reaction|
214743654|NCT00611351|GENETIC|polymorphism analysis|
214743655|NCT00611351|OTHER|flow cytometry|
214743656|NCT00611351|OTHER|laboratory biomarker analysis|
214743657|NCT00611351|OTHER|pharmacogenomic studies|
214743658|NCT00611351|OTHER|pharmacological study|
214743659|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
214743660|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214743661|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
214743662|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
214743663|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
214743664|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
214743665|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
214794036|NCT00130520|DRUG|erlotinib|150mg daily by mouth-erlotinib
214743666|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
214743667|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
214743668|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
214743669|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
214743670|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
214743671|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
214743672|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
214743673|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
214743674|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
214743675|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
214743676|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
214743677|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
214743678|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
214743679|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
214743680|NCT00004885|DRUG|FOLFIRI regimen|
214743681|NCT00004885|DRUG|fluorouracil|
214743682|NCT00004885|DRUG|irinotecan hydrochloride|
214743683|NCT00004885|DRUG|leucovorin calcium|
214743684|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
214743685|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
214743686|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
214743687|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
214743688|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
214743689|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
214743690|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
214743691|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
214794037|NCT05083650|PROCEDURE|Macular hole closure with amniotic membrane with/without internal limiting membrane peeling|Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
214794038|NCT05730140|OTHER|this study did not involve interventions; it only observational study|this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
214794039|NCT00888810|DRUG|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
214743692|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
214743693|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
214743694|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
214743695|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
214743696|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
214743697|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
214743698|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
214743699|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
214743700|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
214743701|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
214743702|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
214743703|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
214743704|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
214743705|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
214743706|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
214743707|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
214743708|NCT00767494|DRUG|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
214743709|NCT00767494|DRUG|Azopt|Eye Drop Suspension, 1 drop BID
214743710|NCT00767494|DRUG|Travatan|Eye Drop Solution, 1 drop BID
214743711|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
214743712|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
214743713|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
214743714|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
214743715|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
214743716|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
214743717|NCT02181335|DRUG|Respimat® Budesonide low dose|
214743718|NCT02181335|DRUG|Respimat® Budesonide high dose|
214743719|NCT02181335|DRUG|Turbohaler® Budesonide|
214743720|NCT02181335|DRUG|Placebo|
214743721|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
214743722|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
214743723|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
214743724|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
214743725|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
214743726|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
214743727|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
214743728|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
214743729|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
214794040|NCT00888810|DRUG|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
214794041|NCT05824312|DRUG|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
214794042|NCT01568008|DRUG|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
214794305|NCT01697722|DRUG|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
214794306|NCT03060005|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
214743730|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
214743731|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
214743732|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
214794043|NCT05832255|DRUG|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
214794044|NCT03107013|DRUG|[14C]-BTD-001|Carbon-14 labeled BTD-001
214794045|NCT00003213|DRUG|dexamethasone|4 mg Dexamethasone in the morning
214743733|NCT00820313|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
214743734|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
214743735|NCT04333875|DEVICE|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
214743736|NCT03252262|OTHER|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
214743737|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
214743738|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
214743739|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
214743740|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
214743741|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
214743742|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
214743743|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
214743744|NCT00545740|DRUG|Placebo|QD orally
214743745|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
214743746|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
214743747|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
214743748|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
214743749|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
214743750|NCT01122992|PROCEDURE|Limbal relaxing incision|
214743751|NCT06356649|PROCEDURE|extubation|Complications after extubation
214743752|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
214743753|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
214743754|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
214743755|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
214743756|NCT04721275|OTHER|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
214743757|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
214743758|NCT02367690|DRUG|Selinexor|Topical gel
214743759|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
214743760|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
214794046|NCT00003213|DRUG|granisetron hydrochloride|1 mg Granisetron in the morning
214645429|NCT06915402|DEVICE|"LMW - CL - HA FACE/BODY"|"The dosage to be used for the individual case is at the discretion of the doctor. The periodicity with which to repeat the procedure depends on different factors, concerning both the physiology of the patient (skin type, individual metabolism, anatomy, age) and lifestyle; another element to consider is related to the implantation techniques adopted. After the first treatment, the result can be retouched after 15 days, repeating the treatment after 9-12 months to maintain the results obtained. Local anesthesia for facial treatments can be performed, in order to ensure the necessary comfort for the patient. The area of intervention must be cleaned with antiseptic solutions before proceeding to the implant. Do not use quaternary ammonium-based disinfectants, as they can react with the HA and form precipitates.LMW - CL - HA FACE/BODY is to be used intracutaneously and must not be injected into the blood vessels. Further details on the injection procedure are reported in the IFU."
214743761|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
214794047|NCT00003213|DRUG|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
214645430|NCT05417490|OTHER|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~* for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~* for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
214743762|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
214794048|NCT00407849|DRUG|triamcinolone acetonide|Intravitreal injection
214743763|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
214743764|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
214743765|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
214743766|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
214743767|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
214743768|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
214743769|NCT02698917|OTHER|High normal PaO2|20-25 kPa
214743770|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
214743771|NCT02698917|OTHER|High normal MAP|80-100 mmHg
214743772|NCT04796454|DRUG|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
214743773|NCT04796454|DRUG|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
214743774|NCT04796454|DRUG|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
214743775|NCT04796454|DRUG|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
214743776|NCT04796454|DRUG|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
214743777|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
214743778|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
214743779|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
214743780|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
214743781|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
214743782|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
214743783|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
214743784|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
214743785|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
214794049|NCT02688400|DRUG|Diacerein|
214794050|NCT02688400|DRUG|Celecoxib|
214794051|NCT02688400|DRUG|Placebo|
214743786|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
214743787|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
214743788|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
214743789|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
214743790|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
214743791|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
214743792|NCT03453593|OTHER|No intervention|No intervention
214743793|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
214743794|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
214743795|NCT02445352|DRUG|Rosuvastatin 5mg|
214743796|NCT02445352|DRUG|DP-R207 5/10mg|
214743797|NCT02445352|DRUG|Rosuvastatin 10mg|
214743798|NCT02445352|DRUG|DP-R207 10/10mg|
214743799|NCT02445352|DRUG|Rosuvastatin 20mg|
214743800|NCT02445352|DRUG|DP-R207 20/10mg|
214743801|NCT02445352|DRUG|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
214743802|NCT02445352|DRUG|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
214743803|NCT02445352|DRUG|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
214743804|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
214743805|NCT05441436|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
214743806|NCT05441436|PROCEDURE|Solid organ transplantation|Solid organ transplantation
214743807|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
214743808|NCT03955211|DRUG|HTX-011|300 mg
214743809|NCT03955211|DRUG|HTX-011|400 mg
214743810|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
214743811|NCT03955211|DRUG|Ibuprofen|400 mg
214743812|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
214743813|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
214743814|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
214743815|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
214743816|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
214743817|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
214743818|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
214743819|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
214743820|NCT01430689|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
214743821|NCT01430689|BIOLOGICAL|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
214743822|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
214743823|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
214743824|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
214743825|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
214743826|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
214743827|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
214743828|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
214743829|NCT01830829|DRUG|Jalyn|study drug
214743830|NCT01830829|DRUG|Placebo|Placebo
214743831|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
214743832|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
214743833|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
214743834|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
214743835|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
214743836|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
214743837|NCT03869489|DEVICE|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
214743838|NCT03869489|DEVICE|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
214743839|NCT03869489|DEVICE|Sham tDCS stimulation|Sham tDCS stimulation will be applied
214743840|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
214743841|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
214743842|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
214743843|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
214743844|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
214743845|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
214743846|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
214743847|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
215030673|NCT07010991|OTHER|Traditional Low Back Pain Education|The first session will be given by an independent/different instructor about the definition, reasons, evaluation and the treatment of low back pain for 2 hours. Afterwards the students will be informed about the content of the next week's interactive course and supplied with the study sources like book, articles by the other lecturer. A week will be given to the students to study and the other week they will meet with the lecturer to discuss over a specific case. At the beginning and end of the courses, outcome measures will taken from the both groups.
214743848|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
214743849|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
214743850|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
214743851|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
214743852|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
214743853|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
214743854|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
214743855|NCT04615429|BIOLOGICAL|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
214743856|NCT04615429|OTHER|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
214743857|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
214743858|NCT01085695|DRUG|rabeprazole|10 mg normal tablet
214743859|NCT01085695|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
214743860|NCT01085695|DRUG|rabeprazole|Type 2 granule containing rabeprazole 10 mg
214743861|NCT01085695|DRUG|rabeprazole|Type 3 granule containing rabeprazole 10 mg
214743862|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
214743863|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
214743864|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
214743865|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
214743866|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
214743867|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
214743868|NCT04145310|DRUG|Placebo + SCO|sublingual drops
215030674|NCT07010055|PROCEDURE|Semi-structured interview|A semi-structured interview will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
215030675|NCT07011134|DRUG|Group (E): receive aminophylline early intraoperatively,|Group E (n=20): patients received aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1)
214743869|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
214743870|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
214743871|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
214743872|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
214743873|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
214743874|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
214743875|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
214743876|NCT06093321|DEVICE|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
214743877|NCT06093321|DEVICE|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
214794052|NCT04886375|PROCEDURE|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
214794053|NCT04886375|PROCEDURE|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
214794307|NCT03060005|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
214794308|NCT05221580|DRUG|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
214743878|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
214743879|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
214743880|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
214743881|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
214743882|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
214743883|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
214743884|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
214743885|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
214743886|NCT00841854|DRUG|bismuth|bismuth 300mg qid
214743887|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
214743888|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
214743889|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
214743890|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
214743891|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
214743892|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
214743893|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
214743894|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
214743895|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
215030676|NCT07011134|DRUG|Group (L) received aminophylline late intraoperatively|Group L (n=20): patients received aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).
214743896|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
214743897|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
214743898|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
214743899|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
214743900|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
214743901|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
214743902|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
214743903|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
214743904|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
214743905|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
214743906|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
214743907|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
214743908|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
214743909|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
214743910|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
214743911|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
214794309|NCT01455753|OTHER|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
214794310|NCT01455753|OTHER|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
214743912|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
214743913|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
214743914|NCT01968629|DRUG|Eovist|
214743915|NCT02254694|OTHER|high heeled shoes|see detailed study description
214743916|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
214743917|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
214743918|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
214743919|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
214743920|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
214743921|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
214743922|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
214743923|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
214743924|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
214743925|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
214743926|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
214743927|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
214743928|NCT02365961|DRUG|ropivicaine|
214743929|NCT02365961|DRUG|clonidine|
214743930|NCT02365961|DRUG|Epinephrine|
214743931|NCT02365961|DRUG|Noropin|
214743932|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
214743933|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
214743934|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
214743935|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
214743936|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
214743937|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
214743938|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
214743939|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
214743940|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
214743941|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
214743942|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
214743943|NCT02098291|DRUG|G17DT|
214743944|NCT04576962|OTHER|Immunization Information System Review|Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System
214743945|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
214743946|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
214743947|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
214743948|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
214743949|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
214743950|NCT02259452|PROCEDURE|Pulmonary Function Tests|
214743951|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
214743952|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
214743953|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
214743954|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
214743955|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
214743956|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
214743957|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
214743958|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
214743959|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
214743960|NCT02132416|DRUG|NSAID|Will be used if tolerated.
214743961|NCT02132416|DRUG|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
214743962|NCT02132416|DRUG|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
214743963|NCT02132416|DRUG|Paracetamol|1g QID will be given to all patients unless allergies.
214743964|NCT02132416|PROCEDURE|Surgical management|Fracture stabilization
214743965|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
214794311|NCT00729859|DRUG|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
214743966|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
214743967|NCT00006082|DRUG|rubitecan|
214743968|NCT00379873|DEVICE|ProAdjuster|
214743969|NCT00031915|DRUG|imatinib mesylate|
214743970|NCT00520091|DRUG|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
214743971|NCT00520091|DRUG|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
214743972|NCT00520091|DRUG|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
214743973|NCT00520091|RADIATION|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
214743974|NCT00520091|PROCEDURE|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
214743975|NCT01646255|DRUG|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
214743976|NCT01646255|DRUG|Placebo Patch|"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
214743977|NCT01646255|DRUG|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
214743978|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
214743979|NCT02865681|DRUG|Menopur|Nasal versus injectable
214743980|NCT02865681|DRUG|Synarel|nasal
214743981|NCT02865681|DRUG|HCG trigger|injectable
214743982|NCT02865681|DRUG|Clomiphene citrate|oral
214743983|NCT02865681|DRUG|Letrozole|Oral
214743984|NCT05588076|OTHER|no intervention|no intervention
214743985|NCT00846911|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
214743986|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
214743987|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
214743988|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
214743989|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
214743990|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
214743991|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
214743992|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
214743993|NCT01362049|OTHER|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
214743994|NCT01362049|OTHER|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
214743995|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
214743996|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
214743997|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
214743998|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
214743999|NCT04919694|PROCEDURE|orbital compression|orbital compression
214744000|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
214744001|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
214744002|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
214744003|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
214744004|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
214744005|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
214744006|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
214744007|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
214744008|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
214744009|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
215030677|NCT07011134|DRUG|Group (C) will receive normal saline post-anesthetic discontinuation.|Group (C) (n=20): patients received normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).
215030678|NCT07010523|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.
215030679|NCT07010523|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
215030680|NCT07010523|DRUG|Cyclophosphamide|D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.
214744010|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
214744011|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
214744012|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
214744013|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
214744014|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
214744015|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
214744016|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
214744017|NCT00073515|DRUG|Alfimeprase|
214744018|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
214744019|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
214744020|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
214744021|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
214744022|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
214744023|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
214744024|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
214744025|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
214744026|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
214744027|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
214744028|NCT02183792|DRUG|Tolvaptan|
214744029|NCT02183792|DRUG|Furosemide|
214744030|NCT05373810|OTHER|Surgery|all interventions are allowed
214744031|NCT04619381|BEHAVIORAL|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
214744032|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
214744033|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
214744034|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
214744035|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
214744036|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
214744037|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
214744038|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
214744039|NCT00411879|DRUG|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
214744040|NCT00411879|DRUG|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
214744041|NCT00408785|DRUG|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
214744042|NCT00408785|DRUG|sodium chloride|sodium chloride 0.9 mg
214744043|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
214744044|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
214744045|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
214744046|NCT02785861|BEHAVIORAL|supervision of physical activity|
214744047|NCT02785861|BEHAVIORAL|distance supervised physical activity|
214744048|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
214744049|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
214744050|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
214744051|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
214744052|NCT00498927|DRUG|temozolomide|
214744053|NCT00498927|GENETIC|protein expression analysis|
214744054|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
214744055|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
214744056|NCT00498927|OTHER|immunoenzyme technique|
214744057|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
214744058|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
214744059|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
214744060|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
214744061|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
215030681|NCT07010419|DRUG|Firmonertinib|Firmonertinib: 240 mg, QD, orally
214744062|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
214744063|NCT04722692|DIAGNOSTIC_TEST|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
215030682|NCT07010419|DRUG|Placebo|Placebo: 240 mg, QD, orally
214744064|NCT04722692|DIAGNOSTIC_TEST|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
214744065|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
214744066|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
214744067|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
214744068|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
214744069|NCT02878135|PROCEDURE|fast application|
214744070|NCT02878135|PROCEDURE|slow application|
214744071|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
214794054|NCT05460442|PROCEDURE|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
214744072|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
214744073|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
214744074|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
214744075|NCT01913015|DRUG|abiraterone acetate|Given PO
214744076|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive low fat breakfast
214744077|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive high fat breakfast
214744078|NCT01913015|OTHER|pharmacological study|Correlative studies
214744079|NCT01913015|OTHER|questionnaire administration|Ancillary studies
214744080|NCT01913015|OTHER|laboratory biomarker analysis|Correlative studies
214744081|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
214744082|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
214744083|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
214744084|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
214744085|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
214744086|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
214744087|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
214744088|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
214744089|NCT03056209|DRUG|Placebo|oral administration, placebo
214744090|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
214744091|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
214744092|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
214744093|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214744094|NCT01319539|OTHER|Pharmacological Study|Correlative studies
214744095|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
214744096|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
214744097|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
214794055|NCT05460442|PROCEDURE|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
214794312|NCT00729859|DRUG|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
214744098|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
214744099|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
214744100|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
214744101|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
214744102|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
214744103|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
214744104|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
214744105|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
214744106|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
214744107|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
214744108|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
214744109|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
214744110|NCT04492514|DRUG|Mavrilimumab|Treatment infusion
214744111|NCT04492514|DRUG|Placebo|Placebo infusion
214744112|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
214744113|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
214744114|NCT05535452|DEVICE|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
214744115|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
214744116|NCT05999773|DRUG|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
214744117|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
214744118|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
214744119|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
214744120|NCT00219310|DRUG|Famciclovir|
214744121|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
214744122|NCT02478658|OTHER|exercise training|high-intensity resistance training
214744123|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
214744124|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
214744125|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
214744126|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214744127|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214744128|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214744129|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
214744130|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
214744131|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
214744132|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
214744133|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
214744134|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
214744135|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
214744136|NCT02515604|DRUG|Misoprostol|
214744137|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
214744138|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
214744139|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
214744140|NCT01787019|OTHER|Oral feeding|
214744141|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
214744142|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
214744143|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
214744144|NCT04276493|BIOLOGICAL|Zanidatamab|Administered intravenously
214744145|NCT04276493|DRUG|Docetaxel|Administered intravenously
214744146|NCT04276493|BIOLOGICAL|Tislelizumab|Administered intravenously
214744147|NCT04276493|DRUG|Capecitabine|Administered orally
214744148|NCT04276493|DRUG|Oxaliplatin|Administered intravenously
214744149|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
214744150|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
214744151|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
214744152|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
214744153|NCT00354120|DRUG|Alentuzumab|Alentuzumab
214744154|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
214744155|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
214744156|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
214744157|NCT05108818|BIOLOGICAL|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
214744158|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
214744159|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
214744160|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
214744161|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
214744162|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
214744163|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
214744164|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
214744165|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
214744166|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
214744167|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
214744168|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
214744169|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
214744170|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
214744171|NCT06108531|OTHER||
214744172|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
214744173|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
214744174|NCT02988115|OTHER|placebo|Matching placebo tablet
214744175|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
214744176|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
214744177|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
214744178|NCT03165227|DRUG|BI 685509|Taken orally
214744179|NCT03165227|DRUG|Placebo|Taken orally
214744180|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
215030683|NCT06679907|DEVICE|WaveLinQ® device|The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.
214744181|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
215030684|NCT06679907|DEVICE|Ellipsys® device|The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
215030685|NCT06679907|DEVICE|No device|Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
214744182|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
214744183|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
214744184|NCT03924960|BEHAVIORAL|Control|Usual care control group
214744185|NCT00231621|DRUG|topiramate|
214744186|NCT03553121|OTHER|walking|walking and not walking
214744187|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
214744188|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
214744189|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
214744190|NCT01396811|DRUG|33525|Daily for 14 days
214744191|NCT01396811|DRUG|Placebo|Daily for 14 days
214744192|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
214744193|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
214744194|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
214744195|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
214744196|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
214744197|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
214744198|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
214744199|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
214744200|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
214744201|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
214744202|NCT03724318|PROCEDURE|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
214744203|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
214744204|NCT05114031|OTHER|Placebo|Saline water
214744205|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
214744206|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
214744207|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
214744208|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
214744209|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
214744210|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
214744211|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
214744212|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214744213|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214744214|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214744215|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
214744216|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
214744217|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
214744218|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
214744219|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
214744220|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
214744221|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
214744222|NCT06404476|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214744223|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
214744224|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
214744225|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
214744226|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
214744227|NCT04880642|DRUG|C21|C21
214744228|NCT04880642|DRUG|Placebo|Placebo
214744229|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
214744230|NCT01223560|OTHER|Exercise|Exercise on tread mill
214744231|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
214744232|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
214744233|NCT02906644|DRUG|lorcaserin|
214744234|NCT02906644|DRUG|nicotine patch|
215030686|NCT07009977|BEHAVIORAL|self-guided mHealth app only|Mindfulness based stress reduction
214744235|NCT02906644|DRUG|placebo lorcaserin|
214744236|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
214744237|NCT01974414|DRUG|orally administered cedar honey|
214744238|NCT02452034|DRUG|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
214744239|NCT02452034|DRUG|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
214744240|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
214744241|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
214744242|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
214744243|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
214744244|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
214744245|NCT02108158|DRUG|Azzalure|
215030687|NCT07009977|BEHAVIORAL|self-guided mHealth app + 'real-time' feedback|Mindfulness based stress reduction with mobile app feedback
214744246|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
214744247|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
214744248|NCT04235959|DRUG|Tirzepatide|Administered SC
214744249|NCT04235959|DRUG|Placebo|Administered SC
214744250|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
214744251|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
214744252|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
214744253|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
214744254|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
214744255|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
214744256|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
214744257|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
214744258|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
214744259|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
214744260|NCT02182856|DRUG|Ipratropium 500 µg|
214744261|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
214744262|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
214744263|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
214744264|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
214744265|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
214744266|NCT06538610|DEVICE|Holter monitor|"Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours."
214744267|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
214744268|NCT02135848|DRUG|GSK1278863|GSK1278863
214744269|NCT02135848|DRUG|Placebo|Placebo
214744270|NCT04815005|OTHER|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
214744271|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
214744272|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
214744273|NCT01162967|DRUG|Benznidazole|Standard dosage
214744274|NCT01162967|DRUG|Posaconazole|
214744275|NCT00993694|DRUG|chemotherapy|
214744276|NCT00993694|DRUG|dapsone|
214744277|NCT00993694|OTHER|medical chart review|
214744278|NCT00993694|PROCEDURE|assessment of therapy complications|
214744279|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
214744280|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
214744281|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
214744282|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
214794056|NCT05460442|PROCEDURE|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
214794313|NCT00729859|DRUG|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
214794314|NCT05095909|DEVICE|Cryo-compression|Programmable intermittent compression with integrated cryo-therapy.
214744283|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
214744284|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
214744285|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
214744286|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
214744287|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
214744288|NCT00316212|DRUG|INS50589 Intravenous Infusion|
214744289|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
214744290|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
214744291|NCT02180854|OTHER|Control group|
214744292|NCT02180854|OTHER|Increased monitoring frequency|
214744293|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
214744294|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
214744295|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
214744296|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
214744297|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
214744298|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
214744299|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
214744300|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
214744301|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
214744302|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
214794315|NCT05095909|OTHER|Cryo-therapy|Subjects are fitted with gel ice packs and wraps.
214794316|NCT05023213|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
214744303|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
214744304|NCT02839590|DEVICE|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
214744305|NCT02839590|DEVICE|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
214744306|NCT02839590|DEVICE|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
214744307|NCT02839590|DEVICE|STARflo|Suprachoroidal Shunt Surgery (STARflo)
214744308|NCT02839590|DEVICE|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
214744309|NCT02839590|DEVICE|iStent implant|Trans-trabecular meshwork implants (iStent implant).
214744310|NCT02839590|DEVICE|Kahook Dual Blade|It removes part of the trabecular meshwork
214744311|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
214794057|NCT05073575|PROCEDURE|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
214794317|NCT00748293|OTHER|Low-residue diet|Commercialized (not yet marketed)low-residue diet
214744312|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
214744313|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
214744314|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
214744315|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
214744316|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
214744317|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
214744318|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
214744319|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
214744320|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
214744321|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
214744322|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
214744323|NCT02283801|DRUG|Eslicarbazepine acetate|
214744324|NCT02283801|DRUG|Lamotrigine|
214744325|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
214744326|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
214744327|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
214744328|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
214744329|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
214744330|NCT02297620|DRUG|Suglat®|oral
214744331|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
214744332|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
214744333|NCT02561104|PROCEDURE|Laser-assisted cataract surgery.|
214744334|NCT02561104|PROCEDURE|Traditional manual phacoemulsification|
214744335|NCT03826316|DRUG|Nalbuphine|Pharmacokinetic study under fasting conditions
214744336|NCT00636506|DEVICE|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
214744337|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
214744338|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
214744339|NCT01822249|DRUG|EPI-743|
214744340|NCT01822249|DRUG|Placebo|
214744341|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
214744342|NCT03742271|DEVICE|senofilcon A|TEST Lens
214744343|NCT06136910|DRUG|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
214744344|NCT01601990|DRUG|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
214744345|NCT01601990|DRUG|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
214744346|NCT03810053|BEHAVIORAL|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
214744347|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
214744348|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
214744349|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
214744350|NCT00444834|DRUG|Carvedilol|50 mg
214744351|NCT00791011|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
214744352|NCT00791011|OTHER|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
214744353|NCT00791011|OTHER|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
214744354|NCT02996240|DIETARY_SUPPLEMENT|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
214744355|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
214744356|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
214744357|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
214744358|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
214744359|NCT03529734|OTHER|12 min running|This was already explained in the description of arm
214744360|NCT03529734|OTHER|Local strengthening exercises|This was already explained in the description of arm
214744361|NCT03735017|OTHER|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
214744362|NCT03735017|OTHER|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
214744363|NCT01723124|PROCEDURE|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
214744364|NCT02513355|BIOLOGICAL|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
214744365|NCT02513355|DRUG|Changchun marina|25mg/m2,d1 and d8,q21d×4
214744366|NCT02513355|DRUG|cisplatin|80mg/m2,d1, q21d×4
214744367|NCT02513355|DRUG|Taxol|135-175mg/m2,d1,q21d×4
214744368|NCT02513355|DRUG|parapl|AUC=5-6,d1,q21d×4
214744369|NCT01376908|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
214744370|NCT01376908|OTHER|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
214744371|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
214744372|NCT02807194|OTHER|spinal anesthesia|
214744373|NCT02807194|OTHER|general anesthesia|
214744374|NCT02807194|PROCEDURE|lumbar disc herniation|
214744375|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
214744376|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
214744377|NCT02430389|DRUG|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
214744378|NCT02430389|DRUG|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
214744379|NCT00369408|DRUG|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
214744380|NCT00369408|DRUG|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
214744381|NCT00898690|GENETIC|cytogenetic analysis|
214744382|NCT00898690|GENETIC|gene expression analysis|
214744383|NCT00898690|GENETIC|microarray analysis|
214744384|NCT00898690|GENETIC|mutation analysis|
214744385|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
214744386|NCT00898690|OTHER|immunohistochemistry staining method|
214744387|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
214794058|NCT05073575|PROCEDURE|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
214794059|NCT02259842|DRUG|BI 34021 FU2 solution|
214794060|NCT02259842|DRUG|BI 34021 FU2 tablet|dose group 4 only
214744388|NCT06049251|OTHER|ELDOA exercises|"The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day."
214744389|NCT06049251|OTHER|Lumbar SNAGS and motor control exercises|"The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps"
214744390|NCT02740036|DEVICE|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
214744391|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
214744392|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
214744393|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
214744394|NCT01551628|DRUG|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
214794061|NCT02259842|DRUG|Placebo|
214744395|NCT01213849|DRUG|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
214744396|NCT01213849|DRUG|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
214744397|NCT01213849|DRUG|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
214744398|NCT01213849|DRUG|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
214744399|NCT04844892|DEVICE|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
214744400|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
214744401|NCT01468844|DRUG|Placebo|Placebo
214744402|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
214744403|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
214744404|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
214744405|NCT00022906|DRUG|Iodine-131 Anti-B1 Antibody|
214744406|NCT01763632|DEVICE|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
214744407|NCT02309216|OTHER|Whol-Body MRI scan|
214744408|NCT02289118|DRUG|[18F]-T807 imaging tracer|Tau Imaging tracer
214744409|NCT03080441|DEVICE|pressure stockings|pressure stockings worn during dialysis throughout treatment period
214744410|NCT03080441|DRUG|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
214744411|NCT03080441|OTHER|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
214744412|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
214744413|NCT02971072|PROCEDURE|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
214744414|NCT02971072|OTHER|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
214744415|NCT02655263|DRUG|Somatropin|Somatropin infusion (Genotropin®)
215030688|NCT07011160|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|Force-steadiness training will be performance either without (sham) or paired with TENS.
214744416|NCT02655263|OTHER|Ketone bodies|ketone bodies infusion
214744417|NCT05136209|PROCEDURE|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
215030689|NCT07011160|BEHAVIORAL|Familiarization|Participants will perform 25 trials of the Grooved Pegboard Test
215030690|NCT07011199|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|Intraoperative trans-portal vein injection of 20 million mesenchymal stem cells derived from umbilical cord tissue, suspended in 5 mL autologous plasma.
214744418|NCT05136209|PROCEDURE|PCCC+A-Vit procedure|PCCC+A-Vit procedure
214744419|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
214744420|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
214744421|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
214744422|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
214744423|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
214744424|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
214744425|NCT04316780|OTHER|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
214744426|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
214744427|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
214744428|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
214744429|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
214744430|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
214744431|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
214744432|NCT04296721|BEHAVIORAL|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
214744433|NCT04296721|BEHAVIORAL|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
214744434|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
214744435|NCT02496390|BIOLOGICAL|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
214744436|NCT02496390|BIOLOGICAL|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
214744437|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
214744438|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
214744439|NCT02777008|DRUG|CTP-543|
214744440|NCT02777008|DRUG|Placebo for CTP-543|
214744441|NCT03152175|DRUG|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
214744442|NCT03152175|DRUG|Placebo|1mg / kg of matched placebo, oral capsule
214744443|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
214744444|NCT03607994|DEVICE|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
214744445|NCT03607994|DEVICE|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
214744446|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
214744447|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
214744448|NCT05189535|DRUG|Placebo|placebo
214744449|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
214744450|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
214744451|NCT02417935|DRUG|Duloxetine|Administered orally
214744452|NCT02417935|DRUG|Pregabalin|Administered orally
214744453|NCT02417935|DRUG|Placebo|Administered orally
214744454|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
214744455|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
214744456|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
214744457|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
214744458|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
214744459|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
214744460|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
214744461|NCT05248776|DRUG|Placebo|Matching placebo tablet.
214744462|NCT02358928|OTHER|Diet Intervention|
214744463|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
214744464|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
214744465|NCT02850276|DRUG|Pyridostigmine|
214744466|NCT04707027|DRUG|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
214744467|NCT04707027|OTHER|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
214744468|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
214744469|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
214744470|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
214744471|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
214744472|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
214744473|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
214744474|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
214744475|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
215030691|NCT07011199|PROCEDURE|Kasai Portoenterostomy|Surgical procedure to create a portoenterostomy for biliary drainage in infants with biliary atresia.
214744476|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
215030692|NCT04581577|OTHER|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
214744477|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
214744478|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
214744479|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
214744480|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
214744481|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
214744482|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
215030693|NCT05064540|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
215030694|NCT05064540|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
215030695|NCT06692764|DRUG|Placebo|"0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets.~Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose."
214744483|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
214744484|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
214744485|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
214744486|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
214744487|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
214744488|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
214744489|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
214744490|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
214744491|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
214744492|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
214744493|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
214744494|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
214744495|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
214744496|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
214744497|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
214744498|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
214744499|NCT02701569|OTHER|Rebound exercise|Repeated jumping on a mini trampoline was administered
214744500|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
214744501|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
214744502|NCT01431456|DRUG|Dabigatran|Dabigatran
214744503|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
214744504|NCT01431456|DRUG|Nadroparin|Nadroparin
214744505|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
214744506|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
214744507|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
214794062|NCT02259842|OTHER|High fat, high calorie breakfast|only for dose groups 3 and 5
214794063|NCT00232115|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214794064|NCT00232115|DRUG|Placebo|Vehicle cream (placebo)
214794065|NCT01103037|DRUG|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
214794066|NCT01103037|DRUG|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
214794067|NCT02465411|DEVICE|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
214794068|NCT06332547|OTHER|Restrictive Transfusion Strategy|Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
214794318|NCT04646057|DEVICE|DuraSorb®|Monofilament Surgical Mesh
214744508|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
214744509|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
214794069|NCT06332547|OTHER|Liberal Transfusion Strategy|Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
214794070|NCT03467477|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
214794071|NCT03467477|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
214794072|NCT02506647|DRUG|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
214744510|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
214744511|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
214744512|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
214744513|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
214744514|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
214744515|NCT01173328|BEHAVIORAL|Normal Breathing|
214744516|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
214744517|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
214744518|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
214744519|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
214744520|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
214794073|NCT02506647|DRUG|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
214794319|NCT03882164|DIAGNOSTIC_TEST|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
214744521|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
214744522|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
214744523|NCT01408862|OTHER|venous puncture|Blood for in vitro studies will be drawn
214744524|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
214744525|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
214744526|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
214744527|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
214744528|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
214744529|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
214744530|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
214744531|NCT02220660|DRUG|BI 1744 CL|
214744532|NCT02220660|DRUG|BI 54903 XX|
214744533|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
214744534|NCT02220660|DRUG|Placebo|
214744535|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
214744536|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
214744537|NCT02415582|OTHER|Control|45 minutes resting sitting
214744538|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
214744539|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
214744540|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
214744541|NCT01886092|DEVICE|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
214744542|NCT01886092|DEVICE|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
214744543|NCT01886092|DEVICE|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
214744544|NCT01886092|DEVICE|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
214744545|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
214744546|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
214744547|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
214744548|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
214744549|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
214744550|NCT00003368|DRUG|irinotecan hydrochloride|
214744551|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
214794320|NCT02623829|DRUG|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
214794321|NCT02623829|DRUG|Saline|1ml of normal saline will be administered
214744552|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
214744553|NCT03656146|OTHER|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
214744554|NCT03656146|OTHER|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
214744555|NCT05275140|OTHER|Physical activity|Combat sports and exercise
214744556|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
214744557|NCT01086267|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
214744558|NCT01086267|DRUG|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
214744559|NCT01086267|DRUG|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
214744560|NCT02079506|DRUG|Candesartan|
214744561|NCT02079506|DRUG|Rosuvastatin|
214744562|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
214744563|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~\- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
214744564|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~\- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
214744565|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
214744566|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
214744567|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
214744568|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
214744569|NCT01813149|OTHER|punch biopsy|
214744570|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
214744571|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
214744572|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
214744573|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
214744574|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
214744575|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
214744576|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
214744577|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
214744578|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
214744579|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
214744580|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
214744581|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
214744582|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
214744583|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
214744584|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
214744585|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
214744586|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
214744587|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
214744588|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
214744589|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
214744590|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
214744591|NCT04490499|BIOLOGICAL|HBVAXPRO™|Single 0.5 mL intramuscular dose
214744592|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
214744593|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
214744594|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
214744595|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
214744596|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
214744597|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
214744598|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
214744599|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
214744600|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
214744601|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
214744602|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
214744603|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
214744604|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
214744605|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
214744606|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
214744607|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
214744608|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
214744609|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
214744610|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
214744611|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
214744612|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
214744613|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
214744614|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
214744615|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
214744616|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
214744617|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
214744618|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
214744619|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
214744620|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
214744621|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
214744622|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
214744623|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
214744624|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
214744625|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
215030696|NCT06692764|DRUG|AZD0780|"Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose."
214744626|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
214744627|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
214744628|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
214744629|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
214744630|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
214744631|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
214744632|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
214744633|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
214744634|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
214744635|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
214744636|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
214744637|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
214744638|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
214744639|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
214744640|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
214744641|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
214744642|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
214744643|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
214744644|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
214744645|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
214744646|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
214744647|NCT00015015|DRUG|Dichloroacetate|
214744648|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
214744649|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
214744650|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
214744651|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
214744652|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
214744653|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
214744654|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
214744655|NCT01083615|DRUG|docetaxel|
214744656|NCT01083615|DRUG|cabazitaxel|
214744657|NCT01083615|DRUG|prednisone|
214744658|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
214744659|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
214744660|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
214744661|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
214744662|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
214744663|NCT01641029|OTHER|No intervention|There is no intervention
214744664|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
214744665|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
214744666|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
214744667|NCT00002986|DRUG|carmustine|
214744668|NCT00002986|DRUG|topotecan hydrochloride|
214744669|NCT02022592|DRUG|Lormetazepam|
214744670|NCT02022592|DRUG|Midazolam|
214744671|NCT00258596|DEVICE|sirolimus-eluting stent|
214744672|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
214744673|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc…
214744674|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
214744675|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
214744676|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
214744677|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
214744678|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
214744679|NCT00362297|DRUG|acyclovir|800 mg orally three times daily for 7 weeks
214744680|NCT00362297|DRUG|valacyclovir|500 mg orally once daily for 7 weeks
214744681|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
214744682|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
214744683|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
214744684|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
214744685|NCT00313742|DRUG|insulin detemir|
214744686|NCT00313742|DRUG|insulin glargine|
214744687|NCT00313742|DRUG|insulin NPH|
214744688|NCT00426842|DRUG|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
214744689|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
214744690|NCT01759095|DEVICE|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
214744691|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
214744692|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
214744693|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
214744694|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
214744695|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
214744696|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
214744697|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
214744698|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
214744699|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
214744700|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
214744701|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
214744702|NCT01070381|DEVICE|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
214744703|NCT01070381|DEVICE|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
214744704|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
214744705|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
214744706|NCT01869686|BIOLOGICAL|Denosumab|60 mg
214744707|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
214744708|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
214744709|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
214744710|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
214744711|NCT04569890|DRUG|Prednisone|10mg GC orally daily
214744712|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
214744713|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
214744714|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
214744715|NCT00000151|DRUG|Aspirin|
214744716|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
214744717|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
214744718|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
214744719|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
214744720|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
214744721|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
214744722|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
214744723|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
214744724|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
214744725|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
214794074|NCT04659733|DRUG|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
214744726|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
214744727|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
214744728|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
214744729|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
214744730|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
214744731|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
214744732|NCT02743494|OTHER|Placebo|Specified dose on specified days
214744733|NCT00000894|DRUG|Cidofovir|
214744734|NCT00000894|DRUG|Probenecid|
214744735|NCT00000894|DRUG|Ganciclovir|
214744736|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
214744737|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
214744738|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
214744739|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
214744740|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
214744741|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
214744742|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
214744743|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
214744744|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
214744745|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
214744746|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
214744747|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
214744748|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
214744749|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
214744750|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
214744751|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
214744752|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
214744753|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
214744754|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
214744755|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
214744756|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
214744757|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
214744758|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
214744759|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
214744760|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
214744761|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
214744762|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
214744763|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
214744764|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
214744765|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
214744766|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
214744767|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
214744768|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
214744769|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
214744770|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
214794075|NCT01497236|DIETARY_SUPPLEMENT|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
214794076|NCT00006291|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214794077|NCT00006291|DRUG|Aldesleukin|
214794078|NCT02015091|BIOLOGICAL|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
214744771|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
214744772|NCT01521494|DRUG|PA21|
214744773|NCT01521494|DRUG|PA21|
214744774|NCT01521494|DRUG|PA21|
214744775|NCT01521494|DRUG|PA21|
214744776|NCT01521494|DRUG|Placebo|
214744777|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
214744778|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
214744779|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
214744780|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
214744781|NCT03515031|DEVICE|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
214744782|NCT03515031|DEVICE|Venturi Mask Oxygenation|delivery of high flow oxygen
214794079|NCT04354194|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
214744783|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
214744784|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
214744785|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
214744786|NCT04120025|BEHAVIORAL|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
214744787|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
214744788|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
214744789|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
214744790|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
214744791|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
214744792|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
214744793|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
214744794|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
214794080|NCT04354194|PROCEDURE|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
214794081|NCT01953666|OTHER|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
214794082|NCT01953666|OTHER|Self - Training at home|Only instructions for a self - training at home
214744795|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
214744796|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
214744797|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
214744798|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
214744799|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
214744800|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
214744801|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
214744802|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
214744803|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
214744804|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
214744805|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
214744806|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
214744807|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
214744808|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
214744809|NCT02020564|BEHAVIORAL|Speed of Processing Training|
214744810|NCT02020564|BEHAVIORAL|Placebo Control|
214744811|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
214744812|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
214744813|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
214744814|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
214744815|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
214744816|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
214794083|NCT02295774|PROCEDURE|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
214794084|NCT02295774|DRUG|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
214794085|NCT01053273|PROCEDURE|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
214744817|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
214744818|NCT00347685|DRUG|tramadol ER|
214744819|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
214744820|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
214744821|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
214744822|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
214744823|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
214744824|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
214744825|NCT00840684|DRUG|amsacrine|
214744826|NCT00840684|DRUG|busulfan|
214744827|NCT00840684|DRUG|cytarabine|
214744828|NCT00840684|DRUG|daunorubicin hydrochloride|
214744829|NCT00840684|DRUG|laromustine|
214744830|NCT00840684|DRUG|melphalan|
214744831|NCT00840684|DRUG|mitoxantrone hydrochloride|
214744832|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214744833|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
214744834|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
214744835|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
214744836|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
214744837|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
214744838|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
214744839|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
214744840|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
214744841|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
214744842|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
214744843|NCT00754312|DRUG|SNDX-275|
214744844|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
214744845|NCT00155428|PROCEDURE|rapid prototyping|
214744846|NCT00155428|PROCEDURE|computed tomography|
214744847|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
214744848|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
214744849|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
214744850|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
214744851|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
214744852|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
214744853|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
214744854|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
214744855|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
214744856|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
214744857|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
214744858|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
214744859|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
214744860|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
214744861|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
214744862|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
214744863|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
214744864|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
214744865|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
214744866|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
214744867|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
214744868|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
214744869|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
214744870|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
214744871|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
214744872|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
214744873|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
214744874|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
214744875|NCT00646191|DRUG|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
214744876|NCT00646191|DRUG|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
214744877|NCT00646191|DRUG|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
214744878|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
214744879|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
214744880|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
214744881|NCT03262285|PROCEDURE|phacoemulsification|removal of cataract using ultrasound waves
214744882|NCT03262285|PROCEDURE|extracapsular cataract extraction|removal of cataract using surgical corneal incision
214744883|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
214744884|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
214744885|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
214744886|NCT05598840|OTHER|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
214744887|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
214744888|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
214744889|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
214794086|NCT01053273|PROCEDURE|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
214794087|NCT01075763|DRUG|Interferon beta-1a|Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
214744890|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
214744891|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
214744892|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
214744893|NCT01425242|DRUG|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
214744894|NCT01425242|DRUG|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
214744895|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
214744896|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
214744897|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
214744898|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
214744899|NCT01156012|DRUG|T2345|One drop of T2345
214744900|NCT01156012|DRUG|Prostaglandin|One drop
214744901|NCT02475564|DRUG|Placebo|40mg of starch
214744902|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
214744903|NCT02961400|OTHER|PUSH text messages|The intervention is designed to remind participants of treatment components.
214744904|NCT02961400|OTHER|PULL text messages|The intervention is designed to remind participants to recall treatment components.
214744905|NCT02961400|BEHAVIORAL|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
214744906|NCT02961400|BEHAVIORAL|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
214744907|NCT01665040|DEVICE|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
214744908|NCT01203111|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
214744909|NCT01203111|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
214744910|NCT05870397|DIAGNOSTIC_TEST|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
214744911|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
214744912|NCT02261402|OTHER|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
214744913|NCT00939094|DRUG|AZD2066|Capsule, once daily
214744914|NCT00939094|DRUG|Placebo|Capsule, once daily
214744915|NCT02382952|DEVICE|Differential Dissector|
214744916|NCT02382952|OTHER|Standard Dissection Method|
214744917|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
214744918|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214744919|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214744920|NCT04146129|DRUG|CDX-0159|Single dose of one of four dosages of CDX-0159
214744921|NCT04146129|DRUG|Normal saline|Single infusion of normal saline
214744922|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214744923|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214744924|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214744925|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214744926|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214744927|NCT00518739|DRUG|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
214744928|NCT02303730|DRUG|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
214794088|NCT01075763|DRUG|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
214794089|NCT00586521|DRUG|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
214744929|NCT02303730|DRUG|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%."
214744930|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
214744931|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
214744932|NCT00004654|DRUG|soy protein isolate|
214744933|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
214744934|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
214744935|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
214744936|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
214744937|NCT00536354|OTHER|Postural Orientation|
214744938|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
214744939|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
214744940|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
214744941|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
214744942|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
214744943|NCT01503229|OTHER|Pharmacological Study|Correlative studies
214744944|NCT01503229|DRUG|Prednisone|Given PO
214744945|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
214744946|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
214744947|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
214744948|NCT01973673|BEHAVIORAL|Bone health educational materials|
214744949|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
214794090|NCT03517852|DEVICE|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
214744950|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
214744951|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
214744952|NCT02623569|DRUG|Ivabradine|Not Provided
214744953|NCT02623569|DRUG|Atenolol|Not Provided
214744954|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
214744955|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
214744956|NCT02609087|DRUG|Sevoflurane|
214744957|NCT02609087|DRUG|Propofol|
214744958|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
214744959|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
214744960|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
214744961|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
214744962|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
214744963|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
214744964|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
214744965|NCT00481533|DRUG|Oxytocin|
214744966|NCT04027127|OTHER|netrin-1 value on admission to hospital|
214744967|NCT00240331|DRUG|10mg Rosuvastatin|
214744968|NCT00240331|DRUG|Placebo|
214744969|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
214744970|NCT03935074|DRUG|intra-arterial administration of melphalan|
214744971|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
214744972|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
214744973|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
214744974|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
214744975|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
214744976|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
214744977|NCT00004173|DRUG|oxaliplatin|
214744978|NCT00004173|DRUG|paclitaxel|
214744979|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
214744980|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
214744981|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
214744982|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
214744983|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
214744984|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
214744985|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
214744986|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
214744987|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
214744988|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
214744989|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
214744990|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
214744991|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
214744992|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
214744993|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
214744994|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
214744995|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
214744996|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
214744997|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
214744998|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
214744999|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
214745000|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
214745001|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
214745002|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
214745003|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
214745004|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
214745005|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
214745006|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
214745007|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
214745008|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
214745009|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
214745010|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
214745011|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
214745012|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
214745013|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
214745014|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
214745015|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
214745016|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
214745017|NCT06580756|OTHER|Short training program|Training in the early identification of addictive disorders in primary care
214745018|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
214745019|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
214745020|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
214745021|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
214745022|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
214745023|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
214745024|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
214745025|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
214745026|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
214745027|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
214745028|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
214745029|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
214745030|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
214745031|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
214745032|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
214745033|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
214745034|NCT00145379|DRUG|Tablet Metformin 500 mg|
214745035|NCT00145379|DRUG|Placebo|
214745036|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
214745037|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
214745038|NCT02179216|OTHER|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
214745039|NCT02179216|OTHER|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
214745040|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
214745041|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
214745042|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
214745043|NCT03927703|DRUG|SB206 12%|Topically once daily
214745044|NCT03927703|DRUG|Placebo|Topically once daily
214745045|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
214745046|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
214745047|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
214745048|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
214745049|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
214745050|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
214745051|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
214745052|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
214745053|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
214745054|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
214745055|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
214745056|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
214745057|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
214745058|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
214745059|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
214745060|NCT06040437|BEHAVIORAL|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
214745061|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
214745062|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
214745063|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
214745064|NCT06497816|OTHER|No intervention|No intervention
214745065|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
214745066|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
214745067|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
214745068|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
214745069|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
214745070|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
214745071|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
214745072|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
214745073|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
214745074|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
214745075|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
214745076|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
214745077|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
214745078|NCT02990273|BIOLOGICAL|Blood transfusion|
214745079|NCT03007472|DEVICE|CI532|Cochlear implant
214745080|NCT03007472|DEVICE|Nucleus 7|Sound processor
214745081|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
214745082|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
214745083|NCT02185443|RADIATION|SBRT|"* 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
214745084|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
214745085|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
214745086|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
214745087|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
214745088|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
214745089|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
214745090|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
214745091|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
214745092|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
214745093|NCT05659875|OTHER|Standard Occupational Therapy Arm Exercise Program|Standard exercise program will be provided addressing shoulder, elbow, forearm, wrist, and hand with expectation that participant will complete 3 times a week. Exercise program will be updated at assessment timepoints as needed with change in arm function.
214745094|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
214745095|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
214745096|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
214745097|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
214745098|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
214745099|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
214745100|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
214745101|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
214745102|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
214745103|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
214745104|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
214745105|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
214745106|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
214745107|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
214745108|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
214745109|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
214745110|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
214745111|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
214745112|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
214745113|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
214745114|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
214745115|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
214745116|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
214745117|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
214745118|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
214745119|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
214745120|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
214745121|NCT05766410|DRUG|Letrozole|Endocrine therapy
214745122|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
214745123|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
214745124|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
214745125|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
214745126|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
214745127|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
214745128|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
214745129|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
214745130|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
214745131|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
214745132|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
214745133|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
214745134|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
214745135|NCT00066274|DRUG|FOLFIRI regimen|
214745136|NCT00066274|DRUG|FOLFOX regimen|
214745137|NCT00066274|DRUG|fluorouracil|
214745138|NCT00066274|DRUG|irinotecan hydrochloride|
214745139|NCT00066274|DRUG|leucovorin calcium|
214745140|NCT00066274|DRUG|oxaliplatin|
214745141|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
214745142|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
214745143|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
214745144|NCT01959087|PROCEDURE|Multiport surgery|
214745145|NCT01978717|PROCEDURE|epidural anesthesia|
214745146|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
214745147|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
214745148|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
214745149|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
214745150|NCT01869920|BEHAVIORAL|Usual care|Usual care
214745151|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
214745152|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
214745153|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
214745154|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
214745155|NCT00899327|GENETIC|DNA methylation analysis|
214745156|NCT00899327|GENETIC|RNA analysis|
214745157|NCT00899327|GENETIC|cytogenetic analysis|
214745158|NCT00899327|GENETIC|gene expression analysis|
214745159|NCT00899327|GENETIC|mutation analysis|
214745160|NCT00899327|GENETIC|polymerase chain reaction|
214745161|NCT00899327|GENETIC|protein expression analysis|
214745162|NCT00899327|OTHER|laboratory biomarker analysis|
214745163|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
214745164|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
214745165|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
214745166|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
214745167|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
214745168|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
214745169|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
214745170|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
214745171|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
214745172|NCT01453439|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
214745173|NCT01453439|BEHAVIORAL|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
214745174|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
214745175|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
214745176|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
214745177|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
214745178|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
214745179|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
214745180|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
214745181|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
214745182|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
214745183|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
214745184|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
214745185|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
214745186|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
214745187|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
214745188|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
214745189|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
214745190|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
214745191|NCT01557140|DRUG|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
214745192|NCT01466439|PROCEDURE|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
214745193|NCT01466439|PROCEDURE|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
214745194|NCT00035412|DRUG|St. John's Wort|
214745195|NCT01020929|DEVICE|Blunt Coude|Type of needle tip
214745196|NCT01020929|DEVICE|Quincke|Type of needle tip
214745197|NCT01020929|DEVICE|Trucath|Type of needle tip
214745198|NCT05553652|DIETARY_SUPPLEMENT|ASTARTE™ oral capsules|1 Capsule daily for 6 months
214745199|NCT05553652|DIETARY_SUPPLEMENT|Placebo oral capsules|1 Capsule daily for 6 months
214745200|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
214745201|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
214745202|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
214745203|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
214745204|NCT05099718|PROCEDURE|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
214745205|NCT05099718|DEVICE|Hyaluronic acid|application 3-times per day for 7 days
214745206|NCT05099718|OTHER|Saline solution (placebo)|application 3-times per day for 7 days
214745207|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
214745208|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
214745209|NCT02705339|DRUG|Rociletinib|
214745210|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
214745211|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
214745212|NCT06326658|OTHER|Bufei Yishen Prescription Granule|The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
214745213|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2\. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
214745214|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
214745215|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
214745216|NCT01833299|PROCEDURE|TACE|
214745217|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
214745218|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
214745219|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
214745220|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
214745221|NCT01017640|DRUG|Mitomycin|Given IV
214745222|NCT01017640|DRUG|Veliparib|Given PO
214745223|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
214745224|NCT00915226|PROCEDURE|Squatting|Squatting
214745225|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
214745226|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
214794322|NCT05825053|BEHAVIORAL|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
214745227|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
214745228|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
214745229|NCT03010358|DRUG|Entospletinib|Given PO
214745230|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
214745231|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
214745232|NCT03010358|OTHER|Pharmacological Study|Correlative studies
214745233|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
214745234|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
214745235|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
214745236|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
214745237|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
214745238|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
214745239|NCT02344758|BEHAVIORAL|gluten-containing diet|
214745240|NCT03520842|DRUG|Methotrexate|Given PO
214745241|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
214745242|NCT03520842|DRUG|Regorafenib|Given PO
214745243|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
214745244|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
214745245|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
214745246|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
214745247|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
214745248|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
214745249|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
214745250|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
214745251|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
214745252|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
214745253|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
214745254|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
214745255|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
214745256|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
214745257|NCT04306003|OTHER|ERAS pathway|See ERAS pathway arm description.
214745258|NCT04306003|OTHER|Standard Perioperative Care|See control arm description.
214745259|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
214745260|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
214745261|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
214745262|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
214745263|NCT03589794|OTHER|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
214745264|NCT03589794|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
214745265|NCT03589794|BIOLOGICAL|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
214745266|NCT00097916|DRUG|memantine HCl|
214745267|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
214745268|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
214745269|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
214745270|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
214745271|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
214745272|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
214745273|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
214745274|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
214745275|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
214745276|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
214745277|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
214745278|NCT03076411|DRUG|Pepsin|
214745279|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
214745280|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
214745281|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
214745282|NCT00006382|PROCEDURE|comparison of screening methods|
214745283|NCT00006382|PROCEDURE|computed tomography|
214745284|NCT00006382|PROCEDURE|radiography|
214745285|NCT00006382|PROCEDURE|study of high risk factors|
214745286|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
214745287|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
214745288|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
214745289|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
214745290|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
214745291|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
214745292|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
214745293|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
214745294|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
214745295|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
214745296|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
214745297|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
214745298|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
214745299|NCT03613766|OTHER|Physical activity program|
214745300|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
214745301|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
214745302|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
214745303|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
214745304|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
214745305|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
214745306|NCT03547219|DRUG|Escitalopram|
214745307|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
214745308|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
214745309|NCT04846543|OTHER|MRI Scan|MRI scan
214745310|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
214745311|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
214745312|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
214745313|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
214745314|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
214745315|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
214745316|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
214745317|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
214745318|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
214745319|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
214745320|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
214745321|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
214745322|NCT01363232|DRUG|BKM120 + MEK162|
214794323|NCT05825053|BEHAVIORAL|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
214745323|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
214745324|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
214745325|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
214745326|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
214745327|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
214745328|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
214745329|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
214745330|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
214745331|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
214745332|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
214745333|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
214745334|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
214745335|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
214745336|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
214745337|NCT01678287|DRUG|ASP1941|oral
214745338|NCT01678287|DRUG|Placebo|oral
214745339|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
214745340|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
214745341|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
214745342|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
214745343|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
214745344|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
214745345|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
214745346|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
214745347|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
214745348|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
214745349|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
214745350|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
214745351|NCT00304421|DRUG|rabeprazole|
214745352|NCT00304421|DRUG|pantoprazole|
214745353|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
214745354|NCT00551694|DRUG|GSK256073A tablets|
214745355|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
214745356|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
214745357|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
214745358|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
214745359|NCT04047472|DRUG|Brolucizumab 6mg|Intravitreal injection
214745360|NCT04047472|DRUG|Aflibercept 2 mg|Intravitreal injection
214745361|NCT04741867|OTHER|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
214745362|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
214745363|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
214745364|NCT01934842|DEVICE|TAP20-C|
214745365|NCT01934842|DEVICE|SAFE-T-FILL|
214745366|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
214745367|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
214745368|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
214745369|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
214745370|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
214745371|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2\_Advanced All-In-One Virtual Reality Headset\_ 128 GB)).
214745372|NCT01977664|OTHER|no intervention|
214745373|NCT02030067|DRUG|RX-3117|
214745374|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
214745375|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
214745376|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
214745377|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
214745378|NCT01682694|DIETARY_SUPPLEMENT|placebo|
214745379|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
214745380|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
214745381|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
214745382|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
214745383|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
214745384|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
214745385|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
214745386|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
214745387|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
214745388|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
214745389|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
214745390|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
214745391|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
214745392|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
214745393|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
214745394|NCT06415916|PROCEDURE|Cardiac ultrasound|Performed 5 times between 0 and 120 minutes
214745395|NCT06415916|PROCEDURE|Lung ultrasound|Performed 5 times between 0 and 120 minutes
214745396|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
214745397|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
214745398|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
214745399|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
214745400|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
214745401|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
214745402|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
214745403|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
214745404|NCT02029885|DEVICE|Sham Control|
214745405|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
214745406|NCT02826083|DIETARY_SUPPLEMENT|XXS|
214745407|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
214745408|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
214745409|NCT01433328|DRUG|Lidocaine|Lidocaine
214745410|NCT01433328|DRUG|Placebo|Placebo
214745411|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
214745412|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
214745413|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
214745414|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
214745415|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
214745416|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
214745417|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
214745418|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
214745419|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
214745420|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
214745421|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
214745422|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
214745423|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
214745424|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
214745425|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
214745426|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
214745427|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
214745428|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
214745429|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
214745430|NCT03000413|DRUG|Ketamine|Active treatment
214745431|NCT03000413|DRUG|Fentanyl|
214745432|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
214745433|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
214745434|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
214745435|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
214745436|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
214745437|NCT02256150|DRUG|Mizoribine (MZR)|
214745438|NCT02256150|DRUG|Cyclophosphamide (CTX)|
214745439|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
214745440|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
214745441|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
214745442|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
214745443|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
214745444|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
214745445|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
214745446|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
214745447|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
214745448|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
214745449|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
214745450|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
214745451|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
214745452|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
214745453|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
214745454|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
214745455|NCT02798159|DRUG|TD0025|
214745456|NCT02798159|DRUG|Sildenafil Citrate 50mg|
214745457|NCT02961153|OTHER|death|
214745458|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
214745459|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
214745460|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
214745461|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2\) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
214745462|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
214745463|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
214745464|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
214745465|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
214745466|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
214745467|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
214745468|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
214745469|NCT00104273|DRUG|Rasagiline|
214745470|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
214745471|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
214745472|NCT03681808|DEVICE|Control|Contact Lens
214745473|NCT03681808|DEVICE|Test|Soft Contact Lens
214745474|NCT00821756|BEHAVIORAL|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
214745475|NCT01860131|BEHAVIORAL|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
214745476|NCT04361721|DRUG|Erenumab|First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
214745477|NCT01529827|DRUG|fludarabine phosphate|Given IV
214745478|NCT01529827|DRUG|melphalan|Given IV
214745479|NCT01529827|RADIATION|total-body irradiation|Undergo TBI
214745480|NCT01529827|DRUG|tacrolimus|Given IV or PO
214745481|NCT01529827|DRUG|mycophenolate mofetil|Given IV or PO
214745482|NCT01529827|DRUG|methotrexate|Given IV
214745483|NCT01529827|OTHER|laboratory biomarker analysis|Correlative studies
214745484|NCT01529827|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
214745485|NCT01529827|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
214745486|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
214745487|NCT05431972|DEVICE|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
214745488|NCT05431972|DEVICE|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
214745489|NCT01758172|DRUG|6% hydroxyethyl starch 130/0.4|
214745490|NCT01758172|DRUG|Albumin|
214745491|NCT06267495|PROCEDURE|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
214745492|NCT01481714|DRUG|Sodium picosulphate, magnesium oxid and citric acid|"* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
214745493|NCT01481714|DRUG|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~\- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
214745494|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
214745495|NCT00315523|DRUG|Levocetirizine|
214745496|NCT04830176|OTHER|dentifrice|use of dentifrices for brushing
214745497|NCT04142762|DRUG|ABI-H2158|ABI-H2158 tablets
214745498|NCT04142762|DRUG|Itraconazole|Itraconazole capsules
214745499|NCT04142762|DRUG|Rifampin|Rifampin capsules
214745500|NCT04142762|DRUG|Midazolam|Midazolam syrup
214745501|NCT04142762|DRUG|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
214745502|NCT04142762|DRUG|Esomeprazole|Esomeprazole capsules
214745503|NCT04142762|DRUG|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
214745504|NCT03463109|OTHER|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
214745505|NCT03463109|OTHER|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
214745506|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
214745507|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
214745508|NCT02158195|BIOLOGICAL|blood samples|
214745509|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
214745510|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
214745511|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
214745512|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
214745513|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
214745514|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
214745515|NCT00476515|DRUG|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
214745516|NCT01681537|DRUG|Lenalidomide|
214745517|NCT01681537|DRUG|Mitoxantrone|
214745518|NCT01681537|DRUG|Etoposide|
214745519|NCT01681537|DRUG|Cytarabine|
214745520|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
214745521|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
214745522|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
214745523|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
214745524|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
214745525|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
214745526|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
214745527|NCT04411472|OTHER|Placebo|Placebo
214745528|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
214745529|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
214745530|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
214745531|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
214745532|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
214745533|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
214745534|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
214745535|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
214745536|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
214745537|NCT02161614|DRUG|Estradiol valerate|
214745538|NCT02161614|DRUG|Placebo|
214745539|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
214745540|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
214745541|NCT01881906|OTHER|Usual care|
214745542|NCT01881906|OTHER|Exercise|
214745543|NCT05751915|DEVICE|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
214745544|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
214745545|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
214745546|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
214745547|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
214745548|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
214745549|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
214745550|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
214745551|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
214745552|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
214745553|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
214745554|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
214745555|NCT00018694|DRUG|Chenodeoxycholic Acid|
214745556|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
214745557|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
214745558|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
214745559|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
214745560|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
214745561|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
214745562|NCT02599740|OTHER|Placebo|Rice only
214745563|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
214745564|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
214745565|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
214745566|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
214745567|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
214745568|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
214745569|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
214745570|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
214745571|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
214745572|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
214745573|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
214745574|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
214745575|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
214745576|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
214745577|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
214745578|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
214745579|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
214745580|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
214745581|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
214745582|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
214745583|NCT02517502|DRUG|Placebo|Matched, blinded placebo
214745584|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
214745585|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
214745586|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
214745587|NCT00072215|DRUG|cisplatin|given IV
214745588|NCT00072215|DRUG|ifosfamide|given IV
214745589|NCT00072215|DRUG|paclitaxel|given IV
214745590|NCT00072215|DRUG|vinblastine|given IV
214745591|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
214745592|NCT00090246|DRUG|MK0869, aprepitant|
214745593|NCT00090246|DRUG|Comparator: ondansetron IV|
214745594|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
214745595|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
214745596|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
214745597|NCT00539825|DRUG|GSK704838|
214745598|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
214745599|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
214745600|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
214745601|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
214745602|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
214745603|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
214745604|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
214745605|NCT00139373|DRUG|donepezil|
214745606|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
214745607|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
214745608|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
214745609|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
214745610|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
214745611|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
214745612|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
214745613|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
214745614|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
214745615|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
214745616|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
214745617|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
214745618|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
214745619|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
214745620|NCT00517634|DRUG|Placebo|Matching Placebo
214745621|NCT03091920|DRUG|IW-1973|Oral Tablet
214745622|NCT03091920|DRUG|Placebo|Oral Tablet
214745623|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
214745624|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
214745625|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
214745626|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
214745627|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
214745628|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
214745629|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
214745630|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
214745631|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
214745632|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
214745633|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
214745634|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
214745635|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
214745636|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
214745637|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
214745638|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
214745639|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
214745640|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
214745641|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
214745642|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
214745643|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
214745644|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
214745645|NCT00056628|DEVICE|The COGNIShunt® System|
214745646|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
214745647|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
214745648|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
214745649|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
214745650|NCT03579862|OTHER|Blood Draw|
214745651|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
214745652|NCT02174406|PROCEDURE|breast ultrasound|
214745653|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
214745654|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
214745655|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
214745656|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
214745657|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
214745658|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
214745659|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
214745660|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
214745661|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
214745662|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
214745663|NCT03463720|OTHER|Infected|Extremity wound, infected
214745664|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
214745665|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
214745666|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
214745667|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
214745668|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
214745669|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
214745670|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
214745671|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
214745672|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
214745673|NCT00381810|DRUG|Methylprednisolone|
214745674|NCT00381810|DRUG|Acetaminophen|
214745675|NCT00381810|DRUG|Diphenhydramine|
214745676|NCT00000799|DRUG|Cidofovir|
214745677|NCT00000799|DRUG|Probenecid|
214745678|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
214745679|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
214745680|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
214745681|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
214745682|NCT02127580|PROCEDURE|BAV|
214745683|NCT02127580|PROCEDURE|without BAV|
214745684|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
214745685|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
214745686|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
214745687|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
214745688|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
214745689|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
214745690|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
214745691|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
214745692|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
214745693|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
214745694|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
214745695|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
214745696|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
214745697|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
214745698|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
214745699|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
214745700|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
214745701|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
214745702|NCT02206230|RADIATION|Hypofractionated radiation therapy|
214745703|NCT02206230|RADIATION|Standard radiation therapy|
214745704|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
214745705|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
214745706|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
214745707|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
214745708|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
214745709|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
214745710|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
214745711|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
214745712|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
214745713|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
214745714|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
214745715|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
214745716|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
214745717|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
214745718|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
214745719|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
214745720|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
214745721|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
214745722|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
214745723|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
214745724|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
214745725|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
214745726|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
214745727|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
214745728|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
214745729|NCT04591704|OTHER|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
214745730|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
214745731|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
214745732|NCT00457093|DRUG|glargine|
214745733|NCT00457093|DRUG|detemir|
214745734|NCT07058740|PROCEDURE|early cholangiography|We perform cholangiography on the early group in advance
214745735|NCT04840914|DRUG|LY3461767|Administered SC.
214745736|NCT04840914|DRUG|Placebo|Administered SC.
214745737|NCT03066661|DRUG|Entrectinib|Open-label expanded access, capsules
214745738|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
214745739|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
214745740|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
214745741|NCT01922336|BIOLOGICAL|SB2|IV infusion
214745742|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
214745743|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
214745744|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
214745745|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~\- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
214745746|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
214745747|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
214745748|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
214745749|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
214745750|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
214745751|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
214745752|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
214745753|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
214745754|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
214745755|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
214745756|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
214745757|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
214745758|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
214745759|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
214745760|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
214745761|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
214745762|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
214745763|NCT02101216|DRUG|Prurisol|Experimental Drug
214745764|NCT02101216|DRUG|Ziagen|Active comparator
214745765|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
214745766|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
214745767|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
214745768|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
214745769|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
214745770|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
214745771|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
214745772|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
214745773|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
214745774|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
214745775|NCT00136994|DRUG|Ziprasidone|
214745776|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
214745777|NCT00133276|OTHER|Placebo|
214745778|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
214745779|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
214745780|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
214745781|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
214745782|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
214745783|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
214745784|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
214745785|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
214745786|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
214745787|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
214745788|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
214745789|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
214745790|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
214745791|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
214745792|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
214745793|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
214745794|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
214745795|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
214745796|NCT00337935|OTHER|Standard of care|
214745797|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
214745798|NCT02974764|OTHER|No intervention/exposures|
214745799|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
214745800|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
214745801|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
214745802|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
214745803|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
214745804|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
214745805|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|\- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
214745806|NCT02873806|DRUG|Topical travoprost|\- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
214745807|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|\- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
214745808|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
214745809|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
214745810|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
214745811|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
214745812|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
214745813|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
214745814|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
214745815|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
214745816|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
214745817|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
214745818|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
214745819|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
214745820|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
214745821|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
214745822|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
214745823|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
214745824|NCT04054531|BIOLOGICAL|KN046|IV infusion
214745825|NCT04054531|DRUG|Paclitaxel|IV infusion
214745826|NCT04054531|DRUG|Pemetrexed|IV infusion
214745827|NCT04054531|DRUG|Carboplatin|IV infusion
214745828|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
214745829|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
214745830|NCT05656729|DIETARY_SUPPLEMENT|DefensePlus|Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
214745831|NCT05656729|DIETARY_SUPPLEMENT|Placebo|Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
214745832|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
214745833|NCT00511966|DRUG|Rabeprazole|As prescribed
214745834|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
214745835|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
214745836|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
214745837|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
214745838|NCT00182572|DRUG|buprenorphine|
214745839|NCT00182572|DRUG|naltrexone|
214745840|NCT00182572|PROCEDURE|behavior therapy|
215030697|NCT06694142|BEHAVIORAL|Rosy app|Participants will be provided a six-month membership subscription to the mobile application ROSY. ROSY will recommend pathways for addressing issues through 1) coaching by board certified coaches or 2) joining a completely anonymous community with other people where they can share experiences and get help as new members of the community to overcome sexual health challenges .Users will work towards their health goals each day using tools from medical and mental health experts . Tools used include 1) virtual workshops and 2) coaching sessions which will provide the opportunity to a) Have an authentic and relatable conversation with an expert b) Explore new pathways to better health experience c) Improve their relationship with themselves, partner, and healthcare providers d) Learn fun ways to improve their everyday wellness e) Access live events from anywhere.
214745841|NCT00182572|PROCEDURE|voucher-based contingency management|
214745842|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
214745843|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
214745844|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
214745845|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
214745846|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
214745847|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
214745848|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
214745849|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
214745850|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
214745851|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
214745852|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
214745853|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
214745854|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
214745855|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
214745856|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
214745857|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
214745858|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
214745859|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
214745860|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
214745861|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
214745862|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
214745863|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
214745864|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
214745865|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
214745866|NCT02314299|DRUG|MTP-131|
214745867|NCT05620849|BEHAVIORAL|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
214745868|NCT02103400|OTHER|Experimental group|Exercise Training Group
214745869|NCT02103400|OTHER|Control group|Exercise control group
214745870|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
214745871|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
214745872|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
214745873|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
214745874|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
214745875|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
214745876|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
214745877|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
214745878|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
214745879|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
214745880|NCT04830813|DRUG|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
214745881|NCT04830813|DRUG|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
214745882|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
214745883|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
214745884|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
214745885|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
214745886|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
214745887|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
214745888|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
214745889|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
214745890|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
214745891|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
214745892|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
214745893|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
214745894|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
214745895|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
214745896|NCT00303004|DRUG|Bosentan and Sildenafil|
214745897|NCT03517150|DEVICE|mandibular advancement device|
214745898|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
214745899|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
214745900|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
214745901|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
214745902|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
214745903|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
214745904|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
214745905|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
214745906|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
214745907|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
214745908|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
214745909|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
214745910|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
214745911|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
214745912|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
214745913|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
214745914|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
214745915|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
214745916|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
214745917|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
214745918|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
214745919|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
214745920|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
214745921|NCT04179864|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
214745922|NCT04179864|DRUG|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
214745923|NCT04179864|DRUG|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
214745924|NCT06280079|DIETARY_SUPPLEMENT|Ultra-high-caloric fatty diet|100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g
214745925|NCT06280079|OTHER|Placebo|\<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g
214745926|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
214745927|NCT00231959|DRUG|Placebo|sugar pill
214745928|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
214745929|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
214745930|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
214745931|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
214745932|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
214745933|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
214745934|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
214745935|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
214745936|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
214745937|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
214745938|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
214745939|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
214745940|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
214745941|NCT01069692|DRUG|SBR759A|9g daily
214745942|NCT01069692|DRUG|SBR759A|12g daily
214745943|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
214745944|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
214745945|NCT04563845|DRUG|Placebo|Placebo will be administered.
214745946|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
214745947|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
214745948|NCT00207831|DRUG|Tegafur and Uracil|
214745949|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
214745950|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
214745951|NCT04731740|DRUG|Lenvatinib|PO
214745952|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
214745953|NCT04731740|DRUG|Chemotherapy|Investigators' choice
214745954|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
214745955|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
214745956|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
214745957|NCT06161766|DRUG|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
214745958|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
214745959|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
214745960|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
214745961|NCT00060320|OTHER|placebo|
214745962|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
214745963|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
214745964|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
214745965|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
214745966|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
214745967|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
214745968|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
214745969|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
214745970|NCT02531074|BEHAVIORAL|Mobile Application|
214745971|NCT02531074|BEHAVIORAL|Food Journal|
214745972|NCT02531074|BEHAVIORAL|Usual Care|
214745973|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
214745974|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
214745975|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
214745976|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
214745977|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
214745978|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
214745979|NCT01551043|BIOLOGICAL|CART-19|
214745980|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
214745981|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
214745982|NCT01031368|DRUG|cytarabine|Given IV
214745983|NCT01031368|DRUG|clofarabine|Given IV
214745984|NCT01031368|DRUG|filgrastim|Given SC
214745985|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
214745986|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
214745987|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
214745988|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
214745989|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
214745990|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
214745991|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
214745992|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
214745993|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
214745994|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
214745995|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
214745996|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
214745997|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
214745998|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
214745999|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
214746000|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
214746001|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
214746002|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
214746003|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
214746004|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
214746005|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
214746006|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
214746007|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
214746008|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
214746009|NCT05707403|DRUG|BI 1015550|Treatment T
214746010|NCT05707403|DRUG|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
214746011|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
214746012|NCT03854552|DRUG|BI 764198|capsule
214746013|NCT03854552|DRUG|Placebo|capsule
214746014|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
214746015|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
214746016|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
214746017|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
214746018|NCT00241371|DRUG|Clofarabine|
214746019|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
214746020|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
214746021|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
214746022|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
214746023|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
214746024|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
214746025|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
214746026|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
214746027|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
214746028|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8\_1
214746029|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
214746030|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
214746031|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
214746032|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
214746033|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
214746034|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
214746035|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
214746036|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
214746037|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
214746038|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
214746039|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
214746040|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
214746041|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
214746042|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
214746043|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
214746044|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
214746045|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
214746046|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
214746047|NCT02083406|DRUG|960mg PQP|
214746048|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
214746049|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
214746050|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
214746051|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
214746052|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
214746053|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
214746054|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
214746055|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
214746056|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
214746057|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
214746058|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
214746059|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
214746060|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
214746061|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
214746062|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
214746063|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
214746064|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
214746065|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
214746066|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
214746067|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
214746068|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
214746069|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
214746070|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
214746071|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
214746072|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
214746073|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
214746074|NCT01247467|OTHER|Breast Tumor Blocks|
214746075|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
214746076|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214746077|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
214746078|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
214746079|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
214746080|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
214746081|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
214746082|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
214746083|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
214746084|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
214746085|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
214746086|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
214746087|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
214746088|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
214746089|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
214746090|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
214746091|NCT02457130|DRUG|Ticagrelor|
214746092|NCT02457130|DRUG|Clopidogrel|
214746093|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
214746094|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
214746095|NCT01809717|OTHER|Weight Lifting Exercises|
214746096|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
214746097|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
214746098|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
214746099|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
214746100|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
214746101|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
214746102|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
214746103|NCT02577107|DRUG|ranibizumab|
214746104|NCT02577107|DRUG|Conbercept|
214746105|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
214746106|NCT00577382|DRUG|Sunitinib|
214746107|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
214746108|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
214746109|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
214746110|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
214746111|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
214746112|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
214746113|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
214746114|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
214746115|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
214746116|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
214746117|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
214746118|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
214746119|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
214746120|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
214746121|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
214746122|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
214746123|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
214746124|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
214746125|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
214746126|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
214746127|NCT04371705|OTHER|control|placebo
214746128|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
214746129|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
214746130|NCT02463812|DRUG|Intralipid|
214746131|NCT02463812|DRUG|Saline|
214746132|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
214746133|NCT01122719|DEVICE|Drug Eluting Stent|
214746134|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
214746135|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
214746136|NCT00372658|DRUG|1% Lidocaine intracervical injection|
214746137|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
214746138|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
214746139|NCT03802331|DRUG|BI 1323495,|single oral doses
214746140|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
214746141|NCT02336191|PROCEDURE|living donor liver transplantation|living donor liver transplantation
214746142|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
214746143|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
214746144|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
214746145|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
214746146|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
214746147|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
214746148|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
214746149|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
214746150|NCT04196010|DRUG|Cladribine|Given IV
214746151|NCT04196010|DRUG|Cytarabine|Given IV
214746152|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
214746153|NCT04196010|DRUG|Mitoxantrone|Given IV
214746154|NCT05015959|OTHER|observation|quality
214746155|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
214746156|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
214746157|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
214746158|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
214746159|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
214746160|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
214746161|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
214746162|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
214746163|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
214746164|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
214746165|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
214746166|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
214746167|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
214746168|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
214746169|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
214746170|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
214746171|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
214746172|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
214746173|NCT00627991|DRUG|Valsartan|
214746174|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
214746175|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
214746176|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
214746177|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
214746178|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
214746179|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
214746180|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
214746181|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
214746182|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
214746183|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
214746184|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
214746185|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
214746186|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
214746187|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
214746188|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
214746189|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
214746190|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
214746191|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
214746192|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
214746193|NCT02833142|DRUG|BIIB033 (opicinumab)|
214746194|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
214746195|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
214746196|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
214746197|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
214746198|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
214746199|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
214746200|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
214746201|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
214746202|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
214746203|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
214746204|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
214746205|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
214746206|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
214746207|NCT02013999|OTHER|standard occupational therapy|
214746208|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
214746209|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
214746210|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
214746211|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
214746212|NCT06601478|BEHAVIORAL|The MedLIFE app|The intervention arm will receive the lifestyle counselling by the MEDLIFE app, and the control arm will go on with standard lifestyle recommendations in the form of a two-page written handout.
214746213|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
214746214|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
214746215|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
214746216|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
214746217|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
214746218|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
214746219|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
214746220|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
214746221|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
214746222|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
214746223|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
214746224|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
214746225|NCT02288416|OTHER|questionnaire administration|Ancillary studies
214746226|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
214746227|NCT02288416|OTHER|Best Practice|
214746228|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
214746229|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
214746230|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
214746231|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
214746232|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
214746233|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
214746234|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
214746235|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
214746236|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
214746237|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
214746238|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
214746239|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
214746240|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
214746241|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
214746242|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
214746243|NCT05298410|OTHER|Limitless|Participants will be instructed to take Limitless for 30 days.
214746244|NCT00758004|DRUG|Atorvastatin|A single dose of 80 mg atrovastatin tablet
214746245|NCT00758004|DRUG|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
214746246|NCT02477540|DRUG|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular"
214746247|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
214746248|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
214746249|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
214746250|NCT02853318|DRUG|Cyclophosphamide|Given PO
214746251|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
214746252|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
214746253|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
214746254|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
214746255|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
214746256|NCT01997333|DRUG|CDX-011|
214746257|NCT01997333|DRUG|Capecitabine|
214746258|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
214746259|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
214746260|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
214746261|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
214746262|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
214746263|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
214746264|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
214746265|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
214746266|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
214746267|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
214746268|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
214746269|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
214746270|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
214746271|NCT00174876|DRUG|Drug Abilify|
214746272|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
214746273|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
214746274|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
214746275|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
214746276|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
214746277|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
214746278|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
214746279|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
214746280|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
214746281|NCT00902473|DRUG|Topiramate|25mg tablets
214746282|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
214746283|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
214746284|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
214746285|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
214746286|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
214746287|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
214746288|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
214746289|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
214746290|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
214746291|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
214746292|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
214746293|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
214746294|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
214746295|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
214746296|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
214746297|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
214746298|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
214746299|NCT00062842|DRUG|Irinotecan|
214746300|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
214746301|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
214746302|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
214746303|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
214746304|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
214746305|NCT01910142|DIETARY_SUPPLEMENT|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
214746306|NCT01910142|DIETARY_SUPPLEMENT|calcium|
214746307|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
214746308|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
214746309|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
214746310|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
214746311|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
214746312|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
214746313|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
214746314|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
214746315|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
214746316|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
214746317|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
214746318|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
214746319|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
214746320|NCT01531244|DRUG|melphalan|Given via ILI
214746321|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
214746322|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
214746323|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
214746324|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
214746325|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
214746326|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
214746327|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
214746328|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
214746329|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
214746330|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
214746331|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
214746332|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
214746333|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
214746334|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
214746335|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
214746336|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
214746337|NCT02884440|DRUG|TAP block ropivacaine|
214746338|NCT02884440|DRUG|TAP block placebo|
214746339|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
214746340|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
214746341|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
214746342|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
214746343|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
214746344|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
214746345|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
214746346|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
214746347|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
214746348|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
214746349|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
214746350|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
214746351|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
214746352|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
214746353|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
214746354|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
214746355|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
214746356|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
214746357|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
214746358|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
214746359|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
214746360|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
214746361|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
214746362|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
214746363|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
214746364|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
214746365|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
214746366|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
214746367|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
214746368|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
214746369|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
214746370|NCT00953784|PROCEDURE|standard operating management|As previously described
214746371|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
214746372|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
214746373|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
214746374|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
214746375|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
214746376|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
214746377|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
214746378|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
214746379|NCT00807768|DRUG|Carboplatin|Given IV
214746380|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
214746381|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
214746382|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
214746383|NCT00807768|DRUG|Paclitaxel|Given IV
214746384|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
214746385|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
214746386|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
214746387|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
214746388|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
214746389|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
214746390|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
214746391|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
214746392|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
214746393|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
214746394|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
214746395|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
214746396|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
214746397|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
214746398|NCT00072098|BIOLOGICAL|adenovirus vector|
214746399|NCT00072098|BIOLOGICAL|interleukin-12 gene|
214746400|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
214746401|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
214746402|NCT00132405|DRUG|ALGRX 3268|
214746403|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
214746404|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
214746405|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
214746406|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
214746407|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
214746408|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
214746409|NCT01888367|DRUG|DFA-02 Placebo Gel|
214746410|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
214746411|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
214746412|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
214746413|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
214746414|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
214746415|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
214746416|NCT04812821|OTHER|questionnaire|questionnaire post delivery
214746417|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
214746418|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
214746419|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
214746420|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
214746421|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
214746422|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
214746423|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
214746424|NCT00000952|DRUG|Ritonavir|
214746425|NCT00000952|DRUG|Lamivudine|
214746426|NCT00000952|DRUG|Zidovudine|
214746427|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
214746428|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
214746429|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
214746430|NCT04916106|DEVICE|Transcutaneous Electroacupuncture|give diffrent parameter TEA treatment for 4 weeks.
214746431|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
214746432|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
214746433|NCT04006431|OTHER|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
214746434|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
214746435|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
214746436|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
214746437|NCT03232151|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
214746438|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
214746439|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
214746440|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
214746441|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
214746442|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
214746443|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
214746444|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
214746445|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
214746446|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
214746447|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
214746448|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
214746449|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
214746450|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
214746451|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
214746452|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
214746453|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
214746454|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
214746455|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
214746456|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
214746457|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
214746458|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
214746459|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
214746460|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
214746461|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
214746462|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
214746463|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
214746464|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
214746465|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
214746466|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
214746467|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
214746468|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
214746469|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
214746470|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
214746471|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
214746472|NCT00636116|BIOLOGICAL|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
214746473|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
214746474|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
214746475|NCT06477523|DRUG|AK104|IV infusion
214746476|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214746477|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214746478|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
214746479|NCT00842829|DRUG|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
214746480|NCT05231291|OTHER|hand grip strength|Observational study
214746481|NCT04348825|DEVICE|Electroconvulsive therapy|
214746482|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
214746483|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
214746484|NCT00287976|DRUG|irinotecan hydrochloride|
214746485|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
214746486|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
214746487|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
214746488|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
214746489|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
214746490|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
214746491|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
214746492|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
214746493|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
214746494|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
214746495|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
214746496|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
214746497|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
214746498|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
214746499|NCT01551381|DRUG|EV-077|twice daily oral administration
214746500|NCT01551381|DRUG|Placebo|twice daily oral administration
214746501|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
214746502|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
214746503|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
214746504|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
214746505|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
214746506|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
214746507|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
214746508|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
214746509|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
214746510|NCT00052013|DRUG|PTK787/ZK 222584|
214746511|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
214746512|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
214746513|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
214746514|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
214746515|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
214746516|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
214746517|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
214746518|NCT01196065|DRUG|RO5313534|single oral dose
214746519|NCT01196065|DRUG|memantine|multiple doses to steady state
214746520|NCT00693524|DRUG|tacrolimus|oral
214746521|NCT00693524|DRUG|Anti-IL2R AB|i.v.
214746522|NCT00693524|DRUG|Mycophenolate mofetil|oral
214746523|NCT00693524|DRUG|prednisone|oral
214746524|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
214746525|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
214746526|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
214746527|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
214746528|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
214746529|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
214746530|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
214746531|NCT00380601|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
214746532|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
214746533|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
214746534|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
214746535|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
214746536|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
214746537|NCT00003824|PROCEDURE|surgical procedure|
214746538|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
214746539|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
214746540|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
214746541|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
214746542|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
214746543|NCT00377273|DRUG|fluorouracil cream 0.5%|
214746544|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
214746545|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
214746546|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
214746547|NCT00367146|DRUG|MMF|
214746548|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
214746549|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
214746550|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
214746551|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
214746552|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
214746553|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
214746554|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
214746555|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
214746556|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
214746557|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
214746558|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214746559|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214746560|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
214746561|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
214746562|NCT00115622|DRUG|fluticasone furoate|
214746563|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
214746564|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
214746565|NCT00000662|DRUG|Zidovudine|
214746566|NCT02628366|OTHER|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
214746567|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
214746568|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
214746569|NCT01213511|PROCEDURE|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
214746570|NCT01213511|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
214746571|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
214746572|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
214746573|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
214746574|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
214746575|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
214746576|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
214746577|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
214746578|NCT02300844|DRUG|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
214746579|NCT02300844|DRUG|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
214746580|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
214746581|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
214746582|NCT01475227|DRUG|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
214746583|NCT01475227|DRUG|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
214746584|NCT01933269|DRUG|FACBC|
214746585|NCT00107601|DRUG|Insulin|
214746586|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
214746587|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
214746588|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
214746589|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
214746590|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
214746591|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
214746592|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
214746593|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
214746594|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
214746595|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
214746596|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
214746597|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
214746598|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
214746599|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
214746600|NCT01024270|DRUG|Misoprostol|
214746601|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
214746602|NCT00001256|DRUG|prednisone and methotrexate|
214746603|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
214746604|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
214746605|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
214746606|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
214746607|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
214746608|NCT00039377|DRUG|imatinib mesylate|Given PO
214746609|NCT00039377|DRUG|methotrexate|Given IT and IV
214746610|NCT00039377|DRUG|vincristine sulfate|Given IV
214746611|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
214746612|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
214746613|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
214746614|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
214746615|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
214746616|NCT00039377|DRUG|tacrolimus|Given IV or PO
214746617|NCT00039377|BIOLOGICAL|filgrastim|Given SC
214746618|NCT00039377|DRUG|etoposide|Given IV
214746619|NCT00039377|DRUG|cyclophosphamide|Given IV
214746620|NCT00039377|DRUG|cytarabine|Given IV
214746621|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
214746622|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
214746623|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
214746624|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
214746625|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
214746626|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
214746627|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
214746628|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
214746629|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
214746630|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
214746631|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
214746632|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
214746633|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
214746634|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
214746635|NCT02452138|OTHER|Severe sepsis management|
214746636|NCT04393259|OTHER|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
214746637|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
214746638|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
214746639|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
214746640|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
214746641|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
214746642|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
214746643|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
214746644|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
214746645|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
214746646|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
214746647|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
214746648|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
214746649|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
214746650|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
214746651|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
214746652|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
214746653|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
214746654|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
214746655|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
214746656|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
214746657|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
214746658|NCT02583854|DEVICE|RY-STOP hemostasis device|
214746659|NCT02583854|DEVICE|TR-Band, Terumo|
214746660|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
214746661|NCT05141110|DRUG|NVP-1705|NVP-1705
214746662|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
214746663|NCT01020812|PROCEDURE|TACE|Standard of Care
214746664|NCT01020812|PROCEDURE|SBRT|Standard of Care
214746665|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
214746666|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
214746667|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
214746668|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
214746669|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
214746670|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
214746671|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
214746674|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
214746675|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
214746676|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
214746677|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
214746678|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
214746679|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
214746680|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
214746681|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
214746682|NCT06724484|PROCEDURE|Surgical management of fracture|Surgical management of fracture
214746683|NCT06724484|OTHER|No intervention|No intervention
214746684|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
214746685|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
214746686|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
214746687|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
214746688|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
214746689|NCT02095834|DRUG|Carfilzomib|Given IV
214746690|NCT02095834|DRUG|Dexamethasone|Given PO or IV
214746691|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
214746692|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
214746693|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
214746694|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
214746695|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
214746696|NCT05083975|DEVICE|Buzzy System|Vibrating Device
214746697|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
214746698|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
214746699|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
214746700|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
214746701|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
214746702|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
214746703|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
214746704|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
214746705|NCT03824106|OTHER|Control|Participants randomized to the control arm will not receive any of the Frailty Management Interventions.
214746706|NCT03824106|BEHAVIORAL|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
214746707|NCT03824106|COMBINATION_PRODUCT|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist."
214746708|NCT03824106|DIETARY_SUPPLEMENT|Protein Supplement|Protein supplementation will be provided.
214746709|NCT03824106|DIETARY_SUPPLEMENT|Vitamin D|1000 IU of oral vitamin D
214746710|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
214746711|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
214746712|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
214746713|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
214746714|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
214746715|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
214746716|NCT02645682|DEVICE|anti-infection CVC|
214746717|NCT02645682|DEVICE|normal CVC|
214746718|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
214746719|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
214746720|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
214746721|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
214746722|NCT02927990|OTHER|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
214746723|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
214746724|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
214746725|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
214746726|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
214746727|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
214746728|NCT06412471|DRUG|SSGJ-707|bispecific antibody
214746729|NCT06412471|DRUG|carboplatin|chemotherapy
214746730|NCT06412471|DRUG|Pemetrexed|chemotherapy
214746731|NCT06412471|DRUG|paclitaxel|chemotherapy
214746732|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
214746733|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
214746734|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
214746735|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
214746736|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
214746737|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
214746738|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
214746739|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
214746740|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
214746741|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
214746742|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
214746743|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
214746744|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
214746745|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
214746746|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
214746747|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
214746748|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
214746749|NCT02540811|DEVICE|dCELL® ACL Scaffold|
214746750|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
214746751|NCT01494753|DRUG|T2345|One drop at 8.00pm.
214746752|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
214794091|NCT04709159|OTHER|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
214746753|NCT05696184|DIAGNOSTIC_TEST|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
214794092|NCT00810732|DRUG|Open|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
214794093|NCT00810732|DRUG|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
214794094|NCT00810732|DRUG|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
214794095|NCT02841306|DRUG|Ursodeoxycholic Acid|
214794096|NCT02103088|BEHAVIORAL|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
214794097|NCT03654456|BIOLOGICAL|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
214794098|NCT00957983|DRUG|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
214746754|NCT05696184|DIAGNOSTIC_TEST|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
214746755|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
214746756|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
214746757|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
214746758|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
214746759|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
214746760|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
214746761|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
214746762|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
214746763|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
214746764|NCT00004058|DRUG|tetradecanoylphorbol acetate|
214746765|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
214746766|NCT03146195|OTHER|Dynamic Magnetic resonance imaging|
214746767|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
214746768|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
214794099|NCT02352883|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214794100|NCT02352883|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy
214794101|NCT02352883|PROCEDURE|Therapeutic Surgical Procedure|Undergo wide local excision
214794102|NCT02352883|RADIATION|Radiation Therapy|Undergo radiation therapy
214794103|NCT02352883|DRUG|Endocrine Therapy|Undergo endocrine therapy
214794104|NCT02352883|OTHER|Quality-of-Life Assessment|Ancillary studies
214794105|NCT02352883|OTHER|Laboratory Biomarker Analysis|Correlative studies
214794106|NCT02352883|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214746769|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
214746770|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
214746771|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
214746772|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
214746773|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
214746774|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
214746775|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
214746776|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
214746777|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
214746778|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
214746779|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
214746780|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
214746781|NCT05593185|BIOLOGICAL|Galinpepimut-S|
214746782|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
214746783|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
214746784|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
214746785|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
214746786|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
214746787|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
214746788|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
214746789|NCT00237146|DRUG|Zoledronic acid|
214746790|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
214746791|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
214746792|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
214746793|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
214746794|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
214746795|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
214746796|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
214746797|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
214746798|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
214746799|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
214746800|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
214746801|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
214746802|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
214746803|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
214746804|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
214746805|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
214746806|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
214746807|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
214746808|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
214746809|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
214746810|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
214746811|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
214746812|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
214746813|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
214746814|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
214746815|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
214746816|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
214746817|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
214746818|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
214746819|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
214746820|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214746821|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
214746822|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
214746823|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
214746824|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
214746825|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
214746826|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
214746827|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
214746828|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
214746829|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
214746830|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
214746831|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
214746832|NCT02530580|DRUG|Placebo|A single oral dose
214746833|NCT00296569|DRUG|MK0686|
214746834|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
214746835|NCT00088660|BIOLOGICAL|PANVAC™-VF|
214746836|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
214746837|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
214746838|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
214746839|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
214746840|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
214746841|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
214746842|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
214746843|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
214746844|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
214746845|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
214746846|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
214746847|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
214746848|NCT02257970|DRUG|Ketoprofen|
214746849|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
214746850|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
214746851|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
214746852|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
214746853|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
214746854|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
214746855|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
214746856|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
214746857|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
214746858|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
214746859|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
214746860|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
214746861|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
214746862|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
214746863|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
214746864|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
214746865|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
214746866|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
214746867|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
214746868|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
214746869|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
214746870|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
214746871|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
214746872|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
214746873|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
214746874|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
214746875|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
214746876|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
214746877|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
214746878|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
214746879|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
214746880|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
214746881|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
214746882|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
214746883|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
214746884|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
214746885|NCT02547064|PROCEDURE|Glidescope guided intubation|
214746886|NCT02547064|DEVICE|GlideScope®|
214746887|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
214746888|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
214746889|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
214746890|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
214746891|NCT00021125|PROCEDURE|adjuvant therapy|
214746892|NCT00021125|RADIATION|radiation therapy|
214746893|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
214746894|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
214746895|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
214746896|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
214746897|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
214746898|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
214746899|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
214746900|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
214746901|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
214746902|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
214746903|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
214746904|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
214746905|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
214746906|NCT00038116|PROCEDURE|placebo|sham surgery
214746907|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214746908|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
214746909|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
214746910|NCT01716585|DRUG|Placebo for ABT-333|Tablet
214746911|NCT01716585|DRUG|Placebo for ribavirin|Capsule
214746912|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
214746913|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
214746914|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
214746915|NCT00003089|DRUG|amifostine trihydrate|
214746916|NCT00003089|DRUG|carboplatin|
214746917|NCT00003089|DRUG|paclitaxel|
214746918|NCT00003089|RADIATION|radiation therapy|
214746919|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
214746920|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
214746921|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
214746922|NCT01794221|PROCEDURE|stitches only|standard of care
214746923|NCT00756379|OTHER|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
214746924|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
214746925|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
214746926|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
214746927|NCT03006042|DRUG|Bupivacaine|
214794107|NCT06057883|DIETARY_SUPPLEMENT|Probiotic|A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
214746928|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
214746929|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
214746930|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
214746931|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
214746932|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
214794108|NCT03845309|BEHAVIORAL|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
214794109|NCT02261428|DEVICE|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
214746933|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
214746934|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
214746935|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
214746936|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
214746937|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
214746938|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
214746939|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
214746940|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
214746941|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
214746942|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
214746943|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
214746944|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
214746945|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
214746946|NCT01072227|PROCEDURE|Sample Collection|Tissue
214746947|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
214746948|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
214746949|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
214746950|NCT00026559|DEVICE|Shock Device|Shock Device
214746951|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
214746952|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
214746953|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
214746954|NCT01909635|BEHAVIORAL|Food Feelings|
214746955|NCT01909635|BEHAVIORAL|Other Feelings|
214746956|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
214746957|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
214746958|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
214746959|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
214746960|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
214746961|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
214746962|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
214746963|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
214746964|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
214746965|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
214746966|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
214746967|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
214746968|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
214746969|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
214746970|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
214746971|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
214746972|NCT01984840|DEVICE|Telemedicine|
214746973|NCT02264132|DRUG|Pramipexole ER tablet|
214746974|NCT02264132|DRUG|Pramipexole IR tablet|
214746975|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
214746976|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
214746977|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
214746978|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
214746979|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
214746980|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
214746981|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
214746982|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
214746983|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
214746984|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
214746985|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
214746986|NCT03161015|DRUG|GBT440|Oral
214794110|NCT02261428|DEVICE|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
214746987|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
214746988|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
214746989|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
214746990|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
214746991|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
214746992|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
214746993|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
214794111|NCT03083483|DEVICE|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
214794112|NCT05531266|OTHER|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10\^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
214794113|NCT05531266|OTHER|glucocorticoids|Participants were treated with glucocorticoids only.
214746994|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
214746995|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
214746996|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
214746997|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
214746998|NCT03451630|BEHAVIORAL|High-Touch|Intensive, in-person and/or telephonic support.
214746999|NCT03451630|BEHAVIORAL|High-Tech|Remote care management and self-directed digital tools.
214794114|NCT03493126|DRUG|Estradiol|17β-estradiol vaginal cream
214747000|NCT03451630|BEHAVIORAL|Optimal Discharge Planning|Transition to other Health Plan disease management programs and/or community resources.
214747001|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
214747002|NCT00389766|DRUG|topotecan hydrochloride|
214747003|NCT00389766|PROCEDURE|chemotherapy|
214747004|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
214747005|NCT00389766|PROCEDURE|radioisotope therapy|
214747006|NCT00389766|PROCEDURE|radionuclide imaging|
214747007|NCT00389766|PROCEDURE|radiosensitization|
214747008|NCT00389766|PROCEDURE|total-body irradiation|
214794115|NCT03493126|OTHER|Placebo|Compounded placebo cream
214747009|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
214747010|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
214747011|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
214747012|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
214747013|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
214747014|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
214747015|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
214747016|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
214747017|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
214747018|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
214747019|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
214747020|NCT02026193|PROCEDURE|oocyte vitrification|
214747021|NCT02026193|PROCEDURE|embryo freezing|
214747022|NCT00040066|PROCEDURE|Cocaine (IV)|
214747023|NCT00090324|DRUG|quetiapine fumarate tablets|
214794116|NCT05326022|DEVICE|Microcurrent therapy|Microcurrent therapy
214794117|NCT05326022|DEVICE|Low Level Laser Therapy|Laser therapy
214794118|NCT05326022|OTHER|Medical therapy|Medical therapy
214794119|NCT04809870|PROCEDURE|surgery|retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
214747024|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
214747025|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
214747026|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
214747027|NCT01927276|OTHER|Gluten Free Flour|
214747028|NCT01927276|OTHER|Wheat Flour|
214747029|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
214747030|NCT00079157|BIOLOGICAL|sargramostim|
214747031|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
214747032|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
214747033|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
214747034|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
214747035|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
214747036|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
214747037|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
214747038|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
214747039|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
214747040|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
214747041|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
214747042|NCT01756482|DRUG|GS-5806|GS-5806, powder for oral solution
214747043|NCT01756482|DRUG|Placebo|
214747044|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
214747045|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
214747046|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
214747047|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
214747048|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
214747049|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
214747050|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
214747051|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
214747052|NCT02112149|BEHAVIORAL|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
214747053|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
214747054|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
214747055|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
214747056|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
214747057|NCT02194192|DRUG|Placebo|Normal saline 10 ml
214747058|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
214747059|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
214747060|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
214747061|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
214747062|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
214747063|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
214747064|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
214747065|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
214747066|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
214747067|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
214747068|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
214747069|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
214747070|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
214747071|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
214747072|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
214747073|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
214747074|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
214747075|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
214747076|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
214747077|NCT02557633|BIOLOGICAL|Placebo|
214747078|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
214747079|NCT01602627|OTHER|pharmacological study|Correlative studies
214747080|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
214747081|NCT00004333|DRUG|NTBC|
214747082|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
214747083|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
214747084|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
214747085|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
214747086|NCT03626389|OTHER|Physiotherapy|
214747087|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
214747088|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
214747089|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
214747090|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
214747091|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
214747092|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
214747093|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
214747094|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
214747095|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
214747096|NCT01118039|DRUG|sunitinib malate|
214747097|NCT01118039|OTHER|immunohistochemistry staining method|
214747098|NCT01118039|OTHER|laboratory biomarker analysis|
214747099|NCT01118039|OTHER|pharmacological study|
214747100|NCT01118039|PROCEDURE|quality-of-life assessment|
214747101|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
214747102|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
214747103|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
214747104|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
214747105|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
214747106|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
214747107|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
214747108|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
214747109|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
214747110|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
214747111|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
214747112|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
214747113|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
214747114|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
214747115|NCT00207493|PROCEDURE|patient referral versus contract referral|
214747116|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
214747117|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
214747118|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
214747119|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
214747120|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
214747121|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
214747122|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
214747123|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
214747124|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
214747125|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
214747126|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
214747127|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
214747128|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
214747129|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
214747130|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
214747131|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
214747132|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
214747133|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
214747134|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
214747135|NCT01140646|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
214747136|NCT01140646|OTHER|questionnaire administration|Ancillary studies
214747137|NCT01140646|PROCEDURE|quality-of-life assessment|Ancillary studies
214747138|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
214747139|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
214747140|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
214747141|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
214747142|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
214747143|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
214747144|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
214747145|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
214747146|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
214747147|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
214747148|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
214747149|NCT03264976|DIAGNOSTIC_TEST|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
214747150|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
214747151|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
214747152|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
214747153|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
214747154|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
214747155|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
214747156|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
214747157|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
214747158|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
214747159|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
214747160|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
214747161|NCT01365897|DRUG|Modafinil|Modafinil 200mg
214747162|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
214747163|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
214747164|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
214747165|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
214747166|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
214747167|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
214747168|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
214747169|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
214747170|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
214747171|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
214747172|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
214747173|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
214747174|NCT04047342|BEHAVIORAL|Welcome email|Email
214747175|NCT04047342|BEHAVIORAL|Loss frame|Email
214747176|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
214747177|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
214747178|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
214747179|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
214747180|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
214747181|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
214747182|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
214747183|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
214747184|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
214747185|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
214747186|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
214747187|NCT00660829|DRUG|Placebo|Placebo
214747188|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
214747189|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
214747190|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
214747191|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
214747192|NCT02966912|OTHER|Open label (none)|
214747193|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
214747194|NCT01742013|DRUG|Placebo|Comparator
214747195|NCT03576456|DRUG|Alprazolam 0.5 mg|receive alprazolam prior to angio
214747196|NCT03576456|DRUG|Placebo Oral Tablet|receive placebo prior to angio
214747197|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
214747198|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
214747199|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
214747200|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
214747201|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
214747202|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
214747203|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
214747204|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
214747205|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
214747206|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
214747207|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
214747208|NCT02554916|DEVICE|Dual-Belt Treadmill|
214747209|NCT00106496|DRUG|Protopic|topical
214747210|NCT00106496|DRUG|Corticosteroid|topical
214747211|NCT00106496|DRUG|placebo|topical
214747212|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
214747213|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
214747214|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
214747215|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
214747216|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
214747217|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
214747218|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
214747219|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
214747220|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
214747221|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
214747222|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
214747223|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
214747224|NCT03060109|OTHER|Blood draw within 12 hours of injury|
214747225|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
214747226|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
214747227|NCT01701531|DRUG|RBCPF|
214747228|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
214747229|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
214747230|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
214747231|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
214747232|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
214747233|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
214747234|NCT02984228|BIOLOGICAL|PRP|
214747235|NCT02984228|DRUG|Hyaluronic Acid|
214747236|NCT02984228|DEVICE|Ultrasound|
214747237|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
214747238|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
214747239|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
214747240|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
214747241|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
214747242|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
214747243|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
214747244|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
214747245|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
214747246|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
214747247|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
214747248|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
214747249|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
214747250|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
214747251|NCT00036660|DRUG|SarCNU|
214747252|NCT00006162|BEHAVIORAL|exercise and diet|
214747253|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
214747254|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
214747255|NCT01130831|DRUG|Lanthanum carbonate|
214747256|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
214747257|NCT02204267|DEVICE|ECG|
214747258|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
214747259|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
214747260|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
214747261|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
214747262|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
214747263|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
214747264|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
214747265|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
214747266|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
214747267|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
214747268|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
214747269|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
214747270|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
214747271|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
214747272|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
214747273|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
214747274|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
214747275|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
214747276|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
214747277|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
214747278|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
214747279|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
214747280|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
214747281|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
214747282|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
214747283|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
214747284|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
214747285|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
214747286|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
214747287|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
214747288|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
214747289|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
214747290|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
214747291|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
214747292|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
214747293|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
214747294|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
214747295|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
214747296|NCT00405795|DEVICE|Envision® Patient Support System|
214747297|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
214747298|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
214747299|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
214747300|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
214747301|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
214747302|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
214747303|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
214747304|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
214747305|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
214747306|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
214747307|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
214747308|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
214747309|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
214747310|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
214747311|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
214747312|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
214747313|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
214747314|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
214747315|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
214747316|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
214747317|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
214747318|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
214747319|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
214747320|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
214747321|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
214747322|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
214747323|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
214747324|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
214747325|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
214747326|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
214747327|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
214747328|NCT00021346|DRUG|carboplatin|
214747329|NCT00021346|DRUG|gemcitabine hydrochloride|
214747330|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
214747331|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
214747332|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
214747333|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
214747334|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
214747335|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
214747336|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
214747337|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
214747338|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
214747339|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
214747340|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
214747341|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
214747342|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
214747343|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
214747344|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
214747345|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
214747346|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
214747347|NCT02297867|DRUG|ADSCs|autologous ADSCs
214747348|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
214747349|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
214747350|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
214747351|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
214747352|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
214747353|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
214747354|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
214747355|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
214747356|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
214747357|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
214747358|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
214747359|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
214747360|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
214747361|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
214747362|NCT01738906|OTHER|Orange juice|
214747363|NCT01738906|OTHER|maltodextrin|
214747364|NCT01738906|OTHER|Vodka|
214747365|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
214747366|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
214747367|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
214747368|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
214747369|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
214747370|NCT03162380|OTHER|Date collection|Date collection
214747371|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
214747372|NCT06313567|OTHER|Observation|observation
214747373|NCT02218424|DRUG|Magnesium|
214747374|NCT02218424|DRUG|Normal saline|
214747375|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
214747376|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
214747377|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
214747378|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
214747379|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
214747380|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
214747381|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
214747382|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
214747383|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
214747384|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
214747385|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
214747386|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
214794120|NCT05518942|BEHAVIORAL|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
214747387|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
214747388|NCT02409251|BEHAVIORAL|Education and feedback|
214747389|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
214747390|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
214747391|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
214747392|NCT02582008|DRUG|Nicotine Replacement|Given NRT
214747393|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
214747394|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
214747395|NCT02582008|DRUG|Varenicline|Given PO
214747396|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
214747397|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
214747398|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
214747399|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
214747400|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
214747401|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
214747402|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
214747403|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
214747404|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
214747405|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
214747406|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
214747407|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
214747408|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
214747409|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
214747410|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
214747411|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
214747412|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
214747413|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
214747414|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
214747415|NCT03968588|DRUG|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
214747416|NCT03968588|DRUG|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
214747417|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
214747418|NCT01197495|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
214747419|NCT00078455|DRUG|ILX651|
214747420|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
214747421|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
214747422|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
214747423|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
214747424|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
214747425|NCT00726167|DEVICE|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
214747426|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
214747427|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
214747428|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
214747429|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
214747430|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
214747431|NCT00175552|BEHAVIORAL|Psychotherapy Training|
214747432|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
214747433|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
214747434|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
214747435|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
214747436|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
214747437|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
214747438|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
214747439|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
214747440|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
214794121|NCT03731182|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
214794122|NCT03731182|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
214747441|NCT05664412|DEVICE|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
214747442|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
214747443|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
214747444|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
214747445|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
214747446|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
214747447|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
214747448|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
214747449|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
214747450|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
214747451|NCT00211133|DRUG|epoetin alfa|
214794123|NCT02007148|DRUG|capecitabine|twice a day
214794124|NCT02007148|DRUG|Docetaxel|cycles repeated every 3 weeks
214747452|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
214747453|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
214747454|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
214747455|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
214747456|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
214747457|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
214747458|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
214747459|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
214747460|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
214747461|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
214747462|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
214747463|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
214747464|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
214747465|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
214747466|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
214747467|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
214747468|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
214747469|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
214747470|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
214747471|NCT05483062|OTHER|galla chinensis|toothpaste
214747472|NCT05483062|OTHER|Stannous fluoride|Toothpaste
214747473|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
214747474|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
214747475|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
214747476|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
214747477|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
214747478|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
214747479|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
214747480|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
214747481|NCT00033683|DRUG|CMF regimen|
214747482|NCT00033683|DRUG|cyclophosphamide|
214747483|NCT00033683|DRUG|docetaxel|
214747484|NCT00033683|DRUG|epirubicin hydrochloride|
214747485|NCT00033683|DRUG|fluorouracil|
214747486|NCT00033683|DRUG|methotrexate|
214747487|NCT00033683|DRUG|tamoxifen citrate|
214747488|NCT00033683|PROCEDURE|adjuvant therapy|
214747489|NCT00033683|RADIATION|radiation therapy|
214747490|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
214747491|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
214747492|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
214747493|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
214747494|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
214747495|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
214747496|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
214747497|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
214794125|NCT01800565|OTHER|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
214747498|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
214747499|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
214747500|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
214747501|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
214747502|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
214747503|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
214747504|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
214747505|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
214747506|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
214747507|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
214747508|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
214747509|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
214747510|NCT03616652|DRUG|Placebo|Placebo pill
214747511|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
214747512|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
214747513|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
214747514|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
214747515|NCT05423275|DEVICE|Negative ion therapy|Negative ion generator
214747516|NCT05423275|DEVICE|Light therapy|Fluorescent light box
214747517|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
214747518|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
214747519|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
214747520|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
214747521|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
214747522|NCT00005874|DRUG|rubitecan|
214747523|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
214747524|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
214747525|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
214747526|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
214747527|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
214747528|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
214747529|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
214747530|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
214747531|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
214747532|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
214747533|NCT02581657|DRUG|Placebo Injection|Placebo Injection
214747534|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
214747535|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
214747536|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
214747537|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
214747538|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
214747539|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
214747540|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
214747541|NCT00313716|OTHER|placebo|an inactive substance
214747542|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
214747543|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
214747544|NCT02010099|DRUG|PP110 Gel|
214747545|NCT02010099|DRUG|PP110 Medicated wipes|
214747546|NCT02010099|DRUG|Preparation-H Cream|
214747547|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214747548|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
214747549|NCT02399345|DRUG|ribavirin (RBV)|tablet
214747550|NCT04620005|OTHER|Observational|Survey
214747551|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
214747552|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
214747553|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
214747554|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
214747555|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
214747556|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
214747557|NCT01041027|DRUG|Paclitaxel|Given IV
214747558|NCT01041027|DRUG|Carboplatin|Given IV
214747559|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
214747560|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214747561|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
214747562|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
214747563|NCT03326882|DEVICE|Endotracheal intubation|
214747564|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
214747565|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
214747566|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
214747567|NCT01907373|DRUG|olmesartan medoxomil|
214747568|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
214747569|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
214747570|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
214747571|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
214747572|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
214747573|NCT02493712|DRUG|Placebo|Placebo
214747574|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
214747575|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
214747576|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
214747577|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
214747578|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
214747579|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
214747580|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
214747581|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
214747582|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
214747583|NCT00002600|BIOLOGICAL|filgrastim|
214747584|NCT00002600|DRUG|carboplatin|
214747585|NCT00002600|DRUG|cyclophosphamide|
214747586|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
214747587|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
214747588|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
214747589|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
214747590|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
214747591|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
214747592|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
214747593|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
214747594|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
214747595|NCT02528643|DRUG|Enzalutamide|Oral capsule
214747596|NCT02528643|DRUG|Placebo|Oral capsule
214747597|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
214747598|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
214747599|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
214747600|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
214747601|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
214747602|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
214747603|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
214747604|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
214747605|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
214747606|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
214747607|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
214747608|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
214747609|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
214747610|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
214747611|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
214747612|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
214747613|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
214747614|NCT05870423|DRUG|olaparib|18 days olaparib during each cycle of PRRT
214747615|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
214747616|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
214747617|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
214747618|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
214747619|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
214747620|NCT04010357|DRUG|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
214747621|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
214747622|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
214747623|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
214747624|NCT00000649|DRUG|Nevirapine|
214747625|NCT00000649|DRUG|Zidovudine|
214747626|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
214747627|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
214747628|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
214747629|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
214747630|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
214747631|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
214747632|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
214747633|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
214747634|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
214747635|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
214747636|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
214747637|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
214747638|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
214747639|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
214747640|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
214747641|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
214747642|NCT02382419|OTHER|Placebo|Applied vaginally
214747643|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
214747644|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
214747645|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
214747646|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
214747647|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
214747648|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
214747649|NCT00002021|DRUG|Foscarnet sodium|
214747650|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
214747651|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
214747652|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
214747653|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
214747654|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
214747655|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
214747656|NCT00004409|DRUG|collagenase|
214747657|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
214747658|NCT04143815|DRUG|Placebo|Intramuscular injection
214747659|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
214747660|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
214747661|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
214747662|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
214747663|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
214747664|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
214747665|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
214747666|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
214747667|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
214747668|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
214747669|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
214747670|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
214747671|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
214747672|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
214747673|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
214747674|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
214747675|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
214747676|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
214747677|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
214747678|NCT04463719|BEHAVIORAL|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
214747679|NCT04463719|BEHAVIORAL|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
214747680|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
214747681|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
214747682|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
214747683|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
214747684|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
214747685|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
214747686|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
214747687|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
214747688|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
214747689|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
214747690|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
214747691|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
214747692|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
214747693|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
214747694|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
214747695|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
214747696|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
214747697|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
214747698|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
214747699|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
214747700|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
214747701|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
214747702|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
214747703|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
214747704|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
214747705|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
214747706|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
214747707|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
214747708|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
214747709|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
214747710|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
214747711|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
214747712|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
214747713|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
214747714|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
214747715|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
214747716|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
214747717|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
214747718|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
214747719|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
214747720|NCT00212615|DRUG|Capecitabine (Xeloda)|
214747721|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
214747722|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
214747723|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
214747724|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
214747725|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
214747726|NCT02503956|PROCEDURE|Crawford tube insertion|
214747727|NCT02503956|DEVICE|Crawford lacrimal tube|
214747728|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
214747729|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
214747730|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
214747731|NCT02028052|DEVICE|22 gauge Vizishot needles|
214747732|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
214747733|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
214747734|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
214747735|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
214747736|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
214747737|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
214747738|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
214747739|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
214747740|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
214747741|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
214747742|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
214794126|NCT01800565|OTHER|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
214747743|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
214747744|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
214747745|NCT02708576|BIOLOGICAL|NGM313|
214747746|NCT02708576|OTHER|Placebo|
214747747|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
214747748|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
214747749|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214747750|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214747751|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214747752|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
214747753|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
214747754|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
214747755|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
214747756|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
214747757|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
214747758|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
214747759|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
214747760|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
214747761|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
214747762|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
214747763|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
214747764|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
214747765|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
214747766|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
214747767|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
214747768|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
214747769|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
214747770|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
214747771|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
214747772|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
214747773|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
214747774|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
214747775|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
214747776|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
214794127|NCT01440530|BEHAVIORAL|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
214747777|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
214747778|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
214747779|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
214747780|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
214747781|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
214747782|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
214747783|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
214747784|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
214747785|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
214747786|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
214747787|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
214747788|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
214747789|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
214747790|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
214747791|NCT00266604|DRUG|Topiramate|
214747792|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
214747793|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
214747794|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
214747795|NCT04455958|DRUG|Placebo Administration|Given PO
214747796|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
214747797|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
214747798|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
214747799|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
214747800|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
214747801|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
214747802|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
214747803|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
214747804|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
214747805|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
214747806|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
214747807|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
214747808|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
214747809|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
214747810|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
214747811|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
214747812|NCT00261599|DRUG|Midazolam HCI|
214747813|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
214747814|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
214747815|NCT00958282|OTHER|placebo|
214747816|NCT03016520|DRUG|DWJ1392|
214747817|NCT03016520|DRUG|DWC20164|
214747818|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
214747819|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
214747820|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
214747821|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
214747822|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
214747823|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
214747824|NCT00374920|DRUG|MEM 1003|
214747825|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
214747826|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
214747827|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
214747828|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
214747829|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
214747830|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
214747831|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
214747832|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
214747833|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
214747834|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
214747835|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
214747836|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
214747837|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
214747838|NCT01992146|DRUG|Target-controlled naloxone-infusion|
214747839|NCT01992146|DRUG|Placebo|
214747840|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
214747841|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
214747842|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
214747843|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
214747844|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
214747845|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
214747846|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
214747847|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
214747848|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
214747849|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
214747850|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
214747851|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
214747852|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
214747853|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
214747854|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
214747855|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
214747856|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
214747857|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
214747858|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
214747859|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
214747860|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
214747861|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
214747862|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
214747863|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
214747864|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
214747865|NCT03485404|DRUG|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
214747866|NCT03485404|DRUG|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
214747867|NCT03485404|OTHER|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
214747868|NCT03485404|OTHER|Placebo for folic acid|yellow tablets that looks exactly like folic acid
214747869|NCT03485404|PROCEDURE|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
214747870|NCT03485404|BEHAVIORAL|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
214747871|NCT00366665|DEVICE|Legacy 20000|
214747872|NCT00366665|DEVICE|Infinit system|
214747873|NCT00730249|DRUG|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
214747874|NCT00730249|DRUG|Placebo|twice daily according to an individual titration schedule
214747875|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
214747876|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
214747877|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
214747878|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
214747879|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
214747880|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
214747881|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
214747882|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
214747883|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
214747884|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
214747885|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
214747886|NCT05278663|DRUG|E6742|E6742 tablet.
214747887|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
214747888|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
214747889|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
214747890|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
214747891|NCT01549327|OTHER|Oncology Interactive Navigator|
214747892|NCT01549327|OTHER|Routine Care|
214747893|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
214747894|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
214747895|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
214747896|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
214747897|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
214747898|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
214747899|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
214747900|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
214747901|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
214747902|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
214747903|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
214747904|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
214747905|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
214747906|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
214747907|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
214747908|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
214747909|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
214747910|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
214747911|NCT01416259|DRUG|Withdraw treatment|
214747912|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
214747913|NCT06424756|DIETARY_SUPPLEMENT|MitoQ|MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
214747914|NCT06424756|DIETARY_SUPPLEMENT|Placebo|MitoQ matched Placebo
214747915|NCT06424756|DRUG|MitoTempo|During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
214747916|NCT06424756|DRUG|Tempol|During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
214747917|NCT06424756|DRUG|L-NAME|During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
214747918|NCT06424756|DRUG|SNP - Sodium Nitroprusside|At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
214747919|NCT01853397|DEVICE|Liposonix System (Model 2)|
214747920|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
214747921|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
214747922|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
214747923|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
214747924|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
214747925|NCT02727452|OTHER|Skin-to-skin contact|
214747926|NCT02132312|DRUG|OMS302|
214747927|NCT02132312|DRUG|Phenylephrine HCl|
214747928|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
214747929|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
214747930|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
214747931|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
214747932|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
214747933|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
214747934|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
214747935|NCT06112249|BEHAVIORAL|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
214747936|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
214747937|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
214747938|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
214747939|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
214747940|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
214747941|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
214747942|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
214747943|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
214747944|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
214747945|NCT06334237|OTHER|personalized treatment|According to the condition of each individuals, the study continues their routine clinical care. The study does not offer anything more than a routine clinical care. It is named personalized treatment because the condition of each individual varies, so the doctor may prescribe or offer clinical advice accordingly. .
214747946|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
214747947|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
214747948|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
214747949|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
214747950|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
214747951|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
214747952|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
214747953|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
214747954|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
214747955|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
214747956|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
214747957|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
214747958|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
214747959|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
214747960|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
214747961|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
214747962|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
214747963|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
214747964|NCT03083262|OTHER|no intervention|None, there is no intervention
214747965|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
214747966|NCT00000131|PROCEDURE|Photocoagulation Therapy|
214747967|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
214747968|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
214747969|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
214747970|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
214747971|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
214747972|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
214747973|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
214747974|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
214747975|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
214747976|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
214747977|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
214747978|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
214747979|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
214747980|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
214747981|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
214747982|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
214747983|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
214747984|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
214747985|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
214747986|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
214747987|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
214747988|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
214747989|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
214747990|NCT03570476|DRUG|Olaparib|Given orally
214747991|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
214747992|NCT02041533|BIOLOGICAL|Nivolumab|
214747993|NCT02041533|DRUG|Gemcitabine|
214747994|NCT02041533|DRUG|Cisplatin|
214747995|NCT02041533|DRUG|Carboplatin|
214747996|NCT02041533|DRUG|Paclitaxel|
214747997|NCT02041533|DRUG|Pemetrexed|
214747998|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
214747999|NCT04177186|OTHER|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
214748000|NCT04177186|COMBINATION_PRODUCT|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
214748001|NCT00641979|DRUG|budesonide|Current product
214748002|NCT00641979|DEVICE|Budesonide|New type device
214748003|NCT00641979|DRUG|Placebo|
214748004|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
214748005|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
214748006|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
214748007|NCT03138798|DEVICE|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
214748008|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
214748009|NCT01483378|OTHER|Choosing to receive the vaccine|
214748010|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
214748011|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
214748012|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
214748013|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
214748014|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
214748015|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
214748016|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
214748017|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
214748018|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
214748019|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
214748020|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
214748021|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
214748022|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
214748023|NCT01907750|DEVICE|biliary drainage tube|
214748024|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
214748025|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
214748026|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
214748027|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
214748028|NCT00527046|DRUG|CP-424,391|
214748029|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
214748030|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
214748031|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
214748032|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
214748033|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
214748034|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
214794128|NCT01440530|OTHER|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
214748035|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
214748036|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
214748037|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
214748038|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
214748039|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
214748040|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
214748041|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
214748042|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
214748043|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
214748044|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
214748045|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
214748046|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
214748047|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
214748048|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
214748049|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
214748050|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214748051|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
214748052|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
214748053|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
214748054|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
214748055|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
214748056|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
214748057|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
214748058|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
214748059|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
214748060|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
214748061|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
214748062|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
214748063|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
214748064|NCT05047601|DRUG|PF-07321332|PF-07321332
214748065|NCT05047601|DRUG|Placebo for PF-07321332|Placebo
214748066|NCT05047601|DRUG|Placebo for Ritonavir|Placebo
214748067|NCT05047601|DRUG|Ritonavir|Ritonavir
214748068|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
214748069|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
214748070|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
214748071|NCT00286234|DRUG|extended release niacin|2 g qpm
214748072|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
214748073|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
214748074|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
214748075|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
214748076|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
214748077|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
214748078|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
214748079|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
214748080|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
214748081|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
214748082|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
214748083|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
214748084|NCT00208572|DRUG|Citalopram|
214748085|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
214748086|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
214748087|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
214748088|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
214748089|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
214748090|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
214794129|NCT05474625|DEVICE|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
214748091|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
214748092|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
214748093|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
214748094|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
214748095|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
214748096|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
214748097|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
214748098|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
214748099|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
214748100|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
214748101|NCT02499380|DEVICE|PneumRx Coil System|
214748102|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
214748103|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
214748104|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
214794130|NCT05474625|DEVICE|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
214748105|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
214748106|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
214748107|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
214748108|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
214748109|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
214748110|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
214748111|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
214748112|NCT02957500|DEVICE|Mediclore® (adhesion barrier)|
214748113|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
214748114|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
214748115|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
214748116|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
214748117|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
214748118|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
214748119|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
214748120|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
214748121|NCT00572858|PROCEDURE|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
214748122|NCT00572858|GENETIC|Blood test|Blood test for genetic testing
214748123|NCT00572858|PROCEDURE|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
214748124|NCT00572858|PROCEDURE|Saliva test|Saliva test for cotisol levels
214748125|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
214748126|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
214748127|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
214748128|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
214748129|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
214748130|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
214748131|NCT03391427|DRUG|Saline|This group will receive saline infusion
214748132|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
214748133|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
214748134|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
214748135|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
214748136|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
214748137|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
214748138|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
214748139|NCT03550508|BIOLOGICAL|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
214748140|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
214748141|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
214748142|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
214748143|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
214748144|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
214748145|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
214748146|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
214748147|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
214748148|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
214748149|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
214748150|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
214748151|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
214748152|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
214748153|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
214748154|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
214748155|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
214748156|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
214748157|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
214748158|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
214748159|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
214748160|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
214748161|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
214748162|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
214748163|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
214748164|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
214748165|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
214748166|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
214748167|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
214748168|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
214748169|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
214748170|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
214748171|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
214748172|NCT02909920|OTHER|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
214748173|NCT02909920|OTHER|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
214748174|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
214748175|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
214748176|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
214748177|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
214748178|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
214748179|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
214748180|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
214748181|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
214748182|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
214794131|NCT05474625|DEVICE|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
214748183|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
214748184|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
214748185|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
214748186|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
214748187|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
214748188|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70\_R84-064)
214748189|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
214748190|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
214748191|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
214748192|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
214748193|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
214748194|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
214748195|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
214748196|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
214748197|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
214748198|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
214748199|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
214748200|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
214748201|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
214748202|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
214748203|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
214748204|NCT03459976|DIAGNOSTIC_TEST|evaluate serum level HE4 in endometrial cancer|"1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer"
214748205|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
214748206|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
214748207|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
214748208|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
214748209|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
214748210|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
214748211|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
214748212|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
214748213|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
214748214|NCT02465541|OTHER|questionnaire administration|Ancillary studies
214748215|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
214748216|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
214748217|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
214748218|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
214748219|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
214748220|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
214748221|NCT03824756|OTHER|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
214748222|NCT03824756|OTHER|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
214748223|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
214748224|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
214748225|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
214748226|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
214748227|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
214748228|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
214748229|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
214748230|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
214748231|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
214748232|NCT02992054|OTHER|stimulating activities|
214748233|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
214748234|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
214748235|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
214748236|NCT03006276|DRUG|DFN-15 Active|
214748237|NCT03006276|OTHER|DFN-15 Placebo|
214748238|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
214748239|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
214748240|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
214748241|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
214748242|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
214748243|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
214748244|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
214748245|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
214748246|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
214748247|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
214748248|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
214748249|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
214748250|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
214748251|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
214748252|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
214748253|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
214748254|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
214748255|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
214748256|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
214748257|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
214748258|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
214748259|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
214748260|NCT00427687|DRUG|AGG-523|
214748261|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
214748262|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
214748263|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
214748264|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
214748265|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
214748266|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214748267|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
214748268|NCT00300794|DRUG|Ketamine|
214748269|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
214748270|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
214748271|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
214748272|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
214748273|NCT02078674|BIOLOGICAL|Placebo|
214748274|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
214748275|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
214748276|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
214748277|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
214748278|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
214748279|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
214748280|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
214748281|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
214748282|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
214748283|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
214748284|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
214748285|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
214748286|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
214748287|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
214748288|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
214748289|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
214748290|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
214748291|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
214748292|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
214748293|NCT01974310|PROCEDURE|Postoperative face-down positioning|
214748294|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
214748295|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
214748296|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
214748297|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
214748298|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
214748299|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
214748300|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
214748301|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
214748302|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
214748303|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
214748304|NCT00466284|DRUG|Tarceva (erlotinib)|
214748305|NCT00158002|DRUG|Topiramate|
214748306|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
214748307|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
214748308|NCT00042575|DRUG|Duloxetine|
214748309|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
214748310|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
214748311|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
214748312|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
214748313|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
214748314|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
214748315|NCT00003576|DRUG|cisplatin|
214748316|NCT00003576|DRUG|fluorouracil|
214748317|NCT00003576|PROCEDURE|surgical procedure|
214748318|NCT00003576|RADIATION|radiation therapy|
214748319|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
214748320|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
214748321|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
214748322|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
214748323|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
214748324|NCT02977741|DRUG|Olanzapine|
214748325|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
214748326|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
214748327|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
214748328|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
214748329|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
214748330|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
214748331|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
214748332|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
214748333|NCT05349214|OTHER|Placebo|placebo s.c.
214748334|NCT05549804|DRUG|KL340399 Intratumoral|KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
214748335|NCT06765642|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The use of this approach aims to potentially maximize motor recovery in chronic stroke by harnessing corticospinal plasticity and modulating motor learning behavior.
214748336|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
214748337|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
214748338|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
214748339|NCT06829602|DIAGNOSTIC_TEST|Rapid Syphilis/HIV point-of-care test|The INSTI Multiplex HIV/Syphilis Duo Antibody Test is a rapid immunoassay that can detect HIV and syphilis antibodies in the blood using finger-prick blood samples. The test is Health Canada-approved.
214748340|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
214748341|NCT01162031|DRUG|Velcade|IV
214748342|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
214748343|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
214748344|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
214748345|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
214748346|NCT06018389|BEHAVIORAL|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
214748347|NCT06018389|BEHAVIORAL|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
214748348|NCT03252808|BIOLOGICAL|TBI-1401(HF10)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
214748349|NCT03252808|DRUG|Gemcitabine|1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
214748350|NCT03252808|DRUG|Nab-paclitaxel|125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
214748351|NCT03252808|DRUG|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
214748352|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
214748353|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
214748354|NCT00772031|DRUG|placebo|an inactive substance
214748355|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
214748356|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
214748357|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
214748358|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
214748359|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
214748360|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
214748361|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
214748362|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
214748363|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
214748364|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
214748365|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
214748366|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
214748367|NCT02063802|BEHAVIORAL|Healthy habits program|
214748368|NCT00005990|DRUG|tipifarnib|
214748369|NCT00005990|DRUG|topotecan hydrochloride|
214748370|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
214748371|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
214748372|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
214748373|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214748374|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
214748375|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
214748376|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
214748377|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
214748378|NCT00755976|DRUG|epirubicin hydrochloride|
214748379|NCT00755976|DRUG|sulindac|
214748380|NCT00755976|OTHER|immunologic technique|
214748381|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
214748382|NCT02204722|DRUG|600mg/day of Imatinib|
214748383|NCT02204722|DRUG|400mg/day of Imatinib|
214748384|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
214748385|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
214748386|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
214748387|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
214748388|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
214748389|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
214748390|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
214748391|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
214748392|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
214748393|NCT00079079|DRUG|carboplatin|
214748394|NCT00079079|DRUG|cisplatin|
214748395|NCT00079079|DRUG|gemcitabine hydrochloride|
214748396|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
214748397|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
214748398|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
214748399|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
214748400|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
214748401|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
214748402|NCT02631434|PROCEDURE|sit-to-stand test|
214748403|NCT02631434|PROCEDURE|six-minutes walking test|
214748404|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
214748405|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
214748406|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
214748407|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
214748408|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
214748409|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
214748410|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
214748411|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
214748412|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
214748413|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
214748414|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
214748415|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
214748416|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
214748417|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
214748418|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
214748419|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
214748420|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
214748421|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
214748422|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
214748423|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
214748424|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
214748425|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
214748426|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
214748427|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
214748428|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
214748429|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
214748430|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
214748431|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
214748432|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
214748433|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
214748434|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
214794132|NCT05474625|OTHER|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
214794133|NCT02883790|DIETARY_SUPPLEMENT|Somnage|Melatonin 1mg, Zinc, Magnesium
214794134|NCT02883790|OTHER|Placebo|Placebo
214794135|NCT00311779|DRUG|Spinosad Creme Rinse|
214794136|NCT00163384|DRUG|Ciclesonide|
214748435|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
214748436|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
214748437|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
214748438|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
214748439|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
214748440|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
214748441|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
214748442|NCT00405925|DRUG|Trizivir|
214748443|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
214748444|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
214748445|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
214748446|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
214748447|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
214748448|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
214748449|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
214748450|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
214748451|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
214748452|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
214748453|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
214748454|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
214748455|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
214748456|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
214748457|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
214748458|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
214748459|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
214748460|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
214748461|NCT01111058|OTHER|Placebo|
214748462|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
214748463|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
214748464|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
214748465|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
214748466|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
214748467|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
214748468|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
214748469|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
214748470|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
214748471|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
214748472|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
214748473|NCT04963517|BEHAVIORAL|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
214748474|NCT04963517|OTHER|Information|"* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations."
214748475|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
214748476|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
214748477|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
214748478|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
214748479|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
214748480|NCT03153436|BIOLOGICAL|Myoinositol|
214748481|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
214748482|NCT00752427|DRUG|Paliperidone ER OROS®|
214748483|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
214748484|NCT02213627|DRUG|Corifollitropin alfa|
214748485|NCT02213627|DRUG|Recombinant FSH|
214748486|NCT02213627|DRUG|HP-hMG|
214748487|NCT00131027|DRUG|Cyclophosphamide|
214748488|NCT00131027|DRUG|Daunorubicin|
214748489|NCT00131027|DRUG|Vincristine|
214748490|NCT00131027|DRUG|Prednisolone|
214748491|NCT00131027|DRUG|L-asparaginase|
214748492|NCT00131027|DRUG|Cytarabine|
214748493|NCT00131027|DRUG|Etoposide|
214748494|NCT00131027|DRUG|Dexamethasone|
214748495|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
214748496|NCT00131027|DRUG|Mercaptopurine|
214748497|NCT00131027|DRUG|Doxorubicin|
214748498|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
214748499|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
214748500|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
214748501|NCT03007680|OTHER|Core muscle activation|
214748502|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
214748503|NCT01065662|DRUG|cediranib|Taken orally daily
214748504|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
214748505|NCT03380091|DRUG|Metformin|Oral medication daily
214748506|NCT03380091|DRUG|Vitamin D|Oral medication daily
214748507|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
214748508|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
214748509|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
214748510|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
214748511|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
214748512|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
214748513|NCT05602818|DRUG|Soticlestat 300 mg|Administered orally.
214748514|NCT05602818|DRUG|Soticlestat 600 mg|Administered orally.
214748515|NCT05602818|DRUG|Soticlestat 900 mg|Administered orally.
214748516|NCT05602818|DRUG|Alprazolam|Administered orally.
214748517|NCT05602818|DRUG|Placebo|Administered orally.
214748518|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
214748519|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
214748520|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
214748521|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
214748522|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
214748523|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
214748524|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
214748525|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
214748526|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
214748527|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
214748528|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
214748529|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
214748530|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
214748531|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
214748532|NCT00538434|BIOLOGICAL|Reslizumab|
214748533|NCT00538434|OTHER|Saline|
214748534|NCT02164058|DEVICE|TandemHeart System|
214748535|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
214748536|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
214748537|NCT03054493|BEHAVIORAL|no intervention|no intervention
214748538|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
214748539|NCT00078689|DRUG|Daclizumab|
214748540|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
214748541|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
214748542|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
214748543|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
214748544|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
214748545|NCT00001422|DRUG|fludarabine|
214748546|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
214748547|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
214748548|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
214748549|NCT02353234|OTHER|Bread|In each arm subjects consume bread
214748550|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
214748551|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
214748552|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
214748553|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
214748554|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
214748555|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
214748556|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
214748557|NCT03605277|DRUG|Asciminib|40 mg single dose
214748558|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
214748559|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
214748560|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
214748561|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
214748562|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
214748563|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
214748564|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
214748565|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
214748566|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
214748567|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
214748568|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
214748569|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
214748570|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
214748571|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
214748572|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
214748573|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
214748574|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
214748575|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
214748576|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
214748577|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
214748578|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214748579|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214748580|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
214748581|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
214748582|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
214748583|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
214748584|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
214748585|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
214748586|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
214748587|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
214748588|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
214748589|NCT00058097|DRUG|tipifarnib|Given orally
214748590|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
214748591|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
214748592|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
214748593|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
214748594|NCT00457951|DRUG|Open-Label|ODSH administered open-label
214748595|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
214748596|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
214748597|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
214748598|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
214748599|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
214748600|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
214748601|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
214748602|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
214748603|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
214748604|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
214748605|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
214748606|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
214748607|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
214748608|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
214748609|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
214748610|NCT01136317|DRUG|Omeprazole|
214748611|NCT01136317|DRUG|Rabeprazole|
214748612|NCT01136317|DRUG|Lactose|
214748613|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
214748614|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
214748615|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
214748616|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
214748617|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
214748618|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
214748619|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
214748620|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
214748621|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
214748622|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
214748623|NCT00425594|DRUG|NuLYTELY|
214748624|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
214748625|NCT02382887|DEVICE|Airtraq|
214748626|NCT02382887|DEVICE|fiberscope|
214748627|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
214748628|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
214748629|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
214748630|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
214748631|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
214748632|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
214748633|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
214748634|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
214748635|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
214748636|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
214748637|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
214748638|NCT01869231|DIETARY_SUPPLEMENT|water|
214748639|NCT00017108|DRUG|chlorambucil|
214748640|NCT00017108|DRUG|cyclophosphamide|
214748641|NCT00017108|DRUG|fludarabine phosphate|
214748642|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
214748643|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
214748644|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
214748645|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
214748646|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
214748647|NCT00004937|DRUG|acridine carboxamide|
214748648|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
214748649|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
214748650|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
214748651|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
214748652|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
214748653|NCT04541394|DEVICE|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
214748654|NCT02698020|PROCEDURE|Room-air|Provision of room-air
214748655|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
214748656|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
214748657|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
214748658|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
214748659|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
214748660|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
214748661|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
214748662|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
214748663|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
214748664|NCT02701933|DRUG|Saline|Saline, intravenous infusion
214748665|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
214748666|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
214748667|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
214748668|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
214748669|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
214748670|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
214748671|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
214748672|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
214748673|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
214748674|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
214748675|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
214748676|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
214748677|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
214748678|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
214748679|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
214748680|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
214748681|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
214748682|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
214748683|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
214748684|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
214748685|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
214748686|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
214748687|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP\_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
214748688|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
214748689|NCT02118909|DRUG|Pracinostat|
214748690|NCT02118909|DRUG|Itraconazole|
214748691|NCT02118909|DRUG|Ciprofloxacin|
214748692|NCT02291952|BEHAVIORAL|Meal schedule|
214748693|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
214748694|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
214748695|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
214748696|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
214748697|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
214748698|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
214748699|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
214748700|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
214748701|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
214748702|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
214748703|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
214748704|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
214748705|NCT03210909|DRUG|BMS-986231|BMS-986231
214748706|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
214748707|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
214748708|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
214748709|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
214748710|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
214748711|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
214748712|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
214748713|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
214748714|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
214748715|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
214748716|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
214748717|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
214794324|NCT04195295|PROCEDURE|Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane|"* In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane"
214748718|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
214748719|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
214748720|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
214748721|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
214748722|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
214748723|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
214748724|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
214748725|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
214748726|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
214748727|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
214748728|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
214748729|NCT06018766|DRUG|LAM-001|LAM-001 administered via dry powder inhaler
214748730|NCT06018766|DRUG|Placebo|Placebo administered via dry powder inhaler
214748731|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
214748732|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
214748733|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
214748734|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
214748735|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
214748736|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
214748737|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
214748738|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
214748739|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
214748740|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
214748741|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
214748742|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
214748743|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
214748744|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
214748745|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
214748746|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
214748747|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
214748748|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
214748749|NCT00917553|DRUG|doxycycline monohydrate|50 mg
214748750|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
214748751|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
214748752|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
214748753|NCT01616173|DRUG|Dexamethasone|8mg/2mL
214748754|NCT01616173|DRUG|Saline|2mL
214748755|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
214748756|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
214748757|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
214748758|NCT00014560|BIOLOGICAL|sargramostim|
214748759|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
214748760|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
214748761|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
214748762|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
214748763|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
214748764|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
214748765|NCT01673204|DRUG|Placebo|
214748766|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
214748767|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
214748768|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
214748769|NCT05610228|OTHER|NO intervention|No intervention
214748770|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
214748771|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
214748772|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
214748773|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
214748774|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
214748775|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
214748776|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
214748777|NCT00000322|BEHAVIORAL|Tyrosine|
214748778|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
214748779|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
214748780|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
214748781|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
214748782|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
214748783|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
214748784|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
214748785|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
214748786|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
214748787|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
214748788|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
214748789|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
214748790|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
214748791|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
214748792|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
214748793|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
214748794|NCT04142697|BEHAVIORAL|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
214748795|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
214748796|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
214748797|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
214748798|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
214748799|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
214748800|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
214748801|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
214748802|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
214748803|NCT01957904|DEVICE|ArterX Surgical Sealant|
214748804|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
214748805|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
214748806|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
214794325|NCT04195295|PROCEDURE|Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material|Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.
214748807|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
214748808|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
214748809|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
214748810|NCT05635110|DRUG|VX-548|Tablets for oral administration.
214748811|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
214748812|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
214748813|NCT05311631|BEHAVIORAL|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
214748814|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
214748815|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
214748816|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
214748817|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
214748818|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
214794326|NCT04195295|PROCEDURE|Open flap debridement procedure in intrabony defects.|full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
214794327|NCT03803566|OTHER|Pegboard practice|Practice of the grooved pegboard test
214794328|NCT03803566|OTHER|Force control practice|Practice performing steady muscle contractions
214748819|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
214748820|NCT01784094|DEVICE|StromaGlide|
214748821|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
214748822|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
214748823|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
214748824|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
214748825|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
214748826|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
214748827|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
214748828|NCT02020811|DEVICE|Sentinel|
214748829|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
214748830|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
214748831|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
214748832|NCT02618681|OTHER||
214748833|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
214748834|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
214748835|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214748836|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214748837|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214748838|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
214748839|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
214748840|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
214748841|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
214748842|NCT04738123|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
214748843|NCT04738123|DRUG|Placebo|Placebo Capsules
214748844|NCT03153085|BIOLOGICAL|TBI-1401(HF10)|"1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
214748845|NCT03153085|DRUG|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
214748846|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
214748847|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
214748848|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
214748849|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
214748850|NCT00006025|DRUG|irinotecan hydrochloride|
214748851|NCT00006025|DRUG|temozolomide|
214748852|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
214748853|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
214748854|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
214748855|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
214748856|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
214748857|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
214748858|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
214748859|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
214748860|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
214748861|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
214748862|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
214748863|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
214748864|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
214748865|NCT03223649|OTHER|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
214748866|NCT03223649|OTHER|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
214748867|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
214748868|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
214748869|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
214748870|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
214748871|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
214748872|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
214748873|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
214748874|NCT01478490|DRUG|mirabegron|oral
214748875|NCT01478490|DRUG|metoprolol|oral
214748876|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
214748877|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
214748878|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
214748879|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
214748880|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
214748881|NCT03023124|DRUG|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
214748882|NCT03023124|DRUG|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
214748883|NCT03023124|DRUG|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
214794329|NCT02197728|DEVICE|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
214794330|NCT00479310|DRUG|Summers 5% L.A.|
214748884|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
214748885|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
214748886|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
214748887|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
214748888|NCT03970603|OTHER|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
214748889|NCT03970603|OTHER|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
214748890|NCT04550143|OTHER|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
214748891|NCT04550143|OTHER|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
214748892|NCT04550143|OTHER|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
214748893|NCT04550143|OTHER|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness."
214748894|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
214748895|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
214748896|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
214748897|NCT06533176|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
214748898|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
214748899|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
214748900|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
214748901|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
214748902|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
214748903|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
214748904|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
214748905|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
214748906|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
214748907|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
214748908|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
214794331|NCT06543836|DRUG|Sintilimab|Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
214748909|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
214748910|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
214748911|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
214748912|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
214748913|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
214748914|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214748915|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214748916|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214748917|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214748918|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
214748919|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
214748920|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
214748921|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
214748922|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
214748923|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
214748924|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
214748925|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
214748926|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
214748927|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
214748928|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
214748929|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
214748930|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
214748931|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
214748932|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
214748933|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
214748934|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
214748935|NCT01252992|GENETIC|Genetic analysis|"1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
214748936|NCT01252992|RADIATION|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
214748937|NCT01252992|OTHER|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
214748938|NCT01252992|OTHER|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
214748939|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
214748940|NCT00083616|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
214748941|NCT00597129|BIOLOGICAL|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
214748942|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
214748943|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
214748944|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
214748945|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
214748946|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
214748947|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
214748948|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
214748949|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
214748950|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
214748951|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
214748952|NCT00091039|DRUG|carboplatin|
214748953|NCT00091039|DRUG|paclitaxel|
214748954|NCT00091039|RADIATION|radiation therapy|
214748955|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
214748956|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
214748957|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
214748958|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
214748959|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
214748960|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
214748961|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
214748962|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
214748963|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
214748964|NCT00769821|OTHER|questionnaire administration|
214748965|NCT00769821|PROCEDURE|assessment of therapy complications|
214748966|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
214748967|NCT00769821|PROCEDURE|quality-of-life assessment|
214748968|NCT04052711|DRUG|FMX-101|
214748969|NCT06520046|OTHER|Experimental Group|Propioceptive exercises
214748970|NCT06520046|OTHER|Control Group|Usual exercises
214748971|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
214748972|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
214748973|NCT02146911|DRUG|Bupropion|
214748974|NCT02146911|DRUG|Varenicline|
214748975|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
214748976|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
214748977|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
214748978|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
214748979|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
214748980|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
214748981|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
214748982|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
214748983|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
214748984|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
214748985|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
214748986|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
214748987|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
214748988|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
214748989|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
214748990|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
214748991|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
214748992|NCT04084275|BEHAVIORAL|breastfeeding education|
214748993|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
214748994|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
214748995|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
214748996|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
214748997|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
214748998|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
214748999|NCT02471625|DEVICE|ClearView Scanning|
214749000|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
214749001|NCT00997906|DRUG|carboplatin,|Given IV
214749002|NCT00997906|DRUG|cisplatin|Given IV
214749003|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
214749004|NCT00997906|DRUG|paclitaxel|Given IV
214749005|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
214749006|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
214749007|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
214749008|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
214749009|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
214749010|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
214749011|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
214749012|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
214749013|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
214749014|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
214749015|NCT00001126|DRUG|Cidofovir|
214749016|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214749017|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
214749018|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
214749019|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
214749020|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
214749021|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
214749022|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
214749023|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
214749024|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
214749025|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
214749026|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
214749027|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
214749028|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
214749029|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
214749030|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
214749031|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
214749032|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
214749033|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
214749034|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
214749035|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
214749036|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
214749037|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
214749038|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
214749039|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
214749040|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
214749041|NCT06724185|DIETARY_SUPPLEMENT|LP28 capsule|LP28 capsule : 5.0×10\^9 CFU/capsule
214749042|NCT06724185|DIETARY_SUPPLEMENT|Placebo Capsule|Maltodextrin
214749043|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
214749044|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
214749045|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
214749046|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
214749047|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
214749048|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
214749049|NCT02557815|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
214749050|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
214749051|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
214749052|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
214749053|NCT02510976|DRUG|prucalopride|
214749054|NCT02510976|DRUG|placebo|
214749055|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
214749056|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
214749057|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
214749058|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
214749059|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
214749060|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
214749061|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
214749062|NCT03377985|PROCEDURE|brachial plexus block|
214749063|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
214749064|NCT03461705|DEVICE|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
214749065|NCT03461705|DEVICE|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
214749066|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
214749067|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
214749068|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
214749069|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
214749070|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
214749071|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
214749072|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
214749073|NCT00982800|DRUG|Placebo Sugar Pill|
214749074|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
214749075|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
214749076|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
214749077|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
214749078|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
214749079|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
214749080|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
214749081|NCT03044730|DRUG|Capecitabine|Given PO
214749082|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
214749083|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
214749084|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
214749085|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
214749086|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
214749087|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
214749088|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
214749089|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
214749090|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
214749091|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
214749092|NCT05524376|OTHER|no intervention|no intervention
214749093|NCT05486715|DRUG|Vit D|Vit D
214749094|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
214749095|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
214749096|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
214749097|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
214749098|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
214749099|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
214749100|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
214749101|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
214749102|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
214749103|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
214749104|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
214749105|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
214749106|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
214749107|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
214749108|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
214749109|NCT03176979|OTHER|Contrast Agent|Given IV
214749110|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
214749111|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
214794137|NCT04106375|BEHAVIORAL|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
214749112|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214749113|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214749114|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
214749115|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
214749116|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
214749117|NCT01304576|OTHER|MRI|Cerebral MRI
214749118|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
214749119|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
214749120|NCT00184730|DRUG|somatropin|
214749121|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
214749122|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
214749123|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
214749124|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
214794138|NCT02006706|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
214794139|NCT02006706|DRUG|methotrexate|10 - 25 mg/week
214749125|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
214749126|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
214749127|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
214749128|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
214749129|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
214749130|NCT02496715|DRUG|Placebo|Placebo inhaler
214749131|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
214749132|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
214749133|NCT01074320|OTHER|Other|Observational study
214749134|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
214749135|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
214749136|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
214749137|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
214749138|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
214749139|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
214749140|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
214749141|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
214749142|NCT00491595|DRUG|High Dose Soy isoflavones|
214749143|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
214749144|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
214749145|NCT02833779|OTHER|Individual exercises|
214749146|NCT02833779|OTHER|Group exercises|
214749147|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
214749148|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
214749149|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
214749150|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
214749151|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
214749152|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
214749153|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
214749154|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
214749155|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
214749156|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
214749157|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
214749158|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
214749159|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
214749160|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
214749161|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
214749162|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
214749163|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
214749164|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
214749165|NCT00977600|DRUG|Ammonul|
214749166|NCT00977600|DRUG|Buphenyl|
214749167|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
214749168|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
214749169|NCT02335359|DRUG|Placebo|Saline
214749170|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
214749171|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
214749172|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
214749173|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
214749174|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
214749175|NCT01786707|OTHER|Hyperbaric oxygen therapy|
214749176|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
214749177|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
214749178|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
214749179|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
214749180|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
214749181|NCT01953380|BEHAVIORAL|extended information|
214749182|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
214749183|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
214749184|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
214749185|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
214749186|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
214749187|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
214749188|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
214749189|NCT02641691|RADIATION|Radiation|
214749190|NCT02641691|DRUG|Oxaliplatin|
214749191|NCT02641691|DRUG|Leucovorin|
214749192|NCT02641691|DRUG|Fluorouracil|
214749193|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
214749194|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
214749195|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
214749196|NCT00383344|PROCEDURE|FDG PET/CT|
214749197|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
214749198|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
214749199|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
214749200|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
214749201|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
214749202|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
214749203|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
214749204|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
214749205|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
214749206|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
214749207|NCT02426359|DRUG|Q301 Cream|
214749208|NCT02426359|DRUG|Placebo|
214749209|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
214749210|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
214749211|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
214749212|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
214749213|NCT05417373|OTHER|calculated radscore|The development cohort is case\_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
214749214|NCT01958944|DRUG|Nitric oxide|
214749215|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
214749216|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
214749217|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
214749218|NCT05794204|DRUG|RMP-A03 - Dose 1|Patients will randomized to low dose of RMP-A03
214749219|NCT05794204|DRUG|RMP-A03 - Dose 2|Patients will be randomized to high dose of RMP-A03
214749220|NCT05794204|DRUG|RMP-A03 Placebo|Patients will be randomized to RMP-A03 Placebo
214749221|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
214749222|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
214749223|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
214749224|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
214749225|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
214749226|NCT06323655|DRUG|Tasimelteon|oral capsule
214749227|NCT06323655|DRUG|Active Control Placebo|oral capsule
214749228|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
214749229|NCT06323655|DRUG|Active Control|oral capsule
214749230|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
214749231|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
214749232|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
214794140|NCT02006706|DRUG|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
214749233|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
214749234|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
214749235|NCT02064491|DRUG|Erlotinib|
214749236|NCT02064491|DRUG|Chemotherapy|
214749237|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
214749238|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
214749239|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
214749240|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
214749241|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
214749242|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
214749243|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
214749244|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
214749245|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
214749246|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
214749247|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
214749248|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
214749249|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
214749250|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
214749251|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
214749252|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
214749253|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
214749254|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
214749255|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
214749256|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
214749257|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
214749258|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
214749259|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
214749260|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
214749261|NCT06690086|PROCEDURE|Lesion biopsy|Lesions enrolled in the study are biopsied to confirm histopathology
214749262|NCT06690086|DEVICE|DermaSensor Device Use|Users are blinded to the DermaSensor Device result
214749263|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
214749264|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
214749265|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
214749266|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
214749267|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
214749268|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
214749269|NCT02928198|DEVICE|ABSORB BVS|
214794332|NCT06543836|DRUG|Fruquintinib or Regorafenib|"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
214794333|NCT06543836|DRUG|Fruquintinib|Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
214749270|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
214749271|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
214749272|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
214749273|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
214749274|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
214749275|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
214749276|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
214749277|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
214749278|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
214749279|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
214749280|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
214749281|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
214749282|NCT00406939|GENETIC|IL-12 gene|
214749283|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
214749284|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
214749285|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
214749286|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
214749287|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
214749288|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
214749289|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
214749290|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
214794334|NCT00261729|DRUG|Paroxetine|paroxetine 20 mg
214794335|NCT00261729|DRUG|Prazosin|Prazosin
214794336|NCT00261729|DRUG|placebo|placebo capsules
214749291|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
214749292|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
214794337|NCT03840746|OTHER|Tomato, onion and lovage soup (TOL)|Soup
214749293|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
214794338|NCT03840746|OTHER|TOL soup with inulin|Soup
214794339|NCT04546906|BIOLOGICAL|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
214794340|NCT01384695|DRUG|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
214749294|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
214749295|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
214749296|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
214749297|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
214749298|NCT00000459|BEHAVIORAL|diet, fat-restricted|
214749299|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
214749300|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
214749301|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
214749302|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
214749303|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
214749304|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
214749305|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
214749306|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
214749307|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
214749308|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
214749309|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
214749310|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
214749311|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
214749312|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
214749313|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
214749314|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
214749315|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
214749316|NCT06344858|DRUG|Ketamine|One bolus of ketammine
214749317|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
214749318|NCT02158949|BEHAVIORAL|mROAD|
214749319|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
214749320|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
214749321|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
214749322|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
214749323|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
214749324|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
214749325|NCT06564961|DRUG|Placebo|1 tab once daily
214749326|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
214749327|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
214749328|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
214794341|NCT01384695|DRUG|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
214749329|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
214749330|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
214749331|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
214749332|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
214749333|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
214749334|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
214749335|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
214749336|NCT04857879|OTHER|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
214749337|NCT06216600|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Participants will undergo ACT in combination with exercise and social support.
214749338|NCT06216600|BEHAVIORAL|Body weight circuit training|Participants will learn and undergo body weight circuit training in combination with ACT and social support.
214749339|NCT06216600|BEHAVIORAL|Empathetic social support|Study participants will participate in empathetic social support
214749340|NCT06216600|OTHER|Control - list of resources|A local list of resources to access exercise, therapy and social support will be provided.
214749341|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
214749342|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
214749343|NCT04792684|DIAGNOSTIC_TEST|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
214749344|NCT06101381|BIOLOGICAL|CART-19|The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
214749345|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
214749346|NCT00794131|BIOLOGICAL|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
214749347|NCT06796712|DIETARY_SUPPLEMENT|Prebiotic fibre fortified bread roll|Subjects will consume a prebiotic fibre-fortified bread roll (10g of added prebiotic fibre/day).
214749348|NCT06796712|DIETARY_SUPPLEMENT|Regular bread roll|Subjects will consume a regular bread roll (0g of added prebiotic fibre blend/day).
214749349|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
214749350|NCT01860456|DRUG|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
214749351|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
214749352|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
214749353|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
214749354|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
214749355|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
214749356|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
214749357|NCT06412289|DIAGNOSTIC_TEST|US-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The ultrasound investigation will be conducted using the ultrasound machine supplied to the Center involved in the trial and usually used in eTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
214749358|NCT06412289|DIAGNOSTIC_TEST|CT-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The CT scan will be performed using the CT machinery equipped by the Center involved in the trial and usually used for the tTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
214749359|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
214749360|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
214749361|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
214749362|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
214749363|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
214749364|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
214749365|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
214749366|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
214749367|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
214749368|NCT00656136|DRUG|placebo|Patients receive placebo once daily
214749369|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
214749370|NCT00752518|DRUG|bortezomib|
214749371|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
214749372|NCT01490385|DEVICE|LED Phototherapy|
214749373|NCT02505945|DRUG|Omeprazole|
214749374|NCT02505945|DEVICE|LINX Reflux Management System|
214749375|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
214749376|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
214749377|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
214749378|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
214749379|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
214749380|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
214749381|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
214749382|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
214749383|NCT01097057|DRUG|Carboplatin|Given IV
214749384|NCT01097057|DRUG|Etoposide|Given IV
214749385|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
214749386|NCT01097057|DRUG|Ifosfamide|Given IV
214749387|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
214749388|NCT01097057|DRUG|Plerixafor|Given SC
214749389|NCT01097057|BIOLOGICAL|Rituximab|Given IV
214749390|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
214749391|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
214749392|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
214749393|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
214749394|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
214749395|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
214749396|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
214749397|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
214749398|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
214749399|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
214749400|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
214749401|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
214749402|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
214749403|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
214749404|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
214749405|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
214749406|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
214749407|NCT03143465|DRUG|Sildenafil|
214749408|NCT03143465|DRUG|Placebo|
214749409|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
214749410|NCT01973920|DRUG|Oshadi Icp|
214749411|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
214749412|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
214749413|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
214749414|NCT01384513|DRUG|Fludarabine|Given IV
214749415|NCT01384513|DRUG|Busulfan|Given IV
214749416|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
214749417|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
214749418|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
214749419|NCT01384513|DRUG|Tacrolimus|Given IV or PO
214749420|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
214749421|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
214749422|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
214749423|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
214749424|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
214749425|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
214749426|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
214749427|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
214749428|NCT05710848|DRUG|STM-416|STM-416 monotherapy
214749429|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
214749430|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
214749431|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
214749432|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
214749433|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
214749434|NCT00218439|DRUG|Placebo|
214749435|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
214749436|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
214749437|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
214749438|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
214749439|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
214749440|NCT00145080|BEHAVIORAL|Disease Management Assessment|
214749441|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
214749442|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
214749443|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
214749444|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
214749445|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
214749446|NCT02136927|DRUG|SPARC1210|
214749447|NCT02136927|DRUG|Reference1210|
214749448|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
214749449|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
214749450|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
214749451|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
214749452|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
214749453|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
214749454|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
214749455|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
214749456|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
214749457|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
214749458|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
214749459|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
214749460|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
214749461|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
214749462|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
214749463|NCT01781130|PROCEDURE|Steroid injection|
214749464|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
214749465|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
214749466|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
214749467|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
214749468|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
214749469|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
214749470|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
214749471|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
214749472|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
214749473|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
214749474|NCT00118885|BEHAVIORAL|Tai Chi Chih|
214794141|NCT02145975|DRUG|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
214794142|NCT02145975|DRUG|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
214749475|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
214749476|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
214749477|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
214749478|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
214794143|NCT00582036|DRUG|Regular Insulin|Use of sliding scale insulin as per Appendix 1
214794144|NCT00582036|DEVICE|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
214749479|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
214749480|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214749481|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
214749482|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
214749483|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
214749484|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
214749485|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
214749486|NCT01196754|OTHER|sevoflurane|
214749487|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
214749488|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
214749489|NCT01395420|DRUG|CAZ104|IV Infusion
214749490|NCT01395420|DRUG|CAZ104|IV Infusion
214749491|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
214749492|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
214749493|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
214749494|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
214749495|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
214749496|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
214749497|NCT01917396|DRUG|Fleet enema|
214749498|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
214749499|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
214749500|NCT01751490|OTHER|physiotherapy|physiotherapy
214749501|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
214749502|NCT05024721|DRUG|HIP2101|Test drug
214749503|NCT05024721|DRUG|RLD2101|Reference drug
214749504|NCT05024721|DRUG|HPP2101|Placebo drug
214749505|NCT05024721|DRUG|HPP2102|Placebo drug
214749506|NCT03939429|DRUG|QPX2015|antibiotic
214749507|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
214749508|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
214749509|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
214749510|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
214749511|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
214749512|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
214749513|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
214749514|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
214749515|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
214749516|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
214749517|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
214749518|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
214749519|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
214749520|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
214749521|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
214749522|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
214749523|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
214749524|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
214749525|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
214749526|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
214749527|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
214749528|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
214749529|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
214749530|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
214794145|NCT01673009|DRUG|Gleevec|Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
214749531|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
214749532|NCT04784676|OTHER|restoration|indirect restoration
214749533|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
214749534|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
214749535|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
214749536|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
214749537|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
214749538|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
214749539|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
214749540|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
214749541|NCT00136344|DRUG|Cefuroxime|
214749542|NCT00136344|DRUG|Levofloxacin|
214749543|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
214749544|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
214749545|NCT00509275|DRUG|W0027|capsule
214749546|NCT00509275|DRUG|Placebo|Placebo
214749547|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
214749548|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
214749549|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
214749550|NCT03950531|OTHER|No intervention|
214749551|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
214749552|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
214749553|NCT00679354|DRUG|cilengitide|Given IV
214749554|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
214749555|NCT00679354|OTHER|pharmacological study|Correlative studies
214749556|NCT01700218|OTHER|telemonitoring|
214749557|NCT01700218|OTHER|control|
214749558|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
214749559|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
214749560|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
214749561|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
214749562|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
214749563|NCT02216539|PROCEDURE|Lung transplantation|
214749564|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
214749565|NCT02492321|DRUG|EBI-005|
214749566|NCT02492321|DRUG|Placebo Comparator|
214749567|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
214749568|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
214749569|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
214749570|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
214749571|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
214749572|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
214749573|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
214749574|NCT00081276|DRUG|triapine|Given IV
214749575|NCT00081276|DRUG|cisplatin|Given IV
214749576|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
214749577|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
214749578|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
214749579|NCT00967356|DRUG|Placebo|Oral suspension
214749580|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
214749581|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
214749582|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
214749583|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
214749584|NCT01934101|DRUG|CHR-5154|CHR-5154
214749585|NCT01934101|DRUG|Placebo|Placebo
214749586|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
214749587|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
214749588|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
214749589|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
214749590|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
214749591|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
214749592|NCT02711085|OTHER|No intervention|No intervention - observational study
214749593|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
214749594|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
214749595|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
214749596|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
214749597|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
214749598|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
214749599|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
214749600|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
214749601|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
214749602|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
214749603|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
214749604|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
214749605|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
214749606|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
214749607|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
214749608|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
214749609|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
214749610|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
214749611|NCT00697255|DRUG|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
214749612|NCT00697255|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
214749613|NCT00697255|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
214749614|NCT00697255|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
214749615|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
214749616|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
214749617|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
214749618|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
214749619|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
214749620|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
214749621|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
214749622|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
214749623|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
214749624|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
214749625|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
214749626|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
214749627|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
214749628|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
214749629|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
214749630|NCT02184312|DRUG|Nevirapine XR low dose|
214749631|NCT02184312|DRUG|Nevirapine XR medium dose|
214749632|NCT02184312|DRUG|Nevirapine XR high dose|
214749633|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
214749634|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
214749635|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
214749636|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
214749637|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
214749638|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
214749639|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
214749640|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
214749641|NCT02243306|DRUG|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
214749642|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
214749643|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
214749644|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
214749645|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
214749646|NCT03080675|DIETARY_SUPPLEMENT|Control|
214749647|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
214749648|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
214749649|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
214749650|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
214749651|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
214749652|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
214749653|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
214749654|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
214749655|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
214749656|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
214749657|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
214749658|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
214749659|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
214749660|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
214749661|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
214749662|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
214749663|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
214749664|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
214749665|NCT00336986|DRUG|recombinant interleukin-21|
214749666|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
214749667|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
214749668|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
214749669|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
214749670|NCT02242305|DRUG|Placebo|
214749671|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
214749672|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
214749673|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
214749674|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
214749675|NCT06268288|DEVICE|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
214749676|NCT06268288|OTHER|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
214749677|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
214749678|NCT06443138|OTHER|Personalized pre-habilitation program|"Each patient will undergo 4 weeks of individualized pre-habilitation before surgery.~Each session (1 session per day) will be carried out autonomously by the patient at home, via a dedicated application (Activiti Pro) installed on their tablet or smartphone."
214749679|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
214749680|NCT01960036|BEHAVIORAL|Womens Health Education|
214749681|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
214749682|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
214749683|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
214749684|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
214749685|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
214749686|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
214749687|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
214749688|NCT02826005|DEVICE|MRI|
214749689|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
214749690|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
214749691|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
214749692|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
214749693|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
214749694|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
214749695|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
214749696|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
214749697|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
214749698|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
214749699|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
214749700|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
214749701|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
214749702|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
214749703|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
214749704|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
214749705|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
214749706|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
214749707|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
214749708|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
214749709|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
214749710|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
214749711|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
214749712|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
214749713|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
214749714|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
214749715|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
214749716|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
214749717|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
214749718|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
214749719|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
214749720|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
214749721|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
214749722|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
214749723|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
214749724|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
214749725|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
214749726|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
214749727|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
214749728|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
214749729|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
214749730|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
214749731|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
214749732|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
214749733|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
214749734|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
214749735|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
214749736|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
214794146|NCT03108365|DEVICE|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
214794147|NCT03108365|DEVICE|Cotton Gauze|Size: 1 x 1 cm
214794148|NCT04161144|DRUG|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
214749737|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
214749738|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
214749739|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
214749740|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
214749741|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
214749742|NCT02367196|DRUG|CC-90002|
214749743|NCT02367196|DRUG|Rituximab|
214749744|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
214749745|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
214749746|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
214749747|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
214749748|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
214749749|NCT00004219|DRUG|granisetron hydrochloride|
214749750|NCT00004219|DRUG|lerisetron|
214749751|NCT00004219|RADIATION|radiation therapy|
214749752|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
214749753|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
214749754|NCT00100711|DRUG|Motexafin Gadolinium|
214749755|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
214749756|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
214749757|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
214749758|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
214749759|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
214749760|NCT01713907|DEVICE|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
214749761|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
214749762|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
214749763|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
214749764|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
214749765|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
214749766|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
214749767|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
214749768|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
214749769|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
214749770|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
214749771|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
214749772|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
214749773|NCT00422955|DRUG|rosiglitazone|
214749774|NCT00397527|DRUG|lactoserum|
214749775|NCT01353976|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
214749776|NCT01353976|OTHER|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
214749777|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
214749778|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
214749779|NCT00004911|PROCEDURE|bowel obstruction management|
214749780|NCT00004911|PROCEDURE|quality-of-life assessment|
214749781|NCT01450566|DRUG|Lidocaine|Use of lidocaine
214749782|NCT01450566|DRUG|Saline|Saline
214749783|NCT06371560|OTHER|Questionnaire|online based questionnaire
214749784|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
214749785|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
214749786|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
214749787|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
214749788|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
214749789|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
214749790|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
214749791|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
214749792|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
214749793|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
214749794|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
214749795|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
214749796|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
214749797|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
214749798|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
214749799|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
214749800|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
214749801|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
214749802|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
214749803|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
214749804|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
214749805|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
214749806|NCT02949544|OTHER|water immersion|warm water immersion
214749807|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
214749808|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
214749809|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
214749810|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
214749811|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
214749812|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
214749813|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
214749814|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
214749815|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
214749816|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
214749817|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
214749818|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
214749819|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
214749820|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
214749821|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
214749822|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
214749823|NCT01817218|DRUG|Platelet Rich Plasma|
214749824|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
214749825|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
214749826|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
214749827|NCT00402662|DRUG|everolimus|
214749828|NCT00402662|DRUG|Imatinib|
214749829|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
214749830|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
214749831|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
214749832|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
214749833|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
214749834|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
214749835|NCT04619043|DEVICE|Ankle Orthotic|
214749836|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
214749837|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
214749838|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
214749839|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
214749840|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
214749841|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
214749842|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
214749843|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
214749844|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
214749845|NCT00702637|DRUG|Modafinil|
214749846|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
214749847|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
214749848|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
214749849|NCT01832753|DRUG|Levothyroxine|
214749850|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
214749851|NCT06717217|PROCEDURE|NURSING EDUCATION GIVEN BEFORE TYMPANOPLASTY SURGERY|EAR CARE TRAINING
214749852|NCT06715761|OTHER|Myofascial release|The sequence of myofascial release is as follows: 30 seconds of contact between the therapist's hands and the entire region of the participant's spine, sliding with medium pressure in a caudocranial direction; palpation of the erector spinae, quadratus lumborum, gluteus and piriformis muscles bilaterally, to identify trigger points, marking each point of tension with a dermographic pencil for subsequent manipulation; 3 cycles of bilateral paravertebral release, by sustained pressure with crossed hands, until the restrictive tissue barrier is found, for 60 seconds; 90 seconds of the vertical rolling technique (superficial elevation of the skin and mobilisation of the tissue with the tips of all the fingers) on the bilateral paravertebrals and, at the end, sliding along the entire length of the bilateral multifidus, with the fingers flexed, using the bony prominence between the proximal and middle phalanges as contact with the skin, in a caudocranial direction and returning craniocaudal.
214749853|NCT06715761|OTHER|Cupping therapy|The acrylic cups (DongBang®) will be placed on the meridional points, as Traditional Chinese Medicine calls them, 1 cup in the central region of each popliteal fossa, the so-called B40 or Wei Zhong point, 6 cups in the region of the quadratus lumborum muscles, more specifically on the BL23 or Shenshu points (approximately 5 centimetres lateral to the edge of the L2 spinous process), BL24 or Qihaishu (approximately 5 centimetres lateral to the edge of the spinous process of L3) and BL25 or Dachangshu (approximately 5 centimetres lateral to the edge of the spinous process of L4) bilaterally, as well as a cup on a single point of the participant's choice, where they report the most lower back pain (ashi point). The cups will be attached to the skin using a gun, applying two suction pressures, and the participant will be asked to signal whether the pressure is strong or weak. The cups will remain attached for 12 minutes on the B40 meridian and 15 minutes on the other meridians. If a cup lo
214749854|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
214749855|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
214749856|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
214749857|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
214749858|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
214749859|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
214749860|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
214749861|NCT00006358|DRUG|temozolomide|
214749862|NCT00006358|DRUG|thalidomide|
214749863|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
214749864|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
214749865|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
214749866|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
214749867|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
214749868|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
214749869|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
214749870|NCT03651011|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
214749871|NCT03651011|PROCEDURE|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
214749872|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
214749873|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
214749874|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
214749875|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
214749876|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
214749877|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
214749878|NCT04927858|DRUG|Empagliflozin|Empagliflozin
214749879|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214749880|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
214749881|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
214749882|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
214749883|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
214749884|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
214749885|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
214749886|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
214749887|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
214749888|NCT01733394|DRUG|lamotrigine|
214749889|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
214749890|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
214749891|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
214749892|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
214749893|NCT01778673|PROCEDURE|Cast immobilization|
214749894|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
214749895|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
214749896|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
214749897|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
214749898|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
214749899|NCT00318032|DRUG|multi-factorial intervention|
214749900|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
214749901|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
214749902|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
214749903|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
214749904|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
214749905|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
214749906|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
214749907|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
214749908|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
214794149|NCT04161144|DRUG|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
214794150|NCT01790022|DRUG|Methylprednisolone|
214749909|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
214749910|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
214749911|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
214749912|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
214749913|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
214749914|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
214749915|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
214749916|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
214749917|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
214749918|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
214749919|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
214749920|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214749921|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
214749922|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
214749923|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
214749924|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
214749925|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
214749926|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
214749927|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
214749928|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
214749929|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
214749930|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
214749931|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
214749932|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
214749933|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
214749934|NCT04979325|OTHER||
214749935|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
214749936|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
214749937|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
214749938|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
214749939|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
214749940|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
214749941|NCT03964896|OTHER|Survey|Complete survey
214749942|NCT03964896|OTHER|Survey Administration|Ancillary studies
214749943|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
214749944|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
214749945|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
214749946|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
214749947|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
214749948|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
214749949|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
214749950|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
214749951|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
214749952|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
214749953|NCT02550418|DRUG|Budesonide|
214749954|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
214749955|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
214749956|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
214749957|NCT04964076|OTHER|No intervention|No intervention
214749958|NCT00474994|DRUG|sunitinib malate|
214749959|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
214749960|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
214749961|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
214749962|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
214749963|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
214749964|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
214749965|NCT00350935|PROCEDURE|fMRI|One 30 minute session
214749966|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
214749967|NCT00030849|DRUG|bexarotene|
214749968|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
214749969|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
214749970|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
214749971|NCT00721513|BIOLOGICAL|cetuximab|
214749972|NCT00721513|DRUG|cisplatin|
214749973|NCT00721513|DRUG|docetaxel|
214749974|NCT00721513|DRUG|fluorouracil|
214749975|NCT00721513|PROCEDURE|computed tomography|
214749976|NCT00721513|PROCEDURE|positron emission tomography|
214749977|NCT00721513|PROCEDURE|quality-of-life assessment|
214749978|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
214749979|NCT00721513|RADIATION|intensity-modulated radiation therapy|
214749980|NCT01700907|DRUG|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
214749981|NCT01700907|DRUG|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
214749982|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
214749983|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
214749984|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
214749985|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
214749986|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
214749987|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
214749988|NCT03231423|OTHER|Drainage|Using drain after operation
214749989|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
214749990|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
214749991|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
214749992|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
214749993|NCT00326339|DRUG|Placebo|Placebo PO bid
214749994|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
214749995|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
214749996|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
214749997|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
214749998|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
214749999|NCT06175000|PROCEDURE|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
214750000|NCT06175000|BIOLOGICAL|Obinutuzumab|Given IV
214750001|NCT06175000|OTHER|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
214750002|NCT04726787|RADIATION|Bridging Radiotherapy|Bridging Radiotherapy will start immediately after leukapheresis and before Tisagenlecleucel treatment
214750003|NCT04148222|OTHER|No intervention|There is no intervention for this study
214750004|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
214750005|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
214750006|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
214750007|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
214750008|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
214750009|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
214750010|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
214750011|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
214794151|NCT04954014|DRUG|Bevacizumab|Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
214750012|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
214750013|NCT06311045|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Participants will take two NAC 600mg capsules daily for four weeks.
214750014|NCT06311045|DIETARY_SUPPLEMENT|Placebo|Participants will take two placebo 600mg capsules daily for four weeks.
214750015|NCT06311045|PROCEDURE|Positive Airway Pressure (PAP) Therapy|All participants will receive PAP therapy per standard of care for OSA.
214750016|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
214750017|NCT05934422|OTHER|Intervention (Study Nutritional Drink)|Study nutritional drink containing a mix of enriched micronutrients, probiotics and myo-inositol.
214750018|NCT05934422|OTHER|Control (Standard Nutritional Drink)|Control nutritional drink containing a standard mix of micronutrients
214750019|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
214750020|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
214794152|NCT04954014|DRUG|BAT|Patients will receive best available treatment for COVID-19.
214750021|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
214750022|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
214750023|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
214750024|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
214750025|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
214750026|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
214750027|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
214750028|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
214750029|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
214750030|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
214750031|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
214750032|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
214750033|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
214750034|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
214750035|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
214750036|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
214750037|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
214750038|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
214750039|NCT06243679|DRUG|Immunotherapy|Monotherapy with PD-1 inhibitors, up to 1 year.
214750040|NCT05935137|DIAGNOSTIC_TEST|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
214750041|NCT03476681|DRUG|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
214750042|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
214750043|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
214750044|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
214750045|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
214750046|NCT00000740|DRUG|Sitamaquine|
214750047|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
214750048|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
214750049|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
214750050|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
214750051|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
214750052|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
214750053|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
214750054|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
214750055|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
214750056|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
214750057|NCT00495963|PROCEDURE|bronchoaleolar lavage|
214750058|NCT00495963|PROCEDURE|Bronchoscopy|
214750059|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
214750060|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
214750061|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
214750062|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
214750063|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
214750064|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
214750065|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
214750066|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
214750067|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
214750068|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
214750069|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
214750070|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
214750071|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
214750072|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
214750073|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
214750074|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
214750075|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
214750076|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
214750077|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
214750078|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
214750079|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
214750080|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
214750081|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
214750082|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
214750083|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
214750084|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
214750085|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
214750086|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
214750087|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
214750088|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
214750089|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
214750090|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
214750091|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
214750092|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
214750093|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
214750094|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
214750095|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
214750096|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
214750097|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
214750098|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
214750099|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
214750100|NCT00719706|DRUG|Placebo|Placebo
214750101|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
214750102|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
214750103|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
214750104|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
214750105|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
214750106|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
214750107|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
214750108|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
214750109|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
214750110|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
214750111|NCT02738073|DRUG|Control: Saline|
214750112|NCT02738073|DRUG|Tranexamic Acid|
214750113|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
214750114|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
214750115|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
214750116|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
214750117|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
214750118|NCT06088017|DRUG|CKD-391(2)|QD, PO
214750119|NCT06088017|DRUG|CKD-331, D337|QD, PO
214750120|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
214750121|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
214750122|NCT01102439|DRUG|Aspirin|81 mg daily
214750123|NCT01102439|DRUG|Aspirin|325 mg daily
214750124|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
214750125|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
214750126|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
214750127|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
214750128|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
214750129|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
214750130|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
214750131|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
214750132|NCT02701374|DRUG|TRK-700|
214750133|NCT02701374|DRUG|Placebo|
214750134|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
214750135|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
214750136|NCT00124865|BIOLOGICAL|rFla-MBP|
214750137|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
214750138|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
214750139|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
214750140|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
214750141|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
214750142|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
214750143|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
214750144|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
214750145|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
214750146|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
214750147|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
214750148|NCT02263976|DRUG|BEA 2180 BR|
214750149|NCT02263976|DRUG|Placebo|
214750150|NCT02263976|DEVICE|Respimat® A 4|
214750151|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
214750152|NCT02263976|DRUG|Spiriva|
214750153|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
214750154|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
214750155|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
214750156|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
214750157|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
214750158|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
214750159|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
214750160|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
214750161|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
214750162|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
214750163|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
214750164|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
214750165|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
214750166|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
214750167|NCT02406586|DRUG|Placebo|One tablet
214750168|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
214750169|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
214750170|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
214750171|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
214750172|NCT00987558|DRUG|Eslicarbazepine acetate|
214750173|NCT00987558|DRUG|Simvastatin|
214750174|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
214750175|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
214750176|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
214750177|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
214750178|NCT05411705|DRUG|Control|Non-rhTPO treatment
214750179|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
214750180|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
214750181|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~\- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
214750182|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~\- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
214750183|NCT02649673|DRUG|LCL161|
214750184|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
214750185|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
214750186|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
214750187|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
214750188|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
214794153|NCT04645095|DEVICE|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
214794154|NCT04645095|DEVICE|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
214750189|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
214750190|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
214750191|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
214750192|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
214750193|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
214750194|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
214750195|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
214750196|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
214750197|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
214750198|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
214750199|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
214750200|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
214750201|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
214750202|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
214750203|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
214750204|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
214750205|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
214750206|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
214750207|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
214750208|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
214794155|NCT00958256|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
214794156|NCT00958256|DRUG|Rituximab|375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
214794157|NCT00958256|DRUG|Cyclophosphamide|300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
214750209|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
214750210|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
214750211|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
214750212|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
214750213|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
214750214|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
214750215|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
214750216|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
214750217|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
214750218|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
214750219|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
214750220|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
214750221|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
214750222|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
214750223|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
214750224|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
214750225|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
214750226|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
214750227|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
214750228|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
214750229|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
214750230|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
214750231|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
214750232|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
214750233|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
214750234|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
214750235|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
214750236|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
214750237|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
214750238|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
214750239|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
214750240|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
214794158|NCT00958256|DRUG|Mesna|600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
214794159|NCT00958256|DRUG|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
214750241|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
214750242|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
214750243|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
214750244|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
214750245|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
214750246|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
214750247|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
214750248|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
214750249|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
214750250|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
214750251|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
214750252|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
214750253|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
214750254|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
214750255|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
214750256|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
214750257|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
214750258|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
214750259|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
214750260|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
214750261|NCT02358707|OTHER|Ibuprofen phonophoresis|
214750262|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
214750263|NCT02450656|DRUG|Afatinib|Tablet
214750264|NCT02450656|DRUG|Selumetinib|Capsule
214750265|NCT02450656|DRUG|Docetaxel|
214750266|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
214750267|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
214750268|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
214750269|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
214750270|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
214750271|NCT04591782|OTHER|Water|Drink 8 oz water
214750272|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
214750273|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
214750274|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
214750275|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
214750276|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
214750277|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
214750278|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
214750279|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
214750280|NCT00497822|PROCEDURE|Aerobic exercise training|
214750281|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
214750282|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
214750283|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
214750284|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
214750285|NCT02190994|DRUG|Hydrocortisone|used intravenously
214750286|NCT02190994|DRUG|Prednisone|used as tablet form
214750287|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
214794160|NCT04535609|DRUG|Mavodelpar|Once daily
214794161|NCT04535609|DRUG|Placebo|Once daily
214794162|NCT02696811|DIETARY_SUPPLEMENT|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
214750288|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
214750289|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
214750290|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
214750291|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
214750292|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
214750293|NCT01493791|DRUG|CDB-2914|
214750294|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
214750295|NCT00231322|DRUG|praziquantel|
214750296|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
214750297|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
214750298|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
214750299|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
214750300|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
214750301|NCT00002715|DRUG|Stanford V regimen|
214750302|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
214750303|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
214750304|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
214750305|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
214750306|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
214750307|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
214750308|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
214750309|NCT00197691|PROCEDURE|blood draws, etc.|
214750310|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
214750311|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
214750312|NCT01399619|DRUG|BI201335|BI201335 for 12w
214750313|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
214750314|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
214750315|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
214750316|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
214750317|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
214750318|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
214750319|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
214750320|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
214794163|NCT02696811|DIETARY_SUPPLEMENT|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
214750321|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
214750322|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
214750323|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
214750324|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
214750325|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
214750326|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
214750327|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
214750328|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
214750329|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
214750330|NCT02425774|PROCEDURE|Vagus stimulation|
214750331|NCT02425774|PROCEDURE|Sham stimulation|
214750332|NCT02425774|DRUG|Prucalopride|
214750333|NCT02425774|DRUG|Placebo|
214750334|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
214750335|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
214750336|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
214750337|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
214750338|NCT00351611|DRUG|placebo|Twice a day, oral administration
214750339|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
214750340|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
214750341|NCT00242645|BEHAVIORAL|Health Information|
214750342|NCT00242645|BEHAVIORAL|Preventive Services|
214750343|NCT00242645|BEHAVIORAL|Computer tailored information|
214750344|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
214750345|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
214750346|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
214750347|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
214750348|NCT02007798|DRUG|normal saline|100 ml per bag
214750349|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
214750350|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
214750351|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
214750352|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
214750353|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
214794164|NCT06441552|OTHER|non-interventional|non-interventional
214750354|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
214750355|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
214750356|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
214750357|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
214750358|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
214750359|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
214750360|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
214750361|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214750362|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
214750363|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
214750364|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
214750365|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
214750366|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
214750367|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
214750368|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
214750369|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
214750370|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
214750371|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
214750372|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
214750373|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
214750374|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
214750375|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
214794165|NCT01518491|DRUG|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
214794166|NCT01518491|OTHER|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
214794167|NCT01775033|OTHER|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
214750376|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
214750377|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
214750378|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
214750379|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
214750380|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
214750381|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
214750382|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
214750383|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
214750384|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
214750385|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
214750386|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
214750387|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
214750388|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
214750389|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
214750390|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
214750391|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
214750392|NCT03907072|DRUG|Placebo|Buffered saline solution
214750393|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
214750394|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
214750395|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
214750396|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
214750397|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
214750398|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
214750399|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
214750400|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
214750401|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
214750402|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
214750403|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
214750404|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
214794168|NCT05624164|PROCEDURE|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
214794169|NCT00765700|DRUG|Topical Ketoprofen 10% Cream|Topical Administration
214794170|NCT00765700|DRUG|Topical Placebo Cream|Topical Administration
214750405|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
214750406|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
214750407|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
214750408|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
214750409|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
214750410|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
214750411|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
214750412|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
214750413|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
214750414|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
214750415|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
214750416|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
214750417|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
214750418|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
214750419|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
214750420|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
214750421|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
214750422|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
214794171|NCT04165681|OTHER|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
214794172|NCT05339009|BIOLOGICAL|BioADM determination in plasma|BioADM determination in plasma
214750423|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
214750424|NCT05216302|BEHAVIORAL|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
214750425|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
214750426|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
214750427|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
214750428|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
214750429|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
214750430|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
214750431|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
214750432|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
214750433|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
214750434|NCT02860676|DRUG|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
214750435|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
214750436|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214750437|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
214750438|NCT06547502|DRUG|GZR4|single dose
214750439|NCT03319160|DEVICE|Wearable Cardioverter Defibrillator|A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
214750440|NCT03473691|DRUG|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
214750441|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
214750442|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
214750443|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
214750444|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
214750445|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
214750446|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
214750447|NCT03001726|DRUG|S1|S1 40mg/m2
214750448|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
214750449|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
214750450|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
214750451|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
214750452|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
214750453|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
214750454|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
214750455|NCT05300256|DEVICE|Sham|Sham
214750456|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
214750457|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
214750458|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
214750459|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
214750460|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
214750461|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
214750462|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
214750463|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
214750464|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
214750465|NCT02543918|DRUG|Boostrix®|Administered by IM injection
214750466|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
214750467|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
214750468|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
214750469|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
214750470|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
214750471|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
214750472|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214750473|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214750474|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214750475|NCT05949528|OTHER|no intervention|no intervention
214750476|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
214750477|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
214750478|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
214750479|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
214750480|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
214750481|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
214750482|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
214750483|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
214750484|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
214750485|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
214750486|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
214750487|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
214750488|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
214750489|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
214750490|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
214750491|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
214750492|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
214750493|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
214750494|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
214750495|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
214750496|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
214750497|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
214750498|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
214750499|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
214750500|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
214750501|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
214750502|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
214750503|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
214750504|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
214750505|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
214750506|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
214750507|NCT02791906|DRUG|ISMN|
214750508|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
214750509|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
214750510|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
214750511|NCT03918356|OTHER|healthy control group|healthy control
214750512|NCT02114346|DRUG|Atorvastatin|
214750513|NCT02114346|DRUG|Placebo|
214750514|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
214750515|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
214750516|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
214750517|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
214750518|NCT01157585|DRUG|paliperidone ER|8 week prospective study
214750519|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
214750520|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
214750521|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
214750522|NCT00003736|DRUG|motexafin gadolinium|
214750523|NCT00003736|PROCEDURE|biopsy|
214750524|NCT00003736|PROCEDURE|breast imaging study|
214750525|NCT00003736|PROCEDURE|comparison of screening methods|
214750526|NCT00003736|PROCEDURE|magnetic resonance imaging|
214750527|NCT00003736|PROCEDURE|study of high risk factors|
214750528|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
214750529|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
214750530|NCT03874208|OTHER|MRI|MRI exam
214794173|NCT05313204|OTHER|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
214750531|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
214750532|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
214750533|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
214750534|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
214750535|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
214750536|NCT00143728|DRUG|Lamivudine|See Detailed Description.
214750537|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
214750538|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
214750539|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
214750540|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
214750541|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
214750542|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
214750543|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
214750544|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
214750545|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
214750546|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
214750547|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
214750548|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
214750549|NCT00307073|DEVICE|Implantable Pulse Generator|
214750550|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
214750551|NCT02918136|DRUG|Cortisone Injectable|
214750552|NCT06376201|DRUG|Amphotericin B cholesterol-sulfate complex for injection|"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
214750553|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
214750554|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
214750555|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
214750556|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
214750557|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
214750558|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
214750559|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
214750560|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
214750561|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
214750562|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
214750563|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
214750564|NCT03602209|PROCEDURE|Removal of infected implant|
214750565|NCT03602209|DRUG|Antibiotic durations|
214750566|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
214750567|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
214750568|NCT04657406|DRUG|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
214750569|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
214750570|NCT05512273|PROCEDURE|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
214750571|NCT05512273|PROCEDURE|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
214750572|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
214750573|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
214750574|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
214750575|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
214750576|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
214750577|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
214750578|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
214750579|NCT04247724|BEHAVIORAL|Recreational handball|
214750580|NCT04247724|BEHAVIORAL|Control|
214750581|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
214750582|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
214750583|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
214750584|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
214750585|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
214750586|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
214750587|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
214750588|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
214750589|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
214750590|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
214750591|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
214750592|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
214750593|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
214750594|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
214750595|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
214750596|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
214750597|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
214750598|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
214750599|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
214750600|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
214750601|NCT01636076|DRUG|QMF149|delivered via Concept1 device
214750602|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
214750603|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
214750604|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
214750605|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
214750606|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
214750607|NCT00002276|DRUG|Ibuprofen|
214750608|NCT00002276|DRUG|Zidovudine|
214750609|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
214750610|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
214750611|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
214750612|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
214750613|NCT00507312|DEVICE|HD medical device (ViScope)|Device
214750614|NCT00507312|DEVICE|CSIRO device|device
214750615|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
214750616|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
214750617|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
214750618|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
214750619|NCT00277862|DRUG|Ribavirin|
214750620|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
214750621|NCT02173158|DRUG|lomitapide|
214750622|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
214750623|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
214750624|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
214750625|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
214750626|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
214750627|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
214750628|NCT05391113|DIAGNOSTIC_TEST|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
214750629|NCT05391113|DIAGNOSTIC_TEST|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
214750630|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
214750631|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
214750632|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
214750633|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
214750634|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
214750635|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
214750636|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
214750637|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
214750638|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
214750639|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
214750640|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
214750641|NCT00935961|DRUG|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
214750642|NCT06143449|OTHER|Observational study - registry|Observational study - registry
214750643|NCT00323479|DRUG|Anastrozole|1mg/Day oral
214750644|NCT01362062|DRUG|Tocilizumab|
214750645|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
214750646|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
214750647|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
214750648|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
214750649|NCT06323863|RADIATION|ultra high resolution CT|imaging study
214750650|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
214750651|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
214750652|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
214750653|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
214750654|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
214750655|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
214750656|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
214750657|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
214750658|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
214750659|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
214794174|NCT05398822|DIAGNOSTIC_TEST|MRI|Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
214750660|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
214750661|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
214750662|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
214750663|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
214750664|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
214750665|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
214750666|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
214750667|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
214750668|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
214750669|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
214750670|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
214750671|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
214750672|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
214750673|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
214750674|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
214750675|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
214750676|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
214750677|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
214750678|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
214750679|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
214750680|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
214750681|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
214750682|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
214750683|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
214750684|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
214750685|NCT00103831|DRUG|Oral Taxane|
214750686|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
214750687|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
214750688|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
214750689|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
214750690|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
214750691|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
214750692|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
214750693|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
214750694|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
214750695|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
214750696|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
214750697|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
214750698|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
214750699|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
214750700|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
214750701|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
214750702|NCT00451776|DRUG|etomidate|patients who received etomidate
214750703|NCT00451776|DRUG|propofol|patients who received propofol
214750704|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
214750705|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
214750706|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
214750707|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~\- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
214750708|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~\- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
214750709|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
214750710|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
214750711|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
214750712|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
214750713|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
214750714|NCT02926833|DRUG|Fludarabine|Administered intravenously
214750715|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
214750716|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
214750717|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
214750718|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
214750719|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
214750720|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
214750721|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
214750722|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
214750723|NCT02776631|DEVICE|Pinloc|Internal fixation device
214750724|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
214750725|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
214750726|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
214750727|NCT01277757|OTHER|Pharmacological Study|Correlative studies
214750728|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
214750729|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
214750730|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
214750731|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
214750732|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
214750733|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
214750734|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
214750735|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
214750736|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
214750737|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
214750738|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
214750739|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
214750740|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
214750741|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
214750742|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
214750743|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
214750744|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
214750745|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
214750746|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
214750747|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
214750748|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
214750749|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
214750750|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
214750751|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
214794175|NCT04245566|PROCEDURE|Prostatic Artery Embolization (PAE)|Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
214750752|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
214750753|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
214750754|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
214750755|NCT00057642|DRUG|Sertraline|
214750756|NCT00057642|DRUG|Venlafaxine Extended Release|
214750757|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
214794176|NCT04245566|DRUG|Pharmacotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
214794177|NCT00096395|DRUG|gemcitabine hydrochloride|Given IV
214750758|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
214750759|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
214750760|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
214794178|NCT00096395|DRUG|sorafenib tosylate|Given orally
214750761|NCT06665009|DEVICE|Manually Opened and Device-Opened Ampoules|this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
214750762|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
214750763|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
214750764|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
214750765|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
214750766|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
214750767|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
214750768|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
214750769|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
214750770|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
214750771|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
214750772|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
214750773|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
214750774|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
214750775|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
214750776|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
214750777|NCT02059473|PROCEDURE|Physiotherapy|
214750778|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
214750779|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
214750780|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
214750781|NCT02479594|OTHER|control|control group without competence-feedback
214750782|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
214750783|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
214750784|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
214750785|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
214750786|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
214750787|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
214750788|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
214794179|NCT00096395|OTHER|laboratory biomarker analysis|Correlative studies
214750789|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
214750790|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
214750791|NCT00001426|DRUG|Cyclophosphamide|
214750792|NCT00001426|DRUG|Paclitaxel|
214750793|NCT00001426|DRUG|Cisplatin|
214750794|NCT00001426|DRUG|G-CSF|
214750795|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
214750796|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
214750797|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
214750798|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
214750799|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
214750800|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
214750801|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
214750802|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750803|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750804|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750805|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750806|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750807|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750808|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750809|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
214750810|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
214750811|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
214750812|NCT00003701|DRUG|carboplatin|
214750813|NCT00003701|DRUG|cisplatin|
214750814|NCT00003701|DRUG|doxorubicin hydrochloride|
214750815|NCT00003701|DRUG|methotrexate|
214750816|NCT00003701|DRUG|paclitaxel|
214750817|NCT00003701|DRUG|vinblastine sulfate|
214750818|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
214750819|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
214750820|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
214750821|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
214750822|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
214750823|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
214750824|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
214750825|NCT00005068|DRUG|fluorouracil|
214750826|NCT00005068|DRUG|irinotecan hydrochloride|
214750827|NCT00005068|DRUG|leucovorin calcium|
214750828|NCT00005068|DRUG|oxaliplatin|
214750829|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
214750830|NCT01014104|DRUG|Control|Normal salin injection
214750831|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
214750832|NCT00077896|PROCEDURE|Direct Current Polarization|
214750833|NCT00223158|DRUG|Liothyronine|
214794180|NCT05451459|OTHER|12-week FMS Intervention|4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
214750834|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
214750835|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
214750836|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
214750837|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
214750838|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
214750839|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
214750840|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
214750841|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
214750842|NCT01674010|DRUG|ELND005|
214750843|NCT01674010|DRUG|Lamotrigine|
214750844|NCT01674010|DRUG|Valproic acid|
214750845|NCT01674010|DRUG|Placebo|
214750846|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
214750847|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
214794181|NCT05451459|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
214794182|NCT00207337|DEVICE|Exhale Drug-Eluting Stent|
214750848|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
214750849|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
214750850|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
214750851|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
214750852|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
214750853|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
214750854|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
214750855|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
214750856|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
214750857|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
214750858|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
214750859|NCT02319018|DRUG|Alisertib|Given PO
214750860|NCT02319018|DRUG|Fluorouracil|Given IV
214750861|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
214750862|NCT02319018|DRUG|Leucovorin Calcium|Given IV
214750863|NCT02319018|DRUG|Oxaliplatin|Given IV
214750864|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
214750865|NCT02617602|OTHER|Control|
214750866|NCT04037579|OTHER|Survey|Non-randomised survey
214750867|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
214750868|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
214750869|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
214750870|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
214750871|NCT04924608|DRUG|Selumetinib|Selumetinib oral capsules (10 mg and 25 mg)
214750872|NCT04924608|OTHER|Placebo|Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
214750873|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
214750874|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
214750875|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
214750876|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
214750877|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
214750878|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
214750879|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
214750880|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
214750881|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
214750882|NCT03096899|OTHER|Observational|Best Supportive Care
214750883|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
214750884|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
214750885|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
214750886|NCT03914456|OTHER|rehabilitation treatment|
214750887|NCT03389633|OTHER|rehabilitation|
214794183|NCT06020885|RADIATION|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
214750888|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
214750889|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
214750890|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
214750891|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
214750892|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
214750893|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
214750894|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
214750895|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
214750896|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
214750897|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
214750898|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
214750899|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
214750900|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
214750901|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
214750902|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
214750903|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
214750904|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
214750905|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
214750906|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
214750907|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
214750908|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
214750909|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
214750910|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
214750911|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
214750912|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
214750913|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
214750914|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
214750915|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
214750916|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
214750917|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
214750918|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
214750919|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
214750920|NCT02849873|DRUG|IDP-123 Lotion|Lotion
214750921|NCT02849873|DRUG|Tazorac Cream|Cream
214750922|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
214750923|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
214794184|NCT06020885|DRUG|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
214750924|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
214750925|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
214750926|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
214750927|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
214750928|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
214750929|NCT00043134|DRUG|decitabine|
214750930|NCT00456586|DRUG|KW-6002 (istradefylline)|
214750931|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
214750932|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
214750933|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
214750934|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
214750935|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
214750936|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
214750937|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
214750938|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
214750939|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
214750940|NCT05915455|OTHER|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
214750941|NCT05915455|OTHER|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
214750942|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
214750943|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
214750944|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
214750945|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
214750946|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
214750947|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
214750948|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
214750949|NCT00346775|DRUG|Flunisolide|Flunisolide
214750950|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
214750951|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
214750952|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
214750953|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
214750954|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1\) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
214750955|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
214750956|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
214750957|NCT00039429|DRUG|atrasentan hydrochloride|
214750958|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
214750959|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
214750960|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
214750961|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
214750962|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
214750963|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
214750964|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
214750965|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
214750966|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
214750967|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
214750968|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
214750969|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
214750970|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
214750971|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
214750972|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
214750973|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
214750974|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
214750975|NCT03157804|DRUG|Plerixafor|Given SC
214750976|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
214750977|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
214750978|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
214750979|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
214750980|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
214750981|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
214750982|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
214750983|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
214750984|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
214750985|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
214750986|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
214750987|NCT04717310|DRUG|Vehicle|Twice a day (BID)
214750988|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
214750989|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
214750990|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
214750991|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
214750992|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
214750993|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
214750994|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
214750995|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
214750996|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
214750997|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
214750998|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
214750999|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
214751000|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
214751001|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
214751002|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
214751003|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
214751004|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
214751005|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
214751006|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
214751007|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
214751008|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
214751009|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
214751010|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
214751011|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
214751012|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
214751013|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
214751014|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
214751015|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
214751016|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
214751017|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
214751018|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
214751019|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
214751020|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
214751021|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
214751022|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
214751023|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
214751024|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
214751025|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
214751026|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
214751027|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
214751028|NCT01358266|DRUG|DE-109 44 ug|Low dose
214751029|NCT01358266|DRUG|DE-109 440 ug|Medium dose
214751030|NCT01358266|DRUG|DE-109 880 ug|High dose
214751031|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
214751032|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
214751033|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
214751034|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
214751035|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
214751036|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
214751037|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
214751038|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
214751039|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
214751040|NCT02151565|DEVICE|HTEMS|
214751041|NCT02151565|DEVICE|TENS|
214751042|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
214751043|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
214751044|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
214751045|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
214751046|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
214751047|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
214751048|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
214751049|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
214751050|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
214751051|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
214751052|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
214751053|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
214751054|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
214751055|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
214751056|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
214751057|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
214751058|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
214751059|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214751060|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
214751061|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
214751062|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
214751063|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
214751064|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
214751065|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
214751066|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
214751067|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
214751068|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
214751069|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
214751070|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
214751071|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
214751072|NCT00665366|DRUG|Lithium|Participant's ongoing dose
214751073|NCT00665366|DRUG|Valproate|Participant's ongoing dose
214751074|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
214751075|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
214751076|NCT04149366|DEVICE|Retainer|Orthodontic retainer
214751077|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
214751078|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
214751079|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
214751080|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
214751081|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
214751082|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
214751083|NCT02557191|OTHER|Observational study|
214751084|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
214751085|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
214751086|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
214751087|NCT00475839|DEVICE|Tension-free Vaginal Tape|
214751088|NCT00475839|DEVICE|Monarc sub-fascial hammock|
214751089|NCT01229865|DRUG|VB-111|
214751090|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
214751091|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
214751092|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
214751093|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
214751094|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
214751095|NCT00594334|DRUG|Risedronate|Weekly Risedronate
214751096|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
214751097|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
214751098|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
214751099|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
214751100|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
214751101|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
214751102|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
214751103|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
214751104|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
214751105|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
214751106|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
214751107|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
214751108|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
214751109|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
214751110|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
214751111|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
214751112|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
214751113|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
214751114|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
214751115|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
214751116|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
214751117|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
214751118|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
214751119|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
214751120|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
214751121|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
214751122|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
214751123|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
214751124|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
214751125|NCT03418025|OTHER|Survey Administration|Ancillary studies
214751126|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
214751127|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
214751128|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
214751129|NCT00207025|DRUG|BMS-275183|
214751130|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
214751131|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
214751132|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
214751133|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
214751134|NCT02726516|OTHER|Placebo|1 sachet per day
214751135|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
214751136|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
214751137|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
214751138|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
214751139|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
214751140|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
214751141|NCT03333564|OTHER|Control|No intervention was given
214751142|NCT02231606|OTHER|Free Glasses|Provide free glasses
214751143|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
214751144|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
214751145|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
214751146|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
214751147|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
214751148|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
214751149|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
214751150|NCT02751372|DRUG|BAY 987517|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
214751151|NCT02751372|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
214751152|NCT06452290|DEVICE|brain 18F-FDG PET-CT|PET scanner, Philips VEREOS PET/CT scanner. Three Philips VEREOS digital PET/CT scanners are installed in the nuclear medicine department.
214751153|NCT05548582|DRUG|OxyCODONE 5 mg Oral Tablet|No opioid prescription after laparoscopic hysterectomy
214751154|NCT05548582|DRUG|Acetaminophen 500 mg Tab|Standard prescription
214751155|NCT05548582|DRUG|Ibuprofen 600 mg|Standard prescription
214751156|NCT03398759|DRUG|Butorphanol|IV injection during induction
214751157|NCT03398759|DRUG|Placebos|IV injection during induction
214751158|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
214751159|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
214751160|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
214751161|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
214751162|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
214751163|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
214751164|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
214751165|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
214751166|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214751167|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
214751168|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
214751169|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
214751170|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
214751171|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
214751172|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
214751173|NCT00742404|DRUG|bortezomib|
214751174|NCT00742404|DRUG|dexamethasone|
214751175|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
214751176|NCT00742404|GENETIC|protein analysis|
214751177|NCT00742404|OTHER|immunologic technique|
214751178|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
214751179|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
214751180|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
214751181|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
214751182|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
214751183|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
214751184|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
214751185|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
214751186|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
214751187|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
214751188|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
214751189|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
214751190|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
214751191|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
214751192|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
214751193|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
214751194|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
214751195|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
214751196|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
214751197|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
214751198|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
214751199|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
214751200|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
214751201|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
214751202|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
214751203|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
214751204|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
214751205|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
214751206|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
214751207|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
214751208|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
214751209|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
214751210|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
214751211|NCT00399542|DRUG|Lubiprostone|
214751212|NCT00399542|DRUG|Placebo|
214751213|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
214751214|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
214751215|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
214751216|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
214751217|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
214751218|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
214751219|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
214751220|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
214751221|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
214751222|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
214751223|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
214751224|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
214751225|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
214751226|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
214751227|NCT00000610|DRUG|magnesium|
214751228|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
214751229|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
214751230|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
214751231|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
214751232|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
214751233|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
214751234|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
214751235|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
214751236|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
214751237|NCT02806804|BIOLOGICAL|one dose test vaccine|
214751238|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
214751239|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
214751240|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
214751241|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
214751242|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
214751243|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
214751244|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
214751245|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
214751246|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
214751247|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
214751248|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
214751249|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
214751250|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
214751251|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
214751252|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
214751253|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
214751254|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
214751255|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
214751256|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
214751257|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
214751258|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
214751259|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
214751260|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
214751261|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
214751262|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
214751263|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
214751264|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
214751265|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
214751266|NCT04039282|DEVICE|myfood24|online website for dietary analysis
214751267|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
214751268|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
214751269|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
214751270|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
214751271|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
214751272|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
214751273|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
214751274|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
214751275|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
214751276|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
214751277|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
214751278|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
214751279|NCT00334893|DRUG|eribulin mesylate|Given IV
214751280|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
214751281|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
214751282|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
214751283|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
214751284|NCT02078557|DRUG|MK-8892|
214751285|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
214751286|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
214751287|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
214751288|NCT00117520|DRUG|Caffeine|
214751289|NCT01830621|DRUG|BBI608|
214751290|NCT01830621|DRUG|Placebo|
214751291|NCT01830621|OTHER|Best Supportive Care|
214751292|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
214751293|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214751294|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214751295|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214751296|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
214751297|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
214751298|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
214751299|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
214751300|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
214751301|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
214751302|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
214751303|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
214751304|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
214751305|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
214751306|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
214751307|NCT06416462|PROCEDURE|antimicrobial photodynamic therapy|When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
214751308|NCT03846310|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
214751309|NCT03846310|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
214751310|NCT03846310|DRUG|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
214751311|NCT03846310|DRUG|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
214751312|NCT03846310|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
214751313|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
214751314|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
214751315|NCT00000912|DRUG|Indinavir sulfate|
214751316|NCT00000912|DRUG|Abacavir sulfate|
214751317|NCT00000912|DRUG|Amprenavir|
214751318|NCT00000912|DRUG|Nelfinavir mesylate|
214751319|NCT00000912|DRUG|Efavirenz|
214751320|NCT00000912|DRUG|Levocarnitine|
214751321|NCT00000912|DRUG|Adefovir dipivoxil|
214751322|NCT00000912|DRUG|Saquinavir|
214751323|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
214751324|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
214751325|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
214751326|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
214751327|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
214751328|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
214751329|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
214751330|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
214751331|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
214751332|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
214751333|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
214751334|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
214751335|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
214751336|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
214751337|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
214751338|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
214794185|NCT06020885|DRUG|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
214751339|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
214751340|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
214751341|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
214751342|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
214751343|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
214751344|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
214751345|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
214751346|NCT06464081|OTHER|Sleep quality assessment|1\. Pediatric Sleep Questionnaire.
214751347|NCT06464081|OTHER|Anthropometry|2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
214751348|NCT06464081|OTHER|Tongue strength assessment|3\. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
214751349|NCT06464081|OTHER|Tongue endurance assessment|6\. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
214751350|NCT06464081|OTHER|Orofacial praxis assessment|8\. Motricité Bucco-Linguo-Faciale (MBLF) test.
214751351|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
214751352|NCT06234501|OTHER|Placebo|Placebo tablet once daily
214751353|NCT01288911|DRUG|enzalutamide|capsules
214751354|NCT01288911|DRUG|bicalutamide|tablets
214751355|NCT05963555|DEVICE|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
214751356|NCT05963555|DEVICE|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
214751357|NCT05963555|DEVICE|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
214751358|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
214751359|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
214751360|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
214751361|NCT02189239|DRUG|Placebo|
214751362|NCT02189239|OTHER|No Treatment|
214751363|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
214751364|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
214751365|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
214751366|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
214751367|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
214751368|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
214751369|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
214751370|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
214751371|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
214751372|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
214751373|NCT04193228|DEVICE|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
214751374|NCT04193228|BEHAVIORAL|Exercise|Ankle muscle strength training
214751375|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
214751376|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
214751377|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
214751378|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
214751379|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
214751380|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
214751381|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
214751382|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
214751383|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
214751384|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
214751385|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
214751386|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
214751387|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
214751388|NCT05776511|PROCEDURE|eVOG|video digital oculography
214751389|NCT04613076|BEHAVIORAL|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
214751390|NCT04613076|BEHAVIORAL|Enhanced Usual Treatment|Enhanced Usual Treatment
214751391|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
214751392|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
214751393|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
214751394|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
214751395|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
214751396|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
214751397|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
214751398|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
214751399|NCT00545974|DRUG|memantine|memantine 10mg BID
214751400|NCT00545974|DRUG|Placebo pill|Placebo pill BID
214751401|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
214751402|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
214751403|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
214751404|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
214751405|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
214751406|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
214751407|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
214751408|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
214751409|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
214751410|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
214751411|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
214751412|NCT02861521|DEVICE|Sham|Sham shoe modification
214751413|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
214751414|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
214751415|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
214751416|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
214751417|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
214751418|NCT00658918|DRUG|Placebo|placebo
214751419|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
214751420|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
214751421|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
214751422|NCT05801016|BEHAVIORAL|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
214751423|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
214751424|NCT00045006|DRUG|vorinostat|
214751425|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
214751426|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
214751427|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
214751428|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
214751429|NCT02438111|GENETIC|metagenome|metagenome
214751430|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
214751431|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
214751432|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
214751433|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
214751434|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
214751435|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
214751436|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
214751437|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
214751438|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
214751439|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
214751440|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
214751441|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
214751442|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
214751443|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
214751444|NCT05405738|OTHER|normal group|control normal group
214751445|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
214751446|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
214751447|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
214751448|NCT02565303|PROCEDURE|Intervertebral space|
214751449|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
214751450|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
214751451|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
214751452|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
214751453|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
214751454|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
214751455|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
214751456|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
214751457|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
214751458|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
214751459|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
214751460|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214751461|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214751462|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214751463|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
214751464|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
214751465|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
214751466|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
214751467|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
214751468|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
214751469|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
214751470|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
214751471|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
214751472|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
214751473|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
214751474|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
214751475|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
214794186|NCT05075603|DRUG|Efineptakin alfa|NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
214794187|NCT05075603|DRUG|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
214794188|NCT05075603|DRUG|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
214751476|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
214751477|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
214751478|NCT00000291|DRUG|Labetalol|
214751479|NCT02983968|OTHER|Description of the cirrhosis management|
214751480|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
214751481|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
214751482|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
214751483|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
214751484|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
214751485|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (\_\_\_mg/m2 iv weekly x 4 weeks)
214751486|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
214751487|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
214751488|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
214751489|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
214751490|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
214751491|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
214751492|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
214751493|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
214751494|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
214751495|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
214751496|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
214751497|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
214751498|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
214751499|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
214751500|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
214751501|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
214751502|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
214751503|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
214751504|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
214751505|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
214751506|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
214751507|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
214751508|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
214751509|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
214751510|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
214751511|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
214751512|NCT06924619|RADIATION|neoadjuvant radiotherapy|Target the primary tumor region with 40-50 Gy in 20-25 fractions.
214751513|NCT06924619|DRUG|cisplatin|The cisplatin will be given concurrently with radiotherapy (25 mg/m² , D1, QW) for 4-5 cycles.
214751514|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
214751515|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
214751516|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
214751517|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
214751518|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
214751519|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
214794189|NCT05075603|DRUG|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
214751520|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
214751521|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
214751522|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
214751523|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
214751524|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
214751525|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
214751526|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
214751527|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
214751528|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
214751529|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
214751530|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
214751531|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
214751532|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
214751533|NCT02919709|BIOLOGICAL|blood taking|
214751534|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
214751535|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
214751536|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
214751537|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
214751538|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
214751539|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
214751540|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
214794190|NCT01176448|DEVICE|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
214751541|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
214751542|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
214751543|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
214751544|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
214751545|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
214751546|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
214751547|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
214751548|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
214751549|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
214751550|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
214751551|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
214751552|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
214751553|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
214751554|NCT01334502|BIOLOGICAL|rituximab|PO
214751555|NCT01334502|DRUG|cyclophosphamide|IV
214751556|NCT01334502|DRUG|doxorubicin hydrochloride|IV
214751557|NCT01334502|DRUG|everolimus|PO
214751558|NCT01334502|DRUG|prednisone|PO
214751559|NCT01334502|DRUG|vincristine sulfate|IV
214751560|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
214751561|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
214751562|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
214751563|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
214751564|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
214751565|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
214751566|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
214751567|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
214751568|NCT00004808|DRUG|fluconazole|
214751569|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
214794191|NCT01176448|DEVICE|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
214751570|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
214751571|NCT01520038|RADIATION|Proton therapy|
214751572|NCT01520038|RADIATION|IMRT|
214751573|NCT03159455|DRUG|BI 1467335|Duration - 28 days
214751574|NCT03159455|DRUG|Placebo|Duration - 28 days
214751575|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
214751576|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
214751577|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
214751578|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
214751579|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
214751580|NCT00021554|DRUG|Enfuvirtide|
214751581|NCT01890876|OTHER|Walking uphill|ascending about 500 m
214751582|NCT01890876|OTHER|Walking downhill|descending about 500 m
214751583|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
214751584|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
214751585|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
214751586|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
214751587|NCT00002110|DRUG|Cysteamine|
214751588|NCT00002110|DRUG|Zidovudine|
214751589|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
214751590|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
214751591|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
214751592|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
214751593|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
214751594|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
214751595|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
214751596|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
214751597|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
214751598|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
214751599|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
214751600|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
214751601|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
214751602|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
214751603|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
214751604|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
214751605|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
214751606|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
214751607|NCT05725642|OTHER|Polysomnography|Polysomnography
214751608|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
214751609|NCT02501642|OTHER|Treatment as usual|Treatment as usual
214751610|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
214751611|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
214751612|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
214751613|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
214751614|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
214751615|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
214751616|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
214751617|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
214751618|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
214751619|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
214751620|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
214751621|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
214751622|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
214751623|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
214751624|NCT02027766|OTHER|Calf muscle stretching|
214751625|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
214751626|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
214751627|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
214751628|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
214751629|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
214751630|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
214751631|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
214751632|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
214751633|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
214751634|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
214751635|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
214751636|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
214751637|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
214751638|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
214751639|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
214751640|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
214751641|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
214751642|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
214751643|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
214751644|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
214751645|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
214751646|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
214751647|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
214751648|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
214751649|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
214751650|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
214751651|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
214751652|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
214751653|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
214751654|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
214751655|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
214751656|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
214751657|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
214751658|NCT03276858|DRUG|CRN00808|Investigational drug
214751659|NCT03276858|DRUG|Placebo Oral Solution|Placebo
214751660|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
214751661|NCT03276858|DRUG|Placebo oral capsule|Placebo
214751662|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
214751663|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
214751664|NCT01756586|DRUG|Dexamethasone|
214751665|NCT01756586|DRUG|Bupivacaine|Control
214751666|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
214751667|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
214751668|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
214751669|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
214751670|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
214751671|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
214751672|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
214751673|NCT05116410|DRUG|HS-20094|Administrated SC
214751674|NCT05116410|DRUG|Placebo|Administrated SC
214751675|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
214751676|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
214751677|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
214751678|NCT02477319|OTHER|Observational|
214751679|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
214751680|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
214751681|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
214751682|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
214751683|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
214751684|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
214751685|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
214751686|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
214751687|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
214751688|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
214751689|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
214751690|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
214751691|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
214751692|NCT01153971|DRUG|rituximab|1
214751693|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
214751694|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
214751695|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
214751696|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
214751697|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
214751698|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
214751699|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
214751700|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
214751701|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
214751702|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
214751703|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
214751704|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
214751705|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
214751706|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
214751707|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
214751708|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
214751709|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
214751710|NCT00953576|DRUG|ketoconazole|
214751711|NCT00953576|DRUG|hydrocortisone|
214751712|NCT00953576|DRUG|dutasteride|
214751713|NCT00953576|DRUG|lapatinib|
214751714|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
214751715|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
214751716|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
214751717|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
214751718|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
214751719|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
214751720|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
214751721|NCT02965027|DRUG|Prazosin|
214751722|NCT02965027|DRUG|Placebo|
214751723|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
214751724|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
214751725|NCT02822729|DRUG|DE-117 ophthalmic solution|
214751726|NCT02822729|DRUG|Timolol ophthalmic solution|
214751727|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
214751728|NCT02122874|OTHER|1200 Kcal diet|
214751729|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
214751730|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
214751731|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
214751732|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
214751733|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
214751734|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
214751735|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
214751736|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
214751737|NCT02681991|DRUG|Renamezin capsule|
214751738|NCT05665257|DEVICE|Inspiratory muscle training|
214751739|NCT05665257|DEVICE|Mini-PEP|
214751740|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
214751741|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
214751742|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
214751743|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
214751744|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
214751745|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
214751746|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
214751747|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
214751748|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
214751749|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
214751750|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
214751751|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
214751752|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
214751753|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
214751754|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
214751755|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
214751756|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
214751757|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
214751758|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
214751759|NCT02062541|OTHER|usual assessment+fast rehabilitation|
214751760|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
214751761|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
214751762|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
214751763|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
214751764|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
214751765|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
214751766|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
214751767|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
214751768|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
214751769|NCT05865002|DRUG|AUR107|Once daily
214751770|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
214751771|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
214751772|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
214751773|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
214751774|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
214751775|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
214751776|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
214751777|NCT02081352|OTHER|Standard care|
214751778|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
214751779|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
214751780|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
214751781|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
214751782|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
214751783|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
214751784|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
214751785|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
214751786|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
214751787|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
214751788|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
214751789|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
214751790|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
214751791|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
214751792|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
214751793|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
214751794|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
214751795|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
214751796|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
214751797|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
214751798|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
214751799|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
214751800|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
214751801|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
214751802|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
214751803|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
214751804|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
214751805|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
214751806|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
214751807|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
214751808|NCT00211575|BEHAVIORAL|Disease Management Assessment|
214751809|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
214751810|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
214751811|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
214751812|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
214751813|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
214794342|NCT03741608|BEHAVIORAL|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
214751814|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
214751815|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
214751816|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
214751817|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
214751818|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
214751819|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
214751820|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
214751821|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
214751822|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
214751823|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
214751824|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
214751825|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
214751826|NCT02454413|OTHER|denture brushing with water and soap|denture brushing with water and soap
214751827|NCT02454413|OTHER|ultrasonic denture cleaning|ultrasonic denture cleaning
214751828|NCT02454413|OTHER|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
214751829|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
214751830|NCT05154994|DRUG|Belinostat|Given IV
214751831|NCT05154994|BIOLOGICAL|Durvalumab|Given IV
214751832|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
214751833|NCT04812678|PROCEDURE|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
214751834|NCT04812678|PROCEDURE|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
214751835|NCT04214483|OTHER|No intervention|There is no intervention for this study.
214751836|NCT05675579|DRUG|Sacituzumab Govitecan|Given by IV (vein)
214751837|NCT05675579|DRUG|Pembrolizumab|Given by IV (vein)
214751838|NCT03757585|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
214751839|NCT03757585|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
214751840|NCT03472586|BIOLOGICAL|Ipilimumab|Given IV
214751841|NCT03472586|BIOLOGICAL|Nivolumab|Given IV
214751842|NCT03472586|DRUG|Embolization Therapy|Undergo immunoembolization
214751843|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
214751844|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
214751845|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
214751846|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
214751847|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
214751848|NCT02461173|DEVICE|shepherd catheter|
214751849|NCT06119269|DIAGNOSTIC_TEST|Therapeutic drug monitoring|At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)
214751850|NCT06119269|DIAGNOSTIC_TEST|Molecular Response|BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib
214751851|NCT02528331|DEVICE|Transcranial magnetic stimulation|
214751852|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
214751853|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
214751854|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read positive messages
214751855|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about positive experiences
214751856|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about neutral topics
214751857|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read neutral messages
214751858|NCT04776941|OTHER|Quality-of-Life Assessment|Ancillary studies
214751859|NCT04776941|OTHER|Questionnaire Administration|Complete questionnaires
214751860|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
214751861|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
214751862|NCT03650218|DEVICE|THIODERM STRONG|Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
214751863|NCT06050928|DRUG|Oral EP262|Once daily
214751864|NCT06008938|GENETIC|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
214751865|NCT06008938|BIOLOGICAL|Factor IX (FIX)|FIX prophylaxis therapy
214751866|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
214751867|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
214751868|NCT05981443|DEVICE|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
214751869|NCT05981443|OTHER|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
214751870|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
214751871|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
214751872|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
214751873|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
214751874|NCT06193343|BEHAVIORAL|Adaptive Daily Step Promotion|"Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps."
214751875|NCT06045026|OTHER|Stannous fluoride|Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
214751876|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
214751877|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
214751878|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
214751879|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
214751880|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
214751881|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
214751882|NCT06566157|DIETARY_SUPPLEMENT|Prebiotic|WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
214751883|NCT06566157|DIETARY_SUPPLEMENT|Maltodextrin (Corn)|Placebo
214751884|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
214751885|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
214794343|NCT03741608|BEHAVIORAL|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
214794344|NCT03349333|DRUG|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
214751886|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
214751887|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
214751888|NCT06383715|BEHAVIORAL|Cognitive-Behavioral Therapy Workshop for Content Moderators|"This 4-session group workshop is based on the principles of Cognitive Behavioral Therapy. It consists of four sessions:~1. Presentation. Scientific evidence of psychological consequences on content moderatos. Psicoeducation on the effects of vicarious trauma exposure.~2. Presentation of the cognitive model. Identification/operationalization of thoughts. Discussion of possible irrational thoughts.~3. Psychoeducation of emotions and their adaptive function. Behavioral strategies of emotions: exposure therapies and behavioral activation.~4. The role of social support. Strategies for appropriate work and sleep hygiene. Strategies for maintaining gains. Farewell."
214751889|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
214751890|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
214751891|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
214751892|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
214751893|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
214751894|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
214751895|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
214751896|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
214751897|NCT00291109|DRUG|letrozole 2.5 mg|
214751898|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
214751899|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
214751900|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
214751901|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
214751902|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
214751903|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
214751904|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
214751905|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
214751906|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
214751907|NCT03885817|BEHAVIORAL|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
214751908|NCT03885817|OTHER|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
214751909|NCT05514444|BIOLOGICAL|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
214751910|NCT05514444|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
214751911|NCT05514444|DRUG|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
214751912|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
214751913|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
214751914|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
214751915|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
214751916|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
214751917|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
214751918|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
214751919|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
214751920|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
214751921|NCT00381017|DRUG|Peg interferon alpha-2b|
214751922|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
214751923|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
214751924|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
214751925|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
214751926|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
214751927|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
214751928|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
214751929|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
214751930|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
214751931|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
214751932|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
214751933|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
214751934|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
214751935|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
214751936|NCT02405182|OTHER|Magnetic Resonance Imaging|
214751937|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
214751938|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
214751939|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
214751940|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
214751941|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
214751942|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
214751943|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
214751944|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
214751945|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
214751946|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
214751947|NCT01074060|DRUG|plerixafor|Given IV
214751948|NCT01074060|BIOLOGICAL|filgrastim|Given SC
214751949|NCT01074060|DRUG|cyclophosphamide|Given IV
214751950|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
214751951|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
214751952|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
214751953|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
214751954|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
214751955|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
214751956|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
214751957|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
214751958|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
214751959|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
214751960|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
214751961|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
214751962|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
214751963|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
214751964|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
214751965|NCT05729516|BEHAVIORAL|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
214751966|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
214751967|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
214751968|NCT05856916|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
214751969|NCT05856916|DIETARY_SUPPLEMENT|Placebo|Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
214794345|NCT03349333|DIETARY_SUPPLEMENT|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
214794346|NCT01675908|PROCEDURE|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
214751970|NCT05705310|BEHAVIORAL|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
214751971|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
214751972|NCT05587933|DRUG|Antispasmodic|Antispasmodic
214751973|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
214751974|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
214751975|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
214751976|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
214751977|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
214751978|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
214751979|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
214751980|NCT05593523|DRUG|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
214751981|NCT05593523|DEVICE|Clinical Fluorescence Imaging Device|OnLume Clinical Imaging System or Commercially-available FDA approved clinical fluorescence imaging device (SPY Elite fluorescence imaging system, SPY-PHI portable handheld imaging system, or EleVision IR platform (also known as VS3-IR system)
214751982|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
214751983|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
214751984|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
214751985|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
214751986|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
214751987|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
214751988|NCT02221882|DRUG|LY3164530|Administered IV.
214751989|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
214751990|NCT00796367|DRUG|Placebo|placebo
214751991|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
214751992|NCT02395445|DEVICE|orotracheal intubation|
214751993|NCT00122395|BEHAVIORAL|Screening via pen and paper|
214751994|NCT00122395|BEHAVIORAL|Screening via audiotape|
214751995|NCT05295810|DRUG|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
214751996|NCT00307775|DRUG|oestradiol|
214751997|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
214751998|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
214751999|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
214752000|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
214752001|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
214752002|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
214752003|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
214752004|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
214752005|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
214752006|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
214752007|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
214752008|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
214752009|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
214752010|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
214752011|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
214752012|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
214794347|NCT01675908|PROCEDURE|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
214794348|NCT00976235|DEVICE|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
214794349|NCT00974883|PROCEDURE|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
214794350|NCT00974883|PROCEDURE|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
214752013|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
214752014|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
214752015|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
214752016|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
214752017|NCT01263652|DRUG|Tramadol|IM/PO tramadol
214752018|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
214752019|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
214752020|NCT00052403|PROCEDURE|anti-cytokine therapy|
214752021|NCT00052403|PROCEDURE|antiangiogenesis therapy|
214752022|NCT00052403|PROCEDURE|antibody therapy|
214752023|NCT00052403|PROCEDURE|biological response modifier therapy|
214752024|NCT00052403|PROCEDURE|growth factor antagonist therapy|
214752025|NCT00052403|PROCEDURE|monoclonal antibody therapy|
214752026|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
214752027|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
214752028|NCT04920786|DRUG|TB006|TB006
214752029|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
214752030|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
214752031|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
214752032|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
214752033|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
214752034|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
214752035|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
214752036|NCT00019331|BIOLOGICAL|aldesleukin|
214752037|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
214752038|NCT00019331|BIOLOGICAL|sargramostim|
214752039|NCT00019331|DRUG|DetoxPC|
214752040|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
214752041|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
214752042|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
214752043|NCT02020681|DEVICE|Fluoride|Single application on day D90
214752044|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
214752045|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
214752046|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
214752047|NCT00516945|DRUG|Lamivudine|
214752048|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
214752049|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
214752050|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
214752051|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
214752052|NCT04236986|DRUG|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
214752053|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
214752054|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
214752055|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
214752056|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
214752057|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
214752058|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
214752059|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
214752060|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
214752061|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
214752062|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
214752063|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
214752064|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
214752065|NCT04224662|OTHER|No intervention|There is no intervention for this study
214752066|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
214752067|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
214752068|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
214752069|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
214752070|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
214752071|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
214794351|NCT05955352|PROCEDURE|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
214794352|NCT01115218|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin C
214752072|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
214752073|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
214752074|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
214752075|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
214752076|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
214752077|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
214752078|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
214752079|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
214752080|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
214752081|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
214752082|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
214752083|NCT00497744|DRUG|Intraperitoneal Cefepime|
214752084|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
214752085|NCT02249377|DRUG|Corticosteroid|Corticosteroid
214752086|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
214752087|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
214752088|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
214752089|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
214752090|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
214752091|NCT01729806|BIOLOGICAL|Rituximab|Given IV
214752092|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
214752093|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
214752094|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
214752095|NCT01326481|DRUG|TRC105|IV
214752096|NCT01326481|DRUG|Capecitabine|oral
214752097|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
214752098|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
214752099|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
214752100|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
214752101|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
214752102|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
214752103|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
214752104|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
214752105|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
214752106|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
214752107|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
214752108|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
214752109|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
214752110|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
214752111|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
214752112|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
214752113|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
214752114|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
214752115|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
214752116|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
214752117|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
214752118|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
214752119|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
214752120|NCT00278213|BIOLOGICAL|alemtuzumab|
214752121|NCT00278213|DRUG|cyclophosphamide|
214752122|NCT00278213|DRUG|fludarabine phosphate|
214752123|NCT00278213|DRUG|mitoxantrone hydrochloride|
214752124|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
214752125|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
214752126|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
214752127|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
214752128|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
214752129|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
214752130|NCT02348931|PROCEDURE|corrective surgery|
214752131|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
214752132|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
214752133|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
214752134|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
214752135|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
214752136|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
214752137|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
214752138|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
214752139|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
214752140|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
214752141|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
214752142|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
214752143|NCT01985152|DRUG|Placebo|
214752144|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
214752145|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
214752146|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
214752147|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
214752148|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
214752149|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
214752150|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
214752151|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
214752152|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
214752153|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
214752154|NCT01294319|DRUG|Mifepristone|
214752155|NCT01294319|DRUG|Placebo|
214752156|NCT01294319|DRUG|Spironolactone|
214752157|NCT01294319|DRUG|Combined|
214752158|NCT01294319|DRUG|Dexamethasone|
214752159|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
214752160|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
214752161|NCT00741624|OTHER|Bandage|one application for one week
214752162|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
214752163|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
214752164|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
214752165|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
214752166|NCT03240666|OTHER|non applicable|non applicable
214752167|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
214752168|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
214752169|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
214752170|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
214752171|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
214752172|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
214752173|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
214752174|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
214752175|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
214752176|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
214752177|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
214752178|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
214752179|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
214752180|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
214752181|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
214752182|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
214752183|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
214752184|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
214752185|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
214752186|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
214752187|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
214752188|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
214752189|NCT00002075|DRUG|Flucytosine|
214752190|NCT00002075|DRUG|Fluconazole|
214752191|NCT00002075|DRUG|Amphotericin B|
214752192|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
214752193|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
214794353|NCT02701478|DRUG|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
214794354|NCT02318121|PROCEDURE|Amniotomy first|rupture of membranes to augment labor
214752194|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
214752195|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
214752196|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
214752197|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
214752198|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
214752199|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
214752200|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
214752201|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
214752202|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
214752203|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
214752204|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
214752205|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
214752206|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
214752207|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
214752208|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
214752209|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
214752210|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
214752211|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
214752212|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
214752213|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
214752214|NCT00302731|DRUG|Estradiol , estriol , progesterone|
214752215|NCT00302731|DRUG|estradiol, progesterone|
214752216|NCT00302731|DRUG|estriol, progesterone|
214752217|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
214752218|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
214752219|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
214752220|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
214752221|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
214752222|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
214752223|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
214752224|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
214752225|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
214752226|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
214752227|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
214752228|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
214752229|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
214752230|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
214752231|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
214752232|NCT02780869|DEVICE|HEMOBLAST Bellows|
214752233|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
214752234|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
214752235|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
214752236|NCT03284931|DRUG|SAGE-217 high dose|high dose
214752237|NCT03284931|DRUG|Placebo|placebo
214752238|NCT03284931|DRUG|SAGE-217 low dose|low dose
214752239|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
214752240|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
214752241|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
214752242|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
214752243|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
214752244|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
214752245|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
214752246|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
214752247|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
214752248|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
214752249|NCT02815670|DRUG|Idarucizumab|
214794355|NCT02318121|PROCEDURE|Oxytocin first|Administration of oxytocin to augment labor
214794356|NCT02318121|PROCEDURE|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
214752250|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
214752251|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
214752252|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
214752253|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
214752254|NCT00004844|PROCEDURE|tissue implantation|
214752255|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
214752256|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
214752257|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
214752258|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
214752259|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
214752260|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
214794357|NCT02318121|DRUG|Oxytocin|
214794358|NCT03713138|DIETARY_SUPPLEMENT|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
214752261|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
214752262|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
214752263|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
214752264|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
214752265|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
214752266|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
214752267|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
214752268|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
214752269|NCT02939326|DRUG|EB-001 injection|
214752270|NCT02939326|DRUG|Placebo injection|
214752271|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
214752272|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
214752273|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
214752274|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
214752275|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
214752276|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
214752277|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
214752278|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
214752279|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
214752280|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
214752281|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
214752282|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
214752283|NCT01209299|GENETIC|DNA methylation analysis|
214752284|NCT01209299|GENETIC|gene expression analysis|
214752285|NCT01209299|OTHER|laboratory biomarker analysis|
214752286|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
214752287|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
214752288|NCT03092141|OTHER|Physical training|
214752289|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
214752290|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
214752291|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
214752292|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
214752293|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
214752294|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
214752295|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
214752296|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
214752297|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
214752298|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
214752299|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
214752300|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
214752301|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
214752302|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
214752303|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
214752304|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
214752305|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
214752306|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
214752307|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
214752308|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
214752309|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
214752310|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
214752311|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
214752312|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
214752313|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
214752314|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
214752315|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
214752316|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
214752317|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
214752318|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
214752319|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
214752320|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
214752321|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
214752322|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
214752323|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
214752324|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
214752325|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
214752326|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
214752327|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
214752328|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
214752329|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
214752330|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
214752331|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
214752332|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
214752333|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
214752334|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
214752335|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
214752336|NCT04366869|DEVICE|overdenture|removal of overdenture at night
214752337|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
214752338|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
214752339|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
214752340|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
214752341|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
214752342|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
214752343|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
214752344|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
214752345|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
214752346|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
214752347|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
214752348|NCT00014066|DRUG|hematoporphyrin derivative|
214752349|NCT00014066|RADIATION|brachytherapy|
214752350|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
214752351|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
214752352|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
214752353|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
214752354|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
214752355|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
214752356|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
214752357|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
214752358|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
214752359|NCT00811499|DRUG|Placebo; oral|matching placebo
214752360|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
214752361|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
214752362|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
214752363|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
214752364|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
214752365|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
214752366|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
214752367|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
214752368|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
214752369|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
214752370|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
214752371|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
214752372|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
214752373|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
214752374|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
214752375|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
214752376|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
214752377|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
214752378|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
214752379|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
214752380|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
214752381|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
214752382|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
214752383|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
214752384|NCT03580746|PROCEDURE|Taping and posteromedial release|
214752385|NCT03580746|PROCEDURE|Ponseti|
214752386|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
214752387|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
214752388|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
214752389|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
214752390|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
214752391|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
214752392|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
214752393|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
214752394|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
214752395|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
214752396|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
214752397|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
214752398|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
214752399|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
214752400|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
214752401|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
214752402|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
214752403|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
214752404|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
214752405|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
214752406|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
214752407|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
214752408|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
214752409|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
214752410|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
214752411|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
214752412|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
214752413|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
214752414|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
214752415|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
214794359|NCT00710203|DEVICE|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
214794360|NCT00710203|PROCEDURE|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
214794361|NCT00710203|PROCEDURE|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
214794362|NCT00710203|OTHER|No treatment|A fourth lesion will not be treated and will serve as a control.
214752416|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
214752417|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
214752418|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
214752419|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
214752420|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
214752421|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
214752422|NCT01710007|DRUG|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
214752423|NCT01710007|DRUG|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
214752424|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
214752425|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
214752426|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
214752427|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
214752428|NCT05620186|OTHER|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
214752429|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
214752430|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
214752431|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
214752432|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
214752433|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
214752434|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
214752435|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
214752436|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
214752437|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
214752438|NCT03632837|DEVICE|Hemoadsorption|see arm description
214752439|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
214752440|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
214752441|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
214752442|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
214752443|NCT06785194|DEVICE|REVIVE samfilcon B custom toric contact lenses|REVIVE samfilcon B custom toric contact lenses
214752444|NCT01291420|BIOLOGICAL|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10\*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
214752445|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
214752446|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
214752447|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
214752448|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
214752449|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
214752450|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
214752451|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
214752452|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
214752453|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
214752454|NCT06522074|DIAGNOSTIC_TEST|Coronary angiography with OCT|Intravascular imaging with Optical Coherence Tomography (OCT) in patients with chronic coronary syndrome who have been indicated for coronary angiographic will be used at the operator's discretion, for diagnostic purposes and/or to guide possible coronary artery disease treatment.
214752455|NCT01793610|DRUG|Comparator Dose (40mg) MDMA HCl|An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg).
214752456|NCT01793610|DRUG|Active Dose 2 (100 mg) MDMA HCl|An initial dose of full-dose 100 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg).
214752457|NCT01793610|DRUG|Active Dose 1 (125 mg) MDMA HCl|An initial dose of full-dose 125 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg).
214752458|NCT01793610|BEHAVIORAL|Psychotherapy|Non-directive manualized therapy
214752459|NCT06793410|BIOLOGICAL|Early start post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.
214752460|NCT06793410|BIOLOGICAL|Late post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.
214752461|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
214752462|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
214752463|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
214752464|NCT04791449|OTHER|Structured exercise program|Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
214752465|NCT05854719|BEHAVIORAL|Speechreading training with an application|The Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
214752466|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
214752467|NCT02176148|DRUG|fluocinonide 0.05% cream|
214752468|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
214752469|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
214752470|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
214752471|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
214752472|NCT06073782|OTHER|Education Group|"The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit."
214752473|NCT06073782|OTHER|Text Message Group|. Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
214752474|NCT05950269|DEVICE|Walking aid|A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).
214752475|NCT05950269|OTHER|Telemonitoring|Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.
214752476|NCT05950269|OTHER|Guidance on safe walking and risk of falling|Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
214752477|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
214752478|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
214752479|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
214752480|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
214752481|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
214752482|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
214752483|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
214794363|NCT02823899|BIOLOGICAL|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
214752484|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
214752485|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
214752486|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
214752487|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
214752488|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
214752489|NCT03646916|OTHER|No dexamethasone|Nothing
214752490|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
214794364|NCT02823899|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
214794365|NCT02807142|BIOLOGICAL|NC 1 cell therapy|All patients will be treated with NC1
214752491|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
214794366|NCT01524042|PROCEDURE|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
214794367|NCT03081715|OTHER|PD-1 Knockout T Cells|Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
214794368|NCT03635853|DRUG|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
214794369|NCT01290393|OTHER|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
214752492|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
214752493|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
214752494|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
214794370|NCT03267264|DEVICE|BD Nano™ vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~2. subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
214752495|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
214752496|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
214752497|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
214752498|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
214752499|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
214752500|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
214752501|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
214752502|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
214752503|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
214752504|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
214752505|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
214752506|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
214752507|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
214752508|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
214752509|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
214752510|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
214752511|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
214752512|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
214752513|NCT03737812|DRUG|elezanumab|solution for infusion
214752514|NCT03737812|DRUG|placebo|solution for infusion
214752515|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
214752516|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
214752517|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
214752518|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
214752519|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
214752520|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
214752521|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
214752522|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
214752523|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
214752524|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
214752525|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
214752526|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
214752527|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
214752528|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
214752529|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
214752530|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
214752531|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
214752532|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
214752533|NCT03644862|DEVICE|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
214752534|NCT00019565|PROCEDURE|magnetic resonance imaging|
214752535|NCT00019565|PROCEDURE|positron emission tomography|
214752536|NCT00019565|RADIATION|fludeoxyglucose F 18|
214752537|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
214752538|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
214752539|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
214752540|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
214752541|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
214752542|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
214752543|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
214752544|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
214752545|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
214752546|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
214752547|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
214752548|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
214752549|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
214752550|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
214752551|NCT03927209|DRUG|BI 1467335|tablet
214752552|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
214752553|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
214752554|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
214752555|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
214752556|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
214752557|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
214752558|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
214752559|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
214752560|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
214752561|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
214752562|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
214752563|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
214794371|NCT03267264|DEVICE|NovoFine® vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~2. subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
214794372|NCT03267264|DEVICE|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~2. subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
214752564|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
214752565|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
214752566|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
214752567|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
214752568|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
214752569|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
214752570|NCT00138281|BIOLOGICAL|FluMist|
214752571|NCT00138281|BIOLOGICAL|Fluzone|
214752572|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
214752573|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
214752574|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
214752575|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
214752576|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
214752577|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
214752578|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
214752579|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
214752580|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
214752581|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
214752582|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
214752583|NCT06401798|DRUG|placebo gel|Methylcellulose gel was applied topically to the pocket
214752584|NCT06401798|DRUG|CWP gel|Methylcellulose gel combined with CWP was applied topically to the pocket
214752585|NCT06401798|DRUG|NCWP gel|Methylcellulose gel combined with NCWP was applied topically to the pocket
214752586|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
214752587|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
214752588|NCT03025295|DRUG|Saline|It is safe Placebo.
214752589|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
214752590|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
214752591|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
214752592|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
214752593|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
214752594|NCT01813162|DRUG|Tenofovir 1% gel|
214752595|NCT01813162|DRUG|Vaginal product|
214752596|NCT02319265|DRUG|Melatonin|Oral liquid
214752597|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
214752598|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
214752599|NCT03911401|DRUG|1% OPA-15406|Twice daily
214752600|NCT03911401|DRUG|Placebos|Twice daily
214752601|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
214752602|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
214752603|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
214752604|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
214752605|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
214752606|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
214752607|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
214752608|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
214752609|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
214752610|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
214752611|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
214752612|NCT02910895|OTHER|tumor biopsy|biopsy
214752613|NCT00462501|BIOLOGICAL|bevacizumab|
214752614|NCT00462501|DRUG|fluorouracil|
214752615|NCT00462501|DRUG|leucovorin calcium|
214752616|NCT00462501|DRUG|oxaliplatin|
214752617|NCT00462501|PROCEDURE|conventional surgery|
214752618|NCT00462501|RADIATION|radiation therapy|
214752619|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
214752620|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
214752621|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA\_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
214752622|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
214752623|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
214752624|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
214752625|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
214752626|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
214752627|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
214752628|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
214752629|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
214752630|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
214752631|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
214752632|NCT06008015|DRUG|BR1015|One tablet administered alone
214752633|NCT06008015|DRUG|BR1015-1|One tablet administered alone
214752634|NCT06008015|DRUG|BR1015-2|One tablet administered alone
214752635|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
214752636|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
214752637|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
214752638|NCT04433858|DRUG|Psilocybin|open-label
214752639|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
214752640|NCT06513494|BEHAVIORAL|Active Students Education plus Teacher Training|The teacher undergoes 30 hours of self-instructional training on vaccination through an online platform tailored for the relevant age group. Additionally, students receive active vaccinations and health education over two months
214752641|NCT06513494|BEHAVIORAL|Active Students Education|Students receive active vaccinations and health education over two months.
214752642|NCT06513494|BEHAVIORAL|Basic Health Unit Active Orientation|Nurses from basic health units will conduct an active orientation session at schools about vaccination for students.
214752643|NCT06513494|OTHER|Usual care|No project interventions will be carried out.
214752644|NCT06567314|DRUG|Ivonescimab|Given by PO
214752645|NCT05718895|DRUG|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
214752646|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
214752647|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
214752648|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
214752649|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
214752650|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"\- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill\_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
214752651|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
214752652|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
214752653|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
214752654|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
214752655|NCT04825639|OTHER|No intervention|no intervention
214752656|NCT05065840|BEHAVIORAL|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
214752657|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
214752658|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
214752659|NCT06339268|BEHAVIORAL|Cognitive training, CogniFit App|A patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.
214752660|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
214752661|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
214752662|NCT04450173|DRUG|Ibrutinib|Given PO
214752663|NCT04450173|BIOLOGICAL|Obinutuzumab|Given IV
214752664|NCT04450173|DRUG|Venetoclax|Given PO
214752665|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
214752666|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
214752667|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
214752668|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
214752669|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
214752670|NCT05017116|DRUG|RBD1016|subcutaneous injection
214752671|NCT05017116|DRUG|Placebo|subcutaneous injection
214752672|NCT05017116|DRUG|Entecavir|Take orally.
214752673|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
214752674|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
214752675|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
214752676|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
214752677|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
214752678|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
214752679|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
214752680|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
214752681|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
214752682|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
214752683|NCT04190199|OTHER|Observational|Cross-sectional only
214752684|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
214752685|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
214752686|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
214752687|NCT05638594|DRUG|Pyrotinib|320mg, qd
214752688|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
214752689|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
214752690|NCT05638594|DRUG|Letrozole|2.5mg，qd
214752691|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
214752692|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
214752693|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
214752694|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
214752695|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
214752696|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
214752697|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
214752698|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
214752699|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
214752700|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
214752701|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
214752702|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
214752703|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
214752704|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
214752705|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
214752706|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
214752707|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
214752708|NCT01889342|BEHAVIORAL|Metacognitive therapy|
214752709|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
214752710|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
214752711|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
214794373|NCT03267264|DEVICE|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~2. subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
214752712|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
214752713|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
214752714|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
214752715|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
214752716|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
214752717|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
214752718|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
214752719|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
214752720|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
214752721|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
214752722|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
214752723|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
214752724|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
214752725|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
214752726|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
214752727|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
214752728|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
214752729|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
214752730|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
214752731|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
214752732|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
214752733|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
214752734|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
214752735|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
214752736|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
214752737|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
214752738|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
214752739|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
214752740|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
214752741|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
214752742|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
214752743|NCT02672475|DRUG|Galunisertib|Given PO
214752744|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
214752745|NCT02672475|DRUG|Paclitaxel|Given IV
214752746|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
214752747|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
214752748|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
214752749|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
214752750|NCT04419558|DRUG|Placebo|Sterile solution for injection
214752751|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
214752752|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
214752753|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
214752754|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
214752755|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
214752756|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
214752757|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
214752758|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
214752759|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
214752760|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
214752761|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
214752762|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
214752763|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
214752764|NCT00967889|GENETIC|gene expression analysis|
214752765|NCT00967889|GENETIC|protein analysis|
214752766|NCT00967889|OTHER|biologic sample preservation procedure|
214752767|NCT00967889|OTHER|laboratory biomarker analysis|
214752768|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
214752769|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
214752770|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
214752771|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
214752772|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
214752773|NCT00084188|BEHAVIORAL|Behavior Therapy|
214752774|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
214752775|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
214752776|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
214752777|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
214752778|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
214752779|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
214752780|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
214752781|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
214752782|NCT05146999|BIOLOGICAL|Placebo|Placebo
214752783|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
214752784|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
214752785|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
214752786|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
214752787|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
214752788|NCT04668157|DRUG|TAK-536|TAK-536 granule formulation
214752789|NCT04100863|OTHER|No Intervention|There is no intervention for this study.
214752790|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
214752791|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
214752792|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
214752793|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
214752794|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
214752795|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
214752796|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
214752797|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
214752798|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
214752799|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
214752800|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
214752801|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
214752802|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
214752803|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
214794374|NCT02559050|OTHER|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
214752804|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
214752805|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
214752806|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
214752807|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
214752808|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
214752809|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
214752810|NCT05968157|DIAGNOSTIC_TEST|Breast MRI|Supplemental MRI (in addition to standard of care MRI).
214752811|NCT05968157|DEVICE|MIRAI|Artificial intelligence software
214752812|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
214752813|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
214752814|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
214752815|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
214752816|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
214752817|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
214752818|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
214752819|NCT00039936|BEHAVIORAL|Self Help|
214752820|NCT00039936|BEHAVIORAL|Partial Self Help|
214752821|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
214752822|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
214752823|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
214752824|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214752825|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214752826|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
214752827|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
214752828|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
214752829|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
214752830|NCT04873609|BEHAVIORAL|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
214752831|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
214752832|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
214752833|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
214752834|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
214752835|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
214794375|NCT05329636|BIOLOGICAL|Fecal Microbial Transplant (FMT)|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
214752836|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
214752837|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
214752838|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
214752839|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
214752840|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
214752841|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
214752842|NCT04781946|PROCEDURE|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
214752843|NCT04781946|PROCEDURE|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
214752844|NCT04781946|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
214752845|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
214752846|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
214752847|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
214752848|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
214752849|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
214752850|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
214752851|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
214752852|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
214752853|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
214752854|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
214752855|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
214752856|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
214752857|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
214752858|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
214752859|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
214752860|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
214752861|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
214752862|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
214752863|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
214752864|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
214752865|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
214752866|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
214752867|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
214752868|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214752869|NCT02442284|DRUG|Ribavirin|Tablet
214752870|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
214752871|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
214752872|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
214752873|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
214752874|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
214752875|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
214752876|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
214752877|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
214752878|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
214794376|NCT05329636|OTHER|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
214752879|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
214752880|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
214752881|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
214752882|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
214752883|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
214752884|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
214752885|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
214752886|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
214752887|NCT02377258|OTHER|Non Interventional|
214752888|NCT03145584|DRUG|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
214752889|NCT03145584|OTHER|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
214752890|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
214752891|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
214752892|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
214752893|NCT05677373|DRUG|Trametinib|Given PO
214752894|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
214752895|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
214752896|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
214752897|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
214752898|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
214752899|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
214752900|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
214752901|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
214752902|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
214752903|NCT02691845|BEHAVIORAL|BA (brief advice)|
214752904|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
214752905|NCT02691845|BEHAVIORAL|HE (health education)|
214752906|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
214752907|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
214752908|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
214752909|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
214752910|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
214752911|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
214752912|NCT01966406|DEVICE|Nasogastric tube|
214752913|NCT01966406|OTHER|No nasogastric tube|
214752914|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
214752915|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
214752916|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
214752917|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
214752918|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
214752919|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
214752920|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
214752921|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
214752922|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
214752923|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
214752924|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
214752925|NCT00039104|DRUG|rebimastat|Given PO
214752926|NCT00039104|DRUG|zoledronic acid|Given IV
214752927|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
214752928|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
214752929|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
214752930|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
214752931|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
214752932|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
214752933|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
214752934|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
214752935|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
214752936|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
214752937|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
214752938|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
214752939|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
214752940|NCT06376942|OTHER|Saline|0.9% saline 2 ml
214752941|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
214752942|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
214752943|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
214752944|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
214752945|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
214752946|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
214752947|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
214752948|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
214752949|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
214752950|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
214752951|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
214752952|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
214752953|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
214752954|NCT02400281|DRUG|Crenolanib besylate|
214752955|NCT02400281|DRUG|Idarubicin|
214752956|NCT02400281|DRUG|Cytarabine|
214752957|NCT02400281|DRUG|Azacytidine|
214752958|NCT02400281|DRUG|Mitoxantrone|
214752959|NCT02400281|DRUG|Etoposide|
214752960|NCT02400281|DRUG|Fludarabine|
214752961|NCT02400281|DRUG|G-CSF|
214752962|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
214752963|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
214752964|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
214752965|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
214752966|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
214752967|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
214752968|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
214752969|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
214752970|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
214752971|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
214752972|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
214752973|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
214752974|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
214752975|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
214752976|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
214752977|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
214752978|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
214752979|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
214752980|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
214752981|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
214752982|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
214752983|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
214752984|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
214752985|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
214752986|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
214752987|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
214752988|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
214752989|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
214752990|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
214752991|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
214752992|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
214752993|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
214752994|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
214752995|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
214752996|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
214752997|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
214752998|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
214752999|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
214753000|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
214753001|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
214753002|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
214753003|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
214753004|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
214753005|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
214753006|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
214753007|NCT00252798|DRUG|Gefitinib|
214753008|NCT00252798|DRUG|Carboplatin|
214753009|NCT00252798|DRUG|Paclitaxel|
214753010|NCT00252798|PROCEDURE|Radiation|
214753011|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
214753012|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
214753013|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
214753014|NCT03216499|OTHER|Pharmacological Study|Correlative studies
214753015|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
214753016|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
214753017|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
214753018|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
214753019|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
214753020|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
214753021|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
214753022|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
214753023|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
214753024|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
214753025|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
214753026|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
214753027|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
214753028|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
214753029|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
214753030|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
214753031|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
214753032|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
214753033|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
214753034|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
214753035|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
214753036|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
214753037|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
214753038|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
214753039|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
214753040|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
214753041|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
214753042|NCT00208715|DRUG|Provigil|
214753043|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
214753044|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
214753045|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
214753046|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
214753047|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
214753048|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
214753049|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
214753050|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
214753051|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
214753052|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
214753053|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
214753054|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
214753055|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
214753056|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
214753057|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
214753058|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
214753059|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
214753060|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
214753061|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
214753062|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
214753063|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
214753064|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
214753065|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
214753066|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
214753067|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
214753068|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
214753069|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
214753070|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
214753071|NCT02744963|OTHER|Free and convenient medicine access|
214753072|NCT00004024|BIOLOGICAL|aldesleukin|
214753073|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
214753074|NCT00004024|BIOLOGICAL|muromonab-CD3|
214753075|NCT00004024|BIOLOGICAL|sargramostim|
214753076|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
214753077|NCT00004024|PROCEDURE|surgical procedure|
214753078|NCT00004024|RADIATION|radiation therapy|
214753079|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
214753080|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
214753081|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
214753082|NCT00508118|DRUG|Nicardipine|on bypass
214753083|NCT00508118|DRUG|0.9% saline|on bypass
214753084|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
214753085|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
214753086|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
214753087|NCT00553319|DRUG|Placebo|Placebo group
214753088|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
214753089|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
214753090|NCT01078974|DRUG|pomalidomide|Taken orally once a day
214753091|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
214753092|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
214753093|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
214753094|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
214753095|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
214753096|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
214753097|NCT00976521|OTHER|No local infusion|Intervention without local infusion
214753098|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
214753099|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
214753100|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
214753101|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
214753102|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
214753103|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
214753104|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
214753105|NCT02220608|BIOLOGICAL|Bortezomib|
214753106|NCT02220608|DRUG|G-CSF|
214753107|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
214753108|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
214753109|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
214753110|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
214753111|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
214753112|NCT02768428|OTHER|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
214753113|NCT05768360|DRUG|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
214753114|NCT05768360|DRUG|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
214753115|NCT05768360|DRUG|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
214753116|NCT05768360|DRUG|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
214753117|NCT05768360|DRUG|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
214753118|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
214753119|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
214753120|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
214753121|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
214753122|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
214753123|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
214753124|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
214753125|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
214753126|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
214753127|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
214753128|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
214753129|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
214753130|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
214753131|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
214753132|NCT03405324|DEVICE|sham tDCS|sham tDCS
214753133|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
214753134|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
214753135|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
214753136|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
214753137|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
214753138|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
214753139|NCT01791088|DRUG|sirolimus|Given PO
214753140|NCT01791088|OTHER|pharmacological study|Correlative studies
214753141|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
214753142|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
214753143|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
214753144|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
214753145|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
214753146|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
214753147|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
214753148|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
214753149|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
214753150|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
214753151|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
214753152|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
214753153|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
214753154|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
214753155|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
214753156|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
214753157|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
214753158|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
214753159|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214753160|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
214753161|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
214753162|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
214753163|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
214753164|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
214753165|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
214753166|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
214753167|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
214753168|NCT03244280|DRUG|MOB015B|Topical formulation
214753169|NCT03039699|DRUG|Ergoferon|
214753170|NCT03039699|DRUG|Placebo|
214753171|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
214753172|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
214753173|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
214753174|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
214753175|NCT02104232|BEHAVIORAL|THPP-I|
214753176|NCT02104232|BEHAVIORAL|EUC|
214753177|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
214753178|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
214753179|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
214753180|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
214753181|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
214753182|NCT00561262|OTHER|questionnaire administration|
214753183|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
214753184|NCT00561262|PROCEDURE|quality-of-life assessment|
214753185|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
214753186|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
214753187|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
214753188|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
214753189|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
214753190|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
214753191|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
214753192|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
214753193|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
214753194|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
214753195|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
214753196|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
214753197|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
214753198|NCT05614544|DRUG|Placebo|Intralipid
214753199|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
214753200|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
214753201|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
214753202|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
214753203|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
214753204|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
214753205|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
214753206|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
214753207|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
214753208|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
214753209|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
214753210|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
214753211|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
214753212|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
214753213|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
214753214|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
214753215|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
214753216|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
214753217|NCT00887562|OTHER|Placebo|Placebo - No idebenone
214753218|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
214753219|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
214753220|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
214753221|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
214753222|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
214753223|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
214753224|NCT00761761|DRUG|Sensoril|
214753225|NCT00761761|OTHER|Placebo|
214753226|NCT06326203|BIOLOGICAL|CELULAS TRONCO|Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
214753227|NCT06326203|DEVICE|CONVENTIONAL DRESSING|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
214753228|NCT03342911|DRUG|Paclitaxel|Given IV
214753229|NCT03342911|DRUG|Carboplatin|Given IV
214753230|NCT03342911|BIOLOGICAL|Nivolumab|Given IV
214753231|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
214753232|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
214753233|NCT04464746|OTHER|implementation of a specific program to improve therapeutic adherence|"1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
214753234|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
214753235|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
214753236|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
214753237|NCT05866445|DEVICE|Wearable BP device|Wearable study BP device to be worn for 8 hours within study participation.
214753238|NCT05866445|DEVICE|24-hour ambulatory blood pressure monitor|24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
214753239|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
214753240|NCT05755958|DEVICE|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
214753241|NCT05755958|DEVICE|SHAM HIFU procedure|SHAM HIFU procedure
214753242|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
214753243|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
214753244|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
214753245|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
214753246|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
214753247|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
214753248|NCT01982942|DRUG|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
214753249|NCT01982942|DRUG|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
214753250|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
214753251|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
214753252|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
214753253|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
214753254|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
214753255|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
214753256|NCT05178290|BEHAVIORAL|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
214753257|NCT05178290|BEHAVIORAL|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
214753258|NCT05178290|BEHAVIORAL|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
214753259|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
214753260|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
214753261|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
214753262|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
214753263|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
214753264|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
214753265|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
214753266|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
214753267|NCT04969653|OTHER|Exposure of venous thromboembolism|Composite of pulmonary embolism and deep vein thrombosis
214753268|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
214753269|NCT05078658|OTHER|Low-carbohydrate diet|The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
214753270|NCT05078658|OTHER|Recommended-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.
214753271|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
214753272|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
214753273|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
214753274|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
214753275|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
214753276|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
214753277|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
214753278|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
214753279|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
214753280|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
214753281|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
214753282|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
214753283|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
214753284|NCT02918968|DRUG|Enzalutamide|Oral Capsule
214753285|NCT02918968|DRUG|Flutamide|Oral tablet
214753286|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
214753287|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
214753288|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
214753289|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
214753290|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
214753291|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
214753292|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
214753293|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
214753294|NCT01388946|DRUG|Ropivacaine 0.75|
214753295|NCT01388946|DRUG|Normal saline|
214753296|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
214753297|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
214753298|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
214753299|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
214753300|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
214753301|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
214753302|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
214753303|NCT00193076|DRUG|Gemcitabine|Gemcitabine
214753304|NCT00193076|DRUG|Carboplatin|Carboplatin
214753305|NCT00193076|DRUG|Trastuzumab|Trastuzumab
214753306|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
214753307|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
214753308|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214753309|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
214753310|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
214753311|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
214753312|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
214753313|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
214753314|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
214753315|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
214753316|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
214753317|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
214753318|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
214753319|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
214753320|NCT05375942|DRUG|Inflectra|1\. To describe the characteristics of patients newly initiated on Inflectra.
214753321|NCT05375942|DRUG|Inflectra|2\. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
214753322|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
214753323|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
214753324|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
214753325|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
214753326|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
214753327|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
214753328|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
214753329|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
214753330|NCT05867186|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
214753331|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
214753332|NCT03454191|PROCEDURE|No injection|No injection
214753333|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
214753334|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
214753335|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
214753336|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
214753337|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
214753338|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
214753339|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
214753340|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
214753341|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
214753342|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
214753343|NCT03562676|OTHER|weightlessness|parabolic flight
214753344|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
214753345|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
214753346|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
214753347|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
214753348|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
214753349|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
214753350|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
214753351|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
214753352|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
214753353|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
214753354|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
214753355|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
214753356|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
214753357|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
214794377|NCT05329636|BIOLOGICAL|Auto Fecal Microbial Transplant (FMT) via enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
214753358|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
214753359|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
214753360|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
214753361|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
214753362|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
214753363|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
214753364|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
214753365|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
214753366|NCT00998166|DRUG|Cisplatin|4\. Cisplatin 75mg/m2 IV over 60-120 minutes
214753367|NCT00998166|DRUG|Bevacizumab|5\. Bevacizumab 15mg/kg IV over 90 minutes
214753368|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
214753369|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
214753370|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
214753371|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
214753372|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
214753373|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
214753374|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
214753375|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
214753376|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
214753377|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
214753378|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
214753379|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
214753380|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
214753381|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
214753382|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
214753383|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
214753384|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
214753385|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
214753386|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
214753387|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
214753388|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
214753389|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
214753390|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
214753391|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
214753392|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
214753393|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
214753394|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
214753395|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
214753396|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
214753397|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
214753398|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
214753399|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
214753400|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
214753401|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
214753402|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
214753403|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
214753404|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
214753405|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
214753406|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
214753407|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
214753408|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
214753409|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
214753410|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
214753411|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
214753412|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
214753413|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
214753414|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
214753415|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
214753416|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
214753417|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
214753418|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
214753419|NCT05851924|DRUG|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle"
214753420|NCT05851924|COMBINATION_PRODUCT|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
214753421|NCT05212246|DRUG|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
214753422|NCT05212246|DRUG|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
214753423|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
214753424|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
214753425|NCT04626947|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab infusion
214753426|NCT00439920|DRUG|High-dose anthracycline|
214753427|NCT02630615|OTHER|Blood draw|Whole blood will be collected using standard phlebotomy procedures
214753428|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
214753429|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
214753430|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
214794378|NCT05911373|OTHER|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
214794379|NCT05911373|OTHER|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
214794380|NCT00622908|DRUG|ISV-403|0.6% TID, 5 days
214753431|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
214753432|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
214753433|NCT05577689|OTHER|Tissue|Tissue will be derived from patients during a standard of care procedure
214753434|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
214753435|NCT06080308|OTHER|No intervention|No intervention
214753436|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
214753437|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
214753438|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
214753439|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
214753440|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
214753441|NCT02967393|DRUG|ccIIV4|
214753442|NCT02967393|DRUG|IIV4|
214753443|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
214753444|NCT02183948|DRUG|Oxytocin|
214753445|NCT02183948|DRUG|Placebo|
214753446|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
214753447|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
214753448|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
214753449|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
214753450|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
214753451|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
214753452|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
214753453|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
214753454|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
214753455|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
214753456|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
214753457|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
214753458|NCT05489432|BEHAVIORAL|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
214753459|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
214753460|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
214753461|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
214753462|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
214753463|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
214753464|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
214753465|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
214753466|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
214753467|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
214753468|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
214753469|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
214753470|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
214753471|NCT02528149|OTHER|blood sample|
214753472|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
214753473|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
214753474|NCT00483782|BIOLOGICAL|bevacizumab|
214753475|NCT00483782|DRUG|carboplatin|
214753476|NCT00483782|DRUG|paclitaxel|
214753477|NCT00483782|OTHER|questionnaire administration|
214753478|NCT00483782|OTHER|study of socioeconomic and demographic variables|
214753479|NCT00483782|PROCEDURE|quality-of-life assessment|
214753480|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
214753481|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
214753482|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
214753483|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
214753484|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
214753485|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
214753486|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
214753487|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
214753488|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
214753489|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
214753490|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
214753491|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
214753492|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
214753493|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
214753494|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
214753495|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
214753496|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
214753497|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
214753498|NCT00015912|DRUG|thalidomide|Given orally
214753499|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
214753500|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
214753501|NCT01274104|OTHER|Placebo|Placebo
214753502|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
214753503|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
214753504|NCT05869188|DRUG|Isotretinoin|"* Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients ."
214753505|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
214753506|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
214753507|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
214753508|NCT02852876|DRUG|ASP2151|Oral
214753509|NCT02852876|DRUG|Placebo|Oral
214753510|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
214753511|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
214753512|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
214753513|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
214753514|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
214753515|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
214753516|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
214753517|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
214753518|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
214753519|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
214753520|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
214753521|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
214753522|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
214753523|NCT00230711|BEHAVIORAL|Physical activity counseling|
214753524|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
214753525|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
214753526|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
214753527|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
214753528|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
214753529|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
214753530|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
214753531|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
214753532|NCT04648943|PROCEDURE|Trabeculectomy|
214753533|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
214753534|NCT03556202|DRUG|Mirikizumab|Administered SC
214753535|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
214753536|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
214753537|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
214753538|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
214753539|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
214753540|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
214753541|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
214753542|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
214753543|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
214753544|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
214753545|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
214753546|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
214753547|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
214753548|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
214753549|NCT00981565|OTHER|Night-cast|individual night time splinting
214753550|NCT02253849|DRUG|Carbamazepine|
214753551|NCT02253849|DRUG|Tipranavir|
214753552|NCT02253849|DRUG|Ritonavir|
214753553|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
214753554|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
214753555|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
214794381|NCT00622908|DRUG|Vehicle|Vehicle of ISV-403 TID, 5 days
214794382|NCT03937466|DEVICE|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
214753556|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
214753557|NCT06446453|DIAGNOSTIC_TEST|Echography-guided Surfactant THERapy (ESTHER)|Decision to administer surfactant therapy using a semi-quantitative lung ultrasound score.
214753558|NCT05156749|DEVICE|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
214753559|NCT05156749|DEVICE|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
214753560|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
214753561|NCT06094075|OTHER|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
214753562|NCT06094075|OTHER|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
214753563|NCT03158532|DRUG|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
214753564|NCT03158532|DRUG|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
214753565|NCT03158532|DRUG|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
214753566|NCT03158532|DRUG|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
214753567|NCT04885036|BEHAVIORAL|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
214794383|NCT00421096|DRUG|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
214794384|NCT00421096|PROCEDURE|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
214794385|NCT00421096|DRUG|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
214794386|NCT03658135|DRUG|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
214794387|NCT03658135|OTHER|Placebo|Inactive ingredient
214753568|NCT04885036|BEHAVIORAL|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
214753569|NCT04479358|DRUG|Tocilizumab|Tocilizumab 40mg
214753570|NCT04479358|DRUG|Tocilizumab|Tocilizumab 120mg
214753571|NCT04479358|OTHER|Standard of Care|Tocilizumab-Free Standard of Care
214753572|NCT04479358|OTHER|Standard of Care|Tocilizumab 400mg or 8mg/kg
214753573|NCT06279000|DRUG|Colchicine|"Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion."
214753574|NCT06279000|DRUG|Placebo|"Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion."
214753575|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
214753576|NCT06068790|DEVICE|28 French sized rigid sheath|The 28Fr is the standard of care sheath size used at this site.
214753577|NCT06068790|DEVICE|22 French sized rigid sheath|The 22Fr is the smaller, investigational sheath size to be used in this study.
214753578|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
214753579|NCT03260322|DRUG|ASP8374|intravenous
214753580|NCT03260322|DRUG|Pembrolizumab|intravenous
214753581|NCT06363461|DRUG|TDM-180935 topical ointment 1.0%|TDM-180935 topical ointment 1.0%
214753582|NCT06363461|DRUG|TDM-180935 topical ointment 2.0%|TDM-180935 topical ointment 2.0%
214753583|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 1|TDM-180935 topical vehicle ointment 1
214753584|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 2|TDM-180935 topical vehicle ointment 2
214753585|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
214753586|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
214753587|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
214753588|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
214753589|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
214753590|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
214753591|NCT00764465|DRUG|Maraviroc|300 mg BID
214753592|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
214753593|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
214753594|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
214753595|NCT06047886|DRUG|Infusion of CD34 selected hematopoietic stem cells|CD34 stem cell isolation and infusion to reduce alloreactive complication of stem cell infusion
214753596|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
214753597|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
214753598|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
214753599|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
214753600|NCT00674440|RADIATION|PET scan|
214753601|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
214753602|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
214753603|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
214753604|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
214753605|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
214753606|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
214753607|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
214753608|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
214753609|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
214753610|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
214753611|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
214753612|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
214753613|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
214753614|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
214753615|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
214753616|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
214753617|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
214753618|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
214753619|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
214753620|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
214753621|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
214753622|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
214753623|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
214753624|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
214753625|NCT02043002|PROCEDURE|18F-FDG-PET scan|
214753626|NCT00281931|BIOLOGICAL|rituximab|
214753627|NCT00281931|DRUG|cyclophosphamide|
214753628|NCT00281931|DRUG|fludarabine phosphate|
214753629|NCT00212082|DRUG|doxorubicin, docetaxel|
214753630|NCT03332225|DRUG|Anakinra|Treatment with anakinra
214753631|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
214753632|NCT03332225|DRUG|Placebo|Treatment with Placebo
214753633|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
214753634|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
214753635|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
214753636|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
214753637|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
214753638|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
214753639|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
214753640|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
214753641|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
214753642|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
214753643|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
214753644|NCT05733208|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
214753645|NCT05733208|PROCEDURE|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
214753646|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
214753647|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
214753648|NCT06260995|OTHER|Social Prescribing Link Worker Intermediary Intervention|Social prescribing link workers \[SPLW\] receive referrals from healthcare professionals, community services, or through self-referral. Individuals are referred for social isolation or social needs, frequent healthcare attendance, or to address a pre-existing health issue. SPLW carry out an in-depth assessment of the individual's needs, and then work with the individual over weeks and months to connect them to community services and supports, which can include local physical activities. They use several strategies during this follow-up period, such as instrumental support (doing things for the individual), empowerment and motivation techniques and/or attending activities with the individual. After the SPLW establishes a connection to a local physical activity, the individual enrols and participates in the chosen activity. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi.
214753649|NCT06260995|OTHER|Local Sports Partnership Community Development Officer Intervention|Local sports partnership community development officers \[LSPO\] mainly receive self-referrals, or can receive referrals, to improve physical activity levels of individuals through participation in physical activity groups delivered by the partnership. LSPO do not carry out an in-depth assessment but may carry out screening before explaining/signposting to local physical activities. They use several strategies to connect the individual to local physical activities, such as attending the first session of the group, providing reassurance and practical support, and keeping the person updated and informed as to upcoming groups. After the LSPO establishes a connection to a local physical activity, the individual enrols and participated in the chosen activity. The LSPO continues to support this engagement during the follow-up period. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi amongst others.
214753650|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
214753651|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
214753652|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
214753653|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
214753654|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
214753655|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
214753656|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
214753657|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
214753658|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
214753659|NCT05466994|OTHER|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
214753660|NCT05466994|OTHER|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
214753661|NCT03894111|OTHER|decesased patients|mortality ratio
214753662|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
214753663|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
214753664|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
214753665|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
214753666|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
214753667|NCT04095039|PROCEDURE|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
214753668|NCT05596409|DRUG|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
214753669|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
214753670|NCT05718323|DRUG|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
214753671|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
214753672|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
214753673|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
214753674|NCT06165471|BEHAVIORAL|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
214753675|NCT06165471|BEHAVIORAL|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
214753676|NCT05206305|DEVICE|GammaSense Stimulation device|Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
214753677|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
214753678|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
214753679|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
214753680|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
214753681|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
214753682|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
214753683|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
214753684|NCT06427577|DRUG|ZhenQi FuZheng granules (ShiDaiYangGuang)|1 bag at a time, twice a day. Oral orally for 4 weeks.
214753685|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
214753686|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
214753687|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
214753688|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
214753689|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
214753690|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
214753691|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
214753692|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
214753693|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
214753694|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
214753695|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
214753696|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
214753697|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
214753698|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
214753699|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
214753700|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
214753701|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
214753702|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
214753703|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
214753704|NCT01467531|DRUG|Dolutegravir|50mg q 24h
214753705|NCT01467531|DRUG|Rlipivirine|25mg q24h
214753706|NCT01467531|DRUG|GSK1265744|30mg q24h
214753707|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
214753708|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
214753709|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
214753710|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
214753711|NCT03205605|DRUG|oxybutynin|patch
214753712|NCT03205605|DRUG|oxybutynin|gel
214753713|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
214753714|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
214753715|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
214753716|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
214753717|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
214753718|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
214753719|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
214753720|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
214753721|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
214753722|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
214753723|NCT00002625|DRUG|topotecan hydrochloride|
214753724|NCT00002625|RADIATION|low-LET electron therapy|
214753725|NCT00002625|RADIATION|low-LET photon therapy|
214794388|NCT05528458|DRUG|Osimertinib 80Mg Tab|Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
214753726|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
214753727|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
214753728|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
214753729|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
214753730|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
214753731|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
214753732|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
214753733|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
214753734|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
214753735|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
214753736|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
214753737|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
214753738|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
214753739|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
214753740|NCT00324519|DEVICE|Foley bulb|
214753741|NCT00324519|DRUG|misoprostol|
214753742|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
214753743|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
214753744|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
214753745|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
214753746|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
214753747|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
214753748|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
214753749|NCT00160147|DRUG|Placebo|Placebo
214753750|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
214753751|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
214753752|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
214753753|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
214753754|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
214753755|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
214753756|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
214753757|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
214753758|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
214753759|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
214753760|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
214753761|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
214753762|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
214753763|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
214753764|NCT00945815|BIOLOGICAL|epratuzumab|
214753765|NCT00945815|DRUG|clofarabine|
214753766|NCT00945815|DRUG|cytarabine|
214753767|NCT00945815|OTHER|laboratory biomarker analysis|
214753768|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
214753769|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
214753770|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
214753771|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
214753772|NCT01061073|DRUG|Omexel|
214753773|NCT01061073|DRUG|spasfon|
214753774|NCT00032058|PROCEDURE|magnetic resonance imaging|
214753775|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
214753776|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
214753777|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
214753778|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
214753779|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
214753780|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
214753781|NCT04227665|OTHER|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
214753782|NCT04227665|OTHER|Altitude|Altitude exposure / altitude exposure Iron metabolism
214753783|NCT02576106|DEVICE|Cryoablation|
214753784|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
214753785|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
214753786|NCT06679920|DEVICE|Optical coherence tomography|Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
214753787|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
214753788|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
214753789|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
214753790|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
214753791|NCT01038609|DRUG|Acetaminophen|
214753792|NCT01038609|DRUG|Morphine Extended Release|
214753793|NCT01038609|DRUG|Placebo|
214753794|NCT01728194|DRUG|Escitalopram|20 mg target dose for 12 weeks
214753795|NCT01728194|OTHER|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
214753796|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
214753797|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
214753798|NCT04493229|DRUG|Oxytocin|IM Oxytocin
214753799|NCT04493229|DRUG|Placebo|Placebo IM
214753800|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
214753801|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
214753802|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
214753803|NCT02357524|DRUG|Oritavancin|
214753804|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
214753805|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
214753806|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
214753807|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
214753808|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
214753809|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
214753810|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
214753811|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
214753812|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
214753813|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
214753814|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
214753815|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
214753816|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
214753817|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
214753818|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
214753819|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
214753820|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
214753821|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
214753822|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
214753823|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
214753824|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
214753825|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
214753826|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
214753827|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
214753828|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
214753829|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
214753830|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
214753831|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
214753832|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
214753833|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
214753834|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
214753835|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
214753836|NCT00114257|DRUG|decitabine|
214753837|NCT00114257|DRUG|romidepsin|
214753838|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
214753839|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
214753840|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
214753841|NCT00459680|DEVICE|Laser acupoint treatment|Laser
214753842|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
214753843|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
214753844|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
214753845|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
214753846|NCT04421105|DRUG|Placebo|
214753847|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
214753848|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
214753849|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
214753850|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
214753851|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
214753852|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
214753853|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
214753854|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
214753855|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
214753856|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
214753857|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
214753858|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
214753859|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
214753860|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
214753861|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
214753862|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
214753863|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
214753864|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
214753865|NCT06083428|DRUG|Control Test|Only spinal anesthesia
214753866|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
214753867|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
214753868|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
214753869|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
214753870|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
214753871|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
214753872|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
214753873|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
214753874|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
214753875|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
214753876|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
214753877|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
214753878|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
214753879|NCT01979003|DRUG|Fluorescein|
214753880|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
214753881|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
214753882|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
214753883|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
214753884|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
214753885|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
214753886|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
214753887|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
214753888|NCT01183299|OTHER|Dietary salt intake|
214753889|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
214753890|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
214753891|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
214753892|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
214753893|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
214753894|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
214753895|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
214753896|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
214753897|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
214753898|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
214753899|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
214753900|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
214753901|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
214753902|NCT00208702|DRUG|Triiodothyronine|
214753903|NCT00208702|OTHER|Placebo|
214753904|NCT00208702|DRUG|Sertraline|
214753905|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
214753906|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
214753907|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
214753908|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
214753909|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
214753910|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
214753911|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
214753912|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
214753913|NCT01884142|OTHER|Aerobic Exercise Training|
214753914|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
214753915|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
214753916|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
214753917|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
214753918|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
214753919|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
214753920|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
214753921|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
214753922|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
214753923|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
214753924|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
214753925|NCT02651038|DRUG|Micafungin|Measurement of PK
214753926|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
214753927|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
214753928|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
214753929|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
214753930|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
214753931|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
214753932|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
214753933|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
214753934|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
214753935|NCT00016068|DRUG|ganciclovir|
214753936|NCT00016068|DRUG|valganciclovir|
214753937|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
214753938|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
214753939|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
214753940|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
214753941|NCT02183220|DRUG|Metamizol|
214753942|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
214753943|NCT02183220|DRUG|Metamizol placebo|
214753944|NCT02183220|DRUG|ASA placebo|
214753945|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
214753946|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
214753947|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
214753948|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
214753949|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
214753950|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
214753951|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
214753952|NCT02033486|DEVICE|TOBI + DBT|
214753953|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
214753954|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
214753955|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
214753956|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
214753957|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
214753958|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
214753959|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
214753960|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
214753961|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
214753962|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
214753963|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
214753964|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
214753965|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
214753966|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
214753967|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
214753968|NCT00166595|DRUG|Risperidone|
214753969|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
214753970|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
214753971|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
214753972|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
214753973|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
214753974|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
214753975|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
214753976|NCT04824118|DIAGNOSTIC_TEST|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
214753977|NCT04824118|DIAGNOSTIC_TEST|Clotting Studies|"Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen"
214753978|NCT04824118|DIAGNOSTIC_TEST|Full Blood Count|For platelet count
214753979|NCT04824118|DIAGNOSTIC_TEST|Quantitative hCG|Serum human chorionic gonadotrophin
214753980|NCT04824118|DIAGNOSTIC_TEST|Pregnancy Test|Point of care urinary pregnancy test
214753981|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
214753982|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
214753983|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
214753984|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
214753985|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
214753986|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
214753987|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
214753988|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
214753989|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
214753990|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
214753991|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
214753992|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
214753993|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
214753994|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
214753995|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
214753996|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
214753997|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
214753998|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
214753999|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
214754000|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
214754001|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
214754002|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
214754003|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
214754004|NCT02911285|DRUG|Placebo|Placebo pills bid
214754005|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
214754006|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
214754007|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
214754008|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
214754009|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
214754010|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
214754011|NCT01207427|DRUG|Placebo|
214754012|NCT01207427|DRUG|ADL5945 0.1 mg|
214754013|NCT01207427|DRUG|ADL5945 0.25 mg|
214754014|NCT01732380|DRUG|Raltitrexed|
214754015|NCT01732380|DRUG|Oxaliplatin|
214754016|NCT01732380|RADIATION|Radiotherapy|
214754017|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
214754018|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
214754019|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
214754020|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
214754021|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
214754022|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
214754023|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
214754024|NCT02986321|DRUG|Budesonide|active control
214754025|NCT02986321|DRUG|Placebo|placebo control
214754026|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
214754027|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
214754028|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
214754029|NCT06722391|OTHER|Resistance Training|Group will receive exercise training.
214754030|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
214754031|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
214754032|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
214754033|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
214754034|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
214754035|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
214754036|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
214754037|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
214754038|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
214754039|NCT02723539|DRUG|MBN-101|Topical application
214754040|NCT02723539|DRUG|Placebo|Topical application
214754041|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
214754042|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
214754043|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
214754044|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
214754045|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
214754046|NCT06526104|DRUG|Tremelimumab|Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
214754047|NCT06526104|DRUG|Durvalumab|Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
214754048|NCT04374461|DRUG|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
214754049|NCT04374461|OTHER|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
214754050|NCT01716221|DRUG|bupropion & Citalopram|
214754051|NCT01716221|DRUG|Bupropion & Placebo|
214754052|NCT01716221|DRUG|Placebo & Citalopram|
214754053|NCT01716221|DRUG|Placebo & Placebo|
214754054|NCT02875743|DRUG|Posaconazole|
214754055|NCT02046551|DRUG|Atomoxetine|
214754056|NCT02046551|DRUG|Placebo|
214754057|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
214754058|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
214754059|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
214754060|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
214754061|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
214754062|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
214754063|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
214754064|NCT00957827|DRUG|placebo|placebo BID for five days
214754065|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
214754066|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
214754067|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
214754068|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
214754069|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
214754070|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
214754071|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
214754072|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
214754073|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
214754074|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
214754075|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
214754076|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
214754077|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
214754078|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
214754079|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
214754080|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
214754081|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
214754082|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
214754083|NCT05965089|BIOLOGICAL|Placebo|Placebo
214754084|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
214754085|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
214754086|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
214754087|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
214754088|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
214754089|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
214754090|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
214754091|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
214754092|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
214754093|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
214754094|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
214754095|NCT06400420|OTHER|Exercise|classic futsal training program
214754096|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
214754097|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
214754098|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
214754099|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
214754100|NCT03085940|DRUG|Placebo|Placebo
214754101|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
214754102|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
214754103|NCT00381602|OTHER|Placebo|
214754104|NCT03742895|DRUG|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
214754105|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
214754106|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
214754107|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
214754108|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
214754109|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
214754110|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
214754111|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
214754112|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
214754113|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
214754114|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
214754115|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
214754116|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
214754117|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
214754118|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
214754119|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
214754120|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
214754121|NCT05957367|DRUG|Inlexisertib|Oral Tablet Formulation
214754122|NCT05957367|DRUG|Ripretinib|Oral Tablet Formulation
214754123|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
214754124|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
214754125|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
214754126|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
214754127|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
214754128|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
214754129|NCT02279082|DRUG|DFN-02|Active Experimental Drug
214754130|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
214754131|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
214754132|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
214754133|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
214754134|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
214754135|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
214754136|NCT00280839|DRUG|Topiramate|
214754137|NCT00280839|DRUG|Placebo|
214754138|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
214754139|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
214754140|NCT01411124|DRUG|placebo|placebo
214754141|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
214754142|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
214754143|NCT00116610|DRUG|picoplatin|
214754144|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
214754145|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
214754146|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
214754147|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
214754148|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
214754149|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
214754150|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
214754151|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
214754152|NCT00333437|DRUG|Mycophenolate mofetil|
214754153|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
214754154|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
214754155|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
214754156|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
214754157|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
214754158|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
214754159|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
214754160|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
214754161|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
214754162|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
214754163|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
214754164|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
214754165|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
214754166|NCT03022526|PROCEDURE|CSE|
214754167|NCT03022526|PROCEDURE|Epidural|
214754168|NCT03022526|DRUG|Bupivacaine / fentaNYL|
214754169|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
214754170|NCT03734874|OTHER|control|no supplementation
214754171|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
214754172|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
214754173|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
214754174|NCT05018533|DRUG|TAKC-02|Inhalation Solution
214754175|NCT05018533|DRUG|Placebo|Inhalation Solution
214754176|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
214754177|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
214754178|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
214754179|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
214754180|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
214754181|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
214754182|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
214754183|NCT00403962|DRUG|vestipitant/paroxetine|
214754184|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
214754185|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
214754186|NCT00482976|DRUG|Ruboxistaurin|
214754187|NCT00482976|DRUG|Placebo|
214754188|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
214754189|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
214754190|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
214754191|NCT00103389|DRUG|PI-88|PI-88+docetaxel
214754192|NCT00103389|DRUG|docetaxel|docetaxel only
214754193|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
214754194|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
214754195|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
214754196|NCT00542165|DRUG|Alfuzosin|
214754197|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
214754198|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
214754199|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
214754200|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
214754201|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
214754202|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
214754203|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
214754204|NCT02027831|DRUG|Indocyanine Green|
214794389|NCT06152913|BEHAVIORAL|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
214754205|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
214754206|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
214754207|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
214754208|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
214754209|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
214754210|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
214754211|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
214754212|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
214754213|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
214754214|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
214754215|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
214754216|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
214754217|NCT00274573|DRUG|Tiotropium bromide|
214754218|NCT02250157|DRUG|Oratecan|
214754219|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
214754220|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
214754221|NCT01097759|PROCEDURE|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
214754222|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
214754223|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
214754224|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
214754225|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
214754226|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
214754227|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
214754228|NCT00798161|DRUG|matching placebo|matching placebo
214754229|NCT03334942|BEHAVIORAL|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
214754230|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
214754231|NCT02989259|DRUG|Apatinib|apatinib 500mg p.o. qd
214754232|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
214754233|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
214754234|NCT06501625|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
214754235|NCT06501625|DRUG|Durvalumab (for the first 8, 21-day, cycles)|1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
214754236|NCT06501625|DRUG|Gemcitabine (for the first 8, 21-day, cycles)|1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
214754237|NCT06501625|DRUG|Cisplatin (for the first 8, 21-day, cycles)|25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
214754238|NCT06501625|DRUG|Durvalumab (starting from cycle 9)|1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
214754239|NCT06501625|DRUG|Ivosidenib Recommended Combination Dose (RCD)|RCD administered orally once daily, taken continuously throughout treatment duration
214754240|NCT03160131|DEVICE|Neuro Vision Technology|Training using Neuro Vision Technology
214754241|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
214754242|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
214754243|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
214754244|NCT06135493|DRUG|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
214754245|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
214754246|NCT04450420|OTHER|Standard training|See arm/group description
214754247|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
214754248|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
214754249|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
214754250|NCT04123743|OTHER|Placebo|Placebo topical cream
214754251|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
214754252|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
214754253|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
214754254|NCT01390376|DRUG|placebo|starch pill
214754255|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
214754256|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
214754257|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
214754258|NCT03373422|DRUG|Placebo|Matching placebo tablets
214754259|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
214754260|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
214754261|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
214754262|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
214754263|NCT02434666|DRUG|CPC-201|
214754264|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
214754265|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
214754266|NCT00006292|DRUG|Infliximab|
214754267|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
214754268|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
214754269|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
214754270|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
214754271|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
214754272|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
214754273|NCT04985916|BIOLOGICAL|Vehicle|topical liniment without investigational product
214754274|NCT04985916|BIOLOGICAL|botulinum toxin, Type A|ET-01 topical liniment
214754275|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
214754276|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
214754277|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
214754278|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
214754279|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
214754280|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
214754281|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
214754282|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
214754283|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
214754284|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
214754285|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
214754286|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
214754287|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
214754288|NCT00266617|DRUG|epoetin alfa|
214754289|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
214754290|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
214754291|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
214754292|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
214754293|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
214754294|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
214754295|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
214754296|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
214754297|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
214754298|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
214754299|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
214754300|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
214754301|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754302|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
214754303|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754304|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
214754305|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754306|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
214754307|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754308|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
214754309|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754310|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
214754311|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
214754312|NCT00295256|BEHAVIORAL|nurse case manager|
214754313|NCT03417245|DRUG|fitusiran|by SC injection
214754314|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
214794390|NCT00113490|BIOLOGICAL|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
214794391|NCT00113490|BIOLOGICAL|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
214794392|NCT04837053|OTHER|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
214754315|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
214754316|NCT04491955|BIOLOGICAL|CV301|CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
214754317|NCT04491955|DRUG|MSB0011359C|"Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
214754318|NCT04491955|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
214754319|NCT04491955|DRUG|NHS-IL12|NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
214754320|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
214754321|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
214754322|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
214754323|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
214754324|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
214754325|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
214754326|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
214754327|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
214754328|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
214754329|NCT02708524|DEVICE|Senofilcon C Contact Lens|
214754330|NCT02708524|DEVICE|Comfilcon A Contact Lens|
214754331|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
214754332|NCT02708524|DEVICE|Samfilcon A Contact Lens|
214754333|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
214754334|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
214754335|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
214754336|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
214754337|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
214754338|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
214754339|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
214754340|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
214754341|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
214794393|NCT04837053|OTHER|Routine care|Care as usual within the included study sites.
214754342|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
214754343|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
214754344|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
214754345|NCT06162611|DRUG|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
214754346|NCT06162611|DEVICE|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
214754347|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
214754348|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
214754349|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
214754350|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
214754351|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
214754352|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
214754353|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
214754354|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
214754355|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
214754356|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
214754357|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
214754358|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
214754359|NCT00016211|RADIATION|radiation therapy|
214754360|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
214754361|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
214754362|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
214754363|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
214754364|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
214754365|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
214754366|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
214754367|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
214754368|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
214754369|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
214754370|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
214754371|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
214754372|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
214754373|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
214754374|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
214754375|NCT01256866|DRUG|Dexmedetomidine|
214754376|NCT01256866|DRUG|Midazolam|
214754377|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
214754378|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
214754379|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
214754380|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
214754381|NCT00139269|DRUG|Docetaxel|
214754382|NCT00139269|DRUG|Cisplatin|
214754383|NCT00139269|DRUG|5-Fluorouracil|
214754384|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
214754385|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
214754386|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
214754387|NCT00161148|DRUG|Probiotics|
214754388|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
214754389|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
214754390|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
214754391|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
214754392|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
214754393|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
214754394|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
214754395|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
214754396|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
214754397|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
214754398|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
214754399|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
214754400|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
214754401|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
214754402|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
214754403|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
214754404|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
214754405|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
214754406|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
214754407|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
214754408|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
214754409|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
214754410|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
214754411|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
214754412|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
214754413|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
214754414|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
214754415|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
214754416|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
214754417|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
214754418|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
214754419|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
214754420|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
214754421|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
214754422|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
214754423|NCT02900508|OTHER|Exergaming training|
214754424|NCT02900508|OTHER|Physical therapy intervention|
214754425|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
214754426|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
214754427|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
214754428|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
214754429|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
214754430|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
214754431|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
214754432|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
214754433|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
214754434|NCT03290131|DRUG|Placebo|Placebo comparator
214754435|NCT00381680|DRUG|vincristine sulfate|Given IV
214754436|NCT00381680|DRUG|prednisone|Given PO
214754437|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
214754438|NCT00381680|DRUG|pegaspargase|Given IM
214754439|NCT00381680|DRUG|cytarabine|Given IT or IV
214754440|NCT00381680|DRUG|methotrexate|Given IT or IV
214754441|NCT00381680|DRUG|dexamethasone|Given PO
214754442|NCT00381680|DRUG|etoposide|Given IV
214754443|NCT00381680|DRUG|cyclophosphamide|Given IV
214754444|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
214754445|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
214754446|NCT00381680|DRUG|asparaginase|Given IM
214754447|NCT00381680|DRUG|mercaptopurine|Given PO
214754448|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
214754449|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
214754450|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
214754451|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
214754452|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
214754453|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
214754454|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
214754455|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
214754456|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
214754457|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
214754458|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
214754459|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
214754460|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
214754461|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
214754462|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
214754463|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
214754464|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
214754465|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
214754466|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
214754467|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
214754468|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
214754469|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
214754470|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
214754471|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
214754472|NCT04211454|OTHER|No intervention|There is no intervention for this study.
214754473|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
214754474|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
214754475|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
214754476|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
214754477|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
214754478|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
214754479|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
214754480|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
214754481|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
214754482|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
214754483|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
214754484|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
214754485|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
214754486|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
214754487|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
214754488|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
214754489|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
214754490|NCT00359866|RADIATION|IMRT with tomotherapy|
214754491|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
214754492|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
214754493|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
214754494|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
214754495|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
214754496|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
214754497|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
214754498|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
214754499|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
214754500|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
214754501|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
214754502|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
214754503|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
214754504|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
214754505|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
214754506|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
214754507|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
214754508|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
214754509|NCT02419443|DRUG|Placebo|Control group
214754510|NCT00734318|DRUG|Flutiform 250/10 micrograms|
214754511|NCT00734318|DRUG|Flutiform 50/5 micrograms|
214754512|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
214754513|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
214754514|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
214754515|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
214754516|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214754517|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
214754518|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
214754519|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
214754520|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
214754521|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214754522|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214754523|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214754524|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
214754525|NCT06129851|DRUG|Relugolix|Given PO
214754526|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
214754527|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
214754528|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
214754529|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
214754530|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
214754531|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
214754532|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
214754533|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
214754534|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
214754535|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
214754536|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
214754537|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
214754538|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
214754539|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
214754540|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
214754541|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
214754542|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
214754543|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
214754544|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
214754545|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
214754546|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
214754547|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
214754548|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
214754549|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
214754550|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
214754551|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
214754552|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
214754553|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
214754554|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
214754555|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
214754556|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
214754557|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO\_QOL.
214754558|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
214754559|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
214754560|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
214754561|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
214754562|NCT02780180|DRUG|QGC001|
214754563|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
214754564|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
214754565|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
214754566|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
214754567|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
214754568|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
214754569|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
214754570|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
214754571|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
214754572|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
214754573|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
214754574|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
214754575|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
214754576|NCT00683462|DRUG|Placebo|
214754577|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
214754578|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
214754579|NCT02190604|DRUG|Placebo|Capsule- oral dose
214754580|NCT02190604|DRUG|QBW251|Capsule - oral dose
214754581|NCT02888782|OTHER|Pharmacist Consultation|
214754582|NCT02797951|DRUG|Galcanezumab|Administered SC
214754583|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
214754584|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
214754585|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
214754586|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
214754587|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
214754588|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
214754589|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
214754590|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
214754591|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
214754592|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
214754593|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
214754594|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
214754595|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
214754596|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
214754597|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
214754598|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
214754599|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
214754600|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
214754601|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
214754602|NCT05113277|BEHAVIORAL|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
214754603|NCT05113277|BEHAVIORAL|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
214754604|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
214754605|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
214754606|NCT01652482|DRUG|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
214754607|NCT01652482|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
214754608|NCT01652482|DRUG|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
214754609|NCT01652482|DRUG|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
214754610|NCT01652482|DRUG|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
214754611|NCT05986955|OTHER|Diet|Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
214754612|NCT05288400|COMBINATION_PRODUCT|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
214754613|NCT05288400|DRUG|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
214754614|NCT05288400|DRUG|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
214754615|NCT05288400|DRUG|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
214754616|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
214754617|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
214754618|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
214754619|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
214754620|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
214754621|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
214754622|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
214754623|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
214754624|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
214754625|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
214754626|NCT05707494|DEVICE|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
214754627|NCT04148378|OTHER|No intervention|There is no intervention for this study.
214754628|NCT06484387|BEHAVIORAL|Social interaction|Participants are required to speak to one another. Participants are given various topics of conversation.
214754629|NCT06133348|BEHAVIORAL|Promoting Resilience in Stress Management Intervention|"PRISM is a manualized, brief, skills-based intervention targeting four resilience resources; PRISM is delivered by trained intervention staff (called coaches within the PRISM program). Session 1, Stress-Management. Session 2, Goal setting. Session 3, Cognitive Restructuring. Session 4, Meaning-Making. Session 5 (optional), Coming Together. Session 6 (optional) involved advance care planning to discuss."
214754630|NCT03800121|BIOLOGICAL|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
214754631|NCT05419765|DIAGNOSTIC_TEST|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
214754632|NCT01952821|OTHER|Six-Minute Walk Test|
214754633|NCT01952821|OTHER|10-Meter Walk Test|
214754634|NCT01952821|OTHER|30-Second Chair Stand|
214754635|NCT01952821|OTHER|Linear Analog Scale of Function|
214754636|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
214754637|NCT01952821|OTHER|FACIT-Fatigue|
214754638|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
214754639|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
214754640|NCT03729752|DRUG|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
214754641|NCT03643224|DEVICE|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
214754642|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
214754643|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
214754644|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
214754645|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
214754646|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
214754647|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
214754648|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
214754649|NCT05644080|RADIATION|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
214754650|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
214754651|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
214754652|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
214754653|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
214754654|NCT05588193|BEHAVIORAL|PVO|post-visit outreach
214754655|NCT05588193|BEHAVIORAL|TSH|tele-sexual health visit during the ED visit
214754656|NCT05690230|OTHER|Virtual reality|Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.
214754657|NCT05690230|OTHER|Environmental changes|A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
214754658|NCT06961916|DEVICE|Active rTMS|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
214754659|NCT06961916|BEHAVIORAL|Cognitive Training|For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes.
214754660|NCT04792528|OTHER|Computerized cognitive training.|COGMED RM program (Pearson Inc., UK)
214754661|NCT04792528|OTHER|Generalized brain training / Active control|Solitaire
214754662|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
214754663|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
214754664|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
214754665|NCT03164304|DRUG|Magnesium Sulfate|intravenous
214754666|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
214754667|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
214754668|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
214754669|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
214754670|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
214754671|NCT02369874|DRUG|Standard of Care|Standard of Care
214754672|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
214754673|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
214754674|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
214754675|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
214754676|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
214754677|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
214754678|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
214754679|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
214754680|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
214754681|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
214754682|NCT03374059|OTHER|Exercise program|
214754683|NCT03374059|OTHER|Life modification|
214754684|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
214754685|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
214754686|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
214754687|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
214754688|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
214754689|NCT02487524|OTHER|QST|Quantitative sensory testing.
214754690|NCT01379911|OTHER|Yogurt|
214754691|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
214754692|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
214754693|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
214754694|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
214754695|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
214754696|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
214754697|NCT00241566|DEVICE|implantation of stimulator|
214754698|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
214754699|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
214754700|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
214754701|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
214754702|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
214754703|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
214754704|NCT04503655|OTHER|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
214754705|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
214754706|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
214754707|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
214754708|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
214754709|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
214754710|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
214754711|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
214754712|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
214754713|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
214754714|NCT02219477|DRUG|dasabuvir|tablet
214754715|NCT02219477|DRUG|ribavirin|tablet
214754716|NCT05674461|OTHER|WhatsApp Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
214754717|NCT05674461|OTHER|Face-to-face Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
214754718|NCT05674461|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
214754719|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
214754720|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
214754721|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
214754722|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
214754723|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
214754724|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
214754725|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
214754726|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
214754727|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
214754728|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
214754729|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
214754730|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
214754731|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
214754732|NCT00883402|PROCEDURE|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
214754733|NCT00283517|DRUG|antipsychotics|as prescribed
214754734|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
214754735|NCT04338685|DRUG|RO7119929|RO7119929 will be administered orally as a capsule
214754736|NCT04338685|DRUG|Tocilizumab|"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV"
214754737|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
214754738|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
214754739|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
214754740|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
214754741|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
214754742|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
214754743|NCT00010634|DRUG|Adaptogenic herbs|
214754744|NCT00010634|DRUG|glutamine|
214754745|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
214754746|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
214754747|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
214754748|NCT00272194|DEVICE|Ambu Laryngeal Mask|
214754749|NCT00272194|DEVICE|Aintree Exchange Catheter|
214754750|NCT00272194|DEVICE|Laryngeal Mask Airway|
214754751|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
214754752|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
214754753|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
214754754|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
214754755|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
214754756|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
214754757|NCT05921851|OTHER|no intervention|no intervention
214754758|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
214754759|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
214754760|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
214754761|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
214754762|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
214754763|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
214754764|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
214754765|NCT00473187|DRUG|somatropin|
214754766|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
214754767|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
214754768|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
214754769|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
214754770|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
214754771|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
214754772|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
214754773|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
214754774|NCT01695707|DRUG|Pioglitazone|see Arm Description
214754775|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
214754776|NCT05705544|DEVICE|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
214754777|NCT05705544|DEVICE|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
214754778|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
214754779|NCT05346887|BEHAVIORAL|Home-based Therapy|The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
214754780|NCT06074341|BEHAVIORAL|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
214754781|NCT06074341|BEHAVIORAL|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
214754782|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
214754783|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
214754784|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
214754785|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
214754786|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
214754787|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
214754788|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
214754789|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
214754790|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
214754791|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
214754792|NCT03335228|DEVICE|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
214754793|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
214754794|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
214754795|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
214754796|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
214754797|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
214754798|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
214754799|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
214754800|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
214754801|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
214754802|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
214754803|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
214754804|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
214754805|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
214754806|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
214754807|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
214754808|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
214754809|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
214754810|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
214754811|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
214754812|NCT06326164|PROCEDURE|kinesio-taping.|A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
214754813|NCT06326164|PROCEDURE|A designed physiotherapy program.|The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
214754814|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
214754815|NCT02987166|DRUG|Pembrolizumab|200 mg
214754816|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
214754817|NCT00086164|DRUG|edifoligide (E2F Decoy)|
214754818|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
214754819|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
214754820|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
214754821|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
214754822|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
214754823|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
214754824|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
214754825|NCT01914042|DRUG|Morphine|
214754826|NCT01914042|DRUG|Milnacipran|
214754827|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
214754828|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
214754829|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
214754830|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
214754831|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
214754832|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
214754833|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
214754834|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
214754835|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
214754836|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
214754837|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
214754838|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
214754839|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
214754840|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
214754841|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
214754842|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
214754843|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
214754844|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
214754845|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
214754846|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
214754847|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
214754848|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
214754849|NCT00004166|DRUG|amifostine trihydrate|
214754850|NCT00004166|PROCEDURE|quality-of-life assessment|
214754851|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
214754852|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
214754853|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
214754854|NCT02389868|DRUG|Lovastatin|
214754855|NCT02536209|DRUG|MT-8554 low dose|
214754856|NCT02536209|DRUG|MT-8554 high dose|
214754857|NCT02536209|DRUG|Oxycodone hydrochloride|
214754858|NCT02536209|DRUG|Placebo|
214754859|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
214754860|NCT00005627|DRUG|carboplatin|
214754861|NCT00005627|DRUG|docetaxel|
214754862|NCT00005627|DRUG|estramustine phosphate sodium|
214754863|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
214754864|NCT06205459|PROCEDURE|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
214754865|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
214754866|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
214754867|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
214754868|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
214754869|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
214754870|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
214754871|NCT00000758|DRUG|Fluorouracil|
214754872|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
214754873|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
214754874|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
214754875|NCT01297621|OTHER|control|follow up, questionnaire responses
214754876|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
214754877|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
214754878|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
214754879|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
214754880|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
214754881|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
214754882|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
214754883|NCT03804476|DRUG|Placebo|Placebo control for this study.
214754884|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
214754885|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
214754886|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
214754887|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
214754888|NCT04881669|DEVICE|obturator|variable bulbs
214754889|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
214754890|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
214754891|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
214754892|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
214754893|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
214754894|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
214754895|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
214754896|NCT01301157|DRUG|M518101|Proper quantity twice a day
214754897|NCT01301157|DRUG|placebo|Proper quantity twice a day
214754898|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
214754899|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
214754900|NCT02778477|OTHER|Placebo|Multiple dose of placebo
214754901|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
214754902|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
214754903|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
214754904|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
214754905|NCT00847002|DEVICE|Standard Wound Care|
214754906|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
214754907|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
214754908|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
214754909|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
214754910|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
214754911|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
214754912|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
214754913|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
214754914|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
214754915|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
214754916|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
214754917|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
214754918|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
214754919|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
214754920|NCT01458535|DRUG|ABT-450|tablets
214754921|NCT01458535|DRUG|ABT-267|tablets
214754922|NCT01458535|DRUG|ribavirin|tablets
214754923|NCT01458535|DRUG|ritonavir|capsules
214754924|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
214754925|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
214754926|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
214754927|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
214754928|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
214754929|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
214754930|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
214754931|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
214754932|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
214754933|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
214754934|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
214754935|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
214754936|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
214754937|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
214754938|NCT02753608|OTHER|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
214754939|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
214754940|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
214754941|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
214754942|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
214754943|NCT02404675|DRUG|icotinib|
214754944|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
214754945|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
214754946|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
214754947|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
214754948|NCT00544349|BIOLOGICAL|cetuximab|
214754949|NCT00544349|DRUG|fluorouracil|
214754950|NCT00544349|DRUG|leucovorin calcium|
214754951|NCT00544349|DRUG|oxaliplatin|
214754952|NCT02854215|OTHER|Collection of additional data with questionnaires|"* questionnaires for quality of life measurements: QLQC30; QLQ-OV28~* questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
214754953|NCT00460421|DRUG|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
214754954|NCT00460421|RADIATION|Total Body irradiation|
214754955|NCT00460421|DRUG|Chemotherapy|High dose etoposide, Cyclophosphamide
214754956|NCT05918952|DIAGNOSTIC_TEST|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
214754957|NCT05918952|OTHER|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
214754958|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
214754959|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
214754960|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
214754961|NCT06104774|BEHAVIORAL|Tai Chi Exercise|The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.
214754962|NCT05136859|PROCEDURE|preserve|preserve the perivascular fat of the target cephalic vein
214754963|NCT05310396|OTHER|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
214754964|NCT05310396|OTHER|Control Formula|Cow's milk-based infant formula with standard nutritional composition
214754965|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
214754966|NCT04602078|DRUG|Atezolizumab 1200 mg/m2|Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.
214754967|NCT04602078|DRUG|Gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.
214754968|NCT04602078|DRUG|Cisplatin 70 mg/m2|Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.
214754969|NCT04001790|BEHAVIORAL|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
214754970|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
214754971|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
214754972|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
214754973|NCT06954467|DRUG|JS207|10 mg/kg q3W or adjust the dose (e.g. 15 mg/kg) based on accumulated data on the safety and efficacy of JS207 from clinical studies.
214754974|NCT06954467|DRUG|JS007|Dose exploration stage: C1-C4, group 1:3 mg/kg, C1D1 once (single dose); Group 2:3 mg/kg, D1, Q6W; Group 3:1 mg/kg,D1, Q3W; ≥C5, 1 mg/kg, Q6W; Dose expansion stage: according to the group medication confirmed in the dose exploration stage.
214754975|NCT04448028|DRUG|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
214754976|NCT04448028|DRUG|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
214754977|NCT06426680|BIOLOGICAL|ILB-3101|There are eight escalating dose cohorts.
214754978|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
214754979|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
214754980|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
214754981|NCT06501885|BEHAVIORAL|Ethnodrama Intervention|The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
214754982|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
214754983|NCT04542304|DRUG|Metolazone|Participants receive a single dose of metolazone.
214754984|NCT04542304|DRUG|Placebo|Participants receive a single dose of placebo to match metolazone.
214754985|NCT05757102|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
214754986|NCT05757102|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
214754987|NCT05757102|DRUG|FF/VI|FF/VI will be administered.
214754988|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
214754989|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
214754990|NCT06959017|GENETIC|Gene Expression Analysis|Each subject analysed for SERPİNH1 and ROCK1 gene exppression
214754991|NCT05807867|BEHAVIORAL|WMM-based intersectional stigma intervention|"Intervention components consist of:~1. psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~2. cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~3. Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
214754992|NCT05807867|BEHAVIORAL|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
214754993|NCT03921008|DRUG|Paclitaxel|-Commercial supply
214754994|NCT03921008|RADIATION|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
214754995|NCT03921008|PROCEDURE|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
214754996|NCT06327113|DRUG|CeFAZolin Injectable Solution|One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
214754997|NCT05524051|DRUG|TIN816|TIN816
214754998|NCT05524051|OTHER|Placebo|Placebo
214754999|NCT03983668|DRUG|CMP-001|Immunostimulatory therapeutic agent
214755000|NCT03983668|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy
214755001|NCT06847763|OTHER|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education applied in the form of one-on-one seminar format, focused on pain neurophysiology, and in the form of speaking sessions. Within the scope of these speaking sessions, pictures, diagrams, graphs, examples, metaphors, and homework assignments explaining the neurophysiology of pain are used.
214755002|NCT06847763|OTHER|Conventional Program|Conventional physiotherapy includes hot packs (20 minutes), ultrasound (1 mHz frequency, 1,5 watt/cm², 5 minutes left/right lumbar region), TENS (100Hz, 20 minutes), and home exercises.
214755003|NCT06077344|PROCEDURE|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation
214755004|NCT06077344|PROCEDURE|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment
214755005|NCT06028373|DRUG|ATG-031|ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
214755006|NCT02669173|DRUG|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
214755007|NCT02669173|DRUG|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
214755008|NCT04881799|DRUG|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
214755009|NCT04881799|DRUG|Placebo|Daily injection
214755010|NCT06182358|DRUG|Lotilaner ophthalmic solution, 0.25%|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
214755011|NCT06182358|DRUG|Vehicle control|Vehicle of XDEMVY administered topically twice a day for approximately 43 days
214755012|NCT01513538|DEVICE|TherapyGuide|Use of TherapyGuide function to help programming the device
214755013|NCT06013384|DEVICE|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
214755014|NCT06013384|DEVICE|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
214755015|NCT00873496|DRUG|Hydroxychloroquine|
214755016|NCT02471898|DRUG|HTX-011|
214755017|NCT02471898|DRUG|Placebo|Saline
214755018|NCT03050879|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
214755019|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
214755020|NCT04934228|DRUG|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
214755021|NCT04934228|DRUG|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
214755022|NCT04934228|DRUG|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
214755023|NCT06015789|OTHER|Questionnaire|Administration of questionnaires for the evaluation of self-care
214755024|NCT05888740|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
214755025|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including STRIDE (Single Tremelimumab Regular Interval Durvalumab), will be collected).
214755026|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including durvalumab + chemotherapy combinations (e.g., Durvalumab + GemCis etc.) will be collected.
214755027|NCT02131805|RADIATION|Electronic Skin Surface Brachytherapy|
214755028|NCT02131805|BEHAVIORAL|Quality of life assessment|
214755029|NCT04260698|BIOLOGICAL|omidubicel|hematopoietic stem cell transplant
214755030|NCT04963231|DRUG|Setmelanotide|SC injection
214755031|NCT04963231|DRUG|Placebo|SC injection
214755032|NCT04951544|OTHER|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
214755033|NCT04951544|OTHER|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
214755034|NCT05214898|BEHAVIORAL|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
214755035|NCT04936776|BEHAVIORAL|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
214755036|NCT06084780|PROCEDURE|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
214755037|NCT06084780|DRUG|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
214755038|NCT06084780|DRUG|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
214755039|NCT06084780|DRUG|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
214755040|NCT05442840|COMBINATION_PRODUCT|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
214755041|NCT01913613|DEVICE|IASD|IASD device implantation
214755042|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214755043|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
214755044|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
214755045|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
214755046|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
214755047|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
214755048|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
214755049|NCT00722618|OTHER|Written materials|2 written materials available on public website
214755050|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
214755051|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
214755052|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
214755053|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
214755054|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
214755055|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
214755056|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
214755057|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
214755058|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
214755059|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
214755060|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
214755061|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
214755062|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
214755063|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
214755064|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
214755065|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
214755066|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
214755067|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
214755068|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
214755069|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
214755070|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
214755071|NCT02040415|DRUG|Placebo drug of DW-1030|
214755072|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
214755073|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
214755074|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
214755075|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
214755076|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
214755077|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
214755078|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
214755079|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
214755080|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
214755081|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
214755082|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
214755083|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
214755084|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
214755085|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
214755086|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
214755087|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
214755088|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
214755089|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
214755090|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
214755091|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
214755092|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
214755093|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
214755094|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
214755095|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
214755096|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
214755097|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
214755098|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
214755099|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
214755100|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
214755101|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
214755102|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
214755103|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
214755104|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
214755105|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
214755106|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
214755107|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
214755108|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
214755109|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
214755110|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
214755111|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
214755112|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
214755113|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
214755114|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
214755115|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
214755116|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
214755117|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
214755118|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
214755119|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
214755120|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
214755121|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
214755122|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
214755123|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
214755124|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
214755125|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
214755126|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
214755127|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
214755128|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
214755129|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
214755130|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
214755131|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
214755132|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
214755133|NCT03045926|DRUG|Diosmectite (Smecta®)|
214755134|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
214755135|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
214755136|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
214755137|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
214755138|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
214755139|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
214755140|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
214755141|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
214755142|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
214755143|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
214755144|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
214755145|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
214755146|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
214755147|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
214755148|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
214755149|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
214755150|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
214755151|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
214755152|NCT05110118|DRUG|LY01008|Single intravenous injection
214755153|NCT05110118|DRUG|Avastin|Single intravenous injection
214755154|NCT05875337|OTHER|Acupressure|Before starting the acupressure point application, the area around the area where the pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.
214755155|NCT05875337|OTHER|Placebo acupressure|Before starting the application to the placebo acupressure point, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Light pressure will be applied to the determined points (1.5 cm away from LI4, LI11 and HT7 points) with the thumb, index or middle finger. Each point will be applied for 2 minutes and the application will last 12 minutes.
214755156|NCT04722627|DRUG|AT-752|Parallel Assignment
214755157|NCT04722627|DRUG|Placebo|Parallel Assignment
214755158|NCT01575158|DRUG|Citalopram|
214755159|NCT01575158|DRUG|Clomipramine|
214755160|NCT01575158|DRUG|placebo|
214755161|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
214755162|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
214755163|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
214755164|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
214755165|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
214755166|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
214755167|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
214755168|NCT03219372|DRUG|Pravastatin Pill|statin
214755169|NCT03219372|DRUG|Placebo Oral Tablet|placebo
214755170|NCT00442741|DRUG|Patupilone|
214755171|NCT00442741|DRUG|Patupilone + Omeprazole|
214755172|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
214755173|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
214755174|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
214755175|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
214755176|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
214755177|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
214755178|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
214755179|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
214755180|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
214755181|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
214755182|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
214755183|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
214755184|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
214755185|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
214755186|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
214755187|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
214755188|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
214755189|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
214755190|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
214755191|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
214755192|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
214755193|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
214755194|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
214755195|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
214755196|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
214755197|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
214755198|NCT03677973|OTHER|Placebo|Matching Placebo
214755199|NCT00450814|DRUG|Cyclophosphamide|Given IV
214755200|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
214755201|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
214755202|NCT00450814|OTHER|Pharmacological Study|Correlative studies
214755203|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
214755204|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
214755205|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
214755206|NCT00401726|DRUG|Venlafaxine ER|
214755207|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
214755208|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
214755209|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
214755210|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
214755211|NCT00242840|DRUG|No intervention; Observational study|
214755212|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
214755213|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
214755214|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
214755215|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
214755216|NCT02267343|DRUG|ONO-4538|
214755217|NCT02267343|DRUG|Placebo|
214755218|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
214755219|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
214755220|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
214755221|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
214755222|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
214755223|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
214755224|NCT04047459|OTHER|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
214755225|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
214755226|NCT00798902|OTHER|Iliac crest autograft|autograft
214755227|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
214755228|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
214755229|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
214755230|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
214755231|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
214755232|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
214755233|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
214755234|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
214755235|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
214755236|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
214755237|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
214755238|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
214755239|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
214755240|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
214755241|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
214755242|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
214755243|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
214755244|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
214755245|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
214755246|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
214755247|NCT00785252|DEVICE|standard central line|placement of a central line
214755248|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
214755249|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
214755250|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
214755251|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
214755252|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
214755253|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
214755254|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
214755255|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
214755256|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
214755257|NCT00003758|DRUG|cytarabine|
214755258|NCT00003758|DRUG|idarubicin|
214755259|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
214755260|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
214755261|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
214755262|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
214755263|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
214755264|NCT05333861|DRUG|hetrombopag|According to prescription
214755265|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
214755266|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
214755267|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
214755268|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
214755269|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
214755270|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
214755271|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
214755272|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
214755273|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
214755274|NCT03412448|OTHER|observation|Observation,
214755275|NCT05034146|DRUG|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
214755276|NCT05034146|DEVICE|PET/CT|68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
214755277|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
214755278|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
214755279|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
214755280|NCT02244385|OTHER|no intervention|
214755281|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
214755282|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
214755283|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
214755284|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
214755285|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
214755286|NCT02694393|DRUG|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
214755287|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
214755288|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
214755289|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
214755290|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
214755291|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
214755292|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
214755293|NCT03735849|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
214755294|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
214755295|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
214755296|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
214755297|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
214755298|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
214755299|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
214755300|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
214755301|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
214755302|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
214755303|NCT04986865|DRUG|ATG-101|ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
214755304|NCT06280092|DRUG|AMSCs|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
214755305|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
214755306|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
214755307|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
214755308|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
214755309|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
214755310|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
214755311|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
214755312|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
214755313|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
214755314|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
214755315|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
214755316|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
214755317|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
214755318|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
214755319|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
214755320|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
214755321|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
214755322|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
214755323|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
214755324|NCT04405115|BEHAVIORAL|Geriatric Assessment|Geriatric Assessment Visit
214755325|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
214755326|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
214755327|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
214755328|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
214755329|NCT06312501|DEVICE|Satelia®Cardio|Use of a remote patient monitoring system by NP Medical.
214755330|NCT06312501|OTHER|Conventional care|No use of RPM solutions for follow-up
214755331|NCT05758701|COMBINATION_PRODUCT|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
214755332|NCT05758701|DEVICE|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
214755333|NCT06105983|DRUG|Sisunatovir|Single Dose
214755334|NCT06105983|DRUG|Rabeprazole 40 mg|Tablets once daily for 7 days
214755335|NCT06105983|DRUG|Sisunatovir suspension|Tablets once daily for 7 days
214755336|NCT06105983|DRUG|Rabeprazole 20 mg|Tablets once daily for 7 days
214755337|NCT01624805|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214755338|NCT01624805|DRUG|Cyclosporine|Given PO
214755339|NCT01624805|BIOLOGICAL|Filgrastim|Given SC
214755340|NCT01624805|DRUG|Methylprednisolone|Given IV or PO
214755341|NCT01624805|BIOLOGICAL|Pegfilgrastim|Given SC
214755342|NCT00629343|DRUG|Azacitidine|Azacitidine will be delivered sub-cutaneously for 5 days
214755343|NCT00629343|DRUG|Temozolomide|Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days
214755344|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
214755345|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
214755346|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
214755347|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
214755348|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
214755349|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
214755350|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
214755351|NCT01439308|DRUG|Placebo|SB-705498 placebo
214755352|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
214755353|NCT00003695|DRUG|chemotherapy|
214755354|NCT00003695|PROCEDURE|surgical procedure|
214755355|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
214755356|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
214755357|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
214755358|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
214755359|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
214755360|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
214755361|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
214755362|NCT02144311|PROCEDURE|PET/CT Scan|
214755363|NCT02144311|PROCEDURE|MRI|
214755364|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
214755365|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
214755366|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
214755367|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
214755368|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
214755369|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
214755370|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
214755371|NCT00138723|DRUG|SPM 907|
214755372|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
214755373|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
214755374|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
214755375|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
214755376|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
214755377|NCT04213690|OTHER|No Intervention|There is no intervention for this study
214755378|NCT00012350|DRUG|FTI|
214755379|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
214755380|NCT00145795|DRUG|Current Regimen|
214755381|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
214755382|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
214755383|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
214755384|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
214755385|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
214755386|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
214755387|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
214755388|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
214755389|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
214755390|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
214755391|NCT01487109|DRUG|Placebo|Matching placebo tablet
214755392|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
214755393|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
214755394|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
214755395|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
214755396|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
214755397|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
214755398|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
214755399|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
214755400|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
214755401|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
214755402|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
214755403|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
214755404|NCT01961765|DRUG|cabozantinib|
214755405|NCT06639477|OTHER|Treatment As Usual|In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
214755406|NCT06639477|BEHAVIORAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
214755407|NCT06639477|BEHAVIORAL|Active Comparator|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
214755408|NCT05416333|DRUG|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
214755409|NCT05416333|OTHER|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
214755410|NCT04218903|BEHAVIORAL|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
214755411|NCT04218903|BEHAVIORAL|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
214755412|NCT06316817|DEVICE|FloPatch|A novel, hands-free ultrasound patch for continuous monitoring of quantitative Doppler in the carotid artery.
214755413|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
214755414|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
214755415|NCT05471791|DEVICE|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
214755416|NCT06799455|DEVICE|Endotracheal tube|participants either receive the ETT during the procedure
214755417|NCT05405530|DEVICE|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
214755418|NCT05405530|DEVICE|regular nasal cannula|Using nasal cannula for oxygenation.
214755419|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
214755420|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
214755421|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
214755422|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
214755423|NCT06456151|DIAGNOSTIC_TEST|Invasive candidiasis test|The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
214755424|NCT06456151|OTHER|Urine sample collection for future research|Patients will be asked to provide a urine sample for future research (urine biobank).
214755425|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
214755426|NCT04456816|DRUG|Placebo|Matching placebo tablet
214755427|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
214755428|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
214755429|NCT05776004|DRUG|CAL02|CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
214755430|NCT05776004|DRUG|Placebo|Physiological 0.9% sodium chloride solution for iv administration
214755431|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
214755432|NCT06072586|DRUG|BDTX-1535|BDTX-1535 is an inhibitor of EGFR mutations
214755433|NCT06072586|DRUG|BDTX-1535 combined with radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT, followed by adjuvant monotherapy with BDTX-1535 continuously in 28-day cycles after RT.
214755434|NCT06072586|DRUG|BDTX-1535 combined with temozolomide and radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT and TMZ, followed by adjuvant BDTX-1535 combined with standard of care TMZ continuously in 28-day cycles after RT.
214755435|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
214755436|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
214755437|NCT06040905|OTHER|Placebo|Starch, dextrin
214755438|NCT05555745|DEVICE|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
214755439|NCT05555745|DEVICE|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
214755440|NCT05382715|DRUG|Ozanimod|Specified Dose on Specified Days
214755441|NCT05956951|DEVICE|Closed-loop auditory stimulation|Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.
214755442|NCT05956951|DEVICE|Sham auditory stimulation|Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
214755443|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
214755444|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
214755445|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
214755446|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
214755447|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
214755448|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
214755449|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
214755450|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
214755451|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
214755452|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
214755453|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
214755454|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
214755455|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
214755456|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
214755457|NCT02440490|BEHAVIORAL|Computerised cognitive training|
214755458|NCT02440490|BEHAVIORAL|Video watching|
214755459|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
214755460|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
214755461|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
214755462|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
214755463|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
214755464|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
214755465|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
214755466|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
214755467|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
214755468|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
214755469|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
214755470|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
214755471|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
214755472|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
214755473|NCT05714839|DRUG|Belantamab|Belantamab will be administered.
214755474|NCT05714839|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214755475|NCT05714839|DRUG|Belantamab and belantamab mafodotin|Belantamab and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
214755476|NCT04790630|OTHER|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|computerized experimental brain-training treatment
214755477|NCT04790630|OTHER|Active Control|computerized intervention that follows recommendations for cognitive fitness
214755478|NCT01612949|OTHER|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
214755479|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
214755480|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
214755481|NCT04148339|OTHER|No Intervention|There is no intervention for this study.
214755482|NCT05303428|OTHER|Neuromodulation with low-intensity focused ultrasound|application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
214755483|NCT01243437|DRUG|ciprofloxacin|"* For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
214755484|NCT01243437|DRUG|doxyxcycline|"* For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
214755485|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
214755486|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
214755487|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
214755488|NCT06977646|PROCEDURE|Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction|The proposed intervention is a variation of classical myectomy, but unlike it, the main substrate for resection is not only the hypertrophied interventricular septum, but the abnormal papillary muscles and interpapillary trabeculae in the left ventricular cavity
214755489|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
214755490|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
214755491|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
214755492|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
214755493|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
214755494|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
214755495|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
214755496|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
214755497|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
214755498|NCT00281736|DRUG|HPPH|Given IV
214755499|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
214755500|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
214755501|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
214755502|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
214755503|NCT02679300|OTHER|Virtual reality exercise group|
214755504|NCT02679300|OTHER|Conventional exercise group (control group)|
214755505|NCT05733013|OTHER|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
214755506|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
214755507|NCT00154986|PROCEDURE|immunohistochemical staining, transfection, invasion assay|
214755508|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
214755509|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
214755510|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
214755511|NCT05525559|DRUG|ET0038|ET0038 for oral administration
214755512|NCT03054311|BEHAVIORAL|Lifestyle Matters|
214755513|NCT06987916|BIOLOGICAL|ssCART-19|autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene
214755514|NCT06984432|DEVICE|XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%)|Injectable implant containing 1.1%, 1.8%, or 2.2% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization to improve skin quality through biorevitalization.
214755515|NCT06984432|DEVICE|Electri (non-cross-linked hyaluronic acid 0.55%)|Injectable implant containing 0.55% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization aimed at improving skin hydration, elasticity, and appearance.
214755516|NCT05946174|OTHER|Intervention Set A|exercise sessions and meals over approximately 12 weeks
214755517|NCT05946174|OTHER|Intervention Set B|exercise sessions and meals over approximately 3 weeks
214755518|NCT05946174|OTHER|Intervention Set C|meals over approximately 3 weeks
214755519|NCT01882166|DRUG|fostimon|
214755520|NCT01882166|DRUG|puregon|
214755521|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
214755522|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
214755523|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
214755524|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
214755525|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
214755526|NCT00984958|DEVICE|Bulkamid expectation|expectance
214755527|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
214755528|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
214755529|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
214755530|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
214755531|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
214755532|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
214755533|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
214755534|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
214755535|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
214755536|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
214755537|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
214755538|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
214755539|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
214755540|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
214755541|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
214755542|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
214755543|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
214755544|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
214755545|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
214755546|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
214755547|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
214755548|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
215030698|NCT06691555|DEVICE|Suprachoroidal silicone tube (SST) shunt|This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.
214755549|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
214755550|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
214755551|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
214755552|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
214755553|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
214755554|NCT06997133|DIETARY_SUPPLEMENT|sucralose|Encapsulated sucralose po BID
214755555|NCT06997133|OTHER|Placebo|Encapsulated lactose po bid
214755556|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
214755557|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
214755558|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
214755559|NCT00363272|DRUG|ispinesib|Given IV
214755560|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
214755561|NCT00363272|OTHER|pharmacological study|Correlative studies
214755562|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
214755563|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
214755564|NCT00282373|DEVICE|mild hypothermia|
214755565|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
214755566|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
214755567|NCT06623032|OTHER|Medium-Chain Fatty Acid (MCFA)|The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)
214755568|NCT06623032|OTHER|Long-Chain Fatty Acid (LCFA)|The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
214755569|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
214755570|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
215030699|NCT06687096|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
215030700|NCT06687096|OTHER|standart diet list|patients prepared with a routine colonoscopy preparation scheme
214755571|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
214755572|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
214755573|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
214755574|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
214755575|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
214755576|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
214755577|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
214755578|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
214755579|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
214755580|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
214755581|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
214755582|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
214755583|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
214755584|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
214755585|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
214755586|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
214755587|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
214755588|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
214755589|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
214755590|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
214755591|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
215030701|NCT06691178|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
215030702|NCT06690567|DEVICE|Impella implantation|To implante Impella
215030703|NCT06368193|DEVICE|Neuralert Monitor|Device to identify upper extremity asymmetry in patients who are high risk for stroke.
214755592|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
214755593|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
214755594|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
214755595|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
214755596|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
214755597|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
214755598|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
214755599|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
214755600|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
214755601|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
214755602|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
214755603|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
214755604|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
214755605|NCT04852809|OTHER|No intervention|This is an observational study
214755606|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
214755607|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
214755608|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
214755609|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
214755610|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
214755611|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
214755612|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
214755613|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
214755614|NCT02661789|DRUG|Placebo|Injection of saline
214755615|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
214755616|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
214755617|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
214755618|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
214755619|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
214755620|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
214755621|NCT02473029|RADIATION|Vascular tomodensitometry|
214755622|NCT02473029|OTHER|Magnetic resonance angiography|
214755623|NCT02473029|OTHER|Vascular ultrasonography|
214755624|NCT02473029|OTHER|Retinal angiography|
214755625|NCT02473029|OTHER|Retinal optical coherence tomography|
214755626|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
214755627|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
214755628|NCT02609529|OTHER|Placebo|
214755629|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
214755630|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
214755631|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
214755632|NCT01632007|DRUG|SYR-472|
214755633|NCT01632007|DRUG|Alogliptin 25 mg|
214755634|NCT01632007|DRUG|Placebo|
214755635|NCT04301271|DRUG|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
214755636|NCT04301271|DRUG|Placebo oral tablet|12 weeks Placebo add-on
214755637|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
214755638|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
214755639|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
214755640|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
214755641|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
214755642|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
214755643|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
214755644|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
214755645|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
214755646|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
214755647|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
214755648|NCT00283673|BEHAVIORAL|Exercise|
214755649|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
214755650|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
214755651|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
214755652|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
214755653|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
214755654|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
214755655|NCT00821847|OTHER|DEXA scan|DEXA scan
214755656|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
214755657|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
214755658|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
214755659|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
214755660|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
214755661|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
214755662|NCT06724822|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
214755663|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
214755664|NCT06721988|DRUG|oxycodone and parecoxib sodium combinations|Participants will receive 0.1ml/kg oxycodone (1mg/ml) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Oxycodone is administered 5 minutes after parecoxib sodium administration.
214755665|NCT06721988|DRUG|Placebo and parecoxib sodium combinations|Participants will receive 0.1ml/kg placebo (0.9% saline) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Placebo is administered 5 minutes after parecoxib sodium administration.
214755666|NCT06722885|RADIATION|Standard radiotherapy treatment|"* 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases"
214755667|NCT06724289|DRUG|Psilocybin 25 mg|25 mg psilocybin administered to each participant in single arm, open-label trial
214755668|NCT06724627|DIAGNOSTIC_TEST|Dermatology/Skin - Other|Belle AI for skin image assessment.
214755669|NCT06724874|OTHER|Web-Based Deep Relaxation Exercise|Web-based deep relaxation exercise videos have been prepared online. Each video lasts approximately 20-25 minutes. The 4-week applications will be sent to pregnant women one video each week and they will be asked to continue the exercises at home 4 times a week.
214755670|NCT06724237|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214755671|NCT06724237|OTHER|Best Practice|Receive standard of care observation
214755672|NCT06724237|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214755673|NCT06724237|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214755674|NCT06724237|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214755675|NCT06724237|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214755676|NCT06724237|DRUG|High Dose Chemotherapy|Receive high dose chemotherapy
214755677|NCT06724237|PROCEDURE|Leukapheresis|Undergo leukapheresis
214755678|NCT06724237|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214755679|NCT06724237|DRUG|Stem Cell Mobilization Therapy|Receive stem cell mobilization therapy
214755680|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
214755681|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
214755682|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
214755683|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
214755684|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
214755685|NCT06722001|BEHAVIORAL|"The Brief insomnia intervention interactive e-book"|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
214755686|NCT06722001|BEHAVIORAL|traditional paper handout|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
214755687|NCT06722729|DRUG|KDT-3594|Oral administration
214755688|NCT06722729|DRUG|Placebo|Oral administration
214755689|NCT06722300|DEVICE|Ultrasonic teeth cleaning plus Tinidazole microneedle patches applying|After gargling with compound chlorhexidine rinse or 3% hydrogen peroxide rinse for 1 minute, ultrasonic teeth cleaning was performed. After teeth cleaning, the wound was rinsed with 3% hydrogen peroxide and bleeding was stopped. After ultrasonic teeth cleaning, two metronidazole oral composite microneedle patches were immediately applied to the upper and lower gums near the inner side of the first molar, especially where the teeth were lost or damaged. The mouth was kept closed for 15 minutes. After the microneedles were fully degraded, the patient could leave the clinic.
214755690|NCT06722105|BIOLOGICAL|2 infusions of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 MSC(AT) (2x10\^6 cells/kg) injection at M3
214755691|NCT06722105|BIOLOGICAL|1 infusion of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 placebo injection at M3
214755692|NCT06722105|OTHER|Placebo|Placebo at M0 and M3
214755693|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
214755694|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
214755695|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
214755696|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
214755697|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
214755698|NCT04613687|DEVICE|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
214755699|NCT06704243|BEHAVIORAL|Peer Support|"The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable."
214755700|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
214755701|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
214755702|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
214755703|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
214755704|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
214755705|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
214755706|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
214755707|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
214755708|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
214755709|NCT06768138|DRUG|Intra-arterial infusion of Alteplase|Patients enrolled in the experimental arm will receive intra-arterial thrombolysis with Alteplase. The dose of Intra-arterial Alteplase is 0.225 mg/kg body weight with a maximal dose of 20 mg
214755710|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
214755711|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
214755712|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
214755713|NCT06597968|DEVICE|AI Based CAD Software (qXR-Ln)|All x-ray images have already been obtained and will then be run through CAD software for secondary nodule detection
214755714|NCT02701907|OTHER|Blood sampling|
214755715|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
214755716|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
214755717|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
214755718|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
214755719|NCT02334891|OTHER|Standard|Standard management
214755720|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
214755721|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
214755722|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
215030704|NCT06694363|BIOLOGICAL|Blood samples|A maximum of 27 ml of blood collected at each visit for metabolic markers analysis
215030705|NCT06694363|BIOLOGICAL|Urine samples|One urine sample collected at each visit for enteric virus infection research
215030706|NCT06694363|BIOLOGICAL|Stool samples|One stool sample collected at each visit for enteric virus infection research
215030707|NCT05461326|PROCEDURE|Quad tendon|quadriceps tendon autograft
215030708|NCT05461326|PROCEDURE|BTB|patellar tendon autograft
214755723|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
214755724|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
214755725|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
214755726|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
214755727|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
214755728|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
214755729|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
214755730|NCT04335084|DRUG|Hydroxychloroquine|Prophylaxis treatment for COVID-19
214755731|NCT04335084|DIETARY_SUPPLEMENT|Vitamin C|Prophylaxis treatment for COVID-19
214755732|NCT04335084|DIETARY_SUPPLEMENT|Vitamin D|Prophylaxis treatment for COVID-19
214755733|NCT04335084|DIETARY_SUPPLEMENT|Zinc|Prophylaxis treatment for COVID-19
214755734|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
214755735|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
214755736|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
214755737|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
214755738|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
214755739|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
214755740|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
214755741|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
214755742|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
214755743|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
214755744|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
214755745|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
214755746|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
214755747|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
214755748|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
214755749|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
214755750|NCT00403429|DRUG|capecitabine|
214755751|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
214755752|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
215030709|NCT04614272|BEHAVIORAL|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
215030710|NCT04614272|BEHAVIORAL|Reading a poem|Reading is a distraction tool for pain management
214755753|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
214755754|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
214755755|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
214755756|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
214755757|NCT00161031|DRUG|Atomoxetine|
214755758|NCT04058665|DEVICE|Floseal|Hemostatic agent
214755759|NCT00031616|DRUG|brivudine phosphoramidate|
214755760|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
214755761|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
214755762|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
214755763|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
214755764|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
214755765|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
214755766|NCT00602082|DRUG|capecitabine|
214755767|NCT00602082|DRUG|cisplatin|
214755768|NCT00602082|DRUG|streptozocin|
214755769|NCT00602082|GENETIC|DNA analysis|
214755770|NCT00602082|GENETIC|RNA analysis|
214755771|NCT00602082|GENETIC|protein analysis|
214755772|NCT00602082|GENETIC|proteomic profiling|
214755773|NCT00602082|OTHER|laboratory biomarker analysis|
214755774|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
214755775|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
214755776|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
214755777|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
214755778|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
214755779|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
214755780|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
214755781|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
214755782|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
214755783|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
214755784|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
214755785|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
214755786|NCT00364338|BEHAVIORAL|gourment cooking workshop|
214755787|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
214755788|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
214755789|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
214755790|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
214755791|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
214755792|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
214755793|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
214755794|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
214755795|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
214755796|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
214755797|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
214755798|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
214755799|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
214755800|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
214755801|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
214755802|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
214755803|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
214755804|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
214755805|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
214755806|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
214755807|NCT00591552|DEVICE|Electrocautery|
214755808|NCT06397248|OTHER|No intervention|No intervention
214755809|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
214755810|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
214755811|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
214755812|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
214755813|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
215030711|NCT03780712|OTHER|Non applicable|No intervention as it is an observational study
215030712|NCT00736151|DRUG|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
215030713|NCT04849507|DEVICE|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
214755814|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
214755815|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
214755816|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
214755817|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
214755818|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
214755819|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
214755820|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
214755821|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
214755822|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
214755823|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
214755824|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
214755825|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
214755826|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
214755827|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
214755828|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
214755829|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
214755830|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
214755831|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
214755832|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
214755833|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
214755834|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
214755835|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
214755836|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
214755837|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
214755838|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
214755839|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
214755840|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
214755841|NCT03229902|BEHAVIORAL|mantra meditation|see study description
214755842|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
214755843|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
214755844|NCT00106717|PROCEDURE|Narrative medicine|
214755845|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
214755846|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
214755847|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
214755848|NCT06450990|OTHER|PLACEBO|Placebo
214755849|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
214755850|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
214755851|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
214755852|NCT00270400|DRUG|nesiritide|
214755853|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
214755854|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
214755855|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
214755856|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
214755857|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
214755858|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
214755859|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
214755860|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
214755861|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
214755862|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
214755863|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
214755864|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
214755865|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
214755866|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
214755867|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
214755868|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
214755869|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
214755870|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
214755871|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
214755872|NCT06724861|OTHER|Explicit Sensory Retraining for the lower extremities|Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.
214755873|NCT06724861|OTHER|no treatment|Usual care
214755874|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
214755875|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
214755876|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
214755877|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
214755878|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
214755879|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
214755880|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
214755881|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
214755882|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
214755883|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
214755884|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
214755885|NCT00165191|DRUG|Doxorubicin|
214755886|NCT00165191|DRUG|Cisplatin|
214755887|NCT00165191|DRUG|5-fluorouracil|
214755888|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
214755889|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
214755890|NCT02584972|OTHER|no intervention required|no intervention required
214755891|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
214755892|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
214755893|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
214755894|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
214755895|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
214755896|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
214755897|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
214755898|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
214755899|NCT04260594|OTHER|basic treatment|basic treatment
214755900|NCT02137473|OTHER|Human milk-based fortifier|
214755901|NCT02137473|OTHER|Bovine protein-based fortifier|
214755902|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
214755903|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
214755904|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
214755905|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
214755906|NCT00329225|DRUG|rosiglitazone|
214755907|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
214755908|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
214755909|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
214755910|NCT02119858|DRUG|indocyanine green solution|Given transperineally
214755911|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
214755912|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
214755913|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
214755914|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
214755915|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
214755916|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
214755917|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
214755918|NCT00395317|OTHER|Placebo|placebo tablet
214755919|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
214755920|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
214755921|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
214755922|NCT00048438|DRUG|paricalcitol|
214755923|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
214755924|NCT01961778|DEVICE|Radio-Frequency Ablation|
214755925|NCT01961778|DEVICE|Cryotherapy|
214755926|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
214755927|NCT06446427|OTHER|Acute high altitude exposure|"Thirty minutes after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 1, high altitude at 3450 masl) is performed."
214755928|NCT06446427|OTHER|Acute high altitude exposure, with supplementary oxygen|"4 hours after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 2, high altitude at 3450 masl) is performed, while the participants receive 4 litres / minute of oxygen via nasal route."
214755929|NCT06446427|OTHER|Subacute high altitude exposure, after having spent a night at high altitude|"After having spent a night at the Research Station Jungfraujoch, a simulated scenario of patient care (Intervention 3, high altitude at 3450 masl) is performed."
214755930|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
214755931|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
214755932|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
214755933|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
214755934|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
214755935|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
214755936|NCT05392920|OTHER|assessment study|there is no intervention in this study
214755937|NCT00213486|DRUG|irinotecan|
214755938|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
214755939|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
214755940|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
214755941|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
214755942|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
214755943|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
214755944|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
214755945|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
214755946|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
214755947|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
214755948|NCT00314275|DEVICE|Endeavor|Drug eluting stent
214755949|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
214755950|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
214755951|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
214755952|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
214755953|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
214755954|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
214755955|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
214755956|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
214755957|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
214755958|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
214755959|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
214755960|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
214755961|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
214755962|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
214755963|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
214755964|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
214755965|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
214755966|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
214755967|NCT03323034|DRUG|Irinotecan|Given IV
214755968|NCT03323034|DRUG|Pevonedistat|Given IV
214755969|NCT03323034|DRUG|Temozolomide|Given PO
214755970|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
214755971|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
214755972|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
214755973|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
214755974|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
214755975|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
214755976|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
214755977|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
214755978|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
214755979|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
214755980|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
214755981|NCT04268394|DRUG|CC-99677|CC-99677
214755982|NCT04268394|DRUG|Methotrexate|Methotrexate
214755983|NCT04268394|DRUG|Sulfasalazine|Sulfasalazine
214755984|NCT04268394|DRUG|Itraconazole|Itraconazole
214755985|NCT04268394|DRUG|Rifampin|Rifampin
214755986|NCT04268394|DRUG|Midazolam|Midazolam
214755987|NCT04268394|DRUG|Digoxin|Digoxin
214755988|NCT04268394|DRUG|Metformin|Metformin
214755989|NCT04268394|DRUG|Rosuvastatin|Rosuvastatin
214755990|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
214755991|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
214755992|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
214755993|NCT02660489|DRUG|OC459|
214755994|NCT02660489|DRUG|Placebo|
214755995|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
214755996|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
214755997|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
214755998|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
214755999|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
214756000|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
214756001|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
214756002|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
214756003|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
214756004|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
214756005|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
214756006|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
214756007|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
214756008|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
214756009|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
214756010|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
214756011|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
214756012|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
214756013|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
214756014|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
214756015|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
214756016|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
214756017|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
214756018|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
214756019|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
214756020|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
214756021|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
214756022|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
214756023|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
214756024|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
214756025|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
214756026|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
214756027|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
214756028|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
214756029|NCT05518058|OTHER|device and exercises|strengthening exercises plus balance training program conducted with type of functional electrical stimulation for muscles
214756030|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
214756031|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
214756032|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
214756033|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
214756034|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
214756035|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
214756036|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
214756037|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
214756038|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
214756039|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
214756040|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
214756041|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
214756042|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
214756043|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
214756044|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
214756045|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
214756046|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
214756047|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
214756048|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
214756049|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
214756050|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
214756051|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
214756052|NCT06379061|OTHER|Adult and Pediatrics|This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.
214756053|NCT00249600|BEHAVIORAL|Contingency management|
214756054|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
214756055|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
214756056|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
214756057|NCT00718809|DRUG|saracatinib|Given orally
214756058|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
214756059|NCT00870415|PROCEDURE|quality-of-life assessment|
214756060|NCT00870415|PROCEDURE|therapeutic conventional surgery|
214756061|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
214756062|NCT00463385|DRUG|Pomalidomide|
214756063|NCT00463385|DRUG|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
214756064|NCT00463385|DRUG|Placebo to pomalidomide|Matching pomalidomide placebo tablets
214756065|NCT00463385|DRUG|Placebo to prednisone|Matching prednisone placebo tablets
214756066|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
214756067|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
214756068|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
214756069|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
214756070|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
214756071|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
214756072|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
214756073|NCT03143933|DRUG|Propofol|I.V propofol
214756074|NCT03143933|DRUG|Fentanyl|
214756075|NCT04398680|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered
214756076|NCT02863874|DEVICE|VicrylPlus®|Suture
214756077|NCT02863874|DEVICE|Vicryl®|Suture
214756078|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
214756079|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
214756080|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
214756081|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
214756082|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
214756083|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
214756084|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
214756085|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
214756086|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
214756087|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
214756088|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
214756089|NCT03467919|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
214756090|NCT03467919|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
214756091|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
214756092|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
214756093|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
214756094|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
214756095|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
214756096|NCT05259059|OTHER|No intervention is involved|No intervention is involved
214756097|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
214756098|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
214756099|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
214756100|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
214756101|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
214756102|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
214756103|NCT05294133|BEHAVIORAL|physical activity|physical activity
214756104|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
214756105|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
214756106|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
214756107|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214756108|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
214756109|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
214756110|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
214756111|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
214756112|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
214756113|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
214756114|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
214756115|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
214756116|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
214756117|NCT00536991|DRUG|Ketoconazole|Given PO
214756118|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
214756119|NCT00536991|OTHER|Pharmacological Study|Correlative studies
214756120|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
214756121|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
214756122|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
214756123|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
214756124|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
214756125|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
214756126|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
214756127|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
214756128|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
214756129|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
214756130|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
214756131|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
214756132|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
214756133|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
214756134|NCT00447265|DRUG|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
214756135|NCT00447265|DRUG|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
214756136|NCT00447265|DRUG|Placebo|
214756137|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
214756138|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
214756139|NCT00910065|DRUG|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
214756140|NCT00317031|DRUG|Acamprosate or Naltrexone|mg\&d 90 days
214756141|NCT05556031|OTHER|Standard care|Standard clinical care
214756142|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
214756143|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
214756144|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
214756145|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
214756146|NCT04121169|DRUG|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
214756147|NCT02204449|BEHAVIORAL|Cardiac Rehabilitation Peer Mentorship|
214756148|NCT00503035|DRUG|Celecoxib|400 mg by mouth twice daily x 6 months
214756149|NCT00503035|PROCEDURE|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
214756150|NCT04861207|DRUG|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
214756151|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
214756152|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
214756153|NCT06269965|DEVICE|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
214756154|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Resistance Exercise Training|Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
214756155|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Endurance Exercise Training|Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
214756156|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
214756157|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
214756158|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
214756159|NCT06567275|PROCEDURE|Erector Spinae Plane Block|Ultrasound-guided erector spinae plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
214756160|NCT06567275|PROCEDURE|Serratus Anterior Plane Block|Ultrasound-guided serratus anterior plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
214756161|NCT06392737|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
214756162|NCT06392737|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
214756163|NCT05567601|DRUG|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
214756164|NCT04211467|OTHER|No Intervention|There is no intervention for this study
214756165|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
214756166|NCT05881031|OTHER|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
214756167|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
214756168|NCT06009523|DEVICE|Transcranial direct current stimulation|1 stimulation per day during 15 days.
214756169|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
214756170|NCT02177370|DRUG|Fenoterol MDI|
214756171|NCT02177370|DRUG|DSCG MDI|
214756172|NCT06262867|DIETARY_SUPPLEMENT|Ready. Set. Food! Stage 1 Mix ins|These supplements contain cow's milk, eggs, and peanuts.
214756173|NCT05268367|BEHAVIORAL|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
214756174|NCT06095557|DEVICE|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
214756175|NCT06570031|DRUG|ONO-4578|Specified dose on specified days
214756176|NCT06570031|DRUG|letrozole|Specified dose on specified days
214756177|NCT06570031|DRUG|Palbociclib|Specified dose on specified days
214756178|NCT06570031|DRUG|abemaciclib|Specified dose on specified days
214756179|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
214756180|NCT05611892|COMBINATION_PRODUCT|18F-FDS PET/CT|20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
214756181|NCT05903690|DRUG|RAG-17|RAG-17 60mg is used
214756182|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
214756183|NCT04643431|DIAGNOSTIC_TEST|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
214756184|NCT06534580|DEVICE|Virtual Reality|"A range of virtual reality software, delivered through the DR.VR (TM) device."
214756185|NCT03234023|BEHAVIORAL|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
214756186|NCT03338257|BEHAVIORAL|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
214756187|NCT06445179|PROCEDURE|Total Laparoscopic Hysterectomy|"The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy."
214756188|NCT06445179|DEVICE|Ureterolysis|unilateral or bilateral ureterolysis with or without bilateral adnexectomy
214756189|NCT02866747|RADIATION|Hypofractionated stereotactic radiation therapy|
214756190|NCT02866747|DRUG|Durvalumab|
214756191|NCT04884594|DRUG|AAV8-hCocH|2e12 vg/kg single infusion intravenous
214756192|NCT04884594|DRUG|AAV8-hCocH|6e12 vg/kg single infusion intravenous
214756193|NCT04884594|DRUG|AAV8-hCocH|4e12 vg/kg single infusion intravenous
214756194|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
214756195|NCT03868410|DEVICE|New Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
214756196|NCT03868410|DEVICE|Conventional Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
214756197|NCT01059175|DEVICE|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
214756198|NCT01059175|DEVICE|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
214756199|NCT06389214|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
214756200|NCT06389214|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
214756201|NCT06580145|DRUG|L-leucine|"L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally."
214756202|NCT06580145|DRUG|L-lysine|"L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally"
214756203|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
214756204|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
214756205|NCT04322929|DRUG|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
214756206|NCT06123481|PROCEDURE|Core Decompression|Standard core decompression procedure is performed by drilling into the necrotic bone of the femoral head. A sham bone marrow aspiration involves advancing a needle to the iliac crest (no bone penetration, no bone marrow aspiration) through a small skin incision.
214756207|NCT06123481|PROCEDURE|Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate|This involves bone marrow aspiration, concentrating the bone marrow aspirate, and injecting 6 milliliters of bone marrow aspirate concentrate into the necrotic femoral head through an opening created by the core decompression.
214756208|NCT03372564|PROCEDURE|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
214756209|NCT06198023|BEHAVIORAL|Educational|The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.
214756210|NCT06198023|BEHAVIORAL|Interactive|The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
214756211|NCT06579027|DEVICE|SPEED Training|Children will use ride-on toys controlled using their affected arm to navigate through their environment and complete playful theme-based challenges. Children will use their affected UE during navigation to start and stop the toy, move steadily forward and backward, turn to the right and left, perform 180° and 360° turns to either side, and avoid obstacles. Children will complete object-based UE tasks requiring gross and fine motor control at intermediate stops during navigation. Navigational tasks will be progressed by increasing complexity of paths (straight to slalom paths needing more directional changes), spaces (wide to narrow spaces), and precision (obstacle courses and mazes requiring skillful navigation, motor planning, and route finding). Object-based tasks will be progressed in terms of force requirements (small to large forces), range of motion (near to far reaches), precision (manipulation of large to small objects), and speed of movements (slow to fast).
214756212|NCT06579027|BEHAVIORAL|CRAFT Training|Children will engage in predominantly seated activities based on conventional occupational therapy to promote unimanual and bimanual UE function. Training sessions will be based on playful child-friendly themes (e.g., dinosaurs, space exploration, aquatic theme, etc.) and all training activities will incorporate the session theme. Activities will involve practice of functional gross and fine motor UE movement patterns that children typically use during daily life. Training will emphasize the use of the affected UE in different roles (i.e., stabilizer, mobilizer, and active and passive assist) during warm-up, building, and art-craft activities. The training will be progressed in terms of forces needed, range of motion, precision, and movement speed.
214756213|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
214756214|NCT04076657|BEHAVIORAL|Brock String Therapy|Oculomotor exercise to improve binocular vision function
214756215|NCT04076657|BEHAVIORAL|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
214756216|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
214756217|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
214756218|NCT05173714|BEHAVIORAL|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
214756219|NCT05173714|BEHAVIORAL|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
214756220|NCT05173714|BEHAVIORAL|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
214756221|NCT05173714|DRUG|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
214756222|NCT05173714|DRUG|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
214756223|NCT05843604|OTHER|Functional MRI|Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
214756224|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
214756225|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
214756226|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
214756227|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
214756228|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
214756229|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
214756230|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
214756231|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
214756232|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
214756233|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
214756234|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
214756235|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
214756236|NCT04679064|DRUG|Niraparib|PARP-inihibitor
214756237|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
214756238|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
214756239|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
214756240|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
214756241|NCT04679064|DRUG|Topotecan|Chemotherapy drug
214756242|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
214756243|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
214756244|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
214756245|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
214756246|NCT04173520|DRUG|DDA|Follow up after SVR
214756247|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
214756248|NCT00157638|DRUG|optimizing therapeutic treatments|
214756249|NCT00157638|BEHAVIORAL|optimizing processes of care|
214756250|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
214756251|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
214756252|NCT05261906|BEHAVIORAL|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
214756253|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
214756254|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
214756255|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
214756256|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
214756257|NCT01878708|DRUG|PEG-L-asparaginase|
214756258|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
214756259|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
214756260|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
214756261|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
214756262|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
214756263|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
214756264|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
214756265|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
214756266|NCT01811004|DEVICE|miraDry|miraDry
214756267|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
214756268|NCT01811004|DEVICE|Botox®|Botox®
214756269|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
214756270|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
214756271|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
214756272|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
214756273|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
214756274|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
214756275|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
214756276|NCT06104423|DRUG|Nebivolol 5 mg|1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.
214756277|NCT06104423|DRUG|Ramipril 2.5/5/10 mg|1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.
214756278|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
214756279|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
214756280|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
214756281|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
214756282|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
214756283|NCT04009122|OTHER|Placebo|Group B
214756284|NCT04337463|DRUG|ATG-008|Tablet
214756285|NCT04337463|DRUG|Toripalimab|IV infusion
214756286|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
214756287|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
214756288|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
214756289|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
214756290|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
214756291|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
214756292|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
214756293|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
214756294|NCT00750061|DRUG|Placebo|Matching placebo
214756295|NCT03950947|DEVICE|Amplatzer vascular plug|See above
214756296|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
214756297|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
214756298|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
214756299|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
214756300|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
214756301|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
214756302|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
214756303|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
214756304|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
214756305|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
214756306|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
214756307|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
214756308|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
214756309|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
214756310|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
214756311|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
214756312|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
214756313|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
214756314|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
214756315|NCT05480046|DRUG|Risperidone ISM|Risperidone ISM is administered every 4 weeks
214756316|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
214756317|NCT03772210|OTHER|Sham|Apparent Stimulation administered
214756318|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
214756319|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
214756320|NCT04435431|DRUG|Mesdopetam|Oral use
214756321|NCT04435431|DRUG|Placebo|Oral use
214756322|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
214756323|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
214756324|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
214756325|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
214756326|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
214756327|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
214756328|NCT02059265|DRUG|Dasatinib|Given PO
214756329|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
214756330|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
214756331|NCT00433368|DRUG|L-Ornithine L-Aspartate|
214756332|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
214756333|NCT00036621|DRUG|BMS-275291|
214756334|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
214756335|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
214756336|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
214756337|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
214756338|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
214756339|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
214756340|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
214756341|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
214756342|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
214756343|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
214756344|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
214756345|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
214756346|NCT01725204|DRUG|Dasatinib + PegIFN|
214756347|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
214756348|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
214756349|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
214756350|NCT04753606|DRUG|Obicetrapib|tablets
214756351|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
214756352|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
214756353|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
214756354|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
214756355|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
214756356|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
214756357|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
214756358|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
214756359|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
214756360|NCT01671462|DEVICE|BD HPV assay on Viper LT|
214756361|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
214756362|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
214756363|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
214756364|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
214756365|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
214756366|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
214756367|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
214756368|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
214756369|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
214756370|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
214756371|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
214756372|NCT02325206|DRUG|dapagliflozin|one administration in the morning
214756373|NCT02325206|DRUG|Placebo|one administration in the morning
214756374|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
214756375|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
214756376|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
214756377|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
214756378|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
214756379|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
214756380|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
214756381|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
214756382|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
214756383|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
214756384|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
214756385|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
214756386|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
214756387|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
214756388|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
214756389|NCT06016556|DRUG|nirmatrelvir, ritonavir|single cohort
214756390|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
214756391|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
214756392|NCT04578600|DRUG|Lenalidomide|Given PO
214756393|NCT04578600|BIOLOGICAL|Obinutuzumab|Given IV
214756394|NCT04578600|DRUG|Oral Azacitidine|Given PO
214756395|NCT05889156|DRUG|NST-1024|400 mg BID
214756396|NCT05889156|OTHER|Placebo|matched placebo to active arm
214756397|NCT04246593|OTHER|Mobile Market program implementation|"Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component"
214756398|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
214756399|NCT03677102|OTHER|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
214756400|NCT03677102|OTHER|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
214756401|NCT06438549|BEHAVIORAL|HCP-CHW Integration into Prenatal Care for Smoking Cessation|CHWs will be integrated into primary care, and subjects will receive CHW home visits (up to 8) that will provide brief behavioral smoking cessation interventions before, during, and after a quit date. This brief behavioral intervention will include watching a video and reviewing self-help materials.
214756402|NCT06438549|OTHER|Control Arm|Standard of Care which provides referrals to community-based smoking cessation resources.
214756403|NCT03571568|BIOLOGICAL|BI-1206|"BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion"
214756404|NCT03571568|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2, as per SmPC
214756405|NCT03571568|BIOLOGICAL|Acalabrutinib|Acalabrutinib 100 mg orally as per SmPC
214756406|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
214756407|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
214756408|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
214756409|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
214756410|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
214756411|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
214756412|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
214756413|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
214756414|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
214756415|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
214756416|NCT02058849|OTHER|Placebo|Placebo
214756417|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
214756418|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
214756419|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
214756420|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
214756421|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
214756422|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
214756423|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
214756424|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
214756425|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
214756426|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
214756427|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
214756428|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
214756429|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
214756430|NCT00002362|DRUG|Abacavir sulfate|
214756431|NCT00002362|DRUG|Efavirenz|
214756432|NCT00002362|DRUG|Emtricitabine|
214756433|NCT00002362|DRUG|Stavudine|
214756434|NCT01422395|PROCEDURE|Freezing|Vitrification
214756435|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
214756436|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
214756437|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
214756438|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
214756439|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
214756440|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
214756441|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
214756442|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
214756443|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
214756444|NCT06906900|DEVICE|TTF-200M and TTF-200A systems|Participants will receive one cycle and treatment will continue as long as the doctor thinks it is in the participant's best interest.
214756445|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
214756446|NCT06910436|DIAGNOSTIC_TEST|Coronary Angiogram|Diagnostic/therapeutic procedure to reopen an occluded coronary artery by inflating a balloon and inserting a stent
214756447|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
214756448|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
214756449|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
214756450|NCT06915259|OTHER|Doula Model of Care|Doula model of care is defined as emotional support, prenatal support, intrapartum support, and postpartum support provided to the birthing individual by a certified doula.
214756451|NCT06735755|DRUG|BEAM-301: Single dose of BEAM-301 administered by IV|BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
214756452|NCT06912984|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training intervention will consist of moderate-intensity aerobic exercise training program consisting of treadmill walking/running and upright cycling. The training program involves 3 training sessions per week for 12 weeks. Each session will be ≈ 60 minutes in duration.
214756453|NCT06917027|OTHER|education|clean intermittent catheterization education
214756454|NCT06913283|PROCEDURE|Pulp Therapy with Mineral trioxide aggregate (MTA)|MTA allowed to set for twenty four hours
214756455|NCT06913283|PROCEDURE|Pulp Therapy with Biodentine|Biodentine is triturated before use
214756456|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
214756457|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
214756458|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
214756459|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
214756460|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
214756461|NCT00121251|DRUG|Capecitabine|Given PO
214756462|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
214756463|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
214756464|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
214756465|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
214756466|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
214756467|NCT02899884|OTHER|No Intervention|
214756468|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
214756469|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
214756470|NCT06931197|BEHAVIORAL|Contingency management|"If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. great job!). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
214756471|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
214756472|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
214756473|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
214756474|NCT01099670|DRUG|Placebo|Placebo
214756475|NCT06934421|DEVICE|Ultrasound-Guided Genicular Nerve Radiofrequency Ablation|This intervention involves a single-session ultrasound-guided thermal radiofrequency ablation of the superomedial, superolateral, and inferomedial genicular nerves in patients with moderate to severe knee osteoarthritis. Target points follow anatomical references described by Fonkoue et al. and validated in cadaveric studies, differing from classical approaches. Under ultrasound guidance, monopolar RF cannulas are placed, with sensory and motor stimulation confirming accurate positioning. Local anesthesia (2% lidocaine) is applied. Lesions are performed at 85°C for 90 seconds per site. The radiofrequency generator used is CE-marked for pain procedures. The study evaluates a novel targeting protocol, not the safety or effectiveness of the device itself. No fluoroscopy is used. The procedure is performed once. Participants are followed for two years to assess outcomes.
214756476|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
214756477|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
214756478|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
214756479|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
214756480|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
214756481|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
214756482|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
214756483|NCT00394173|DRUG|Placebo|Matching placebo
214756484|NCT06943365|OTHER|Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies|Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray
214756485|NCT06943365|GENETIC|DPP6 risk haplotype|Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies
214756486|NCT06942065|PROCEDURE|Sham-BFR|The exercise protocol for the operated leg (with sham pressure of 20mmHg) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
214756487|NCT06942065|PROCEDURE|Blood Flow Restriction Training|The exercise protocol for the operated leg (with a BFR pressure of 60% of the LOP) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
214756488|NCT06942091|OTHER|Traumatic Brain Injury (TBI)|Presence of TBI identified by intracerebral hemorrhage on brain computed tomography (CT) at emergency department; not actively assigned by investigators but used to stratify comparison groups.
214756489|NCT06942390|DEVICE|Micro-Needling Combined with ketofin and metformin|After micro-needling, topical ketotifen is applied to one half of the face and topical metformin to the other half. Between sessions, patients continue daily application of both treatments.
214756490|NCT06942390|DRUG|ketofin and metformin Alone|This arm includes 51 patients receiving daily applications of topical ketotifen on one half of their face and topical metformin on the other half without undergoing micro-needling sessions.
214756491|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral, fasting
214756492|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal
214756493|NCT06942299|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal or fasting
214756494|NCT06935643|OTHER|Birth Ball|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, the pregnant woman will have a birth ball application for 10 minutes. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
214756495|NCT06935643|OTHER|Perineal Massage|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out. When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, 10 minutes of perineal massage will be applied to the pregnant woman. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
214756496|NCT06935643|OTHER|Control Group|"Pregnant women in the control group will not receive any intervention. Pregnant women in this group will only receive routine midwifery care.~Written and verbal consent will be obtained by giving information about the study.Pregnancy Diagnosis Form will be filled.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, Visual Analog Scale (VAS) will be completed. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed."
214756497|NCT06937385|DRUG|0.5% Bupivacaine HCl|bilateral cervical injections of 0.5% bupivacaine into the paraspinous muscle at the c6-7 location for headache treatment
214756498|NCT06937385|DRUG|standard IV treatment for headache|physicians choice of IV medications in treatment of headache
214756499|NCT06942130|OTHER|Artificial intelligence|Incorporating artificial intelligence as an aid to video-based skill learning
214756500|NCT06942130|OTHER|Video|Skill learning solely through videos
214756501|NCT06942988|BIOLOGICAL|intracavernous platelet rich plasma therapy|intracavernous platelet-rich plasma therapy for erectile dysfunction
214756502|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
214756503|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
214756504|NCT02277418|DEVICE|VAVL|Videolaryngoscope
214756505|NCT02277418|DEVICE|MIL|Direct laryngoscopy
214756506|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
214756507|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
214756508|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
214756509|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
214756510|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
214756511|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
214756512|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
214756513|NCT04964739|BEHAVIORAL|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
214756514|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
214756515|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
214756516|NCT01761461|DRUG|TS-1, oxaliplatin|
214756517|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
214756518|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
214756519|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
214756520|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
214756521|NCT00066573|DRUG|anastrozole|Given orally
214756522|NCT00066573|DRUG|exemestane|Given orally
214756523|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
214756524|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
214756525|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
214756526|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
214756527|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
214756528|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
214756529|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
214756530|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
214756531|NCT00662974|OTHER|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
214756532|NCT00662974|OTHER|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
214756533|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
214756534|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
214756535|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
214756536|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
214756537|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
214756538|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
214756539|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
214756540|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
214756541|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
214756542|NCT00076544|DRUG|Ziconotide|
214756543|NCT00000172|DRUG|Galantamine|
214756544|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
214756545|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
214756546|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
214756547|NCT04662424|OTHER|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
214756548|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
214756549|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
214756550|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
214756551|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
214756552|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
214756553|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
214756554|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
214756555|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
214756556|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
214756557|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
214756558|NCT00252668|DRUG|Etanercept|
214756559|NCT00252668|DRUG|Methotrexate|
214756560|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
214756561|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
214756562|NCT01406327|DRUG|Ambrisentan|Ambrisentan
214756563|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
214756564|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
214756565|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
214756566|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
214756567|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
214756568|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
214756569|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
214756570|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
214756571|NCT00856570|DRUG|warfarin|Oral
214756572|NCT00856570|DRUG|YM178|Oral
214756573|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
214756574|NCT00093327|PROCEDURE|Acupuncture|
214756575|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
214756576|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
214756577|NCT03651440|OTHER|PNF|PNF
214756578|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
214756579|NCT03651440|OTHER|Physical Therapy|Physical Therapy
214756580|NCT03651440|OTHER|Control|Control group
214756581|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
214756582|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
214756583|NCT02646566|DRUG|APD421|
214756584|NCT02646566|DRUG|Placebo|
214756585|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
214756586|NCT02191033|BEHAVIORAL|Smoking counseling|
214756587|NCT02191033|BEHAVIORAL|Text messaging|
214756588|NCT02191033|DRUG|Nicotine patch|
214756589|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
214756590|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
214756591|NCT00190476|DRUG|Weekly docetaxel alone|
214756592|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
214756593|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
214756594|NCT02815540|PROCEDURE|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
214756595|NCT02815540|DRUG|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
214756596|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
214756597|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
214756598|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
214756599|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
214756600|NCT01738282|DRUG|Baclofen|
214756601|NCT01738282|DRUG|Placebo (for baclofen)|
214756602|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
214756603|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
214756604|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
214756605|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
214756606|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
214756607|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
214756608|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
214756609|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
214756610|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
214756611|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
214756612|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
214756613|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
214756614|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
214756615|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
214756616|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
214756617|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
214756618|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
214756619|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
214756620|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
214756621|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
214756622|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
215030714|NCT06769750|OTHER|leg-lift maneuver|"Patients will be monitored as usual using an SpO2 sensor placed on the index finger of the limb contralateral to the pressure cuff, giving the PI value, a tensiometer taking blood pressure (systolic, diastolic and mean) every 2 minutes, and an ECG.~A transthoracic cardiac echocardiogram will be performed with measurement of the sub-aortic time-velocity integral, and the same measurement will be performed 1 min after a passive leg-lift to see if this maneuver significantly increases systolic ejection volume. The PI value and blood pressure will be measured at each of these maneuvers."
214756623|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
214756624|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
214756625|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
214756626|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
214756627|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
214756628|NCT04182386|PROCEDURE|Portal vein embolization|Selective preoperative portal vein embolization
214756629|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
214756630|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
214756631|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
214756632|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
214756633|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
214756634|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
214756635|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
214756636|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
214756637|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
214756638|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
214756639|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
214756640|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
214756641|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
215030715|NCT06769750|OTHER|leg-lift maneuver|The perfusion index (PI) value and arterial pressure will be measured at each of manoeuvre
215030716|NCT04376008|PROCEDURE|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
214756642|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
214756643|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
214756644|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
214756645|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
214756646|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
214756647|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
214756648|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
214756649|NCT04621227|DRUG|Midazolam|2mg single dose
214756650|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
214756651|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
214756652|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
214756653|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
214756654|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
214756655|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
214756656|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
214756657|NCT01548573|DRUG|Dexamethasone|Given PO
214756658|NCT01548573|PROCEDURE|Tandem autologous stem cell transplant|
214756659|NCT01548573|DRUG|Cisplatin|Given IV
214756660|NCT01548573|DRUG|Doxorubicin|Given IV
214756661|NCT01548573|DRUG|Cyclophosphamide|Given IV or PO
214756662|NCT01548573|DRUG|Etoposide|Given IV
214756663|NCT01548573|DRUG|Bortezomib|Given IV
214756664|NCT01548573|DRUG|Thalidomide|Given PO
214756665|NCT01548573|DRUG|Melphalan|Given IV
214756666|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
214756667|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
214756668|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
214756669|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
214756670|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
214756671|NCT04666012|BIOLOGICAL|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
214756672|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
215030717|NCT04376008|PROCEDURE|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
214756673|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
214756674|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
214756675|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
214756676|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
214756677|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
214756678|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
214756679|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
214756680|NCT00558831|DRUG|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
214756681|NCT00558831|DRUG|Moisturizing Lotion|
214756682|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
214756683|NCT04926467|DRUG|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
214756684|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
214756685|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
214756686|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
214756687|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
214756688|NCT01974869|DRUG|Anti-tumor necrosis factor alpha agents|Treatment with biologics
214756689|NCT05617495|OTHER|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
214756690|NCT06785064|BEHAVIORAL|Reduced Food Variety (RFV)|Participants engaged in reduced food variety (RFV) will be asked to choose a few high-calorie, low nutrient main meals and snacks to eat regularly. At the beginning of each month, they will choose one main meal (entrée) to eat at least 2 times a week and one snack food to eat at least 4 times a week within the month. They will have the option to keep or change their main meal and snack options from month to month.
214756691|NCT06785064|BEHAVIORAL|Home-based Resistance Training (HBRT)|Participants assigned to receive home-based resistance training (also called strength training or lifting weights) will be asked to engage in at-home exercises that strengthen muscles at least 2 days each week (≤45 minutes per home session) and track their progress. They will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first two months of Phase 2 to learn these skills. They will receive exercise plans and equipment (sets of dumbbells, a rack to hold the dumbbells, and an exercise mat) needed to complete exercises.
214756692|NCT06785064|BEHAVIORAL|Buddy Training and Support (BTS)|"Participants assigned to buddy training and support will be asked to identify an eligible friend or family member who is over 18 years old that can be their buddy. Study staff will contact the buddy to be sure they are eligible, willing, and have all the details they need. The participant's buddy will be asked to attend up to 6 training sessions with the study staff, so they can learn the best ways to support the participant during the program. After the buddy completes training, they will be asked to check in with the participant 1-2 times each week about their progress."
214756693|NCT06785064|BEHAVIORAL|Acceptance and Commitment (ACT) Workshops|Participants assigned to receive Acceptance and Commitment (ACT) Workshops will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first three months of Phase 2. These workshops will help them develop skills to handle tough thoughts about weight control, keep their values in mind, and be mindful of their decisions and the impact of their decisions related to weight control. They will also be asked to apply ACT skills regularly during the rest of Phase 2.
214756694|NCT06835127|PROCEDURE|Infrainguinal peripheral endovascular revascularization|Percutaneous endovascular angioplasty and/or stenting of infrainguinal arteries (femoropopliteal and/or infrapopliteal arteries) under local anesthesia and adjunct mild conscious sedation.
214756695|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
214756696|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
214756697|NCT06300580|DRUG|ABBV-932|Oral Capsule
214756698|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
214756699|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
214756700|NCT04148313|OTHER|No Intervention|There is no intervention for this study.
214756701|NCT05216419|DRUG|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
214756702|NCT01342445|DRUG|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
214756703|NCT01342445|DRUG|Placebo|
214756704|NCT06212427|DIETARY_SUPPLEMENT|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
214756705|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
214756706|NCT04208178|DRUG|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
214756707|NCT04208178|DRUG|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
214756708|NCT04208178|DRUG|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
214756709|NCT04208178|DRUG|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
214756710|NCT05933655|BEHAVIORAL|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
214756711|NCT05141266|BEHAVIORAL|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
214756712|NCT05141266|OTHER|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
214756713|NCT06341972|BEHAVIORAL|Cognitive behavioral therapy based self-management for anxiety|Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
214756714|NCT05512533|DEVICE|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
214756715|NCT02392078|DEVICE|NeuroBlate System|
214756716|NCT04961645|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.
214756717|NCT04961645|BEHAVIORAL|Computer-based Test|Participants will be seated comfortably in a chair and asked to complete a simple computer-based task where they imagine walking through a room and press a button indicating if they can leave through a door on the left, center, or right wall. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
214756718|NCT04961645|BEHAVIORAL|Behavioral-based Test|Participants will be asked to complete a simple behavioral task that will require them to walk around in a small room and search for hidden objects. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
214756719|NCT02652793|DRUG|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
214756720|NCT02652793|DRUG|Lamivudine|Lamivudine 300 mg once dailly
214756721|NCT05899166|OTHER|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
214756722|NCT05899166|OTHER|Standard diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
214756724|NCT04148248|OTHER|No intervention|There is no intervention for this study
214756725|NCT04800029|OTHER|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
214756726|NCT04800029|OTHER|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
214756727|NCT04800029|OTHER|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
214756728|NCT03913936|OTHER|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
214756729|NCT05168930|DRUG|Venetoclax|C4-15
214756730|NCT05168930|DRUG|Zanubrutinib|C1-15
214756731|NCT04914975|OTHER|Neuromuscular electrical stimulation|The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
214756732|NCT02957149|OTHER|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
214756733|NCT02957149|DEVICE|Angel Concentrated Platelet Rich Plasma System|
214756734|NCT06232616|PROCEDURE|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
214756735|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
214756736|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
214756737|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
214756738|NCT06419634|DRUG|BMS-986497|Specified dose on specified days
214756739|NCT06419634|DRUG|Azacitidine|Specified dose on specified days
214756740|NCT06419634|DRUG|Venetoclax|Specified dose on specified days
214756741|NCT06190249|BIOLOGICAL|LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-144), followed by IL-2.
214756742|NCT06190249|DRUG|Cyclophosphamide|Given by IV.
214756743|NCT06190249|DRUG|Mesna|Given by IV.
214756744|NCT06190249|DRUG|Fludarabine|Given by IV.
214756745|NCT06190249|BIOLOGICAL|Interleukin-2 (IL-2)|Given by IV.
214756746|NCT06190249|DRUG|Pembrolizumab|Given by IV.
214756747|NCT05763667|DRUG|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
214756748|NCT05763667|DRUG|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
214756749|NCT06296628|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
214756750|NCT06296628|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
214756751|NCT04951206|DEVICE|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
214756752|NCT04951206|DRUG|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
214756753|NCT05450198|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
214756754|NCT05450198|BIOLOGICAL|Placebo|Placebo comparator to MK-6194 administered SC
214756755|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
214756756|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
214756757|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
214756758|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
214756759|NCT00185146|DRUG|Pactimibe|
214756760|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
214756761|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
214756762|NCT06585670|OTHER|Calm Health - smartphone application|Participants randomized to the intervention arm of the study will be given free access to a mobile phone application called Calm Health, which they will use to engage in guided meditation and mindfulness modules for at least 10 minutes per day for 8 weeks.
214756763|NCT06131398|DRUG|AMG 355|Short-term intravenous (IV) infusion
214756764|NCT06131398|DRUG|Pembrolizumab|Short-term IV infusion
214756765|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
214756766|NCT06827678|OTHER|No Intervention: Observational Cohort|No intervention
214756767|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
214756768|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
214756769|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
214756770|NCT00005803|DRUG|Carmustine|Given IV
214756771|NCT00005803|DRUG|Cyclophosphamide|Given IV
214756772|NCT00005803|DRUG|Cyclosporine|Given PO
214756773|NCT00005803|DRUG|Cytarabine|Given IV
214756774|NCT00005803|DRUG|Etoposide|Given IV
214756775|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
214756776|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
214756777|NCT00005803|DRUG|Melphalan|Given IV
214756778|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
214756779|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
214756780|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
214756781|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
214756782|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
214756783|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
214756784|NCT04100616|OTHER|No intervention|There is no intervention for this study
214756785|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
214756786|NCT05877508|OTHER|Placebo|Placebo infusion
214756787|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
214756788|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
214756789|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
214756790|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
214756791|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
214756792|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
214756793|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
214756794|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
214756795|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
214756796|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
214756797|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
214756798|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
214756799|NCT01748162|DRUG|Prednisolone IF needed|
214756800|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
214756801|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
214756802|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
214756803|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
214756804|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
214756805|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
214756806|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
214756807|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
214756808|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
214756809|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
214756810|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
214756811|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
214756812|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
214756813|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
214756814|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
214756815|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
214756816|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
214756817|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
214756818|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
214756819|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
214756820|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
214756821|NCT03324373|DRUG|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
214756822|NCT03324373|DRUG|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
214756823|NCT03324373|PROCEDURE|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
214756824|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
214756825|NCT02433522|DRUG|Placebo|
214756826|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
214756827|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
214756828|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
214756829|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
214756830|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
214756831|NCT06250660|DIETARY_SUPPLEMENT|Strawberry Intervention|"This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries."
214756832|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
214756833|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
214756834|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
214756835|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
214756836|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
214756837|NCT04389008|OTHER|no interventions|no interventions
214756838|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
214756839|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
214756840|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
214756841|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
214756842|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
214756843|NCT03948646|DRUG|Vehicle|Vehicle gel
214756844|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
214756845|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
214756846|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
214756847|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
214756848|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
214756849|NCT06385275|DRUG|Vitamin K1 500 µg|One pill daily for 4 weeks.
214756850|NCT06385275|DRUG|K1 1000 µg|One pill daily for 4 weeks.
214756851|NCT06385275|DRUG|Vitamin K2 (MK-7) 300 µg|One pill daily for 4 weeks.
214756852|NCT06385275|OTHER|Placebo|Placebo pill daily for 4 weeks.
214756853|NCT05355506|DEVICE|Application|Knowledge \& record
214756854|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
214756855|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
214756856|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
214756857|NCT01901393|DRUG|IV ibuprofen|
214756858|NCT01901393|DRUG|Ketorolac|
214756859|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
214756860|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
214756861|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
214756862|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
214756863|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
214756864|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
214756865|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
214756866|NCT00843739|DEVICE|sham EMST|Four week sham device training program
214756867|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
214756868|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
214756869|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
214756870|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
214756871|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
214756872|NCT01439776|DRUG|Vit D|800IU/day
214756873|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
214756874|NCT02823782|OTHER|neuropsychological assessment|
214756875|NCT04585906|BEHAVIORAL|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
214756876|NCT00004199|DRUG|cisplatin|
214756877|NCT00004199|DRUG|gemcitabine hydrochloride|
214756878|NCT00004199|DRUG|prinomastat|
214756879|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
214756880|NCT04160949|OTHER|No Intervention|There is no intervention for this study.
214756881|NCT04054713|DIAGNOSTIC_TEST|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
214756882|NCT04054713|DIAGNOSTIC_TEST|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
214756883|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
214756884|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
214756885|NCT01713374|OTHER|no intervention|control visit
214756886|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
214756887|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
214756888|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
214756889|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
214756890|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
214756891|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
214756892|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
214756893|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
214756894|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
214756895|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
214756896|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
214756897|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
214756898|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
214756899|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
214756900|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
214756901|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
214756902|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
214756903|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
214756904|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
214756905|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
214756906|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
214756907|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
214756908|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
214756909|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
214756910|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
214756911|NCT05926687|BEHAVIORAL|Social Communication|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
214756912|NCT05926687|BEHAVIORAL|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
214756913|NCT05926687|BEHAVIORAL|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour once/week
214756914|NCT05926687|BEHAVIORAL|Social Communication + Add Tools|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
214756915|NCT05926687|BEHAVIORAL|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour every other week
214756916|NCT05926687|BEHAVIORAL|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
214756917|NCT00038428|DRUG|TLK286|
214756918|NCT01694849|DRUG|GFT505 80mg|
214756919|NCT01694849|DRUG|GFT505 120mg|
214756920|NCT01694849|DRUG|Placebo|
214756921|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
214756922|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
214756923|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
214756924|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
214756925|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
214756926|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
214756927|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
214756928|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
214756929|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
214756930|NCT02688881|DRUG|sirolimus|Rapamune
214756931|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
214756932|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
214756933|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
214756934|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
214756935|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
214756936|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
214756937|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
214756938|NCT02223520|DRUG|Placebo ointment and placebo cloths|
214756939|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
214756940|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
214756941|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
214756942|NCT02489682|OTHER|Long-form written Informed consent information|
214756943|NCT02489682|OTHER|Short-form written Informed consent information|
214756944|NCT02489682|OTHER|Video Informed consent information|
214756945|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
214756946|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
214756947|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
214756948|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
214756949|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
214756950|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
214756951|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
214756952|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
214756953|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
214756954|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
214756955|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
214756956|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
214756957|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
214756958|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
214756959|NCT00596466|DRUG|pregabalin|pregabalin
214756960|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
214756961|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
214756962|NCT02223624|OTHER|walking and light weights|
214756963|NCT02223624|OTHER|eccentric aerobic exercise|
214756964|NCT02223624|OTHER|concentric aerobic exercise|
214756965|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
214756966|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
214756967|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
214756968|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
214756969|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
214756970|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
214756971|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
214756972|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
214756973|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
214756974|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
214756975|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
214756976|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
214756977|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
214756978|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
214756979|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
214756980|NCT03133429|DEVICE|MER|carotid artery stenting
214756981|NCT05128656|OTHER|serology|serology at M3 and serology at M6
214756982|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
214756983|NCT03907111|DEVICE|placebo|traditional gauze
214756984|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
214756985|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
214756986|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
214756987|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
214756988|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
214756989|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
214756990|NCT00752206|DRUG|Saracatinib|Oral Agent
214756991|NCT00752206|DRUG|Placebo|Oral Agent
214756992|NCT03529539|DRUG|PSV|
214756993|NCT00117975|BIOLOGICAL|galiximab|given IV
214756994|NCT00117975|BIOLOGICAL|rituximab|Given IV
214756995|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
214756996|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
214756997|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
214756998|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
214756999|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
214757000|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
214757001|NCT00037908|PROCEDURE|Strength training|
214757002|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
214757003|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
214757004|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
214757005|NCT00353392|DEVICE|Laser Therapy|
214757006|NCT04717466|BIOLOGICAL|Secukinumab|300mg subcutaneous injection
214757007|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
214757008|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
214757009|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
214757010|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
214757011|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
214757012|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
214757013|NCT05990725|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
214757014|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
214757015|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
214757016|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
214757017|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
214757018|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
214757019|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
214757020|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
214757021|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
214757022|NCT05021315|DRUG|10% povidone iodine|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
214757023|NCT04616183|DRUG|Abemaciclib|Given PO
214757024|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
214757025|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
214757026|NCT05016219|DEVICE|Circadian-Effective Light|Narrowband blue light
214757027|NCT05016219|DEVICE|Rhythmic Light|40 hertz (Hz) flicker
214757028|NCT05016219|DEVICE|Placebo Light|Narrowband red light
214757029|NCT05016219|DEVICE|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
214757030|NCT03155061|DRUG|ONO-4578|ONO-4578 specified dose on specified days
214757031|NCT03155061|DRUG|ONO-4538|ONO-4538 specified dose on specified days
214757032|NCT05876923|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214757033|NCT05876923|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
214757034|NCT05876923|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
214757035|NCT05876923|OTHER|Electronic Health Record Review|Ancillary studies
214757036|NCT05876923|OTHER|Exercise Intervention|Undergo aerobic based training program
214757037|NCT05876923|PROCEDURE|Physical Examination|Undergo measurement of height/weight and vital signs
214757038|NCT05876923|OTHER|Questionnaire Administration|Ancillary studies
214757039|NCT05876923|PROCEDURE|Spirometry|Undergo spirometry
214757040|NCT05876923|OTHER|Physical Performance Testing|Undergo muscular strength and functional endurance measurements
214757041|NCT05876923|OTHER|Best Practice|Receive usual care
214757042|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
214757043|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
214757044|NCT05363878|BEHAVIORAL|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
214757045|NCT06357299|BEHAVIORAL|Small Bottle Size|Small sized bottle
214757046|NCT06357299|BEHAVIORAL|Standard Bottle Size|Standard sized bottle
214757047|NCT06357299|BEHAVIORAL|Clear Bottle|Clear bottle
214757048|NCT06357299|BEHAVIORAL|Opaque Bottle|Opaque bottle
214757049|NCT02510417|BIOLOGICAL|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
214757050|NCT05081531|RADIATION|Adaptive Radiotherapy|All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.
214757051|NCT05770401|BEHAVIORAL|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
214757052|NCT05770401|BEHAVIORAL|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
214757053|NCT04884256|DRUG|CBT-004|Dose response study
214757054|NCT00402298|DRUG|Full Dose Midomafetamine HCl|Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2.5 hours later by 62.5 mg midomafetamine HCl orally during the course of a day-long therapy session.
214757055|NCT00402298|DRUG|Low Dose Midomafetamine HCl|Participants will receive an initial dose of 25 mg midomafetamine HCl orally followed 2.5 hours later by a supplemental dose of 12.5 mg midomafetamine HCl orally during the course of each of two day-long therapy sessions.
214757056|NCT00480077|DEVICE|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
214757057|NCT05868135|BEHAVIORAL|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
214757058|NCT04214015|OTHER|No intervention|There is no intervention for this study
214757059|NCT06510894|DRUG|Sotagliflozin|Sodium-glucose cotransporter-1/2 inhibitor
214757060|NCT04214548|OTHER|No Intervention|There is no intervention for this study
214757061|NCT06770049|BEHAVIORAL|Standard Lifestyle Intervention (SLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts in a 12-month structured follow up. Participants will meet with a registered dietician as well as member of the study team to learn more about their intervention. Diets will be prescribed for each participant with a 30% calorie deficit calculated from measured REE. Macronutrient composition will be guided based on the patient preference. Participants will be prescribed 150 minutes of physical activity per week (spread across 4-5 days) and recommendations to reach 10,000 steps daily. During the first 12 weeks, participants will be scheduled a 12-week behavioral program focusing on self-monitoring and stimulus control using cognitive-behavioral approaches to promote adherence to diet and exercise prescriptions.
214757062|NCT06770049|BEHAVIORAL|Phenotype-tailored Lifestyle Intervention (PLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts. The recommendations will be determined a priori to tailor for each obesity phenotype
214757063|NCT05879614|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
214757064|NCT06806865|PROCEDURE|Periarticular nerve group block (PENG)|The pericapsular nerve group (PENG) block targets the nerves that supply the hip capsule. The continuous PENG block will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used.
214757065|NCT06806865|PROCEDURE|Continuous supra-inguinal fascia iliaca compartment block (SIFICB)|The supra-inguinal fascia iliaca compartment block (SIFICB) targets the femoral, lateral femoral cutaneous, and obturator nerves. Under ultrasound guidance, 30 mL of 0.25% bupivacaine is administered, followed by catheter placement for continuous infusion at 5 mL/h.
214757066|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
214757067|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
214757068|NCT04119440|OTHER|Placebo|Administrations of placebo via the intramuscular route
214757069|NCT05356182|OTHER|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
214757070|NCT00393783|BIOLOGICAL|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
214757071|NCT03328078|DRUG|Emavusertib|Emavusertib will be provided as a tablet dosage form to be taken BID.
214757072|NCT03328078|DRUG|Ibrutinib|Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
214757073|NCT05969678|BEHAVIORAL|breathing training|receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete
214757074|NCT03104491|DRUG|Inotuzumab Ozogamicin|"Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)"
214757075|NCT05085236|PROCEDURE|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
214757076|NCT05085236|PROCEDURE|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
214757077|NCT04784455|DRUG|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
214757078|NCT03572283|DRUG|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
214757079|NCT04631510|DRUG|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
214757080|NCT05324449|DRUG|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
214757081|NCT04211428|OTHER|No intervention|There is no intervention for this study
214757082|NCT06801054|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|All patients will receive a second dose of tenecteplase.
214757083|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
214757084|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
214757085|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
214757086|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
214757087|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
214757088|NCT04150809|OTHER|No intervention|There is no intervention for this study
214757089|NCT05219110|OTHER|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing \< 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
214757090|NCT05219110|OTHER|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
214757091|NCT04899206|DRUG|With an Antidepressant Drug|Current users of an antidepressant drug.
214757092|NCT04899206|DRUG|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
214757093|NCT03196518|PROCEDURE|PET Imaging|PET/CT study immediately after injection
214757094|NCT03196518|OTHER|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
214757095|NCT06279910|DRUG|Calcifediol|Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
214757096|NCT05265975|DRUG|ATG-010|Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
214757097|NCT05265975|DRUG|Lenalidomide|Oral administration,QD, Days 1-21 of each cycle
214757098|NCT05265975|DRUG|Rituximab|Intravenous injection Days 1 of each cycle, Cycles 1-6
214757099|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
214757100|NCT05295888|DEVICE|Temporal Interference stimulation|TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
214757101|NCT05295888|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
214757102|NCT04920968|DRUG|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
214757103|NCT04920968|DRUG|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
214757104|NCT03050723|DEVICE|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
214757105|NCT06446765|BEHAVIORAL|mindfulness-based Neurofeedback|Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
214757106|NCT06446765|OTHER|control Neurofeedback|Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
214757107|NCT06308952|DRUG|Atorvastatin 20mg|Eligible subjects screened will enter the pretreatment period (at least 24 hours) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). Additionally, the patient was started on basic dual anti-platelet (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
214757108|NCT03210545|DRUG|Betamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
214757109|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
214757110|NCT05363397|DRUG|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
214757111|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
214757112|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
214757113|NCT05793489|OTHER|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
214757114|NCT05307237|DEVICE|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
214757115|NCT05307237|DEVICE|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
214757116|NCT04099979|OTHER|No Intervention|There is no intervention for this study
214757117|NCT06339203|DEVICE|Irrisept|450ml low concentration (0.05%) Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water
214757118|NCT06339203|DRUG|Normal Saline|450mL
214757119|NCT06017713|BEHAVIORAL|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
214757120|NCT05923203|OTHER|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
214757121|NCT05660070|BEHAVIORAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
214757122|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
214757123|NCT05762276|BIOLOGICAL|Placebo|Normal saline
214757124|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
214757125|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
214757126|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
214757127|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
214757128|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
214757129|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
214757130|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
214757131|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
214757132|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
214757133|NCT00618046|DRUG|Oxcarbazepine|
214757134|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
214757135|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
214757136|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
214757137|NCT00262119|DEVICE|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
214757138|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
214757139|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
214757140|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
214757141|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
214757142|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
214757143|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
214757144|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
214757145|NCT02116374|OTHER|Physiopathology study|
214757146|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
214757147|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
214757148|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
214757149|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
214757150|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
214757151|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
214757152|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
214757153|NCT04865536|DRUG|TBI-223 1800 mg|3 x 600 mg SR1 tablets
214757154|NCT04865536|DRUG|TBI-223 2400mg|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
214757155|NCT04865536|DRUG|TBI-223 Placebo|Placebo SR and IR tablets for TBI-223
214757156|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
214757157|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
214757158|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
214757159|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
214757160|NCT05774080|OTHER|Observational|Observational
214757161|NCT05551585|DEVICE|Transcranial pulse stimulation|TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,
214757162|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
214757163|NCT02427620|DRUG|Cyclophosphamide|Given IV
214757164|NCT02427620|DRUG|Cytarabine|Given IV
214757165|NCT02427620|DRUG|Dexamethasone|Given PO or IV
214757166|NCT02427620|DRUG|Doxorubicin|Given IV
214757167|NCT02427620|DRUG|Doxorubicin Hydrochloride|Given IV
214757168|NCT02427620|DRUG|Ibrutinib|Given PO
214757169|NCT02427620|OTHER|Laboratory Biomarker Analysis|Correlative studies
214757170|NCT02427620|DRUG|Methotrexate|Given IV
214757171|NCT02427620|BIOLOGICAL|Rituximab|Given IV
214757172|NCT02427620|DRUG|Vincristine|Given IV
214757173|NCT02427620|DRUG|Vincristine Sulfate|Given IV
214757174|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
214757175|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
214757176|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
214757177|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
214757178|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
214757179|NCT05261126|DRUG|Enclitide Chloride|Enclitide Chloride administered orally
214757180|NCT05261126|DRUG|Placebo|Placebo matching enclitide chloride administered orally
214757181|NCT00005607|DRUG|FOLFIRI regimen|
214757182|NCT00005607|DRUG|fluorouracil|
214757183|NCT00005607|DRUG|irinotecan hydrochloride|
214757184|NCT00005607|DRUG|leucovorin calcium|
214757185|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
214757186|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
214757187|NCT04999969|DRUG|AZD0171|AZD0171
214757188|NCT04999969|DRUG|Durvalumab|Durvalumab
214757189|NCT04999969|DRUG|Gemcitabine|Chemotherapy (Standard-of-Care)
214757190|NCT04999969|DRUG|Nab-paclitaxel|Chemotherapy (Standard-of-Care)
214757191|NCT04647916|BIOLOGICAL|Sacituzumab Govitecan|Given IV
214757192|NCT05060549|DRUG|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
214757193|NCT03901274|BEHAVIORAL|Wellness|The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
214757194|NCT03901274|BEHAVIORAL|Partnership|The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
214757195|NCT05570604|BEHAVIORAL|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
214757196|NCT05570604|BEHAVIORAL|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
214757197|NCT05570604|BEHAVIORAL|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
214757198|NCT05570604|BEHAVIORAL|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
214757199|NCT05570604|BEHAVIORAL|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
214757200|NCT05570604|BEHAVIORAL|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
214757201|NCT04774991|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
214757202|NCT05739682|PROCEDURE|Local anaesthetic injection of 4% articaine with 1:100000 epinephrine|Buccal infiltration injection using a side loading aspirating syringe and a 30-gauge needle
214757203|NCT05739682|PROCEDURE|Tooth isolation|Rubber dam application to the affected tooth
214757204|NCT05739682|PROCEDURE|Access cavity preparation|Complete removal of caries, undermined tooth structure, and defective restoration. Access cavity preparation with complete removal of the pulp chamber roof using a sterile bur other than the ones used for caries removal.
214757205|NCT05739682|PROCEDURE|Root canal shaping and cleaning|Working length determination using an electronic apex locator and then canal instrumentation using Hyflex CM rotary files up to size 40.04 with irrigation using 2.5% NaOCl between files.
214757206|NCT05739682|PROCEDURE|Final irrigation with antimicrobial-corticosteroid mixture|1 ml of levofloxacin will be withdrawn in a 3ml plastic syringe followed by 1 ml of fluconazole and 1 ml of dexamethasone sodium phosphate, the whole solution is then passively delivered into the canal using a 30-gauge side vented needle reaching 1 mm shorter than the working length. The solution will be left inside the canal for 5 minutes
214757207|NCT05739682|PROCEDURE|Final irrigation with cold saline|Frozen sterile saline will be brought at room temperature and monitored using a digital liquid thermometer till the temperature reaches 2.5°c. 4ml are then withdrawn in a 5ml plastic syringe and delivered inside the canal in 1 minute. The process is then repeated 5 times so that the canal receives 20 ml of 2.5°c cold saline for 5 minutes.
214757208|NCT05739682|PROCEDURE|Temporary restoration and patient's instructions|The canals are dried using paper points and the access cavity is sealed using a non-eugenol temporary filling.
214757209|NCT05739682|PROCEDURE|Root canal obturation|After the 1st visit by 3 days to 1 week, the patient is scheduled for a second appointment for root canal obturation.
214757210|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
214757211|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
214757212|NCT06354686|DEVICE|TMS Tolerability|The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
214757213|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
214757214|NCT06210321|OTHER|Prescription of escitalopram using pharmacogenetic testing|Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
214757215|NCT06230393|DEVICE|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
214757216|NCT04708223|DEVICE|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
214757217|NCT04708223|DEVICE|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
214757218|NCT06548113|DEVICE|TMS|transcranial magnetic brain stimulation
214757219|NCT04691674|PROCEDURE|Endoscopy|Endoscopic removal of the pancreatic stent
214757220|NCT04437667|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application. Participants will be instructed to engage in a minimum of 10 hours of gameplay over the holiday period each year. The game will automatically collect for analysis data related to participants' in-game behavior, e.g. time spent playing, scores on knowledge-based mini-games, choices made in the narrative game, components to which the player was exposed. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma; and promote parent-child dialogue.
214757221|NCT04437667|BEHAVIORAL|Control Mobile Phone Game|Independent gameplay of control game. Total respondent burden: participants will be invited to engage in at least 10 hours of gameplay during each long school holiday (November-December).
214757222|NCT06037603|BEHAVIORAL|Brain & Walk Exercise Every Day (BraW-Day)|The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
214757223|NCT03716349|DIAGNOSTIC_TEST|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
214757224|NCT03716349|OTHER|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
214757225|NCT03716349|DRUG|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
214757226|NCT03716349|DEVICE|rubber dam|The area will be isolated with rubber dam isolation
214757227|NCT03716349|OTHER|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
214757228|NCT03716349|PROCEDURE|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
214757229|NCT03716349|PROCEDURE|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
214757230|NCT03716349|PROCEDURE|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
214757231|NCT03716349|OTHER|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
214757232|NCT03716349|PROCEDURE|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
214757233|NCT03716349|PROCEDURE|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
214757234|NCT03716349|OTHER|Consent|The consent form will be signed, copy will be provided to the patient
214757235|NCT03716349|OTHER|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
214757236|NCT03716349|RADIATION|xray|When necessary a radiograph (xray) will be obtained
214757237|NCT03716349|OTHER|Release of medical information signed|The release of medical information form will be signed
214757238|NCT03716349|OTHER|Oral Exam|An Oral Exam will be completed
214757239|NCT03716349|OTHER|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
214757240|NCT03716349|OTHER|Clinical Assessment|A clinical assessment will be completed by the evaluators
214757241|NCT03716349|DEVICE|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
214757242|NCT03716349|DEVICE|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
214757243|NCT06324864|BEHAVIORAL|START NOW Adapted|"The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions."
214757244|NCT06053307|BEHAVIORAL|Acceptance commitment therapy|The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
214757245|NCT05434754|OTHER|eHealth Tool|text messaging algorithm
214757246|NCT04527380|DRUG|Ixekizumab|Administered SC
214757247|NCT04527380|DRUG|Adalimumab|Administered SC
214757248|NCT06241768|OTHER|mPATH-CRC Web app|Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening
214757249|NCT05410418|DRUG|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
214757250|NCT05410418|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
214757251|NCT05127837|BEHAVIORAL|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
214757252|NCT06521320|DIAGNOSTIC_TEST|speaking valve combined with airway pressure|All patients were given speaking valves and airway pressure was measured to assess upper airway patency.
214757253|NCT06521320|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
214757254|NCT03978988|DEVICE|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
214757255|NCT03978988|DRUG|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
214757256|NCT03978988|DRUG|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
214757257|NCT03978988|PROCEDURE|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
214757258|NCT05311878|DEVICE|EEG-based perceptual training|Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
214757259|NCT05311878|DEVICE|Behavior based perceptual training|Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
214757260|NCT06137040|DRUG|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg"
214757261|NCT06137040|OTHER|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
214757262|NCT05688943|PROCEDURE|Spinal Anesthesia|Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
214757263|NCT05688943|PROCEDURE|General Anesthesia|General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
214757264|NCT04525755|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
214757265|NCT04525755|DRUG|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
214757266|NCT05241249|DRUG|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
214757267|NCT05241249|DRUG|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
214757268|NCT05241249|DRUG|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
214757269|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
214757270|NCT04081805|PROCEDURE|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
214757271|NCT04081805|PROCEDURE|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
214757272|NCT04081805|DRUG|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
214757273|NCT06127121|BEHAVIORAL|Digital Art Activity|"* complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again"
214757274|NCT03671746|DRUG|Ketorolac|Participants will receive Ketorolac at 15 mg IV every 6 hours for their first 5 days of hospitalization
214757275|NCT03671746|DRUG|Saline Solution|Participants will receive 1 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
214757276|NCT05065554|DRUG|Acalabrutinib|Dose per protocol, oral twice daily per cycle
214757277|NCT05065554|DRUG|Rituximab|Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
214757278|NCT04996173|DEVICE|Spray cryotherapy|A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
214757279|NCT04996173|DEVICE|Ballon Dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.
214757280|NCT04996173|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
214757281|NCT04100889|OTHER|No Intervention|There is no intervention for this study.
214757282|NCT05437211|DEVICE|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
214757283|NCT05721976|BEHAVIORAL|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
214757284|NCT02566304|DRUG|Fludarabine|Given IV
214757285|NCT02566304|RADIATION|Total-Body Irradiation|Undergo TBI
214757286|NCT02566304|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
214757287|NCT02566304|DRUG|Cyclophosphamide|Given IV
214757288|NCT02566304|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
214757289|NCT02566304|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
214757290|NCT02566304|DRUG|Tacrolimus|Given PO
214757291|NCT02566304|DRUG|Mycophenolate mofetil|Given IV
214757292|NCT02566304|OTHER|Laboratory Biomarker Analysis|Correlative studies
214757293|NCT04210817|OTHER|No Intervention|There is no intervention for this study
214757294|NCT03172195|PROCEDURE|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
214757295|NCT03172195|BIOLOGICAL|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
214757296|NCT03172195|BIOLOGICAL|blood sample|Blood sample will be collected in more.
214757297|NCT04100005|OTHER|No intervention|There is no intervention for this study.
214757298|NCT05102929|DEVICE|active intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
214757299|NCT05102929|DEVICE|sham intermittent Theta Burst Stimulation (iTBS)|"Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons."
214757300|NCT06421311|DRUG|nivolumab|According to approved product label (France)
214757301|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
214757302|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
214757303|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
214757304|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
214757305|NCT05535738|DRUG|Dupilumab|300mg
214757306|NCT05535738|DRUG|Adalimumab|40mg
214757307|NCT05535738|DRUG|Ustekinumab|45mg
214757308|NCT05535738|DRUG|Guselkumab|100mg
214757309|NCT05535738|DRUG|Canakinumab|150mg
214757310|NCT05535738|DRUG|Sarilumab|200mg
214757311|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
214757312|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
214757313|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
214757314|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
214757315|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
214757316|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
214757317|NCT02265874|DRUG|Habitrol|Patch used daily for 28 weeks
214757318|NCT02265874|DRUG|Placebo to Habitrol|
214757319|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
214757320|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
214757321|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
214757322|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
214757323|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
214757324|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
214757325|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
214757326|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
214757327|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
214757328|NCT00138866|DRUG|Risedronate|
214757329|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
214757330|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
214757331|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
214757332|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
214757333|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
214757334|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
214757335|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
214757336|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
214757337|NCT04567771|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
214757338|NCT04567771|OTHER|Questionnaire Administration|Complete adverse event assessments
214757339|NCT04567771|RADIATION|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
214757340|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
214757341|NCT04036942|PROCEDURE|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
214757342|NCT04036942|PROCEDURE|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
214757343|NCT06051474|DRUG|Nicotine Replacement Product|Adults will receive a 2-week supply of nicotine patches to place on skin (14mg or 21mg; dosing depending on tobacco use per package insert) and oral nicotine mini-lozenges (2mg, 4mg, dosing depending on tobacco use per package insert). All participants will also receive a single smoking cessation counseling session with a physician. Surveys will be completed pre-intervention, within 24 hours of hospital discharge, and 2-weeks after hospital discharge.
214757344|NCT05921604|DRUG|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
214757345|NCT05921604|DRUG|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
214757346|NCT05312411|BIOLOGICAL|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
214757347|NCT05312411|DRUG|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
214757348|NCT04875611|DRUG|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
214757349|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
214757350|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
214757351|NCT02184234|DRUG|Antistax film coated tablets|
214757352|NCT04832009|DRUG|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
214757353|NCT04832009|DRUG|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
214757354|NCT04832009|DRUG|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
214757355|NCT04832009|DRUG|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
214757356|NCT04513015|DIETARY_SUPPLEMENT|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
214757357|NCT04513015|DIETARY_SUPPLEMENT|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
214757358|NCT06452316|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
214757359|NCT02118467|DRUG|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
214757360|NCT02118467|DRUG|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
214757361|NCT02118467|DRUG|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
214757362|NCT02118467|DRUG|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
214757363|NCT06805383|BEHAVIORAL|Phone call|Phone call to patients randomized to experimental arm.
214757364|NCT06805383|OTHER|Mailed FIT Kit|FIT Kit mailed to patient address in EMR.
214757365|NCT04902378|DEVICE|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
214757366|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
214757367|NCT06321471|DEVICE|AeviceMD|AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
214757368|NCT06380075|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
214757369|NCT06380075|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
214757370|NCT06380075|DEVICE|Clarus imaging|Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
214757371|NCT05847751|DEVICE|Aortic valve replacement|Trans Aortic Valve Replacement (TAVI)
214757372|NCT02478281|DRUG|Methylene Blue|
214757373|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
214757374|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
214757375|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
214757376|NCT00056472|DRUG|Olanzapine|10-20mg/day
214757377|NCT00056472|DRUG|Sertraline|150-200mg/day
214757378|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
214757379|NCT02278042|OTHER|Beverage Consumption|
214757380|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
214757381|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
214757382|NCT06560658|DRUG|Psilocybin|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period.
214757383|NCT06560658|BEHAVIORAL|Meditation|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period. In addition to meditating during their sessions, participants will also meet online five days a week for meditation instruction and practice.
214757384|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
214757385|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
214757386|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
214757387|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
214757388|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
214757389|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
214757390|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
214757391|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
214757392|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
214757393|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
214757394|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
214757395|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
214757396|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
214757397|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
214757398|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
214757399|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
214757400|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
214757401|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
214757402|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
214757403|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
214757404|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
214757405|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
214757406|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
214757407|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
214757408|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
214757409|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
214757410|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
214757411|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
214757412|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
214757413|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
214757414|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
214757415|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
214757416|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
214757417|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
214757418|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
214757419|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
214757420|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
214757421|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
214757422|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
214757423|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
214757424|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
214757425|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
214757426|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
214757427|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
214757428|NCT06615245|BEHAVIORAL|No VR vs. immersive high tech VR|No VR vs. immersive High Tech VR
214757429|NCT06615245|BEHAVIORAL|Plausible control vs immersive High Tech VR|plausible control condition vs. immersive high tech VR
214757430|NCT00181051|DEVICE|Alaris AEP monitor|
214757431|NCT03174457|DRUG|Micafungin|Intravenous
214757432|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
214757433|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
214757434|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
214757435|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
214757436|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
214757437|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
214757438|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
214757439|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
214757440|NCT00040001|DRUG|DTI-0009|
214757441|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
214757442|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
214757443|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
214757444|NCT01564680|OTHER|placebo|normal saline
214757445|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
214757446|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
214757447|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
214757448|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
214757449|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
214757450|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
214757451|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
214757452|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
214757453|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
214757454|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
214757455|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
214757456|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
214757457|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
214757458|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
214757459|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
214757460|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
214757461|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
214757462|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
214757463|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
214757464|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
214757465|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
214757466|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
214757467|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
214757468|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
214757469|NCT02729350|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
214757470|NCT02729350|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
214757471|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
214757472|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
214757473|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
214757474|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
214757475|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
214757476|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
214757477|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
214757478|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
214757479|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
214757480|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
214757481|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
214757482|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
214757483|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
214757484|NCT03724422|RADIATION|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
214757485|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
214757486|NCT02173132|DRUG|Acetyl-L-carnitine|
214757487|NCT02173132|OTHER|Placebo|
214757488|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
214757489|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
214757490|NCT04766632|DEVICE|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
214757491|NCT05578586|DRUG|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
214757492|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
214757493|NCT06467916|BEHAVIORAL|Behavioral Treatment|anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
214757494|NCT03978936|BEHAVIORAL|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
214757495|NCT03978936|BEHAVIORAL|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
214757496|NCT05793788|BEHAVIORAL|Outreach Text Messages|"The investigators will send randomized participants an SMS message encouraging them to click provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures. Message content will vary based on randomization arm as noted below."
214757497|NCT05793788|BEHAVIORAL|Specific|The message will inform patients that the care team has identified tests/screenings that they are due for.
214757498|NCT05793788|BEHAVIORAL|General|The message will inform patients that the care team has identified a care gap in their record.
214757499|NCT05793788|BEHAVIORAL|Elevating Intentions|The message will point out that even if patients feel healthy, their doctor recommends them to take care of their health gaps.
214757500|NCT05793788|BEHAVIORAL|Prompting Action|The message will prompt patients to take care of their health gaps right away before they forget.
214757501|NCT03687957|DRUG|rhIL-7-hyFc|-Given by intramuscular injection
214757502|NCT03687957|DRUG|Placebo|-Given by intramuscular injection
214757503|NCT03687957|DRUG|Temozolomide|-Standard of care
214757504|NCT03687957|RADIATION|Radiation therapy|-Standard of care
214757505|NCT03687957|PROCEDURE|Blood sample|"* Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression"
214757506|NCT00823563|PROCEDURE|30 cc blood draw|
214757507|NCT00823563|PROCEDURE|Intravascular ultrasound (IVUS)|
214757508|NCT00823563|PROCEDURE|Coronary pressure/flow wire testing|
214757509|NCT00823563|PROCEDURE|Coronary pressure/flow testing: Acetycholine challenge|
214757510|NCT00823563|PROCEDURE|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
214757511|NCT00823563|PROCEDURE|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
214757512|NCT04711655|PROCEDURE|ARMA (antireflux ablation of the cardiac mucosa)|is an endoscopy in which argon gas ablation of the cardiac mucosa
214757513|NCT04711655|PROCEDURE|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
214757514|NCT05216016|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
214757515|NCT06477588|BEHAVIORAL|Health Navigation|Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
215030718|NCT03193385|PROCEDURE|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
214757516|NCT06477588|BEHAVIORAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
214757517|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
214757518|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
214757519|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
214757520|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
214757521|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
214757522|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
214757523|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
214757524|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
214757525|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
214757526|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
214757527|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
214757528|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
214757529|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
214757530|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
214757531|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
214757532|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
215030719|NCT00543127|DRUG|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
214757533|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
214757534|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
214757535|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
214757536|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
214757537|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
214757538|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
214757539|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
214757540|NCT06309069|OTHER|None, purely observational study|None, purely observational study
214757541|NCT00094146|DRUG|Sandostatin LAR Depot|
214757542|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
214757543|NCT00082134|DRUG|ILX651|
214757544|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
214757545|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
214757546|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
214757547|NCT00489411|OTHER|placebo|Given orally
214757548|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
214757549|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
214757550|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
214757551|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
214757552|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
214757553|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
214757554|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
214757555|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
214757556|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
214757557|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
214757558|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
214757559|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
214757560|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
214757561|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
214757562|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
214757563|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
214757564|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
214757565|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
215030720|NCT00543127|DRUG|Anastrozole|1 mg oral Anastrozole per day during 5 years.
214757566|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
214757567|NCT06566729|OTHER|Peripheral blood sample collection|In this study, peripheral blood samples would be collected before adjuvant chemotherapy, after adjuvant chemotherapy and every 3 months thereafter until 2 years after surgery.
214757568|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
214757569|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
214757570|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
214757571|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
214757572|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
214757573|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
214757574|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
214757575|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
214757576|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
214757577|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
214757578|NCT00267917|DEVICE|Berodual Respimat|
214757579|NCT00267917|DEVICE|Berodual HFA-MDI|
214757580|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
214757581|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
214757582|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
214757583|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
214757584|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
214757585|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
214757586|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
214757587|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
214757588|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
214757589|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
214757590|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
214757591|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
214757592|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
214757593|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
214757594|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
214757595|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
214757596|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
214757597|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
214757598|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
214757599|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
214757600|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
214757601|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
214757602|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
214757603|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
214757604|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
214757605|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
214757606|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
214757607|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
214757608|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
214757609|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
214757610|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
214757611|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
214757612|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
214757613|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
214757614|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
214757615|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
214757616|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
214757617|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
214757618|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
214757619|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
214757620|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
214757621|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
214757622|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
214757623|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
214757624|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
214757625|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
214757626|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
214757627|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
214757628|NCT00308555|DRUG|Cannabis|
214757629|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
214757630|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
214757631|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
214757632|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
214757633|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
214757634|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
214757635|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
214757636|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
214757637|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
214757638|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
214757639|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
214757640|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
214757641|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
214757642|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
214757643|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
214757644|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
214757645|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
214757646|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
214757647|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
214757648|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
214757649|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
214757650|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
214757651|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
214757652|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
214757653|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
214757654|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if… then…. This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
214757655|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
214757656|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
214757657|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
214757658|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
214757659|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
214757660|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
214757661|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
214757662|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
214757663|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
214757664|NCT03869905|DRUG|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
214757665|NCT03869905|DRUG|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
214757666|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
214757667|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
214757668|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
214757669|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
214757670|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
214757671|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
214757672|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
214757673|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
214757674|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
214757675|NCT00052507|DRUG|bortezomib|
214757676|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
214757677|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
214757678|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
214757679|NCT02974270|DRUG|Leuprolide|
214757680|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
214757681|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
214757682|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
214757683|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
214757684|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
214757685|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
214757686|NCT05416567|PROCEDURE|Endovascular embolization|Therapeutic endovascular embolization in general anesthesia
214757687|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
214757688|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
214757689|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
214757690|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
214757691|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
214757692|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
214757693|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
214757694|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
214757695|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
214757696|NCT01224769|DRUG|bendamustine +/- rituximab|
214757697|NCT00910000|DRUG|Vorinostat|
214757698|NCT00910000|DRUG|Carboplatin|
214757699|NCT00910000|DRUG|Gemcitabine|
214757700|NCT05630989|OTHER|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
214757701|NCT05630989|DRUG|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
214757702|NCT05630989|DRUG|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
214757703|NCT05630989|DRUG|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
214757704|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
214757705|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
214757706|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
214757707|NCT03125382|DEVICE|Carelink System|Patients start to perform device data transmission through Carelink system
214757708|NCT03125382|DEVICE|In office standard visit|Patients start or maintain in office standard visits
214757709|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
214757710|NCT06522360|DRUG|Brigatinib|Given by mouth
214757711|NCT06522360|DRUG|Carboplatin|Given by mouth
214757712|NCT06522360|DRUG|Pemetrexed|Given by vein
214757713|NCT02686749|DEVICE|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
214757714|NCT02686749|DRUG|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
214757715|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
214757716|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
214757717|NCT06960460|OTHER|Dental implant surgery with ZygoFixU implants|Adult patients who have had dental implant surgery.
214757718|NCT03778957|DRUG|Durvalumab|Durvalumab IV (intravenous)
214757719|NCT03778957|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
214757720|NCT03778957|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
214757721|NCT03778957|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
214757722|NCT05979987|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
214757723|NCT05979987|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
214757724|NCT05979987|BEHAVIORAL|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
214757725|NCT05979987|BEHAVIORAL|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
214757726|NCT03241511|OTHER|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
214757727|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
214757728|NCT05978492|DRUG|TXN10128|TXN10128: Oral administration once daily everyday
214757729|NCT05978492|DRUG|Irinotecan|Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle
214757730|NCT05978492|DRUG|Paclitaxel|IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)
214757731|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
214757732|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
214757733|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
214757734|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
214757735|NCT06509880|BIOLOGICAL|Placebo|Placebo
214757736|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
214757737|NCT02844231|OTHER|Single-photon emission computed tomography|
214757738|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214757739|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
214757740|NCT02504099|DRUG|ribavirin|Tablet
214757741|NCT06125847|GENETIC|NGGT006|Single intravenous infusion of NGGT006 at dose 1 (7.5e12vg/kg), dose 2 (1.5e13vg/kg) , dose 3 (3e13vg/kg) and dose 4 (4e13vg/kg).
214757742|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
214757743|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
214757744|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
214757745|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
214757746|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
214757747|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
214757748|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
214757749|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
214757750|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
214757751|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
214757752|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
214757753|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
214757754|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
214757755|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
214757756|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
214757757|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
214757758|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
214757759|NCT05240313|BEHAVIORAL|kiR venezolano|A multi-week intervention focused on drug refusal skills and self-regulation.
214757760|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
214757761|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
214757762|NCT00516698|GENETIC|polymorphism analysis|
214757763|NCT00516698|OTHER|high performance liquid chromatography|
214757764|NCT00516698|OTHER|laboratory biomarker analysis|
214757765|NCT00516698|PROCEDURE|radiomammography|
214757766|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
214757767|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
214757768|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
214757769|NCT04651569|OTHER|Observational study|none, Observational study
214757770|NCT06240468|OTHER|not have|not have
214757771|NCT04864704|OTHER|dry needling|Physical therapy
214757772|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
214757773|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
214757774|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
214757775|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
214757776|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain…~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)"
214757777|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
214757778|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
214757779|NCT05056909|OTHER|Standard of care|Standard of care
214757780|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
214757781|NCT00390338|BIOLOGICAL|polarized dendritic cells|
214757782|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
214757783|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
214757784|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
214757785|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
214757786|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
214757787|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
214757788|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
214757789|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
214757790|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
214757791|NCT03522506|DRUG|Modafinil|Modafinil tablets.
214757792|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
214757793|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
214757794|NCT02152930|DRUG|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
214757795|NCT06312917|BEHAVIORAL|Physical activity|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
214757796|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
214757797|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
214757798|NCT04366518|DRUG|Rivastigmine Transdermal System|Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
215030721|NCT02513641|DEVICE|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of \~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
215030722|NCT02853084|DRUG|HL2351|The dose will be adjusted based on disease activities
214757799|NCT04366518|DRUG|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
214757800|NCT04366518|DRUG|Placebo Patch|Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
214757801|NCT04366518|DRUG|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
214757802|NCT01522755|DEVICE|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
214757803|NCT03532399|DRUG|Bivalirudin|"CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos\_f/6317841), but will ultimately be determined by patient's primary provider."
214757804|NCT05312658|PROCEDURE|External aortic compression|External aortic compression by assistant in cesarean section.
214757805|NCT02388906|DRUG|Ipilimumab|Specified dose on specified days
214757806|NCT02388906|DRUG|Nivolumab|Specified dose on specified days
214757807|NCT02388906|OTHER|Placebo matching Ipilimumab|Specified dose on specified days
214757808|NCT02388906|OTHER|Placebo matching Nivolumab|Specified dose on specified days
214757809|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
214757810|NCT04008121|COMBINATION_PRODUCT|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
214757811|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
214757812|NCT04008121|COMBINATION_PRODUCT|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
214757813|NCT06636526|GENETIC|The i4i PRODICT™ test.|The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
214757814|NCT06636526|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all participants identified as high risk from the i4i PRODICT™ test for three years in order to track development of cancer in the future.
214757815|NCT06636526|PROCEDURE|MRI Scan|MRI scan will be offered to participants identified in the high-risk category of the i4i PRODICT™ test depending on their PSA test results. Where PSA is above age-specific threshold (\&gt;2.5ug/L for people with prostates (PwPs) aged 40-50 years and \&gt;3.5ug/L for PwPs aged 50-55 years), those with raised PSA levels will be referred for multiparametric MRI at The Royal Marsden Hospital.
214757816|NCT06636526|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to to participants identified in the high-risk category of the i4i PRODICT™ test depending on their MRI results. Where a lesion is visible on MRI (defined as a PIRAD score ≥3) onward referral will be made for a transperineal targeted prostate biopsy (or current gold standard NHS practice).
214757817|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
214757818|NCT04365387|DRUG|Nemolizumab|Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
214757819|NCT04365387|DRUG|Placebo|Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
214757820|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
214757821|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
214757822|NCT05440942|DRUG|Trametinib|Trametinib will be administered orally once daily via tablet.
214757823|NCT05440942|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily (BID) via tablet.
214757824|NCT05440942|DRUG|Retifanlimab|Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
214757825|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
214757826|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
214757827|NCT06798389|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post-appointment follow-up call.
214757828|NCT03804853|OTHER|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
214757829|NCT05043857|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
214757830|NCT04594772|DRUG|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
214757831|NCT04594772|DRUG|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
214757832|NCT04594772|RADIATION|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
214757833|NCT04594772|PROCEDURE|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
214757834|NCT04298203|DRUG|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
214757835|NCT04298203|DIETARY_SUPPLEMENT|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
214757836|NCT04298203|OTHER|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
214757837|NCT04785287|BIOLOGICAL|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
214757838|NCT04785287|BIOLOGICAL|Nivolumab|Given IV
214757839|NCT04785287|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214757840|NCT04810377|PROCEDURE|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
214757841|NCT05637879|DRUG|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
214757842|NCT05637879|OTHER|Placebo|Compounded, inactive pill equal in appearance to active study drug
214757843|NCT04741256|BEHAVIORAL|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
214757844|NCT05658432|OTHER|Exercise via telehealth|Same as arm/group description
214757845|NCT05658432|OTHER|Exercise unsupervised|Same as arm/group description
214757846|NCT04469790|BEHAVIORAL|SIT+WALK|Participants will interrupt their sitting for one week
214757847|NCT04469790|BEHAVIORAL|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
214757848|NCT04708717|BEHAVIORAL|Stimulation Rate|Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
214757849|NCT04708717|BEHAVIORAL|Electrode Location|Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
214757850|NCT06160414|DRUG|Metformin|Participants will receive Metformin orally, after fasting.
214757851|NCT06160414|DRUG|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
214757852|NCT06160414|DRUG|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
214757853|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
214757854|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
214757855|NCT06545552|DIETARY_SUPPLEMENT|An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast|Hard shell capsule containing 280mg of the oral formulation
214757856|NCT06545552|DIETARY_SUPPLEMENT|Placebo|Hard shell capsule containing maltodextrine
214757857|NCT05479708|DEVICE|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
214757858|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
214757859|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
214757860|NCT06071767|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
214757861|NCT06071767|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
214757862|NCT06071767|BIOLOGICAL|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
214757863|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
214757864|NCT06071767|DRUG|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
214757865|NCT06071767|DRUG|GS-5423|Administered via intravenous (IV) infusion at week 7
214757866|NCT06071767|DRUG|GS-2872|Administered via IV infusion at week 7
214757867|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
214757868|NCT06071767|BIOLOGICAL|Placebo|Placebos for vaccines, VES, and bnAbs
214757869|NCT06467981|OTHER|Retrospective study|The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.
214757870|NCT05329961|DRUG|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
214757871|NCT05355545|BEHAVIORAL|Virtually supervised exercise|Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
214757872|NCT05355545|BEHAVIORAL|Health education|Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
214757873|NCT06798922|RADIATION|Standard post-operative radiotherapy without flap sparing (current practice)|Standard post-operative radiotherapy without flap sparing (current practice)
214757874|NCT06798922|RADIATION|Post-operative radiotherapy with flap sparing|Post-operative radiotherapy with flap sparing
214757875|NCT05598255|DRUG|Dexamethasone|During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).
214757876|NCT05598255|PROCEDURE|Caudale Blockade with levobupivacaine|Administration of levobupivacaine 0,25%0,5ml/kg through the hiatus sacralis lege artis, before incision.
214757877|NCT05598255|PROCEDURE|Dorsal penile nerve block with levobupivacaine|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.
214757878|NCT06066424|DRUG|Rimiducid|Given by (IV) vein
214757879|NCT06066424|DRUG|TROP2-CAR-NK Cells|Given by (IV) vein
214757880|NCT06066424|DRUG|Fludarabine phosphate|Given by (IV) vein
214757881|NCT06066424|DRUG|Cyclophosphamide|Given by (IV) vein
214757882|NCT02392312|DRUG|ATF-Fresenius S|intravenous
214757883|NCT02717156|PROCEDURE|Computed Tomography|Correlative studies
214757884|NCT02717156|OTHER|Laboratory Biomarker Analysis|Correlative studies
214757885|NCT02717156|BIOLOGICAL|Pembrolizumab|Given IV
214757886|NCT02717156|PROCEDURE|Positron Emission Tomography|Correlative studies
214757887|NCT02717156|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214757888|NCT04591093|DEVICE|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
214757889|NCT02780310|DRUG|Lenvatinib|
214757890|NCT05690282|DRUG|Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|Multimodal Pain Management to minimize patients' reliance on opioids.
214757891|NCT06500819|DRUG|B7-H3CART Dose (Intravenous)|"Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg"
214757892|NCT06137742|DRUG|PF-07868489|Experimental Treatment
214757893|NCT06137742|DRUG|Placebo for PF-07868489|Placebo
214757894|NCT05866107|DEVICE|"Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention (SWIM trial)"|"Participants receive a digital-behavioral intervention via Huawei Health App and smart scale:~1. Weekly weigh-ins (auto-synced)~2. Dietary logging (≥3x/week) with calorie-deficit targets~3. Biweekly exercise plans (150-300 min/week)~4. Weekly motivational messages~Implementation:~Staggered rollout: Batch 1 (Month 3-6), Batch 2 (Month 5-6). Includes 2-week training. Effectiveness monitored via app metrics and adherence. Routine care maintained."
214757895|NCT04715451|OTHER|Novel Swaddle|A novel swaddling method.
214757896|NCT05751473|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
214757897|NCT05751473|BEHAVIORAL|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
214757898|NCT04410991|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
214757899|NCT04410991|DRUG|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
214757900|NCT04410991|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
214757901|NCT04410991|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
214757902|NCT05545007|RADIATION|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
214757903|NCT05545007|PROCEDURE|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
214757904|NCT06579079|OTHER|Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy.
214757905|NCT06579079|OTHER|Waitlist Comparison - Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy. Participating schools receiving this treatment will wait one year before developing an implementation strategy for testing.
214757906|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
214757907|NCT06167096|OTHER|Water|Water
214757908|NCT05870202|OTHER|screening tool|The screening tool identifies areas of treatment burden in patients with type 2 diabetes. The tool is in the form of a brief questionnaire that the patient completes prior to a clinical appointment. The patient's responses to the questionnaire are then included in the discussion with the patient's primary care clinician during the clinical visit.
214757909|NCT04256018|DRUG|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
214757910|NCT04256018|RADIATION|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
214757911|NCT06638801|BEHAVIORAL|Coach-led caregiver-implemented early literacy and developmental programming|Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
214757912|NCT06638801|BEHAVIORAL|Reach Out and Read Training|Reach Out and Read parent training
214757913|NCT04208217|BEHAVIORAL|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
214757914|NCT04208217|BEHAVIORAL|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
214757915|NCT03282123|DRUG|Midomafetamine|80 to 120 mg MDMA
214757916|NCT03282123|BEHAVIORAL|Manualized therapy|Non-directive therapy conducted during MDMA-assisted therapy session
214757917|NCT06022159|RADIATION|Hypofractionated Radiation Therapy|The Hypofractionated Intensity-Modulated Radiation Therapy will be delivered in 5 fractions of 6 Gy each on the Planning Target Volume (PTV). The total dose of 30 Gy will be administered in approximately 1 week.
214757918|NCT06022159|PROCEDURE|Conservative treatment|A wide en bloc resection is required (amputation is excluded) while ensuring the best functional preservation. The surgical procedure will take place about 1,5 to 2 months after the end of the radiation therapy.
215030723|NCT03807648|OTHER|Data Inclusion|Patients in this group will be included in the project
215030724|NCT02235688|DRUG|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
215030725|NCT02235688|DRUG|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
215030726|NCT02235688|DRUG|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
215030727|NCT02235688|DRUG|gemcitabine|
214757919|NCT04082234|BEHAVIORAL|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
214757920|NCT04082234|OTHER|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
214757921|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
214757922|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
214757923|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
214757924|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
214757925|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
214757926|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
214757927|NCT01955824|DRUG|1% lignocaine|
214757928|NCT01955824|DRUG|2% lignocaine|
214757929|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
214757930|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
214757931|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
214757935|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
214757936|NCT01367626|DRUG|letrozole|2.5 mg tablet
214757937|NCT01367626|DRUG|letrozole|2.5 mg tablet
214757938|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
214757939|NCT04214470|OTHER|No intervention|There is no intervention for this study
214757940|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
214757941|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
214757942|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
214757943|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
214757944|NCT00911560|BIOLOGICAL|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or \>2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
214757945|NCT00911560|BIOLOGICAL|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
214757946|NCT06150183|BIOLOGICAL|BNT314|Intravenous infusion
214757947|NCT01211405|DRUG|Low dose MDMA-assisted therapy|30 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg 1.5 to 2 hours later
214757948|NCT01211405|DRUG|Medium dose MDMA-assisted therapy|75 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg 1.5 to 2 hours later
214757949|NCT01211405|DRUG|Full dose MDMA-assisted therapy|125 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg 1.5 to 2 hours later
214757950|NCT01211405|BEHAVIORAL|Therapy|Non-directive therapy during each session
214757951|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
214757952|NCT05011357|DRUG|Saline Control|Saline infusion
214757953|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
214757954|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
215030728|NCT02122185|DRUG|metformin hydrochloride|Given PO
215030729|NCT02122185|DRUG|placebo|Given PO
215030730|NCT02122185|DRUG|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
214757955|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
214757956|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
214757957|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
214757958|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
214757959|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
214757960|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
214757961|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
214757962|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
214757963|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
214757964|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
214757965|NCT01197846|DRUG|Placebo|Placebo
214757966|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
214757967|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
214757968|NCT00243620|DEVICE|Vacuum therapy (device)|
214757969|NCT04155567|DRUG|TAK-123|TAK-123 infusion
214757970|NCT00003266|DRUG|methylphenidate hydrochloride|
214757971|NCT00003266|PROCEDURE|quality-of-life assessment|
214757972|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
214757973|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
214757974|NCT06221111|DRUG|Rimegepant 75 MG [Nurtec]|placebo controlled trial
214757975|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214757976|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
214757977|NCT02596074|DRUG|Vehicle topical gel|
214757978|NCT01463631|DRUG|LY3007113|Administered orally
214757979|NCT05847023|BEHAVIORAL|LUNA|see description above
214757980|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
214757981|NCT04689334|OTHER|Outcome|The number of surgeries
214757982|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
214757983|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
214757984|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
214757985|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
214757986|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
214757987|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
214757988|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
214757989|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
214757990|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
214757991|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
214757992|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
214757993|NCT00078663|BEHAVIORAL|Oral Care|
214757994|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
214757995|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
214757996|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
214757997|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
214757998|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
214757999|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
214758000|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
214758001|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
214758002|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
214758003|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
214758004|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
214758005|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
214758006|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
214758007|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
214758008|NCT03804554|OTHER|Non-Interventional|Non-Interventional
214758009|NCT06288607|DEVICE|High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)|Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. Patients are to be treated with two macro-focused handpieces with focal depths at 3.0 mm (D3.0) and 4.5 mm (D4.5) on both side. Following the treatment, local cooling with an ice pack was performed for 10 min to reduce redness and swelling. Patients were followed up at 2, 4, 6, and 8 weeks. Clinical images and non-invasive skin assessments were collected at baseline and during each visit.
214758010|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
214758011|NCT00667069|DRUG|triptorelin|
214758012|NCT00667069|PROCEDURE|adjuvant therapy|
214758013|NCT00667069|RADIATION|3-dimensional conformal radiation therapy|
214758014|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
214758015|NCT06502002|DRUG|Placebo|normal saline infusion
214758016|NCT04394858|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214758017|NCT04394858|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
214758018|NCT04394858|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214758019|NCT04394858|DRUG|Olaparib|Given PO
214758020|NCT04394858|OTHER|Quality-of-Life Assessment|Ancillary studies
214758021|NCT04394858|DRUG|Temozolomide|Given PO
214758022|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
214758023|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
214758024|NCT05754632|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
214758025|NCT06279273|DEVICE|Transcranial direct current stimulation|Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
214758026|NCT01298323|BEHAVIORAL|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
214758027|NCT01298323|DRUG|Vandetanib|Treatment 300mg vandetanib opel label.
214758028|NCT01333046|BIOLOGICAL|Antigen-Escalation Stage|"Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~* Day 0: PRAME-specific T cells~* Day 28: PRAME- and SSX-specific T cells~Schedule Two:~* Day 0: PRAME- and SSX-specific T cells~* Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~* Day 0: PRAME/SSX/MAGE-specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
214758029|NCT01333046|BIOLOGICAL|Dose-Escalation Stage|"Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2~DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2~DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2"
214758030|NCT01333046|BIOLOGICAL|azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~1. ANC \>1,000 or Platelets \>50,000 (or any other grade I AE attributable to aza)~   Adjustment: None~2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~   Adjustment: 50% dose reduction~3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion"
214758031|NCT01333046|BIOLOGICAL|Pediatric multiTAA T cells Stage|Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
214758032|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
214758033|NCT05354349|DRUG|PRA023 SC|Drug
214758034|NCT05354349|DRUG|Placebo IV|Placebo
214758035|NCT05354349|DRUG|Placebo SC|Placebo
214758036|NCT05354349|DRUG|PRA023 IV High Dose|Drug
214758037|NCT04723264|BEHAVIORAL|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
214758038|NCT04089566|DRUG|Nusinersen|Administered as specified in the treatment arm
214758039|NCT06815055|OTHER|Quality of life questionnary|Subjects will be call 1 month and 6 months after prostetectomy to evaluate the type of reeducation received and they will be evaluated with the help of QoL questionnaries : KHQ-HR QoL and ICIQ-SF QoL
214758040|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
214758041|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
214758042|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
214758043|NCT03572153|BEHAVIORAL|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
214758044|NCT03572153|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
214758045|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
214758046|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
214758047|NCT06986109|DRUG|Ketamine|Ketamine (concentration 5mg/ml) will be administered at 0.05-ml/kg over 5-minutes followed by continuous intraoperative ketamine infusion of 0.05-ml/kg /h.
215030731|NCT00131885|DIETARY_SUPPLEMENT|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
214758048|NCT06986109|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
214758049|NCT06986109|DRUG|Placebo|Normal saline bolus 0.05-ml/kg will be administered over 5-minutes and it will be followed by continuous intraoperative normal saline infusion at 0.05-ml/kg /h.
214758050|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
214758051|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
214758052|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
214758053|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
214758054|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
214758055|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
214758056|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
214758057|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
214758058|NCT05852301|OTHER|no intervention|no intervention, observational study only
214758059|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
214758060|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214758061|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
214758062|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
214758063|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
214758064|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
214758065|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
214758066|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
214758067|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
214758068|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
214758069|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
214758070|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
214758071|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
214758072|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
214758073|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
214758074|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
214758075|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
214758076|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
214758077|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
214758078|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
214758079|NCT06995131|DIAGNOSTIC_TEST|Del 1|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. DEL 1 will be analyzed by ELISA
214758080|NCT06995131|DIAGNOSTIC_TEST|IL 17|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. IL 17 levels will be analyzed by ELISA
214758081|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
214758082|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
214758083|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
214758084|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
214758085|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
214758086|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
214758087|NCT03115723|PROCEDURE|Coronary angiography|
214758088|NCT05173025|DRUG|Fimasartan|\- Fimasartan group: fimasartan, 60 mg once a day, oral administration
214758089|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
214758090|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
214758091|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
214758092|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
214758093|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
214758094|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
214758095|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
214758096|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
214758097|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
214758098|NCT04235673|DRUG|placebo|orally administered drops
214758099|NCT07000214|DEVICE|Peripheral magnetic stimulation|During the warm-up exercise, 10-Hz rPMS will be applied to the tibialis anterior with an on-time of 4 seconds (40 pulses per train), followed by an off-time (inter-train interval) of 8 seconds, for a total of 25 trains for each leg. During the one-leg stance exercise, 20-Hz rPMS will be applied to the plantar surface of the standing foot for 3 seconds of on-time (60 pulses per train), followed by 12 seconds of off-time, for a total of 20 trains for each foot. Stimulation intensity will be set at 110% of MCT for the warm-up exercise and 120% of MCT for the treatment during the one-leg stance exercise.
214758100|NCT07000214|BEHAVIORAL|Balance training|The warm-up exercise consists of 25 repetitions of 4-second active contractions of the tibialis anterior muscle in each leg while seated. Following the warm-up, participants will stand on the MAGBATA platform and perform 20 cycles of one-leg stance exercises under the supervision of a physiotherapist. Each cycle lasts 20 seconds, consisting of 3 seconds of one-leg stance while the other leg is raised about 10 centimeters above the ground, followed by 12 seconds of rest during which the participant stands on both legs, keeping their arms close to their body and hands free. The same sequence will then be repeated for the other leg. To prevent falling, participants will wear a safety belt around the waist, allowing the physiotherapist to assist if they lose balance. Participants will also be allowed to grab the walker positioned in front of them to prevent falling.
214758101|NCT07000214|OTHER|Sham stimulation|During the warm-up exercise, the stimulation coil will be placed perpendicular to the participants' shin. The same parameter settings will be used, except for the intensity, which will be set at 30% of the maximum stimulator output (MSO). Sham stimulation during the one-leg stance exercise is achieved by disconnecting the coil mounted in MAGBATA and placing an alternate coil, connected to the magnetic stimulator placed behind the participants so they can hear a clicking pattern similar to that of the rPMS-BT arm.
214758102|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
214758103|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
214758104|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
214758105|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
214758106|NCT06999486|OTHER|CAT well-being test|Evaluate the psychometric properties (e.g., reliability, validity) of the Computerized Adaptive Testing (CAT) system for assessing the well-being of caregivers of children with Type 1 Diabetes (T1D).
214758107|NCT06858085|OTHER|Turkish Version of the Late Life Function and Disability Instrument|The Late Life Function and Disability Instrument (LLFDI) was developed to assess significant changes in functional and disability categories
214758108|NCT07005882|DRUG|Elacestrant|Preoperative treatment
214758109|NCT07005882|RADIATION|PULSAR|Preoperative treatment
214758110|NCT07006038|DEVICE|Veinlite PEDI2|The Veinlite PEDI2 used before the catheter insertion.
214758111|NCT07007455|BEHAVIORAL|wrist extensor strength training with BFR.|Wrist extensor strength training without BFR.
214758112|NCT06867367|BEHAVIORAL|Isha Kriya and Naddi Shuddhi|Isha Kriya, a 15-minute guided meditation, and Nadi Shuddhi, a 3-5-minute alternate-nostril breathing practice. Participants in the intervention groups will be instructed to practice ideally twice or at least once daily.
214758113|NCT07005180|DRUG|HBI-002|Oral liquid containing carbon monoxide
214758114|NCT07005180|DRUG|Vehicle (placebo)|Vehicle control (placebo)
214758115|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1000mg
214758116|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1500mg
214758117|NCT07007221|DRUG|Metformin|8 weeks of Metformin
214758118|NCT07007221|OTHER|Placebo|8 weeks placebo drug
214758119|NCT07007221|DRUG|Metformin|12 weeks of Metformin
214758120|NCT07007221|DRUG|Fluoxetine|12 weeks of Fluoxetine
214758121|NCT07007221|DRUG|Metformin+Fluoxetine|12 weeks of Metformin+Fluoxetine
214758122|NCT07007221|OTHER|double placebo|12 weeks of double placebo
214758123|NCT07006337|OTHER|Surgical Operating Room Enrichment Course|The intervention consists of multiple structured training sessions delivered during the gynecology rotation. Sessions include lectures on surgical principles and gynecologic procedures. The course is taught by OBGYN physicians and is designed to enhance students' proficiency in surgical techniques, perioperative care, and management of gynecologic emergencies. Educational materials are based on relevant surgical guidelines and textbooks
214758124|NCT07006337|OTHER|Active Comparator #1|Active Comparator #1
214758125|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
214758126|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
214758127|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
214758128|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
214758129|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
214758130|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
214758131|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
214758132|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
214758133|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
214758134|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
214758135|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
214758136|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
214758137|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
214758138|NCT04373616|BIOLOGICAL|ACI-24|injections
214758139|NCT04373616|BIOLOGICAL|Placebo|injections
214758140|NCT05810415|DIAGNOSTIC_TEST|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
214758141|NCT05818215|OTHER|NO intervention|NO intervention
214758142|NCT02490111|DRUG|DWJ1319|
214758143|NCT02490111|DRUG|Placebo|
215030732|NCT00131885|DIETARY_SUPPLEMENT|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
215030733|NCT00131885|DRUG|Levonorgestrel|Levonorgestrel in a single oral dose
215030734|NCT04266912|DRUG|Avelumab|Given IV
215030735|NCT04266912|DRUG|Berzosertib|Given IV
215030736|NCT06858683|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16pm) followed by a 16 h fasting period.
215030737|NCT06858683|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period.
214758144|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
214758145|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
214758146|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
214758147|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
214758148|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
214758149|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
214758150|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
214758151|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
214758152|NCT00001658|DRUG|Amoxicillin|
214758153|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
214758154|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
214758155|NCT01255449|DRUG|albuterol|400 mcg by inhalation
214758156|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
214758157|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
214758158|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
214758159|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
214758160|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
214758161|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
214758162|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
214758163|NCT00106860|DRUG|a benzodiazepine drug|
214758164|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
214758165|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
214758166|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
214758167|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
214758168|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
214758169|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
214758170|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
214758171|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
214758172|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
214758173|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
214758174|NCT01156636|DRUG|Placebo|
214758175|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
214758176|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
214758177|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
214758178|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
214758179|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
214758180|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
214758181|NCT03138707|OTHER|patients who die|
214758182|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
214758183|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
214758184|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
214758185|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
214758186|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
214758187|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
214758188|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
214758189|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
214758190|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
214758191|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
214758192|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
214758193|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
214758194|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
214758195|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
214758196|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
214758197|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
214758198|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
215030738|NCT06667869|DRUG|Sedative|Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
215030739|NCT02953457|BIOLOGICAL|Durvalumab|Given IV
215030740|NCT02953457|OTHER|Laboratory Biomarker Analysis|Correlative studies
214758199|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
214758200|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
214758201|NCT01042431|OTHER|No Intervention|No intervention
214758202|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
214758203|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
214758204|NCT06722898|DIETARY_SUPPLEMENT|Supplement|Contains ingredients believed to reduce Blood Alcohol Concentration and symptoms of alcohol impairment.
214758205|NCT06722898|DIETARY_SUPPLEMENT|Placebo|Placebo
214758206|NCT06722508|BEHAVIORAL|exercise and nutritional prehabilitation|The study involves a behavioral intervention (exercise and nutritional prehabilitation) designed to assess outcomes related to feasibility, acceptability, and safety in head and neck cancer patients. Outcomes are being measured following the intervention over a defined period (from diagnosis through 1-month post-surgery).
214758207|NCT06722638|OTHER|Use of Virtual Reality Headset|Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
214758208|NCT06723730|PROCEDURE|Upper Quadrant Core Strengthening protocol|"Upper Quadrant Core Strengthening protocol Core strengthening protocol will comprise of following four week protocol.~1. Week one Scapular postural correction and shoulder shrugging exercises~2. Week two External rotation at 0 degree~3. Week three Internal rotation at 0 degree~4. Week four Standing row at 45 and 90 degree , Anterior shoulder stretch and Thoracic exercise in sitting"
214758209|NCT06723730|PROCEDURE|Mobilization with movement|"In addition to upper quadrant core strengthening protocol participants will also perform mobilization with movement.~Mobilization with movement protocol will comprise of following forms.~1. Acromioclavicular joint glides~2. Scapular glides~3. Glenohumeral joint glides ( inferior glides, postero-lateral glides, postero-inferior)"
214758210|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
214758211|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
214758212|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
214758213|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
214758214|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
214758215|NCT06892834|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214758216|NCT06892834|DRUG|Sodium Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214758217|NCT06892834|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
214758218|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
214758219|NCT06523166|PROCEDURE|Transesophageal echocardiography (TEE)|TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
214758220|NCT06523166|PROCEDURE|Cardiac CTA|Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
214758221|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
214758222|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
214758223|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
215030741|NCT02953457|DRUG|Olaparib|Given PO
215030742|NCT02953457|BIOLOGICAL|Tremelimumab|Given IV
215030743|NCT06905223|DIETARY_SUPPLEMENT|MQU10|MQU10 consists of a blend of food-grade probiotic strains (20 billion CFU daily) and prebiotic compounds.
214758224|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
214758225|NCT06911957|DIETARY_SUPPLEMENT|Prebiotic blend|10g of prebiotic fibre blend powder
214758226|NCT06911957|DIETARY_SUPPLEMENT|Placebo|10g of matched placebo powder
214758227|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
214758228|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
214758229|NCT06518616|BEHAVIORAL|10-day meditation intervention|prerecorded meditation units delivered by smartphone app
214758230|NCT06518616|BEHAVIORAL|10-day health education intervention|prerecorded health education units delivered by smartphone app
214758231|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
214758232|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
214758233|NCT06222138|OTHER|The samples described below will be collected:|"For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure."
214758234|NCT06942273|RADIATION|hyperthermia|hyperthermia over the carpal tunnel area and adjacent areas
214758235|NCT06942273|OTHER|physical exercise|Performing therapeutic physical exercise focused on the flexor muscles of the hand and neural stretching
214758236|NCT06942273|OTHER|splint|imposition of a night splint
214758237|NCT06943300|OTHER|Aerboic Training|Group A will perform Aerobic training exercises will be conducted 2 times per 12 weeks in which the warm up phase for 10 minutes. 30 minutes of aerobic exercise like walking, jogging, cycling, calisthenics, rhythmic exercises, continuous slow running, sit ups and cool down phase for stretching Phase 1: stretching of upper limb, trunk, lower limb muscles for 10 minutes. Phase 2: Individualized walking, jogging, cycling, rhythmic exercises, continuous slow running, sit ups Phase 3: Cool down exercise for 10 minutes.
214758238|NCT06943300|OTHER|Circuit Training|The training program will consist of 10 types of resistance and aerobic exercise and will be done 2 times per week for 12 weeks. Specifically, the resistance exercise program comprises of push-up, squat, crunches, lunge and superman exercise. An aerobic exercise program comprises of light jumping, running on the spot, foot stamping, stepping and jumping jack. Phase 1: In Warm up period, dynamic stretching for 10 minutes. Phase 2: Resistance and aerobic exercise (push-up, squat, crunches, lunge and superman exercise, light jumping, running on the spot, foot stamping, stepping and jumping jack) Phase 3: In cool down period, static stretching for 10 minutes.
214758239|NCT06942208|DIETARY_SUPPLEMENT|Low-dose iron (ferrous sulfate)|Encapsulated low-dose ferrous sulphate (40mg elemental iron)
214758240|NCT06942208|DIETARY_SUPPLEMENT|Yeast-bound iron (ferrous sulfate)|Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)
214758241|NCT06942208|DIETARY_SUPPLEMENT|High-dose iron (ferrous sulfate)|Encapsulated high-dose ferrous sulphate (150mg elemental iron)
214758242|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
214758243|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
214758244|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
214758245|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
214758246|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
214758247|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
214758248|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
214758249|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
214758250|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
214758251|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
214758252|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
214758253|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
214758254|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
214758255|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
214758256|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
214758257|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
214758258|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
214758259|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
214758260|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
214758261|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
214758262|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
214758263|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
214758264|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
214758265|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
214758266|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
214758267|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
214758268|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
214758269|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
214758270|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
214758271|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
214758272|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
214758273|NCT03563729|DRUG|Trametinib|In combination with trametinib
214758274|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
214758275|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
214758276|NCT02696837|DEVICE|ETT|
214758277|NCT02696837|DEVICE|Proseal LMA|
214758278|NCT02696837|DRUG|Rocuronium|
214758279|NCT02696837|OTHER|No Muscle Relaxant|
214758280|NCT02696837|DRUG|Rocuronium|
214758281|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
214758282|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
214758283|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
214758284|NCT02500173|RADIATION|Radiation|Radiation therapy
214758285|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
214758286|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
214758287|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
214758288|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
214758289|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
214758290|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
214758291|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
214758292|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
214758293|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
214758294|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
214758295|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
214758296|NCT00608127|DEVICE|LupusorbTM|Single treatment
214758297|NCT06648408|PROCEDURE|Balett Training|The ballet training will happen twice a week for six weeks, with each session lasting 60 minutes, for a total of 12 sessions. These sessions will be held in groups of 10 to 12 children and led by experienced ballet teachers. The classes will follow a beginner-level ballet routine, introducing the kids to ballet techniques in a fun and playful way, making sure they learn the movements step by step. Each lesson will follow the same structure, allowing the children to improve their skills week after week. In addition to the group sessions, the children will be given a 10-minute daily home exercise program. This will include simple ballet exercises they learned in their first class, which they should practice on the five days when they don't have ballet sessions. The children will track their practice in a child-friendly diary designed just for them.
214758298|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
214758299|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
214758300|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
214758301|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
214758302|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
214758303|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
214758304|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
214758305|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
214758306|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
214758307|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
214758308|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
214758309|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
214758310|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
214758311|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
214758312|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
214758313|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
214758314|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
214758315|NCT02670356|DIETARY_SUPPLEMENT|Fish oil|two 750 mg/capsules/day
214758316|NCT02670356|DIETARY_SUPPLEMENT|Krill oil|one 300 mg capsule/day
214758317|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
214758318|NCT05703009|DRUG|Placebo|Placebo
214758319|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
214758320|NCT02389621|DRUG|Placebo|Tablets for oral administration
214758321|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
214758322|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
214758323|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
214758324|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
214758325|NCT01782638|BEHAVIORAL|deep brain stimulation|
214758326|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
214758327|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
214758328|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
214758329|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
214758330|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
214758331|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
214758332|NCT02999646|OTHER|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
214758333|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
214758334|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
214758335|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
214758336|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
214758337|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
214758338|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
214758339|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
214758340|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
214758341|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
214758342|NCT01002118|DRUG|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
214758343|NCT01002118|DRUG|Placebo|4 capsules each day for 16 weeks
214758344|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
214758345|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
214758346|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
214758347|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
214758348|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
214758349|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
214758350|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
214758351|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
214758352|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
214758353|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
214758354|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
214758355|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
214758356|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
214758357|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
214758358|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
214758359|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
214758360|NCT01511562|DRUG|carmustine|Given IV
214758361|NCT01511562|DRUG|cytarabine|Given IV
214758362|NCT01511562|DRUG|etoposide|Given IV
214758363|NCT01511562|DRUG|thiotepa|Given IV
214758364|NCT01511562|PROCEDURE|stem cell transplant|
214758365|NCT01511562|DRUG|G-CSF|
214758366|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
214758367|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
214758368|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
214758369|NCT02494882|DRUG|Ruxolitinib|
214758370|NCT02494882|DRUG|Dasatinib|
214758371|NCT02494882|DRUG|Dexamethasone|
214758372|NCT00231530|DRUG|topiramate|
214758373|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
214758374|NCT00201630|DRUG|Uroxatrol (drug)|
214758375|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
214758376|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
214758377|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
214758378|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
214758379|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
214758380|NCT01473602|DRUG|Teriparatide|Administered by SC injection
214758381|NCT01473602|DRUG|Placebo|Administered by SC injection
214758382|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
214758383|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
214758384|NCT00020995|PROCEDURE|therapeutic dietary intervention|
214758385|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
214758386|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
214758387|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
214758388|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
214758389|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
214758390|NCT01587807|DRUG|LPS|50 μg
214758391|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
214758392|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
214758393|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
214758394|NCT00449761|DRUG|LBH589|
214758395|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
214758396|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
214758397|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
214758398|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
214758399|NCT01969201|DRUG|Urofollitrophin|
214758400|NCT01969201|DRUG|Follitrophin alpha|
214758401|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
214758402|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
214758403|NCT00625768|DRUG|AS1409|Study drug
214758404|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
214758405|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
214758406|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
214758407|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
214758408|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
214758409|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
214758410|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
214758411|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
214758412|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
214758413|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
214758414|NCT01422876|DRUG|high dose FDC|once daily
214758415|NCT01422876|DRUG|BI 10773 high dose|once daily
214758416|NCT01422876|DRUG|high dose FDC placebo|once daily
214758417|NCT01422876|DRUG|low dose FDC placebo|once daily
214758418|NCT01422876|DRUG|high dose FDC placebo|once daily
214758419|NCT01422876|DRUG|high dose FDC placebo|once daily
214758420|NCT01422876|DRUG|low dose FDC placebo|once daily
214758421|NCT01422876|DRUG|low dose FDC placebo|once daily
214758422|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
214758423|NCT01422876|DRUG|low dose FDC|once daily
214758424|NCT01422876|DRUG|high dose FDC placebo|once daily
214758425|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
214758426|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
214758427|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
214758428|NCT01422876|DRUG|linagliptin|once daily
214758429|NCT01422876|DRUG|low dose FDC placebo|once daily
214758430|NCT01422876|DRUG|linagliptin placebo|once daily
214758431|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
214758432|NCT01422876|DRUG|linagliptin placebo|once daily
214758433|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
214758434|NCT01422876|DRUG|linagliptin placebo|once daily
214758435|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
214758436|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
214758437|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
214758438|NCT01422876|DRUG|linagliptin placebo|once daily
214758439|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
214758440|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
214758441|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
214758442|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
214758443|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
214758444|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
214758445|NCT01166074|BIOLOGICAL|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
214758446|NCT00374465|DRUG|Verapamil|
214758447|NCT00374465|DRUG|Carvedilol|
214758448|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
214758449|NCT00305331|DRUG|Domperidone (drug)|
214758450|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
214758451|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
214758452|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
214758453|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
215030744|NCT05134883|OTHER|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
214758454|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
214758455|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
214758456|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
214758457|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
214758458|NCT00540735|PROCEDURE|photodynamic therapy|
214758459|NCT00567086|DRUG|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
214758460|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
214758461|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
214758462|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
214758463|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
214758464|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
214758465|NCT02423564|OTHER|Placebo|
214758466|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
214758467|NCT01541410|DEVICE|Vascutek Hybrid Graft|Single Group Assignment
214758468|NCT06491719|OTHER|NCR300（Allogenic Ipsc-derived Natural Killer cells ）|"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."
214758469|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
214758470|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
214758471|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
214758472|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
214758473|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
214758474|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
214758475|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
214758476|NCT04800159|DRUG|Placebo|Vaporization of placebo
214758477|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214758478|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
214758479|NCT02515175|DRUG|Placebo|0.9% Normal Saline
214758480|NCT02952300|PROCEDURE|neolix|single rotation file
214758481|NCT02952300|PROCEDURE|wave one|single reciprocation file
214758482|NCT02016027|DRUG|Carica folia|
214758483|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
214758484|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
214758485|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
214758486|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
214758487|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
214758488|NCT00054639|BIOLOGICAL|rituximab|Given IV
214758489|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
214758490|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
214758491|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
214758492|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
214758493|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
214758494|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
214758495|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
214758496|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
214758497|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
214758498|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
214758499|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
214758500|NCT00238108|DRUG|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
214758501|NCT00238108|DRUG|Placebo|Placebo
214758502|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
214758503|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
214758504|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
214758505|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
214758506|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
214758507|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
214758508|NCT03291249|OTHER|placebo|Placebo oral solution
214758509|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
214758510|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
214758511|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
214645431|NCT05417490|DEVICE|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~* characterization of alerts~* structured follow-up of remote patients.~This non-medical human assistance is provided by:~* nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~* to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~* remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
214645432|NCT02979977|DRUG|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
214645433|NCT02979977|DRUG|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
214645434|NCT06104306|DRUG|B/F/TAF|Tablets administered without regard to food
214758512|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
214758513|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
214758514|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
214758515|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
214758516|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
214758517|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
214758518|NCT03207607|OTHER|Snack skipping|no snack
214758519|NCT02192307|DEVICE|Potassium oxalate|
214758520|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
214758521|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
214758522|NCT06023511|DEVICE|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
214758523|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
214758524|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
214758525|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
214758526|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
214645435|NCT06357676|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214645436|NCT06357676|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214645437|NCT06357676|PROCEDURE|Computed Tomography|Undergo CT scan or FDG PET/CT
214645438|NCT06357676|PROCEDURE|Echocardiography|Undergo echocardiography
214645439|NCT06357676|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
214645440|NCT06357676|BIOLOGICAL|Glofitamab|Given IV
214645441|NCT06357676|DRUG|Ibrutinib|Given PO
214645442|NCT06357676|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214645443|NCT06357676|BIOLOGICAL|Obinutuzumab|Given IV
214645444|NCT05623891|DRUG|177Lu-B5-IgG4|177Lu-B5-IgG4 injection followed by SPECT scan
214758527|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
214758528|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
214758529|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
214758530|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
214758531|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
214758532|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
214758533|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
214758534|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
214758535|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
214758536|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
214758537|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
214758538|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
214758539|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
214758540|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
214758541|NCT02846987|DRUG|Abemaciclib|
214645445|NCT04272931|PROCEDURE|Portal and Hepatic Vein Embolization|Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)
214645446|NCT02596659|PROCEDURE|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
214645447|NCT02596659|PROCEDURE|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
214645448|NCT02596659|PROCEDURE|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
214645449|NCT01820442|DRUG|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
214645450|NCT01820442|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
214645451|NCT00392184|PROCEDURE|Accelerated partial breast irradiation|
214645452|NCT05574257|DRUG|Propofol|Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
214645453|NCT05574257|DRUG|Remimazolam|Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
214645454|NCT05900804|OTHER|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
214758542|NCT02395094|BEHAVIORAL|Child Life|"Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU"
214758543|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
214758544|NCT04645342|DEVICE|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
214758545|NCT04645342|DEVICE|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
214758546|NCT06786091|OTHER|Pelvic floor muscle training rehabilitation|The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week.
214758547|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
214758548|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
214758549|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
214758550|NCT04161066|DRUG|Psilocybin with facilitated counseling|open-label pilot study
214758551|NCT05205109|DRUG|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
214758552|NCT05205109|DRUG|KEYTRUDA ®( Pembrolizumab)|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1."
214758553|NCT05047237|BEHAVIORAL|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
214758554|NCT04051606|DRUG|Regorafenib|Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.
214758555|NCT03319901|DRUG|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
214758556|NCT03319901|DRUG|Standard Chemotherapy|Standard treatment of chemotherapy is administered
214758557|NCT06190912|DRUG|Bryostatin 1|Eligible participants will be treated with bryostatin over a 26-week period. Doses 1, 2, 8, and 9 of the study drug will be a loading dose 20% higher (i.e., 24 µg) than the assigned fixed dose and will be administered one week apart. Otherwise, the assigned fixed dose is 20 µg. Drug is administered intravenously (IV) by continuous infusion over 45(±5) minutes. Participants are scheduled to receive 14 doses over 26 weeks.
214758558|NCT05028816|DEVICE|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
214758559|NCT05028816|OTHER|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
214758560|NCT05028816|DEVICE|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
214758561|NCT05028816|OTHER|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
214758562|NCT06964425|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Insertion of a endoscopic fiber-optic Raman probe under fluoroscopic control during endoscopic retrograde cholangiopancreatography to measure Raman spectra of extrahepatic cholangiocarcinoma and healthy bile duct.
214758563|NCT05064436|DRUG|11C-BMS-986196|Specified dose on specified days
214758564|NCT06008808|DRUG|Ruxolitinib|Ruxolitinib is provided by Incyte Corporation.
214758565|NCT06008808|DRUG|Abatacept|Abatacept is commercially available.
214758566|NCT04552769|DRUG|Abemaciclib|200 mg orally
214758567|NCT05011760|RADIATION|Baseline [C-11]NPA PET Scan|Radiotracer
214758568|NCT05011760|DRUG|d-amphetamine|Oral, 0.5 mg/Kg
214758569|NCT05011760|RADIATION|Post-amphetamine [C-11]NPA PET Scan|Radiotracer
214758570|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
214758571|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
214758572|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
214758573|NCT04463771|DRUG|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
214758574|NCT04463771|DRUG|epacadostat|epacadostat will be administered orally BID.
214758575|NCT04463771|DRUG|pemigatinib|pemigatinib will be administered orally QD.
214758576|NCT04463771|DRUG|INCAGN02385|INCAGN2385 will be administered every 2 weeks
214758577|NCT04463771|DRUG|INCAGN02390|INCAGN2390 will be administered every 2 weeks
214758578|NCT06367764|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
214758579|NCT06367764|BEHAVIORAL|STAIR Narrative Therapy|STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
214758580|NCT06209060|BEHAVIORAL|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
214758581|NCT06209060|BEHAVIORAL|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
214758582|NCT03396445|DRUG|Boserolimab|IV infusion
214758583|NCT03396445|BIOLOGICAL|Pembrolizumab|IV infusion
214758584|NCT03396445|DRUG|Pemetrexed|IV infusion
214758585|NCT03396445|DRUG|Carboplatin|IV infusion
214758586|NCT03396445|DRUG|Nab-paclitaxel|IV infusion
214758587|NCT01892397|DEVICE|Optune (NovoTTF-100A)|
214758588|NCT06583993|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per RECIST v1.1 criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
214758589|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
214758590|NCT05216575|DRUG|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
214758591|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
214758592|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
214758593|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
214758594|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
214758595|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
214758596|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
214758597|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
214758598|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214758599|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
214758600|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
214758601|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
214758602|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
214758603|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
214758604|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
214758605|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
214758606|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
214758607|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
214758608|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
214758609|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
214758610|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
214758611|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
214758612|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
214758613|NCT01716546|DRUG|Pazopanib|
214758614|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
214758615|NCT04148274|OTHER|No intervention|There is no intervention for this study.
214758616|NCT06717256|BEHAVIORAL|training|The diabetes education booklet is a collection of information designed by the researcher. These interventions will continue for 1.5 months, with a total of 6 sessions for each type 2 DM individual, lasting approximately 120 minutes (2 hours per week and 12 hours in total after 6 weeks), and will be carried out as reminders afterwards. In these sessions, agendas will be created appropriately on regular eating habits, physical activity, regular monitoring of blood sugar, compliance with treatment, problem-solving ability, coping strategies and minimizing risks, conflicts regarding self-management and skin care behaviors of the patient will be tried to be resolved, the patient's suitability and adaptation to the change phase will be determined, their willingness to change will be questioned, and the change plan will be helped in the matters of care and self-management.
214758617|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
214758618|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
214758619|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
214758620|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
214758621|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
214758622|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
214758623|NCT00000518|PROCEDURE|electrophysiology|
214758624|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
214758625|NCT00000518|DRUG|imipramine|
214758626|NCT00000518|DRUG|mexiletine|
214758627|NCT00000518|DRUG|procainamide|
214758628|NCT00000518|DRUG|quinidine|
214758629|NCT00000518|DRUG|sotalol|
214758630|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
214758631|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
214758632|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
214758633|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
214758634|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
214758635|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
214758636|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
214758637|NCT02224495|BEHAVIORAL|Structured exercise training|
214758638|NCT01829659|DRUG|Ticagrelor|
214758639|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
214758640|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
214758641|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
214758642|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
214758643|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
214758644|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
214758645|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
214758646|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
214758647|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
214758648|NCT02010671|OTHER|Survey|Survey
214758649|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
214758650|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
214758651|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
214758652|NCT02332044|DRUG|Erdos|capsule, 300mg
214758653|NCT02332044|DRUG|Talion|tablet, 10mg
214758654|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
214758655|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
214758656|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
214758657|NCT03583801|OTHER|without aromatherapy|no intervention
214758658|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
214758659|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
214758660|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
214758661|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
214758662|NCT02378870|DRUG|Placebo|
214758663|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
214758664|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
214758665|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
214758666|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
214758667|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
214758668|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
214758669|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
214758670|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
214758671|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
214758672|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
214758673|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
214758674|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
214758675|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
214758676|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
214758677|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
214758678|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
214758679|NCT01001091|DRUG|AL-38583 ophthalmic solution|
214758680|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
214758681|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
214758682|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
214758683|NCT01987570|DRUG|Allopurinol|
214758684|NCT01987570|DRUG|Placebo|
214758685|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
214758686|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
214758687|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
214758688|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
214758689|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
214758690|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
214758691|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
214758692|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
214758693|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
214758694|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
214758695|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
214758696|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
214758697|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
214758698|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
214758699|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
214758700|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
214758701|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
214758702|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
214758703|NCT03992456|BIOLOGICAL|Panitumumab|Given IV
214758704|NCT03992456|OTHER|Quality-of-Life Assessment|Ancillary studies
214758705|NCT03992456|OTHER|Questionnaire Administration|Ancillary studies
214758706|NCT03992456|DRUG|Regorafenib|Given PO
214758707|NCT03992456|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214758708|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
214758709|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
214758710|NCT01977625|DRUG|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
214758711|NCT01977625|OTHER|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
214758712|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
214758713|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
214758714|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
214758715|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
214758716|NCT02594384|DRUG|LAM-002A|25 mg capsules or 50 mg capsules
214758717|NCT02594384|DRUG|Rituximab|375 mg/m2 by vein
214758718|NCT02594384|DRUG|Atezolizumab|1200 mg by vein
214758719|NCT02427568|DRUG|Midomafetamine HCl|Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.
214758720|NCT02427568|DRUG|Placebo|Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.
214758721|NCT02427568|BEHAVIORAL|Therapy|Manualized therapy
214758722|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
214758723|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
214758724|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
214758725|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
214758726|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
214758727|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
214758728|NCT02073591|OTHER|Ceradan Cream|
214758729|NCT02073591|OTHER|Ceradan Wash|
214758730|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
214794192|NCT06201273|BEHAVIORAL|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
214645455|NCT04536064|PROCEDURE|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
214645456|NCT02424279|PROCEDURE|Splanchnicectomy|
214645457|NCT00955435|OTHER|Non-interventional|Patients receive induction hormones\* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
214645458|NCT00955435|GENETIC|Protein expression analysis|
214645459|NCT00955435|GENETIC|Proteomic profiling|
214645460|NCT00955435|OTHER|Laboratory biomarker analysis|
214645461|NCT00003031|DRUG|amphotericin B deoxycholate|
214645462|NCT00003031|DRUG|voriconazole|
214645463|NCT05285501|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
214645464|NCT05285501|BEHAVIORAL|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
214645465|NCT05285501|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
214645466|NCT03211390|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
214645467|NCT03211390|DIAGNOSTIC_TEST|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
214645468|NCT02152345|DRUG|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
214645469|NCT02152345|DRUG|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
214758731|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
214758732|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
214758733|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
214758734|NCT05572814|BEHAVIORAL|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
214758735|NCT05572814|BEHAVIORAL|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
214758736|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
214758737|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
214758738|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
214758739|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
214758740|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
214758741|NCT01449149|RADIATION|Proton Therapy|
214758742|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
214758743|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
214758744|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
214758745|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
214758746|NCT06959004|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (4.0 pmol/kg/min) over 20 minutes.
214758747|NCT06959004|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
214758748|NCT05971329|DEVICE|Cervical Fusion (ZetaFuse™ Bone Graft)|Fusion of the C3-C7 cervical vertebral bodies
214758749|NCT06474325|BEHAVIORAL|Intervention via mobile application|Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
214758750|NCT05720039|DEVICE|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
214758751|NCT05720039|PROCEDURE|Open NSM|open nipple-sparing mastectomy procedures
214758752|NCT04546126|DRUG|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
214758753|NCT04546126|DRUG|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
214758754|NCT04546126|COMBINATION_PRODUCT|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
214758755|NCT06243731|OTHER|No Intervention|This is a non-interventional study.
214758756|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
214758757|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
214758758|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
214758759|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
214758760|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
214758761|NCT04624204|BIOLOGICAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
214758762|NCT04624204|BIOLOGICAL|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
214758763|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
214758764|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
214758765|NCT04624204|DRUG|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
214758766|NCT04624204|DRUG|Olaparib matching placebo|Olaparib matching placebo BID
214758767|NCT04624204|DRUG|Etoposide 100 mg/m^2|Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
214758768|NCT04624204|DRUG|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
214758769|NCT04624204|RADIATION|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
214758770|NCT04624204|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
214758771|NCT05791955|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
214758772|NCT05791955|BEHAVIORAL|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
214758773|NCT05791955|BEHAVIORAL|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
214758774|NCT01917149|DRUG|Benazepril|
214758775|NCT01917149|DRUG|Valsartan|
214758776|NCT01917149|DRUG|Metoprolol|
214758777|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
214758778|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
214758779|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
214758780|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
214758781|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
214758782|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
214758783|NCT00761085|DRUG|Morphine|Standard of care for pain management of acute episode of pain
214758784|NCT00761085|DRUG|Methadone|Compare to standard of care for pain management of acute episode of pain
214758785|NCT00083356|PROCEDURE|Wisdom tooth extraction|
214758786|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
214758787|NCT06488430|BEHAVIORAL|Multidomain intervention package for preventing cognitive decline|Participants with mild cognitive impairment will be identified and they will participate in a pilot study for one-month duration. During pilot study they will be subjected to a multidomain intervention including nutritional advice, physical activity, cognitive stimulation training, social support and engagement and management of vascular risk factors.
214758788|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
214758789|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
214758790|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
214758791|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
214758792|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
214758793|NCT05792852|BEHAVIORAL|ENGAGE|ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
214758794|NCT05733520|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
214645470|NCT02152345|DRUG|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
214645471|NCT02152345|DRUG|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
214645472|NCT02152345|DRUG|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
214645473|NCT02152345|PROCEDURE|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
214645474|NCT03675867|OTHER|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
214645475|NCT00013286|DEVICE|Prevention Diabetic Foot Ulcer|
214645476|NCT05770986|OTHER|Group A|the patient must attain the goal repetitions (and holds when required) at one level before progressing to the next level. The principal investigator will provide extensive education to the patient while progressing through the program. Three resistance bands will be used through the exercise progression; yellow band (low resistance), green band (moderate resistance) to blue band (high resistance). The patient will progress to more advanced level if he/she can sustain the position with high resistance band (blue) for one minute with three isometric holds of each exercise on each limb. three sets for 10 repetitions will be performed) Phases 1-3 of the program are focused on GMax activation. Phases 4- 5 are focused on GMax strength, and the final three phases emphasize functional applications of the GMax during ballistic tasks.
214645477|NCT05770986|OTHER|Group B|Flexibility exercises of the back muscles: knee to chest stretch, bridging, stretching exercises for hip flexors, piriformis, adductors and hamstring will be performed, with a hold of position for 30 s and with repetitions (3-5 times). Static stretches will be held for 30 seconds to induce changes in flexibility and will be repeated for three sets. Three sessions of stretching per week will be performed b. Prone resisted hip extension 10 repetitions for two sets. c. Hot pack: for 10 minutes. d. TENS: The electrodes will be placed over the area of most severe pain for 15 minutes.
214645478|NCT04696640|BEHAVIORAL|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
214645479|NCT01916980|DRUG|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
214645480|NCT04439279|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214645481|NCT06438679|DRUG|Tofacitinib 5 MG|Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral
214645482|NCT06184347|OTHER|Rapid tests for HBsAg|"Participants in the screening group will firstly receive the HBsAg screening using a finger blood test.~The laboratory examination includes blood routine test (white blood cell count \[WBC\], red blood cell count \[RBC\], hemoglobin \[HGB\], platelet count \[PLT\]), liver function (total bilirubin \[TBIL\], albumin \[ALB\], alanine aminotransferase \[ALT\]), HBV serologic markers, alpha-fetoprotein(AFP) , abnormal Prothrombin II (PIVKA II) and HBV-DNA.~The imaging examination includes liver ultrasound, abdominal CT, or MRI. HBsAg-positive participants also undergo liver ultrasound examination. If suspicious liver nodules or elevated AFP levels are detected, further refinement through abdominal CT or MRI is recommended."
214645483|NCT02766660|DEVICE|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
214645484|NCT02324270|DRUG|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
214645485|NCT02324270|OTHER|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
214645486|NCT01292967|DIETARY_SUPPLEMENT|Low flavanol chocolate|48 mg of total flavanols from cocoa
214645487|NCT01292967|DIETARY_SUPPLEMENT|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
214645488|NCT01292967|DIETARY_SUPPLEMENT|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
214645489|NCT05182346|PROCEDURE|Manual therapy|"* Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points."
214645490|NCT05848934|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
214645491|NCT05848934|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
214645492|NCT02269722|DEVICE|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
214645493|NCT02269722|DEVICE|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
214645494|NCT05510505|DRUG|CD20 monoclonal antibody|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
214645495|NCT05510505|DRUG|ATG|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
214645496|NCT03521791|DRUG|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
214645497|NCT03521791|OTHER|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
214645498|NCT04340622|DEVICE|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
214645499|NCT04340622|DEVICE|Sham|Light-emitting diode covered with aluminium foil
214645500|NCT05156294|DEVICE|NovoMatrix|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
214645501|NCT05156294|OTHER|Control|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
214645502|NCT05357131|BEHAVIORAL|Hypnosis without VR (HYP)|"HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used."
214645503|NCT05357131|DEVICE|Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort.
214645504|NCT04024501|DRUG|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
214645505|NCT04024501|DRUG|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
214645506|NCT04024501|DRUG|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
214645507|NCT04024501|DRUG|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
214645508|NCT04024501|DRUG|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
214645509|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
214758795|NCT05733520|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
214758796|NCT01550237|RADIATION|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
214758797|NCT01550237|RADIATION|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
214758798|NCT04213651|OTHER|No intervention|There is no intervention for this study
214758799|NCT04211402|OTHER|No Intervention|There is no intervention for this study
214758800|NCT01860937|PROCEDURE|leukapheresis or collection of PBMCs|
214758801|NCT01860937|DRUG|cyclophosphamide based chemotherapy regimens|
214758802|NCT01860937|BIOLOGICAL|modified T cells|
214758803|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
214758804|NCT06647849|PROCEDURE|centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases|"The simulation training sessions for the announcement consultation are set up directly in the centers participating in the with training arm of the study, after the first phase of patient inclusion. These sessions will take place in situ in the center's maternity ward, and will be run by a single team trained in simulation and announcement.~This team of trainers is identical for all centers randomized in the with training arm, and is made up of two trainers: an obstetrician-gynecologist and a psychologist."
214758805|NCT06647849|OTHER|centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department|"In the participating centers included in the no training arm, interns will have no specific training in announcement. Patients will receive information concerning the diagnosis of a terminated pregnancy or miscarriage from interns not trained in simulation.~During the course of the study, training in the announcement of a miscarriage will be offered to interns from centers in the no training group."
214758806|NCT00568490|PROCEDURE|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
214758807|NCT00568490|PROCEDURE|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
214758808|NCT03261492|BEHAVIORAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
214758809|NCT03261492|BEHAVIORAL|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
214758810|NCT06671938|DRUG|exidavnemab|The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
214758811|NCT06671938|DRUG|Placebo Comparator|The trial medication will be administered as an intravenous (IV) infusion
214758812|NCT04855253|DRUG|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
214758813|NCT04855253|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV daily for 3 days. Days -5, -4 and -3. Taken in combination with Cyclophosphamide
214758814|NCT04855253|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine. Days -5, -4 and -3.
214758815|NCT04855253|DRUG|Tisagenlecleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
214758816|NCT04855253|DRUG|Axicabtagene Ciloleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
214758817|NCT04855253|DRUG|Lisocabtagene Maraleucel Intravenous Suspension|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
214758818|NCT05917210|BEHAVIORAL|Standard TB-EC|Standard TB-EC by healthcare workers
214758819|NCT05917210|BEHAVIORAL|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
214758820|NCT05658354|OTHER|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
214758821|NCT05861284|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
214758822|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
214758823|NCT03862222|OTHER|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
214758824|NCT03862222|OTHER|Pupillometry|Participants will complete a task studying pupillary response to light
214758825|NCT03862222|OTHER|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
214758826|NCT03862222|DIAGNOSTIC_TEST|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
214758827|NCT03862222|GENETIC|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
214758828|NCT03862222|OTHER|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
214758829|NCT03862222|OTHER|Gait Assessment|Gait assessment will be conducted by trained researcher
214758830|NCT03862222|OTHER|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
214758831|NCT06418659|DRUG|CD-801|"CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA (CD-801 or CD-GA-102) therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per mRECIST criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
214758832|NCT03589729|DRUG|Cladribine|Given IV
214758833|NCT03589729|DRUG|Cytarabine|Given IV
214758834|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
214758835|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
214758836|NCT03589729|DRUG|Idarubicin|Given IV
214758837|NCT04100980|OTHER|No Intervention|There is no intervention for this study
214758838|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
214758839|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
214758840|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
214758841|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
214758842|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
214758843|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
214758844|NCT06967259|DRUG|ENA-001|Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.
214758845|NCT06967259|DRUG|Placebo Comparator|Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.
214758846|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
214758847|NCT01215968|DRUG|Placebo|Administered subcutaneously
214758848|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
214758849|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
214758850|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
214758851|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
214758852|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
214758853|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
214758854|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
214758855|NCT05939440|OTHER|Usual Care|As in Arm description
214758856|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
214758857|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
214758858|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
214758859|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
214758860|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
214758861|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
214758862|NCT04056650|DRUG|L-theanine|up to 250 mg
214758863|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
214758864|NCT04056650|DEVICE|N1 app|N1 App on mobile device
214758865|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
214758866|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
214758867|NCT05798325|OTHER|2MWT|Two minutes walk tests.
214758868|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
214758869|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
214758870|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
214758871|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
214758872|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
214758873|NCT05798325|OTHER|10mWT|10 meters walking Test.
214758874|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
214758875|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
214758876|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
214758877|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
214758878|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
214758879|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
214758880|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
214758881|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
214758882|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
214758883|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
214758884|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
214758885|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
214758886|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
214758887|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
214758888|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
214758889|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
214758890|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
214758891|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
214758892|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
214758893|NCT00423501|DRUG|Placebo|sc weekly
214758894|NCT00423501|DRUG|taspoglutide|20mg sc weekly
214758895|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
214758896|NCT00423501|DRUG|taspoglutide|5mg sc weekly
214758897|NCT00423501|DRUG|taspoglutide|10mg sc weekly
214758898|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
214758899|NCT03125707|OTHER|Registry study|
214758900|NCT03621566|OTHER|No intervention|Routine care (registry)
214758901|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
214758902|NCT05935046|BEHAVIORAL|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
214758903|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
214758904|NCT05891834|DRUG|INV-202|tablet, once daily, oral
214758905|NCT05891834|DRUG|Placebo|tablet, once daily, oral
214758906|NCT06971094|GENETIC|GC101 adeno-associated virus injection|Self-complementary recombinant adeno-associated viral vector (scAAV) containing a single-stranded transgene encoding a codon-optimized human SMN1 gene
214758907|NCT06116890|DRUG|KHK4951|KHK4951 eye drop for 44 weeks until end of the trial
214758908|NCT06116890|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
214758909|NCT05643573|DRUG|Asundexian (BAY2433334)|Once a day
214758910|NCT05643573|DRUG|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
214758911|NCT05643573|DRUG|Asundexian matching placebo|Placebo to asundexian, once a day
214758912|NCT05643573|DRUG|Apixaban matching placebo|Placebo to apixaban, twice a day
214758913|NCT02308085|OTHER|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
214758914|NCT04026867|OTHER|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
214758915|NCT04026867|OTHER|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
214758916|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
214758917|NCT06087822|DEVICE|IMD SiPore21®|The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c
214758918|NCT06080490|DRUG|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
214758919|NCT06472934|OTHER|Transcatheter aortic valve replacement in the absence of B-blocker treatment|Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.
214758920|NCT06472934|OTHER|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
214758921|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
214758922|NCT05718336|OTHER|Integrated care|multi-discipline care program
214758923|NCT04946994|BEHAVIORAL|HIIT|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
214758924|NCT04946994|BEHAVIORAL|CME|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
214758925|NCT06244212|OTHER|Demonstration of applying triamcinolone cream|Live demonstration of applying 1 fingertip unit of triamcinolone cream
214758926|NCT06244212|BEHAVIORAL|Mobile App Use|Additional mobile application that provides amount dispensed and adherence data.
214758927|NCT06244212|OTHER|Standard of Care|Written/verbal instructions only
214758928|NCT06108947|DRUG|Aspirin|Aspirin discontinuation
214758929|NCT03583255|DRUG|Dexamethasone|Given PO
214758930|NCT03583255|BEHAVIORAL|Exercise Intervention|Complete resistance training and moderate intensity walking
214758931|NCT03583255|OTHER|Placebo Administration|Given PO
214758932|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
214758933|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
214758934|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
214758935|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
214758936|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
214758937|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
214758938|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
214758939|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
214758940|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
214645510|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
214645511|NCT00680836|DRUG|Placebo|orally two times per day for 14 days
214645512|NCT00680836|DRUG|Rifaximin|550 mg orally two times per day for 14 days
214645513|NCT03786432|DEVICE|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
214645514|NCT05697133|OTHER|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
214645515|NCT05697133|OTHER|control|control grup
214645516|NCT03547557|DEVICE|Exablate 2000 strappable system|
214645517|NCT00945919|DRUG|Oxymorphone ER|Rapid Opioid rotation/titration
214645518|NCT04607395|RADIATION|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
214645519|NCT01630525|OTHER|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
214645520|NCT01630525|OTHER|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
214645521|NCT01630525|OTHER|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
214645522|NCT00239850|BEHAVIORAL|lifestyle changes|
214645523|NCT04406870|DRUG|Sirolimus Oral Product|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
214645524|NCT04406870|DRUG|propranolol|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
214645525|NCT01973309|DRUG|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
214645526|NCT03729778|BIOLOGICAL|Prevnar-13|One time administration of prevnar-13 vaccine
214645527|NCT02688517|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
214645528|NCT02688517|OTHER|Laboratory Biomarker Analysis|Correlative studies
214645529|NCT00321165|DRUG|taurolidine|
214645530|NCT01601899|DRUG|Stavudine|30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg
214645531|NCT01601899|DRUG|Stavudine|20 mg po BD if wt \< 60kg, or 30 mg po BD if wt \> 60kg
214645532|NCT01601899|DRUG|Tenofovir|300 mg po QD
214645533|NCT02043925|DRUG|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
214645534|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
214645535|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
214645536|NCT03655834|DRUG|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
214645537|NCT04793399|DRUG|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
214645538|NCT04793399|DRUG|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
214645539|NCT00410176|BEHAVIORAL|sanitation and personal hygiene|
214645540|NCT01133145|PROCEDURE|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
214645541|NCT02452333|PROCEDURE|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
214645542|NCT02452333|PROCEDURE|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
214758941|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
214758942|NCT06620744|DEVICE|Sponsor MCG deivce|Unshielded device measuring cardiac magnetic fields.
214758943|NCT06395649|DEVICE|Classical rTMS to M1|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.
214758944|NCT06395649|DEVICE|rTMS to the High connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.
214758945|NCT06395649|DEVICE|rTMS to the low connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
214758946|NCT06395649|DEVICE|Sham rTMS|Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
214758947|NCT05035394|PROCEDURE|Cataract surgery|Cataract Surgery in a standardized fashion
214758948|NCT05035394|PROCEDURE|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
214758949|NCT05035394|PROCEDURE|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
214758950|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
214758951|NCT05412225|DIAGNOSTIC_TEST|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
214758952|NCT05412225|RADIATION|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
214758953|NCT05412225|PROCEDURE|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
214758954|NCT06578624|DRUG|SA53-OS (phase 1)|Dose escalation phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years. Single participant cohorts will be enrolled until a Grade 2 or greater toxicity is observed and then 3+3 multi-participant cohorts will be enrolled until the MTD is identified.
214758955|NCT06578624|DRUG|SA53-OS (phase 2)|Dose expansion phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years at the MTD identified in phase 1.
214758956|NCT06805370|BEHAVIORAL|Mailed Additional FIT Kit|Mailed additional FIT Kits in November 2024.
214758957|NCT06805370|OTHER|Usual Care|This group was sent an annual FIT Kit per usual care.
214758958|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
214758959|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
214758960|NCT06056505|PROCEDURE|partial kidney nephrectomy|surgery for partial nephrectomy
214758961|NCT06056505|DEVICE|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
214758962|NCT06056505|DEVICE|Innersight 3D software|investigational product to generate the 3D model
214758963|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
214758964|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
214758965|NCT04550260|DRUG|Durvalumab|Durvalumab intravenous infusion
214758966|NCT04550260|DRUG|Placebo|Durvalumab matching placebo for intravenous infusion
214758967|NCT04550260|DRUG|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
214758968|NCT04550260|DRUG|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
214758969|NCT04550260|RADIATION|Radiation|50-64Gy in total
214758970|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
214758971|NCT05959551|DEVICE|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
214758972|NCT04049474|DEVICE|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
214758973|NCT03547661|OTHER|P-Dragees rosa Lichtenstein|Placebo dragées
214758974|NCT06502821|OTHER|questtionnaire|questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
214758975|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
214758976|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
214758977|NCT02981979|DRUG|Leflunomide(LEF)|"Leflunomide:~For LEF arm, 20mg per day, p.o. through the whole study. For placebo group, 20mg per day, p.o. from week 25 to week 52."
214758978|NCT02981979|DRUG|Prednisone Acetate Tablets|Prednisone (5mg/tab): basic therapy, start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day.
214758979|NCT02981979|DRUG|Placebos|2 tabs/d used in placebo arm for the first 24 weeks.
214758980|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
214758981|NCT02259777|OTHER|high fat, high caloric meal|
214758982|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
214758983|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
214758984|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
214758985|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
214758986|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
214758987|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
214758988|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
214758989|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
214758990|NCT02730832|OTHER|Questionnaires completed at D0|
214758991|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
214758992|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
214758993|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
214758994|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
214758995|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
214758996|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
214758997|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
214758998|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
214758999|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
214759000|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
214759001|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
214759002|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
214759003|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
214759004|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
214759005|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
214759006|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
214759007|NCT05951205|BIOLOGICAL|Exa-cel|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
214759008|NCT06984419|DEVICE|Cross-linked hyaluronic acid dermal filler|Alexa Volume is a CE-marked, cross-linked hyaluronic acid dermal filler used for aesthetic correction of midface volume loss. It was administered subcutaneously or to the upper periosteum in adult female participants according to standardized procedures.
214759009|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
214759010|NCT06605118|DRUG|Placebo|250 mL of normal saline
214759011|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
214759012|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
214759013|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
214759014|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
214759015|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
214759016|NCT06821074|DEVICE|Defocus-enhanced spectacles|Vision function training while wearing defocus-enhanced spectacles
214759017|NCT06821074|DEVICE|Single vision spectacles|Vision function training while wearing single vision spectacles
214759018|NCT06661694|DRUG|Treatment A|Single 875 mg dose of mevrometostat standard tablet formulation
214759019|NCT06661694|DRUG|Treatment B|Single 875 mg dose of mevrometostat alternative tablet formulation
214645543|NCT02452333|OTHER|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
214645544|NCT02452333|OTHER|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
214645545|NCT02441361|OTHER|Exercise training|Exercise training will comprise aerobic and strength exercises
214645546|NCT06412692|OTHER|The Motivational Interviewing Technique|Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
214645547|NCT00022074|DRUG|gabapentin|
214645548|NCT00022074|PROCEDURE|quality-of-life assessment|
214645549|NCT05293730|BEHAVIORAL|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
214759020|NCT06661694|DRUG|Treatment C|Single 875 mg dose of mevrometostat alternative tablet formulation
214759021|NCT06661694|DRUG|Treatment D|Single 875 mg dose of mevrometostat alternative tablet formulation
214759022|NCT05053334|DRUG|Omalizumab Prefilled Syringe|150mg/ml of Omalizumab prefilled syringe
214645550|NCT05293730|OTHER|Usual Care|Routine treatment in primary care
214645551|NCT02058732|OTHER|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
214645552|NCT06193473|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
214645553|NCT01653730|DEVICE|Eclipse 3 portable oxygen concentrator|
214645554|NCT01653730|DEVICE|EverGo portable oxygen concentrator|
214645555|NCT01653730|DEVICE|iGo portable oxygen concentrator|
214645556|NCT03446495|DRUG|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
214645557|NCT00925600|BIOLOGICAL|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
214645558|NCT00925600|BIOLOGICAL|Placebo|Prefilled syringe for subcutaneous (SC) injection
214645559|NCT05357456|BEHAVIORAL|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
214645560|NCT05357456|PROCEDURE|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
214645561|NCT06958718|PROCEDURE|Ultrasound Guided erector spinae plane block (UB)|Ultrasound Guided erector spinae plane block (UB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine .. After the surgical incision is closed and before extubation, while the patient remains in the prone position. A linear high-frequency transducer (L6-12 linear array transducer (6-12 MHz) on GE Healthcare logiq p7, made in Korea) will be positioned in a sagittal orientation, 4 cm lateral to the L3 transverse process. A 22 G × 88 mm block needle will be inserted in the craniocaudal direction, with the needle tip placed beneath the erector spinae muscle and above the hyperechoic transverse process. The needle tip position will be confirmed via saline injection. Once correct needle placement is verified, 40 mL of 0.25% bupivacaine, combined with 0.5 μg/kg dexmedetomidine 15 will be administered divided on both sides.
214645562|NCT06958718|PROCEDURE|Surgical erector spinae plane block (SB)|Surgical erector spinae plane block (SB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine ..This volume will be divided into 8 injections, four 5 ml injections on each side. The surgeons will perform the block just before starting the wound closure stage. The surgical ESP block technique consists of injections at four bilateral levels, starting from one level above the operated vertebra and covering all surgical segments using a 22G × 88 mm needle. The needle will be inserted to contact the transverse process, and the injectate will be delivered between the erector spinae muscle and the transverse process at each level.
214645563|NCT06958718|DRUG|Dexmedetomidine|0.5 μg/kg dexmedetomidine added to block solution
214645564|NCT06958718|DRUG|Bupivacaine Hcl 0.5% Inj|40 ml Bupivacaine HCL
214645565|NCT03396328|BEHAVIORAL|conventional low salt education|conventional low salt education
214645566|NCT03396328|BEHAVIORAL|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
214645567|NCT00120614|BEHAVIORAL|Premature infant behavior and development information|
214645568|NCT00120614|BEHAVIORAL|Parental activities to support premature infant information|
214645569|NCT02395549|DRUG|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
214645570|NCT02395549|DRUG|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
214645571|NCT02395549|DRUG|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
214645572|NCT02395549|DRUG|Vehicle Control Gel|
214645573|NCT01682005|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
214645574|NCT01974817|BIOLOGICAL|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
214645575|NCT05512949|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
214645576|NCT03593915|COMBINATION_PRODUCT|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
214645577|NCT03551548|DRUG|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
214645578|NCT03551548|DRUG|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
214645579|NCT01825902|DRUG|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
214759023|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
214759024|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
214759025|NCT00854776|DRUG|lansoprazole|30 mg once daily
214759026|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
214759027|NCT00045136|DRUG|melphalan|
214759028|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
214759029|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
214759030|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
214759031|NCT02463500|OTHER|DFU|Standard care.
214759032|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
214759033|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
214759034|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
214759035|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
214759036|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
214759037|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
214759038|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
214759039|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
214759040|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
214759041|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg twice daily (BID)
214759042|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg once daily (OD)
214759043|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
214759044|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
214759045|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
214759046|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
214759047|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
214759048|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
214759049|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
215030745|NCT05134883|OTHER|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
215030746|NCT05690204|DRUG|SAP-001|Test the efficacy and safety of SAP-001 versus placebo
215030747|NCT04003402|DRUG|ASP8062|oral
215030748|NCT04003402|DRUG|Alcohol|oral
215030749|NCT04003402|DRUG|ASP8062 Placebo|oral
215030750|NCT04003402|DRUG|Alcohol Placebo|oral
215030751|NCT04191135|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
214645580|NCT01825902|RADIATION|fludeoxyglucose F 18|Undergo 18F-FDG PET
214645581|NCT01825902|PROCEDURE|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
214645582|NCT01825902|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
214645583|NCT01825902|OTHER|laboratory biomarker analysis|Correlative studies
214645584|NCT04366999|PROCEDURE|SG|SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.
214645585|NCT04366999|PROCEDURE|RYGB|RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
214645586|NCT04366999|PROCEDURE|OAGB|OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
214645587|NCT06102304|DEVICE|Focused Extracorpeal Shock wave|Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.
214645588|NCT06102304|DEVICE|Sham Extracorpeal shock wave|(EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
214645589|NCT06584409|DEVICE|Laser Pen|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
214645590|NCT06584409|OTHER|Observation|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
214645591|NCT04609878|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
214645592|NCT04609878|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
214645593|NCT04609878|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
214645594|NCT04609878|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
214645595|NCT01097928|PROCEDURE|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
214645596|NCT04660643|DRUG|Tirzepatide|Administered SC
214645597|NCT04660643|OTHER|Placebo|Administered SC
214645598|NCT00152152|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
214645599|NCT01438697|BEHAVIORAL|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
214645600|NCT01438697|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
214645601|NCT02090712|PROCEDURE|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
214645602|NCT06092294|BEHAVIORAL|Tactical training in numerical superiority and numerical inferiority|"In the present study, the SSGs training sessions will be carried out in the following areas:~2c1: length 11.5m and width 9m (total: 103.5m2), equivalent to 34.5m2 for each player.~3c2: length 14m and width 12m (total: 168m2), equivalent to 33.6m2 for each player.~4c3: length 17m and width 14m (total: 238m2), equivalent to 34m2 per each player."
214645603|NCT06092294|BEHAVIORAL|Conventional training in numerical equality|Coach who will run the CG training program will be different from the coach who will run the GE training program. As with the GE, a coach will also be assigned to the CG to record, quantify and monitor the training stimuli of this comparison group, who will record it on forms designed for this purpose.
215030752|NCT04191135|DRUG|Olaparib|oral tablets
214759050|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
214759051|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
214759052|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
214759053|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
214759054|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
214759055|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
214759056|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
214759057|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
214759058|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
214759059|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
214759060|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
214759061|NCT00439010|DRUG|[123I] AV 39|
214759062|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
214759063|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
214759064|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
214759065|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
214759066|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
214759067|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
215030753|NCT04191135|DRUG|Carboplatin|IV infusion
215030754|NCT04191135|DRUG|Gemcitabine|IV infusion
214759068|NCT06596044|BEHAVIORAL|VA BIC|VA BIC is a suicide prevention strategy that is designed to meet the needs of Veterans who receive acute psychiatric treatment. VA BIC can be delivered by a trained mental health provider (e.g., mental health nurse, social worker, psychologist, psychiatrist). VA BIC includes two synergistic elements to support the patient after a mental health discharge. The elements include a brief educational session, where the patient receives a one-on-one, one-hour, personalized educational session on suicide prevention. The session incorporates aspects of motivational interviewing. The patient then receives 7 regular follow-up contacts that are conducted by the interventionist. Here the interventionist monitors symptoms, assesses treatment adherence, reviews the safety plan, and assists the patient with engaging in steps to promote their well-being. The sessions incorporate aspects of motivational interviewing. Of note patients in this arm will also receive standard care.
214759069|NCT06596044|OTHER|Standard Care|Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.
214759070|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
214759071|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique with PRP as protective layer|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
214759072|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
214759073|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
214759074|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
214759075|NCT06686862|DRUG|ibuprofen|Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.
214759076|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
214759077|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
214759078|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
214759079|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
214759080|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
214759081|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
214759082|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
214759083|NCT02944604|DRUG|PEG-rhG-CSF|
214759084|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
214759086|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
214759087|NCT06722495|RADIATION|SBRT|Patient will receive SBRT (8Gy\*3F) in combination with the original regimen of neoadjuvant immunochemotherapy in course 3. Gross tumor target volume (GTV) based on the primary foci clearly identified by clinical and imaging examinations. The GTV was discharged 3 mm to generate a Planning target volume (PTV). the target area (PTV) was dosed accordingly to the PTV.
214759088|NCT06723769|DEVICE|rTMS treatment|Repetitive transcranial magnetic stimulation (rTMS) is a new physiotherapy technique for the treatment of PSD Compared to other strategies, it has the advantages of simple operation, non-invasive, painless, and safe. Studies have comprehensively shown that rTMS can effectively improve depressive symptoms in PSD patients
214759089|NCT06723769|OTHER|conventional treatment|general treatment of stabilizing vital signs (such as antidepressants, stabilizing blood pressure, stabilizing blood sugar, etc. ) and conventional rehabilitation treatment (hemiplegic limb comprehensive training, swallowing speech training, cognitive perception training, etc. ).
214759090|NCT06724536|OTHER|non interventional study with the use of biological samples.|"Patients will undergo to the follow evaluations:~Gut microbiome on stool samples by NGS (16S rRNA gene amplicon sequencing); Markers of impaired intestinal permeability \[diaminoxidase (DAO), serum zonulin\], and markers of inflammation of the GI tract (fecal calprotectin); Plasma inflammatory indices, cytokines (by Luminex), markers of autoimmunity, and metabolic profile; Acquired and adaptive immunity by multiparametric flow cytometry on PB samples."
214759091|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
214759092|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
214759093|NCT06724458|OTHER|Resistance exercise|All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
214759094|NCT06722625|OTHER|Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process|Receiving remote care facilitated by a specialized informatic system to support the physician
214759095|NCT06895460|DRUG|Budesonide Formoterol|Investigator Selection
214759096|NCT06895460|DRUG|Placebo|Placebo: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
214759097|NCT06895460|DRUG|Immune Modulators (Staphylococcus and Neisseria Tablets)|Staphylococcus and Neisseria Tablets: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
214759098|NCT05689554|BEHAVIORAL|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
214759099|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
214759100|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
214759101|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
214759102|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
214759103|NCT06761716|BEHAVIORAL|Ericksonian Hypnotherapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will focus on tailored hypnotic suggestions, subconscious communication techniques, and trauma-focused interventions specifically designed to address PTSD symptoms. Sessions will be conducted by a certified hypnotherapist under clinical supervision.
214759104|NCT06761716|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will utilize cognitive restructuring techniques, exposure exercises, and behavioral interventions aimed at reducing PTSD symptoms. Sessions will be led by a licensed psychotherapist trained in trauma-focused CBT.
214759105|NCT06787742|PROCEDURE|full pulpotomy|access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign
214759106|NCT06893484|DIAGNOSTIC_TEST|Weekly high-sensitivity urine pregnancy tests|Participants will take a high-sensitivity urine pregnancy test at home weekly for up to 4 weeks compared to the taking just one home urine pregnancy test at 4-5 weeks. Participants will also complete short weekly questionnaires on their pregnancy symptoms and follow-up care.
214759107|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
214759108|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
214759109|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
214759110|NCT05111652|OTHER|observational|observational electromiographic musculature activation
214759111|NCT05469893|DRUG|Teclistamab|Intravenous (IV) dosage and timing per protocol design
214759112|NCT05469893|DRUG|Lenalidomide|Oral, dosage and timing per protocol design
214759113|NCT05469893|DRUG|Dexamethasone|Oral, dosage and timing per protocol design
214759114|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
214759115|NCT06929507|DRUG|Intravitreal injection of Faricimab or Aflibercept 2 mg|Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally
214759116|NCT06943482|DRUG|Prednisolone|20mg of prednisolone will be prescribed, taken orally, and daily for first month followed by tapering doses of 15mg over one month, then 12.5mg for one month, proceeding to 10mg for one month, subsequently taking 7.5mg for one month, and lastly 5mg for one month.
214759117|NCT06943482|DRUG|Methotrexate|10mg of methotrexate will be prescribed to be taken once a week for one month. The dosage will be increased to 15mg of methotrexate taken once a week on the 1st (T1) month clinical visit and will be further increased to 20mg of methotrexate taken once a week on the 2nd (T2) month clinical visit. There will be no further escalation of dosage after this visit.
214759118|NCT06943482|DRUG|Folic Acid 5 MG|5mg of folic acid is to be taken together with methotrexate once a week.
214759119|NCT06943482|DRUG|Omeprazole 20 mg|Omeprazole will be prescribed at 20mg to protect the stomach lining.
214759120|NCT06943092|DRUG|Piroxicam group|Experimental drug
214759121|NCT06943092|DRUG|Diclofenac group|Active drug
214759122|NCT06942533|DEVICE|EMST with SpiroGym app|"Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States). Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app.~The SpiroGym app video feedback: During a correct performance of the expiratory manoeuvre with the expiratory handheld device, the exhalation valve opens, and the air flow increases the sound level detected by the microphone. Simultaneously, the application gives visual feedback on the mobile phone screen in real time using a curve depicting the current sound level, and the task of the patient is to keep the curve in the training zone depicted by two lines corresponding to the low and high level, respectively."
214759123|NCT06942533|DEVICE|EMST without SpiroGym app|Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States) without video feedback . Participants will be instructed to perform five sets of five forceful expirations.
214759124|NCT06943508|OTHER|Conventional Therapy|Conventional Therapy group: Group A will be control group which will recieve conventional physical therapy program like curl up, lateral step up and sit to stand for 6 weeks( 5 sessions per week)
214759125|NCT06943508|OTHER|Nordic Walk|Nordic Walk group: Group B will recieve Nordic walking for 6 weeks ( 5 sessions per week)
214759126|NCT01441882|DRUG|Dasatinib|Given PO
214759127|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
214759128|NCT01441882|OTHER|Pharmacological Study|Correlative studies
214759129|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
214759130|NCT01302366|DRUG|TBL12|
214759131|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
214759132|NCT02010359|DRUG|Placebo|Placebo pill
214759133|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
214759134|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
214759135|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
214759136|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
214759137|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
214759138|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
214759139|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
214759140|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
214759141|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
214759142|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
214759143|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
214759144|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
214759145|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
214759146|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
214759147|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
214759148|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
214759149|NCT00467051|DRUG|Carboplatin|Given IV
214759150|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
214759151|NCT00467051|DRUG|Ifosfamide|Given IV
214759152|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214759153|NCT00467051|DRUG|Paclitaxel|Given IV
214759154|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
214759155|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
214759156|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
214759157|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
214759158|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
214759159|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
214759160|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
214759161|NCT05950529|OTHER|No product|no product
214759162|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
214759163|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
214759164|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
214759165|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
214759166|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
214759167|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
214759168|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
214759169|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
214759170|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
214759171|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
214759172|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
214759173|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
214759174|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
214759175|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
214759176|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
214759177|NCT01977131|OTHER|Cells|
214759178|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
214759179|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
214759180|NCT00001080|DRUG|Lamivudine|
214759181|NCT00470301|DRUG|tipifarnib|Given orally
214759182|NCT00470301|DRUG|paclitaxel|Given IV
214759183|NCT00470301|DRUG|doxorubicin|Given IV
214759184|NCT00470301|DRUG|cyclophosphamide|Given IV
214759185|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
214759186|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
214759187|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
214759188|NCT00058994|DRUG|anecortave acetate|
214759189|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
214759190|NCT02277665|BEHAVIORAL|CUD Treatment|
214759191|NCT02277665|BEHAVIORAL|Tobacco Treatment|
214759192|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
214759193|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
214759194|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
214759195|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
214759196|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
214759197|NCT06839872|DRUG|Pirtobrutinib|Patients will receive pirtobrutinib orally with dosing schedule as prescribed
214759198|NCT06839872|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule as prescribed.
214759199|NCT02050945|BEHAVIORAL|Resistance training|
214759200|NCT02050945|BEHAVIORAL|Endurance training|
214759201|NCT03217422|BIOLOGICAL|VAY736|VAY736
214759202|NCT03217422|OTHER|Placebo|Placebo control with conversion to active VAY736
214759203|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
214759204|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
214759205|NCT06402435|DRUG|Lvonescimab (AK112)|"8Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion (for patients with axillary lymph node metastasis) or 6Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion and axillary lymph node metastasis (for patients without axillary lymph node metastasis) will be administered at first.~Then the first cycle of chemotherapy + AK112 will be given within 24 hours after the end of SBRT.~The total eight cycles of preoperative chemotherapy combined with immunotherapy will be administered.~Surgical resection will be performed within 4-6 weeks after the completion of the eighth cycle.~The chemotherapy regimen consists of: Four cycles of doxorubicin 50 mg/m² (Q3W) + cyclophosphamide 600 mg/m² (Q3W), followed by Four cycles of albumin-bound paclitaxel 125 mg/m², Day 1 and Day 8 (every 28 days).~The immunotherapy drug used is Ivonescimab (AK112) (20mg/kg) , administered every 3 weeks concurrently with chemotherapy for 8 cycles."
214759206|NCT03113760|DRUG|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
214759207|NCT03113760|OTHER|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
214759208|NCT01406548|DRUG|BPS804 20mg/Kg|
214759209|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
214759210|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
214645604|NCT01406067|BEHAVIORAL|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
214759211|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
214759212|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
214645605|NCT01406067|BEHAVIORAL|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
214645606|NCT02856750|DRUG|Gabapentin|Gabapentin 300 mg three times daily x30 days
214645607|NCT05122637|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
214645608|NCT05122637|DEVICE|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
214645609|NCT00648167|DRUG|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
214645610|NCT04762628|DIETARY_SUPPLEMENT|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
214645611|NCT04762628|DIETARY_SUPPLEMENT|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
214645612|NCT04762628|OTHER|Standard of care|Standard of care
214645613|NCT01688050|DEVICE|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
214759213|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
214759214|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
214759215|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
214759216|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
214759217|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
214759218|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
214759219|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
214759220|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
214759221|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
214759222|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
214759223|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
214759224|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
214759225|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
214759226|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
214759227|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
214759228|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
214759229|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
214759230|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
214759231|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
214759232|NCT02704988|PROCEDURE|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
214759233|NCT02704988|PROCEDURE|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
214759234|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
214759235|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
214759236|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
214759237|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
214759238|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
214759239|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
214759240|NCT02071472|OTHER|DP medication reconciliation|
214759241|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
214759242|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
214759243|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
214759244|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
214759245|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
214759246|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
214759247|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
214759248|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
214759249|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
214759250|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
214759251|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
214759252|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
214759253|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
214759254|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
214759255|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
214759256|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
214759257|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
214759258|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
214759259|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
214759260|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
214759261|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
214759262|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
214759263|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
214759264|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
214759265|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
214759266|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
214759267|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
214759268|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
214759269|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
214759270|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
214759271|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
214759272|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
214759273|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
214759274|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
214759275|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
214759276|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
214759277|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
214759278|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
214759279|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
214759280|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
214759281|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
214759282|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
214759283|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
214759284|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
214759285|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
214759286|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
214759287|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
214759288|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
214759289|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
214759290|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
214759291|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
214759292|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
214759293|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
214759294|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
214759295|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
214759296|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
214759297|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
214759298|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
214759299|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
214759300|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1\) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
214759301|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214759302|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
214759303|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
214759304|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
214759305|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
214759306|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
214759307|NCT06409325|DEVICE|MST|MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
214759308|NCT06409325|DEVICE|ECT|The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
214759309|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
214759310|NCT04925622|DIAGNOSTIC_TEST|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
214759311|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
214759312|NCT06568835|BEHAVIORAL|exercise|such as walking, jogging, swimming, Tai Chi, etc. It needs to be at a certain frequency and intensity
214759313|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214759314|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
214759315|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
214759316|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
214759317|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
214759318|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
214759319|NCT00000868|BIOLOGICAL|MF59|
214759320|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
214759321|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
214759322|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
214759323|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
214759324|NCT06430268|PROCEDURE|implant decontamination with titanium curette|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.
214759325|NCT06430268|DEVICE|implant decontamination with Air-Flow device|Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
214759326|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
214759327|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
214759328|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
214759329|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
214759330|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
214759331|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
214759332|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
214759333|NCT06565845|PROCEDURE|Surgery|patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
214759334|NCT06565845|DRUG|triple anti-tuberculosis drug|Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
214759335|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
214759336|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
214759337|NCT06115707|OTHER|The lying flat (0°-10°) head position for 72 hours|The lying flat (0°-10°) head position for 72 hours after endovascular therapy.
214759338|NCT06115707|OTHER|The The head elevation (30°-40°) position for 72 hours|The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
214759339|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
214759340|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
215030755|NCT06921499|BEHAVIORAL|Va Meh Du (Mental Health Education)|Participants randomized to Va Meh Du (mental health education) will receive 20-30 minutes of mental health education each week for roughly 5 weeks. Mental health education will be evidence-based, using sports psychology practices, and culturally targeted toward Karenni refugees.
214759341|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
214759342|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
214759343|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
214759344|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
214759345|NCT03414658|DRUG|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
214759346|NCT03414658|DRUG|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
214759347|NCT03414658|DRUG|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
214759348|NCT03414658|DRUG|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
214759349|NCT01162993|PROCEDURE|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
214759350|NCT06636136|DEVICE|OPRA|Surgery
214759351|NCT05842122|BEHAVIORAL|Client-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 250 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 0 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
214759352|NCT05842122|BEHAVIORAL|Implementor-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 250 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
214759353|NCT05842122|BEHAVIORAL|Counselor-supported delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
214759354|NCT05842122|BEHAVIORAL|Referral to clinic-based PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) referral to clinic-based PrEP/PEP services~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP referral~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP referral \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
214759355|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
214759356|NCT03987555|OTHER|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
214759357|NCT03987555|OTHER|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
214759358|NCT03987555|OTHER|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
214759359|NCT06433557|DRUG|Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections|For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
214759360|NCT03173625|DRUG|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
214759361|NCT03173625|DRUG|Placebo|Sterile 0.9% w/v sodium chloride solution
214759362|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide (NAM)|500 mg a day
214759363|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|1000 mg a day
214759364|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
214759365|NCT05517122|DIETARY_SUPPLEMENT|Microcrystalline cellulose|500 mg a day
214759366|NCT00147290|DEVICE|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
214759367|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
214759368|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
214759369|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
214759370|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
214759371|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
214759372|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
214759373|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
214759374|NCT05048875|DRUG|Cohort 1 - Group 1 JNJ High Dose|High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days
214759375|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Medium Dose|Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days
214759376|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Low Dose|Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days
214759377|NCT05048875|DRUG|Cohort 1 - Group 1/2 Placebo|Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.
214759378|NCT04957979|OTHER|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues"
214759379|NCT04957979|OTHER|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
214759380|NCT06626737|DRUG|Dapagliflozin (DAPA)|Participants will take Dapagliflozin 10mg every day in -1 to 14 days
214759381|NCT06374381|BEHAVIORAL|PEACE Online Resources|The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.
214759382|NCT06374381|BEHAVIORAL|PEACE Weekly Group Facilitation|Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.
214759383|NCT06374381|BEHAVIORAL|PEACE Weekly Individual Facilitation|Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
214759384|NCT05740956|DRUG|HS-10502|HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
214759385|NCT06535347|BEHAVIORAL|Information about scheduling a follow-up appointment|Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
214759386|NCT02318342|DRUG|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
214759387|NCT03914547|BEHAVIORAL|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
214759388|NCT03914547|BEHAVIORAL|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
214759389|NCT06058988|DRUG|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
214759390|NCT05525663|BEHAVIORAL|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
214759391|NCT06488300|DRUG|Ribavirin|"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"
214759392|NCT06488300|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5 days
214759393|NCT06488300|DRUG|Favipiravir|Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
214759394|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
214759395|NCT02255422|DRUG|Omaveloxolone capsules, 2.5 mg|
214759396|NCT02255422|DRUG|omaveloxolone capsules, 5 mg|
214759397|NCT02255422|DRUG|omaveloxolone capsules, 10 mg|
214759398|NCT02255422|DRUG|Placebo capsules|
214759399|NCT02255422|DRUG|omaveloxolone capsules, 20 mg|
214759400|NCT02255422|DRUG|omaveloxolone capsules, 40 mg|
214759401|NCT02255422|DRUG|omaveloxolone capsules, 80 mg|
214759402|NCT02255422|DRUG|omaveloxolone capsules, 160 mg|
214759403|NCT06340503|DEVICE|Research-grade accelerometer|Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit. Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
214759404|NCT06340503|OTHER|National Comprehensive Cancer Network (NCCN) Education Materials|The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
214759405|NCT06340503|DEVICE|Garmin Vivofit activity tracker|This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
214759406|NCT06340503|OTHER|Exercise Consultation Calls|The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
214759407|NCT06340503|OTHER|Interview|The interviews will be conducted by a trained Q-PRO interviewer and audio recorded. Interviews are expected to last approximately 30 minutes. Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
214759408|NCT06340503|OTHER|Physical Activity Index Assessment (Intervention Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 1, 3, 6, 9 and 12 while on study
214759409|NCT06340503|OTHER|Physical Activity Index Assessment (Control Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.
214759410|NCT06340503|OTHER|Health Surveys|Various health surveys will be completed to assess participant health and physical activities.
214759411|NCT06542614|DRUG|TQH3906 capsules|To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
214759412|NCT06542614|DRUG|Placebo of TQH3906 capsules|Placebo without drug substance.
214759413|NCT04411641|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
214759414|NCT04411641|DRUG|Placebo to match Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
214759415|NCT06176989|DRUG|Enasidenib|100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
214759416|NCT05155423|OTHER|mask for immobilization|mask for immobilization
214759417|NCT05155423|OTHER|Elekta BodyFix|Elekta BodyFix
214759418|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
214759419|NCT05482282|BIOLOGICAL|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
214759420|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
214759421|NCT05482282|BIOLOGICAL|Pentabio|3 doses of Pentabio
214759422|NCT04501562|OTHER|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
214759423|NCT04501562|OTHER|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
214759424|NCT04501562|OTHER|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
214759425|NCT04501562|OTHER|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
214759426|NCT03810417|DRUG|Digoxin Antibodies Fab Fragments|Digoxin antibodies
214759427|NCT03810417|OTHER|Placebo|Saline
214759428|NCT03810417|DIAGNOSTIC_TEST|Baseline EO > 360 pM|Baseline ouabain concentration \> 360 pM
214759429|NCT03810417|DIAGNOSTIC_TEST|EO < 360 pM|Baseline ouabain concentration \< 360 pM
214759430|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
214759431|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
214759432|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
214759433|NCT05776225|PROCEDURE|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
214759434|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
214759435|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
214759436|NCT04148326|OTHER|No Intervention|There is no intervention for this study.
214759437|NCT05707273|DRUG|Autologous Anti-CD19 CAR-expressing T Lymphocytes|Given IV
214759438|NCT05707273|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214759439|NCT05707273|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate
214759440|NCT05707273|DRUG|Cyclophosphamide|Given IV
214759441|NCT05707273|DRUG|Fludarabine|Given IV
214759442|NCT05707273|PROCEDURE|Leukapheresis|Undergo T-cell leukapheresis
214759443|NCT05707273|OTHER|Questionnaire Administration|Complete questionnaires
214759444|NCT06216132|COMBINATION_PRODUCT|BIOPIN-6 Active Implant with Naltrexone|An extended release formulation of naltrexone implanted in the subcutaneous space.
214759445|NCT06216132|DEVICE|BIOPIN-6 Placebo Implant|The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
214759446|NCT03449238|DRUG|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
214759447|NCT04050761|BIOLOGICAL|Nivolumab|Specified dose on Specific Days
214759448|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
214759449|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
214759450|NCT04275999|DRUG|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
214759451|NCT04275999|BEHAVIORAL|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
214759452|NCT04275999|DEVICE|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
214759453|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
214759454|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
214759455|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
214759456|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
214759457|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
214759458|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
214759459|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
214759460|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
214759461|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
214759462|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
214759463|NCT00005658|DRUG|Glycine|
214759464|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
214759465|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
214759466|NCT03222570|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
214759467|NCT03222570|DRUG|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
214759468|NCT03222570|OTHER|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
214759469|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
214759470|NCT05932979|OTHER|Placebo|Starch
214759471|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
214759472|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
214759473|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
214759474|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
214759475|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
214759476|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
214759477|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
214759478|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
214759479|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
214759480|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
214759481|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
214759482|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
214759483|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
214759484|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
214759485|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
214759486|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
214759487|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
214759488|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
214759489|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
214759490|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
214759491|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
214759492|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
214759493|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
214759494|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
214759495|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
214759496|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
214759497|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
214759498|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
214759499|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
214759500|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214759501|NCT00104858|DRUG|Cyclosporine|Given PO
214759502|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
214759503|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
214759504|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
214759505|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
214759506|NCT00104858|OTHER|Pharmacological Study|Correlative studies
214759507|NCT00104858|BIOLOGICAL|Rituximab|Given IV
214759508|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
214759509|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7\_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7\_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
214759510|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
214759511|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
214759512|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
214759513|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
214759514|NCT06264830|DEVICE|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
214759515|NCT06264830|PROCEDURE|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
214759516|NCT06021431|DEVICE|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.~Combination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling."
214759517|NCT06021431|OTHER|Treatment as Usual|Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving
214759518|NCT04963777|DIETARY_SUPPLEMENT|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
214759519|NCT04963777|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
214759520|NCT04988724|BEHAVIORAL|Exercise training|Exercise training with aerobic and strength training, 30 min per session
214759521|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
214759522|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
214759523|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
214759524|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
214759525|NCT05477901|OTHER|Supplemental cash transfer|Supplemental cash transfer ($40/month)
214759526|NCT04840979|DRUG|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
214759527|NCT04840979|DRUG|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
214759528|NCT05163353|DEVICE|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
214759529|NCT03643133|DRUG|Mifamurtide|48 doses overall over 36 weeks
214759530|NCT03643133|COMBINATION_PRODUCT|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
214759531|NCT06503224|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
214759532|NCT05768880|BIOLOGICAL|SC-CAR4BRAIN|Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
214759533|NCT05151484|DRUG|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
214759534|NCT05151484|DRUG|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
214759535|NCT06120231|DIAGNOSTIC_TEST|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
214759536|NCT06199531|GENETIC|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
214759537|NCT03198650|DRUG|Acalabrutinib|Acalabrutinib
214759538|NCT03198650|DRUG|Obinutuzumab|Obinutuzumab
214759539|NCT05182840|DRUG|BI 690517|Film-coated tablets
214759540|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
214759541|NCT05182840|DRUG|Empagliflozin|Empagliflozin
214759542|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
214759543|NCT04935164|OTHER|Psychiatric evaluations|At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
214759544|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
214759545|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
214759546|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
214759547|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
214759548|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
214759549|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
214759550|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
214759551|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
214759552|NCT00863265|OTHER|Placebo|
214759553|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
214759554|NCT04567849|BEHAVIORAL|message|patient portal message
214759555|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
214759556|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
214759557|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
214759558|NCT02268214|DRUG|Dapagliflozin|Tablets
214759559|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
214759560|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
214759561|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
214759562|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
214759563|NCT04342390|OTHER|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
214759564|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
214759565|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
214759566|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
214759567|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
214759568|NCT05339139|COMBINATION_PRODUCT|Dialysis|In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
214759569|NCT04563039|DEVICE|Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer|Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.
214759570|NCT04563039|DEVICE|Standard Ureteroscopic Laser Lithotripsy|Standard of care Ureteroscopic Laser Lithotripsy
214759571|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
214759572|NCT06103734|COMBINATION_PRODUCT|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
214759573|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
214759574|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
214759575|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
214759576|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
214759577|NCT05836857|BEHAVIORAL|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
214759578|NCT05836857|BEHAVIORAL|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
214759579|NCT04950426|DRUG|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
214759580|NCT06192108|DRUG|Orforglipron|Administered orally
214759581|NCT06192108|DRUG|Dapagliflozin|Administered orally
214759582|NCT01891318|RADIATION|radiosurgery|Undergo radiosurgery
214759583|NCT01891318|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214759584|NCT01891318|PROCEDURE|quality-of-life assessment|Ancillary studies
214759585|NCT06523725|DRUG|PO BRC-003 (High Cannabidiol Cannabis Extract)|The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).
214759586|NCT06523725|DRUG|Placebo|Placebo
214759587|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
214759588|NCT06350630|DRUG|Hydroxychloroquine Oral Tablet|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
214759589|NCT06350630|DRUG|Placebo oral tablet|placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
214759590|NCT05685355|DIAGNOSTIC_TEST|Standardized intraoral photography|Mouth photos will be taken with a plastic retractor to retract the subject's cheek and lips. This is a standard clinical procedure that is non-invasive and does not cause any harm or adverse effect on subjects.
214759591|NCT00318357|DEVICE|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
214759592|NCT00318357|DEVICE|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
214759593|NCT02643992|OTHER|DOAC concentration measurement|
214759594|NCT03982381|DRUG|Metformin|Active comparator
214759595|NCT03982381|DRUG|Dapagliflozin 10 MG|Experimental treatment
214759596|NCT05124886|OTHER|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
214759597|NCT05266144|PROCEDURE|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
214759598|NCT05932875|OTHER|Exercise Training|4 day per week concurrent exercise training program
214759599|NCT00696592|DRUG|Bevacizumab (Avastin), Verteporfin (Visudyne)|
214759600|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
214759601|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
214759602|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
214759603|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
214759604|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
214759605|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
214759606|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
214759607|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
214759608|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
214759609|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
214759610|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
214759611|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
214759612|NCT04792489|BIOLOGICAL|zamtocabtagene autoleucel (MB-CART2019.1)|Chimeric antigen receptor (CAR) T cell therapy
214759613|NCT04792489|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214759614|NCT04792489|DRUG|Fludarabine|Lymphodepleting chemotherapy
214759615|NCT04792489|DRUG|Bendamustine|Lymphodepleting chemotherapy
214759616|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
214759617|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
214759618|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
214759619|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
214759620|NCT01754610|BEHAVIORAL|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
214759621|NCT04564339|DRUG|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
214759622|NCT04564339|DRUG|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
214759623|NCT04564339|OTHER|Background Therapy|Participants will receive background therapy consistent with the standard of care.
214759624|NCT04100603|OTHER|No Intervention|There is no intervention for this study
214759625|NCT00003230|DRUG|paclitaxel|
214759626|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
214759627|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
214759628|NCT06811090|OTHER|Tele-rehabilitation|Rehabilitation service provided remotely through information and communication technologies.
214759629|NCT06811090|OTHER|Hospital rehabilitation|Rehabilitation program that will be carried out in person at the North Physical Medicine and Rehabilitation Unit. The program will be carried out by a physiotherapist and the patient will be taught: Information about the disease and self-care, Exercise module (Stretching, strengthening and proprioception), and phased gait re-education.
215030756|NCT06921499|BEHAVIORAL|Active Compartor|Participants randomized to comparison will receive 20-30 minutes of team-building activities each week for roughly 5 weeks.
214759630|NCT05984628|PROCEDURE|human umbilical cord mesenchymal stem cells|After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
214759631|NCT05984628|PROCEDURE|blank solvent|After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
214759632|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
214759633|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
214759634|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
214759635|NCT05933278|BIOLOGICAL|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
214759636|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
214759637|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
214759638|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
214759639|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
214759640|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
214759641|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
214759642|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
214759643|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
214759644|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
214759645|NCT03892967|OTHER|Interview|Participate in interview
214759646|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
214759647|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
214759648|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
214759649|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
214759650|NCT01054443|DRUG|Placebo|Tablet
214759651|NCT01054443|DRUG|Lusutrombopag|Tablet
214759652|NCT06991387|OTHER|Myofascial Release|A single session of myofascial release techniques including Single Arm Pull, Lateral Neck Shoulder Release, Thoracic Transverse Release, and Anterior Cervical Release applied by a physiotherapist trained in manual therapy.
214759653|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
214759654|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
214759655|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
214759656|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
214759657|NCT06992596|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
214759658|NCT06992596|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
214759659|NCT06140407|DRUG|Cisplatin|Receive Cisplatin
214759660|NCT06140407|DRUG|Carboplatin|Receive Carboplatin
214759661|NCT06140407|DRUG|Etoposide|Receive Etoposide
214759662|NCT06140407|BIOLOGICAL|Pembrolizumab|Receive Pembrolizumab by IV
214759663|NCT06140407|PROCEDURE|Computed Tomography|Undergo Computed Tomography
214759664|NCT06140407|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
214759665|NCT06140407|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
214759666|NCT06140407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214759667|NCT06140407|RADIATION|Radiation Therapy|Undergo Radiation Therapy
214759668|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
214759669|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
214759670|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
214759671|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
214759672|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
214759673|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
214759674|NCT02977052|DRUG|Ipilimumab|
214759675|NCT02977052|DRUG|Nivolumab|
214759676|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
214759677|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
214759678|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
214759679|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
214759680|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
214759681|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
214759682|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
214759683|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
214759684|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
214759685|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
214759686|NCT06854952|DRUG|TERN-601|Investigational drug
214759687|NCT06854952|OTHER|Matching Placebo|Matching placebo
214759688|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
214759689|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
214759690|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
214759691|NCT00100282|DRUG|PPI-1019 (APAN)|
214759692|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
214759693|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
214759694|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
214759695|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
214759696|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
214759697|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
214759698|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
214759699|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
214759700|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
214759701|NCT00516217|BIOLOGICAL|galiximab|
214759702|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
214759703|NCT02409017|PROCEDURE|Insulin drip|
214759704|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
214759705|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
214759706|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
214759707|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
214759708|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
214759709|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
214759710|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
214759711|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
214759712|NCT02839213|DRUG|Hyoscine Butyl bromide|
214759713|NCT02839213|DRUG|Saline|
214759714|NCT01869959|DRUG|LY2405319|Administered SC
214759715|NCT01869959|DRUG|Placebo|Administered SC
214759716|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
214759717|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
214759718|NCT06861881|DEVICE|Dexcom G7 Continuous Glucose Monitor|Dexcom G7 continuous glucose monitor will be placed prior to cardiac surgery. It will be worn continuously throughout the perioperative period and during the time admitted to the Cardiovascular Intensive Care Unit.
214759719|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging|Participants in the harm messaging arm will receive messages about the 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking.
214759720|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging Contextualized to Outcome Expectancies|Participants in the harm messaging contextualized to outcome expectancies arm will receive messages about the health harm and nicotine addiction risks of cigarillo smoking (i.e., 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking) contextualized to one of the following themes: 1) smoking sensory experience, 2) anticipated pleasure, relaxation, and satisfaction from smoking, 3) social persona/admiration related to smoking, and 4) that smoking does not align with personal values and authenticity.
214759721|NCT06861673|DEVICE|Pulmonary vein isolation|concomitant PVI and LAAC
214759722|NCT07000526|DRUG|Isoflurane|Inhaled sedation with isoflurane via Sedaconda ACD-S
214759723|NCT07000526|DRUG|Propofol|Intravenous sedation with Propofol 20 mg/ml
214759724|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
214759725|NCT07004309|PROCEDURE|Microfluidic sperm sorting|Sperm selection using the ZyMot Microfluidic Sperm Separation Device. Process involves loading semen into microfluidic channels to isolate motile sperm with low DNA fragmentation.
214759726|NCT07004309|PROCEDURE|Density Gradient Centrifugation|Sperm preparation using a discontinuous density gradient technique with SpermGrad and SpermRinse media. Centrifugation separates motile sperm for use in ICSI.
214759727|NCT06598397|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
214759728|NCT06598397|BEHAVIORAL|Peer Mentoring|Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
214759729|NCT06598397|BEHAVIORAL|Skills-based Text Messaging|NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
214759730|NCT06598397|DRUG|Combination NRT|If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
214759731|NCT07006012|DRUG|RGL-305|RGL-305 is administered intravenously with a recommended rate of 3-5 mL /min. The interval after the first administration was 3 weeks, and then every 2 weeks was a cycle, each cycle was given d1, and up to 5 cycles of cell transfusion were received.
214759732|NCT07005492|DIAGNOSTIC_TEST|radiological and clinical examination|Standard radiological (periapical radiography) and clinical (inspection, percussion, palpation tests etc.) examinations were performed.
214759733|NCT07005908|OTHER|Physical evaluations of post-COVID-19 individuals|In this study, pain, posture and musculoskeletal disorders were evaluated in post-COVID-19 individuals. The data to be obtained from all these evaluations were collected from the individuals at one time and over a period of approximately 1 hour at the most.
214759734|NCT07007338|BIOLOGICAL|Supplementary blood samples and urines samples|Supplementary blood and urines samples realised during routine visits
214759735|NCT07005843|DEVICE|The Elana Anastomotic System|The Elana Anastomotic System is a medical device and is intended to create a suture less blood vessel anastomosis in Coronary Artery Bypass Grafting (CABG) procedures on the beating heart, without blo
214759736|NCT07005323|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
214759737|NCT07005388|BEHAVIORAL|Cognitive behavioral therapy for psychosis|Cognitive behavioral therapy for psychosis is a group protocol design specially for psychotic patients to treat their positive and negative symptoms
215030757|NCT06931639|BEHAVIORAL|Safe Alternatives for Teens and Youth (SAFETY)|Please see description of experimental arm (arm one)
215030758|NCT06931639|BEHAVIORAL|Enhanced Treatment As Usual|Please see description of active comparator arm (arm two).
214759738|NCT07005271|BEHAVIORAL|virtual reality|The exercises in this group consist of four different games, including: (1) MasterChef, which involves performing daily living tasks in a virtual kitchen environment such as slicing tomatoes and cheese, adding salt, cracking and adding eggs, and stirring with a fork to prepare an omelet; (2) PinchPeg, where participants use a pinch grip to grasp rods generated in the center of a virtual environment and place them into holes on a pegboard, followed by removing and returning them to their original location; (3) Hold and Put, which requires the use of a standard palmar grasp to pick up virtual cups or cans and place them onto designated shelves; and (4) bPuzzle, a task that integrates cognitive and fine motor exercises by requiring participants to change the color of a puzzle using finger movements and place the pieces into the correct positions using hand gestures.
214759739|NCT07005271|BEHAVIORAL|Conventional treatment|Participants will be asked to complete puzzles consisting of 30 to 50 pieces, with 3 to 4 different puzzles used to eliminate the learning effect. They will perform the Nine-Hole Peg Test, which is similar to the PinchPeg game in the virtual reality group, by picking up pegs one by one from a container and placing them into holes on the board as quickly as possible using only the evaluated hand; this will be used for training purposes. Additionally, participants will be instructed to cut out geometric shapes with dotted outlines using scissors, aiming to follow the lines accurately. Finally, they will sort objects by placing the correct number and color of items into designated locations according to a predetermined pattern, and use a magnetic fishing rod to catch wooden fish, promoting both fine motor skills and task-oriented hand function.
214759740|NCT07005453|DEVICE|SCALE-EYE (1)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then with SCALE-EYE and lastly by biopsy-forceps assisted measurement.
214759741|NCT07005453|DEVICE|SCALE-EYE (2)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then by biopsy-forceps assisted measurement and lastly with SCALE-EYE.
214759742|NCT07007351|DEVICE|Intradermal injection|The product is the first solution with free hyaluronic acid boosted with silicium the administration mode is same as any other intradermal multi-injection procedure
214759743|NCT07007377|OTHER|Follow-up|Follow-up
214759744|NCT06999590|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
214759745|NCT06999590|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
214759746|NCT06999590|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
214759747|NCT07007130|DRUG|Actrapid insulin|0.1 IU/kg of short-acting human insulin diluted in 100 mL of normal saline, instilled intraperitoneally before closure
214759748|NCT07007130|DRUG|Normal saline|100 mL normal saline intraperitoneally
214759749|NCT07005544|DEVICE|RealityCare|Participants utilized a Virtual Reality scenario that simulated a complete handwashing sequence with water and soap, including an instructional display demonstrating the correct hand hygiene technique.
214759750|NCT07006766|OTHER|Microsurgical Training Models|"Four models will be compared: Japanese shirataki konjac noodle, Dragon skin silicone vessel, standard silicone vessel from Microsurgery and Regenerative Medicine (MSRM) lab, and the blue-blood chicken thigh model."
214759751|NCT07006116|OTHER|Synchronous/asynchronous online course|"* Synchronous weekly 90-120-minute-long sessions that will be conducted on a videoconferencing platform (i.e., Zoom). If participants miss a synchronous session.~* Asynchronous online course: available segments of the online course with asynchronous instructional materials delivered 2-4 days in between sessions, and supplemental course materials that will be received by mail."
214759752|NCT07006870|OTHER|Virtual Reality plus Balance Exercise Training|Virtual reality balance training will be completed using the BRU system's preloaded programs for postural training and rehabilitation. Rehabilitation exercises will include tasks performed standing with virtual reality headset on whereby the visual and vestibular systems will be stressed and will be customized according to the participant's needs and ability to tolerate the training stimulus. Postural training exercises will be used to develop limits of stability, with 3 exercises performed requiring participants to move their center of mass to collect rings/blocks through a course within a given amount of time. Each of the 3 postural training exercises contained 15 levels of varying difficulty. Sessions will be tailored to everyone, with progression of increasing the level of difficulty or time of exposure for each exercise. Participants at this group will be also participate in a Balance exercise training program for 40 min/3 times per week for 8 weeks.
214759753|NCT07006870|OTHER|Balance Exercise Training|Each session of balance exercises will be composed of three phases, including warm-up, balance training and cool down. The warm-up phase will involve gentle stretching for calf, hamstring, quadriceps, iliopsoas muscles, as well as anterior, posterior and lateral step-ups for 5-10 minutes. The active phase will be performed on a balance training for 20 minutes. It included heel and toe raises, one-legged stance for each extremity, shifting weight anteriorly, posteriorly, laterally and diagonally, step-ups, narrow walking, backward walking, sideward walking, stepping over obstacles, passing balls arranged on the training mat in a circle, and throwing and catching a ball on the training mat. A rest period of 1 minute will be given between each component. The program will be ended with 5-10 minutes of cool down. During the cool-down phase, patients will perform deep breathing exercises and static exercises for back extensors in a recumbent position.
214759754|NCT05896670|DRUG|licaminlimab|ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks.
214759755|NCT05896670|OTHER|vehicle of OCS-02|inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks.
214759756|NCT05896670|OTHER|Artificial tears|Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days.
214759757|NCT04900506|PROCEDURE|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
215030759|NCT05884528|BIOLOGICAL|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
214759758|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
214759759|NCT05590624|OTHER|Lower-Carbohydrate Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 45% fats, 35% carbs, 20% protein"
214759760|NCT05590624|OTHER|Low-Fat Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 70% carbs, 20% protein, 10% fat"
214759761|NCT06613685|DRUG|GS-1720|Tablets administered orally without regard to food
214759762|NCT06613685|DRUG|GS-4182|Tablets administered orally without regard to food
214759763|NCT06613685|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
214759764|NCT06613685|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
214759765|NCT06613685|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
214759766|NCT06613685|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
214759767|NCT07006402|PROCEDURE|Reverse NAGS(experimental)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Reverse NAGs on hypomobile segments at level T1-T4.~In these type of mobilization, the inferior facet glides up on the superior. The mobilizations are repeated \<6 times and then movements are reassessed. If no change occurs, the process will be repeated upto 10 minutes with resting period."
214759768|NCT07006402|PROCEDURE|Grade III Ventro-Cranial Translatoric Glides(standard protocol)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Grade III Ventro-Cranial Translatoric Glides on hypomobile segments at level T1-T4.~The mobilization will be applied and sustained for 30-40 seconds and will be continued for 10-15 minutes in a cyclic manner.~The grades of mobilization will be tapered as per individual needs."
214759769|NCT07006779|BEHAVIORAL|Music intervention|Engaging into conversation during procedure
214759770|NCT07006779|BEHAVIORAL|Conversation|Engaging patients into conversation
214759771|NCT07002632|DRUG|Dexpanthenol 5 % Topical Ointment|Dexpanthenol is a topical agent, a derivative of pantothenic acid (a B-complex vitamin), used for its moisturizing and skin regenerative properties. The formulation studied was a 5% dexpanthenol in a water-in-oil emulsion.
214759772|NCT07007143|DRUG|Experimental: Aspirin monotherapy|Aspirin monotherapy
214759773|NCT07007143|DRUG|Active Comparator: Aspirin+Clopidogrel|Aspirin+Clopidogrel
214759774|NCT07005804|GENETIC|transcriptomic and metabolomic analysis|Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
214759775|NCT07005531|PROCEDURE|Ultrasound-Guided Microbubble Clearance During Circuit Priming|CRRT circuits will be primed under real-time ultrasound monitoring. A portable ultrasound probe will be used to scan key points in the circuit and filter to detect and guide the removal of residual microbubbles before treatment. The process is considered complete when three consecutive scans (at 2-minute intervals) show no detectable microbubbles.
214759776|NCT07007208|DRUG|a positon emission tomography (PET) exam|TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)
214759777|NCT07007208|OTHER|MRI Contrast|"Data acquisition will include different sequences (anatomical MRI, resting fMRI). The MRI sequences performed will be anatomical imaging (i.e. T1 imaging, FLAIR), a diffusion sequence, a neuromelanin-sensitive sequence and functional imaging at rest (i.e. the resting state, which allows the functional connectivity within the so-called default network to be assessed)."
214759778|NCT07007208|OTHER|oculometry assessment|Pupillometry and oculometry will be conducted using an EyeBrain medical device (class IIa). Several cognitive tasks will be submitted to the participant, during which the same measurements will be taken. Different stimuli will be presented on the computer screen (visual scenes, text, geometric shapes) during the eye tracking measurement, and an instruction (cognitive task, such as semantic categorization, free exploration of the gaze, reading, saccade execution) will be associated with each type of stimulus. The successive stimuli will be spaced more than 7 secondes apart in order to allow the pupillary response to the first stimulus to be recorded and then to return to the basal diameter before presentation of the next stimulus.
214759779|NCT07007208|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through 6 interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare.
214759780|NCT07005557|DRUG|Chemotherapy|Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.
214759781|NCT07005557|DRUG|CDK4/6 Inhibitor|All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)
214759782|NCT07005557|DRUG|Endocrine therapy|Endocrine therapy (letrozole/anastrozole/exemestane)
214759783|NCT07005076|OTHER|Experimental Group|Participants in the experimental group will participate in a conventional exercise program similar to the control group, but with the addition of a technology-assisted exercise program. The intervention group will receive training with a reaction time measurement set using lights and an exercise set. The reaction time measurement and exercise set will be used, where light pods are placed in different positions, such as on a table, mirror, and floor, and patients will be instructed to extinguish the lit light as quickly as possible. The difficulty level of the sessions will be progressively increased by adjusting factors such as the duration of light activation, colors, the number of illuminated pods, their placement locations, and the distance between them.
214759784|NCT04008108|OTHER|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
214759785|NCT07006506|DRUG|Belumosudil|Belumosudil is an oral selective inhibitor of Rho-GTPase-associated coiled-coil kinase 2 (ROCK2)
214759786|NCT07007000|DEVICE|Temporary cardio-neural pacing|After routine ventricular lead implantation, a coronary sinus sheath will be delivered to RA septum, posterior to CS ostium, at the expected location of parasympathetic ganglion plexus. Pace mapping will be performed with a pacing lead at 30Hz, variable amplitude (20, 10, 5V) at 1ms pulse width. An electrophysiology catheter may be used where necessary for pace-mapping the response. At the site where lowest output can generate 30% prolongation of ventricular CL, the lead is fixed for 2-5mm depth. The output is tested again to achieve 50% prolongation of ventricular CL (at 20, 10, 5, 2, 1V). Fluoroscopic image will be collected with contrast injection at the sheath. Repositioning of lead can be performed if the rate suppression cannot be achieved with 3V@0.4ms. Implanted lead will serve as an atrial sensing and pacing lead and will not be removed at the end of procedure. Patient will be connected to a dual to a dual chamber pacemaker with device programming per usual clinical care.
214759787|NCT07006974|OTHER|SMCs|patients with SMCs
214759788|NCT07007065|DRUG|Surabgene Lomparvovec (ABBV-RGX-314)|subretinal injection
214759789|NCT07007065|DRUG|Ranibizumab Control|intravitreal injection
214759790|NCT03653052|DRUG|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
214759791|NCT07005895|OTHER|Hydration assessment via mobile app|Open the Gatorade Sports Science Institute (GSSI) branded mobile application and click on 'Complete Hydration Assessment'
214759792|NCT07006259|OTHER|Bobath Therapy|Treatment with bobath therapy
214759793|NCT07006259|OTHER|Bobath therapy plus virtual reality|Treatment with bobath therapy plus virtual reality
214759794|NCT07006259|OTHER|Home exercises|Treatment with home exercises
214759795|NCT07005700|DIAGNOSTIC_TEST|Targeted genomic sequencing|Single 0.5 mL venous or capillary blood sample.
214759796|NCT07005856|OTHER|Soft tissue mobilization|Soft tissue mobilization: mobilization participants' soft tissue by using hands
214759797|NCT07005856|OTHER|Stretching|Stretching: help patients do the movement that they're limited to stretch their soft tissue
214759798|NCT07005856|OTHER|Hot pack|Add an hot pack on participants' shoulder
214759799|NCT07006415|DEVICE|Brain-computer interface rehabilitation|10 sessions of motor imagery rehearsal rehabilitation using a brain-computer interface with functional electrical stimulation and a virtual avatar
214759800|NCT07006675|DRUG|600 mg Ibuprofen|Treatment patients will receive oral ibuprofen 600 mg three times a day (tid) for up to six weeks. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs. For patients who have a clinical concern regarding NSAID and prophylactic anticoagulation, the treating physician may consider prescribing misoprostol.
215030760|NCT05884528|BIOLOGICAL|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
214759801|NCT06867666|BEHAVIORAL|In Person CBT-I|6-week CBT-I delivered in-person at the TBI Clinic at NMCSD or via telehealth on a secure, Health Insurance Portability and Accountability Act (HIPAA) compliant platform by a doctoral-level clinician.
214759802|NCT06867666|BEHAVIORAL|CBT-I via COAST|6-week CBT-I delivered remotely via a clinician supervised digital platform by a doctoral-level clinician.
214759803|NCT05595499|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214759804|NCT05595499|DRUG|Fisetin|Given PO
214759805|NCT05595499|DRUG|Placebo Administration|Given PO
214759806|NCT05595499|OTHER|Quality-of-Life Assessment|Ancillary studies
214759807|NCT05595499|OTHER|Questionnaire Administration|Ancillary studies
214759808|NCT07011589|BIOLOGICAL|Efgartigimod|Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks
214759809|NCT07006207|OTHER|olfactory stimulation|the patients have a sniff-test
214759810|NCT07006207|OTHER|functional MRI|patients have a an f MRI
214759811|NCT07007078|DRUG|dihydroartemisinin|DHA 40mg tid for 90 days
214759812|NCT07005193|DEVICE|Using rang hood during cooking|Cooking ventilation facilities
214759813|NCT07005193|BEHAVIORAL|Using liquefied gas for cooking|Using liquefied gas instead of solid fuels for cooking
214759814|NCT07006545|OTHER|Return to Activity Battery|The main target parameters are muscle mass (sonography), muscle strength (isometric maximum strength measurement), neuromuscular activation (surface EMG), functionality (e.g. 6MWT, chair rising test), knee swelling and subjective assessment of everyday and leisure activities, quality of life (e.g. SF-36) and return to work
214759815|NCT07005661|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet apheresis was initiated immediately after central venous catheterization and completed before systemic heparinization using the XTRA system (LivaNova, UK). Whole blood was collected at \~60 mL/min via central venous access, \~300 mL per cycle, anticoagulated with sodium citrate. After separation, autologous platelet rich plasma and concentrated RBCs were obtained. The process was repeated for 4-6 cycles, collecting plasma equal to \~20-30% of estimated blood volume (Nadler formula). Crystalloids or colloids were infused during the procedure, and RBCs from the prior cycle were reinfused to maintain hemodynamic stability. Platelet rich plasma was stored in collection bags, agitated at room temperature, and reinfused after heparin neutralization .
214759816|NCT07005661|PROCEDURE|Standard Blood Management|Perioperative transfusion is based on intraoperative hemodynamics and internal environment. Routine blood salvage is performed, with tranexamic acid given throughout (30 mg/kg IV loading dose, 16 mg/kg/h IV maintenance, 2 mg/kg for CPB priming). CPB is primed with 1500 ml using an integrated oxygenator, without ultrafiltration emphasis. At surgery's end, heparin-protamine neutralization is guided by a decision-making system, with point-of-care coagulation monitoring to selectively transfuse blood products based on coagulation abnormalities.
214759817|NCT06872151|DEVICE|Gel containing a Propionibacterium extract|Patients will apply 1 ml of gel (equal to one phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
214759818|NCT06872151|DRUG|Hyaluronic acid and silver sulfadiazine|Patients will apply 1ml of gel (equal to a phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
214759819|NCT05078047|DRUG|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
214759820|NCT07011563|BEHAVIORAL|Intervention|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, b) individualized information about HIV risk reduction including PrEP, and c) use of motivational interviewing strategies to discuss barriers to PrEP.~Parents: brief (\~20-30 min) web-based, interactive learning module (module) designed to provide information about sexual health communication (SHC) best practices, HIV prevention strategies (e.g., condoms, STI testing, PrEP), as well as build practical skills around SHC using evidence-based behavior change methods (e.g., building confidence, aligning values with actions)."
214759821|NCT07011563|BEHAVIORAL|Control|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, and b) didactic information about condom use, STI testing (including HIV), and PrEP (but not motivational interviewing or individualized information on HIV risk reduction).~Parent: brief written information on a digital platform (i.e., website) with advice about talking to youth about sexual health with web-links to resources about STI/HIV prevention and PrEP. This information will not be interactive or use behavior change methods."
214759822|NCT07013877|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
215030761|NCT05884528|BIOLOGICAL|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
215030762|NCT05884528|BIOLOGICAL|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
215030763|NCT06933043|DRUG|NAV-240|Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.
215030764|NCT06933043|DRUG|Placebo|Three doses of matching placebo will be administered to participants.
214759823|NCT06125483|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
214759824|NCT06372197|DRUG|Psilocybin|Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
214759825|NCT07007169|DIETARY_SUPPLEMENT|The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food.|The intervention group will receive personalized education and guidance from a nutrition therapist.
214759826|NCT07007169|OTHER|Standard Diet|The control group will continue their normal diet, and not receive guidance or participate in group sessions.
214759827|NCT07006363|OTHER|IASTM|IASTM: For the application, the participant is seated on a chair, puts his hands together on the bed in front of him and puts his head on his hands (Figure 4). Vaseline cream is applied to the area to be applied to ensure that the Graston Technique instruments slide more easily in the tissue. The application area is the area between the mastoid processes proximally, the acromial processes laterally, and the T2 vertebra level distally. The researcher who will perform the application stands behind the participant. Application is performed for 10 minutes at a 45o angle with 3 different Graston instruments.
214759828|NCT07007286|DRUG|ETV,TDF,TAF,TMF combination with PEG IFNα-2b|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
214759829|NCT07007286|DRUG|ETV,TDF,TAF or TMF|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
214759830|NCT06684314|DRUG|Efanesoctocog alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
214759831|NCT05775718|DRUG|Zoster Vaccine Recombinant|Injection
214759832|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
214759833|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
214759834|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
214759835|NCT07005349|OTHER|Quality improvement program|The intervention comprises two mandatory risk assessments (preoperatively in theatre and postoperatively prior to discharge from the recovery area) which are linked to hospital-specific responses. Assessments for bleeding will occur intraoperatively (through direct vision, haemodynamic changes and/or measurement of blood loss) and postoperatively (with the use of the rapid assessment tool). If bleeding is diagnosed at any point, the THUMB checklist will be used to activate bundled care. On discharge from recovery, high-risk patients will be scheduled to receive a postoperative ward visit within four hours, when a further assessment for bleeding will occur.
214759836|NCT07006246|DRUG|Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)|Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
214759837|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
214759838|NCT04416451|DRUG|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
214759839|NCT04416451|DRUG|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
214759840|NCT06316557|DEVICE|iTBS group|iTBS on the contralesional cerebellum, twice a day for seven days
214759841|NCT06316557|DEVICE|control group|shame stimulation on the contralesional cerebellum, twice a day for seven days
214759842|NCT06869330|BEHAVIORAL|psychosocial|Measure changes in mental health indicators like depression, anxiety, and stress levels using validated scales (e.g. DASS 21).
214759843|NCT07019688|OTHER|Standard Information|Participants will receive only the standard written information routinely provided prior to dental procedures. This version does not include any additional content related to frequently asked questions.
214759844|NCT07019688|OTHER|Clinician Information|Participants will receive written information prepared by clinicians, which includes responses to the most frequently asked questions collected from patients undergoing same procedures.
214759845|NCT07019688|OTHER|AI Info|Participants will receive written information generated by ChatGPT, based on the identified frequently asked questions and formulated specifically for this study.
214759846|NCT04479241|BIOLOGICAL|lerapolturev|Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
214759847|NCT04479241|BIOLOGICAL|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
214759848|NCT07007481|DEVICE|Purrble|"The intervention takes the form of an interactive plush toy, which was co-designed with children to support in-the-moment soothing. The device is framed as an anxious creature, in need of care and attention when it feels distressed. This distress is indicated by a simulated heartbeat using embedded electronics to produce vibration patterns of i) frantic and anxious, to ii) slow, steady and relaxed. When held, the device emits a frantic heartbeat which can be slowed by stroking movements registered by embedded sensors. Once the device has been soothed for long enough, the heartbeat transitions into a purring vibration indicating a relaxed state. This transition can be achieved in under 1 minute but is dependent on the device-human interaction."
214759849|NCT06690164|DRUG|Atorvastatin 40mg Tablet|once a day for 30 days
214759850|NCT06690164|DRUG|Omeprazole 20mg Capsule|once a day for 30 days
214759851|NCT05947084|OTHER|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
214759852|NCT04571658|OTHER|Communication|The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.
214759853|NCT07023484|DIAGNOSTIC_TEST|KELIM|(i) Patients with KELIM =\>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery
214759854|NCT07023484|DRUG|Carboplatin plus Paclitaxel|Neoadjuvant chemotherapy
214759855|NCT07023484|PROCEDURE|Interval debulking surgery|Interval debulking surgery
214759856|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
214759857|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
214759858|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
214759859|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
214759860|NCT06871306|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|taVNS was performed using the Vagustim device (Vagustim Health Technologies, Teknokent, Istanbul, Türkiye) at the tragus and concha regions for 30 minutes, with a frequency of 25 Hz and a pulse width of 300 µs in both groups. The difference in stimulation between the groups depends only on to which ear it was applied. Electrical stimulation was increased in 0.1 mA steps until the detection threshold was reached.
214759861|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
214759862|NCT05692427|DEVICE|Cryopen - Cryotherapy|Cryotherapy with N20
214759863|NCT06597747|DEVICE|Audio processor|MED-EL SONNET 3 (EAS) audio processor
214759864|NCT02576951|DRUG|Galcanezumab|Administered SC
214759865|NCT02576951|DRUG|Placebo|Administered SC
214759866|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
214759867|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
214759868|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
214759869|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
214759870|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
214759871|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
214759872|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
214759873|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
214759874|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
214759875|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
214759876|NCT07031193|PROCEDURE|Foam roller instructions for pain reduction|Foam rolling procedure with pain reduction instructions over hamstring muscle group
214759877|NCT07031193|PROCEDURE|Foam rolling for range of motion improvement|Foam rolling over hamstring muscle group with range of motion improvement instructions.
214759878|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
214759879|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
214759880|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
214759881|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
214759882|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
214759883|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
214759884|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
214759885|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
214759886|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
214759887|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
214759888|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
214759889|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
214759890|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
214759891|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
214759892|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
214759893|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
214759894|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
214759895|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
214759896|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
214759897|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
214759898|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
214759899|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
214759900|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
214759901|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
214759902|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
214759903|NCT02215915|PROCEDURE|DES implantation|
214759904|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
214759905|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
214759906|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
214759907|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
214759908|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
214759909|NCT00028015|DRUG|SarCNU|
214759910|NCT05539378|BEHAVIORAL|Auditory Stimulation|enhancement of sleep slow wave activity through acoustic stimulation
214759911|NCT05539378|BEHAVIORAL|Sham (no stimulation)|Playing no tones during sleep but still recording brain activity
214759912|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
214759913|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
214759914|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
214759915|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
214759916|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
214759917|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
214759918|NCT00000721|DRUG|CD4 Antigens|
214759919|NCT01352923|OTHER|blood test|preparation of blood platelets
214759920|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
214759921|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
214759922|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
214759923|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
214759924|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
214759925|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
214759926|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
214759927|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
214759928|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
214759929|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
214759930|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
214759931|NCT04300556|DRUG|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
214759932|NCT04300556|DRUG|Prednisone|Prednisone administered orally.
214759933|NCT04300556|DRUG|Prednisolone|Prednisolone administered orally.
214759934|NCT04300556|DRUG|Dexamethasone|Dexamethasone administered orally.
214759935|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
214759936|NCT02827747|OTHER|Placebo|Placebo pill
214759937|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
214759938|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
214759939|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
214759940|NCT06716008|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
214759941|NCT06716008|OTHER|Manual Diaphragm Release|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
214759942|NCT06278571|BEHAVIORAL|Educational intervention with App and web site education|This group will only receive intervention with access to the educational website from home, where they will review the different modules focused on diabetes care, nutrition and exercise. in addition to the usual medical care by your treating physician.
214759943|NCT06278571|BEHAVIORAL|Educational interventión with web site education|This group will receive, in addition to nutritional therapy, diabetes education through an educational site, to learn more about the most important aspects of diabetes care. In addition to the usual medical care by your treating physician.
214759944|NCT06278571|OTHER|Control group with nutritional therapy|This group will receive only the usual medical care by your treating physician.
214759945|NCT06875986|DRUG|Brexpiprazole (Rexulti)|In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.
214759946|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
214759947|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
214759948|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
214759949|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
214759950|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
214759951|NCT07034755|OTHER|autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy|The efficacy of autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy was evaluated in patients with multiple myeloma who either achieved partial response (PR) or better (but not complete response \[CR\]) after four cycles of first-line chemotherapy, or those who achieved CR but had high-risk factors.
214759952|NCT06722469|OTHER|WCI|The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
214759953|NCT06724211|OTHER|Treatment bundle of care|The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
214759954|NCT06724211|OTHER|Control Group|Routine clinical care for kidney transplant patients
214759955|NCT06723223|DIAGNOSTIC_TEST|Traditional Peritoneal Equilibrium Test|The first day started with a traditional PET consisting of a 240-minutes dwell with 2.3% glucose PD solutions. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
214759956|NCT06723223|DIAGNOSTIC_TEST|Combined Peritoneal Equilibrium Test|The PET test on the first day (Day 1) was followed by a short (60 min) combined PET with 4.25% glucose solution. On the second day (Day 2), the combined PET was repeated. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
214759957|NCT06722066|DEVICE|Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves|Device: Edwards SAPIEN 3 valve, Medtronic Evolut valve, Boston Acurate Neo valve, or Abbott Navitor Access route: transfemorak, subclavian, transapical, transcarotid, or transcaval The use of balloon dilation will be left to the discretion of the operator.
214759958|NCT06724263|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
214759959|NCT06723067|DEVICE|Wearable wireless breast pump|As above
214759960|NCT06723847|PROCEDURE|Robotic pancreaticoduodenectomy|All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
214759961|NCT06722456|DIAGNOSTIC_TEST|Analysis of protein signatures in stool samples|Stool protein signatures are to be established in parallel to standard clinical evaluation of the intestinal inflammatory activity.
214759962|NCT06724042|DRUG|ISM5939|ISM5939 tablets will be administered orally once daily (QD).
214759963|NCT06724042|DRUG|Cisplatin|Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
214759964|NCT06724042|DRUG|Docetaxel|Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
214759965|NCT06724042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
214759966|NCT06724770|OTHER|Resilience training intervention|Training intervention on tools and strategies to strengthen the resilience of work teams in healthcare centres.
214759967|NCT06724107|RADIATION|UVC|It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
214759968|NCT06722287|BEHAVIORAL|Caregiver Mental Health Mobile Application Intervention|The mobile application includes self-care tools, caregiving management tools, and online support groups
214759969|NCT07043855|DRUG|single dose preoperative antibiotic|Arm A is a single preoperative dose of cefazolin administered immediately before surgery
214759970|NCT07043855|DRUG|Prolonged perioperative antibiotics|Preoperative Single-Dose Cefoxitin followed by Three-Day Cefotaxime and Metronidazole Prophylaxis
214759971|NCT07043920|OTHER|Behavioral Assessment (No therapeutic intervention will be administered)|"Participants will complete two validated questionnaires:~The Fagerström Test for Nicotine Dependence (FTND) - to assess levels of nicotine dependence.~The International Physical Activity Questionnaire - Short Form (IPAQ-SF) - to quantify weekly physical activity levels (walking, moderate, vigorous)."
214759972|NCT06719661|DRUG|Dapagliflozin 10mg|Uncontrolled type 2 diabetic patients receive dapagliflozin 10 mg tablet once daily. They are asked to take it for 3 months, then return for their final assessment after 3 months
214759973|NCT06719661|OTHER|Clinical Pharmacist-led Intervention|Patients with uncontrolled type 2 diabetes will undergo dosage intensification of their dual or triple oral hypoglycemic medicines up to maximum daily doses. Further, they will be advised on specific dietary modification, education on the importance of adherence, strategies to improve adherence, including giving pill boxes, and regular follow-up every month via telephone-based communication.
214759974|NCT06719661|OTHER|Standard therapy group|Patients are receiving their standard dual or triple oral hypoglycemic therapy only.
214759975|NCT06878612|BIOLOGICAL|Polyphenol whole tumor cell vaccine|3 patients enrolled in each dose group, and planned dose groups of 5 x 10\*6, 2 x 10\*7, and 5 x 10\*7 cells/dose. The dosing regimen consisted of 5 doses of basal immunization and subsequent individualized treatment. In the basal immunization, the administration times were D0, D14, D28, D42, and D56. After completion of the 5 doses of basal immunization, the subsequent individualized treatment was decided by the investigator based on the subject's tumor assessment, i.e., 1 vaccination per month for a total of 4 doses.
214759976|NCT06724250|DEVICE|Biofeedback therapy|Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.
214759977|NCT06724250|DRUG|Botulinum Toxin A (Botox )|Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
214759978|NCT07042880|OTHER|No intervention|No intervention
214759979|NCT06724744|OTHER|Aerobic training|For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.
214759980|NCT06724744|OTHER|Manual Diaphragm Release|The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
214759981|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
214759982|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
214759983|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
214759984|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
214759985|NCT06170528|DEVICE|AURA_ALZ|AURA\_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA\_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
214759986|NCT01896518|DRUG|Nicotine polacrilex|
214759987|NCT01896518|DRUG|Tobacco lozenge|
214759988|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
214759989|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
214759990|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
214759991|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
214759992|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
214759993|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
214759994|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
214759995|NCT00002329|DRUG|Celgosivir hydrochloride|
214759996|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
214759997|NCT01902992|DRUG|Depiquick Birch (DPG103)|
214759998|NCT01902992|DRUG|Placebo|
214759999|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
214760000|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
214760001|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
214760002|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
214760003|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
214760004|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
214760005|NCT01578109|DRUG|Sorafenib|Given PO
214760006|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
214760007|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
214760008|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
214760009|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
214760010|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
214760011|NCT00292006|DEVICE|Computerized tomography|
214760012|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
214760013|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
214760014|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
214760015|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
214760016|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
214760017|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
214760018|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
214760019|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
214760020|NCT00632138|BEHAVIORAL|exercise intervention|
214760021|NCT00632138|OTHER|questionnaire administration|
214760022|NCT00632138|PROCEDURE|biofeedback|
214760023|NCT00632138|PROCEDURE|management of therapy complications|
214760024|NCT00632138|PROCEDURE|psychosocial assessment and care|
214760025|NCT00632138|PROCEDURE|quality-of-life assessment|
214760026|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
214760027|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
214760028|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
214760029|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
214760030|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
214760031|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
214760032|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
214760033|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
214760034|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
214760035|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
214760036|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
214760037|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
214760038|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
214760039|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
214760040|NCT01019746|DRUG|propofol|propofol administration
214760041|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
214760042|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
214760043|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
214760044|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
214760045|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
214760046|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
214760047|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
214760048|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
214760049|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
214760050|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
214760051|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
214760052|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
214760053|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
214760054|NCT01802762|DEVICE|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
214760055|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
214760056|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
214760057|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
214760058|NCT02763007|DRUG|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
214760059|NCT02763007|DRUG|alogliptin|nesina add on metformin
214760060|NCT02763007|DRUG|pioglitazone|actos add on metformin
214760061|NCT00144859|DRUG|SB681323|
214760062|NCT02916056|DRUG|Azeliragon 5mg|
214760063|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
214760064|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
214760065|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
214760066|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
214760067|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
214760068|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
214760069|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
214760070|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
214760071|NCT02536625|OTHER|prospective study|
214760072|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
214760073|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
214760074|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
214760075|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
214760076|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
214760077|NCT00611780|RADIATION|tube voltage|standard 120 kV
214760078|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
214760079|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
214760080|NCT02191969|BEHAVIORAL|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
214760081|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
214760082|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
214760083|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
214760084|NCT01683331|DRUG|Insulin treatment for hyperglycemia|
214760085|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
214760086|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
214760087|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
214760088|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
214760089|NCT04167839|OTHER|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
214760090|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
214760091|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
214760092|NCT00421369|DRUG|sertraline|
214760093|NCT00421369|DRUG|triiodothyronine (T3)|
214760094|NCT00421369|DRUG|reboxetine|
214760095|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
214760096|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
214760097|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
214760098|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
214760099|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
214760100|NCT03001427|BEHAVIORAL|Structured center-based lifestyle intervention|
214760101|NCT03001427|BEHAVIORAL|Standard education and physician advice|
214760102|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
214760103|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
214760104|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
214760105|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
214760106|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
214760107|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
214760108|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
214760109|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
214760110|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
214760111|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
214760112|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
214760113|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
214760114|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
214760115|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
214760116|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
214760117|NCT04352907|DEVICE|Continuous Glucose Sensor|Continuous glucose sensor results will be compared with arterial glucose samples
214760118|NCT04669756|PROCEDURE|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
214760119|NCT04669756|PROCEDURE|placebo operation|in arm D sutures are transabdominal only
214760120|NCT03877276|DIETARY_SUPPLEMENT|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
214760121|NCT03877276|DIETARY_SUPPLEMENT|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
214760122|NCT03877276|DIETARY_SUPPLEMENT|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
214760123|NCT03877276|DIETARY_SUPPLEMENT|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
214760124|NCT03877276|DIETARY_SUPPLEMENT|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
214760125|NCT03877276|DIETARY_SUPPLEMENT|Sodium oxalate drink|a prepared sodium oxalate drink
214760126|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
214760127|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
214760128|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
214760129|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
214760130|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
214760131|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
214760132|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
214760133|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
214760134|NCT05383703|DRUG|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
214760135|NCT05868187|BEHAVIORAL|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
214760136|NCT04861168|PROCEDURE|driving pressure guided ventilation|driving pressure guided ventilation
214760137|NCT04861168|PROCEDURE|Conventional protective lung strategy|Conventional protective lung strategy
214760138|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
214645614|NCT04870476|BEHAVIORAL|"Internet-delivered treatment: One step at the time"|The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
214760139|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
214760140|NCT06827626|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive-Behavioural Therapy for Insomnia (CBT-I) includes behavioral methods, cognitive methods, and sleep hygiene counselling.
214760141|NCT06827626|BEHAVIORAL|Sleep hygiene counselling|Sleep hygiene counselling includes common instructions to improve sleep.
214760142|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
214760143|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
214760144|NCT06214065|DIAGNOSTIC_TEST|fMRI|fMRI will be performed pre- and post-rTMS
214760145|NCT06214065|DEVICE|rTMS|TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
214760146|NCT05077774|DEVICE|Harmony TPV System|Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
214760147|NCT00526162|DEVICE|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
214760148|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
214760149|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
214760150|NCT05465330|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min
214760151|NCT05465330|DRUG|Desflurane, Propofol|After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
214760152|NCT05443659|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214760153|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
214760154|NCT05283226|DRUG|NRC-2694-A|300 mg orally once daily
214760155|NCT05283226|DRUG|Paclitaxel|175 mg/m² IV infusion over approximately 3 hours
214760156|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
214760157|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
214760158|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
214760159|NCT04211376|OTHER|No Intervention|There is no intervention for this study
214760160|NCT03009175|DEVICE|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
214760161|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
214760162|NCT05727267|BIOLOGICAL|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
214760163|NCT05727267|BIOLOGICAL|TherVacB|Administration of the described combinations via the intramuscular route
214760164|NCT05791942|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
214760165|NCT05791942|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
214760166|NCT05791942|BEHAVIORAL|Behavioral: Action prompt|The message will prompt people to take care of the health gap right away before it slips their mind.
214760167|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
214760168|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
214760169|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
214760170|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
214760171|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
214760172|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
214760173|NCT05028894|OTHER|No intervention|No intervention
214760174|NCT06020378|DRUG|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
214760175|NCT04638439|DRUG|P1101 + Nivolumab + Entecavir|P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks), followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks), with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.
214760176|NCT03110107|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214760177|NCT03110107|BIOLOGICAL|BMS-986218|Specified dose on specified days
214760178|NCT03110107|BIOLOGICAL|Nivolumab|Specified dose on specified days
214760179|NCT04634877|BIOLOGICAL|Pembrolizumab|IV infusion
214760180|NCT04634877|DRUG|Carboplatin|IV infusion
214760181|NCT04634877|DRUG|Paclitaxel|IV infusion
214760182|NCT04634877|DRUG|Placebo for pembrolizumab|IV infusion
214760183|NCT04634877|DRUG|Docetaxel|IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
214760184|NCT04634877|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
214760185|NCT04634877|RADIATION|External Beam Radiotherapy (EBRT)|≥4500 cGY given according to local practice, at the discretion of the investigator
214760186|NCT04634877|DRUG|Cisplatin (as radiosensitizer)|If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
214760187|NCT04634877|RADIATION|Brachytherapy|Given according to local practice, at the discretion of the investigator
214760188|NCT05614128|OTHER|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
214760189|NCT02940301|DRUG|Ibrutinib|Given PO
214760190|NCT02940301|OTHER|Laboratory Biomarker Analysis|Correlative studies
214760191|NCT02940301|BIOLOGICAL|Nivolumab|Given IV
214760192|NCT06630663|BEHAVIORAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
214760193|NCT06630663|BEHAVIORAL|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
214760194|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
214760195|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
214760196|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles
214760197|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
214760198|NCT06025565|DIAGNOSTIC_TEST|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
214760199|NCT04238624|DRUG|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
214760200|NCT04238624|DRUG|Trametinib|Participants will receive trametinib 2 mg orally once a day
214760201|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
214760202|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
214760203|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
214760204|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
214760205|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
214760206|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
214760207|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
214760208|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
214760209|NCT00070070|BIOLOGICAL|sargramostim|
214760210|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
214760211|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
214760212|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
214760213|NCT02052206|PROCEDURE|Shoulder replacement surgery|
214760214|NCT00006049|DRUG|carboplatin|
214760215|NCT00006049|DRUG|gefitinib|
214760216|NCT00006049|DRUG|paclitaxel|
214760217|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
214760218|NCT03007615|OTHER|Intimate Lubricant Gel|
214760219|NCT05981365|DRUG|Voxelotor|Drug drug interaction
214760220|NCT05981365|DRUG|Bupropion|Drug drug interaction
214760221|NCT05981365|DRUG|Repaglinide|Drug drug interaction
214760222|NCT05981365|DRUG|Flurbiprofen|Drug drug interaction
214760223|NCT05981365|DRUG|Omeprazole|Drug drug interaction
214760224|NCT05981365|DRUG|Midazolam|Drug drug interaction
214760225|NCT05981365|DRUG|Metformin|Drug drug interaction
214760226|NCT05981365|DRUG|Furosemide|Drug drug interaction
214760227|NCT05981365|DRUG|Rosuvastatin|Drug drug interaction
214760228|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
214760229|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
214760230|NCT05053581|OTHER|Survey|Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
214760231|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
214760232|NCT01727804|OTHER|Laser in caries prevention|
214760233|NCT03927989|BEHAVIORAL|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
214760234|NCT03927989|OTHER|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
214760235|NCT05960461|BEHAVIORAL|FMF (Families Moving Forward) Connect Pro|"FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app"
214760236|NCT05960461|BEHAVIORAL|ECHO (Extension of Community Healthcare Outcomes) implementation.|Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.
214760237|NCT05960461|BEHAVIORAL|Self-Directed Learning implementation.|Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
214760238|NCT04632485|DEVICE|Ultrasound imaging|Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.
214760239|NCT04632485|DEVICE|Magnetic Resonance Imaging (MRI)|Head and Neck MRI exam with contrast
214760240|NCT04632485|OTHER|Neurocognitive testing|Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills
214760241|NCT04632485|DEVICE|Transcranial Doppler (TCD)|Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes
214760242|NCT04632485|DEVICE|Pulse Wave Doppler|Pulse wave Doppler will be used to acquire a Doppler waveform in the right common carotid artery and the right femoral artery
214760243|NCT06237855|OTHER|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
214760244|NCT06256900|OTHER|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
214760245|NCT06256900|OTHER|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
214760246|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
214760247|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
214760248|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
214760249|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
214760250|NCT00384072|DRUG|bazedoxifene BZA-20|
214760251|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
214760252|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
214760253|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
214760254|NCT02444676|OTHER|Stratification and outcomes|No necessary
214760255|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
214760256|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
214760257|NCT01700894|BEHAVIORAL|Walking Program|
214760258|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
214760259|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
214760260|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
214760261|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
214760262|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
214760263|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
214760264|NCT03378531|DRUG|AEB1102|modified human arginase I
214760265|NCT01757873|DRUG|Z160|
214760266|NCT01757873|DRUG|Placebo|
214760267|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
214760268|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
214760269|NCT06540352|DRUG|Mannitol|Placebo in tablets
214760270|NCT00007735|DRUG|Doxycycline (200mg/day) or Placebo|
214760271|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
214760272|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
214760273|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
214760274|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
214760275|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
214760276|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
214760277|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
214760278|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
214760279|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
214760280|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
214760281|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
214760282|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
214760283|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
214760284|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
214760285|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
214760286|NCT05361005|DRUG|Placebo|Intravenous injection
214760287|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
214760288|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
214760289|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
214760290|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
214760291|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
214760292|NCT06635408|DIAGNOSTIC_TEST|cystatin c|a biomarker to assess renal function
214760293|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
214760294|NCT00009750|BIOLOGICAL|filgrastim|
214760295|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
214760296|NCT00009750|DRUG|cyclosporine|
214760297|NCT00009750|DRUG|paclitaxel|
214760298|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
214760299|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
214760300|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
214760301|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
214760302|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
214760303|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
214760304|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
214760305|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
214760306|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
214760307|NCT00396357|DRUG|Vildagliptin|
214760308|NCT00396357|DRUG|metformin|
214760309|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
214760310|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
214760311|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
214760312|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
214760313|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
214760314|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
214760315|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
214760316|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
214760317|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
214760318|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
214760319|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
214760320|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
214760321|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
214760322|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
214760323|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
214760324|NCT00000658|DRUG|Bleomycin sulfate|
214760325|NCT00000658|DRUG|Vincristine sulfate|
214760326|NCT00000658|DRUG|Doxorubicin hydrochloride|
214760327|NCT00000658|DRUG|Cyclophosphamide|
214760328|NCT00000658|DRUG|Allopurinol|
214760329|NCT00000658|DRUG|Methotrexate|
214760330|NCT00000658|DRUG|Cytarabine|
214760331|NCT00000658|DRUG|Leucovorin calcium|
214760332|NCT00000658|DRUG|Sargramostim|
214760333|NCT00000658|DRUG|Dexamethasone|
214760334|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
214760335|NCT02719613|DRUG|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
214760336|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
214760337|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
214760338|NCT02719613|DRUG|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
214760339|NCT02719613|DRUG|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
214760340|NCT02719613|DRUG|Pomalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
214760341|NCT02719613|DRUG|Nivolumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
214760342|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
214760343|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
214760344|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
214760345|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
214760346|NCT05978375|PROCEDURE|TARP|Using TARP technique.
214760347|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
214760348|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
214760349|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
214760350|NCT03401502|DRUG|Placebos|Oral, b.i.d
214760351|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
214760352|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
214760353|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
214760354|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
214760355|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
214760356|NCT00488098|DRUG|GSK372475|
214760357|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
214760358|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
214760359|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
214760360|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
214760361|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
214760362|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
214760363|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
214760364|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
214760365|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
214760366|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
214760367|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
214760368|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
214760369|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
214760370|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
214760371|NCT04622540|PROCEDURE|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
214760372|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
214760373|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
214760374|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
214760375|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
214760376|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
214760377|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
214760378|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
214760379|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
214760380|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
214760381|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
214760382|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
214760383|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
214760384|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
214760385|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
214760386|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
214760387|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
214760388|NCT02001038|OTHER|Survey|
214760389|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
214760390|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
214760391|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
214760392|NCT01708694|DIETARY_SUPPLEMENT|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
214760393|NCT01708694|DIETARY_SUPPLEMENT|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
214760394|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
214760395|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
214760396|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
214760397|NCT06281522|OTHER|Operated patients with hydatid cyst of the lung|File screening and blood test results will be evaluated
214760398|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
214760399|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
214760400|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
214760401|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
214760402|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
214760403|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
214760404|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
214760405|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
214760406|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
214760407|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
214760408|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
214760409|NCT05680987|PROCEDURE|RFN-Advanced Retrograde Femoral Nailing System|RFN-Advanced Retrograde Femoral Nailing System for patients with a distal femur or femoral shaft fracture requiring surgery
214760410|NCT06165679|DRUG|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
214760411|NCT06165679|DRUG|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
214760412|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
214760413|NCT02195271|DRUG|Melatonin|
214760414|NCT03660059|DRUG|Peficitinib|Oral
214760415|NCT03660059|DRUG|Plaebo|Oral
214760416|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
214760417|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
214760418|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
214760419|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
214760420|NCT02331680|DRUG|OPC-41061|
214760421|NCT02331680|DRUG|OPC-41061|
214760422|NCT02331680|DRUG|Placebo|
214760423|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
214760424|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
214760425|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
214760426|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
214760427|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
214760428|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
214760429|NCT02042807|DRUG|Placebo|
214760430|NCT02042807|DRUG|MCS®|
214760431|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
214760432|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
214760433|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
214760434|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
214760435|NCT05939388|DEVICE|Auricular Acupressure Pads|Pads containing seeds that are placed on specific sites of the ear that are thought to help with pain.
214760436|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
214760437|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
214760438|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
214760439|NCT06648434|DRUG|Zunsemetinib|Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.
214760440|NCT06648434|DRUG|mFOLFIRINOX|Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
214760441|NCT06273904|DEVICE|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
214760442|NCT06273904|DEVICE|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
214760443|NCT04477343|DRUG|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
214760444|NCT04477343|DRUG|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
214760445|NCT05922761|DRUG|Belumosudil|Kinase inhibitor, tablet taken orally
214760446|NCT05922761|DRUG|Fluticasone|Via inhalation by metered-dose inhaler.
214760447|NCT05922761|DRUG|Azithromycin|Semi-synthetic macrolide antibiotic, taken orally
214760448|NCT05922761|DRUG|Prednisone|Corticosteroid, taken orally
214760449|NCT05922761|DRUG|Montelukast|Leukotriene Receptor Antagonist, taken orally
214760450|NCT01068041|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
214760451|NCT00602667|DRUG|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
214760452|NCT00602667|DRUG|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
214760453|NCT00602667|DRUG|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
214760454|NCT00602667|DRUG|Intermediate-Risk Therapy|"Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan."
214760455|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with VR-IOMSs|Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs
214760456|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with COMS|Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)
214760457|NCT04639531|BEHAVIORAL|No Orientation and Mobility Training|No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
214760458|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
214760459|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
214760460|NCT01569321|DEVICE|MRI|
214760461|NCT01569321|DEVICE|PET-CT scan|
214760462|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
214760463|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
214760464|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
214760465|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
214760466|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
214760467|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
214760468|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
214760469|NCT04387487|BEHAVIORAL|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
214760470|NCT05524805|DEVICE|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
214760471|NCT05273060|PROCEDURE|3D Nasal Reconstruction Planning|3D molds or models to use in the reconstruction of nasal cartilage
214760472|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
214760473|NCT06209268|DRUG|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
214760474|NCT06209268|DRUG|Placebo|0.9% NaCl 1 ml per day in five consecutive days
214760475|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
215030765|NCT06688890|OTHER|Surgical hand rub with the reference product; n-propanol 60%.|Propanol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
214760476|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
214760477|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
214760478|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
214760479|NCT04103645|DRUG|Vactosertib|50 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
214760480|NCT04103645|DRUG|Vactosertib|100 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
214760481|NCT04103645|DRUG|Vactosertib|150 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
214760482|NCT04103645|DRUG|Vactosertib|200 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
214760483|NCT04103645|DRUG|Vactosertib|The lowest dose level of vactosertib for which no DLT was observed in Tier 1 AND The lowest dose level for which at least one of the 12 subjects enrolled on Tier 1 met Criteria for Clinical Benefit. Or, if a single dose level does not fulfil both Criterion 1 and Criterion 2, the starting dose level for Tier 2 will lowest dose from Tier 1 for which no DLT was identified.
214760484|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
214760485|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
214760486|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
214760487|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
214760488|NCT05198323|DRUG|LT3001 Drug Product|LT3001 Drug Product administered once by intravenous infusion
214760489|NCT05198323|DRUG|Placebo|Placebo administered once by intravenous infusion
214760490|NCT06975605|DRUG|Radiprodil + co-administered drugs|"Study drug radiprodil will be administered asbelow in a sequential manner.~\- Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.~Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg."
214760491|NCT02159742|OTHER|Data Collection|
214760492|NCT04410978|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
214760493|NCT04410978|DRUG|Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
214760494|NCT04410978|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
214760495|NCT04410978|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
214760496|NCT04820179|DRUG|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
214760497|NCT05864326|DEVICE|Warm group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.
214760498|NCT05864326|DEVICE|Room temperature group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
214760499|NCT05603572|DRUG|KAT-101|oral dosage form
214760500|NCT05603572|DRUG|KAT-201|IT dosage form
214760501|NCT04871282|DRUG|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
214760502|NCT04871282|OTHER|Placebo|Placebo to match AL102
214760503|NCT05761574|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
214760504|NCT05761574|DRUG|Naproxen Sodium|Naproxen Sodium will be administered orally.
214760505|NCT05761574|DRUG|Acetaminophen|Acetaminophen will be administered orally.
214760506|NCT05761574|DRUG|Placebo|Placebo will be administered orally.
214760507|NCT06240117|PROCEDURE|Intraoperative cellular salvage|When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If \>100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
214760508|NCT06212011|OTHER|Functional Neuromuscular Electrical Stimulation|The functional NMES technique involves the application of electrical stimulation during functional activity. In our study, in the functional neuromuscular electrical simulation group, neuromuscular electrical stimulation will be applied to the lumbar multifidus muscle while individuals perform the activity of standing up from sitting.
214760509|NCT06212011|OTHER|Conventional Neuromuscular Electrical Stimulation|The conventional neuromuscular electrical simulation technique, electrical stimulation is applied without the individual performing voluntary contractions. In our study, conventional NMES will be applied to the lumbar multifidus muscle with the individual lying in the prone position and the individual will not elicit any voluntary contractions during the simulation.
214760510|NCT04813484|BEHAVIORAL|Kickin it with the Gulz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
214760511|NCT05396950|DEVICE|CPAP|CPAP in conjunction with radiotherapy
214760512|NCT05105126|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
214760513|NCT05105126|DEVICE|Sham tDCS|Sham tDCS
214760514|NCT05862246|OTHER|Clinical examination|No intervention, only clinical examination
214760515|NCT02662621|OTHER|blood samples|
214760516|NCT02662621|OTHER|Urine samples|
214760517|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
214760518|NCT04133675|DEVICE|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
214760519|NCT04133675|DEVICE|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
214760520|NCT00102011|PROCEDURE|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
214760521|NCT00102011|PROCEDURE|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
214760522|NCT00102011|PROCEDURE|screening colonoscopy|Patients undergo baseline screening colonoscopy
214760523|NCT00102011|PROCEDURE|standard follow-up care|Standard care
214760524|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
214760525|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
214760526|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
214760527|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
214760528|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
214760529|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
214760530|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
214760531|NCT04560088|BEHAVIORAL|Mindfulness|Mindfulness-based mobile health intervention.
214760532|NCT04560088|BEHAVIORAL|Breathing|Breathing mobile health intervention.
214760533|NCT05653388|OTHER|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
214760534|NCT04402125|BEHAVIORAL|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
214760535|NCT05366842|DRUG|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
214760536|NCT05366842|PROCEDURE|Radical prostatectomy|Standard care (no placement of tissue)
214760537|NCT06466655|DRUG|MitoTempol|One intradermal microdialysis probes will be perfused with MitoTempol (0.5 mM) during a standard local skin heating protocol.
214760538|NCT06466655|DRUG|Lactated Ringer's (control)|One intradermal microdialysis probes will be perfused with lactated Ringer's (control) during a standard local skin heating protocol.
214760539|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
214760540|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
214760541|NCT04099446|OTHER|Non-interventional|There is no intervention for this study
214760542|NCT02202811|BEHAVIORAL|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
214760543|NCT00798122|PROCEDURE|Intravascular ultrasound|intravascular ultrasound
214760544|NCT00798122|PROCEDURE|MRI|cardiac MRI
214760545|NCT04100915|OTHER|No Intervention|There is no intervention for this study
214760546|NCT06808802|DRUG|Retatrutide|Administered subcutaneously (SC)
214760547|NCT06808802|DRUG|Metoprolol|Administered orally
214760548|NCT03968055|OTHER|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
215030766|NCT06688890|OTHER|Surgical hand rub with the product P1; Sorbectol for 1 min.|Sorbectol hand rub for 1 min. The applied volume of product is sufficient to keep the hand moist for a total time of 1 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
214760549|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
214760550|NCT06653777|DRUG|Pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
214760551|NCT04853914|DEVICE|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
214760552|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
214760553|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
214760554|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
214760555|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
214760556|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
214760557|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
214760558|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
214760559|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
214760560|NCT06520098|DRUG|Venetoclax|VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
214760561|NCT06520098|DRUG|Ibrutinib, Acalabrutinib, Zanubrutinib|IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
214760562|NCT05726383|DRUG|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
214760563|NCT06106633|DEVICE|TriNaV|Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
214760564|NCT00885677|DEVICE|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
214760565|NCT03277638|DRUG|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
214760566|NCT03277638|DRUG|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
214760567|NCT03277638|DRUG|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
214760568|NCT03277638|PROCEDURE|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
214760569|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
214760570|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
214760571|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
214760572|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
214760573|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
214760574|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
214760575|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
214760576|NCT05687266|DRUG|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214760577|NCT05687266|DRUG|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214760578|NCT05687266|DRUG|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
214760579|NCT05687266|DRUG|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
214760580|NCT05687266|DRUG|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
214760581|NCT05687266|DRUG|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214760582|NCT05687266|DRUG|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
214760583|NCT02008396|DRUG|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
214760584|NCT02008396|DRUG|Midomafetamine HCl|Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
214760585|NCT02008396|BEHAVIORAL|Therapy|Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
214760586|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
214760587|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
214760588|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
214760589|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
214760590|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
214760591|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
214760592|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
214760593|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
214760594|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
214760595|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
214760596|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
214760597|NCT07007039|OTHER|Datos Health App|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and/or strength bouts completed over 3 month period. Individualized goals will be selected and set with a customized amount by a rehabilitation provider with at least monthly follow up contact to modify goals.
214760598|NCT07007468|OTHER|Abdominal Massage|Abdominal massage is a massage technique performed with soft and rhythmic movements applied to the abdomen. Abdominal massage is an inexpensive, non-invasive, non-harmful, non-invasive method that can be applied by nurses for the treatment of constipation or by teaching the patient and his/her family. During the application of abdominal massage, effleurage (patting), abdominal effleurage , petrissage (kneading), abdominal petrissage maneuvers are applied.
214760599|NCT07005089|PROCEDURE|Laparotomy or laparoscopic ovarian cystectomy|to evaluate diagnostic accuracy of ultrasound and tumors markers in diagnosis of complex ovarian cysts in adolescent with histopathological correlation.
214760600|NCT05962463|PROCEDURE|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
214760601|NCT05962463|PROCEDURE|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
214760602|NCT05405218|DEVICE|CTR with Ultrasound Guidance using the UltraGuideCTR device|Carpal Tunnel Release with Ultrasound Guidance using UltraGuideCTR device
214760603|NCT05405218|PROCEDURE|mOCTR|Mini Open Carpal Tunnel Release
214760604|NCT07006168|DRUG|Ketorolac 15mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
214760605|NCT07006168|DRUG|Triamcinolone Acetonide 40mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
214760606|NCT07006168|DRUG|Ropivacaine HCL 1% 15ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
214760607|NCT07006168|DRUG|0.9 % Normal Saline 35ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
214760608|NCT07006168|DRUG|Adrenaline 1:1000 0.5ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
214760609|NCT06870279|DRUG|CGC738|CAR-NKT Cells treatment
214760610|NCT05025800|DRUG|CD47 Antagonist ALX148|Given IV
214760611|NCT05025800|DRUG|Lenalidomide|Given PO
214760612|NCT05025800|BIOLOGICAL|Rituximab|Given IV
214760613|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
214760614|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
214760615|NCT00069654|PROCEDURE|Forearm blood flow study|
214760616|NCT00069654|PROCEDURE|Brachial artery reactivity study|
214760617|NCT00069654|PROCEDURE|Treadmill exercise test|
214760618|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
214760619|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
214760620|NCT02218619|DRUG|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
214760621|NCT02218619|DRUG|Sugar Pill (placebo)|Placebo
214760622|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
214760623|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
214760624|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
214760625|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
214760626|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
214760627|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
214760628|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
214760629|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
214760630|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
214760631|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
214760632|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
214760633|NCT06709612|DRUG|AMT-143 hydrogel containing containing ropivacaine|AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine HCl equivalence basis). AMT-143 hydrogel will be provided as pre-filled syringes for administration via instillation into the surgical site after surgery and prior to suture.
214760634|NCT06709612|DRUG|Ropivacaine|5 mL Ropivacaine 10 mg/mL (1%) solution
214760635|NCT06709612|OTHER|Placebo|Saline Placebo
214760636|NCT06712433|DRUG|2% intranasal mupirocin ointment|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
214760637|NCT06712433|DRUG|4% chlorhexidine gluconate body cleanser|Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.
214760638|NCT06723093|BEHAVIORAL|Social Medicine Housing Initiative|"Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies."
214760639|NCT06724653|DRUG|RAS blocker tapering group|RAS blocker tapering out
214760640|NCT06724653|DRUG|Beta blocker tapering out|Beta blocker tapering out group
214760641|NCT06722937|OTHER|Observation|Observe the clinical natural changes of eye parameters of the subjects.
214760642|NCT06722196|DRUG|topical amiodarone|amiodarone soaked patch placed on the left atrial roof at the end of surgery
214760643|NCT06722196|OTHER|saline solution patch|saline solution soaked patch placed on left atrial roof at the end of surgery
214760644|NCT06724367|DEVICE|Transspinal direct current stimulation|Direct current electrical stimulation applied non-invasively to the spinal cord.
214760645|NCT06724367|DEVICE|Sham Comparator|transspinal direct current stimulation simulated
214760646|NCT06722820|DRUG|LPH-5|LPH-5
214760647|NCT06722820|DRUG|Placebo|Placebo
214760648|NCT06723977|OTHER|Auditory Hallucination Based Voice Hearing Simulation|"1. st stage: Preparation of the environment, introduction, providing information about the purpose, duration and content of the application, application of data collection tools and distribution of the information brochure were provided.~2. nd stage: Introducing the recording devices and headphones, performing the first task simultaneously while listening to the prepared three-dimensional sound recording (watching a city promotional film and answering verbal questions about this film), performing the second task simultaneously while listening to the prepared three-dimensional voice recording (telling a story). (reading the text and answering the questions about this story text in writing) were applied.~3. rd stage: Information about the next application time of the measurement tools was provided.~Additional stage: Data collection tools were reapplied."
214760649|NCT06724497|PROCEDURE|face scanning pre and post orthognathic surgery|patient will be scanned pre operative using both scanners and then undergo orthognathic surgery then will be rescanned again 6 montsh later
214760650|NCT06724393|OTHER|Blood flow restrictions in combination with low-intensity resistance training|Blood flow restrictions in combination with low-intensity resistance training to test if an online intervention (telehealth) can improve functional capacity and balance in older adults
214760651|NCT06710626|DEVICE|Assistive Robotic Arm|The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.
214760652|NCT07047768|OTHER|No intervention : data-based study|No intervention : data-based study
214760653|NCT07048444|OTHER|N/A as observational study|N/A as observational study design
214760654|NCT04954027|BEHAVIORAL|Questionnaires|"5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator"
214760655|NCT07047729|OTHER|Early oral feeding|Liquid diet will be initiated within 24 hours after surgery and, if well-tolerated without vomiting, will transition to a regular diet over the subsequent 24 hours
214760656|NCT07047729|OTHER|Standard oral feeding|Standard diet (late feeding), including liquid filtrates, will only be introduced after the resolution of the ileus, during which these patients will remain NPO (nothing by mouth).
214760657|NCT07048691|DIAGNOSTIC_TEST|G.E HEALTHCARE ultrasound machine with high-resolution convex probe|After approval from the institutional ethical committee, a total number of patients presenting to the Radiology and Peads Neurosurgery department of Allied Hospital, Faisalabad, that met the inclusion criteria was selected. After obtaining informed consent from each patient and attendant of the patient, transabdominal ultrasound was examined longitudinal, transverse and oblique plans, ultrasound with a high- resolution convex probe was used by the radiologist
214760658|NCT07048782|OTHER|Observational assessment of clinical outcomes|This is a non-interventional observational study. No treatment or behavioral intervention is administered.
214760659|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 2D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 2D imaging colonoscope
214760660|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 3D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 3D imaging colonoscope
214760661|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
214760662|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
214760663|NCT07048600|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|"Monotherapy ACT-i, with no behavioral components, is a brief and low-intensity treatment that has recently been detailed by experts in the field in a session-by-session guideline, intending to help people affected by chronic insomnia. The key components of the sessions are psychoeducation, mindfulness, values and actions derived from chosen values, and defusion.~An adapted, brief and online version of the intervention was developed by the authors of this study. Both interventions were matched in terms of overall duration and delivery format. Each session was tailored to follow a comparable format. Therapeutic alliance, psychoeducation, sleep hygiene, relaxation training and homework was targeted in the first session. In the second session, ACT-i focused on values, acceptance strategies and psychological flexibility. This version will be published online upon request. Each session will last 120 min. They will be delivered once per week, for two consecutive weeks."
214760664|NCT07048600|BEHAVIORAL|Attentional Control Group|The focus of the sessions will be on participants, on general topics. It will not include any active, psychological intervention components, such as cognitive restructuring or ACT processes. No recommendations or psychological guidance will be given. Each session will last 120 minutes. It will be held once per week, for two weeks.
214760665|NCT07047417|DIAGNOSTIC_TEST|CLE and ROSE|All patients undergo white light bronchoscopy after general anesthesia to rule out abnormalities in the lumen and clear the airways. After locating the target lymph node using convex probe endobronchial ultrasound (CP-EBUS), the target lymph node is routinely explored using the grayscale, blood flow and elastography modes CP-EBUS. Puncture is performed using a puncture needle under the guidance of CP-EBUS, and then the CLE probe is inserted into the target lymph node through the puncture needle. Sodium fluorescein is intravenously injected before CLE imaging. Under the guidance of CP-EBUS, the CLE probe is slowly moved to examine the target lesion. According to the real-time CLE images, the ideal biopsy location is identified. After the CLE examination is completed, cryobiopsy is performed at the ideal biopsy location confirmed by CLE under the guidance of CP-EBUS. After sampling, ROSE of the samples is performed.
214760666|NCT07048119|BEHAVIORAL|Japi 1.0|The intervention has ten sessions, and two sessions of 30 minutes were delivered each week for 5 weeks. Sessions numbers 1 to 5 were focused on emotional recognition and inhibitory control. Sessions numbers 6 to 10 worked on working memory and social competence. Each session had eight activities and five tasks per activity with increasing difficulty levels.
214760667|NCT07046975|DRUG|Torsemide and Spironolactone tablet|Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet
214760668|NCT07046975|DRUG|Torsemide Tablets and Spironolactone Tablets|10 mg Torsemide tablet and 25 mg Spironolactone tablet given together
214760669|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
214760670|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
214760671|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
214760672|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
214760673|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
214760674|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
214760675|NCT07048249|DRUG|Romiplostim (AMG-531)|Romiplostim may be started as supportive care, as early as cycle 1 day 1; all patients MUST initiate romiplostim no later than 2 weeks from the start of the 5th cycle of chemotherapy (see exception below for patients with platelet count of 200,000 or greater). If plt count \< 200,000/mm3, patients will start romiplostim based on their weight
214760676|NCT07048613|DIAGNOSTIC_TEST|MRI (mpMRI)|: Combines T2-weighted imaging, Diffusion-weighted imaging (DWI), and Dynamic contrast-enhanced MRI (DCE-MRI) to provide detailed anatomical images and assess tissue characteristics.
214760677|NCT07046806|DRUG|Deucrictibant XR tablet|Deucrictibant 40 mg XR tablet for prophylaxis
214760678|NCT07046806|DRUG|Placebo comparator to XR tablet|Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis
214760679|NCT07046806|DRUG|Deucrictibant 20 mg capsule|Deucrictibant active drug for on-demand treatment of angioedma attacks
214760680|NCT07046806|DRUG|Placebo comparator to 20 mg capsule|Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks
214760681|NCT07047287|OTHER|global postural reeducation exercise|The global postural reeducation exercise involves a sequence of active, moderate postures as well as exercises that are designed to realign joints, stretch shortened muscles, in addition, strengthen the contraction of the antagonist's muscles to prevent postural asymmetry. There are eight different therapeutic postures in the GPR approach that should be held for 15 to 20 min while lying, sitting, or standing. Only two or three postures have been proposed to encourage treatment standardization+ conventional therapy
214760682|NCT07047287|OTHER|pilates exercises|the patients will receive pilates in the form of single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions
214760683|NCT07047287|OTHER|conventional therapy|the patients will receive conventional physiotherapy treatment which consists of routine physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl up exercises etc along with ultrasound and Transcutaneous electrical nerve stimulation (TENS).
214760684|NCT07048522|DRUG|Nimodipine|A continuous dose of 4 mg/h (20 ml/h) of nimodipine solution will be administered continuously 1 h prior to start of operation until 1 h after start of the procedure. • The nimodipine dose will be then reduced to 2 mg/h (10 ml/h) until 24 hrs after the end of the procedure.
214760685|NCT07048522|DRUG|Isotonic Saline|A continuous dose of 20 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 1 h after start of the procedure. The normal saline dose will be then reduced to 10 ml/h until 24 h after the end of the procedure.
214760686|NCT07047313|OTHER|jones and mulligan therapy|for jones technique in upper trapezius and suboccipital muscles, the participants supine , the therapist used manual palpation to locate the tender area in the UT and sub-ossipital muscles. Once detected, pressure to the tender area was progressively increased . The participant was then repositioned passively to decrease the stress under palpation, resulting in a 70% subjective decrement in pain. That position was maintained for 90 s. eventually, the participant returned to the neutral position slowly and passively. for mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees) exercises
214760687|NCT07047313|OTHER|mulligan therapy|mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees). The hand, which was touching the spinous process, should be relaxed in order not to squeeze too hard. The source of the power of gliding on the joint surface must come from the opposite hand of the patient-contacting hand. Gliding was applied rhythmically (three times per second) and the width of gliding starts from the middle to the end+ exercises
214760688|NCT07047313|OTHER|exercises program|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
214760689|NCT07047963|DIAGNOSTIC_TEST|ENDI (Neuropsychological Evaluation in Intellectual Disability)|This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
215030767|NCT06688890|OTHER|Surgical hand rub with the product P2; Sorbectol for 3 min.|Sorbectol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
214760690|NCT07047339|DRUG|Probiotics 6600|"As the core commensal bacteria of human body, probiotic 6600 has a unique ability to synthesize adhesins and exopolysaccharides. The intestinal protective effect is mediated by the following mechanisms: (1) regulation of Treg/Th17 balance by producing short-chain fatty acids (SCFAs); (2) activation of TLR2/MyD88 pathway inhibits NF-κB inflammatory cascade; (3) Upregulation of zonula occludens-1 enhances intestinal barrier function. Notably, this strain specifically metabolized arabinoxylan to produce the anti-inflammatory metabolite indole lactate, which has important therapeutic value in the colitis microenvironment.~Probiotic 6600 capsules are enteric capsules (containing probiotic 6600 10\^11 CFU/ capsule), taken orally twice a day (after meals in the morning and evening), one capsule each time, and taken with warm water. The drug was stored at 2-8℃."
214760691|NCT07047339|DRUG|Placebo|The placebo capsules were also enteric-coated capsules, and were taken orally twice a day (morning and evening after meals), one capsule each time, with warm water.
214760692|NCT07048509|OTHER|Control-no treatment|30 minutes of rest
214760693|NCT07048509|OTHER|Exercise|30 minutes of Moderate-Intensity Continuous Exercise
214760694|NCT07048509|OTHER|Exercise|30 minutes of High-Intensity Interval Exercise
214760695|NCT07048704|DRUG|Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics|"Participants will receive a seven-day course of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics. The bacteriophage therapy consists of a pathogen-specific cocktail containing four purified, lytic bacteriophages selected based on pre-treatment sensitivity testing of the participant's bacterial isolate. Each phage cocktail targets one of the following antibiotic-resistant pathogens: Pseudomonas aeruginosa, Klebsiella spp., Stenotrophomonas maltophilia, Escherichia coli, Staphylococcus aureus, or Achromobacter xylosoxidans.~Phage cocktails are administered IV twice daily at a concentration of 1x10⁹ PFU/mL, following antibiotic infusion. The first three doses are observed in clinic; remaining doses are self-administered at home via PICC line. All phages are produced under GMP conditions and screened to be lytic-only, free of known toxin, resistance, or lysogeny genes."
214760696|NCT06722144|BEHAVIORAL|Animal-assisted Therapy|By the professor leader makes social interaction, and helping residents with rehabilitation through the Doctor dogs.
214760697|NCT06722794|PROCEDURE|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene Suture|This novel technique of fixating the plate of Ahmed glaucoma valve to the sclera using a single flanged prolene suture is an efficient, safe, fast, and reproducible technique that combines the benefits of both fixing the plate providing excellent stability without the complications of free plate techniques and at the same time, minimizing both the risks of conventional old valve plate fixation techniques and the concerns of the relative technical difficulty of suturing due to the difficult access to the posterior globe
214760698|NCT06724835|DRUG|XKDCT293|Autologous targeted Nectin4 chimeric antigen receptor T cell injection
214760699|NCT06724835|OTHER|CAR-T cell|Nectin-4-CAR-T
214760700|NCT06722040|OTHER|Implementation of a pediatric triage track|In 2023, a pediatric triage track was implemented at MH1813 to route calls concerning children to specialists in pediatrics, ensuring better expertise.
214760701|NCT06722339|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|"Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects."
214760702|NCT06727266|DIAGNOSTIC_TEST|Shoulder ultrasound|The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.
214760703|NCT05436067|DEVICE|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
214760704|NCT05436067|OTHER|Traditional Physical Therapy|Delivery of vestibular rehabilitation through traditional physical therapy.
214760705|NCT07047833|BEHAVIORAL|Plyometric Training with Hamstring Strengthening|This intervention consisted of a six-week training protocol involving both plyometric exercises and targeted hamstring strengthening. Sessions were conducted twice per week, lasting 60 minutes each. Plyometric drills included squat jumps, depth jumps, and lateral jumps, while hamstring exercises included Nordic hamstring curls and machine-based leg curls. All sessions included a standardized 15-minute warm-up and a 5-minute cool-down. The program was designed to enhance lower limb strength, balance, and neuromuscular control for ACL injury prevention in female amateur athletes.
214760706|NCT07047833|BEHAVIORAL|Plyometric Training Only|This intervention involved a six-week plyometric-only training program delivered twice weekly for 40-minute sessions. Exercises included squat jumps, depth jumps, and lateral jumps, performed with progressive intensity and control. Each session included a standardized 15-minute warm-up and a 5-minute cool-down. The program aimed to improve lower limb power, balance, and functional mobility to reduce the risk of ACL injuries in female amateur athletes.
214760707|NCT07047261|PROCEDURE|Adjunctive use of Xanthan-Chlorexidine based gel|"The chlorhexidine and xanthan-based gel contains 0.5% chlorhexidine digluconate, 1% chlorhexidine dihydrochloride, and 0.5% xanthan gel. Xanthan is a polymer that creates a three-dimensional, pseudo-plastic network with water, forming a stable gel that allows a slow and prolonged release of chlorhexidine, allowing effectiveness for about 30 days. Chlorhexidine digluconate is released immediately upon application, whereas Chlorhexidine dihydrochloride is gradually delivered the following days, providing bacteriostatic and bactericidal effects for up to two weeks, helping the prevention of recolonization of treated site.~The clinician cleaned and dried the implant site using compressed air and applied the XanCHX gel on the implant sites assigned to the test group, positioning the blunt needle at the bottom of the pocket and gently extruding the product while moving it out of the site. Finally, the patient was instructed not to drink or rinse for the following hour."
214760708|NCT06723496|BEHAVIORAL|Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.|is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.
214760709|NCT06723496|BEHAVIORAL|parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer|It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors
214760710|NCT06723496|BEHAVIORAL|Symptom Checklist -90- Revised (SCL-90-R) for parents|It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions
214760711|NCT06723496|BEHAVIORAL|posttraumatic stress disorders by posttraumatic check list -5 (PCL-5) for parents|It is a 20 -item measure that assess the 20 DSM-5 symptoms of PTSD.
214760712|NCT06887062|DRUG|Bosentan|6 weeks of treatment with Bosentan, a dual endothelin receptor antagonist, administered to the large vessel vasculitis patient group
214760713|NCT06599684|DRUG|INV-102|0.7% Ophthalmic Solution
214760714|NCT07047352|OTHER|Empirical treatment|Empirical treatment to cover carbapenem-resistant enterobacterales
214760715|NCT07047495|OTHER|prostate patient|patients with prostate cancer treated with RT at IEO
214760716|NCT07047495|OTHER|breast patients|patients with breast cancer treated with RT at IEO
214760717|NCT07047430|DEVICE|Portable air cleaner with HEPA filter|The Winix 9800 is a true HEPA air cleaner that has been AHAM (Association of Home Appliance Manufacturers) Verifide® for rooms that are 500 square feet in size. The air cleaner has a washable fine mesh pre-filter that captures large airborne particles, an activated carbon filter that reduces volatile organic compounds and odors, and a true HEPA filter that captures 99.99% of airborne allergens as small as 0.003 microns in size.
214760718|NCT07047430|DEVICE|Less effective portable air cleaner (no HEPA)|Winix 9800 air cleaner, with data logging energy use monitor is installed in the child's bedroom. In the sham group, the Winix 9800 true HEPA filter and activated carbon filter were removed. This was an internal modification and not visible to the user. The air cleaner still included a washable fine mesh pre-filter that captures large airborne particles.
214760719|NCT07048353|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
214760720|NCT04468984|DRUG|Navitoclax|Tablet; Oral
214760721|NCT04468984|DRUG|Ruxolitinib|Tablet; Oral
214760722|NCT04468984|DRUG|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
214760723|NCT06722742|DRUG|Ketamine only|Inj: Ketamine given to group K following spinal anesthesia
214760724|NCT06722742|DRUG|Tramadol|Inj Tramadol given to group T following spinal anesthesia
214760725|NCT07048301|OTHER|BUHOS app|In this study, the BUHOS app initiative will be implemented among participants in the intervention group. BUHOS will be a two-weeks nursing intervention that includes monitoring KAB, employing Education, Guidance and Counseling (education videos), and Surveillance (reminder messages), and assessing the outcomes.
214760726|NCT07048301|OTHER|Control Group|No intervention will be made to the patients in the control group, and the training videos prepared after the study is completed will be shared.
214760727|NCT07047404|DRUG|BP1.4979|selective dopamine D3 partial agonist
214760728|NCT07047404|DRUG|Placebo|matching placebo of BP1.4979 30mg tablet
214760729|NCT07047950|BEHAVIORAL|Individual Education and Counseling Program|"The educational programme entitled HBM Approach to Prevent CHD was designed by the researcher and delivered as a presentation. The educational sessions were conducted face-to-face at the Cardiology Outpatient Clinic of Van Yüzüncü Yıl University Dursun Odabaş Medical Center and lasted approximately 35-45 minutes. In addition, follow-up telephone calls were made to individuals in the intervention group twice at two-month intervals.~The content of the educational programme was developed based on a comprehensive literature review using resources from the Turkish Society of Cardiology, the WHO, the Ministry of Health, the Turkish Public Health Institution, evidence-based research and previous studies. The programme covered topics such as the definition of CHD, risk factors, treatment, complications, perceived susceptibility and severity of CHD, perceived benefits, barriers and strategies to overcome them, self-efficacy, and rules for engaging in physical activity and maintaining a health"
214760730|NCT07046962|OTHER|Intervention Type Device: Manual pump expressing breast milk|"Since this study aimed to examine the macronutrient content of milks expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, hand pumping and electric pumping.~Hand expressing: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
214760731|NCT07046962|OTHER|Intervention Type Device: Hand pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Manual pump expressing: Milk was expressed with a manual pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
214760732|NCT07046962|OTHER|Intervention Type Device: Electric pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Electric pump expressing: Milk was expressed with an electric pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
214760733|NCT07045285|DEVICE|Antibacterial Vicryl Plus 2/0|antibacterial Vicryl Plus 2/0 sutures are multifilament absorbable synthetic sutures that are coated with triclosan, a purified antimicrobial.
214760734|NCT07045285|DEVICE|Standard Vicryl 2/0|Vicryl rapid coated 2/0 sutures are multifilament absorbable synthetic sutures not treated with any antimicrobial.
214760735|NCT07048171|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using bone graft(DFDBA) and iPRF with collagen membrane in test group and bone graft and iPRF without collagen membrane in control group
214760736|NCT07047521|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
214760737|NCT07048678|COMBINATION_PRODUCT|preoperative respiratory exercises|Participants in Group 1 will receive a combination of preoperative respiratory exercises designed to improve lung function and reduce the risk of postoperative pulmonary complications. The intervention includes:
215030768|NCT06688890|OTHER|Surgical hand rub with the product P3; Sorbectol for 5 min.|Sorbectol hand rub for 5 min. The applied volume of product is sufficient to keep the hand moist for a total time of 5 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
214760738|NCT07048678|COMBINATION_PRODUCT|Standard Care (Control Group)|Participants in Group 2 will receive standard preoperative care provided by the hospital, which includes routine instructions related to surgery such as fasting guidelines, medication administration, and anesthesia protocols. No preoperative respiratory exercises (incentive spirometry, chest physiotherapy, or deep breathing exercises) will be provided to this group. This group serves as a control to compare the outcomes with the intervention group.
214760739|NCT07048821|DIETARY_SUPPLEMENT|Dietary modification|3-month dietary plan
214760740|NCT07043816|BEHAVIORAL|PharmaTE Trial|In addition to standard care, patients in the PharmaTE trial interventional group will receive tele-education led by a clinical pharmacist who has completed a training course and is certified as a diabetes educator. The tele-education program is comprised of five individualized educational sessions, each lasting approximately 20-30minutes and held at two-month intervals. These sessions are conducted via Zoom or telephone based on patient preference. Before the beginning of each session, participants will receive a reminder message along with the Zoom meeting invitation link about the session, covering various educational topics related to diabetes management. Additionally, after each session, patients will receive a brochure summarizing what has been discussed.
214760741|NCT07048652|DIAGNOSTIC_TEST|High-Resolution Computed Tomography|High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.
214760742|NCT07048275|BEHAVIORAL|Virtual Reality Chest Percussion Teaching Program|Participants will be assessed at two time points: on the day of hospital admission or transfer, and on the fourth day after the teaching intervention.
214760743|NCT06719947|DEVICE|Active HD-tDCS|10 sessions of anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) with a defined electrical current intensity over the cortical representation zone of the left diaphragmatic motor cortex
214760744|NCT06719947|DEVICE|Simulated HD-tDCS|10 sessions of sham anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) over the cortical representation zone of the left diaphragmatic motor cortex. The device will provide a 30-second ramp and then maintain a minimal, non-effective continuous current
214760745|NCT07047092|DEVICE|Non-invasive Ventilation (NIV)|Patients will receive a dedicated training for the use of their NIV in the home setting. The training is the same provided in the usual care of patients established on NIV. They will choose a home care provider for the delivery of NIV as per standard care in France. A telemonitoring of adherence to NIV will be performed.
214760746|NCT07047092|DEVICE|Continous Positive Airway Pressure (CPAP)|Patients will receive a dedicated training the use of their CPAP in the home setting. The training is the same provided in the usual care of patients established on CPAP. They will choose a home care provider for the delivery of CPAP as per standard care in France. Follow-up of CPAP will be performed according to standard care in France and will therefore include a telemonitoring of adherence to CPAP.
214760747|NCT06893887|DRUG|FOLFOX4|FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles
214760748|NCT06893887|DRUG|Adebrelimab|Adebrelimab 1200mg, intravenous infusion, every 3 weeks
214760749|NCT06893887|DRUG|Apatinib|Apatinib 250mg, oral, once daily.
214760750|NCT06893887|DRUG|Icaritin|Epimedium extract soft capsules 2.4g, oral, 2 times daily.
214760751|NCT06893887|DRUG|SHR-1701|SHR1701，30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
214760752|NCT06893887|DRUG|QL1706|QL1706，5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
214760753|NCT06893887|DRUG|Bevacizumab|Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.
214760754|NCT06893887|PROCEDURE|HAIC|Hepatic Arterial Infusion Chemotherapy
214760755|NCT06893887|PROCEDURE|Local treatment|Local treatment of oligo-metastases.
214760756|NCT06893887|DRUG|The original treatment regimen|Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.
214760757|NCT06329921|OTHER|PTT protocol|Patients will be monitored using the nurse-managed PTT protocol.
214760758|NCT06329921|OTHER|anti-Xa protocol|Patients will be monitored using the pharmacy-managed anti-Xa protocol.
214760759|NCT07047066|DRUG|Fluzoparib with Temozolomide|"Fluzoparib: 100mg, po.bid. Q4W, d1-28, for a total of 6 cycles~Temozolomide (TMZ): 150-200 mg/m2, po. Q4W, d1-5, for a total of 6 cycles~If unacceptable toxicity occurs and a dose reduction is required, it is recommended to first reduce the dose from 100 mg (2 tablets) to 50 mg (1 tablet) twice a day. If further dose reduction is required, it is recommended to reduce the dose from 50 mg (1 tablet) twice a day to 50 mg (1 tablet) once a day. If it is still intolerable, the patient should withdraw from the clinical study.~The TMZ dose is adjusted by the investigator according to standard chemotherapy requirements. Adjuvant TMZ treatment of less than 6 cycles is allowed depending on the subject's condition (e.g. confirmed disease progression, intolerable toxicity, etc.). Tumor assessment is performed during two cycles of TMZ (q8w±7 days) during the study or when clinically indicated"
214760760|NCT04170244|OTHER|AD subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
214760761|NCT04170244|OTHER|PS subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
215030769|NCT06943378|BIOLOGICAL|Monoclonal antibody JST-010|Active study drug
215030770|NCT06943378|DRUG|Placebo|Placebo
214760762|NCT04170244|OTHER|Healthy control visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
214760763|NCT06267989|PROCEDURE|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
214760764|NCT06267989|PROCEDURE|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
214760765|NCT04111627|BEHAVIORAL|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
214760766|NCT04111627|DRUG|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
214760767|NCT06746623|DIAGNOSTIC_TEST|Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.|"Esocheck (EC)/Esoguard (EG): EC is a encapsulated balloon device available commercially from Lucid Diagnostics (New York, NY). EG assay uses bisulfite sequencing for detection of aberrant methylation in the vimentin and cyclin A1 genomic loci, respectively.~EGD (upper endoscopy): EGD will be performed by gastroenterologists practicing in the Louis Stokes Cleveland VA Medical Center Endoscopy laboratories on the same day when EC/EG is performed."
214760768|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
214760769|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
214760770|NCT06822413|OTHER|No Interventions|All blood samples from participating patients were obtained from routine clinical blood tests conducted during hospital admission or other necessary medical evaluations, followed by serum extraction.
214760771|NCT06760481|DRUG|Tiragolumab|Given by IV
214760772|NCT06760481|DRUG|Atezolizumab|Given by IV
214760773|NCT06760481|RADIATION|Radiation Therapy|Given by IV
214760774|NCT06373432|OTHER|Fingerstick|Fingerstick to check glucose value during labor.
214760775|NCT04810858|OTHER|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
214760776|NCT04810858|OTHER|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
214760777|NCT04810858|BEHAVIORAL|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
214760778|NCT05345392|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
214760779|NCT05345392|BEHAVIORAL|Health and Wellness Intervention (HWI)|The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
214760780|NCT03422848|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
214760781|NCT03422848|BEHAVIORAL|general life style advice|oral and written advice on diet and physical activity
214760782|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
214760783|NCT06887972|DRUG|Suzetrigine|Tablets for oral administration.
214760784|NCT03384836|OTHER|Laboratory Biomarker Analysis|Correlative studies
214760785|NCT03384836|BIOLOGICAL|Pembrolizumab|Given IV
214760786|NCT03384836|DRUG|Propranolol Hydrochloride|Given PO
214760787|NCT00157820|DEVICE|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
214760788|NCT00157820|DEVICE|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF \& GemIII AT as DC ICDs (DC true and SC sim arms)
214760789|NCT01721369|DIAGNOSTIC_TEST|Transient Loss of Consciousness (T-LOC)|
214760790|NCT06792695|DRUG|Volrustomig|Volrustomig will be administered as intravenous (IV) infusion.
214760791|NCT06792695|DRUG|FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|FOLFIRI will be administered as IV infusion.
214760792|NCT06792695|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion.
214760793|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214760794|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
214760795|NCT06868589|DRUG|Methadone|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
214760796|NCT06868589|DRUG|ketamine|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
214760797|NCT06868589|DRUG|Hydromorphone|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
214760798|NCT06868589|DRUG|fentanyl|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
214760799|NCT06747338|DRUG|KN026|KN026
214760800|NCT06747338|DRUG|HB1801|HB1801
214760801|NCT06747338|DRUG|Pertuzumab|Pertuzumab
214760802|NCT06747338|DRUG|Trastuzumab|Trastuzumab
214760803|NCT06747338|DRUG|Docetaxel|Docetaxel
214760804|NCT06747338|DRUG|Carboplatin|Carboplatin
214760805|NCT06449326|DEVICE|Active Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
214760806|NCT06449326|DEVICE|Sham Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
214760807|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (5×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Five patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
214760808|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (3.25×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
214760809|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (2×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
214760810|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 2: Expansion Study. ssCART-19 cells combined with FTCs at the optimal biological dosage determined in the Phase 1 study were given to expanded Philadelphia chromosome-positive B-ALL patients with remission. The 5×10\^6 cells/kg of CD19+ FTCs was the optimal biological dose determined in phase I. Therefore, CD19+ FTCs at 5×10\^6 cells/kg were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle, while ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. The Bayesian optimal design was applied to perform the futility assessment at the specified interim analyses. Thirty-four evaluable subjects were recruited, and all the patients received at least two cycles of ssCART-19 consolidation.
214760811|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
214760812|NCT06772597|DRUG|Setmelanotide|Setmelanotide (daily subcutaneous injection)
214760813|NCT06910306|DEVICE|Device :DaRT seeds|The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle
214760814|NCT06768658|DRUG|TAK-951|TAK-951 subcutaneous injection.
214760815|NCT06768658|DRUG|TAK-951 Placebo|TAK-951 placebo-matching subcutaneous injection.
214760816|NCT05657457|DRUG|Tenecteplase|intra-arterial tenecteplase
214760817|NCT05044039|DRUG|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
214760818|NCT06934200|DRUG|Omalizumab|omalizumab injections
214760819|NCT06936982|OTHER|Sports Exercise|The exercise intervention program used a combination of moderate-intensity aerobic exercise and resistance exercise in the form of exercise day time: 9:00 a.m. to 10:30 a.m., in which 10min warm-up exercise after 45min aerobic exercise, each aerobic exercise 10-12min, with a rest in the middle of the rest 3-5min. resistance exercise was placed in the aerobic exercise after the resistance exercise, resistance exercise using 3 movements, 2 groups, each group 10 times. Each movement was performed 10 times, with a 3-min break between each movement in each group and a 5-min break between groups. 15-min stretching exercises were performed after the exercise. The RPE scale was examined during the exercise, and the subjects were asked about the RPE scale level at the end of every 10 min during the exercise.
214760820|NCT06936982|OTHER|control group|No intervention
214760821|NCT06942182|DRUG|Isomyosamine 250mg|Isomyosamine 250 mg capsules dosed 4 times daily
214760822|NCT06942182|DRUG|Placebo 250 mg|Placebo 250 mg capsule 4 times daily
214760823|NCT06941935|OTHER|Etiological Classification and Digital Intervention|Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medication initiation, participants will continue to monitor their blood pressure through home diaries. Monthly evaluations will be conducted, and if blood pressure fails to reach the target value, medication adjustments will be made based on the blood pressure diary until target levels are achieved. This regimen will be maintained long-term.
214760824|NCT06943703|DRUG|Sclerotherapy with intralesional bleomycin injection|The intervention studied is intralesional Bleomycin injection, which involves the direct injection of Bleomycin, a chemotherapeutic agent, into the lymphangioma lesions. This minimally invasive procedure is aimed at reducing the size of the lymphangioma by disrupting the abnormal growth of lymphatic vessels. The dosage of Bleomycin is tailored based on the patient's body weight, typically ranging from 1 to 3 mg per kg of body weight per injection. The intervention is distinct from other treatments, such as surgical excision or other sclerotherapy agents, as it specifically utilizes Bleomycin's mechanism of action to induce tissue sclerosis and promote lesion regression without the need for invasive surgery. This intervention may require multiple treatment sessions, depending on the size, location of the lymphangioma, and individual's response to therapy, with the goal of achieving long-term effectiveness and improving cosmetic outcomes.
214760825|NCT06943430|OTHER|laughter yoga|Participants in the intervention group received laughter yoga sessions twice a week for a total of four weeks.
214760826|NCT06942845|OTHER|non-intervention|non-intervention
214760827|NCT06203067|BEHAVIORAL|Standard of Care|Quarterly clinic visits with endocrinology provider.
214760828|NCT06203067|BEHAVIORAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
214760829|NCT06941909|OTHER|Mindfulness-Based Self-Compassion|The intervention consisted of weekly online group training and counseling sessions over an 8-week period. Following each session, participants were provided with a practice guide and audio recordings to support home-based practice.
214760830|NCT06943053|DEVICE|Isolate waterproof dressing (Opsite)|Application of standard Opsite® waterproof dressing directly over the surgical incision following primary total knee arthroplasty. No additional drape or coverage was applied. The dressing remained in place until removal.
214760831|NCT06943053|DEVICE|Ioban coverage group|Application of Ioban® iodine-impregnated antimicrobial incise drape over the standard waterproof dressing following primary total knee arthroplasty. The Ioban drape extends 2 cm beyond all edges of the dressing and remains in place until removal.
214760832|NCT06943677|DRUG|TQB3019 capsules|TQB3019 capsule is a targeted protein degrader
214760833|NCT06943040|OTHER|There will be no intervention on the participants within the scope of this study.|There will be no intervention on the participants within the scope of this study.
214760834|NCT04148235|OTHER|No Intervention|There is no intervention for this study
214760835|NCT06943248|OTHER|Image-Sand Play Therapy|Over the course of seven sessions, the child initially engaged in chaotic sandbox play, showing difficulty in altering or organizing his scenes. By the fourth session, he began experimenting with different symbols, including familiar TV characters. From the fifth session onward, his play gained structure, evolving into strategic battle scenarios involving animals, loggers, and castles. By the seventh session, hero figures emerged, and the therapist noted improved classroom behavior and cooperation, though social challenges with peers remained.
214760836|NCT06943248|OTHER|Table Top Training Program with Weighted Cuff|"Task include: Stacking cones Lift a cone with one hand and stack it on top of a fixed cone. (The difficulty level was controlled by using resistance bands of varying weights or instructing patients to sit or stand while performing the task.) Task Therapy Program Stacking 3 × 3 cm blocks Pick up blocks one at a time by using one hand and stack them. (The difficulty level was controlled by using resistance bands of varying weights.) Tailwind Use both hands to push the handles of an instrument up and down to the sounds of a metronome.~(The difficulty level was controlled by varying the angle.) Pinch exerciser Take a pinch pin and put it on a rod. (The difficulty level was controlled by varying the resistance of the pinch pin (5 grades) and the diameter of the rod (3 grades).) O'Connor Tweezer Dexterity Test Pick up a pin (2.5 cm long) and put it in a 15 mm hole. (The difficulty level was controlled by using different tweezers.)"
214760837|NCT06943625|OTHER|tDCS|"Transcranial direct current stimulation protocol involves 20 minutes of anodal stimulation, with the anodal electrode placed over the motor cortex (primary motor area), and cathodal stimulation applied to the contralateral supraorbital area.~The intensity of the current will be set to 1.5 mA, with the current density ranging from approximately 0.03 to 0.06 mA, with the electrode measuring of 5x7cm. To ensure a gradual and comfortable experience for participants, the current will ramp up and down over 30 seconds at the beginning and end of each session. Each stimulation session will last for 20 minutes, with participants undergoing five sessions per week. The entire intervention protocol will be carried out over a period of four weeks"
214760838|NCT06943625|OTHER|Green light|Green light exposure will be administered using light with a wavelength of about 520 nm. The sessions will take place in a dimly lit room to minimize external light interference and enhance the therapeutic effect of the green light. Each exposure session will last for 2 hours, with participants receiving 3 to 5 sessions per week. The light intensity will be set to 100 lux, a level that is both safe and effective for migraine treatment. The entire intervention protocol will span over four weeks to allow for sufficient evaluation of the effects. During each session, participants will be seated comfortably in a chair to ensure they are relaxed and able to tolerate light exposure without discomfort.
214760839|NCT06943625|OTHER|medicine|Advised medicine by the medical doctors will be utilized by the participants of the study
214760840|NCT06943417|DEVICE|Over the scope clip|over the scope clip group
214760841|NCT04971720|DRUG|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
214760842|NCT04971720|DRUG|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
214760843|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
214760844|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
214760845|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
214760846|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
214760847|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
214760848|NCT00563706|DRUG|risperidone|
214760849|NCT00563706|OTHER|placebo|
214760850|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
214760851|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
214760852|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
214760853|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
214760854|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
214760855|NCT01528839|DRUG|Placebo|
214760856|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
214760857|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
214760858|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
214760859|NCT04592666|DRUG|Pemetrexed|standard dose
214760860|NCT04592666|DRUG|Carboplatin|AUC=5
214760861|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
214760862|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
214760863|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
214760864|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
214760865|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
214760866|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
214760867|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
214760868|NCT02189928|OTHER|Usual care|
214760869|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
214760870|NCT02594254|OTHER|Placebo|Placebo
214760871|NCT06650293|DRUG|Vitamin D|Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
214760872|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
214760873|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
214760874|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
214760875|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
214760876|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
214760877|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
214760878|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
214760879|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
214760880|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
214760881|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
214760882|NCT06501131|OTHER|full-spectrum light exposure|Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
214760883|NCT06501131|OTHER|specific spectrum absence light exposure|Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
214760884|NCT04220073|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
214760885|NCT04220073|DRUG|placebo|placebo
214760886|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
214760887|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
214760888|NCT02364882|DRUG|Sildenafil|
214760889|NCT00299546|DRUG|Placebo|SC injections
214760890|NCT00299546|BIOLOGICAL|Golimumab 50 mg|SC injections
214760891|NCT00299546|BIOLOGICAL|Golimumab 100 mg|SC injections
214760892|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
214760893|NCT03099265|DRUG|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
214760894|NCT03099265|DRUG|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
214760895|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
214760896|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
214760897|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
214760898|NCT06380101|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
214760899|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
214760900|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
214760901|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
214760902|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
214760903|NCT05424939|PROCEDURE|Colectomy|Colon resection
214760904|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
214760905|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
214760906|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
214760907|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
214760908|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
214760909|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
214760910|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
214760911|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
214760912|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
214760913|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
214760914|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
214760915|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
214760916|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
214760917|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
214760918|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
214760919|NCT01800500|OTHER|questionnaire administration|Ancillary studies
214760920|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
214760921|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
214760922|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
214760923|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
214760924|NCT03488537|DEVICE|AeonoseTM|Breath test
214760925|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
214760926|NCT00153751|DRUG|Holopon|holopon
214760927|NCT00153751|OTHER|placebo|placebo
214760928|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
214760929|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
214760930|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
214760931|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
214760932|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
214760933|NCT03309072|DEVICE|tDCS|active tDCS
214760934|NCT03309072|DEVICE|sham tDCS|sham tDCS
214760935|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
214760936|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
214760937|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
214760938|NCT00018343|DRUG|estrogen|
214760939|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
214760940|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
214760941|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
214760942|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
214760943|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
214760944|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
214760945|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
214760946|NCT02484131|BEHAVIORAL|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
214760947|NCT02484131|BEHAVIORAL|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
214760948|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
214760949|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
214760950|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
214760951|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
214760952|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
214760953|NCT00219024|DRUG|aliskiren|
214760954|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
214760955|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
215030771|NCT06951620|OTHER|HIIT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to High intensity training (HIIT)
214760956|NCT00396318|DRUG|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
214760957|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
214760958|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
214760959|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
214760960|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
214760961|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
214760962|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
214760963|NCT00000847|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214760964|NCT00000847|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214760965|NCT00000847|BIOLOGICAL|rgp120/HIV-1 SF-2|
214760966|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
214760967|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
214760968|NCT00152594|DRUG|voriconazole|
214760969|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
214760970|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
214760971|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
214760972|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
214760973|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
214760974|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
214760975|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
214760976|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
214760977|NCT00036556|DRUG|Atrasentan|
214760978|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
214760979|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214760980|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
214760981|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
214760982|NCT01638260|DRUG|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
214760983|NCT01638260|BEHAVIORAL|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
214760984|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
214760985|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
214760986|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
214760987|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
214760988|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
214760989|NCT00626574|DRUG|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
214760990|NCT00626574|DRUG|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
214760991|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
214760992|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
214760993|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
214760994|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
214760995|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
214760996|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
214760997|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
214760998|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
214760999|NCT01009073|DRUG|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
214761000|NCT01009073|DRUG|erlotinib|150 mg of erlotinib is taken orally once daily.
214761001|NCT01009073|DRUG|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
214761002|NCT01009073|DRUG|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
214761003|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
214761004|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
214761005|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
214761006|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
214761007|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
214761008|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
214761009|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
214761010|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
214761011|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
215030772|NCT06951620|OTHER|MICT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to Moderate intensity training
214761012|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
214761013|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
214761014|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
214761015|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
214761016|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
214761017|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
214761018|NCT03491800|BEHAVIORAL|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
214761019|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
214761020|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
214761021|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
214761022|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
214761023|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
214761024|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
214761025|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
214761026|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
214761027|NCT02303977|DRUG|Abraxane|
214761028|NCT02303977|DRUG|Gemcitabine|
214761029|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
214761030|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
214761031|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
214761032|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
214761033|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
214761034|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
214761035|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
214761036|NCT04341727|DRUG|Azithromycin|Antibiotic
214761037|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
214761038|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
214761039|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
214761040|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
214761041|NCT00088504|DRUG|Merimepodib|
214761042|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
214761043|NCT00088504|DRUG|Ribavirin (Copegus®)|
214761044|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
214761045|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
214761046|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
214761047|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
214761048|NCT01861730|BIOLOGICAL|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
214761049|NCT01861730|BIOLOGICAL|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
214761050|NCT06702150|BEHAVIORAL|Changing the nursing care model to the primary nursing model|The nurses received training in primary nursing care before the start of the intervention. The model was tested and implemented in early April 2022. Since then, all patients admitted to the unit have been assigned to a primary nurse within the first 48 hours. This nurse is responsible for developing and monitoring the patient's care plan, assessing care needs, implementing the care plan and evaluating the outcomes. This nurse is also responsible for coordinating care needs and discharge planning with other healthcare professionals. When the primary nurse is not working, another nurse from his or her team continues the care plan that he or she has defined. All patients admitted to the unit who met the selection criteria were informed about the study and, if they agreed to take part, completed a self-care competence questionnaire at admission (baseline), at discharge and one month after discharge. They also completed a questionnaire on satisfaction with nursing care at discharge.
214761051|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
214761052|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
214761053|NCT02516917|BEHAVIORAL|Attention Training Technique|
214761054|NCT05604521|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
214761055|NCT05604521|BIOLOGICAL|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
214761056|NCT05604521|OTHER|Normal Saline|0.9% sodium chloride
214761057|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
214761058|NCT03981315|DIAGNOSTIC_TEST|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
214761059|NCT03981315|DIAGNOSTIC_TEST|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
214761060|NCT03981315|DIAGNOSTIC_TEST|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
214761061|NCT03981315|DIAGNOSTIC_TEST|Microbiological bile test|Determination of the microbiological composition of the bile
214761062|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
214761063|NCT06048198|OTHER|No intervention|No intervention
214761064|NCT00672308|OTHER|Benefiber|
214761065|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
214761066|NCT00672308|OTHER|Benefiber with ORS|
214761067|NCT00672308|OTHER|Benefiber with ORS|
214761068|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
214761069|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
214761070|NCT03350880|OTHER|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
214761071|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
214761072|NCT02599610|OTHER|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
214761073|NCT02599610|DEVICE|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
214761074|NCT04476459|DRUG|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
214761075|NCT04476459|DRUG|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
214761076|NCT04296071|OTHER|Research study|Blood and tracheal aspirates will be collected
214761077|NCT04377516|OTHER|pelvic floor muscle training|pelvic floor muscle training
214761078|NCT04377516|OTHER|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
214761079|NCT04377516|OTHER|education of pelvic girdle|education of pelvic girdle
214761080|NCT04390100|DRUG|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
214761081|NCT04390100|OTHER|Platelet rich fibrin|coverage of the free gingival graft area in the palate
214761082|NCT04390100|OTHER|Gel foam|coverage of the free gingival graft area in the palate
214761083|NCT01277107|DRUG|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
214761084|NCT01277107|DRUG|Placebo capsule|Identical placebo capsule
214761085|NCT01491737|DRUG|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
214761086|NCT01491737|DRUG|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
214761087|NCT01491737|DRUG|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
214761088|NCT01491737|DRUG|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
214761089|NCT04311411|DRUG|Tirzepatide|Administered SC.
214761090|NCT04311411|DRUG|Placebo|Administered SC.
214761091|NCT04311411|DRUG|Liraglutide|Administered SC.
214761092|NCT04500054|OTHER|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
214761093|NCT03212443|PROCEDURE|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
214761094|NCT03212443|PROCEDURE|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
214761095|NCT01976663|DEVICE|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
214761096|NCT01976663|DEVICE|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
214761097|NCT06604949|DRUG|LP-003 200mg|Subcutaneous injection of 200 mg LP-003
214761098|NCT06604949|DRUG|Placebo|Subcutaneous injection of placebo
214761099|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
214761100|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
214761101|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
214761102|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
214761103|NCT05785299|DIAGNOSTIC_TEST|Cow's milk|clinical introduction of cow's milk
214761104|NCT05785299|DIAGNOSTIC_TEST|Placebo|clinical introduction of placebo
214761105|NCT05785299|DIAGNOSTIC_TEST|Home introduction|home introduction of cow's milk
214761106|NCT02365818|BIOLOGICAL|CG0070|
214761107|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
214761108|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
214761109|NCT05726110|DRUG|Selinexor|Given PO
214761110|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
214761111|NCT05726110|DRUG|Daunorubicin|Given per standard of care
214761112|NCT05726110|DRUG|Cytarabine|Given per standard of care
214761113|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
214761114|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
214761115|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
214761116|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
214761117|NCT04764825|DRUG|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
214761118|NCT04764825|DRUG|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
214761119|NCT05842330|DRUG|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
214761120|NCT05842330|DRUG|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
214761121|NCT04461678|DIAGNOSTIC_TEST|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
214761122|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
214761123|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
214761124|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
214761125|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
214761126|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
214761127|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
214761128|NCT03642249|BEHAVIORAL|E-learning|delirium care video
214761129|NCT03777839|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
214761130|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
214761131|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
214761132|NCT05963217|BIOLOGICAL|TBI-2001|"Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
214761133|NCT05963217|DRUG|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
214761134|NCT05963217|DRUG|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
214761135|NCT05644756|BEHAVIORAL|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
214761136|NCT06505694|DIETARY_SUPPLEMENT|Alcohol Alternative Herbal Tincture (Test Product)|The test product contains organic vegetable glycerin, distilled water, organic elderberries, organic bilberries, organic beetroot juice powder, organic California poppy (whole plant), organic tart cherry, organic hawthorn berries, organic blue vervain (aerial parts), organic ceylon cinnamon bark, organic black pepper fruit, and L-theanine.
214761137|NCT06505694|DIETARY_SUPPLEMENT|Placebo|The placebo is designed to match the test product in appearance and taste but does not contain the active herbal ingredients. Participants will take 2 ml of the placebo directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks. The placebo contains organic vegetable glycerin, distilled water, organic beet juice powder, organic tart cherries, organic ceylon cinnamon chips, and natural green food coloring (derived from spirulina and turmeric).
214761138|NCT05087888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214761139|NCT05087888|PROCEDURE|Magnetic Resonance Imaging|Undergo functional MRI
214761140|NCT05087888|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
214761141|NCT05087888|OTHER|Questionnaire Administration|Complete questionnaires
214761142|NCT05219643|DEVICE|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
214761143|NCT05219643|DEVICE|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
214761144|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
214761145|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
214761146|NCT06551467|BEHAVIORAL|Online Ayurveda Program for Detox and Lifestyle|The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
214761147|NCT06537505|DRUG|Adebrelimab|Q3W,IV
214761148|NCT06537505|DRUG|Apatinib|QoD
214761149|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
214761150|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
214761151|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
214761152|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
214761153|NCT03699995|OTHER|Confocal Microscopy|Undergo confocal microscopy
214761154|NCT03699995|OTHER|Dermoscopy|Undergo digital dermoscopy
214761155|NCT03699995|PROCEDURE|Imaging Procedure|Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
214761156|NCT03699995|DRUG|Lidocaine|Given SC
214761157|NCT03699995|PROCEDURE|Punch Biopsy|Undergo punch biopsy
214761158|NCT03699995|PROCEDURE|Shave Biopsy|Undergo shave biopsy
214761159|NCT05165277|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
214761160|NCT05713916|OTHER|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
214761161|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
214761162|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
214761163|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
214761164|NCT02989623|RADIATION|Copper Cu 64 TP3805|Given Intravenously
214761165|NCT02989623|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo copper Cu 64 TP3805 PET/CT scan
214761166|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
214761167|NCT06594588|BEHAVIORAL|Aerobic exercise|Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
214761168|NCT04199312|DEVICE|Magnetic Muscle Stimulation (MMS) device|The MMS device will be used to perform the treatments.
214761169|NCT06575062|PROCEDURE|Direct Pulp Capping with ProRoot MTA|In this intervention, following the removal of carious dentin, the pulp tissue is directly exposed. ProRoot MTA is carefully applied over the exposed pulp to create a protective barrier. The material is mixed according to the manufacturer's instructions and placed directly onto the pulp exposure site. A light pressure is applied to ensure a good adaptation of the material. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
214761170|NCT06575062|PROCEDURE|Pulpotomy with ProRoot MTA|In this procedure, after the removal of the coronal pulp tissue, ProRoot MTA is applied over the exposed root canal orifices. The MTA is mixed according to the manufacturer's instructions and placed in the pulp chamber to cover the root canal entrances. The material is carefully adapted to create a seal that prevents bacterial contamination and promotes tissue healing. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
214761171|NCT04099368|BEHAVIORAL|Musical pitch training|Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
214761172|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
214761173|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
214761174|NCT03066011|DRUG|Posaconazole|Oral and intravenous
214761175|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
214761176|NCT00478933|DEVICE|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
214761177|NCT00478933|PROCEDURE|Blood sampling|Blood sampling
214761178|NCT06794983|OTHER|In-person visit with study team member|Participants meet with a study team member before they are released from prison.
214761179|NCT06794983|OTHER|In-person visit with NCM|Participants meet with a NCM before they are released from prison.
214761180|NCT06794983|OTHER|Phone calls and texts|Study team member calls and texts participants after they are released from prison.
214761181|NCT06794983|OTHER|Phone calls and texts - NCM|Nurse case manager calls and texts participants after they are released from prison.
214761182|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
214761183|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
214761184|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I\_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
214761185|NCT00617175|DEVICE|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
214761186|NCT00617175|DEVICE|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
214761187|NCT00002634|BIOLOGICAL|filgrastim|
214761188|NCT00002634|BIOLOGICAL|monoclonal antibody 3F8|
214761189|NCT00002634|DRUG|cisplatin|
214761190|NCT00002634|DRUG|cyclophosphamide|
214761191|NCT00002634|DRUG|doxorubicin hydrochloride|
214761192|NCT00002634|DRUG|etoposide|
214761193|NCT00002634|DRUG|mesna|
214761194|NCT00002634|DRUG|perfosfamide|
214761195|NCT00002634|DRUG|vincristine sulfate|
214761196|NCT00002634|PROCEDURE|autologous bone marrow transplantation|
214761197|NCT00002634|PROCEDURE|in vitro-treated bone marrow transplantation|
214761198|NCT00002634|RADIATION|low-LET cobalt-60 gamma ray therapy|
214761199|NCT00002634|RADIATION|low-LET photon therapy|
214761200|NCT00002634|RADIATION|radioisotope therapy|
214761201|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
214761202|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
214761203|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
214761204|NCT00261352|DRUG|Tesaglitazar|
214761205|NCT00261352|DRUG|Metformin|
214761206|NCT00261352|DRUG|Fenofibrate|
214761207|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
214761208|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
214761209|NCT01821131|OTHER|muffin|
214761210|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
214761211|NCT02675660|DRUG|Placebo|placebo capsules once daily
214761212|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
214761213|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
214761214|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
214761215|NCT00544570|BIOLOGICAL|filgrastim|
214761216|NCT00544570|DRUG|carmustine|
214761217|NCT00544570|DRUG|cyclophosphamide|
214761218|NCT00544570|DRUG|etoposide|
214761219|NCT00544570|DRUG|melphalan|
214761220|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
214761221|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
214761222|NCT00544570|RADIATION|radiation therapy|
214761223|NCT00544570|RADIATION|total-body irradiation|
214761224|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
214761225|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
214761226|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
214761227|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
214761228|NCT05568654|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen, UAT and procalcitonin testing.
214761229|NCT05568654|OTHER|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
214761230|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
214761231|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
214761232|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
214761233|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
214761234|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
214761235|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
214761236|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
214761237|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
214761238|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
214761239|NCT00423137|DRUG|BIBW 2948 BS|Capsule
214761240|NCT00423137|DRUG|Placebo|Capsule
214761241|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
214761242|NCT04943627|DRUG|Topotecan|Chemotherapy
214761243|NCT04943627|DRUG|Vinorelbine|Chemotherapy
214761244|NCT04943627|DRUG|Gemcitabine|Chemotherapy
214761245|NCT04943627|DRUG|Irinotecan|Chemotherapy
214761246|NCT04943627|DRUG|Pemetrexed|Chemotherapy
214761247|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
214761248|NCT03478982|DRUG|Placebos|single dose for inhalation
214761249|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
214761250|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
214761251|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
214761252|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
214761253|NCT03698825|DRUG|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
214761254|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
214761255|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
214761256|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
214761257|NCT03023358|DRUG|chidamide|30mg po twice a week
214761258|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
214761259|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
214761260|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
214761261|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
214761262|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
214761263|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
214761264|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
214761265|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
214761266|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
214761267|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
214761268|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
214761269|NCT02352831|DRUG|Tosedostat|
214761270|NCT02352831|DRUG|Capecitabine|
214761271|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
214761272|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
214761273|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
214761274|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
214761275|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
214761276|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
214761277|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
214761278|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
214761279|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
214761280|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
214761281|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
214761282|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
214761283|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
214761284|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
214761285|NCT00000147|DRUG|Methylprednisolone|
214761286|NCT00000147|DRUG|Prednisone|
214761287|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
214761288|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
214761289|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
214761290|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
214761291|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
214761292|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
214761293|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
214761294|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
214761295|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
214761296|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
214761297|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
214761298|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
214761299|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
214761300|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
214761301|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
214761302|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
214761303|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
214761304|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
214761305|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
214761306|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
214761307|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
214761308|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
214761309|NCT02432027|DRUG|Daivonex cream|comparator
214761310|NCT02432027|DRUG|Diprosis gel|comparator
214761311|NCT01298362|DRUG|Aromatase Inhibitors|
214761312|NCT01298362|DRUG|Chemotherapy|
214761313|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
214761314|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
214761315|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
214761316|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
214761317|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
214761318|NCT04804319|OTHER|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
214761319|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
214761320|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
214761321|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
214761322|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
214761323|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
214761324|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
214761325|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
214761326|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
214761327|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
214761328|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
214761329|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
214761330|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
214761331|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
214761332|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
214761333|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
214761334|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
214761335|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
214761336|NCT04141085|OTHER|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
214761337|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
214761338|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
214761339|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
214761340|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
214761341|NCT00762073|DRUG|budesonide|oral suspension
214761342|NCT00762073|DRUG|placebo|oral suspension matching budesonide
214761343|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
214761344|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
214761345|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
214761346|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
214761347|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
214761348|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
214761349|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
214761350|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
214761351|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
214761352|NCT04034875|OTHER|Questionnaire|questionnaire
214761353|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
214761354|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
214761355|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
214761356|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
214761357|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
214761358|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
214761359|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
214761360|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
214761361|NCT04954625|PROCEDURE|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
214761362|NCT04954625|PROCEDURE|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
214761363|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
214761364|NCT00326625|DRUG|Placebo|
214761365|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
214761366|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
214761367|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
214761368|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
214761369|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
214761370|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
214761371|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
214761372|NCT06568627|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
214761373|NCT06568627|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
214761374|NCT01265875|DRUG|Human Secretin|Dose Escalation
214761375|NCT05275673|DRUG|sapanisertib|capsules for oral administration
214761376|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
214761377|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
214761378|NCT04614402|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
214761379|NCT04614402|DEVICE|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
214761380|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
214761381|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
214761382|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
214761383|NCT05803941|DRUG|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.
214761384|NCT06829719|BIOLOGICAL|TTV DNAemia|Every 3 months, one sample added at the same time (7mL) of a routine laboratory analysis for TTV DNAemia
214761385|NCT06829719|OTHER|EQ-5D-5L questionnaire|Completed every 6 months and each time a complication of interest occurs
214761386|NCT06829719|BIOLOGICAL|Biological tests|Biological tests as routine care procedure (creatinine, CNI pre-dose trough level) will be performed every 6 months
214761387|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
214761388|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
214761389|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
214761390|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
214761391|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
214761392|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
214761393|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
214761394|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
214761395|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
214761396|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
214761397|NCT06091826|DRUG|NFL-101|Subcutaneous injections
214761398|NCT06091826|DRUG|Placebo|Subcutaneous injections
214761399|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
214761400|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
214761401|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
214761402|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
214761403|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
214761404|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
214761405|NCT02147015|DRUG|Glucocorticoids|
214761406|NCT02147015|DRUG|Antibiotics|
214761407|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
214761408|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
214761409|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
214761410|NCT02147015|OTHER|Physical treatments|
214761411|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
214761412|NCT06116799|DEVICE|Orthotic|Arch support orthotic
214761413|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
214761414|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
214761415|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
214761416|NCT05735119|DEVICE|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
214761417|NCT04041063|DEVICE|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
214761418|NCT04041063|PROCEDURE|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
214761419|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
214761420|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
214761421|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
214761422|NCT03906565|DRUG|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
214761423|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
214761424|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
214761425|NCT06043830|DRUG|Acetazolamide|Acetazolamide 250 mg 2 capsules by mouth nightly
214761426|NCT06043830|OTHER|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly
214761427|NCT00400985|DEVICE|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
214761428|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
214761429|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
214761430|NCT03142919|BIOLOGICAL|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
214761431|NCT03142919|BIOLOGICAL|Placebo|Saline solution
214761432|NCT03792633|BIOLOGICAL|huCART19|IV injection
214761433|NCT05382637|DRUG|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
215030773|NCT04945681|BIOLOGICAL|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 5 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
215030774|NCT05690464|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
215030775|NCT05690464|DIETARY_SUPPLEMENT|placebo|placebo
214761434|NCT06131723|BEHAVIORAL|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
214761435|NCT05522816|DRUG|KX01 0.01% (0.1 mg/g)|Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
214761436|NCT05522816|DRUG|Placebo|Contains same excipients with KX01 but do not contain Tirbanibulin
214761437|NCT05522816|DRUG|KX01 0.1% (1.0 mg/g)|Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
214761438|NCT05522816|DRUG|KX01 1% (10 mg/g) for 5 days|Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
214761439|NCT05522816|DRUG|KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles|Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
214761440|NCT05128955|DEVICE|Splenic artery embolization with vascular embolic coils or plugs|Splenic artery embolization with vascular embolic coils or plugs
214761441|NCT02565537|PROCEDURE|LASIK|WFG vs. WFO LASIK
214761442|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
214761443|NCT06566768|DRUG|Deucravacitinib|Specified dose on specified days
214761444|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
214761445|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
214761446|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
214761447|NCT05038228|DRUG|Apixaban|Anticoagulant
214761448|NCT05038228|DRUG|Rivaroxaban|Anticoagulant
214761449|NCT05038228|DRUG|Dabigatran|Anticoagulant
214761450|NCT05038228|DRUG|Vitamin K antagonist (VKA)|Anticoagulant
214761451|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
214761452|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
214761453|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
214761454|NCT05221762|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) at 3 Tesla
214761455|NCT06308263|DRUG|Tuvusertib [14C]Tuvusertib microtracer|Participants will receive single oral dose of Tuvusertib containing a \[14C\] Tuvusertib microtracer solution on Day 1 of period 1 under fasted conditions.
214761456|NCT06308263|DRUG|Tuvusertib|Participants will also receive a single oral dose of Tuvusertib on Day 1 of Period 1 or Period 1a, and daily single oral dose of Tuvusertib for 2 weeks in 21 days cycle of Period 2.
214761457|NCT06308263|DRUG|Tuvusertib + [14C]Tuvusertib microdose bolus injection|In Period 1a, participants will receive on Day 1 of Period 1 a single oral dose of tuvusertib and an intravenous (IV) (14C) tuvusertib microdose as bolus injection.
214761458|NCT05182476|DRUG|Placebo|Oral tablets
214761459|NCT05182476|DRUG|Luvadaxistat|Oral tablets
214761460|NCT00900471|OTHER|biologic sample preservation procedure|
214761461|NCT00900471|OTHER|medical chart review|
214761462|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
214761463|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
214761464|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
214794394|NCT01253720|BEHAVIORAL|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
214761465|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
214761466|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
214761467|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
214761468|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
214761469|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
214761470|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
214761471|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
214761472|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
214761473|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
214761474|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
214761475|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
214761476|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
214761477|NCT06253195|DRUG|BGB-43395|Administered orally.
214761478|NCT06253195|DRUG|Fulvestrant|Administered via intramuscular injection.
214761479|NCT06253195|DRUG|Letrozole|Administered orally.
214761480|NCT06588972|DIETARY_SUPPLEMENT|Medium Chain Triglyceride solution|Placebo
214761481|NCT06588972|OTHER|Cannabis Sativa|Group 2: Cannabis sativa extract with CBD (45mg/day).
214794395|NCT02476526|DRUG|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
214794396|NCT02476526|DRUG|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
214761482|NCT05146726|OTHER|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
214761483|NCT05146726|OTHER|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
214761484|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
214761485|NCT06978062|DRUG|Bemarituzumab|• Bemarituzumab will be given as a IV infusion
214761486|NCT06978062|DRUG|FLOT|FLOT will be given as a IV infusion
214761487|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
214761488|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
214761489|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
214761490|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
214761491|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
214761492|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
214761493|NCT04071769|DRUG|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
214761494|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
214761495|NCT06537583|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
214761496|NCT06537583|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
214761497|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
214761498|NCT06603948|DEVICE|Spectral Focused Imaging|Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy
214761499|NCT06603948|DEVICE|White Light Imaging|Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
214761500|NCT06588725|BEHAVIORAL|Play Nicely|Multimedia tool and handbook designed to educate parents about healthy discipline strategies.
214761501|NCT06588725|BEHAVIORAL|Cavity Prevention Handout|Two page handout with information about how to prevent cavities.
214761502|NCT06589908|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
214761503|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
214761504|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
214761505|NCT03884556|DRUG|TTX-030|Variable dose and schedule
214761506|NCT03884556|DRUG|Pembrolizumab|Dose and schedule per standard of care
214761507|NCT03884556|DRUG|Gemcitabine|Dose and schedule per standard of care
214761508|NCT03884556|DRUG|nab paclitaxel|Dose and schedule per standard of care
214761509|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
214761510|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
214761511|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
214761512|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
214761513|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
214761514|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
214761515|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
214761516|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
214761517|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
214761518|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
214761519|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
214761520|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
214761521|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
214761522|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
214761523|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
214761524|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
214761525|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
214761526|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
214761527|NCT06311851|DRUG|Bevacizumab|Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
214761528|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
214761529|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
214761530|NCT05534958|DEVICE|Accexible|Speech Analysis
214761531|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
214761532|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
214761533|NCT04162756|DRUG|Fludarabine|Administered per package insert
214761534|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
214761535|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
214761536|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
214761537|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
214761538|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
214761539|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
214761540|NCT06991673|BEHAVIORAL|Behavioral Treatment|"Positive Activity Interventions within Ane-Roadmap App~Positive Piggy Bank - Capture happy moments by mentally savoring them, recording details, and depositing them into a piggy bank. Open it when you need a boost.~Gratitude Diary - Write two unique things daily for which you're grateful. Smile as you record them to enhance gratitude.~Savoring - Each day, spend 2-3 minutes fully enjoying two positive experiences. Log them for reflection.~Pleasant Activity Scheduling - Plan and engage in enjoyable activities at least twice weekly. Treat them as important appointments.~Random Acts of Kindness - Perform five intentional kind acts in a day, four for others and one for yourself.~Signature Strengths - Use a personal strength in a new way daily and reflect on its impact.~Love Letter - Express deep appreciation to a loved one in a heartfelt letter and share it with them.~Engaging with Beauty - Keep a log of beautiful moments in nature, art, or human kindness."
214794397|NCT02476526|DRUG|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
214761541|NCT04959019|BEHAVIORAL|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
214761542|NCT04959019|BEHAVIORAL|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
214761543|NCT01058707|DRUG|MLN0128|MLN0128 capsules
214761544|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
214761545|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
214761546|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
214761547|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
214761548|NCT00371748|DEVICE|Express2|Coronary Stent System
214761549|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
214761550|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
214761551|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
214761552|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
214761553|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
214761554|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
214761555|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
214761556|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
214761557|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
214761558|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
214761559|NCT06670261|OTHER|Data collection|Retrospective pseudo-anonymized clinical and scannographic data from the routine management of patients in rhino-sinusology consultations.
214761560|NCT00179101|PROCEDURE|Deep Brain Stimulation|
214761561|NCT02984904|OTHER|survey|survey
214761562|NCT00828009|BIOLOGICAL|bevacizumab|IV
214761563|NCT00828009|BIOLOGICAL|Tecemotide|
214761564|NCT00828009|DRUG|carboplatin|IV
214761565|NCT00828009|DRUG|cyclophosphamide|IV
214761566|NCT00828009|DRUG|paclitaxel|IV
214761567|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
214761568|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
214761569|NCT06864533|DRUG|Docetaxel|Chemotherapy will start 4-8 weeks after the completion of radiotherapy. The chemotherapy regimen will consist of docetaxel 75 mg/m² administered intravenously on Day 1, repeated every 21 days for a total of 4-6 cycles. In cases of significant neuroendocrine differentiation and if well-tolerated, a combination of docetaxel and carboplatin (docetaxel 75 mg/m² and carboplatin AUC 4-6) will be used. Pre-treatment with dexamethasone will be administered to reduce potential side effects.
214761570|NCT06854406|DRUG|Varenicline|Initial, 0.5 mg orally once daily for 3 days, then 0.5 mg every 12 hours on days 4 through 7, and then 1 mg in morning of day 8. Medication is taken after eating and with a full glass of water.
214761571|NCT06995742|DEVICE|Device Array Use|Study participants assigned to the intervention study arm will wear a wireless Bluetooth capable vital sign detection array, with one device externally worn on each of their chest, one finger, and one arm, with healthcare providers using an additional oral temperature probe.
214761572|NCT06995742|DEVICE|Routine Vital Sign Measurement|Study participants randomized to the control arm will have their vital signs obtained by routine means, without use of the wireless vital sign device array.
214761573|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
214761574|NCT06999109|BEHAVIORAL|TEAM-LEADS|TEAM-LEADS will be an online, self-administered intervention for stress reduction and cardiovascular health behavior promotion in adolescents and young adults with juvenile-onset systemic lupus erythematosus and dermatomyositis
214761575|NCT06999707|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
214761576|NCT06999707|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
214761577|NCT06999707|DRUG|Durvalumab|Treatment Duration Guidelines: \* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years. \* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years. \* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.
214794398|NCT02476526|PROCEDURE|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
214761578|NCT07002489|DIETARY_SUPPLEMENT|Nuotelande Shuhuajun Study Product|Participants in this arm need to take in the assigned product - Nuotelande Shuhuajun Study Product, 1 capsule per day, for 14 consecutive days. Don't take in similar products in the following 7 days (regression phase).
214761579|NCT07000604|OTHER|Mouth Care Training|Patients will be educated on how to care for their mouths after using inhaled medication.
214761580|NCT06672159|DEVICE|Two defibrillators|DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.
214761581|NCT06672159|DEVICE|One defibrillator|Standard OHCA treatment according to existing guidelines.
214761582|NCT07006740|PROCEDURE|MR-guided Focused Ultrasound Thalamotomy|This intervention involves a unilateral magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy targeting the ventral intermediate nucleus (VIM) of the thalamus. The procedure is non-invasive and uses MRI guidance to deliver focused ultrasound energy to ablate the target area. It is performed without surgical incisions or implanted devices. The intervention is intended for patients with medication-refractory essential tremor. Participants receiving this intervention will be followed for 12 months to assess efficacy and safety.
214761583|NCT07005167|PROCEDURE|endocrowns|endocrowns made of HC hard blocks or cerasmart blocks to restore endo treated molars
214761584|NCT07005167|PROCEDURE|endocrowns|endocrowns made of Cerasmart blocks to restore endo treated molars
214761585|NCT07005232|DEVICE|defibrillation lead|This is a device registry for the OmniaSecure™ defibrillation lead. The OmniaSecure lead is a steroid eluting, integrated bipolar, nonretractable screw-in, catheter delivered, transvenous ventricular lead with a Right Ventricular (RV) defibrillation coil electrode. The lead is designed for pacing, sensing, cardioversion, and defibrillation therapies, and has application for patients whom transvenous ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated.
214761586|NCT07005674|BEHAVIORAL|Cycle Nation|Participants will be asked to attend nine weekly 90-minute face-to-face sessions, delivered by trained facilitators at community cycling organisations. Sessions include off road cycling skills and on-road group rides, behaviour change techniques (e.g. goal setting), and bicycle maintenance training. Two extra group rides will be offered during the programme for additional practice, along with two catch-up sessions at the end for those who missed any content. Participants will be added to a WhatsApp group to encourage peer communication. Bicycles, helmets, and locks will be loaned to participants for 10-12 weeks to support participation.
214761587|NCT07005674|BEHAVIORAL|Cycling Scotland standard cycling session|Participants will be asked to participate in Cycling Scotland's 'Introduction to On-Road Cycling' a single 2-2.5-hour session that is offered as standard. The session covers key cycling skills such as hazard awareness, road positioning, and communicating with other road users. Activities are tailored to participants' needs and may include navigating junctions, using shared infrastructure, and performing U-turns. Bicycles and helmets will be provided for the session.
214761589|NCT07006935|BEHAVIORAL|Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness|The Clubhouse Model (CM) is a strengths-focused, evidence-based, and comprehensive approach to psychosocial rehabilitation for serious mental illness. The CM uses an intentional community of support to create a safe and holistic setting to practice real-world functioning. The core of the CM is the 'work-ordered day', a concept where members, as opposed to patients, are integral to and needed for the successful daily operation of the Clubhouse. Members choose a 'work unit' each day of attendance. Most clubhouses have four work units, such as (1) Administration (e.g., database management); (2) Hospitality (e.g., Clubhouse cafe); (3) Membership (e.g., employment programs); and (4) Communications (e.g., newsletter). Other unique aspects include its voluntary and humanistic nature, prioritization of member choice, unrestricted and flexible membership, and the elimination of provider-patient hierarchy. The CM has a sophisticated accreditation process based on 37 international standards.
214761590|NCT07006935|BEHAVIORAL|Usual Community-Based Mental Health Care|Usual care includes services typically available in the community at mental health agencies, including case management, including Assertive Community Treatment, counseling, peer support services, psychoeducational support groups, family support groups, supported education/employment, permanent supportive housing, and medication management.
214761591|NCT07005596|DEVICE|Passy-Muir Speaking Valve|This intervention group receives early speaking valve intervention during ventilator weaning.
214761592|NCT07005596|BEHAVIORAL|Standard Non-Verbal Communication Methods|This control group continues using conventional non-verbal communication methods such as gestures and lip-reading.
214761593|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab|Short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
214761594|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy|Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
214761595|NCT07006194|DIETARY_SUPPLEMENT|Nicotinamide Tablet|One nicotinamide tablet per day during the month preceding surgery
214761596|NCT06303713|DRUG|Carboplatin|Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.
214761597|NCT06303713|DRUG|177Lu-PSMA-617|Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
214761598|NCT04880850|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
214761599|NCT04880850|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
214761600|NCT04880850|DRUG|Insulin aspart|Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
214761601|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
214761602|NCT03189706|DRUG|Irinotecan|50mg/m\^2/day IV will be administered from day 1-5
214761603|NCT03189706|DRUG|temozolomide|(given concurrently with Irinotecan) 150mg/m\^2/day orally
214761604|NCT03189706|BIOLOGICAL|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
214761605|NCT03189706|DRUG|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
214761606|NCT07006428|DEVICE|Clareon PanOptix or PanOptix Toric IOLs|Bilateral implantation of the Clareon PanOptix or PanOptix Toric IOLs.
214761607|NCT07006428|DEVICE|Comparable multifocal IOL|Bilateral implantation of a comparable multifocal IOL
214761608|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.
214761609|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.
214761610|NCT03405155|BIOLOGICAL|Nivolumab|Given IV
214761611|NCT07006610|DEVICE|Kinesio Tex® Gold Taping|Elastic kinesio tape applied postoperatively to the facial region and left in place for 5 days.
214761612|NCT07006610|DEVICE|Hilotherm® Facial Cooling System|A polyurethane facial mask delivering continuous +17°C water cooling for 48 hours post-surgery.
214761613|NCT06697028|OTHER|Usability and Comparison|PACER will be used to assess cardiorespiratory fitness in individuals with rheumatic diseases. The results will be compared with those of healthy individuals, and the relationship between body composition and VO2 max will be examined.
214761614|NCT07022535|DIAGNOSTIC_TEST|KELIM|"(i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable.~(ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery"
214761615|NCT07022535|DRUG|Carboplatin plus Paclitaxel|Chemotherapy as neaodjuvant chemotherapy
214761616|NCT07022535|PROCEDURE|Interval debulking surgery|Interval debulking surgery
214761617|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #25/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #25/0.4 rotary file. After mechanical preparation, passive ultrasonic irrigation (PUI) was performed using a VDW Ultra device with an IRRI S 21/25 ultrasonic tip. Irrigation was activated with 3% sodium hypochlorite (NaOCl) in three 20-second cycles, using 1 ml per cycle. The ultrasonic tip was placed 2 mm short of the working length without contacting canal walls.
214761618|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #35/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #35/0.4 rotary file. The same passive ultrasonic irrigation protocol was applied as in Arm 1, using 3% NaOCl in three 20-second cycles with 1 ml per cycle. The ultrasonic tip was positioned 2 mm short of the working length without contacting the canal walls.
214761619|NCT06699394|DRUG|Teclistamab (Tec)|Teclistamab is administered subcutaneously with higher step-up doses (SUDs). Patients receive teclistamab with SUDs: 0.2 and 0.7 mg/kg and 1.5 mg/kg in Cycle 1 (2-4 days between doses). 3 mg/kg every 4 weeks will be used in subsequent cycles.
214761620|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
214761621|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
214761622|NCT00034476|DRUG|sPLA2 Inhibitor|
214761623|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
214761624|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
214761625|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
214761626|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
214761627|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
214761628|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
214761629|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
214761630|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
214761631|NCT06710119|OTHER|Visual Feedback|Visual feedback of foot loading during gait.
214761632|NCT06716710|BEHAVIORAL|Art therapy group|In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, a mandala coloring session will be held 3 days a week, 2 times a week under the supervision of the researcher. In order to ensure standardization in the pregnant women included in the study group, each pregnant woman will be given the same mandala work box (36 colored coloring pencils, file, eraser, pencil sharpener and the same mandala prints for all pregnant women). The selection of mandala patterns will be determined by the researchers. In the second week of the training, the researcher will evaluate the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of birth scale. At the end of the four-week activity, the researcher will evaluate again.
214761633|NCT06716710|OTHER|Control group|In addition to the medical treatments that the pregnant women in the control group will receive in the clinic for 4 weeks, no other application will be made. After two weeks, the researcher will evaluate them using the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of childbirth scale. At the end of the fourth week, the researcher will evaluate them again.
214761634|NCT03577418|BEHAVIORAL|Templated, clinician-facilitated intervention to align everyday living preferences assessment|"In step 1, persons living with dementia or cognitive impairment (PLWD/CI) will complete the PELI (hereafter, assessment PELI-CI for Cognitive Impairment) to articulate their preferences. In step 2, care partners will consider the preferences of PLWD/CI; care partners will complete concurrent but separate proxy PELI assessments from the perspective of the PLWD/CI (i.e., as if acting as surrogate decision-makers; hereafter assessment PELI-CP for Care Partner). In the Intervention (step 3), the study clinician will ask the PLWD/CI to identify up to 3 social engagement preferences that matter most to them. Second, in discussion with the PLWD/CI and care partner, the study clinician will review areas where there is a difference in ratings between the PELI-CI and PELI-CP. The study clinician will then ask the PLWD/CI to identify up to 3 items of disagreement that are most important for the care partner to know about. A 1-page Preferences Priorities document will then be created."
214761635|NCT06724952|DRUG|MTX S.C or IM and Silymarin 140 mg tab|IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
214761636|NCT06724952|DRUG|MTX S.C or IM|IM or SC Methotrexate plus placebo tablet once daily for 3 months.
214761637|NCT06724783|DEVICE|Collagen membrane|Implant placement with simultaneous GBR covered with a collagen membrane
214761638|NCT07046780|DRUG|Observation arm|To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world
214761639|NCT07048665|DIAGNOSTIC_TEST|CT Imagesa in HCCT|Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter
214761640|NCT06884917|OTHER|Sleep Hygiene Training|Written consent will be obtained from the women, and a Personal Information Form will be applied. The General Comfort Scale (GCS) will be applied to the women. The Pittsburgh Sleep Quality Index (PSQI) will be applied to the women. Each level will include the physical, socio-cultural, psycho-spiritual, and environmental dimensions where the requirements to ensure comfort arise.
214761641|NCT06732882|DRUG|AZD4604|Participants will receive AZD4604 via Genuair/Turbuhaler device.
214761642|NCT06732882|OTHER|Placebo|Participants will receive placebo via Genuair/Turbuhaler device.
214761643|NCT06732882|DEVICE|Genuair|Participants will either receive AZD4604 or placebo via Genuair device.
214761644|NCT06732882|DEVICE|Turbuhaler|Participants will receive either AZD4604 or placebo via Turbuhaler device.
214761645|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
214761646|NCT07047222|BEHAVIORAL|Behavioral change communication (BCC) module|The behavior change communication (BCC) module was designed to enhance awareness and promote effective management of menstrual disorders through structured lifestyle and behavioral guidance. It consisted of three 1-hour sessions: (1) education on menstrual disorders and related risk factors; (2) healthy dietary practices; and (3) physical activity (including yoga) and other lifestyle improvements. Sessions were held from May 20 to June 30, 2023, at three public universities in Bangladesh and were delivered by trained female educators. All session dates were approved by university authorities. Activities included interactive presentations, yoga demonstrations, pamphlet distribution, quizzes, and gift giveaways. To reinforce and support behavior change, follow-up visits were conducted every two months from July 15, 2023, to January 15, 2024.
214794399|NCT03982966|DIETARY_SUPPLEMENT|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
214794400|NCT03915938|DRUG|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
214794401|NCT03915938|DRUG|Placebo|Administered in an identical way than ketamine.
214761647|NCT06736548|BEHAVIORAL|The Sleep Treatment Education Program Together (STEP-Together)|STEP-Together is delivered in a single videoconference group session delivered live by a presenter. During the session, the participants are able to see and hear the presenter, view the presentation slides, and ask questions. The presentation includes educational information on the problem of insomnia after cancer and specific suggestions for improving sleep. Suggestions are presented in four sections addressing lifestyle issues, sleep environment, sleep timing, and managing expectations and challenges. During the course of the session, participants are asked to use these suggestions to develop an individual sleep action plan they will use to improve their sleep.
214761648|NCT06736548|BEHAVIORAL|Coaching Session|Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
214761649|NCT07048730|OTHER|Questionnaire|"A standardized questionnaire was specifically developed for the study to explore:~* Women's socio-demographic data~* Data about their hematological disease (type of leukemia, conditioning protocol, relapses, graft-versus-host disease etc.)~* Information received by patients prior to transplantation concerning gynecological complications~* Symptoms, screening, diagnosis and treatment of the main gynecological complications~* Patients fertility (spontaneous or after assisted reproductive treatments)"
214761650|NCT07046884|BEHAVIORAL|Integrated Oncological Decision-making Model|In the IODM-based practice, the following three information components should be incorporated when forming a personalized treatment plan: 1. State-of-the-art oncological treatment options with advantages and disadvantages; 2. General health status based on physical, psychosocial, and emotional functioning; 3. Goals and preferences of the patient, both in treatment and daily life. Together with the professionals, optimal tools and strategies to integrate these components within the care path will be discussed.
214761651|NCT07047898|DRUG|The group receiving dexmedetomidine infusion|Dexmedetomidine will be administered intravenously at an infusion dose of 0.2-0.7 µg/kg/hour during the maintenance phase of anesthesia.
214761652|NCT07047898|DRUG|The group not receiving dexmedetomidine infusion|Infusion will not be given.
214761653|NCT07046845|DIETARY_SUPPLEMENT|Perelel Prenatal Vitamin|Daily Perelel prenatal vitamin supplement throughout pregnancy
214761654|NCT07046845|DIETARY_SUPPLEMENT|Generic Prenatal Vitamin|Daily generic prenatal vitamin supplement throughout pregnancy.
214761655|NCT06212544|BEHAVIORAL|Immediate Intervention|Enhanced microeconomic intervention
214761656|NCT06212544|BEHAVIORAL|Delayed Intervention|Usual care and then access to enhanced microeconomic intervention
214761657|NCT06896565|DRUG|nano hydroxy apatite varnish|Intervention (1)
214761658|NCT06896565|DRUG|Potassium Nitrate Gel|Intervention (2)
214761659|NCT06896565|DRUG|Varnishes, Fluoride|Control
214761660|NCT06748690|PROCEDURE|mucosal cutting biopsy|"Under intravenous anesthesia, the patient inserted a gastroscopy (Olympus GIF-260J) through the mouth and used a disposable high-frequency cutting knife to cut open the surface mucosa of the tumor. Biopsy forceps were used to extract tissue that could be fully evaluated for pathological examination. Use a disposable hemostatic clip to suture the mucosal incision, and after thorough observation of the hemostasis, withdraw from the endoscope.~("
214761661|NCT06748690|PROCEDURE|endoscopic ultrasound-guided-fine needle aspiration|2\) EUS-FNA group: Standard (Endoscopic Ultrasonography-Guided Fine-Needle Aspiration) EUS-FNA technology was used, and electronic linear array ultrasound endoscopy (GF-UCT-260, Olympus, Japan) was used to scan and locate the lesion. Puncture needle (Boston Scientific, USA) was used for aspiration biopsy. The thickness of the puncture needle depends on the size, hardness, and location of the tumor.
214761662|NCT03222856|DRUG|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
214761663|NCT03222856|DRUG|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
214761664|NCT05925322|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
214761665|NCT05925322|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
215030776|NCT05855044|OTHER|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
214761666|NCT06742502|DRUG|Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)|First strategy of targeted immunotherapy followed by chemotherapy for PMBL. Participants will first receive sintilimab(200mg) plus rituximab(375mg/m2) for 2 cycles. If patients achieve CR or CMR, they will continue to receive 2 courses of sintilimab plus rituximab, followed by 4 cycles of R-CHOP. Patients will receive 6 courses of R-CHOP if they do not achieve CR or CMR after 2 cycles of sintilimab plus rituximab. Patients will undergo PET-CT assessment and will receive 6 cycles of maintenance treatment with nintedanib if CR/CMR/PR is achieved and will be withdrawn from the study if SD/PD occurs. Total treatment cycles will not exceed 14 cycles.
214761667|NCT06898255|DRUG|GFS202A injection|Participants will receive GFS202A intravenously every 3 weeks (Q3W) in a 21-day cycle. The treatment duration was 12 weeks.
214761668|NCT03934372|DRUG|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
214761669|NCT04587687|DRUG|Bendamustine Hydrochloride|Given IV
214761670|NCT04587687|DRUG|Brentuximab Vedotin|Given IV
214761671|NCT02346747|BIOLOGICAL|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
214794402|NCT02462538|DRUG|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
214761672|NCT02346747|OTHER|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
214761673|NCT06900881|COMBINATION_PRODUCT|Kefir Mouth Wash|A kefir-based mouthwash was developed with active bacterial and yeast cultures, including Lactococcus lactis, Lactococcus cremoris, Lactococcus diacetylactis, Lactobacillus acidophilus, Saccharomyces cerevisiae, and Kluyveromyces lactis, along with maltodextrin and 3% fat milk. The recipe also calls for milk from Pegah, Iran. The milk is initially heated to boiling point and then allowed to cool to room temperature (25°C). After cooling, the kefir powder will be dissolved in the cooled milk and mixed well. For every 1 liter of milk, 3g of kefir starter yogurt (Yogourmet, France) will be added. The inoculated milk will then be transferred into a clean, airtight container, and the lid will be sealed. The container will be left at room temperature for approximately 24 hours until the kefir curd forms. After 24 hours, the kefir will be refrigerated for about 8 hours to halt the fermentation process.
214761674|NCT06900881|DRUG|Chlorhexidine 0,12%Biofresh Mouthwash|Chlorhexidine mouthwash is used as a standard treatment (Scitra Co for Biofresh LIC, P.O. Box 87218, Dubai, U.A.E.). It contains 0.12% Chlorhexidine Digluconate, purified water, sodium saccharin, cremophor, flavor, and glycerin.
214761675|NCT06805877|OTHER|Predictive Analytics and Clinical Decision Support|The intervention will include automated EHR notifications to clinicians at 16 OCHIN community health centers about patients who are likely to benefit from PrEP. These patients will be identified by an HIV prediction model that was developed and validated during the pilot phase of this study using historical OCHIN EHR data. For patients above a preselected threshold of predicted HIV risk, clinicians will be notified at the point of care that the patient may benefit from PrEP and will be provided with EHR-based tools to support discussions and prescribing. The intervention will also include coaching on PrEP and the decision support tool, as well as project team support during the trial period.
214761676|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
214761677|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
214761678|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
214761679|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
214761680|NCT05844176|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international and local guidelines
214761681|NCT06902610|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and combines a musical and cognitive training program and written language training program.
214761682|NCT04213703|OTHER|No intervention|There is no intervention for this study
214761683|NCT06076889|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
214761684|NCT06894446|DIETARY_SUPPLEMENT|Numeta G13%E|Dose selected and dosing schedule are as deemed appropriate by the ordering attending physician in conjunction with the Investigator.
214761685|NCT06894446|DIETARY_SUPPLEMENT|Compounded Parenteral Nutrition (cPN) solution|Will be administered as institutional SOC procedure for the hospital.
214761686|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
214761687|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
214761688|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
214761689|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
214761690|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
214761691|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
214761692|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
214761693|NCT01887366|DRUG|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
214761694|NCT01887366|DRUG|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
214761695|NCT01887366|DRUG|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
214761696|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
214761697|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
214761698|NCT01314859|DRUG|Nifedipine|"* Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
214761699|NCT01314859|DRUG|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
214761700|NCT00016406|BIOLOGICAL|filgrastim|
214761701|NCT00016406|DRUG|cyclophosphamide|
214761702|NCT00016406|DRUG|doxorubicin|
214761703|NCT00016406|DRUG|paclitaxel|
214761704|NCT00016406|PROCEDURE|surgery|
214761705|NCT01502800|DRUG|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
214761706|NCT01502800|DRUG|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
214761707|NCT01502800|DRUG|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
214761708|NCT01502800|DRUG|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
214761709|NCT01827085|DEVICE|Conventional Macintosh laryngoscope|
214761710|NCT01827085|DEVICE|Stortz videolaryngoscope|
214761711|NCT06270537|DEVICE|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
214761712|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
214761713|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
214761714|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
214761715|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
214761716|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
214761717|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
214761718|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
214761719|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
214761720|NCT05647733|PROCEDURE|Low splanchnic blood volume restrictive fluid management strategy|Hemodynamic goal-directed restrictive fluid management strategy.
214761721|NCT05647733|PROCEDURE|Optimized cardiac output liberal fluid management strategy|Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
214761722|NCT05647733|PROCEDURE|Phlebotomy|Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
214761723|NCT01243645|BEHAVIORAL|biofeedback training|
214761724|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
214761725|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
214761726|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
214761727|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
214761728|NCT02337543|DRUG|Placebo|Placebo
214761729|NCT00202254|BEHAVIORAL|Physiotherapy|
214761730|NCT00202254|BEHAVIORAL|Occupational therapy|
214761731|NCT00202254|BEHAVIORAL|Speech pathology|
214761732|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
214761733|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
214761734|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
214761735|NCT03315780|DRUG|Dulaglutide|Administered SC
214761736|NCT03315780|DRUG|Placebo|Administered SC
214761737|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
214761738|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
214761739|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
214761740|NCT00003582|DRUG|amifostine trihydrate|
214761741|NCT00003582|DRUG|cisplatin|
214761742|NCT00003582|DRUG|fluorouracil|
214761743|NCT00003582|DRUG|paclitaxel|
214761744|NCT00003582|PROCEDURE|quality-of-life assessment|
214761745|NCT00003582|RADIATION|radiation therapy|
214761746|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
214761747|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
214761748|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
214761749|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
214761750|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
214761751|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
214761752|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
214761753|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
214761754|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
214761755|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
214761756|NCT00473928|DRUG|POT-4|Single intravitreal injection.
214761757|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
214761758|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
214761759|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
214761760|NCT06439186|DRUG|Lidocain|Local anesthesia
214761761|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
214761762|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
214761763|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
214761764|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
214761765|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
214761766|NCT01947010|BIOLOGICAL|Prevenar 13|
214761767|NCT01947010|BIOLOGICAL|Pneumovax|
214761768|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
214761769|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
214761770|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
214761771|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
214761772|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
214761773|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
214761774|NCT01716442|DRUG|Placebo|
214761775|NCT02472600|DRUG|Colistin|
214761776|NCT02472600|DRUG|Neomycin|
214761777|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
214761778|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
214761779|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
214761780|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
214761781|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
214761782|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
214761783|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
214761784|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
214761785|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
214761786|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
214761787|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
214761788|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
214761789|NCT01636011|OTHER|Light Touch sham|Light Touch sham
214761790|NCT05454189|DEVICE|Reduced IPD Flush Schedule|IPD flush every 12 weeks
214761791|NCT05454189|DEVICE|Standard IPD Flush Schedule|IPD flush every 4 weeks
214761792|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
214761793|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
214761794|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
214761795|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
214761796|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
214761797|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
214761798|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
214761799|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761800|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761801|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761802|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761803|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761804|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761805|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
214761806|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
214761807|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
214761808|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
214761809|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
214761810|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
214761811|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214761812|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
214761813|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
214761814|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
214761815|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214761816|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
214761817|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
214761818|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
214761819|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
214761820|NCT02665858|OTHER|OCT Imaging|
214761821|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
214761822|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
214761823|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
214761824|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
214761825|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
214761826|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
214761827|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
214761828|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
214761829|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
214761830|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
214761831|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY\_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY\_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
214761832|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY\_1) or in phase 2 of the study (subjects randomized to study arm ACWY\_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
214761833|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
214761834|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
214761835|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
214761836|NCT01863394|OTHER|Screening by mothers|
214761837|NCT01863394|OTHER|Active comparator: Screening by community health workers|
214761838|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
214761839|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
214761840|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
214761841|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
214761842|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
214761843|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
214761844|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
214761845|NCT02246244|DRUG|Escitalopram|
214761846|NCT02246244|OTHER|Placebo|
214761847|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
214761848|NCT03542864|OTHER|Control|Progress registration of body composition values
214761849|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
214761850|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
214761851|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
214761852|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
214761853|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
214761854|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
214761855|NCT02491086|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT
214761856|NCT02491086|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling
214761857|NCT00013910|DRUG|NNC 90-1170|
214761858|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
214761859|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
214761860|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
214761861|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
214761862|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
214761863|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
214761864|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
214761865|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
214761866|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
214761867|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
214761868|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
214761869|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
214761870|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
214761871|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
214761872|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
214761873|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
214761874|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
214761875|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
214761876|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
214761877|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
214761878|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
214761879|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
214761880|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
214761881|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
214761882|NCT01075126|DRUG|Depakote|
214761883|NCT01075126|DRUG|Lithium|
214761884|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
214761885|NCT00003104|RADIATION|radiation therapy|
214761886|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
214761887|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
214761888|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
214761889|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
214761890|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
214761891|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
214761892|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
214761893|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
214761894|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
214761895|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
214761896|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
214761897|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
214761898|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
214761899|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
214761900|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
214761901|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
214761902|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
214761903|NCT00008034|DRUG|capecitabine|
214761904|NCT00008034|DRUG|cyclophosphamide|
214761905|NCT00008034|DRUG|epirubicin hydrochloride|
214761906|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
214761907|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
214761908|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
214761909|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
214761910|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
214761911|NCT01800812|BIOLOGICAL|Injections of OM-174|
214761912|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
214761913|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
214761914|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
214761915|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
214761916|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
214761917|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
214761918|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
214761919|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
214761920|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
214761921|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
214761922|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
214761923|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
214761924|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
214761925|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
214761926|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
214761927|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
214761928|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
214761929|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
214761930|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
214761931|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
214761932|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
214761933|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
214761934|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
214761935|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
214761936|NCT00560573|DRUG|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
214761937|NCT00560573|DRUG|Cisplatin|"Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
214761938|NCT00560573|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
214761939|NCT00560573|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
214761940|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
214761941|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
214761942|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
214761943|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
214761944|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
214761945|NCT00347776|DRUG|azithromycin|oral antibiotic
214761946|NCT00347776|DRUG|topical tetracycline|
214761947|NCT00823680|DRUG|Placebo|po bid for 4 weeks
214761948|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
214761949|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
214761950|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
214761951|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
214761952|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
214761953|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
214761954|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
214761955|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
214761956|NCT00594568|DRUG|LY450139|Administered orally once daily
214761957|NCT00594568|DRUG|Placebo|Administered orally once daily
214761958|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
214761959|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
214761960|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
214761961|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
214761962|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
214761963|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
214761964|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
214761965|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
214761966|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
214761967|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
214761968|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
214761969|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
214761970|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
214761971|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
214761972|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
214761973|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
214761974|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
214761975|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
214761976|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
214761977|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
214761978|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214761979|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
214761980|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
214761981|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
214761982|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
214761983|NCT00518531|DRUG|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
214761984|NCT00518531|DRUG|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
214761985|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
214761986|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
214761987|NCT00032825|DRUG|Ketaconazole|
214761988|NCT00032825|DRUG|Docetaxel|
214761989|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
214761990|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
214761991|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
214761992|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
214761993|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
214761994|NCT04406363|OTHER|non interventional|non interventional
214761995|NCT00087763|DRUG|Macugen ™ (pegaptanib sodium injection)|
214761996|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
214761997|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
214761998|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
214761999|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
214762000|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
214762001|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
214762002|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
214762003|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
214762004|NCT02351206|RADIATION|x-ray, MRI|
214762005|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
214762006|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
214762007|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
214762008|NCT01326611|DRUG|Clarithromycin|
214762009|NCT01326611|DRUG|Dextrose|
214762010|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
214762011|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
214762012|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
214762013|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
214762014|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
214762015|NCT06195358|DEVICE|Mobile Health (Smartphone) Application|The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
214762016|NCT06195358|OTHER|Printed Caregiving Materials|The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
214762017|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
214762018|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
214762019|NCT03653637|BEHAVIORAL|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
214762020|NCT03653637|BEHAVIORAL|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
214762021|NCT00096317|DRUG|ixabepilone|
214762022|NCT00096317|DRUG|ketoconazole|
214762023|NCT00551473|DRUG|Lavoltidine|
214762024|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
214762025|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
214762026|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
214762027|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
214762028|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
214762029|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
214762030|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
214762031|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
214762032|NCT01231880|DRUG|Monthly IPT using DP|Given every month
214762033|NCT01231880|DRUG|Placebo given every month|No active ingredient
214762034|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
214762035|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
214762036|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
214762037|NCT01741259|DRUG|Meperidine|
214762038|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
214762039|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
214762040|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
214762041|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
214762042|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
214762043|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
214762044|NCT03165630|BEHAVIORAL|Transportation incentives|Free transportation only for the first 3 months post-discharge.
214762045|NCT03165630|BEHAVIORAL|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
214762046|NCT02342574|DRUG|F901318|Administration of active compound
214762047|NCT02342574|DRUG|Placebo|Administration of placebo
214762048|NCT06514586|DRUG|Oxytocin|Oxytocin gel 600 IU . 1mg/g
214762049|NCT06514586|OTHER|Hydroxypropyl methylcellulose|Placebo
214762050|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
214762051|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
214762052|NCT00976859|BEHAVIORAL|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
214762053|NCT00976859|BEHAVIORAL|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
214762054|NCT02384837|DEVICE|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
214762055|NCT05388032|BEHAVIORAL|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to \<2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
214762056|NCT03173807|BEHAVIORAL|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
214762057|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
214762058|NCT04651582|BEHAVIORAL|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
214762059|NCT04651582|BEHAVIORAL|Cognitive Stimulating Activities|20 hours of traditional computer games
214762060|NCT02414165|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
214762061|NCT02414165|DRUG|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
214762062|NCT02414165|DRUG|Lomustine|
214762063|NCT02414165|DRUG|Temozolomide|
214762064|NCT02414165|BIOLOGICAL|Bevacizumab|
214762065|NCT06098131|OTHER|Neurodynamic|Neurodynamic Slider and Tensioner Technique
214762066|NCT01644461|OTHER|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
214762067|NCT06563492|DEVICE|insole|evaluation of individuals using different insoles
214762068|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
214762069|NCT06698263|DRUG|Isotretinoin|ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
214762070|NCT06698263|DRUG|Control group (placebo)|placebo administration
214762071|NCT03681769|DEVICE|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
214762072|NCT03681769|DEVICE|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214762073|NCT03681769|DEVICE|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
214762074|NCT03681769|DEVICE|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214762075|NCT02705417|PROCEDURE|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
214762076|NCT02705417|PROCEDURE|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
214762077|NCT02705417|PROCEDURE|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
214762078|NCT02705417|PROCEDURE|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
214762079|NCT02705417|PROCEDURE|arteriovenous graft placement|surgical placement of arteriovenous graft
214762080|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
214762081|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
214762082|NCT00000254|DRUG|0.2% isoflurane|
214762083|NCT00000254|DRUG|0.4% isoflurane|
214762084|NCT00000254|DRUG|0.6% isoflurane|
214762085|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
214762086|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
214762087|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
214762088|NCT01637207|OTHER|Palpation|Group A: Palpation Group
214762089|NCT01637207|OTHER|Ultrasound|Group B: Ultrasound Group
214762090|NCT06566807|DRUG|Orelabrutinib, obinutuzumab|orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
214762091|NCT01888978|DRUG|Gem-OX|
214762092|NCT01888978|DRUG|Gem-5FU|
214762093|NCT01888978|DRUG|Gem-Tax|
214762094|NCT01888978|DRUG|Modified FOLFOX-6|
214762095|NCT01888978|DRUG|Ox-Tax|
214762096|NCT01888978|DRUG|FOLFIRI|
214762097|NCT01888978|DRUG|Tax-Iri|
214762098|NCT05341583|DRUG|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
214762099|NCT05341583|DRUG|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
214762100|NCT00003769|DRUG|perillyl alcohol|
214762101|NCT00003769|PROCEDURE|surgical procedure|
214762102|NCT02305329|DRUG|BIA 9-1067|
214762103|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
214762104|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
214762105|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
214762106|NCT06701448|DIAGNOSTIC_TEST|robotic bronchosopy|robotic bronchoscopy
214762107|NCT06701448|DIAGNOSTIC_TEST|Electromagnetic Navigation Bronchoscopy|Electromagnetic Navigation Bronchoscopy
214762108|NCT06701448|DIAGNOSTIC_TEST|Fluoroscopy bronchoscopy|Fluoroscopy bronchoscopy
214762109|NCT05674864|DRUG|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
214762110|NCT03722849|DRUG|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
214762111|NCT03722849|DRUG|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
214762112|NCT03722849|OTHER|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
214762113|NCT03962218|PROCEDURE|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
214762114|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
214762115|NCT01955031|OTHER|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
214794403|NCT02462538|DRUG|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
214762116|NCT01955031|OTHER|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
214762117|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
214762118|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
214762119|NCT02354352|DRUG|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
214762120|NCT02354352|DRUG|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
214762121|NCT05657964|DEVICE|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
214762122|NCT02885259|DRUG|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
214762123|NCT05211037|DIAGNOSTIC_TEST|Kidney function assessment|kidney clearance measured by scintigraphy
214794404|NCT06057519|DRUG|Optimised dose rifampicin|Optimized dose of rifampicin
214794405|NCT06057519|DRUG|Standard dose rifampicin|Standard dose rifampicin
214762124|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
214762125|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
214762126|NCT02495974|DRUG|enzalutamide|oral
214762127|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
214762128|NCT03354143|OTHER|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
214762129|NCT03354143|OTHER|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
214762130|NCT02437526|OTHER|Analytic treatment interruption|
214762131|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
214762132|NCT04328311|OTHER|Watermelon Juice|500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
214762133|NCT04328311|OTHER|Water|500 mL low nitrate water
214762134|NCT00160771|BEHAVIORAL|Joint Motion Analysis|Joint motion will be recorded for analysis.
214762135|NCT04973644|DEVICE|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
214762136|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
214762137|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
214762138|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
214762139|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
214762140|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
214762141|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
214762142|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
214762143|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
214762144|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
214762145|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
214762146|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
214762147|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
214762148|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
214762149|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
214762150|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
214762151|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
214762152|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
214762153|NCT04938869|OTHER|Survey Administration|Ancillary studies
214794406|NCT02162758|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules
214794407|NCT02162758|DRUG|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
214794408|NCT03467334|DIETARY_SUPPLEMENT|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
214794409|NCT03467334|DIETARY_SUPPLEMENT|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
214794410|NCT03467334|DRUG|Simethicone 20 MG|Standard treatment for infant colic
214762154|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
214762155|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214762156|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214762157|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
214762158|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
214762159|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1\) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
214762160|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
214762161|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
214762162|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
214762163|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
214762164|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
214762165|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
214762166|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
214762167|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
214762168|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
214762169|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
214762170|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
214762171|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
214762172|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
214762173|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
214762174|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
214762175|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
214762176|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
214762177|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
214762178|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
214762179|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
214762180|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
214762181|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
214762182|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
214762183|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
214762184|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
214762185|NCT04128059|OTHER|placebo|placebo
214762186|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
214762187|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
214762188|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
214762189|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
214762190|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
214762191|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
214762192|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
214762193|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
214762194|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
214762195|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
214762196|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
214762197|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
214762198|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
214762199|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
214762200|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
214762201|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
214762202|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
214762203|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
214762204|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
214762205|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
214762206|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
214762207|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
214762208|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
214762209|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
214762210|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
214762211|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
214762212|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
214762213|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
214762214|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
214762215|NCT00104962|DRUG|lenalidomide|Given orally
214762216|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
214762217|NCT03005262|DRUG|MLN8237|
214762218|NCT01975129|DRUG|Vagitocin|
214762219|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
214762220|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
214762221|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
214762222|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
214762223|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
214762224|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
214762225|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
214762226|NCT00062075|DRUG|romidepsin|Given IV
214762227|NCT01388101|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
214762228|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
214762229|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
214762230|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
214762231|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
214762232|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
214762233|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
214762234|NCT04688502|OTHER|High intensity interval training|High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
214762235|NCT04688502|OTHER|Continuous exercise training|5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
214762236|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
214762237|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
214762238|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
214762239|NCT01958593|DRUG|Placebo|Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
214762240|NCT01958593|DRUG|Midomafetamine HCl|Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
214762241|NCT01958593|BEHAVIORAL|Psychotherapy|Psychotherapy before and after experimental sessions.
214762242|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
214762243|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
214762244|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
214762245|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
214762246|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
214762247|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
214762248|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
214762249|NCT02553291|BEHAVIORAL|SystemCHANGE|
214762250|NCT02553291|BEHAVIORAL|Control|
214762251|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
214762252|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
214762253|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
214762254|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
214762255|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
214762256|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
214762257|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
214762258|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
214762259|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
214762260|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
214762261|NCT00040209|DRUG|JP 1730|
214762262|NCT00040209|DRUG|IV Levodopa|
214762263|NCT00040209|DRUG|IV Apomorphine|
214762264|NCT06650605|DRUG|123I-ATT001|123I-ATT001
214762265|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
214762266|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
214762267|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
214762268|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
214762269|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
214762270|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
214762271|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
214762272|NCT03689595|OTHER|Sample of Blood|Collection of blood sample from participants
214762273|NCT01912547|PROCEDURE|Blood draw for TEG analysis|Blood drawn for TEG analysis
214762274|NCT06505902|OTHER|Exercise|Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.
214762275|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
214794411|NCT03336541|DRUG|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
214762276|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
214762277|NCT02288650|OTHER|early refeeding|
214762278|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
214762279|NCT05967533|DRUG|Fermented Wheat Germ Extract|Given orally (PO)
214762280|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
214762281|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
214762282|NCT04593277|OTHER|Internet Mobile Technology|Use INSPIRE mobile application
214762283|NCT04593277|OTHER|Internet-Based Intervention|Access to a study-specific control website
214762284|NCT04593277|OTHER|Questionnaire Administration|Ancillary studies
214762285|NCT04593277|PROCEDURE|Supportive Care|Receive telehealth stepped care
214762286|NCT04593277|OTHER|Informational Intervention|Receive printed SCP materials
214762287|NCT06477354|DIETARY_SUPPLEMENT|ACEMg|Softgel capsules
214762288|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
214762289|NCT04373330|BEHAVIORAL|Intensive Lifestyle Intervention|There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
214762290|NCT05922033|DRUG|Patient-led Insulin (intervention group)|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
214762291|NCT05922033|DRUG|Provider-led Insulin (standard care)|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
214762292|NCT06222879|DRUG|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
214762293|NCT06222879|DRUG|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
214762294|NCT06222879|DRUG|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
214762295|NCT06490874|DEVICE|CGM device - Metformin group|Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
214762296|NCT06490874|DEVICE|CGM device - Insulin group|Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
214762297|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
214762298|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
214762299|NCT01355653|DEVICE|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
214762300|NCT01355653|DEVICE|ThermaCare heatwrap|heatwrap, topical, one time application, 8 hour duration
214762301|NCT05014672|DRUG|Setanaxib|Oral tablets, 400mg per tablet
214762302|NCT05014672|DRUG|Placebo|Oral tablets
214762303|NCT06431308|BEHAVIORAL|nutritional intervention|A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent . If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received.
214762304|NCT05662111|DRUG|Etidronate|The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.
214762305|NCT05662111|DRUG|Placebo|Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
214762306|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
214762307|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
214762308|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
214762309|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
214762310|NCT05631847|PROCEDURE|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
214762311|NCT05631847|DRUG|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
214762312|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
214762313|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
214762314|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
214762315|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
214762316|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
214762317|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
214762318|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
214762319|NCT05397847|BEHAVIORAL|Education|"Rational Drug Use in Elderly Individuals~1. Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~2. Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training."
214762320|NCT05397847|OTHER|Rational Drug Use Guide|At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
214762321|NCT05397847|OTHER|Medicine Box|Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
214762322|NCT05397847|BEHAVIORAL|Counseling|After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.
214762323|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
214762324|NCT04973007|DRUG|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
214762325|NCT04973007|DRUG|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
214762326|NCT05054725|DRUG|RMC-4630|RMC-4630 administered orally as a capsule
214762327|NCT05054725|DRUG|Sotorasib|Sotorasib administered orally as a tablet
214762328|NCT03093688|BIOLOGICAL|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
214762329|NCT06256484|DRUG|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
214762330|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
214762331|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
214762332|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
214762333|NCT00065169|DRUG|Celecoxib|
214762334|NCT06575244|OTHER|Community-based sailing|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
214762335|NCT06575244|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
214762336|NCT06277921|PROCEDURE|Elective Surgery for gastric cancer|Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
214762337|NCT06525623|OTHER|Recommendation: No Further Resuscitation|Treatment teams are encouraged not to administer any additional fluids
214762338|NCT06525623|OTHER|Recommendation: Resuscitation with Crystalloid|Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
214762339|NCT06525623|OTHER|Recommendation: Resuscitation with Colloid|Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
214762340|NCT06525623|OTHER|Recommendation: Standard of Care IV Albumin|Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
214762341|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
214762342|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
214762343|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
214762344|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
214762345|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
214762346|NCT02401724|OTHER|Transcranial direct current stimulation|
214762347|NCT02401724|OTHER|Action Training|
214762348|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
214762349|NCT03885401|BEHAVIORAL|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
214762350|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
214762351|NCT03287154|DEVICE|Active tDCS stimulations|20 min, 2mA
214762352|NCT03287154|DEVICE|Sham tDCS|20 min, Sham
214762353|NCT06975189|DEVICE|Lung ultrasound group|Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.
214762354|NCT06975189|DIAGNOSTIC_TEST|Standard Care|Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.
214762355|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
214762356|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
214762357|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
214762358|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
214762359|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
214762360|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
214762361|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
214762362|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
214762363|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
214762364|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
214762365|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
214762366|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
214762367|NCT05534646|DRUG|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
214762368|NCT05534646|DRUG|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
214762369|NCT03860038|DRUG|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
214762370|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
214762371|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
214762372|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
214762373|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
214762374|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
214762375|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
214762376|NCT00308230|PROCEDURE|Six minute walk test|
214762377|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
214762378|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
214762379|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
214762380|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
214762381|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
214762382|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
214762383|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
214762384|NCT06995352|DRUG|Popliteal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
214762385|NCT06995352|DRUG|Adductor canal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
214762386|NCT06995352|DRUG|Continuous popliteal nerve block with normal saline|A perineurial infusion of normal saline (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
214762387|NCT06995352|DRUG|Popliteal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
214762388|NCT06995352|DRUG|Adductor canal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
214762389|NCT06995352|DRUG|Continuous popliteal nerve block with unencapsulated bupivacaine|A perineurial infusion of unencapsulated bupivacaine 0.125% (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
214762390|NCT06674629|DEVICE|High flow oxygen therapy|Application of high flow oxygen therapy through asymmetric cannula at 40 and 60 L/m
214762391|NCT07000409|OTHER|Medical management regimen|Patients will receive the standard medical regimen alone.
214762392|NCT07000409|OTHER|Erector spinae plane (ESP) block|Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.
214762393|NCT06669585|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
214762394|NCT07000656|DEVICE|Micturition Desire-Relaxation Training Device|The device was developed by Shanghai Children's Medical Center in collaboration with Shanghai University of Engineering Science. It plays relaxation videos through a VR device and monitors the subjects' brain waves in real time using electroencephalography to evaluate their relaxation levels. The relaxation material is adjusted accordingly, and urination is recorded after training. Urine is collected and analyzed with a flow meter, generating a diagnostic report.
214762395|NCT07000656|DEVICE|Sham device|Participants diagnosed with nocturnal enuresis, daytime urinary incontinence, and urinary frequency will be screened at Shanghai Children's Medical Center, and eligible patients will be recruited. Participants will be randomly assigned to the sham training group, in which they will wear the device without powering it on for 10 minutes each session, 5-10 times a day, for 4 weeks.
214762396|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
214762397|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
214762398|NCT03313297|DRUG|Placebo|Matching placebo
214762399|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
214762400|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
214762401|NCT07005609|DIETARY_SUPPLEMENT|Snakehead fish meal|Subjects in the treatment group received snakehead fish meal daily for about 3 months until delivery. The meal contained carbohydrate, protein, vegetables and fruits. Snakehead fish was given +- 100 g per serving.
214762402|NCT07005830|BEHAVIORAL|Twin Hearts Meditation|Twin Hearts Meditation (THM) is a 21-minute guided meditation practice developed by Master Choa Kok Sui as part of Pranic Healing \& Arhatic Yoga (Sui, 2005).
214762403|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
214762404|NCT07005622|OTHER|O2 Trainer|The O2 Trainer uses varying caps to limit airflow during inspiration.
214762405|NCT07005622|OTHER|Deep breathing|Comparator/placebo for the control group
214762406|NCT07006285|OTHER|Measure of T2 biomarkers|"T2 Biomarkers are estimated via induced sputum:~Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution.~Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge"
214762407|NCT06365424|DRUG|Fenofibrate|Fenofibrate (200 mg/day)
214762408|NCT06365424|DRUG|UDCA|Ursodeoxycholic acid (13-15 mg/kg/day)
214762409|NCT07028983|BEHAVIORAL|Active Music Group (AMG)|Active music group is a music therapy intervention where participants actively make/play music in groups. The sessions will be conducted by an appropriately qualified music therapist.
214762410|NCT07028983|BEHAVIORAL|Music Listening Group (MLG)|Music listening group is a music therapy intervention where participants partake in music listening in groups. The sessions will be conducted by an appropriately qualified music therapist.
214762411|NCT07028983|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as provided locally, which may include pharmacological and/or non-pharmacological interventions (e.g. mindfulness-based intervention, structured physical activity).
214762412|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
214762413|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
214762414|NCT07028463|BEHAVIORAL|ALERT-ED|Patient receives link to the Livi Chatbot in After Visit Summary
214762415|NCT06702228|DIAGNOSTIC_TEST|Six minute walk test (6MWT)|Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
214762416|NCT06702228|DIAGNOSTIC_TEST|Computer-tomography of the thorax (CT Thorax)|Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
214762417|NCT06702228|OTHER|Quality of life questionnaires.|Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
214762418|NCT06702228|DIAGNOSTIC_TEST|Genetic Testing|10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
214762419|NCT06702228|DIAGNOSTIC_TEST|Spirometry|We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
214762420|NCT06702228|DIAGNOSTIC_TEST|Serology|Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
214762421|NCT06702228|OTHER|Other Quality of Life Questionnaires|Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months
214762422|NCT06702228|OTHER|PatientMPower Home Monitoring App|Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
214762423|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
214762424|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
214762425|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
214762426|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
214762427|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
214762428|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
214762429|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
214762430|NCT06429800|DRUG|ATA3219|ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
214762431|NCT07040969|DRUG|Spray of spirulina derivatives|An oral spray formulated with purified spirulina-derived exosomes.
214762432|NCT07040969|DRUG|Spray of placebo|The placebo oral spray will be formulated with inactive ingredients matched in appearance and flavor profile to the active spirulina-derived product.
214762433|NCT07040969|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
214762434|NCT06713746|DIAGNOSTIC_TEST|growth differentiation factor 15|rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
214762435|NCT06722703|PROCEDURE|shock wave lithotripsy|Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.
214762436|NCT06722703|PROCEDURE|Flexible ureteroscope lithotripsy|All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
214762437|NCT06724146|DEVICE|Sofwave and Pure Impact|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated."
214762438|NCT06723990|DRUG|Neoadjuvant standard treatment for HER2+|NEOADJUVANT SETTING
214762439|NCT06723990|DRUG|Adjuvant standard treatment for HER2+|ADJUVANT SETTING
214762440|NCT06185335|GENETIC|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
214762441|NCT06185335|GENETIC|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
214762442|NCT06185335|GENETIC|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
214762443|NCT07044115|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
214762444|NCT07044115|DRUG|placebo|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
214762445|NCT06723249|DIETARY_SUPPLEMENT|stingless bee honey|Participants under intervention group will receive 20g of stingless bee honey in a packet form but participants under control group will not receive any stingless bee honey
214762446|NCT07048080|BEHAVIORAL|(P)rehabilitation Progresive Resistance Exercise Training|The (p)rehabilitation intervention program will be based on supervised whole-body RET performed 3 times/week before (2-week) and up to 12 weeks after surgery, with one day in-between sessions. Training will consist of a 10-min warm-up, followed by one warm-up and 4 sets on leg press, leg-extension and leg abductor machines. Upper body exercises (chest press, lat pulldown and horizontal row will be performed with 2 sets of each exercise. During the 2-week training before surgery, the workload will be increased from 70% (week 1) to 80% (week 2) of 1RM (10 repetitions in each set). After surgery, the workload will be increasing from 50% of 1RM to 80% from the last 6 weeks. All the participants included in the per-protocol analysis must complete at least 80% of the training sessions. We will take into consideration the mobility precautions so as not to dislocate the prosthesis (avoid hip flexion of 90 degrees and more; do not perform adduction exercises and hip rotations).
214762447|NCT07048080|BIOLOGICAL|Prehabilitation Group Deuterated Water|In a sub-study, the first 10 participants of the (P)rehabilitation group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of prehabilitation.
214762448|NCT07048080|BIOLOGICAL|Usual Care Group Deuterated Water|In a sub-study, the first 10 participants of the Usual Care group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of usual care.
214762449|NCT07048080|OTHER|Usual Care|Participants assigned to the usual care group will receive the usual therapy, medical monitoring, and educational lectures after surgery. No intervention is planned before total hip replacement surgery. The patient is hospitalized for surgery. At hospital discharge, the usual care group will start with standard rehabilitation (sessions: 1st month, 2-3x/week, 2nd month 1-2x/week and 3rd month 1x/month) based on mobility and strength exercises without using progressive RET with machines until 3 months after surgery.
214762450|NCT07046832|DEVICE|Augmented Reality Guided Biopsy|Augmented Reality system in adjunct to standard of care guidance for needle guidance during a percutaneous biopsy
214762451|NCT07046832|DEVICE|Ultrasound Guided Biopsy|Ultrasound guided biopsy as a part of standard of care.
214762452|NCT07044934|OTHER|No Intervention: Observational Cohort|This observational cohort includes female patients undergoing non-cardiac surgery. No intervention was administered as part of the study protocol. Preoperative serum uric acid levels were measured, and patients were followed for the development of postoperative acute kidney injury. Data were analyzed retrospectively to assess the association between uric acid levels and acute kidney injury, with subgroup analyses based on menopausal status (premenopausal vs. postmenopausal women).
214762453|NCT04595422|OTHER|Educational Intervention|Undergo training consisting of a 60-minute educational session
214762454|NCT04595422|OTHER|Educational Intervention|Receive lung cancer screening educational materials
214762455|NCT04595422|OTHER|Questionnaire Administration|Complete questionnaire
214762456|NCT04595422|OTHER|Survey Administration|Ancillary studies
214762457|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
214762458|NCT07048548|BEHAVIORAL|Thyroid Function Monitoring|This study will include healthcare professionals from the radiology and nuclear medicine departments at INMOL Cancer Hospital with at least one year of radiation exposure. A total of 44 participants will be selected through purposive sampling. Data will be collected using a structured questionnaire and blood tests for thyroid hormones (TSH, T3, T4) to assess thyroid function. Blood analysis will be conducted using CLIA or ELISA methods. The aim is to detect any association between low-dose radiation exposure and thyroid dysfunction.
214762459|NCT07048054|DRUG|TrophiPatch: allogeneic adipose-derived stromal cell patch|Topical application of an allogeneic adipose-derived stromal cell patch
214762460|NCT07047469|PROCEDURE|Group (1): spinal anesthesia with median approach|patients undergoing orthopedic surgery will receive spinal anesthesia with median approach under ultrasound guided techniques
214762461|NCT07047469|PROCEDURE|Group (2): spinal anesthesia with paramedian approach|patients undergoing orthopedic surgery will receive spinal anesthesia with paramedian approach under ultrasound guided techniques
214762462|NCT05131828|DRUG|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
214762463|NCT05131828|DRUG|Placebo|Placebo tablets to match both metformin and clemastine tablets.
214762464|NCT06896968|BEHAVIORAL|Earthquake Preparedness and Awareness Training|Earthquake Preparedness and Awareness Training + standard education
214762465|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
214762466|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
214762467|NCT06828380|RADIATION|Particle beam radiation therapy|The prescribed dose and fractionation for proton therapy to the PTV will be determined by the physician, taking into account the dose-volume constraints of normal tissues such as the liver and bowel.
214762468|NCT06861452|DRUG|RR001|RR001, a cell-based gene therapy administered following administration of chemotherapy (Nab-PTX 125 mg/mq and GEM 1000 mg/mq)
214762469|NCT04299646|RADIATION|Steretactic radiotherapy|Steretactic radiotherapy
214762470|NCT06821204|OTHER|Health education group|Participants will be given one session (40 minutes) of training on the definition and importance of hygiene, the rules and importance of hand washing, the importance of cleaning make-up materials, which method, material and how often they should be cleaned, and the health risks that may occur if they are not cleaned.
214762471|NCT06821204|OTHER|control group|No intervention will be applied to participants in this group.
214762472|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
214762473|NCT06898281|PROCEDURE|intracardiac echocardiography (ICE)-guided catheter ablation|Intracardiac echocardiography (ICE)-guided catheter ablation.
214762474|NCT06898281|PROCEDURE|Pressure-sensing catheter ablation alone|Pressure-sensing catheter ablation alone
214762475|NCT06904300|DRUG|AK112 + paclitaxel|AK112 (20 mg/kg IV, D1/D15) + paclitaxel (80 mg/m² IV, D1/D8/D15), Q4W
214762476|NCT06904300|DRUG|Paclitaxel ± ramucirumab|Paclitaxel (80 mg/m² IV, D1/D8/D15) ± ramucirumab (8 mg/kg IV, D1/D15), Q4W
214762477|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
214762478|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
214762479|NCT06853626|DIAGNOSTIC_TEST|QuidelOrthos TriageTrue hs-cTnI whole-blood assay|Already described
214762480|NCT06902285|DRUG|Magnesium Threonate|Participants will receive a daily 145 mg pill by mouth 30 minutes before going to sleep
214762481|NCT06902285|OTHER|Control|Participants will receive two sugar pills daily by mouth 30 minutes before going to sleep
214762482|NCT06905691|OTHER|Conventional Training|Patients will execute the concentric and eccentric phases unilaterally, maintaining consistent load levels, with each phase lasting 2 seconds.
214762483|NCT06905691|OTHER|Eccentric Training|The concentric phase will be performed bilaterally in approximately 1 second, followed by the unilateral eccentric phase lasting approximately 3 seconds.
214762484|NCT04960280|DEVICE|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
214762485|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
214762486|NCT06440005|DRUG|AGX101|Antibody Drug Conjugate
214762487|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
214762488|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
214762489|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure and videos containing information about mental health problems.
214762490|NCT06909539|DEVICE|Home Pelvic Floor Trainer|"The intervention utilizes a perineometer device with biofeedback features.~This device employs external electrodes to measure pelvic floor muscle strength. It then provides real-time feedback through a smartphone application during exercise sessions. The application uses gamification to engage users and track progress. Patients can choose between two games: a bird game or a space-themed game. In the bird game, patients activate their pelvic floor muscles to make the bird fly upward. In the space game, pelvic floor contractions fire a laser or activate a shield. A visual bar displays the strength of pelvic floor contractions. Games are designed to be played for 5 minutes daily, 7 days a week, with increasing difficulty as the user progresses through levels."
214762491|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen)|"Combination of two procedures Preoxygenation prior to intubation with NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen).~During intubation, NIV is stopped and apneic oxygenation is maintained with HFNO"
214762492|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation)|Single procedure Preoxygenation prior to intubation with NIV (Non Invasive Ventilation).
214762493|NCT06029517|OTHER|Education Intervention|Receive Indigneous SIPin intervention
214762494|NCT06029517|OTHER|Interview|Complete interviews
214762495|NCT06029517|PROCEDURE|Discussion|Attend focus groups
214762496|NCT06910605|DRUG|"drug holidays (D)"|Participants omit three consecutive daily doses of ADHD-medication (stimulant).
214762497|NCT06929988|OTHER|Creanz Lotion|"Mode of Usage: Apply sufficient quantity of Creanz Nourishing Body lotion to face and body for smooth and moisturised skin.~Frequency: Twice a Day Route of Administration: Topical"
214762498|NCT06933225|OTHER|WOW fusion Microneedling Device, 1.00 mm|One treatment session on the whole face, on D0 and second treatment on D30.
214762499|NCT06935877|DRUG|Hyaluronic acid injection|traditional rehabilitation programs
214762500|NCT06935877|DRUG|Triamcinolone Acetonide injection|traditional rehabilitation programs
214762501|NCT06937242|DEVICE|Ottobock C-Leg 4 Microprocessor Knee|Subjects in the intervention group who can walk more than 0.83m/s in the 2-minute walk test (2MWT) will receive the Ottobock C-Leg 4, a stance-and-swing microprocessor knee.
214762502|NCT06937242|DEVICE|Ottobock Kenevo|Subjects in the intervention group who can walk up to 0.83m/s (3km/hr) in the 2-minute walk test (2MWT) will receive the Kenevo, a stance-only microprocessor knee.
214762503|NCT06943131|OTHER|YWTL EXERCISES|YWTL exercises are shoulder and upper back exercises to improve posture, strengthen upper back. Each letter represents different arm position that copies shape of letter.
214762504|NCT06943131|OTHER|Closed kinetic chain exercises|Closed kinetic chain exercises include corner stretch hold, sleeper stretch hold - lawn mover and robbery maneuver, Scapula clock exercises, wall wash. Low row exercise maneuver, Scapular stabilization of Black burn exercises, press up, push up.
214762505|NCT06936579|DEVICE|proprioceptive stimulation|"Condition without proprioceptive stimulation: Participants will not receive the stimulus, and MEP activity will be recorded under the same motor cortex stimulation conditions.~Condition with proprioceptive stimulation 1: Participants will receive proprioceptive stimulation through the output plunger, applied continuously for 15 seconds, with 20-second rest intervals, over a total duration of 5 minutes. MEP activity will then be recorded via motor cortex stimulation.~Condition with proprioceptive stimulation 2: Participants will receive proprioceptive stimulation continuously during the application of TMS pulses while MEP activity is recorded."
214762506|NCT06940804|BIOLOGICAL|CLDN6 CAR-T|Intravenous (IV) infusion
214762507|NCT06940804|BIOLOGICAL|CLDN6 RNA-LPX|IV injection
214762508|NCT06942442|DRUG|Physician's Choice|Patients who are HLA-A\*02:01-negative and ineligible to receive tebentafusp will be prospectively enrolled onto a separate study arm and treated with physicians' choice of treatment. They will also be radiographically assessed at the same schedule as patients treated with tebentafusp, if feasible, and kept on this treatment arm until progression of disease or unacceptable toxicity on the physicians' choice regimen.
214762509|NCT06942442|DRUG|Tebentafusp|Patients who screen positive for HLA-A\*02:01 and meet the eligibility requirements will be treated with weekly tebentafusp
214794412|NCT03336541|DRUG|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
214794413|NCT03356613|OTHER|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
214762510|NCT06942559|DEVICE|EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation.~500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5 ms inter-pulse interval will be applied at an average inter-burst interval of 2 s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
214762511|NCT06942559|DEVICE|Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot.~High-frequency rTMS consisting of 50 trains at 20 Hz (2 s on, 18 s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
214762512|NCT06943079|DEVICE|Effect of Hold Relax technique with Blood Flow Restriction technique on functional outcome|Participants are randomly allocated to group A through computerised generated method. The both combine intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
214762513|NCT06943079|OTHER|Effect of Hold Relax technique without Blood Flow Restriction technique on functional outcomes|Participants are randomly allocated to group B through computerised generated method. The intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
214762514|NCT06943261|OTHER|task oriented training|The 8-week intervention program targets fine motor and functional play skills in children through progressive weekly activities. Week 1 focuses on eye-hand coordination (e.g., stacking blocks, bead stringing), followed by grasp and release control in Week 2 (e.g., object transfer tasks). Week 3 enhances reaching and precision (e.g., targeting and catching), while Week 4 develops bilateral coordination (e.g., buttoning, tearing paper). Week 5 works on visual-motor planning (e.g., drawing, tracing), and Week 6 encourages daily functional play (e.g., pouring, pretend cooking). Week 7 combines skills (e.g., dressing a doll, coin placement), and Week 8 consolidates learning through review and practice of previous tasks.
214762515|NCT06943261|OTHER|conventional therapy|The control group will receive standard physical therapy consisting of general exercises aimed at improving overall strength, flexibility, and gross motor skills, without specifically targeting visual-motor integration or fine motor skills. Sessions will also include non-specific recreational activities such as free play or unstructured tasks. The intervention will be conducted three times per week, with each session lasting 45-60 minutes, over a total duration of 8 weeks.
214762516|NCT06943274|OTHER|Standardized Walking Course Activities|"A randomized controlled trial investigate the effect of a standard walking obstacle course on balance, gait and endurance in children with ASD. Activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces.~* Balance activities~* Gait activities~* Endurance activities Start with easier task and end with difficulties. SWOC activities performs 2 to 3 times a week for 4weeks."
214762517|NCT06943274|OTHER|Common Physical Activities|Either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running, climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy.
214762518|NCT06942169|BEHAVIORAL|Mindfulness-Based Self-Compassion Training|Mindfulness-Based Self-Compassion Training is a very comprehensive approach that addresses the awareness and acceptance of individuals towards their bodies, as well as encouraging them to live a conscious life. Studies found that self-compassion increases well-being during menopause (Brown, 2015; Arab et al., 2020). Psychiatric nursing is a special field that works to evaluate, diagnose, and enhance mental health in every area where people are present.
214762519|NCT06941883|DRUG|Botulinum toxin injection under anatomical landmark|Patients received botulinum toxin injections under the anatomical landmark.
214762520|NCT06941883|DRUG|Ultrasound-guided botulinum toxin injection|Patients received ultrasound-guided botulinum toxin injection
214762521|NCT06941896|DEVICE|Use of the Atalante Exoskeleton|"Assisted verticalization (sit-to-stand transition)~Orthostatic stabilization (unsupported standing posture)~Assisted locomotion (stabilized walking)"
214762522|NCT06941805|DIAGNOSTIC_TEST|Physical Fitness|Physical fitness levels of blue- and white-collar university workers were measured and compared.
214762523|NCT06941805|DIAGNOSTIC_TEST|Physical activity|Weekly physical activity levels of blue- and white-collar university workers were measured and compared.
214762524|NCT06938698|OTHER|PROM collection|PROM collection using a digital health web application. PROMs will be based on the HF Standard Set created by the International Consortium of Health Outcomes Measurements (ICHOM), adapted to the patient follow-up protocol already in use by GEstIC. Half the participants will complete the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and the other half will complete the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
214762525|NCT06943391|DEVICE|laser|patients subjected to a tooth extraction and immediately given an intraoral PBM session with an EPIC X Biolase diode laser (BIOLASE, Inc. USA), with a voltage of 100-240 V, 1.5 A, a power of 0.5 W, and an application of an energy of 15J per cm², for 10-30 seconds at 1 mm of the tissue with an sterile surgical tip. It was applied at three points in the area: buccal, pala-tal/lingual, and occlusal to stimulate the tissue.
214762526|NCT06943352|OTHER|Sensory Bins|The sensory bin is a basket filled with different objects of different shapes, sizes, and textures.
214762527|NCT06943352|OTHER|Drawing and Painting|Colored pencils and watercolors will be used.
214762528|NCT06942663|OTHER|Surveillance|Close monitoring for disease recurrence.
214762529|NCT06942663|DRUG|Adjuvant Chemotherapy|The adjuvant chemotherapy regimen will be standardized based on current clinical guidelines and may include combinations of agents such as fluoropyrimidines and oxaliplatin with or without docetaxel. Treatment until the progression of the process is detected or the maximum effect of therapy is achieved (the maximum duration of treatment is 3 months).
214762530|NCT06943651|DEVICE|HealthyW8 Digital Twin of healthy lifestyle recommendations|The applied intervention with the developed healthy lifestyle recommender system will be unique and is not used in any other clinical study. However, a large number of intervention studies on young adults' obesity, considering nudging (e.g. 60 in www.clinical.trials.gov), were found. Among the registered clinical trials in the referred database, 3 considered young adults obesity and saliva salivary analysis, but with a different purpose. Moreover, the type of digital solution that will be tested will put together different aspects that are not usually to see together in the same application. These different lifestyle aspects will be used for personalized recommendations.
214762531|NCT06942013|DEVICE|Computer-Guided Autogenous Cortical Shell Technique (Study Group)|"This study utilizes two patient-specific 3D-printed surgical guides to enhance precision in bone harvesting and fixation for horizontal ridge augmentation in the anterior mandible.~Chin Harvesting Guide~This tooth-supported guide is placed on the exposed mandibular symphysis to ensure accurate osteotomy cuts for harvesting a cortical bone shell.~It directs piezo drill cuts (superior, inferior, and vertical) to minimize errors and prevent damage to vital structures.~Bone Block Fixation Guide~After harvesting, this guide helps in precise fixation of the cortical shell onto the recipient site.~It includes pre-planned screw holes to ensure stable positioning of the graft and improve surgical accuracy.~These guides enhance precision, reduce surgical time, and improve graft stability, making the computer-guided technique superior to the traditional free-hand method."
214762532|NCT06942013|PROCEDURE|Free-Hand Autogenous Cortical Shell Technique (Control group)|In this group, horizontal ridge augmentation of the anterior mandible is performed using a free-hand technique without computer-guided assistance. Autogenous cortical bone is harvested from the mandibular symphysis using a conventional osteotomy performed manually. The harvested cortical shell is adapted and fixated at the recipient site using titanium mini screws, based on the surgeon's clinical judgment and intraoperative assessment. Bone particulate grafting using a 1:1 ratio of autogenous bone and xenograft material is packed into the defect to enhance volume stability. This approach may result in increased variability in graft positioning, longer surgical time, and higher dependence on surgeon experience.
214762533|NCT06941649|PROCEDURE|Expansive open-door laminoplasty via intermuscular space approach|The cervical laminoplasty via intermuscular space approach will apply bilateral blunt dissection to create the operative space between capital semispinalis muscle and cervical semispinalis muscle
214762534|NCT06941649|PROCEDURE|cervical single-door laminoplasty via the conventional approach|The cervical laminoplasty via the conventional approach will apply median dissection of the cervical spinous ligament and seperate muscles to expose the whole lamina of cervical vertebrae.
214762535|NCT06941870|DRUG|Efanesoctocog alfa|Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous
214794414|NCT03356613|OTHER|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
214794415|NCT04471935|DEVICE|At home Speech Hero therapy app|Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
214794416|NCT02368613|DRUG|DW-3102|
214762536|NCT06955936|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoadsorption. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The therapy will be performed once no later than 4 hours after the diagnosis of cardiogenic shock.~The duration of hemoadsorption is from 4 to 12 hours. The rate of hemoadsorption is from 80 to 150 ml/min. Anticoagulation is systemic (heparin or sodium citrate)."
214762537|NCT05442190|DRUG|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
214762538|NCT05442190|DRUG|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
214762539|NCT04633824|OTHER|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
214762540|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
214762541|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
214762542|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
214762543|NCT05643651|DRUG|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
214762544|NCT05643651|DRUG|Aspirin or Clopidogrel|Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[1.0 mg/kg; once daily\]
214762545|NCT05643651|DRUG|Warfarin|Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
214762546|NCT06060314|PROCEDURE|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
214762547|NCT06060314|PROCEDURE|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
214762548|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
214762549|NCT05610813|DRUG|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
214762550|NCT05610813|DRUG|Opioid therapy|The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
214762551|NCT02871466|DRUG|stem cells infusion|
214762552|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
214762553|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
214762554|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
214762555|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
214762556|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
214762557|NCT03923907|BEHAVIORAL|EIM intervention group|As in arm description
214762558|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
214762559|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
214762560|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
214762561|NCT01970423|DEVICE|conventional right ventricular stimulation|
214762562|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
214762563|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
214762564|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
214762565|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
214762566|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
214762567|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
214762568|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
214762569|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
214762570|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
214762571|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
214762572|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
214762573|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
214762574|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
214762575|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
214762576|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
214762577|NCT00246675|DRUG|Frusemide|
214762578|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
214762579|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
214762580|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
214762581|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
214762582|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
214762583|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
214762584|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
214762585|NCT02881866|DRUG|Furosemide|
214762586|NCT02881866|DRUG|Saline|
214762587|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
214762588|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
214762589|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
214762590|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
214762591|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
214762592|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
214762593|NCT02524366|DEVICE|Artificial Urinary Sphincter|
214762594|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
214762595|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
214762596|NCT04928625|DRUG|SHR-A1904|SHR-A1904
214762597|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
214762598|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
214762599|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
214762600|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
214762601|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
214762602|NCT01807780|BIOLOGICAL|biological monitoring|
214762603|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
214762604|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
214762605|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
214762606|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
214762607|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
214762608|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
214762609|NCT02157181|DRUG|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
214762610|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
214762611|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
214762612|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
214762613|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
214762614|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
214762615|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
214762616|NCT00243672|DRUG|Atorvastatin|
214762617|NCT00243672|DRUG|Gemfibrozil|
214762618|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
214762619|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
214762620|NCT03361332|OTHER|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
214762621|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
214762622|NCT05557968|OTHER|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
214762623|NCT05557968|OTHER|Action Observation Therapy (AO)|"The video consists of :~1. Ascending and descending the step box.~2. Ascending and descending the stairs in the treatment room.~3. Holding the handrails to climb and descend the stairs inside and outside the building.~4. Climbing and descending the stairs inside and outside the building without holding the handle.~5. Climbing and descending the sidewalk block"
214762624|NCT06346080|OTHER|Survey|Discrete choice survey
214762625|NCT04029766|DRUG|HSK3486|
214762626|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
214762627|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
214762628|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
214762629|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
214762630|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
214762631|NCT02070367|OTHER|Somatosensory rehabilitation|
214762632|NCT02070367|OTHER|Usual treatment: physiotherapy|
214762633|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
214762634|NCT00685763|RADIATION|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
214762635|NCT06701916|BEHAVIORAL|Intervention group.|The intervention will be carried out by a multidisciplinary team composed of nurses, doctors, social workers, and psychologists from each hospital. Through this intervention, a narrative from the patients will be obtained regarding their goals, desires, capabilities, and resources related to their health situation. A health plan will be jointly created, reflecting both short- and long-term objectives, identifying the resources available to the person and within their immediate environment, and outlining how they want and expect to receive support from healthcare professionals.
214762636|NCT06701916|BEHAVIORAL|Usual care|Usual care for the outpatient management of Chronic Heart Failure.
214794417|NCT06274606|OTHER|Exercise Group|Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
214762637|NCT04602208|PROCEDURE|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
214762638|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
214762639|NCT02306018|DEVICE|EV1000™/volumeView™|
214762640|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
214762641|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
214762642|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
214762643|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
214762644|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
214762645|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
214762646|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
214762647|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
214762648|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
214762649|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
214762650|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
214762651|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
214762652|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
214762653|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
214762654|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
214762655|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
214762656|NCT01853969|OTHER|Typing assessment|
214762657|NCT05286580|BEHAVIORAL|Morbidity and mortality conference toolkit|"* Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form"
214762658|NCT05984329|OTHER|Retrospective analysis of patients' choice|Retrospective analysis of patients' choice of tonic or Burst DR(TM) waves for their analgesic effect.
214762659|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
214762660|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
214762661|NCT00027573|BIOLOGICAL|filgrastim|
214762662|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214762663|NCT00027573|DRUG|cyclophosphamide|
214762664|NCT00027573|DRUG|fludarabine phosphate|
214762665|NCT00027573|DRUG|methotrexate|
214762666|NCT00027573|DRUG|tacrolimus|
214762667|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
214762668|NCT06537531|OTHER|Compare VCI scale|Compare VCI scale
214762669|NCT01205373|DRUG|BI 671800|High dose oral drinking solution
214762670|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
214762671|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1\) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
214762672|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
214762673|NCT01262274|DRUG|Anastrozole|ANA is given 1mg daily for 24 weeks.
214762674|NCT01262274|DRUG|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
214762675|NCT00216073|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
214762676|NCT00216073|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
214762677|NCT00216073|DRUG|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
214762678|NCT03818867|PROCEDURE|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
214762679|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
214762680|NCT04485624|OTHER|No intervention|Observational study
214762681|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
214762682|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
214762683|NCT06613412|DIAGNOSTIC_TEST|Remote Robotic Bronchoscopy system|Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
214762684|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
214762685|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
214762686|NCT03109613|DEVICE|Positive end-expiratory pressure (PEEP)|level changes as per arm description
214762687|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
214762688|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
214762689|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
214762690|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
214762691|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
214762692|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
214762693|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
214762694|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
214762695|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
214762696|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
214762697|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
214762698|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
214762699|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
214762700|NCT05905874|OTHER|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
214762701|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
214762702|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
214762703|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
214762704|NCT03891732|DIAGNOSTIC_TEST|MRI prostate|plain biparametric MRI prostate
214762705|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
214762706|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
214762707|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
214762708|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214762709|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214762710|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214762711|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214762712|NCT06101251|BEHAVIORAL|Driving Tips|Each week participants will receive a safe driving tip for one of the four behaviors via text message.
214762713|NCT06101251|BEHAVIORAL|Standard Feedback|Each week participants will receive a text message showing their overall driving score (out of 100) and subscores for distraction, hard braking, fast acceleration, and speeding (all running averages). The scoreboard will indicate whether their scores have gone up, down, or stayed the same. The message will include a link to a dashboard.
214762714|NCT06101251|BEHAVIORAL|Assigned Focus Area Feedback|Each week feedback will focus the participant's attention on the driving behavior with the greatest opportunity for improvement based on their baseline driving behavior. Participants will be assigned a goal for the week of a score 5 points (3 points in the case of Driver Focus) better than their baseline for that area. If they meet the goal, they will be given a new goal 5 points higher; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be assigned a new behavior to focus on.
214762715|NCT06101251|BEHAVIORAL|Study Dashboard (Standard)|By clicking the link in the feedback text, they will be able to view a weekly dashboard that provides detailed information about their baseline, best, last, and average scores for each of the four behaviors, plus descriptions of the four behaviors.
214762716|NCT06101251|BEHAVIORAL|Study Dashboard (focused)|Same as standard study dashboard, except participants will see at the top of the dashboard how well they are doing relative to their weekly goals.
214762717|NCT06101251|BEHAVIORAL|UBI-like Behavioral Incentive|At the end of the 12-week intervention period, their overall driving score will be translated into a $0-$100 reward amount. For example, a participant with an overall driving score of 84 at the end of the intervention period would receive $84 in compensation.
214762718|NCT06101251|BEHAVIORAL|Sef-Chosen Focus Area Feedback|Participants will be asked to select which driving behavior they want to focus on improving, and to set a goal for the week that is above their baseline score. If they meet the goal, they will be asked to set a new, higher goal; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be asked if they want to focus on a new behavior.
214762719|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
214762720|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
214762721|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
214762722|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
214762723|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
214762724|NCT00471237|DRUG|Teriparatide|PTH (1-34)
214762725|NCT00471237|DRUG|Alendronate|Bisphosphonate
214762726|NCT00373282|DRUG|Triamcinolone acetonide|
214762727|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
214762728|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
214762729|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
214762730|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
214762731|NCT01510704|DRUG|APD421|IV
214762732|NCT01510704|DRUG|Placebo|IV
214762733|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
214762734|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
214762735|NCT02208518|DEVICE|EUS-elastography|
214762736|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
214762737|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
214762738|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
214762739|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
214762740|NCT02763410|OTHER|PRBC transfusion|
214762741|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
214762742|NCT00802295|DRUG|Low dosis Gonadotrophin|
214762743|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
214762744|NCT01387958|DRUG|LCQ908|
214762745|NCT01387958|DRUG|Placebo|
214762746|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
214762747|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
214762748|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
214762749|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
214762750|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
214762751|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
214762752|NCT00051766|BEHAVIORAL|Computer-based Intervention|
214762753|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
214762754|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
214762755|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
214762756|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
214762757|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
214762758|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
214762759|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
214762760|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
214762761|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
214762762|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
214762763|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
214762764|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
214762765|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
214762766|NCT03204006|DRUG|sterile saline|normal saline preinduction
214762767|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
214762768|NCT01283659|OTHER|Standard Imaging|
214762769|NCT01283659|OTHER|Advanced Imaging|
214762770|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
214762771|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
214762772|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
214762773|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
214762774|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
214762775|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
214762776|NCT02966366|DEVICE|Cochlear implant|
214762777|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
214762778|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
214762779|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
214762780|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
214762781|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
214762782|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
214762783|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
214762784|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
214762785|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
214762786|NCT00286936|DRUG|Zolpidem|
214762787|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
214762788|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
214762789|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
214762790|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
214762791|NCT02766959|OTHER|Observational study|
214762792|NCT02217397|DEVICE|OA, CPAP, combination therapy|
214762793|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
214762794|NCT00557700|DRUG|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
214762795|NCT00557700|DRUG|Administration of placebo|Administration of placebo
214762796|NCT00021476|BEHAVIORAL|Behavioral treatments|
214762797|NCT00021476|BEHAVIORAL|Physical therapy|
214762798|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
214762799|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
214762800|NCT03813160|DRUG|Lenabasum 20 mg|oral capsule
214762801|NCT03813160|DRUG|Lenabasum 5 mg|oral capsule
214762802|NCT03813160|DRUG|Placebo|oral capsule
214762803|NCT00004646|DRUG|prednisone|
214762804|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
214762805|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
214762806|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
214762807|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
214762808|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
214762809|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
214762810|NCT01856296|PROCEDURE|Biopsy|
214762811|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
214762812|NCT04369885|DEVICE|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
214762813|NCT00262483|DRUG|VX-950|
214762814|NCT00262483|DRUG|ribavirin|
214762815|NCT00262483|DRUG|peginterferon alfa-2a|
214762816|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
214762817|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
214762818|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
214762819|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
214762820|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
214762821|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
214762822|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
214762823|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
214762824|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
214762825|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
214762826|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
214762827|NCT05054621|BIOLOGICAL|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
214762828|NCT05054621|BIOLOGICAL|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
214762829|NCT06193044|DRUG|Amlodipine/Valsartan|Amlodipine 10 mg \&valsartan 160 mg
214762830|NCT06193044|DRUG|Amlodipine 10 mg &valsartan 160 mg (Exforge)|Amlodipine 10 mg \&valsartan 160 mg
214762831|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
214762832|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
214762833|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
214762834|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
214762835|NCT06567665|DIETARY_SUPPLEMENT|Leucine|Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
214762836|NCT00138801|DRUG|Ceftriaxone|
214762837|NCT00138801|DRUG|Doxycycline|
214762838|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
214762839|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
214762840|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
214762841|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
214762842|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
214762843|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
214762844|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
214762845|NCT01894542|DIETARY_SUPPLEMENT|Control|
214762846|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
214762847|NCT06568718|DRUG|bovhyaluronidase azoximer|Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
214762848|NCT06568718|DRUG|tamsulosin|Tamsulosin 0.4mg per os every day
214762849|NCT02122744|DEVICE|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
214762850|NCT02122744|DEVICE|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
214762851|NCT02277548|DRUG|Lyrica 300 mg|Lyrica 300 mg per day
214762852|NCT02277548|DRUG|Placebo|
214762853|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
214762854|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
214762855|NCT05527301|DRUG|Placebo|Placebo
214762856|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
214762857|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
214762858|NCT02018601|PROCEDURE|BRILMA|
214762859|NCT02018601|PROCEDURE|paravertebral block|
214762860|NCT02018601|DRUG|dexketoprofen|
214762861|NCT02018601|DRUG|paracetamol|
214762862|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
214762863|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
214762864|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
214762865|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
214762866|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
214762867|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
214762868|NCT03868176|OTHER|short message service|short message service
214762869|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
214762870|NCT01843439|DIETARY_SUPPLEMENT|Magnesium|
214762871|NCT01843439|BEHAVIORAL|Education for asthma action plan|
214762872|NCT01843439|BEHAVIORAL|hot-lines for acute exacerbation of asthma|
214762873|NCT01843439|BEHAVIORAL|Inhaler technique training|
214762874|NCT00544713|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
214762875|NCT00544713|DRUG|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
214762876|NCT01035112|PROCEDURE|MRI|
214762877|NCT02981667|OTHER|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
214762878|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
214762879|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
214762880|NCT06345183|COMBINATION_PRODUCT|Nivolumab + Ipilimumab combination therapy|As per product label
214762881|NCT06345183|COMBINATION_PRODUCT|Pembrolizumab + Lenvatinib combination therapy|As per product label
214762882|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
214762883|NCT02234427|DRUG|Aspirin|2-week aspirin therapy (81mg/day)
214762884|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
214762885|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
214762886|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
214762887|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
214762888|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
214762889|NCT03933709|OTHER|recommended diet|WHO Diet
214762890|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
214762891|NCT04356196|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
214762892|NCT04356196|DRUG|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
214762893|NCT04356196|DRUG|Placebo oral tablet|Placebo oral tablet
214762894|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
214762895|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
214762896|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
214762897|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
214762898|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
214762899|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
214762900|NCT03562923|DRUG|Placebo|Placebo Product
214762901|NCT01766141|OTHER|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
214762902|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
214762903|NCT01870921|DRUG|Ticagrelor|90mg/tablet, 1 tablet bid
214762904|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
214762905|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
214762906|NCT01590537|DRUG|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
214762907|NCT01590537|DEVICE|Copper IUD|Copper device, inserted intrauterine
214762908|NCT05914987|OTHER|Targeted Therapy|Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.
214762909|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
214762910|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
214762911|NCT03640442|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
214762912|NCT03640442|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
214762913|NCT02364414|DEVICE|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
214762914|NCT05148286|DRUG|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
214762915|NCT05148286|DRUG|Placebo|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
214762916|NCT05581199|DRUG|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214762917|NCT05581199|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214762918|NCT05581199|DRUG|Placebo|Matching placebo SC
214762919|NCT06544954|DIETARY_SUPPLEMENT|Freeze-dried grape powder|48 grams powder
214762920|NCT06544954|OTHER|Placebo powder|48 grams powder
214762921|NCT06224413|OTHER|No Intervention|This is non-interventional study.
214762922|NCT03659617|DEVICE|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
214762923|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
214762924|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
214762925|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
214762926|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
214762927|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
214762928|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
214762929|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
214762930|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
214762931|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
214762932|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
214762933|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
214762934|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. \- Installation of a short stretch belt (urgo K2® kit)~2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. \- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
214762935|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
214762936|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
214762937|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
215030777|NCT06336213|DRUG|Ampicillin-sulbactam|If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
214762938|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
214762939|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
214762940|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
214762941|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
214762942|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
214762943|NCT02231502|OTHER|Vegetable-based convenience food|
214762944|NCT02231502|OTHER|Vegetable meal|
214762945|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
214762946|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
214762947|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
214762948|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
214762949|NCT00210366|DRUG|Idarubicin|
214762950|NCT01405989|DRUG|darexaban|oral
214762951|NCT01405989|DRUG|ketoconazole|oral
214762952|NCT01048710|OTHER|No intervention|
214762953|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
214762954|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
214762955|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
214762956|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
214762957|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
214762958|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
214762959|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
214762960|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
214762961|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
214762962|NCT02335411|DRUG|cisplatin|IV infusion
214762963|NCT02335411|DRUG|5-FU|IV infusion
214762964|NCT02335411|DRUG|capecitabine|oral tablets
214762965|NCT02101957|DRUG|RP103|
214762966|NCT02101957|DRUG|Placebo|
214762967|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
214762968|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
214762969|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
214762970|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
214762971|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
214762972|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
214762973|NCT00566397|DRUG|Placebo|Placebo
214762974|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
214762975|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
214762976|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
214762977|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
214762978|NCT04519294|DEVICE|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
214762979|NCT04519294|DEVICE|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
214762980|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
214762981|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
214762982|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
214762983|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
214762984|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
214762985|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
214762986|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
214762987|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
214762988|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
214762989|NCT06577714|DIAGNOSTIC_TEST|Electromechanical wave imaging (EWI)|EWI is a high-frame rate ultrasound technique that images the electromechanical wave corresponding to the propagation of the onset of myocardial contraction in response to electrical activation, namely electromechanical coupling.
214762990|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
214762991|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
214762992|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
214762993|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
214762994|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
214762995|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
214762996|NCT04486859|DEVICE|IPC|mechanical prevention
214762997|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
214762998|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
214762999|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
214763000|NCT04636437|DRUG|Doravirine 100 Mg|Participants received a 100 mg tablet by mouth daily with or without food.
214763001|NCT04636437|DRUG|Integrase strand transfer inhibitors|INSTIs were acquired through the standard of care locally.
214763002|NCT04636437|DRUG|Tenofovir alafenamide/emtricitabine|NRTIs (TAF/FTC) were acquired through the standard of care locally.
214763003|NCT04636437|DRUG|tenofovir disproxil fumarate/emtricitabine|NRTIs (TDF/FTC) were acquired through the standard of care locally.
214763004|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
214763005|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
214763006|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
214763007|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
214763008|NCT03486015|DRUG|Sterile water|2 ml of sterile water
214763009|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
214763010|NCT01074853|DRUG|propranolol|10mg twice daily escalated to 80mg once daily
214763011|NCT01074853|DRUG|placebo|Matched placebo
214763012|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
214763013|NCT05493683|DRUG|Tislelizumab|400mg，q6w
214763014|NCT05499481|DRUG|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~\- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~\- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
214763015|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
214763016|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
214763017|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
214763018|NCT04928677|DRUG|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
214763019|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
215030778|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
215030779|NCT04188548|DRUG|LY3484356|Administered orally
215030780|NCT04188548|DRUG|Abemaciclib|Administered orally
214763020|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
214763021|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
214763022|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
214763023|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
214763024|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
214763025|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
214763026|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
214763027|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
214763028|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
214763029|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
214763030|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
214763031|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
214763032|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
215030781|NCT04188548|DRUG|Everolimus|Administered orally
215030782|NCT04188548|DRUG|Alpelisib|Administered orally
215030783|NCT04188548|DRUG|Trastuzumab|Administered intravenously
214763033|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
214763034|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
214763035|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
214763036|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
214763037|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
214763038|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
214763039|NCT02743598|DRUG|Liraglutide|
214763040|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
214763041|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
214763042|NCT02030509|OTHER|Quick diagnosis program|
214763043|NCT06405087|DRUG|Vedolizumab SC|Vedolizumab subcutaneous injection.
214763044|NCT06405087|OTHER|No Intervention|As this is an observational cohort, no intervention will be administered.
214763045|NCT06167083|DIAGNOSTIC_TEST|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
214763046|NCT04209673|OTHER|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
214763047|NCT04209673|OTHER|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
214763048|NCT04913285|DRUG|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
214763049|NCT04913285|DRUG|KIN-2787 and binimetinib|Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles
214763050|NCT06293963|BEHAVIORAL|Guideline Daily Amounts label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
214763051|NCT06293963|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
214763052|NCT06293963|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
214763053|NCT06293963|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
214763054|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
214763055|NCT06013371|DRUG|Placebo Ointment|matching placebo
214763056|NCT05919043|OTHER|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
214763057|NCT05919043|OTHER|Lower limb-based movement priming (LL-priming)|Repetitive lower limb movements administered to the beat of a metronome.
214763058|NCT05919043|OTHER|Sham priming|Auditory stimulation.
214763059|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
214763060|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
214763061|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
214763062|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
214763063|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
214763064|NCT05456607|BEHAVIORAL|Mood Monitoring|The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
214763065|NCT05477147|DEVICE|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
214763066|NCT04581473|DRUG|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
214763067|NCT04581473|DRUG|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
214763068|NCT06228534|PROCEDURE|Root coverage with tunneling technique|THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
214763069|NCT06374732|BEHAVIORAL|High-intensity interval training|The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.
214763070|NCT06374732|BEHAVIORAL|Control group|The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
214763071|NCT04961437|OTHER|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~\- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
214763072|NCT05980260|OTHER|Symptom-based Dosing Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.
214763073|NCT05980260|OTHER|Scheduled Opioid Taper Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
214763074|NCT02702375|OTHER|Fructose-containing Sugars|
214763075|NCT06978114|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214763076|NCT06978114|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
214763077|NCT06591455|DRUG|Fenofibrate|Fenofibrate 200mg/day
214763078|NCT06591455|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 13-15mg/kg/day
214763079|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
214763080|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
214763081|NCT06610760|DRUG|Ursodeoxycholic Acid|Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214763082|NCT06610760|DRUG|Placebo|Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214763083|NCT06588296|DRUG|Ixekizumab|Administered SC
214763084|NCT06588296|DRUG|Tirzepatide|Administered SC
214763085|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
214763086|NCT00774722|DRUG|Metronidazole|10% ointment, three times daily for 14 days
214763087|NCT05774756|DRUG|Setmelanotide|Solution for daily subcutaneous injection
214763088|NCT05774756|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
214763089|NCT06610266|DRUG|Weifuchun|Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214763090|NCT06610266|DRUG|Folic Acid|Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
214763091|NCT00912756|DRUG|cilostazol|200 mg/day BID
214794418|NCT05040685|PROCEDURE|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
214794419|NCT03065309|DRUG|Remifentanil|bolus dose
214763092|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
214763093|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
214763094|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
214763095|NCT00390676|DRUG|ADH -1 and carboplatin|
214763096|NCT00390676|DRUG|ADH -1 and docetaxel|
214763097|NCT00390676|DRUG|ADH -1 and capecitabine|
214763098|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
214763099|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
214763100|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
214763101|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
214763102|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
214763103|NCT00000362|BEHAVIORAL|Chin-down position|
214763104|NCT00000362|BEHAVIORAL|Thickened liquid administration|
214763105|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
214763106|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
214763107|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
214763108|NCT06670482|DEVICE|Non-invasive ventilation (NIV)|Delivery of positive airway pressure to the lungs via an interface, such as a mask.
214763109|NCT06995703|BEHAVIORAL|Pre-Visit Patient Text Message|Patients will be sent a text message reminder 1 day prior to their scheduled primary care visit. This message will remind them of their upcoming appointment, highlight that they may be overdue for their mammogram, and encourage them to speak with their provider or schedule now by using the provided online scheduling link or phone number. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
214763110|NCT06995703|BEHAVIORAL|Post-Visit Patient Text Messages|Patients will be sent text message reminders 4 days and 14 days after their completed primary care visit if they have not yet scheduled or completed their screening mammogram. The message delivered at 4 days post-visit will remind the patient to schedule and that appointments are available for them. The message delivered at 14-days post-visit will again encourage the patient to schedule their mammogram, if one has not already been scheduled or completed. Both messages will include a scheduling phone number and link to self-schedule online. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
214763111|NCT06995703|BEHAVIORAL|Smart Data Element (SDE)|The clinician-facing Smart Data Element (SDE) in the EHR will be visible to the provider and care team during the visit encounter. The SDE will display as a section in pre-charting, check-in, and rooming and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding scheduling an overdue mammogram and including results from prior work that show that patients are more likely to complete their screening if they receive an order and recommendation from their provider.
214763112|NCT00012766|BEHAVIORAL|Integrated team care|
214763113|NCT06993662|COMBINATION_PRODUCT|Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.
214763114|NCT06993662|COMBINATION_PRODUCT|Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD
214763115|NCT06993662|COMBINATION_PRODUCT|Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.|The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
214794420|NCT06159062|DRUG|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
214794421|NCT06159062|DRUG|Placebo|Placebo do not consist any active ingredients.
214794422|NCT06483659|DRUG|Oxytocin|Intravenous Oxytocin infusion
214794423|NCT06483659|DRUG|Placebo|0.9% Saline
214763116|NCT06993662|COMBINATION_PRODUCT|Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.
214763117|NCT06993662|COMBINATION_PRODUCT|Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders|The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.
214763118|NCT06993662|COMBINATION_PRODUCT|Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics) and individual cognitive behavioral psychotherapy by personality disorders.
214763119|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
214763120|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
214763121|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
214763122|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
214763123|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
214763124|NCT02461407|DRUG|Anlotinib|Anlotinib p.o. qd
214763125|NCT02461407|DRUG|Placebo|Placebo p.o. qd
214763126|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
214763127|NCT05071235|DEVICE|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
214763128|NCT05071235|DEVICE|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
214763129|NCT05071235|DEVICE|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
214763130|NCT05071235|DEVICE|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
214763131|NCT05071235|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
214763132|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
214763133|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
214763134|NCT06994871|OTHER|Aerobic exercise|"Intensity of exercise：Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR).~Time of aerobic exercise：from 30 to 45 minutes each day, five days a week."
214763135|NCT06994871|OTHER|Resistance exercise|"The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 3 times a week.~Intensity of equipment trainings: 70% 1-RM. Exercise volume: 15-20 repetitions for a set, from 2 sets to 4 sets gradually.~Body weight trainings: 15-30 repetitions for a set, from 2 sets to 4 sets gradually."
214763136|NCT06994871|OTHER|combined exercise|"Subjects conduct both aerobic and resistance trainings. Details of aerobic training session: Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR) from 50-55 minutes each day, 3-4 days a week.~Details of resistance training session: The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 2 times a week."
214763137|NCT05368428|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
214763138|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
214763139|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
214763140|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
214763141|NCT01977482|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
214763142|NCT01977482|DRUG|Placebo|Matching placebo tablet for GSK1278863
214763143|NCT01977482|DRUG|rhEPO|rhEPO will be procured from local market
214763144|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
214763145|NCT00209560|DRUG|fospropofol disodium|
214763146|NCT06099509|OTHER|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
214763147|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
214763148|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
214763149|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
214763150|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
214794424|NCT00526578|BEHAVIORAL|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
214794425|NCT02730715|DRUG|Basiliximab|Periodic blood collection to monitor Treg cells
214763151|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
214763152|NCT00805857|DRUG|Tipranavir|
214763153|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
214763154|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
214763155|NCT05230342|DIETARY_SUPPLEMENT|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
214763156|NCT05230342|OTHER|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
214763157|NCT06673966|OTHER|Regular follow-up assessments without intervention.|Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.
214763158|NCT06673966|OTHER|Cross-sectional assessment|Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
214763159|NCT00024271|BIOLOGICAL|recombinant interferon gamma|
214763160|NCT00024271|DRUG|cisplatin|
214763161|NCT00024271|DRUG|doxorubicin hydrochloride|
214763162|NCT00024271|DRUG|gemcitabine hydrochloride|
214763163|NCT00024271|DRUG|mitomycin C|
214763164|NCT00024271|PROCEDURE|conventional surgery|
214763165|NCT00024271|PROCEDURE|hyperthermia treatment|
214763166|NCT00024271|RADIATION|radiation therapy|
214763167|NCT03826771|BEHAVIORAL|Power training|high-intensity lower extremity resistance training
214763168|NCT03826771|BEHAVIORAL|Stretching|upper and lower body range of motion exercises
214763169|NCT06999174|DIAGNOSTIC_TEST|Multiparametric MRI|Diagnostic multiparametric liver MRI, performed at three time points: before (≤14 days), 24 hours after, and 4-6 weeks after TACE or 3 months after SIRT.
214763170|NCT06865144|DRUG|Netarsudil ophthalmic solution 0.02%|Apply one drop in each eye every evening
214763171|NCT06865144|DRUG|Artificial tears|Apply one drop in each eye every evening
214763172|NCT02500147|DRUG|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
214763173|NCT02500147|DRUG|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
214763174|NCT05460832|DRUG|MBS2320 5 mg|Oral capsule
214763175|NCT05460832|DRUG|MBS2320 20 mg|Oral capsule
214763176|NCT05460832|DRUG|MBS2320 40 mg|Oral capsule
214763177|NCT05460832|DRUG|Placebo|Oral capsule
214763178|NCT05554471|DEVICE|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
214763179|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
214763180|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
214763181|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
214763182|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
214763183|NCT07005635|OTHER|Listening Music|Music group students listen Beethoven Moonlight Sonata during scrubing hands
214763184|NCT07005635|OTHER|Alarm|Alarm group students listen alarm sound at the end of the (2 min) during scrubing hands
214763185|NCT07005869|PROCEDURE|brachial plexus tumors excision|excision of brachial plexus tumors
214763186|NCT07005440|OTHER|Functional Training|Each training session includes a preparation phase (warm-up, neuromuscular activation, dynamic stretching, and core activation), followed by two main modules: motor skill development (walking, jumping, crawling, throwing, pushing, catching) and physical fitness (balance, agility, endurance). Sessions conclude with motor skill consolidation and static stretching. Training spans 12 weeks: once weekly during weeks 1-8, and twice weekly during weeks 9-12
214763187|NCT07005440|OTHER|Dynamic Play Exercise|This includes warm-up (for 3-5 mins), rhythmic exercise (5-10 mins), games (7-10 mins) and free play exercises (10-15 mins). This group will receive the lesson once a week during week 1-8 and twice a week during 9-12 weeks
214763188|NCT07006155|DEVICE|Images|PET/CT images
214763189|NCT07005310|DEVICE|Powerglide pro™|A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.
214763190|NCT07005310|DEVICE|Introcan safety deep access|The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.
214763191|NCT07006688|DRUG|Ivosidenib Oral Tablet|500mg Ivosidenib taken orally once daily for continuous 28-day cycles
214763192|NCT07007156|OTHER|NECPAL positive|This group has a positive result for NECPAL scale
214763193|NCT07005583|DRUG|QL1706 Plus Olaparib|QL1706: 5 mg/kg administered via intravenous (IV) infusion every 3 weeks (Q3W). Olaparib: 300 mg (two 150 mg tablets) taken orally twice daily (BID). Treatment will continue until protocol-defined discontinuation criteria are met, including disease progression, unacceptable toxicity, withdrawal of consent, or death.
214763194|NCT07007507|BEHAVIORAL|Aerobic Exercise|Aerobic exercise is performed by repeating sequences of light to moderate intensity activities for extended periods of time.(12) The American Heart Association recommends that for stroke survivors, exercise intensity should be 40%-70% of VO2 reserve or heart rate (HR) reserve; 55%-80% HR max; RPE 11-14 Borg rating of perceived exertion (RPE) scale 6-20 scale, 3-5 days/week, 30-60 min/session (or multiple 10 min sessions)
214763195|NCT07006805|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide
214763196|NCT07006051|OTHER|Exposed group|All subjects are tested pre-season for their sport. They are then prospectively followed for orthopaedic and/or concussive injury. If injuries occur, then repeat testing is performed.
214763197|NCT07007325|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor PET-CT
214763198|NCT07007026|OTHER|Immersive Virtual Reality|The intervention program was implemented over a period of eight weeks, with three ses-sions per week, each lasting 35 minutes.
214763199|NCT07007026|OTHER|Traditional Home-based Exercises|The participants were instructed to adhere to the exercise program thrice weekly for a period of eight weeks.
214763200|NCT04624828|PROCEDURE|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
214763201|NCT04624828|DRUG|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
214763202|NCT04624828|BIOLOGICAL|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
214763203|NCT07008391|DIAGNOSTIC_TEST|high sensitivity Troponin I|Study participants in the intervention group will have the high-sensitivity Troponin I blood test analyzed during emergency medical service (EMS) care using the point-of-care Siemens Atellica® VTLi system. The test result will be documented in the EMS electronic medical record (FRAPP), transmitted along with the ECG, and communicated verbally to the receiving hospital during handover.
214763204|NCT05017831|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
214763205|NCT05017831|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
214763206|NCT07005336|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles
214763207|NCT07005336|DRUG|Sintilimab|Intravenous infusion at a recommended dose of 200 mg once every 3 weeks，at most 35 cycles
214763208|NCT07005336|DRUG|Pemetrexed|Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses.
214763209|NCT07005336|DRUG|Gemcitabine|1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles
214763210|NCT07005336|DRUG|Cisplatin Or Carboplatin|"Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles~Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles"
214763211|NCT07006857|OTHER|Exercise|Exercise without music
214763212|NCT07006857|OTHER|Low Frequency|396 Hertz (Hz), 417 Hz, 528 Hz, 639 Hz
214763213|NCT07006857|OTHER|High Frequency Music|741 Hz, 852 Hz, 963 Hz
214763214|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
214763215|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
214794426|NCT02730715|DRUG|Thymoglobulin|Periodic blood collection to monitor Treg cells
214763216|NCT07005778|OTHER|Traditional pain education|Participants in the control group received a 70-minute lecture based on the biomedical model of pain. Educational content included anatomical pathways for pain process (receptors, Aδ and C fibers, spinal cord, and ascending tracts), mechanisms of action potential generation, and the Gate Control Theory. The role of the brain was briefly addressed in the context of descending inhibition. While the Neuromatrix Theory was mentioned, the presentation lacked metaphorical or narrative-based content. Case examples centered on inflammation and tissue injury.
214763217|NCT07005778|OTHER|PNE-based education|"Students in the intervention group received a 70-minute lecture grounded in the biopsychosocial model of pain. The session emphasized that pain is not a direct result of tissue damage, but rather a complex and context-dependent output of the brain. The lecture explored how pain emerges from the brain's interpretation of various inputs, including sensory signals, prior experiences, beliefs, emotions, and environmental factors.~Instructional strategies included the use of clinically relevant metaphors and storytelling to promote reconceptualization of pain. Examples such as the alarm system were used to illustrate peripheral and central sensitization, while real-life anecdotes (a player unaware of injury during a game or a nail-in-foot case with no significant damage) highlighted the dissociation between nociception and pain experience."
214763218|NCT07006753|PROCEDURE|Transvaginal Diverticulum Wall Filling and Coverage Technique|This surgical intervention is a modified transvaginal technique for the treatment of circumferential female urethral diverticulum (UD). Instead of performing a complete diverticulectomy, the procedure utilizes the patient's own demucosalized diverticular wall to fill the diverticular cavity and reinforce closure of the ostium. The technique aims to preserve the integrity of the dorsal urethra, reduce the risk of fistula, minimize dead space, and improve functional outcomes such as continence and sexual function. This approach is specifically designed for circumferential UD, which poses unique anatomical and surgical challenges.
214763219|NCT07011602|BEHAVIORAL|8-week Physical Activity and Nutrition Program|Participants will be enrolled in an 8-week (Monday-Friday) daily physical activity program where treatment group participants will receive daily physical activity via organized games and daily lutein (6mg/d) snacks.
214763220|NCT06627322|DRUG|Dual-combination therapy|Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
214763221|NCT06627322|DRUG|Triple-combination therapy|Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
214763222|NCT06627322|DEVICE|Dexcom G7, Pasta|Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
214763223|NCT02051673|BIOLOGICAL|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
214763224|NCT07029490|OTHER|Chatbot|The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.
214763226|NCT00208858|DRUG|Topiramate|
214763227|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
214763228|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
214763229|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
214763230|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
214763231|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
214763232|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
214763233|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
214763234|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
214763235|NCT07034352|BEHAVIORAL|Health Impact 360|Participants will be assigned to a team and teams will meet 1-2 times per week for sessions at a local community organization. Sessions will be up to 2 hours long and will include two parts: (1) 30-60 minutes of activities related to physical, mental, social, financial, and community health, and (2) 60-75 minutes of group physical activity (walking), including stretches to warm up and cool down.
214763236|NCT07034352|OTHER|Usual care - Wait list control|Participants will be on this for approximately 16 weeks and be asked to complete data collection information at baseline and 16 weeks.
214763237|NCT07036484|BEHAVIORAL|Online program|We tested the feasibility of the introductory modules of an online couple-based program (STORK), designed to be grounded in empirically established risk and protective factors associated with couples' perinatal sexual well-being. STORK is a web-based program including psychoeducation and behavioral tasks to be completed by couples
214763238|NCT07035249|DRUG|Low Dose DCSZ11|Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).
214763239|NCT07035249|DRUG|Medium Dose DCSZ11|Patients will receive DCSZ11 at 800 mg Q3W.
214763240|NCT07035249|DRUG|High Dose DCSZ11|Patients will receive DCSZ11 at 1200 mg Q3W.
214763241|NCT07035249|DRUG|Standard Treatment|The available standard treatment for head and neck cancer patients.
214763242|NCT07037043|DRUG|hydrocortisone plus fludrocortisone|"* Hydrocortisone 200 mg/day for 5 days or until ICU discharge, starting at the initiation of cardiopulmonary bypass (CPB), administered intravenously via syringe pump in a double-blind manner~* Fludrocortisone 50 µg/day in the morning for 5 days or until ICU discharge, administered orally or via nasogastric tube (if the patient is sedated), diluted in a glass of water, in a double-blind manner"
214763243|NCT07037043|DRUG|placebo of hydrocortisone plus fludrocortisone|"* Placebo for hydrocortisone (0.9% NaCl) administered following the same protocol as fludrocortisone in the intervention group~* Placebo for fludrocortisone (capsule containing microcrystalline cellulose diluted in a glass of water) administered following the same protocol as fludrocortisone in the intervention group"
214763244|NCT05583838|DRUG|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
214763245|NCT05583838|DRUG|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
214763246|NCT07038551|DRUG|Naldemedine|over-encapsulated capsule of either 0.2 mg of naldemedine
214763247|NCT07038551|DRUG|Placebo|over-encapsulated capsule of placebo
214763248|NCT06717958|DRUG|Ivosidenib 250 MG (milligram)|oral
214763249|NCT06708416|DRUG|ONO-1110|ONO-1110 tablets once a day
214763250|NCT06708416|DRUG|Placebo|Placebo tablets once daily
214763251|NCT07040696|DEVICE|Venous excess ultrasound score (VEXUS)|Doppler examination of inferior vena cave, portal vein, hepatic vein, and intrarenal vein will be conducted by an experienced operator
214763252|NCT06709976|DEVICE|Vaginal microbiome swab|All swabs were collected using FLOQSwabs™ (Copan Italia SpA, Brescia, Italy). The patients were instructed to spread the labia with one hand, insert the swab 3-5 cm beyond the vaginal orifice with the other hand, and rotate the swab along the vaginal wall for 10-15 seconds.
214763253|NCT06709976|DEVICE|Menstrual Blood Collection via Menstrual Cup|Self-collect menstrual blood during 24 hours in 2 blocks of 12 hours
214763254|NCT06722950|DRUG|CAPEOX|CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
214763255|NCT06722950|DRUG|Placebo|Placebo：3 times a day (daily), taken with boiled water.
214763256|NCT06722950|DRUG|AC591|AC591 : 3 times a day (daily), taken with boiled water.
214763257|NCT06722911|DRUG|Nimotuzumab|Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
214763258|NCT06722911|DRUG|AG|Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
214763259|NCT06723002|DRUG|Atherolive 500mg/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
214763260|NCT06723002|DRUG|Atherolive 1000/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
214763261|NCT06723002|DRUG|Placbo_Atherolive|"Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
214763262|NCT06723964|DRUG|AP505|AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
214763263|NCT06723548|DRUG|Telitacicept|Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
214763264|NCT06723756|DRUG|Treatment A: BGF MDI HFO|Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.
214794427|NCT05945199|DEVICE|tDCS|"* 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group"
214763265|NCT06723756|DRUG|Treatment B: BGF MDI HFA|Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
214763266|NCT07043608|DRUG|Zanzalintinib|Given orally (PO)
214763267|NCT07043608|DRUG|Investigator Choice of Bone Strengthening Agents (BSA)|One BSA will be chosen, at the discretion of the investigator and given intravenously (IV)
214763268|NCT07043608|RADIATION|Non-Investigational Radiation Therapy (RT)|Non-investigational RT is permitted for symptomatic bone metastases.
214763269|NCT07043608|PROCEDURE|Bone Scan|Undergo Bone Scan
214763270|NCT07043608|PROCEDURE|Computerized tomography (CT) Scan|Undergo Imaging
214763271|NCT06925646|PROCEDURE|Finger hyperperfusion via adenosine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be increased by brachial artery infusions of adenosine administered at 6.25 mcg/100ml tissue per minute for 30 minutes into the brachial artery to increase blood flow by 5 to 10-fold."
214763272|NCT06925646|PROCEDURE|Finger hypoperfusion via by norepinephrine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be decreased to \~25% of baseline, by infusing norepinephrine at 4 ng/100ml of tissue per minute for 30 minutes."
214763273|NCT06925646|PROCEDURE|Baseline hypoxic test|Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.
214763274|NCT07047443|DRUG|SHR- A1811|HER2 ADC
214763275|NCT07047742|DIETARY_SUPPLEMENT|lemon juice|in this study for the first arm fresh lemon juice two times daily is advised
214763276|NCT07047742|DIETARY_SUPPLEMENT|Roselle|for the second arm Roselle tea is advised tow times per day
214763277|NCT07047742|OTHER|Education on urolithiasis management|all the arms except control group receive education about urolithiasis management
214763278|NCT07047924|DEVICE|MCOK-01|The investigational device is a Rigid Gas Permeable contact lenses for orthokeratology. MCOK-01 applied the reverse geometry design and adopted the lens material which possesses the highest oxygen permeability among all the materials for orthokeratology lens.
214763279|NCT07047625|BEHAVIORAL|control group (Routine nursing)|the implementation of routine treatment and nursing measures, including (1) Monitoring vital signs: according to the condition of vital signs change detection, found abnormal, timely notify the doctor, comply with medical treatment, observe the curative effect. (2) Relieve pain: tell patients the method of distraction, follow the doctor's advice, and observe the curative effect. (3) Improve disease awareness: Inform patients or family members of disease-related knowledge, examination, diagnosis and treatment, surgery and other purposes, significance and precautions. (4) Ensure patient safety: strengthen safety education, strict three check seven pairs, bed placed a variety of safety warning signs. (5) Avoid the occurrence of unexpected risks: guide patients and their families to prevent burns, trauma, etc. (6) Prevention of infection: strict implementation of disinfection and isolation system, the implementation of hand hygiene norms, reduce visits. (7) Raise the affected limb, early f
214763280|NCT07047625|BEHAVIORAL|Experimental group （Health education path）|On the basis of the control group, the health education path nursing program was adopted. The specific intervention measures were as follows: ① A program implementation team was set up, including 2 urologists, 2 nurses and 1 psychological counselor. All members have received relevant professional training; ②Two nurses were the main liaisons for the intervention and were responsible for monitoring the treatment and nursing of patients throughout the course. The workflow was as follows: starting from the patient's discomfort experience, the patient was managed according to the nursing procedure steps. By assessing the patient's existing discomfort symptoms, interventional cognitive intervention and psychological intervention, and based on the intervention plan proposed in this study, a health education path nursing plan was developed for patients from the aspects of diet, liquid intake, position adjustment, and symptomatic intervention (see Table 1). In the process of intervention, feedb
214763281|NCT07046988|DRUG|Terbinafine Tablets|"Oral administration once daily:~For patients weighing \<20 kg: 62.5 mg qd; For patients weighing 20-40 kg: 125 mg qd; For patients weighing \>40 kg: 250 mg qd; Total 8 weeks."
214763282|NCT06722859|PROCEDURE|Open surgical decompression in degenerative lumbar canal stenosis|Open surgical decompression in degenerative lumbar canal stenosis
214763283|NCT06722859|PROCEDURE|Microsurgical decompression|Microsurgical decompression of degenerative lumbar canal stenosis
214763284|NCT06724354|OTHER|The Surgical Site Infections Precaution Package Form includes the parameters that should be applied to patients before, during and after surgery.|Surgical site infections are a preventable cause of morbidity following surgical procedures. Strategies to reduce SSI rates should address preoperative, perioperative and postoperative factors, and multiple interventions can be combined into 'bundles'. Adoption of these measures may reduce SSIs, but this is dependent on a high level of package compliance. The aim of this study was to evaluate the change in SSI rates after the implementation of the SSI prevention package after neurosurgical operations. It is thought that if the results of our study are positive, the package form created will be pioneered for use in other patient groups. In addition, reducing SSI rates will shorten the postoperative recovery time of patients and reduce hospital costs.
214763285|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
214763286|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
214763287|NCT07048145|DEVICE|Vaginal Kegel Exercise Ball|A 90-gram medical-grade silicone device with internal jiggle balls used intravaginally for 30 minutes daily in the first 3 weeks and 1 hour daily in the final 3 weeks.
214763288|NCT07048145|BEHAVIORAL|Pelvic Floor Muscle Training|Participants will perform daily Kegel exercises for 6 weeks, starting with 5 sets per day and increasing to 10 sets per day in the final 3 weeks. Each set consists of 10 fast and 10 slow contractions.
214763289|NCT06928831|OTHER|Experimental|Course materials were shared with the students in the flipped group one week before the theoretical lesson. Google Classroom platform was used so that students could easily access these materials and repeat them at any time and frequency they wanted. A link and QR code were shared with the students to log in to the system. The frequency of downloading and watching the course materials was monitored by the researcher. Next week, the theoretical course was taught in line with the flipped learning model.
214763290|NCT06928831|OTHER|Experimental|The link to the mobile application developed for mobile learning was shared with the students in this group. Students were given 2 weeks to use the application, and students had the opportunity to read and watch the content in the application at any time and frequency they wanted.
214763291|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
214763292|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
214763293|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
214763294|NCT06053203|OTHER|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
214763295|NCT05412290|DRUG|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
214763296|NCT06903975|DRUG|prabotulinumtoxinA-xvfs|Each participant will receive 60 units (U) of prabotulinumtoxinA-xvfs into each SCM for a total of 120 U. Participants will return in 2 weeks to determine if any touch-up injection is needed.
214763297|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
214763298|NCT06876597|DEVICE|Motor-cognitive interactive robot|Motor-cognitive interactive robot-assisted training integrates motor and cognitive rehabilitation using an upper limb rehabilitation robot. If patients cannot actively lift the robotic arm, an eye-tracking mode detects movement intention and guides the arm along predefined trajectories, adjusting motor and cognitive loads dynamically. As motor function improves, training shifts to an active mode with increased resistance. Patients complete cognitive tasks before moving the robotic arm, while the system monitors movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load progresses by increasing robotic arm speed or resistance, while cognitive load advances based on task accuracy, ensuring personalized and adaptive rehabilitation.
214763299|NCT06876597|DEVICE|Motor-focused robot|Motor-focused robot-assisted training primarily emphasizes motor rehabilitation through the use of an upper limb rehabilitation robot. When patients are unable to actively lift the robotic arm, an eye-tracking mode is employed to guide movements, with adjustments made solely to the motor load. As motor function improves, the training transitions to an active mode, progressively increasing resistance while maintaining a constant, minimal level of cognitive difficulty. Patients are required to complete cognitive tasks before initiating movement of the robotic arm, while the system monitors key movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load is progressively increased by adjusting the speed or resistance of the robotic arm, while cognitive load remains consistently at the lowest level throughout the training.
214763300|NCT06876597|BEHAVIORAL|Conventional rehabilitation training|Conventional rehabilitation training adheres to internationally established guidelines and employs task-oriented approaches tailored to activities of daily living (ADLs). The therapeutic regimen incorporates fundamental motor skill exercises, including but not limited to grasp-and-release maneuvers, targeted reaching, fine motor skill development (e.g., button manipulation, zipper operation), and bilateral coordination tasks (e.g., garment folding, towel wringing). The intervention protocol emphasizes progressive task difficulty and functional task integration, with each session lasting 60 minutes. The treatment schedule consists of daily sessions, five times per week, over a four-week duration.
214763301|NCT06935747|COMBINATION_PRODUCT|Medical device: beta-tricalcium phosphate|The description of the intervention for BTCP in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. BTCP is indicated for the treatment of segmental and cavitary bone loss, aesthetic repairs, and bone augmentations (such as inlay or onlay grafts); for filling dental alveolar bone; for dental implant placement; and for the stabilization of osteotomies and prostheses in dentistry.
214763302|NCT06935747|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
214763303|NCT06939322|OTHER|Use of the Log-AFTER software|The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients
214763304|NCT06942416|DRUG|Paclitaxel and Cisplatin/ Carboplatin|Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Carboplatin 0.3-0.4g/m², intravenous infusion, Day 1, Q3W .Duration: 4-6 cycles.
214763305|NCT06942416|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab 5mg/kg, intravenous infusion, Day 1, Q3W. Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
214763306|NCT06942416|RADIATION|Radiotherapy|Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases. Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases. Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 4-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions. echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy.
214763307|NCT06942546|DEVICE|Wrist orthosis|The wrist orthosis referred in this study is two different prefabricated (of the shelf) types; a semi-rigid orthosis in elastic fabric with a volar splint or a short elastic wrist orthosis without a splint. Both ment to be worn when the person use the hand in everyday occupation.
214763308|NCT06941623|DIAGNOSTIC_TEST|Ultrasonography of gastric residual volume|Gastric ultrasound will be performed by the radiologist on each participant before the study and at 0, 10, 20, 30, 60, 90, 120 minutes after drinking in the position of head upright 45 degree with left lateral decubitus to evaluate the gastric residual volume and time to empty gastric antrum. If time to empty gastric antrum is extended, ultrasound will be serial performed at 150 and 180 minutes.
214763309|NCT06941623|DIAGNOSTIC_TEST|Point-of-care testing of glucose|We will perform the point-of-care test of glucose before the study and at 60, and 120 minutes after drinking.
214763310|NCT06941623|OTHER|Hunger numeric rating scale|Hunger will be measured by a numeric rating scale(NRS) before drinking, 60 and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of hunger levels, defined by numbers from 0 to 10, where 0 represents the lowest level of hunger and 10 represents the highest.
214763311|NCT06941623|OTHER|Thirst numeric rating scale|Thirst will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of thirst levels, defined by numbers from 0 to 10, where 0 represents the lowest level of thirst and 10 represents the highest.
214763312|NCT06941623|OTHER|Nausea numeric rating scale|Nausea will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of nausea levels, defined by numbers from 0 to 10, where 0 represents the lowest level of nausea and 10 represents the highest.
214763313|NCT06942403|OTHER|Associated product 1 : RV2666C|Applied twice a day minimum during 7 days (from Day 1 to Day 7)
214763314|NCT06942403|OTHER|Associated product 2 MORNING : RV5000A|"Applied in the mornings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
214763315|NCT06942403|OTHER|Test product : RV4983A|"Applied once a day, at the evening. Avoid contact with eyes. If sensations of discomfort appear, allow more time between applications.~* From Day 8 to Day 95 (87 days) for post LASER and post peeling subjects~* From Day 8 to Day 176 (169 days) for post-injections subjects"
214763316|NCT06942403|OTHER|Associated product 2 EVENING: RV5000A|"Applied in the evenings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
214763317|NCT06942715|OTHER|Electric Induction Cookstoves|The intervention consists of high-quality, locally available electric induction cookstoves with one or two burners, each equipped with cloud-connected data loggers, and includes compatible cookware.
214763318|NCT06942338|DEVICE|Corsano CardioWatch 287-2|Temperature readings from wearable Cardiowatch BT sensor, wearable Radius-T BT sensor, tympanic temperature and rectal temperature will be collected. Each participant will remain in the study as long as the rectal temperature is measured with a maximum of 24 hours. Other than the wearable Cardiowatch, the Radius-T sensors, and the rectal thermometer no additional interventions will take place due to the study. Temperature monitoring of patients will be performed according to hospitals routine care and will not be affected by the study. Patients may receive additional treatment to ensure best care.
214763319|NCT06942156|DRUG|Everolimus|Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit
214763320|NCT06942156|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1.5g BID(total 3g daily), PO
214763321|NCT06942975|OTHER|Patients with turberculosis|The study plans to collect data from patients with microbiological confirmation of tuberculosis, notified to the SS Hospital Infection Surveillance and Control Antimicrobial Stewardship, in the period between 2019 and 2023, taken in charge by the SC Infectious Diseases of the A.O. SS Antonio e Biagio and Cesare Arrigo of Alessandria (Piedmont Region, Italy).
214763322|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
214763323|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
214763324|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
214763325|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
214763326|NCT06941636|DRUG|5U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 2 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 5 U/0.1 mL. Each patient will receive a total dose of 50 U, administered bilaterally into the masseter and temporalis muscles.
214763327|NCT06941636|DRUG|10U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 1 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 10 U/0.1 mL. Each patient will receive a total dose of 100 U, administered bilaterally into the masseter and temporalis muscles.
214763328|NCT06943313|DIAGNOSTIC_TEST|68Ga-pAKTi PET/CT probe|A total of 20 patients with breast cancer will be enrolled. Screening will be conducted within 14 days prior to administration of 68Ga-pAKTi (from Day -14 to Day -1). Subjects who meet all inclusion criteria and none of the exclusion criteria will receive an intravenous injection of 68Ga-pAKTi on Day 0, followed by PET/CT imaging.
214763329|NCT06941948|OTHER|PSQI|PSQI
214763330|NCT06943586|GENETIC|CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)|CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
214763331|NCT06943118|PROCEDURE|Chemical Peels|Chemical peel is a dermatological procedure in which chemical solution is applied to the skin to remove the top layer
214763332|NCT06942468|DRUG|Topical nano preparation of Phenytoin|Topical nano preparation of Phenytoin will be used to treat atrophic post-acne scars. It will be in form of spanlastics.
214763333|NCT06942468|DEVICE|Fractional CO2 laser|Fractional CO2 laser will be used alone for treatment of atrophic post acne scars.
214763334|NCT04224506|OTHER|No intervention|There is no intervention for this study.
214763335|NCT05987163|DEVICE|GP0116|GP0116 is an injectable, sterile, transparent product.
214763336|NCT05987163|DEVICE|Active Comparator: FDA approved dermal filler device (RHA 3)|FDA approved dermal filler device (RHA 3)
214793986|NCT04958083|DIAGNOSTIC_TEST|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
214793987|NCT05939661|RADIATION|Radiation|Neoadjuvant radiation therapy : 5Gyx5
214793988|NCT05939661|DRUG|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
214793989|NCT05939661|PROCEDURE|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
214793990|NCT00221390|DRUG|Ropinirole (+ physical therapy)|
214793991|NCT00221390|DRUG|(vs.) Placebo + physical therapy|
214793992|NCT02070848|OTHER|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
214793993|NCT02070848|OTHER|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
214793994|NCT02070848|OTHER|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
214793995|NCT02232074|OTHER|Patient navigation enhanced with legal support|
214763337|NCT03899545|OTHER|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
214763338|NCT03899545|OTHER|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
214763339|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
214763340|NCT05205824|OTHER|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
214763341|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
214763342|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
214763343|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
214763344|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
214763345|NCT00003876|PROCEDURE|surgical procedure|
214763346|NCT00003876|RADIATION|iodine I 125|
214763347|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
214763348|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
214763349|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
214763350|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
214763351|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
214763352|NCT00006014|DRUG|semaxanib|
214763353|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
214763354|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
214763355|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
214763356|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
214763357|NCT02118818|GENETIC|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
214763358|NCT04920162|OTHER|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
214763359|NCT03290976|OTHER|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
214763360|NCT03290976|OTHER|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
214763361|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
214763362|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
214763363|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
214763364|NCT03296059|OTHER|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
214763365|NCT03296059|OTHER|conventional treatment|neonates is treated with conventional treatment.
214763366|NCT00544778|BIOLOGICAL|filgrastim|
214763367|NCT00544778|DRUG|dexrazoxane hydrochloride|
214763368|NCT00544778|DRUG|doxorubicin hydrochloride|
214763369|NCT00544778|DRUG|ifosfamide|
214763370|NCT00544778|DRUG|irinotecan hydrochloride|
214763371|NCT00544778|GENETIC|protein expression analysis|
214763372|NCT00544778|OTHER|immunoenzyme technique|
214763373|NCT00544778|PROCEDURE|adjuvant therapy|
214763374|NCT00544778|PROCEDURE|conventional surgery|
214763375|NCT00544778|PROCEDURE|neoadjuvant therapy|
214763376|NCT00544778|RADIATION|radiation therapy|
214763377|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
214763378|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
214763379|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
214763380|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
214763381|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
214763382|NCT02185820|DRUG|Carfilzomib|
214763383|NCT02185820|DRUG|Pomalidomide|
214763384|NCT02185820|DRUG|Dexamethasone|
214763385|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
214763386|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
214763387|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
214763388|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
214763389|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
214763390|NCT00848965|DRUG|Placebo|Placebo comparator
214763391|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
214763392|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
214763393|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
214763394|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
214763395|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
214763396|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
214763397|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
214763398|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
214763399|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
214763400|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
214763401|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
214763402|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
214763403|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
214763404|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
214763405|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
214763406|NCT02041182|BEHAVIORAL|Pre-Visit Questionnaire|
214763407|NCT01826006|DEVICE|Excimer laser|
214763408|NCT01826006|DEVICE|Manual Thrombus Aspiration|
214763409|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
214763410|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
214763411|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
214763412|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
214763413|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
214763414|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
214763415|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
214763416|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
214763417|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
214763418|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
214763419|NCT06542445|DRUG|Oral CBD oil enriched with terpenes|"Stage I dosing, increasing titration:~days 1-2: 2.5 mg/kg BW/day; days 3-4: 5 mg/kg BW/day; day 5-7: 7.5 mg/kg BW/day; days 8-35: 10 mg/kg BW/day.~Stage II dosing, increasing titration:~days 36-37: 2.5 mg/kg BW/day; days 38-39: 5 mg/kg BW/day; day 40-42: 7.5 mg/kg BW/day; days 43-70:10 mg/kg BW/day."
214763420|NCT06542445|DRUG|Oral Placebo|Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
214763421|NCT06043219|OTHER|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
214793996|NCT03843957|OTHER|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
214763422|NCT06043219|OTHER|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
214763423|NCT06043219|OTHER|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
214763424|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
214763425|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
214763426|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
214763427|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
214763428|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
214763429|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
214763430|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
214763431|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
214763432|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
214763433|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
214763434|NCT02951182|DRUG|TEZ|
214763435|NCT02951182|DRUG|IVA|
214763436|NCT02951182|DRUG|VX-440|
214763437|NCT02951182|DRUG|Matched Placebo|
214763438|NCT01335620|DRUG|Raltegravir|400 mg twice daily
214763439|NCT01335620|DRUG|Tenofovir|245 mg once daily
214763440|NCT01335620|DRUG|Emtricitabine|200mg once daily
214763441|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
214763442|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
214763443|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
214763444|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
214763445|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
214763446|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
214763447|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
214763448|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
214763449|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
214763450|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
214763451|NCT00283621|DRUG|Adriamycin|
214763452|NCT00283621|DRUG|Ifosfamide|
214763453|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
214763454|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
214793997|NCT03843957|OTHER|mPATH-Checkin|The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
214763455|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
214763456|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
214763457|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
214763458|NCT03384576|OTHER|No music|No music played in emergency waiting room
214763459|NCT00563927|PROCEDURE|Conventional RT|
214763460|NCT00563927|DRUG|Cisplatin|
214763461|NCT00563927|DRUG|5-fluorouracil|
214763462|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
214763463|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
214763464|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
214763465|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
214763466|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
214763467|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
214763468|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
214763469|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
214763470|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
214763471|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
214763472|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
214763473|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
214763474|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
214763475|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
214763476|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
214763477|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
214763478|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
214763479|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214763480|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
214763481|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
214763482|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
214763483|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
214763484|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
214763485|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
214763486|NCT02992808|DRUG|recombinant gonadotropins|
214763487|NCT02992808|DRUG|HP-HMG|
214763488|NCT01995656|DRUG|Placebo - Capsule|Administered orally
214763489|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
214763490|NCT01995656|DRUG|Placebo - Solution|Administered orally
214763491|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
214763492|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
214763493|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
214763494|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
214763495|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
214763496|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
214763497|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
214763498|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
214763499|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
214763500|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
214763501|NCT06263543|DRUG|Sacituzumab govitecan|IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
214763502|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
214763503|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
214763504|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
214763505|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
214763506|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
214763507|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
214763508|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
214763509|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
214763510|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
214763511|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
214763512|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
214763513|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
214763514|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214763515|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214763516|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
214763517|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
214763518|NCT02190162|DRUG|Tantum Verde® mouthwash|
214763519|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
214763520|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
214763521|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
214763522|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
214763523|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
214763524|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
214763525|NCT04707612|OTHER|No intervention.|No intervention.
214763526|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
214763527|NCT01946295|DRUG|Placebo|
214763528|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
214763529|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
214763530|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
214763531|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
214763532|NCT00421746|DRUG|Piboserod|
214763533|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
214763534|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
214763535|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
214763536|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
214763537|NCT00552422|DRUG|domperidone|10mg orally four times per day
214763538|NCT03484858|OTHER|High glycaemic index meal and exercise|
214763539|NCT03484858|OTHER|High glycaemic index meal and rest|
214763540|NCT03484858|OTHER|Low glycaemic index meal and exercise|
214763541|NCT03484858|OTHER|Low glycaemic index meal and rest|
214763542|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
214763543|NCT01650142|OTHER|No intervention|No intervention
214763544|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
214763545|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
214763546|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
214763547|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
214763548|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
214763549|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
214763550|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
214763551|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
214763552|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
214763553|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
214763554|NCT02237768|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
214763555|NCT02237768|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
214763556|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
214763557|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
214763558|NCT02743182|DRUG|Pegylated interferon alfa-2a|
214763559|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
214763560|NCT06537336|DEVICE|lung function|lung function tests using spirometry
214763561|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
214763562|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
214763563|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
214763564|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
214763565|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
214763566|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
214763567|NCT02269800|DRUG|Normal saline|Tid, 7 days
214763568|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
214763569|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
214763570|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
214763571|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
214763572|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
214763573|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
214763574|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
214763575|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
214763576|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
214763577|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
214763578|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
214763579|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
214763580|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
214763581|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
214763582|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
214763583|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
214763584|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
214763585|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
214763586|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
214763587|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
214763588|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
214763589|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
214763590|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
214763591|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
214763592|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
214763593|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
214763594|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
214763595|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
214763596|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
214763597|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
214794428|NCT05945199|BEHAVIORAL|Assessment of risk behaviours|Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
214794429|NCT05945199|OTHER|Scales|EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
214763598|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
214763599|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
214763600|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
214763601|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
214763602|NCT01761123|BIOLOGICAL|VXA-A1.1|
214763603|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
214763604|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
214763605|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
214763606|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
214763607|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
214763608|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
214763609|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
214763610|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
214763611|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
214763612|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
214763613|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
214763614|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
214763615|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
214763616|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
214794430|NCT03019965|DRUG|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
214763617|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
214763618|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
214763619|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
214763620|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
214763621|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
214763622|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
214763623|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
214763624|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
214763625|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
214763626|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
214763627|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
214763628|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
214763629|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
214763630|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
214763631|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
214794431|NCT03019965|DRUG|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
214794432|NCT03019965|DRUG|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
214794433|NCT03019965|DRUG|Extended Imipenem|Imipenem administered in 6 hours infusion.
214763632|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
214763633|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
214763634|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
214763635|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
214763636|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
214763637|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
214763638|NCT00399204|DRUG|Pioglitazone vs Metformin|
214763639|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
214763640|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
214763641|NCT02615652|OTHER|no intervention|no intervention, observational study
214763642|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
214763643|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
214763644|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
214763645|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
214763646|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
214763647|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
214763648|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
214763649|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
214763650|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
214763651|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
214763652|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
214763653|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
214763654|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
214763655|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
214763656|NCT01977703|OTHER|Ultra Conservative ICD Programming|
214763657|NCT01977703|OTHER|Traditional ICD Programming|
214763658|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
214763659|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
214763660|NCT01923207|DRUG|DX-2930|
214763661|NCT01923207|DRUG|Placebo|placebo, subcutaneous administration
214763662|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
214763663|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
214763664|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
214763665|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
214763666|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
214763667|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
214763668|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
214763669|NCT03529045|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
214763670|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
214763671|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
214763672|NCT01649999|DRUG|peficitinib|oral
214763673|NCT01649999|DRUG|Placebo|oral
214763674|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
214763675|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
214763676|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
214763677|NCT03176953|DRUG|topiramate|active medication
214763678|NCT03176953|BEHAVIORAL|prolonged exposure|psychotherapy
214763679|NCT03176953|DRUG|placebo|non-active medication
214763680|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
214763681|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
214763682|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
214763683|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
214763684|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
214763685|NCT04067856|DRUG|Bevacizumab Injection|Intravitreal injection
214763686|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
214763687|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
214763688|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
214763689|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
214763690|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
214794434|NCT03019965|DRUG|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
214794435|NCT03019965|DRUG|Extended Meropenem|Meropenem administered in 8 hours infusion.
215030784|NCT04188548|DRUG|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
215030785|NCT04188548|DRUG|Pertuzumab|Administered intravenously
214763691|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
214763692|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
214763693|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
214763694|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
214763695|NCT04138173|BEHAVIORAL|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
214763696|NCT00039572|DRUG|boronophenylalanine-fructose complex|
214763697|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
214763698|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
214763699|NCT01588678|DRUG|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
214763700|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
214763701|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
214763702|NCT02550509|DEVICE|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
214763703|NCT02550509|DEVICE|elastography|elastography to patient with stoke
214763704|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
214763705|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
214763706|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
214763707|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
214763708|NCT00138658|DRUG|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
214763709|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
214763710|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
214763711|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
214763712|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
214763713|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
214763714|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
214763715|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
214763716|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
214763717|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
214763718|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
214763719|NCT04269746|DIAGNOSTIC_TEST|CCAT1|Long Non coding RNA
214763720|NCT00297063|DRUG|Rosiglitazone|
214763721|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
214763722|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
214763723|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
214763724|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
214763725|NCT03125564|PROCEDURE|Sham|Infusion of sham
214763726|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
214763727|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
214763728|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
214763729|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
214763730|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
214763731|NCT04836832|DRUG|Acalabrutinib|Given PO
214763732|NCT04836832|DRUG|Duvelisib|Given PO
214763733|NCT00771654|DRUG|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
214763734|NCT00771654|OTHER|Placebo|daily for one year
214763735|NCT05244109|OTHER|Blood sample|Blood samples (2 times; 21mL per visit)
214763736|NCT05244109|DRUG|anti-TNF antibody administration|Anti-TNF antibody administration, according to current recommendations and randomization results
214763737|NCT05244109|DRUG|anti-IL-17 antibody administration|Anti-IL-17 antibody administration, according to current recommendations and randomization results
214763738|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
214763739|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
214763740|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
214763741|NCT02374008|DRUG|Ropivacaine|
214763742|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
214763743|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
214763744|NCT00142961|DRUG|Atomoxetine|atomoxetine
214763745|NCT00142961|OTHER|placebo|
214763746|NCT05950828|BEHAVIORAL|SkillTalk|A subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
214763747|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
214763748|NCT03733301|DRUG|Baricitinib|Administered orally.
214763749|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
214763750|NCT03733301|DRUG|Placebo|Administered orally.
214763751|NCT03415139|DRUG|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
214763752|NCT03415139|DRUG|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
214763753|NCT03415139|DRUG|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
214763754|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
214763755|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
214763756|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
214763757|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
214763758|NCT05619484|DEVICE|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
214763759|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
214763760|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
214763761|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
214763762|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
214763763|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
214763764|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
214763765|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
214763766|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
214763767|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
214763768|NCT05518565|OTHER|No intervention|No intervention
214763769|NCT00577031|DRUG|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
214763770|NCT00577031|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
214763771|NCT00577031|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
214763772|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
214763773|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
214763774|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
214763775|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
214763776|NCT05919069|DRUG|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
214763777|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
214763778|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
214763779|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
214763780|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
214763781|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
214763782|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
214763783|NCT05923333|DIETARY_SUPPLEMENT|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
214763784|NCT05923333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214763785|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
214763786|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
214763787|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
214763788|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
214763789|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
214763790|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
214763791|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
214763792|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
214763793|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
214763794|NCT04469322|DIAGNOSTIC_TEST|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
214763795|NCT04469322|DIAGNOSTIC_TEST|Sham Test|"Names of 53 medications listed with use as directed"
214763796|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
214763797|NCT02241200|DRUG|DA3880|
214763798|NCT02241200|DRUG|Aranesp|
214763799|NCT00109278|BIOLOGICAL|V205C, measles, mumps, and rubella virus vaccine live|
214763800|NCT00109278|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
214763801|NCT01470352|DRUG|Doluxetine|30 mg/d
214763802|NCT01470352|DRUG|Placebo|suger pill 30mg/d
214763803|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
214763804|NCT03323021|OTHER|Standard of Care|Standard of Care
214763805|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
214763806|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
214763807|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
214763808|NCT03490331|OTHER|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
214763809|NCT04172727|DRUG|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
214763810|NCT04172727|DRUG|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
214763811|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
214763812|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
214763813|NCT06067191|DRUG|RV299|Oral Suspension
214763814|NCT06067191|DRUG|Placebo|matching placebo
214763815|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
214763816|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
214763817|NCT04764669|DRUG|E2027|Oral hypromellose capsules.
214763818|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
214763819|NCT05875116|BEHAVIORAL|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
214763820|NCT05875116|BEHAVIORAL|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
214763821|NCT05875116|BEHAVIORAL|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
214763822|NCT04776135|DRUG|MT-1186|Suspension
214794436|NCT01659567|DRUG|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
214794437|NCT01659567|DRUG|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
214794438|NCT05936944|OTHER|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
214763823|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
214763824|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
214763825|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
214763826|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
214763827|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
214763828|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
214763829|NCT02972086|BEHAVIORAL|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
214763830|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
214763831|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
214763832|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
214763833|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
214763834|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
214763835|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
214794439|NCT01409044|OTHER|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
214794440|NCT01303562|OTHER|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
214794441|NCT02846948|OTHER|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
214763836|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
214763837|NCT01759056|DRUG|AVX 470|active comparator
214763838|NCT01759056|DRUG|Placebo|
214763839|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
214763840|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
214763841|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
214763842|NCT05355194|OTHER|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
214763843|NCT05355194|OTHER|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
214763844|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
214763845|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
214763846|NCT01783860|DRUG|Azithromycin|
214763847|NCT01783860|DRUG|Doxycycline|
214763848|NCT00455923|DRUG|Seretide|Seretide
214763849|NCT00455923|DRUG|Flixotide|Flixotide
214763850|NCT01742390|DRUG|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
214763851|NCT01742390|DRUG|risperidone or paliperidone|
214763852|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
214763853|NCT05879796|DRUG|cis-platinum|chemotherapeutics
214763854|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
214763855|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
214763856|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
214763857|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
214763858|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
214763859|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
214763860|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
214763861|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
214763862|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
214763863|NCT05418517|PROCEDURE|Tracheostomy|temporary tracheostomy insertion
214763864|NCT05418517|PROCEDURE|Overnight intubation|Patient who had overnight intubation
214763865|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
214763866|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
214763867|NCT02623530|OTHER|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
214763868|NCT03992261|DRUG|Halobetasol Topical Foam|Foam
214763869|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
214763870|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
214763871|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
214763872|NCT00024557|DRUG|IL13-PE38QQR|
214763873|NCT00024557|PROCEDURE|targeted fusion protein therapy|
214763874|NCT00024557|PROCEDURE|surgery|
214763875|NCT03278639|BEHAVIORAL|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
214763876|NCT03278639|BEHAVIORAL|Kinesiology|Training will be directed to ameliorate gait and balance
214763877|NCT00832286|DRUG|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
214763878|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
214763879|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
214763880|NCT01365741|OTHER|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
214763881|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214763882|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
214763883|NCT04962958|DRUG|Donafenib|administration of Donafenib
214763884|NCT02208934|DRUG|PBF-999|5, 10, 20 and 40 mg of PBF-999
214763885|NCT02208934|DRUG|Placebo|Placebo for all dosis of PBF-999
214763886|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
214763887|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
214763888|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
214763889|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
214763890|NCT03184402|DRUG|DWJ1252|tablet
214763891|NCT03184402|DRUG|Gasmotin|tablet
214763892|NCT03184402|DRUG|Placebo of Gasmotin|tablet
214763893|NCT03184402|DRUG|Placebo of DWJ1252|tablet
214763894|NCT05702827|DRUG|Bupivacaine-Meloxicam|All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
214763895|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
214763896|NCT02792400|DRUG|LY2403021 placebo|
214763897|NCT02792400|PROCEDURE|Standardised liquid meal|
214763898|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
214763899|NCT02792400|DRUG|Linagliptin placebo|
214763900|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
214763901|NCT02792400|DRUG|Empagliflozin placebo|
214763902|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
214763903|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
214763904|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
214763905|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
214763906|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
214763907|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
214763908|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
214763909|NCT03861533|OTHER|survey|Cross-Reference
214763910|NCT02230332|DRUG|Alendronate|
214763911|NCT02230332|DRUG|Placebo|
214763912|NCT02187406|PROCEDURE|Modified ankle athletic taping|
214763913|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
214763914|NCT03365869|DRUG|Sirolimus|Sirolimus or placebo were added to patients every day
214763915|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
214763916|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
214763917|NCT00103155|PROCEDURE|conventional surgery|
214763918|NCT00103155|PROCEDURE|radiofrequency ablation|
214763919|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
214763920|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
214763921|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
214763922|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
214763923|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
214763924|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
214763925|NCT03943199|DIAGNOSTIC_TEST|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
214763926|NCT05505851|OTHER|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
214763927|NCT05505851|OTHER|Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
214763928|NCT06039007|DIETARY_SUPPLEMENT|7-day Fasting-Mimicking Diet (7-DAY FMD)|This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
214763929|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
214763930|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
214763931|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
214763932|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
214763933|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
214763934|NCT04237779|BIOLOGICAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
214763935|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
214763936|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
214763937|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
214763938|NCT03724292|DRUG|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
214763939|NCT03724292|DRUG|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
214763940|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
214763941|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214763942|NCT02168205|DRUG|Pomalidomide|Capsules
214763943|NCT02168205|OTHER|Caffeine|Capsules
214763944|NCT02168205|OTHER|Tobacco|Cigarettes
214763945|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
214763946|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
214763947|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
214763948|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
214763949|NCT00127192|DRUG|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
214763950|NCT00127192|DRUG|Comparator: placebo (unspecified)|placebo QD 12-weeks
214763951|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
214763952|NCT03659032|PROCEDURE|Educational Physical Therapy|
214763953|NCT05790200|DRUG|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
214763954|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
214763955|NCT04127994|OTHER|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
214763956|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
214763957|NCT02257411|DEVICE|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
214763958|NCT05519527|DRUG|Part 1 (STI-6129)|Given by vein (IV)
214763959|NCT05519527|DRUG|Part 2 (STI-6129)|Given by vein (IV)
214763960|NCT06416527|DEVICE|Photobiomodulation (Experimental)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each).
214763961|NCT06416527|PROCEDURE|Pompage Technique (manual therapy)|To perform cervical Pompage the patient lies comfortably on their back or sits upright. The therapist locates the target area on the cervical spine. Using gentle pressure, the therapist applies traction to the cervical spine, stretching the muscles and fascia. The traction is held for 20 seconds. The therapist then releases the traction, allowing the cervical spine to return to its neutral position. This process will be repeated 3 times, with adjustments made based on the patient's response and comfort level.
214763962|NCT06416527|DEVICE|Photobiomodulation (Placebo)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each) with the device turned off (inactive), simulating the time with a recorded beep sound.
214763963|NCT04762771|DRUG|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
214763964|NCT04706520|DIETARY_SUPPLEMENT|Study Beverage Consumption|All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
214763965|NCT00693056|DRUG|Placebo|Placebo (w/o API)
214763966|NCT00693056|DRUG|RX-10100 5mg|5 mg/dose of RX-10100
214763967|NCT00693056|DRUG|RX-10100 10mg|10 mg/dose of RX-10100
214763968|NCT00693056|DRUG|RX-10100 15mg|15 mg/dose of RX-10100
214763969|NCT05620706|BIOLOGICAL|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
214763970|NCT01696227|DRUG|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
214763971|NCT05160675|OTHER||No intervention
214763972|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
214763973|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
214763974|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
214763975|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
214763976|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
214763977|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
214763978|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
214763979|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
214763980|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
214763981|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
214763982|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
214763983|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
214763984|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
214763985|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
214763986|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
214763987|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
214763988|NCT01454037|PROCEDURE|Radiation|Radiate prostate
214763989|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
214763990|NCT00227591|DRUG|lenalidomide|Given orally (PO)
214763991|NCT00227591|DRUG|prednisone|Given PO
214763992|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
214763993|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
214763994|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
214763995|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
214763996|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
214763997|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
214763998|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
214763999|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
214764000|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
214764001|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
214794442|NCT02044172|PROCEDURE|Radical prostatectomy|radical prostatectomy
214764002|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
214764003|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
214764004|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
214764005|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
214764006|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
214764007|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
214764008|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
214764009|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
214764010|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
214764011|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
214764012|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
214764013|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
214764014|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
214764015|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
214764016|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
214764017|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
214764018|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
214764019|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
214764020|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
214764021|NCT00150137|DRUG|Methimazole|
214764022|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
214764023|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
214764024|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
214764025|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
214764026|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
214764027|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
214764028|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
214764029|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
214764030|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
214764031|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
214764032|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
214764033|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
214764034|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
214764035|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
214764036|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
214764037|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
214764038|NCT04150107|OTHER|Placebo|Fish oil capsule
214764039|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
214764040|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
214764041|NCT06135129|DEVICE|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
214764042|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
214764043|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
214764044|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
214764045|NCT02894541|DRUG|CKD-519 100mg|
214764046|NCT02894541|DRUG|CKD-519 200mg|
214764047|NCT02894541|DRUG|CKD-519 100mg|
214764048|NCT02894541|DRUG|CKD-519 200mg|
214764049|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
214794443|NCT02044172|RADIATION|Conformal radiation therapy|Conformal radiation therapy, external beam
214764050|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
214764051|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
214764052|NCT02905695|DRUG|Chirocaine|
214764053|NCT02905695|OTHER|Placebo|
214764054|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
214764055|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
214764056|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
214764057|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
214764058|NCT06453707|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
214764059|NCT00005009|BIOLOGICAL|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
214764060|NCT03542500|BEHAVIORAL|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
214764061|NCT03542500|BEHAVIORAL|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
214764062|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
214764063|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
214764064|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
214764065|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
214764066|NCT00568464|DRUG|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
214764067|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
214764068|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
214764069|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
214764070|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
214764071|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
214764072|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1\. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
214764073|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
214764074|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
214764075|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
214764076|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
214764077|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
214764078|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
214764079|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
214764080|NCT04199741|DRUG|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
214764081|NCT04199741|DRUG|SC16.56, Phase I, Cohort 2|7.5mg
214764082|NCT04199741|DRUG|SC16.56, Phase I, Cohort 3|22.5mg
214764083|NCT04199741|DRUG|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
214764084|NCT05963022|DRUG|Tirzepatide|Administered SC
214764085|NCT05963022|DRUG|Placebo|Administered SC
214764086|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
214764087|NCT04455620|BIOLOGICAL|BNT151|intravenous (IV)
214764088|NCT05492188|BEHAVIORAL|Operant Conditioning of Cutaneous Reflexes|This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
214764089|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
214764090|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
214764091|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
214764092|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
214764093|NCT01883141|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
214764094|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
214764095|NCT06339632|OTHER|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|"The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session."
214764096|NCT06339632|OTHER|Transcutaneous electrical diaphragm stimulation (TEDS)|The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
214764097|NCT06852612|DIETARY_SUPPLEMENT|Fructose|40g fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
214764098|NCT06852612|DIETARY_SUPPLEMENT|Fructose and galactose|10g galactose (mostly from lactose) plus 40g of fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
214764099|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
214764100|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
214764101|NCT00306124|DRUG|Levodopa|
214764102|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
214764103|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
214794444|NCT02044172|OTHER|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
214764104|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
214764105|NCT00116246|PROCEDURE|McRobert's manoeuvre|
214764106|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
214764107|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
214764108|NCT00066417|DRUG|cyclophosphamide|
214764109|NCT00066417|DRUG|cyclosporine|
214764110|NCT00066417|DRUG|fludarabine phosphate|
214764111|NCT00066417|DRUG|methylprednisolone|
214764112|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
214764113|NCT00066417|DRUG|thiotepa|
214764114|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
214764115|NCT00066417|PROCEDURE|biological therapy|
214764116|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
214764117|NCT00066417|PROCEDURE|bone marrow transplantation|
214764118|NCT00066417|PROCEDURE|chemotherapy|
214764119|NCT00066417|PROCEDURE|leukocyte therapy|
214764120|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
214764121|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
214764122|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
214764123|NCT00066417|PROCEDURE|radiation therapy|
214764124|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
214764125|NCT01994369|DRUG|EC17|
214764126|NCT03010163|OTHER|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
214764127|NCT03010163|OTHER|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
214764128|NCT03010163|OTHER|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
214764129|NCT03010163|OTHER|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
214764130|NCT04678440|DRUG|[18F]F-AraG Imaging|Total body PET imaging using \[18F\]F-AraG
214764131|NCT05487625|BEHAVIORAL|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214764132|NCT05487625|BEHAVIORAL|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214764133|NCT05487625|BEHAVIORAL|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214764134|NCT05487625|BEHAVIORAL|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214764135|NCT05487625|BEHAVIORAL|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
214764136|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
214764137|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
214764138|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
214764139|NCT04620590|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
214764140|NCT03539952|DRUG|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
214764141|NCT03539952|DRUG|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
214764142|NCT03539952|DRUG|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
214764143|NCT03539952|DRUG|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-\<W108)
214764144|NCT06604884|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
214764145|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
214764146|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
214764147|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
214764148|NCT03336918|DRUG|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
214764149|NCT06615986|DIETARY_SUPPLEMENT|Cardiosyn|Two sachets by mouth daily. Each dose (sachet) is 8.1 grams. For 2 doses it will be 16.2 grams per person per day.
214764150|NCT05470777|COMBINATION_PRODUCT|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5\*10\^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Modified BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
214764151|NCT07048470|DIETARY_SUPPLEMENT|Synbiotic|The patients received synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
214764152|NCT07048470|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
214764153|NCT07047846|OTHER|Dynamic soft tissue mobilization|Begin with gentle heat application or light massage to warm up the tissue for 5 minutes. Assess the range of motion and identify specific areas of tightness and pain. - Use hands or specialized tools to apply sustained pressure to the fascia and underlying muscles, concentrating on the scapular, pectoral, deltoidal, and rotator cuff muscles. Apply specific DSTM techniques to the identified muscles, gradually increasing the intensity as tolerated by the patient. Follow up with gentle stretching and strengthening exercises to maintain the gained ROM and improve muscle function.For subscapular are release Gentle circular movements over the subscapularis region to decrease the tension and increase the freedom of this muscle.For Supraspinatus and Infraspinatus Work Specific exercise over these muscles to help relieve pain and improve the shoulder joint.
214764154|NCT07047846|OTHER|Bowen Technique and 3 moves|As the client sits, take a position across from the shoulder that needs attention. Hold the side you are working on by its forearm. Arrange the forearm so that it is horizontal at about chest level, keeping the elbow at a 90˚ angle and the shoulder apart from the trunk. Move 1: This is an anterior move that involves placing the fingers of the other hand over the midpoint of the triceps and posterior deltoid tendon, which is situated deeper. The ideal way to execute the exercise is to adduct the shoulder joint to its maximum ROM while placing the thumb of the same hand on the humeral head.Move 2: After the shoulder has fully adducted to the other side, strike the humeral head percussionally in the neck's direction. Move 3: Put the arm back in the beginning position and work the anterior deltoid at its midpoint with a supero-lateral move. Then take a pause for 2 minutes and repeat the moves. Complete 3 sets of all these moves in 35 minutes including 2 minutes pause after these 3 moves.
214764155|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
214764156|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
214764157|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
214764158|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
214764159|NCT06830174|DEVICE|Starstim system|Transcranial direct current stimulation (tDCS)
214764160|NCT06943235|DRUG|Probiotics|Subjects received probiotics before radiotherapy
214764161|NCT06943235|RADIATION|concurrent Hyperfractionated Radiotherapy|Increase radiation dose on the basis of conventional radiotherapy
214764162|NCT06941779|DEVICE|Cueing|Inertial sensors (via a smartphone worn on the lower back) will capture and analyze validated gait-related characteristics (via a gold-standard inertial system worn on both feet). Personalised auditory cues (via smartphone) will be examined for their ability to correct variable gait. To reduce burden on participants (i.e., minimal number of wearable sensors) and to streamline data capture and deliver auditory cues, a single smartphone and a gold standard reference (2 inertial wearables on each foot) will only be used. All devices attached over clothes via belt attachments.
214764163|NCT06942728|DEVICE|nLIFE EyeFitness|A software called nLIFE EyeFitness, certified as a Class I Medical device, allows to carry out individualized rehabilitation exercises at home, using own PC or tablet, with monitoring by the Center's operators.
214764164|NCT00519948|DRUG|new MPS, opti-free express no rub MPS|
214764165|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
214764166|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
214764167|NCT04846049|OTHER|Comprehensive Care|"1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration"
214764168|NCT04846049|OTHER|Standard Care|No intervention or treatment will be provided.
214764169|NCT05060913|DRUG|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
214764170|NCT05060913|DRUG|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
214764171|NCT02287142|PROCEDURE|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
214764172|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
214764173|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
214764174|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
214764175|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
214764176|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
214764177|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
214764178|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
214764179|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
214764180|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
214764181|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
214764182|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
214764183|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
214764184|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
214764185|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
214764186|NCT02087865|DRUG|donepezil HCL|
214764187|NCT02087865|DRUG|Placebo|
214764188|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
214764189|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
214764190|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
214764191|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
214764192|NCT03014427|OTHER|Biological Database|Biological Database
214764193|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
214764194|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
214764195|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
214764196|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
214764197|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
214764198|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
214764199|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
214764200|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
214764201|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
214764202|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
214764203|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
214764204|NCT01392469|DRUG|Sildenafil|Oral Administration
214764205|NCT01392469|DRUG|Bosentan|Oral Administration
214764206|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
214764207|NCT03255226|DRUG|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
214764208|NCT04686968|PROCEDURE|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
214764209|NCT04686968|PROCEDURE|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
214764210|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
214764211|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
214764212|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
214764213|NCT00511329|DRUG|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
214764214|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
214764215|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
214764216|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
214764217|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
214764218|NCT00003652|DRUG|cisplatin|
214764219|NCT00003652|DRUG|fluorouracil|
214764220|NCT00003652|PROCEDURE|neoadjuvant therapy|
214764221|NCT00003652|RADIATION|radiation therapy|
214764222|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
214764223|NCT05511805|OTHER|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
214764224|NCT05511805|OTHER|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
214764225|NCT05511805|OTHER|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
214764226|NCT05511805|DEVICE|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
214764227|NCT05511805|DEVICE|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
214764228|NCT05511805|DEVICE|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
214764229|NCT05511805|DEVICE|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
214764230|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
214764231|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
214764232|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
214764233|NCT01836094|DRUG|Placebo|oral, one time
214764234|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
214764235|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
214764236|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
214764237|NCT01261650|DEVICE|transcranial direct current stimulation|
214764238|NCT01261650|DEVICE|sham treatment|
214764239|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
214764240|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
214764241|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
214764242|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
214764243|NCT05645263|OTHER|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
214764244|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
214764245|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
214764246|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
214764247|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
214764248|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
214764249|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
214764250|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
214764251|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
214764252|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
214764253|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
214764254|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC\_ASC)
214764255|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
214764256|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
214764257|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
214764258|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
214764259|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
214764260|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
214764261|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
214764262|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
214764263|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
214764264|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
214764265|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
214764266|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
214764267|NCT02492152|DEVICE|Study group|Dianatal
214764268|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
214764269|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
214764270|NCT03476837|BEHAVIORAL|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
214764271|NCT03476837|BEHAVIORAL|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
214764272|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
214764273|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
214764274|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
214764275|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
214764276|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
214764277|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
214764278|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
214764279|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
214764280|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
214764281|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
214764282|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
214764283|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
214764284|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
214764285|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
214764286|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
214764287|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
214764288|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
214764289|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
214764290|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
214764291|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
214764292|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
214764293|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
214764294|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
214764295|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
214764296|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
214764297|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
214764298|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
214764299|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
214764300|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
214764301|NCT04625907|RADIATION|radiotherapy|Ionising radiation
214764302|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
214764303|NCT03015207|DRUG|NNC0194-0499|
214764304|NCT03015207|DRUG|Placebo|
214764305|NCT03862807|DRUG|Patisiran|Patisiran was administered via IV infusion.
214764306|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
214764307|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
214764308|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
214764309|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
214764310|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
214764311|NCT04362761|DRUG|IVA|Tablet for oral administration.
214764312|NCT00003861|OTHER|laboratory biomarker analysis|
214764313|NCT05595161|BEHAVIORAL|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
214764314|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
214764315|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
214764316|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
214764317|NCT04729504|BEHAVIORAL|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
214764318|NCT05992285|DEVICE|transcranial magnetic stimulation|the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
214764319|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
214764320|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
214764321|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
214764322|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
214764323|NCT02396238|DEVICE|Celution Device|ADRCs prepared using the investigational Celution Device
214764324|NCT02396238|OTHER|Placebo|Placebo
214764325|NCT01771627|DRUG|varenicline|Given PO
214764326|NCT01771627|DRUG|nicotine patch|
214764327|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
214764328|NCT03486327|DRUG|BR55|A novel targeted ultrasound contrast agent
214764329|NCT02755727|PROCEDURE|Platelet Rich Plasma Injection|See Arms
214764330|NCT02755727|PROCEDURE|Open Surgical Release|See arms
214764331|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
214764332|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
214764333|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
214764334|NCT03770182|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
214764335|NCT03126682|DRUG|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
214764336|NCT02504060|DRUG|Starch Placebo|
214764337|NCT02504060|DRUG|N-acetyl-D-glucosamine|
214764338|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
214764339|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
214764340|NCT03347929|DRUG|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
214764341|NCT03347929|DRUG|Placebo|10 days treatment with Placebo1 tablet twice daily
214764342|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
214764343|NCT00096473|DRUG|Donepezil hydrochloride|
214764344|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
214764345|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
214764346|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
214764347|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
214764348|NCT01570127|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
214764349|NCT01570127|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
214764350|NCT01570127|PROCEDURE|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
214764351|NCT01570127|OTHER|Waiting|No interventions were applied to the patients in this group.
214764352|NCT01534429|PROCEDURE|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
214764353|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
214764354|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
214764355|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
214764356|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
214764357|NCT02074982|DRUG|AIN457 300 mg|
214764358|NCT02074982|DRUG|ustekinumab 45/90 mg|
214764359|NCT02074982|DRUG|placebo secukinumab|Placebo
214764360|NCT02046239|PROCEDURE|Suture Group|
214764361|NCT02046239|BIOLOGICAL|Staple Group (control)|
214764362|NCT02350439|DRUG|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
214764363|NCT03425773|BIOLOGICAL|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
214764364|NCT02817269|OTHER|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
214764365|NCT02817269|OTHER|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
214764366|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
214764367|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
214764368|NCT03540446|DEVICE|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
214764369|NCT03065517|DEVICE|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
214764370|NCT03065517|DEVICE|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
214764371|NCT06247579|OTHER|Dietary polystyrene microplastics from disposable plastic tableware|Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
214764372|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
214764373|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
214764374|NCT04132102|DRUG|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
214764375|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
214764376|NCT03348319|OTHER|radiation|Scanning cadaver organs
214764377|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
214764378|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
214764379|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
214764380|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
214764381|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
214764382|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
214764383|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
214764384|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
214764385|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
214764386|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
214764387|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
214764388|NCT00836238|BEHAVIORAL|Interview|Physical Function and Symptom Assessment Interviews
214764389|NCT00836238|OTHER|Physical Function Tests|3 physical function tests.
214764390|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
214764391|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
214764392|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
214764393|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
214764394|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
214764395|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
214764396|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
214764397|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
214764398|NCT03847532|GENETIC|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
214764399|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
214764400|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
214764401|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
214764402|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
214764403|NCT00798707|DRUG|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
214764404|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
214764405|NCT06079437|PROCEDURE|Cheer|Maximum isometric contraction was performed with cheering.
214764406|NCT06079437|PROCEDURE|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
214764407|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
214764408|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
214764409|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
214764410|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
214764411|NCT00107809|DRUG|Modafinil|
214764412|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
214764413|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
214764414|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
214764415|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
214764416|NCT03473145|BEHAVIORAL|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.
214764417|NCT03473145|DEVICE|activPAL inclinometer|Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
215030786|NCT05583890|DEVICE|Continuous glucose monitors|Participants will wear continuous glucose monitors for a 7 day period.
214764418|NCT03473145|OTHER|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
214764419|NCT05174273|BIOLOGICAL|Fecal Microbiota Transplantation|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
214764420|NCT01937546|PROCEDURE|Primary delivery of anterior shoulder|
214764421|NCT01937546|PROCEDURE|Primary delivery posterior shoulder|
214764422|NCT00249327|BEHAVIORAL|education|
214764423|NCT02525627|DEVICE|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
214764424|NCT02525627|DEVICE|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
214764425|NCT02525627|DEVICE|Symax stem|Orthopaedic implant
214764426|NCT02525627|DEVICE|Accolade TMZF stem|Orthopaedic implant
214764427|NCT01382680|DEVICE|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
214764428|NCT02416167|DRUG|FYU-981|
214764429|NCT02416167|DRUG|Placebo|
214764430|NCT03746080|DRUG|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
214764431|NCT03746080|DRUG|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
214764432|NCT03746080|RADIATION|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
214764433|NCT03746080|RADIATION|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
214764434|NCT02094573|DRUG|Brigatinib|Brigatinib tablets
214764435|NCT01473589|DRUG|Teriparatide|Administered by SC injection
214764436|NCT01473589|DRUG|Placebo|Administered by SC injection
214764437|NCT01473589|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
214764438|NCT01473589|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
214764439|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
214764440|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
214764441|NCT03178474|OTHER|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
214764442|NCT03178474|OTHER|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
214764443|NCT03178474|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
214764444|NCT06080503|RADIATION|LT-SABR|42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
214764445|NCT06080503|RADIATION|IMRT|63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
214764446|NCT03256526|DRUG|Placebo|0 mg
214764447|NCT03256526|DRUG|PF-06835919 Low Dose|75 mg once daily
214764448|NCT03256526|DRUG|PF-06835919 High Dose|300 mg once daily
214764449|NCT06704139|DRUG|Morphine - .25 mg|Fifty patients will receive intrathecal morphine
214764450|NCT06704139|DRUG|fentanyl + morphine|Fifty patients will receive intrathecal morphine and fentanyl
214764451|NCT06704139|DRUG|Ondansetron + Dexamethasone|All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
214764452|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
214764453|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
214764454|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
214764455|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
214764456|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
215030787|NCT05583890|DEVICE|Activity tracker|Participants will wear the activity tracker for a 7 day period.
214764457|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
214764458|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
214764459|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
214764460|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
214764461|NCT00185107|DRUG|Colesevelam Hydrochloride|
214764462|NCT00185107|DRUG|Ezetimibe|
214764463|NCT00185107|DRUG|Simvastatin|
214764464|NCT04904978|OTHER|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
214764465|NCT04904978|OTHER|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
214764466|NCT01876628|DRUG|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
214764467|NCT01876628|DRUG|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
214764468|NCT01876628|DRUG|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
214764469|NCT04965896|OTHER|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
214764470|NCT04965896|OTHER|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
214764471|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214764472|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214764473|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214764474|NCT03213769|DRUG|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
214764475|NCT03213769|DRUG|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
214764476|NCT05052827|DIETARY_SUPPLEMENT|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
214764477|NCT05052827|DIETARY_SUPPLEMENT|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
214764478|NCT05052827|DIETARY_SUPPLEMENT|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
214764479|NCT05883527|OTHER|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
214764480|NCT05883527|OTHER|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
214764481|NCT04640701|OTHER||
214764482|NCT00566969|DRUG|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
214764483|NCT00566969|DRUG|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
214764484|NCT00566969|DRUG|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
214764485|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
214764486|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
214764487|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
214764488|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
214764489|NCT01626794|BIOLOGICAL|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
214764490|NCT01626794|BIOLOGICAL|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
214764491|NCT01626794|BIOLOGICAL|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
214764492|NCT00018174|DRUG|Fluoxetine|
214764493|NCT00018174|BEHAVIORAL|Behavioral group smoking cessation treatment|
214764494|NCT00018174|DRUG|Placebo|
214764495|NCT06111131|DEVICE|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
214764496|NCT02049580|DRUG|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
214764497|NCT02049580|DRUG|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
214764498|NCT02049580|DRUG|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
214764499|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
214764500|NCT05940467|OTHER|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
214764501|NCT00633295|DRUG|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
214764502|NCT04095546|OTHER|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
214764503|NCT01054469|PROCEDURE|TAP block placement with placebo|20 ml of normal saline (placebo)
214764504|NCT01054469|PROCEDURE|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
214764505|NCT03308123|OTHER|Observational study, not interventional|Not an intervention study
214764506|NCT05226013|DRUG|Polyglycol lated urate oxidase for injection|Single dose escalation
214764507|NCT05226013|DRUG|Placebo|Placebo
214764508|NCT03606109|DRUG|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
214764509|NCT00619671|DRUG|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
214764510|NCT04839133|DEVICE|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
214764511|NCT00820183|OTHER|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
214764512|NCT00006397|DRUG|Indinavir sulfate|
214764513|NCT00006397|DRUG|Ritonavir|
214764514|NCT00006397|DRUG|Stavudine|
214764515|NCT00006397|DRUG|Didanosine|
214764516|NCT00718978|PROCEDURE|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
214764517|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
214764518|NCT06567457|BIOLOGICAL|SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
214764519|NCT06567457|BIOLOGICAL|SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
214764520|NCT03669640|DRUG|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
214764521|NCT03669640|DRUG|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
214764522|NCT03464786|DEVICE|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
214764523|NCT03464786|DEVICE|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
214764524|NCT01953731|DRUG|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
214764525|NCT01953731|DRUG|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
214764526|NCT04464382|PROCEDURE|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
214764527|NCT04464382|PROCEDURE|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
214764528|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
214764529|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
214764530|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
214764531|NCT05553600|DEVICE|Tampon BR|Modified Regular Absorbency Tampons
214764532|NCT05553600|DEVICE|Tampon CR|Reference Regular Absorbency Tampons
214764533|NCT05553600|DEVICE|Tampon BS|Modified Super Absorbency Tampons
214764534|NCT05553600|DEVICE|Tampon CS|Reference Super Absorbency Tampons
214764535|NCT05712915|OTHER|RRT operation|"A retrospective observational study was conducted at a 990-bed tertiary care referral teaching hospital from April 2014 to December 2020. The RRT implemented in April 2017 as a part-time RRT operating 8 hours on weekdays. In March 2018, operation time was extended to 15 hours on weekdays and finally, extended to 24 hours a day, 7 days a week in February 2019.~Impact of RRT operation on CPR incidence was retrospective analyzed without any prospective intervention."
214764536|NCT01319747|PROCEDURE|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
214764537|NCT01319747|PROCEDURE|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
214764538|NCT06329076|DRUG|Losartan|Administration of losartan tablets (50 mg)
214764539|NCT06329076|DRUG|Placebo|Administration of placebo tablets
214764540|NCT00861731|DRUG|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
214764541|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
214764542|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
214764543|NCT01063439|DRUG|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
214764544|NCT03585868|OTHER|Placebo|Beverage with no flavonoids
214764545|NCT03585868|OTHER|Flavonoids|Flavonoids-enriched cacao beverage
214764546|NCT03585868|DIETARY_SUPPLEMENT|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
214764547|NCT00368914|DRUG|sirolimus|
214764548|NCT00368914|OTHER|laboratory biomarker analysis|
214764549|NCT00368914|OTHER|pharmacological study|
214764550|NCT00368914|PROCEDURE|biopsy|
214764551|NCT06563050|PROCEDURE|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
214764552|NCT06563050|PROCEDURE|Lidocaine spray|Subjects in group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
214764553|NCT06563050|PROCEDURE|Combination of nebulized lidocaine and lidocaine spray|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
214764554|NCT00171756|DRUG|valsartan/atenolol|
214764555|NCT02802137|DRUG|tafluprost|
214764556|NCT02802137|DRUG|tafluprost and dorzolamide/timolol|
214764557|NCT03852407|DRUG|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
214764558|NCT03852407|DRUG|Melphalan|100mg/m² on day -2
214764559|NCT03852407|DRUG|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
214764560|NCT03852407|DRUG|Cyclophosphamid|50 mg/kg on days +3 and +4.
214764561|NCT01861600|OTHER|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
214764562|NCT01861600|OTHER|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
214764563|NCT01861600|OTHER|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
214764564|NCT01861600|OTHER|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
214764565|NCT01861600|OTHER|Human Milk|Human Milk
214764566|NCT06143683|PROCEDURE|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
214764567|NCT06143683|PROCEDURE|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
214764568|NCT01502917|DRUG|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
214764569|NCT01502917|RADIATION|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
214764570|NCT06145880|DIAGNOSTIC_TEST|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
214764571|NCT00665704|BEHAVIORAL|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
214764572|NCT05033379|BEHAVIORAL|Control|Importance of sleep
214764573|NCT05033379|BEHAVIORAL|Resilience coaching|Arena Strive
214764574|NCT05301452|RADIATION|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
214764575|NCT05301452|RADIATION|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
214764576|NCT05301452|PROCEDURE|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
214764577|NCT01408056|DRUG|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
214764578|NCT01408056|DRUG|Mupirocin 2% Ointment|Topical application twice per day for 60 days
214764579|NCT04798430|DRUG|lerodalcibep|PCSK9 inhibitor
214764580|NCT05957913|DRUG|Truvada (tenofovir/emtricitabine)|Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
214764581|NCT02902757|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214764582|NCT02902757|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
214764583|NCT02902757|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214764584|NCT04943913|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214764585|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
214764586|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
214764587|NCT05873959|BIOLOGICAL|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
214764588|NCT06405152|OTHER|Chart review|Retrospective Chart Review
214764589|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
214764590|NCT06488469|BEHAVIORAL|Psychological Interventions for children and adolescents|"Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets"
214764591|NCT01016925|PROCEDURE|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
214764592|NCT02141373|DEVICE|Glubran 2|
214764593|NCT06370039|DRUG|INV-102|INV-102 Ophthalmic Solution
214764594|NCT06370039|DRUG|Vehicle|Vehicle Ophthalmic Solution
214764595|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
214764596|NCT02384200|DRUG|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
214764597|NCT02384200|DRUG|ampicillin|IV (2 g)
214764598|NCT02384200|DRUG|gentamicin|IV (5 mg/kg)
214764599|NCT02384200|DRUG|vancomycin|IV (1 g)
214764600|NCT02384200|DRUG|ceftriaxone|IV (2 g)
214764601|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
214764602|NCT06219499|OTHER|Placebo|Placebo
214764603|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
214764604|NCT02014428|DRUG|Placebo|
214764605|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
214764606|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
214764607|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
214764608|NCT02116309|DRUG|Rectal Indomethacin|
214764609|NCT02116309|DRUG|Epinephrine|
214764610|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
214764611|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
214764612|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
214764613|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
214764614|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
214764615|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
214764616|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
214764617|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
214764618|NCT02206100|DRUG|enoxaparin|
214764619|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
214764620|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
214764621|NCT03005717|DRUG|LIPO-202|
214764622|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
214764623|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
214764624|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
214764625|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
214764626|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
214764627|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
214764628|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
214764629|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
214764630|NCT00578448|DRUG|Belatacept|IV infusion
214764631|NCT02129257|DRUG|AFLIBERCEPT|
214764632|NCT02129257|DRUG|Irinotecan|
214764633|NCT02129257|DRUG|5-Fluorouracil|
214764634|NCT02129257|DRUG|Folinic Acid|
214764635|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
214764636|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
214764637|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
214764638|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
214764639|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
214764640|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
214764641|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
214764642|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
214764643|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
214764644|NCT04257773|BEHAVIORAL|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
214764645|NCT00236730|DRUG|topiramate|
214764646|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
214764647|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
214764648|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
214764649|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
215030788|NCT05583890|BEHAVIORAL|Food Diary|Participants will complete a food diary of everything they eat for 7 days.
214764650|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
214764651|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
214764652|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
214764653|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
214764654|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
214764655|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
214764656|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
214764657|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
214764658|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
214764659|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
214764660|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
214764661|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
214764662|NCT02416505|BEHAVIORAL|Verbal+Video|
214764663|NCT03253601|BEHAVIORAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
214764664|NCT03862469|PROCEDURE|Individualized laboratory test|Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
214764665|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
214764666|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
214764667|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
214764668|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
214764669|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
214764670|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
214764671|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
214764672|NCT04918095|DEVICE|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
214764673|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
214764674|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
214794445|NCT01628081|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
214764675|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
214764676|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
214764677|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
214764678|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
214764679|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
214764680|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
214764681|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
214764682|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
214764683|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
214764684|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
214764685|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
214764686|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
214764687|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
214764688|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
214764689|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin|
214764690|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
214764691|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
214764692|NCT02758509|DRUG|Ledipasvir/Sofosbuvir|
214764693|NCT02758509|DRUG|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
214764694|NCT02758509|DRUG|Daclatasvir+Sofosbuvir|
214764695|NCT02758509|DRUG|Simeprevir+Sofosbuvir|
214764696|NCT00939965|DRUG|isotretinoin|
214764697|NCT00939965|GENETIC|DNA analysis|
214764698|NCT00939965|GENETIC|polymerase chain reaction|
214764699|NCT00939965|OTHER|laboratory biomarker analysis|
214764700|NCT00939965|OTHER|pharmacological study|
214764701|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
214764702|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
214764703|NCT05193435|OTHER|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
214764704|NCT05193435|OTHER|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
214764705|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
214764706|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
214764707|NCT01188759|DRUG|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
214764708|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
214764709|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
214764710|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
214764711|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
214764712|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
214764713|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
214764714|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
214764715|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
214764716|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
214764717|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
214764718|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
214764719|NCT01816334|DRUG|methylprednisolone|
214764720|NCT01816334|DRUG|Ketoprofen|
214764721|NCT01816334|DRUG|Sodium Chloride|
214764722|NCT01010724|DRUG|bIAP|
214764723|NCT01010724|DRUG|Placebo|
214764724|NCT04911075|DRUG|85% TCA Solution|"* TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
214764725|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
214764726|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
214764727|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
214764728|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
215030789|NCT05583890|BEHAVIORAL|Questionnaires|Participants will complete FACT-Hep, DiPcare-Q and health inequality related questions.
214764729|NCT00557830|DRUG|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
214764730|NCT00557830|DRUG|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
214764731|NCT00552812|DEVICE|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
214764732|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
214764733|NCT00001972|DRUG|15 O Water|
214764734|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
214764735|NCT00210925|DRUG|topiramate|
214764736|NCT03889405|DEVICE|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
214764737|NCT03889405|DEVICE|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
214764738|NCT03889405|DEVICE|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
214764739|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
214764740|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
214764741|NCT05718505|DEVICE|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
214764742|NCT05718505|DEVICE|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
214764743|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
214764744|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
214764745|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
214764746|NCT03009591|OTHER|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver."
214794446|NCT01628081|DIETARY_SUPPLEMENT|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
214764747|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
214764748|NCT03829020|DRUG|Bortezomib|Given SC
214764749|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
214764750|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
214764751|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
214764752|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
214764753|NCT04120701|DRUG|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
214764754|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
214764755|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
214764756|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
214764757|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
214764758|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
214764759|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
214764760|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
214764761|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
214764762|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
214764763|NCT05013827|BEHAVIORAL|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
214764764|NCT03823859|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
214764765|NCT03823859|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
214764766|NCT03823859|DIAGNOSTIC_TEST|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
214764767|NCT02264509|PROCEDURE|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
214764768|NCT06244095|OTHER|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
214764769|NCT06244095|OTHER|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
214764770|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
214764771|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
214764772|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
214794447|NCT03213210|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
214794448|NCT02510716|BEHAVIORAL|SGR|
214794449|NCT02510716|BEHAVIORAL|Support message only|
214794450|NCT04582396|PROCEDURE|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
214764773|NCT02969473|DRUG|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
214764774|NCT02969473|DRUG|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
214764775|NCT06568666|OTHER|Lumbar spinal manipulation|Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
214764776|NCT06568666|OTHER|Sacroiliac joint manipulation|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
214764777|NCT04171089|BEHAVIORAL|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
214764778|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
214764779|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
214764780|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
214764781|NCT06185140|OTHER|TELEA platform|TELEA platform
214764782|NCT05159739|GENETIC|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
214764783|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
214764784|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
214764785|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
214764786|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
214764787|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
214764788|NCT01754805|DRUG|peficitinib|oral
214764789|NCT01754805|DRUG|methotrexate|oral
214764790|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
214764791|NCT00346970|DRUG|Placebo|Placebo tablets
214764792|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
214764793|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
214764794|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
214764795|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
214764796|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
214764797|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
214764798|NCT03107442|BEHAVIORAL|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
214764799|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
214764800|NCT05510739|BEHAVIORAL|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
214764801|NCT05510739|BEHAVIORAL|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
214764802|NCT02738866|DRUG|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
214764803|NCT02738866|DRUG|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
214764804|NCT00139243|DRUG|Taxotere|
214764805|NCT00139243|DRUG|Cisplatin|
214764806|NCT00139243|DRUG|5-Fluorouracil|
214764807|NCT00139243|DRUG|Leucovorin|
214764808|NCT03929601|DRUG|Rituximab-pvvr|All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart.
214764809|NCT03929601|DRUG|Abatacept|Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL).
214764810|NCT03929601|DRUG|Sterile Sodium Chloride|Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to \<50 kg receive 0.7 mL and \> 50 kg receive 1.0 mL.
214764811|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
214764812|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
214764813|NCT02775383|OTHER|Therapeutic|Observational Study
214764814|NCT05764733|DRUG|Bisphosphonate|Medicine used to treat bone problems, called osteopenia or osteoporosis.
214764815|NCT05764733|BEHAVIORAL|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
214764816|NCT05764733|OTHER|Placebo|Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
214764817|NCT04616768|OTHER|PRO questionnaire|These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
214764818|NCT04616768|OTHER|Step monitoring|A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
214764819|NCT04616768|OTHER|Active nudge text feedback|"Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.)."
214764820|NCT04616768|OTHER|PROStep Dashboard (clinicians)|"The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~1. Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~2. Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~3. A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~4. Whether the patient has had an outpatient palliative care visit~5. Whether the patient has had a documented Serious Illness Conversation"
214764821|NCT00295919|DRUG|fenretinide lipid matrix|
214764822|NCT00295919|DRUG|ketoconazole|
214764823|NCT00295919|OTHER|laboratory biomarker analysis|
214764824|NCT00295919|OTHER|pharmacological study|
214764825|NCT06228456|DRUG|Ticagrelor 60mg|Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
214764826|NCT06228456|DRUG|Clopidogrel|Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
214764827|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
214764828|NCT05349734|OTHER|upper body blanket|applying upper body blanket with forced-air blower set to 43℃
214764829|NCT05349734|OTHER|full underbody blanket|applying full underbody blanket with forced-air blower set to 43℃
214764830|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
214764831|NCT00031902|BIOLOGICAL|bleomycin sulfate|
214764832|NCT00031902|BIOLOGICAL|rituximab|
214764833|NCT00031902|DRUG|prednisolone|
214764834|NCT00031902|DRUG|vincristine sulfate|
214764835|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
214764836|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
214764837|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
214764838|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
214764839|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
214764840|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
214764841|NCT02463058|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
214764842|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
214764843|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
214764844|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
214764845|NCT01603927|DEVICE|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
214764846|NCT06021054|DRUG|Veligrotug (VRDN-001)|Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor
214764847|NCT06021054|DRUG|Placebo|5 IV infusions of placebo
214764848|NCT06662422|DEVICE|Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System|The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
214764849|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
214764850|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
214764851|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
214764852|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
214764853|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
214764854|NCT05376293|BEHAVIORAL|Behavioral Internet program|The 12-week behavioral Internet program is designed to increase physical activity to recommended levels. Participants will be asked to plan and report aerobic exercise weekly, watch weekly video lessons, and complete brief weekly homework assignments.
214764855|NCT05376293|BEHAVIORAL|Informational newsletter condition|Newsletters will focus on the health benefits of regular physical activity, exercise safety, and will provide information on national exercise guidelines.
214764856|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
214764857|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
214764858|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
214764859|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
214764860|NCT06859710|DRUG|Placebo|Vaporized Placebo
214764861|NCT06859710|DRUG|THC|Vaporized THC (20 mg)
214764862|NCT06859710|DRUG|CBD 20 mg|Vaporized CBD (20 mg)
214764863|NCT06859710|DRUG|CBD 40 mg|Vaporized CBD (40 mg)
214764864|NCT06859710|DRUG|CBD 80 mg|Vaporized CBD (80 mg)
214764865|NCT06859359|OTHER|Hypertension Disorders of Pregnancy (HDP) Implementation Bundle|The HDP Implementation Bundle will consist of 4 main blocks namely; patient education, home BP monitoring, a contextualized follow-up protocol and provision of free anti-hypertensives if need. Collectively, these will lead to design and development of a contextualized home BP monitoring program.
214764866|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
214764867|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
214764868|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
214764869|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
214764870|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
214764871|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
214764872|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
214764873|NCT02908191|DRUG|ABI-H0731|
214764874|NCT02908191|DRUG|Placebo for ABI-H0731|
214764875|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
214764876|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
214764877|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
214764878|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
214764879|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
214764880|NCT01826929|OTHER|Therapeutic education|
214764881|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
214764882|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
214764883|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
214764884|NCT02183168|DRUG|Meloxicam suppository|
214764885|NCT02183168|DRUG|Meloxicam tablet|
214764886|NCT02183168|DRUG|Indomethacin|
214764887|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
214764888|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
214764889|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
214764890|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
214764891|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
214764892|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
214764893|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
214764894|NCT05838755|DRUG|GSK3858279|GSK3858279 will be administered
214764895|NCT05838755|DRUG|Placebo|Placebo will be administered
214764896|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
214764897|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
214764898|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
214764899|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
214764900|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
214764901|NCT00036868|BIOLOGICAL|trastuzumab|
214764902|NCT00036868|DRUG|CMF regimen|
214764903|NCT00036868|DRUG|cyclophosphamide|
214764904|NCT00036868|DRUG|fluorouracil|
214764905|NCT00036868|DRUG|methotrexate|
214764906|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
214764907|NCT02618096|DRUG|Oxytocin|
214764908|NCT02618096|DRUG|Dinoprostone|
214764909|NCT02618096|PROCEDURE|Membrane sweeping|
214764910|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
214764911|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
214764912|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
214764913|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
214764914|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
214764915|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
214764916|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
214764917|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
214764918|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
214764919|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
214764920|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
214764921|NCT00004454|GENETIC|lymphocyte gene therapy|
214764922|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
214764923|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
214764924|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
214764925|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
214764926|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
214764927|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
214764928|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
214764929|NCT06669117|DRUG|VERT-002|Route of Administration: Intravenous
214764930|NCT06995118|PROCEDURE|HUAXI hole 1|A small incision of 2mm is made at the junction of the upper outer edge of the areola and the skin, through which the scalpel is placed to assist in the resection of breast glands in reverse-sequence nipple-sparing mastectomy and direct-to-implant breast reconstruction.
214764931|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
214764932|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
214764933|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
214764934|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
214764935|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
214764936|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
214764937|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
214764938|NCT06722963|DRUG|fentanyl|Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
214764939|NCT06722963|DRUG|Nalbuphine|Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
214764940|NCT07048067|PROCEDURE|Carotid endarterectomy (CEA)|carotid endarterectomy (CEA) with the use of Baxter VASCU-GUARD vascular patches
214764941|NCT07048626|COMBINATION_PRODUCT|PRP treatment|PRP treatment involves drawing a blood sample, processing it to concentrate platelets, and then injecting that concentrated plasma back into the body, typically at the site of an injury or area needing regeneration. The procedure aims to utilize the growth factors within the platelets to accelerate healing and tissue repair.
214764942|NCT07048626|COMBINATION_PRODUCT|low level laser therapy post prp treatment|will receive low-level laser therapy post prp treatment upto 12 weeks .Low-level laser therapy (LLLT) is a non-invasive treatment for hair loss that uses low-intensity laser light to stimulate hair follicles and improve blood circulation. It's often used on its own or combined with other therapies like PRP.
214764943|NCT07046871|BEHAVIORAL|1. Intervention Name (Arm 1) Name: Adapted Basketball Program with Video Support Type: Behavioral Description: A 7-week basketball intervention for adolescents with obesity, combining pedagogically a|A 7-week basketball intervention for adolescents with obesity, combining pedagogically adapted activities with pre-session video instruction delivered via a private Facebook group.
214764944|NCT07046871|BEHAVIORAL|ADAPT Adapted Basketball Program|A 7-week adapted basketball intervention including non-competitive, inclusive drills tailored to adolescents with obesity, without any video supplementation.
214764945|NCT07047807|BEHAVIORAL|PDAC-PATHWAYS|A digital app for patients initiating neoadjuvant therapy for PDAC
214764946|NCT07047807|OTHER|Usual Care|Routine treatment
214764947|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 150mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 150mg.
214764948|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 300mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 300mg.
214764949|NCT07047105|DIETARY_SUPPLEMENT|Placebo|Microcristalline Cellulose MCC
214764950|NCT07047105|DIETARY_SUPPLEMENT|Caffeine 75mg|Caffeine anhydrous Pulver, 75mg
214764951|NCT07048561|OTHER|observation alone|No interventions will be conducted during the one-year observation period, maintaining participants' normal daily living conditions.
214764952|NCT06723119|OTHER|Resveratrol (VRES) 500 mg oral once daily.|Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
214764953|NCT06723119|OTHER|Placebo 500 mg oral once daily.|Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
214764954|NCT07048327|OTHER|No intervention (observational study)|No intervention (observational study)
214764955|NCT07048457|PROCEDURE|Radical cystectomy|The intervention in this clinical trial consists of definitive surgical management through radical cystectomy with bilateral pelvic lymph node dissection (PLND), urinary diversion, and metastasectomy of surgically resectable or previously radiated metastatic disease. Surgical approach may be either open or robotic, based on surgeon discretion and patient-specific factors. The PLND will be performed in a standard oncologic fashion, including dissection of the common iliac, external iliac, internal iliac, and obturator nodal basins bilaterally. In cases where metastatic lymph nodes are identified beyond these regions, the lymph node dissection may be extended to achieve gross resection of involved nodal disease within the abdomen or retroperitoneum.
214764956|NCT07048431|DIAGNOSTIC_TEST|Shear Wave Elastography Measurement|It is a non-invasive imaging technique used to evaluate tissue stiffness. This method involves the use of ultrasound-based shear wave elastography to assess bilateral tibial nerve, by measuring the speed of shear wave propagation through the tissue. Stiffness values are expressed in kilopascals (kPa).
214764957|NCT06742788|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is an emerging, non-invasive adjunctive therapy.~The taVNS protocol is configured with a pulse width of 500 µs, a frequency of 25 Hz, and a current intensity titrated to each patient's pain tolerance threshold (range: 0.5-2.0 mA). The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.~The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks."
214764958|NCT06742788|DEVICE|sham transcutaneous auricular vagus nerve stimulation (staVNS)|The sham transcutaneous auricular vagus nerve stimulation (staVNS) serves as a sub-threshold therapeutic stimulus functions as a sham stimulus. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 0.1 mA. The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime. The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
214764959|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
214764960|NCT01525407|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
214764961|NCT01525407|DRUG|Atorvastatin Calcium|Given PO
214764962|NCT01525407|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
214764963|NCT01209000|PROCEDURE|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
214764964|NCT03220282|OTHER|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
214764965|NCT03220282|OTHER|Preterm infant formula|Preterm formula determined by clinical practice
214764966|NCT06928610|BEHAVIORAL|HeartMath Resilience Program|Resiliency-based intervention designed to reduce stress, build resilience, and maintain energy levels.
214764967|NCT05227053|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter|Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
214764968|NCT06901713|OTHER|cognitive behaviour thearpy|Participants will access the CBT text materials through a dedicated platform
214764969|NCT06901713|OTHER|mindfulness|Participants will access the mindfulness audio via a compatible device
214764970|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
214764971|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
214764972|NCT06910267|BEHAVIORAL|APS Treatment as Usual|APS agencies conduct in-home investigations of alleged abuse and neglect against disabled and older adults. Investigations result in short-term stop-gap measures, primarily brief case-management centering on referral linkage to community-based services and provision of resource allocation. No direct psychological services or treatments are provided by APS, however referral to other services is also standard.
214764973|NCT06910267|BEHAVIORAL|Intervention-Behavioral Activation (BA)|Participants will be will be guided through 8 one-hour sessions via home telehealth by the study community health worker. Each weekly \< 60 minute BA session will include modules focusing on 1) Psychoeducation for depression and techniques for self-management, including pharmacologic and psychosocial treatment options; 2) Introduction of BA and guided problem-solving techniques to enhance self efficacy for managing depression and other chronic illnesses; 3) BA and problem-solving techniques to support medication management and adherence strategies; 4) BA to develop strategies and techniques for communicating with health providers and/or support resources to foster positive mood and self management; and 5) Developing a relapse prevention plan, which includes identifying triggers for lower functioning, support resources, and practice of BA techniques.
214764974|NCT06935149|DRUG|18-PSMA|Intravenous push 4 MBq/kg per patient (for a 70 kg patient, 280 MBq of \[18F\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \[18F\]FPSMA, intravenous flushing was performed with 20 ml of normal saline.
214764975|NCT06936306|PROCEDURE|GBT|GBT Protocol
214764976|NCT06936306|DEVICE|Master|Use master piezon
214764977|NCT06936306|PROCEDURE|scalling|scalling
214764978|NCT06942117|OTHER|Experimental|Approximately 280 grams of caffeine containing coffee will be given
214764979|NCT06942117|OTHER|Placebo|Decaffeinated coffee will be given.
214764980|NCT06942364|OTHER|Action Observation Therapy|"The AOT video comprised four specific tasks designed to improve lower extremity function, balance, and gait (Figure 1):~1. Sitting Balance: Movements to enhance balance while seated (Figure 2).~2. Sit-to-Stand Transition: Exercises to facilitate the transition from sitting to standing.~3. Walking and Balance: Gait and balance training on a parallel bar or flat surface.~4. Single-Leg Balance: Activities focused on improving balance on one leg. For each task, children observed the movement for 1 minute, then practiced the action for 5 minutes. A 1-minute rest period was allowed between tasks, with a total AOT session lasting 30 minutes. All sessions were conducted by the same physiotherapist."
214764981|NCT06942364|OTHER|conventional physiotherapy|Conventional physiotherapy is a widely used therapeutic approach that focuses on improving physical function, mobility, and overall quality of life through evidence-based techniques. It typically includes exercises for strength, flexibility, balance, and coordination, along with manual therapy, postural training, and education about movement and body mechanics. This traditional method is commonly applied in the rehabilitation of patients with neurological, orthopedic, and musculoskeletal conditions. In pediatric populations, such as children with cerebral palsy, conventional physiotherapy plays a vital role in promoting motor development, enhancing functional independence, and preventing secondary complications.
214764982|NCT06942195|OTHER|Ca-1000|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 1000 mg, stimulates gut hormones and motility, will be 'higher dose' in this condition.
214764983|NCT06942195|OTHER|Ca-500|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 500 mg, stimulates gut function. In this condition, it will be considered 'lower dose.'
214764984|NCT06942195|OTHER|Control|Saline (an isotonic solution containing 2.8 g of sodium chloride (NaCl), dissolved in 225 mL of distilled water).
214764985|NCT06941675|OTHER|Hybrid Closed-Loop Artificial Pancreas System|Hybrid Closed-Loop Artificial Pancreas System Group: Uses an open-source system with Novo Nordisk ultra-rapid-acting insulin (approval: J20050097, 3 mL: 300 U). Daily insulin dose calculated at 0.3-0.6 U/(kg\*d) based on weight; system auto-adjusts basal rate. Physicians prescribe bolus doses, entered by nurses via AAPS software. Glucose correction uses CGM + 4 daily capillary tests (fasting, 2h post-meal). AAPS features hypoglycemia prediction suspend (pauses basal if glucose ≤4.4 mmol/L, resumes upon recovery) and alarms (\<3.9 mmol/L, ensures nighttime alert).
214764986|NCT06943742|DIAGNOSTIC_TEST|Magnetoencephalography plus Computed Tomography/Magnetic Resonance Imaging|Use Magnetoencephalography and Computed Tomography/Magnetic Resonance Imaging in the preoperative assessment of pediatric brain tumors.
214764987|NCT06942884|DRUG|Dexmedetomidine and dexamethasone in addition to bupivacaine in rectus sheath block|addition of dexmedetomidine to dexamethasone in rectus sheath block
214764988|NCT06942884|DRUG|dexamethsone in addition to bupivacaine in rectus sheath block|addition of dexamethasone in rectus sheath block
214764989|NCT06943326|OTHER|nutrition monitoring|There is no investigator intervention in the study. Patients' nutrition is recorded for one week from the beginning of the study.
214764990|NCT06939309|PROCEDURE|Acupuncture|In this study, both the acupuncture SC group and the acupuncture CS group will receive two acupuncture treatments in one session. The SC group will first receive acupuncture at the standardized acupoint followed by the controlled acupoint, while the CS group will first receive acupuncture at the controlled acupoint followed by the standardized acupoint.
214764991|NCT06939309|PROCEDURE|Rehabilitation|Participants will complete a 30-minute rehabilitation session, which includes electrotherapy and thermotherapy applied to the shoulder.
214764992|NCT06941688|DRUG|Decitabine with GemOx|Each treatment cycle consists of 3 weeks, and a total of 6 cycles will be administered. The drugs will be administered sequentially in the following order: decitabine, gemcitabine, and oxaliplatin. Decitabine will be administered at a dose of 7.5 mg/m² on days 1 to 5; gemcitabine at 1000 mg/m² on days 1 and 8; and oxaliplatin at 100 mg/m² on day 1 of each cycle.
214764993|NCT06941688|DRUG|GemOx|Each treatment cycle spans 3 weeks, with a total of 6 cycles planned. Gemcitabine will be administered at a dose of 1000 mg/m² on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1 of each cycle.
214764994|NCT06942000|DRUG|dexmedetomidine 3mcg group|3mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
214764995|NCT06942000|DRUG|dexmedetomidine 5mcg|5mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
214764996|NCT06942000|DRUG|preservative-free 0.9% saline.|(0.5 ml) preservative-free 0.9% saline
214764997|NCT06941662|DIAGNOSTIC_TEST|computer vision, remote monitoring, blood, urine, wrist bands, mobile-app|This is a low burden study that relies on a combination of cutting edge remote monitoring methods to deliver individualized evaluations to participants in their homes.
214764998|NCT06942026|DRUG|Control 1|Researchers will perform oral care with ozonated water and hypochlorous acid solution to restore oral mucous membrane integrity.
214764999|NCT06942520|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
214765000|NCT06942520|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
214765001|NCT06942520|BIOLOGICAL|Aflibercept (2.0 mg)|Commercially available Active Comparator
214765002|NCT06941584|DIAGNOSTIC_TEST|Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay|To evaluate the prevalence of specific autoantibodies (AQP4, AChR, LGI1, and CASPR2) in the population of patients carrying AIRE mutations (second cohort)
214765003|NCT06941584|GENETIC|AIRE single gene sequencing|To assess the prevalence of AIRE gene mutations in patients with NMOSD associated with AQP4 autoantibodies, myasthenia gravis (MG) associated with AChR autoantibodies, acquired neuromyotonia, and autoimmune encephalitis associated with CASPR2 and LGI1 autoantibodies (first cohort)
214765004|NCT06941584|GENETIC|Molecular typing of HLA class I and II alleles|To assess the HLA haplotypes of class I and II by comparing patients with and without AIRE mutations, as well as those with and without autoimmune neurological diseases
214765005|NCT06943560|BEHAVIORAL|Emotion Regulation Selection Flexibility Training|7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on days without sessions. Psychoeducation includes information on selection of appropriate strategy according to the regulatory selection flexibility rule (i.e., distraction for high intensity vs reappraisal in low intensity). In the computerized task participants are exposed to emotional words and are asked to select a regulatory strategy in a flexible matter according to the regulatory selection flexibility rule, and receive feedback on whether they chose flexibly or not. Following , they are instructed to implement the chosen strategy. Homework includes choosing two daily events one of high intensity and a second one of low intensity, and describe which strategy they selected and how they implemented their chosen strategy according to the flexibility rule.
214793998|NCT03843957|OTHER|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
214765006|NCT06943560|BEHAVIORAL|Emotion Regulation Active control Training|"All the interventional sections are similar to the experimental group except that in the control group we omit the regulatory selection rule that defines which strategy is compatible with which emotional situation.~7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on the days without sessions. Psychoeducation explicitly included information on regulatory strategies (without the regulatory selection flexibility rule). In the computerized task participants are exposed to the same emotional words and are asked to choose freely a regulatory strategy (without the regulatory selection flexibility rule or feedback), and implement it. Homework includes choosing two daily events and selecting and implementing a regulatory strategy (without the regulatory selection flexibility rule)."
214765007|NCT06943339|OTHER|Standard enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the standard enteral nutrition group for standard product (1kkal/1ml) intake. No intervention will be made by the researchers during the treatment process of the patients.
214765008|NCT06943339|OTHER|High energy and protein enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the high energy and protein enteral nutrition group for the intake of high energy and protein containing product (1.5kkal/1ml + protein content increased). No intervention will be made by the researchers during the treatment process of the patients.
214765009|NCT06949748|DRUG|Flecainide (monotherapy)|"• Medication: Flecainide acetate, administered orally.~* Initial Dosing and Titration:~* Patients were started on an appropriate dose based on body weight and renal function.~* The typical starting dose was 100-150 mg per day, split into two doses.~* Dosing was titrated as needed, depending on patient response and tolerability, under close ECG and clinical monitoring.~* Monitoring Protocol:~* Continuous ECG monitoring during drug initiation (especially in-hospital or via Holter).~* Regular outpatient follow-up visits, including:~* 12-lead ECGs~* Holter monitoring~* Echocardiography (to monitor LVEF and assess for reverse remodeling)~* ECG parameters (QRS width, QTc interval) were closely monitored for proarrhythmic changes."
214765010|NCT06531512|DRUG|Xianglei Tangzu Gao|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
214765011|NCT06531512|OTHER|Vehicle Cream|Cream base of Xianglei Tangzu Gao
214765012|NCT05801094|DRUG|QL1604|QL1604 3 mg/kg Q3W
214765013|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
214765014|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
214765015|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
214765016|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
214765017|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
214765018|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
214765019|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
214765020|NCT04196439|PROCEDURE|continuous epidural analgesia|injection of local anaesthetic into epidural space
214765021|NCT04196439|PROCEDURE|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
214765022|NCT04440631|OTHER|no intervention, observational only|no intervention, observational only
214765023|NCT05752344|OTHER|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
214765024|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
214765025|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
214765026|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
214765027|NCT05354141|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214765028|NCT05354141|OTHER|Intravenous normal saline|Placebo
214765029|NCT03666819|DEVICE|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
214765030|NCT03666819|OTHER|Questionnaire Administration|Ancillary studies
214765031|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
214765032|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
214765033|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
214765034|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
214765035|NCT00000423|BEHAVIORAL|Social support group|
214765036|NCT00000423|BEHAVIORAL|Social support and education group|
214765037|NCT03140527|DRUG|PTI-801|Active
214765038|NCT03140527|DRUG|Placebo|Placebo
214765039|NCT03140527|DRUG|PTI-808|Active
214765040|NCT03140527|DRUG|Placebo|Placebo
214765041|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
214765042|NCT03356431|OTHER|Supervised group exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
214765043|NCT03356431|OTHER|Home-based exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
214765044|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
214765045|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
214765046|NCT01441401|DRUG|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
214765047|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
214765048|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
214765049|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
214765050|NCT04907994|OTHER|Cohort|Nothing. Only implementation of a cohort with data collection via the SNDS.
214765051|NCT00002074|DRUG|Fluconazole|
214765052|NCT00002074|DRUG|Amphotericin B|
214765053|NCT00339066|DRUG|Sertraline|
214765054|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
214765055|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
214765056|NCT06319573|OTHER|Counseling Supported by Univfy® Report|The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
214765057|NCT06319573|OTHER|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
214765058|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
214765059|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
214765060|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
214765061|NCT01732666|DRUG|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
214765062|NCT01732666|DRUG|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
214765063|NCT01732666|DRUG|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
214765064|NCT04177173|DRUG|Simvastatin 20 mg|improvement of disease activity
214765065|NCT04177173|DRUG|Methotrexate 10 mg|improvement of disease activity
214765066|NCT04049448|DRUG|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
214765067|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
214765068|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
214765069|NCT03877848|DEVICE|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
214765070|NCT02985567|OTHER|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
214765071|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
214765072|NCT03328468|OTHER|Breathing Exercise|Breathing exercise for stroke patients
214765073|NCT03113201|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
214765074|NCT03113201|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
214765075|NCT05902767|OTHER|Nuts|"* A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines"
214765076|NCT05902767|OTHER|Control|\- Dietary counselling on how to follow the Australian Dietary Guidelines
214765077|NCT03469440|OTHER|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
214765078|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
214765079|NCT01506986|DRUG|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
214765080|NCT01506986|DRUG|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
214765081|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil + boswellic acid supplement|This supplement contains frankincense essential oil and boswellic acid as its active ingredients.
214765082|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil supplement|This supplement contains frankincense essential oil as its active ingredient.
214765083|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
214765084|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
214765085|NCT05533112|OTHER|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
214765086|NCT04682210|DRUG|Sintilimab|Sintilimab 200mg IV Q3W
214765087|NCT04682210|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
214765088|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
214765089|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
214765090|NCT04950413|OTHER|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
214765091|NCT04950413|OTHER|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
214765092|NCT04950413|DEVICE|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
214765093|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
214765094|NCT03080402|DEVICE|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
214765095|NCT00896038|DRUG|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
214765096|NCT00896038|DRUG|Placebo|Non-active placebo
214765097|NCT05138900|RADIATION|SBRT|SBRT for central non small cell lung cancer
214765098|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
214765099|NCT00390507|PROCEDURE|Post-tetanic count frequency|
214765100|NCT03032237|OTHER|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
214765101|NCT03032237|OTHER|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
214765102|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
214765103|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
214765104|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
214765105|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
214765106|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
214765107|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
214765108|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
214765109|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
214765110|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
214765111|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
214765112|NCT03858920|DEVICE|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
214765113|NCT03858920|PROCEDURE|Low-dose non-contrast CT|CT scan as part of routine research care
214765114|NCT06700902|BEHAVIORAL|Taking Action|Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
214765115|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
214765116|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
214765117|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
214765118|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
214765119|NCT01889927|OTHER|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
214765120|NCT00929201|DRUG|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
214765121|NCT00929201|DRUG|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
214765122|NCT00929201|DRUG|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
214765123|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
214765124|NCT02384239|DRUG|Palbociclib|Given orally (PO)
214765125|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
214765126|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
214765127|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
214765128|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
214765129|NCT01299272|DRUG|LY2216684|
214765130|NCT01299272|DRUG|Placebo|
214765131|NCT01299272|DRUG|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
214765132|NCT02501655|DEVICE|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
214765133|NCT02501655|DEVICE|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
214794451|NCT04582396|PROCEDURE|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
214765134|NCT06356038|PROCEDURE|intra-operative phrenic nerve infiltration|patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
214765135|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
214765136|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
214765137|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
214765138|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
214765139|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
214765140|NCT00090337|PROCEDURE|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
214765141|NCT00090337|PROCEDURE|standard follow-up care|Patients undergo standard care
214765142|NCT00308100|DRUG|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
214765143|NCT00308100|DRUG|5% Albumin|5% albumin, administered intra- and perioperatively
214765144|NCT02995928|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
214765145|NCT02995928|PROCEDURE|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
214765146|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
214765147|NCT02650609|DRUG|Methylprednisolone|
214765148|NCT02650609|DRUG|Placebo|
214765149|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
214765150|NCT06116994|OTHER|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
214765151|NCT06116994|OTHER|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
214765152|NCT00630994|DRUG|Dacogen|
214765153|NCT00159367|DEVICE|Repetitive magnetic stimulation to the quadriceps|
214765154|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
214765155|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
214765156|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
214765157|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
214765158|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
214765159|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
214765160|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
214765161|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
214765162|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
214765163|NCT00664417|BIOLOGICAL|Physiological saline|0.5 mL, IM, 2 injections
214765164|NCT03035981|OTHER|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765165|NCT03035981|OTHER|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765166|NCT03035981|OTHER|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765167|NCT03035981|OTHER|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765168|NCT03035981|OTHER|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765169|NCT03035981|OTHER|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765170|NCT03035981|OTHER|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
214765171|NCT03130855|DRUG|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
214765172|NCT03130855|DRUG|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
214765173|NCT01224418|DRUG|Tacrolimus|oral
214765174|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
214765175|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
214765176|NCT04583384|DIAGNOSTIC_TEST|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
214765177|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
214765178|NCT04185207|OTHER|no intervention|There is no intervention.
214765179|NCT06568445|DRUG|Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）|one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
214765180|NCT06568445|DRUG|as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）|as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
214765181|NCT03533608|BEHAVIORAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
214765182|NCT00122148|BEHAVIORAL|Feedback on provision of care|
214765183|NCT06700382|DRUG|capecitabine|different methods of treatment for capecitabine
214765184|NCT04872127|DEVICE|proximal embolism protection device|a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
214765185|NCT04872127|DEVICE|distal embolism protection device|a distal SpiderFX will be used as the embolism protection device during CAS
214765186|NCT03541668|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
214765187|NCT03541668|DRUG|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
214765188|NCT03286426|DIAGNOSTIC_TEST|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
214765189|NCT05241626|DIAGNOSTIC_TEST|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
214765190|NCT05359640|OTHER|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
214765191|NCT02255773|BEHAVIORAL|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
214765192|NCT02255773|BEHAVIORAL|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
214765193|NCT06558630|PROCEDURE|Endotracheal intubation|Over the course of several years as many as possible ED centres in the Netherlands will be included in the collection of all data involving airway management. Airway management is defined as the process of planning, preparation and execution of endotracheal intubation.
214765194|NCT06125886|DIAGNOSTIC_TEST|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
214765195|NCT00871104|DRUG|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
214765196|NCT00871104|DRUG|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
214765197|NCT03196739|DEVICE|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
214765198|NCT06073041|OTHER|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then receive an in-depth standardized onboard training.
214765199|NCT05368714|BEHAVIORAL|Economic Empowerment (EE)|EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.
214765200|NCT05368714|BEHAVIORAL|Multiple Family Group based Family Strengthening (MFG-based FS)|MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.
214765201|NCT05368714|BEHAVIORAL|EE plus MFG-based FS|EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
214765202|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
214765203|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
214765204|NCT03514121|BIOLOGICAL|FPA150|A monoclonal antibody against B7-H4
214765205|NCT03514121|BIOLOGICAL|Pembrolizumab|An anti-PD1 antibody
214765206|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
214765207|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
214765208|NCT03637270|DIETARY_SUPPLEMENT|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
214765209|NCT03637270|OTHER|Exercise training|Including aerobic cycling training and progressive resisted exercise
214765210|NCT00380575|DRUG|YM087|
214765211|NCT05078632|OTHER|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
214765212|NCT05399407|OTHER|Health e-coaching|Management of overweight / obesity
214765213|NCT01493063|OTHER|Physiopathology|Samples of breastmilk and infant serum and questionnaires.
214765214|NCT00609063|DRUG|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
214765215|NCT00609063|DRUG|Placebo|Placebo capsules taken daily for 6 months
214765216|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
214765217|NCT04329013|OTHER|Left lateral Position during intervention|Left lateral position during EGD
214765218|NCT04329013|OTHER|Prone Position during intervention|Prone position during EGD
214765219|NCT01855321|DRUG|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
214765220|NCT01855321|DRUG|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
214765221|NCT04425642|DRUG|Glucose/Amino acids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
214765222|NCT04425642|DRUG|Glucose/Amino acids/Lipids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
214765223|NCT02437981|DRUG|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
214765224|NCT04714684|DEVICE|Fitostimoline proctogel|Medical device for topical use for the treatment of fissures
214765225|NCT04714684|DEVICE|Fitostimoline proctogel + muscle relaxant|medical device for topical use for the treatment of fissures
214765226|NCT00949052|GENETIC|DNA analysis|
214765227|NCT00949052|GENETIC|polymorphism analysis|
214765228|NCT00949052|OTHER|laboratory biomarker analysis|
214765229|NCT00949052|OTHER|medical chart review|
214765230|NCT00949052|OTHER|questionnaire administration|
214765231|NCT00949052|PROCEDURE|assessment of therapy complications|
214765232|NCT00949052|PROCEDURE|evaluation of cancer risk factors|
214765233|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
214765234|NCT02980029|OTHER|Placebo|Placebo
214765235|NCT04931147|DRUG|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
214765236|NCT04931147|DRUG|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
214765237|NCT01922973|OTHER|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
214765238|NCT01900392|BEHAVIORAL|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
214765239|NCT04861831|OTHER|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
214765240|NCT00457431|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
214765241|NCT06649591|BEHAVIORAL|Survey|The intervention is an email based survey as described in the study description.
214765242|NCT06562439|BEHAVIORAL|Sickle Cell Collaboration for Child Development|The Sickle Cell Collaboration for Child Development (SCCCD) combines the Parents as Teachers curriculum with experienced occupational therapy to help families and children meet their learning and developmental goals.
214765243|NCT06703268|DRUG|HSK7653 10 mg|HSK7653 10 mg Q2W
214765244|NCT06703268|DRUG|Daily DPP-4 inhibitor|Daily DPP-4 inhibitor
214765245|NCT06539143|DRUG|Lidocaine|The Paracervical Block with lidocaine for manual vacuum aspiration
214765246|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
214765247|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
214765248|NCT04676386|DIAGNOSTIC_TEST|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
214765249|NCT01200316|PROCEDURE|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
214765250|NCT01200316|PROCEDURE|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
214765251|NCT01200316|BEHAVIORAL|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
214765252|NCT03667586|BEHAVIORAL|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
214765253|NCT05001763|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
214765254|NCT05001763|DRUG|Placebo|Glucose, 2mg, tablet.
214765255|NCT03422081|DIAGNOSTIC_TEST|arterial doppler ultrasound|doppler ultrasound
214765256|NCT04707066|BEHAVIORAL|Treatment As Usual (TAU)|Treatment As Usual
214765257|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
214765258|NCT04707066|BEHAVIORAL|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
214765259|NCT04707066|BEHAVIORAL|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
214765260|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
214765261|NCT03172390|DEVICE|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
214765262|NCT01466959|OTHER|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
214765263|NCT01466959|OTHER|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
214765264|NCT03286400|DEVICE|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
214765265|NCT02260752|PROCEDURE|hysterectomy|surgical removal of the uterus
214765266|NCT02260752|PROCEDURE|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
214765267|NCT02260752|PROCEDURE|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
214765268|NCT02260752|DRUG|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
214765269|NCT02260752|PROCEDURE|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
214765270|NCT02260752|PROCEDURE|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
214765271|NCT02260752|PROCEDURE|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
214765272|NCT05500235|BEHAVIORAL|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
214765273|NCT05500235|BEHAVIORAL|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
214765274|NCT05179980|OTHER|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
214765275|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
214765276|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
214765277|NCT06359964|PROCEDURE|Transperineal Biopsy without antibiotics prophylaxis|Transperineal Biopsy without antibiotics prophylaxis
214765278|NCT06359964|PROCEDURE|Transperineal Biopsy with antibiotics prophylaxis|Transperineal Biopsy with antibiotics prophylaxis
214765279|NCT05447559|DRUG|Cefazolin|Intravenous administration of 2 g cefazolin
214765280|NCT05447559|DRUG|Water for injection|Intravenous administration of 10mL sterile water for injection
214765281|NCT06236152|DRUG|Ferrous sulfate|Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.
214765282|NCT06236152|DRUG|Deltacortril|Deltacortil 10mg was given orally once daily for 4 to 6 weeks
214765283|NCT06340087|OTHER|10% Sucrose|10% sucrose corresponding to a regular soft drink
214765284|NCT06340087|DRUG|Sucrose+ Hesperetin|Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
214765285|NCT06340087|OTHER|7% Sucrose|7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
214765286|NCT04219800|BEHAVIORAL|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
214765287|NCT04219800|BEHAVIORAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
214765288|NCT00514709|BIOLOGICAL|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
214765289|NCT00514709|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, IM
214765290|NCT00514709|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine.
214765291|NCT03102788|BEHAVIORAL|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
214765292|NCT03102788|BEHAVIORAL|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
214765293|NCT00826176|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
214765294|NCT02543229|DRUG|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
214765295|NCT02543229|DRUG|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
214765296|NCT02406365|DEVICE|Diagnostic imaging aid for one-visit management of cervical lesions|
214765297|NCT01921725|DEVICE|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
214765298|NCT03593239|OTHER|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
214765299|NCT03593239|OTHER|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
214765300|NCT03593239|OTHER|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
214765301|NCT03593239|OTHER|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
214765302|NCT03593239|OTHER|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
214765303|NCT03593239|OTHER|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
214765304|NCT03593239|OTHER|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
214765305|NCT03593239|OTHER|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
214765306|NCT03593239|OTHER|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
214765307|NCT03593239|OTHER|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
214765308|NCT00317967|DRUG|Atorvastatin|80 mg pills daily
214765309|NCT00317967|DRUG|Placebo|80 mg pills daily
214765310|NCT05296369|DRUG|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
214793999|NCT03843957|OTHER|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
214765311|NCT00752401|DRUG|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
214765312|NCT00752401|DRUG|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
214765313|NCT06079801|DEVICE|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
214765314|NCT06079801|DRUG|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
214765315|NCT04430101|PROCEDURE|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
214765316|NCT04430101|PROCEDURE|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
214765317|NCT03823339|DRUG|Insulin degludec/liraglutide|Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
214765318|NCT01340703|PROCEDURE|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
214765319|NCT06566508|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide Intracanal medication
214765320|NCT06566508|DRUG|Leddermix Intracanal medication|Leddermix Intracanal medication
214765321|NCT06566508|DRUG|Asiaticoside Intracanal medication|Asiaticoside Intracanal medication
214765322|NCT06057233|DIAGNOSTIC_TEST|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
214765323|NCT02881970|DRUG|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
214765324|NCT01687400|DRUG|decitabine|
214765325|NCT00002628|BIOLOGICAL|filgrastim|
214765326|NCT00002628|DRUG|carboplatin|
214765327|NCT00002628|DRUG|cyclophosphamide|
214765328|NCT00002628|DRUG|mesna|
214765329|NCT00002628|DRUG|paclitaxel|
214765330|NCT00002628|PROCEDURE|peripheral blood stem cell transplantation|
214765331|NCT03932747|OTHER|pre- Hydratión skin|Measurement of hydration of the skin.
214765332|NCT03932747|OTHER|post- Hydratión skin|Measurement of hydration of the skin.
214765333|NCT04475068|PROCEDURE|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
214765334|NCT02995265|DEVICE|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
214765335|NCT02995265|OTHER|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
214765336|NCT00437710|PROCEDURE|cell therapy, bone marrow derived stem cell|
214765338|NCT03016104|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214765339|NCT03016104|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
214765340|NCT03016104|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
214765341|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
214765342|NCT05255354|DEVICE|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
214765343|NCT03032575|BEHAVIORAL|SEARCH010/RV254|
214765344|NCT00436397|RADIATION|radiation therapy|
214765345|NCT03953768|DEVICE|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
214765346|NCT04800822|DRUG|PF-07284892|PF-07284892
214765347|NCT04800822|DRUG|lorlatinib|lorlatinib
214765348|NCT04800822|DRUG|binimetinib|binimetinib
214765349|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
214765350|NCT04800822|DRUG|encorafenib|encorafenib
214765351|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
214765352|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
214765353|NCT04846920|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
214765354|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
214765355|NCT05854745|BEHAVIORAL|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
214765356|NCT05854745|BEHAVIORAL|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
214765357|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
214765358|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214765359|NCT01970280|DRUG|Enoxaparin|
214765360|NCT02530320|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
214765361|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
214765362|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
214765363|NCT00297882|DRUG|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
214765364|NCT00297882|DRUG|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
214765365|NCT03665246|BEHAVIORAL|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
214765366|NCT03534635|DRUG|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
214765367|NCT03534635|DRUG|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
214765368|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
214765369|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
214765370|NCT04484987|OTHER|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
214765371|NCT04484987|OTHER|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
214765372|NCT03944798|OTHER|Frequency: Every 3 Months|every 3 months
214765373|NCT03944798|OTHER|Frequency: Every 6 Months|every 6 months
214765374|NCT03944798|OTHER|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
214765375|NCT03944798|OTHER|Imaging Modality: Chest CT|Chest computed tomography (CT)
214765376|NCT04242264|OTHER|Placebo|0.9% Sterile Normal Saline, USP
214765377|NCT04242264|BIOLOGICAL|Shigella sonnei strain 53G|1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
214765378|NCT04242264|BIOLOGICAL|WRSs2|10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
214765379|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
214765380|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
214765381|NCT05948917|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
214765382|NCT05097066|PROCEDURE|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
214765383|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
214765384|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
214765385|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
214765386|NCT01550354|DRUG|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
214765387|NCT01550354|DRUG|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
214765388|NCT01550354|DRUG|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
214765389|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
214794000|NCT00536926|DEVICE|Home spirometry with data transfer via cell phone|home spirometry recording
214765390|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
214765391|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
214765392|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
214765393|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
214765394|NCT00775827|DRUG|fenofibrate 160 mg tablets|
214765395|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
214765396|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
214765397|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
214765398|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
214765399|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
214765400|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
214765401|NCT01067729|DEVICE|AWBAT Wound Dressing|
214765402|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
214765403|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
214765404|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
214765405|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
214765406|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
214765407|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
214765408|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214765409|NCT01177865|OTHER|informational intervention|
214765410|NCT01177865|OTHER|questionnaire administration|
214765411|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
214765412|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
214765413|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
214765414|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
214765415|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
214765416|NCT01292291|OTHER|biologic sample preservation procedure|
214765417|NCT01292291|OTHER|laboratory biomarker analysis|
214765418|NCT01292291|OTHER|study of socioeconomic and demographic variables|
214765419|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214765420|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214765421|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
214765422|NCT01292291|PROCEDURE|quality-of-life assessment|
214765423|NCT01292291|PROCEDURE|transperineal prostate biopsy|
214765424|NCT01292291|PROCEDURE|transrectal prostate biopsy|
214765425|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
214765426|NCT00433771|DEVICE|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
214765427|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
214765428|NCT01145872|BEHAVIORAL|Health Enhancement Program|
214765429|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
214765430|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
214765431|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
214794001|NCT00536926|DEVICE|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
214794002|NCT00536926|DEVICE|Home spirometer w/o BT|Standard home spirometry
214765432|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
214765433|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
214765434|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
214765435|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
214765436|NCT04208165|OTHER|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
214765437|NCT04208165|OTHER|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
214765438|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
214765439|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
214765440|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
214765441|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
214765442|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
214765443|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
214765444|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
214765445|NCT04509440|DRUG|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
214765446|NCT04509440|DRUG|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
214765447|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
214765448|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
214765449|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
214765450|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
214765451|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
214765452|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
214765453|NCT02585375|DRUG|Preserved latanoprost 0.005%|
214765454|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
214765455|NCT02353572|DRUG|Melphalan|Given IV
214765456|NCT02353572|DRUG|Bortezomib|Given IV
214765457|NCT02353572|DRUG|Dexamethasone|Given IV
214765458|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
214765459|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
214765460|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
214765461|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
214765462|NCT00256217|DRUG|Anastrozole|1 mg. oral every day for 2 - 4 weeks
214765463|NCT00000549|DRUG|estrogen replacement therapy|
214765464|NCT00000549|DRUG|hormone replacement therapy|
214765465|NCT00000549|DRUG|estrogens|
214765466|NCT00000549|DRUG|progestins|
214765467|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
214765468|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
214765469|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
214765470|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
214765471|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
214765472|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
214765473|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
214765474|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
214765475|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
214765476|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
214765477|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
214765478|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
214765479|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
214765480|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
214765481|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
214765482|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
214765483|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
214765484|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
214765485|NCT00080925|BIOLOGICAL|filgrastim|
214765486|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
214765487|NCT00080925|BIOLOGICAL|rituximab|
214765488|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214765489|NCT00080925|DRUG|cyclophosphamide|
214765490|NCT00080925|DRUG|cyclosporine|
214765491|NCT00080925|DRUG|cytarabine|
214765492|NCT00080925|DRUG|doxorubicin hydrochloride|
214765493|NCT00080925|DRUG|etoposide|
214765494|NCT00080925|DRUG|fludarabine phosphate|
214765495|NCT00080925|DRUG|prednisone|
214765496|NCT00080925|DRUG|vincristine sulfate|
214765497|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
214765498|NCT05242146|DRUG|GB5121|Capsule containing GB5121
214765499|NCT01556646|DRUG|Tolvaptan|15 to 30mg qd titrated to sodium concentration
214765500|NCT06700486|PROCEDURE|SOCKET SHIELD|in implant dentistry
214765501|NCT06700486|PROCEDURE|Immediate implant and sticky bone|in implant dentistry
214765502|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
214765503|NCT00002373|DRUG|Maribavir|
214765504|NCT03474952|PROCEDURE|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
214765505|NCT03474952|PROCEDURE|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
214765506|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
214765507|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
214765508|NCT01179256|DIETARY_SUPPLEMENT|CURCUMIN|oral supplementation of curcumin 2000mg
214765509|NCT01179256|OTHER|no intervention other than stopping study|no intervention other than stopping study
214765510|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
214765511|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
214765512|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
214765513|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
214765514|NCT05269615|DRUG|Valsartan 80 mg|The well-established angiotensin II receptor blocker (ARB) valsartan will be used in the present study to selectively block AT1 receptors. Valsartan is a generic medication widely used in hypertensive patients since 1996 as well as safely applied in physiological studies comprising healthy individuals.1-3 A minimal valsartan dose of 80 mg known to acutely reduce circulating EPO levels in healthy individuals will be provided 4 hours before starting Study 1 to optimize AT1 blockade according to valsartan's half-life.1-3 The same dose of valsartan (80 mg) will be provided 4 hours before each ET session in Study 2. The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
214765515|NCT05269615|DRUG|Placebo|The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
214765516|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
214765517|NCT01830257|OTHER|sending message|Sending the suggestive short message
214765518|NCT01776060|OTHER|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
214765519|NCT01139801|DRUG|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
214765520|NCT01139801|DRUG|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
214765521|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
214765522|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
214765523|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of low-fat milk (fat <1.5%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
214765524|NCT06536868|DRUG|Tislelizumab|Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
214765525|NCT06536868|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
214765526|NCT06536868|DRUG|Carboplatin or Cisplatin|Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
214765527|NCT06536868|RADIATION|Thoracic radiotherapy|IMRT 30-45Gy/10-15f
214765528|NCT04482101|OTHER|Root canal obturation|Root canal filling
214765529|NCT03759301|DRUG|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
214765530|NCT03759301|DRUG|Placebo saline solution|same volume as growth hormone ampule used
214765531|NCT04907916|OTHER|SIRTUIN1|The NAD dependent deacetylase activity of Sirtuin1
214765532|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
214765533|NCT05869019|OTHER|education|Premature baby care training will be provided.
214765534|NCT06567132|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
214765535|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
214765536|NCT01596049|DEVICE|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
214765537|NCT01735864|DRUG|Indirubin 200μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
214765538|NCT01735864|DRUG|Indirubin 100 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
214765539|NCT01735864|DRUG|Indirubin 50 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
214765540|NCT01735864|DRUG|Indirubin 10 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
214765541|NCT00722007|DEVICE|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
214765542|NCT00858611|DRUG|VRC-FLUDNA047-00-VP|
214765543|NCT00858611|DRUG|Flulaval (Registered) Seasonal Influenza Vaccine|
214765544|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
214765545|NCT02310815|DEVICE|ReSure Sealant|
214765546|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
214765547|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
214765548|NCT00513578|BIOLOGICAL|sargramostim|
214765549|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
214765550|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
214765551|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
214765552|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
214765553|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
214765554|NCT00417820|DRUG|BCT194|
214765555|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
214765556|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214765557|NCT01244516|DEVICE|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
214765558|NCT01244516|DEVICE|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
214765559|NCT01244516|DEVICE|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
214765560|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
214765561|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
214765562|NCT02215434|DRUG|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
214765563|NCT02215434|DRUG|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
214765564|NCT04256135|OTHER|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
214765565|NCT04256135|OTHER|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
214765566|NCT01700335|DRUG|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
214765567|NCT05095896|OTHER|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
214765568|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
214765569|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
214765570|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
214765571|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
214765572|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
214765573|NCT01576731|DRUG|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
214765574|NCT01576731|DRUG|Tenofovir, Emtricitabine, Raltegravir|Combination drug
214765575|NCT03387267|DEVICE|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
214765576|NCT02233465|PROCEDURE|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
214765577|NCT01135901|BEHAVIORAL|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
214765578|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
214765579|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
214765580|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
214765581|NCT00244881|DRUG|cediranib maleate|Given orally
214765582|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
214765583|NCT02179385|BEHAVIORAL|Health Coaching|
214765584|NCT01213004|PROCEDURE|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
214765585|NCT01213004|PROCEDURE|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
214765586|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
214765587|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
214765588|NCT03664024|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
214765589|NCT03664024|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
214765590|NCT03664024|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
214765591|NCT03664024|DRUG|Cisplatin|Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
214765592|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
214765593|NCT01984931|DRUG|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
214765594|NCT01984931|DRUG|Metoclopramide hydrochloride monohydrate|
214765595|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
214765596|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
214765597|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
214765598|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
214765599|NCT05346939|DEVICE|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
214765600|NCT02292407|DEVICE|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
214765601|NCT04180371|DRUG|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
214765602|NCT04180371|DRUG|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
214765603|NCT05343793|OTHER|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
214765604|NCT05343793|OTHER|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
214765605|NCT05343793|OTHER|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
214765606|NCT05343793|OTHER|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
214765607|NCT00638118|DRUG|Fexofenadine|
214765608|NCT06701175|PROCEDURE|Nerve Block|anterolateral geniculate nerve block
214765609|NCT06701175|PROCEDURE|Portal Anesthesia|portal anesthesia
214765610|NCT03159611|DRUG|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
214765611|NCT03159611|DRUG|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
214765612|NCT06697483|DRUG|Daratumumab|Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.
214765613|NCT06697483|DRUG|Lenalidomide|"Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance."
214765614|NCT03394794|DEVICE|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
214765615|NCT01291069|DRUG|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
214765616|NCT01291069|DRUG|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
214765617|NCT02120482|DEVICE|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
214765618|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
214765619|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
214765620|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
214765621|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
214765622|NCT01779466|DRUG|Desmopressin|
214765623|NCT01779466|DRUG|Placebo (not active)|
214765624|NCT02651246|OTHER|data collection|
214765625|NCT03865550|DRUG|Isotonic saline|Placebo
214765626|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
214765627|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
214765628|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
214765629|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
214765630|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
214765631|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
214765632|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
214765633|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
214765634|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
214765635|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
214765636|NCT02391194|DRUG|AVB-620|
214765637|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
214765638|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
214765639|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
214765640|NCT04530227|DRUG|Pemetrexed|chemotherapy
214765641|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
214765642|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
214765643|NCT02182726|DRUG|MOBEC|
214765644|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
214765645|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
214765646|NCT00370929|BEHAVIORAL|Meditation|
214765647|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
214765648|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
214765649|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
214765650|NCT00003401|DRUG|carmustine|
214765651|NCT00003401|DRUG|cisplatin|
214765652|NCT00003401|DRUG|cyclophosphamide|
214765653|NCT00003401|DRUG|dexamethasone|
214765654|NCT00003401|DRUG|etoposide|
214765655|NCT00003401|DRUG|gemcitabine hydrochloride|
214765656|NCT00003401|DRUG|melphalan|
214765657|NCT00003401|DRUG|paclitaxel|
214765658|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
214765659|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
214765660|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
214765661|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
214765662|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
214765663|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
214765664|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
214765665|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
214765666|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
214765667|NCT01927159|OTHER|Placebo|
214765668|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
214765669|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
214765670|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
214765671|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
214765672|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
214765673|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
214765674|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
214765675|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
214765676|NCT01872832|DRUG|RDEA3170 and Placebo|
214765677|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
214765678|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
214765679|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
214765680|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
214765681|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
214765682|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
214765683|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
214765684|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
214765685|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
214765686|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
214765687|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
214765688|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
214765689|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
214765690|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
214765691|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
214765692|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
214765693|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
214765694|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
214765695|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
214765696|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
214765697|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
214765698|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
214765699|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
214765700|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
214765701|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
214765702|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
214765703|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
214765704|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
214765705|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
214765706|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
214765707|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
214765708|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
214765709|NCT02060227|PROCEDURE|Open Latarjet procedure|
214765710|NCT02060227|PROCEDURE|Arthroscopic Bankart repair|
214765711|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
214765712|NCT06567171|PROCEDURE|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures.|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures. Parental use of pain relief strategies (PURPS) and parental postoperative pain management (PPPM) tools were used to collect data on the adequacy of knowledge of the use of different pain relief strategies and the skill of parental pain assessment, respectively. We used Spearman's rank correlation coefficient was used to determine the relationships between pain score given by parents and nurses. The statistical tests were performed at a 95% confidence interval and a 5% significance level.
214765713|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
214765714|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
214765715|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
214765716|NCT00274807|BIOLOGICAL|filgrastim|
214765717|NCT00274807|DRUG|cytarabine|
214765718|NCT00274807|DRUG|etoposide|
214765719|NCT00274807|DRUG|mitoxantrone hydrochloride|
214765720|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
214765721|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
214765722|NCT02222168|DRUG|BI 409306|film-coated tablet
214765723|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
214765724|NCT01572610|DRUG|RTA 402|once a day, oral administration
214765725|NCT06196970|OTHER|Pilate exercises|After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
214765726|NCT06196970|OTHER|Burpees exercises|"After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set."
214765727|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
214765728|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
214765729|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
214765730|NCT00530621|DRUG|placebo|oral, daily
214765731|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
214765732|NCT00518011|DRUG|Erlotinib|150 mg po daily
214765733|NCT00518011|DRUG|Gemcitabine|As prescribed
214765734|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
214765735|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
214765736|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
214765737|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
214794003|NCT04023565|DRUG|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
214794004|NCT05694325|OTHER|peripheral blood and bone marrow withdrawal|samples evaluation
214765738|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
214765739|NCT05676164|DEVICE|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
214765740|NCT05676164|DEVICE|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
214765741|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
214765742|NCT05270512|DEVICE|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
214765743|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
214765744|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
214765745|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
214765746|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
214765747|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
214765748|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
214765749|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
214765750|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
214765751|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
214765752|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
214765753|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
214765754|NCT04190056|DRUG|Tamoxifen|Given PO
214765755|NCT04190056|DRUG|Vorinostat|Given PO
214765756|NCT04372810|PROCEDURE|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
214765757|NCT04372810|PROCEDURE|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
214765758|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
214765759|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
214765760|NCT00029159|OTHER|placebo|an inactive substance
214765761|NCT01248000|PROCEDURE|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
214765762|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
214765763|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
214765764|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
214765765|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
214765766|NCT02263677|DRUG|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
214765767|NCT04045405|DRUG|CDR132L|i.v. administration
214765768|NCT03258515|DRUG|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
214765769|NCT03258515|OTHER|Placebo|AZD6094 matching placebo without any pharmacological activity.
214765770|NCT03258515|DRUG|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
214765771|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
214765772|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
214765773|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
214765774|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
214765775|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
214765776|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
214765777|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
214765778|NCT03166969|PROCEDURE|Holter 21 days|
214765779|NCT04797637|DEVICE|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
214765780|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765781|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765782|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765783|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765784|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765785|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765786|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765787|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
214765788|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
214765789|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
214765790|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
214765791|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
214765792|NCT00482664|DRUG|Placebo|Tablets for oral administration
214765793|NCT01526707|DRUG|inhaled steroid|inhaled budesonide for 7 days
214765794|NCT01860690|DRUG|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
214765795|NCT03952962|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
214765796|NCT06810180|BEHAVIORAL|Go/No-Go Task|A computerized test in which participants are presented with red and green spaceship stimuli. They are told to press the spacebar in response to green spaceships (80% of trials) and withhold their response to red spaceships (20% of trials).
214765797|NCT06810180|BEHAVIORAL|Delay discounting task|Participants make decisions between smaller, immediate rewards and larger, delayed rewards. The amount of the immediate reward and delay time are manipulated to identify individual delay discounting curves, or how the reward value decreases as a function of delay.
214765798|NCT06810180|BEHAVIORAL|Mirror Tracing Persistence Task|A computerized test in which participants trace a star line drawing with a computer cursor using a trackpad with reversed directional controls. There are increasing levels of difficulty with participants being told they could quit the task during the very hard third star that they try to trace.
214765799|NCT06810180|BEHAVIORAL|Spatial Span|Participants are instructed to attend to a computer screen to keep track of the order in which a happy face stimuli appears in a sequence of boxes positioned on the screen. They are presented with 2 trials at each level of difficulty, increasing from 2 stimuli by 1 additional stimuli per trial until they respond incorrectly for both trials within a level. There are two task conditions, forward and backward span, with the participant responding in the reverse order that the stimuli were presented for backward span.
214765800|NCT06810180|BEHAVIORAL|Stop Signal Task|A computerized test in which participants are presented with a right or left facing arrow and are instructed to press a response button indicating the direction of the arrow. On 25% of the trials, an auditory beep is presented (i.e., stop signal) following the onset of the arrow (i.e., go signal) and participants are instructed to withhold their response when they hear the stop signal.
214765801|NCT06810180|BEHAVIORAL|Flanker task|A computerized test in which a group of arrows are presented on the screen with the central arrow (target) pointing in the same/opposite direction as the 4 surrounding arrows (flankers). Participants are instructed to respond as quickly and accurately as possible to the central target arrow.
214765802|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
214765803|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
214765804|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
214765805|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
214765806|NCT02061293|DRUG|Psilocybin|
214765807|NCT02061293|DRUG|Diphenhydramine|
214765808|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
214765809|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
214765810|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
214765811|NCT01866605|DEVICE|Bair Hugger|Forced air warming
214765812|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
214765813|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
214765814|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
214765815|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
214765816|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
214765817|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
214765818|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
214765819|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
214765820|NCT06720948|DEVICE|ION 3D Facet Screw System|Observational study of subjects previously implanted with ION 3D Facet Screw System.
214765821|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 5|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 5.
214765822|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 6|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 6.
214765823|NCT07047911|OTHER|Observational only - surgical management not assigned by study|Observational only - surgical management not assigned by study
214765824|NCT07047560|DRUG|fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev)|"Liposomal irinotecan (II): 30 mg/m² IV on D1 and D3, Q2W; Fluorouracil (5-FU): Q2W;~* 400 mg/m² IV bolus on D1~* Followed by 2400 mg/m² continuous IV infusion over 46-48 hours Leucovorin (LV): 400 mg/m² IV infusion on D1 Bevacizumab: 5 mg/kg IV infusion on D1, Q2W."
214765825|NCT07047755|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan
214765826|NCT07047755|DRUG|Pertuzumab|Pertuzumab
214765827|NCT07047079|OTHER|Preoperative rehabilitation exercises + Usual care|"1. Preoperative rehabilitation exercises~   1. Intervention methods: At the time of admission, the investigator demonstrated the content of preoperative rehabilitation exercises and provided a guidebook. Participants exercise on their own for approximately 3-7 days from the day of admission to the day of surgery as directed by the investigator and the manual.~  2. Exercise content:~      * Pulmonary function exercises: including abdominal breathing exercises and effective cough learning.~     * Muscle strength exercises: including straight leg raises and lateral leg raises.~     * Knee range of motion exercises: including knee flexion exercises and knee extension exercises.~     * ankle pump exercise~2. Usual care: Provided by a ward nurse."
214765828|NCT07047079|OTHER|The navigator guides the whole process of preoperative rehabilitation exercise + Usual care|"1. The navigator guides the whole process of preoperative rehabilitation exercise~   1. On the day of admission, the same intervention as in the preoperative rehabilitation autonomous exercise group was added:~      * Exercise Verification: Subjects demonstrate prescribed exercises to ensure correct execution.~     * Education \& Rapport:The navigator establishes therapeutic rapport and provides essential disease education.~  2. During the preoperative period (admission to surgery), the navigator implements:~      * Daily Supervised Exercise: Two 20-minute face-to-face rehabilitation sessions in the patient's room daily.~     * Standardized Reminders:Daily exercise adherence reminders via We Chat at 19:00-20:00.~     * Comprehensive Support: assessing needs and connecting to resources,,offering psychosocial/emotional support ,verbal interpretation, addressing exercise barriers and developing self-management skills~2. Usual care: Provided by a ward nurse."
214765829|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office|2.00x10⁸ HB-adMSCs IV at the doctor's office.
214765830|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR|100 million stem cells (1.00x10⁸ HB-adMSCs) in the corpora cavernosa of the penis suspended in a 4 cc of sterile saline. 50 million stem cells (5.0x 10⁷ HB-adMSCs) along the right neurovascular bundle and 50 million cell (5.0x 10⁷ HB-adMSCs) along the left neurovascular bundle of the penis suspended in a 4 cc of sterile saline during the surgery
214765831|NCT07048314|DRUG|Placebo in the OR|4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis during the surgery .
214765832|NCT07048314|DRUG|Placebo in clinic|30 mL syringe of the product should be mixed into a 250cc bag of sodium chloride solution 0.9% for infusion. should be administered intravenously, with a dosing rate of 4-5mL/min.
214765833|NCT06761469|OTHER|Implementing active-case finding strategies|Implementation of a multifactorial active-case finding strategy, including: (1) raising awareness among the population about leprosy; (2) theoretical and practical educational training for healthcare workers; (3) georeferencing of historical and existing cases in the municipality (from 2012 to 2023) and of new cases diagnosed throughout the study (dynamic changes); (4) screening tools for signs/symptoms of the disease (application of Leprosy Suspicion Questionnaire); and (5) serological profile (rapid test) of patients with reported signs/symptoms (positive answers Leprosy Suspicion Questionnaire).
214765834|NCT05014074|OTHER|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
214765835|NCT06779617|DEVICE|SEPSys|The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
214765836|NCT06779617|DEVICE|RESCUE|The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
214765837|NCT06828887|DRUG|LV232 40mg|LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
214765838|NCT06828887|DRUG|LV232 60mg|LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
214765839|NCT06828887|DRUG|Escitalopram|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
214765840|NCT06828887|DRUG|Placebo|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
214765841|NCT06926426|BEHAVIORAL|oral function training|A 12-week program including oral muscle strengthening, pronunciation drills, and swallowing-related exercises designed to improve oral function in older adults.
214765842|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
214765843|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
214765844|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
214765845|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
214765846|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
214765847|NCT06446973|OTHER|35 patients with meniscus tear|Have meniscus pathologies in one or both knees confirmed by MRI.
214765848|NCT06936540|OTHER|Virtual Tour|The intervention group will be trained by the researcher with a virtual tour material about surgical environments via a tablet computer.
214765849|NCT06936540|OTHER|No Interventions|The control group will not receive any intervention other than verbal training in the routine of the organization.
214765850|NCT06932588|DIAGNOSTIC_TEST|Biomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT|"The i-STAT TBI cartridge is a point-of-care, whole-blood, biomarker-based assay that measures the level of biomarkers associated with brain injury in the bloodstream 24 hours after injury. Blood samples (5-10cc of whole blood) will be collected upon admission during a routine blood draw in the ED. These samples will be tested using the iSTAT system for mild TBI biomarkers.~In a subset of admitted patients, serial blood draws and iSTAT testing will be performed at 4, 8, 16, and 24 hours, depending on the patient's length of stay."
214765851|NCT06942325|DEVICE|OTC self-fitting hearing aid|OTC hearing aid to be compared to prescription hearing aid
214765852|NCT06942325|DEVICE|Prescription hearing aid|Prescription hearing aid used as active comparator to the OTC self-fitting hearing aid
214765853|NCT06942624|BIOLOGICAL|Phage Therapy|Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).
214765854|NCT06943690|PROCEDURE|Single-port robotic surgery|In this group, patients will be operated using a single-port surgical robot system. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen. The surgical procedure followed the principle of total mesorectal excision.
214765855|NCT06943690|PROCEDURE|Multi-port robotic surgery|In this group, patients will be operated using a multi-port surgical robot system. Surgical instruments enter the abdominal cavity through 4 separate trocars. The surgical procedure followed the principle of total mesorectal excision.
214765856|NCT06943170|OTHER|Aerobic Exercise and Low Calorie Diet|Group A: Aerobic Exercise with Low calorie diet Group B: Aerobic Exercise without Low Calorie Diet
214765857|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
214765858|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
214765859|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
214765860|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
214765861|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
214765862|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
214765863|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
214765864|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
214765865|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
214765866|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
214765867|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
214765868|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
214765869|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
214765870|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
214765871|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
214765872|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
214765873|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
214765874|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
214765875|NCT03829527|BEHAVIORAL|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
214765876|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
214765877|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
214765878|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
214765879|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
214765880|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
214765881|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
214765882|NCT05104268|DEVICE|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
214765883|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
214765884|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
214765885|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
214765886|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
214765887|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
214765888|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
214765889|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
214765890|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
214765891|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
214765892|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
214765893|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
214765894|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
214765895|NCT03144115|DRUG|Oxytocin|
214765896|NCT03144115|DRUG|Placebos|
214765897|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
214765898|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
214765899|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
214765900|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
214765901|NCT00000227|DRUG|Buprenorphine|
214765902|NCT06703827|BEHAVIORAL|The metacognitive training group|The MCT will consist of spending 90 minutes a week in a small online group setting working through a series of workshops. Participants will also be asked to complete homework each week and they will be supported with this. Interviews and questionnaires regarding symptoms and thinking errors will be used before and immediately after the intervention. The participants who attended the group and improved in their symptoms and thinking errors will be invited to an interview asking them what worked for them and how they found the group.
214765903|NCT03088280|DRUG|Thymoglobulin|reduced dose (3mg/Kg)
214765904|NCT00242567|DRUG|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
214765905|NCT00242567|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
214765906|NCT00001001|DRUG|Zidovudine|
214765907|NCT03925116|OTHER|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
214765908|NCT06648317|OTHER|FDG-PET|All study participants will undergo 18F-FDG PET/CT scan within 1 week
214765909|NCT06451679|OTHER|Observational|Observational prospective study
214765910|NCT00571909|PROCEDURE|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
214765911|NCT03112707|DRUG|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
214765912|NCT03112707|DRUG|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
214765913|NCT03303807|DEVICE|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
214765914|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
214765915|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
214765916|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
214765917|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
214765918|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
214765919|NCT03494673|DIAGNOSTIC_TEST|BOLD MRI|"1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
214765920|NCT06567717|DRUG|Zinc|Zinc has not previously been investigated in the treatment of IPF.
214765921|NCT06567717|OTHER|Placebos for zinc and nicotinamide riboside|These will be identical in appearance to the active substances
214765922|NCT06567717|DRUG|Nicotinamide riboside|Nicotinamide riboside has not previously been investigated in the treatment of IPF.
214765923|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
214765924|NCT00002879|DRUG|cladribine|
214765925|NCT01022177|PROCEDURE|acupuncture|acupuncture of the eye in traditional chinese schematics
214765926|NCT00379925|BEHAVIORAL|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
214765927|NCT04960774|OTHER|Observational study, no intervention|Observational study, no intervention
214765928|NCT02191930|DRUG|B-CAP|
214765929|NCT02191930|DRUG|Brentuximab Vedotin|
214765930|NCT05332080|PROCEDURE|Telerehabilitation via application on cell phone|Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
214765931|NCT05643027|BEHAVIORAL|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
214765932|NCT05229562|DRUG|BIIB122|Administered as specified in the treatment arm.
214765933|NCT01064830|DRUG|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
214765934|NCT01064830|DRUG|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
214765935|NCT03956901|OTHER|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
214765936|NCT05130086|DRUG|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
214794005|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
214765937|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
214765938|NCT06573697|OTHER|low-frequency continuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
214765939|NCT06573697|OTHER|discontinuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
214765940|NCT06573697|OTHER|dilatational wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
214765941|NCT06542068|BEHAVIORAL|Line Bot Assistance|"The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.)."
214765942|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
214765943|NCT06019286|DIAGNOSTIC_TEST|SCINEXA score|\- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
214765944|NCT04149769|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
214765945|NCT04930536|DRUG|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
214765946|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
214765947|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
214765948|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
214765949|NCT06537206|OTHER|Application Footbath|The foot bath application for the experimental group will be applied with water at 38-40 degrees Celsius for an average of 10 minutes under thermometer control. Immediately afterward, the second physiological parameters will be measured.
214765950|NCT04835207|OTHER|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
214765951|NCT01542879|PROCEDURE|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
214765952|NCT01542879|PROCEDURE|18-F-FDG PET scan|
214765953|NCT01542879|DRUG|Ferumoxytol|
214765954|NCT01542879|PROCEDURE|18-F-FDG PET/MR scan|
214765955|NCT02816554|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
214765956|NCT02816554|BIOLOGICAL|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
214765957|NCT02816554|BIOLOGICAL|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
214765958|NCT02816554|BIOLOGICAL|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
214765959|NCT01387672|DRUG|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
214765960|NCT01387672|OTHER|Placebo|Placebo ointment
214765961|NCT04443673|DIETARY_SUPPLEMENT|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
214765962|NCT00154830|BEHAVIORAL|cerebral palsy|
214765963|NCT00154830|BEHAVIORAL|crouch gait|
214765964|NCT01926301|PROCEDURE|continuous veno-venous hemodialysis|
214765965|NCT01093040|DRUG|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
214765966|NCT01093040|DRUG|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
214765967|NCT01093040|DRUG|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
214765968|NCT01211496|BEHAVIORAL|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
214765969|NCT01211496|BEHAVIORAL|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
214765970|NCT01150409|DRUG|hydrocortisone|1\) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
214765971|NCT01150409|DRUG|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
214765972|NCT00441207|DRUG|Ascorbic Acid|Delivered via IV Infusion.
214765973|NCT03649607|OTHER|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
214765974|NCT04442178|DRUG|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
214765975|NCT04442178|DRUG|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
214765976|NCT06567080|BIOLOGICAL|JWCAR201|JWCAR201 is a autologous CAR-T targeting CD19/CD20
214765977|NCT05515627|DRUG|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
214765978|NCT06004401|DRUG|Vonopazan +Amoxicillin|Vonopazan 20mg 2//day+Amoxicillin
214765979|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
214765980|NCT06004401|DRUG|Vonopazan +Minocycline|Vonopazan 20mg 2/day+Minocycline 100mg 2/day
214765981|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
214765982|NCT01909817|PROCEDURE|Routine coronary angiogram|
214765983|NCT04691739|OTHER|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
214765984|NCT06113263|PROCEDURE|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
214765985|NCT06113263|PROCEDURE|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
214765986|NCT04108884|DEVICE|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
214765987|NCT04108884|DEVICE|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
214765988|NCT03079869|DRUG|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
214765989|NCT00387231|PROCEDURE|Percutaneous coronary angioplasty/intervention (PCI)|
214765990|NCT00387231|DRUG|Anti-ischemic drug therapy|
214765991|NCT02411110|COMBINATION_PRODUCT|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
214765992|NCT02411110|COMBINATION_PRODUCT|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
214765993|NCT01863095|BEHAVIORAL|Personalized Feedback and Exercise|
214765994|NCT00864409|DRUG|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
214765995|NCT00864409|DRUG|saline.9%|Wound infiltration with 170 mL sterile saline
214765996|NCT00561093|DRUG|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214765997|NCT00561093|DIETARY_SUPPLEMENT|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214765998|NCT00561093|DIETARY_SUPPLEMENT|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214765999|NCT00561093|DRUG|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214766000|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214766001|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
214766002|NCT03806478|DRUG|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
214766003|NCT03806478|OTHER|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
214766004|NCT04934891|DRUG|ION547|ION547 will be administered by SC injection.
214766005|NCT04934891|DRUG|Placebo|ION547-matching placebo will be administered by SC injection.
214766006|NCT04580511|DEVICE|CELLIS (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in abdominal reconstruction
214766007|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
214766008|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
214766009|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
214766010|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
214766011|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
214766012|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
214766013|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
214766014|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
214766015|NCT06288490|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
214766016|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
214766017|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
214766018|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
214766019|NCT01722058|DRUG|Peptide application|
214766020|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
214766021|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
214766022|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
214766023|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
214766024|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
214766025|NCT03901352|DRUG|Placebo|Matching placebo tablets for oral administration
214766026|NCT03901352|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
214766027|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
214766028|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
214766029|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
214766030|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
214766031|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
214766032|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
214766033|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
214766034|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
214766035|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
214794006|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
214794007|NCT02857881|PROCEDURE|De-epithelization and therapeutic photokeratectomy|
214794008|NCT05170555|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.
214766036|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
214766037|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
214766038|NCT04492488|DRUG|MRG002|Administrated intravenously
214766039|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
214766040|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
214766041|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
214766042|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
214766043|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
214766044|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
214766045|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
214766046|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
214766047|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
214766048|NCT04909879|DRUG|Placebo|Excipient solution
214766049|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
214766050|NCT00026156|DRUG|docetaxel|
214766051|NCT00026156|DRUG|vinorelbine tartrate|
214766052|NCT00226447|DRUG|Pegylated Interferon|
214766053|NCT00226447|DRUG|Lamivudine|
214766054|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
214766055|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
214766056|NCT04551027|BEHAVIORAL|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
214766057|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
214766058|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
214794009|NCT05170555|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
214766059|NCT06126770|BEHAVIORAL|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
214766060|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
214766061|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
214766062|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
214766063|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
214766064|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
214766065|NCT02263222|DRUG|MDT-10013|
214766066|NCT00795379|BEHAVIORAL|Interoceptive Exposure|Exposure to internal stimuli.
214766067|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
214766068|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
214766069|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
214766070|NCT03916692|DIETARY_SUPPLEMENT|Carbohydrate drink|Meal replacement drink containing 200 kcal
214766071|NCT03916692|DIETARY_SUPPLEMENT|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
214766072|NCT03916692|DIETARY_SUPPLEMENT|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
214766073|NCT02286284|DEVICE|Apheresis for extracorporal removal of sFlt-1|
214766074|NCT04934969|DIETARY_SUPPLEMENT|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
214766075|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
214766076|NCT06107127|PROCEDURE|STOP|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
214766077|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
214766078|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
214766079|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
214766080|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
214766081|NCT00270179|DRUG|epoetin alfa|
214766082|NCT00874042|DRUG|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
214766083|NCT05131893|DRUG|Tamoxifen|endocrine therapy
214766084|NCT05131893|DRUG|Goserelin|endocrine therapy
214766085|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
214766086|NCT05131893|DRUG|Epirubicin|chemotherapy
214766087|NCT05131893|DRUG|cyclophosphamide|chemotherapy
214766088|NCT05131893|DRUG|Docetaxel|chemotherapy
214766089|NCT05131893|DRUG|paclitaxel|chemotherapy
214766090|NCT05131893|DRUG|trastuzumab|biological treatment
214766091|NCT05131893|DRUG|pertuzumab|biological treatment
214766092|NCT05131893|DRUG|Capecitabine|chemotherapy
214766093|NCT00535873|DRUG|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
214766094|NCT06150001|DRUG|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
214766095|NCT06150001|DRUG|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
214766096|NCT06150001|DRUG|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
214766097|NCT00143416|DRUG|Pegvisomant|
214766098|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
214766099|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
214766100|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
214766101|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
214766102|NCT05982158|BEHAVIORAL|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
214766103|NCT05982158|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
214766104|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
214766105|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
214766106|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
214766107|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
214766108|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
214766109|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
214766110|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766111|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766112|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766113|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766114|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766115|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766116|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766117|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766118|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
214766119|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
214766120|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
214766121|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
214766122|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
214766123|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
214766124|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
214766125|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
214766126|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
214766127|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
214766128|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
214766129|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
214766130|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
214766131|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
214766132|NCT03223506|DRUG|Paracetamol|
214766133|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
214766134|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
214766135|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
214766136|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
214766137|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
214766138|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
214766139|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
214766140|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
214766141|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
214766142|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
214766143|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
214766144|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
214766145|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
214766146|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
214766147|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
214766148|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
214766149|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
214766150|NCT05450900|OTHER|Microcellulose filler|supplement, oral
214766151|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
214766152|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
214766153|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
214766154|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
214766155|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
214766156|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
214766157|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
214766158|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
214766159|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
214766160|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
214766161|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
214766162|NCT05351437|DRUG|Placebo|0.9% saline
214766163|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
214766164|NCT03026842|DRUG|Decitabine|20 mg/m2/day for 5 days
214766165|NCT03026842|DRUG|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
214766166|NCT03026842|DRUG|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
214766167|NCT03026842|DRUG|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
214766168|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
214766169|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
214766170|NCT05517746|DRUG|BAY2395840 tablet|tablets, oral administration
214766171|NCT05517746|DRUG|BAY2395840 oral solution|solution, oral administration
214766172|NCT05517746|DRUG|Placebo oral solution|Placebo matching BAY2395840, oral administration
214766173|NCT05517746|DRUG|Placebo tablet|Placebo matching BAY2395840, oral administration
214766174|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
214766175|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
214766176|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
214766177|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
214766178|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
214766179|NCT02998645|DRUG|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
214766180|NCT02998645|DRUG|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained"
214766181|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
214766182|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
214766183|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
214766184|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
214766185|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
214766186|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
214766187|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
214766188|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
214766189|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
214766190|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
214766191|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
214766192|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
214766193|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
214766194|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
214766195|NCT06566222|PROCEDURE|chemoradiotherapy after surgery|chemoradiotherapy after surgery vs preoperative chemoradiotherapy
214766196|NCT06566222|OTHER|High-risk Factors|High-risk Factors vs low-risk Factors
214766197|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
214766198|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
214766199|NCT04611152|DRUG|KSI-301|Intravitreal Injection
214766200|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
214766201|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214766202|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
214766203|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
214766204|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
214766205|NCT05343247|DIAGNOSTIC_TEST|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
214766206|NCT05343247|DIAGNOSTIC_TEST|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
214766207|NCT00580931|DRUG|Nicotinamide|1500 mg twice a day for 6 months
214766208|NCT00580931|DRUG|Enduramide placebo|1 tab twice a day
214766209|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
214766210|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
214766211|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
214766212|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
214766213|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
214766214|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
214766215|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
214766216|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
214766217|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
214766218|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
214766219|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
214766220|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
214766221|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
214766222|NCT00390091|DRUG|abetimus sodium (LJP 394)|
214766223|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
214766224|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
214766225|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
214766226|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
214766227|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
214766228|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
214766229|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
214766230|NCT00956813|OTHER|placebo|Given orally
214766231|NCT01615900|OTHER|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
214766232|NCT00134472|PROCEDURE|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
214766233|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
214766234|NCT00120380|DRUG|Aerosolized iloprost|
214766235|NCT00120380|DRUG|Placebo|
214766236|NCT02944682|OTHER|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
214766237|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214766238|NCT00240786|DRUG|acetaminophen extended release|
214766239|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
214766240|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
214766241|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
214766242|NCT02362243|OTHER|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
214766243|NCT02362243|OTHER|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
214766244|NCT00170898|DRUG|Lumiracoxib|
214766245|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
214766246|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
214766247|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
214766248|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
214766249|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
214766250|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
214766251|NCT02687763|BIOLOGICAL|ProQuad|"2\) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."
214766252|NCT04736316|BEHAVIORAL|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
214766253|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
214766254|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
214766255|NCT00117013|DRUG|Topotecan|
214766256|NCT05421715|OTHER|TELEDUC-DIAB|"* Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
214766257|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
214766258|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
214766259|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
214766260|NCT06014359|DRUG|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
214766261|NCT06014359|DRUG|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
214766262|NCT04551859|OTHER|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
214766263|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
214766264|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
214766265|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
214766266|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
214766267|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
214766268|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
214766269|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
214766270|NCT05043220|DEVICE|PPG and PROM|description will follow
214766271|NCT06701162|PROCEDURE|Ultrasoud-guided TAP block|the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.
214766272|NCT06701162|PROCEDURE|Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block|the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
214766273|NCT02204839|DRUG|Basal insulin dose|
214766274|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
214766275|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
214766276|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
214766277|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
214766278|NCT02864953|DRUG|BIIB093|Administered as specified in the treatment arm.
214766279|NCT02864953|DRUG|Placebo|Administered as specified in the treatment arm.
214766280|NCT05090085|OTHER|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
214766281|NCT05090085|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
214766282|NCT05090085|OTHER|3m ESPE etch|32% phosphoric acid
214766283|NCT05090085|OTHER|OT Primer|Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
214766284|NCT06073873|DRUG|Ozanimod|According to local product label
214766285|NCT06277466|DRUG|Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs|Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
214766286|NCT06277466|DRUG|Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs|"The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing."
214766287|NCT02487407|DRUG|ODM-109|ODM-109 1 mg capsule for oral administration.
214766288|NCT02487407|DRUG|Placebo for ODM-109|Placebo capsule for oral administration.
214766289|NCT04897334|DEVICE|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
214766290|NCT04897334|DEVICE|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
214766291|NCT04897334|BEHAVIORAL|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
214766292|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e4|
214766293|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e5|
214766294|NCT02076139|OTHER|Distilled water|
214766295|NCT00394992|DRUG|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
214766296|NCT00394992|DRUG|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
214766297|NCT06542887|DRUG|Atomoxetine|Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
214766298|NCT06542887|DRUG|Black Seed Oil Cap/Tab|Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
214766299|NCT06330545|RADIATION|Radiation therapy|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
214766300|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
214766301|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
214766302|NCT04440761|OTHER|Observation only|Observation only
214766303|NCT06621173|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, after enrollment, the investigator will determine the HNF4α srRNA dose, whether to combine it with immunotherapy, and the dose and schedule of the combination, based on the patient's treatment history and the safety/efficacy data of HNF4α srRNA administered via peripheral vein for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or colorectal cancer. Participants initially on HNF4α srRNA monotherapy who are considered for combination with immunotherapy must complete at least two treatment cycles and the post - treatment safety assessment."
214766304|NCT05117294|DRUG|Bocidelpar|Oral
214766305|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
214766306|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
214766307|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
214766308|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
214766309|NCT01023022|OTHER|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
214766310|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
214766311|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
214766312|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
214766313|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
214766314|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
214766315|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
214766316|NCT01919853|BEHAVIORAL|Mindfulness-Based Stress Reduction|
214766317|NCT01919853|BEHAVIORAL|Attention Control|
214766318|NCT04686500|DEVICE|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
214766319|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
214766320|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
214766321|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
214766322|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
214766323|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
214766324|NCT02614352|DRUG|Atorvastatin + Candesartan|
214766325|NCT02614352|DRUG|AG1502|
214766326|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
214766327|NCT02919033|OTHER|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
214766328|NCT02919033|DEVICE|Self-management|"* Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App."
214766329|NCT02919033|OTHER|PCTM intervention|"* Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website."
214766330|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
214766331|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
214766332|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
214766333|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
214766334|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
214766335|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
214766336|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
214766337|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
214766338|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
214766339|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
214766340|NCT05428267|OTHER|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
214766341|NCT05428267|OTHER|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
214766342|NCT06184646|DIETARY_SUPPLEMENT|Prune|30 g of prune/day
214766343|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
214766344|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
214766345|NCT06441266|DRUG|KeraStat cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions. The intervention is a topical cream applied at least twice daily starting at start of radiation therapy until 1-month from the end of radiation therapy completion
214766346|NCT06441266|DEVICE|M-PART Assessments via MyCap|The M-PART approach harnesses the remote data collection capabilities of MyCap to facilitate remote collection or data including but not limited to toxicity assessments, quality of life surveys, and patient-provided photographs of the skin in the treated area
214766347|NCT06441266|OTHER|Clinical Assessments|Participants will undergo assessments at baseline (prior to radiation therapy start), weekly during and after radiation therapy until 1-month post-radiation therapy. Medical history will be collected at baseline including primary cancer site, HPV status (if oropharyngeal cancer primary), laterality, TNM classification, stage, surgical resection prior to radiation therapy, weight, body mass index and patient self-reported Fitzpatrick skin phototype.
214766348|NCT06441266|OTHER|Feedback phone interview|Participant satisfaction, perceptions and preferences with using M-PART will be discussed.
214766349|NCT05018286|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
214766350|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
214766351|NCT04184882|DRUG|Bocidelpar|Oral
214766352|NCT04184882|DRUG|Placebo|Oral
214794010|NCT02435979|OTHER|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
214766353|NCT06230692|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
214766354|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
214766356|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
214766357|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
214766358|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
214766359|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
214766360|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
214766361|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
214766362|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
214766363|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
214766364|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
214766365|NCT02058264|DRUG|BBI-4000|
214766366|NCT03252015|DRUG|Probe Drug Cocktail|Administered orally
214766367|NCT03252015|DRUG|Lasmiditan|Administered orally
214766368|NCT03252015|DRUG|Placebo|Administered orally
214766369|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
214766370|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
214766371|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
214766372|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
214766373|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
214766374|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
214766375|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
214766376|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
214766377|NCT05163925|DEVICE|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
214766378|NCT03886402|DEVICE|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
214766379|NCT00307138|DRUG|hetastarch|
214766380|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
214766381|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
214766382|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
214766383|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
214766384|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
214766385|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
214766386|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
214766387|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
214766388|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
214766389|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
214766390|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
214766391|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
214766392|NCT00002738|DRUG|leucovorin calcium|
214766393|NCT00002738|DRUG|trimetrexate glucuronate|
214766394|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
214766395|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
214766396|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
214766397|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
214766398|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
214766399|NCT01159652|DRUG|zaleplon|10 mg
214766400|NCT01159652|DRUG|zolpidem extended release|12.5 mg
214766401|NCT01159652|DRUG|bedtime placebo|placebo
214766402|NCT01159652|DRUG|middle of the night placebo|placebo
214766403|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
214766404|NCT02604849|DRUG|Neomycin|
214766405|NCT02604849|DRUG|Streptomycin|
214766406|NCT02604849|DRUG|Gentamicins|
214766407|NCT03628872|PROCEDURE|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
214766408|NCT03628872|DEVICE|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
214766409|NCT03628872|DEVICE|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
214766410|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
214766411|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
214766412|NCT01998659|DRUG|Placebo|Oral drinking solution
214766413|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
214766414|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
214766415|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
214766416|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
214766417|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
214766418|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
214766419|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
214766420|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
214766421|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
214766422|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
214766423|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
214766424|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
214766425|NCT00061568|DRUG|Sirolimus|Sirolimus
214766426|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
214766427|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
214766428|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
214766429|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
214766430|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
214766431|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
214766432|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
214766433|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
214766434|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
214766435|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
214766436|NCT03444909|DEVICE|cardiotocograph|Monitoring of 20 min with the cardiotocograph
214766437|NCT03444909|DEVICE|Toconaute|Monitoring of 20 min withToconaute
214766438|NCT03444909|DEVICE|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
214766439|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
214766440|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
214766441|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
214766442|NCT01238523|PROCEDURE|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
214766443|NCT01238523|PROCEDURE|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
214766444|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
214766445|NCT03803514|DRUG|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
214766446|NCT04376073|DRUG|Niraparib|Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
214766447|NCT04376073|DRUG|Anlotinib|Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
214766448|NCT00005886|DRUG|arzoxifene hydrochloride|
214766449|NCT00005886|DRUG|tamoxifen citrate|
214766450|NCT02653469|OTHER|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
214766451|NCT02653469|OTHER|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
214766452|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
214766453|NCT03190707|BEHAVIORAL|Intervention|"1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed."
214766454|NCT04995510|OTHER|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
214766455|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
214766456|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
214766457|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
214766458|NCT02496442|DEVICE|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
214766459|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
214766460|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
214766461|NCT04450316|DRUG|Placebo|1 tab nightly
214766462|NCT01396499|DRUG|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
214766463|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
214766464|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
214766465|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
214766466|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
214766467|NCT02725840|RADIATION|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
214766468|NCT02725840|RADIATION|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
214766469|NCT02725840|PROCEDURE|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
214766470|NCT02725840|PROCEDURE|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
214766471|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
214766472|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214766473|NCT00903409|DRUG|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
214766474|NCT00461396|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
214766475|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
214766476|NCT00797316|DRUG|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
214766477|NCT00797316|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
214766478|NCT01555242|DRUG|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
214766479|NCT01516684|DRUG|placebo administration|Given topically
214766480|NCT01516684|DRUG|EMLA|Given topically
214766481|NCT01516684|DRUG|propofol|Given IV
214766482|NCT01516684|DRUG|fentanyl citrate|Given IV
214766483|NCT00227734|DRUG|capecitabine and oxaliplatin + cetuximab|cetuximab
214766484|NCT00227734|DRUG|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
214766485|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
214766486|NCT06439511|DEVICE|Darwin smartphone app|The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
214766487|NCT06439511|DEVICE|Pulse oxymetry|Heart rate will be measured with pulsoe oximetry (gold standard)
214766488|NCT05787496|DRUG|NC525|Monoclonal antibody specific for LAIR-1
214766489|NCT06584708|OTHER|Low-volume high intensity interval training|"Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes"
214766490|NCT06584708|OTHER|Moderate intensity continuous exercise|"Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes"
214766491|NCT06154772|OTHER|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
214766492|NCT02070718|DRUG|Standard Dose Kappa Agonist|
214766493|NCT02070718|DRUG|Half Dose Kappa Agonist|
214766494|NCT02070718|OTHER|Placebo|
214766495|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
214766496|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
214766497|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
214766498|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
214766499|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
214766500|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
214766501|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
214766502|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
214766503|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
214766504|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
214766505|NCT01934777|DRUG|placebo pearls|placebo
214766506|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
214766507|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
214766508|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
214766509|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
214766510|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
214766511|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
214766512|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
214766513|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
214766514|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214766515|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214766516|NCT05141045|DIETARY_SUPPLEMENT|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
214766517|NCT05141045|DIETARY_SUPPLEMENT|placebo|placebo
214766518|NCT05227807|BEHAVIORAL|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
214766519|NCT05227807|BEHAVIORAL|Usual care|routine care including written mouth exercise instructions
214766520|NCT01031342|PROCEDURE|Early colonoscopy|Colonoscopy within 12 hours of presentation
214766521|NCT01031342|PROCEDURE|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
214766522|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
214766523|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04\_0 Page 45-46)"
214766524|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
214766525|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
214766526|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
214766527|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
214766528|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
214766529|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
214766530|NCT05077072|OTHER|Best Practice|Receive SOC
214766531|NCT05077072|OTHER|Counseling|Participate in CHAT counseling intervention
214766532|NCT05077072|PROCEDURE|Electroencephalography|Undergo EEG
214766533|NCT05077072|BEHAVIORAL|Neurofeedback|Undergo NFB intervention
214766534|NCT05077072|OTHER|Questionnaire Administration|Ancillary studies
214766535|NCT06185764|DRUG|VX-670|Solution for intravenous administration.
214766536|NCT06185764|DRUG|Placebo|Solution for intravenous administration.
214766537|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
214766538|NCT04933708|BEHAVIORAL|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
214766539|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
214766540|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
214766541|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
214766542|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
214766543|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
214766544|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
214766545|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
214766546|NCT02127788|DRUG|Micafungin|intravenous
214766547|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
214766548|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
214766549|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
214766550|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
214766551|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
214766552|NCT02143479|DRUG|Tacrolimus|oral
214766553|NCT05310578|PROCEDURE|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
214766554|NCT04141761|DIETARY_SUPPLEMENT|Visbiome|This group will receive Visbiome probiotic in powder form.
214766555|NCT04141761|OTHER|Placebo|This group will receive a placebo in powder form.
214766556|NCT05309993|DEVICE|PTNS|See arm description
214766557|NCT05309993|DEVICE|TENS|See arm description
214766558|NCT06281184|DRUG|Methotrexate|Methotrexate 5-25 mg x 1 per week, combined with folic acid 1mg daily.
214766559|NCT06281184|OTHER|Treatment as usual|No specific treatment after MERINO-trial
214766560|NCT05968300|BEHAVIORAL|INFORMED-Living Well|1\) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging
214766561|NCT05968300|BEHAVIORAL|Text Messaging Only|A 6-week automated SMS text messaging
214766562|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
214766563|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
214766564|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
214766565|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
214766566|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
214766567|NCT06649799|DEVICE|LenSx|The patients in Group 1 conduct FLACS under LenSx
214766568|NCT06649799|DEVICE|Z8|The patients in Group 1 conducted FLACS using Z8
214766569|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
214766570|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
214766571|NCT02866201|OTHER|Rectal swab|
214766572|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
214766573|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
214766574|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
214766575|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
214766576|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
214766577|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
214766578|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
214766579|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
214766580|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
214766581|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
214766582|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
214766583|NCT03542253|PROCEDURE|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
214766584|NCT03494816|DRUG|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
214766585|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
214766586|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
214766587|NCT06127862|OTHER|No training was given|No training was given
214766588|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
214766589|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
214766590|NCT02046655|DRUG|Corifollitropin alfa|
214766591|NCT02046655|DRUG|rFSH|
214766592|NCT06995729|DRUG|Zavegepant|Zavegepant 5 mg or 10 mg (dose is weight-dependent)
214766593|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
214766594|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
214766595|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
214766596|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
214766597|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
214766598|NCT02831686|DRUG|Selinexor|
214766599|NCT02831686|DRUG|Ixazomib|
214766600|NCT02831686|DRUG|Dexamethasone|
214766601|NCT04116359|DRUG|Cisplatin|Given IV
214766602|NCT04116359|DRUG|Etoposide|Given IV
214766603|NCT04116359|DRUG|Etoposide Phosphate|Given IV
214766604|NCT04116359|DRUG|Molibresib|Given PO
214766605|NCT04116359|DRUG|Molibresib Besylate|Given PO
214766606|NCT01126359|DRUG|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
214766607|NCT01126359|DRUG|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
214766608|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
214766609|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
214766610|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
214766611|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
214766612|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
214766613|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
214766614|NCT03141346|BEHAVIORAL|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
214766615|NCT03141346|BEHAVIORAL|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
214766616|NCT03141346|OTHER|Home water delivery|Home delivery of bottled water administered over 24 months
214766617|NCT05419635|DRUG|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
214766618|NCT04078893|OTHER|telephone recruitment|using telephone to recruit inactive donors on two different methods
214766619|NCT00902486|DRUG|INCB028050|4 mg capsules QD
214766620|NCT00902486|DRUG|INCB028050|7 mg capsules QD
214766621|NCT00902486|DRUG|INCB028050|10 mg capsule QD
214766622|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
214766623|NCT00364416|OTHER|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
214766624|NCT03328286|BEHAVIORAL|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
214766625|NCT00488007|DEVICE|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
214766626|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
214766627|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
214766628|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
214766629|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
214766630|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
214766631|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
214766632|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
214766633|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
214766634|NCT06874855|DRUG|Lemborexant|Lemborexant tablet administered orally once daily
214766635|NCT06874855|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily
214766636|NCT07040267|DIAGNOSTIC_TEST|Thumb evaluations|"There is no therapeutic or experimental intervention in this study. All procedures will be limited to diagnostic evaluations. The study will include non-invasive biomechanical and sensory assessments to compare the thumb muscle characteristics and sensory discrimination between smartphone-addicted and non-addicted university students.~Specifically, muscle tone, stiffness, and elasticity will be measured using the MyotonPro™ device, and thumb sensory sensitivity will be evaluated using a Baseline Aesthesiometer with a two-point discrimination test. These assessments will be conducted during a single laboratory visit and will not involve any treatment, medication, or behavioral intervention.~This is a purely observational study aimed at identifying potential associations between smartphone usage patterns and thumb neuromuscular or sensory changes."
214766637|NCT07047248|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
214766638|NCT07047248|OTHER|Placebo PBM|A placebo whole body red light will be carried out during 20 minutes
214766639|NCT00381667|DRUG|GW642444M|M salt
214766640|NCT00381667|DRUG|GW642444H|H salt
214766641|NCT00381667|OTHER|placebo|placebo
214766642|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
214766643|NCT06942312|DIAGNOSTIC_TEST|Ketoisocaproic acid breath test|13C-alpha-ketoisocaproic acid breath test to estimate hepatic mitochondrial reductive stress (1 mg/kg body weight; oral dose; study duration 390 min)
214766644|NCT06942312|DIAGNOSTIC_TEST|Ammonium Chloride|15N-ammonium chloride stable isotope test to estimate ureagenesis (20 mg/kg body weight; oral dose; study duration 390 min)
214766645|NCT06942312|DIAGNOSTIC_TEST|Bicarbonate de sodium|13C-bicarbonate breath test to estimate body bicarbonate pool size and gastric emptying (0.5 mg/kg body weight; oral dose; study duration 390 min)
214766646|NCT06942312|DIAGNOSTIC_TEST|Deuterated Water|Deuterated water stable isotope test to estimate hepatic de novo lipogenesis and gluconeogenesis (3 g/kg body water; oral dose; duration: overnight)
214766647|NCT06942312|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|A standard 2-hour 75-gram oral glucose tolerance test to assess glucose tolerance and whole body metabolism
214766648|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
214766649|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
214766650|NCT00739206|DRUG|SAR97276A|Dose based on body weight
214766651|NCT01826032|DEVICE|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
214766652|NCT01826032|OTHER|Standard care for OSA|sleep higiene and dietary counseling
214766653|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
214766654|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
214766655|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
214766656|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
214766657|NCT03939728|RADIATION|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
214766658|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
214766659|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
214766660|NCT04028570|RADIATION|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
214766661|NCT05058027|DEVICE|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
214766662|NCT05058027|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
214766663|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
214766664|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
214766665|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
214766666|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
214766667|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
214766668|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
214766669|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
214766670|NCT00584831|DEVICE|senofilcon A|toric contact lens
214766671|NCT00584831|DEVICE|balafilcon A|toric contact lens
214766672|NCT00584831|DEVICE|omafilcon A|toric contact lens
214766673|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
214766674|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
214766675|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
214766676|NCT03300804|DRUG|Placebo|Placebo herb formulation
214766677|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
214766678|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
214766679|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
214766680|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
214766681|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
214766682|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
214766683|NCT01017731|DRUG|Moxifloxacin|Administered orally
214766684|NCT01017731|DRUG|Diphenhydramine|Administered IV
214766685|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
214766686|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
214766687|NCT05378269|OTHER|Placebo|Placebo vaginal insert
214766688|NCT00359073|DRUG|montelukast|10 mg everyday
214766689|NCT00359073|DRUG|placebo|like placebo
214766690|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
214766691|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
214766692|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
214766693|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
214766694|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
214766695|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
214766696|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
214766697|NCT04285736|DRUG|Conventional Treatment|
214766698|NCT02238639|PROCEDURE|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
214766699|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
214766700|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
214766701|NCT01371006|DRUG|normal dose|efavirenz once daily
214766702|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
214766703|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
214766704|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
214766705|NCT01495104|DRUG|RO4917838|Multiple doses
214766706|NCT01495104|DRUG|valproate|Multiple doses
214766707|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
214766708|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
214766709|NCT00330772|DRUG|Aspirin|
214766710|NCT00330772|DRUG|Clopidogrel|
214766711|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
214766712|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
214766713|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
214766714|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
214766715|NCT00182273|PROCEDURE|Canalith repositioning maneuver (CRM)|
214766716|NCT06557473|DRUG|Lidocaine IV|1.5mg/kg IV for induction of GA
214766717|NCT06557473|DRUG|Fentanyl|Fentanyl IV 2 µg/kg for GA induction
214766718|NCT05276869|OTHER|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
214766719|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
214766720|NCT06653686|OTHER|Hyperthermia combined with oral febuxostat.|Extracorporeal high-frequency hyperthermia combined with oral febuxostat
214766721|NCT06653686|DRUG|Febuxostat|The control group subjects were administered oral febuxostat.
214766722|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
214766723|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
214766724|NCT04338646|OTHER|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
214766725|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
214766726|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
214766727|NCT01721200|OTHER|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
214766728|NCT01721200|OTHER|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
214766729|NCT05500456|DEVICE|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
214766730|NCT05500456|DEVICE|Fixed appliances|Conventional wires and brackets will be used.
214766731|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
214766732|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
214766733|NCT03926728|BIOLOGICAL|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
214766734|NCT03926728|BIOLOGICAL|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
214766735|NCT03926728|BIOLOGICAL|CTH522 ID|24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
214766736|NCT03926728|BIOLOGICAL|CTH522 TO|24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
214766737|NCT03926728|BIOLOGICAL|Placebo (Saline)|Placebo only given as IM, ID and TO.
214766738|NCT00140101|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214766739|NCT00140101|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214766740|NCT04862052|PROCEDURE|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
214766741|NCT02729545|OTHER|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
214766742|NCT02729545|DRUG|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
214766743|NCT04372888|BEHAVIORAL|choice decision frame|active choice for genetic testing
214766744|NCT04372888|BEHAVIORAL|opt-in decision frame|"gain frame for genetic testing"
214766745|NCT04372888|BEHAVIORAL|opt-out decision frame|"loss frame for genetic testing"
214766746|NCT04372888|BEHAVIORAL|enhanced choice (context) decision frame|consequences of genetic testing
214766747|NCT04372888|BEHAVIORAL|enhanced choice (norms) decision frame|social norms for genetic testing
214766748|NCT04372888|BEHAVIORAL|enhanced choice (affect) decision frame|commitments for genetic testing
214766749|NCT05635773|DEVICE|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
214766750|NCT05385276|PROCEDURE|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
214766751|NCT05385276|PROCEDURE|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
214766752|NCT03647280|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
214766753|NCT03647280|DRUG|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
214766754|NCT02629380|BIOLOGICAL|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
214766755|NCT02629380|PROCEDURE|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
214766756|NCT02056431|BEHAVIORAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
214766757|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
214766758|NCT05486663|OTHER|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
214766759|NCT04832984|BEHAVIORAL|Mobile health|Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
214766760|NCT04832984|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
214766761|NCT00534521|DEVICE|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
214766762|NCT00534521|DEVICE|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
214766763|NCT02267759|DEVICE|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
214766764|NCT02267759|DEVICE|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
214766765|NCT00768105|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
214766766|NCT00768105|DRUG|Placebo|Dosing to match AZD1656
214766767|NCT06539780|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
214766768|NCT03072329|PROCEDURE|Pudendal nerve block|
214766769|NCT03072329|DRUG|Bupivacaine|
214766770|NCT05526924|RADIATION|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
214766771|NCT05526924|DRUG|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
214766772|NCT05526924|DRUG|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
214766773|NCT05526924|DRUG|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
214766774|NCT05526924|DRUG|Tislelizumab|An anti-cancer drug.
214766775|NCT01956123|DRUG|Follitropin Delta (FE 999049)|
214766776|NCT01956123|DRUG|Follitropin Alfa (GONAL-F)|
214766777|NCT03582059|PROCEDURE|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
214766778|NCT03582059|PROCEDURE|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
214766779|NCT05084807|OTHER|Endoscopy|"* A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
214766780|NCT00398632|DRUG|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
214766781|NCT04449640|PROCEDURE|Hysteroscopic septum resection.|Resection of a uterine septum by hysteroscopic surgery.
214766782|NCT06204536|OTHER|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
214766783|NCT03596086|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
214766784|NCT04794582|DEVICE|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
214766785|NCT02397174|OTHER|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
214766786|NCT02397174|OTHER|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
214766787|NCT03574194|DIETARY_SUPPLEMENT|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
214766788|NCT01467401|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
214766789|NCT01467401|DRUG|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
214766790|NCT04242368|DRUG|Isotonic saline|Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
214766791|NCT04242368|DRUG|Hypertonic Nasal Wash|Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
214766792|NCT04242368|DRUG|Fluticasone Propionate|Fluticasone nasal spray administered two sprays to each nare twice a day
214766793|NCT06459076|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)|Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1.
214766794|NCT00736060|OTHER|Observational|Summary of clinical and laboratory data
214766795|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 14 days|
214766796|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 28 days|
214766797|NCT02102529|PROCEDURE|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
214766798|NCT03795064|PROCEDURE|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
214766799|NCT03795064|PROCEDURE|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
214766800|NCT03540407|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
214766801|NCT03540407|DIETARY_SUPPLEMENT|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
214766802|NCT02470078|DEVICE|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
214766803|NCT02470078|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
214766804|NCT06513988|DEVICE|MI-BCI combined with tDCS treatment|The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
214766805|NCT01642693|RADIATION|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
214766806|NCT01642693|OTHER|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
214766807|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
214766808|NCT06540183|PROCEDURE|Percutaneous intramyocardial septal radiofrequency ablation|Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) is an innovative minimally invasive ablation treatment. Under the real-time transthoracic echocardiography guidance, a radiofrequency electrode needle is introduced into the hypertrophied interventricular septum via the percutaneous intramyocardial approach. Then the needle tip is pushed to the target region of the interventricular septal (IVS) basal segment 8 to 10 mm from the subaortic valve. The main objective of PIMSRA is to reduce ventricular septal hypertrophy and left ventricular outflow tract obstruction by means of thermal ablation.
214766809|NCT05725577|OTHER|care via the telemedicine system|Care via the telemedicine system
214766810|NCT05725577|OTHER|Routine care|Routine care
214766811|NCT03232554|DRUG|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
214766812|NCT03232554|DRUG|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
214766813|NCT03232554|DRUG|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
214766814|NCT06568653|PROCEDURE|exosome|human placenta mesenchymal stem cell-derived exosome
214766815|NCT06568653|PROCEDURE|routine conventional fistulotomy|routine conventional fistulotomy
214766816|NCT00002902|DRUG|irinotecan hydrochloride|
214766817|NCT00002902|DRUG|raltitrexed|
214766818|NCT00504842|DRUG|MRX-801|
214766819|NCT00504842|DRUG|Placebo|
214766820|NCT00219752|DRUG|Imatinib mesylate 400 mg|
214766821|NCT04058600|BEHAVIORAL|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
214766822|NCT01474148|DEVICE|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
214766823|NCT05292079|DEVICE|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
214766824|NCT04219956|OTHER|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
214766825|NCT03568929|DRUG|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
214766826|NCT06385665|BEHAVIORAL|Graded companionship|Accompanying levels are divided into beginner, intermediate and advanced
214766827|NCT00265863|DRUG|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
214766828|NCT00776269|PROCEDURE|argon laser and radiofrequency|
214766829|NCT00295308|DRUG|Clonidine|clonidine up to 0.3 mg/day oral
214766830|NCT00295308|DRUG|Placebo|oral capsules daily
214766831|NCT03596060|DRUG|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
214766832|NCT03596060|DRUG|Propofol|Propofol will be used for introduction in general anesthesia.
214766833|NCT03596060|DRUG|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
214766834|NCT03596060|DRUG|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
214766835|NCT03596060|DRUG|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
214766836|NCT01731574|DRUG|dapivirine|
214766837|NCT01731574|DRUG|miconazole|
214766838|NCT04955873|DEVICE|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
214766839|NCT04955873|DEVICE|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
214766840|NCT01777607|DEVICE|IMPELLA® RP|
214766841|NCT01908998|OTHER|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
214766842|NCT04259801|DRUG|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
214766843|NCT04259801|DRUG|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
214766844|NCT04259801|DRUG|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
214766845|NCT04259801|DRUG|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
214766846|NCT01130701|OTHER|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
214766847|NCT06201598|DEVICE|Group 1 - Intervention 1|Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
214766848|NCT03401762|BEHAVIORAL|MCI|EMG-controlled game
214766849|NCT03401762|BEHAVIORAL|Sham MCI|Sham control game
214766850|NCT03425786|BEHAVIORAL|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
214766851|NCT03425786|BEHAVIORAL|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
214766852|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
214766855|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
214766856|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
214766857|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
214766858|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
214766859|NCT04793815|PROCEDURE|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
214766860|NCT04793815|DRUG|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
214766861|NCT05804240|DIAGNOSTIC_TEST|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
214766862|NCT03246321|COMBINATION_PRODUCT|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
214766863|NCT02118896|DRUG|FK506E|oral
214766864|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
214766865|NCT00011999|DRUG|cisplatin|
214766866|NCT00011999|DRUG|paclitaxel|
214766867|NCT00011999|PROCEDURE|conventional surgery|
214766868|NCT00011999|RADIATION|radiation therapy|
214766869|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
214766870|NCT06522828|DRUG|carboplatin|chemotherapy
214766871|NCT06522828|DRUG|paclitaxel|chemotherapy
214766872|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
214766873|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
214766874|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
214766875|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
214766876|NCT04040738|PROCEDURE|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
214766877|NCT04040738|PROCEDURE|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
214766878|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
214766879|NCT02448212|DRUG|TS-121|Oral
214766880|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
214766881|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
214766882|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
214766883|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
214766884|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
214766885|NCT04426019|BEHAVIORAL|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
214766886|NCT04426019|BEHAVIORAL|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
214766887|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
214766888|NCT02930538|OTHER|Survey|Completing a survey on RedCap
214766889|NCT03684473|BEHAVIORAL|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
214766890|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
214766891|NCT01845181|DRUG|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
214766892|NCT01845181|DRUG|Placebo|1 or 2 or 3 capsules of placebo.
214766893|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
214766894|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
214766895|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
214766896|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
214766897|NCT00811031|DRUG|Taxotere|75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
214766898|NCT00811031|DRUG|Prednisone|5 mg twice a day by mouth.
214766899|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
214766900|NCT02050373|RADIATION|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
214766901|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
214766902|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
214766903|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
214766904|NCT06274697|DEVICE|Evaluation by magnetic sensor|Evaluation by magnetic sensor on arm and leg
214766905|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
214766906|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
214766907|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
214766908|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
214766909|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
214766910|NCT03046966|PROCEDURE|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds"
214766911|NCT03046966|OTHER|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
214766912|NCT02867748|PROCEDURE|TVT-Abbrevo|
214766913|NCT02867748|PROCEDURE|Serasis|
214766914|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
214766915|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
214766916|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
214766917|NCT02560207|DRUG|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
214766918|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
214766919|NCT04537130|BIOLOGICAL|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
214766920|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
214766921|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
214766922|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
214766923|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
214766924|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
214766925|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
214766926|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
214766927|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
214766928|NCT02148835|OTHER|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
214766929|NCT02148835|OTHER|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
214766930|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
214766931|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
214766932|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
214766933|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
214766934|NCT04012008|OTHER|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
214766935|NCT04012008|OTHER|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
214766936|NCT04038307|DRUG|paracetamol|1gm
214766937|NCT04038307|DRUG|Saline Solution|100ml
214766938|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
214766939|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
214766940|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
214766941|NCT00132600|DRUG|bacitracin (allergen)|
214766942|NCT00331604|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
214766943|NCT00331604|DRUG|insulin detemir|Injection s.c., 50% of daily dose.
214766944|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
214766945|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
214766946|NCT03911882|DIETARY_SUPPLEMENT|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
214766947|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
214766948|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
214766949|NCT04051840|DRUG|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
214766950|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
214766951|NCT05859893|BEHAVIORAL|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
214766952|NCT03259646|BEHAVIORAL|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
214766953|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
214766954|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
214794011|NCT02435979|OTHER|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
214766955|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
214766956|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
214766957|NCT04112615|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
214766958|NCT00759668|DEVICE|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
214766959|NCT00759668|DEVICE|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
214766960|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH\_DETINBACK Tangerine Mix)
214766961|NCT00410839|PROCEDURE|ALA rich diet|
214766962|NCT03915041|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
214766963|NCT03915041|DEVICE|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
214766964|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
214766965|NCT03480165|DRUG|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
214766966|NCT03480165|DRUG|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
214766967|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
214766968|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
214766969|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
214766970|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
214766971|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
214766972|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
214766973|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
214766974|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
214766975|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766976|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766977|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766978|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766979|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766980|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766981|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766982|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214766983|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
214766984|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
214766985|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
214766986|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
214766987|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
214766988|NCT03890835|PROCEDURE|MTA Pulpotomy.|Pulpotomy using MTA.
214766989|NCT03890835|PROCEDURE|Biodentine Pulpotomy|Pulpotomy using Biodentine
214766990|NCT02591602|OTHER|Teleradiology Service|Teleradiology Service at home or in nursing homes
214766991|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
214766992|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
214766993|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
214766994|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
214766995|NCT02091388|DRUG|LY03004|
214766996|NCT02091388|DRUG|Risperdal® Consta®|
214766997|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
214766998|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
214766999|NCT01410565|DRUG|Apaziquone|Apaziquone 4 mg in 40 mL diluent
214767000|NCT01410565|DRUG|Placebo|Placebo for Double Blind Phase
214767001|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
214767002|NCT06388265|OTHER|Trifold information|Additional detailed and written information about the procedure will be given to the participants
214767003|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
214767004|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
214767005|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
214767006|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
214767007|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
214767008|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
214767009|NCT02394379|DEVICE|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
214767010|NCT04060979|DRUG|Nitric Oxide|Nitric Oxide given intermittently via inhalation
214767011|NCT04060979|OTHER|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
214767012|NCT03121664|DRUG|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
214767013|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
214767014|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
214767015|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
214767016|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
214767017|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
214767018|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
214767019|NCT02446496|DRUG|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
214767020|NCT02446496|DRUG|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
214767021|NCT00631709|OTHER|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
214767022|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
214767023|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
214767024|NCT00369798|PROCEDURE|PET scan|
214767025|NCT00369798|DRUG|Rolipram|
214767026|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
214767027|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
214794012|NCT05602090|DRUG|4 IU of recombinant GH (Somatotropin )|4 IU of recombinant GH
214767028|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
214767029|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
214767030|NCT01618903|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
214767031|NCT01618903|DRUG|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
214767032|NCT03853980|DEVICE|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
214767033|NCT03300882|OTHER|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
214767034|NCT02122939|DRUG|Escitalopram|
214767035|NCT06393816|DRUG|Durvalumab with etoposide and Carboplatin/Cisplatin|"Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months"
214767036|NCT00983255|DRUG|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
214767037|NCT00983255|DRUG|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
214767038|NCT02023723|DIETARY_SUPPLEMENT|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
214767039|NCT02023723|DIETARY_SUPPLEMENT|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
214767040|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
214767041|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
214767042|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
214767043|NCT01131208|GENETIC|gene expression analysis|
214767044|NCT01131208|OTHER|laboratory biomarker analysis|
214767045|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
214767046|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
214767047|NCT00124579|DRUG|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
214767048|NCT00124579|DRUG|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
214767049|NCT00124579|DRUG|thalidomide|100 mg/d PO days 1-21 every 21 days
214767050|NCT04747678|DRUG|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
214767051|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
214767052|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
214767053|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
214767054|NCT01080911|DRUG|Morphine|spinal morphine 0.05 mg
214767055|NCT01080911|DRUG|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
214767056|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
214767057|NCT05912153|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT of the foot and ankle
214767058|NCT05912153|DIAGNOSTIC_TEST|MRI|MRI of the foot and ankle
214767059|NCT05778227|DRUG|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
214767060|NCT05778227|DRUG|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
214767061|NCT05778227|DRUG|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
214767062|NCT05778227|DRUG|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
214767063|NCT00915980|PROCEDURE|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
214767064|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
214767065|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
214767066|NCT00632476|OTHER|Placebo|Placebo capsule once a day
214767067|NCT00632476|DIETARY_SUPPLEMENT|Vitamin C|A 500-mg vitamin C capsule once a day
214767068|NCT03724591|PROCEDURE|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
214767069|NCT03724591|PROCEDURE|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
214767070|NCT05922592|PROCEDURE|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
214767071|NCT05922592|PROCEDURE|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
214767072|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
214767073|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
214767074|NCT00002680|BIOLOGICAL|filgrastim|
214767075|NCT00002680|DRUG|cyclophosphamide|
214767076|NCT00002680|DRUG|megestrol acetate|
214767077|NCT00002680|DRUG|melphalan|
214767078|NCT00002680|DRUG|tamoxifen citrate|
214767079|NCT00002680|DRUG|thiotepa|
214767080|NCT00002680|PROCEDURE|conventional surgery|
214767081|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
214767082|NCT00002680|RADIATION|radiation therapy|
214767083|NCT04935931|DRUG|Naltrexone|naltrexone 50 mg PO x 1
214767084|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
214767085|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
214767086|NCT06393673|DRUG|HS-10384 tablet Dose 1|Administered orally QD
214767087|NCT06393673|DRUG|HS-10384 tablet Dose 2|Administered orally QD
214767088|NCT06393673|DRUG|HS-10384-matched placebo tablets|Administered orally QD
214767089|NCT04344782|DRUG|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
214767090|NCT04083274|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214767091|NCT04083274|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
214767092|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
214767093|NCT03287141|DIAGNOSTIC_TEST|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
214767094|NCT03287141|DEVICE|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
214767095|NCT03287141|DEVICE|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
214767096|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
214767097|NCT00868816|DRUG|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
214767098|NCT00868816|DRUG|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
214767099|NCT00424632|DRUG|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
214767100|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
214767101|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
214767102|NCT04393831|PROCEDURE|Retzius sparing|Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
214767103|NCT00345826|DRUG|dasatinib|
214767104|NCT00713765|DRUG|AZD3480|18 total doses of 40 mg, on days 1-18
214767105|NCT00713765|DRUG|Donepezil|One single dose of mg on day 5
214767106|NCT06652230|OTHER|Smile Arc Marginal Ridge Approach (SAMRA)|Smile Arc Marginal Ridge Approach (SAMRA) is a new orthodontic bonding technique proposed by Dr. Dalia El Bokle where she stated that it provides more accurate orthodontic results and less time and effort needed during finished. No randomized clinical trials are done on this new approach yet so our study is the first one to test it. 0.018-inch MBT brackets will be used in our study.
214767107|NCT06652230|OTHER|MBT Chart Method|For our comparator group MBT Chart Method will be used. Using charts during orthodontic bonding procedures is considered the gold standard. 0.018-inch brackets will be used.
214767108|NCT03539939|PROCEDURE|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
214767109|NCT03049371|OTHER|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
214767110|NCT02513693|DRUG|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
214767111|NCT02513693|DRUG|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
214767112|NCT05188807|DIAGNOSTIC_TEST|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
214767113|NCT03003728|DRUG|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
214767114|NCT03003728|DRUG|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
214767115|NCT03003728|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
214767116|NCT03003728|BIOLOGICAL|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
214767117|NCT03003728|DRUG|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
214767118|NCT01984229|DRUG|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
214767119|NCT01984229|DRUG|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
214767120|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
214767121|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
214767122|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
214767123|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
214767124|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
214767125|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
214767126|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
214767127|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
214767128|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
214767129|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
214767130|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
214767131|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
214767132|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
214767133|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
214767134|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
214767135|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
214767136|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
214767137|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
214767138|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
214767139|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
214767140|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
214767141|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
214767142|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
214767143|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
214767144|NCT05303844|DRUG|H101|H101 intratumorally injection starts at day 0.
214767145|NCT05303844|DRUG|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214767146|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
214767147|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
214767148|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
214767149|NCT02959398|DEVICE|Standard mammography|Standard mammography
214767150|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
214767151|NCT02139969|DEVICE|GreenLight XPS Laser System|
214767152|NCT00006092|DRUG|Arsenic Trioxide|
214767153|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
214767154|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
214767155|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
214767156|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
214767157|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
214767158|NCT00301639|DRUG|OROS methylphenidate hydrochloride|
214767159|NCT00301639|DRUG|methylphenidate hydrochloride|
214767160|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
214767161|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
214767162|NCT06262490|DEVICE|Traditional ultrasound therapy|Ultrasound therapy for 2 session per week for until completing 12 treatment sessions (six weeks) with frequencies up to 3 MHz are used clinically to promote healing
214767163|NCT06262490|OTHER|Pelvic floor rehabilitation|Pelvic floor rehabilitation for 3 sessions per week for (six weeks) until completing 18 sessions with sessions lasting between 30-45 minutes
214767164|NCT01096862|DRUG|peficitinib|oral
214767165|NCT01096862|DRUG|Placebo|oral
214767166|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
214767167|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
214767168|NCT04065386|DEVICE|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
214767169|NCT04065386|DEVICE|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
214767170|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
214767171|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
214767172|NCT00088400|DRUG|TransMID|
214767173|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
214767174|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
214767175|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
214767176|NCT06436469|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) Program|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
214767177|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
214767178|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
214767179|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
214767180|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
214767181|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
214767182|NCT06211075|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia with Motivational Interviewing|This intervention implements elements of Cognitive Behavioural Therapy for Insomnia with motivational interview techniques incorporated into the intervention, aiming to build long-lasting motivation, better rapport with the patients and self-efficacy to increase engagement rate despite its remotely delivered format. The whole intervention is delivered online.
214767183|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
214767184|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
214767185|NCT01306968|DRUG|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
214767186|NCT01306968|OTHER|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
214767187|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
214767188|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
214767189|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
214767190|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
214767191|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
214767192|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
214767193|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
214767194|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
214767195|NCT05553028|PROCEDURE|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
214767196|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
214767197|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
214767198|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
214767199|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
214767200|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
214767201|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
214767202|NCT04526379|BEHAVIORAL|Questionnaires|Evaluation of behavioral disorders of children with PWS by questionnaires
214767203|NCT04526379|DEVICE|t-VNS|Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
214767204|NCT02850783|PROCEDURE|89Zr-nanocoll and Indocyanine Green|
214767205|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
214767206|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
214767207|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
214767208|NCT00232245|DRUG|Fish oil|
214767209|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
214767210|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
214767211|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
214767212|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
214767213|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
214767214|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
214767215|NCT05385783|DRUG|Placebo|Placebo
214767216|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
214767217|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
214767218|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
214767219|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
214767220|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
214767221|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
214767222|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
214767223|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
214767224|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
214767225|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
214767226|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
214767227|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
214767228|NCT05303727|DRUG|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
214767229|NCT05303727|DRUG|Fludarabine|30 mg/m2/day for 5 days
214767230|NCT05303727|DRUG|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
214767231|NCT05303727|DRUG|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
214767232|NCT05303727|DRUG|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
214767233|NCT05303727|DRUG|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
214767234|NCT05303727|DRUG|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
214767235|NCT05303727|DRUG|Cyclosporine|2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
214767236|NCT05303727|DRUG|Tacrolimus|0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
214767237|NCT05303727|DRUG|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
214767238|NCT05303727|DRUG|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
214767239|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
214767240|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
214767241|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
214767242|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
214767243|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
214767244|NCT00014300|DRUG|glufosfamide|
214767245|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
214767246|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
214767247|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
214767248|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
214767249|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
214767250|NCT03378999|DIETARY_SUPPLEMENT|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
214767251|NCT03378999|DIETARY_SUPPLEMENT|Control|Capsules containing microcrystalline cellulose
214767252|NCT02949219|OTHER|Laboratory Biomarker Analysis|Correlative studies
214767253|NCT02949219|BIOLOGICAL|Pembrolizumab|Given IV
214767254|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
214767255|NCT03203746|DRUG|Lycopene + SRP|
214767256|NCT03203746|PROCEDURE|SRP only|
214767257|NCT01379365|DEVICE|Cryo-Touch III|Percutaneous treatment with the device
214767258|NCT04297254|DRUG|Lenvatinib|Lenvatinib capsules.
214767259|NCT03932474|COMBINATION_PRODUCT|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
214767260|NCT03932474|OTHER|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
214767261|NCT01679418|DEVICE|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
214767262|NCT01679418|OTHER|No-drain after surgery|After surgery, no drain was put
214767263|NCT04819282|DIAGNOSTIC_TEST|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
214767264|NCT02316743|DRUG|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
214767265|NCT02606864|DRUG|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
214767266|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
214767267|NCT06604299|BEHAVIORAL|Meditation-enhanced Cognitive Behavioral Therapy|Self-guided online intervention
214767268|NCT03782688|DIAGNOSTIC_TEST|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
214767269|NCT04037683|DRUG|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
214767270|NCT04037683|DRUG|Oxytocin|Oxytocin infusion
214767271|NCT02660775|BEHAVIORAL|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)"
214767272|NCT02660775|BEHAVIORAL|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
214767273|NCT02660775|BEHAVIORAL|Healthy controls|only social cognitive measures
214767274|NCT06656390|DRUG|ALK201|Administered intravenously, once every 3 weeks
214767275|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
214767276|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
214767277|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
214767278|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
214767279|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
214767280|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
214767281|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
214767282|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
214767283|NCT06652594|BEHAVIORAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to theirchild's myopia progression at baseline, 1 month, 3 months, 6 months.
214767284|NCT06652594|BEHAVIORAL|Control|Parents in the control group will not receive eye health education informationfrom doctors and nurses.
214767285|NCT02622607|DRUG|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
214767286|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
214767287|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
214767288|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
214767289|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
214767290|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
214767291|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
214767292|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
214767293|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767294|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
214767295|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767296|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767297|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767298|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767299|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
214767300|NCT05044143|OTHER|Monitoring the length of the uterine cervix using transvaginal ultrasound|Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
214767301|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
214767302|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
214767303|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
214767304|NCT06650397|OTHER|Placebo|Traditional maize
214767305|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
214767306|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
214767307|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
214767308|NCT01101269|DRUG|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
214767309|NCT01101269|DRUG|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
214767310|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
214767311|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
214767312|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
214767313|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
214767314|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
214767315|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
214767316|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
214767317|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
214767318|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
214767319|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
214767320|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
214767321|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
214767322|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
214767323|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
214767324|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
214767325|NCT02042573|DEVICE|rTMS|
214767326|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
214767327|NCT02042573|OTHER|Genetic samples|
214767328|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
214767329|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
214767330|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
214767331|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
214767332|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
214767333|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
214767334|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
214767335|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
214767336|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
214767337|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
214767338|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
214767339|NCT00000856|DRUG|Foscarnet sodium|
214767340|NCT00000856|DRUG|Ganciclovir|
214767341|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
214767342|NCT01704482|DRUG|placebo|
214767343|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
214767344|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
214767345|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
214767346|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
214767347|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
214767348|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214767349|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
214767350|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
214767351|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
214767352|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
214767353|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
214767354|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
214767355|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
214767356|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
214767357|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
214767358|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
214767359|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
214767360|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
214767361|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
214767362|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
214767363|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
214767364|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
214767365|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
214767366|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
214767367|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
214767368|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
214767369|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
214767370|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
214767371|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
214767372|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
214767373|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
214767374|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
214767375|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
214767376|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
214767377|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
214767378|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
214767379|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
214767380|NCT01701180|DRUG|Placebo|
214767381|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
214767382|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
214767383|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
214767384|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
214767385|NCT02392377|DRUG|Oxaliplatin|Given IV
214767386|NCT02392377|DRUG|Leucovorin Calcium|Given IV
214767387|NCT02392377|DRUG|Fluorouracil|Given IV
214767388|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
214767389|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
214767390|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
214767391|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
214767392|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
214767393|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
214767394|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
214767395|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
214767396|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
214767397|NCT00985127|DRUG|placebo|administered daily for 21 days
214767398|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
214767399|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
214767400|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
214767401|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
214767402|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
214767403|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
214767404|NCT00757198|DRUG|remifentanil|remifentanil infusion
214767405|NCT00757198|DRUG|remifentanil|remifentanil infusion
214767406|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
214767407|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
214767408|NCT00034593|DRUG|ALIMTA|
214767409|NCT00034593|DRUG|gemcitabine|
214767410|NCT04607265|DIAGNOSTIC_TEST|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
214767411|NCT02048059|DRUG|ANG1005|
214767412|NCT00730067|DRUG|sildenafil|Sildenafil 50 mg three times daily
214767413|NCT00730067|DRUG|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
214767414|NCT03906773|OTHER|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
214767415|NCT06167798|OTHER|biopsy|two 2 mm gingival biopsies were obtained.
214767416|NCT02242331|DRUG|Micardis®|
214767417|NCT00288782|DRUG|Mirtazapine|
214767418|NCT00003276|DRUG|irinotecan hydrochloride|
214767419|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
214767420|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
214767421|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
214767422|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
214767423|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
214767424|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
214767425|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
214767426|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
214767427|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
214767428|NCT07006129|PROCEDURE|Perineorrhaphy|Concomitant perineorrhaphy
214767429|NCT07006129|PROCEDURE|No perineorrhaphy|No concomitant perineorrhaphy
214767430|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
214767431|NCT06723600|OTHER|Information|Nurse-led family member information
214767432|NCT06723483|PROCEDURE|Distraction Plate|This technique deals with comminuted distal radius fracture using a distraction plate. The plate was inserted by minimally invasive skin incisions, fixed from the 2end metacarpal distally to the 2end extensor compartment at intact radius proximally Spaning the comminution, Restoring the Radial Length, Radial Inclination, Volar Tilt
214767433|NCT07042542|OTHER|Mulligan Spinal Mobilization with Arm Movement|In the neurodynamic SNAGs technique, participants sat on a chair. The therapist placed the medial border of the distal phalanx of one thumb under the facet joints of the C5, C6, and C7 levels, respectively. Then, the therapist placed the tip of the other thumb on the lateral side of the first thumb. In neurodynamic spinal mobilization combined with arm movement, the therapist provided manual contact to the affected spinous process level by supporting the medial aspect of one thumb with the index finger of the other hand. The therapist applied a transverse shift from the affected side to the unaffected side, but only in the transverse plane. While the glide was in progress, the patient was asked to perform neurodynamic movements for the median nerve, including scapular depression, shoulder abduction, elbow extension, forearm supination, and wrist and finger extension, all without crossing the pain limit for the affected side.
214767434|NCT07042542|OTHER|Conventional Neurodynamic Mobilization|A neurodynamic mobilization technique involving a specific sequence of movements along the median nerve line was applied. For the right side, the procedure was performed as follows: The individual was placed supine on a stretcher. The therapist stood on the right side of the stretcher, facing the participant, with their right leg in front of their left leg. The individual's arm rested on the therapist's right thigh, and the therapist held the individual's right hand with his left hand. During the procedure, the therapist placed one hand on the individual's shoulder to depress the shoulder girdle by pressing the scapula downward. The individual's shoulder was abducted 90° and laterally rotated, and the forearm was supinated. The wrist, thumb, and fingers were extended. In this position, the therapist dynamically alternated between simultaneous elbow flexion/wrist extension and simultaneous elbow extension/wrist flexion.
214767435|NCT07042542|BEHAVIORAL|Tendon Gliding and Hand Strengthening Exercises|Tendon glide exercises were performed in five consecutive positions. Each position was practiced for seven seconds, with three sets of five repetitions and one minute of rest between sets. Participants were asked to perform the exercises three times during the day. Hand muscle strengthening exercises were performed by placing a tire on the fingertips, abducting the fingers, and stretching the tire to strengthen the intrinsic muscles and fingers. Resistance could be increased by thickening the tire or adding a second one. Participants were given a grip strength exercise. The hand grip exercise strengthened the extrinsic muscles. Finger flexion and extension exercises strengthened the hand and finger muscles. Participants were asked to perform 10 repetitions of each exercise in each session and to perform the strengthening exercises three times during the day.
214767437|NCT07047573|BIOLOGICAL|PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer|Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.
214767438|NCT07048639|DIAGNOSTIC_TEST|4D-CT (Four-Dimensional Computed Tomography)|To assess tumor and organ motion during breathing
214767439|NCT07047534|DEVICE|Real-time EEG-triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulation target: left dorsolateral prefrontal cortex (DLPFC; F3 electrode position, 10-20 EEG system); Frequency: 10 Hz; Intensity: 110% of resting motor threshold (RMT); Pulse number: 2000 pulses/session (20 trains of 100 pulses, 30-second inter-train interval); EEG triggering: Stimulation pulses synchronized to the peak of the participant's ongoing θ-wave (4-7 Hz) activity. Duration: 20 sessions over 4 weeks.
214767440|NCT07047534|BEHAVIORAL|Group Therapy|Semi-closed group therapy; 10 participants/group, 2 sessions/week, 90 minutes/session for 4 weeks (total 8 sessions). Content included: Sessions 1-2: Emotional recognition and expression training; Sessions 3-4: Cognitive restructuring; Sessions 5-6: Impulse control training; Sessions 7-8: Self-esteem building and future planning.
214767441|NCT06724120|OTHER|No interventions|No interventions
214767442|NCT06736743|DIAGNOSTIC_TEST|SMART Tool for Feeding Skill Assessment|Infant Oral Feeding Skill Assessment (FSA) done using SMART Tool
214767443|NCT07047989|BIOLOGICAL|NWRD09 injection|NWRD09 administered by intramuscular injection
215030790|NCT05753683|BEHAVIORAL|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
214767444|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
214767445|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
214767446|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
214767447|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
214767448|NCT06937281|RADIATION|SABR|Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)
214767449|NCT06236373|OTHER|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
214767450|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
214767451|NCT03902249|DRUG|Dexamethasone|
214767452|NCT06694974|BEHAVIORAL|APP calculation for FIB-4|the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
214767453|NCT06694974|BEHAVIORAL|Standard Care (in control arm)|The standard group proceeds as regular practice
214767454|NCT06693336|DRUG|SMS001|One time administration
214767455|NCT02561728|DEVICE|Hangar Helmet|Child will be fitted with the Hangar Helmet
214767456|NCT02561728|DEVICE|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
214767457|NCT01900353|OTHER|brushing methods|
214767458|NCT02791581|DIAGNOSTIC_TEST|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
214767459|NCT04313686|BEHAVIORAL|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
214767460|NCT04313686|BEHAVIORAL|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
214767461|NCT00118196|DRUG|arsenic trioxide|
214767462|NCT00118196|DRUG|azacitidine|
214767463|NCT02243059|DRUG|Gadofosveset trisodium (Ablavar™ )|
214767464|NCT02243059|DEVICE|MRI|
214767465|NCT04794452|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
214767466|NCT04794452|DEVICE|Manual toothbrush|Device on plaque removal efficacy
214767467|NCT00739687|DRUG|ALT-711|200 mg tablet BID for 9 months.
214767468|NCT00739687|DRUG|Placebo|200 mg tablet BID for 9 months.
214767469|NCT06200688|OTHER|PEANUT BALL|"Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring."
214767470|NCT03515837|BIOLOGICAL|pembrolizumab|IV infusion
214767471|NCT03515837|DRUG|pemetrexed|IV infusion
214767472|NCT03515837|DRUG|carboplatin|IV infusion
214767473|NCT03515837|DRUG|cisplatin|IV infusion
214767474|NCT03515837|DRUG|saline solution|IV infusion
214767475|NCT02319954|PROCEDURE|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
214767476|NCT01964898|BEHAVIORAL|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
214767477|NCT01964898|BEHAVIORAL|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
214767478|NCT01964898|DRUG|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
214767479|NCT01964898|OTHER|Printed Self-help materials for Smoking Cessation|
214767480|NCT05883020|OTHER|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
214767481|NCT05883020|OTHER|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
214767482|NCT01609127|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
214767483|NCT01609127|DRUG|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
214767484|NCT01609127|DRUG|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
214767485|NCT00429091|DRUG|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
214767486|NCT00429091|DRUG|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
214767487|NCT00429091|DRUG|placebo|Subjects will take BID for up to four weeks
214767488|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
214767489|NCT01444469|DRUG|Placebo|Lactose powder
214767490|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
214767491|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
214767492|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
214767493|NCT04309760|OTHER|MRI|Subjects will receive structural and functional (resting state) MRI
214767494|NCT06318091|BIOLOGICAL|platelet poor plasma gel|injection of platelet poor plasma gel in the dark circles around the eye to rejuvenate and improve pigmentation
214767495|NCT06318091|BIOLOGICAL|nanofat|injection of nanofat in the dark circles around the eye to rejuvenate and improve pigmentation
214767496|NCT04881331|OTHER|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
214767497|NCT02703974|BEHAVIORAL|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
214767498|NCT02703974|BEHAVIORAL|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
214767499|NCT02703974|BEHAVIORAL|Nudge|"A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
214767500|NCT02703974|BEHAVIORAL|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
214767501|NCT01281631|DRUG|NP001|Low dose of NP001
214767502|NCT01281631|DRUG|NP001|High dose of NP001
214767503|NCT01281631|DRUG|Placebo|normal saline
214767504|NCT04245930|PROCEDURE|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
214767505|NCT04245930|PROCEDURE|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
214767506|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
214767507|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
214767508|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
214767509|NCT05496101|PROCEDURE|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
214767510|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
214767511|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
214767512|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
214767513|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
214767514|NCT03526679|DRUG|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
214767515|NCT03526679|DRUG|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
214767516|NCT01738490|DEVICE|Bone anchored hearing implant|
214767517|NCT05764837|OTHER|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
214767518|NCT00310700|BIOLOGICAL|Meningococcal C conjugate vaccine|
214767519|NCT02855788|DRUG|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
214767520|NCT05789511|DEVICE|High Resolution Electrogastography|a new generation 64- channel high-resolution electrogastrography recording technology by Alimetry Limited that is able to record and analyze body surface gastric mapping/ HR-EGG
214767521|NCT05831267|OTHER|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
214767522|NCT05831267|OTHER|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
214767523|NCT05831267|OTHER|Negative control|this group will not receive any material.
214767524|NCT03282617|BIOLOGICAL|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
214767525|NCT05388136|PROCEDURE|Conventional follow up schedule with imaging|Frequent of follow up visit and imaging
214767526|NCT05388136|PROCEDURE|Deintensified follow up schedule without imaging|Less intense follow up visit without imaging
214767527|NCT01658982|OTHER|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
214767528|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
214767529|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
214767530|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
214767531|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
214767532|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
214767533|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
214767534|NCT04946474|DRUG|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
214767535|NCT00696631|DRUG|Dronedarone (SR33589)|oral administration
214767536|NCT00696631|DRUG|Placebo|oral administration
214767537|NCT03165331|OTHER|Ung Face IT|Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
214767538|NCT01932801|DRUG|XR-NTX|
214767539|NCT01932801|OTHER|Placebo|
214767540|NCT01932801|BEHAVIORAL|HRC|
214767541|NCT00174486|DRUG|UK0369,003|
214767542|NCT00174486|DRUG|Cialis (Tadalafil)|
214767543|NCT04465916|DRUG|EYP001a|Oral tablets
214767544|NCT04465916|DRUG|Placebo|Oral tablets
214767545|NCT04465916|DRUG|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
214767546|NCT01776619|DRUG|PF-06305591|14 day repeated 20mg BID doses
214767547|NCT01776619|DRUG|Placebo|14 day repeated BID doses
214767548|NCT01776619|DRUG|PF-06305591|14 day repeated 80mg BID doses
214767549|NCT01776619|DRUG|Placebo|14 day repeated BID doses
214767550|NCT01776619|DRUG|PF-06305591|14 day repeated 40mg BID doses
214767551|NCT01776619|DRUG|Placebo|14 day repeated BID doses
214767552|NCT01776619|DRUG|PF-06305591|14 day repeated BID doses
214767553|NCT01776619|DRUG|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
214767554|NCT03300232|BEHAVIORAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
214767555|NCT03603405|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
214767556|NCT00795483|DRUG|Zoledronic acid|Zoledronic Acid 5mg/year
214767557|NCT00795483|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications
214767558|NCT00795483|DRUG|Zoledronic acid|Zoledronic acid (5mg/2years)
214767559|NCT03478345|BEHAVIORAL|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
214767560|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
214767561|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
214767562|NCT02494947|BEHAVIORAL|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
214767563|NCT02494947|OTHER|Usual care|
214767564|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
214767565|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
214767566|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
214767567|NCT00817869|OTHER|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
214767568|NCT01635127|DRUG|Canakinumab|150mg s.c.
214645615|NCT01747057|BEHAVIORAL|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation\* and with sinus rhythm.~1. PPV \>12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ \[(PPmax+PPmin)/2\] x100 (during 5 respiratory cycles)~2. SVV \> 12% (15). SVV: Stroke volume variation~   * A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV \< 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP\>12).~● Non-preload responsive patients (defined as PPV or SVV \< 12%) will resume the same protocol as responders when fluid response parameters are negative."
214645616|NCT01747057|BEHAVIORAL|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (\> 65mmHg) or CVP \> 12mmHg. If CVP reaches \> 12 mmHg and MAP remains \< 65mmHg, norepinephrine should be started to reach MAP \> 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output \< 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC\>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
214767569|NCT01635127|DRUG|Placebo|Constituent of canakinumab
214767570|NCT03519360|OTHER|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
214767571|NCT03519360|OTHER|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
214767572|NCT00387868|DRUG|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33
214767573|NCT00387868|PROCEDURE|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
214767574|NCT00387868|RADIATION|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
214767575|NCT03576469|BIOLOGICAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
214767576|NCT05088980|DEVICE|VOLBELLA with Lidocaine|Facial Injection
214767577|NCT00484120|DRUG|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
214767578|NCT00484120|DRUG|Placebo cream|Placebo cream
214767579|NCT00115466|PROCEDURE|Non-surgical autologous implant of ASCs|
214767580|NCT02838329|OTHER|warming of ropivacaine for BT|
214767581|NCT02838329|DRUG|Ropivicaine|
214767582|NCT01906580|DRUG|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
214767583|NCT01906580|DRUG|Entecavir|0.5mg,oral administration every day
214767584|NCT00448630|OTHER|No intervention|Non-interventional study
214767585|NCT03991065|DIAGNOSTIC_TEST|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
214767586|NCT00800722|DRUG|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
214767587|NCT02107963|BIOLOGICAL|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
214767588|NCT02107963|DRUG|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
214767589|NCT02107963|DRUG|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
214767590|NCT04372563|OTHER|aortic prosthetics|aortic prosthetics
214767591|NCT06514924|OTHER|height and weight measurement|Height and weight measurements and socioeconomic status survey
214767592|NCT06072755|DEVICE|Finger pulse oximetry probe|This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
214767593|NCT06072755|DEVICE|Transreflectance oximetry probe|This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
214767594|NCT00468312|DRUG|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
214767595|NCT00468312|DRUG|Placebo|Two sprays in each nostril in the morning
214767596|NCT00713713|PROCEDURE|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
214767597|NCT04201418|DRUG|Patisiran|Patisiran-lipid complex injection, for intravenous use
214767598|NCT01052038|DRUG|Placebo administration|Placebo administration
214767599|NCT01052038|DRUG|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
214767600|NCT01052038|DRUG|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
214767601|NCT01277406|DRUG|4SC-201(Resminostat)|oral administration
214767602|NCT01277406|DRUG|FOLFIRI|i.v. administration
214767603|NCT04098159|DEVICE|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
214767604|NCT06541236|PROCEDURE|Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix|Incorporation of various bone grafting materials for alveolar ridge preservation
214767605|NCT02587000|DRUG|Ulipristal acetate|
214767606|NCT02587000|DRUG|Placebo|
214767607|NCT02594137|PROCEDURE|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
214645617|NCT01872338|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
214645618|NCT01872338|BEHAVIORAL|Treatment as usual|VA standard care for suicide prevention
214645619|NCT04733547|PROCEDURE|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
214645620|NCT04733547|DEVICE|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
214645621|NCT04733547|DRUG|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is \<1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces \>1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
214645622|NCT04733547|DRUG|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
214645623|NCT04733547|DEVICE|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
214645624|NCT03658369|DIETARY_SUPPLEMENT|Lanconone®|2 capsules
214645625|NCT03658369|DIETARY_SUPPLEMENT|Methyl crystalline cellulose|2 Capsules
214645626|NCT02614079|DEVICE|DSSEP|Collision testing after the placement of SCS leads
214645627|NCT03729947|DEVICE|Subfascial closed suction drain|Ch 14 closed suction drain
214645628|NCT00140894|DRUG|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
214645629|NCT00140894|DRUG|Comparator: placebo / Duration of Treatment: 24 weeks|
214645630|NCT03558347|DEVICE|short implants with splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
214645631|NCT03558347|DEVICE|short implants with non-splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
214645632|NCT00518479|DRUG|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
214645633|NCT00518479|DRUG|Valsartan 160mg OD; Moxonidine 400mcg OD|
214645634|NCT02224131|DRUG|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
214645635|NCT02224131|DRUG|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
214645636|NCT03077932|OTHER|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
214645637|NCT02455635|PROCEDURE|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath \& 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
214645638|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with No/Mild Sleep Apnea|Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.
214645639|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with Moderate/Severe Sleep Apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
214767608|NCT05719844|DIAGNOSTIC_TEST|Neuropsychological tests|"List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)"
214767609|NCT03976076|DRUG|JBPOS0101|JBPOS0101 (investigational product)
214767610|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
214767611|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
214767612|NCT01095029|DEVICE|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
214767613|NCT04740801|DEVICE|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
214767614|NCT01325701|DRUG|ibrutinib|ibrutinib is an inhibitor of BTK
214767615|NCT02378467|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
214767616|NCT02378467|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
214767617|NCT02812368|DRUG|Clonidine|
214767618|NCT02812368|DRUG|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
214767619|NCT05673369|DRUG|CKD-387|1 Tablet
214767620|NCT05673369|DRUG|D484|1 Tablet
214767621|NCT04650516|DEVICE|Virtual reality|20 minutes treatment in virtual reality
214767622|NCT04650516|DEVICE|Digital control|20 minutes digital control movie on tablet without virtual reality
214767623|NCT00717158|BEHAVIORAL|Usual medical care|
214767624|NCT00717158|BEHAVIORAL|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
214767625|NCT06515717|DIETARY_SUPPLEMENT|ketone ester|oral supplement
214767626|NCT06515717|DIETARY_SUPPLEMENT|dextrose (placebo)|oral supplement calorie and taste matched to ketone supplement
214767627|NCT06349434|DEVICE|MyoMo|To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).
214767628|NCT06349434|OTHER|conventional therapy|To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
214767629|NCT06217835|OTHER|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
214767630|NCT06217835|OTHER|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
214767631|NCT02255734|DRUG|Acyclovir|
214767632|NCT04976335|DEVICE|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
214767633|NCT00869141|DRUG|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
214767634|NCT01954784|DRUG|fludarabine phosphate|
214767635|NCT01954784|RADIATION|total-body irradiation|Undergo TBI
214767636|NCT01954784|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
214767637|NCT01954784|DRUG|cyclosporine|Given PO
214767638|NCT01954784|DRUG|mycophenolate mofetil|Given PO
214767639|NCT01954784|DRUG|bortezomib|Given SC
214767640|NCT01954784|DRUG|lenalidomide|Given PO
214767641|NCT01954784|OTHER|laboratory biomarker analysis|Correlative studies
214767642|NCT04616079|DRUG|REGN6490|Single dose of REGN6490
214767643|NCT04616079|DRUG|Placebo|Placebo matching single dose of REGN6490
214767644|NCT04511884|DIAGNOSTIC_TEST|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
214767645|NCT02515981|BEHAVIORAL|NH Medicaid Incentives Program|
214645640|NCT03229720|DEVICE|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
214645641|NCT03649399|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
214645642|NCT00344097|PROCEDURE|Soy protein|
214645643|NCT01261819|DEVICE|cystoscopy|
214645644|NCT01443780|DIETARY_SUPPLEMENT|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
214645645|NCT04428801|BIOLOGICAL|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
214645646|NCT02917460|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
214645647|NCT00536172|DRUG|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
214645648|NCT00536172|DRUG|Placebo|Placebo distribution matches the active medication.
214645649|NCT03624322|DRUG|Zyprexa IM|5mg
214645650|NCT03624322|DRUG|Zydis|10mg orally disintegrating wafer
214645651|NCT03624322|DRUG|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
214645652|NCT03624322|DEVICE|I231 POD® Device|Precision Olfactory Delivery (POD) device
214645653|NCT02373761|DEVICE|Stryker Triathlon Tritanium primary knee|
214645654|NCT06312787|DRUG|VX-118|Tablets and Suspension for Oral Administration
214645655|NCT00000690|DRUG|Dextran sulfate|
214645656|NCT01286857|DEVICE|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
214645657|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the morning (AM) for 7 days
214645658|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD AM for 7 days
214645659|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to study eye, QD AM for 7 days
214645660|NCT01528787|OTHER|AR-13324 Ophthalmic Solution Vehicle|Administered to study eye, QD AM for 7 days
214645661|NCT01564836|BEHAVIORAL|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
214645662|NCT06203301|BEHAVIORAL|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~1. Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~2. Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~3. Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
214645663|NCT05752929|DRUG|Insulin|correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme
214645664|NCT05752929|DRUG|insulin|correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
214645665|NCT05193565|DRUG|Sirolimus|Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
214645666|NCT05193565|DRUG|Mycophenolate mofetil|Up to 1g BID(total 2g daily), PO
214645667|NCT04924855|OTHER|Blood sampling (4 per year)|Blood sampling (4 per year)
214645668|NCT04957186|OTHER|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
214645669|NCT04957186|OTHER|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
214645670|NCT02377895|DRUG|Nasapaque Nasal Solution|
214645671|NCT02377895|DRUG|Placebo Saline Nasal Solution|
214645672|NCT00918151|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study
214645673|NCT02572284|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
214645674|NCT02572284|PROCEDURE|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
214645675|NCT02572284|OTHER|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
214645676|NCT00778973|DRUG|sertraline 100 mg tablets|
214645677|NCT03882424|BIOLOGICAL|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
214645678|NCT03882424|BIOLOGICAL|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
214645679|NCT03882424|BIOLOGICAL|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
214645680|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
214645681|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
214645682|NCT04255667|PROCEDURE|Eyelid margin crush|after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
214645683|NCT05316714|PROCEDURE|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
214645684|NCT04536220|DIAGNOSTIC_TEST|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
214645685|NCT05213988|DIETARY_SUPPLEMENT|Intermittent Fasting|Intermittent fasting meal pattern
214645686|NCT05213988|DRUG|Fibrates|Bezafibrate 400 mg/day
214645687|NCT05213988|DIETARY_SUPPLEMENT|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
214645688|NCT01868984|DRUG|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
214645689|NCT01868984|PROCEDURE|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
214645690|NCT03244007|PROCEDURE|Vitrectomy|
214645691|NCT05491785|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
214645692|NCT05491785|DRUG|Cebranopadol 800 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
214645693|NCT05491785|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
214645694|NCT05491785|DRUG|Oxycodone 30 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
214645695|NCT05491785|DRUG|Oxycodone 60 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
214645696|NCT05491785|DRUG|Placebo|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
214645697|NCT02538484|DRUG|Letrozole|Aromatase inhibitor
214645698|NCT02538484|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 free fatty acid
214645699|NCT02859155|PROCEDURE|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
214645700|NCT03696992|PROCEDURE|Tandem colonoscopy|Tandem colonoscopy with different image modalities
214645701|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
214645702|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
214645703|NCT02693314|DIETARY_SUPPLEMENT|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
214645704|NCT04821583|DRUG|Hydrocortisone|Hydrocortisone is orally administered.
214645705|NCT04821583|DRUG|Placebo|Placebo is orally administered.
214645706|NCT01961544|DRUG|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
214645707|NCT05679362|BEHAVIORAL|online brief CBT intervention|Cognitive behavioral therapy
214645708|NCT00269529|PROCEDURE|femoral nerve block|
214645709|NCT00269529|PROCEDURE|knee infiltration and injection via catheter|
214645710|NCT00892554|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
214645711|NCT00892554|DIETARY_SUPPLEMENT|Corn/soy oil|Capsules taken once daily
214645712|NCT03498274|DEVICE|Fitting System|End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.
214645713|NCT03498274|DEVICE|Traditional Fitting System|The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
214645714|NCT02300454|DEVICE|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
214645715|NCT02300454|DEVICE|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
214645716|NCT05509478|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
214645717|NCT05509478|DRUG|PD-1 inhibitors|Regular dose intravenously every 3 weeks
214645718|NCT02327091|DRUG|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
214645719|NCT01656902|DRUG|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
214645720|NCT01656902|PROCEDURE|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
214645721|NCT02733874|DRUG|Compound Clobetasol Propionate Ointment|
214645722|NCT02733874|DRUG|Calcipotriol Betamethasone Ointment|
214645723|NCT03665285|DRUG|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
214645724|NCT00378170|DEVICE|intubation of patients undergoing elective surgery|
214645725|NCT04082260|DRUG|Alemtuzumab Injection [Lemtrada]|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
214645726|NCT01554930|DRUG|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
214645727|NCT01554930|DRUG|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
214645728|NCT05935254|DEVICE|Plaque removal efficacy of children's electric toothbrush (Oral-B D100 Vitality; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with an electric toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
214645729|NCT05935254|DEVICE|Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
214645730|NCT00022087|DIETARY_SUPPLEMENT|calcium salts|1000 mg PO per day
214645731|NCT00022087|DIETARY_SUPPLEMENT|cholecalciferol|400 IU PO per day
214645732|NCT00022087|DRUG|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
214767646|NCT01483612|BEHAVIORAL|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
214767647|NCT04957914|DRUG|Insulin Glargine|Administered SC
214767648|NCT04957914|DRUG|LY3209590|Administered SC
214767649|NCT00500695|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
214767650|NCT00500695|BEHAVIORAL|Psychoeducation|Psychoeducation
214767651|NCT01570218|BEHAVIORAL|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
214767652|NCT01778452|PROCEDURE|endometrial biopsy|endometrial biopsy
214767653|NCT00254488|DRUG|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
214767654|NCT00254488|DRUG|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
214767655|NCT02491307|OTHER|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
214767656|NCT05066607|DRUG|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
214767657|NCT01053078|DRUG|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
214767658|NCT01053078|OTHER|Placebo|1 month treatment; placebo tablet once daily for 28 days
214767659|NCT04404530|DRUG|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
214767660|NCT02312531|DRUG|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
214767661|NCT01728363|DRUG|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
214767662|NCT02077660|DIETARY_SUPPLEMENT|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
214767663|NCT02077660|OTHER|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
214767664|NCT01643928|BIOLOGICAL|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
214767665|NCT01643928|BIOLOGICAL|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
214767666|NCT01643928|BIOLOGICAL|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
214767667|NCT03745573|BEHAVIORAL|Empateach|Empateach is a behavioural intervention for teachers.
214767668|NCT05257174|DIETARY_SUPPLEMENT|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
214767669|NCT05257174|DIETARY_SUPPLEMENT|Placebo|intake Placebo twice daily for three months
214767670|NCT06567288|PROCEDURE|spencer mscle energy technique|The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
214767671|NCT04715737|DRUG|Vasopressin|Administration of vasopressin (20IU) intranasally
214767672|NCT04715737|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
214767673|NCT04715737|DRUG|Placebo|Administration of placebo intranasally
214767674|NCT04243005|PROCEDURE|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
214767675|NCT04243005|PROCEDURE|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
214767676|NCT06701227|OTHER|In Situ Simulation|"The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker."
214767677|NCT02426827|DEVICE|Spinal Cord Stimulation|
214767678|NCT04441801|OTHER|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
214767679|NCT00355680|DEVICE|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
214767680|NCT00355680|DEVICE|Green Laser (Iridex)|Already available green laser
214767681|NCT01058044|OTHER|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
214767682|NCT06377969|DEVICE|ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation|The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
214767683|NCT02453867|OTHER|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels \> 5ng/ml) Stop mycophenolate at month 6
214767684|NCT02453867|DRUG|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
214767685|NCT02453867|DRUG|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
214767686|NCT02453867|DRUG|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
214767687|NCT05383976|OTHER|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
214767688|NCT00712660|DRUG|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
214767689|NCT00712660|OTHER|no intervention|Treatment as usual
214767690|NCT00379366|DEVICE|External ionizing radiations|14 Gy in one time
214767691|NCT01385670|DEVICE|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
214767692|NCT01318200|PROCEDURE|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
214767693|NCT01318200|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
214767694|NCT00092651|DRUG|MK0653A, ezetimibe (+) simvastatin|
214767695|NCT00092651|DRUG|Comparators: simvastatin and ezetimibe|
214767696|NCT03692078|OTHER|OTDN product 1|Oral tobacco-derived nicotine product
214767697|NCT03692078|OTHER|OTDN product 2|Oral tobacco-derived nicotine product
214767698|NCT03692078|OTHER|Tobacco Cessation|Tobacco Cessation
214767699|NCT03620773|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214767700|NCT03620773|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
214767701|NCT03620773|PROCEDURE|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
214767702|NCT03620773|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
214767703|NCT01005680|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
214767704|NCT01005680|DRUG|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
214767705|NCT01005680|DRUG|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
214767706|NCT03576131|BIOLOGICAL|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
214767707|NCT01339858|DRUG|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
214767708|NCT01339858|OTHER|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
214767709|NCT01862718|PROCEDURE|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
214767710|NCT01862718|PROCEDURE|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
214767711|NCT00704990|DIETARY_SUPPLEMENT|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
214767712|NCT00002338|DRUG|Raluridine|
214767713|NCT05074602|DRUG|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
214767714|NCT05074602|DRUG|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
214767715|NCT01456000|DEVICE|EAS-AC (HeartLight)|Pulmonary vien isolation
214767716|NCT01456000|PROCEDURE|Control Arm Ablation|Treatment with standard ablation.
214767717|NCT03823677|PROCEDURE|Hypoxia|hypoxia
214767718|NCT04590898|DEVICE|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
214767719|NCT02600273|OTHER|Usual brand cigarettes|Usual brand cigarettes
214767720|NCT02600273|OTHER|Lower nicotine content cigarettes|SPECTRUM research cigarettes
214767721|NCT02600273|OTHER|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
214767722|NCT02600273|OTHER|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
214767723|NCT04166877|DRUG|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
214767724|NCT04166877|DRUG|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
214767725|NCT04305184|DRUG|ASP0598|ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
214767726|NCT04305184|OTHER|Placebo|Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
214767727|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
214767728|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
214767729|NCT05623449|OTHER|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
214767730|NCT05623449|OTHER|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
214767731|NCT05623449|PROCEDURE|pain scale|Measurement of pain intensity
214767732|NCT05623449|PROCEDURE|hypnosis consultation|5 hypnosis consultation
214767733|NCT05623449|PROCEDURE|Maintenance|Qualitative assessment
214767734|NCT05623449|OTHER|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
214767735|NCT03506646|DIETARY_SUPPLEMENT|Placebo|Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
214767736|NCT03506646|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
214767737|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
214767738|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
214767739|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
214767740|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
214767741|NCT02963909|BIOLOGICAL|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
214645733|NCT02371265|OTHER|Adherence and retention package|"Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~* Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~* Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision."
214645734|NCT06348381|OTHER|No intervention|No intervention
214645735|NCT03287258|OTHER|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
214645736|NCT03287258|OTHER|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
214645737|NCT01175291|DRUG|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).
214645738|NCT01175291|DRUG|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
214645739|NCT00809107|DRUG|HCG|5000IU
214645740|NCT03228368|DRUG|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
214645741|NCT06035822|OTHER|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
214645742|NCT03450083|DRUG|Benralizumab|30mg Benralizumab will be delivered subcutaneously
214645743|NCT03450083|DRUG|Placebo|Subcutaneous placebo injection
214645744|NCT00943995|DRUG|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
214645745|NCT01711827|DRUG|Isavuconazole|oral
214645746|NCT01711827|DRUG|Prednisone|oral
214645747|NCT00454493|DRUG|Omacor (omega-3-acid ethyl esters)|
214645748|NCT02822456|PROCEDURE|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
214645749|NCT03076983|DEVICE|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
214645750|NCT00511680|BEHAVIORAL|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
214645751|NCT05546619|DRUG|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
214645752|NCT02906254|OTHER|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
214645753|NCT02906254|OTHER|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
214645754|NCT05346107|DRUG|pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage|The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
214645755|NCT00235105|DRUG|Adalimumab 40 mg sc every other week|
214645756|NCT03213366|BEHAVIORAL|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
214767742|NCT02963909|OTHER|Placebo|0.9% Sodium Chloride 5 mcg
214767743|NCT02963909|BIOLOGICAL|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
214767744|NCT02963909|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
214767745|NCT03069365|DRUG|Glecaprevir/pibrentasvir|Film-coated tablet
214767746|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
214767747|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
214767748|NCT04668131|DRUG|Sodium hyaluronate eye drops|eye drops, three times a day
214767749|NCT04668131|OTHER|acupuncture|three times a week
214767750|NCT01965431|DRUG|BI 207127|Medium dose oral administration
214767751|NCT01965431|DRUG|BI 207127 placebo|
214767752|NCT01965431|DRUG|Faldaprevir placebo|
214767753|NCT01965431|DRUG|Faldaprevir|Medium dose oral administration
214767754|NCT01965431|DRUG|Moxifloxacin (Avalox®)|
214767755|NCT04635631|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
214767756|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
214767757|NCT02393066|DRUG|Propofol|Sedation
214767758|NCT02393066|DRUG|Dexmedetomidine|Sedation
214767759|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
214767760|NCT02341872|OTHER|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
214767761|NCT02341872|OTHER|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
214767762|NCT04342130|DRUG|Morphine|30 mg oral tablet
214767763|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214767764|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
214767765|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
214767766|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
214767767|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
214767768|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
214767769|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
214767770|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
214767771|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
214767772|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
214767773|NCT02886494|DRUG|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
214767774|NCT02886494|DRUG|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
214767775|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
214767776|NCT06232135|OTHER|CBCT scan|analysis of the CBCT scan to assign a calcification stage to the subject's lower left third molar and accordingly calculate the estimated age of each subject
214767777|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
214767778|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
214767779|NCT06124534|DEVICE|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
214767780|NCT02084329|DEVICE|Weighted Compression Vest|
214767781|NCT01436942|BEHAVIORAL|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
214767782|NCT03843307|DEVICE|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
214767783|NCT00363428|BEHAVIORAL|exercise intervention|life style
214767784|NCT00363428|BEHAVIORAL|smoking cessation intervention|Life style
214767785|NCT00363428|OTHER|counseling intervention|life style
214767786|NCT00363428|OTHER|educational intervention|life style
214767787|NCT00363428|PROCEDURE|conventional surgery|life style
214767788|NCT00363428|PROCEDURE|pulmonary complications management/prevention|life style
214767789|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
214767790|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
214767791|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
214767792|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
214767793|NCT04406129|BIOLOGICAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool.
214767794|NCT04406129|OTHER|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug.
214767795|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
214767796|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
214767797|NCT00649155|DRUG|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
214767798|NCT00649155|DRUG|Cipro® XR Tablets (500 mg|500mg, single dose fasting
214767799|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
214767800|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
214767801|NCT03740828|DEVICE|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
214767802|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
214767803|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
214767804|NCT00457418|DRUG|PEG-Intron|
214767805|NCT01459679|DEVICE|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
214767806|NCT01459679|DEVICE|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
214767807|NCT01459679|DEVICE|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
214767808|NCT01459679|DRUG|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
214767809|NCT01785472|DRUG|LCZ696|LCZ696 200 mg tablet
214767810|NCT01785472|DRUG|Olmesartan|Olmesartan 20 mg capsule
214767811|NCT01785472|DRUG|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
214767812|NCT01785472|DRUG|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
214767813|NCT02776215|DRUG|tasimelteon|Melatonin receptor agonist
214767814|NCT00595127|DRUG|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
214767815|NCT00595127|DRUG|Fludarabine|Fludarabine (30mg/m\^2/day x 5 days)
214767816|NCT00595127|RADIATION|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
214767817|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
214767818|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
214767819|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
214767820|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
214767821|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
214767822|NCT01327989|DEVICE|Solitaire™ FR device|Mechanical Thrombectomy
214767823|NCT03858660|OTHER|No intervention|No intervention
214767824|NCT02086968|DRUG|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
214767825|NCT02086968|DRUG|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
214767826|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
214767827|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
214767828|NCT06283069|BEHAVIORAL|compilation of a questionnaire about LifeStyle|compilation of a questionnaire about LifeStyle
214767829|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
214767830|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
214767831|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
214767832|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
214767833|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
214767834|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
214767835|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
214767836|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
214767837|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
214767838|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
214767839|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
214767840|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
214767841|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
214767842|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
214767843|NCT05109416|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
214767844|NCT05109416|DRUG|Saline 0.9%|Isotonic crystaloid
214767845|NCT03267316|BIOLOGICAL|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
214767846|NCT03267316|DRUG|Cisplatin|Standard of care treatment
214767847|NCT03267316|DRUG|Gemcitabine|Standard of care treatment
214767848|NCT03267316|DRUG|Nab-paclitaxel|Standard of care treatment
214767849|NCT03267316|DRUG|Carboplatin|Standard of care treatment
214767850|NCT03267316|DRUG|Pemetrexed|Standard of care treatment
214767851|NCT04061655|DRUG|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
214767852|NCT04061655|OTHER|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
214767853|NCT05260658|DRUG|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
214767854|NCT05260658|DRUG|Placebo|CFTX-1554 matching placebo
214767855|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
214767856|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
214767857|NCT02417207|DRUG|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
214767858|NCT02417207|DRUG|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
214767859|NCT02672488|DRUG|Sorafenib|Standard treatment for advanced HCC
214767860|NCT02672488|DRUG|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
214767861|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
214767862|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
214767863|NCT02231671|DRUG|ALS-008176|
214767864|NCT02231671|DRUG|ALS-008112|
214645757|NCT03213366|BEHAVIORAL|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
214767865|NCT05455593|BEHAVIORAL|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
214767866|NCT05455593|BEHAVIORAL|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
214767867|NCT05455593|BEHAVIORAL|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
214767868|NCT01048411|DRUG|Naja-comp.|homeopathic remedy
214767869|NCT01048411|DRUG|Placebo|s.c. injection of NaCl-solution three times a week
214767870|NCT01915485|RADIATION|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
214767871|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
214767872|NCT03753893|OTHER|No intervention used|no intervention used
214767873|NCT03123120|DRUG|Spesolimab|12 weeks treatment
214767874|NCT03123120|DRUG|Placebo|12 weeks treatment
214767875|NCT06565520|DEVICE|transcranial direct current stimulator|"The total amount of participation time per qualified subject will be approximately 150 minutes over two sessions. The participant screening session will take approximately 30 minutes, which is an appropriate amount of time to complete all screening tasks. The tDCS and sham sessions will take approximately a total of 120 minutes over two sessions.~The first session will include a screening (30 minutes) to ensure they qualify for the study, followed by a treatment session (60 minutes): including non-invasive brain stimulation combined with hip strengthening exercises and functional movement testing at UNLV Maryland Campus. Subjects will return for a second treatment session (60 minutes) 2 weeks after the first."
214767876|NCT01977560|BEHAVIORAL|Intensive Lifestyle Intervention|Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
214767877|NCT01977560|BEHAVIORAL|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
214767878|NCT02989467|DRUG|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
214767879|NCT02989467|DRUG|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
214767880|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
214767881|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
214767882|NCT00203892|BIOLOGICAL|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
214767883|NCT00203892|BIOLOGICAL|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
214767884|NCT00203892|BIOLOGICAL|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
214767885|NCT00137462|DRUG|torcetrapib/atorvastatin|
214767886|NCT00137462|DRUG|atorvastatin|
214767887|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
214767888|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
214767889|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
214767890|NCT03080272|OTHER|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
214767891|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
214767892|NCT00806416|DRUG|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
214767893|NCT00806416|DRUG|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
214767894|NCT00806416|DIETARY_SUPPLEMENT|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
214767895|NCT02871336|OTHER|Data collection|
214767896|NCT05598619|DIETARY_SUPPLEMENT|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
214767897|NCT05598619|OTHER|placebo|Colon delivered placebo once a day for 12 weeks
214767898|NCT02709759|BEHAVIORAL|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
214767899|NCT02709759|BEHAVIORAL|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
214767900|NCT02709759|BEHAVIORAL|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
214767901|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
214767902|NCT00081978|DRUG|TMC125|
214767903|NCT01654211|DRUG|danoprevir|single iv infusion
214767904|NCT01654211|DRUG|danoprevir|single oral dose
214767905|NCT01654211|DRUG|placebo|single iv infusion
214767906|NCT01654211|DRUG|ritonavir|oral doses
214767907|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
214767908|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
214767909|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
214767910|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
214767911|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
214767912|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
214767913|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
214767914|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
214767915|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
214767916|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
214767917|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
214767918|NCT01291186|DRUG|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
214767919|NCT01291186|DRUG|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
214767920|NCT01291186|DRUG|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
214767921|NCT01291186|DRUG|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
214767922|NCT01291186|DRUG|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
214767923|NCT01291186|DRUG|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
214767924|NCT01291186|DRUG|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
214767925|NCT01291186|DRUG|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
214767926|NCT01291186|DRUG|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
214767927|NCT01291186|DRUG|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
214767928|NCT01291186|DRUG|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
214767929|NCT01291186|DRUG|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
214767930|NCT03490539|DRUG|Mycophenolate Mofetil|oral tablets
214767931|NCT03490539|DRUG|Azathioprine|oral tablet
214767932|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
214767933|NCT05105035|DRUG|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
214767934|NCT05105035|DRUG|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
214767935|NCT05105035|DRUG|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
214767936|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
214767937|NCT01402193|DRUG|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
214767938|NCT01402193|DRUG|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
214767939|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
214767940|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
214767941|NCT06080191|DRUG|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR\_Lenti\_ALLO~A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0"
214767942|NCT05503160|BEHAVIORAL|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
214767943|NCT05907044|BIOLOGICAL|RQ3013|0.15mL/dose containing mRNA 30μg
214767944|NCT05907044|BIOLOGICAL|RQ3025|0.15mL/dose containing mRNA 30μg
214767945|NCT05907044|BIOLOGICAL|RQ3027|0.15mL/dose containing mRNA 30μg
214767946|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
214767947|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
214767948|NCT02875431|PROCEDURE|Patients undergo ACDF or cervical vertebral body replacement|
214767949|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
214767950|NCT04432129|BEHAVIORAL|IBBIS II|"The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support."
214767951|NCT04432129|BEHAVIORAL|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
214767952|NCT05302414|BEHAVIORAL|Board game-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a board game-based teaching approach.
214767953|NCT05302414|BEHAVIORAL|Simulation-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a simulation-based teaching approach.
214767954|NCT05302414|BEHAVIORAL|Lecture-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through an interactive lecture-based approach.
214767955|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
214767956|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
214767957|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
214767958|NCT01610284|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
214767959|NCT01610284|DRUG|BKM120|BKM120 100 mg once daily
214767960|NCT01610284|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
214767961|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
214767962|NCT04537052|PROCEDURE|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
214767963|NCT03327532|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
214767964|NCT03327532|PROCEDURE|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
214767965|NCT03327532|BIOLOGICAL|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
214767966|NCT03327532|OTHER|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
214767967|NCT03327532|BIOLOGICAL|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
214767968|NCT03327532|PROCEDURE|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
214767969|NCT03262519|DIAGNOSTIC_TEST|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
214767970|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
214767971|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
214767972|NCT05596552|DRUG|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
214767973|NCT05596552|DRUG|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
214767974|NCT04035694|OTHER|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
214767975|NCT06700694|OTHER|Technology-assisted, family-engaged in-bed activities|Technology-assisted, family-engaged in-bed activities include handgrip interactive games, virtual reality butterfly catching, virtual reality magic cube games, and immersive in-bed cycling, performed 20 minutes per session, twice daily, five days a week, primarily assisted by family members.
214767976|NCT06700694|OTHER|Protocol-oriented early mobilization program|The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
214767977|NCT05474794|DIAGNOSTIC_TEST|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
214767978|NCT05474794|DIAGNOSTIC_TEST|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
214767979|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
214767980|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
214767981|NCT05672394|DRUG|Bupivacaine|bupivacaine
214767982|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
214767983|NCT02405494|DIETARY_SUPPLEMENT|Beverage 1|
214767984|NCT02405494|DIETARY_SUPPLEMENT|Beverage 2|
214767985|NCT02405494|DIETARY_SUPPLEMENT|Beverage 3|
214767986|NCT02405494|DIETARY_SUPPLEMENT|Beverage 4|
214767987|NCT02405494|DIETARY_SUPPLEMENT|Beverage 5|
214767988|NCT02405494|DIETARY_SUPPLEMENT|Beverage 6|
214767989|NCT02405494|DIETARY_SUPPLEMENT|Beverage 7|
214767990|NCT02405494|DIETARY_SUPPLEMENT|Beverage 8|
214767991|NCT02405494|DIETARY_SUPPLEMENT|Beverage 9|
214767992|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
214767993|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
214767994|NCT02395601|DRUG|CPI-1205|Small molecule inhibitor of the enzyme EZH2
214767995|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
214767996|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
214767997|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
214767998|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
214767999|NCT02657746|OTHER|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
214768000|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
214768001|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
214768002|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
214768003|NCT06061601|DEVICE|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
214768004|NCT01102972|DRUG|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
214768005|NCT01102972|DRUG|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
214768006|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
214768007|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
214768008|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
214768009|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
214768010|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
214768011|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
214768012|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
214768013|NCT02024386|DRUG|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
214768014|NCT03487614|BEHAVIORAL|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
214768015|NCT06564155|DEVICE|carotid duplex|measure Carotid intima media thickness
214768016|NCT06439316|BEHAVIORAL|Sedentary behavior|Total sedentary time was assessed by self-reported daily hours of sitting
214768017|NCT06439316|BEHAVIORAL|Depressive symptoms|depressive symptoms were assessed by Patient Health Questionnaire 9 scale
214768018|NCT06543095|OTHER|Pain level|Post-operative pain levels of the patients with detected using VAS score.
214768019|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
214768020|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
214768021|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
214768022|NCT02854722|DRUG|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
214768023|NCT02854722|DRUG|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
214768024|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
214768025|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
214768026|NCT00448110|DRUG|placebo|placebo
214768027|NCT04924738|BEHAVIORAL|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
214768028|NCT01508923|DRUG|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
214768029|NCT01508923|DRUG|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
214768030|NCT01184781|DEVICE|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
214768031|NCT05760638|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
214768032|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
214768033|NCT01614158|DEVICE|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
214768034|NCT01614158|OTHER|D-BCVA|D-BCVA using EDTRS chart
214768035|NCT01614158|OTHER|RAPD|RAPD using swinging flashlight test
214768036|NCT01614158|DEVICE|IOP|IOP using applanation tonometer
214768037|NCT01614158|DEVICE|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
214768038|NCT01614158|OTHER|Fundus photography|Optic disk morphology will be documented by fundus photography
214768039|NCT03112096|DRUG|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
214768040|NCT01125358|DRUG|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
214768041|NCT01125358|DRUG|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
214768042|NCT04434235|OTHER|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
214768043|NCT01157065|DRUG|AL-78898A|Investigational treatment
214768044|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
214768045|NCT04332835|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
214768046|NCT04332835|DRUG|Standard Therapy|Standard therapy defined by institutional protocol.
214768047|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
214768048|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
214768049|NCT01764776|DRUG|LDE225|LDE225
214768050|NCT00318409|DRUG|Bupropion|
214768051|NCT00318409|DRUG|Placebo|
214768052|NCT04995302|PROCEDURE|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
214768053|NCT04995302|PROCEDURE|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
214768054|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
214768055|NCT01591902|DRUG|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
214768056|NCT01591902|DRUG|Placebo-Control|3.0 mL vials
214768057|NCT01304017|OTHER|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
214768058|NCT01304017|OTHER|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
214768059|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
214768060|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
214768061|NCT01060007|RADIATION|External beam radiation|
214768062|NCT01060007|DRUG|Oxaliplatin|
214768063|NCT01060007|DRUG|Leucovorin|
214768064|NCT01060007|DRUG|5-FU|
214768065|NCT01060007|DRUG|Capecitabine|
214768066|NCT00742859|DRUG|betrixaban|orally, once daily for at least 3 months
214768067|NCT00742859|DRUG|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
214768068|NCT06567184|BEHAVIORAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
214768069|NCT05428059|OTHER|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
214768070|NCT06132100|DEVICE|digitalized incentive spirometry|digitalized incentive spirometry
214768071|NCT06132100|DEVICE|traditional incentive spirometry|traditional incentive spirometry
214768072|NCT06251154|DEVICE|Lens 1|Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
214768073|NCT06251154|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
214768074|NCT04022759|BEHAVIORAL|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
214768075|NCT04022759|BEHAVIORAL|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
214768076|NCT00956709|DRUG|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
215030791|NCT05753683|BEHAVIORAL|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
214768077|NCT00956709|DRUG|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
214768078|NCT03501407|DIAGNOSTIC_TEST|Blood samples|1 or 2 blood samples will be collected from the patient.
214768079|NCT03501407|DIAGNOSTIC_TEST|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
214768080|NCT04064931|DIAGNOSTIC_TEST|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
214768081|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
214768082|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
214768083|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
214768084|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
215030792|NCT05496972|BEHAVIORAL|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
215030793|NCT05851417|DEVICE|Fast Field-Cycling (FFC) imaging|FFC scan
215030794|NCT00468247|DEVICE|Navigator|Navigator circulatory mgt system
215030795|NCT00468247|OTHER|Conventional care|Conventional haemodynamic care
214768085|NCT05171920|DRUG|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
214768086|NCT05171920|DRUG|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
214768087|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
214768088|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
214768089|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
214768090|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
214768091|NCT04522310|OTHER|MR-Pro-ADM|Dosage of MR-pro-ADM
214768092|NCT02097966|DRUG|Daclatasvir|
214768093|NCT02097966|DRUG|Sofosbuvir|
214768094|NCT02097966|DRUG|Ribavirin|
214768095|NCT03864367|DEVICE|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
214768096|NCT02960724|OTHER|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
214768097|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
214768098|NCT01288417|DRUG|boceprevir|10 days of boceprevir 800mg TID
214768099|NCT01288417|DRUG|raltegravir|raltegravir 400mg single dose
214768100|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
214768101|NCT04527549|DRUG|Hydroxychloroquine|Given PO
214768102|NCT04527549|DRUG|Placebo Administration|Given PO
214768103|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
214768104|NCT05589649|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block
214768105|NCT05589649|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block
214768106|NCT00486642|DRUG|Bicalutamide|Given PO
214768107|NCT00486642|OTHER|Laboratory Biomarker Analysis|Correlative studies
214768108|NCT00486642|DRUG|Pazopanib Hydrochloride|Given PO
214768109|NCT00486642|OTHER|Pharmacological Study|Correlative studies
214768110|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
214768111|NCT02284152|BEHAVIORAL|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
214768112|NCT03706209|DRUG|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
214768113|NCT03706209|DRUG|Placebo|hard gelatin capsules containing no active ingredient
214768114|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
214768115|NCT06567951|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
215030796|NCT06040788|PROCEDURE|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
214768116|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
214768117|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
214768118|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
214768119|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
214768120|NCT04457531|DRUG|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
214768121|NCT04457531|OTHER|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
214768122|NCT06144931|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
215030797|NCT05354219|OTHER|Imaging|Imaging with 3 iris cameras
214768123|NCT06420427|DIAGNOSTIC_TEST|Assess the risk of recurrence and the efficacy of medication|Evaluation of recurrence risk and medication efficacy through liquid biopsy
214768124|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
214768125|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
214768126|NCT05634629|PROCEDURE|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
214768127|NCT05634629|PROCEDURE|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
214768128|NCT02437929|PROCEDURE|Mobilization|
214768129|NCT02437929|PROCEDURE|Positioning|
214768130|NCT02437929|PROCEDURE|Personal Hygiene Care|
214768131|NCT02437929|PROCEDURE|Bladder catheterization|
214768132|NCT02437929|PROCEDURE|Wound care|
214768133|NCT02437929|PROCEDURE|Subcutaneous drugs administration|
214768134|NCT06701292|DEVICE|PVS-PVI targeted ablation|"Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI."
214768135|NCT06701292|DEVICE|Wide area circumferential ablation (WACA)|After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
214768136|NCT04125160|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
214768137|NCT04125160|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
214768138|NCT02815189|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
214768139|NCT02815189|DRUG|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
214768140|NCT05813665|DRUG|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
214768141|NCT05813665|DRUG|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
214768142|NCT04451109|DEVICE|Dilapan-S|Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
214768143|NCT00686231|DRUG|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
214768144|NCT00686231|DRUG|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
214768145|NCT00686231|DRUG|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
214768146|NCT00686231|DRUG|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
214768147|NCT00686231|DRUG|Placebo|Topical skin moisturizing cream with same appearance as active agent
214768148|NCT06694168|PROCEDURE|Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery|The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
215030798|NCT02115087|PROCEDURE|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
215030799|NCT02115087|DRUG|Morphine|
214768149|NCT06694168|PROCEDURE|REGEND001 Autologous Therapy Product|L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.
214768150|NCT05282810|OTHER|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
214768151|NCT00445458|DRUG|HKI-272|
214768152|NCT00445458|DRUG|Paclitaxel|
214768153|NCT05339542|OTHER|platelet rich plasma|derived from patient own blood
214768154|NCT05339542|DRUG|MethylPREDNISolone 40 MG|active comparative intervention
214768155|NCT01527942|DRUG|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
214768156|NCT01527942|DRUG|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
214768157|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
214768158|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
214768159|NCT03634007|BIOLOGICAL|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
214768160|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
214768161|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
214768162|NCT02367807|DRUG|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
214768163|NCT03987737|PROCEDURE|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
214768164|NCT03833856|PROCEDURE|colonoscopy perforation|The development of perforation after colonoscopy
214768165|NCT05225116|DRUG|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
214768166|NCT05225116|DRUG|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
214768167|NCT05225116|RADIATION|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
214768168|NCT00029042|DRUG|Infliximab|
214768169|NCT00728988|DRUG|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
214768170|NCT00728988|DRUG|Atorvastatin|40mg daily after PCI for 30 days.
214768171|NCT00116207|DRUG|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
214768172|NCT01247753|BEHAVIORAL|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
214768173|NCT03412994|DRUG|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
214768174|NCT03412994|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
214768175|NCT00764816|OTHER|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
214768176|NCT00764816|OTHER|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
214768177|NCT02238886|DIETARY_SUPPLEMENT|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
214768178|NCT00710060|BEHAVIORAL|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
214768179|NCT00710060|BEHAVIORAL|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
214768180|NCT04620863|OTHER|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
214768181|NCT04620863|OTHER|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
214768182|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
214645758|NCT02836015|BEHAVIORAL|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
214645759|NCT00151671|DRUG|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
214645760|NCT00151671|DRUG|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
214645761|NCT02286388|PROCEDURE|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
214645762|NCT02286388|PROCEDURE|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
214645763|NCT02286388|DEVICE|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
214645764|NCT02286388|DEVICE|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
214645765|NCT02671331|PROCEDURE|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
214645766|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
214645767|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
214645768|NCT04991337|BEHAVIORAL|Detraining group|Detraining is defined as exercise corresponding to a heart rate ≤75% of maximum heart rate and ≤80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 weeks.
214645769|NCT04991337|BEHAVIORAL|Control group|At least three weekly sessions of high intensity exercise, corresponding to a heart rate ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
214645770|NCT01311466|PROCEDURE|Liver transplantation|
214645771|NCT00687284|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214645772|NCT00666926|DRUG|PF00562271|125 mg twice daily \[BID\] with food, tablet
214645773|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
214645774|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
214645775|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
214768183|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
214768184|NCT00937859|DRUG|SER120|SER120
214768185|NCT00937859|DRUG|Placebo|Placebo
214768186|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
214794452|NCT04582396|BEHAVIORAL|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
214645776|NCT01180803|DEVICE|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
214645777|NCT01180803|DEVICE|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
214645778|NCT02567929|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
214645779|NCT02567929|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
214645780|NCT01727258|DEVICE|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
214645781|NCT01727258|DRUG|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
214645782|NCT01727258|DRUG|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
214768187|NCT05157529|DEVICE|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
214768188|NCT05157529|DEVICE|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
214768189|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
214768190|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
214768191|NCT04992897|DEVICE|Remote Electrical Neuromodulation (REN)|Acute migraine treament
214768192|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
214768193|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
214768194|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
214768195|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
214768196|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
214768197|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
214768198|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
214768199|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
214768200|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
214768201|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
214768202|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
214768203|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
214768204|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
214768205|NCT00394862|DRUG|multivitamin|
214768206|NCT01166126|DRUG|temsirolimus|Given IV
214768207|NCT01166126|DRUG|selumetinib|Given orally
214768208|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
214768209|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
214768210|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
214768211|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
214768212|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
214768213|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
214768214|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
214768215|NCT02549391|DRUG|KHK7580|Oral administration
214768216|NCT02549391|DRUG|KRN1493|Oral administration
214768217|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
214768218|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
214768219|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
214768220|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
214768221|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
214768222|NCT00327080|PROCEDURE|MRI|
214768223|NCT00327080|DRUG|L-NMMA|
214768224|NCT00327080|DRUG|Acetylcholine|
214768225|NCT04469868|BEHAVIORAL|No opioids at discharge|"Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues."
214768226|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
214768227|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
214768228|NCT00700037|DRUG|high-dose atorvastatin|20mg/day
214768229|NCT00700037|DRUG|low-dose atorvastatin|5mg/day
214768230|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
214768231|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
214768232|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
214768233|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
214768234|NCT02380248|OTHER|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
214768235|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
214768236|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
214768237|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
214768238|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~\--------------------------------------------------------------------------------"
214768239|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
214768240|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
214768241|NCT00900276|OTHER|immunologic technique|
214768242|NCT00900276|OTHER|laboratory biomarker analysis|
214768243|NCT00900276|OTHER|mass spectrometry|
214768244|NCT00605839|DEVICE|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
214768245|NCT00605839|DEVICE|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
214768246|NCT00605839|OTHER|Usual Care|This intervention was usual care, without either device.
214768247|NCT06343142|OTHER|Nuts|Isocaloric meal with nuts
214768248|NCT06343142|OTHER|Nut-free meal|Isocaloric meal without nuts
214768249|NCT00590785|DRUG|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
214768250|NCT00590785|DRUG|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
214768251|NCT00590785|DRUG|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
214768252|NCT00590785|DRUG|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
214768253|NCT00590785|DRUG|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
214768254|NCT00181974|DRUG|Tisseel Fibrin Sealant|
214768255|NCT01059552|DRUG|vorinostat|vorinostat once daily for 12 weeks of therapy
214768256|NCT01119352|DRUG|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
214768257|NCT01119352|DRUG|Placebo|Oral suspension, once daily. Totally 8 doses
214768258|NCT04959708|OTHER|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
214768259|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
214768260|NCT05351606|DRUG|Bupropion|Given orally
214768261|NCT05351606|DRUG|Nicotine patch|Given transdermally
214768262|NCT05351606|DRUG|Nicotine lozenge|Given orally
214768263|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
214768264|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
214768265|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
214768266|NCT02305069|DRUG|Pioglitazone|Described elsewhere
214768267|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
214768268|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
214768269|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
214768270|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
214768271|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
214768272|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
214768273|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
214768274|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
214768275|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
214768276|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
214768277|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
214768278|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
214794453|NCT01650324|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
214794454|NCT01650324|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
214794455|NCT00648518|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
214794456|NCT00648518|DRUG|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
214794457|NCT05042141|DIETARY_SUPPLEMENT|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
214794458|NCT05042141|DIETARY_SUPPLEMENT|Placebo oral capsule|Placebo
214645783|NCT05616702|OTHER|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~* prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~* Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~* Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~* Duration: 15 mins~* Frequency: 3 sessions/ week~* Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
214645784|NCT05616702|OTHER|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
214645785|NCT04166279|OTHER|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
214645786|NCT04166279|OTHER|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
214645787|NCT01305863|DEVICE|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
214645788|NCT01305863|DEVICE|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
214645789|NCT05236998|DRUG|SID1903 (FDC)|Single oral administration of SID1903 (FDC) after an overnight fast
214645790|NCT05236998|DRUG|Dapagliflozin and Sitagliptin|Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
214645791|NCT05572463|COMBINATION_PRODUCT|Sintilimab + IBI110|IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
214645792|NCT05334446|BEHAVIORAL|The Effect of the Mobile Application|"This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control."
214645793|NCT04801628|DEVICE|Active Tecar|Active Tecar
214645794|NCT04801628|DEVICE|Placebo Tecar|Placebo Tecar
214645795|NCT04972994|PROCEDURE|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
214645796|NCT00784667|DRUG|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
214645797|NCT00784667|DRUG|Erlotinib|100mg orally daily continuously
214645798|NCT02170116|DRUG|BIBR 1048 MS dose 1|
214645799|NCT02170116|DRUG|BIBR 1048 MS dose 2|
214645800|NCT02170116|DRUG|BIBR 1048 MS dose 3|
214645801|NCT02170116|DRUG|BIBR 1048 MS dose 4|
214645802|NCT02170116|DRUG|BIBR 1048 MS dose 5|
214645803|NCT02170116|DRUG|Placebo to BIBR 1048 MS|
214645804|NCT03556215|DEVICE|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
214645805|NCT03556215|PROCEDURE|Myringotomy|Myringotomy will be performed using a standard procedure.
214645806|NCT00820573|DRUG|Sitagliptin|tablet, 100 mg/day, 6 weeks
214645807|NCT00820573|DRUG|Metformin|tablet, 1000 mg/ bid, 6 weeks
214645808|NCT00820573|DRUG|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
214645809|NCT00820573|DRUG|Placebo|Placebo 6 weeks
214645810|NCT01271621|DEVICE|Intubation|Endotracheal intubation
214645811|NCT06439849|DRUG|S-Gboxin|S-Gboxin (lyophilized form of S-Gboxin) for the treatment diffuse midline glioma with H3 K27M / H3 K28M mutation
214645812|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Healthy Controls|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to healthy controls
214645813|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in NAFLD Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to NAFLD participants (defined as simple steatosis through NASH)
214645814|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Fibrosis Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to liver fibrosis stage (F0-F4)
214645815|NCT01756729|DEVICE|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
214645816|NCT02388373|DRUG|Fluticasone 250/formoterol 10|
214645817|NCT02388373|DRUG|Fluticasone 250/salmeterol 25|
214645818|NCT02388373|DRUG|Fluticasone 125/formoterol 5|
214768279|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
214768280|NCT03029559|OTHER|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
214768281|NCT03029559|OTHER|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
214768282|NCT03029559|OTHER|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
214768283|NCT00381134|DRUG|losartan 100 mg orally once daily|
214768284|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
214768285|NCT00381134|DRUG|placebo once orally once daily|
214768286|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
214768287|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
214768288|NCT02792088|DRUG|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
214768289|NCT02792088|DRUG|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
214768290|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
214768291|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
214768292|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
214768293|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
214768294|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
214768295|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
214768296|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
214768297|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
214768298|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
214768299|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
214768300|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
214768301|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
214768302|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
214768303|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
214768304|NCT00763126|BEHAVIORAL|stress level|Stress levels
214768305|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
214768306|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
214768307|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
214768308|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
214768309|NCT03935451|DRUG|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
214768310|NCT03935451|DRUG|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
214768311|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
214768312|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
214768313|NCT00435240|BEHAVIORAL|Paleolithic diet|
214768314|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
214645819|NCT00002520|DRUG|nicotine|
214645820|NCT00002520|BEHAVIORAL|Usual Care|
214645821|NCT04458844|OTHER|Exercise|Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
214645822|NCT04676048|BIOLOGICAL|ASC618|ASC618 will be given as a single IV infusion
214645823|NCT06011720|OTHER|Improved transition of care.|Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
214645824|NCT03728205|BEHAVIORAL|Yoga|Twice weekly yoga sessions for 12 weeks
214645825|NCT02456688|DRUG|Imrecoxib|
214645826|NCT02471716|BIOLOGICAL|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
214645827|NCT00317213|DRUG|LIBERTAL- a phospholipid mixture|
214645828|NCT06314555|OTHER|Blood sample|Blood sample to analyse the values of sFlt-1 and PlGF
214645829|NCT06314555|OTHER|Vascular-renal sample|Usual vascular-renal sample to analyse the values of sFlt-1 and PlGF
214645830|NCT05863117|DIAGNOSTIC_TEST|Reveal Rapid TP (from MedMira)|Point of care tests for HIV and Syphilis
214645831|NCT05087537|PROCEDURE|Valve ablation|Valve ablation
214645832|NCT05087537|PROCEDURE|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
214645833|NCT04013594|DIETARY_SUPPLEMENT|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
214645834|NCT02840851|DEVICE|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
214645835|NCT02840851|DEVICE|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
214645836|NCT01267448|DRUG|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
214645837|NCT01267448|DRUG|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
214645838|NCT01267448|DRUG|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
214645839|NCT02981069|DRUG|Dapagliflozin|10mg
214645840|NCT02981069|DRUG|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
214645841|NCT02981069|DRUG|Placebo|Placebo for Dapagliflozin
214645842|NCT03074929|BEHAVIORAL|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
214645843|NCT00073320|DRUG|Paliperidone Palmitate|
214645844|NCT03198130|DRUG|REGN2810|Intravenous (IV) use
214645845|NCT01360645|DRUG|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
214645846|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
214645847|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
214645848|NCT01014585|DRUG|Placebo|Placebo tablets administered orally twice daily
214645849|NCT01014585|DRUG|Milnacipran|Milnacipran tablets administered orally twice daily
214645850|NCT05618873|DEVICE|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
214645851|NCT05618873|DEVICE|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
214645852|NCT00562380|BIOLOGICAL|ganitumab|
214645853|NCT00562380|OTHER|laboratory biomarker analysis|
214645854|NCT00562380|OTHER|pharmacological study|
214645855|NCT00562380|PROCEDURE|biopsy|
214768315|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
214768316|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
214768317|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
214768318|NCT06658275|OTHER|Constraint-induced movement therapy|During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
214768319|NCT06658275|OTHER|Hand Arm Bimanual Intensive Training -HABIT|For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
214768320|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
214768321|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
214768322|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
214645856|NCT03459573|BEHAVIORAL|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
214645857|NCT03459573|BEHAVIORAL|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
214645858|NCT03459573|BEHAVIORAL|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
214768323|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
214768324|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
214768325|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
214768326|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
214768327|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
214768328|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
214768329|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
214768330|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
214768331|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
214768332|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
214768333|NCT00083226|DRUG|doxorubicin|Given IV
214768334|NCT00083226|DRUG|bortezomib|Given IV
214768335|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
214768336|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
214768337|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
214768338|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
214768339|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
214768340|NCT01258452|DRUG|CHF 5074|Drug is administered to subject in a fasting state
214768341|NCT01258452|DRUG|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
214768342|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
214768343|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
214768344|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
214768345|NCT01462188|PROCEDURE|Immediate stenting|Primary coronary stenting
214768346|NCT01462188|PROCEDURE|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
214768347|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
214768348|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
214768349|NCT02626273|RADIATION|weight loss|
214768350|NCT03840031|OTHER|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
214768351|NCT03840031|OTHER|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
214768352|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
214768353|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
214768354|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
214768355|NCT00465322|DRUG|fluvastatin|
214768356|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
214768357|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
214768358|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
214768359|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
214768360|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
214768361|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
214768362|NCT02468167|DRUG|Lauromacrogol|
214768363|NCT03363724|OTHER|HaGuide version 1.0 software module|
214768364|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
214768365|NCT02163746|PROCEDURE|Surgical Deroofing|
214768366|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
214768367|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
214768368|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
214768369|NCT05853237|DEVICE|laser therapy for wound management|comparison between laser effect on post median sternotomy incision compared to traditional wound care
214768370|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
214768371|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
214768372|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
214768373|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
214768374|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
214768375|NCT03907709|BEHAVIORAL|In-Home Addiction Treatment Program|"* Treatment was delivered per treatment protocol~* Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~* Urine drug screens administered randomly~* Appointments were scheduled per protocol for 52 weeks~* Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
214768376|NCT03356366|OTHER|MRI 3T|Magnetic Resonance Imaging 3 Tesla
214768377|NCT03356366|OTHER|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
214768378|NCT03356366|OTHER|MRI 7T|Magnetic Resonance Imaging 7 Tesla
214768379|NCT03530007|DRUG|Normal saline|normal saline used for prevention of spinal shivering
214768380|NCT03530007|DRUG|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
214768381|NCT03530007|DRUG|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
214768382|NCT02973178|DEVICE|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
214768383|NCT01935557|DRUG|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
214768384|NCT01935557|DRUG|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
214768385|NCT00101140|DRUG|anti-thymocyte globulin|
214768386|NCT00101140|DRUG|fludarabine phosphate|
214768387|NCT00101140|DRUG|thiotepa|
214768388|NCT00101140|PROCEDURE|biological therapy|
214768389|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
214768390|NCT00101140|PROCEDURE|chemotherapy|
214768391|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
214768392|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
214768393|NCT00101140|PROCEDURE|radiation therapy|
214768394|NCT03642886|BEHAVIORAL|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
214768395|NCT05784363|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
214768396|NCT05784363|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
214768397|NCT01317069|DRUG|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
214768398|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
214768399|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
214768400|NCT04444362|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
214768401|NCT06063291|DRUG|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
214768402|NCT06063291|DRUG|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
214768403|NCT02682173|OTHER|MR Abdomen|
214768404|NCT05088382|DEVICE|LH Urine Test|Test for the qualitative measurement of LH in urine
214768405|NCT00897039|OTHER|flow cytometry|
214768406|NCT00897039|OTHER|immunohistochemistry staining method|
214768407|NCT05681104|DIAGNOSTIC_TEST|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
214768408|NCT05681104|DIAGNOSTIC_TEST|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
214768409|NCT05681104|DIAGNOSTIC_TEST|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
214768410|NCT03586986|DIAGNOSTIC_TEST|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
214768411|NCT00178763|DEVICE|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
214768412|NCT00178763|OTHER|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
214768413|NCT00178763|OTHER|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
214768414|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
214768415|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
214768416|NCT05005000|BIOLOGICAL|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
214768417|NCT05005000|DRUG|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
214768418|NCT05660837|BEHAVIORAL|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session"
214768419|NCT05660837|BEHAVIORAL|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp"
214768420|NCT03121560|DEVICE|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
214768421|NCT03121560|DEVICE|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
214768422|NCT03955718|BEHAVIORAL|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
214768423|NCT03955718|BEHAVIORAL|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
214768424|NCT00034359|DRUG|ACH-126,443|
214768425|NCT00034359|DRUG|Lamivudine|
214768426|NCT00034359|DRUG|Placebo|
214768427|NCT03509688|DRUG|entecavir+resveratrol|entecavir+resveratrol
214768428|NCT03509688|DRUG|Entecavir|Entecavir
214768429|NCT03509688|DRUG|entecavir+thymosin α1|entecavir+thymosin α1
214768430|NCT00830271|DEVICE|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
214768431|NCT00830271|DEVICE|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
214768432|NCT00583128|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
214768433|NCT00583128|DRUG|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
214768434|NCT05231161|DIAGNOSTIC_TEST|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
214768435|NCT06583148|OTHER|Best Practice|Receive usual care
214768436|NCT06583148|BEHAVIORAL|Smoking Cessation Intervention|Receive the smoke-free home program
214768437|NCT06583148|OTHER|Survey Administration|Ancillary studies
214768438|NCT00242450|DRUG|Metoclopramide|
214768439|NCT00665509|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
214768440|NCT06675695|DRUG|New use of osimertinib|New use of osimertinib described in electronic health records is used as the exposure.
214768441|NCT06675695|DRUG|New use of erlotinib or gefitinib|"New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference."
214768442|NCT01072318|DRUG|Letrozole|Letrozole 2.5mg
214768443|NCT03944538|BEHAVIORAL|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
214768444|NCT03944538|BEHAVIORAL|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
214768445|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
214794459|NCT04857619|OTHER|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
214768446|NCT06202807|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214768447|NCT06202807|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214768448|NCT06202807|BEHAVIORAL|comprehensive rehabilitation therapy|"Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214768449|NCT00418509|DRUG|Mometasone furoate|
214768450|NCT00418509|DRUG|Formoterol fumarate|
214768451|NCT03208218|DRUG|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
214768452|NCT03208218|DRUG|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
214768453|NCT03443973|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
214768454|NCT03443973|DRUG|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
214768455|NCT01585064|OTHER|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
214768456|NCT01585064|OTHER|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
214768457|NCT01585064|OTHER|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
214768458|NCT00264082|DRUG|Zometa(drug)|
214768459|NCT06701695|PROCEDURE|Periarticular Injection (PAI)|Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
214768460|NCT06701695|PROCEDURE|Control (Standard treatment)|The control group received the conventional treatment protocol.
214768461|NCT00189696|DRUG|YM060|
214768462|NCT01386619|BIOLOGICAL|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
214768463|NCT00704717|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
214768464|NCT00704717|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
214768465|NCT02268019|PROCEDURE|tourniquet application|
214768466|NCT02268019|DRUG|epinephrine injection|
214768467|NCT01476345|DRUG|LY2963016|Administered subcutaneously
214768468|NCT01476345|DRUG|Lantus|Administered subcutaneously
214768469|NCT02209454|DRUG|Enantyum® oral solution|One dose of 25 mg DKP oral solution
214768470|NCT02209454|DRUG|Keral® tablet|One dose of 25 mg DKP tablet
214768471|NCT01945554|PROCEDURE|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
214768472|NCT01945554|PROCEDURE|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
214768473|NCT01945554|DRUG|Mephamesone|
214768474|NCT01945554|DRUG|0.5% bupivacaine (Bupivacain®)|
214768475|NCT01945554|DRUG|Kenacort®|
214768476|NCT00207974|DRUG|Marine active|
214768477|NCT02139085|DEVICE|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
214768478|NCT02139085|DEVICE|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
214768479|NCT03403920|OTHER|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
214768480|NCT01520766|DEVICE|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
214768481|NCT01520766|DEVICE|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
214768482|NCT05644938|PROCEDURE|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
214768483|NCT05644938|PROCEDURE|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
214768484|NCT04906473|DRUG|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
214768485|NCT03151967|DRUG|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
214768486|NCT03151967|DRUG|Placebo|vaginal applicator with medium containing no drug
214768487|NCT00197184|BIOLOGICAL|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
214768488|NCT00197184|BIOLOGICAL|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
214768489|NCT05200507|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
214768490|NCT00366678|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
214768491|NCT00366678|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
214768492|NCT00366678|DRUG|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
214768493|NCT04292171|DRUG|Gabapentin|Preoperative treatment with Gabapentin
214768494|NCT04292171|DRUG|Placebos|Preoperative treatment with Placebo
214768495|NCT00317083|PROCEDURE|Cough reflex test|
214768496|NCT04296461|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
214768497|NCT04622488|DRUG|Diclofenac Potassium|\- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
214768498|NCT02337426|DRUG|Dimethyl Fumarate|Given PO
214768499|NCT02337426|DRUG|Temozolomide|Given PO
214768500|NCT02337426|RADIATION|Radiation Therapy|Undergo radiation therapy
214768501|NCT01308073|DEVICE|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
214768502|NCT04720573|DRUG|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
214768503|NCT04720573|DRUG|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
214768504|NCT01777191|DRUG|Ixekizumab Auto-Injector|Administered SC by auto-injector
214768505|NCT01777191|DRUG|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
214768506|NCT00591526|DRUG|Arac|Ommit ARAC in the chemotherapy
214768507|NCT04350073|DEVICE|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
214768508|NCT04350073|DEVICE|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
214768509|NCT04350073|DEVICE|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
214768510|NCT01581073|DRUG|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
214768511|NCT04829422|DRUG|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
214794460|NCT01333241|BEHAVIORAL|Lifestyle behavior interventon grop|
214794461|NCT01333241|OTHER|Placebo Comparator: Control group|
214768512|NCT06410573|BEHAVIORAL|Breast Self-Examination and Practice|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
214768513|NCT02015286|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
214768514|NCT00732784|DRUG|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
214768515|NCT00732784|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
214768516|NCT04711512|BEHAVIORAL|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
214768517|NCT04711512|BEHAVIORAL|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
214768518|NCT00334269|BEHAVIORAL|Health messaging at weekly home visits by health counsellor|
214768519|NCT00334269|BEHAVIORAL|Weekly home delivery of bottled spring water|
214768520|NCT00334269|BEHAVIORAL|Weekly afterschool physical activity program for 5-18y.o.|
214768521|NCT00334269|BEHAVIORAL|Cooking classes and grocery store tours with dietician|
214768522|NCT00334269|BEHAVIORAL|Pedometers to track/increase weekly physical activity|
214768523|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
214768524|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
214768525|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy SHAM|"Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application."
214768526|NCT03025659|OTHER|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
214768527|NCT06533891|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
214768528|NCT06533891|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
214768529|NCT06533891|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
214768530|NCT06292910|DIAGNOSTIC_TEST|arterial and central venous blood gas analysis, lactate|blood gas analysis
214768531|NCT02814669|DRUG|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
214768532|NCT02814669|DRUG|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
214768533|NCT02897453|DEVICE|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
214768534|NCT01823237|DEVICE|Transcranial Magnetic Stimulation|
214768535|NCT04591600|DRUG|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
214768536|NCT04591600|DRUG|Standard of care|"Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
214768537|NCT05697107|DRUG|Ripretinib Oral Tablet|Oral kinase inhibitor
214768538|NCT00315328|DRUG|Atropine|Atropine 1% each weekend day in the sound eye
214768539|NCT00315328|DEVICE|Patching|Patching 2 hours per day
214768540|NCT00315328|PROCEDURE|Near activities|near visual activities for at least one hour per day
214768541|NCT00753909|DRUG|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
214768542|NCT00753909|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
214768543|NCT00753909|DRUG|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
214768544|NCT03313154|OTHER|Neuropsychiatric screening|"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
214768545|NCT04504097|BEHAVIORAL|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
214768546|NCT04504097|DIAGNOSTIC_TEST|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
214768547|NCT01950195|PROCEDURE|Stereotactic Radiosurgery (SRS)|
214768548|NCT01950195|BIOLOGICAL|Ipilimumab|
214768549|NCT06346600|GENETIC|SKG0106|Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
214768550|NCT00153868|BIOLOGICAL|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
214768551|NCT03962660|OTHER|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
214768552|NCT03962660|OTHER|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
214768553|NCT00997672|DRUG|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
214768554|NCT00997672|DRUG|Placebo|
214794462|NCT02796235|OTHER|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
214794463|NCT01314690|OTHER|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
214645859|NCT02239822|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks."
214645860|NCT02239822|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
214645861|NCT03674021|OTHER|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
214645862|NCT03287180|BEHAVIORAL|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
214645863|NCT03287180|OTHER|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
214645864|NCT03981432|BEHAVIORAL|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214768555|NCT04924946|OTHER|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"* Time to monitor blood pressure values in target targets~* Need for administration of another antihypertensive drug~* Disappearance of organ failure attributable to hypertension~* Weaning from an extra-renal purification~* Weaning from mechanical ventilation~* Improved kidney function~* Iatrogenic hypotension~* Need for suspension of treatment~* Other side effect"
214645865|NCT03981432|BEHAVIORAL|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214645866|NCT03981432|BEHAVIORAL|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
214645867|NCT01324557|PROCEDURE|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
214645868|NCT03418532|COMBINATION_PRODUCT|MP0250 DARPin® drug candidate, Osimertinib|Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
214645869|NCT06257914|DIAGNOSTIC_TEST|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
214645870|NCT04178772|DEVICE|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
214645871|NCT02808390|DRUG|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
214645872|NCT02808390|DRUG|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
214645873|NCT02808390|DRUG|Placebo|Placebo BID for 8 Weeks
214645874|NCT05537714|BEHAVIORAL|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
214645875|NCT00773279|DEVICE|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
214645876|NCT00773279|DEVICE|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
214645877|NCT05192369|DRUG|CTP-543|CTP-543 12 mg (1 x 12 mg tablet), dosed with water
214645878|NCT05192369|DRUG|CTP-543|CTP-543 48 mg (4 x 12 mg tablet) dosed with water
214645879|NCT05192369|DRUG|Moxifloxacin|Moxifloxacin (1 x 400 mg tablet) dosed with water
214645880|NCT05192369|DRUG|Placebo|Placebo (1 tablet) dosed with water
214645881|NCT05816863|DRUG|pabolizumab|pabolizumab IV every 3 weeks (q3w)
214645882|NCT01409460|PROCEDURE|Oburator Nerve block|Use of selective pain block.
214645883|NCT01409460|PROCEDURE|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
214645884|NCT00018902|DRUG|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
214645885|NCT00018902|DRUG|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
214645886|NCT00018902|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
214645887|NCT00018902|DRUG|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
214645888|NCT03718845|BEHAVIORAL|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
214645889|NCT02557425|OTHER|No intervention in PROTECT|
214645890|NCT03163654|PROCEDURE|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
214768556|NCT03628001|PROCEDURE|ERCP|Pts will be randomized with or without sphinterectomy.
214794464|NCT02720003|DEVICE|LTX DCB|Treatment with a drug-coated balloon
214794465|NCT00358384|DRUG|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
214768557|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
214768558|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
214768559|NCT01898858|DEVICE|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
214768560|NCT01898858|DEVICE|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
214768561|NCT01898858|DEVICE|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
214768562|NCT05399186|OTHER|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
214768563|NCT02803190|BEHAVIORAL|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
214768564|NCT02803190|BEHAVIORAL|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
214768565|NCT02686710|DRUG|Sevoflurane|
214768566|NCT02686710|DRUG|Propofol|
214768567|NCT04918810|DRUG|Docetaxel intermittent|After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
214768568|NCT00881595|DRUG|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
214768569|NCT00881595|RADIATION|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
214768570|NCT00881595|PROCEDURE|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
214768571|NCT04896723|DIAGNOSTIC_TEST|Sexual function questionnaire|Sexual function questionnaire and cognitive screening assessments
214768572|NCT01398449|RADIATION|Elective nodal irradiation (ENI)|
214768573|NCT01398449|OTHER|Adjuvant chemotherapy only|
214768574|NCT05124990|DIAGNOSTIC_TEST|thermal imaging|no risk infrared thermal image would be used to capture pictures of the patients joints that are reported to be painful during a rheumatoid arthritis flare along iwth labs such as esr and crp. these will then be fed to a machine learning algorithm that will learn to predict the DAS 28 score for the RA patient and their flare.
214768575|NCT06023303|DEVICE|Potenza|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
214768576|NCT06023303|DEVICE|Morpheus|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
214768577|NCT02469675|DEVICE|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
214768578|NCT02469675|DEVICE|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
214768579|NCT02469675|DEVICE|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
214768580|NCT01715259|DRUG|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
214768581|NCT01715259|DRUG|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
214768582|NCT05947799|OTHER|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
214768583|NCT05947799|OTHER|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
214768584|NCT00053599|DRUG|Simvastatin|
214768585|NCT05349032|DIETARY_SUPPLEMENT|Curcumin|Oral supplement
214768586|NCT03816956|DRUG|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
214768587|NCT03816956|OTHER|Placebo|Placebo comparator
214768588|NCT04253756|DEVICE|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
214768589|NCT05776732|OTHER|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
214768590|NCT03319693|GENETIC|Somatic Genetic|NGS analysis
214768591|NCT04861415|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
214768592|NCT04861415|RADIATION|Conventionally Fractionated Radiation|External beam radiation therapy treatment
214768593|NCT00471588|DRUG|Pramipexole, Amisulpride|Study Drug
214768594|NCT01910597|DRUG|SBG|
214768595|NCT06541483|PROCEDURE|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
214768596|NCT06541483|PROCEDURE|conventional general anesthesia (CGA)|(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
214768597|NCT01033201|OTHER|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
214768598|NCT04061057|DRUG|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
214768599|NCT04061057|DRUG|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
214768600|NCT00388674|DRUG|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
214768601|NCT00388674|DRUG|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
214768602|NCT02561013|DEVICE|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
214768603|NCT02561013|DEVICE|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
214768604|NCT01208168|DRUG|NAB001|nail lacquer, once daily, 52 weeks
214768605|NCT01208168|DRUG|Vehicle alone|nail lacquer, once daily, 52 weeks
214768606|NCT05366153|DIAGNOSTIC_TEST|Coronary CT|Screening/Management Plan
214768607|NCT06672198|PROCEDURE|ERAC protocol|our study aimed to evaluate pre-peri-post operative practices in women who underwent elective cesarean section (CS) according to the ERAC protocol. In this context, this study aimed to describe the implementation status of the recommendations regarding the ERAC protocol in CS operations, to identify the missing aspects of the ERAC protocol and to raise awareness about its benefits.
214768608|NCT03435822|OTHER|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
214768609|NCT03435822|OTHER|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
214768610|NCT01068795|DRUG|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
214768611|NCT06542549|DRUG|AK104|The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
214768612|NCT02726373|OTHER|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
214768613|NCT00400426|PROCEDURE|Radiotherapy|20 Gy in 4 fx
214768614|NCT04254731|DRUG|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
214768615|NCT00354731|DRUG|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
214768616|NCT00354731|DRUG|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
214768617|NCT02585973|DRUG|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
214768618|NCT02585973|DRUG|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
214768619|NCT02585973|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
214768620|NCT00759174|DRUG|No intervention|No intervention occurs in this observational study.
214768621|NCT01890109|BIOLOGICAL|Erenumab|Administered via subcutaneous injection.
214768622|NCT01890109|DRUG|Placebo|Administered via subcutaneous injection
214768623|NCT05355987|OTHER|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
214768624|NCT05355987|OTHER|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
214768625|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
214768626|NCT01225237|DRUG|Ramosetron|oral
214768627|NCT01225237|DRUG|Placebo|oral
214768628|NCT00540007|DRUG|Lenalidomide|
214768629|NCT02028156|OTHER|Partially Hydrolyzed Infant Formula|Commercially available infant formula
214768630|NCT00053027|BIOLOGICAL|rituximab|
214768631|NCT00053027|DRUG|cladribine|
214768632|NCT05808894|PROCEDURE|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
214768633|NCT04261322|RADIATION|x ray exposure|exposure of whole body to x ray
214768634|NCT04628143|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
214768635|NCT04976387|DRUG|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
214768636|NCT04976387|DRUG|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
214768637|NCT04976387|DRUG|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
214768638|NCT03455647|BEHAVIORAL|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
214768639|NCT02080065|PROCEDURE|living donor liver transplantation|
214768640|NCT06003491|DEVICE|Intra-articular Cages|Using reduction using posterior intra-articular distraction and fusion technique with cages.
214768641|NCT03105882|DEVICE|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
214768642|NCT04552080|DRUG|Amoxicillin|Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
214768643|NCT04552080|OTHER|Placebo|Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
214768644|NCT02331069|DRUG|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
214768645|NCT02331069|OTHER|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
214768646|NCT00568776|DRUG|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
214768647|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
214768648|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
214768649|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
214768650|NCT05335473|DRUG|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
214768651|NCT02532140|DRUG|WCK 5107 250 mg to 2000 mg|
214768652|NCT02532140|DRUG|Cefepime 2000 mg|
214768653|NCT02532140|DRUG|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
214768654|NCT02532140|DRUG|Placebo|
214768655|NCT02700074|OTHER|No Intervention|Intervention is not a part of this study.
214768656|NCT00488839|DRUG|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
214768657|NCT00488839|DRUG|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
214768658|NCT00488839|DRUG|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
214768659|NCT00488839|DRUG|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
214768660|NCT00488839|DRUG|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
214768661|NCT00488839|DRUG|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
214768662|NCT00488839|DRUG|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
214768663|NCT00488839|DRUG|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
214768664|NCT00488839|DRUG|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
214768665|NCT03701490|DRUG|Progesterone subcutaneous|25 mg/twice a day.
214768666|NCT03701490|DRUG|Progesterone Vaginal Product|200 mg three times a day.
214768667|NCT04118855|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
214768668|NCT04118855|DRUG|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
214768669|NCT01097850|DRUG|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
214768670|NCT04434638|OTHER|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
214768671|NCT04434638|OTHER|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
214768672|NCT01674959|RADIATION|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
214768673|NCT00415142|DRUG|saredutant (SR48968)|oral administration (capsules)
214768674|NCT00415142|DRUG|placebo|oral administration (capsules)
214768675|NCT00415142|DRUG|escitalopram|oral administration (capsules)
214768676|NCT03801759|DRUG|Vadadustat|Oral dose 600 mg
214768677|NCT03801759|DRUG|Furosemide|Oral Furosemide
214768678|NCT03801759|DRUG|Adefovir|Oral Adefovir
214768679|NCT03801759|DRUG|Digoxin|Oral Digoxin
214768680|NCT06058507|DIAGNOSTIC_TEST|CT angiography|No intervention was made
214768681|NCT00850005|BIOLOGICAL|Intravenous immunoglobulin|2 g/kg divided over five days
214768682|NCT00850005|BIOLOGICAL|Normal Saline|Same volume as experimental arm
214768683|NCT01576627|DIETARY_SUPPLEMENT|zinc citrate|10 mg of zinc as either zinc citrate
214768684|NCT01576627|DIETARY_SUPPLEMENT|Zinc Gluconate|10 mg of zinc as either zinc gluconate
214768685|NCT01576627|DIETARY_SUPPLEMENT|Zinc oxide|10 mg of zinc as either zinc oxide
214768686|NCT04160676|DRUG|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
214768687|NCT04160676|DRUG|Normal saline|Normal saline
214768688|NCT02111382|OTHER|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
214768689|NCT02111382|OTHER|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
214768690|NCT06539494|DRUG|Omeprazole 40 MG|Proton pump inhibitor twice a day for 4 weeks
214768691|NCT00996632|PROCEDURE|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
214768692|NCT00996632|PROCEDURE|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
214768693|NCT02049554|OTHER|Preconception Care Screener|
214768694|NCT00334828|DRUG|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
214768695|NCT00334828|DRUG|Placebo|Matching placebo; intravenous infusion.
214768696|NCT03409497|OTHER|Concord Grape Juice|Concord Grape Juice
214768697|NCT03409497|OTHER|Low flavonoid low essence beverage|Low flavonoid low essence beverage
214768698|NCT03409497|OTHER|Low flavonoid beverage|Low flavonoid beverage
214768699|NCT05501002|DEVICE|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
214768700|NCT05489380|DEVICE|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
214794466|NCT00358384|DRUG|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
214645891|NCT03163654|PROCEDURE|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
214645892|NCT05984563|DEVICE|Cardiopulmonary bypass|CPB will be ensured as usual care: priming volume will be set as 1200 to 1500 mL. Patient blood management and hemodynamic management will be left at the discretion of the anesthesiologist in charge of the patient. Anticoagulation during CPB will be handled through an initial heparin bolus of 300-400 UI/kg followed by additional boluses to maintain ACT above 400 s. Non-heparin-coated bypass circuits incorporating an integrated phosphorylcholine-coated oxygenation system will be used.
214645893|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
214645894|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
214645895|NCT02744157|BEHAVIORAL|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
214645896|NCT03215784|DIETARY_SUPPLEMENT|Fish Oil|
214645897|NCT03215784|DIETARY_SUPPLEMENT|Probiotic|
214645898|NCT03215784|DIETARY_SUPPLEMENT|Placebo|
214645899|NCT03221894|DIETARY_SUPPLEMENT|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
214645900|NCT05857176|OTHER|COVID-19 Vaccine questionnaire|An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).
214645901|NCT05797272|PROCEDURE|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
214645902|NCT00067704|BEHAVIORAL|Trauma writing|
214645903|NCT00067704|BEHAVIORAL|Writing about daily events|
214645904|NCT06370416|DRUG|Trilaciclib|After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
214645905|NCT04513470|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
214794467|NCT00358384|DRUG|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
214794468|NCT00358384|DRUG|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
214794469|NCT06090656|DRUG|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
214645906|NCT03588377|DEVICE|Pulse Oximetry|"Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under \<5 children with symptoms of cough or difficulty breathing~Case definition:~1. Birth - 6 days: Fast breathing +/- Low oxygen in blood \<92% (Hypoxemia)~2. 7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood \<92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor."
214645907|NCT01912625|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214645908|NCT01912625|DRUG|Carboplatin|Given IV
214768701|NCT05358392|OTHER|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
214768702|NCT03004963|DEVICE|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
214768703|NCT03004963|DEVICE|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
214768704|NCT05880485|RADIATION|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
214768705|NCT04018937|DRUG|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
214768706|NCT04018937|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
214768707|NCT04018937|DRUG|Melphalan|Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
214768708|NCT06095362|DRUG|Bevacizumab-IRDye800CW|All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
214768709|NCT01598740|DRUG|CLP|Oral administration
214768710|NCT01598740|DRUG|Spironolactone|oral administration
214768711|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
214768712|NCT00812045|DRUG|Placebo|
214768713|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
214768714|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
214768715|NCT05830123|DRUG|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214768716|NCT01910701|BEHAVIORAL|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
214768717|NCT06471738|DRUG|Zanubrutinib|BTK inhibitor
214768718|NCT06471738|BIOLOGICAL|Rituximab|Monoclonal antibody to CD20
214768719|NCT06471738|DRUG|Venetoclax|BCL-2 inhibitor
214768720|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
214768721|NCT01856348|DRUG|Vitamin D|
214768722|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
214768723|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
214768724|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
214768725|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
214768726|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
214768727|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
214768728|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
214768729|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
214768730|NCT02708940|OTHER|Participatory technology development|Creating mobile support tools by patients and their therapists
214768731|NCT02708940|OTHER|Usual Care|Usual care as part of the UCLA PHP and IOP programs
214768732|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
214768733|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
214768734|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
214768735|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
214768736|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
214768737|NCT00576849|DRUG|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
214768738|NCT00576849|DRUG|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
214768739|NCT00576849|DRUG|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
214768740|NCT02712736|OTHER|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
214768741|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
214768742|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
214768743|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
214768744|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
214768745|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
214768746|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
214645909|NCT01912625|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
214645910|NCT01912625|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214645911|NCT01912625|OTHER|Laboratory Biomarker Analysis|Correlative studies
214645912|NCT01912625|DRUG|Paclitaxel|Given IV
214645913|NCT01912625|OTHER|Pharmacological Study|Correlative studies
214645914|NCT01912625|DRUG|Trametinib|Given PO
214645915|NCT04052581|PROCEDURE|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
214645916|NCT04285333|PROCEDURE|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
214645917|NCT04285333|PROCEDURE|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
214645918|NCT00508391|DEVICE|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
214645919|NCT00682058|OTHER|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
214645920|NCT03311256|DIAGNOSTIC_TEST|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
214645921|NCT01692678|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
214645922|NCT01692678|DRUG|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
214645923|NCT04750460|DRUG|Teriparatide|Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
214645924|NCT01332682|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
214645925|NCT01332682|BEHAVIORAL|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
214645926|NCT02762487|DEVICE|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
214645927|NCT05825690|OTHER|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
214645928|NCT04869267|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Session 1:~This session aims to let the participants get familiar with the interventionist. The interventionist will tell them the purpose of the program and basic rules. And the interventionist will promise their privacy protection.~Session 2:~This session includes how to separate thoughts/feelings/sensations related to diagnose with advanced lung cancer and experience of fatigue with facts and see these feelings in an objective way with observing self.~Session 3:~This session mainly aims to help participants understand the importance of values, differentiate values from goals and clarify their personal values.~Session 4:~This session aims at helping patients practice to engaging in committed action based on chosen values, motivated to change behavior in consistency with life direction and health goal."
214645929|NCT04869267|OTHER|Usual care|The usual care mainly includes treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge
214645930|NCT00802360|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
214645931|NCT00802360|DRUG|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
214768747|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
214768748|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
214768749|NCT03896373|OTHER|Blood samples|Blood samples
214768750|NCT01179191|DRUG|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
214768751|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
214768752|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
214768753|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
214768754|NCT05349760|DRUG|Placebo|Saline/D5W
214768755|NCT06346756|OTHER|Treatment of dental caries.|The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
214768756|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
214768757|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
214768758|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
214768759|NCT03297801|DIETARY_SUPPLEMENT|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
214768760|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
214768761|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
214768762|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
214768763|NCT02741609|DEVICE|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
214768764|NCT02001285|DRUG|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
214768765|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
214768766|NCT02801838|DRUG|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
214768767|NCT01177735|DRUG|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
214768768|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
214768769|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
214768770|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
214768771|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
214768772|NCT04749121|DEVICE|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
214768773|NCT04749121|DRUG|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
214768774|NCT04749121|DEVICE|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
214768775|NCT04749121|DEVICE|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
214768776|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
214768777|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
214768778|NCT03224741|BEHAVIORAL|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
214768779|NCT03224741|BEHAVIORAL|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
214768780|NCT03224741|BEHAVIORAL|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
214768781|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
214768782|NCT04450979|DIETARY_SUPPLEMENT|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
214768783|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
214768784|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
214768785|NCT01104935|DRUG|trastuzumab monotherapy|
214768786|NCT01104935|DRUG|trastuzumab and chemotherapy|
214768787|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
214768788|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
214768789|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
214768790|NCT06264271|BEHAVIORAL|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
214768791|NCT01068093|DRUG|Ezetimibe|10mg daily
214768792|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
214768793|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
214768794|NCT02405351|BEHAVIORAL|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
214768795|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
214768796|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
214768797|NCT05398731|OTHER|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
214768798|NCT04859647|OTHER|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
214768799|NCT06469476|BEHAVIORAL|depression post partum|visit post partum
214768800|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
214768801|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
214768802|NCT00118222|DRUG|porfimer sodium|All patients receive porfimer sodium IV.
214768803|NCT00118222|PROCEDURE|adjuvant therapy|All patients receive porfimer sodium IV.
214768804|NCT00118222|PROCEDURE|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
214768805|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
214768806|NCT05137639|PROCEDURE|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
214768807|NCT01366365|DRUG|methylnaltrexone|
214768808|NCT01366365|DRUG|placebo|
214768809|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
214768810|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
214768811|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
214768812|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
214768813|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
214768814|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
214768815|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
214768816|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
214768817|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
214768818|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
214768819|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
214768820|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
214768821|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
214768822|NCT05263869|DRUG|MRG002|Administrated intravenously
214768823|NCT06114017|BEHAVIORAL|Social Media Abstention|People will stop or reduce their social media use for one week.
214768824|NCT06041269|DRUG|Rosnilimab|PD-1 agonist antibody
214768825|NCT06041269|DRUG|Placebo|Placebo
214768826|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
214768827|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
214768828|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
214768829|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
214768830|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
214768831|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
214768832|NCT01294709|DRUG|telcagepant|
214768833|NCT01294709|DRUG|Placebo to telcagepant|
214768834|NCT06521281|BEHAVIORAL|Chan-Chuang qigong|Twice daily, every 15 minutes Chan-Chuang qigong
214768835|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
214768836|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
214768837|NCT02514031|DRUG|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
214768838|NCT02514031|DRUG|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
214768839|NCT02514031|DRUG|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
214768840|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
214768841|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
214768842|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
214768843|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
214768844|NCT01793285|DRUG|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
214768845|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
214768846|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
214768847|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
214768848|NCT01146886|DRUG|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
214768849|NCT01146886|DRUG|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
214768850|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
214768851|NCT01596088|DRUG|Dexrazoxane|
214645932|NCT00802360|DRUG|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
214645933|NCT00802360|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
214645934|NCT00802360|DRUG|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
214645935|NCT01418495|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214645936|NCT01418495|OTHER|Pharmacological Study|Correlative studies
214645937|NCT00189644|PROCEDURE|6 FEC 100|
214645938|NCT00189644|PROCEDURE|4 FEC 100 followed by 4 Taxol|
214645939|NCT02041962|BEHAVIORAL|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
214645940|NCT02041962|OTHER|Educational Control|
214645941|NCT01799057|DRUG|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
214645942|NCT01799057|DRUG|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
214645943|NCT00000815|BIOLOGICAL|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
214645944|NCT00000815|BIOLOGICAL|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
214645945|NCT01812967|DIETARY_SUPPLEMENT|Milk Fat|
214645946|NCT01812967|DIETARY_SUPPLEMENT|Milk Protein|
214645947|NCT01812967|DIETARY_SUPPLEMENT|Lactose|
214645948|NCT01812967|OTHER|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
214645949|NCT01812967|DIETARY_SUPPLEMENT|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
214645950|NCT02765451|BEHAVIORAL|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
214645951|NCT01670266|DRUG|ONO-9054|
214645952|NCT01670266|DRUG|Placebo|
214645953|NCT00874302|DRUG|Proellex|One 25mg capsule taken orally once every day.
214645954|NCT00874302|DRUG|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
214645955|NCT01196559|DRUG|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
214645956|NCT02838173|PROCEDURE|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
214645957|NCT02838173|PROCEDURE|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
214645958|NCT02838173|PROCEDURE|serratus plane bloc : placebo|
214645959|NCT02838173|PROCEDURE|tissue infiltration : placebo|
214645960|NCT03308864|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
214645961|NCT03308864|BEHAVIORAL|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
214645962|NCT00617877|DRUG|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
214645963|NCT00617877|DRUG|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
214645964|NCT03653598|OTHER|Atrial Fibrillation|Data collection on Atrial Fibrillation
214768852|NCT05648097|DEVICE|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
214768853|NCT00232778|DEVICE|GAMMA-Iridium-192 catheter|
214768854|NCT05372211|OTHER|not use of any intervention|not use of any intervention
214768855|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
214768856|NCT05311215|DRUG|SL-1002|SL-1002 injectable solution
214768857|NCT05311215|DRUG|Placebo|Matching placebo injectable solution
214768858|NCT04365829|DEVICE|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
214768859|NCT00954694|DEVICE|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
214768860|NCT04727580|DRUG|HSK7653 10mg Q2W|HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
214768861|NCT04727580|DRUG|HSK7653 25mg Q2W|HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
214768862|NCT04727580|DRUG|Placebo|Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
214768863|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
214768864|NCT03837340|OTHER|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
214768865|NCT03837340|OTHER|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
214768866|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768867|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768868|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768869|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768870|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768871|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768872|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768873|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
214768874|NCT01612780|DEVICE|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
214768875|NCT05005130|OTHER|TASKPEN|"TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)"
214768876|NCT00023426|DRUG|rifapentine|
214768877|NCT04395040|OTHER|Semi-structured interview|Semi-structured interview
214794470|NCT06090656|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
214768878|NCT03910101|PROCEDURE|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
214768879|NCT06547814|BEHAVIORAL|Standard implementation webinar and online training|The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, vaccine eligibility, mechanisms of action, and outcomes. The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.
214768880|NCT06547814|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and at least 8, 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
214768881|NCT06402890|DIETARY_SUPPLEMENT|Resistance training with collagen supplementation|"Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week."
214768882|NCT01950338|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
214768883|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
214768884|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
214768885|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
214768886|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
214768887|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
214768888|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
214768889|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
214768890|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
214768891|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
214768892|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
214768893|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
214768894|NCT06109402|DRUG|TQB2450|Specified dose on specified days
214768895|NCT06109402|DRUG|Carboplatin|Specified dose on specified days
214768896|NCT06109402|DRUG|Pemetrexed|Specified dose on specified days
214768897|NCT06109402|DRUG|Nab-paclitaxel|Specified dose on specified days
214768898|NCT06109402|PROCEDURE|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
214768899|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768900|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768901|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768902|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768903|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768904|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768905|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
214768906|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
214768907|NCT03016988|DRUG|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
214768908|NCT03016988|DRUG|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
214768909|NCT03016988|DRUG|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
214768910|NCT06422832|OTHER|HeartLogic or TriageHF Algorithms for implantable devices|Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
214768911|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
215030800|NCT02323711|DEVICE|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
214645965|NCT04301141|OTHER|Virtual Reality Assisted Cognitive Behavioural Therapy|The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
214645966|NCT01225562|DRUG|Ticagrelor 90 mg|Oral dose twice a day
214645967|NCT01225562|DRUG|Ticagrelor 60 mg|Oral dose twice a day
214645968|NCT01225562|DRUG|Ticagrelor Placebo|Oral dose twice a day
214645969|NCT00838019|PROCEDURE|Intrabone administration of umbilical cord blood|Single administration
214645970|NCT03633188|BIOLOGICAL|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~* Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~* Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~* Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
214645971|NCT03856151|DEVICE|"HEALTHY BOX Powered heating pad (electronic moxibustion)"|Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
214645972|NCT04408807|OTHER|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
214645973|NCT04408807|OTHER|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
214645974|NCT01692808|DRUG|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
214645975|NCT01692808|DRUG|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
214645976|NCT02111733|OTHER|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
214645977|NCT05274230|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
214645978|NCT00786045|OTHER|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
214768912|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
214768913|NCT00335985|DRUG|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
214768914|NCT00335985|DRUG|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
214768915|NCT05736809|OTHER|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
214768916|NCT05736809|OTHER|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
214768917|NCT05736809|OTHER|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
214768918|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
214768919|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
214768920|NCT00568516|DRUG|ASP3550|subcutaneous administration
214645979|NCT06148961|PROCEDURE|botox prior to modified lip repostioning|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
214645980|NCT04617366|OTHER|Individualized rTMS strategy|It will adjust the rTMS parameters based on the results of fNIRS.
214645981|NCT04617366|OTHER|Traditional rTMS strategy|The patients will always be given low-frequency rTMS to contralesional M1.
214645982|NCT01481896|DEVICE|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
214645983|NCT00165958|PROCEDURE|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
214768921|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
214768922|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
214768923|NCT03310606|OTHER|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
214768924|NCT03750916|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
214768925|NCT01129518|BIOLOGICAL|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
214645984|NCT00165958|PROCEDURE|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
214645985|NCT02295722|DRUG|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
214645986|NCT02295722|DRUG|Melphalan|200 mg/m2
214645987|NCT02295722|OTHER|ASCT|Day 0 - Stem cell infusion
214645988|NCT00145990|DRUG|methacholine|
214645989|NCT00145990|DEVICE|KoKo Digidoser|
214645990|NCT00145990|DEVICE|Rosethal Dosimeter|
214645991|NCT04323930|DEVICE|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
214645992|NCT03152240|OTHER|Non intervention|Non intervention
214645993|NCT01682850|BEHAVIORAL|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
214645994|NCT01682850|OTHER|Usual Care|
214768926|NCT01129518|BIOLOGICAL|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
214768927|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
214768928|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
214768929|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
214768930|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
214768931|NCT05550025|DRUG|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
214768932|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
214768933|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
214768934|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
214768935|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
214768936|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
214768937|NCT02297607|DIETARY_SUPPLEMENT|Tube Feeding|
214768938|NCT04978194|OTHER|University-based intervention to promote better management of emotions and learning|It included 9 video capsules (that take place over 9 weeks), with the following themes: stress information, learning information, emotion and stress regulation strategies, cognitive and metacognitive learning strategies, motivation for learning, physical activity, diet, sleep, and managing worry and uncertainty. It is based on previous online student mental health intervention studies. It presents two innovative aspects: elements and examples specific to the COVID-19 pandemic and the addition of modules focused on learning strategies. The different modules were designed by 5 associate professors, 2 Master students in clinical psychology and 2 undergraduate students in psychology. For the control group, the videos will be posted every week on a You Tube channel and broadcast on a private discord group. For the hybrid group, student will have to attend 10 lessons of 2 hours. These courses include the viewing of videos and a time for discussion between students and the teacher.
214768939|NCT00163371|DRUG|Ciclesonide|
214768940|NCT04681807|BEHAVIORAL|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
214768941|NCT04681807|BEHAVIORAL|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
214768942|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
214768943|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
214768944|NCT05268523|BEHAVIORAL|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
214768945|NCT05268523|BEHAVIORAL|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
214768946|NCT04074798|BEHAVIORAL|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
214768947|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
214768948|NCT06414265|DEVICE|Transcatheter mitral valve replacement|The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
214768949|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
214768950|NCT00263393|DRUG|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
214768951|NCT00263393|BEHAVIORAL|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
214768952|NCT02143401|OTHER|Laboratory Biomarker Analysis|Correlative studies
214768953|NCT02143401|BIOLOGICAL|Navitoclax|Given PO
214768954|NCT02143401|OTHER|Pharmacological Study|Correlative studies
214768955|NCT02143401|DRUG|Sorafenib|Given PO
214768956|NCT02143401|DRUG|Sorafenib Tosylate|Given PO
214768957|NCT01825499|OTHER|Registry|
214768958|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
214768959|NCT03972709|DRUG|Sham Control|Sham control
214768960|NCT05894668|OTHER|ECIRS|Endoscopic Combined Intrarenal Surgery
214768961|NCT00045396|DRUG|tipifarnib|Given orally
214768962|NCT05552235|DEVICE|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
214768963|NCT05552235|OTHER|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
214768964|NCT04454619|DRUG|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
214768965|NCT02360059|DRUG|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
214768966|NCT02360059|OTHER|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
214768967|NCT02360059|BEHAVIORAL|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
214768968|NCT02360059|OTHER|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
214768969|NCT05189145|DRUG|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
214768970|NCT05189145|OTHER|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
214768971|NCT05189145|DIAGNOSTIC_TEST|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
214768972|NCT05189145|DRUG|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
214768973|NCT05189145|OTHER|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily
214768974|NCT05189145|DRUG|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
214768975|NCT04557982|PROCEDURE|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
214768976|NCT01136044|OTHER|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
214768977|NCT00852072|PROCEDURE|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
214768978|NCT00852072|PROCEDURE|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
214768979|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
215030801|NCT03514134|BEHAVIORAL|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
214645995|NCT03871114|DRUG|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
214645996|NCT00805896|DRUG|Songyou|4g/pack
214645997|NCT00805896|DRUG|placebo|4g/pack
214645998|NCT04333082|OTHER|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
214645999|NCT00501267|DRUG|solabegron and oxybutynin|
214646000|NCT01818726|DRUG|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
214646001|NCT01818726|DRUG|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
214646002|NCT01818726|DRUG|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
214646003|NCT00199979|DRUG|Nevirapine|
214646004|NCT06446557|DRUG|treatment adaptation guided by ctDNA variation|"after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA."
214646005|NCT06446557|DRUG|standard management|At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
214646006|NCT02525289|OTHER|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
214768980|NCT05161559|PROCEDURE|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
214768981|NCT05161559|PROCEDURE|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
214768982|NCT05161559|PROCEDURE|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
214768983|NCT05192954|DEVICE|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
214768984|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
214768985|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
214768986|NCT01339000|DRUG|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
214768987|NCT01339000|BIOLOGICAL|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
214768988|NCT01339000|BIOLOGICAL|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
214768989|NCT01339000|BIOLOGICAL|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
214768990|NCT01339000|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
214768991|NCT01339000|BIOLOGICAL|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
214768992|NCT05151796|DRUG|Aspirin|Daily aspirin intake for cardiovascular prevention
214768993|NCT00601276|DRUG|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
214646007|NCT02525289|OTHER|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
214646008|NCT03798288|BEHAVIORAL|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
214646009|NCT03798288|OTHER|Usual care|Participants will receive usual care
214646010|NCT03594968|DIAGNOSTIC_TEST|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
214646011|NCT04673097|OTHER|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
214646012|NCT04673097|OTHER|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
214646013|NCT02249702|DRUG|gemcitabine + docetaxel|
214646014|NCT02249702|DRUG|trabectedin|
214646015|NCT04959357|DIAGNOSTIC_TEST|Two dimensional speckle tracking imaging|lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
214646016|NCT03611699|DRUG|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
214646017|NCT03611699|DRUG|Placebo|Placebo inhaler
214768994|NCT00601276|DRUG|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
214768995|NCT01895088|DEVICE|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
214768996|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
214768997|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
214768998|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
214768999|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
214769000|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
214769001|NCT00053911|DRUG|anastrozole|
214769002|NCT00053911|DRUG|cyclophosphamide|
214769003|NCT00053911|DRUG|docetaxel|
214769004|NCT00053911|DRUG|epirubicin hydrochloride|
214769005|NCT00053911|DRUG|fluorouracil|
214769006|NCT00053911|DRUG|goserelin acetate|
214769007|NCT00053911|DRUG|tamoxifen citrate|
214769008|NCT00053911|PROCEDURE|adjuvant therapy|
214769009|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
214769010|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
214769011|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
214769012|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
214769013|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
214769014|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
214769015|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
214769016|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
214769017|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
214769018|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
214769019|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
214769020|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
214769021|NCT00077870|DRUG|ocrelizumab|
214769022|NCT00118209|BIOLOGICAL|rituximab|IV
214769023|NCT00118209|DRUG|cyclophosphamide|IV
214769024|NCT00118209|DRUG|doxorubicin|IV or CIVI
214769025|NCT00118209|DRUG|vincristine|IV or CIVI
214769026|NCT00118209|DRUG|prednisone|oral
214769027|NCT00118209|DRUG|etoposide|CIVI
214769028|NCT00118209|DRUG|filgrastim|IV
214769029|NCT00118209|DRUG|pegfilgrastim|IV
214769030|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
214769031|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
214769032|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
214769033|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
214769034|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
214769035|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
214769036|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
214769037|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
214769038|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
215030802|NCT03514134|BEHAVIORAL|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
214769039|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
214769040|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
214646018|NCT00216970|DIETARY_SUPPLEMENT|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
214646019|NCT05495295|DRUG|PhOx430|"A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
214769041|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
214769042|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
214769043|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
214769044|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
214769045|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
214769046|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
214769047|NCT00139802|DEVICE|Coronary Stent Implantation|
214769048|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
214769049|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
214769050|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
214769051|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
214769052|NCT01976637|OTHER|no compression|no compression stockings worn during the study
214769053|NCT01976637|DEVICE|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
214769054|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
214769055|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
214769056|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
214769057|NCT05641246|DRUG|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
214769058|NCT05641246|DRUG|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
214769059|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
214769060|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
214769061|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
214769062|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
214769063|NCT04486807|DIAGNOSTIC_TEST|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
214769064|NCT04503031|DEVICE|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
214769065|NCT04503031|DEVICE|cylindrical endotracheal tube|endotracheal tube is intubated
214769066|NCT01935882|DRUG|Artemether-lumefantrine combination|
214769067|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
214769068|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
215030803|NCT02471144|BIOLOGICAL|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
214769069|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
214769070|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
214769071|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
214769072|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
214769073|NCT01387360|DEVICE|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
214769074|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
214769075|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
214769076|NCT05647200|DRUG|Treatment: additional albumin during cardiopulmonary bypass|Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
214769077|NCT05647200|DRUG|control: additional ringers during cardiopulmonary bypass|Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
214769078|NCT00061646|DRUG|ABT-510/Thrombospondin-1 mimetic|
214769079|NCT00061646|DRUG|Carboplatin/Taxol|
214769080|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
214769081|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
214769082|NCT04807231|BIOLOGICAL|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
214769083|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
214769084|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
214769085|NCT05286931|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
214769086|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
214769087|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
214769088|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214769089|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
214769090|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
214769091|NCT00345969|DRUG|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
214769092|NCT00345969|BEHAVIORAL|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
214769093|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
214769094|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
214769095|NCT01842516|DRUG|LCB01-0371 800mg|LCB0-0371 800mg
214769096|NCT01842516|DRUG|LCB01-0371 1200mg|LCB01-0371 1200mg
214769097|NCT01842516|DRUG|Placebo|Placebo
214769098|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
214769099|NCT00960687|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
214769100|NCT00960687|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
214769101|NCT05121779|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
214769102|NCT05121779|DRUG|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
214769103|NCT06700603|DRUG|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
214769104|NCT00530452|DRUG|CG100649|Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
214769105|NCT00530452|DRUG|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
214769106|NCT06646991|DEVICE|Nasal canula - up to 6 liters per minute|"Oxygen will be administered via nasal cannula up to 6 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
214769107|NCT06646991|DEVICE|Nasal canula - up to 15 liters per minute|"Oxygen will be administered via nasal cannula up to 15 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
214769108|NCT06646991|DEVICE|Open oxygen mask|"Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
214769109|NCT06646991|DEVICE|Simple oxygen face mask|"Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
214769110|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
214769111|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
214769112|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
214769113|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
214769114|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
214769115|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
214769116|NCT00050050|DRUG|Drug therapy|
214769117|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
214769118|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
214769119|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
214769120|NCT00127296|DEVICE|FlexPen®|
214769121|NCT00127296|DEVICE|vial and syringe|
214769122|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
214769123|NCT02873195|DRUG|Atezolizumab|Given IV
214769124|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
214769125|NCT02873195|DRUG|Capecitabine|Given PO
214769126|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
214769127|NCT02873195|OTHER|Placebo|Given IV
214769128|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
214769129|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
214769130|NCT02174549|DRUG|Tirapazamine|Intra-arterial injection into the tumor feeding artery
214769131|NCT02174549|PROCEDURE|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
215030804|NCT02471144|BIOLOGICAL|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
214769132|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
214769133|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
214769134|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
214769135|NCT01711814|DRUG|peficitinib|oral
214769136|NCT05004181|BIOLOGICAL|BNT162b2|Intramuscular (IM)
214769137|NCT05004181|BIOLOGICAL|Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
214769138|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.7)|Intramuscular (IM)
214769139|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.617.2)|Intramuscular (IM)
214769140|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
214769141|NCT05004181|OTHER|Observational|No vaccination within 3 months after Visit 1.
214769142|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
214769143|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
214769144|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
214769145|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
214769146|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
214769147|NCT03470896|PROCEDURE|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
214769148|NCT03470896|PROCEDURE|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
214769149|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
214769150|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
214769151|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
214769152|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
214769153|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
214769154|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
214769155|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
214769156|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
214769157|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
214769158|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
214769159|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
214769160|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
214769161|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
214769162|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
214769163|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
214769164|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
214769165|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
214769166|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
214769167|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
214769168|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
214769169|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
214769170|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
214769171|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
214769172|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
214769173|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
214769174|NCT00608075|DRUG|Lithium|600 - 1800 mg
214769175|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
214769176|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
214769177|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
214769178|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
214769179|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
214769180|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
214769181|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
214769182|NCT02472431|OTHER|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
214769183|NCT02472431|PROCEDURE|Liposuction|
214769184|NCT02472431|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
214769185|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
214769186|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
214769187|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
214769188|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
214769189|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
214769190|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
214769191|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
214769192|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
214769193|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
214769194|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
214769195|NCT05171712|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
214769196|NCT06330207|BEHAVIORAL|Clinical decision support tool|The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
214769197|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
214769198|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
214769199|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
214769200|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
214769201|NCT02427425|DEVICE|TENS|
214769202|NCT01015456|DRUG|mycophenolate sodium|per oral, twice daily, for 12 months
214769203|NCT01015456|DRUG|cyclophosphamide|intravenous, monthly, for 6 months
214769204|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
214769205|NCT00880867|DRUG|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
214769206|NCT05471063|DRUG|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
214769207|NCT05471063|DRUG|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
214769208|NCT05471063|DRUG|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
214769209|NCT03538314|DRUG|UV1|UV1 (300 microgram)
214769210|NCT03538314|DRUG|GM-CSF|GM-CSF (37,5 or 75 microgram)
214769211|NCT06082609|PROCEDURE|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
214769212|NCT04542902|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
214769213|NCT04542902|PROCEDURE|Blood sampling|An amount of a person's blood taken from their body for use in medical.
214769214|NCT04542902|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
214769215|NCT03993288|DRUG|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
214769216|NCT03993288|DRUG|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
214769217|NCT05036447|OTHER|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
214769218|NCT00915473|DRUG|bupivicaine|2.5 mL 0.5% bupivicaine
214769219|NCT00915473|DRUG|normal saline|2.75 mL normal saline
214769220|NCT00915473|DRUG|methylprednisolone|0.5 mL 20 mg methylprednisolone
214769221|NCT00915473|DRUG|lidocaine|0.25 mL 1% lidocaine
214769222|NCT02488473|DRUG|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
214769223|NCT02488473|DRUG|Ropivacaine|20 ml Ropivacaine 5mg/ml
214769224|NCT02488473|DRUG|Isotonic Saline|Placebo
214769225|NCT00831467|BIOLOGICAL|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
214769226|NCT01389024|DRUG|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
214769227|NCT01389024|DRUG|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
214769228|NCT00263796|DRUG|Oxytocin|10 international units = 1 cc, IV over 4 hours
214769229|NCT00263796|DRUG|Placebo|Normal Saline, IV over 4 hours
214769230|NCT05743686|DEVICE|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
214769231|NCT01900379|PROCEDURE|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
214769232|NCT01900379|OTHER|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
214769233|NCT00887107|DRUG|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
214769234|NCT00276965|DRUG|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
214769235|NCT00276965|DRUG|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
214769236|NCT06540573|DIAGNOSTIC_TEST|Laboratory tests (examination)|Laboratory tests (examination) to be performed include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function tests and kidney function tests; rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and C-C Motif Chemokine Ligand 21 (CCL21).
214769237|NCT06540573|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) This questionnaire is used to assess the health status of osteoarthritis patients introduced in 1988 (13). It is consisted of 33 items which evaluates the health and function of the patient from various aspects including: clinical symptoms (5 questions), severity of joint stiffness (2 questions), degree of pain (9 questions), and activity of daily living (17 questions).The test questions are scored on a scale of 0-4, which correspond to: None(0),Mild (1),Moderate (2),Severe(3),and Extreme (4).The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores.Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
214769238|NCT06540573|DIAGNOSTIC_TEST|The Disease Activity Score28 (DAS28)|The Disease Activity Score (DAS) was created as a numerical tool for quantifying and assessing disease activity in rheumatoid arthritis (RA).The DAS28 (Disease Activity Score using 28 joint counts) was developed from the original DAS (Disease Activity Score).The DAS28 evaluates the disease activity by assessing the number of tender and swollen joints in a patient. Specifically, it considers 28 joints. The DAS28 also takes into account a blood marker of inflammation, typically the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level.A patient with a DAS28 score of less than 2.6 is in remission; a score greater than or equal to 2.6 and less than 3.1 indicates low activity; a score greater than or equal to 3.1 and \<5.1 indicates moderate activity and a score 5.1 or more indicates high activity
214769239|NCT06540573|DIAGNOSTIC_TEST|Patient global assessment (PGA)|Patient global assessment (PGA) of disease activity will be reported by patients. PGA was developed in the late 1970s and was initially designed for the measurement of self-assessed pain in RA \[8\], although it has since been used to evaluate RA more globally. It is interesting to note that the way PGA is used in clinical practice covers, in fact, two very different concepts, one related to global health and the other to overall disease activity. They are both usually used under the heading of PGA without further specification for which is being assessed.
214769240|NCT06540573|DIAGNOSTIC_TEST|Physician global assessment (PhGA)|Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
214769241|NCT06540573|DIAGNOSTIC_TEST|Health Assessment Questionnaire (HAQ)|Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
214769242|NCT06540573|DIAGNOSTIC_TEST|Clinical disease activity index (CDAI)|Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76
214769243|NCT06540573|DIAGNOSTIC_TEST|The Simplified Disease Activity Index (SDAI)|The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as \>26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17
214769244|NCT06540573|DIAGNOSTIC_TEST|Knee Radiography|Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity
214769245|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
214769246|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
214769247|NCT00413465|DRUG|Escherichia Coli Endotoxin|
214769248|NCT01491373|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
214769249|NCT01491373|DEVICE|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
214769250|NCT05831787|OTHER|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
214769251|NCT03257137|OTHER|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
214769252|NCT03909373|OTHER|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
214769253|NCT02733601|OTHER|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
214769254|NCT01245595|DRUG|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
214769255|NCT01245595|DRUG|Placebo|Normal Saline
214769256|NCT01283711|DEVICE|apollo device|RF treatments for wrinkles and rhytides reduction
214794471|NCT02832856|BEHAVIORAL|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
214769257|NCT03185247|BEHAVIORAL|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
214769258|NCT05467865|OTHER|ZELIAKIDE|"The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process."
214769259|NCT04518319|DRUG|Omega-3 polyunsaturated fatty acids|Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
214769260|NCT04518319|BEHAVIORAL|Xbox aerobic exercise|Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
214769261|NCT04518319|DEVICE|transcranial direct current stimulation,tDCS|Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
214769262|NCT04518319|DRUG|Olanzapine|Patients will take only olanzapine pills.
214769263|NCT02143089|DEVICE|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
214769264|NCT04121299|DRUG|Carvedilol|Carvedilol 40mg Extended Release Once Daily
214769265|NCT04121299|DRUG|Amlodipine|Amlodipine 10mg Once Daily
214769266|NCT03618082|DRUG|Anesthesic agent guided by ANI (Interventional Group)|Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
214769267|NCT03618082|DRUG|Administration of the lowest effective concentration of desflurane (Interventional Group)|Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
214769268|NCT06413589|OTHER|SMOF lipid 20%|Drug: SMOF lipid 20% SMOF 20%, a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
214769269|NCT06413589|OTHER|standard treatment for clozapine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg) \[29\].~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
214769270|NCT02449967|PROCEDURE|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
214769271|NCT04871724|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 1 and 14
214769272|NCT04871724|DRUG|Fluconazole|Subjects will receive fluconazole once daily on Days 5 to 18
214769273|NCT04252690|DEVICE|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
214769274|NCT05112679|DEVICE|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
214794472|NCT02832856|BEHAVIORAL|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
214794473|NCT00708422|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
214769275|NCT05112679|DEVICE|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
214769276|NCT00791284|DRUG|Intermediate release (IR) Paliperidone|
214769277|NCT06123975|OTHER|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
214769278|NCT03500887|DEVICE|intragastric bag|
214769279|NCT05567588|COMBINATION_PRODUCT|Drug: Pembrolizumab|200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
214769280|NCT04143997|DIAGNOSTIC_TEST|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
214769281|NCT04033627|PROCEDURE|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
214769282|NCT01222182|DRUG|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
214769283|NCT01385501|OTHER|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
214769284|NCT05005676|DIAGNOSTIC_TEST|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
214769285|NCT05436301|OTHER|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
214769286|NCT01461369|DRUG|Diclofenac|35 mg bid Capsules
214769287|NCT01461369|DRUG|Diclofenac|35 mg tid Capsules
214769288|NCT01461369|DRUG|Placebo|Capsules
214769289|NCT01247974|DEVICE|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
214769290|NCT00364273|DRUG|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
214769291|NCT00364273|DRUG|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
214769292|NCT00364273|DRUG|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
214769293|NCT04144231|BEHAVIORAL|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
214769294|NCT04144231|BEHAVIORAL|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
214769295|NCT01594580|OTHER|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
214769296|NCT01594580|OTHER|Non-impregnated scrubs|
214769297|NCT02228369|DRUG|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
214769298|NCT02228369|DRUG|AZD9291|AZD9291 160mg once daily
214769299|NCT00695604|DRUG|Placebo|Placebo via MDI.
214769300|NCT00695604|DRUG|Fluticasone|Fluticasone MDI.
214769301|NCT06700564|OTHER|PET scan of FDG|The enrolled patients will undergo PET examination, and the radiation dose generated during the examination will not cause physiological damage to the patients
214769302|NCT04604496|DRUG|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
214794474|NCT00708422|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
214794475|NCT00181922|DRUG|ziprasidone (Geodon)|
214769303|NCT05587517|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
214769304|NCT05587517|OTHER|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
214769305|NCT00734617|DRUG|Nicotine Patch|"Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
214769306|NCT02125617|DRUG|Abiraterone|1000 mg/day
214769307|NCT02125617|DRUG|Prednisolone|10 mg/day
214769308|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
214769309|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
214769310|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
214769311|NCT01304563|BIOLOGICAL|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
214769312|NCT03906786|BEHAVIORAL|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
214769313|NCT06540755|GENETIC|genetic polymorphism analysis|Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
214769314|NCT00212810|DRUG|Topiramate|
214769315|NCT00976313|PROCEDURE|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
214769316|NCT00976313|OTHER|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
214769317|NCT01614808|OTHER|laboratory biomarker analysis|Correlative studies
214769318|NCT02029313|DRUG|Montelukast|
214769319|NCT02029313|DRUG|Montelukast sodium|
214769320|NCT03390452|BEHAVIORAL|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
214769321|NCT05202600|PROCEDURE|Appendectomy|Surgical removal of the vermiform appendix.
214769322|NCT02367729|DEVICE|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
214769323|NCT02367729|DEVICE|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
214769324|NCT02454322|DRUG|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
214769325|NCT00438932|DRUG|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
214769326|NCT00438932|DIETARY_SUPPLEMENT|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
214769327|NCT00438932|DIETARY_SUPPLEMENT|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
214769328|NCT00438932|DRUG|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
214769329|NCT03686137|OTHER|Data collection|Colelction of pre-operative, surgical and post-surgical data
214769330|NCT05430282|OTHER|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
214769331|NCT05430282|OTHER|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
214769332|NCT01284231|DRUG|MEDI-565|MEDI-565 will be administered by IV infusion
214769333|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
214769334|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
214769335|NCT01284231|DRUG|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
214769336|NCT05582200|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
214769337|NCT05741775|OTHER|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
214769338|NCT05741775|OTHER|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
214769339|NCT02036827|DRUG|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
214769340|NCT01365676|DRUG|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
214769341|NCT01365676|DRUG|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
214769342|NCT04783844|DIAGNOSTIC_TEST|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
214769343|NCT06538103|PROCEDURE|Eye soft surgery|Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
214769344|NCT06538103|OTHER|Physical Rehabilitation|Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
214769345|NCT00145652|DRUG|Neo-Recormon and Venofer|
214769346|NCT03358342|OTHER|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
214769347|NCT05512286|RADIATION|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
214769348|NCT05512286|RADIATION|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
214769349|NCT06539637|COMBINATION_PRODUCT|OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}|10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery
214769350|NCT06539637|OTHER|Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop|Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
214769351|NCT04391400|DIAGNOSTIC_TEST|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
214769352|NCT04391400|DIAGNOSTIC_TEST|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~* At least 2mL to 5mL of peripheral blood.~* Collected in EDTA tubes.~* Shipped to ambient LabPMM, LLC within 2 days.~* Specimen Collections:~* Collected at the same time as the NP specimen sent for COVID-19 testing.~* Collected two to three weeks post the original patient's COVID-19 testing."
214769353|NCT03975088|PROCEDURE|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
214769354|NCT01979588|OTHER|What's Going Around tool|Provider has access to the What's Going Around tool
214769355|NCT01979588|OTHER|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
214769356|NCT02952937|DRUG|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
214769357|NCT02952937|DRUG|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
214769358|NCT01372254|BEHAVIORAL|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
214769359|NCT01372254|BEHAVIORAL|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
214769360|NCT01372254|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
214769361|NCT05769322|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214769362|NCT05098444|BEHAVIORAL|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
214769363|NCT05098444|OTHER|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
214769364|NCT05415618|OTHER|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
214769365|NCT05415618|DEVICE|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
214769366|NCT05415618|OTHER|Nerve gliding|Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
214769367|NCT04222218|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
214769368|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
214769369|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
214769370|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
214769371|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
214769372|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
214769373|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
214769374|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
214769375|NCT03367949|OTHER|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
214769376|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
214769377|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
214769378|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
214769379|NCT02432521|OTHER|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
214769380|NCT01062100|DEVICE|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
214769381|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
214769382|NCT00960232|DRUG|placebo|placebo
214769383|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
214769384|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
214769385|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
214769386|NCT02742818|DEVICE|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
214769387|NCT02742818|DEVICE|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
214769388|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
214769389|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
214769390|NCT01260194|DRUG|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
214769391|NCT02249065|DRUG|Brimonidine|
214769392|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
214769393|NCT00969267|OTHER|ear-acupuncture A|with needle stimulation
214769394|NCT00969267|OTHER|stimulation B|with bread stimulation on ear acupuncture point
214769395|NCT00969267|OTHER|stimulation C|without needle stimulation
214769396|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
214769397|NCT03840473|BEHAVIORAL|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
214769398|NCT03840473|BEHAVIORAL|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
214769399|NCT03840473|BEHAVIORAL|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
214769400|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
214769401|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
214769402|NCT04074122|DIAGNOSTIC_TEST|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
214769403|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
214769404|NCT02878239|OTHER|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
214769405|NCT02878239|OTHER|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
214769406|NCT05611710|DRUG|Placebo|"Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
214769407|NCT05611710|DRUG|Anakinra|"Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
214769408|NCT05322421|OTHER|Topical Olive Oil|Olive oil will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
214769409|NCT05322421|OTHER|Sodium bicarbonate 5% solution|Sodium bicarbonate 5% solution will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
214769410|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
214769411|NCT02502084|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
214769412|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
214769413|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
214769414|NCT00171899|DRUG|imatinib mesylate|
214769415|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
214769416|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
214769417|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
214769418|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
214769419|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
214769420|NCT04917029|DRUG|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
214769421|NCT04917029|DRUG|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
214769422|NCT04917029|DRUG|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
214769423|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
214769424|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
214769425|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
214769426|NCT06565871|DRUG|Placebo Injection|SC
214769427|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
214769428|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
214769429|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
214769430|NCT00259311|DRUG|LY2422347|
214769431|NCT00259311|DRUG|placebo|
214769432|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
214769433|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
214769434|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
214769435|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
214769436|NCT06566053|OTHER|Observation|Observation
214769437|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
214769438|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
214769439|NCT02822612|DEVICE|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
214769440|NCT05761522|OTHER|transthoracic echocardiography|"* Concerning the main judgment criterion and the secondary judgment criteria:~  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~ * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~ * Tricuspid Annular Systolic Excursion (TAPSE) (mm)~ * S wave at the tricuspid ring (cm/s)~* Other parameters collected systematically:~  * Surface of the left ventricle (end-systolic and end-diastolic),~ * Global strain of the left ventricle~ * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~ * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~ * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
214769441|NCT03284515|BIOLOGICAL|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
214769442|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
214769443|NCT06538571|DIAGNOSTIC_TEST|Near infrared spectroscopy|Noninvasive monitor for venous saturation
214769444|NCT00163527|DRUG|Roflumilast|
214769445|NCT04473339|PROCEDURE|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
214769446|NCT04473339|PROCEDURE|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
214769447|NCT02784002|DRUG|Ridinilazole|
214769448|NCT02784002|DRUG|Fidaxomicin|
214769449|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy|"Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;"
214769450|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based.
214769451|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy|"Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller."
214769452|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based
214769453|NCT04007406|DRUG|dexfadrostat phosphate|DP13 systemic administration
214769454|NCT03446716|BEHAVIORAL|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
214769455|NCT04272255|DRUG|scopolamine HBr|Nasal Gel
214769456|NCT04272255|DRUG|Transdermal Scopolamine|Patch
214769457|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
214769458|NCT05674721|DRUG|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
214769459|NCT05674721|DRUG|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
214769460|NCT02285452|DRUG|Zingiberis Rhizoma plv.|
214769461|NCT02285452|DRUG|Sinapis nigrea semen|
214769462|NCT02285452|DRUG|Placebo|
214769463|NCT02256059|PROCEDURE|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
214769464|NCT01831518|DEVICE|CRT Implant|
214769465|NCT01831518|DEVICE|Body Surface ECG Mapping|
214769466|NCT02067585|DIETARY_SUPPLEMENT|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
214769467|NCT00197470|PROCEDURE|IL-1, TNF-alpha, Il-10|
214769468|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
214769469|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
214769470|NCT01506570|BIOLOGICAL|Placebo|One SC injection at Day 0 and Day 180 of placebo
214769471|NCT03814213|OTHER|CGA|Multi-level Health assessment
214769472|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
214769473|NCT05538039|OTHER|Distract with play dough|Distract with play dough
214769474|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
214769475|NCT05538039|OTHER|Control group|Routine nursing care
214769476|NCT02689726|DRUG|GTL001+|
214769477|NCT02689726|DRUG|Aldara|5% imiquimod cream
214769478|NCT00255476|DRUG|gefitinib|
214769479|NCT00255476|DRUG|cisplatin|
214769480|NCT00255476|DRUG|5-flourouracil|
214769481|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
214769482|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
214769483|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
214769484|NCT02962869|DRUG|BAY987517|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
214769485|NCT02962869|OTHER|Untreated skin|One site is patched without treatment as control
214769486|NCT01883531|DRUG|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
214769487|NCT01883531|DRUG|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
214769488|NCT04474288|DIAGNOSTIC_TEST|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
214769489|NCT03433807|DRUG|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
214769490|NCT01885507|OTHER|Pass recommendations on ventilation factors and extubation|"* the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
214769491|NCT03544606|DRUG|isosorbide mononitrate|40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
214769492|NCT03544606|DRUG|Placebos|In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
214769493|NCT00533585|DRUG|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
214769494|NCT00533585|DRUG|Paclitaxel|200 mg/m\^2 By Vein Over 3 Hours on Day 1.
214769495|NCT00533585|DRUG|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
214769496|NCT00533585|DRUG|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
214769497|NCT05409807|DEVICE|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
214769498|NCT05409807|DEVICE|Ultrasound guided|Ultrasound guided interscalene nerve block
214769499|NCT00446771|DRUG|Mannitol|
214769500|NCT01093716|DEVICE|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
214769501|NCT03501017|OTHER|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
214769502|NCT03501017|OTHER|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
214769503|NCT02269501|OTHER|Exercise treatment|
214769504|NCT01879709|BEHAVIORAL|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
214769505|NCT01879709|BEHAVIORAL|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
214769506|NCT01879709|OTHER|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
214769507|NCT00091507|DRUG|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
214769508|NCT00091507|DRUG|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
214769509|NCT04918927|DRUG|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
214769510|NCT04918927|DRUG|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
214769511|NCT04918927|OTHER|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
214769512|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
214769513|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
214769514|NCT06568965|OTHER|De-stress & happy gut powder-U001|Take one sachet daily, 30 minutes before breakfast, for 60 days
214769515|NCT06568965|OTHER|De-Stress & Happy Gut powder-I001|Take one sachet daily, 30 minutes before breakfast, for 60 days
214769516|NCT06568965|OTHER|Placebo Powder 001|Take one sachet daily, 30 minutes before breakfast, for 60 days
214769517|NCT03933982|DRUG|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
214769518|NCT05672160|DIAGNOSTIC_TEST|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
214769519|NCT01057160|DRUG|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
214769520|NCT01579292|BEHAVIORAL|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
214769521|NCT01579292|BEHAVIORAL|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
214769522|NCT03622086|OTHER|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
214769523|NCT00935415|DRUG|Montelukast|Montelukast 5 mg
214769524|NCT00935415|DRUG|Placebo|capsules of matching placebo
214769525|NCT01872858|DRUG|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
214769526|NCT01872858|DRUG|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
214769527|NCT06538909|DEVICE|VR|Virtual reality that simulates obstacles on the road during walking
214769528|NCT00893230|DIETARY_SUPPLEMENT|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
214769529|NCT00893230|DIETARY_SUPPLEMENT|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
214769530|NCT05254093|OTHER|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
214769531|NCT05254093|OTHER|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
214769532|NCT06123494|DRUG|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
214769533|NCT06123494|DRUG|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
214769534|NCT03392415|PROCEDURE|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
214769535|NCT01073059|DRUG|Valproic acid and Ertapenem|
214769536|NCT00200590|DRUG|acetaminophen and nalbuphine|
214769537|NCT00200590|DRUG|acetaminophen and morphine|
214769538|NCT00200590|DRUG|acetaminophen and reduced dosage of prostaglandin|
214769539|NCT04200781|DRUG|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
214769540|NCT04200781|DRUG|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
214769541|NCT05013749|PROCEDURE|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
214769542|NCT05013749|PROCEDURE|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
214769543|NCT00003119|BIOLOGICAL|filgrastim|
214769544|NCT00003119|BIOLOGICAL|sargramostim|
214769545|NCT00003119|DRUG|carboplatin|
214769546|NCT00003119|DRUG|cyclophosphamide|
214769547|NCT00003119|DRUG|doxorubicin hydrochloride|
214769548|NCT00003119|DRUG|etoposide|
214769549|NCT00003119|PROCEDURE|adjuvant therapy|
214769550|NCT00003119|PROCEDURE|conventional surgery|
214769551|NCT00003119|RADIATION|radiation therapy|
214769552|NCT00246441|DRUG|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
214769553|NCT00246441|DRUG|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
214769554|NCT02806635|BEHAVIORAL|OurRelationship|
214769555|NCT02806635|BEHAVIORAL|PREP Online|
214769556|NCT02017535|DRUG|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
214769557|NCT02017535|BEHAVIORAL|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
214769558|NCT06435598|OTHER|video-based health education|The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
214769559|NCT05785026|OTHER|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
214769560|NCT05785026|OTHER|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
214769561|NCT05613920|BEHAVIORAL|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
214769562|NCT02421770|OTHER|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
214769563|NCT02421770|OTHER|placebo|
214769564|NCT05353426|PROCEDURE|Paragastric autonomic neural blockade|Paragastric autonomic neural blockade with Bupivacaine
214769565|NCT02935946|OTHER|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
214769566|NCT01393626|DRUG|Placebo|oral tablets twice daily
214769567|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
214769568|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
214769569|NCT01578343|DRUG|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation"
214769570|NCT01902524|DRUG|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
214769571|NCT01179139|OTHER|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
214769572|NCT03820999|OTHER|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
214769573|NCT04959006|DIETARY_SUPPLEMENT|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
214769574|NCT04959006|DIETARY_SUPPLEMENT|Placebo|Placebo
214769575|NCT01898117|DRUG|Carbo/cyclo|
214769576|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
214769577|NCT01898117|DRUG|Paclitaxel|
214769578|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
214769579|NCT05214599|DRUG|Budesonide Gel|Twice daily regimen
214769580|NCT02602561|DIETARY_SUPPLEMENT|HMB|
214769581|NCT02602561|DIETARY_SUPPLEMENT|Placebo|
214769582|NCT04717232|OTHER|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
214769583|NCT04717232|OTHER|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
214769584|NCT02902107|DEVICE|CivaSheet|
214769585|NCT02902107|RADIATION|Brachytherapy|
214769586|NCT02902107|PROCEDURE|surgical resection|
214769587|NCT05760482|DIAGNOSTIC_TEST|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
214769588|NCT05760482|BEHAVIORAL|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
214769589|NCT06003673|COMBINATION_PRODUCT|neoadjuvant therapy|The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.
214769590|NCT00410592|DRUG|Esomeprazole 40mg|
214769591|NCT00410592|DRUG|Pantoprazole 40mg|
214769592|NCT00410592|DRUG|Lansoprazole 30mg|
214769593|NCT00478634|DRUG|RAD001, Cetuximab, Irinotecan|
214769594|NCT05818163|DEVICE|electroencephalography spectral analysis|"Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device.~The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis."
214769595|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
214769596|NCT05166473|OTHER|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
214769597|NCT05166473|OTHER|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
214769598|NCT05402865|DRUG|Denosumab|Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
214769599|NCT06692166|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
214769600|NCT06692166|DRUG|Chemotherapy|1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
214769601|NCT03506425|DRUG|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
214769602|NCT01804530|DRUG|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
214769603|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
214769604|NCT00209495|DRUG|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
214769605|NCT01141049|DRUG|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
214769606|NCT01141049|OTHER|Placebo|Placebo, TID
214769607|NCT02284295|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
214769608|NCT02284295|OTHER|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
214769609|NCT04526249|DEVICE|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
214769610|NCT01925378|DRUG|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
214769611|NCT01370434|DRUG|PAD combination|"* Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11"
214769612|NCT00892424|DRUG|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
214769613|NCT02233881|DRUG|Atrovent® - inhalets|
214769614|NCT00405210|DRUG|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
214769615|NCT02484235|OTHER|HIIT|Group training with HIIT 3 times per week during 10 sessions
214769616|NCT02484235|OTHER|Strength|Group training with strength exercises 3 times per week during 10 sessions
214769617|NCT03952663|PROCEDURE|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
214769618|NCT03952663|PROCEDURE|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
214769619|NCT02677675|BEHAVIORAL|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
214769620|NCT02643394|DRUG|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
214769621|NCT02643394|DRUG|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
214769622|NCT03468374|DEVICE|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
214769623|NCT03468374|DEVICE|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
214769624|NCT04427956|PROCEDURE|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
214769625|NCT04427956|DRUG|Isotonic riboflavin|CXL protocol with isotonic riboflavin
214769626|NCT04427956|DRUG|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
214769627|NCT04427956|PROCEDURE|Iontophoresis|CXL protocol with iontophoresis and ricrolin
214769628|NCT04471558|OTHER|Music|A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
214769629|NCT04088734|DRUG|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
214769630|NCT04539158|DEVICE|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
214769631|NCT01345890|PROCEDURE|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
214769632|NCT01222559|DRUG|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
214769633|NCT01222559|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
214769634|NCT04193033|OTHER|FLOW intervention|The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
214769635|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
214769636|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
214769637|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
214769638|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
214769639|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
214769640|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
214769641|NCT04431622|DEVICE|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
214769642|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
214769643|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
214769644|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
214769645|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
214769646|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
214769647|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
214769648|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
214769649|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
214769650|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
214769651|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
214769652|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
214769653|NCT01764594|OTHER|Placebo|Placebo comparator
214769654|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
214769655|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
214769656|NCT02765958|DEVICE|portable ECG devise|
214769657|NCT00245258|DRUG|Sildenafil Citrate|
214769658|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
214769659|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
214769660|NCT01743664|BEHAVIORAL|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
214769661|NCT01743664|BEHAVIORAL|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
214769662|NCT02125734|DRUG|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
214769663|NCT02125734|DRUG|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
214769664|NCT01591499|DEVICE|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
214769665|NCT01591499|DEVICE|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
214769666|NCT03230695|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
214769667|NCT03230695|DEVICE|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
214769668|NCT03230695|DEVICE|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
214769669|NCT02903095|DRUG|TD-1439|
214769670|NCT02903095|DRUG|Placebo|
214769671|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
214769672|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
214769673|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
214769674|NCT06700642|OTHER|Educational intervention|"In this study, 3 intervention tools were developed by the researchers. The first of these, 'Rational Drug Use Trainer Guide', was used for trainer training and standardisation of the education given to patients. The sample rational drug use presentations prepared by the Ministry of Health, Turkiye Medicines and Medical Devices Agency, Department of Rational Drug Use were combined in terms of content, enriched with information obtained from the literature and developed for the use of family physicians working in primary health care institutions in their clinical practices.~'Rational Drug Use Individual Education Presentation' was prepared by the researchers in line with the 'Rational Drug Use Trainer Guide'. It has been prepared in a format suitable for individual education presentation with the most concise and understandable content suitable for use during primary healthcare service delivery.~'Rational Drug Use Patient Brochure' was prepared by the researchers in a similar content."
214769675|NCT01135316|DRUG|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
214769676|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
214769677|NCT00973531|DEVICE|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
214769678|NCT00973531|DEVICE|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
214769679|NCT02801201|DRUG|Midazolam|
214769680|NCT02801201|DRUG|Bupivacaine|
214769681|NCT00003892|DRUG|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
214769682|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
214769683|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
214769684|NCT06426186|PROCEDURE|Right-stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia
214769685|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
214769686|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
214769687|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
214769688|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
214769689|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
214769690|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
214769691|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
214769692|NCT04203758|OTHER|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
214769693|NCT04203758|OTHER|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
214769694|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
214769695|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
214769696|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
214769697|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
214769698|NCT04361552|OTHER|Best Practice|Receive standard of care
214769699|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
214769700|NCT01347983|DRUG|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
214769701|NCT04653701|COMBINATION_PRODUCT|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
214769702|NCT04493099|DRUG|Alvocidib Hydrochloride|Given IV
214769703|NCT04493099|DRUG|Decitabine|Given IV
214769704|NCT04493099|DRUG|Venetoclax|Given PO
214769705|NCT00143546|DRUG|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
214769706|NCT06652048|DRUG|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
214769707|NCT06652048|DRUG|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
214769708|NCT06652048|DRUG|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
214769709|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
214769710|NCT02704130|DEVICE|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
214769711|NCT02704130|PROCEDURE|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
214769712|NCT06701708|OTHER|Participants are not assigned to interventions based on a protocol.|Participants are not assigned to interventions based on a protocol.
214769713|NCT06521138|BEHAVIORAL|Motivational interviewing group|The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
214769714|NCT06521138|OTHER|Control group|Participants in the control group will receive routine care at the center.
214769715|NCT04807634|DRUG|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
214769716|NCT01770639|PROCEDURE|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
214769717|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
214769718|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
214769719|NCT00509340|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
214769720|NCT04120714|DEVICE|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
214769721|NCT04120714|DEVICE|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
214769722|NCT04120714|OTHER|Questionnaires|"* visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale"
214769723|NCT05529641|OTHER|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
214769724|NCT05529641|OTHER|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
214769725|NCT06280794|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
214769726|NCT06280794|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
214769727|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
214769728|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
214769729|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
214769730|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
214769731|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
214769732|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
214769733|NCT05744219|DRUG|Placebo|Placebo
214769734|NCT04318041|DRUG|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
214769735|NCT04318041|DRUG|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
214769736|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
214769737|NCT05495425|DRUG|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
214769738|NCT05495425|DRUG|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
214769739|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
214769740|NCT05217901|DRUG|14C-labeled ASP0367|Oral
214769741|NCT06076538|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging|PET/MR scan utilizing FDG Radiopharmaceutical
214769742|NCT05558189|DEVICE|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
214769743|NCT03940742|DRUG|Tirzepatide|Administered SC
214769744|NCT00903942|RADIATION|radiation therapy|1\) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
214769745|NCT00903942|DRUG|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
214769746|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
214769747|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
214769748|NCT01103375|DRUG|isotretinoin|Given PO
214769749|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
214769750|NCT01103375|GENETIC|protein expression analysis|Correlative study
214769751|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
214769752|NCT06623526|DRUG|YHR2402|Test Drug: YHR2402
214769753|NCT06623526|DRUG|YHR2402+YHR2403|Test Drug: YHR2402+YHR2403
214769754|NCT01527786|DRUG|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
214769755|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
214769756|NCT02032823|DRUG|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
214769757|NCT02032823|DRUG|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
214769758|NCT02183701|DRUG|Telmisartan|
214769759|NCT02183701|DRUG|Losartan + Hydrochlorothiazide|
214769760|NCT02183701|DRUG|Placebo|
214769761|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
214769762|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
214769763|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
214769764|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
214769765|NCT03889197|DRUG|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
214769766|NCT05246111|DRUG|[14C]Berzosertib|Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
214769767|NCT05246111|DRUG|Berzosertib|Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
214769768|NCT05246111|DRUG|Topotecan|Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
214769769|NCT05565872|BEHAVIORAL|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
214769770|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
214769771|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
214769772|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
214769773|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
214769774|NCT02034500|BIOLOGICAL|S. sonnei 1790GAHB|
214769775|NCT02034500|BIOLOGICAL|Placebo|
214769776|NCT05844644|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
214769777|NCT02208388|DEVICE|computed tomography perfusion guided treatment|
214769778|NCT02208388|DEVICE|Fractional flow reserve guided treatment|
214769779|NCT00486577|PROCEDURE|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
214769780|NCT00486577|PROCEDURE|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
214769781|NCT01445873|DRUG|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
214769782|NCT04479488|OTHER|Hospital admission|Usual care.
214769783|NCT04479488|OTHER|Non-hospitalization procedures|Usual care.
214769784|NCT03989037|DRUG|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
214769785|NCT03989037|DRUG|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
214769786|NCT03989037|DRUG|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
214769787|NCT03989037|DRUG|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
214769788|NCT03078192|DRUG|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
214769789|NCT03078192|DEVICE|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
214769790|NCT00000754|DRUG|Interferon alfa-2a|
214769791|NCT00000754|DRUG|Zidovudine|
214769792|NCT00000754|DRUG|Zalcitabine|
214769793|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
214769794|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
214769795|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
214769796|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
214769797|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
214769798|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.
214769799|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
214769800|NCT00002037|DRUG|Trifluridine|
214769801|NCT00006001|DRUG|semaxanib|
214769802|NCT06123897|OTHER|Regular follow-up assessments without intervention.|Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.
214769803|NCT06123897|OTHER|Cross-sectional assessment|Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
214769804|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
214769805|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
214769806|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
214769807|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
214769808|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
214769809|NCT03549143|OTHER|IBS|No intervention, description of routine practice only
214769810|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
214769811|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
214769812|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
214769813|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
214769814|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
214769815|NCT04062643|DIAGNOSTIC_TEST|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
214769816|NCT00000705|DRUG|Zidovudine|
214769817|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
214769818|NCT02508649|DRUG|selepressin|
214769819|NCT02508649|DRUG|placebo|
214769820|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
214769821|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
214769822|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
214769823|NCT02392975|PROCEDURE|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
214769824|NCT02392975|PROCEDURE|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
214769825|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
214769826|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
214769827|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
214769828|NCT04461626|DEVICE|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
214769829|NCT02360124|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
214769830|NCT02360124|OTHER|Water as placebo|topical application of water as a placebo in the control arm
214769831|NCT02360124|OTHER|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
214769832|NCT00417859|DEVICE|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
214769833|NCT03739684|DRUG|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
214769834|NCT03739684|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
214769835|NCT01888159|PROCEDURE|Bilateral Salpingectomy|
214769836|NCT01888159|PROCEDURE|Tubal sterilization with bipolar energy|
214769837|NCT06505213|OTHER|no intervention|no intervention
214769838|NCT01115699|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
214769839|NCT04556500|OTHER|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
214769840|NCT06375954|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
214769841|NCT06375954|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
214769842|NCT06375954|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
214769843|NCT05431348|DEVICE|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
214769844|NCT05431348|DIAGNOSTIC_TEST|Serum Cortisol|Level of cortisol in serum will be determined
214769845|NCT05431348|OTHER|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
214769846|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
214769847|NCT03755856|OTHER|Questionnaire|Health-related quality of life
214769848|NCT04331392|BEHAVIORAL|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
214769849|NCT04331392|BEHAVIORAL|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
214769850|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
214769851|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
214769852|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
214769853|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
214769854|NCT05924672|DRUG|Radium-223|Given IV
214769855|NCT05924672|PROCEDURE|PSMA Positron Emission Tomography (PET) Scan|Undergo PSMA PET/CT
214769856|NCT05924672|DRUG|Technetium Tc 99M Medronate|Undergo MDP
214769857|NCT02160054|DRUG|Graceptor®|oral
214769858|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
214769859|NCT04308382|BEHAVIORAL|Health Risk Assessment|"Heath Risk Assessment consists of:~* Survey to include questions about physical activity, stress, hope, household hunger and demographics.~* Lipid panel and HbA1c~* Height and Weight, blood pressure and resting pulse"
214769860|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
214769861|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
214769862|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
214769863|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
214769868|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
214769869|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
214769870|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
214769871|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
214769872|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
214769873|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
214769874|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
214769875|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
214769876|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
214769877|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
214769878|NCT03594175|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
214769879|NCT03594175|DRUG|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
214769880|NCT03594175|DRUG|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
214769881|NCT06489847|DIAGNOSTIC_TEST|SPPB++ Application|Participants will have video data collected as they perform the SPPB test one time.
214769882|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
214769883|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
214769884|NCT05416125|DRUG|Lisdexamfetamine Dimesylate|Vyvanse treatment
214769885|NCT05416125|BEHAVIORAL|Lifestyle therapy|Lifestyle treatment
214769886|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
214769887|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
214769888|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
214769889|NCT04719728|DIAGNOSTIC_TEST|Aided pure tone audiometry|aided response, speech, evoked potential
214769890|NCT06406894|OTHER|Conventional physical therapy|"lower limb muscle stretching ( pelvic bridging, Knee to chest,cat and camel stretch) (30 seconds hold and 3 sets of 5 repetitions with 1 min rest interval in between each set, per session on daily basis for only one week for immediate results and for long term effect on alternate 3 days in remaining 2nd ,3rd week).~Treatment protocol will be given on daily basis to check immediate effect and for long term effect treatment will be given in alternating 3 days for remaining 2 weeks. Total 12 session were given (3 weeks)."
214769891|NCT06406894|OTHER|Superficial back line relaxation (SMIT & CCFE)|Experimental group was given superficial back line relaxation includes SMIT \& CCFE along with conventional therapy includes lower limb muscle stretching. SMIT For short term effect 10-12 repetitions per session, on daily basis for 1st week. For long term effect 10-12 repetitions per session, for 3 alternate days in remaining 2nd\&3rd week. CCFE For short term effect 3 sets of 10 reps , 10 sec hold , 1 min rest after each set, on daily basis for 1st week. For long term effect 3 sets of 10 reps, 10 sec hold , 1 min rest after each set, for 3 alternate days , remaining 2nd \& 3rd week. Conventional therapy lower limb muscle stretching ( For short term effect 30 seconds hold , 3 sets of 5 repetitions , 1 min rest after each set, per session on daily basis for 1st week , for long term effect on alternate 3 days in remaining 2nd ,3rd week). Total 12 sessions were given (3 weeks).
214769892|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
214769893|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
214769894|NCT04983095|RADIATION|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
214769895|NCT04983095|COMBINATION_PRODUCT|androgen deprivation therapy|Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
214769896|NCT04983095|RADIATION|Radiotherapy|RT to the prostate for de novo patients
214769897|NCT06147856|DRUG|mRNA-3210|IV infusion
214769898|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
214769899|NCT02159651|DRUG|tacrolimus|oral
214769900|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
214769901|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
214769902|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
214769903|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
214769904|NCT04233788|DEVICE|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
214769905|NCT06173713|DEVICE|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
214769906|NCT04824560|BEHAVIORAL|Blood pressure education|One page teaching protocol performed by pharmacy students; phone follow-up
214769907|NCT04580472|DRUG|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
214769908|NCT04580472|OTHER|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
214769909|NCT05631652|DEVICE|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
214769910|NCT06348823|DIAGNOSTIC_TEST|volume survey|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
214769911|NCT05362955|DRUG|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
214769912|NCT04873830|BIOLOGICAL|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
214769913|NCT04873830|PROCEDURE|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
214769914|NCT06146517|OTHER|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
214769915|NCT06146517|OTHER|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
214769916|NCT06146517|OTHER|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
214769917|NCT06470737|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
214769918|NCT06470737|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
214769919|NCT06470737|OTHER|Cowhage|This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
214769920|NCT06470737|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
214769921|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
214769922|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
214769923|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
214769924|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
214769925|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
214769926|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
214769927|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
214769928|NCT02329496|DEVICE|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
214769929|NCT05187507|OTHER|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
214769930|NCT05187507|OTHER|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
214769931|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
214769932|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
214769933|NCT04278872|DRUG|SJX-653|administered orally once daily
214769934|NCT04278872|DRUG|Placebo|administered orally once daily
214769935|NCT05437718|OTHER|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
214769936|NCT04900415|DRUG|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
214769937|NCT04900415|DEVICE|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
214769938|NCT04631185|DRUG|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
214769939|NCT04631185|DRUG|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
214769940|NCT01205542|BEHAVIORAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
214769941|NCT01205542|BEHAVIORAL|Reference|Health check and advice to continue ordinary physical activity
214769942|NCT00351156|PROCEDURE|Blood sample|
214769943|NCT01991184|DRUG|GDC-0853|Multiple escalating doses
214769944|NCT06232538|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
214769945|NCT02781688|BEHAVIORAL|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
214769946|NCT05800327|DRUG|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
214769947|NCT06271941|PROCEDURE|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
214769948|NCT06271941|PROCEDURE|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
214769949|NCT03920527|DRUG|Itraconazole 400 mg|Duration of itraconazole
214769950|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
214769951|NCT05572424|OTHER|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
214769952|NCT00996008|DRUG|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
214769953|NCT00996008|DRUG|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
214769954|NCT02428959|DRUG|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
214769955|NCT04275232|BIOLOGICAL|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
214769956|NCT01929837|DEVICE|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
214769957|NCT01929837|DEVICE|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
214769958|NCT01929837|DEVICE|sham E-field navigated rTMS|
214769959|NCT01929837|DEVICE|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
214769960|NCT00547209|DRUG|air|60% air combined with 40% oxygen for ventilation
214769961|NCT00547209|DRUG|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
214769962|NCT03291847|DEVICE|fetal monitoring|Maternal fetal monitoring
214769963|NCT03291847|DRUG|Buprenorphine Naloxone|Treatment for opioid use disorder
214769964|NCT01987843|DRUG|MT-1303-Low|
214769965|NCT01987843|DRUG|MT-1303-Middle|
214769966|NCT01987843|DRUG|MT-1303-High|
214769967|NCT01987843|DRUG|Placebo|
214769968|NCT03576430|DEVICE|active stress handling|biofeed back stress handling
214769969|NCT05292430|OTHER|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
214769970|NCT06159439|DIAGNOSTIC_TEST|Contrast enhanced ultrasound scan|Contrast enhanced ultrasound using Sonovue microbubble contrast
214769971|NCT06159439|DIAGNOSTIC_TEST|MRI scan|Arterial-spin labelling magnetic resonance imaging
214769972|NCT06383143|OTHER|no intervention|no intervention
214769973|NCT04192786|OTHER|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
214769974|NCT04192786|OTHER|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
214769975|NCT04192786|OTHER|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
214769976|NCT00367679|DRUG|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
214769977|NCT03715673|DIAGNOSTIC_TEST|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
214769978|NCT02805582|DRUG|10ml ropivacain 0.5%|Ultrasound guided nerve block
214769979|NCT01826968|PROCEDURE|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
214769980|NCT05274399|OTHER|surveys and questionnaires|The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
214646020|NCT05495295|DRUG|PhOx430|The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
214769981|NCT06334978|OTHER|Osteopathic intervention|The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
214769982|NCT01286337|PROCEDURE|bipolar vessel sealing|
214769983|NCT01286337|PROCEDURE|control|
214769984|NCT04921046|DRUG|lignocaine|After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
214769985|NCT04921046|DRUG|Midazolam 1 milligram Prefilled Syringe|after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
214769986|NCT02953262|BEHAVIORAL|My HealtheVet Brochure|Participants will receive a mailed brochure with basic My HealtheVet content.
214769987|NCT02953262|BEHAVIORAL|My HealtheVet Training Guide for Veterans Living with Diabetes|Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
214646021|NCT04106622|PROCEDURE|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
214646022|NCT00000927|DRUG|BufferGel|
214646023|NCT05512871|BEHAVIORAL|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
214646024|NCT03538769|OTHER|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
214646025|NCT04753892|OTHER|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
214646026|NCT01054079|OTHER|laboratory biomarker analysis|Correlative study
214646027|NCT01054079|PROCEDURE|quality-of-life assessment|Ancillary study
214646028|NCT01054079|OTHER|questionnaire administration|Ancillary study
214646029|NCT01054079|DRUG|cinacalcet hydrochloride|Given PO
214769988|NCT02953262|BEHAVIORAL|My HealtheVet Group Training|Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
214769989|NCT02953262|BEHAVIORAL|My HealtheVet Individual Training|Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
214769990|NCT01747239|DRUG|Cabazitaxel|25 mg/m2 IV every three weeks
214769991|NCT02148731|OTHER|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
214769992|NCT02177864|DIETARY_SUPPLEMENT|Fiber|
214769993|NCT02177864|OTHER|Placebo (low fiber bar)|
214769994|NCT00479739|DRUG|Salmeterol/fluticasone propionate or formoterol/budesonide|
214769995|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
214769996|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
214769997|NCT01838863|BIOLOGICAL|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
214769998|NCT01838863|DRUG|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
214769999|NCT03650179|OTHER|Observational study : No intervention|Observational study : No intervention. Only exporting data
214770000|NCT04656171|RADIATION|MRI of the hand and forearm,|MRI of the hand and forearm,
214770001|NCT04979078|DEVICE|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
214770002|NCT04731909|DRUG|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
214770003|NCT04731909|DRUG|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
214770004|NCT04731909|DRUG|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
214770005|NCT04731909|DRUG|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
214770006|NCT05805956|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
214770007|NCT01426828|BIOLOGICAL|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
214770008|NCT02133911|DRUG|Ranolazine|
214770009|NCT02446197|OTHER|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
214770010|NCT03541798|PROCEDURE|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
214770011|NCT03541798|PROCEDURE|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
214770012|NCT03349437|DEVICE|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
214770013|NCT03349437|OTHER|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
214770014|NCT03525327|OTHER|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
214770015|NCT00504127|DRUG|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
214770016|NCT00504127|DRUG|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
214770017|NCT00504127|DRUG|Naproxen 500 mg bid|Naproxen 500 mg bid
214770018|NCT00504127|DRUG|placebo|placebo
214770019|NCT05796531|BEHAVIORAL|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
214770020|NCT05796531|BEHAVIORAL|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
214770021|NCT03154931|OTHER|CBT-SG|To support the group.
214770022|NCT03154931|OTHER|CFT-G|Teach compassionate skills.
214770023|NCT04156282|PROCEDURE|knot burial technique|surgical suturing intervention
214770024|NCT04156282|PROCEDURE|classical closure|surgical suturing intervention
214770025|NCT05137301|DEVICE|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
214770026|NCT04889794|OTHER|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
214770027|NCT02738489|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
214770028|NCT04209244|DIETARY_SUPPLEMENT|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
214770029|NCT04209244|DIETARY_SUPPLEMENT|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
214770030|NCT03569566|OTHER|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
214770031|NCT03006822|OTHER|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
214770032|NCT03006822|OTHER|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
214770033|NCT03006822|OTHER|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
214770034|NCT02764073|DEVICE|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
214770035|NCT02764073|DEVICE|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
214770036|NCT02764073|DEVICE|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
214770037|NCT02214004|DRUG|Trastuzumab|"\- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
214770038|NCT02214004|DRUG|Letrozole|\- Daily letrozole 2.5 mg/day for 24 weeks
214770039|NCT01103401|DRUG|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
214770040|NCT01103401|DRUG|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
214770041|NCT03849079|OTHER|Hyponut|Prick tests with hyponut
214770042|NCT02406742|DRUG|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
214770043|NCT02406742|DRUG|Ibrutinib|
214646030|NCT04138160|OTHER|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
214646031|NCT04138160|OTHER|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
214646032|NCT00358605|DEVICE|The Klearway™ oral appliance|See Detailed Description.
214646033|NCT00775489|DRUG|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
214646034|NCT00775489|DRUG|Saline|control group will receive normal saline inhaler
214646035|NCT02952183|DEVICE|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
214646036|NCT01536301|DRUG|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
214646037|NCT01536301|DRUG|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
214646038|NCT04196114|DEVICE|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
214646039|NCT00611247|DRUG|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
214646040|NCT03683602|OTHER|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
214646041|NCT03683602|OTHER|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
214646042|NCT00565617|DEVICE|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
214646043|NCT00242476|DRUG|MK0822A|
214646044|NCT02342132|DEVICE|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
214646045|NCT02342132|DEVICE|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
214646046|NCT02342132|DEVICE|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
214646047|NCT03357393|DRUG|Midazolam|Midazolam is givenas sedation to the Control arm.
214646048|NCT03357393|DRUG|Propofol-Lipuro|Propofol is given as sedation to both intervention arms.
214646049|NCT03357393|DRUG|morphine-scopolamine|Given as premedication for the Control arm and one of the interventions arms.
214646050|NCT03357393|DRUG|Glycopyrrolate|Given as premedication for one of the intervention arms..
214646051|NCT01446419|DEVICE|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
214646052|NCT01446419|DEVICE|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
214646053|NCT00464178|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
214646054|NCT02308683|DIETARY_SUPPLEMENT|Moringa oleifera|12 weeks supplementation
214646055|NCT03311048|OTHER|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
214646056|NCT03311048|OTHER|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
214646057|NCT00124111|DRUG|pegfilgrastim|
214646058|NCT00124111|DRUG|cyclophosphamide|
214646059|NCT00124111|DRUG|methotrexate|
214646060|NCT00124111|DRUG|5-fluorouracil|
214646061|NCT02052557|DRUG|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
214770044|NCT02406742|DRUG|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
214770045|NCT03797573|DEVICE|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
214770046|NCT03797573|DEVICE|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
214770047|NCT02726672|DEVICE|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
214770048|NCT04215653|DRUG|Anaprazole Sodium|administered orally once every 30-60 minutes before breakfast for 4 weeks
214770049|NCT04215653|DRUG|Rabeprazole|administered orally once every 30-60 minutes before breakfast for 4 weeks
214770050|NCT04215653|DRUG|Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
214770051|NCT04215653|DRUG|Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
214770052|NCT06371547|OTHER|Stretching Exercise|Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.
214770053|NCT04760574|DIAGNOSTIC_TEST|Testosterone|Serum total testosterone and free testosterone level
214770054|NCT01188005|DEVICE|n-CPAP|administration of continuous positive airway pressure through a nasal device
214770055|NCT01188005|DEVICE|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
214770056|NCT01188005|DRUG|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
214770057|NCT03548324|DEVICE|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
214770058|NCT03548324|DEVICE|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
214770059|NCT02039817|DRUG|IDN-6556|
214770060|NCT04458428|OTHER|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
214770061|NCT06492018|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
214770062|NCT06568848|COMBINATION_PRODUCT|EKKO therapy|In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
214770063|NCT06568848|DIAGNOSTIC_TEST|Conservative Treatment|In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
214770064|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
214770065|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
214770066|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
214770067|NCT02235415|DRUG|Motens® (lacidipine)|
214770068|NCT02636166|OTHER|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
214770069|NCT02636166|OTHER|Professional pregnancy test|Alere Professional use pregnancy test
214770070|NCT02636166|OTHER|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
214770071|NCT05365594|DEVICE|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
214770072|NCT05365594|DEVICE|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
214770073|NCT06520267|DRUG|Antibiotic therapy|Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
214770074|NCT04404816|DRUG|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
214770075|NCT05116761|BIOLOGICAL|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
214770076|NCT05116761|OTHER|Saline|Placebo Saline
214770077|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.
214770078|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
214770079|NCT02106793|DRUG|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
214770080|NCT02106793|DRUG|Identical placebo solution|Identical placebo solution
214770081|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
214770082|NCT01563029|DRUG|Fluticasone Furoate|current asthma medicine
214770083|NCT01563029|DRUG|Fluticasone Propionate|Fluticasone propionate
214770084|NCT01563029|DRUG|Placebo|placebo
214770085|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
214770086|NCT00552682|DRUG|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
214770087|NCT00131573|DEVICE|bion|battery powered bion microstimulator
214770088|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
214770089|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
214770090|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
214770091|NCT00256841|DRUG|Chemotherapy|
214770092|NCT00256841|PROCEDURE|Radiation Therapy|
214770093|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
214770094|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
214770095|NCT04375735|DRUG|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
214770096|NCT04650984|DRUG|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
214770097|NCT04650984|DRUG|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
214770098|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
214770099|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
214770100|NCT05150340|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
214770101|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
214770102|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
214770103|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
214770104|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
214770105|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
214770106|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
214770107|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
214770108|NCT01615822|DRUG|Placebo|
214770110|NCT06470841|DRUG|CHG Combined With Venetoclax and Azacytidine|"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."
214770111|NCT03978897|DEVICE|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
214770112|NCT03978897|OTHER|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
214770113|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
214770114|NCT06566248|DRUG|TQA3810 tablets+NUC|TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
214770115|NCT06566248|DRUG|Placebo+NUC|"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."
214770116|NCT04317547|BEHAVIORAL|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
214770117|NCT04317547|BEHAVIORAL|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
214770118|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
214770119|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
214770120|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
214770121|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
214770122|NCT03654365|OTHER|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
214770123|NCT03654365|OTHER|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
214770124|NCT01487018|PROCEDURE|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
214770125|NCT01487018|PROCEDURE|Traditional Surgery|To compare with the experamental group.
214770126|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
214770127|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
214770128|NCT01687777|BIOLOGICAL|OrthADAPT|
214770129|NCT06393907|DEVICE|Hemostatic Forceps|The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.
214770130|NCT06393907|DEVICE|Bipolar Electrocautery Probes|The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.
214770131|NCT00003786|DRUG|irofulven|
214770132|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
214770133|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
214770134|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
214770135|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
214770136|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214770137|NCT00986609|OTHER|flow cytometry|Correlative studies
214770138|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
214770139|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
214770140|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
214770141|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
214770142|NCT00537056|DRUG|Sunitinib|50 mg/day po
214770143|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
214770144|NCT01940276|DRUG|Abiraterone acetate|
214770145|NCT01940276|DRUG|Prednisone|
214770146|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
214770147|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
214770148|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
214770149|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
214770150|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
214770151|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
214770152|NCT00012194|DRUG|7-hydroxystaurosporine|Given IV
214770153|NCT00012194|DRUG|cisplatin|Given IV
214770154|NCT00012194|OTHER|laboratory biomarker analysis|Correlative studies
214770155|NCT05298215|BIOLOGICAL|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
214770156|NCT05298215|OTHER|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
214770157|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
214770158|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
214770159|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
214770160|NCT02628418|OTHER|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
214770161|NCT02628418|DEVICE|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
214770162|NCT02628418|OTHER|Specific hand rehabilitation performed by physiotherapist|"The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
214770163|NCT05494580|DRUG|Pamiparib|Oral
214770164|NCT05494580|DRUG|Surufatinib|Oral
214770165|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
214770166|NCT04196699|BEHAVIORAL|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
214770167|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
214770168|NCT01071083|DRUG|natalizumab|300 mg intravenous every 4 weeks
214770169|NCT01071083|DRUG|interferon beta 1-a|30 ug intramuscular once per week
214770170|NCT01071083|DRUG|methylprednisolone|1000 mg intravenous every 4 weeks
214770171|NCT01071083|OTHER|IV placebo|placebo intravenous every 4 weeks
214770172|NCT01071083|DRUG|glatiramer acetate|20 mg subcutaneous once daily
214770173|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
214770174|NCT06701604|DIETARY_SUPPLEMENT|Single Strain Probiotic + Milk Protein|• Both conditions matched flavor, color, and serving size
214770175|NCT06701604|DIETARY_SUPPLEMENT|Placebo + Milk Protein|• Both conditions matched flavor, color, and serving size
214770176|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
214770177|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
214770178|NCT04885816|DEVICE|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
214770179|NCT04885816|DEVICE|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
214770180|NCT01544816|OTHER|Snack Product|control food product
214770181|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 1
214770182|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 2
214770183|NCT06417723|PROCEDURE|Maxillary nerve block|It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
214770184|NCT03891875|COMBINATION_PRODUCT|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
214770185|NCT03891875|COMBINATION_PRODUCT|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
214770186|NCT02388607|OTHER|measurements|performance measurements
214770187|NCT04466956|DEVICE|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
214770188|NCT00872365|BEHAVIORAL|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
214770189|NCT00872365|DIETARY_SUPPLEMENT|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
214770190|NCT00872365|OTHER|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
214770191|NCT04437407|DEVICE|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
214770192|NCT04437407|DEVICE|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
214770193|NCT04437407|DEVICE|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
214770194|NCT04437407|DEVICE|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
214770195|NCT04437407|DEVICE|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
214770196|NCT04437407|DEVICE|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
214770197|NCT04437407|DEVICE|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
214770198|NCT03449420|DIAGNOSTIC_TEST|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
214770199|NCT00203931|DRUG|Cetuximab|
214770200|NCT00203931|DRUG|Pemetrexed|
214770201|NCT01947257|OTHER|the measure TRVMAX|by transthoracic echocardiography
214770202|NCT01947257|OTHER|the measure of the pulmonary artery|by transesophageal ultrasound
214770203|NCT01947257|OTHER|the direct measure of the pulmonary pressures|by right catheterization
214770204|NCT05357209|DEVICE|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
214770205|NCT00351078|DRUG|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
214770206|NCT00877214|DRUG|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
214770207|NCT00877214|DRUG|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
214770208|NCT02421107|OTHER|Glysure CGM|
214770209|NCT02421107|OTHER|iStat intermittent testing|
214770210|NCT06169020|DEVICE|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
214770211|NCT06169020|DEVICE|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
214770212|NCT02426125|DRUG|Ramucirumab|Administered IV
214770213|NCT02426125|DRUG|Docetaxel|Administered IV
214770214|NCT02426125|DRUG|Placebo|Administered IV
214770215|NCT05941299|DEVICE|REGENERA breast implant implantation|"Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up"
214770216|NCT04345887|DRUG|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
214770217|NCT04345887|DRUG|Placebo oral tablet|2 x1 placebo tablet
214770218|NCT04871178|BEHAVIORAL|Mindfulness-based intervention|"Eight, 2-hour instructor-led MBI group sessions once a week for 8 weeks, combined with formal meditative training at home for 20 minutes per day, 6 days a week.~Course material consists of facts booklet, weekly training manuals, audio recordings on a CD, with the five formal guided meditative exercises (body scan, breathing anchor, breathing space, mindful movements, sitting meditation).~The weekly home-work also included informal training of being present in daily life activities.~The program is provided according to the standard MBI protocol. Compared to MBSR and MBCT durations of formal meditative practices are shorter and no 'all-day in silence' session is included. Because of participants' physical limitations and safety, the 'mindful movements' sequence, is adapted and performed in a sitting position.~Adherence to the MBI was followed by self-reported weekly training in manuals asked to be submitted at group sessions."
214770219|NCT00004232|BIOLOGICAL|filgrastim|
214770220|NCT00004232|DRUG|cyclosporine|
214770221|NCT00004232|DRUG|methylprednisolone|
214770222|NCT00004232|DRUG|prednisone|
214770223|NCT00004232|PROCEDURE|allogeneic bone marrow transplantation|
214770224|NCT00004232|PROCEDURE|peripheral blood stem cell transplantation|
214770225|NCT06537245|OTHER|Massage|Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
214770226|NCT02858076|DRUG|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
214770227|NCT02858076|PROCEDURE|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
214770228|NCT04789811|OTHER|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
214770229|NCT04789811|OTHER|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
214770230|NCT06060639|DIAGNOSTIC_TEST|transthoracic echocardiography|E wave, A wave, e' and vdi measurement
214770231|NCT06030479|DRUG|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
214770232|NCT06030479|DRUG|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
214770233|NCT03839784|COMBINATION_PRODUCT|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
214770234|NCT02899442|OTHER|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
214770235|NCT02079428|OTHER|No interventions|
214770236|NCT04098471|PROCEDURE|transanal local excision following radiotherapy|transanal local excision following radiotherapy
214770237|NCT05341076|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
214770238|NCT05341076|DRUG|Oxytocin|oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
214770239|NCT05341076|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
214770240|NCT04641754|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
214770241|NCT03506854|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
214770242|NCT00096200|DRUG|Carboplatin|Given IV
214770243|NCT00096200|DRUG|Paclitaxel|Given IV
214770244|NCT00096200|DRUG|Sorafenib Tosylate|Given orally
214770245|NCT06472375|DIAGNOSTIC_TEST|holter|ambulant heart rate monitor (holter) for 24 hour.
214770246|NCT01850901|PROCEDURE|Renal sympathetic denervation|
214770247|NCT06283745|OTHER|Platelet-rich Plasma (PRP)|Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.
214770248|NCT06283745|OTHER|Saline|Saline intranasal injection (sham injection)
214770249|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
214770250|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
214770251|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
214770252|NCT03438474|PROCEDURE|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
214770253|NCT03438474|PROCEDURE|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
214770254|NCT04843501|BEHAVIORAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
214770255|NCT04843501|BEHAVIORAL|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
214770256|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
214770257|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
214770258|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
214770259|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
214770260|NCT03648385|DRUG|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
214770261|NCT03648385|OTHER|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
214770262|NCT06254963|OTHER|sand jump training|A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
214770263|NCT06254963|OTHER|land jump training|A series of progressive jumping activities on land increasing in difficulty over the 6 week period
214770264|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
214770265|NCT02121405|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
214770266|NCT02121405|RADIATION|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
214770267|NCT02121405|DRUG|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
214770268|NCT02121405|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
214770269|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
214770270|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
214770271|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
214770272|NCT01914289|PROCEDURE|Resection|
214770273|NCT01914289|RADIATION|Radiotherapy|
214770274|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
214770275|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
214770276|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
214770277|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
214770278|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
214770279|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
214770280|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
214770281|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
214770282|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
214770283|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
214770284|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
214770285|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
214770286|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
214770287|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
214770288|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
214770289|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
214770290|NCT00116545|DRUG|troglitazone|
214770291|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
214770292|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
214770293|NCT04059900|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
214770294|NCT04059900|DRUG|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
214770295|NCT01955473|DRUG|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
214770296|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
214770297|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
214770298|NCT03973086|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
214770299|NCT01138852|DRUG|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
214770300|NCT01138852|DRUG|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
214770301|NCT04011111|PROCEDURE|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
214770302|NCT03311828|BIOLOGICAL|Daratumumab|Given IV
214770303|NCT03311828|DRUG|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
214770304|NCT03311828|PROCEDURE|Positron Emission Tomography|Undergo PET
214770305|NCT03311828|OTHER|Pharmacological Study|Correlative studies
214770306|NCT03701516|DEVICE|etafilcon A with novel molding process|TEST Lens
214770307|NCT03701516|DEVICE|etafilcon A with current molding process|CONTROL Lens
214770308|NCT00478673|DEVICE|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
214770309|NCT00478673|DEVICE|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
214770310|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
214770311|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
214770312|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
214770313|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
214770314|NCT01924572|PROCEDURE|cord milking|
214770315|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
214770316|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
214770317|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
214770318|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
214770319|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
214770320|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
214770321|NCT05564494|PROCEDURE|Bankart Repair|Patients Randomized to Bankart Repair Group
214770322|NCT05564494|PROCEDURE|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
214770323|NCT04383769|OTHER|questionnaires survey|data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
214770324|NCT00403923|DIETARY_SUPPLEMENT|Lactose in water|
214770325|NCT05597514|OTHER|3D printed educational model|Slide-based presention plus 3D printed airway suction model
214770326|NCT05597514|OTHER|Tranditional model education|Slide-based presention plus tranditional model
214646062|NCT02052557|DRUG|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
214770327|NCT06650241|OTHER|Behavioral therapy|
214770328|NCT06650241|OTHER|Lip Bumper Therapy|
214770329|NCT06650241|OTHER|Modified Twin-Block Therapy|
214770330|NCT00191256|DRUG|Gemcitabine|
214770331|NCT00191256|DRUG|Carboplatin|
214770332|NCT00191256|DRUG|Paclitaxel|
214770333|NCT00928785|BIOLOGICAL|REPEVAX|1 dose of 0.5 mL at Day 0
214770334|NCT00928785|BIOLOGICAL|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
214770335|NCT05917314|OTHER|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~* Limosilactobacillus fermentum K7-Lb1~* Limosilactobacillus fermentum K8-Lb1~* Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
214770336|NCT05917314|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
214770337|NCT00358670|BIOLOGICAL|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
214770338|NCT00358670|BIOLOGICAL|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
214770339|NCT06274385|DIETARY_SUPPLEMENT|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
214770340|NCT06274385|OTHER|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
214770341|NCT00000282|DRUG|Pemoline|
214646063|NCT01228903|DRUG|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
214646064|NCT01228903|OTHER|Placebo|Placebo tablets with no active ingredient
214646065|NCT04497025|OTHER|Immersive Virtual-based vestibular rehabilitation|Vestibular rehabilitation based on virtual environment using a head mounted display
214646066|NCT04497025|OTHER|Conventional vestibular rehabilitation protocol|"Cawthorne-Cooksey vestibular rehabilitation exercises."
214646067|NCT01557166|DRUG|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
214646068|NCT01557166|DRUG|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
214646069|NCT04724473|DRUG|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214646070|NCT02986230|OTHER|CP-CDS|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
214646071|NCT00620243|PROCEDURE|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
214646072|NCT04492280|DRUG|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
214646073|NCT02989792|GENETIC|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
214646074|NCT02989792|OTHER|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
214646075|NCT03390738|DRUG|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
214646076|NCT00502190|DEVICE|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
214646077|NCT00282841|OTHER|ultrasound|single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
214770342|NCT06541925|DEVICE|Injection with the needle-free (NF) system|Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
214770343|NCT06541925|DEVICE|Injection with the traditional method (TM)|The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
214770344|NCT05083559|DEVICE|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
214770345|NCT05083559|DEVICE|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
214770346|NCT03907540|DRUG|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
214770347|NCT03907540|DRUG|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
214770348|NCT03907540|DRUG|[14C]-KD025 200 mg capsule|test investigational medicinal product
214770349|NCT06520722|DIAGNOSTIC_TEST|Prolapse scoring system|"A FIXED APCD classification system :~A: Associated symptoms:~FIXED:~F: frequency I: infection X: sex problems E: everted mass(external protrusion of mass from the valva as PV lump sensation ,heaviness,itching and ulceration) D: digitation(patient need to digitate to complete the act of micturation or defecation)~APCD:~A: Dependent point on anterior wall. P: Dependent point on posterior wall. C: Cuff point either cervix or vault. Distance to hymen in centimeters (minus above or plus below) after pushing the opposite wall during maximal straining D: Dimensions; base diameter of vestibule/ perineal length.~The staging system will be interpreted as follows:~Normal:~A-3 P-3 C-8 D 2/2~Stages:~0: No prolapse.~A/P-2 OR C-7 to C-2 A,P or C-1 to +1 A,P or C ˃ +1~X component: (alone or with any stage):~Dimension disruption: ˃2 or \<2"
214770350|NCT01721824|BEHAVIORAL|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
214770351|NCT00303134|DRUG|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
214770352|NCT03039517|DEVICE|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
214770353|NCT03039517|DEVICE|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
214770354|NCT04008082|DRUG|Lenvatinib|Lenvatinib capsule.
214770355|NCT06290739|PROCEDURE|lymph nodes dissection|Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
214770356|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
214770357|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
214770358|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
214770359|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
214770360|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
214770361|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
214770362|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
214770363|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
214770364|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
214770365|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
214770366|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
214770367|NCT06313697|BIOLOGICAL|placebo|single dose
214770368|NCT04461431|PROCEDURE|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
214770369|NCT06070701|PROCEDURE|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
214770370|NCT06070701|PROCEDURE|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
214770371|NCT06070701|DRUG|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
214770372|NCT06070701|DRUG|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
214770373|NCT03428217|DRUG|CB-839|Oral glutaminase inhibitor
214770374|NCT03428217|DRUG|Cabozantinib|Oral receptor tyrosine kinase inhibitor
214770375|NCT03428217|DRUG|Placebo|Placebo tablets
214770376|NCT06065475|BEHAVIORAL|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, injecting 2.5ml of 2% lidocaine on the surface of the thyroid cartilage each side.
214770377|NCT06185556|PROCEDURE|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
214770378|NCT06185556|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
214770379|NCT05899218|BEHAVIORAL|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
214770380|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
214770381|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
214770382|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
214770383|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
214770384|NCT05049460|DEVICE|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
214770385|NCT05049460|DEVICE|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
214770386|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
214770387|NCT04066192|DRUG|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
214770388|NCT04066192|DRUG|Placebo|A medically inert placebo medication will be used as described in the study arms.
214770389|NCT05131282|DIAGNOSTIC_TEST|Blood test of PE risk|A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE
214770390|NCT05131282|DIAGNOSTIC_TEST|Blood test of Preterm PE risk|A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE
214770391|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
214770392|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
214770393|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
214770394|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
214770395|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
214770396|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
214770397|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
214770398|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
214770399|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
214770400|NCT06136676|BEHAVIORAL|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
214770401|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
214770402|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
214770403|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
214770404|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
214770405|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
214770406|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
214770407|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
214770408|NCT03151226|DEVICE|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
214770409|NCT00208000|DRUG|Marine active|
214770410|NCT03620760|DRUG|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
214770411|NCT03620760|DRUG|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
214770412|NCT03620760|DRUG|Aspirin|Aspirin 100 mg once daily dose
214770413|NCT03086980|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
214770414|NCT03086980|OTHER|Treatment as Usual|Usual Care will be provided.
214770415|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
214770416|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
214770417|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
214770418|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
214770419|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
214770420|NCT06426992|PROCEDURE|Microwave ablation|Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.
214770421|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
214770422|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
214770423|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
214770424|NCT00138827|DRUG|Biotene (mouth care)|
214770425|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
214770426|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
214770427|NCT04117958|DRUG|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
214770428|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
214770429|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
214770430|NCT03050528|BEHAVIORAL|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
214770431|NCT03050528|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
214770432|NCT02612649|DRUG|Ramosetron|Oral
214770433|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
214770434|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
214770435|NCT05872451|DRUG|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
214770436|NCT05872451|DIAGNOSTIC_TEST|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
214770437|NCT01016431|OTHER|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
214770438|NCT01016431|OTHER|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
214770439|NCT00391118|DRUG|enzastaurin|
214770440|NCT00391118|DRUG|carboplatin|
214770441|NCT00391118|DRUG|paclitaxel|
214770442|NCT00391118|DRUG|placebo|
214770443|NCT02591017|DRUG|Morphine|
214770444|NCT02591017|DRUG|Ketamine|
214770445|NCT02591017|DRUG|Placebo|
214770446|NCT02591017|DRUG|Chitosan|
214770447|NCT03054168|DRUG|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
214770448|NCT03054168|DRUG|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
214770449|NCT03054168|OTHER|Placebo|
214770450|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
214770451|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
214770452|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
214770453|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
214770454|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
214770455|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
214770456|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
214770457|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
214770458|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
214770459|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
214770460|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
214770461|NCT06390423|DIAGNOSTIC_TEST|Passive leg raise, SVI via bioreactance, Echo based VTI|No interventions other than fluid challenge
214770462|NCT05860049|OTHER|Conventional physiotherapy|All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.
214770463|NCT05860049|OTHER|Core stability|All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.
214770464|NCT05860049|DEVICE|Instrument assisted soft tissue mobilization|Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
214770465|NCT06565377|BEHAVIORAL|Multimodal biopsychosocial teleprehabilitation|"Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet."
214770466|NCT06565377|OTHER|Best-evidence prehabilitation advice|Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
214770467|NCT06568913|DIAGNOSTIC_TEST|CBC|Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
214770468|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
214770469|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
214770470|NCT05473247|BEHAVIORAL|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
214770471|NCT05243134|OTHER|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
214770472|NCT03533335|OTHER|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
214770473|NCT04574037|OTHER|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
214770474|NCT06232707|DRUG|Alnuctamab|Specified dose on specified days
214770475|NCT06232707|DRUG|Pomalidomide|Specified dose on specified days
214770476|NCT06232707|DRUG|Daratumumab|Specified dose on specified days
214770477|NCT06232707|DRUG|Elotuzumab|Specified dose on specified days
214770478|NCT06232707|DRUG|Carfilzomib|Specified dose on specified days
214770479|NCT06232707|DRUG|Dexamethasone|Specified dose on specified days
214770480|NCT00392717|DRUG|Atorvastatin|
214770481|NCT00392717|DRUG|Fish oils|
214770482|NCT01946087|PROCEDURE|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
214770483|NCT01946087|PROCEDURE|Control group|keeping the cuff deflated
214770484|NCT04770194|DRUG|SP-8008 Prototype Capsule A|Oral
214770485|NCT04770194|DRUG|SP-8008 Prototype Capsule B|Oral
214770486|NCT04770194|DRUG|Placebo|Oral
214770487|NCT03434808|OTHER|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
214770488|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
214770489|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
214770490|NCT03370627|BIOLOGICAL|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
214770491|NCT06543251|OTHER|High-intensity interval training group (HIIT)|The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
214770492|NCT06543251|OTHER|Moderate continuous training group (MCT)|Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
214770493|NCT06543251|OTHER|Sedentary control group (CON)|The control group had normal daily life.
214770494|NCT04975113|OTHER|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
214770495|NCT04975113|OTHER|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
214770496|NCT01874015|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
214770497|NCT01874015|BIOLOGICAL|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
214770498|NCT01345058|DRUG|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day."
214770499|NCT01345058|DRUG|levetiracetam|Low dose ≤1500 mg/day, High dose \>1500 mg/day
214770500|NCT04181697|DEVICE|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
214770501|NCT04181697|DEVICE|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
214770502|NCT05775237|DIETARY_SUPPLEMENT|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
214770503|NCT05775237|DIETARY_SUPPLEMENT|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
214770504|NCT05775237|DIETARY_SUPPLEMENT|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
214770505|NCT02820324|DRUG|Oliceridine|
214770506|NCT02820324|DRUG|Placebo|
214770507|NCT02820324|DRUG|Morphine|
214770508|NCT06541171|OTHER|Magnetic resonance imaging as fpr clinical practice|An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.
214770509|NCT01892020|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
214770510|NCT01892020|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
214770511|NCT04398888|OTHER|Banxie Xiexin Decoction (BXD)|A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
214770512|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
214770513|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
214770514|NCT00402779|DRUG|Erlotinib|150 mg by mouth daily
214770515|NCT00402779|DRUG|Placebo|Tablet by mouth daily
214770516|NCT04661163|OTHER|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
214770517|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
214770518|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
214770519|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
214770520|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
214770521|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
214770522|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
214770523|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
214770524|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
214770525|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
214770526|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
214770527|NCT04014556|DRUG|Aflibercept|Aflibercept
214770528|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
214770529|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
214770530|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
214770531|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
214770532|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
214770533|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
214770534|NCT05967767|DEVICE|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
214770535|NCT05967767|DEVICE|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
214770536|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
214770537|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
214770538|NCT00094900|DRUG|IL-1 Trap|
214770539|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
214770540|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
214770541|NCT03026868|PROCEDURE|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
214770542|NCT01305135|DRUG|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
214770543|NCT02149199|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
214770544|NCT02149199|DRUG|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
214770545|NCT02149199|DRUG|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
214770546|NCT03775382|OTHER|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
214770547|NCT03775382|OTHER|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
214770548|NCT03563235|DRUG|Xulin Jiangu granules|Xulin Jiangu granules tablets
214770549|NCT03563235|DRUG|Calcitriol capsules|Calcitriol capsules tablets
214770550|NCT05840601|DEVICE|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
214770551|NCT05840601|DEVICE|Comparator|Unmodified commercially available prosthetic hand.
214770552|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
214770553|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
214770554|NCT04914559|OTHER|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
214770555|NCT04914559|OTHER|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
214770556|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
214770557|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
214770558|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
214770559|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
214770560|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
214770561|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
214770562|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
214770563|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
214770564|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
214770565|NCT05397288|BEHAVIORAL|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
214770566|NCT05397288|BEHAVIORAL|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
214770567|NCT05397288|BEHAVIORAL|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~* 1st month: group talk (1 time/week), individual consultation (2 times/week)~* 2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~* 3rd month: group talk (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
214770568|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
214770569|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
214770570|NCT05027425|DRUG|Durvalumab|1500 mg IV, Q4W
214770571|NCT05027425|DRUG|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
214770572|NCT05027425|PROCEDURE|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
214770573|NCT06653478|OTHER|No Intervention|No Intervention
214770574|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
214770575|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
214770576|NCT00334477|DRUG|tadalafil|
214770577|NCT03793309|DRUG|Vitamin D|Oral vitamin D
214770578|NCT01806259|DRUG|Ketorolac 30 mg IV|Active drug
214770579|NCT01806259|DRUG|Placebos|Placebo looking like the Active drug
214770580|NCT01995058|DRUG|cabozantinib|Tablets taken orally
214770581|NCT01995058|DRUG|abiraterone|Tablets taken orally daily
214770582|NCT01995058|DRUG|prednisone|Tablets taken orally twice daily
214770583|NCT03001856|PROCEDURE|Oblique Intradermal Suture|
214770584|NCT03001856|PROCEDURE|Intradermal Suture|
214770585|NCT03271541|DRUG|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
214770586|NCT02957461|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
214770587|NCT06515496|DIETARY_SUPPLEMENT|Scale HLV Clinical Formula Hair Vitamins|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
214770588|NCT06515496|OTHER|Placebo|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
214770589|NCT02800278|OTHER|observational|describe bone status and outcome of odontoid fracture
214770590|NCT04643054|DIETARY_SUPPLEMENT|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
214770591|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
214770592|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
214770593|NCT01500434|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
214770594|NCT01500434|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
214770595|NCT01500434|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
214770596|NCT03309631|DIAGNOSTIC_TEST|In vitro Diagnostic|
214770597|NCT00191620|DRUG|Gemcitabine|
214770598|NCT00191620|DRUG|cisplatin|
214770599|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
214770600|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
214770601|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
214770602|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
214770603|NCT06594094|GENETIC|HG302|Once intravenous injection; The duration of the study is about 32 weeks for each subject, including a 6 weeks screening period, enrollment visit, treatment visit, and 26 weeks follow-up period.
214770604|NCT01407107|DRUG|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
214770605|NCT01407107|DRUG|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
214770606|NCT01407107|DRUG|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
214770607|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
214770608|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
214770609|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
214770610|NCT05764434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
214770611|NCT01307488|DRUG|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
214770612|NCT01307488|DRUG|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
214770613|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
214770614|NCT06607692|DRUG|Olaparib; 177Lu-DOTATATE|7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
214770615|NCT06596382|DIETARY_SUPPLEMENT|Tocotrienol rich-vitamin E|Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome
214770616|NCT06596382|DIETARY_SUPPLEMENT|Placebo|Replicate for tocotrienol rich-vitamin E without any active ingredients
214770617|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
214770618|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
214770619|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
214770620|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
214770621|NCT01827072|DRUG|NPB-01|
214770622|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
214770623|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
214770624|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
214770625|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
214770626|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
214770627|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
214770628|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
214770629|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
214770630|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
214770631|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
214770632|NCT01916759|DRUG|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
214770633|NCT04252040|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
214770634|NCT01465074|DRUG|Nicotine polacrilex|4 mg
214770635|NCT01465074|DRUG|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
214770636|NCT00958698|OTHER|Communication Intervention|Ancillary studies
214770637|NCT00958698|OTHER|Educational Intervention|Ancillary studies
214770638|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
214770639|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
214770640|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
214770641|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
214770642|NCT00058045|BIOLOGICAL|aldesleukin|
214770643|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
214770644|NCT02662556|DRUG|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
214770645|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
214770646|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
214770647|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
214770648|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
214770649|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
214770650|NCT03441373|DRUG|Placebo|once daily during 5 days.
214770651|NCT00788008|DRUG|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
214770652|NCT00213629|OTHER|transcriptome analysis|transcriptome analysis from muscle biopsy
214770653|NCT00213629|OTHER|T cell repertoire analysis|blood T cell repertoire analysis
214770654|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
214770655|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
214770656|NCT06056323|DRUG|HB0045 Drug Product|Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
214770657|NCT06538714|OTHER|MIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling."
214770658|NCT06538714|OTHER|MIIT + HIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling."
214770659|NCT06538714|OTHER|Control group|"Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling."
214770660|NCT01038531|OTHER|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
214770661|NCT01038531|OTHER|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
214770662|NCT04382560|OTHER|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
214770663|NCT04382560|OTHER|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
214770664|NCT00005879|DRUG|arzoxifene|one tablet daily
214770665|NCT00005879|DRUG|Placebo|matched tablet dialy
214770666|NCT05207176|DRUG|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
214770667|NCT00363935|DRUG|Dexmedetomidine|
214770668|NCT02352207|OTHER|identification of a pulmonary malformation in the fetus|
214770669|NCT06430307|DRUG|Saussurea Involucrata Liquid Tonic|This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
214770670|NCT02790619|DEVICE|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
214770671|NCT02790619|DEVICE|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
214770672|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
214770673|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
214770674|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
214770675|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
214770676|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
214646078|NCT04812626|DRUG|5-Fluorouracil|Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
214770677|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
214770678|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
214770679|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
214770680|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
214770681|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
214770682|NCT06395584|DEVICE|White Light LED|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
214770683|NCT06395584|DEVICE|Green Light LED|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
214770684|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
214770685|NCT03980561|DRUG|Varenicline|Active medication
214770686|NCT03980561|DRUG|Placebo|Inactive medication
214770687|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
214770688|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
214646079|NCT05844215|DIAGNOSTIC_TEST|MMP-9 and TIMP-1|Examine level of serum MMP-9 and TIMP-1
214646080|NCT02445586|DRUG|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
214646081|NCT02445586|DRUG|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
214646082|NCT02445586|DRUG|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
214646083|NCT06103903|BEHAVIORAL|Questionnaire|Questionnaire according to age (6-13;14-17); the parents for minors and adults
214646084|NCT01833884|OTHER|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
214646085|NCT03359876|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
214646086|NCT03359876|DRUG|Warfarin sodium|Individually adjusted dose
214646087|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Clinician-Guided version|Internet delivered Cognitive Behavioral Therapy- Guided version
214646088|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Self-Guided version|Internet delivered Cognitive Behavioral Therapy- Self-Guided version
214646089|NCT00004183|DRUG|capecitabine|
214646090|NCT03618056|BIOLOGICAL|AIDSVAX® B/E|Administered by intramuscular injection
214646091|NCT02199899|DRUG|BIIF 1149 BS - single rising doses|
214646092|NCT02199899|DRUG|Placebo|
214646093|NCT02385279|DEVICE|MiStent|Percutaneous Coronary Intervention
214646094|NCT02385279|DEVICE|XIENCE EES|Percutaneous Coronary Intervention
214646095|NCT05589285|BIOLOGICAL|Injection of autologous whole blood to the plantar fascia|Patients assigned in this group will have 2 ml of blood withdrawn from a peripheral vein, then mixed with 1 mL Lidocaine 2% for a total of 3mL volume in one syringe. The patient will be asked to lie down in the clinic bed, and the injection will be administered to the plantar fascia by the principal investigator using a sterile technique.
214646096|NCT05589285|DEVICE|Injection of normal saline to the plantar fascia|This will be the control group receiving sham injection. Patients will have 2 ml of blood withdrawn from a peripheral vein for blinding proposes. They will be asked to lie down on the clinic bed, 1 ml of normal saline will be administered under sterile technique by the principal investigator. The blood that was withdrawn initially will be discarded.
214646097|NCT00212147|DRUG|General anesthesia with nitrous oxide|
214646098|NCT00212147|DRUG|General anesthesia without nitrous oxide|
214646099|NCT01990261|DRUG|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
214646100|NCT05152290|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214646101|NCT00804388|PROCEDURE|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
214646102|NCT02534636|DRUG|BMS-986165|
214646103|NCT02534636|DRUG|Interferon alpha-2a recombinant|
214646104|NCT02534636|DRUG|Famotidine|
214646105|NCT02534636|OTHER|Placebo|
214646106|NCT00744900|DRUG|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
214646107|NCT00624390|DEVICE|Sepraspray|
214646108|NCT00954109|BEHAVIORAL|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
214646109|NCT03929887|OTHER|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
214646110|NCT01893398|OTHER|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
214646111|NCT02153099|DRUG|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
214646112|NCT02153099|DRUG|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
214646113|NCT00004001|DRUG|docetaxel|
214646114|NCT00004001|DRUG|estramustine|
214646115|NCT00004001|DRUG|mitoxantrone|
214646116|NCT00004001|DRUG|prednisone|
214646117|NCT01677715|DIETARY_SUPPLEMENT|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
214646118|NCT01677715|DIETARY_SUPPLEMENT|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
214646119|NCT01445678|DRUG|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
214646120|NCT01445678|DRUG|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
214646121|NCT01318330|DRUG|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
214646122|NCT02721537|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Three capsules, twice per day for 84 days
214646123|NCT02721537|OTHER|Matching placebo|Three matching capsules, twice per day for 84 days
214646124|NCT04299295|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
214646125|NCT04299295|DEVICE|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
214646126|NCT01393197|OTHER|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
214646127|NCT01845038|DRUG|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
214646128|NCT01845038|DRUG|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
214646129|NCT01845038|DRUG|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
214646130|NCT02307370|DEVICE|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
214646131|NCT01744132|BEHAVIORAL|Aim 3: Contract|
214646132|NCT05821140|PROCEDURE|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
214646133|NCT05821140|OTHER|oral health check up|regular preventive follow-up visit (every 6 months)
214646134|NCT02482584|DEVICE|CPAP|CPAP intervention
214646135|NCT02482584|OTHER|Control|Control
214646136|NCT06237894|OTHER|Multisensory Stimulation|Multisensory Stimulation
214646137|NCT02667080|OTHER|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
214646138|NCT02667080|OTHER|2 hours of sexual abstinence|2 hours of sexual abstinence
214646139|NCT04625127|DEVICE|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
214646140|NCT04625127|OTHER|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
214646141|NCT04625127|OTHER|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
214646142|NCT00004156|BIOLOGICAL|MUC1-KLH vaccine/QS21|
214646143|NCT01923688|OTHER|Informatics Alert/Nurse/physician responders|
214646144|NCT05325320|BEHAVIORAL|SMI/SIA Stigma Reduction Intervention|Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.
214646145|NCT05325320|OTHER|Disaster Preparedness Course|Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
214646146|NCT05154292|BEHAVIORAL|Serious Game: Emotional Health Island (SAEM)|This intervention aims to aim to develop competencies for emotional regulation through exposure and acceptance strategies. This intervention is applied through a serious game developed for this purpose. the adolescent will complete a series of missions aimed at developing skills related to psychological flexibility, namely, greater psychological acceptance, mindfulness in the present moment, and committed actions in the direction of personal values. This serious game is guided by a therapist.
214646147|NCT03088865|DIAGNOSTIC_TEST|aspirating first blood volume into a regular blood collection tube|order of blood drawing
214646148|NCT02833246|OTHER|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
214646149|NCT02833246|OTHER|usual care|
214646150|NCT03575715|DEVICE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
214646151|NCT02843620|DIETARY_SUPPLEMENT|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
214646152|NCT02843620|OTHER|Placebo|Excipients only
214646153|NCT06264115|PROCEDURE|Laparoscopic Cholecystectomy|Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
214646154|NCT02793037|DEVICE|Zirconia resin bonded bridge|
214770689|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
214770690|NCT00230217|DRUG|Rasburicase (SR29142)|
214770691|NCT05832242|OTHER|Ultrasound|Point-of-care ultrasound in the emergency department
214770692|NCT06360679|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted and retrieved once treatment is completed
214770693|NCT05406596|DEVICE|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
214770694|NCT03162120|DRUG|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
214770695|NCT03162120|DRUG|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
214770696|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
214770697|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
214770698|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
214770699|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
214770700|NCT05549986|OTHER|Observational|Observational
214770701|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
214770702|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
214770703|NCT00228878|PROCEDURE|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
214770704|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
214770705|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
214770706|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
214770707|NCT04591327|PROCEDURE|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
214770708|NCT02334839|OTHER|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
214770709|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
214770710|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
214770711|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
214770712|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
214770713|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
214770714|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
214770715|NCT04225416|OTHER|Questionnaire/Structured Interview|No intervention
214770716|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
214770717|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
214770718|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
214770719|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
214770720|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
214770721|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
214770722|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
214770723|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
214770724|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
214770725|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
214770726|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
214770727|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
214770728|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
214770729|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
214770730|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
214770731|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
214770732|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
214770733|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
214770734|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
214770735|NCT02041000|OTHER|Adipose Derived Stem Cells|
214770736|NCT02805673|PROCEDURE|Osteopathy|
214770737|NCT00901420|PROCEDURE|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
214770738|NCT00901420|BEHAVIORAL|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
214770739|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
214770740|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
214770741|NCT00187174|DRUG|Everolimus|The drug is given orally in 28 day courses.
214770742|NCT05475535|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
214770743|NCT05475535|BEHAVIORAL|Self-Compassion|Self-Compassion focused exercises
214770744|NCT05475535|BEHAVIORAL|Active Control|Engagement in a mobile application (Cooperation skills)
214770745|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
214770746|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
214770747|NCT04282733|BEHAVIORAL|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
214770748|NCT00131937|DRUG|sorafenib tosylate|Given orally
214770749|NCT06317870|PROCEDURE|Intrathecal morphine|"Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding."
214770750|NCT06317870|PROCEDURE|Pericapsular nerve group block (PENG)|"Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected."
214770751|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
214770752|NCT06418074|DIETARY_SUPPLEMENT|Ketone Monoester (KE4)|Each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4) 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
214770753|NCT06418074|OTHER|Placebo|Each subject will receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
214770754|NCT02108366|DRUG|Celecoxib|Celecoxib 200mg daily
214770755|NCT02108366|DRUG|Oseltamivir|Oseltamivir 75mg bid
214770756|NCT02108366|DRUG|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
214770757|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
214770758|NCT04499391|OTHER|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
214770759|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
214770760|NCT03313401|DRUG|Aflibercept|Intravitreal aflibercept injection
214770761|NCT03313401|DEVICE|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
214770762|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
214770763|NCT00745459|DRUG|NPO-11|20 mL NPO-11
214770764|NCT00171080|DRUG|valsartan|
214770765|NCT00171080|DRUG|irbesartan|
214770766|NCT00002560|BIOLOGICAL|monoclonal antibody 3F8|
214770767|NCT00002560|BIOLOGICAL|sargramostim|
214770768|NCT05073276|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
214770769|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
214770770|NCT01186744|DRUG|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
214770771|NCT01186744|DRUG|CP-690,550|10 mg oral BID
214770772|NCT01186744|DRUG|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
214770773|NCT01186744|DRUG|CP-690,550|5 mg oral BID
214770774|NCT02547779|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
214770775|NCT02547779|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
214770776|NCT01020773|BEHAVIORAL|spontaneous breathing trial|
214770777|NCT00769782|PROCEDURE|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
214770778|NCT01280565|DRUG|Masitinib|Masitinib 7.5 mg/kg/day
214770779|NCT01280565|DRUG|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
214770780|NCT05812222|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
214770781|NCT01409018|DRUG|Itraconazole|pharmacokinetics
214770782|NCT02675426|DRUG|Placebo|Tablet; Oral
214770783|NCT02675426|DRUG|Upadacitinib|Tablet; Oral
214770784|NCT02726217|BEHAVIORAL|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
214770785|NCT02726217|BEHAVIORAL|Standard of Care Reminders and Self Assessments|
214770786|NCT02614937|DRUG|ranibizumab|0.5 mg IVT ranibizumab
214770787|NCT02614937|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
214770788|NCT03719729|DRUG|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
214770789|NCT02131337|OTHER|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
214770790|NCT04768829|DRUG|Moringa oleifera leaf 10mg/100ml|ear drops
214770791|NCT04768829|DRUG|Ear Drop|plain ear drop formulation without moringa
214770792|NCT02321215|OTHER|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
214770793|NCT01990079|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
214770794|NCT01990079|DRUG|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
214770795|NCT01990079|OTHER|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
214770796|NCT01990079|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
214770797|NCT01990079|OTHER|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
214770798|NCT03759418|DEVICE|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
214770799|NCT00233376|PROCEDURE|Access to an antibiotic decision support system|
214770800|NCT00233376|BEHAVIORAL|Distribution of local antibiotic guidelines|
214770801|NCT00953927|BIOLOGICAL|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
214770802|NCT00953927|BIOLOGICAL|Candida Skin Test Antigen|1 test, administered once as a placebo control.
214770803|NCT04231994|DEVICE|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
214770804|NCT03225066|DEVICE|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
214770805|NCT01652573|DRUG|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
214770806|NCT01652573|DRUG|Saline Nasal Spray Placebo|
214770807|NCT02797626|PROCEDURE|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
214770808|NCT03614065|DRUG|endostar|endostatin
214770809|NCT03614065|DRUG|Placebos|saline solution
214770810|NCT03614065|RADIATION|radiotherapy|radiotherapy
214770811|NCT00934622|DEVICE|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
214770812|NCT01453101|DRUG|Fludarabine monophosphate, melphalan, Bortezomib|"* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
214770813|NCT02060240|BEHAVIORAL|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
214770814|NCT05780944|BEHAVIORAL|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
214770815|NCT04662086|DRUG|Acebilustat|100 mg capsule administered orally once daily
214770816|NCT04662086|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
214770817|NCT01506063|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
214770818|NCT01856686|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
214770819|NCT01856686|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
214770820|NCT00079963|DIETARY_SUPPLEMENT|Vitamin C|1000 mg/day
214770821|NCT00079963|DIETARY_SUPPLEMENT|Vitamin E|800 IU/day
214770822|NCT00079963|DIETARY_SUPPLEMENT|Placebo|
214770823|NCT03284424|BIOLOGICAL|Pembrolizumab|IV infusion
214770824|NCT02706041|PROCEDURE|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
214770825|NCT02706041|PROCEDURE|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
214770826|NCT04647279|DIAGNOSTIC_TEST|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
214770827|NCT00602979|DEVICE|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
214770828|NCT00602979|DEVICE|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
214770829|NCT00602979|DEVICE|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
214770830|NCT00602979|DEVICE|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
214770831|NCT00602979|DEVICE|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
214770832|NCT00729703|DEVICE|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
214770833|NCT00729703|DEVICE|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
214770834|NCT05633095|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
214770835|NCT04304846|OTHER|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
214770836|NCT01424618|DRUG|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
214770837|NCT01424618|DRUG|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
214770838|NCT00431236|DRUG|Oral Casopitant (GW679769)|
214770839|NCT00431236|DRUG|IV Casopitant (GW679769)|
214770840|NCT00431236|DRUG|IV ondansetron hydrochloride|
214770841|NCT00431236|DRUG|Oral dexamethasone|
214770842|NCT04950803|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
214770843|NCT04950803|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
214770844|NCT00004288|DRUG|olsalazine|
214770845|NCT02534207|DRUG|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
214770846|NCT05747261|GENETIC|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
214770847|NCT05747261|GENETIC|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
214770848|NCT05747261|GENETIC|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
214770849|NCT02040207|DRUG|AM-101|AM-101 gel for intratympanic injection
214770850|NCT03203005|DRUG|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
214770851|NCT02263586|BEHAVIORAL|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
214770852|NCT06541977|BEHAVIORAL|Behavioral to reduce sedentary behvaior|This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
214770853|NCT06541977|BEHAVIORAL|Physical activity|This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
214770854|NCT06541977|PROCEDURE|Bariatric Surgery|In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
214770855|NCT01031225|DRUG|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
214770856|NCT02962739|DRUG|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
214770857|NCT06257186|OTHER|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
214770858|NCT01293318|OTHER|No intervention|No intervention
214770859|NCT02301962|DRUG|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
214770860|NCT01638637|DEVICE|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
214770861|NCT03336645|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
214770862|NCT00532454|DRUG|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
214770863|NCT00999245|OTHER|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
214770864|NCT00999245|OTHER|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
214770865|NCT01608776|DEVICE|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
214770866|NCT01608776|OTHER|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
214770867|NCT05652894|DRUG|HX008|Drug: HX008 200 mg ,Q3W
214770868|NCT05652894|DRUG|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI."
214770869|NCT00694031|PROCEDURE|Hemodialysis|3 times per week
214770870|NCT00694031|PROCEDURE|On-line hemodiafiltration|3 times per week
214770871|NCT06293573|DEVICE|Whole-body vibration|GROUP A : will receive whole body vibration exercises combined with resistance exercises
214770872|NCT06293573|OTHER|aerobic exercises|Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.
214770873|NCT06293573|OTHER|resistance exercises|Group c: will receive progressive resistance exercises with diet modification life style.
214770874|NCT04006691|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
214770875|NCT03999229|DRUG|SNO|S-nitrosylating agent (SNO) Inhalation
214770876|NCT03999229|DRUG|Normal Saline|Normal Saline transfusion
214770877|NCT03999229|DRUG|Red Blood Cell|Blood transfusion (RBCs)
214770878|NCT02410031|DRUG|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
214770879|NCT05829473|OTHER|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
214770880|NCT05829473|OTHER|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
214770881|NCT02837263|RADIATION|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
214770882|NCT02837263|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
214770883|NCT00774202|DRUG|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
214770884|NCT00774202|DRUG|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
214770885|NCT00150475|PROCEDURE|Powered Air purifying respirator|
214770886|NCT00197509|BEHAVIORAL|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
214770887|NCT05038410|DRUG|Wobenzym®|Wobenzym®
214770888|NCT05038410|OTHER|Placebo|Microcrystalline cellulose
214770889|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
214770890|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
214770891|NCT04645732|BEHAVIORAL|Personalized exercise therapy and self-management support program|See description under Arms
214770892|NCT04645732|OTHER|Usual care|See description under Arms
214770893|NCT01268683|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
214770894|NCT04738552|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
214770895|NCT03888131|DRUG|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
214770896|NCT03888131|DRUG|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
214770897|NCT02216214|DRUG|Mirabegron|oral tablet
214770898|NCT02216214|DRUG|Placebo|oral tablet
214770899|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
214770900|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
214770901|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
214770902|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
214770903|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
214770904|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
214770905|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
214770906|NCT06234124|DEVICE|Variable Friction Shoe Training|The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
214770907|NCT06234124|DEVICE|Ankle Foot Orthosis (AFO) Training|The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
214770908|NCT06156631|BEHAVIORAL|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
214770909|NCT02645266|DRUG|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
214770910|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
214770911|NCT01410747|DRUG|Tacrolimus|oral
214770912|NCT06102824|DRUG|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
214770913|NCT06102824|DRUG|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
214770914|NCT06102824|DRUG|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
214770915|NCT06102824|DRUG|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
214770916|NCT06102824|DRUG|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
214770917|NCT06102824|DRUG|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
214770918|NCT06102824|DRUG|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
214770919|NCT06102824|DRUG|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
214770920|NCT06102824|DRUG|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
214770921|NCT06102824|DRUG|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
214770922|NCT06102824|DRUG|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
214770923|NCT03430037|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
214770924|NCT03430037|DRUG|Placebo oral capsule|Placebo
214770925|NCT04137770|OTHER|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
214770926|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
214770927|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
214770928|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214770929|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214770930|NCT00713830|DEVICE|Pen auto-injector|
214770931|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
214770932|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
214770933|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
214770934|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
214770935|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
214770936|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
214770937|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
214770938|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
214770939|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
214770940|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
214770941|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
214770942|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
214770943|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
214770944|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
214770945|NCT00490399|DRUG|gemcitabine|
214770946|NCT00490399|DRUG|cisplatin|
214770947|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
214770948|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
214770949|NCT05165173|DIETARY_SUPPLEMENT|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
214770950|NCT05165173|DIETARY_SUPPLEMENT|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
214770951|NCT00174473|DRUG|Voriconazole|
214770952|NCT00357708|DRUG|decitabine|Given IV
214770953|NCT00357708|DRUG|vorinostat|Given orally
214770954|NCT00357708|OTHER|laboratory biomarker analysis|Correlative studies
214770955|NCT00357708|OTHER|pharmacological study|Correlative studies
214770956|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
214770957|NCT05550259|PROCEDURE|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
214770958|NCT04683874|DEVICE|3D printed tray|3D printed tray
214770959|NCT03981614|DRUG|Binimetinib|Given PO
214770960|NCT03981614|DRUG|Palbociclib|Given PO
214770961|NCT03981614|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214770962|NCT03323359|DEVICE|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
214770963|NCT03323359|PROCEDURE|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
214770964|NCT00182208|DEVICE|Veno-device (Venowave)|
214770965|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
214770966|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
214770967|NCT06540820|DIAGNOSTIC_TEST|Dexa or Biompedance analysis with clinical and biochemical evaluations|All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
214770968|NCT02404272|OTHER|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
214770969|NCT02836704|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
214770970|NCT02836704|DRUG|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
214770971|NCT02836704|DRUG|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
214770972|NCT05315986|DIETARY_SUPPLEMENT|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
214770973|NCT05315986|BEHAVIORAL|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
214770974|NCT05315986|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
214770975|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
214770976|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
214770977|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
214770978|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
214770979|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
214770980|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
214770981|NCT03716804|DRUG|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
214770982|NCT03716804|DRUG|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
214770983|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
214770984|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
214770985|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
214770986|NCT05559242|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
214770987|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
214770988|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
214770989|NCT00499252|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
214770990|NCT04629300|BEHAVIORAL|Supportive Care Mobile Application|Tablet computer with application providing modules on skills for managing symptoms and coping.
214770991|NCT04629300|OTHER|Usual Care|Standard oncology care with monitoring of supportive care services usage
214770992|NCT03667742|DIAGNOSTIC_TEST|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
214770993|NCT00397072|DRUG|ZK 219477|
214770994|NCT02964052|OTHER|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
214770995|NCT00566631|DRUG|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
214770996|NCT03801018|OTHER|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
214770997|NCT02076230|DRUG|[14C] TH-302 (Label 1)|\[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
214770998|NCT02076230|DRUG|[14C] TH-302 (Label 2)|\[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
214770999|NCT02076230|DRUG|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
214771000|NCT04335565|OTHER|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
214771001|NCT02968641|DRUG|Lonafarnib|antiviral farnesyltransferase inhibitor
214771002|NCT02968641|DRUG|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
214771003|NCT05954338|DRUG|DWC202307|DWC202307
214771004|NCT05954338|DRUG|DWJ1543|DWJ1543
214771005|NCT05954338|DRUG|DWC202216|DWC202216
214771006|NCT04718727|DRUG|Placebo|oral Placebo tablets one-hour preoperatively
214771007|NCT04718727|DRUG|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
214771008|NCT04718727|DRUG|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
214771009|NCT03387735|OTHER|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
214771010|NCT03387735|BEHAVIORAL|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
214771011|NCT05204849|DEVICE|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
214771012|NCT05204849|PROCEDURE|Standard ventriculostomy|Standard passive external ventricular drainage
214771013|NCT05145647|RADIATION|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.
214771014|NCT05145647|DEVICE|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
214771015|NCT02953418|DEVICE|Radiofrequency ablation|RFA
214771016|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
214771017|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
214771018|NCT03020966|DRUG|Acetaminophen|Oral acetaminophen, intravenous placebo
214771019|NCT03020966|DRUG|Acetaminophen|Intravenous acetaminophen, oral placebo
214771020|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
214771021|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
214771022|NCT00527527|PROCEDURE|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
214771023|NCT00527527|OTHER|placebo control|Placebo for comparison with flexion distraction treatment
214771024|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
214771025|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
214771026|NCT02099331|DRUG|Melatonin|
214771027|NCT02099331|DRUG|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
214771028|NCT04512391|PROCEDURE|Ultrasound guided Erector Spinae Plane Block (ESPB)|Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
214771029|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
214771030|NCT04130594|OTHER|placebo|placebo
214771031|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
214771032|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
214771033|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
214771034|NCT02379650|DRUG|Hydroxychloroquine (HCQ)|
214771035|NCT02379650|DRUG|Placebo|
214771036|NCT01215955|DRUG|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
214771037|NCT01215955|DRUG|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
214771038|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
214771039|NCT02507271|OTHER|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
214771040|NCT02507271|OTHER|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
214771041|NCT04011904|OTHER|Cross-over study|Traditional Inuit Diet vs Westernized Diet
214771042|NCT05485571|DEVICE|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
214771043|NCT02517346|OTHER|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
214771044|NCT02517346|OTHER|Telemonitoring|Follow up by telemonitoring system during 3 months
214771045|NCT00093067|DRUG|daptomycin|
214771046|NCT02912884|DRUG|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
214771047|NCT02258399|BEHAVIORAL|Exercise|Moderate intensity exercise
214771048|NCT02258399|DIETARY_SUPPLEMENT|Breakfast|Breakfast consumption
214771049|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
214771050|NCT03613194|PROCEDURE|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
214771051|NCT02341794|DRUG|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
214771052|NCT00571220|PROCEDURE|gastric bypass surgery|weight loss bariatric surgery
214771053|NCT00571220|OTHER|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
214771054|NCT06376773|PROCEDURE|combination chemotherapy with Apatinib or Camrelizumab|Apatinib, chemotherapy alone, Camrelizumab
214771055|NCT01339468|DRUG|Advagraf|oral
214771056|NCT01339468|DRUG|Prograf|oral
214771057|NCT01339468|DRUG|Prograf|intravenous
214771058|NCT01040546|BEHAVIORAL|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
214771059|NCT01040546|BEHAVIORAL|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
214771060|NCT00396981|DEVICE|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
214771061|NCT00396981|DEVICE|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
214771062|NCT06540924|OTHER|single nucleotide polymorphisms|The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
214771063|NCT02494583|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
214771064|NCT02494583|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
214771065|NCT02494583|DRUG|5-FU|5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
214771066|NCT02494583|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
214771067|NCT02494583|DRUG|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
214771068|NCT01931501|DRUG|Torrent's Montelukast Sodium Chewable Tablets 5mg|
214771069|NCT01931501|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
214771070|NCT06566287|OTHER|Immediate implant|Immediate Implant with Socket Shield Group
214771071|NCT06566287|OTHER|Delayed implant|Delayed Implant with Socket preserved with socket Shield and dentin graft Group
214771072|NCT01749618|BEHAVIORAL|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
214771073|NCT06565832|PROCEDURE|One-Minute Sit-to-Stand Test|This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
214771074|NCT06565832|PROCEDURE|Chester Step Test|This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
214771075|NCT03210142|PROCEDURE|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
214771076|NCT03666299|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
214771077|NCT03666299|DRUG|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
214771078|NCT02993016|PROCEDURE|patient-specific instruments|
214771079|NCT02993016|DEVICE|The Signature™ Vanguard|
214771080|NCT02993016|PROCEDURE|conventional instruments|
214771081|NCT02993016|DEVICE|Vanguard PS(posterior stabilized)|
214771082|NCT05443009|DRUG|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
214771083|NCT05443009|DRUG|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
215030805|NCT02471144|BIOLOGICAL|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
215030806|NCT02471144|BIOLOGICAL|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
214771084|NCT00116129|DRUG|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
214771085|NCT03001869|DRUG|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
214771086|NCT03712046|DIAGNOSTIC_TEST|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
214771087|NCT02102022|DRUG|ADI-PEG 20 plus modified FOLFOX6|
214771088|NCT05785416|OTHER|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
214771089|NCT05785416|OTHER|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
214771090|NCT05348018|DEVICE|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
214771091|NCT05221476|OTHER|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
214771092|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
214771093|NCT02072174|DRUG|Anaferon for Children|Anaferon for children: For oral use.
214771094|NCT02659826|DEVICE|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
214771095|NCT02659826|DEVICE|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
214771096|NCT02659826|DEVICE|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
214771097|NCT02659826|DEVICE|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
214771098|NCT02659826|DEVICE|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
214771099|NCT02659826|DEVICE|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
214771100|NCT02659826|DEVICE|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
214771101|NCT02582359|DRUG|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
214771102|NCT02582359|DRUG|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
214771103|NCT02582359|DRUG|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
215030807|NCT02311803|PROCEDURE|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
215030808|NCT02311803|PROCEDURE|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
215030809|NCT02572531|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
215030810|NCT02572531|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
215030811|NCT04271800|BIOLOGICAL|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
215030812|NCT05880212|OTHER|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
214771104|NCT05531838|DEVICE|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
214771105|NCT04331418|DRUG|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
214771106|NCT04331418|PROCEDURE|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
214771107|NCT01563393|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
214771108|NCT01563393|OTHER|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
214771109|NCT04608656|OTHER|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
214771110|NCT04608656|OTHER|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
214771111|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
214771112|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
214771113|NCT03405701|PROCEDURE|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
214771114|NCT03405701|PROCEDURE|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
214771115|NCT04222556|BEHAVIORAL|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
214771116|NCT04222556|BEHAVIORAL|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
214771117|NCT04832178|DIETARY_SUPPLEMENT|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~* S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~* Betaine hydrochloride 250 mg~* Vitamin C 80 mg~* Vitamin B1 1.1 mg~* Vitamin B2 1.4 mg~* Vitamin B6 1.4 mg~* Vitamin B12 2,5 µg~* Folic Acid 200 µg~* Selenium 37 µg"
214771118|NCT04832178|OTHER|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
214771119|NCT06568770|DRUG|USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK|"With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected"
214771120|NCT06568770|DRUG|PERICAPSULAR NERVE BLOCK|"an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected."
214771121|NCT03884907|PROCEDURE|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
214771122|NCT03821688|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass
214771123|NCT03821688|PROCEDURE|OAGB|one anastomosis gastric bypass
214771124|NCT03821688|PROCEDURE|LSG|laproscopic sleeve gastrectomy
214771125|NCT00004086|BIOLOGICAL|filgrastim|
214771126|NCT00004086|DRUG|cisplatin|
214771127|NCT00004086|DRUG|cytarabine|
214771128|NCT00004086|DRUG|etoposide|
214771129|NCT00004086|DRUG|ifosfamide|
214771130|NCT00004086|PROCEDURE|autologous bone marrow transplantation|
214771131|NCT00004086|PROCEDURE|peripheral blood stem cell transplantation|
214771132|NCT00004086|RADIATION|indium In 111 LL2 IgG|
214771133|NCT00004086|RADIATION|yttrium Y 90 epratuzumab|
214771134|NCT02515461|DEVICE|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
214771135|NCT00921765|DRUG|Saline|Saline single bolus dose followed by saline single bolus dose iv
214771136|NCT00921765|DRUG|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
214771137|NCT00921765|DRUG|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
214771138|NCT00921765|DRUG|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
214771139|NCT02192541|DRUG|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
214771140|NCT02192541|DRUG|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
214771141|NCT05467709|DRUG|Midazolam|2 mg Day 1 and Day 16
214771142|NCT05467709|DRUG|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
214771143|NCT02127229|PROCEDURE|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
214771144|NCT01519895|BEHAVIORAL|Telephone intervention|counseling and education support
214771145|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
214771146|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
214771147|NCT04752085|DIAGNOSTIC_TEST|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
214771148|NCT02460133|DRUG|Paritaprevir|
214771149|NCT02460133|DRUG|Ritonavir|
214771150|NCT02460133|DRUG|Dasabuvir|
214771151|NCT02460133|DRUG|Ombitasvir|
214771152|NCT02460133|DRUG|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
214771153|NCT00196573|PROCEDURE|Shoulder bursectomy alone|
214771154|NCT06563973|OTHER|Milk odor|One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
214771155|NCT06563973|OTHER|Pacifier|To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
214771156|NCT00425282|DRUG|RWJ-333369|
214771157|NCT04143477|DRUG|peficitinib|Oral
214771158|NCT01272739|DIETARY_SUPPLEMENT|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
214771159|NCT01272739|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
214771160|NCT06701981|OTHER|Filter comparison|Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device
214771161|NCT00003981|DRUG|indisulam|
214771162|NCT06290258|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
214771163|NCT02357407|DRUG|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
214771164|NCT02357407|DRUG|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
214771165|NCT01456871|PROCEDURE|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
214771166|NCT01456871|PROCEDURE|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
214771167|NCT02756078|DEVICE|TEST Contact Lens|
214771168|NCT02756078|DEVICE|CONTROL Contact Lens|
214771169|NCT00005893|DRUG|anti-thymocyte globulin|
214771170|NCT00005893|DRUG|busulfan|
214771171|NCT00005893|DRUG|cyclophosphamide|
214771172|NCT00005893|PROCEDURE|Bone marrow transplantation|
214771173|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
214771174|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
214771175|NCT05349188|OTHER|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
214771176|NCT02528630|OTHER|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
214771177|NCT02528630|OTHER|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
214771178|NCT05860608|DEVICE|Us2.ai (AI-enabled report) handheld echocardiogram|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
214771179|NCT05605457|DEVICE|PRG barrier coat + nanohybrid composite|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
214771180|NCT05605457|DEVICE|resin modified glass ionomer|RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction
214771181|NCT06066866|OTHER|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
214771182|NCT00943384|DEVICE|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
214771183|NCT00574379|DRUG|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
214771184|NCT00574379|DRUG|Placebo|Placebo tablets twice daily for 14 days
214771185|NCT06566066|OTHER|no intervention|register study without intervention
214771186|NCT00553033|PROCEDURE|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
214771187|NCT01920074|DRUG|Nitroglycerin Ointment 0.4%|
214771188|NCT03821831|DEVICE|Continuous Positive Airway Pressure|CPAP machine
214771189|NCT03821831|DEVICE|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
214771190|NCT05324709|BEHAVIORAL|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
214771191|NCT01210885|BIOLOGICAL|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
214771192|NCT04004273|BEHAVIORAL|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
214771193|NCT05409599|OTHER|Exercises|Exercises
214771194|NCT00438685|BEHAVIORAL|Outpatient MST/OPTION-A|
214771195|NCT00438685|BEHAVIORAL|Usual Services|
214771196|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM)|
214771197|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).|
214771198|NCT00213031|DRUG|Carraguard (PC-515)|
214771199|NCT01890018|BEHAVIORAL|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
214771200|NCT01890018|BEHAVIORAL|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
214771201|NCT01890018|BEHAVIORAL|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
214771202|NCT06439615|DRUG|Baricitinib 4 MG|Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
214771203|NCT06439615|OTHER|Standard treatment|Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
214771204|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
214771205|NCT02275039|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
214771206|NCT02275039|DRUG|gemcitabine hydrochloride|Given IV
214771207|NCT02275039|OTHER|laboratory biomarker analysis|Correlative studies
214771208|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
214771209|NCT03259867|DRUG|Nivolumab Injectable Product|a PD-1 immune check inhibitor
214771210|NCT03259867|COMBINATION_PRODUCT|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
214771211|NCT03023007|PROCEDURE|Loco-regional anaesthesia|Loco-regional anaesthesia
214771212|NCT03304990|OTHER|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
214771213|NCT04036786|BEHAVIORAL|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
214771214|NCT04036786|BEHAVIORAL|standard care|standard pregnancy follow up
214771215|NCT00835068|OTHER|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
214771216|NCT05117073|DIAGNOSTIC_TEST|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
214771217|NCT01419873|DRUG|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
214771218|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
214771219|NCT05008419|BEHAVIORAL|Narrative discourse treatment|The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
214771220|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
214771221|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
214771222|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
214771223|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
214771224|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
214771225|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
214771226|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
214771227|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
214771228|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
214771229|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
214771230|NCT01280305|DRUG|placebo|Placebo bid
214771231|NCT00101374|DRUG|Leflunomide|
214771232|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
214771233|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
214771234|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
214771235|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
214771236|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
214771237|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
214771238|NCT02575807|DRUG|Epacadostat|PO BID
214771239|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
214771240|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
214771241|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
214771242|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
214771243|NCT02180659|DRUG|sublingual buprenorphine tablets|
214771244|NCT02180659|DRUG|Buprenorphine implant|
214771245|NCT02180659|DRUG|placebo implants|
214771246|NCT02180659|DRUG|sublingual placebo tablets|
214771247|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
214771248|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
214771249|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
214771250|NCT04265209|DRUG|SPECT|\[123I\]-FP-CIT SPECT imaging procedure
214771251|NCT04265209|DRUG|PET|\[18F\] LBT-999 PET imaging procedure
214771252|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
214771253|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
214771254|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
214771255|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
214771256|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
214771257|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
214771258|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
214771259|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
214771260|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
214771261|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
214771262|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
214771263|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
214771264|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
214771265|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
214771266|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
214771267|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
214771268|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
214771269|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
214771270|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
214771271|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
214771272|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
214771273|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
214771274|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
214771275|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
214771276|NCT05153590|DRUG|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
214771277|NCT04473729|OTHER|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
214771278|NCT01413152|BIOLOGICAL|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
214771279|NCT02619370|BEHAVIORAL|Conversation card game|
214771280|NCT02619370|BEHAVIORAL|Active Control|
214771281|NCT04356092|DIAGNOSTIC_TEST|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
214771282|NCT02959554|DRUG|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
214771283|NCT02959554|DRUG|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
214771284|NCT02959554|DRUG|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
214771285|NCT01158976|DIETARY_SUPPLEMENT|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
214771286|NCT01158976|OTHER|Placebo|soybean oils with strawberry flavoring
214771287|NCT03147001|OTHER|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
214771288|NCT03147001|OTHER|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
214771289|NCT00769431|OTHER|educational intervention|
214771290|NCT00769431|OTHER|study of socioeconomic and demographic variables|
214771291|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
214771292|NCT02978729|OTHER|Telephone remote genetic counseling|
214771293|NCT03422796|DRUG|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214771294|NCT03422796|DRUG|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214771295|NCT03422796|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
214771296|NCT06539286|DEVICE|Laser Irradiation|three different laser wavelengths will be used
214771297|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
214771298|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
214771299|NCT05186727|OTHER|Family History education|The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
214771300|NCT05186727|OTHER|Patient Ambassador|The support of a Patient Ambassador in addition to the education is also tested.
214771301|NCT00481871|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
214771302|NCT00481871|DRUG|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
214771303|NCT00481871|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
214771304|NCT00481871|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
214771305|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
214771306|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
214771307|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
214771308|NCT01411475|OTHER|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
214771309|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
214771310|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
214771311|NCT01395693|DEVICE|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
214771312|NCT03332212|DRUG|Empagliflozin|12 weeks
214771313|NCT03332212|DRUG|Placebo|12 Weeks
214771314|NCT03311386|DRUG|Actilyse|thrombolytic therapy
214771315|NCT06017856|OTHER|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
214771316|NCT03273010|PROCEDURE|Free gingival graft|Free gingival graft was harvested from palatal donor site
214771317|NCT03273010|PROCEDURE|Cyanoacrylate application|Periacyrl was applied on palatal wounds
214771318|NCT01807910|DRUG|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
214771319|NCT04381468|DRUG|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
214771320|NCT04381468|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
214771321|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
214771322|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
214771323|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
214771324|NCT01923961|PROCEDURE|HDF NaCl|
214771325|NCT01923961|PROCEDURE|Hemodialysis|
214771326|NCT01923961|PROCEDURE|Standard Predilution Hemodiafiltration|
214771327|NCT00607906|DRUG|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
214771328|NCT00607906|DRUG|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
214771329|NCT00607906|DRUG|Placebo|Subjects will also receive placebo capsules.
214771330|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
214771331|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
214771332|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
214771333|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
214771334|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
214771335|NCT00397904|BIOLOGICAL|cetuximab|
214771336|NCT00397904|DRUG|cisplatin|
214771337|NCT00397904|DRUG|irinotecan hydrochloride|
214771338|NCT00397904|OTHER|immunohistochemistry staining method|
214771339|NCT00397904|OTHER|laboratory biomarker analysis|
214771340|NCT00397904|PROCEDURE|biopsy|
214771341|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
214771342|NCT02058368|DRUG|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
214771343|NCT02058368|DRUG|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
214771344|NCT02058368|DRUG|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
214771345|NCT02058368|DRUG|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
214771346|NCT04141670|DRUG|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
214771347|NCT02591316|OTHER|no intervention|
214771348|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
214771349|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
214771350|NCT06354959|BEHAVIORAL|Prehabilitation|8-week community based prehab program
214771351|NCT05945147|DRUG|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
214771352|NCT05945147|DRUG|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
214771353|NCT05945147|DRUG|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
214771354|NCT06564467|DRUG|JMT202|subcutaneous injection
214771355|NCT06564467|DRUG|Placrbo|subcutaneous injection
214771356|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
214771357|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
214771358|NCT05719129|BEHAVIORAL|Date With Destiny (DWD) Seminar|6 days of immersive seminar
214771359|NCT03681275|DRUG|Tofacitinib 10 MG [Xeljanz]|administered twice daily for two days
214771360|NCT03681275|DRUG|Placebo to match Tofacitinib|administered twice daily for two days
214771361|NCT04824300|PROCEDURE|erector spinae block|Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
214771362|NCT05072145|OTHER|Telemedicine|Receiving care in a tele-ED hospital
214771363|NCT01217567|PROCEDURE|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
214771364|NCT01217567|PROCEDURE|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
214771365|NCT00719758|DRUG|TRK-100STP (BERASUS LA)|oral
214771366|NCT00719758|DRUG|AST-120 (Kremezin®)|oral
214771367|NCT06702358|OTHER|Potential Therapeutic Implications of laser Acupoints on Visceral Fat and Hormonal Changes in Post-menopausal Women|Application of laser acupuncture ( E M E ) on 10 acupuncture procedure for each woman which will be detected by therapist according to Acupuncture points Will stimulate St 25 (Tianshu), St 36 (Zusanli), Liv 3 (Taichong); P 6 (Neiguan), H 7 (Shenmen) for the psychical aspect of the therapy and Auriculothera- py: 55 (Shenmen) and 87 (Stomach) Each point stimulating will be Stimulation time, 30 s/point
214771368|NCT01652872|BIOLOGICAL|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
214771369|NCT01652872|OTHER|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
214771370|NCT02184169|DEVICE|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
214771371|NCT02184169|DEVICE|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
214771372|NCT02790372|OTHER|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
214771373|NCT03173521|BIOLOGICAL|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
214771374|NCT04179123|DEVICE|Customised PAP interfaces|Customised PAP interfaces
214771375|NCT04681495|BEHAVIORAL|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
214771376|NCT06567990|DIAGNOSTIC_TEST|Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.|"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"
214771377|NCT02542722|BEHAVIORAL|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
214771378|NCT02542722|BEHAVIORAL|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
214771379|NCT00713622|DRUG|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
214771380|NCT00713622|DRUG|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
214771381|NCT03857139|DRUG|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
214771382|NCT04529096|DRUG|LY3016859|Administered IV
214771383|NCT04529096|DRUG|Placebo|Administered IV
214771384|NCT01216319|DEVICE|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
214771385|NCT04663711|BEHAVIORAL|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
214771386|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
214771387|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
214771388|NCT01695837|BEHAVIORAL|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
214771389|NCT02357173|OTHER|electronic cigarette|
214771390|NCT02357173|OTHER|cigarette group|
214646155|NCT05673941|OTHER|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
214771391|NCT06541106|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma."
214771392|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
214771393|NCT03447054|BEHAVIORAL|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
214771394|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
214771395|NCT03447054|BEHAVIORAL|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
214771396|NCT03087929|OTHER|Follow up|
214771397|NCT05692739|DRUG|Insulin|see arm description
214771398|NCT05692739|DRUG|Cyclosporins|see arm description
214771399|NCT05692739|DRUG|Artificial tears|see arm description
214771400|NCT04483570|PROCEDURE|Redo-tethering operation|
214771401|NCT00390572|BEHAVIORAL|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
214771402|NCT05405478|DRUG|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
214771403|NCT05405478|DIAGNOSTIC_TEST|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
214771404|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
214771405|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
214771406|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
214771407|NCT00823875|DRUG|control group|routine treatment
214771408|NCT06025487|BIOLOGICAL|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
214771409|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
214771410|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
214771411|NCT02392559|DRUG|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
214771412|NCT02392559|DRUG|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
214771413|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
214771414|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
214771415|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
214771416|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
214771417|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
214771418|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
214771419|NCT01966107|DRUG|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
214646156|NCT05060757|DIAGNOSTIC_TEST|biotax|patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample
214646157|NCT06176937|DRUG|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
214646158|NCT06176937|OTHER|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
214646159|NCT05860348|DEVICE|Barostim™ System|Implantation of the Barostim™ System
214646160|NCT00738478|DEVICE|nasogastric tube|insertion of nasogastric tube for 2 days after operation
214646161|NCT00738478|DEVICE|without nasogastric tube|without nasogastric tube after operation
214646162|NCT00883532|DRUG|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated
214646163|NCT00883532|DRUG|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
214646164|NCT03885128|DEVICE|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
214646165|NCT03885128|DEVICE|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
214646166|NCT03344003|DRUG|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
214646167|NCT04686630|OTHER|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
214646168|NCT04431830|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
214646169|NCT05455047|DIAGNOSTIC_TEST|PET-CT at 18F-FDG|PET-CT at 18f6FDG in nuclear medicine departement of Nancy's hospital
214646170|NCT01678183|BEHAVIORAL|Monthly Financial Incentive|A cash payment.
214646171|NCT01678183|BEHAVIORAL|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
214646172|NCT02456428|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646173|NCT02456428|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646174|NCT02456428|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
214646175|NCT02456428|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646176|NCT02456428|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646177|NCT02456428|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646178|NCT02456428|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214646179|NCT02456428|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
214646180|NCT00030342|BIOLOGICAL|recombinant interferon alfa|
214646181|NCT00030342|BIOLOGICAL|sargramostim|
214646182|NCT00030342|BIOLOGICAL|therapeutic autologous lymphocytes|
214646183|NCT00030342|DRUG|fluorouracil|
214771420|NCT01966107|DRUG|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
214771421|NCT00538707|BEHAVIORAL|2-minute Bondet test|2-minute Bondet test
214771422|NCT00532779|DRUG|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
214771423|NCT00532779|DRUG|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
214771424|NCT00532779|DRUG|Placebo|
214771425|NCT00532779|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
214771426|NCT02246231|DEVICE|MR imaging|
214771427|NCT03138135|BEHAVIORAL|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
214771428|NCT03138135|BEHAVIORAL|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
214771429|NCT00689273|DRUG|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
214771430|NCT00689273|DRUG|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
214771431|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
214771432|NCT03676673|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
214771433|NCT01238172|OTHER|dietary education and counseling|
214771434|NCT01238172|OTHER|prostate cancer foundation booklet|
214771435|NCT01556165|DRUG|rasagiline|1 mg/day, tablets, once daily, orally
214771436|NCT01556165|DRUG|placebo|tablets, once daily, orally
214771437|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
214771438|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
214771439|NCT02639195|OTHER|Treatment|Retrospective chart review of patients treated with manual therapy.
214771440|NCT02531698|BIOLOGICAL|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
214771441|NCT02531698|BIOLOGICAL|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
214771442|NCT02531698|OTHER|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
214771443|NCT05268965|BEHAVIORAL|Experimental: group comparison|"* Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality"
214771444|NCT00701558|DRUG|Erlotinib|150 mg po daily
214771445|NCT00701558|DRUG|Gemcitabine|1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
214771446|NCT05481554|BIOLOGICAL|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
214771447|NCT00116376|DRUG|AEE788|
214771448|NCT00395200|PROCEDURE|MSC Treatment|Intravenous administration of up to 2x10\^6 autologous MSCs per kg
214771449|NCT03485508|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
214771450|NCT03943407|DRUG|Zyclara 3.75 % Topical Cream|The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
214771451|NCT03943407|DRUG|Prudoxin|The anti-histamine cream Prudoxin, containing 5% doxepin hydrochloride (1 g contains 50 mg of doxepin) (Healthpoint, San Antonio, TX) will be applied on the volar forearm. Two adhesive patches 4×4 cm (1mm thick, 3M foam adhesive tape, 3M, St. Paul, MN) each with a 3.5×3.5 cm center cut out (to deposit 1.2 grams of cream) will be each placed 3 cm distal and 3 cm proximal to the center of the volar aspect of each arm. Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1 h and 30 minutes.
214771452|NCT03943407|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction. . A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
214771453|NCT03943407|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip. The active substance delivered (mucunain) has been calculated to be in the nanogram range. The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
214771454|NCT03943407|OTHER|L-menthol|L-menthol (≥99.9%, TRPM8 agonist; (Sigma Aldrich, Broendby, Denmark) is dissolved in 96% ethanol at concentrations of 40%(w/v) L-menthol. A 1 mL aliquot is dispensed onto a 3 × 3 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape. In between the cotton pad and the medical tape, a layer of parafilm will be added to avoid evaporation. This configuration was subsequently applied for 1 h.
214771455|NCT03943407|OTHER|Trans-cinnamaldehyde (CA)|CA will be obtained from Sigma Aldrich (Brøndby, Denmark) and dissolved in 90% ethanol at a concentration of 10% (vol/vol) CA. One ml aliquot of CA is dispensed onto a 3x3 cm cotton pad and placed on a 5x5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic film will be added to inhibit the evaporation of the solutions. This configuration will be applied for 1 h.
214771456|NCT05531591|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
214771457|NCT05531591|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
214771458|NCT05531591|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
214771459|NCT05531591|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
214771460|NCT05531591|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
214771461|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
214771462|NCT05021120|DRUG|AK127|Subjects will receive AK127 by intravenous administration
214771463|NCT05021120|DRUG|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
214771464|NCT06701084|GENETIC|Genomic Sequencing|Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.
214771465|NCT06700681|DRUG|Propofol|TIVA induction and maintain with Propofol.
214771466|NCT06700681|DRUG|Remimazolam|TIVA induction and maintain with Remimazolam.
214771467|NCT06700681|DEVICE|With intubation and controlled ventilation to maintain airway|Patient receives intubation and controlled ventilation to maintain airway.
214771468|NCT06700681|DEVICE|Maintain spontaneous ventilation without intubation|Patient maintains spontaneous ventilation without intubation.
214771469|NCT06701123|DEVICE|uMAT-R mobile app with coaching component|uMAT-R recovery mobile app with coaching component
214771470|NCT06702267|DEVICE|arterial blood samplers with needles PICO70 and safePICO syringes.|"PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation.~safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle."
214771471|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
214771472|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
214771473|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
214771474|NCT06713954|BEHAVIORAL|Dietary assessment|Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
214771475|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
214771476|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
214771477|NCT06702514|OTHER|Exercise|After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
214771478|NCT06702514|OTHER|Paraffin|It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
214771479|NCT06702514|OTHER|Balneotherapy|The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
214771480|NCT06703086|DIETARY_SUPPLEMENT|Berberine Hydrochloride group|The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.
214771481|NCT06703086|BEHAVIORAL|nutritional plan|nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months
214771482|NCT06703086|BEHAVIORAL|controlled moderate aerobic exercise|controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.
214771483|NCT06702475|DIAGNOSTIC_TEST|Home Sleep Test with Watch PAT-one|Each participant will have a Watch-PAT one home sleep test, recording pulse oximetry, pulse tonometry, wrist actigraphy, snoring (by microphone), and chest motion by accelerometer.
214771484|NCT06703515|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
214771485|NCT06703515|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
214771486|NCT06703294|PROCEDURE|Crow's feet injection filling|Patients with crow's feet of different degree were randomly divided into two groups, which were injected with bovine collagen and humanized collagen respectively
214771487|NCT06703294|PROCEDURE|Humanized collagen filling crow's feet|Bovine collagen filling crow's feet
214771488|NCT06713967|PROCEDURE|Metformin (Glucophage)|In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
214771489|NCT06713967|PROCEDURE|Standard Care (Diet and Exercise Only)|In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
214771490|NCT06722690|BEHAVIORAL|eTSF|eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
214771491|NCT06722690|BEHAVIORAL|Educational materials|Educational materials on drinking problems and a list of local/online AA meetings.
214771492|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
214771493|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
214771494|NCT06722131|OTHER|Sampling|"Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)"
214771495|NCT06723353|OTHER|Visceral Manipulation Therapy|Visceral Manipulation (VM) is a manual therapy consisting of gentle, specifically placed manipulations that encourage normal mobility, tone, and inherent tissue motion of the viscera and their connective tissues. These manipulations can potentially improve the structural integrity of the abdominal cavity and enhance the physiological functioning of the organs. VM will be administered by certified therapists trained in this specialized technique, focusing on reducing the Inter-Recti Distance (IRD) and associated symptoms of DRA.
214771496|NCT06723353|OTHER|Abdominal Kinesio Taping|Kinesio Taping (KT) involves the application of a thin, stretchable tape over and around muscles to enhance function, reduce inflammation, and support muscles in movement on a 24hr/day basis. It is non-restrictive, allowing for full range of motion. In this study, KT will be applied in a crisscross pattern across the abdomen to support the abdominal muscles affected by DRA, potentially aiding in muscle function and reducing pain and discomfort.
214771497|NCT06723353|OTHER|Combined Visceral Manipulation and Kinesio Taping|This intervention combines Visceral Manipulation and Kinesio Taping to leverage the benefits of both modalities. The combination aims to enhance the functional and structural support of the abdominal region by improving organ function through VM and providing muscular support through KT. This dual approach is hypothesized to offer a synergistic benefit, potentially providing a more effective treatment for reducing IRD and improving overall abdominal function.
214771498|NCT06723353|OTHER|Postpartum Core Strengthening Program|The Core Strengthening Program is designed to strengthen the deep core muscles, including the transverse abdominis, multifidus, and the pelvic floor muscles. Exercises will be tailored to accommodate postpartum women and will be progressively adjusted to match improvements in strength and endurance. The program includes supervised training sessions focusing on enhancing core stability, which is crucial for postpartum recovery and long-term spinal and pelvic health.
214771499|NCT06722573|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214771500|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash without erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash without erythritol.
214771501|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash with erythritol.
214771502|NCT06723054|OTHER|high fluoride 500 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a high fluoride 500 ppm F mouthwash with erythritol.
214771503|NCT06723782|BIOLOGICAL|AMTRIX-D|Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
214771504|NCT06722404|DIETARY_SUPPLEMENT|Standard therapeutic foods|All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days
214771505|NCT06722404|COMBINATION_PRODUCT|Therapeutic foods plus Synbiotics|the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
214771506|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
214771507|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
214771508|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
214771509|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
214771510|NCT04796142|OTHER|medication reconciliation|medication reconciliation
214771511|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
214771512|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
214771513|NCT05366725|DRUG|Avelumab|As provided in real world practice
214771514|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
214771515|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
214771516|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
214771517|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
214771518|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
214771519|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
214771520|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
214771521|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
214771522|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
214771523|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
214771524|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
214771525|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
214771526|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
214771527|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
214771528|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
214771529|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
214771530|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
214771531|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
214771532|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
214771533|NCT04032522|OTHER|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
214771534|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
214771535|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
214771536|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
214771537|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
214771538|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
214771539|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
214771540|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
214771541|NCT02937285|DRUG|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
214771542|NCT02937285|DRUG|Mitoxantrone|10 mg / m² monthly infusion for 6 months
214771543|NCT04338256|BEHAVIORAL|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
214771544|NCT00572468|DRUG|Simvastatin|40 mg of simvastatin
214771545|NCT00572468|OTHER|Placebo|placebo
214771546|NCT05900739|BEHAVIORAL|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
214771547|NCT00736138|PROCEDURE|training and pellots|training and pellots
214771548|NCT03969979|DIAGNOSTIC_TEST|Shear wave elastography|shear wave elastogrophy will be performed
214771549|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
214771550|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
214771551|NCT03427788|DRUG|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
214771552|NCT03427788|DRUG|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
214771553|NCT00228332|DRUG|Administration of zinkgluconaat or placebo|
214771554|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
214771555|NCT05340842|OTHER|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
214771556|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
214771557|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
214771558|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
214771559|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
214771560|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
214771561|NCT03877484|DEVICE|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
214771562|NCT05302700|BEHAVIORAL|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
214771563|NCT06317337|OTHER|focused ultrasound cavitation augmented with aerobic exercises|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
214771564|NCT05673915|DEVICE|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
214771565|NCT05673915|DEVICE|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
214771566|NCT02026882|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
214771567|NCT05983029|DIAGNOSTIC_TEST|Intergluteal Cleft|Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line
214771568|NCT05983029|DIAGNOSTIC_TEST|Neuraxial Midline|Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line
214771569|NCT05983029|DIAGNOSTIC_TEST|Horizontal Distance between Vertical Markings|The horizontal distance between these two vertical marks will be measured at the level of the intercristal line
214771570|NCT04445129|DEVICE|Portable EEG Device|Portable EEG device is lightweight and designed for nighttime wear.
214771571|NCT04445129|DEVICE|Portable ECG Device|Portable ECG device is waterproof and will be adhered to the chest of the participant.
214771572|NCT04445129|DEVICE|Accelerometry|Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
214771573|NCT01393717|DRUG|brentuximab vedotin|Given IV
214771574|NCT01660490|PROCEDURE|ORIF|Open reduction internal fixation of the proximal femur
214771575|NCT02406703|DRUG|Chloroprocaine|
214771576|NCT02406703|DRUG|Mepivacaine|
214771577|NCT00731510|DIETARY_SUPPLEMENT|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
214771578|NCT00731510|DIETARY_SUPPLEMENT|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
214771579|NCT04252508|OTHER|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
214771580|NCT05000918|DIETARY_SUPPLEMENT|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
214771581|NCT03149965|OTHER|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
214771582|NCT04794400|OTHER|oxygen mask|All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
214771583|NCT05761132|DRUG|Pembrolizumab|neoadjuvant immunotherapy
214771584|NCT04739852|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
214771585|NCT01664000|DRUG|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
214771586|NCT04461652|PROCEDURE|prophylactic air-extraction catheter drainage|This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
214771587|NCT05066100|OTHER|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
214771588|NCT04876859|PROCEDURE|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
214771589|NCT04876859|PROCEDURE|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
214771590|NCT03046537|DIAGNOSTIC_TEST|Breath test|Collecting breath test from participants
214771591|NCT03963856|OTHER|parbolic flight|weightlessness during parabolic flight
214771592|NCT01741909|BEHAVIORAL|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
214771593|NCT04408300|PROCEDURE|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
214771594|NCT02269007|BIOLOGICAL|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
214771595|NCT01739088|OTHER|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
214771596|NCT01739088|OTHER|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
214771597|NCT05318807|OTHER|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~1. Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~2. Patient Activation Measure - to measure patient activation~3. Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~4. Patient Generated Subjective Global Assessment - to identify malnutrition risk~5. Emotions thermometer - to detect emotional disorders and identify risk"
214771598|NCT05318807|OTHER|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~* Review the initial questionnaires to inform the personalised plan and goal setting~* Complete a further four questionnaires related to quality of life, diet and exercise~* Measure handgrip strength~* Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
214771599|NCT05318807|OTHER|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
214771600|NCT01286688|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
214771601|NCT02038959|OTHER|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
214771602|NCT00005578|BIOLOGICAL|bleomycin sulfate|
214771603|NCT00005578|BIOLOGICAL|filgrastim|
214771604|NCT00005578|DRUG|cyclophosphamide|
214771605|NCT00005578|DRUG|dexrazoxane hydrochloride|
214771606|NCT00005578|DRUG|doxorubicin hydrochloride|
214771607|NCT00005578|DRUG|etoposide|
214771608|NCT00005578|DRUG|prednisone|
214771609|NCT00005578|DRUG|vincristine sulfate|
214771610|NCT00005578|RADIATION|radiation therapy|
214771611|NCT04738188|PROCEDURE|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
214771612|NCT04738188|PROCEDURE|cTACE|Transcatheter arterial chemoembolization
214771613|NCT04738188|DEVICE|Drug-eluting Beads|Drug-eluting beads
214771614|NCT04738188|DRUG|Epirubicin|Chemotherapy drug for intra-arterial infusion
214771615|NCT00534209|BIOLOGICAL|Allogeneic B7.1/HLA-A1|Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
214771616|NCT00534209|OTHER|Placebo|Given intradermally
214771617|NCT00646256|BEHAVIORAL|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
214771618|NCT03233737|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
214771619|NCT03233737|DEVICE|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
214771620|NCT03233737|DEVICE|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
214771621|NCT02083588|DEVICE|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
214771622|NCT04901871|DRUG|0.02 mg/kg, age<65|Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
214771623|NCT04901871|DRUG|0.07 mg/kg, age<65|Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
214771624|NCT04901871|DRUG|0.12 mg/kg, age<65|Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
214771625|NCT04901871|DRUG|0.17 mg/kg, age<65|Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
214771626|NCT04901871|DRUG|0.22 mg/kg, age<65|Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
214771627|NCT04901871|DRUG|0.27 mg/kg, age<65|Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
214771628|NCT04901871|DRUG|0.02 mg/kg, age≥65|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
214771629|NCT04901871|DRUG|0.07 mg/kg, age≥65|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
214771630|NCT04901871|DRUG|0.12 mg/kg, age≥65|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
214771631|NCT04901871|DRUG|0.17 mg/kg, age≥65|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
214771632|NCT04901871|DRUG|0.22 mg/kg, age≥65|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
214771633|NCT04901871|DRUG|0.27 mg/kg, age≥65|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
214771634|NCT02080533|OTHER|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
214771635|NCT03117777|BEHAVIORAL|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
214771636|NCT01638754|PROCEDURE|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
214771637|NCT01638754|PROCEDURE|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
214771638|NCT01136005|OTHER|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
214771639|NCT01136005|OTHER|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
214771640|NCT01561586|DRUG|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
214771641|NCT01561586|DRUG|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
214771642|NCT00245427|DRUG|all macrolide antibiotics|Varies based on antibiotic
214771643|NCT00245427|DRUG|all beta-lactam antibiotics|Varies based on antibiotic
214771644|NCT03533920|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
214771645|NCT02759627|OTHER|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training."
214771646|NCT04395131|DEVICE|Clearum HF Hemodialyzer|the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
214771647|NCT02757131|OTHER|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
214771648|NCT06282068|DIAGNOSTIC_TEST|AI computer-aided detection software|non-invasive
214771649|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
214771650|NCT00872573|DEVICE|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
214771651|NCT03725267|DRUG|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
214771652|NCT03725267|DRUG|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
214771653|NCT04619472|DEVICE|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
214771654|NCT05543863|DIAGNOSTIC_TEST|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
214771655|NCT01788163|GENETIC|EGFR mutation test|EGFR mutation being tested in tissue and blood
214771656|NCT00545441|DEVICE|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
214771657|NCT00545441|DEVICE|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
214771658|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
214771659|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
214771660|NCT00650637|DRUG|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
214771661|NCT00650637|DRUG|nelfinavir|1250 mg twice a day
214771662|NCT00650637|DRUG|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
214771663|NCT00650637|DRUG|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
214771664|NCT00650637|OTHER|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
214771665|NCT00650637|DRUG|nelfinavir|nelfinavir 1250 mg twice a day
214771666|NCT00650637|DRUG|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
214771667|NCT00265239|DRUG|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
214771668|NCT06700434|OTHER|Bleaching treatment|"After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session."
214771669|NCT04095819|PROCEDURE|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
214771670|NCT04095819|PROCEDURE|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
214771671|NCT04704817|OTHER|obsevation|prospective data collection for colonic or rectal surgery
214771672|NCT02773641|DRUG|Botulinum Toxin Type A|
214771673|NCT02773641|DRUG|Sterile Saline Solution|
214771674|NCT03596879|BEHAVIORAL|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
214771675|NCT03596879|BEHAVIORAL|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
214771676|NCT06211803|DIAGNOSTIC_TEST|Positron-Emission Tomography Imaging|Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
214771677|NCT06701110|DRUG|[U-14C] WX-081|A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
214771678|NCT02298595|DRUG|cisplatin|75 mg/m2 IV day 1 of each cycle
214771679|NCT02298595|DRUG|Cetuximab|XXXX day 1, 8, and 15 of each cycle
214771680|NCT02298595|DRUG|BYL719|200, 250, 300, or 350 mg/day by mouth every day
214771681|NCT03610646|DRUG|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
214771682|NCT03610646|DRUG|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
214771683|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
214771684|NCT02532023|DIETARY_SUPPLEMENT|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
214771685|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
214771686|NCT02532023|DIETARY_SUPPLEMENT|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
214771687|NCT05877235|DIETARY_SUPPLEMENT|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
214771688|NCT05877235|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 60 days
214771689|NCT04460521|DRUG|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
214771690|NCT04460521|DEVICE|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
214771691|NCT00467038|BEHAVIORAL|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
214771692|NCT02803138|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
214771693|NCT02803138|DRUG|Dasabuvir|Tablet
214771694|NCT02803138|DRUG|Ribavirin|Tablet
214771695|NCT02803138|BEHAVIORAL|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
214771696|NCT06576375|DRUG|Dapagliflozin|oral Dapagliflozin
214771697|NCT06576375|DRUG|Metformin|oral metformin
214771698|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
214771699|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
214771700|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
214771701|NCT00792675|OTHER|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
214771702|NCT02719015|DRUG|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
214771703|NCT02719015|DRUG|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
214771704|NCT00424515|DRUG|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
214771705|NCT05204628|DRUG|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
214771706|NCT05204628|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
214771707|NCT06408454|DIAGNOSTIC_TEST|Gingival crevicular fluid collection|Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
214771708|NCT06408454|DIAGNOSTIC_TEST|periodontal test|A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
214771709|NCT06537908|DRUG|Anti-PD-1/PD-L1 antibodies|Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
214771710|NCT06537908|DRUG|Anti-VEGF|Anti-VEGF Intravenous injection for at least 6 months
214771711|NCT01133444|DRUG|Finasteride|Finasteride tablets 1 mg
214771712|NCT03402165|DRUG|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir|Response to DAAD's and developing HCC
214771713|NCT00111774|DRUG|ABX-EGF|
214771714|NCT02095626|DRUG|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
214771715|NCT02095626|DRUG|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
214771716|NCT04256057|DRUG|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
214771717|NCT00267020|DRUG|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
214771718|NCT00267020|DRUG|gemcitabine|1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
214771719|NCT01283373|DRUG|DSTP3086S|DSTP3086S administered intravenously
214771720|NCT01283373|DRUG|DSTP3086S|Escalating intravenous dose
214771721|NCT00013182|BEHAVIORAL|social activity|
214771722|NCT00276731|DRUG|carboplatin|
214771723|NCT00276731|DRUG|cisplatin|
214771724|NCT00276731|DRUG|cyclophosphamide|
214771725|NCT00276731|DRUG|etoposide|
214771726|NCT00276731|DRUG|vincristine sulfate|
214771727|NCT00276731|PROCEDURE|conventional surgery|
214771728|NCT00276731|PROCEDURE|neoadjuvant therapy|
214771729|NCT00276731|RADIATION|radiation therapy|
214771730|NCT01094873|BIOLOGICAL|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
214771731|NCT01094873|BIOLOGICAL|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
214771732|NCT06084273|OTHER|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
214771733|NCT06084273|OTHER|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
214771734|NCT03851731|DRUG|Naltrexone|Intranasal spray
214771735|NCT03851731|DRUG|Naloxone|Intranasal spray
214771736|NCT03851731|DRUG|Naltrexol|Intranasal spray
214771737|NCT02832882|PROCEDURE|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
214771738|NCT02832882|PROCEDURE|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
214771739|NCT04071366|DRUG|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
214771740|NCT04071366|DRUG|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
214771741|NCT04071366|DRUG|Placebo|Participants will receive placebo twice daily.
214771742|NCT04071366|BIOLOGICAL|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
214771743|NCT00816517|BIOLOGICAL|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
214771744|NCT04023318|BEHAVIORAL|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
214771745|NCT00291512|BEHAVIORAL|Theory-based counseling program|
214771746|NCT05675384|DEVICE|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
214771747|NCT05675384|DEVICE|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
214771748|NCT02941237|DEVICE|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
214771749|NCT04366778|DIAGNOSTIC_TEST|TEM-tPA|325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
214771750|NCT00021229|DRUG|imatinib mesylate|"* Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
214771751|NCT00021229|RADIATION|local irradiation therapy|"* Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
214771752|NCT02306473|DRUG|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
214771753|NCT06004076|OTHER|Release of upper track of deep front fascial line|I will work on upper track of deep front fascial line, I will make release to diaphragm,mediastinum,scalene muscles, scalene fascia,Fascia endothoracic, transversus thoracis,Infrahyoid muscles, fascia pretracheal and Suprahyoid muscles.
214771754|NCT06004076|OTHER|Corrective exercises for upper crossed syndrome|strength for scapular muscles and deep neck flexor
214771755|NCT04386668|OTHER|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
214771756|NCT04386668|OTHER|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
214771757|NCT01380860|PROCEDURE|Colostomy with mesh implantation|Colostomy with mesh implantation
214771758|NCT01380860|PROCEDURE|Simple colostomy|Colostomy with no mesh implantation.
214771759|NCT02278731|OTHER|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
214771760|NCT03774173|DRUG|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
214771761|NCT04911673|BEHAVIORAL|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
214771762|NCT04911673|DIETARY_SUPPLEMENT|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
214771763|NCT02237118|DEVICE|Mepitel One|
214771764|NCT02237118|DEVICE|UrgoTul|
214771765|NCT04090684|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
214771766|NCT05539599|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
214771767|NCT01303588|BEHAVIORAL|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
214771768|NCT01303588|BEHAVIORAL|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
214771769|NCT01001715|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
214771770|NCT01001715|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
214771771|NCT03582007|DRUG|Murepavadin|Murepavadin + ertapenem
214771772|NCT03582007|DRUG|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
214771773|NCT06520228|BEHAVIORAL|Active video games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
214771774|NCT06520228|BEHAVIORAL|Traditional sports games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
214771775|NCT00552227|DRUG|ruboxistaurin|oral 32 mg daily
214771776|NCT00552227|OTHER|placebo|placebo
214771777|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
214771778|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
214771779|NCT02962531|DRUG|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
214771780|NCT00399490|DRUG|RN624 (PF-04383119)|50 mcg/kg
214771781|NCT00149552|DIETARY_SUPPLEMENT|zinc|supplementation with zinc gluconate
214771782|NCT04622865|DRUG|Masitinib|Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.
214771783|NCT04622865|DRUG|Isoquercetin|Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.
214771784|NCT04622865|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
214771785|NCT04500691|OTHER|pain intensity reporting|pain intensity reporting
214771786|NCT06542276|DEVICE|Thermal Vectored Pulsation|The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
214771787|NCT02100527|DRUG|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
214771788|NCT02100527|DRUG|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
214771789|NCT04507529|OTHER|Peer-mentoring|Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
214771790|NCT05801640|OTHER|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
214771791|NCT05801640|OTHER|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
214771792|NCT05617573|PROCEDURE|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
214771793|NCT02828748|OTHER|no intervention in patients treatment, only biopsy taken|
214771794|NCT03371680|DRUG|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
214771795|NCT02525146|OTHER|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
214771796|NCT05135143|COMBINATION_PRODUCT|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
214771797|NCT02065973|BIOLOGICAL|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
214771798|NCT04190966|BEHAVIORAL|Integrated Behavioural therapy|Integrated smoking cessation behavioural therapy
214771799|NCT04190966|DRUG|Integrated Pharmacotherapy|Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
214771800|NCT04190966|DEVICE|Integrated Web-based application|Integrated smoking cessation web-based application
214771801|NCT00003673|DRUG|chemotherapy|
214771802|NCT00003673|DRUG|gemtuzumab ozogamicin|
214771803|NCT06362616|RADIATION|Preoperative accelerated partial breast irradiation|Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
214771804|NCT06362616|PROCEDURE|Breast conserving surgery|Patients will be treated with breast conserving surgery.
214771805|NCT06362616|PROCEDURE|Sentinel node procedure|Patients will undergo a (repeat) sentinel node procedure.
214771806|NCT06362616|PROCEDURE|Biopsy track removal|The biopsy track will be surgically removed.
214771807|NCT02404779|DRUG|cisatracurium besilate|
214771808|NCT02404779|OTHER|Placebo|
214771809|NCT04296799|DRUG|SMP-100|SAD/MAD
214771810|NCT04296799|DRUG|Placebo|Placebo
214771811|NCT02387788|DRUG|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
214771812|NCT05786053|PROCEDURE|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
214771813|NCT02499406|BEHAVIORAL|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
214771814|NCT02399488|DEVICE|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
214771815|NCT02691312|DEVICE|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
214771816|NCT00480363|PROCEDURE|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
214771817|NCT01506817|PROCEDURE|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
214771818|NCT06521034|DRUG|FHND-9041|"In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled."
214771819|NCT03153059|OTHER|Stool frequency|This study is just observational study.
214771820|NCT06025500|DIAGNOSTIC_TEST|31P-Magnetic Resonance Spectroscopy (31P-MRS)|31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
214771821|NCT06036901|DIAGNOSTIC_TEST|Coronary CT|Coronary CT evaluation
214771822|NCT03848000|OTHER|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
214771823|NCT03848000|BEHAVIORAL|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
214771824|NCT04938063|OTHER|Assessing the correlation between Functional Impairment and Parenting Stress|Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
214771825|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
214771826|NCT00326300|DRUG|methylphenidate hydrochloride extended-release tablets|
214771827|NCT04701658|DRUG|Bamlanivimab|Administered intravenously.
214771828|NCT02493023|DEVICE|navigated bronchoscopy|
214771829|NCT04729634|OTHER|Mobilization|Mobilization and breathing exercises according to clinical care
214771830|NCT03880864|RADIATION|Ultrasound|Lung ultrasound
214771831|NCT04230954|DRUG|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
214771832|NCT04230954|DRUG|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
214771833|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
214771834|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
214771835|NCT02866695|DRUG|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
214771836|NCT03224234|DEVICE|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
214771837|NCT03224234|DEVICE|Insulclock without feedback|Not feedback on insulin administration.
214771838|NCT02235961|DRUG|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
214771839|NCT02235961|DRUG|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
214771840|NCT02235961|DRUG|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
214771841|NCT05016765|DEVICE|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
214771842|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
214771843|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
214771844|NCT04311359|DRUG|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
214771845|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
214771846|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
214771847|NCT06423937|DRUG|combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab|"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
214771848|NCT00792142|DRUG|bortezomib|Given IV
214771849|NCT00792142|DRUG|dexamethasone|Given orally
214771850|NCT00792142|DRUG|melphalan|Given IV
214771851|NCT00792142|DRUG|thalidomide|Given orally
214771852|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
214771853|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
214771854|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
214771855|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
214771856|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
214771857|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
214771858|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
214771859|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
214771860|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
214771861|NCT03843034|GENETIC|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
214771862|NCT00828581|DRUG|lorcaserin|
214771863|NCT00274664|DEVICE|6 hours occlusion by patching|
214771864|NCT00274664|DEVICE|12 hours occlusion by patching|
214771865|NCT02564952|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
214771866|NCT02564952|DRUG|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
214771867|NCT02924337|DRUG|Placebo|
214771868|NCT02924337|DRUG|Imeglimin|
214771869|NCT02924337|DRUG|Moxifloxacin|
214771870|NCT00756652|DEVICE|Mentor Silicone Gel-Filled Breast Implants|
214771871|NCT00756652|DEVICE|Saline Breast Implants|
214771872|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
214771873|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
214771874|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
214771875|NCT05723861|DEVICE|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
214771876|NCT03813394|DRUG|pembrolizumab|-Pembrolizumab in Solution for Injection
214771877|NCT03813394|DRUG|bevacizumab|"* Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution"
214771878|NCT05596227|DRUG|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
214771879|NCT05596227|DRUG|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
214771880|NCT05596227|DRUG|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
214771881|NCT05596227|DRUG|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
214771882|NCT05596227|OTHER|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
214771883|NCT05596227|OTHER|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
214771884|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
214771885|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
214771886|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
214771887|NCT05537246|PROCEDURE|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
214771888|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
214771889|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
214771890|NCT06540040|DEVICE|Aquacel Ag|Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.
214771891|NCT06540040|DEVICE|OPSITE|OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.
214771892|NCT06540040|DEVICE|MEPILEX POST OP BORDER|MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
214771893|NCT06540040|DEVICE|Traditional Dressing|Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
214771894|NCT06213389|DEVICE|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
214771895|NCT06213389|DEVICE|Macintosh Blade|Patient will be intubated with Macintosh Blade
214771896|NCT02502565|OTHER|Uric acid level|
214771897|NCT01850108|DRUG|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT"
214771898|NCT01850108|DRUG|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
214771899|NCT01850108|DRUG|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
214771900|NCT01850108|DRUG|Mesna|Days 3 \& 4 after BMT: 40 mg/kg IV
214771901|NCT01850108|DRUG|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
214771902|NCT01850108|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
214771903|NCT01850108|PROCEDURE|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
214771904|NCT01850108|RADIATION|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
214771905|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
214771906|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
214771907|NCT06523309|OTHER|Electroacupuncture treatment|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
214771908|NCT06133907|GENETIC|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
214771909|NCT05905809|DEVICE|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
214771910|NCT05905809|DEVICE|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
214771911|NCT00038467|DRUG|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
214771912|NCT00038467|DRUG|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
214771913|NCT05531799|PROCEDURE|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~\- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
214771914|NCT01988493|DRUG|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
214771915|NCT01988493|DRUG|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
214771916|NCT01988493|DRUG|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
214771917|NCT01988493|DRUG|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
214771918|NCT01988493|DRUG|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
214771919|NCT03406611|DRUG|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
214771920|NCT03406611|DRUG|Placebo|Normal saline for subcutaneous injection
214771921|NCT06701253|DIAGNOSTIC_TEST|point of care ultrasound|Point of care ultrasound for upper airway evaluation.
214771922|NCT06700577|DIAGNOSTIC_TEST|Gene expert|Gene expert and XDR to detect multidrug resistance between tb patient
214771923|NCT06700577|GENETIC|Ultra xpert and xdr xpert|Detect resistance between tyberculous patient
214771924|NCT05309031|OTHER|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
214771925|NCT06336174|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
214771926|NCT06336174|PROCEDURE|Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
214771927|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
214771928|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
214771929|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
214771930|NCT03127943|DRUG|Lidocaine|Efficacy for mandibular molar and canine anesthesia
214771931|NCT05425823|OTHER|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
214771932|NCT01805258|DRUG|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
214771933|NCT01805258|DRUG|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
214771934|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
214771935|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
214771936|NCT05996549|DRUG|Quadrivalent Influenza Vaccine|All high-risk groups have been getting one dose of seasonal influenza vaccination (Inactivated Influenza Vaccine ), except children aged six months to 8 years, who will receive two doses four weeks apart. All vaccines are in the southern hemisphere, as Bangladesh's influenza season matches the southern hemisphere areas.
214771937|NCT00486213|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
214771938|NCT00486213|OTHER|Placebo|
214771939|NCT06562335|OTHER|Booster|See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
214771940|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
214771941|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
214771942|NCT02368119|BIOLOGICAL|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
214771943|NCT02368119|OTHER|Placebo|IM injection injection of Phosphate Buffered Saline
214771944|NCT05314413|PROCEDURE|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
214771945|NCT06229379|DEVICE|"Digital twin patient"|"Digital twin patient can serve as patients with specific diseases for medical students to acquire disease history and thus practice clinical questioning skills."
214771946|NCT06229379|BEHAVIORAL|Interaction with real patients|As in traditional medical education, medical students need to interact with real patients to practice history collection skills.
214771947|NCT06568900|OTHER|cigarette smoking|continue smoking usual brand of cigarette
214771948|NCT06568900|OTHER|tobacco flavored and unflavored pouch|provide tobacco flavored and unflavored options of nicotine pouch
214771949|NCT06568900|OTHER|unrestricted flavor options pouch|provide unrestricted flavor options of nicotine pouch
214771950|NCT05455411|BEHAVIORAL|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
214771951|NCT05455411|BEHAVIORAL|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
214771952|NCT02280915|OTHER|Savoury food product|
214771953|NCT00698607|DEVICE|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
214771954|NCT00698607|DEVICE|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
214771955|NCT00698607|DRUG|6-month clopidogrel therapy|Use clopidogrel for 6 months
214771956|NCT00698607|DRUG|12-month clopidogrel therapy|Use clopidogrel for 12 months
214771957|NCT01447628|DRUG|Saline|intravenous, no active drug
214771958|NCT01447628|DRUG|Ferinject or CosmoFer|Intravenous, 1000 mg iron
214771959|NCT02977494|DRUG|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
214771960|NCT02977494|DRUG|Bortezomib|
214771961|NCT02977494|DRUG|Dexamethasone|
214771962|NCT00185731|DRUG|Atorvastatin|80 mg orally once daily
214771963|NCT03087773|DRUG|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
214771964|NCT03087773|DRUG|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
214771965|NCT04656782|OTHER|Imaging survey|Participation as expert panelist in the imaging survey.
214771966|NCT04656782|OTHER|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
214771967|NCT02519582|DRUG|Niclosamide|2 g per day orally
214771968|NCT00295529|BEHAVIORAL|Multifaceted educational intervention|Educational materials available at end of study
214771969|NCT05875064|COMBINATION_PRODUCT|Restoration with resin composite and polyvinyl crown|Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
214771970|NCT05875064|PROCEDURE|Restoration with conventional resin composite|Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
214771971|NCT00764244|PROCEDURE|Vitrectomy|Vitrectomy
214771972|NCT00764244|DRUG|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
214771973|NCT00764244|PROCEDURE|Laser photocoagulation|Laser photocoagulation
214771974|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
214771975|NCT02624817|DRUG|Sulfonylurea|See Arm description.
214771976|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
214771977|NCT04916067|DEVICE|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
214771978|NCT03347474|PROCEDURE|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
214771979|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
214771980|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
214771981|NCT03008252|OTHER|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
214771982|NCT03008252|OTHER|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
214771983|NCT01059942|OTHER|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
214771984|NCT01059942|OTHER|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
214771985|NCT00898742|GENETIC|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
214771986|NCT00898742|GENETIC|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
214771987|NCT00898742|OTHER|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
214771988|NCT00934778|PROCEDURE|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
214771989|NCT01844869|DRUG|omacetaxine mepesuccinate|
214771990|NCT00639158|DRUG|ABT-335|135 mg capsule, daily, 12 weeks
214771991|NCT00639158|DRUG|placebo|placebo capsule, daily, 12 weeks
214771992|NCT00639158|DRUG|atorvastatin|40 mg, tablet, daily, 12 weeks
214771993|NCT00639158|DRUG|ezetimibe|10 mg capsule, daily, 12 weeks
214771994|NCT02802007|DEVICE|Elipse Intragastric Balloon|
214771995|NCT03403712|DRUG|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
214771996|NCT03403712|DRUG|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
214771997|NCT03403712|DRUG|dexamethasone|Oral dexamethasone (12 mg)
214771998|NCT00164086|DRUG|atorvastatin|
214771999|NCT02232685|DEVICE|18F-Choline PET/CT|18F-Choline PET/CT
214772000|NCT04264988|PROCEDURE|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
214772001|NCT05988411|DEVICE|Renal Denervation|Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
214772002|NCT05988411|DEVICE|Catheter Ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
214772003|NCT05728918|DIETARY_SUPPLEMENT|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
214772004|NCT05728918|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
214772005|NCT00001729|DRUG|Ribavirin|
214772006|NCT03455114|DEVICE|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
214772007|NCT03789058|DRUG|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
214772008|NCT03147521|OTHER|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
214772009|NCT04341207|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
214772010|NCT04341207|DRUG|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
214772011|NCT01787188|DRUG|Meloxicam Test Capsules|
214772012|NCT01787188|DRUG|Meloxicam Test Capsules|
214772013|NCT01787188|DRUG|Placebo Capsules|
214772014|NCT01825915|PROCEDURE|Laparoscopic Hysterectomy|
214772015|NCT01825915|PROCEDURE|Laparoscopic Supracervical Hysterectomy|
214772016|NCT03386071|DRUG|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
214772017|NCT05807347|DRUG|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
214772018|NCT04532489|DRUG|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
214772019|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
214772020|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
214772021|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
214772022|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
214772023|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
214772024|NCT05972954|DRUG|OMT-28|once daily
214772025|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
214772026|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
214772027|NCT02611531|BEHAVIORAL|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
214772028|NCT02611531|BEHAVIORAL|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
214772029|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
214772030|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
214772031|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
214772032|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
214772033|NCT04292756|PROCEDURE|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
214772034|NCT04292756|PROCEDURE|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
214772035|NCT04292756|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
214772036|NCT04292756|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
214772037|NCT04292756|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
214772038|NCT04292756|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
214772039|NCT04292756|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
214772040|NCT04292756|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
214772041|NCT04292756|DIAGNOSTIC_TEST|IOP|Ophthalmic examination
214772042|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
214772043|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
214772044|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
214772045|NCT06565910|DRUG|Liposomal bupivacaine plus bupivacaine|Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.
214772046|NCT06565910|DRUG|Ropivacaine|Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.
214772047|NCT01267968|DRUG|GSK2251052|1500 mg (dosing detailed in Arm description)
214772048|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
214772049|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
214772050|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
214772051|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
214772052|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
214772053|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
214772054|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
214772055|NCT02788955|BEHAVIORAL|Dietary counselling|
214772056|NCT02788955|OTHER|Dietary Protein|
214772057|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
214772058|NCT06566560|OTHER|redispensing oral anticancer drugs|"Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy."
214772059|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
214772060|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
214772061|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
214772062|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
214772063|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
214772064|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
214772065|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
214772066|NCT03779282|DRUG|Dexmedetomidine|see descriptions
214772067|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
214772068|NCT02617446|DRUG|Placebo|IV of matching saline solution
214772069|NCT02617446|DRUG|Istaroxime|IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
214772070|NCT05031286|OTHER|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
214772071|NCT05665712|PROCEDURE|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
214772072|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
214772073|NCT01904084|DEVICE|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
214772074|NCT01904084|DEVICE|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
214772075|NCT05015803|COMBINATION_PRODUCT|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
214772076|NCT05015803|BEHAVIORAL|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
214772077|NCT05015803|BEHAVIORAL|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
214772078|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
214772079|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
214772080|NCT06701799|PROCEDURE|CAF+ L-PRF 1 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
214772081|NCT06701799|PROCEDURE|CAF+ L-PRF 2 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
214772082|NCT00301925|BIOLOGICAL|pegfilgrastim|
214772083|NCT00301925|DRUG|capecitabine|
214772084|NCT00301925|DRUG|cyclophosphamide|
214772085|NCT00301925|DRUG|epirubicin hydrochloride|
214772086|NCT00301925|DRUG|fluorouracil|
214772087|NCT00301925|DRUG|methotrexate|
214772088|NCT00301925|PROCEDURE|adjuvant therapy|
214772089|NCT02578043|DRUG|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
214772090|NCT02578043|DRUG|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
214772091|NCT02578043|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
214772092|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
214772093|NCT05910450|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
214772094|NCT05910450|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
214772095|NCT00530088|DRUG|porfimer sodium|IV
214772096|NCT00530088|DRUG|Photdynamic Therapy (PDT)|
214772097|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
214772098|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
214772099|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
214772100|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
214772101|NCT00902278|BIOLOGICAL|Flulaval|one 0.5-mL dose via intramuscular injection
214772102|NCT00902278|BIOLOGICAL|Fluvirin|one 0.5-mL dose via intramuscular injection
214772103|NCT00902278|BIOLOGICAL|Fluzone|one 0.5-mL dose via intramuscular injection
214772104|NCT00902278|BIOLOGICAL|Fluarix|one 0.5-mL dose via intramuscular injection
214772105|NCT00902278|BIOLOGICAL|Afluria|one 0.5-mL dose via intramuscular injection
214772106|NCT01741428|BEHAVIORAL|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
214772107|NCT05810961|BIOLOGICAL|efgartigimod IV|infusion of efgartigimod
214772108|NCT05810961|OTHER|placebo|infusion of placebo
214772109|NCT05954611|BIOLOGICAL|GR2002 injection|one single dose of GR2002 injection
214772110|NCT05954611|BIOLOGICAL|Placebo|one single dose of placebo
214772111|NCT01691261|BIOLOGICAL|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
214772112|NCT06312761|DRUG|Relugolix 120Mg Tab|Relugolix 120 mg single dose - All subjects
214772113|NCT06312761|DIETARY_SUPPLEMENT|Curcumin|Curcumin 630 mg single dose
214772114|NCT06312761|DRUG|Testosterone Undecanoate 237 MG Oral Capsule|Testosterone Undecanoate 237 MG Oral Capsule
214772115|NCT04439097|OTHER|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
214772116|NCT04439097|OTHER|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
214772117|NCT06496711|OTHER|Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients|The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
214772118|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
214772119|NCT02343497|DIETARY_SUPPLEMENT|Astaxanthin|
214772120|NCT02343497|DIETARY_SUPPLEMENT|Placebo|
214772121|NCT04534387|OTHER|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
214772122|NCT04534387|OTHER|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
214772123|NCT05290805|DIAGNOSTIC_TEST|ECMO flow rate reduction|ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
214772124|NCT00197561|DIETARY_SUPPLEMENT|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
214772125|NCT00197561|DIETARY_SUPPLEMENT|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
214772126|NCT04419428|DEVICE|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
214772127|NCT00668369|PROCEDURE|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
214772128|NCT06117566|DRUG|WX390|WX390 tablet, once a day
214772129|NCT06117566|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
214772130|NCT02362646|BIOLOGICAL|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
214772131|NCT02362646|DRUG|Control Solution|
214772132|NCT00141479|DRUG|Bifeprunox|
214772133|NCT05395702|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
214772134|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
214772135|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
214772136|NCT06701214|OTHER|Blood collection|Blood will be taken from participants already undergoing blood collection
214772137|NCT06701214|OTHER|Saliva collection|Undergo saliva collection
214772138|NCT06701214|OTHER|Bone marrow collection|Bone marrow will be taken from participants already undergoing bone marrow collection
214772139|NCT00865306|BEHAVIORAL|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
214772140|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
214772141|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
214772142|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
214772143|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
214772144|NCT02292732|DRUG|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
214772145|NCT02292732|DRUG|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
214772146|NCT02292732|DRUG|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
214772147|NCT02292732|DRUG|Placebo|Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
214772148|NCT02656875|DRUG|TRV130|
214772149|NCT00559975|BIOLOGICAL|Subunit influenza vaccine|0.5 mL single dose vaccine
214772150|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
214772151|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
214772152|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
214772153|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
214772154|NCT02181842|DRUG|Pioglitazone|Pioglitazone tablets
214772155|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
214772156|NCT03056716|PROCEDURE|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
214772157|NCT04160416|DRUG|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
214772158|NCT06567522|DRUG|Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%|Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
214772159|NCT04769908|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
214772160|NCT04769908|DRUG|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
214772161|NCT04769908|DRUG|Sintilimab|Sintilimab, IV, 200mg, q3w
214772162|NCT05663216|OTHER|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
214772163|NCT00388115|PROCEDURE|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
214772164|NCT00388115|PROCEDURE|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
214772165|NCT00388115|PROCEDURE|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
214772166|NCT06568978|OTHER|Assessments of respiratory parameters|respiratory muscle strength, respiratory function test
214772167|NCT05593783|PROCEDURE|lithotripsy|lithotripsy
214772168|NCT05766761|BEHAVIORAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
214772169|NCT00929864|DRUG|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
214772170|NCT00929864|DRUG|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
214772171|NCT01403428|OTHER|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
214772172|NCT04234373|OTHER|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
214772173|NCT01858129|DRUG|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
214772174|NCT01858129|DRUG|placebo|
214772175|NCT04507789|OTHER|exercise intervention|Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
214772176|NCT04507789|OTHER|routine radiotherapy protokol|This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
214772177|NCT02624349|DRUG|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
214772178|NCT02684669|DRUG|Naloxone|active drug infusion
214772179|NCT02684669|DRUG|Normal saline|placebo comparator
214772180|NCT04737811|OTHER|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
214772181|NCT03039205|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
214772182|NCT03039205|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
214772183|NCT05069428|DRUG|Ramelteon 8mg|administered crushed, orally at 20:30
214772184|NCT03178019|OTHER|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
214772185|NCT02199834|BEHAVIORAL|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
214772186|NCT02199834|BEHAVIORAL|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
214772187|NCT06373419|DEVICE|TFL|Participant undergoing bladder tumour resection that has been randomized to this arm.
214772188|NCT06373419|DEVICE|MOSES holmium laser|Participant undergoing bladder tumour resection that has been randomized to this arm.
214772189|NCT06525155|DRUG|Triptorelin Embonate|Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
214772190|NCT06525155|DRUG|Triptorelin Embonate|Treatment 2: 3.75 mg once after surgery at week-12
214772191|NCT04754919|OTHER|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
214772192|NCT04754919|OTHER|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
214772193|NCT02674074|DEVICE|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
214772194|NCT06545526|DRUG|celecoxib monotherapy|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
214772195|NCT06545526|DRUG|celecoxib and metformin combination|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
214772196|NCT06272448|OTHER|Telerehabilitation|The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation…), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
214772197|NCT03974516|DRUG|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
214772198|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
214772199|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
214772200|NCT03474640|BIOLOGICAL|Part A|Part A: 80, 240, and 480 mg IV every 14 days.
214772201|NCT03474640|BIOLOGICAL|Part B|Part B: 240 mg IV every 3 weeks
214772202|NCT06389968|DEVICE|Light stimulation|see arm description
214772203|NCT06389968|DEVICE|Sham light stimulation|see arm description
214772204|NCT03454672|DEVICE|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
214772205|NCT03454672|DEVICE|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
214772206|NCT06110338|DRUG|placebo|placebo iv. once.
214772207|NCT06110338|DRUG|IBI355|IBI355 iv. once.
214772208|NCT05198349|DRUG|M1069|Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
214772209|NCT06569680|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"
214772210|NCT04175691|GENETIC|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
214772211|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
214772212|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
214772213|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
214772214|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
214772215|NCT00367601|DRUG|Erlotinib|Erlotinib 150 mg qd days 1-21
214772216|NCT00367601|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
214772217|NCT02647632|DRUG|Grazoprevir/Elbasvir|
214772218|NCT02647632|DRUG|Sofosbuvir|
214772219|NCT02647632|DRUG|Ribavirin|
214772220|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
214772221|NCT06542354|BEHAVIORAL|Physical exercise|Physical exercises personally scheduled consisting of daily aerobic exercise(30mins) of fast walking(≥5km) and resisitance training.
214772222|NCT06542354|DIETARY_SUPPLEMENT|Nutrition supplement|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Oral nutrition supplement (ENSURE) is provided daily seperated in 2 doses
214772223|NCT06542354|BEHAVIORAL|Mental support|Relaxation exercise and psychological counselling delivered by weekly telephone follow-up
214772224|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
214772225|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
214772226|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
214772227|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
214772228|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
214772229|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
214772230|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
214772231|NCT03004417|DRUG|CHF 6001 Dose1|CHF 6001 plus placebo
214772232|NCT03004417|DRUG|CHF 6001 Dose2|CHF 6001 only (high dose)
214772233|NCT03004417|OTHER|Placebo|Placebo only
214772234|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
214772235|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
214772236|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
214772237|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
214772238|NCT00458016|DRUG|MB07803|Daily oral administration
214772239|NCT00458016|DRUG|Placebo|Daily oral administration
214772240|NCT05179434|PROCEDURE|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
214772241|NCT05179434|PROCEDURE|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
214772242|NCT05410769|BEHAVIORAL|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
214772243|NCT02804191|DRUG|LO2A|eye drop solution.
214772244|NCT02804191|DRUG|Saline|Placebo
214772245|NCT00629668|GENETIC|TNF-alpha and HBV genotype|
214772246|NCT00629668|OTHER|TNF-alpha and HBV genotypes|
214772247|NCT05496595|DRUG|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
214772248|NCT06567158|OTHER|Moderate carbohydrate diet|During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.
214772249|NCT06567158|OTHER|Traditional diet|During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
214772250|NCT03757741|DIAGNOSTIC_TEST|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
214772251|NCT03757741|DIAGNOSTIC_TEST|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
214772252|NCT01058876|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
214772253|NCT03735238|OTHER|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
214772254|NCT03890861|BEHAVIORAL|Physical activity|Promotion of physical activity to the current federal physical activity guidelines.
214772255|NCT03890861|BEHAVIORAL|Successful Aging|Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
214772256|NCT04730973|DRUG|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
214772257|NCT04730973|OTHER|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
214772258|NCT02810496|GENETIC|blood collection for mutation characterization|
214772259|NCT03393312|DEVICE|Transcranial direct current stimulation (tDCS)|Electric current
214772260|NCT05923541|DRUG|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
214772261|NCT04288323|DRUG|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
214772262|NCT02988310|OTHER|No intervention|
214772263|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
214772264|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
214772265|NCT03534830|DIAGNOSTIC_TEST|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
214772266|NCT00711165|DRUG|Placebo|2 puffs, qd
214772267|NCT00711165|DRUG|Mometasone Furoate|400 mcg, qd for 8 weeks
214772268|NCT05359341|DRUG|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
214772269|NCT05359341|DRUG|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
214772270|NCT05359341|DRUG|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
214772271|NCT05359341|DRUG|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
214772272|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
214772273|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
214772274|NCT05576285|DIAGNOSTIC_TEST|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
214772275|NCT01242332|DRUG|Pregabalin|75 mg po 2 hrs before surgery
214772276|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
214772277|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
214772278|NCT02704299|BIOLOGICAL|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
214772279|NCT02383537|OTHER|Diabetes|the trial is observational with no intervention
214772280|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
214772281|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
214772282|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
214772283|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
214772284|NCT00000891|DRUG|Ritonavir|
214772285|NCT00000891|DRUG|Saquinavir|
214772286|NCT00000891|DRUG|Delavirdine mesylate|
214772287|NCT00000891|DRUG|Lamivudine|
214772288|NCT00000891|DRUG|Stavudine|
214772289|NCT00000891|DRUG|Zidovudine|
214772290|NCT00000891|DRUG|Didanosine|
214772291|NCT02317094|OTHER|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
214772292|NCT02317094|DRUG|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
214772293|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
214772294|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
214772295|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
214772296|NCT02604238|DRUG|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
214772297|NCT03791515|DRUG|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
214772298|NCT03791515|DRUG|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
214772299|NCT06386471|OTHER|Whole grain rye bread|Single consumption of 4.3 oz of whole grain rye bread
214772300|NCT06386471|OTHER|Refined grain rye bread|Single consumption of 4.3 oz of refined grain rye bread
214772301|NCT06381401|DRUG|bupivacaine 0.25%|superficial cervical plexus block using 10 ml of bupivacaine 0.25%
214772302|NCT06381401|DRUG|bupivacaine 0.125%|superficial cervical plexus block using 10 ml of bupivacaine 0.125%
214772303|NCT04229758|DRUG|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
214772304|NCT01556464|DEVICE|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
214772305|NCT03376984|COMBINATION_PRODUCT|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
214772306|NCT03376984|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
214772307|NCT05161546|DEVICE|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
214772308|NCT05161546|DEVICE|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
214772309|NCT05161546|BEHAVIORAL|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
214772310|NCT05161546|DEVICE|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
214772311|NCT06565754|OTHER|BFR|"Blood flow restriction training is an accessory to a variety of different exercise modes (e.g., resistance exercise, walking, cycling) has recently become a popular research topic. It involves the application of pressurized cuffs to the proximal portion of each lower extremity or upper extremity. It enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet or cuff.~The 3rd Generation SmartCuffs® pump (SmartCuffs® 3.0 PRO) is Personalized Pressure feature which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it is calculate arterial occlusion pressure and set the optimal pressure for patient's body. There is no need for an external doppler probe or hand pump. This unit will do everything for patient. Smart Cuffs 3rd generation is FDA Approved Listed Class 1 device.~The automatized tourniquet (Smart Tools) contains a ring-shaped single- chamber"
214772312|NCT06565754|OTHER|strengthening exercise|Quadriceps strengthening exercises are part of the treatment of PFPS, but the heavy resistance exercises may aggravate knee pain. Blood flow restriction training (BFRT) provides a low-load quadriceps strengthening method to treat PFPS (Giles et al., 2017).
214772313|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
214772314|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
214772315|NCT05920707|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
214772316|NCT05920707|DRUG|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
214772317|NCT05920707|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
214772318|NCT03176511|BEHAVIORAL|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
214772319|NCT03176511|BEHAVIORAL|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
214772320|NCT03850262|RADIATION|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
214772321|NCT04980417|PROCEDURE|concomitant cholecystectomy|delayed cholecystectomy
214772322|NCT04425369|PROCEDURE|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
214772323|NCT00291356|DRUG|GSK189075 oral tablets|
214772324|NCT00291356|DRUG|GW869682 oral tablets|
214772325|NCT05359380|OTHER|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
214772326|NCT06164431|DRUG|ZSP1273 tablet|Participants receive ZSP1273 tablet orally.
214772327|NCT06164431|DRUG|zsp1273 granules|Participants receive ZSP1273 granules orally.
214772328|NCT05093192|OTHER|Exercise trial|Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
214772329|NCT02251431|DRUG|BYDUREON|Exenatide-extended release, Cohorts A and B
214772330|NCT02251431|DRUG|Placebo|Cohort A only
214772331|NCT02752451|OTHER|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
214772332|NCT02752451|OTHER|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
214772333|NCT02752451|OTHER|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
214772334|NCT02493088|OTHER|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
214772335|NCT01841398|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
214772336|NCT01841398|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
214772337|NCT00981864|RADIATION|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
214772338|NCT01838278|BEHAVIORAL|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
214772339|NCT05133843|PROCEDURE|Assession of complete coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
214772340|NCT03764592|OTHER|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
214772341|NCT06427954|BEHAVIORAL|Digital Health App|access to a digital health app
214772342|NCT06476171|DIAGNOSTIC_TEST|Determination of the level of the studied biomarkers|Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
214772343|NCT04925453|COMBINATION_PRODUCT|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
214772344|NCT04925453|COMBINATION_PRODUCT|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
214772345|NCT06210516|DEVICE|PowerBreathe|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
214772346|NCT06210516|OTHER|Conventional Physiotherapy|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
214772347|NCT04708626|OTHER|Description and analysis|Collection of clinical, laboratory and radiological data from medical records.
214772348|NCT04708626|OTHER|Description and analysis|Collection of laboratory data.
214772349|NCT00408135|DRUG|telithromycin (HMR3647)|
214772350|NCT04982718|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
214772351|NCT04982718|DIAGNOSTIC_TEST|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
214772352|NCT05775536|DRUG|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
214772353|NCT05775536|DIETARY_SUPPLEMENT|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
214772354|NCT02959372|OTHER|lung ultrasound|
214772355|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
214772356|NCT00206037|DEVICE|COLLOSS E|
214772357|NCT00206037|DEVICE|TomoFix Plate|
214772358|NCT02908607|DEVICE|Thermal imaging|Examination of the cervix by thermal imaging camera
214772359|NCT03061773|OTHER|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
214772360|NCT03061773|BEHAVIORAL|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
214772361|NCT02815930|OTHER|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
214772362|NCT01120522|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
214772363|NCT03957317|OTHER|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
214772364|NCT03526796|PROCEDURE|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
214772365|NCT05975463|PROCEDURE|HAIC|hepatic artery infusion for 3-4 times.
214772366|NCT05975463|DRUG|Adebrelimab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
214772367|NCT05975463|DRUG|Bevacizumab|hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
214772368|NCT03186963|PROCEDURE|No immobilization|Conventional wrist dressing
214772369|NCT03186963|PROCEDURE|Volar splint|Volar plaster splint
214772370|NCT03302299|DRUG|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
214772371|NCT03302299|DRUG|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
214772372|NCT00850837|DRUG|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
214772373|NCT00850837|DRUG|HEC gel|5 g application of hydroxyethylcellulose gel
214772374|NCT02902380|DRUG|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
214772375|NCT02902380|DRUG|control group|0.9% saline infusion
214772376|NCT00357474|PROCEDURE|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
214772377|NCT00357474|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
214772378|NCT00006044|DRUG|therapeutic testosterone|
214772379|NCT04153201|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg
214772380|NCT00485368|DRUG|Coversyl (perindopril)|
214772381|NCT02162901|BEHAVIORAL|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
214772382|NCT02162901|BEHAVIORAL|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
214772383|NCT02162901|BEHAVIORAL|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
214772384|NCT02162901|BEHAVIORAL|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
214772385|NCT02162901|BEHAVIORAL|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
214772386|NCT04282044|BIOLOGICAL|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
214772387|NCT04282044|COMBINATION_PRODUCT|Fludarabine|25mg/m IV (five doses given from Day -7 until Day -3)
214772388|NCT04282044|COMBINATION_PRODUCT|Cyclophosphamide|60mg/kg intravenous (IV) (two doses given on Day -7 and -6)
214772389|NCT02602964|OTHER|Deep neuromsucular block|Deep or standard neuromuscular block
214772390|NCT05570968|PROCEDURE|C-arm device|Percutaneous Transluminal Angioplasty
214772391|NCT04466696|BEHAVIORAL|ERAS protocol|items of ERAS protocol applied
214772392|NCT00858234|DRUG|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
214772393|NCT00858234|DRUG|Bortezomib|Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
214772394|NCT04318535|DRUG|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
214772395|NCT04318535|DRUG|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
214772396|NCT04318535|DRUG|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
214772397|NCT04715386|DRUG|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
214772398|NCT06317363|OTHER|Base Line + ACEPELLA|Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
214772399|NCT06317363|OTHER|Base Line + Manual Chest Physiotherapy|The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
214772400|NCT01629134|DEVICE|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
214772401|NCT01678924|DRUG|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
214772402|NCT01678924|DRUG|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
214772403|NCT04264663|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
214772404|NCT04264663|DRUG|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
214772405|NCT02808663|BIOLOGICAL|fecal calprotectin concentration|
214772406|NCT02808663|BIOLOGICAL|blood collection|
214772407|NCT01733186|BIOLOGICAL|CARTISTEM®|
214772408|NCT00757263|GENETIC|polymorphism analysis|
214772409|NCT00757263|OTHER|laboratory biomarker analysis|
214772410|NCT00757263|OTHER|questionnaire administration|
214772411|NCT01207063|OTHER|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
214772412|NCT03711669|BEHAVIORAL|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
214772413|NCT04923269|DRUG|LY3532226|Administered SC.
214772414|NCT04923269|DRUG|Placebo|Administered SC.
214772415|NCT01480908|PROCEDURE|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
214772416|NCT01480908|PROCEDURE|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
214772417|NCT01480908|PROCEDURE|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
214772418|NCT01480908|PROCEDURE|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
214772419|NCT00640614|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
214772420|NCT05110950|PROCEDURE|No suction EBUS-TBNA|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
214772421|NCT05110950|PROCEDURE|Passive suction through dedicated EBUS-TBNA syringe|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
214772422|NCT05110950|PROCEDURE|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.."
214772423|NCT04559217|BIOLOGICAL|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
214772424|NCT00669136|DRUG|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
214772425|NCT00529802|DRUG|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
214772426|NCT06540300|OTHER|rTMS stimulation of right IPL|The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
214772427|NCT02692352|OTHER|Goal Management Training|Goal Management training, 8 sessions of 2 hours
214772428|NCT02692352|OTHER|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
214772429|NCT05736952|DRUG|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
214772430|NCT01997099|DEVICE|CADD®-Solis VIP Pump|
214772431|NCT01997099|DEVICE|CADD™ Solis Medication Safety Software Administrator|
214772432|NCT02409537|DIETARY_SUPPLEMENT|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
214772433|NCT02409537|DIETARY_SUPPLEMENT|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
214772434|NCT02409537|OTHER|placebo|the individuals were given placebo for 1 month
214772435|NCT04498156|OTHER|No intervention|No intervention, observational study
214772436|NCT05048771|OTHER|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
214772437|NCT06542783|BEHAVIORAL|referring to the results of AI model output|determining the ANA pattern type with or without referring to the results of AI model output.
214772438|NCT00926653|DRUG|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
214772439|NCT04858074|DRUG|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
214772440|NCT02007369|BEHAVIORAL|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
214772441|NCT02007369|BEHAVIORAL|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
214772442|NCT01573494|OTHER|Sampling of blood|7,5 ml of blood
214772443|NCT03569020|OTHER|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
214772444|NCT05472857|BIOLOGICAL|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
214772445|NCT06310473|DRUG|Cadonilimab|10mg/kg intravenous (IV) every 3 weeks ;
214772446|NCT06310473|DRUG|Oxaliplatin|130mg/m², iv drip for 2h, d1, q3w;
214772447|NCT06310473|DRUG|Capecitabine|1000mg/m² po, Bid, d1-14, q3w ;
214772448|NCT02428231|DRUG|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
214772449|NCT02830230|DRUG|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
214772450|NCT04052074|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
214772451|NCT04052074|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
214772452|NCT02277639|DEVICE|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
214772453|NCT02156466|DRUG|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
214772454|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
214772455|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
214772456|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
214772457|NCT02156466|DRUG|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
214772458|NCT05226468|DRUG|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
214772459|NCT05538169|DEVICE|low-level laser diode (Pioon Laser)|"Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session."
214772460|NCT00470119|BEHAVIORAL|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
214772461|NCT00470119|BEHAVIORAL|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
214772462|NCT01784419|DRUG|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
214772463|NCT01784419|DRUG|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
214772464|NCT06539455|DRUG|standard anti-TB treatment|standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
214772465|NCT06286410|OTHER|Bespoke glasses prescription worn during amblyopia treatment.|The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
214772466|NCT00944008|DRUG|DepoCyte|
214772467|NCT05134259|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
214772468|NCT01462552|DRUG|Lapatanib|Prescription of lapatinib (Tykerb)
214772469|NCT00624975|BIOLOGICAL|Peru-15 Vaccine|up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
214772470|NCT00624975|BIOLOGICAL|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
214772471|NCT00637052|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
214772472|NCT02010970|DRUG|Group 1 AZD3293|AZD3293 oral solution
214772473|NCT02010970|DRUG|Group 2 AZD3293|AZD3293 oral solution
214772474|NCT02010970|DRUG|Group 3 AZD3293|AZD3293 oral solution
214772475|NCT02010970|DRUG|Group 1 Itraconazole|itraconazole capsule
214772476|NCT02010970|DRUG|Group 2 Diltiazem|Diltiazem ER tablet
214772477|NCT02010970|DRUG|Group 3 Midazolam|midazolam syrup
214772478|NCT01598415|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
214772479|NCT01598415|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
214772480|NCT01794156|BEHAVIORAL|Cognitive behavior therapy|
214772481|NCT01794156|BEHAVIORAL|Mindfulness-based stress reduction|
214772482|NCT01794156|BEHAVIORAL|Inference-based therapy|
214772483|NCT02253654|DRUG|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
214772484|NCT01298154|OTHER|Dietary intervention|Dietary treatments with beverages
214772485|NCT01630265|OTHER|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
214772486|NCT01630265|OTHER|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
214772487|NCT02751086|PROCEDURE|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
214772488|NCT02751086|PROCEDURE|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
214772489|NCT01249391|DEVICE|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
214772490|NCT03329586|OTHER|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
214772491|NCT01066273|DEVICE|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
214772492|NCT02486471|PROCEDURE|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
214772493|NCT02486471|OTHER|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
214772494|NCT00975273|BEHAVIORAL|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
214772495|NCT00975273|BEHAVIORAL|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
214772496|NCT04693182|OTHER|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
214772497|NCT00069160|DRUG|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
214772498|NCT00069160|DRUG|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
214772499|NCT00069160|OTHER|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
214772500|NCT04675073|PROCEDURE|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
214772501|NCT01566669|DRUG|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
214772502|NCT01566669|DRUG|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
214772503|NCT03091894|DRUG|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
214772504|NCT03091894|DRUG|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
214772505|NCT02023320|DIETARY_SUPPLEMENT|Low dose of blueberry dry powder|
214772506|NCT02023320|DIETARY_SUPPLEMENT|High dose of blueberry dry powder|
214772507|NCT05351073|DRUG|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
214772508|NCT03456726|DRUG|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
214772509|NCT02615873|DRUG|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
214772510|NCT04470622|DRUG|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
214772511|NCT04470622|DRUG|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
214772512|NCT03171610|DRUG|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
214772513|NCT03171610|DRUG|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
214772514|NCT00002269|DRUG|Ampligen|
214772515|NCT00002269|DRUG|Zidovudine|
214772516|NCT00464256|DRUG|rimonabant|
214772517|NCT00268554|DRUG|dipyridamole|
214772518|NCT00268554|DRUG|caffeine|
214772519|NCT02576054|BIOLOGICAL|V501|Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
214772520|NCT01190098|DRUG|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
214772521|NCT01190098|DRUG|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
214772522|NCT02281071|PROCEDURE|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
214772523|NCT01767545|DRUG|Dexamethasone implant|
214772524|NCT01767545|DRUG|Bevacizumab|
214772525|NCT02957682|DRUG|Praluent (Alirocumab)|
214772526|NCT02957682|DRUG|Placebo|
214772527|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|600 IU daily oral supplementation
214772528|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU supplementation bi-monthly
214772529|NCT05423301|PROCEDURE|Experimental|Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
214772530|NCT05423301|PROCEDURE|Control|The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
214772531|NCT06538363|BEHAVIORAL|Education|Personalized training advice
214772532|NCT06538363|BEHAVIORAL|Generic Education|Generic training advice
214772533|NCT01392586|PROCEDURE|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
214772534|NCT01392586|OTHER|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
214772535|NCT01470586|PROCEDURE|Surgery for colorectal cancer|Surgical resection of colorectal cancer
214772536|NCT02490527|DIETARY_SUPPLEMENT|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
214772537|NCT02490527|DRUG|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
214772538|NCT02490527|OTHER|Placebo|A substance that has no therapeutic effect and will act as a control.
214772539|NCT02034227|DRUG|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
214772540|NCT04856579|PROCEDURE|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
214772541|NCT02775227|DRUG|Hydrocortisone|
214772542|NCT02775227|DRUG|Pasireotide|
214772543|NCT05640882|OTHER|VRET|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
214772544|NCT05640882|OTHER|VRET OLFACTION|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
214772545|NCT03778359|DRUG|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
214772546|NCT03778359|DEVICE|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
214772547|NCT03778359|DRUG|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
214772548|NCT03778359|DRUG|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
214772549|NCT00709475|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214772550|NCT05190900|OTHER|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
214772551|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
214772552|NCT05476276|DRUG|ISA specific|ISA specific interventions will be listed in their protocols.
214772553|NCT06527846|DRUG|JARDIANCE®|JARDIANCE®
214772554|NCT03179956|DRUG|Ribociclib|Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
214772555|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
214772556|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
214772557|NCT03560115|DIAGNOSTIC_TEST|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
214772558|NCT05210998|OTHER|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
214772559|NCT05210998|OTHER|Gradual Aerobic exercise training|Aerobic exercise Group
214772560|NCT01372527|OTHER|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
214772561|NCT02632227|PROCEDURE|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
214772562|NCT05380882|DRUG|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
214772563|NCT04127682|OTHER|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
214772564|NCT05949931|DRUG|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
214772565|NCT05949931|DRUG|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
214772566|NCT02476760|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214772567|NCT02476760|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
214772568|NCT02476760|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
214772569|NCT02476760|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214772570|NCT02476760|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214772571|NCT02476760|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214772572|NCT02476760|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
214772573|NCT02476760|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
214772574|NCT04586569|OTHER|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
214772575|NCT01551394|DRUG|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
214772576|NCT01551394|DRUG|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
214772577|NCT05070689|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
214772578|NCT00871065|DRUG|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
214772579|NCT02833558|DEVICE|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
214772580|NCT02833558|PROCEDURE|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
214772581|NCT05151822|OTHER|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
214772582|NCT05151822|OTHER|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
214772583|NCT05151822|OTHER|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
214772584|NCT05151822|OTHER|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
214772585|NCT04759716|OTHER|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
214772586|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
214772587|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
214772588|NCT04973839|BEHAVIORAL|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
214772589|NCT04973839|BEHAVIORAL|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
214772590|NCT00854386|DRUG|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
214772591|NCT00854386|DRUG|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
214772592|NCT05451134|OTHER|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
214772593|NCT01382134|DRUG|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
214772594|NCT01382134|DRUG|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
214772595|NCT06537024|PROCEDURE|RTSA|
214772596|NCT02677402|OTHER|immersion|
214772597|NCT02751255|DRUG|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
214772598|NCT00438295|PROCEDURE|temperature control|
214772599|NCT04983823|OTHER|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
214772600|NCT04983823|OTHER|Usual care|This will be provided by participants' usual healthcare professional(s).
214772601|NCT03372395|OTHER|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
214772602|NCT04651218|BEHAVIORAL|exericse|participants perform aerobic exercise until they expend 500 kcal
214772603|NCT01835808|DEVICE|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
214772604|NCT00188279|PROCEDURE|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
214772605|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
214772606|NCT06536699|RADIATION|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
214772607|NCT06536699|RADIATION|Radiotherapy - Conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
214772608|NCT04365842|BEHAVIORAL|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
214772609|NCT04365842|OTHER|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
214772610|NCT00765999|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
214772611|NCT01226615|DRUG|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
214772612|NCT01226615|DRUG|Placebo|Two placebo capsules taken once a day for four months.
214772613|NCT01738009|OTHER|Induction of flow limitation|
214772614|NCT00951717|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
214772615|NCT05761015|DRUG|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
214772616|NCT00875537|OTHER|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
214772617|NCT00875537|OTHER|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
214772618|NCT00003607|RADIATION|radiation therapy|
214772619|NCT00414011|DRUG|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
214772620|NCT00414011|DRUG|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
214772621|NCT00668109|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
214772622|NCT00668109|DRUG|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
214772623|NCT01532011|DRUG|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
214772624|NCT01532011|DRUG|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
214772625|NCT02476851|DEVICE|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
214772626|NCT02476851|DEVICE|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
214772627|NCT04075045|BEHAVIORAL|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
214772628|NCT04075045|BEHAVIORAL|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
214772629|NCT04075045|BEHAVIORAL|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
214772630|NCT06515340|OTHER|Allulose Dose 1|5 gram consumed orally
214772631|NCT06515340|OTHER|Allulose Dose 2|10 gram consumed orally
214772632|NCT06515340|OTHER|Allulose Dose 3|20 gram consumed orally
214772633|NCT00040625|DRUG|Pemetrexed|
214772634|NCT00040625|DRUG|Cisplatin|
214772635|NCT01399125|DRUG|Rivastigmine Patch|Once-daily target patch size 10 cm²
214772636|NCT01399125|DRUG|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
214772637|NCT01399125|DRUG|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
214772638|NCT01399125|DRUG|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
214772639|NCT04249063|DRUG|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
214772640|NCT04249063|DRUG|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
214772641|NCT05492019|DRUG|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
214772642|NCT05492019|DRUG|Placebo|Oral placebo identical to Doxycycline
214772643|NCT03638102|BEHAVIORAL|Sleep extension|Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching
214772644|NCT03638102|BEHAVIORAL|Healthy living|Participants will receive weekly health education
214772645|NCT05384327|OTHER|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
214772646|NCT05384327|OTHER|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
214772647|NCT04215120|DRUG|Desidustat Oral Tablet|Desidustat tablet
214772648|NCT04215120|DRUG|Epoetin Alfa|Epoetin Injection
214772649|NCT03945760|DRUG|Baricitinib|Baricitinib 2 mg
214772650|NCT03945760|DRUG|Placebo|Placebo
214772651|NCT00296829|BIOLOGICAL|Inactivated, split-virion influenza vaccine|
214772652|NCT06045429|DRUG|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
214772653|NCT06045429|DRUG|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
214772654|NCT05628766|OTHER|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
214772655|NCT05709626|DRUG|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
214772656|NCT05709626|DRUG|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
214772657|NCT01027026|OTHER|Early discharge|The patients are discharged the same day as coronary angiography.
214772658|NCT01027026|OTHER|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
214772659|NCT00647426|DRUG|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
214772660|NCT05027373|DRUG|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
214772661|NCT05027373|DRUG|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
214772662|NCT00148473|DRUG|Misoprostol|
214772663|NCT02374931|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
214772664|NCT02374931|PROCEDURE|Positron Emission Tomography|Undergo 18F-FES PET/CT
214772665|NCT02374931|PROCEDURE|Computed Tomography|Undergo 18F-FES PET/CT
214772666|NCT02374931|OTHER|Laboratory Biomarker Analysis|Correlative studies
214772667|NCT01480882|PROCEDURE|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
214772668|NCT01480882|DEVICE|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
214772669|NCT03996382|DIAGNOSTIC_TEST|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
214772670|NCT03235973|DRUG|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
214772671|NCT05748522|OTHER|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
214772672|NCT05748522|PROCEDURE|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
214772673|NCT01410695|DRUG|masitinib 3 mg|
214772674|NCT01410695|DRUG|masitinib 6.0 mg|
214772675|NCT01410695|DRUG|methotrexate|
214772676|NCT01410695|DRUG|Placebo (methotrexate)|
214772677|NCT01410695|DRUG|Placebo (masitinib)|
214772678|NCT00804349|DEVICE|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
214772679|NCT03078803|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
214772680|NCT03078803|BIOLOGICAL|Placebo|Transfer of water only
214772681|NCT02252484|OTHER|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
214772682|NCT02252484|OTHER|Standard of Care|Standard of Care for this patient population.
214772683|NCT01635686|DRUG|DWP422 25mg|
214772684|NCT01635686|DRUG|ENBREL 25MG PFS INJ.|
214772685|NCT06703463|DRUG|MK-1167|Administered via oral capsule per dosing regimen.
214772686|NCT06703463|DRUG|Diltiazem|Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
214772687|NCT01891786|BEHAVIORAL|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
214772688|NCT01891786|BEHAVIORAL|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
214772689|NCT06514118|RADIATION|residual tumor irradiation|lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
214772690|NCT04949984|DEVICE|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
214772691|NCT05267184|PROCEDURE|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
214772692|NCT05267184|PROCEDURE|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
214772693|NCT06087302|BEHAVIORAL|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
214772694|NCT00822679|DRUG|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
214772695|NCT00822679|OTHER|Placebo|Subjects are given placebo for 3 consecutive nights
214772696|NCT00116259|DRUG|Aripiprazole|
214772697|NCT04934332|PROCEDURE|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
214772698|NCT04934332|PROCEDURE|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
214772699|NCT04934332|PROCEDURE|Clinical examination|Weekly clinical examination from week-2 to week-5.
214772700|NCT04300907|DEVICE|Provant Infinity Therapy System|Treatment with the Provant Infinity Therapy System, PEMF device
214772701|NCT03343054|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
214772702|NCT05394428|OTHER|No intervention|No intervention
214772703|NCT02172183|DRUG|Psychopharmacological treatment|methylphenidate or atomoxetine
214772704|NCT02172183|BEHAVIORAL|CBT group|
214772705|NCT06438354|BIOLOGICAL|subgingival instrumentation plus Perisolv / hyaDent BG|Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.
214772706|NCT06438354|PROCEDURE|subgingival instrumentation|Group B: sites requiring re-treatment are subjected to subgingival scaling
214772707|NCT06540157|OTHER|Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)|Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
214772708|NCT06540157|OTHER|Sham group|Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
214772709|NCT01048268|DRUG|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
214772710|NCT01048268|DRUG|Placebo|copy GIP infusion rates
214772711|NCT02498899|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
214772712|NCT02498899|BEHAVIORAL|Video|Participants watch a video lasting about 4 minutes.
214772713|NCT03578276|DRUG|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
214772714|NCT03578276|DRUG|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
214772715|NCT03578276|DRUG|Gatifloxacin Ophthalmic|Antibiotic
214772716|NCT03578276|DRUG|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
214772717|NCT02626182|DRUG|sildenafil|active sildenafil
214772718|NCT02626182|DRUG|placebo|sugar pill that looks like sildenafil tablets
214772719|NCT00923494|DRUG|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
214772720|NCT00923494|DRUG|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
214772721|NCT00923494|DRUG|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
214772722|NCT00037973|BEHAVIORAL|ventilation feedback|
214772723|NCT00037973|BEHAVIORAL|exercise|
214772724|NCT00325429|DRUG|Vildagliptin|
214772725|NCT05774873|DRUG|IBI334 D|Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772726|NCT05774873|DRUG|IBI334 C|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772727|NCT05774873|DRUG|IBI334 A|Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772728|NCT05774873|DRUG|IBI334 B|Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772729|NCT05774873|DRUG|IBI334 F|Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772730|NCT05774873|DRUG|IBI334 E|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
214772731|NCT04316598|DRUG|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
214772732|NCT04316598|DRUG|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
214772733|NCT04904432|GENETIC|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
214772734|NCT06155825|BEHAVIORAL|no intervention|Group 4 will receive no intervention
214772735|NCT06155825|DRUG|nonnutritive suckling|Group 1 will receive nonnutritive suckling
214772736|NCT06155825|DRUG|oral glucose 25%|Group 2 will receive oral glucose 25%
214772737|NCT06155825|BEHAVIORAL|facilitated tuckling|Group 3 will undergo facilitated tuckling
214772738|NCT02343822|OTHER|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
214772739|NCT02343822|OTHER|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
214772740|NCT00883740|DRUG|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
214772741|NCT00883740|DRUG|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
214772742|NCT01986400|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
214772743|NCT00523887|DRUG|Fentanyl transdermal therapeutic system|
214772744|NCT06147609|DEVICE|lower lingual holding arch space maintainer|lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar
214772745|NCT06147609|DEVICE|Removable partial denture space maintainer|Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
214772746|NCT05715788|DRUG|Nitric oxide|Nitric oxide inhalation at 20 ppm
214772747|NCT05715788|BEHAVIORAL|prone positioning|vatilation in prone position
214772748|NCT00981409|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
214772749|NCT00981409|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
214772750|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery without mesh|retrospective study
214772751|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery with mesh|
214772752|NCT00921219|DRUG|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
214772753|NCT04152252|OTHER|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
214772754|NCT04152252|BEHAVIORAL|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
214772755|NCT00390949|BEHAVIORAL|Peer education among commercial sex workers and clients|
214772756|NCT00390949|BEHAVIORAL|Condom distribution and promotion|
214772757|NCT00390949|PROCEDURE|Syndromic treatment of sexually transmitted infections|
214772758|NCT00390949|PROCEDURE|Systemic counselling for STI patients|
214772759|NCT04765254|OTHER|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
214772760|NCT05684497|BEHAVIORAL|LBPSP in Pregnancy|LBPSP is a 50-minute interactive presentation as face to face program according to Pender's Health Promotion Model Parameters.
214772761|NCT00101894|DRUG|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
214772762|NCT00101894|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
214772763|NCT00101894|BIOLOGICAL|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
214772764|NCT00101894|DRUG|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
214772765|NCT02556931|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
214772766|NCT02556931|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
214772767|NCT02556931|RADIATION|Total body irradiation|Day -1: 200 cGy in a single fraction
214772768|NCT02556931|DRUG|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
214772769|NCT02556931|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
214772770|NCT00022126|DRUG|asparaginase|
214772771|NCT00022126|DRUG|cyclophosphamide|
214772772|NCT00022126|DRUG|cyclosporine|
214772773|NCT00022126|DRUG|cytarabine|
214772774|NCT00022126|DRUG|daunorubicin hydrochloride|
214772775|NCT00022126|DRUG|dexamethasone|
214772776|NCT00022126|DRUG|doxorubicin hydrochloride|
214772777|NCT00022126|DRUG|mercaptopurine|
214772778|NCT00022126|DRUG|methotrexate|
214772779|NCT00022126|DRUG|methylprednisolone|
214772780|NCT00022126|DRUG|pegaspargase|
214772781|NCT00022126|DRUG|thioguanine|
214772782|NCT00022126|DRUG|vincristine sulfate|
214772783|NCT00022126|PROCEDURE|allogeneic bone marrow transplantation|
214772784|NCT00022126|RADIATION|radiation therapy|
214772785|NCT06127004|OTHER|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
214772786|NCT06127004|OTHER|Supportive Counselling|Se arm/group descriptions
214772787|NCT02987504|DRUG|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
214772788|NCT02732886|DEVICE|Medifoam®|Foam Dressing
214772789|NCT02732886|DEVICE|Betafoam®|Foam dressing including Betadine iodine
214772790|NCT03150134|DRUG|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
214772791|NCT03150134|DRUG|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
214772792|NCT05815186|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
214772793|NCT05815186|DRUG|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
214772794|NCT03361917|DEVICE|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
214772795|NCT00323635|DRUG|tolterodine|tablet, 4 mg, daily, 1 month
214772796|NCT02228746|DIETARY_SUPPLEMENT|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
214772797|NCT01558869|DRUG|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
214772798|NCT01558869|DRUG|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
214772799|NCT01558869|DRUG|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
214772800|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
214772801|NCT06260319|GENETIC|Whole genome sequencing and Genome-Epigenome-Phenome Associations|"* Whole genome sequencing (WGS) and bioinformatics analysis~* Functional validation~* Genome-Epigenome-Phenome Associations"
214772802|NCT04477317|DRUG|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
214772803|NCT04477317|DRUG|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
214772804|NCT01653223|DRUG|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
214772805|NCT04083066|DRUG|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
214772806|NCT03869684|DRUG|MT-0814|Randomly assigned dose
214772807|NCT03869684|DRUG|Placebo|Placebo manufactured to mimic MT-0814
214772808|NCT05330143|DRUG|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
214772809|NCT05330143|DRUG|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
214772810|NCT05330143|DRUG|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
214772811|NCT05330143|DRUG|Placebo|0.9% saline vials administered subcutaneously once 4 week.
214772812|NCT05695079|OTHER|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
214772813|NCT05695079|OTHER|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
214772814|NCT05695079|OTHER|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
214772815|NCT05200806|OTHER|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
214772816|NCT03903952|DIETARY_SUPPLEMENT|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
214772817|NCT00646100|PROCEDURE|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
214772818|NCT05084937|OTHER|CeliCAT form|Systematic summary to support transition
214772819|NCT00654888|PROCEDURE|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
214772820|NCT00654888|DRUG|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
214772821|NCT06170840|DRUG|QY101Placebo/QY101 ointment|External use for BID
214772822|NCT04114526|OTHER|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
214772823|NCT05880420|DEVICE|Caregiver operations with medication accessories|After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
214772824|NCT05880420|DEVICE|Nurse operations with medication accessories|Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
214772825|NCT02860273|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
214772826|NCT02860273|DEVICE|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
214772827|NCT00381446|DEVICE|Marketed contact lens care products|
214772828|NCT00078312|DRUG|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
214772829|NCT05555186|DEVICE|BWL classrooms (Experimental)|Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.
214772830|NCT05555186|DEVICE|DWL classrooms (Comparison)|Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
214772831|NCT02069886|DRUG|deferasirox|125, 250, 500 mg dispersable tablets
214772832|NCT03460119|DEVICE|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
214772833|NCT05262933|OTHER|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
214772834|NCT05262933|OTHER|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
214772835|NCT06266975|DEVICE|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
214772836|NCT05294770|OTHER|Optisource® Plus: Very Low Calorie Diet treatment|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
214772837|NCT05294770|OTHER|Hypocaloric Mediterranean Diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
214772838|NCT02296788|BEHAVIORAL|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
214772839|NCT01968837|OTHER|Cervical cancer screening|
214772840|NCT06224478|OTHER|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
214772841|NCT02039583|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
214772842|NCT01096407|OTHER|laboratory biomarker analysis|Collection of urine samples
214772843|NCT01096407|OTHER|questionnaire administration|Completion of questionnaires
214772844|NCT01096407|PROCEDURE|assessment of therapy complications|An assessment will be completed.
214772845|NCT03424694|RADIATION|HDR brachytherapy as monotherapy|
214772846|NCT05160727|DRUG|Tislelizumab|200mg ivgtt d1 q3w
214772847|NCT05160727|DRUG|Irinotecan|"Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w."
214772848|NCT05160727|RADIATION|radiotherapy|radiotherapy
214772849|NCT05784727|DEVICE|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
214772850|NCT02400827|OTHER|malignant cells|
214772851|NCT05718882|DRUG|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
214772852|NCT03429374|DEVICE|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
214772853|NCT03429374|DEVICE|Absorbable tack|Absorbable tack
214772854|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
214772855|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
214772856|NCT04840901|DRUG|Lebrikizumab|Administered SC.
214772857|NCT05446376|DRUG|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
214772858|NCT05864235|BEHAVIORAL|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
214772859|NCT05864235|BEHAVIORAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
214772860|NCT05864235|BEHAVIORAL|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
214772861|NCT05354206|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
214772862|NCT05354206|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
214772863|NCT05354206|OTHER|Training with some stimulation|Motor task combined with real or sham stimulation
214772864|NCT06320080|DRUG|TQB2223 injection|TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
214772865|NCT06320080|DRUG|Penpulimab Injection|Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
214772866|NCT00826865|DRUG|Levetiracetam|750 mg tablet
214772867|NCT00085826|DRUG|Exisulind|
214772868|NCT01984619|DEVICE|Cryotherapy for the utilization of wrinkle reduction (iovera)|
214772869|NCT06702202|DRUG|Mixture of local anesthetics|Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
214772870|NCT06702202|DRUG|0.5% hyperbaric bupivacaine|Given in Subarachnoid block group (Group S)
214772871|NCT04045600|BEHAVIORAL|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
214772872|NCT04045600|BEHAVIORAL|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
214772873|NCT04045600|BEHAVIORAL|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
214772874|NCT04744064|DIETARY_SUPPLEMENT|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
214772875|NCT05380830|OTHER|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
214772876|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
214772877|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
214772878|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
214772879|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
214772880|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
214772881|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
214772882|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
214772883|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
214772884|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
214772885|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
214772886|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
214772887|NCT03121989|DRUG|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
214772888|NCT03121989|OTHER|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
214772889|NCT03121989|DRUG|NAC|Participants will be receiving NAC as part of their clinical treatment.
214772890|NCT04911660|DRUG|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
214772891|NCT04911660|OTHER|Placebo|1 placebo capsule per day for 14 days
214772892|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
214772893|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
214772894|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
214772895|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
214772896|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
214772897|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
214772898|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
214772899|NCT05601193|OTHER|autologous platelet-rich plasma|autologous PRP preparation was done by segregation of PRP following the centrifugation
214772900|NCT02209272|DRUG|bacteriostatic saline|
214772901|NCT02209272|DRUG|buffered lidocaine|
214772902|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
214772903|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
214772904|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
214772905|NCT06417203|PROCEDURE|spinal anesthesia with hyberbaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
214772906|NCT06417203|PROCEDURE|spinal anesthesia with hypobaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
214772907|NCT04210700|PROCEDURE|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
214772908|NCT04210700|PROCEDURE|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
214772909|NCT04449588|DRUG|BDB-001 Injection|BDB-001 Injection+Conventional treatment
214772910|NCT04449588|OTHER|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
214772911|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
214772912|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
214772913|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
214772914|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
214772915|NCT05388201|OTHER|N95|3M N95 Respirator
214772916|NCT05388201|OTHER|KN95|KN95 Mask (with and without clip)
214772917|NCT05388201|OTHER|KF94|KF94 Mask (with and without clip)
214772918|NCT05388201|OTHER|Surgical|Surgical Mask (with and without clip)
214772919|NCT04816500|DEVICE|Automatic ischemic conditioning treatment instrument|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
214772920|NCT04816500|DRUG|Regular treatment|Antiplatelet agents and statins administration, vascular risk factors control.
214772921|NCT01631370|PROCEDURE|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
214772922|NCT03292965|DRUG|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
214772923|NCT03292965|DRUG|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
214772924|NCT00853931|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
214772925|NCT00946465|DRUG|Ramipril 10 Capsule (Sandoz)|
214772926|NCT00946465|DRUG|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
214772927|NCT02667496|DRUG|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
214772928|NCT02667496|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
214772929|NCT02667496|DRUG|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
214772930|NCT00501696|DRUG|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
214772931|NCT00501696|DRUG|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
214772932|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
214772933|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
214772934|NCT04188860|DRUG|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
214772935|NCT06702280|DIETARY_SUPPLEMENT|IgY supplement|Ingesting the immune supplement over the experimental period
214772936|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
214772937|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
214772938|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
214772939|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
214772940|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
214772941|NCT03257774|OTHER|Adhesive strip A|Strip consisting of a newly developed adhesive
214772942|NCT03257774|OTHER|Adhesive strip B|Strip consisting of a newly developed adhesive
214772943|NCT03257774|OTHER|Adhesive strip C|Strip consisting of a newly developed adhesive
214772944|NCT06096181|DRUG|Remifentanil TIVA|Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.
214772945|NCT06096181|DRUG|Dexmedetomidine TIVA|Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.
214772946|NCT06096181|DRUG|Propofol TIVA|Propofol is an anesthetic drug that causes sleep during surgery.
214772947|NCT05760924|DEVICE|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
214772948|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
214772949|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
214772950|NCT04886232|DEVICE|VP1 Lido US|Hyaluronic acid dermal filler containing lidocaine
214772951|NCT04886232|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid dermal filler containing lidocaine
214772952|NCT00945971|OTHER|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
214772953|NCT01544374|OTHER|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
214772954|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
214772955|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
214772956|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
214772957|NCT05892965|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
214772958|NCT05548543|DRUG|HCP2202|Take it once per period.
214772959|NCT05548543|DRUG|RLD2202|Take it once per period.
214772960|NCT05548543|DRUG|RLD2203|Take it once per period.
214772961|NCT00130663|DEVICE|PDA blood pressure screening program and chart reminder|
214772962|NCT04425954|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
214772963|NCT00146133|BEHAVIORAL|diet, exercise|
214772964|NCT06701487|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of Pavlovian-to-instrumental transfer (PIT) effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
214772965|NCT06701487|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
214772966|NCT06701487|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
214772967|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Quantity Frequency: Alcohol, Cannabis, (Meth-) Amphetamine, Cocaine)~* SCID: AUD and SUD (Cannabis, Methamphetamine, Amphetamine, Cocaine) criteria and last year \& depressive symptoms \& symptoms for Mania and psychotic disorder (acute and lifetime) MiniDIPS psychotic disorders"
214772968|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T and STAI-S)~* Adult ADHD Self-Report Scale (ASRS)~* Alcohol Use Disorders Identification Test (AUDIT)~* CAS -A (Alkohol)~* Cannabis Use Disorders Identification Test (CUDIT)~* Fragebogen zu Gedanken und Gefühle 14 Items (FGG-14)~* Fragebogen zur Sozialen Unterstützung (F-SozU-K14)~* Trierer Inventar zum chronischen Stress (TICS)~* Oslo 3-Items-Social-Support Scale (Oslo-3)~* Social Readjustment Rating Scale (SRRS)~* International Trauma Questionnaire (ITQ)~* Positive and Negative Affect Schedule (PANAS)"
214772969|NCT06701487|BEHAVIORAL|Neuropsychological tests|"* Digit-Symbol-Test (DST)~* Digit Span Task~* Value-based decision-making task (VBDM)"
214772970|NCT04221217|DRUG|Icosapent|Icosapent (MND-2119) capsules.
214772971|NCT00221052|DRUG|Diclofenac|
214772972|NCT01270607|PROCEDURE|Acupuncture|Treatment given twice per week for 4 weeks
214772973|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.
214772974|NCT06700655|PROCEDURE|Corneal transplantation|The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.
214772975|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation combined corneal stromal stem cell group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
214772976|NCT03537222|DIAGNOSTIC_TEST|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
214772977|NCT04040907|DRUG|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
214772978|NCT04040907|DRUG|Placebo|Placebo and active drug will have the same appearance
214772979|NCT04415177|DEVICE|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
214772980|NCT04415177|DEVICE|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
214772981|NCT02618252|DEVICE|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
214772982|NCT02618252|DEVICE|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
214772983|NCT03821142|DEVICE|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
214772984|NCT03649256|DIAGNOSTIC_TEST|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
214772985|NCT00627458|BIOLOGICAL|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
214772986|NCT03411122|DRUG|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
214772987|NCT03411122|DRUG|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
214772988|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
214772989|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
214772990|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
214772991|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
214772992|NCT00913861|BEHAVIORAL|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
214772993|NCT00913861|DRUG|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
214772994|NCT00913861|BEHAVIORAL|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
214772995|NCT01535391|DRUG|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
214772996|NCT00168740|DRUG|rituximab|
214772997|NCT02311543|DRUG|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
214772998|NCT00159081|DRUG|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
214772999|NCT05523310|OTHER|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
214773000|NCT03778190|PROCEDURE|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
214773001|NCT01979302|OTHER|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
214773002|NCT01979302|OTHER|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
214773003|NCT00155259|DRUG|Docetaxel , Cisplatin , Capecitabine|
214773004|NCT05174078|OTHER|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
214773005|NCT05174078|OTHER|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
214773006|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min|when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
214773007|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min|the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
214773008|NCT04671160|DIAGNOSTIC_TEST|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
214773009|NCT06124326|DIETARY_SUPPLEMENT|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
214773010|NCT06404281|BIOLOGICAL|γδ T-PD-1 Ab cells|Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
214773011|NCT03573115|DRUG|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
214773012|NCT06565689|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
214773013|NCT01447979|DEVICE|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
214773014|NCT05234242|PROCEDURE|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
214773015|NCT01538589|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
214773016|NCT03224117|DRUG|DWJ211|inject the Drug into submental fat via subcutaneous
214773017|NCT03224117|DRUG|Normal saline|inject the Drug into submental fat via subcutaneous
214773018|NCT04538768|PROCEDURE|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
214773019|NCT04538768|PROCEDURE|Direct suture|direct fascia suture
214773020|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
214773021|NCT02765542|OTHER|Automated disease assessment & self-care support phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
214773022|NCT05109273|PROCEDURE|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
214773023|NCT00741117|PROCEDURE|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
214773024|NCT00741117|PROCEDURE|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
214773025|NCT00741117|PROCEDURE|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
214773026|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
214773027|NCT01734213|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
214773028|NCT01734213|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
214773029|NCT03252574|OTHER|A|AIR+ Smart Mask Only
214773030|NCT03252574|OTHER|B|AIR+ Smart Mask with micro-ventilator
214773031|NCT01909388|RADIATION|MRI-TRUS fusion guided real time HDR|
214773032|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
214773033|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
214773034|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
214773035|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
214773036|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
214773037|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
214773038|NCT00989365|OTHER|Aerobic training|Treadmill training
214773039|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
214773040|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
214773041|NCT00514501|DRUG|Iodofiltic acid I 123|
214773042|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
214773043|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
214773044|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
214773045|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
214773046|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
214773047|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
214773048|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
214773049|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
214773050|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
214773051|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
214773052|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
214773053|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
214773054|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
214773055|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
214773056|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
214773057|NCT01898624|DRUG|mirabegron|oral
214773058|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
214773059|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
214773060|NCT02603536|OTHER|WelTel|An evidence-based, text messaging solution for improving patient adherence.
214773061|NCT01875419|DEVICE|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
214773062|NCT01875419|BEHAVIORAL|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
214773063|NCT00924573|DRUG|Metformin|oral administration
214773064|NCT00924573|DRUG|placebo|oral administration
214773065|NCT00924573|DRUG|Glimepiride (HOE490)|oral administration
214773066|NCT00991146|DRUG|canakinumab|canakinumab
214773067|NCT01246297|OTHER|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
214773068|NCT01246297|OTHER|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
214773069|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
214773070|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
214773071|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
214773072|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
214773073|NCT02504463|DRUG|Samidorphan IV|Single IV administration
214773074|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
214773075|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
214773076|NCT06499935|OTHER|Rigid Taping|It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
214773077|NCT06499935|OTHER|Kinesio-Taping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
214773078|NCT06499935|OTHER|Sham Taping|Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
214773079|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
214773080|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
214773081|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
214773082|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
214773083|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
214773084|NCT01132170|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
214773085|NCT06047249|BEHAVIORAL|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
214773086|NCT06047249|BEHAVIORAL|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
214773087|NCT04265456|DRUG|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
214773088|NCT04265456|DRUG|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
214773089|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
214773090|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
214773091|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
214773092|NCT02587325|DRUG|nab-sirolimus|nab-sirolimus is an mTOR inhibitor
214773093|NCT01273584|DRUG|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
214773094|NCT01273584|DRUG|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
214773095|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
214773096|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
214773097|NCT01831596|DEVICE|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
214773098|NCT06328543|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
214773099|NCT06328543|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
214773100|NCT00682097|DRUG|RO4998452|Escalating oral doses
214773101|NCT00682097|DRUG|placebo|Oral doses
214773102|NCT00002066|DRUG|Thymopentin|
214773103|NCT05898009|GENETIC|blood sample for BRCA2 mutation detection|blood sample
214773104|NCT03784612|BEHAVIORAL|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
214773105|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
214773106|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
214773107|NCT05439291|PROCEDURE|Regular Epilation Regimen|Epilation using laser device
214773108|NCT05439291|PROCEDURE|Surgical excision|Excision of pilonidal pit with trephine
214773109|NCT05925309|DRUG|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
214773110|NCT05925309|DRUG|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
214773111|NCT05887518|DEVICE|Socks Developed with Wearable Technology|This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
214773112|NCT06381375|OTHER|Anti Tuberculosis Drug|"1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)."
214773113|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
214773114|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
214773115|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
214773116|NCT05924555|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
214773117|NCT05924555|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
214773118|NCT05924555|OTHER|Echography of upper leg|Determine upper leg muscle size
214773119|NCT05924555|OTHER|Hand grip strength with hand dynamometer|Determine muscle strength
214773120|NCT05924555|OTHER|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
214773121|NCT05940688|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
214773122|NCT05940688|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
214773123|NCT05940688|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
214773124|NCT06594289|PROCEDURE|In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake|"The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake)."
214773125|NCT04395885|OTHER|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
214773126|NCT02452775|BIOLOGICAL|OC-L|
214773127|NCT02452775|OTHER|Montanide|
214773128|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
214773129|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
214773130|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
214773131|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
214773132|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
214773133|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
214773134|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
214773135|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
214773136|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
214773137|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
214773138|NCT02681627|OTHER|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
214773139|NCT02681627|OTHER|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
214773140|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
214773141|NCT02006355|DRUG|Ropivacaine|
214773142|NCT01898884|DRUG|VP 20629|
214773143|NCT01898884|DRUG|Placebo|
214773144|NCT00013273|PROCEDURE|Physical Conditioning|
214773145|NCT02424799|DRUG|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
214773146|NCT02424799|DRUG|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
214773147|NCT02424799|DRUG|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
214773148|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
214773149|NCT00831038|PROCEDURE|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
214773150|NCT06702488|DRUG|dexmedetomidine|20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
214773151|NCT06702982|BEHAVIORAL|tele-nursing educational program|The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
214773152|NCT06703047|DRUG|ATRA+pd-1+chemo|All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
214773153|NCT06703047|DRUG|placebo+PD-1+chemo|Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
214773156|NCT02549885|OTHER|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
214773157|NCT02549885|OTHER|Static stretching|Static stretching of neck muscles.
214773158|NCT05183230|BEHAVIORAL|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
214773159|NCT05183230|BEHAVIORAL|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
214773160|NCT01379079|DRUG|Acetylsalicylic acid|aspirin intake at bedtime
214773161|NCT01379079|DRUG|Acetylsalicylic acid lysinate|aspirin intake on awakening
214773162|NCT01523769|PROCEDURE|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
214773163|NCT03446079|OTHER|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
214773164|NCT04113538|DRUG|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
214773165|NCT01004900|PROCEDURE|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
214773166|NCT01004900|DRUG|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
214773167|NCT01973842|DRUG|0.1 mg triptorelin|
214773168|NCT01973842|DRUG|0.2 mg triptorelin|
214773169|NCT01973842|DRUG|0.4 mg triptorelin|
214773170|NCT03711942|PROCEDURE|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
214773171|NCT03711942|PROCEDURE|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
214773172|NCT03711942|PROCEDURE|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
214773173|NCT03373409|DRUG|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
214773174|NCT03373409|DRUG|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
214773175|NCT03373409|DRUG|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
214773176|NCT00003583|DRUG|amifostine trihydrate|
214773177|NCT00003583|DRUG|cisplatin|
214773178|NCT00003583|DRUG|etoposide|
214773179|NCT00003583|RADIATION|radiation therapy|
214773180|NCT06348654|BEHAVIORAL|introduction of digital listening may improve the quality of life of patients withe breast cancer|Introduction of a digital listening and communication pathway aimed at improving the quality of life of patients with advanced HER2-negative breast cancer
214773181|NCT02185235|DEVICE|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
214773182|NCT02185235|DEVICE|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
214773183|NCT02185235|OTHER|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
214773184|NCT04093726|OTHER|lollipop|chewing lollipop for 20min
214773185|NCT01014026|OTHER|Screening test|Two Vaginal self sampling devices and HPV test
214773186|NCT01336608|DRUG|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
214773187|NCT01336608|DRUG|Vilanterol|Inhaled long acting beta-agonist
214773188|NCT01336608|DRUG|Placebo|Placebo
214773189|NCT00080288|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
214773190|NCT00080288|DRUG|Placebo|Matching placebo tablets once daily
214773191|NCT03044431|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
214773192|NCT00211666|BEHAVIORAL|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
214773193|NCT01325857|PROCEDURE|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
214773194|NCT01325857|PROCEDURE|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
214773195|NCT01325857|PROCEDURE|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
214773196|NCT05744531|OTHER|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
214773197|NCT02169531|DRUG|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
214773198|NCT03970668|DRUG|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
214773199|NCT03970668|DRUG|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
214773200|NCT05443217|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
214773201|NCT02913508|DRUG|Vedolizumab intravenous injection|Vedolizumab intravenous injection
214773202|NCT02913508|DRUG|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
214773203|NCT01938521|DIETARY_SUPPLEMENT|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
214773204|NCT01938521|DIETARY_SUPPLEMENT|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
214773205|NCT01440023|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
214773206|NCT01440023|BEHAVIORAL|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
214773207|NCT01440023|BEHAVIORAL|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
214773208|NCT00525564|DRUG|Placebo|Placebo diskus inhalation powder
214773209|NCT00525564|DRUG|Salmeterol diskus inhalation powder|50 micrograms twice a day
214773210|NCT02924103|DEVICE|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
214773211|NCT02874638|DIETARY_SUPPLEMENT|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
214773212|NCT02874638|DIETARY_SUPPLEMENT|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
214773213|NCT02874638|DIETARY_SUPPLEMENT|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
214773214|NCT02874638|DIETARY_SUPPLEMENT|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
214773215|NCT00941252|DRUG|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
214773216|NCT01757236|DRUG|VANCOMYCIN|
214773217|NCT01757236|DRUG|CEFTRIAXONE|
214773218|NCT01757236|DRUG|CLINDAMYCIN|
214773219|NCT01757236|DRUG|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
214773220|NCT01757236|DRUG|FLUOROQUINOLONE|
214773221|NCT01757236|DRUG|LINEZOLID|
214773222|NCT01757236|DRUG|RIFAMPIN|
214773223|NCT00188071|DRUG|paracetamol|
214773224|NCT00188071|DRUG|ketoprofen|
214773225|NCT00188071|DRUG|ketoprofen + paracetamol|
214773226|NCT03948737|DRUG|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
214773227|NCT03948737|DRUG|Placebo oral tablet|
214773228|NCT03654911|DIAGNOSTIC_TEST|EEG|EEG
214773229|NCT03654911|GENETIC|ApoE|ApoE
214773230|NCT00752154|DRUG|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
214773231|NCT02328547|DRUG|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
214773232|NCT02328547|DRUG|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
214773233|NCT00659854|DIETARY_SUPPLEMENT|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
214773234|NCT00659854|DIETARY_SUPPLEMENT|milk based formula|Babies will be given a milk based formula for 12 weeks
214773235|NCT00044005|DRUG|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
214773236|NCT00044005|DRUG|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
214773237|NCT00044005|DRUG|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
214773238|NCT01732198|BIOLOGICAL|NU300|
214773239|NCT01732198|BIOLOGICAL|ActHIB|
214773240|NCT01732198|BIOLOGICAL|Prevnar 13|
214773241|NCT00344305|BIOLOGICAL|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
214773242|NCT01952639|DIETARY_SUPPLEMENT|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
214773243|NCT00079144|BIOLOGICAL|NY-ESO-1 peptide vaccine|
214773244|NCT00079144|BIOLOGICAL|aldesleukin|
214773245|NCT00079144|BIOLOGICAL|filgrastim|
214773246|NCT00079144|BIOLOGICAL|incomplete Freund's adjuvant|
214773247|NCT00079144|BIOLOGICAL|therapeutic autologous lymphocytes|
214773248|NCT00079144|DRUG|cyclophosphamide|
214773249|NCT00079144|DRUG|fludarabine phosphate|
214773250|NCT03347227|PROCEDURE|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
214773251|NCT03799094|DRUG|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
214773252|NCT03799094|DRUG|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
214773253|NCT00176501|BIOLOGICAL|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
214773254|NCT01139892|PROCEDURE|Surgical management|
214773255|NCT01139892|PROCEDURE|Endovascular management|
214773256|NCT01204073|DRUG|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
214773257|NCT01274273|DRUG|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
214773258|NCT01274273|DRUG|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
214773259|NCT01274273|DRUG|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
214773260|NCT04024280|OTHER|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
214773261|NCT00209430|DRUG|Iodixanol 320 mgI/mL|
214773262|NCT00003273|BIOLOGICAL|filgrastim|
214773263|NCT00003273|DRUG|carboplatin|
214773264|NCT00003273|DRUG|cisplatin|
214773265|NCT00003273|DRUG|cyclophosphamide|
214773266|NCT00003273|DRUG|etoposide|
214773267|NCT00003273|DRUG|leucovorin calcium|
214773268|NCT00003273|DRUG|methotrexate|
214773269|NCT00003273|DRUG|temozolomide|
214773270|NCT00003273|DRUG|thiotepa|
214773271|NCT00003273|DRUG|vincristine sulfate|
214773272|NCT00003273|PROCEDURE|autologous bone marrow transplantation|
214773273|NCT00003273|PROCEDURE|peripheral blood stem cell transplantation|
214773274|NCT00003273|RADIATION|radiation therapy|
214773275|NCT01336218|DRUG|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
214773276|NCT01336218|DRUG|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
214773277|NCT03612713|DRUG|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
214773278|NCT03612713|DRUG|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
214773279|NCT01018342|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
214773280|NCT01018342|DRUG|Macrobid® Capsules 100 mg|
214773281|NCT05437484|BEHAVIORAL|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
214773282|NCT00606879|DRUG|SGX523 Capsules|This is a dose escalation study
214773283|NCT00830388|DRUG|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
214773284|NCT04256005|OTHER|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
214773285|NCT03783845|COMBINATION_PRODUCT|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
214773286|NCT06456398|OTHER|Virtual reality|"Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans."
214773287|NCT02698631|PROCEDURE|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
214773288|NCT02698631|PROCEDURE|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~* Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~* In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
214773289|NCT03745027|DIAGNOSTIC_TEST|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
214773290|NCT00507182|PROCEDURE|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
214773291|NCT03152227|OTHER|ACGG|50 high-producing chicks to households along with provision of technical input on production
214773292|NCT03152227|BEHAVIORAL|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
214773293|NCT00131430|DRUG|taranabant|
214773294|NCT05014425|PROCEDURE|pancreaticoduodenectomy|
214773295|NCT05089240|DEVICE|Ophthalmic lens with extra power|
214773296|NCT01143272|DRUG|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
214773297|NCT01143272|DRUG|Placebo|Placebo
214773298|NCT01726335|DRUG|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
214773299|NCT04393155|OTHER|COVID-19+ observational|This is observational -- there is no intervention
214773300|NCT00545181|DRUG|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
214773301|NCT00545181|DRUG|Metronidazole control|oral metronidazole therapy alone
214773302|NCT06541717|OTHER|Video-Based Fertility Awareness Training|Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
214773303|NCT04605523|PROCEDURE|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
214773304|NCT01456702|PROCEDURE|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
214773305|NCT01875133|OTHER|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
214773306|NCT01411670|DRUG|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
214773307|NCT01411670|DRUG|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
214773308|NCT01411670|DRUG|Placebo comparator|Standard treatment
214773309|NCT01543607|DEVICE|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
214773310|NCT02868307|BEHAVIORAL|Answering questionnaire|
214773311|NCT01917578|DEVICE|Ultrasound|"1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards."
214773312|NCT01917578|PROCEDURE|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
214773313|NCT01917578|PROCEDURE|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
214773314|NCT01917578|DEVICE|Pathologic Large Tissue Selected Table|"1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~2. Each piece of breast tissues by cutting with the table has 3mm thickness."
214773315|NCT01917578|DEVICE|Leica TP1020|"Procedure:~1. Alcohol 70 % 1h~2. Alcohol 80 % 1h~3. Alcohol 85 % 1h~4. Alcohol 90 % 1h~5. Alcohol 95 % 1h~6. Alcohol Ⅰ 100 % 1h~7. Alcohol Ⅱ 100 % 1h~8. Xylene Ⅰ 2h~9. Xylene Ⅱ 2h~10. Xylene Ⅲ 2h~11. Paraffin 6h~12. Paraffin 6h"
214773316|NCT01917578|DEVICE|Pathologic Large Tissue Embedded Table|"1. The table is made of brass .It is applying for a chinese patent.~2. The table can simultaneously embed 8 piece of breast tissues."
214773317|NCT01917578|DEVICE|Leica SM2000 R|Each of paraffin section has 4 um thickness.
214773318|NCT01917578|PROCEDURE|HE Stain|"Procedure:~1. Xylene Ⅰ 60℃ 15-20 minutes~2. Xylene Ⅱ 60℃ 15-20 minutes~3. Alcohol 100% Ⅰ 3-5 minutes~4. Alcohol 100% Ⅱ 3-5 minutes~5. Alcohol 95% Ⅱ 3-5 minutes~6. Alcohol 90% Ⅱ 3-5 minutes~7. Wash in running tap water for 3 minutes~8. Hematoxylin 5-10 minutes~9. Wash in running tap water for 3 minutes~10. Differentiate in 1% acid alcohol for 30 seconds~11. Wash in running tap water for 1 minute~12. Bluing in 0.2% ammonia water for 30-60 seconds~13. Wash in running tap water for 3 minutes~14. Counterstain in eosin Y solution for 30-60 seconds~15. Wash in running tap water for 1 minute~16. Alcohol 90% Ⅱ 2-3 minutes~17. Alcohol 95% Ⅱ 2-3 minutes~18. Alcohol 100% Ⅱ 3-5 minutes~19. Alcohol 100% Ⅱ 3-5 minutes~20. Xylene Ⅲ 5-10 minutes~21. Xylene Ⅳ 5-10 minutes~22. Mounting with neutral resin"
214773319|NCT01917578|DEVICE|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
214773320|NCT01917578|DEVICE|Epson V600|"1. Each slice that has been microscopically outlined is scanned by Epson V600.~2. Every image by scanning should be saved as JPG."
214773321|NCT01917578|DEVICE|MRI|"1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.~3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
214773322|NCT01917578|PROCEDURE|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~3. Observe the shrinkage modes in three-dimensional space.~4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
214773323|NCT01917578|DEVICE|Mammography|"1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size and calcification extent refers to WHO standards.~3. Calcification extent is not only measured in mammography image but also under microscope."
214773324|NCT01917578|DRUG|TAC,TC,TA,CAF,CEF|"1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
214773325|NCT01917578|DRUG|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
214773326|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
214773327|NCT02184507|DIETARY_SUPPLEMENT|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
214773328|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
214773329|NCT02184507|DRUG|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
214773330|NCT02872337|BEHAVIORAL|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
214773331|NCT02872337|BEHAVIORAL|Group Preoperative Education Session (per the standard of care)|
214773332|NCT01528878|RADIATION|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
214773333|NCT01335178|BEHAVIORAL|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project \[parents.org.il\];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
214773334|NCT00778271|DRUG|Gabapentin 400mg capsules|
214773335|NCT02458898|BEHAVIORAL|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
214773336|NCT01000545|DRUG|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
214773337|NCT01000545|DRUG|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
214773338|NCT01433198|OTHER|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
214773339|NCT01953627|PROCEDURE|Surgical procedure with the system Kymerax|
214773340|NCT01953627|DEVICE|The system Kymerax|
214773341|NCT01796860|OTHER|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
214773342|NCT00634582|DRUG|paricalcitol|
214773343|NCT00634582|OTHER|immunoenzyme technique|
214773344|NCT00634582|OTHER|laboratory biomarker analysis|
214773345|NCT00634582|PROCEDURE|dual x-ray absorptometry|
214773346|NCT00634582|PROCEDURE|quality-of-life assessment|
214773347|NCT03724669|BEHAVIORAL|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
214773348|NCT03724669|BEHAVIORAL|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
214773349|NCT00149669|BEHAVIORAL|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
214773350|NCT05741268|BEHAVIORAL|Dialectical behavior therapy|14\) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
214773351|NCT02903927|DEVICE|Implantation of CT LUCIA IOL|
214773352|NCT02903927|DEVICE|Implantation of Acrysof IQ SN60WF IOL|
214773353|NCT00166374|PROCEDURE|balloon kyphoplasty|
214773354|NCT02458365|BEHAVIORAL|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
214773355|NCT02458365|BEHAVIORAL|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
214773356|NCT03793595|DEVICE|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
214773357|NCT03793595|DEVICE|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
214773358|NCT03395574|DRUG|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
214773359|NCT03395574|DRUG|Normal saline|drug will be given after 30 minutes as placebo in control group
214773360|NCT03565666|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
214773361|NCT03565666|DRUG|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
214773362|NCT03565666|OTHER|Usual care|Usual care
214773363|NCT02282007|BEHAVIORAL|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
214773364|NCT01035593|PROCEDURE|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
214773365|NCT01035593|DRUG|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
214773366|NCT05991778|DEVICE|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
214773367|NCT05991778|DIAGNOSTIC_TEST|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
214773368|NCT05991778|DIAGNOSTIC_TEST|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
214773369|NCT05988593|DIETARY_SUPPLEMENT|placebo|consume one bottle (30 mL) per day
214773370|NCT05988593|DIETARY_SUPPLEMENT|MelaGene+|consume one bottle (30 mL) per day
214773371|NCT01472315|DRUG|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
214773372|NCT01472315|DRUG|Placebo|Placebo pills were taken in same way as active comparator
214773373|NCT02703454|PROCEDURE|FIRM-guided RF ablation|
214773374|NCT02703454|PROCEDURE|Conventional RF ablation|
214773375|NCT01226654|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
214773376|NCT00984828|DRUG|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
214773377|NCT01019278|RADIATION|proton beam radiation therapy|Undergo external proton beam radiation
214773378|NCT01019278|RADIATION|radiation therapy treatment planning/simulation|
214773379|NCT01019278|DRUG|cisplatin|Given IV
214773380|NCT00791154|DRUG|AMG 479|AMG 479 is administered to subjects
214773381|NCT00791154|DRUG|Etoposide|Etoposide is administered to subjects
214773382|NCT00791154|DRUG|Placebo|Placebo is administered with Carboplatin and Etoposide
214773383|NCT00791154|DRUG|AMG 102|AMG 102 is administered to subjects
214773384|NCT00791154|DRUG|Carboplatin|Carboplatin is administered to some subjects in combination
214773385|NCT00791154|DRUG|Cisplatin|Cisplatin is administered to some subjects in combination
214773386|NCT04960254|BEHAVIORAL|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy \& Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
214773387|NCT02913651|DEVICE|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
214773388|NCT03549845|BEHAVIORAL|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
214773389|NCT02284373|OTHER|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
214773390|NCT02284373|OTHER|Routine wound care for venous ulcers and lymphedema|wound care /dressings
214773391|NCT02284373|DEVICE|Flexitouch pneumonic compression|pneumonic compression only
214773392|NCT04428060|OTHER|PERSEUS CPR|Resuscitation based on patient physiology
214773393|NCT04428060|OTHER|Standard CPR|Resuscitation based on current guidelines
214773394|NCT00447291|DRUG|Supplement: Omega-3 Fish Oil|
214773395|NCT00447291|BEHAVIORAL|Multi-Disciplinary Nutrition & Exercise program|
214773396|NCT06568926|DIAGNOSTIC_TEST|Serum Ferritin level|follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
214773397|NCT04252326|OTHER|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
214773398|NCT06056531|OTHER|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
214773399|NCT06056531|OTHER|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
214773400|NCT00122031|DEVICE|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
214773401|NCT06190873|BEHAVIORAL|post-discharge rehabilitation training|Telephone training will be provided for post-discharge rehabilitation
214773402|NCT01206946|DRUG|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
214773403|NCT01206946|OTHER|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
214773404|NCT02665026|PROCEDURE|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
214773405|NCT00685048|BEHAVIORAL|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
214773406|NCT00685048|BEHAVIORAL|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
214773407|NCT00685048|BEHAVIORAL|four 50-minute individual therapy sessions of MET & CBT|MET \& CBT
214773408|NCT00710086|DRUG|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
214773409|NCT00710086|DRUG|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
214773410|NCT04161118|DRUG|CTL019|IV Infusion
214773411|NCT02413879|DEVICE|CleanCision|Wound protection during colorectal surgery.
214773412|NCT00128518|DRUG|Indapamide (T2)|1.5 mg/day during 4 weeks
214773413|NCT00128518|DRUG|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
214773414|NCT00128518|DRUG|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
214773415|NCT00128518|DRUG|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
214773416|NCT01681979|DRUG|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
214773417|NCT02757261|DEVICE|Laser|Low-level laser therapy administrated to acupoints
214773418|NCT02757261|DEVICE|Occlusal splint|Occlusal splint with expander
214773419|NCT02757261|DEVICE|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
214773420|NCT05171127|PROCEDURE|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
214773421|NCT06566495|DEVICE|collection of microbiological material from reusable tourniquets|"Microbiological analysis~The material was collected in each group in the same way."
214773422|NCT00179374|BEHAVIORAL|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
214773423|NCT00179374|BEHAVIORAL|Print educational intervention|diabetes educational materials by mail
214773424|NCT00843063|DRUG|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
214773425|NCT01803035|DRUG|LTX-109 1 %|
214773426|NCT01803035|DRUG|LTX-109 2 %|
214773427|NCT01803035|DRUG|Placebo gel|
214773428|NCT01106118|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
214773429|NCT06155149|OTHER|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
214773430|NCT06155149|OTHER|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
214773431|NCT03555500|OTHER|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
214773432|NCT04876807|DRUG|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
214773433|NCT04876807|DRUG|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
214773434|NCT06416007|RADIATION|Lattice therapy (LRT)|5 Fractions LRT
214773435|NCT01131702|DRUG|Ranitidine|Ranitidine Tablets, 300 mg
214773436|NCT02093650|DRUG|black cohosh extract|Black cohosh extract 80 mg
214773437|NCT02093650|DRUG|Placebo|Soy bean oil
214773438|NCT02307188|DEVICE|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
214773439|NCT00123331|DRUG|Cyclosporine discontinuation|
214773440|NCT00123331|DRUG|Rapamycin medication|
214773441|NCT03272867|DIETARY_SUPPLEMENT|ProManna|
214773442|NCT01207401|DRUG|Lidocaine|1% Lidocaine
214773443|NCT00439751|DRUG|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
214773444|NCT00006225|BIOLOGICAL|filgrastim|
214773445|NCT00006225|BIOLOGICAL|recombinant flt3 ligand|
214773446|NCT00006225|BIOLOGICAL|recombinant human thrombopoietin|
214773447|NCT00006225|BIOLOGICAL|recombinant interleukin-3|
214773448|NCT00006225|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214773449|NCT01508325|DRUG|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
214773450|NCT01508325|DRUG|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
214773451|NCT04299737|OTHER|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
214773452|NCT05870826|OTHER|Multiwave locked system laser therapy|High intensity laser therapy
214773453|NCT05870826|OTHER|Sham laser therapy|Sham laser therapy
214773454|NCT02696018|DEVICE|Ultrasonography|Ultrasonographic assessment of the diaphragm function
214773455|NCT01329705|DEVICE|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
214773456|NCT01329705|OTHER|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized"
214773457|NCT05932927|BIOLOGICAL|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
214773458|NCT06038266|PROCEDURE|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
214773459|NCT00727896|BEHAVIORAL|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
214773460|NCT00727896|DRUG|Diabetes Treatment|Life style modification and drug therapy
214773461|NCT03966573|RADIATION|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
214773462|NCT03966573|OTHER|Evaluating function|Test function and physical capasity
214773463|NCT03966573|OTHER|Forms|Forms for evaluating quality of life, pain, function
214773464|NCT00675701|DRUG|placebo|capsules
214773465|NCT00675701|DRUG|lixivaptan|capsules
214773466|NCT00675701|DRUG|moxifloxacin|tablets
214773467|NCT04429373|PROCEDURE|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
214773468|NCT04429373|PROCEDURE|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
214773469|NCT02543164|OTHER|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
214773470|NCT02543164|OTHER|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
214773471|NCT04259879|OTHER|Fasting|Food intake restriction
214773472|NCT03543046|DEVICE|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
214773473|NCT06700408|DRUG|Dachaihu Decoction combined Erzhiwan with variation|Chinese medicine granules
214773474|NCT06700408|OTHER|Placebo granules|Placebo granules
214773475|NCT01227954|RADIATION|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
214773476|NCT06538545|BEHAVIORAL|Sitting position is used in Experimental Arms 1-2|sitting position Comparison of sitting position and lithotomy position in labor
214773477|NCT00666731|OTHER|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
214773478|NCT00666731|OTHER|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
214773479|NCT00666731|OTHER|study of socioeconomic and demographic variables|Repository
214773480|NCT00666731|PROCEDURE|Excess human biological tissue|Tissue procurement.
214773481|NCT00666731|PROCEDURE|quality-of-life assessment|Cancer care.
214773482|NCT04521439|DIAGNOSTIC_TEST|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
214773483|NCT01495169|DRUG|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
214773484|NCT02840214|DEVICE|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
214773485|NCT02840214|DEVICE|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
214773486|NCT00004375|PROCEDURE|ultraviolet A-1 light treatment|
214773487|NCT01296152|DRUG|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
214773488|NCT02353299|DRUG|Silenor 6 mg|Silenor 6 mg single nighttime dose.
214773489|NCT02353299|DRUG|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
214773490|NCT02353299|DRUG|Placebo|placebo single nighttime dose-1.5 hours
214773491|NCT02353299|DRUG|Placebo|placebo single nighttime dose-4 hours
214773492|NCT01096706|DRUG|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
214773493|NCT01096706|DRUG|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
214773494|NCT01096706|DRUG|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
214773495|NCT01096706|DRUG|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
214773496|NCT01096706|DRUG|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
214773497|NCT01268137|PROCEDURE|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
214773498|NCT01416298|OTHER|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and \> 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching \>10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after \>10% is achieved is acceptable and now will be put into standard clinical practice.
214773499|NCT03081195|BEHAVIORAL|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
214773500|NCT06419803|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
214773501|NCT03949283|DIAGNOSTIC_TEST|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
214773502|NCT03949283|DRUG|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
214773503|NCT06180577|DEVICE|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
214773504|NCT06030271|DEVICE|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
214773505|NCT01256346|DEVICE|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
214773506|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
214773507|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
214773508|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
214773509|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
214773510|NCT00149773|BEHAVIORAL|Cognitive Therapy|
214773511|NCT00146003|DRUG|Efalizumab treatment|
214773512|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
214773513|NCT03199846|OTHER|Non-Interventional|Non-Interventional
214773514|NCT05367934|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch for stress
214773515|NCT06540677|OTHER|Musical training|Musical training with Meludia software, an online self-paced music training application
214773516|NCT05340517|PROCEDURE|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
214773517|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
214773518|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
214773519|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
214773520|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
214773521|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
214773522|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
214773523|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
214773524|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
214773525|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
214773526|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
214773527|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
214773528|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
214773529|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
214773530|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
214773531|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
214773532|NCT01396473|BEHAVIORAL|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
214773533|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
214773534|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
214773535|NCT04057118|DRUG|SKI-O-703|Oral administration, twice per day
214773536|NCT04057118|DRUG|Placebo|Oral administration, twice per day
214773537|NCT02231307|DRUG|SUBLIVAC FIX Birch|
214773538|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
214773539|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
214773540|NCT02787785|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
214773541|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
214773542|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
214773543|NCT06180174|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
214773544|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
214773545|NCT05220865|PROCEDURE|Hall Technique|"* Only food scraps or debris will be removed from the caries cavity.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
214773546|NCT05220865|PROCEDURE|Modified Hall Technique|"* Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
214773547|NCT05764200|DIETARY_SUPPLEMENT|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
214773548|NCT05764200|DIETARY_SUPPLEMENT|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
214773549|NCT01315054|BEHAVIORAL|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
214773550|NCT01315054|BEHAVIORAL|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
214773551|NCT01315054|OTHER|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
214773552|NCT00848666|DRUG|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
214773553|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
214773554|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
214773555|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
214773556|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
214773557|NCT02296671|DRUG|Pemetrexed|
214773558|NCT02296671|DRUG|Oxaliplatin|
214773559|NCT02296671|DRUG|Leucovorin|
214773560|NCT02296671|DRUG|Fluorouracil|
214773561|NCT02296671|GENETIC|Germline genotyping analyses for TSER|
214773562|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
214773563|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
214773564|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
214773565|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
214773566|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
214773567|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
214773568|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
214773569|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
214773570|NCT02275182|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
214773571|NCT02275182|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
214773572|NCT03818542|DRUG|ABBV-181|intravenous infusion
214773573|NCT03818542|DRUG|ABBV-368|intravenous infusion
214773574|NCT03818542|DRUG|ABBV-927|intravenous infusion
214773575|NCT03818542|DRUG|ABBV-927|intratumoral injection
214773576|NCT00003166|DRUG|bryostatin 1|Given IV
214773577|NCT00003166|DRUG|vincristine sulfate|Given IV
214773578|NCT00003166|OTHER|laboratory biomarker analysis|Correlative studies
214773579|NCT03250507|DRUG|Bupivacaine|0.25% bupivacaine for TAP block
214773580|NCT03250507|DRUG|Liposomal bupivacaine|Exparel for TAP block
214773581|NCT03250507|DRUG|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
214773582|NCT05213507|DRUG|aerosol inhaled Amikacin Sulfate Injection|0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
214773583|NCT05213507|OTHER|conventional therapy|According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
214773584|NCT01839565|DEVICE|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
214773585|NCT02902666|DRUG|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
214773586|NCT02902666|DRUG|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
214773587|NCT04295109|DRUG|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
214773588|NCT01817335|PROCEDURE|psychosocial assessment and care|Participate in psycho-educational program
214773589|NCT01817335|OTHER|educational intervention|Participate in psycho-educational program
214773590|NCT01817335|OTHER|communication skills training|Participate in psycho-educational program
214773591|NCT01817335|OTHER|questionnaire administration|Ancillary studies
214773592|NCT01771419|DEVICE|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
214773593|NCT01771419|DEVICE|Cannulotome CT-25mm Cook Medical|
214773594|NCT05829382|DIETARY_SUPPLEMENT|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
214773595|NCT05829382|DIETARY_SUPPLEMENT|Placebo|Capsule containing placebo administered daily by the participant during the trial period
214773596|NCT03289637|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
214773597|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
214773598|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
214773599|NCT02718976|PROCEDURE|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
214773600|NCT02718976|PROCEDURE|Ultrasound guided lumbar plexus block (Shamrock)|
214773601|NCT02718976|DRUG|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
214773602|NCT00103259|DRUG|bortezomib|Given IV
214773603|NCT00103259|DRUG|irinotecan hydrochloride|Given IV
214773604|NCT00103259|OTHER|laboratory biomarker analysis|Optional correlative studies
214773605|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
214773606|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
214773607|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
214773608|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
214773609|NCT03845855|OTHER|virtual reality|Virtual reality with a game
214773610|NCT03845855|OTHER|robotic gait|robotic gait therapy
214773611|NCT04416295|DEVICE|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
214773612|NCT01572428|PROCEDURE|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
214773613|NCT01572428|PROCEDURE|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
214773614|NCT05233371|OTHER|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
214773615|NCT05233371|OTHER|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~* Frequency and duration of rehabilitation sessions by type of health professionals,~* Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
214773616|NCT05233371|OTHER|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
214773617|NCT01884870|PROCEDURE|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
214773618|NCT01537575|BIOLOGICAL|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
214773619|NCT01537575|BIOLOGICAL|Saline solution|Placebo
214773620|NCT03330028|DRUG|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
214773621|NCT03330028|DRUG|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
214773622|NCT03330028|DRUG|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
214773623|NCT03330028|DRUG|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
214773624|NCT03330028|DRUG|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
214773625|NCT03330028|DRUG|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
214773626|NCT01906801|DRUG|Glucosamine sulfate|
214773627|NCT01906801|DRUG|Diacerein|
214773628|NCT01906801|DRUG|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
214773629|NCT05512715|PROCEDURE|radioactive iodine|radioactive iodine 15mci
214773630|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
214773631|NCT02629237|OTHER|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
214773632|NCT00850382|DRUG|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
214773633|NCT00850382|DRUG|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
214773634|NCT00850382|DRUG|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
214773635|NCT04101721|DRUG|aflibercept|Administered IVT
214773636|NCT04101721|PROCEDURE|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
214773637|NCT05420818|PROCEDURE|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
214773638|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
214773639|NCT03986918|DEVICE|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
214773640|NCT01972607|OTHER|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
214773641|NCT06138678|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
214773642|NCT04736576|DEVICE|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
214773643|NCT00886873|DRUG|Mifepristone|
214773644|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
214773645|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
214773646|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
214773647|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
214773648|NCT05851976|DRUG|Naproxen|Naproxen 500mg twice daily for 16 days
214773649|NCT05851976|DRUG|Duloxetine|Duloxetine 60mg daily for 14 days
214773650|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
214773651|NCT02426294|DRUG|Pioglitazone|
214773652|NCT02426294|DRUG|Glimepiride|
214773653|NCT00993629|DRUG|pregnenolone|"Administered adjunctively to treatment as usual"
214773654|NCT00993629|DRUG|placebo|adjunctive placebo
214773655|NCT06536725|OTHER|Building Organoid-on-chips models|This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
214773656|NCT02107768|OTHER|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1\. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
214773657|NCT05584839|OTHER|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
214773658|NCT01155258|DRUG|temsirolimus|Given IV
214773659|NCT01155258|DRUG|vinorelbine ditartrate|Given IV
214773660|NCT01418534|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
214773661|NCT05302037|BIOLOGICAL|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
214773662|NCT02958774|RADIATION|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
214773663|NCT00716027|BEHAVIORAL|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
214773664|NCT00716027|BEHAVIORAL|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
214773665|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
214773666|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
214773667|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
214773668|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
214773669|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
214773670|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
214773671|NCT00535301|DEVICE|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
214773672|NCT00535301|PROCEDURE|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
214773673|NCT06459401|DEVICE|Propulsion Neuroprosthesis|A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
214773674|NCT01087801|DRUG|ChiRhoStim|Human Secretin for Injection
214773675|NCT01087801|DRUG|Placebo|Saline for Injection
214773676|NCT05961319|DEVICE|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
214773677|NCT00542958|DRUG|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
214773678|NCT05960708|DRUG|YH35324|Subcutaneous injection of YH35324
214773679|NCT05960708|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
214773680|NCT05960708|DRUG|Placebo|Subcutaneous injection of None of active ingredient
214773681|NCT03146507|RADIATION|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
214773682|NCT03146507|RADIATION|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
214773683|NCT03146507|RADIATION|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
214773684|NCT04330482|BEHAVIORAL|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
214773685|NCT04330482|BEHAVIORAL|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
214773686|NCT06523465|DRUG|Simvastatin combined with Amlodipine besylate|6-month treatment of Simvastatin combined with Amlodipine besylate
214773687|NCT06523465|DRUG|Simvastatin combined with Spironolactone and Amlodipine besylate.|6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
214773688|NCT06523465|DRUG|Amlodipine besylate combined Spironolactone|6-month treatment of Amlodipine besylate combined with Spironolactone
214773689|NCT02079389|DEVICE|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
214773690|NCT04671329|DEVICE|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
214773691|NCT04592731|DRUG|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
214773692|NCT04592731|DRUG|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
214773693|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
214773694|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
214773695|NCT01906034|BEHAVIORAL|Exercise with supervision|
214773696|NCT01906034|BEHAVIORAL|Home-based without supervision|
214773697|NCT05822024|BEHAVIORAL|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
214773698|NCT05349890|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
214773699|NCT05349890|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
214773700|NCT05349890|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
214773701|NCT02223598|DRUG|CB-5083|
214773702|NCT02223598|DRUG|Dexamethasone|
214773703|NCT01819701|DIETARY_SUPPLEMENT|LC-1000|L-carnitine 1000 mg /d
214773704|NCT01819701|DIETARY_SUPPLEMENT|LC-2000|L-carnitine: 2000 mg/d
214773705|NCT01819701|DIETARY_SUPPLEMENT|Q10-150|Coenzyme Q10: 150 mg/d
214773706|NCT01819701|DIETARY_SUPPLEMENT|Q10-300|Coenzyme Q10: 300 mg/d
214773707|NCT01819701|OTHER|Placebo|
214773708|NCT05144477|BEHAVIORAL|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
214773709|NCT03875300|BEHAVIORAL|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
214773710|NCT04632563|OTHER|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
214773711|NCT02670993|BEHAVIORAL|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
214773712|NCT02670993|BEHAVIORAL|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
214773713|NCT05148455|OTHER|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
214773714|NCT05148455|DIAGNOSTIC_TEST|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
214773715|NCT05148455|OTHER|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
214773716|NCT03273712|RADIATION|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
214773717|NCT03273712|DIAGNOSTIC_TEST|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
214773718|NCT03273712|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
214773719|NCT06700421|DRUG|Adebrelimab + Apatinib|Adebrelimab combined with apatinib
214773720|NCT04138602|DEVICE|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
214773721|NCT04138602|DEVICE|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
214773722|NCT03111407|PROCEDURE|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
214773723|NCT06102707|DRUG|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
214773724|NCT06652555|OTHER|Group 1|without Intervention
214773725|NCT03022019|DEVICE|ReNovaCell|
214773726|NCT06267118|DRUG|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
214773727|NCT06267118|DRUG|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
214773728|NCT01341158|DRUG|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
214773729|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
214773730|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
214773731|NCT03299218|DIETARY_SUPPLEMENT|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
214773732|NCT03299218|BEHAVIORAL|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
214773733|NCT03299218|OTHER|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
214773734|NCT04831931|OTHER|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
214773735|NCT00179218|DRUG|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
214773736|NCT00179218|BEHAVIORAL|exercise|leg press exercise; every other day, 3 days per week, for 6 months
214773737|NCT00181831|DEVICE|Proton Magnetic Resonance Spectroscopy|
214773738|NCT04072744|DEVICE|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
214773739|NCT04072744|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
214773740|NCT06440486|DIETARY_SUPPLEMENT|Probiotics|Serum and fecal samples were collected at the beginning and end of the study to evaluate the effects of probiotic consumption on immune markers, metabolites, and gut microbiota before and after administration.
214773741|NCT01938742|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
214773742|NCT01938742|DRUG|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
214773743|NCT06566794|DRUG|Caffeine Tablet|0,5 x 100 mg tablet (50 mg caffeine).
214773744|NCT06566794|DRUG|Bupropion Hydrochloride Capsels|1 x 20 mg tablet.
214773745|NCT06566794|DRUG|Repaglinide Capsels|1 x 0,05 mg tablet.
214773746|NCT06566794|DRUG|Flurbiprofen Capsels|1 x 10 mg tablet.
214773747|NCT06566794|DRUG|Omeprazole 10 MG|1 x 10 mg tablet.
214773748|NCT06566794|DRUG|Dextromethorphan Oral Solution|5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
214773749|NCT06566794|DRUG|Midazolam oral solution|0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
214773750|NCT06566794|DRUG|Simvastatin tablets|1 x 10 mg tablet.
214773751|NCT06566794|DRUG|Placebo|2 x placebo tablets in the Placebo Phase/Arm
214773752|NCT06566794|DRUG|Carvedilol|2 x 25 mg tablets
214773753|NCT06566794|DRUG|Diclofenac|1 x 50 mg tablet (three times daily for three days)
214773754|NCT03843268|DEVICE|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
214773755|NCT03843268|DEVICE|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
214773756|NCT00789568|DRUG|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
214773757|NCT00789568|DRUG|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
214773758|NCT00789568|DRUG|Moxifloxacin placebo|Moxifloxacin placebo tablet
214773759|NCT06520995|OTHER|Educational video program|Diabetes education video contents are as follows; Type 2 diabetes definition, symptoms and the effect of diabetes on cognitive functions, Medical nutrition therapy and healthy nutrition recommendations in Type 2 diabetes, The importance of diabetes and exercise, Oral antidiabetic treatments, Insulin treatment, Hypoglycemia symptoms, findings and treatment, Macrovascular complications in diabetes, Microvascular complications in diabetes, Foot Protection and care recommendations, Diabetes self-care skills and problem-solving strategies, Diabetes and stress management.
214773760|NCT06520995|OTHER|A mobile application|This mobile application is a science-based application that patients can access via their smartphone or tablet. It consists of verbal, numerical, visual, logical, memory and attention categories and contains 24 different gamified mind exercises
214773761|NCT02139579|DRUG|Bevacizumab|7.5 mg/kg every 3 weeks
214773762|NCT03751527|DEVICE|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
214773763|NCT03547596|OTHER|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
214773764|NCT06500299|DRUG|HDM1002 100 mg QD|HDM1002 tablets 100mg daily, 12weeks
214773765|NCT06500299|DRUG|HDM1002 200 mg QD 12weeks|HDM1002 tablets 200mg daily, 12weeks
214773766|NCT06500299|DRUG|HDM1002 400 mg QD 12weeks|HDM1002 tablets 400mg daily, 12weeks
214773767|NCT06500299|DRUG|Placebo|Matching placebo will be provided
214773768|NCT02617173|DEVICE|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
214773769|NCT00481273|DRUG|Azacitidine|Physician's discretion
214773770|NCT02268045|BIOLOGICAL|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
214773771|NCT02268045|BIOLOGICAL|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
214773772|NCT02412696|DEVICE|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
214773773|NCT02412696|OTHER|Nasal Dilator Strips|Nasal dilator strips
214773774|NCT03797339|OTHER|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
214773775|NCT03797339|OTHER|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
214773776|NCT03797339|OTHER|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
214773777|NCT03797339|OTHER|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
214773778|NCT01154673|DRUG|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
214773779|NCT01154673|DRUG|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
214773780|NCT01154673|DRUG|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
214773781|NCT01154673|DRUG|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
214773782|NCT03768388|DRUG|levoketoconazole|food effect
214773783|NCT03456973|BEHAVIORAL|Nurse AMIE|Supportive care software platform
214773784|NCT05199207|BEHAVIORAL|Physical activity programm|adapted physical activity during 3 month
214773785|NCT01461148|BIOLOGICAL|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
214773786|NCT04215107|OTHER|Standard breakfast meal|"The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting."
214773787|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
214773788|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
214773789|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
214773790|NCT02677337|OTHER|Educational Program|
214773791|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
214773792|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
214773793|NCT00329758|DRUG|Placebo|
214773794|NCT04672824|BIOLOGICAL|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
214773795|NCT04672824|OTHER|Saline|0.5ml saline placebo
214773796|NCT03159000|DRUG|Saline|1ml of 1/3 saline
214773797|NCT03159000|COMBINATION_PRODUCT|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
214773798|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
214773799|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
214773800|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
214773801|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
214773802|NCT04420000|OTHER|Control|Treatment as usual
214773803|NCT05121688|OTHER|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
214773804|NCT00000510|DRUG|aspirin|
214773805|NCT00000510|DRUG|dipyridamole|
214773806|NCT00000510|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214773807|NCT04113564|DRUG|Remimazolam|
214773808|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773809|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773810|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773811|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
214773812|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773813|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773814|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773815|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773816|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773817|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773818|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773819|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773820|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
214773821|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773822|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773823|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773824|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773825|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773826|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773827|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773828|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
214773829|NCT01289990|DRUG|Sitagliptin 100mg|Sitagliptin once daily
214773830|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
214773831|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773832|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773833|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773834|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773835|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
214773836|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773837|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
214773838|NCT03023098|DEVICE|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
214773839|NCT03023098|DEVICE|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
214773840|NCT05174559|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
214773841|NCT01854801|OTHER|Individual medical Care|Individual medical care in occupational and environmental diseases centers
214773842|NCT01854801|OTHER|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
214773843|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
214773844|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
214773845|NCT00567346|DRUG|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
214773846|NCT00567346|DRUG|grass pollen extract|Patients will receive matching placebo sublingually
214773847|NCT04289467|DRUG|Fenfluramine|Open-label
214773848|NCT04639739|BIOLOGICAL|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
214773849|NCT03406832|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
214773850|NCT03406832|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
214773851|NCT03406832|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
214773852|NCT02494310|DEVICE|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
214773853|NCT06018246|DIETARY_SUPPLEMENT|Malnutrition five-step treatment model + conventional nutritional intervention|"1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
214773854|NCT06018246|OTHER|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
214773855|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
214773856|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
214773857|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
214773858|NCT05085197|DRUG|Placebo|Intravenous injection
214773859|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
214773860|NCT05085197|DRUG|Placebo|Intravenous injection
214773861|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
214773862|NCT05085197|DRUG|Placebo|Intravenous injection
214773863|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
214773864|NCT05085197|DRUG|Placebo|Intravenous injection
214773865|NCT04089163|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
214773866|NCT04089163|DRUG|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
214773867|NCT02253407|BIOLOGICAL|MMR vaccine|
214773868|NCT00005609|BIOLOGICAL|rituximab|
214773869|NCT05633901|OTHER|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
214773870|NCT05633901|OTHER|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
214773871|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
214773872|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
214773873|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
214773874|NCT03417674|COMBINATION_PRODUCT|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
214773875|NCT06566755|DRUG|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
214773876|NCT01666067|DRUG|placebo|
214773877|NCT01666067|DRUG|vytorin|
214773878|NCT01666067|DRUG|simvastatin|
214773879|NCT01278446|OTHER|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
214773880|NCT01278446|OTHER|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
214773881|NCT05052879|DRUG|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
214773882|NCT05052879|DRUG|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
214773883|NCT05052879|OTHER|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
214773884|NCT05052879|OTHER|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
214773885|NCT06113783|DEVICE|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
214773886|NCT04923906|DRUG|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
214773887|NCT04923906|DRUG|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
214773888|NCT01488071|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
214773889|NCT01488071|DRUG|Agomelatine|encapsulated tablets, daily, orally
214773890|NCT06472050|DRUG|Romosozumab|osteoporosis treatment
214773891|NCT06472050|DRUG|Denosumab|osteoporosis treatment
214773892|NCT04449354|DEVICE|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
214773893|NCT05224297|RADIATION|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
214773894|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
214773895|NCT05789420|OTHER|P1R stick|Regular flavor tobacco stick
214773896|NCT05789420|OTHER|P1M stick|Mentholated flavor tobacco stick
214773897|NCT05789420|OTHER|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
214773898|NCT02720094|DRUG|Cabotegravir Oral Tablet|30 mg tablet
214773899|NCT02720094|DRUG|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
214773900|NCT02720094|DRUG|Placebo for TDF/FTC tablets|
214773901|NCT02720094|DRUG|Placebo for cabotegravir oral tablet|
214773902|NCT02720094|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
214773903|NCT02720094|DRUG|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
214773904|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
214773905|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
214773906|NCT05317000|DRUG|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
214773907|NCT05317000|DRUG|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
214773908|NCT05317000|DRUG|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
214773909|NCT06235125|DRUG|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
214773910|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
214773911|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
214773912|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
214773913|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
214773914|NCT01220128|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
214773915|NCT01220128|DRUG|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
214773916|NCT01220128|DRUG|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
214773917|NCT01220128|DRUG|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773918|NCT01220128|DRUG|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
214773919|NCT01220128|DRUG|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773920|NCT01220128|DRUG|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773921|NCT01220128|DRUG|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773922|NCT01220128|DRUG|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773923|NCT01220128|DRUG|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773924|NCT01220128|DRUG|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
214773925|NCT06090500|PROCEDURE|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
214773926|NCT06090500|PROCEDURE|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
214773927|NCT06090500|PROCEDURE|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
214773928|NCT02913261|DRUG|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
214773929|NCT02913261|DRUG|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
214773930|NCT03478774|DRUG|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher\&Paykel.
214773931|NCT03478774|DRUG|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
214773932|NCT03478774|DRUG|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
214773933|NCT03478774|PROCEDURE|Jaw thrust|Continuous
214773934|NCT03478774|PROCEDURE|Videolaryngoscopy|Continuous
214773935|NCT03478774|DRUG|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
214773936|NCT00285350|DRUG|mycophenolate mofetil|
214773937|NCT02390466|BIOLOGICAL|VAC-3S|Administered via intra-muscular injection in the arm
214773938|NCT04931758|OTHER|Pain Questionnaire|Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
214773939|NCT06543004|COMBINATION_PRODUCT|AH plus sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
214773940|NCT06543004|COMBINATION_PRODUCT|Bioceramic sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
214773941|NCT03286595|OTHER|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
214773942|NCT02460315|PROCEDURE|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
214773943|NCT02460315|PROCEDURE|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
214773944|NCT04164394|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
214773945|NCT04164394|DIETARY_SUPPLEMENT|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
214773946|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
214773947|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
214773948|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
214773949|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
214773950|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
214773951|NCT04803773|DEVICE|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
214773952|NCT03305783|PROCEDURE|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
214773953|NCT06568887|COMBINATION_PRODUCT|Dextrose Water|Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
214773954|NCT06568887|COMBINATION_PRODUCT|Corticosteroid Injection|Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
214773955|NCT06568991|DIETARY_SUPPLEMENT|Low Protein Rice MATSUBUMAI|"Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group."
214773956|NCT03089931|PROCEDURE|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
214773957|NCT01016158|DRUG|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
214773958|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
214773959|NCT01111994|DRUG|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
214773960|NCT03951181|BEHAVIORAL|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
214773961|NCT04568642|DEVICE|Activate FiO2 controller|Closed-loop FiO2 controller will be activated in the experimental arm
214773962|NCT04568642|DEVICE|Deactivate FiO2 controller|Closed-loop FiO2 controller will be deactivated in the experimental arm
214773963|NCT05288374|DRUG|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
214773964|NCT05288374|DRUG|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
214773965|NCT05685693|PROCEDURE|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
214773966|NCT05685693|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
214773967|NCT02865473|DRUG|Pilocarpine|topical instillation into the study eye
214773968|NCT04599673|DRUG|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
214773969|NCT04599673|OTHER|normal saline|10 ml normal saline
214773970|NCT06503523|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL
214773971|NCT06503523|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
214773972|NCT06503523|OTHER|Cowhage|This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
214773973|NCT06503523|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
214773974|NCT01550068|DIAGNOSTIC_TEST|Echocardiography|
214773975|NCT04099082|OTHER|samples|blood sample nasal swab
214773976|NCT00004328|DRUG|enalapril|
214773977|NCT00004328|DRUG|polystyrene sulfonate|
214773978|NCT02340078|DEVICE|HA IDF II plus|
214773979|NCT02340078|DEVICE|HA IDF II|
214773980|NCT00935896|PROCEDURE|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
214773981|NCT00935896|PROCEDURE|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
214773982|NCT00935896|OTHER|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
214773983|NCT05619809|DIETARY_SUPPLEMENT|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
214773984|NCT05619809|DIETARY_SUPPLEMENT|Protein supplement|Daily ingestion of protein supplement.
214773985|NCT05619809|DIETARY_SUPPLEMENT|Placebo supplement|Daily ingestion of a placebo dietary supplement.
214773986|NCT01702766|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
214773987|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
214773988|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
214773989|NCT00444665|DRUG|Travatan-Z|
214773990|NCT04285892|DEVICE|CAPA-IVM|"CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house."
214773991|NCT04657458|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214773992|NCT02737072|DRUG|LY2510924|Administered SQ
214773993|NCT02737072|DRUG|Durvalumab|Administered IV
214773994|NCT06568354|OTHER|Yoga|The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
214773995|NCT06568354|OTHER|Motor control exercises|Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
214773996|NCT00567996|DRUG|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
214773997|NCT00567996|DRUG|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
214773998|NCT00567996|DRUG|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
214773999|NCT00567996|DRUG|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
214774000|NCT02827188|OTHER|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
214774001|NCT03930056|DEVICE|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
214774002|NCT03930056|DEVICE|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
214774003|NCT06567236|OTHER|3D software|Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
214774004|NCT02170142|DEVICE|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
214774005|NCT00937599|DIETARY_SUPPLEMENT|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
214774006|NCT03430557|PROCEDURE|PRP|platelet rich plasma
214774007|NCT03430557|PROCEDURE|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
214774008|NCT04562298|BIOLOGICAL|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
214774009|NCT04245397|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
214774010|NCT04245397|DRUG|Decitabine|Decitabine is a hypomethylating agent.
214774011|NCT05357742|BEHAVIORAL|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
214774012|NCT05357742|BEHAVIORAL|Enhanced usual care|During each session participants will receive DKD education only.
214774013|NCT05461248|PROCEDURE|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
214774014|NCT05461248|PROCEDURE|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
214774015|NCT00323687|DRUG|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
214774016|NCT04181216|DEVICE|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
214774017|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
214774018|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
214774019|NCT02524665|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
214774020|NCT02524665|OTHER|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
214774021|NCT02524665|OTHER|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
214774022|NCT02524665|OTHER|Skin Perfecting Lotion|Available over the counter.
214774023|NCT04196270|DRUG|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
214774024|NCT00157729|DRUG|pyridoxal-5'-phosphate with and without ACE inhibitor|
214774025|NCT03128073|DEVICE|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
214774026|NCT05297149|BEHAVIORAL|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
214774027|NCT05297149|BEHAVIORAL|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
214774028|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
214774029|NCT02642991|DEVICE|Phenacite|contact lens
214774030|NCT02642991|DEVICE|comfilcon A|contact lens
214774031|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
214774032|NCT00199095|DRUG|Adriamycin|
214774033|NCT00199095|DRUG|Cyclophosphamide|
214774034|NCT00199095|DRUG|Cytarabine|
214774035|NCT00199095|DRUG|Dexamethasone|
214774036|NCT00199095|DRUG|Idarubicin|
214774037|NCT00199095|DRUG|Ifosfamide|
214774038|NCT00199095|DRUG|Methotrexate|
214774039|NCT00199095|DRUG|Mercaptopurine|
214774040|NCT00199095|DRUG|VM26|
214774041|NCT00199095|DRUG|Vincristine|
214774042|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
214774043|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
214774044|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
214774045|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
214774046|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
214774047|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
214774048|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
214774049|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
214774050|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
214774051|NCT01301378|PROCEDURE|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
214774052|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
214774053|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
214774054|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
214774055|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
214774056|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
214774057|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
214774058|NCT00407966|DRUG|alvocidib|Given IV
214774059|NCT00407966|DRUG|cytarabine|Given IV
214774060|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
214774061|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
214774062|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
214774063|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
214774064|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
214774065|NCT01999322|DRUG|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
214774066|NCT01999322|DRUG|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
214774067|NCT02272972|OTHER|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
214774068|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
214774069|NCT02200614|DRUG|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
214774070|NCT02200614|DRUG|Placebo|Matching placebo 2 tablets twice daily with food.
214774071|NCT04379102|OTHER|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
214774072|NCT04503707|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
214774073|NCT02941822|DRUG|Ambroxol|Details outlines in the intervention description.
214774074|NCT06702397|DEVICE|Microscope|The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.
214774075|NCT06702397|DEVICE|Surgical loupes|Surgical loupes offer magnification of 3.5-5x.
214774076|NCT06702566|DRUG|PD-1 and PD-L1 inhibitor|"PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab."
214646184|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using closing system|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the SDD group prior to the procedure, the femoral access will be closed with a closure system. Ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
214646185|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using figure-of-eight stitch|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the ONS group prior to the procedure, the femoral access will be closed with a figure-of-eight suture. The ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
214646186|NCT04899297|OTHER|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
214646187|NCT06467773|RADIATION|Radiation: PET-MRI with [18F]-DPA-714|Radiation: PET-MRI with \[18F\]-DPA-714
214646188|NCT01020864|DRUG|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
214646189|NCT01020864|DRUG|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
214646190|NCT01020864|DRUG|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
214774077|NCT06702566|DRUG|Targeted drugs|Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
214774078|NCT06702566|DRUG|chemotherapy drugs|Chemotherapy drugs are determined based on the investigator's decision.
214774079|NCT03216798|OTHER|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
214774080|NCT00834288|DRUG|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
214774081|NCT00834288|DRUG|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
214774082|NCT00443131|BIOLOGICAL|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
214774083|NCT00350337|BIOLOGICAL|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
214774084|NCT00350337|BIOLOGICAL|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
214774085|NCT00350337|BIOLOGICAL|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
214774086|NCT00350337|OTHER|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
214774087|NCT04347031|DRUG|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
214774088|NCT04347031|DRUG|Hydroxychloroquine|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
214774089|NCT04347031|COMBINATION_PRODUCT|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
214774090|NCT04347031|COMBINATION_PRODUCT|Hydroxychloroquine + azithromycin + / - tocilizumab|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
214774091|NCT06530160|OTHER|ELISA|Enzyme-linked immunosorbent assay
214774092|NCT05722340|PROCEDURE|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
214774093|NCT05722340|PROCEDURE|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
214774094|NCT00391092|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
214774095|NCT00391092|DRUG|Docetaxel|100mg/m2 iv every 3 weeks
214646191|NCT06883981|BEHAVIORAL|Free and Cued Recall Memory. Temporal Sequence and Spatial Memory|Memory for real-world episodic experiences will be tested in the laboratory first with free recall (spoken narration of their recollections from each environment) and then with cued recall, in which participants will be cued with an event image from the CAPTURE app, a map location, or a relative time and asked to recall the other two non-cued pieces of episodic information (event, place, or time). Because we will know the 'ground truth', the cued recall test will allow us to measure how accurately the participant is able to remember key details of each episode. We will also assess temporal order memory by asking participants to arrange 1st person images in the order in which they occurred, and we will assess spatial memory by asking them to place each image on a schematic map of the venue.
214774096|NCT00391092|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
214774097|NCT05404568|PROCEDURE|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
214774098|NCT05802342|DRUG|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
214774099|NCT01665573|DRUG|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
214646192|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (40:1)|Myo-inositol and D-chiro-inositol (40:1 ratio), 2 grams (twice a day) for three months
214646193|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (3.6:1)|Myo-inositol and D-chiro-inositol (3.6:1 ratio), 1.4 grams (once daily) for three months
214646194|NCT06729775|OTHER|Data report back preference by life span|Data report back preference by life span.
214646195|NCT06733532|DIETARY_SUPPLEMENT|Berry Propel Fitness Water|Subject will consume 1 Liter of commercially available Berry Propel Fitness Water at a rate of 250 milliliters per 7.5 minutes
214774100|NCT01665573|DRUG|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
214774101|NCT01445431|OTHER|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
214774102|NCT01445431|OTHER|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
214646196|NCT06733532|DIETARY_SUPPLEMENT|Essentia Hydroboost Raspberry Pomegranate|Subject will consume 1 Liter of commercially available Essentia Hydroboost Raspberry Pomegranate at a rate of 250 milliliters per 7.5 minutes
214646197|NCT06733532|DIETARY_SUPPLEMENT|Smart Water|Subject will consume 1 Liter of commercially available Smart Water at a rate of 250 milliliters per 7.5 minutes.
214646198|NCT06729125|DEVICE|transcranial photobiomodulation|Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).
214774103|NCT01788137|DRUG|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
214774104|NCT01788137|DRUG|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
214774105|NCT03461315|OTHER|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
214774106|NCT00923728|DRUG|AVN944|
214774107|NCT01901146|DRUG|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
214774108|NCT01901146|DRUG|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
214774109|NCT01901146|DRUG|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
214774110|NCT01901146|PROCEDURE|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
214774111|NCT04238468|PROCEDURE|Intradermal stromal vascular fraction injection|After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
214774112|NCT00297492|BEHAVIORAL|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
214774113|NCT00297492|BEHAVIORAL|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
214774114|NCT00297492|BEHAVIORAL|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
214774115|NCT00297492|DRUG|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
214774116|NCT00297492|DRUG|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
214774117|NCT03367273|OTHER|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
214774118|NCT05891873|DIAGNOSTIC_TEST|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
214774119|NCT05891873|DIAGNOSTIC_TEST|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
214774120|NCT05891873|DIAGNOSTIC_TEST|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
214774121|NCT05891873|DIAGNOSTIC_TEST|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
214774122|NCT05891873|DIAGNOSTIC_TEST|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
214774123|NCT05891873|DIAGNOSTIC_TEST|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
214774124|NCT05891873|DIAGNOSTIC_TEST|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
214774125|NCT02664766|BEHAVIORAL|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
214646199|NCT06729125|OTHER|exercises training|balance exercises and others
214646200|NCT06893679|OTHER|Qigong sensory training|Participants will be received 15 mints massage therapy 2 times in a day and 5 days a week for 8 weeks. Before and after 8 week of intervention, Assessment of sensory modulation scale (ASMS) will be used to check the sensory modulation level and strength and difficulties questionnaire (SDQ) will be used to check the behavior. Data will be collected from Nishtar Hospital Multan. The pre and post intervention assessments will be done.
214646201|NCT06883357|BEHAVIORAL|Graded repetitive arm supplementary program (GRASP)|Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program. home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. Participants in experimental group will receive Home GRASP program which will be executed 1hour at home per day. In addition, Participants will be requested to return hospital for follow-up and adjusting the training program in group discussion 3 times per week, lasting 4-6 weeks, and totally 12-18 sessions.
214646202|NCT03631706|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
214646203|NCT03631706|DRUG|Pembrolizumab|Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
214646204|NCT06638463|BEHAVIORAL|My Health Coach app|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
214646205|NCT04715555|DEVICE|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
214646206|NCT04715555|DEVICE|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
214646207|NCT04715555|DEVICE|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
214646208|NCT04715555|OTHER|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
214646209|NCT06886802|PROCEDURE|Posterior Uniportal Endoscopic Cervical Decompression|Posterior Uniportal Endoscopic Cervical Decompression
214646210|NCT02805205|DRUG|PEG-rhG-CSF|
214646211|NCT05738122|OTHER|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
214646212|NCT05027932|OTHER|IN Placebo|The placebo is normal saline in two syringes administered IN.
214646213|NCT05027932|OTHER|IM Placebo|The placebo is normal saline in a syringe administered IM.
214646214|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It is administered either IM or IN depending on the assigned treatment group.
214646215|NCT06910930|DEVICE|DidgeriTU|the study device that immitate the principle of didgeridoo for expiratory muscle exercise
214646216|NCT06910930|DEVICE|Sham device|a device that look alike DidgeriTU but without resistance plate
214646217|NCT06912243|OTHER|Educational animation about the process of ear tube surgery|A nurse will explain the process of ear tube surgery to children in an educational video. This educational video scenario includes information about a child's fears before surgery, the structure of the ear, what they are most curious about, what an ear tube is, what happens during and after surgery. The educational video will be made by a person specialized in computer technologies. Artificial intelligence will be used in the vocalization of the educational video. Expert opinion will be taken for the instructional video. The duration of the educational video is planned to be in the range of 3-4 minutes in total.
214646218|NCT06912243|OTHER|Control-Standard Care|The standard information given to all children who had ear tube surgery in the relevant ward will be given to the children in the control group.
214646219|NCT02514512|DEVICE|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
214646220|NCT06917612|PROCEDURE|Normal diagnostic laparoscopy|The appendix is left in situ e.g., not resected and no other surgical resection is needed to treat other diseases
214646221|NCT06917612|PROCEDURE|Negative appendectomy|The appendix is resected but is without histopathological-confirmed inflammation and no other surgical resection is needed to treat other diseases
214646222|NCT06917261|DIAGNOSTIC_TEST|nasopharyngeal swab.|The only additional procedure related to the study is a nasopharyngeal swab.
214774126|NCT05833373|DEVICE|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
214774127|NCT05833373|DEVICE|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
214774128|NCT04567173|DRUG|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
214774129|NCT02966522|DRUG|Thalidomide|
214774130|NCT02966522|DRUG|Dexamethasone|
214774131|NCT00968396|PROCEDURE|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
214774132|NCT00968396|PROCEDURE|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
214774133|NCT00968396|DRUG|Melphalan|100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
214774134|NCT01586117|DRUG|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
214774135|NCT00002196|DRUG|CI-1012|
214774136|NCT04446819|DEVICE|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
214774137|NCT04953208|DEVICE|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
214774138|NCT04953208|DEVICE|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
214774139|NCT04953208|BEHAVIORAL|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
214774140|NCT04953208|BEHAVIORAL|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
214774141|NCT03338049|DEVICE|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
214774142|NCT04554407|DEVICE|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
214774143|NCT02414854|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
214774144|NCT02414854|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
214774145|NCT02414854|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
214774146|NCT02414854|DRUG|Albuterol/Salbutamol|Oral inhalation as needed
214774147|NCT02414854|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed
214774148|NCT05377333|DRUG|LY3457263|Administered SC.
214774149|NCT05377333|DRUG|Placebo|Administered SC.
214774150|NCT05377333|DRUG|Dulaglutide|Administered SC.
214774151|NCT05380622|DIAGNOSTIC_TEST|Coronary CT angiography|"Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab."
214774152|NCT01357031|DRUG|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
214774153|NCT01357031|DRUG|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
214774154|NCT01357031|DRUG|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
214774155|NCT06515444|BEHAVIORAL|10 minutes program|The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
214774156|NCT06515444|BEHAVIORAL|1 hour PD program|The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
214774157|NCT02807324|OTHER|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
214774158|NCT00629629|BEHAVIORAL|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
214774159|NCT03888092|DRUG|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
214774160|NCT06146543|OTHER|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
214774161|NCT05810974|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
214774162|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
214774163|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
214774164|NCT02308865|OTHER|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
214774165|NCT06354439|DRUG|Letrozole tablets|10 mg of letrozole PO for 7 days
214774166|NCT06354439|DRUG|Methotrexate Sodium|100 mg of methotrexate IM, single dose
214774167|NCT06146504|DIETARY_SUPPLEMENT|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
214774168|NCT06146504|OTHER|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
214774169|NCT06361316|DRUG|Irinotecan liposome injection|Postoperative adjuvant therapy
214774170|NCT04624750|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
214774171|NCT03891979|DRUG|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
214774172|NCT03891979|DRUG|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
214774173|NCT03891979|DRUG|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
214774174|NCT02083770|BEHAVIORAL|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
214774175|NCT00171119|DRUG|valsartan|
214774176|NCT05285332|PROCEDURE|surgical treatment 1|Mastectomy OR Breast conserving surgery
214774177|NCT05285332|PROCEDURE|surgical treatment 2|Resection of metastasis
214774178|NCT05285332|DRUG|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
214774179|NCT01780688|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
214774180|NCT01780688|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
214774181|NCT04657237|PROCEDURE|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
214774182|NCT05131997|DRUG|AD-221|PO, Once daily(QD), 8 weeks
214774183|NCT05131997|DRUG|AD-221A|PO, Once daily(QD), 8 weeks
214774184|NCT05131997|DRUG|AD-221B|PO, Once daily(QD), 8 weeks
214774185|NCT05131997|DRUG|AD-221C|PO, Once daily(QD), 8 weeks
214646223|NCT06917534|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with drug addiction specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
214646224|NCT06916897|DRUG|sevasemten|single dose 10mg sevasemten administered orally
214646225|NCT06916897|DRUG|Verapamil|multiple doses 240mg verapamil
214646226|NCT06915870|DRUG|Dapagliflozin 10 mg daily|Dapagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
214646227|NCT06915870|DRUG|Empagliflozin 10 MG OD|Empagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
214646228|NCT06915506|DRUG|Shenfu Injection|"This intervention combines traditional Chinese medicine (TCM) with modern critical care practices to distinguish it from conventional sepsis therapies. Key unique features include:~TCM-Based Intervention:~Shenfu Injection: A standardized herbal extract derived from Panax ginseng and Aconitum carmichaelii , prepared under Chinese Pharmacopoeia guidelines.~Mechanism: Targets mitochondrial dysfunction and endothelial glycocalyx repair, with preclinical evidence of anti-inflammatory, anti-apoptotic, and vasoregulatory effects.~Precision Delivery Protocol:~Dosage: 60 mL (1 mL/kg for patients \<60 kg) administered via syringe pump-controlled continuous infusion over 3 hours, ensuring stable plasma concentrations.~Timing: Initiated only after hemodynamic stabilization (≥1 hour of stable vasopressor requirements post-fluid resuscitation), aligning with the golden window for vascular repair in sepsis."
214646229|NCT04129060|DRUG|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
214646230|NCT02453074|OTHER|Online survey - Follow up for Better Care|
214646231|NCT02297802|DRUG|PD-0325901|
214646232|NCT06272370|OTHER|Asthma Symptom Monitoring online tools|All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above
214646233|NCT06272370|DRUG|Inhaled Steroids|participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
214646234|NCT06272370|DRUG|Azithromycin Pill|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
214646235|NCT05301478|DEVICE|standard of care insole|standard of care diabetic insole
214646236|NCT05301478|DEVICE|3D Printed Insole - pressure based|3D Printed Insole - pressure based
214646237|NCT05301478|DEVICE|3D Printed Insole - FEA|3D Printed Insole - FEA
214646238|NCT06519656|DRUG|Mazdutide|In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
214646239|NCT06787664|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214646240|NCT04692831|COMBINATION_PRODUCT|89Zr-ss-pertuzumab PET/CT|Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
214646241|NCT00783016|DRUG|Morphine|
214646242|NCT03409822|DEVICE|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
214646243|NCT00145847|DRUG|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
214646244|NCT03695913|OTHER|Normal Diet|"Phase I (regular diet):~all participants will eat their normal diet and will log their food."
214646245|NCT03695913|OTHER|Low carb diet|"Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food"
214646246|NCT03695913|DEVICE|CGM with no real time feedback|Phase I will collect CGM without real time feedback
214646247|NCT03695913|DEVICE|CGM with real time feedback)|Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
214646248|NCT03695913|BEHAVIORAL|Education material|"Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make."
214646249|NCT00544869|DRUG|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
214646250|NCT04574596|OTHER|no Intervention|This is an observational study. There is no intervention
214646251|NCT03988907|DRUG|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
214646252|NCT03988907|DRUG|Midazolam|single dose administration of 2 mg midazolam
214646253|NCT02810964|DRUG|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
214646254|NCT02810964|DRUG|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
214646255|NCT05946772|DRUG|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
214646256|NCT05946772|DRUG|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
214774186|NCT00688610|OTHER|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
214774187|NCT00897273|GENETIC|comparative genomic hybridization|
214774188|NCT00897273|GENETIC|gene expression analysis|
214774189|NCT00897273|OTHER|study of socioeconomic and demographic variables|
214774190|NCT00897273|PROCEDURE|evaluation of cancer risk factors|
214774191|NCT00897273|PROCEDURE|study of high risk factors|
214774192|NCT00795782|PROCEDURE|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
214774193|NCT00606801|DRUG|Galantamine|Galantamine 8 mg/day
214774194|NCT00606801|DRUG|placebo|sugar pill
214774195|NCT02465580|DRUG|hrIL-2 active|active group: placebo group =1:1
214774196|NCT02465580|DRUG|hrIL-2 placebo|active group: placebo group =1:1
214774197|NCT05303831|OTHER|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
214774198|NCT00552526|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet is a very strict high fat diet
214774199|NCT00552526|DRUG|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
214774200|NCT02515357|BEHAVIORAL|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
214774201|NCT02515357|BEHAVIORAL|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
214774202|NCT02515357|BEHAVIORAL|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
214774203|NCT02232139|DRUG|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
214774204|NCT05459545|DEVICE|Use of Eko CORE and Eko CORE 500 electronic stethoscope|Auscultation of heart sounds using electronic stethoscopes
214774205|NCT01586767|RADIATION|Proton radiation therapy|Daily proton radiation therapy
214774206|NCT01586767|RADIATION|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
214774207|NCT03413969|BEHAVIORAL|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
214774208|NCT04891367|OTHER|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
214774209|NCT01284244|DEVICE|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
214774210|NCT01284244|DEVICE|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
214774211|NCT01533272|DRUG|Tenofovir, emtricitabine, maraviroc|experimental drug
214774212|NCT01533272|DRUG|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
214774213|NCT02323139|DRUG|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
214774214|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
214774215|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
214774216|NCT00822263|DRUG|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
214774217|NCT00822263|DRUG|Placebo|Control for study
214774218|NCT02063386|DRUG|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
214774219|NCT01318941|DRUG|Ranibizumab|
214774220|NCT01318941|OTHER|Ranibizumab|
214774221|NCT01159119|DRUG|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
214774222|NCT01159119|DRUG|Zenpep|Capsules taken for daily for 28 days during treatment period 2
214774223|NCT01159119|DRUG|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
214646257|NCT02249741|DRUG|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
214646258|NCT05855265|DEVICE|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
214646259|NCT00469950|BEHAVIORAL|exercise training|Exercise training in groups
214646260|NCT01276171|PROCEDURE|Ultrasound|Participants will place arterial line using ultrasound technique
214646261|NCT01276171|PROCEDURE|Doppler|Participants will place arterial line using doppler technique
214646262|NCT01276171|PROCEDURE|Palpation|Participants will place arterial line using Palpation technique
214646263|NCT02273583|DRUG|continuous oral cyclophosphamide and methotrexate|
214646264|NCT02975843|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
214646265|NCT01688024|DRUG|Mitomycin C|
214646266|NCT01688024|DRUG|Normal saline|
214646267|NCT00002559|BIOLOGICAL|filgrastim|
214646268|NCT00002559|DRUG|cisplatin|
214646269|NCT00002559|DRUG|ifosfamide|
214646270|NCT00002559|DRUG|paclitaxel|
214646271|NCT05588570|BEHAVIORAL|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
214646272|NCT04691583|OTHER|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
214646273|NCT01042080|DEVICE|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
214646274|NCT01042080|OTHER|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
214646275|NCT05167773|DEVICE|tonometer|A subject undergoes intraocular pressure measurement with tonometer
214646276|NCT03674151|DEVICE|Silver Nylon dressing|Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
214646277|NCT03674151|DEVICE|Manuka-Honey|Manuka-Honey dressing on split-skin grafted third-degree burn wound
214646278|NCT03674151|DEVICE|Povidone-Iod (PVP-Iod)|Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
214646279|NCT03674151|DEVICE|Hydrogel|Hydrogel dressing on split-skin grafted third-degree burn wound
214646280|NCT00325078|DRUG|Infliximab|
214646281|NCT02569060|OTHER|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
214646282|NCT02569060|OTHER|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
214646283|NCT02569060|OTHER|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
214646284|NCT02569060|BEHAVIORAL|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
214646285|NCT03404466|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
214646286|NCT03932799|OTHER|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
214774224|NCT01614613|DEVICE|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774225|NCT01614613|DEVICE|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774226|NCT01614613|DEVICE|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774227|NCT01614613|DEVICE|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774228|NCT01614613|DEVICE|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774229|NCT01614613|DEVICE|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214774230|NCT05580549|DIAGNOSTIC_TEST|Alcohol biomarker Phosphatidylethanol (PEth)|The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
214774231|NCT00046384|DRUG|aripiprazole|
214774232|NCT00440375|DRUG|Rosiglitazone|
214774233|NCT01557452|DRUG|Givinostat|ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
214774234|NCT00124475|DRUG|alitretinoin|
214774235|NCT03251209|OTHER|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
214774236|NCT03251209|OTHER|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
214774237|NCT03251209|OTHER|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
214774238|NCT05839093|DEVICE|Inferior Alveolar Nerve Block Group|A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
214774239|NCT05839093|DEVICE|Intraligamentary Injection Group|An infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. Then, an intraligamentary injection was performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle. The needle was placed alongside the tooth and inserted at a 30 angle relative to the longitudinal axis of the crown with the needle between the teeth and the bone. Then, in the mesiobuccal, distobuccal, mesiolingual and distolingual portions of teeth, 0.18 mL of the solution was injected. Five minutes later, the teeth were isolated and the endodontic procedure was started.
214774240|NCT02036528|DRUG|Gentamicin Topical Gel|
214774241|NCT02036528|DRUG|Ciprofloxacin|
214774242|NCT02036528|DRUG|Doxycycline|
214774243|NCT04168047|PROCEDURE|Barostat procedure|Pressure threshold will be measured during the barostat procedure
214774244|NCT04168047|OTHER|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
214774245|NCT04168047|OTHER|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
214774246|NCT02777853|DIETARY_SUPPLEMENT|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
214774247|NCT02777853|DIETARY_SUPPLEMENT|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
214774248|NCT00503854|BEHAVIORAL|Questionnaire|Ancillary studies
214774249|NCT04496882|DRUG|Vemlidy|25mg Tenofovir Alafenamide
214774250|NCT00451269|DEVICE|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
214774251|NCT06542094|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
214774252|NCT01944189|DIETARY_SUPPLEMENT|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
214774253|NCT01869712|OTHER|Cupping therapy|
214774254|NCT01869712|OTHER|Acupuncture|
214774255|NCT00159666|DRUG|pregabalin|
214774256|NCT04681274|DEVICE|Image features extraction and clustering|"The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures."
214774257|NCT04681274|DEVICE|Phenotype signature database building|Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
214774258|NCT01425931|PROCEDURE|Heart Lung machine|measurement of microcirculation with O2C device
214774259|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
214774260|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
214774261|NCT06543186|OTHER|Oral health education lecture|Conventional oral health education will be given by trained and calibrated dentists.
214774262|NCT06543186|OTHER|Oral health education via mHealth on WhatsaApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material
214774263|NCT06543186|OTHER|Oral health education via Metaverse platform on Meta-OHE|For oral health education intervention via Meta-OHE, it will be done via computer.
214774264|NCT02016755|BIOLOGICAL|HGF Plasmid|Intramuscular injection in the affected limb.
214774265|NCT01881217|DRUG|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
214774266|NCT03928613|BEHAVIORAL|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
214774267|NCT06120179|DEVICE|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
214774268|NCT03067506|OTHER|No intervention|No intervention
214774269|NCT01485588|DRUG|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
214774270|NCT01485588|DRUG|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
214774271|NCT01485588|DRUG|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
214774272|NCT01582828|PROCEDURE|Epicardial (surgical) ablation|"* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure"
214774273|NCT01582828|PROCEDURE|Hybrid|"Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
214774274|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
214774275|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
214774276|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
214774277|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
214774278|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
214774279|NCT01493609|BEHAVIORAL|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
214774280|NCT06132412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
214774281|NCT06132412|OTHER|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
214774282|NCT05218317|DIAGNOSTIC_TEST|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
214774283|NCT04656574|BEHAVIORAL|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
214774284|NCT02733458|DRUG|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
214774285|NCT02733458|RADIATION|Radiotherapy|Radiotherapy: 50-56Gy
214774286|NCT00221572|PROCEDURE|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
214774287|NCT00552617|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
214774288|NCT00552617|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
214774289|NCT00552617|DRUG|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
214774290|NCT00552617|DRUG|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
214774291|NCT03800186|OTHER|Proximal type A|Patients with fracture of proximal type A
214774292|NCT03800186|OTHER|Proximal type B|Patients with fracture of proximal type B
214774293|NCT03800186|OTHER|Proximal type C|Patients with fracture of proximal type C
214774294|NCT03800186|OTHER|femoral shaft|Patients with fracture of femoral shaft
214774295|NCT03800186|OTHER|distal femur|Patients with fracture of distal femur
214774296|NCT01111084|DRUG|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
214774297|NCT03307902|BIOLOGICAL|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
214774298|NCT03307902|BIOLOGICAL|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
214774299|NCT03307902|BIOLOGICAL|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
214774300|NCT03663959|PROCEDURE|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
214774301|NCT03663959|PROCEDURE|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
214774302|NCT06232759|DRUG|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
214774303|NCT04947059|DRUG|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
214774304|NCT04947059|DRUG|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
214774305|NCT05558852|PROCEDURE|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
214774306|NCT03220152|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
214774307|NCT02149537|DRUG|hydroxyurea|
214774308|NCT00306137|DRUG|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach"
214774309|NCT00306137|DRUG|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
214774310|NCT06036537|DIAGNOSTIC_TEST|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
214774311|NCT06301737|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
214774312|NCT06301737|PROCEDURE|Injection|the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214774313|NCT06301737|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214774314|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
214774315|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
214774316|NCT00386854|BEHAVIORAL|physical training|
214774317|NCT02533505|DRUG|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
214774318|NCT02533505|DRUG|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
214774319|NCT01432782|DRUG|Placebo|Saline 4 ml
214774320|NCT01432782|DRUG|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
214774321|NCT06418360|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
214774322|NCT06418360|DEVICE|conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack|10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
214774323|NCT05194280|PROCEDURE|Robotic surgery|Robotic-assisted donornephrectomy
214774324|NCT00337129|DRUG|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
214774325|NCT03141931|DIETARY_SUPPLEMENT|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
214774326|NCT03141931|DIETARY_SUPPLEMENT|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
214774327|NCT04809038|OTHER|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
214774328|NCT04809038|OTHER|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor\_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
214774329|NCT04809038|OTHER|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
214774330|NCT00513565|DRUG|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
214774331|NCT03306602|DEVICE|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
214774332|NCT03306602|DEVICE|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
214774333|NCT05745064|DRUG|TL-925|TL-925 is an eye drop.
214774334|NCT05745064|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
214774335|NCT03990246|OTHER|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
214774336|NCT03990246|OTHER|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
214774337|NCT03990246|OTHER|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
214774338|NCT03990246|OTHER|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
214774339|NCT03608696|DRUG|Buprenorphine|buprenorphine 0.075 mg/ml solution
214774340|NCT01866995|DRUG|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
214774341|NCT01866995|OTHER|standard prostatostasis therapy|
214774342|NCT05799365|OTHER|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
214774343|NCT04189406|OTHER|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
214774344|NCT02377687|OTHER|observational study|
214774345|NCT04015479|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
214774346|NCT04015479|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
214774347|NCT02741752|PROCEDURE|Decortication|cortical bone perforation
214774348|NCT04498299|DIAGNOSTIC_TEST|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
214774349|NCT00306852|PROCEDURE|Baerveldt implant|Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
214774350|NCT00306852|PROCEDURE|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
214774351|NCT02046499|DRUG|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
214774352|NCT02046499|DRUG|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
214774353|NCT04954209|OTHER|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
214774354|NCT04954209|OTHER|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
214774355|NCT04766593|OTHER|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living."
214646287|NCT03932799|OTHER|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
214646288|NCT01775631|BIOLOGICAL|Urelumab|
214646289|NCT01775631|BIOLOGICAL|Rituximab|
214646290|NCT01206855|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
214646291|NCT01206855|OTHER|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
214646292|NCT01274247|DRUG|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
214646293|NCT05212740|DRUG|Corticosteroid|The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
214646294|NCT05212740|OTHER|Exercise|The exercise program will be performed two times per week for six weeks for 12 sessions.
214646295|NCT03760484|DRUG|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
214646296|NCT03760484|BIOLOGICAL|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
214646297|NCT00568555|DRUG|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
214646298|NCT00568555|DRUG|Placebo - sugar pill|Placebo pill once daily
214646299|NCT03513653|DIAGNOSTIC_TEST|Echocardiography with speckle-tracking imaging|"1. Measurement of left ventricular ejection fraction and global longitudinal strain~2. Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~3. Measurement of right ventricular global longitudinal strain"
214646300|NCT05242250|DEVICE|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
214646301|NCT00657384|DRUG|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
214646302|NCT00657384|DRUG|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
214646303|NCT01307033|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
214646304|NCT01307033|DRUG|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
214646305|NCT01307033|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
214646306|NCT01307033|DRUG|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
214646307|NCT04376437|DRUG|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
214646308|NCT00693199|DRUG|amlodipine|amlodipine 5mg once daily for 28 days
214646309|NCT00693199|DRUG|terazosin|terazosin 2 mg once daily for 28 days
214646310|NCT00693199|DRUG|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
214646311|NCT00555087|DRUG|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
214646312|NCT01231555|DRUG|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
214646313|NCT01231555|DRUG|GSK2248761 200 mg once daily|2x100 mg capsules
214646314|NCT01231555|DRUG|Efavirenz 600 mg once daily|1x600mg tablet
214646315|NCT06018779|OTHER|Cryoultrasound therapy plus high-intensity laser therapy|Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
214646316|NCT06018779|OTHER|diathermy plus high-intensity laser therapy|Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
214646317|NCT00947531|DRUG|Cerebrolysin|
214646318|NCT00947531|DRUG|0.9% Saline Solution|
214646319|NCT01226290|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
214646320|NCT04223245|BEHAVIORAL|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
214646321|NCT04223245|BEHAVIORAL|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
214646322|NCT05750992|PROCEDURE|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
214646323|NCT05750992|PROCEDURE|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
214646324|NCT03856944|DEVICE|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
214646325|NCT00212173|DRUG|Sibutramine|
214646326|NCT00212173|DIETARY_SUPPLEMENT|Slim Fast|
214646327|NCT03948230|BIOLOGICAL|Salt with / without water|Drinks with and without a salt containing capsule
214774356|NCT02583607|DEVICE|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
214646328|NCT04257331|BEHAVIORAL|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
214774357|NCT06337968|PROCEDURE|Circum-psoas Block|Ultrasound-guided circum-psoas block with 40 mL of treatment drug (Ropivacaine 0.2% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
214774358|NCT06337968|PROCEDURE|Sham block|Perform ultrasound scanning without puncture.
214646329|NCT02023658|OTHER|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
214646330|NCT02835885|DEVICE|Digitmer High Voltage Stimulator model DS7A TENS unit|
214646331|NCT03902678|PROCEDURE|EUS guided fine needle aspiration of portal vein thrombus|endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
214646332|NCT02130713|DRUG|Third generation fluoroquinolone|Prulifloxacin 600 mg
214646333|NCT02130713|DIETARY_SUPPLEMENT|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
214646334|NCT01773421|DRUG|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
214646335|NCT01773421|DRUG|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
214646336|NCT01486576|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
214646337|NCT01486576|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
214646338|NCT05072444|DRUG|QPX7728|beta lactamase inhibitor
214646339|NCT05072444|DRUG|QPX2014|antibiotic
214646340|NCT03526289|BIOLOGICAL|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
214646341|NCT03526289|OTHER|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
214646342|NCT04523974|PROCEDURE|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
214646343|NCT02804763|DRUG|Placebo|Solution for infusion, 0,9% saline
214646344|NCT02804763|DRUG|Dapirolizumab pegol (DZP)|Solution for infusion
214646345|NCT02310048|DRUG|MT-1303-FormA|
214646346|NCT02310048|DRUG|MT-1303-FormB|
214646347|NCT06310148|COMBINATION_PRODUCT|The Chronic Disease Co-Care (CDCC) Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
214646348|NCT01992809|DIETARY_SUPPLEMENT|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
214646349|NCT01809548|OTHER|Early intervention group|solid food will be introduced between week 10 and 12
214646350|NCT01809548|OTHER|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
214646351|NCT03371563|DRUG|Antibiotics|Patients were treated with antibiotics for Lyme disease.
214646352|NCT03371563|OTHER|no intervention|controls were not given antibiotics
214646353|NCT05513014|DRUG|Secukinumab|Patients with Psoriasis who initiated Secukinumab
214646354|NCT05246540|OTHER|Data collection|Data collection
214646355|NCT04274348|OTHER|Skin biopsies and blood samples|Two skin biopsies and 30 ml of blood will be collected.
214646356|NCT02245048|OTHER|Carotid Intima-Media Thickness (CIMT)|
214646357|NCT03530384|OTHER|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
214646358|NCT03530384|OTHER|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
214646359|NCT03105739|OTHER|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
214774359|NCT06358807|PROCEDURE|Arthroscopic microfracture with intraoperative local PRP gel injection|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
214774360|NCT06358807|PROCEDURE|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
214774361|NCT01467570|DIETARY_SUPPLEMENT|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
214774362|NCT01467570|DIETARY_SUPPLEMENT|ESPGHAN ORS|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
214774363|NCT02156349|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
214774364|NCT02156349|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
214774365|NCT04262869|DRUG|Carboplatin|Given IV
214774366|NCT04262869|BIOLOGICAL|Durvalumab|Given IV
214774367|NCT04262869|DRUG|Paclitaxel|Given IV
214774368|NCT04262869|DRUG|Pemetrexed|Given IV
214774369|NCT01098734|DRUG|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
214774370|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
214774371|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
214774372|NCT05131490|BEHAVIORAL|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~1. Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~2. Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~3. Module 3: Current developments on gynecological cancers will be included.~4. Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~5. Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
214774373|NCT01450579|BIOLOGICAL|ASP7373|Intermuscular administration
214774374|NCT01450579|BIOLOGICAL|Placebo|Intramuscular administration
214774375|NCT04221087|DRUG|Placebos|Sugar water based on same ml dosing of intervention arm drug
214774376|NCT04221087|DRUG|Dexamethasone Oral|0.6mg/kg/dose - single oral dose administration to intervention arm
214774377|NCT01092299|DRUG|AZD1446|ER Fast, 90mg, p.o. capsule
214774378|NCT01092299|DRUG|AZD1446|ER Moderate, 90mg, p.o. capsule
214774379|NCT01092299|DRUG|AZD1446|ER Slow, 90mg, p.o. capsule
214774380|NCT01092299|DRUG|AZD1446|MR
214774381|NCT01092299|DRUG|AZD1446|IR, 90 mg p.o. capsule
214774382|NCT01092299|DRUG|Placebo|IR
214774383|NCT01092299|DRUG|Placebo|ER/MR
214774384|NCT01222715|BIOLOGICAL|Bevacizumab|Given IV
214774385|NCT01222715|DRUG|Cyclophosphamide|Given IV
214774386|NCT01222715|OTHER|Laboratory Biomarker Analysis|Correlative studies
214774387|NCT01222715|DRUG|Temsirolimus|Given IV
214774388|NCT01222715|DRUG|Vinorelbine Tartrate|Given IV
214774389|NCT03552354|DRUG|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
214774390|NCT05415982|OTHER|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
214774391|NCT04692220|OTHER|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
214774392|NCT02425865|DRUG|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
214774393|NCT01381822|DRUG|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
214774394|NCT03183271|RADIATION|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
214774395|NCT03372369|OTHER|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
214774396|NCT03372369|OTHER|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
214774397|NCT05739227|OTHER|allogenic CD19-CAR-NK cells|The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10\^6/kg, 5x10\^6/kg, 2x10\^7/kg) after FCE chemotherapy
214774398|NCT02239601|OTHER|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
214774399|NCT02218931|BEHAVIORAL|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
214774400|NCT02218931|OTHER|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
214646360|NCT02078479|PROCEDURE|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
214646361|NCT02078479|PROCEDURE|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
214646362|NCT06005584|DEVICE|Spinal Cord Stimulation - High Frequency SCS|"High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks."
214646363|NCT06005584|DEVICE|Spinal Cord Stimulation - Burst SCS|"Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks."
214646364|NCT06005584|DEVICE|Spinal Cord Stimulation - Sham SCS|This intervention will last up to 6 weeks.
214646365|NCT03751267|PROCEDURE|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
214646366|NCT01487421|DRUG|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
214646367|NCT01487421|DRUG|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
214646368|NCT00875758|PROCEDURE|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
214646369|NCT00875758|PROCEDURE|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
214646370|NCT05035121|DIETARY_SUPPLEMENT|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
214646371|NCT05035121|DIETARY_SUPPLEMENT|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
214646372|NCT05035121|BEHAVIORAL|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
214646373|NCT01113151|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
214646374|NCT01113151|OTHER|Placebo|3 placebo tablets daily for 12 weeks
214646375|NCT04656990|BEHAVIORAL|Integrated Intervention|Gross motor and social-emotional integrated intervention
214646376|NCT03010540|DRUG|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
214646377|NCT03010540|DRUG|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
214646378|NCT02018692|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
214646379|NCT02018692|DIETARY_SUPPLEMENT|Placebo:Starch|Starch powder
214646380|NCT01269164|PROCEDURE|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
214646381|NCT02174718|DIETARY_SUPPLEMENT|Transdermal D Patch|
214646382|NCT02174718|DIETARY_SUPPLEMENT|Oral vitamin D3|
214646383|NCT02174718|DIETARY_SUPPLEMENT|Placebo patch|
214646384|NCT02174718|DIETARY_SUPPLEMENT|Oral placebo|
214646385|NCT03657459|BEHAVIORAL|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities) that reflect patient behaviors
214646386|NCT01693445|DRUG|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
214646387|NCT04833803|BEHAVIORAL|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
214646388|NCT01800721|BEHAVIORAL|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
214646389|NCT01800721|BEHAVIORAL|SNAP Control|Behavioral: SNAP control 7 group sessions
214646390|NCT02512458|DRUG|Cabazitaxel|
214646391|NCT00282243|DRUG|tacrolimus modified release (MR)|Oral
214646392|NCT00282243|DRUG|tacrolimus|Oral
214646393|NCT03453892|DRUG|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
214646394|NCT03453892|DRUG|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
214646395|NCT03453892|RADIATION|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
214646396|NCT03453892|DRUG|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
214646397|NCT01383031|PROCEDURE|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
214646398|NCT01383031|PROCEDURE|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
214774401|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
214774402|NCT04682639|DRUG|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
214774403|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
214774404|NCT01743768|DRUG|SB010|Treatment group (n=19), receiving the active drug substance.
214774405|NCT01743768|DRUG|Placebo|Treatment group (n=19), receiving placebo.
214774406|NCT00769158|DRUG|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
214774407|NCT00769158|OTHER|Placebo|Placebo Comparator
214774408|NCT01392170|DRUG|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
214774409|NCT04144387|PROCEDURE|Myelogram|Two additional myelograms will be performed comparing to standard of care.
214774410|NCT03870737|DEVICE|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
214774411|NCT02632383|DEVICE|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder"
214774412|NCT05171699|OTHER|electroacupuncture|The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
214774413|NCT05171699|OTHER|shame electroacupuncture|The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
214646399|NCT03151889|DEVICE|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
214646400|NCT03242655|BEHAVIORAL|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
214646401|NCT01734148|BEHAVIORAL|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
214646402|NCT05381506|DRUG|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
214646403|NCT01070329|DRUG|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
214646404|NCT01070329|DRUG|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
214646405|NCT00492219|DEVICE|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
214646406|NCT00492219|DEVICE|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
214646407|NCT02758964|OTHER|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
214646408|NCT01504932|DIETARY_SUPPLEMENT|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
214646409|NCT01504932|OTHER|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
214646410|NCT01504932|OTHER|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
214646411|NCT01504932|OTHER|pharmacological study|Correlative studies
214646412|NCT03045003|BEHAVIORAL|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
214646413|NCT05424393|DRUG|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
214646414|NCT05424393|DRUG|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
214646415|NCT02863848|DIETARY_SUPPLEMENT|OraftiR inulin-type fructans|
214646416|NCT02863848|DIETARY_SUPPLEMENT|Placebo|maltodextrin
214646417|NCT04584177|BEHAVIORAL|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
214646418|NCT04584177|BEHAVIORAL|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
214646419|NCT00425490|DRUG|sitagliptin|
214646420|NCT02247869|DRUG|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
214646421|NCT03269981|RADIATION|Whole breast irradiation|Radiotherapy to the whole breast alone.
214646422|NCT03269981|RADIATION|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
214774414|NCT05958459|OTHER|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
214774415|NCT05958459|OTHER|no intervention|no intervention
214774416|NCT06122571|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
214774417|NCT02535247|DRUG|MK-3475|
214774418|NCT02535247|DRUG|Copanlisib|
214774419|NCT00802776|PROCEDURE|Femtosecond laser assisted keratoplasty|
214774420|NCT00802776|PROCEDURE|PKP|
214774421|NCT00732394|OTHER|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
214774422|NCT01547273|PROCEDURE|bone graft inside socket only|bone graft inside socket only
214774423|NCT01547273|PROCEDURE|bone graft inside and outside socket|bone graft inside and outside socket
214774424|NCT01547273|PROCEDURE|no bone graft|no bone graft
214774425|NCT01266473|OTHER|Physiotherapy|Physiotherapy for Airway Clearance
214774426|NCT00549120|DRUG|Propranolol|40 mg tablets
214774427|NCT00549120|DRUG|Salbutamol|Metered dose inhaler (600 μg)
214774428|NCT00549120|DRUG|Ipratropium|Metered dose inhaler (40 μg)
214774429|NCT00549120|DRUG|Placebo|Placebo for propranolol tablets
214774430|NCT06701266|DEVICE|Point of Care Test|PoCT as a chairside test, ELISA as a gold standard
214774431|NCT05532046|DRUG|BAY2413555 Dose 1|BAY2413555 Dose 1
214774432|NCT05532046|DRUG|BAY2413555 Dose 2|BAY2413555 Dose 2
214774433|NCT05532046|DRUG|Placebo to BAY2413555|Placebo to BAY2413555
214774434|NCT01376180|DRUG|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
214774435|NCT02821117|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
214774436|NCT04266119|BEHAVIORAL|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
214774437|NCT05282355|DIETARY_SUPPLEMENT|Astaxanthin|Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.
214774438|NCT05282355|DIETARY_SUPPLEMENT|Placebo|To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
214774439|NCT05920018|DIETARY_SUPPLEMENT|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
214774440|NCT05920018|DIETARY_SUPPLEMENT|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
214774441|NCT05920018|OTHER|Maltose placebo|Daily application of four sachets for 48 weeks
214774442|NCT05920018|OTHER|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
214774443|NCT00938418|RADIATION|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
214774444|NCT02320838|DEVICE|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214774445|NCT02320838|DEVICE|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214774446|NCT02320838|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214774447|NCT00419900|PROCEDURE|diagnosis of breast cancer by x-ray diffraction of hair|
214774448|NCT01770678|OTHER|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
214774449|NCT03895307|OTHER|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
214774450|NCT03895307|OTHER|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
214774451|NCT03895307|OTHER|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
214774452|NCT04141137|DEVICE|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
214774453|NCT00305071|DRUG|compound cranberry extract tablet|
214774454|NCT03405909|DIAGNOSTIC_TEST|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
214774455|NCT03405909|DIAGNOSTIC_TEST|MRI|CE-MRI following standardized protocol
214774456|NCT03405909|DIAGNOSTIC_TEST|Histology|diagnostic liver biopsy
214774457|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
214774458|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
214774459|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
214774460|NCT05597163|DRUG|low concentration atropine (0.01%)|0.01% atropine eye drop
214774461|NCT05597163|DRUG|low concentration atropine (0.025%)|0.025% atropine eye drop
214774462|NCT05597163|DRUG|low concentration atropine (0.05%)|0.05% atropine eye drop
214774463|NCT05597163|DRUG|Placebo|Placebo eye drop
214774464|NCT03964220|DRUG|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
214774465|NCT03964220|DRUG|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
214774466|NCT06111560|OTHER|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
214774467|NCT03940027|PROCEDURE|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
214646423|NCT05997277|DRUG|Deucravacitinib|Deucravacitinib is a stable deuterium-containing compound (where deuterium is a stable, nonradioactive isotope of hydrogen) and a potent, highly selective small molecule inhibitor of TYK2. Deucravacitinib has a unique mode of binding that provides the high selectivity over the other members of the JAK family of nonreceptor tyrosine kinases. 1 active oral tablet (6mg) in the morning and evening for 16weeks.
214646424|NCT05997277|DRUG|Placebo|Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
214646425|NCT03790943|DIAGNOSTIC_TEST|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
214646426|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
214646427|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
214646428|NCT06057610|DRUG|SHR-A1811 Injection|SHR-A1811 Injection
214646429|NCT06057610|DRUG|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
214646430|NCT06057610|DRUG|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
214646431|NCT06508944|DRUG|vaginal 17 beta-estradiol|"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
214646432|NCT06508944|DRUG|Placebo|"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
214646433|NCT06508944|BEHAVIORAL|Behavioral modifications|Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
214646434|NCT05294731|DRUG|BGB-16673|Orally administered
214646435|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
214646436|NCT00700180|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
214646437|NCT00700180|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
214646438|NCT00700180|DRUG|Carboplatin-based chemotherapy|As prescribed
214646439|NCT04954807|DIETARY_SUPPLEMENT|human milk fortified|HMF will be given 6 scoops a day
214646440|NCT04954807|DIETARY_SUPPLEMENT|placebo|Placebo will be given six scoops a day
214646441|NCT00083187|DRUG|hydroxyurea|
214646442|NCT00083187|DRUG|laromustine|
214646443|NCT01072409|DEVICE|Nucleus 5 Cochlear implant|Cochlear implant surgery
214646444|NCT01072409|DEVICE|Cochlear implantation|Implantation
214646445|NCT02944916|DEVICE|IryPump R Set|
214646446|NCT04682158|DRUG|Carboplatin|Given IV
214646447|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
214646448|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
214646449|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
214646450|NCT04682158|DRUG|Paclitaxel|Given IV
214646451|NCT03798886|OTHER|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
214646452|NCT03798886|OTHER|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
214646453|NCT03798886|OTHER|embryo transfer|we will do transfer when the endometrium is ready
214646454|NCT01291901|BIOLOGICAL|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
214774468|NCT02034994|BEHAVIORAL|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
214774469|NCT00060489|DRUG|SEROQUEL (quetiapine fumarate) Tablets|
214774470|NCT03218631|DRUG|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
214774471|NCT05212831|DEVICE|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
214774472|NCT03183973|BIOLOGICAL|PRF|patients who will receive PRF suspension
214774473|NCT03183973|BIOLOGICAL|placebo group|patients who will receive Placebo
214774474|NCT04217031|OTHER|No intervention|No intervention
214774475|NCT00127348|DEVICE|CPAP (Continuous Positive Airway Pressure)|
214774476|NCT05418257|OTHER|(exposure) telemedicine|medical counseling or treatment only using phone
214774477|NCT02918825|DRUG|Olanzapine|Olanzapine
214774478|NCT02918825|DRUG|Paliperidone|Paliperidone
214774479|NCT06134765|DRUG|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
214774480|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
214774481|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
214774482|NCT04951973|DIAGNOSTIC_TEST|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
214774483|NCT01273922|BIOLOGICAL|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
214774484|NCT00720473|DRUG|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
214774485|NCT03386669|DRUG|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
214774486|NCT00884663|DRUG|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
214774487|NCT00884663|DRUG|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
214774488|NCT00884663|DRUG|placebo|placebo tablets and capsules
214774489|NCT02428634|BEHAVIORAL|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
214774490|NCT02428634|BEHAVIORAL|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
214774491|NCT00690924|DRUG|calcitriol|Oral
214774492|NCT00690924|OTHER|laboratory biomarker analysis|Correlative Study
214774493|NCT00690924|OTHER|pharmacological study|Correlative Study
214774494|NCT03202186|DRUG|Progesterone oral capsule|Oral capsule treatment
214774495|NCT03202186|DRUG|Placebo oral capsule|Oral capsule treatment
214774496|NCT02748616|DRUG|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
214774497|NCT03552679|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
214774498|NCT00589693|DRUG|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
214774499|NCT00589693|DRUG|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
214774500|NCT00589693|DRUG|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
214774501|NCT05578885|PROCEDURE|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
214774502|NCT02670512|DEVICE|Telehome Monitoring|
214774503|NCT01682512|DRUG|BI 695500|
214774504|NCT01682512|DRUG|BI 695500|
214774505|NCT01682512|DRUG|Rituxan®|
214774506|NCT01682512|DRUG|Rituxan®|
214774507|NCT01682512|DRUG|MabThera®|
214774508|NCT06336226|PROCEDURE|Brachio basilic arterio venous fistula one stage versus two stage|Comparative study between one stage brachio basilic arterio venous fistula versus two stage
214774509|NCT06374121|DEVICE|PerSorb cartridge (CytoSorbents Europe GmbH, Germany)|This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.
214774510|NCT06374121|DEVICE|PerLife PerKidney|The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
214774511|NCT04400253|BEHAVIORAL|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
214774512|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
214774513|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
214774514|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
214774515|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
214774516|NCT06348173|DRUG|Mepolizumab|Compare the response to mepolizumab and benralizumab before and after treatment
214774517|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
214774518|NCT06566105|GENETIC|precision medicine approach|precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
214774519|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
214774520|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
214774521|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
214774522|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
214774523|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
214774524|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
214774525|NCT01080209|DRUG|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
214774526|NCT01080209|OTHER|Sham|Patients who recieved sham in a previous study.
214774527|NCT03986645|DEVICE|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
214774528|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
214774529|NCT00109629|DRUG|VRC-HIVDNA016-00-VP|
214774530|NCT00109629|DRUG|VRC-HIVADV014-00|
214774531|NCT02030834|BIOLOGICAL|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
214774532|NCT00857493|BIOLOGICAL|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
214774533|NCT00857493|BIOLOGICAL|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
214774534|NCT00741520|DEVICE|CPAP|Control - no treatment
214774535|NCT00741520|DEVICE|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
214774536|NCT00561405|BEHAVIORAL|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
214774537|NCT00561405|BEHAVIORAL|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
214774538|NCT01132235|BIOLOGICAL|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
214774539|NCT05187663|PROCEDURE|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH \& Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
214774540|NCT05187663|PROCEDURE|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
214774541|NCT05474261|PROCEDURE|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
214774542|NCT01281579|DRUG|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
214774543|NCT01281579|DRUG|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
214774544|NCT01281579|DRUG|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
214774545|NCT00896883|DEVICE|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
214774546|NCT05418387|BEHAVIORAL|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
214774547|NCT05418387|BEHAVIORAL|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
214774548|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
214774549|NCT06568809|OTHER|Time interval between recovery of body temperature and operation|The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
214774550|NCT02572427|OTHER|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
214774551|NCT02572427|OTHER|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
214774552|NCT04741945|DRUG|Metformin|2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
214774553|NCT06635577|BEHAVIORAL|Verbal Interference Task|"During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace."
214774554|NCT04911127|DRUG|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
214774555|NCT04911127|DRUG|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
214774556|NCT04911127|DRUG|Placebo capsules|MCT oil capsules as placebo for CBD
214774557|NCT05190640|DIETARY_SUPPLEMENT|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
214774558|NCT06299631|PROCEDURE|Ileocolic resection|Ileocolic resection by open or laparoscopic approach
214774559|NCT02390973|PROCEDURE|Sleeve Gastrectomy|
214774560|NCT02390973|PROCEDURE|Roux-en-Y Gastric Bypass|
214774561|NCT02390973|PROCEDURE|Biliopancreatic Diversion with Duodenal Switch|
214774562|NCT02390973|OTHER|Medical management|
214774563|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
214774564|NCT00679094|OTHER|placebo|Given orally
214774565|NCT00679094|OTHER|pharmacological study|Correlative studies
214774566|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
214774567|NCT05675072|DRUG|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
214774568|NCT05675072|DRUG|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
214774569|NCT05070169|PROCEDURE|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
214774570|NCT00142324|DRUG|Donepezil|
214774571|NCT00792818|DRUG|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
214774572|NCT00792818|DRUG|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
214774573|NCT06234605|DRUG|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
214774574|NCT06234605|DRUG|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
214646455|NCT01291901|BIOLOGICAL|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
214646456|NCT02244151|DRUG|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
214646457|NCT02244151|DRUG|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
214646458|NCT05464745|DRUG|PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
214646459|NCT05464745|DRUG|Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
214646460|NCT03588741|DRUG|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
214646461|NCT05030727|DIAGNOSTIC_TEST|record of pNGAL|Preoperative (0.hour baseline), postoperative 24.,48. BUN, Creatinine, Lactate values in the blood of the patients at 1 hour, and for plasma NGAL, blood samples will be taken at the preoperative, postoperative 6th and 24th hours. And the results will be recorded.
214646462|NCT05892887|DRUG|Bupivacaine 0.25% Injectable Solution|Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
214646463|NCT04547257|DEVICE|Seraph 100|Bloodfiltration with Seraph 100
214646464|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
214646465|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
214646466|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
214646467|NCT00793793|DRUG|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
214646468|NCT00793793|DRUG|Placebo|
214646469|NCT00950170|PROCEDURE|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
214646470|NCT04148092|DRUG|ripretinib|orally administered solid dosage form
214646471|NCT05588323|DRUG|Naldemedine|Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
214646472|NCT06496672|PROCEDURE|Modified long arm cast|A shorter cast that frees the wrist
214646473|NCT06496672|PROCEDURE|Traditional long arm cast|Current standard of care where the cast extends up to the palmar bar
214646474|NCT03416283|BEHAVIORAL|Remote Monitoring|Remote BP monitoring and medication adherence
214646475|NCT03416283|BEHAVIORAL|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
214774575|NCT04556877|PROCEDURE|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
214774576|NCT00568100|PROCEDURE|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
214774577|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
214774578|NCT00279149|PROCEDURE|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
214774579|NCT06520241|OTHER|Pregnant|Data were collected using the Personal Information Form, Depression-Anxiety-Stress Scale (DASS-21), and Oral Health Impact Scale (OHIP-14-TR).
214774580|NCT04903717|BEHAVIORAL|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
215030813|NCT05880212|OTHER|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
214646476|NCT05364411|RADIATION|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
214646477|NCT05364411|RADIATION|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
214646478|NCT03169426|DRUG|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
214646479|NCT02084446|DRUG|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
214646480|NCT02084446|DRUG|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
214646481|NCT02084446|DRUG|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
214646482|NCT02084446|DRUG|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
214646483|NCT02084446|DRUG|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
214646484|NCT02084446|DRUG|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
214646485|NCT02410694|DRUG|Ixazomib|
214646486|NCT02410694|DRUG|Thalidomide|
214646487|NCT02410694|DRUG|Dexamethasone|
214646488|NCT04364204|OTHER|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
214646489|NCT04364204|OTHER|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
214646490|NCT01928628|DRUG|Lercanidipine 10mg|
214646491|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg|
214646492|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg|
214646493|NCT01928628|DRUG|Lercanidipin 10mg Placebo|
214646494|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg Placebo|
214646495|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg Placebo|
214646496|NCT05855733|DEVICE|radiofrequency treatment|patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
214646497|NCT03239431|OTHER|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
214646498|NCT02374866|OTHER|closer monitoring|
214646499|NCT00263263|DEVICE|sirolimus-eluting stent|
214646500|NCT00263263|DEVICE|bare metal stent|
214646501|NCT02661594|DRUG|APD421 5 mg|Therapeutic dose of amisulpride
214646502|NCT02661594|DRUG|APD421 40 mg|Supra-therapeutic dose of amisulpride
214646503|NCT02661594|DRUG|Moxifloxacin|Positive control for assay sensitivity
214646504|NCT02661594|DRUG|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
214646505|NCT02522767|DRUG|Mesalamine|
214646506|NCT02522767|DRUG|Placebo|
214774581|NCT01325896|DRUG|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
214774582|NCT04700215|DEVICE|BiPAP|To give bilevel positive airway pressure to the lungs
214774583|NCT04700215|DEVICE|Incentive spirometry|IS for 15 minutes after every 4 hours
214774584|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
214774585|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
214774586|NCT05145660|RADIATION|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
214774587|NCT05145660|DRUG|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
214774588|NCT03883789|DIAGNOSTIC_TEST|FibroScan|FibroScan will be used to assess liver stiffness
214774589|NCT05092802|DRUG|HLX208|450mg bid po
214774590|NCT04333199|BEHAVIORAL|Timely|Email
214774591|NCT04333199|BEHAVIORAL|Transparency|Email
214774592|NCT04333199|BEHAVIORAL|Foot-in-the-door|Email
214774593|NCT03695042|OTHER|Blood Flow Restriction Training with Exercise|The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
214774594|NCT05350358|DEVICE|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
214774595|NCT03287102|PROCEDURE|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
214774596|NCT05308576|BIOLOGICAL|SCTV01E|D0; intramuscular injection
214646507|NCT00705978|DRUG|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
214646508|NCT00705978|DRUG|Placebo|placebo
214646509|NCT03913663|OTHER|vestibuloocular training|using vestibulo ocular training program for training neglect patient
214646510|NCT03913663|OTHER|regular exercise training for hemiplegic patients|Traditional gait training program.
214646511|NCT05657184|DRUG|REGEND001|Transplantation of REGEND001 for dose escalation.
214646512|NCT01260155|DRUG|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
214646513|NCT01260155|DRUG|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
214774597|NCT05308576|BIOLOGICAL|Placebo|D0; intramuscular injection
214774598|NCT04085263|PROCEDURE|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
214774599|NCT04085263|PROCEDURE|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
214774600|NCT02198755|DEVICE|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
214774601|NCT02198755|DEVICE|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
214774602|NCT02203188|PROCEDURE|Lid debridgement scaling|
214774603|NCT04840628|OTHER|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
214774604|NCT01093365|DRUG|Varenicline|"* 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days"
214774605|NCT01468974|DEVICE|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
214774606|NCT00002126|DRUG|Filgrastim|
214774607|NCT03441958|BIOLOGICAL|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
214774608|NCT03295968|OTHER|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
214774609|NCT06301256|DRUG|TIRZEPATIDE|Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
214774610|NCT00998582|DRUG|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
214774611|NCT04000373|DEVICE|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
214774612|NCT00000160|PROCEDURE|Xenon Photocoagulation|
214774613|NCT00000160|PROCEDURE|Argon Photocoagulation|
214774614|NCT00000160|PROCEDURE|Photocoagulation|
214774615|NCT02711579|DRUG|Celecoxib|
214774616|NCT02711579|DRUG|Placebo|
215030814|NCT01809665|DEVICE|ICD/CRT-P therapy|
215030815|NCT01809665|OTHER|MRI|
215030816|NCT04883476|OTHER|Observation study only|
214774617|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
214774618|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
214774619|NCT01032330|DEVICE|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
214774620|NCT02434796|BEHAVIORAL|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
214774621|NCT02434796|BEHAVIORAL|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
214774622|NCT03250013|DRUG|ADHD medications|
214774623|NCT01995006|DRUG|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
214774624|NCT01995006|DRUG|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
214774625|NCT06542744|DEVICE|Training with the Emagina device at home until birth|The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
214646514|NCT01260155|DRUG|E5501|Treatment C: 40 mg new tablet formulation administered with food
214646515|NCT01823068|DRUG|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
214646516|NCT01222650|DRUG|KSO-0400|
214646517|NCT01222650|DRUG|KSO-0400|
214646518|NCT01222650|DRUG|Silodosin|
214646519|NCT01222650|DRUG|Placebo|
214774626|NCT06542744|OTHER|No intervention|The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
214646520|NCT03082001|DRUG|12% Sucrose|
214646521|NCT03082001|DRUG|24% Sucrose|
214646522|NCT00892580|DRUG|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
214646523|NCT01705691|DRUG|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
214774627|NCT04230785|GENETIC|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
214774628|NCT01677403|DRUG|Tobramycin|Nebulised 80mg twice daily
214774629|NCT01677403|DRUG|Saline|Nebulised 5mls 0.9% Saline twice daily
214774630|NCT01117714|PROCEDURE|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
214646524|NCT01705691|DRUG|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
214646525|NCT01705691|DRUG|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
214646526|NCT01705691|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
214646527|NCT04887402|DRUG|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation"
214646528|NCT00078364|PROCEDURE|MRI|
214646529|NCT02446392|OTHER|No intervention.|
214646530|NCT03640884|DRUG|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
214646531|NCT03492684|PROCEDURE|total hip arthroplasty|total hip arthroplasty and EMG
214646532|NCT05202626|DIAGNOSTIC_TEST|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
214646533|NCT00214461|BIOLOGICAL|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
214646534|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
214646535|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
214646536|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
214646537|NCT02913313|DRUG|BMS-986207|Specified dose on specified days
214646538|NCT02913313|BIOLOGICAL|Nivolumab|Specified dose on specified days
214646539|NCT02913313|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214646540|NCT03025256|PROCEDURE|Biospecimen Collection|Correlative studies
214646541|NCT03025256|PROCEDURE|Computed Tomography|Undergo CT
214646542|NCT03025256|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture for cerebrospinal fluid collection
214646543|NCT03025256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of brain and spine
214646544|NCT03025256|BIOLOGICAL|Nivolumab|Given IV or IT
214646545|NCT03025256|PROCEDURE|Positron Emission Tomography|Undergo PET
214646546|NCT06494280|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
214774631|NCT02690584|BEHAVIORAL|Metacognitive therapy|
214774632|NCT00335790|PROCEDURE|Hyperbaric Therapy|
214774633|NCT02192216|BEHAVIORAL|Exercise|
214774634|NCT05094986|BEHAVIORAL|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
214774635|NCT05094986|OTHER|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
214774636|NCT01186952|BEHAVIORAL|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
214774637|NCT01186952|BEHAVIORAL|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
214774638|NCT02791711|OTHER|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
214774639|NCT03351127|RADIATION|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
214774640|NCT04307537|PROCEDURE|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
214774641|NCT04685941|DRUG|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
214774642|NCT04685941|OTHER|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
214774643|NCT00821522|PROCEDURE|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
214774644|NCT01155284|DRUG|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
214774645|NCT01155284|DRUG|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
214774646|NCT06528860|DEVICE|MiSight® 1 day soft contact lenses|Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.
214774647|NCT06528860|DEVICE|Proclear® 1 day soft contact lenses|Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
214774648|NCT04775368|OTHER|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
214774649|NCT05795517|DRUG|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
214774650|NCT05795517|DRUG|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
214774651|NCT05795517|DRUG|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
214774652|NCT05795517|DRUG|Placebo|placebo ，QD，oral，Day1 to week 12
214774653|NCT05795517|DRUG|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
214774654|NCT02856451|BIOLOGICAL|Nivolumab|Specified dose on specified days
214774655|NCT03497988|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
214774656|NCT03497988|DRUG|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
214774657|NCT01766310|DRUG|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
214774658|NCT01766310|DRUG|placebo|sugar tablet manufactured to mimic folic acid tablet
214774659|NCT03584035|BEHAVIORAL|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
214774660|NCT03584035|BEHAVIORAL|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
214774661|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
214774662|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
214774663|NCT05951231|PROCEDURE|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
214774664|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation|Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
214774665|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation|Healing Progression: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
214774666|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
214774667|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
214774668|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
214774669|NCT03180983|BEHAVIORAL|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
214774670|NCT03030638|DRUG|Olodaterol|Drug
214774671|NCT03030638|DRUG|Indacaterol|Drug
214774672|NCT02441959|PROCEDURE|Lumbar discectomy Open|Open Discectomy
215030817|NCT03199183|RADIATION|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
214774673|NCT02441959|PROCEDURE|Lumbar discectomy Endoscopic|Endoscopic Discectomy
214774674|NCT04518475|DRUG|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
214774675|NCT04518475|DRUG|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
214774676|NCT00216424|DRUG|Capecitabine (Xeloda)|
214774677|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
214774678|NCT02996461|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
214774679|NCT06222398|DEVICE|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
214774680|NCT03785652|DRUG|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
214774681|NCT03785652|DRUG|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
214774682|NCT03785652|DRUG|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
214774683|NCT03785652|DRUG|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
214774684|NCT03785652|DRUG|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
214774685|NCT05535842|OTHER|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
214774686|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
214774687|NCT02606370|OTHER|Unstable shoe|Wearing Unstable shoes during 1 month
214774688|NCT03466788|OTHER|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
214774689|NCT06704061|BEHAVIORAL|Yoga|A 12-week online yoga course designed to treat pain.
214774690|NCT06704061|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A 12-week behavioral therapy course designed to treat pain.
214774691|NCT02553005|PROCEDURE|Acupuncture|
214774692|NCT02328404|DRUG|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
214774693|NCT02328404|DRUG|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
214774694|NCT02618772|DRUG|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
214774695|NCT02618772|DRUG|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
214774696|NCT04348292|DRUG|Durvalumab|Given IV
214774697|NCT04348292|DRUG|Sirolimus|Given PO
214774698|NCT03192566|DRUG|Tylenol|Dosing of Tylenol for post operative pain control
214774699|NCT01417208|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
214774700|NCT06212375|BEHAVIORAL|Vegetable variety|Either children are offered a variety of three vegetables or a single vegetable.
214774701|NCT06212375|BEHAVIORAL|Vegetable offering strategy|Either children can decide when to eat their vegetables or parents initiate a moment.
214774702|NCT03771768|RADIATION|Diode laser 980nm&100 mWatt|Diode laser 980 nm \&100 milli Watt.
214774703|NCT03771768|DRUG|Triamcinolone Acetonide|0.1 \&5gm paste 4 times/day
214774704|NCT06567535|PROCEDURE|Navigation and endoscopy|The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
214774705|NCT04093479|OTHER|blood samples|blood samples will be taken repeatedly
214774706|NCT06543134|PROCEDURE|surgery|ENT surgery lasting more than half an hour
214774707|NCT06543134|PROCEDURE|sedation scale|Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
214774708|NCT00266461|DRUG|Daikenchuto Extract Granules (TU-100)|
214774709|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
214774710|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
214774711|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
214774712|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
214774713|NCT04640909|OTHER|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
214774714|NCT00684216|DRUG|capecitabine|200 mg, BID, PO, QD until progression of disease
214774715|NCT00684216|DRUG|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
214774716|NCT02296047|DRUG|Placebo|physiological saline
214774717|NCT02296047|DRUG|ipratropium bromide|80 µg inhalation once
214774718|NCT02296047|DRUG|salbutamol|400 µg inhalation once
214774719|NCT04234152|OTHER|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
214774720|NCT04234152|OTHER|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
214774721|NCT04529499|DRUG|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
214774722|NCT04529499|DRUG|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
214774723|NCT04068155|DEVICE|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
215030818|NCT03199183|OTHER|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
214774724|NCT04359420|OTHER|BC-Predict|BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
214774725|NCT04359420|OTHER|NHS Breast Screening Programme|usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
214774726|NCT02604186|OTHER|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
214774727|NCT02604186|OTHER|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
214774728|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
214774729|NCT03109860|BEHAVIORAL|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
214774730|NCT00758706|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
214774731|NCT00758706|DRUG|Placebo|Dosing to match AZD1236
214774732|NCT02507115|BEHAVIORAL|TMAP|Text messages for Alcohol Risk Reduction
214774733|NCT02507115|BEHAVIORAL|Mojo Texts|Motivational texts not alcohol related
214774734|NCT03874533|DEVICE|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
214774735|NCT01039584|DRUG|Butoconazole Nitrate Vaginal Cream|vaginal cream
214774736|NCT01039584|DRUG|Placebo|vaginal cream
214774737|NCT01039584|DRUG|Gynazole 1 vaginal cream|vaginal cream
214774738|NCT04828629|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
214774739|NCT01460121|DEVICE|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
214774740|NCT01460121|DEVICE|Placebo|
214774741|NCT01494649|DRUG|Test Toothpaste|0.454% stannous fluoride toothpaste
214774742|NCT01494649|DRUG|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
214774743|NCT01855100|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
214774744|NCT03467971|DRUG|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
214774745|NCT06542211|BEHAVIORAL|Intervention plan for improving ankle dorsiflexion limitation group (experimental group)|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
214774746|NCT06542211|BEHAVIORAL|Plantar fasciitis routine rehabilitation group|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
214774747|NCT00247130|DRUG|Omeprazole|
214774748|NCT00247130|DRUG|Ranitidine|
214774749|NCT03791619|DEVICE|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
214774750|NCT03791619|DEVICE|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
214774751|NCT05413902|DRUG|Toradol|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774752|NCT05413902|DRUG|Morphine|Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
214774753|NCT05413902|DRUG|Orphenadrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774754|NCT05413902|DRUG|Gabapentin|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774755|NCT05413902|DRUG|Acetaminophen|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774756|NCT05413902|DRUG|Bupivacaine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774757|NCT05413902|DRUG|Epinephrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774758|NCT05413902|DRUG|Xylocaine Injectable Solution|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774759|NCT05413902|DRUG|Methylprednisolone|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
214774760|NCT01966341|BEHAVIORAL|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
214774761|NCT01966341|DRUG|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
214774762|NCT04711122|DRUG|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
214774763|NCT01174368|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
214774764|NCT04717869|DIAGNOSTIC_TEST|Ultrasound|2D ultrasound image collection
214774765|NCT04717869|DIAGNOSTIC_TEST|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
214774766|NCT04717869|OTHER|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
214774767|NCT04114578|OTHER|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
214774768|NCT06150872|DEVICE|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
214774769|NCT06033703|DRUG|Netarsudil Ophthalmic|Topical administration of Netarsudil
214774770|NCT05120752|OTHER|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
214774771|NCT04446117|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
214774772|NCT04446117|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
214774773|NCT04446117|DRUG|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
214774774|NCT04446117|DRUG|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
214774775|NCT04446117|DRUG|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
214774776|NCT03203265|OTHER|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
214774777|NCT03203265|OTHER|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
215030819|NCT03199183|GENETIC|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
215030820|NCT00003645|DRUG|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
214774778|NCT03203265|OTHER|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
214774779|NCT05425277|BEHAVIORAL|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
214774780|NCT05425277|BEHAVIORAL|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
214774781|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
214774782|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
214774783|NCT06593366|BIOLOGICAL|Fecal Microbiota Transplant|An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
214774784|NCT06593366|DRUG|Placebo|Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
214774785|NCT02416089|DEVICE|Tampostat|
214774786|NCT02416089|DEVICE|Condom catheter tamponade|
214774787|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1\. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
214774788|NCT03278483|DRUG|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
214774789|NCT03278483|DRUG|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
214774790|NCT03311217|BEHAVIORAL|Healthy retail strategies|
214774791|NCT05510856|OTHER|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
214774792|NCT05510856|OTHER|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
214774793|NCT05510856|OTHER|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
214774794|NCT04946071|BEHAVIORAL|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
214774795|NCT00881049|DRUG|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
214774796|NCT04744077|BEHAVIORAL|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
214774797|NCT04744077|BEHAVIORAL|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
214774798|NCT03953911|BIOLOGICAL|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
214774799|NCT03953911|BEHAVIORAL|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
214774800|NCT05255783|DEVICE|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
214774801|NCT06498557|OTHER|Peripheral nerve block methods|We apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.
214774802|NCT01361698|BEHAVIORAL|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
214774803|NCT04699721|DRUG|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
214774804|NCT01029080|OTHER|no interventions|No interventions
214774805|NCT00826722|DRUG|Levetiracetam|1000 mg tablet
214774806|NCT01236053|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
214774807|NCT06569004|DEVICE|randomised study, two group (experimental and control)|Use of IR beam before peripheral intravenous catheter application
214774808|NCT01734421|OTHER|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
214774809|NCT01734421|DEVICE|Cell phone Aplication for Smarth Phone|
214774810|NCT02515552|BEHAVIORAL|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
214774811|NCT00000135|DRUG|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
214774812|NCT00000135|OTHER|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
214774813|NCT05863182|BEHAVIORAL|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
215030821|NCT00003645|DRUG|Leuprolide Acetate|50 mg tablet orally daily for 12 months
215030822|NCT04402307|OTHER|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
214646547|NCT06494280|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
215030823|NCT01888861|DIETARY_SUPPLEMENT|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
214646548|NCT03289416|COMBINATION_PRODUCT|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
214646549|NCT03289416|COMBINATION_PRODUCT|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
214646550|NCT04233229|DEVICE|t:slim X2 with Control-IQ|closed-loop in patients at home for three months
214646551|NCT04233229|OTHER|home healthcare services|home healthcare services from Air Liquide in patients at home for three months
214646552|NCT04233229|OTHER|usual care for daily insulin treatment|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
214646553|NCT04642846|OTHER|Silver Diamine Fluoride (SDF)|Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
214646554|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
214646555|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
214646556|NCT00841763|BIOLOGICAL|Placebo (PL)|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
214646557|NCT00841763|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
214646558|NCT00841763|BIOLOGICAL|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
214646559|NCT00841763|BIOLOGICAL|Adjuvanted trivalent influenza virus vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
214646560|NCT02505282|OTHER|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
214646561|NCT06343506|DEVICE|Grassroots Ankle Flex|This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The Ankle Flex device is used to stretch patients into a dorsiflexion position by securing the foot to the base of the device and the shin to the leg strap attached to the pulley system. The patients can then pull the handle of the pulley system, giving them the mechanical advantage to gently mobilize their ankle into dorsiflexion with their foot firmly secured to the base of the device. This can allow for a deeper and more controlled stretch than previous stretching methods done during at home care.
214646562|NCT04628923|OTHER|QUADRATUS LUMBORUM BLOCK|QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
214646563|NCT06429995|RADIATION|Radiotherapy|
214646564|NCT01884831|BIOLOGICAL|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
214646565|NCT02631538|DRUG|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
214646566|NCT02631538|DRUG|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
214646567|NCT02631538|DRUG|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
214646568|NCT02631538|DRUG|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
214646569|NCT04677439|DRUG|Flumatinib|600 mg of Flumatinib orally daily for 24 months
214646570|NCT01609595|DRUG|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
214646571|NCT04475692|BEHAVIORAL|Repetitive, task-specific upper limb practice|A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.
214646572|NCT04475692|OTHER|Conventional care|Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
214646573|NCT01901835|PROCEDURE|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
214646574|NCT01901835|OTHER|survey administration|Ancillary studies
214646575|NCT01901835|PROCEDURE|quality-of-life assessment|Ancillary studies
214646576|NCT03416361|DIETARY_SUPPLEMENT|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
214646577|NCT06419114|DEVICE|Optical Coherence Tomography|Comparing the localization ability of OCT and R-EBUS in Peripheral Pulmonary Lesions and the predictive ability of lung cancer pathological classification
214646578|NCT03402997|DIAGNOSTIC_TEST|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
214646579|NCT02436460|BIOLOGICAL|AbGn-168H|Humanized monoclonal antibody
214774814|NCT05096026|BEHAVIORAL|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
214774815|NCT05096026|BEHAVIORAL|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
214774816|NCT01311505|DRUG|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
214774817|NCT01311505|DRUG|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
214774818|NCT06582888|DRUG|Varenicline Tartrate|varenicline (target dose 1mg twice daily)
214774819|NCT06582888|DRUG|Placebo|matched placebo
214774820|NCT06567964|PROCEDURE|Erector Spinae Plane Block(ESPB)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
215030824|NCT01888861|DRUG|placebo|the patients in this arm were received 900mg placebo through NG tube.
215030825|NCT02574793|DEVICE|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
215030826|NCT06800209|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain.
214646580|NCT01748604|OTHER|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
214646581|NCT01748604|DEVICE|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
214646582|NCT01748604|OTHER|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
214646583|NCT01748604|DEVICE|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
214646584|NCT05670080|BEHAVIORAL|Motor Imagery|Motor imagery is the imagining of action without its physical execution and motor imagery elicits activity in brain regions that are normally activated during actual task performance. The brain perceives real experiences and the visualization process as similar. For this reason, imagery is considered a mental exercise
214646585|NCT05670080|BEHAVIORAL|Physical Therapy|Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.
214646586|NCT00964431|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
214646587|NCT00964431|DRUG|Placebo|Capsules 2 Single-Dose
214646588|NCT00964431|DRUG|Indomethacin Test (lower dose)|20-mg single dose
214646589|NCT00964431|DRUG|Indomethacin Test (upper dose)|40-mg single dose
214646590|NCT00440726|DRUG|Bortezomib|Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
214646591|NCT00440726|DRUG|Dexamethasone|10 mg/m2/day divided BID, oral administration for 14 days.
214646592|NCT00440726|DRUG|PEG-asparaginase|2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
214646593|NCT00440726|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on Day 1
214646594|NCT00440726|DRUG|Cytarabine|"Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
214646595|NCT00440726|DRUG|Methotrexate|"Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
214646596|NCT00440726|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
214646597|NCT00440726|DRUG|Triple IT Therapy|"Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* \>=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg"
214646598|NCT01482910|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
214646599|NCT01482910|DRUG|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
214646600|NCT00305942|DRUG|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
214646601|NCT00305942|DRUG|carboplatin|Carboplatin AUC=5 IV day 1 only .
214646602|NCT00308763|DRUG|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
214646603|NCT00308763|DRUG|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
214646604|NCT04519996|PROCEDURE|US Internal Jugular Vein Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position."
214646605|NCT04519996|PROCEDURE|US Inferior Vena Cava Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100."
214646606|NCT05586126|DRUG|Sevoflurane|sevoflurane inhalation
214646607|NCT03455699|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
214646608|NCT03455699|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
214646609|NCT03455699|DEVICE|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
214646610|NCT06549140|OTHER|Augmented reality exercise program|Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide an entire exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).
214646611|NCT06549140|OTHER|Traditional exercise program|Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
214646612|NCT02814149|PROCEDURE|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
214646613|NCT02814149|PROCEDURE|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
214646614|NCT03370770|DRUG|Afatinib|GILOTRIF, GIOTRIF, XOVOLTIB
215030827|NCT06800209|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
215030828|NCT04060238|DIAGNOSTIC_TEST|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
214774821|NCT06567964|PROCEDURE|Wound infiltration|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
214774822|NCT03022799|DRUG|KM-819|
214774823|NCT03022799|DRUG|Placebo|
214774824|NCT05503914|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
214774825|NCT03137758|DRUG|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
214774826|NCT00759759|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
214774827|NCT00759759|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
214774828|NCT01592227|DRUG|Marketed paracetamol|Marketed paracetamol
214774829|NCT01592227|DRUG|Experimental paracetamol formulation|Experimental paracetamol formulation
214774830|NCT02432456|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
214774831|NCT02432456|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
214774832|NCT02432456|PROCEDURE|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
214774833|NCT02432456|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
214774834|NCT02432456|DRUG|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
214774835|NCT02432456|DRUG|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
214774836|NCT02432456|DRUG|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
214774837|NCT02432456|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
214774838|NCT05677984|PROCEDURE|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
214774839|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
214774840|NCT02618707|OTHER|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
214774841|NCT03970252|DRUG|Fluorouracil|Given IV
214774842|NCT03970252|DRUG|Irinotecan|Given IV
214774843|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
214774844|NCT03970252|DRUG|Leucovorin|Given IV
214774845|NCT03970252|DRUG|Leucovorin Calcium|Given IV
214774846|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
214774847|NCT03970252|DRUG|Oxaliplatin|Given IV
214774848|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214774849|NCT04567160|DRUG|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
214774850|NCT04567160|DRUG|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
214774851|NCT04443231|DEVICE|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
214774852|NCT04923607|DRUG|TQC2731|TQC2731 injection
214774853|NCT04923607|DRUG|Placebo|Matching placebo with no active ingredients
214774854|NCT01508572|DRUG|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
215030829|NCT02199912|PROCEDURE|Biopsy of adipose and muscular tissue|
214646615|NCT03370770|DRUG|Osimertinib|on T790M resistance mutation was developed
214646616|NCT00524160|DRUG|Fentanyl transdermal patch|
214646617|NCT00123565|DRUG|Hexadecasaccharide (SR123781A)|
214646618|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
214646619|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
214646620|NCT04305015|DEVICE|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
214646621|NCT04305015|OTHER|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
214646622|NCT03175341|DRUG|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
214646623|NCT03175341|DRUG|Placebos|100 ml normal saline 0.9%
214646624|NCT03881969|BEHAVIORAL|Financial Payment of £100|No financial payment
214646625|NCT00173862|DRUG|Gemcitabine, Ifosfamide|
214646626|NCT00234039|DRUG|gemcitabine hydrochloride|
214646627|NCT01284504|DRUG|Celecoxib|200 mg tablet oral
214646628|NCT01284504|OTHER|placebo|Placebo, tab
214646629|NCT02279030|OTHER|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
214646630|NCT00110019|DRUG|Carboplatin|Given IV
214646631|NCT00110019|OTHER|Laboratory Biomarker Analysis|Correlative studies
214646632|NCT00110019|DRUG|Paclitaxel|Given IV
214646633|NCT00110019|OTHER|Pharmacological Study|Correlative studies
214646634|NCT00110019|OTHER|Placebo|Given PO
214646635|NCT00110019|DRUG|Sorafenib Tosylate|Given PO
214646636|NCT03897751|DEVICE|ABT12 Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
214646637|NCT03897751|DEVICE|COMPLETE Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
214646638|NCT03897751|DEVICE|Sensitive Eyes® Rewetting Drops|For use as needed during the study.
214646639|NCT00510185|OTHER|systematic coronary intervention|Coronary angiography within 72 hrs
214774855|NCT06309121|DIETARY_SUPPLEMENT|Postbiotic ABB C3|A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
215030830|NCT02199912|OTHER|Blood sampling|
214646640|NCT00510185|OTHER|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
214646641|NCT03142698|PROCEDURE|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
214646642|NCT04426695|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
214646643|NCT04426695|DRUG|Placebo|Placebo IV Single Dose
214646644|NCT04303000|DRUG|Opioid Overdose Education with Naloxone Distribution|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with a naloxone kit.
214646645|NCT04303000|DRUG|Opioid Overdose Education|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
214646646|NCT02590484|PROCEDURE|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
214646647|NCT05389488|DEVICE|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
214646648|NCT05389488|DEVICE|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
214646649|NCT03618745|DEVICE|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
214646650|NCT03429127|OTHER|Normal saline|Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
214646651|NCT03429127|OTHER|Balanced fluid|Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
214646652|NCT00559273|DRUG|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
214646653|NCT00559273|DRUG|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
214646654|NCT01717131|PROCEDURE|Surgery for standard axillary node dissection|
214646655|NCT01717131|OTHER|No axillary lymph node dissection|No surgery on axillary lymph node
214646656|NCT04803760|OTHER|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
214646657|NCT04703569|PROCEDURE|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
214646658|NCT04703569|PROCEDURE|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
214646659|NCT01648257|DRUG|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
214646660|NCT01648257|DRUG|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
214646661|NCT01648257|DRUG|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
214646662|NCT00716469|DRUG|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
214646663|NCT05398614|BIOLOGICAL|SENL101|Patients will be treated with CD7 CAR-T cells
214646664|NCT04297215|DEVICE|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D\&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
214774856|NCT06309121|DIETARY_SUPPLEMENT|Placebo|A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
214774857|NCT06309121|DIETARY_SUPPLEMENT|Follow-up Postbiotic ABB C3 (Optional)|Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
215030831|NCT02199912|OTHER|Calorimetry|
215030832|NCT02199912|OTHER|Impedance measure|Evaluation of physical composition (non-invasive method)
214646665|NCT04297215|DEVICE|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
214646666|NCT04297215|DEVICE|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
214646667|NCT00196417|DRUG|Standard heparin (UFH) versus certoparin (LMWH)|
214646668|NCT02663739|DEVICE|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
214646669|NCT01897467|BEHAVIORAL|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
214646670|NCT01897467|BEHAVIORAL|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
214646671|NCT01160601|DRUG|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
214646672|NCT01160601|DRUG|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
214646673|NCT00732745|DRUG|docetaxel|Given IV
214646674|NCT00732745|DRUG|oxaliplatin|Given IV
214646675|NCT00732745|DRUG|vandetanib|Given orally
214646676|NCT00732745|OTHER|placebo|Given orally
214646677|NCT06547983|OTHER|Personalized nutritional advice|Participants in the intervention group received personalized nutrition advice based on their dietary habits, weight, anthropometric data and physical activity.
214646678|NCT06547983|OTHER|Personalized nutritional advice and food boxes|Participants in the intervention plus group received the personalized nutrition advice while also receiving food boxes which are composed based on the personalized nutritional advice.
214646679|NCT02798926|DEVICE|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
214646680|NCT05442619|PROCEDURE|Venous blood collection|Venous blood will be drawn from newborns.
214646681|NCT06419283|PROCEDURE|Middle Cerebral Artery Stent Implantation|Middle Cerebral Artery Stent Implantation
214646682|NCT06419283|DRUG|standard treatment with aspirin.|standard treatment with aspirin.
214646683|NCT05480319|OTHER|EDICARS|The investigators propose to (1) Embed the EDICAS into our hospital information system (HIS) in real-time at ED triage to identify high-risk patients (EDICAS 6+); and (2) Distribute wearable smart wristbands to high-risk patients to augment vital signs monitoring and send alerts based on GBTM results. The detection and intervention components together form the rapid response system, the Emergency Department In-hospital Cardiac Arrest Response System (EDICARS).
214646684|NCT05480319|OTHER|Usual care|Usual care will be assigned to this arm. No additional interventions.
214646685|NCT02603744|BIOLOGICAL|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
214646686|NCT03642145|DRUG|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
214646687|NCT00506857|DRUG|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
214646688|NCT00506857|DRUG|Fludarabine|30 mg/m\^2 by vein daily x 4 days.
214646689|NCT01016873|DEVICE|IRay|Low voltage stereotactic radiotherapy system
214646690|NCT03387787|DEVICE|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
214646691|NCT03387787|DRUG|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
214646692|NCT04401033|BEHAVIORAL|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
214646693|NCT04401033|PROCEDURE|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
214646694|NCT04401033|PROCEDURE|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
214646695|NCT03073746|OTHER|Health Search|
214646696|NCT03073746|OTHER|Standard Search|
215030833|NCT02199912|OTHER|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
214774858|NCT05166369|BEHAVIORAL|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
214774859|NCT05166369|BEHAVIORAL|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
214774860|NCT03101215|DIETARY_SUPPLEMENT|phosphorus|adding of phosphorus to high carbohydrate meal
214774861|NCT01456494|OTHER|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
214774862|NCT01456494|OTHER|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
214774863|NCT02543515|PROCEDURE|office hysteroscopy|diagnostic procedure
214774864|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
214774865|NCT04497571|PROCEDURE|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
214774866|NCT04497571|PROCEDURE|Conventional drilling|Implants placed using drilling technique
214774867|NCT02130895|OTHER|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with \>=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
214774868|NCT00770354|DRUG|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
214774869|NCT00770354|DRUG|Letrozole|Daily 2.5 mg oral letrozole tablet
214774870|NCT06602037|DIAGNOSTIC_TEST|[89Zr]Zr-DFO-SHR1920|Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
214774871|NCT06602037|DIAGNOSTIC_TEST|[18F]F-RESCA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.
214774872|NCT06602037|DIAGNOSTIC_TEST|[68Ga]Ga-NOTA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.
214774873|NCT00517257|DRUG|Atorvastatin|80 mg orally once daily for 24 weeks
214774874|NCT00517257|DRUG|Placebo|Placebo tablet orally once daily for 24 weeks
214774875|NCT05862714|DRUG|Fluconazole|400 mg stat. Follow up at 4 weeks
214774876|NCT05862714|DRUG|Itraconazole|1000 mg stat. Follow up at 4 weeks
214774877|NCT01713478|OTHER|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
214774878|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
214774879|NCT06346197|DRUG|Balstilimab|Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
214774880|NCT06346197|DRUG|Botensilimab|Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
214774881|NCT06346197|DRUG|Folfox Protocol|oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
214774882|NCT06346197|DRUG|XELOX|Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
214774883|NCT06346197|DRUG|Nivolumab|240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
214774884|NCT06354972|PROCEDURE|Minimally invasive surgical procedure|All the experimental sites underwent a minimally-invasive surgical technique (MIST) procedure under magnification (Cortellini and Tonetti 2007). The full-thickness flap was minimally raised both on the buccal and oral side, avoiding vertical releasing incisions. Granulation tissue was scraped from the bony surfaces of the defect, and the root was debrided using minicurettes/ultrasonic device and chemically treated by EDTA. Regenerative procedure was carried out using a combination of enamel matrix derivatives and bone xenograft. The flaps were then repositioned and sutured in order to obtain passive primary closure.
214774885|NCT04654286|PROCEDURE|Nerve transfer procedure|"1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
214774886|NCT04654286|PROCEDURE|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
214774887|NCT06425419|DRUG|Topotecan|20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
214774888|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
214774889|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
214774890|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
214774891|NCT01810393|DRUG|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
214774892|NCT04379973|DRUG|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
214774893|NCT05886673|OTHER|experimental cream|experimental cream
214774894|NCT05886673|OTHER|standard of care|standard of care
214774895|NCT01241812|BEHAVIORAL|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
214774896|NCT00365469|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
214774897|NCT00365469|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
214774898|NCT03853213|BEHAVIORAL|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
214774899|NCT03853213|BEHAVIORAL|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
214774900|NCT02898064|DEVICE|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
214774901|NCT02898064|OTHER|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
214774902|NCT04779385|PROCEDURE|PIPAC|"under general anaesthesia, a laparoscopy was performed using an open laparoscopic technique to prevent intestinal wounds, which would contraindicate the procedure. A 12 mmHg pneumoperitoneum was created, and to ensure the safety of the procedure the pressure of the pneumoperitoneum was maintained constant throughout the procedure. Two laparoscopic balloon trocars (of 11 and 12 mm) were used. A thorough exploration of the abdomen, Peritoneal Cancer Index assessment, images, peritoneal biopsies, and ascites cytology (in the case of ascites) were performed prior to administration of the chemotherapy aerosol.~For carcinomas of gastric origin, Doxurubicin at a dose of 1.5 mg/m2 was administered in combination with Cisplatin 7.5 mg/m2 diluted in 40 and 150 mL of 0.9% sodium chloride, respectively. In the case of contraindication, Oxaliplatine at a dose of 92 mg/m2 in a 5% dextrose solution was recommended."
214774903|NCT06568185|DRUG|Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA|BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
214774904|NCT00000478|DRUG|atenolol|
214774905|NCT00000478|DRUG|nifedipine|
214774906|NCT00000478|DRUG|diltiazem|
214774907|NCT00000478|DRUG|isosorbide dinitrate|
214774908|NCT00000478|PROCEDURE|coronary artery bypass coronary artery bypass|
214774909|NCT00000478|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214774910|NCT04462133|DIAGNOSTIC_TEST|Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)|Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
215030834|NCT02199912|OTHER|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
215030835|NCT02199912|OTHER|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
215030836|NCT02199912|OTHER|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
214646697|NCT00395967|DRUG|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
214646698|NCT02953145|DRUG|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
214646699|NCT05479292|OTHER|Sars-CoV-2 outbreak|Sars-CoV-2 pandemic's impact on provision of healthcare for cancer patients
214646700|NCT03118947|DRUG|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
214646701|NCT05429567|DRUG|Fentanyl|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
214646702|NCT03653390|BEHAVIORAL|EnhanceWellness for Disability (EW-D)|Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
214646703|NCT03653390|BEHAVIORAL|Wellness Education|Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
214774911|NCT02858518|OTHER|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
214774912|NCT04737915|BEHAVIORAL|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
214774913|NCT04737915|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
215030837|NCT02199912|OTHER|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
215030838|NCT00943137|DRUG|5-Fluorouracil|"Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
214646704|NCT01109940|BIOLOGICAL|AIN457A|
214646705|NCT04765605|DEVICE|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
214646706|NCT00002969|DRUG|paclitaxel|
214646707|NCT01351441|BEHAVIORAL|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
214646708|NCT01351441|OTHER|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
214646709|NCT01351441|OTHER|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
214646710|NCT01351441|BEHAVIORAL|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
214646711|NCT05837741|DIETARY_SUPPLEMENT|Standard hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
214646712|NCT05837741|DIETARY_SUPPLEMENT|Leucine-enriched hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
214646713|NCT03031600|DIAGNOSTIC_TEST|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
214774914|NCT02535676|DEVICE|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
214774915|NCT00244660|PROCEDURE|Frequent blood pressure measurements|
214774916|NCT00244660|BEHAVIORAL|Education|
214774917|NCT01040676|BEHAVIORAL|Automated Telephone Nutrition Support|See Intervention Group description.
214774918|NCT02854189|DEVICE|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
214646714|NCT03031600|DIAGNOSTIC_TEST|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
214646715|NCT05261854|DEVICE|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
214646716|NCT05261854|OTHER|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
214646717|NCT00323999|PROCEDURE|Hysteroscopic resection of fibroids, polyps and endometrium.|
214646718|NCT05347641|DRUG|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
214646719|NCT05901467|DRUG|kisspeptin 112-121|One IV bolus of kisspeptin 112-121
214646720|NCT05901467|DRUG|GnRH|One IV bolus of gonadotropin-releasing hormone
214646721|NCT03983395|BIOLOGICAL|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
214646722|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
214646723|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
214646724|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
214646725|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
214646726|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
214646727|NCT03983395|BIOLOGICAL|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
214646728|NCT03983395|BIOLOGICAL|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
214774919|NCT06567366|BIOLOGICAL|CAR T-cell therapy|Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
214774920|NCT06567366|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."
214774921|NCT06567366|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
214774922|NCT01169831|OTHER|Exercise Training|2 weeks of daily aerobic exercise training
214774923|NCT01169831|OTHER|Exercise Cessation|Stopping all exercise for 2 weeks
214774924|NCT04218344|OTHER|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
214774925|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
214774926|NCT00047554|DRUG|Travoprost, 0.004% ophthalmic solution|
214774927|NCT01892605|BEHAVIORAL|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
214774928|NCT04721327|OTHER|remote CI programming|provision of CI programming provided remotely via Zoom in a 2 hour session
214774929|NCT00833976|DRUG|Lovaza|4 grams per day
214774930|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT active|Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
214774931|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
214774932|NCT01755780|OTHER|Left interscalene block|
214774933|NCT01755780|OTHER|Right interscalene block|
214774934|NCT03911960|BEHAVIORAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
214774935|NCT03911960|BEHAVIORAL|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
214774936|NCT03515889|BEHAVIORAL|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
214774937|NCT03515889|BEHAVIORAL|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
214774938|NCT06700746|PROCEDURE|Prolotherapy|Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions
214774939|NCT06700746|DEVICE|Extracorporeal shock wave therapy (ESWT)|Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
214774940|NCT06540482|DIAGNOSTIC_TEST|Reliability test|The test was administered two days apart to evaluate the reliability of the retest test.
214774941|NCT02670980|DEVICE|Intelligent Retinal Implant System|
214774942|NCT01518465|DRUG|dalteparin|Given SC
214774943|NCT01518465|DRUG|lenalidomide|Given PO
214774944|NCT01518465|DRUG|dexamethasone|Given PO
214774945|NCT01518465|OTHER|laboratory biomarker analysis|Correlative studies
214774946|NCT03872622|OTHER|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
214774947|NCT05762120|OTHER|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase"
214774948|NCT04682431|DRUG|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
214774949|NCT04682431|DRUG|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
214774950|NCT04682431|DRUG|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
214774951|NCT04682431|DRUG|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
214774952|NCT04682431|DRUG|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
214774953|NCT04682431|DRUG|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
214774954|NCT04682431|DRUG|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
214774955|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
214774956|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
214774957|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
214774958|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
214774959|NCT04682431|DRUG|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
214774960|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774961|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774962|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774963|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774964|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774965|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
214774966|NCT06256731|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214774967|NCT02239692|DRUG|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
214774968|NCT06539039|PROCEDURE|non surgical periodontal therapy|participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
214774969|NCT03679312|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
214774970|NCT03679312|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
214774971|NCT03232749|PROCEDURE|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
214774972|NCT03232749|DRUG|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
214774973|NCT03232749|DEVICE|Ultrasound|ultrasound-guided IACSI
214774974|NCT02433535|DRUG|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
214774975|NCT02433535|OTHER|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
214774976|NCT06254521|DRUG|Tislelizumab combined with chemotherapy|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic"
214774977|NCT05898490|BEHAVIORAL|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
214774978|NCT05224479|OTHER|Traditional workflow triage|Workflow triage is based on order location, STAT designation, and first-in-first-out status.
214774979|NCT05224479|OTHER|Machine learning workflow triage|Workflow triage is based on the machine learning model's confidence of abnormality.
214774980|NCT05224479|OTHER|Random workflow triage|Workflow triage is based on random order.
214774981|NCT03362242|DRUG|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
214774982|NCT03362242|OTHER|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214774983|NCT03967106|OTHER|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
214774984|NCT03967106|OTHER|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
214774985|NCT03414307|PROCEDURE|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
214774986|NCT03414307|DEVICE|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
214774987|NCT03232905|DRUG|PF-06651600|PF-06651600 will be administered as tablet
214774988|NCT03232905|DRUG|Placebo|Matching placebo will be administered as tablet
214774989|NCT06476873|BEHAVIORAL|Online self-questionnaire.|"Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French.~An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available.~The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press."
214774990|NCT05164848|DRUG|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
214774991|NCT05164848|DRUG|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
214774992|NCT01047904|DEVICE|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
214774993|NCT05233774|DRUG|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
214774994|NCT05233774|OTHER|Placebo|Placebo
214774995|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
214774996|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
214774997|NCT01038882|DRUG|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation
214774998|NCT01038882|OTHER|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
214774999|NCT01614925|DEVICE|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
214775000|NCT01614925|PROCEDURE|Periodontal surgery|Periodontal surgery alone
214775001|NCT06522230|OTHER|Fascial Stretch Therapy|Fascial Stretch Protocol uses a combination of circumduction, traction, proprioceptive neuromuscular facilitation (PNF) and specific FST maneuvers. Stretch is applied in both active \& passive methods taking into consideration: (1) Oscillatory - slow passive joint oscillations (back and forth movement in a regular rhythm). Small controlled oscillations help with proprioceptors around the joints, acilitates blood flow, gently stretches the ligaments, tendons, nerves, \& muscles and slows the nervous system down; (2) Traction - allows for assessment of the joint capsule movement and to decompress the joint. (3) Movement - designed to enhance the reflexes and are intentionally gentle to maximize benefits; (4) PNF - helps improve flexibility by alternating muscle contractions and relaxations. This stimulates the neuromuscular system, allowing muscles to relax deeper and increase range of motion. (5) Breath - allows the body to increase oxygen consumption to facilitate recovery.
214775002|NCT03519022|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
214775003|NCT03519022|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
214775004|NCT03519022|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
214775005|NCT02359734|OTHER|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
214775006|NCT06209424|BEHAVIORAL|Habitual Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).
214775007|NCT06209424|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
214775008|NCT06209424|BEHAVIORAL|Resistance Exercise|Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups
214775009|NCT00137358|PROCEDURE|Radiation Therapy|
214775010|NCT00137358|DRUG|Cisplatin|
214775011|NCT00137358|DRUG|Amifostine|
214775012|NCT00611741|DRUG|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
214775013|NCT03633019|DRUG|rhTPO|high dose rhTPO ih
214775014|NCT03096717|DIAGNOSTIC_TEST|colonoscopy and histology|colonic biopsies for detection of dysplasia
214775015|NCT01291719|DEVICE|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
214775016|NCT03365219|DEVICE|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
214775017|NCT03365219|OTHER|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
214775018|NCT05578417|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
214775019|NCT02359084|BEHAVIORAL|Family Navigation|
214775020|NCT02359084|BEHAVIORAL|Conventional Care Management|
214775021|NCT01774695|BEHAVIORAL|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
214775022|NCT01672814|DRUG|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
214775023|NCT01672814|DEVICE|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
214775024|NCT04372212|DEVICE|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
214775025|NCT04313023|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
214775026|NCT04313023|DRUG|Placebo|Sterile saline for inhalation
214775027|NCT01980316|DRUG|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
214775028|NCT01980316|DRUG|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
214775029|NCT03256708|DIETARY_SUPPLEMENT|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
214775030|NCT03256708|DIETARY_SUPPLEMENT|Placebo|Inactive ingredients
214775031|NCT00303264|DRUG|dexloxiglumide|
214775032|NCT00303264|DRUG|Nexium (esomeprazole)|
214775033|NCT05202613|DRUG|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
214775034|NCT00786019|BEHAVIORAL|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
214775035|NCT00786019|DRUG|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
214775036|NCT01496690|DRUG|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
214775037|NCT01496690|DRUG|Pregabalin Placebo Capsules|Parallel to Active Comparator
214775038|NCT04268784|DRUG|DNL343|Single and repeating oral dose(s)
214775039|NCT04268784|DRUG|Placebo|Single and repeating oral dose(s)
214775040|NCT02437890|BIOLOGICAL|ALX-0061|
214775041|NCT02437890|BIOLOGICAL|Placebo|
214775042|NCT02479932|OTHER|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
214775043|NCT02479932|OTHER|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
214775044|NCT00005588|RADIATION|radiation therapy|
214775045|NCT04146454|OTHER|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
214775046|NCT02314273|DRUG|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
214775047|NCT01148680|BIOLOGICAL|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
214775048|NCT00553748|DRUG|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
214775049|NCT00673322|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
214775050|NCT05976217|DRUG|Venetoclax|100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
214775051|NCT00798824|PROCEDURE|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
214775052|NCT00798824|PROCEDURE|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
214775053|NCT00798824|DEVICE|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
214775054|NCT00798824|DEVICE|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
214775055|NCT02701816|DEVICE|innova stent (Boston scientific)|
214775056|NCT06036173|OTHER|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
214775057|NCT06036173|OTHER|breast cancer surgery|be diagnosed and undergo surgery
214775058|NCT04778176|COMBINATION_PRODUCT|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
214775059|NCT03451227|DRUG|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
214775060|NCT03451227|DRUG|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
214775061|NCT04723173|DEVICE|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
214775062|NCT04723173|DEVICE|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
214775063|NCT02996448|DRUG|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
214775064|NCT05163431|DEVICE|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
214775065|NCT02766686|RADIATION|Radiotherapy with protons|
214775066|NCT02766686|RADIATION|Radiotherapy with photons|
214775067|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
214775068|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
214775069|NCT00088023|DRUG|PT-523 for Injection|
214775070|NCT04843800|PROCEDURE|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
214775071|NCT01876199|BEHAVIORAL|intense follow up|
214775072|NCT04821570|BIOLOGICAL|COVID-19 Vaccine|Per recommended dosing schedule
214775073|NCT03614871|OTHER|Epidemiological study|
214775074|NCT02033577|PROCEDURE|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
214775075|NCT02033577|PROCEDURE|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
214775076|NCT06253754|OTHER|MRI examination|All included subjects will be examined with MRI
214775077|NCT00388479|DRUG|Alvimopan|
214775078|NCT04349176|DRUG|Dose|Randomized to either 100U or 155U
214775079|NCT01422720|DRUG|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
214775080|NCT03508362|DEVICE|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
214775081|NCT04189289|PROCEDURE|ESP block group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
214775082|NCT04189289|PROCEDURE|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
214775083|NCT01241162|BIOLOGICAL|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
214775084|NCT02082262|DRUG|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
214775085|NCT01559831|BIOLOGICAL|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
214775086|NCT01852773|PROCEDURE|Open repair of thoracic aorta injury|open surgical management of aortic injury
214775087|NCT01852773|PROCEDURE|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
214775088|NCT00038129|PROCEDURE|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
214775089|NCT00982774|BIOLOGICAL|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
214775090|NCT02068404|DRUG|Nifedipine|
214775091|NCT02104401|DEVICE|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
214775092|NCT04812704|DIETARY_SUPPLEMENT|Whey protein|Patient receive protein supplement in liquid form after each exercice session
214775093|NCT02837367|DIETARY_SUPPLEMENT|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
214775094|NCT05041244|DEVICE|Negative pressure wound therapy delivered through VAC|Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
214775095|NCT05041244|DEVICE|Standard of care|"Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated."
214775096|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775097|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775098|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775099|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775100|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775101|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775102|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775103|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
214775104|NCT05294614|BEHAVIORAL|"Sonreír es diveritdo - Smiling is fun"|Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on… what?; a relapse prevention module.
214775105|NCT03239795|OTHER|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
214775106|NCT00773981|PROCEDURE|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
214775107|NCT01375569|DRUG|TRC105|
214775108|NCT01259518|DRUG|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
214775109|NCT01259518|DRUG|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
214775110|NCT00309413|DRUG|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
214775111|NCT00309413|DRUG|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
214775112|NCT03541213|PROCEDURE|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
214775113|NCT03541213|PROCEDURE|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
214775114|NCT03541213|BIOLOGICAL|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
214775115|NCT03275779|BEHAVIORAL|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
214775116|NCT03275779|BEHAVIORAL|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
214775117|NCT02891564|BEHAVIORAL|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
214775118|NCT02891564|OTHER|Control Mobile 3D video game|expectancy-matched control game
214775119|NCT04765852|OTHER|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
214775120|NCT04765852|OTHER|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
214775121|NCT04765852|OTHER|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
214775122|NCT05368233|OTHER|ERAS protocol|ERAS protocol whch helps to optimise the length of hospital stay.
214775123|NCT03827785|DEVICE|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
214775124|NCT03827785|DEVICE|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
214775125|NCT03828656|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
214775126|NCT00490737|DRUG|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
214775127|NCT02067988|DEVICE|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
214775128|NCT01074307|DRUG|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
214775129|NCT01074307|DRUG|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
214775130|NCT02023788|BIOLOGICAL|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
214775131|NCT05661656|PROCEDURE|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
214775132|NCT01293409|OTHER|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
214775133|NCT01134588|OTHER|Paper questionnaire|
214775134|NCT01134588|OTHER|Touch screen questionnaire|
214775135|NCT04422015|OTHER|No intervention|No intervention
214775136|NCT03325452|BIOLOGICAL|venous lactate|value of venous lactate
214775137|NCT02798237|OTHER|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
214775138|NCT02798237|OTHER|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
214775139|NCT00460252|PROCEDURE|insulin titration applying a computer algorithm|
214775140|NCT06218888|DRUG|Tislelizumab|Tislelizumab 200mg，D1, Q3W
214775141|NCT06218888|DRUG|Fruquintinib|Fruquintinib 3mg ,D1-D14, Q3W
214775142|NCT06218888|DRUG|Chidamide|Chidamide 30mg
214775143|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Pre-Workout Supplement|"The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
214775144|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|"The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
214775145|NCT06540378|DRUG|Stiripentol|
214775146|NCT06130709|PROCEDURE|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
214775147|NCT02625207|DRUG|Maraviroc (Part 1)|300 mg twice daily x 5 days
214775148|NCT02625207|DRUG|Maraviroc (Part 2)|150 mg once daily x 10 days
214775149|NCT02625207|DRUG|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
214775150|NCT01480271|DRUG|2 ng GSK2445053|2ng GSK2445053 administered intranasally
214775151|NCT01480271|DRUG|20ng GSK2445053|20ng GSK2445053 administered intranasally
214775152|NCT01480271|DRUG|100ng GSK2445053|100ng GSK2445053 administered intranasally
214775153|NCT01480271|DRUG|200ng GSK2445053|200ng GSK2445053 administered intranasally
214775154|NCT01480271|DRUG|400ng GSK2445053|400ng GSK2445053 administered intranasally
214775155|NCT01480271|DRUG|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
214775156|NCT01480271|DRUG|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
214775157|NCT01480271|DRUG|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
214775158|NCT01480271|DRUG|Placebo|Placebo administered intranasally
214775159|NCT00192088|DRUG|pemetrexed|
214775160|NCT00192088|DRUG|oxaliplatin|
214775161|NCT04365088|DRUG|Deflazacort 30 MG Oral Tablet|After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
214775162|NCT04365088|DRUG|Sugar pill|Sugar pill
214775163|NCT00362856|DRUG|larazotide acetate|capsule
214775164|NCT00362856|DRUG|Placebo|capsule
214775165|NCT03744988|DIAGNOSTIC_TEST|serum androgen levels|measurement of serum free and total testosterone
214775166|NCT02162511|DEVICE|CliniMACS CD34+ cell enrichment and T-cell depletion|
214775167|NCT00003061|DRUG|cytarabine|
214775168|NCT00003061|DRUG|methotrexate|
214775169|NCT00003061|RADIATION|radiation therapy|
214775170|NCT04624061|BEHAVIORAL|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
214775171|NCT01160198|DRUG|ferrous ascorbate|100 mg elemental iron
214775172|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
214775173|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
214775174|NCT00448682|DRUG|Docetaxel|
214775175|NCT00448682|DRUG|Floxuridine|
214775176|NCT00448682|DRUG|Leucovorin|
214775177|NCT00448682|DRUG|Oxaliplatin|
214775178|NCT06119373|OTHER|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
214775179|NCT06119373|OTHER|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
214775180|NCT02163031|DEVICE|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
214775181|NCT00817258|DRUG|cisplatin|Cisplatin 40mg/m2,weekly
214775182|NCT00817258|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
214775183|NCT05658107|DRUG|BI 765423|BI 765423
214775184|NCT05658107|DRUG|Placebo|Placebo
214775185|NCT05779488|DIETARY_SUPPLEMENT|maca|2.25 g of Maca extract, twice per day for 12 weeks
214775186|NCT05779488|DIETARY_SUPPLEMENT|placebo|2.25 g of starch, twice per day for 12 weeks
214775187|NCT05020197|DIAGNOSTIC_TEST|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
214775188|NCT00549107|DRUG|Levosimendan|
214775189|NCT00549107|DRUG|Milrinone|
214775190|NCT02085005|DRUG|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
214775191|NCT02085005|DRUG|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
214775192|NCT02085005|DRUG|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
214775193|NCT00893867|DRUG|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
214775194|NCT00893867|DRUG|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
214775195|NCT05478486|DRUG|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
214775196|NCT05614479|OTHER|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
214775197|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
214775198|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
214775199|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
214775200|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
214775201|NCT02476500|PROCEDURE|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
214775202|NCT05842577|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
214775203|NCT05842577|OTHER|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
214775204|NCT02866019|DEVICE|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
214775205|NCT05824299|PROCEDURE|General Anesthesia|Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.
214775206|NCT05824299|PROCEDURE|Spinal Anesthesia|Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
214775207|NCT02855632|DRUG|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
214775208|NCT02855632|DRUG|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
214775209|NCT02855632|DRUG|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
214775210|NCT02855632|OTHER|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
214775211|NCT02530632|DRUG|Propofol|General anesthesia maintained with intravenous propofol infusion
214775212|NCT02530632|DRUG|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
214775213|NCT02530632|PROCEDURE|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
214775214|NCT05064488|DRUG|Evobrutinib|Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
214775215|NCT05064488|DRUG|Digoxin|Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
214775216|NCT05064488|DRUG|Metformin|Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
214775217|NCT05064488|DRUG|Rosuvastatin|Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
214775218|NCT05064488|DRUG|Sumatriptan|Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
214775219|NCT02766088|PROCEDURE|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
214775220|NCT01331083|DRUG|PX-866|PX-866: 8mg orally taken daily
214775221|NCT01400672|BIOLOGICAL|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
214775222|NCT01400672|DRUG|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
214775223|NCT01400672|RADIATION|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
214775224|NCT06058468|PROCEDURE|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration \>30% is achieved or if radiofrequency time exceeds 120 seconds.
214775225|NCT06058468|PROCEDURE|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
214775226|NCT02917616|OTHER|Alkaline drinking-water|
214775227|NCT02917616|OTHER|Neutral drinking-water|
214775228|NCT05880563|DRUG|[18F]-RoSMA-18-d6|\[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
214775229|NCT01498419|DRUG|Moxifloxacin (M)|
214775230|NCT01498419|DRUG|Pretomid (Pa)|
214775231|NCT01498419|DRUG|Pyrazinamide (Z)|
214775232|NCT01498419|DRUG|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
214775233|NCT04078919|DIETARY_SUPPLEMENT|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
214775234|NCT04078919|OTHER|Low calorie diet|Low calorie diet
214775235|NCT03555890|DRUG|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
214775236|NCT03555890|DRUG|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
214775237|NCT05397600|DRUG|Bimatoprost Ophthalmic|Eyedrops
214775238|NCT00172094|DRUG|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
214775239|NCT00172094|DRUG|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
214775240|NCT00172094|DRUG|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
214775241|NCT06544473|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 14 days
214775242|NCT06544473|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 14 days
214775243|NCT00200473|DRUG|Nebivolol|
214775244|NCT05504369|OTHER|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
214775245|NCT05504369|OTHER|Placebo tape|Tape without nano particles applied to the skin
214775246|NCT05777369|DRUG|Rituximab|375 mg/m2, d0
214775247|NCT05777369|DRUG|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
214775248|NCT05777369|DRUG|Cyclophosphamide|750 mg/m2, d1
214775249|NCT05777369|DRUG|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
214775250|NCT05777369|DRUG|Prednisone|60 mg/m2, d1\~d5
214775251|NCT01818414|DRUG|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
214775252|NCT01818414|DRUG|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D\&E
214775253|NCT02946502|PROCEDURE|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
214775254|NCT01286207|DRUG|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
214775255|NCT01286207|DRUG|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
214775256|NCT01286207|DRUG|Standard Care|Active standard care
214775257|NCT05980351|OTHER|exercise|The children will receive exercise program(stretching exercise,range of motion exercise and isometric exercise)
214775258|NCT01383954|DRUG|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
214775259|NCT00450177|DRUG|Ferrous Sulfate|Iron group
214775260|NCT00450177|DRUG|Placebo Oral Tablet|Placebo group
214775261|NCT05974865|BEHAVIORAL|Healthy Babies and Healthy Moms|
214775262|NCT05974865|BEHAVIORAL|Baby Basics Prenatal Guide|
214775263|NCT02613416|DRUG|Denosumab|monthly subcutaneous injections
214775264|NCT05620459|PROCEDURE|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
214775265|NCT02706600|BEHAVIORAL|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
214775266|NCT02706600|BEHAVIORAL|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
214775267|NCT01173588|OTHER|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
214775268|NCT00303433|DRUG|Namenda|
214775269|NCT00763269|DRUG|Triclosan, Silicon dioxide, fluoride|Brush twice daily
214775270|NCT00763269|DRUG|Triclosan, fluoride|Brush twice daily
214775271|NCT01971229|OTHER|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
214775272|NCT01971229|OTHER|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
214775273|NCT04638725|OTHER|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
214775274|NCT05049304|OTHER|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
214775275|NCT05049304|OTHER|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
214775276|NCT00425516|DRUG|Taxotere|
214775277|NCT00425516|DRUG|5-Fluorouracil|
214775278|NCT00425516|DRUG|Epirubicin|
214775279|NCT00425516|DRUG|Cyclophosphamide|
214775280|NCT06538233|DRUG|Buffered articaine|Injecting buffered articaine in maxillary anterior region and evaluate pain response.
214775281|NCT06538233|DRUG|Non buffered articaine|Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
214775282|NCT03355807|DRUG|Magnesium|The magnesium group (group Mg, n \_ 40) received an additional infusion of MgSO4
214775283|NCT01089985|DRUG|Autologous serum eyedrops|3 times a day for the duration of the study
214775284|NCT05668715|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
214775285|NCT05699811|BIOLOGICAL|MSC-IFNα|MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks
214775286|NCT05699811|DRUG|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
214775287|NCT05699811|DRUG|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
214775288|NCT05699811|DRUG|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
214775289|NCT04325061|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
214775290|NCT01398982|DRUG|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
214775291|NCT01398982|DRUG|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
214775292|NCT03174925|DEVICE|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
214775293|NCT02235337|DRUG|Riboflavin 400mg daily|
214775294|NCT04368182|BIOLOGICAL|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
214775295|NCT00451594|DRUG|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~1. Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~2. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~3. If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~4. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~5. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
214775296|NCT00451594|DRUG|Prednisolone|"Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
214775297|NCT04247594|DRUG|Voxelotor|synthetic small molecule supplied as 500 mg tablets
214775298|NCT02846740|DEVICE|Alpha-Stim®.|cranial electrical stimulation
214775299|NCT02846740|BEHAVIORAL|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
214775300|NCT01518621|RADIATION|Radiation|Whole brain radiation
214775301|NCT01518621|DRUG|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
214775302|NCT02913469|DRUG|Morphine|The patients in group A would be administrated intravenous morphine 5mg
214775303|NCT02913469|DRUG|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
214775304|NCT02913469|DRUG|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
214775305|NCT06460246|DEVICE|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
214775306|NCT00814619|BIOLOGICAL|panitumumab|Given IV
214775307|NCT00814619|DRUG|capecitabine|Given orally
214775308|NCT00814619|PROCEDURE|therapeutic conventional surgery|Patients undergo surgical resection
214775309|NCT00814619|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
214775310|NCT06334250|DEVICE|Catheter ablation of atrial fibrillation using Pulsed Field Ablation|Pulsed Field Ablation of atrial fibrillation at the time of left atrial appendage occlusion
214775311|NCT06334250|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion using the Watchman device
214775312|NCT04878250|DRUG|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
214775313|NCT05137418|BIOLOGICAL|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
214775314|NCT02344459|DEVICE|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
214775315|NCT04227652|DRUG|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
214775316|NCT02349009|DRUG|C-82 Topical Gel, 1%|active
214775317|NCT02349009|DRUG|C-82 Topical Gel, Placebo|placebo
214775318|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
214775319|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
214775320|NCT04064437|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
214775321|NCT04064437|DIAGNOSTIC_TEST|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
214775322|NCT04064437|DIAGNOSTIC_TEST|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
214775323|NCT01330615|DRUG|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
214775324|NCT01330615|DRUG|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
214775325|NCT00047437|BEHAVIORAL|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
214775326|NCT02609178|PROCEDURE|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
214775327|NCT02609178|PROCEDURE|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
214775328|NCT01128153|DRUG|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
214775329|NCT01128153|DRUG|Placebo|tablet once daily for 24 weeks to be taken orally
214775330|NCT04784845|BIOLOGICAL|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
214775331|NCT01251692|PROCEDURE|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
214775332|NCT03746886|OTHER|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
214775333|NCT02933827|DRUG|ELIXCYTE|Adipose-derived stem cells (ADSCs)
214775334|NCT02719782|BIOLOGICAL|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
214775335|NCT03451331|DRUG|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
214775336|NCT03451331|DRUG|Gemcitabine|1000 mg/m\^2
214775337|NCT03451331|DRUG|Carboplatin|AUC 4.5 (based on the Calvert formula)
214775338|NCT03451331|DRUG|Oxaliplatin|130 mg/m\^2
214775339|NCT06204276|DEVICE|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
214775340|NCT06204276|DEVICE|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
214775341|NCT05114265|DRUG|KUR-101|Single oral dose of KUR-101
214775342|NCT05114265|DRUG|OxyNorm|Single oral dose of OxyNorm
214775343|NCT05114265|DRUG|Placebo|Single oral dose of placebo
214775344|NCT00127257|BEHAVIORAL|Biofeedback|
214775345|NCT00127257|DRUG|Diazepam|
214775346|NCT00127257|BEHAVIORAL|Pelvic floor retraining|
214775347|NCT02046785|OTHER|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
214775348|NCT06580782|DRUG|Calcium Carbonate 500 MG|Calcium Carbonate 500mg, orally, every 4 hours.
214775349|NCT06580782|DRUG|Standard Dose Synthetic Pitocin|The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
214775350|NCT02915588|OTHER|early isometric loading after rotator cuff surgery|
214775351|NCT02915588|OTHER|passive motion after rotator cuff surgery|
214775352|NCT03545360|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-703 device
214775353|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
214775354|NCT00755573|DRUG|placebo|Regime as described for pregabalin
214775355|NCT02572180|BEHAVIORAL|EMG-based biofeedback training|
214775356|NCT02572180|BEHAVIORAL|NIRS-based neurofeedback training|
214775357|NCT03676959|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
214775358|NCT03676959|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
214775359|NCT03676959|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
214775360|NCT01447316|OTHER|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
214775361|NCT00572156|DRUG|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
214775362|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
214775363|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
214775364|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
214775365|NCT03008031|PROCEDURE|CESM with a reduced dose of contrast agent|
214775366|NCT02261974|DEVICE|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
214775367|NCT02261974|DEVICE|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
214775368|NCT03523013|DEVICE|CPAP|CPAP treatment with different pressure for OSA patients
214775369|NCT06260384|OTHER|electrocardiogram|it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
214775370|NCT03368547|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214775371|NCT03368547|RADIATION|Gallium Ga 68 Gozetotide|Given IV
214775372|NCT03368547|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214775373|NCT00195585|DRUG|Isovorin|
214775374|NCT00195585|DRUG|UFT|
214775375|NCT06531265|PROCEDURE|Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy|Bronchoscopic evaluation of endobronchial lesion with biopsy and cryotherapy for recanalisation
214775376|NCT05765929|OTHER|Non-operative treatment|Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
214775377|NCT01347879|DRUG|Visonac PDT|cream application prior to illumination with red light
214775378|NCT01347879|DRUG|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
214775379|NCT04097119|DIETARY_SUPPLEMENT|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
214775380|NCT04768764|PROCEDURE|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
214775381|NCT04768764|PROCEDURE|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
214775382|NCT04768764|DRUG|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
214775383|NCT04768764|PROCEDURE|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
214775384|NCT01201954|DRUG|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
214775385|NCT00447707|BEHAVIORAL|Positive Choice|
214775386|NCT02071381|DRUG|DW330SR 45mg|
214775387|NCT02071381|DRUG|DW1030 75mg|
214775388|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
214775389|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
214775390|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
214775391|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
214775392|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
214775393|NCT03187288|DRUG|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
214775394|NCT01125007|DEVICE|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
214775395|NCT03296215|OTHER|Observational|To determine different patterns of admission and their Outcome
214775396|NCT01238822|DRUG|Methylphenidate|18 mg methylphenidate
214775397|NCT01238822|DRUG|placebo|Placebo
214775398|NCT01238822|DRUG|Methylphenidate|36 mg methylphenidate
214775399|NCT01238822|DRUG|Methylphenidate|54 mg methylphenidate
214775400|NCT02529800|DRUG|HIP1402|Tamsulosin HCl 0.4mg
214775401|NCT02529800|DRUG|HGP0412|Tamsulosin HCl 0.2mg
214775402|NCT02591784|DRUG|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
214775403|NCT02591784|RADIATION|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
214775404|NCT02248337|DRUG|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
214775405|NCT06543511|OTHER|Genetic Blood Test|Germline genetic testing using skin fibroblasts
214775406|NCT04537585|COMBINATION_PRODUCT|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
214775407|NCT04537585|DRUG|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
214775408|NCT04078087|DRUG|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
214775409|NCT04078087|DRUG|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
214775410|NCT00864487|DRUG|Neratinib|HKI-272
214775411|NCT01150513|DRUG|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
214775412|NCT01150513|DRUG|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
214775413|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
214775414|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
214775415|NCT06236126|PROCEDURE|1% Lidocaine Injection|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal) or subcutaneously (Group Subcutaneous).
214775416|NCT03598673|DRUG|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
214775417|NCT01261429|DRUG|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
214775418|NCT00075465|DRUG|docetaxel|
214775419|NCT00075465|DRUG|epirubicin hydrochloride|
214775420|NCT00289939|BEHAVIORAL|Motivational interviewing to reduce risk for HIV and DV|
214775421|NCT03932838|OTHER|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
214775422|NCT03375996|DRUG|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
214775423|NCT00004009|DRUG|tipifarnib|
214775424|NCT01364246|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
214775425|NCT00876109|DRUG|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
214775426|NCT05134727|DRUG|AZD5055|Healthy participants will receive AZD5055
214775427|NCT05134727|DRUG|Placebo|Healthy participants will receive placebo
214775428|NCT04989231|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
214775429|NCT04989231|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
214775430|NCT01839227|OTHER|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
214775431|NCT04483427|COMBINATION_PRODUCT|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
214775432|NCT02552394|DRUG|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
214775433|NCT01772394|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
214775434|NCT01772394|BEHAVIORAL|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
214775435|NCT02554344|DRUG|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
214775436|NCT05435872|DEVICE|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
214775437|NCT02783508|DRUG|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
214775438|NCT02783508|DRUG|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
214775439|NCT05606913|DRUG|dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
214775440|NCT05606913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
214775441|NCT04820335|BEHAVIORAL|Structured External Memory Aid Treatment (SEMAT)|"During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase."
214775442|NCT01818219|PROCEDURE|Records of EADI derived parameters|
214775443|NCT05873075|OTHER|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
214775444|NCT02145000|BIOLOGICAL|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
214775445|NCT02145000|BIOLOGICAL|Placebo|
214775446|NCT02539979|DRUG|Paracetamol|
214775447|NCT02539979|DRUG|Placebo - Normal Saline|Normal Saline 100cc
214775448|NCT04734431|BIOLOGICAL|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
214775449|NCT01262729|PROCEDURE|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
214775450|NCT01262729|DRUG|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
214775451|NCT06542731|DRUG|ONO-4578|Specified dose on specified days
214775452|NCT06542731|DRUG|ONO-4538|Specified dose on specified days
214775453|NCT06542731|DRUG|Docetaxel|Specified dose on specified days
214775454|NCT06542731|DRUG|Ramucirumab|Specified dose on specified days
214775455|NCT05020730|DRUG|PTM-001|PTM-001 (400 mg) every day for 12 weeks
214775456|NCT05020730|DRUG|Placebo|Matching placebo every day for 12 weeks
214775457|NCT00996918|DRUG|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
214775458|NCT00996918|DRUG|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
214775459|NCT01754480|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
214775460|NCT01754480|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
214775461|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
214775462|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
214775463|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
214775464|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
214775465|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
214775466|NCT00391040|BEHAVIORAL|SGS education|
214775467|NCT04250896|OTHER|Control group|Standard child care in health unit plus exposure to EsIAN
214775468|NCT04250896|BEHAVIORAL|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
214775469|NCT02341209|DRUG|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
214775470|NCT03384407|DEVICE|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
214775471|NCT04177745|OTHER|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
214775472|NCT04177745|OTHER|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
214775473|NCT00187057|DRUG|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
214775474|NCT00187057|DRUG|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
214775475|NCT00187057|DRUG|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
214775476|NCT00187057|DRUG|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
214775477|NCT00187057|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
214775478|NCT01249690|DRUG|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
214775479|NCT01249690|DRUG|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
214775480|NCT02703779|DRUG|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
214775481|NCT02703779|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
214775482|NCT02703779|DRUG|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
214775483|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
214775484|NCT04432818|BEHAVIORAL|Pack Health's digital life coaching (DLC)|Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
214775485|NCT03169660|DRUG|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
214775486|NCT05933226|BEHAVIORAL|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
214775487|NCT04440007|DRUG|Abivertinib|Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
214775488|NCT04440007|OTHER|Standard of Care|Standard of Care as determined by the Investigator
214775489|NCT00282425|BIOLOGICAL|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
214775490|NCT01248611|DRUG|fentanyl|nasally, dose titrated to effect
214775491|NCT00854607|OTHER|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
214775492|NCT05078801|PROCEDURE|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
214775493|NCT05078801|PROCEDURE|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
214775494|NCT03607656|DRUG|Oxaliplatin|Oxaliplatin powder injection
214775495|NCT03607656|DRUG|Capecitabine|Capecitabine tablet
214775496|NCT03607656|OTHER|TCM|TCM decoction orally taken twice a day for at least 3 months
214775497|NCT03607656|DRUG|S-1|S-1 capsule
214775498|NCT03607656|DRUG|Docetaxel|Docetaxel injection
214775499|NCT03607656|DRUG|5-FU|5-FU injection
214775500|NCT02394353|DEVICE|Transient hepatic elastography|
214775501|NCT05449158|PROCEDURE|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
214775502|NCT04390035|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
214775503|NCT02735226|OTHER|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
214775504|NCT03054935|OTHER|Indirect Calorimetry|Measurement of resting energy expenditure
214775505|NCT04976088|DRUG|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
214775506|NCT04976088|DRUG|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
214775507|NCT04976088|DRUG|Placebo|Placebo: Placebo plaster, topical application once a day.
214775508|NCT06568120|DEVICE|dragon themed nebulizer masks|This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
214775509|NCT02059369|PROCEDURE|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
214775510|NCT02059369|PROCEDURE|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
214775511|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
214775512|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
214775513|NCT03959137|OTHER|None - Common practice|None - Common practice
214775514|NCT06325176|OTHER|Cryotherapy|During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
214775515|NCT06325176|DEVICE|Infrared light therapy|Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
214775516|NCT01651494|DRUG|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
214775517|NCT01651494|OTHER|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
214775518|NCT06271135|BEHAVIORAL|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
214775519|NCT01268319|DEVICE|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
214775520|NCT01268319|DEVICE|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
214775521|NCT01268319|DEVICE|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
214775522|NCT06390358|OTHER|Tefillin|Wrapping of arm
214775523|NCT01314222|DRUG|BMS-954561|
214775524|NCT01314222|DRUG|Pregabalin|
214775525|NCT01314222|DRUG|Placebo matching BMS-954561|
214775526|NCT01314222|DRUG|Placebo matching Pregabalin|
214775527|NCT05928273|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
214775528|NCT02253758|DRUG|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
214775529|NCT00190684|DRUG|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
214775530|NCT06540599|DRUG|Analgesic|comparing the effectiveness of analgesics in endometrial biopsy
214775531|NCT04778007|OTHER|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
214775532|NCT02832739|DEVICE|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
214775533|NCT06536816|OTHER|Game Profile-based training Group|Game profile-based training is a methodology in sports, including football, where training sessions are designed to simulate the specific conditions and challenges that players face during actual games. Coaches analyze individual and team performance data to identify patterns, positions, and scenarios commonly encountered in matches. The training is then structured to replicate these situations, helping players develop the skills, tactics, and decision-making abilities required in real-game scenarios. This approach aims to make training more targeted and relevant to the dynamics of competitive play.
214775534|NCT06536816|OTHER|Small-sided games Group|"small-sided game in football, often referred to as a SSG, is a practice or training activity where players compete in a reduced playing area with fewer players than a full team."
214775535|NCT06536816|OTHER|Combined training Group with both Game Profile-based training and Small-sided Games|Combined training Group with both Game Profile-based training and Small-sided Games
214775536|NCT03334526|OTHER|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
214775537|NCT03334526|OTHER|mental training|The task to imagine for the training group will be an abduction of the thumb
214775538|NCT03334526|OTHER|electrical stimulation|electrical stimulation of the muscles
214775539|NCT03304210|DRUG|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
214775540|NCT02872155|OTHER|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
214775541|NCT02872155|DRUG|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
214775542|NCT02872155|DRUG|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
214775543|NCT04717999|BIOLOGICAL|NKG2D CAR-T|The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.
214775544|NCT03732729|DEVICE|massage chair|Patient should use massage chair, twice per day, for 30minutes
214775545|NCT00136734|DRUG|Methylphenidate|
214775546|NCT00136734|OTHER|placebo|placebo
214775547|NCT03661294|DIAGNOSTIC_TEST|GE Healthcare Metabolic Oxygenator|
214775548|NCT00429468|DRUG|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
214775549|NCT00085722|PROCEDURE|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
214775550|NCT00085722|PROCEDURE|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
214775551|NCT00085722|OTHER|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
214775552|NCT05762510|GENETIC|GMCN-508B (LentiRed)|LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
214775553|NCT06500039|OTHER|Positive Psychological Intervention Program|An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
214775554|NCT06500039|OTHER|Writing Daily Routines|An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
214775555|NCT00829439|DRUG|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
214775556|NCT04992481|PROCEDURE|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
214775557|NCT04992481|PROCEDURE|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
214775558|NCT04992481|PROCEDURE|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
214775559|NCT04992481|PROCEDURE|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
214775560|NCT06340971|OTHER|Policy|"We will work with stakeholders' policy groups e.g. RCOG, RCM, RCP and policy makers e.g. Department for Health and Social Care, Transport Emissions at the Greater London Authority or Mayor of London's office to disseminate our findings and develop public health messages.~We aim to develop guidance on how pregnant women and their families can reduce their exposure to air pollution by highlighting for example travel routes with less pollution and wear face masks."
214775561|NCT04514328|DEVICE|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
214775562|NCT00418080|DRUG|bicalutamide|
214775563|NCT01002131|DEVICE|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
214775564|NCT05181761|OTHER|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
214775565|NCT02221583|DRUG|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
214775566|NCT02221583|DRUG|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
214775567|NCT02221583|DRUG|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
214775568|NCT06514209|DRUG|cisatracurium|The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
214775569|NCT04250519|DRUG|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
214775570|NCT00104117|DRUG|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
214775571|NCT06541418|BEHAVIORAL|Transtheoretic Model Based Behavior Change Program|The Behavior Change Program was implemented in 7 sessions of 50 minutes, once a week. Each session in the Behavior Change Program; The warm-up exercise consisted of giving general information about the purpose and the main theme of the session, discussion and feedback on the subject, and the planning of the next week, and a closing process. The Transtheoretic Model Based Behavior Change Program was prepared by the researcher with reference to the behavior change programs in the literature and the elements of the Transtheoretic model.
214775572|NCT01545752|OTHER|teaching by non-interactive CD|teaching book with non-interactive CD
214775573|NCT01545752|OTHER|Interactive CD|Teaching book with interactive CD
214775574|NCT00732342|BEHAVIORAL|Contingency Management|Prizes given for targeted behavior of abstinence
214775575|NCT03027973|DRUG|UPA|Experimental drug
214775576|NCT03027973|DRUG|TEA|Active comparator
214775577|NCT03027973|DRUG|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
214775578|NCT03027973|DRUG|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
214775579|NCT05771116|PROCEDURE|ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:|catheter will be placed for ERECTOR SPINAE PLANE BLOCK
214775580|NCT05771116|PROCEDURE|PARAVERTEBRAL BLOCK:|catheter will be placed for PARAVERTEBRAL BLOCK
214775581|NCT01797952|DRUG|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
214775582|NCT01797952|OTHER|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
214775583|NCT00123487|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
214775584|NCT00123487|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
214775585|NCT02345863|DRUG|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
214775586|NCT02345863|DRUG|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
214775587|NCT02345863|DRUG|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
214775588|NCT01987024|DEVICE|Actim Partus® test|
214775589|NCT01987024|OTHER|usual procedure|
214775590|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
214775591|NCT02265640|DRUG|BIIL 284 BS boli|
214775592|NCT02265640|DRUG|BIIL 284 BS tablet C|
214775593|NCT02265640|OTHER|standard breakfast|
214775594|NCT02470442|DRUG|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
214775595|NCT02470442|DRUG|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
214775596|NCT05365022|DEVICE|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
214775597|NCT01350531|BEHAVIORAL|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
214775598|NCT01350531|BEHAVIORAL|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
214775599|NCT01785043|DRUG|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
214775600|NCT01785043|DRUG|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
214775601|NCT02314949|PROCEDURE|intestinal transplantation|
214775602|NCT06566625|DIAGNOSTIC_TEST|Cardiac MRI (CMR) examination|"An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)"
214775603|NCT06541743|DEVICE|Regular Toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
214775604|NCT06541743|DEVICE|Musical toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
214775605|NCT06541743|DEVICE|Electric toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
214775606|NCT03248778|BEHAVIORAL|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
214775607|NCT06611033|BIOLOGICAL|V118C|Intramuscular Administration
214775608|NCT06611033|BIOLOGICAL|V118|Intramuscular Administration
214775609|NCT06611033|BIOLOGICAL|PREVNAR 20™|Intramuscular Administration
214775610|NCT06611033|BIOLOGICAL|Saline|Intramuscular Administration
214775611|NCT00995488|DRUG|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
214775612|NCT02238470|DRUG|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
214775613|NCT03345953|DRUG|BP 1.4979|Double blind versus placebo
214775614|NCT03345953|DRUG|Placebo|Double blind versus placebo
214775615|NCT05354336|DRUG|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
214775616|NCT05354336|DRUG|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
214775617|NCT05354336|DRUG|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
214775618|NCT04501341|BIOLOGICAL|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
214775619|NCT04501341|BIOLOGICAL|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
214775620|NCT02493985|OTHER|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
214775621|NCT02493985|OTHER|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
214775622|NCT04326569|OTHER|Blood sample|Blood sample to quantify copeptin
214775623|NCT02865642|DRUG|Serotonin Uptake Inhibitors|
214775624|NCT02865642|DRUG|Placebo|
214775625|NCT00701168|DEVICE|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
214775626|NCT01819389|DRUG|Imatinib and Nilotinib|
214775627|NCT06390111|DRUG|nadofaragene firadenovec|The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
214775628|NCT04339361|DRUG|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
214775629|NCT04339361|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
214775630|NCT04339361|DRUG|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
214775631|NCT02740660|DRUG|Caffeine 100mg / Albuterol 4mg|
214775632|NCT02740660|DRUG|Placebo|
214775633|NCT02740660|BEHAVIORAL|Family weight management counseling|
214775634|NCT06267677|DIETARY_SUPPLEMENT|High protein liquid formula|liquid and high amount of protein
214775635|NCT02876705|OTHER|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
214775636|NCT03529318|PROCEDURE|Biopsies from endoscopy|"1\) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
214775637|NCT03408236|DRUG|Botulinum toxin type A|Experimental
214775638|NCT03408236|DRUG|Botulinum toxin type A|Active Comparator
214775639|NCT03443219|DEVICE|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
214775640|NCT03443219|DEVICE|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
214775641|NCT04183218|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
214775642|NCT04183218|DEVICE|Cardiac Event Monitor|Receive cardiac monitor
214775643|NCT04183218|OTHER|Chemoradiotherapy|Undergo CRT
214775644|NCT04183218|RADIATION|Radiation Therapy|Undergo RT
214775645|NCT03672396|BEHAVIORAL|Home-based exercise|The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
214775646|NCT06701097|BEHAVIORAL|Emotion regulation training|Man is a social being and therefore interacts with his environment. In the process of interaction, they can transfer their feelings, thoughts, and information. However, the interaction process may not always continue smoothly. People's inability to express their emotions appropriately today negatively affects communication. The reason why people cannot express their emotions may be the high level of alexithymia. The concept of alexithymia means having difficulty in recognizing, expressing, and naming emotions. High levels of alexithymia in students, who are future healthcare professionals, can negatively affect themselves, other healthcare professionals and the patients they care for; it can cause burnout in healthcare professionals, decrease the quality of care they provide and cause them to experience interpersonal communication conflicts.
214775647|NCT06703866|OTHER|Non Small Cell Lung Cancer (NSCLC)|"Application of value based medicine predictive model"
214775648|NCT06703788|DRUG|A fiixed combination of Chinese herbal medicine|a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
214775649|NCT06703788|DEVICE|Laser acupuncture|Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
214775650|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
214775651|NCT01814917|DRUG|CBPB|
214775652|NCT06702709|OTHER|Instrument Assisted Soft Tissue Mobilization|The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds
214775653|NCT06702709|OTHER|Neurodevelopmental Therapy|The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
214775654|NCT06702605|DRUG|XNW5004 tablets|XNW5004 will be administered orally as tablets.
214775655|NCT06702917|DEVICE|GSI Cardiac Scan|"The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan."
214775656|NCT06702917|OTHER|Standard of Care CCTA|The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
214775657|NCT06702917|OTHER|Research CCTA|The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
214775659|NCT06702670|DRUG|Treatment with Diphenhydramine|Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
214775660|NCT06702670|COMBINATION_PRODUCT|Usual Care|Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.
214775661|NCT06703775|OTHER|Low level laser therapy (LLLT)|The first experimental will receive LLLT using the Fisioline Lumix 2 (Italy). Participants will be placed in a comfortable, supported sitting position and will wear protective eyeglasses to prevent retinal damage. The LLLT (GaAs type, 1-10 mW, 904 nm) will be applied to the most painful points on the deltoid and/or upper trapezius muscles. Treatment will target a minimum of two and a maximum of four painful points, with each point irradiated for 3-4 minutes, for a total session duration of up to 15 minutes.
214775662|NCT06703775|OTHER|Neural mobilization techniques|The second experimental will receive Neural Mobilization Therapy (NMT). The procedure will begin by positioning the patient in a sitting position. The initial positioning will involve placing the patient's arm at their side with the elbow bent at 90 degrees. The therapist will gently extend the patient's shoulder (moving the arm backward) while keeping the elbow bent, creating tension on the axillary nerve. This tension will be held for a few seconds, ensuring it remains within the patient's tolerance and does not cause discomfort or pain. The shoulder will then be slowly returned to the initial position, releasing the tension on the nerve. This sequence of tension and release will be repeated, gradually increasing the range of motion as tolerated. The treatment will consist of three sets of 10 repetitions, with a one-minute rest between sets, performed three times per week for a total of 12 sessions over four weeks.
214775663|NCT06703775|OTHER|Conventional physical therapy program|The following exercises will be performed by the patients of three groups. Pendulum exercise, Isometric Scapular Retraction, Rotator cuff exercise, Wall creeping exercise, Active assisted ROM exercises, Codman exercises. Each exercise will be performed for all movements namely flexion extension and abduction-adduction, one sets of each 10-15 repetitions within pain-free range and instructed to carry out their activities of daily living.
214775664|NCT06410859|DRUG|"Botulinum Toxin Type A for Injection,also known as HengLi®"|This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
214775665|NCT04942964|DRUG|Bocidelpar|Oral
214775666|NCT06703528|DEVICE|cryoablation|The therapeutic cryoablation agent used in this trial was liquid nitrogen with an evaporation temperature of -196°C, which was transported to the ablation pen through a vacuum line to exchange energy at the heart site to perform cryoablation.
214775667|NCT06702813|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
214775668|NCT06519266|DEVICE|PHP|Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
214775669|NCT06519266|DRUG|IPI1/NIVO3|Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
214775670|NCT06519266|DRUG|IPI3/NIVO1|Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
214775671|NCT00500656|DRUG|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
214775672|NCT00500656|DRUG|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
214775673|NCT00500656|DRUG|Oral Placebo|hard capsule matched to tranexamic acid
214775674|NCT00500656|DRUG|S.C. Placebo|solution for injection, matched to icatibant for injection
214775675|NCT02548117|DRUG|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
214775676|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
214775677|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
214775678|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
214775679|NCT04479943|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
214775680|NCT04479943|OTHER|Surveys and Focus groups|Nurses will answer surveys about nurse behavior, changes in self-efficacy, frequency and distance of patient ambulation, documentation of ambulation, qualitative data collected to determine barriers to implementation
214775681|NCT01098058|OTHER|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
214775682|NCT01098058|OTHER|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
214775683|NCT05720793|COMBINATION_PRODUCT|FMT Capsule + SIMBA Capsule|Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
214775684|NCT06463756|OTHER|AI|"Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis."
214775685|NCT03548454|DRUG|Duloxetine|Open label prescription
214775686|NCT03548454|DRUG|Desipramine|Open label prescription
214775687|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
214775688|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
214775689|NCT06495268|OTHER|Individualised data-driven hearing rehabilitation|"HA fittings will be conducted with the Real-Ear Measurements (REM) method that is recommended by the latest ISO-standard (21388:2020) and by the preliminary results of the BREM study at KUH. After the fitting of the HAs, participants' auditory-related outcomes will be immediately assessed using DigiKuulo and re-fitting is performed if needed based on the following criteria:~1. The absolute improvement in the DIN test is less than 1,5dB (SNR), OR~2. The absolute result of the DIN test is more than -8,5 dB (SNR) OR~3. The participant is unsatisfied with the HA fitting~Participants are invited to intervention-related monitoring appointments at 3, 6 and 12 months after the primary HA fitting. At these visits, auditory outcomes of the rehabilitation are assessed via DigiKuulo and re-fittings are performed as needed."
214775690|NCT06495268|OTHER|Standard care hearing rehabilitation|HA will be fitted with automatic algorithms by HA manufacturers and REM-fitting is only applied in complex cases based on the hearing rehabilitator's clinical judgement. Three months after the HA fitting, participants will be contacted via phone call to inquire about the status of the rehabilitation. Additional monitoring visits may be offered based on the participant's feedback. After the 3-month monitoring phone call participants will be advised to further contact the study team if they are dissatisfied with the amplification or for any other problem with their device.
214775691|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
214775692|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
214775693|NCT01400373|DEVICE|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
214775694|NCT05640583|DEVICE|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
214775695|NCT01604954|BEHAVIORAL|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
214775696|NCT01604954|BEHAVIORAL|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
214775697|NCT01604954|BEHAVIORAL|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
214775698|NCT06304545|DRUG|Camrelizumab|Camrelizumab IV 200mg
214775699|NCT06304545|DRUG|Chemotherapy|Capecitabine PO oxaliplatin IV
214775700|NCT06304545|RADIATION|Radiotherapy|Radiotherapy 50Gy /45Gy /25 fractions
214775701|NCT02836197|BEHAVIORAL|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
214775702|NCT04543305|DRUG|PRT1419|PRT1419 will be administered orally
214775703|NCT00436527|DRUG|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
214775704|NCT00036582|DRUG|Clozapine|
214775705|NCT06047782|OTHER|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
214775706|NCT06306794|OTHER|crochet octopus|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
214775707|NCT02328001|BEHAVIORAL|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
214775708|NCT01408576|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
214775709|NCT01408576|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
214775710|NCT05474560|DRUG|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
214775711|NCT05474560|DRUG|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
214775712|NCT05474560|BEHAVIORAL|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
214775713|NCT05040035|DIAGNOSTIC_TEST|ACT measurement|Measurement of active clotting time (ACT)
214775714|NCT02026102|BEHAVIORAL|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
214775715|NCT04688814|PROCEDURE|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
214775716|NCT04688814|DRUG|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
214775717|NCT06045832|DEVICE|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
214775718|NCT06045832|DEVICE|Water|Water
214775719|NCT03719261|DRUG|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
214775720|NCT03719261|DRUG|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
214775721|NCT00423228|DRUG|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
214775722|NCT00423228|DRUG|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
214775723|NCT02878811|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
214775724|NCT05384197|DRUG|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
214775725|NCT05384197|DRUG|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
214775726|NCT03076528|OTHER|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
214775727|NCT03076528|OTHER|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
214775728|NCT06398561|BEHAVIORAL|Active Patient Program|"The Active Patient Program is a peer-leader intervention that consist of training patients with a chronic disease or mental health illness for improve the symptoms of that pathology.~Training is carried out in groups of about 12-15 patients and usually has 2 patient trainers. These patients lead the sessions through the theoretical content they have integrated, motivation, group leadership, exchange of experiences and promotion of communication. In this way they favor problem-solving by the patients who attend the sessions, thus improving their self-management and self-efficacy.~In the group formed by patients who are trainers and patients who benefit from the sessions, a climate of trust is created that favors the expression of emotions on both sides, empathy and assertiveness. In addition to fostering socio-affective bonds between the participants and increasing perceived social and emotional support."
214775729|NCT02105597|OTHER|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
214775730|NCT05348707|OTHER|epidemiology|To review medical records to describe diagnosis and severity of the disease.
214775731|NCT05348707|OTHER|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
214775732|NCT00554177|DRUG|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
214775733|NCT00554177|DRUG|Placebo|2 doses of 1200mg, administered 2-3 days apart
214775734|NCT05706454|DRUG|Ramatroban|"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."
214775735|NCT05706454|DRUG|Placebo|Matching placebo will be administered orally twice a day
214775736|NCT02770053|PROCEDURE|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
214775737|NCT04281654|OTHER|Active Social Conversation|Active Social Conversation
214775738|NCT04184154|OTHER|Questionnaires|The self-questionnaire of 104 questions collected personal and socio-demographics data, global and sexual quality of life characteristics (European Organisation for Research and Treatment of Cancer \[EORTC\] quality of life questionnaires: QLQ-C30 and gynecologic and cervical cancer specific-questionnaire QLQ-CX24), vaginal dilatators and moisturizers use, and barriers and facilitators of their use. Clinical data were extracted from the patients' medical files. Vaginal stenosis was evaluated at 6 weeks after the end of brachytherapy and after 1-year follow-up by in-town gynecologists or in our Institute, and censored in case of complete vaginal obliteration
214775739|NCT06141954|DEVICE|Ultrasound waves therapy|Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
214775740|NCT06141954|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
214775741|NCT05558605|DIAGNOSTIC_TEST|AI-guided echo|AI-guided echocardiography
214775742|NCT05558605|DIAGNOSTIC_TEST|Standard echo|Standard echocardiography
214775743|NCT04064528|DIETARY_SUPPLEMENT|Amino Acids|10 g bolus of essential amino acids
214775744|NCT06538805|OTHER|Minimal invasive management of dental caries|Minimal invasive management of dental caries among dentists
214775745|NCT00788723|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
214775746|NCT01042002|BEHAVIORAL|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
214775747|NCT01254994|DRUG|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
214775748|NCT01254994|DRUG|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
214775749|NCT01289431|DRUG|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
214775750|NCT01289431|DRUG|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
214775751|NCT04175873|OTHER|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
214775752|NCT03367286|OTHER|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
214775753|NCT02069834|DRUG|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
214775754|NCT02069834|DRUG|Arm 2 (control)|Continuation of existing HAART at the time of randomization
214775755|NCT03125824|DEVICE|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
214775756|NCT03682627|PROCEDURE|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
214775757|NCT03682627|PROCEDURE|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
214775758|NCT05244174|DEVICE|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
214775759|NCT03665480|DRUG|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
214775760|NCT06568640|PROCEDURE|Superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
214775761|NCT06332365|COMBINATION_PRODUCT|Acetonide triamcinolone 0.2% +hyaluronicacid 1%|topical application cream form twice a day for 4 weeks
214775762|NCT06332365|DRUG|Corticoid Acetonide triamcinolone 0.2%|topical application cream form twice a day for 4 weeks
214775763|NCT06332365|DRUG|Hyaluronic acid 1%|topical application cream form twice a day for 4 weeks
214775764|NCT05232565|PROCEDURE|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
214775765|NCT03434626|BEHAVIORAL|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
214775766|NCT03434626|OTHER|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
214775767|NCT02559531|DEVICE|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
214775768|NCT03801395|OTHER|There is no intervention|No intervention
214775769|NCT06191510|PROCEDURE|Bio-Oss Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
214775770|NCT06191510|PROCEDURE|Mucograft Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
214775771|NCT00802269|PROCEDURE|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
214775772|NCT01327638|DRUG|etoricoxib|Patients with SpA/AS who took etoricoxib
214775773|NCT01327638|DRUG|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
214775774|NCT01327638|DRUG|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
214775775|NCT05828433|OTHER|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
214775776|NCT05828433|OTHER|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
214775777|NCT02557568|OTHER|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
214775778|NCT03904667|OTHER|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
214775779|NCT00563524|DRUG|ILV-094|SC and IV administration on days 1, 14, 28, and 42
214775780|NCT01230502|DRUG|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
214775781|NCT01230502|OTHER|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
214775782|NCT01230502|OTHER|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
214775783|NCT04767542|DRUG|Intravenous Infusion|analgesic
214775784|NCT04767542|PROCEDURE|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
214775785|NCT00102388|DRUG|vildagliptin|
214775786|NCT00102388|DRUG|Gliclazide|
214775787|NCT00817778|DRUG|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
214775788|NCT00817778|DRUG|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
214775789|NCT05424107|OTHER|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
214775790|NCT04780659|BIOLOGICAL|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
214775791|NCT06542328|DEVICE|ERI CVX-air portable X-ray system|investigational device
214775792|NCT06542328|DEVICE|Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)|The commercially available comparator equipment used for pulmonology.
214775793|NCT06542328|DEVICE|Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)|The commercially available comparator equipment used for Orthopaedic.
214775794|NCT00253461|PROCEDURE|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
214775795|NCT00253461|PROCEDURE|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
214775796|NCT00253461|RADIATION|11C topotecan|Phase I and II: IV over 10 minutes
214775797|NCT00253461|RADIATION|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
214775798|NCT01669044|DRUG|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
214775799|NCT01669044|DRUG|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
214775800|NCT03039582|DIAGNOSTIC_TEST|Bidigital palpation|palpation of the anovaginal distance with two fingers
214775801|NCT03039582|DIAGNOSTIC_TEST|Perineal ultrasound|ultrasound measurement of the anovaginal distance
214775802|NCT00619086|DRUG|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
214775803|NCT00619086|DRUG|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
214775804|NCT06079086|DEVICE|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
214775805|NCT00002484|RADIATION|radiation therapy|
214775806|NCT00823459|DRUG|Everolimus|Given PO
214775807|NCT00823459|OTHER|Archival Tissue Analysis|Correlative studies
214775808|NCT02360397|DRUG|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
214775809|NCT05801354|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
214775810|NCT05801354|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
214775811|NCT05344066|OTHER|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
214775812|NCT05344066|OTHER|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
214775813|NCT01499927|OTHER|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
214775814|NCT06141382|OTHER|English Langugae-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
214775815|NCT06141382|OTHER|English Language-Narrative intervention|Narrative intervention with the help of only pictures in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administred thrice a week in 45-minute long session for 6 weeks.
214775816|NCT06141382|OTHER|Urdu Langusge-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
214775817|NCT06141382|OTHER|Urdu Language-Narrative intervention|Narrative intervention with the help of only pictures in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
214775818|NCT06141382|OTHER|Bilingual-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
214775819|NCT06141382|OTHER|Bilingual-Narrative intervention|Narrative intervention with the help of only pictures in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
214775820|NCT04229316|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
214775821|NCT05415319|BEHAVIORAL|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
214775822|NCT03250910|DRUG|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
214775823|NCT03250910|DRUG|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
214775824|NCT01676584|DRUG|RO6811135|single ascending doses sc
214775825|NCT01676584|DRUG|placebo|single doses sc
214775826|NCT01824459|DRUG|S-1|S-1：40\~60mg bid，d1\~14 q3W
214775827|NCT01824459|DRUG|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
214775828|NCT01824459|DRUG|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
214775829|NCT00130000|DRUG|Eculizumab|
214775830|NCT01537549|DRUG|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
214775831|NCT05806333|DIAGNOSTIC_TEST|FAPI PET|Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
214775832|NCT00192751|BEHAVIORAL|Psychoeducational group sessions|
214775833|NCT04396483|PROCEDURE|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
214775834|NCT04396483|PROCEDURE|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
214775835|NCT06092645|DRUG|surufatinib plus cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
214775836|NCT01063725|DIETARY_SUPPLEMENT|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
214775837|NCT01063725|OTHER|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
214775838|NCT01208922|DRUG|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
214775839|NCT01208922|DRUG|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
214775840|NCT02880163|DEVICE|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
214775841|NCT04519203|DEVICE|SPI|Either standard monitoring alone or added with SPI
214775842|NCT04519203|DEVICE|Standard|Standard monitoring alone
214775843|NCT05526274|DIAGNOSTIC_TEST|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
214775844|NCT00955760|DRUG|Neramexane|Drug-Drug Interaction Study
214775845|NCT00420888|DRUG|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
214775846|NCT00420888|DRUG|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
214775847|NCT01185730|PROCEDURE|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
214775848|NCT01752322|DRUG|Lidocaine 5% medicated plaster|
214775849|NCT01752322|DRUG|Placebo plaster|
214775850|NCT00716586|DRUG|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
214775851|NCT01261416|DRUG|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
214775852|NCT02287506|OTHER|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
214775853|NCT04668118|DRUG|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
214775854|NCT00566618|DRUG|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
214775855|NCT00566618|DRUG|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
214775856|NCT04182984|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
214775857|NCT01542684|DRUG|Azacytidine|Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
214775858|NCT01542684|DRUG|GM-CSF|250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
214775859|NCT02923115|DRUG|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
214775860|NCT02923115|DRUG|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
214775861|NCT02923115|DRUG|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
214775862|NCT04790409|DRUG|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
214775863|NCT03086083|BEHAVIORAL|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
214775864|NCT03086083|BEHAVIORAL|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
214775865|NCT02832076|PROCEDURE|Subcutaneous negative suction drain for 10 days|
214775866|NCT02832076|PROCEDURE|No subcutaneous drain|
214775867|NCT02279576|DRUG|Pazopanib|Pazopanib 800mg/day continuously administered.
214775868|NCT02279576|DRUG|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
214775869|NCT00133094|DRUG|Simvastin|
214775870|NCT00133094|PROCEDURE|Computer-based decision support technology|
214775871|NCT06700629|PROCEDURE|Distal Penile Hypospadias (Disorder)|"Three operations which are Tubularized incised plate urethroplasty (TIP), Mathieu and meatal advancement and glanuplasty (MAGPI).~A three experienced operators with number of operations done by each one more than one hundred operation in the last year.~The operators will be fixed for each surgical technique as follows:~1. Doctor (A) for Matheiu. ( 35 operations)~2. Doctor (M) for MAGPI. ( 35 operations)~3. Doctor (S) for TIP ( 35 operations). Tubularized incised plate urethroplasty:(3,6) Indication: for distal penile hypospadias with or without penile curvature with any width of the uretheral plate and also for any type of distal hypospadias associated with curvature.~Key steps for this operation are as follows:~Glans retraction using stay suture 4-0 or 5-0 silk. Uretheral catheter pass through hypospadic meatus to bladder. Parallel longitudenal incision is done 1-2mm proximal to hypospadic meatus. A circumferential incision is made 2-3 mm below coronal sulcus dorsally"
214775872|NCT04155957|OTHER|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
214775873|NCT04155957|DEVICE|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
214775874|NCT05017376|PROCEDURE|small incision lenticular extraction|In patients with the same degree of myopia, different optical zones were designed for operation
214775875|NCT06698614|DIAGNOSTIC_TEST|MRI|MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).
214775876|NCT06698614|DIAGNOSTIC_TEST|Blood tests|full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
214775877|NCT06698614|DIAGNOSTIC_TEST|Urine tests|Urine protein, Urine creatinine
214775878|NCT06698614|DIAGNOSTIC_TEST|Cardiovascular analysis|24 hour blood pressure, arterial stiffness
214775879|NCT03943121|PROCEDURE|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
214775880|NCT03943121|PROCEDURE|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
214775881|NCT03061279|DEVICE|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
214775882|NCT03061279|DEVICE|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
214775883|NCT00287352|DRUG|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
214775884|NCT00287352|DRUG|Olanzapine and placebo|Olanzapine continuing as clinically indicated
214775885|NCT02971332|PROCEDURE|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
214775886|NCT06701942|OTHER|Multiple family group intervention therapy|"Overview The intervention will be implemented at designated clinics where adolescents living with HIV/AIDS (ALHIV) and their families currently receive care. These sites will provide the MFG intervention alongside standard care services. All eligible adolescents and their family members who consent to participate will be included in the intervention group.~Program Structure The MFG intervention consists of 16 structured sessions, each running for 90 minutes. Sessions will be scheduled to coincide with clinic days over a 14-week period to maximize accessibility and attendance. Parent peers and community health workers, trained by the research team, will facilitate these group sessions.~Session Format Sessions on the MFGT will begin with introducing participants to one another, the facilitators, and the program curriculum. Subsequent sessions will concentrate on areas such as respectful communication, support, resilience building, problem-solving, conflict resolution, stress management"
214775887|NCT02648399|PROCEDURE|surgery：BCND（bilateral central lymph node dissection）|
214775888|NCT02648399|PROCEDURE|surgery：UCND（unilateral central lymph node dissection）|
214775889|NCT04056299|BIOLOGICAL|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
214775890|NCT04056299|BIOLOGICAL|Placebo powder|Placebo powder provided in capsules
214775891|NCT05588375|BEHAVIORAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
214775892|NCT05021588|PROCEDURE|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
214775893|NCT05305378|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
214775894|NCT01219088|DRUG|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
214775895|NCT05152407|OTHER|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
214775896|NCT01514409|DIETARY_SUPPLEMENT|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
214775897|NCT01514409|DIETARY_SUPPLEMENT|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
214775898|NCT01079078|DRUG|Acetaminophen|
214775899|NCT06542861|OTHER|High-frequency simulation-based team training|"The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments."
214775900|NCT05605184|OTHER|Survey|Survey
214775901|NCT03840642|BEHAVIORAL|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
214775902|NCT03840642|BEHAVIORAL|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
214775903|NCT03380182|OTHER|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
214775904|NCT03380182|OTHER|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
214775905|NCT02414074|BEHAVIORAL|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
214775906|NCT02414074|BEHAVIORAL|Parent Education|Everyday Parenting is a parent training curriculum.
214775907|NCT03082820|DIAGNOSTIC_TEST|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
214775908|NCT03082820|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
214775909|NCT03082820|DIAGNOSTIC_TEST|Nerve conduction studies (NCS)|NCS were performed with patients only.
214775910|NCT00068406|RADIATION|3-Dimensional Conformal Radiation Therapy|
214775911|NCT00068406|DRUG|Cisplatin|Given IV
214775912|NCT00068406|PROCEDURE|Conventional Surgery|
214775913|NCT04071275|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
214775914|NCT04071275|OTHER|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
214775915|NCT06279936|OTHER|Neuropsychological battery|COVID-19 patients with persistent complaints of cognitive disabilities (more than 4 weeks post-infection) in daily life are examined with an extensive neuropsychological test battery (see below) at the outpatient clinic of the University Psychiatric Centre in Duffel and at the University Hospital Antwerp. This battery covers a broad range of reliable and valid tests divided into six cognitive domains: attention, memory, visuospatial functions, language, executive functions and psychomotor speed/coordination. The neuropsychological examination lasts an average of 2 hours per participant. The tests are carried out by the same experienced neuropsychologist and also follow a standardized sequence. In addition to the neuropsychological assessment, two self-report scales are filled out by each patient. These scales are used to detect possible complaints of fatigue and possible cognitive problems which are experienced by the patient during daily life activities.
214775916|NCT06279936|OTHER|Surveys and symptom severity questionnaires|Both self-rated surveys and clinician administered questionnaires
214775917|NCT06279936|OTHER|Blood withdrawal|"Blood samples will be collected in a standardized manner by venipuncture. Two blood vials will be collected and processed to perform the following analyses:~* serum collection tube(s) allowing for HERV-W ENV and serological assays~* plasma collection tubes for the assessment of other immune-related biomarkers (including but not limited to CRP, IL-6, IL-1b, TNF-a, IFN-g, tryptophan, kynurenine, 3-OH-kynurenine, quinolinic acid, kynurenic acid, enzymes of the kynurenine pathway)."
214775918|NCT06279936|OTHER|Saliva swabs|Salivary cortisol measures will be used as functional measure of the HPA axis activity, as the unbound cortisol fraction in saliva is highly correlated to plasma cortisol. Baseline diurnal cortisol and CAR levels will be measured using saliva, collected at home with Salivette® (Sarstedt) synthetic swabs. The rationale behind the choice of home sampling, is to maximize normal circumstances and to minimize stress related to the measuring procedure.
214775919|NCT05251415|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity.
214775920|NCT01716507|PROCEDURE|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
214775921|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
214775922|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
214775923|NCT02052037|DIETARY_SUPPLEMENT|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
214775924|NCT02052037|DIETARY_SUPPLEMENT|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
214775925|NCT02212561|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
214775926|NCT02212561|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
214775927|NCT02212561|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
214775928|NCT02212561|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
214775929|NCT06013761|OTHER|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
214775930|NCT01098383|DRUG|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
214775931|NCT01098383|DRUG|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
214775932|NCT00002227|DRUG|Efavirenz|
214775933|NCT00002227|DRUG|Lamivudine|
214775934|NCT00002227|DRUG|Stavudine|
214775935|NCT05610982|BEHAVIORAL|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
214775936|NCT01875991|DRUG|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
214775937|NCT01875991|DRUG|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
214775938|NCT04188769|DEVICE|constant deep pressure applied by an air splint|inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
214775939|NCT04188769|DEVICE|intermittent deep pressure applied by an air splint|continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
214775940|NCT04188769|DEVICE|uninflated air splint|no deep pressure applied by the air splint
214775941|NCT04188769|OTHER|contralateral movement|non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
214775942|NCT05265169|DEVICE|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
214775943|NCT02419469|DRUG|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
214775944|NCT02419469|DRUG|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
214775945|NCT02419469|DRUG|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
214775946|NCT02419469|DRUG|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
214775947|NCT02419469|DRUG|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
214775948|NCT02419469|DRUG|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
214775949|NCT02419469|DRUG|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
214775950|NCT02419469|DRUG|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
214775951|NCT02419469|DRUG|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
214775952|NCT02419469|DRUG|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
214775953|NCT02419469|DRUG|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
214775954|NCT02419469|DRUG|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
214775955|NCT02419469|DRUG|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
214775956|NCT03244397|OTHER|Physical therapy + educational strategy|See arm/group descriptions
214775957|NCT03244397|BEHAVIORAL|Educational strategy|See arm/group descriptions
214775958|NCT02454972|DRUG|lurbinectedin (PM01183)|
214775959|NCT03397563|DEVICE|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
214775960|NCT03397563|DEVICE|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
214775961|NCT06478446|OTHER|observation|HD patients were observed and evaluated with three scales.
214775962|NCT04132739|BEHAVIORAL|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
214775963|NCT04132739|BEHAVIORAL|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
214775964|NCT04132739|BEHAVIORAL|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
214775965|NCT00229541|PROCEDURE|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
214775966|NCT05695235|DEVICE|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
214775967|NCT05695235|DEVICE|Oura ring|Wearable sleep tracking device
214775968|NCT05695235|BEHAVIORAL|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
214775969|NCT03720184|PROCEDURE|HAR|"HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk"
214775970|NCT04057755|DRUG|botulinum toxin A|
214775971|NCT04057755|DRUG|NaCl|
214775972|NCT02887612|OTHER|ctDNA test|
214775973|NCT04074213|DRUG|Clozapine|Clozapine treatment
214775974|NCT01826318|BEHAVIORAL|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
214775975|NCT06433349|OTHER|Survey and interviews|Questionnaires and interviews
214775976|NCT01795703|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
214775977|NCT01795703|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
214775978|NCT00416403|DRUG|fluvastatin sodium|Given orally
214775979|NCT00416403|PROCEDURE|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
214775980|NCT01377233|DRUG|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
214775981|NCT01377233|DRUG|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
214775982|NCT01377233|DRUG|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
214775983|NCT01377233|DRUG|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
214775984|NCT01377233|DRUG|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
214775985|NCT05998733|DIAGNOSTIC_TEST|Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring|"* Correlation analysis of sepsis severity with FDP and D-Dimer~* Discussion on the critical value and area under the curve of FDP and D-Dimer in diagnosis of sepsis~* Differences in age and sex of FDP and D-Dimer in diagnosis of sepsis~* Effect of FDP and D-Dimer diagnosis of sepsis on severe conversion rate and all-cause mortality of patients~* The difference of thromboelastogram in patients with sepsis of different severity~* Thromboelastogram items (R time α Correlation between angle, k time, maximum blood clot strength and comprehensive coagulation index) and sepsis"
214775986|NCT06059742|OTHER|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
214775987|NCT06059742|OTHER|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
214775988|NCT01774006|OTHER|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
214775989|NCT01785875|DRUG|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
214775990|NCT03112993|DRUG|sugammadex|once at the end of the surgery
214775991|NCT03112993|DRUG|Neostigmine|once at the end of the surgery
214775992|NCT01131728|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
214775993|NCT04363411|OTHER|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
214775994|NCT04905654|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
214775995|NCT04905654|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
214775996|NCT04597554|DIETARY_SUPPLEMENT|Cranberry|Cranberry beverage and gummies supplement
214775997|NCT04597554|DIETARY_SUPPLEMENT|Placebo|Placebo beverages and gummies supplement
214775998|NCT06171997|OTHER|Swaddling after bath group|"The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale."
214775999|NCT03310203|DIAGNOSTIC_TEST|Iron|Labelled iron
214776000|NCT01182714|PROCEDURE|immediate removal of in-dwelling catheter|
214776001|NCT01182714|PROCEDURE|24 hours delayed removal of catheter|
214776002|NCT00301431|DRUG|DVS-233|
214776003|NCT05245773|OTHER|Automated SMS program to support post-discharge transitions of care|The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
214776004|NCT06527820|BEHAVIORAL|Talk About It (conversation aid)|"Talk About It is a conversation aid aimed to increase awareness of options and prompt discussion."
214646729|NCT04619394|OTHER|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
214646730|NCT04619394|OTHER|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
214646731|NCT01262976|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 2 doses
214646732|NCT01262976|BIOLOGICAL|Physiological saline|Intramuscular, 2 doses
214646733|NCT04735276|DEVICE|HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.
214646734|NCT02516670|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
214646735|NCT02516670|DRUG|Docetaxel|Given IV
214646736|NCT02516670|OTHER|Laboratory Biomarker Analysis|Correlative studies
214646737|NCT02516670|OTHER|Pharmacological Study|Correlative studies
214646738|NCT02516670|OTHER|Placebo|Given IV
214646739|NCT02516670|OTHER|Quality-of-Life Assessment|Ancillary studies
214646740|NCT01858233|BEHAVIORAL|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
214646741|NCT01385735|DRUG|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
214646742|NCT01385735|DRUG|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
214646743|NCT02276859|DRUG|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
214646744|NCT02276859|DRUG|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
214646745|NCT02276859|DRUG|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
214646746|NCT03227367|OTHER|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
214646747|NCT03671057|DEVICE|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
214646748|NCT03671057|DRUG|Midazolam|current practice in Jessa
214646749|NCT05360667|OTHER|Standard care plus plus Exergame-based multicomponent training program|"The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)"
214646750|NCT05360667|OTHER|Standard care|The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
214646751|NCT03686566|DRUG|13C-glucose|Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
214646752|NCT03686566|OTHER|No glucose infusion|Only includes standard pre-operation nursing care
214646753|NCT02769728|DEVICE|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
214646754|NCT03129074|DRUG|Varlitinib|everyday
214646755|NCT03129074|DRUG|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
214646756|NCT01552681|BIOLOGICAL|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
214646757|NCT01552681|OTHER|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
214646758|NCT05574179|DRUG|Dexmedetomidine injection|Inj precedex 200mcg in 1ml given in stat doses
214646759|NCT05574179|DRUG|Midazolam|Inj.midazolam 5mg/5ml given in stat doses
214646760|NCT02690194|DEVICE|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
214646761|NCT02690194|DEVICE|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
214776005|NCT00489931|DRUG|VRC-AVIDNA036-00-VP|
214776006|NCT05785520|DEVICE|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
214776007|NCT00595426|DRUG|YM150|Oral
214776008|NCT00595426|DRUG|Warfarin|Oral
214776009|NCT01398592|DRUG|Vildagliptin|50mg vildagliptin bid
214776010|NCT01398592|DRUG|Sitagliptin|100mg sitagliptin po qd
214776011|NCT00689663|PROCEDURE|Laparoscopic cholecystectomy|Randomized to three arm.
214776012|NCT03716999|OTHER|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
214776013|NCT04283487|DIETARY_SUPPLEMENT|Fructans|500ml 0.9% normal saline containing 40g fructans
214776014|NCT04283487|DIETARY_SUPPLEMENT|Glucose|500ml 0.9% normal saline containing 40g glucose
214776015|NCT04283487|DIETARY_SUPPLEMENT|Saline|500ml 0.9% normal saline
214776016|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
214776017|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
214776018|NCT00695981|PROCEDURE|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
214776019|NCT00695981|PROCEDURE|Conservative treatment|Physiotherapy according to a standardized protocol
214776020|NCT02149862|OTHER|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
214776021|NCT04991311|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
214776022|NCT03794999|DRUG|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
214776023|NCT03794999|DRUG|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
214776024|NCT00129532|DRUG|1.0% C31G SAVVY vaginal gel|
214776025|NCT00755937|OTHER|Data collection post infusion|
214776026|NCT00991042|OTHER|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
214776027|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
214776028|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
214776029|NCT01676311|DRUG|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
214776030|NCT01676311|DRUG|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
214776031|NCT05177237|DRUG|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
214776032|NCT01669278|DEVICE|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
214776033|NCT01680289|PROCEDURE|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
214776034|NCT01680289|PROCEDURE|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
214776035|NCT01440595|DRUG|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
214776036|NCT01440595|DRUG|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
214776037|NCT01440595|DRUG|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
214776038|NCT01440595|DRUG|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
214776039|NCT05099783|DIAGNOSTIC_TEST|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
214776040|NCT04912635|OTHER|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
214776041|NCT04208191|BEHAVIORAL|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
214776042|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)|the intervention is conducting electrical posterior box isolation plus rotor modulation ablation
214776043|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation group (BO group)|the intervention is conducting electrical posterior box isolation alone
214776044|NCT01950806|OTHER|Pecan-containing diet|
214776045|NCT01950806|OTHER|Nut-free diet|
214776046|NCT01062022|BEHAVIORAL|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
214776047|NCT01062022|BEHAVIORAL|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
214776048|NCT01223196|DRUG|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
214776049|NCT01223196|DRUG|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
214776050|NCT00323271|BEHAVIORAL|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
214776051|NCT00323271|OTHER|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
214776052|NCT04657978|PROCEDURE|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
214776053|NCT00123110|DRUG|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
214776054|NCT00123110|DRUG|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
214776055|NCT00123110|DRUG|placebo pill|matching pill twice a day for 12 weeks
214776056|NCT00123110|DRUG|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
214776057|NCT03801278|DRUG|FPA144|Bemarituzumab administration every two weeks
214776058|NCT03855462|DEVICE|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months."
214776059|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
214776060|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
214776061|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
214776062|NCT03875131|OTHER|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~  * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
214776063|NCT05180630|DEVICE|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
214776064|NCT05180630|DEVICE|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
214776065|NCT05180630|DEVICE|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
214776066|NCT02093468|DRUG|MST-188|
214776067|NCT02093468|DRUG|Saline|
214776068|NCT05482438|DEVICE|Polyethylene|Wear measurement
214776069|NCT05942131|OTHER|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
214776070|NCT06406231|DEVICE|comparing efficacy of TENS and PEMF in knee osteoarthritis|"Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups."
214776071|NCT04774809|DRUG|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
214776072|NCT04774809|DRUG|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
214776073|NCT04774809|OTHER|Placebo Comparator: Vehicle|Placebo
214776074|NCT05152004|DRUG|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
214776075|NCT05152004|DRUG|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
214776076|NCT05152004|DRUG|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
214776077|NCT05152004|DRUG|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
214776078|NCT06433986|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
214776079|NCT06433986|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
214776080|NCT04676607|DRUG|SHR7390|SHR7390
214776081|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
214776082|NCT01294605|BIOLOGICAL|Boostrix™ (dTpa)|Intramuscular, 3 doses
214776083|NCT01294605|BIOLOGICAL|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
214776084|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
214776085|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
214776086|NCT03922815|DRUG|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
214776087|NCT03922815|DRUG|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
214776088|NCT05645055|OTHER|treat these patients with biologics|treat these patients with biologics
214776089|NCT05606159|DIETARY_SUPPLEMENT|Bacillus velezensis DSM 33864|1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
214776090|NCT05606159|DIETARY_SUPPLEMENT|Placebo|1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
214776091|NCT00705796|DRUG|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
214776092|NCT00705796|DRUG|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
214776093|NCT03899506|DRUG|Olanzapine|Patients receiving Olanzapine per the ED protocol
214776094|NCT03899506|DRUG|Midazolam|Patients receiving Midazolam per the ED protocol
214776095|NCT05066347|DEVICE|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
214776096|NCT04275388|DRUG|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
214776097|NCT04275388|DRUG|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
214646762|NCT05463809|DRUG|Continuous Gastrocnemius plane block with ropivacaine|After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.
214646763|NCT05463809|DRUG|oxycodone|The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
214646764|NCT01822808|DRUG|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
214646765|NCT01822808|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
214646766|NCT04417829|DEVICE|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
214646767|NCT04203485|BIOLOGICAL|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
214646768|NCT04203485|DRUG|Apatinib Mesylate 250mg|Apatinib Mesylate 250mg po qd
214646769|NCT04203485|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium for injection 500 mg/m2 q3w
214646770|NCT04203485|DRUG|Paclitaxel injection|Paclitaxel injection 175 mg/m2 q3w
214646771|NCT04203485|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min q3w
214646772|NCT05048160|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
214646773|NCT00687791|DEVICE|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
214646774|NCT03900390|PROCEDURE|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
214646775|NCT05675007|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
214646776|NCT05675007|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
214646777|NCT01987908|DRUG|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
214646778|NCT01987908|OTHER|Placebo|
214646779|NCT02986594|DRUG|Aspirin|
214646780|NCT02986594|DRUG|Heparin|
214646781|NCT01629407|OTHER|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
214646782|NCT00797693|DRUG|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
214646783|NCT05704478|DRUG|Vericiguat|soluble guanylate cyclase stimulator
214646784|NCT02765074|DRUG|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
214646785|NCT02950792|DEVICE|ViewRay MRI|ViewRay Magnetic Resonance Imaging
214646786|NCT02950792|RADIATION|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
214646787|NCT02459379|RADIATION|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
214646788|NCT01560273|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
214776098|NCT01184378|DIETARY_SUPPLEMENT|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
214776099|NCT01518985|DRUG|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
214776100|NCT01518985|DRUG|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
214776101|NCT01518985|OTHER|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
214776102|NCT01466673|DRUG|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
214776103|NCT01466673|DRUG|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
214776104|NCT00294931|DRUG|irinotecan|
214776105|NCT00294931|DRUG|carboplatin|
214776106|NCT00294931|DRUG|bevacizumab|
214776107|NCT02424656|PROCEDURE|MRI|EEG-functional MRI, structural MRI, diffusion MRI
214776108|NCT02424656|PROCEDURE|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
214776109|NCT02424656|PROCEDURE|FDG-PET|
214776110|NCT02424656|OTHER|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
214776111|NCT04324307|DRUG|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
214776112|NCT04324307|COMBINATION_PRODUCT|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
214776113|NCT04324307|COMBINATION_PRODUCT|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
214776114|NCT02857296|OTHER|interview and observation|
214776115|NCT02009982|PROCEDURE|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
214776116|NCT02009982|DEVICE|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
214776117|NCT00597727|DRUG|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
214776118|NCT00597727|DRUG|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
214776119|NCT02043093|BEHAVIORAL|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
214776120|NCT02725671|DEVICE|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
214776121|NCT02007746|OTHER|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
214776122|NCT02007746|OTHER|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
214776123|NCT02007746|PROCEDURE|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
214776124|NCT00311571|DRUG|Ethidronate|
214776125|NCT00311571|BEHAVIORAL|Physical training|
214776126|NCT05965622|BEHAVIORAL|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
214776127|NCT05965622|BEHAVIORAL|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
214776128|NCT00965263|BIOLOGICAL|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
214776129|NCT02682433|DEVICE|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
214776130|NCT02682433|DEVICE|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
214776131|NCT00963599|DRUG|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
214776132|NCT00963599|DRUG|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
214776133|NCT00963599|DRUG|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
214776134|NCT00963599|DRUG|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
214776135|NCT02135094|DEVICE|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
214776136|NCT02135094|DEVICE|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
214776137|NCT00243282|BEHAVIORAL|Relaxation Response (instruction, pocket practice card prov)|
214776138|NCT00243282|BEHAVIORAL|Mindfulness training using model developed from UMass|
214776139|NCT00148694|DRUG|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
214776140|NCT06529458|OTHER|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
214776141|NCT06529458|OTHER|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
214776142|NCT06529458|OTHER|Control Group|No interference will be made
214776143|NCT05176301|RADIATION|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
214776144|NCT02549274|OTHER|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
214776145|NCT02549274|OTHER|physiotherapy|14 physiotherapy sessions (2 by week)
214776146|NCT02634567|BEHAVIORAL|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
214776147|NCT00867126|DRUG|pioglitazone hydrochloride|
214776148|NCT00867126|OTHER|laboratory biomarker analysis|
214776149|NCT00867126|OTHER|questionnaire administration|
214776150|NCT00867126|PROCEDURE|quality-of-life assessment|
214776151|NCT05700110|OTHER|Non-Interventional|Non-interventional
214776152|NCT02022410|OTHER|CAS after primary and revision TKA|CAS and RAPT
214776153|NCT00839007|DRUG|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
214776154|NCT03496207|DRUG|Placebo|Placebo
214776155|NCT03496207|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
214776156|NCT03496207|OTHER|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
214776157|NCT04496778|DEVICE|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
214776158|NCT04496778|OTHER|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
214776159|NCT02034617|BEHAVIORAL|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
214776160|NCT01235858|PROCEDURE|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
214776161|NCT01235858|PROCEDURE|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
214776162|NCT04382690|BEHAVIORAL|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
214776163|NCT04626765|DRUG|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
214776164|NCT04626765|DRUG|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
214776165|NCT04626765|DRUG|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
214776166|NCT04626765|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
214776167|NCT04626765|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
214776168|NCT03923114|RADIATION|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
214776169|NCT06540612|OTHER|Aerobic exercise|Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
214776170|NCT06540612|BEHAVIORAL|Physical activity counseling|Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
214776171|NCT03454100|BEHAVIORAL|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
214776172|NCT06129331|DRUG|Amyloid-specific treatment|Amyloid-specific treatment
214776173|NCT06129331|OTHER|No amyloid-specific treatment|No amyloid-specific treatment
214776174|NCT00765466|DRUG|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
214776175|NCT04832165|OTHER|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
214776176|NCT00921804|DRUG|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
214776177|NCT00921804|DRUG|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
214776178|NCT00921804|DRUG|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
214776179|NCT00921804|DRUG|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
214776180|NCT02164539|DRUG|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
214776181|NCT02164539|DRUG|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
214776182|NCT02164539|DRUG|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
214776183|NCT01255722|DRUG|iobitridol|single IV injection
214776184|NCT01255722|DRUG|iopromide|Single IV injection
214776185|NCT01255722|DRUG|iomeprol|Single IV injection
214776186|NCT01833221|DRUG|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
214776187|NCT05301166|BEHAVIORAL|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
214776188|NCT05301166|OTHER|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
214776189|NCT02245360|DRUG|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
214776190|NCT02245360|DRUG|placebo|placebo tablet given once daily over 60 days
214776191|NCT02533323|DRUG|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
214776192|NCT02533323|DRUG|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
214776193|NCT02533323|DRUG|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
214776194|NCT01788059|OTHER|injection the mesenchymal stem cell in non union site|
214776195|NCT03835975|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
214776196|NCT03835975|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
214776197|NCT03835975|BIOLOGICAL|20vPnC|Pneumococcal conjugate vaccine
214776198|NCT02267252|OTHER|Antibody-sperm binding|
214776199|NCT01188642|BEHAVIORAL|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
214776200|NCT04580173|DIAGNOSTIC_TEST|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
214776201|NCT00061945|DRUG|allopurinol|Given PO
214776202|NCT00061945|DRUG|cyclophosphamide|Given IV
214776203|NCT00061945|DRUG|daunorubicin hydrochloride|Given IV
214776204|NCT00061945|DRUG|vincristine sulfate|Given IV
214776205|NCT00061945|DRUG|dexamethasone|Given PO and as eye drops
214776206|NCT00061945|DRUG|asparaginase|Given SC
214776207|NCT00061945|BIOLOGICAL|filgrastim|Given SC
214776208|NCT00061945|DRUG|imatinib mesylate|Given PO
214776209|NCT00061945|DRUG|methotrexate|Given IT, IV, and PO
214776210|NCT00061945|DRUG|cytarabine|Given IV
214776211|NCT00061945|DRUG|trimethoprim-sulfamethoxazole|Given PO
214776212|NCT00061945|DRUG|mercaptopurine|Given PO
214776213|NCT00061945|DRUG|leucovorin calcium|Given IV and PO
214776214|NCT00061945|BIOLOGICAL|alemtuzumab|Given SC
214776215|NCT00061945|DRUG|acyclovir|Given PO
214776216|NCT00061945|OTHER|laboratory biomarker analysis|Correlative studies
214776217|NCT00061945|OTHER|pharmacological study|Correlative studies
214776218|NCT01781689|PROCEDURE|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
214776219|NCT01781689|OTHER|Rehabilitation programs|include occupational therapy and physical therapy
214776220|NCT03341715|DRUG|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
214776221|NCT03341715|OTHER|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
214776222|NCT02816749|PROCEDURE|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
214776223|NCT02816749|PROCEDURE|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
214776224|NCT04641273|DRUG|BAY1817080|Tablet, intake orally.
214776225|NCT04641273|DRUG|Placebo for BAY1817080|Tablet, intake orally.
214776226|NCT04641273|DRUG|Placebo for Pregabalin|Capsule, intake orally.
214776227|NCT04641273|DRUG|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
214776228|NCT03874585|BEHAVIORAL|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
214776229|NCT03874585|BEHAVIORAL|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
214776230|NCT04270552|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
214776231|NCT04270552|DRUG|Placebo|Matched tablets without any active substance.
214776232|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
214776233|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
214776234|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
214776235|NCT04628221|DEVICE|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
214776236|NCT04239638|DIAGNOSTIC_TEST|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
214776237|NCT04902261|DRUG|Tislelizumab|Tislelizumab 200 mg every three weeks
214776238|NCT04902261|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
214776239|NCT04902261|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
214776240|NCT06315725|OTHER|Sweet taste perception with/without sweet taste blockade|In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.
214776241|NCT00099320|DRUG|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
214776242|NCT00099320|DRUG|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
214776243|NCT04622618|DRUG|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
214776244|NCT04991896|DRUG|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
214776245|NCT04916288|DEVICE|central venous cathterization|central venous catheterization through the right internal jugular vein
214776246|NCT03744806|DRUG|Bevacizumab Injection|
214776247|NCT06416761|GENETIC|genetic polymorphisms|
214776248|NCT05473858|DRUG|OraVerse Injectable Product|injection of oraverse,
214776249|NCT05473858|DEVICE|diode laser|patient exposed to diode laser
214776250|NCT01656967|DEVICE|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
214776251|NCT01656967|DEVICE|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
214776252|NCT02313519|DIETARY_SUPPLEMENT|Probiotics|Probiotics are prepared in capsule form
214776253|NCT02313519|DIETARY_SUPPLEMENT|Placebo|Glucose powder
214776254|NCT02364219|OTHER|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
214776255|NCT02364219|DEVICE|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
214776256|NCT00975884|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
214776257|NCT05186922|BIOLOGICAL|CM326|CM326 injection
214776258|NCT05186922|OTHER|Placebo|Placebo
214776259|NCT05417126|BIOLOGICAL|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
214776260|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
214776261|NCT03604601|PROCEDURE|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
214776262|NCT03983746|DEVICE|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
214776263|NCT04536467|DRUG|Goserelin|chemotherapy+goserelin
214776264|NCT04536467|DRUG|Chemotherapy|standard chemotherapy
214776265|NCT05525299|BEHAVIORAL|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, \_\_\_\_\_ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
214776266|NCT06221683|DRUG|Homoharringtonine|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
214776267|NCT06221683|DRUG|Cytarabine|100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
214776268|NCT06221683|DRUG|Etoposide|100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
214776269|NCT06221683|DRUG|Venetoclax|100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
214776270|NCT06221683|DRUG|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
214776271|NCT06221683|DRUG|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
214776272|NCT06221683|DRUG|Idarubicin Hydrochloride|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
214776273|NCT06221683|DRUG|Sorafenib|100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
214776274|NCT06221683|DRUG|Gilteritinib|20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
214776275|NCT06221683|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
214776276|NCT00179153|DIETARY_SUPPLEMENT|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
214776277|NCT02747251|OTHER|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
214776278|NCT02747251|OTHER|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
214776279|NCT05906498|DRUG|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
214776280|NCT05906498|DRUG|Vitamin E|vitamin E possessing an anti-inflammatory action
214776281|NCT05166512|BEHAVIORAL|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
214776282|NCT05166512|BEHAVIORAL|DPP|Standard DPP
214776283|NCT04974593|OTHER|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
214776284|NCT03145558|DRUG|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
214776285|NCT03145558|DRUG|Doxorubicin|Standard of care for TACE
214776286|NCT05044832|BEHAVIORAL|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
214776287|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
214776288|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
214776289|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
214776290|NCT02450409|PROCEDURE|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
214776291|NCT02450409|PROCEDURE|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
214776292|NCT03999346|OTHER|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
214776293|NCT02139306|DRUG|Ataluren (PTC124®)|Oral Ataluren TID
214776294|NCT02139306|DRUG|Placebo|Oral Placebo TID
214776295|NCT04237259|OTHER|Parent-administered TCM pediatric massage training|"Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects)."
214776296|NCT04237259|OTHER|Progressive Muscle Relaxation Exercise|The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
214776297|NCT03810742|DRUG|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
214776298|NCT05060952|DIAGNOSTIC_TEST|Calprotectin Lateral Flow Test|Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate
214776299|NCT03438305|OTHER|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
214776300|NCT03438305|OTHER|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
214776301|NCT03166306|DIAGNOSTIC_TEST|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
214776302|NCT01067989|DRUG|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
214776303|NCT03658356|OTHER|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
214776304|NCT01284816|PROCEDURE|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
214776305|NCT00405483|PROCEDURE|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
214776306|NCT00405483|PROCEDURE|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
214776307|NCT05576597|DRUG|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
214776308|NCT02418559|DRUG|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
214776309|NCT02418559|DRUG|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
214776310|NCT02418559|DRUG|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
214776311|NCT02418559|DRUG|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
214776312|NCT04078659|DRUG|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
214776313|NCT04078659|DRUG|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
214776314|NCT04078659|DRUG|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
214776315|NCT04078659|DRUG|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
214776316|NCT04078659|DRUG|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
214776317|NCT04078659|DRUG|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
214776318|NCT04078659|PROCEDURE|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
214776319|NCT01175161|DEVICE|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
214776320|NCT05627388|OTHER|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
214776321|NCT05139901|DRUG|Dornase Alfa|inhalations twice daily
214776322|NCT05139901|DRUG|Saline|inhalations twice daily
214776323|NCT06033183|BIOLOGICAL|Blood sample|Blood sample collection : 2 X 5 ml
214776324|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
214776325|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
214776326|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
214776327|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
214776328|NCT02956005|DRUG|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
214776329|NCT04384926|PROCEDURE|Elective Cancer Surgery|Planned, curative cancer surgery
214776330|NCT03909971|DRUG|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
214776331|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
214776332|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
214776333|NCT02809534|DRUG|Anlotinib|Anlotinib p.o. qd
214776334|NCT01033175|PROCEDURE|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
214776335|NCT01033175|PROCEDURE|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
214776336|NCT03013517|DRUG|Viaskin Peanut 250µg|DBV712 250 µg, once daily
214776337|NCT02341976|OTHER|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
214776338|NCT01185639|RADIATION|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
214776339|NCT00866528|DRUG|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
214776340|NCT00866528|DRUG|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
214776341|NCT05991492|DEVICE|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I|Digital insomnia treatment
214776342|NCT06320093|OTHER|SOUND Intervention|The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
214776343|NCT03354923|BEHAVIORAL|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
214776344|NCT05524207|PROCEDURE|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
214776345|NCT04801030|BEHAVIORAL|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
214776346|NCT05567094|DRUG|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
214776347|NCT05567094|DRUG|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
214776348|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
214776349|NCT04814888|OTHER|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
214776350|NCT03461029|DEVICE|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
214776351|NCT04185701|OTHER|SiVIEW software|Eye examination by a technician with the SiVIEW software
214776352|NCT04185701|OTHER|Expert|Eye examination by an expert including optimal correction in distance and near vision
214776353|NCT06537284|BEHAVIORAL|ImRs-DSR|Imagery Rescripting with Memory Reconsolidation Disruption
214776354|NCT06537284|BEHAVIORAL|ImRs|Imagery Rescripting regular
214776355|NCT00739622|DRUG|TMC278|
214776356|NCT04696627|OTHER|Questionnaire|Participants from all 3 groups will be interviewed
214776357|NCT00593931|OTHER|fMRI|Functional Magnetic Resonance Imaging without contrast
214776358|NCT02440074|OTHER|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
214776359|NCT06289335|DRUG|saline solution|20 mL of saline
214776360|NCT04808960|DIAGNOSTIC_TEST|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine \& Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
214776361|NCT00927979|DRUG|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
214776362|NCT00927979|DRUG|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
214776363|NCT00927979|DRUG|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
214776364|NCT06541821|OTHER|survey evaluation|assessment of physical activity, fear of movement, and ostomy compliance
214776365|NCT04886869|DIETARY_SUPPLEMENT|caffeine|oral consumption
214776366|NCT01353794|DRUG|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
214776367|NCT06392321|DRUG|Fentanyl|comparison between bupivacaine, bupivacaine and fentanyl.
214776368|NCT06392321|DRUG|Dexmedetomidine|comparison between bupivacaine, bupivacaine and dexmedetomidine..
214776369|NCT05801107|DRUG|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
214776370|NCT02379676|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
214776371|NCT02379676|DRUG|Clopidogrel|Clopidogrel 75mg once daily for 30 days
214776372|NCT03881722|DIETARY_SUPPLEMENT|Mg alginate|Mg alginate after feedings
214776373|NCT01479556|DRUG|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
214776374|NCT01479556|DRUG|Placebo|150mg BID p.o.
214776375|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
214776376|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
214776377|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
214776378|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
214776379|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
214776380|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
214776381|NCT00281827|DRUG|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
214776382|NCT00281827|DRUG|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
214776383|NCT00281827|DRUG|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
214776384|NCT00281827|PROCEDURE|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
214776385|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
214776386|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
214776387|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
214776388|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
214776389|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
214776390|NCT01861717|DRUG|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
214776391|NCT00975338|OTHER|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
214776392|NCT00975338|OTHER|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
214776393|NCT05774769|PROCEDURE|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
214776394|NCT05128331|DIETARY_SUPPLEMENT|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
214776395|NCT05128331|DIETARY_SUPPLEMENT|Placebo|dietary supplement that is made of cellulose.
214776396|NCT02256319|DRUG|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
214776397|NCT02256319|DRUG|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
214776398|NCT03668925|RADIATION|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
214776399|NCT06039098|DEVICE|DCS|DCS monitoring of brain
214776400|NCT02579369|OTHER|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
214776401|NCT02579369|DEVICE|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
214776402|NCT00399919|DRUG|Propionyl-L-Carnitine|2 grams per day for six months
214776403|NCT00399919|DRUG|PLC|2 grams/day for six months
214776404|NCT06125873|DRUG|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
214776405|NCT06365931|DEVICE|Percutaneous neuromodulation|Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
214776406|NCT06365931|DEVICE|Transcutaneous neuromodulation|Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
214776407|NCT06365931|DEVICE|Placebo-percutaneous|Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.
214776408|NCT06365931|DEVICE|Placebo-transcutaneous|patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.
214776409|NCT06365931|DEVICE|Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)|Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.
214776410|NCT02670200|BEHAVIORAL|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
214776411|NCT03033069|DRUG|Brexpiprazole|Brexpiprazole oral tablets.
214776412|NCT03033069|DRUG|Sertraline|Sertraline oral capsules.
214776413|NCT03033069|DRUG|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
214776414|NCT03033069|DRUG|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
214776415|NCT00430638|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
214776416|NCT00430638|DRUG|Placebo|Oral tablets administered for once daily for 12 weeks
214776417|NCT05517863|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
214776418|NCT04992169|BEHAVIORAL|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
214776419|NCT04793165|DEVICE|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
214776420|NCT05048745|PROCEDURE|interval appendectomy|interval appendectomy
214776421|NCT00062036|BIOLOGICAL|aldesleukin|
214776422|NCT00062036|BIOLOGICAL|filgrastim|
214776423|NCT00062036|BIOLOGICAL|incomplete Freund's adjuvant|
214776424|NCT00062036|BIOLOGICAL|interleukin-2 gene|
214776425|NCT00062036|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214776426|NCT00062036|DRUG|cyclophosphamide|
214776427|NCT00062036|DRUG|fludarabine phosphate|
214776428|NCT01987258|BEHAVIORAL|Interval Walking|
214776429|NCT01987258|BEHAVIORAL|Continuous walking|
214776430|NCT02843347|PROCEDURE|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
214776431|NCT01779349|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
214776432|NCT02972151|DRUG|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
214776433|NCT02972151|OTHER|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
214776434|NCT00583245|OTHER|Gait Training|Gait training with physical therapist 2/week for 3 months
214776435|NCT04156867|DEVICE|Dynesys|discectomy with Dynesys
214776436|NCT00279799|BEHAVIORAL|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
214776437|NCT00279799|BEHAVIORAL|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
214776438|NCT04675528|DRUG|DHP107(Oral paclitaxel)|DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
214776439|NCT02431481|DRUG|LEE011|400 mg
214776440|NCT04101084|OTHER|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
214776441|NCT06678191|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
214776442|NCT03761121|OTHER|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
214776443|NCT04247646|DIETARY_SUPPLEMENT|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
214776444|NCT04247646|DIETARY_SUPPLEMENT|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
214776445|NCT05900531|DRUG|K-757|administered orally
214776446|NCT05900531|DRUG|K-757 and open-label sitagliptin|both administered orally
214776447|NCT05900531|DRUG|Matching placebo to K-757|administered orally
214776448|NCT05900531|DRUG|Matching placebo to K-757 and matching placebo to K-833|both administered orally
214776449|NCT05900531|DRUG|K-757 and K-833|both administered orally
214776450|NCT05900531|DRUG|Matching placebo to K-757, open-label sitagliptin|both administered orally
214776451|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
214776452|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
214776453|NCT00272623|PROCEDURE|Seldinger technique or venous cut-down for port placement|
214776454|NCT06697756|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
214776455|NCT06697756|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
214776456|NCT06696170|DEVICE|CellFX nano-pFA 360 Endocardial Ablation Catheter System|The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
214776457|NCT06701344|DRUG|Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)|"Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days"
214776458|NCT06701344|DRUG|Golidocitinib|"Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT."
214776459|NCT06700863|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
214776460|NCT06700785|DIETARY_SUPPLEMENT|Lysine butyrate|Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.
214776461|NCT06700785|DIETARY_SUPPLEMENT|Sodium Butyrate|Oral sodium butyrate supplement.
214776462|NCT06700785|DIETARY_SUPPLEMENT|Tributyrin|Oral tributyrin supplement.
214776463|NCT06701877|BEHAVIORAL|Circle of security Parenting (COS-P)|The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).
214776464|NCT06701877|BEHAVIORAL|Traitement as usual (TAU)|TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
214776465|NCT02926053|PROCEDURE|Surgical removal of tumor tissue for T cell production|Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
214776466|NCT02926053|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
214776467|NCT02926053|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
214776468|NCT02926053|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
214776469|NCT02926053|DRUG|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
214776470|NCT01909752|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
214776471|NCT01909752|BIOLOGICAL|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
214776472|NCT01909752|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
214776473|NCT01909752|DRUG|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
214776474|NCT01909752|BIOLOGICAL|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
214776475|NCT05220904|DEVICE|spectacles|Spectacle is the the most common treatment for refractive errors.
214646789|NCT01363687|DEVICE|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
214646790|NCT03715426|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
214646791|NCT00712374|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
214646792|NCT02047669|BEHAVIORAL|Biopsychosocial|
214646793|NCT02047669|BEHAVIORAL|Reference|
214646794|NCT04598542|DRUG|Lorecivivint (LOR)|0.07 mg
214646795|NCT04598542|DRUG|Triamcinolone acetonide (TA)|40 mg
214646796|NCT03106532|DRUG|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
214646797|NCT03106532|DRUG|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
214646798|NCT03106532|DRUG|Placebo ophthalmic solution|3 drops daily, 28 days
214646799|NCT00354601|DRUG|capecitabine|oral capecitabine twice daily on days 1-21
214646800|NCT00354601|DRUG|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
214646801|NCT01766947|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
214646802|NCT01135732|PROCEDURE|brush cytology|brush cytology during ERCP
214646803|NCT04732754|DIETARY_SUPPLEMENT|Aerobic exercise + Theobroma cocoa (AETC)|Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
214646804|NCT04732754|DIETARY_SUPPLEMENT|Control Group (CG)|Daily consumption of placebo capsules for 8 weeks
214646805|NCT04732754|DIETARY_SUPPLEMENT|Aerobic Exercise (AE)|Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
214646806|NCT04732754|DIETARY_SUPPLEMENT|Theobroma Cocoa (TC)|Daily consumption of 500mg cocoa in capsules for 8 weeks.
214646807|NCT03603652|DEVICE|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
214646808|NCT05684640|DRUG|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
214646809|NCT05684640|DRUG|Placebo|Tablets, Oral, 0mg, BID
214646810|NCT04431115|OTHER|Interviews|Interviews for stakeholders
214646811|NCT02195492|DRUG|Synvisc®|
214646812|NCT04711096|PROCEDURE|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
214646813|NCT02532855|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet
214646814|NCT02532855|DRUG|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
214646815|NCT02532855|DRUG|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
214646816|NCT02532855|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
214646817|NCT02532855|DRUG|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
214646818|NCT02532855|DRUG|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
214776476|NCT05220904|DEVICE|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
214776477|NCT06703762|OTHER|He-Ne low level laser (LLL)|Patients in the experimental group will receive treatment with LLLT. The ulcer bed will be irradiated locally with red light (660 nm). The ulcer size and its depth will be used as the basis to calculate the duration of exposure needed to deliver 3-10 J/cm² for 15 to 20 minutes. The application will take place in 3 sessions per week for 4 weeks. Each patient will be asked to lie in a supine position with the ulcer easily exposed to the laser beam, and they will be instructed to wear laser glasses and avoid looking directly at the beam until the end of the session.
214776478|NCT06703762|OTHER|Conventional traditional treatment|All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
214776479|NCT03030482|PROCEDURE|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
214776480|NCT01903213|DRUG|bixalomer|Oral
214776481|NCT05458895|OTHER|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776482|NCT05458895|OTHER|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776483|NCT05458895|OTHER|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776484|NCT05458895|OTHER|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776485|NCT05458895|OTHER|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776486|NCT05458895|OTHER|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776487|NCT05458895|OTHER|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776488|NCT05458895|OTHER|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
214776489|NCT06313294|OTHER|Tracking application app|An app will be implemented for mobile monitoring in patients who use continuous postoperative ambulatory regional analgesia.
214776490|NCT06313294|OTHER|Telephone interview|Patients who use continuous postoperative outpatient regional analgesia will be followed up using the current traditional method of post-discharge telephone call.
214776491|NCT04590417|DRUG|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
214776492|NCT04648774|PROCEDURE|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
214776493|NCT04648774|PROCEDURE|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
214776496|NCT06236334|BEHAVIORAL|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
214776497|NCT04528992|OTHER|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
214776498|NCT04528992|OTHER|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
214776499|NCT00750009|OTHER|educational intervention|Patients receive a tailored intervention or generic information
214776500|NCT05731388|DIAGNOSTIC_TEST|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
214776501|NCT01644578|PROCEDURE|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
214776502|NCT01287780|DEVICE|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
214776503|NCT05578755|BEHAVIORAL|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
214776504|NCT05578755|BEHAVIORAL|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
214776505|NCT00802529|DRUG|Methylprednisolone|2 transtympanic injections at interval of two weeks.
214776506|NCT00802529|DRUG|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
214776507|NCT01757366|DRUG|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
214776508|NCT01757366|DRUG|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
214776509|NCT01041937|PROCEDURE|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
214776510|NCT01041937|PROCEDURE|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
214776511|NCT00444873|DRUG|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
214776512|NCT00803673|DRUG|100mcg|100mcg '719
214776513|NCT00803673|DRUG|500mcg|500mcg '719
214776514|NCT00803673|DRUG|1000mcg|1000mcg '719
214776515|NCT00803673|DRUG|Placebo|Placebo '719
214776516|NCT03751319|OTHER|CGA|Comprehensive Geriatric Assessment
214776517|NCT06673550|PROCEDURE|Intragastric balloon|Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.
214776518|NCT04323449|DEVICE|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
214776519|NCT03772184|PROCEDURE|Cervical inversion|inverting the cervical lip after delivery
214776520|NCT00267579|BEHAVIORAL|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
214776521|NCT02399059|PROCEDURE|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
214776522|NCT02399059|PROCEDURE|Normal saline lavage|Peritoneal irrigation with normal saline
214776523|NCT02120859|DEVICE|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
214776524|NCT02120859|DEVICE|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
214776525|NCT02793375|DRUG|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
214776526|NCT02793375|DRUG|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
214776527|NCT05931952|OTHER|Buteyko breathing technique|"Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
214776528|NCT05931952|OTHER|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
214776529|NCT00593099|DRUG|Bupropion|BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
214776530|NCT00593099|DRUG|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
214776531|NCT02627885|BEHAVIORAL|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
214776532|NCT02627885|OTHER|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
214776533|NCT04216537|DIAGNOSTIC_TEST|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
214776534|NCT00063700|PROCEDURE|reducing exposure to marketing pressures|
214776535|NCT00467337|PROCEDURE|Medial-Wedge Insole intervention|
214776536|NCT06538454|BEHAVIORAL|Resistance training|"The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions."
214776537|NCT02113969|DEVICE|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
214776538|NCT05537337|BEHAVIORAL|Multicomponent Intervention|"The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution"
214776539|NCT00783978|OTHER|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
214776540|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
214776541|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
214776542|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
214776543|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
214776544|NCT03530033|DRUG|Lidocaine|Local injection of lidocaine reduces muscle tremor
214776545|NCT01700751|DRUG|brentuximab vedotin|
214776546|NCT01472809|DRUG|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
214776547|NCT01472809|DRUG|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
214776548|NCT01907724|DRUG|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
214776549|NCT01907724|DRUG|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
214776550|NCT01907724|DRUG|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
214776551|NCT01907724|DRUG|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
214776552|NCT00039416|DRUG|imatinib mesylate|Given orally
214776553|NCT00039416|OTHER|laboratory biomarker analysis|Correlative studies
214776554|NCT06311539|OTHER|Theraband Strengthening Exercise Program|"Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00)."
214776555|NCT02869295|DRUG|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
214776556|NCT01084603|DRUG|Oral Nicotine|A new l mg oral nicotine product
214776557|NCT01084603|DRUG|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
214776558|NCT01084603|DRUG|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
214776559|NCT04959110|DIAGNOSTIC_TEST|Pharmacokinetic study|"* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter"
214776560|NCT02360410|BEHAVIORAL|Check Yourself App with Feedback|
214776561|NCT02483481|DIAGNOSTIC_TEST|shear wave ultrasound elastography|shear wave ultrasound elastography
214776562|NCT06173895|DRUG|LY3454738|Administered subcutaneously (SC)
214776563|NCT05720728|DIAGNOSTIC_TEST|collection of blood samples|For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
214776564|NCT03775148|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
214776565|NCT03906149|COMBINATION_PRODUCT|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
214776566|NCT03906149|COMBINATION_PRODUCT|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
214776567|NCT06176859|OTHER|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
214776568|NCT00482287|DRUG|MTR105|Intravenous administration, dose escalating (4 arms), single dose
214776569|NCT00001633|PROCEDURE|Coronary magnetic resonance angiography imaging|
214776570|NCT03103659|OTHER|personalised care plan|Quality of life assessement in elderly cancer patients
214776571|NCT00505128|PROCEDURE|Endoscopic sphincterotomy|procedure
214776572|NCT03447483|OTHER|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
214776573|NCT03028883|OTHER|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
214776574|NCT01918111|PROCEDURE|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
214776575|NCT01918111|DRUG|adenosine infusion treatment|Continue hypertensive medication
214776576|NCT06182007|PROCEDURE|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
214776577|NCT04629183|OTHER|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
214776578|NCT03533530|DIAGNOSTIC_TEST|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
214776579|NCT03533530|DIAGNOSTIC_TEST|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
214776580|NCT03533530|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
214776581|NCT03862625|DEVICE|a modular adaptive seating system|
214776582|NCT03862625|OTHER|home exercise program for scoliosis|
214776583|NCT06541782|BEHAVIORAL|Dyadic CAT-based Intervention|The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.
214776584|NCT06541782|BEHAVIORAL|Psycho-Educational Parent Counseling|This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
214776585|NCT06700954|OTHER|legume-rich Planetary Health Diet|legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein
214776586|NCT06700954|OTHER|control diet based on Western Diet low in legumes|diet based on the Western dietary pattern including animal protein sources (= control diet)
214776587|NCT01791127|DEVICE|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
214776588|NCT00520494|DRUG|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
214776589|NCT00002774|DRUG|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
214776590|NCT00002774|DRUG|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
214776591|NCT00002774|DRUG|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
214776592|NCT00002774|RADIATION|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
214776593|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
214776594|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
214776595|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
214776596|NCT01257529|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
214776597|NCT04870931|PROCEDURE|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
214776598|NCT02966574|DEVICE|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
214776599|NCT01307631|DRUG|Akt Inhibitor MK2206|Given PO
214776600|NCT01307631|OTHER|Laboratory Biomarker Analysis|Correlative studies
214776601|NCT05218031|BEHAVIORAL|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
214776602|NCT05182931|DRUG|Dabrafenib 75 MG|Refer arm description
214776603|NCT05182931|DRUG|Trametinib 2 MG|Refer arm description
214776604|NCT03471182|BEHAVIORAL|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
214776605|NCT03471182|DRUG|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
214776606|NCT03471182|RADIATION|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.
214776607|NCT03471182|OTHER|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
214776608|NCT03970382|BIOLOGICAL|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
214776609|NCT03970382|BIOLOGICAL|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
214776610|NCT03970382|BIOLOGICAL|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
214776611|NCT00422773|DRUG|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
214776612|NCT04167280|DRUG|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
214776613|NCT04167280|DRUG|placebo metered dose inhaler|matched MDI to deliver inactive drug
214776614|NCT00161330|DRUG|oral amoxicilline/clavulanic acid|
214776615|NCT00161330|DRUG|iv ceftriaxone|
214776616|NCT04977817|DIETARY_SUPPLEMENT|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
214776617|NCT00063596|DRUG|Vitamin A supplementation|
214776618|NCT04742816|DIAGNOSTIC_TEST|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
214776619|NCT04742816|DRUG|Iohexol|Iohexol clearance measurement
214776620|NCT02820935|DRUG|CC-220|
214776621|NCT02820935|DRUG|Rifampin|
214776622|NCT02820935|DRUG|Itraconazole|
214776623|NCT04440163|BIOLOGICAL|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
214776624|NCT04440163|BIOLOGICAL|Saline|Placebo
214776625|NCT04440163|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
214776626|NCT04440163|BIOLOGICAL|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
214776627|NCT06232369|DEVICE|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
214776628|NCT06232369|DEVICE|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
214776629|NCT02344914|DEVICE|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
214776630|NCT00106379|DRUG|Truvada (tenofovir DF + emtricitabine)|
214776631|NCT00106379|DRUG|Emtriva (emtricitabine)|
214776632|NCT00106379|DRUG|Viread (tenofovir DF)|
214776633|NCT02229487|OTHER|Oral glucose tolerance|
214776634|NCT02018042|DRUG|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
214776635|NCT06237699|OTHER|Digital ICU diary|A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
214776636|NCT02258607|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
214776637|NCT02258607|DRUG|Trametinib|Trametinib tablet administered orally once daily
214776638|NCT03151785|OTHER|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
214776639|NCT03151785|OTHER|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
214776640|NCT03151785|OTHER|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
214776641|NCT04456985|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
214776642|NCT04456985|DIETARY_SUPPLEMENT|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
214776643|NCT02656615|DRUG|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
214776644|NCT04276285|PROCEDURE|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
214776645|NCT04276285|PROCEDURE|US TAP|Subcostal TAP block will be performed after surgery under US guidance
214776646|NCT04835415|PROCEDURE|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
214776647|NCT04835415|PROCEDURE|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
214776648|NCT06102837|BIOLOGICAL|tumor vaccine|tumor vaccine produced by our team
214776649|NCT06102837|RADIATION|Radiotherapy|conventional treatment in clincial
214776650|NCT06102837|DRUG|Chemotherapy|conventional treatment in clinical
214776651|NCT06102837|PROCEDURE|Surgery|conventional treatment in clinical
214776652|NCT03860571|DRUG|Placebo|Oral tablet
214776653|NCT03860571|DRUG|BT-11|Oral tablet
214776654|NCT05107154|BEHAVIORAL|Dialectical Behavioural Therapy|DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
214776655|NCT03412461|OTHER|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
214776656|NCT03412461|OTHER|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
214776657|NCT05741983|PROCEDURE|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
214776658|NCT05741983|DEVICE|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
214776659|NCT06330077|DRUG|Ifenprodil|Treatment administration
214776660|NCT06330077|DRUG|Placebo|Treatment administration
214776661|NCT05525637|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
214776662|NCT05525637|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
214776663|NCT05525637|DRUG|Placebo|Match placebo tablets, once daily in the evening
214776664|NCT01954082|DRUG|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
214776665|NCT01954082|DRUG|Placebo|% glucose(dextrose)
214776666|NCT01491282|OTHER|Enabling and disabling VNS|No intervention
214776667|NCT04629131|BIOLOGICAL|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
214776668|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 1, given once
214776669|NCT04629131|BIOLOGICAL|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
214776670|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 2, given once
214776671|NCT04629131|BIOLOGICAL|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
214776672|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 3, given once
214776673|NCT04629131|BIOLOGICAL|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
214776674|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 4, given once
214776675|NCT04405674|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
214776676|NCT04405674|DRUG|Carboplatin|Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
214776677|NCT04405674|DRUG|Pemetrexed|Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
214776678|NCT04405674|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
214776679|NCT04405674|DRUG|Nab paclitaxel|Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
214776680|NCT03804931|PROCEDURE|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
214776681|NCT03804931|PROCEDURE|Infusion of Saline|Infusion of Saline
214776682|NCT03804931|DRUG|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
214776683|NCT05585268|OTHER|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
214776684|NCT02190344|DEVICE|8-channel paddle coil|MRI Coil
214776685|NCT03213080|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
214776686|NCT03077594|DEVICE|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
214776687|NCT03077594|OTHER|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
214776688|NCT03077594|DEVICE|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
214776689|NCT04670029|OTHER|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
214776690|NCT02299674|OTHER|Level overground ambulation|
214776691|NCT03520621|OTHER|No intervention|no intervention
214776692|NCT00077779|DRUG|Adalimumab|
214776693|NCT01145703|DIETARY_SUPPLEMENT|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
214776694|NCT01145703|DIETARY_SUPPLEMENT|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
214776695|NCT01145703|OTHER|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
214776696|NCT01145703|OTHER|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
214776697|NCT02910310|OTHER|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
214776698|NCT01787214|DIETARY_SUPPLEMENT|Full dose|20% of daily energy needs supplied by walnuts
214776699|NCT01787214|DIETARY_SUPPLEMENT|Half dose|10% of daily energy needs supplied by walnuts
214776700|NCT01787214|DIETARY_SUPPLEMENT|Control|Walnut free meals
214776701|NCT02873481|BEHAVIORAL|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
214776702|NCT02552381|OTHER|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
214776703|NCT02346981|BEHAVIORAL|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
214776704|NCT02154113|DEVICE|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
214776705|NCT02154113|DEVICE|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
214776706|NCT03165890|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
214776707|NCT03165890|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
214776708|NCT03189264|PROCEDURE|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
214776709|NCT02408406|OTHER|Communication Intervention|Use PatientCareAnywhere system
214776710|NCT02408406|OTHER|Educational Intervention|Use PatientCareAnywhere system
214776711|NCT02408406|OTHER|Internet-Based Intervention|Use PatientCareAnywhere system
214776712|NCT02408406|OTHER|Quality-of-Life Assessment|Ancillary studies
214776713|NCT02408406|OTHER|Questionnaire Administration|Ancillary studies
214776714|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
214776715|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
214776716|NCT01843907|BEHAVIORAL|Empowerment|To give patients the necessary resources to take care of their own health
214776717|NCT01843907|OTHER|Conversation with nurse|To find out, if the nurse, using her ....
214776718|NCT03899337|DRUG|Acalabrutinib|100mg capsule, PO, BD
214776719|NCT03899337|DRUG|Cyclophosphamide|750mg/m\^2, IV bolus
214776720|NCT03899337|DRUG|Doxorubicin|50mg/m\^2, IV bolus
214776721|NCT03899337|DRUG|Vincristine|1.4mg/m\^2, IV infusion
214776722|NCT03899337|DRUG|Prednisolone|40mg/m\^2, PO, OD
214776723|NCT03899337|DRUG|Rituximab|375mg/m\^2, IV infusion
214776724|NCT01700920|PROCEDURE|bone marrow aspirate|
214776725|NCT00707174|DRUG|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
214776726|NCT00707174|DRUG|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
214776727|NCT00139386|DRUG|Candesartan|Candesartan Cilexetil (4-12 mg per day)
214776728|NCT01453374|DRUG|VIVITROL 380mg|380 mg IM injection given once monthly
214776729|NCT02227537|DEVICE|Providence Nighttime Bracing System|Providence Nighttime Bracing System
214776730|NCT02227537|DEVICE|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
214776731|NCT03155828|DEVICE|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
214776732|NCT03283865|DIAGNOSTIC_TEST|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
214776733|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
214776734|NCT03348501|OTHER|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
214776735|NCT04506346|DIAGNOSTIC_TEST|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
214776736|NCT04441203|DEVICE|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
214776737|NCT02163629|BEHAVIORAL|Stress management|
214776738|NCT02566967|DRUG|tofacitinib|oral tofacitinib will be taken 2 times daily
214776739|NCT06702254|BEHAVIORAL|Experimental: Psychological manualized treatment with CBT and ACT|The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.
214776740|NCT06702254|OTHER|Treatment as usual|This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
214776741|NCT06424704|DIAGNOSTIC_TEST|Microbiological culture|Samples taken from chronic suppurative otitis media patients in the Medical Microbiology Laboratory of Selçuk University Faculty of Medicine will be planted in 5% sheep blood Columbia agar, eosin methylene blue agar and saboraud dextrose agar, and the media will be incubated at 37oC for 24-48 hours. Growing bacteria and fungi were examined using traditional methods \[Gram staining, catalase test, coagulase test, bacitracin disk, PYR test (L-pyrrolidonyl-β-naphthylamide), oxidase test, IMViC test, lactophenol cotton blue, etc.\] and VITEK 2 (bioMerieux, France).
214776742|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
214776743|NCT02011516|DRUG|Baclofen|
214776744|NCT02011516|BEHAVIORAL|Psychosocial|
214776745|NCT02011516|DRUG|Placebo|
214776746|NCT05614466|OTHER|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
214776747|NCT03715660|DIAGNOSTIC_TEST|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
214776748|NCT06476743|OTHER|Sensory Integration Therapy|This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
214776749|NCT06476743|OTHER|Balance Board Training|This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
214776750|NCT01825616|DIETARY_SUPPLEMENT|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
214776751|NCT01825616|OTHER|Placebo|Mushroom powder without vitamin D2
214776752|NCT06567938|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
214776753|NCT02236390|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
214776754|NCT02236390|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
214776755|NCT00709735|DRUG|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
214776756|NCT00709735|DRUG|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
214776757|NCT03939403|DRUG|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
214776758|NCT04547478|DIAGNOSTIC_TEST|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
214776759|NCT06422156|RADIATION|Stereotactic body radiation|Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
214776760|NCT06422156|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
214776761|NCT06422156|DRUG|mono-chemotherapy|Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
214776762|NCT00003692|PROCEDURE|therapeutic thoracoscopy|
214776763|NCT00003692|PROCEDURE|video-assisted surgery|
214776764|NCT00547807|OTHER|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
214776765|NCT00547807|OTHER|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
214776766|NCT02998515|DEVICE|Companion (Liquid oxygen device)|
214776767|NCT02998515|DEVICE|Activox (concentrator)|
214776768|NCT05430009|RADIATION|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
214776769|NCT05430009|DRUG|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
214776770|NCT05652816|PROCEDURE|Split-thickness skin graft|Transplantation of autologous skin to burn area
214776771|NCT05652816|BIOLOGICAL|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
214776772|NCT05652816|BIOLOGICAL|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
214776773|NCT00666718|DRUG|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
214776774|NCT00666718|DRUG|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
214776775|NCT00666718|DRUG|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
214776776|NCT00233350|DEVICE|use of navigated 3D ultrasound during surgery|
214776777|NCT00654446|DRUG|Rosuvastatin|
214776778|NCT00654446|DRUG|Simvastatin|
214776779|NCT05467449|DEVICE|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
214776780|NCT04583631|PROCEDURE|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
214776781|NCT00569335|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
214776782|NCT01498900|DRUG|repaglinide|Prescription according to the product labelling at the physicians' discretion
214776783|NCT00657917|DRUG|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
214776784|NCT00689208|DRUG|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
214776785|NCT00689208|DRUG|Physostigmine|0,12ug/kg/min
214776786|NCT00689208|DRUG|Placebo Sodium|
214776787|NCT02709122|DEVICE|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
214776788|NCT02492295|DRUG|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
214776789|NCT03015909|DRUG|Somatropin|
214776790|NCT00810615|OTHER|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
214776791|NCT00810615|OTHER|Sham treatment|
214776792|NCT02525562|DEVICE|Triathlon Total Knee System with X3 insert|Total knee replacement
214776793|NCT02525562|DEVICE|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
214776794|NCT02525562|DEVICE|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
214776795|NCT02525562|PROCEDURE|Total Knee Replacement|Total Knee Replacement
214776796|NCT02525562|PROCEDURE|Partial Knee Resurfacing|Partial Knee Resurfacing
214776797|NCT02567266|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
214776798|NCT02567266|BEHAVIORAL|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
214776799|NCT02567266|BEHAVIORAL|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
214776800|NCT03235531|DRUG|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
214776801|NCT03235531|DRUG|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
214776802|NCT05036239|OTHER|Eccentric biceps curls|10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
214776803|NCT03179501|DRUG|NP001|NP001
214776804|NCT03179501|DRUG|Placebo|Normal saline
214776805|NCT00343122|PROCEDURE|echocardiography for intrapulmonary vasodilatation|
214776806|NCT04501549|PROCEDURE|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
214776807|NCT01225315|DRUG|Placebo|Matching placebo administered orally twice daily
214776808|NCT01225315|DRUG|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
214776809|NCT00243815|DRUG|ibuprofen|
214776810|NCT03402620|DRUG|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
214776811|NCT03644459|BIOLOGICAL|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
214776812|NCT01255696|BIOLOGICAL|ALV003|
214776813|NCT01255696|BIOLOGICAL|ALV003 placebo|
214776814|NCT02822807|BIOLOGICAL|Blood sampling|
214776815|NCT02813707|OTHER|QoL questionnaire regarding the long term complication|Micronutrients evaluation
214776816|NCT02572973|OTHER|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
214646819|NCT04981275|OTHER|No intervention study|This observational study will only collect data, not provide any intervention to participants.
214646820|NCT04697329|DRUG|Preincisional infiltration with levobupivacaine|Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
214646821|NCT04846361|OTHER|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
214646822|NCT04846361|OTHER|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
214646823|NCT00434044|DRUG|Enbrel (etanercept)|
214646824|NCT02668367|DRUG|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
214646825|NCT02668367|DRUG|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
214646826|NCT02568358|OTHER|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
214646827|NCT01780792|OTHER|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
214646828|NCT05252793|BEHAVIORAL|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
214646829|NCT05848661|DEVICE|AUDISSEE|AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
214646830|NCT05848661|DEVICE|Placebo|The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
214776817|NCT04067024|PROCEDURE|Local anesthesia made by surgeon|infiltration with local anesthetics
214776818|NCT04067024|PROCEDURE|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
214776819|NCT03313479|DRUG|Dexmedetomidine|Dexmedetomidine will be given with GS
214776820|NCT03963999|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
214776821|NCT03963999|DRUG|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
214776822|NCT04024085|OTHER|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
214776823|NCT05921331|DEVICE|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
214776824|NCT05921331|OTHER|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
214776825|NCT06410040|DRUG|Lorlatinib|lolatinib 100mg qd po
214776826|NCT02343562|DIETARY_SUPPLEMENT|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
214776827|NCT02343562|DIETARY_SUPPLEMENT|Placebo|Multivitamin off-the-counter.
214776828|NCT03090919|BIOLOGICAL|Platelet transfusion|
214776829|NCT03090919|OTHER|Saline|
214776830|NCT04676919|DEVICE|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
214776831|NCT04676919|DEVICE|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
214776832|NCT04676919|DEVICE|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
214776833|NCT02197754|OTHER|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
214776834|NCT03896919|DIAGNOSTIC_TEST|HLA-DQ by luminex technology in kidney transplantation|HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
214776835|NCT05589428|DIETARY_SUPPLEMENT|Low sodium bread|Bread low in sodium
214776836|NCT05589428|OTHER|Placebo|Normal bread from bakery
214776837|NCT02883387|OTHER|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
214776838|NCT02883387|OTHER|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
214776839|NCT05529628|DIAGNOSTIC_TEST|Cytokine levels|Preoperative cytokine levels of the patients
214776840|NCT01077531|DRUG|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
214776841|NCT01077531|DRUG|Matching placebo|Matching placebo for intravenous infusion
214776842|NCT01448265|PROCEDURE|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
214776843|NCT03113825|DEVICE|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
214776844|NCT03113825|DRUG|AVB-620|AVB-620 will be administered IV before the surgical procedure.
214776845|NCT02139605|PROCEDURE|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
214776846|NCT02643966|DEVICE|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
214776847|NCT01866982|PROCEDURE|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
214776848|NCT01866982|PROCEDURE|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
214776849|NCT04368325|DIAGNOSTIC_TEST|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
214776850|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
214776851|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
214776852|NCT00213213|DRUG|Sucrose|
214776853|NCT00764049|DEVICE|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
214776854|NCT01406275|DRUG|Amoxicillin and clavulanate|
214776855|NCT01904552|DEVICE|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
214776856|NCT05312255|BEHAVIORAL|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
214776857|NCT05312255|DRUG|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
214776858|NCT05312255|DRUG|Propranolol|Given PO
214776859|NCT05312255|OTHER|Quality-of-Life Assessment|Ancillary studies
214776860|NCT05312255|OTHER|Questionnaire Administration|Ancillary studies
214776861|NCT05312255|OTHER|Resistance Training|Undergo strength training for 6 months
214776862|NCT05312255|OTHER|Short-Term Fasting|Participate in intermittent fasting
214776863|NCT04608084|BIOLOGICAL|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
214776864|NCT02197169|DRUG|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
214776865|NCT02197169|DRUG|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
214776866|NCT00459589|BEHAVIORAL|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
214776867|NCT00459589|BEHAVIORAL|usual nutritional care|usual nutritional care
214776868|NCT04466774|DIAGNOSTIC_TEST|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
214776869|NCT04466774|DEVICE|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
214776870|NCT03115060|DRUG|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
214776871|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
214776872|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
214776873|NCT02339428|DRUG|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
214776874|NCT02339428|DRUG|Placebo|Inactive pill manufactured to mimic diclofenac tablet
214776875|NCT03343145|BIOLOGICAL|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
214776876|NCT03343145|BIOLOGICAL|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
214776877|NCT00677677|BIOLOGICAL|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
214776878|NCT01832688|OTHER|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
214776879|NCT06701396|DRUG|Tasimelteon|Oral capsule
214776880|NCT06701396|DRUG|Placebo|Oral capsule
214776881|NCT00438035|PROCEDURE|ECG spectral|
214776882|NCT00081835|DRUG|NP-016 Vaccine Immune Globulin (IV-VIG)|
214776883|NCT03923816|DRUG|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
214776884|NCT06479746|BEHAVIORAL|Emotional support|Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
214776885|NCT01578252|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
214776886|NCT01578252|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
214776887|NCT06338800|BEHAVIORAL|One session exposure with Virtual Reality|Participants will receive one session exposure with virtual reality from their therapists.
214776888|NCT00086931|DRUG|capecitabine|oral dose escalating, twice daily.
214776889|NCT00086931|DRUG|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
214776890|NCT00086931|PROCEDURE|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
214776891|NCT00086931|PROCEDURE|neoadjuvant therapy|chemotherapy and radiation prior to surgery
214776892|NCT00086931|RADIATION|radiation therapy|once daily 5 days a week for 5.5 weeks
214776893|NCT03756207|PROCEDURE|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
214776894|NCT04698278|DEVICE|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
214776895|NCT04493554|DRUG|Vasopressin|Administration of vasopressin (20 IU) intranasally
214776896|NCT04493554|DRUG|Placebo|Administration of placebo intranasally
214776897|NCT04816162|DRUG|ketofol|prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
214776898|NCT04816162|DRUG|dexmedetomidine|2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
214776899|NCT04816162|OTHER|normal saline|normal saline 0.9% in a syringe pump
214776900|NCT03611751|DRUG|BMS-986165|Specified dose on specified days
214776901|NCT03611751|OTHER|Placebo|Specified dose on specified days
214776902|NCT03611751|DRUG|Apremilast|Specified dose on specified days
214776903|NCT05303480|DRUG|Chlormethine|Chlormethine gel 0.016%
214776904|NCT05224518|BEHAVIORAL|elastic band training|elastic band training include stretching exercises
214776905|NCT02306434|BEHAVIORAL|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
214776906|NCT02306434|OTHER|Standard care-counselling|Standard care (Counselling by midwives)
214776907|NCT02441179|OTHER|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
214776908|NCT02441179|OTHER|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
214776909|NCT02441179|OTHER|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
214776910|NCT02702271|DEVICE|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
214776911|NCT02462239|OTHER|Whole-body FDG PET-CT|
214776912|NCT00297206|DRUG|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
214776913|NCT03091400|DRUG|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
214776914|NCT03091400|DRUG|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
214776915|NCT02593084|BEHAVIORAL|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
214776916|NCT02593084|BEHAVIORAL|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
214776917|NCT00902252|DEVICE|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
214776918|NCT00902252|DEVICE|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
214776919|NCT00902252|DEVICE|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
214776920|NCT05955235|OTHER|Not Applicable(Observation Study)|Not Applicable(Observation Study)
214776921|NCT02588742|DIETARY_SUPPLEMENT|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
214776922|NCT02588742|DIETARY_SUPPLEMENT|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
214776923|NCT00064935|PROCEDURE|Endometrial biopsy|
214776924|NCT00393770|DRUG|L-acetylcarnitine|250-500 mg/kg/die.
214776925|NCT04690387|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
214776926|NCT04690387|OTHER|GM-CSF|GM-CSF as an adjuvant
214776927|NCT04529161|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
214776928|NCT04529161|DIETARY_SUPPLEMENT|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
214776929|NCT05969028|DEVICE|igel|First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
214776930|NCT05969028|PROCEDURE|Compression Rate|Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
214776931|NCT01257828|DRUG|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
214776932|NCT01257828|DRUG|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
214776933|NCT00667498|DRUG|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
214776934|NCT00667498|DRUG|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
214776935|NCT01319305|DEVICE|FinESS Sinus Treatment|balloon sinuplasty
214776936|NCT04416672|OTHER|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~* the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~* the Hospital Anxiety and Depression Scale (HADS)~* The Patients' Global Impression of Change (PGIC) Scale."
214776937|NCT00958685|DIETARY_SUPPLEMENT|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
214776938|NCT00958685|DIETARY_SUPPLEMENT|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
214776939|NCT01003548|DEVICE|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
214776940|NCT01003548|DEVICE|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
214776941|NCT00995540|DRUG|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
214776942|NCT00995540|DRUG|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
214776943|NCT00995540|DRUG|Placebo|Placebo tid subcutaneous injection for 12 weeks
214776944|NCT02044965|OTHER|Antibiotic|2 mg/kg per day via oral ingestion.
214776945|NCT02044965|DRUG|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
214776946|NCT01359072|OTHER|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
214776947|NCT03887819|DIAGNOSTIC_TEST|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
214776948|NCT04517981|BEHAVIORAL|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
214776949|NCT04517981|OTHER|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
214776950|NCT06567795|DEVICE|Hemotag|Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
214776951|NCT02780921|PROCEDURE|prehabilitation|
214776952|NCT02780921|OTHER|nutritional support|
214776953|NCT03319381|BEHAVIORAL|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
214776954|NCT02620319|DEVICE|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
214776955|NCT00051636|DRUG|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
214776956|NCT00051636|DRUG|Risedronate|Oral risedronate 30 mg capsules.
214776957|NCT00051636|DRUG|Placebo to Risedronate|Oral placebo of risedronate capsules.
214776958|NCT00051636|DRUG|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
214776959|NCT00051636|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
214776960|NCT04495192|GENETIC|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
214776961|NCT01426321|OTHER|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
214776962|NCT06282666|PROCEDURE|Spinal anesthesia|Before the beginning of surgery, all patients will be anesthetized with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 1.5 - 2.5 mL solution. A pencil point spinal needle will be used.
214776963|NCT06282666|PROCEDURE|lumbar erector spinae plane block|Investigators will perform the lumbar ESPB under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, we will leave a catheter in the ESP. Then, we used 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL.
214776964|NCT06282666|PROCEDURE|Epidural analgesia|After identifying the epidural space and spinal anesthesia (combined technique), a catheter will be placed in the epidural space. Investigators will give an epidural catheter a test dose of 2% lidocaine (2 mL). At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL).
214776965|NCT06282666|PROCEDURE|patient-controlled analgesia|Each participant will receive a pump with oxycodone (1mg/ml) using a patient-controlled analgesia (PCA) technique, a bolus of 1 mL, and a lockout of 5 minutes for the first postoperative day.
214776966|NCT06282666|DIAGNOSTIC_TEST|Timed Up and Go test|Investigators will measure the time the patient took to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while rotating 180 degrees. We will assess the patient before the surgery and 24 and 48 hours after hip replacement.
214776967|NCT06282666|DIAGNOSTIC_TEST|neuropathic pain symptom inventory|The Neuropathic Pain Symptom Inventory (0-100; 0 denotes no pain, 100 the most severe pain) will be evaluated before the surgery and three and six months following the procedure.
214776968|NCT06282666|DIAGNOSTIC_TEST|Lovett test|A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
214776969|NCT06282666|DIAGNOSTIC_TEST|Visual analog scale|Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.
214776970|NCT06282666|DIAGNOSTIC_TEST|Quality of Recovery 40|Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.
214776971|NCT06282666|DIAGNOSTIC_TEST|Ability to sit, stand upright, and walk|A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
214776972|NCT02528422|DRUG|Acyl-Ghrelin|
214776973|NCT04367922|BEHAVIORAL|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
214776974|NCT01669668|PROCEDURE|radiofrequency ablation|Undergo RFA
214776975|NCT01669668|PROCEDURE|laparoscopy|Undergo laparoscopic ultrasound
214776976|NCT02015468|OTHER|Early mobilization|Early weightbearing and physiotherapy
214776977|NCT02015468|OTHER|Late mobilization|Late mobilization, none-weightbearing and home exercises
214776978|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
214776979|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
214776980|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
214776981|NCT00862888|DRUG|PF-00446687|Single 200mg dose as an oral solution
214776982|NCT00862888|DRUG|Placebo|Placebo for oral solution
214776983|NCT00862888|DRUG|Placebo|Placebo for tablet
214776984|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
214776985|NCT00862888|DRUG|PF-00446687|Single 125 mg dose as an oral solution
214776986|NCT00862888|DRUG|PF-00446687|Single 175 mg dose as an oral solution
214776987|NCT00862888|DRUG|PF-00446687|Single 20 mg dose as an oral solution
214776988|NCT00862888|DRUG|Placebo|Placebo for oral solution
214776989|NCT00862888|DRUG|Placebo|Placebo for tablet
214776990|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
214776991|NCT04810507|DRUG|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
214776992|NCT00479765|DRUG|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
214776993|NCT02105831|OTHER|Contrast ultrasound skeletal muscle perfusion imaging|1\. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
214776994|NCT00348569|DEVICE|64 Channel VCT|
214776995|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
214776996|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid|Ascorbic acid
214776997|NCT02580201|BIOLOGICAL|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
214776998|NCT03056001|DRUG|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
214776999|NCT03056001|DRUG|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
214777000|NCT00177099|DRUG|FK506, GP11046, GP11511|
214777001|NCT05889026|DEVICE|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
214777002|NCT05889026|PROCEDURE|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
214777003|NCT01836003|OTHER|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women"
214777004|NCT03757052|DIAGNOSTIC_TEST|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
214777005|NCT05241899|DRUG|Fruquintinib + RC48|Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
214777006|NCT01364298|DRUG|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram \[mg\] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
214777007|NCT01364298|DRUG|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
214777008|NCT02869828|DEVICE|Monitoring by arterial catheter and Spot-on|
214777009|NCT02869828|DEVICE|Monitoring by oesophagal probe and Spot-on|
214777010|NCT04162730|OTHER|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
214777011|NCT06146686|DEVICE|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
214777012|NCT06146686|DEVICE|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
214777013|NCT04895228|PROCEDURE|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
214777014|NCT01745484|OTHER|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
214777015|NCT06542770|DEVICE|Early implant of cardiac monitor|ICM implant 3-4 days after the stroke and prior to discharge. All devices (Abbott Confirm or Jot) were implanted subcutaneously under local anaesthesia in the left chest region and programmed with an specific algorithm for AF detection set at 30 seconds for detection. All patients were included in remote monitoring system (Merlin), which was programmed to send alerts in case of registering episodes qualifying for AF detection, and a monthly routine registration. All ICM recordings were reviewed by a specialized cardiologist.
214777016|NCT00294632|DRUG|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
214777017|NCT00294632|DRUG|Rituximab|375 mg/m\^2 By Vein Weekly for 4 Weeks
214777018|NCT06439264|OTHER|bentonite clay gel with hydroxyapatite|bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
214777019|NCT05959707|BIOLOGICAL|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
214777020|NCT05959707|BIOLOGICAL|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
214777021|NCT05959707|BIOLOGICAL|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
214777022|NCT01162018|PROCEDURE|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
214777023|NCT01162018|OTHER|placebo|
214777024|NCT02533388|DEVICE|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
214777025|NCT02533388|DEVICE|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
214777026|NCT04064333|DEVICE|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
214777027|NCT02726737|DRUG|sodium bicarbonate|
214777028|NCT02726737|DRUG|Lidocaine|
214777029|NCT02726737|DRUG|sterile distilled water|
214777030|NCT00344526|DRUG|Melphalan|
214777031|NCT00344526|DRUG|Dexamethasone|
214777032|NCT00344526|PROCEDURE|Autologous stem cell transplantation|
214777033|NCT06157489|OTHER|Kinesio tape|Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
214777034|NCT03707522|BEHAVIORAL|Growth mindset|10 minute interactive article describing neuroplasticity
214777035|NCT03707522|BEHAVIORAL|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
214777036|NCT03707522|BEHAVIORAL|Control|10 minute interactive article describing activity scheduling
214777037|NCT06362304|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
214777038|NCT05980858|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate|Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
214777039|NCT05980858|OTHER|Placebo|Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
214777040|NCT06375837|DEVICE|an alkasite-based restorative material|Cention N
214777041|NCT06375837|DEVICE|hybrid resin composite|Gradia Direct Anterior
214777042|NCT06375837|DEVICE|a highly filled flowable resin composite|G-aenial Universal Flo
214777043|NCT02020655|OTHER|Shear- force model|Shear- force model
214777044|NCT01528046|DRUG|Vincristine|Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
214777045|NCT01528046|DRUG|Irinotecan|Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
214777046|NCT01528046|DRUG|Temozolomide|Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
214777047|NCT01528046|DRUG|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
214777048|NCT06564337|DEVICE|Surveyed zirconia crown|Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
214777049|NCT06110221|OTHER|Periodontal clinical measurements, GCF and saliva sampling|"Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
214777050|NCT00420849|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
214777051|NCT00420849|DRUG|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
214777052|NCT05106998|DEVICE|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
214777053|NCT04528277|DRUG|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
214777054|NCT01548183|BEHAVIORAL|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
214777055|NCT04287452|OTHER|Control|Control
214777056|NCT04287452|OTHER|Dog Therapy|Exposure to certified therapy dogs and their handler.
214777057|NCT04354402|OTHER|No intervention|No intervention
214777058|NCT00261937|DRUG|Inhaled Furosemide vs Placebo (Normal Saline)|
214777059|NCT03360526|DEVICE|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
214777060|NCT03360526|PROCEDURE|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
214777061|NCT02512991|OTHER|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
214777062|NCT02946619|BEHAVIORAL|Self-Regulation Condition|
214777063|NCT02946619|BEHAVIORAL|Enhanced self-Regulation Condition|
214777064|NCT00659581|DRUG|Telmisartan|Oral administration
214777065|NCT01190826|DRUG|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
214777066|NCT01190826|DRUG|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
214777067|NCT01190826|DRUG|Placebo|Placebo administered once by inhalation
214777068|NCT01337609|DRUG|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
214777069|NCT01337609|OTHER|Placebo (sugar pill)|1 pill daily for 60 days
214777070|NCT01337609|OTHER|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
214777071|NCT05854277|OTHER|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
214777072|NCT01010321|DEVICE|confocal microscopy|non-invasive imaging
214777073|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
214777074|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
214777075|NCT01963221|RADIATION|fludeoxyglucose(18f)|
214777076|NCT01963221|OTHER|blood sample|
214777077|NCT01963221|OTHER|cardiac and aortic magnetic resonance imaging|
214777078|NCT01963221|OTHER|carotid femoral pulse wave velocity|
214777079|NCT01963221|RADIATION|positron emission tomography|
214777080|NCT01963221|RADIATION|computed tomography|
214777081|NCT03162354|OTHER|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
214777082|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
214777083|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
214777084|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 2.5-minute intervals|Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
214777085|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 5-minute intervals|Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
214777086|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
214777087|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
214777088|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
214777089|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
214777090|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
214777091|NCT06255730|PROCEDURE|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214777092|NCT06255730|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214777093|NCT06566924|OTHER|Control|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'.
214777094|NCT06566924|OTHER|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made availa
214777095|NCT04280939|PROCEDURE|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
214777096|NCT03394274|OTHER|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
214777097|NCT00105352|PROCEDURE|Mixed Meal Tolerance Test|
214777098|NCT00105352|PROCEDURE|Glucagon Stimulation Test|
214777099|NCT00881452|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
214777100|NCT00881452|DRUG|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
214777101|NCT00743119|DRUG|Placebo capsules|Placebo capsules
214777102|NCT00743119|DRUG|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
214777103|NCT00743119|DRUG|Low dose Dronabinol|Dronabinol 10mg
214777104|NCT00743119|DRUG|High dose Dronabinol|Dronabinol 20mg
214777105|NCT00743119|DRUG|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
214777106|NCT00743119|DRUG|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
214777107|NCT03334916|DRUG|YMC026|YMC026 20mL TID
214777108|NCT03334916|DRUG|Placebo|Placebo 20mL TID
214777109|NCT02001870|PROCEDURE|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
214777110|NCT02001870|PROCEDURE|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
214777111|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
214777112|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
214777113|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
214777114|NCT04241185|DRUG|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
214777115|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
214777116|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
214777117|NCT04241185|RADIATION|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
214777118|NCT04241185|DRUG|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
214777119|NCT04241185|DRUG|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
214777120|NCT04241185|DRUG|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
214777121|NCT04241185|DRUG|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
214777122|NCT04241185|DRUG|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
214777123|NCT05887674|BEHAVIORAL|Diet intervention|Low inflammatory-index diet
214777124|NCT05887674|BEHAVIORAL|Exercise|Guided muscle strength training and stretching exercises
214777125|NCT05887674|BEHAVIORAL|Cognitive training|Cognitive training will be implemented in person
214777126|NCT06465706|DEVICE|LAmbre investigational device|Randomized 1:1 to either experimental group or control group.
214777127|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
214777128|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
214777129|NCT06153667|DEVICE|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
214777130|NCT05151172|DEVICE|endovascular thrombectomy (EVT)|minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
214777131|NCT05151172|OTHER|Standarad medical care|Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
214777132|NCT04816877|DRUG|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
214777133|NCT05927207|OTHER|TRIP|TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
214777134|NCT05938335|GENETIC|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
214777135|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
214777136|NCT06541613|DRUG|local anesthetic injection (bupivacaine)|The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
214777137|NCT06541613|OTHER|normal saline injection|the control group will receive 30ml of normal saline bilaterally into the external oblique intercostal plane on both sides
214777138|NCT00727298|BIOLOGICAL|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
214777139|NCT03717974|OTHER|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
214777140|NCT03717974|OTHER|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
214777141|NCT01309828|DRUG|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
214777142|NCT01309828|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
214777143|NCT00295620|DRUG|Anastrozole|1mg tablet daily
214777144|NCT04179474|DRUG|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
214777145|NCT04179474|DRUG|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
214777146|NCT04179474|DRUG|Galcanezumab|2 SC injections of galcanezumab 120 mg \[Intervention C\].
214777147|NCT02643810|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
214777148|NCT01357785|PROCEDURE|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
214777149|NCT02556632|DRUG|Curcumin-based Gel|Applied topically
214777150|NCT02556632|PROCEDURE|Dermatologic Complications Management|Apply HPR Plus topically
214777151|NCT02556632|OTHER|Laboratory Biomarker Analysis|Correlative studies
214777152|NCT02556632|OTHER|Placebo|Apply placebo gel topically
214777153|NCT02556632|OTHER|Questionnaire Administration|Ancillary studies
214777154|NCT04175652|BEHAVIORAL|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
214777155|NCT03934437|BEHAVIORAL|mLTCR|mHealth-enhanced Linkage to Care and Retention
214777156|NCT03934437|BEHAVIORAL|LTCR|Linkage and Retention Services (Standard-of-Care)
214777157|NCT02574260|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection.
214777158|NCT01397656|PROCEDURE|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
214777159|NCT01397656|PROCEDURE|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
214777160|NCT00057785|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
214777161|NCT00057785|DRUG|fluorouracil|1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
214777162|NCT00057785|RADIATION|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
214777163|NCT04718272|PROCEDURE|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
214777164|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
214777165|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
214777166|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
214777167|NCT05278949|OTHER|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
214777168|NCT04561934|DRUG|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
214777169|NCT04561934|OTHER|resin modified glassionomer cement|resin modified glassionomer cement
214777170|NCT02630004|DRUG|Melatonin oral gel 3%|
214777171|NCT02630004|DRUG|Placebo oral gel|
214777172|NCT04501263|BEHAVIORAL|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
214777173|NCT06541912|PROCEDURE|conventional implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
214777174|NCT06541912|PROCEDURE|UV implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
214777175|NCT02414490|DRUG|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
214777176|NCT01155635|DRUG|Carvedilol|Use of Carvedilol with any dose
214777177|NCT01155635|DRUG|No Carvedilol|No use of Carvedilol
214777178|NCT04056091|PROCEDURE|Back rub stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
214777179|NCT04056091|PROCEDURE|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
214777180|NCT06536920|DIAGNOSTIC_TEST|Migraine screening questionnaire|Screening test
214777181|NCT06540274|PROCEDURE|lumbar surgery|Discectomy, lumbar fusion or laminectomy
214777182|NCT06542471|DEVICE|Dual intramedullary nailing|\- Elastic nailing for radius under image guidance through distal entry point and physeal sparing technique.
214777183|NCT06542471|DEVICE|Dual plating|\- ORIF for radius done first through volar approach.
214777184|NCT02936479|DRUG|C1-INH (Berinert)|
214777185|NCT06536946|BIOLOGICAL|Immunohistochemical staining|Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
214777186|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
214777187|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
214777188|NCT00046020|DRUG|Venlafaxine ER|
214777189|NCT01552629|DRUG|QGE031|
214777190|NCT01552629|DRUG|Placebo|
214777191|NCT01552629|DRUG|Cyclosporine A|
214777192|NCT03841903|DIAGNOSTIC_TEST|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
214777193|NCT05445037|DEVICE|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
214777194|NCT05445037|DEVICE|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
214777195|NCT01658215|DRUG|V0116 transdermal patch (Test treatment )|
214777196|NCT01658215|DRUG|Nicotine transdermal patch (Reference treatment )|
214777197|NCT05065242|BEHAVIORAL|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
214777198|NCT05287802|OTHER|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
214777199|NCT05287802|OTHER|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
214777200|NCT00156286|DRUG|Gleevec|
214777201|NCT03368872|OTHER|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
214777202|NCT03368872|OTHER|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
214777203|NCT03368872|OTHER|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
214777204|NCT02437539|DRUG|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
214777205|NCT02437539|DEVICE|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
214777206|NCT05811260|OTHER|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
214777207|NCT05811260|OTHER|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
214777208|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
214777209|NCT06025786|COMBINATION_PRODUCT|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
214777210|NCT01413685|OTHER|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
214777211|NCT01164137|BEHAVIORAL|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
214777212|NCT00241319|DRUG|R89674 (generic name not yet established)|
214777213|NCT04523831|DRUG|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
214777214|NCT04523831|DRUG|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
214777215|NCT01854515|DRUG|Budesonide|
214777216|NCT01854515|DRUG|Dexamethasone acetate|
214777217|NCT02999919|PROCEDURE|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
214777218|NCT02322242|DRUG|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
214777219|NCT02322242|DRUG|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
214777220|NCT01406769|PROCEDURE|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
214777221|NCT01406769|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
214777222|NCT01406769|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
214777223|NCT04196582|DEVICE|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
214777224|NCT00350194|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
214777225|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
214777226|NCT00006385|BIOLOGICAL|MART-1 antigen|
214777227|NCT00006385|BIOLOGICAL|gp100 antigen|
214777228|NCT00006385|BIOLOGICAL|incomplete Freund's adjuvant|
214777229|NCT00006385|BIOLOGICAL|recombinant interferon alfa|
214777230|NCT00006385|BIOLOGICAL|sargramostim|
214777231|NCT00006385|BIOLOGICAL|tyrosinase peptide|
214777232|NCT00296452|BEHAVIORAL|behavior|
214777233|NCT06222411|OTHER|evaluate the impact of organizational interventions for physician development on wellbeing|There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
214777234|NCT02780999|DEVICE|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
214777235|NCT02780999|DEVICE|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
214777236|NCT02858167|DEVICE|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
214777237|NCT03078530|DRUG|Placebo|This is a pill with inactive ingredients
214777238|NCT03078530|DRUG|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
214777239|NCT03078530|DRUG|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
214777240|NCT02146235|BEHAVIORAL|Psycho-Music Therapy|
214777241|NCT01189071|DRUG|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
214777242|NCT02367781|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
214777243|NCT02367781|DRUG|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
214777244|NCT02367781|DRUG|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
214777245|NCT02367781|DRUG|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
214777246|NCT01488799|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
214777247|NCT05302284|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
214777248|NCT05302284|DRUG|Toripalimab|3.0 mg/kg IV every 2 weeks
214777249|NCT05302284|DRUG|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
214777250|NCT05302284|DRUG|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
214777251|NCT05302284|DRUG|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
214777252|NCT01972542|DIETARY_SUPPLEMENT|Oral fat tolerance test|
214777253|NCT04297553|PROCEDURE|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
214777254|NCT04297553|PROCEDURE|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
214777255|NCT01676259|DRUG|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
214777256|NCT01676259|DRUG|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
214777257|NCT01676259|DRUG|Folfirinox|Folfirinox or modified Folfirinox
214777258|NCT03291678|PROCEDURE|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
214777259|NCT03291678|PROCEDURE|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
214777260|NCT04716400|BEHAVIORAL|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
214777261|NCT02623426|DRUG|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
214777262|NCT02623426|DRUG|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
214777263|NCT02623426|DRUG|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
214777264|NCT06177509|OTHER|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
214777265|NCT05886283|PROCEDURE|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
214777266|NCT05886283|PROCEDURE|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
214777267|NCT05886283|PROCEDURE|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
214777268|NCT03791255|DRUG|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
214777269|NCT03791255|DRUG|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
214777270|NCT04454957|BEHAVIORAL|Mastering Diabetes|Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
214777271|NCT06617013|OTHER|Discontinuation of GERD therapy|GERD therapy will be discontinued at time of enrollment.
214777272|NCT04659837|BEHAVIORAL|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
214777273|NCT06694571|BEHAVIORAL|Skin cancer prevention educational presentation and activities|"An intervention visit, lasting up to 90 minutes, will take place during fall, immediately following completion of a baseline survey. This intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. During the intervention visit, participants will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity.~One month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text."
214777274|NCT01031134|BEHAVIORAL|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
214777275|NCT01031134|OTHER|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
214777276|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
214777277|NCT06696729|PROCEDURE|Topical Mirabilite Application for Postoperative Gastrointestinal Patients|Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.
214777278|NCT06696729|PROCEDURE|Standard Postoperative Care for Gastrointestinal Patients|Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
214777279|NCT06696469|DIAGNOSTIC_TEST|Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients|The applicability and reliability of virtual reality systems are important factors to consider. Based on this, this study aimed to investigate the feasibility of using BeCureTM virtual reality in the evaluation of upper extremity functions after stroke.The feasibility of using BeCureTM virtual reality in stroke patients will be determined according to the System Usability Scale (SUS) score.The safety of the use of BeCureTM virtual reality in stroke patients will be assessed with a patient feedback questionnaire. The relationship between the use of BeCureTM virtual reality and cognitive functions in stroke patients will be determined by the Montreal Cognitive Assessment Scale and Mini Mental State Examination.It was aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications.
214777280|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
214777281|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
214777282|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
214777283|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers."
214777284|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
214777285|NCT06700772|PROCEDURE|mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone|open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .
214777286|NCT06700772|PROCEDURE|mixing autogenous bone with bovine bone|open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
214777287|NCT06233175|OTHER|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
214777288|NCT06233175|OTHER|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
214777289|NCT05052320|DEVICE|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
214777290|NCT04581031|DEVICE|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
214777291|NCT04581031|OTHER|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
214777292|NCT03342326|OTHER|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
214777293|NCT03342326|OTHER|Music Experience Questionnaire|questions about the past music training
214777294|NCT03342326|OTHER|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
214777295|NCT03342326|OTHER|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
214777296|NCT03871569|OTHER|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
214777297|NCT00226902|PROCEDURE|Changing hemoglobin concentration|
214777298|NCT02280642|BIOLOGICAL|Both 2nd and 3rd doses on time|
214777299|NCT02280642|BIOLOGICAL|2nd dose late and 3rd dose on time|
214777300|NCT02280642|BIOLOGICAL|2nd dose on time and 3rd dose late|
214777301|NCT02280642|BIOLOGICAL|Both doses late|
214777302|NCT05087199|DIAGNOSTIC_TEST|Rt-PCR.|Nasopharyngeal swab for Rt-PCR for COVID-19
214777303|NCT06292806|DRUG|FSH-R|controlled ovarian stimulation for IVF
214777304|NCT04040959|DRUG|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
214777305|NCT03586037|DRUG|AD-2011 10/20 mg|AD-2011 10/20 mg tablet
214777306|NCT03586037|DRUG|AD-2012 80mg|AD-2012 80mg tablet
214777307|NCT03586037|DRUG|AD-2011 10/20 mg + AD-2012 80mg|AD-2011 10/20 mg + AD-2012 80mg tablet
214777308|NCT01758315|OTHER|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
214777309|NCT05040815|RADIATION|chemo-radiation treatment|Radiotherapy (RT) with concurrent 5-fluorouracil and mitomycin-C (5FU/MMC) combination is the treatment of choice for non-metastatic locally advanced anal squam
214777310|NCT04946422|PROCEDURE|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
214777311|NCT02056574|DRUG|NA-1|
214777312|NCT02056574|DRUG|Placebo|
214777313|NCT05449327|DRUG|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
214777314|NCT06542627|DEVICE|Freestyle Libre|Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
214777315|NCT05347082|DRUG|Cholecalciferol|Tablets of 4000 IU
214777316|NCT01253889|DRUG|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
214777317|NCT01253889|OTHER|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
214777318|NCT04154566|OTHER|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
214777319|NCT01528631|OTHER|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
214777320|NCT01528631|OTHER|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
214777321|NCT02585531|DRUG|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
214777322|NCT02585531|DRUG|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
214777323|NCT04150926|OTHER|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
214777324|NCT04150926|OTHER|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
214777325|NCT04150926|OTHER|Quinoa base|The effect of black currant puree will be compared with quinoa base
214777326|NCT03724968|DRUG|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
214777327|NCT03724968|DRUG|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
214777328|NCT03724968|DRUG|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
214777329|NCT06540313|OTHER|Stellate Ganglion Block|Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
214777330|NCT03190018|DEVICE|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
214777331|NCT01142466|DRUG|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
214777332|NCT01804192|OTHER|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
214777333|NCT00681824|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
214777334|NCT00681824|PROCEDURE|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
214777335|NCT03724916|DRUG|TAK-079|TAK-079 subcutaneous injection.
214777336|NCT03724916|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
214777337|NCT04315831|DRUG|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
214777338|NCT01897558|DEVICE|Pacemaker implantation|
214777339|NCT05321121|DRUG|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
214777340|NCT05321121|OTHER|Placebo|The control arm will receive an infusion of normal saline
214777341|NCT02760784|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
214777342|NCT02615379|DEVICE|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
214777343|NCT05934552|DRUG|Lactulose|lactulose and lactobacillus acidophilus on ckd patients
214777344|NCT00683332|DRUG|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
214777345|NCT05037552|PROCEDURE|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
214777346|NCT05037552|PROCEDURE|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
214777347|NCT00631800|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
214777348|NCT00665197|RADIATION|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
214777349|NCT00665197|RADIATION|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
214777350|NCT00176852|DRUG|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
214777351|NCT00176852|DRUG|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
214777352|NCT00176852|DRUG|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
214777353|NCT00176852|RADIATION|Total Body Irradiation|300 cGY Day -1
214777354|NCT00176852|PROCEDURE|Stem cell infusion|Given Day 0
214777355|NCT01001676|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
214777356|NCT01001676|DEVICE|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
214646831|NCT01934569|DRUG|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
214646832|NCT01409603|DRUG|darexaban|oral
214646833|NCT01409603|DRUG|Naproxen|oral
214646834|NCT02857218|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
214646835|NCT02857218|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
214646836|NCT05034900|OTHER|Chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.
214646837|NCT05034900|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) device|Shaker® device will be used.
214646838|NCT00142129|DRUG|Bortezomib (Velcade)|
214646839|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
214646840|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
214646841|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
214646842|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
214646843|NCT02296411|DRUG|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
214646844|NCT02296411|DRUG|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
214646845|NCT04856241|OTHER|Coaching|Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.
214646846|NCT04856241|OTHER|Peer support|Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.
214646847|NCT04856241|OTHER|Educational materials|Prep-to-Play program resources are available online for coaches and players to view
214646848|NCT01960855|DRUG|ABT-494|ABT-494 capsule administered orally twice daily (BID).
214646849|NCT01960855|DRUG|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
214646850|NCT02328066|DEVICE|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
214646851|NCT06175897|PROCEDURE|Deep Brain Stimulation|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
214646852|NCT06175897|PROCEDURE|non-Deep Brain Stimulation|Patients with PD were given their original drug dose and did not receive DBS.
214646853|NCT00217347|DEVICE|Esophageal Capsule Endoscopy|
214646854|NCT02058147|DRUG|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
214646855|NCT02058147|DRUG|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
214646856|NCT02058147|DRUG|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
214777357|NCT04562025|DRUG|UC-MSCs|3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
214777358|NCT04562025|DRUG|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
214777359|NCT02123069|DEVICE|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
214777360|NCT02123069|DRUG|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
214777361|NCT02123069|DRUG|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
214777362|NCT02123069|DRUG|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
214777363|NCT02123069|DRUG|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
214777364|NCT01501201|PROCEDURE|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
214777365|NCT01501201|DRUG|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
214777366|NCT02841540|DRUG|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
214777367|NCT00871598|DRUG|BTT1023|intravenous, three infusions over three weeks
214777368|NCT00871598|DRUG|Placebo|intravenous, three infusions over three weeks
214777369|NCT00871598|DRUG|BTT1023|Test challenge
214777370|NCT06352398|PROCEDURE|erector spina plan block|erector spina plan block
214777371|NCT06352398|PROCEDURE|Serratus posterior superior intercostal plan block (SPSIPB)|Serratus posterior superior intercostal plan block (SPSIPB)
214777372|NCT06352398|DRUG|0.25% bupivacaine|Before the operation, 0.25% bupivacaine 30 ml was administered to both groups.
214777373|NCT03584204|DIAGNOSTIC_TEST|imaging|computed tomography, magnetic resosnance imaging, ultrasound
214777374|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
214777375|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
214777376|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
214777377|NCT00796289|DRUG|clomiphene citrate|Oral, 50 mg daily for 5 days
214777378|NCT00796289|DRUG|placebo clomiphene citrate|oral, taken for 5 days
214777379|NCT00796289|DRUG|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
214777380|NCT05875766|OTHER|Osteopathy|4 sessions of osteopathy after DIDT surgery
214777381|NCT05875766|OTHER|Physiotherapy|Physiotherapy after DIDT surgery (reference treatment)
214777382|NCT02574507|BEHAVIORAL|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
214777383|NCT05552092|DEVICE|Esophageal temperature monitoring according to the depth|"Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured."
214777384|NCT05552092|OTHER|Anatomical landmark|For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
214777385|NCT02795949|DRUG|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
214777386|NCT02795949|DRUG|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
214777387|NCT00488046|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
214777388|NCT05001373|BIOLOGICAL|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
214777389|NCT05001373|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
214777390|NCT03095963|OTHER|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
214777391|NCT03095963|DRUG|levothyroxin|replacement therapy for hypothyroidism
214777392|NCT05674266|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
214777393|NCT05674266|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
214777394|NCT00639587|DRUG|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
214777395|NCT00639587|DRUG|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
214777396|NCT03591107|OTHER|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
214777397|NCT03591107|OTHER|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
214777398|NCT03940326|DRUG|Levetiracetam|Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
214777399|NCT03940326|DRUG|Valproate|Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
214777400|NCT02330250|OTHER|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
214777401|NCT02330250|OTHER|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
214777402|NCT02464527|BEHAVIORAL|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
214777403|NCT02464527|OTHER|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
214777404|NCT04596930|PROCEDURE|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
214777405|NCT01407575|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
214777406|NCT01407575|DRUG|Placebo|matched placebo
214777407|NCT02755233|OTHER|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
214777408|NCT04030884|DIETARY_SUPPLEMENT|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
214777409|NCT03712137|DEVICE|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
214777410|NCT03712137|OTHER|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
214777411|NCT04800900|OTHER|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
214777412|NCT01222871|DRUG|Triamcinolone|Triamcinolone soaked nasopore dressing
214777413|NCT01222871|DRUG|Saline soaked sponge|saline soaked sponge
214777414|NCT05250947|DEVICE|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
214777415|NCT05250947|DRUG|Platelet Rich Plasma|6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
214777416|NCT02934386|DEVICE|WinMedical WinPack device|
214777417|NCT02545010|DRUG|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
214777418|NCT02545010|RADIATION|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
214777419|NCT03836729|DRUG|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
214777420|NCT03836729|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
214777421|NCT03536247|PROCEDURE|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
214777422|NCT03536247|PROCEDURE|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
214777423|NCT04272177|OTHER|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
214777424|NCT01483222|DEVICE|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
214777425|NCT01483222|DEVICE|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
214777426|NCT05068206|DRUG|AK105 injection|AK105 is programmed death 1（PD-1） monoclonal antibody
214777427|NCT05068206|DRUG|Anlotinib hydrochloride capsule|Anlotinib is small molecule multi-target tyrosine kinase inhibitor.
214777428|NCT05068206|DRUG|CapeOX|CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
214777429|NCT05068206|DRUG|Bevacizumab|Bevacizumab is a recombinant human monoclonal antibody.
214777430|NCT00190320|PROCEDURE|Induction of labor vs waiting|
214777431|NCT01270841|DRUG|Placebo|Placebo capsule 1x daily for 3 months
214777432|NCT01270841|DRUG|topical testosterone|testosterone gel applied 1x daily for 3 months
214777433|NCT01270841|DRUG|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
214777434|NCT06520436|PROCEDURE|Arthroscopic-Assisted Reduction|The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
214777435|NCT02122159|BIOLOGICAL|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
214777436|NCT03638752|OTHER|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
214777437|NCT04637685|DEVICE|Centurion Phacoemulsification System|Infusion Pressure
214777438|NCT02688309|DRUG|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
214777439|NCT02688309|PROCEDURE|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
214777440|NCT02688309|PROCEDURE|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
214777441|NCT04406883|DRUG|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
214777442|NCT02851953|DEVICE|Aqueduct-100|
214777443|NCT04442373|DIAGNOSTIC_TEST|Rotational thromboelastometry|1.8 ml blood sample
214777444|NCT04388527|BIOLOGICAL|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
214777445|NCT03012620|DRUG|Pembrolizumab|Treatment
214777446|NCT03980860|OTHER|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
214777447|NCT06539091|DRUG|Fluzoparib|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
214777448|NCT06539091|DRUG|Apatinib Mesylate|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
214777449|NCT03706274|DRUG|CX-188|CX-188
214777450|NCT03568526|OTHER|Educational Intervention|Attend a therapy session
214777451|NCT03568526|BEHAVIORAL|Exercise Intervention|Complete exercise
214777452|NCT03568526|OTHER|Quality-of-Life Assessment|Ancillary studies
214777453|NCT03568526|OTHER|Questionnaire Administration|Ancillary studies
214777454|NCT03568526|OTHER|Survey Administration|Ancillary studies
214777455|NCT01099280|DRUG|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
214777456|NCT01099280|DRUG|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
214777457|NCT01153022|OTHER|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
214777458|NCT01692431|DIETARY_SUPPLEMENT|EPA|High fat meal containing EPA
214777459|NCT01692431|DIETARY_SUPPLEMENT|DHA|High fat meal containing DHA
214777460|NCT01692431|DIETARY_SUPPLEMENT|Placebo|High fat meal containing negligible EPA/DHA content
214777461|NCT02827422|OTHER|not provided|
214777462|NCT02264301|DRUG|Puerarin injection 400 mg|
214777463|NCT02264301|DRUG|Qingkailing injection 40 ml|
214777464|NCT04753918|DRUG|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
214777465|NCT04753918|DRUG|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
214777466|NCT04753918|PROCEDURE|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
214777467|NCT04753918|DEVICE|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
214777468|NCT01046721|DRUG|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
214777469|NCT01046721|DRUG|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
214777470|NCT01368679|PROCEDURE|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
214777471|NCT02377284|OTHER|Photograph|Add a photograph to a chef card.
214777472|NCT00782275|DRUG|bevacizumab|
214777473|NCT00782275|DRUG|temsirolimus|
214777474|NCT00858559|DEVICE|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
214777475|NCT00858559|DEVICE|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
214777476|NCT04394052|DIAGNOSTIC_TEST|MR imaging|Medical imaging
214777477|NCT02577900|DEVICE|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
214777478|NCT02577900|DEVICE|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
214777479|NCT02577900|DEVICE|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
214777480|NCT02639507|PROCEDURE|Vitrectomy|
214777481|NCT00406107|DRUG|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
214777482|NCT03851107|BEHAVIORAL|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
214777483|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214777484|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214777485|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214777486|NCT00612794|DRUG|exenatide once weekly|subcutaneous injection, once weekly
214777487|NCT00612794|DRUG|placebo|subcutaneous injection, once weekly
214777488|NCT00787566|DRUG|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
214777489|NCT01074021|DRUG|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
214777490|NCT01074021|DRUG|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
214777491|NCT00543790|DRUG|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
214777492|NCT00417027|PROCEDURE|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
214777493|NCT03214757|OTHER|treatment of anemia.|drug treatment of anemia.
214777494|NCT05694429|OTHER|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
214777495|NCT05716191|OTHER|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
214777496|NCT00544557|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
214777497|NCT01535248|OTHER|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
214777498|NCT00214630|DRUG|rosuvastatin calcium|
214777499|NCT00214630|DRUG|atorvastatin|
214777500|NCT03782857|BEHAVIORAL|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
214777501|NCT04091269|DEVICE|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
214777502|NCT06502041|PROCEDURE|MARPE with MOP|mini-screw assisted rapid palatal expansion with micro-osteoperforation
214777503|NCT06502041|PROCEDURE|MARPE without MOP|mini-screw assisted rapid palatal expansion without micro-osteoperforation
214777504|NCT00272337|DRUG|Aspirin|Dosage
214777505|NCT03105115|DRUG|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
214777506|NCT03105115|DRUG|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
214777507|NCT00476684|PROCEDURE|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
214777508|NCT00476684|PROCEDURE|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
214777509|NCT01444274|DEVICE|Obalon Gastric Balloon(s)|One or two balloons administered per patient
214777510|NCT00142844|DRUG|Naltrexone|
214777511|NCT00142844|DRUG|Disulfiram|
214777512|NCT00142844|DRUG|Placebo|
214777513|NCT00386100|DRUG|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
214777514|NCT00386100|DRUG|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
214777515|NCT00386100|DRUG|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
214777516|NCT00386100|DRUG|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
214777517|NCT00386100|DRUG|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
214777518|NCT00386100|DRUG|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
214777519|NCT00386100|DRUG|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
214777520|NCT00386100|DRUG|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
214777521|NCT04167488|DEVICE|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
214777522|NCT00730470|DRUG|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
214777523|NCT02222285|OTHER|Medical Food : Vayarin_005|
214777524|NCT02222285|OTHER|Placebo|
214777525|NCT00491673|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
214777526|NCT00491673|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
214777527|NCT01731860|DEVICE|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
214777528|NCT04816422|OTHER|Proprioceptive neuromuscular facilitation|"rocedure~1. Bilateral upper extremity pattern for trunk by Chopping, Lifting~2. Bilateral lower extremity pattern for trunk.~3. Trunk lateral flexion.~4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion."
214777529|NCT04816422|OTHER|Conventional treatment|"Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
214777530|NCT02464085|OTHER|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
214777531|NCT03467828|GENETIC|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
214777532|NCT05759169|OTHER|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
214777533|NCT03944018|BEHAVIORAL|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
214777534|NCT06462209|OTHER|ladder training|"Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step."
214777535|NCT06462209|OTHER|plyometric training|In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
214777536|NCT02020785|OTHER|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
214777537|NCT02020785|OTHER|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
214777538|NCT02328807|PROCEDURE|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
214777539|NCT03744065|PROCEDURE|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
214777540|NCT03744065|PROCEDURE|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
214777541|NCT03905499|DEVICE|Robotic assisted therapy with MJS (multi joint system) Tecnobody|The intervention will include 18 30-minutes trainings evenly distributed over a time period of 6 weeks and will be administered by the same two physiotherapists at the Schulthess clinic based on the standardized protocol
214777542|NCT03905499|OTHER|Usual Care|Patients randomized in the usual care will receive standard of care treatment without receiving any active intervention
214777543|NCT03140085|BIOLOGICAL|PYO Phage|Intravescial instillation
214777544|NCT03140085|DRUG|Antibiotics|Oral application
214777545|NCT03140085|OTHER|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
214777546|NCT02583178|DEVICE|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
214777547|NCT04494282|PROCEDURE|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
214777548|NCT02991261|DRUG|SPARC001 type I|Treatment type I
214777549|NCT02991261|DRUG|SPARC001 type II|Treatment type II
214777550|NCT02991261|DRUG|Reference001 type I|Hydrocodone-acetaminophen
214777551|NCT02991261|DRUG|Reference001 type II|Hydrocodone Acetaminophen
214777552|NCT01418261|DEVICE|Renal denervation (Symplicity Catheter System)|
214777553|NCT01418261|DIAGNOSTIC_TEST|Renal angiogram|
214777554|NCT00886782|DRUG|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
214777555|NCT02633761|DRUG|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
214777556|NCT02633761|DRUG|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
214777557|NCT02633761|DRUG|Misoprostol 200mcg|Buccal misoprostol 200mcg
214777558|NCT02729493|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
214777559|NCT02119182|BEHAVIORAL|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
214777560|NCT02119182|BEHAVIORAL|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
214777561|NCT02119182|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
214777562|NCT02119182|PROCEDURE|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
214646857|NCT02058147|DRUG|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
214646858|NCT04009993|DEVICE|A-BIRTHPERFORM digital tool|use of A-BIRTHPERFORM digital tool
214646859|NCT03640832|OTHER|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
214646860|NCT03640832|OTHER|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
214646861|NCT02642926|PROCEDURE|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
214646862|NCT02642926|PROCEDURE|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
214646863|NCT05537545|PROCEDURE|Soft tissue grafting|A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
214646864|NCT03312569|PROCEDURE|Right Colectomy with Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
214646865|NCT03312569|PROCEDURE|Right Colectomy with Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
214646866|NCT01857609|DRUG|Metformin|
214646867|NCT01857609|DRUG|Metformin and Pantoprazole|
214646868|NCT01857609|DRUG|Metformin and Rabeprazole|
214646869|NCT00211107|DRUG|Dapoxetine|
214646870|NCT02544412|BEHAVIORAL|novel mindfulness-based well-being training|
214646871|NCT02868203|DEVICE|OCT|OCT after stent implantation
214646872|NCT02868203|DEVICE|eLuting stent|
214646873|NCT01358903|DRUG|RO5429083|Cohorts receiving multiple escalating doses iv
214646874|NCT01358903|DRUG|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
214646875|NCT03996330|DIAGNOSTIC_TEST|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
214646876|NCT00681239|DIETARY_SUPPLEMENT|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
214646877|NCT00639080|OTHER|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
214646878|NCT04240587|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
214646879|NCT01995929|PROCEDURE|transnasal functional endoscopy|
214646880|NCT04285775|DEVICE|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
214646881|NCT04328506|DRUG|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
214646882|NCT04328506|DRUG|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
214646883|NCT02262169|DRUG|Omeprazole|2 Omeprazole capsules 20 mg, once daily
214646884|NCT02262169|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
214646885|NCT02262169|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
214646886|NCT02262169|DRUG|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
214777563|NCT05528289|DEVICE|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
214777564|NCT05528289|DEVICE|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
214777565|NCT05691673|OTHER|No intervention|Observational during 16 weeks
214777566|NCT03933319|DRUG|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
214777567|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
214777568|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
214777569|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
214777570|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
214777571|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
214777572|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
214777573|NCT00947245|DRUG|Placebo|Capsules, Oral, Single Dose, One day
214777574|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours, 14 days
214777575|NCT00947245|DRUG|Placebo|Capsules, Oral, Once Daily, 14 days
214777576|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
214777577|NCT04014101|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
214777578|NCT04014101|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor.
214777579|NCT03798522|PROCEDURE|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
214777580|NCT03798522|DRUG|Nalbuphine|in nalbuphine for analgesia after GA
214777581|NCT03284073|PROCEDURE|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
214777582|NCT03160365|PROCEDURE|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
214777583|NCT06290869|BEHAVIORAL|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention|In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.
214777584|NCT06290869|BEHAVIORAL|E-Referral to the Tobacco Quitline|In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
214777585|NCT01612702|DRUG|Dexamethasone|Dexamethasone 10 mg intravenous administration
214777586|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
214777587|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
214777588|NCT00755508|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
214777589|NCT00755508|DRUG|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
214777590|NCT00755508|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
214777591|NCT01016821|DRUG|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
214777592|NCT05634018|DIAGNOSTIC_TEST|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
214777593|NCT06061718|DRUG|iDose TR|anchored intracameral implant containing travoprost
214777594|NCT03791918|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214777595|NCT03791918|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214777596|NCT03791918|PROCEDURE|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
214777597|NCT03791918|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
214777598|NCT02156518|PROCEDURE|Vocal Function Exercises|Vocal Function Exercises
214777599|NCT02156518|PROCEDURE|Vocal Hygiene|Vocal Hygiene
214777600|NCT03577652|DRUG|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
214777601|NCT03636542|DRUG|liposomal bupivacaine|Experimental
214777602|NCT03636542|DRUG|bupivacaine|Active comparator
214777603|NCT05033015|PROCEDURE|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
214777604|NCT02773888|DEVICE|HS-1000|
214777605|NCT03910582|PROCEDURE|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
214777606|NCT03910582|PROCEDURE|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
214777607|NCT00966082|PROCEDURE|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
214777608|NCT00966082|PROCEDURE|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
214777609|NCT02947373|DRUG|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
214777610|NCT01935531|DRUG|3% diclofenac in 2.5% hyaluronic acid gel|
214777611|NCT05698420|DEVICE|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
214777612|NCT05698420|DEVICE|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
214777613|NCT04212182|DEVICE|HFNC|HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
214777614|NCT04212182|DEVICE|NPPV|NPPV is the standard therapy for ventilatory failure in AECOPD.
214777615|NCT03512626|DEVICE|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
214777616|NCT03512626|DEVICE|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
214777617|NCT04039165|BEHAVIORAL|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
214777618|NCT06013020|DRUG|NOAC+DAPT|Century Clot-guided rivaroxaban plus DAPT.
214777619|NCT06013020|DRUG|DAPT|Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
214777620|NCT01725074|BEHAVIORAL|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening"
214777621|NCT01725074|BEHAVIORAL|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
214777622|NCT02331030|PROCEDURE|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
214777623|NCT02331030|PROCEDURE|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
214777624|NCT02331030|PROCEDURE|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
214777625|NCT02331030|DRUG|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
214777626|NCT02331030|DRUG|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
214777627|NCT02677610|DRUG|MSRD-100|MSRD-100 is a topical gel.
214777628|NCT02677610|DRUG|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
214777629|NCT03101579|DRUG|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
214777630|NCT03101579|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
214777631|NCT03101579|DRUG|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
214777632|NCT03101579|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
214777633|NCT00559884|DRUG|GSK189075 (Modified and immediate release formulations)|
214777634|NCT00701935|DRUG|placebo|subcutaneous injection, twice a day
214777635|NCT00701935|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
214777636|NCT04905719|DIAGNOSTIC_TEST|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
214777637|NCT04373161|DEVICE|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen \<92% or for worsening symptoms.
214777638|NCT02478593|BEHAVIORAL|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
214777639|NCT03912688|DEVICE|acupoint stimulation|
214777640|NCT03912688|DEVICE|single acupoint|
214777641|NCT03912688|DEVICE|dual acupoints|
214777642|NCT00703378|DRUG|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
214777643|NCT00469534|PROCEDURE|IMRT|
214777644|NCT02344134|BIOLOGICAL|NBP607|0.5 mL, intramuscular, a single dose
214777645|NCT02344134|BIOLOGICAL|Agrippal S1|0.5 mL, intramuscular, a single dose
214777646|NCT04952441|BEHAVIORAL|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
214777647|NCT01542736|DRUG|Carboplatin|Administered concurrently with craniospinal radiation.
214777648|NCT01542736|DRUG|Vincristine|Administered concurrently with craniospinal radiation.
214777649|NCT01542736|RADIATION|24 Gy|Craniospinal radiation.
214777650|NCT06120452|OTHER|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
214777651|NCT03674827|BIOLOGICAL|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
214646887|NCT04429126|BEHAVIORAL|Acupressure|Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
214646888|NCT02154425|PROCEDURE|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
214646889|NCT02154425|BIOLOGICAL|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
214646890|NCT02908516|DRUG|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
214646891|NCT02908516|DRUG|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
214646892|NCT03143803|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
214646893|NCT03143803|DRUG|Placebo|Similar looking inactive powder
214646894|NCT03790592|DEVICE|trifocal IOL|intraocular lens
214646895|NCT02500004|RADIATION|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
214646896|NCT02500004|RADIATION|DXA scanning|Body composition: DXA scanning, D2O and MRI.
214646897|NCT02500004|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
214646898|NCT02500004|PROCEDURE|Blood sampling|Systemic inflammatory profile: blood sampling.
214646899|NCT02500004|OTHER|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
214646900|NCT02500004|DEVICE|Accelerometry|Physical activity level: accelerometry.
214646901|NCT02500004|OTHER|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
214646902|NCT00643630|DEVICE|Tetrix|Twice daily topical application
214646903|NCT00643630|DEVICE|Tetrix|Twice daily topical application
214646904|NCT01162421|BIOLOGICAL|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
214646905|NCT01162421|DRUG|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
214646906|NCT05176912|OTHER|Exercise|Reformer Pilates exercises will given for 8 weeks, 3 days in a week
214646907|NCT02431416|DRUG|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
214646908|NCT02431416|DRUG|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
214646909|NCT03603769|DIETARY_SUPPLEMENT|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
214646910|NCT03603769|DIETARY_SUPPLEMENT|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
214646911|NCT02244242|DRUG|Tamsulosin hydrochloride|
214777652|NCT04379661|BEHAVIORAL|Online support Group|12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
214777653|NCT05990205|DRUG|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
214777654|NCT05990205|BEHAVIORAL|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
214777655|NCT04102228|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
214777656|NCT04102228|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
214777657|NCT04102228|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
214777658|NCT01559961|DRUG|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
214777659|NCT05751083|OTHER|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises"
214777660|NCT05751083|OTHER|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down."
214777661|NCT01783483|DEVICE|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
214777662|NCT01783483|DEVICE|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
214777663|NCT02832791|PROCEDURE|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
214777664|NCT02832791|PROCEDURE|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
214777665|NCT02619331|PROCEDURE|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
214777666|NCT06567093|OTHER|Baby Foot and Leg Massage|"Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down."
214777667|NCT02934269|DRUG|Placebo|
214777668|NCT02934269|DRUG|CC-90006|
214777669|NCT00828490|BEHAVIORAL|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
214646912|NCT04055103|OTHER|Monthly feedback, education and linking hospitals|\- Give monthly feedback from LROI-data (revision rate \& patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
214646913|NCT00838591|DRUG|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
214646914|NCT00838591|DRUG|Placebo|
214777670|NCT00828490|BEHAVIORAL|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
214777671|NCT00828490|BEHAVIORAL|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
214777672|NCT02761265|PROCEDURE|Surgical intervention|Surgery to correct spinal deformity
214777673|NCT02761265|OTHER|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
214777674|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
214777675|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
214777676|NCT05229315|DRUG|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
214777677|NCT05229315|PROCEDURE|Intensity modulated radiotherapy|Intensity modulated radiotherapy
214777678|NCT00442715|PROCEDURE|Exercise chalenge test|
214777679|NCT03398928|OTHER|Acupuncture|Acupuncture added to usual care
214777680|NCT06204172|DEVICE|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
214777681|NCT06204172|OTHER|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
214777682|NCT01140269|OTHER|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
214777683|NCT04681222|PROCEDURE|LFCN|LFCN block was performed in combination with PENG block
214777684|NCT04681222|PROCEDURE|Wound infiltration|Wound infiltration was performed in combination with PENG block
214777685|NCT01633749|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
214777686|NCT04130919|DRUG|Tilpisertib|Tablets administered orally once daily
214777687|NCT04130919|DRUG|Placebo|Tablets administered orally once daily
214777688|NCT00458718|DRUG|rimonabant (SR141716)|
214777689|NCT00737321|PROCEDURE|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
214777690|NCT04699643|DRUG|EVER4010001|Please refer to information in arm/group descriptions.
214777691|NCT02624518|DRUG|68Ga-RM2|Imaging with PET/MRI
214777692|NCT02624518|PROCEDURE|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
214777693|NCT02624518|PROCEDURE|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
214777694|NCT02947282|OTHER|Educational Workshop|They will attend a 2 hour class on pelvic floor health
214777695|NCT05573373|DRUG|Parimparib|The dosage and protocol of the drug were carried out according to the description.
214777696|NCT05573373|DRUG|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
214777697|NCT05573373|DRUG|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
214777698|NCT01168882|DRUG|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
214777699|NCT01682473|DRUG|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
214777700|NCT03720522|PROCEDURE|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
214777701|NCT03720522|PROCEDURE|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
214777702|NCT03720522|PROCEDURE|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
214777703|NCT03720522|PROCEDURE|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
214777704|NCT00370396|BIOLOGICAL|Synflorix|1 dose injected IM in the right thigh or deltoid.
214777705|NCT00370396|BIOLOGICAL|Prevenar|1 dose injected IM in the right thigh or deltoid.
214777706|NCT00370396|BIOLOGICAL|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
214777707|NCT00637442|DRUG|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
214777708|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
214777709|NCT01511900|DRUG|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
214777710|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
214777711|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
214777712|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
214777713|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
214777714|NCT00251771|PROCEDURE|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
214777715|NCT00615771|PROCEDURE|Day 3 embryo transfer|Standard of care
214777716|NCT00615771|PROCEDURE|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
214777717|NCT01462695|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214777718|NCT01462695|OTHER|Pharmacological Study|Correlative studies
214777719|NCT01462695|DRUG|Sunitinib Malate|Given PO
214777720|NCT03251183|DIAGNOSTIC_TEST|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
214777721|NCT03251183|DIAGNOSTIC_TEST|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
214777722|NCT03251183|DIAGNOSTIC_TEST|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
214777723|NCT03251183|DIAGNOSTIC_TEST|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
214777724|NCT03251183|DIAGNOSTIC_TEST|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
214777725|NCT02012205|PROCEDURE|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
214777726|NCT02400905|DEVICE|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
214777727|NCT03355222|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
214777728|NCT02647554|DRUG|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
214777729|NCT02647554|DRUG|Placebo|matching placebo every 8 hours for 10 days
214777730|NCT05494775|DRUG|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
214777731|NCT05692466|DIAGNOSTIC_TEST|Comprehensive molecular panel test|Lab test
214777732|NCT05692466|OTHER|EORTC QLQ-30|Quality of life questionnaire
214777733|NCT04516694|BEHAVIORAL|Financial incentive (gain)|Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
214777734|NCT04516694|BEHAVIORAL|Financial incentive (loss)|Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
214777735|NCT02854566|DEVICE|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
214777736|NCT00665717|DRUG|Pravastatin|40 mg tablet; QD; 4 days
214777737|NCT00665717|DRUG|Raltegravir|400mg tablet; BD 4 days
214777738|NCT00665717|DRUG|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
214777739|NCT05742061|DRUG|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
214777740|NCT05742061|OTHER|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
214777741|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
214777742|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo MR DENSE imaging
214777743|NCT01547637|PROCEDURE|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
214777744|NCT01547637|PROCEDURE|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
214777745|NCT06254391|DRUG|Low-dose aspirin|Implementation of low-dose aspirin (30 mg)
214777746|NCT05165017|BIOLOGICAL|AlloRx Stem Cells®|Umbilical cord-derived allogeneic mesenchymal stem cells
214777747|NCT05165017|OTHER|Placebo control|Placebo infusion without mesenchymal stem cells
214777748|NCT01872468|BEHAVIORAL|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
214777749|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
214777750|NCT00908531|DRUG|letrozole (Femara)|tablet 2.5 mg daily
214777751|NCT00127764|DRUG|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
214777752|NCT00148928|BIOLOGICAL|P501-AS15 vaccine|
214777753|NCT03886428|OTHER|100% portion size|Entree portion size 100% of baseline
214777754|NCT03886428|OTHER|125% portion size|Entree portion size 125% of baseline
214777755|NCT03886428|OTHER|150% portion size|Entree portion size 150% of baseline
214777756|NCT03886428|OTHER|175% portion size|Entree portion size 175% of baseline
214777757|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
214777758|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
214777759|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
214777760|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
214777761|NCT04853888|BEHAVIORAL|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
214777762|NCT05128487|DRUG|NDI-101150|NDI-101150 capsules
214777763|NCT05128487|DRUG|Pembrolizumab|Pembrolizumab IV infusion
214777764|NCT01358708|DRUG|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
214777765|NCT01358708|DRUG|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
214777766|NCT01890694|DRUG|Tolvaptan|15 mg once daily
214777767|NCT01890694|DRUG|Placebo|15 mg once daily
214777768|NCT01890694|BEHAVIORAL|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
214777769|NCT01890694|BEHAVIORAL|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
214777770|NCT01890694|BIOLOGICAL|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
214777771|NCT01890694|BIOLOGICAL|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
214777772|NCT01890694|PROCEDURE|Ascites Evaluation|Ascites will be assessed at every visit.
214777773|NCT01890694|PROCEDURE|Edema|Edema will be assessed at every visit.
214777774|NCT04363736|DRUG|Tociliuzumab|Participants will receive IV TCZ.
214777775|NCT00431574|PROCEDURE|dosing|
214777776|NCT03567239|DEVICE|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
214777777|NCT06009432|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
214777778|NCT06129487|BEHAVIORAL|Narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
214777779|NCT06129487|BEHAVIORAL|Non-narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
214777780|NCT01824108|PROCEDURE|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
214777781|NCT01824108|PROCEDURE|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
214777782|NCT01887860|OTHER|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
214777783|NCT02754505|OTHER|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
214777784|NCT02754505|OTHER|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
214777785|NCT00709020|DRUG|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
214777786|NCT00709020|OTHER|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
214777787|NCT00709020|OTHER|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
214777788|NCT00709020|OTHER|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
214777789|NCT00709020|OTHER|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
214777790|NCT00709020|OTHER|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
214777791|NCT00709020|OTHER|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
214777792|NCT04318249|BEHAVIORAL|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
214777793|NCT04318249|BEHAVIORAL|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
214777794|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
214777795|NCT02595541|DRUG|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
214777796|NCT02595541|DRUG|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
214777797|NCT03998215|BIOLOGICAL|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
214777798|NCT03125629|DRUG|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
214777799|NCT03125629|DRUG|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
214777800|NCT03125629|DEVICE|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
214777801|NCT03125629|DEVICE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
214777802|NCT03933839|BEHAVIORAL|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
214777803|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
214777804|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
214777805|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
214777806|NCT05780515|BIOLOGICAL|ANX009|ANX009 will be administered per schedule specified in the arm description.
214777807|NCT04106947|OTHER|Questionnaires|Questionnaires
214777808|NCT05851612|PROCEDURE|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
214777809|NCT05851612|PROCEDURE|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
214777810|NCT05851612|PROCEDURE|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
214777811|NCT00103415|BEHAVIORAL|Endurance training|
214777812|NCT00103415|BEHAVIORAL|Weight-lifting training|
214777813|NCT06536582|BIOLOGICAL|Platelet rich growth factor injection (autologous product)|All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
214777814|NCT02970175|DRUG|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
214777815|NCT02970175|PROCEDURE|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
214777816|NCT02970175|PROCEDURE|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
214777817|NCT02955992|BEHAVIORAL|Improving communication during the end-of-life process|
214777818|NCT04068571|BEHAVIORAL|I-PUSH|Innovative partnership for universal and sustainable healthcare
214777819|NCT01814995|BEHAVIORAL|Nutrition/Physical Activity Intervention|Please see Arm description.
214777820|NCT04800913|DIAGNOSTIC_TEST|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
214777821|NCT04800913|DIAGNOSTIC_TEST|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
214777822|NCT05632757|BEHAVIORAL|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
214777823|NCT04542330|BIOLOGICAL|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
214777824|NCT04542330|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
214777825|NCT03564509|DRUG|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
214777826|NCT03564509|DRUG|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
214777827|NCT03564509|DRUG|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
214777828|NCT03564509|DRUG|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
214777829|NCT03564509|DRUG|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
214777830|NCT03564509|OTHER|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
214777831|NCT03113175|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
214777832|NCT03113175|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
214777833|NCT03984136|BEHAVIORAL|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
214777834|NCT03984136|BEHAVIORAL|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
214777835|NCT02856620|OTHER|Observational only|Observational only
214777836|NCT06653790|BEHAVIORAL|Psychosocial stimulations|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
214777837|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
214777838|NCT05103410|DRUG|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
214777839|NCT05103410|DRUG|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
214777840|NCT05480488|DRUG|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
214777841|NCT05480488|DRUG|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
214777842|NCT05480488|DRUG|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
214777843|NCT02176642|DRUG|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
214777844|NCT02176642|DEVICE|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
214777845|NCT02176642|DRUG|Placebo|Tablet taken by mouth daily for 6 weeks
214777846|NCT03510013|PROCEDURE|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
214777847|NCT03510013|DRUG|Sevoflurane|Drug used for wash-in protocol
214777848|NCT00653887|OTHER|Biofeedback|4 sessions of biofeedback one session each week
214777849|NCT00653887|OTHER|Placebo|4 sessions, one each week, of discussion about anorectal disease
214777850|NCT00508235|BEHAVIORAL|Questionnaire|Questionnaire about the patient's relationship with their best friend.
214777851|NCT04419077|BEHAVIORAL|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
214777852|NCT00217971|DRUG|Dronabinol|Dronabinol
214777853|NCT00217971|DRUG|Placebo|placebo
214777854|NCT02989610|DEVICE|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
214777855|NCT02989610|DEVICE|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
214777856|NCT01532349|DRUG|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
214777857|NCT04609865|DRUG|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
214777858|NCT04609865|DRUG|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
214777859|NCT00116285|BIOLOGICAL|Ragweed MATA MPL|
214777860|NCT02073188|DEVICE|iBGStar|
214777861|NCT02073188|DEVICE|Traditional Glucometer|
214777862|NCT01083901|BEHAVIORAL|Resistance training|high intensity progressive resistance exercise training
214777863|NCT01066039|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
214777864|NCT00808015|DRUG|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
214777865|NCT04508621|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
214777866|NCT04508621|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
214777867|NCT03168269|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
214777868|NCT03567200|BEHAVIORAL|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
214777869|NCT06610279|DRUG|TAK-951|TAK-951 SC injection
214777870|NCT06610279|DRUG|Placebo|TAK-951 matching placebo SC injection
214777871|NCT06081946|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
214777872|NCT06081946|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
214777873|NCT03528967|DRUG|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
214777874|NCT03528967|DRUG|Aspirin 100 mg Oral Tablet, Enteric Coated|
214777875|NCT03717298|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
214777876|NCT04212741|DIETARY_SUPPLEMENT|A+ HA(tm)|oral solution of hyaluronic acid mixture
214777877|NCT04212741|DIETARY_SUPPLEMENT|Placebo|oral solution with no-active ingredients
214777878|NCT06540365|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
214777879|NCT01725737|DRUG|GlyTI-M|
214777880|NCT01725737|DRUG|Placebo|Placebo Comparator: starch
214777881|NCT00084617|DRUG|oxaliplatin|Given IV
214777882|NCT00084617|DRUG|irinotecan hydrochloride|Given IV
214777883|NCT00084617|DRUG|capecitabine|Given orally
214777884|NCT00377715|DRUG|Dimebon|
214777885|NCT00377715|DRUG|Placebo|
214777886|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
214777887|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
214777888|NCT01625286|DRUG|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
214777889|NCT01625286|DRUG|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
214777890|NCT00928135|DRUG|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
214777891|NCT00928135|DRUG|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
214777892|NCT03199898|DIAGNOSTIC_TEST|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
214777893|NCT03749525|DRUG|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
214777894|NCT04364542|PROCEDURE|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
214777895|NCT04364542|PROCEDURE|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
214777896|NCT04364542|PROCEDURE|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
214777897|NCT03338673|DEVICE|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
214777898|NCT03338673|OTHER|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
214777899|NCT00140738|BIOLOGICAL|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
214777900|NCT04187469|DRUG|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
214777901|NCT04187469|DRUG|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
214777902|NCT00402207|DRUG|extrafine HFA-beclomethasone|
214777903|NCT00402207|DRUG|HFA-fluticasone|
214777904|NCT04471792|DRUG|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
214777905|NCT04471792|DIETARY_SUPPLEMENT|Cellulose|Cellulose will be used in combination with muscle stretching.
214777906|NCT00327652|DRUG|CRS-100|Live-attenuated Listeria monocytogenes
214777907|NCT03747094|DRUG|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
214777908|NCT03747094|DRUG|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
214777909|NCT01845701|DRUG|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
214777910|NCT01845701|DRUG|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
214777911|NCT01845701|DRUG|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
214777912|NCT00434148|DRUG|Pasireotide|
214777913|NCT01005407|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
214777914|NCT01005407|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
214777915|NCT04369079|OTHER|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
214777916|NCT04369079|OTHER|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
214777917|NCT01624155|BEHAVIORAL|Education|EMR referral to teratogen and contraception counseling
214777918|NCT04709029|DRUG|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
214777919|NCT04709029|DRUG|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
214777920|NCT04169425|PROCEDURE|elective diverting ileostomy|
214777921|NCT01832545|OTHER|Aquatic Exercise|
214777922|NCT01832545|BEHAVIORAL|Educational Program|Control Group
214777923|NCT00275236|DRUG|Rotigotine|
214777924|NCT06420401|DIETARY_SUPPLEMENT|araboxylan|During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
214777925|NCT06420401|DIETARY_SUPPLEMENT|inulin|During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
214777926|NCT06420401|DIETARY_SUPPLEMENT|inulin and araboxylan|During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
214777927|NCT06420401|DIETARY_SUPPLEMENT|placebo control|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
214777928|NCT04399850|OTHER|Hypnosis group|Patients who receive hypnosis
214777929|NCT06303882|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
214777930|NCT06303882|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
214777931|NCT06303882|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
214777932|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
214777933|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume."
214777934|NCT00731601|DRUG|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
214777935|NCT00731601|DRUG|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
214777936|NCT00828516|OTHER|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
214777937|NCT03862937|DIETARY_SUPPLEMENT|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
214777938|NCT03862937|OTHER|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
214777939|NCT02980562|DRUG|Polyethylene Glycols|(Split dose 2L PEG-Asc)
214777940|NCT02980562|DRUG|Bisacodyl|(1L PEG-Asc plus bisacodyl)
214777941|NCT05602974|RADIATION|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
214777942|NCT05602974|OTHER|regular follow-up|regular follow-up
214777943|NCT02215239|BEHAVIORAL|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
214777944|NCT02350322|OTHER|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
214777945|NCT02350322|OTHER|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
214777946|NCT02350322|DIETARY_SUPPLEMENT|Supplement|Omega-3 capsules three times a week for 12 weeks
214777947|NCT01051973|BEHAVIORAL|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
214777948|NCT01051973|BEHAVIORAL|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
214777949|NCT01531062|DRUG|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
214777950|NCT01531062|DIETARY_SUPPLEMENT|black sticky rice|300 mg capsule bid, 56 days
214777951|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
214777952|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
214777953|NCT02118207|OTHER|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
214777954|NCT03633773|BIOLOGICAL|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
214777955|NCT00300573|DRUG|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
214777956|NCT00990093|DEVICE|test intermittent catheter|CH 12 hydrophilic coated catheter
214777957|NCT00990093|DEVICE|Intermittent catheterization|CH 12 hydrophilic catheter
214777958|NCT02218515|PROCEDURE|Open Flap Debridement|Open Flap Debridement (Control Group)
214777959|NCT02218515|BIOLOGICAL|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
214777960|NCT02218515|BIOLOGICAL|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
214777961|NCT02095210|OTHER|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
214777962|NCT00393978|DRUG|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
214777963|NCT00393978|DRUG|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
214777964|NCT05285631|DEVICE|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
214777965|NCT04556838|DRUG|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
214777966|NCT04556838|DRUG|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
214777967|NCT04556838|DRUG|Vehicle|VVN001 Ophthalmic Solution Vehicle
214777968|NCT04196088|DEVICE|Ultivision Artificial Intelligence Software|Screening Colonoscopy
214777969|NCT04196088|DEVICE|No Artificial Intelligence Software enhancement|Screening Colonoscopy
214777970|NCT03339531|RADIATION|2D radiotherapy|
214777971|NCT03760965|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214777972|NCT03760965|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214777973|NCT02680730|BEHAVIORAL|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
214777974|NCT00995930|DRUG|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
214777975|NCT00995930|DRUG|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
214777976|NCT03327142|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
214777977|NCT06611475|OTHER|MMSE ≤26|A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
214777978|NCT06114810|BIOLOGICAL|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
214777979|NCT01880541|OTHER|hypnosedation|hypnosedation
214777980|NCT01880541|OTHER|general anesthésia|general anesthesia
214777981|NCT05381883|OTHER|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
214777982|NCT06442826|OTHER|Non-invasive auricular stimulation|"Single session TniAS stimulation will be achieved by applying four stimulation patches. These patches consist of stainless steel spheres with a diameter of 1.2 mm, covered with adhesive circular paper measuring 8 mm in diameter.~Point 1. Located in the Triangular Fossa, upper and central level at the vertex of the Fossa, at junction between the upper root and the lower root of the Antihelix.~Point 2. Located in the inner part of the Cymba (upper) conchae, in the angle formed by the lower root of the antihelix and the ascending branch of the Helix.~Point 3. Located in the middle depression of the Cavum (lower) conchae.~Poinit 4. It is located at the inner superior quadrant of Lobe, below the external curve of the Intertragus notch, in a depression 3-4 mm from the insertion of the lobe to the face."
214777983|NCT06442826|OTHER|Sham auricular stimulation (SAS)|"Sham intervention will be conducted following the exact same procedure as the TniAS group, with the only difference being the use of sham stimulation patches. These sham patches will consist of the same patches utilized in the TniAS group, except for the absence of the stainless steel spheres. During the application of these sham patches, the investigator will adhere to the identical process as in the TniAS group, with the exception that no palpation will be performed to locate the exact points, and only minimal pressure required for patch adherence will be applied to minimize any substantial stimulation. Participants in the SAS group will also be explicitly instructed not to stimulate the points until the removal of the patches.~The removal of the sham stimulation patches will follow the precise protocol applied in the TniAS group, ensuring consistency in the study procedures across both groups."
214777984|NCT05003167|DEVICE|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
214777985|NCT05969782|DEVICE|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
214777986|NCT01667965|BEHAVIORAL|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
214777987|NCT01116765|OTHER|no stimulation of the oral structure|
214777988|NCT01116765|OTHER|stimulation of the oral structure|
214777989|NCT06529276|OTHER|Augmented reality clinical learning|Clinical learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation, using augmented reality immersive learning technology.
214777990|NCT06529276|OTHER|Control arm regular clinical learning|Regular bedside learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation,
214777991|NCT05725707|BEHAVIORAL|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
214777992|NCT04626557|PROCEDURE|biopsy|biopsy of the endometrium
214777993|NCT06696313|DEVICE|Insignia|"* Insignia hip stem~* Trident hemispherical shell~* X3 polyethylene liner~* Metal or ceramic head"
214777994|NCT05416359|DRUG|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
214777995|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
214777996|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
214777997|NCT06702345|OTHER|encapsulated 10^4 CFU toxigenic. C. difficile spores|12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.
214777998|NCT06702345|DRUG|Vancomycin|oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
214777999|NCT06702345|DRUG|Clindamycin|oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
214778000|NCT06701383|DEVICE|Cryoablation|Pulmonary vein isolation using cryoablation
214778001|NCT06701786|PROCEDURE|Compressive Sutures (CSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1mm, 2 horizontal incisions of approximately 3mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed . The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones. Three compressive sutures will be placed on the repositioned flap.
214778002|NCT06701786|PROCEDURE|Without Compressive Sutures (WCSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; than then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
214778003|NCT06700837|OTHER|Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea|To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
214778004|NCT06702215|DEVICE|Cross-modal paired associative stimulation (cm-PAS) protocol|The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
214778005|NCT06702085|BEHAVIORAL|Lifestyle Management|patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
214778006|NCT06702098|DRUG|iNK cells|Induced pluripotent stem cells derived NK cells.
214778007|NCT06697821|PROCEDURE|D2＋CME|Whether to perform the whole mesogastric excision
214778008|NCT02161939|DRUG|Daclatasvir (BMS-790052)|
214778009|NCT02161939|DRUG|Sofosbuvir|
214778010|NCT01612052|DRUG|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
214778011|NCT04815408|DRUG|BGB-A317|PD-1 antibody，Tislelizumab (BGB-A317)
214778012|NCT04815408|DRUG|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
214778013|NCT00049010|GENETIC|comparative genomic hybridization|
214778014|NCT00049010|GENETIC|cytogenetic analysis|
214778015|NCT00049010|GENETIC|fluorescence in situ hybridization|
214778016|NCT00049010|OTHER|immunohistochemistry staining method|
214778017|NCT01368757|DRUG|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
214778018|NCT06702826|DRUG|Cadonilimab combined with SRS|Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
214778019|NCT06702306|DIAGNOSTIC_TEST|Ultrasound Surveillance|Lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 and 12 months.
214778020|NCT06702735|BEHAVIORAL|Rainbow tool|The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
214778021|NCT06702735|BEHAVIORAL|Feedback|Feedback sessions with health care professional based on the Rainbow tool.
214778022|NCT06704113|DRUG|meloxicam 7,5mg|Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
214778023|NCT06702943|DRUG|Tigecycline (Tygacil)|tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
214778024|NCT06702943|DRUG|Colistimethate sodium (CMS)|Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
214778025|NCT06704048|OTHER|Cardiac rehabilitation|Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
214778026|NCT06704035|DIAGNOSTIC_TEST|Early OGTT Results Revealed|Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
214778027|NCT02934568|DRUG|LEE011|Single agent LEE011 or in combination with other treatments
214778028|NCT06702904|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
214778029|NCT06702904|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
214778030|NCT06702904|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
214778031|NCT06702904|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
214778032|NCT06703684|OTHER|Cross-sectional observational study|This is a cross-sectional observational study. No intervention will be given.
214778033|NCT03086642|DRUG|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
214778034|NCT06724939|OTHER|self-adhesive bulk-fill resin composite|surefil one self-adhesive bulk-fill composite
214778035|NCT01275521|DRUG|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
214778036|NCT01275521|DRUG|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
214778037|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
214778038|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
214778039|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
214778040|NCT02842086|DRUG|F/TAF|200/25 mg tablet administered orally once daily
214778041|NCT02842086|DRUG|F/TDF|200/300 mg tablet administered orally once daily
214778042|NCT02842086|DRUG|F/TAF Placebo|Tablet administered orally once daily
214778043|NCT02842086|DRUG|F/TDF Placebo|Tablet administered orally once daily
214778044|NCT06425146|PROCEDURE|Cytobrush sample|Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients
214778045|NCT06425146|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam
214778046|NCT01961635|DEVICE|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
214778047|NCT01961635|DEVICE|Zirconia abutments|place zirconia abutment on the day of implant placement
214778048|NCT01961635|DEVICE|Titanium Abutments|place titanium abutment on the day of implant placement
214778049|NCT01961635|DEVICE|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
214778050|NCT01961635|PROCEDURE|Subcrestal|place implant 2mm below crestal bone
214778051|NCT01961635|DEVICE|platform-switch|abutment platform is narrow than implant diameter
214778052|NCT01961635|PROCEDURE|one-time one-abutment|place the final abutment on the day of surgery and not remove it
214778053|NCT01961635|PROCEDURE|Torque 20 n/cm2|the amount of torque applied to the abutment
214778054|NCT03751124|DRUG|Relugolix|Relugolix 40 mg tablet administered orally once daily
214778055|NCT03751124|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
214778056|NCT03751124|DRUG|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
214778057|NCT03751124|DRUG|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
214778058|NCT04777591|DRUG|Liposomal bupivacaine TAP block|Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
214778059|NCT04777591|DRUG|Bupivacain|Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
214778060|NCT04920565|DEVICE|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
214778061|NCT05647694|OTHER|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
214778062|NCT04594200|BEHAVIORAL|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
214778063|NCT05290272|DEVICE|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
214778064|NCT01998035|DRUG|RomiDEPsin 10 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"
214778065|NCT01998035|DRUG|Oral 5-Azacitidine 100 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"
214778066|NCT01998035|DRUG|Romidepsin 14 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"
214778067|NCT01998035|DRUG|Oral 5-Azacitidine 200 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"
214778068|NCT01998035|DRUG|Oral 5-Azacitidine 300 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"
214778069|NCT00555399|DRUG|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
214778070|NCT00555399|DRUG|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days."
214778071|NCT00555399|PROCEDURE|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
214778072|NCT00555399|DRUG|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
214778073|NCT05525429|BEHAVIORAL|Nutrition Education|Multidimensional nutrition education will be provided.
214778074|NCT03910010|DRUG|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
214778075|NCT06516549|OTHER|Skipping rope and informational pamphlet|The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
214778076|NCT05392712|DEVICE|Magnetometer|inspection equipment for magnetocardiography
214778077|NCT03914937|OTHER|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
214778078|NCT03914937|OTHER|Music|Music of the patient's choice will be played
214778079|NCT05166421|BIOLOGICAL|AZD7442|AZD7442 will be administered via IM route.
214778080|NCT05166421|BIOLOGICAL|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
214778081|NCT05166421|BIOLOGICAL|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
214778082|NCT05166421|BIOLOGICAL|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
214778083|NCT05166421|BIOLOGICAL|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
214778084|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
214778085|NCT02516878|PROCEDURE|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
214778086|NCT05027009|PROCEDURE|Physical Examination|Undergo total body exam
214778087|NCT05027009|OTHER|Solar Simulated Light|Undergo exposures to simulated sunlight
214778088|NCT05633537|PROCEDURE|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
214778089|NCT05633537|RADIATION|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
214778090|NCT05407337|BEHAVIORAL|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
214778091|NCT02588352|DIETARY_SUPPLEMENT|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
214778092|NCT00000737|DRUG|Dronabinol|
214778093|NCT00000737|DRUG|Megestrol acetate|
214778094|NCT02546037|DEVICE|FX100 dialyzer|comparison of dialyzers
214778095|NCT02546037|DEVICE|SOLACEA 21H|comparison of dialyzers
214778096|NCT03958071|DRUG|Nintedanib|Nintedanib initiators
214778097|NCT03958071|DRUG|Pirfenidone|Pirfenidone initiators
214778098|NCT03958071|OTHER|Untreated Cohort|Untreated
214778099|NCT06497361|BIOLOGICAL|PRG-2311|PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
214778100|NCT00454311|PROCEDURE|Biopsy of Day 3 Embryo|
214778101|NCT00454311|PROCEDURE|· day embryo biopsy|
214778102|NCT02035683|PROCEDURE|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
214778103|NCT03829033|RADIATION|Radiotherapy|Radiotherapy with either photons or protons.
214778104|NCT00294320|DRUG|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
214778105|NCT00294320|OTHER|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
214778106|NCT05861440|DRUG|Prednisolone|adjunct steroid per study protocol
214778107|NCT05861440|DRUG|standard anti-tuberculosis agents|standard anti-tuberculosis agents
214778108|NCT05355831|DEVICE|Active Transcranial Direct Current Stimulation|See arm/group description
214778109|NCT05355831|DEVICE|Sham stimulation|See arm/group description
214778110|NCT01215682|DIETARY_SUPPLEMENT|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
214778111|NCT01215682|DIETARY_SUPPLEMENT|placebo|sweetened water
214778112|NCT01858558|BIOLOGICAL|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
214778113|NCT01858558|DRUG|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
214778114|NCT05721716|BEHAVIORAL|Mindfulness Booster Course|The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
214778115|NCT05721716|BEHAVIORAL|Usual care|Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
214778116|NCT05775263|PROCEDURE|CT angiogram|CT angiography of the brain 30 minutes from establishment of NRP
214778117|NCT00343642|DRUG|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
214778118|NCT00343642|DRUG|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
214778119|NCT00343642|DIETARY_SUPPLEMENT|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
214778120|NCT01051999|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine powder
214778121|NCT01051999|DIETARY_SUPPLEMENT|L-alanine|L-alanine oral powder
214778122|NCT00546832|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
214778123|NCT00546832|DRUG|celecoxib|
214778124|NCT00546832|OTHER|placebo|
214778125|NCT03470909|PROCEDURE|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
214778126|NCT03470909|PROCEDURE|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
214778127|NCT00256100|DRUG|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
214778128|NCT00515385|DRUG|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
214778129|NCT00515385|DRUG|MGAWN1|Single IV dose
214778130|NCT00515385|OTHER|Placebo|Single IV dose
214778131|NCT02316678|OTHER|No intervention|There is no intervention
214778132|NCT02268188|OTHER|education|Attend classes as part of Harvesting Health program
214778133|NCT02268188|OTHER|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
214778134|NCT02268188|BEHAVIORAL|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
214778135|NCT02268188|OTHER|questionnaire administration|Ancillary studies
214778136|NCT02268188|OTHER|laboratory biomarker analysis|Correlative studies
214778137|NCT02268188|OTHER|quality-of-life assessment|Ancillary studies
214778138|NCT04084028|BEHAVIORAL|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
214778139|NCT04084028|BEHAVIORAL|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
214778140|NCT04084028|BEHAVIORAL|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
214778141|NCT02043561|OTHER|induction of urge by rectal distension|
214778142|NCT04515511|OTHER|4% gelatin|Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
214778143|NCT04149054|BEHAVIORAL|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
214778144|NCT05974345|DRUG|Inclisiran sodium|Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
214778145|NCT05974345|DRUG|Placebo|Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
214778146|NCT05974345|DRUG|Ezetimibe|Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
214778147|NCT05974345|DRUG|Evolocumab|Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
214778148|NCT05897762|BEHAVIORAL|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
214778149|NCT03521544|OTHER|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
214778150|NCT03989180|DEVICE|C-Scan System|"* Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~* The recorder will be secured to their lower back to test its functionality"
214778151|NCT00779844|PROCEDURE|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
214778152|NCT00779844|PROCEDURE|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
214778153|NCT01140620|DRUG|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
214778154|NCT01140620|DRUG|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
214778155|NCT01140620|DRUG|saline|saline infusion. Duration approximately 3 hours
214778156|NCT01140620|DRUG|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
214778157|NCT02380066|DRUG|Anyu Peibo|Placebo
214778158|NCT02768220|DRUG|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
214778159|NCT02768220|DRUG|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
214778160|NCT00569231|DRUG|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
214778161|NCT01914822|DRUG|methylphenidate hydrochloride|
214778162|NCT01914822|DRUG|Sugar pill (placebo)|
214778163|NCT00004739|DRUG|Antiretroviral therapy|
214778164|NCT01957631|DRUG|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
214778165|NCT01957631|BIOLOGICAL|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
214778166|NCT00002273|DRUG|Ganciclovir|
214778167|NCT02071758|BIOLOGICAL|LEISH-F3 + SLA-SE|
214778168|NCT02071758|BIOLOGICAL|LEISH-F3 + GLA-SE|
214778169|NCT02100241|PROCEDURE|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
214778170|NCT00821041|BEHAVIORAL|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
214778171|NCT04989621|DRUG|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
214778172|NCT04989621|DRUG|Orelabrutinib|Orelabrutinib 150mg po qd
214778173|NCT03974581|OTHER|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
214778174|NCT03974581|OTHER|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
214778175|NCT00700310|DRUG|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
214778176|NCT00700310|DRUG|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
214778177|NCT00700310|DRUG|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
214778178|NCT00700310|DRUG|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
214778179|NCT02739802|DRUG|Coppertone(BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
214778180|NCT04331652|PROCEDURE|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
214778181|NCT05659706|OTHER|cognitive evaluations and non cognitive evaluations|Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
214778182|NCT02076932|BEHAVIORAL|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
214778183|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
214778184|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
214778185|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
214778186|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
214778187|NCT04397354|DRUG|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
214778188|NCT04397354|DRUG|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
214778189|NCT04397354|DRUG|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
214778190|NCT06112405|OTHER|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
214778191|NCT06112405|OTHER|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
214778192|NCT04806477|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
214778193|NCT04806477|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
214778194|NCT05189483|DRUG|Albumin-Bound Paclitaxel|Enrolled patients will receive 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
214778195|NCT05189483|DRUG|Camrelizumab|Enrolled patients will receive the following treatment: 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
214778196|NCT06190782|COMBINATION_PRODUCT|PD-1 inhibitor+/- chemotherapy combined with local therapy|"1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation"
214778197|NCT06190782|DRUG|systemic therapy alone|"1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)"
214778198|NCT01664273|DRUG|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
214778199|NCT01882231|OTHER|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
214778200|NCT06540092|DIAGNOSTIC_TEST|ultrasound|ultrasound measurements during first trimester
214778201|NCT00918229|DEVICE|balloon implant|Absorbable perirectal spacer implantation
214778202|NCT00918229|PROCEDURE|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
214778203|NCT03666546|DRUG|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
214778204|NCT03666546|DRUG|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
214778205|NCT03666546|DRUG|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
214778206|NCT03666546|DRUG|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
214778207|NCT03666546|DRUG|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
214778208|NCT03666546|DRUG|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
214778209|NCT01913873|OTHER|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
214778210|NCT01864720|BEHAVIORAL|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
214778211|NCT01864720|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
214778212|NCT01837420|DRUG|VB-201 80mg|
214778213|NCT01837420|DRUG|VB-201 160mg|
214778214|NCT01837420|DRUG|Placebo|
214778215|NCT00818831|DRUG|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
214778216|NCT05025982|PROCEDURE|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
214778217|NCT01999231|BIOLOGICAL|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
214778218|NCT01572831|OTHER|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and \>4,000).
214778219|NCT00003682|DRUG|doxorubicin hydrochloride|
214778220|NCT00003682|DRUG|methylprednisolone|
214778221|NCT00888030|OTHER|there are no interventions currently listed for this study|
214778222|NCT03060148|DEVICE|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
214778223|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered SC
214778224|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered IV
214778225|NCT03053622|BIOLOGICAL|Mirikizumab Reference|Administered SC
214778226|NCT05066074|PROCEDURE|Distal Radial Vascular Access|Distal Radial Vascular Access
214778227|NCT03648086|OTHER|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
214778228|NCT02598622|DRUG|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
214778229|NCT02598622|DRUG|Placebo|Placebo is taken 2 times a day for days 1 through 21.
214778230|NCT05043727|COMBINATION_PRODUCT|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
214778231|NCT05043727|COMBINATION_PRODUCT|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
214778232|NCT06016101|OTHER|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~* Pill counting~* Morisky questionnaire"
214778233|NCT06016101|OTHER|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~* Evaluation of user experience~* Evaluation of the report produced by the application"
214778234|NCT01127386|DRUG|Lenalidomide|25mg od, dose reduction according to toxicity
214778235|NCT01127386|DRUG|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
214778236|NCT01127386|OTHER|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
214778237|NCT03406039|BEHAVIORAL|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
214778238|NCT01746563|DRUG|Ranibizumab|Intravitreal injection
214778239|NCT01746563|PROCEDURE|Laser therapy|Laser therapy
214778240|NCT02881463|OTHER|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
214778241|NCT01561118|OTHER|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
214778242|NCT03608410|OTHER|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
214778243|NCT00158795|BIOLOGICAL|Haemophilus Influenza type b vaccine|
214778244|NCT02272881|PROCEDURE|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
214778245|NCT02272881|PROCEDURE|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
214778246|NCT00077402|DRUG|fenretinide|
214778247|NCT04575038|DRUG|Brequinar|Dihydroorotate dehydrogenase inhibitor (DHODHi)
214778248|NCT04575038|DRUG|Placebo|Placebo capsules
214778249|NCT03191019|BEHAVIORAL|Mobile-phone app for smoking cessation|Android App for smoking cessation
214778250|NCT04972136|DEVICE|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
214778251|NCT04972136|DEVICE|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
214778252|NCT03455335|DRUG|20 million hMSCs|
214778253|NCT03455335|DRUG|40 million hMSCs|
214778254|NCT03455335|DRUG|80 million hMSCs|
214778255|NCT03728699|DIAGNOSTIC_TEST|Sample Collection Blood|Collected from each patient twice weekly.
214778256|NCT03728699|DIAGNOSTIC_TEST|Stool Sample|Collected from each patient twice weekly.
214778257|NCT01168700|DRUG|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
214778258|NCT01168700|DRUG|Placebo|Placebo 1.2 g per day for 12 weeks.
214778259|NCT01339078|PROCEDURE|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
214778260|NCT01339078|PROCEDURE|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
214778261|NCT02579785|BEHAVIORAL|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
214778262|NCT03054961|DEVICE|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
214778263|NCT04322227|DRUG|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
214778264|NCT04322227|DRUG|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
214778265|NCT04322227|DRUG|Placebo (treatment C)|Placebo, BID capsules, orally
214778266|NCT02037373|BIOLOGICAL|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
214778267|NCT02037373|BIOLOGICAL|Plasma|Plasma as prescribed by the treating physician.
214778268|NCT04345731|OTHER|Over the counter drug labels|A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
214778269|NCT01358019|DRUG|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
214778270|NCT06160479|DRUG|Calcium supplement|Different amount of calcium supplement in pregnancy
214778271|NCT03398655|DRUG|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
214778272|NCT03398655|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
214778273|NCT06542510|BEHAVIORAL|working night shift|working night shift
214778274|NCT03171506|OTHER|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
214778275|NCT03171506|OTHER|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
214778276|NCT04377178|DEVICE|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
214778277|NCT04377178|DEVICE|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
214778278|NCT04202354|DRUG|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
214778279|NCT04202354|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
214778280|NCT02270905|DEVICE|dCELL® Meniscus|decellularised porcine xenograft
214778281|NCT05530642|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire \& Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
214778282|NCT01318733|DRUG|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
214778283|NCT02621827|OTHER|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
214778284|NCT03038282|DIETARY_SUPPLEMENT|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
214778285|NCT03038282|OTHER|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
214778286|NCT05436691|OTHER|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
214778287|NCT00813501|BIOLOGICAL|immunosuppressive therapy|
214778288|NCT00813501|OTHER|immunological diagnostic method|
214778289|NCT00813501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214778290|NCT01292460|DRUG|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
214778291|NCT05216328|DRUG|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
214778292|NCT05216328|DRUG|Magnesium hydroxide 724mg|Information already included in arm/group description.
214778293|NCT02088294|BEHAVIORAL|Lifestyle Education (LS)|See arm description
214778294|NCT02088294|BEHAVIORAL|LS + Stress Reduction Guided Imagery|See Arm Description
214778295|NCT02088294|BEHAVIORAL|LS + Activity/Eating Guided Imagery|See arm description
214778296|NCT06008639|DEVICE|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
214778297|NCT06008639|DEVICE|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
214778298|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
214778299|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
214778300|NCT06353035|OTHER|Rewilding|Private yards of the intervention study subjects will be modified with vegetation and deadwood.
214778301|NCT01902134|DRUG|Placebo|Placebo single oral dose (first 8 hours)
214778302|NCT01902134|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
214778303|NCT01902134|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
214778304|NCT01902134|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
214778305|NCT01902134|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
214778306|NCT01902134|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
214778307|NCT01902134|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
214778308|NCT05613335|PROCEDURE|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
214778309|NCT05613335|PROCEDURE|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
214778310|NCT00305110|DRUG|2 mg IV hydromorphone|
214778311|NCT05802095|DEVICE|Supplemental Feeding Tube Device|One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
214778312|NCT03518710|OTHER|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~* Process evaluation:~* Oculomotors: DEM test (5min)~* Visuo-attention: computerized STROOP (15min)~* Visuo-Perceptive: DTVP3 (30min)~* Phonological \& lexical: Exalang (10min)"
214778313|NCT03518710|OTHER|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~\- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
214778314|NCT05693181|BIOLOGICAL|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10\*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
214778315|NCT05693181|OTHER|Control vehicle (sterile saline)|Sterile saline infusion in control patients
214778316|NCT01824069|OTHER|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
214778317|NCT00678379|DRUG|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
214778318|NCT00678379|DRUG|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
214778319|NCT00678379|DRUG|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
214778320|NCT05488652|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
214778321|NCT04897100|PROCEDURE|Achilles tendon tenotomy|Achilles tendon tenotomy during Ponseti treatment for clubfoot
214778322|NCT01835470|DRUG|Abatacept|
214778323|NCT01405885|BIOLOGICAL|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778324|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778325|NCT01405885|BIOLOGICAL|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778326|NCT01405885|BIOLOGICAL|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778327|NCT01405885|BIOLOGICAL|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778328|NCT01405885|BIOLOGICAL|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778329|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
214778330|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
214778331|NCT01405885|BIOLOGICAL|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
214778332|NCT01405885|BIOLOGICAL|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
214778333|NCT00343811|DRUG|Modafinil|
214778334|NCT04839237|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
214778335|NCT04839237|DRUG|Liraglutide;metformin|The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
214778336|NCT05952427|OTHER|ACE Questionnaire|The only intervention consists of completing the validated ACE questionnaire
214778337|NCT02046473|PROCEDURE|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
214778338|NCT03867227|DEVICE|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
214778339|NCT00543582|DRUG|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
214778340|NCT04036227|DRUG|GS-248|GS-248 oral solution
214778341|NCT04036227|DRUG|Placebo|Placebo oral solution with the same composition to match active drug
214778342|NCT02086526|DRUG|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
214778343|NCT03312582|DRUG|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
214778344|NCT03312582|PROCEDURE|Placebo|
214778345|NCT02565082|OTHER|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
214778346|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
214778347|NCT02565082|OTHER|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
214778348|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
214778349|NCT01363401|BIOLOGICAL|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
214778350|NCT01363401|OTHER|Control group|No treatment of HYNR-CS inj
214778351|NCT02267850|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
214778352|NCT02267850|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
214778353|NCT02267850|DEVICE|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
214778354|NCT00989040|DRUG|usual treatment: Versatis|"* To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~* To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
214778355|NCT05074563|OTHER|REsOluTioN (Resilience Enhancement Online Training for Nurses)|The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
214778356|NCT05074563|OTHER|Control|Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
214778357|NCT05438290|DRUG|DPCP|topical immunomodulator
214778358|NCT03005379|DRUG|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
214778359|NCT03005379|DRUG|Placebo|Oral capsule-delivered placebo
214778360|NCT02938910|OTHER|non interventional study|Non invasive imaging study without interventional procedures
214778361|NCT01505595|OTHER|Proprioceptive training|12 weeks
214778362|NCT01505595|OTHER|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
214778363|NCT04335110|BEHAVIORAL|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
214778364|NCT02886481|DEVICE|perioperative monitoring|
214778365|NCT01805310|OTHER|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
214778366|NCT01805310|OTHER|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
214778367|NCT04514146|OTHER|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
214778368|NCT00803946|DRUG|Ibuprofen Tablets, 800 mg|
214778369|NCT00350519|DRUG|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
214778370|NCT00350519|DRUG|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
214778371|NCT05826106|PROCEDURE|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
214778372|NCT02197221|DRUG|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
214778373|NCT02197221|DRUG|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
214778374|NCT00058617|BIOLOGICAL|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
214778375|NCT05103059|DIAGNOSTIC_TEST|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
214778376|NCT00591487|DRUG|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
214778377|NCT00410215|DRUG|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
214778378|NCT00410215|DRUG|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
214778379|NCT00410215|DRUG|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
214778380|NCT01838161|BEHAVIORAL|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
214778381|NCT01838161|BEHAVIORAL|Part III|•video educational
214778382|NCT01838161|BEHAVIORAL|Part I|Parental Interviews
214778383|NCT02595528|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
214778384|NCT02595528|DRUG|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
214778385|NCT02595528|DRUG|AGN-190584 vehicle|Vehicle to AGN-190584
214778386|NCT02595528|DRUG|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
214778387|NCT02595528|DRUG|AGN-199201 vehicle|Vehicle to AGN-199201
214778388|NCT02345928|DRUG|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
214778389|NCT02345928|DRUG|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
214778390|NCT02345928|DRUG|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
214778391|NCT02345928|DRUG|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
214778392|NCT02391883|DRUG|Clopidogrel|
214778393|NCT02177747|OTHER|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
214778394|NCT02177747|DEVICE|Smartphone|
214778395|NCT00407433|DRUG|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
214778396|NCT05103397|DRUG|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
214778397|NCT05103397|DRUG|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
214778398|NCT05103397|DRUG|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
214778399|NCT00630682|DRUG|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
214778400|NCT00630682|DRUG|Placebo|9 weeks of placebo 60mg capsules QD.
214778401|NCT00948025|DEVICE|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
214778402|NCT00948025|OTHER|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
214778403|NCT06274125|PROCEDURE|Robotic-Assisted Laparoscopic Radical Prostatectomy|To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
214778404|NCT01637961|DRUG|Alisertib|Given PO
214778405|NCT01637961|OTHER|Laboratory Biomarker Analysis|Correlative studies
214778406|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
214778407|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
214778408|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
214778409|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
214778410|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
214778411|NCT05940883|DRUG|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
214778412|NCT03639961|BEHAVIORAL|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
214778413|NCT03639961|BEHAVIORAL|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
214778414|NCT05827783|PROCEDURE|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
214778415|NCT05827783|PROCEDURE|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
214778416|NCT01838083|DRUG|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
214778417|NCT04651283|OTHER|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
214778418|NCT04651283|OTHER|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
214778419|NCT03317145|DEVICE|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
214778420|NCT03317145|DEVICE|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
214778421|NCT01878747|BEHAVIORAL|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
214778422|NCT04321733|DRUG|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
214778423|NCT04324398|OTHER|Cryotherapy|cold application
214778424|NCT02292433|DRUG|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
214778425|NCT02292433|DRUG|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
214778426|NCT02292433|DRUG|Placebo|tablets, breakfast plus lunch, 7 days
214778427|NCT06093828|DEVICE|TriFlo Tricuspid Flow Optimizer|An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
214778428|NCT03602898|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214778429|NCT03602898|DRUG|Busulfan|Given IV or PO
214778430|NCT03602898|DRUG|Cyclophosphamide|Given IV
214778431|NCT03602898|DRUG|Cyclosporine|Given IV or PO
214778432|NCT03602898|DRUG|Fludarabine Phosphate|Given IV
214778433|NCT03602898|DRUG|Methotrexate|Given IV
214778434|NCT03602898|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
214778435|NCT03602898|OTHER|Quality-of-Life Assessment|Ancillary studies
214778436|NCT03602898|OTHER|Questionnaire Administration|Ancillary studies
214778437|NCT03602898|DRUG|Tacrolimus|Given IV or PO
214778438|NCT03602898|RADIATION|Total-Body Irradiation|Undergo TBI
214778439|NCT03671265|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
214778440|NCT03671265|RADIATION|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
214778441|NCT03671265|DRUG|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
214778442|NCT03101293|DRUG|TAK-831|TAK-831 film-coated tablet.
214778443|NCT06091774|DEVICE|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
214778444|NCT02833857|DRUG|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
214778445|NCT03182920|DRUG|Lasmiditan|Oral administration
214778446|NCT03182920|DRUG|Placebo|Oral administration
214778447|NCT04718857|BEHAVIORAL|Online education|health education
214778448|NCT03637673|OTHER|No intervention|No intervention
214778449|NCT03815357|OTHER|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
214778450|NCT01091376|DRUG|Erlotinib|Erlotinib 150mg/day
214778451|NCT01091376|RADIATION|Thoracic radiotherapy|60-70Gy/30-35f
214778452|NCT05088824|PROCEDURE|hernia repair by desarda technique|It involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. This is a physiological repair and is tension free, can be used in strangulated hernia
214778453|NCT00769899|DRUG|AZD7325|Capsule for oral, single dose
214778454|NCT00769899|DRUG|Placebo|Placebo capsule for oral, single dose
214778455|NCT04681456|BEHAVIORAL|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
214778456|NCT02881073|OTHER|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
214778457|NCT01929148|PROCEDURE|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
214778458|NCT01929148|PROCEDURE|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
214778459|NCT01454882|BEHAVIORAL|Effects of Clothing|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
214778460|NCT01454882|BEHAVIORAL|Effects of Temperature|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
214778461|NCT01454882|BEHAVIORAL|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
214778462|NCT01454882|BEHAVIORAL|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
214778463|NCT01454882|BEHAVIORAL|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
214778464|NCT03914144|OTHER|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
214778465|NCT02288689|DEVICE|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
214778466|NCT05028686|OTHER|No intervention|Observational cohort
214778467|NCT03448809|BEHAVIORAL|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
214778468|NCT03448809|BEHAVIORAL|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
214778469|NCT04075188|DRUG|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
214778470|NCT04987307|DRUG|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
214778471|NCT04987307|DRUG|Placebo|Placebo will be administered by SC injection.
214778472|NCT05319977|BEHAVIORAL|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
214778473|NCT00028938|BIOLOGICAL|epoetin alfa|
214778474|NCT00028938|DRUG|carboplatin|
214778475|NCT00028938|DRUG|paclitaxel|
214778476|NCT00028938|RADIATION|radiation therapy|
214778477|NCT03333382|DEVICE|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
214778478|NCT03333382|DEVICE|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
214778479|NCT02257827|RADIATION|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
214778480|NCT02523729|DIETARY_SUPPLEMENT|Anke Malz|non-alcoholic malt drink
214778481|NCT02746029|OTHER|Clinical examination|
214778482|NCT03296774|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
214778483|NCT03296774|BEHAVIORAL|Usual Care|
214778484|NCT00550420|DRUG|Rosiglitazone XR|experimental drug
214778485|NCT02845973|BIOLOGICAL|gut microbiota|
214778486|NCT05110430|OTHER|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
214778487|NCT05309174|PROCEDURE|USG-guided iSLN block|Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
214778488|NCT02554825|BEHAVIORAL|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
214778489|NCT02554825|BEHAVIORAL|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
214778490|NCT06379022|BEHAVIORAL|Plaque control|Subjects are motivated for optimal oral hygiene
214778491|NCT01305265|DEVICE|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
214778492|NCT03606239|RADIATION|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
214778493|NCT03538522|DRUG|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
214778494|NCT03538522|DRUG|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
214778495|NCT03538522|DRUG|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
214778496|NCT03538522|DRUG|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
214778497|NCT00685022|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI"
214778498|NCT00685022|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI"
214778499|NCT00670267|DRUG|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
214778500|NCT03512067|DEVICE|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
214778501|NCT02270840|DEVICE|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
214778502|NCT00006096|DRUG|cisplatin|
214778503|NCT00006096|RADIATION|radiation therapy|
214778504|NCT06173986|DRUG|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
214778505|NCT06173986|DRUG|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
214778506|NCT06173986|RADIATION|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
214778507|NCT00677586|PROCEDURE|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
214778508|NCT00677586|PROCEDURE|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
214778509|NCT00819858|DIETARY_SUPPLEMENT|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
214778510|NCT01177319|DRUG|Glutathione|
214778511|NCT05764902|BEHAVIORAL|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
214778512|NCT01178112|DRUG|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
214778513|NCT01178112|DRUG|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
214778514|NCT01178112|DRUG|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
214778515|NCT01178112|DRUG|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
214778516|NCT01178112|OTHER|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
214778517|NCT03635619|OTHER|No intervention|No intervention
214778518|NCT03733184|PROCEDURE|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
214778519|NCT01637259|DRUG|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
214778520|NCT01637259|DRUG|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
214778521|NCT01637259|DRUG|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
214778522|NCT03205007|BEHAVIORAL|Health promotion nutrition program|Health promotion nutrition program
214778523|NCT05990647|DIAGNOSTIC_TEST|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
214778524|NCT05990647|DIAGNOSTIC_TEST|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
214778525|NCT05990647|DIAGNOSTIC_TEST|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
214778526|NCT05990647|DIAGNOSTIC_TEST|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
214778527|NCT00572247|BEHAVIORAL|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
214778528|NCT01862120|DRUG|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
214778529|NCT01862120|DRUG|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
214778530|NCT01862120|DRUG|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
214778531|NCT01862120|DRUG|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
214778532|NCT02773446|BIOLOGICAL|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
214778533|NCT03432026|DEVICE|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
214778534|NCT00330200|DRUG|ISIS 113715|
214778535|NCT03237611|DRUG|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
214778536|NCT03237611|DRUG|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
214778537|NCT03237611|DRUG|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
214778538|NCT03237611|DRUG|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
214778539|NCT05450497|DRUG|Propofol|comparing sedative agents
214778540|NCT05450497|DRUG|Dexmedetomidine|comparing sedative agents
214778541|NCT05450497|DRUG|Dexmedetomidine and propofol|comparing sedative agents
214778542|NCT04929197|DEVICE|PERSBRA|"After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA."
214778543|NCT00865982|DRUG|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
214778544|NCT04042974|DRUG|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
214778545|NCT04042974|DRUG|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
214778546|NCT01724476|DRUG|folate with B12|
214778547|NCT01724476|DRUG|placebo|
214778548|NCT03063489|DRUG|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
214778549|NCT03953365|PROCEDURE|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
214778550|NCT01673165|OTHER|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
214778551|NCT01673165|OTHER|Specialized Formula|Infants will receive our standard of care - specialized formula
214778552|NCT01430182|DRUG|Methadone|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
214778553|NCT01430182|DRUG|Morphine|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
214778554|NCT01613131|DRUG|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
214778555|NCT01613131|DRUG|Estradiol|Topical, .06%, Applied once daily for 50 days.
214778556|NCT01613131|DRUG|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
214778557|NCT04568369|DEVICE|rTMS|See treatment arm description.
214778558|NCT06382467|DRUG|Remimazolam besylate + propofol MCT|remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
214778559|NCT06382467|DRUG|Propofol MCT|Propofol MCT 2-8 mcg/ml using target-controlled infusion
214778560|NCT04641572|OTHER|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
214778561|NCT03094208|OTHER|dual task balance training|balance exercises with cognitive and motor dual tasks
214778562|NCT03094208|OTHER|traditional balance training|balance exercises
214778563|NCT05822700|PROCEDURE|Kirschner wire|Transfixing femoral head Kirschner wire
214778564|NCT01814761|DRUG|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
214778565|NCT01997528|DEVICE|Change of blood flow or sweep gas flow ( ILA Activve)|
214778566|NCT06020105|BEHAVIORAL|NURLIFE|After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
214778567|NCT00038883|DRUG|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
214778568|NCT03137082|DRUG|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
214778569|NCT03137082|DRUG|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
214778570|NCT03413527|DEVICE|rTMS|rTMS Treatment
214778571|NCT01416376|DRUG|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
214778572|NCT01416376|DRUG|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
214778573|NCT00206466|DRUG|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
214778574|NCT00206466|DRUG|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
214778575|NCT02768740|DRUG|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
214778576|NCT01362114|DRUG|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
214778577|NCT01362114|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
214778578|NCT00939705|DRUG|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
214778579|NCT01020305|DRUG|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
214778580|NCT01020305|DRUG|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
214778581|NCT04063566|PROCEDURE|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
214778582|NCT04063566|PROCEDURE|Prostate-specific antigen (PSA) test|Blood test for PSA levels
214778583|NCT04314427|PROCEDURE|Roux-en-Y gastric bypass|
214778584|NCT04314427|PROCEDURE|Sleeve gastrectomy|
214778585|NCT01653483|DRUG|GSK573719|Novel Dry-Powder Inhaler
214778586|NCT01653483|DRUG|GSK573719matched-placebo|Novel Dry-Powder Inhaler
214778587|NCT04843176|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
214778588|NCT04843176|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
214778589|NCT02184494|DEVICE|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
214778590|NCT01017029|DRUG|Everolimus|
214778591|NCT01017029|DRUG|Mycophenolate mofetil + Everolimus|
214778592|NCT04426526|DEVICE|BTL 799-2|High power magnet system
214778593|NCT04156191|DRUG|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
214778594|NCT04156191|DRUG|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
214778595|NCT06529224|OTHER|Online questionnaire|An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
214778596|NCT01671384|DRUG|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
214778597|NCT01671384|DRUG|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
214778598|NCT04934514|BIOLOGICAL|IAH0968|IAH0968 is an investigational product.
214778599|NCT04934514|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenous infusion
214778600|NCT04934514|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 intravenous infusion
214778601|NCT01702350|DRUG|GSK2251052|Oral formulation of an an antibacterial
214778602|NCT05934032|OTHER|observational, non-interventional|observational, non-interventional
214778603|NCT01779947|DRUG|Estradiol Vaginal Tablets 10 mcg|
214778604|NCT01779947|DRUG|placebo|
214778605|NCT00718965|DRUG|AVE5530|one tablet in the evening with dinner
214778606|NCT00718965|DRUG|Placebo|one tablet in the evening with dinner
214778607|NCT00618774|DRUG|telmisartan40/amlodipine5|
214778608|NCT00618774|DRUG|telmisartan80/amlodipine5|
214778609|NCT00136019|DRUG|SPM 927|
214778610|NCT04342403|DIAGNOSTIC_TEST|Quality of Life|Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
214778611|NCT00092079|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
214778612|NCT05245981|DEVICE|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
214778613|NCT02350010|DEVICE|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
214778614|NCT04116346|OTHER|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
214778615|NCT00446264|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
214778616|NCT00446264|DRUG|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
214778617|NCT02056275|OTHER|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
214778618|NCT02056275|OTHER|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
214778619|NCT04801979|DIAGNOSTIC_TEST|Incremental Step Test|"Performance of the incremental step test (number of steps) for the assessment of exercise capacity. The step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
214778620|NCT00398359|BEHAVIORAL|Motivational Interviewing (physicians)|Identifying and referring children with BMI \>93%.
214778621|NCT00398359|BEHAVIORAL|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
214778622|NCT04025970|GENETIC|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
214778623|NCT05364099|DRUG|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
214778624|NCT05364099|DRUG|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
214778625|NCT05364099|PROCEDURE|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
214778626|NCT03619499|DEVICE|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
214778627|NCT03372499|DIETARY_SUPPLEMENT|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
214778628|NCT02753400|DRUG|emixustat hydrochloride|Tablet for oral administration
214778629|NCT02753400|OTHER|Placebo|Placebo tablets for oral administration contain only inactive ingredients
214778630|NCT01824771|OTHER|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
214778631|NCT02796196|OTHER|Medical Chart Review|Review of medical chart
214778632|NCT02796196|DEVICE|Monitoring Device|Wearable physical activity monitoring device
214778633|NCT02796196|PROCEDURE|Physical Therapy|Undergo primarily self-directed physical therapy
214778634|NCT01415921|DRUG|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
214778635|NCT01815021|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
214778636|NCT01815021|DIETARY_SUPPLEMENT|crystalline calcium supplements|
214778637|NCT00600288|DRUG|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
214778638|NCT00600288|DRUG|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
214778639|NCT00377728|DRUG|GSK256066|
214778640|NCT04980521|OTHER|The radon app|Participants will be asked to use the radon app.
214778641|NCT04980521|OTHER|Print brochure|Participants will receive print brochures.
214778642|NCT03440203|OTHER|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
214778643|NCT02660385|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
214778644|NCT02660385|BEHAVIORAL|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
214778645|NCT02287337|PROCEDURE|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
214778646|NCT02287337|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
214778647|NCT00154037|DRUG|Pioglitazone (drug) and/or candesartan (drug)|
214778648|NCT01132456|DEVICE|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
214778649|NCT05122585|PROCEDURE|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
214778650|NCT05172856|DRUG|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
214778651|NCT01300845|PROCEDURE|Humidification|From randomization, oxygen therapy is humidified
214778652|NCT01300845|PROCEDURE|No Humidification|oxygen therapy is never humidified
214778653|NCT02352506|OTHER|Blood draw for measurement of MIF|Observational study, no intervention
214778654|NCT02883309|OTHER|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
214778655|NCT01527825|BIOLOGICAL|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
214778656|NCT01527825|BIOLOGICAL|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
214778657|NCT01830920|DRUG|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
214778658|NCT01830920|DRUG|Placebo|A normal saline solution identical in appearance to the active drug solution
214778659|NCT05789303|DRUG|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
214778660|NCT05789303|DRUG|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
214778661|NCT05789303|DRUG|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
214778662|NCT05789303|DRUG|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
214778663|NCT03726086|DIAGNOSTIC_TEST|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
214778664|NCT02997969|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
214778665|NCT02997969|BIOLOGICAL|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
214778666|NCT02997969|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
214778667|NCT00896701|OTHER|flow cytometry|
214778668|NCT00896701|OTHER|immunologic technique|
214778669|NCT00896701|OTHER|laboratory biomarker analysis|
214778670|NCT02841605|PROCEDURE|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
214778671|NCT02841605|PROCEDURE|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
214778672|NCT00002084|DRUG|Valacyclovir hydrochloride|
214778673|NCT00002084|DRUG|Acyclovir|
214778674|NCT03628222|DEVICE|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
214778675|NCT03628222|DEVICE|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
214778676|NCT01990898|DRUG|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
214778677|NCT03358732|DEVICE|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
214778678|NCT01878500|DEVICE|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
214778679|NCT02103634|DEVICE|NaF PET/MRI|
214778680|NCT02103634|DEVICE|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
214778681|NCT02103634|DEVICE|FDG PET/CT|
214778682|NCT03402126|OTHER|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
214778683|NCT02442752|DRUG|Dexlansoprazole|Dexlansoprazole capsules
214778684|NCT01220089|BEHAVIORAL|Standard maintenance|Participants will receive written materials in months 7-18
214778685|NCT01220089|BEHAVIORAL|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
214778686|NCT03354962|COMBINATION_PRODUCT|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
214778687|NCT03354962|COMBINATION_PRODUCT|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
214778688|NCT04009473|COMBINATION_PRODUCT|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
214778689|NCT01457729|BEHAVIORAL|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
214778690|NCT02846467|OTHER|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
214778691|NCT02846467|OTHER|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
214778692|NCT00390169|BEHAVIORAL|Mindfulness Meditation-Based Stress Reduction|
214778693|NCT00390169|BEHAVIORAL|Supportive-Expressive Group Therapy|
214778694|NCT00101205|DRUG|oxaliplatin|Given IV
214778695|NCT00101205|DRUG|etoposide|Given IV
214778696|NCT05880628|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)"
214778697|NCT00146237|DRUG|phenytoin|
214778698|NCT00309127|BEHAVIORAL|Multidisciplinary team care|
214778699|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
214778700|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
214778701|NCT01243866|OTHER|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
214778702|NCT01243866|OTHER|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
214778703|NCT00720304|DRUG|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
214778704|NCT00720304|DRUG|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
214778705|NCT00720304|GENETIC|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778706|NCT00720304|GENETIC|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778707|NCT00720304|OTHER|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778708|NCT00720304|OTHER|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778709|NCT00720304|OTHER|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778710|NCT00720304|OTHER|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
214778711|NCT00720304|PROCEDURE|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
214778712|NCT00720304|RADIATION|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
214778713|NCT00720304|RADIATION|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
214778714|NCT06542692|DEVICE|Whole Body Vibration|treatment duration, frequency
214778715|NCT06542692|DEVICE|physical therapy modalities|ultrasound, hot pack, tens
214778716|NCT01933412|BIOLOGICAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
214778717|NCT01933412|BIOLOGICAL|Engerix B Hepatitis B Vaccine|
214778718|NCT03660514|BEHAVIORAL|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
214778719|NCT01822964|DEVICE|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
214778720|NCT01822964|DEVICE|Placebo - current clinical practice, no cooling|
214778721|NCT01333475|DRUG|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
214778722|NCT04514809|OTHER|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
214778723|NCT04811911|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
214778724|NCT04811911|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
214778725|NCT03526185|DRUG|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
214778726|NCT03526185|DRUG|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
214778727|NCT04948385|DRUG|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
214778728|NCT04948385|PROCEDURE|No sedation|No sedation
214778729|NCT02981602|DRUG|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
214778730|NCT02981602|DRUG|Placebo|Placebo
214778731|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
214778732|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.
214778733|NCT02270931|DEVICE|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
214778734|NCT01489696|DRUG|mirabegron|oral
214778735|NCT01489696|DRUG|tamsulosin|oral
214778736|NCT04839588|OTHER|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
214778737|NCT00238056|DRUG|domperidone Drug|
214778738|NCT00612079|DRUG|Sertindole|oral 3 x 4mg
214778739|NCT00612079|DRUG|Placebo|3 x 4mg Placebo
214778740|NCT01632683|DEVICE|C-MAC|C-MAC arm
214778741|NCT01632683|DEVICE|Glidescope|Glidescope arm
214778742|NCT00970931|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
214778743|NCT00970931|DRUG|placebo|Oral placebo once a day, for 18 months
214778744|NCT02059031|DRUG|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
214778745|NCT02059031|DRUG|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
214778746|NCT02059031|DRUG|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
214778747|NCT05154188|DEVICE|Neuro Cochlear Implant system|Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose
214778748|NCT04506125|OTHER|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
214778749|NCT04506125|OTHER|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
214778750|NCT05037942|OTHER|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
214778751|NCT05037942|OTHER|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
214778752|NCT03695406|BEHAVIORAL|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
214778753|NCT01706770|DEVICE|enfilcon A|
214778754|NCT01706770|DEVICE|galyfilcon A|
214778755|NCT00944385|DRUG|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
214778756|NCT01247896|DRUG|PF-05190457|Single Dose 2 mg
214778757|NCT01247896|DRUG|PF-05190457|Single Dose 10 mg
214778758|NCT01247896|DRUG|PF-05190457|Single Dose 30 mg
214778759|NCT01247896|DRUG|PF-05190457|Single Dose 100 mg
214778760|NCT01247896|DRUG|PF-05190457|Single Dose 300 mg
214778761|NCT01247896|DRUG|PF-05190457|Single Dose 600 mg
214778762|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined with food
214778763|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined
214778764|NCT01247896|DRUG|Placebo|Single Dose Placebo
214778765|NCT04603079|BEHAVIORAL|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q\&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
214778766|NCT02869932|RADIATION|Lung CT scan|Lung CT scan without injection
214778767|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
214778768|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
214778769|NCT00423488|DRUG|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
214778770|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
214778771|NCT00423488|DRUG|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
214778772|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
214778773|NCT00423488|DRUG|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
214778774|NCT02282111|DEVICE|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
214778775|NCT02282111|DEVICE|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
214778776|NCT03523507|DEVICE|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
214778777|NCT03523507|DEVICE|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
214778778|NCT00056082|DRUG|celecoxib|Celecoxib daily for 12 months
214778779|NCT06319521|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214778780|NCT06319521|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778781|NCT06319521|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778782|NCT06319521|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778783|NCT01258816|DRUG|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
214778784|NCT02818179|RADIATION|THERMOGRAPHY IMAGING|
214778785|NCT05840666|OTHER|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
214778786|NCT05840666|OTHER|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
214778787|NCT05840666|OTHER|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
214778788|NCT05862519|DIETARY_SUPPLEMENT|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
214778789|NCT05862519|DIETARY_SUPPLEMENT|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds \& Flaxseed. Taken from Day 7 through Day 21.
214778790|NCT05862519|DIETARY_SUPPLEMENT|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
214778791|NCT05862519|DIETARY_SUPPLEMENT|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
214778792|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
214778793|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
214778794|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
214778795|NCT02953197|RADIATION|FDG-PET guided radiation dose escalation|Selective dose escalation
214778796|NCT00158327|BEHAVIORAL|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
214778797|NCT00158327|BEHAVIORAL|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
214778798|NCT05616611|RADIATION|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
214778799|NCT05616611|OTHER|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
214778800|NCT05616611|RADIATION|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
214778801|NCT06370195|BEHAVIORAL|Comprehensive rehabilitation|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.
214778802|NCT06370195|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778803|NCT06370195|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778804|NCT06370195|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214778805|NCT02095119|DRUG|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
214778806|NCT02095119|DRUG|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is \>/= 60. The administration form will be intravenously.
214778807|NCT02095119|DRUG|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation \< 60). The administration form will be intravenously.
214778808|NCT02095119|PROCEDURE|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
214778809|NCT00063960|DRUG|floxuridine|
214778810|NCT00063960|DRUG|irinotecan hydrochloride|
214778811|NCT01773174|DRUG|dabigatran etexilate|age \& weight adjusted equivalent of adult dose
214778812|NCT04358731|BIOLOGICAL|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
214778813|NCT04358731|BIOLOGICAL|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
214778814|NCT01770197|DRUG|IV rt-PA|IV rt-PA treatment
214778815|NCT02368769|DEVICE|During Tele-expertise|
214778816|NCT03966196|OTHER|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
214778817|NCT06530992|OTHER|tucking break|"All participants will provide a semen sample for sperm analysis after 2-7 days of abstinence from ejaculation, a venous blood sample will be taken at the same time, and quality of life will be assessed using a questionnaire.~Participants in the study group are then asked to refrain from tucking or wearing tight underwear for at least 73 days. At least 73 days (10.5 weeks) after the first spermiogram, another semen collection is scheduled after 2-7 days of abstinence from ejaculation for the preparation of a spermiogram, a venous blood sample is taken at the same time, and quality of life is assessed in all participants. At this point, depending on the participant's wishes, it is possible to perform sperm cryopreservation for fertility preservation before starting gender affirming hormonal treatment."
214778818|NCT03479242|OTHER|no interventions|no interventions are planned
214778819|NCT01749033|OTHER|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
214778820|NCT01749033|OTHER|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
214778821|NCT01749033|OTHER|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
214778822|NCT03577119|DIETARY_SUPPLEMENT|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
214778823|NCT03577119|DIETARY_SUPPLEMENT|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
214778824|NCT03998774|BEHAVIORAL|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
214778825|NCT00068237|PROCEDURE|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
214778826|NCT00068237|RADIATION|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
214778827|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
214778828|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
214778829|NCT05728216|OTHER|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
214778830|NCT00262184|DRUG|Soy Isoflavone|
214778831|NCT02813785|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
214778832|NCT02813785|DRUG|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
214778833|NCT05940519|OTHER|Dynamic taping technique|The dynamic taping method as specified in the literature will be applied to the right and left lumbar paravertebral muscles in the dynamic taping group. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
214778834|NCT05940519|OTHER|Sham taping|Sham taping will be applied with a surgical patch while the patient is in a comfortable position without any technique or stretching.Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
214778835|NCT05584774|PROCEDURE|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
214778836|NCT04573361|OTHER|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
214778837|NCT04573361|OTHER|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
214778838|NCT02795130|PROCEDURE|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
214778839|NCT01469988|DRUG|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
214778840|NCT06569693|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
214778841|NCT06569693|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
214778842|NCT00812227|BEHAVIORAL|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
214778843|NCT05446480|DRUG|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
214778844|NCT05446480|DRUG|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
214778845|NCT05446480|OTHER|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
214778846|NCT01677169|DIETARY_SUPPLEMENT|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
214778847|NCT01677169|DIETARY_SUPPLEMENT|Placebo|
214778848|NCT04722081|OTHER|physical therapy|physical therapy-specific exercises
214778849|NCT00383019|DRUG|Xalatan|latanoprost 0.005%, one rop once daily in evening
214778850|NCT00383019|DRUG|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
214778851|NCT03046147|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
214778852|NCT03797222|DIETARY_SUPPLEMENT|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if \>17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive \<600 IU daily, or for any subjects who prefer liquid medication to capsules.
214778853|NCT03703739|DIETARY_SUPPLEMENT|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
214778854|NCT03703739|DIETARY_SUPPLEMENT|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
214778855|NCT03703739|DIETARY_SUPPLEMENT|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
214778856|NCT03703739|DIETARY_SUPPLEMENT|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
214778857|NCT03703739|DIETARY_SUPPLEMENT|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
214778858|NCT03703739|DIETARY_SUPPLEMENT|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
214778859|NCT03703739|DIETARY_SUPPLEMENT|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
214778860|NCT05590325|DRUG|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
214778861|NCT06324214|DIETARY_SUPPLEMENT|Urolithin A (Mitopure)|Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
214778862|NCT06324214|OTHER|Placebo|Placebo.
214778863|NCT06007209|OTHER|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
214778864|NCT02889536|OTHER|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
214778865|NCT01389206|DRUG|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
214778866|NCT05353491|BEHAVIORAL|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
214778867|NCT05353491|BEHAVIORAL|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
214778868|NCT00712491|DRUG|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
214778869|NCT00712491|DRUG|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
214778870|NCT04084912|DRUG|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
214778871|NCT04084912|DRUG|Saline Solution|intravenous injection of one ampoule saline
214778872|NCT01760694|OTHER|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
214778873|NCT01649245|DRUG|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
214778874|NCT03223285|BEHAVIORAL|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
214778875|NCT03223285|BEHAVIORAL|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
214778876|NCT00924183|OTHER|Treatment-as-usual|
214778877|NCT00725725|BEHAVIORAL|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
214778878|NCT00725725|DRUG|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
214778879|NCT00725725|DRUG|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
214778880|NCT00725725|DRUG|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
214778881|NCT04207554|DEVICE|Test Device-Strip Format|Sponsor's investigational device
214778882|NCT04207554|DEVICE|Test Device-Cassette Format|Sponsor's investigational device
214778883|NCT04207554|DEVICE|Predicate Device|Commercially available device
214778884|NCT04289584|OTHER|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
214778885|NCT04363931|PROCEDURE|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
214778886|NCT04363931|PROCEDURE|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
214778887|NCT01253876|DIETARY_SUPPLEMENT|soy milk, Caw's milk|
214778888|NCT06588413|DRUG|Olanzapine|Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
214778889|NCT00068653|DRUG|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
214778890|NCT00068653|DRUG|ZD1839|ZD1839 250 mg po every day, taken with or without food.
214778891|NCT06682949|BEHAVIORAL|Sleep Extension|Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.
214778892|NCT06682949|BEHAVIORAL|Daytime Routine|Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
214778893|NCT00378482|DRUG|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
214778894|NCT00891501|PROCEDURE|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
214778895|NCT00891501|PROCEDURE|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
214778896|NCT06116448|OTHER|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
214778897|NCT06116448|OTHER|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
214778898|NCT06116448|OTHER|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
214778899|NCT04725565|BEHAVIORAL|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
214778900|NCT04725565|BEHAVIORAL|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
214778901|NCT02551302|DEVICE|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
214778902|NCT02551302|DEVICE|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
214778903|NCT00127569|DRUG|Rituximab|
214778904|NCT05151094|OTHER|Observation|Observation of clinical outcomes and comparison to non-treated patients
214778905|NCT03235765|DIAGNOSTIC_TEST|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
214778906|NCT03250065|DEVICE|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
214778907|NCT06246526|DEVICE|Evoke|The Saluda Medical Evoke® CL-SCS System (Evoke System). The Evoke System measures and records spinal cord (SC) activation resulting from stimulation via evoked compound action potentials (ECAPs). The Evoke System can be programmed to provide ECAP-controlled, closed-loop SCS or open-loop, fixed-output (traditional) SCS; ECAPs may be measured and recorded in either stimulation mode.
214778908|NCT00359840|DRUG|darbepoetin alfa|
214778909|NCT01566474|DRUG|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
214778910|NCT01566474|DRUG|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
214778911|NCT04901130|DEVICE|Computer-aided Real-time Automatic Quality Control System (AQCS)|Automatic quality-control system(AQCS), developed based on deep convolutional neural network (DCNN) models, could improve the colonoscopists' performance during withdrawal phase and significantly increase polyp and adenoma detection.
214778912|NCT01284569|BIOLOGICAL|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
214778913|NCT01284569|BIOLOGICAL|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
214778914|NCT04635904|BEHAVIORAL|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
214778915|NCT04635904|BEHAVIORAL|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
214778916|NCT00115258|OTHER|parenteral nutrition titrated to measured REE|
214778917|NCT02507258|DEVICE|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
214778918|NCT05140863|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
214778919|NCT05140863|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
214778920|NCT05140863|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
214778921|NCT01915381|OTHER|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
214778922|NCT05079152|BIOLOGICAL|COVAX+PPV23;COVAX+IIV4|1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
214778923|NCT05079152|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
214778924|NCT05079152|BIOLOGICAL|PPV23 for the 1st dose and IIV4 for the 2nd dose|1st dose: PPV23 only; 2nd dose: IIV4 only
214778925|NCT04147052|BEHAVIORAL|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
214778926|NCT03546699|DIAGNOSTIC_TEST|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~* To describe clinical characteristics and outcomes for these patients.~* To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
214778927|NCT02917356|OTHER|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
214778928|NCT02917356|OTHER|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
214778929|NCT02917356|OTHER|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
214778930|NCT02488902|DRUG|Placebo|Placebo
214778931|NCT02488902|DRUG|Tafenoquine 25mg|Tafenoquine 25mg
214778932|NCT02488902|DRUG|Tafenoquine 50mg|Tafenoquine 50mg
214778933|NCT02488902|DRUG|Tafenoquine 100 mg|Tafenoquine 100 mg
214778934|NCT02488902|DRUG|Tafenoquine 200 mg|Tafenoquine 200 mg
214778935|NCT02488902|DRUG|Mefloquine 250 mg|Mefloquine 250 mg
214778936|NCT04087382|DEVICE|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
214778937|NCT04087382|OTHER|non intervention group|medical treatment (Asprin, statin, nootropic drug)
214778938|NCT02450760|OTHER|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
214778939|NCT04244994|DEVICE|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
214778940|NCT03880929|OTHER|no intervention|no intervention
214778941|NCT02824991|PROCEDURE|detection of local twitch response intensities during dry needling|
214778942|NCT01854073|DRUG|Hyoscine butyl bromide|
214778943|NCT01854073|DRUG|Normal saline|
214778944|NCT03786874|OTHER|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
214778945|NCT03786874|OTHER|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
214778946|NCT03786874|OTHER|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
214778947|NCT00299273|BEHAVIORAL|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
214778948|NCT02789124|OTHER|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
214778949|NCT02373735|OTHER|crystalloid|Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
214778950|NCT02373735|OTHER|colloid|Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%
214778951|NCT02373735|OTHER|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%
214778952|NCT02373735|OTHER|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
214778953|NCT01776450|DEVICE|Endovascular AAA repair|
214778954|NCT02387307|DRUG|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
214778955|NCT00681577|BIOLOGICAL|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
214778956|NCT01523522|OTHER|Myoblast injection|Autologous myoblast injection in the anal sphincter
214778957|NCT01523522|PROCEDURE|saline solution injection|saline solution injection in anal sphincter
214778958|NCT05059782|DRUG|chemotherapy, targeted therapeutics, immunotherapy|Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
214778959|NCT05059782|RADIATION|IFRT, IMRT or SBRT|IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）
214778960|NCT02369627|DEVICE|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
214778961|NCT02369627|DEVICE|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
214778962|NCT02369627|OTHER|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
214778963|NCT04472182|DRUG|Fluoride varnish with xylitol coated calcium and phosphate|Fluoride varnish with xylitol coated calcium and phosphate
214778964|NCT04431531|OTHER|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
214778965|NCT04431531|OTHER|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
214778966|NCT02268331|OTHER|Active Surveillance|
214778967|NCT02268331|OTHER|Passive Surveillance|
214778968|NCT01373476|DRUG|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
214778969|NCT01373476|DRUG|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
214778970|NCT01037101|BEHAVIORAL|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
214778971|NCT01037101|BEHAVIORAL|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
214778972|NCT01037101|DRUG|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
214778973|NCT01037101|DRUG|Placebo|50 mg placebo administered 30 minutes before the session
214778974|NCT00581386|DEVICE|LTS-D|supra-glottic airway device
214778975|NCT00581386|DEVICE|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
214778976|NCT00581386|DEVICE|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
214778977|NCT02639819|DRUG|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
214778978|NCT05787210|OTHER|Conventiional Physiotherapy|The Control group will be administered with Conventional Physiotherapy that Includes 5 minutes of trunk control training, 5 minutes walking in the hall with And without the therapist assistance, walker or crutches, and finally 5 minutes of Breathing exercises for Relaxation
214778979|NCT05787210|OTHER|Quadriceps Strength Training|The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
214778980|NCT01252836|DEVICE|AWBAT-D|Application of AWBAT-D bioengineered device
214778981|NCT01355523|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
214778982|NCT01355523|DRUG|Placebo|6 mg oral placebo daily 1 hour before bedtime
214778983|NCT05011019|DRUG|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
214778984|NCT00720733|BEHAVIORAL|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
214778985|NCT00720733|BEHAVIORAL|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning \& Purpose.
214778986|NCT01949207|PROCEDURE|EVLA|Endovenous laser ablation of great saphenous vein
214778987|NCT01949207|PROCEDURE|phlebectomies|removal of incompetent veins
214778988|NCT01949207|PROCEDURE|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
214778989|NCT01278199|OTHER|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 \> 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
214778990|NCT01278199|OTHER|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
214778991|NCT00707122|OTHER|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1\. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
214778992|NCT00707122|OTHER|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
214778993|NCT03875430|DIETARY_SUPPLEMENT|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
214778994|NCT02221622|DRUG|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
214778995|NCT02221622|DRUG|Placebo injection (intravenous solution)|Placebo intravenous infusion
214778996|NCT03753373|OTHER|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
214778997|NCT03753373|OTHER|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
214778998|NCT03746301|DRUG|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
214778999|NCT06530043|OTHER|Senobi exercises|Senobi exercise began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.
214779000|NCT06530043|OTHER|Jacobsons Muscular relaxation exercises|Jacobsons Muscular relaxation exercises started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.
214779001|NCT04031066|DRUG|Velmanase Alfa|infusion i.v. treatment
214779002|NCT04031066|DRUG|Placebo|infusion i.v. treatment
214779003|NCT01005264|DEVICE|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
214779004|NCT01005264|DEVICE|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
214779005|NCT01433952|DIETARY_SUPPLEMENT|Thiamine|Vitamin B1
214779006|NCT01433952|DIETARY_SUPPLEMENT|Placebo|Placebo
214779007|NCT00503932|PROCEDURE|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
214779008|NCT00503932|DRUG|Capecitabine|825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
214779009|NCT02444156|OTHER|Indoor rowing|
214779010|NCT05221385|DRUG|Gentulizumab|Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
214779011|NCT02107937|BIOLOGICAL|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
214779012|NCT02107937|BIOLOGICAL|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
214779013|NCT02107937|DRUG|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
214779014|NCT00644098|DIETARY_SUPPLEMENT|soluble fibre complex and medium chain triglycerides|
214779015|NCT00644098|DIETARY_SUPPLEMENT|cellulose and soybean oil|
214779016|NCT05459051|DIAGNOSTIC_TEST|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
214779017|NCT05459051|DIAGNOSTIC_TEST|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
214779018|NCT02169661|OTHER|Burger and Beetroot Study|50% fat, 10% beetroot extract
214779019|NCT03318328|OTHER|survey|
214779020|NCT05260983|BEHAVIORAL|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
214779021|NCT05260983|BEHAVIORAL|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
214779022|NCT01308983|DRUG|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
214779023|NCT01497873|DRUG|Topotecan|1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
214779024|NCT01497873|DRUG|Belotecan|0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
214779025|NCT01611168|OTHER|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
214779026|NCT05016076|DRUG|Dexamethasone 8 mg|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
214779027|NCT05016076|DIAGNOSTIC_TEST|Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)|A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
214779028|NCT05016076|DEVICE|Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy|In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
214779029|NCT05016076|DEVICE|Goal-directed hemodynamic therapy targeting cardiac index|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
214779030|NCT05016076|DRUG|Placebo (0.9% sodium chloride)|Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
214779031|NCT05824468|DRUG|Zimberelimab|Injectable solution
214779032|NCT05824468|DRUG|Lenvatinib|Capsule
214779033|NCT04129034|DEVICE|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
214779034|NCT02543086|DRUG|KAE609|Study drug
214779035|NCT02543086|DRUG|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
214779036|NCT00155441|BEHAVIORAL|cognitive-behavioral therapy|
214779037|NCT06545734|PROCEDURE|Direct Ischemic Post-conditioning|After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
214779038|NCT06545734|PROCEDURE|Endovascular therapy|Thrombectomy alone.
214779039|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
214779040|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
214779041|NCT03134417|DIETARY_SUPPLEMENT|Placebo|Daily placebo are given to participants daily for 12 weeks.
214779042|NCT00240084|DRUG|nesiritide (Natrecor(TM))|administration of IV nesiritide
214779043|NCT05506475|PROCEDURE|Blood samples|venous blood collected in a 5 mL EDTA tube
214779044|NCT01011907|DRUG|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
214779045|NCT01011907|DRUG|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
214779046|NCT00969059|DRUG|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
214779047|NCT00969059|DRUG|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
214779048|NCT01272193|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
214779049|NCT01272193|DRUG|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
214779050|NCT02685956|DEVICE|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
214779051|NCT02175654|DRUG|Regorafenib|
214779052|NCT01440647|PROCEDURE|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
214779053|NCT01440647|PROCEDURE|Extubation to CPAP|After extubation infants were placed on CPAP
214779054|NCT02609282|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|
214779055|NCT02354365|DEVICE|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
214779056|NCT00612482|OTHER|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
214779057|NCT06161740|PROCEDURE|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
214779058|NCT04137991|DEVICE|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
214779059|NCT04137991|OTHER|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
214779060|NCT01406873|DRUG|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
214779061|NCT01406873|DRUG|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
214779062|NCT01497574|DRUG|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
214779063|NCT01497574|DRUG|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
214779064|NCT02194166|DRUG|Trastuzumab|Trastuzumab IV or SC will be administered as described.
214779065|NCT02194166|DRUG|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
214779066|NCT02194166|DRUG|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
214779067|NCT00184431|BEHAVIORAL|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
214779068|NCT00781131|DRUG|Pregabalin|pregabalin 75 or 150 mg
214779069|NCT00781131|DRUG|Placebo|lactulose placebo
214779070|NCT01968681|PROCEDURE|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
214779071|NCT03254719|OTHER|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
214779072|NCT05778708|BEHAVIORAL|Tai-Chi intervention|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
214779073|NCT05778708|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
214779074|NCT01808014|DRUG|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
214779075|NCT05183100|PROCEDURE|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
214779076|NCT05183100|PROCEDURE|Lying in supine|Lying in supine position for about 13 minutes.
214779077|NCT04273152|DIAGNOSTIC_TEST|advanced glycation endproducts reader|advanced glycation endproducts reader
214779078|NCT00004699|DRUG|insulin-like growth factor I|
214779079|NCT00736099|DRUG|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
214779080|NCT00736099|DRUG|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
214779081|NCT03526952|OTHER|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
214779082|NCT03526952|OTHER|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
214779083|NCT01866488|DRUG|Misoprostol|
214779084|NCT01866488|OTHER|Placebo|
214779085|NCT03893409|OTHER||this is a observation study, no any intervention in patients
214779086|NCT00237328|DRUG|Heparin|Heparin will be used as the intra-operative anticoagulant
214779087|NCT02290028|DEVICE|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
214779088|NCT02601911|DRUG|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
214779089|NCT02601911|DRUG|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
214779090|NCT02601911|OTHER|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
214779091|NCT03202511|DRUG|Probenecid Oral Tablet|Included in arm/group descriptions.
214779092|NCT03202511|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
214779093|NCT05844683|OTHER|2% chlorhexidine digluconate solution|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
214779094|NCT05844683|OTHER|usual baths|Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
214779095|NCT02982447|DEVICE|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
214779096|NCT02982447|DEVICE|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
214779097|NCT05105477|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
214779098|NCT05105477|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
214779099|NCT01188954|DRUG|doxycycline|50 ml/mg
214779100|NCT01188954|OTHER|No intervention|Normal Saline/Water
214779101|NCT03569254|DEVICE|Neomedlight Phototherapy Blanket|The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
214779102|NCT03569254|DEVICE|Ohmeda-Fiber Optic Phototherapy Blanket|This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
214779103|NCT05102045|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
214779104|NCT05102045|OTHER|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
214779105|NCT05102045|DRUG|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
214779106|NCT05102045|DRUG|Memantine|Memantine were given for Alzheimer's disease. .
214779107|NCT05967312|DIAGNOSTIC_TEST|Minuteful Kidney Test Kit|The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
214779108|NCT00164606|BEHAVIORAL|Positive Parenting Program (Triple-P)|
214779109|NCT04283747|DIAGNOSTIC_TEST|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
214779110|NCT03392376|DRUG|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
214779111|NCT03392376|OTHER|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
214779112|NCT04595227|DEVICE|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
214779113|NCT00096382|BIOLOGICAL|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
214779114|NCT00096382|BIOLOGICAL|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.
214779115|NCT00096382|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
214779116|NCT00096382|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
214779117|NCT00096382|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
214779118|NCT00096382|RADIATION|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
214779119|NCT04013022|BEHAVIORAL|Exercise History|The groups will be divided based on their exercise history
214779120|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
214779121|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
214779122|NCT05249010|PROCEDURE|acupuncture and moxibustion|Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
214779123|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
214779124|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
214779125|NCT02108613|BEHAVIORAL|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
214779126|NCT02108613|BEHAVIORAL|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
214779127|NCT02108613|BEHAVIORAL|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
214779128|NCT01974570|DIETARY_SUPPLEMENT|Marealis refined peptide concentrate|2 tablets, once per day before noon
214779129|NCT01974570|DIETARY_SUPPLEMENT|Placebo|2 tablets, once per day before noon
214779130|NCT05136456|DRUG|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
214779131|NCT05136456|DRUG|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
214779132|NCT05136456|DRUG|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
214779133|NCT03640000|DIAGNOSTIC_TEST|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
214779134|NCT01456585|OTHER|Gemcitabine|
214779135|NCT01456585|DRUG|CP-870,893|
214779136|NCT02020733|DEVICE|Balloon catheter|
214779137|NCT02020733|DEVICE|metal cannula|
214779138|NCT05610930|OTHER|Front-of-pack label NutriScore 2.0|"Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire."
214779139|NCT06019130|DRUG|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
214779140|NCT06019130|DRUG|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
214779141|NCT06019130|DRUG|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
214779142|NCT06019130|DRUG|Gemcitabine|Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis
214779143|NCT06019130|RADIATION|Radiotherapy|After induction therapy in all patients
214779144|NCT06019130|DRUG|Interferon beta-1a|In patients \< 26 years after end of radiochemotherapy for 6 months
214779145|NCT06019130|PROCEDURE|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
214779146|NCT06019130|PROCEDURE|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
214779147|NCT06019130|BEHAVIORAL|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
214779148|NCT04383080|PROCEDURE|Acupuncture|acupuncture at specific acupuncture points
214779149|NCT04383080|DEVICE|Low-level laser therapy|low level laser emission on specific acupuncture points
214779150|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
214779151|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
214779152|NCT04156074|DIETARY_SUPPLEMENT|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
214779153|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
214779154|NCT00443950|DRUG|Etanercept|
214779155|NCT05101356|BIOLOGICAL|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
214779156|NCT05101356|BIOLOGICAL|Sargramostim|Given SC
214779157|NCT05101356|BIOLOGICAL|Pembrolizumab|Given IV per standard of care
214779158|NCT03709407|OTHER|cervical stimuli|Manouvres Godoy
214779159|NCT03709407|OTHER|terminus|Manouvres Vodder
214779160|NCT03709407|OTHER|Placebo|placebo manouvre
214779161|NCT03709407|OTHER|Control group|lie down
214779162|NCT04278365|BEHAVIORAL|Positive affect training|Behavioral training involving position emotion enhancement
214779163|NCT02177773|PROCEDURE|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
214779164|NCT02177773|DRUG|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
214779165|NCT02177773|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
214779166|NCT02177773|PROCEDURE|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
214779167|NCT04363294|DIAGNOSTIC_TEST|PYP scan|99mTc-labeled pyrophosphate
214779168|NCT04596462|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
214779169|NCT02540720|DRUG|Dexamethasone|
214779170|NCT02540720|DRUG|Gamma globulin|
214779171|NCT02540720|PROCEDURE|Hemoperfusion|
214779172|NCT03901222|DEVICE|tDCS|20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
214779173|NCT02206724|RADIATION|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
214779174|NCT02917928|DIETARY_SUPPLEMENT|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
214779175|NCT02917928|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
214779176|NCT00004861|DRUG|gemcitabine hydrochloride|
214779177|NCT00004861|DRUG|tacedinaline|
214779178|NCT03157310|DRUG|Gefitinib|Daily oral administration of 250 mg Gefitinib
214779179|NCT06327477|PROCEDURE|Biopsy|Undergo biopsy
214779180|NCT06327477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214779181|NCT06327477|PROCEDURE|Computed Tomography|Undergo CT
214779182|NCT06327477|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
214779183|NCT06327477|PROCEDURE|Resection|Undergo surgical resection
214779184|NCT06327477|RADIATION|Spatially-fractionated Radiation Therapy|Undergo P-SFRT
214779185|NCT06280027|OTHER|survey|An online survey was generated to quantitatively evaluate the level of esthetic perception.
214779186|NCT04701476|DRUG|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
214779187|NCT04701476|DRUG|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
214779188|NCT04701476|DRUG|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
214779189|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
214779190|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
214779191|NCT05654857|DIAGNOSTIC_TEST|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
214779192|NCT06530420|PROCEDURE|Umbilical hernia repair surgery|collected information about: gender, age, comorbidities, body weight, time of surgery, hernia size and treatment methods and reccurence
214779193|NCT03384420|BIOLOGICAL|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
214779194|NCT00289731|BIOLOGICAL|TWINRIX™|Intramuscular injection, 3 doses
214779195|NCT00289731|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
214779196|NCT00289731|BIOLOGICAL|HAVRIX™|Intramuscular injection, 2 doses
214779197|NCT00289731|BIOLOGICAL|HB VAX PRO™|Intramuscular injection, 3 doses
214779198|NCT00289731|BIOLOGICAL|Vaqta™|Intramuscular injection, 2 doses
214779199|NCT06290414|DIAGNOSTIC_TEST|infrared thermal camera|capturing thermographic imaging of gingiva to detect thermal changes due to inflammation as a result of periodontal disease
214779200|NCT04378010|DRUG|EDP-305 1.5 mg|Tablet
214779201|NCT04378010|DRUG|EDP-305 2 mg|Tablet
214779202|NCT04378010|DRUG|Placebo|Tablet
214779203|NCT01596816|RADIATION|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
214779204|NCT01596816|PROCEDURE|Fiducials placement|Placement of intra-prostatic markers for the tracking
214779205|NCT01596816|RADIATION|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
214779206|NCT02019979|DRUG|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
214779207|NCT02019979|BEHAVIORAL|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
214779208|NCT02513459|DRUG|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
214779209|NCT02513459|DRUG|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
214779210|NCT00838500|DRUG|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
214779211|NCT00838500|DRUG|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
214779212|NCT02600806|DRUG|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
214779213|NCT02600806|DRUG|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
214779214|NCT05175456|OTHER|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
214779215|NCT05175456|DEVICE|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
214779216|NCT05842083|BEHAVIORAL|On-site supportive communication training|On-site supportive communication training
214779217|NCT02856997|DRUG|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
214779218|NCT00747747|BIOLOGICAL|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
214779219|NCT00747747|DEVICE|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
214779220|NCT04093947|OTHER|Observational study|Observational and prospective study
214779221|NCT03339635|DRUG|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
214779222|NCT03339635|DRUG|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
214779223|NCT03273127|DRUG|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
214779224|NCT03273127|DRUG|Placebo|Abediterol matching placebo without any pharmacological activity.
214779225|NCT00125476|BEHAVIORAL|Exercise|
214779226|NCT03806894|DIAGNOSTIC_TEST|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
214779227|NCT02784860|DRUG|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
214779228|NCT02784860|DRUG|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
214779229|NCT04674176|DRUG|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
214779230|NCT04023994|DRUG|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
214779231|NCT04023994|DRUG|Placebo|Participants will be administered a single intravenous dose of matching placebo.
214779232|NCT02496260|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
214779233|NCT02496260|PROCEDURE|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
214779234|NCT00923195|DRUG|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
214779235|NCT00923195|DRUG|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
214779236|NCT00923195|DRUG|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
214779237|NCT00923195|PROCEDURE|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
214779238|NCT00923195|DRUG|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
214779239|NCT00923195|DRUG|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
214779240|NCT00923195|DRUG|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
214779241|NCT00923195|GENETIC|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
214779242|NCT00923195|GENETIC|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
214779243|NCT04725526|DEVICE|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
214779244|NCT02516631|DRUG|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
214779245|NCT02516631|DRUG|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
214779246|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
214779247|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
214779248|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
214779249|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
214779250|NCT02314520|DEVICE|peripherally inserted central catheter|Any complication associated with central access
214779251|NCT02314520|DEVICE|centrally inserted central catheter|Central access not associated with any complication
214779252|NCT02423174|PROCEDURE|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
214779253|NCT02423174|DEVICE|FMwand Surgical System|
214779254|NCT02427373|DIETARY_SUPPLEMENT|fish oil ethyl ester|
214779255|NCT02427373|DIETARY_SUPPLEMENT|fish oil triglyceride|
214779256|NCT02427373|DIETARY_SUPPLEMENT|krill oil|
214779257|NCT06479044|DIAGNOSTIC_TEST|Herrmann Brain Model|The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
214779258|NCT02700802|OTHER|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
214779259|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
214779260|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
214779261|NCT06168305|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
214779262|NCT03047382|OTHER|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
214779263|NCT06185712|BEHAVIORAL|Nurse-led disease management education|Nurse-led disease management education was applied to the intervention group
214779264|NCT03205384|PROCEDURE|surgery|
214779265|NCT06463938|OTHER|Active comparator|CPP-ACP paste will be applied on exposed area
214779266|NCT06463938|DEVICE|Experimental group|Lasotronix will be applied following its protocol
214779267|NCT06463938|COMBINATION_PRODUCT|Combination of laser and paste|This group will receive the combination of above two treatments
214779268|NCT06463938|BEHAVIORAL|Control group|this will be a control group
214779269|NCT03567915|OTHER|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
214779270|NCT05961254|DEVICE|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
214779271|NCT00626483|BIOLOGICAL|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10\^7) is being assessed.
214779272|NCT00626483|DRUG|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
214779273|NCT02651896|RADIATION|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
214779274|NCT00467818|DRUG|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
214779275|NCT00467818|OTHER|Placebo|Same dosage as that of omega 3 fatty acids
214779276|NCT06531291|DRUG|Surufatinib|250 mg, po, qd, q3w
214779277|NCT06531291|DRUG|Serplulimab|200 mg, iv, d1, q3w
214779278|NCT06531291|DRUG|standard chemotherapy|Decided by PI
214779279|NCT04031027|DRUG|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
214779280|NCT05817526|DRUG|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
214779281|NCT05817526|PROCEDURE|Autograft harvesting from chin|Autograft
214779282|NCT05065463|DRUG|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
214779283|NCT03587181|PROCEDURE|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
214779284|NCT00599183|OTHER|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
214779285|NCT04214951|DRUG|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
214779286|NCT04214951|DRUG|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
214779287|NCT03903640|DEVICE|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
214779288|NCT03903640|BIOLOGICAL|Nivolumab|-Standard of care
214779289|NCT03903640|BIOLOGICAL|Ipilimumab|-Standard of care
214779290|NCT00004686|DRUG|methotrexate|
214779291|NCT00004686|DRUG|prednisone|
214779292|NCT01523795|OTHER|Motion-controlled video gaming|Play of motion-controlled video games for one hour
214779293|NCT01523795|OTHER|Traditional video gaming|Participants played traditional video games for one hour
214779294|NCT01523795|OTHER|Television watching|Participants watched television for one hour
214779295|NCT06389279|OTHER|PENG block group|Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
214779296|NCT06389279|OTHER|FIC block group|Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
214779297|NCT06389279|OTHER|Femoral block group|Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
214779298|NCT06389279|OTHER|Control group|No intervention
214779299|NCT01422733|DRUG|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
214779300|NCT01422733|DRUG|dexamethasone|1 mg PO twice
214779301|NCT01422733|DRUG|Cosyntropin|250 micrograms IV twice
214779302|NCT01422733|DRUG|rhCG|25 mcg IV twice
214779303|NCT01563471|DRUG|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
214779304|NCT01563471|DRUG|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
214779305|NCT06528249|DRUG|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
214779306|NCT01907659|OTHER|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
214779307|NCT04999228|DRUG|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
214779308|NCT04999228|DRUG|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
214779309|NCT05305183|DRUG|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
214779310|NCT02143947|DEVICE|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
214779311|NCT02143947|DEVICE|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
214779312|NCT01244815|DRUG|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
214779313|NCT01244815|DRUG|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
214779314|NCT01244815|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
214779315|NCT01887509|DEVICE|Probe-based confocal laser endomicroscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
214779316|NCT01887509|PROCEDURE|Rectoscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
214779317|NCT01887509|PROCEDURE|EUS|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
214779318|NCT01887509|PROCEDURE|Biopsy and resection|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
214779319|NCT02466100|BEHAVIORAL|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
214779320|NCT01173159|DRUG|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
214779321|NCT02872402|BEHAVIORAL|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
214779322|NCT02872402|BEHAVIORAL|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
214779323|NCT01313728|DRUG|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
214779324|NCT01313728|DRUG|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
214779328|NCT05795062|DRUG|apixaban|patients treated with apixaban
214779329|NCT05795062|DRUG|warfarin|patients treated with warfarin
214779330|NCT02558660|BEHAVIORAL|Education|Educational intervention about an existing SNAP healthy food incentive program
214779331|NCT02558660|BEHAVIORAL|voucher|$10 voucher to spend on produce at farmers markets
214779332|NCT01946971|DRUG|Lansoprazole|
214779333|NCT01946971|DRUG|Placebo|
214779334|NCT03007537|DRUG|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
214779335|NCT03007537|DRUG|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
214779336|NCT03007537|PROCEDURE|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
214779337|NCT05699577|DIAGNOSTIC_TEST|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
214779338|NCT00333073|DEVICE|Bulkamid|initial injection with option for second (if required)
214779339|NCT04310748|DRUG|Total Intravenous Anesthesia(TIVA)|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded"
214779340|NCT04310748|DRUG|Inhalation Anesthesia|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded."
214779341|NCT03456362|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
214779342|NCT00318266|DEVICE|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
214779343|NCT05226156|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
214779344|NCT00878137|DEVICE|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
214779345|NCT04184479|BEHAVIORAL|LEVAmethod by Bertz et al|Ordinary treatment
214779346|NCT05331846|BEHAVIORAL|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
214779347|NCT04403373|BEHAVIORAL|Waitlist control|waitlist control
214779348|NCT04403373|BEHAVIORAL|Moderate-intensity walking exercise|walking exercise
214779349|NCT04403373|BEHAVIORAL|Vigorous-intensity walking exercise|walking exercise
214779350|NCT00418756|DRUG|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
214779351|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
214779352|NCT03494205|DRUG|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
214779353|NCT03494205|DRUG|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
214779354|NCT03876873|PROCEDURE|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
214779355|NCT03876873|DEVICE|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
214779356|NCT03547531|OTHER|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
214779357|NCT03547531|OTHER|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
214779358|NCT02649608|DRUG|0.04 mg Lu AE04621|0.04 mg dose group
214779359|NCT02649608|DRUG|0.08 mg Lu AE04621|0.08mg dose group
214779360|NCT02649608|DRUG|0.2 mg Lu AE04621|0.2 mg dose group
214779361|NCT02649608|DRUG|0.4 mg Lu AE04621|0.4 mg dose group
214779362|NCT02649608|DRUG|0.6 mg Lu AE04621|0.6 mg dose group
214779363|NCT02649608|DRUG|0.8 mg Lu AE04621|0.8 mg dose group
214779364|NCT02649608|DRUG|1.0 mg Lu AE04621|1.0 mg dose group
214779365|NCT02649608|DRUG|1.2 mg Lu AE04621|1.2 mg dose group
214779366|NCT05724316|DIETARY_SUPPLEMENT|Vitamin D supplement|N/A (says not to repeat information here)
214779367|NCT02007187|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
214779368|NCT02007187|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
214779369|NCT02007187|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
214779370|NCT05371418|PROCEDURE|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
214779371|NCT05371418|DEVICE|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
214779372|NCT05450042|DEVICE|SELUTION SLR DCB|Sirolimus DCB
214779373|NCT05450042|DEVICE|Paclitaxel DCB|Paclitaxel DCB
214779374|NCT02117479|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
214779375|NCT02117479|DRUG|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
214779376|NCT02117479|DRUG|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
214779377|NCT05627349|DEVICE|wrist splinting|standard wrist splinting at night for 2 weeks
214779378|NCT05627349|DEVICE|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
214779379|NCT01283607|BEHAVIORAL|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
214779380|NCT02444182|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
214779381|NCT02444182|DIETARY_SUPPLEMENT|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
214779382|NCT03014531|OTHER|almond|
214779383|NCT03014531|OTHER|high-carbohydrate control food|
214779384|NCT01412710|DRUG|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
214779385|NCT02300818|DEVICE|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
214779386|NCT02300818|DRUG|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
214779387|NCT03859570|DRUG|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
214779388|NCT03859570|DRUG|Placebos|Placebo
214779389|NCT01333631|DRUG|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
214779390|NCT01485705|OTHER|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
214779391|NCT01959230|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
214779392|NCT01959230|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
214779393|NCT01959230|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
214779394|NCT01959230|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
214779395|NCT03428048|PROCEDURE|Hybrid procedure|Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
214779396|NCT03428048|PROCEDURE|Endocardial ablations|ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
214779397|NCT03428048|PROCEDURE|left atrial appendage occlusion|A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
214779398|NCT05284474|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
214779399|NCT00391937|DEVICE|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
214779400|NCT05547100|DRUG|LYBALVI|5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
214779401|NCT02348619|DRUG|JZP-110|
214779402|NCT04805281|OTHER|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
214779403|NCT04805281|OTHER|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
214779404|NCT06452433|DRUG|gumarontinib|300 mg , qd ,po, expect 6 months.
214779405|NCT06452433|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|According to the actual situation of patients. Take as recommended, expect 6 months.
214779406|NCT02744625|DRUG|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
214779407|NCT02744625|DRUG|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
214779408|NCT02744625|DRUG|Propofol for light sedation|Propofol for light sedation
214779409|NCT03631459|DRUG|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
214779410|NCT06537986|BEHAVIORAL|Neurocognitive and psychosocial intervention module|"The module comprised of various intervention methods that include- I. Cognitive Retraining: Pen-and-paper-based cognitive rehabilitation program that is divided into five hierarchically graded modules: Attention, Visual Processing, Memory, Information Processing, and Executive Functions.~2.Cognitive-behavioral interventions. Cognitive-behavioral interventions would be carried out for activities scheduling, problem-solving teachings, anger management techniques, modifications of negative cognitions, stigma address measures, and irrational beliefs about epilepsy, etc.~3\. Marital/Family counseling: Marital/family counseling would be done to ensure family understanding of the patient's illness, his/her treatment, prognosis, and outcome. Family complications arising due to illness would also be discussed. Individual and personal needs of the husband, a wife will also be discussed."
214779411|NCT01092390|DIETARY_SUPPLEMENT|Lovaza (fish oil)|4 grams per day
214779412|NCT00811200|DRUG|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
214779413|NCT00811200|DRUG|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
214779414|NCT00811200|OTHER|sham|at baseline one sham-injection
214779415|NCT06295575|DIETARY_SUPPLEMENT|probiotics containing Bifidobacterium infantis and Lactobacillus|Patients were provided with probiotics containing Bifidobacterium infantis and Lactobacillus. This intervention was started the day after patients' administration and lasted until the day before discharge.
214779416|NCT06295575|DIETARY_SUPPLEMENT|placebos containing lactose|Patients received lactose as placebo.This intervention was started the day after patients' administration and lasted until the day before discharge.
214779417|NCT00103103|DRUG|bortezomib|
214779418|NCT00103103|DRUG|fluorouracil|
214779419|NCT00103103|DRUG|leucovorin calcium|
214779420|NCT02058433|OTHER|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
214779421|NCT02058433|OTHER|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
214779422|NCT00135291|PROCEDURE|Leukoreduced blood transfusion|
214779423|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with lupin protein|\- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
214779424|NCT01598649|DIETARY_SUPPLEMENT|Mannitol|\- Placebo capsules containing mannitol (four capsules per day)
214779425|NCT01598649|DIETARY_SUPPLEMENT|Arginine|\- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
214779426|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
214779427|NCT00002747|DRUG|cisplatin|
214779428|NCT00002747|DRUG|fluorouracil|
214779429|NCT00002747|PROCEDURE|conventional surgery|
214779430|NCT00002747|RADIATION|low-LET cobalt-60 gamma ray therapy|
214779431|NCT00002747|RADIATION|low-LET photon therapy|
214779432|NCT03992612|OTHER|control group: usual medical care|The patients received usual medical care.
214779433|NCT03992612|BEHAVIORAL|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
214779434|NCT01684306|DRUG|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
214779435|NCT01684306|DRUG|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
214779436|NCT06701500|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
214779437|NCT06701500|BEHAVIORAL|Action Sequence Task (AST)|Participants need to press four keys according to the cue location; two keys are associated with high reward, while the other two are associated with low reward in case of correct and timely responses. The explicit goal is to maximize the reward. While in half of the trials the cues are presented in a random order, in the other half of the trials, participants repeatedly perform a fixed action sequence of 12 elements (habit condition). The degree of action sequence chunking (i.e. automation) is assessed via the differences in error rates and reaction times between the random and fixed order condition (habit parameter). Importantly, 15% of all trials are dual- target trials. In these the goal-directed system (press high reward key) and the action sequence (press sequence key) can either be in line (congruent trials) or in conflict (incongruent trials) with each other, thus the interference between goal-directed and habitual control can be tested.
214779438|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Structured Clinical Interview for DSM Disorders (SCID) Current Depression:~  * SCID Mania~ * SCID alcohol use disorder (AUD)~ * SCID tobacco use disorder (TUD)~* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Alcohol quantity-frequency~* Tobacco quantity-frequency~* Cannabis and other substances quantity-frequency"
214779439|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorders Identification Test (CUDIT)~* Adult ADHD Self-Report Scale (ASRS)"
214779440|NCT06701500|BEHAVIORAL|Neuropsychology tests|"* Digit-Symbol-Test (DST)~* Go/Nogo Simon task~* Counting Stroop Task~* Value-based decision-making task (VBDM)"
214779441|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
214779442|NCT04720885|PROCEDURE|kind of surgery|hysteroscopy, curettage, other
214779443|NCT02487979|DRUG|Glembatumumab Vedotin|Given IV
214779444|NCT02487979|OTHER|Laboratory Biomarker Analysis|Correlative studies
214779445|NCT02487979|OTHER|Pharmacological Study|Correlative studies
214779446|NCT04833452|PROCEDURE|Endoscopic dacryocystorhinostomy|Endoscopic DCR
214779447|NCT00447694|DRUG|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
214779448|NCT00712907|DIETARY_SUPPLEMENT|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
214779449|NCT00712907|DIETARY_SUPPLEMENT|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
214779450|NCT00712907|OTHER|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
214779451|NCT05730088|OTHER|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
214779452|NCT05730088|OTHER|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
214779453|NCT05730088|OTHER|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
214779454|NCT05762263|BEHAVIORAL|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
214779455|NCT04688983|DRUG|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
214779456|NCT04688983|DRUG|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
214779457|NCT04688983|DRUG|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
214779458|NCT04740112|OTHER|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
214779459|NCT04896918|BEHAVIORAL|Tobacco use|
214779460|NCT00656396|DEVICE|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
214779461|NCT00656396|PROCEDURE|Control Intervention|Standard care
214779462|NCT02420665|DRUG|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
214779463|NCT02420665|DEVICE|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
214779464|NCT02420665|BEHAVIORAL|Phone Call|Study staff follow up with participant by phone one month after procedure.
214779465|NCT02420665|PROCEDURE|Colposcopy|Colposcopy performed after visual inspection of cervix.
214779466|NCT02420665|DRUG|Acetic Acid|3 - 5% added to cervix before visual inspection.
214779467|NCT04821050|DEVICE|Sacral nerve stimulation|"A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
214779468|NCT04821050|DEVICE|Sham stimulation|"Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
214779469|NCT04822428|OTHER|Osteopathic manipulation|Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
214779470|NCT05375682|OTHER|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
214779471|NCT02540473|BEHAVIORAL|Manualized Therapy|Relational psychotherapy mothers
214779472|NCT02540473|BEHAVIORAL|Control Group|one hour of free time to do with as they wish
214779473|NCT00570726|DRUG|Ranibizumab (Lucentis)|
214779474|NCT00837031|DRUG|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
214779475|NCT00837031|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
214779476|NCT03763617|DEVICE|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
214779477|NCT04767217|DRUG|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
214779478|NCT04767217|DRUG|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
214779479|NCT01000142|PROCEDURE|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
214779480|NCT01000142|PROCEDURE|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
214779481|NCT05817084|PROCEDURE|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
214779482|NCT05817084|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
214779483|NCT01887379|DRUG|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
214779484|NCT05691699|DRUG|ABBV-903|Capsule; oral
214779485|NCT05691699|DRUG|Placebo for ABBV-903|Capsule; oral
214779486|NCT05691699|DRUG|Itraconazole|Capsule; oral
214779487|NCT01886170|OTHER|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
214779488|NCT01931137|DRUG|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
214779489|NCT01217528|DEVICE|device settings for group A|VT zone: 350ms VF zone: 280ms
214779490|NCT01217528|DEVICE|Device settings for group B|VT zone: 320ms VF zone: 250ms
214779491|NCT02501031|DIETARY_SUPPLEMENT|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
214779492|NCT01638793|DEVICE|Microcap (Oridion, Needham, MA, USA)|
214779493|NCT01638793|DEVICE|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
214779494|NCT02722824|DEVICE|Electro-stimulation|
214779495|NCT02722824|OTHER|Placebo|
214779496|NCT03386149|DRUG|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~* Rehmannia Root 1.7g~* Achyranthes Root 1.0g~* Cornus Fruit 1.0g~* Dioscorea Rhizome 1.0g~* Psyllium Husk 1.0g~* Alisma Rhizome 1.0g~* Hoelen 1.0g~* Moutan Root Bark 1.0g~* Cinnamon Bark 0.3g~* Pulvis Aconiti Tuberis Purificatum 0.3g"
214779497|NCT03386149|DRUG|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
214779498|NCT03386149|PROCEDURE|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
214779499|NCT05278585|PROCEDURE|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
214779500|NCT06314984|OTHER|Group I A (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].
214779501|NCT06314984|OTHER|Group I B (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the conventional needle syringe \[Infiltration\].
214779502|NCT06314984|DEVICE|Group II A (Comfort-in Jet Injector)|The injection site was isolated using a cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].
214779503|NCT06314984|DEVICE|Group II B (Comfort-in Jet Injector)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
214779504|NCT01574599|OTHER|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
214779505|NCT05045794|DEVICE|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
214779506|NCT05045794|OTHER|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
214779507|NCT00717873|DEVICE|Airway clearance Device|Provided by the Vest Airway clearance system
214779508|NCT05338710|OTHER|STELLA-FTD|Behavioral intervention for caregivers for those with FTD
214779509|NCT03957278|DEVICE|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
214779510|NCT04627220|DIAGNOSTIC_TEST|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
214779511|NCT00772252|OTHER|liver support treatment|plasma exchange for liver support treatment
214779512|NCT03172585|OTHER|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
214779513|NCT03172585|OTHER|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
214779514|NCT05986071|DRUG|M1774|• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
214779515|NCT05986071|DRUG|Fulvestrant injection|Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
214779516|NCT01507831|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
214779517|NCT01507831|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
214779518|NCT01507831|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
214779519|NCT05114226|DRUG|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
214779520|NCT04656522|BEHAVIORAL|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
214779521|NCT02352740|DIETARY_SUPPLEMENT|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
214779522|NCT02352740|DIETARY_SUPPLEMENT|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
214779523|NCT06399419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214779524|NCT06399419|PROCEDURE|Bone Scan|Undergo bone scan
214779525|NCT06399419|BIOLOGICAL|CBM588 Capsules|Given PO
214779526|NCT06399419|PROCEDURE|Computed Tomography|Undergo CT
214779527|NCT06399419|BIOLOGICAL|Ipilimumab|Given IV
214779528|NCT06399419|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214779529|NCT06399419|BIOLOGICAL|Nivolumab|Given IV
214779530|NCT06479759|DRUG|LM-108 antibody and sintilimab|Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
214779531|NCT06479759|DRUG|LM-108 antibody and sintilimab and chemotherapy|Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
214779532|NCT01431755|DEVICE|Restylane SubQ|Treatment with up to 2 ml of the product
214779533|NCT01431755|DEVICE|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
214779534|NCT00316576|PROCEDURE|Blood sampling for PCR|
214779535|NCT05130866|DRUG|REC-2282|Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
214779536|NCT05130866|DRUG|Placebo|Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
214779537|NCT02693600|PROCEDURE|Ligamentoplasty with partial trapeziectomy|
214779538|NCT02693600|PROCEDURE|Ligamentoplasty with total trapeziectomy|
214779539|NCT05339828|PROCEDURE|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
214779540|NCT05377866|OTHER|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
214779541|NCT04283838|BEHAVIORAL|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
214779542|NCT01831531|DRUG|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28
214779543|NCT01831531|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
214779544|NCT03966469|OTHER|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
214779545|NCT03966469|OTHER|Patient Present Only|Patient presents to their preoperative appointment without a support person.
214779546|NCT02112422|DRUG|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
214779547|NCT02112422|DRUG|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
214779548|NCT00332345|DRUG|brimonidine/timolol fixed combination|
214779549|NCT04334330|DRUG|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214779550|NCT04380701|BIOLOGICAL|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214779551|NCT04380701|BIOLOGICAL|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214779552|NCT04380701|BIOLOGICAL|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214779553|NCT04380701|BIOLOGICAL|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
214779554|NCT00193570|DRUG|Topotecan|
214779555|NCT00193570|DRUG|Docetaxel|
214779556|NCT04943055|PROCEDURE|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
214779557|NCT04943055|PROCEDURE|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
214779558|NCT00868114|BIOLOGICAL|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
214779559|NCT02077751|DRUG|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
214779560|NCT05201820|DEVICE|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
214779561|NCT00358774|PROCEDURE|homeopathic nasal spray|
214779562|NCT00363129|DIETARY_SUPPLEMENT|vitamin E|Given orally
214779563|NCT00363129|OTHER|placebo|Given orally
214779564|NCT04564040|DRUG|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
214779565|NCT04564040|DRUG|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
214779566|NCT04564040|DRUG|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
214779567|NCT04564040|DRUG|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
214779568|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779569|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779570|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779571|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779572|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779573|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779574|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779575|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
214779576|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
214779577|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
214779578|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
214779579|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
214779580|NCT00492466|DRUG|Interferon-beta-1a|dosage and frequency as per label
214779581|NCT00492466|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
214779582|NCT00899665|GENETIC|fluorescence in situ hybridization|
214779583|NCT00899665|GENETIC|microarray analysis|
214779584|NCT00899665|GENETIC|molecular diagnostic method|
214779585|NCT00899665|OTHER|immunohistochemistry staining method|
214779586|NCT00899665|OTHER|laboratory biomarker analysis|
214779587|NCT00899665|PROCEDURE|biopsy|
214779588|NCT00899665|PROCEDURE|immunoscintigraphy|
214779589|NCT02266966|DRUG|F2695|
214779590|NCT02266966|DRUG|Placebo|
214779591|NCT02162030|BEHAVIORAL|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
214779592|NCT04703725|BEHAVIORAL|Psychosocial Care|"1. First Follow-Up: One of the implementation of the module~2. Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~3. Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~4. Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~5. Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~6. Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~7. Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
214779593|NCT03457337|DRUG|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
214779594|NCT03457337|DRUG|Gefitinib|Gefitinib: 250mg, 1 day, orally
214779595|NCT03296553|DRUG|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
214779596|NCT03296553|DRUG|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
214779597|NCT03659968|OTHER|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
214779598|NCT03612401|DRUG|Mirabegron|Beta-3 adenoreceptor agonist
214779599|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of extended release capsules
214779600|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
214779601|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
214779602|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
214779603|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
214779604|NCT05280873|DRUG|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
214779605|NCT05280873|DRUG|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
214779606|NCT04981626|OTHER|Clinical and experimental session|"Psychologic profile with standardized interview and scales (see below for details: SCID, BDI, STAI, BPQ, EDE Q, Pictorial Body Image Scale (PBIS) and EDI).~Measure the stomach-brain synchrony during EEG/EGG resting state, the distribution of voluntary actions across the respiratory phase, and the distribution of saccadic eye movements across the cardiac-cycle."
214779607|NCT00406822|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
214779608|NCT00032708|BIOLOGICAL|Dryvax|
214779609|NCT02204683|DRUG|Aflibercept|Intravitreal aflibercept
214779610|NCT01070277|DRUG|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
214779611|NCT01070277|DRUG|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
214779612|NCT04352491|OTHER|No intervention|No intervention
214779613|NCT02713243|DRUG|LJN452|Capsules containing LJN452
214779614|NCT02713243|DRUG|Placebo to LJN452|Capsules containing placebo to LJN452
214779615|NCT02741362|OTHER|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
214779616|NCT02741362|OTHER|Lipoaspiration|
214779617|NCT02888925|OTHER|Mooney test|
214779618|NCT02888925|OTHER|Benton Face Recognition test|
214779619|NCT02888925|OTHER|Face inversion effect test|
214779620|NCT02888925|OTHER|Face composite effect test|
214779621|NCT02888925|OTHER|Cambridge Face Memory Test|
214779622|NCT02888925|OTHER|Matching different view test|
214779623|NCT02888925|OTHER|Memorizing and recognition of new faces test|
214779624|NCT02888925|OTHER|Memorizing and recognition of new objects test|
214779625|NCT02888925|OTHER|Recognition of celebrities and access to semantic information test|
214779626|NCT02888925|PROCEDURE|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
214779627|NCT03951597|DRUG|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
214779628|NCT04318002|BIOLOGICAL|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
214779629|NCT05204940|BEHAVIORAL|Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Analyzing mechanisms of the LLD-dementia relationship through fMRI acquisitions and analyses, to capture the specific brain networks implicated in executive function and episodic memory decline.
214779630|NCT05204940|BEHAVIORAL|Neuropsychological Data|Neuropsychological Data, including Montreal Cognitive Assessment (MoCA), Wide Range Achievement Test-4 (WRAT-4) Reading subtest, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Delis-Kaplan Executive Function System (D-KEFS) (Color Word Interference, Trail Making and Verbal Fluency).
214779631|NCT05204940|BEHAVIORAL|Clinical Scales|Clinical scales, including the Everyday Cognition Scale (E-Cog), Global Clinical Dementia Rating (CDR), Performance Assessment of Selfcare Skills (PASS)--CIADL (Cognitive Instrumental Activities of Daily Living) Short version, Patient Health Questionnaire (PHQ-9), and Suicide Risk Assessments (Suicide Questions, Baseline Suicidal Ideation, Suicide Intent Scale, Beck Lethality Scale, Decision Outcome Inventory, Columbia-Suicide Severity Rating Scale, and High Suicide Risk Protocol).
214779632|NCT05469503|DIETARY_SUPPLEMENT|TOTUM-854|12 weeks of TOTUM-854 supplementation
214779633|NCT05469503|DIETARY_SUPPLEMENT|Placebo|12 weeks of placebo supplementation
214779634|NCT03952936|OTHER|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
214779635|NCT05448768|DEVICE|TBS for Amyloid-positive MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
214779636|NCT05448768|DEVICE|TBS for Amyloid-negative MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
214779637|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
214779638|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
214779639|NCT03823365|BIOLOGICAL|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109"
214779640|NCT02527616|DEVICE|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
214779641|NCT05429853|DIETARY_SUPPLEMENT|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
214779642|NCT02614885|DEVICE|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
214779643|NCT01492712|DRUG|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
214779644|NCT01492712|DRUG|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
214779645|NCT01619085|DRUG|Nintedanib|Nintedanib twice a day
214779646|NCT00811265|DEVICE|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
214779647|NCT06537635|DEVICE|Cubii seated compact elliptical trainer|The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
214779648|NCT03125915|BEHAVIORAL|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
214779649|NCT03125915|BEHAVIORAL|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
214779650|NCT03125915|BEHAVIORAL|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
214779651|NCT06585943|BEHAVIORAL|Forced Rate Exercise + Rehab|The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
214779652|NCT06585943|BEHAVIORAL|Rehabilitation|The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
214779653|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
214779654|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
214779655|NCT01837485|DRUG|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
214779656|NCT01837485|DRUG|Placebo|Placebo pill was applied 3 times a day for 3 months
214779657|NCT02336698|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
214779658|NCT02336698|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
214779659|NCT02336698|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
214779660|NCT05436496|BIOLOGICAL|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10\^6 cells/kg body weight via IV
214779661|NCT02582801|DRUG|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
214779662|NCT03820778|DIAGNOSTIC_TEST|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
214779663|NCT03516838|DRUG|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
214779664|NCT03516838|DRUG|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
214779665|NCT03912350|DRUG|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
214779666|NCT03079674|OTHER|observational only- no intervention|observational only- no intervention
214779667|NCT04455594|DRUG|Almonertinib|Oral, 110mg QD
214779668|NCT04455594|DRUG|Erlotinib|Oral, 150mg QD
214779669|NCT04455594|DRUG|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
214779670|NCT04455594|DRUG|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
214779671|NCT04455594|DRUG|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
214779672|NCT05219773|DEVICE|NuvoAir Air Next spirometer|"* The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey."
214779673|NCT03996707|OTHER|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery
214779674|NCT03996707|OTHER|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot \& ankle surgery
214779675|NCT01458119|DRUG|migalastat hydrochloride|Oral capsule QOD
214779676|NCT00435825|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
214779677|NCT04427930|BIOLOGICAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
214779678|NCT05991245|OTHER|Collecting datas|Blood, Tissue and Urine samples
214779679|NCT04741139|DRUG|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
214779680|NCT02517099|DRUG|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
214779681|NCT02517099|DRUG|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
214779682|NCT02517099|DRUG|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
214779683|NCT01123980|DRUG|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
214779684|NCT01123980|DRUG|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
214779685|NCT01123980|DRUG|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
214779686|NCT01123980|DRUG|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
214779687|NCT00017030|DRUG|trabectedin|
214779688|NCT01225991|DRUG|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
214779689|NCT05550675|OTHER|Questionnaires|Disease specific questionnaires
214779690|NCT02313116|DEVICE|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
214779691|NCT03491319|PROCEDURE|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
214779692|NCT03491319|PROCEDURE|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
214779693|NCT03491319|PROCEDURE|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
214779694|NCT05329415|DIAGNOSTIC_TEST|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
214779695|NCT03779685|PROCEDURE|General anesthesia|Sevoflurane and morphine
214779696|NCT03779685|PROCEDURE|Regional anesthesia|Paravertebral block
214779697|NCT00789828|DRUG|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
214779698|NCT00789828|DRUG|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
214779699|NCT02476734|OTHER|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
214779700|NCT00181116|DRUG|Levetiracetam|
214779701|NCT04252352|DEVICE|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
214779702|NCT00584896|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
214779703|NCT04667273|PROCEDURE|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
214779704|NCT04667273|PROCEDURE|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
214779705|NCT02942173|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
214779706|NCT04934111|DRUG|LNP-nCOV saRNA-02 Vaccine|a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
214779707|NCT06248073|BEHAVIORAL|on-line self-management training|To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
214779708|NCT06248073|BEHAVIORAL|onsite task-related training|Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
214779709|NCT00955188|OTHER|computer-assisted intervention|
214779710|NCT00955188|OTHER|educational intervention|
214779711|NCT00955188|OTHER|medical chart review|
214779712|NCT06177041|DRUG|M108 monoclonal antibody|M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
214779713|NCT06177041|DRUG|Placebo|Placebo will be administered as a minimum 2-hour IV infusion.
214779714|NCT06177041|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
214779715|NCT06177041|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
214779716|NCT02094937|DRUG|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
214779717|NCT02094937|DRUG|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
214779718|NCT02094937|DRUG|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
214779719|NCT02094937|DRUG|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
214779720|NCT02094937|DRUG|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
214779721|NCT02094937|DRUG|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
214779722|NCT01133392|DRUG|Insulin lispro A|20 units (U) subcutaneously (SC).
214779723|NCT01133392|DRUG|Insulin lispro B|20 U subcutaneously (SC).
214779724|NCT02953132|DRUG|MT-4129|
214779725|NCT02953132|DRUG|Placebo|
214779726|NCT04765189|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
214779727|NCT04765189|DIETARY_SUPPLEMENT|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
214779728|NCT04765189|DIETARY_SUPPLEMENT|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
214779729|NCT04765189|DIETARY_SUPPLEMENT|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
214779730|NCT06697977|DIETARY_SUPPLEMENT|phytosterols|2 grams of phytosterols given as 7 pills per day
214779731|NCT06697977|DIETARY_SUPPLEMENT|placebo|placebo 7 pills per day
214779732|NCT06701760|DRUG|Sodium Lactate|sodium lactate
214779733|NCT06701760|DRUG|placebo|infusion of sodium chloride
214779734|NCT02521831|DRUG|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
214779735|NCT02521831|DRUG|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
214779736|NCT06700941|BIOLOGICAL|HPV vaccine|"The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated."
214779737|NCT06703411|DRUG|Iron Sucrose IV|IV iron sucrose 200mg per visit
214779738|NCT06703411|DRUG|Standard Medical Therapy|Standard of care (HFrEF 4 pillars treatment)
214779739|NCT06703372|OTHER|Diode Laser 980 nm, 0.2W|diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone
214779740|NCT06703372|OTHER|Placebo Diode laser|the tip of the instrument will be sealed with blue rubber to prevent the passage of light
214779741|NCT06703970|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
214779742|NCT06703970|DEVICE|Platelet Rich Plasma Joint Injection|\~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
214779743|NCT06703008|OTHER|TEE hemodynamic monitoring|Transesophageal echocardiography monitoring to guide administration of fluids, vasopressor and inotropes during liver transplantation in order to avoid hypotension.
214779744|NCT00452998|PROCEDURE|Q-switched fd Nd:yag in Laser Iridotomy|
214779745|NCT06702956|PROCEDURE|laser corticotomy|stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy
214779746|NCT06702956|PROCEDURE|Conventional tooth movement|tooth movement us done using wires and brackets
214779747|NCT06512389|DRUG|Oral solution|300 mg taken morning and evening
214779748|NCT06195267|DRUG|Sivelestat|The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
214779749|NCT06195267|DRUG|Blank control|Patients only received standard treatment and care.
214779750|NCT05788237|BIOLOGICAL|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
214779751|NCT05788237|BIOLOGICAL|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
214779752|NCT05788237|BIOLOGICAL|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
214779753|NCT05788237|DRUG|Placebo|0.9% saline for injection
214779754|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
214779755|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
214779756|NCT05824975|DRUG|GI-102 subcutaneous (SC)|0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
214779757|NCT05824975|DRUG|GI-102|Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
214779758|NCT05824975|DRUG|doxorubicin|Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
214779759|NCT05824975|DRUG|paclitaxel|Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
214779760|NCT05824975|DRUG|bevacizumab|Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
214779761|NCT05824975|DRUG|eribulin|Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
214779762|NCT05824975|DRUG|trastuzumab deruxtecan (T-DXd)|T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
214779763|NCT05824975|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
214779764|NCT05824975|DRUG|GI-102|Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
214779765|NCT04905927|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
214779766|NCT01981629|DEVICE|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
214779767|NCT05077683|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
214779768|NCT05077683|DRUG|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
214779769|NCT05528926|OTHER|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
214779770|NCT05528926|OTHER|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
214779771|NCT05528926|DRUG|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
214779772|NCT05676138|OTHER|Measuring PK and PD indices in patients who receive conventional treatment|Measuring plasma concentration of commonly used antibiotics in NTM-PD
214779773|NCT00087399|DRUG|gabapentin|
214779774|NCT00087399|DRUG|antidepressant|
214779775|NCT00359554|BIOLOGICAL|VAXIGRIPPE|
214779776|NCT02661282|BIOLOGICAL|Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Given IV
214779777|NCT02661282|OTHER|Laboratory Biomarker Analysis|Correlative studies
214779778|NCT02661282|DRUG|Temozolomide|Given PO
214779779|NCT02661282|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214779780|NCT03229382|DRUG|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
214779781|NCT00524576|BIOLOGICAL|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
214779782|NCT01849939|DRUG|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
214779783|NCT01017458|DRUG|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
214779784|NCT01017458|DRUG|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
214779785|NCT01017458|DRUG|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
214779786|NCT01017458|DRUG|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
214779787|NCT00172302|DRUG|vitamin C, intravenous injection|
214779788|NCT06149195|DIAGNOSTIC_TEST|Standard medical care for heart failure|Standard treatment and care for heart failure patients from the heart failure center of Sichuan Provincial People's Hospital.
214779789|NCT04749810|DRUG|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
214779790|NCT01809795|OTHER|Blueberry Smoothie|
214779791|NCT01809795|OTHER|Sham Smoothie|
214779792|NCT00207714|DRUG|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
214779793|NCT00207714|DRUG|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
214779794|NCT00207714|DRUG|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
214779795|NCT00207714|DRUG|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
214779796|NCT03627195|DRUG|DSP-1349M|DSP-1349M injectable
214779797|NCT03627195|DRUG|placebo|placebo injection
214779798|NCT03503708|DRUG|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
214779799|NCT02939638|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
214779800|NCT02939638|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
214779801|NCT02580318|DEVICE|breathalyzer|
214779802|NCT02165566|DRUG|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
214779803|NCT02165566|DRUG|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
214779804|NCT06536790|OTHER|hang clean training|This include hang clean training thrice a week for twelve weeks
214779805|NCT06536790|OTHER|half squat training|This include half squat training thrice a week for twelve weeks
214779806|NCT03951870|BEHAVIORAL|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
214779807|NCT03951870|BIOLOGICAL|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
214779808|NCT04033900|DEVICE|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
214779809|NCT04170959|DRUG|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
214779810|NCT04170959|OTHER|No metformin|Standard of care without metformin.
214779811|NCT01503359|DIETARY_SUPPLEMENT|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
214779812|NCT01653470|DRUG|Paclitaxel|
214779813|NCT01653470|DRUG|5-Fluorouracil (5FU)|
214779814|NCT01653470|DRUG|Carboplatin|
214779815|NCT01653470|DRUG|Leucovorin|
214779816|NCT01653470|DRUG|Irinotecan|
214779817|NCT01653470|DRUG|Paclitaxel|
214779818|NCT01653470|DRUG|BMS-906024|
214779819|NCT00945152|DRUG|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
214779820|NCT00945152|DRUG|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
214779821|NCT06290700|BEHAVIORAL|Neonatal Care education|Participants who met the study inclusion criteria were provided with information about the purpose and conduct of the study, and their consent to participate was then obtained. The interviews were conducted in the breastfeeding room at the Uşak Dikilitaş Family Health Centre. The data were collected between November 2022 and November 2023. The Family Health Centre has two vaccination rooms, two antenatal care rooms, two observation rooms, and two breastfeeding rooms. Each pregnant woman was individually enrolled in an education session held in the breastfeeding room. The breastfeeding room was approximately 20 m², which was considered standard for accommodating training for an average of three pregnant women. The breastfeeding room was quiet, had a suitable temperature, and was located on the first floor in the middle of the corridor.
214779822|NCT01361906|BEHAVIORAL|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
214779823|NCT01883999|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
214779824|NCT00328042|BEHAVIORAL|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
214779825|NCT00328042|BEHAVIORAL|Information Only|This is an individual self-paced at home study program.
214779826|NCT05614999|OTHER|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
214779827|NCT02997956|DRUG|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
214779828|NCT02997956|PROCEDURE|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
214779829|NCT03038178|DRUG|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
214779830|NCT03564756|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C per day
214779831|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
214779832|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
214779833|NCT00071409|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
214779834|NCT05198115|BEHAVIORAL|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
214779835|NCT04275661|PROCEDURE|Ultrasound (US) bi-level erector spinae block|nerve block
214779836|NCT04275661|DRUG|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
214779837|NCT04275661|DRUG|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
214779838|NCT04275661|DRUG|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
214779839|NCT00833547|DRUG|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
214779840|NCT00833547|DRUG|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
214779841|NCT01735877|OTHER|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
214779842|NCT01735877|OTHER|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
214779843|NCT05540977|DRUG|Donepezil|Donepezil 5mg QN
214779844|NCT05540977|OTHER|Usual care|Usual care
214779845|NCT02358954|PROCEDURE|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
214779846|NCT02358954|PROCEDURE|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
214779847|NCT02358954|PROCEDURE|3D Turntable|
214779848|NCT02358954|PROCEDURE|Vection stimulation|
214779849|NCT06565728|DRUG|Vitamin D3 2000 UNT Oral Tablet|To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
214779850|NCT02104128|DRUG|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
214779851|NCT00686790|BIOLOGICAL|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
214779852|NCT05837065|OTHER|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
214779853|NCT03295539|DEVICE|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
214779854|NCT03167814|DIETARY_SUPPLEMENT|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
214779855|NCT00274014|DRUG|Tiotropium|
214779856|NCT01140178|DRUG|HPPH|Given IV
214779857|NCT02542150|DRUG|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
214779858|NCT02542150|DRUG|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
214779859|NCT06270030|DRUG|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
214779860|NCT06270030|DRUG|LNZ100 (Aceclidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
214779861|NCT06270030|DRUG|Placebo (Vehicle) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
214779862|NCT00370669|DRUG|bevacizumab|
214779863|NCT00370669|DRUG|triamcinolone acetonide|
214779864|NCT00838669|DRUG|Extended release OROS paliperidone|
214779865|NCT02082912|DRUG|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
214779866|NCT02082912|OTHER|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
214779867|NCT02082912|DEVICE|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
214779868|NCT03426319|DIAGNOSTIC_TEST|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
214779869|NCT06450600|BEHAVIORAL|Multiple Sclerosis Therapeutic Education Program|"The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience."
214779870|NCT01110499|DRUG|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
214779871|NCT01110499|DRUG|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
214779872|NCT01110499|DRUG|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
214779873|NCT01110499|DRUG|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
214779874|NCT01110499|DRUG|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
214779875|NCT01110499|DRUG|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
214779876|NCT01110499|DRUG|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
214779877|NCT01110499|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
214779878|NCT02986152|BEHAVIORAL|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
214779879|NCT02858856|DRUG|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
214779880|NCT02412956|BEHAVIORAL|SmokefreeMOM Text|
214779881|NCT03604354|DRUG|Tapentadol 100 MG Oral Tablet|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
214779882|NCT03604354|DRUG|Pregabalin 150mg|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
214779883|NCT04737668|OTHER|Intrathecal pump refill with Virtual Reality|VR game
214779884|NCT04737668|OTHER|Intrathecal pump refill with distraction|Video
214779885|NCT04737668|OTHER|Intrathecal pump refill|daily routine care for pump refill
214779886|NCT01846832|DRUG|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
214779887|NCT01846832|DRUG|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
214779888|NCT01846832|DRUG|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is \< 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is \> or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
214779889|NCT05291156|DRUG|Cetuximab|"Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week."
214779890|NCT05291156|DRUG|Avelumab|Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
214779891|NCT01577966|DRUG|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
214779892|NCT06344988|OTHER|The exercise program|The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.
214779893|NCT06344988|OTHER|Online education presentation|This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
214779894|NCT06344988|DEVICE|Smart band|Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
214779895|NCT01122043|DEVICE|Endoglide|Device
214779896|NCT05926336|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
214779897|NCT05926336|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
214779898|NCT00403364|DRUG|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
214779899|NCT00353938|DRUG|3,4-methylenedioxymethamphetamine (125 mg)|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
214779900|NCT00353938|DRUG|3,4-methyelendioxymethamphetamine (25 mg)|Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
214779901|NCT00353938|BEHAVIORAL|Therapy|Non-directive therapy performed by a team of two co-therapists
214779902|NCT03381885|BEHAVIORAL|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
214779903|NCT03381885|BEHAVIORAL|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
214779904|NCT00873951|OTHER|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
214779905|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
214779906|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
214779907|NCT00873951|DIETARY_SUPPLEMENT|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
214779908|NCT02002117|OTHER|DNA mass|DNA mass spectrometry
214779909|NCT03309410|DIAGNOSTIC_TEST|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
214779910|NCT00140998|DRUG|17 beta estradiol|
214779911|NCT00001427|DRUG|9-aminocamptothecin|
214779912|NCT03552120|BEHAVIORAL|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
214779913|NCT03552120|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
214779914|NCT02974374|DRUG|PF-06835919|Single or repeated, escalating dose
214779915|NCT02974374|OTHER|Placebo|Single or repeated, escalating dose
214779916|NCT01686178|BEHAVIORAL|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
214779917|NCT01380314|DRUG|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
214779918|NCT01380314|DRUG|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
214779919|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect \& cigarettes are available.
214779920|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
214779921|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
214779922|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
214779923|NCT04376489|BEHAVIORAL|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
214779924|NCT04376489|BEHAVIORAL|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
214779925|NCT04376489|BEHAVIORAL|Joy|Smart phone app that teaches participants to practice breathing exercise.
214779926|NCT04376489|BEHAVIORAL|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
214779927|NCT04376489|BEHAVIORAL|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
214779928|NCT00697112|DRUG|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
214779929|NCT04847297|PROCEDURE|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
214779930|NCT04847297|PROCEDURE|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
214779931|NCT04601662|PROCEDURE|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
214779932|NCT04601662|OTHER|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
214779933|NCT00736333|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles
214779934|NCT05433337|DEVICE|Digital ACT|Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
214779935|NCT02958748|OTHER|taking blood sample|
214779936|NCT00984906|OTHER|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
214779937|NCT03911089|OTHER|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
214779938|NCT01861119|DRUG|Silicone gel Kelo-cort™;|
214779939|NCT01861119|DRUG|Onion extract gel Contractubex™|
214779940|NCT05606692|DRUG|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
214779941|NCT05606692|DRUG|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
214779942|NCT04126733|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
214779943|NCT04126733|BIOLOGICAL|Nivolumab (Opdivo)|Administered on day 1 of every treatment cycle.
214779944|NCT03346928|PROCEDURE|Head and neck reconstruction|Head and neck free flap reconstruction
214779945|NCT01538316|DIETARY_SUPPLEMENT|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
214779946|NCT01538316|DIETARY_SUPPLEMENT|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
214779947|NCT01538316|DIETARY_SUPPLEMENT|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
214779948|NCT00459381|DRUG|pazopanib hydrochloride|Given orally
214779949|NCT00459381|OTHER|laboratory biomarker analysis|Correlative studies
214779950|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (high dose)|From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
214779951|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (low dose)|From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
214779952|NCT05502068|DIETARY_SUPPLEMENT|Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion|This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
214779953|NCT02629133|BEHAVIORAL|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
214779954|NCT03216954|DRUG|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
214779955|NCT03216954|DRUG|Placebos|Subjects will receive placebo capsules
214779956|NCT03216954|DRUG|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
214779957|NCT00276705|DRUG|cisplatin|
214779958|NCT00276705|DRUG|cyclophosphamide|
214779959|NCT00276705|DRUG|doxorubicin hydrochloride|
214779960|NCT00276705|DRUG|thalidomide|
214779961|NCT00276705|PROCEDURE|adjuvant therapy|
214779962|NCT00276705|PROCEDURE|conventional surgery|
214779963|NCT00276705|PROCEDURE|neoadjuvant therapy|
214779964|NCT05463783|DRUG|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
214779965|NCT05463783|DRUG|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
214779966|NCT02598193|DRUG|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
214779967|NCT02598193|DRUG|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
214779968|NCT04383704|OTHER|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
214779969|NCT05138198|BEHAVIORAL|Mediterranean Diet & Physical Activity|"At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals"
214779970|NCT05138198|BEHAVIORAL|Usual Care|As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
214779971|NCT03376074|DEVICE|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
214779972|NCT03376074|OTHER|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
214779973|NCT00006129|DRUG|testosterone|
214779974|NCT02480855|OTHER|Questionnaire and feedback|
214779975|NCT01393548|DRUG|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
214779976|NCT01393548|DRUG|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
214779977|NCT01382901|DRUG|Ferric Carboxymaltose (FCM)|
214779978|NCT01382901|DRUG|Placebo|
214779979|NCT05309707|DEVICE|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
214779980|NCT04437082|DEVICE|optical coherence tomography|imaging structural and vascular features of the eye
214779981|NCT03796299|DIAGNOSTIC_TEST|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
214779982|NCT02182011|DRUG|Tenecteplase|
214779983|NCT02182011|DRUG|Alteplase|
214779984|NCT02182011|DRUG|Streptokinase|
214779985|NCT03123211|DRUG|Veliparib|Veliparib will be administered orally.
214779986|NCT01004796|GENETIC|cytogenetic analysis|
214779987|NCT01004796|GENETIC|microarray analysis|
214779988|NCT01004796|GENETIC|mutation analysis|
214779989|NCT01004796|OTHER|immunohistochemistry staining method|
214779990|NCT01004796|OTHER|immunologic technique|
214779991|NCT01004796|OTHER|mass spectrometry|
214779992|NCT03496935|DEVICE|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
214779993|NCT00279578|DRUG|ReFacto (Recombinant factor VIII) and Tranexamic acid|
214779994|NCT02641171|OTHER|Specimen sampling|exhaled air samples blood samples fecal samples
214779995|NCT06640244|OTHER|Sunscreen|To be used by all participants throughout the study
214779996|NCT06640244|OTHER|Cosmetic product G18|Cosmetic face care product
214779997|NCT06640244|OTHER|Cosmetic product N70|Cosmetic face care product
214779998|NCT06640244|OTHER|Cosmetic product D79|Cosmetic face care product
214779999|NCT06640244|OTHER|Cosmetic product E84|Cosmetic face care product
214780000|NCT06640244|OTHER|Cosmetic product C68|Cosmetic face care product
214780001|NCT02523274|DRUG|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
214780002|NCT02523274|DRUG|Placebo|Vegetable-based cellulose
214780003|NCT02523274|BEHAVIORAL|Exercise|Multi-modal exercise regimen, 3 days/week
214780004|NCT03181178|DIETARY_SUPPLEMENT|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
214780005|NCT03181178|DIETARY_SUPPLEMENT|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
214780006|NCT03181178|BEHAVIORAL|Nutrition education|This intervention provided nutrition education sessions
214780007|NCT04748809|OTHER|Diet 1|Dietary intervention
214780008|NCT04748809|OTHER|Diet 2|Dietary intervention
214780009|NCT04106401|OTHER|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
214780010|NCT04106401|OTHER|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
214780011|NCT04106401|OTHER|physical activity monitoring|recording of physical activity by actimetry
214780012|NCT04106401|OTHER|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
214780013|NCT04106401|OTHER|24-hour blood pressure|recorded by ambulatory device
214780014|NCT01776996|DRUG|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
214780015|NCT05100849|PROCEDURE|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
214780016|NCT05100849|PROCEDURE|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
214780017|NCT02354976|DRUG|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
214780018|NCT02354976|DRUG|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
214780019|NCT02354976|DRUG|Fenofibrate 200mg|200mg capsule administered once daily
214780020|NCT02354976|DRUG|Placebo|Placebo matching to fenofibrate 200mg
214780021|NCT03621020|DIAGNOSTIC_TEST|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
214780022|NCT03621020|DIAGNOSTIC_TEST|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
214780023|NCT00085852|BIOLOGICAL|BLVR|10 mL Hydrogel
214780024|NCT03726437|BEHAVIORAL|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
214780025|NCT03726437|BEHAVIORAL|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
214780026|NCT00623909|DEVICE|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
214780027|NCT03373266|DRUG|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
214780028|NCT03373266|DRUG|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
214780029|NCT06403566|OTHER|hand massage|three group randomized controlled trials
214780030|NCT01111630|DRUG|recomon (Epoetin Beta)|administer once weekly
214780031|NCT01111630|DRUG|recomon (Epoetin Beta)|administer three times weekly
214780032|NCT01896700|DRUG|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
214780033|NCT01896700|DRUG|Placebo|Escalating matched dose of placebo
214780034|NCT00773552|DRUG|solifenacin succinate|5mg PO Qday x 90 days
214780035|NCT00773552|DRUG|placebo|1 tab PO Qday x 90 days
214780036|NCT06133699|PROCEDURE|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
214780037|NCT06133699|DIAGNOSTIC_TEST|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
214780038|NCT00971399|DRUG|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
214780039|NCT00971399|DRUG|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
214780040|NCT03554642|DEVICE|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
214780041|NCT03554642|BEHAVIORAL|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
214780042|NCT04608578|BEHAVIORAL|Silver|A serious game to improve mental health in youth
214780043|NCT00117585|OTHER|Treatment Phase 1|"* Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma"
214780044|NCT00117585|DRUG|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet"
214780045|NCT00117585|OTHER|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
214780046|NCT02569840|DIETARY_SUPPLEMENT|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
214780047|NCT03118765|DRUG|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
214780048|NCT03118765|DRUG|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
214780049|NCT03118765|DRUG|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
214780050|NCT04664569|OTHER|observational study|observational study
214780051|NCT05012735|DRUG|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
214780052|NCT05012735|DEVICE|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
214780053|NCT00849524|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
214780054|NCT04844996|PROCEDURE|Surgical induction of endometriotic explants|"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"
214780055|NCT01399021|OTHER|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
214780056|NCT01399021|OTHER|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
214780057|NCT00802633|DEVICE|Stapling device during radical cystectomy|Hemostasis
214780058|NCT00802633|DEVICE|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
214780059|NCT01637675|DRUG|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
214780060|NCT01637675|DRUG|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
214780061|NCT04084054|DIAGNOSTIC_TEST|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
214780062|NCT01498107|BEHAVIORAL|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
214780063|NCT04514770|DRUG|Misoprostol|rupture of membrane early and late
214780064|NCT00065897|PROCEDURE|Amniocentesis|
214780065|NCT00065897|PROCEDURE|Transabdominal chorionic villus sampling (TA CVS)|
214780066|NCT02536131|OTHER|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
214780067|NCT01693276|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
214780068|NCT01693276|DRUG|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
214780069|NCT01693276|RADIATION|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
214780070|NCT04881591|DEVICE|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
214780071|NCT00411801|BIOLOGICAL|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
214780072|NCT00411801|BIOLOGICAL|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
214780073|NCT01340365|BEHAVIORAL|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
214780074|NCT01340365|BEHAVIORAL|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
214780075|NCT06098222|BEHAVIORAL|Slow breathing exercise training|Slow breathing exercise training will be given by the researcher in a single one-hour session in the meeting room of the unit 24 hours after the PCI and/or the next day. After a 20-minute silent rest in the training, patients will be asked to breathe slowly through the nostrils for 4 seconds and slowly exhale through the mouth for 6 seconds to reach 6-8 breaths/min. The patient will rest for 5 seconds after every 6 slow breaths. During the training period, a stopwatch will be used by observing the patient's chest and abdominal movements in order to determine whether the patients have reached the required respiratory rate.
214780076|NCT00108758|DRUG|activated recombinant human factor VII|
214780077|NCT04895319|DEVICE|Computer-assisted surgery|The reconstruction was performed with the help of virtual surgical plan and 3D printed models.
214780078|NCT03810664|DRUG|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
214780079|NCT00165711|DRUG|Mecobalamin|
214780080|NCT04769128|OTHER|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
214780081|NCT00240305|DRUG|Rosuvastatin|
214780082|NCT05717283|DIAGNOSTIC_TEST|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
214780083|NCT02234258|BEHAVIORAL|Cognitive behavioral social skills|
214780084|NCT02234258|BEHAVIORAL|Psychoeducation|
214780085|NCT03779594|DRUG|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
214780086|NCT01187160|PROCEDURE|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
214780087|NCT04744896|DEVICE|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
214780088|NCT04744896|DEVICE|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
214780089|NCT01198119|DEVICE|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared"
214780090|NCT01198119|PROCEDURE|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
214780091|NCT01198119|PROCEDURE|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
214780092|NCT00947518|DRUG|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
214780093|NCT00947518|DRUG|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
214780094|NCT05824156|BIOLOGICAL|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
214780095|NCT05824156|OTHER|Placebo|Placebo
214780096|NCT00004582|DRUG|Lopinavir/Ritonavir|
214780097|NCT00004582|DRUG|Efavirenz|
214780098|NCT02173626|BEHAVIORAL|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
214780099|NCT03214458|DEVICE|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
214780100|NCT03806322|OTHER|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
214780101|NCT03806322|OTHER|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
214780102|NCT03580759|BEHAVIORAL|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
214780103|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
214780104|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
214780105|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
214780106|NCT04454970|DEVICE|Urethrotech Urethral catheterisation device (UCD)|Urethral indwelling catheter
214780107|NCT04454970|DEVICE|Bardia Aquafil long term catheter|Urethral indwelling catheter
214780108|NCT03700528|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
214780109|NCT00618423|DRUG|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
214780110|NCT00618423|DRUG|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
214780111|NCT01796431|DRUG|Eviplera®|
214780112|NCT00879970|DRUG|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
214780113|NCT00879970|DRUG|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
214780114|NCT00879970|DRUG|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
214780115|NCT00879970|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D factor intervention
214780116|NCT00879970|DIETARY_SUPPLEMENT|Placebo|Vitamin D factor intervention
214780117|NCT03492983|DIETARY_SUPPLEMENT|Intervention group|10 g/day of high cocoa content chocolate for six months.
214780118|NCT03218735|PROCEDURE|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
214780119|NCT03218735|PROCEDURE|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
214780120|NCT00729196|BEHAVIORAL|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
214780121|NCT00401856|DRUG|Eplerenone|50mg oral route
214780122|NCT00401856|DRUG|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
214780123|NCT02638961|OTHER|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
214780124|NCT02638961|OTHER|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
214780125|NCT02638961|OTHER|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
214780126|NCT04981405|BIOLOGICAL|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
214780127|NCT02845102|OTHER|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
214780128|NCT01610167|DEVICE|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214780129|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214780130|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214780131|NCT06247293|PROCEDURE|intraperitoneal hyperthermic perfusion chemotherapy|"（1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding."
214780132|NCT03956511|OTHER|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
214780133|NCT03453502|BEHAVIORAL|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
214780134|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/vilanterol
214780135|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium
214780136|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol
214780137|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium/vilanterol
214780138|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone propionate/salmeterol
214780139|NCT03662711|DRUG|Bronchodilator Agents|Beclometasone dipropionate/formoterol
214780140|NCT03662711|DRUG|Bronchodilator Agents|Budesonide formoterol
214780141|NCT03662711|DRUG|Bronchodilator Agents|Glycopyrronium
214780142|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium
214780143|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium
214780144|NCT03662711|DRUG|Bronchodilator Agents|Formoterol
214780145|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol glycopyrronium
214780146|NCT03662711|DRUG|Bronchodilator Agents|Salmeterol
214780147|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium olodaterol
214780148|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium/formoterol
214780149|NCT03662711|DRUG|Bronchodilator Agents|Olodaterol
214780150|NCT03662711|DRUG|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
214780151|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
214780152|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
214780153|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: intravenous
214780154|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
214780155|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
214780156|NCT02282826|DRUG|acyclovir|Pharmaceutical form:tablet Route of administration: oral
214780157|NCT05769192|OTHER|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
214780158|NCT05769192|OTHER|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
214780159|NCT03105089|PROCEDURE|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
214780160|NCT04180189|OTHER|Weighted fiber blanket|Using weighted blanket for four weeks
214780161|NCT01315366|DIETARY_SUPPLEMENT|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
214780162|NCT01315366|DIETARY_SUPPLEMENT|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
214780163|NCT01856231|BEHAVIORAL|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
214780164|NCT04103411|OTHER|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
214780165|NCT05569733|DIAGNOSTIC_TEST|simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)|All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).
214780166|NCT02866123|OTHER|ultrasonography|
214780167|NCT02866123|RADIATION|pulmonary radiography|
214780168|NCT01721967|DRUG|Ranolazine|
214780169|NCT06352931|DEVICE|transcranial and transcranial dopp;er|"All patients will be subjected to Transcranial ultrasound examination and compared with other neuroimaging modalities: CT brain or MRI brain and/or MRA \& MRV.~Patients suspected to have ischemic or hemorrhagic disorder, CNS infection or increase intracranial pressure will be evaluated with transcranial Doppler ultrasound and compared with other neuroimaging modalities."
214780170|NCT04888260|OTHER|Laboratory parameter levels in blood samples|Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
214780171|NCT02087228|DEVICE|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
214780172|NCT02087228|DEVICE|radiofrequency energy ablation device|
214780173|NCT00762983|DRUG|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
214780174|NCT00751153|DRUG|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
214780175|NCT02182258|DRUG|BIBF 1120 soft gelatine capsule|
214780176|NCT02182258|DRUG|BIBF 1120 intravenous solution|
214780177|NCT02182258|DRUG|Placebo ampoule|
214780178|NCT01938300|DRUG|Magnesium Sulfate|
214780179|NCT01938300|DRUG|Normal saline|
214780180|NCT03901027|BEHAVIORAL|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
214780181|NCT06536686|GENETIC|Silent myocardial ischemia, STEMI|Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs
214780182|NCT04695639|OTHER|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
214780183|NCT04695639|OTHER|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
214780184|NCT04695639|OTHER|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
214780185|NCT00606268|DRUG|Micafungin|IV
214780186|NCT03145610|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
214780187|NCT03145610|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
214780188|NCT02540707|DRUG|solifenacin|solifenacin 5 mg per day for 12 weeks
214780189|NCT02540707|DRUG|mirabegron|mirabegron 25 mg per day for 12 weeks
214780190|NCT00627627|DRUG|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
214780191|NCT03445247|OTHER|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
214780192|NCT04918537|DIETARY_SUPPLEMENT|Walnuts|30g of plain walnuts in addition to habitual food intakes
214780193|NCT06583538|OTHER|Giraffe Healthcare|"An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks"
214780194|NCT05088525|PROCEDURE|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
214780195|NCT03567330|BEHAVIORAL|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
214780196|NCT03567330|BEHAVIORAL|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
214780197|NCT05036915|PROCEDURE|Pacifier randomly|"Common Action Steps:~1. Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~2. Inclusion and exclusion criteria are evaluated.~3. Study group is determined in line with the randomization order of the newborn to be included in the study.~4. First part of the patient information and follow-up form is completed.~5. Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~\* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~1. Common procedure steps are applied.~2. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~3. Second part of the patient information and follow-up form is completed daily."
214780198|NCT05036915|PROCEDURE|Pacifier other|"Procedure Steps of the Experimental Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~  1. Common procedure steps are applied.~ 2. Pacifier is given for 5 min before each feeding.~ 3. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~ 4. Second part of the patient information and follow-up form is completed daily."
214780199|NCT05491278|DRUG|Fospropofol disodium for injection|Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
214780200|NCT05491278|DRUG|Propofol|Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
214780201|NCT03355859|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
214780202|NCT05042453|DEVICE|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
214780203|NCT04808765|PROCEDURE|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
214780204|NCT06053879|OTHER|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
214780205|NCT01563432|DRUG|Feburic®|80 mg\*1 tablet
214780206|NCT01563432|DRUG|TMX-67|40 mg\*2 tablets
214780207|NCT02740933|DRUG|Demeclocycline|
214780208|NCT02440932|DIETARY_SUPPLEMENT|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
214780209|NCT02440932|OTHER|Normal (control) diet|Breakfast, lunch and open buffet dinner
214780210|NCT05166655|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
214780211|NCT02001428|DRUG|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
214780212|NCT00890227|PROCEDURE|Traditional technique|All level open instrumented posterior spinal fusions
214780213|NCT00890227|PROCEDURE|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
214780214|NCT00202657|PROCEDURE|echocardiography|
214780215|NCT04390074|OTHER|COVID-19 and Intensive Care|No intervention, observational.
214780216|NCT00227656|BIOLOGICAL|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
214780217|NCT00227656|DRUG|Capecitabine|1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
214780218|NCT04785833|DRUG|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
214780219|NCT03777787|DIETARY_SUPPLEMENT|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
214780220|NCT03777787|DIETARY_SUPPLEMENT|Water|A single intragastric administration of water
214780221|NCT06562530|DEVICE|high tone power therapy|sessions are applied for 30 minutes, 3 times per week, for 3 months
214780222|NCT06562530|DEVICE|transcutaneous electrical nerve stimulation (TENS)|sessions are applied for 30 minutes, 3 times per week, for 3 months
214780223|NCT06562530|OTHER|selected physical therapy program|sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
214780224|NCT06279481|OTHER|Nonpharmacological method|Virtual reality
214780225|NCT00883259|DRUG|Metformin|850 mg twice daily
214780226|NCT00883259|OTHER|Placebo|Microcristallyne cellulose 1 table twice daily
214780227|NCT03439293|DRUG|Ixazomib|Ixazomib capsule.
214780228|NCT03439293|DRUG|Daratumumab|Daratumumab IV infusion.
214780229|NCT03439293|DRUG|Dexamethasone|Dexamethasone tablets.
214780230|NCT00493181|DRUG|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
214780231|NCT00660049|DEVICE|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
214780232|NCT00660049|OTHER|SNaP|Daily use
214780233|NCT00660049|OTHER|SNaP|Daily application per protocol
214780234|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
214780235|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
214780236|NCT05912179|DIAGNOSTIC_TEST|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
214780237|NCT06516393|DEVICE|The radial shock wave device|The r-ESWT+Kinesio Tape Application
214780238|NCT02991833|OTHER|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
214780239|NCT02991833|OTHER|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
214780240|NCT00614458|DRUG|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
214780241|NCT04379388|BEHAVIORAL|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
214780242|NCT04128449|DIETARY_SUPPLEMENT|docosahexaenoic acid|5 dragees every 24 hours
214780243|NCT04128449|DIETARY_SUPPLEMENT|Placebo|5 dragees every 24 hours
214780244|NCT00657397|DRUG|Methadone|Methadone sirup once daily
214780245|NCT05946642|DRUG|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
214780246|NCT05946642|DRUG|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
214780247|NCT01284595|DRUG|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
214780248|NCT00348218|DEVICE|NeuroVision|
214780249|NCT01356186|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
214780250|NCT01672307|DRUG|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
214780251|NCT01672307|DRUG|Placebo|Placebo is applied twice daily to the other eyebrow.
214780252|NCT05408533|DEVICE|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
214780253|NCT01086735|BIOLOGICAL|donor lymphocyte infusion|Donor T-cell transduction
214780254|NCT00760188|DEVICE|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
214780255|NCT03143088|BEHAVIORAL|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
214780256|NCT05100394|RADIATION|Laser Therapy|Therapeutic laser therapy was applied.
214780257|NCT05100394|OTHER|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
214780258|NCT03233373|DEVICE|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
214780259|NCT00897429|PROCEDURE|laboratory biomarker analysis|Correlative studies
214780260|NCT03994419|PROCEDURE|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
214780261|NCT05001399|BEHAVIORAL|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
214780262|NCT03743675|BEHAVIORAL|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
214780263|NCT03743675|BEHAVIORAL|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
214780264|NCT00189267|DRUG|Imiquimod 5 % Cream|
214780265|NCT00447187|DRUG|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
214780266|NCT00447187|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
214780267|NCT04663269|DRUG|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
214780268|NCT04663269|DRUG|Control Test|Peritubal block - standard local analgesic administration
214780269|NCT00751972|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
214780270|NCT01866683|BEHAVIORAL|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
214780271|NCT01866683|BEHAVIORAL|1 month waiting period|waiting or detraining period
214780272|NCT00035399|PROCEDURE|Acupuncture|
214780273|NCT05005650|PROCEDURE|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
214780274|NCT01940237|BEHAVIORAL|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
214780275|NCT01771861|OTHER|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
214780276|NCT04857216|DEVICE|Perfusion Index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
214780277|NCT06526130|PROCEDURE|General anaesthesia|Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
214780278|NCT06526130|PROCEDURE|Neuraxial anaesthesia|spinal or epidural injections of local anesthetic with or without opioid
214780279|NCT02766400|BEHAVIORAL|Guided Training|
214780280|NCT02766400|BEHAVIORAL|Directed Training|
214780281|NCT00204932|DRUG|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
214780282|NCT00667433|DRUG|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
214780283|NCT05735782|DIAGNOSTIC_TEST|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
214780284|NCT05735782|DIAGNOSTIC_TEST|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
214780285|NCT04834999|OTHER|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
214780286|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
214780287|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
214780288|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
214780289|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
214780290|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
214780291|NCT05211752|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
214780292|NCT03593772|BEHAVIORAL|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
214780293|NCT05338437|DEVICE|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
214780294|NCT04793828|BEHAVIORAL|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
214780295|NCT02224300|BEHAVIORAL|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
214780296|NCT03801213|DEVICE|urinary catheterization|Urinary catheterization with pain controlled
214780297|NCT03801213|PROCEDURE|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
214780298|NCT05365347|BEHAVIORAL|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
214780299|NCT04135456|DRUG|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
214780300|NCT03499249|DRUG|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
214780301|NCT01297569|DRUG|Ranibizumab|
214780302|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
214780303|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
214780304|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
214780305|NCT00089115|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
214780306|NCT00089115|BIOLOGICAL|rituximab|
214780307|NCT00089115|BIOLOGICAL|sargramostim|
214780308|NCT04295044|DIETARY_SUPPLEMENT|high protein diet|receive 1.8g protein/kg
214780309|NCT04295044|DIETARY_SUPPLEMENT|normal protein diet|receive 1g protein/kg
214780310|NCT02954120|OTHER|no intervention provided|
214780311|NCT02736526|PROCEDURE|recession or resection of the horizontal extraocular muscles|
214780312|NCT03690726|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
214780313|NCT03690726|OTHER|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
214780314|NCT02503566|DEVICE|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
214780315|NCT00206219|DRUG|Gefitinib|
214780316|NCT00206219|DRUG|methotrexate|
214780317|NCT04888741|DRUG|Thymoglobulin|GVHD prophylaxis
214780318|NCT04888741|DRUG|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
214780319|NCT04888741|DRUG|Cyclosporine|immunosuppressant
214780320|NCT04888741|DRUG|Sirolimus|immunosuppressant
214780321|NCT04888741|DRUG|Mycophenolate Mofetil|immunosuppressant
214780322|NCT03390634|OTHER|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
214794193|NCT06201273|BEHAVIORAL|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
214780323|NCT06070168|OTHER|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
214780324|NCT03768609|DRUG|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
214780325|NCT03768609|DRUG|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
214780326|NCT01989195|DRUG|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
214780327|NCT04407468|PROCEDURE|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
214780328|NCT04499235|DRUG|Mometasone furoate|Topical mometasone furoate
214780329|NCT04499235|DRUG|AKST4290|Oral AKST4290
214780330|NCT04499235|DRUG|Placebo|Oral placebo
214780331|NCT03262545|DRUG|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
214780332|NCT03262545|DRUG|Placebos|Physical properties of placebos are consistent with apatinib
214780333|NCT03882216|PROCEDURE|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
214780334|NCT03882216|PROCEDURE|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
214780335|NCT05627908|OTHER|Contrast-enhanced ultrasound|Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
214780336|NCT04397250|BEHAVIORAL|High-intensity interval training|Arm-cranking exercise
214780337|NCT02491619|PROCEDURE|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
214780338|NCT02731833|OTHER|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
214780339|NCT02731833|OTHER|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
214780340|NCT01565382|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
214780341|NCT02537067|DRUG|CHONDRON|"1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
214780342|NCT01559818|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
214780343|NCT04703530|OTHER|hot footbath|The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
214780344|NCT00512356|BIOLOGICAL|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
214794194|NCT06374030|PROCEDURE|Endotracheal intubation|All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
214794195|NCT04071600|DRUG|Neuropeptide Y|Intranasal
214780345|NCT02026037|BEHAVIORAL|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
214780346|NCT04071626|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
214780347|NCT04071626|DRUG|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
214780348|NCT05117866|DRUG|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
214780349|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
214780350|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
214780351|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
214780352|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
214780353|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
214780354|NCT05155020|BIOLOGICAL|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
214780355|NCT05802979|DRUG|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
214780356|NCT02903316|PROCEDURE|Fluids|
214780357|NCT03812601|PROCEDURE|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
214780358|NCT01374906|DRUG|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).
214780359|NCT01374906|DRUG|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
214780360|NCT01374906|DRUG|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
214780361|NCT06545448|PROCEDURE|Percutaneous Coronary Intervention (PCI)|A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
214780362|NCT04887974|PROCEDURE|canine retraction|Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
214780363|NCT02505165|BEHAVIORAL|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
214780364|NCT02505165|OTHER|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
214780365|NCT04559165|OTHER|sericin and chitosan cream|sericin and chitosan cream
214780366|NCT01796041|DRUG|Indocyanine Green|
214780367|NCT05578833|DIAGNOSTIC_TEST|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
214794196|NCT04071600|OTHER|Placebo|intranasal
214794197|NCT01345032|OTHER|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
214780368|NCT05578833|DIAGNOSTIC_TEST|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
214780369|NCT05578833|DIAGNOSTIC_TEST|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
214780370|NCT04412876|DRUG|Duloxetine|Duloxetine 30 mg qd
214780371|NCT04412876|DRUG|Imipramine|Imipramine 25mg qd
214780372|NCT02453100|BEHAVIORAL|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
214780373|NCT02453100|BEHAVIORAL|Education|Education on simple ways to manage incontinence
214780374|NCT00257088|BEHAVIORAL|whole day first grade program|
214780375|NCT05050357|DEVICE|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
214780376|NCT05050357|DRUG|Progestins Norethindrone|oral ethisteron twice daily for three months
214780377|NCT05706428|DEVICE|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
214780378|NCT05706428|DEVICE|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
214780379|NCT00094315|DRUG|Cocaine (IV)|
214780380|NCT04992338|DEVICE|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
214780381|NCT02795780|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
214780382|NCT02795780|PROCEDURE|PET Scan|positron emission tomography (PET) scan
214780383|NCT06037031|DRUG|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
214780384|NCT03175445|OTHER|CBCT scan by planmeca promax|software measurement tool of CBCT
214780385|NCT00902291|BIOLOGICAL|AGS-1C4D4|IV infusion
214780386|NCT00902291|BIOLOGICAL|Gemcitabine|IV infusion
214780387|NCT03564535|DEVICE|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
214794198|NCT01345032|OTHER|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
214780388|NCT03564535|DEVICE|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
214780389|NCT00783562|OTHER|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
214780390|NCT00783562|OTHER|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
214780391|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with Er:YAG laser|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.
214780392|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with neutral sodium fluoride gel|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
214780393|NCT02830490|OTHER|functional tests|Test-retest reliability of physical function in hemodialysis patients
214780394|NCT01671735|OTHER|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
214780395|NCT04716673|OTHER|Down-phase targeted auditory stimulation|The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
214780396|NCT02475980|BEHAVIORAL|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
214780397|NCT04582409|DRUG|HSY244|HSY244 concentrate solution for injection via intravenous infusion
214780398|NCT04582409|OTHER|Placebo|Placebo concentrate solution for injection via intravenous infusion
214780399|NCT00016835|PROCEDURE|Supra-gingival scaling and placebo|Included in arm/group description.
214780400|NCT00016835|PROCEDURE|Subgingival scaling and metronidazole|Included in arm/group description.
214780401|NCT00016835|PROCEDURE|Subgingival scaling and doxycycline|Included in arm/group description.
214780402|NCT00000394|PROCEDURE|Acupuncture therapy|
214780403|NCT04307225|DEVICE|Zenicor|Handheld Thumb ECG monitoring device
214780404|NCT04218006|GENETIC|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
214780405|NCT01203319|BIOLOGICAL|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
214780406|NCT01203319|BIOLOGICAL|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
214780407|NCT01203319|BIOLOGICAL|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
214780408|NCT01990066|BEHAVIORAL|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
214780409|NCT05554874|OTHER|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
214780410|NCT05554874|OTHER|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
214780411|NCT00665626|DRUG|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
214780412|NCT00665626|DRUG|Placebo|Placebo, orally, twice-a-day
214780413|NCT04166669|DRUG|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
214780414|NCT04166669|DRUG|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
214780415|NCT04166669|DRUG|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
214780416|NCT04147611|DEVICE|BAHA|Participant's pediatric bone conduction hearing device.
214780417|NCT04147611|DEVICE|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
214780418|NCT04147611|DEVICE|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
214780419|NCT04147611|DEVICE|Hearing Aid|Participant's unilateral hearing aid with contralateral plug.
214780420|NCT03539731|DRUG|Fluorine F 18 DASA-23|Given IV
214780421|NCT03539731|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214780422|NCT01532037|OTHER|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
214780423|NCT01532037|OTHER|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
214780424|NCT05924568|OTHER|Educational session with Keep Your Move in the Tube and PrimusRS|
214780425|NCT01010230|DEVICE|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
214780426|NCT01010230|DEVICE|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
214780427|NCT00530439|OTHER|Lifestyle intervention|Dietician counselling and physical training
214780428|NCT00530439|OTHER|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
214780429|NCT00530439|BEHAVIORAL|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
214780430|NCT01799213|DRUG|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
214780431|NCT01799213|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
214780432|NCT01259700|BEHAVIORAL|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
214780433|NCT01259700|BEHAVIORAL|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
214780434|NCT04654156|DIAGNOSTIC_TEST|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
214780435|NCT01188070|BEHAVIORAL|Usual Care|Educational materials
214780436|NCT01188070|BEHAVIORAL|Psycho-education|Educational group sessions
214780437|NCT01188070|BEHAVIORAL|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
214780438|NCT01629693|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
214780439|NCT01629693|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
214780440|NCT02665611|BEHAVIORAL|intervention for improvement of adherence|intervention for improvement of adherence
214780441|NCT02665611|BEHAVIORAL|treatment as usual|The control group will be treated according to the usual stadard of care.
214780442|NCT00031837|DRUG|dalteparin|
214780443|NCT00031837|DRUG|gemcitabine hydrochloride|
214780444|NCT00031837|PROCEDURE|quality-of-life assessment|
214780445|NCT01176474|BIOLOGICAL|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
214780446|NCT01176474|DRUG|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
214780447|NCT01176474|BIOLOGICAL|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
214780448|NCT01176474|DRUG|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
214780449|NCT01176474|DRUG|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
214794199|NCT01003132|OTHER|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
214780450|NCT01176474|PROCEDURE|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
214780451|NCT02038400|DEVICE|KINETUBE medical Device|
214780452|NCT02038400|DEVICE|insertion of tympanic ventilation tubes (tympanostomy)|
214780453|NCT05598463|DEVICE|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
214780454|NCT01973270|BEHAVIORAL|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
214780455|NCT03779100|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214780456|NCT03779100|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214780457|NCT01308658|DRUG|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
214780458|NCT01308658|DRUG|ritonavir|on Day 3
214780459|NCT02134769|DEVICE|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
214780460|NCT01925807|BEHAVIORAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
214780461|NCT03352817|OTHER|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
214780462|NCT05709054|OTHER|Experimental: Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Breathing Retraining Exercises group:~Diaphragm manual therapy will be carried out and consists of a technique intended to stretch and mobilise the diaphragmatic muscle fibers indirectly. The maneuver will be performed in two sets of 10 repetitions, within a 1-minute interval for 10 minutes.~Breathing retraining exercises will be implemented for 30 minutes, consisting of:~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
214780463|NCT05709054|OTHER|Sham Breathing Retraining Exercises Group B|"Sham Breathing Retraining Exercises Group B:~Breathing retraining exercises will be implemented for 30 minutes, consisting of :~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
214780464|NCT02151162|BEHAVIORAL|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
214780465|NCT02151162|DIETARY_SUPPLEMENT|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
214780466|NCT02151162|BEHAVIORAL|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
214780467|NCT02151162|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
214780468|NCT01529749|DRUG|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
214780469|NCT01529749|DRUG|EFV/FTC/TDF|600/200/245 mg, od, oral
214780470|NCT01529749|DRUG|FTC/TDF + MK-0518|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
214780471|NCT01529749|DRUG|FTC/TDF+MK-0518+Losartan|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
214780472|NCT04385199|BIOLOGICAL|Convalescent plasma|One 200mL transfusion of ABO compatible convalescent plasma over 3 hours
214780473|NCT05356351|DRUG|RC48- ADC|RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
214780474|NCT05747833|OTHER|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
214780475|NCT03333681|BIOLOGICAL|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
214780476|NCT03423706|PROCEDURE|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
214780477|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
214780478|NCT00124566|DRUG|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
214780479|NCT00124566|DRUG|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m\^2 per day, once every 3 weeks.
214780480|NCT00124566|DRUG|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
214780481|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
214780482|NCT01318265|DRUG|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
214780483|NCT04918615|PROCEDURE|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
214780484|NCT01988428|DRUG|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
214780485|NCT05485428|OTHER|High-intensity interval training|12-weeks of high intensity interval exercise, 30 minutes thrice weekly
214780486|NCT04972006|BEHAVIORAL|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
214780487|NCT02555059|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
214780488|NCT01140984|DRUG|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
214780489|NCT02778763|DRUG|CBLB612|4 μg CBLB612 SQ
214780490|NCT02778763|DRUG|Placebo|
214780491|NCT00056459|DRUG|Vatalanib|
214780492|NCT02053571|PROCEDURE|TIPS with 3D Overlay|
214780493|NCT05839860|OTHER|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
214780494|NCT05839860|OTHER|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
214780495|NCT05839860|OTHER|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
214780496|NCT04130945|OTHER|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
214780497|NCT02084979|BEHAVIORAL|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
214780498|NCT01354600|OTHER|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
214780499|NCT03306784|OTHER|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
214780500|NCT02101320|DEVICE|TRECAM|using the camera during the surgery
214780501|NCT00273247|DRUG|Interferon alpha-2b|
214780502|NCT04261517|DRUG|Hydroxychloroquine|Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
214780503|NCT03855124|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
214780504|NCT01992770|BEHAVIORAL|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
214780505|NCT01992770|BEHAVIORAL|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
214780506|NCT01992770|BEHAVIORAL|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
214780507|NCT02828228|DRUG|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
214780508|NCT02828228|DRUG|Placebo|placebo once a day for 26 weeks
214780509|NCT04123483|DRUG|EnBrace HR Softgel|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
214780510|NCT01733719|PROCEDURE|ER plus RFA|
214780511|NCT01733719|PROCEDURE|ER plus APC|2 litres/minute, 70 watts
214780512|NCT00721461|BIOLOGICAL|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
214780513|NCT06338683|DRUG|Olanzapine 2.5 MG|Oral olanzapine 2.5 mg once daily at bedtime until disease progression
214780514|NCT06338683|DRUG|Standard anti-tumor treatment|Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
214780515|NCT06338683|DIETARY_SUPPLEMENT|Nutritional advice|All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition
214780516|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
214780517|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
214780518|NCT05911347|DIETARY_SUPPLEMENT|Psyllium|15g psyllium added to inulin solution to form a gel
214780519|NCT05911347|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
214780520|NCT05911347|DIETARY_SUPPLEMENT|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
214780521|NCT00560183|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
214780522|NCT00560183|DRUG|Placebo|Capsules
214780523|NCT05214157|PROCEDURE|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
214780524|NCT02148783|DRUG|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
214780525|NCT02148783|DRUG|Placebo|
214780526|NCT00634192|DRUG|tobramycin|1x300mg/d inhaled
214780527|NCT00634192|DRUG|tobramycin|2x300mg/d inhaled
214780528|NCT06157333|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
214780529|NCT06315608|DRUG|MRG-001|MRG-001 is a clear liquid solution for subcutaneous injection
214780530|NCT06684405|DIETARY_SUPPLEMENT|sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)|
214780531|NCT06684405|DIETARY_SUPPLEMENT|Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.|
214780532|NCT05519267|BEHAVIORAL|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
214780533|NCT05519267|BEHAVIORAL|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
214780534|NCT06542003|BEHAVIORAL|Movin' and Groovin' for Wellness|Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
214780535|NCT06703931|DEVICE|Measures performed on all subjects|In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
214780536|NCT05674071|BEHAVIORAL|Articulation/HVT|Osteopathy 1
214780537|NCT05674071|BEHAVIORAL|Soft-tissue massage|Osteopathy 2
214780538|NCT05674071|BEHAVIORAL|Craniosacral techniques|Osteopathy 3
214780539|NCT05674071|BEHAVIORAL|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
214780540|NCT06017011|OTHER|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
214780541|NCT03880331|PROCEDURE|Debridement|Aggressive vs Minimal Debridement
214780542|NCT01113294|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
214780543|NCT03978169|DIAGNOSTIC_TEST|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
214780544|NCT05620680|BIOLOGICAL|CD7 CAR-T cells|patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
214780545|NCT01589029|DRUG|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
214780546|NCT04071392|PROCEDURE|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
214780547|NCT05053919|DEVICE|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
214780548|NCT05053919|DEVICE|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
214780549|NCT01255579|DRUG|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
214780550|NCT01255579|DRUG|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
214780551|NCT03352219|BEHAVIORAL|Reality Check|
214780552|NCT03352219|BEHAVIORAL|Physical Activity Attention Control|
214780553|NCT00872391|RADIATION|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
214780554|NCT05205668|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
214780555|NCT05205668|BIOLOGICAL|Placebo|Placebo administered intravenously
214780556|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus moderate intensity exercise|
214780557|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus health education|
214780558|NCT00205465|DRUG|VX-765|
214780559|NCT03634631|OTHER|Focused Ultrasound|Test ultrasound in 7T MRI scanner
214780560|NCT00860574|DRUG|treosulfan|Given IV
214780561|NCT00860574|DRUG|fludarabine phosphate|Given IV
214780562|NCT00860574|RADIATION|total-body irradiation|Low dose starting at 2Gy
214780563|NCT00860574|PROCEDURE|peripheral blood stem cell transplantation|Given IV per institutional standard practice
214780564|NCT00860574|DRUG|tacrolimus|Given IV or PO
214780565|NCT00860574|PROCEDURE|allogeneic bone marrow transplantation|Given IV per institutional standard practice
214780566|NCT00860574|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
214780567|NCT00860574|DRUG|methotrexate|Given IV
214780568|NCT01704235|OTHER|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
214780569|NCT01246986|DRUG|LY2157299|Administered orally
214780570|NCT01246986|DRUG|Sorafenib|Administered orally
214780571|NCT01246986|DRUG|Ramucirumab|Administered IV
214780572|NCT04948255|OTHER|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
214780573|NCT05948436|PROCEDURE|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
214780574|NCT02006407|RADIATION|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
214780575|NCT02006407|DEVICE|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
214780576|NCT02006407|BEHAVIORAL|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
214780577|NCT01655433|DEVICE|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
214780578|NCT01655433|OTHER|No Hypothermia Treatment|
214780579|NCT02542228|OTHER|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
214780580|NCT04937751|DIAGNOSTIC_TEST|biomarkers|galactomannan, betaDglucan, resistance markers
214780581|NCT04329650|DRUG|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
214780582|NCT04329650|DRUG|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
214780583|NCT00045604|DRUG|cisplatin|
214780584|NCT00045604|DRUG|imatinib mesylate|
214780585|NCT00045604|DRUG|irinotecan hydrochloride|
214780586|NCT03582501|OTHER|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
214780587|NCT02845635|OTHER|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
214780588|NCT03569163|DEVICE|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
214780589|NCT00201734|DRUG|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
214780590|NCT00201734|DRUG|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
214780591|NCT00201734|DRUG|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
214780592|NCT00438958|BIOLOGICAL|filgrastim|Given on day 0.
214780593|NCT00438958|PROCEDURE|allogeneic bone marrow transplantation|Given on day 0
214780594|NCT00438958|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
214780595|NCT02624921|OTHER|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
214780596|NCT06263465|OTHER|Lactobacillus cispatus|10\^9 cfu,5 days
214780597|NCT06263465|OTHER|placebo|0 cfu,5 days
214780598|NCT02911779|PROCEDURE|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
214780599|NCT01683552|DRUG|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
214780600|NCT01683552|DRUG|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
214780601|NCT01683552|DRUG|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
214780602|NCT06250400|BIOLOGICAL|human histaglobulin|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
214780603|NCT06250400|BIOLOGICAL|placebo|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
214780604|NCT06250400|DRUG|Loratadine 10 Mg|orally, 10mg once a day for 4 weeks
214780605|NCT06217952|DRUG|SPL84|SPL84 solution for nebulization
214780606|NCT06217952|OTHER|Placebo|Placebo solution for nebulization
214780607|NCT02410070|PROCEDURE|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
214780608|NCT04551352|DRUG|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
214780609|NCT04551352|DRUG|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
214780610|NCT04551352|DRUG|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
214780611|NCT04551352|DRUG|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
214780612|NCT01335399|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780613|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780614|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780615|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780616|NCT01335399|DRUG|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780617|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780618|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214780619|NCT01416142|DEVICE|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
214780620|NCT01416142|DEVICE|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
214780621|NCT05183399|DEVICE|GORE® VIABAHN® Endoprosthesis|
214780622|NCT00003299|DRUG|cisplatin|
214780623|NCT00003299|DRUG|etoposide|
214780624|NCT00003299|DRUG|paclitaxel|
214780625|NCT02464059|DRUG|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
214780626|NCT02050607|OTHER|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
214780627|NCT05888207|DRUG|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
214780628|NCT05888207|DRUG|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
214780629|NCT03402178|DRUG|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
214780630|NCT03402178|DRUG|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
214780631|NCT03503227|DRUG|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
214780632|NCT03503227|DRUG|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
214780633|NCT05755594|PROCEDURE|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
214780634|NCT02557594|DRUG|Viread 300mg|single dose administration after 10hr fasting
214780635|NCT02557594|DRUG|DA-2802 319mg|single dose administration after 10hr fasting
214780636|NCT01698762|OTHER|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
214780637|NCT01698762|OTHER|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
214780638|NCT01698762|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
214794200|NCT02910609|DEVICE|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
214780639|NCT01447329|OTHER|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
214780640|NCT01447329|DRUG|Standard Treatment|
214780641|NCT04261478|DEVICE|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
214780642|NCT04261478|DRUG|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
214780643|NCT05469854|DRUG|Linaprazan glurate|"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."
214780644|NCT05469854|DRUG|Placebo|Single dose, oral tablets
214780645|NCT02008331|DIETARY_SUPPLEMENT|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
214780646|NCT06530082|BIOLOGICAL|CircFam53B-219aa DC vaccine|Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.
214780647|NCT06530082|DRUG|camrelizumab|Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
214780648|NCT00820391|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
214780649|NCT00820391|BEHAVIORAL|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
214780650|NCT03008629|DEVICE|Podofix nail brace|Podofix nail brace
214780651|NCT03008629|DEVICE|Combiped nail brace|Combiped nail brace
214780652|NCT03008629|DEVICE|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
214780653|NCT05148130|DIAGNOSTIC_TEST|oral glucose tolerance test|GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
214780654|NCT03209830|DRUG|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
214780655|NCT03209830|DRUG|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
214780656|NCT00150930|DEVICE|narrowband UVB phototherapy at home|
214780657|NCT02932384|BEHAVIORAL|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
214780658|NCT02932384|BEHAVIORAL|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
214780659|NCT03036995|DRUG|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
214780660|NCT03036995|OTHER|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
214780661|NCT03218410|PROCEDURE|surgical pulmonary embolectomy|
214780662|NCT03218410|COMBINATION_PRODUCT|catheter-directed thrombolysis|
214780663|NCT02112812|DRUG|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
214780664|NCT02112812|DRUG|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
214780665|NCT02112812|DRUG|Eradication therapy for Helicobacter pylori|
214780666|NCT05516212|DIETARY_SUPPLEMENT|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
214780667|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_1 supplementation|"CAFMIPS\_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
214780668|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_2 supplementation|"CAFMIPS\_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
214780669|NCT05516212|DIETARY_SUPPLEMENT|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
214780670|NCT00000512|DRUG|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
214780671|NCT00000512|DRUG|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
214780672|NCT00000512|DRUG|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
214780673|NCT00000512|OTHER|Placebo for colestipol|Placebo for colestipol.
214780674|NCT00000512|OTHER|Placebo for lovastatin|Placebo for lovastatin
214780675|NCT04856995|OTHER|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
214780676|NCT02355795|BEHAVIORAL|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
214780677|NCT02355795|BEHAVIORAL|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
214780678|NCT02355795|BEHAVIORAL|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
214780679|NCT01615302|PROCEDURE|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
214780680|NCT01615302|OTHER|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
214780681|NCT05692752|OTHER|No intervention|Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
214780682|NCT06467500|DRUG|Cadonilimab (AK104)|Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
214780683|NCT02060552|DRUG|Diacerein|oral administration of IL-1βinhibitory
214780684|NCT02060552|DRUG|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
214780685|NCT02060552|DRUG|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
214780686|NCT01180842|OTHER|Yoga treatment program|yoga program designed specifically for the patient with CF
214780687|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
214780688|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
214780689|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
214780690|NCT00568152|DIETARY_SUPPLEMENT|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
214780691|NCT00568152|DIETARY_SUPPLEMENT|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
214780692|NCT00568152|DRUG|Aspirin|75mg dispersable aspirin taken daily for 14 days
214780693|NCT01027637|OTHER|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
214780694|NCT05680311|BIOLOGICAL|measurement of serum autotaxin serum level|autotaxin expression
214780695|NCT01281878|DRUG|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
214780696|NCT02642107|RADIATION|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
214780697|NCT02642107|RADIATION|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
214780698|NCT02505711|BEHAVIORAL|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
214780699|NCT00569283|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214780700|NCT03187054|PROCEDURE|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
214780701|NCT00304954|DRUG|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
214780702|NCT00304954|DRUG|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
214780703|NCT00304954|OTHER|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
214780704|NCT00304954|DRUG|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
214780705|NCT01058382|DRUG|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
214780706|NCT01058382|DRUG|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
214780707|NCT00228540|DRUG|Modafinil|
214780708|NCT04162392|OTHER|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
214780709|NCT04162392|OTHER|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
214780710|NCT01692080|BEHAVIORAL|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
214780711|NCT04961229|BIOLOGICAL|The Pfizer mRNA-based BNT162b2 vaccine|"participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response)."
214780712|NCT00894465|DRUG|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
214780713|NCT00894465|DRUG|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
214780714|NCT03990389|DEVICE|Chatbot Intervention|a chatbot will be used to monitor depression severity
214780715|NCT04133090|PROCEDURE|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
214794201|NCT03736109|GENETIC|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
214794202|NCT00455052|DRUG|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
214794203|NCT02456532|DRUG|placebo|six months of nightly placebo
214780716|NCT04133090|PROCEDURE|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
214780717|NCT02149550|OTHER|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
214780718|NCT02149550|OTHER|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
214780719|NCT02149550|OTHER|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
214780720|NCT02149550|OTHER|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
214780721|NCT02149550|OTHER|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
214780722|NCT02149550|OTHER|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
214780723|NCT00699634|DRUG|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
214780724|NCT06298279|BEHAVIORAL|Tunneled Delivery|Participants will be offered a pre-determined pathway to completing the 8-week course
214780725|NCT06298279|BEHAVIORAL|Personalized Delivery|Participants will be able to complete course modules at their own pace and in the order that most interests them.
214780726|NCT06298279|BEHAVIORAL|Standard Resources|Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.
214780727|NCT06298279|BEHAVIORAL|Enhanced Social Learning Resources|Participants will receive additional intervention content.
214780728|NCT06298279|BEHAVIORAL|Transdiagnostic Self-Guided ICBT|An ICBT course that is completed without the guidance of a therapist.
214780729|NCT05064865|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
214780730|NCT05064865|DIETARY_SUPPLEMENT|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
214780731|NCT00538187|DRUG|obatoclax mesylate|Given IV
214780732|NCT00538187|DRUG|bortezomib|Given IV
214780733|NCT00538187|OTHER|laboratory biomarker analysis|correlative study
214780734|NCT00538187|OTHER|pharmacological study|correlative study
214780735|NCT04340700|DRUG|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
214780736|NCT05543070|RADIATION|Low-dose radiotherapy|Electron Beam/3D-CRT/IMRT/VMAT
214780737|NCT00042042|BEHAVIORAL|Family based educational program|
214780738|NCT01039285|DRUG|Curosurf|2.5 ml/kg instilled in the trachea
214780739|NCT01039285|OTHER|Air|2.5ml/kg of Air will be instilled in the trachea
214780740|NCT00410852|PROCEDURE|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
214780741|NCT00410852|PROCEDURE|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
214780742|NCT00410852|PROCEDURE|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
214780743|NCT02521454|BEHAVIORAL|MBRT|
214780744|NCT01400854|DRUG|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
214780745|NCT02459639|OTHER|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
214780746|NCT02459639|OTHER|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
214780747|NCT00245622|BIOLOGICAL|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
214780748|NCT00245622|BIOLOGICAL|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
214780749|NCT04878874|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
214780750|NCT04878874|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
214794204|NCT02456532|DRUG|Zolpidem CR|six months of nightly zolpidem
214794205|NCT02456532|DRUG|Eszopiclone|
214780751|NCT04261933|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
214780752|NCT03899974|OTHER|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
214780753|NCT01326702|DRUG|Bendamustine Hydrochloride|Given IV
214780754|NCT01326702|OTHER|Pharmacological Study|Correlative studies
214780755|NCT01326702|BIOLOGICAL|Rituximab|Given IV
214780756|NCT01326702|DRUG|Veliparib|Given PO
214780757|NCT03615079|BEHAVIORAL|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
214780758|NCT05489679|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
214780759|NCT04886570|DEVICE|hip arthroplasty|Hip arthroplasty is a kind of joint reconstruction surgery, which has been successfully utilized for treatment of osteoarthritis or hip fracture for decades. In this surgery, implants is applied to reconstruct hip joint, and usually comprised of four components, including femoral stem, femoral head, acetabular cup and liner.
214780760|NCT05683470|DRUG|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
214780761|NCT06373406|DRUG|MHB036C|An antibody-drug conjugate therapy
214780762|NCT06526715|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
214780763|NCT04573400|OTHER|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
214780764|NCT02926378|PROCEDURE|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
214780765|NCT04339088|OTHER|Questionnaires|Questionnaires to assess quality of life
214780766|NCT03630588|COMBINATION_PRODUCT|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
214780767|NCT03630588|COMBINATION_PRODUCT|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
214780768|NCT03524937|DRUG|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
214780769|NCT03524937|DRUG|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
214780770|NCT03524937|DRUG|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
214780771|NCT00328237|PROCEDURE|Cord Blood Transplant|
214780772|NCT01835132|DEVICE|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
214780773|NCT00856778|DEVICE|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
214780774|NCT04133571|DRUG|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
214780775|NCT01255228|OTHER|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
214780776|NCT02599883|RADIATION|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
214780777|NCT03208933|DRUG|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
214780778|NCT03476447|OTHER|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
214780779|NCT03476447|OTHER|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
214780780|NCT04901754|DRUG|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
214780781|NCT02214498|DRUG|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
214780782|NCT02214498|DRUG|Placebo|
214794206|NCT01000337|DRUG|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
214794207|NCT01000337|DRUG|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
214780783|NCT01294878|DRUG|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
214780784|NCT00877682|PROCEDURE|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
214780785|NCT01333176|PROCEDURE|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If \< 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result \>6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~1. Did the clients who were counseled to do so get follow-up blood tests?~2. Were all the formal diagnostic tests performed?~3. Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~4. Did the family physicians find this useful?"
214780786|NCT01333176|PROCEDURE|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
214780787|NCT01333176|PROCEDURE|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
214780788|NCT01333176|PROCEDURE|Blood test|HbA1c blood test
214780789|NCT01333176|PROCEDURE|Blood test|HbA1c finger poke blood test
214780790|NCT03150030|OTHER|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
214780791|NCT03150030|DEVICE|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
214780792|NCT03150030|DEVICE|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
214780793|NCT02805374|DRUG|ASP1517|Oral
214780794|NCT03836274|DIETARY_SUPPLEMENT|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
214780795|NCT00407043|DRUG|Lotemax|
214780796|NCT00407043|DRUG|Restasis|
214780797|NCT00551486|PROCEDURE|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
214794208|NCT03235778|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
214780798|NCT03016663|PROCEDURE|Technique of Breast Lipofilling|"1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
214780799|NCT01980082|DRUG|Cefazolin|Antibiotic
214780800|NCT01980082|DRUG|Placebo|Placebo
214780801|NCT02952794|PROCEDURE|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
214780802|NCT00331773|RADIATION|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
214780803|NCT00331773|RADIATION|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
214780804|NCT04537702|BEHAVIORAL|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
214780805|NCT04537702|BEHAVIORAL|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
214780806|NCT03810833|DEVICE|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
214780807|NCT00379587|DRUG|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
214780808|NCT00379587|DRUG|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
214780809|NCT03168685|DEVICE|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
214780810|NCT01585233|DRUG|ASKP1240|Intravenous
214780811|NCT01585233|DRUG|Placebo|Intravenous
214780812|NCT03335709|BEHAVIORAL|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
214780813|NCT03198637|DRUG|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
214780814|NCT03198637|DRUG|clinical assessment|
214780815|NCT06045585|BIOLOGICAL|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
214780816|NCT05948293|DEVICE|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
214780817|NCT05948293|PROCEDURE|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
214780818|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
214780819|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
214780820|NCT05329428|OTHER|Usual Antenatal Care|In early pregnancy (gestational week \<15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
214780821|NCT05478005|PROCEDURE|Femoral nerve block|Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
214780822|NCT05478005|PROCEDURE|Intra-articular block|Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
214780823|NCT02996253|PROCEDURE|FHL transfer|endoscopic transfer og flexor hallucis longus
214780824|NCT04609527|PROCEDURE|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
214780825|NCT03808220|BEHAVIORAL|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
214780826|NCT03808220|BEHAVIORAL|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
214780827|NCT03808220|BEHAVIORAL|Side effect|investigate the presence of any side effect
214780828|NCT04146220|DRUG|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
214780829|NCT06527976|DRUG|Dexmedetomidine|dexmedetomedine added to bupivacaine for adductor canal block
214780830|NCT06527976|DRUG|Dexamethasone|dexamethasone added to bupivacaine for adductor canal block
214780831|NCT00628394|DRUG|Atomoxetine|40mg 2po qam
214780832|NCT00628394|DRUG|Placebo|40mg 2po qam
214780833|NCT05644912|DEVICE|Transanal irrigation (TAI)|Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
214780834|NCT00525031|DRUG|Temozolomide (TMZ)|150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
214780835|NCT00525031|DRUG|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
214780836|NCT00830063|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
214780837|NCT00830063|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
214780838|NCT00830063|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
214780839|NCT00830063|OTHER|placebo|placebo to match tanezumab and naproxen dosing
214780840|NCT04485286|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
214780841|NCT06013709|DEVICE|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
214780842|NCT00380913|DRUG|Cesamet™ (nabilone)|
214780843|NCT02490566|OTHER|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
214780844|NCT02459613|DRUG|99mTc-Annexin V-128 SPECT|
214780845|NCT00652379|DRUG|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
214780846|NCT00652379|DRUG|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
214780847|NCT02140164|DRUG|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
214780848|NCT01234259|DEVICE|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
214780849|NCT00780715|DRUG|Gliclazide MR|30mg daily increased to 60mg if HbA1c \> 7% at 3 months
214780850|NCT00780715|DRUG|Sitagliptin|Sitagliptin 100mg daily for 6 months
214780851|NCT00780715|DRUG|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c \>7% at 3 months. 6 months duration
214780852|NCT00780715|DRUG|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
214780853|NCT02468661|DRUG|INC280 single agent|
214780854|NCT02468661|DRUG|erlotinib|
214780855|NCT03339791|PROCEDURE|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
214780856|NCT03339791|PROCEDURE|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
214780857|NCT03253978|RADIATION|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
214780858|NCT05146466|BEHAVIORAL|E-MATVR|It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
214780859|NCT05146466|BEHAVIORAL|E-MATE|It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
214780860|NCT04663126|DRUG|Tc-99m tilmanocept|IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
214780861|NCT03108079|DEVICE|Cystosure Urinary Access System|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
214780862|NCT03108079|DEVICE|Foley Catheter|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
214780863|NCT05547815|BIOLOGICAL|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
214780864|NCT00661674|DRUG|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
214780865|NCT00661674|DRUG|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
214780866|NCT00661674|OTHER|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
214780867|NCT00933660|OTHER|ERC-training by instructor|Standard way of training with an instructor
214780868|NCT00933660|OTHER|Web-based training only|Experimental way of training with a web based training application
214780869|NCT00933660|OTHER|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
214780870|NCT01872689|DRUG|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
214780871|NCT01872689|DRUG|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
214780872|NCT01872689|DRUG|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
214780873|NCT04835766|DIAGNOSTIC_TEST|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
214780874|NCT01401920|OTHER|leg elevation|bilateral passive leg elevation for 30 seconds
214780875|NCT01401920|OTHER|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
214780876|NCT01401920|OTHER|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
214780877|NCT01401920|OTHER|control group|supine position without passive leg elevation or trendelenburg position
214780878|NCT06118359|BEHAVIORAL|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
214780879|NCT00881959|DEVICE|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
214780880|NCT06530537|DRUG|Cilostazol|Cilostazol 100mg twice daily
214780881|NCT06530537|DRUG|Aspirin|Aspirin 100mg once daily
214780882|NCT03859661|DIETARY_SUPPLEMENT|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
214780883|NCT06546111|DRUG|Placebo|Drug :placebo tab PO BID for 14 days.
214780884|NCT06546111|DRUG|Daflon|Daflon 500 mg tab PO BID for 14 days.
214780885|NCT03202628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214780886|NCT03202628|DRUG|Dexamethasone|Given PO
214780887|NCT03202628|DRUG|Ixazomib Citrate|Given PO
214780888|NCT03202628|OTHER|Laboratory Biomarker Analysis|Correlative studies
214780889|NCT03202628|DRUG|Pomalidomide|Given PO
214780890|NCT01780727|PROCEDURE|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
214780891|NCT02189876|BEHAVIORAL|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
214780892|NCT02189876|BEHAVIORAL|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
214780893|NCT00686374|BIOLOGICAL|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
214794209|NCT03235778|DRUG|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
214780894|NCT05021627|PROCEDURE|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
214780895|NCT05021627|PROCEDURE|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
214780896|NCT03706326|BIOLOGICAL|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
214780897|NCT03706326|BIOLOGICAL|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
214780898|NCT03706326|COMBINATION_PRODUCT|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
214780899|NCT00087191|DRUG|EF5|Given IV
214780900|NCT00087191|DRUG|motexafin lutetium|Given IV
214780901|NCT00087191|OTHER|pharmacological study|Correlative studies
214780902|NCT04569955|BEHAVIORAL|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
214780903|NCT01725113|DRUG|Calcitriol|3 times weekly
214780904|NCT01725113|DRUG|Paricalcitol|3 times weekly
214780905|NCT04200703|OTHER|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
214780906|NCT04033133|DEVICE|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
214780907|NCT00542516|DRUG|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
214780908|NCT00542516|DRUG|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
214780909|NCT01573923|BIOLOGICAL|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
214780910|NCT01573923|BIOLOGICAL|Conventional therapy|Conventional therapy without cell therapy
214780911|NCT04417790|DIAGNOSTIC_TEST|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
214780912|NCT03575559|BEHAVIORAL|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
214780913|NCT03575559|BEHAVIORAL|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
214780914|NCT03575559|BEHAVIORAL|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
214780915|NCT02579083|DRUG|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
214780916|NCT02579083|DRUG|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
214780917|NCT03287466|DRUG|Oxygen|targeted oxygen therapy
214780918|NCT00174499|DRUG|2 mg nicotine gum|2 mg nicotine gum
214780919|NCT00174499|DRUG|4 mg nicotine gum|4 mg nicotine gum
214780920|NCT03888833|DEVICE|ECMO|ECMO installation
214780921|NCT02702752|OTHER|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
214780922|NCT01808209|DEVICE|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
214780923|NCT01808209|DEVICE|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
214780924|NCT03231527|PROCEDURE|coronary artery bypass grafting (CABG)|myocardial revascularization
214780925|NCT01987284|DRUG|SER100|
214780926|NCT01987284|DRUG|Placebo|
214780927|NCT04877392|DIETARY_SUPPLEMENT|Lavender essential oil|Use of inhaled lavender essential oil
214780928|NCT03430089|BIOLOGICAL|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
214780929|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
214780930|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
214780931|NCT03263871|DIETARY_SUPPLEMENT|PTM202|PTM202 given twice daily for 30 days.
214780932|NCT03263871|DIETARY_SUPPLEMENT|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
214780933|NCT05084534|DRUG|Midodrine|"Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)"
214780934|NCT05084534|OTHER|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
214780935|NCT03066440|DRUG|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
214780936|NCT03066440|DRUG|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
214780937|NCT03937973|BEHAVIORAL|Social rejection|Social rejection paradigm
214780938|NCT05187312|PROCEDURE|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
214780939|NCT05187312|PROCEDURE|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
214780940|NCT05959369|DIAGNOSTIC_TEST|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
214780941|NCT02145403|DRUG|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
214780942|NCT02145403|DRUG|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
214780943|NCT01260428|DEVICE|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
214780944|NCT03947788|BEHAVIORAL|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
214780945|NCT06272851|DEVICE|optical coherence tomography|measuring choroidal thickness using optical coherence tomography
214780946|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
214780947|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
214780948|NCT00918632|DRUG|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
214780949|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
214780950|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
214780951|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
214780952|NCT03723590|DEVICE|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
214780953|NCT03716102|DEVICE|PCI with implantation with DES|PCI with implantation with DES
214780954|NCT01792856|OTHER|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
214780955|NCT01792856|OTHER|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
214780956|NCT04882111|BEHAVIORAL|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
214780957|NCT01106352|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
214780958|NCT01106352|DRUG|Docetaxel|Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
214780959|NCT03944707|DRUG|LOU064 100 mg|LOU064 100 mg once daily orally administered as two 50 mg capsules
214780960|NCT03944707|DRUG|Placebo|Placebo once daily administered orally as capsules
214780961|NCT05890326|BEHAVIORAL|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
214780962|NCT05890326|BEHAVIORAL|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
214780963|NCT05890326|BEHAVIORAL|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
214780964|NCT00183469|DRUG|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
214780965|NCT00183469|DRUG|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
214780966|NCT00183469|DRUG|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
214780967|NCT02951884|PROCEDURE|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
214780968|NCT02951884|DRUG|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
214780969|NCT03433326|DRUG|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
214780970|NCT01462474|DRUG|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
214780971|NCT01462474|DRUG|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
214780972|NCT01462474|RADIATION|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
214780973|NCT00965913|DRUG|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
214780974|NCT00965913|DRUG|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
214780975|NCT00965913|DRUG|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
214780976|NCT02366065|DRUG|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
214780977|NCT02577042|DRUG|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
214780978|NCT02577042|DRUG|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
214780979|NCT02577042|DRUG|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
214780980|NCT05373433|DRUG|SSD8432 750mg|Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
214780981|NCT05373433|DRUG|SSD8432 placebo|Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
214780982|NCT04229797|PROCEDURE|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
214780983|NCT00751998|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
214780984|NCT02713503|OTHER|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
214780985|NCT02713503|OTHER|VisionCoach|Visual field evaluation using VisionCoach
214780986|NCT06036654|DEVICE|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
214780987|NCT05760378|DRUG|Famitinib|TKI
214780988|NCT05760378|DRUG|Camrelizumab|PD1 inhibitor
214780989|NCT05760378|DRUG|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
214780990|NCT05330845|BIOLOGICAL|IL6 assessment|Blood IL6 will be assessed during trial
214780991|NCT05330845|BIOLOGICAL|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
214780992|NCT03618459|OTHER|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
214780993|NCT02487368|DEVICE|Needle stimulation pad|
214780994|NCT02955810|DRUG|Daratumumab|
214780995|NCT02955810|DRUG|Cyclophosphamide|
214780996|NCT02955810|DRUG|Bortezomib|
214780997|NCT02955810|DRUG|Dexamethasone|
214780998|NCT04509752|OTHER|Survey|An online survey will be sent to each clinic to answer the survey questions.
214780999|NCT05867173|OTHER|Experimental Speech Processing Strategy|Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.
214781000|NCT03184103|DIAGNOSTIC_TEST|anti streptolysin o titre and serum complement test|diagnostic lab test
214781001|NCT02429401|BEHAVIORAL|Non-adapted brief motivational interview|1\) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
214781002|NCT02429401|BEHAVIORAL|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
214781003|NCT01965535|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
214781004|NCT01965535|DRUG|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
214781005|NCT01965535|DRUG|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
214781006|NCT01965535|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
214781007|NCT03066635|DRUG|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
214781008|NCT03066635|DRUG|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
214781009|NCT03643406|OTHER|Mental Fatigue|modified stroop task
214781010|NCT03643406|OTHER|Control|documentary
214781011|NCT05178043|DRUG|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
214781012|NCT05178043|DRUG|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
214781013|NCT00639665|OTHER|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
214781014|NCT03126851|OTHER|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
214781015|NCT05103085|DIAGNOSTIC_TEST|Rapid diagnostic orientation test (TROD) for Hepatitis C|Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
214781016|NCT02983227|DRUG|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
214781017|NCT04677582|BEHAVIORAL|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
214781018|NCT04188496|OTHER|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
214781019|NCT04188496|OTHER|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
214781020|NCT02996370|OTHER|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
214781021|NCT02996370|OTHER|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
214781022|NCT02996370|OTHER|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
214781023|NCT02996370|OTHER|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
214781024|NCT02996370|OTHER|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
214781025|NCT05622552|DEVICE|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
214781026|NCT05622552|DEVICE|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
214781027|NCT02179931|DRUG|Flupentixol/melitracen film-coated tablet|
214781028|NCT02179931|DRUG|Flupentixol/melitracen coated tablet (Deanxit®)|
214781029|NCT04348344|BEHAVIORAL|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
214781030|NCT01212731|RADIATION|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
214781031|NCT01212731|RADIATION|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
214781032|NCT01212731|BEHAVIORAL|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
214781033|NCT01212731|DEVICE|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
214781034|NCT02693652|BIOLOGICAL|CVI-HBV-002|"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"
214781035|NCT00986154|DRUG|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
214781036|NCT00986154|DRUG|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
214781037|NCT00986154|DRUG|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
214781038|NCT01032759|DRUG|Memantine|20 mg, BID
214781039|NCT01032759|DRUG|Placebo|BID
214781040|NCT01227096|DEVICE|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
214781041|NCT00520247|DRUG|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
214781042|NCT00068445|DRUG|lamotrigine|
214781043|NCT00068445|OTHER|Placebo|
214781044|NCT00812305|DRUG|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
214781045|NCT00812305|DRUG|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
214781046|NCT02666365|PROCEDURE|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
214781047|NCT02666365|PROCEDURE|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
214781048|NCT01332513|DRUG|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
214781049|NCT01332513|DRUG|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
214781050|NCT01332513|DRUG|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
214781051|NCT01332513|DRUG|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
214781052|NCT01332513|DRUG|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
214781053|NCT01332513|DRUG|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
214781054|NCT02011802|DEVICE|Algosteril TM|
214781055|NCT02011802|DEVICE|Sorbact TM|
214781056|NCT02440100|DRUG|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
214781057|NCT02440100|DRUG|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
214781058|NCT02440100|DRUG|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
214781059|NCT00533884|OTHER|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
214781060|NCT00533884|OTHER|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
214781061|NCT00533884|OTHER|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
214781062|NCT06181682|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine
214781063|NCT06181682|DRUG|Midazolam|Intranasal midazolam
214781064|NCT01493531|DRUG|Lesinurad|Tablets, 200 mg QD
214781065|NCT01493531|DRUG|Lesinurad|Tablets, 400 mg QD
214781066|NCT01493531|DRUG|Placebo|Tablets, Placebo QD
214781067|NCT01493531|DRUG|Allopurinol|Tablets
214781068|NCT00724074|DEVICE|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
214781069|NCT00724074|DEVICE|Usual Care|Usual Care
214781070|NCT01946282|OTHER|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
214781071|NCT01946282|OTHER|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
214781072|NCT01946282|OTHER|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
214781073|NCT05595174|BIOLOGICAL|self ligating bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed
214781074|NCT05595174|BIOLOGICAL|conventional bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
214781075|NCT05595174|BIOLOGICAL|conventional bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment
214781076|NCT05595174|BIOLOGICAL|self ligating bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
214781077|NCT04668222|DRUG|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
214781078|NCT04668222|DRUG|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
214781079|NCT04668222|DRUG|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
214781080|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
214781081|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
214781082|NCT04380324|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
214781083|NCT04380324|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
214781084|NCT06536634|OTHER|SAES|The experimental intervention consists of SAES with a glove or adhesive electrodes at 20Hz, 300µs, intensity between 2-10mA, during 30 minutes per day, 5x/week, for 5 weeks, combined with conventional occupation therapy. The subsequent therapy sessions will take place at home, with in-between telephone checks.
214781085|NCT06536634|OTHER|TAU|Treatment as usual
214781086|NCT01431235|BEHAVIORAL|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
214781087|NCT06105619|DRUG|PLB1001|PLB1001 is a capsule in the form of 300mg,twice daily.
214781088|NCT06105619|DRUG|Temozolomide|100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
214781089|NCT06105619|DRUG|Cisplatin combined with Etoposide|Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
214781090|NCT05860790|DIAGNOSTIC_TEST|Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery|This is a clinical prediction model that uses perioperative clinical indicators and laboratory tests to predict the occurrence of VTE after neurosurgery.
214781091|NCT01279590|DRUG|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
214781092|NCT01279590|DRUG|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
214781093|NCT01279590|DRUG|Placebo|2 placebo capsules twice daily for 12 weeks
214781094|NCT01362959|DRUG|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
214781095|NCT01362959|OTHER|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
214781096|NCT05081752|DEVICE|OTSC Stentfix|Stent placement with fixation of the esophageal stent using OTSC Stentfix.
214781097|NCT05081752|PROCEDURE|Stent Suturing / Endoscopic Clips|Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
214781098|NCT00388570|DEVICE|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
214781099|NCT00179452|BEHAVIORAL|Yoga|
214781100|NCT05991570|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
214781101|NCT03501199|OTHER|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
214781102|NCT03501199|OTHER|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
214781103|NCT03501199|OTHER|no extra material|filling the buccal gap with no material after immediate dental implant placement
214781104|NCT03501199|PROCEDURE|tooth extraction|extraction of tooth which is unrestorable
214781105|NCT03501199|PROCEDURE|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
214781106|NCT03501199|OTHER|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
214781107|NCT03501199|PROCEDURE|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
214781108|NCT03031431|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
214781109|NCT01205529|DRUG|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
214781110|NCT03398460|DIAGNOSTIC_TEST|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
214781111|NCT01537965|DEVICE|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~* elastography with Fibroscan®~* ultrasound elastography in supersonic mode with Aixplorer®~* ultrasound analysis of the surface liver with QRS software,~* quantification of acoustic structure with Aplio XG,~* elastography ARFI with Acuson S2000."
214781112|NCT01195389|DEVICE|Resonator|Treatment group vs. Placebo group
214781113|NCT03346031|PROCEDURE|music therapy|patients will listen to music with an MP3 headset
214781114|NCT02128867|OTHER|Assisted Autogenic Drainage (AAD)|
214781115|NCT02128867|OTHER|bouncing and AAD|
214781116|NCT02128867|OTHER|bouncing|
214781117|NCT01147016|BIOLOGICAL|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
214781118|NCT01147016|DRUG|cyclophosphamide|As prescribed by physician, standard of care.
214781119|NCT01147016|DRUG|doxorubicin hydrochloride|As prescribed by physician, standard of care.
214781120|NCT01147016|DRUG|paclitaxel|As prescribed by physician, standard of care.
214781121|NCT01147016|OTHER|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
214781122|NCT01147016|PROCEDURE|neoadjuvant therapy|As prescribed by physician, standard of care.
214781123|NCT01147016|PROCEDURE|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
214781124|NCT03779516|OTHER|Saline|Effect of saline on postoperative sore throat
214781125|NCT03779516|OTHER|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
214781126|NCT01027884|DRUG|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
214781127|NCT01027884|DRUG|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
214781128|NCT01925742|OTHER|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
214781129|NCT01925742|OTHER|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
214781130|NCT01925742|OTHER|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
214781131|NCT01925742|OTHER|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
214781132|NCT01925742|OTHER|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
214781133|NCT03670537|DIAGNOSTIC_TEST|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
214781134|NCT00971685|DRUG|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
214781135|NCT05997485|DRUG|Nirmatrelvir/Ritonavir|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
214781136|NCT03241407|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
214781137|NCT03241407|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
214781138|NCT00032370|PROCEDURE|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
214781139|NCT00032370|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
214781140|NCT00032370|PROCEDURE|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
214781141|NCT01039571|PROCEDURE|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
214781142|NCT02059187|DRUG|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
214781143|NCT02059187|DRUG|Lantus™|Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
214781144|NCT02059187|DRUG|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
214781145|NCT03774927|DEVICE|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
214781146|NCT03774927|DEVICE|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
214781147|NCT03774927|DEVICE|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
214781148|NCT02226809|DEVICE|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
214781149|NCT04975282|DEVICE|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
214781150|NCT04975282|DEVICE|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
214781151|NCT03070431|RADIATION|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
214781152|NCT02220140|BEHAVIORAL|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
214781153|NCT01889862|DRUG|BMN165 20mg/day|BMN165 20mg/day self-administered daily
214781154|NCT01889862|DRUG|BMN165 40mg/day|BMN165 40mg/day self-administered daily
214781155|NCT01889862|DRUG|Placebo|Non-drug placebo, self-administered daily
214781156|NCT02087579|DRUG|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
214781157|NCT02087579|DRUG|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
214781158|NCT02087579|DRUG|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
214781159|NCT02087579|DRUG|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
214781160|NCT02087579|DRUG|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
214781161|NCT02087579|DRUG|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
214781162|NCT02087579|DRUG|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
214781163|NCT03598452|DRUG|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
214781164|NCT00266552|DRUG|risperidone|
214781165|NCT04337190|BIOLOGICAL|blood sampling|blood sampling at the day of admission, day 3 and day 7
214781166|NCT02857374|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
214781167|NCT02857374|DRUG|Fluorescein Sodium Injection|Given IV
214781168|NCT02857374|OTHER|Laboratory Biomarker Analysis|Correlative studies
214781169|NCT02857374|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
214781170|NCT00004187|DRUG|capecitabine|
214781171|NCT00004187|DRUG|oxaliplatin|
214781172|NCT03884933|OTHER|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
214781173|NCT05145296|COMBINATION_PRODUCT|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
214781174|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
214781175|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
214781176|NCT02481479|DRUG|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
214781177|NCT00845026|DRUG|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
214781178|NCT00845026|DRUG|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
214781179|NCT00845026|DRUG|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
214781180|NCT00845026|DRUG|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
214781181|NCT02393534|OTHER|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
214781182|NCT01517334|DRUG|Minocycline HCl Microspheres|
214781183|NCT01325532|DEVICE|Active CES|CES current
214781184|NCT01325532|DEVICE|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
214781185|NCT04032275|OTHER|Chronic hepatitis B infection|Chronic hepatitis B infection patients
214781186|NCT03012815|DRUG|Gabapentin|Gabapentin administered as a taper
214781187|NCT03012815|DRUG|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
214781188|NCT03012815|DRUG|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
214781189|NCT00889785|BEHAVIORAL|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
214781190|NCT00889785|BEHAVIORAL|Usual Care|Will receive usual care and monthly phone calls as an active control.
214781191|NCT05178147|DEVICE|Compression bandaging without reference to GraduCheck pressure measurements|To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
214781192|NCT05178147|DEVICE|Compression bandaging using GraduCheck pressure measurements to monitor compression pressure|To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
214781193|NCT01252238|DRUG|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
214781194|NCT01252238|DRUG|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
214781195|NCT01252238|DRUG|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
214781196|NCT01090128|DRUG|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
214781197|NCT01090128|DRUG|doxorubicin|50 mg/m2 every 3 weeks
214781198|NCT01090128|DRUG|cyclophosphamide|500 mg/m2 given every 3 weeks
214781199|NCT05603078|RADIATION|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
214781200|NCT00390156|BIOLOGICAL|bevacizumab|5 mg/kg
214781201|NCT00390156|DRUG|cyclophosphamide|Current dose 50 mg
214781202|NCT00390156|DRUG|imatinib|Current dose 400 mg
214781203|NCT00748813|BIOLOGICAL|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
214781204|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
214781205|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
214781206|NCT02265887|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
214781207|NCT06468735|DIAGNOSTIC_TEST|sarcopenia assessment|"Quadriceps muscle thickness measurement at the midpoint between the anterior superior iliac spine and the upper pole of the patella.~Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia"
214781208|NCT06468735|DIAGNOSTIC_TEST|visceral fat thickness measurement|Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.
214781209|NCT03857685|PROCEDURE|In-vitro model|In-vitro model of posterior capsule opacification by culturing the lens capsule
214781210|NCT04882683|DRUG|Prednisone|0.75 mg per kilogram per day for three months
214781211|NCT04882683|DRUG|Azathioprine|1 mg per kilogram per day for three months
214781212|NCT04882683|DRUG|Adalimumab|40mg every two weeks for three months
214781213|NCT04882683|BIOLOGICAL|umbilical cord blood mononuclear cells|Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10\^8).
214781214|NCT01203774|DRUG|Glargine insulin|20-180 units per day
214781215|NCT02565485|DRUG|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
214781216|NCT03449056|DRUG|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
214781217|NCT03307512|DRUG|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
214781218|NCT03307512|DRUG|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
214781219|NCT04402515|DRUG|TIO/OLO|Tiotropium/Olodaterol
214781220|NCT04402515|DRUG|ICS|inhaled cortocosteroids
214781221|NCT03875560|BIOLOGICAL|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
214781222|NCT03875560|DRUG|Placebo|Inactive
214781223|NCT05599204|OTHER|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
214781224|NCT05599204|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
214781225|NCT04862104|BEHAVIORAL|Intervention group|In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
214781226|NCT02169583|DRUG|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
214781227|NCT02169583|DRUG|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
214781228|NCT02169583|DRUG|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
214781229|NCT02169583|DRUG|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
214781230|NCT00437437|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
214781231|NCT05600179|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
214781232|NCT02530879|DRUG|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
214781233|NCT02530879|BEHAVIORAL|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
214781234|NCT02530879|OTHER|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
214781235|NCT01853007|BEHAVIORAL|COACH Program|
214781236|NCT05483439|DRUG|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
214781237|NCT05483439|DRUG|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
214781238|NCT05483439|DRUG|traditional herbal medicine|traditional herbal medicine
214781239|NCT06371079|DEVICE|phakic intraocular lens implantation traditional|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of both cohesive and dispersive OVD
214781240|NCT06371079|DEVICE|phakic intraocular lens implantation reduced OVD|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of only cohesive OVD without using dispersive OVD.
214781241|NCT01847625|OTHER|simulator|
214781242|NCT00424931|DRUG|JNJ-17216498|50mg one time
214781243|NCT00424931|DRUG|JNJ-17216498|10mg one time
214781244|NCT00424931|DRUG|Modafinil|200 mg X 2
214781245|NCT01399073|BEHAVIORAL|virtual reality setup|testing for neglect in a virtual reality setup
214781246|NCT01399073|BEHAVIORAL|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
214781247|NCT01399073|OTHER|c-mri|structural and functional (resting state) imaging
214781248|NCT05895214|PROCEDURE|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
214781249|NCT00420355|DRUG|atazanavir|Atazanavir 300 mg daily on Days 6-12.
214781250|NCT00420355|DRUG|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
214781251|NCT06135519|PROCEDURE|Autologous Mesenchymal stem cells injection|Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
214781252|NCT06135519|PROCEDURE|Homogenized fat injection|Autologous fat will be harvested, homogenized and injected.
214781253|NCT03216681|DRUG|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
214781254|NCT03216681|DRUG|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
214781255|NCT03029000|DRUG|Tbo-filgrastim|solution for subcutaneous injection
214781256|NCT06015217|DRUG|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
214781257|NCT00152386|DRUG|Certolizumab pegol (CDP870)|
214781258|NCT01845090|DRUG|Lanthanum carbonate|the effect on serum FGF23
214781259|NCT01845090|DRUG|Calcium Carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
214781260|NCT00296582|BEHAVIORAL|Gastric Motor Function Measurement|
214781261|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
214781262|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
214781263|NCT01874730|OTHER|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
214781264|NCT01874730|DRUG|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
214781265|NCT01874730|OTHER|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
214781266|NCT00414986|BEHAVIORAL|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
214781267|NCT00414986|BEHAVIORAL|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
214781268|NCT00414986|BEHAVIORAL|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
214781269|NCT02061709|BIOLOGICAL|Ragweed-SPIRE|
214781270|NCT02061709|BIOLOGICAL|Placebo|
214781271|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
214781272|NCT03022929|BEHAVIORAL|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
214781273|NCT02431715|DRUG|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
214781274|NCT03276962|BIOLOGICAL|RTS,S/AS01E (Full dose)|Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
214781275|NCT03276962|BIOLOGICAL|RTS,S/AS01E (1/5th dose)|Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
214781276|NCT03276962|BIOLOGICAL|Rabies vaccine|Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
214781277|NCT00411762|DRUG|Capecitabine|
214781278|NCT00411762|DRUG|PHY906|
214781279|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
214781280|NCT03399435|COMBINATION_PRODUCT|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
214781281|NCT03399435|COMBINATION_PRODUCT|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
214781282|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
214781283|NCT03399435|DRUG|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
214781284|NCT03399435|DRUG|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
214781285|NCT03399435|DRUG|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
214781286|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
214781287|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
214781288|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
214781289|NCT04664283|DEVICE|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
214781290|NCT02758951|OTHER|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
214781291|NCT02758951|COMBINATION_PRODUCT|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
214781292|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
214781293|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
214781294|NCT02758951|PROCEDURE|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy in case of sufficient clinical condition, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
214781295|NCT02758951|PROCEDURE|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after randomisation.
214781296|NCT05727592|DIETARY_SUPPLEMENT|Althernanthera Sissoo|15g of Althernanthera Sissoo consumed with lunch or dinner per day.
214781297|NCT05727592|BEHAVIORAL|Dietary Consultation|Dietary consultation to improve the intakes of vegetables daily
214781298|NCT05155072|DRUG|DW1903|DW1903
214781299|NCT05155072|DRUG|DW1903-R1|DW1903-R1
214781300|NCT05155072|DRUG|DW1903-R2|DW1903-R2
214781301|NCT01311310|OTHER|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
214781302|NCT01933139|OTHER|Audio-visual presentation|
214781303|NCT04127968|DRUG|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
214781304|NCT04127968|DRUG|Oil|Children in control group will receive equal volume of oil.
214781305|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
214781306|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
214781307|NCT01468168|DRUG|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
214781308|NCT04658446|DEVICE|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
214781309|NCT04658446|DEVICE|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
214781310|NCT04839315|BIOLOGICAL|mRNA COVD19 vaccine|Subjects will receive two doses of mRNA based COVID19 vaccines.
214781311|NCT00646178|DRUG|adalimumab|40 mg adalimumab eow Week 0 - Week 12
214781312|NCT00646178|DRUG|placebo for adalimumab|placebo eow Week 0 - Week 12
214781313|NCT01682278|DEVICE|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
214781314|NCT00827073|DRUG|tetracaine 0.5%|betadine 5%
214781315|NCT00827073|DRUG|Lidocaine 2% Jelly|Betadine 5%
214781316|NCT00000773|DRUG|Atovaquone|
214781317|NCT05614388|DIAGNOSTIC_TEST|COVID-19 Self testing and related messaging|Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
214781318|NCT02488707|PROCEDURE|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
214781319|NCT02488707|PROCEDURE|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
214781320|NCT02995694|DRUG|Estradiol|Estradiol Vaginal Cream
214781321|NCT02995694|DRUG|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
214781322|NCT02995694|DRUG|Reference|Estrace Vaginal Cream
214781323|NCT00904189|RADIATION|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
214781324|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
214781325|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
214781326|NCT03836365|OTHER|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
214781327|NCT03836365|OTHER|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
214781328|NCT04472065|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
214781329|NCT04472065|OTHER|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
214781330|NCT05322265|PROCEDURE|laparoscopic surgery for renal and adrenal diseases|type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
214781331|NCT02190383|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
214781332|NCT04974645|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
214781333|NCT04974645|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
214781334|NCT04822961|DRUG|Placebo|Senaparib-matched placebo capsules
214781335|NCT04822961|DRUG|Senaparib|20 mg capsules
214781336|NCT04660409|DIAGNOSTIC_TEST|Blood test for serum Adropin|Blood test for serum Adropin
214781337|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
214781338|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
214781339|NCT00913588|DRUG|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
214781340|NCT04477083|DRUG|inhalable hydroxychloroquine (HCQ)|inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
214781341|NCT04477083|DRUG|supportive and symptomatic treatment|supportive and symptomatic treatment
214781342|NCT03049137|PROCEDURE|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
214781343|NCT03049137|PROCEDURE|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
214781344|NCT03049137|DRUG|Platelet-rich fibrin (PRF)|
214781345|NCT03049137|DEVICE|implant|
214781346|NCT05803538|DEVICE|SMS, telephone interview or diary card|SMS, telephone interview or diary card
214781347|NCT02898766|OTHER|Enteral Nutrition Formula|
214781348|NCT04171986|DRUG|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
214781349|NCT05862116|OTHER|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
214781350|NCT02523079|BEHAVIORAL|Cognitive Behavioral Group Therapy for Insomnia|
214781351|NCT02523079|BEHAVIORAL|Cognitive Behavioral Self-help Therapy for Insomnia|
214781352|NCT02523079|BEHAVIORAL|Sleep Hygiene Guidance|
214781353|NCT05504616|OTHER|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
214781354|NCT00558519|DRUG|cyclophosphamide|
214781355|NCT00558519|DRUG|cytarabine|
214781356|NCT00558519|DRUG|daunorubicin hydrochloride|
214781357|NCT00558519|DRUG|dexamethasone|
214781358|NCT00558519|DRUG|doxorubicin hydrochloride|
214781359|NCT00558519|DRUG|mercaptopurine|
214781360|NCT00558519|DRUG|methotrexate|
214781361|NCT00558519|DRUG|pegaspargase|
214781362|NCT00558519|DRUG|thioguanine|
214781363|NCT00558519|DRUG|vincristine sulfate|
214781364|NCT00558519|RADIATION|radiation therapy|
214781365|NCT01710878|DEVICE|Intergard Synergy Graft|
214781366|NCT03820973|BEHAVIORAL|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
214781367|NCT06305637|DRUG|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
214781368|NCT06305637|DRUG|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
214781369|NCT06305637|DRUG|Placebo|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
214781370|NCT02838290|OTHER|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
214781371|NCT02838290|OTHER|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
214781372|NCT05485857|PROCEDURE|Arrangement of small intestine order before close the abdomen|After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
214781373|NCT03124056|DEVICE|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
214781374|NCT01977859|DRUG|Nesiritide|
214781375|NCT01977859|DRUG|Saline|
214781376|NCT01993433|DRUG|DRM02|
214781377|NCT01993433|OTHER|Vehicle|
214781378|NCT03275168|BEHAVIORAL|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
214781379|NCT03275168|BEHAVIORAL|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
214781380|NCT02998333|PROCEDURE|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
214781381|NCT03459833|DRUG|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
214781382|NCT02293811|OTHER|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
214781383|NCT00629486|GENETIC|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
214781384|NCT04170049|BEHAVIORAL|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
214781385|NCT04711863|DRUG|Fluvoxamine|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
214781386|NCT04711863|DRUG|Placebo|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
214781387|NCT00061958|DRUG|arsenic trioxide|Given IV
214781388|NCT01336309|BEHAVIORAL|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
214781389|NCT02949778|PROCEDURE|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
214781390|NCT02949778|DRUG|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
214781391|NCT02949778|DRUG|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
214781392|NCT00869089|DRUG|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
214781393|NCT05571657|BEHAVIORAL|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
214781394|NCT00566215|PROCEDURE|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
214781395|NCT00566215|PROCEDURE|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
214781396|NCT00097084|DRUG|insulin detemir|
214781397|NCT00097084|DRUG|insulin glargine|
214781398|NCT00097084|DRUG|insulin aspart|
214781399|NCT05385796|OTHER|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
214781400|NCT05385796|OTHER|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
214781401|NCT02803645|BIOLOGICAL|blood sample|
214781402|NCT04643782|DEVICE|ANNE Sleep|ANNE sleep system
214781403|NCT00324090|BEHAVIORAL|High and low glycemic index|
214781404|NCT02495870|OTHER|Pork|
214781405|NCT00120068|BEHAVIORAL|Nursing inservices|
214781406|NCT00120068|PROCEDURE|Academic detailing to MDs; concurrent review and feedback|
214781407|NCT02232269|OTHER|Black Coffee|
214781408|NCT02232269|OTHER|Grapefruit Juice|
214781409|NCT02232269|OTHER|Water|
214781410|NCT02232269|DRUG|Felodipine|
214781411|NCT06419673|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
214781412|NCT06419673|DRUG|Cisplatin|IV infusion
214781413|NCT06419673|DRUG|Carboplatin|IV infusion
214781414|NCT06419673|RADIATION|Brachytherapy and External Beam Radiotherapy|Brachytherapy and External Beam Radiotherapy
214781415|NCT00293475|DRUG|Carboplatin|Given IA
214781416|NCT00293475|DRUG|Mannitol|Given IA
214781417|NCT00293475|DRUG|Methotrexate|Given IA
214781418|NCT00293475|OTHER|Quality-of-Life Assessment|Ancillary studies
214781419|NCT00293475|BIOLOGICAL|Rituximab|Given IV
214781420|NCT00293475|DRUG|Sodium Thiosulfate|Given IV
214781421|NCT02969733|DRUG|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
214781422|NCT02969733|DRUG|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
214781423|NCT02969733|DRUG|isotonic saline serum intravenous administration|
214781424|NCT01963676|DEVICE|tDCS|
214781425|NCT01963676|DEVICE|Sham stimulation|
214781426|NCT05402631|PROCEDURE|Epidural Injection|patient receives an epidural injection due to lower back pain
214781427|NCT05402631|PROCEDURE|Periradicular Injection|patient receives a periradicular injection due to lower back pain
214781428|NCT00736931|DRUG|Brivaracetam|Brivaracetam 10 mg tablets
214781429|NCT00736931|DRUG|levetiracetam|500mg tablets
214781430|NCT00736931|DRUG|lorazepam|lorazepam 2 mg over encapsulated tablets
214781431|NCT00736931|OTHER|placebo|placebo capsules
214781432|NCT01246973|DRUG|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
214781433|NCT01246973|DRUG|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
214781434|NCT00766506|DEVICE|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
214781435|NCT00766506|DEVICE|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
214781436|NCT05979051|DRUG|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
214781437|NCT05979051|DRUG|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
214781438|NCT01297192|DRUG|solifenacin succinate|Oral
214781439|NCT01297192|DRUG|mirabegron|Oral
214781440|NCT00769678|DEVICE|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
214781441|NCT02801851|BEHAVIORAL|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
214781442|NCT04048720|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
214781443|NCT02686489|OTHER|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
214781444|NCT02686489|OTHER|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
214781445|NCT02228031|DRUG|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
214781446|NCT02228031|OTHER|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
214781447|NCT01560091|DRUG|silodosin|8mg PO Qday
214781448|NCT01560091|PROCEDURE|Extra-corporeal shock wave lithotripsy|ESWL
214781449|NCT01560091|DRUG|Tamsulosin|Tamsulosin 0.4mg PO Qday
214781450|NCT05487872|BEHAVIORAL|Mindfulness skills training to reduce experiential avoidance and anxiety symptoms|The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
214781451|NCT02496221|DRUG|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
214781452|NCT02496221|DRUG|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
214781453|NCT02496221|DRUG|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
214781454|NCT01114542|DRUG|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
214781455|NCT01114542|DRUG|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
214781456|NCT03262233|COMBINATION_PRODUCT|nicotine|
214781457|NCT03262233|OTHER|placebo|
214781458|NCT02980328|DEVICE|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
214781459|NCT02980328|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
214781460|NCT04302428|BIOLOGICAL|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
214781461|NCT04302428|BIOLOGICAL|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
214781462|NCT04945161|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
214781463|NCT04945161|OTHER|Placebo|Placebo
214781464|NCT01893983|BEHAVIORAL|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
214781465|NCT00735033|OTHER|Physiotherapy with Swiss Ball|
214781466|NCT00268151|DRUG|Oxaliplatin|
214781467|NCT00268151|DRUG|Capecitabine|
214781468|NCT02872545|PROCEDURE|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
214781469|NCT02872545|PROCEDURE|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
214781470|NCT02872545|PROCEDURE|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
214781471|NCT03613077|PROCEDURE|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
214781472|NCT01120600|DRUG|Odanacatib|One 50 mg tablet once weekly
214781473|NCT01120600|DRUG|Placebo for Odanacatib|One 50 mg tablet once weekly
214781474|NCT01120600|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
214781475|NCT01120600|DIETARY_SUPPLEMENT|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
214781476|NCT05054166|OTHER|No intervention, it was a retrospective study.|This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.
214781477|NCT01165242|BIOLOGICAL|Meningococcal vaccine GSK 134612|One intramuscular injection
214781478|NCT01165242|BIOLOGICAL|Menactra®|One intramuscular injection
214781479|NCT00003070|DRUG|enalapril maleate|
214781480|NCT00003070|PROCEDURE|quality-of-life assessment|
214781481|NCT00798785|DRUG|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
214781482|NCT00798785|DRUG|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
214781483|NCT00798785|DRUG|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
214781484|NCT00798785|PROCEDURE|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels \>= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
214781485|NCT03252132|OTHER|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
214781486|NCT03770000|DRUG|Tenalisib|Tenalisib, BID orally daily
214781487|NCT03770000|DRUG|Romidepsin|Romidepsin IV
214781488|NCT02917837|OTHER|Usual QCNL DI utilization report|See arm descriptions.
214781489|NCT02917837|OTHER|New DI utilization report|See arm descriptions.
214781490|NCT02917837|OTHER|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
214781491|NCT03877237|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
214781492|NCT03877237|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
214781493|NCT00944437|DEVICE|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
214781494|NCT00944437|DEVICE|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
214781495|NCT03843437|DEVICE|Tencel Therapeutic Garments|Children age 6 months to 3 years will wear a Tencel full body suit with feet and mittens, while children age 3-6 years will wear Tencel long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
214781496|NCT03843437|DEVICE|Cotton Therapeutic Garments|Children age 6 months to 3 years will wear a cotton full body suit with feet and mittens, while children age 3-6 years will wear cotton long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
214781497|NCT01234688|OTHER|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
214781498|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started
214781499|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
214781500|NCT03104088|DIAGNOSTIC_TEST|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
214781501|NCT03104088|DIAGNOSTIC_TEST|MOCA|Montreal cognitive assessment (MOCA) in German
214781502|NCT01318785|OTHER|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
214781503|NCT03687437|DIAGNOSTIC_TEST|Blood sample|Complete blood count
214781504|NCT05058937|DIAGNOSTIC_TEST|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
214781505|NCT01073683|PROCEDURE|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
214781506|NCT01073683|DRUG|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
214781507|NCT00959387|DRUG|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
214781508|NCT00959387|RADIATION|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
214781509|NCT00651547|DRUG|budesonide/formoterol|
214781510|NCT00651547|DRUG|budesonide|
214781511|NCT00651547|DRUG|formoterol|
214781512|NCT04719247|PROCEDURE|Pulpotomy|Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
214781513|NCT00142454|DRUG|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
214781514|NCT00142454|BIOLOGICAL|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
214781515|NCT03031405|DRUG|Oxytocin nasal spray|
214781516|NCT03031405|DRUG|Placebos|Placebo nasal spray
214781517|NCT02544945|OTHER|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
214781518|NCT02544945|OTHER|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
214781519|NCT00566098|BIOLOGICAL|MILs|
214781520|NCT00566098|DRUG|Melphalan|
214781521|NCT00566098|BIOLOGICAL|PCV13|
214781522|NCT01860482|DRUG|Newrabell® Tablet 10mg|
214781523|NCT05818631|DIAGNOSTIC_TEST|fusion cognitive prostate biopsy|A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
214781524|NCT00006031|PROCEDURE|Needle localized breast biopsy with specimen x-ray|
214781525|NCT00006031|PROCEDURE|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
214781526|NCT05481580|DIAGNOSTIC_TEST|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
214781527|NCT05944770|OTHER|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
214781528|NCT05944770|OTHER|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
214781529|NCT01656954|PROCEDURE|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
214781530|NCT03213054|BIOLOGICAL|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
214781531|NCT03213054|RADIATION|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
214781532|NCT02236754|DRUG|18 F-FP-DTBZ|The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
214781533|NCT02236754|RADIATION|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
214781534|NCT01082445|DRUG|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
214781535|NCT01082445|DRUG|Placebo|Placebo
214781536|NCT04242381|OTHER|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
214781537|NCT04242381|OTHER|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
214781538|NCT04242381|OTHER|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
214781539|NCT04242381|OTHER|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
214781540|NCT04168762|OTHER|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
214781541|NCT04089280|DIETARY_SUPPLEMENT|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
214781542|NCT04089280|OTHER|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
214781543|NCT00382291|DRUG|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
214781544|NCT00382291|DRUG|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
214781545|NCT00382291|DRUG|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
214781546|NCT01127191|OTHER|military equipment|Military exercise of 24 hours
214781547|NCT02309918|DRUG|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
214781548|NCT04551079|DRUG|TAK-994|TAK-994 tablets.
214781549|NCT04551079|DRUG|Placebo|TAK-994 placebo-matching tablets.
214781550|NCT04684810|BEHAVIORAL|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
214781551|NCT05767255|DRUG|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
214781552|NCT05767255|DRUG|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
214781553|NCT05751395|DEVICE|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
214781554|NCT05992649|OTHER|physical therapy|Aquatic physiotherapy in warm water
214781555|NCT03618966|DEVICE|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
214781556|NCT00086879|DRUG|carmustine|
214781557|NCT00086879|DRUG|erlotinib hydrochloride|
214781558|NCT00086879|DRUG|temozolomide|
214781559|NCT01725815|BEHAVIORAL|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
214781560|NCT02580188|DRUG|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
214781561|NCT03049956|DIAGNOSTIC_TEST|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
214781562|NCT00285415|DRUG|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
214781563|NCT05006183|PROCEDURE|PCI|Percutaneous coronary intervention with Drug-Eluting Stents
214781564|NCT00265083|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
214781565|NCT00265083|BIOLOGICAL|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
214781566|NCT00265083|BIOLOGICAL|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
214781567|NCT01951547|PROCEDURE|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
214781568|NCT01951547|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
214781569|NCT02916160|DRUG|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
214781570|NCT04852991|PROCEDURE|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
214781571|NCT04852991|PROCEDURE|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
214781572|NCT06529640|PROCEDURE|SCTG followed by coronally postionting flap|The SCTG will be harvested from the palate followed by coronally postionting flap
214781573|NCT06529640|PROCEDURE|periosteal flap followed by coronally postionting flap|he periosteal pedicle graft obtained is then turned over the exposed root surface then followed by coronally postionting flap
214781574|NCT04242186|OTHER|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
214781575|NCT00004161|DRUG|fenretinide|
214781576|NCT00004161|DRUG|Placebo|
214781577|NCT00534092|DEVICE|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
214781578|NCT05999981|PROCEDURE|Transversalis Fascia Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance between transversus abdominis muscle and transversalis fascia bilaterally
214781579|NCT05999981|PROCEDURE|Transversus Abdominis Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally
214781580|NCT02323295|RADIATION|Radiation (Surgical Arm)|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
214781581|NCT02323295|RADIATION|Radiation (Non-surgical Arm)|Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
214781582|NCT02323295|PROCEDURE|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
214781583|NCT03011463|DRUG|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
214781584|NCT03011463|DRUG|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
214781585|NCT03011463|DRUG|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
214781586|NCT03011463|DRUG|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
214781587|NCT04562584|DEVICE|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
214781588|NCT01155063|OTHER|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
214781589|NCT01314703|DRUG|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
214781590|NCT01314703|DRUG|70% isopropyl alcohol|10.5 ml applicator
214781591|NCT03504332|PROCEDURE|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
214781592|NCT03797976|DEVICE|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
214781593|NCT03872960|PROCEDURE|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
214781594|NCT06012591|OTHER|Quality improvement recommendations (action plans)|Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
214781595|NCT04303494|BIOLOGICAL|immunisation|combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
214781596|NCT01551550|PROCEDURE|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
214781597|NCT01551550|PROCEDURE|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
214781598|NCT01551550|PROCEDURE|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
214781599|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
214781600|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
214781601|NCT04917900|DRUG|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
214781602|NCT02476552|DRUG|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
214781603|NCT02476552|DRUG|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)
214781604|NCT02476552|DRUG|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
214781605|NCT03094806|DEVICE|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
214781606|NCT03094806|DEVICE|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
214781607|NCT01402115|DIETARY_SUPPLEMENT|Polycan|polycan 150 mg/d for 12 weeks
214781608|NCT01402115|DIETARY_SUPPLEMENT|Placebo|Placebo 150mg/d for 12 weeks
214781609|NCT06404697|RADIATION|Boost irradiation|High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
214781610|NCT01363791|OTHER|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
214781611|NCT00180830|DRUG|Glivec|
214781612|NCT00180830|DRUG|Gleevec|
214781613|NCT00460473|DRUG|Dexmedetomidine|
214781614|NCT00460473|DRUG|Placebo|
214781615|NCT06245616|DIETARY_SUPPLEMENT|Consumption of olive pomace olive oil by alzheimer's patients|Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
214781616|NCT06245616|DIETARY_SUPPLEMENT|Consumption of high-oleic sunflower oil by alzheimer's patients|Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
214781617|NCT03557710|BEHAVIORAL|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
214781618|NCT00744510|OTHER|Reflexology|10 weekly sessions of 45 minutes each
214781619|NCT02058810|DEVICE|Nasal high flow|
214781620|NCT02058810|DEVICE|Conventional nasal oxygen|
214781621|NCT02770716|DRUG|Terlipressin|Terlipressin solution for injection
214781622|NCT02770716|OTHER|Placebo|Matching placebo solution for injection
214781623|NCT05269719|PROCEDURE|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
214781624|NCT04697355|DIETARY_SUPPLEMENT|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
214781625|NCT02918838|BEHAVIORAL|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
214781626|NCT02918838|BEHAVIORAL|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
214781627|NCT02918838|BEHAVIORAL|Control Group|
214781628|NCT01710852|DRUG|ISIS CRP Rx|
214781629|NCT01710852|DRUG|Placebo|
214781630|NCT00861237|DRUG|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
214781631|NCT00861237|DRUG|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
214781632|NCT00444132|DRUG|clopidogrel|
214781633|NCT03989115|DRUG|RMC-4630|RMC-4630 for oral administration
214781634|NCT03989115|DRUG|Cobimetinib|Cobimetinib for oral administration
214781635|NCT03989115|DRUG|Drug: Osimertinib|Osimertinib for oral administration
214781636|NCT01777685|DRUG|Sulpiride|
214781637|NCT00077688|DRUG|TOCOSOL Paclitaxel|
214781638|NCT03230032|DEVICE|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
214781639|NCT05559554|DRUG|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
214781640|NCT05559554|DRUG|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
214781641|NCT02499354|DRUG|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
214781642|NCT02499354|DRUG|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
214781643|NCT04119583|DEVICE|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
214781644|NCT04119583|OTHER|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
214781645|NCT04119583|OTHER|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
214781646|NCT03900546|DEVICE|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
214781647|NCT01514266|DRUG|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
214781648|NCT01514266|DRUG|Placebo|
214781649|NCT03367026|DRUG|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
214781650|NCT02135874|DRUG|Clofarabine|Given IV
214781651|NCT02135874|DRUG|Cytarabine|Given IV
214781652|NCT02135874|DRUG|Dexamethasone|Given IV
214781653|NCT02135874|DRUG|Idarubicin|Given IV
214781654|NCT02135874|BIOLOGICAL|Rituximab|Given IV
214781655|NCT02135874|DRUG|Sorafenib|Given PO
214781656|NCT02135874|DRUG|Sorafenib Tosylate|Given PO
214781657|NCT02135874|DRUG|Vincristine|Given IV
214781658|NCT02135874|DRUG|Vincristine Sulfate|Given IV
214781659|NCT03947606|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
214781660|NCT04259411|DEVICE|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
214781661|NCT05775809|DRUG|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
214781662|NCT05775809|DEVICE|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
214781663|NCT02655354|BEHAVIORAL|Motivational Interviewing|
214781664|NCT02655354|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
214781665|NCT02655354|BEHAVIORAL|Care Management|
214781666|NCT02655354|DRUG|Fluoxetine|Anti-depressant
214781667|NCT02655354|DRUG|Fluvoxamine|Anti-depressant
214781668|NCT02655354|DRUG|Paroxetine|Anti-depressant
214781669|NCT02655354|DRUG|Sertraline|Anti-depressant
214781670|NCT02655354|DRUG|Citalopram|Anti-depressant
214781671|NCT02655354|DRUG|Venlafaxine|Anti-depressant
214781672|NCT02655354|DRUG|Duloxetine|Anti-depressant
214781673|NCT02655354|DRUG|Mirtazapine|Anti-depressant
214781674|NCT02655354|DRUG|Diphenhydramine|Sleep medication
214781675|NCT02655354|DRUG|Trazodone|Sleep medication
214781676|NCT02655354|DRUG|Prazosin|Sleep medication
214781677|NCT01759381|DEVICE|Negative pressure wound therapy (NPWT)|
214781678|NCT01460927|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
214781679|NCT01465776|OTHER|laboratory biomarker analysis|Correlative studies
214781680|NCT01465776|OTHER|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
214781681|NCT00947063|DRUG|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
214781682|NCT00947063|DRUG|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
214781683|NCT00447603|DRUG|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
214781684|NCT00447603|DRUG|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
214781685|NCT00447603|DRUG|Placebo for Losartan|
214781686|NCT00447603|DRUG|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
214781687|NCT02639208|OTHER|PatientsLikeMe (PLM)|
214781688|NCT05768828|DIAGNOSTIC_TEST|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
214781689|NCT02786498|DRUG|Vitamin D3|
214781690|NCT02786498|OTHER|Placebo|
214781691|NCT05812105|OTHER|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
214781692|NCT05861609|PROCEDURE|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
214781693|NCT05861609|PROCEDURE|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
214781694|NCT05861609|PROCEDURE|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
214781695|NCT01697007|BIOLOGICAL|HIVIS DNA vaccine|
214781696|NCT01697007|DEVICE|Zetajet|
214781697|NCT01697007|DEVICE|Derma Vax Electroporation|
214781698|NCT01697007|BIOLOGICAL|Modified Vaccinia Ankara (MVA-CDMR)|
214781699|NCT04096391|DEVICE|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
214781700|NCT04096391|DRUG|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
214781701|NCT01749176|BEHAVIORAL|SMS texting intervention|
214781702|NCT01749176|BEHAVIORAL|Control-Usual Care|
214781703|NCT00003557|DRUG|dolastatin 10|
214781704|NCT02783391|DEVICE|ECoG and intracortical electrodes|
214781705|NCT00263081|DRUG|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
214781706|NCT00263081|DRUG|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
214781707|NCT03723291|COMBINATION_PRODUCT|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care \[a structured programme of rehabilitation exercises\] for 6 months
214781708|NCT03723291|PROCEDURE|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
214781709|NCT06047158|DRUG|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
214781710|NCT03070210|PROCEDURE|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
214781711|NCT03070210|PROCEDURE|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
214781712|NCT06529315|OTHER|Point-of-Care Ultrasound|The investigators will use point-of-care ultrasound to exam participants including lungs, heart, liver, spleen, kidney and bladder, etc.
214781713|NCT05033223|OTHER|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
214781714|NCT06552377|DEVICE|Ultrasound Attenuation imaging measurement|Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
214781715|NCT05940870|DEVICE|Nerivio|Patients with migraine who received the Nerivio device for migraine prevention therapy
214781716|NCT02396069|DRUG|JPI-289|PARP-1 inhibitor
214781717|NCT02396069|DRUG|Placebo|Placebo
214781718|NCT06312774|OTHER|This is observational study|This is observational study
214781719|NCT04540120|DRUG|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
214781720|NCT04540120|DRUG|placebo capsules|Hard opaque capsules containing 0 mg of API.
214794210|NCT04365751|PROCEDURE|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
214794211|NCT02171533|DRUG|dabigatran|
214794212|NCT02171533|DRUG|Verapamil|
214781721|NCT05366556|BEHAVIORAL|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
214781722|NCT01533857|DIETARY_SUPPLEMENT|hot water|Hot water and placebo capsule
214781723|NCT01533857|DIETARY_SUPPLEMENT|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
214781724|NCT05193331|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
214781725|NCT04128878|DRUG|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
214781726|NCT04128878|DRUG|Dofetilide|Same as described above with sotalol.
214781727|NCT02410837|PROCEDURE|Electromagnetic Navigation Bronchoscopy|
214781728|NCT02974413|BEHAVIORAL|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
214781729|NCT02356965|DRUG|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
214781730|NCT02356965|DRUG|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
214781731|NCT02603159|DRUG|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
214781732|NCT02603159|RADIATION|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
214781733|NCT01124682|PROCEDURE|diagnostic cystoscopy|
214781734|NCT01124682|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214781735|NCT01124682|PROCEDURE|implanted fiducial-based imaging|
214781736|NCT01124682|PROCEDURE|quality-of-life assessment|
214781737|NCT01124682|RADIATION|3-dimensional conformal radiation therapy|
214781738|NCT01124682|RADIATION|image-guided radiation therapy|
214781739|NCT01124682|RADIATION|selective external radiation therapy|
214781740|NCT03768882|DRUG|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
214781741|NCT03768882|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
214781742|NCT00118573|PROCEDURE|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
214781743|NCT00118573|PROCEDURE|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
214781744|NCT03786809|DRUG|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
214781745|NCT03786809|DRUG|Placebo|patients of the placebo group will use placebo once a day for 28 days
214781746|NCT02965469|BEHAVIORAL|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
214781747|NCT06527573|DEVICE|active repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
214794213|NCT02171533|DRUG|Verapamil ER|
214794214|NCT00138905|DEVICE|UMTS mobile basestation radiation|
214794215|NCT03062566|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
214781748|NCT06527573|DEVICE|sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
214781749|NCT05474937|DRUG|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
214781750|NCT05474937|DRUG|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
214781751|NCT00765323|DRUG|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
214781752|NCT00765323|DRUG|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
214781753|NCT03941171|PROCEDURE|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
214781754|NCT03941171|OTHER|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
214781755|NCT03941171|OTHER|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
214781756|NCT00919802|DRUG|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
214781757|NCT00919802|OTHER|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
214781758|NCT03603431|DRUG|MRG-110|Single ascending doses of MRG-110
214781759|NCT03603431|DRUG|Placebo|Single doses of placebo
214781760|NCT03603431|DRUG|MRG-110|Multiple ascending doses of MRG-110
214781761|NCT03603431|DRUG|Placebo|Multiple doses of Placebo
214781762|NCT02684383|BIOLOGICAL|rDEN3∆30|10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
214781763|NCT02684383|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
214781764|NCT03175783|DEVICE|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
214781765|NCT02910453|PROCEDURE|Pulmonary lobectomy|
214781766|NCT04804982|OTHER|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
214781767|NCT03187483|PROCEDURE|orthodontic treatment|orthodontic treatment in maxillary crowding
214781768|NCT05827900|BEHAVIORAL|Metacognitive Training|Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
214781769|NCT02467088|OTHER|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
214781770|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
214781771|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
214781772|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
214781773|NCT02921347|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
214781774|NCT04669899|DRUG|JTX-8064|Specified dose on specified days
214781775|NCT04669899|DRUG|pimivalimab|Specified dose on specified days
214781776|NCT01377961|DRUG|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
214781777|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
214781778|NCT01377961|OTHER|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
214781779|NCT01377961|OTHER|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
214781780|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
214781781|NCT01377961|OTHER|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
214781782|NCT00001428|DRUG|5-fluorouracil|
214781783|NCT01840683|DEVICE|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
214781784|NCT05480527|DEVICE|Transcutaneous pulsed radiofrequency current|Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
214781785|NCT03675191|DRUG|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
214781786|NCT03675191|DRUG|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
214781787|NCT05153291|PROCEDURE|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
214781788|NCT05153291|PROCEDURE|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
214781789|NCT01094366|PROCEDURE|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
214781790|NCT01094366|PROCEDURE|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
214781791|NCT01423565|DEVICE|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
214781792|NCT05450666|OTHER|mobility exercises|Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
214781793|NCT06259942|OTHER|İntervention 1 group (underbody heater group only)|Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
214781794|NCT06259942|OTHER|İntervention 2 group (group using both underbody heater and heated iv liquid)|IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
214781795|NCT06259942|OTHER|Control Group|no active heating treatment was applied in this group
214781796|NCT03315156|DIAGNOSTIC_TEST|Electrogustometery|Taste assessment using EGM
214781797|NCT02236156|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
214781798|NCT02236156|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
214781799|NCT02236156|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
214781800|NCT01947556|DRUG|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
214781801|NCT04816188|OTHER|Exercise Therapy and Activity Modification|Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
214781802|NCT04534192|DEVICE|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
214781803|NCT00130481|DRUG|Atorvastatin 20 mg daily for 3 months|
214781804|NCT00095095|DEVICE|Lumbar Interbody Fusion|
214781805|NCT03077633|PROCEDURE|Cervical Cerclage placement|Cervical Cerclage placement
214781806|NCT03077633|DRUG|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
214781807|NCT02362854|PROCEDURE|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
214781808|NCT02362854|DEVICE|DL application in peri-implantitis|Diode laser application in the diseased implants.
214781809|NCT04696562|BEHAVIORAL|Deep Breathing Exercise with Triflo|The investigators will do deep breathing exercises 5-10 times an hour with the triflo device.
214781810|NCT03909321|BEHAVIORAL|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
214781811|NCT02309203|DEVICE|FRED|Flow Re-Direction Endoluminal Device
214781812|NCT05907200|OTHER|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
214781813|NCT05907200|OTHER|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
214781814|NCT03932487|OTHER|urinary iodine and urine BPA|urinary iodine and urine BPA
214781815|NCT06129552|PROCEDURE|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
214781816|NCT05730985|DIETARY_SUPPLEMENT|Miotrof® formula|1 sachet per day for 4 months
214781817|NCT05730985|DIETARY_SUPPLEMENT|Placebo formula|1 sachet per day for 4 months
214781818|NCT02712385|OTHER|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
214781819|NCT02712385|DEVICE|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
214781820|NCT02712385|PROCEDURE|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
214781821|NCT02712385|BEHAVIORAL|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
214781822|NCT02861183|DEVICE|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
214781823|NCT02861183|DEVICE|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
214781824|NCT00411697|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
214781825|NCT04857385|DEVICE|Radial artery hemostasis|Each of the devices will be assessed for radial artery hemostasis.
214781826|NCT06254209|DIETARY_SUPPLEMENT|Botanicals extracts|Powder included in capsules for daily administration
214781827|NCT06254209|DIETARY_SUPPLEMENT|Placebo|Maltodextrin included in capsules for daily administration
214781828|NCT01510665|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
214781829|NCT01510665|DIETARY_SUPPLEMENT|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
214781830|NCT01510665|BEHAVIORAL|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
214781831|NCT00430157|DRUG|GSK256066|
214781832|NCT02415010|DEVICE|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
214781833|NCT02415361|OTHER|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
214781834|NCT00630669|PROCEDURE|Rubber band ligation|placing rubber bands around the internal hemorrhoids
214781835|NCT00630669|PROCEDURE|Bipolar coagulation|using electricity to cauterize
214781836|NCT01428024|DEVICE|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
214781837|NCT01428024|DEVICE|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
214781838|NCT04837625|OTHER|no interventions|no interventions
214781839|NCT02416583|DRUG|Oxytocin|
214781840|NCT02416583|DRUG|Dinoprostone|
214781841|NCT02416583|PROCEDURE|Membrane sweeping|
214781842|NCT02139345|DEVICE|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
214781843|NCT02139345|DEVICE|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
214781844|NCT04678453|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
214781845|NCT02042690|PROCEDURE|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
214781846|NCT02042690|DRUG|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
214781847|NCT00106028|DRUG|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
214781848|NCT00106028|DRUG|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
214781849|NCT04281056|PROCEDURE|Tooth removal and their replacement by means of a denture|Teeth have been removed and replaced by means of dentures for at least one year
214781850|NCT01548469|OTHER|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
214781851|NCT01548469|OTHER|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
214781852|NCT01280981|DRUG|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
214781853|NCT04008342|OTHER|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
214781854|NCT06438783|DRUG|1200mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
214781855|NCT06438783|DRUG|1800mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
214781856|NCT00743691|OTHER|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
214781857|NCT05498831|OTHER|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
214781858|NCT04773171|OTHER|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
214781859|NCT04773171|OTHER|Conventional training programmes|Existing conventional activities in the settings
214781860|NCT05147285|OTHER|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
214781861|NCT05147285|OTHER|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
214781862|NCT05147285|OTHER|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
214781863|NCT02996617|DRUG|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
214781864|NCT02996617|DRUG|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
214781865|NCT04974359|DRUG|Lu AG06466|Lu AG06466 - capsules
214781866|NCT04974359|DRUG|Placebo|Placebo - capsules
214781867|NCT00486499|PROCEDURE|I-125 versus Pd-103 radioactive seed insertion|
214781868|NCT05742854|PROCEDURE|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
214781869|NCT05742854|DRUG|Oxytocin|Oxytocin
214781870|NCT05742854|DRUG|Carbetocin|Carbetocin
214781871|NCT06043999|PROCEDURE|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
214781872|NCT06043999|OTHER|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
214781873|NCT04312919|BEHAVIORAL|Family Based Activity Intervention|Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
214781874|NCT03292783|DRUG|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
214781875|NCT04726514|DEVICE|SleepFlex|SleepFlex Program
214781876|NCT04675060|DRUG|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
214781877|NCT03263520|DRUG|Nandrolone Decanoate|Drug administration
214781878|NCT03263520|DRUG|Dexamethasone|Drug administration
214781879|NCT04655482|DRUG|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
214781880|NCT02448472|OTHER|Observational study, none intervention|
214781881|NCT05517005|DIETARY_SUPPLEMENT|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
214781882|NCT06235645|DIAGNOSTIC_TEST|Lung ultrasound (LUS)|"If included, an LUS will be performed by an experienced operator, blinded to the results of the chest CT and PFT.~A linear probe (4 to 12 MHz) will be used. The patient will be installed́ in a semi-seated position with the homolateral arm above the head for the anterior and axillary evaluation then, depending on his comfort, in a seated position or in right then left lateral decubitus, arms alongside the body, for the posterior evaluation. It will be practiced by experienced operators (pneumologist) and according to a validated protocol allowing the exploration of 14 intercostal spaces. LUT will be timed, recorded and anonymized.~The operator will note the 3 ultrasound signs (total number of B lines, pleural line thickening and percentage of pleural line irregularity), their location and severity.~The radiologist, on his part, will evaluate the patient's chest CT (gold standard), blinded to the results of the LUS, to make or not the diagnosis of RA-ILD."
214781883|NCT01552005|DRUG|Saxagliptin|No Intervention
214781884|NCT01256398|BIOLOGICAL|Alemtuzumab|Given IV
214781885|NCT01256398|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
214781886|NCT01256398|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
214781887|NCT01256398|DRUG|Cyclophosphamide|Given IV
214781888|NCT01256398|DRUG|Cytarabine|Given IV
214781889|NCT01256398|DRUG|Dasatinib|Given PO
214781890|NCT01256398|DRUG|Daunorubicin Hydrochloride|Given IV
214781891|NCT01256398|DRUG|Dexamethasone|Given PO or IV
214781892|NCT01256398|DRUG|Etoposide Phosphate|Given IV
214781893|NCT01256398|BIOLOGICAL|Filgrastim|Given SC
214781894|NCT01256398|DRUG|Fludarabine Phosphate|Given IV
214781895|NCT01256398|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
214781896|NCT01256398|OTHER|Laboratory Biomarker Analysis|Correlative studies
214781897|NCT01256398|DRUG|Leucovorin Calcium|Given IV or PO
214781898|NCT01256398|DRUG|Melphalan|Given IV
214781899|NCT01256398|DRUG|Mercaptopurine|Given PO
214781900|NCT01256398|DRUG|Methotrexate|Given IT, IV, or PO
214781901|NCT01256398|BIOLOGICAL|Pegfilgrastim|Given SC
214781902|NCT01256398|OTHER|Pharmacological Study|Correlative studies
214781903|NCT01256398|DRUG|Tacrolimus|Given IV or PO
214781904|NCT01256398|DRUG|Vincristine Sulfate|Given IV
214781905|NCT05854173|DIAGNOSTIC_TEST|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
214781906|NCT05854173|DIAGNOSTIC_TEST|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
214781907|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 1|Single inhaled dose of SP-101 and doxorubicin Dose 1
214781908|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 2|Single inhaled dose of SP-101 and doxorubicin Dose 2
214781909|NCT03649906|PROCEDURE|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
214781910|NCT04615286|OTHER|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
214781911|NCT04615286|OTHER|Standard (long course) of antibiotics|4-6 weeks of antibiotics
214781912|NCT03448601|OTHER|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
214781913|NCT03448601|OTHER|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
214781914|NCT06307678|DRUG|Calcium Hydroxide|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
214781915|NCT06307678|DRUG|Calcium Silicate|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
214781916|NCT01238211|DRUG|Cytarabine|Given IV
214781917|NCT01238211|DRUG|Dasatinib|Given PO
214781918|NCT01238211|DRUG|Daunorubicin Hydrochloride|Given IV
214781919|NCT01238211|OTHER|Laboratory Biomarker Analysis|Correlative studies
214781920|NCT04428502|DRUG|Enbrel|As provided in real world practice
214781921|NCT05203588|DRUG|Denosumab 60 mg/ml Injectable Solution [Prolia]|Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
214781922|NCT05203588|DRUG|calcium and vitamin D|calcium (≥1·0 g) and vitamin D (≥400 IU).
214781923|NCT03654092|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
214781924|NCT03172260|DEVICE|E Balance Pro Therapy|Micro-current treatment
214781925|NCT04307030|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
214781926|NCT02375646|DRUG|Warfarin|
214781927|NCT02375646|DRUG|LMW Heparin|
214781928|NCT05841966|DIAGNOSTIC_TEST|Transoral Ultrasound|The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
214781929|NCT02073305|OTHER|No Sleep Apnea|No intervention
214781930|NCT02073305|OTHER|Sleep Apnea - untreated|No intervention
214781931|NCT02073305|DEVICE|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
214781932|NCT02055183|DRUG|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
214781933|NCT04930198|BEHAVIORAL|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
214781934|NCT01166997|DEVICE|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
214781935|NCT01166997|DRUG|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
214781936|NCT01856374|DEVICE|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
214781937|NCT01856374|DEVICE|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
214781938|NCT01856374|DRUG|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
214781939|NCT01856374|DRUG|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
214781940|NCT05924451|BEHAVIORAL|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
214781941|NCT00002973|DRUG|melphalan|
214781942|NCT00002973|PROCEDURE|hyperthermia treatment|
214781943|NCT03550794|DRUG|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
214781944|NCT03550794|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
214781945|NCT01626131|BEHAVIORAL|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
214781946|NCT01626131|BEHAVIORAL|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
214781947|NCT00297986|DEVICE|Helmet|Evaluation of different interfaces for NPPV
214781948|NCT00449930|DRUG|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
214781949|NCT00449930|DRUG|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
214781950|NCT01124526|DRUG|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
214781951|NCT01864525|DRUG|Octanoic acid|
214781952|NCT01864525|DRUG|Inactive capsule|
214781953|NCT06128031|OTHER|questionaire|"Psychiatric interview: this will be assessed by (SCID-5)semi structural clinical interview based on Diagnostic and Statistical manual of Mental disorders-5 criteria~-Psychometric assessment include; Hamilton depression rating scale(7) and Hamilton anxiety rating scale(8) , used to score the symptoms of anxiety or depression Quality of life assessment: will be assessed by the Patient assessment of constipation-quality of life questionnaire"
214781954|NCT05465707|BIOLOGICAL|CM313 2 mg/kg|Once 1 week, intravenous infusion.
214781955|NCT05465707|BIOLOGICAL|CM313 4 mg/kg|Once 1 week, intravenous infusion.
214781956|NCT05465707|BIOLOGICAL|CM313 8 mg/kg|Once 1 week, intravenous infusion.
214781957|NCT05465707|BIOLOGICAL|CM313 16 mg/kg|Once 1 week, intravenous infusion.
214781958|NCT05465707|BIOLOGICAL|Placebo|Once 1 week, intravenous infusion.
214781959|NCT01543815|BEHAVIORAL|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
214781960|NCT01543815|BEHAVIORAL|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
214781961|NCT01543815|OTHER|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
214781962|NCT02252497|DRUG|Active comparator : Tranexamic Acid (Exacyl)|"* 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours ."
214781963|NCT02252497|DRUG|Placebo comparator : physiologic serum|"* 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours"
214781964|NCT04610073|BEHAVIORAL|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
214781965|NCT03156582|OTHER|Data collecting|
214781966|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
214781967|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
214781968|NCT06309472|DRUG|Mirtazapine|30mg mirtazapine at night, escalated to 45mg after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
214781969|NCT06309472|DRUG|Placebo|1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
214781970|NCT06538168|BEHAVIORAL|Diabetes Self-Management Education (DSME)|The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
214781971|NCT03138239|RADIATION|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
214781972|NCT01884116|DRUG|NSAID patch|
214781973|NCT01884116|DRUG|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
214781974|NCT01884116|DRUG|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
214781975|NCT01884116|DRUG|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
214781976|NCT02688816|DEVICE|Xpert HPV|Point-of-care HPV DNA PCR test
214781977|NCT02688816|DEVICE|OncoE6|Point-of-care E6 oncoprotein test
214781978|NCT02786186|DRUG|Secikinumab|
214781979|NCT06457464|DRUG|Chemotherapy|combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
214781980|NCT05269017|DRUG|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
214781981|NCT05269017|DRUG|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
214781982|NCT06339021|PROCEDURE|OCT-guided PCI|OCT-guided PCI based on MLD MAX algorithm
214781983|NCT06339021|PROCEDURE|Conventional angiography-based PCI|Conventional angiography-based PCI
214781984|NCT06339021|DRUG|DAPT de-escalation|Aspirin and clopidogrel 30 days after DES implantation
214781985|NCT06339021|DRUG|default DAPT regimen|Aspirin and ticagrelor 30 days after DES implantation
214781986|NCT05792410|DRUG|SHR-A1811 & Dalpiciclib Isethionate Tablets|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral
214781987|NCT05792410|DRUG|SHR-A1811 & Fulvestrant|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
214781988|NCT05792410|DRUG|SHR-A1811 & Bevacizumab injection|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
214781989|NCT03954964|BEHAVIORAL|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
214781990|NCT00067288|BEHAVIORAL|Meaning-Centered Group Psychotherapy|
214781991|NCT00067288|BEHAVIORAL|Standard Supportive Group Psychotherapy|
214781992|NCT01484171|DRUG|idarubicin|idarubicin 10-12 mg/m2 for three days
214781993|NCT01484171|BIOLOGICAL|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
214781994|NCT00029328|DRUG|etanercept|
214781995|NCT03712228|BIOLOGICAL|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
214781996|NCT03712228|DRUG|Placebo|Buffer without active ingredient
214781997|NCT03513978|OTHER|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
214781998|NCT03513978|OTHER|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
214781999|NCT01353105|PROCEDURE|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
214782000|NCT05798871|PROCEDURE|Subgingival erythritol air polishing|"The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement"
214782001|NCT05798871|PROCEDURE|Conventional root planing|The intervention will start with supragingival debridement followed by root planing by curette.
214782002|NCT04001205|DRUG|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
214782003|NCT04793438|BEHAVIORAL|Motive-specific intervention|Three appointments are made with the patients of the intervention group within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. The time frame of 45 minutes for each intervention must be strictly adhered to. Patients are additionally asked to complete tasks between the sessions. All appointments take place in the Psychiatric University Hospital directly on the ward.
214782004|NCT04793438|BEHAVIORAL|Supportive conversations|Since we want to check whether the patients benefit from the specific intervention and not only from getting more speaking time, patients without the motive-specific intervention should also be given three sessions, in which no intervention takes place. They will be carried out in the sense of supportive conversations (i.e. conversations that do not follow a specific psychotherapy concept). All appointments take place in the Psychiatric University Hospital directly on the ward.
214782005|NCT04034199|DRUG|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
214782006|NCT04034199|DRUG|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
214782007|NCT02766387|OTHER|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
214782008|NCT02194231|DRUG|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
214782009|NCT02295280|DRUG|Metoclopramide|IV
214782010|NCT02295280|DRUG|Diphenhydramine|iv
214782011|NCT02295280|DRUG|Codeine|PO
214782012|NCT03229239|PROCEDURE|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
214782013|NCT03382210|OTHER|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
214782014|NCT02219295|DIETARY_SUPPLEMENT|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
214782015|NCT02219295|DIETARY_SUPPLEMENT|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
214782016|NCT02219295|DIETARY_SUPPLEMENT|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
214782017|NCT02219295|OTHER|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
214782018|NCT05535595|DRUG|genotyping and selection of renin-angiotensin system blocker|"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping"
214782019|NCT05535595|DRUG|Perindopril|perindopril 4 mg/d without genotyping
214782020|NCT05402319|COMBINATION_PRODUCT|Antibiotic combination therapy|Anti-infective treatment with at least two different types of sensitive antibiotics.
214782021|NCT05680207|BEHAVIORAL|Diabetes self- management education (DSME) program|We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
214782022|NCT04700735|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
214782023|NCT01755611|DRUG|Minocycline 100mg|Test product
214782024|NCT01755611|DRUG|Minocycline 100mg|Reference product
214782025|NCT00732771|DRUG|LCI699|
214782026|NCT02868905|PROCEDURE|Blood sample|
214782027|NCT00990028|DRUG|Rosuvastatin|20 mg oral, for 10 days
214782028|NCT00990028|DRUG|Placebo|20 mg vehicle
214782029|NCT00567528|DRUG|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
214782030|NCT00567528|DRUG|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
214782031|NCT03001011|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214782032|NCT03001011|DRUG|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
214782033|NCT02494687|DRUG|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
214782034|NCT02494687|DRUG|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
214782035|NCT02494687|DRUG|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
214782036|NCT01276028|PROCEDURE|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
214782037|NCT02875067|BIOLOGICAL|Pembrolizumab|
214782038|NCT02875067|DRUG|Lenalidomide|
214782039|NCT05415826|PROCEDURE|slow-release dexamethasone implant|The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
214782040|NCT00065065|DRUG|Rosiglitazone|4mg orally twice daily for 12 weeks
214782041|NCT00065065|DRUG|Placebo|pill that looks identical to rosiglitazone
214782042|NCT00786266|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
214782043|NCT00786266|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
214782044|NCT01535157|DRUG|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
214782045|NCT01241565|DEVICE|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
214782046|NCT01800669|OTHER|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
214782047|NCT01800669|OTHER|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
214782048|NCT03841565|BIOLOGICAL|Daratumumab|Given IV
214782049|NCT03841565|DRUG|Dexamethasone|Given PO
214782050|NCT03841565|DRUG|Pomalidomide|Given PO
214782051|NCT02135367|BIOLOGICAL|PRP|injections of Platelet rich Plasma
214782052|NCT02873468|DRUG|Florence 30 μg/mL|10 mL, oral, twice a day.
214782053|NCT02873468|DRUG|Florence 60 μg/mL|10 mL, oral, twice a day.
214782054|NCT02873468|DRUG|Florence 90 μg/mL|10 mL, oral, twice a day.
214782055|NCT02873468|OTHER|Placebo|10 mL, oral, twice a day.
214782056|NCT03020836|BEHAVIORAL|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
214782057|NCT03020836|BEHAVIORAL|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
214782058|NCT00004158|DRUG|melphalan|
214782059|NCT00004158|PROCEDURE|peripheral blood stem cell transplantation|
214782060|NCT00004158|RADIATION|holmium Ho 166 DOTMP|
214782061|NCT03888716|DRUG|KL1333|25 and 100 mg KL1333 encapsulated tablets
214782062|NCT03888716|DRUG|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
214782063|NCT05723341|DRUG|Bupivacain|%0,25
214782064|NCT05723341|DRUG|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
214782065|NCT06174519|DEVICE|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
214782066|NCT02622503|DRUG|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
214782067|NCT02260141|DIETARY_SUPPLEMENT|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
214782068|NCT05288673|DRUG|ALXN1210|ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
214782069|NCT05288673|DRUG|Placebo|Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
214782070|NCT03125057|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
214782071|NCT01050673|DEVICE|VERSAJET|Hydro-surgery debridement
214782072|NCT01050673|PROCEDURE|Scalpel or blade|Conventional Surgical Debridement
214782073|NCT00690768|DRUG|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
214782074|NCT00690768|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
214782075|NCT02762968|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar to the experimental treatments.
214782076|NCT02762968|DIETARY_SUPPLEMENT|HMB|Capsules containing calcium HMB.
214782077|NCT02762968|DIETARY_SUPPLEMENT|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
214782078|NCT01485224|DRUG|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
214782079|NCT04618952|DRUG|Calcium D|calcium D supplementation given to postmenopausal females
214782080|NCT04618952|DRUG|Placebo|Placebo
214782081|NCT00447018|DRUG|20% mannitol|
214782082|NCT00447018|DRUG|7.45% hypertonic saline solution|
214782083|NCT03056352|DRUG|Metoclopramide|Intravenous medication drip
214782084|NCT03056352|DRUG|Diphenhydramine|Intravenous medication drip
214782085|NCT02122510|DRUG|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
214782086|NCT02122510|DRUG|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
214782087|NCT05719610|OTHER|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
214782088|NCT05719610|OTHER|Swiss Ball Exercises|Swiss Ball Exercises
214782089|NCT04322968|DRUG|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
214782090|NCT01077115|PROCEDURE|Laparoscopic cholecystectomy|
214782091|NCT01077115|PROCEDURE|Open Surgery|
214782092|NCT03884595|DIAGNOSTIC_TEST|IG, IPF, NRBC, CRP, PCT, presepsin|Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
214782093|NCT00796159|DRUG|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
214782094|NCT04971915|OTHER|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
214782095|NCT02529085|OTHER|blood samples|blood samples for the bank
214782096|NCT00691145|DRUG|tacrolimus ointment|transdermal
214782097|NCT05020054|DEVICE|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
214782098|NCT05020054|DEVICE|placebo tecartherapy|tecartherapy with equipment turned off
214782099|NCT02758587|DRUG|Defactinib|cross reference with arm/group descriptions
214782100|NCT02758587|DRUG|Pembrolizumab|cross reference with arm/group descriptions
214782101|NCT02581761|DRUG|CYTOTEC|synthetic prostaglandin E1
214782102|NCT02581761|OTHER|Placebo|no active material
214782103|NCT00949390|BEHAVIORAL|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
214782104|NCT05146869|DRUG|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
214782105|NCT01956682|DIETARY_SUPPLEMENT|HA formula + starch + L. reuteri|
214782106|NCT01424774|DRUG|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
214782107|NCT01254045|DRUG|placebo|intranasal placebo (48 international units)
214782108|NCT01254045|DRUG|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
214782109|NCT01254045|DRUG|oxytocin 48IU|intranasal oxytocin (48 international units)
214782110|NCT02971605|DRUG|Psilocybin|25 mg/70 kg Psilocybin
214782111|NCT03624270|DRUG|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
214782112|NCT04036578|DEVICE|A 12-week PFMT bio-assisted surface electromyographic program|
214782113|NCT00597207|DEVICE|AutoPulse|Mechanical device that provides chest compression
214782114|NCT00597207|OTHER|Manual|Manual chest compression
214782115|NCT03406689|DRUG|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
214782116|NCT03406689|DRUG|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
214782117|NCT03406689|DRUG|Artificial tear|One drop Artificial Tears will be instilled 45' prior to the IVI.
214782118|NCT00520351|DRUG|ClearCare|contact lens care system
214782119|NCT00520351|DRUG|Optifree Replenish|contact lens care system
214782120|NCT02917954|DEVICE|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
214782121|NCT00601328|DRUG|Calcitriol|
214782122|NCT04229277|DIAGNOSTIC_TEST|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
214782123|NCT03845322|DRUG|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
214782124|NCT03845322|DRUG|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
214782125|NCT02341963|DRUG|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
214782126|NCT02996006|PROCEDURE|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
214782127|NCT00028730|BIOLOGICAL|anti-thymocyte globulin|
214782128|NCT00028730|BIOLOGICAL|filgrastim|
214782129|NCT00028730|DRUG|cyclophosphamide|
214782130|NCT00028730|DRUG|fludarabine phosphate|
214782131|NCT00028730|DRUG|thiotepa|
214782132|NCT00028730|PROCEDURE|allogeneic bone marrow transplantation|
214782133|NCT00028730|RADIATION|radiation therapy|
214782134|NCT06152159|OTHER|data collection|Data collection
214782135|NCT00995332|DRUG|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
214782136|NCT02122471|DRUG|Plecanatide|
214782137|NCT02122471|DRUG|Placebo|
214782138|NCT02717936|PROCEDURE|Immunohistochemistry using Pancytokeratin Staining|
214782139|NCT04553484|DIAGNOSTIC_TEST|No intervention|No intervention
214782140|NCT03849170|BEHAVIORAL|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
214782141|NCT03849170|OTHER|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
214782142|NCT01311856|BEHAVIORAL|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
214782143|NCT01311856|BEHAVIORAL|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
214782144|NCT01311856|BEHAVIORAL|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
214782145|NCT01311856|BEHAVIORAL|Exercise and Diet|15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
214782146|NCT02097368|PROCEDURE|tongue strength measurement|tongue strength measurement
214782147|NCT02097368|PROCEDURE|respiratory function measurement|respiratory function measurement
214782148|NCT02097368|PROCEDURE|swallowing tests|swallowing tests
214782149|NCT02097368|OTHER|Magnetic resonance imaging|Magnetic resonance imaging
214782150|NCT04009954|OTHER|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
214782151|NCT00196443|DEVICE|urea contained compressing stockings|
214782152|NCT00196443|DEVICE|compressing stockings|
214782153|NCT01298596|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
214782154|NCT01298596|PROCEDURE|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
214782155|NCT04359186|OTHER|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
214782156|NCT02593734|DRUG|olanzapine|oral antipsychotic drug therapy
214782157|NCT02593734|DRUG|risperidone|oral antipsychotic drug therapy
214782158|NCT02593734|DRUG|amitryptaline|oral antidepressant drug therapy
214782159|NCT02593734|DRUG|fluoxetine|oral drug therapy for depression
214782160|NCT05598645|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
214782161|NCT05598645|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
214782162|NCT01812291|BEHAVIORAL|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement"
214782163|NCT01812291|BEHAVIORAL|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
214782164|NCT01812291|BEHAVIORAL|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
214782165|NCT01812291|BEHAVIORAL|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes"
214782166|NCT04128696|DRUG|feladilimab|feladilimab is available as an intravenous infusion.
214782167|NCT04128696|DRUG|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
214782168|NCT04128696|DRUG|Placebo|Placebo is available as an intravenous infusion.
214782169|NCT05294198|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract capsule
214782170|NCT02353429|DRUG|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
214782171|NCT00585039|DRUG|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
214782172|NCT01818037|PROCEDURE|Cataract surgery|
214782173|NCT06078995|DRUG|Tenecteplase|Thrombolysis wtih rhTNK-tPA
214782174|NCT06078995|DRUG|Alteplase|Thrombolysis wtih rt-PA
214782175|NCT00951899|DRUG|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
214782176|NCT00951899|OTHER|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
214782177|NCT00951899|BEHAVIORAL|Diet|Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
214782178|NCT00951899|DRUG|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
214782179|NCT04929522|PROCEDURE|local anesthesia|technique for local anesthesia
214782180|NCT04580524|PROCEDURE|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
214782181|NCT04580524|PROCEDURE|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
214782182|NCT03222167|DRUG|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
214782183|NCT01077349|PROCEDURE|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis \>1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).
214782184|NCT01077349|PROCEDURE|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine \> 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea \> 36 mmol/l OR~* Or life threatening hyperkalemia"
214782185|NCT02015299|DRUG|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
214782186|NCT02015299|DRUG|placebo|one tablet matching placebo/day for 26 weeks
214782187|NCT06016413|DRUG|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
214782188|NCT06016413|DRUG|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
214782189|NCT06016413|DRUG|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
214782190|NCT01508156|DRUG|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
214782191|NCT01508156|DRUG|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
214782192|NCT05023954|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
214782193|NCT02983526|DEVICE|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
214782194|NCT00874900|OTHER|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
214782195|NCT00874900|OTHER|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
214782196|NCT00874900|OTHER|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
214782197|NCT02028702|DIETARY_SUPPLEMENT|Placebo|water with color
214782198|NCT02028702|DIETARY_SUPPLEMENT|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
214782199|NCT05482087|DRUG|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
215030839|NCT01927614|RADIATION|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
214782200|NCT01901211|OTHER|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
214782201|NCT02133352|DRUG|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
214782202|NCT00133315|DRUG|Infliximab|
214782203|NCT00133315|DRUG|Etanercept|
214782204|NCT00133315|DRUG|Adalimumab|
214782205|NCT03137485|PROCEDURE|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
214782206|NCT03137485|PROCEDURE|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
214782207|NCT03137485|DEVICE|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
214782208|NCT02796898|DRUG|SM88 (Cohort 1)|"* Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
214782209|NCT02796898|DRUG|SM88 (Cohort 2)|"* Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
214782210|NCT00206622|DRUG|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
214782211|NCT00206622|DRUG|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
214782212|NCT00206622|DRUG|Placebo transdermal|Placebo
214782213|NCT00471185|DRUG|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
214782214|NCT02170129|DEVICE|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
214782215|NCT02170129|DEVICE|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
214782216|NCT05734170|DIETARY_SUPPLEMENT|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
214782217|NCT05734170|DIETARY_SUPPLEMENT|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
214782218|NCT05734170|DIETARY_SUPPLEMENT|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
214782219|NCT03782584|OTHER|modified pilates exercise|modified exercises from original pilates exercises.
214782220|NCT03782584|OTHER|daily life advises|they will be given daily life advises to prevent neck pain
214782221|NCT00579254|DRUG|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
214782222|NCT01208259|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214782223|NCT01208259|BEHAVIORAL|Interpersonal Therapy (IPT)|
214782224|NCT02557672|DRUG|Prothrombin complex concentrate (Human)|PCC (Kcentra)
214782225|NCT02557672|BIOLOGICAL|Fresh frozen plasma (FFP)|FFP
214782226|NCT00376428|DRUG|Gentamicin|
214782227|NCT00875719|DEVICE|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
214782228|NCT00875719|DEVICE|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
214782229|NCT01531868|OTHER|Video|Video of physician
214782230|NCT01531868|OTHER|Video|Video of physician
214782231|NCT01531868|OTHER|Video|Video of physician
214782232|NCT01531868|OTHER|Video|Video of physician
214782233|NCT01531868|OTHER|Video|Video of physician
214782234|NCT01531868|OTHER|Video|Video of physician
214782235|NCT04768023|DRUG|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
214782236|NCT04768023|DRUG|Placebo|Matching amount of vegetable oil to the vitamin D3.
214782237|NCT05323500|OTHER|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
214782238|NCT00595387|OTHER|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
214782239|NCT00595387|OTHER|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
214782240|NCT03705169|BIOLOGICAL|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
214782241|NCT03705169|BIOLOGICAL|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
214782242|NCT06468683|BIOLOGICAL|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
214782243|NCT02657083|DEVICE|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
214782244|NCT02657083|DEVICE|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
214782245|NCT04817098|BEHAVIORAL|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
214782246|NCT06412068|DRUG|Combined anti-PD-1 and R-CHOP|Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
214782247|NCT02038101|BEHAVIORAL|Education and Feedback|"1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email"
214782248|NCT04264559|DIAGNOSTIC_TEST|Infrared thermal imaging|A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
214782249|NCT04264559|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes."
214782250|NCT06198985|PROCEDURE|Dynamic balance exercise with tecnobody prokin 252 balance device|Dynamic balance exercise with tecnobody prokin 252 balance device
214782251|NCT00332137|DRUG|Tolterodine|
214782252|NCT00185328|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
214782253|NCT03276533|DRUG|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
214782254|NCT03276533|DRUG|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
214782255|NCT03276533|DRUG|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
214782256|NCT03276533|DRUG|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
214782257|NCT00560547|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
215030840|NCT04725838|DEVICE|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
214782258|NCT03473847|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
214782259|NCT03473847|DEVICE|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
214782260|NCT03473847|DEVICE|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
214782261|NCT03473847|DEVICE|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
214782262|NCT03816800|DIETARY_SUPPLEMENT|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
214782263|NCT03816800|DIETARY_SUPPLEMENT|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
214782264|NCT02464878|DRUG|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
214782265|NCT02464878|PROCEDURE|Islet Transplantation|
214782266|NCT02464878|DRUG|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
214782267|NCT02464878|DRUG|Basiliximab|Basiliximab will be used for subsequent transplants.
214782268|NCT02464878|DRUG|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
214782269|NCT00973778|OTHER|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
214782270|NCT02878278|DRUG|Chidamide BIW|Chidamide is given 30mg, twice a week
214782271|NCT02878278|DRUG|Chidamide QD|Chidamide is given 10mg,QD
214782272|NCT04180254|PROCEDURE|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
214782273|NCT05003128|DEVICE|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
214782274|NCT05605028|BEHAVIORAL|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
214782275|NCT05605028|OTHER|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
214782276|NCT04463277|BEHAVIORAL|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
214782277|NCT04463277|BEHAVIORAL|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
214782278|NCT04463277|BEHAVIORAL|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
214782279|NCT02971865|BEHAVIORAL|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
214782280|NCT02971865|OTHER|Control group traditional primary care|No change in care usually given
214782281|NCT00562692|DRUG|Nesiritide|Nesiritide 4 hour infusion
214782282|NCT00562692|DRUG|Placebo|Placebo infusion
214782283|NCT02460874|DRUG|Glyburide|1.25mg, twice a day
214782284|NCT02460874|OTHER|Placebo|1.25mg, twice a day
214782285|NCT01690520|DRUG|Cyclophosphamide|Given IV
214782286|NCT01690520|DRUG|Cyclosporine|Given IV or PO
214782287|NCT01690520|BIOLOGICAL|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
214782288|NCT01690520|DRUG|Fludarabine Phosphate|Given IV
214782289|NCT01690520|DRUG|Mycophenolate Mofetil|Given IV or PO
214782290|NCT01690520|DRUG|Thiotepa|Given IV
214782291|NCT01690520|RADIATION|Total-Body Irradiation|Undergo high dose or middle intensity TBI
214782292|NCT01690520|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
214782293|NCT05789680|PROCEDURE|Surgical treatment of parathyroid carcinoma|Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
214782294|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine Needle aspiration
214782295|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
214782296|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
214782297|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
214782298|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
214782299|NCT02945280|DRUG|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
214782300|NCT01146730|BEHAVIORAL|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
214782301|NCT01146730|BEHAVIORAL|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
214782302|NCT06274216|DRUG|Vitamin D3|5000 IU of vitamin D3 orally every day for 12 weeks
214782303|NCT06274216|DRUG|Vitamin E 400|400mg of vitamin E orally every day for 12 weeks
214782304|NCT04317963|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
214782305|NCT04317963|DRUG|Standard CDI treatment|Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
214782306|NCT05626010|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
214782307|NCT05626010|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
214782308|NCT00076323|DRUG|Primaquine|
214782309|NCT03634332|DRUG|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
214782310|NCT03634332|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
214782311|NCT00119132|DRUG|artesunate-amodiaquine|
214782312|NCT00119132|DRUG|sulphadoxine-pyrimethamine|
214782313|NCT02009956|DEVICE|Subjects receiving DESyne Novolimus Eluting CSS|
214782314|NCT04316897|DEVICE|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
214782315|NCT03197805|DIAGNOSTIC_TEST|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
214782316|NCT04006847|DRUG|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
214782317|NCT04006847|DRUG|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
214782318|NCT03341598|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
214782319|NCT03341598|PROCEDURE|R|Restorative procedure to treat tooth structure loss.
214782320|NCT03341598|PROCEDURE|MC|Xenogenous graft placed in the surgical site.
214782321|NCT00010933|DRUG|chamomile tea|
214782322|NCT00010933|PROCEDURE|Relaxation/Guided Imagery|
214782323|NCT05350254|OTHER|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
214782324|NCT05350254|OTHER|Standard chiropractic care|Standard care based on clinician's judgement
214782325|NCT03980327|DIETARY_SUPPLEMENT|probiotic|Lactobacillus probiotic
214782326|NCT03980327|DIETARY_SUPPLEMENT|medium chain triglyceride oil|
214782327|NCT04512027|OTHER|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
214782328|NCT04512027|OTHER|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
214782329|NCT03165266|DIAGNOSTIC_TEST|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~1. . Right Ventricle fractional area change.~2. . Tricuspid annular plane systolic excursion .~3. . Tissue Doppler derived tricuspid annular systolic velocity.~4. . Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~* Right ventricular basal, mid ,and longitudinal dimensions.~* Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
214782330|NCT04451382|BIOLOGICAL|OnabotulinumtoxinA (BoNTA)|
214782331|NCT04451382|PROCEDURE|Percutaneous tibial nerve stimulation (PTNS)|
214782332|NCT06186440|DRUG|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
214782333|NCT06186440|DRUG|Temozolomide|Temozolomide
214782334|NCT03156517|DEVICE|Deep Brain Stimulation|
214782335|NCT01324063|BIOLOGICAL|sargramostim|
214782336|NCT01324063|DRUG|amsacrine|
214782337|NCT01324063|DRUG|cytarabine|
214782338|NCT01324063|DRUG|daunorubicin hydrochloride|
214782339|NCT01324063|PROCEDURE|quality-of-life assessment|
214782340|NCT06232863|DRUG|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
214782341|NCT01164735|OTHER|Laboratory Biomarker Analysis|Correlative studies
215030841|NCT03929679|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
215030842|NCT04284111|DEVICE|Orthokeratology lenses|Orthokeratology lenses
214782342|NCT05471219|OTHER|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
214782343|NCT01375010|DRUG|Vitamin D3|2000 mg QD
214782344|NCT01375010|OTHER|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
214782345|NCT01375010|DRUG|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
214782346|NCT00163436|DRUG|Ciclesonide|
214782347|NCT01050166|OTHER|Transplantation of labeled islets|
214782348|NCT02614703|DRUG|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
214782349|NCT02614703|OTHER|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
214782350|NCT02402933|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
214782351|NCT01562470|OTHER|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
214782352|NCT00994032|PROCEDURE|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
214782353|NCT00994032|OTHER|Medical treatment|standard antalgic medical treatment
214782354|NCT01440478|DRUG|LY2140023|Administered orally
214782355|NCT01440478|DRUG|Ammonium chloride|Administered orally
214782356|NCT01440478|DRUG|Sodium bicarbonate|Administered orally
214782357|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
214782358|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
214782359|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
214782360|NCT00852956|DRUG|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
214782361|NCT01681771|BEHAVIORAL|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
214782362|NCT01681771|BEHAVIORAL|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
214782363|NCT03560505|DIAGNOSTIC_TEST|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
214782364|NCT02823873|DEVICE|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
214782365|NCT01917903|BEHAVIORAL|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
214782366|NCT01917903|BEHAVIORAL|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
214782367|NCT03148288|DIETARY_SUPPLEMENT|Vitamin D|VItamin D
214782368|NCT03148288|DIETARY_SUPPLEMENT|placebo|placebo
214782369|NCT03154333|DRUG|diacerein 1% ointment|diacerein 1% ointment administered topically
214782370|NCT03154333|DRUG|A placebo ointment|vehicle ointment administered topically
214782371|NCT02301780|DRUG|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
214782372|NCT02301780|DRUG|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
214782373|NCT05081076|DEVICE|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain \& Glaze Kit, following the manufacturer's instructions.
214782374|NCT05081076|DEVICE|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
214782375|NCT01773694|BEHAVIORAL|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
214782376|NCT04116294|OTHER|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
214782377|NCT06200389|DIAGNOSTIC_TEST|microbiology testing|Vulvovaginal Candidiases patients diagnosed by microbiology testing can be included
215030843|NCT01788878|BEHAVIORAL|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
214782378|NCT02351973|DRUG|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
214782379|NCT02351973|DRUG|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
214782380|NCT02351973|DRUG|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
214782381|NCT00361257|DRUG|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
214782382|NCT00361257|DRUG|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
214782383|NCT02096029|OTHER|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
214782384|NCT02096029|BEHAVIORAL|Ask, Advise, Refer (physician brief advice)|
214782385|NCT04023630|DRUG|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
214782386|NCT04023630|DRUG|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
214782387|NCT04023630|DRUG|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
214782388|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
214782389|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
214782390|NCT03157063|DIAGNOSTIC_TEST|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
214782391|NCT02757534|DRUG|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
214782392|NCT00047294|DRUG|celecoxib|
214782393|NCT00047294|DRUG|temozolomide|
214782394|NCT00047294|DRUG|thalidomide|
214782395|NCT00047294|PROCEDURE|adjuvant therapy|
214782396|NCT01797419|DRUG|GS-5806|Single dose, oral liquid, .5 mL/kg
214782397|NCT01797419|DRUG|Placebo|Single dose, oral liquid, .5 mL/kg
214782398|NCT05585619|OTHER|Pain treatment|Any pain treatment to include medications, procedures, or referrals
214782399|NCT02976012|DRUG|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
214782400|NCT02976012|PROCEDURE|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
215030844|NCT00107575|BEHAVIORAL|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
215030845|NCT00107575|OTHER|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
214782401|NCT04928833|OTHER|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
214782402|NCT04928833|OTHER|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
214782403|NCT04303052|DEVICE|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
214782404|NCT04303052|DEVICE|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
214782405|NCT03895593|OTHER|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
214782406|NCT04543981|DIAGNOSTIC_TEST|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
214782407|NCT04296383|DRUG|Azithromycin plus Xiyanping injection|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
214782408|NCT04296383|DRUG|Azithromycin|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
214782409|NCT01403454|BEHAVIORAL|Interactive Health Communication Application|web-based application
214782410|NCT04440345|DRUG|IBI362|Administered by subcutaneous injection
214782411|NCT04440345|DRUG|Placebo|Administered by subcutaneous injection
214782412|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product|Coated Tablets
214782413|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product|Coated Tablets
214782414|NCT05610605|OTHER|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
214782415|NCT05926882|DRUG|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
214782416|NCT03243539|PROCEDURE|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
214782417|NCT02919475|DRUG|JTE-051|Active drug tablets containing JTE-051
214782418|NCT02919475|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
214782419|NCT01683253|DRUG|Levodopa/Carbidopa(200mg/50mg)|
214782420|NCT01683253|DRUG|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
214782421|NCT00425789|PROCEDURE|Treatment with Hyperbaric oxygen|
214782422|NCT03757962|OTHER|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
214782423|NCT03674710|PROCEDURE|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782424|NCT03674710|PROCEDURE|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782425|NCT03674710|PROCEDURE|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782426|NCT03674710|PROCEDURE|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782427|NCT03674710|PROCEDURE|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782428|NCT03674710|PROCEDURE|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
214782429|NCT00522327|OTHER|remote simultaneous medical interpreting|remote simultaneous medical interpretation
214782430|NCT00522327|OTHER|usual and customary|usual and customary interpreting
214782431|NCT00522327|OTHER|ENglish speaking|English speakers
214782432|NCT06156969|DEVICE|Robot-Assisted Gait Training|"Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes."
214782433|NCT04663880|OTHER|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
214782434|NCT04663880|OTHER|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
214782435|NCT04663880|OTHER|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
214782436|NCT05316103|DEVICE|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
214782437|NCT01360957|DIETARY_SUPPLEMENT|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
214782438|NCT03809013|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
214782439|NCT04916925|DRUG|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
214782440|NCT04916925|DRUG|Clomid|CLOMID is adrug used for ovulation induction
214782441|NCT02370784|DRUG|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
214782442|NCT02370784|DRUG|Placebo|oral drug of similar appearance to atorvastatin
214782443|NCT00744887|DRUG|Darunavir|
214782444|NCT02580578|OTHER|No Intervention|No intervention is administered in this study.
214782445|NCT00775983|DEVICE|laminaria|place device in cervix for dilation
214782446|NCT00775983|DEVICE|Dilapan-S|Place in cervix for dilation.
214782447|NCT04602351|BEHAVIORAL|Communication|policies on communication and informed consent in ICU
214782448|NCT02962882|DEVICE|Mepilex Border|Multi-layer Foam Dressings
214782449|NCT02615327|DIETARY_SUPPLEMENT|8 g Polydextrose|8g of Polydextrose
214782450|NCT02615327|DIETARY_SUPPLEMENT|12 g Polydextrose|12 g of Polydextrose
214782451|NCT02615327|DIETARY_SUPPLEMENT|16 g Polydextrose|16 g of Polydextrose
214782452|NCT02615327|DIETARY_SUPPLEMENT|Placebo|0 g of Polydextrose
214782453|NCT02999373|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
214782454|NCT03953781|DRUG|Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males|
214782455|NCT03953781|DRUG|Effect of levetiracetam on epileptic males reproductive function|
214782456|NCT01312779|DEVICE|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
214782457|NCT03387410|DRUG|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
214782458|NCT05296681|DRUG|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
214782459|NCT04315012|OTHER|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
214782460|NCT04262310|OTHER|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
214782461|NCT00674219|DRUG|Memantine|Namenda 10mg BID for 12 weeks
214782462|NCT03096613|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
214782463|NCT01663714|BIOLOGICAL|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
214782464|NCT00597584|DRUG|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
214782465|NCT00597584|DRUG|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
214782466|NCT05334602|PROCEDURE|Addition of dermal fat graft as protection over bone graft|A barrier membrane
214782467|NCT04063384|OTHER|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
214782468|NCT04063384|OTHER|Placebo beverage|placebo beverage conditions.
214782469|NCT02209779|DRUG|BIBR 796 BS|
214782470|NCT02209779|DRUG|Placebo|
214782471|NCT02896088|OTHER|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
214782472|NCT00004797|DRUG|fructose|
214782473|NCT00004797|DRUG|placebo|
214782474|NCT06391905|DRUG|PCSK9 inhibitor in combination with standard advanced first-line regimen group|Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
214782475|NCT06391905|DRUG|standard advanced first-line regimen group|Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
214782476|NCT03706677|DEVICE|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
214782477|NCT03706677|DEVICE|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
214782478|NCT04835298|OTHER|Dyspnea|questionnaires
214782479|NCT06481696|DIETARY_SUPPLEMENT|Resveratrol-based multivitamin supplement|Natural polyphenol and vitamins
214782480|NCT06481696|DIETARY_SUPPLEMENT|Folic acid|Supplementation with folic acid at the standard dosage of 0.4 mg/die
214782481|NCT06481696|PROCEDURE|IVF/ICSI|In vitro fertilization/IntraCytoplasmic Sperm Injection
214782482|NCT06481696|DRUG|Follitropin Alfa|Controlled Ovarian Stimulation
214782483|NCT06481696|DRUG|Ganirelix Acetate 0.5 MG/ML [Fyremadel]|GnRH Antagonist
214782484|NCT06481696|DRUG|hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously|For the induction of oocyte maturation
214782485|NCT01901991|PROCEDURE|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
214782486|NCT01901991|PROCEDURE|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
214782487|NCT02754791|DEVICE|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
214782488|NCT02754791|DEVICE|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
214782489|NCT03246568|PROCEDURE|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
214782490|NCT03246568|PROCEDURE|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
214782491|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
214782492|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
214782493|NCT05002465|DRUG|68Ga-PSMA-11|Injection of 68Ga PSMA-11
214782494|NCT05002465|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
214782495|NCT01110980|OTHER|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
214782496|NCT01110980|OTHER|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
214782497|NCT03440281|DIAGNOSTIC_TEST|Uterine artery doppler|Uterine artery Doppler pulsatility indices
214782498|NCT03440281|DIAGNOSTIC_TEST|Maternal serum homocysteine estimation|
214782499|NCT00204750|PROCEDURE|Bougie Dilation|Bougie dilation will be performed as standard
214782500|NCT00204750|PROCEDURE|Needle-knife incision|Needle-knife incision will be performed
214782501|NCT03392090|OTHER|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
214782502|NCT00660790|OTHER|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
214782503|NCT03555721|OTHER|Oral examination with incandescent light|Suspicious oral lesions will be identified by oral examination with incandescent light.
214782504|NCT03555721|OTHER|Oral examination with OralID|OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
214782505|NCT03555721|DIAGNOSTIC_TEST|Biopsy|Tissue will be collected to identify pre-cancerous or cancerous cells
214782506|NCT03555721|DIAGNOSTIC_TEST|CytID|CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
214782507|NCT03555721|DIAGNOSTIC_TEST|hpvID|hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
214782508|NCT02323659|DRUG|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
214782509|NCT02323659|DRUG|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
214782510|NCT01093859|DRUG|PRX-105|Sterile solution for intravenous injection
214782511|NCT02791659|RADIATION|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
214782512|NCT02961452|OTHER|Cross reaction detection|
214782513|NCT06267599|PROCEDURE|ACAR-Style Bladder Suture|In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
214782514|NCT03648333|DRUG|Exforge tab. 10/160mg|
214782515|NCT03648333|DRUG|Lodivixx tab. 5/160mg|
214782516|NCT05153356|DEVICE|Personal Kinetigraph, Kinesia 360|10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
214782517|NCT03526107|OTHER|CF Control|CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine
214782518|NCT03526107|OTHER|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
214782519|NCT03526107|OTHER|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
214782520|NCT05008237|DRUG|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
214782521|NCT04648761|BIOLOGICAL|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
214782522|NCT03840811|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
214782523|NCT03840811|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
214782524|NCT03840811|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
214782525|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
214782526|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
214782527|NCT00077428|DRUG|bortezomib|Given IV
214782528|NCT00077428|DRUG|doxorubicin hydrochloride|Given IV
214782529|NCT00077428|OTHER|laboratory biomarker analysis|Correlative studies
214782530|NCT03197961|COMBINATION_PRODUCT|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
214782531|NCT03197961|DRUG|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
214782532|NCT05774509|BIOLOGICAL|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
214782533|NCT00123383|DRUG|Modafinil|
214782534|NCT01904383|DRUG|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
214782535|NCT05995145|BEHAVIORAL|Active hamstring flexibility exercises with hip flexion mobilization|8 weeks x 5 times per week for 20 min. In the experimental intervention, the exercise program will be based on participant education, home-based individual exercises, and regular group meetings for check-ups by a physiotherapist according to a precise set schedule.
214782536|NCT01625845|DRUG|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
214782537|NCT01625845|OTHER|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
214782538|NCT01625845|BEHAVIORAL|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
214782539|NCT06402747|DRUG|Clopidogrel|Clopidogrel 75mg once daily
214782540|NCT06402747|DRUG|Cilostazol|Cilostazol 200mg per day
214782541|NCT05886699|OTHER|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
214782542|NCT05886699|OTHER|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
214782543|NCT01654146|DRUG|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
214782544|NCT01654146|DRUG|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
214782545|NCT01654146|DRUG|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
214782546|NCT01654146|DRUG|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
214782547|NCT05237700|OTHER|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
214782548|NCT03358394|BEHAVIORAL|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
214782549|NCT02134574|BIOLOGICAL|hematologic malignancy|hematologic malignancy with a sampling of blood
214782550|NCT04108169|PROCEDURE|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
214782551|NCT03735784|BEHAVIORAL|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
214782552|NCT03536676|OTHER|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
214782553|NCT03536676|OTHER|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
214782554|NCT02960074|BIOLOGICAL|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
214782555|NCT03446560|DEVICE|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
214782556|NCT03446560|DEVICE|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
214782557|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
214782558|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
214782559|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
214782560|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
214782561|NCT04398394|DEVICE|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
214782562|NCT02853929|BIOLOGICAL|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
214782563|NCT01294592|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
214782564|NCT01294592|DRUG|tamsulosin|Take 1 capsule daily when escalation criteria met
214782565|NCT04912466|DRUG|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
214782566|NCT03955666|BIOLOGICAL|PRV-3279 or placebo|bi-specific antibody-based molecule
214782567|NCT01492257|OTHER|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
214782568|NCT00480220|PROCEDURE|Global care and support program|
214782569|NCT00190866|DRUG|Duloxetine|
214782570|NCT00190866|DRUG|placebo|
214782571|NCT02762565|DEVICE|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
214782572|NCT05460026|OTHER|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
214782573|NCT05460026|OTHER|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
214782574|NCT02891265|BEHAVIORAL|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
214782575|NCT02305420|DEVICE|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
214782576|NCT02305420|DEVICE|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
214782577|NCT03549130|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
214782578|NCT03549130|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
214782579|NCT02539030|PROCEDURE|Microfracture|simple microfracture
214782580|NCT02539030|DEVICE|CartiFill|add collagen when doing microfracture
214782581|NCT00526773|OTHER|telephone management plus a motivational intervention|heart failure intervention
214782582|NCT00526773|OTHER|telephone management with standard patient education|heart failure intervention
214782583|NCT04832074|OTHER|Dry Needling|Real Dry Needling in the most active Myofascial Trigger Point
214782584|NCT04832074|OTHER|Sham Dry Needling|Sham Dry Needling in the same location, but not piercing the skin
214782585|NCT03446274|DRUG|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
214782586|NCT00218686|BEHAVIORAL|psychoeducational|psychoeducational
214782587|NCT00218686|BEHAVIORAL|control|VTC
214782588|NCT01113710|DRUG|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
214782589|NCT06482710|DEVICE|Pinwheel|The children in the intervention group were given breathing exercises with pinwheels.
214782590|NCT05654610|DEVICE|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
214782591|NCT01026610|DRUG|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
214782592|NCT01026610|DRUG|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
214782593|NCT01026610|DRUG|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
214782594|NCT02102581|PROCEDURE|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
214782595|NCT01858246|DEVICE|Bonebridge|
214782596|NCT01858246|DEVICE|Bone Anchored Hearing Aid|
214782597|NCT01729416|OTHER|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
214782598|NCT01729416|OTHER|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
214782599|NCT04202302|PROCEDURE|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
214782600|NCT00623623|PROCEDURE|primary PCI|Standard primary PCI
214782601|NCT00623623|DRUG|enoxaparin|Adjunctive treatment
214782602|NCT00623623|PROCEDURE|catheterisation|Routine or rescue coronary intervention
214782603|NCT00623623|DRUG|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
214782604|NCT00623623|DRUG|clopidogrel|Adjunctive treatment
215030846|NCT05024344|PROCEDURE|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
215030847|NCT05024344|DRUG|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
214782605|NCT05305521|PROCEDURE|transcrestal sinus floor elevation|Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
214782606|NCT05305521|PROCEDURE|Implant placement|"Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament"
214782607|NCT01078623|DRUG|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
214782608|NCT01078623|DRUG|Placebo|Placebo control twice daily
214782609|NCT01078623|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
214782610|NCT01078623|DRUG|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
214782611|NCT01078623|DRUG|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
214782612|NCT02905721|PROCEDURE|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
214782613|NCT01162590|BIOLOGICAL|Rotarix ™|Oral, single dose
214782614|NCT01162590|BIOLOGICAL|Placebo|Oral, single dose
214782615|NCT02330679|DRUG|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
214782616|NCT02330679|DRUG|Placebo|
214782617|NCT06144814|DRUG|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
214782618|NCT06144814|DRUG|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
214782619|NCT04504864|DRUG|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
214782620|NCT04504864|DRUG|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
214782621|NCT03641118|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
214782622|NCT04689958|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
214782623|NCT04689958|DRUG|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
214782624|NCT00701766|DRUG|BI 2536|
214782625|NCT02186808|DEVICE|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
214782626|NCT05270187|OTHER|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
214782627|NCT05270187|OTHER|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
214782628|NCT03476356|DRUG|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
214782629|NCT03476356|DRUG|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
214782630|NCT02947061|DRUG|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
214782631|NCT02947061|DRUG|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
214782632|NCT04104711|OTHER|Home visits, health education|
214782633|NCT02785133|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
214782634|NCT02785133|DRUG|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
214782635|NCT02785133|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
214782636|NCT02424565|DRUG|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
214782637|NCT02424565|OTHER|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
214782638|NCT06222463|DEVICE|Evone|Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
214782639|NCT02140684|DEVICE|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
214782640|NCT00647608|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
214782641|NCT00647608|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fed
214782642|NCT02373384|DRUG|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
214782643|NCT02373384|BEHAVIORAL|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
214782644|NCT02373384|DIETARY_SUPPLEMENT|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
214782645|NCT00003966|DRUG|defibrotide|
214782646|NCT01814579|DEVICE|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
214782647|NCT01814579|DEVICE|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
214782648|NCT03650400|DRUG|Fevipiprant|Chewable tablet
214782649|NCT02081170|PROCEDURE|Autologous platelet concentrate|"1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery"
214782650|NCT01181856|BIOLOGICAL|MVA 85A|Single injection of 1 x 108 pfu MVA85A
214782651|NCT03430700|DRUG|Pembrolizumab|Intravenous infusion
214782652|NCT01768000|BEHAVIORAL|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
214782653|NCT03010085|PROCEDURE|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
214782654|NCT03010085|PROCEDURE|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
214782655|NCT04878978|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis will be used to sample the amniotic fluid for Biofire detection of microorganism and to direct antibiotic treatment
214782656|NCT04878978|OTHER|Routine care without amniocentesis|Routine clinical care
214782657|NCT04820959|BIOLOGICAL|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
214782658|NCT04820959|BIOLOGICAL|Blood sampling|Pre-operative blood sampling
214782659|NCT04800107|BIOLOGICAL|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
214782660|NCT04800107|BIOLOGICAL|Placebo capsule|Placebo capsule
214782661|NCT04716959|PROCEDURE|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
214782662|NCT04716959|PROCEDURE|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
214782663|NCT05539183|PROCEDURE|Blood withdrawal|Blood withdrawal
214782664|NCT03422783|DEVICE|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
214782665|NCT03422783|DIAGNOSTIC_TEST|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
214782666|NCT03422783|DIAGNOSTIC_TEST|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
214782667|NCT03422783|BIOLOGICAL|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
214782668|NCT01809054|DRUG|Arixtra|
214782669|NCT01809054|DEVICE|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
214782670|NCT01809054|DRUG|Aspirin|
214782671|NCT00950833|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
214782672|NCT01319097|OTHER|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
214782673|NCT01892995|DRUG|Ketamine|
214782674|NCT00593996|OTHER|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
214782675|NCT04699981|OTHER|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
214782676|NCT04699981|OTHER|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
214782677|NCT05710302|OTHER|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
214782678|NCT01426256|DIETARY_SUPPLEMENT|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
214782679|NCT04366700|PROCEDURE|Periapical surgery with autograft and collagen membrane|periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
214782680|NCT04366700|PROCEDURE|Periapical surgery with collagen membrane|periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
214782681|NCT02561988|DRUG|Avapritinib|
214782682|NCT04866797|OTHER|cyclic merocyanine|long-UVA absorber
214782683|NCT04866797|OTHER|Placebo|Placebo
214782684|NCT01942798|DEVICE|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
214782685|NCT01942798|DEVICE|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
214782686|NCT05687305|OTHER|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
214782687|NCT04965220|DRUG|HLX 208|take orally
214782688|NCT04457869|DRUG|F520|3mg/kg every 3 weeks
214782689|NCT00106262|DRUG|Velcade (bortezomib)|
214782690|NCT00106262|DRUG|Irinotecan|
214782691|NCT01541462|OTHER|Weaning|Decrease assistance provided by the ventilator
214782692|NCT03465410|DRUG|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
214782693|NCT03465410|DRUG|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
215030848|NCT05024344|DRUG|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
214782694|NCT00622141|DRUG|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
214782695|NCT01396642|OTHER|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
214782696|NCT04132232|DIAGNOSTIC_TEST|knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels|Will use the Smokerlyzer® device at each visit and be provided information on exhaled carbon monoxide and fetal carboxyhemoglobin. Risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin level will be provided.
214782697|NCT00701428|DRUG|Losartan|Losartan 50 mg daily during 6 + 6 weeks
214782698|NCT00701428|OTHER|CPAP|CPAP during the second 6 week-period
214782699|NCT06287697|OTHER|No intervention|No intervention
214782700|NCT02168647|BEHAVIORAL|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
214782701|NCT02168647|OTHER|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
214782702|NCT04738877|DIAGNOSTIC_TEST|Body fat measurement|Body fat measurement using skinfolds
214782703|NCT04738877|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
214782704|NCT04738877|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography
214782705|NCT04738877|DIAGNOSTIC_TEST|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
214782706|NCT02944643|OTHER|Mindfulness and Support Groups|
214782707|NCT00368537|DRUG|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
214782708|NCT00368537|DRUG|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
214782709|NCT04248855|DRUG|KAN-101|Intravenous (IV) infusion
214782710|NCT04248855|DRUG|Placebo|Intravenous (IV) infusion
214782711|NCT00374543|DRUG|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
214782712|NCT00374543|DRUG|Placebo|Placebo administered daily for 8 weeks
214782713|NCT02693496|OTHER|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
214782714|NCT05139693|DEVICE|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
214782715|NCT02655627|OTHER|Internet based exercise training|
214782716|NCT02655627|OTHER|group exercise training|
214782717|NCT02655627|OTHER|Physical activity counselling via a brochure|
214782718|NCT05483920|BEHAVIORAL|One-time educational video|One-time educational video
214782719|NCT05483920|BEHAVIORAL|One-time educational video plus automated text messaging|Educational video plus automated text messaging
214782720|NCT06230120|DEVICE|Spinal Cord Stimulation|"Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)"
214782721|NCT06230120|DEVICE|Sham|Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
214782722|NCT01368276|BIOLOGICAL|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
214782723|NCT01368276|DRUG|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
214782724|NCT01427920|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
214782725|NCT03086720|PROCEDURE|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
214782726|NCT03086720|PROCEDURE|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
214782727|NCT02788331|OTHER|No intervention|
214782728|NCT02856074|BIOLOGICAL|prise de sang|
214782729|NCT02856074|OTHER|quality of life questionnaire|
214782730|NCT01977326|BEHAVIORAL|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
214782731|NCT01977326|OTHER|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
214782732|NCT01956357|OTHER|Aquatic exercise|
214782733|NCT01956357|OTHER|Land Exercise|
214782734|NCT05779319|DEVICE|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
214782735|NCT04228302|DRUG|EC5026 oral capsule|"5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo."
214782736|NCT04228302|OTHER|Placebo oral capsule|5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
214782737|NCT00497471|DRUG|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
214782738|NCT00497471|DRUG|iron (2 mg/kg/daily)|
214782739|NCT01674478|DIETARY_SUPPLEMENT|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
214782740|NCT01674478|DIETARY_SUPPLEMENT|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
214782741|NCT05273385|DEVICE|Nanodropper|Device to apply liquid medication to eyes
214782742|NCT03967132|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
214782743|NCT03967132|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
214782744|NCT03967132|OTHER|Reference Group|Human milk, breast feeding ad libitum
214782745|NCT02281409|BIOLOGICAL|Mogamulizumab (KW-0761)|
214782746|NCT05784571|OTHER|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
214782747|NCT05784571|OTHER|Modified Physical Performance Test|A test of physical functioning
214782748|NCT05784571|OTHER|Hand grip strength|A test of hand grip strength using a hand dynamometer.
214782749|NCT05784571|OTHER|6-minute walk test|Self-paced test of walking capacity.
214782750|NCT05784571|PROCEDURE|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
214782751|NCT03918551|DRUG|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
214782752|NCT03918551|DRUG|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
214782753|NCT02732561|DEVICE|Alpha Stim device|cranial electrotherapy stimulation device
214782754|NCT02732561|DEVICE|Sham device|Sham device
214782755|NCT05900661|DRUG|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
214782756|NCT05900661|DRUG|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
214782757|NCT05900661|DRUG|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
214782758|NCT02933983|OTHER|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
214782759|NCT02791776|OTHER|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
214782760|NCT06406647|OTHER|retrocalvicular block|retrocalvicular block in upper limb orthopedic Surgey
214782761|NCT00435695|DRUG|GSK163090|
214782762|NCT02454309|DIETARY_SUPPLEMENT|Cranberry concentrate|
214782763|NCT02454309|DIETARY_SUPPLEMENT|Placebo|
214782764|NCT01202994|DRUG|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
214782765|NCT02528318|COMBINATION_PRODUCT|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
214782766|NCT02528318|DEVICE|nCPAP alone|nCPAP therapy
214782767|NCT02021266|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
214782768|NCT03855319|BEHAVIORAL|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
214782769|NCT05566379|OTHER|Mindfulness - Mindful Awareness Practices ( MAPs)|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
214782770|NCT01373892|PROCEDURE|Bariatric surgery|
214782771|NCT02039479|DRUG|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
214782772|NCT02039479|DRUG|Placebo|Placebo as ADD-on to every necessary treatment as usual
214782773|NCT00842088|DRUG|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
214782774|NCT00842088|DRUG|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
214782775|NCT00837577|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
214782776|NCT00837577|DRUG|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
214782777|NCT00837577|DRUG|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
214782778|NCT00349882|DEVICE|soft contact lens|
214782779|NCT00349882|DRUG|Marketed multipurpose disinfection regimen|
214782780|NCT03365921|BIOLOGICAL|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
214782781|NCT02294552|DRUG|Cyclophosphamide|
214782782|NCT02294552|DRUG|Busulfan|
214782783|NCT02294552|DRUG|Fludarabine monophosphate|
214782784|NCT02294552|DRUG|Tacrolimus|
214782785|NCT02294552|DRUG|Mycophenolate mofetil|
214782786|NCT02294552|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
214782787|NCT02044276|DRUG|lipegfilgrastim|6 mg
214782788|NCT02044276|DRUG|pegfilgrastim|6 mg
214782789|NCT04074473|DRUG|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
214782790|NCT04074473|PROCEDURE|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
214782791|NCT04074473|OTHER|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
214782792|NCT01540682|DRUG|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
214782793|NCT01540682|DRUG|Cetuximab|\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
214782794|NCT01540682|RADIATION|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.
214782795|NCT03605537|DRUG|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
214782796|NCT03359928|BEHAVIORAL|Boxing|as already discussed
214782797|NCT03359928|BEHAVIORAL|Stair stepping|as already discussed
214782798|NCT03359928|BEHAVIORAL|Stair climbing|as already discussed
214782799|NCT04416828|DEVICE|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
214782800|NCT04416828|DEVICE|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
214782801|NCT01987661|DEVICE|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
214782802|NCT01987661|DEVICE|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
214782803|NCT02400073|DEVICE|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
214782804|NCT04624841|DRUG|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
214782805|NCT01602198|DRUG|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
214782806|NCT01602198|DRUG|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
214782807|NCT04075383|PROCEDURE|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
214782808|NCT04075383|PROCEDURE|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
214782809|NCT01807962|DRUG|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
214782810|NCT01807962|DRUG|sterile saline|Placebo = 5ml of sterile saline solution
214782811|NCT03374150|BEHAVIORAL|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
214782812|NCT04828902|PROCEDURE|cardiac surgery|Any heart surgery on or without cardiopulmonary bypass performed under general anesthesia in the Cardiac Surgical Department, Medical University of Gdańsk.
214782813|NCT06496906|PROCEDURE|Tooth extraction|A regular closed tooth extraction was performed with the different devices from each arm.
214782814|NCT06496906|DEVICE|Benex|Benex was used to perform the intervention.
214782815|NCT06496906|DEVICE|Physics Forceps|Physics forceps were used to perform the intervention.
214782816|NCT06496906|DEVICE|Conventional Extraction Forceps|Conventional Extraction Forceps were used to perform the intervention.
214782817|NCT01484665|OTHER|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
214782818|NCT00323674|DEVICE|Polysoft Mesh|Polysoft Mesh is used.
214782819|NCT00323674|DEVICE|Light Weight Mesh|Light Weight Mesh is used.
214782820|NCT01710826|BIOLOGICAL|Genz-682452|Capsules for oral administration.
214782821|NCT01710826|BIOLOGICAL|Placebo|Placebo capsules matching the Genz-682452 capsules.
214782822|NCT02580890|DEVICE|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
214782823|NCT02580890|DEVICE|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
214782824|NCT04311138|OTHER|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
214782825|NCT04311138|OTHER|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
214782826|NCT00272961|DRUG|Placebo|placebo tablet once daily for 12 weeks
214782827|NCT00272961|DRUG|TBC3711|10 mg tablets once daily for 10 weeks
214782828|NCT00272961|DRUG|TBC3711|50 mg tablet once daily for 10 weeks
214782829|NCT00272961|DRUG|TBC3711|100 mg tablet once daily for 10 weeks
214782830|NCT00272961|DRUG|TBC3711|200 mg tablet once daily for 10 weeks
214782831|NCT02065791|DRUG|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
214782832|NCT02065791|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily
214782833|NCT05332626|DIETARY_SUPPLEMENT|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10\^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
214782834|NCT05332626|DIETARY_SUPPLEMENT|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
214782835|NCT03145883|OTHER|Home-Based Aerobic Exercise|
214782836|NCT04098549|OTHER|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
214782837|NCT04098549|OTHER|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
214782838|NCT04728087|DEVICE|ACCEL® Absorbable Hemostat Powder|Up to 2 bellows (10 grams nominal) of ACCEL®
214782839|NCT04728087|DEVICE|Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)|Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
214782840|NCT04455074|OTHER|FN scale auto-questionnaire|Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
214782841|NCT00362570|DRUG|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
214782842|NCT06537492|PROCEDURE|REBOA|"The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant."
214782843|NCT06537492|DEVICE|Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)|Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).
214782844|NCT06537492|DEVICE|Mechanical Chest Compression Device with Active Chest Decompression|In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.
214782845|NCT06537492|DEVICE|Impedance Threshold Device|In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
214782846|NCT03058497|DEVICE|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
214782847|NCT03825952|DEVICE|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
214782848|NCT03774979|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
214782849|NCT00018746|DEVICE|repetitive transcranial magnetic stimulation|
214782850|NCT01339884|DRUG|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
214782851|NCT04117217|DIAGNOSTIC_TEST|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
214782852|NCT01890785|DRUG|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
214782853|NCT04908956|DRUG|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
214782854|NCT04908956|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
214782855|NCT01094509|BEHAVIORAL|Tai Chi|Tai Chi classes and exercises
214782856|NCT01094509|BEHAVIORAL|Guided autobiography|Autobiographical writing in class and at home
214782857|NCT01094509|BEHAVIORAL|Qigong|Qigong classes and exercises (exploratory)
214782858|NCT01094509|BEHAVIORAL|Successful aging|Seminar series on the theme of successful aging
214782859|NCT01094509|BEHAVIORAL|Combination|Combination of Tai Chi exercises and autobiographical writing
214782860|NCT01094509|BEHAVIORAL|Comparison|No assigned behavioral activity (exploratory)
214782861|NCT00973856|OTHER|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
214782862|NCT00973856|OTHER|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
214782863|NCT05012085|OTHER|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
214782864|NCT04336488|DRUG|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
214782865|NCT04336488|DRUG|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
214782866|NCT06221345|DRUG|Systane HYDRATION® Preservative-Free Lubricant Eye Drops|The HPG/HA group will receive Systane HYDRATION® Preservative-Free Lubricant Eye Drops and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
214782867|NCT06221345|DRUG|Optive Fusion® Lubricant Eye Drops (Unit Dose)|The CMC/HA group will receive Optive Fusion® Lubricant Eye Drops (Unit Dose) and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
214782868|NCT01964105|DEVICE|3D Imaging|
214782869|NCT00368238|DRUG|Recombinant human erythropoietin alfa (drug)|
214782870|NCT00368238|DRUG|Aspirin (drug)|
214782871|NCT00368238|DRUG|Clopidogrel (drug)|
214782872|NCT00575328|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
214782873|NCT00575328|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
214782874|NCT05941468|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
214782875|NCT02124746|DRUG|Momelotinib|Momelotinib tablets administered orally once daily
214782876|NCT03180346|DEVICE|PICO|Single Use Negative Pressure Dressing
214782877|NCT03180346|DEVICE|Aquacel|Occlusive surgical dressing infused with ionized silver
214782878|NCT02205866|OTHER|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
214782879|NCT05279326|BEHAVIORAL|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
214782880|NCT01428726|DRUG|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
214782881|NCT06134973|DIAGNOSTIC_TEST|ultrasonic testing|ultrasonic testing
214782882|NCT04575974|OTHER|No intervention|No intervention
214782883|NCT00397839|DRUG|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
214782884|NCT00397839|DRUG|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
214782885|NCT00064779|DRUG|IL13-PE38QQR|
214782886|NCT00064779|PROCEDURE|targeted fusion protein therapy|
214782887|NCT00064779|PROCEDURE|surgery|
214782888|NCT00449579|DEVICE|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
214782889|NCT02445989|DRUG|NuvaRing|Provide NuvaRing to women seeking contraception
214782890|NCT03000868|PROCEDURE|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
214782891|NCT03000868|PROCEDURE|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
214782892|NCT04427514|DEVICE|Telemedicine software for data transmission and analysis in CAPD.|Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
214782893|NCT02487173|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
214782894|NCT02487173|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
214782895|NCT02487173|DEVICE|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
214782896|NCT03301428|OTHER|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
214782897|NCT03301428|OTHER|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
214782898|NCT00124449|DRUG|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g"
214782899|NCT00124449|DRUG|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
214782900|NCT02680977|OTHER|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
214782901|NCT02680977|OTHER|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
214782902|NCT02680977|OTHER|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
214782903|NCT02680977|DRUG|LD+DDCI|Levodopa plus Benserazide
214782904|NCT02680977|DRUG|LD-DDCI|Levodopa without any DDCI
214782905|NCT02680977|OTHER|Placebo|Groundnuts powder
214782906|NCT00571922|DRUG|Acamprosate|2 gr/day (333 mg, TID)
214782907|NCT00571922|DRUG|placebo|matching placebo
214782908|NCT03459781|BEHAVIORAL|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
214782909|NCT03459781|BEHAVIORAL|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
214782910|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
214782911|NCT04080882|OTHER|Placebo|Treatment of platysmal bands
214782912|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
214782913|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
214782914|NCT04136197|DIAGNOSTIC_TEST|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
214782915|NCT04465383|DEVICE|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
214782916|NCT04465383|DRUG|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
214782917|NCT00350857|DRUG|Extended-Release Carbamazepine|
214782918|NCT06398080|DRUG|aflibercept 8 mg|No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
214782919|NCT00868582|OTHER|PET scanning in cancer|Collection of institutional practice PET imaging data
214782920|NCT02522949|DEVICE|ColdZyme® mouth spray|
214782921|NCT02522949|DEVICE|Placebo|
214782922|NCT05031962|DEVICE|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
214782923|NCT06079853|BEHAVIORAL|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
214782924|NCT05958810|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
214782925|NCT05958810|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
214782926|NCT04257240|PROCEDURE|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
214782927|NCT04257240|PROCEDURE|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
214782928|NCT01392859|DRUG|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
214782929|NCT02191579|BIOLOGICAL|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
214782930|NCT02191579|DRUG|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
214782931|NCT04403191|DRUG|Ondansetron|ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
214782932|NCT04403191|DRUG|isopropyl alcohol 70% inhalation|inhalation every 15 min for 4 times then repeated after 6 hours
214782933|NCT04403191|PROCEDURE|laparoscopic appendectomy|all patients received post operatively after laparoscopic appenectomy
214782934|NCT02681107|RADIATION|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
214782935|NCT00389649|DEVICE|heart rate setting|
214782936|NCT01399424|DRUG|CP|Immunization
214782937|NCT03932435|DRUG|Fisrt period TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
214782938|NCT03932435|DRUG|Fisrt period TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
214782939|NCT03932435|OTHER|Washout period|7 days
214782940|NCT03932435|DRUG|Second period TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
214782941|NCT03932435|DRUG|Second period TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
214782942|NCT06542185|OTHER|online education|online education
214782943|NCT00003669|DRUG|arzoxifene hydrochloride|
214782944|NCT04389619|DEVICE|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
214782945|NCT04389619|PROCEDURE|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
214782946|NCT00203632|DRUG|rosiglitazone/placebo|
214782947|NCT04297488|DIETARY_SUPPLEMENT|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
214782948|NCT00821990|DRUG|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
214782949|NCT00821990|OTHER|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
214782950|NCT00831922|DRUG|masitinib (AB1010)|3 mg/kg/day
214782951|NCT00831922|DRUG|masitinib (AB1010)|6 mg/kg/day
214782952|NCT00964223|DRUG|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
214782953|NCT00964223|DRUG|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
214782954|NCT01892423|OTHER|Cetaphil Moisturizing Lotion Daily Advance|
214782955|NCT06375031|DRUG|HR011408 injection; HR011408 injection Placebo|"Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum"
214782956|NCT06375031|DRUG|NovoRapid®; HR011408 injection Placebo|"Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum"
214782957|NCT06375031|DRUG|HR011408 injection Placebo; HR011408 injection|"Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum"
214782958|NCT02717338|BEHAVIORAL|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
214782959|NCT02717338|BEHAVIORAL|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
215030849|NCT03768336|OTHER|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
214782960|NCT02717338|BEHAVIORAL|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
214782961|NCT01581762|PROCEDURE|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
214782962|NCT02271815|OTHER|Oral Hygiene|Oral Hygiene
214782963|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of placebo
214782964|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
214782965|NCT04048174|OTHER|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
214782966|NCT04048174|OTHER|Saline irrigation|Nasal and sinus irrigation with saline solution
214782967|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
214782968|NCT05700929|BEHAVIORAL|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
214782969|NCT05587478|DRUG|EDP-323|Oral administration
214782970|NCT05587478|DRUG|Placebo|Placebo to match EDP-323, oral administration
214782971|NCT00074009|DRUG|bortezomib|
214782972|NCT02693678|OTHER|Massage|
214782973|NCT02693678|DEVICE|DIathermy|
214782974|NCT02693678|DEVICE|Sham diathermy|
214782975|NCT00811070|DRUG|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
214782976|NCT01588587|DRUG|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
214782977|NCT01588587|DRUG|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
214782978|NCT01588587|DRUG|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
214782979|NCT00373659|DRUG|Ranibizumab (Lucentis)|
214782980|NCT04632693|PROCEDURE|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
214782981|NCT04632693|PROCEDURE|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
214782982|NCT03673475|PROCEDURE|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
214782983|NCT01364259|DRUG|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
214782984|NCT01364259|PROCEDURE|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
214782985|NCT00280501|DRUG|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
214782986|NCT00280501|DRUG|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
214782987|NCT00280501|DRUG|Placebo|Placebo
214782988|NCT05113901|DRUG|Methylprednisolone|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
214782989|NCT05113901|DRUG|Placebo|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
214782990|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782991|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782992|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782993|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782994|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782995|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
214782996|NCT02407028|DRUG|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
214782997|NCT02407028|OTHER|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
214782998|NCT04863326|BEHAVIORAL|Making Proud Choices|
214782999|NCT04863326|BEHAVIORAL|Business as usual|
214783000|NCT04728737|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
214783001|NCT04728737|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
214783002|NCT04728737|OTHER|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
214783003|NCT01782950|DRUG|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
214783004|NCT01585831|DRUG|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
214783005|NCT01585831|DRUG|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
214783006|NCT02046369|DRUG|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
214783007|NCT02046369|DRUG|Placebo|Placebo Comparator once daily
214783008|NCT02398500|BIOLOGICAL|LMG324|IVT injection
214783009|NCT02398500|BIOLOGICAL|Ranibizumab 0.5 mg|IVT injection
214783010|NCT02398500|BIOLOGICAL|Sham|Fake injection used for masking purposes
214783011|NCT03120520|DRUG|Plecanatide|
214783012|NCT03120520|DRUG|Matching placebo|
214783013|NCT05264766|DEVICE|Cooling helmet on|Cooling helmet with circulating cold water
214783014|NCT05264766|DEVICE|Cooling helmet off|Cooling helmet without circulating cold water
214783015|NCT03927781|DRUG|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
214783016|NCT06085742|DRUG|Cyclophosphamide|60mg/m2 PO once a day (21 continuous days)
214783017|NCT06085742|DRUG|Methotrexate|10mg/m2 PO BID on days 1, 8, and 15
214783018|NCT06085742|DRUG|Capecitabine|825mg/m2 PO BID on days 1-14
214783019|NCT03707483|COMBINATION_PRODUCT|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
214783020|NCT06460987|DRUG|Finerenone|Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
214783021|NCT06460987|DRUG|RAS inhibitor|Receive RAS inhibitor treatment as specified in the KDIGO guidelines
214783022|NCT06460987|DRUG|Immune Suppressant|Receive immune suppressant treatment as specified in the KDIGO guidelines
214783023|NCT02551003|DRUG|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
214783024|NCT02551003|DEVICE|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
214783025|NCT06025175|RADIATION|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
214783026|NCT06025175|OTHER|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
214783027|NCT04382456|DIETARY_SUPPLEMENT|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
214783028|NCT06225778|OTHER|Exercise|6-week online exercise group
214783029|NCT00003290|BIOLOGICAL|gonadotrophin releasing hormone|
214783030|NCT00003290|RADIATION|radiation therapy|
214783031|NCT00512187|OTHER|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
214783032|NCT04316052|OTHER|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
214783033|NCT04316052|OTHER|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
214783034|NCT05683314|PROCEDURE|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
214783035|NCT06424925|OTHER|Artificial intelligence for the prediction of clinical outcomes|Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
214783036|NCT01305317|DRUG|Lipitor|Atorvastatin 20mg daily for 6 months
214783037|NCT01759537|DEVICE|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
214783038|NCT01759537|DEVICE|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
214783039|NCT00420290|DRUG|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
214783040|NCT00420290|DRUG|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
214783041|NCT06700499|DRUG|AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)|AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
214783042|NCT06703112|DIAGNOSTIC_TEST|An auxiliary diagnostic model for ovarian tumors|Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).
214783043|NCT06703749|DEVICE|Treatment with BTL-899M|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.
214783044|NCT06703749|DEVICE|Treatment with BTL-899M with intensities below therapeutic threshold|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
214783045|NCT02597283|DEVICE|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
214783046|NCT02597283|DEVICE|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
214783047|NCT03174509|PROCEDURE|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
214783048|NCT03174509|PROCEDURE|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
214783049|NCT03423589|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
214783050|NCT05689034|DRUG|Azvudine|Azvudine po. 5mg daily for 7 days
214783051|NCT05689034|DRUG|Placebo|Placebo po. 5 tablets daily for 7 days
214783052|NCT02172716|PROCEDURE|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
214783053|NCT03456869|DEVICE|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
214783054|NCT04733235|DRUG|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
214783055|NCT02334956|OTHER|Brain MRI|
214783056|NCT03833037|OTHER|Soft tissue sarcomas in adults|Adult sinovial sarcoma
214783057|NCT02092961|DRUG|Fostamatinib|Fostamatinib 100mg twice daily.
214783058|NCT02092961|DRUG|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
214783059|NCT02092961|DRUG|Placebo of Fostamatinib|Placebo bid for 6 weeks.
214783060|NCT02092961|DRUG|Placebo of Adalimumab|Placebo injection once every two weeks.
214783061|NCT02594345|OTHER|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
214783062|NCT04317729|DEVICE|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
214783063|NCT00226694|DRUG|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
214783064|NCT00226694|OTHER|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
214783065|NCT00854620|DRUG|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
214783066|NCT01623830|BEHAVIORAL|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
214783067|NCT00683150|OTHER|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
214783068|NCT06172010|DRUG|Clindamycin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
214783069|NCT06172010|DRUG|Rifampicin and levofloxacin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
214783070|NCT06057285|DEVICE|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
214783071|NCT06091410|BIOLOGICAL|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
214783072|NCT06091410|BIOLOGICAL|influenza vaccine|inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
214783073|NCT01792284|DRUG|LY2605541|
214783074|NCT01792284|DRUG|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
214783075|NCT03551366|BEHAVIORAL|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
214783076|NCT03551366|BEHAVIORAL|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
214783077|NCT05446090|DIAGNOSTIC_TEST|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
214783078|NCT05446090|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
214783079|NCT05446090|DIAGNOSTIC_TEST|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
214783080|NCT05446090|PROCEDURE|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
214783081|NCT05446090|DIAGNOSTIC_TEST|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
214783082|NCT05446090|DIAGNOSTIC_TEST|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
214783083|NCT05446090|DIAGNOSTIC_TEST|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
214783084|NCT05446090|DIAGNOSTIC_TEST|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
214783085|NCT05446090|DIAGNOSTIC_TEST|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
214783086|NCT05446090|OTHER|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
214783087|NCT05446090|OTHER|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
214783088|NCT05446090|OTHER|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
214783089|NCT05446090|OTHER|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
214783090|NCT05446090|OTHER|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
214783091|NCT05446090|OTHER|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
214783092|NCT05446090|OTHER|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
214783093|NCT05446090|OTHER|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
214783094|NCT00145756|DRUG|low sodium high potassium salt substitute|
214783095|NCT03595709|DRUG|3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
214783096|NCT02609737|DEVICE|PET/CT Imaging|
214783097|NCT02609737|RADIATION|68Ga-DOTA-JR11|
214783098|NCT02609737|RADIATION|177Lu-DOTA-JR11|
214783099|NCT01226147|DRUG|Tamibarotene|4mg/day for 24 weeks.
214783100|NCT04636398|BEHAVIORAL|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
214783101|NCT06383377|DEVICE|Tooth extraction and bone graft procedure|"The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated."
214783102|NCT01169649|DRUG|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
214783103|NCT02304874|OTHER|Phlebotomy|
214783104|NCT06012058|DIAGNOSTIC_TEST|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
214783105|NCT06012058|DIAGNOSTIC_TEST|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
214783106|NCT05740670|OTHER|Dr. Kellyann's Bone Broth|Participants will have two bone broth phases, each three weeks in length. Bone broth phases will be separated by a one-week maintenance phase. A one-week maintenance phase will also occur after the second bone broth phase. Each week of a broth phase will consist of five feeding days and five fasting days. On feeding days, participants will consume one packet of bone broth, twice each day, as snacks between meals. On fasting days, participants will consume one packet of bone broth every two hours for a total of seven packets each day.
214783107|NCT05683795|OTHER|Consensus study|Modified-Delphi study and consensus meetings
214783108|NCT01304446|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
214783109|NCT01928446|DRUG|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
214783110|NCT01928446|DRUG|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
214783111|NCT04370184|PROCEDURE|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
214783112|NCT01123785|DRUG|INO-8875|eye drops for 14 days in one eye
214783113|NCT01123785|DRUG|Placebo|Matched vehicle-control
214783114|NCT02855190|OTHER|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
214783115|NCT00532519|DRUG|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
214783116|NCT02473328|DRUG|Atazanavir 200 mg/r|"1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
214783117|NCT03781297|OTHER|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
214783118|NCT03781297|OTHER|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
214783119|NCT01274728|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
214783120|NCT00740727|DRUG|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
214783121|NCT00740727|PROCEDURE|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
214783122|NCT04364165|BEHAVIORAL|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
214783123|NCT04364165|BEHAVIORAL|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
214783124|NCT02915510|DIETARY_SUPPLEMENT|Glycomacropeptide-based protein substitute|
214783125|NCT01847313|DRUG|Liraglutide|Daily administration of liraglutide for 6 months
214783126|NCT06346236|DRUG|L-thyroxine at a dose of 7.5 µg/kg/d for THOP|Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
214783127|NCT06346236|OTHER|THOP without treatment|Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.
214783128|NCT06346236|OTHER|NoTHOP|Subjects diagnosed no-THOP (as previously defined)
214783129|NCT05056337|DRUG|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
214783130|NCT05056337|DRUG|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
214783131|NCT05056337|PROCEDURE|TACE|Hepatic arterial chemoembolization
214783132|NCT05139407|DIAGNOSTIC_TEST|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
214783133|NCT00116415|DRUG|efavirenz; didanosine EC; lamivudine|
214783134|NCT03337737|DIETARY_SUPPLEMENT|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
214783135|NCT03337737|OTHER|Placebo|
214783136|NCT04366388|DEVICE|ActivPAL3 VT (PAL Technologies Ltd).|. The ActivPAL will be fitted by a trained research assistant on the mid-thigh of the participants' dominant leg. ActivPALs have an inclinometer that detects the joint angle of the thigh to capture lying, sitting, standing, and stepping activities.
214783137|NCT02619071|PROCEDURE|Tumor sampling|Bone marrow aspirate, blood sampling
214783138|NCT02619071|BIOLOGICAL|Constiutional DNA sampling|Buccal swab or Hair follicles
214783139|NCT00478361|DRUG|Gemcitabine hydrochloride|Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.
214783140|NCT00478361|DRUG|Paclitaxel|135 mg/m\^2 IV over 1 hour
214783141|NCT00478361|DRUG|Doxorubicin hydrochloride|Doxorubicin 40 mg/m\^2 IV over 20 minutes
214783142|NCT00478361|DRUG|Pegfilgrastim|Subcutaneously injection on day 1.
214783143|NCT03100253|DRUG|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
214783144|NCT03100253|DRUG|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
214783145|NCT03100253|DRUG|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
214783146|NCT03100253|DRUG|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
214783147|NCT03100253|DRUG|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
214783148|NCT03100253|DRUG|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
214783149|NCT03645083|BEHAVIORAL|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
214783150|NCT03645083|BEHAVIORAL|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
214783151|NCT03639597|DEVICE|VytronUS Ablation System|
214783152|NCT06192082|PROCEDURE|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
214783153|NCT06192082|PROCEDURE|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
214783154|NCT05091606|PROCEDURE|Perfusion İndex in Patients with Spinal Anesthesia|Comparison of lower and upper extremity perfusion index values
214783155|NCT04891588|DRUG|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
214783156|NCT04126057|DEVICE|SightGlass Vision DOT Spectacle Lenses|Subjects randomized to test vs control, left eyes and right eyes
214783157|NCT00680576|BEHAVIORAL|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
214783158|NCT00680576|BEHAVIORAL|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
214783159|NCT02658682|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
214783160|NCT02658682|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
214783161|NCT02367079|DEVICE|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
214783162|NCT04262375|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
214783163|NCT04262375|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
214783164|NCT02832297|OTHER|Vectra DA|
214783165|NCT02832297|OTHER|Usual Care|
214783166|NCT00515073|DRUG|Paclitaxel|50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
214783167|NCT00515073|RADIATION|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
214783168|NCT00515073|DRUG|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
214783169|NCT00515073|DRUG|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
214783170|NCT00515073|DRUG|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
214783171|NCT04312555|DRUG|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
214783172|NCT02706002|DEVICE|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
214783173|NCT02706002|PROCEDURE|hip prosthesis|all patients in the study will undergo hip prosthesis
214783174|NCT00273195|DEVICE|Implantable Cardioverter Defibrillator|
214783175|NCT05510713|DEVICE|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
214783176|NCT00929903|DRUG|pazopanib hydrochloride|Given orally
214783177|NCT00929903|OTHER|pharmacological study|Correlative studies
214783178|NCT05816733|DRUG|Dapagliflozin|Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
214783179|NCT05816733|DRUG|Placebo|Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
214783180|NCT04813900|OTHER|Lung ultrasound|Lung ultrasound in order to calculate lung ultrasound score
214783181|NCT01456052|DRUG|Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally.
214783182|NCT01456052|DRUG|Placebo|Matching placebo administered orally.
214783183|NCT04536233|BIOLOGICAL|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
214783184|NCT04536233|OTHER|physiological saline|The physiological saline was injected on the wound
214783185|NCT02947932|DRUG|Resveratrol|pre-ERCP intervention
214783186|NCT02947932|DRUG|Indomethacin|post-ERCP intervention in high risk patients
214783187|NCT04292574|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
214783188|NCT05004818|PROCEDURE|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
214783189|NCT05004818|PROCEDURE|Sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
214783190|NCT00463866|DRUG|Budesonide/formoterol|
214783191|NCT03150121|PROCEDURE|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
214783192|NCT03150121|PROCEDURE|Blood sample|5-10mL of blood will be drawn from participants.
214783193|NCT03150121|DEVICE|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
214783194|NCT05760079|DIETARY_SUPPLEMENT|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
214783195|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
214783196|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
214783197|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
214783198|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
214783199|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
214783200|NCT05448859|PROCEDURE|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
214783201|NCT04956406|BEHAVIORAL|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
214783202|NCT04956406|OTHER|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
214783203|NCT02265952|DRUG|REGN1500 250 mg SC/15 mg/kg IV/450 mg SC|Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
214783204|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine A dose|Inactivated vaccine against EV71, three doses, 28 days interval
214783205|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine B dose|Inactivated vaccine against EV71, three doses, 28 days interval
214783206|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine C dose|Inactivated vaccine against CVA16, three doses, 28 days interval
214783207|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine D dose|Inactivated vaccine against CVA16, three doses, 28 days interval
214783208|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine E dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
214783209|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine high dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
214783210|NCT04182932|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
214783211|NCT00740259|DRUG|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
214783212|NCT02062606|DEVICE|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
214783213|NCT02751333|PROCEDURE|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
214783214|NCT02751333|PROCEDURE|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
214783215|NCT02751333|DEVICE|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
214783216|NCT02751333|DEVICE|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
214783217|NCT01331785|DRUG|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
214783218|NCT00736528|DRUG|PF-04447943|05 mg BID for 14 days
214783219|NCT00736528|DRUG|PF-04447943|15 mg BID for 14 days
214783220|NCT00736528|DRUG|PF-04447943|45mg BID for 14 days
214783221|NCT00736528|DRUG|Placebo|Placebo for 14 days
214783222|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
214783223|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
214783224|NCT01042977|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
214783225|NCT01042977|DRUG|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
214783226|NCT02287454|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
214783227|NCT02198677|PROCEDURE|Anterior to posterior pressures|Anterior to posterior pressures
214783228|NCT02198677|PROCEDURE|Lateral glide|Lateral glide
214783229|NCT01239147|OTHER|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
214783230|NCT01239147|OTHER|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
214783231|NCT04028583|OTHER|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
214783232|NCT04028583|OTHER|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
214783233|NCT02685761|PROCEDURE|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
214783234|NCT02685761|PROCEDURE|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
214783235|NCT05687045|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
214783236|NCT05687045|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
214783237|NCT00653497|BEHAVIORAL|Aquatic exercise|"Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration"
214783238|NCT01823445|OTHER|Xylitol disk|
214783239|NCT02630745|PROCEDURE|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
214783240|NCT02630745|PROCEDURE|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
214783241|NCT00655005|OTHER|questionnaire administration|Newly diagnosed HNC patients
214783242|NCT00655005|PROCEDURE|quality-of-life assessment|following treatment
214783243|NCT05170828|DRUG|Cyclophosphamide|pre-transplant conditioning treatment
214783244|NCT05170828|DRUG|Fludarabine|pre-transplant conditioning treatment
214783245|NCT05170828|RADIATION|Total Body Irradiation|pre-transplant conditioning treatment
214783246|NCT05170828|DRUG|Busulfan|pre-transplant conditioning treatment
214783247|NCT05170828|DRUG|Mesna|given with cyclophosphamide
214783248|NCT05170828|DRUG|Sirolimus|post-transplant treatment for GVHD
214783249|NCT05170828|DRUG|Mycophenolate Mofetil|post-transplant treatment for GVHD
214783250|NCT05170828|DRUG|Filgrastim|post-transplant treatment for GVHD
214783251|NCT05170828|DRUG|Cyclophosphamide|post-transplant treatment for GVHD
214783252|NCT05170828|PROCEDURE|Bone Marrow Transplant|Transplant with investigational bone marrow product
214783253|NCT04303845|DRUG|Erenumab|140 mg of erenumab via subcutaneous injection
214783254|NCT03192683|DEVICE|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
214783255|NCT03192683|DEVICE|Regular sling|
214783256|NCT02883673|DEVICE|Jada System|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
214783257|NCT02903576|PROCEDURE|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
214783258|NCT02903576|PROCEDURE|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
214783259|NCT00499720|DRUG|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
214783260|NCT06528574|DEVICE|Conventional root canal treatment|Root canals will be irrigated by only side perforated needle
214783261|NCT06528574|DEVICE|Ultrasonic|Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
214783262|NCT06528574|DEVICE|Apical negative pressure|Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system
214783263|NCT06528574|DEVICE|Combined Ultrasonic and negative pressure|Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
214783264|NCT03955692|DEVICE|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
214783265|NCT02300376|DRUG|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
214783266|NCT06102889|DIAGNOSTIC_TEST|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
214783267|NCT04356573|DIETARY_SUPPLEMENT|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
214783268|NCT04356573|DIETARY_SUPPLEMENT|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
214783269|NCT02025582|DEVICE|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
214783270|NCT03645226|DIAGNOSTIC_TEST|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
214783271|NCT05139966|DRUG|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
214783272|NCT03952910|OTHER|Online pain education program|Online pain education program
214783273|NCT05314569|DRUG|Ketamine- dexmedetomidine|ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery
214783274|NCT05314569|DRUG|Fentanyl- midazolam|Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
214783275|NCT05314569|DRUG|Isoflurane|Anesthetic inhalational gas
214783276|NCT00796484|DRUG|XL888|Administered orally
214783277|NCT03568500|DEVICE|Digital Medicine System|DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
214783278|NCT03568500|DRUG|Aripiprazole|Dosage determined by the healthcare professionals.
214783279|NCT03568500|DRUG|Olanzapine|Dosage determined by the healthcare professionals.
214783280|NCT03568500|DRUG|Quetiapine|Dosage determined by the healthcare professionals.
214783281|NCT03568500|DRUG|Risperidone|Dosage determined by the healthcare professionals.
214783282|NCT04480099|DRUG|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
214783283|NCT04480099|DRUG|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
214783284|NCT05398575|BEHAVIORAL|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
214783285|NCT03438799|DEVICE|Cordio System|App, cloud and web device
214783286|NCT04352842|OTHER|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
214783287|NCT01577537|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
214783288|NCT01577537|DRUG|Placebo|Vaginal gel, daily for 7 days
214783289|NCT03454633|PROCEDURE|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
215030850|NCT03768336|OTHER|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
215030851|NCT01224288|PROCEDURE|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
215030852|NCT04245098|PROCEDURE|Carpal tunnel syndrome surgery|Biopsy
214783290|NCT04625582|BEHAVIORAL|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
214783291|NCT04625582|BEHAVIORAL|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
214783292|NCT02798068|DRUG|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
214783293|NCT03101163|BIOLOGICAL|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
214783294|NCT03101163|OTHER|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
214783295|NCT03713710|BEHAVIORAL|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
214783296|NCT03713710|BEHAVIORAL|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
214783297|NCT06106503|RADIATION|chest x-ray|chest x-ray after rigid bronchoscopy for patient with foreign body inhalation
214783298|NCT06106503|OTHER|clinical examination|no investigations well be done unless needed
214783299|NCT05842395|DRUG|Vitamin C|Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.
214783300|NCT05842395|DRUG|Placebo|Participants with distal radius fractures will take daily Placebo orally for three months.
214783301|NCT04648410|OTHER|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
214783302|NCT05121181|OTHER|delphi project|delphy study
214783303|NCT02277223|DIETARY_SUPPLEMENT|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
214783304|NCT02277223|DRUG|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
214783305|NCT06165120|PROCEDURE|Bracka's repair using preputial graft|"Staged repair:~1. Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~3. Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
214783306|NCT06165120|PROCEDURE|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~1. Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~3. Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
214783307|NCT02755480|DEVICE|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
214783308|NCT02784925|DEVICE|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
214783309|NCT04281368|OTHER|Analysis of IUFD|Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy
214783310|NCT00000819|DRUG|Prednisone|
214783311|NCT02406833|DRUG|TGF-β2 antisense oligonucleotide|intravitreal injection
214783312|NCT02406833|PROCEDURE|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
214783313|NCT01990885|DRUG|BL-7010|
214783314|NCT01990885|DRUG|Placebo|
214783315|NCT06339593|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
214783316|NCT04436328|PROCEDURE|Surgical treatment|Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).
214783317|NCT04436328|OTHER|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
214783318|NCT05402449|OTHER|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
214783319|NCT05402449|DIETARY_SUPPLEMENT|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
214783320|NCT00991770|OTHER|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
214783321|NCT00991770|OTHER|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
214783322|NCT02008721|DRUG|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
214783323|NCT02008721|DRUG|Placebo|Placebo
214783324|NCT05033613|OTHER|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
214783325|NCT00541281|DRUG|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
214783326|NCT00541281|DRUG|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
214783327|NCT00541281|DRUG|prednisone|2x5 mg a day
214783328|NCT02579330|DEVICE|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
214783329|NCT02579330|OTHER|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
214783330|NCT01156571|DRUG|cangrelor P2Y12 (platelet) inhibitor|
214783331|NCT01156571|DRUG|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
214783332|NCT01156571|DRUG|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
214783333|NCT03410381|OTHER|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
214783334|NCT03192059|DRUG|Pembrolizumab|Efficacy of the combined treatment
214783335|NCT03192059|RADIATION|Radiation|Efficacy of the combined treatment
214783336|NCT03192059|DRUG|Vitamin D|Efficacy of the combined treatment
214783337|NCT03192059|DRUG|Aspirin|Efficacy of the combined treatment
214783338|NCT03192059|DRUG|Lansoprazole|Efficacy of the combined treatment
214783339|NCT03192059|DRUG|Cyclophosphamide|Efficacy of the combined treatment
214783340|NCT03192059|DIETARY_SUPPLEMENT|Curcumin|Efficacy of the combined treatment
214783341|NCT00063128|DRUG|insulin|"* Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only."
214783342|NCT00063128|DRUG|human insulin inhalation powder (HIIP)|"* Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
214783343|NCT01266174|DRUG|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
214783344|NCT01266174|DRUG|Placebo|Placebo to match eltoprazine
214783345|NCT01303991|OTHER|Hexvix PDT with Karl Storz T-Light|
214783346|NCT04090996|DIAGNOSTIC_TEST|Dual TAsk|"Motor assessment includes:~* posturographic examination in Single-task (ST) and Double-task (DT)~* an analysis of ST and DT walking;~* Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
214783347|NCT04110795|OTHER|No Intervention|No Intervention
214783348|NCT01989507|DRUG|Nicotine|
214783349|NCT01989507|BEHAVIORAL|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
214783350|NCT03404661|DRUG|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
214783351|NCT03867851|DRUG|IBsolvMIR|Study drug IBsolvMIR
214783352|NCT03867851|DRUG|Heparin|Clinical praxis
214783353|NCT06084507|DRUG|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
214783354|NCT06084507|DRUG|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
214783355|NCT03285334|DEVICE|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
214783356|NCT03285334|DEVICE|iRace files|rotary mechanical preparation
214783357|NCT04873349|DIETARY_SUPPLEMENT|Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)|two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
214783358|NCT05917093|BEHAVIORAL|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
214783359|NCT05493033|PROCEDURE|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
214783360|NCT05493033|PROCEDURE|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
214783361|NCT06133088|DRUG|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
214783362|NCT05479968|DEVICE|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
214783363|NCT01475669|BIOLOGICAL|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
214783364|NCT01475669|BIOLOGICAL|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
214783365|NCT04248374|OTHER|Taste Intensity|Taste intensity with and without sour adaptation
214783366|NCT04987671|DRUG|AMX0035|Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
214783367|NCT03832933|BEHAVIORAL|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
214783368|NCT03832933|BEHAVIORAL|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
214783369|NCT01736410|DRUG|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
214783370|NCT00089310|RADIATION|technetium-99|0.25 mCi in 4 equal doses
214783371|NCT05645679|DEVICE|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
214783372|NCT01188161|DEVICE|Rotating Chair|Subjects will be spun in rotating chair
214783373|NCT03680482|OTHER|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
214783374|NCT03680482|OTHER|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
214783375|NCT00747422|DEVICE|Ulthera™ System|ultrasound treatment
214783376|NCT03362528|DEVICE|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
214783377|NCT05676879|OTHER|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
214783378|NCT05273606|DEVICE|MiSight mutifocal soft contact lens|Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.
214783379|NCT05273606|DEVICE|Proclear 1 Day soft contact lens|Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.
214783380|NCT00626587|DEVICE|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
214783381|NCT00267007|DRUG|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
214783382|NCT00267007|DRUG|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
214783383|NCT06568133|DRUG|UIC201603 and co-administration of UIC201603 and UIC201604|"* UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days"
214783384|NCT06568133|DRUG|UIC201604 and co-administration of UIC201603 and UIC201604|"* UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604"
214783385|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783386|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783387|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783388|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783389|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783390|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
214783391|NCT06568198|DEVICE|Real tACS|α-tACS at a frequency of alpha band at S1
214783392|NCT06568198|DEVICE|Sham tACS|Sham tACS with no stimulation applied
214783393|NCT03236493|DRUG|PF-06700841|PF-06700841 will be administered as tablet
214783394|NCT03236493|DRUG|Placebo|Matching placebo will be administered as tablet
214783395|NCT02264457|DEVICE|T-flex Aspheric Toric IOL|
214783396|NCT02264457|DEVICE|AT TORBI toric IOL|
214783397|NCT01270373|DRUG|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
214783398|NCT01270373|DRUG|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
214783399|NCT02740673|DEVICE|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
214783400|NCT03673839|OTHER|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
214783401|NCT03673839|OTHER|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
214783402|NCT03673839|OTHER|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
214783403|NCT03673839|OTHER|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
214783404|NCT02908698|DRUG|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
214783405|NCT02908698|DRUG|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
214783406|NCT00175383|DRUG|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
215030853|NCT04974476|OTHER|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
214783407|NCT05666674|OTHER|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
214783408|NCT01303874|DRUG|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
214783409|NCT01303874|DRUG|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
214783410|NCT03095482|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
214783411|NCT03095482|BEHAVIORAL|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
214783412|NCT01595074|OTHER|medical chart review|Correlative studies
214783413|NCT01595074|OTHER|laboratory biomarker analysis|Correlative studies
214783414|NCT00465504|PROCEDURE|iontophoresis|See Detailed Description.
214783415|NCT04583839|BEHAVIORAL|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
214783416|NCT03109522|PROCEDURE|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
214783417|NCT03109522|PROCEDURE|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
214783418|NCT06568250|BEHAVIORAL|RAMP program|The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
214783419|NCT06383208|DIAGNOSTIC_TEST|lipid metabolomics|Extract 4 milliliters of fasting peripheral venous blood from enrolled patients for targeted lipid metabolism metabolomics research. Utilize a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system to conduct metabolomics analysis on patient blood samples.
214783420|NCT00764803|DEVICE|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
214783421|NCT00764803|DEVICE|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
214783422|NCT03522090|DIAGNOSTIC_TEST|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
214783423|NCT04627870|DEVICE|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
214783424|NCT04627870|DEVICE|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
214783425|NCT02272582|DEVICE|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
214783426|NCT02272582|OTHER|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
214783427|NCT02289027|BIOLOGICAL|cAd3-EBOZ vaccine|
214783428|NCT02289027|BIOLOGICAL|Placebo (for cAd3-EBOZ vaccine)|Diluent
214783429|NCT01825876|DRUG|Evacetrapib|Oral administration
214783430|NCT01825876|DRUG|Warfarin|Oral administration
214783431|NCT03333460|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
214783432|NCT05350982|DEVICE|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
214783433|NCT04965402|DRUG|BMS-986166|Specified dose on specified days
214783434|NCT04965402|OTHER|Placebo|Specified dose on specified days
214783435|NCT03542318|OTHER|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
214783436|NCT05149287|DRUG|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
214783437|NCT05149287|OTHER|Placebo|1% lidocaine and saline
214783438|NCT00962182|DRUG|STAN1|3-4 capsules/day at meals
214783439|NCT00962182|DRUG|Placebo enzyme|3-4 capsules/day at meals
214783440|NCT00962182|DRUG|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
214783441|NCT02094430|DRUG|biological: human fibrinogen concentrate|
214783442|NCT01463566|DEVICE|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
214783443|NCT00711867|DEVICE|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
214783444|NCT00711867|DEVICE|Bair Hugger|Arizant Bair Hugger temperature management system.
214783445|NCT04293640|DIAGNOSTIC_TEST|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
214783446|NCT03230968|BEHAVIORAL|Integral Action Program for Respiration|
214783447|NCT05161663|BEHAVIORAL|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
214783448|NCT04133519|DEVICE|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
214783449|NCT04133519|DEVICE|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
214783450|NCT05548218|OTHER|Automated health education using a digital health pathway|MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
215030854|NCT05604586|DIETARY_SUPPLEMENT|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
215030855|NCT05604586|DIETARY_SUPPLEMENT|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
214783451|NCT04829279|OTHER|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
214783452|NCT00931567|BIOLOGICAL|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
214783453|NCT00931567|DEVICE|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
214783454|NCT06248034|DEVICE|Smartphone application with tele-monitoring rehabilitation|This Smartphone application includes an automated criterion-based progression based on participant's regular recorded self-measurement of knee range-of-motion and five-repetition-sit-to-stand. The rehabilitation program is designed to (i) increase knee range-of-motion, (ii) strengthen lower limb strength, (iii) improve postural balance, and (iv) improve physical function.
214783455|NCT06248034|PROCEDURE|Hospital-based rehabilitation program|Participants will be provided with the usual preoperative, inpatient physiotherapy and a physiotherapy house visit within the first 2-weeks postoperation. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion.
214783456|NCT01434706|OTHER|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
214783457|NCT03931057|DRUG|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
214783458|NCT03931057|DRUG|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
214783459|NCT05747365|DIAGNOSTIC_TEST|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
214783460|NCT02751060|OTHER|No intervention|
214783461|NCT01558531|DEVICE|DEB|paclitaxel-eluting balloon angioplasty
214783462|NCT01558531|DEVICE|POBA|conventional balloon angioplasty
214783463|NCT05187403|DRUG|Laquinimod|Eye-drops
214783464|NCT05187403|DRUG|Placebo|Eye-drops
214783465|NCT00475852|DRUG|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
214783466|NCT00475852|DRUG|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
214783467|NCT04366466|OTHER|suicide attempt patient using PEPS Program|"The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group."
214783468|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
214783469|NCT02174900|DRUG|Artemether-Lumefantrine (AL) combination|
214783470|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
214783471|NCT02512770|PROCEDURE|endoscopic dilatation|
214783472|NCT03433118|DEVICE|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
214783473|NCT05599906|OTHER|questionnaires|Completion of 3 questionnaires (HADS; SF-12; FAS) at the beginning and end of the rehabilitation and after 3 months
214783474|NCT03686800|DEVICE|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
214783475|NCT01218737|DRUG|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
214783476|NCT01218737|DRUG|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
214783477|NCT04844307|OTHER|Shorter duration higher frequency PT|The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.
214783478|NCT04844307|OTHER|Standard PT|The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
214783479|NCT04405193|DRUG|N-acetyl cysteine|Eligible patients will be randomised to receive N-acetylcysteine or placebo
214783480|NCT04405193|DRUG|Placebo|Matching Placebo
214783481|NCT05485688|OTHER|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
214783482|NCT05771831|BIOLOGICAL|Thrombosomes®|The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
214783483|NCT05771831|BIOLOGICAL|Standard platelet concentrate|The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
214783484|NCT04394910|DIETARY_SUPPLEMENT|Pomegranate Juice|
214783485|NCT04394910|DIETARY_SUPPLEMENT|Placebo Juice|
214783486|NCT00297479|BEHAVIORAL|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
214783487|NCT00297479|DRUG|Nicotine|6 weeks of nicotine patch therapy
214783488|NCT00297479|BEHAVIORAL|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
214783489|NCT00297479|BEHAVIORAL|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
214783490|NCT01545687|DIETARY_SUPPLEMENT|Lactobacillus brevis CD2 lozenge|Dissolved orally
214783491|NCT01545687|OTHER|placebo|Dissolved orally
214783492|NCT03349177|DRUG|Epirubicin|100mg/m2
214783493|NCT03349177|DRUG|Fluorouracil|500mg/m2
214783494|NCT03349177|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
214783495|NCT03349177|DRUG|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
214783496|NCT04819347|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
214783497|NCT04819347|DRUG|3BNC117|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
214783498|NCT01664494|DRUG|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
214783499|NCT03196791|DRUG|Sugammadex Sodium|"1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
214783500|NCT04503252|OTHER|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
214783501|NCT04503252|OTHER|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
214783502|NCT04503252|OTHER|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
214783503|NCT04503252|OTHER|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
214783504|NCT04503252|OTHER|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
214783505|NCT04607642|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
214783506|NCT04607642|RADIATION|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
214783507|NCT04607642|DRUG|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
214783508|NCT04607642|OTHER|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
214783509|NCT04070456|OTHER|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
214783510|NCT00133107|DRUG|efalizumab|
214783511|NCT02948478|OTHER|Exposed|Precarious patients
214783512|NCT02948478|OTHER|Non exposed|Non precarious patients
214783513|NCT03786289|BIOLOGICAL|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
214783514|NCT03786289|BIOLOGICAL|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
214783515|NCT01301131|OTHER|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
214783516|NCT01301131|OTHER|control|usual oral care
214783517|NCT02212431|DRUG|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
214783518|NCT03947047|DIAGNOSTIC_TEST|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
214783519|NCT02273206|BEHAVIORAL|Prevention Care Management for Depression and Cancer Screening|
214783520|NCT02273206|BEHAVIORAL|Prevention Care Management for Cancer Screening|
214783521|NCT02803723|PROCEDURE|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
214783522|NCT02803723|PROCEDURE|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
214783523|NCT02238977|DRUG|Fluoxetine|Antidepressant
214783524|NCT02238977|DRUG|Bupropion|Antidepressant
214783525|NCT02370966|DIETARY_SUPPLEMENT|Berry powder|Berry and gingivitis trial
214783526|NCT05484375|DRUG|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
214783527|NCT01557270|DRUG|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
214783528|NCT01557270|DRUG|saline|ropivacaine + saline placebo, single shot perineural application
214783529|NCT00373685|DRUG|Celecoxib|open-label
214783530|NCT00373685|DRUG|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
214783531|NCT03754816|PROCEDURE|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
214783532|NCT03754816|DRUG|Levobupivacaine|Levobupivacaine
214783533|NCT01789281|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
214783534|NCT01789281|DRUG|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
214783535|NCT00602550|DRUG|Zidovudine|
214783536|NCT01963819|OTHER|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
214783537|NCT05957718|DRUG|TKTX cream|TKTX cream was used in several studies on Tatto and laser
214783538|NCT00097123|DRUG|Misoprostol|
214783539|NCT06539299|PROCEDURE|Socket Preservation|After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.
214783540|NCT05064696|OTHER|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
214783541|NCT05064696|DEVICE|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
214783542|NCT02746705|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
214783543|NCT02746705|DEVICE|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
214783544|NCT02746705|BEHAVIORAL|Cognitive Training Program|
214783545|NCT03545737|OTHER|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
214783546|NCT03545737|OTHER|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
214783547|NCT03768219|BIOLOGICAL|APVO210|APVO210
214783548|NCT03768219|BIOLOGICAL|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
214783549|NCT00624403|DEVICE|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
214783550|NCT00624403|DEVICE|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
214783551|NCT04714099|DRUG|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
214783552|NCT04714099|DRUG|Placebo|Placebo
214783553|NCT04393805|DRUG|Low Molecular Weight Heparin|Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
214783554|NCT02163811|BEHAVIORAL|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
214783555|NCT02163811|BEHAVIORAL|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
214783556|NCT06231797|DIAGNOSTIC_TEST|AI algorithm conducted on 12-lead ECG and transthoracic echocardiography|12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.
214783557|NCT04486183|OTHER|capillary blood samples|The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
214783558|NCT05447585|DEVICE|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
214783559|NCT05447585|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
214783560|NCT02103647|DRUG|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
214783561|NCT02103647|DRUG|sustained release tablet|sustained release tablet
214783562|NCT04783259|OTHER|Structured approach|Structured approach with a narrow learning objective. The structured approach concerns a pre-escape room lecture and post-escape room debriefing
214783563|NCT05407675|DRUG|BMS-986408|Specified dose on specified days
214783564|NCT05407675|BIOLOGICAL|Nivolumab|Specified dose on specified days
214783565|NCT05407675|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214783566|NCT05407675|BIOLOGICAL|Platinum-doublet chemotherapy|Specified dose on specified days
214783567|NCT05407675|DRUG|Rabeprazole|Specified dose on specified days
214783568|NCT04407195|OTHER|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
214783569|NCT00769015|BEHAVIORAL|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
214783570|NCT00769015|BEHAVIORAL|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
214783571|NCT05073263|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
214783572|NCT04150588|DRUG|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
214783573|NCT03940586|DRUG|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
214783574|NCT03940586|DRUG|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
214783575|NCT03940586|DRUG|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
214783576|NCT02522754|BIOLOGICAL|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
214783577|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
214783578|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
214783579|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
214783580|NCT02862535|DRUG|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
214783581|NCT02862535|DRUG|S-1|Administered orally
214783582|NCT02862535|DRUG|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
214783583|NCT02862535|DRUG|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
214783584|NCT02862535|DRUG|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
214783585|NCT01341522|PROCEDURE|MRI exam|MRI exam
214783586|NCT01341522|PROCEDURE|control|waiting room
214783587|NCT06024863|DIAGNOSTIC_TEST|Screening stress test on a bicycle ergometer (usual practise)|
214783588|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA
214783589|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
214783590|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
214783591|NCT03929224|DRUG|Medicinal honey|Treat healing surgical site with medicinal honey
214783592|NCT03929224|DRUG|Bacitracin|Treat healing surgical site with bacitracin
214783593|NCT00046371|DRUG|THERATOPE® vaccine|
214783594|NCT00303381|DRUG|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
214783595|NCT00303381|DRUG|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
215030856|NCT06252584|DRUG|Vaccines, Peptide|Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
214783596|NCT00303381|DRUG|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
214783597|NCT02276911|DRUG|Ibuprofen|
214783598|NCT02276911|OTHER|normal saline|
214783599|NCT04091685|DEVICE|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
214783600|NCT04304950|DRUG|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
214783601|NCT04304950|DRUG|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
214783602|NCT03213561|DEVICE|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
214783603|NCT03077828|DRUG|Carboplatin|Given IV
214783604|NCT03077828|DRUG|Etoposide|Given IV
214783605|NCT03077828|DRUG|Ifosfamide|Given IV
214783606|NCT03077828|OTHER|Laboratory Biomarker Analysis|Correlative studies
215030857|NCT00010478|PROCEDURE|Acupuncture|
214783607|NCT03077828|BIOLOGICAL|Pembrolizumab|Given IV
214783608|NCT03338270|DIAGNOSTIC_TEST|MRI|MRI sequence without intravenous contrast
214783609|NCT05681377|DRUG|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
214783610|NCT03536819|DEVICE|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
214783611|NCT06160674|OTHER|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
214783612|NCT05202691|OTHER|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
214783613|NCT05202691|OTHER|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
214783614|NCT02769000|RADIATION|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
214783615|NCT02769000|RADIATION|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
214783616|NCT04220034|BIOLOGICAL|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
214783617|NCT03788798|DEVICE|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
214783618|NCT00140556|RADIATION|Chemoradiotherapy|External beam radiation daily (M-F)
214783619|NCT00140556|DRUG|Cisplatin|Cisplatin week 1 and 5 of radiation
214783620|NCT00140556|DRUG|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
214783621|NCT00140556|DRUG|Erlotinib|Erlotinib daily during radiation
214783622|NCT03654807|BEHAVIORAL|High Intensity Walking|70-80% HRmax
214783623|NCT03654807|BEHAVIORAL|Casual Speed Walking|Self selected pace
214783624|NCT05621200|DEVICE|Transcranial stimulation over the cerebellar hemispheres|Single session of Transcranial stimulation over the cerebellar hemispheres
214783625|NCT00345683|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
214783626|NCT00345683|BIOLOGICAL|PedvaxHIB|Booster dose by intramuscular injection
214783627|NCT00345683|BIOLOGICAL|Prevnar|Booster dose by intramuscular injection
214783628|NCT00345683|BIOLOGICAL|M-M-R II|Single dose by subcutaneous injection
214783629|NCT00345683|BIOLOGICAL|Varivax|Single dose by subcutaneous injection
214783630|NCT00937053|OTHER|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
214783631|NCT00937053|OTHER|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
214783632|NCT00937053|OTHER|Platelet transfusion|Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
214783633|NCT03495700|PROCEDURE|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
214783634|NCT03495700|PROCEDURE|DBBM|The use of bovine xenograft will be analysed
214783635|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
214783636|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
214783637|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
214783638|NCT04288115|DRUG|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
214783639|NCT04288115|OTHER|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
214783640|NCT00842894|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
214783641|NCT00842894|DRUG|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
214783642|NCT01692418|DRUG|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
214783643|NCT01692418|DRUG|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
214783644|NCT04175678|OTHER|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
214783645|NCT04175678|OTHER|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
214783646|NCT04175678|OTHER|Standard care|Observational
214783647|NCT00057018|PROCEDURE|Constraint-induced movement therapy|
214783648|NCT03938298|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
214783649|NCT03938298|OTHER|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
214783650|NCT01412073|DRUG|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
214783651|NCT01412073|DRUG|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
214783652|NCT03634488|DRUG|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
214783653|NCT03634488|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
214783654|NCT03797365|OTHER|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
214783655|NCT03797365|BEHAVIORAL|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on…
214783656|NCT00817466|DRUG|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1\) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
214783657|NCT00817466|DRUG|Isotonic saline|2ml NaCl 9mg/ml.
214783658|NCT06543017|OTHER|Experimental group|This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
214783659|NCT06521606|PROCEDURE|Primary open reduction and internal fixation|The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.
214783660|NCT06521606|PROCEDURE|Temporary external fixator|). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
214783661|NCT00729365|DRUG|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
214783662|NCT00729365|DRUG|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
214783663|NCT00729365|DRUG|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
214783664|NCT02720224|DRUG|Estetrol|15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
214783665|NCT06355960|DRUG|GROUP Dexmedetomidine|Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
214783666|NCT06355960|DRUG|GROUP B|Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
214783667|NCT06355960|DRUG|GROUP C|Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
214783668|NCT03178422|DRUG|CQSS2|Nicotine Replacement Therapy
214783669|NCT03178422|DRUG|NicoDerm CQ Patch|Nicotine Replacement Therapy
214783670|NCT03909568|PROCEDURE|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
214783671|NCT04005105|BEHAVIORAL|Intensive management|Management based on premorbid MAP and MPP
214783672|NCT06542848|OTHER|Physiotherapy and Rehabilitation Practices|The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
214783673|NCT01696474|DRUG|Bortezomib|
214783674|NCT00415961|DEVICE|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
214783675|NCT05053178|BEHAVIORAL|Mindfulness-based mandala activity|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented
214783676|NCT00475111|BEHAVIORAL|Cognitive Behavior Therapy for Pain (CBT-P)|
214783677|NCT00475111|BEHAVIORAL|Mindfulness Meditation for Emotion Regulation (MM-ER)|
214783678|NCT00475111|BEHAVIORAL|Rheumatoid arthritis education|
214783679|NCT00189345|BIOLOGICAL|anti-EpCAM x anti-CD3 (removab)|
214783680|NCT01154127|DRUG|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
214783681|NCT01154127|DRUG|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
214783682|NCT05209061|OTHER|Biopsy|Participants included in the study, will have a full thickness biopsy of the middle of the appendix taken, after the resected bowel has been removed during surgery.
214783683|NCT03074279|OTHER|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
214783684|NCT01196481|DRUG|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
214783685|NCT01196481|PROCEDURE|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
214783686|NCT01770782|PROCEDURE|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
214783687|NCT01770782|OTHER|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
214783688|NCT02151396|BEHAVIORAL|Working memory training|
214783689|NCT02151396|DEVICE|Functional magnetic resonance imaging (fMRI)|
214783690|NCT03883971|OTHER|3D printed model|Same as previously reported in arm descriptions
214783691|NCT03883971|OTHER|Placebo|nothing other than the ultrasound
214783692|NCT03343977|DRUG|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
214783693|NCT03343977|DRUG|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
214783694|NCT00676026|DRUG|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
214783695|NCT00676026|DRUG|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
214783696|NCT00676026|DRUG|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
214783697|NCT01335152|BEHAVIORAL|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
214783698|NCT00577954|PROCEDURE|Multimodal MRI|Multimodal MRI
214783699|NCT02623309|BIOLOGICAL|Allogeneic (Allo) hematopoietic stem cell transplantation|
214783700|NCT05564702|OTHER|traditional drug treatment|The patients in this arm will be given doctor specified dosage.
214783701|NCT05564702|OTHER|Opt-IVF predicted dosage|The patients in this arm will be given dosage predicted by Opt-IVF.
214783702|NCT01169844|BIOLOGICAL|AIN457A|
214783703|NCT01169844|OTHER|Other|
214783704|NCT00349310|DRUG|Pramipexole|
214783705|NCT04271683|PROCEDURE|Pressure controlled ventilation with PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
214783706|NCT04271683|PROCEDURE|Manual ventilation without PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
214783707|NCT00201929|PROCEDURE|Standard Decision Board|
214783708|NCT00201929|PROCEDURE|Computer Decision Board|
214783709|NCT00201929|PROCEDURE|Paper Decision Board|
214783710|NCT04736979|DRUG|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
214783711|NCT00754195|OTHER|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
214783712|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
214783713|NCT05037409|DRUG|Placebo|Intravenous infusion
214783714|NCT00318344|DRUG|Atuna Racemosa|
214783715|NCT03843255|OTHER|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
214783716|NCT03843255|OTHER|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
214783717|NCT01183845|PROCEDURE|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
214783718|NCT02611245|DRUG|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
214783719|NCT05358561|DIETARY_SUPPLEMENT|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
214783720|NCT00472706|PROCEDURE|excision|excision 3 mm margin
214783721|NCT00472706|PROCEDURE|Photodynamic therapy|Photodynamic therapy
214783722|NCT05514028|OTHER|Salivary samples|"For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)"
214783723|NCT01888328|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
214783724|NCT06097611|DRUG|Tranexamic Acid administration|Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
214783725|NCT03418077|DIETARY_SUPPLEMENT|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
214783726|NCT03418077|DIETARY_SUPPLEMENT|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
214783727|NCT00165854|DRUG|E7070|
214783728|NCT02115737|BEHAVIORAL|Dialectical Behavior Therapy Skills Group|
214783729|NCT02115737|BEHAVIORAL|Psychoeducation group treatment|
214783730|NCT03299530|OTHER|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
214783731|NCT02964728|DRUG|Botulinum Neurotoxin Type A|topical injection
214783732|NCT02964728|OTHER|Normal saline|topical injection
214783733|NCT03755700|DRUG|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
214783734|NCT03755700|DRUG|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
214783735|NCT03755700|DRUG|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
214783736|NCT03755700|DRUG|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
214783737|NCT03755700|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
214783738|NCT02588131|DRUG|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
214783739|NCT01289938|DRUG|Diphenhydramine|Diphenhydramine 50 mg oral once
214783740|NCT01289938|DRUG|Metoclopramide|10 mg i.v. metoclopramide once
214783741|NCT02056405|DRUG|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
214783742|NCT02056405|DRUG|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
214783743|NCT01773278|DRUG|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
214783744|NCT01773278|DRUG|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
214783745|NCT02348970|DEVICE|ONIRIS®|sleeping test
214783746|NCT02348970|DEVICE|TALI|sleeping test
214783747|NCT03503656|DEVICE|epidural catheter placement|insertion of an epidural catheter using Compuflo System
214783748|NCT00529568|DRUG|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
214783749|NCT00529568|DRUG|placebo|double-blind matched placebo control daily oral administration
214783750|NCT02669628|PROCEDURE|Surgical technique|Laparoscopic surgery
214783751|NCT02669628|PROCEDURE|Alcohol sclerotherapy|US-guided sclerotherapy
214783752|NCT04676516|DRUG|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
214783753|NCT04446832|OTHER|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
214783754|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
214783755|NCT00931385|DRUG|BI 1744|BI1744 Respimat Med Dose Once Daily
214783756|NCT00931385|DRUG|bi1744|1744 low dose
214783757|NCT00931385|DRUG|Placebo|Placebo Respimat and Foradil Placebo
214783758|NCT00931385|DRUG|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
214783759|NCT01210742|DEVICE|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
214783760|NCT01210742|OTHER|Routine management|Routine non-operative management for knee OA (NICE guidelines)
214783761|NCT01201356|DRUG|Fingolimod|0.5 mg/day
214783762|NCT01783899|DEVICE|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
214783763|NCT00796211|DRUG|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
214783764|NCT00796211|DRUG|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
214783765|NCT00796211|DRUG|Nortriptyline|0.1% nortriptyline HCl topical cream
214783766|NCT00796211|DRUG|Calcipotriol|0.005% calcipotriol topical cream
214783767|NCT00796211|OTHER|Placebo|Vehicle of CRx-197 topical cream (placebo)
214783768|NCT04401787|PROCEDURE|Anterior resection for upper rectal cancer in obese|Anterior resection for upper rectal cancer in obese
214783769|NCT04933669|DRUG|Imatinib|Imatinib neoadjuvant therapy
214783770|NCT03889457|OTHER|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
214783771|NCT03010202|DRUG|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
214783772|NCT03010202|DRUG|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
214783773|NCT02584205|DEVICE|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
214783774|NCT02784717|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
214783775|NCT00034515|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|
214783776|NCT02295683|DEVICE|Renal Denervation|
214783777|NCT03360656|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
214783778|NCT00952185|OTHER|cytology specimen collection procedure|
214783779|NCT00952185|OTHER|fluorescent antibody technique|
214783780|NCT00952185|PROCEDURE|assessment of therapy complications|
214783781|NCT05215041|OTHER|Non intervention|If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
214783782|NCT04612205|DEVICE|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
214783783|NCT04612205|OTHER|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
214783784|NCT05781477|BEHAVIORAL|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
214783785|NCT03374137|BIOLOGICAL|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
214783786|NCT00738920|BEHAVIORAL|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
214783787|NCT00738920|BEHAVIORAL|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
214783788|NCT00738920|BEHAVIORAL|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
214783789|NCT06284707|OTHER|swimming training|2 sessions per week of swimming training
214783790|NCT06284707|OTHER|rhythmic gymnastics training|2 training sessions of rhythmic gymnastics
214783791|NCT02129530|BEHAVIORAL|Community Social Mobilization program|
214783792|NCT05162885|PROCEDURE|Socket Preservation technique|Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama\&salama Class 3 labial wall defect
214783793|NCT02619734|BIOLOGICAL|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
214783794|NCT03635684|DRUG|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
214783795|NCT04821492|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD expressed in absolute values as g/cm2 and T-scores
214783796|NCT03821324|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
214783797|NCT05907902|DRUG|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
214783798|NCT03667625|OTHER|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
214783799|NCT03667625|OTHER|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
214783800|NCT04662684|DRUG|Rivaroxaban 10 MG|No intervention
214783801|NCT06536829|OTHER|Myofacial release technique and sciatic nerve slider technique|Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
214783802|NCT06536829|OTHER|Myofacial release technique|0week,6 week, 12 weeks
214783803|NCT04070599|BIOLOGICAL|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
214783804|NCT00393835|DRUG|Azithromycin SR|
214783805|NCT03371238|BEHAVIORAL|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
214783806|NCT04742725|DRUG|Placebo|Placebo
214783807|NCT04742725|DRUG|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
214783808|NCT05244382|OTHER|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
214783809|NCT03917563|DEVICE|WATCHMAN LAA occluder|WATCHMAN LAA occluder
214783810|NCT00812435|DRUG|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
214783811|NCT01130805|DRUG|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
214783812|NCT01101581|DRUG|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).
214783813|NCT01101581|DRUG|90Y-epratuzumab tetraxetan|
214783814|NCT01101581|DRUG|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
214783815|NCT01921036|PROCEDURE|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
214783816|NCT01921036|PROCEDURE|combined exercise|Moderate endurance and resistance exercise once a week over six months
214783817|NCT05182983|OTHER|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
214783818|NCT04621097|DEVICE|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
214783819|NCT04621097|OTHER|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
214783820|NCT04621097|DRUG|Medication|regular medications
214783821|NCT04079842|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
214783822|NCT04147481|OTHER|Group Abdominal Nerve Block with local anesthetics|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
214783823|NCT04147481|OTHER|Group Abdominal Nerve Block with saline|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
214783824|NCT02904200|DEVICE|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
214783825|NCT02904200|DEVICE|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
214783826|NCT04124978|DEVICE|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
214783827|NCT00198978|DRUG|Cyclophosphamide|
214783828|NCT00198978|DRUG|Dexamethasone / Prednisolone|
214783829|NCT00198978|DRUG|Cytarabine|
214783830|NCT00198978|DRUG|Idarubicin|
214783831|NCT00198978|DRUG|Granulocyte-Colony-Stimulating Factor|
214783832|NCT00198978|DRUG|Mercaptopurine|
214783833|NCT00198978|DRUG|Methotrexate|
214783834|NCT00198978|DRUG|Rituximab|
214783835|NCT00198978|DRUG|HDARAC|
214783836|NCT00198978|DRUG|Vincristine|
214783837|NCT00198978|DRUG|Depocyte|
214783838|NCT00198978|DRUG|Asparaginase|
214783839|NCT04713228|DEVICE|ARTSENS Pen|ARTerial Stiffness Evaluation for Noninvasive Screening
214783840|NCT02225028|BEHAVIORAL|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
214783841|NCT04444752|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
214783842|NCT04444752|DRUG|placebo|subcutaneous(SC) injection
214783843|NCT03625817|BEHAVIORAL|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having \>800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
214783844|NCT02543736|DEVICE|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
214783845|NCT05837598|BEHAVIORAL|Virtual Cancer and Mental Health Tumor Board|The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
214783846|NCT06427330|DRUG|Inotuzumab ozogamicin|"1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2"
214783847|NCT04460599|OTHER|Observation|Observation of recorded neurological signs
214783848|NCT05256732|DRUG|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
214783849|NCT05256732|OTHER|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
214783850|NCT05256732|DRUG|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
214783851|NCT05256732|OTHER|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
214783852|NCT05256732|DRUG|AT-527|AT-527 administered twice daily (BID)
214783853|NCT05256732|DRUG|AT-527 single dose|AT-527 single dose fasted/fed cross-over
214783854|NCT01347398|PROCEDURE|PSG|Sleep study made by PSG (polysomnography)
214783855|NCT01347398|PROCEDURE|MicroMESAM system|Sleep study made by MicroMESAM system
214783856|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
214783857|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
214783858|NCT01067859|DRUG|Placebo|Infusion of placebo during 48 hours
214783859|NCT06703905|PROCEDURE|Expanded pancreaticoduodenectomy surgery|Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
214783860|NCT06703905|PROCEDURE|Pancreaticoduodenectomy|Traditional minimally invasive pancreaticoduodenectomy
214783861|NCT01883518|BIOLOGICAL|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
214783862|NCT05756413|BEHAVIORAL|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
214783863|NCT05860712|OTHER|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
214783864|NCT05549128|DEVICE|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
214783865|NCT05549128|DEVICE|Photobiomodulation sham|The red laser (DMC) will be applied off. I
214783866|NCT04510220|DRUG|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
214783867|NCT04510220|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
214783868|NCT01416649|DRUG|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
214783869|NCT01823484|DEVICE|AN 69 ST hemofilter|
214783870|NCT01823484|DEVICE|AN 69 hemofilter|
214783871|NCT03256175|PROCEDURE|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
214783872|NCT06009900|DEVICE|Low intensity laser treatment|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
214783873|NCT06009900|DRUG|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
214783874|NCT00251628|OTHER|Standard Care|standard care
214783875|NCT00251628|OTHER|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
214783876|NCT00251628|OTHER|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
214783877|NCT00251628|OTHER|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
214783878|NCT02270983|DRUG|Linaclotide 145 micrograms|
214783879|NCT02270983|DRUG|Linaclotide 290 micrograms|
214783880|NCT02270983|DRUG|Placebo|Matching placebo
214783881|NCT02957786|DRUG|Cytisine|Cytisine tablets
214783882|NCT02957786|BEHAVIORAL|Behavioural support|Withdrawal-orientated cessation support
214783883|NCT02957786|DRUG|Varenicline|Varenicline tablets
214783884|NCT00124176|DRUG|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
214783885|NCT00124176|DRUG|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
214783886|NCT02926391|DEVICE|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
214783887|NCT03058939|DRUG|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
214783888|NCT03058939|DRUG|Perjeta|Only administered to patients with HER2-positive disease.
214783889|NCT03058939|DRUG|Herceptin SC|Only administered to patients with HER2-positive disease.
214783890|NCT03058939|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
214783891|NCT03058939|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
214783892|NCT03058939|DRUG|LHRH agonist|Administered to all premenopausal patients.
214783893|NCT03058939|DRUG|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
214783894|NCT03058939|DRUG|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
214783895|NCT00928252|DRUG|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
214783896|NCT02519283|BEHAVIORAL|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
214783897|NCT02519283|BEHAVIORAL|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up."
214783898|NCT05826249|DRUG|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
214783899|NCT01652118|DRUG|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
214783900|NCT01652118|DRUG|Saline|
214783901|NCT00381056|BEHAVIORAL|Labor and Delivery Team Coordination Course|
214783902|NCT04047212|DIAGNOSTIC_TEST|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
214783903|NCT04047212|DIAGNOSTIC_TEST|periodontal examination|Periodontal clinical examination to all by periodontal charting
214783904|NCT00526695|DRUG|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
214783905|NCT06215781|PROCEDURE|Fully digital workflow of prosthetic fixed dental crown|The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
214783906|NCT06215781|PROCEDURE|Combined digital and conventional workflows of prosthetic fixed dental crown|The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
214783907|NCT06215781|PROCEDURE|Fully conventional workflow of prosthetic fixed dental crown|The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
214783908|NCT01605461|DRUG|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
214783909|NCT00530400|DRUG|cefuroxime|preoperative intravenous 1.5g cefuroxime
214783910|NCT00530400|DRUG|placebo|preoperative intravenous placebo
214783911|NCT05730777|DRUG|Bifidobacterium Bifidum Oral Capsule|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
214783912|NCT05730777|DRUG|Cisplatin|Patients in the control group will receive conventional antitumor treatment only.
214783913|NCT05730777|DRUG|Carboplatin|Patients in the control group will receive conventional antitumor treatment only.
214783914|NCT05730777|DRUG|Paclitaxel|Patients in the control group will receive conventional antitumor treatment only.
214783915|NCT05730777|DRUG|Atlizumab|Patients in the control group will receive conventional antitumor treatment only.
214783916|NCT05611268|DRUG|Pentoxifylline|Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
214783917|NCT06090747|BEHAVIORAL|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
214783918|NCT06090747|BEHAVIORAL|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
214783919|NCT02024698|DEVICE|omafilcon A|contact lens
214783920|NCT02024698|DEVICE|etafilcon A|contact lens
214783921|NCT06504108|PROCEDURE|Calcium silicate-based sealer full Pulpotomy|Using calcium silicate-based sealer as a capping agent after full pulpotomy
214783922|NCT06504108|PROCEDURE|Calcium silicate-based premixed putty full Pulpotomy|Using calcium silicate-based premixed putty as a capping agent after full pulpotomy
214783923|NCT06504108|PROCEDURE|Full Pulpotomy|Using combination between calcium silicate-based sealer and calcium silicate-based premixed putty as a capping agent after full pulpotomy
214783924|NCT01285531|DEVICE|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
214783925|NCT06147219|PROCEDURE|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
214783926|NCT05079854|DRUG|Intraocular Instillation Solution|Intracameral Moxifloxacin 0.5%
214783927|NCT05079854|DRUG|Moxifloxacin Ophthalmic|Topical Moxifloxacin 0.5%
214783928|NCT04158856|DRUG|Pyrotinib|400mg po every day
214783929|NCT04158856|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
214783930|NCT06484192|DRUG|Naproxen 500 Mg|participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
214783931|NCT06484192|DRUG|Ketorolac|participants will receive Ketorolac (15 mg) immediately after surgery
214783932|NCT06484192|DRUG|OxyCODONE 5 mg Oral Tablet|participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
214783933|NCT06484192|DRUG|Metaxalone 800 MG|participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
214783934|NCT00331630|DRUG|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214783935|NCT00331630|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214783936|NCT03072836|OTHER|analysing microbiota|16SRNA gene sequencing of feces
214783937|NCT06541392|OTHER|breakfast 6.30 am|This group will have breakfast time from 6.30 to 7.30 am
214783938|NCT06541392|OTHER|breakfast 7.31 am|This group will have breakfast time from 7.31 to 8.31 am
214783939|NCT03501784|DEVICE|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
214783940|NCT03501784|DEVICE|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
214783941|NCT02764489|BIOLOGICAL|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
214783942|NCT03526367|DRUG|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
214783943|NCT03526367|DRUG|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
214783944|NCT04618835|DIAGNOSTIC_TEST|40-Steps-test|40 steps performed on the spot
214783945|NCT06064981|BEHAVIORAL|Text message nudges|"Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life)."
214783946|NCT06064981|BEHAVIORAL|Commitment contract|"In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone."
214783947|NCT00293670|DRUG|Goserelin (Zoladex)|
214783948|NCT02038634|DRUG|Betamethasone|
214783949|NCT02038634|DEVICE|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
214783950|NCT00693784|BIOLOGICAL|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
214783951|NCT00860106|OTHER|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
214783952|NCT01072032|DEVICE|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
214783953|NCT01664052|DEVICE|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
214783954|NCT01664052|DEVICE|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
214783955|NCT01664052|DEVICE|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
214783956|NCT01508585|BEHAVIORAL|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
214783957|NCT03336632|DRUG|Chidamide|20 mg orally, twice weekly from D-7 to D+14
214783958|NCT03336632|DRUG|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
214783959|NCT03336632|DRUG|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
214783960|NCT00326885|DRUG|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
214783961|NCT05141578|BEHAVIORAL|Luci Coach Assisted Intervention|"The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24."
214783962|NCT03649737|BEHAVIORAL|Exercise Intervention|Attend supervised and unsupervised exercise sessions
214783963|NCT03649737|OTHER|Survey Administration|Ancillary studies
214783964|NCT03649737|OTHER|Quality-of-Life Assessment|Ancillary studies
214783965|NCT01369251|BEHAVIORAL|Hygiene|
214783966|NCT01369251|PROCEDURE|Usual alcohol care|
214783967|NCT03651661|DRUG|human insulin|human insulin administered as nasal spray
214783968|NCT03651661|DRUG|placebo|placebo administered as nasal spray
214783969|NCT03651661|DIAGNOSTIC_TEST|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
214783970|NCT01706198|DRUG|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
214783971|NCT01706198|DRUG|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
214783972|NCT06524778|RADIATION|brachytherapy|Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
214783973|NCT02052128|DRUG|onapristone|
214783974|NCT03294083|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
214783975|NCT03294083|BIOLOGICAL|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
214783976|NCT05565183|DIAGNOSTIC_TEST|MRI (with injection of contrast product)|All patients included in the study will undergo two MRI examinations (with injection of contrast product) before and after the ablation procedure.
214783977|NCT05127811|DRUG|ZN-d5|BION design
214783978|NCT00950183|DEVICE|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
214783979|NCT00950183|OTHER|Ice|postoperative cold therapy
214783980|NCT02309554|OTHER|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
214783981|NCT02309554|OTHER|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
214783982|NCT02309554|OTHER|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
214783983|NCT04313283|BEHAVIORAL|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
214783984|NCT04014998|OTHER|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
214783985|NCT00411047|DRUG|gefitinib|oral drug taken daily around the same time
214783986|NCT04387747|OTHER|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
214783987|NCT00903890|OTHER|Survey|Survey asking questions regarding the subjects cardiac and general health.
214783988|NCT05731102|DIAGNOSTIC_TEST|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
214783989|NCT01374399|BEHAVIORAL|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
214783990|NCT03742674|OTHER|Follow up|No intervention
214783991|NCT04295460|DRUG|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
214783992|NCT04161794|OTHER|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
214783993|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
214783994|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
214783995|NCT04189276|BIOLOGICAL|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
214783996|NCT04189276|BIOLOGICAL|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
214783997|NCT02911389|OTHER|Home PT via web-based platform|
214783998|NCT02911389|OTHER|Home PT via paper manual|
214783999|NCT02911389|OTHER|outpatient PT|
214784000|NCT05299229|DIAGNOSTIC_TEST|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
214784001|NCT02415166|BIOLOGICAL|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
214784002|NCT02415166|OTHER|NaCl-saline placebo|placebo
214784003|NCT00463892|PROCEDURE|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
214784004|NCT06238492|BEHAVIORAL|game-like computerized activities|Experimental
214784005|NCT06238492|BEHAVIORAL|Placebo|game-like computerized activities
214784006|NCT03208348|OTHER|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
214784007|NCT00919958|BIOLOGICAL|PLX-PAD IM injection|Single treatment; multiple injections
214784008|NCT05028101|PROCEDURE|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
214784009|NCT05028101|BEHAVIORAL|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
214784010|NCT02099968|BEHAVIORAL|Comprehensive Lifestyle Modification|"* Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
214784011|NCT02099968|BEHAVIORAL|Standard Lifestyle Modification / modified DASH|"* Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation"
214784012|NCT02274467|DEVICE|Trans-catheter electric stimulation test|
214784013|NCT04044846|BEHAVIORAL|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
214784014|NCT01473758|DRUG|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
214784015|NCT01473758|DRUG|Placebo|tablet, od, oral administration in the morning after breakfast
214784016|NCT04497324|BIOLOGICAL|Convalescent plasma|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
214784017|NCT04749186|DEVICE|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
214784018|NCT05085314|PROCEDURE|Ngenuity digital 3D microscope|Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX
214784019|NCT05085314|PROCEDURE|Conventional microscope|Cataract surgery under topical anesthesia with a conventional microscope
214784020|NCT02517710|PROCEDURE|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
214784021|NCT04998643|DIAGNOSTIC_TEST|Muscle ultrasound to estimate lean body mass|The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
214784022|NCT03826381|DIAGNOSTIC_TEST|Magnetic resonance (MR) spectroscopy of the liver|Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
214784023|NCT03826381|DIAGNOSTIC_TEST|Fibroscan|Transient Elastography for Measurement of liver fibrosis.
214784024|NCT03826381|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
214784025|NCT03826381|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
214784026|NCT03826381|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
214784027|NCT03826381|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
214784028|NCT00717210|DRUG|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
214784029|NCT00717210|RADIATION|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
214784030|NCT01677910|DRUG|Telotristat etiprate|Telotristat etiprate tablets.
214784031|NCT01677910|DRUG|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
214784032|NCT05088512|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214784033|NCT01713712|BEHAVIORAL|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
214784034|NCT05517512|DIAGNOSTIC_TEST|Estimation of Protein 13|"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."
214784035|NCT00782236|DEVICE|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
214784036|NCT05434208|OTHER|Nurse-led telephonic calls|active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
214784037|NCT04221555|DRUG|Docetaxel, Oxaliplatin, S-1 and Durvalumab|"1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
214784038|NCT04221555|DRUG|Durvalumab and Tremelimumab|"1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment."
214784039|NCT02788123|DRUG|bismuth tripotassium dicitrate|oral
214784040|NCT02788123|DRUG|pantoprazole|oral
214784041|NCT01114113|DRUG|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
214784042|NCT01114113|DEVICE|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
214784043|NCT01114113|DEVICE|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
214784044|NCT01114113|DEVICE|SmartPill capsule|SmartPill capsule
214784045|NCT04051138|OTHER|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
214784046|NCT05499364|BEHAVIORAL|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
214784047|NCT05499364|BEHAVIORAL|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
214784048|NCT04229303|DRUG|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily \[BID\]) or 4 \[20mg BID\]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily \[QD\]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 \[20mg BID\] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
214784049|NCT04229303|DRUG|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
214784050|NCT02705079|OTHER|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
214784051|NCT02763579|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
214784052|NCT02763579|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214784053|NCT02763579|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214784054|NCT02763579|DRUG|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
214784055|NCT02254733|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
214784056|NCT02254733|OTHER|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
214784057|NCT00606684|DRUG|GW642444 6.25|GW642444 6.25
214784058|NCT00606684|DRUG|GW642444 3mcg|once daily
214784059|NCT00606684|DRUG|GW642444 12.5mcg|GW642444 12.5mcg
214784060|NCT00606684|DRUG|GW642444 25mcg|GW642444 25mcg
214784061|NCT00606684|DRUG|GW642444 50mcg|GW642444 50mcg
214784062|NCT00606684|OTHER|placebo|placebo
214784063|NCT01178359|DRUG|nitrite|
214784064|NCT05236075|DEVICE|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
214784065|NCT02144259|DRUG|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
214784066|NCT02144259|DRUG|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
214784067|NCT03760133|DRUG|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
214784068|NCT02537132|OTHER|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
214784069|NCT00943800|DRUG|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
214784070|NCT00943800|PROCEDURE|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
214784071|NCT00943800|PROCEDURE|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
214784072|NCT00943800|DRUG|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
214784073|NCT00943800|DRUG|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
214784074|NCT04264299|PROCEDURE|T tube drainage|closure of common bile duct over T tube
214784075|NCT04264299|PROCEDURE|Primary closure|Primary closure of common bile duct
214784076|NCT04264299|PROCEDURE|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
214784077|NCT02917200|DRUG|Moxifloxacin|Oral route
214784078|NCT02917200|DEVICE|DAV132|Oral route
214784079|NCT02917200|OTHER|Negative control|Oral route
214784080|NCT04368052|DIAGNOSTIC_TEST|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
214784081|NCT01882400|DRUG|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
214784082|NCT04014400|OTHER|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
214784083|NCT00586300|OTHER|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
214784084|NCT00586300|BEHAVIORAL|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
214784085|NCT00586300|OTHER|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
214784086|NCT01998685|DRUG|Propofol|
214784087|NCT01998685|DRUG|remifentanyl|
214784088|NCT01998685|DRUG|Midazolam|
214784089|NCT01998685|DRUG|Fentanyl|
214784090|NCT01998685|DRUG|Sevoflurane|
214784091|NCT02023632|BEHAVIORAL|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
214784092|NCT02023632|BEHAVIORAL|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
214784093|NCT02023632|BEHAVIORAL|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
214784094|NCT02684500|DEVICE|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
214784095|NCT01623661|OTHER|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
214784096|NCT01410383|DRUG|Placebo|Tablets taken daily
214784097|NCT01410383|DRUG|Eprotirome|Tablets taken daily
214784098|NCT01410383|DRUG|Eprotirome|Tablets taken daily
214784099|NCT03753997|BEHAVIORAL|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
214784100|NCT01451905|DRUG|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
214784101|NCT01451905|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
214784102|NCT04895618|DEVICE|Erchonia GVL|Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
214784103|NCT05652920|BIOLOGICAL|Ori-C101|Hepatic arterial infusion
214784104|NCT03974594|DRUG|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
214784105|NCT03974594|DRUG|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
214784106|NCT01900873|DEVICE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
214784107|NCT01900873|DEVICE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
214784108|NCT00410722|DIETARY_SUPPLEMENT|Whole wheat and bran muffin|
214784109|NCT00410722|DIETARY_SUPPLEMENT|Mixed tree nuts|
214784110|NCT06536712|BIOLOGICAL|Mesenchymal Stem Cells Derived Exosomes|Mesenchymal Stem Cells Derived Exosomes will be administered intraperitoneally to patients at the end of their surgery
214784111|NCT06536712|OTHER|Placebo|10 patients will receive intraperitoneal placebo at the end of their surgery
214784112|NCT02207647|OTHER|no intervention|
214784113|NCT00162383|DRUG|Debrisoquine|
214784114|NCT00162383|DRUG|Mephenytoin|
214784115|NCT00162383|DRUG|Dapsone|
214784116|NCT00162383|DRUG|Caffeine|
214784117|NCT01104233|DEVICE|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
214784118|NCT06113523|BIOLOGICAL|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
214784119|NCT03522584|BIOLOGICAL|Durvalumab|Given IV
214784120|NCT03522584|OTHER|Laboratory Biomarker Analysis|Correlative studies
214784121|NCT03522584|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214784122|NCT03522584|BIOLOGICAL|Tremelimumab|Given IV
214784123|NCT03522584|PROCEDURE|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
214784124|NCT00910858|DRUG|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
214784125|NCT00910858|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
214784126|NCT03040076|BEHAVIORAL|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
214784127|NCT03040076|BEHAVIORAL|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
214784128|NCT04625920|DEVICE|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
214784129|NCT02189694|DEVICE|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
214784130|NCT02189694|DEVICE|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
214784131|NCT02189694|DEVICE|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
214784132|NCT04169282|DEVICE|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
214784133|NCT02844374|OTHER|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
214784134|NCT00698022|DRUG|Risperidone|risperidone daily for 28 days
214784135|NCT00698022|DRUG|Mifepristone|mifepristone daily for 28 days
214784136|NCT00698022|DRUG|Risperidone-matched placebo|risperidone-matched placebo daily for 28 days
214784137|NCT00698022|DRUG|Mifepristone-matched placebo|mifepristone-matched placebo daily for 28 days
214784138|NCT01666886|DEVICE|Mandibular Advancement Device (MAD)|
214784139|NCT00621686|BIOLOGICAL|bevacizumab|
214784140|NCT00621686|DRUG|sorafenib tosylate|
214784141|NCT01703741|DRUG|Testosterone Gel (FE 999093)|
214784142|NCT04716114|DRUG|SKLB1028|SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
214784143|NCT04716114|DRUG|Salvage Chemotherapy|Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
214784144|NCT02269202|DRUG|Midazolam, tablet|
214784145|NCT02269202|DRUG|Crobenetine, i.v. infusion|
214784146|NCT02269202|DRUG|Placebo|
214784147|NCT01170364|DRUG|Sibutramine|1 week of active sibutramine (15mg)
214784148|NCT01170364|DRUG|Placebo|2 weeks of placebo
214784149|NCT01604213|DRUG|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
214784150|NCT01604213|DRUG|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
214784151|NCT01381900|DRUG|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
214784152|NCT01381900|DRUG|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
214784153|NCT01381900|DRUG|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
214784154|NCT01381900|DRUG|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
214784155|NCT01381900|DRUG|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
214784156|NCT02455700|DEVICE|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
214784157|NCT00002806|DRUG|lomustine|
214784158|NCT00002806|DRUG|procarbazine hydrochloride|
214784159|NCT00002806|DRUG|vincristine sulfate|
214784160|NCT00002806|RADIATION|low-LET photon therapy|
214784161|NCT06358352|DIETARY_SUPPLEMENT|Lutein / Zeaxanthin|lutein extract from lutein oral capsules
214784162|NCT06358352|BIOLOGICAL|Platelet rich fibrin|platelet rich fibrin extracted from patient's blood after centrifuging
214784163|NCT05947552|DRUG|Serum ferritin|Serum ferritin in CKD patients
214784164|NCT02222142|DRUG|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
214784165|NCT02056899|DRUG|Gabapentin|
214784166|NCT03027570|BEHAVIORAL|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
214784167|NCT03027570|BEHAVIORAL|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
214784168|NCT03027570|OTHER|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
214784169|NCT00774332|DRUG|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
214784170|NCT02244437|DRUG|Ibuprofen|
214784171|NCT02244437|DRUG|Acetaminophen|
214784172|NCT06528587|PROCEDURE|narrow diameter implant|Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
214784173|NCT02911883|DEVICE|Optical Coherence Tomography Angiography|
214784174|NCT01617733|DRUG|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
214784175|NCT02367053|DRUG|ZP4207|
214784176|NCT02367053|DRUG|Glucagon|
214784177|NCT00493753|PROCEDURE|Acupuncture|
214784178|NCT05661877|OTHER|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
214784179|NCT05661877|OTHER|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
214784180|NCT01137305|OTHER|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
214784181|NCT04927754|BEHAVIORAL|Behavioral guidance|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
214784182|NCT04927754|OTHER|Pain assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was assessed the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's pain during dental care.
214784183|NCT04927754|OTHER|Dental anxiety assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was evaluated the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's dental anxiety during treatment sessions.
214784184|NCT00892697|DRUG|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
214784185|NCT00892697|DRUG|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
214784186|NCT00892697|DRUG|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
214784187|NCT03189797|OTHER|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
214784188|NCT04450498|BIOLOGICAL|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects \> 2 years of age and have shown to be safe and immunogenic.
214784189|NCT04450498|BIOLOGICAL|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
214784190|NCT04244747|DEVICE|induction of labor by breast stimulation|
214784191|NCT04244747|DEVICE|induction of labor by catheter balloon|
214784192|NCT05777265|OTHER|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
214784193|NCT06379399|DRUG|Cetuximab|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;
214784194|NCT06379399|DRUG|Trifluridine/Tipiracil|"Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;"
214784195|NCT02833402|DEVICE|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
214784196|NCT02400320|DRUG|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
214784197|NCT02400320|DRUG|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
214784198|NCT02400320|OTHER|Saline|Saline
214784199|NCT04767789|DIETARY_SUPPLEMENT|NZ-GHMH-01|Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
214784200|NCT04767789|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
214784201|NCT05885230|PROCEDURE|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
214784202|NCT05885230|DRUG|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
214784203|NCT04945720|PROCEDURE|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
214784204|NCT04945720|DRUG|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
214784205|NCT03341273|DRUG|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
214784206|NCT03341273|OTHER|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
214784207|NCT03341273|DEVICE|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
214784208|NCT02558426|PROCEDURE|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
214784209|NCT02041494|DEVICE|Ventralight|
214784210|NCT02041494|DEVICE|Strattice|
214784211|NCT04558216|DRUG|Vonoprazan|20 mg tablets administered orally
214784212|NCT04558216|DRUG|Rifampin|600 mg (Two 300 mg capsules)
214784213|NCT00685919|DRUG|Carbidopa|200 mg every 6 hours for 5 doses given orally
214784214|NCT00685919|DRUG|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
214784215|NCT03435432|DIETARY_SUPPLEMENT|Glucose|Glucose drink
214784216|NCT03435432|DIETARY_SUPPLEMENT|Water|Control
214784217|NCT01717456|OTHER|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
214784218|NCT01717456|DIETARY_SUPPLEMENT|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
214784219|NCT01717456|DRUG|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
214784220|NCT01717456|BEHAVIORAL|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
214784221|NCT01717456|BEHAVIORAL|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
214784222|NCT01717456|BEHAVIORAL|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
214784223|NCT01717456|OTHER|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
214784224|NCT04872426|OTHER|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
214784225|NCT05311852|DIETARY_SUPPLEMENT|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
214784226|NCT05311852|DIETARY_SUPPLEMENT|Placebo|assumption of a placebo product 2 time/day for 8 weeks
214784227|NCT00800098|DRUG|herbal topical cream|
214784228|NCT02447510|PROCEDURE|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
214784229|NCT02447510|PROCEDURE|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
214784230|NCT02447510|PROCEDURE|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
214784231|NCT01857791|BEHAVIORAL|multidisciplinary, behavior modification|
214784232|NCT01844934|OTHER|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
214784233|NCT00149292|DRUG|LY2140023|
214784234|NCT00149292|DRUG|olanzapine|
214784235|NCT00149292|DRUG|placebo|
214784236|NCT05144620|DIAGNOSTIC_TEST|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
214784237|NCT06244303|DRUG|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)|Toothpaste, toothbrush \& mouthwash regime
214784238|NCT06244303|DRUG|manual toothbrush + Colgate dental cream|toothpaste + toothbrush
214784239|NCT02489890|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
214784240|NCT03139214|BEHAVIORAL|Parenting Intervention|
214784241|NCT04881955|DRUG|[14C]-Ecopipam|\[14C\]-Ecopipam
214784242|NCT00282555|DRUG|S-Tenatoprazole-Na (STU-Na)|
214784243|NCT00914797|DRUG|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
214784244|NCT05455749|DIETARY_SUPPLEMENT|holoBLG|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)
214784245|NCT01178983|DEVICE|surface electromyography|Surface electromyography (SEMG) telebiofeedback
214784246|NCT01178983|DEVICE|surface electromyography|conventional biofeedback
214784247|NCT05778370|DEVICE|Swept Source Optical Coherence Tomography(Topcon DRI Triton)|Topcon DRI Triton
214784248|NCT00275535|DRUG|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
214784249|NCT00275535|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
214784250|NCT00275535|DRUG|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
214784251|NCT00275535|DRUG|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
214784252|NCT00275535|DRUG|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
214784253|NCT05224921|OTHER|Not applicable (cohort study)|This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
214784254|NCT06539806|DRUG|Losartan 50mg Tab|The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
214784255|NCT00054015|DRUG|triapine|
214784256|NCT02438865|DRUG|Immediate instillation of intravesical chemotherapy-Epirubicin-|
214784257|NCT02438865|DRUG|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
214784258|NCT03818919|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
214784259|NCT03818919|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
214784260|NCT03818919|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
214784261|NCT03818919|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
214784262|NCT03818919|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
214784263|NCT03818919|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
214784264|NCT05541601|OTHER|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
214784265|NCT02964065|BIOLOGICAL|Live-Attenuated influenza Vaccine(LAIV)|
214784266|NCT02964065|BIOLOGICAL|Placebo|
214784267|NCT00184964|PROCEDURE|CT-scan, PET-scan|
214784268|NCT06118671|BEHAVIORAL|personalized lifestyle intervention by AI|The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
214784269|NCT03751020|BEHAVIORAL|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
214784270|NCT03751020|BEHAVIORAL|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
214784271|NCT03751020|OTHER|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
214784272|NCT00033631|RADIATION|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
214784273|NCT00033631|RADIATION|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
214784274|NCT01740492|DRUG|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
214784275|NCT01740492|DRUG|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
214784276|NCT01740492|OTHER|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
214784277|NCT02134691|BEHAVIORAL|Prolonged Exposure|
214784278|NCT02134691|BEHAVIORAL|Applied Relaxation|
214784279|NCT04938401|OTHER||
214784280|NCT05143086|OTHER|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
214784281|NCT05143086|OTHER|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
214784282|NCT05143086|OTHER|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
214784283|NCT05143086|OTHER|Placebo|Use 10 ml of mouthwash without fluoride
214784284|NCT00528879|DRUG|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
214784285|NCT00528879|DRUG|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
214784286|NCT00528879|DRUG|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
215030858|NCT04667689|BEHAVIORAL|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
215030859|NCT06959342|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS sessions on five consecutive days for 20 minutes.
214784287|NCT04438629|DRUG|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
214784288|NCT05347030|OTHER|Acupuncture|During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
214784289|NCT05347030|OTHER|Sham Acupuncture|During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
214784290|NCT06458725|DEVICE|Magnetic Resonance Imaging (MRI)|"\- Three MRI :~* two on an MR-Linac 1.5 Tesla (10 to 17 days apart)~* one on a standard 1.5 Tesla MRI"
214784291|NCT00109135|DRUG|taranabant|
214784292|NCT00307619|DRUG|topiramate|
214784293|NCT04537819|DRUG|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
214784294|NCT04537819|DRUG|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
214784295|NCT00078819|DRUG|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
214784296|NCT00078819|DRUG|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
214784297|NCT05602935|DRUG|Camrelizumab|200mg, intravenously, d1
214784298|NCT05602935|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
214784299|NCT05602935|PROCEDURE|Surgery|Surgery
214784300|NCT04656093|BEHAVIORAL|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
214784301|NCT04656093|BEHAVIORAL|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
214784302|NCT04656093|BEHAVIORAL|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
214784303|NCT04656093|BEHAVIORAL|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
214784304|NCT00956683|PROCEDURE|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
214784305|NCT00956683|PROCEDURE|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
214784306|NCT05693857|OTHER|Cardiovascular prevention guidelines|Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making
214784307|NCT00916422|BIOLOGICAL|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
214784308|NCT00916422|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
214784309|NCT04364724|OTHER|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
214784310|NCT03174041|DRUG|Midazolam|Single dose midazolam
214784311|NCT03174041|DRUG|GDC-0853|Multiple doses GDC-0853 for 6 days
214784312|NCT03174041|DRUG|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
214784313|NCT03174041|DRUG|Rosuvastatin|Single dose rosuvastatin
214784314|NCT03174041|DRUG|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
214784315|NCT03174041|DRUG|Simvastatin|Single dose simvastatin
214784316|NCT03174041|DRUG|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
214784317|NCT03174041|DRUG|GDC-0853|Single dose GDC-0853
214784318|NCT03174041|DRUG|Itraconazole|Multiple doses itraconazole for 6 days
214784319|NCT03174041|DRUG|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
214784320|NCT03473834|OTHER|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
214784321|NCT03473834|BEHAVIORAL|Medication|The control group will be received the normal medication from their doctor.
214784322|NCT01353924|BIOLOGICAL|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
214784323|NCT01353924|BIOLOGICAL|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
214784324|NCT05466513|OTHER|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
214784325|NCT00139490|BEHAVIORAL|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
215030860|NCT06959342|BEHAVIORAL|Inhibition Training|Computerized Training of inhibitory control (Go-/No-Go task with pictures of preferred alcohol) on five consecutive days.
215030861|NCT01395134|DEVICE|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
214784326|NCT00139490|BEHAVIORAL|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
214784327|NCT00139490|BEHAVIORAL|Control Group|Usual Care
214784328|NCT02908828|DIETARY_SUPPLEMENT|Calanus oil|
214784329|NCT02908828|DIETARY_SUPPLEMENT|placebo dietary oil|
214784330|NCT04000828|DEVICE|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
214784331|NCT00323609|PROCEDURE|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
214784332|NCT00323609|PROCEDURE|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
214784333|NCT01052805|PROCEDURE|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
214784334|NCT02217345|DRUG|Growth hormone|growth hormone, Genotropin (Pfizer)
214784335|NCT02217345|DRUG|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
214784336|NCT00267293|DRUG|Acetaminophen|Given for fever control 15mg/kg
214784337|NCT00267293|DRUG|Ibuprofen|Given for fever control 10 mg/kg
214784338|NCT03575182|OTHER|Gait retraining program|Supervised gait retraining with verbal and real-time visual feedback.
214784339|NCT04846218|DRUG|hCG|
214784340|NCT04846218|DRUG|Progesterone|
214784341|NCT04846218|DRUG|Triptorelin|
214784342|NCT01864473|OTHER|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
214784343|NCT05401331|DEVICE|Treadmilll|Hemodynamic changes before and after treadmill use
214784344|NCT05401331|OTHER|mask|mask
214784345|NCT00274144|DRUG|telmisartan 40 mg|
214784346|NCT00274144|DRUG|placebo 40 mg|
214784347|NCT02857725|DRUG|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214784348|NCT02857725|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214784349|NCT01204060|OTHER|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
214784350|NCT01204060|OTHER|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
214784351|NCT03108391|DEVICE|Ambu AuraGain|
214784352|NCT03108391|DEVICE|LMA Supreme|
214784353|NCT04382157|DRUG|Mablet 360 mg|Slow-released magnesium hydroxide
214784354|NCT04382157|DRUG|Placebo|Placebo
214784355|NCT05934279|DEVICE|Resistance Training|All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
214784356|NCT05221879|OTHER|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
214784357|NCT00164203|BEHAVIORAL|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
214784358|NCT00164203|BEHAVIORAL|School-based CBT|12 sessions, weekly
214784359|NCT00164203|BEHAVIORAL|activity control condition|weekly games \& activities x 12 weeks
214784360|NCT04607603|DRUG|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
214784361|NCT04607603|DRUG|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
214784362|NCT02844179|DRUG|HTBZ|
214784363|NCT05163379|OTHER|MOBILIZATION|EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
214784364|NCT06547879|BEHAVIORAL|Hypertension Self Management Program|The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
214784365|NCT01850303|DRUG|Pemetrexed|
214784366|NCT01850303|DRUG|Gemcitabine|
214784367|NCT01850303|DRUG|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
214784368|NCT06452823|PROCEDURE|Catheter Ablation|catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
214784369|NCT04926896|PROCEDURE|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
214784370|NCT04926896|PROCEDURE|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
214784371|NCT01222806|DEVICE|Repetitive Transcranial Magnetic Stimulation|
214784372|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
214784373|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
214784374|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
214784375|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
214784376|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
214784377|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
214784378|NCT00950599|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
214784379|NCT01514656|OTHER|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
214784380|NCT01514656|OTHER|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
214784381|NCT01514656|OTHER|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
214784382|NCT04863456|PROCEDURE|Total resection|Total resection of HIPA in a single surgery
214784383|NCT04863456|PROCEDURE|Staged resection|HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date
214784384|NCT04863456|PROCEDURE|Subtotal resection followed by stereotactic radiation therapy|HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
214784385|NCT03596918|BIOLOGICAL|Bleomycin Sulfate|Given IV
214784386|NCT03596918|OTHER|Laboratory Biomarker Analysis|Correlative studies
214784387|NCT03596918|OTHER|Quality-of-Life Assessment|Ancillary studies
214784388|NCT03596918|OTHER|Questionnaire Administration|Ancillary studies
214784389|NCT03596918|DRUG|Vincristine Sulfate|Given IV
214784390|NCT02930109|DRUG|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
214784391|NCT02930109|DRUG|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
214784392|NCT00907036|BIOLOGICAL|alemtuzumab|
214784393|NCT00907036|BIOLOGICAL|donor lymphocytes|
214784394|NCT00907036|DRUG|cyclosporine|
214784395|NCT00907036|DRUG|fludarabine phosphate|
214784396|NCT00907036|DRUG|melphalan|
214784397|NCT00907036|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214784398|NCT03364985|DRUG|DWP16001|DWP16001 tablets
214784399|NCT03364985|DRUG|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
214784400|NCT03364985|DRUG|Dapagliflozin|Forxiga®
214784401|NCT05499156|OTHER|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
214784402|NCT00751569|OTHER|blood donation|obtaining cord blood
214784403|NCT00971204|DEVICE|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
214784404|NCT05061667|PROCEDURE|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
214784405|NCT05061667|PROCEDURE|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
215030862|NCT00621283|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
215030863|NCT00775658|DRUG|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
214784406|NCT00971672|OTHER|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
214784407|NCT05750225|OTHER|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
214784408|NCT05750225|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
214784409|NCT05086081|DRUG|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
214784410|NCT05086081|DRUG|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
214784411|NCT02356081|OTHER|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
214784412|NCT02541695|BIOLOGICAL|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
214784413|NCT05244824|OTHER|Adaptation into Turkish, Examining The Reliability and Validity for People with RA|Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
214784414|NCT02436135|DRUG|Idelalisib|Idelalisib tablets administered orally for 24 weeks
214784415|NCT02436135|DRUG|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
214784416|NCT05207319|OTHER|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
214784417|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
214784418|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
214784419|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
214784420|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
214784421|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
214784422|NCT00700284|DRUG|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
214784423|NCT00700284|DRUG|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
214784424|NCT00218621|PROCEDURE|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
214784425|NCT02420899|DRUG|rosuvastatin|10mg/d or 20mg/d,po
214784426|NCT06356870|PROCEDURE|BMAC MIXED WITH ALLOGRAFT|Study group
214784427|NCT06356870|PROCEDURE|Cancellous bone from anterior iliac crest|Control group
214784428|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
214784429|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
214784430|NCT00512174|OTHER|BladderScan BVI 3000|
214784431|NCT02729194|DRUG|Pazopanib|
214784432|NCT02729194|OTHER|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
214784433|NCT01282827|DEVICE|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
214784434|NCT01282827|DEVICE|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
214784435|NCT05580926|BEHAVIORAL|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
214784436|NCT05580926|OTHER|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
214784437|NCT02372682|DEVICE|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
214784438|NCT00839020|PROCEDURE|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
214784439|NCT00839020|PROCEDURE|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
214784440|NCT03689140|BEHAVIORAL|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
214784441|NCT03689140|BEHAVIORAL|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
214784442|NCT03689140|BEHAVIORAL|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
214784443|NCT03227822|PROCEDURE|Short spot stenting|
214784444|NCT03227822|PROCEDURE|Long lesion stenting|
214784445|NCT03139565|BIOLOGICAL|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
214784446|NCT03139565|BIOLOGICAL|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
214784447|NCT06242522|OTHER|Telephone interview|Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
214784448|NCT00493363|DRUG|Artesunate|Artesunate 2 mg/kg/day for 7 days
214784449|NCT00493363|DRUG|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
214784450|NCT00274755|DRUG|chemotherapy|
214784451|NCT00274755|PROCEDURE|conventional surgery|
215030864|NCT00775658|DRUG|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
215030865|NCT03502681|DRUG|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"
215030866|NCT03502681|DRUG|Avelumab|Days 1, 15 Avelumab (10mg/kg)
214784452|NCT00274755|PROCEDURE|magnetic resonance imaging|
214784453|NCT00274755|PROCEDURE|magnetic resonance spectroscopic imaging|
214784454|NCT00274755|RADIATION|radiation therapy|
214784455|NCT03568825|PROCEDURE|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
214784456|NCT05535712|DEVICE|Lung Anatomic Resection (Da Vinci SP)|To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
214784457|NCT05521490|OTHER|Usual Care Control|30 minutes of physical activity on each school day.
214784458|NCT05521490|BEHAVIORAL|Physical Activity Enhanced Curriculum|Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
214784459|NCT04567199|OTHER|Observational, retrospective|retrospective analysis of observed results, for both study groups.
214784460|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
214784461|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
214784462|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
214784463|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
214784464|NCT03803085|BEHAVIORAL|Control condition|Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
214784465|NCT03803085|BEHAVIORAL|Treatment condition|Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
214784466|NCT03826485|DRUG|PRIC|Pranlukast hydrate 50mg
214784467|NCT03826485|DRUG|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
214784468|NCT02118753|DRUG|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
214784469|NCT04073693|DIETARY_SUPPLEMENT|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
214784470|NCT03154528|DIAGNOSTIC_TEST|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
214784471|NCT02996435|BEHAVIORAL|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
214784472|NCT02996435|OTHER|No Intervention|Participants will receive physician- or nurse-guided standard of care.
215030867|NCT06333106|OTHER|POCUS diagnostic value|Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room
215030868|NCT03720366|DRUG|enasidenib|enasidenib
215030869|NCT03720366|DRUG|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
215030870|NCT03720366|DRUG|Arm 2 Probes|digoxin and rosuvastatin
215030871|NCT03720366|DRUG|Arm 3 probes|pioglitazone
214784473|NCT03850054|PROCEDURE|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
214784474|NCT02023502|OTHER|collection of urine and blood sample|
214784475|NCT02085707|PROCEDURE|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
214784476|NCT02085707|PROCEDURE|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
214784477|NCT02076191|DRUG|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
214784478|NCT02076191|DRUG|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
214784479|NCT05085860|BEHAVIORAL|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
214784480|NCT05085860|BEHAVIORAL|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
214784481|NCT05326152|BIOLOGICAL|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
214784482|NCT05326152|BIOLOGICAL|Intralesional saline|Intralesional saline
214784483|NCT03216200|DEVICE|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
214784484|NCT06536842|OTHER|Postoperative Drain Placement|These drains will be placed with the intention to decrease the incidence of postoperative hematoma
214784485|NCT06536842|OTHER|No Postoperative Drain Placement|Participant will undergo lumbar spine fusion surgery and will not receive a postoperative drain
214784486|NCT04056507|PROCEDURE|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
214784487|NCT01987700|DEVICE|FLEX-HD|
214784488|NCT01987700|DEVICE|Strattice|
214784489|NCT00069407|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy
214784490|NCT05297071|DEVICE|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
214784491|NCT05297071|DEVICE|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
214784492|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
214784493|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
214784494|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
214784495|NCT05798858|DIAGNOSTIC_TEST|NIPT|universal nipt in group a, NIPT for intermediate risk in Group B
214784496|NCT05743790|DIETARY_SUPPLEMENT|RS2-control-RS4|Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
214784497|NCT05743790|DIETARY_SUPPLEMENT|RS4-control-RS2|Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
214784498|NCT01407679|DRUG|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
214784499|NCT03615456|PROCEDURE|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
214784500|NCT03615456|PROCEDURE|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
214784501|NCT03124485|PROCEDURE|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
214784502|NCT03124485|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
214784504|NCT01696383|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
214784505|NCT04922398|BIOLOGICAL|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
214784506|NCT04922398|DRUG|Normal saline|0.9% normal saline will be injected in each ovary
214784507|NCT04921683|DEVICE|BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation|"Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total \~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA \<= 190W/cm2, ISPTA \<= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface."
214784508|NCT03221439|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
214784509|NCT03221439|OTHER|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
214784510|NCT03348046|DRUG|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
214784511|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
214784512|NCT01684722|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214784513|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D3 placebo
214784514|NCT01684722|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214784515|NCT05953922|OTHER|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
214784516|NCT06527495|DRUG|Sorafenib|Sorafenib Tablets (200 -400 mg) twice daily
214784517|NCT02168075|DRUG|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
214784518|NCT02168075|DRUG|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
214784519|NCT02168075|DRUG|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
214784520|NCT02168075|DRUG|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
214784521|NCT03256383|DEVICE|Lead testing|Fingerstick
214784522|NCT04490083|PROCEDURE|Extra corporeal shock wave lithotripsy|ESWL will be performed with a third generation electromagnetic lithotripter (Delta Compact, Dornier Med Tech, Germany) This has both fluoroscopy and ultrasound imaging facility. Radio opaque calculi will be targeted directly while a naso pancreatic tube (NPT) was placed for all radiolucent calculi and contrast was passed through this to localize the calculi. Between 5000 and 6000 shocks were delivered per session with frequency of 90 shocks per minute. The aim will be to fragment the calculi to \<3 mm or demonstrate a decrease in heterogeneity or density of the calculi in the main pancreatic duct. Shocks will be delivered on consecutive days till fragmentation is achieved. If there is no fragmentation after four sessions of ESWL the procedure will be labeled as unsuccessful and patient will be advised surgery. Procedures will be performed under epidural anesthesia.
214784523|NCT04148183|DRUG|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
214784524|NCT04148183|DRUG|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
214784525|NCT04148183|DRUG|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
214784526|NCT02964897|BEHAVIORAL|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
214784527|NCT02964897|BEHAVIORAL|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
214784528|NCT01559974|DRUG|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
214784529|NCT01559974|DRUG|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
214784530|NCT04302766|DRUG|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
214784531|NCT01002157|DIETARY_SUPPLEMENT|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
214784532|NCT01002157|OTHER|Placebo capsules|Capsules containing no Menaquinone-7
214784533|NCT00912470|PROCEDURE|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
214784534|NCT02345486|OTHER|0.9% sodium chloride|
214784535|NCT02345486|OTHER|Physiologically balanced fluid|
214784536|NCT00863057|DRUG|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
214784537|NCT00863057|DRUG|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
214784538|NCT00863057|DRUG|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
214784539|NCT00863057|DRUG|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
214784540|NCT03163095|DEVICE|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
214784541|NCT03163095|OTHER|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
214784542|NCT03979677|BEHAVIORAL|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
214784543|NCT05507554|DRUG|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
214784544|NCT05507554|DRUG|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
215030872|NCT05495438|OTHER|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
215030873|NCT02724241|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
214784545|NCT05507554|DRUG|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
214784546|NCT04317833|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
214784547|NCT04317833|DRUG|Placebo|matched placebo
214784548|NCT01919957|OTHER|No intervention|
214784549|NCT04351282|RADIATION|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
214784550|NCT05578573|DEVICE|KARAHOC device|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.
214784551|NCT05578573|DEVICE|Angiocatheter|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
214784552|NCT06189183|RADIATION|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
214784553|NCT01637311|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
214784554|NCT01945099|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
214784555|NCT01945099|DRUG|hyaluronidase|
214784556|NCT01945099|DRUG|Lispro-PH20|
214784557|NCT02517359|DRUG|RV6153 single dose|Safety and tolerability of single doses
214784558|NCT02517359|DRUG|RV6153 matching placebo single dose|Safety and tolerability of single doses
214784559|NCT02517359|DRUG|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
214784560|NCT02517359|DRUG|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
214784561|NCT02517359|DRUG|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
214784562|NCT02517359|DRUG|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
214784563|NCT03910803|DRUG|Brodalumab|"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."
214784564|NCT04586790|DRUG|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
214784565|NCT04586790|DRUG|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
214784566|NCT04586790|DRUG|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
214784567|NCT03063632|BIOLOGICAL|Interferon Gamma-1b|Given SC
214784568|NCT03063632|OTHER|Laboratory Biomarker Analysis|Ancillary studies
214784569|NCT03063632|BIOLOGICAL|Pembrolizumab|Given IV
214784570|NCT03295799|OTHER|Patient Self-Management|Patient will manage their own warfarin therapy.
214784571|NCT04340232|DRUG|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
214784572|NCT05511285|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
214784573|NCT00927888|DRUG|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
214784574|NCT00927888|DRUG|Placebo|placebo is identical in appearance in comparison to active drug.
214784575|NCT00299585|PROCEDURE|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
214784576|NCT03952156|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
214784577|NCT03952156|GENETIC|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
214784578|NCT00686478|DRUG|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
214784579|NCT02741271|DRUG|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
214784580|NCT02741271|DRUG|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
214784581|NCT02741271|DRUG|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
214784582|NCT02741271|DRUG|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
214784583|NCT02741271|DRUG|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
214784584|NCT01612156|DRUG|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
214784585|NCT01612156|DRUG|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
214784586|NCT00062556|DRUG|Niacin Extended Release and Lovastatin Tablets|
214784587|NCT04656015|DEVICE|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~* Regional or global myocardial signal intensity increase in T2-weighted images~* Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~* There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
214784588|NCT03799978|DRUG|ACT-541468|ACT-541468 50 mg film-coated tablets
214784589|NCT02570165|DRUG|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
214784590|NCT02570165|DRUG|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
214784591|NCT02570165|DRUG|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
215030874|NCT02724241|OTHER|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
214784592|NCT00794326|DRUG|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
214784593|NCT03988725|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800 IU once daily
215030875|NCT02724241|OTHER|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
214784594|NCT05340556|GENETIC|Blood sample|Blood sample of 12 ml EDTA plasma.
214784595|NCT05340556|GENETIC|Swap test|receive swab tests for collecting cells from the oral mucosa
214784596|NCT03121781|OTHER|respiratory support- interface|change interface to RAM cannula
214784597|NCT03121781|OTHER|respiratory support- interface|change interface to binasal prongs
214784598|NCT05796622|BEHAVIORAL|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIVST-Chatbot
214784599|NCT05796622|BEHAVIORAL|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIVST-OIC
214784600|NCT02451969|BIOLOGICAL|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
214784601|NCT02451969|BIOLOGICAL|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
214784602|NCT04274088|PROCEDURE|Cataract surgery|Phacoemulsification surgery
214784603|NCT04007588|DRUG|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
214784604|NCT04007588|DRUG|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
214784605|NCT04007588|DRUG|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
214784606|NCT01384864|DRUG|proflavine|2-6 ml of 0.01% proflavine
214784607|NCT03956667|OTHER|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
214784608|NCT01430104|DRUG|Teriparatide|Administered subcutaneously during the Treatment Period
214784609|NCT01430104|DRUG|Aspara-CA 600 mg|Administered orally throughout the study
214784610|NCT01430104|DRUG|Alfarol 1.0 µg|Administered orally throughout the study
214784611|NCT00091182|DRUG|oxaliplatin|Given IV
214784612|NCT03627182|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
214784613|NCT03627182|DRUG|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
214784614|NCT00821457|DRUG|Juvista|250ng
214784615|NCT00821457|DRUG|Placebo|Powder for solution for injection
214784616|NCT00821457|DRUG|Juvista|500ng
214784617|NCT00879424|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
214784618|NCT00879424|DIETARY_SUPPLEMENT|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
214784619|NCT03545529|OTHER|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
214784620|NCT04484922|DRUG|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
214784621|NCT04484922|DRUG|Normal saline|continuous infusion of normal saline during the surgery
214784622|NCT06545058|PROCEDURE|Penile block|Penile block with local anesthetics
214784623|NCT04360603|DEVICE|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
214784624|NCT04360603|DEVICE|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
214784625|NCT05951517|DRUG|MMF|MMF treat refractory gastrointestinal Henoch-Schönlein purpura
214784626|NCT01001871|DIETARY_SUPPLEMENT|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
214784627|NCT01001871|DIETARY_SUPPLEMENT|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
214784628|NCT04396470|DEVICE|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
214784629|NCT03279484|DEVICE|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
214784630|NCT05658289|PROCEDURE|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
214784631|NCT05658289|PROCEDURE|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
214784632|NCT04238780|PROCEDURE|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
214784633|NCT04238780|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
215030876|NCT04371055|OTHER|7-day Holter ECG|7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
215030877|NCT04371055|OTHER|Implantable cardiac monitor|Continuous rhythm monitoring using an implantable cardiac monitor
214784634|NCT02850445|DRUG|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
214784635|NCT02850445|OTHER|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
214784636|NCT02850445|OTHER|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
214784637|NCT02850445|OTHER|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
214784638|NCT05140018|PROCEDURE|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
214784639|NCT05140018|COMBINATION_PRODUCT|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
214784640|NCT05140018|PROCEDURE|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
214784641|NCT05559294|BEHAVIORAL|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
214784642|NCT05559294|BEHAVIORAL|Education and care as Usual (ECAU)|Active control
214784643|NCT03629847|DRUG|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
214784644|NCT06182683|DIAGNOSTIC_TEST|optical coherence tomography and fractional flow reserve|The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.
214784645|NCT06182683|DIAGNOSTIC_TEST|Coronary angiography|The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography
214784646|NCT05478603|DRUG|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
214784647|NCT05578222|DRUG|Pembrolizumab|Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
214784651|NCT04049695|BEHAVIORAL|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
214784652|NCT04049695|BEHAVIORAL|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
214784653|NCT00533520|DRUG|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
214784654|NCT02472977|DRUG|Ulocuplumab|
214784655|NCT02472977|DRUG|Nivolumab|
214784656|NCT00072033|DRUG|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
214784657|NCT04525690|BEHAVIORAL|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
214784658|NCT06547853|BEHAVIORAL|Physical exercise|Groups will be enrolled in a 12-week exercise program. The intervention will be carried out in a highly complex oncology center in Maceió-AL, using the FITT components of the prescription: frequency (4 days a week), intensity (aerobic part through musical beats, subjective perception scale and resistance exercises through a number of maximum repetitions), the time of each session will be 45 minutes, the type of activity offered will be combined exercise training and aerobic exercise training (i.e., walking).
214784659|NCT05091814|RADIATION|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
214784660|NCT04875156|OTHER|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
214784661|NCT02158910|DRUG|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
214784662|NCT01893866|DRUG|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
214784663|NCT01893866|DRUG|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
214784664|NCT02590978|PROCEDURE|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
214784665|NCT02590978|PROCEDURE|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
214784666|NCT01439841|DIETARY_SUPPLEMENT|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
214784667|NCT01439841|DIETARY_SUPPLEMENT|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
214784668|NCT03185299|OTHER|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
214784669|NCT03185299|OTHER|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
214784670|NCT05826769|DIETARY_SUPPLEMENT|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
214784671|NCT05884138|OTHER|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
214784672|NCT03805178|DRUG|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
214784673|NCT03805178|DRUG|Carfilzomib|20mg/m2 Plasmapheresis
214784674|NCT04309955|PROCEDURE|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
214784675|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
214784676|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
214784677|NCT02475967|OTHER|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
214784678|NCT02475967|OTHER|Control group|The control group patients receive conventional cardiac care alone.
214784679|NCT01618773|DRUG|0.1% adapalene / 2.5% benzoyl peroxide|topical application
214784680|NCT05103488|OTHER|Comprehensive palliative care|CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
214784681|NCT05103488|OTHER|Standard of care|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
214784682|NCT06539065|DEVICE|VR interactive games|The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
214784683|NCT04890704|DRUG|Curcuminoid|Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
214784684|NCT04890704|DRUG|Placebo|Identical capsules were used for the placebo from the same manufacturer.
214784685|NCT03182686|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
214784686|NCT03182686|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
214784687|NCT00757666|DEVICE|Rate adaptive pacemaker|Accelerometer sensor
214784688|NCT00757666|DEVICE|Rate adaptive pacemaker|Minute ventilation sensor
214784689|NCT01783925|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
214784690|NCT04672057|OTHER|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
214784691|NCT00524875|DRUG|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
214784692|NCT03483844|DIAGNOSTIC_TEST|GE CT 750 HD|Low-dose dual-energy CT imaging
214784693|NCT03271463|BEHAVIORAL|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
214784694|NCT01025193|DRUG|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
214784695|NCT03833453|BEHAVIORAL|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
214784696|NCT03833453|BEHAVIORAL|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
214784697|NCT06528327|OTHER|Pre coated impants|Pre coated impants with microstructured bioactive antimicrobial coating with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
214784698|NCT06528327|OTHER|Non coated implant surface|Non-coated implant with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
214784699|NCT02378506|BIOLOGICAL|etanercept|50mg subcutaneous, once weekly, 24 weeks
214784700|NCT02431884|PROCEDURE|collect body fluids/tissues & med history|collect tissues/fluids \& history
214784701|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
214784702|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
214784703|NCT00176683|PROCEDURE|Capnography|device which measures carbon dioxide at intubation
214784704|NCT01606137|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
214784705|NCT04522011|OTHER|intraoperative or postoperative hyperthermic intraperitoneal chemotherapy|Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
214784706|NCT01999387|DIETARY_SUPPLEMENT|Allergenic food|
214784707|NCT03571854|DEVICE|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
214784708|NCT03571854|DEVICE|Group VCV|Volume controlled ventilation
214784709|NCT03281434|DIETARY_SUPPLEMENT|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
214784710|NCT03281434|DIETARY_SUPPLEMENT|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
214784711|NCT00012584|DRUG|methylphenidate|
214784712|NCT00012584|DRUG|fluvoxamine|
215030878|NCT04371055|OTHER|Standard of care|Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
214784713|NCT04582097|DRUG|Ramipril|angiotensin-converting enzyme inhibitor
214784714|NCT04582097|DRUG|placebo|same odor, color and size as the drug but without the active ingredient
214784715|NCT01004484|OTHER|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
214784716|NCT01004484|OTHER|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
214784717|NCT01321112|DRUG|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
214784718|NCT00355069|BEHAVIORAL|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
214784719|NCT06528223|DIAGNOSTIC_TEST|biopsy or operation|To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
215030879|NCT06790303|DRUG|Feladilimab|Feladilimab will be administered.
214784720|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
214784721|NCT01575119|BEHAVIORAL|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
214784722|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
214784723|NCT01575119|BEHAVIORAL|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
214784724|NCT05704218|BIOLOGICAL|blood sample|the patient will have a blood sample in order to perform serology tests
214784725|NCT02266706|DRUG|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
214784726|NCT02266706|DRUG|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
214784727|NCT02266706|DRUG|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
214784728|NCT02266706|DRUG|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
214784729|NCT02266706|DRUG|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
214784730|NCT03349918|BEHAVIORAL|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
214784731|NCT02544633|DRUG|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
214784732|NCT01977352|DRUG|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
214784733|NCT01977352|DRUG|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
214784734|NCT04933578|BEHAVIORAL|Dental anxiety scales|"* The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (\>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25."
214784735|NCT02115685|OTHER|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
214784736|NCT04549909|OTHER|collect retrospectively data|Analyse the incidence of BPL in these populations
214784737|NCT03066154|DRUG|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
214784738|NCT03066154|DRUG|androgen deprivation therapy|ADT according to the standard of care
214784739|NCT03066154|RADIATION|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
214784740|NCT05559216|OTHER|Plyometric Training|Plyometric training exercises are being given to the participants to see the changes after the 8 week period
214784741|NCT00677924|DRUG|Zalutumumab|Solution for infusion
214784742|NCT02468479|OTHER|No relevant intervention.|No relevant intervention.
214784743|NCT04859855|PROCEDURE|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
214784744|NCT04859855|PROCEDURE|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
214784745|NCT02872181|PROCEDURE|Supine|Placed in Supine position
214784746|NCT02872181|PROCEDURE|Left uterine displacement|Placed in 15 degrees left uterine displacement
214784747|NCT00208910|BEHAVIORAL|Odorant Cue|
214784748|NCT01904578|OTHER|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
214784749|NCT01904578|OTHER|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
214784750|NCT02754323|DEVICE|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
214784751|NCT04401319|DEVICE|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
214784752|NCT04401319|DEVICE|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
215030880|NCT06790303|DRUG|Ipilimumab|Ipilimumab will be administered
215030881|NCT06497140|DRUG|Ethiodized Oil-based emulsion|Embolization of genicular arteries
214784753|NCT04401319|DEVICE|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
214784754|NCT04401319|DEVICE|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
214784755|NCT04401319|DEVICE|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
214784756|NCT04401319|DEVICE|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
214784757|NCT05697484|DEVICE|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
214784758|NCT02732587|DRUG|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
214784759|NCT03695133|BEHAVIORAL|Group-based interventions|"1. Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~2. Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
214784760|NCT06205199|DRUG|Hydromorphone was injected into the subarachnoid space|The dose of hydromorphone is 50 micrograms
214784761|NCT02257632|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
214784762|NCT02257632|DRUG|Aflibercept 2 mg|Administered as an intravitreal injection
214784763|NCT06401200|OTHER|bar retained implant overdenture|use of bar attachment in completely edentulous patient
214784764|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
214784765|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
214784766|NCT05640310|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
214784767|NCT01080027|DRUG|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
214784768|NCT06382779|PROCEDURE|reverse shoulder arthroplasty|resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty
214784769|NCT05403021|BEHAVIORAL|GETCare Intervention|This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
214784770|NCT03739359|OTHER|nasal cannula gas flow|High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
214784771|NCT01063478|DRUG|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
214784772|NCT00000695|DRUG|Interferon beta-1b|
214784773|NCT00000695|DRUG|Zidovudine|
214784774|NCT04963465|DIAGNOSTIC_TEST|Ferning on microscopy|Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
214784775|NCT00242762|DRUG|ZD1839 (IRESSA™)|
214784776|NCT00242762|DRUG|Docetaxel|
214784777|NCT00242762|DRUG|Cisplatin|
214784778|NCT03876574|PROCEDURE|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
214784779|NCT03876574|DRUG|Gemcitabine|Given intra-arterially for 30 minutes
214784780|NCT03876574|DRUG|Floxuridine|Given intra-arterially continuously for 14 days
214784781|NCT03876574|DRUG|dexamethasone|Given intra-arterially continuously with 5-FUDR
214784782|NCT01773512|DRUG|Rosuvastatin|All patients will be using rosuvastatin 40 mg
214784783|NCT01059071|DRUG|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
214784784|NCT01059071|DRUG|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
214784785|NCT00171496|DRUG|Cyclosporine microemulsion|
214784786|NCT00171496|DRUG|Tacrolimus|
214784787|NCT02673164|BIOLOGICAL|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
214784788|NCT01536691|DRUG|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
215030882|NCT06497140|PROCEDURE|Sham-operation|Mimicked catheterization and embolization of genicular arteries
215030883|NCT03413995|DRUG|Rucaparib|Continuous dosing
215030884|NCT06481423|BEHAVIORAL|dCBT-I|A digital cognitive behavioral intervention course that addresses multiple aspects such as basic sleep knowledge, sleep hygiene, sleep behaviors, improving negative cognition, and improving emotions. The intervention is delivered through video, audio, and text formats.
214784789|NCT01536691|DRUG|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
215030885|NCT06481423|BEHAVIORAL|Relaxing music|Participants can freely listen relaxing music
214784790|NCT01092520|DRUG|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
214784791|NCT00826631|PROCEDURE|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
214784792|NCT02909725|OTHER|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
215030886|NCT05845307|DRUG|Control Group|Given by PO
215030887|NCT05845307|DRUG|TTI-101|Given by PO
214784793|NCT02909725|OTHER|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
214784794|NCT02909725|OTHER|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
214784795|NCT03763331|DEVICE|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
214784796|NCT03763331|DEVICE|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
214784797|NCT05482672|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
214784798|NCT05482672|BEHAVIORAL|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
214784799|NCT05482672|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
214784800|NCT05482672|BEHAVIORAL|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
214784801|NCT02958540|BIOLOGICAL|SynGEM|Prime / boost vaccination in each group
214784802|NCT02958540|OTHER|placebo|prime /boost vaccination
214784803|NCT03654534|DIETARY_SUPPLEMENT|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
214784804|NCT00936884|DRUG|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
214784805|NCT00936884|DRUG|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
214784806|NCT04741503|OTHER|Breast Cancer Screening Decision Support Tool|-Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
214784807|NCT04741503|OTHER|National Cancer Institute Breast Cancer Screening PDQ|-Provides current information about breast cancer screening and is meant to inform and help patients
214784808|NCT05703555|DRUG|Tusamitamab ravtansine|Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
214784809|NCT00217412|DRUG|vorinostat|Given orally
214784810|NCT00217412|DRUG|isotretinoin|Given orally
214784811|NCT05974410|DRUG|AVM0703|small molecule immunomodulatory drug
214784812|NCT05974410|DRUG|Hydrocortisone|physiologic circadian glucocorticoid
214784813|NCT05974410|DRUG|Proton pump inhibitor|
214784814|NCT02241681|DIETARY_SUPPLEMENT|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
214784815|NCT05658614|BIOLOGICAL|Sm14 recombinant vaccine+ GLA-SE adjuvant|rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
214784816|NCT05480618|BEHAVIORAL|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~1. frequency (between 0.25 and 0.1 Hz)~2. Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~3. with and without ujjayi (yogic throat restriction)~4. with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
214784817|NCT02280421|DRUG|ASP2151 400mg + 100mg ciclosporin|
214784818|NCT02280421|DRUG|ASP2151 1200mg + 100mg ciclosporin|
214784819|NCT02797964|DRUG|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
214784820|NCT01859390|DRUG|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
214784821|NCT01859390|DIETARY_SUPPLEMENT|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
214784822|NCT04022070|OTHER|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
214784823|NCT04733352|OTHER|acupuncture|to conduct acupuncture on different acupoints
214784824|NCT01088152|BEHAVIORAL|Celiac school|Structured education of adult celiac patients at 10 sessions.
214784825|NCT01088152|BEHAVIORAL|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
214784826|NCT00840359|PROCEDURE|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
214784827|NCT00840359|PROCEDURE|Cryotherapy|Cryotherapy for 2 times 20 sec
214784828|NCT02057952|BEHAVIORAL|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
214784829|NCT04868409|DRUG|Suxamethonium|1 mg/kg for tracheal intubation after 60 seconds
214784830|NCT04868409|DRUG|Rocuronium|1 mg/kg for tracheal intubation after 60 seconds
214784831|NCT05165251|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
214784832|NCT05165251|DRUG|Amlodipine 5mg|amlodipine 5mg QD
214784833|NCT05165251|OTHER|Lifestyle intervention|Lifestyle intervention
214784834|NCT01567371|DEVICE|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
214784835|NCT02604069|DEVICE|Continuous Glucose Monitor|
214784836|NCT04460989|PROCEDURE|arthroplasty|total knee replacement
214784837|NCT05874869|DRUG|Dihydroartemisinin-piperaquine|The drug will be administered once a day for three consecutive days for three months (March, April, and May)
214784838|NCT03432299|PROCEDURE|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
214784839|NCT02982382|OTHER|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
214784840|NCT02982382|OTHER|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
214784841|NCT02982382|OTHER|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
214784842|NCT02888769|BEHAVIORAL|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
214784843|NCT04881526|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
214784844|NCT04881526|DIETARY_SUPPLEMENT|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
214784845|NCT03599310|BEHAVIORAL|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
214784846|NCT03599310|BEHAVIORAL|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
214784847|NCT01275313|DEVICE|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
214784848|NCT01275313|DEVICE|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
214784849|NCT06240962|OTHER|Strength Training|They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
214784850|NCT06240962|OTHER|Mindfulness Exercise|They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
214784851|NCT05547230|OTHER|questionnaires|The same tests will be applied to all participants in an objective way.
214784852|NCT04520035|DRUG|camrelizumab|Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
214784853|NCT04520035|DRUG|Paclitaxel|Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
214784854|NCT04520035|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy
214784855|NCT03215485|BEHAVIORAL|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
214784856|NCT03215485|BEHAVIORAL|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
214784857|NCT03215485|OTHER|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
214784858|NCT03790085|DRUG|Risperidone|Risperidone tablet
214784859|NCT03790085|DRUG|Olanzapine|Olanzapine tablet
214784860|NCT03790085|DRUG|Aripiprazole|Aripiprazole tablet
214784861|NCT03154320|OTHER|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
214784862|NCT03154320|OTHER|Standard treatment|Standard treatment
214784863|NCT01682174|OTHER|Control Drink|
214784864|NCT01682174|OTHER|Experimental Drink|
214784865|NCT05893212|BEHAVIORAL|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
214784866|NCT05893212|BEHAVIORAL|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
214784867|NCT04634110|DRUG|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
214784868|NCT05057195|RADIATION|Interstitial radiation therapy|From 30 to 50 Gy,
214784869|NCT05057195|RADIATION|Postoperative external beam therapy|50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
214784870|NCT03807323|BEHAVIORAL|Lifestyle counselling and exercise|"The program consists of:~1. Instructor-led training twice a week,~2. One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~3. Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
214784871|NCT04709900|DIAGNOSTIC_TEST|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
214784872|NCT03411590|OTHER|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
214784873|NCT05575960|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents (IPT-A)|Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
214784874|NCT02965820|DEVICE|Opti-Free® PureMoist® contact lens solution|
214784875|NCT02965820|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
214784876|NCT02965820|DEVICE|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
214784877|NCT02229240|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
214784878|NCT02229240|DRUG|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
214784879|NCT00309075|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
214784880|NCT05638152|OTHER|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~* natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~* Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~* Music available to patients~* Comfort Talk communication course for PACU nurses"
214784881|NCT01694615|PROCEDURE|Cryoprobe biopsy|
214784882|NCT01694615|PROCEDURE|Forceps Biopsy|
214784883|NCT00914433|DRUG|TPI 1100|1 dose only increasing dose
215030888|NCT04721691|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
215030889|NCT04721691|OTHER|Placebo|Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.
215030890|NCT02007161|DRUG|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
214784884|NCT03929939|BEHAVIORAL|Exercise training and healthy eating (overseen by IEEM research team)|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
214784885|NCT06486363|DRUG|Aspirin combined with clopidogrel|Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
214784886|NCT06486363|DRUG|Aspirin combined with half-dose ticagrelor|Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
214784887|NCT01573091|PROCEDURE|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
214784888|NCT03567720|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
214784889|NCT03567720|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
214784890|NCT03567720|DEVICE|Immunopulse|Device that administers electroporation
214784891|NCT03567720|DRUG|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
214784892|NCT03567720|DRUG|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
214784893|NCT02472392|DRUG|Rabbit anti-thymocyte globulin|Active treatment
214784894|NCT02472392|DRUG|Busulfan|comparitor
214784895|NCT02472392|DRUG|Melphalan|comparitor
214784896|NCT02472392|DRUG|Fludarabine|comparitor
214784897|NCT02472392|DRUG|Cyclophosphamide|comparitor
214784898|NCT04082962|DRUG|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
214784899|NCT02718495|DRUG|PTI-428|
214784900|NCT02718495|DRUG|Placebo|
214784901|NCT04249089|BEHAVIORAL|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
215030891|NCT05268861|BEHAVIORAL|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
215030892|NCT05268861|BEHAVIORAL|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
214784902|NCT02079948|DRUG|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression."
214784903|NCT02079948|DRUG|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression"
214784904|NCT02079948|PROCEDURE|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
214784905|NCT02079948|PROCEDURE|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
214784906|NCT00372827|DRUG|Brinzolamide 1% added to Travoprost 0.004%|
214784907|NCT03207360|BEHAVIORAL|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
214784908|NCT01967888|DRUG|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
214784909|NCT01967888|DRUG|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
214784910|NCT02199652|DRUG|Prazosin|
214784911|NCT02199652|DRUG|Placebo|
214784912|NCT00049634|DRUG|busulfan|
214784913|NCT00049634|DRUG|cyclophosphamide|
214784914|NCT00049634|DRUG|cyclosporine|
214784915|NCT00049634|DRUG|methotrexate|
214784916|NCT00049634|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214784917|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
214784918|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
214784919|NCT02505100|OTHER|Touching relaxant|
214784920|NCT02505100|OTHER|Hypnoses|
214784921|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
214784922|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol/ Triclosan|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
214784923|NCT00553540|DEVICE|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
214784924|NCT05805475|OTHER|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
214784925|NCT05805475|OTHER|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
214784926|NCT06021977|DRUG|Zanubrutinib|Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
214784927|NCT06087393|DEVICE|CONVIVO|Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
214784928|NCT04193059|DRUG|Paclitaxel|paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
214784929|NCT04193059|DRUG|Carboplatin|carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
214784930|NCT04193059|DRUG|Epirubicin|epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
214784931|NCT04193059|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
214784932|NCT04193059|DRUG|Trastuzumab|trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
214784933|NCT04193059|DRUG|Pertuzumab|pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
214784934|NCT04193059|DRUG|Docetaxel|docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
214784935|NCT05386745|BEHAVIORAL|physical activity|A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
214784936|NCT03770871|DRUG|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
214784937|NCT03770871|DRUG|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
214784938|NCT02622074|BIOLOGICAL|Pembrolizumab|200 mg administered Q3W as an IV infusion.
214784939|NCT02622074|DRUG|Nab-paclitaxel|125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.
214784940|NCT02622074|DRUG|Anthracycline (doxorubicin)|60 mg/m\^2 administered Q3W as an IV injection.
214784941|NCT02622074|DRUG|Cyclophosphamide|600 mg/m\^2 administered Q3W as an IV infusion.
214784942|NCT02622074|DRUG|Carboplatin|AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
214784943|NCT02622074|DRUG|Paclitaxel|80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.
214784944|NCT04574778|DRUG|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
214784945|NCT00313053|DRUG|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
214784946|NCT00313053|DRUG|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
214784947|NCT02505776|DRUG|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
214784948|NCT04622384|OTHER|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
214784949|NCT00454974|DEVICE|Wearable artificial kidney|
214784950|NCT02114931|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
214784951|NCT00590356|DEVICE|StarClose®|Closure device for femoral artery suture site occlusion
214784952|NCT00590356|DEVICE|AngioSeal®|Closure device for femoral artery suture site occlusion
214784953|NCT03555370|BEHAVIORAL|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
214784954|NCT03555370|BEHAVIORAL|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
214784955|NCT04572620|DRUG|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
214784956|NCT04572620|DRUG|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
214784957|NCT05394142|DRUG|Placebo|Comparator arm with placebo
214784958|NCT05394142|DRUG|Pioglitazone|Pioglitazone 7.5 mg/day
215030893|NCT03907202|DRUG|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
215030894|NCT06549777|BEHAVIORAL|SE-group|Psychoeducation and information about treatment possibilities + SE-treatment
215030895|NCT06549777|BEHAVIORAL|Control|Psychoeducation and information about treatment possibilities + Phone
215030896|NCT06518928|OTHER|Artificial Intelligence assisted sperm selection|SiD software for sperm selection
214784959|NCT05394142|DRUG|Spironolactone|Spironolactone 50 mg/day
214784960|NCT05394142|DRUG|Metformin|Metformin 850 mg/day
214784961|NCT01691755|DRUG|Placebo|oral doses once a day for 26 weeks
214784962|NCT01691755|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
214784963|NCT02578732|DRUG|FOLFOXA|"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."
214784964|NCT04706975|DRUG|difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg administered twice daily
214784965|NCT04706975|DRUG|Placebo|Oral Placebo administered twice daily
214784966|NCT03592381|PROCEDURE|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
214784967|NCT03592381|PROCEDURE|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
214784968|NCT05593406|DEVICE|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
214784969|NCT05593406|OTHER|Control Group|NDT treatment 2 sessions per week
214784970|NCT02115191|DEVICE|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
214784971|NCT02115191|PROCEDURE|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
214784972|NCT03870997|BEHAVIORAL|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
214784973|NCT03870997|BEHAVIORAL|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
214784974|NCT04411459|OTHER|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
214784975|NCT04670757|DRUG|CPL409116|IMP administration, tablets contain CPL409116 as an active ingredient
214784976|NCT04670757|DRUG|Placebo|Placebo comparator
214784977|NCT03911609|OTHER|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
214784978|NCT03911609|OTHER|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
214784979|NCT02875171|DRUG|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
214784980|NCT00535509|RADIATION|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
214784981|NCT00535509|OTHER|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
214784982|NCT00535509|DRUG|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
214784983|NCT05974748|DRUG|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
214784984|NCT05974748|DRUG|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
214784985|NCT06150378|DRUG|Corticosteroid|Patients that receive an injection with corticosteroid
214784986|NCT06150378|BIOLOGICAL|Plathet rich plasma|Patients that receive an injection with Plathet-rich plasma
214784987|NCT03335020|DEVICE|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
215030897|NCT00991640|BEHAVIORAL|2-day preceptorship on obesity management|
214784988|NCT03335020|DEVICE|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
214784989|NCT03335020|DRUG|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
214784990|NCT03335020|OTHER|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
214784991|NCT03335020|DEVICE|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
214784992|NCT03565211|DRUG|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
214784993|NCT01859325|BIOLOGICAL|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
214784994|NCT01859325|BIOLOGICAL|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
214784995|NCT01859325|BIOLOGICAL|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
214784996|NCT01859325|DRUG|Placebo|
214784997|NCT03811197|BEHAVIORAL|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
214784998|NCT03811197|BEHAVIORAL|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
214784999|NCT03811197|BEHAVIORAL|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
214785000|NCT03845179|OTHER|Placebo|Saline infusion
214785001|NCT03845179|OTHER|GIP receptor antagonist|Used for infusion on study days
214785002|NCT03845179|DRUG|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
214785003|NCT03845179|OTHER|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
215030898|NCT02144532|DEVICE|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
215030899|NCT02098603|BEHAVIORAL|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
215030900|NCT04744116|OTHER|Cellular Therapy|Given ds-MSCs IV
215030901|NCT04744116|DRUG|Ruxolitinib|Given PO
214785004|NCT02981797|OTHER|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
214785005|NCT01894984|DRUG|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
214785006|NCT01894984|DRUG|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
214785007|NCT02572583|DRUG|Liugan Shuangjie Heji|
214785008|NCT02572583|DRUG|Shufeng Jiedu Capsule|
214785009|NCT02572583|DRUG|Oseltamivir Phosphate Capsule|
214785010|NCT01584336|PROCEDURE|LATG|"1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy."
214785011|NCT01791283|PROCEDURE|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
214785012|NCT06521788|DEVICE|AI-assisted breast ultrasound|AI-assisted breast ultrasound in community-based breast cancer screening
214785013|NCT06521788|DEVICE|Routine breast ultrasound|Routine breast ultrasound conducted by primary care physicians
214785014|NCT05066087|BEHAVIORAL|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
214785015|NCT05066087|OTHER|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
214785016|NCT04093973|DIAGNOSTIC_TEST|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
214785017|NCT00906685|DRUG|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
214785018|NCT00906685|DRUG|Sham bevacizumab injection|Sham intravitreal injection
214785019|NCT00580333|DRUG|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
214785020|NCT00580333|DRUG|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
214785021|NCT00580333|DRUG|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
214785022|NCT00580333|DRUG|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
214785023|NCT00580333|DRUG|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
214785024|NCT02499185|DEVICE|Nephro Check Test|Urine sample
214785025|NCT02499185|OTHER|serum creatinine measurement|Blood sample
214785026|NCT05851482|DIAGNOSTIC_TEST|High resolution manometry|Standard chicago classification 4.0 HRM protocol
214785027|NCT00406432|DRUG|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
214785028|NCT06006351|OTHER|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
214785029|NCT06006351|OTHER|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
214785030|NCT00000318|DRUG|Buprenorphine|"1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication"
214785031|NCT05295251|OTHER|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
214785032|NCT01834573|BEHAVIORAL|physical exercise|10 weeks physical exercise; three times a week
214785033|NCT00293826|DRUG|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
214785034|NCT00293826|DRUG|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
214785035|NCT00293826|DRUG|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
214785036|NCT00293826|DRUG|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
214785037|NCT03458026|OTHER|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
214785038|NCT03458026|OTHER|Without connected object|Any intervention except follow-up visit
214785039|NCT05792865|DRUG|paxlovid|Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
214785040|NCT05792865|DRUG|No paxlovid|Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
214785041|NCT05792865|DRUG|Paxlovid|Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.
214785042|NCT04916860|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
214785043|NCT01666925|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu
214785044|NCT01666925|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
214785045|NCT05756868|BEHAVIORAL|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
214785046|NCT05309837|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose-enriched food products
214785047|NCT05309837|DIETARY_SUPPLEMENT|placebo-controlled|Control food products
214785048|NCT00844727|DRUG|Rofecoxib|
214785049|NCT00844727|DRUG|placebo|placebo pills
214785050|NCT00108901|BEHAVIORAL|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
214785051|NCT03840135|DRUG|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
214785052|NCT03840135|OTHER|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
214785053|NCT00667719|DRUG|Aliskiren|300 mg tablet
214785054|NCT00667719|DRUG|Amlodipine|5 mg tablet
214785055|NCT00667719|DRUG|Hydrochlorothiazide|12.5 mg and 25 mg capsule
214785056|NCT02506725|OTHER|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
214785057|NCT01894113|PROCEDURE|transbronchial lung biopsy|
214785058|NCT01452113|DRUG|Vildagliptin|one 50 mg tablet per os
214785059|NCT01779908|DIETARY_SUPPLEMENT|Vitamin D|
214785060|NCT01779908|OTHER|Placebo|
214785061|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period I)
214785062|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period II)
214785063|NCT04494178|OTHER|Placebo|Intervention period I
214785064|NCT04494178|OTHER|Placebo|Intervention period II
214785065|NCT01726478|DRUG|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
214785066|NCT01726478|DRUG|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
214785067|NCT05956171|OTHER|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
214785068|NCT05956171|OTHER|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
214785069|NCT02605083|DRUG|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
214785070|NCT02455583|BEHAVIORAL|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
214785071|NCT03124797|DEVICE|RD DCI Sensor|Noninvasive pulse oximeter sensor
214785072|NCT01695798|BIOLOGICAL|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
214785073|NCT02122211|DRUG|Betaine supplement|
214785074|NCT01827371|BIOLOGICAL|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
214785075|NCT01081483|DRUG|ABT-072|See arm description for more information
214785076|NCT01081483|DRUG|Placebo|See arm description for more information
214785077|NCT02887482|BIOLOGICAL|GLS-5700|GLS 5700 at 2 mg DNA/dose
214785078|NCT02887482|BIOLOGICAL|Placebo|
214785079|NCT03773094|DRUG|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
214785080|NCT03773094|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
214785081|NCT03320473|DEVICE|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
214785082|NCT00618631|DRUG|Nicotine|
214785083|NCT00618631|DRUG|Carfentanil|
214785084|NCT04433845|DRUG|Psilocybin|Open-label
214785085|NCT00248820|PROCEDURE|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
214785086|NCT03474289|DRUG|SHR-1316|Monotherapy
214785087|NCT04399902|DEVICE|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
214785088|NCT00240864|DRUG|placebo|
214785089|NCT00240864|DRUG|acetaminophen|
214785090|NCT00240864|DRUG|ibuprofen|
214785091|NCT02100566|BEHAVIORAL|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
214785092|NCT02100566|BEHAVIORAL|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
214785093|NCT00877266|PROCEDURE|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
214785094|NCT03413865|OTHER|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
214785095|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
214785096|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a sham face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
214785097|NCT05064202|DEVICE|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
214785098|NCT05064202|DRUG|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
214785099|NCT06547203|DRUG|Cetuximab|Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks
214785100|NCT06547203|DRUG|Toripalimab|Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
214785101|NCT06547203|DRUG|Irinotecan|Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
214785102|NCT02662608|DRUG|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
214785103|NCT04818151|DRUG|Warfarin|Warfarin treatment for VTE
214785104|NCT04818151|DRUG|Apixaban|Apixaban treatment for VTE
214785105|NCT04598672|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
214785106|NCT00509210|DRUG|telaprevir (VX-950)|
214785107|NCT03351413|OTHER|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
214785108|NCT04189419|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
214785109|NCT04189419|OTHER|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
214785110|NCT05268731|PROCEDURE|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
214785111|NCT05268731|PROCEDURE|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
214785112|NCT05268731|PROCEDURE|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
214785113|NCT00459082|DRUG|Dexmedetomine|
214785114|NCT06416137|DIAGNOSTIC_TEST|Neuropsychological tests|Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
214785115|NCT02757300|DEVICE|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
214785116|NCT02757300|DEVICE|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
214785117|NCT00492388|DRUG|PMI-150 (intranasal ketamine)|intranasal dosing
214785118|NCT00492388|DRUG|placebo|placebo
214785119|NCT01361607|DRUG|Nabiximols|
214785120|NCT01361607|DRUG|Placebo (GA-0034)|
214785121|NCT00540709|DRUG|Insulin Glargine|
214785122|NCT01736137|OTHER|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
214785123|NCT03997331|OTHER|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
214785124|NCT03997331|OTHER|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
214785125|NCT01809314|DRUG|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
214785126|NCT01682941|DIETARY_SUPPLEMENT|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
214785127|NCT01682941|DIETARY_SUPPLEMENT|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
214785128|NCT02012179|OTHER|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
214785129|NCT04665479|OTHER|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
214785130|NCT06081725|BEHAVIORAL|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
214785131|NCT06081725|BEHAVIORAL|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
214785132|NCT06081725|BEHAVIORAL|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
214785133|NCT06081725|BEHAVIORAL|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
214785134|NCT06417957|OTHER|cultural competence training|The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
214785135|NCT03037684|DIAGNOSTIC_TEST|neurophysiology|electrophysiologic measurements of peripheral nerves
214785136|NCT06422611|DEVICE|Impression methods|Both digital and conventional impressions were taken from same patients
214785137|NCT04423653|BEHAVIORAL|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
214785138|NCT04656951|DRUG|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
214785139|NCT03031457|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
214785140|NCT04513340|DRUG|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
214785141|NCT01634022|PROCEDURE|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
214785142|NCT01814137|DRUG|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
214785143|NCT01814137|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
214785144|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
214785145|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
214785146|NCT05935774|BIOLOGICAL|Atezolizumab|Given IV
214785147|NCT05935774|PROCEDURE|Biopsy|Undergo biopsy
214785148|NCT05935774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214785149|NCT05935774|PROCEDURE|Computed Tomography|Undergo CT
214785150|NCT05935774|OTHER|Electronic Health Record Review|Ancillary studies
214785151|NCT05935774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214785152|NCT05935774|DRUG|Trabedersen (OT-101)|Given IV
214785153|NCT01328392|DRUG|Dexlansoprazole|30mg a day, 3 months
214785154|NCT02856867|DRUG|Nintedanib|
214785155|NCT02856867|DRUG|Fluorouracil|
214785156|NCT02856867|DRUG|Leucovorin|
214785157|NCT02856867|DRUG|Oxaliplatin|
214785158|NCT02856867|DRUG|Placebo|
214785159|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
214785160|NCT00219557|DRUG|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
214785161|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
214785162|NCT00833781|BIOLOGICAL|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
214785163|NCT00833781|BIOLOGICAL|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
214785164|NCT00654043|DRUG|Torsemide|tablets, 20 Mg, single-dose
214785165|NCT00654043|DRUG|Demadex|Tablets, 20 mg, single-dose
214785166|NCT03205514|DIAGNOSTIC_TEST|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
214785167|NCT04848350|OTHER|Lavender essential oil|Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
214785168|NCT02711150|DEVICE|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
214785169|NCT01042496|DRUG|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
214785170|NCT01042496|PROCEDURE|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
214785171|NCT05684250|BEHAVIORAL|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
214785172|NCT00417599|BEHAVIORAL|Lifestyle Intervention|lifestyle intervention .
214785173|NCT00417599|OTHER|control group|waiting list control group
214785174|NCT01427803|DRUG|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
214785175|NCT01484990|DRUG|Levodopa-Carbidopa|Intestinal Gel
214785176|NCT02531828|DEVICE|Application of dressings for surgical correction.|Dressing for surgical correction
214785177|NCT02531828|DEVICE|POLYSHAFT®|
214794216|NCT03602326|OTHER|Neurodevelopmental Therapy-Bobath group|Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
214785178|NCT05871697|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
214785179|NCT05871697|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
214785180|NCT00410566|DRUG|rhASM|Single dose of 0.03mg/kg body weight IV
214785181|NCT00410566|DRUG|rhASM|Single dose of 0.1mg/kg body weight IV
214785182|NCT00410566|DRUG|rhASM|Single dose of 0.3mg/kg body weight IV
214785183|NCT00410566|DRUG|rhASM|Single dose of 0.6mg/kg body weight IV
214785184|NCT00410566|DRUG|rhASM|Single dose of 1.0mg/kg body weight IV
214785185|NCT04727346|RADIATION|CBCT|Cone Beam Computed Tomography
214785186|NCT04727346|PROCEDURE|DISE|Drug Induced Sleep Endoscopy
214785187|NCT03412019|OTHER|Music|Selections of Mozart piano sonatas
214785188|NCT03082391|DEVICE|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
214785189|NCT03082391|DEVICE|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
214785190|NCT03875391|DRUG|Oxytocin|Drug: Oxytocin nasal spray
214785191|NCT03875391|DRUG|Placebo|Drug: Placebo nasal spray
214785192|NCT02048397|OTHER|Pulmonary Rehabilitation|
214785193|NCT02048397|DIETARY_SUPPLEMENT|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
214785194|NCT02447484|BEHAVIORAL|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
214785195|NCT02447484|BEHAVIORAL|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
214785196|NCT01279642|DEVICE|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
214785197|NCT01279642|OTHER|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
214785198|NCT01445132|DRUG|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
214785199|NCT00676585|DRUG|Normal Saline|Normal Saline
214785200|NCT00676585|DRUG|Hydrocortisone|Hydrocortisone 100mg
214785201|NCT02445170|PROCEDURE|Amputation|Transmetatarsal or below-knee amputation
214785202|NCT00048971|GENETIC|mutation analysis|
214785203|NCT00048971|GENETIC|polymorphic microsatellite marker analysis|
214785204|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
214785205|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
214785206|NCT03086239|DRUG|Rovalpituzumab tesirine|Intravenous
214785207|NCT00665522|DRUG|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
214785208|NCT00665522|DRUG|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
214785209|NCT02831530|DRUG|Abemaciclib|
214785210|NCT00248339|DRUG|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
214785211|NCT00248339|DRUG|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
214785212|NCT00248339|DRUG|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
214785213|NCT04915586|DRUG|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
214785214|NCT04638855|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
214785215|NCT04638855|DEVICE|Placebo|No device after hysteroscopy surgery
214785216|NCT01072019|OTHER|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
214785217|NCT03342508|DEVICE|Fetal Pillow|see arm description
214785218|NCT01692171|DRUG|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
214785219|NCT03666182|OTHER|No Intervention|No Intervention
214785220|NCT06483672|DRUG|Furmonertinib|Furmonertinib 80mg, once daily, orally
214785221|NCT06483672|DRUG|Anlotinib|Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
214785222|NCT01720940|DRUG|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
214785223|NCT01720940|DRUG|intermittent vancomycin infusion|
214785224|NCT01023269|DEVICE|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
214785225|NCT04390139|DRUG|XCEL-UMC-BETA|Administration on top of the standard administered treatment
214785226|NCT04390139|OTHER|Placebo|Administration on top of the standard administered treatment
214785227|NCT00585091|DRUG|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
214785228|NCT06259110|DIAGNOSTIC_TEST|Multiplex PCR|multiplex PCR is a molecular biology technique that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample
214785229|NCT06168955|OTHER|skin biopsy|skin biopsy for cell culture and N-homocysteinylation study
214785230|NCT00182221|PROCEDURE|MDA D-Dimer Testing|
214785231|NCT03704779|BEHAVIORAL|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
214785232|NCT05686733|DEVICE|SEAL Device|Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
214785233|NCT05131503|OTHER|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
214785234|NCT02758002|PROCEDURE|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
214785235|NCT05171803|OTHER|No intervention|No intervention, prospective, cohort study.
214785236|NCT04466449|DIAGNOSTIC_TEST|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
214785237|NCT06370299|OTHER|(exposure of) MDR carriage|The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
214785238|NCT01833949|PROCEDURE|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
214785239|NCT01833949|PROCEDURE|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
214785240|NCT02457624|BEHAVIORAL|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
214785241|NCT01215123|DRUG|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
214785242|NCT00947011|DRUG|Placebo|1 tablet 100 mg once a day
214785243|NCT00947011|DRUG|Januvia|1 tablet 100 mg once a day
214785244|NCT01885637|OTHER|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
214785245|NCT03634670|OTHER|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
214785246|NCT03229031|DRUG|ES135|ES135 will be administered via intrathecal
214785247|NCT02166242|DRUG|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
214785248|NCT01527539|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
214785249|NCT00022425|DRUG|perillyl alcohol|
214785250|NCT02922114|OTHER|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
214785251|NCT03366285|DIAGNOSTIC_TEST|Attachment story completion taks (ASCT)|Bonding quality
214785252|NCT01830556|DRUG|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
214785253|NCT03090009|DRUG|Flurbiprofen|100 mg twice a day for 14 days
214785254|NCT03090009|DRUG|Placebo Oral Tablet|placebo group
214785255|NCT01993420|DRUG|DRM02|
214785256|NCT01993420|OTHER|Vehicle|
214785257|NCT00814658|DRUG|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
214785258|NCT00814658|DRUG|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
214785259|NCT00814658|DRUG|Placebo|Matching placebo three times a day (tid).
214785260|NCT01939600|OTHER|Starch-free breakfast|Starch-free breakfast alone
214785261|NCT01939600|OTHER|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
214785262|NCT01939600|OTHER|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
214785263|NCT01939600|OTHER|Amioca|Starch-free breakfast plus 56.4g amioca starch
214785264|NCT06263309|DIAGNOSTIC_TEST|Femoral neck shortening measurement|We examine femoral neck shortening in patients with femoral neck fractures.
214785265|NCT01741857|BIOLOGICAL|human umbilical cord derived MSC transplantation for SLE|
214785266|NCT05266456|BIOLOGICAL|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
214785267|NCT05266456|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
214785268|NCT02545413|DRUG|Probiotic VSL#3|
214785269|NCT02545413|DRUG|Placebo|
214785270|NCT06035783|DEVICE|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
214785271|NCT03639272|PROCEDURE|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
214785272|NCT04767490|PROCEDURE|Standard Duodenal Switch|
214785273|NCT04767490|PROCEDURE|Single Anastomosis Duodenal Switch|
214785274|NCT03356587|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
214785275|NCT02485496|DEVICE|Endovascular abdominal repair|
214785276|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
214785277|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
214785278|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
214785279|NCT01720628|OTHER|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
214785280|NCT00004843|PROCEDURE|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
214785281|NCT00004843|OTHER|Observation|Usual care
214785282|NCT05252806|DIAGNOSTIC_TEST|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
214785283|NCT06546683|OTHER|Short-Chain Fatty Acids|Colon-delivery capsules of Short-Chain Fatty Acids will be administered in a ratio of 60:20:20, thus 150 mmol of acetate, 50 mmol of propionate and 50 mmol of butyrate equivalent to 20g of fibers, once daily, one week
214785284|NCT06546683|OTHER|Placebo|Microcrystalline Cellulose will be used as placebo, one daily, one week
214785285|NCT01787474|DRUG|Cytarabine|Given IV
214785286|NCT01787474|BIOLOGICAL|Filgrastim|Given SC
214785287|NCT01787474|BIOLOGICAL|Filgrastim-sndz|Given SC
214785288|NCT01787474|DRUG|Fludarabine Phosphate|Given IV
214785289|NCT01787474|OTHER|Laboratory Biomarker Analysis|Correlative studies
214785290|NCT01787474|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
214785291|NCT00831727|BEHAVIORAL|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
214785292|NCT00831727|BEHAVIORAL|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
214785293|NCT02687204|DRUG|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
214785294|NCT02687204|DRUG|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
214785295|NCT00198081|DRUG|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
214785296|NCT00198081|DRUG|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
214785297|NCT04829409|PROCEDURE|Paravertebral block|Patients receive ultrasound-guided paravertebral block
214785298|NCT04829409|PROCEDURE|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
214785299|NCT04829409|PROCEDURE|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
214785300|NCT06007573|DRUG|The control group received oral nimodipine tablets|The control group received oral nimodipine tablets
214785301|NCT05195554|OTHER|Psycho-educational intervention|Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
214785302|NCT02436395|PROCEDURE|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
214785303|NCT02436395|PROCEDURE|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
214785304|NCT05272098|OTHER|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
214785305|NCT05272098|OTHER|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
214785306|NCT03057288|DEVICE|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
214785307|NCT00253097|BEHAVIORAL|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
214785308|NCT03084978|PROCEDURE|General Anesthesia|General anesthesia by standard endotracheal intubation.
214785309|NCT03084978|PROCEDURE|Conscious Sedation|Conscious sedation
214785310|NCT03679845|DRUG|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
214785311|NCT04745325|BEHAVIORAL|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
214785312|NCT01019005|DEVICE|Catheter|Catheter inserted into either perineural tibial nerve or wound
214785313|NCT05097378|DRUG|Encorafenib + Binimetinib|"Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity"
214785314|NCT05097378|DRUG|Standard Adjuvant Treatment|Standard Adjuvant Treatment
214785315|NCT04630366|DRUG|NST-1024|NST-1024
214785316|NCT04630366|DRUG|Placebo|Matching placebo to NST-1024
214785317|NCT03060031|DRUG|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
214785318|NCT03060031|DRUG|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
214785319|NCT02606682|DRUG|NPT200-11|Single doses of NPT200-11capsules, orally administered
214785320|NCT02606682|DRUG|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
214785321|NCT04979065|DIETARY_SUPPLEMENT|Probiotics, Vitamin D|Combination of two supplement that given separately
214785322|NCT04979065|OTHER|Placebo|Placebo with inactive ingredient
214785323|NCT02825472|BEHAVIORAL|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
214785324|NCT04413669|PROCEDURE|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
214785325|NCT04953481|OTHER|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
214785326|NCT00738010|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
214785327|NCT00738010|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
214785328|NCT00738010|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
214785329|NCT06249217|BEHAVIORAL|Good Nights Sleep Program|The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
214785330|NCT01416207|DRUG|Avonex|4 weekly injections of Avonex (IM)
214785331|NCT00112515|DRUG|modafinil|
214785332|NCT00112515|PROCEDURE|cognitive assessment|
214785333|NCT00112515|PROCEDURE|psychosocial assessment and care|
214785334|NCT00112515|PROCEDURE|quality-of-life assessment|
214785335|NCT04280393|DEVICE|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
214785336|NCT01652261|DRUG|ABVD + FDG-PET/CT Scan treatment adaptation|
214785337|NCT01652261|DRUG|BEACOPPesc|
214785338|NCT02688101|DRUG|DpC|iron chelator
214785339|NCT01316588|OTHER|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
214785340|NCT01316588|OTHER|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
214785341|NCT00646087|DRUG|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
214785342|NCT00646087|DRUG|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
214785343|NCT01068873|DRUG|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
214785344|NCT04267016|DIAGNOSTIC_TEST|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
214785345|NCT00479401|DRUG|Pramipexol Extended Release|
214785346|NCT00479401|DRUG|Pramipexol Immediate Release|
214785347|NCT00479401|DRUG|Placebo|
214785348|NCT04825509|DEVICE|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
214785349|NCT00141531|DRUG|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
214785350|NCT06543160|OTHER|Immediate SSC and early breastfeeding during CS|Upon birth, the neonate is promptly placed prone on the mother's chest, with their head turned to one side for optimal skin contact. The drying process begins within 5 seconds and is completed within 20 to 30 seconds while the neonate remains on the mother's chest. Delayed cord clamping is practiced, with the cord clamped approximately 1-3 minutes after birth. Breastfeeding cues such as tongue movements or head turning are monitored, and the obstetric nurse assists the mother in initiating breastfeeding as soon as possible. SSC continues throughout the cesarean procedure, and upon completion, the newborn is temporarily separated from the mother for safety during transfer to the surgical cart. SSC is resumed immediately post-transfer and continues for a cumulative duration of at least 90 minutes. The neonate's skin color, breathing, and feeding responses are continuously observed.
214785351|NCT06543160|OTHER|Delayed SSC and breastfeeding after CS|The neonate is dried within 20-30 seconds after birth, the cord is clamped after 1-3 minutes, and then the neonate is sent to the ward to wait for the mother to complete the surgery. Immediate SSC is initiated within one hour after birth and maintained with the mother for at least 90 minutes post-surgery, during which the neonate's skin color and breathing are continuously monitored. The obstetric nurse supports the mother in initiating breastfeeding at the earliest opportunity.
214785352|NCT06543160|OTHER|Routine newborn care|Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
214785353|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
214785354|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
214785355|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
214785356|NCT02777931|DRUG|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
214785357|NCT02777931|DRUG|Placebo|Matching placebo capsules
214785358|NCT01004120|DIETARY_SUPPLEMENT|Bimuno|5.5g daily intake
214785359|NCT01004120|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily intake
214785360|NCT05717088|OTHER|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively."
214785361|NCT02759211|OTHER|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
214785362|NCT02759211|OTHER|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
214785363|NCT01493726|DRUG|ALKS 9072, Low dose|IM injection, given monthly
214785364|NCT01493726|DRUG|ALKS 9072, Med dose|IM injection, given monthly
214785365|NCT01493726|DRUG|ALKS 9072, High dose|IM injection, given monthly
214785366|NCT01493726|DRUG|Placebo|Dosed matched placebo IM injection, given monthly
214785367|NCT03918395|DIETARY_SUPPLEMENT|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
214785368|NCT03918395|DIETARY_SUPPLEMENT|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
214785369|NCT03039374|OTHER|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
214785370|NCT02226939|DRUG|BILN 2061 ZW|
214785371|NCT02226939|DRUG|Placebo|
214785372|NCT06485492|PROCEDURE|Implant an aneurysm embolization system|The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
214785373|NCT06243081|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
214785374|NCT03881579|BEHAVIORAL|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
214785375|NCT04811222|DIAGNOSTIC_TEST|Ga-DOTATATE PETMRI scan|Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
214785376|NCT04495465|OTHER|Radial Shock Wave Therapy|2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
214785377|NCT04495465|OTHER|Manual Therapy|25 minute massage to neck muscles
214785378|NCT04495465|OTHER|placebo shock waves|3 minutes of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
214785379|NCT01436669|DEVICE|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
214785380|NCT04069104|BEHAVIORAL|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
214785381|NCT04069104|BEHAVIORAL|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
214785382|NCT04069104|BEHAVIORAL|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
214785383|NCT04069104|BEHAVIORAL|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
214785384|NCT05641272|BIOLOGICAL|3,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
214785385|NCT05641272|BIOLOGICAL|9,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
214785386|NCT05641272|OTHER|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
214785387|NCT01535846|BEHAVIORAL|Conscious food tasting intervention|Six weekly 2-hour workshops
214785388|NCT01571635|DRUG|SOTATERCEPT (ACE-011)|0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
214785389|NCT03865524|DEVICE|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
214785390|NCT03865524|DEVICE|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
214785391|NCT03472833|DRUG|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
214785392|NCT03472833|DRUG|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
214785393|NCT00003985|DRUG|KRN7000|
214785394|NCT02868281|DRUG|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
214785395|NCT02868281|DRUG|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
214785396|NCT01462500|DRUG|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
214785397|NCT01313000|PROCEDURE|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
214785398|NCT01722266|DRUG|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
214794217|NCT03602326|OTHER|Standart Rehabilitation Group (SR group)|Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
215030902|NCT02759510|DRUG|Norepinephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
214785399|NCT01722266|DRUG|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
214785400|NCT00047489|DRUG|ABT-751|
214785401|NCT05472285|DIETARY_SUPPLEMENT|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
214785402|NCT05472285|DIETARY_SUPPLEMENT|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
214785403|NCT00055874|BIOLOGICAL|recombinant interferon alfa|
214785404|NCT00055874|DRUG|cytarabine|
214785405|NCT00055874|DRUG|hydroxyurea|
214785406|NCT00055874|DRUG|imatinib mesylate|
214785407|NCT00055874|PROCEDURE|allogeneic bone marrow transplantation|
214785408|NCT00055874|PROCEDURE|autologous bone marrow transplantation|
214785409|NCT00055874|PROCEDURE|peripheral blood stem cell transplantation|
214785410|NCT00650559|PROCEDURE|Chest wall enlargement|Widening sternotomy
214785411|NCT03874806|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
214785412|NCT03874806|DRUG|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
214785413|NCT04821882|DRUG|Dextrose|10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
214785414|NCT01785186|DRUG|SQ109|SQ109 300 mg
214785415|NCT01785186|DRUG|Rifampicin|Rifampicin 10 to 35 mg/kg
214785416|NCT01785186|DRUG|Moxifloxacin|Moxifloxacin 400mg
214785417|NCT01785186|DRUG|isoniazid|isoniazid 75 mg
214785418|NCT01785186|DRUG|pyrazinamide|pyrazinamide 400 mg
214785419|NCT01785186|DRUG|ethambutol|ethambutol 275 mg
214785420|NCT01785186|DIETARY_SUPPLEMENT|pyridoxine|pyridoxine 25 mg
214785421|NCT03124381|DEVICE|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
214785422|NCT03124381|DEVICE|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
214785423|NCT04192617|DRUG|SM03|SM03: 600 mg intravenous (IV)
214785424|NCT04192617|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
214785425|NCT04192617|DRUG|Methotrexate|methotrexate: 7.5-20 mg/week oral
214785426|NCT04684784|DEVICE|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
214785427|NCT04684784|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
214785428|NCT01132287|OTHER|FID 112903|lubricant eye drop FID 112903
214785429|NCT03392961|DRUG|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
214785430|NCT03392961|OTHER|Placebo comparator|Placebo tablet for oral use
214785431|NCT04496089|DIAGNOSTIC_TEST|89Zr-girentuximab|A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
214785432|NCT01823315|DRUG|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
214785433|NCT01823315|DRUG|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, \>4h)
214785434|NCT01823315|BIOLOGICAL|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
214785435|NCT03437460|DRUG|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
214785436|NCT03437460|DIETARY_SUPPLEMENT|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
214785437|NCT01936168|DEVICE|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
214785438|NCT01936168|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
214785439|NCT02678221|DRUG|Sildenafil citrate|
214785440|NCT02678221|DRUG|Aspirin|
214785441|NCT05012137|PROCEDURE|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
214785442|NCT05012137|DRUG|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
214785443|NCT02883829|BEHAVIORAL|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
214785444|NCT02883829|BEHAVIORAL|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
214785445|NCT05454423|OTHER|the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication|"-Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding"
214785446|NCT05454423|OTHER|traditional physical therapy + anti-hyperuricemia medication|"traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17."
214785447|NCT06307808|DRUG|Tacrolimus|Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus
214785448|NCT06307808|DRUG|Belatacept|Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
214785449|NCT00188695|PROCEDURE|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
214785450|NCT02533999|DEVICE|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
214785451|NCT02533999|DEVICE|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
214785452|NCT06080984|DRUG|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL)."
214785453|NCT06080984|DRUG|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
214785454|NCT01913730|DRUG|Bortezomib|
214785455|NCT01913730|DRUG|Dexamethasone|
214785456|NCT03501342|OTHER|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
214785457|NCT03501342|OTHER|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
214785458|NCT03080194|DRUG|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
214785459|NCT03080194|DRUG|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
214785460|NCT04898725|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 4800IU daily
214785461|NCT03348982|BEHAVIORAL|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
214785462|NCT02593890|DEVICE|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
214785463|NCT04649801|PROCEDURE|Atrial fibrillation ablation|Catheter ablation
214785464|NCT00291330|DRUG|dabigatran etexilate 150 mg|twice daily
214785465|NCT00291330|DRUG|warfarin (INR 2-3)|prn to maintain INR (2-3)
214785466|NCT05882968|DIAGNOSTIC_TEST|kidney function tests|using GFR test according to kdigo guide lines
214785467|NCT03765944|DRUG|sirolimus|SIngle administration under fasted condition
214785468|NCT01080105|BEHAVIORAL|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
214785469|NCT01080105|BEHAVIORAL|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
214785470|NCT01080105|BEHAVIORAL|Educational website|Participants will receive access to a static educational website for 12 weeks.
214785471|NCT01593150|DRUG|Pradaxa|Pradaxa for 3 weeks prior to DC
214785472|NCT01593150|PROCEDURE|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
214785473|NCT01593150|OTHER|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
214785474|NCT06538974|DEVICE|Hands-free exoskeleton|During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
214785475|NCT02754180|DRUG|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
214785476|NCT02754180|RADIATION|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
214785477|NCT01829295|DRUG|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.
214785478|NCT01829295|DRUG|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
214785479|NCT01829295|DRUG|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
214785480|NCT05766215|BEHAVIORAL|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
214785481|NCT03028194|PROCEDURE|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
214785482|NCT03028194|PROCEDURE|Placebo|No procedure after delivery of the placenta
214785483|NCT04721756|DRUG|18F-LY3546117 Injection|370 megabecquerel (MBq) intravenous injection
214785484|NCT04721756|PROCEDURE|PET Scan|positron emission tomography (PET) scan
214785485|NCT04537325|DEVICE|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
214785486|NCT04776174|DEVICE|Ultrasound using the telerobotic Melody system|The children will first have a telerobotic ultrasound abdominal, pulmonary or cardiac followed by a classical ultrasound.
214785487|NCT00863369|BIOLOGICAL|rituximab|Given IV
214785488|NCT00863369|DRUG|bortezomib|Given IV
214785489|NCT00863369|DRUG|gemcitabine hydrochloride|Given IV
214785490|NCT00863369|OTHER|questionnaire administration|Ancillary studies
214785491|NCT04582448|DRUG|Insulin icodec|A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
214785492|NCT02390219|DRUG|Lumacaftor|
214785493|NCT02390219|DRUG|Ivacaftor|
214785494|NCT02662322|OTHER|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
214785495|NCT02662322|OTHER|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
214785496|NCT02662322|OTHER|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
214785497|NCT02662322|OTHER|peripheral intravenous catheterization|peripheral intravenous catheterization
214785498|NCT06271421|DEVICE|NanoTherm therapy|Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.
214785499|NCT06271421|PROCEDURE|Glioma Resection|Removal of brain tumor - gross total ressection
214785500|NCT06271421|RADIATION|radiotherapy according to Stupp protocol|The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.
214785501|NCT06271421|DRUG|chemotherapy according to Stupp protocol|Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
214785502|NCT02778178|DRUG|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
214785503|NCT02778178|DRUG|Placebo|20 mL saline 0.9%, per side
214785504|NCT02778178|DEVICE|ultrasound|
214785505|NCT02683733|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
214785506|NCT02683733|DRUG|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
214785507|NCT00271804|DRUG|bortezomib|
214785508|NCT03876158|DEVICE|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
214785509|NCT00054119|DRUG|Cositecan|Given IV
214785510|NCT00054119|OTHER|Pharmacological Study|Correlative studies
214785511|NCT04101136|DRUG|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
214785512|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
214785513|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
214785514|NCT05459168|DEVICE|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
214785515|NCT05879900|OTHER|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
214785516|NCT05879900|OTHER|Physical Education classes|Physical Education classes according their previously planned contents.
214785517|NCT00174759|DRUG|Clopidogrel|
214794218|NCT01610466|PROCEDURE|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
214785518|NCT06304870|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214785519|NCT06304870|DRUG|Lidocaine|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
214785520|NCT06304870|PROCEDURE|Injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process.
214785521|NCT02033876|DRUG|Ursodiol|
214785522|NCT05217056|OTHER|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
214785523|NCT01360632|DRUG|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
214785524|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
214785525|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
214785526|NCT01491490|DRUG|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
214785527|NCT01491490|DRUG|Placebo|Capsules taken once a day for 6 weeks
214785528|NCT02672774|PROCEDURE|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
214785529|NCT02672774|DEVICE|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
214785530|NCT06208761|OTHER|Triphala capsule supplementation and high-intensity interval training|Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
214785531|NCT02885935|OTHER|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
214785532|NCT02885935|OTHER|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
214785533|NCT01538706|OTHER|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
214785534|NCT06702540|DEVICE|Biosensor chip|An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
214785535|NCT00764998|BIOLOGICAL|Fluviral|
214785536|NCT00581594|PROCEDURE|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
214785537|NCT00581594|PROCEDURE|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
214785538|NCT03875183|DRUG|INL1|Capsules
214785539|NCT03875183|OTHER|Placebo|Capsules
214785540|NCT03608072|DRUG|BI 690517|3 sequential dose groups
214785541|NCT03608072|DRUG|Placebo|3 sequential dose groups
214785542|NCT02462382|PROCEDURE|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
214785543|NCT02462382|DRUG|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
214785544|NCT02462382|DRUG|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
214785545|NCT04157270|DEVICE|Penumbra System|Penumbra System
214785546|NCT04583488|DRUG|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
214785547|NCT06011473|DEVICE|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
214785548|NCT01528566|BEHAVIORAL|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
214785549|NCT01528566|BEHAVIORAL|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
214785550|NCT06340542|OTHER|Thoracic Mobility exercises|Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.
214785551|NCT06340542|OTHER|Manual Release technique|Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
214785552|NCT03839888|DRUG|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
214785553|NCT01846247|OTHER|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
214785554|NCT01846247|OTHER|Standard care|
214785555|NCT04351191|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
214785556|NCT04351191|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
214785557|NCT04351191|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
214785558|NCT04351191|DRUG|Placebo|Standard of Care plus placebo
214785559|NCT01681043|BEHAVIORAL|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks"
214785560|NCT05399719|OTHER||no intervention
214785561|NCT06496113|PROCEDURE|Minimally invasive liver resection|Patients underwent liver resection either by robotic or laparoscopic approach
214785562|NCT00612833|PROCEDURE|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
214785563|NCT05737888|OTHER|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
214785564|NCT05737888|OTHER|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
214785565|NCT05737888|BEHAVIORAL|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
214785566|NCT04741685|DEVICE|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
214785567|NCT04741685|DEVICE|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
214785568|NCT00003637|DRUG|cisplatin|
214785569|NCT00003637|DRUG|fluorouracil|
214785570|NCT00003637|RADIATION|radiation therapy|
214785571|NCT00845754|DRUG|ketorolac|15mg IV every6 hours for 4doses
214785572|NCT00845754|DRUG|saline|15mg IV every 6hrs for 4 doses
214785573|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
214785574|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
214785575|NCT00308373|DRUG|Metformin vs Thiazolidinedione (Pioglitazone)|
214785576|NCT01119976|BEHAVIORAL|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
214785577|NCT01119976|BEHAVIORAL|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
214785578|NCT04966897|DIETARY_SUPPLEMENT|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
214794219|NCT01612000|BIOLOGICAL|PanBlok|Intramuscular injection
214794220|NCT01612000|BIOLOGICAL|rHA adjuvant|Intramuscular injection
214794221|NCT00377052|DRUG|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
214785579|NCT04966897|DIETARY_SUPPLEMENT|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
214785580|NCT05871879|DIAGNOSTIC_TEST|The 5-item modified frailty index|The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
214785581|NCT03089632|OTHER|Gluten-free diet|One-month gluten-free diet
214785582|NCT05235594|DEVICE|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
214785583|NCT01060774|DRUG|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
214785584|NCT01060774|DRUG|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
214785585|NCT05636878|OTHER|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
214785586|NCT03250650|DEVICE|TTNS|Transcutaneous tibial electric stimulation
214785587|NCT03250650|DEVICE|ES+TTNS|Transvaginal electric stimulation
214785588|NCT03355378|PROCEDURE|gum chewing|chewing gum orally for 30 minutes
214785589|NCT01084005|DRUG|linagliptin|patients receive linagliptin 5 mg tablets once daily
214785590|NCT01084005|DRUG|placebo|patients receive placebo matching linagliptin 5 mg once daily
214785591|NCT02967198|DEVICE|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
214785592|NCT02967198|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
214785593|NCT04495777|OTHER|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
214785594|NCT05574582|PROCEDURE|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
214785595|NCT01753531|DEVICE|Flu Symptoms|
214785596|NCT01483976|OTHER|Oral medical nutritional supplement|orally over a three hour period
214785597|NCT01483976|OTHER|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
214785598|NCT04544891|OTHER|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
214785599|NCT00732329|BEHAVIORAL|Occupational Therapy|"optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy"
214785600|NCT01211574|BEHAVIORAL|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
214785601|NCT01211574|BEHAVIORAL|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
214785602|NCT01211574|BEHAVIORAL|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
214785603|NCT02223026|DRUG|Linagliptin/metformin FDC|
214785604|NCT02223026|OTHER|high-fat, high caloric meal|
214785605|NCT04033939|DRUG|HSK3486|
214785606|NCT04033939|DRUG|Propofol|
214785607|NCT04033939|DRUG|Placebo|
214785608|NCT04960696|DIAGNOSTIC_TEST|OSDI|Change of OSDI in distance education
214785609|NCT04960696|DIAGNOSTIC_TEST|tear break up time|Change of tear break up time in distance education
214785610|NCT04960696|DIAGNOSTIC_TEST|schirmer|Change of schirmer in distance education
214785611|NCT01132716|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
214785612|NCT04605419|PROCEDURE|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
214785613|NCT03569319|BEHAVIORAL|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
214785614|NCT03569319|BEHAVIORAL|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
214785615|NCT03569319|BEHAVIORAL|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
214794222|NCT00377052|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
214785616|NCT02480010|DRUG|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
214785617|NCT05485181|BEHAVIORAL|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
214785618|NCT03015142|DEVICE|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
214785619|NCT02967133|DRUG|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
214785620|NCT02967133|DRUG|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
214785621|NCT05431309|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
214785622|NCT05431309|OTHER|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
214785623|NCT01518452|BEHAVIORAL|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
214785624|NCT01518452|BEHAVIORAL|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
214785625|NCT03016585|OTHER|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
214785626|NCT01034137|DRUG|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
214785627|NCT01034137|DRUG|placebo MTX|orally weekly
214785628|NCT01034137|DRUG|placebo TCZ|iv every 4 weeks
214785629|NCT01034137|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
214785630|NCT00005583|DRUG|cisplatin|
214785631|NCT00005583|DRUG|doxorubicin hydrochloride|
214785632|NCT00005583|DRUG|epirubicin hydrochloride|
214785633|NCT00005583|PROCEDURE|adjuvant therapy|
214785634|NCT00005583|PROCEDURE|conventional surgery|
214785635|NCT00005583|RADIATION|radiation therapy|
214785636|NCT01718054|DIETARY_SUPPLEMENT|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
214785637|NCT01718054|DIETARY_SUPPLEMENT|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
214785638|NCT01718054|DRUG|Chloroquine|
214785639|NCT00936377|DRUG|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
214785640|NCT00936377|OTHER|Placebo|Normal saline for five days.
214785641|NCT01764854|DRUG|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
214785642|NCT01764854|DRUG|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
214785643|NCT01764854|DRUG|AZD1722 (out-patient)|doses between 5 and 45 mg BID
214785644|NCT01764854|DRUG|Placebo|Placebo, size and color matched to experimental drug
214785645|NCT03391297|BEHAVIORAL|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
214785646|NCT00521898|PROCEDURE|Descemet Membrane Endothelial Keratoplasty (DMEK)|
214785647|NCT04372498|DRUG|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
214785648|NCT04211298|DRUG|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
214785649|NCT04211298|DRUG|Propofol|Propofol
214785650|NCT03509298|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214785651|NCT03509298|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214785652|NCT00406198|PROCEDURE|venovenous hemofiltration|
214785653|NCT05044442|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
214785654|NCT05044442|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
214785655|NCT04497480|BEHAVIORAL|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
214785656|NCT02311426|OTHER|Observational study|Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
214785657|NCT06545240|DIAGNOSTIC_TEST|Mid-upper arm circumference|Mid-upper arm circumference was taken using non-stretchable band SECA 202
214794223|NCT04954131|BIOLOGICAL|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
214794224|NCT04954131|OTHER|Placebo|Saline solution (0.9%)
214785658|NCT02165579|OTHER|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
214785659|NCT03377556|OTHER|Laboratory Biomarker Analysis|Correlative studies
214785660|NCT03377556|OTHER|Pharmacological Study|Correlative studies
214785661|NCT03377556|DRUG|Talazoparib|Given PO
214785662|NCT04038151|DEVICE|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
214785663|NCT04038151|DEVICE|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
214785664|NCT00057447|DRUG|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
214785665|NCT00057447|DRUG|Rituximab|375 mg per square meters, IV, 1x per week
214785666|NCT01630200|DRUG|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
214785667|NCT01630200|DRUG|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
214785668|NCT03828123|BIOLOGICAL|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
214785669|NCT01593527|DRUG|ACZ885|Canakinumab 150 mg s.c.
214785670|NCT01593527|DRUG|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
214785671|NCT02655172|OTHER|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
214785672|NCT02655172|OTHER|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
214785673|NCT03689296|OTHER|Questionnaires (Phase 3)|"* CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale"
214785674|NCT03689296|OTHER|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
214785675|NCT03689296|OTHER|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
214785676|NCT00654706|DRUG|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
214785677|NCT00654706|DRUG|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
214785678|NCT01730677|DRUG|Lapatinib|lapatinib 1000mg, once daily
214785679|NCT01730677|DRUG|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
214785680|NCT05923164|DIAGNOSTIC_TEST|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
214794225|NCT02173704|BIOLOGICAL|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
214785681|NCT05923164|DIAGNOSTIC_TEST|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
214785682|NCT04105790|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
214785683|NCT04317573|DEVICE|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
214785684|NCT05353374|DRUG|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
214785685|NCT05353374|DRUG|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
214785686|NCT00277680|PROCEDURE|Laparoscopic bilateral occlusion of uterine artery|
214785687|NCT00277680|PROCEDURE|Radiological embolization (UFE)|
214785688|NCT00567281|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
214785689|NCT00567281|DEVICE|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
214785690|NCT03182608|DIAGNOSTIC_TEST|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
214785691|NCT01891513|BEHAVIORAL|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
214785692|NCT01891513|DRUG|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
214785693|NCT01891513|DRUG|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
214785694|NCT01891513|DRUG|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
214785695|NCT04739449|BEHAVIORAL|Coaching, Cleaning, Communication, Collaboration|"1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise"
214785696|NCT00208949|DRUG|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
214785697|NCT00208949|DRUG|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
214785698|NCT01684566|DEVICE|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
214785699|NCT01684566|OTHER|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
214785700|NCT02999464|OTHER|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
214785701|NCT02999464|OTHER|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
214785702|NCT02849821|OTHER|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
214785703|NCT02849821|OTHER|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
214785704|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
214785705|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
214785706|NCT04091542|DEVICE|Optiflow/Ventilator|Participants will have 2 days with optiflow, 2 days with ventilator.
214785707|NCT05465915|DEVICE|Electroconvulsive therapy|Patients are treated with ECT.
214785708|NCT02523911|DRUG|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
214785709|NCT02523911|DRUG|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
214785710|NCT02523911|DRUG|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
214785711|NCT00672971|OTHER|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
214785712|NCT00672971|OTHER|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
214785713|NCT01153061|DEVICE|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
214785714|NCT01153061|DEVICE|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
214785715|NCT00505609|BEHAVIORAL|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
214785716|NCT06074471|PROCEDURE|ultrasound guided supraclavicular brachial plexus block|"Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))"
214785717|NCT01924871|DRUG|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
214785718|NCT01924871|DRUG|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
214785719|NCT02736227|DRUG|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
214785720|NCT01765985|DEVICE|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
214785721|NCT01765985|DEVICE|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
214785722|NCT04120194|BIOLOGICAL|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
214785723|NCT04120194|BIOLOGICAL|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
214785724|NCT04481971|DRUG|Prednisolone|Tablets
214785725|NCT04481971|DRUG|lactose in capsules gelatin|Tablets
214785726|NCT05448144|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
214785727|NCT00300092|DRUG|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
214794226|NCT02173704|BIOLOGICAL|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
214785728|NCT00613678|BEHAVIORAL|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
214785729|NCT00613678|BEHAVIORAL|Education|The health education program is based on educational materials from the Arthritis Foundation.
214785730|NCT02469974|DRUG|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
214785731|NCT02469974|DRUG|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
214785732|NCT02469974|DRUG|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
214785733|NCT03297359|BIOLOGICAL|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
214785734|NCT05140161|DEVICE|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
214785735|NCT04790305|DRUG|Huaier Granule|The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
214785736|NCT03455023|OTHER|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
214785737|NCT00271999|BEHAVIORAL|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
214785738|NCT01917188|BEHAVIORAL|Full simulation and education|
214785739|NCT01917188|BEHAVIORAL|See simulation room, usual education|
214785740|NCT00123058|BEHAVIORAL|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
214785741|NCT00123058|DEVICE|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
214785742|NCT03701620|DIAGNOSTIC_TEST|HRV monitoring|HRV monitoring derived from electrocardiogram
214785743|NCT04399720|PROCEDURE|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
214785744|NCT00827359|DRUG|Everolimus|Tablet form taken orally once a day
214785745|NCT01340950|DRUG|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
214785746|NCT01340950|DRUG|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
214785747|NCT01802840|DIETARY_SUPPLEMENT|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
214785748|NCT02343016|DEVICE|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
214785749|NCT01159769|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
214785750|NCT02555618|BIOLOGICAL|TAK-850|TAK-850 subcutaneous injection
214785751|NCT02555618|BIOLOGICAL|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
214785752|NCT03076671|BEHAVIORAL|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
214785753|NCT05612737|PROCEDURE|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
214785754|NCT01584726|DRUG|Magnesium Sulfate|single dose of magnesium sulfate nebulization
214785755|NCT05319340|OTHER|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
214785756|NCT02063698|DRUG|auranofin|Given PO
214785757|NCT02063698|OTHER|placebo|Given PO
214785758|NCT02063698|OTHER|questionnaire administration|Ancillary studies
214785759|NCT02734615|DRUG|LSZ102|LSZ102
214785760|NCT02734615|DRUG|LEE011|LEE011
214785761|NCT02734615|DRUG|BYL719|BYL719
214785762|NCT00851266|BIOLOGICAL|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1\) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
214785763|NCT00851266|BIOLOGICAL|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
214794227|NCT03256968|DRUG|Ataluren|ataluren
214794228|NCT04088214|PROCEDURE|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
214794229|NCT01989520|DRUG|Phase IIb formulation|Single oral dose 45mg AZD5069
214785764|NCT05077306|OTHER|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
214785765|NCT02098356|OTHER|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
214785766|NCT00325494|DRUG|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
214785767|NCT02896868|DRUG|LY3041658|Administered IV.
214785768|NCT02896868|DRUG|Placebo|Administered IV.
214785769|NCT04400695|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
214785770|NCT04400695|DRUG|Paclitaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
214785771|NCT04400695|DRUG|Docetaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
214785772|NCT04400695|DRUG|Vinorelbine Tartrate Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
214785773|NCT04400695|DRUG|Capecitabine Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
214785774|NCT03560622|DEVICE|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
214785775|NCT01005550|DRUG|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
214785776|NCT01005550|DRUG|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
214785777|NCT01005550|DRUG|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
214785778|NCT01005550|DRUG|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
214785779|NCT00428194|DRUG|cisplatin|40 mg/m\^2 every 7 days during radiation
214785780|NCT00428194|DRUG|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
214785781|NCT00428194|PROCEDURE|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
214785782|NCT03908983|DEVICE|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
214785783|NCT03335943|DRUG|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
214785784|NCT03111979|DIETARY_SUPPLEMENT|beta-alanine|
214785785|NCT03111979|DIETARY_SUPPLEMENT|Placebo|
214785786|NCT02439242|DRUG|fluid challenge of saline|250 ml of saline
214785787|NCT01151787|DRUG|cyclobenzaprine hydrochloride|15mg daily for 3 months
214785788|NCT01151787|DRUG|placebo|placebo
214785789|NCT03989960|PROCEDURE|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
214785790|NCT03989960|PROCEDURE|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
214785791|NCT03276910|DRUG|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
214785792|NCT03276910|DRUG|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
214785793|NCT00410410|DRUG|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
214785794|NCT00410410|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
214785795|NCT00410410|DRUG|abatacept|"\~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
214785796|NCT01712412|DRUG|IW-9179|
214785797|NCT01712412|DRUG|Placebo|
214785798|NCT01232257|DRUG|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
214785799|NCT03114189|PROCEDURE|footbath|
214785800|NCT03114189|BEHAVIORAL|care of sleep|
214785801|NCT02357550|DRUG|ketone|3-OHB is infused intravenously.
214785802|NCT02357550|DRUG|placebo|Saline infusion.
214785803|NCT06481826|DRUG|Glofitamab|Glofitamab given in standard dosage
214785804|NCT00229112|DRUG|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
214785805|NCT00229112|DRUG|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
214785806|NCT05030857|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
214785807|NCT05030857|DRUG|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
214785808|NCT00988234|PROCEDURE|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
214785809|NCT00988234|PROCEDURE|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
214785810|NCT00988234|PROCEDURE|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
214785811|NCT00988234|PROCEDURE|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
214785812|NCT01953783|DRUG|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
214785813|NCT03535883|DRUG|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
214785814|NCT03553277|OTHER|transfluthrin|passive emanator with formulated transfluthrin
214785815|NCT03553277|OTHER|placebo|passive emanator with formulated inert ingredients
214785816|NCT04800055|OTHER|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
214785817|NCT04897971|DIAGNOSTIC_TEST|Medium enriched for newly synthesized antibodies in spine infection|Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
214785818|NCT05007691|DEVICE|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
214785819|NCT04275219|DRUG|Tongfu capsules|Tongfu capsules include 5 herbals
214785820|NCT04275219|DRUG|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
214785821|NCT03611114|DIETARY_SUPPLEMENT|Blood orange juice|
214785822|NCT03611114|DIETARY_SUPPLEMENT|Control drink|
214785823|NCT04597606|OTHER|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
214785824|NCT04597606|DEVICE|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
214785825|NCT04597606|DEVICE|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
214785826|NCT02832908|OTHER|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
214785827|NCT02752256|DRUG|Tissue Plasminogen Activator|
214785828|NCT00132431|DRUG|Sensipar|
214785829|NCT04013256|OTHER|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
214785830|NCT04013256|OTHER|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
214785831|NCT04735237|PROCEDURE|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
214785832|NCT04735237|PROCEDURE|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
214785833|NCT04647344|DRUG|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
214785834|NCT04647344|DRUG|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
214785835|NCT02159859|DRUG|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
214785836|NCT05806359|DRUG|Danicamtiv|Specified dose on specified days
214785837|NCT05806359|DRUG|Placebo|Specified dose on specified days
214785838|NCT05092711|BEHAVIORAL|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
214785839|NCT05092711|DRUG|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
214785840|NCT01930084|OTHER|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
214785841|NCT01930084|OTHER|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
214785842|NCT01930084|BEHAVIORAL|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
214785843|NCT01930084|OTHER|Non-cash Financial Incentives|Non-cash Financial Incentives
214785844|NCT06288165|DEVICE|Coronary Sinus Reducer Implantation|Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
214785845|NCT03150836|DRUG|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
214785846|NCT03150836|DRUG|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
214785847|NCT03150836|RADIATION|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
214785848|NCT01271933|DRUG|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
214785849|NCT01271933|DRUG|placebo|matching placebo tablet; given once daily
214785850|NCT01424956|DEVICE|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
214785851|NCT04497090|DEVICE|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
214785852|NCT04497090|DEVICE|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
214785853|NCT06276179|DRUG|Oxycodone|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
214785854|NCT06276179|DRUG|Bupivacaine|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
214785855|NCT06526767|DEVICE|Vibrabot capsules twice a week|Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
214785856|NCT06526767|DEVICE|Vibrabot capsules three times a week|Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
214785857|NCT06526767|DEVICE|Vibrabot capsules five times a week|Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
214785858|NCT06526767|DEVICE|Vibrabot capsules loading dose|Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
214785859|NCT04009057|OTHER|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
214785860|NCT03856671|DRUG|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
214785861|NCT01433133|BIOLOGICAL|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
214785862|NCT03062865|OTHER|No intervention|
214785863|NCT01138150|DRUG|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
214785864|NCT01138150|DRUG|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
214785865|NCT05496114|DEVICE|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
214785866|NCT01897597|DRUG|BI 144807 high dose|oral solution
214785867|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
214785868|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
214785869|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
214785870|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
214785871|NCT01897597|DRUG|BI 144807 intermediate dose|oral solution
214785872|NCT01897597|DRUG|BI 144807 high dose|tablet
214785873|NCT05085054|DRUG|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
214785874|NCT01713153|DRUG|Misoprostol|600 mcg misoprostol oral
214785875|NCT01713153|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
214785876|NCT06344442|DRUG|Arginine vasopressin|low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
214785877|NCT06344442|DRUG|Norepinephrine|Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
214785878|NCT05200702|DEVICE|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
214785879|NCT02880904|OTHER|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
214785880|NCT01788722|DRUG|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
214785881|NCT05085964|DRUG|RNA antisense oligonucleotide for intravitreal injection|"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
214785882|NCT03676023|DRUG|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
214785883|NCT04841239|OTHER|Herbal topical formulation|
214785884|NCT01040221|DRUG|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
214785885|NCT02914366|DRUG|Ambroxol|
214785886|NCT02914366|OTHER|Placebo|
214785887|NCT04525742|OTHER|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
214785888|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
214785889|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
214785890|NCT04539509|BEHAVIORAL|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
214785891|NCT04539509|BEHAVIORAL|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
214785892|NCT04539509|DEVICE|Monitoring|Activity monitoring using a Fitbit.
214785893|NCT01089049|DIETARY_SUPPLEMENT|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
214785894|NCT02077192|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
214785895|NCT05649631|DIETARY_SUPPLEMENT|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
214785896|NCT02197182|DRUG|LUXSOL copper containing cream|Active comparator arm
214785897|NCT02197182|DRUG|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
214785898|NCT02106169|BEHAVIORAL|Therapeutic education group|
214785899|NCT03559010|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
214785900|NCT00807625|DRUG|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
214785901|NCT00807625|DEVICE|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
214785902|NCT04271150|DEVICE|Self-etch|Universal adhesive with self-etch mode
214785903|NCT04271150|DEVICE|Total-etch|Universal adhesive with total-etch mode
214785904|NCT06134739|OTHER|No intervention.|Observational study, no intervention.
214785905|NCT03999281|OTHER|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
214785906|NCT00012155|BIOLOGICAL|NV1020|
214785907|NCT00059514|BEHAVIORAL|Modified Project Toward No Tobacco Use|
214785908|NCT06321237|DEVICE|Vagus nerve stimulation for 8 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks
214785909|NCT06321237|DEVICE|Vagus nerve stimulation for the first 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks
214785910|NCT06321237|DEVICE|Vagus nerve stimulation for the last 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks
214785911|NCT06321237|DEVICE|Pseudostimulus|The patient is given some electrical stimulation but not vagus nerve stimulation
214785912|NCT03156270|DEVICE|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
214785913|NCT04343911|DEVICE|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
214785914|NCT00644371|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
214785915|NCT01888471|PROCEDURE|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
214785916|NCT01888471|OTHER|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
214785917|NCT01768078|PROCEDURE|Intravitreal injection of Betamethasone + antibiotics|
214785918|NCT01768078|PROCEDURE|Intravitreal injection of antibiotics|
214785919|NCT03582293|DRUG|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
214785920|NCT03582293|DRUG|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
214785921|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
214785922|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
214785923|NCT00591253|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
214785924|NCT02005354|DEVICE|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).
214785925|NCT02005354|DRUG|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
214785926|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
214785927|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
214785928|NCT03428659|OTHER|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
214785929|NCT03986749|PROCEDURE|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
214785930|NCT02501109|DRUG|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
214785931|NCT04826185|DRUG|IMB-1018972|Modified release (MR) oral tablet
214785932|NCT04826185|DRUG|Placebo|Matching oral tablet
214785933|NCT05037682|OTHER|Dissemination and Implementation Research|The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
214785934|NCT00002777|DRUG|exemestane|
214785935|NCT00002777|DRUG|tamoxifen citrate|
214785936|NCT04964622|DRUG|nurofen|tablet
214785937|NCT00773526|DRUG|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
214785938|NCT04809779|DRUG|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
214785939|NCT02827513|DRUG|CTN SR1|
214785940|NCT02827513|DRUG|CTN XR1|
214785941|NCT02827513|DRUG|CTN XR2|
214785942|NCT02827513|DRUG|CTN XR3|
214785943|NCT04525157|DRUG|Afamelanotide|
214785944|NCT04525157|DRUG|Placebo|
214785945|NCT05881200|DEVICE|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
214785946|NCT00592020|PROCEDURE|Short Transverse Incision|Short Transverse Incision for kidney transplantation
214785947|NCT00592020|PROCEDURE|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
214785948|NCT01457131|DRUG|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
214785949|NCT01457131|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
214785950|NCT01457131|OTHER|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
214785951|NCT01604382|DRUG|General Anesthesia|General Anesthesia as described above
214785952|NCT01604382|DRUG|Neuraxial anesthesia|Neuraxial anesthesia as described above
214785953|NCT03574246|DRUG|chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15|chlorhexidine gluconate + benzydamine hydrochloride oral rinse
214785954|NCT03574246|OTHER|%0.9 NaCl Solution|isotonic sodium chloride
214785955|NCT00798083|DRUG|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
214785956|NCT03242382|DRUG|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
214785957|NCT04911920|OTHER|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
214785958|NCT01741480|OTHER|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
214785959|NCT01741480|OTHER|routine care|
214785960|NCT01562431|OTHER|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
214785961|NCT02801591|PROCEDURE|Conventional ovarian stimulation proctol without rhGH|
214785962|NCT00096369|DRUG|tamoxifen citrate|
214785963|NCT00609895|DRUG|INSULIN GLARGINE|
214785964|NCT05127603|BEHAVIORAL|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
214785965|NCT01841359|DRUG|Pramlintide|See description above (arm description).
214785966|NCT05846828|OTHER|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~1. Verbal ability.~2. Abstract/Visual ability.~3. Quantaitive potential.~4. Short-Term Memory Scales"
214785967|NCT00740467|BIOLOGICAL|anti-thymocyte globulin|
214785968|NCT00740467|DRUG|busulfan|
214785969|NCT00740467|DRUG|cyclophosphamide|
214785970|NCT00740467|DRUG|cyclosporine|
214785971|NCT00740467|DRUG|fludarabine phosphate|
214785972|NCT00740467|DRUG|mycophenolate mofetil|
214785973|NCT00740467|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214785974|NCT01783769|BEHAVIORAL|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
214785975|NCT02168270|DIETARY_SUPPLEMENT|ascorbic acid|Given IV
214785976|NCT02168270|DRUG|temozolomide|Given PO
214785977|NCT02168270|OTHER|quality-of-life assessment|Ancillary studies
214785978|NCT02168270|OTHER|laboratory biomarker analysis|Correlative studies
214785979|NCT02248532|BIOLOGICAL|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
214785980|NCT04780737|PROCEDURE|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
214785981|NCT01324245|DRUG|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
214785982|NCT01190306|DEVICE|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
214785983|NCT01190306|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
214785984|NCT04571957|OTHER|No Intervention|No Intervention
214785985|NCT05031481|DRUG|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
214785986|NCT05031481|DRUG|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
214785987|NCT05031481|DRUG|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
214785988|NCT05031481|DRUG|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
214785989|NCT01875445|DRUG|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
214785990|NCT01875445|DRUG|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
214785991|NCT05354245|DIETARY_SUPPLEMENT|Fibre supplement (potato-pectin)|Fibre supplement
214785992|NCT05354245|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214785993|NCT05354245|DIETARY_SUPPLEMENT|High-protein diet|High-protein diet
214785994|NCT01102777|BEHAVIORAL|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
214785995|NCT01102777|OTHER|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
214785996|NCT05837559|OTHER|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
214785997|NCT03233282|OTHER|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
214785998|NCT03233282|OTHER|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
214785999|NCT03233282|OTHER|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
214786000|NCT03233282|OTHER|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
214786001|NCT03233282|OTHER|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
214786002|NCT03233282|OTHER|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786003|NCT03233282|OTHER|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786004|NCT03233282|OTHER|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786005|NCT03233282|OTHER|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786006|NCT03233282|OTHER|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786007|NCT03233282|OTHER|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
214786008|NCT06107088|DIETARY_SUPPLEMENT|Active 1|lactase enzyme
214786009|NCT06107088|DIETARY_SUPPLEMENT|Active 2|lactase-bacterial strain combination
214786010|NCT06107088|DIETARY_SUPPLEMENT|Active 3|bacterial strain alone
214786011|NCT06107088|DIETARY_SUPPLEMENT|Placebo|placebo
214786012|NCT04804332|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
214786013|NCT04804332|OTHER|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
214786014|NCT01449058|DRUG|BYL719|taken orally
214786015|NCT01449058|DRUG|MEK162|taken orally
214786016|NCT06286566|DEVICE|Implant placement with soi surface in diabetic subjects|Implants placement with SOI surface in subjects with diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
214786017|NCT06286566|DEVICE|Implant placement with soi surface in healthy subjects|Implants placement with SOI surface in subjects without diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
214786018|NCT00771901|DRUG|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
214786019|NCT00771901|OTHER|placebo|7 pills daily for 4 weeks
214786020|NCT00771901|DRUG|sodium phenylbutyrate|20g/day for four weeks.
214786021|NCT00001144|DRUG|Modified bone marrow stem cell transplantation|
214786022|NCT01675869|BEHAVIORAL|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
214786023|NCT01675869|BEHAVIORAL|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
214786024|NCT00947765|BIOLOGICAL|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
214786025|NCT00947765|DRUG|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
214786026|NCT03902756|OTHER|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
214786027|NCT01740856|OTHER|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
214786028|NCT01740856|OTHER|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
214786029|NCT03036033|DEVICE|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
214786030|NCT04388033|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
214786031|NCT04388033|DRUG|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
214786032|NCT04388033|DRUG|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
214786033|NCT03922659|COMBINATION_PRODUCT|Transcranial magnetic stimulation and Cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
214786034|NCT04380571|DEVICE|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
214794230|NCT01989520|DRUG|Putative phase III formulation|Single oral dose 45mg AZD5069
214786035|NCT04380571|DEVICE|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
214786036|NCT04380571|OTHER|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
214786037|NCT01965652|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
214786038|NCT01965652|DRUG|Placebo|Placebo tablet taken orally once a day
214786039|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
214786040|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
214786041|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
214786042|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
214786043|NCT02758093|BEHAVIORAL|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
214786044|NCT02758093|OTHER|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
214786045|NCT05073900|PROCEDURE|Rhomboid intercostal block|two regional anesthesia block techniques are applied
214786046|NCT02922803|DRUG|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
214786047|NCT02922803|DRUG|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
214786048|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
214786049|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
214786050|NCT00591422|DRUG|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
214786051|NCT02583620|GENETIC|blood sample|A blood test is realized on the subject
214786052|NCT01328054|DRUG|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
214786053|NCT01328054|DRUG|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
214786054|NCT05588830|DRUG|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
214786055|NCT05588830|DRUG|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
214786056|NCT00180869|PROCEDURE|transfusion of allogeneic red blood cell concentrate|
214786057|NCT00180869|PROCEDURE|transfusion of leuko-reduced red blood cell concentrate|
214786058|NCT05500495|OTHER|no intervention|no intervention
214786059|NCT06424678|OTHER|Only data collection in the Utstein template|The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
214786060|NCT03549663|DRUG|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
214794231|NCT01989520|DRUG|Slow dissolution variant 1|Single oral dose 45mg AZD5069
214794232|NCT01989520|DRUG|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
214786061|NCT03549663|DRUG|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
214786062|NCT03493698|DRUG|Midazolam|Midazolam
214786063|NCT03493698|DRUG|Inarigivir|Inarigivir
214786064|NCT03760510|DEVICE|Tube Fastener|Endotrachel tube secured with tube fastener
214786065|NCT03760510|DEVICE|Adhesive Tape|Endotracheal tube secured with adhesive tape.
214786066|NCT01491659|DIETARY_SUPPLEMENT|Idoform Plus|orally once daily
214786067|NCT01491659|DIETARY_SUPPLEMENT|Placebo|orally once daily
214786068|NCT03170505|PROCEDURE|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
214786069|NCT03111888|DEVICE|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
214786070|NCT01016860|DRUG|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
214786071|NCT01016860|DRUG|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
214786072|NCT00000531|DEVICE|defibrillators, implantable|
214786073|NCT00000531|DRUG|amiodarone amiodarone|
214786074|NCT00000531|DRUG|sotalol|
214786075|NCT04341818|OTHER|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
214786076|NCT04341818|OTHER|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
214786077|NCT04341818|OTHER|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
214786078|NCT06219382|DEVICE|Neurorehabilitation ecosystem|Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
214786079|NCT00987987|PROCEDURE|donor lymphocyte infusion|regulatory T cells depletion
214794233|NCT01989520|DRUG|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
214786080|NCT04566783|DIAGNOSTIC_TEST|Psychological/psychiatric examination|Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
214786081|NCT04566783|DIAGNOSTIC_TEST|Neurological examination|Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
214786082|NCT04566783|DIAGNOSTIC_TEST|Gynecological/urological examination|Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
214786083|NCT04566783|DIAGNOSTIC_TEST|Laboratory assessment|Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
214786084|NCT04566783|DIAGNOSTIC_TEST|Structural and Functional Magnetic Resonance Imaging|"1. Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~2. Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~3. High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~4. Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~5. Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~6. Functional MRI to assess brain response towards sexual cue reactivity."
214786085|NCT02112903|DRUG|Encapsulated vortioxetine IR tablet, 20 mg|
214786086|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 5.5)|
214786087|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 6.0)|
214786088|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 7.0)|
214786089|NCT00235833|BIOLOGICAL|adalimumab|40 mg every other week (eow), subcutaneous (sc)
214786090|NCT00887627|DRUG|conivaptan hydrochloride|intravenous
214786091|NCT01344395|DRUG|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
214786092|NCT01344395|DRUG|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
214786093|NCT06319391|OTHER|CYP3A5*1*、CYP3A5*1*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
214786094|NCT06319391|OTHER|CYP3A5*3*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
214786095|NCT05729100|OTHER|Oral carbohydrate-electrolyte solution|Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)
214786096|NCT05729100|OTHER|Control|Standard clear fluid (water)
214786097|NCT00139204|PROCEDURE|C11 Methionine PET scan|
214794234|NCT05378906|DRUG|DRV/COBI FDC|Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
214794235|NCT05378906|DRUG|COBI|Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.
214786098|NCT05512325|DRUG|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
214786099|NCT01288833|DEVICE|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
214786100|NCT03275701|DRUG|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
214786101|NCT06120010|DEVICE|MRI|To detect prevalence of anatomical variants of dural sinuses by MRV
214786102|NCT05481060|OTHER|Screen-based simulation|In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
214786103|NCT01877707|OTHER|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
214786104|NCT00492089|DRUG|bevacizumab|Given IV
214786105|NCT00492089|DRUG|placebo|Given IV
214786106|NCT00492089|PROCEDURE|magnetic resonance imaging|
214786107|NCT00492089|PROCEDURE|quality-of-life assessment|
214786108|NCT02631109|DRUG|Pegaspargase|2000U/m2 day5
214786109|NCT02631109|DRUG|doxorubicin|25mg/m2 day1
214786110|NCT02631109|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
214786111|NCT02631109|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
214786112|NCT00566709|PROCEDURE|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
214786113|NCT04157634|DIAGNOSTIC_TEST|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
214786114|NCT05385029|DRUG|Thyroxine|treatment for hypothyroidism or hyperthyroidism
214786115|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
214786116|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 3, single dose
214786117|NCT01387308|DRUG|Fostamatinib|Oral tablets, 100 mg, single dose
214786118|NCT01387308|DRUG|Fostamatinib|Oral tablets, 150 mg, single dose
214786119|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
214786120|NCT01653197|BEHAVIORAL|Control|No scratch off element
214786121|NCT01653197|BEHAVIORAL|Curiosity|The recipient will be prompted to scratch off for answer to question.
214786122|NCT01653197|BEHAVIORAL|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
214786123|NCT01340274|BEHAVIORAL|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
214786124|NCT01340274|BEHAVIORAL|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
214786125|NCT02355548|OTHER|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
214786126|NCT01754181|DRUG|Insulin|the intervention is applied only at the dose of insulin
214786127|NCT02178449|DRUG|Dexamethasone acetate|
214786128|NCT02178449|DRUG|Placebo|
214786129|NCT02178449|DRUG|Ropivacaine|
214786130|NCT03443869|DRUG|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
214786131|NCT03443869|DRUG|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
214786132|NCT03443869|DRUG|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
214786133|NCT03443869|DRUG|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
214786134|NCT03443869|DRUG|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
214786135|NCT03443869|DRUG|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
214786136|NCT00001622|PROCEDURE|investigate the relationship between in vivo and in vitro vascular responses|
214786137|NCT05509322|OTHER|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
214786138|NCT05509322|OTHER|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
214786139|NCT04755881|OTHER|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
214786140|NCT00035165|DRUG|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
214786141|NCT04052399|DEVICE|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
214786142|NCT04052399|DEVICE|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
214786143|NCT04052399|DEVICE|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
214786144|NCT00299728|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
214786145|NCT01951183|DRUG|Placebo|RO681135 placebo subcutaneously daily
214786146|NCT01951183|DRUG|RO6811135|Subcutaneously daily
214786147|NCT01626378|DRUG|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
214786148|NCT01626378|DRUG|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
214786149|NCT00301106|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
214786150|NCT06528028|DRUG|CAZ/AVI|continuous infusion is used
214786151|NCT06528028|DRUG|CAZ/AVI|2h-infusion is used
214786152|NCT01718210|DRUG|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
214786153|NCT01718210|DRUG|CONTROL|group of controls treated with a standard IVF medium
214786154|NCT01572961|DRUG|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
214786155|NCT01572961|DRUG|Placebo|
214786156|NCT05455970|OTHER|Rhythmic auditory stimulation (RAS)|A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
214786157|NCT04076306|OTHER|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
214786158|NCT06359678|DEVICE|NorthStar|Throughout the real-time MRI-guided ablation procedure, the operator will assess the precision of the NorthStar 3D navigation software. Before commencing the actual ablation, the operator will confirm the alignment of the 3D anatomical shell, generated in NorthStar through specific electrical signals. Post the ablation procedure, a secondary alignment verification will be conducted to detect any potential drift or shift.
214786159|NCT03474705|DEVICE|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
214786160|NCT02826603|DRUG|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
214786161|NCT02826603|DRUG|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
214786162|NCT03958981|DRUG|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
214786163|NCT03958981|DRUG|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
214786164|NCT04846556|OTHER|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
214786165|NCT02531230|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
214786166|NCT01269983|OTHER|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
214786167|NCT03221946|DRUG|Diclofenac Sodium|tablet of 50mg,
214786168|NCT03221946|DRUG|Diclofenac sodium|Transdermal patch 100 mg
214786169|NCT03221946|DRUG|Diclofenac|intra muscular injection 100mg
214786170|NCT03654209|DEVICE|Argon Plasma Coagulation|APC will be applied to the perimeter of the resection site
214786171|NCT03654209|DEVICE|Snare Tip Soft Coagulation|STSC will be applied to the perimeter of the resection site
214786172|NCT03681106|DEVICE|Kinesio Tex|Kinesio Tex tape on the operated limb
214786173|NCT01337050|DRUG|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
214786174|NCT00003102|BIOLOGICAL|Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)|cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.
214786175|NCT00583596|DEVICE|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
214786176|NCT00583596|OTHER|Objective Performance Criteria|Compare results of device closure to objective performance criteria
214794236|NCT05378906|DRUG|DRV|Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
214786177|NCT01955603|DRUG|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
214786178|NCT01955603|DRUG|placebo|Placebo administered corresponding to NNC0215-0384 treatment
214786179|NCT04939974|DIETARY_SUPPLEMENT|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
214786180|NCT06194097|PROCEDURE|adenoidectomy versus endoscopic sinus surgery with adenoidectomy|adenoidectomy versus endoscopic sinus surgery
214786181|NCT03502421|DRUG|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
214786182|NCT00656019|DRUG|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
214786183|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
214786184|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
214786185|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
214786186|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
214786187|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
214786188|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
214786189|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
214786190|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
214786191|NCT02972970|DEVICE|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
214786192|NCT01503242|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214786193|NCT01503242|DRUG|Cyclosporine|Given PO
214786194|NCT01503242|DRUG|Fludarabine Phosphate|Given IV
214786195|NCT01503242|DRUG|Mycophenolate Mofetil|Given IV or PO
214786196|NCT01503242|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214786197|NCT01503242|RADIATION|Total-Body Irradiation|Undergo TBI
214786198|NCT01503242|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
214786199|NCT04060472|DRUG|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
214786200|NCT00787670|OTHER|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
214786201|NCT00787670|PROCEDURE|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
214786202|NCT00787670|OTHER|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
214786203|NCT02808806|OTHER|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
214786204|NCT06320899|DEVICE|SpineShape System IV straight rod elastic|Implantation of SpineShape System IV straight rod elastic
214786205|NCT06320899|DEVICE|SpineShape System IV straight rod medium|Implantation of SpineShape System IV straight rod medium (mid-flex)
214786206|NCT06320899|DEVICE|SpineShape System IV straight rod stiff|Implantation of SpineShape System IV straight rod stiff (low-flex)
214786207|NCT00096486|DRUG|everolimus|
214786208|NCT00096486|DRUG|gefitinib|
214786209|NCT01306461|DRUG|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
214786210|NCT01306461|DRUG|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
214786211|NCT01645228|RADIATION|coronary calcium score measurement|
214786212|NCT01645228|BIOLOGICAL|high sensitivity C reactive protein measurement|
214786213|NCT01645228|PROCEDURE|ankle brachial index measurement|
214786214|NCT04528628|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
214786215|NCT04528628|DRUG|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
214786216|NCT04528628|COMBINATION_PRODUCT|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
214786217|NCT03558997|DRUG|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
214786218|NCT03558997|DRUG|Timothy Grass SCIT|Timothy grass extract was administered SC.
214786219|NCT03558997|DRUG|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
214786220|NCT03558997|DRUG|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
214786221|NCT02589769|OTHER|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
214786222|NCT02589769|OTHER|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
214786223|NCT00934037|PROCEDURE|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
214786224|NCT00934037|OTHER|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
214786225|NCT03780933|DIETARY_SUPPLEMENT|vitamin c|vitamin c IV 10 G
214786226|NCT02711189|DRUG|Oxytocin|Oxytocin nasal spray given in dose 80
214786227|NCT02711189|OTHER|Placebo|
214786228|NCT01569503|DEVICE|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
214786229|NCT02144493|OTHER|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
214786230|NCT02144493|OTHER|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
214786231|NCT01015911|DRUG|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
214786232|NCT02230085|OTHER|Administration of the questionnaire and monitoring of CPAP adherence|
214786233|NCT03793075|DRUG|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
214786234|NCT03793075|DRUG|Propofol|propofol 17 mcg /kg/min
214786235|NCT04779411|OTHER|Weekly Food Frequency Questionnaire|A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.
214786236|NCT04779411|OTHER|Monthly Food Frequency Questionnaire|A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
214786237|NCT04779411|OTHER|24-Hour Diet Recall|the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.
214786238|NCT04779411|OTHER|Electronic Device Use Questionnaire|1\. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.
214786239|NCT04779411|OTHER|24-Hour Electronic Device Use Diary|Participants asked to record their electronic device use in hours and minutes over 24 hours.
214786240|NCT01986790|BEHAVIORAL|Plain Language|
214786241|NCT01986790|BEHAVIORAL|Plain Language + Visuals|
214786242|NCT01986790|BEHAVIORAL|Plain Language + Narratives|
214786243|NCT01968616|DRUG|Ranibizumab, 0.5mg, Intravitreal|
214786244|NCT00137085|DRUG|ketamine|
214786245|NCT00897533|GENETIC|gene mapping|
214786246|NCT00897533|GENETIC|polymorphism analysis|
214786247|NCT00897533|OTHER|diagnostic laboratory biomarker analysis|
214786248|NCT00897533|OTHER|immunohistochemistry staining method|
214786249|NCT03479385|BEHAVIORAL|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
214786250|NCT03479385|BEHAVIORAL|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
214786251|NCT00196222|PROCEDURE|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
214786252|NCT00196222|PROCEDURE|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
214786253|NCT00280774|DRUG|Memantine|
215030903|NCT02759510|DRUG|Phenylephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
214786254|NCT03268031|DIAGNOSTIC_TEST|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
214786255|NCT04729218|BEHAVIORAL|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
214786256|NCT03101423|DRUG|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
214786257|NCT03101423|DRUG|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
214786258|NCT01920373|DRUG|Group A (corticosteroid injection group)|
214786259|NCT01920373|BIOLOGICAL|Group B (platelet rich plasma injection group)|
214786260|NCT02173301|DRUG|XP23829 400 mg QD|active dose 1
214786261|NCT02173301|DRUG|XP 23829 800 mg QD|active dose 2
214786262|NCT02173301|DRUG|XP23829 400 mg BID|active dose 3
214786263|NCT02173301|DRUG|Placebo|control
214786264|NCT00481962|DRUG|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
214786265|NCT02340156|GENETIC|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
214786266|NCT02340156|DRUG|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
214786267|NCT05715606|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
214786268|NCT03016078|DEVICE|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
214786269|NCT01710306|BEHAVIORAL|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
214786270|NCT04504929|DEVICE|Sham tape|Use sham type on the pitching shoulder
214786271|NCT04504929|DEVICE|Dynamic tape|Use dynamic type on the pitching shoulder for supporting internal rotation
214786272|NCT01247688|DRUG|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
214786273|NCT01247688|DRUG|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
214786274|NCT01247688|RADIATION|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
214786275|NCT01247688|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
214786276|NCT03700710|BEHAVIORAL|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
214786277|NCT03700710|BEHAVIORAL|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
214786278|NCT02247570|PROCEDURE|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
214786279|NCT02123459|DRUG|Cephalexin|Administered orally
214786280|NCT05738564|DRUG|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
214786281|NCT01494220|DEVICE|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
214786282|NCT00681408|DRUG|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
214786283|NCT00681408|DRUG|Placebo|Fish oil placebo pills
214786284|NCT00254397|DRUG|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
214786285|NCT00254397|BIOLOGICAL|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
214786286|NCT00254397|BIOLOGICAL|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
214786287|NCT04624191|OTHER|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
214786288|NCT05953285|OTHER|Sleep restriction|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
215030904|NCT02593214|DEVICE|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
214786289|NCT00528437|DRUG|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
214786290|NCT04181996|DRUG|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
214786291|NCT04181996|DRUG|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
214786292|NCT03727464|BEHAVIORAL|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
214786293|NCT03727464|BEHAVIORAL|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
214786294|NCT03727464|BEHAVIORAL|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
214786295|NCT03727464|DRUG|Propofol|Propofol general anesthesia
214786296|NCT03727464|DRUG|Sevoflurane|Sevoflurane general anesthesia
214786297|NCT06432621|PROCEDURE|using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation|patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
214786298|NCT00967200|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214786299|NCT00967200|OTHER|pharmacogenomic studies|pharmacogenomic studies
214786300|NCT02116491|DEVICE|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
214786301|NCT01035320|DRUG|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
214786302|NCT05898282|OTHER|observation|since this is a cross sectional observational study any form of intervention was not applicable
214786303|NCT00344630|DEVICE|TAXUS Stent and Cypher Stent|
214786304|NCT03501550|DRUG|CDI-31244|investigational drug
214786305|NCT03501550|DRUG|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
214786306|NCT04158479|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
214786307|NCT01386879|DRUG|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
214786308|NCT01743677|DRUG|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
214786309|NCT01743677|DRUG|Placebo|Single dose placebo tablets (5 tablets)
214786310|NCT01743677|DRUG|Moxifloxacin|Single dose Avelox 400 mg tablet
214786311|NCT06680089|DRUG|[18F]RCCB6|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
214786312|NCT00563303|DRUG|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
214786313|NCT00563303|DRUG|NaCl|48mL from Day 1 to Day 6
214786314|NCT01244607|DRUG|Placebo|single i.v. administration
214786315|NCT01244607|DRUG|NI-0801|single i.v. administration
214786316|NCT02818478|OTHER|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
214786317|NCT05463458|OTHER|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
214786318|NCT00990119|DEVICE|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
214786319|NCT00990119|DEVICE|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
214786320|NCT05185687|BEHAVIORAL|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
214786321|NCT05185687|BEHAVIORAL|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
214786322|NCT05185687|BEHAVIORAL|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
214786323|NCT06418087|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]|"Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit."
214786324|NCT03092089|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
214786325|NCT03092089|DEVICE|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
214786326|NCT03092089|PROCEDURE|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
214786327|NCT00288171|DRUG|Placebo|placebo capsule twice daily for one month
214786328|NCT00288171|DRUG|Allopurinol|Allopurinol 200mg twice daily for one month
214786329|NCT06421623|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
214786330|NCT01078415|DEVICE|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
214786331|NCT00972153|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
214786332|NCT00972153|DEVICE|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
214786333|NCT05576909|DRUG|Donafenib|"0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy"
214786334|NCT05576909|PROCEDURE|TACE|For downstaging treatment
214786335|NCT05273398|DRUG|nasal diazepam|Nasal administration of diazepam
214786336|NCT00002594|BIOLOGICAL|Sargramostim|Given IV
214786337|NCT00002594|DRUG|cyclophosphamide|Given IV
214786338|NCT00002594|DRUG|melphalan|Given IV
214786339|NCT00002594|PROCEDURE|autologous bone marrow transplantation|
214786340|NCT00002594|PROCEDURE|bone marrow ablation with stem cell support|
214786341|NCT00002594|PROCEDURE|peripheral blood stem cell transplantation|
214786342|NCT04136626|DEVICE|Perspectives OCD|The app-delivered cognitive behavioral therapy (CBT) in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
214786343|NCT04136626|DEVICE|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
214786344|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
214786345|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
214786346|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
214786347|NCT06384365|BEHAVIORAL|Physical activity|The control and the athletic group differ in the degree of physical acitvity
214786348|NCT02477007|DRUG|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
214786349|NCT02477007|DRUG|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
214786350|NCT02477007|DRUG|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
214786351|NCT02477007|DRUG|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
214786352|NCT02593188|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
214786353|NCT02880215|BEHAVIORAL|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
214786354|NCT02880215|BEHAVIORAL|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
214786355|NCT03210233|PROCEDURE|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
214786356|NCT06203691|DIETARY_SUPPLEMENT|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre \& post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
214786357|NCT06203691|DIETARY_SUPPLEMENT|Non-Supplementation Group|Intervention will measure strength pre \& post operatively. Intervention group will not receive liquid supplements.
214786358|NCT01213355|DRUG|Placebo|Capsule, single dose, oral, 1 day
214786359|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
214786360|NCT01213355|DRUG|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
214786361|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
214786362|NCT01213355|DRUG|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
214786363|NCT01213355|DRUG|scopolamine|injectable subcutaneous formulation, single dose, 1 day
214786364|NCT01213355|DRUG|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
214786365|NCT01213355|DRUG|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
214786366|NCT01213355|DRUG|Donepezil|Tablet, 10mg, single dose, 1 day
214786367|NCT01213355|DRUG|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
214786368|NCT03673384|DEVICE|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
214786369|NCT03673384|DEVICE|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
214786370|NCT03673384|DRUG|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
214786371|NCT03673384|DRUG|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
214786372|NCT06312085|DEVICE|Endofill|Endofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
214786373|NCT01071109|PROCEDURE|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
214786374|NCT02191956|BEHAVIORAL|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
214786375|NCT06232356|DIAGNOSTIC_TEST|Mobile Web App|all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
214786376|NCT03405337|DRUG|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
214786377|NCT03405337|DRUG|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
214786378|NCT00409188|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
214786379|NCT00409188|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
214786380|NCT00409188|DRUG|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
214786381|NCT01260571|DRUG|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
214786382|NCT05139654|OTHER|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
214786383|NCT05139654|OTHER|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
214786384|NCT05139654|OTHER|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
214786385|NCT02879747|DRUG|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
214786386|NCT01950754|BEHAVIORAL|standing with both feet|
214786387|NCT01950754|BEHAVIORAL|descent of the platform|
214786388|NCT01950754|BEHAVIORAL|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
214786389|NCT05651529|DIETARY_SUPPLEMENT|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
214786390|NCT05651529|DIETARY_SUPPLEMENT|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
214786391|NCT02495610|OTHER|Gait analysis and MRI:|"* Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
214786392|NCT02330120|DRUG|propofol|
214786393|NCT02330120|DRUG|dexmedetomidine|
214786394|NCT01393990|DRUG|LY2228820|Administered orally
214786395|NCT01393990|DRUG|Midazolam|
214786396|NCT01393990|DRUG|Tamoxifen|
214786397|NCT04712006|DRUG|JNJ-64304500|Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
214786398|NCT00645775|DIETARY_SUPPLEMENT|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
214786399|NCT00143754|PROCEDURE|Hydration|
214786400|NCT05427565|OTHER|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
214786401|NCT05427565|OTHER|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
214786402|NCT03397628|OTHER|FIFA 11 for health|
214786403|NCT00275028|DRUG|cediranib maleate|Given orally
214786404|NCT01167855|OTHER|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
214786405|NCT01167855|OTHER|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
214786406|NCT01167855|OTHER|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
214786407|NCT01167855|OTHER|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
214786408|NCT01167855|OTHER|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
214786409|NCT02720952|DRUG|Infacort®|dry granule formulation of hydrocortisone
214786410|NCT05821712|DRUG|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
214786411|NCT05821712|DRUG|0.057% sodium fluoride Mouthwash|mouthwash
214786412|NCT05164549|DRUG|Buprenorphine Injectable Product|Investigational Medicinal Product
214786413|NCT05164549|DRUG|Methadone|Standard of Care
214786414|NCT05164549|DRUG|Buprenorphine|Standard of Care
214786415|NCT05558722|DRUG|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
214786416|NCT04352413|DRUG|PLM60|Administration: Intravenous infusion
214786417|NCT01995617|BIOLOGICAL|Placebo|normal saline, 0.5 mL per dose
214786418|NCT01995617|BIOLOGICAL|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
214786419|NCT01995617|BIOLOGICAL|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
214786420|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
214786421|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
214786422|NCT01995617|BIOLOGICAL|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
214786423|NCT01995617|BIOLOGICAL|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
214786424|NCT01193621|DRUG|haloperidol, PET|"1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
214786425|NCT05971121|DRUG|ciprofol|Ciprofol were used for sedation in ICU hypotensive patients
214786426|NCT04371484|OTHER|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
214786427|NCT03811379|DRUG|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
214786428|NCT03895099|DRUG|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
214786429|NCT03895099|DRUG|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
214786430|NCT03895099|DRUG|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
214786431|NCT03895099|DRUG|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
214786432|NCT03895099|DRUG|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
214786433|NCT02257359|DRUG|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
214786434|NCT02680795|DRUG|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
214786435|NCT01044147|BEHAVIORAL|VLM-S|Online program for weight loss - standard
214786436|NCT01044147|BEHAVIORAL|VLM-M|Online program for weight loss - modulated
214786437|NCT01044147|BEHAVIORAL|OGR|Online program for weight loss - resources
214786438|NCT06177678|DRUG|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
214786439|NCT06177678|DRUG|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
214786440|NCT00720798|DRUG|Tocilizumab|For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
214786441|NCT00720798|DRUG|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
214786442|NCT00720798|DRUG|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
214786443|NCT00720798|DRUG|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
214786444|NCT00778947|PROCEDURE|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
214786445|NCT00778947|PROCEDURE|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
214786446|NCT00892398|DRUG|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
214786447|NCT00892398|PROCEDURE|standard care|standard post-operative care after trabeculectomy with mitomycin C
214786448|NCT05461820|DRUG|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
214786449|NCT01455558|DRUG|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
214786450|NCT00433381|BIOLOGICAL|Bevacizumab|Given IV
214786451|NCT00433381|DRUG|Irinotecan Hydrochloride|Given IV
214786452|NCT00433381|DRUG|Temozolomide|Given orally
214786453|NCT01014390|DEVICE|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
214786454|NCT01519609|DRUG|bowel prep before endoscopy|bowel prep before colonoscopy
214786455|NCT00501761|BEHAVIORAL|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
214786456|NCT00501761|BEHAVIORAL|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
214786457|NCT00501761|BEHAVIORAL|Suggested Exercise Program|Exercise program performed over 7 days.
214786458|NCT05381259|BEHAVIORAL|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
214786459|NCT05561309|DRUG|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
214786460|NCT03064542|DRUG|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
214786461|NCT05963256|DEVICE|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
214786462|NCT00466297|BEHAVIORAL|Face-to-face communication interactions|
214786463|NCT00198497|DRUG|Placebo|
214786464|NCT00198497|DRUG|Vitrase|Hyaluronidase 55 IU in saline solution
214786465|NCT00198497|DRUG|Vitrase|Hyaluronidase 75 IU in saline solution
214786466|NCT03496870|DRUG|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
214786467|NCT03496870|DRUG|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
214786468|NCT02036281|DRUG|Substance P-Saporin|
214786469|NCT02270879|PROCEDURE|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
214786470|NCT04529148|DRUG|Ginkgo biloba dropping pills，best western medicine treatment|oral
214786471|NCT04529148|DRUG|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
214786472|NCT02371798|DRUG|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
214786473|NCT05930574|PROCEDURE|Abdominal surgery|surgical interventions by gastrointestinal emergencies, hepatobiliary emergencies and trauma
214786474|NCT00406757|DRUG|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
214786475|NCT00406757|DRUG|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
214786476|NCT00406757|DRUG|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
214786477|NCT00406757|DRUG|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
214786478|NCT00465686|DEVICE|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
214786479|NCT00465686|DEVICE|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
214786480|NCT05647486|OTHER|30-day postoperative outcome|The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
214786481|NCT02450942|DRUG|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
214786482|NCT03575429|BEHAVIORAL|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
214786483|NCT03575429|BEHAVIORAL|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
214786484|NCT04591418|DEVICE|Rotary handpieces|Dental Caries removal
214786485|NCT04591418|DEVICE|Er:YAG laser|Dental Caries removal
214786486|NCT02429154|OTHER|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
214786487|NCT02429154|OTHER|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
214786488|NCT03601247|DEVICE|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
214786489|NCT03293927|DRUG|Fentanyl|The patient will receive IV fentanyl
214786490|NCT03293927|DRUG|Dexmedetomidine|The patient will receive IV dexemedetomidine
214786491|NCT05644691|OTHER|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
214786492|NCT05644691|OTHER|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
214786493|NCT03103581|DRUG|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
214786494|NCT04134975|PROCEDURE|Spine surgery|surgery with pedicle screw placement between L1 and S1
214786495|NCT05938452|DRUG|Glyceryl Tribenzoate|Oral Solution
214786496|NCT00549198|DRUG|Abacavir/lamivudine and efavirenz|
214786497|NCT00549198|DRUG|Tenofovir/Emtricitabine and efavirenz|
214786498|NCT02245776|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
214786499|NCT00249548|BEHAVIORAL|Contingency management|
214786500|NCT04755322|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
214786501|NCT04755322|DRUG|Folic acid|5 mg
214786502|NCT04755322|DRUG|Low-dose aspirin|75 mg
214786503|NCT06503744|PROCEDURE|ablation|ablation
214786504|NCT05271201|OTHER|treadmill exercise (mild)|mild intensity treadmill training.
214786505|NCT05271201|OTHER|treadmill exercise (moderate)|moderate-intensity treadmill training
214786506|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
214786507|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
214786508|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
214786509|NCT00200395|DRUG|Tarceva|OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
214786510|NCT06044558|DRUG|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
214786511|NCT06044558|DRUG|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
214786512|NCT06044558|DRUG|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
214786513|NCT02189616|BEHAVIORAL|SMS reminder|send weekly mobile phone short message reminders to the intervention group
214786514|NCT02189616|OTHER|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
214786515|NCT02189616|OTHER|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
214786516|NCT01810796|DRUG|Ranolazine|Ranolazine versus placebo
214786517|NCT02116686|DEVICE|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
214786518|NCT04532541|OTHER|Monogenic lupus screening|This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
214786519|NCT04634721|DRUG|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
214786520|NCT04430270|BEHAVIORAL|Survey|Sequential Assignment
214786521|NCT05101499|PROCEDURE|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
214786522|NCT05101499|PROCEDURE|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
214786523|NCT04580056|PROCEDURE|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
214786524|NCT02477761|DIETARY_SUPPLEMENT|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
214786525|NCT03830047|DEVICE|nd yag laser|nd yag laser will be applied on the vulval warts
214786526|NCT04027010|OTHER|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
214786527|NCT04360421|DRUG|Liposomal bupivacaine|"Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia."
214786528|NCT00472446|DRUG|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
214786529|NCT00472446|DRUG|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
214786530|NCT00270374|DRUG|nesiritide|
214786531|NCT05824182|DEVICE|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
214786532|NCT01532882|DRUG|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
214786533|NCT01532882|DRUG|Placebo|tablet, PO, 1 per day during 28 days
214786534|NCT00000992|DRUG|Itraconazole|
214786535|NCT05653791|DIAGNOSTIC_TEST|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
214786536|NCT01521728|OTHER|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
214786537|NCT01521728|OTHER|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
214786538|NCT01521728|OTHER|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
214786539|NCT01165684|DRUG|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
214786540|NCT01165684|DRUG|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
214786541|NCT01165684|DRUG|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
214786542|NCT00671879|DRUG|Carisoprodol SR 700 mg|700 mg twice daily tablet
214786543|NCT00671879|DRUG|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
214786544|NCT00671879|DRUG|Placebo|placebo tablet
214786545|NCT03135379|DEVICE|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
214786546|NCT03135379|DEVICE|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
214786547|NCT01081184|BIOLOGICAL|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
214786548|NCT04633837|DEVICE|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
214786549|NCT05043532|PROCEDURE|2 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
214786550|NCT05043532|PROCEDURE|3 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
214786551|NCT00005615|BIOLOGICAL|Interferon alfa|Interferon alfa as outlined in treatment arm.
214786552|NCT00005615|RADIATION|Radiation therapy|Radiation therapy as outlined in treatment arm.
214786553|NCT03179683|DEVICE|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
214786554|NCT00901628|DRUG|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
214786555|NCT00901628|DRUG|morphine sulfate|10mg intraoperative periarticular injection
214786556|NCT00901628|DRUG|ketorolac|30 mg intraoperative periarticular injection
214786557|NCT00901628|DRUG|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
214786558|NCT00901628|DRUG|cefuroxime|750mg intraoperative periarticular injection
214786559|NCT02203747|OTHER|Administration of patient self-assessment|
214786560|NCT05334654|DRUG|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
214786561|NCT05334654|DRUG|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
214786562|NCT00608205|DRUG|cisplatin|Given IV
214786563|NCT00608205|DRUG|fluorouracil|Given IV
214786564|NCT00608205|RADIATION|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
214786565|NCT03965312|DEVICE|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
214786566|NCT03965312|DEVICE|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
214786567|NCT03965312|DEVICE|Patient monitor|Temperature will be measured using a commercially available patient monitor.
214786568|NCT01892774|PROCEDURE|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
214786569|NCT04850638|DRUG|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
214786570|NCT01797120|DRUG|Fulvestrant|"Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
214786571|NCT01797120|DRUG|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
214786572|NCT01797120|DRUG|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
214786573|NCT00427986|DRUG|Galactose, intravenous|
214786574|NCT03308110|DRUG|PF-06650833|Two formulations of PF-006650833
214786575|NCT00185419|DRUG|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
214786576|NCT00185419|DRUG|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
214786577|NCT02462421|DRUG|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
214786578|NCT02856256|DIETARY_SUPPLEMENT|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
214786579|NCT05915052|PROCEDURE|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
214786580|NCT05915052|PROCEDURE|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
214786581|NCT02117193|OTHER|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
214786582|NCT02117193|OTHER|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
214786583|NCT00051428|PROCEDURE|Reiki (distant and direct-contact)|
214786584|NCT00886665|DRUG|placebo|placebo, 4 g, powder, oral, 3 times a day
214786585|NCT00886665|DRUG|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
214786586|NCT01895920|OTHER|Blood sample|
214786587|NCT01909466|DRUG|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
214786588|NCT01720186|DEVICE|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
214786589|NCT01339910|DRUG|Fludarabine and Busulfan|"(Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
214786590|NCT01339910|DRUG|Fludarabine and Melphalan|"(Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2"
214786591|NCT01339910|DRUG|Busulfan and Fludarabine|"(Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)"
214786592|NCT01339910|DRUG|Busulfan and Cyclophosphamide|"(Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
214786593|NCT01339910|DRUG|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
214786594|NCT00365612|DRUG|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
214786595|NCT03622502|DRUG|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
214786596|NCT03622502|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
214786597|NCT03622502|DRUG|Normal saline|Normal saline was infused over 10 min before end of the surgery
214786598|NCT04999514|BEHAVIORAL|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
214786599|NCT03150979|OTHER|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
214786600|NCT03150979|OTHER|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
214786601|NCT00164879|PROCEDURE|Endoscopic stenting followed by elective laparoscopic resection|
214786602|NCT04732299|OTHER|MRI examination|Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
214786603|NCT03187652|DIAGNOSTIC_TEST|CT Perfusion Study|Brain and cardiac CT perfusion scan
214786604|NCT03187652|DIAGNOSTIC_TEST|Echocardiogram|Speckle tracking Echocardiography
214786605|NCT03187652|DIAGNOSTIC_TEST|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
214786606|NCT03187652|DIAGNOSTIC_TEST|MRI|MRI to assess white matter changes
214786607|NCT06404593|DIAGNOSTIC_TEST|Blood sampling|Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
214786608|NCT05676333|DRUG|Secukinumab|
214786609|NCT03513354|OTHER|Soil group|Exercises in soil.
214786610|NCT03513354|OTHER|Pool group|Exercises in pool.
214786611|NCT01095757|DRUG|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
214786612|NCT04363125|DIAGNOSTIC_TEST|Pathology result|Pathology result of rectal biopsy
214786613|NCT05107440|OTHER|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
214786614|NCT03836781|DRUG|Ketorolac|Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
214786615|NCT03836781|DRUG|Chlorhexidine 2%|Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
214786616|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786617|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786618|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786619|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786620|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786621|NCT01567306|BIOLOGICAL|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
214786622|NCT04072718|RADIATION|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
214786623|NCT03761836|DEVICE|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
214786624|NCT05306379|DRUG|Simvastatin|Oral dose 40 mg
214786625|NCT05306379|DRUG|Voclosporin|Oral dose 23.7 mg twice daily
214786626|NCT00138359|DRUG|Niclosamide|
214786627|NCT00004659|PROCEDURE|irradiation|
214786628|NCT00004659|PROCEDURE|radiosurgery|
214786629|NCT03468036|OTHER|none, does not apply|none: does not apply
214786630|NCT01334788|OTHER|sleep deprivation|Sleep restriction
214786631|NCT01334788|OTHER|Normal sleep|These are subjects who are randomized to sleep normally.
214786632|NCT00738673|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
214786633|NCT03858881|BEHAVIORAL|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
214786634|NCT03858881|BEHAVIORAL|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
214786635|NCT03858881|BEHAVIORAL|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
214786636|NCT00431262|DRUG|antabuse (disulfiram)|
214786637|NCT04531033|DIETARY_SUPPLEMENT|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
214786638|NCT04531033|DIETARY_SUPPLEMENT|Placebo|placebo made to match dietary supplement being tested.
214786639|NCT01188733|DRUG|Long acting octreotide 10mg|Comparison of different doses
214786640|NCT01188733|DRUG|Long acting Octreotide 30mg|Comparison of drug doses
214786641|NCT01188733|DRUG|Saline|Comparison of drug doses
214786642|NCT01140074|DRUG|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
214786643|NCT02699580|DEVICE|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
214786644|NCT02699580|PROCEDURE|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
214786645|NCT01508026|DRUG|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
214786646|NCT01508026|DRUG|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
214786647|NCT01508026|DRUG|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
214786648|NCT01508026|DRUG|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
214786649|NCT01508026|DRUG|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
214786650|NCT01508026|DRUG|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
214786651|NCT01508026|DRUG|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
214786652|NCT01508026|DRUG|Placebo|Dose matched placebo, oral administration
214786653|NCT00045448|DRUG|alvocidib|
214786654|NCT00045448|DRUG|docetaxel|
214786655|NCT03038113|DRUG|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
214786656|NCT03038113|DRUG|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
214786657|NCT03038113|DRUG|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
214786658|NCT03258359|BIOLOGICAL|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
214786659|NCT05117099|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
214786660|NCT04138459|OTHER|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork"
214786661|NCT02925273|OTHER|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand"
214786662|NCT02925273|OTHER|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
214786663|NCT02789007|OTHER|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
214786664|NCT02125188|DRUG|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
214786665|NCT02125188|DRUG|saline|saline 100ml ivdrip before surgery
214786666|NCT00813371|DEVICE|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
214786667|NCT00813371|DEVICE|ARDSnet protocol|ARDSnet protocol
214786668|NCT00570856|DRUG|Folic acid|Folic acid 5 mg/day
214786669|NCT00570856|DRUG|Placebo|Placebo similar to the folic acid tablets, 1/day
214786670|NCT05726773|PROCEDURE|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
214786671|NCT05726773|PROCEDURE|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
214786672|NCT04063618|PROCEDURE|Osteopathic Manipulative Therapy|The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.
214786673|NCT04063618|PROCEDURE|Standard of Care Concussion Treatment|Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
214786674|NCT01418352|DRUG|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
214786675|NCT01418352|DRUG|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
214786676|NCT00407459|DRUG|Bevacizumab, Pemetrexed, Carboplatin|"* Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
214786677|NCT00619619|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
214786678|NCT02787226|DRUG|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
214786679|NCT02787226|DRUG|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
214786680|NCT02195960|DIETARY_SUPPLEMENT|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
214786681|NCT02195960|DIETARY_SUPPLEMENT|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
214786682|NCT01735591|DIETARY_SUPPLEMENT|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
214786683|NCT01735591|DIETARY_SUPPLEMENT|Probiotic|Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
214786684|NCT00004871|DRUG|azacitidine|
214786685|NCT00004871|DRUG|sodium phenylbutyrate|
214786686|NCT03381066|DRUG|gefitinib, pemetrexed,cisplatin|"* Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~* Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
214786687|NCT03381066|DRUG|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
214786688|NCT03628352|DRUG|Tricaprilin|Tricaprilin with flavoring agents added
214786689|NCT05035485|DRUG|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
214786690|NCT05035485|DRUG|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
214786691|NCT03786913|DIAGNOSTIC_TEST|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
214786692|NCT06240845|OTHER|High-level laser therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
214786693|NCT06240845|OTHER|Low-level laser therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
214786694|NCT06321666|OTHER|WB-MRI|All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
214786695|NCT01434459|DRUG|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
214786696|NCT01092702|DRUG|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
214786697|NCT05678621|DRUG|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
214786698|NCT05678621|DRUG|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
214786699|NCT05678621|DRUG|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
214786700|NCT06180811|OTHER|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
214786701|NCT06180811|OTHER|Usual Standard of Care|Participants will receive the usual standard of care.
214786702|NCT04283383|OTHER|Primary Care Clinical Ultrasound Classroom (AECAP)|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
214786703|NCT03804801|DIETARY_SUPPLEMENT|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
214786704|NCT02627365|BEHAVIORAL|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
214786705|NCT03263819|DIAGNOSTIC_TEST|Oral glucose tolerance test|75 grams of glucose
214786706|NCT05903599|OTHER|Anodal transcranial direct current stimulation|The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.
214786707|NCT05903599|OTHER|Sham Stimulation|"postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises."
214786708|NCT00000606|PROCEDURE|Lung volume reduction surgery|
214786709|NCT02514187|DRUG|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
214786710|NCT02514187|DRUG|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
214786711|NCT03151499|DRUG|BI 409306|Reference and Test Treatment
214786712|NCT03151499|DRUG|Rifampicin|Test Treatment
214786713|NCT01319071|OTHER|Blood sample|Extraction of blood sample from top-level athletes
214786714|NCT00125931|DRUG|Talwin Nx|Talwin NX 50mg po twice
214786715|NCT03269175|OTHER|Brain MRI|Brain MRI will be performed
214786716|NCT03269175|OTHER|Blood sampling|Blood samples will be taken
214786717|NCT00229450|DRUG|Estrogen|0.625 mg/day of conjugated Estrogen
214786718|NCT00002119|DRUG|WF10|
214786719|NCT02749019|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
214786720|NCT05452538|DEVICE|Transfusion|Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
214786721|NCT05206136|DEVICE|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
214786722|NCT01691365|DIETARY_SUPPLEMENT|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
214786723|NCT01691365|DRUG|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
214786724|NCT05048732|DRUG|18F-FluorApoTrace|-The dose of 18F-FluorApoTrace to be given is 5 mCi
214786725|NCT01566799|DRUG|Metformin|metformin 500 mg/day po for 24 weeks.
214786726|NCT06546878|PROCEDURE|Cardiac Rehabilitation (Phase I) - nurse intervention|"The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT\_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver."
214786727|NCT02324985|DRUG|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
214786728|NCT02324985|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
214786729|NCT00002185|DRUG|Nelfinavir mesylate|
214786730|NCT06038188|BEHAVIORAL|SIT LESS Booster|"Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote"
214786731|NCT06528678|DEVICE|Intraocular lens|Lens exchange with an intraocular lens
214786732|NCT05445115|DEVICE|Mollie device|medical device
214786733|NCT03998228|DIAGNOSTIC_TEST|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~* Radiological examination of BMD;~* Calculation of the FRAX® score;~* Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
214786734|NCT00103870|PROCEDURE|Electrodermal stimulation|
214786735|NCT00103870|PROCEDURE|Music listening task|
214786736|NCT01405170|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
214786737|NCT01405170|DRUG|methylprednisolone|tablets 32 mg single dose
214786738|NCT00421785|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
214786739|NCT03551678|DEVICE|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
214786740|NCT01047085|PROCEDURE|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
214786741|NCT03845478|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
214786742|NCT03845478|BEHAVIORAL|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
214786743|NCT03652961|DRUG|Abatacept|Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
214786744|NCT03652961|DRUG|DMARDs|Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
214786745|NCT04758871|DRUG|Dydrogesterone 10 MG Oral Tablet|10 mg three times daily
214786746|NCT04758871|DRUG|Micronized progesterone|2x 200 mg vaginal tablets two times daily
214786747|NCT06090578|OTHER|TabCAT Brain Health Assessment Clinical Pathway|Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates who will then perform the TabCAT-BHA tablet-based test. The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline. The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate. Nursing support is available to support the PCP in making the diagnosis and to consult to the family via telephone post-diagnosis to address immediate care needs.
214786748|NCT01856985|DRUG|Misoprostol|
214786749|NCT01856985|DRUG|Mifepristone|
214786750|NCT02818556|DRUG|Restalyne Silk|
214786751|NCT02818556|DRUG|Belotero Balance|
214786752|NCT03506009|DRUG|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
214786753|NCT03506009|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
214786754|NCT03725787|DEVICE|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
214786755|NCT04778527|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
214786756|NCT04778527|DRUG|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
214786757|NCT02109926|OTHER|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
214786758|NCT03892681|OTHER|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
214786759|NCT04497610|DIAGNOSTIC_TEST|Breath sample|Patient will blow into a tube 5 times.
214786760|NCT01783496|DEVICE|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
214786761|NCT01893502|BEHAVIORAL|Telephone counselling from Quitline|
214786762|NCT02561312|OTHER|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
214786763|NCT02561312|OTHER|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
214786764|NCT06256250|PROCEDURE|pulpectomy treatment will be done using the adaptive xp endo shaper.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
214786765|NCT06256250|PROCEDURE|pulpectomy treatment will be done using FANTA AF baby files.|"the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~* BTF1: #20, taper 04, Yellow~* BTF2: #25, taper 04, Red~* BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown."
214786766|NCT06256250|PROCEDURE|pulpectomy treatment will be done using hand k files.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
214786767|NCT03119064|DRUG|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
214786768|NCT03119064|DRUG|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
214786769|NCT02627014|OTHER|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
214786770|NCT02627014|OTHER|Home physical therapy|once a day: 15 minutes
214786771|NCT02627014|OTHER|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
214786772|NCT02627014|OTHER|Home physical therapy in cervical region|once a day: 15 minutes
214786773|NCT02449603|DRUG|Exenatide|
214786774|NCT02449603|DRUG|Biphasic insulin Aspart 30|
214786775|NCT02361021|OTHER|- Weaning from mechanical ventilation|
214786776|NCT03231618|DIETARY_SUPPLEMENT|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
214786777|NCT00502541|DRUG|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
214786778|NCT00502541|PROCEDURE|Standard of Care|Repeat macular grid laser or observation
214786779|NCT02539563|OTHER|peanut shaped birthing ball|peanut ball will be utilized
214786780|NCT00686920|DRUG|Rifaximin|Oral
214786781|NCT03654898|BEHAVIORAL|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
214786782|NCT03654898|BEHAVIORAL|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
214786783|NCT02067715|DRUG|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
214786784|NCT01513785|DRUG|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
214786785|NCT01513785|DRUG|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
214786786|NCT00190307|DRUG|aspirin 75 mg/day|aspirin 75 mg/day
214786787|NCT00442585|DRUG|S(+)-ibuprofen|
214786788|NCT00404586|DRUG|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
214786789|NCT00404586|DRUG|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
214786790|NCT00404586|DRUG|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
214786791|NCT05350683|PROCEDURE|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
214786792|NCT02059577|DIETARY_SUPPLEMENT|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
214786793|NCT06546436|DRUG|CARC-101C|Subjects enrolled in the project will received a one-dose injection of CARC-101C
214786794|NCT03110952|BIOLOGICAL|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
214786795|NCT03110952|BIOLOGICAL|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
214786796|NCT03110952|OTHER|Placebo|0.5 mL vial
214786797|NCT02839356|DRUG|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
214786798|NCT02839356|DRUG|normal saline|20-mL irrigation with physiological saline over the entire papilla
214786799|NCT05887830|DRUG|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
214786800|NCT05887830|OTHER|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
214786801|NCT00819650|DRUG|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
214786802|NCT01620983|BEHAVIORAL|Pain Coping Skills Training|
214786803|NCT01620983|BEHAVIORAL|Arthritis Education|
214786804|NCT01620983|OTHER|Usual Care|
214786805|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
214786806|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
214786807|NCT03944486|DEVICE|Feasibility of OnTrack|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
214786808|NCT03548376|OTHER|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
214786809|NCT01566292|DRUG|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
214786810|NCT03873519|OTHER|Chromatic Environment|Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
214786811|NCT03873519|OTHER|Room Orientation|Room will be facing North or South
214786812|NCT04694040|DEVICE|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
214786813|NCT03626610|BEHAVIORAL|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
214786814|NCT05544747|OTHER|Action Observation Therapy|"following phases will be included in action observation therapy group:~1. upper limb active range of motion (AROM) exercises.~2. reaching movement or object manipulation.~3. upper limb functional tasks."
214786815|NCT05544747|OTHER|Mirror Therapy|"following phases will be included in mirror therapy group:~1. AROM exercises),~2. reaching movement or object manipulation, and~3. functional task practice"
214786816|NCT01670461|BEHAVIORAL|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
214786817|NCT01670461|BEHAVIORAL|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
214786818|NCT02448628|DRUG|CS-3150|
214786819|NCT00545233|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
214786820|NCT00545233|DRUG|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
214786821|NCT00545233|DRUG|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
214786822|NCT04708405|OTHER|Observation|Follow up and observe under standard of care given
214786823|NCT00446654|DRUG|CGC-11047|16.5 mg (3.3%) subconjunctival injection
214786824|NCT01712230|DRUG|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
214786825|NCT01712230|BEHAVIORAL|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
214786826|NCT01712230|DRUG|Placebo|Placebo
214786827|NCT03047954|DRUG|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
214786828|NCT03047954|DRUG|Placebo - Cap|Matching Placebo capsule administered
214786829|NCT01504867|DRUG|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
214786830|NCT01504867|DRUG|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
214786831|NCT06021262|OTHER|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
214786832|NCT04182139|OTHER|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
214786833|NCT02332135|PROCEDURE|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
214786834|NCT02332135|DRUG|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
214786835|NCT06282796|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software
214786836|NCT04190238|OTHER|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
214786837|NCT04190238|OTHER|Physical therapy|specific for spasticity
214786838|NCT06527716|OTHER|Teaching Strategy|"Experimental group:~Get involved in the LINE digital media course learning platform.~1. LINE digital media course study period:~   Research subjects need to complete the aforementioned three pre-measurement forms before they can join the LINE digital media course. In this lesson plan design, at the end of a single class, there will be a summary of the key points of the class; after the end of a single class, there will be 5 to 10 questions accompanying the class. When the research subjects have finished answering, Regardless of whether the answer is correct or not, the system will display Problem Solution Analysis. The study time for this stage is 1 month.~2. WorkShop Learning~Control group:~Intervention in regular education course learning platform. The above-mentioned digital media courses will be placed on the educational platform of the college for research subjects to watch and learn."
214786839|NCT05535517|OTHER|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
214786840|NCT05535517|OTHER|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
214786841|NCT05535517|OTHER|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
214786842|NCT05535517|OTHER|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
214786843|NCT05535517|OTHER|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
214786844|NCT05535517|OTHER|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
214786845|NCT04246190|DRUG|CKD-501 and D759|Reference drug, CKD-501 1T and D759 1T, QD, PO
214786846|NCT04246190|DRUG|CKD-396|Reference drug, CKD-396 1T, QD, PO
214786847|NCT03096574|OTHER|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
214786848|NCT02519972|DEVICE|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
214786849|NCT06326268|DEVICE|Phototherapy system CareMin650TM|"* As part of preventive treatment: Photobiomodulation sessions will be carried out at a dose of 3 joules for 1 minute 51 seconds, 3 times a week (for a maximum duration of 4 to 6 weeks).~* As part of curative treatment (i.e. for patients developing mucositis, from grade I): photobiomodulation will be carried out at a curative dose of 6 joules daily (for a maximum duration of 4 to 6 weeks ) for 3 minutes 34 seconds."
214786850|NCT00371488|DRUG|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
214786851|NCT02291107|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
214786852|NCT02291107|OTHER|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
214786853|NCT00334620|PROCEDURE|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
214786854|NCT04559620|OTHER|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
214786855|NCT00567944|DEVICE|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
214786856|NCT06527729|DRUG|sildenafil-loaded liposomes|Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
214786857|NCT06527729|DRUG|minoxidil gel|Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
214786858|NCT06363201|DIETARY_SUPPLEMENT|Ocoxin Oral solution|Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
214786859|NCT03525665|OTHER|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
214786860|NCT05209490|PROCEDURE|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed."
214786861|NCT05209490|PROCEDURE|femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
214786862|NCT03099967|DEVICE|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
214786863|NCT04021901|DEVICE|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
214786864|NCT00425659|DEVICE|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
214786865|NCT00425659|DEVICE|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
214786866|NCT00425659|DEVICE|CPAP|usual practice
214786867|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative PPI|sleeve + preoperative PPI
214786868|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative Placebo|sleeve + preoperative Placebo
214786869|NCT04368585|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
214786870|NCT04368585|DRUG|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
214786871|NCT04368585|DRUG|Omeprazole|40 mg (1 x 40 mg capsule) omeprazole administered QD
214786872|NCT05093283|DEVICE|Virtual Reality Glasses|Virtual Reality Glasses
214786873|NCT02151461|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
214786874|NCT02151461|DRUG|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
214786875|NCT02151461|DRUG|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
214786876|NCT02151461|DRUG|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
214786877|NCT04072978|DEVICE|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
214786878|NCT02748005|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|one cap once a day
214786879|NCT00707915|DRUG|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
214786880|NCT05881109|DRUG|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
214786881|NCT00003633|DRUG|docetaxel|
214786882|NCT00003633|DRUG|estramustine phosphate sodium|
214786883|NCT00003633|DRUG|mitoxantrone hydrochloride|
214786884|NCT00003633|DRUG|prednisone|
214786885|NCT04336267|DEVICE|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
214786886|NCT04336267|DEVICE|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
214786887|NCT06000189|PROCEDURE|Standardized skin surface biopsies (SSSB)|Skin samples will be obtained from four regions of the participants' faces, including the forehead, right cheek, left cheek, and the nose, before phototherapy and after 20 sessions of phototherapy. The SSSB will be performed as follows: a 1 cm² square will be drawn on a glass slide using a ruler. The skin areas to be sampled will be gently swabbed with a dry gauze to induce irritation by this way to obtain more mites. Then, one drop of cyanoacrylate adhesive will be dropped onto the marked area on the glass slide, and the adhesive surface of the slide will be pressed onto the skin surface for approximately one minute. Afterwards, the slide will be gently lifted, and the sampled area will be examined under a light microscope at x10 and x40 magnifications after applying immersion oil. The presence of more than five Demodex mites per square centimeter will be defined as increased Demodex density.
214786888|NCT00360867|DRUG|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
214786889|NCT05474612|OTHER|kinesiology taping with conventional therapy|Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
214786890|NCT05474612|OTHER|Instrument assisted soft tissue mobilization with conventional therapy|IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
214786891|NCT05425108|DEVICE|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
214786892|NCT00871169|DRUG|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
214786893|NCT03724721|PROCEDURE|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
214786894|NCT03239275|PROCEDURE|Biocreative therapy|
214786895|NCT01040013|PROCEDURE|Laparoscopy|Laparoscopic Left-Colectomy
214786896|NCT01040013|PROCEDURE|left colectomy by laparotomy|PatientS will be operated by laparotomy
214786897|NCT05531045|DIAGNOSTIC_TEST|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
214786898|NCT01365845|RADIATION|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
214786899|NCT01365845|RADIATION|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
214786900|NCT06336889|PROCEDURE|Pelvic Angioembolization|Embolization is performed by placing a small catheter inside the blood vessels that supply the area that is bleeding. Carefully navigating the catheter, under image guidance, to the safest and farthest point, a variety of different materials can then be used to block the bleeding vessels.
214786901|NCT01993394|OTHER|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
214786902|NCT01993394|OTHER|gas mixture|breathing air, 44.5%O2 or 100%O2
214786903|NCT00786110|DRUG|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
214786904|NCT00786110|DRUG|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
214786905|NCT04664608|DEVICE|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
214786906|NCT03210259|DRUG|Humira®|Duration - 58 weeks
214786907|NCT03210259|DRUG|BI 695501|Duration - 58 weeks
214786908|NCT03782649|DEVICE|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
214786909|NCT02110706|DRUG|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
214786910|NCT02110706|DRUG|Placebo|The placebo group will receive a vehicle control infusion
214786911|NCT02087059|DRUG|Ruxolitinib|
214786912|NCT00252187|DRUG|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
214786913|NCT00252187|OTHER|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
214786914|NCT03334487|DRUG|Dexamethasone|Oral
214786915|NCT03334487|DRUG|Rovalpituzumab tesirine|Intravenous
214786916|NCT03465228|DEVICE|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
214786917|NCT03465228|DEVICE|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
214786918|NCT03465228|OTHER|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
214786919|NCT01901315|PROCEDURE|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
214786920|NCT01901315|PROCEDURE|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
214786921|NCT00767689|DRUG|Vitamin B 6|vitamin b6 100 mg po daily
214786922|NCT00767689|DRUG|placebo|placebo is given in the placebo arm
214786923|NCT03764059|DEVICE|Filtek™ Bulk Fill Posterior Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
214786924|NCT03764059|DEVICE|Filtek™ Z350XT Universal Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
214786925|NCT01608633|OTHER|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
214786926|NCT02720315|PROCEDURE|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
214786927|NCT00001951|DRUG|TMTDS|
214786928|NCT04797715|DRUG|AXS-05|AXS-05 tablets, taken twice daily
214786929|NCT04797715|DRUG|Placebo|Placebo tablets, taken twice daily
214786930|NCT04604483|DEVICE|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
214786931|NCT02693184|OTHER|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
214786932|NCT02693184|OTHER|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
214786933|NCT06531096|BEHAVIORAL|v-DOT|Video directly observed therapy
214786934|NCT04938206|PROCEDURE|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
214786935|NCT05017493|COMBINATION_PRODUCT|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
214786936|NCT04405206|DRUG|Oxaliplatin|OXA 130mg/m2
214786937|NCT04405206|DRUG|Capecitabine|Cape 1000mg/m2
214786938|NCT04405206|RADIATION|intensity modulated radiotherapy|IMRT 50.4Gy/22f
214786939|NCT04405206|PROCEDURE|DRE-Endoscopy-MRI-CEA|examination process in follow up
214786940|NCT04405206|PROCEDURE|Nonoperative Management|Watch and Wait
214786941|NCT04405206|PROCEDURE|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
214786942|NCT04405206|PROCEDURE|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
214786943|NCT04405206|BEHAVIORAL|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
214786944|NCT00557973|DRUG|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
214786945|NCT00557973|DRUG|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
214786946|NCT00557973|DRUG|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
214786947|NCT00557973|DRUG|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
214786948|NCT01708876|DRUG|Artesunate-mefloquine|
214786949|NCT01708876|DRUG|Chloroquine|
214786950|NCT01708876|DRUG|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
214786951|NCT02082613|PROCEDURE|Lord´s procedure|
214786952|NCT02082613|PROCEDURE|Sclerotherapy|
214786953|NCT06175195|BEHAVIORAL|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
214786954|NCT01525706|DRUG|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
214786955|NCT04499456|OTHER|Personalised Normative Feedback|The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
214786956|NCT03139747|DRUG|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
214786957|NCT03139747|DRUG|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
214786958|NCT04109157|DIAGNOSTIC_TEST|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
214786959|NCT01665053|DEVICE|PROMUS Element Plus|A drug eluting coronary stent system
214786960|NCT01665053|DEVICE|SYNERGY|A drug eluting coronary stent system
214786961|NCT04698122|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
214786962|NCT04698122|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214786963|NCT04698122|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214786964|NCT00006081|DRUG|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
214786965|NCT00006081|DRUG|Paclitaxel (Taxol)|80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
214786966|NCT02152787|DRUG|Injection of propofol 1.0mg/kg|
214786967|NCT02152787|DRUG|propofol 0.5mg/kg|
214786968|NCT02152787|DRUG|normal saline|
214786969|NCT01033383|DIETARY_SUPPLEMENT|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
214786970|NCT01033383|DIETARY_SUPPLEMENT|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
214786971|NCT03787745|PROCEDURE|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
214786972|NCT03787745|PROCEDURE|Conventional|State of the art primary PCI, however thrombectomy is not allowed
214786973|NCT01792258|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
214786974|NCT04052100|OTHER|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must\_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
214786975|NCT04052100|OTHER|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
214786976|NCT00200928|BIOLOGICAL|BCG|
214786977|NCT02568995|DRUG|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
214786978|NCT01261325|DRUG|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
214786979|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
214786980|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
214786981|NCT01261325|DRUG|Antiepileptic drugs with market authorization available per country|
214786982|NCT01001663|DEVICE|FemoSeal®|Closure device for femoral artery access closure
214786983|NCT01001663|OTHER|Manual compression|Conventional manual compression
214786984|NCT01878656|DRUG|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
214786985|NCT01878656|DRUG|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
214786986|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
214786987|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
214786988|NCT03844568|DEVICE|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
214786989|NCT01017679|DRUG|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
214786990|NCT03718156|OTHER|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
214786991|NCT00692926|BIOLOGICAL|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
214786992|NCT04521400|DRUG|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
214786993|NCT04521400|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
214786994|NCT04521400|DRUG|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
214786995|NCT02725970|OTHER|survey|Cross-sectional survey
214786996|NCT01609660|DIETARY_SUPPLEMENT|Saccharomyces boulardii|100mg daily for seven days prior to surgery
214786997|NCT06479304|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
214786998|NCT06479304|DRUG|Prednisone tablet|Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
214786999|NCT03348215|OTHER|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
214787000|NCT04800445|DIAGNOSTIC_TEST|Salivary CRP|Salivary C reactive protein in neonatal sepsis
214787001|NCT01742325|BEHAVIORAL|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
214787002|NCT01815411|DIETARY_SUPPLEMENT|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
214787003|NCT03357432|OTHER|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
214787004|NCT02799316|OTHER|HBV core antibodies testing. • Real time PCR testing.|"* HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies."
214787005|NCT03469271|DRUG|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
214787006|NCT03469271|OTHER|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
214787007|NCT03469271|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
214787008|NCT03469271|OTHER|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
214787009|NCT03469271|DEVICE|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
214787010|NCT02382978|OTHER|nurse-provided well child visit|
214787011|NCT01174641|OTHER|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
214787012|NCT01174641|OTHER|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
214787013|NCT03841721|DRUG|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
214787014|NCT04976868|DRUG|Pimecrolimus 1% Top Cream|Elidel® as prescribed within routine clinical practice
214787015|NCT06458686|DRUG|Vit D|Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
214787016|NCT06458686|OTHER|Placebo|Placebo is a non drug formulation
214787017|NCT02761369|DEVICE|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
214787018|NCT00990561|DRUG|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
214787019|NCT00990561|DRUG|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
214787020|NCT05494554|DEVICE|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
214787021|NCT06530485|DIETARY_SUPPLEMENT|Microbiota-directed food|MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.
214787022|NCT06530485|DIETARY_SUPPLEMENT|Khichuri|Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.
214787023|NCT04249206|PROCEDURE|Root Canal Treatment|
214787024|NCT03920436|DIETARY_SUPPLEMENT|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
214787025|NCT03920436|DIETARY_SUPPLEMENT|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
214787026|NCT03876756|OTHER|postpartum acute urinary retention|Collection of risk factors
214787027|NCT03876756|OTHER|no postpartum acute urinary retention|Collection of risk factors
214787028|NCT03404206|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
214787029|NCT03404206|DRUG|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
214787030|NCT03404206|DRUG|Placebo|Matching placebo, 2 tablets, oral, single dose
214787031|NCT00949130|DRUG|NXL103|BID for 7-14 days
214787032|NCT00949130|DRUG|Linezolid|BID for 7-14 days
214787033|NCT01248312|DEVICE|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
214787034|NCT01248312|DEVICE|sentec monitor|transcutaneous monitoring
214787035|NCT02756000|PROCEDURE|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
214787036|NCT02756000|PROCEDURE|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
214787037|NCT03032497|DEVICE|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
214787038|NCT03187080|PROCEDURE|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
214787039|NCT03187080|OTHER|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
214787040|NCT03187080|PROCEDURE|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
214787041|NCT03187080|DRUG|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
214787042|NCT06039670|PROCEDURE|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
214787043|NCT03872700|DRUG|Intranasal fentanyl|Fentanyl Citrate
214787044|NCT03872700|DRUG|Placebo|Sterile Water Up to 5Cc
214787045|NCT05205785|DIETARY_SUPPLEMENT|Human Milk Oligosaccharide Mix|Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.
214787046|NCT05205785|OTHER|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
214787047|NCT04888650|OTHER|questionnaire|electronic questionnaire
214787048|NCT04188925|DEVICE|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
214787049|NCT04188925|DEVICE|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
214787050|NCT00163410|DRUG|Ciclesonide|
214787051|NCT03849794|OTHER|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
214787052|NCT03849794|OTHER|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
214787053|NCT05426252|DRUG|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
214787054|NCT05426252|DRUG|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
214787055|NCT00141284|DRUG|nelfinavir 1,250 mg twice daily|
214787056|NCT00141284|DRUG|Zidovudine 300 mg twice daily|
214787057|NCT00141284|DRUG|Lamivudine 150 mg twice daily|
214787058|NCT02189083|DRUG|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
214787059|NCT02330081|DEVICE|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood."
214787060|NCT00722111|DEVICE|lingual press|lingual press (high-intensity, oral, non-swallowing)
214787061|NCT00722111|BEHAVIORAL|effortful swallowing|effortful swallowing (high-intensity swallowing)
214787062|NCT00722111|BEHAVIORAL|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
214787063|NCT00722111|BEHAVIORAL|non-oral sham (control) exercise|non-oral sham (control) exercise
214787064|NCT00700869|PROCEDURE|mechanical ventilation|mechanical ventilation
214787065|NCT00002189|DRUG|Paclitaxel|
214787066|NCT03016559|OTHER|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
214787067|NCT00111189|DRUG|Placebo|Placebo every 4 wk up to 24 mo
214787068|NCT00111189|DRUG|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
214787069|NCT04269278|DRUG|0 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
214787070|NCT04269278|DRUG|0.25 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
214787071|NCT04269278|DRUG|0.5 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
214787072|NCT04269278|DRUG|0.75 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
214787073|NCT03210675|DIAGNOSTIC_TEST|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
214787074|NCT04117152|OTHER|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
214787075|NCT04809428|PROCEDURE|vNOTES salpingectomy|Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
214787076|NCT04809428|PROCEDURE|Laparoscopic salpingectomy|Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
214787077|NCT00007241|DEVICE|Isometric exercise|
214787078|NCT00005091|DRUG|exatecan mesylate|
214787079|NCT02707432|BEHAVIORAL|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
214787080|NCT00636428|DRUG|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
214787081|NCT04887545|DIAGNOSTIC_TEST|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
214787082|NCT05935800|BEHAVIORAL|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
214787083|NCT01957657|DRUG|BI 207127|oral administration
214787084|NCT01957657|DRUG|faldaprevir|oral administration
214787085|NCT01957657|DRUG|BI 207127|oral administration
214787086|NCT01957657|DRUG|BI 207127|oral administration
214787087|NCT01957657|DRUG|BI 207127|oral administration
214787088|NCT01957657|DRUG|faldaprevir|oral administration
214787089|NCT01957657|DRUG|faldaprevir|oral administration
214787090|NCT01957657|DRUG|faldaprevir|oral administration
214787091|NCT03331965|DRUG|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
214787092|NCT03331965|DRUG|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
214787093|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
214787094|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
214787095|NCT03338465|DEVICE|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
214787096|NCT01030276|OTHER|Bright light therapy|Bright light therapy
214787097|NCT01030276|OTHER|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
214787098|NCT00616928|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
214787099|NCT00616928|BIOLOGICAL|Placebo|Two intramuscular injections at Days 0 and 21.
214787100|NCT04593680|DRUG|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
214787101|NCT02926183|DRUG|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
214787102|NCT00973037|DRUG|Tamoxifen|Tamoxifen 20mg qd
214787103|NCT06344702|DEVICE|CPAP|70% of nights use CPAP for more than 4 hours
214787104|NCT03242993|DRUG|[18F]-AzaFol|\[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
214787105|NCT03242993|DRUG|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
214787106|NCT03995303|OTHER|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
214787107|NCT06346054|DIAGNOSTIC_TEST|Breath analysis|Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
214787108|NCT06346054|DIAGNOSTIC_TEST|Blood analysis|Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
214787109|NCT00482313|DRUG|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
214787110|NCT00482313|DRUG|Placebo|Sugar pill
214787111|NCT03354156|DRUG|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
214787112|NCT02204215|DEVICE|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
214787113|NCT02204215|OTHER|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
214787114|NCT06330428|BEHAVIORAL|Sexuality-Based Family Planning Education via Podcast|The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
214787115|NCT03372083|DRUG|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
214787116|NCT01122472|DRUG|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
214787117|NCT01122472|DRUG|Placebo|Daily for 3 weeks every 4 weeks for 24 months
214787118|NCT00802750|DEVICE|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
214787119|NCT00802750|DEVICE|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
214787120|NCT01224756|DRUG|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
214787121|NCT01224756|DRUG|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
214787122|NCT03967483|DRUG|Indometacin|patient who are taken indomatacin for headaches and migraine
214787123|NCT05464290|PROCEDURE|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
214787124|NCT01725945|BEHAVIORAL|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
214787125|NCT02123056|DRUG|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
214787126|NCT02123056|DRUG|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
214787127|NCT00405977|DRUG|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
214787128|NCT00405977|DRUG|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
214787129|NCT01574989|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
214787130|NCT01574989|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35\^2 electrodes.
214787131|NCT04862390|DEVICE|Continuous glucose monitoring|Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan
214787132|NCT03057587|DEVICE|NIRS Monitoring|NIRS data will be collected throughout the surgery
214787133|NCT01438723|DRUG|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
214787134|NCT01438723|DRUG|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
214787135|NCT04117308|PROCEDURE|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
214787136|NCT04117308|PROCEDURE|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
214787137|NCT05126381|BEHAVIORAL|Smoking|The Study contains patients who are allowed to smoke
214787138|NCT05126381|BEHAVIORAL|non-somking|The Study contains patients who are not allowed to smoke
214787139|NCT05186610|PROCEDURE|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
214787140|NCT02874495|BEHAVIORAL|Psychological tests|Related to affective and cognitive dimensions of pain.
214787141|NCT02874495|DEVICE|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
214787142|NCT02874495|BEHAVIORAL|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
214787143|NCT01025856|OTHER|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
214787144|NCT01025856|OTHER|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
214787145|NCT01025856|OTHER|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
214787146|NCT01025856|OTHER|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
214787147|NCT04921033|DIETARY_SUPPLEMENT|EEN (Nestle Modulen®)|35kcal/kg/day for every patient
214787148|NCT04921033|DRUG|Standart of care|"* Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
214787149|NCT04812509|DRUG|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
214787150|NCT04812509|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
214787151|NCT03350048|DIAGNOSTIC_TEST|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
214787152|NCT04459663|DRUG|Toripalimab injection combine with Axitinib|The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
214787153|NCT04177069|DIETARY_SUPPLEMENT|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
214787154|NCT00133718|DRUG|Combined lifestyle intervention and optimisation of pharmacological treatment|"1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care"
214787155|NCT00598559|DRUG|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
214787156|NCT05924711|OTHER|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
214787157|NCT06105281|BEHAVIORAL|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
214787158|NCT03381248|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
214787159|NCT03381248|OTHER|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
214787160|NCT03381248|OTHER|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
214787161|NCT01368003|DRUG|STA9090|200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
214787162|NCT01368003|DRUG|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
214787163|NCT04816097|DRUG|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
214787164|NCT02681965|BEHAVIORAL|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
214787165|NCT03715595|OTHER|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
214787166|NCT02419859|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
214787167|NCT02419859|DRUG|Insulin, Asp(B28)-|a fast-acting analog of human insulin
214787168|NCT02200133|OTHER|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
214787169|NCT00306969|DRUG|bexarotene|
214787170|NCT00306969|DEVICE|photopheresis|
214787171|NCT02943681|BIOLOGICAL|Measles vaccine|
214787172|NCT02501850|DRUG|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
214787173|NCT02501850|DRUG|metformin|Treatment with metformin and/or sulphonilurea
214787174|NCT03596996|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
214787175|NCT03596996|DIETARY_SUPPLEMENT|Placebo|Placebo with identical appearance comparison intervention arm
214787176|NCT00548990|BEHAVIORAL|cardiovascular exercise training|
214787177|NCT00548990|BEHAVIORAL|flexibility/balance control|
214787178|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
214787179|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
214787180|NCT03974152|OTHER|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
214787181|NCT02739815|DRUG|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
214787182|NCT02739815|DRUG|Tranexamic Acid|Tranexamic acid
214787183|NCT02089828|OTHER|autologous purified CD34+ cells|
214787184|NCT02089828|OTHER|autologous peripheral blood mononuclear cells|
214787185|NCT05958277|DRUG|Vitamin B3|Vitamin B3 upto 16 mg/day
214787186|NCT05958277|DRUG|Vitamin B12|Vit B12 upto 250 mcg per day
214787187|NCT01414946|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
214787188|NCT01414946|OTHER|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
214787189|NCT02714686|BEHAVIORAL|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
214787190|NCT01466686|RADIATION|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
214787191|NCT01466686|DRUG|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
214787192|NCT05472610|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
214787193|NCT03729765|DEVICE|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
214787194|NCT04517006|BEHAVIORAL|Self-focused acts|Completion of daily acts for personal enjoyment.
214787195|NCT04517006|BEHAVIORAL|Prosocial acts|Completion of daily acts for the benefit of others.
214787196|NCT05896059|DRUG|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
214787197|NCT05896059|DRUG|Anlotinib|Anlotinib，12mg，oral administration，QD.
214787198|NCT01317732|DEVICE|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
214787199|NCT03232528|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
214787200|NCT03232528|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
214787201|NCT02025309|DEVICE|Neuromuscular monitorisation|
214787202|NCT04484597|DIAGNOSTIC_TEST|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
214787203|NCT03093545|BIOLOGICAL|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
214787204|NCT03093545|BIOLOGICAL|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
214787205|NCT04579497|OTHER|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
214787206|NCT04579497|OTHER|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
214787207|NCT04579497|OTHER|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
214787208|NCT04579497|OTHER|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
214787209|NCT06262698|BEHAVIORAL|Experiment group|The experimental group will receive six weeks of HBM-based training.
214787210|NCT06262698|OTHER|Pre-post test|The TCM Attitude Scale (CACMAS), Medication Health Belief Scale
214787211|NCT05992545|DEVICE|Mobile application 'DangDang Care' under usual care|"The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care."
214787212|NCT03238768|OTHER|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
214787213|NCT03238768|OTHER|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
214787214|NCT00827827|OTHER|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
214787215|NCT00827827|OTHER|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
214787216|NCT04093180|PROCEDURE|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
214787217|NCT04093180|PROCEDURE|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
214787218|NCT02831062|OTHER|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
214787219|NCT00131989|DRUG|sorafenib tosylate|Given orally
214787220|NCT00131989|OTHER|pharmacological study|Correlative studies
214787221|NCT00131989|OTHER|laboratory biomarker analysis|Correlative studies
214787222|NCT01429402|DRUG|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
214787223|NCT01429402|DRUG|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
214787224|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
214787225|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
214787226|NCT05765955|DRUG|POLB 001|Investigational Medicinal Product
214787227|NCT05765955|DRUG|Placebo|Matching Placebo
214787228|NCT03775356|OTHER|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
214787229|NCT00359853|DRUG|Oral norfloxacin|
214787230|NCT05869097|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
214787231|NCT05869097|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
214787232|NCT01617564|DRUG|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
214787233|NCT01617564|OTHER|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
214787234|NCT01093079|PROCEDURE|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
214787235|NCT01093079|PROCEDURE|Open partial nephrectomy|Open partial nephrectomy
214787236|NCT02477566|DRUG|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
214787237|NCT02477566|DRUG|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
214787238|NCT04948190|BEHAVIORAL|Testing with medical detection dogs|Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
214787239|NCT04549259|BEHAVIORAL|Group-Based Social Support|This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
214787240|NCT04549259|BEHAVIORAL|HIV Stigma Reduction|"This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011)."
214787241|NCT04549259|BEHAVIORAL|Strengths-Based Case Management (SBCM)|The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
214787242|NCT04549259|BEHAVIORAL|Personalized Technology Detailing|Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
214787243|NCT00318552|DRUG|Meropenem|
214787244|NCT01823549|OTHER|questionnaire administration|Ancillary studies
214787245|NCT01765556|DRUG|ketoconazole|multiple doses of ketoconazole in Period B and C
214787246|NCT01765556|DRUG|vemurafenib|single dose of vemurafenib in Period A and C
214787247|NCT02326428|DEVICE|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
214787248|NCT02326428|DRUG|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
214787249|NCT06303583|DRUG|paclitaxel|paclitaxel, 50 mg/m2, QW\*5
214787250|NCT06303583|DRUG|carboplatin|area under the curve of2mg/mL/min, QW\*5
214787251|NCT06303583|DRUG|tislelizumab|200mg Q3W, 2cycles
214787252|NCT06303583|RADIATION|radiotherapy|41.4Gy in 23 fractions
214787253|NCT03216733|DEVICE|COMBO|PCI with COMBO stent
214787254|NCT03216733|DEVICE|ORSIRO|PCI with ORSIRO stent
214787255|NCT02596997|DRUG|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
214787256|NCT06524791|OTHER|bacteriophage detection|bacteriophage detection
214787257|NCT04746014|DIAGNOSTIC_TEST|Clearblue Pregnancy Test|Urine Pregnancy Test
214787258|NCT02884206|DRUG|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
214787259|NCT02884206|DRUG|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
214787260|NCT02884206|DRUG|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
214787261|NCT02884206|DRUG|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
214787262|NCT05117892|OTHER|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
214787263|NCT00112489|DRUG|carboplatin|
214787264|NCT00112489|DRUG|paclitaxel|
214787265|NCT04744844|PROCEDURE|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
214787266|NCT02867904|DRUG|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
214787267|NCT02867904|DRUG|Marcaine (4ml 0.5%, injection)|Control
214787268|NCT02233179|DEVICE|Removable cast walker|Offloading device that can be removed by patients.
214787269|NCT02233179|DEVICE|Irremovable cast walker|Offloading device that cannot be removed by patients.
214787270|NCT04806984|OTHER|Participant outreach|Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
214787271|NCT02979379|OTHER|Pain|
214787272|NCT02437214|OTHER|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
214787273|NCT02447536|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
214787274|NCT02447536|BIOLOGICAL|BCG-Russia-I (Serum Institute of India)|See above
214787275|NCT03646981|DEVICE|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
214787276|NCT01549288|BEHAVIORAL|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
214787277|NCT01549288|OTHER|no dietetic input|continuation of anti-epileptic medication without any dietetic input
214787278|NCT00716183|BIOLOGICAL|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
214787279|NCT00716183|BIOLOGICAL|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
214787280|NCT00716183|BIOLOGICAL|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
214787281|NCT00716183|DRUG|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
214787282|NCT03418883|OTHER|Mirror therapy|
214787283|NCT04156269|BIOLOGICAL|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214787284|NCT05218863|OTHER|No intervention|No intervention
214787285|NCT05751629|DRUG|Dostarlimab|Dostarlimab was administered.
214787286|NCT05751629|DRUG|Bevacizumab|Bevacizumab was administered.
214787287|NCT05751629|DRUG|Niraparib|Niraparib was administered.
214787288|NCT04866589|BEHAVIORAL|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
214787289|NCT04676191|DEVICE|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
214787290|NCT04676191|DEVICE|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
214787291|NCT01136226|DRUG|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
214787292|NCT02553239|DEVICE|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
214787293|NCT02231710|BIOLOGICAL|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
214787294|NCT02971410|OTHER|Laboratory Biomarker Analysis|Correlative studies
214787295|NCT02971410|OTHER|Quality-of-Life Assessment|Ancillary studies
214787296|NCT02971410|DRUG|Simvastatin|Given PO
214787297|NCT01385410|BEHAVIORAL|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
214787298|NCT02775890|BEHAVIORAL|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (\>85 grams).
214787299|NCT00287287|DRUG|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
214787300|NCT00908752|DRUG|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
214787301|NCT00908752|OTHER|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
214787302|NCT00908752|PROCEDURE|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
214787303|NCT00225199|DRUG|Visanne (BAY86-5258, SH T00660AA)|orally once daily
214787304|NCT00225199|DRUG|Placebo|orally once daily
214787305|NCT05582733|OTHER|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
214787306|NCT05582733|OTHER|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
214787307|NCT02840656|OTHER|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
214787308|NCT02840656|OTHER|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
214787309|NCT03316859|DRUG|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
214787310|NCT03316859|OTHER|Placebo pill|Placebo pill administered 1 hour pre-operatively
214787311|NCT00295854|DRUG|MN-001 BID|Eligible patients received 500 mg MN-001 bid
214787312|NCT00295854|DRUG|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
214787313|NCT00295854|DRUG|Placebo|Eligible patients received placebo
214787314|NCT05986877|DRUG|STSA-1201 Subcutaneous injection|Subcutaneous injection
214787315|NCT05986877|DRUG|Placebo|Subcutaneous injection
214787316|NCT00672620|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
214787317|NCT00672620|DRUG|Duloxetine|Duloxetine capsules
214787318|NCT00672620|DRUG|Placebo|Placebo-matching capsules
214787319|NCT00772577|DRUG|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
214787320|NCT00772577|DRUG|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
214787321|NCT03211156|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
214787322|NCT03211156|OTHER|Placebo|Placebo
214787323|NCT05671289|DIAGNOSTIC_TEST|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
214787324|NCT04577274|DIETARY_SUPPLEMENT|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
214787325|NCT04577274|DIETARY_SUPPLEMENT|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
214787326|NCT04577274|DIETARY_SUPPLEMENT|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
214787327|NCT04893148|DRUG|IGlarLixi|Changing to iGlarLixi from insulin glargine
214787328|NCT04893148|DRUG|Dulaglutide|Add dulaglutide to insulin glargine
214787329|NCT04604665|OTHER|High frequency postural change|"Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs."
214787330|NCT04604665|OTHER|Conventional care|Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
214787331|NCT02598648|OTHER|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
214787332|NCT02598648|OTHER|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
214787333|NCT00448955|DRUG|ARD-0403|ARD-0403
214787334|NCT03804099|DRUG|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
214787335|NCT05166993|DEVICE|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
214787336|NCT02197533|OTHER|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
214787337|NCT01174056|DRUG|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
214787338|NCT01174056|DRUG|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
214787339|NCT01174056|DRUG|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
214787340|NCT01174056|DRUG|Pioglitazone|PPAR-gamma agonist
214787341|NCT04253431|DEVICE|Droplet lancing device (HTL-Strefa S.A.)|
214787342|NCT04253431|DEVICE|Microlet 2 lancing device (Bayer)|
214787343|NCT04253431|DEVICE|OneTouch Delicia lancing device (LifeScan)|
214787344|NCT04253431|DEVICE|ReliOn lancing device (ReliOn)|
214787345|NCT04253431|DEVICE|Accu-Chek Softclix lancing device (Roche)|
214787346|NCT04253431|DEVICE|BGStar lancing device (Sanofi Aventis)|
214787347|NCT04253431|DEVICE|Ultra-Fine 33G lancets (BD)|
214787348|NCT04253431|DEVICE|Droplet 33G lancets (HTL-Strefa S.A.)|
214787349|NCT04253431|DEVICE|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
214787350|NCT04253431|DEVICE|HaemoFine 33G lancets (HTL-Strefa S.A.)|
214787351|NCT04253431|DEVICE|Softclix 28 G lancets (Roche)|
214787352|NCT04253431|DEVICE|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
214787353|NCT04253431|DEVICE|GlucoJect Dual S lancing device (Menarini)|
214787354|NCT04253431|DEVICE|Microlet 28G lancets (Bayer)|
214787355|NCT04253431|DEVICE|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
214787356|NCT01461200|OTHER|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
214787357|NCT02333409|PROCEDURE|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
214787358|NCT04988659|OTHER|Exposures|Exposures
214787359|NCT05103267|DEVICE|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
214787360|NCT00505505|DRUG|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
214787361|NCT03255031|OTHER|Ketogenic Diet (KD)|For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
214787362|NCT03255031|OTHER|Standard American (SA) Meals and Shakes|For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
214787363|NCT01228396|DRUG|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
214787364|NCT04304326|OTHER|Resistence Exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
214787365|NCT00384696|DRUG|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke \>10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
214787366|NCT00384696|BEHAVIORAL|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
214787367|NCT05509634|DRUG|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
214787368|NCT05509634|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
214787369|NCT04050800|DRUG|Carbon 11 Butanol|Two sequential administrations of a PET tracer
214787370|NCT03334565|DEVICE|Low efficiency air filtration systems|Subjects were exposed to low-efficiency filtered air.
214787371|NCT03334565|DEVICE|High efficiency air filtration systems|Subjects were exposed to high-efficiency filtered air.
214787372|NCT03334565|DEVICE|Air filtration systems without filters (sham)|Subjects were exposed to unfiltered air.
214787373|NCT05228119|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
214787374|NCT03563027|BEHAVIORAL|Social Incentive Gamification|Game-based intervention with points and levels
214787375|NCT03563027|BEHAVIORAL|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
214787376|NCT03563027|BEHAVIORAL|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
214787377|NCT03670979|PROCEDURE|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
214787378|NCT05360433|DRUG|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
214787379|NCT00000452|DRUG|naltrexone (Revia)|
214787380|NCT00000452|BEHAVIORAL|Compliance Enhancement Tech.|
214787381|NCT00000452|BEHAVIORAL|Cognitive Behavior Therapy|
214787382|NCT00415532|DRUG|Medical Standard of Care for ITP|
214787383|NCT00415532|BIOLOGICAL|Romiplostim|
214787384|NCT00135642|BIOLOGICAL|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
214787385|NCT00135642|PROCEDURE|Venepuncture: 20 ml blood sample taken on 2 separate visits|
214787386|NCT04121000|PROCEDURE|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
214787387|NCT04878406|DRUG|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
214787388|NCT04878406|DRUG|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
214787389|NCT04878406|DRUG|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
214787390|NCT04878406|DRUG|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
214787391|NCT04155788|BEHAVIORAL|Food Exposure|Participants will complete a meal exposure using one of their feared foods.
214787392|NCT05863988|OTHER|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
214787393|NCT05863988|OTHER|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
214787394|NCT00894985|BIOLOGICAL|heparin sodium - blausiegel|heparin sodium 5.000UI
214787395|NCT00894985|BIOLOGICAL|heparin sodium - APP|heparin sodium 5.000 USP - APP
214787396|NCT06010056|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
214787397|NCT06010056|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
214787398|NCT03058978|DEVICE|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
214787399|NCT03409185|DEVICE|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
214787400|NCT03409185|DEVICE|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
214787401|NCT03765671|DRUG|Elafibranor|120mg oral single dose
214787402|NCT05954078|DRUG|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
214787403|NCT05954078|DRUG|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
214787404|NCT00170885|DRUG|Everolimus|
214787405|NCT02307409|OTHER|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
214787406|NCT04050332|BEHAVIORAL|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
214787407|NCT04290078|DEVICE|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
214787408|NCT04290078|OTHER|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
214787409|NCT06527482|PROCEDURE|Autologous Osteoperiosteal Transplantation|After full exposure of the lesion, the center of the cystic lesion was determined and drilled perpendicularly using a 2-mm pin. Then, a 4.5-mm cannulated bore was used to drill the lesion until the cyst was reached, and a small bone socket was created. A harvester tube matching the diameter of the cyst was used to enlarge the bone socket with care to avoid damage to the adjacent normal cartilage. The cystic lesion was debrided thoroughly, and the sclerotic wall of the cyst was freshened using a curette. The harvester tube with a matched diameter was driven in to a depth of 15 to 20 mm at the 2-cm proximal part of the anterior superior iliac spine perpendicularly without violation of the lateral wall of the crest. When necessary, small pieces of cancellous bone were also harvested from the iliac crest using a bone curette then grafted into the peripheral area of the cyst to fill up the remaining space of the cyst around the bone socket in the talus.
214787410|NCT01698320|DRUG|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
214787411|NCT01698320|DRUG|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
214787412|NCT00359970|DRUG|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
214787413|NCT00359970|DRUG|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
214787414|NCT00359970|DRUG|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
214787415|NCT00359970|OTHER|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
214787416|NCT05158491|DRUG|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
214787417|NCT04340414|DEVICE|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
214787418|NCT01189240|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214787419|NCT01189240|BIOLOGICAL|bevacizumab|Given IV
214787420|NCT01189240|OTHER|laboratory biomarker analysis|Correlative studies
214787421|NCT01189240|OTHER|pharmacological study|Correlative studies
214787422|NCT03522740|OTHER|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
214787423|NCT01264211|DRUG|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
214787424|NCT01264211|DRUG|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
214787425|NCT04726917|BEHAVIORAL|Pulmonary rehabilitation|Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
214787426|NCT03107351|DEVICE|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
214787427|NCT03107351|DEVICE|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
214787428|NCT05733650|BIOLOGICAL|Epcoritamab|Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
214787429|NCT03564925|PROCEDURE|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
214787430|NCT03564925|PROCEDURE|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
214787431|NCT00386724|DEVICE|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
214787432|NCT00386724|DEVICE|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
214787433|NCT02501239|BEHAVIORAL|Accept Yourself!|
214787434|NCT02501239|BEHAVIORAL|Weight Watchers|
214787435|NCT06544486|PROCEDURE|Caries Removal|The cavity preparation and restoration were performed by a single operator. Infected dentin tissue was selectively removed. The differentiation between infected and affected dentin was determined by the clinician through the visual-tactile method.Isolation was achieved with cotton rolls and suction.
214787436|NCT06544486|PROCEDURE|Filling|Sectional matrix systems and interdental wedges were used to achieve an anatomical contour and contact. Then, the selected materials were placed in the cavity according to the manufacturers' recommendations.
214787437|NCT05208411|BEHAVIORAL|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll \& Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
214787438|NCT01409356|BEHAVIORAL|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
214787439|NCT03779399|OTHER|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
214787440|NCT04788589|OTHER|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
214787441|NCT02008110|DRUG|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
214787442|NCT02008110|DRUG|CA125 guided strategy|Consider statins in all patients in the active arm
214787443|NCT02008110|DRUG|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
214787444|NCT02008110|OTHER|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
214787445|NCT02008110|DRUG|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
214787446|NCT02008110|DRUG|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
214787447|NCT01199406|DRUG|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
214787448|NCT02394431|OTHER|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
214787449|NCT02394431|OTHER|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
214787450|NCT02394431|OTHER|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
214787451|NCT00390988|PROCEDURE|blood sampling|
214787452|NCT01208402|DRUG|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
214787453|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
214787454|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
214787455|NCT00384358|OTHER|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
214787456|NCT01162395|DRUG|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
214787457|NCT00002571|BIOLOGICAL|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
214787458|NCT00002571|BIOLOGICAL|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
214787459|NCT00002571|DRUG|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
214787460|NCT00002571|DRUG|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
214787461|NCT00002571|DRUG|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
214787462|NCT00002571|DRUG|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
214787463|NCT00002571|DRUG|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
214787464|NCT00002571|DRUG|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
214787465|NCT00002571|DRUG|prednisone|60 mg/m2 po QD x 14days for 6 cycles
214787466|NCT00002571|DRUG|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
214787467|NCT00002571|DRUG|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
214787468|NCT00002571|RADIATION|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
214787469|NCT00002571|DRUG|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
214787470|NCT05725278|BEHAVIORAL|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
214787471|NCT05725278|OTHER|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
214787472|NCT02175407|DRUG|ASP1707|oral
214787473|NCT02175407|DRUG|itraconazole|oral
214787474|NCT05478811|DEVICE|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
214787475|NCT05478811|DEVICE|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
214787476|NCT03811249|DEVICE|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
214787477|NCT05086120|OTHER|eCARIBOU|A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
214787478|NCT00078468|DRUG|PELITREXOL/AG-2037|
214787479|NCT01583751|PROCEDURE|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
214787480|NCT05910710|GENETIC|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
215030905|NCT05061823|DRUG|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
214787481|NCT04482010|OTHER|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
214787482|NCT05063019|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging and enterography before surgery
214787483|NCT06251128|BEHAVIORAL|Stroke Self management Program|"Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants"
214787484|NCT04111133|DRUG|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
214787485|NCT04111133|DRUG|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
214787486|NCT05079893|OTHER|Case control study|Observational case control study
214787487|NCT03900611|DEVICE|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
214787488|NCT03974984|PROCEDURE|Colon Resection|All patients undergo laparoscopic colon cancer resection.
214787489|NCT03974984|PROCEDURE|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
214787490|NCT03974984|DRUG|NSAID|NSAID administered according to standard operating procedure postoperatively
214787491|NCT00706706|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
214787492|NCT01943461|DRUG|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
214787493|NCT01943461|DRUG|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
214787494|NCT01943461|DRUG|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
214787495|NCT01207128|DRUG|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
214787496|NCT00001728|DRUG|Fosamax (Alendronate)|
214787497|NCT03534297|DRUG|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
214787498|NCT03534297|DRUG|Placebo capsules|Hard opaque capsules containing 0 mg of API.
214787499|NCT00648453|DRUG|Clopidogrel (Plavix)|
214787500|NCT02232451|DEVICE|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
214787501|NCT02232451|DEVICE|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
214787502|NCT02175966|DRUG|DCV/ASV/BMS-791325|
214787503|NCT02175966|DRUG|Ribavirin|
214787504|NCT02175966|DRUG|Sofosbuvir|
214787505|NCT02175966|DRUG|Peginterferon α-2a|
214787506|NCT02807766|BEHAVIORAL|Behavior modification|Each group has 30 subjects and experiences six months' training.
214787507|NCT02807766|BEHAVIORAL|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
214787508|NCT02807766|BEHAVIORAL|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
214787509|NCT02807766|BEHAVIORAL|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
214787510|NCT05909306|OTHER|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
214787511|NCT02122094|BEHAVIORAL|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
214787512|NCT01448031|DRUG|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
214787513|NCT01448031|DRUG|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
214787514|NCT00564369|OTHER|CDC HIV testing recommendations|Current vs. prior CDC recommendations
214787515|NCT04657510|OTHER|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
214787516|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
214787517|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
214787518|NCT01478503|DRUG|mirabegron OCAS|oral
214787519|NCT01478503|DRUG|Placebo|oral
214787520|NCT02500017|DIETARY_SUPPLEMENT|Melatonin|5mg rapid release melatonin capsule
214787521|NCT02500017|OTHER|Placebo|matching placebo capsule
214787522|NCT03807154|BEHAVIORAL|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
214787523|NCT03807154|BEHAVIORAL|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
214787524|NCT01708928|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214787525|NCT02595333|DRUG|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
214787526|NCT02595333|DRUG|Group S1|sufentanil was administered for analgesia in primary cesarean section
214787527|NCT02595333|DRUG|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
214787528|NCT02595333|DRUG|Group S2|sufentanil was administered for analgesia in repeated cesarean section
214787529|NCT01154153|DRUG|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
214787530|NCT01154153|DRUG|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
214787531|NCT01154153|DRUG|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
214787532|NCT01154153|DRUG|Claritin® Syrup|Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
214787533|NCT02916381|PROCEDURE|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
214787534|NCT02916381|PROCEDURE|General anaesthesia|
214787535|NCT03164590|DRUG|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
214787536|NCT03164590|DRUG|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
214787537|NCT03164590|DRUG|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
214787538|NCT06503796|DRUG|Lamivudine|4mg/kg/d, oral
214787539|NCT06503796|DRUG|Interferon|Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
214787540|NCT03201471|DRUG|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
214787541|NCT02854683|DRUG|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
214787542|NCT02854683|DIETARY_SUPPLEMENT|Oral Rehydration Solution|1 liter of ORS solution given by mouth
214787543|NCT02347878|DRUG|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
214787544|NCT01203683|BEHAVIORAL|Active computer-based training|8 sessions across 4 weeks.
214787545|NCT01203683|BEHAVIORAL|Inert computer training|8 sessions across 4 weeks.
214787546|NCT02775253|OTHER|Chronic cold acclimation|
214787547|NCT05278377|BEHAVIORAL|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
214787548|NCT02638857|PROCEDURE|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
214787549|NCT02638857|BIOLOGICAL|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
214787550|NCT02638857|DRUG|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
214787551|NCT02638857|DRUG|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
214787552|NCT02638857|DRUG|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
214787553|NCT02638857|BIOLOGICAL|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
214787554|NCT00377026|BEHAVIORAL|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
214787555|NCT00887003|DRUG|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
214787556|NCT00887003|DRUG|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
214787557|NCT00887003|DRUG|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
214787558|NCT00887003|DRUG|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
214787559|NCT00887003|DRUG|Depo-Medrol|80mg Depo-Medrol
214787560|NCT02376985|PROCEDURE|Oral management|
214787561|NCT02376985|DRUG|Everolimus|
214787562|NCT01261533|DEVICE|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
214787563|NCT03183466|PROCEDURE|arthroscopic repair|
214787564|NCT03183466|PROCEDURE|arthroscopic debridement|
214787565|NCT02006966|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
214787566|NCT02006966|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
214787567|NCT00778557|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
214787568|NCT03677778|PROCEDURE|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
214787569|NCT03677778|OTHER|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
214787570|NCT04283578|DRUG|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
214787571|NCT04283578|DRUG|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
214787572|NCT05287659|DIETARY_SUPPLEMENT|meal replacements or supplementation with leucine|meal replacements or animal protein or supplementation with leucine
214787573|NCT00210626|DRUG|PROCRIT|40,000 IU/mL/week for max of 12 weeks
214787574|NCT00210626|DRUG|Placebo|40,000 IU/mL/week for max of 12 weeks
214787575|NCT01227668|DRUG|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
214787576|NCT01227668|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
214787577|NCT00343850|DRUG|Asacol (mesalamine)|
214787578|NCT04452799|DRUG|Hesperidin and Diosmin mixture|Interventional Clinical Trial
214787579|NCT05140642|OTHER|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
214787580|NCT05140642|OTHER|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
214787581|NCT02629952|OTHER|Blueberry Tea|Blueberry Tea
214787582|NCT00738556|DEVICE|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
214787583|NCT04487756|DRUG|Atezolizumab 1200 mg in 20 ML Injection|"\- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~\- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)"
214787584|NCT04487756|BIOLOGICAL|ADC Vaccine|\- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
214787585|NCT04487756|DRUG|Carboplatin|\- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
214787586|NCT05206032|OTHER|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
214787587|NCT01886456|DEVICE|Laser trabeculoplasty|
214787588|NCT01671787|DRUG|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
214787589|NCT01671787|DRUG|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
214787590|NCT03951428|DIAGNOSTIC_TEST|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
214787591|NCT02060656|DRUG|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
214787592|NCT02060656|DRUG|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
214787593|NCT02060656|DRUG|Rituximab|375mg/m2 IV D1, D15 every 28 days
214787594|NCT02060656|DRUG|Cisplatin|100mg/m2 IV D15 every 28 days
214787595|NCT02060656|DRUG|Lenalidomide|25mg PO D1-21 every 28 days
214787596|NCT05808556|DEVICE|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
214787597|NCT05808556|DEVICE|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
214787598|NCT00794261|DRUG|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
214787599|NCT00794261|DRUG|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
214787600|NCT03720756|OTHER|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
214787601|NCT03500770|DEVICE|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
214787602|NCT02350530|DRUG|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214787603|NCT02350530|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214787604|NCT02473510|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
214787605|NCT02473510|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
214787606|NCT01306253|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
214787607|NCT01690065|DRUG|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
214787608|NCT00003747|DRUG|carboplatin|
214787609|NCT00003747|DRUG|temozolomide|
214787610|NCT03736395|BEHAVIORAL|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
214787611|NCT03736395|BEHAVIORAL|Control|Schools in this condition will receive a four-day training session about SWPBIS.
214787612|NCT06537856|OTHER|Health Belief Model Based Cardiovascular Disease Risk Factor Prevention Education|"In line with the literature review, Health Belief Model-Based Cardiovascular Disease Risk Factor Prevention Training was created in order to increase the level of knowledge of firefighters regarding cardiovascular disease risk factors, improve their awareness and positively affect their quality of life. This training was given in 3 different sessions by meeting face-to-face with firefighters in the training hall of the fire stations. Each session lasted 40 minutes. Answers were given to the questions asked at the end of the session. The training was organized under the following main headings:~Perceived Sensitivity, Perceived Seriousness, Perceived Barriers, Perceived Self-Efficacy, Health Motivation/Activators"
214787613|NCT06537856|BEHAVIORAL|Reminder Short Messages|After the Health Belief Model-Based health education, 39 text messages were sent via WhatsApp application 3-4 times a week for 3 months to increase the effectiveness of the education and the motivation of firefighters in CVD prevention.
214787614|NCT05587101|DIAGNOSTIC_TEST|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
214787615|NCT05587101|DIAGNOSTIC_TEST|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
214787616|NCT05587101|DIAGNOSTIC_TEST|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
214787617|NCT03312725|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
214787618|NCT03208283|DIAGNOSTIC_TEST|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
214787619|NCT03208283|DIAGNOSTIC_TEST|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
214787620|NCT04242966|OTHER|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
214787621|NCT04242966|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
214787622|NCT04242966|OTHER|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
214787623|NCT01637025|DEVICE|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
214787624|NCT01637025|DEVICE|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
214787625|NCT02170701|DRUG|BIBR 1048|Ascending doses (in mg) given twice daily
214787626|NCT02611206|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
214787627|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
214787628|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
214787629|NCT01906099|OTHER|nutritional intervention|
214787630|NCT01906099|OTHER|life style modification|
214787631|NCT03089099|OTHER|Blood drawing|Blood drawing
214787632|NCT02280356|RADIATION|external beam radiation therapy|
214787633|NCT02280356|RADIATION|brachytherapy|
214787634|NCT02280356|BEHAVIORAL|questionnaires|
214787635|NCT00412815|BEHAVIORAL|Exercise training|
214787636|NCT03670407|PROCEDURE|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
214787637|NCT02958878|DRUG|Tamsulosin|
214787638|NCT02958878|DRUG|Placebo Oral Capsule|
214787639|NCT03785483|BEHAVIORAL|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
214787640|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
214787641|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
214787642|NCT02971514|BEHAVIORAL|Flossing before Brushing|
214787643|NCT02971514|BEHAVIORAL|Brushing before Flossing|
214787644|NCT00029185|DRUG|Dehydrex|
214787645|NCT00306631|DRUG|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
214787646|NCT00728559|DRUG|bupivacain 0.5%|trocar site injection
214787647|NCT00067158|DRUG|nicotine transdermal system|
214787648|NCT01548950|DRUG|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
214787649|NCT00249457|BEHAVIORAL|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
214787650|NCT05642559|OTHER|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
214787651|NCT05682794|PROCEDURE|transanal total mesorectal excision|transanal TME
214787652|NCT04976049|PROCEDURE|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
214787653|NCT05723627|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
214787654|NCT05723627|DRUG|Propofol|Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
214787655|NCT00468923|DRUG|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
214787656|NCT00468923|DRUG|Rosuvastatin|Rosuvastatin 10 mg once daily
214787657|NCT00194818|DRUG|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
214787658|NCT00776633|DRUG|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
214787659|NCT00776633|DRUG|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
214787660|NCT00776633|DRUG|oral anticoagulation|
214787661|NCT03564899|BEHAVIORAL|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
214787662|NCT03564899|BEHAVIORAL|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
214787663|NCT02524106|DRUG|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
214787664|NCT02524106|DRUG|Placebo|placebo
214787665|NCT03853083|DEVICE|Hypoxi Equipment|Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
214787666|NCT03853083|DEVICE|Recumbent Bicycle|Recumbent bike is a piece of exercise equipment used as the comparison group
214787667|NCT00293969|DRUG|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
214787668|NCT03721848|BEHAVIORAL|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
214787669|NCT03721848|BEHAVIORAL|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
214787670|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
214787671|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
214787672|NCT02277821|DEVICE|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
214787673|NCT03370484|DIETARY_SUPPLEMENT|Control|Water with 80 mg sucralose
214787674|NCT03370484|DIETARY_SUPPLEMENT|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
214787675|NCT01011322|DRUG|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
214787676|NCT01011322|DRUG|placebo|placebo
214787677|NCT02528578|DEVICE|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
214787678|NCT02528578|OTHER|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
214787679|NCT04053478|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
214787680|NCT04053478|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
214787681|NCT04053478|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
214787682|NCT04053478|DRUG|Vasopressin|Vasopressin, at applicable concentrations based on literature
214787683|NCT00648856|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
214787684|NCT00648856|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fed
214787685|NCT01806883|BEHAVIORAL|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
214787686|NCT01806883|BEHAVIORAL|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
214787687|NCT05371301|DRUG|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
214787688|NCT05371301|PROCEDURE|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
214787689|NCT04759495|DEVICE|Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)|rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
214787690|NCT04759495|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)|FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
214787691|NCT05447429|PROCEDURE|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
214787692|NCT05447429|DRUG|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
214787693|NCT02277795|DEVICE|AccuCirc|Circumcision with the use of the AccuCirc device.
214787694|NCT03767673|DIAGNOSTIC_TEST|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
214787695|NCT03767673|DIAGNOSTIC_TEST|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
214787696|NCT03767673|DIAGNOSTIC_TEST|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
214787697|NCT03767673|DIAGNOSTIC_TEST|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
214787698|NCT03767673|DIAGNOSTIC_TEST|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
214787699|NCT03767673|DIAGNOSTIC_TEST|weight|Determined by Kilogram on a medical weight scale
214787700|NCT03767673|OTHER|age|Determination of age by patient's Report and past medical history
214787701|NCT02182960|DRUG|Ibuprofen syrup|
214787702|NCT02182960|DRUG|Brufen syrup|
214787703|NCT03786510|BEHAVIORAL|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
214787704|NCT03786510|BEHAVIORAL|Intensive + Maintenance program|"Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
214787705|NCT03786510|BEHAVIORAL|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
214787706|NCT03496532|DEVICE|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
214787707|NCT03496532|DEVICE|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
214787708|NCT03496532|DEVICE|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
214787709|NCT03496532|DEVICE|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
214787710|NCT03496532|DEVICE|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
214787711|NCT04624022|DIAGNOSTIC_TEST|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
214787712|NCT04456465|OTHER|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
214787713|NCT01016496|OTHER|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
214787714|NCT01016496|OTHER|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
214787715|NCT01051622|OTHER|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
214787716|NCT04171388|DRUG|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
214787717|NCT04171388|DIETARY_SUPPLEMENT|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) \>=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC \<23 cm
214787718|NCT04171388|DRUG|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
214787719|NCT04171388|OTHER|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
214787720|NCT01437137|DEVICE|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
214787721|NCT01437137|DEVICE|i-gel™|Insertion of I-gel
214787722|NCT02586545|OTHER|Shared care|
214787723|NCT00236327|DRUG|fentanyl|
214787724|NCT02022371|PROCEDURE|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
214787725|NCT06066307|OTHER|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
214787726|NCT04976140|BIOLOGICAL|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
214787727|NCT00000295|DRUG|Micronized Progesterone|
214787728|NCT05252078|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
214787729|NCT05252078|DRUG|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
214787730|NCT03361956|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
214787731|NCT03361956|DRUG|Placebo|Participants will receive matching placebo tablet orally.
214787732|NCT03361956|DRUG|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
214787733|NCT00408876|DRUG|Duloxetine|
214787734|NCT00408876|DRUG|Placebo|
214787735|NCT03605615|OTHER|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
214787736|NCT03385187|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
214787737|NCT02006147|DRUG|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
214787738|NCT03198988|DEVICE|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
214787739|NCT02767622|PROCEDURE|Liver transplantation|
214787740|NCT01488019|DRUG|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
214787741|NCT01488019|DRUG|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
214787742|NCT02793063|OTHER|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
214787743|NCT00263978|DRUG|Defibrotide|
214787744|NCT04698057|DRUG|Placebo|The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
214787745|NCT04698057|DRUG|Amoxicillin Clavulanate|Will be administred to all patients
214787746|NCT04698057|DRUG|Ciprofloxacin|Will be administred to patients in the standard of care arm
214787747|NCT02758054|BEHAVIORAL|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
214787748|NCT00657878|DRUG|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
214787749|NCT00657878|DRUG|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
214787750|NCT00657878|DRUG|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
214787751|NCT00657878|DRUG|Topotecan|dosing and schedule according to Institutional guidelines
214787752|NCT00657878|DRUG|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
214787753|NCT03158428|OTHER|CSD170202AA|A moist snuff product
214787754|NCT03158428|OTHER|CSD170202AB|A moist snuff product
214787755|NCT06214026|DEVICE|META-Arc foot locked|Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.
214787756|NCT06214026|DEVICE|META-Arc foot unlocked|Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
214787757|NCT02400710|BEHAVIORAL|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
214787758|NCT02400710|BEHAVIORAL|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
214787759|NCT02561390|PROCEDURE|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
214787760|NCT02561390|OTHER|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
214787761|NCT00871728|DRUG|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
214787762|NCT02546284|DRUG|lenzilumab|
214787763|NCT04346290|DRUG|Dexmedetomidine|Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
214787764|NCT04204486|BEHAVIORAL|Exercise|Functional strength training, 1 hour, 3 times a week.
214787765|NCT04147715|DRUG|S-648414|Tablet for oral administration
214787766|NCT04147715|DRUG|Placebo|Tablet for oral administration
214787767|NCT04147715|DRUG|Midazolam|Solution for oral administration
214787768|NCT04147715|DRUG|Dolutegravir|Tablet for oral administration
214787769|NCT02024828|OTHER|Early/Slow|
214787770|NCT02024828|OTHER|Early/Fast|
214787771|NCT02024828|OTHER|Late/Slow|
214787772|NCT02024828|OTHER|Late/Fast|
214787773|NCT05621642|OTHER|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
214787774|NCT05621642|OTHER|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
214787775|NCT05621642|OTHER|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
214787776|NCT01004081|DRUG|BIIB021|BID orally for 28 days
214787777|NCT01004081|DRUG|BIIB021|TIW orally for 28 days
214787778|NCT01004081|DRUG|exemestane (Aromasin)|Daily in tablet form for 28 days
214787779|NCT04596449|OTHER|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
214787780|NCT00014521|DRUG|karenitecin|
214787781|NCT02439606|DEVICE|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
214787782|NCT02439606|DEVICE|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
214787783|NCT01270022|OTHER|Implementation|
214787784|NCT01270022|OTHER|dissemination|
214787785|NCT02541656|PROCEDURE|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
214787786|NCT00577759|OTHER|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
214787787|NCT00577759|OTHER|Passive Intervention|Provision of tools to help with referrals to community resources
214787788|NCT00577759|OTHER|No intervention|No intervention
214787789|NCT02893852|BEHAVIORAL|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
214787790|NCT02893852|BEHAVIORAL|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
214787791|NCT06358378|DEVICE|Aktiia SA Bracelet|The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
214787792|NCT00242775|DRUG|Budesonide/formoterol Turbuhaler|
214787793|NCT00242775|DRUG|Salmeterol/fluticasone Diskus|
214787794|NCT01626859|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
214787795|NCT01626859|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
214787796|NCT01626859|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
214787797|NCT01545219|DIETARY_SUPPLEMENT|Prebiotic|8g/day xylo-oligosaccharide
214787798|NCT01545219|DIETARY_SUPPLEMENT|Bi-07|10\^9 CFU B. lactis / day
214787799|NCT01545219|DIETARY_SUPPLEMENT|Synbiotic|8g/day xylo-oligosaccharide + 10\^9 CFU Bi-07
214787800|NCT01545219|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
214787801|NCT00039507|PROCEDURE|conventional surgery|
214787802|NCT00039507|PROCEDURE|radiofrequency ablation|
214787803|NCT04025619|DEVICE|tape|Sports tape
214787804|NCT02629965|DRUG|tiotropium|fixed dose combination
214787805|NCT02629965|DRUG|olodaterol|fixed dose combination
214787806|NCT02629965|DRUG|tiotropium|
214787807|NCT02103738|OTHER|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
214787808|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
214787809|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
214787810|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
214787811|NCT00918697|PROCEDURE|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
214787812|NCT00918697|PROCEDURE|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
214787813|NCT05738109|OTHER|Self-Talk Journals|Participants randomized to the intervention group will receive a physical copy of the 91-day self-talk journal during the baseline meeting. Participants will also be introduced the purpose of the journal and its intended usage (i.e., daily journaling). Intervention participants will not be offered guidance or feedback on the journal after these initial instructions, in order to emulate an ad libitum usage. Control group participants will not receive any contact with the researchers outside of the planned questionnaires and to receive their journal at the three-month timepoint.
214787814|NCT04916171|OTHER|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
214787815|NCT00654303|DRUG|Rosuvastatin|
214787816|NCT01811797|DEVICE|Low Intensity Shockwave by Renova|
214787817|NCT01811797|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
214787818|NCT03682783|DIAGNOSTIC_TEST|Fundus Image|Fundus image of optic nerve
214787819|NCT00657956|DEVICE|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
214787820|NCT02059733|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
214787821|NCT04928911|BIOLOGICAL|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
214787822|NCT00905489|DRUG|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
214787823|NCT00905489|DRUG|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
214787824|NCT00088777|BEHAVIORAL|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
214787825|NCT00088777|BEHAVIORAL|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
214787826|NCT03496454|OTHER|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
214787827|NCT03207659|PROCEDURE|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
214787828|NCT03207659|PROCEDURE|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
214787829|NCT02407756|DRUG|Dupilumab|
214787830|NCT02535052|BIOLOGICAL|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
214787831|NCT01674842|RADIATION|Radiation Therapy|Once daily, Monday - Friday for six weeks
214787832|NCT01674842|DRUG|Cisplatin|Intravenously, once weekly for six weeks
214787833|NCT02783742|BEHAVIORAL|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
214787834|NCT06407895|OTHER|Lower Limb Fitness Program|the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity
214787835|NCT06407895|OTHER|Routine Therapy|In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
214787836|NCT00895583|DRUG|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
214787837|NCT00895583|DRUG|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
214787838|NCT00895583|DRUG|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
214787839|NCT04624269|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
214787840|NCT00924066|DRUG|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
214787841|NCT06223581|OTHER|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
214787842|NCT04453566|OTHER|Online Survey|Online Survey
214787843|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
214787844|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
214787845|NCT05830448|BEHAVIORAL|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
214787846|NCT05830448|BEHAVIORAL|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
214787847|NCT02260375|BIOLOGICAL|Mesenchymal Stromal Cells|
214787848|NCT05062109|BEHAVIORAL|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~* Muscle rehabilitation developed with a physiotherapist or physical activity monitor~* Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~* Cognitive and physical stimulation Exergame~* Psychological support by a psychologist~* Information in the form of videos on the main risks and important points to know and prepare before and after surgery~* Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~* One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
214787849|NCT04049552|DRUG|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
214787850|NCT04049552|DRUG|Placebo|Petrolatum ointment placebo
214787851|NCT01164423|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
214787852|NCT00548353|DRUG|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
214787853|NCT00548353|DRUG|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
214787854|NCT05752305|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
214787855|NCT05752305|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
214787856|NCT02328261|DRUG|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
214787857|NCT05175079|DEVICE|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
214787858|NCT05175079|OTHER|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
214787859|NCT00333333|PROCEDURE|Cord blood|Cord blood will be obtained at the time of delivery.
214787860|NCT02479828|DRUG|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
214787861|NCT02479828|DRUG|Ropivacaine|
214787862|NCT02479828|DEVICE|ultrasound|
214787863|NCT02479828|DRUG|Placebo|
214787864|NCT05009628|PROCEDURE|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
214787865|NCT05009628|PROCEDURE|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
214787866|NCT05009628|PROCEDURE|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
214787867|NCT03553784|OTHER|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
214787868|NCT06526897|PROCEDURE|Biopsy|Undergo biopsy
214787869|NCT06526897|PROCEDURE|Chest Computed Tomography|Undergo chest CT
214787870|NCT06526897|PROCEDURE|Chest Radiography|Undergo CXR
214787871|NCT06526897|OTHER|Quality-of-Life Assessment|Ancillary studies
214787872|NCT06526897|OTHER|Questionnaire Administration|Ancillary studies
214787873|NCT06527053|DEVICE|obturator|special maxillofacial device to close hollow defects
214787874|NCT03658278|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
214787875|NCT00643110|DRUG|D50 glucose|D50 glucose would be administered, if necessary.
214787876|NCT01191255|DRUG|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
214787877|NCT00036777|DRUG|carboplatin|Given IV
214787878|NCT00036777|DRUG|7-hydroxystaurosporine|Given IV
214787879|NCT00036777|OTHER|pharmacological study|Correlative studies
214787880|NCT05163002|BEHAVIORAL|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
214787881|NCT05555082|OTHER|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
214787882|NCT06525441|OTHER|Plant-based Diet|Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
214787883|NCT06525441|OTHER|Animal-based Diet|Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
214787884|NCT00920335|OTHER|tumoral sample|Ependymoma tumoral sample
214787885|NCT05744661|OTHER|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
214787886|NCT05744661|OTHER|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
214787887|NCT02196506|DRUG|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
214787888|NCT02196506|DRUG|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
214787889|NCT01396759|PROCEDURE|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
214787890|NCT01396759|PROCEDURE|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
214787891|NCT01396759|PROCEDURE|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
214787892|NCT00202553|DRUG|Perindopril|
214787893|NCT05602233|OTHER|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
214787894|NCT05602233|OTHER|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
214787895|NCT00368329|DRUG|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
214787896|NCT00368329|DRUG|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
214787897|NCT00368329|DRUG|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
214787898|NCT00368329|DRUG|Carboplatin|AUC 2, based onCalvert formula IV infusion
214787899|NCT00323583|DRUG|paclitaxel|
214787900|NCT00323583|DRUG|oxaliplatin|
214787901|NCT00323583|DRUG|leucovorin|
214787902|NCT00323583|DRUG|5-fluorouracil|
214787903|NCT00323583|DRUG|glutathione|
214787904|NCT00323583|DRUG|calcium and magnesium|
214787905|NCT00323583|PROCEDURE|Chemotherapy|
214787906|NCT00323583|PROCEDURE|Chemoprotection|
214787907|NCT00323583|PROCEDURE|Complementary and alternative therapy|
214787908|NCT06481553|DRUG|first line treatment|Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
214787909|NCT05843838|PROCEDURE|Hypotension during spinal anesthesia for cesarean section|Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value
214787910|NCT05843838|DIAGNOSTIC_TEST|Mini-mental test|"A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated."
214787911|NCT05843838|PROCEDURE|Spinal anesthesia|It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
214787912|NCT05843838|DIAGNOSTIC_TEST|The Bromage scale|"The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet"
214787913|NCT05843838|DRUG|Heavy Bupivacaine for spinal anesthesia|Routine clinical heavy bupivacaine doses
214787914|NCT03165643|DIAGNOSTIC_TEST|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
214787915|NCT00094783|PROCEDURE|MRI|
214787916|NCT06325982|DRUG|Triethanolamine cream|"Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months.~Preparation method: Pull out the syringe piston, add 15ml triethanolamine cream, add 30ml normal saline, gently pat, shake well.~Specific methods of retention enema: at night before going to bed, empty urine and feces, prepare enema liquid into the syringe, connect the special catheter, and insert the other end of the special catheter into the anus (the special catheter can be applied with lubricant such as tea oil before insertion). The patient remained prone and semi-seated. Use a special catheter, insert a special catheter about 15cm from the anus, and inject enteral liquid while withdrawing, so that the liquid is retained in the rectum; The above treatment was performed before bed and retained overnight."
214787917|NCT04087083|OTHER|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
214787918|NCT04087083|OTHER|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
214787919|NCT04344054|BIOLOGICAL|RV3-BB|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
214787920|NCT04344054|BIOLOGICAL|Trivalent P2-VP8|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
214787921|NCT04344054|BIOLOGICAL|Rotarix|1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
214787922|NCT04344054|BIOLOGICAL|RV3-BB birth dose|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
214787923|NCT04344054|BIOLOGICAL|Trivalent P2-VP8 Booster dose|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
214787924|NCT05617820|DRUG|Estradiol|Vaginal Insert, 4 mcg tablet
214787925|NCT05617820|DRUG|Imvexxy|Estradiol 4 mcg Vaginal Insert
214787926|NCT05617820|DRUG|Placebo|Vehicle Vaginal Insert
214787927|NCT03644602|DIETARY_SUPPLEMENT|low FODMAPs diet|Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
214787928|NCT03994094|OTHER|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
214787929|NCT04953585|PROCEDURE|radical gastrectomy|According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
214787930|NCT01724970|DEVICE|ProSeal|Patients will be ventilated with PLMA
214787931|NCT01724970|DEVICE|Supreme LMA|Patients will be ventilated with SLMA
214787932|NCT03903484|OTHER|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
214787933|NCT01715415|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214787934|NCT01715415|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
214787935|NCT01715415|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
214787936|NCT01715415|DRUG|Placebo for ABT-333|Tablet
214787937|NCT01715415|DRUG|Placebo for ribavirin|Capsule
214787938|NCT01015612|DEVICE|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
214787939|NCT00066807|DRUG|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
214787940|NCT00066807|DRUG|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
214787941|NCT00066807|DRUG|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
214787942|NCT00066807|DRUG|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
214787943|NCT00066807|PROCEDURE|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
214787944|NCT00066807|PROCEDURE|ovarian irradiation|Bilateral ovarian irradiation.
214787945|NCT01418729|DRUG|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
214787946|NCT06012175|DIETARY_SUPPLEMENT|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
214787947|NCT06012175|DIETARY_SUPPLEMENT|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
214787948|NCT00005960|BIOLOGICAL|filgrastim|
214787949|NCT00005960|DRUG|cyclophosphamide|
214787950|NCT00005960|DRUG|docetaxel|
214787951|NCT00005960|DRUG|doxorubicin hydrochloride|
214787952|NCT00005960|PROCEDURE|pain therapy|
214787953|NCT01438333|DIETARY_SUPPLEMENT|lactobacillus brevis tablets|5 tablets a day for 6 weeks
214787954|NCT01438333|DIETARY_SUPPLEMENT|PLACEBO|5 tablets a day for 6 weeks
214787955|NCT03177356|PROCEDURE|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
214787956|NCT03177356|PROCEDURE|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
214787957|NCT05028751|DRUG|Lanraplenib|Orally via tablets
214787958|NCT05028751|DRUG|Gilteritinib|Orally via tablets
214787959|NCT05787977|OTHER|Visual Feedback and Rhythmic Auditory Cue|Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
214787960|NCT05550558|DRUG|Anlotinib + Camrelizumab|Anlotinib PO plus Camrelizumab IV
214787961|NCT03586830|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
214787962|NCT03586830|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
214787963|NCT03586830|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
214787964|NCT03586830|DRUG|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
214787965|NCT04578548|DRUG|GLPG2737|Capsules administered orally
214787966|NCT04578548|DRUG|Placebo|Matching placebo capsules administered orally
214787967|NCT02248285|DEVICE|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
214787968|NCT00395083|BEHAVIORAL|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
214787969|NCT05452577|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
214787970|NCT05452577|DRUG|Estazolam 1Mg Tab|1mg tablet once daily
214787971|NCT03904498|DRUG|Tolcapone|Tolcapone 100 mg tablets
214787972|NCT03904498|DRUG|Placebo|Placebo tablets
214787973|NCT06394921|PROCEDURE|2 day cardiopulmonary exercise test|Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
214787974|NCT00628745|OTHER|None. Observational Study.|
214787975|NCT04825080|DIAGNOSTIC_TEST|duplex ultrasound and computed tomography angiography|Identification of carotid artery stenosis \> 60% NASCET criteria
214787976|NCT03570580|OTHER|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
214787977|NCT03322462|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
214787978|NCT03322462|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
214787979|NCT01976390|DRUG|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
214787980|NCT01976390|DRUG|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
214787981|NCT04289220|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
214787982|NCT00916890|DRUG|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
214787983|NCT00916890|DRUG|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
214787984|NCT00916890|DRUG|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
214787985|NCT00916890|DRUG|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
214787986|NCT06544551|DRUG|Peginterferon Alfacon-2|Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
214787987|NCT06544551|DRUG|Peginterferon Alfacon-2 placebo|Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
214787988|NCT02265848|OTHER|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
214787989|NCT02265848|OTHER|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
214787990|NCT04142346|BEHAVIORAL|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
214787991|NCT03321058|BEHAVIORAL|Assessment|Assessment of patients' medication organisation and comprehension of generics
214787992|NCT01704664|DIETARY_SUPPLEMENT|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
214787993|NCT01704664|DRUG|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
214787994|NCT01704664|DIETARY_SUPPLEMENT|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
214787995|NCT01704664|DRUG|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
214787996|NCT02660411|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
214787997|NCT02660411|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
214787998|NCT06544083|DIAGNOSTIC_TEST|Proteomics|Proteomic is performed on all blood samples.
214787999|NCT02127047|DRUG|Sitagliptin|
214788000|NCT02127047|DRUG|Exercise|
214788001|NCT05760703|DRUG|STSG-0002 Injection|Intravenous infusion
214788002|NCT01133821|DRUG|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
214788003|NCT01133821|DRUG|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
214788004|NCT00325403|DRUG|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
214788005|NCT00325403|OTHER|Placebo|Placebo oral tablet twice daily
214788006|NCT05177757|OTHER|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
214788007|NCT00580359|DRUG|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
214788008|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
214788009|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
214788010|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
214788011|NCT04320459|DIAGNOSTIC_TEST|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
214788012|NCT04320459|DIAGNOSTIC_TEST|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
214788013|NCT04320459|DIAGNOSTIC_TEST|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
214788014|NCT06092606|DRUG|Control group:DH001 placebo|Dosage: DH001 placebo (8 tablets)
214788015|NCT06092606|DRUG|Trial group: DH001 low-dose group|Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)
214788016|NCT06092606|DRUG|Trial group: DH001 high-dose group|Dosage: DH001 400mg (8 tablets).
214788017|NCT05426122|OTHER|Barley rice protein concentrate shake|At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
214788018|NCT05426122|OTHER|Pea protein concentrate shake|At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
214788019|NCT05426122|OTHER|Whey protein concentrate shake|At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
214788020|NCT06234046|DRUG|Rifaximin 550Mg Tab|group (1) received Rifaximin as 550 mg twice daily dosage for six months.
214788021|NCT06234046|DRUG|Ciprofloxacin 750 MG|group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.
214788022|NCT06234046|DIAGNOSTIC_TEST|ascitic fluid sample|aspiration of ascitic fluid sample and analysis for differential cell count
214788023|NCT04767269|DRUG|Cuminum Cyminum|Cuminum Cyminum mouthwash in chronic gingivitis patients
214788024|NCT04767269|DRUG|herbal Mouthwash|herbal mouthwash in chronic gingivitis patients
214788025|NCT04596501|OTHER|Early and late postmenopausal women|The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.
214788026|NCT03500939|DRUG|Medical oxygen|inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
214788027|NCT03500939|OTHER|Standard of care|e.g. thrombectomy, thrombolysis
214788028|NCT00711906|DRUG|Cotrimoxazole|Cotrimoxazole
214788029|NCT00711906|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
214788030|NCT03129737|PROCEDURE|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
214788031|NCT03129737|PROCEDURE|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
214788032|NCT03572933|DRUG|ganaxolone|active drug
214788033|NCT03572933|DRUG|Placebo|inactive
214788034|NCT02685605|PROCEDURE|Standard surgery|
214788035|NCT02685605|RADIATION|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
214788036|NCT02685605|RADIATION|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
214788037|NCT02685605|DRUG|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
214788038|NCT01501383|DRUG|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
214788039|NCT01501383|DRUG|Placebo|Matching placebo
214788040|NCT01501383|DRUG|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
214788041|NCT00004110|BIOLOGICAL|monoclonal antibody 3F8|
214788042|NCT00004110|DRUG|etoposide|
214788043|NCT00004110|DRUG|isotretinoin|
214788044|NCT00739479|DIETARY_SUPPLEMENT|Weight Loss|Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
214788045|NCT00003833|GENETIC|DNA stability analysis|
214788046|NCT00003833|GENETIC|gene mapping|
214788047|NCT00418782|DRUG|naproxen|
214788048|NCT00418782|DRUG|CE-224535|
214788049|NCT00418782|DRUG|placebo|
214788050|NCT05586620|PROCEDURE|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
214788051|NCT05586620|PROCEDURE|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
214788052|NCT01847573|DRUG|HT-100|May be administered in either fed or fasted state
214788053|NCT01761526|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
214788054|NCT02625766|PROCEDURE|LC fracture surgical fixation|
214788055|NCT02625766|PROCEDURE|LC fracture non-operative management|
214788056|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 1.5mg/ day|Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
214788057|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 2.0mg/ day|Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
214788058|NCT04443322|DRUG|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
214788059|NCT04443322|DRUG|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
214788060|NCT01527448|DRUG|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
214788061|NCT02413073|PROCEDURE|Whole Body Vibration|We wil use vibration in patients with kidney disease
214788062|NCT01467063|DIETARY_SUPPLEMENT|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
214788063|NCT01467063|DIETARY_SUPPLEMENT|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
214788064|NCT03575039|DEVICE|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
214788065|NCT03164863|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
214788066|NCT00064181|DRUG|FOLFIRI regimen|
214788067|NCT00064181|DRUG|capecitabine|
214788068|NCT00064181|DRUG|celecoxib|
214788069|NCT00064181|DRUG|fluorouracil|
214788070|NCT00064181|DRUG|irinotecan hydrochloride|
214788071|NCT00064181|DRUG|leucovorin calcium|
214788072|NCT05717881|DIETARY_SUPPLEMENT|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
214788073|NCT05717881|DIETARY_SUPPLEMENT|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
214788074|NCT05399810|OTHER|Computer Application (ICOGNI) Training|Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
214788075|NCT03306108|DEVICE|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
214788076|NCT00763984|BEHAVIORAL|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
214788077|NCT00763984|BEHAVIORAL|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
214788078|NCT00040859|DRUG|capecitabine|
214788079|NCT00040859|DRUG|oxaliplatin|
214788080|NCT03453359|DEVICE|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
214788081|NCT03453359|DEVICE|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
214788082|NCT00633152|DRUG|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
214788083|NCT00633152|DRUG|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
214788084|NCT00633152|DRUG|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
214788085|NCT01556685|OTHER|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
214788086|NCT01556685|OTHER|Blood Sample|For evaluation of interferon-related Nab
214788087|NCT01556685|GENETIC|Blood Sample|genetic evaluation - predisposition to Nab generation
214788088|NCT00647049|DRUG|methotrexate|8000mg/m2 i.v., max. 2 cycles
214788089|NCT00647049|DRUG|Rituximab|375mg/m2, max. 8 times
214788090|NCT00647049|DRUG|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
214788091|NCT00647049|DRUG|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
214788092|NCT00647049|DRUG|Carmustin|400mg/m2 i.v. for 1 day
214788093|NCT00195806|DRUG|divalproex sodium|
214788094|NCT01907087|BIOLOGICAL|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
214788095|NCT02049359|OTHER|Texting|Bidirectional texting once weekly for 12 weeks
214788096|NCT03273387|DRUG|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
214788097|NCT03273387|DRUG|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
214788098|NCT02345278|DRUG|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
214788099|NCT02345278|OTHER|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
214788100|NCT03273985|OTHER|Dry needling|Trigger point deep dry needling
214788101|NCT03273985|OTHER|Ischemic compression|Trigger point ischemic compression
214788102|NCT05216978|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
214788103|NCT02180061|BIOLOGICAL|Pembrolizumab|IV infusion
214788104|NCT00840983|PROCEDURE|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
214788105|NCT00217854|PROCEDURE|Bronchoscopic|Bronchoscopic procedure
214788106|NCT00594633|OTHER|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
214788107|NCT00437151|OTHER|More frequent than normal office visits|Mode of patient reminder
214788108|NCT00437151|OTHER|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
214788109|NCT00437151|OTHER|Parenteral involvement / intervention reminders|Mode of patient reminder
214788110|NCT00437151|OTHER|No intervention or reminders|Mode of patient reminder
214788111|NCT01129154|DRUG|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
214788112|NCT01923246|BEHAVIORAL|Single WEB intervention|Brief WEB intervention recieved once
214788113|NCT01923246|BEHAVIORAL|Repeated WEB intervention|WEB intervention recieved twice.
214788114|NCT01923246|BEHAVIORAL|Single IVR intervention|IVR intervention recieved once
214788115|NCT01923246|BEHAVIORAL|Repeated IVR intervention|IVR intervention recieved twice
214788116|NCT06104930|OTHER|Explorative biomarker study|Analysis of blood biomarker
214788117|NCT00093639|DRUG|everolimus|
214788118|NCT00093639|DRUG|imatinib mesylate|
214788119|NCT00652873|DRUG|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
214788120|NCT00652873|DRUG|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
214788121|NCT05868057|DRUG|SHR7280 tablets|SHR7280 tablets 1 time
214788122|NCT05868057|DRUG|SHR7280 dry suspension|SHR7280 dry suspension 1 time
214788123|NCT01405950|DRUG|Zanaflex Capsules|0.025 mg/kg
214788124|NCT01405950|DRUG|Zanaflex Capsules|0.05 mg/kg
214788125|NCT01405950|DRUG|Zanaflex Capsules|0.075 mg/kg
214788126|NCT01405950|DRUG|Zanaflex Capsules|0.1 mg/kg
214788127|NCT04018144|DIAGNOSTIC_TEST|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
214788128|NCT02727140|BEHAVIORAL|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
214788129|NCT02727140|BEHAVIORAL|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
214788130|NCT01517724|DRUG|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
214788131|NCT00736619|OTHER|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
214788132|NCT03690479|DEVICE|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
214788133|NCT03690479|DEVICE|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
214788134|NCT06543602|DIAGNOSTIC_TEST|multi-model monitoring and alert|All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
214788135|NCT04485000|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
214788136|NCT02410252|DEVICE|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
214788137|NCT04371614|BEHAVIORAL|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
214788138|NCT01125995|RADIATION|early CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
214788139|NCT01125995|RADIATION|late CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
214788140|NCT02717975|PROCEDURE|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
214788141|NCT02717975|PROCEDURE|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
214788142|NCT03818737|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
214788143|NCT03818737|BIOLOGICAL|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
214788144|NCT03818737|BIOLOGICAL|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
214788145|NCT03818737|DRUG|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
214788146|NCT00673985|OTHER|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
214788147|NCT00673985|DEVICE|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
214788148|NCT03999437|DRUG|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
214788149|NCT03999437|DRUG|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
214788150|NCT03999437|DRUG|Vehicle Control|Topical liquid solution
214788151|NCT00851032|OTHER|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
214788152|NCT00174733|DRUG|Ciclesonide (XRP1526)|
214788153|NCT04675983|DRUG|Sintilimab|Administered IV
214788154|NCT04675983|DRUG|Ramucirumab|Administered IV
214788155|NCT04675983|DRUG|Cisplatin|Administered IV
214788156|NCT04675983|DRUG|5-fluorouracil|Administered IV
214788157|NCT04675983|DRUG|Oxaliplatin|Administered IV
214788158|NCT04675983|DRUG|Capecitabine|Administered orally
214788159|NCT00891683|DRUG|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
214788160|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
214788161|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
214788162|NCT02405611|BEHAVIORAL|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
214788163|NCT04756609|PROCEDURE|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
214788164|NCT04756609|OTHER|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
214788165|NCT03104153|PROCEDURE|Early-drain removal|Drain removal at hospital discharge
214788166|NCT01890083|BEHAVIORAL|Exercise|
214788167|NCT01890083|BEHAVIORAL|Health Education|
214788168|NCT04155697|DRUG|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
214788169|NCT04155697|DRUG|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
214788170|NCT03867591|OTHER|Gastro-AD®|"The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents."
214788171|NCT03867591|OTHER|Placebo|The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
214788172|NCT05322564|OTHER|Standardized opiate prescription|The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
214788173|NCT02363582|OTHER|formula|An infant formula contains prebiotics and lactoferrin
214788174|NCT01772368|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
214788175|NCT01772368|DRUG|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
214788176|NCT01772368|DRUG|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
214788177|NCT01772368|DRUG|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
214788178|NCT01452529|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
214788179|NCT01452529|DRUG|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
214788180|NCT03551730|COMBINATION_PRODUCT|PRT064445/Enoxaparin|
214788181|NCT03551730|COMBINATION_PRODUCT|Placebo/Enoxaparin|
214788182|NCT03551730|DRUG|Placebo|
214788183|NCT05325892|COMBINATION_PRODUCT|This is an observational study|This is an observational study
214788184|NCT00227825|BEHAVIORAL|Motivational interviewing|
214788185|NCT03833596|DRUG|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
214788186|NCT03833596|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
214788187|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
214788188|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
214788189|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
214788190|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
214788191|NCT00403286|DRUG|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
214788192|NCT00403286|DRUG|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
214788193|NCT00403286|DRUG|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
214788194|NCT00403286|DRUG|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
214788195|NCT02363010|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
214788196|NCT02363010|BEHAVIORAL|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
214788197|NCT02363010|BEHAVIORAL|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
214788198|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
214788199|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
214788200|NCT00472550|DRUG|esomeprazole 20 mg|
214788201|NCT00996866|DRUG|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
214788202|NCT00996866|DRUG|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
214788203|NCT03854084|OTHER|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
214788204|NCT03854084|OTHER|Control group|Simulation of the techniques was used in the interventional group
214788205|NCT03154879|DEVICE|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
214788206|NCT00330421|DRUG|sorafenib tosylate|Given PO
214788207|NCT00330421|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214788208|NCT00330421|OTHER|laboratory biomarker analysis|Correlative studies
214788209|NCT00330421|OTHER|pharmacological study|Correlative studies
214788210|NCT00330421|PROCEDURE|computed tomography|Correlative studies
214788211|NCT00330421|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
214788212|NCT03958279|DIAGNOSTIC_TEST|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
214788213|NCT03958279|DIAGNOSTIC_TEST|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
214788214|NCT02600728|BEHAVIORAL|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
214788215|NCT02600728|BEHAVIORAL|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
214788216|NCT01988311|DRUG|psilocybin|dose manipulation as described in the protocol
214788217|NCT00046423|DRUG|ABI-007|
214788218|NCT02519426|PROCEDURE|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
214788219|NCT00892827|DRUG|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
214788220|NCT06349720|BEHAVIORAL|respiratory rehabilitation|"Emote respiratory rehabilitation:Patients wear monitoring devices and upload real-time monitoring data such as vital signs through the FREE rehabilitation app installed on their personal phones. Medical staff monitor changes in patients' vital signs in real time through the FREE rehabilitation app on the medical end, and adjust respiratory rehabilitation plans based on their phone or video guidance.~Outpatient respiratory rehabilitation:Traditional outpatient respiratory rehabilitation is based on a group approach, with individualized intensity determined based on baseline assessment results, and is conducted under supervision twice a week for a period of 12 weeks."
214788221|NCT03136991|DRUG|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
214788222|NCT03136991|DRUG|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
214788223|NCT03341286|DRUG|TK3|Tryptophan and thiamine as on oral supplement
214788224|NCT01003886|DRUG|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
214788225|NCT02444312|BEHAVIORAL|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
214788226|NCT02444312|BEHAVIORAL|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
214788227|NCT06014450|RADIATION|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
214788228|NCT00484523|PROCEDURE|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
214788229|NCT05291143|BEHAVIORAL|Short videos on blood pressure monitoring|Short videos on blood pressure monitoring
214788230|NCT03666637|PROCEDURE|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
214788231|NCT01200056|DRUG|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
214788232|NCT06031311|DIAGNOSTIC_TEST|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
214788233|NCT02691897|DRUG|Melatonin|Melatonin 3mg once daily at bedtime
214788234|NCT02691897|DRUG|Placebo|Placebo 1 tablet once daily at bedtime
214788235|NCT03907280|DRUG|BI 1265162 (T1)|oral solution
214788236|NCT03907280|DRUG|BI 1265162 (T2)|Solution for inhalation
214788237|NCT03907280|DRUG|BI 1265162 (R)|concentrate for i.v. solution
214788238|NCT03907280|DRUG|BI 1265162 (T3)|Solution for inhalation
214788239|NCT05571527|BIOLOGICAL|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
214788240|NCT05571527|DRUG|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
214788241|NCT01764620|OTHER|Elastic taping applied with tension|
214788242|NCT01764620|OTHER|Elastic taping applied without tension|
214788243|NCT01764620|OTHER|Fatigue protocol|
214788244|NCT05042635|DRUG|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
214788245|NCT05042635|DRUG|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
214788246|NCT02491788|DRUG|Suvorexant|
214788247|NCT02491788|DRUG|Placebo|
214788248|NCT02903433|OTHER|High-intake avocados|Families will receive 14 avocados on a weekly basis.
214788249|NCT02903433|OTHER|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
214788250|NCT02903433|BEHAVIORAL|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
214788251|NCT02903433|BEHAVIORAL|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
214788252|NCT00035633|DRUG|Entecavir|
214788253|NCT04537676|OTHER|No intervention, this is an observational study|No intervention
214788254|NCT00048360|DRUG|Extended-release bupropion hydrochloride|
214788255|NCT02123927|DRUG|TAK-438|TAK-438 tablets
214788256|NCT02123927|DRUG|Placebo|TAK-438 placebo-matching tablets
214788257|NCT02051127|OTHER|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
214788258|NCT00527189|BEHAVIORAL|Balance Exercises|Home based balance exercises based on Otago Exercise programme
214788259|NCT03065127|BEHAVIORAL|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
214788260|NCT03065127|BEHAVIORAL|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
214788261|NCT03065127|BEHAVIORAL|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
214788262|NCT05813782|BEHAVIORAL|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
214788263|NCT03204591|OTHER|No intervention|No intervention
214788264|NCT04435613|OTHER|protective mechanical ventilation strategies|1\. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
214788265|NCT05134064|DEVICE|total-body PET/CT|PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
214788266|NCT00815490|DEVICE|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
214788267|NCT01616303|DRUG|Carboplatin|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
214788268|NCT01616303|DRUG|Paclitaxel|Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
214788269|NCT01616303|BIOLOGICAL|oregovomab|oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
214788270|NCT01234779|DRUG|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
214788271|NCT01234779|DRUG|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
214788272|NCT01234779|DRUG|olanzapine|15 mg orally daily, 4 weeks
214788273|NCT01234779|DRUG|placebo|orally daily, 4 weeks
214788274|NCT04648579|DEVICE|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
214788275|NCT04648579|OTHER|Control|Hospital usual care regarding vital signs collection and TRR activation.
214788276|NCT04892459|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
214788277|NCT04892459|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
214788278|NCT02028000|PROCEDURE|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
214788279|NCT02028000|PROCEDURE|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
214788280|NCT02028000|PROCEDURE|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
214788281|NCT06203899|BEHAVIORAL|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
214788282|NCT06203899|BEHAVIORAL|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
214788283|NCT01454700|DEVICE|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
214788284|NCT01454700|OTHER|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
214788285|NCT00673361|DRUG|Concurrent decrescendo biochemotherapy regimen|"* Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days"
214788286|NCT00673361|DRUG|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
214788287|NCT01338428|BEHAVIORAL|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
214788288|NCT01338428|BEHAVIORAL|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
214788289|NCT00338247|DRUG|lapatinib + capecitabine|Experimental
214788290|NCT04568447|DEVICE|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
214788291|NCT00815451|DIETARY_SUPPLEMENT|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
214788292|NCT00815451|DIETARY_SUPPLEMENT|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
214788293|NCT03104790|BIOLOGICAL|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
214788294|NCT00829413|DRUG|SonoVue®|SonoVue (2.4 mL)
214788295|NCT06422117|DRUG|HSK16149 20mg-40mg BID|Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
214788296|NCT06422117|DRUG|Placebo|Placebo, oral, 2 capsules twice daily
214788297|NCT01464827|DRUG|ABT-450|ABT-450 tablets
214788298|NCT01464827|DRUG|ABT-333|ABT-333 tablets
214788299|NCT01464827|DRUG|ABT-267|ABT-267 tablets
214788300|NCT01464827|DRUG|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
214788301|NCT01464827|DRUG|Ritonavir|Ritonavir capsules
214788302|NCT00281294|DRUG|Fontolizumab|
214788303|NCT02688894|OTHER|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
214788304|NCT02203565|DRUG|Dakin's solution|Applied topically
214788305|NCT02203565|RADIATION|radiation therapy|Undergo radiation therapy
214788306|NCT02203565|OTHER|questionnaire administration|Ancillary studies
214788307|NCT02203565|OTHER|laboratory biomarker analysis|Optional correlative studies
214788308|NCT06541366|OTHER|case-control study|physical examination and Survey Form
214788309|NCT00535522|DRUG|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
214788310|NCT00535522|DRUG|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
214788311|NCT01414465|DRUG|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
214788312|NCT02757586|GENETIC|shRNA|Using shRNA interfered the expression of the gene of CLL
214788313|NCT03487796|BEHAVIORAL|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
214788314|NCT03487796|OTHER|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
214788315|NCT01831063|BEHAVIORAL|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
214788316|NCT04871217|DIAGNOSTIC_TEST|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
214788317|NCT04833712|RADIATION|Stereotactic Radioablation|Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
214788318|NCT03252795|PROCEDURE|uterus transplantation|transplantation of a uterus from a deceased donor
214788319|NCT04057781|PROCEDURE|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
214788320|NCT04057781|PROCEDURE|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
214788321|NCT02129023|DEVICE|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
214788322|NCT02949323|OTHER|urinary stone|patients of group one have urinary stones
214788323|NCT00030108|DRUG|ixabepilone|
214788324|NCT01871779|OTHER|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
214788325|NCT01871779|OTHER|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
214788326|NCT04999332|DRUG|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
214788327|NCT04272775|DRUG|Ixazomib|Ixazomib capsules.
214788328|NCT04272775|DRUG|Lenalidomide|Lenalidomide capsules.
214788329|NCT04272775|DRUG|Dexamethasone|Dexamethasone tablets.
214788330|NCT01492270|PROCEDURE|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
214788331|NCT01492270|PROCEDURE|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
214788332|NCT01492270|PROCEDURE|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
214788333|NCT01492270|PROCEDURE|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
214788334|NCT02507206|DRUG|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
214788335|NCT02507206|DRUG|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
214788336|NCT01530685|DIETARY_SUPPLEMENT|Glycabiane|2 gelule per day for 4 months
214788337|NCT01530685|DIETARY_SUPPLEMENT|placebo|2 gelules per day for 4 months
214788338|NCT04887883|BEHAVIORAL|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
214788339|NCT00719381|DRUG|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
214788340|NCT03650582|DRUG|Glucagon|Intranasal glucagon
214788341|NCT03650582|DRUG|Placebo|Intranasal placebo
214788342|NCT00124020|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
214788343|NCT00124020|DRUG|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
214788344|NCT04665674|OTHER|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
214788345|NCT00418873|DRUG|Zotepine|Oral
214788346|NCT00418873|DRUG|Risperidone|Oral
214788347|NCT02587702|OTHER|β-Palmitate Content|
214788348|NCT02587702|OTHER|Placebo|
214788349|NCT02587702|OTHER|β-Palmitate Content Naturely in Human Milk|
214788350|NCT05865509|OTHER|Escape room|Students were given training on stress response using the escape room method.
214788351|NCT05865509|OTHER|Storytelling|Students were given training on stress response using the storytelling method.
214788352|NCT03872037|PROCEDURE|Selective removal of carious tissue and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
214788353|NCT03872037|PROCEDURE|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
214788354|NCT04277611|PROCEDURE|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
214788355|NCT04701697|DRUG|Recombinant Human Albumin Injection|Participants will receive Recombinant Human Albumin Injection of intravenous infusion
214788356|NCT04701697|DRUG|HumanAlbumin|Participants will receive HumanAlbumin of intravenous infusion
214788357|NCT01051609|OTHER|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
214788358|NCT01051609|OTHER|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
214788359|NCT01051609|BEHAVIORAL|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
214788360|NCT01051609|OTHER|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
214788361|NCT01051609|PROCEDURE|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
214788362|NCT04299997|OTHER|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
214788363|NCT02043366|DRUG|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
214788364|NCT02043366|DRUG|Butorphanol|Butorphanol is intravenously administrated
214788365|NCT02043366|DRUG|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
214788366|NCT02043366|DRUG|Remifentanil|Remifentanil is intravenously administrated
214788367|NCT02043366|DRUG|Sufentanil|Sufentanil is intravenously administrated
214788368|NCT05819567|DEVICE|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
214788369|NCT06542965|OTHER|Non-Interventional Research|Non-Interventional Research
214788370|NCT02079792|PROCEDURE|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
214788371|NCT02079792|PROCEDURE|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
214788372|NCT00521248|DRUG|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
214788373|NCT00521248|DRUG|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
214788374|NCT04572568|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
214788375|NCT01127581|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214788376|NCT01127581|DRUG|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214788377|NCT00772564|DRUG|Atorvastatin|Oral Atorvastatin
214788378|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
214788379|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seeds|4.1 grams (1½ teaspoons/\~0.15ounces) of pumpkin seeds
214788380|NCT01313390|DRUG|docetaxel|
214788381|NCT01313390|DRUG|everolimus|
214788382|NCT01313390|OTHER|laboratory biomarker analysis|
214788383|NCT01313390|OTHER|pharmacological study|
214788384|NCT01489956|BIOLOGICAL|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
214788385|NCT01489956|BIOLOGICAL|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
214788386|NCT01489956|BIOLOGICAL|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
214788387|NCT01567215|PROCEDURE|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
214788388|NCT01567215|DRUG|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
214788389|NCT01567215|PROCEDURE|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
214788390|NCT00891774|DEVICE|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
214788391|NCT05488184|DIETARY_SUPPLEMENT|Flavoured Oral Nutritional Supplement (ONS)|Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
214788392|NCT00004143|DRUG|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
214788393|NCT02236533|DIETARY_SUPPLEMENT|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
214788394|NCT01977092|BEHAVIORAL|Motivational interviewing case management|
214788395|NCT01977092|BEHAVIORAL|Resource referrals|
214788396|NCT02927847|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
214788397|NCT02927847|DRUG|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
214788398|NCT02927847|BEHAVIORAL|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
214788399|NCT02927847|BEHAVIORAL|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
214788400|NCT03619252|BIOLOGICAL|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
214788401|NCT03619252|DRUG|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
214788402|NCT01501942|DRUG|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
214788403|NCT01501942|DRUG|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
214788404|NCT00723554|DRUG|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
214788405|NCT00723554|DRUG|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
214788406|NCT00672022|DRUG|Zavesca (Miglustat)|
214788407|NCT03994588|PROCEDURE|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
214788408|NCT00698178|OTHER|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
214788409|NCT00593138|DRUG|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
214788410|NCT03113058|COMBINATION_PRODUCT|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
214788411|NCT06544798|GENETIC|AAV2-hAQP1|Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
214788412|NCT01405820|DRUG|natalizumab IV|natalizumab for IV Infusion
214788413|NCT01405820|DRUG|natalizumab SC|natalizumab for Subcutaneous Injection
214788414|NCT01405820|DRUG|IV Placebo|Intravenous placebo to natalizumab
214788415|NCT01405820|DRUG|SC Placebo|Subcutaneous placebo to natalizumab
214788416|NCT05120011|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
214788417|NCT05120011|DIETARY_SUPPLEMENT|L-leucine|L-leucine
214788418|NCT03421652|DRUG|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
214788419|NCT03421652|RADIATION|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
214788420|NCT06158061|DIAGNOSTIC_TEST|tryptase enzyme level|"In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy."
214788421|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin)|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
214788422|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
214788423|NCT02165670|DEVICE|Coronary stenting with CE-marked stent|
214788424|NCT02619799|DRUG|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
214788425|NCT02619799|DRUG|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
214788426|NCT05373875|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
214788427|NCT01142297|DEVICE|dental implant and modified dental implant|standard SLA surface and chemically modified surface
214788428|NCT01635985|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
214788429|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
214788430|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
214788431|NCT01635985|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
214788432|NCT01635985|DRUG|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
214788433|NCT01635985|DRUG|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
214788434|NCT01614509|PROCEDURE|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
214788435|NCT01614509|PROCEDURE|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
214788436|NCT02336997|PROCEDURE|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
214788437|NCT02336997|PROCEDURE|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1\*10e6 cells/cm2.
214788438|NCT02336997|PROCEDURE|PLACEBO|Saline will be injected into expanded skin.
214788439|NCT04468087|DRUG|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
214788440|NCT04468087|DRUG|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
214788441|NCT04468087|DRUG|Sofusbuvir + Daclastavir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
214788442|NCT04468087|DRUG|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
214788443|NCT04468087|DRUG|Placebo Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
214788444|NCT04468087|DRUG|Placebo Sofusbuvir + Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
214788445|NCT01319682|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
214788446|NCT01319682|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
214788447|NCT05698381|DIETARY_SUPPLEMENT|Liquid vinegar|2 tablespoons consumed twice daily with meals
214788448|NCT05698381|DIETARY_SUPPLEMENT|Vinegar pill|2 pills consumed upon waking
214788449|NCT05124431|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
214788450|NCT05124431|DRUG|everolimus|5mg po，qd
214788451|NCT02778568|BEHAVIORAL|Resistance training|Resistance training exercises
214788452|NCT02778568|BEHAVIORAL|Control|Stretching exercises
214788453|NCT00878449|DRUG|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
214788454|NCT00878449|DRUG|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
214788455|NCT02015923|PROCEDURE|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
214788456|NCT02015923|DRUG|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
214788457|NCT02038985|OTHER|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
214788458|NCT01186783|DRUG|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
214788459|NCT03235583|DEVICE|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
214788460|NCT05394558|DRUG|AsiDNA|Administration of AsiDNA followed by radiotherapy
214788461|NCT01689974|DRUG|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
214788462|NCT01689974|RADIATION|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
214788463|NCT04448691|DIAGNOSTIC_TEST|CCTA|requested follow up CCTA
214788464|NCT01952574|DRUG|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
214788465|NCT01952574|DRUG|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
214788466|NCT01952574|DRUG|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
214788467|NCT01952574|DRUG|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
214788468|NCT02692430|OTHER|No intervention is studied|
214788469|NCT01916564|OTHER|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
214788470|NCT01916564|OTHER|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
214788471|NCT02477904|OTHER|Ketogenic Diet|Dietary
214788472|NCT01991587|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
214788473|NCT01991587|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
214788474|NCT01991587|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
214788475|NCT01991587|BIOLOGICAL|Placebo|A single dose of placebo
214788476|NCT02555709|DRUG|VTP-43742|VTP-43742 administered as an oral capsule once daily
214788477|NCT02555709|DRUG|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
214788478|NCT02555709|DRUG|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
214788479|NCT02129374|PROCEDURE|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
214788480|NCT03801733|DRUG|Vadadustat|Oral dose of 600 mg QD
214788481|NCT03801733|DRUG|Simvastatin|Oral Simvastatin
214788482|NCT03801733|DRUG|Rosuvastatin|Oral Rosuvastatin
214788483|NCT03801733|DRUG|Atorvastatin|Oral Atorvastatin
214788484|NCT03801733|DRUG|Pravastatin|Oral Pravastatin
214788485|NCT03801733|DRUG|Sulfasalazine|Oral Sulfasalazine
214788486|NCT02045628|BEHAVIORAL|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
214788487|NCT02733237|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
214788488|NCT02733237|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
214788489|NCT05267574|DRUG|REN001|Once daily dosing
214788490|NCT05431283|DRUG|Tofacitinib|This study aims to assess the effectiveness of TOFA
214788491|NCT06547723|OTHER|MBSR and physiotherapy|"In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures."
214788492|NCT06547723|OTHER|physiotherapy|In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
214788493|NCT06011421|DEVICE|Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant
214788494|NCT03605706|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
214788495|NCT03605706|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
214788496|NCT03605706|DRUG|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
214788497|NCT04741360|OTHER|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
214788498|NCT06441981|BEHAVIORAL|Education|Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
214788499|NCT06230471|DRUG|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
214788500|NCT06230471|DRUG|Pembrolizumab and Lenvatinib|Pembrolizumab and Lenvatinib
214788501|NCT06230471|DRUG|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
214788502|NCT02974114|DRUG|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
214788503|NCT02974114|DRUG|Paracetamol|Test product containing 500 mg paracetamol
214788504|NCT02974114|OTHER|Placebo|Placebo to match paracetamol 665mg sustained release tablets
214788505|NCT03720483|DRUG|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
214788506|NCT03720483|DRUG|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
214788507|NCT04051632|DEVICE|Medtronic 670G insulin pump|"* percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range"
214788508|NCT03543033|DRUG|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
214788509|NCT05238506|DRUG|Intravenous lidocaine|Intraoperative intravenous lidocaine infusion.
214788510|NCT05238506|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
214788511|NCT05070520|DRUG|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
214788512|NCT03282435|BIOLOGICAL|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
214788513|NCT03282435|OTHER|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
214788514|NCT03282435|BIOLOGICAL|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
214788515|NCT04652921|DIETARY_SUPPLEMENT|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
214788516|NCT04652921|OTHER|Inulin|A dietary supplement provided as powder dissolved in a glass of water
214788517|NCT01580020|BIOLOGICAL|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
214788518|NCT01580020|DRUG|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
214788519|NCT03834584|DRUG|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
214788520|NCT00075894|DRUG|L-alanosine|
214788521|NCT03238950|OTHER|Porcine model|participants to conduct training on porcine model
214788522|NCT03238950|OTHER|Synthetic model|participants to conduct training on synthetic model
214788523|NCT04482114|RADIATION|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
214788524|NCT00224250|PROCEDURE|One- versus two-layer hysterotomy closure|
214788525|NCT01724359|DRUG|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
214788526|NCT06014632|OTHER|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
214788527|NCT06014632|OTHER|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
214788528|NCT01534975|DIAGNOSTIC_TEST|contrast agent|we are randomizing patients to different contrast agents.
214788529|NCT02658409|BIOLOGICAL|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
214788530|NCT02658409|BIOLOGICAL|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
214788531|NCT06432205|PROCEDURE|surgery|any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery
214788532|NCT06536933|DIAGNOSTIC_TEST|Abdominal Ultrasound|Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis
214788533|NCT03503474|OTHER|No intervention|There is no intervention, this is observational only
214788534|NCT01408407|OTHER|Aveeno cream|Apply cream on irradiated area twice a day
214788535|NCT01408407|OTHER|Alkagin paste|Apply Alkagin paste three times a day.
214788536|NCT01517568|DRUG|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
214788537|NCT04921150|OTHER|standardization management|Apply standardization management to improve the outcomes of pregnancy
214788538|NCT01334736|BEHAVIORAL|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
214788539|NCT01334736|BEHAVIORAL|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
214788540|NCT01334736|BEHAVIORAL|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
214788541|NCT01334736|BEHAVIORAL|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
214788542|NCT03863652|PROCEDURE|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
214788543|NCT02189395|DRUG|NPH and regular insulin|
214788544|NCT02189395|DRUG|glargine and humalog|
214788545|NCT00919139|OTHER|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
214788546|NCT01335464|DRUG|placebo|placebo matching BIBF1120, BID
214788547|NCT01335464|DRUG|BIBF 1120|BIBF1120 BID (twice daily)
214788548|NCT01595490|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
214788549|NCT05927805|OTHER|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
214788550|NCT05927805|OTHER|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
215030906|NCT05328622|BEHAVIORAL|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
214788551|NCT02971345|PROCEDURE|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
214788552|NCT02971345|DEVICE|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
214788553|NCT02971345|DEVICE|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
214788554|NCT02971345|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
214788555|NCT02971345|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
214788556|NCT02971345|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
214788557|NCT00503126|DRUG|bivalirudin|anticoagulation
214788558|NCT00168337|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
214788559|NCT00168337|OTHER|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
214788560|NCT02963298|PROCEDURE|Continuous renal replacement therapy|
214788561|NCT04949867|DRUG|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
214788562|NCT04949867|DEVICE|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
214788563|NCT01082198|BIOLOGICAL|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
214788564|NCT01082198|BIOLOGICAL|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
214788565|NCT01082198|BIOLOGICAL|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
214788566|NCT01082198|BIOLOGICAL|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
214788567|NCT01082198|BIOLOGICAL|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
214788568|NCT01082198|OTHER|flow cytometry|
214788569|NCT01082198|PROCEDURE|adjuvant therapy|
214788570|NCT04988945|PROCEDURE|TACE|Procedure of TACE will be standardized.
214788571|NCT04988945|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
214788572|NCT04988945|DRUG|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
214788573|NCT04988945|DRUG|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
214788574|NCT00231049|DRUG|AG-707|
214788575|NCT02765828|OTHER|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
214788576|NCT05625711|DEVICE|The endovascular interventional surgical instrument control system|The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
214788577|NCT03286647|PROCEDURE|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
214788578|NCT03343106|BEHAVIORAL|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
214788579|NCT03343106|BEHAVIORAL|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
214788580|NCT04362033|DIAGNOSTIC_TEST|Passive Leg Raising (PLR) and PEEP increment (PEEP)|PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position
214788581|NCT00593333|DEVICE|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
214788582|NCT00593333|DEVICE|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
214788583|NCT01752920|DRUG|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
214788584|NCT01752920|DRUG|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
214788585|NCT01752920|DRUG|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
214788586|NCT01752920|DRUG|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
214788587|NCT02327520|OTHER|Colitis with CDI treatment|All patients will be treated with standard treatment
214788588|NCT00384891|DEVICE|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
214788589|NCT00384891|DRUG|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
214788590|NCT01738581|DEVICE|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
214788591|NCT01738581|BEHAVIORAL|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
215030907|NCT04661488|DEVICE|AI driven triage-system|AI driven triage-system
214788592|NCT01738581|BEHAVIORAL|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
214788593|NCT04236310|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
214788594|NCT04236310|DRUG|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
214788595|NCT04236310|DRUG|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
214788596|NCT04236310|DRUG|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
214788597|NCT03483181|DRUG|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
214788598|NCT03483181|DRUG|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
214788599|NCT03286413|PROCEDURE|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
214788600|NCT03603236|DIAGNOSTIC_TEST|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
214788601|NCT03603236|DIAGNOSTIC_TEST|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
214788602|NCT06460428|BEHAVIORAL|Interactive video usage|The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
214788603|NCT00604656|DRUG|insulin aspart|
214788604|NCT02157233|BEHAVIORAL|Rest|
214788605|NCT02157233|BEHAVIORAL|Exercise|
214788606|NCT00696709|BIOLOGICAL|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
214788607|NCT00696709|BIOLOGICAL|Comparator: Placebo|Placebo; 4-dose regimen administered \~30 days apart.
214788608|NCT03999125|DRUG|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
214788609|NCT03999125|DRUG|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
214788610|NCT03999125|DRUG|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
214788611|NCT02682290|OTHER|Expectoration and measurement of sputum rheological properties|
214788612|NCT01186978|RADIATION|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
214788613|NCT03822962|DRUG|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
214788614|NCT03822962|OTHER|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
214788615|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
214788616|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System Containing Placebo Product
214788617|NCT03979209|DRUG|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
214788618|NCT05882981|OTHER|Sit and reach test|It will be used to measure the flexibility of the participants.
214788619|NCT05882981|OTHER|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
214788620|NCT05882981|OTHER|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
214788621|NCT05882981|OTHER|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
214788622|NCT05882981|OTHER|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
214788623|NCT01684449|DRUG|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
214788624|NCT02801448|DRUG|sulforaphane|sulforaphane-containing broccoli sprout extracts
214788625|NCT02801448|DRUG|Placebo|Maltodextrine-based placebo without sulforaphane
214788626|NCT03985033|OTHER|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
214788627|NCT06016933|DRUG|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
214788628|NCT06016933|PROCEDURE|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
214788629|NCT03110393|DEVICE|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
214788630|NCT03110393|DEVICE|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
214788631|NCT04998253|DRUG|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
214788632|NCT02925767|DEVICE|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
214788633|NCT02925767|DEVICE|308-nm excimer laser|XTRAC, PhotoMedex, US
214788634|NCT03871400|PROCEDURE|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
214788635|NCT01033864|DRUG|MMF|1 g per day b.i.d. p.o. for at least 1 month
214788636|NCT01033864|DRUG|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
214788637|NCT01033864|DRUG|Prednisone|5 mg per day p.o.
214788638|NCT01754090|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
214788639|NCT01754090|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
214788640|NCT01754090|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
214788641|NCT03491605|OTHER|peripheral EBV-DNA load|No intervention
214788642|NCT04182750|OTHER|Pharmacist consultation|"The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use."
214788643|NCT04556669|BIOLOGICAL|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
214788644|NCT06302712|BEHAVIORAL|Traditional Islamically Integrated Psychotherapy|Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.
214788645|NCT02245191|DRUG|Ephedrine|5mg after Spinal Anesthesia
214788646|NCT02245191|DRUG|Phenylephrine|100mcg after Spinal Anesthesia
214788647|NCT02245191|DRUG|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
214788648|NCT02724137|BEHAVIORAL|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
214788649|NCT02724137|OTHER|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
214788650|NCT02136732|OTHER|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
214788651|NCT02136732|OTHER|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
214788652|NCT05092334|OTHER|proprioceptive exercises|proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
214788653|NCT05092334|OTHER|Strengthening exercise|strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
214788654|NCT05634187|DEVICE|Functional endoscopy|Transnasal endoscopy by an ultrathin video endoscope
214788655|NCT03264066|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
214788656|NCT03264066|DRUG|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
214788657|NCT03264066|DRUG|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
214788658|NCT04495387|DRUG|Chemotherapy|standard adjuvat chemotherapy for reast and colo cancer
214788659|NCT01165814|DRUG|Naproxen Tramadol|
214788660|NCT00382330|DRUG|Ciclopirox|
214788661|NCT04305223|PROCEDURE|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
214788662|NCT04305223|OTHER|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
214788663|NCT01266382|DEVICE|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
214788664|NCT05197010|OTHER|Home based exercise program via a smartphone application|Daily home based exercise program (30min/day, 7days/week for 6 weeks).
214788665|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
214788666|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
214788667|NCT00926289|DRUG|Hydrochlorothiazide|Hydrochlorothiazide25mg
214788668|NCT00686803|DRUG|PL3994|Study drug
214788669|NCT00686803|DRUG|Placebo|Placebo
214788670|NCT06220461|DIETARY_SUPPLEMENT|Folic acid|Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
214788671|NCT01272557|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
214788672|NCT01272557|DRUG|Sorafenib|Sorafenib 400 mg bid (oral) continuously
214788673|NCT02602340|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
214788674|NCT03140306|DIAGNOSTIC_TEST|Patients who have had split dose CT|Computed tomography
214788675|NCT02208583|DRUG|Docetaxel & Prednisone|Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
214788676|NCT02208583|DRUG|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
214788677|NCT02208583|DRUG|cisplatin & Etoposide|cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
214788678|NCT02208583|DRUG|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
214788679|NCT02115256|DRUG|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
214788680|NCT02115256|DRUG|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
214788681|NCT04829695|DRUG|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
214788682|NCT04829695|DRUG|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
214788683|NCT06424847|BEHAVIORAL|Lifestyle intervention (physical activity and diet)|"The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet."
214788684|NCT06424847|BEHAVIORAL|Lifestyle (physical activity and diet) and Sleep intervention|"Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits."
214788685|NCT06424847|BEHAVIORAL|Health education intervention|Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
214788686|NCT03058510|PROCEDURE|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
214788687|NCT05551377|OTHER|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
214788688|NCT01297257|DEVICE|Stent implantation|Single arm, open label stent implantation
214788689|NCT02478060|BIOLOGICAL|Birch-SPIRE|
214788690|NCT02478060|BIOLOGICAL|Placebo|
214788691|NCT04984850|OTHER|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
214788692|NCT00617435|DIETARY_SUPPLEMENT|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
214788693|NCT00617435|DIETARY_SUPPLEMENT|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
214788694|NCT00617435|DIETARY_SUPPLEMENT|control diet|Mixed of different oil
214788695|NCT06126042|DRUG|Test Product|DRL\_AB, Pre Filled Syringe; Solution for injection
214788696|NCT06126042|DRUG|Reference product|USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
214788697|NCT06126042|DRUG|Reference Medicinal Product|EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
214788698|NCT01213719|DIETARY_SUPPLEMENT|creatine|20g/d throughout 10 days
214788699|NCT01213719|DIETARY_SUPPLEMENT|betaine|2g/d throughout 10 days
214788700|NCT01213719|DIETARY_SUPPLEMENT|dextrose|dextrose (placebo), 20 g/d throughout 10 days
214788701|NCT01213719|DIETARY_SUPPLEMENT|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
214788702|NCT04881890|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
214788703|NCT01179282|BIOLOGICAL|dust mite extract or placebo|intervention will be to stop study drug or placebo
214788704|NCT04140006|DRUG|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
214788705|NCT04140006|DRUG|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
214788706|NCT04140006|DRUG|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
214788707|NCT04140006|DRUG|Control|Flapped surgery for insertion of dental implant without topical application of any gel
214788708|NCT06503042|DRUG|Chemotherapy combined with immunotherapy|Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
214788709|NCT06503042|DRUG|Chemotherapy only|Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
214788710|NCT01273103|DRUG|200mg [14C]- GSK2248761|single oral suspension dose of \[14C\]- GSK2248761 200 mg
214788711|NCT02393196|DRUG|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
214788712|NCT02393196|DRUG|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
214788713|NCT04523415|OTHER|without intervention, just retrospectively review the data about patients|without intervention
214788714|NCT02934828|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
214788715|NCT02934828|DRUG|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
214788716|NCT02668302|COMBINATION_PRODUCT|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
214788717|NCT02668302|OTHER|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
214788718|NCT03495193|OTHER|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
214788719|NCT03495193|BEHAVIORAL|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
214788720|NCT04109378|PROCEDURE|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
214788721|NCT04967716|OTHER|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
214788722|NCT04967716|OTHER|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
214788723|NCT05363124|OTHER|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
214788724|NCT05363124|OTHER|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
214788725|NCT01657487|DRUG|Fluticasone/Salmeterol high dose|
214788726|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
214788727|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
214788728|NCT03031522|RADIATION|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
214788729|NCT05250349|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography with standard measurements
214788730|NCT05250349|DIAGNOSTIC_TEST|Doppler sonography|Transcarotid and transcranial Doppler sonography
214788731|NCT05250349|DIAGNOSTIC_TEST|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
214788732|NCT04163692|OTHER|Progressive relaxation exercises|"Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things."
214788733|NCT04413747|BEHAVIORAL|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
214788734|NCT04413747|BEHAVIORAL|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
214788735|NCT04413747|BEHAVIORAL|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
214788736|NCT02161952|DRUG|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
214788737|NCT02161952|DRUG|Matched equivalent placebo|
214788738|NCT03799887|BEHAVIORAL|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
214788739|NCT03799887|BEHAVIORAL|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
214788740|NCT03799887|BEHAVIORAL|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
214788741|NCT03333525|OTHER|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
214788742|NCT04120168|GENETIC|Laboratory Tests|"* Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
214788743|NCT00162786|DRUG|Rupatadine|
214788744|NCT00162786|DRUG|Hydroxyzine|
214788745|NCT00162786|DRUG|Placebo|
214788746|NCT03509051|BIOLOGICAL|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
214788747|NCT02746159|DEVICE|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
214788748|NCT01152281|BEHAVIORAL|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
214788749|NCT01152281|BEHAVIORAL|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
214788750|NCT01152281|BEHAVIORAL|Minimal Control|Control messages to increase awareness of HIV risk
214788751|NCT01152281|BEHAVIORAL|Instrumental|Instrumental messages with stories of people living with HIV
214788752|NCT01152281|BEHAVIORAL|Empowering|Empowering messages with stories of people living with HIV
214788753|NCT04984109|PROCEDURE|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
214788754|NCT04984109|PROCEDURE|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
214788755|NCT00526890|DIETARY_SUPPLEMENT|selenomethionine|Oral Twice daily
214788756|NCT00526890|DRUG|carboplatin|Weekly IV
214788757|NCT00526890|DRUG|paclitaxel|Weekly IV
214788758|NCT00526890|OTHER|laboratory biomarker analysis|Correlative Study
214788759|NCT00526890|RADIATION|radiation therapy|Undergoing radiation Therapy
214788760|NCT03640936|BEHAVIORAL|Induced Sputum|Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
214788761|NCT03421860|DRUG|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
214788762|NCT03421860|DRUG|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
214788763|NCT03421860|DRUG|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
214788764|NCT03421860|DRUG|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
214788765|NCT04960475|OTHER|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
214788766|NCT04960475|OTHER|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
214788767|NCT04960475|OTHER|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
214788768|NCT04706871|DEVICE|taVNS|"taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear."
214788769|NCT04706871|DEVICE|tnVNS|"tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear."
214788770|NCT01934374|BEHAVIORAL|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
214788771|NCT05707429|OTHER|The Arabic version of The International Index of Erectile Function (IIEF-5)|The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of \< 22 is defined as ED .
214788772|NCT05707429|OTHER|The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)|was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
214788773|NCT05707429|OTHER|Assessment of depression and anxiety|Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
214788774|NCT05707429|OTHER|The Fatigue assessment scale (16)|It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
214788775|NCT05707429|OTHER|• Quality of life assessment|Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
214788776|NCT05707429|OTHER|The Female Sexual Function Index (FSFI)|The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
214788777|NCT02523365|PROCEDURE|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
214788778|NCT03529955|DRUG|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
214788779|NCT00790075|DRUG|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was \>30 minutes.
214788780|NCT04323007|DIAGNOSTIC_TEST|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
214788781|NCT00922337|DEVICE|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
214788782|NCT00931853|DRUG|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
214788783|NCT05168059|DRUG|Clevidipine 0.5 MG/ML Intravenous Emulsion|Effectiveness and safety of clevidipine
214788784|NCT03740685|DIAGNOSTIC_TEST|High sesitive C reactive protien|High sesitive C reactive protien will be evaluated at admission time and after 36 hours
214788785|NCT00580983|RADIATION|IMRT|
214788786|NCT00580983|DRUG|Paclitaxel|
214788787|NCT00580983|DRUG|Carboplatin|
214788788|NCT00580983|DRUG|Cisplatin|
214788789|NCT00580983|DRUG|5-Fluorouracil|
214788790|NCT01677442|PROCEDURE|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
214788791|NCT01677442|PROCEDURE|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
214788792|NCT02746458|OTHER|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
214788793|NCT02746458|DEVICE|Delfi PTSII Tourniquet System|
214788794|NCT00125567|DRUG|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
214788795|NCT00125567|DRUG|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
214788796|NCT01315483|OTHER|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
214788797|NCT04437069|OTHER|Decision Aid|Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).
214788798|NCT04437069|OTHER|Values Clarification Exercise|The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
214788799|NCT04591769|DEVICE|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
214788800|NCT01986842|DIETARY_SUPPLEMENT|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
214788801|NCT00642031|DRUG|Triciribine|15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
214788802|NCT05186350|PROCEDURE|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
214788803|NCT05186350|PROCEDURE|ESWL+ ERCP|ESWL + Stone removal through ERCP
214788804|NCT02717286|PROCEDURE|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
214788805|NCT03740100|DRUG|Bimiralisib|Bimiralisib capsules
214788806|NCT03368495|BIOLOGICAL|Co-administration of MMR/YF|Both MMR \& yellow fever vaccines administered on Day 0.
214788807|NCT03368495|BIOLOGICAL|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
214788808|NCT03368495|BIOLOGICAL|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
214788809|NCT01472588|BEHAVIORAL|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
214788810|NCT01472588|BEHAVIORAL|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
214788811|NCT01472588|OTHER|Self Help|Public education/information booklet on weight management.
214788812|NCT03980795|OTHER|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
214788813|NCT04548895|DEVICE|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
214788814|NCT03655210|DRUG|HL151|HL151(1Tab) once a day for 4 weeks of treatments
214788815|NCT03655210|DRUG|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
214788816|NCT01226875|PROCEDURE|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
214788817|NCT03287479|PROCEDURE|Gavi® Vitrification|A closed, semi-automated vitrification system
214788818|NCT03287479|PROCEDURE|Cryotop® Vitrification|An open, manual vitrification system
214788819|NCT02457728|DEVICE|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
214788820|NCT01984281|BEHAVIORAL|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
214788821|NCT03089528|DEVICE|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
214788822|NCT03089528|DEVICE|laringoscope|the trachea will be intubated with a laringoscope
214788823|NCT02836340|DRUG|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
214788824|NCT03387059|DEVICE|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
214788825|NCT04877184|DEVICE|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~* transcranial ultrasound stimulation: during 4 weeks~* rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
214788826|NCT04877184|DEVICE|Rehabilitation|"The participants in control group would received rehabilitation therapy.~\- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
214788827|NCT01263899|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
214788828|NCT06064253|BEHAVIORAL|health education|adherence to treatment
214788829|NCT04823871|PROCEDURE|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
214788830|NCT05482984|OTHER|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
214788831|NCT01859702|DRUG|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
214788832|NCT05840497|OTHER|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
214788833|NCT00644605|DRUG|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
214788834|NCT00644605|DRUG|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
214788835|NCT00644605|DRUG|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
214788836|NCT00644605|DRUG|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
214788837|NCT06110585|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
214788838|NCT06110585|PROCEDURE|Sham|A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
214788839|NCT05385744|BIOLOGICAL|BCD-132|anti-CD20 monoclonal antibody
214788840|NCT05385744|DRUG|Teriflunomide|Teriflunomide 14 mg
214788841|NCT06316960|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
214788842|NCT06316960|DRUG|Azacitidine Injection|75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
214788843|NCT06316960|DRUG|Decitabine Injection|20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
214788844|NCT06316960|DRUG|Idarubicin Hydrochloride|5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
214788845|NCT06316960|DRUG|Cytarabine|10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
214788846|NCT06316960|DRUG|Granulocyte Colony-Stimulating Factor|300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
214788847|NCT06246851|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
214788848|NCT05738356|COMBINATION_PRODUCT|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
214788849|NCT04203706|OTHER|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
214788850|NCT03369756|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
214788851|NCT00519012|DRUG|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
214788852|NCT00519012|DRUG|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
214788853|NCT03786666|PROCEDURE|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
214788854|NCT03805204|PROCEDURE|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
214788855|NCT02468557|DRUG|Idelalisib|Tablets administered orally twice daily
214788856|NCT02468557|DRUG|Nab-paclitaxel|125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
214788857|NCT02468557|DRUG|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
214788858|NCT04262596|OTHER|Interactive Consulting System|Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
214788859|NCT04262596|OTHER|A traditional patient decision aid brochure|Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
214788860|NCT02878850|OTHER|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
214788861|NCT00982410|BEHAVIORAL|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
214788862|NCT00982410|BEHAVIORAL|educational supportive group|A control condition providing social support and education about pain and/or drug use.
214788863|NCT02386410|BEHAVIORAL|Group parent training for anxious parents|
214788864|NCT02386410|BEHAVIORAL|Internet delivered parent training for anxious parents|
214788865|NCT03522779|DIETARY_SUPPLEMENT|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
214788866|NCT03522779|OTHER|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
214788867|NCT03522779|OTHER|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
214788868|NCT03316079|OTHER|Chest physiotherapy techniques|Respiratory manual CPT
214788869|NCT03316079|DEVICE|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
214788870|NCT04967313|BEHAVIORAL|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
214788871|NCT03247296|DRUG|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
214788872|NCT03167099|PROCEDURE|Full Weight Bearing|full weight bearing after fixation of a distal femur fracture
214788873|NCT02687282|OTHER|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
214788874|NCT05087394|OTHER|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
214788875|NCT05188040|OTHER|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
214788876|NCT03574155|BEHAVIORAL|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
214788877|NCT00770003|DRUG|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
214788878|NCT00770003|DRUG|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
214788879|NCT04524299|RADIATION|chest radiation(IMRT)|Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
214788880|NCT04524299|DRUG|Concurrent chemotherapy twice a week|"During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy"
214788881|NCT04524299|DRUG|Concurrent chemotherapy once a week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
214788882|NCT01093742|DRUG|HM10560A|Subcutaneously administrate at 0 hour on Day 1
214788883|NCT01093742|DRUG|Placebo|Placebo
214788884|NCT01280799|BEHAVIORAL|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
214788885|NCT04388059|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
214788886|NCT04014959|DEVICE|Transcranial Magnetic Stimulation|"Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. Repetitive TMS (rTMS) is FDA-approved for depression treatment.~TMS is administered over 5 study visits: an initial TMS/fMRI session, a 3-day TMS intervention regimen, and a post-intervention TMS/fMRI session. During TMS/fMRI sessions, participants receive single pulses of TMS pre/post a short round of Intermittent Theta Burst Stimulation (iTBS), a modified rTMS protocol. Throughout the 3-day intervention regimen, participants receive two full rounds of iTBS daily.~All study participants receive active TMS."
214788887|NCT01016652|DEVICE|etafilcon A multifocal contact lens|low-add multifocal contact lens
214788888|NCT01016652|DEVICE|etafilcon A Contact Lens|standard sphere contact lens
214788889|NCT02060461|DEVICE|FS200 femtosecond laser LASIK|
214788890|NCT02060461|DEVICE|IntraLase femtosecond laser LASIK|
214788891|NCT04190654|DRUG|KW-6356|Single oral dose of KW-6356
214788892|NCT03822052|OTHER|Lactated ringers|IV fluid
214788893|NCT03822052|OTHER|5% dextrose lactated ringers|IV fluid
214788894|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
214788895|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
214788896|NCT01271114|DRUG|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
214788897|NCT01271114|DRUG|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
214788898|NCT00876278|DEVICE|*AT.Smart 46LC|Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
214788899|NCT04857307|DRUG|Alprazolam|"* Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points."
214788900|NCT02034799|BIOLOGICAL|Bioseal Fibrin Sealant|
214788901|NCT02034799|OTHER|Standard of Care (SoC)|
214788902|NCT06546241|BEHAVIORAL|Celebrandome|This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
214788903|NCT04892966|DIAGNOSTIC_TEST|TXI Light Imaging|Standard Colonoscopy using TXI imaging
214788904|NCT04892966|DIAGNOSTIC_TEST|WLI Imaging|Standard Colonoscopy using White Light Imaging
214788905|NCT05321810|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
214788906|NCT05321810|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
214788907|NCT03827213|DRUG|Exparel|A shot of long acting local anesthetic for post operative pain management
214788908|NCT03827213|DEVICE|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
214788909|NCT04043520|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
214788910|NCT04043520|DRUG|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
214788911|NCT04043520|DRUG|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
214788912|NCT04043520|DRUG|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
214788913|NCT00830674|DRUG|Placebo|single dose IV or SC administration
214788914|NCT00830674|DRUG|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
214788915|NCT01956279|DRUG|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
214788916|NCT01956279|DRUG|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
214788917|NCT03781856|BEHAVIORAL|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
214788918|NCT03781856|BEHAVIORAL|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
214788919|NCT03192774|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
214788920|NCT03083210|DRUG|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
214788921|NCT02404597|DEVICE|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
214788922|NCT01479452|PROCEDURE|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
214788923|NCT01479452|OTHER|Usual care|Non-surgical obesity treatment
214788924|NCT06527352|DEVICE|glottis mask airway|the glottis mask airway is used for maintaining ventilation during general anesthesia
214788925|NCT06527352|OTHER|tulip shaped|the tulip shaped mask airway is with a tulip shaped tip
214788926|NCT06527352|OTHER|classical shaped|the classical shaped mask airway is with a water-drop shaped tip
214788927|NCT05168956|OTHER|Collect data of medical record|"Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
214788928|NCT05858385|OTHER|Intervention based on key factors identified by the severe RIOM prediction model|Intervention based on key factors identified by the severe RIOM prediction model
214788929|NCT00240006|PROCEDURE|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
214788930|NCT02989766|BEHAVIORAL|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
214788931|NCT00401219|DRUG|conjugated estrogens/progestin (MPA)|
214788932|NCT03961464|DRUG|d-cycloserine|Single dose
214788933|NCT03961464|DRUG|Placebo|Single dose
214788934|NCT01892579|BEHAVIORAL|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
214788935|NCT01892579|OTHER|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
214788936|NCT04388891|DEVICE|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
214788937|NCT02506166|DEVICE|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
214788938|NCT04296357|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
214788939|NCT04296357|OTHER|Physical development and General Health|Physical development and General health examination
214788940|NCT04296357|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
214788941|NCT03987438|BEHAVIORAL|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
214788942|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
214788943|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
214788944|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
214788945|NCT04782102|BEHAVIORAL|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
214788946|NCT06484036|PROCEDURE|periodontal treatment strategy|Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
214788947|NCT02806232|DRUG|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
214788948|NCT02806232|DRUG|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
214788949|NCT02806232|DRUG|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
214788950|NCT03445975|PROCEDURE|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
214788951|NCT03592875|BEHAVIORAL|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
214788952|NCT05583383|DRUG|camrelizumab|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
214788953|NCT00387998|OTHER|AHRQ staying healthy booklet|educational booklet about prevention
214788954|NCT00387998|OTHER|Risk primer|Know your chances booklet
214788955|NCT04586647|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
214788956|NCT05073653|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
214788957|NCT05073653|DIAGNOSTIC_TEST|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
214788958|NCT04133181|DEVICE|3D guide|Use of a 3D guide in endodontic surgery
214788959|NCT04133181|DEVICE|Mock guide|Use of a mock guide in endodontic surgery
214788960|NCT03308448|DRUG|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
214788961|NCT01817348|PROCEDURE|Lidocaine group|"* Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
214788962|NCT01817348|OTHER|Physiotherapy (PT)|\- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
214788963|NCT06430879|DEVICE|VICTORY PATCH|Drug- free, non-invasive patch (VICTORY Patch) with haptic vibrotactile trigger technology (VTT)
214788964|NCT06430879|DEVICE|Sham Patch without VTT|Sham Patch without haptic vibrotactile trigger technology (VTT)
214788965|NCT05207215|OTHER|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
214788966|NCT03803709|DIETARY_SUPPLEMENT|inulin|inulin given at different dosis from day 3 to day 20
214788967|NCT03803709|DIETARY_SUPPLEMENT|placebo|maltodextrine given at different dosis from day 3 to day 20
214788968|NCT03213756|DEVICE|Isometric exercises using Hand grip and elastic bands|"* Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~* Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
214788969|NCT00434161|DRUG|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
214788970|NCT00434161|DRUG|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
214788971|NCT00434161|DRUG|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
214788972|NCT05293028|DRUG|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
214788973|NCT01387282|DRUG|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
214788974|NCT01387282|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
214788975|NCT04936971|DRUG|Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm|Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
214788976|NCT04936971|OTHER|no intervention|Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
214788977|NCT02100865|DEVICE|Solar powered oxygen|
214788978|NCT02100865|DEVICE|Oxygen from cylinders|
214788979|NCT00295126|PROCEDURE|cellular therapy : Autologous platelet concentrate (APC)|
215030908|NCT04999267|OTHER|INVEST|The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.
215030909|NCT06572774|BEHAVIORAL|C3Link Strategies|Education sessions and community liaison support to link to services
214788980|NCT01921426|DRUG|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
214788981|NCT00040872|BIOLOGICAL|filgrastim|
214788982|NCT00040872|BIOLOGICAL|monoclonal antibody 3F8|
214788983|NCT00040872|BIOLOGICAL|sargramostim|
214788984|NCT00040872|DRUG|carboplatin|
214788985|NCT00040872|DRUG|cisplatin|
214788986|NCT00040872|DRUG|cyclophosphamide|
214788987|NCT00040872|DRUG|doxorubicin hydrochloride|
214788988|NCT00040872|DRUG|etoposide|
214788989|NCT00040872|DRUG|isotretinoin|
214788990|NCT00040872|DRUG|thiotepa|
214788991|NCT00040872|DRUG|topotecan hydrochloride|
214788992|NCT00040872|DRUG|vincristine sulfate|
214788993|NCT00040872|PROCEDURE|autologous bone marrow transplantation|
214788994|NCT00040872|PROCEDURE|bone marrow ablation with stem cell support|
214788995|NCT00040872|PROCEDURE|conventional surgery|
214788996|NCT00040872|PROCEDURE|drug resistance inhibition treatment|
214788997|NCT00040872|PROCEDURE|peripheral blood stem cell transplantation|
214788998|NCT00040872|PROCEDURE|syngeneic bone marrow transplantation|
214788999|NCT00040872|RADIATION|radiation therapy|
214789000|NCT04581538|DEVICE|Intervention of parallel arm 2|"This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care."
215030910|NCT04523519|BEHAVIORAL|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
215030911|NCT04523519|BEHAVIORAL|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
214789001|NCT04581538|DEVICE|Intervention of parallel arm 3|"Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed."
214789002|NCT02269215|DRUG|BIII 890 CL|
214789003|NCT02269215|DRUG|Placebo|
214789004|NCT05163509|COMBINATION_PRODUCT|Unity-based MR-Linac guided Radiotherapy|The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
214789005|NCT02934295|BIOLOGICAL|Determination of Anti-Rubella Antibody, E1|
214789006|NCT00821392|DRUG|Febuxostat|
214789007|NCT06544304|DEVICE|PMMA|PMMA 30%
214789008|NCT00352157|BEHAVIORAL|Revival Soy Dietary Supplement|
215030912|NCT04336566|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg
214789009|NCT01489722|DRUG|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
214789010|NCT01267266|DRUG|saracatinib|Given orally
214789011|NCT01267266|OTHER|hydrocortisone/placebo|Given orally
214789012|NCT03557138|BEHAVIORAL|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
214789013|NCT00002582|DRUG|CMF regimen|
214789014|NCT00002582|DRUG|cyclophosphamide|
214789015|NCT00002582|DRUG|doxorubicin hydrochloride|
214789016|NCT00002582|DRUG|fluorouracil|
214789017|NCT00002582|DRUG|goserelin acetate|
214789018|NCT00002582|DRUG|leuprolide acetate|
214789019|NCT00002582|DRUG|methotrexate|
214789020|NCT00002582|DRUG|tamoxifen citrate|
214789021|NCT00002582|PROCEDURE|oophorectomy|
214789022|NCT00002582|RADIATION|radiation therapy|
214789023|NCT02881476|OTHER|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
214789024|NCT06544213|BEHAVIORAL|Control Group|60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.
214789025|NCT06544213|BEHAVIORAL|Countermeasure Supine Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position."
214789026|NCT06544213|BEHAVIORAL|Countermeasure AG-Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.~The supine bike exercise is performed in a short arm centrifuge in rotation. Volunteers will start pedalling and the centrifuge will start at 0.15 Gz less than individual's threshold.~Every 4 minutes thereafter, the AG will be increased by 0.15 Gz, synchronized with the ramping up of cycle ergometer interval intensity. The AG will increase only up to 70 % of their tolerance level,.~It will then decrease by 0.15 Gz every 4 minutes, and until the 30-minute exercise is completed."
214789027|NCT02889328|DRUG|Regorafenib|Regorafenib 100mg continuous dosing arm
214789028|NCT01724398|OTHER|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
214789029|NCT01724398|OTHER|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
214789030|NCT01724398|OTHER|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
214789031|NCT01724398|OTHER|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
214789032|NCT02497391|DRUG|Evacetrapib|administered orally
214789033|NCT01470794|BIOLOGICAL|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
214789034|NCT01470794|DRUG|Toca FC|
214789035|NCT03657199|DIAGNOSTIC_TEST|Cardiac computed tomography|Routine computed tomography of the heart before discharge
214789036|NCT00783679|DEVICE|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
214789037|NCT06243978|BEHAVIORAL|liebria|Participants will receive access to the digital health intervention liebria in addition to TAU
214789038|NCT06243978|OTHER|information brochure on hypertension|Participants will receive an information brochure on hypertension
214789039|NCT00213954|PROCEDURE|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
214789040|NCT00878345|DRUG|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
214789041|NCT00878345|DRUG|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
214789042|NCT00401882|DRUG|Epinephrine|Epinephrine (1 mg) IV additional doses
214789043|NCT00401882|DRUG|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
214789044|NCT05118282|BEHAVIORAL|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
214789045|NCT05118282|BEHAVIORAL|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
214789046|NCT02850523|OTHER|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
214789047|NCT01828255|DEVICE|SENSIMED Triggerfish®|
214789048|NCT01271764|OTHER|no drug|The role of G9a protein in patients with endometrial cancer
214789049|NCT03978702|OTHER|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
214789050|NCT05001490|OTHER|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
214789051|NCT01087879|DRUG|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
214789052|NCT01087879|DRUG|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
214789053|NCT01087879|DRUG|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
214789054|NCT06177379|OTHER|healthy volunteer|Volunteers age between 50 and 75 years
214789055|NCT00439608|DRUG|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
214789056|NCT03389984|DIAGNOSTIC_TEST|cutaneous|SKIN BIOPSY
215030913|NCT04336566|DIETARY_SUPPLEMENT|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
214789057|NCT01486706|DRUG|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
214789058|NCT01486706|DRUG|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
214789059|NCT01486706|DRUG|Placebo drugs|will titrate medications similar to the active drug group
214789060|NCT01464359|DRUG|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
214789061|NCT01464359|DRUG|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.
214789062|NCT01464359|RADIATION|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
214789063|NCT01464359|DRUG|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
214789064|NCT01464359|DRUG|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
214789065|NCT01464359|DRUG|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours
214789066|NCT01464359|BIOLOGICAL|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
214789067|NCT01464359|BIOLOGICAL|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
214789068|NCT06417606|DRUG|Lenvatinib|Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
214789069|NCT00279942|DIETARY_SUPPLEMENT|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
214789070|NCT00279942|OTHER|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
214789071|NCT05124756|DEVICE|Bioelectric stimulation|The sessions will include 20 minutes for stimulation of the thigh muscles and 45 minutes for stimulation of the kidneys. The electrodes will be placed on the motor point of the quadriceps muscle in both lower limbs. The neuromuscular electric stimulation will be applied by symmetrical biphasic pulsed current, at an 80 Hz frequency, 400 ms pulse width, 10 s contraction time, rest time decreasing as the protocol advanced, at reciprocal mode. The intensity will be individually adjusted to produce visible muscle contraction. Concomitant, two electrodes will be placed in the abdominal corresponding to the kidney anatomical site and two electrodes on the dorsal region at the level of the 10th thoracic vertebra. The stimulation of the kidneys will include in addition to Klotho, precise signals for several pro-regenerative proteins. The intensity of the electric current will be individually adjusted to sensory stimulation.
214789072|NCT04843085|OTHER|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
214789073|NCT04705909|DRUG|Pitavastatin|Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
214789074|NCT04705909|DRUG|placebo|patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
214789075|NCT05489185|DRUG|Tranexamic acid|Intravenous or topical administration
214789076|NCT05489185|OTHER|Physiologic saline|Placebo
214789077|NCT01877928|DEVICE|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
215030914|NCT00889330|DRUG|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
215030915|NCT00889330|DRUG|Placebo|Vehicle without active, one drop in each eye at each of two visits.
214789078|NCT01877928|DEVICE|standard CPAP|Standard of care postoperative treatment for OSA.
214789079|NCT04108377|DRUG|Roflumilast|Roflumilast capsule
214789080|NCT04108377|DRUG|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
214789081|NCT04511351|DRUG|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
214789082|NCT03392597|BEHAVIORAL|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
214789083|NCT03392597|BEHAVIORAL|Programming-as-Usual|Usual afterschool programming.
214789084|NCT02557945|DRUG|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
214789085|NCT02557945|DRUG|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
214789086|NCT02429869|DRUG|everolimus|
214789087|NCT00658320|DRUG|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
214789088|NCT00658320|DRUG|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
214789089|NCT00658320|DRUG|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
214789090|NCT00658320|DRUG|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
214789091|NCT00658320|DRUG|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
214789092|NCT06405776|DRUG|lidocaine|Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
214789093|NCT06405776|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
214789094|NCT02956720|DEVICE|UltraShape Power|non-invasive body contouring procedure
214789095|NCT06462157|OTHER|Compassionate Mind Training|Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
214789096|NCT03712969|DRUG|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
214789097|NCT00003235|DRUG|carboplatin|
214789098|NCT00003235|DRUG|paclitaxel|
214789099|NCT00003235|RADIATION|radiation therapy|
214789100|NCT02542124|BIOLOGICAL|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
214789102|NCT04361019|OTHER|On-Line Survey|A survey has been sent by email to the students of the participating universities
214789103|NCT01169090|DRUG|SK-0403|SK-0403
214789104|NCT01169090|DRUG|Placebo|Placebo
214789105|NCT01169090|DRUG|Sitagliptin|Sitagliptin
214789106|NCT04556110|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
214789107|NCT04556110|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
214789108|NCT02210884|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
214789109|NCT06045481|DRUG|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
214789110|NCT02577081|OTHER|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
214789111|NCT02229006|RADIATION|18F-NaF PET-CT|
214789112|NCT00789802|DRUG|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
214789113|NCT00789802|DRUG|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
214789114|NCT00789802|DRUG|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
214789115|NCT01371513|OTHER|continuous screening|practice patterns for screening prostate cancer
214789116|NCT05261113|PROCEDURE|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
214789117|NCT02171936|OTHER|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
214789118|NCT04434313|DEVICE|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
214789119|NCT01975090|DEVICE|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
214789120|NCT05585359|OTHER|injectable platelet rich fibrin augmented with Vitamin C|According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
214789121|NCT01373606|DRUG|Terlipressin|
214789122|NCT02960815|BIOLOGICAL|Intanza|
214789123|NCT02960815|BIOLOGICAL|Mutagrip|
214789124|NCT02960815|DRUG|Aldara|
214789125|NCT05598437|DEVICE|Dry eye device|Dry eye analysis
214789126|NCT04763837|DEVICE|Intraureteral stent|This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
214789127|NCT04763837|DEVICE|Conventional Double-J stent|This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
214789128|NCT05849428|DEVICE|Freestyle Libre 3|Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
214789129|NCT00000898|DRUG|Ritonavir|
214789130|NCT00000898|DRUG|Nelfinavir mesylate|
214789131|NCT00000898|DRUG|Saquinavir|
214789132|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
214789133|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
214789134|NCT04528095|DRUG|Clozapine|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
214789135|NCT04528095|DEVICE|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
214789136|NCT04528095|DEVICE|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
214789137|NCT02011594|DRUG|Nimotuzumab|400mg Q2W intravenously
214789138|NCT02011594|DRUG|Placebo|Normal saline
214789139|NCT00746668|BEHAVIORAL|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
214789140|NCT00746668|BEHAVIORAL|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
214789141|NCT00746668|BEHAVIORAL|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
214789142|NCT05661929|OTHER|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
214789143|NCT00557882|DEVICE|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
214789144|NCT05539573|DEVICE|Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.|"The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure."
214789145|NCT06529263|OTHER|newborn massage|Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
214789146|NCT01753479|OTHER|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
214789147|NCT03877055|DRUG|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
214789148|NCT03877055|DRUG|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
214789149|NCT00387712|OTHER|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
214789150|NCT00387712|OTHER|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
214789151|NCT02224521|DRUG|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
214789152|NCT02224521|DRUG|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
214789153|NCT02224521|DRUG|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
214789154|NCT02224521|DRUG|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
214789155|NCT02224521|DRUG|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
214789156|NCT02224521|DRUG|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
214789157|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|15 Gy in one treatment
214789158|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
214789159|NCT01433900|DRUG|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
214789160|NCT01433900|DRUG|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
214789161|NCT03943342|DRUG|Ibrutinib|Given PO
214789162|NCT03943342|DRUG|Venetoclax|Given PO
214789163|NCT06541470|PROCEDURE|Cutting needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
214789164|NCT06541470|PROCEDURE|Abrams needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
214789165|NCT01783106|DRUG|Ciprofloxacin|experimental
214789166|NCT01783106|DRUG|Doxycycline|experimental
214789167|NCT01783106|DRUG|Hydroxychloroquine|oral
214789168|NCT01783106|DRUG|Budesonide|active comparator
214789169|NCT03119532|OTHER|Receive metric feedback email|If the provider received an email about the participants performance metrics
214789170|NCT00322309|OTHER|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
214789171|NCT00322309|DRUG|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
214789172|NCT01907737|OTHER|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
214789173|NCT01907737|OTHER|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
214789174|NCT01907737|OTHER|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
214789175|NCT01907737|OTHER|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
214789176|NCT03929211|DRUG|CPI-613|Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
214789177|NCT03929211|DRUG|Hydroxychloroquine|Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
214789178|NCT02384681|OTHER|Exposure to auditory fatigue|12-hour auditory exposure
214789179|NCT02449291|DRUG|APD421|
214789180|NCT02449291|DRUG|Placebo|
214789181|NCT01981486|DRUG|Placebo Tablets|BID modified-release tablets
214789182|NCT01981486|DRUG|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
214789183|NCT06286839|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L.
214789184|NCT02509728|DIETARY_SUPPLEMENT|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
214789185|NCT02509728|DIETARY_SUPPLEMENT|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
214789186|NCT02509728|DIETARY_SUPPLEMENT|standard nutrition|standard nutrition
214789187|NCT02668783|DRUG|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
214789188|NCT02668783|DRUG|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
214789189|NCT02668783|DRUG|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
214789190|NCT01492582|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
214789191|NCT01492582|OTHER|laboratory biomarker analysis|Correlative studies
214789192|NCT01492582|OTHER|survey administration|Ancillary studies
214789193|NCT01492582|OTHER|medical chart review|Ancillary studies
214789194|NCT00356720|DRUG|Azithromycin|
214789195|NCT03035838|DRUG|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
214789196|NCT06191367|OTHER|Aerobic Exercises|Aerobic Exercises
214789197|NCT06191367|DEVICE|Incentive Spirometer Device|is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.
214789198|NCT06191367|OTHER|Traditional Chest Physiotherapy|"1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration."
214789199|NCT01499914|BIOLOGICAL|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
214789200|NCT04212702|DRUG|Hormonal therapy-based treatments|Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only
214789201|NCT00027469|PROCEDURE|MRI|
214789202|NCT02613637|OTHER|Registry|
214789203|NCT02318498|PROCEDURE|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
214789204|NCT04467697|DRUG|SOV2012-F1|Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
214789205|NCT02095847|PROCEDURE|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
214789206|NCT02095847|DRUG|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
214789207|NCT02490423|OTHER|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
214789208|NCT04523558|DEVICE|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
214789209|NCT01056757|DRUG|Ribavirin|1000 mg bid, po, q28days
214789210|NCT01172600|OTHER|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
214789211|NCT01172600|OTHER|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
214789212|NCT03554421|PROCEDURE|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
214789213|NCT00909727|DRUG|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
214789214|NCT00909727|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
214789215|NCT04113395|OTHER|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
214789216|NCT03801629|DRUG|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
214789217|NCT03801629|DRUG|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
214789218|NCT02033265|PROCEDURE|Brachial plexus block|Ultrasound guided axillary brachial plexus block
214789219|NCT04228510|PROCEDURE|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
214789220|NCT03540810|DRUG|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
214789221|NCT03540810|DRUG|Placebo|The patients will receive placebo with their usual treatment
214789222|NCT05825118|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
214789223|NCT03004521|DRUG|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
214789224|NCT03004521|DRUG|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
214789225|NCT05747079|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
214789226|NCT05747079|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
214789227|NCT05747079|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
214789228|NCT00520507|DRUG|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
214789229|NCT00520507|DRUG|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
214789230|NCT04081337|DRUG|Tirzepatide|Administered SC
214789231|NCT04081337|DRUG|Placebo|Administered SC
214789232|NCT00525109|OTHER|No Intervention|No intervention
214789233|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
214789234|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
214789235|NCT04485988|DRUG|Beta blocker|Duration of medication
214789236|NCT04463433|BEHAVIORAL|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
214789237|NCT04463433|BEHAVIORAL|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
214789238|NCT00819728|DRUG|Docetaxel|35mg/m2 IV each week for 4 weeks
214789239|NCT00819728|DRUG|Irinotecan|50mg/m2 IV each week for 4 weeks
214789240|NCT01843283|BEHAVIORAL|Daily Enhancement Meaningful Activity (DEMA)|
214789241|NCT01843283|BEHAVIORAL|Information Support (IS)|
214789242|NCT02563483|BEHAVIORAL|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
214789243|NCT02716883|PROCEDURE|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
214789244|NCT01352650|DRUG|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
214789245|NCT01352650|DRUG|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
214789246|NCT01578707|DRUG|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
214789247|NCT01578707|DRUG|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
214789248|NCT01799590|DRUG|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
214789249|NCT02780778|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
214789250|NCT02780778|DRUG|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
214789251|NCT04561128|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
214789252|NCT04561128|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels
214789253|NCT02231190|DRUG|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
214789254|NCT02231190|DRUG|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
214789255|NCT00352495|DRUG|carboplatin|
214789256|NCT00352495|DRUG|vinblastine sulfate|
214789257|NCT02320279|DEVICE|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
214789258|NCT03706638|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
214789259|NCT05072301|BEHAVIORAL|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
214789260|NCT05072301|BEHAVIORAL|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
214789261|NCT03502629|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
214789262|NCT02162329|BEHAVIORAL|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
214789263|NCT02162329|PROCEDURE|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
214789264|NCT02162329|PROCEDURE|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
214789265|NCT02162329|BEHAVIORAL|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
214789266|NCT02383147|DEVICE|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
214789267|NCT02383147|DEVICE|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
214789268|NCT06483607|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
214789269|NCT06483607|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
214789270|NCT03777475|PROCEDURE|transarterial infusion|transarterial infusion
214789271|NCT04689477|DEVICE|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
214789272|NCT00730522|DRUG|CPP-109 vigabatrin|tablets, bid for 12 weeks
214789273|NCT00730522|DRUG|Matching Placebo|tablets, bid, 12 weeks
214789274|NCT02775968|DRUG|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
214789275|NCT05045209|OTHER|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
214789276|NCT03175120|DRUG|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
214789277|NCT03175120|DRUG|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
214789278|NCT00678392|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
214789279|NCT00678392|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
214789280|NCT00954967|BEHAVIORAL|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
214789281|NCT00477828|DEVICE|Continuous positive airway pressure|
214789282|NCT02099279|DEVICE|echocardiography examination|patients underwent echocardiography examination
214789283|NCT06136052|OTHER|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
214789284|NCT05817799|DRUG|L-Carnitine 500Mg thrice daily|L-Carnitine 500mg oral thrice daily
214789285|NCT05817799|DRUG|1g L-Carnitine IV three times a week|1g IV L-Carnitine three times a week
214789286|NCT01235052|RADIATION|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
214789287|NCT00514137|DRUG|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
214789288|NCT03603756|DRUG|SHR-1210|a novel anti-PD-1 antibody
214789289|NCT03603756|DRUG|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
214789290|NCT03603756|DRUG|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
214789291|NCT03603756|DRUG|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
214789292|NCT03603756|DRUG|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
214789293|NCT03341507|DEVICE|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
214789294|NCT03341507|DEVICE|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
214789295|NCT03882047|DRUG|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
214789296|NCT03882047|DRUG|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
214789297|NCT03882047|DRUG|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
214789298|NCT03882047|DRUG|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
214789299|NCT03761433|DEVICE|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
214789300|NCT04690777|PROCEDURE|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
214789301|NCT04690777|PROCEDURE|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
214789302|NCT01665170|DRUG|Passiflora incarnata|3 x 1 tablet per day for 3 days
214789303|NCT01665170|DRUG|Placebo|3 x 1 ablet per day for 3 days
214789304|NCT02152020|BEHAVIORAL|Survey|
214789305|NCT00938652|DRUG|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
214789306|NCT00938652|DRUG|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
214789307|NCT04109911|DIETARY_SUPPLEMENT|Fermented oyster extract|Fermented oyster extract 1,200 mg/day for 12 weeks
214789308|NCT04109911|DIETARY_SUPPLEMENT|Placebo|Placebo
214789309|NCT03541564|DRUG|BMS-986165|Specified dose on specified days
214789310|NCT03541564|DRUG|Moxifloxacin|Specified dose on specified days
214789311|NCT03541564|OTHER|Placebo|Specified dose on specified days
214789312|NCT05106933|OTHER|Plain water|Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
214789313|NCT05106933|OTHER|Carborie|carbohydrate drink
214789314|NCT06484023|OTHER|Survey|quality of life questionnaire
214789315|NCT04931420|DRUG|Standard of Care Chemotherapy|"* If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
214789316|NCT04931420|PROCEDURE|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
214789317|NCT04931420|PROCEDURE|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
214789318|NCT04931420|RADIATION|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
214789319|NCT04931420|RADIATION|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
214789320|NCT04931420|PROCEDURE|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
214789321|NCT04931420|PROCEDURE|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
214789322|NCT04931420|OTHER|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
214789323|NCT01522352|PROCEDURE|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
214789324|NCT04787406|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period."
214789325|NCT01743365|DRUG|Cisplatin-5FU-Afatinib|
214789326|NCT02002780|BEHAVIORAL|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
214789327|NCT04480203|OTHER|Stressproffen cognitive based stress management|The participants will download an app (Stressproffen 2A) with cognitive based stress management.
214789328|NCT04480203|OTHER|Stressproffen mindfulness based intervention|The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
214789329|NCT04480203|OTHER|Control|The participants will receive no app. (They will be able to download it after the end of the 3 year study).
214789330|NCT00881270|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
214789331|NCT01664195|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
214789332|NCT00441584|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
214789333|NCT00441584|DRUG|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
214789334|NCT02003040|DEVICE|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
214789335|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
214789336|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
214789337|NCT00678067|DIETARY_SUPPLEMENT|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
214789338|NCT00678067|OTHER|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
214789339|NCT04560764|DEVICE|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
214789340|NCT04560764|DEVICE|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
214789341|NCT04560764|DEVICE|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
214789342|NCT04560764|OTHER|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
214789343|NCT04296864|DRUG|Dupilumab|monoclonal antibody
214789344|NCT01584609|DEVICE|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
214789345|NCT01584609|DEVICE|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
214789346|NCT04615676|OTHER|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
214789347|NCT02307474|RADIATION|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
214789348|NCT02307474|DRUG|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
214789349|NCT03457025|DRUG|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
214789350|NCT03457025|DRUG|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
214789351|NCT03457025|DEVICE|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
214789352|NCT01584778|OTHER|eosinophil cationic protein|Serum eosinophil cationic protein levels
214789353|NCT02673671|DEVICE|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
214789354|NCT04849026|DRUG|Clozaril 100 mg (Clozapine)|2 Doses/Day for 10 days
214789355|NCT04849026|DRUG|WID-CLZ18|2 Doses/Day for 10 days
214789356|NCT00147264|DRUG|Telmisartan (Micardis®) vs. Placebo|
214789357|NCT00147264|BEHAVIORAL|Low-Glycemic Index Diet vs. Control Diet|
214789358|NCT04585555|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
214789359|NCT00945425|DRUG|AZD7325|oral capsule, once or twice daily, 7 days
214789360|NCT00945425|DRUG|Placebo|oral capsule, once or twice daily, 7 days
214789361|NCT06123403|DIAGNOSTIC_TEST|blood methotrexate level and Cystatin C level|blood methotrexate level and Cystatin C level
214789362|NCT02232503|GENETIC|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
214789363|NCT03483285|DEVICE|airtraq|airtraq videolaryngoscope
214789364|NCT03483285|DEVICE|storz|storz videolaryngoscope
214789365|NCT00500409|DRUG|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
214789366|NCT00500409|DRUG|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
214789367|NCT00305370|DRUG|Aripiprazole|
214789368|NCT01475188|DRUG|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
214789369|NCT01475188|OTHER|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
214789370|NCT03877874|DRUG|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
214789371|NCT01891591|PROCEDURE|Roux-en-Y gastric bypass (RYGP)|
214789372|NCT01172353|DRUG|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
214789373|NCT01172353|DRUG|saline|hydration with saline 1ml/Kg/h for 6 hours
214789374|NCT00770991|DRUG|Black raspberry (BRB) Slurry|20 grams BRB Slurry
214789375|NCT00770991|DRUG|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
214789376|NCT00770991|DRUG|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
214789377|NCT02648373|BEHAVIORAL|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
214789378|NCT02648373|OTHER|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
214789379|NCT00240357|PROCEDURE|Lifestyle Regulation|
214789380|NCT02684695|OTHER|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
214789381|NCT02684695|OTHER|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
214789382|NCT03985501|OTHER|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
214789383|NCT03216330|OTHER|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
214789384|NCT02232048|OTHER|Transthoracic Echocardiogram|
214789385|NCT03563950|DRUG|Rifampin|Specified dose on specified days
214789386|NCT03563950|DRUG|BMS-986224|Specified dose on specified days
214789387|NCT02275988|DRUG|K-877|
214789388|NCT02275988|DRUG|Clarithromycin|
214789389|NCT01687309|DRUG|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
214789390|NCT01687309|DRUG|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
214789391|NCT01687309|OTHER|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
214789392|NCT01687309|OTHER|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
214789393|NCT01126515|PROCEDURE|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
214789394|NCT01126515|PROCEDURE|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
214789395|NCT00132509|DRUG|DFIL|Alteplase : 0.8mg/kg over 90 minutes
214789396|NCT00132509|DRUG|NINDS|Alteplase : 0.9mg/kg over 60 minutes
214789397|NCT00310778|DRUG|high sodium diet|high sodium diet
214789398|NCT00310778|DRUG|low sodium diet|low sodium diet
214789399|NCT00310778|DRUG|ramipril 10 mg|ramipril 10 mg
214789400|NCT00310778|DRUG|valsartan 160 mg|valsartan 160 mg
214789401|NCT00310778|DRUG|candesartan 8 mg|candesartan 8 mg
214789402|NCT00310778|DRUG|atenolol 50 mg|atenolol 50 mg
214789403|NCT02957409|DRUG|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
214789404|NCT00859625|PROCEDURE|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
214789405|NCT03212196|PROCEDURE|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
214789406|NCT03212196|PROCEDURE|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
214789407|NCT00696358|RADIATION|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
214789408|NCT00696358|RADIATION|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
214789409|NCT04450303|BEHAVIORAL|Telehealth CBT|The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
214789410|NCT01405976|DEVICE|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
214789411|NCT03291457|DRUG|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
214789412|NCT03291457|DRUG|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
214789413|NCT02631928|DRUG|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
214789414|NCT02631928|DRUG|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
214789415|NCT04665505|BEHAVIORAL|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
214789416|NCT04665505|BEHAVIORAL|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
214789417|NCT04630197|BEHAVIORAL|e-CBT|The description is provided in the treatment arm description.
214789418|NCT03465891|DRUG|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
214789419|NCT03465891|RADIATION|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
214789420|NCT02387320|OTHER|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
214789421|NCT01841320|OTHER|Integrated methadone and antiretroviral therapy (iMART) clinic|
214789422|NCT00614159|DRUG|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
214789423|NCT00614159|DRUG|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
214789424|NCT03109990|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
214789425|NCT03109990|DRUG|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
214789426|NCT01001169|BIOLOGICAL|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
214789427|NCT05872074|DIAGNOSTIC_TEST|Coronary angiography plus percutenous coronary intervention|"1. wire both branches, MV and SB, with two coronary guide wires.~2. Main branch pre-dilation~3. Side branch pre-dilation using (ordinary balloon in group A and Drug coated balloon in group B for the side branch)~4. Main vessel stenting~5. Proximal optimization technique (POT) of the main vessel stent"
214789428|NCT01945138|DEVICE|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
214789429|NCT02040766|DRUG|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
214789430|NCT02040766|DRUG|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
214789431|NCT02040766|DRUG|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
214789432|NCT02040766|DRUG|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
214789433|NCT02040766|DRUG|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
214789434|NCT00645489|BEHAVIORAL|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
214789435|NCT00645489|OTHER|wait list|Wait list
214789436|NCT01608295|DRUG|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
214789437|NCT01608295|DRUG|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
214789438|NCT00914888|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
214789439|NCT00914888|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
214789440|NCT00914888|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
215030916|NCT05537389|DEVICE|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
214789441|NCT00914888|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
214789442|NCT04418141|DRUG|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
214789443|NCT01249105|DRUG|MK-2206|Taken orally once a week
214789444|NCT00635388|OTHER|Placebo|oral, placebo, once/day for 12 weeks
214789445|NCT00635388|OTHER|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
214789446|NCT00635388|OTHER|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
214789447|NCT04777773|OTHER|dual-task training|dual-task training
214789448|NCT04638686|DRUG|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
214789449|NCT04638686|DRUG|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
214789450|NCT04111237|BEHAVIORAL|Two Finger technique|two finger method for chest compression provuision
214789451|NCT04111237|BEHAVIORAL|Two Thumb Technique|Two thumb technique
214789452|NCT04657484|DRUG|Medium dose prednisolone|Same as arm description
214789453|NCT04657484|DRUG|Low dose prednisolone|Same as arm description
214789454|NCT04944602|BIOLOGICAL|SYN008|injection of 300 mg
214789455|NCT04944602|BIOLOGICAL|Omalizumab for injection|injection of 300 mg
214789456|NCT02116283|BEHAVIORAL|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
214789457|NCT02116283|OTHER|Smartphone|Participants will use an Android-based smartphone as their own for one month
214789458|NCT00455663|BEHAVIORAL|Cognitive Adaptation Training|Environmental supports for all independent living skills
214789459|NCT00455663|BEHAVIORAL|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
214789460|NCT00455663|OTHER|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
214789461|NCT03289975|OTHER|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
214789462|NCT00638170|BIOLOGICAL|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
214789463|NCT00638170|BIOLOGICAL|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
214789464|NCT02388178|DRUG|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
214789465|NCT02388178|DRUG|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
214789466|NCT02388178|DRUG|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
214789467|NCT01928654|DEVICE|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
214789468|NCT01928654|DEVICE|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
214789469|NCT02950753|DRUG|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
214789470|NCT02950753|DRUG|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
214789471|NCT00097071|DRUG|insulin lispro|
214789472|NCT00097071|DRUG|insulin aspart|
214789473|NCT01234428|PROCEDURE|Laparoscopic surgery|Gastric banding
214789474|NCT01234428|PROCEDURE|gastric banding|laparoscopic gastric banding
214789475|NCT02755545|DRUG|Product A|Product A applied topically to the entire face or other affected area of the skin once daily
214789476|NCT02755545|DRUG|Product B|Product B applied topically to affected area of the skin 1 to 3 times daily
214789477|NCT00481247|DRUG|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
214789478|NCT00481247|DRUG|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
214789479|NCT02535000|DRUG|Duloxetine|duloxetine 60 mg
214789480|NCT02535000|DRUG|Placebo|placebo
214789481|NCT00376142|BEHAVIORAL|Psychological theory-based behaviour change interventions|
214789482|NCT05771311|DEVICE|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
214789483|NCT05771311|DEVICE|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
214789484|NCT01918709|DRUG|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789485|NCT01918709|DRUG|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789486|NCT01918709|DRUG|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789487|NCT01918709|DRUG|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789488|NCT01918709|DRUG|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789489|NCT01918709|DRUG|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
214789490|NCT04317781|BIOLOGICAL|Tagraxofusp-erzs|Given IV
214789491|NCT06462001|BIOLOGICAL|Bacillus Calmette-Guerin Vaccine Intravesical|BCG (Oncotice) is administered intravesically as per usual standard of care
214789492|NCT06462001|DRUG|Mitomycin|MMC is administered intravesically as per usual standard of care
214789493|NCT01620489|DRUG|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
214789494|NCT01620489|DRUG|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
214789495|NCT03705884|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
214789496|NCT03705884|DRUG|Prednisolone|Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
214789497|NCT03378349|BEHAVIORAL|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
214789498|NCT03378349|BEHAVIORAL|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
214789499|NCT01210183|DRUG|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
214789500|NCT04256993|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
214789501|NCT04256993|DRUG|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
214789502|NCT01766011|OTHER|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
214789503|NCT02804828|DIETARY_SUPPLEMENT|Individualized mitochondrial cocktail|Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
214789504|NCT02804828|DIETARY_SUPPLEMENT|Placebo|6 months for the double-blind phase
214789505|NCT04443283|OTHER|No intervention|This is a observation study, with no intervention
214789506|NCT03668028|BIOLOGICAL|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
214789507|NCT03668028|PROCEDURE|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
214789508|NCT06206733|DRUG|ASKB589|ASKB589 will be administered as a minimum 3-hour IV infusion
214789509|NCT06206733|DRUG|Oxaliplatin|Oxaliplatin will be administered as a minimum 2-hour IV infusion
214789510|NCT06206733|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
214789511|NCT06206733|DRUG|Tislelizumab|Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
214789512|NCT06206733|DRUG|Placebo|Placebo will be administered as a minimum 3-hour IV infusion
214789513|NCT02804269|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
214789514|NCT02804269|OTHER|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
214789515|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
214789516|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
214789517|NCT04813822|DRUG|Miconazole Nitrate 2%|Active Comparator
214789518|NCT04166981|PROCEDURE|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
214789519|NCT04166981|PROCEDURE|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
214789520|NCT01810926|BIOLOGICAL|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
214789521|NCT01810926|DRUG|Rituximab|single infusion of200 mg/m2 on day -1
214789522|NCT01810926|DRUG|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
214789523|NCT01810926|DRUG|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
214789524|NCT01810926|DRUG|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
214789525|NCT01810926|DRUG|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
214789526|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
214789527|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
214789528|NCT01873768|DRUG|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
214789529|NCT01873768|DRUG|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
214789530|NCT00670878|DRUG|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
214789531|NCT00670878|DRUG|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
214789532|NCT00947856|DRUG|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
214789533|NCT05053893|DRUG|Roxadustat;Sacubitril Valsartan Sodium Tablets;|Select the appropriate dose according to the patient's situation
214789534|NCT05053893|DRUG|EPO; ACEI / ARB|Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
214789535|NCT04978285|OTHER|Anemia|Depends on Day 3 Hb result
214789536|NCT02659878|PROCEDURE|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
214789537|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
214789538|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
214789539|NCT02351128|DRUG|Lanreotide|
214789540|NCT02956824|OTHER|Standard care|Current care
214789541|NCT05727293|OTHER|noting|Non intervention
214789542|NCT00270699|BIOLOGICAL|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
214789543|NCT00270699|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-200,201
214789544|NCT04749524|DIAGNOSTIC_TEST|Medial-Olivocochlear Reflex (MOCR) Strength Measurement|Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.
214789545|NCT02305368|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
214789546|NCT01709383|DEVICE|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
214789547|NCT01709383|DEVICE|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
214789548|NCT01109459|OTHER|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
214789549|NCT01109459|OTHER|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
214789550|NCT00119977|PROCEDURE|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
214789551|NCT04402554|BEHAVIORAL|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
214789552|NCT03294512|BEHAVIORAL|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
214789553|NCT01038583|DRUG|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
214789554|NCT01038583|DRUG|Placebo|100 mg enteric-coated placebo
214789555|NCT00729235|DEVICE|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
214789556|NCT00729235|DEVICE|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
214789557|NCT01193517|DRUG|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
214789558|NCT01193517|DRUG|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
214789559|NCT01193517|DRUG|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
214789560|NCT01193517|DRUG|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
214789561|NCT01360450|DRUG|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.
214789562|NCT01360450|DRUG|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
214789563|NCT04185558|DEVICE|ActiGraft|Whole Blood Clot (WBC) gel
214789564|NCT04185558|DEVICE|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
215030917|NCT02346279|OTHER|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
215030918|NCT02956473|DEVICE|Supine MRI|
215030919|NCT02956473|OTHER|Neoadjuvant Therapy (NAT)|
215030920|NCT02956473|DEVICE|Ultrasound|
215030921|NCT02956473|DEVICE|Mammography|
214789565|NCT04237571|BEHAVIORAL|CANE Meal Program|Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
214789566|NCT05388188|DRUG|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
214789567|NCT04083014|DRUG|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
214789568|NCT02874963|PROCEDURE|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
214789569|NCT02874963|DEVICE|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
214789570|NCT02874963|DRUG|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
214789571|NCT01581983|BEHAVIORAL|Internet Mindfulness Meditation|one hour session each week for six weeks
214789572|NCT01581983|BEHAVIORAL|Individual Mindfulness Meditation|one hour session each week for six weeks
214789573|NCT02387814|DRUG|Abemaciclib|Administered Orally
214789574|NCT05585502|OTHER|Training (minute oscillation stretching)|The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
214789575|NCT03621085|DRUG|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
214789576|NCT03621085|OTHER|Placebo|Subjects will receive placebo
214789577|NCT06410937|PROCEDURE|thyroidectomy without drain|thyroidectomy without subcutaneous suction drain
214789578|NCT06410937|PROCEDURE|thyroidectomy with drain|hyroidectomy with subcutaneous suction drain
214789579|NCT02086656|DRUG|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
214789580|NCT01512979|DRUG|metformin|1000 mg to 2000 mg per day
214789581|NCT01512979|DRUG|linagliptin|5 mg daily
214789582|NCT01512979|DRUG|metformin placebo|0 to 2 tablets daily
214789583|NCT01512979|DRUG|metformin placebo|4 tablets daily
214789584|NCT03266549|PROCEDURE|botulinum toxin augmented surgery|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
214789585|NCT03266549|PROCEDURE|conventional surgery|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia. The standard correction tables will be used as a guide for the amount of muscle recession and, or resection.
214789586|NCT05497011|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
214789587|NCT05547893|OTHER|simulation|participating a simulated clinical ethical situation with simulation patients
214789588|NCT04082975|DRUG|NVP-1203|Oral dose for 7 days
214789589|NCT04082975|DRUG|NVP-1203-R|Oral dose for 7 days
214789590|NCT04082975|DRUG|NVP-1203 placebo|Oral dose for 7 days
214789591|NCT04082975|DRUG|NVP-1203-R placebo|Oral dose for 7 days
214789592|NCT04841278|DEVICE|EUS/ERCP|EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
214789593|NCT00050895|DRUG|Lopinavir/ritonavir|
214789594|NCT00050895|DRUG|Efavirenz|
214789595|NCT00050895|DRUG|Stavudine|
214789596|NCT00050895|DRUG|Zidovudine|
214789597|NCT00050895|DRUG|Lamivudine|
214789598|NCT00050895|DRUG|Tenofovir disoproxil fumarate|
214789599|NCT04185831|DRUG|Atezolizumab|PD-L1 inhibitor
214789600|NCT04185831|DRUG|Everolimus|MTOR inhibitor
214789601|NCT04185831|DRUG|Cobimetinib|MEK inhibitor
214789602|NCT04185831|DRUG|Niraparib|PARP inhibitor
214789603|NCT01893151|DRUG|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
214789604|NCT01893151|DRUG|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
214789605|NCT05529719|OTHER|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
214789606|NCT00961051|DEVICE|Investigational MPS|Multi-purpose solution
214789607|NCT00961051|DEVICE|Opti-Free|Multi-purpose solution
214789608|NCT01337154|DRUG|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
214789609|NCT01337154|DRUG|Placebo|Tablets, orally, daily
214789610|NCT03287596|DEVICE|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
214789611|NCT01873079|DRUG|Esomeprazole|
214789612|NCT01873079|OTHER|Standard care|No PPI or other study medication given
215030922|NCT02956473|PROCEDURE|Standard of Care|
214789613|NCT01653574|DRUG|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
214789614|NCT06189261|OTHER|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
214789615|NCT06306495|OTHER|International Physical Activity Survey|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
214789616|NCT06073795|PROCEDURE|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
214789617|NCT01531348|OTHER|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
214789618|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
214789619|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
214789620|NCT06140511|DIAGNOSTIC_TEST|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study \[Ferri et al. Sleep 2018:zsy187\] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
214789621|NCT03654261|BEHAVIORAL|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
214789622|NCT02856815|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
214789623|NCT02139683|DEVICE|HIFU treatment|HIFU treatment in patients with fibroadenoma
214789624|NCT02272348|OTHER|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
214789625|NCT02272348|OTHER|Usual diabetes management.|
214789626|NCT02896660|DEVICE|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
214789627|NCT03208257|DRUG|Esmolol|Esmolol hydrochloride infusion
214789628|NCT05700357|PROCEDURE|TPVB with 20 ml|The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
214789629|NCT05700357|PROCEDURE|TPVB with 25 ml|The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
214789630|NCT05700357|PROCEDURE|TPVB with 30 ml|The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
214789631|NCT04969952|OTHER|For interventional module|Using vedio to assist physicians introducing advance care planning to cancer patients
215030923|NCT02956473|DEVICE|Standard MRI|
214789632|NCT03787108|OTHER|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
214789633|NCT01211847|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
214789634|NCT01211847|DRUG|Placebo|Placebo matching DCCR
214789635|NCT04822662|BEHAVIORAL|Epilepsy Education Programme|Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
214789636|NCT00470444|PROCEDURE|Transfusion with Red Blood Cells|Units of donated Red blood cells
214789637|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of red blood cells
214789638|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of donated red blood cells
214789639|NCT06066385|PROCEDURE|Small bites technique|Closure of the fascia after midline laparotomy using a slowly resorbalbe 2.0 suture, with 0.5 cm bites, and 0.5 cm between the stitches, at least resulting in a 1:4 wound length:suture length ratio.
214789640|NCT06066385|PROCEDURE|Conventional large bites closure|Closure of a midline laparotomy using a slowy resorbable thick suture (e.g. PDS loop) with large bites and large steps (\>= 1 cm).
214789641|NCT01402583|DRUG|PEG IFN/Ribavirin|PEG IFN/Ribavirin
215030924|NCT03898011|DRUG|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
215030925|NCT03898011|DRUG|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
214789642|NCT02002247|DRUG|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
214789643|NCT02002247|DRUG|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
214789644|NCT04968743|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
214789645|NCT04192799|BEHAVIORAL|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
214789646|NCT04192799|BEHAVIORAL|ED admission|Process of pediatric admission is through the emergency department
214789647|NCT01551329|DRUG|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
214789648|NCT00874757|DRUG|Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
214789649|NCT04058678|DRUG|Danazol/Placebo|This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
214789650|NCT04058678|OTHER|Without intervention|Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
214789651|NCT05763433|OTHER|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
214789652|NCT02946957|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
214789653|NCT02946957|BEHAVIORAL|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
214789654|NCT04261257|OTHER|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out."
214789655|NCT02026414|DIETARY_SUPPLEMENT|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
214789656|NCT02026414|OTHER|Exercise|
214789657|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
214789658|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
214789659|NCT03616834|DRUG|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
214789660|NCT00759148|DRUG|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
214789661|NCT00759148|OTHER|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
214789662|NCT02954679|OTHER|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
214789663|NCT04593290|DEVICE|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
214789664|NCT00846378|PROCEDURE|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
214789665|NCT00846378|PROCEDURE|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
214789666|NCT00803959|OTHER|Office evaluation|Office evaluation
214789667|NCT00803959|OTHER|UDS|Urodynamics
214789668|NCT05133128|OTHER|blood samples|blood samples
214789669|NCT01580761|BEHAVIORAL|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
214789670|NCT00311818|DRUG|Insulin glargine|
215030926|NCT06100120|PROCEDURE|Implant placement|Placement of osteointegrated implants
215030927|NCT02494115|PROCEDURE|subcutaneous drainage|
214789671|NCT04363983|BIOLOGICAL|Blood sampling|"Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,…; methylation) and circulating tumor cells."
214789672|NCT04363983|PROCEDURE|Liver biopsy|"An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.~This biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.~This biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed."
214789673|NCT04363983|BIOLOGICAL|Stool collect|"Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Analysis will be performed for microbiota and metabolism analysis."
214789674|NCT04383002|DRUG|Nitric Oxide|iNO will be given at 160ppm for 6 hours, once a day, for 2 days
214789675|NCT02314533|DRUG|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
214789676|NCT05710185|DRUG|Deucravacitinib|See arm/group description
214789677|NCT04538963|DEVICE|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
214789678|NCT00977925|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
214789679|NCT00977925|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
214789680|NCT04155164|DRUG|Metformin|Participants will receive Metformin at 1000mg for 12 months.
214789681|NCT04155164|DRUG|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
214789682|NCT03492073|BEHAVIORAL|Emotional Supportive Mindfulness-based Program|Mindfulness training
214789683|NCT03492073|BEHAVIORAL|Emotional Supportive Program|Narrative-orientated therapy.
214789684|NCT00708929|PROCEDURE|Squatting|Squatting for 6 minutes
214789685|NCT04505514|DRUG|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
214789686|NCT04505514|DRUG|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
214789687|NCT04505514|DRUG|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
214789688|NCT04376723|OTHER|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
214789689|NCT05702359|OTHER|Glucose as reference food|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789690|NCT05702359|OTHER|Control juice|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789691|NCT05702359|OTHER|Juice with vitamin D3|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789692|NCT05702359|OTHER|Juice with n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789693|NCT05702359|OTHER|Juice with probiotics|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789694|NCT05702359|OTHER|Juice with probiotics, vitamin D3, and n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
214789695|NCT00003533|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214789696|NCT04822870|PROCEDURE|quadratus lumborum block|Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
214789697|NCT04822870|PROCEDURE|iliohypogastric/ilioinguinal nerve block|Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
214789698|NCT04822870|PROCEDURE|epidural analgesia|Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
214789699|NCT01555281|DRUG|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
214789700|NCT01555281|DRUG|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
214789701|NCT01555281|DRUG|Dexamethasone|40 mg (for patients \<75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
214789702|NCT03306056|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
214789703|NCT03306056|OTHER|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
214789704|NCT03306056|OTHER|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
214789705|NCT03306056|OTHER|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks"
214789706|NCT05058144|DIETARY_SUPPLEMENT|Drinkable solution|the volunteer will consume the volume 300 ml of water with
214789707|NCT02802514|DRUG|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
214789708|NCT02802514|DRUG|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
214789709|NCT02802514|DRUG|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
214789710|NCT02802514|DRUG|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
214789711|NCT03242122|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
214789712|NCT03242122|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
214789713|NCT03242122|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
214789714|NCT03242122|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
214789715|NCT03242122|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
214789716|NCT06530069|OTHER|exposures|exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
214789717|NCT03467412|DRUG|FOL-005|intradermal injection
214789718|NCT03467412|DRUG|Placebo|intradermal injection
214789719|NCT06528041|OTHER|Inulin|12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
214789720|NCT06528041|OTHER|Maltodextrin|6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
214789721|NCT01100684|DRUG|Asimadoline|0.5 mg Asimadoline BID
214789722|NCT01100684|DRUG|Placebo|Placebo
214789723|NCT03408600|OTHER|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
214789724|NCT01889511|BEHAVIORAL|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
214789725|NCT00544583|PROCEDURE|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
214789726|NCT00544583|PROCEDURE|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
214789727|NCT05890066|PROCEDURE|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
214789728|NCT00222677|DRUG|aspirin|100 mg daily
214789729|NCT04380220|DIAGNOSTIC_TEST|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
214789730|NCT04522414|OTHER|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
214789731|NCT01806974|OTHER|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
214789732|NCT01583387|OTHER|1-Increased water intake regimen|Arm 1-Intervention
214789733|NCT01583387|OTHER|2-Non-modified water intake regimen|Arm 2-Control
214789734|NCT04316858|DRUG|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
214789735|NCT04316858|DIETARY_SUPPLEMENT|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
214789736|NCT04316858|DIETARY_SUPPLEMENT|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
214789737|NCT03395444|DEVICE|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
214789738|NCT04910230|DRUG|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
214789739|NCT00225082|DRUG|Nucleoside analogue switch|stavudine switched to tenofovir
214789740|NCT03779191|DRUG|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
214789741|NCT03779191|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
214789742|NCT03607630|OTHER|Imagery Rescripting|psychological therapy
214789743|NCT06021548|OTHER|Blood sample|Finger stick blood spots will be collected at V0 and M12
214789744|NCT06021548|OTHER|Saliva sample|Saliva sample will be collected at V0
214789745|NCT06021548|OTHER|Hair sample|Hair sample will be collected at V0 (optional)
214789746|NCT04721457|DRUG|Distilled Water|Control group
214789747|NCT04721457|DRUG|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
214789748|NCT04721457|DRUG|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
214789749|NCT04721457|DRUG|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
214789750|NCT04721457|DRUG|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
214789751|NCT04721457|OTHER|No rinse group|second control group
214789752|NCT01977430|DRUG|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
214789753|NCT05692674|RADIATION|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
214789754|NCT03433001|DRUG|Ixazomib|Ixazomib capsules
214789755|NCT03433001|DRUG|Lenalidomide|Lenalidomide capsules
214789756|NCT03433001|DRUG|Dexamethasone|Dexamethasone tablets
214789757|NCT04834557|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214789758|NCT04834557|DRUG|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214789759|NCT04834557|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214789760|NCT04894422|OTHER|Observational intervention|Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
215030928|NCT01058746|OTHER|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
214789761|NCT06379074|BEHAVIORAL|Improving sleep health and resilience during pregnancy|"Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician.~Sessions' contents:~1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy;~2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques;~3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques;~4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques;~5. Sleep in the postpartum and the development of sleep regulation in children;~6. Relapse prevention and focus on acquired skills and how to prioritize sleep."
214789762|NCT06379074|BEHAVIORAL|Information on pregnancy-related issues|"Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions."
214789763|NCT00551122|BIOLOGICAL|filgrastim|
214789764|NCT00551122|BIOLOGICAL|lenograstim|
214789765|NCT00551122|BIOLOGICAL|pegfilgrastim|
214789766|NCT00551122|DRUG|cisplatin|
214789767|NCT00551122|DRUG|gemcitabine hydrochloride|
214789768|NCT00551122|DRUG|ifosfamide|
214789769|NCT00551122|DRUG|paclitaxel|
214789770|NCT00969839|DEVICE|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
214789771|NCT00820235|DEVICE|OsseoSpeed™|OsseoSpeed™ implant
214789772|NCT00820235|DEVICE|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
214789773|NCT00820235|DEVICE|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
214789774|NCT05333419|DRUG|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
214789775|NCT01396941|BEHAVIORAL|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
214789776|NCT01336010|DRUG|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
214789777|NCT01336010|DRUG|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
214789778|NCT04254523|DEVICE|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
214789779|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
214789780|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
214789781|NCT00551564|DRUG|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
214789782|NCT02193984|BEHAVIORAL|Peer support|
214789783|NCT00793052|DRUG|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
214789784|NCT00171509|DRUG|Cyclosporine microemulsion|
214789785|NCT03926078|OTHER|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
214789786|NCT03926078|RADIATION|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
214789787|NCT03926078|RADIATION|CT scan|CT scans will be acquired and used to calculate the HI and EHI
214789788|NCT03491878|PROCEDURE|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
214789789|NCT03491878|PROCEDURE|Open|Open cholecystectomy including segments IVB and V
214789790|NCT00752661|DRUG|Tramadol Hydrochloride; JNS013|
214789791|NCT00054483|DRUG|bortezomib|Given IV
214789792|NCT00054483|OTHER|laboratory biomarker analysis|Correlative studies
214789793|NCT00054483|OTHER|pharmacological study|Correlative studies
214789794|NCT05728177|COMBINATION_PRODUCT|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
214789795|NCT00682383|DRUG|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
214789796|NCT01409850|DEVICE|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
214789797|NCT01409850|DEVICE|Soft splint|
214789798|NCT02030574|DRUG|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
214789799|NCT06178146|DRUG|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
214789800|NCT06178146|DRUG|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
214789801|NCT01411267|DRUG|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
214789802|NCT01411267|DRUG|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age"
214789803|NCT01411267|DRUG|Etoposide|150 mg/m2/day IV on days 1 through 5.
214789804|NCT01411267|DRUG|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
214789805|NCT02342444|DRUG|Enoxaparin Sodium Injection 30 mg BID|
214789806|NCT02342444|DRUG|Enoxaparin Sodium Injection 40 mg QD|
214789807|NCT05581186|OTHER|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
214789808|NCT05581186|OTHER|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
214789809|NCT05581186|OTHER|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
214789810|NCT01055249|DRUG|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
214789811|NCT01055249|DRUG|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
214789812|NCT01768728|PROCEDURE|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
214789813|NCT01768728|PROCEDURE|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
214789814|NCT02450565|OTHER|Questionnaire|
214789815|NCT01165996|OTHER|flow cytometry|Correlative studies
214789816|NCT01165996|OTHER|DNA methylation analysis|Correlative studies
214789817|NCT01165996|OTHER|cytogenetic analysis|Correlative studies
214789818|NCT01165996|DRUG|decitabine|Given subcutaneously
214789819|NCT01165996|GENETIC|microarray analysis|Correlative studies
214789820|NCT01165996|GENETIC|gene expression analysis|Correlative studies
214789821|NCT01165996|OTHER|pharmacological study|Correlative studies
214789822|NCT01165996|GENETIC|polymorphism analysis|Correlative studies
214789823|NCT03824210|OTHER|App|Mobile phone app
214789824|NCT00679523|DRUG|AN2690 Solution, 5.0%|Once daily application for 180 days
214789825|NCT00679523|DRUG|AN2690 Solution, 7.5%|Once daily application for 180 days
214789826|NCT02506790|DRUG|metformin|
214789827|NCT02506790|DRUG|Melatonin|
214789828|NCT02506790|DRUG|Toremifene|
214789829|NCT04854720|DEVICE|Fuji® II LC CAPSULE|"Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions."
214789830|NCT04854720|DEVICE|Clinpro™ XT Varnish|"Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions."
214789831|NCT04854720|DEVICE|Beautifil Flow|"Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions."
214789832|NCT04854720|DEVICE|Fuji Triage® CAPSULE|"Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions."
214789833|NCT06398782|DEVICE|body composition assessment|body composition of cancer survivors were assessed by Dual-energy X-ray absorptiometry
214789834|NCT04120220|OTHER|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
214789835|NCT04120220|OTHER|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
214789836|NCT01103557|PROCEDURE|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
214789837|NCT01399723|DRUG|Amoxicillin|Oral 45mg/kg 12 hourly
214789838|NCT01399723|DRUG|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
214789839|NCT02386059|DRUG|PLACEBO|received normal saline, intravenously
214789840|NCT02386059|DRUG|Dexamethasone|4 mg, intravenously, at the start of surgery
214789841|NCT02386059|DRUG|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
214789842|NCT02386059|DRUG|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
214789843|NCT00118300|DRUG|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
214789844|NCT00118300|RADIATION|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)\* intracavitary brachytherapy once weekly in weeks 4-8.
214789845|NCT00118300|RADIATION|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
214789846|NCT02935075|DRUG|Tenofovir disoproxil fumarate|Oral daily
214789847|NCT02935075|DRUG|Lamivudine|Oral daily
214789848|NCT02935075|DRUG|Efavirenz|Oral daily
214789849|NCT01727245|OTHER|Obese|gastric bypass
214789850|NCT01727245|OTHER|Control group|Cholecystectomy and anti-reflux surgery
214789851|NCT03140592|PROCEDURE|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
214789852|NCT05074082|PROCEDURE|Flap reconstruction|Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
214789853|NCT00389506|BIOLOGICAL|LMB-2 immunotoxin|
214789854|NCT00389506|DRUG|cyclophosphamide|
214789855|NCT00389506|DRUG|fludarabine phosphate|
214789856|NCT00389506|OTHER|pharmacological study|
214789857|NCT04259606|DIETARY_SUPPLEMENT|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
214789858|NCT04259606|OTHER|Calcined magnesia|White, odor, color and flavorless thin powder.
214789859|NCT03051256|DRUG|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
214789860|NCT03051256|DRUG|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
214789861|NCT04272359|DRUG|Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas|"Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety."
214789862|NCT05721144|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
214789863|NCT02311023|OTHER|Intermittent fasting|
214789864|NCT06301555|BEHAVIORAL|Reinforcement learning algorithm powered cognitive and behavioral intervention|Reinforcement learning algorithm powered cognitive and behavioral intervention
214789865|NCT06301555|BEHAVIORAL|cognitive and behavioral intervention|cognitive and behavioral intervention
214789866|NCT03175237|OTHER|Mirror Therapy|
214789867|NCT04395365|DRUG|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
214789868|NCT04395365|DRUG|Placebo oral tablet|Placebo
214789869|NCT04152629|DRUG|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
214789870|NCT04152629|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
214789871|NCT04392089|DEVICE|Masimo, LidCO|"* Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO"
214789872|NCT00268346|DRUG|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
214789873|NCT06546644|BEHAVIORAL|Structured school-based intervention|A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
214789874|NCT03092908|DIETARY_SUPPLEMENT|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
214789875|NCT03092908|DIETARY_SUPPLEMENT|placebo (water)|Administer 5 ml placebo (water) three times a day.
214789876|NCT00000275|DRUG|Flupenthixol|
214789877|NCT01945632|DEVICE|conventional gracey curettes|
214789878|NCT01945632|DEVICE|Vertically oscillating ultrasonic device|
214789879|NCT01945632|DEVICE|piezoelectric ultrasonic scraper|
214789880|NCT02776007|DEVICE|Libre Flash CGMS|
214789881|NCT02776007|DEVICE|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
214789882|NCT05487456|OTHER|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
214789883|NCT05487456|OTHER|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
214789884|NCT05487456|OTHER|CIG|Ad libitum use of subject's own preferred brand of cigarettes
214789885|NCT05487456|OTHER|Smoking Abstinence|Abstention from cigarette smoking
214789886|NCT06325878|GENETIC|Genome-wide association study|Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP
214789887|NCT06193278|DEVICE|Neuromodulation|Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
214789888|NCT00688285|OTHER|automated clinical alerts|automated clinical alerts in the electronic medical record
214789889|NCT00688285|OTHER|provider education|PCP education session on CKD
214789890|NCT01554761|PROCEDURE|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
214789891|NCT01554761|DEVICE|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
214789892|NCT00981253|BEHAVIORAL|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
214789893|NCT00981253|BEHAVIORAL|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
214789894|NCT00294723|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
214789895|NCT00294723|DRUG|glimepiride|8 mg capsule
214789896|NCT00294723|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
214789897|NCT00294723|DRUG|placebo|Glimepiride placebo, 8mg capsule
214789898|NCT00294723|DRUG|placebo|Liraglutide placebo, 200 mcl
214789899|NCT00294723|DRUG|placebo|Liraglutide placebo, 300 mcl
214789900|NCT00752791|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
214789901|NCT02254148|DRUG|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
214789902|NCT02254148|DRUG|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
214789903|NCT02254148|DRUG|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
214789904|NCT02254148|DRUG|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
214789905|NCT02254148|DRUG|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
214789906|NCT02254148|DRUG|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
214789907|NCT02254148|DRUG|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
214789908|NCT05730686|PROCEDURE|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
214789909|NCT00062140|DRUG|cyclophosphamide|
214789910|NCT00062140|PROCEDURE|allogeneic bone marrow transplantation|
214789911|NCT00062140|PROCEDURE|peripheral blood stem cell transplantation|
214789912|NCT00062140|RADIATION|radiation therapy|
214789913|NCT05736965|DRUG|Selinexor|Selinexor 60mg, PO d3,10,17
214789914|NCT05736965|DRUG|Azacitidine|Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
214789915|NCT05736965|DRUG|Venetoclax|Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
214789916|NCT04356521|PROCEDURE|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
214789917|NCT04356521|PROCEDURE|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
214789918|NCT06314321|OTHER|Baduanjin exercise|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
214789919|NCT00103675|PROCEDURE|Acupuncture|
214789920|NCT04676932|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
214789921|NCT03717285|PROCEDURE|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
214789922|NCT03717285|PROCEDURE|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
214789923|NCT06503341|OTHER|Cardiovascular risk assesment|ASCVD Score and WHO Cardiovascular Risk score.
214789924|NCT03813485|OTHER|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
214789925|NCT03813485|OTHER|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
214789926|NCT01297647|PROCEDURE|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
214789927|NCT04189094|DRUG|Sintilimab|Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
214789928|NCT04189094|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
214789929|NCT04189094|DRUG|Cisplatin|cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
214789930|NCT04189094|RADIATION|radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
214789931|NCT00001228|DRUG|Interferon|
214789932|NCT02179684|PROCEDURE|Baby-sitter surgery N. fascialis|
214789933|NCT02179684|OTHER|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
214789934|NCT00427622|OTHER|physiologic testing|
214789935|NCT01557647|DRUG|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
214789936|NCT01557647|DRUG|Placebo|placebo inhalation solution
214789937|NCT05388682|DEVICE|Percutaneous transluminal pulmonary angioplasty|Percutaneous transluminal pulmonary angioplasty
214789938|NCT05694468|OTHER|Psychomotor Relaxation|Psychomotor relaxation sessions.
214789939|NCT01958281|DRUG|SOF|Tablet(s) administered orally once daily
214789940|NCT01958281|DRUG|RBV|200 mg tablet administered orally once daily
214789941|NCT01958281|DRUG|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
214789942|NCT02784106|DRUG|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
214789943|NCT02784106|DRUG|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
214789944|NCT02784106|DRUG|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
214789945|NCT05677607|DIAGNOSTIC_TEST|Magnetic resonance imaging|Imaging diagnostics mainly based on Magnetic resonance imaging.
214789946|NCT00805909|DRUG|NI-0401|5 daily infusions with escalating doses of NI-0401
214789947|NCT04897828|DEVICE|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
214789948|NCT00218309|DRUG|Hydromorphone|
214789949|NCT05635149|RADIATION|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
214789950|NCT04117165|DIAGNOSTIC_TEST|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
214789951|NCT04117165|DRUG|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
214789952|NCT05353556|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
214789953|NCT05353556|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
214789954|NCT01694511|PROCEDURE|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
214789955|NCT01694511|PROCEDURE|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
214789956|NCT05113225|PROCEDURE|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
214789957|NCT04206852|PROCEDURE|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
214789958|NCT03075033|DEVICE|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
214789959|NCT03075033|DEVICE|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
214789960|NCT02920164|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
214789961|NCT02920164|DEVICE|Placebo acupuncture|Placebo acupuncture with placebo needles
214789962|NCT03222141|DEVICE|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
214789963|NCT04495491|OTHER|pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
214789964|NCT04495491|OTHER|plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
214789965|NCT04495491|OTHER|mixing mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
214789966|NCT04086706|PROCEDURE|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
214789967|NCT02448459|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
214789968|NCT06201624|DRUG|Isotretinoin|Patients will receive 1mg/kg/day for 3 months
214789969|NCT06201624|DRUG|Triple combination formula|Patients are instructed to apply the triple combination formula at night daily for 3 months
214789970|NCT00751374|DRUG|gentamicin|topical gentamicin cream on daily basis
214789971|NCT00751374|DRUG|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
214789972|NCT00798889|DRUG|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
214789973|NCT01641744|BEHAVIORAL|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
214789974|NCT01641744|BEHAVIORAL|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
214789975|NCT03674164|OTHER|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
214789976|NCT00617461|DRUG|GEn 1200mg/day|1200mg/day gabapentin enacarbil
214789977|NCT00617461|DRUG|GEn 3600mg/day|3600mg/day gabapentin enacarbil
214789978|NCT03833388|DRUG|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
214789979|NCT03833388|DRUG|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
214789980|NCT02381821|OTHER|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
214789981|NCT02381821|DRUG|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
214789982|NCT05895370|BIOLOGICAL|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
214789983|NCT05895370|DRUG|Interleukin-2|500,000IU/m\^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
214789984|NCT04414501|BEHAVIORAL|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
214789985|NCT03314766|DEVICE|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
214789986|NCT00358826|DRUG|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
214789987|NCT00358826|DRUG|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
214789988|NCT05259111|OTHER|Home hospital|Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
214789989|NCT00903383|DRUG|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
214789990|NCT00903383|DRUG|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
214789991|NCT00903383|DRUG|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
214789992|NCT00903383|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
214789993|NCT01195922|DRUG|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
214789994|NCT00997581|DRUG|apremilast|apremilast 20 mg taken twice daily by mouth
214789995|NCT00997581|DRUG|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
214789996|NCT04687163|DRUG|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
214789997|NCT04687163|DRUG|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
214789998|NCT04687163|DRUG|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
214789999|NCT01727479|OTHER|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
214790000|NCT01727479|OTHER|Placebo|
214790001|NCT00743067|DRUG|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
214790002|NCT05128409|DRUG|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
214790003|NCT05128409|DRUG|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
214790004|NCT01110681|DEVICE|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
214790005|NCT01821625|DRUG|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
214790006|NCT03868449|OTHER|Question Prompt List|Question prompt list
214790007|NCT03868449|OTHER|3 questions|3 questions from the AskShareKnow model
214790008|NCT04170166|PROCEDURE|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
214790009|NCT04170166|PROCEDURE|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
214790010|NCT04571242|DEVICE|DTM Programming|DTM-SCS programming
214790011|NCT04571242|DEVICE|Conventional SCS programming|Conventional SCS programming
214790012|NCT02837978|DRUG|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
214790013|NCT02837978|DRUG|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
214790014|NCT03019393|OTHER|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
214790015|NCT05029323|DIAGNOSTIC_TEST|Fast HUTT|Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
214790016|NCT05029323|DIAGNOSTIC_TEST|Conventional HUTT|Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
214790017|NCT06135532|PROCEDURE|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
214790018|NCT00977964|OTHER|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
214790019|NCT00977964|OTHER|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
214790020|NCT00977964|OTHER|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
214790021|NCT00977964|OTHER|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
214790022|NCT00977964|OTHER|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
214790023|NCT00977964|OTHER|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
214790024|NCT00320593|DEVICE|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
214790025|NCT00320593|DEVICE|Single Vision Lenses (SVLs)|Single vision lenses
214790026|NCT03485131|DEVICE|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
214790027|NCT03485131|DEVICE|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
214790028|NCT06282588|DRUG|Darolutamide|2x300 mg tablets twice daily, for up to 96 weeks
214790029|NCT06282588|DRUG|Darolutamide matched placebo|2x300 mg tablets twice daily, for up to 96 weeks
214790030|NCT06282588|RADIATION|Radiotherapy|Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
214790031|NCT06282588|DRUG|Zoladex 3.6Mg Implant|3.6 mg, subcutaneous use
214790032|NCT06282588|DRUG|Zoladex LA|10.8 mg, subcutaneous use
214790033|NCT06282588|DRUG|Decapeptyl sustained release 22.5 mg|22.5 mg, intramusculair injection
214790034|NCT06282588|DRUG|Decapeptyl sustained release 11.25 mg|11.25 mg, intramusculair injection
214790035|NCT06282588|DRUG|Depo-Eligard 45 mg|45 mg, subcutaneous use
214790036|NCT06282588|DRUG|Depo-Eligard 22.5 mg|22.5 mg, subcutaneous use
214790037|NCT06282588|DRUG|Depo-Eligard 7.5 mg|7.5 mg, subcutaneous use
214790038|NCT06282588|DRUG|Firmagon 120 MG Injection|120 mg, subcutaneous use
214790039|NCT06282588|DRUG|Firmagon 80 MG Injection|80 mg, subcutaneous use
214790040|NCT06282588|DRUG|Docetaxel|75 mg per square m, IV infusion
214790041|NCT00338494|DRUG|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
214790042|NCT04881422|BEHAVIORAL|B-HIPE (Brief High Impact Preparatory Experience)|The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
214790043|NCT06056700|BEHAVIORAL|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
214790044|NCT03086668|PROCEDURE|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
214790045|NCT03086668|PROCEDURE|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
214790046|NCT02118701|OTHER|Shared Decision-Making educational training|
214790047|NCT00662714|DRUG|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
214790048|NCT00662714|DRUG|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
214790049|NCT01217203|DRUG|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
214790050|NCT00457665|DRUG|Nelfinavir|
214790051|NCT00457665|DRUG|Efavirenz|
214790052|NCT00003054|DRUG|paclitaxel|
214790053|NCT00212771|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
214790054|NCT00212771|DRUG|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
214790055|NCT06039787|BEHAVIORAL|single bout of moderate intensity continuous training (MICT)|the MICT consists of 60 min continuous cycling
214790056|NCT06039787|BEHAVIORAL|single bout of High Intensity Interval Training (HIIT)|HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
214790057|NCT06039787|BEHAVIORAL|waiting control|sitting in a waiting room for 60 min
214790058|NCT01716754|DRUG|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
214790059|NCT01716754|DRUG|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
214790060|NCT01716754|DRUG|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
214790061|NCT00565370|DRUG|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
214790062|NCT01847196|DEVICE|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
214790063|NCT04371419|BEHAVIORAL|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later."
214790064|NCT03759769|OTHER|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
214790065|NCT03759769|OTHER|Video game|'Kart' driving video game
214790066|NCT02931565|DRUG|Olinciguat|oral tablet
214790067|NCT02931565|DRUG|Matching Placebo|oral tablet
214790068|NCT04127591|OTHER|exosome|Collect exosomes in peripheral blood of patients and extract miRNAs from them.
214790069|NCT00638157|DRUG|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
214790070|NCT00638157|DRUG|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
214790071|NCT06252194|DRUG|Metformin and doxycycline|Metformin 500 mg tablet twice daily
214790072|NCT03208959|DRUG|HTI-1090|IDO/TDO inhibitor
214790073|NCT00280787|DRUG|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
214790074|NCT00280787|DRUG|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
214790075|NCT00280787|DRUG|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
214790076|NCT00280787|DRUG|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
214790077|NCT00280787|RADIATION|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
214790078|NCT01871987|DRUG|FK949E|oral
214790079|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
214790080|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
214790081|NCT06163833|OTHER|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
214790082|NCT01283633|DEVICE|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
214790083|NCT03622333|GENETIC|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
214790084|NCT04370145|DRUG|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
214790085|NCT04370145|DRUG|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
214790086|NCT04370145|DRUG|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
214790087|NCT03801837|DIETARY_SUPPLEMENT|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\]
214790088|NCT03801837|DIETARY_SUPPLEMENT|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
214790089|NCT02532777|DRUG|Prednisone|
214790090|NCT02532777|DRUG|Cyclophosphamide(CTX)|
214790091|NCT02532777|DRUG|Mycophenolate mofetil(MMF)|
214790092|NCT02532777|DRUG|Leflunomide(LEF)|
214790093|NCT02532777|DRUG|Angiotensin-converting enzyme inhibitor(ACEI)|
214790094|NCT02532777|DRUG|Methylprednisolone|
214790095|NCT02544061|BIOLOGICAL|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
214790096|NCT02544061|DRUG|Placebo|single subcutaneous dose
214790097|NCT00189397|DRUG|azathioprine and corticosteroids for Parthenium dermatitis|
214790098|NCT04451265|OTHER|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
214790099|NCT05941091|BEHAVIORAL|HafifMod Programme|"MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos."
214790100|NCT05941091|BEHAVIORAL|Distribution of printed material|In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
214790101|NCT03459326|OTHER|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)"
214790102|NCT04221581|DEVICE|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
214790103|NCT04756141|DEVICE|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
214790104|NCT04177810|DRUG|Cemiplimab|Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
214790105|NCT04177810|DRUG|Plerixafor|Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
214790106|NCT01851590|DEVICE|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
214790107|NCT01851590|DRUG|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
214790108|NCT01851590|DRUG|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
214790109|NCT03267030|DRUG|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
214790110|NCT00417313|DEVICE|periosteal electro-acupuncture (osteopuncture).|
214790111|NCT01714505|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
214790112|NCT00394745|DRUG|Valsartan|
214790113|NCT05571761|BEHAVIORAL|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
214790114|NCT03082456|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
214790115|NCT03082456|DIAGNOSTIC_TEST|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
214790116|NCT03082456|DIAGNOSTIC_TEST|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
214790117|NCT01438554|DRUG|Pazopanib|
214790118|NCT01438554|DRUG|GSK1120212|
214790119|NCT01513057|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
214790120|NCT01513057|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
214790121|NCT03103009|DRUG|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
214790122|NCT03229993|DIAGNOSTIC_TEST|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
214790123|NCT03128593|DRUG|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
214790124|NCT05618483|DEVICE|Nasal Spray|The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
214790125|NCT02611752|DRUG|CAM2038|CAM2038 subcutaneous injection
214790126|NCT01735045|DEVICE|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
214790127|NCT01735045|DEVICE|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
214790128|NCT04300777|DEVICE|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
214790129|NCT00310856|BIOLOGICAL|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
214790130|NCT00310856|BIOLOGICAL|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
214790131|NCT00310856|BIOLOGICAL|DTaP-Hib-IPV|
214790132|NCT00310856|BIOLOGICAL|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
214790133|NCT00310856|BIOLOGICAL|MMR|
214790134|NCT00310856|BIOLOGICAL|Varicella|
214790135|NCT02047942|BEHAVIORAL|Center-based cardiac rehabilitation|
214790136|NCT02047942|BEHAVIORAL|Home-based training with telemonitoring guidance|
214790137|NCT05343949|OTHER|HIIT exercise program ABC|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
214790138|NCT05343949|OTHER|HIIT exercise program CAB|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
214790139|NCT05343949|OTHER|HIIT exercise program BCA|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
214790140|NCT02947113|DRUG|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
214790141|NCT02947113|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
214790142|NCT02947113|DRUG|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
214790143|NCT02947113|DRUG|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
214790144|NCT02984839|DEVICE|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
214790145|NCT02657993|BEHAVIORAL|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
214790146|NCT02657993|BEHAVIORAL|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
214790147|NCT00443352|DRUG|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
214790148|NCT02462070|DRUG|IDP-118 Lotion|Lotion
214790149|NCT02462070|DRUG|IDP-118 Vehicle Lotion|Lotion
214790150|NCT03449628|DIETARY_SUPPLEMENT|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
214790151|NCT03449628|DIETARY_SUPPLEMENT|PLACEBO|1 capsule, b.i.d. for 12 weeks
214790152|NCT03954028|PROCEDURE|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
214790153|NCT00321711|DRUG|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
214790154|NCT00321711|BIOLOGICAL|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
214790155|NCT00321711|DRUG|Azacitidine|hypomethylating agent
214790156|NCT00321711|DRUG|Decitabine|hypomethylating agent
214790157|NCT00508378|BEHAVIORAL|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
214790158|NCT00508378|BEHAVIORAL|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
214790159|NCT01643083|DRUG|Rifaximin|Rifaximin 400mg tid for 2 wk
214790160|NCT01643083|DRUG|Placebo|Placebo for 2 week
214790161|NCT05544383|BEHAVIORAL|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
214790162|NCT05544383|OTHER|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
214790163|NCT02141178|DRUG|Bupivacaine|
214790164|NCT02141178|DRUG|Exparel|
214790165|NCT00059995|BIOLOGICAL|iratumumab|
214790166|NCT02843074|DRUG|elotuzumab|Given intravenously (IV)
214790167|NCT02843074|DRUG|Lenalidomide|Given by IV
214790168|NCT02843074|DRUG|Dexamethasone|Given orally (PO) or by IV
214790169|NCT02843074|PROCEDURE|autologous stem cell transplantation|
214790170|NCT00005042|DRUG|semaxanib|
214790171|NCT01696864|DEVICE|Hand tutor rehabilitation device|A rehabilitation device for the hand
214790172|NCT01696864|DEVICE|Arm tutor rehabilitation device|A rehabilitation device for the arm
214790173|NCT06546280|DRUG|Camrelizumab|Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
214790174|NCT06546280|DRUG|Apatinib|Apatinib 250 mg will be taken orally once daily.
214790175|NCT00005782|DRUG|Granulocyte colony-stimulating factor|
214790176|NCT00005782|PROCEDURE|Leukapheresis|
214790177|NCT01832090|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
214790178|NCT00133302|DRUG|Standard CHOP|
214790179|NCT00133302|DRUG|Bi-CHOP (dose intensified CHOP)|
214790180|NCT05049889|OTHER|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
214790181|NCT05049889|OTHER|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
214790182|NCT05049889|DEVICE|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
214790183|NCT05049889|DEVICE|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
214790184|NCT05049889|BIOLOGICAL|Blood collection|Several blood samples will be collected at visit 1 and 2.
214790185|NCT06527092|DEVICE|Virtual Reality|VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems
214790186|NCT06527092|DEVICE|Bubbles|A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
214790187|NCT00522288|DEVICE|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
214790188|NCT00522288|DEVICE|Spectacle|Spectacles for the treatment of myopia
214790189|NCT01077206|DRUG|Simvastatin|80mg daily versus 40mg daily, for 21 days.
214790190|NCT00058357|DRUG|lidocaine|
214790191|NCT00058357|OTHER|placebo|
214790192|NCT02343887|OTHER|neuropsychological tests|
214790193|NCT02343887|OTHER|STAI-Y scale for anxiety|
214790194|NCT02343887|OTHER|Beck scale for depression|
214790195|NCT02343887|OTHER|without intervention|
214790196|NCT01982487|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
214790197|NCT01982487|DRUG|IDO1 inhibitor INCB024360|Given PO
214790198|NCT01982487|OTHER|laboratory biomarker analysis|Correlative studies
214790199|NCT01982487|OTHER|pharmacological study|Correlative studies
214790200|NCT05081674|DRUG|Alectinib|600mg 1OD
214790201|NCT05081674|DRUG|Pembrolizumab|200mg every 21 days
214790202|NCT05081674|DRUG|Nivolumab|6mg/kg every 4 weeks
214790203|NCT05081674|DRUG|Erlotinib|150mg
214790204|NCT01387100|BEHAVIORAL|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
214790205|NCT05303142|OTHER|Heat Tolerance Assessment|60-90 minutes exercise in hot (34 °C; 45% R.H.) conditions at 60%VO2max
214790206|NCT04025385|OTHER|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
214790207|NCT05157607|BEHAVIORAL|Family Connections Protocol for Relatives of Patients with SBD.|Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
214790208|NCT05157607|BEHAVIORAL|Treatment as Usual Optimized Protocol (TAU-O)|Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.
214790209|NCT02325700|PROCEDURE|Aortic repair|Aortic bypass
214790210|NCT03846271|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
214790211|NCT03846271|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
214790212|NCT00939133|DRUG|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
214790213|NCT00939133|DRUG|vehicle gel|Placebo
214790214|NCT03393442|DIAGNOSTIC_TEST|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
214790215|NCT01536756|OTHER|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
214790216|NCT01536756|OTHER|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
214790217|NCT02600169|DRUG|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
214790218|NCT05332210|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
214790219|NCT04202900|OTHER|phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
214790220|NCT01075620|DEVICE|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
214790221|NCT01075620|DEVICE|LPS RP|non-posterior stabilized rotating platform design
214790222|NCT01799733|OTHER|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
214790223|NCT01799733|OTHER|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
214790224|NCT03158259|OTHER|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
214790225|NCT01211769|DRUG|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
214790226|NCT01211769|DRUG|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
214790227|NCT01211769|DRUG|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
214790228|NCT01211769|DRUG|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
214790229|NCT01214330|DEVICE|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
214790230|NCT04965610|OTHER|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
214790231|NCT04965610|OTHER|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
214790232|NCT00349063|DEVICE|soft contact lens|
214790233|NCT00349063|DRUG|Soft contact lens multipurpose disinfection regimen|
214790234|NCT06383559|DRUG|Lenvatinib and Sintilimab|XELOX regimen combined with Sintilimab and Lenvatinib
214790235|NCT01996176|BEHAVIORAL|Intervention group|"The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
214790236|NCT01996176|BEHAVIORAL|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
214790237|NCT04222322|DEVICE|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
214790238|NCT04222322|OTHER|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
214790239|NCT04639687|BEHAVIORAL|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
214790240|NCT01730859|OTHER|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
214790241|NCT01055444|DRUG|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
214790242|NCT01348542|DRUG|Trazodone|50 mg once a day, for 3 months
214790243|NCT01348542|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
214790244|NCT00038519|DRUG|Amprenavir/ritonavir|
214790245|NCT00038519|DRUG|Saquinavir/ritonavir|
214790246|NCT03409679|DRUG|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
214790247|NCT03409679|DRUG|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
214790248|NCT00001128|DRUG|Interleukin-12|
214790249|NCT00001128|DRUG|Paromomycin sulfate|
214790250|NCT00001128|DRUG|Azithromycin|
214790251|NCT04996810|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
214790252|NCT04996810|BIOLOGICAL|Botox®|Botulinum toxin Type A
214790253|NCT04866485|DRUG|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
214790254|NCT00884130|PROCEDURE|laparoscopic colorectal resection|
214790255|NCT00884130|PROCEDURE|open colorectal resection|
214790256|NCT03402893|DRUG|ONEXTON Topical Gel|Onexton gel applied once daily to face
214790257|NCT00852085|BEHAVIORAL|Enhanced community service|Two educational sessions and volunteering at a local community service site
214790258|NCT00852085|BEHAVIORAL|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
214790259|NCT00016055|BIOLOGICAL|lymphokine-activated killer cells|
214790260|NCT00016055|DRUG|temozolomide|
214790261|NCT04139174|PROCEDURE|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
214790262|NCT05055791|DRUG|SYHX1903|SYHX1903 tablets, orally, qd
214790263|NCT01484028|DEVICE|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
214790264|NCT01484028|DEVICE|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
214790265|NCT01484028|DEVICE|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
214790266|NCT02414425|PROCEDURE|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
214790267|NCT02414425|PROCEDURE|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
214790268|NCT02414425|DRUG|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
214790269|NCT01956227|BEHAVIORAL|Home-based exercise|exercise to look at balance and lower limb strength record in diary
214790270|NCT01956227|BEHAVIORAL|Education|sessions to discuss self-management ideas to modify risk of falling
214790271|NCT01956227|BEHAVIORAL|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
214790272|NCT00047242|DRUG|7-hydroxystaurosporine|
214790273|NCT00047242|DRUG|irinotecan hydrochloride|
214790274|NCT05562336|DEVICE|Optical coherence tomography angiography|Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
214790275|NCT03500965|BEHAVIORAL|text-only PWL|control condition (no image)
214790276|NCT03500965|BEHAVIORAL|graphic PWL|pictorial warning
214790277|NCT03500965|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
214790278|NCT03500965|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
214790279|NCT01308281|PROCEDURE|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
214790280|NCT01308281|PROCEDURE|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
214790281|NCT04235647|OTHER|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
214790282|NCT04235647|OTHER|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
214790283|NCT02922959|BEHAVIORAL|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
214790284|NCT02922959|DRUG|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
214790285|NCT02922959|BEHAVIORAL|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
214790286|NCT05178589|DEVICE|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
214790287|NCT05178589|DEVICE|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
214790288|NCT05928000|DRUG|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
214790289|NCT00492206|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
214790290|NCT00981604|PROCEDURE|SILS|Single Incision Laparoscopic Cholecystectomy
214790291|NCT00981604|PROCEDURE|Standard Laparoscopic Cholecystectomy|4 port technique
214790292|NCT01199601|BEHAVIORAL|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
214790293|NCT00209209|DRUG|Rituximab|antibody
214790294|NCT00209209|DRUG|Cyclophosphamide|chemotherapy
214790295|NCT00209209|DRUG|Doxorubicin|chemotherapy
214790296|NCT00209209|DRUG|Vincristine|chemotherapy
214790297|NCT00209209|DRUG|Prednisone|coricosteroide
214790298|NCT00209209|DRUG|Fludarabine|chemotherapy
214790299|NCT00209209|DRUG|Interferon-alpha|cytokine
214790300|NCT00209209|DRUG|pegylated formula Interferon-alpha 2b|cytokine
214790301|NCT00209209|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
214790302|NCT00209209|PROCEDURE|chemotherapy: R-FC|immuno-chemotherapy
214790303|NCT00209209|PROCEDURE|Interferon maintenance|cytokine
214790304|NCT00209209|PROCEDURE|Rituximab maintenance|antibody
214790305|NCT00790374|DRUG|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
214790306|NCT00790374|DRUG|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
214790307|NCT00790374|DRUG|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
214790308|NCT01555606|OTHER|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
214790309|NCT03361514|BEHAVIORAL|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
214790310|NCT03361514|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
214790311|NCT03717389|OTHER|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
214790312|NCT03107949|DEVICE|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
214790313|NCT01000857|DRUG|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
214790314|NCT02273674|DEVICE|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
214790315|NCT02273674|DEVICE|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
214790316|NCT00146770|BIOLOGICAL|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
214790317|NCT00146770|BIOLOGICAL|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
214790318|NCT00146770|BIOLOGICAL|placebo|Placebo for 26 weeks
214790319|NCT01398579|PROCEDURE|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
214790320|NCT01789008|OTHER|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
214790321|NCT04319666|DEVICE|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
214790322|NCT03867383|DRUG|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
214790323|NCT03867383|DRUG|Placebo|60 milliliters normal saline
214790324|NCT02861352|OTHER|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
214790325|NCT03291977|DRUG|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
214790326|NCT03291977|PROCEDURE|White-light surgery|The surgery will be performed under classical conditions
214790327|NCT00036413|DRUG|TCH346|
214790328|NCT04502875|DRUG|PRP|Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
214790329|NCT04502875|DRUG|PPP|PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
214790330|NCT01842048|OTHER|Hyperthermia|
214790331|NCT01842048|RADIATION|External-beam radiotherapy|
214790332|NCT01505465|DRUG|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
214790333|NCT01505465|DRUG|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
214790334|NCT05133895|DRUG|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
214790335|NCT05235308|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
214790336|NCT02742779|DRUG|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
214790337|NCT02742779|DRUG|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
214790338|NCT03013166|OTHER|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
214790339|NCT03120156|DEVICE|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
214790340|NCT03120156|DEVICE|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
214790341|NCT03120156|OTHER|No insoles|control group with no insoles in the shoes
214790342|NCT04058483|OTHER|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
214790343|NCT03830528|DRUG|KW-6356 Low Dose|KW-6356 will be administered as single doses.
214790344|NCT03830528|DRUG|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
214790345|NCT03830528|DRUG|KW-6356 High Dose|KW-6356 will be administered as single doses.
214790346|NCT03830528|DRUG|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
214790347|NCT03830528|DRUG|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
214790348|NCT03830528|DRUG|Placebo|All study cohorts (except Part C) are placebo controlled.
214790349|NCT03561948|PROCEDURE|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
214790350|NCT03561948|PROCEDURE|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
214790351|NCT02185781|OTHER|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
214790352|NCT03775681|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
214790353|NCT03775681|OTHER|Interview|Ancillary studies
214790354|NCT03775681|DEVICE|Laryngeal Mask Airway|Wear LMA
214790355|NCT03151239|DIETARY_SUPPLEMENT|NMN supplement|Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
214790356|NCT03151239|OTHER|Placebo|Intervention will last at least 8 weeks in the form of two capsules.
214790357|NCT00788619|PROCEDURE|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
214790358|NCT00788619|PROCEDURE|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
214790359|NCT01855126|OTHER|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
214790360|NCT01855126|OTHER|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
214790361|NCT06496087|DIETARY_SUPPLEMENT|DEPREXIL|The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
214790362|NCT01063530|DEVICE|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
214790363|NCT01063530|DEVICE|DIstilled water|Application of distilled water in cervical lesions
214790364|NCT06537895|OTHER|EDCRN questionnaires|Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset.
214790365|NCT01149616|DRUG|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
214790366|NCT01149616|DRUG|placebo|2 ml normal saline IV x1
214790367|NCT05351385|PROCEDURE|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
214790368|NCT05351385|PROCEDURE|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
214790369|NCT05351385|PROCEDURE|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
214790370|NCT05351385|PROCEDURE|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
214790371|NCT05351385|PROCEDURE|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
214790372|NCT05351385|PROCEDURE|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
214790373|NCT00900809|BIOLOGICAL|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
214790374|NCT05608590|DRUG|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
214790375|NCT05491564|DEVICE|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
214790376|NCT04733131|DRUG|Conversion to a belatacept regimen|belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
214790377|NCT04078230|PROCEDURE|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
214790378|NCT00708630|BEHAVIORAL|Extended information on side effects|More detailed information on possible side effects of vaccine
214790379|NCT00146289|DRUG|MICARDIS® (telmisartan)|
214790380|NCT03776409|DRUG|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
214790381|NCT03776409|DRUG|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
214790382|NCT00314379|DRUG|Vitamin E 400IU/day|
214790383|NCT03475732|DRUG|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
214790384|NCT04633759|OTHER|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
214790385|NCT01488266|DRUG|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
214790386|NCT01488266|DRUG|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
214790387|NCT04605952|DIAGNOSTIC_TEST|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
214790388|NCT01357356|DRUG|SER120 (750 ng/day)|
214790389|NCT01357356|DRUG|SER120 (1000 ng/day)|SER120 (1000 ng/day)
214790390|NCT01357356|DRUG|SER120 (1500 ng/day)|
214790391|NCT01357356|DRUG|Placebo|
214790392|NCT05448703|OTHER|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
214790393|NCT01363609|DRUG|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
214790394|NCT01363609|DRUG|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
214790395|NCT01363609|DRUG|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
214790396|NCT03944785|DRUG|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
214790397|NCT01960933|PROCEDURE|Percutaneous coronary intervention|
214790398|NCT01960933|PROCEDURE|FFR|
214790399|NCT03201783|OTHER|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
214790400|NCT03201783|OTHER|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
214790401|NCT02410148|DEVICE|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
214790402|NCT01748890|DEVICE|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
214790403|NCT05368142|DRUG|Nocardia rubra Cell Wall Skeleton|Nocardia rubra cell wall skeleton for external application
214790404|NCT05368142|DRUG|Silver ions dressing|Silver ions dressing for external application
214790405|NCT02669264|DRUG|ADCT-402|Intravenous infusion
214790406|NCT06483152|OTHER|Metro Transit Pass|A transit pass that enables riders to use the Minneapolis Metro Transit system that will paid for by the study for 6 months
214790407|NCT06483152|OTHER|Standard of Care|The current standard of care for Ryan White eligible clients is to receive two $10 bus cards a month from a case manager
214790408|NCT02521675|BEHAVIORAL|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
214790409|NCT02521675|BEHAVIORAL|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90min after lunch These activities shall not exceed one hour"
214790410|NCT02521675|BEHAVIORAL|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
214790411|NCT02521675|DEVICE|Holter Glycemic Ipro2, Medtronic|
214790412|NCT00002407|DRUG|Indinavir sulfate|
214790413|NCT00002407|DRUG|Nevirapine|
214790414|NCT00002407|DRUG|Lamivudine|
214790415|NCT00002407|DRUG|Stavudine|
214790416|NCT00002407|DRUG|Didanosine|
214790417|NCT03577184|DRUG|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
214790418|NCT03731351|PROCEDURE|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
214790419|NCT03967236|OTHER|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
214790420|NCT02347930|OTHER|kidney ultrasound|kidney ultrasound
214790421|NCT04978025|DRUG|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
214790422|NCT04978025|DRUG|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
214790423|NCT04501471|BEHAVIORAL|SAAF-T|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
214790424|NCT04501471|BEHAVIORAL|Fuel for Families|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
214790425|NCT05718388|OTHER|Physical therapy exercises|For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
214790426|NCT05718388|OTHER|Isokinetic training|Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
214790427|NCT02100852|DRUG|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
214790428|NCT05720481|OTHER|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
214790429|NCT05720481|OTHER|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
214790430|NCT05072691|DIAGNOSTIC_TEST|CSF immunoglobulin (Ig) free light chains (FLC) dosage|CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
214790431|NCT04275947|OTHER|nCapp, a cell phone-based auto-diagnosis system|Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
214790432|NCT04003870|DEVICE|CASO|Customized arch support orthoses (CASO)
214790433|NCT04003870|DEVICE|HL|Orthotic Heel Lift (HL)
214790434|NCT03716505|DEVICE|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
214790435|NCT03716505|DEVICE|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
214790436|NCT06226454|DRUG|VX-993|Suspension for oral administration.
214790437|NCT06226454|DRUG|Placebo|Suspension for oral administration.
214790438|NCT01688037|DRUG|NBI-98854|25 mg capsule
214790439|NCT01688037|DRUG|NBI-98854|50 mg capsule
214790440|NCT01688037|DRUG|Placebo|
214790441|NCT00328874|DRUG|Coenzyme Q10|
214790442|NCT04646122|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography parameters
214790443|NCT03776851|DRUG|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
214790444|NCT02502409|OTHER|Standard care with blood and urine sample collection|
214790445|NCT04179591|OTHER|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
214790446|NCT04179591|OTHER|Orthesis|Customized arch support insoles
214790447|NCT00468741|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
214790448|NCT00468741|BEHAVIORAL|CHESS|informational services of CHESS available to subject
214790449|NCT00468741|BEHAVIORAL|CHESS|CHESS informational services and social support available to subject
214790450|NCT02116413|PROCEDURE|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
214790451|NCT02116413|PROCEDURE|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
214790452|NCT03982849|DRUG|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
214790453|NCT03982849|DRUG|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
214790454|NCT03363282|PROCEDURE|Pterygium Excision|Pterygium excision is the first step for repair
214790455|NCT06049667|DRUG|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
214790456|NCT01420835|OTHER|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
214790457|NCT01420835|OTHER|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
214790458|NCT00618397|DRUG|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
214790459|NCT05544851|OTHER|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
214790460|NCT04036383|OTHER|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
214790461|NCT04036383|OTHER|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
214790462|NCT04036383|OTHER|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
214790463|NCT06186167|PROCEDURE|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
214790464|NCT02659267|BEHAVIORAL|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
214790465|NCT06527001|OTHER|No intervention|This is an observational study and did not involve interventions.
214790466|NCT02678897|DRUG|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
214790467|NCT02678897|DRUG|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
214790468|NCT03518697|BEHAVIORAL|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
214790469|NCT00141596|DRUG|Cardura XL 4 mg bd|
214790470|NCT00141596|DRUG|Amiloride 5 mg bd|
214790471|NCT00141596|DRUG|Furosemide 40 mg bd|
214790472|NCT01168128|OTHER|Tailored Change Strategy|e.g. Education, decision support tools
214790473|NCT02032290|PROCEDURE|Assessment of Coronary Flow Reserve|
214790474|NCT02032290|PROCEDURE|Percutaneous coronary intervention|
214790475|NCT02032290|DRUG|ticagrelor loading|
214790476|NCT02032290|DRUG|Clopidogrel loading|
214790477|NCT02611999|BEHAVIORAL|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
214790478|NCT02611999|BEHAVIORAL|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
214790479|NCT03646253|OTHER|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
214790480|NCT01879800|BEHAVIORAL|Acceptance and Commitment Therapy plus Illness Management|
214790481|NCT05684926|OTHER|Telerehabilitation yoga|Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
214790482|NCT00846196|DRUG|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
214790483|NCT00846196|DRUG|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
214790484|NCT02514590|DEVICE|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
214790485|NCT02401893|BIOLOGICAL|Influenza Vaccine|Everyone immunized as recommended by current guidelines
214790486|NCT03429296|OTHER|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
214790487|NCT04277195|DIAGNOSTIC_TEST|SPAG5 Assay|Testing for SPAG5 expression in the tumour.
214790488|NCT04062461|OTHER|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
214790489|NCT04062461|OTHER|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
214790490|NCT03473470|DEVICE|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
214790491|NCT03473470|DEVICE|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
214790492|NCT04896359|DIETARY_SUPPLEMENT|Vitamin C|12.5 grams of ascorbic acid
214790493|NCT04896359|OTHER|Placebo|vehicle
214790494|NCT01623232|BIOLOGICAL|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~1. Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~2. Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~3. Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
214790495|NCT01623232|BIOLOGICAL|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4\. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
214790496|NCT03280537|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
214790497|NCT03280537|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
214790498|NCT04078139|DRUG|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214790499|NCT04078139|DRUG|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214790500|NCT02751632|BEHAVIORAL|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
214790501|NCT02751632|BEHAVIORAL|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
214790502|NCT02751632|DRUG|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
214790503|NCT02751632|DRUG|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
214790504|NCT02751632|BEHAVIORAL|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
214790505|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
214790506|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
214790507|NCT03908112|BEHAVIORAL|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
214790508|NCT03908112|BEHAVIORAL|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
214790509|NCT03908112|BEHAVIORAL|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
214790510|NCT01526915|PROCEDURE|Bone curettage + PRF|Bone curettage and PRF insertion
214790511|NCT01526915|PROCEDURE|Bone curettage alone|Bone curettage without PRF insertion
214790512|NCT04365283|PROCEDURE|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
214790513|NCT04365283|OTHER|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
214790514|NCT03083132|DRUG|modafinil 50mg|1 capsule oral daily
214790515|NCT03083132|DRUG|Placebo oral capsule|1 capsule oral daily
214790516|NCT06541535|DRUG|Fluid resuscitation with isotonic saline only|"Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
214790517|NCT06541535|DRUG|Fluid resuscitation with Ringer Lactate|"Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
214790518|NCT06541275|DIAGNOSTIC_TEST|brain MRI and CT|The diagnostic tests will be conducted at 6, 12, and 24 months of follow-up.
214790519|NCT02995837|OTHER|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
214790520|NCT02995837|OTHER|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
214790521|NCT02995837|OTHER|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
214790522|NCT02995837|OTHER|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
214790523|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium"
214790524|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS)|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected"
214790525|NCT03878355|PROCEDURE|functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique with middle turbinate preservation
214790526|NCT01745328|DRUG|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
214790527|NCT01745328|DRUG|TCM|Subject is treated with TCM for 4 weeks.
214790528|NCT01745328|DRUG|LVX-AMX|treatment with placebo from 2 to 4 weeks.
214790529|NCT06210412|BEHAVIORAL|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
214790530|NCT02004847|DEVICE|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
214790531|NCT05409911|DRUG|S-217622|Tablet for oral administration
214790532|NCT00861783|DRUG|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
214790533|NCT00861783|DRUG|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
214790534|NCT03342898|BIOLOGICAL|YF-17D|YF-17D SC injection.
214790535|NCT03342898|BIOLOGICAL|TDV|TDV SC injection.
214790536|NCT03342898|DRUG|Placebo|Normal Saline (0.9% NaCl) SC injection.
214790537|NCT05866146|OTHER|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
214790538|NCT05866146|OTHER|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
214790539|NCT03565549|BEHAVIORAL|Mnemonic|A mnemonic used as a memory aid
214790540|NCT03565549|BEHAVIORAL|CCHR rule|A list of the CCHR items
214790541|NCT00000654|DRUG|Fialuridine|
214790542|NCT01903577|OTHER|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
214790543|NCT01903577|OTHER|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
214790544|NCT00043706|DRUG|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
214790545|NCT02745002|DEVICE|navigated bronchoscopy|
214790546|NCT03165565|BEHAVIORAL|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
214790547|NCT03165565|BEHAVIORAL|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
214790548|NCT03997448|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
214790549|NCT03997448|DRUG|Abemaciclib|Abemiciclib 150mg PO
214790550|NCT02661126|DRUG|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
214790551|NCT03110666|BIOLOGICAL|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
214790552|NCT05408286|BEHAVIORAL|administration of questionnaires|administration of questionnaires
214790553|NCT04208139|DIAGNOSTIC_TEST|IVUS|IVUS
214790554|NCT03932084|BEHAVIORAL|Control group|"During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
214790555|NCT03932084|BEHAVIORAL|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
214790556|NCT04758650|DRUG|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
214790557|NCT04632823|COMBINATION_PRODUCT|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
214790558|NCT01182233|RADIATION|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
214790559|NCT01544790|PROCEDURE|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
214790560|NCT03892759|OTHER|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
214790561|NCT04725149|OTHER|500 ml base solution|Color, taste, aroma, and calorie matched water base
214790562|NCT04725149|OTHER|500 ml containing 30 ml tart cherry concentrate diluted with water and base solution|Montmorency cherry concentrate
214790563|NCT04725149|OTHER|500 ml containing 60 ml tart cherry concentrate diluted with water only|Montmorency cherry concentrate
214790564|NCT03698526|DEVICE|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
214790565|NCT02912013|DEVICE|Me Mini|Home use hair removal device
214790566|NCT04914715|DEVICE|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
214790567|NCT04914715|DEVICE|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
214790568|NCT02361190|DRUG|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
214790569|NCT02361190|DRUG|Placebo|Administration of 1ml aqueous saline spray
214790570|NCT03916653|PROCEDURE|osseous resection using piezoelectric device in surgical crown lengthening|In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
214790571|NCT03916653|PROCEDURE|Osseous resection using conventional rotary instruments in surgical crown lengthening|For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
214790572|NCT01151813|DRUG|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
214790573|NCT01151813|DRUG|Placebo|Placebo
214790574|NCT02194309|DRUG|Telmisartan low|
214790575|NCT02194309|DRUG|Telmisartan high|
214790576|NCT02194309|DRUG|amlodipine|
214790577|NCT00521456|DRUG|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
214790578|NCT05624359|DRUG|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
214790579|NCT05624359|DRUG|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
214790580|NCT01361399|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
214790581|NCT01361399|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
214790582|NCT01361399|DRUG|Lidocain|Single oral application of Lidocain (as lozenge)
214790583|NCT01361399|DRUG|Placebo|Single oral application of Placebo (as lozenge)
214790584|NCT00395798|DEVICE|Soft or stiff cervical collar(device), neck school(behavior)|
214790585|NCT02620345|DRUG|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)"
214790586|NCT02620345|DRUG|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)"
214790587|NCT00423956|PROCEDURE|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
214790588|NCT00617110|OTHER|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
214790589|NCT00617110|OTHER|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
214790590|NCT06044181|PROCEDURE|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
214790591|NCT02772536|OTHER|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
214790592|NCT01519583|BEHAVIORAL|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
214790593|NCT01519583|BEHAVIORAL|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
214790594|NCT01519583|BEHAVIORAL|Control Group|Maintain usual physical activity, and return for follow-up measures.
214790595|NCT00600197|BEHAVIORAL|back school|A kind of educational program for low back pain
214790596|NCT06338397|OTHER|SCANN|Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
214790597|NCT01428505|RADIATION|[18F]PBR111|radioligand to assess binding to TSPO
214790598|NCT06267261|DEVICE|KOLMI® surgical face mask (OP-Air)|12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
214790599|NCT00087061|DRUG|gimatecan|
214790600|NCT02917447|BEHAVIORAL|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
214790601|NCT02917447|BEHAVIORAL|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
214790602|NCT05938153|OTHER|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
214790603|NCT02482805|BEHAVIORAL|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
214790604|NCT00440154|DRUG|AVE5530|
214790605|NCT00440154|DRUG|placebo|
214790606|NCT00440154|DRUG|ezetimibe|
214790607|NCT02347670|BEHAVIORAL|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
214790608|NCT02347670|BEHAVIORAL|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
214790609|NCT04590469|OTHER|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
214790610|NCT06081751|BEHAVIORAL|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
214790611|NCT06081751|BEHAVIORAL|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
214790612|NCT03890185|COMBINATION_PRODUCT|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
214790613|NCT03890185|DRUG|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
214790614|NCT03049683|OTHER|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
214790615|NCT01972022|DEVICE|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
214790616|NCT01972022|DEVICE|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
214790617|NCT04544176|OTHER|Observational|There will be no interventions in this study, it is purely observational using data already collected.
214790618|NCT01144663|BIOLOGICAL|Nimenrix™|4- or 3-dose intramuscular injection
214790619|NCT01144663|BIOLOGICAL|Menjugate®|3-dose intramuscular injection
214790620|NCT01144663|BIOLOGICAL|NeisVac-CTM|3-dose intramuscular injection
214790621|NCT01144663|BIOLOGICAL|Infanrix™ hexa|4-dose intramuscular injection
214790622|NCT01144663|BIOLOGICAL|Synflorix™|4-dose intramuscular injection
214790623|NCT05905848|DRUG|administering RASI (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
214790624|NCT05905848|DRUG|administering CCB (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
214790625|NCT05518435|OTHER|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
214790626|NCT05533346|BEHAVIORAL|with WISE (Walking Instruction based on Self-Efficacy)|Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
214790627|NCT05533346|BEHAVIORAL|without WISE (Walking Instruction based on Self-Efficacy)|The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
214790628|NCT05503004|BEHAVIORAL|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
214790629|NCT05503004|BEHAVIORAL|Standard care|Standard care before surgery
214790630|NCT03081767|DIAGNOSTIC_TEST|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
214790631|NCT04437342|OTHER|PHQ-9 (Patient Health Questionnaire) Depression Scale|9 question questionnaire for assessment of depression
214790632|NCT04437342|OTHER|GAD-7 (General Anxiety Disorder) scale|7 question questionnaire for assessment of General Anxiety Disorder
214790633|NCT04437342|OTHER|38 questions questionnaire|38 questions questionnaire
214790634|NCT04437342|OTHER|EPDS (Edinburgh Postnatal Depression Scale)|10 questions scale for detection of postpartum depression
214790635|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
214790636|NCT00147381|DRUG|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
214790637|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
214790638|NCT04826796|BEHAVIORAL|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
214790639|NCT03775395|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214790640|NCT03775395|DRUG|Sorafenib|400mg BID daily oral dosing
214790641|NCT03775395|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214790642|NCT03780894|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
214790643|NCT03780894|BIOLOGICAL|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
214790644|NCT03780894|DRUG|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
214790645|NCT01335477|DRUG|placebo|placebo matching BIBF 1120 BID
214790646|NCT01335477|DRUG|BIBF 1120|BIBF 1120 BID (twice daily)
214790647|NCT01400269|BEHAVIORAL|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
214790648|NCT05266781|PROCEDURE|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
214790649|NCT05266781|PROCEDURE|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
214790650|NCT00565981|DRUG|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
214790651|NCT00565981|DRUG|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
214790652|NCT05628623|DRUG|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
214790653|NCT05628623|DRUG|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
214790654|NCT05628623|DRUG|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
214790655|NCT05628623|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
214790656|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
214790657|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
214790658|NCT05455242|BEHAVIORAL|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
214790659|NCT02067793|DRUG|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
214790660|NCT02067793|DRUG|Placebo|Single intravenous injection into the arm on Day 0
214790661|NCT02067793|DRUG|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
214790662|NCT02067793|DRUG|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
214790663|NCT06437132|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
214790664|NCT01206361|DRUG|XALACOM|Xalacom eye drops
214790665|NCT01206361|DRUG|Duotrav|Duotrav eye drops
214790666|NCT01206361|DRUG|Ganfort|Ganfort eye drops
214790667|NCT00322257|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
214790668|NCT00322257|DRUG|insulin detemir|Injection s.c., 50% of daily dose
214790669|NCT00322257|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
214790670|NCT00190853|DRUG|Duloxetine|
214790671|NCT03085082|DIAGNOSTIC_TEST|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
214790672|NCT01506089|OTHER|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
214790673|NCT03385096|DRUG|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
214790674|NCT03385096|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
214790675|NCT03385096|DRUG|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
214790676|NCT03385096|DRUG|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
214790677|NCT02815904|OTHER|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
214790678|NCT02815904|OTHER|Conventional handling|Positioning of preterm infants for optimal physiological development
214790679|NCT02815904|OTHER|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
214790680|NCT02815904|OTHER|Kangaroo Mother Care|Providing skin to skin human touch
214790681|NCT00228904|PROCEDURE|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
214790682|NCT00228904|PROCEDURE|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
214790683|NCT02386592|DRUG|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
214790684|NCT02386592|BEHAVIORAL|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
214790685|NCT02386592|BEHAVIORAL|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
214790686|NCT02386592|OTHER|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
214790687|NCT04144296|DIAGNOSTIC_TEST|Study procedure|"* Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line"
214790688|NCT01423435|DRUG|TRK-100STP|oral
214790689|NCT00373724|PROCEDURE|radiofrequency denervation|
214790690|NCT01007916|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
214790691|NCT01007916|DEVICE|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
214790692|NCT06153524|BEHAVIORAL|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
214790693|NCT06153524|BEHAVIORAL|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
214790694|NCT05585463|PROCEDURE|acupuncture|Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
214790695|NCT02660190|DRUG|hexaminoavolunate|
214790696|NCT02660190|PROCEDURE|WL cystoscopy|
214790697|NCT00958581|DRUG|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
214790698|NCT00958581|DRUG|Normal Saline|Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
214790699|NCT00958581|DRUG|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
214790700|NCT00380003|DRUG|EVT 201|
214790701|NCT00349895|DEVICE|Coronary stent implantation|Percutaneous Coronary Intervention
214790702|NCT02546713|OTHER|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
214790703|NCT02546713|OTHER|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
214790704|NCT00682721|DRUG|Placebo|Matching placebo two pills once daily
214790705|NCT00682721|DRUG|Valacyclovir|1 gram daily x number of days active in the study
214790706|NCT03971942|BEHAVIORAL|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
214790707|NCT03971942|BEHAVIORAL|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
214790708|NCT04658875|DIETARY_SUPPLEMENT|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
214790709|NCT04658875|OTHER|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
214790710|NCT04658875|OTHER|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
214790711|NCT04658875|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
214790712|NCT04658875|OTHER|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
214790713|NCT04576806|OTHER|Body temperature|Warming of administered fluid bolus
214790714|NCT04576806|DRUG|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
214790715|NCT04576806|OTHER|Room temperature|Cooling of administered fluid bolus
214790716|NCT05774106|BEHAVIORAL|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
214790717|NCT01663909|BEHAVIORAL|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
214790718|NCT02509871|OTHER|Body composition measurement|DXA, impedance
214790719|NCT02040428|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|
214790720|NCT02040428|BIOLOGICAL|Topical hemostat|
214790721|NCT03339882|DRUG|Remifemin|Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
214790722|NCT03765268|PROCEDURE|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
214790723|NCT03765268|PROCEDURE|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
214790724|NCT00913965|DRUG|Atenolol Tablets 100 mg (Cord Laboratories)|
214790725|NCT00913965|DRUG|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
214790726|NCT01038557|BIOLOGICAL|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
214790727|NCT00631865|BIOLOGICAL|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
214790728|NCT02001779|DEVICE|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
214790729|NCT02001779|DEVICE|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
214790730|NCT05830006|PROCEDURE|Microfat grafting|Microfat grafting in cleft lip nasal deformities
214790731|NCT01417897|DRUG|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
214790732|NCT01417897|DRUG|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
214790733|NCT01417897|DRUG|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
214790734|NCT01508273|BEHAVIORAL|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
214790735|NCT01508273|BEHAVIORAL|Website|Website access given that allows participant to track exercise behavior and help to set goals.
214790736|NCT01508273|BEHAVIORAL|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
214790737|NCT01508273|BEHAVIORAL|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
214790738|NCT01508273|BEHAVIORAL|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
214790739|NCT03602690|DRUG|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
214790740|NCT00992264|BEHAVIORAL|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
214790741|NCT00992264|BEHAVIORAL|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
214790742|NCT00992264|BEHAVIORAL|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
215030929|NCT01058746|OTHER|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
215030930|NCT02085980|DEVICE|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
214790743|NCT00992264|BEHAVIORAL|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
214790744|NCT01135771|OTHER|glucose and insulin IV to alter blood glucose|
214790745|NCT04373109|BEHAVIORAL|Observation|Observation of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
214790746|NCT02046291|DRUG|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
214790747|NCT03471962|OTHER|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
214790748|NCT01927757|BIOLOGICAL|Etanercept|Administered by subcutaneous injection
214790749|NCT01927757|DRUG|Methotrexate|Background methotrexate at least 15 mg weekly
214790750|NCT02585674|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214790751|NCT02585674|DEVICE|MyStar DoseCoach|Glucose meter
214790752|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered as a single dose
214790753|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered as a single dose
214790754|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered as a single dose
214790755|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered as a single dose
214790756|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered as a single dose
214790757|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered daily for 14 days
214790758|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered daily for 14 days
214790759|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered daily for 14 days
214790760|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered daily for 14 days
214790761|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered daily for 14 days
214790762|NCT02110420|DRUG|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
214790763|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered as a single oral dose
214790764|NCT02110420|DRUG|CC-90001|CC-90001 720mg will be administered as a single oral dose
214790765|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered daily for 14 days
214790766|NCT04990622|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
214790767|NCT06465823|DRUG|Bumetanide|"Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing."
214790768|NCT06465823|DRUG|Placebo|Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
214790769|NCT01216111|DRUG|Paclitaxel Cisplatin|"Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6"
214790770|NCT01216111|DRUG|fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
214790771|NCT03454971|OTHER|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
214790772|NCT04050397|OTHER|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
214790773|NCT04050397|OTHER|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
214790774|NCT02457858|DRUG|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
214790775|NCT03804320|OTHER|Active Surveillance|
214790776|NCT01838902|DRUG|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
214790777|NCT01838902|DRUG|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
214790778|NCT01838902|DRUG|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
214790779|NCT01838902|DRUG|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
214790780|NCT03069079|PROCEDURE|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
214790781|NCT01499875|DRUG|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
214790782|NCT05411042|DEVICE|Dance somatosensory game|dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
214790783|NCT03265899|DRUG|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
214790784|NCT03265899|DRUG|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
214790785|NCT00604409|RADIATION|SIRT|Undergo SIRT
214790786|NCT00604409|DRUG|capecitabine|Given PO
214790787|NCT05226520|DIETARY_SUPPLEMENT|Experimental probiotic product|Probiotic supplementation
214790788|NCT05226520|OTHER|Placebo comparator|Placebo
214790789|NCT03295643|DEVICE|Mobile smoking cessation program and CO breath sensor device|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
214790790|NCT00899288|PROCEDURE|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
214790791|NCT00676000|PROCEDURE|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
214790792|NCT00676000|PROCEDURE|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
214790793|NCT02760550|OTHER|No intervention|Participants of all three groups completed a questionnaire.
214790794|NCT06358183|OTHER|No intervention|no intervention used
214790795|NCT05822596|DEVICE|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
214790796|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
214790797|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
214790798|NCT00449072|DRUG|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
214790799|NCT00449072|DRUG|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
214790800|NCT02326077|OTHER|Ultrasound|Monitoring of the mechanism of labor
214790801|NCT02326077|OTHER|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
214790802|NCT02326077|OTHER|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
214790803|NCT03395821|BEHAVIORAL|Conventional training|traditional training according to residency program
214790804|NCT03395821|BEHAVIORAL|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
214790805|NCT03739190|DEVICE|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
214790806|NCT04318470|DIAGNOSTIC_TEST|mNGS|Metagenomic next generation sequencing for microbial DNA
214790807|NCT00041574|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
214790808|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
214790809|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
214790810|NCT00032162|DRUG|carboplatin|AUC 6 q4w
214790811|NCT00032162|DRUG|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
214790812|NCT06340464|OTHER|GNRI, PNI, MNA|Nutrition scoring systems
214790813|NCT05162404|BEHAVIORAL|Video Education Program|"The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
214790814|NCT02210767|OTHER|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
214790815|NCT02210767|OTHER|Walnut Control Diet|2-3% ALA but no walnuts provided
214790816|NCT02210767|OTHER|Low ALA Diet|ALA replaced by oleic acid
214790817|NCT00417274|DRUG|Quinacrine|100 mg daily
214790818|NCT01038570|DRUG|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
214790819|NCT01038570|DRUG|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
214790820|NCT03659409|BEHAVIORAL|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
214790821|NCT03659409|BEHAVIORAL|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
214790822|NCT05893056|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
214790823|NCT05893056|DRUG|Tislelizumab|a PD-1 immune check inhibitor
214790824|NCT05893056|DRUG|Lenvatinib|Lenvatinib capsules
214790825|NCT00004193|DRUG|ISIS 2503|
214790826|NCT00192127|BIOLOGICAL|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
214790827|NCT00192127|OTHER|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
214790828|NCT01880710|PROCEDURE|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
214790829|NCT01880710|PROCEDURE|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
214790830|NCT01268176|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU once per month for 3 months
214790831|NCT01252433|OTHER|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
214790832|NCT00409890|DRUG|Hyoscine Butyl Bromide|
214790833|NCT02278679|PROCEDURE|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
214790834|NCT04243174|BEHAVIORAL|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
214790835|NCT02971956|DRUG|Pembrolizumab|Immune checkpoint inhibitor
214790836|NCT00850278|OTHER|FLT-PET imaging|Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
214790837|NCT02370706|DRUG|PIM447|pan-pim inhibitor
214790838|NCT02370706|DRUG|Ruxolitinib|JAK1/JAK2 inhibitor
214790839|NCT02370706|DRUG|LEE011|CDK4/6 inhibitor
214790840|NCT03437759|BIOLOGICAL|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
214790841|NCT00636831|DRUG|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
214790842|NCT01460251|DRUG|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
214790843|NCT05289622|DEVICE|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
214790844|NCT00532597|PROCEDURE|On-line hemodiafiltration|
214790845|NCT00532597|PROCEDURE|Low flux hemodialysis|
214790846|NCT00427492|DRUG|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
214790847|NCT00427492|DRUG|Placebo|
214790848|NCT01761357|OTHER|answering to questionnaires of quality of live|
214790849|NCT01806233|PROCEDURE|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
214790850|NCT01806233|PROCEDURE|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
214790851|NCT00101608|DRUG|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
214790852|NCT01608009|DRUG|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
214790853|NCT00195598|DRUG|VENLAFAXINE|
214790854|NCT00195598|DRUG|Paroxetine|
214790855|NCT04023279|OTHER|TENS|100 Hz and 100 usec for 20 minutes
214790856|NCT04023279|OTHER|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
214790857|NCT03379077|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
214790858|NCT01840956|BIOLOGICAL|HAVG|HAVG is implanted into patients' arm.
214790859|NCT00261157|DEVICE|InTouch Telerounding Robot|
214790860|NCT03891056|PROCEDURE|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
214790861|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
214790862|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
214790863|NCT00604110|OTHER|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF\<45%), is hemodynamically favourable.
214790864|NCT01767441|PROCEDURE|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
214790865|NCT01767441|PROCEDURE|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
214790866|NCT01767441|PROCEDURE|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
214790867|NCT01767441|OTHER|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
214790868|NCT01638936|DRUG|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
214790869|NCT01280370|PROCEDURE|Abdominal surgery|intraoperative mesh implantation
214790870|NCT02022007|DRUG|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
214790871|NCT02022007|DRUG|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
214790872|NCT02022007|DRUG|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
214790873|NCT06482970|OTHER|Neuromuscular exercise plus pain neuroscience education|"The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).~Pain neuroscience education will take an active, person-centered approach through their own fear-avoidance beliefs."
214790874|NCT06482970|OTHER|Neuromuscular exercise|The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).
214790875|NCT06482593|DRUG|Zinc-Oxide Eugenol Sealer|Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
214790876|NCT06482593|DRUG|AH-Plus Epoxy Resin Sealer|Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
214790877|NCT06482593|DRUG|Bio-C Sealer|Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
214790878|NCT05778279|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
214790879|NCT00655421|OTHER|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
215030931|NCT02485184|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
215030932|NCT02485184|DRUG|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
215030933|NCT02485184|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
215030934|NCT02485184|DRUG|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
214790880|NCT00655421|DEVICE|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
214790881|NCT00655421|OTHER|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
214790882|NCT02896465|OTHER|Oral rehydration solution|
214790883|NCT02896465|OTHER|Zinc|
214790884|NCT02896465|OTHER|Human milk oligosaccharides|
214790885|NCT02896465|OTHER|Breastfeeding|
214790886|NCT03198299|DEVICE|MEI BIN insoles|wearing insoles for 12 weeks
214790887|NCT00362986|DRUG|sunscreen|
214790888|NCT00362986|OTHER|placebo|
214790889|NCT03508895|OTHER|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
214790890|NCT03508895|OTHER|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
214790891|NCT03508895|OTHER|Casein protein|The intervention was provided in the form of a smoothie.
214790892|NCT02862639|DEVICE|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
214790893|NCT02862639|DEVICE|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
214790894|NCT04951050|DEVICE|Rapamycin target eluting stent|Rapamycin target eluting stent
214790895|NCT06207825|DIAGNOSTIC_TEST|Test images and videos|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.
214790896|NCT02087046|DEVICE|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
214790897|NCT00296114|PROCEDURE|Serum and DNA Samples|To collect serum and DNA samples from subjects
214790898|NCT01107535|BIOLOGICAL|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
214790899|NCT00740064|DRUG|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
214790900|NCT04427696|BEHAVIORAL|Aerobic walking intervention|Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
214790901|NCT06542926|PROCEDURE|liver resection|Resection of non-colorectal liver metastases
214790902|NCT03673189|DEVICE|sensors|Acquisition and transmission of exploitable recordings in the public targeted by the DS, that is to say which allow to draw clinical information in relation to the objectives of the DS (detection of the cardiac rhythm): data without artefact (saturation), in a good signal to noise ratio.
214790903|NCT00425529|DEVICE|Module AOX (attached to Sondalis ISO)|
214790904|NCT04087668|PROCEDURE|Monitored Anesthesia Care|MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
214790905|NCT04087668|PROCEDURE|General Anesthesia|Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
214790906|NCT04087668|PROCEDURE|Induction Without Neuromuscular Blockade|Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
214790907|NCT02945462|BIOLOGICAL|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
214790908|NCT04455568|DEVICE|use EKG Wisdom bracelet|Non-invasive Wearable Device (use EKG Wisdom bracelet)
214790909|NCT05265026|BEHAVIORAL|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at \> 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: \>85% of HRmax).
214790910|NCT04409366|OTHER|Conventional Crown Lengthening (CCL)|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days
214790911|NCT04409366|OTHER|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
214790912|NCT04777630|DIAGNOSTIC_TEST|None, neuroimaging|Observation only to observe differences in neuroimaging
214790913|NCT00260325|DRUG|valdecoxib|
214790914|NCT01745978|PROCEDURE|Precut papillotomy|
214790915|NCT01480856|PROCEDURE|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
214790916|NCT01480856|PROCEDURE|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
214790917|NCT04217278|DRUG|Vyxeos|Vyxeos administered by intravenous infusion
214790918|NCT04217278|DRUG|Fludarabine|Fludarabine administered by intravenous infusion
214790919|NCT04217278|DRUG|Busulphan|Busulphan administered by intravenous infusion
214790920|NCT04217278|DRUG|Thiotepa|Thiotepa administered by intravenous infusion
214790921|NCT04217278|DRUG|Cytarabine|Cytarabine administered by intravenous infusion
214790922|NCT02320474|DRUG|Aflibercept|
214790923|NCT01507896|BIOLOGICAL|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
214790924|NCT04811261|DRUG|Intravenous Infusion of UCLSCs|The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
214790925|NCT00735683|DRUG|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
214790926|NCT00735683|DRUG|Placebo|includes diet, physical activity, and lifestyle modification
214790927|NCT01433835|DRUG|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
214790928|NCT01433835|OTHER|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
214790929|NCT03931083|DIAGNOSTIC_TEST|Screening for CIN2+/HSIL|The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
214790930|NCT02641613|PROCEDURE|retroclavicular block|retroclavicular block for forearm or hand surgery
214790931|NCT02641613|PROCEDURE|supraclavicular block|supraclavicular block for forearm or hand surgery
214790932|NCT04852536|DEVICE|Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS|5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.
214790933|NCT01189864|DRUG|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
214790934|NCT01189864|DRUG|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
214790935|NCT01189864|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
214790936|NCT02242513|DEVICE|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
214790937|NCT02242513|DRUG|Xylocaine|
214790938|NCT01638702|OTHER|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
214790939|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
214790940|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
214790941|NCT00621179|DRUG|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
214790942|NCT00621179|OTHER|No intervention|
214790943|NCT02916979|DRUG|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
214790944|NCT02916979|DRUG|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
214790945|NCT02916979|BIOLOGICAL|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
214790946|NCT02916979|DRUG|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
214790947|NCT02246842|BIOLOGICAL|D-Gam® (human anti-D immunoglobulin)|
214790948|NCT02246842|BIOLOGICAL|Rhophylac® (human anti-D immunoglobulin)|
214790949|NCT01292200|BEHAVIORAL|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
214790950|NCT01292200|BEHAVIORAL|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
214790951|NCT04615442|DEVICE|Epihunter|Subjects wear epihunter during routine video EEG
214790952|NCT02988752|DEVICE|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
214790953|NCT02988752|DEVICE|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
215030935|NCT02987140|BEHAVIORAL|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
215030936|NCT02465008|DRUG|Levobupivacaine|
214790954|NCT01413399|DRUG|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
214790955|NCT03672500|DRUG|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
214790956|NCT03672500|OTHER|Sham injection|Sham injection of the perineum
214790957|NCT00192699|DEVICE|Bimetric femoral stem|Cemented Bi-Metric femoral stem
214790958|NCT01725477|DRUG|methylen blue &normal saline|Washing after dye injection
215030937|NCT02465008|DRUG|Placebo|
214790959|NCT01725477|DRUG|methylene blue|
214790960|NCT01725477|DRUG|metheylne blue with normal saline|
214790961|NCT01117961|BEHAVIORAL|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
214790962|NCT00735241|DEVICE|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
214790963|NCT00735241|DRUG|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
214790964|NCT00735241|DRUG|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
214790965|NCT00735241|DRUG|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
214790966|NCT00192296|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
214790967|NCT00192296|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
214790968|NCT00192296|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
214790969|NCT00192296|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
214790970|NCT04805684|DEVICE|LUS Twelve area|Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
214790971|NCT04805684|DEVICE|LUS Fourteen area|Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
214790972|NCT00962299|DRUG|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
214790973|NCT00962299|DRUG|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
214790974|NCT00882622|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
214790975|NCT00882622|PROCEDURE|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
214790976|NCT05783583|DEVICE|Remote Digital Slit Lamp|Slit Lamp Examination
214790977|NCT04459481|DEVICE|bending angle|patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
214790978|NCT01338844|DIETARY_SUPPLEMENT|Myo-inositol|
214790979|NCT01338844|DIETARY_SUPPLEMENT|D-chito-Inositol|
214790980|NCT01545635|DRUG|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
214790981|NCT01545635|DRUG|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
214790982|NCT05026515|BEHAVIORAL|Parents|To observe the influence of the parents/caregivers behavior on their child during dental treatment
214790983|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
214790984|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
214790985|NCT00818623|DRUG|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
214790986|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
214790987|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
214790988|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
214790989|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
214790990|NCT00818623|DRUG|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
214790991|NCT03564548|DRUG|PPP001|Group assigned to PPP001
214790992|NCT03564548|DRUG|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
214790993|NCT05418348|DRUG|GTX-104|new formulation of nimodipine injection for IV infusion
214790994|NCT05418348|DRUG|Nimodipine Capsules|Nimodipine capsules (reference formulation)
214790995|NCT00188370|PROCEDURE|high frequency ultrasound imaging|
214790996|NCT05747638|BEHAVIORAL|Revised Children's Manifest Anxiety Scale (RCMAS)|All participants will be invited to complete a paper questionnaire.
214790997|NCT00910182|PROCEDURE|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
214790998|NCT01684410|BIOLOGICAL|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
214790999|NCT01684410|BIOLOGICAL|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
214791000|NCT01684410|BIOLOGICAL|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
215030938|NCT02424162|DEVICE|+2.75 diopters multifocal intraocular lens|
214791001|NCT03998085|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
214791002|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
214791003|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
214791004|NCT02587156|DIETARY_SUPPLEMENT|Meal serving|To investigate impact of habituated protein level
214791005|NCT05555589|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
214791006|NCT05555589|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
214791007|NCT03016182|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
214791008|NCT03016182|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
214791009|NCT02649231|DRUG|Ketamine|0.8 mg/kg ketamine
214791010|NCT02649231|DRUG|Placebo|0.9% saline
214791011|NCT02649231|BEHAVIORAL|Psychological Therapy|Manualised relapse prevention based CBT
214791012|NCT02649231|BEHAVIORAL|Alcohol Education|Simple education about alcohol effects
214791013|NCT02818283|DIETARY_SUPPLEMENT|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
214791014|NCT02818283|OTHER|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
214791015|NCT01944228|DEVICE|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
214791016|NCT01944228|DEVICE|Sham Stimulation|Catheter placed in the IJV without stimulation
214791017|NCT05425966|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
214791018|NCT00162435|DRUG|Warfarin|
214791019|NCT00359437|DRUG|Satavaptan|oral administration once daily
214791020|NCT00359437|DRUG|placebo|oral administration once daily
214791021|NCT01801696|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
214791022|NCT01801696|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
214791023|NCT04179071|DRUG|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
214791024|NCT04179071|DRUG|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
214791025|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
214791026|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
214791027|NCT04905979|DRUG|AD113|Two oral capsules administered before bed
214791028|NCT04905979|DRUG|Atomoxetine|Two oral capsules administered before bed
214791029|NCT02689895|OTHER|modified directly administered anti-retroviral therapy (mDAART)|As described before
214791030|NCT02768623|OTHER|Pharmacist led Asthma Management|
214791031|NCT02768623|OTHER|Pharmacist Intervention (when requested by patient)|
214791032|NCT02140489|DRUG|amosartan|
214791033|NCT02140489|DRUG|rosuvastatin|
214791034|NCT02140489|DRUG|amosartan and rosuvastatin|
214791035|NCT02419482|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
214791036|NCT02419482|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
214791037|NCT02390622|OTHER|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
214791038|NCT00841256|BIOLOGICAL|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
214791039|NCT00841256|DRUG|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
215030939|NCT02424162|DEVICE|+3.25 diopters multifocal intraocular lens|
215030940|NCT03129997|DIETARY_SUPPLEMENT|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
214791040|NCT05105711|BEHAVIORAL|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
214791041|NCT05350098|OTHER|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
214791042|NCT05350098|OTHER|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
214791043|NCT00496106|BEHAVIORAL|Telephone counseling|6 telephone counseling sessions
214791044|NCT00496106|BEHAVIORAL|Telephone interview|telephone interview
214791045|NCT01504828|DRUG|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
214791046|NCT04298125|BEHAVIORAL|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
214791047|NCT05664750|DRUG|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
214791048|NCT05664750|DRUG|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
214791049|NCT02184949|PROCEDURE|Percutaneous Coronary Intervention|
214791050|NCT02184949|PROCEDURE|Primary Percutaneous Coronary Intervention|
214791051|NCT04164485|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
214791052|NCT04164485|BIOLOGICAL|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
214791053|NCT03842371|OTHER|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
214791054|NCT00686036|DRUG|vandetanib|300 mg orally, once daily for up to 18 months
214791055|NCT00686036|DRUG|Placebo|
214791056|NCT00523393|DRUG|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
214791057|NCT00523393|DRUG|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
214791058|NCT00674180|BEHAVIORAL|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
214791059|NCT00674180|BEHAVIORAL|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
214791060|NCT00674180|BEHAVIORAL|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
214791061|NCT02972411|BEHAVIORAL|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
214791062|NCT02972411|DRUG|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
214791063|NCT00294424|PROCEDURE|Short waiting time|
214791064|NCT00294424|PROCEDURE|Non-fixed waiting time|
214791065|NCT04359992|OTHER|Extra blood sample|3 extra blood samples at day 0, 2 and 7
214791066|NCT03676374|DRUG|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
214791067|NCT03676374|DRUG|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
214791068|NCT02413697|DEVICE|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
214791069|NCT02413697|DEVICE|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
214791070|NCT03579147|DEVICE|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
214791071|NCT00236782|DRUG|norelgestromin + ethinyl estradiol; mercilon|
214791072|NCT01927081|BEHAVIORAL|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
214791073|NCT01927081|BEHAVIORAL|gentle exercise|Patients learn gentle exercise and breathing techniques
214791074|NCT02261571|OTHER|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
214791075|NCT00891878|DRUG|capecitabine|Given orally
214791076|NCT00891878|DRUG|sunitinib malate|Given orally
214791077|NCT03792971|DRUG|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
214791078|NCT03792971|DRUG|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
214791079|NCT04899856|DEVICE|TransAeris|TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
214791080|NCT00877175|DRUG|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
214791081|NCT01478633|DRUG|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
214791082|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
214791083|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
214791084|NCT02251587|OTHER|Standard Weight Management Program|Standard Diet program based on diet and exercise.
214791085|NCT02251587|OTHER|Sensible Weigh Program|Weight loss program designed for low income women.
214791086|NCT00258973|PROCEDURE|Carotid Ultrasound performed in office practice|
214791087|NCT02353000|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
214791088|NCT02353000|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
214791089|NCT01185288|BIOLOGICAL|Adalimumab|Adalimumab in pre-filled syringes
214791090|NCT01185288|DRUG|Methotrexate|Methotrexate capsule
214791091|NCT00781755|DRUG|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
214791092|NCT00781755|BEHAVIORAL|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
214791093|NCT05617859|DRUG|Lenvatinib mesylate capsule|Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
214791094|NCT06209788|PROCEDURE|experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
214791095|NCT01004692|DEVICE|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
214791096|NCT05803278|OTHER|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
214791097|NCT02048254|RADIATION|brachytherapy|
214791098|NCT02048254|RADIATION|IMRT|
214791099|NCT00160030|DRUG|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
214791100|NCT00160030|DRUG|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
214791101|NCT06271811|PROCEDURE|Flossing band|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
215030941|NCT03295942|DRUG|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
215030942|NCT00684385|DRUG|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
214791102|NCT06271811|OTHER|Conventional physiotherapy|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
214791103|NCT04985214|OTHER|Questionnaire|Questionnaire on the quality of life
214791104|NCT05834790|OTHER|Mobile Augmented Reality (MAR) for oral health education program|MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
214791105|NCT05834790|OTHER|Lecture-based oral health education program|The oral health education program that will be delivered by traditional lecture-based process
214791106|NCT02127996|DRUG|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
214791107|NCT02127996|DRUG|placebo|Normal saline
214791108|NCT02088528|DEVICE|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
214791109|NCT02088528|PROCEDURE|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
214791110|NCT02539095|DEVICE|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
214791111|NCT02539095|DEVICE|Normal saline|"1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
214791112|NCT02587442|DRUG|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
214791113|NCT05690568|OTHER|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
214791114|NCT03272256|DRUG|IM156|Sequential 3+3 design.
214791115|NCT03027336|DIETARY_SUPPLEMENT|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
214791116|NCT03027336|DIETARY_SUPPLEMENT|Placebo|patients will take one tablet daily for 12 weeks.
214791117|NCT06454500|OTHER|Clinical decision support|A 48 hour expiration on orders placed for indwelling urinary catheters.
214791118|NCT01004211|PROCEDURE|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
214791119|NCT01004211|PROCEDURE|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
214791120|NCT01199432|DRUG|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
214791121|NCT01199432|DRUG|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
214791122|NCT01199432|DRUG|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
214791123|NCT03083249|OTHER|Gardasil|None-data gathering only
214791124|NCT01494688|DRUG|Paclitaxel|Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
214791125|NCT01494688|DRUG|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
214791126|NCT06206499|PROCEDURE|soft tissue augmentation|"Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants."
214791127|NCT02691806|OTHER|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
214791128|NCT00756847|DRUG|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
214791129|NCT00756847|DRUG|paclitaxel|Intravenous injection dosed once every three weeks
214791130|NCT00756847|DRUG|carboplatin|Intravenous injection dosed once every three weeks
214791131|NCT03556917|COMBINATION_PRODUCT|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
214791132|NCT00948402|DRUG|Metformin|metformin 1250 mg three times daily
214791133|NCT00948402|DRUG|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
214791134|NCT03645070|DEVICE|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
214791135|NCT03645070|DEVICE|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
214791136|NCT01252628|DRUG|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
214791137|NCT01252628|DRUG|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
214791138|NCT01252628|DRUG|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
214791139|NCT01252628|DRUG|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
214791140|NCT01999309|DRUG|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
214791141|NCT01999309|DRUG|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
214791142|NCT02834065|DEVICE|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
214791143|NCT03476915|OTHER|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
214791144|NCT01200394|DRUG|PF-00489791|Tablet, 20 mg once daily for 12 weeks
214791145|NCT01200394|DRUG|Placebo|Tablet, placebo once daily for 12 weeks
214791146|NCT03179475|DRUG|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
214791147|NCT02056730|DRUG|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
214791148|NCT02666430|DRUG|Mylan's insulin glargine|
214791149|NCT02666430|DRUG|Lantus®|
214791150|NCT02297906|DRUG|Ketorolac|Non-steroidal anti-inflammatory drug
214791151|NCT02847533|PROCEDURE|blood sample|blood sample for concentration levels of inflammatory markers
214791152|NCT02847533|BEHAVIORAL|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
214791153|NCT03828461|BEHAVIORAL|Facilitated group therapy with behavioral practice; 16 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
214791154|NCT06144359|OTHER|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~\- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
214791155|NCT01577095|OTHER|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
214791156|NCT01577095|DRUG|TZD|Rosiglitazone 8 mg single dose
214791157|NCT02100956|DRUG|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
214791158|NCT02100956|DRUG|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
214791159|NCT03035227|PROCEDURE|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
214791160|NCT03035227|DRUG|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
214791161|NCT03458507|DEVICE|Switch of nocturnal NIV interface|"1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
214791162|NCT00576199|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
214791163|NCT00576199|PROCEDURE|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
214791164|NCT00457379|BEHAVIORAL|physical exercise|
214791165|NCT02473991|RADIATION|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
214791166|NCT00859469|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
214791167|NCT00859469|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
214791168|NCT03091166|DRUG|Dexmedetomidine|
214791169|NCT03890250|OTHER|Aerobic exercise|A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
214791170|NCT03890250|OTHER|Neuromuscular electrical stimulation|Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
214791171|NCT02405910|DRUG|Nab-paclitaxel|
214791172|NCT02405910|DRUG|Gemcitabine|
214791173|NCT04914793|DEVICE|Antimicrobial prescribing guideline mobile phone application (MicroGuide)|This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
214791174|NCT04373759|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
214791175|NCT04373759|OTHER|Modified Rankin score|"0 - no symptoms at all~1. \- no significant disability despite symptoms; able to carry out all usual duties and activities~2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. \- Moderate disability; requiring some help, but able to walk without assistance~4. \- Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. \- Dead"
214791176|NCT02220907|DRUG|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
214791177|NCT03376958|DRUG|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
214791178|NCT00366379|DRUG|GK Activator (2)|25-200mg po bid for 20 weeks
214791179|NCT04266678|BEHAVIORAL|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
214791180|NCT03111147|DEVICE|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
214791181|NCT03111147|DEVICE|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
214791182|NCT01701778|DRUG|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
214791183|NCT01701778|DRUG|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
214791184|NCT01701778|DRUG|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
214791185|NCT01701778|DRUG|sevoflurane|Induction and maintain anaesthesia
214791186|NCT00902824|BIOLOGICAL|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)
214791187|NCT00902824|BIOLOGICAL|TBC-M4|Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
214791188|NCT00902824|OTHER|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
214791189|NCT05921084|BEHAVIORAL|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
214791190|NCT05921084|BEHAVIORAL|General dietary advice|General dietary advice
214791191|NCT06008405|DRUG|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
214791192|NCT06155799|DEVICE|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
214791193|NCT05004857|BEHAVIORAL|Book reading|Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
214791194|NCT02140073|DRUG|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
214791195|NCT02140073|DRUG|omeprazole|40mg in the morning
214791196|NCT05379569|DRUG|Fludarabine|The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
214791197|NCT03780569|DEVICE|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
214791198|NCT03780569|RADIATION|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
214791199|NCT03780569|DRUG|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m\^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m\^2 in the absence of toxicity."
214791200|NCT02867020|DRUG|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
214791201|NCT02867020|DRUG|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
214791202|NCT02867020|DRUG|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
214791203|NCT02867020|DRUG|Prednisone|Subjects will receive prednisone 10mg/day.
214791204|NCT03065283|PROCEDURE|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
214791205|NCT03065283|PROCEDURE|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
214791206|NCT02886975|BEHAVIORAL|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
214791207|NCT00095199|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
214791208|NCT00095199|BIOLOGICAL|Cetuximab|Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
214791209|NCT00095199|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
214791210|NCT04650607|OTHER|Adverse event after injection of phages|rate and description of adverse event after injection of phages
214791211|NCT00217828|DRUG|citalopram|
214791212|NCT03754491|BEHAVIORAL|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
214791213|NCT06385977|BEHAVIORAL|lifestyle|Life habits and personal preferences
214791214|NCT06385977|BEHAVIORAL|sexual habits|Sexual experience and activities
214791215|NCT06385977|DRUG|medication|use of medication
214791216|NCT01493297|OTHER|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
214791217|NCT01896297|DRUG|Pradaxa, dabigatran etexilate|75mg BID by oral
214791218|NCT00388882|DRUG|tiotropium|
214791219|NCT00388882|DRUG|ipratropium bromide / albuterol|
214791220|NCT03719183|DIAGNOSTIC_TEST|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
214791221|NCT03719183|DIAGNOSTIC_TEST|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements"
214791222|NCT03719183|DIAGNOSTIC_TEST|Multiplex FISH (M-FISH)|24-color karyotyping
214791223|NCT02496871|BEHAVIORAL|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
214791224|NCT02496871|BEHAVIORAL|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
214791225|NCT02429700|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
214791226|NCT02429700|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
214791227|NCT02429700|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
214791228|NCT02429700|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
214791229|NCT02429700|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
214791230|NCT04783363|OTHER|Snoezelen session|before one of two repeated invasive care
214791231|NCT01343628|DRUG|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
214791232|NCT01343628|DRUG|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
214791233|NCT00864942|DRUG|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
214791234|NCT00864942|DRUG|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
214791235|NCT00864942|DRUG|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
214791236|NCT00864942|DRUG|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
214791237|NCT01098240|DRUG|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
214791238|NCT01098240|OTHER|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
214791239|NCT01070394|DRUG|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
214791240|NCT02360657|DRUG|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
214791241|NCT02360657|DRUG|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
214791242|NCT02360657|DRUG|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
214791243|NCT04989062|DIAGNOSTIC_TEST|Fibroscan|Controlled attenuation parameter and liver stiffness measurement are measured.
214791244|NCT04989062|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
214791245|NCT04989062|DIAGNOSTIC_TEST|Urine unclear magnetic resonance metabolomics|Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
214791246|NCT04989062|DIAGNOSTIC_TEST|Hand grip strength|Hand grip strength in both hands is measured by hand-held dynamometer.
214791247|NCT05181137|DRUG|SHR0302|Oral tablets taken once daily (QD)
214791248|NCT05181137|DRUG|Placebo|Oral tablets taken once daily (QD)
214791249|NCT01880645|PROCEDURE|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
214791250|NCT01880645|PROCEDURE|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
214791251|NCT01880645|PROCEDURE|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
214791252|NCT01860391|DEVICE|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
214791253|NCT02281630|DRUG|KWA-0711|
214791254|NCT02281630|DRUG|Placebo|
214791255|NCT06360731|OTHER|4-7-8 breathing exercise technique and informative session on tinnitus|Participants in experimental group will be individually provided with informative session on tinnitus for one hour by researchers. During the informative session, the participants will be given general information about tinnitus and will be informed about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus. In the same session, after one hour of informative session, the 4-7-8 breathing exercise method will be demonstrated by the same researchers. In addition, a video showing how to perform the 4-7-8 breathing exercise technique will be sent as a text message to their cell phones.
214791256|NCT06360731|OTHER|Informative session on tinnitus|Participants in control group will be individually provided with informative session on tinnitus only for one hour by researchers G.K. and G.S.U. from both clinics. During the informative session, the participants will be given general information about tinnitus and inform about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus.
214791257|NCT05765045|DIAGNOSTIC_TEST|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
214791258|NCT00634283|DRUG|venlafaxine|venlafaxine IR 150mg
214791259|NCT00206206|PROCEDURE|Hyperglycemia Protocol Procedure|
214791260|NCT03118739|DRUG|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
214791261|NCT03118739|DRUG|Placebo|Capsule administered orally, once daily for 24 weeks
214791262|NCT02938806|OTHER|No intervention|No intervention
214791263|NCT02657720|DEVICE|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
214791264|NCT02657720|DEVICE|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
214791265|NCT02657720|DEVICE|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
214791266|NCT06338020|OTHER|Adaptive variable-resistance training|"The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
214791267|NCT06338020|OTHER|Standard physical therapy|The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
214791268|NCT03804645|DRUG|Treatment A|Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
214791269|NCT03804645|DRUG|Treatment B|Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
214791270|NCT03804645|DRUG|Treatment C|Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
214791271|NCT03804645|DRUG|Treatment D|Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
214791272|NCT03687021|DRUG|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
214791273|NCT04801602|DIAGNOSTIC_TEST|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
214791274|NCT03764410|PROCEDURE|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
214791275|NCT00893542|DRUG|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
214791276|NCT03982056|OTHER|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
214791277|NCT00669955|DRUG|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
214791278|NCT00669955|DRUG|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
214791279|NCT04066179|DRUG|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
214791280|NCT04066179|DRUG|Prednisolone|Prednisolone 40 mg for initial 7 days
214791281|NCT03311009|DRUG|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
214791282|NCT03311009|DRUG|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
214791283|NCT03311009|DRUG|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
214791284|NCT03311009|DRUG|Placebo|Matching placebo provided as oral tablets q.d.
214791285|NCT00367406|DEVICE|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
214791286|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
214791287|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
214791288|NCT01066481|DRUG|Placebo|Placebo three times daily for 6 months
214791289|NCT05491174|BEHAVIORAL|DBT-Informed skills group|10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
214791290|NCT05480917|OTHER|Patients receiving PsoPlus care|As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
214791291|NCT01208142|OTHER|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
214791292|NCT01208142|DEVICE|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
214791293|NCT00228462|DRUG|Seroquel (quetiapine)|
214791294|NCT02743442|DEVICE|da Vinci® Si™|
214791295|NCT02022501|DRUG|DE-120|
214791296|NCT00003938|DRUG|liposomal amphotericin B|
214791297|NCT03591549|DRUG|Faslodex|intramuscular injection monthly
214791298|NCT03591549|DRUG|Zoladex|intramuscular injection monthly
214791299|NCT01033344|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
214791300|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
214791301|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
214791302|NCT03061760|PROCEDURE|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
214791303|NCT03061760|DIAGNOSTIC_TEST|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
214791304|NCT03061760|DIAGNOSTIC_TEST|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
214791305|NCT01573247|DRUG|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
214791306|NCT02975271|DRUG|Serlopitant|
214791307|NCT02975271|DRUG|Placebo|Matching placebo
214791308|NCT01432132|BEHAVIORAL|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
214791309|NCT01432132|BEHAVIORAL|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
214791310|NCT03323632|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
214791311|NCT05974020|OTHER|Control|No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
214791312|NCT05974020|OTHER|Intrinsic Muscle Training|"In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program."
214791313|NCT05974020|OTHER|Aerobic Exercise|In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
214791314|NCT04261296|OTHER|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
214791315|NCT04261296|OTHER|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
214791316|NCT04261296|OTHER|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
214791317|NCT00609778|DEVICE|LUCAS|Mechanical chest compression
214791318|NCT00609778|OTHER|Conventional manual resuscitation method|Manual compression
214791319|NCT01170260|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
214791320|NCT01170260|BEHAVIORAL|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
214791321|NCT01170260|BEHAVIORAL|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
214791322|NCT02267733|DRUG|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
214791323|NCT05723497|OTHER|Elderberry juice|Participants will consume elderberry juice 1-week.
214791324|NCT05723497|OTHER|Placebo beverage|Participants will consume placebo for 1-week.
214791325|NCT01439100|DRUG|Oxycodone/Naloxone Prolonged Release tablets|
214791326|NCT01439100|DRUG|Placebo|Dummy tablet
214791327|NCT04317053|BEHAVIORAL|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
214791328|NCT05919459|BEHAVIORAL|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
214791329|NCT05919459|BEHAVIORAL|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
214791330|NCT06324253|PROCEDURE|bilateral Erector spine block,A dose of 30 ml 0.125% Bupivacaine will be injected.|will receive bilateral Erector Spinae Block after induction of anesthesia
214791331|NCT06324253|PROCEDURE|Thoracic epidural analgesia|will receive Thoracic Epidural Block before induction of anesthesia .a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour
214791332|NCT04847609|DEVICE|GentleCath™ Air catheter|Patients
214791333|NCT06447454|RADIATION|radiotherapy|radiotherapy
214791334|NCT06447454|DRUG|gemcitabine + cisplatin|Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.
214791335|NCT06447454|DRUG|slulimumab|Slulimumab, 4.5mg/kg intravenous infusion, Q3W
214791336|NCT01077713|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
214791337|NCT01077713|DRUG|cisplatin|60mg/m2 on day 1 of each 3 week cycle
214791338|NCT01077713|DRUG|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
214791339|NCT01077713|DRUG|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
214791340|NCT03507439|DEVICE|AVIVO Mobile Patient Management (MPM) System|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
214791341|NCT03507439|DEVICE|VitalPatch biosensor|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
214791342|NCT03507439|DEVICE|DynaPort Move Monitor|Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study
214791343|NCT06224582|DRUG|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
214791344|NCT06224582|DRUG|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
214791345|NCT00289458|BEHAVIORAL|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
214791346|NCT00289458|BEHAVIORAL|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
214791347|NCT00289458|BEHAVIORAL|Control|no exercise
214791348|NCT04274192|OTHER|Synchronized HFNC at 6 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
214791349|NCT04274192|OTHER|Continuous HFNC at 6 liters per minute (LPM)|Standard HFNC therapy at 6 LPM
214791350|NCT04274192|OTHER|Synchronized HFNC at 8 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
214791351|NCT04274192|OTHER|Continuous HFNC at 8 liters per minute (LPM)|Standard HFNC therapy at 8 LPM
214791352|NCT06210269|DRUG|Moxifloxacin 400mg|Oral antibiotic
214791353|NCT06210269|OTHER|Placebo|Oral placebo
214791354|NCT01848652|DRUG|infusion of MYOCET|
214791355|NCT06526871|PROCEDURE|Low-Level Laser acceleration|This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .
214791356|NCT06526871|PROCEDURE|clear aligner therapy|Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
214791357|NCT01557595|DEVICE|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
214791358|NCT03908021|DIAGNOSTIC_TEST|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
214791359|NCT06114433|OTHER|3D printed educational model|Slide-based presention plus 3D printed educational model
214791360|NCT06114433|OTHER|Traditional model education|Slide-based presention plus traditional model
214791361|NCT01717898|DRUG|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
214791362|NCT01717898|DRUG|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
214791363|NCT01717898|DRUG|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
214791364|NCT03632174|OTHER|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
214791365|NCT03632174|OTHER|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
214791366|NCT03265470|DRUG|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
214791367|NCT03265470|DRUG|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
214791368|NCT01607775|DEVICE|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
214791369|NCT01607775|DEVICE|PMMA-cage|The in-house produced cervical cage will be implanted
214791370|NCT04219202|RADIATION|Proton radiation|Therapeutic radiation Treatment with Protons
214791371|NCT04219202|RADIATION|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
214791372|NCT03673826|DRUG|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
214791373|NCT03673826|DRUG|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
214791374|NCT03673826|DRUG|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
214791375|NCT01883089|BEHAVIORAL|Motivational Enhancement Therapy|
214791376|NCT01604044|DRUG|Meropur 150 a day|one subcutaneous injection a day
214791377|NCT01604044|DRUG|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
214791378|NCT03778866|OTHER|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
214791379|NCT04230226|DIETARY_SUPPLEMENT|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
214791380|NCT04230226|OTHER|Placebo|Placebo product consumed prior and after exercise
214791381|NCT04606563|DRUG|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
214791382|NCT04606563|DRUG|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
214791383|NCT04606563|DRUG|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
214791384|NCT04606563|DRUG|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
214791385|NCT04606563|DRUG|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
214791386|NCT04606563|DRUG|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
214791387|NCT04606563|DRUG|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
214791388|NCT04606563|DRUG|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
214791389|NCT02986763|BIOLOGICAL|Questionnaire, blood, urine, hair and dust samplings|
214791390|NCT05659550|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
214791391|NCT00258622|DRUG|NS1209|
214791392|NCT00258622|DRUG|Lidocaine|
214791393|NCT02770950|DRUG|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
214791394|NCT02770950|DRUG|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
214791395|NCT02770950|DRUG|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
214791396|NCT01621490|BIOLOGICAL|Nivolumab|
214791397|NCT01621490|DRUG|Ipilimumab|
214791398|NCT02253277|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
214791399|NCT02253277|DRUG|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
214791400|NCT05870553|DRUG|CTP0301-A|Bowel Preparation
214791401|NCT05870553|DRUG|CTP0301-B|Bowel Preparation
214791402|NCT05870553|DRUG|Cool prep|Bowel Preparation
214791403|NCT00461500|DRUG|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
214791404|NCT00461500|DRUG|Fluticasone propionate|FP 100
214791405|NCT01240005|BIOLOGICAL|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
214791406|NCT05215899|OTHER|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
214791407|NCT00002252|DRUG|Octreotide|
214791408|NCT04360811|DIAGNOSTIC_TEST|COVID 19 diagnostic test by PCR|"1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis"
214791409|NCT05031728|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
214791410|NCT01806597|BIOLOGICAL|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
214791411|NCT01806597|BIOLOGICAL|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
214791412|NCT01806597|BIOLOGICAL|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
214791413|NCT04154709|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
214791414|NCT05925153|OTHER|No intervention|No intervention
214791415|NCT00879554|BIOLOGICAL|CVX-045|Weekly, intravenous dose
214791416|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia With Tragus Pressure|Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
214791417|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia Without Tragus Pressure|Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
214791418|NCT05627609|DEVICE|311 nm narrowband UVB irradiation|Participants will be irradiated with 311nm UVB for 5 days per week and 4 weeks in total.
214791419|NCT03873480|PROCEDURE|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
214791420|NCT01909622|DIETARY_SUPPLEMENT|Vitamin D|
214791421|NCT01909622|DIETARY_SUPPLEMENT|No vitamin D|
214791422|NCT06094868|DRUG|Fruquintinib|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
214791423|NCT04276038|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
214791424|NCT05116995|DRUG|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
214791425|NCT05116995|DRUG|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
214791426|NCT02149303|DRUG|Dabigatran 75 mg|PO BID
214791427|NCT02149303|DRUG|Dabigatran 150 mg|PO BID
214791428|NCT04000503|BEHAVIORAL|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
214791429|NCT04491149|DEVICE|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
214791430|NCT02247479|DRUG|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
214791431|NCT02247479|OTHER|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
214791432|NCT03849313|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
214791433|NCT00226720|PROCEDURE|Outpatient detoxification program|Outpatient detoxification program
214791434|NCT04552574|DIETARY_SUPPLEMENT|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
214791435|NCT05389410|DEVICE|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
214791436|NCT05389410|DEVICE|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
214791437|NCT06214377|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.
214791438|NCT06214377|DEVICE|Sham Transcranial Direct Current Stimulation|The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
214791439|NCT06214377|DRUG|Dopaminergic medication|After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
214791440|NCT04112251|DIETARY_SUPPLEMENT|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
214791441|NCT01572649|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
214791442|NCT01572649|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
214791443|NCT03699267|OTHER|US-guided Bilateral TAP block|
214791444|NCT02705053|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
214791445|NCT02705053|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
214791446|NCT04611256|BIOLOGICAL|MSC|Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach
214791447|NCT04611256|DRUG|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
214791448|NCT04807127|DRUG|Immune checkpoint blockade|ICI, administered as standard-of-care treatment
214791449|NCT04807127|DRUG|Targeted therapy|TKI, administered as standard-of-care treatment
214791450|NCT04807127|RADIATION|Radiotherapy|RT, administered as standard-of-care treatment
214791451|NCT01840189|OTHER|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
214791452|NCT01840189|OTHER|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
214791453|NCT01073020|DEVICE|Allergan Adjustable Gastric Band Surgery|
214791454|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group
214791455|NCT01073020|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) Surgery|
214791456|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
214791457|NCT00135213|BEHAVIORAL|training in smoking cessation|
214791458|NCT03961776|DEVICE|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
214791459|NCT00889590|DRUG|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
214791460|NCT01218620|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214791461|NCT01218620|DRUG|Ketoconazole|Given PO
214791462|NCT01218620|DRUG|Rifampin|Given PO
214791463|NCT01218620|DRUG|Midazolam Hydrochloride|Given IV
214791464|NCT01218620|DRUG|Omeprazole|Given PO
214791465|NCT01218620|DRUG|Tolbutamide|Given PO
214791466|NCT01218620|DRUG|Dextromethorphan Hydrobromide|Given PO
214791467|NCT01218620|OTHER|Pharmacological Study|Correlative studies
214791468|NCT01218620|OTHER|Laboratory Biomarker Analysis|Correlative studies
214791469|NCT05989360|DIAGNOSTIC_TEST|Lung Clearance Index|Normative values in healthy children from ethnic backgrounds
214791470|NCT00276874|DRUG|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
214791471|NCT00276874|DRUG|Placebos|Placebo; 0 mg; oral; daily
214791472|NCT03807882|OTHER|Bilateral M-ECT|Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
214791473|NCT03807882|DRUG|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
214791474|NCT02607761|OTHER|Video|Video-Audio Media
214791475|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
214791476|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
214791477|NCT05434481|OTHER|Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases|"* For each patient: a segment of aorta will be sampled and cutted into 4 parts~  * 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.~ * 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.~ * 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.~* For each patient, 2 arterial blood samples will be collected before general anaesthesia~  * One tube of whole blood stored at -80°C for metabolomic analysis.~ * One tube of blood stored at -80°C for plasma cytokines"
214791478|NCT05680350|PROCEDURE|Laparoscopic Exploration|Laparoscopic Exploration to diagnose \& grade endometriosis
214791479|NCT05680350|DIAGNOSTIC_TEST|Estimation of Plasma Expression level of MICRO RNA 203 & 210|"estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR"
214791480|NCT03287050|DRUG|Pembrolizumab|200 mg IV q 21 days
214791481|NCT03287050|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
214791482|NCT00623025|DRUG|Creon 25000|6 to 9 capsules Creon 25000 per day
214791483|NCT00623025|DRUG|Placebo|6 to 9 capsules placebo per day
214791484|NCT04642950|DRUG|Sargramostim|250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.
214791485|NCT04642950|DRUG|Placebo|2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
214791486|NCT02275923|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
214791487|NCT05584475|BEHAVIORAL|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
214791488|NCT00583869|DRUG|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
214791489|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
214791490|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
214791491|NCT02452060|DRUG|Ketamine|0.4mg/kg infusion
214791492|NCT02452060|OTHER|Placebo Comparator|0.4mg/kg infusion
214791493|NCT00004576|DRUG|LY300164|
214791494|NCT03091530|OTHER|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
214791495|NCT03091530|OTHER|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
214791496|NCT02951663|DIETARY_SUPPLEMENT|Protein|
214791497|NCT03031899|PROCEDURE|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
214791498|NCT03031899|DIAGNOSTIC_TEST|Rose Bengal|the lesions stained positive were subjected to biopsy
214791499|NCT03031899|DIAGNOSTIC_TEST|toluidine blue|the lesions stained positive were subjected to biopsy
214791500|NCT05772299|RADIATION|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
214791501|NCT05772299|DEVICE|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
214791502|NCT04160078|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) Intervention|"* 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
214791503|NCT03740698|DEVICE|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
214791504|NCT03740698|DEVICE|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
214791505|NCT03401645|OTHER|Wrist Alarm|Wrist device with alarm timer
214791506|NCT03401645|BEHAVIORAL|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
214791507|NCT03120585|OTHER|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR \>4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
214791508|NCT03732105|RADIATION|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
214791509|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
214791510|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
214791511|NCT05773079|DRUG|Toripalimab|Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
214791512|NCT00489203|DRUG|beclomethasone dipropionate|Given orally
214791513|NCT00489203|DRUG|placebo|Given orally
214791514|NCT00489203|DRUG|tacrolimus|Given after transplant
214791515|NCT00489203|DRUG|methotrexate|Given after transplant
214791516|NCT00489203|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
214791517|NCT02457013|DEVICE|HFNC|Hygh flow nasal canula HFNC
214791518|NCT02457013|DEVICE|nCPAP|nasal nCPAP
214791519|NCT03238027|DRUG|Axatilimab|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
214791520|NCT03238027|DRUG|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
214791521|NCT05852782|OTHER|White Light therapy|Participants will be exposed to broadband light for one hour
214791522|NCT05852782|OTHER|Blue light therapy|Participants will be exposed to blue light for one hour
214791523|NCT05852782|OTHER|Red light therapy|Participants will be exposed to re light for one hour
214791524|NCT05852782|OTHER|Darkness|Participants will be in complete darkness for one hour
214791525|NCT01039220|BIOLOGICAL|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
214791526|NCT06218420|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
214791527|NCT00469820|BIOLOGICAL|autologous tumor cell vaccine|
214791528|NCT00469820|BIOLOGICAL|peripheral blood lymphocyte therapy|
214791529|NCT03788525|BEHAVIORAL|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
214791530|NCT03788525|BEHAVIORAL|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
214791531|NCT04942041|OTHER|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
214791532|NCT00397319|DRUG|Growth Hormone|
214791533|NCT02902731|DRUG|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
214791534|NCT02902731|DRUG|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
214791535|NCT00514293|DRUG|bexarotene|
214791536|NCT00514293|DRUG|capecitabine|
214791537|NCT00514293|DRUG|carboplatin|
214791538|NCT00514293|DRUG|cisplatin|
214791539|NCT00514293|DRUG|docetaxel|
214791540|NCT00514293|DRUG|tretinoin|
214791541|NCT04289636|BEHAVIORAL|Behavioral weight loss program|Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
214791542|NCT04289636|BEHAVIORAL|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
214791543|NCT04289636|BEHAVIORAL|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
214791544|NCT00289627|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
214791545|NCT04385810|PROCEDURE|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
214791546|NCT02565342|PROCEDURE|Interscalene brachial plexus block|
214791547|NCT01045499|DEVICE|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
214791548|NCT01573520|OTHER|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
214791549|NCT04543045|OTHER|not an intervention|not an intervention
214791550|NCT01469364|DRUG|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
214791551|NCT01469364|PROCEDURE|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
214791552|NCT04137263|OTHER|DOSE formulation|over-the-counter topical
214791553|NCT03005470|DEVICE|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
214791554|NCT03005470|DEVICE|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
214791555|NCT03005470|DEVICE|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
214791556|NCT03005470|OTHER|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
214791557|NCT00495118|DRUG|risperidone|
214791558|NCT03043274|DRUG|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
214791559|NCT03000400|BEHAVIORAL|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
214791560|NCT03000400|BEHAVIORAL|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
214791561|NCT01162499|DRUG|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
214791562|NCT01162499|OTHER|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
214791563|NCT01590433|DRUG|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
214791564|NCT01590433|DRUG|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
214791565|NCT01590433|BEHAVIORAL|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
214791566|NCT04381585|DEVICE|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
214791567|NCT03309800|DRUG|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
214791568|NCT03309800|DRUG|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
214791569|NCT05855915|DIAGNOSTIC_TEST|Kinesio taping|Kinesotaping will be applied with routine physical therapy
214791570|NCT05855915|DIAGNOSTIC_TEST|Sham taping|Sham taping will be applied with routine physical therapy
214791571|NCT04468971|BIOLOGICAL|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
214791572|NCT04468971|DRUG|Placebo|Expicient
214791573|NCT05079737|OTHER|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
214791574|NCT00555009|DRUG|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
214791575|NCT00555009|DRUG|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
214791576|NCT05480878|DRUG|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214791577|NCT05480878|DRUG|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214791578|NCT05480878|DRUG|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214791579|NCT00367315|DRUG|Lumiracoxib|
214791580|NCT01786811|BEHAVIORAL|Training|"1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
214791581|NCT04568928|DEVICE|OLTP/PE + FES|12 sessions OLTP/PE + FES
214791582|NCT05944705|DIETARY_SUPPLEMENT|Immune Support Supplement|Cannabinoid and co-active emulsion
214791583|NCT02545153|DRUG|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
214791584|NCT02545153|DRUG|Control|No fibrin sealant applied
214791585|NCT05198128|DRUG|Calcium intravenous infsuion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
214791586|NCT05198128|DRUG|0.9 % saline|0.9 % saline
214791587|NCT05400265|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
214791588|NCT05400265|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
214791589|NCT01386346|DRUG|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
214791590|NCT01386346|DRUG|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
214791591|NCT01386346|DRUG|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
214791592|NCT01386346|DRUG|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
214791593|NCT03558100|BEHAVIORAL|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
214791594|NCT03493737|BEHAVIORAL|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
214791595|NCT00989261|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
214791596|NCT03535909|DIAGNOSTIC_TEST|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
214791597|NCT02459054|DEVICE|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
214791598|NCT05289765|OTHER|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
214791599|NCT05289765|OTHER|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
214791600|NCT00718159|DRUG|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
214791601|NCT04024956|DEVICE|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
214791602|NCT01258491|DRUG|Nicotinic Acids|
214791603|NCT03905291|DRUG|MT921|Formulated as an injectable solution
214791604|NCT03905291|DRUG|Placebo|normal saline
214791605|NCT05589935|DIETARY_SUPPLEMENT|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
214791606|NCT00164320|BEHAVIORAL|TEAM|
214791607|NCT00597233|DRUG|insulin aspart|
214791608|NCT00597233|DRUG|soluble human insulin|
214791609|NCT00597233|DRUG|insulin NPH|
214791610|NCT04715607|DIAGNOSTIC_TEST|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
214791611|NCT03784456|DIETARY_SUPPLEMENT|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
214791612|NCT03784456|DIETARY_SUPPLEMENT|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
214791613|NCT03199248|PROCEDURE|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
214791614|NCT03304509|OTHER|Telematic follow-up|Telematic follow-up by using a platform with videoconference
214791615|NCT06384144|OTHER|Expectant Management of First Trimester Miscarriage|Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
214791616|NCT06384144|OTHER|Medical Management of First Trimester Miscarriage|Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
214791617|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light|A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
214791618|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light|The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
214791619|NCT06380465|OTHER|"The water extract of Biang variety purple sweet potato"|"Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring"
214791620|NCT04752436|BEHAVIORAL|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
214791621|NCT03718338|PROCEDURE|Evaluation|Undergo clinical evaluations
214791622|NCT03718338|OTHER|Quality-of-Life Assessment|Ancillary studies
214791623|NCT03181438|PROCEDURE|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
214791624|NCT03181438|PROCEDURE|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
214791625|NCT06054932|DRUG|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
214791626|NCT06054932|DRUG|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
214791627|NCT00612326|PROCEDURE|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
214791628|NCT05178407|DIETARY_SUPPLEMENT|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
214791629|NCT05178407|DIETARY_SUPPLEMENT|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
214791630|NCT02619604|OTHER|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
214791631|NCT00289601|DRUG|eptifibatide|
214791632|NCT02498522|DRUG|Metformin|83 patients will continue metformin until end of 1st trimester
214791633|NCT03532009|DRUG|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
214791634|NCT03532009|DRUG|Placebo|Oral use for approximately 3 months
214791635|NCT04573842|OTHER|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
214791636|NCT03933657|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
214791637|NCT03330756|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
214791638|NCT03330756|PROCEDURE|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
214791639|NCT02649283|DEVICE|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
214791640|NCT02649283|PROCEDURE|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
214791641|NCT00684333|DEVICE|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
214791642|NCT00624156|BEHAVIORAL|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
214791643|NCT00624156|BEHAVIORAL|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
214791644|NCT03463525|DRUG|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
214791645|NCT03463525|DRUG|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
214791646|NCT03678636|DEVICE|Silver antimicrobial dressing|Silver dressing suitable for exudate level
214791647|NCT03678636|DEVICE|Standard care|Usual care for wound type and condition
214791648|NCT02553369|OTHER|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
214791649|NCT01224210|DRUG|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
214791650|NCT00354510|DRUG|GW842470X cream|
214791651|NCT04861896|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
214791652|NCT02229266|BIOLOGICAL|NK cells|
214791653|NCT02229266|DRUG|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
214791654|NCT03803722|DEVICE|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
214791655|NCT00451932|DRUG|FK778|
214791656|NCT03801096|BEHAVIORAL|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).
214791657|NCT03801096|BEHAVIORAL|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
214791658|NCT01916785|DRUG|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
214791659|NCT03582371|PROCEDURE|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
214791660|NCT03582371|PROCEDURE|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
214791661|NCT02125578|DRUG|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
214791662|NCT02125578|DRUG|Placebo|Each participant will receive placebo every other week or every 4 weeks.
214791663|NCT01732965|OTHER|Phototherapy|
214791664|NCT01732965|OTHER|Phototherapy and Photochemotherapy|
214791665|NCT00872560|DEVICE|NovoFine® needle 6 mm|
214791666|NCT00872560|DEVICE|NovoFine® needle 8 mm|
214791667|NCT00857025|BIOLOGICAL|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
214791668|NCT00857025|OTHER|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
214791669|NCT00857025|OTHER|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
214791670|NCT00857025|OTHER|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
214791671|NCT00737230|OTHER|educational intervention|
214791672|NCT00737230|OTHER|questionnaire administration|
214791673|NCT00737230|PROCEDURE|assessment of therapy complications|
214791674|NCT00737230|PROCEDURE|gastrointestinal complications management/prevention|
214791675|NCT00737230|PROCEDURE|management of therapy complications|
214791676|NCT00737230|PROCEDURE|quality-of-life assessment|
214791677|NCT06543225|OTHER|No intervention|No intervention
214791678|NCT00681863|DRUG|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
214791679|NCT00681863|DRUG|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
214791680|NCT00681863|DRUG|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
214791681|NCT00681863|DRUG|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
214791682|NCT00681863|DRUG|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
214791683|NCT06253468|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
214791684|NCT01677455|DRUG|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
214791685|NCT03294161|DRUG|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
214791686|NCT03294161|DRUG|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
214791687|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
214791688|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
214791689|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
214791690|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
214791691|NCT03741218|OTHER|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
214791692|NCT04810195|DEVICE|Boston Scientific Acurate neo2 TAVR device|The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.
214791693|NCT03693690|PROCEDURE|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
214791694|NCT01333033|DRUG|Oxaliplatin|Given IV
214791695|NCT01333033|DRUG|Leucovorin Calcium|Given IV
214791696|NCT01333033|DRUG|Fluorouracil|Given IV
214791697|NCT01333033|DRUG|Carboplatin|Given IV
214791698|NCT01333033|DRUG|Paclitaxel|Given IV
214791699|NCT01333033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214791700|NCT01333033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214791701|NCT01333033|RADIATION|Radiation Therapy|Undergo RT
214791702|NCT04793503|OTHER|conventional complete denture|the complete denture constructed by packing technique
214791703|NCT04793503|OTHER|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
214791704|NCT04793503|OTHER|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
214791705|NCT03035279|DRUG|SC-006|Intravenous
214791706|NCT03035279|DRUG|ABBV-181|Intravenous
214791707|NCT01439503|BEHAVIORAL|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
214791708|NCT02323906|DRUG|CC-122|Investigational new drug
214791709|NCT02323906|DRUG|Sorafenib|Kinase inhibitor
214791710|NCT03687125|DRUG|Tinostamustine|Participants received tinostamustine IV injection.
214791711|NCT03687125|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
214791712|NCT06112457|OTHER|Survey|Anonymous self-administered questionnaire
214791713|NCT00000616|BEHAVIORAL|diet, sodium-restricted|
214791714|NCT00000616|BEHAVIORAL|diet, fat-restricted|
214791715|NCT00000616|BEHAVIORAL|exercise|
214791716|NCT00000616|BEHAVIORAL|diet, reducing|
214791717|NCT00000616|BEHAVIORAL|alcohol drinking|
214791718|NCT01403350|DEVICE|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
214791719|NCT00720850|DRUG|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
214791720|NCT04037566|GENETIC|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
214791721|NCT04037566|DRUG|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
214791722|NCT04037566|DRUG|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
214791723|NCT01992107|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
214791724|NCT01992107|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
214791725|NCT01992107|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
214791726|NCT00804609|DRUG|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
214791727|NCT00804609|DRUG|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
214791728|NCT02035137|RADIATION|131I-MIBG|
214791729|NCT02035137|DRUG|Vincristine|
214791730|NCT02035137|DRUG|Irinotecan|
214791731|NCT02035137|DRUG|Vorinostat|
214791732|NCT01723956|PROCEDURE|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
214791733|NCT01723956|PROCEDURE|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
214791734|NCT05877820|BIOLOGICAL|Tislelizumab|Intravenous infusion
214791735|NCT05877820|DRUG|Lenvatinib|Oral tablet
214791736|NCT05639387|PROCEDURE|actual tVNS|Active tVNS (stimulation on cymba conchae --\> nervus vagus stimulation)
214791737|NCT05639387|PROCEDURE|sham tVNS|Sham tVNS (stimulation on earlobe --\> no nervus vagus stimulation)
214791738|NCT01288859|OTHER|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
214791739|NCT01288859|OTHER|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
214791740|NCT01288859|OTHER|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
214791741|NCT01288859|OTHER|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
214791742|NCT01288859|OTHER|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
214791743|NCT01288859|OTHER|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
214791744|NCT02663089|DRUG|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.
214791745|NCT02663089|DRUG|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
214791746|NCT02663089|DRUG|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
214791747|NCT04061564|DEVICE|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
214791748|NCT05610501|PROCEDURE|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
214791749|NCT00568269|PROCEDURE|Open repair|Open repair is according to the Lichtenstein technique
214791750|NCT00568269|PROCEDURE|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
214791751|NCT00799006|DRUG|Placebo|Subjects will be given placebo or PF-04620110
214791752|NCT00799006|DRUG|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
214791753|NCT02621515|DRUG|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
214791754|NCT00818714|RADIATION|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
214791755|NCT00268710|DRUG|docetaxel|
214791756|NCT00603343|DRUG|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
214791757|NCT00603343|DRUG|placebo|placebo corresponding to body weight
214791758|NCT03588390|DRUG|BI 1323495|Low strength tablet
214791759|NCT03588390|DRUG|BI 1323495|Middle strength tablet
214791760|NCT03588390|DRUG|BI 1323495|High strength tablet
214791761|NCT03588390|DRUG|Placebo|Placebo to low strength tablet
214791762|NCT03588390|DRUG|Placebo|Placebo to middle strength tablet
214791763|NCT03588390|DRUG|Placebo|Placebo to high strength tablet
214791764|NCT01214603|DRUG|LY2090314|Administered intravenously
214791765|NCT03980379|DRUG|304 injection|Monoclonal antibodies, 100mg/10ml per injection
214791766|NCT03980379|DRUG|rituximab injection|100mg/10ml per injection ，manufactured by Roche
214791767|NCT00471406|PROCEDURE|Photodynamic Therapy with Verteporfin|
214791768|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
214791769|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
214791770|NCT01919294|DRUG|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
214791771|NCT06103526|DIETARY_SUPPLEMENT|Immunonutrition|enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
214791772|NCT03849365|DRUG|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
214791773|NCT06318650|BIOLOGICAL|Demineralized Dentin Matrix|"preparation of Allogenic Demineralized Dentin Matrix: Extracted teeth will be collected from the Departments of oral maxillofacial surgery and periodontics, Cairo university. Cleaning the teeth from any caries, Filings, cement, tartar, soft tissue debris and prosthetic components will be performed using a diamond bur under abundant irrigation with physiological water. Then it will be proceeded to the following steps~1\. (Washing with Distilled water ) 2. (Quick Freezing with liquid nitrogen, then Grinding to particle size of 300- 800 μm). 3.(Ultrasonic Cleaning cycles, 1st with Distilled water , 2nd with 5-7% Hydrogen Perioxide then 3rd with Distilled water for at 60-80 o) 4. (Defatting with Chloroform Methanol Solution1:0.5. 5. (Demineralization with0.5N HCL) 6. (Dehydration with Neutral Ethyl Alcohol then Defatting with Chloroform Methanol Solution 1:0.5 for ) 7. (Washing with Normal Saline \& Freeze Drying then Sterilization using Ethylene oxide gas)."
214791774|NCT06318650|BIOLOGICAL|Demineralized freeze-dried bone allograft (DFDBA)|combination allograft, is a particulate bone graft combining 70% mineralized ground cortical with 30% demineralized ground cortical Particle sizing: 250 - 1000um.
214791775|NCT02010723|PROCEDURE|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
214791776|NCT02010723|DRUG|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
214791777|NCT05851235|OTHER|Prehabilitation course|During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
214791778|NCT05333250|DRUG|Modafinil|Modafinil
214791779|NCT05333250|OTHER|Placebo|Placebo
214791780|NCT06400849|DEVICE|cryotherapy alone of the upper or lower limbs|Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
214791781|NCT06400849|DEVICE|cryotherapy and crompression of the upper or lower limbs|Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
214791782|NCT02444533|DRUG|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
214791783|NCT05588206|RADIATION|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
214791784|NCT01388647|DRUG|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
214791785|NCT01388647|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
214791786|NCT01388647|DRUG|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
214791787|NCT01544166|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants \<2 years of age.
214791788|NCT05074589|DRUG|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
214791789|NCT05074589|DRUG|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
214791790|NCT05635825|OTHER|Observational Survey|Collection of a 4-day food record
214791791|NCT06467422|DEVICE|tTIS on dACC, theta frequency (5 Hz)|"Device: Transcranial electric stimulation device~The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.006 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 6 Hz can be generated in the target area. The experimental group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model."
214791792|NCT06467422|DEVICE|tTIS on dACC, High frequency|The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The sham group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.
214791793|NCT02064426|DRUG|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
214791794|NCT02064426|BIOLOGICAL|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
214791795|NCT03567057|DRUG|ADS-5102, 274 mg|Oral capsules
214791796|NCT03316937|PROCEDURE|Types of scalers|Scaling
214791797|NCT01006707|DRUG|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
214791798|NCT04931628|DRUG|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
214791799|NCT04931628|DRUG|0.9% NaCl|0.9% NaCl
214791800|NCT01760278|DRUG|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
214791801|NCT00244920|DRUG|bicalutamide|
214791802|NCT00244920|DRUG|leuprolide acetate|
214791803|NCT00244920|DRUG|squalamine lactate|
214791804|NCT00244920|PROCEDURE|adjuvant therapy|
214791805|NCT00244920|PROCEDURE|antiandrogen therapy|
214791806|NCT00244920|PROCEDURE|antiangiogenesis therapy|
214791807|NCT00244920|PROCEDURE|conventional surgery|
214791808|NCT00244920|PROCEDURE|neoadjuvant therapy|
214791809|NCT00244920|PROCEDURE|releasing hormone agonist therapy|
214791810|NCT00708331|DEVICE|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
214791811|NCT01159327|DRUG|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
214791812|NCT06143735|DRUG|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
214791813|NCT02801058|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
214791814|NCT02131896|OTHER|Interventional arm-Mediterranean diet|
214791815|NCT02131896|OTHER|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
214791816|NCT00490061|DRUG|Lapatinib|1500 mg po daily orally
214791817|NCT00490061|PROCEDURE|Radiotherapy (radiation)|Standard of Care
214791818|NCT00490061|DEVICE|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
214791819|NCT00490061|DEVICE|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
214791820|NCT00631111|DRUG|effervescent ibuprofen tablets|
214791821|NCT00631111|DRUG|effervescent Aspirin plus Vitamin C tablets|
214791822|NCT00631111|DRUG|ibuprofen tablets|
214791823|NCT00631111|DRUG|placebo|
214791824|NCT00843453|OTHER|blood collection|blood collection
214791825|NCT00843453|DRUG|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
214791826|NCT06364605|DEVICE|Rehabilitation with the iReach novel multisensory medical device|From the results of Phases 1,2 and 3, in Phase 4 a medical device for spatial and sensorimotor rehabilitation in infants aged 3 to 36 months will be tested and developed.
214791827|NCT01155583|DRUG|azacitidine|Given by subcutaneous injection (SC)
214791828|NCT01155583|DRUG|lenalidomide|Given orally
214791829|NCT01155583|DRUG|dexamethasone|Given orally
214791830|NCT01155583|OTHER|DNA methylation analysis|Correlative studies
214791831|NCT01155583|OTHER|gene expression analysis|Correlative studies
214791832|NCT01155583|OTHER|bone marrow aspiration|Correlative studies
214791833|NCT01155583|OTHER|immunohistochemistry staining method|Correlative studies
214791834|NCT01155583|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
214791835|NCT01155583|OTHER|flow cytometry|Correlative studies
214791836|NCT03820193|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
214791837|NCT03820193|DRUG|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
214791838|NCT03820193|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
214791839|NCT03820193|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
214791840|NCT03820193|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
214791841|NCT03820193|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
214791842|NCT00471835|PROCEDURE|computed tomography|
214791843|NCT00471835|PROCEDURE|positron emission tomography|
214791844|NCT00471835|RADIATION|stereotactic body radiation therapy|
214791845|NCT05505123|DRUG|Sevoflurane|induction and maintenance with sevoflurane for deep sedation
214791846|NCT05505123|DRUG|Propofol|induction and maintenance with propofol for deep sedation
214791847|NCT03179618|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
214791848|NCT03179618|DRUG|Lipid Regulating Drugs|Mainly including statins
214791849|NCT03179618|DRUG|Coronary Vasodilator|Mainly including nitrates
214791850|NCT03179618|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
214791851|NCT05085613|BEHAVIORAL|Corrective message framing and humor|The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
214791852|NCT00952484|BIOLOGICAL|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
214791853|NCT00952484|BIOLOGICAL|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
214791854|NCT03316313|DIAGNOSTIC_TEST|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
214791855|NCT02422290|DRUG|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
214791856|NCT00927459|DRUG|PRO-040201|Single dose IV infusion
214791857|NCT00927459|DRUG|Placebo|placebo
214791858|NCT00953979|DRUG|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
214791859|NCT04402749|OTHER|Nephrectomy|Patients underwent nephrectomy
214791860|NCT01375933|BIOLOGICAL|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
214791861|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
214791862|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
214791863|NCT00362700|DRUG|Clevudine|
214791864|NCT00886483|DEVICE|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
214791865|NCT00886483|DEVICE|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
214791866|NCT05233683|DRUG|Caudal block|Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
214791867|NCT05233683|DRUG|Dorsal penile nerve block plus ring block|"It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective."
214791868|NCT05233683|PROCEDURE|Circumcision with Plastibell|Circumcision with Plastibell
214791869|NCT05233683|PROCEDURE|Conventional Dissection Method|Conventional Dissection Method
214791870|NCT00650156|BIOLOGICAL|adalimumab|40 mg single sc dose
214791871|NCT00650156|BIOLOGICAL|adalimumab|80 mg single sc dose
214791872|NCT02160197|DEVICE|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
214791873|NCT02160197|DEVICE|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
214791874|NCT01811277|DRUG|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
214791875|NCT00548977|OTHER|Drawing blood to study genetic polymorphism|
214791876|NCT01982383|DEVICE|Micropulse Laser Treatment|
214791877|NCT01982383|OTHER|No treatment|
214791878|NCT04347447|OTHER|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
214791879|NCT04192825|PROCEDURE|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
214791880|NCT02033525|DRUG|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
214791881|NCT02033525|OTHER|Rehabilitation|Standard rehabilitation program
214791882|NCT00704223|DRUG|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
214791883|NCT04523805|BEHAVIORAL|Adapted judo programme|"The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~* Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~* Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~* Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~* Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting)."
214791884|NCT03077997|BEHAVIORAL|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, \& diabetes distress in people with type 2 diabetes mellitus.
214791885|NCT02307383|DRUG|Lactitol|
214791886|NCT02307383|DRUG|Lactobacillus|
214791887|NCT00585351|DRUG|Ranitidine|50 mg single dose injection of Ranitidine
214791888|NCT00585351|DRUG|Placebo|50 mg single dose injection of normal saline (placebo)
214791889|NCT00585351|OTHER|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
214791890|NCT00585351|OTHER|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
214791891|NCT05403411|OTHER|Distance education for nursing students on critical thinking|The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
214791892|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
214791893|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
214791894|NCT03662919|DRUG|Infliximab|Administered as specified in the treatment arm.
214791895|NCT03662919|DRUG|Adalimumab|Administered as specified in the treatment arm.
214791896|NCT02659202|DEVICE|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
214791897|NCT00788190|PROCEDURE|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
214791898|NCT00788190|OTHER|Conservative Management|Conservative management of Distal Radius Fractures
214791899|NCT03510299|DEVICE|Mcgrath|McGrath assisted insertion of LMA flexible
214791900|NCT03510299|DEVICE|Control|Digital manipulation technique of LMA flexible insertion
214791901|NCT03931096|OTHER|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
214791902|NCT02741492|PROCEDURE|Transversus Abdominis Plane Block|Continuous Nerve Block
214791903|NCT02741492|PROCEDURE|Sham Block|Continuous Sham Catheter
214791904|NCT03757455|PROCEDURE|ERAS protocol preoperative actions|"First appointment:~\- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
214791905|NCT03757455|PROCEDURE|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
214791906|NCT03757455|PROCEDURE|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~\- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
214791907|NCT01482624|DEVICE|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
214791908|NCT01482624|PROCEDURE|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
214791909|NCT03378622|OTHER|Anchor|Anchor technique for mesh attachment
214791910|NCT03378622|OTHER|Suture|Suture technique for mesh attachment
214791911|NCT01842958|DEVICE|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
214791912|NCT01842958|DEVICE|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
214791913|NCT01332409|DRUG|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
214791914|NCT02887209|BEHAVIORAL|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
214791915|NCT02224209|DEVICE|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~1. The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~2. Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
214791916|NCT02224209|DEVICE|a balloon, stent|"Routine stenting procedure:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
214791917|NCT04020107|OTHER|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
214791918|NCT01016509|DRUG|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.
214791919|NCT01016509|DRUG|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
214791920|NCT01829477|DRUG|TAK-875|TAK-875 50 mg tablets
214791921|NCT01829477|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
214791922|NCT01829477|DRUG|Glimepiride|Glimepiride tablet.
214791923|NCT03401905|PROCEDURE|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
214791924|NCT03401905|PROCEDURE|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
214791925|NCT06264947|DEVICE|laser acupuncture|wavelength: 808nm energy: 18j power: 100mw
214791926|NCT06264947|DEVICE|sham laser acupuncture|wavelength: 0nm energy: 0j power: 0mw
214791927|NCT05433428|DRUG|Lubricant Eye Drops|Prolonged use of lubricant eye drops pre and post-op.
214791928|NCT05433428|DRUG|Preservative Free|Preservative free eye drops
214791929|NCT05433428|DRUG|Preservative|Eyedrops with preservatives
214791930|NCT01953497|DRUG|URC102|
214791931|NCT01953497|DRUG|Placebo|
214791932|NCT03960697|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
214791933|NCT01919268|DEVICE|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
214791934|NCT01919268|DEVICE|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
214791935|NCT03090984|DEVICE|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
214791936|NCT03090984|DEVICE|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
214791937|NCT03090984|DEVICE|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
214791938|NCT00002175|DRUG|Dinitrochlorobenzene|
214791939|NCT02511236|BEHAVIORAL|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
214791940|NCT02511236|BEHAVIORAL|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
214791941|NCT02511236|DRUG|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
214791942|NCT00003942|BIOLOGICAL|RevM10 gene|
214791943|NCT00003942|BIOLOGICAL|RevM10/polAS gene|
214791944|NCT00003942|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214791945|NCT00003942|PROCEDURE|peripheral blood stem cell transplantation|
214791946|NCT02210351|DEVICE|MRI test|
214791947|NCT00380471|DEVICE|Bath PUVA|
214791948|NCT04310410|COMBINATION_PRODUCT|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
214791949|NCT06138535|DEVICE|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
214791950|NCT01836835|OTHER|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
214791951|NCT01836835|OTHER|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
214791952|NCT02408666|OTHER|Interview|
214791953|NCT04459195|BEHAVIORAL|2 Minute Static Stretching|Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
214791954|NCT04459195|BEHAVIORAL|5 Minute Static Stretching|Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
214791955|NCT06103409|BIOLOGICAL|Implantation of allogeneic MSCs on burn wounds|Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
214791956|NCT01336894|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214791957|NCT01336894|RADIATION|iodine I 125|Undergo seed implant radiotherapy
214791958|NCT01336894|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
214791959|NCT01664689|PROCEDURE|Microcoaxial Phacoemulsification|
214791960|NCT01073436|OTHER|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
214791961|NCT05034731|DEVICE|Remote Fitting|Processors will be programmed using remote fitting application.
214791962|NCT05034731|DEVICE|In-Office Fitting|Processors will be programmed using standard Target CI application.
214791963|NCT05585658|BIOLOGICAL|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
214791964|NCT01649141|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
214791965|NCT03020602|OTHER|Laboratory Biomarker Analysis|Correlative studies
214791966|NCT03020602|OTHER|Pharmacological Study|Correlative studies
214791967|NCT03020602|DRUG|Ubidecarenone Injectable Nanosuspension|Given IV
214791968|NCT05670652|OTHER|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
214791969|NCT02746263|DRUG|IV acetaminophen|
214791970|NCT02746263|DRUG|Oral acetaminophen|
214791971|NCT02746263|DRUG|Morphine|Patient controlled analgesia
214791972|NCT00323947|DRUG|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
214791973|NCT01325207|RADIATION|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
214791974|NCT04044430|DRUG|Binimetinib|Given PO
214791975|NCT04044430|DRUG|Encorafenib|Given PO
214791976|NCT04044430|BIOLOGICAL|Nivolumab|Given IV
214791977|NCT04044430|OTHER|Questionnaire Administration|Ancillary studies
214791978|NCT00602030|DRUG|Entinostat|Entinostat tablets on Days 1 and 15 of a 28-day cycle.
214791979|NCT00602030|DRUG|Placebo|Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
214791980|NCT00602030|DRUG|Erlotinib|Erlotinib 150 mg tablets once daily.
214791981|NCT06485024|DEVICE|Modeling Resin|it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
214791982|NCT05743283|DEVICE|SynEx Wound Cleanser|SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
214791983|NCT05743283|OTHER|Saline|The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.
214791984|NCT04919928|DEVICE|Cochlear Implant and Hearing aid in bimodal solution|"Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear."
214791985|NCT04919928|DEVICE|Bilateral hearing aids|Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
214791986|NCT00371800|DRUG|cinnamon|
214791987|NCT05300932|DRUG|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
214791988|NCT05300932|DRUG|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
214791989|NCT00650299|DRUG|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
214791990|NCT00650299|DRUG|Xanax XR® Tablets 3 mg|3mg, single dose fed
214791991|NCT03327896|OTHER|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
214791992|NCT05305209|OTHER|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
214791993|NCT05305209|OTHER|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
214791994|NCT01669395|OTHER|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
214791995|NCT01669395|OTHER|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
214791996|NCT00283686|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
214791997|NCT00283686|DRUG|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
214791998|NCT00283686|DRUG|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
214791999|NCT00283686|OTHER|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
214792000|NCT00283686|OTHER|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
214792001|NCT01999790|PROCEDURE|blepharotomy|upper eyelid surgery by blepharotomy
214792002|NCT01999790|PROCEDURE|posterior approach|upper eyelid surgery by posterior approach
214792003|NCT03892148|DRUG|Furosemide|Protocol for the use of diuretics
214792004|NCT03892148|DRUG|Hydrochlorothiazide|Protocol for the use of diuretics
214792005|NCT02987595|OTHER|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
214792006|NCT02987595|OTHER|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
214792007|NCT02628340|OTHER|Ex-vivo analysis|
214792008|NCT02531022|BEHAVIORAL|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
214792009|NCT02531022|BEHAVIORAL|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
214792010|NCT05583175|DRUG|Venetoclax plus RIC|Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.
214792011|NCT00956228|RADIATION|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
214792012|NCT00670475|DRUG|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
214792013|NCT00670475|DIETARY_SUPPLEMENT|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
214792014|NCT05358210|BEHAVIORAL|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
214792015|NCT05358210|BEHAVIORAL|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
214792016|NCT05476679|DRUG|RZL-012|50mg/ml drug formulation
214792017|NCT05476679|DRUG|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
214792018|NCT05476679|DRUG|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
214792019|NCT05476679|DRUG|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
214792020|NCT05476679|DRUG|RZL-012+facial and neck wrap|Universal Facial Band
214792021|NCT02632656|OTHER|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
214792022|NCT06095258|DRUG|Traditional Chinese medicine treatment|About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
214792023|NCT06095258|DRUG|Western medicine treatment|Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
214792024|NCT03991832|DRUG|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
214792025|NCT03991832|DRUG|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
214792026|NCT04122222|BIOLOGICAL|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
214792027|NCT06048900|DEVICE|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
214792028|NCT01775761|DRUG|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
214792029|NCT01775761|DRUG|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
214792030|NCT01775761|DRUG|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
214792031|NCT06485037|BEHAVIORAL|Time-restricted eating|Self-selected 10-hour eating window for 2 months
214792032|NCT00788528|DRUG|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
214792033|NCT01735058|DRUG|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
214792034|NCT01735058|DRUG|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
214792035|NCT00125996|DRUG|Venofer (intravenous iron sucrose)|
214792036|NCT01569828|DRUG|LCZ696A|
214792037|NCT01569828|DRUG|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
214792038|NCT04738279|DEVICE|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
214792039|NCT04738279|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
214792040|NCT01973114|DRUG|Latanoprost|
214792041|NCT01973114|OTHER|Placebo|
214792042|NCT01128647|DIETARY_SUPPLEMENT|Fructose:glucose drink|
214792043|NCT01128647|DIETARY_SUPPLEMENT|glucose drink|
214792044|NCT03717610|PROCEDURE|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
214792045|NCT00467584|DRUG|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
214792046|NCT00467584|DRUG|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
214792047|NCT00467584|DRUG|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
214792048|NCT00685971|DIETARY_SUPPLEMENT|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
214792049|NCT00685971|DIETARY_SUPPLEMENT|placebo|5 drops once daily for 12 weeks
214792050|NCT02077959|DRUG|lenalidomide|Given PO
214792051|NCT02077959|BIOLOGICAL|pidilizumab|Given IV
214792052|NCT02077959|OTHER|pharmacological study|Correlative studies
214792053|NCT02077959|OTHER|laboratory biomarker analysis|Correlative studies
214792054|NCT01597895|DRUG|Maraviroc|Maraviroc 150 mg BID x 5 days with food
214792055|NCT01597895|DRUG|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
214792056|NCT01597895|DRUG|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
214792057|NCT04919083|OTHER|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
214792058|NCT04919083|OTHER|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
214792059|NCT03831633|DRUG|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~\- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
214792060|NCT03831633|DRUG|Standard of Care|"* oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
214792061|NCT05442983|DRUG|PanCytoVir™ (probenecid)|Active drug
214792062|NCT05442983|DRUG|Placebo|Matching placebo
214792063|NCT00494104|DIETARY_SUPPLEMENT|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
214792064|NCT01332110|DEVICE|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
214792065|NCT00319956|DRUG|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
214792066|NCT00319956|DRUG|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
214792067|NCT01146132|DIETARY_SUPPLEMENT|Conventional diet +/- wine|usual eating habits
214792068|NCT01146132|DIETARY_SUPPLEMENT|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
214792069|NCT04616417|PROCEDURE|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
214792070|NCT02607800|DRUG|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
214792071|NCT02607800|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
214792072|NCT00753714|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214792073|NCT00753714|DRUG|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214792074|NCT00753714|DRUG|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214792075|NCT02549742|PROCEDURE|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
214792076|NCT02549742|DEVICE|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
214792077|NCT02549742|DRUG|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
214792078|NCT03256513|OTHER|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
214792079|NCT03256513|OTHER|conventional controlling|control blood pressure by conventional strategy
214792080|NCT02486796|BIOLOGICAL|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
214792081|NCT02486796|DRUG|Coenzyme Q10|Preparation of coenzyme Q10
214792082|NCT02486796|DRUG|Melatonin|Preparation of melatonin
214792083|NCT01513668|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
214792084|NCT00002719|BIOLOGICAL|filgrastim|
214792085|NCT00002719|DRUG|amsacrine|
214792086|NCT00002719|DRUG|carmustine|
214792087|NCT00002719|DRUG|cytarabine|
214792088|NCT00002719|DRUG|etoposide|
214792089|NCT00002719|DRUG|idarubicin|
214792090|NCT00002719|DRUG|mitoxantrone hydrochloride|
214792091|NCT00002719|PROCEDURE|peripheral blood stem cell transplantation|
214792092|NCT01268449|RADIATION|Low dose laser|5mv laser with a wavelength of 650nm
214792093|NCT01268449|RADIATION|Placebo|The act of radiating laser to the ear is done while the set is off.
214792094|NCT00016926|DRUG|capecitabine|
214792095|NCT00310427|DRUG|LY686017|50 mg administered orally on a daily basis
214792096|NCT00310427|DRUG|Placebo|Administered on a daily basis
214792097|NCT01821027|DRUG|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
214792098|NCT01821027|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
214792099|NCT01080430|OTHER|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
214792100|NCT06484959|OTHER|Assigned Interventions|Assigned Interventions
214792101|NCT02072564|OTHER|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
214792102|NCT04389879|OTHER|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
214792103|NCT01911585|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
214792104|NCT01297010|DRUG|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
214792105|NCT01297010|DRUG|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
214792106|NCT04773093|DRUG|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
214792107|NCT04773093|DRUG|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
214792108|NCT05783479|DRUG|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
214792109|NCT05783479|DRUG|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
214792110|NCT00629616|DRUG|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
214792111|NCT00629616|DRUG|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
214792112|NCT03746678|OTHER|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
214792113|NCT02789111|DRUG|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
214792114|NCT02789111|DRUG|Placebo|Placebo twice daily up to 15 doses
214792115|NCT02262949|DEVICE|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
214792116|NCT05678920|OTHER|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
214792117|NCT00367185|DRUG|Thalidomide|
214792118|NCT01626885|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
214792119|NCT02141386|OTHER|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
214792120|NCT02362906|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
214792121|NCT02362906|DRUG|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
214792122|NCT02362906|DRUG|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
214792123|NCT02362906|DRUG|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
214792124|NCT02362906|DRUG|second generation cephalosporin|
214792125|NCT02362906|DRUG|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
214792126|NCT02362906|DRUG|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
214792127|NCT05092061|OTHER|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
214792128|NCT05092061|OTHER|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
214792129|NCT02493725|DRUG|Eculizumab|
214792130|NCT02493725|DRUG|Placebo|
214792131|NCT04636749|DEVICE|Erbium laser|Vaginal laser therapy
214792132|NCT04636749|DEVICE|Sham laser|Sham laser therapy
214792133|NCT05725590|PROCEDURE|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
214792134|NCT05725590|PROCEDURE|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
214792135|NCT05645458|OTHER|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
214792136|NCT03954561|PROCEDURE|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
214792137|NCT03954561|PROCEDURE|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
214792138|NCT03619161|OTHER|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
214792139|NCT03619161|OTHER|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
214792140|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
214792141|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
214792142|NCT01562795|DRUG|corticosteroids|corticosteroids plus artificial tear substitute
214792143|NCT01562795|DRUG|artificial tear substitute|artificial tear substitute alone
214792144|NCT03277781|OTHER|Screening|Screening for AAA
214792145|NCT04053881|DRUG|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
214792146|NCT04215055|DEVICE|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
214792147|NCT05979181|PROCEDURE|Cesarean hysterectomy|Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
214792148|NCT02397681|OTHER|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
214792149|NCT05105165|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
214792150|NCT00673790|DRUG|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
214792151|NCT00673790|DRUG|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
214792152|NCT00673790|DRUG|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
214792153|NCT06545422|OTHER|St. John's wort oil|To examine the effect of regularly applied St. John's Wort oil on skin moisture.
214792154|NCT06545422|OTHER|Barrier Cream|To examine the effect of regularly applied barrier cream on skin moisture.
214792155|NCT01785784|DRUG|rhGM-CSF Gel|
214792156|NCT00374413|DEVICE|Artificial disk|Implant
214792157|NCT00374413|DEVICE|Artificial disc|Implant
214792158|NCT04326842|PROCEDURE|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
214792159|NCT04326842|DEVICE|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
214792160|NCT01533428|DRUG|Capsaicin 8%|Capsaicin 8% transdermal delivery system
214792161|NCT01533428|DRUG|Placebo|Placebo Patch
214792162|NCT03247283|DRUG|BMS-986205|Carbon 14 tagged BMS-986205
214792163|NCT04165278|OTHER|hyperthermic baths|Taking hyperthermic baths
214792164|NCT04032678|DEVICE|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
214792165|NCT04032678|DEVICE|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
214792166|NCT02234297|DRUG|BLZ-100|
214792167|NCT05442333|PROCEDURE|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures."
214792168|NCT00094133|PROCEDURE|hot flashes attenuation|
214792169|NCT00094133|PROCEDURE|hypnotherapy|
214792170|NCT03974633|COMBINATION_PRODUCT|Injection|All information is included in the Arm/group descriptions
214792171|NCT00004451|DRUG|Glucose|
214792172|NCT01179633|DEVICE|OPLON active patch|
214792173|NCT01179633|DEVICE|Sham patch|
214792174|NCT01492062|DEVICE|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
214792175|NCT01869322|DEVICE|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
214792176|NCT01869322|DEVICE|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
214792177|NCT00627718|DEVICE|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
214792178|NCT01483872|DRUG|NAC/Tigecycline/Heparin combination lock solution|
214792179|NCT01483872|DRUG|Standard anticoagulant (Heparin or Citrate)|
214792180|NCT04309409|DRUG|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
214792181|NCT01692158|DRUG|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
214792182|NCT00457522|BEHAVIORAL|Nurse/community health worker telephone intervention|
214792183|NCT02353065|PROCEDURE|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
214792184|NCT02353065|RADIATION|Bedside x-ray|Portable x-ray of fracture post-reduction
214792185|NCT01104519|DRUG|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
214792186|NCT01104519|DRUG|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
214792187|NCT01364870|DEVICE|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
214792188|NCT01364870|DEVICE|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
214792189|NCT04203407|BEHAVIORAL|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
214792190|NCT04203407|BEHAVIORAL|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
214792191|NCT00680875|BEHAVIORAL|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
214792192|NCT01890707|PROCEDURE|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
214792193|NCT01890707|PROCEDURE|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
214792194|NCT06278402|DRUG|Tofacitinib|Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
214792195|NCT04965649|GENETIC|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
214792196|NCT05286528|DRUG|Bosutinib|Bosutinib as prescribed in real world
214792197|NCT05286528|DRUG|Imatinib|Imatinib as prescribed in real world
214792198|NCT05286528|DRUG|Nilotinib|Nilotinib as prescribed in real world
214792199|NCT05286528|DRUG|Dasatinib|Dasatinib as prescribed in real world
214792200|NCT05286528|DRUG|Ponatinib|Ponatinib as prescribed in real world
214792201|NCT06104696|PROCEDURE|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
214792202|NCT04027764|DRUG|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
214792203|NCT00506753|BEHAVIORAL|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
214792204|NCT00506753|BEHAVIORAL|RT/SU|Relaxation Training followed by Treatment as Usual
214792205|NCT02872649|DRUG|Dabigatran|
214792206|NCT02872649|DRUG|Phenprocoumon|
214792207|NCT00125359|DRUG|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
214792208|NCT01150448|DRUG|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
214792209|NCT01150448|DRUG|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
214792210|NCT03182257|DRUG|ONO-7579|ONO-7579 Tablets
214792211|NCT02451670|BEHAVIORAL|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
214792212|NCT04932356|OTHER|Therapeutic education by phone|The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.
214792213|NCT04932356|OTHER|Therapeutical education traditional|The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
214792214|NCT01677559|DRUG|MLN8237|
214792215|NCT01677559|DRUG|nab-Paclitaxel|
214792216|NCT01513551|BIOLOGICAL|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
214792217|NCT01513551|BIOLOGICAL|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
214792218|NCT01513551|BIOLOGICAL|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
214792219|NCT06442683|DIAGNOSTIC_TEST|TTE simulation-based medical training|half-day simulation-based neonatal echocardiography training.
214792220|NCT04393506|DRUG|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
214792221|NCT04393506|DRUG|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
214792222|NCT04393506|PROCEDURE|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
214792223|NCT04393506|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
214792224|NCT05569148|COMBINATION_PRODUCT|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
214792225|NCT03202836|DRUG|progesterone|vaginal utrogestan
214792226|NCT03202836|DRUG|Tocolytics|tocolysis for 48 hours
214792227|NCT03202836|DRUG|Steroids|antenatal corticosteroids for 48 hours
214792228|NCT00116922|DRUG|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
214792229|NCT05909475|DIETARY_SUPPLEMENT|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
214792230|NCT05909475|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
214792231|NCT00649870|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
214792232|NCT00649870|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fed
214792233|NCT00099736|DRUG|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
214792234|NCT00099736|DRUG|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
214792235|NCT00099736|DRUG|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
214792236|NCT04053790|DRUG|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
214792237|NCT04053790|OTHER|placebo|a tablet of placebo every 12 hours given by mouth
214792238|NCT01768806|BEHAVIORAL|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
214792239|NCT01768806|BEHAVIORAL|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
214792240|NCT05587088|DRUG|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
214792241|NCT05587088|DRUG|Placebo|Placebo in pill
214792242|NCT04852003|DRUG|SHR0410 Injection|SHR0410 Injection
214792243|NCT04852003|DRUG|Placebo|Placebo for SHR0410 Injection
214792244|NCT04852003|DRUG|Morphine|Morphine
214792245|NCT00094302|DRUG|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
214792246|NCT00094302|DRUG|Placebo|Placebo of spironolactone
214792247|NCT03940001|BIOLOGICAL|Sintilimab|Other Name: (IBI308)
214792248|NCT03940001|DRUG|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
214792249|NCT03940001|RADIATION|Radiation|IMRT or VMAT
214792250|NCT00005520|DRUG|Hydrochlorothiazide|
214792251|NCT00005520|DRUG|Candesartan|
214792252|NCT03881826|OTHER|collection of clinical data and biological samples|"* nutritional assessement~* cachexia symptoms~* urine, feces and blood samples"
214792253|NCT02779582|DRUG|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
214792254|NCT02779582|DRUG|Placebo|pill with no effect
214792255|NCT03056326|DRUG|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
214792256|NCT03056326|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
214792257|NCT03056326|DRUG|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
214792258|NCT03056326|DRUG|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
214792259|NCT01928914|DRUG|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
214792260|NCT01928914|DRUG|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
214792261|NCT01928914|DRUG|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
214792262|NCT01928914|DRUG|moxifloxacin|moxifloxacine given on Day 3 only
214792263|NCT01928914|DRUG|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
214792264|NCT01928914|DRUG|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
214792265|NCT04561310|OTHER|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
214792266|NCT04561310|OTHER|Active release technique|"Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
214792267|NCT00514995|DRUG|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
214792268|NCT06201481|PROCEDURE|anterior and posterior full coverage crowns|Teeth preparation,crown fitting and cementation
214792269|NCT06302855|DIAGNOSTIC_TEST|dental expertise|dental visit based on dental expertise
214792270|NCT03004690|DEVICE|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
214792271|NCT03004690|DEVICE|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
214792272|NCT06093256|DEVICE|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
214792273|NCT03705351|DEVICE|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
214792274|NCT03705351|DRUG|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
214792275|NCT03705351|RADIATION|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
214792276|NCT00446498|DEVICE|CPAP and Non Invasive Ventilation|
214792277|NCT02780661|DEVICE|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
214792278|NCT02780661|DEVICE|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
214792279|NCT02780661|OTHER|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
214792280|NCT03321747|RADIATION|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
214792281|NCT05994456|DRUG|PD-1 inhibitor|240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
214792282|NCT01806688|OTHER|gluten-free high protein snack #1|buckwheat groats 30g serving
214792283|NCT01806688|OTHER|gluten-free snack with similar energy density but 1/2 the protein as snack #1|32g serving of corn nuts
214792284|NCT01806688|OTHER|non-caloric control|water
214792285|NCT01806688|OTHER|gluten-free high protein and high fibre snack #2|buckwheat and pinto bean flour pita bread 50g serving
214792286|NCT01806688|OTHER|gluten-free snack with similar energy density, but less protein and fibre than snack #2|50g serving of rice bread
214792287|NCT05089994|PROCEDURE|US guided injection|using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
214792288|NCT03642574|PROCEDURE|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
214792289|NCT04298164|BEHAVIORAL|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
214792290|NCT04298164|BEHAVIORAL|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
214792291|NCT04776551|PROCEDURE|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
214792292|NCT01717014|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
214792293|NCT05436821|DEVICE|Auricular vagus nerve stimulation|Autonomic nerve system regulation
214792294|NCT05436821|DEVICE|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
214792295|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
214792296|NCT05621538|DEVICE|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
214792297|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
214792298|NCT05621538|DEVICE|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
214792299|NCT02240407|GENETIC|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10\^13 vg per TA muscle (range of 7.64 x 10\^11 vg/gm to 4.6 x 10\^11 vg/gm based on TA weight).
214792300|NCT02240407|DRUG|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
214792301|NCT02240407|OTHER|saline|Same volume as rAAV9-DES-hGAA injection will be used.
214792302|NCT02240407|DRUG|Rituxan|Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
214792303|NCT02240407|DRUG|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
214792304|NCT02240407|DRUG|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
214792305|NCT02240407|DRUG|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
214792306|NCT02240407|DRUG|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
214792307|NCT03097393|DIAGNOSTIC_TEST|measure Serum procalcitonin level|measuring procalcitonin level
214792308|NCT02371083|OTHER|Extended timing of pessary care|
214792309|NCT00337805|OTHER|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
214792310|NCT03191721|PROCEDURE|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
214792311|NCT03191721|PROCEDURE|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
214792312|NCT03191721|PROCEDURE|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
214792313|NCT03191721|DRUG|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
214792314|NCT03191721|DRUG|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
214792315|NCT03191721|PROCEDURE|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
214792316|NCT05107284|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
214792317|NCT05107284|BEHAVIORAL|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
214792318|NCT01127490|DRUG|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
214792319|NCT01127490|PROCEDURE|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
214792320|NCT02319681|BEHAVIORAL|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
214792321|NCT02319681|BEHAVIORAL|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
214792322|NCT03548714|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
214792323|NCT03548714|OTHER|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
214792324|NCT02203136|PROCEDURE|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
214792325|NCT02203136|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
214792326|NCT03657979|DRUG|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
214792327|NCT03657979|DRUG|Placebo|TAP-block with placebo
214792328|NCT04669821|DRUG|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
214792329|NCT04669821|DRUG|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
214792330|NCT05126875|RADIATION|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
214792331|NCT02089542|OTHER|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
214792332|NCT00006170|DRUG|Bupropion|smoking cessation medication aid
214792333|NCT00006170|DRUG|Placebo|A matched placebo pill
214792334|NCT00006170|BEHAVIORAL|weight concerns intervention|cognitive behavioral treatment to address weight concners
214792335|NCT00006170|BEHAVIORAL|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
214792336|NCT00312000|DRUG|capecitabine-irinotecan|"1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
214792337|NCT00312000|DRUG|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
214792338|NCT04449042|PROCEDURE|airway management during sedation or general anesthesia|airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
214792339|NCT03562299|DEVICE|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
214792340|NCT00322556|DRUG|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
214792341|NCT05786807|DRUG|K-CAB|Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
214792342|NCT05151978|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
214792343|NCT03591978|DIAGNOSTIC_TEST|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
214792344|NCT05965193|DEVICE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
214792345|NCT05965193|DEVICE|Nasal oxygen|For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
214792346|NCT05965193|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
214792347|NCT01205698|OTHER|Nutritional drink|
214792348|NCT00793728|PROCEDURE|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
214792349|NCT02058628|DRUG|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
214792350|NCT02058628|DRUG|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
214792351|NCT01225328|BEHAVIORAL|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
214792352|NCT01226277|DRUG|GDC-0917|Oral repeating dose
214792353|NCT04727697|OTHER|Augmented Reality|Patients will receive the preoperative AR experience during their immediately preoperative office visit. The duration of the exposure is approximately 15 minutes.
214792354|NCT04727697|OTHER|Standard of Care preoperative teaching and handouts|At preoperative appointments, patients receive verbal teaching and written handouts about day of surgery instructions and expectations.
214792355|NCT01767597|OTHER|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
214792356|NCT01767597|OTHER|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
214792357|NCT03386097|OTHER|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
214792358|NCT05566665|DIAGNOSTIC_TEST|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
214792359|NCT02961920|DEVICE|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
214792360|NCT02961920|DEVICE|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
214792361|NCT04661462|OTHER|online survey|We invite volunteers after COVID-19 to participate in an online survey.
214792362|NCT04530786|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
214792363|NCT04141410|DRUG|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
214792364|NCT04141410|DEVICE|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
214792365|NCT05216614|DRUG|Fluvoxamine|Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
214792366|NCT05216614|DRUG|Placebo|lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
214792367|NCT03417349|DEVICE|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
214792368|NCT04653870|OTHER|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
214792369|NCT04653870|OTHER|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
214792370|NCT04336956|OTHER|hospitalized children with Covid19|All patients under 18 years hospitalized with a covid19 diagnosis
214792371|NCT00955032|DEVICE|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
214792372|NCT00955032|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
214792373|NCT05875415|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
214792374|NCT05875415|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
214792375|NCT04527471|DRUG|Ensifentrine Dose 1|Study drug delivered twice daily via pMDI
214792376|NCT04527471|DRUG|Placebo pMDI|Placebo delivered twice daily via pMDI
214792377|NCT05147454|OTHER|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
214792378|NCT02721797|PROCEDURE|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
214792379|NCT01753037|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
214792380|NCT01753037|OTHER|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
215030943|NCT01817400|OTHER|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
214792381|NCT05720871|DEVICE|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
214792382|NCT05720871|DEVICE|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
214792383|NCT06135285|DEVICE|Control subjects|The subject will be repositioned from the prone to recovery position
214792384|NCT03215173|BEHAVIORAL|Fit After Baby|Mobile application
214792385|NCT03215173|BEHAVIORAL|Text4Baby Control Group|Receive free text messages
214792386|NCT04280172|OTHER|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
214792387|NCT04280172|OTHER|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
214792388|NCT00624767|DRUG|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
214792389|NCT00624767|DRUG|NovoLog|NovoLog at doses up to 30 IU
214792390|NCT03020472|BIOLOGICAL|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
214792391|NCT03636321|PROCEDURE|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
214792392|NCT01021995|DRUG|echinacea|drops, 0.9 ml, tid for 4 months
214792393|NCT01021995|DRUG|placebo|drops, 0.9 ml tid for 4 months
214792394|NCT04799210|DEVICE|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
214792395|NCT00096265|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
214792396|NCT00096265|DRUG|Erlotinib Hydrochloride|Given orally
214792397|NCT00096265|RADIATION|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
214792398|NCT00096265|DRUG|Temozolomide|Given orally
214792399|NCT02890823|DRUG|Cholecalciferol|
214792400|NCT01506323|BEHAVIORAL|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
214792401|NCT01506323|BEHAVIORAL|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
214792402|NCT05385679|PROCEDURE|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
214792403|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
214792404|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
214792405|NCT01748500|DRUG|Pantoprazole|
214792406|NCT04499183|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|15 gram/day fructo- and galacto-oligosaccharides
214792407|NCT02192905|BEHAVIORAL|Diabetes Prevention Program Lifestyle Intervention|
214792408|NCT04352374|OTHER|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
214792409|NCT04352374|DEVICE|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
214792410|NCT00246974|DRUG|Gemcitabine|intravenous
214792411|NCT00246974|DRUG|Cisplatin|intravenous
214792412|NCT00246974|DRUG|Gefitinib|oral
214792413|NCT04674098|DEVICE|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
214792414|NCT01957683|DEVICE|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
214792415|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
214792416|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
214792417|NCT01501695|DRUG|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
214792418|NCT01501695|DRUG|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
214792419|NCT01501695|DRUG|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
214792420|NCT02638831|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
214792421|NCT02638831|DRUG|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
214792422|NCT03811041|OTHER|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
214792423|NCT03811041|OTHER|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
214792424|NCT03811041|OTHER|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
214792425|NCT02219191|DRUG|puerarin tablet 50 mg|
214792426|NCT02219191|DRUG|Atorvastatin tablet 20 mg|Approval No.: H19990258
214792427|NCT04145908|PROCEDURE|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
214792428|NCT02497833|DIETARY_SUPPLEMENT|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
214792429|NCT02497833|OTHER|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
214792430|NCT00291395|DRUG|PGI2|
214792431|NCT02636127|OTHER|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~\- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
214792432|NCT01400282|DEVICE|High frequency spinal cord stimulation|
214792433|NCT02585882|OTHER|Fluoride table salt|
214792434|NCT02067780|DRUG|Levofloxacin 500mg|One tablet per day for 7days.
214792435|NCT02414880|DRUG|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
214792436|NCT02414880|DRUG|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
214792437|NCT02414880|DRUG|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
214792438|NCT01383525|DEVICE|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
214792439|NCT05371522|RADIATION|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain \[18F\]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
214792440|NCT01989065|BEHAVIORAL|Lifestyle counseling|see arm description
214792441|NCT01989065|BEHAVIORAL|Text Messaging|See Arm Description
214792442|NCT03522922|DEVICE|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
214792443|NCT03522922|DRUG|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
214792444|NCT00544765|DRUG|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
214792445|NCT00544765|DRUG|NX|Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
214792446|NCT05764122|DRUG|BIIB131|Administered as specified in the treatment arm.
214792447|NCT05764122|DRUG|Placebo|Administered as specified in the treatment arm.
214792448|NCT02943525|PROCEDURE|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
214792449|NCT05159310|PROCEDURE|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
214792450|NCT01241409|DRUG|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
214792451|NCT01241409|DRUG|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
214792452|NCT01241409|DRUG|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
214792453|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Treat)|Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.
214792454|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Placebo)|Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.
214792455|NCT00580853|DRUG|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
214792456|NCT00580853|DRUG|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
214792457|NCT00580853|DRUG|Placebo|Placebo
214792458|NCT03270176|DRUG|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
214792459|NCT03270176|DRUG|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
214792460|NCT01626820|BIOLOGICAL|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
214792461|NCT05713474|DIAGNOSTIC_TEST|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
214792462|NCT05713474|DIAGNOSTIC_TEST|Conventional EMG|Diagnostic EMG exam with conventional EMG
214792463|NCT04266691|OTHER|nonIntervention|nonIntervention
214792464|NCT04032873|OTHER|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
214792465|NCT04032873|OTHER|Physician|The monetary cost information is relayed by the patient's physician
214792466|NCT04032873|OTHER|Study Team|The monetary cost information is relayed by a member of the study team
214792467|NCT04032873|OTHER|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
214792468|NCT04032873|OTHER|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
214792469|NCT04579926|OTHER|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
214792470|NCT03940430|DRUG|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
214792471|NCT03940430|DRUG|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
214792472|NCT02267057|DRUG|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
214792473|NCT02267057|DRUG|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
214792474|NCT02267057|DRUG|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
214792475|NCT02267057|DRUG|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
214792476|NCT02588573|DEVICE|etafilcon A (control)|contact lens
214792477|NCT02588573|DEVICE|somofilcon A (test)|contact lens
214792478|NCT03534986|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
214792479|NCT03534986|DEVICE|Hill-Rom The Vest|High-frequency chest wall oscillation vest
214792480|NCT03534986|DEVICE|Respirtech inCourage|High-frequency chest wall oscillation vest
214792481|NCT03534986|DEVICE|Electromed SmartVest|High-frequency chest wall oscillation vest
214792482|NCT04604184|DRUG|BI 764198|BI 764198
214792483|NCT04604184|DRUG|Placebo|Placebo
214792484|NCT06543641|DIAGNOSTIC_TEST|Coronary computed tomography angiography|All patients received coronary computed tomography angiography.
214792485|NCT06543641|DIAGNOSTIC_TEST|Invasive coronary angiography|According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
214792486|NCT02051803|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
214792487|NCT02051803|BEHAVIORAL|Health Education (HE)|
214792488|NCT03513497|OTHER|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
214792489|NCT02025114|DRUG|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
214792490|NCT00821210|DEVICE|Sham CPAP|CPAP with pressure of 3cm H2O
214792491|NCT00821210|DEVICE|CPAP of optimal pressure|CPAP of optimal pressure
214792492|NCT05876702|DEVICE|endoscopy|use of upper endoscopy with i-scan specially , in diagnosis of esophageal lesions and comparison of results with histopathology.
214792493|NCT03294538|DRUG|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
214792494|NCT03294538|DRUG|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
214792495|NCT03294538|DRUG|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
214792496|NCT04247490|DIAGNOSTIC_TEST|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
214792497|NCT02942251|OTHER|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
214792498|NCT02942251|OTHER|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
214792499|NCT02942251|OTHER|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
214792500|NCT02942251|OTHER|Laboratory abnormality|This group will be suggested to more safety antidepressants.
214792501|NCT02942251|OTHER|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
214792502|NCT02942251|OTHER|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
214792503|NCT02984306|DIETARY_SUPPLEMENT|Cherry powder|
214792504|NCT02984306|DIETARY_SUPPLEMENT|Placebo|
214792505|NCT05737056|OTHER|Management of rheumatoid purpura|Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
214792506|NCT00422656|DRUG|Perifosine|
214792507|NCT01977261|PROCEDURE|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
214792508|NCT01977261|PROCEDURE|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
214792509|NCT05670054|DRUG|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
214792510|NCT02410525|DRUG|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
214792511|NCT02410525|DRUG|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
214792512|NCT02410525|DRUG|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
214792513|NCT04431986|OTHER|No intervention: secondary use of a database|Statistical analyses
214792514|NCT04319484|DRUG|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
214792515|NCT04319484|DRUG|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
214792516|NCT04000321|OTHER|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
214792517|NCT04000321|OTHER|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
214792518|NCT06543147|OTHER|breast cancer and breast self- examination education|The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
214792519|NCT06169098|PROCEDURE|Auricular acupressure on the left ear|Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
214792520|NCT06169098|PROCEDURE|Auricular acupressure on the right ear|Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
214792521|NCT06169098|PROCEDURE|Sham auricular acupressure|Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
214792522|NCT03788577|DIETARY_SUPPLEMENT|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
214792523|NCT03788577|DIETARY_SUPPLEMENT|Placebo|Placebo
214792524|NCT01323348|BEHAVIORAL|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~* Measurement of HbA1c in office with immediate feedback~* Measurement of blood pressure with immediate feedback~* Assessment of retinopathy risk with immediate feedback~* Personalized risk assessment reports based on current HbA1c~* Brief assessment of patient understanding of key issues with immediate feedback~* Supplemental diabetes management educational materials (provided at baseline only)~* Feedback to primary care provider~* Email reminder to study participants with email access of individualized risk assessment findings"
214792525|NCT01627873|DRUG|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
214792526|NCT01627873|DRUG|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
214792527|NCT02391428|PROCEDURE|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
214792528|NCT02391428|DIETARY_SUPPLEMENT|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
214792529|NCT01773564|DEVICE|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
214792530|NCT01773564|DEVICE|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
214792531|NCT00000882|DRUG|Indinavir sulfate|
214792532|NCT00000882|DRUG|Delavirdine mesylate|
214792533|NCT00000882|DRUG|Lamivudine|
214792534|NCT00000882|DRUG|Stavudine|
214792535|NCT00000882|DRUG|Zidovudine|
214792536|NCT00885690|DRUG|Sertindole|Sertindole 16-24 mg once daily
214792537|NCT00885690|DRUG|Olanzapine|Olanzapine 10-20 mg
214792538|NCT05056142|PROCEDURE|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
214792539|NCT05056142|PROCEDURE|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
214792540|NCT00503620|DRUG|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
214792541|NCT00647582|PROCEDURE|adjuvant therapy|
214792542|NCT00647582|PROCEDURE|therapeutic conventional surgery|
214792543|NCT00647582|RADIATION|intraoperative radiation therapy|
214792544|NCT00647582|RADIATION|radiation therapy|
214792545|NCT06412562|DIAGNOSTIC_TEST|The Maudsley 3-item Visual Analogue Scale (M3VAS)|Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
214792546|NCT01349439|DRUG|Propranolol|1mg per Kg (participant weight)
214792547|NCT01349439|DRUG|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
214792548|NCT00719784|DEVICE|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
214792549|NCT03260764|DEVICE|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
214792550|NCT03260764|DEVICE|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
214792551|NCT03260764|DEVICE|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
214792552|NCT03260764|DEVICE|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
214792553|NCT01191021|DRUG|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
214792554|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
214792555|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
214792556|NCT04356859|DRUG|Albumin Human|Addition of albumin during acute resuscitation following burn injury
214792557|NCT00656500|BEHAVIORAL|Standard brief advice|Brief general assistance with smoking cessation
214792558|NCT00656500|BEHAVIORAL|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
214792559|NCT00719342|DRUG|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
214792560|NCT00719342|OTHER|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
214792561|NCT06053099|OTHER|Plasma ctDNA|"* Plasma ctDNA before surgery (optional)~* Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~* Plasma ctDNA every 6 months~* Plasma ctDNA at relapse"
214792562|NCT06053099|OTHER|FFPE blocks|"* Surgery FFPE blocks~* FFPE blocks at relapse (optional)"
214792563|NCT00153088|DRUG|Telmisartan capsule 40 mg|
214792564|NCT00153088|DRUG|Placebo|
214792565|NCT00153088|DRUG|Telmisartan capsule 80 mg|
214792566|NCT05091788|DEVICE|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
214792567|NCT01943071|BEHAVIORAL|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
214792568|NCT04299854|DRUG|Dinoprostone 10mg|Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
214792569|NCT04299854|DEVICE|single balloon Foley catheter|A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
214792570|NCT04906577|OTHER|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
214792571|NCT04906577|OTHER|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
214792572|NCT00303745|DRUG|capecitabine|
214792573|NCT00303745|DRUG|irinotecan hydrochloride|
214792574|NCT01024933|BEHAVIORAL|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
214792575|NCT01024933|BEHAVIORAL|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
214792576|NCT01787825|DEVICE|PillCam SB2 capsule|Capsule Endoscopy system
214792577|NCT01787825|DEVICE|CapsoCam SV-1|Capsule endoscopy
214792578|NCT06396468|DRUG|sevoflurane|sevoflurane (1-1.2 MAC)
214792579|NCT06396468|DRUG|propofol|100-400 mcg/kg /min of propofol
214792580|NCT01555320|DRUG|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
214792581|NCT01555320|DRUG|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
214792582|NCT02547857|OTHER|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
214792583|NCT04646174|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
214792584|NCT04646174|BEHAVIORAL|American Lung Association self-management strategies for smoking cessation|Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
214792585|NCT02323490|PROCEDURE|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
214792586|NCT02323490|PROCEDURE|without microfractures|standard procedure meniscal repair without augmentation.
214792587|NCT04394754|DEVICE|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
214792588|NCT04394754|OTHER|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
214792589|NCT04394754|OTHER|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
214792590|NCT04943809|DEVICE|POD 26P AY FT|Routine cataract surgery
214792591|NCT04943809|DEVICE|POD 26P AY F|Routine cataract surgery
214792592|NCT06401083|DRUG|Caffeine citrate|20 mg/kg caffeine-citrate before the planned extubation.
214792593|NCT03799263|PROCEDURE|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
214792594|NCT04807114|DRUG|Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)
214792595|NCT04807114|DRUG|Chemotherapy + Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
214792596|NCT00929409|DRUG|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
214792597|NCT00929409|DRUG|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
214792598|NCT03912207|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
214792599|NCT03912207|OTHER|Saline placebo|Saline is a routinely used placebo.
214792600|NCT03125083|BIOLOGICAL|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
214792601|NCT06076681|DRUG|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
214792602|NCT06076681|DRUG|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
214792603|NCT06076681|DRUG|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
214792604|NCT05282160|DEVICE|Epino|The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
214792605|NCT04191239|DEVICE|GE ventilator with two different modes|GE ventilator with two different modes
214792606|NCT01338636|DRUG|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
214792607|NCT01021436|DRUG|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
214792608|NCT02385526|DEVICE|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
214792609|NCT02756312|OTHER|IV Anesthesia|The patients will receive intravenous anesthesia
214792610|NCT02756312|OTHER|IH anesthesia|The patients will receive inhalation anesthesia
214792611|NCT04725084|OTHER|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
214792612|NCT04725084|OTHER|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
214792613|NCT04725084|OTHER|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
214792614|NCT04061889|OTHER|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
214792615|NCT04421794|DEVICE|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
214792616|NCT04421794|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
214792617|NCT01798485|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
214792618|NCT01798485|DRUG|Ganetespib|Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
214792619|NCT01164033|DRUG|RO5045337|single oral dose
214792620|NCT04011969|DIAGNOSTIC_TEST|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
214792621|NCT04011969|DIAGNOSTIC_TEST|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~1. Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~2. NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
214792622|NCT04011969|DIAGNOSTIC_TEST|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~1. Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~2. Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
214792623|NCT06187922|DRUG|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
214792624|NCT06187922|PROCEDURE|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
214792625|NCT03426930|OTHER|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
214792626|NCT03426930|OTHER|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
214792627|NCT00219661|PROCEDURE|drainage of subglottic secretions (HiLo Evac tube)|
214792628|NCT02806349|DIETARY_SUPPLEMENT|American Ginseng|herb
214792629|NCT02806349|DIETARY_SUPPLEMENT|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
214792630|NCT02806349|DIETARY_SUPPLEMENT|Control|Fiber matched control for intervention (corn starch and wheat bran)
214792631|NCT03361423|DEVICE|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
214792632|NCT03361423|DEVICE|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
214792633|NCT02310477|DRUG|regorafenib|regorafenib for all groups
214792634|NCT01254409|BIOLOGICAL|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
214792635|NCT01254409|OTHER|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
214792636|NCT03263299|DRUG|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
214792637|NCT03263299|DRUG|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
214792638|NCT03263299|DRUG|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
214792639|NCT04414956|DIAGNOSTIC_TEST|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
214792640|NCT04414956|DIAGNOSTIC_TEST|AFP|AFP will be tested using serum sample every 6 months.
214792641|NCT04414956|DIAGNOSTIC_TEST|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
214792642|NCT04414956|DIAGNOSTIC_TEST|Sonography|Sonography will be tested by experts every 6 months.
214792643|NCT04414956|DIAGNOSTIC_TEST|CT|Contrast-enhanced CT will be tested annually.
214792644|NCT05317156|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
214792645|NCT01934296|DEVICE|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
214792646|NCT03156166|PROCEDURE|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
214792647|NCT01392898|DRUG|liraglutide|liraglutide 1.8 mg q.d.
214792648|NCT01392898|DRUG|Insulin|insulin dosed according titration scheme
214792649|NCT01695070|DRUG|Melatonin|4mg prolonged release melatonin oral tablets twice daily
214792650|NCT05002907|OTHER|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
214792651|NCT05002907|OTHER|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
214792652|NCT05002907|OTHER|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
214792653|NCT05002907|OTHER|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
214792654|NCT05002907|OTHER|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
214792655|NCT05002907|OTHER|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
214792656|NCT05002907|OTHER|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
214792657|NCT01076166|DRUG|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
214792658|NCT03075657|DRUG|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
214792659|NCT03075657|DRUG|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
214792660|NCT03075657|DRUG|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
214792661|NCT03075657|DRUG|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
214792662|NCT02235428|DRUG|Ipratropium bromide|
214792663|NCT02235428|DRUG|Placebo|
214792664|NCT02235428|DRUG|Salbutamol|
214792665|NCT06381726|DIAGNOSTIC_TEST|Resting State Functional Magnetic Resonance Imaging (rs-fMRI)|rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop
214792666|NCT06381726|BEHAVIORAL|Up-front Motor Rehabilitation|personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop
214792667|NCT06381726|DRUG|Up-front Chemotherapy|Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
214792668|NCT05189561|OTHER|near-infrared scanner|"Tests to be administered: Near Infra-Red Scanning of the head at the bedside.~Time taken for testing: Two minutes~Biological samples collected: None~Frequency of testing/collection: Once~Risks for the participants while being tested: None"
214792669|NCT02625415|DEVICE|Vitamin B6 cream|Topical Vitamin B6 cream
214792670|NCT02625415|DEVICE|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
215030944|NCT01817400|DIETARY_SUPPLEMENT|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
215030945|NCT01817400|DRUG|Aspirin|
214792671|NCT04992052|DEVICE|Bone wax|The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
214792672|NCT00303992|BIOLOGICAL|trastuzumab|
214792673|NCT00303992|DRUG|irinotecan hydrochloride|
214792674|NCT02970669|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
214792675|NCT02970669|DRUG|enalapril|Enalapril tablet taken orally.
214792676|NCT02970669|DRUG|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
214792677|NCT02970669|DRUG|matching placebo enalapril|matching placebo enalapril tablet taken orally
214792678|NCT05717829|PROCEDURE|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
214792679|NCT03843177|OTHER|No intervention|No intervention will be performed. Only assessment will be done.
214792680|NCT04253925|OTHER|Kegel exercises|global postural correction exercises
214792681|NCT04217668|DRUG|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
214792682|NCT03521999|BEHAVIORAL|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
214792683|NCT03521999|OTHER|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
214792684|NCT01564758|DRUG|Linezolid|"1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
214792685|NCT00000372|DRUG|D-cycloserine|
214792686|NCT00000372|DRUG|Glycine|
214792687|NCT00000372|DRUG|Clozapine|
214792688|NCT00000372|DRUG|Placebo|
214792689|NCT05030090|BEHAVIORAL|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
214792690|NCT05030090|DIETARY_SUPPLEMENT|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
214792691|NCT05030090|COMBINATION_PRODUCT|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
214792692|NCT04447274|DRUG|Camrelizumab and Apatinib|Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
214792693|NCT04711629|OTHER|Clinical Tests|Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
214792694|NCT03237585|BEHAVIORAL|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
214792695|NCT00219856|DRUG|Propofol|"* Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~* Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
214792696|NCT00219856|DRUG|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
214792697|NCT00219856|DRUG|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
214792698|NCT00875368|DRUG|maraviroc|maraviroc dose dependent on co-medication
214792699|NCT00875368|DRUG|Placebo|Placebo drug
214792700|NCT05293587|BEHAVIORAL|Physical Activity|Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
214792701|NCT01538342|OTHER|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
214792702|NCT01538342|OTHER|2 biopsies|
214792703|NCT01538342|OTHER|biopsy|1 biopsy ok healthy skin
214792704|NCT01842451|DRUG|VX-135|
214792705|NCT01842451|DRUG|Daclatasvir|
214792706|NCT01766674|BEHAVIORAL|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
214792707|NCT00006381|BIOLOGICAL|trastuzumab|
214792708|NCT00006381|DRUG|celecoxib|
214792709|NCT05498285|BEHAVIORAL|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
214792710|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
214792711|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
214792712|NCT00739856|PROCEDURE|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
214792713|NCT02354378|DRUG|Dexmedetomidine|
214792714|NCT02354378|OTHER|Memory Test|
214792715|NCT02140450|DRUG|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
214792716|NCT02140450|DRUG|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
214792717|NCT02140450|DRUG|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
214792718|NCT02140450|DRUG|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
214792719|NCT02140450|DRUG|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
214792720|NCT00795561|PROCEDURE|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
214792721|NCT00795561|PROCEDURE|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
214792722|NCT02776761|BIOLOGICAL|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
214792723|NCT02776761|BIOLOGICAL|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
214792724|NCT02776761|BIOLOGICAL|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
214792725|NCT00646152|DRUG|Poly-ICLC|
214792726|NCT01212783|BEHAVIORAL|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
214792727|NCT01212783|BEHAVIORAL|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
214792728|NCT05584527|OTHER|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
214792729|NCT05584527|OTHER|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
214792730|NCT05584527|OTHER|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
214792731|NCT00989079|DRUG|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
214792732|NCT00989079|DRUG|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
214792733|NCT01195571|BIOLOGICAL|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
214792734|NCT00177112|PROCEDURE|clean patient preparation for cystoscopy|
214792735|NCT00177112|PROCEDURE|sterile patient preparation for cystoscopy|
214792736|NCT04324879|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
214792737|NCT01636297|BEHAVIORAL|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
214792738|NCT01636297|BEHAVIORAL|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
214792739|NCT02081261|PROCEDURE|Coronary artery bypass surgery|coronary artery bypass surgery
214792740|NCT00058279|BIOLOGICAL|aldesleukin|
214792741|NCT00058279|BIOLOGICAL|ipilimumab|
214792742|NCT01498484|BIOLOGICAL|EBV-specific T cells (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
214792743|NCT00256542|DRUG|Alkalinized Lidocaine-Heparin|
214792744|NCT03432195|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
214792745|NCT02122081|RADIATION|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
214792746|NCT02122081|DRUG|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
214792747|NCT02122081|BIOLOGICAL|anti-thymocyte globulin|
214792748|NCT02122081|DRUG|tacrolimus|Given IV or PO
214792749|NCT02122081|DRUG|methotrexate|Given IV
214792750|NCT02122081|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
214792751|NCT02122081|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
214792752|NCT02122081|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
214792753|NCT02122081|OTHER|laboratory biomarker analysis|Correlative studies
214792754|NCT02907112|BEHAVIORAL|Meat reduction|Advice, Motivational material and food products provided to participants
214792755|NCT05593198|PROCEDURE|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
214792756|NCT05593198|PROCEDURE|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
214792757|NCT03697421|OTHER|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
214792758|NCT03697421|OTHER|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
214792759|NCT01200472|DRUG|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
214792760|NCT01200472|DRUG|Placebo|Placebo capsules identical to apremilast
214792761|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
214792762|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
214792763|NCT05881148|OTHER|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
214792764|NCT05881148|OTHER|Standard carbon-free sprinting spiked-shoes|cf
214792765|NCT03108105|DEVICE|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
214792766|NCT00278512|BIOLOGICAL|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
214792767|NCT00278512|BIOLOGICAL|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
214792768|NCT00278512|DRUG|Cyclophosphamide|Causes prevention of the cell division
214792769|NCT00278512|DRUG|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
214792770|NCT00278512|DRUG|G-CSF|Hematopoietic growth factor
214792771|NCT00278512|DRUG|Campath-1h|Humanized monoclonal antibody against CD52 antigen
214792772|NCT00278512|DRUG|Fludarabine|inhibits DNA synthesis or repair
214792773|NCT00278512|DRUG|Tacrolimus|immune suppressive drug
214792774|NCT00278512|DRUG|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
214792775|NCT05240339|OTHER|Observation of minor phenomena|observation twice a year over 3 years
214792776|NCT01202747|DEVICE|LipiFlow System|In-office treatment for meibomian gland dysfunction
214792777|NCT00364403|BEHAVIORAL|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
214792778|NCT00364403|BEHAVIORAL|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
214792779|NCT00838474|OTHER|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
214792780|NCT01620177|DRUG|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
214792781|NCT01620177|DRUG|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
214792782|NCT04041609|DRUG|LYR-210|A single administration of LYR-210 depot
214792783|NCT04041609|OTHER|Sham comparator|Sham comparator
214792784|NCT02729688|DEVICE|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
214792785|NCT02729688|DEVICE|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
214792786|NCT03083054|BIOLOGICAL|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
214792787|NCT05499494|OTHER|Beautifil Flow Plus X F00 injectable composite|bioactive injectable composite
214792788|NCT05499494|OTHER|Tetric N ceram resin composite|Nano hybrid resin composite
214792789|NCT01037166|DRUG|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
214792790|NCT03869749|BEHAVIORAL|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
214792791|NCT03869749|BEHAVIORAL|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
214792792|NCT04597762|DRUG|Cyclosporin|Cyclosporin eyedrops
214792793|NCT04597762|DRUG|Hydrocortisone|Hydrocortisone eyedrops
214792794|NCT02277873|BEHAVIORAL|pregnancy|Observational study in order to establish relationship between moon and births
214792795|NCT01348295|OTHER|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
214792796|NCT02879721|DRUG|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
214792797|NCT02879721|DRUG|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
214792798|NCT05283239|OTHER|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
214792799|NCT02292238|DRUG|Benfotiamine|"* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
214792800|NCT02970643|DRUG|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
214792801|NCT02970643|DRUG|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
214792802|NCT01251926|DRUG|EZN-2208|
214792803|NCT01251926|DRUG|Bevacizumab|
214792804|NCT03001609|DRUG|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
214792805|NCT01950988|DEVICE|Manual toothbrush reference|
214792806|NCT01950988|PROCEDURE|Measure of the dental plaque|
214792807|NCT01950988|DEVICE|Manual toothbrush Broscyl®|
214792808|NCT03149588|DRUG|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
214792809|NCT03149588|DRUG|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
214792810|NCT01789320|DRUG|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
214792811|NCT04935827|OTHER|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November"
214792812|NCT04935827|OTHER|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
214792813|NCT05841381|DRUG|Pyrotinib|pyrotinib: 400mg orally daily for 1 year
214792814|NCT05841381|DRUG|Trastuzumab|8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
214792815|NCT05841381|DRUG|Paclitaxel|80mg/m2 per week for a total of 12 weeks
214792816|NCT00667927|DRUG|Busulfan|See Detailed Description section for description of treatment plan.
214792817|NCT00667927|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
214792818|NCT00667927|DRUG|Mesna|See Detailed Description section for description of treatment plan.
214792819|NCT04890600|BEHAVIORAL|well-being assessment|exploration of emotional, cognitive and behavioural resources of healthcare professionals
214792820|NCT00425737|BIOLOGICAL|Rotarix|
214792821|NCT04603963|DEVICE|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
214792822|NCT02044978|DEVICE|Zoledronate-coated dental implant|
214792823|NCT01129999|BEHAVIORAL|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
214792824|NCT01129999|BEHAVIORAL|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
214792825|NCT03184454|DEVICE|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
214792826|NCT01103505|DIAGNOSTIC_TEST|ForeseeHome AMD Monitoring Device|Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
214792827|NCT05815381|OTHER|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
214792828|NCT01912105|DEVICE|Airway medix closed suction system|
214792829|NCT01912105|DEVICE|standard closed suctioning systems|
214792830|NCT00097019|DRUG|bevacizumab|
214792831|NCT06527989|DRUG|Ceftriaxone 2000 mg|antibiotic prophylaxis
214792832|NCT01166971|DEVICE|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
214792833|NCT01166971|DEVICE|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
214792834|NCT03417622|PROCEDURE|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
214792835|NCT03417622|DRUG|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
214792836|NCT03417622|PROCEDURE|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
214792837|NCT03417622|PROCEDURE|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
214792838|NCT01861327|DRUG|CO2|carbon dioxide (CO2) as arterial contrast media
214792839|NCT01861327|DRUG|Iodine contrast media|Iodine as arterial contrast media
214792840|NCT05448716|DIAGNOSTIC_TEST|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
214792841|NCT05448716|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
214792842|NCT00935987|DRUG|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
214792843|NCT05254366|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
214792844|NCT04046042|OTHER|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
214792845|NCT04046042|OTHER|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
214792846|NCT04043013|DEVICE|Mini-Taurus® (Rocky Mountain©) Brackets|
214792847|NCT04043013|DEVICE|Smart Clip® SL3 High Torque (3M Unitek©)|
214792848|NCT04043013|DEVICE|Tip-Edge Plus® (TP Orthodontics©)|
214792849|NCT04043013|DEVICE|Victory® (3M Unitek©)|
214792850|NCT03387033|DEVICE|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
214792851|NCT00601484|DRUG|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
214792852|NCT00601484|DRUG|Placebo|placebo IV, single dose
214792853|NCT01197313|OTHER|Home-based exercise|
214792854|NCT03966170|DRUG|Citicoline|Citicoline as neuroprotector
214792855|NCT03966170|DRUG|Placebo oral tablet|placebo drug
214792856|NCT00548288|DRUG|pamidronate|
214792857|NCT03294278|OTHER|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
214792858|NCT02864680|OTHER|Electroretinography|
214792859|NCT02864680|OTHER|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
214792860|NCT02864680|OTHER|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
214792861|NCT02864680|OTHER|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
214792862|NCT02864680|OTHER|CAST (cannabis abuse screening test)|
214792863|NCT02864680|OTHER|PANSS (Positive And Negative Symptoms Scale) test|
214792864|NCT02864680|OTHER|Delayed Matching to Sample (DMS) test|
214792865|NCT02864680|OTHER|Spatial Working Memory (SWM) test|
214792866|NCT02864680|OTHER|Rapid Visual Information Processing (RVP) test|
214792867|NCT02864680|OTHER|Test for attentional performance (TAP) / Divided Attention|
214792868|NCT02864680|OTHER|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
214792869|NCT06356376|DEVICE|Heat Stimulation|Heat stimulation at a painful, but to the subject tolerable level.
214792870|NCT02130206|OTHER|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
214792871|NCT02130206|OTHER|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
214792872|NCT02130206|OTHER|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
214792873|NCT02130206|OTHER|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
214792874|NCT00376779|BIOLOGICAL|Infanrix hexa Vaccine|
214792875|NCT00352079|BIOLOGICAL|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
214792876|NCT00352079|DRUG|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
214792877|NCT00352079|PROCEDURE|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
214792878|NCT04954456|DRUG|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
214792879|NCT04523142|DRUG|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
214792880|NCT06102629|PROCEDURE|laparoscopy / laparotomy|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
214792881|NCT06102629|OTHER|NO INTERVENTION|".We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3\. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
214792882|NCT06091800|OTHER|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
214792883|NCT02460848|OTHER|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
214792884|NCT02460848|OTHER|Outpatient therapeutic program and counseling|
214792885|NCT00162604|DRUG|Cefuroxime|
214792886|NCT05469282|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701 (Ceragem Master V6)
214792887|NCT04780503|DIAGNOSTIC_TEST|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
214792888|NCT04901000|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
214792889|NCT04057053|DRUG|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
214792890|NCT03123822|DEVICE|Glasses|Glasses traditionally prescribed for refractive error
214792891|NCT02214927|DRUG|BI 11634 tablet|
214792892|NCT02214927|DRUG|BI 11634 drinking solution|
214792893|NCT00545337|DRUG|Insuline glulisine|
214792894|NCT00060957|DRUG|Botulinum toxin type A|
214792895|NCT06301633|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214792896|NCT06301633|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214792897|NCT06301633|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214792898|NCT02687477|PROCEDURE|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
214792899|NCT02687477|PROCEDURE|Sham procedure|patient in the sham group will receive sham procedure
214792900|NCT02382471|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
214792901|NCT02382471|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
214792902|NCT01589003|OTHER|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
214792903|NCT01589003|OTHER|High GI growing up milk|High glycaemic index growing up milk
214792904|NCT03847883|DRUG|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
214792905|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II SC|
214792906|NCT01463683|BIOLOGICAL|1XP HEPTAVAX™-II SC|
214792907|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II IM|
214792908|NCT04890275|OTHER|Blood flow restricted resistance exercise (BFR)|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
214792909|NCT04890275|OTHER|Resistance exercise without blood flow restricted (NON-BFR)|Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
215030946|NCT01817400|DRUG|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
215030947|NCT02374255|BEHAVIORAL|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
214792910|NCT01816152|OTHER|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
214792911|NCT01816152|OTHER|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
214792912|NCT00008099|BIOLOGICAL|MUC1 antigen/SB AS-2|
214792913|NCT01423838|DRUG|Solifenacin|5 mg, oral, once in a day
214792914|NCT01423838|DRUG|Oxybutynin|5 mg, oral, three times in a day
214792915|NCT00918671|OTHER|No new specific intervention|No new specific intervention
214792916|NCT06057298|PROCEDURE|Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)|"Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model:~* Oxaliplatin 360 mg/mq for 30 min.~* Oxaliplatin 200 mg/mq for 120 min.~* Mitomycin-C 35mg/mq for 60 min.~* Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)"
214792917|NCT05494905|OTHER|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
214792918|NCT05494905|OTHER|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
214792919|NCT01618305|DRUG|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
214792920|NCT01618305|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
214792921|NCT01618305|DRUG|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
214792922|NCT03246698|OTHER|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
214792923|NCT03246698|OTHER|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
214792924|NCT03246698|OTHER|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
214792925|NCT03383393|DRUG|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
214792926|NCT01106872|DRUG|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
214792927|NCT02708277|DEVICE|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
214792928|NCT02708277|DEVICE|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
214792929|NCT01873638|PROCEDURE|Cholecystectomy|
214792930|NCT03687099|OTHER|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
214792931|NCT05286099|OTHER|Imaging examination and/or blood test|Imaging examination and/or blood test will be performed at a certain time
214792932|NCT00775697|DRUG|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
214792933|NCT00775697|DRUG|Montelukast|montelukast 4 mg day for 4 weeks
214792934|NCT02346539|DRUG|Nicotine polacrilex|Single Acute dose
214792935|NCT01960816|DEVICE|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
214792936|NCT06537518|DRUG|Dexamethasone injection|Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
214792937|NCT06537518|DRUG|Bupivacaine 0.375% Injectable Solution|Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
214792938|NCT06537518|DRUG|Bupivacaine 0.5% Injectable Solution|20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
214792939|NCT00030173|DRUG|Epothilone D (KOS-862)|
214792940|NCT03058536|DEVICE|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
214792941|NCT03058536|DRUG|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
214792942|NCT03058536|OTHER|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
214792943|NCT02730065|BEHAVIORAL|Structured Aerobic Dance Training Group|Systematic physical activity
214792944|NCT02730065|BEHAVIORAL|Stretching plus education|Weekly group based stretching with psychoeducation and health education
214792945|NCT02099266|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
214792946|NCT01841606|DRUG|Ondansetron|4mg of IV ondansetron
214792947|NCT01841606|OTHER|Normal saline|10mL of IV normal saline
214792948|NCT04434859|OTHER|No intervention|No intervention
214792949|NCT03152461|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214792950|NCT04895410|BIOLOGICAL|Lemzoparlimab|Intravenous (IV) infusion
214792951|NCT04895410|DRUG|Dexamethasone|Oral tablet or IV infusion/injection
214792952|NCT04895410|DRUG|Carfilzomib|IV infusion
214792953|NCT04895410|DRUG|Pomalidomide|Oral capsule
214792954|NCT04895410|BIOLOGICAL|Daratumumab|Subcutaneous (SC) injection
214792955|NCT01118728|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214792956|NCT00408733|OTHER|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
214792957|NCT01591031|DRUG|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
214792958|NCT01591031|DRUG|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
214792959|NCT02371967|DRUG|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
214792960|NCT01260480|OTHER|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
214792961|NCT04133480|DRUG|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
215030948|NCT03106714|DIAGNOSTIC_TEST|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
214792962|NCT00785122|DRUG|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
214792963|NCT00785122|DRUG|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
214792964|NCT02417090|DRUG|Insulin|Pregnant women who used insulin to treat gestational diabetes
214792965|NCT02417090|DRUG|Metformin|Pregnant women who used metformin to treat gestational diabetes
214792966|NCT01026688|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
214792967|NCT01026688|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
214792968|NCT04898985|DIAGNOSTIC_TEST|ImmunoSEQ|experiment assay
214792969|NCT00508586|DRUG|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
214792970|NCT04345471|DRUG|Desvenlafaxine 100 mg|once daily dosing for 8 weeks
214792971|NCT04345471|DRUG|Desvenlafaxine 50 mg|once daily dosing for 8 weeks
214792972|NCT04345471|DRUG|Placebo|once daily dosing for 8 weeks
214792973|NCT02373475|OTHER|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
214792974|NCT02373475|OTHER|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
214792975|NCT03665571|DIAGNOSTIC_TEST|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
214792976|NCT05484271|PROCEDURE|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
214792977|NCT00274209|PROCEDURE|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
214792978|NCT05778149|DRUG|Aumolertinib,Anlotinib|Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
214792979|NCT01672372|DIETARY_SUPPLEMENT|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
214792980|NCT01672372|DIETARY_SUPPLEMENT|Placebo Max Stress B|
214792981|NCT02525029|DRUG|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
214792982|NCT05571085|OTHER|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
214792983|NCT05571085|OTHER|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
214792984|NCT00200005|DEVICE|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
214792985|NCT03896490|BEHAVIORAL|Attention Control Training|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
214792986|NCT03896490|BEHAVIORAL|Control|The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
214792987|NCT02394132|DRUG|Imiquimod|
214792988|NCT02394132|RADIATION|Radiotherapy|
214792989|NCT05232578|RADIATION|Early salvage radiotherapy (eSRT)|"eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
214792990|NCT05232578|RADIATION|Delayed Salvage radiotherapy (dSRT)|"dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
214792991|NCT02260765|DEVICE|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
214792992|NCT02688127|DRUG|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
215030949|NCT02093520|PROCEDURE|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
214792993|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
215030950|NCT02093520|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
215030951|NCT03014089|BIOLOGICAL|mRNA-1325|Escalating dose levels
215030952|NCT03014089|OTHER|Placebo|
214792994|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
214792995|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
214792996|NCT06052371|DEVICE|VerioVue (Enhancements) blood glucose monitoring system|VerioVue meter with expanded haematocrit range
214792997|NCT01352559|DRUG|responders|Antidepressants administration for 6 weeks under therapeutic dose
214792998|NCT01352559|DRUG|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
214792999|NCT03773328|BIOLOGICAL|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
214793000|NCT00122850|DRUG|Duloxetine|
214793001|NCT00122850|DRUG|venlafaxine|
214793002|NCT00122850|DRUG|placebo|
214793003|NCT00003782|DRUG|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
214793004|NCT00003782|DRUG|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
214793005|NCT00003782|DRUG|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
214793006|NCT00152321|BEHAVIORAL|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
214793007|NCT00152321|BEHAVIORAL|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
214793008|NCT00152321|OTHER|Usual Care|
214793009|NCT03017599|DEVICE|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
214793010|NCT03362151|OTHER|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
214793011|NCT03362151|OTHER|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
214793012|NCT03362151|OTHER|White rice|White rice (Approximately 43 grams carbohydrate per meal)
214793013|NCT00000614|DRUG|warfarin|
214793014|NCT01082107|OTHER|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (\> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
214793015|NCT05378087|RADIATION|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
214793016|NCT05378087|PROCEDURE|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
214793017|NCT01056549|DRUG|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
214793018|NCT00385541|DRUG|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
214793019|NCT00385541|DRUG|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
215030953|NCT01520441|DRUG|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
215030954|NCT02792322|DEVICE|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
215030955|NCT02995200|BEHAVIORAL|Accelerometer Based Feedback|
214793020|NCT03414164|DIETARY_SUPPLEMENT|procyanidine|natural antioxidants
214793021|NCT03015090|DRUG|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
214793022|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
214793023|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
214793024|NCT03516747|DIAGNOSTIC_TEST|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
214793025|NCT03516747|DIAGNOSTIC_TEST|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
214793026|NCT03052166|DEVICE|QT Ultrasound scan|QT Ultrasound scan
214793027|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
214793028|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
214793029|NCT06217133|DEVICE|CPAP|"Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage."
214793030|NCT04541888|DRUG|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
214793031|NCT04541888|DRUG|Placebo|Placebo
214793032|NCT04541888|DRUG|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
214793033|NCT06398769|DEVICE|SecuFix UM|All surgeries were performed using Secufix UM.
214793034|NCT06398769|DEVICE|VCare UM|All surgeries were performed using VCare UM.
214793035|NCT00406978|DRUG|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
214793036|NCT00406978|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
214793037|NCT00406978|DRUG|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
214793038|NCT00406978|DRUG|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
214793039|NCT02012647|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
214793040|NCT02012647|PROCEDURE|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
214793041|NCT05016349|DRUG|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
214793042|NCT05016349|DRUG|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
214793043|NCT05016349|DRUG|Mifepristone|Mifepristone 200mg capsules daily for 28 days
214793044|NCT05016349|DRUG|Cannabidiol|Liquid taken orally for daily for 28 days
214793045|NCT05016349|DRUG|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
214793046|NCT05016349|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
214793047|NCT05016349|DRUG|Standard therapy|Patients will receive the approved standard therapy tamoxifen
214793048|NCT05188521|DRUG|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
214793049|NCT05188521|DRUG|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 12 weeks
214793050|NCT04582266|DRUG|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
214793051|NCT01657539|DIETARY_SUPPLEMENT|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
214793052|NCT01657539|DIETARY_SUPPLEMENT|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
214793053|NCT01341639|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
214793054|NCT01341639|BIOLOGICAL|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
214793055|NCT01341639|BIOLOGICAL|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
214793056|NCT01341639|BIOLOGICAL|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
214793057|NCT01341639|BIOLOGICAL|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
214793058|NCT02788422|OTHER|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
214793059|NCT02788422|OTHER|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
214793060|NCT01132118|DRUG|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
214793061|NCT03703713|DRUG|Sodium chloride|Treatment with Sodium chloride
214793062|NCT01557491|PROCEDURE|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
214793063|NCT01557491|PROCEDURE|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
214793064|NCT04942379|OTHER|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
214793065|NCT04942379|OTHER|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
214793066|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
215030956|NCT00434941|DRUG|Capecitabine|
215030957|NCT00434941|RADIATION|Radiotherapy|
215030958|NCT01342055|DRUG|Apetrol ES|sequences of administered drugs
214793067|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
214793068|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
214793069|NCT03914313|DEVICE|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
214793070|NCT04585321|DRUG|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
214793071|NCT04585321|DRUG|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
214793072|NCT03728842|OTHER|Blood collection for laboratory studies|Peripheral whole blood will be collected
214793073|NCT03728842|OTHER|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
214793074|NCT04782115|BIOLOGICAL|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
214793075|NCT04782115|BIOLOGICAL|Conbercept|KH902(Conbercept）
214793076|NCT01298388|OTHER|medical chart review|
214793077|NCT01298388|OTHER|questionnaire administration|
214793078|NCT01298388|OTHER|study of socioeconomic and demographic variables|
214793079|NCT06354803|OTHER|proprioceptive training|Proprioceptive training using swiss ball for 12 sessions
214793080|NCT00171782|DRUG|VALSARTAN+HYDROCHLOROTHIAZIDE|
215030959|NCT03618069|DIAGNOSTIC_TEST|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
215030960|NCT03182855|DRUG|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
214793081|NCT06051396|PROCEDURE|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
214793082|NCT00494975|DEVICE|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
214793083|NCT00084539|RADIATION|Radiation therapy|
214793084|NCT04123041|OTHER|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
214793085|NCT03818490|OTHER|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
214793086|NCT04741100|OTHER|Ex-vivo analysis|Ex-vivo analysis
214793087|NCT00796237|DEVICE|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
214793088|NCT00796237|OTHER|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
214793089|NCT00850902|OTHER|High Humidity (HH)|High Humidity Level
214793090|NCT00850902|OTHER|Moderate Humidity|Moderate Humidity Level
214793091|NCT03942510|OTHER|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
214793092|NCT00784212|DRUG|BGG492|
214793093|NCT00784212|DRUG|BGG492|
214793094|NCT00784212|DRUG|Placebo|
214793095|NCT01312610|DIETARY_SUPPLEMENT|High flavanone orange juice|High flavonone orange juice drink.
214793096|NCT01312610|DIETARY_SUPPLEMENT|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
214793097|NCT00281619|DRUG|CellCept (mycophenolate mofetil)|
214793098|NCT00281619|BEHAVIORAL|Dietary Monitoring|
214793099|NCT00281619|BEHAVIORAL|Drug Diary|
214793100|NCT00281619|PROCEDURE|Blood Sampling|
214793101|NCT02516566|OTHER|PEEP|Mechanical ventilation with PEEP 8 cmH2O
214793102|NCT03717766|DEVICE|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
214793103|NCT02742090|DRUG|Umbralisib|Umbralisib was administered as a tablet(s), orally once daily.
215030961|NCT03182855|DRUG|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
215030962|NCT00797303|DRUG|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
215030963|NCT01969929|PROCEDURE|20G Vitrectomy|
215030964|NCT01969929|PROCEDURE|23G vitrectomy|
215030965|NCT05516173|DIAGNOSTIC_TEST|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
215030966|NCT06402305|DIAGNOSTIC_TEST|Lipid profile|Abdominal ultrasound and lipid profile will be done
215030967|NCT02310269|DRUG|Pasireotide|
215030968|NCT00321932|DIETARY_SUPPLEMENT|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
215030969|NCT00321932|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
214793104|NCT00782002|BIOLOGICAL|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
214793105|NCT02611284|PROCEDURE|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
214793106|NCT02611284|PROCEDURE|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
214793107|NCT01299038|DRUG|rosuvastatin|Taken orally once a day for 4 weeks
214793108|NCT03867903|DEVICE|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
214793109|NCT03867903|OTHER|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
214793110|NCT05954715|OTHER|Ischaemic Preconditioning|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
214793111|NCT05954715|OTHER|Sham|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
214793112|NCT00543361|DRUG|MK0767|Duration of Treatment: 52 Weeks
214793113|NCT00543361|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
214793114|NCT00543361|DRUG|Comparator: metformin|Duration of Treatment: 52 Weeks
214793115|NCT05127083|RADIATION|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
214793116|NCT00832078|DEVICE|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
214793117|NCT00832078|DEVICE|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
214793118|NCT02916173|DRUG|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
214793119|NCT02916173|DRUG|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
214793120|NCT01006668|DRUG|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
214793121|NCT01006668|DRUG|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
214793122|NCT03355742|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
214793123|NCT03355742|DRUG|DAPT|1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
214793124|NCT02267096|BEHAVIORAL|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
214793125|NCT02267096|BEHAVIORAL|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
214793126|NCT06320379|DIETARY_SUPPLEMENT|Zypan|The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosol™ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals
214793127|NCT06320379|DIETARY_SUPPLEMENT|Placebo Comparator|The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%\*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)
214793128|NCT00050921|DRUG|somatropin|
214793129|NCT00050921|BIOLOGICAL|Hepatitis A virus, inactivated|
214793130|NCT00050921|DRUG|Keyhole-Limpet Hemocyanin|
214793131|NCT00000464|DRUG|amiodarone|
214793132|NCT00000464|DRUG|imipramine|
214793133|NCT00000464|DRUG|mexiletine|
214793134|NCT00000464|DRUG|procainamide|
214793135|NCT00000464|DRUG|propafenone|
214793136|NCT00000464|DRUG|quinidine|
214793137|NCT00000464|DRUG|sotalol|
214793138|NCT05379543|OTHER|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
214793139|NCT03229252|DRUG|Placebo Inhalation Solution|Normal Saline Inhalation Solution
214793140|NCT03229252|DRUG|SPX-101|SPX-101 Inhalation Solution
214793141|NCT00855452|PROCEDURE|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
214793142|NCT02990832|DEVICE|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
214793143|NCT05170256|DRUG|Trastuzumab|Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
214793144|NCT03957733|DRUG|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
214793145|NCT00208156|DRUG|Mifepristone|
214793146|NCT02006485|DRUG|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
214793147|NCT02006485|DRUG|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
214793148|NCT02006485|DRUG|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
214793149|NCT03588156|DRUG|Benapenem|Dose-escalation For 11 level dose groups A1 \~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
214793150|NCT03588156|DRUG|Placebo|Placebo
214793151|NCT03244956|DRUG|Trametinib|2mg daily for a maximum of 6 weeks of treatment
214793152|NCT03244956|DRUG|Dabrafenib|150mg twice daily
214793153|NCT03244956|RADIATION|131I|5.5 GBq
214793154|NCT03244956|DRUG|rhTSH|0.9mg on two consecutive days after 35 days of treatment
214793155|NCT03760393|BEHAVIORAL|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
214793156|NCT05432271|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
214793157|NCT05432271|BEHAVIORAL|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
214793158|NCT05432271|BEHAVIORAL|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
214793159|NCT05432271|BEHAVIORAL|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
214793160|NCT05432271|BEHAVIORAL|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
214793161|NCT03639428|DRUG|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
214793162|NCT04951128|DRUG|Tranexamic acid injection|Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
214793163|NCT04951128|OTHER|Local anesthetic control|Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).
214793164|NCT05313828|DRUG|Acyclovir|acyclovir 4 times /day
214793165|NCT05313828|DRUG|Tobramycin|tobramycin 4 times /day
214793166|NCT05313828|DRUG|Fluorometholone|Fluorometholone 4 times/ day
214793167|NCT05313828|DRUG|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
214793168|NCT03055533|BEHAVIORAL|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
214793169|NCT00909077|DRUG|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
214793170|NCT00909077|DRUG|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
214793171|NCT02770183|DEVICE|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
214793172|NCT05508451|PROCEDURE|Double jaw surgery|A type of orthognathic surgery
214793173|NCT03158298|OTHER|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
214793174|NCT01070641|DRUG|Carvedilol|Carvedilol 12.5mg QD
214793175|NCT01070641|PROCEDURE|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
214793176|NCT05349903|OTHER|Rice flour|Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793177|NCT05349903|OTHER|Alternanoligosaccharide 15|Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793178|NCT05349903|OTHER|Inulin|Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793179|NCT05349903|OTHER|Waxy potato starch|Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793180|NCT05349903|OTHER|Waxy potato starch + epigallocatechin gallate (EGCG)|A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793181|NCT05349903|OTHER|Chickpea flour + epigallocatechin gallate (EGCG)|A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
214793182|NCT06578104|DEVICE|PulseSelect™ PFA system|Ablation using the PulseSelect™ PFA system
214793183|NCT04251182|DRUG|15mg T3D-959|Oral administration once daily in the morning
214793184|NCT04251182|DRUG|30 mg T3D-959|Oral administration once daily in the morning
214793185|NCT04251182|DRUG|45 mg T3D-959|Oral administration once daily in the morning
214793186|NCT04251182|DRUG|Placebos|Oral administration once daily in the morning
214793187|NCT01466803|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
214793188|NCT01466803|DRUG|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
214793189|NCT03799601|DRUG|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
214793190|NCT03799601|DRUG|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
215030970|NCT00321932|DRUG|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
214793191|NCT03799601|DRUG|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
214793192|NCT04381884|DRUG|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
214793193|NCT05646121|DEVICE|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
214793194|NCT06059170|BEHAVIORAL|LARS score/ EORTC QLQ C30|administering questionnaire
214793195|NCT02891200|OTHER|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
214793196|NCT02891200|OTHER|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
214793197|NCT02958956|DRUG|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
214793198|NCT04611659|BEHAVIORAL|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
214793199|NCT04840407|BEHAVIORAL|SHARP coach intervention|The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
214793200|NCT02044471|OTHER|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
215030971|NCT03487133|DRUG|bortezomib/dexamethasone|"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
215030972|NCT00157872|DRUG|MK0966; rofecoxib|
215030973|NCT00157872|DRUG|Comparator: naproxen tablet 500 mg|
214793201|NCT03465371|OTHER|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
214793202|NCT03465371|OTHER|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
214793203|NCT03465371|OTHER|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
214793204|NCT03752593|OTHER|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
214793205|NCT03814109|DRUG|LENINGRADO association|1 coated sustained-release tablet, oral, once a day.
214793206|NCT03814109|DRUG|Indapamide SR 1.5 MG|1 coated sustained-release tablet, oral, once a day.
214793207|NCT03814109|DRUG|Levamlodipine 2.5/ 5 mg|1 tablet, oral, once a day.
214793208|NCT03814109|OTHER|Leningrado association Placebo|1 coated sustained-release tablet, oral, once a day.
214793209|NCT03814109|OTHER|Indapamide SR Placebo|1 coated sustained-release tablet, oral, once a day.
214793210|NCT03814109|OTHER|Levamlodipine placebo|1 tablet, oral, once a day.
214793211|NCT00202137|BEHAVIORAL|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
215030974|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
215030975|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
214793212|NCT00202137|BEHAVIORAL|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
214793213|NCT02588183|DEVICE|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
214793214|NCT06528483|DRUG|Sacituzumab Govitecan + Zimberelimab|"Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice."
214793215|NCT00002583|DRUG|cisplatin|50 mg/m2 IV
214793216|NCT00002583|DRUG|vinorelbine ditartrate|25 mg/m2 IV
214793217|NCT00004498|GENETIC|Adenoviral Vector-Mediated Gene Transfer|
214793218|NCT06393101|DRUG|BRC-002|BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
214793219|NCT06393101|DRUG|BRC-002 Placebo|Oral solution of mono-, di-, and triglycerides
214793220|NCT00003520|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214793221|NCT02729155|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
214793222|NCT02729155|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
214793223|NCT02729155|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
214793224|NCT02729155|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
214793225|NCT02318927|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
214793226|NCT00736320|DRUG|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
214793227|NCT00736320|RADIATION|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
214793228|NCT04921280|BEHAVIORAL|Internet based Cognitive Behavioural Therapy|"The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures."
214793229|NCT05966857|DEVICE|Wearable: Smartwatch|The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
214793230|NCT01811446|DEVICE|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
214793231|NCT00268320|DEVICE|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
214793232|NCT01871467|DRUG|Sargramostim|
214793233|NCT05779150|OTHER|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
214793234|NCT05779150|OTHER|Standard Cream|placebo cream
214793235|NCT04480463|DRUG|SCD411|IVT (intravitreal) injection
214793236|NCT04480463|DRUG|Aflibercept|IVT injection
214793237|NCT02240758|PROCEDURE|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
214793238|NCT05729750|DIAGNOSTIC_TEST|Trans abdominal ultrasound for assess biophysical profile|The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
214793239|NCT00017563|DRUG|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
214793240|NCT00017563|DRUG|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
214793241|NCT00017563|PROCEDURE|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
214793242|NCT00511563|DRUG|GW876008 and GSK561679|GW876008 and GSK561679
214793243|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
214793244|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
214793245|NCT00444795|DRUG|sunitinib malate|Sunitinib : dosing not pre-determined
214793246|NCT03788681|DRUG|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
214793247|NCT03788681|DRUG|Placebo Oral Tablet|placebo
214793248|NCT01908114|BEHAVIORAL|Enhanced Community mobilization|
214793249|NCT01908114|BIOLOGICAL|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
214793250|NCT00545012|DRUG|Levetiracetam|
214793251|NCT00988169|DRUG|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
214793252|NCT00290121|DRUG|Olanzapine|
214793253|NCT00704418|DRUG|Bromfenac|sterile ophthalmic solution
214793254|NCT00704418|DRUG|Placebo|sterile ophthalmic solution
214793255|NCT04690413|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
214793256|NCT00757913|DIETARY_SUPPLEMENT|n-3 enriched nutrition|
214793257|NCT02322879|DRUG|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
214793258|NCT02322879|OTHER|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
214793259|NCT02322879|DRUG|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
214793260|NCT02962011|DEVICE|Knotless barbed suture|uterine incision closure
214793261|NCT02962011|DEVICE|polyglactin 910|uterine incision closure
214793262|NCT01541956|DRUG|Metformin|500 mg twice daily
214793263|NCT01541956|DRUG|vildagliptin|Vildagliptin 50 mg twice daily
214793264|NCT00003361|DRUG|decitabine|
214793265|NCT03265496|PROCEDURE|Clinical exam|Clinical exam is performed before treatment start
214793266|NCT03265496|PROCEDURE|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
214793267|NCT03265496|PROCEDURE|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
214793268|NCT03265496|DRUG|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
214793269|NCT03265496|PROCEDURE|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
214793270|NCT03265496|BIOLOGICAL|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
214793271|NCT02637076|DRUG|Xyrem|single 3.0 gram dose
214793272|NCT02112240|OTHER|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
214793273|NCT02112240|DRUG|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
214793274|NCT02112240|OTHER|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
214793275|NCT02112240|PROCEDURE|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
214793276|NCT02112240|RADIATION|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
214793277|NCT04170179|PROCEDURE|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
214793278|NCT04170179|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214793279|NCT04170179|DRUG|Toripalimab|240mg intravenously every 3 weeks
214793280|NCT02346968|OTHER|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
214793281|NCT02494128|OTHER|Education|Education in group leadership
214793282|NCT01148290|PROCEDURE|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
214793283|NCT01148290|PROCEDURE|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
214793284|NCT03064412|BIOLOGICAL|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
214793285|NCT03064412|BIOLOGICAL|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
214793286|NCT02642627|DEVICE|Bellafill|
214793287|NCT04459546|BEHAVIORAL|patient education, training booklet, 3 months tele health|Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
214793288|NCT02771665|OTHER|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
214793289|NCT02710071|DRUG|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
214793290|NCT02710071|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
214793291|NCT01633827|DRUG|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
214793292|NCT01633827|DRUG|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
214793293|NCT01633827|OTHER|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
214793294|NCT01633827|OTHER|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
214793295|NCT03306576|DEVICE|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
214793296|NCT03306576|DEVICE|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
214793297|NCT03581474|DEVICE|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
214793298|NCT02470195|BEHAVIORAL|workshop|workshop for procedural simulation for education in difficult airway situation
214793299|NCT03709082|DRUG|Palbociclib 75mg|Oral Administration
214793300|NCT03709082|DRUG|Letrozole 2.5mg|Oral Adminstration
214793301|NCT03709082|DRUG|T-DM1|Intravenous Administration
214793302|NCT03709082|DRUG|Palbociclib 100mg|Oral Administration
214793303|NCT03709082|DRUG|Palbociclib 125mg|Oral Administration
214793304|NCT03709082|DRUG|Palbociclib|Oral Administration
214793305|NCT02637557|DRUG|IW-3718|
214793306|NCT02637557|DRUG|Matching Placebo|
214793307|NCT02637557|DRUG|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
214793308|NCT01773148|DEVICE|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
214793309|NCT00613574|DRUG|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
214793310|NCT00176904|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
214793311|NCT00176904|DRUG|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
214793312|NCT01751412|RADIATION|Proton Radiation|
214793313|NCT02018146|OTHER|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
214793314|NCT02018146|OTHER|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
214793315|NCT01711021|DRUG|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
214793316|NCT01711021|DRUG|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
214793317|NCT05382923|BEHAVIORAL|Bright Light|3 consecutive days of 1 hour bright light
214793318|NCT05382923|BEHAVIORAL|Bright Light + Exercise + Melatonin|3 consecutive days of bright light, exercise, and melatonin
214793319|NCT05382923|BEHAVIORAL|Control|3 consecutive days of dim red light + light stretching + placbo
214793320|NCT06456203|DIAGNOSTIC_TEST|AI|Artificial intelligence triage and reporting system
214793321|NCT02020603|DEVICE|epinephrine injection plus soft coagulation using hemostatic forceps|
214793322|NCT02020603|DEVICE|epinephrine injection plus argon plasma coagulation|
214793323|NCT01760603|PROCEDURE|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
214793324|NCT04200508|OTHER|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
214793325|NCT01803152|BIOLOGICAL|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
214793326|NCT01803152|BIOLOGICAL|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
214793327|NCT01803152|DRUG|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
214793328|NCT01803152|DRUG|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
214793329|NCT01803152|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
214793330|NCT04485052|DRUG|IBI188|anti-CD47 Monoclonal antibody
214793331|NCT04485052|DRUG|Azacitidine|Demethylation drugs
214793332|NCT04485052|DRUG|Decitabine|Demethylation drugs
214793333|NCT04771000|DRUG|Ambrisentan|Endothelin receptor antagonist
214793334|NCT04771000|DRUG|Placebo|Placebo
214793335|NCT03430375|DEVICE|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
214793336|NCT03430375|DEVICE|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
214793337|NCT01373775|OTHER|Patient charts reviewing|Reviewing chart and identifying risk factors
214793338|NCT05059756|DEVICE|PTNS|PTNS and PFR
214793339|NCT05059756|DEVICE|Sham PTNS|Sham PTNS and PFR
214793340|NCT03734237|BIOLOGICAL|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
214793341|NCT03734237|BIOLOGICAL|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
214793342|NCT03734237|BIOLOGICAL|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
214793343|NCT02711956|DRUG|ZEN003694|
214793344|NCT02711956|DRUG|Enzalutamide|
214793345|NCT00555256|DRUG|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
214793346|NCT00035009|DRUG|MK0869, aprepitant|
214793347|NCT00035009|DRUG|Comparator: paroxetine HCL|
214793348|NCT01784133|DRUG|omiganan|
214793349|NCT01784133|DRUG|placebo|
214793350|NCT02137083|DRUG|Docetaxel|75mg/m2 D2 every 21 days
214793351|NCT02137083|DRUG|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
214793352|NCT02840383|OTHER|Delayed Intervention|Schools not receiving intervention until two years after implementation.
214793353|NCT02840383|OTHER|Intervention|intervention at the beginning of study.
214793354|NCT00306345|BEHAVIORAL|Outreach|
214793355|NCT01844583|DRUG|Alisertib|Alisertib tablets
214793356|NCT01844583|DRUG|Esomeprazole|Esomeprazole capsules
214793357|NCT01844583|DRUG|Rifampin|Rifampin capsules
214793358|NCT01625377|DRUG|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
214793359|NCT01625377|DRUG|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
214793360|NCT01625377|DRUG|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
214793361|NCT01625377|DRUG|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
214793362|NCT01625377|DRUG|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
215030976|NCT05787041|OTHER|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
214793363|NCT03231254|DEVICE|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
214793364|NCT01000753|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214793365|NCT01997554|OTHER|Blood sample|An extra blood sample of 10 ml is collected
214793366|NCT03028662|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
214793367|NCT03368989|DRUG|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
214793368|NCT00445289|DEVICE|SmartCare/PS|
214793369|NCT06202157|OTHER|LMB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
214793370|NCT06202157|OTHER|DHB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
214793371|NCT04509973|DRUG|Dexamethasone|ATC code: H02AB02
214793372|NCT00020891|PROCEDURE|computed tomography|
214793373|NCT00020891|RADIATION|radiation therapy|
214793374|NCT04990830|DRUG|Inhaled Low molecular weight heparin|Application with Soft Mist Inhaler
214793375|NCT04990830|DRUG|Standard Treatment|Control Group
214793376|NCT00279448|DRUG|exemestane|On tablet of 25 mg per day during 5 years
214793377|NCT00279448|DRUG|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
214793378|NCT03246230|BIOLOGICAL|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
214793379|NCT03246230|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
214793380|NCT02470039|DRUG|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
214793381|NCT02470039|DRUG|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
214793382|NCT02470039|DRUG|placebo|Administered once daily
214793383|NCT05096325|DEVICE|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
214793384|NCT01448135|OTHER|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
214793385|NCT01448135|OTHER|Osmolite 1.2|High protein enteral formula
214793386|NCT03340168|OTHER|Bisphenol-S|Oral and dermal exposure in volunteers
214793387|NCT02271555|DRUG|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
214793388|NCT02271555|DRUG|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
214793389|NCT02271555|DRUG|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
214793390|NCT03422146|OTHER|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
214793391|NCT03422146|OTHER|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
214793392|NCT01412541|PROCEDURE|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
214793393|NCT01412541|DEVICE|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
214793394|NCT03329118|DRUG|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
214793395|NCT03616613|DIAGNOSTIC_TEST|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
214793396|NCT03881813|DEVICE|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
214793397|NCT02366221|OTHER|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
214793398|NCT02366221|OTHER|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
214793399|NCT04964999|OTHER|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
214793400|NCT04774575|BIOLOGICAL|biomarker-guided strategy|Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
214793401|NCT00959959|DRUG|TOK-001|2 capsules (325 mg each), once per day
214793402|NCT00959959|DRUG|TOK-001|4 capsules (325 mg each), once per day
214793403|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), once per day
214793404|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day
214793405|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day with supplement
214793406|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
214793407|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), once per day
214793408|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
214793409|NCT02442856|DEVICE|Thigh Cuff|
214793410|NCT05267756|DEVICE|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
214793411|NCT00979160|DRUG|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
214793412|NCT04472975|DRUG|Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS|Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
214793413|NCT02517190|OTHER|Parabolic flight|
214793414|NCT02517190|OTHER|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
214793415|NCT02517190|OTHER|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
214793416|NCT02517190|OTHER|cellular energy metabolism measurements|purines, lactate
214793417|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
214793418|NCT02207621|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
214793419|NCT02207621|OTHER|Placebo|1 drop QD, AM, OU
214793420|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
214793421|NCT02827903|DRUG|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
214793422|NCT02827903|DRUG|Metformin + placebo|Group II: Metformin + placebo,
214793423|NCT02827903|DRUG|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
214793424|NCT00534625|DRUG|zileuton|Single injection of zileuton 150 mg
214793425|NCT00534625|DRUG|placebo|Single injection of placebo
214793426|NCT00534625|DRUG|zileuton|Single injection of zileuton 300 mg
214793427|NCT05008289|DEVICE|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
214793428|NCT05008289|DEVICE|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
214793429|NCT03686709|DIAGNOSTIC_TEST|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
214793430|NCT01477437|OTHER|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
214793431|NCT05367856|DRUG|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
214793432|NCT04383756|BIOLOGICAL|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
214793433|NCT04383756|BIOLOGICAL|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
214793434|NCT01363037|DRUG|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
214793435|NCT01363037|DRUG|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
214793436|NCT01363037|OTHER|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
214793437|NCT01363037|DRUG|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
214793438|NCT02833415|DRUG|[U-13C3] glycerol|Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
214793439|NCT02833415|DRUG|Empagliflozin|Active drug
214793440|NCT02833415|DRUG|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
214793441|NCT01173809|DRUG|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
214793442|NCT01173809|DRUG|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
214793443|NCT04806009|BEHAVIORAL|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
214793444|NCT04806009|BEHAVIORAL|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
214793445|NCT00141752|DEVICE|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
214793446|NCT01530815|DRUG|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
214793447|NCT00963183|DRUG|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
214793448|NCT00963183|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
214793449|NCT06117488|DEVICE|endoscopy|gastro duodenal endoscoe
214793450|NCT05053698|OTHER|Aqueous flare measurement|Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
214793451|NCT01712880|PROCEDURE|open debridement with modular exchange|
214793452|NCT01712880|PROCEDURE|one stage exchange|
214793453|NCT02123992|DEVICE|Elevate Apical and Posterior|
214793454|NCT02123992|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
214793455|NCT03955679|GENETIC|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
214793456|NCT01769378|DRUG|Placebo|Administered SQ
214793457|NCT01769378|DRUG|Dulaglutide|Administered SQ
214793458|NCT01769378|DRUG|Glimepiride|Administered PO
215030977|NCT05787041|OTHER|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
214793459|NCT05260645|BEHAVIORAL|Back School|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
214793460|NCT03475797|DEVICE|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
214793461|NCT03475797|OTHER|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
214793462|NCT04305964|DEVICE|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
214793463|NCT04305964|DIAGNOSTIC_TEST|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
214793464|NCT05305274|OTHER|screening|This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
214793465|NCT01621425|OTHER|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
214793466|NCT01621425|OTHER|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
214793467|NCT01621425|OTHER|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
214793468|NCT02324972|DRUG|AQX-1125|Synthetic SHIP1 activator
214793469|NCT02324972|DRUG|Placebo|
214793470|NCT04259840|OTHER|Observation|Soft tissue implant measurements
214793471|NCT00006443|DRUG|Indinavir sulfate|
214793472|NCT00006443|DRUG|Nelfinavir mesylate|
214793473|NCT00006443|DRUG|Lamivudine|
214793474|NCT00006443|DRUG|Stavudine|
214793475|NCT01829009|OTHER|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
214793476|NCT01161654|DRUG|naratriptan hydrochoride|2.5 mg tablet
214793477|NCT02285127|PROCEDURE|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
214793478|NCT05731427|DIAGNOSTIC_TEST|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
214793479|NCT05731427|DRUG|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
214793480|NCT03352427|DRUG|Dasatinib|60 mg/m2 orally twice daily
214793481|NCT03352427|DRUG|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
214793482|NCT05285280|DIAGNOSTIC_TEST|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
214793483|NCT04281680|DRUG|Pasireotide 0.9 MG/ML|900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
214793484|NCT03478059|BEHAVIORAL|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
214793485|NCT02737215|DEVICE|CPAP|patients will receive CPAP therapy with Auto-CPAP
214793486|NCT03148574|DRUG|Misoprostol|intrauterine tablets
214793487|NCT03148574|DRUG|Oxytocin|intravenous
214793488|NCT02380846|OTHER|White rice|Control - white rice
214793489|NCT02380846|OTHER|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
214793490|NCT02380846|OTHER|Rice with fish|Treatment 2 - steamed white rice with steamed fish
214793491|NCT02380846|OTHER|Rice with egg white|Treatment 3 - steamed white rice with egg white
214793492|NCT02380846|OTHER|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
215030978|NCT06563648|OTHER|shotblocker|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
214793493|NCT06404411|OTHER|Assigned interventions|Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.
214793494|NCT06404411|OTHER|conventional rehabilitation|Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
214793495|NCT03166982|PROCEDURE|transvaginal approach|
214793496|NCT03166982|PROCEDURE|laparoscopic approach|
214793497|NCT01462565|DRUG|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
214793498|NCT01462565|DRUG|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
214793499|NCT02899130|DRUG|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
214793500|NCT02899130|DRUG|Placebo|Inactive compound that is similar looking as the intervention
214793501|NCT01238848|DRUG|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
214793502|NCT01238848|DRUG|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
214793503|NCT00576901|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
214793504|NCT00576901|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
214793505|NCT00576901|DRUG|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
214793506|NCT02004704|DRUG|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
214793507|NCT01755858|DRUG|Bendavia|
214793508|NCT01755858|DRUG|Placebo|
214793509|NCT00241917|BEHAVIORAL|Hepatitis C educational video|
214793510|NCT00241917|OTHER|Video|Prevention education video about hepatitis C
214793511|NCT03466190|PROCEDURE|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
214793512|NCT03466190|PROCEDURE|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
214793513|NCT04714619|DRUG|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
214793514|NCT05247710|PROCEDURE|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
214793515|NCT02613923|BEHAVIORAL|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
214793516|NCT02613923|BEHAVIORAL|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
214793517|NCT02613923|PROCEDURE|Blood Draw|blood sample measured for stress and sleep markers
214793518|NCT02613923|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
214793519|NCT02613923|OTHER|Insomnia Severity Index (ISI)|
214793520|NCT02613923|OTHER|SF-12 quality of life survey|
214793521|NCT01408966|DIETARY_SUPPLEMENT|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
214793522|NCT01408966|DIETARY_SUPPLEMENT|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
214793523|NCT01739283|OTHER|GIP|
214793524|NCT01739283|OTHER|GLP-1|
214793525|NCT01739283|OTHER|Saline|
214793526|NCT05861726|BEHAVIORAL|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 \& 70% maximum heart rate
214793527|NCT05861726|OTHER|None (control group)|None (the control group)
214793528|NCT01653665|DRUG|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
214793529|NCT01653665|DRUG|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
214793530|NCT01443065|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
214793531|NCT01443065|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
214793532|NCT01443065|DRUG|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
214793533|NCT01443065|DRUG|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
214793534|NCT01443065|DRUG|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
214793535|NCT05166265|DEVICE|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
214793536|NCT05896631|OTHER|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
214793537|NCT05896631|OTHER|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
214793538|NCT04318665|DIAGNOSTIC_TEST|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
214793539|NCT01259869|DRUG|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
214793540|NCT00175019|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
214793541|NCT00175019|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
214793542|NCT00175019|DRUG|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
214793543|NCT01808664|BEHAVIORAL|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
214793544|NCT01808664|BEHAVIORAL|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
214793545|NCT03164603|DRUG|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
214793546|NCT03209570|OTHER|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
214793547|NCT03209570|OTHER|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
214793548|NCT06211985|DIAGNOSTIC_TEST|Copeptin level measurement|Throughout the study period, a total of 202 eligible patients were admitted to the hospital. Twenty-four patients were excluded due to lack of consent from their families, and an additional 103 patients were excluded based on the predefined exclusion criteria. In the control group, 72 individuals without chronic or acute diseases were initially eligible, but 46 of them were excluded due to lack of consent from their families. The study included patients who met the inclusion criteria and whose families provided consent, and it concluded upon reaching a total of 25 patients for each group. Additional blood samples were collected from each child within every group to assess copeptin levels, in conjunction with routine tests
214793549|NCT05991661|DRUG|XKH001 Injection|100mg/ml，1ml/vial
214793550|NCT05991661|DRUG|XKH001 Placebo Injection|1ml/vial
214793551|NCT00928083|DRUG|OZ439 50mg API capsules|
214793552|NCT00928083|DRUG|OZ439 200mg API capsules|
214793553|NCT00928083|DRUG|OZ439 400mg aqueous dispersion|
214793554|NCT00928083|DRUG|OZ439 800mg aqueous dispersion|
214793555|NCT00928083|DRUG|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
214793556|NCT00928083|DRUG|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
214793557|NCT00928083|DRUG|OZ439 1600mg aqueous dispersion|
214793558|NCT00928083|DRUG|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
214793559|NCT00928083|DRUG|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
214793560|NCT00928083|DRUG|Placebo|
214793561|NCT00928083|DRUG|OZ439 200mg aqueous dispersion|
214793562|NCT00118053|BIOLOGICAL|herceptin|
214793563|NCT00118053|DRUG|carboplatin|
214793564|NCT00118053|DRUG|docetaxel|
214793565|NCT00118053|PROCEDURE|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
214793566|NCT00118053|PROCEDURE|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
214793567|NCT00128453|DRUG|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily
214793568|NCT00128453|DRUG|Placebo|placebo
214793569|NCT01601197|BEHAVIORAL|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
214793570|NCT00028665|BIOLOGICAL|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
214793571|NCT00028665|BIOLOGICAL|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
214793572|NCT00028665|DRUG|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
214793573|NCT00028665|DRUG|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
214793574|NCT00028665|DRUG|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
214793575|NCT00028665|DRUG|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
214793576|NCT00028665|PROCEDURE|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
214793577|NCT00028665|PROCEDURE|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
214793578|NCT00028665|RADIATION|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
214793579|NCT04338867|RADIATION|Whole-brain radiotherapy|Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
214793580|NCT00220701|DRUG|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
214793581|NCT01586247|DIETARY_SUPPLEMENT|Synbiotic|8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis
214793582|NCT01586247|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
214793583|NCT01586247|DIETARY_SUPPLEMENT|Prebiotic|8g/day galacto-oligosaccharide
214793584|NCT01586247|DIETARY_SUPPLEMENT|Probiotic|10\^9 CFU/day B.lactis
214793585|NCT01199757|DRUG|Fluticasone furoate|cohort of patients receiving fluticasone furate
214793586|NCT01199757|DRUG|mometasone furoate|cohort receiving mometasone furoate
214793587|NCT01199757|DRUG|fluticasone propionate|cohort of patients on fluticasone propionate
214793588|NCT05665582|OTHER|Family program|A 4-day psychoeducational family program.
214793589|NCT00755326|DRUG|HLXL|Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
214793590|NCT01102465|DRUG|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
214793591|NCT02140957|BEHAVIORAL|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
214793592|NCT04574310|OTHER|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
214793593|NCT04932733|OTHER|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
214793594|NCT04932733|OTHER|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
214793595|NCT02076477|RADIATION|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
214793596|NCT02076477|DRUG|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
214793597|NCT02076477|DRUG|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
214793598|NCT02076477|DRUG|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
214793599|NCT04686136|DRUG|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
214793600|NCT04035590|PROCEDURE|No drain|Mastectomy with flap fixation without low vacuum drainage
214793601|NCT04035590|PROCEDURE|With drain|Mastectomy with flap fixation with low vacuum drainage
214793602|NCT04122274|BEHAVIORAL|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
214793603|NCT04122274|BEHAVIORAL|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
214793604|NCT04122274|BEHAVIORAL|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
214793605|NCT03551249|DEVICE|Focused ultrasound (FUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
214793606|NCT05417048|DIAGNOSTIC_TEST|Blood Sample|Up to 5mL of blood via venipuncture
214793607|NCT04719000|DRUG|rhFSH+rhLH|300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
214793608|NCT04719000|DRUG|rhFSH|300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
214793609|NCT00003078|DRUG|cisplatin|
214793610|NCT00003078|DRUG|fluorouracil|
214793611|NCT00003078|RADIATION|brachytherapy|
214793612|NCT00003078|RADIATION|radiation therapy|
214793613|NCT04469608|BEHAVIORAL|acupuncture|Traditional Chinese medicine clinical daycare
214793614|NCT04041570|BIOLOGICAL|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
214793615|NCT02980848|OTHER|Screening digital mammography|Screening with digital mammography alone
214793616|NCT02980848|OTHER|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
214793617|NCT02980848|OTHER|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
214793618|NCT02980848|OTHER|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
214793619|NCT02980848|OTHER|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
214793620|NCT02185612|BEHAVIORAL|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
214793621|NCT03122002|DRUG|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
214793622|NCT03122002|DIAGNOSTIC_TEST|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
214793623|NCT03122002|OTHER|Intravascular therapy|Intravascular therapy including thrombectomy
214793624|NCT03122002|OTHER|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
214793625|NCT03122002|OTHER|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
214793626|NCT01054508|DRUG|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
214793627|NCT00774358|DRUG|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
214793628|NCT03758365|DRUG|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793629|NCT03758365|DRUG|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793630|NCT03758365|DRUG|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793631|NCT03758365|DRUG|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793632|NCT03758365|DRUG|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793633|NCT03758365|DRUG|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793634|NCT03758365|DRUG|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
214793635|NCT01111110|DEVICE|anti-static then static|Albuterol using static chambers
214793636|NCT01111110|DEVICE|Static then anti-static chamber|albuterol with Static then anti-static chambers
214793637|NCT01082653|BIOLOGICAL|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
214793638|NCT04115449|DRUG|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
214793639|NCT04115449|DRUG|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
214793640|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
214793641|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
214793642|NCT00384033|DRUG|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
214793643|NCT00384033|DRUG|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
214793644|NCT01961791|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
214793645|NCT01851161|PROCEDURE|computed tomography|Undergo conventional CT scan in both supine and prone positioning
214793646|NCT01851161|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
214793647|NCT01851161|RADIATION|radiation therapy|Undergo radiation therapy
214793648|NCT00290745|DRUG|letrozole|
214793649|NCT00290745|DRUG|tamoxifen citrate|
214793650|NCT00290745|PROCEDURE|conventional surgery|
214793651|NCT00290745|PROCEDURE|neoadjuvant therapy|
214793652|NCT02750306|DRUG|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
214793653|NCT02750306|DRUG|Placebo|Placebo to suvorexant
214793654|NCT03787485|BEHAVIORAL|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
214793655|NCT03381547|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
214793656|NCT03848585|DEVICE|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
214793657|NCT03848585|OTHER|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
214793658|NCT00942461|PROCEDURE|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
214793659|NCT00942461|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
214793660|NCT03969459|BIOLOGICAL|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
214793661|NCT03969459|BIOLOGICAL|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
214793662|NCT03969459|BIOLOGICAL|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
214793663|NCT03969459|OTHER|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
214793664|NCT01032395|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
214793665|NCT01032395|BIOLOGICAL|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
214793666|NCT01032395|BIOLOGICAL|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
214793667|NCT04750005|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
214793668|NCT04750005|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
214793669|NCT04750005|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
214793670|NCT04750005|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
214793671|NCT00992069|DRUG|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
214793672|NCT00992069|DRUG|TMC207|Single oral dose of 400 mg in the morning
214793673|NCT01689259|DRUG|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
214793674|NCT01689259|DRUG|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
214793675|NCT01689259|DRUG|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
214793676|NCT01689259|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
214793677|NCT01502618|BEHAVIORAL|Focus Group|N/A. Protocol is the focus group
214793678|NCT05753384|DRUG|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
214793679|NCT02737306|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214793680|NCT02737306|DRUG|Placebo|Placebo in parenteral solution.
214793681|NCT00297271|OTHER|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
214793682|NCT03337178|BEHAVIORAL|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
214793683|NCT03337178|BEHAVIORAL|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
214793684|NCT01497483|DRUG|Pravastatin alone|Pravastatin 40 mg with placebo.
214793685|NCT01497483|DRUG|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
214793686|NCT05152342|BEHAVIORAL|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
214793687|NCT05152342|BEHAVIORAL|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
214793688|NCT01857193|DRUG|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
214793689|NCT01857193|DRUG|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
214793690|NCT01857193|DRUG|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
214793691|NCT04232397|DRUG|Anlotinib|anlotinib 8mg qd po
214793692|NCT01362933|PROCEDURE|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
214793693|NCT03263481|PROCEDURE|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
214793694|NCT00464750|DEVICE|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
214793695|NCT03147196|DRUG|Bicalutamide|Given PO
214793696|NCT03147196|OTHER|Laboratory Biomarker Analysis|Correlative studies
214793697|NCT03147196|OTHER|Questionnaire Administration|Ancillary studies
214793698|NCT03147196|DRUG|Raloxifene Hydrochloride|Given PO
214793699|NCT03821220|BEHAVIORAL|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
214793700|NCT03821220|BEHAVIORAL|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
214793701|NCT03821220|BEHAVIORAL|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
214793702|NCT04642573|OTHER|non interventional|non interventional
214793703|NCT01171066|DEVICE|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
214793704|NCT05673668|DEVICE|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
214793705|NCT01987622|PROCEDURE|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
214793706|NCT01987622|PROCEDURE|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
214793707|NCT01776281|BEHAVIORAL|Kangaroo Mother Care|
214793708|NCT01776281|BEHAVIORAL|Standard Care|
214793709|NCT05520424|DIETARY_SUPPLEMENT|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
214793710|NCT06109558|DRUG|LMV-12(HE003)|1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
214793711|NCT05343156|DRUG|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
214793712|NCT04886115|OTHER|Neuromuscular evaluation|"Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump"
214793713|NCT04886115|OTHER|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~\- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
214793714|NCT04886115|OTHER|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
214793715|NCT04886115|OTHER|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
214793716|NCT04886115|OTHER|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
214793717|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)"
214793718|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient & soy protein supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)"
214793719|NCT02975089|DIETARY_SUPPLEMENT|Nutrition education on balanced diet & food supplement|"1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)"
215030979|NCT06563648|OTHER|local cold application|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.
214793720|NCT02397070|PROCEDURE|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
214793721|NCT02397070|DEVICE|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
214793722|NCT02521441|BIOLOGICAL|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
214793723|NCT02521441|BIOLOGICAL|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
214793724|NCT01915732|DRUG|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
214793725|NCT01915732|DRUG|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
214793726|NCT02407379|PROCEDURE|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
214793727|NCT02407379|PROCEDURE|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
214793728|NCT02478307|OTHER|Cognitive Therapy|
214793729|NCT02478307|OTHER|Mindfulness Meditation|
214793730|NCT02478307|OTHER|Mindfulness-Based Cognitive Therapy|
214793731|NCT00915057|DRUG|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
214793732|NCT04626999|PROCEDURE|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
214793733|NCT04626999|PROCEDURE|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
214793734|NCT03530956|DEVICE|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
214793735|NCT01775020|DIETARY_SUPPLEMENT|L-arginine|
214793736|NCT01720082|PROCEDURE|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
214793737|NCT01720082|PROCEDURE|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
214793738|NCT01575522|OTHER|Laboratory Biomarker Analysis|Correlative studies
214793739|NCT01575522|DRUG|Tivantinib|Given PO
215030980|NCT06563648|OTHER|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
215030981|NCT05495568|BIOLOGICAL|CT-P17|CT-P17 40mg will be subcutaneous administered
215030982|NCT05495568|BIOLOGICAL|EU-approved Humira|subcutaneous administration
215030983|NCT03388827|DEVICE|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
215030984|NCT03388827|DRUG|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
215030985|NCT02331758|BEHAVIORAL|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
214793740|NCT01505257|BEHAVIORAL|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
214793741|NCT03155984|DRUG|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
214793742|NCT04033809|DIETARY_SUPPLEMENT|Multigrain powder (S)|A twice daily high fiber multigrain powder supplementation for 12 weeks
214793743|NCT01601678|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
214793744|NCT01601678|PROCEDURE|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
214793745|NCT04385446|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
214793746|NCT04172298|OTHER|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
214793747|NCT04172298|OTHER|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
214793748|NCT04172298|OTHER|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
214793749|NCT02051881|OTHER|Taking intestinal biopsies|
214793750|NCT04168476|OTHER|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
214793751|NCT04168476|OTHER|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
214793752|NCT01994603|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
214793753|NCT01994603|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
214793754|NCT02015793|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
214793755|NCT02015793|BIOLOGICAL|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
214793756|NCT05890456|BEHAVIORAL|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
214793757|NCT05890456|BEHAVIORAL|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
214793758|NCT05084690|OTHER|Unilateral resistance training|Unilateral resistance training of the elbow flexors
214793759|NCT05084690|OTHER|Illusionary mirror visual feedback|Modified Ramachandran's mirror box
214793760|NCT01685970|DRUG|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
214793761|NCT01685970|DRUG|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
214793762|NCT06482866|OTHER|Cottle's septoplasty and radiocoagulation conchoplasty|Cottle's septoplasty and radiocoagulation conchoplasty Study group - added nasal splits; Control group - nasal splits weren't used.
214793763|NCT01818570|DRUG|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
214793764|NCT01818570|DRUG|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
214793765|NCT04383990|OTHER|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
214793766|NCT03935659|DEVICE|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
214793767|NCT03935659|PROCEDURE|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
214793768|NCT02588625|DRUG|BMS-986020|
214793769|NCT02588625|OTHER|Placebo|
214793770|NCT02424981|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
214793771|NCT00525967|DRUG|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
214793772|NCT04592991|DIAGNOSTIC_TEST|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
214793773|NCT04592991|DIAGNOSTIC_TEST|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
214793774|NCT01643369|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
214793775|NCT01643369|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
214793776|NCT01643369|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
214793777|NCT01862328|DRUG|MLN4924|"MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle"
214793778|NCT01862328|DRUG|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle"
214793779|NCT01862328|DRUG|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
214793780|NCT01862328|DRUG|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~\- Docetaxel on Day 1 of each cycle"
214793781|NCT01862328|DRUG|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~\- Carboplatin on Day 1 of each cycle"
214793782|NCT05265195|OTHER|Mixed Methods study|Mixed Methods study
214793783|NCT04748211|PROCEDURE|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
215030986|NCT04260958|OTHER|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
215030987|NCT03257657|BEHAVIORAL|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
214793784|NCT04748211|PROCEDURE|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
214793785|NCT02482571|DEVICE|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
214793786|NCT02404740|DEVICE|Pulse oximetry|Pulse oximetry
214793787|NCT04775784|DIAGNOSTIC_TEST|Determination of SARS-CoV2 presence in CNS|Brain tissue sampling
214793788|NCT03158142|DRUG|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
214793789|NCT04576767|OTHER|anaesthetic|different states of consciousness
214793790|NCT03857113|PROCEDURE|PSMA-radioguided surgery|PSMA-radioguided surgery
214793791|NCT00927121|DEVICE|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
214793792|NCT01599208|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
214793793|NCT05751681|OTHER|progestin primed ovarian stimulation protocol|progestin primed ovarian stimulation protocol
214793794|NCT05751681|DRUG|dydrogesterone (Duphaston, Abbott)|20 mg oral dose of dydrogesterone (Duphaston, Abbott)
214793795|NCT05751681|DRUG|Cetrotide|0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
214793796|NCT06026982|DIETARY_SUPPLEMENT|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
215030988|NCT03257657|BEHAVIORAL|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
215030989|NCT04809337|OTHER|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
214793797|NCT06428708|DIAGNOSTIC_TEST|[18F] PSMA-1007 PET/CT|\[18F\] PSMA-1007 PET/CT scan
214793798|NCT02942303|DRUG|Dysport|
214793799|NCT02942303|PROCEDURE|lateral orbicularis injection|
214793800|NCT02942303|PROCEDURE|Lateral orbicularis + corrugator injection|
214793801|NCT05299268|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
214793802|NCT05299268|BEHAVIORAL|No pain (Isotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
214793803|NCT04432948|OTHER|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
214793804|NCT04432948|OTHER|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
214793805|NCT04432948|OTHER|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
214793806|NCT04429451|BIOLOGICAL|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
214793807|NCT00065858|DRUG|BufferGel|
214793808|NCT01446913|DEVICE|Standard CPAP Intervention|
214793809|NCT01446913|BEHAVIORAL|Enhanced CPAP Intervention|
214793810|NCT02521948|DEVICE|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
214793811|NCT02427607|DRUG|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
214793812|NCT05508100|BIOLOGICAL|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
214794476|NCT04843163|BEHAVIORAL|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
214794477|NCT01684358|DEVICE|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
214794478|NCT00336310|DRUG|Repaglinide|
214794479|NCT04212039|DRUG|Saline Solution|0.5 ml/kg saline
214794480|NCT04212039|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
214794481|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
214794482|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
214794483|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
214794484|NCT00244322|DRUG|LY450139 dihydrate|
214794485|NCT00244322|DRUG|placebo|
214794486|NCT04998409|DEVICE|Monofocal lens|not applicable as patients are already implanted with the monofocal lens
214794487|NCT02241603|BEHAVIORAL|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
214794488|NCT02053532|PROCEDURE|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
214794489|NCT02297009|PROCEDURE|Buccal swab|Buccal swabs will be taken from the volunteers
214794490|NCT01654107|BEHAVIORAL|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
214794491|NCT01654107|BEHAVIORAL|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
214794492|NCT01654107|DRUG|Nicotine lozenge|12-weeks 4mg nicotine lozenge
214794493|NCT04089709|BEHAVIORAL|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
214794494|NCT00427128|DRUG|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
214794495|NCT00427128|DRUG|placebo|Week 13-36.
214794496|NCT05307861|DEVICE|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
214794497|NCT05307861|DEVICE|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
214794498|NCT02744183|BEHAVIORAL|Exercise|Moderate intensity exercise
214794499|NCT02744183|BEHAVIORAL|Breakfast|Breakfast consumption
214794500|NCT02744183|BEHAVIORAL|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
214794501|NCT00299156|DRUG|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
214794502|NCT00493571|DRUG|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
214794503|NCT06546215|DRUG|Digoxin|Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
214794504|NCT01491620|DEVICE|532 nm KTP laser|Laser treatment sessions on the neck and/or chest
214794505|NCT00638365|BIOLOGICAL|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
214794506|NCT00638365|OTHER|Placebo|Placebo single-dose administered intravenously
214794507|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
214794508|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
214794509|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
214794510|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
214794511|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
214794512|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
214794513|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
214794514|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
214794515|NCT05538884|PROCEDURE|Intertransverse process block|The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
214794516|NCT03749265|OTHER|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
214794517|NCT06485895|DIAGNOSTIC_TEST|test IGRA|BLOOD SAMPLES
214794518|NCT06485895|DIAGNOSTIC_TEST|TEST QUATIFERON TB Gold Plus|BLOOD SAMPLES
214794519|NCT04216069|OTHER|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
214646916|NCT04529291|OTHER|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
214646917|NCT05358132|DEVICE|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
214646918|NCT01694043|OTHER|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
214646919|NCT01694043|OTHER|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
214646920|NCT05876403|OTHER|Conventional|The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
214646921|NCT05876403|OTHER|PNF|The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
214646922|NCT03522129|DRUG|CT1812|Active Study Drug
214646923|NCT03522129|DRUG|Placebo|Non-active study drug
214646924|NCT03567902|DEVICE|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
214646925|NCT03567902|DEVICE|Direct laryngoscope intubation|Direct laryngoscope intubation
214646926|NCT00737451|BEHAVIORAL|blood sampling|blood sampling 10ml from the study subjects
214646927|NCT05489978|BEHAVIORAL|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~1. Para-social contact~   * Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~  * Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~2. Participatory learning techniques~   * Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~  * Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~3. Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
214646928|NCT02747030|DRUG|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
214646929|NCT00836433|BEHAVIORAL|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
214646930|NCT00836433|BEHAVIORAL|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
214646931|NCT02061865|DRUG|REGN2176-3|
214646932|NCT02604940|DRUG|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
214646933|NCT02604940|DRUG|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
214646934|NCT02349178|DRUG|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
214646935|NCT02349178|DRUG|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
214646936|NCT02349178|DRUG|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
214646937|NCT02161159|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
214646938|NCT03885271|OTHER|Hall Technique|The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
214646939|NCT03885271|OTHER|Formecresol Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
214646940|NCT06405464|DRUG|VOCABRIA 30Mg Tablet|CAB 30 mg Film-coated tablets
214646941|NCT06405464|DRUG|EDURANT 25Mg Tablet|RPV 25 mg film-coated tablets
214646942|NCT06405464|DRUG|Cabotegravir Injectable Suspension|CAB LA 600 mg prolonged release suspension for injection (3 mL)
214646943|NCT06405464|DRUG|Rilpivirine Injectable Suspension|RPV LA 900 mg prolonged release suspension for injection (3 mL)
214646944|NCT06405464|BIOLOGICAL|Intact proviral DNA assay|HIV-1 latent reservoir size
214646945|NCT06405464|BIOLOGICAL|Full-length sequencing|Proviral DNA
214646946|NCT02867761|DRUG|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
214646947|NCT02867761|DRUG|Placebo|27.5/15.6 mcg placebo
214794520|NCT04216069|OTHER|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
214794521|NCT01523964|OTHER|Testing with EIM|
214794522|NCT03871608|OTHER|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
214794523|NCT03871608|OTHER|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
214794524|NCT00747175|DRUG|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
214794525|NCT00747175|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
214794526|NCT00211159|DRUG|EPAX 1050TG|
214794527|NCT05409677|OTHER|This was a retrospective study with no intervention other than normal treatment|This was a retrospective study with no intervention other than normal treatment
214794528|NCT04025788|DEVICE|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
214794529|NCT02815878|BEHAVIORAL|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
214794530|NCT03614377|DIAGNOSTIC_TEST|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
214794531|NCT00963157|DRUG|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
214794532|NCT00963157|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
214794533|NCT01507857|BIOLOGICAL|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
214794534|NCT01507857|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
214794535|NCT00233857|PROCEDURE|Auricular acupuncture|
214794536|NCT04415125|DIAGNOSTIC_TEST|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
214794537|NCT04868526|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
214794538|NCT00946257|DRUG|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
214794539|NCT01166568|DEVICE|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
214646948|NCT04506294|BEHAVIORAL|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
214646949|NCT01928160|DRUG|pemetrexed disodium|Given IV
214646950|NCT01928160|DRUG|carboplatin|Given IV
214646951|NCT01928160|DRUG|cisplatin|Given IV
214646952|NCT01928160|DRUG|erlotinib hydrochloride|Given PO
214646953|NCT01928160|OTHER|laboratory biomarker analysis|Correlative studies
214646954|NCT03083028|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
214646955|NCT03083028|PROCEDURE|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
214646956|NCT01931059|DRUG|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
214646957|NCT01931059|OTHER|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
214646958|NCT01213212|OTHER|Caloric restriction|Caloric restriction.
214646959|NCT01213212|OTHER|No intervention|"Diet ad libitum"
214646960|NCT05345925|DEVICE|Moderato|Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.
214646961|NCT00578643|DRUG|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
214646962|NCT00578643|BIOLOGICAL|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
214646963|NCT00578643|DRUG|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
214646964|NCT00578643|DRUG|Fludarabine|"Day -5 through Day -2~30 mg/m\^2"
214646965|NCT00578643|DRUG|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
214646966|NCT00578643|PROCEDURE|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.
214646967|NCT06264700|BEHAVIORAL|Video Directly Observed Therapy (VDOT)|VDOT is an adherence-promoting intervention that involves partnering with an adolescent with SCD (or caregiver of a young patient with SCD) and observing the patient administer their hydroxyurea. In this study, VDOT will be delivered by a small business partner, Scene Health, via a smart phone app.
214794540|NCT02520557|OTHER|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
214794541|NCT05805553|DRUG|Propranolol|2mg/kg/day in 3-4 dividd doses
214794542|NCT05805553|DRUG|Nandrolone Decanoate|1mg/kg weekly
214794543|NCT02230397|OTHER|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
214794544|NCT02230397|OTHER|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
214794545|NCT03516383|DEVICE|PWVi|
214794546|NCT02647983|DRUG|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
214794547|NCT05097872|OTHER|Diet|Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
214794548|NCT02928913|OTHER|No intervention|
214794549|NCT06141070|OTHER|Standard systemic therapy + radiotherapy|Combined systemic therapy + radiation
214794550|NCT06141070|DRUG|Standard systemic therapy|Chemoimmunotherapy or immunotherapy
214794551|NCT01328275|DRUG|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
214794552|NCT01229085|DRUG|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
214794553|NCT02548507|OTHER|observational study, no intervention|
214794554|NCT00996671|DRUG|GSK2256098|focal adhesion kinase inhibitor given as a single dose
214794555|NCT00996671|DRUG|Placebo|Placebo to be used as comparator for GSK2256098
214794556|NCT01652365|BEHAVIORAL|RDT Training and Subsidy Offered|
214794557|NCT01652365|BEHAVIORAL|Information/Education Campaign|
214794558|NCT01654380|DRUG|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
214794559|NCT01654380|OTHER|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
214794560|NCT00347542|DRUG|Vitamin D|
214794561|NCT02101632|DIETARY_SUPPLEMENT|Bee Venom Ointment|2 weeks
214794562|NCT02101632|OTHER|Vaseline Ointment|2 weeks
214794563|NCT03432013|BEHAVIORAL|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
214794564|NCT03432013|BEHAVIORAL|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
214794565|NCT00655577|BEHAVIORAL|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
214794566|NCT00684671|BIOLOGICAL|Twinrix|Intramuscular injection, single dose in left deltoid.
214794567|NCT00684671|BIOLOGICAL|Engerix-B|Intramuscular injection, single dose in left deltoid.
214794568|NCT00684671|BIOLOGICAL|Havrix|Intramuscular injection, single dose in right deltoid.
214794569|NCT00684671|BIOLOGICAL|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
214794570|NCT00684671|BIOLOGICAL|Vaqta|Intramuscular injection, single dose in right deltoid.
214794571|NCT01923077|DRUG|Simvastatin|usual care with Simvastatin
214794572|NCT01923077|DRUG|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
214794573|NCT03335371|DRUG|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
214794574|NCT03335371|DRUG|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
214794575|NCT03335371|DRUG|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
214794576|NCT01323764|DEVICE|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
214794577|NCT01759199|PROCEDURE|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
214794578|NCT00003237|DRUG|cisplatin|
214794579|NCT00003237|DRUG|paclitaxel|
214794580|NCT00003237|PROCEDURE|surgical procedure|
214794581|NCT01618799|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
214794582|NCT01618799|DRUG|Lamotrigine|2 x 25 mg tablet once a day
214794583|NCT02582970|DRUG|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
214794584|NCT02582970|DRUG|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
214794585|NCT02582970|DRUG|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
214794586|NCT02582970|DRUG|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
214794587|NCT00977288|DRUG|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
214794588|NCT00977288|DRUG|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
214794589|NCT00977288|DRUG|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
214794590|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
214794591|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
214794592|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
214794593|NCT05291078|DEVICE|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
214794594|NCT05577793|OTHER|Mother's Voice|The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.
214794595|NCT05577793|OTHER|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
214794596|NCT05577793|OTHER|Mother's Voice +Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
214794597|NCT05577793|OTHER|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
214794598|NCT03629093|DRUG|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
214794599|NCT01964742|GENETIC|blood samples|
214794600|NCT05933005|DEVICE|D-kit/EF1|"D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills."
214794601|NCT05933005|DEVICE|Sham group program|The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
214794602|NCT05894161|OTHER|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day."
214794603|NCT04132661|DRUG|Bisacodyl 5 milligram|one single dose
214794604|NCT04132661|DRUG|Placebo oral tablet|one single dose
214794605|NCT04894747|DIETARY_SUPPLEMENT|Bolus ingestion of protein|Ingestion of 25g of protein
214794606|NCT01684553|BEHAVIORAL|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
214794607|NCT01684553|BEHAVIORAL|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
214794608|NCT01820039|OTHER|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
214794609|NCT06485375|DIAGNOSTIC_TEST|EMG|Disposable bipolar surface electrodes will be used. The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres. Doing so the position of the electrodes results as follows: Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
214794610|NCT05129579|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
214794611|NCT05129579|OTHER|no intervention|No intervention will be made in the control group.
214794612|NCT01725451|DRUG|Testosterone|Administered topically to axillae
214794613|NCT01725451|OTHER|Deodorant Spray|Administered topically to axillae
214794614|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
214794615|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
214794616|NCT03308019|DEVICE|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
214794617|NCT03308019|PROCEDURE|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
214467259|NCT06539247|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation Technique with Electrical Muscle Stimulation (PNF + EMS)|"This arm received a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program consisted of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) and Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS applied to the affected ankle dorsiflexors for 10 minutes with the same parameters."
214794618|NCT04679870|DRUG|GB2064|GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
214794619|NCT02410512|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
214794620|NCT02410512|DRUG|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
214794621|NCT00143156|DRUG|pregabalin|
214794622|NCT03562806|DIAGNOSTIC_TEST|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
214794623|NCT04536259|BEHAVIORAL|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
214794624|NCT04536259|BEHAVIORAL|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
214794625|NCT04536259|BEHAVIORAL|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
214794626|NCT00091598|DRUG|Ambrisentan|
214794627|NCT03101943|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
214794628|NCT03101943|OTHER|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
214794629|NCT03101943|OTHER|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
214794630|NCT03857022|DEVICE|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
214794631|NCT02777060|PROCEDURE|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
214794632|NCT02777060|PROCEDURE|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
214794633|NCT03295058|DRUG|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
214794634|NCT03295058|DRUG|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
214794635|NCT03295058|PROCEDURE|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
214794636|NCT03295058|DRUG|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
214794637|NCT00437281|DRUG|Placebo|Placebo
214794638|NCT00437281|DRUG|Pregabalin|Orally-administered pregabalin
214794639|NCT05621486|BIOLOGICAL|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
214794640|NCT04853810|OTHER|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
214794641|NCT01682161|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
214794642|NCT02848430|DIETARY_SUPPLEMENT|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
214794643|NCT03617484|DRUG|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
214794644|NCT03617484|DRUG|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
214794645|NCT01236833|DRUG|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
214794646|NCT00601354|BEHAVIORAL|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
214794647|NCT00601354|DRUG|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
214794648|NCT05868109|DRUG|inhaled nitric oxide (iNO)|In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
214794649|NCT05868109|DRUG|Sham|In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
214467260|NCT05975359|DEVICE|Interi Manifold Drain System|The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
214794650|NCT01519128|DRUG|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
214794651|NCT01519128|DRUG|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
214794652|NCT05358873|DEVICE|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
214794653|NCT05358873|DEVICE|Placebo|Normal saline
214794654|NCT04766918|PROCEDURE|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
214794655|NCT04766918|PROCEDURE|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
214794656|NCT01592799|PROCEDURE|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
214794657|NCT01592799|OTHER|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: \< 6 months; 6-23 months; 24-59 months; \> 5 years.
214794658|NCT02027779|BIOLOGICAL|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
214794659|NCT02027779|BIOLOGICAL|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
214794660|NCT01656889|BIOLOGICAL|HP-802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
214794661|NCT01656889|BIOLOGICAL|Vehicle|(fibrinogen solution \& thrombin solution without cells)
214794662|NCT03144856|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
214794663|NCT02153307|DEVICE|Implantable loop recorders system Reveal ICM LINQ®,|
214794664|NCT00003536|DRUG|antineoplaston A10|
214794665|NCT00003536|DRUG|methotrexate|
214794666|NCT00003536|PROCEDURE|alternative product therapy|
214794667|NCT00003536|PROCEDURE|biological therapy|
214794668|NCT00003536|PROCEDURE|biologically based therapies|
214794669|NCT00003536|PROCEDURE|cancer prevention intervention|
214794670|NCT00003536|PROCEDURE|chemotherapy|
214794671|NCT00003536|PROCEDURE|complementary and alternative therapy|
214794672|NCT00003536|PROCEDURE|differentiation therapy|
214794673|NCT06464809|OTHER|kinesio taping (KT)|
214794674|NCT03149913|DEVICE|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
214794675|NCT03149913|DEVICE|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
214794676|NCT05980988|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
214794677|NCT05980988|DIETARY_SUPPLEMENT|Placebo|Placebo
214794678|NCT04550949|DRUG|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
214794679|NCT04550949|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
214794680|NCT04469738|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
214467261|NCT05975359|DEVICE|Jackson Pratt Drain System|The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
214467262|NCT05700071|DIAGNOSTIC_TEST|MRI|MRI without contrast agent
214467263|NCT04850898|BIOLOGICAL|SAB-176|Treatment of influenza
214794681|NCT04469738|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
214794682|NCT00423800|DRUG|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
214794683|NCT00756028|DRUG|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
214794684|NCT00756028|DRUG|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
214794685|NCT04164953|PROCEDURE|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
214794686|NCT05699707|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Participants will consume a ketone monoester drink (0.75 k/kg body mass) with venous blood samples obtained before and after (30, 60 and 90 minutes) drink consumption.
214794687|NCT06334926|OTHER|no intervention, retrospective data analysis|not applicable, retrospective data analysis
214794688|NCT01181661|BEHAVIORAL|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
214467264|NCT04850898|OTHER|Placebo|Placebo Control
214467265|NCT06455839|BEHAVIORAL|Guided Resipiration Mindfulness Therapy (GRMT)|GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
214794689|NCT01181661|BEHAVIORAL|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
214794690|NCT01576588|DRUG|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
214794691|NCT01576588|DRUG|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
214794692|NCT03756753|DIAGNOSTIC_TEST|Results available to provider|Results of point of care testing are given to provider
214794693|NCT05374863|DEVICE|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
214794694|NCT05374863|DEVICE|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
214794695|NCT05374863|DEVICE|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
214794696|NCT03908255|DRUG|Branch Chain Amino Acid|Nutritional supplementation
214794697|NCT03908255|OTHER|maltodextrin|Placebo
214794698|NCT00121654|DEVICE|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
214794699|NCT01968733|DRUG|Solithromycin|
214794700|NCT01968733|DRUG|Moxifloxacin|
214794701|NCT03960918|BEHAVIORAL|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
214794702|NCT04813250|OTHER|ventilation mode setting|Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
214646968|NCT06264700|BEHAVIORAL|Health Reminder Tip Alerts|"Participants randomized to this arm will receive an automated, daily, short health or safety tip alert (e.g. Time to get moving! You should be active for at least 30 minutes each day) to receive during the 180-day intervention period on their smartphone. The daily tip will be unrelated to hydroxyurea adherence. After the 180-day intervention period, participants complete a 180-day ongoing monitoring period where they will no longer receive these messages, but they will be reminded to continue to use their electronic adherence monitoring device. All participants will be offered a smart phone with a data plan at enrollment to ensure equal opportunity for participation."
214646969|NCT02305862|DRUG|Rosuvastatin 5mg|drug intervention
214646970|NCT02305862|DRUG|Rosuvastatin 20mg|drug intervention
214646971|NCT01910714|BEHAVIORAL|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
214646972|NCT01910714|BEHAVIORAL|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
214646973|NCT04934787|DEVICE|ENMS-BSF assisted gait training|"1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
214646974|NCT00317525|DEVICE|Spectacle Lenses|
214646975|NCT04003688|DRUG|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
214646976|NCT04003688|DRUG|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
214646977|NCT04003688|DRUG|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
214646978|NCT06176157|DIETARY_SUPPLEMENT|vitamin D2, vitamin D3|comparing parentral D2, D3, to oral D2, D3
214646979|NCT02878980|BEHAVIORAL|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
214646980|NCT02878980|OTHER|Laboratory Biomarker Analysis|Correlative studies
214646981|NCT02878980|OTHER|Quality-of-Life Assessment|Ancillary studies
214646982|NCT02878980|OTHER|Questionnaire Administration|Ancillary studies
214646983|NCT00004260|BIOLOGICAL|recombinant interleukin-12|
214464452|NCT06564948|OTHER|Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention|"The FSJS+Navigator intervention adds an Emergency Department (ED)-based Systems Navigator, a community health worker with lived experience (as family member or patient) with criminal justice and mental health systems, to the FSJS. This navigator will enhance communication between Cambridge Police Department (CPD), Cambridge Health Alliance (CHA), and community agencies by being the needed point person within the healthcare system (the FSJS intervention only has a CPD-based social worker) to maintain communication to improve mental health services and prevent deeper justice involvement. The Navigator engages with the FSJS process in step i) of the above sequence, engaging the patient in the CHA ED and obtaining consent. The Navigator then discusses the case with the presenting CPD officer, and relays critical information about the context of the service call to ED staff. Next, the Navigator will administer the baseline CAT-MH/SS and assess additional needs (employment, housing, food)."
214646984|NCT00004260|BIOLOGICAL|rituximab|
214646985|NCT05982587|OTHER|Survivorship passport (SurPass) delivery|"The Survivorship Passport (SurPass) is a digital tool developed thanks to several EU projects to help Childhood Cancer Survivors (CCS), their families and health care providers (HCPs) in the follow-up process after completion of anticancer treatment. It comprises two main components: Treatment Summary including demographic, diagnosis and treatment data and personalized Survivorship Care Plan providing individual follow-up care recommendations The SurPass assists both CCS and HCPs to improve Long-Term Follow-Up care, in a partnership, supporting CCS empowerment and satisfaction with care, as well as shared decision-making by CCS and HCPs.~The aim of the PCSP implementation study is to evaluate feasibility and outcomes (personal and economic) of implementing the SurPass v2.0 in six clinics located in Austria, Belgium, Germany, Italy, Lithuania and Spain by using interoperability procedures according to Health Level 7- Fast Healthcare Interoperability Resource (HL7-FHIR) standards."
214646986|NCT01967290|DEVICE|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
214646987|NCT01967290|DEVICE|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
214646988|NCT03847142|OTHER|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
214646989|NCT03847142|OTHER|Outpatient primary care|Usual care delivered through the outpatient primary care setting
214646990|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|100 000 U drops is given once
214646991|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|500 U drops given once
214646992|NCT02002260|DEVICE|Levonorgestrel intrauterine system|
214646993|NCT02002260|DRUG|Combined oral contraceptives|
214646994|NCT01301430|DRUG|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
214646995|NCT04699604|DRUG|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.
214646996|NCT04699604|DRUG|Placebo|Placebo
214646997|NCT06706661|OTHER|Nutritional treatment|At the day of discharge the intervention group (IG) receives a package containing foods and drinks covering dietary requirements for the next 24 h. Further, a goodie-bag containing samples of protein-rich milk-based drinks is provided. At day 4 after discharge, the IG receives dietetic counselling including a recommendation of daily exercise, and an individual nutrition plan. Information regarding recommendations of nutritional therapy after discharge is systematically and electronically communicated to the municipality. The dietician performes telephone follow-ups on day 30 and a home visit at 12 weeks
214646998|NCT06716905|DRUG|ACT500 tablets|Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1
214646999|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
214647000|NCT06716905|DRUG|ACT500 tablets|Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.
214647001|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
214647002|NCT05084482|OTHER|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
214647003|NCT06916988|BEHAVIORAL|Sports Stars Brazil|Modified sports interventions promote physical activity participation in individuals with ASD by addressing intrinsic factors, however they do not address contextual barriers, such as environmental and interpersonal factors, which also influence participation. Factors like bullying, parents' perceptions often prioritizing therapy intervention, and challenges faced in community programs (as the lack of adaptations in existing programs to meet their needs) are some of these obstacles, which reduce adherence to physical activities (Jachyra et al., 2021). Therefore, it may be necessary to combine interventions targeting intrinsic factors, such as Sports Stars, with those that address the extrinsic contextual factors impacting the participation of adolescents with ASD in their community.
214647004|NCT06916988|BEHAVIORAL|context-centered therapy|"The complimentary approach of combining intrinsic (Sports Stars) and extrinsic (PREP) interventions aligns with the relationships between the person, their environment, and the quantity and quality of their participation proposed in the family of participation related constructs (Imms et al., 2017). By recognizing that participation depends on both the individual's abilities and the contexts and conditions in which it occurs, professionals can adopt a more holistic and tailored approach to individual needs (Imms et al., 2015)."
214647005|NCT06917170|BEHAVIORAL|Structured Music Therapy Program|"Description:~Content: Participants engage in passive music therapy sessions where they listen to pre-selected music with smooth rhythms and harmonies (e.g., classical, ambient, or instrumental tracks). The music is chosen to align with evidence-based criteria for promoting relaxation and emotional regulation.~Frequency: Daily (1 session/day).~Duration: 1 hour per session, for a total of 14 sessions over 2 weeks.~Setting: Conducted in a quiet, controlled environment to minimize external distractions.~Goal: To reduce symptoms of psychological distress (depression, anxiety, stress) and enhance self-efficacy through auditory stimulation and emotional engagement."
214794703|NCT05477329|DEVICE|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
214794704|NCT02363751|DRUG|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
214794705|NCT04938778|OTHER|PNF|PNF Participants will engage in 8 weeks of 14 hours per night fasting
214794706|NCT05950724|DRUG|Etanercept Injection [Enbrel]|25 mg subcutaneous injection
214794707|NCT03664856|OTHER|interview|The patient will be asked to answer the questions that the interviewer will ask him.
214794708|NCT03849781|DEVICE|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
214794709|NCT03171714|DEVICE|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
214794710|NCT03171714|DEVICE|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
214794711|NCT03520283|OTHER|Interview|Ancillary studies
214794712|NCT03520283|OTHER|Questionnaire Administration|Ancillary studies
214794713|NCT03520283|BEHAVIORAL|System Support Mapping|Complete MAP
214794714|NCT04056143|DIAGNOSTIC_TEST|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
214794715|NCT06496919|DRUG|Recombinant Mutant Human Tumor Necrosis Factor|The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
214794716|NCT05476874|PROCEDURE|Open Mini-Laparotomy|A 5-cm paraumbilical skin is made, and the abdominal wall is incised in layers. The distal catheter tip is inserted into the peritoneal cavity in a craniocaudal direction, and the abdominal wound is sutured in layers.
214794717|NCT05476874|PROCEDURE|Abdominal Puncture|An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
214794718|NCT05682495|DRUG|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
214794719|NCT05682495|DRUG|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
214794720|NCT05682495|DRUG|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
214794721|NCT05682495|DRUG|ARM D|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
214794722|NCT05682495|DRUG|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
214794723|NCT05682495|DRUG|ARM F|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
214794724|NCT00977002|OTHER|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
214794725|NCT00977002|OTHER|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
214794726|NCT03339037|DEVICE|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
214794727|NCT03339037|DEVICE|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
214794728|NCT05241821|PROCEDURE|Mechanical thrombectomy|Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
214794729|NCT05241821|DRUG|Thrombolytic Agent|Drug aimed to dissolve thrombus affecting the cerebral circulation
214794730|NCT01577511|BIOLOGICAL|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
214794731|NCT02114307|DEVICE|REVITIVE IX|neuromuscular electrical stimulation device
214794732|NCT00332761|DRUG|Caduet|
214794733|NCT02264951|DIETARY_SUPPLEMENT|Tributyrin|a triglyceride containing three C4-acids
214794734|NCT02264951|DIETARY_SUPPLEMENT|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
214794735|NCT02264951|DIETARY_SUPPLEMENT|Olive oil|a triglyceride containing mostly three oleic acids
214794736|NCT02264951|DIETARY_SUPPLEMENT|Carrot|mainly water and glucose
214794737|NCT00902083|DRUG|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
214794738|NCT00902083|PROCEDURE|surgery|remove tumor surgery
214794739|NCT00902083|DRUG|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
214794740|NCT00902083|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
214794741|NCT06369337|DIAGNOSTIC_TEST|Ultrasound|The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
214794742|NCT05994781|DEVICE|EasyDew MD regen cram|No intervention
214794743|NCT00211783|PROCEDURE|fMRI|there is no intervention
214794744|NCT02669680|DRUG|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
214794745|NCT02669680|OTHER|Standard therapy|
214794746|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
214794747|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
214794748|NCT03262181|OTHER|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
214794749|NCT03262181|OTHER|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
214794750|NCT04643678|DRUG|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
214794751|NCT04643678|OTHER|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
214794752|NCT06464328|BEHAVIORAL|Tai Chi Combined with Music Therapy Intervention|Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for twelve weeks
214794753|NCT06464328|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for twelve weeks
214794754|NCT06464328|BEHAVIORAL|Tai Chi intervention only|Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice; twice a week for twelve weeks
214794755|NCT02010047|DEVICE|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
214794756|NCT01026961|DRUG|Phenylephrine HCL|Phenylephrine HCL 10mg
214794757|NCT01026961|DRUG|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
214794758|NCT06378983|DRUG|Oral isotretinoin|Oral isotretinoin
214794759|NCT06378983|OTHER|Oral isotretinoin combined with microneedle radiofrequency therapy|Oral isotretinoin combined with microneedle radiofrequency therapy
214794760|NCT01625156|OTHER|Laboratory Biomarker Analysis|Correlative studies
214794761|NCT01625156|OTHER|Pharmacological Study|Correlative studies
214794762|NCT01625156|DRUG|Temsirolimus|Given IV
214794763|NCT01625156|DRUG|Tivantinib|Given PO
214794764|NCT02178709|DRUG|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
214794765|NCT05679765|DRUG|Greater Occipital Nerve Block with dexamethasone and lidocaine|Ultrasound guided Greater occipital nerve block on the side of headache
214794766|NCT05679765|DRUG|Greater Occipital Nerve Block with 0.9% saline|Ultrasound guided Greater occipital nerve block on the side of headache
214794767|NCT03281499|OTHER|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
214794768|NCT01209052|DRUG|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
214794769|NCT01209052|OTHER|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
214794770|NCT00006470|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
214794771|NCT00006470|BIOLOGICAL|monoclonal antibody 3H1 anti-idiotype vaccine|
214794772|NCT00006470|RADIATION|radiation therapy|
214794773|NCT01241461|DRUG|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
214794774|NCT01143025|DRUG|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
214794775|NCT01143025|DRUG|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
214794776|NCT01143025|DRUG|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
214794777|NCT02036372|DRUG|Liraglutide|
214794778|NCT02036372|DRUG|Insulin bolus|
214794779|NCT02036372|DRUG|GIK infusion|continuous infusion
214794780|NCT01650922|PROCEDURE|phlebotomy|
214794781|NCT01650922|PROCEDURE|biopsy|
214794782|NCT02156648|OTHER|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
214794783|NCT04493450|OTHER|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
214794784|NCT00169533|DRUG|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
214794785|NCT02941809|BEHAVIORAL|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
214794786|NCT05348109|OTHER|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
214794787|NCT04786652|DEVICE|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
214794788|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
214794789|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2\) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
214794790|NCT05296915|DEVICE|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
214794791|NCT05296915|DEVICE|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
214794792|NCT05296915|BEHAVIORAL|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
214794793|NCT04390854|BIOLOGICAL|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
214794794|NCT04390854|BIOLOGICAL|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
214794795|NCT03500848|DRUG|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
214794796|NCT03500848|DRUG|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
214794797|NCT03500848|DRUG|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
214794798|NCT03500848|DRUG|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
214794799|NCT01604681|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
214794800|NCT01604681|DIETARY_SUPPLEMENT|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
214794801|NCT05861648|DRUG|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
214794802|NCT05861648|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement: Placebo
214794803|NCT00202449|DRUG|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
214794804|NCT00202449|DRUG|paroxetine|20 mg taken at 10a for duration of the study
214794805|NCT00202449|DRUG|Placebo|Placebo
214794806|NCT04809181|DRUG|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
214794807|NCT00002965|BIOLOGICAL|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
214794808|NCT03825458|OTHER|Blood sampling|Blood sampling at each clinical follow-up visit.
214794809|NCT04743258|PROCEDURE|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.
214794810|NCT04743258|PROCEDURE|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
214794811|NCT05993338|DIAGNOSTIC_TEST|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
214794812|NCT05777538|OTHER|hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days.
214794813|NCT05777538|OTHER|foot exercises|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each.
214794814|NCT01379781|BEHAVIORAL|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
214794815|NCT05782790|BEHAVIORAL|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
214794816|NCT05782790|BEHAVIORAL|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
214794817|NCT01045590|DRUG|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
214794818|NCT01045590|DRUG|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
214794819|NCT02586103|DEVICE|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
214794820|NCT03041766|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
214794821|NCT03041766|DRUG|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
214794822|NCT01586858|OTHER|Observational|Observational study of subjects previously enrolled in the RAVE trial
214794823|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
214794824|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
214794825|NCT05228314|OTHER|Squalene based adjuvant|Squalene based adjuvant
214794826|NCT05228314|OTHER|CpG/alum adjuvant|CpG/alum adjuvant
214794827|NCT02689908|RADIATION|computed tomography|low dose protocol of thorax ct
214794828|NCT04983121|DRUG|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
214794829|NCT01526538|DRUG|d-cycloserine|50 mg d-cycloserine
214794830|NCT01526538|DRUG|sugar pill|placebo
214794831|NCT03296475|PROCEDURE|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
214794832|NCT05129852|OTHER|Sage oil group|Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
214794833|NCT05129852|BEHAVIORAL|Reiki group|Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
214794834|NCT01880970|OTHER|starter infant formula with pro and prebiotics|
214794835|NCT01880970|OTHER|Placebo comparator|
214794836|NCT02377336|DRUG|GS-6615|GS-6615 tablets administered orally
214794837|NCT02377336|DRUG|Placebo|Placebo to match GS-6615 tablets administered orally
214794838|NCT03604419|DRUG|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
214794839|NCT03604419|DRUG|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
214794840|NCT03604419|DRUG|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
214794841|NCT03604419|DRUG|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
214794842|NCT03237819|DRUG|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
214794843|NCT03237819|DRUG|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
214794844|NCT03329027|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
214794845|NCT03329027|DEVICE|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
214794846|NCT01802502|DRUG|Rifampicin intravenous|
214794847|NCT01802502|DRUG|Oral rifampicin|
214794848|NCT04089982|DRUG|Varenicline|Chantix
214794849|NCT04089982|DRUG|Placebo oral tablet|Placebo
214794850|NCT01775592|DRUG|Arterakin (DHA-PPQ)|
214794851|NCT02730078|BEHAVIORAL|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
214794852|NCT02730078|BEHAVIORAL|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
214794853|NCT04849988|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
214794854|NCT04849988|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
214794855|NCT03889756|DRUG|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
214794856|NCT03889756|DRUG|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
214794857|NCT03185065|DRUG|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
214794858|NCT03185065|DRUG|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
214794859|NCT03185065|DRUG|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
214794860|NCT03185065|DRUG|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
214794861|NCT04107974|DEVICE|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
214794862|NCT04107974|PROCEDURE|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
214794863|NCT01535326|PROCEDURE|air insufflation|insufflate air during the insertion of colonoscopy
214794864|NCT01535326|PROCEDURE|water immersion|infuse water during insertion, aspirate water during withdrawal
214794865|NCT01535326|PROCEDURE|water exchange|infuse and remove water during insertion phase of colonoscopy
214794866|NCT00826930|DRUG|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
214794867|NCT05048303|PROCEDURE|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
214794868|NCT04055402|OTHER|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
214794869|NCT04055402|OTHER|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
214794870|NCT05533502|DIETARY_SUPPLEMENT|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
214794871|NCT05533502|DIETARY_SUPPLEMENT|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
214794872|NCT03444116|DIAGNOSTIC_TEST|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
214794873|NCT03444116|DIAGNOSTIC_TEST|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
214794874|NCT03444116|BEHAVIORAL|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
214794875|NCT00929500|BEHAVIORAL|MAST program|MAST program: twice a week for 4 months
214794876|NCT01052116|DRUG|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
214794877|NCT01052116|DRUG|Placebo|Placebo
214794878|NCT01104207|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
214794879|NCT01104207|DEVICE|placebo rTMS|placebo rTMS
214794880|NCT05543148|OTHER|Questionnaire|Evaluate hearing loss and communication and conversation disabilities
214794881|NCT02268422|DRUG|Buprenorphine|7 day patch
214794882|NCT00020345|DRUG|fluorouracil|
214794883|NCT00020345|DRUG|gemcitabine|
214794884|NCT03346395|BEHAVIORAL|Problem solving based intervention|Problem solving based intervention
214794885|NCT03346395|BEHAVIORAL|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
214794886|NCT04186390|OTHER|Simulation training in small bowel capsule endoscopy|Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
214794887|NCT01927536|DEVICE|White LED Flashlight|white light setting
214794888|NCT01927536|DEVICE|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
214794889|NCT01132599|DIETARY_SUPPLEMENT|C-11 choline|
214794890|NCT01132599|RADIATION|18F-fluoromethylcholine|
214794891|NCT05057156|BEHAVIORAL|cognitive rehabilitation|patients have to use an app with cognitive games
214794892|NCT01289509|DRUG|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
214794893|NCT01289509|DRUG|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
214794894|NCT03362437|DRUG|BMS-986177|Form A
214794895|NCT03362437|DRUG|BMS-986177|Form B
214794896|NCT02243020|DEVICE|Vagus Nerve Stimulation (VNS)|
214794897|NCT00836927|DRUG|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
214794898|NCT00836927|DRUG|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
214794899|NCT00631176|BEHAVIORAL|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
214794900|NCT01201746|PROCEDURE|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
214794901|NCT01201746|PROCEDURE|Periodontal therapy|Scaling, root planning and oral hygiene instructions
214794902|NCT04064229|DEVICE|ivWatch Model 400 with SmartTouch Sensor|The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
214794903|NCT04064229|DEVICE|ivWatch Model 400 with Fiber Optic Sensor|The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
214794904|NCT01992289|DRUG|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
214794905|NCT00001074|DRUG|Hydroxyurea|
214794906|NCT00001074|DRUG|Didanosine|
214794907|NCT04193631|DRUG|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
214794908|NCT05711030|PROCEDURE|Thoracic paravertebral block multiple (3) injections|already described in arm description
214794909|NCT05711030|PROCEDURE|Thoracic paravertebral block single injection|already described in arm description
214794910|NCT02518230|DEVICE|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
214794911|NCT02518230|DEVICE|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
214794912|NCT05943925|OTHER|No intervention|no intervention
214794913|NCT05943925|DIETARY_SUPPLEMENT|Probiotic supplement|A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.
214464453|NCT04600713|OTHER|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
214464454|NCT06408220|PROCEDURE|Biopsy|Undergo tissue biopsy
214794914|NCT00004776|DRUG|topiramate|
214794915|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
214794916|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
214794917|NCT00614055|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
214794918|NCT00614055|DRUG|metformin|Tablets, 1500-2000 mg/day
214794919|NCT04138849|DRUG|BBT-877 single dose|Oral capsule, single dose.
214794920|NCT04138849|DRUG|Placebo single dose|Oral capsule, single dose.
214794921|NCT00208390|DEVICE|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
214794922|NCT02708290|OTHER|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
214794923|NCT05157321|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
214794924|NCT05157321|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
214794925|NCT06015373|DRUG|supress the night dose of carvedilol|already described
214794926|NCT03972982|DRUG|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
214794927|NCT03972982|DRUG|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
214794928|NCT00332293|DRUG|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
214794929|NCT00332293|DRUG|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
214794930|NCT03749655|BEHAVIORAL|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
214794931|NCT01537484|PROCEDURE|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
214794932|NCT03164954|DIAGNOSTIC_TEST|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
214794933|NCT05688930|OTHER|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
214794934|NCT05688930|OTHER|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
214794935|NCT00132002|DRUG|vorinostat|Given PO
214794936|NCT00132002|OTHER|laboratory biomarker analysis|Correlative studies
214794937|NCT03853577|OTHER|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
214794938|NCT05393947|OTHER|patient education|It is planned to provide education to patients about the side effects of chemotherapy.
214794939|NCT02497677|BEHAVIORAL|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
214794940|NCT02497677|BEHAVIORAL|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
214794941|NCT02337179|PROCEDURE|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
214794942|NCT03182179|DRUG|Ondansetron 4 MG|Ondansetron is taken orally BD
214794943|NCT03182179|DRUG|Placebo|Placebo is taken orally BD
214794944|NCT03145532|OTHER|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
214464455|NCT06408220|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214464456|NCT06408220|PROCEDURE|Breath Test|Undergo H. pylori breath test
214464457|NCT06408220|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
214464458|NCT06408220|OTHER|Questionnaire Administration|Complete questionnaires
214464459|NCT04376502|RADIATION|Radiation Therapy|Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (Gy) in 5 fractions), and after a 1-week interval during which ICI is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).
214794945|NCT00619632|BEHAVIORAL|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
214794946|NCT00619632|BEHAVIORAL|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
214794947|NCT00619632|BEHAVIORAL|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
214794948|NCT01022788|BEHAVIORAL|Home-based counselling|
214794949|NCT03584737|DIAGNOSTIC_TEST|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
214794950|NCT03584737|DIAGNOSTIC_TEST|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
214794951|NCT03584737|DIAGNOSTIC_TEST|PCR assay|Semiquantitative real-time PCR assay
214794952|NCT05702177|DRUG|Daridorexant 25 mg|A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
214794953|NCT05702177|DRUG|Daridorexant 50 mg|A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
214794954|NCT05702177|DRUG|Placebo|A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
214794955|NCT03480711|PROCEDURE|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
214794956|NCT03480711|PROCEDURE|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
214794957|NCT05414474|OTHER|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
214794958|NCT05414474|OTHER|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
214794959|NCT05414474|OTHER|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
214794960|NCT05414474|OTHER|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
214794961|NCT05414474|OTHER|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
214794962|NCT05414474|OTHER|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
214794963|NCT01095003|DRUG|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
214794964|NCT01095003|DRUG|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
214794965|NCT03354247|BEHAVIORAL|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
214794966|NCT04147754|PROCEDURE|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
214794967|NCT04147754|PROCEDURE|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
214794968|NCT04147754|PROCEDURE|Erector spinae block|Preoperative erector spinae block at physician discretion
214794969|NCT02873390|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
214794970|NCT05492591|DRUG|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
214794971|NCT05492591|DRUG|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
214794972|NCT05492591|DRUG|Valacyclovir|Valacyclovir is a positive control drug.
214794973|NCT03141489|DIETARY_SUPPLEMENT|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
214794974|NCT04401566|OTHER|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
214794975|NCT04401566|OTHER|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
214794976|NCT04401566|OTHER|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
214794977|NCT04403048|PROCEDURE|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
215031554|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab) expansion cohort|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
214794978|NCT04403048|PROCEDURE|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
214794979|NCT05755425|DEVICE|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
215031555|NCT02245659|DEVICE|CPAP|Continuous Positive Airway Pressure
215031556|NCT02245659|OTHER|Nasal dilator strip|Nasal dilator strip to be worn nightly
215031557|NCT06637553|COMBINATION_PRODUCT|Adlay formula|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
214794980|NCT05755425|DEVICE|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
214794981|NCT04703946|OTHER|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~1. Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~2. Association or not of the AG with sex.~3. Association or not of the AG with gestational age.~4. Association or not of the AG with other minor and major malformations."
214794982|NCT04759508|DIETARY_SUPPLEMENT|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
214794983|NCT04759508|DIETARY_SUPPLEMENT|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
214794984|NCT04473508|DRUG|Local administration of ropivacaine|Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery
214794985|NCT04473508|DRUG|Local administration of placebo (saline solution)|injection of saline solution in addition with conventional anesthesia for spine surgery
214794986|NCT05936879|OTHER|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
214794987|NCT05936879|OTHER|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
214794988|NCT06542159|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.
214794989|NCT06542159|RADIATION|Conventional SBRT|SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
214794990|NCT06424899|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
214794991|NCT06424899|RADIATION|radical chemoradiotherapy|The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
214794992|NCT06424899|DRUG|Platinum based chemotherapy|Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
214794993|NCT03267342|BEHAVIORAL|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
214794994|NCT03267342|BEHAVIORAL|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
214794995|NCT03267342|BEHAVIORAL|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
214794996|NCT03267342|BEHAVIORAL|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
214794997|NCT00000909|DRUG|Aldesleukin|
214794998|NCT01769209|DRUG|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
214794999|NCT01769209|DRUG|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
214795000|NCT01769209|DRUG|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
214795001|NCT01769209|DRUG|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
214795002|NCT01769209|DRUG|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
214795003|NCT01769209|DRUG|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
214795004|NCT01769209|DRUG|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
214795005|NCT02266836|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
214795006|NCT00967642|DRUG|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
214795007|NCT03842943|DRUG|Pembrolizumab|Preoperative infusions
214795008|NCT03842943|DRUG|Talimogene Laherparepvec|Preoperative intralesional injection
214795009|NCT03777670|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
214795010|NCT00049036|BIOLOGICAL|rituximab|Given IV
214795011|NCT00049036|DRUG|etoposide|Given IV
214795012|NCT00049036|DRUG|doxorubicin hydrochloride|Given IV
214795013|NCT00049036|DRUG|vincristine sulfate|Given IV
214795014|NCT00049036|DRUG|prednisone|Given orally
214795015|NCT00049036|DRUG|cyclophosphamide|Given IV
214795016|NCT00049036|OTHER|laboratory biomarker analysis|Correlative studies
214795017|NCT03029533|DRUG|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
214795018|NCT03029533|DRUG|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
214795019|NCT05602922|COMBINATION_PRODUCT|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
214795020|NCT05602922|OTHER|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
214795021|NCT02302573|DRUG|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
214795022|NCT05303922|DIAGNOSTIC_TEST|Dual-energy CT|Dual-energy CT
214795023|NCT05303922|DIAGNOSTIC_TEST|MRI|MRI
214795024|NCT05287139|OTHER|Quality of Life|Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
214795025|NCT01645800|DRUG|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
214795026|NCT01645800|DRUG|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
214795027|NCT03036579|DEVICE|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
214795028|NCT00993057|DRUG|Insulin|Adjustable insulin infusion scale with loading doses
214795029|NCT06124430|OTHER|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
214795030|NCT01758302|BEHAVIORAL|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
214795031|NCT01758302|BEHAVIORAL|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
214795032|NCT01758302|OTHER|Cookies|Participants are asked to taste test chocolate chip cookies
214795033|NCT01758302|OTHER|Vegetables|Participants are asked to taste test raw celery or radishes
214795034|NCT01758302|BEHAVIORAL|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
214795035|NCT03604120|DEVICE|Preoxygenation with high flow therapy by nasal cannula|Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
214795036|NCT03604120|DEVICE|Preoxygenation by standard Facial mask|"* For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation."
214795037|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fasted state.
215031558|NCT06637553|COMBINATION_PRODUCT|Placebo|Same weight as the adlay formula but did not include the active compound
214795038|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fed state.
214795039|NCT06302231|BEHAVIORAL|Dietary Approach|Intermittent fasting plus energy restriction without aerobic exercise training.
214795040|NCT06544317|BEHAVIORAL|physical training|All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
214795041|NCT02848599|DRUG|morphine|
214795042|NCT02848599|DRUG|levobupivacaine|
214795043|NCT02352337|DRUG|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
214795044|NCT02352337|DRUG|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
214795045|NCT02352337|DRUG|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
214795046|NCT02352337|DRUG|Gemcitabine|Gemcitabine perfusion
214795047|NCT05873894|DEVICE|EEG|EEG recordings and analysis. Sensory evoked potentials analysis Motor evoked potentials studies
214795048|NCT02375126|PROCEDURE|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
214795049|NCT05372081|OTHER|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
214795050|NCT04700995|PROCEDURE|NiTi instruments|Root canal filling removal
214795051|NCT05089123|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
214795052|NCT05089123|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
214795053|NCT02337933|DRUG|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
214795054|NCT02337933|DRUG|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
214795055|NCT01790165|DRUG|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
214795056|NCT00274703|DRUG|mepolizumab|
214795057|NCT04572100|OTHER|Transoral Robotic Surgery (TORS) or Radiotherapy|Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
214795058|NCT04572100|OTHER|Chemotherapy and Low-Dose Radiotherapy|Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
214795059|NCT04572100|OTHER|Chemotherapy and High-Dose Radiotherapy|Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
214795060|NCT04572100|DRUG|Paclitaxel|This drug will be combined with carboplatin during induction therapy for 9 weeks.
214795061|NCT04572100|DRUG|Carboplatin|This drug will be combined with paclitaxel during induction therapy for 9 weeks.
214795062|NCT00992407|DRUG|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
214795063|NCT00992407|DRUG|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
214795064|NCT05361278|OTHER|Chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
215031029|NCT04503369|BEHAVIORAL|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
214464460|NCT06527339|OTHER|Dry Needling with Vibration|In the PS+V technique, no movements will be performed with the needle once it is correctly inserted. Instead, only vibratory stimulus will be applied for 10 minutes. Since this is a completely novel technique, the optimal duration of application is not yet known; however, it is considered that 10 minutes may be sufficient to demonstrate an effect.
214795065|NCT05361278|OTHER|Activated chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
214795066|NCT05361278|OTHER|Chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the gel after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
214795067|NCT05361278|OTHER|Activated chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
214795068|NCT05361278|OTHER|Sodium hypochlorite solution|"* Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
214795069|NCT04204577|DRUG|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
214795070|NCT05415566|COMBINATION_PRODUCT|toy nebulizer and toy mask|The treatment was administered using therapeutic play.
214795071|NCT02462824|BEHAVIORAL|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
214795072|NCT00513968|GENETIC|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
214795073|NCT00513968|DRUG|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
214795074|NCT04653220|OTHER|Control 1|25g glucose dissolve in 250ml of water
214795075|NCT04653220|OTHER|Control 2|25g glucose dissolve in 250ml of water
214795076|NCT04653220|OTHER|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
214795077|NCT04653220|OTHER|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
214795078|NCT04653220|OTHER|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
214795079|NCT04653220|OTHER|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
214795080|NCT04653220|OTHER|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
214795081|NCT04653220|OTHER|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
214795082|NCT05272358|OTHER|NETSARC network|MDTB and/or surgery in NETSARC network
214795083|NCT02072759|DIETARY_SUPPLEMENT|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)"
214795084|NCT02072759|DIETARY_SUPPLEMENT|Placebo|
214795085|NCT00035087|DRUG|epothilone b|
214795086|NCT00006075|DRUG|Chlorhexidine gluconate|
214795087|NCT04868448|BIOLOGICAL|Covid-19 vaccines|Observation of individuals who received one or more doses of covid-19 vaccines.
214795088|NCT04835948|DRUG|single dose of Anti-thymocyte globulin|Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
214795089|NCT00200122|DEVICE|Spinal Cord Stimulation|
214795090|NCT03656796|OTHER|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
214795091|NCT03656796|OTHER|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
214795092|NCT05583812|DRUG|FB2001 for inhalation|FB2001 once or twice daily inhalation
214795093|NCT05583812|DRUG|FB2001 for inhalation placebo|FB2001 placebo once or twice daily inhalation
214795094|NCT02586766|BEHAVIORAL|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
214795095|NCT05969470|DEVICE|Internal fixation with short intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
215031030|NCT00690339|DEVICE|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
215031031|NCT04992273|DRUG|casirivimab+imdevimab|Single dose administered based on weight
214795096|NCT05969470|DEVICE|Internal fixation with long intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
214795097|NCT06373575|PROCEDURE|Lung and inferior vena cava ultrasound guidance|The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.
214795098|NCT06373575|PROCEDURE|Conventional protocol guidance|Fluid removal using conventional protocol including blood pressure and physical examination
214795099|NCT03615937|BEHAVIORAL|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
214795100|NCT03615937|BEHAVIORAL|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
214795101|NCT03615937|BEHAVIORAL|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
214795102|NCT03615937|OTHER|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
214795103|NCT03615937|OTHER|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
214795104|NCT02398188|DRUG|LIPO-202|
214795105|NCT02398188|DRUG|Placebo|
214795106|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214795107|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214795108|NCT00782509|DRUG|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
214795109|NCT05012345|PROCEDURE|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
214795110|NCT05857839|OTHER|Myofascial release|Patients will get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks
214795111|NCT05857839|OTHER|pelvic Support belt|The support belt will be worn for less than two to three hours at a time and it will be used 4 times a week
214464461|NCT06527339|OTHER|Conventional Dry Needling|"In the conventional PS technique, the needle will be inserted into the MTrP using the fast-in and fast-out technique described by Hong (1994) at an approximate frequency of 1 insertion per second (1 Hz) without completely withdrawing the needle from the skin. This technique will be maintained for 30 seconds in an attempt to elicit a local twitch response. After the procedure, the treated area will be firmly compressed with a cotton pad for three seconds."
214795112|NCT04278469|DRUG|Chemotherapy Drugs, Cancer|Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
214795113|NCT01827007|OTHER|Volume expansion with gelofusine|
214839804|NCT01102452|DIETARY_SUPPLEMENT|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
214839805|NCT03090490|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
214839806|NCT03090490|OTHER|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
214795114|NCT01153048|OTHER|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
214795115|NCT01902680|RADIATION|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
214795116|NCT04875065|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
214795117|NCT03286582|DRUG|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
214795118|NCT03286582|DRUG|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
214795119|NCT02918162|DRUG|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
214795120|NCT02918162|DRUG|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
214795121|NCT00395226|DRUG|zinc sulfate|zinc sulfate 220 mg bis for 90 days
214795122|NCT00395226|DRUG|placebo|placebo bid for 90 days
214795123|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
214795124|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
214795125|NCT04842058|OTHER|Mobilisation procedure|A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.
214795126|NCT00295958|BIOLOGICAL|LMB-2 immunotoxin|
214795127|NCT00295958|BIOLOGICAL|MART-1 antigen|
214795128|NCT00295958|BIOLOGICAL|gp100 antigen|
214795129|NCT00295958|BIOLOGICAL|incomplete Freund's adjuvant|
214795130|NCT04172363|DRUG|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
214795131|NCT03190746|DIAGNOSTIC_TEST|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
214795132|NCT01396681|DRUG|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4\~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
214795133|NCT00263809|DEVICE|Pathogen Reduction Technology|
214795134|NCT03665909|OTHER|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
214795135|NCT02873988|OTHER|bronchial epithelial cell culture|
214795136|NCT06496737|BEHAVIORAL|Moderate-Intensity Interval Training (MIIT)|Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches, three times a week for 12 weeks
214795137|NCT06496737|BEHAVIORAL|High-Intensity Interval Training (HIIT)|High-Intensity Interval Training (HIIT) is developed by university badminton coaches, three times a week for 12 weeks
215031032|NCT02427490|BEHAVIORAL|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
214795138|NCT04800653|PROCEDURE|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
214795139|NCT00001776|DEVICE|Cadwell Rapid Rate Magnetic Stimulator|
214795140|NCT05733247|OTHER|Copenhagen adductor exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
214795141|NCT05733247|OTHER|The adduction and abduction partner exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
214795142|NCT02142244|PROCEDURE|Near infra red sentinel node biopsy|Explicated in the protocol arm
214795143|NCT02142244|DRUG|Indocyanine green|Explicated in the protocol arm
214795144|NCT02142244|DEVICE|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
214795145|NCT02642666|BEHAVIORAL|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
214795146|NCT00628823|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten containing foods removed from diet
214795147|NCT04502069|DRUG|Opaganib|500 mg Q12 hours orally
214795148|NCT04735016|DEVICE|DiamondTemp™ Ablation System|A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
214795149|NCT06367569|DIAGNOSTIC_TEST|Screening for trilateral retinoblastoma with MRI|The diagnostic accuracy of the screening program, baseline screening with MRI followed by follow-up of suspicious pineal glands in heritable retinoblastoma patients.
214795150|NCT05229757|OTHER|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
214795151|NCT05229757|OTHER|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
214795152|NCT02475083|OTHER|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
214795153|NCT02475083|OTHER|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
214795154|NCT03799666|OTHER|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
214795155|NCT03799666|OTHER|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
214795156|NCT01798459|DRUG|Methylphenidate|
214795157|NCT05142436|OTHER|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
214795158|NCT05142436|OTHER|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
214795159|NCT05142436|OTHER|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
214795160|NCT05142436|OTHER|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
214795161|NCT05142436|OTHER|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
214795162|NCT03376594|DRUG|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
214795163|NCT03376594|DRUG|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
214795164|NCT02551289|OTHER|Gluten free diet|Patients will follow a gluten free diet
214795165|NCT01531465|OTHER|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
215031033|NCT02427490|OTHER|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
214795166|NCT01531465|OTHER|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
214795167|NCT06125613|BEHAVIORAL|Experimental|"In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total."
214839807|NCT04395599|OTHER|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
214839808|NCT03399006|DEVICE|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
215031034|NCT02000102|DRUG|Intravitreal Injection of Aflibercept|
214795168|NCT04152928|DIAGNOSTIC_TEST|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
214795169|NCT02243956|OTHER|Flavanol rich food product|polyphenol rich test product
214795170|NCT02374918|DEVICE|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
214795171|NCT02374918|DEVICE|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
214795172|NCT02374918|DEVICE|HC wavelength-1 bright light|30 minutes of light exposure
214795173|NCT02374918|DEVICE|HC wavelength-2 bright light|30 minutes of light exposure
214795174|NCT00760383|DIETARY_SUPPLEMENT|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
214795175|NCT00760383|DIETARY_SUPPLEMENT|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
214795176|NCT00219258|DRUG|Zoledronic acid|
214795177|NCT00282256|DRUG|tacrolimus modified release (MR)|Oral
214795178|NCT00282256|DRUG|tacrolimus|Oral
214795179|NCT05100758|DIETARY_SUPPLEMENT|Active Hexoses Correlated Compound|Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
214795180|NCT05530356|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214795181|NCT05530356|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
214795182|NCT05530356|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
214795183|NCT05530356|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
214795184|NCT05530356|RADIATION|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
214795185|NCT05092490|PROCEDURE|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
214795186|NCT05092490|PROCEDURE|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
214795187|NCT02879019|OTHER|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
214795188|NCT02879019|OTHER|Walking training group|Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
214795189|NCT04484337|DRUG|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
214795190|NCT04484337|DRUG|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
214795191|NCT04484337|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
214795192|NCT04484337|DRUG|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
214464462|NCT00912041|DEVICE|Placement of the BrainGate2 sensor(s) into the motor-related cortex|Up to six 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one, two, or three percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
214795193|NCT04484337|DRUG|Topical steroid|Steroid will be available for topical application
214795194|NCT04484337|DRUG|Placebo creams/gels|Placebo creams/gels will be available for topical application
214795195|NCT04484337|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
214795196|NCT00868309|BIOLOGICAL|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
214795197|NCT00868309|BIOLOGICAL|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
214795198|NCT03309449|DEVICE|Syringe and needle|Intramuscular administration of simulated naloxone
214795199|NCT03309449|DEVICE|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
214795200|NCT03309449|DEVICE|Nasal spray|Nasal spray administration of simulated naloxone
214795201|NCT01616732|DRUG|Testosterone|TU im
214795202|NCT01616732|DRUG|placebo|placebo im
214795203|NCT05132309|COMBINATION_PRODUCT|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
214795204|NCT04621409|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
214795205|NCT04621409|BIOLOGICAL|Placebo|IV infusion of saline, approximately 5 hours
214795206|NCT03567109|OTHER|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
214795207|NCT05743920|BEHAVIORAL|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
214795208|NCT01569451|DRUG|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
214795209|NCT01569451|DRUG|Glatiramer Acetate|20 mg injected subcutaneously daily
214795210|NCT01569451|OTHER|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
214795211|NCT01621464|DEVICE|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
214795212|NCT01513148|DEVICE|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
214795213|NCT02833038|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
214795214|NCT02833038|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
214795215|NCT04303338|PROCEDURE|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
214795216|NCT00802802|DRUG|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
214795217|NCT00802802|DRUG|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
214795218|NCT00638599|DEVICE|LMA®|LMA® is placed after anesthesia induction and removed after the operation
214795219|NCT00638599|DEVICE|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
214795220|NCT04419337|DRUG|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
214795221|NCT01450709|DIETARY_SUPPLEMENT|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
214795222|NCT00208988|PROCEDURE|Educational handout about prostate cancer screening|
214795223|NCT00208988|PROCEDURE|Simple cue for patient to talk to doctor|
214795224|NCT03252470|PROCEDURE|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
214795225|NCT02175797|DEVICE|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
214795226|NCT04652453|OTHER|Geriatrics Bundle|Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
214795227|NCT01042483|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
214839809|NCT03399006|DEVICE|Doppler Ultrasound|"measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
214795228|NCT06303999|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214795229|NCT06303999|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214795230|NCT03532685|PROCEDURE|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
214795231|NCT03061409|DIETARY_SUPPLEMENT|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
214464463|NCT06689722|OTHER|chiropractic|Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.
214795232|NCT03061409|DIETARY_SUPPLEMENT|Placebo|served as placebo
214795233|NCT05300984|OTHER|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
214795234|NCT05300984|OTHER|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
214464464|NCT06689722|OTHER|sham|The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.
214464465|NCT06689722|OTHER|ergonomics|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
214795235|NCT05300984|OTHER|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
214795236|NCT05485675|BEHAVIORAL|Stand & Move at Work|Web-based platform only.
214464466|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
214795237|NCT05485675|BEHAVIORAL|Stand & Move at Work+|Web-based platform and support from an expert facilitator
214795238|NCT00343980|DRUG|rosiglitazone|Tablets, 4 mg once or twice a day.
214795239|NCT00343980|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
214795240|NCT00343980|DRUG|glimepiride|Tablets, 4 mg/day.
214795241|NCT00854009|DRUG|BLI-489|
214795242|NCT00854009|DRUG|Placebo|
214795243|NCT04740021|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
214795244|NCT04740021|DRUG|Carboplatin|AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
214795245|NCT04740021|DRUG|Etoposide|100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
214795246|NCT06138379|OTHER|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
214795247|NCT06138379|OTHER|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
214795248|NCT02167464|DRUG|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
214795249|NCT02167464|OTHER|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
214795250|NCT02167464|DRUG|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
214795251|NCT04769466|OTHER|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
214795252|NCT02903056|OTHER|Rett Syndrome|Diagnosis of Rett Syndrome
214795253|NCT05062850|OTHER|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
214795254|NCT03284775|DEVICE|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
214795255|NCT00967538|DRUG|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
214795256|NCT02901899|DRUG|Guadecitabine|Given SC
214795257|NCT02901899|OTHER|Laboratory Biomarker Analysis|Correlative studies
214795258|NCT02901899|BIOLOGICAL|Pembrolizumab|Given IV
214795259|NCT00341354|BEHAVIORAL|Prolonged Mechanical Ventilation|
214795260|NCT02314377|DRUG|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
214795261|NCT00482547|DEVICE|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
214795262|NCT00482547|DEVICE|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
214795263|NCT04997343|OTHER|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
214795264|NCT04997343|OTHER|clinical assessment|"Clinical evaluation, performed at each time point, will include:~* The assessment of clinical disability using EDSS score~* The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk \[T25FW\]), upper limbs (nine-hole peg test \[9HPT\]) and cognitive (three-second paced auditory serial addition test \[PASAT3\]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
214795265|NCT01576978|BEHAVIORAL|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
214795266|NCT03196947|DRUG|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
214795267|NCT03239132|BEHAVIORAL|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
214795268|NCT03239132|BEHAVIORAL|Meditation educational materials|Meditation educational materials
214795269|NCT04449159|DIETARY_SUPPLEMENT|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
214795270|NCT04449159|DIETARY_SUPPLEMENT|Placebo|Placebo
214795271|NCT03309891|DRUG|GX-H9|subcutaneous injection (weekly or twice-monthly)
214795272|NCT03309891|DRUG|Genotropin|subcutaneous injection (daily)
214795273|NCT00092859|DRUG|MK0557|
214795274|NCT00510549|PROCEDURE|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
214795275|NCT03939169|OTHER|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
214795276|NCT02920411|OTHER|Pediatopic Treatment Cream|Applied twice a day minimum.
214795277|NCT02920411|OTHER|Pediatopic Body lotion|Applied at libitum.
214795278|NCT00936975|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
214795279|NCT03436628|DEVICE|MyT1DHero|A mobile phone application
214795280|NCT02003495|BIOLOGICAL|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
214795281|NCT02003495|BIOLOGICAL|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
214795282|NCT02003495|BIOLOGICAL|MPV-A Vaccine Group|0.5ml, intramuscular
214795283|NCT02003495|BIOLOGICAL|MCV-AC Vaccine Group|0.5ml, intramuscular
214795284|NCT02003495|BIOLOGICAL|Hib Vaccine Group|0.5ml, intramuscular
214795285|NCT02405507|DIETARY_SUPPLEMENT|wheat bread with wheat germ|
214795286|NCT02405507|DIETARY_SUPPLEMENT|wheat bread without wheat germ|
214795287|NCT03586336|DEVICE|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
214795288|NCT03586336|DEVICE|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
214795289|NCT02089490|DEVICE|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
214795290|NCT02933593|DRUG|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
214795291|NCT02933593|DRUG|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
214795292|NCT02933593|DRUG|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
214795293|NCT03002649|DRUG|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
214795294|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
214795295|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Placebo|
214795296|NCT00638859|DRUG|Telithromycin (HMR3647)|
214464467|NCT06521645|OTHER|electroacupuncture|electrical stimulation is given through needles inserted into the skin
214795297|NCT04170699|PROCEDURE|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
214795298|NCT02184273|DRUG|Magnesium metamizol|
214795299|NCT02184273|DRUG|Placebo|
214795300|NCT03919201|OTHER|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
214795301|NCT03919201|OTHER|No exercise intervention group|Control group: no exercise intervention
214795302|NCT00581620|BIOLOGICAL|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
214795303|NCT00619385|DRUG|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
214795304|NCT00317161|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
214795305|NCT02190461|PROCEDURE|Early Respiratory Rehabilitation Program|
214795306|NCT02190461|PROCEDURE|Conventional Respiratory Rehabilitation Program|
214795307|NCT02535819|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
214795308|NCT02535819|PROCEDURE|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
214795309|NCT05869942|DIAGNOSTIC_TEST|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
214795310|NCT05869942|DIAGNOSTIC_TEST|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
214795311|NCT00805298|DRUG|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
214795312|NCT00805298|DRUG|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
214795313|NCT00805298|DRUG|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
214795314|NCT00805298|DRUG|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
214795315|NCT04784195|BEHAVIORAL|Observation|Verification of morfology and functionality of neck muscles
214795316|NCT04529642|DIAGNOSTIC_TEST|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
214795317|NCT01543100|OTHER|blood and bone marrow samples|"Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
214464468|NCT06521645|OTHER|sham needle|needles are inserted shallowly into the skin
214464469|NCT01423656|DRUG|LEO 29102|
214464470|NCT01423656|DRUG|Placebo|Placebo Comparator: LEO 29102 vehicle
214464471|NCT03748953|DRUG|Ixazomib|Ixazomib Capsules
214795318|NCT03788499|OTHER|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
214795319|NCT04936997|BIOLOGICAL|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
214795320|NCT03160677|OTHER|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
214795321|NCT03160677|OTHER|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
214795322|NCT05933096|DIAGNOSTIC_TEST|Contrast-enhanced multispectral optoacoustic tomography|Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
214795323|NCT03674008|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
214795324|NCT03674008|DRUG|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
214795325|NCT01672346|PROCEDURE|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
214795326|NCT01851070|DRUG|Allogeneic Mesenchymal Precursor Cells|
214795327|NCT01851070|DRUG|Normal Saline|
214795328|NCT02523456|BEHAVIORAL|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
214795329|NCT02523456|BEHAVIORAL|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
214795330|NCT00134836|BEHAVIORAL|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
214795331|NCT03678961|BEHAVIORAL|external rotation of leg|external rotation of leg by 45 degrees
214795332|NCT03678961|BEHAVIORAL|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
214795333|NCT01127009|DRUG|bortezomib|Given IV
214795334|NCT01127009|DRUG|mitoxantrone hydrochloride|Given IV
214795335|NCT01127009|DRUG|etoposide|Given IV
214795336|NCT01127009|DRUG|cytarabine|Given IV
214795337|NCT01127009|OTHER|flow cytometry|Correlative studies
214795338|NCT00334490|DRUG|Sildenafil|12.5 mg Sildenafil once with optional second dose
214795339|NCT00334490|DRUG|Sildenafil|12.5 mg orally once with optional second dose
214795340|NCT00334490|DRUG|Placebo|Oral Placebo in 5 mls distilled water
214795341|NCT06396520|OTHER|No intervention, observational|No intervention, observational
214795342|NCT01388023|DIETARY_SUPPLEMENT|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
214795343|NCT02255513|DRUG|HLD200|
214795344|NCT02255513|DRUG|Placebo|
214795345|NCT04810923|PROCEDURE|i-PRF|intra-articular i-PRF injection after arthrocentesis
214795346|NCT04810923|PROCEDURE|Arthrocentesis|Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
214795347|NCT01232673|PROCEDURE|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
214795348|NCT03845946|BEHAVIORAL|angioedema|electronic tracking book
214795349|NCT02041702|DIAGNOSTIC_TEST|Non-Diagnostic Cardiac MRI scan|
214795350|NCT02809092|BIOLOGICAL|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
214795351|NCT01484405|PROCEDURE|posterior approach|Surgical approach for Total Hip Arthroplasty
214795352|NCT01484405|PROCEDURE|anterolateral approach|anterolateral surgical approach
214795353|NCT00203307|DRUG|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
214795354|NCT00203307|DRUG|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
214795355|NCT05462288|DEVICE|Entia Liberty|Home monitoring blood analyser
214795356|NCT02177955|DRUG|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
214795357|NCT02177955|DRUG|10 mg diazepam|10 mg midazolam 45 minutes before surgery
214795358|NCT03730103|OTHER|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
214795359|NCT04958980|BEHAVIORAL|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
214795360|NCT02975466|DEVICE|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
214795361|NCT02975466|DEVICE|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
214795362|NCT02975466|DEVICE|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
214795363|NCT00349505|PROCEDURE|hyper thermic chemo + surgery|
214795364|NCT03109366|BEHAVIORAL|Online patient-provider communication service|
214795365|NCT02034331|DRUG|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
214795366|NCT02034331|DRUG|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
214795367|NCT02034331|DRUG|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
214795368|NCT02034331|OTHER|Heat application|For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
214795369|NCT02499549|DRUG|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
214795370|NCT04088578|OTHER|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
214795371|NCT04088578|OTHER|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
214795372|NCT04088578|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
214795373|NCT04387110|DRUG|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
214795374|NCT04645290|BEHAVIORAL|"Intervention group: Educational Intervention KARER"|"Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~* Module 0: the introduction~* Module 1: called Identifying my role as a caregiver~* Module 2: called Strategies to strengthen care~* Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~\- One season of practices abilities of 4 hours."
214795375|NCT01488578|DRUG|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
214795376|NCT05668871|DRUG|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
214795377|NCT05928728|DRUG|Colchicine|Colchicine 0.5 mg once daily
214795378|NCT05928728|DRUG|Placebo|Placebo once daily
214795379|NCT00672828|BEHAVIORAL|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
214795380|NCT00672828|BEHAVIORAL|Interactive computer intervention|
214795381|NCT00134888|DRUG|Buprenorphine/naloxone|
214795382|NCT03455179|OTHER|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
215031035|NCT05393492|BEHAVIORAL|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
215031036|NCT03713450|DEVICE|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
214464472|NCT06026241|OTHER|Collecting data from the medical record|Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
214464473|NCT03388944|BEHAVIORAL|PCT group|In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
214795383|NCT03455179|OTHER|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
214795384|NCT03455179|OTHER|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
214795385|NCT02592694|DRUG|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
214795386|NCT02592694|DEVICE|thrombus aspiration|manual thrombus aspiration
214795387|NCT04740684|OTHER|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
214795388|NCT02308111|DRUG|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
214795389|NCT02308111|DRUG|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
214795390|NCT01342679|DRUG|dasatinib|100mg QD
214795391|NCT04405934|OTHER|Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures|Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
214795392|NCT01965561|DEVICE|CRoC|Use of Combat Ready Clamp (CRoC)
214795393|NCT01965561|DEVICE|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
214795394|NCT01965561|DEVICE|JETT|Use of Junctional Emergency Treatment Tool (JETT)
214795395|NCT01965561|DEVICE|SJT|Use of SAM Junctional Tourniquet (SJT)
214795396|NCT03271528|DRUG|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
214795397|NCT03271528|DRUG|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
214795398|NCT03277183|DRUG|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
214795399|NCT03277183|DRUG|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
214795400|NCT01561183|PROCEDURE|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
214795401|NCT01561183|PROCEDURE|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
214795402|NCT01561183|PROCEDURE|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
214795403|NCT01561183|PROCEDURE|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
214795404|NCT00873210|DRUG|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
214795405|NCT04184310|OTHER|Modified perineal linear stapler resection for external rectal prolapse|After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
214795406|NCT06546579|DIAGNOSTIC_TEST|Skin sampling|All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
214795407|NCT00625690|OTHER|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
214795408|NCT00625690|PROCEDURE|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
214795409|NCT00625690|PROCEDURE|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
214795410|NCT00625690|PROCEDURE|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
214795411|NCT00717756|DRUG|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
214795412|NCT04867161|DIAGNOSTIC_TEST|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
214795413|NCT03753854|DIAGNOSTIC_TEST|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
214795414|NCT03753854|BIOLOGICAL|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
214795415|NCT03753854|BIOLOGICAL|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
214795416|NCT03753854|OTHER|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
214795417|NCT03753854|OTHER|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
214795418|NCT06483958|BEHAVIORAL|palliative care protocol|"1. Symptom management~2. Respect for patient and family autonomy.~3. Respectful management of clinical information.~4. Provision of holistic care and support."
214795419|NCT00929357|DRUG|DMARDs or Biologics|
214795420|NCT04217226|DEVICE|Perfusion index derived parameters|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time."
214795421|NCT00026104|DRUG|gemcitabine hydrochloride|Given IV
214795422|NCT00026104|DRUG|paclitaxel|Given IV
214795423|NCT00026104|DRUG|tipifarnib|Given orally
214795424|NCT00026104|RADIATION|radiation therapy|Undergo radiation therapy
214795425|NCT02957279|DRUG|Antibiotics|In the sepsis group, antibiotics were used when needed.
214795426|NCT01873859|DRUG|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
214795427|NCT03013933|DRUG|Brentuximab Vedotin|Given IV
214795428|NCT03013933|DRUG|Cyclosporine|Given PO
214795429|NCT03013933|OTHER|Pharmacokinetic Study|Correlative studies
214795430|NCT03013933|DRUG|Verapamil|Given PO
214795431|NCT03013933|DRUG|Verapamil Hydrochloride|Given PO
214795432|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test|Skin Prick Testing with inhalant allergens
214795433|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
214795434|NCT05493696|DEVICE|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
214795435|NCT05493696|OTHER|Traditional physical therapy program|applied 3 times/week for 12 weeks
214795436|NCT03977584|DRUG|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
214795437|NCT03977584|DRUG|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
214795438|NCT03977584|OTHER|[^18F]GTP1|IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
214795439|NCT02634060|DEVICE|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
214795440|NCT06094374|BEHAVIORAL|observation of physical activity behavior|"An observational study will be conducted to gather data on multiple levels aiming to identify diverse digital phenotypes related to PA behavior among community-dwelling older adults.~A hybrid approach will be employed, combining both cross-sectional and longitudinal data collection methods. The overall aim is to employ data analysis to identify patterns of PA - behavior (referred to as phenotypes) and to pinpoint prognostic factors that affect PA outcomes.~This integrated strategy will be complemented by four distinct measurement approaches, ensuring a comprehensive assessment of the research objectives. These measurement approaches include:self-reporting, clinical, ecological momentary and time series assessment."
214795441|NCT02220465|BEHAVIORAL|PA+ Smoking Cessation (LMPA)|
214795442|NCT02220465|BEHAVIORAL|Standard Care Smoking Counseling (SCC)|
214795443|NCT01042366|BIOLOGICAL|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
214795444|NCT02172248|DRUG|BI 10773|
214795445|NCT02172248|DRUG|Metformin|
214795446|NCT05346549|BEHAVIORAL|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
214795447|NCT05346549|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
214795448|NCT02277457|RADIATION|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
214795449|NCT02277457|DRUG|Erlotinib|150 mg once daily
214795450|NCT02277457|DRUG|Crizotinib|250 mg twice daily
214795451|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
214795452|NCT00990613|DRUG|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
214795453|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
214795454|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
214795455|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
214795456|NCT06265935|BEHAVIORAL|Experimental Group|It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
214795457|NCT00002174|DRUG|Thalidomide|
214795458|NCT01933828|PROCEDURE|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
214795459|NCT01933828|PROCEDURE|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
214795460|NCT01933828|DEVICE|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
214795461|NCT06178679|DRUG|ST-100 (vezocolmitide)|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
214795462|NCT06178679|DRUG|Vehicle|Vehicle Ophthalmic Solution
214795463|NCT01066052|DRUG|r-hGH|Subcutaneous administration.
214795464|NCT03350022|PROCEDURE|Sham Feeding|Sham feeding will be offered to participants.
214795465|NCT02442479|BEHAVIORAL|resistance training|
214795466|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
214795467|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
214795468|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
214795469|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
214795470|NCT01475656|DRUG|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
214795471|NCT03419663|DIETARY_SUPPLEMENT|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
214795472|NCT01680679|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine (TIV)|
214795473|NCT01680679|BIOLOGICAL|Inactivated poliovirus vaccine (IPV), trivalent|
214795474|NCT01027442|DEVICE|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
214795475|NCT01027442|DEVICE|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
214795476|NCT01027442|DEVICE|Dental Implants|Dental implants placed via conventional free-hand method
214795477|NCT04883736|DRUG|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214795478|NCT04883736|DRUG|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214795479|NCT04883736|DRUG|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214795480|NCT00907309|BEHAVIORAL|iMET|Participants will receive the iMET intervention
214795481|NCT00907309|BEHAVIORAL|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
214795482|NCT02426619|DEVICE|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
214795483|NCT02426619|DEVICE|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
214795484|NCT05178355|DRUG|KVD824|Active
214795485|NCT05178355|DRUG|Placebo to KVD824|Placebo
214795486|NCT06262711|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).
214795487|NCT06262711|DIETARY_SUPPLEMENT|Placebo|Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
214795488|NCT02038478|BIOLOGICAL|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
214795489|NCT02880072|DIETARY_SUPPLEMENT|phosphate orally|4 different preparations of phosphate
214795490|NCT05837364|OTHER|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
214795491|NCT02437799|OTHER|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
214795492|NCT00630565|BIOLOGICAL|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
214795493|NCT00630565|DRUG|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
214795494|NCT00630565|DRUG|cyclophosphamide|4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
214795495|NCT00630565|DRUG|dexamethasone|20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
214795496|NCT00630565|DRUG|etoposide|300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
214795497|NCT00630565|PROCEDURE|bone marrow transplantation|Day 0 infusion of bone marrow cells
214795498|NCT00630565|PROCEDURE|hematopoietic stem cell transplantation|Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)
214795499|NCT00630565|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
214795500|NCT00630565|RADIATION|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
215031037|NCT03713450|DEVICE|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
214795501|NCT01532245|OTHER|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
214795502|NCT01532245|OTHER|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
214795503|NCT01532245|OTHER|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
214795504|NCT01835145|DRUG|Cabozantinib S-malate|Given PO
214795505|NCT01835145|DRUG|Dacarbazine|Given IV
214795506|NCT01835145|OTHER|Laboratory Biomarker Analysis|Correlative studies
214795507|NCT01835145|DRUG|Temozolomide|Given PO
214795508|NCT02729896|DRUG|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
214795509|NCT02729896|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
214795510|NCT02729896|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
214795511|NCT02729896|DRUG|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
215031038|NCT00688740|DRUG|Docetaxel|intravenous
215031039|NCT00688740|DRUG|5-fluorouracil|intravenous
215031040|NCT00688740|DRUG|Doxorubicin|intravenous
214795512|NCT03497533|BIOLOGICAL|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
214795513|NCT02335970|OTHER|Training group|"After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
214795514|NCT01261520|BEHAVIORAL|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
214795515|NCT01101009|DRUG|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
214795516|NCT01101009|DRUG|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
214795517|NCT03846921|DIAGNOSTIC_TEST|Laboratory blood test|Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
214795518|NCT03724110|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
214795519|NCT05692921|OTHER|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
214795520|NCT05692921|OTHER|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
214795521|NCT02177097|BIOLOGICAL|Blood samples|4 x 10 ml blood samples.
214795522|NCT02431403|DRUG|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
214795523|NCT03120702|DEVICE|Investigational Rainbow SpHb sensor|Investigational Rainbow SpHb sensor
214795524|NCT04987177|OTHER|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
214795525|NCT02066584|OTHER|Sibling oocyte incubation|
214795526|NCT06234852|BEHAVIORAL|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
214795527|NCT06234852|BEHAVIORAL|Glucocorticoid maintenance group|Daily 5-mg prednisolone over 24 weeks
214795528|NCT02212405|DEVICE|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
214795529|NCT02212405|OTHER|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
214795530|NCT01816698|DRUG|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
214795531|NCT01816698|DRUG|Placebo|Placebo: 1 package once a day after meals, 12 weeks
214795532|NCT02494245|OTHER|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
214795533|NCT04753736|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
214795534|NCT00798551|BEHAVIORAL|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
214795535|NCT03279679|PROCEDURE|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
214795536|NCT03279679|PROCEDURE|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
214795537|NCT03279679|DEVICE|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
214795538|NCT03279679|DRUG|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
214795539|NCT00028353|DRUG|GTX-006 (Acapodene)|
214795540|NCT00367588|BEHAVIORAL|Low bacterial diet|
214795541|NCT00748007|DRUG|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
214795542|NCT05071547|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
215031041|NCT00688740|DRUG|Cyclophosphamide|intravenous
214795543|NCT05071547|OTHER|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
214795544|NCT03405285|DEVICE|Connected Catheter|The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
214795545|NCT05164809|DEVICE|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
214795546|NCT00698425|OTHER|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
214795547|NCT00698425|DRUG|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
214795548|NCT02286518|DRUG|TAK-114 10 mg capsule|
214795549|NCT02286518|DRUG|TAK-114 matched placebo|
214795550|NCT03650933|BIOLOGICAL|G-CHOP|6 cycles(each cycle is 3 weeks)
214795551|NCT03650933|BIOLOGICAL|R-CHOP|6 cycles(each cycle is 3 weeks)
214795552|NCT05770258|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
214795553|NCT01983020|DRUG|Lidocaine|
214795554|NCT01983020|DRUG|Ketamine|
214795555|NCT01983020|OTHER|Saline|
214795556|NCT06121869|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
214795557|NCT06121869|DIETARY_SUPPLEMENT|Leucine|Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
214795558|NCT06121869|DIETARY_SUPPLEMENT|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
214795559|NCT00588393|DRUG|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
214795560|NCT01309919|DEVICE|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
214795561|NCT01309919|OTHER|Diary|Subjects will keep a bleeding diary for three months
214795562|NCT01018888|DEVICE|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
214795563|NCT04875234|DEVICE|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
214795564|NCT06347497|DRUG|Zonisamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214795565|NCT06347497|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214795566|NCT00319449|DRUG|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
214795567|NCT00319449|DRUG|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
214795568|NCT00319449|DRUG|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
214795569|NCT02102490|DRUG|Abemaciclib|Administered orally
214795570|NCT00618969|OTHER|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
214795571|NCT00897442|OTHER|Laboratory Biomarker Analysis|Correlative studies
214795572|NCT02289924|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
214795573|NCT00062309|RADIATION|radiation therapy|
214795574|NCT01346410|RADIATION|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
214795575|NCT06528262|DRUG|Enavogliflozin|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
214795576|NCT06528262|DRUG|Placebo|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
214795577|NCT00979628|DRUG|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
214795578|NCT00979628|DRUG|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
214795579|NCT00979628|DRUG|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
214795580|NCT01962883|OTHER|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
214795581|NCT04288596|OTHER|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
214795582|NCT06175702|DRUG|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
214795583|NCT06175702|DRUG|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
214795584|NCT06175702|DRUG|Imatinib|600 mg per day from 1 to up to 5 years
214795585|NCT06175702|DRUG|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
214795586|NCT06175702|DRUG|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
214795587|NCT06175702|DRUG|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
214795588|NCT06175702|DRUG|Ponatinib|15 mg per day from consolidation start up to 5 years
214795589|NCT06175702|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
214795590|NCT06175702|PROCEDURE|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
214795591|NCT06175702|DRUG|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
214795592|NCT06175702|DRUG|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
214795593|NCT01629875|DRUG|Generic equivalent of Clostridium Botulinum A Toxin|
214795594|NCT01629875|DRUG|Botox (Clostridium Botulinum A Toxin)|
214795595|NCT03482713|DRUG|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
214795596|NCT03482713|DRUG|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
214795597|NCT01823003|RADIATION|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall \> 1 cm, tumour size \< 2 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
214795598|NCT01823003|RADIATION|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall \> 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
214795599|NCT01823003|RADIATION|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
214795600|NCT01823003|RADIATION|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
214795601|NCT04546607|OTHER|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
214795602|NCT00966225|DIETARY_SUPPLEMENT|LIP-01|comparison of different dosages of natural health product
214795603|NCT02492490|OTHER|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
214795604|NCT02492490|DRUG|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
214795605|NCT01824758|DRUG|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
214795606|NCT01824758|DRUG|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
214795607|NCT01824758|DRUG|rocuronium|0.05 mg/kg rocuronium
214795608|NCT01824758|DRUG|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
214795609|NCT00704795|OTHER|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
214795610|NCT00704795|OTHER|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
214795611|NCT00386464|DEVICE|noninvasive positive pressure ventilation|
214795612|NCT05701371|OTHER|Biological samples collection|blood drawing + feces collection in a dedicated device
214795613|NCT02146430|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
214795614|NCT02146430|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
214795615|NCT02146430|DRUG|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
214795616|NCT02146430|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
214795617|NCT05284890|DRUG|CC-99677|Specified dose on specified days
214795618|NCT01894711|DRUG|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
214795619|NCT01893905|DRUG|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
214795620|NCT01893905|DRUG|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
214795621|NCT01768858|DRUG|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
214795622|NCT03312530|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
214795623|NCT03312530|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
214795624|NCT03312530|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
214795625|NCT03985670|DRUG|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
214795626|NCT03985670|DRUG|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
214795627|NCT00909493|OTHER|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
214795628|NCT04505033|DRUG|HB0017|HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
214795629|NCT04505033|DRUG|placebo|A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
215031042|NCT05688085|DRUG|Irbesartan High/Amlodipine FDC|Irbesartan High/Amlodipine FDC
214795630|NCT01539915|DRUG|BCT194|Topically applied BCT194 cream (0.5%)
214795631|NCT02541526|DRUG|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
214795632|NCT02541526|DRUG|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
214795633|NCT05367388|DRUG|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
214795634|NCT05367388|DRUG|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
214795635|NCT05064462|OTHER|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
214795636|NCT03343522|BEHAVIORAL|Exercise|A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
215031043|NCT05688085|DRUG|Irbesartan High|Co-administration of Irbesartan High and Amlodipine
214795637|NCT01424839|RADIATION|craniospinal irradiation|"* Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~* Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
214795638|NCT01424839|DRUG|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
214795639|NCT01424839|RADIATION|ventricular irradiation|"* Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
214795640|NCT01424839|DRUG|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
214795641|NCT01424839|DRUG|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
214795642|NCT01424839|RADIATION|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
214795643|NCT02792413|DRUG|Denosumab|Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
214795644|NCT02792413|DRUG|NaCl (placebo)|Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
214795645|NCT04341740|PROCEDURE|Bone Marrow Aspirate|bone marrow aspiration
214795646|NCT00996554|PROCEDURE|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
214795647|NCT00996554|PROCEDURE|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
214795648|NCT03923179|DRUG|Pyrotinib|Pyrotinib, 400mg qd
214795649|NCT03923179|DRUG|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
214795650|NCT02643901|BIOLOGICAL|GW003|single SC injection
214795651|NCT01548781|BEHAVIORAL|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
214795652|NCT06539364|DIAGNOSTIC_TEST|Quality of life surveys were conducted|Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
214795653|NCT02072356|RADIATION|yttrium Y 90 glass microspheres|Given Interartrial
214795654|NCT02072356|OTHER|laboratory biomarker analysis|Alpha-fetoprotein assay
214795655|NCT02072356|DRUG|TheraSphere|TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
214795656|NCT01001897|DRUG|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
214795657|NCT01001897|DRUG|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
214795658|NCT03417128|BEHAVIORAL|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
214795659|NCT02132299|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
214795660|NCT02132299|BIOLOGICAL|Normal Saline (Placebo)|
215031044|NCT05688085|DRUG|Amlodipine|Co-administration of Irbesartan High and Amlodipine
215031045|NCT05994287|DRUG|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
214795661|NCT02132299|BIOLOGICAL|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
214795662|NCT01797471|RADIATION|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
214795663|NCT02303561|BEHAVIORAL|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
214795664|NCT02303561|BEHAVIORAL|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
214795665|NCT01419106|DEVICE|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
214795666|NCT01558141|OTHER|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
214795667|NCT01558141|OTHER|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
214795668|NCT02463617|OTHER|magnetic resonance imaging|
214795669|NCT00268502|OTHER|study of socioeconomic and demographic variables|
215031046|NCT05994287|DRUG|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
215031047|NCT05994287|DRUG|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
214795670|NCT00268502|PROCEDURE|fatigue assessment and management|
214795671|NCT00268502|PROCEDURE|management of therapy complications|
214795672|NCT00268502|PROCEDURE|psychosocial assessment and care|
214795673|NCT00268502|PROCEDURE|quality-of-life assessment|
214795674|NCT01693484|DRUG|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
214795675|NCT01691859|DRUG|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
214795676|NCT04820842|DRUG|TAK-994|TAK-994 tablets.
214795677|NCT04820842|DRUG|Placebo|Placebo-matching tablets.
214795678|NCT01917409|DEVICE|conventional laryngoscopy|the device is to assist nasotracheal intubation
214795679|NCT01917409|DEVICE|video-stylet|the device is to guide the nasotracheal tube into trachea
214795680|NCT00928837|DIETARY_SUPPLEMENT|Flavocoxid 500 mg|flavonoid mixture
214795681|NCT00928837|DRUG|Naproxen|non-steroidal anti-inflammatory drug
214795682|NCT00928837|OTHER|Placebo|Placebo
214795683|NCT00928837|OTHER|flavocoxid 250 mg|Medical food product
214795684|NCT01073306|BIOLOGICAL|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
214795685|NCT01073306|OTHER|Placebo|Subcutaneous injection of placebo
214795686|NCT03968471|BEHAVIORAL|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
214795687|NCT05492071|DEVICE|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
214795688|NCT05492071|OTHER|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
214795689|NCT01493765|OTHER|Simulator training with expert scoring|Residents will be trained using surgical simulation
214795690|NCT02725944|DEVICE|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
214795691|NCT00093964|DRUG|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
214795692|NCT00093964|DRUG|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
214795693|NCT03651115|DIAGNOSTIC_TEST|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
214795694|NCT03076177|OTHER|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
214795695|NCT00423761|DRUG|midazolam|
214795696|NCT00423761|DRUG|GW876008|
214795697|NCT01167920|OTHER|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
214795698|NCT04001608|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
214795699|NCT04001608|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
214795700|NCT06195670|DRUG|Experimental|SCRT: 5\*5Gy for 5 days, after a one-week rest, with fruquintinib plus sintilimab followed; Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w; Sintilimab: intravenous infusion, 200mg, on day 1, q3w.
214795701|NCT06195670|DRUG|Active Comparator|Capecitabine: bid po, 1000mg/m², on days 1-14, q3w; Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.
214795702|NCT04253561|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.
214795703|NCT04253561|DRUG|Trastuzumab|600 mg every 3 weeks
214795704|NCT04253561|DRUG|Pertuzumab|420 mg every 3 weeks
214795705|NCT03778047|DRUG|Enzalutamide|oral
214795706|NCT03778047|DRUG|HC1119|oral
214795707|NCT04641429|BEHAVIORAL|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
214795708|NCT04641429|BEHAVIORAL|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
214795709|NCT04110028|DRUG|Nicotinamide riboside|Nicotinamide riboside in different doses
214795710|NCT04110028|DRUG|Placebo|Placebo
214795711|NCT01836848|PROCEDURE|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
214795712|NCT03106090|OTHER|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
214795713|NCT02503579|BEHAVIORAL|physical training|physical activity program, 30 minutes
214795714|NCT06322927|OTHER|Patient Interview|Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
214795715|NCT05973227|DEVICE|use of the TRIDENT system|usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
214795716|NCT01090765|DRUG|TRC105|
214795717|NCT00589095|OTHER|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
214795718|NCT02401542|DRUG|Vofatamab|
214795719|NCT02401542|DRUG|Docetaxel|
214795720|NCT02401542|DRUG|Placebo|
214795721|NCT02623959|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
214795722|NCT02623959|DRUG|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
214795723|NCT02623959|DRUG|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
214795724|NCT02623959|OTHER|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
214795725|NCT02623959|DRUG|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
214795726|NCT02623959|BEHAVIORAL|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
214795727|NCT03057899|DRUG|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
214795728|NCT03057899|DRUG|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
214795729|NCT05271474|DEVICE|ANNE ONE Platform|ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
214795730|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
214795731|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
214795732|NCT02336737|DEVICE|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
214795733|NCT02336737|DRUG|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
214795734|NCT02336737|DRUG|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
214795735|NCT04447638|PROCEDURE|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
214795736|NCT03476720|DEVICE|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
214795737|NCT05394168|BIOLOGICAL|HLX53|There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.
214795738|NCT02517801|DIETARY_SUPPLEMENT|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
214795739|NCT02517801|DIETARY_SUPPLEMENT|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
214795740|NCT03931863|DRUG|Ondansetron 4mg|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
214795741|NCT03931863|DRUG|Ondansetron 8mg|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
214795742|NCT03931863|DRUG|100ml normal saline 0.9 percent|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
214795743|NCT04302779|BEHAVIORAL|Solid Model|Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
214795744|NCT04302779|BEHAVIORAL|Liquid Model|To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
214795745|NCT02396381|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
214795746|NCT02396381|OTHER|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
214795747|NCT04826510|DRUG|Perospirone hydrochloride tablets|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
214795748|NCT04826510|DRUG|Lithium carbonate + perospirone hydrochloride|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
214795749|NCT04826510|DRUG|Lithium Carbonate Pill|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
214795750|NCT02934750|BEHAVIORAL|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~1. Breathe in through your nose (as if you are smelling something) for about 2 seconds.~2. Pucker your lips like you're getting ready to blow out candles on a birthday cake.~3. Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~4. Repeat."
214795751|NCT03197064|DRUG|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
214795752|NCT00509964|DRUG|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
214795753|NCT00509964|DRUG|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
214795754|NCT00519337|DRUG|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
214795755|NCT00519337|DRUG|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
214795756|NCT00635778|DRUG|dalotuzumab|Administered as an IV infusion over one to two hours
214795757|NCT02679677|DEVICE|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
214795758|NCT01884025|BEHAVIORAL|Get Moving and Get Well|Walking Class
214795759|NCT01884025|BEHAVIORAL|Health and Humor Class|Class about the role of humor in health
214795760|NCT05773183|DRUG|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
214795761|NCT05773183|DRUG|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
214795762|NCT05883176|DRUG|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
214795763|NCT04060368|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
214795764|NCT04060368|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
214795765|NCT03146091|OTHER|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
214795766|NCT03146091|OTHER|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
214795767|NCT00215462|DRUG|Vinorelbine|
214795768|NCT00314938|DRUG|PHA-794428|
214795769|NCT05105373|BEHAVIORAL|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~1. Poor parental bonding and child attachment;~2. Harsh parenting~3. Inequitable socialisation by gender~4. Parental conflict."
214795770|NCT00414531|DRUG|Atorvastatin|20 to 80 mg per day
214795771|NCT00361322|DRUG|clindamycin phosphate|
214795772|NCT00361322|DRUG|salicylic acid|
214795773|NCT05103722|OTHER|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
214795774|NCT02384616|OTHER|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
214795775|NCT05779449|DIETARY_SUPPLEMENT|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~1. packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~   From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~2. capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
214795776|NCT05779449|DIETARY_SUPPLEMENT|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
214795777|NCT05779449|PROCEDURE|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
214795778|NCT05779449|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
214795779|NCT02324465|DEVICE|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
214795780|NCT02324465|DEVICE|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
214795781|NCT01580878|DRUG|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
214795782|NCT01580878|DRUG|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
214795783|NCT01580878|DRUG|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
214795784|NCT02059993|DEVICE|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
214795785|NCT01226056|DRUG|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
214795786|NCT05159609|DEVICE|Closed loop auditory stimulus|50ms of low volume pink noise delivered during slow wave sleep
214795787|NCT03868137|DRUG|Ibuprofen|3 doses of Ibuprofen 800 mg
214795788|NCT03868137|DRUG|Placebos|Placebo
214795789|NCT02655237|DRUG|Relugolix|Relugolix tablets
214795790|NCT02655237|DRUG|Relugolix Placebo|Relugolix placebo-matching tablets
214795791|NCT02655237|DRUG|Leuprorelin|Leuprorelin injection
214795792|NCT02655237|DRUG|Leuprorelin Placebo|Leuprorelin placebo-matching injections
214795793|NCT00153283|DRUG|Gabapentin|
214795794|NCT00928954|DRUG|gabapentin|increasing to 1200 mg/day
214795795|NCT00928954|DRUG|memantine|increasing to 40 mg/day
214795796|NCT06101654|DEVICE|Pulse oximeter|Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
214795797|NCT02842697|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
214795798|NCT02842697|PROCEDURE|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
214795799|NCT02842697|PROCEDURE|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
214795800|NCT05832463|DIETARY_SUPPLEMENT|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
214795801|NCT05832463|DIETARY_SUPPLEMENT|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
214795802|NCT01860976|DRUG|Abatacept|
214795803|NCT01860976|DRUG|Placebo|
214795804|NCT06269276|BEHAVIORAL|Caregiver Contribution to Self-Care in Ostomy Patient Index|This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.
214795805|NCT06220292|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214795806|NCT06220292|DEVICE|Intermittent Oral-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214795807|NCT06220292|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214795808|NCT02227862|DRUG|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
214795809|NCT02227862|DRUG|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
214795810|NCT02457429|DEVICE|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
214795811|NCT02457429|OTHER|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
214795812|NCT02457429|OTHER|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
214795813|NCT00964626|DRUG|cisplatin|
214795814|NCT00964626|DRUG|paclitaxel|
214795815|NCT05770726|DIETARY_SUPPLEMENT|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
214795816|NCT05331222|DRUG|JT-1|JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
215031048|NCT04505800|DIETARY_SUPPLEMENT|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
214795817|NCT06371248|BEHAVIORAL|Steady Feet|Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.
214795818|NCT06371248|OTHER|Usual care for fall prevention|CGH's usual care for fall prevention, which include fall prevention materials and advice.
214795819|NCT00310258|BEHAVIORAL|Drug use prevention intervention|
214795820|NCT03847376|DRUG|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter \[mL\] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
214795821|NCT01336829|DRUG|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
214795822|NCT01336829|DRUG|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
214795823|NCT01336829|DRUG|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
214795824|NCT01336829|DRUG|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
214795825|NCT05814081|PROCEDURE|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
214795826|NCT03745625|DRUG|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
214795827|NCT03745625|DRUG|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
214795828|NCT05629949|DRUG|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
214795829|NCT05629949|DRUG|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
214795830|NCT05629949|DRUG|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
214795831|NCT02892500|DRUG|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
214795832|NCT02892500|DRUG|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
214795833|NCT00575406|DRUG|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
214795834|NCT00575406|DRUG|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
214795835|NCT00575406|DRUG|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
214795836|NCT00575406|DRUG|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
214795837|NCT00575406|DRUG|Vincristin|i.v., 2mg, d1 of each treatment cycle
214795838|NCT00575406|DRUG|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
214795839|NCT02115906|OTHER|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
214795840|NCT02115906|OTHER|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
214795841|NCT02115906|OTHER|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
214795842|NCT02490488|DRUG|Masitinib|
214795843|NCT02490488|DRUG|Gemcitabine|
214795844|NCT02490488|DRUG|Placebo|
214795845|NCT03445195|DRUG|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
215031049|NCT04505800|DIETARY_SUPPLEMENT|Maltose|Maltose
215031050|NCT02101255|DEVICE|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
214795846|NCT03445195|DRUG|Placebo|Matching 1g IV solution.
214795847|NCT03445195|DRUG|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
214795848|NCT01134081|BIOLOGICAL|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
214795849|NCT01134081|PROCEDURE|Free Gingival Graft|Harvested tissue from palate
214795850|NCT05709509|DRUG|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
214795851|NCT05709509|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
214795852|NCT05709509|OTHER|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
214795853|NCT04982146|DRUG|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
214795854|NCT04982146|DRUG|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
214795855|NCT02419313|DRUG|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
214795856|NCT02419313|DRUG|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
214795857|NCT01447264|PROCEDURE|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
214795858|NCT01447264|PROCEDURE|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
214795859|NCT05705713|RADIATION|chest computed tomography (CT)|Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
214795860|NCT04801966|DRUG|Trametinib|2 mg per day, continuous
214795861|NCT04801966|DRUG|Cobimetinib|60 mg/day for 21 days of a 28 day cycle
214795862|NCT04801966|DRUG|Binimetinib|45 mg/twice a day, continuous
214795863|NCT04801966|DRUG|Alpelisib|300 mg/day, continuous
214795864|NCT04801966|DRUG|Vemurafenib|960 mg/twice per day, continuous
214795865|NCT04801966|DRUG|Dabrafenib|150 mg/twicce per day, continuous
214795866|NCT04801966|DRUG|Encorafenib|450 mg/day, continuous
214795867|NCT04801966|DRUG|Palbociclib|125 mg/day, day 1-21 of a 28 day cycle
214795868|NCT04801966|DRUG|Olaparib|300 mg/twice per day, continuous
214795869|NCT04801966|DRUG|Ribociclib|600 mg/day, on day 1 -21 of a 28 day cycle
214795870|NCT04801966|DRUG|Abemaciclib|150 mg twice/day, continuous
214795871|NCT04801966|DRUG|Talazoparib|1 mg/day, on day 1 -28 of each 28 day cycle
214795872|NCT04801966|DRUG|Nivolumab|240 mg IV once every 2 weeks
214795873|NCT04801966|DRUG|Atezolizumab|1200 mg IV on Day 1 of a 21 day cycle
214795874|NCT04801966|DRUG|Pembrolizumab|200 mg IV on day 1 of a 21 day cycle
214795875|NCT03353909|DEVICE|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
214795876|NCT03072680|BEHAVIORAL|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
214795877|NCT03072680|BEHAVIORAL|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
214795878|NCT03072680|BEHAVIORAL|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
214795879|NCT00620763|OTHER|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
214795880|NCT00620763|OTHER|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
214795881|NCT03797664|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
214795882|NCT03797664|DRUG|Placebo|Phosphate Buffer Diluent oral solution
214795883|NCT01141725|DRUG|bendamustine hydrochloride|Given IV
214795884|NCT01141725|DRUG|idarubicin|Given IV
214795885|NCT02490709|PROCEDURE|Local excision|Local excision for rectal cancer with good response
214795886|NCT04956666|DRUG|Lyophilized S95014|"Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015."
214795887|NCT02907203|DEVICE|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
214795888|NCT03172780|DRUG|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
214795889|NCT03172780|DRUG|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
214795890|NCT03172780|DRUG|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
214795891|NCT00355628|DRUG|KW-2246 (fentanyl citrate)|KW-2246
214795892|NCT06367400|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire|Questionnaire with 22 questions of symptoms of OSDB
214795893|NCT02780570|PROCEDURE|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
214795894|NCT00930488|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
214795895|NCT00418483|BIOLOGICAL|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795896|NCT00418483|BIOLOGICAL|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795897|NCT00418483|BIOLOGICAL|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795898|NCT00418483|BIOLOGICAL|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
214795899|NCT00418483|BIOLOGICAL|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795900|NCT00418483|BIOLOGICAL|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795901|NCT00418483|BIOLOGICAL|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
214795902|NCT00783796|DEVICE|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
214795903|NCT03943251|DRUG|HEC113995PA•H2O tablet|2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
214795904|NCT03943251|DRUG|Placebo tablet|2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
214795905|NCT06087874|DIETARY_SUPPLEMENT|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
214795906|NCT06087874|DIETARY_SUPPLEMENT|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
214795907|NCT06099314|DRUG|Fruquintinib+PD-1 inhibitors|Third-line treatment with fruquintinib combined with PD-1 inhibitors. Fruquintinib: 5mg,Oral once daily,2 weeks on/1 week off,Q3W； PD-1 inhibitor：for example, Sintilimab,iv,200mg, Q3W.
214795908|NCT06099314|DRUG|Fruquintinib+TAS-102|Fourth-line treatment with fruquintinib combined with TAS-102 . Fruquintinib: 3-5mg(Depending on the patient's physical condition), Oral once daily,3 weeks on/1 week off,Q4W； TAS-102:orally, 35mg/m2 twice daily (maximum dose 80mg in a single dose) for days 1-5, repeated every 14 days.
214795909|NCT04210895|OTHER|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
214795910|NCT04210895|OTHER|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
215031051|NCT02101255|DEVICE|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
215031052|NCT05416814|DIETARY_SUPPLEMENT|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
215031559|NCT06675045|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
214795911|NCT00186914|BIOLOGICAL|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
214795912|NCT01490281|BEHAVIORAL|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
214795913|NCT01490281|BEHAVIORAL|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
214795914|NCT01834521|OTHER|Web-based screening and tailored support|
214795915|NCT02046421|DRUG|mifepristone|Given PO
214795916|NCT02046421|DRUG|carboplatin|Given IV
214795917|NCT02046421|DRUG|gemcitabine hydrochloride|Given IV
214795918|NCT02046421|OTHER|laboratory biomarker analysis|Correlative studies
214795919|NCT02046421|OTHER|pharmacological study|Correlative studies
214795920|NCT04884581|DEVICE|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
214795921|NCT06154863|DRUG|RAI|Radioactive iodine
214795922|NCT03299153|OTHER|barberry juice|
214795923|NCT01816477|DEVICE|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
214795924|NCT01816477|DRUG|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
214795925|NCT00819247|DRUG|Degarelix|Given as a subcutaneous injection.
214795926|NCT01415466|DRUG|Cresto|tablet, 20mg
214795927|NCT01415466|DRUG|Olmetec|tablet, 40mg
214795928|NCT01415466|DRUG|Cresto, Olmetec|tablet, 20mg and 40mg
214795929|NCT01766921|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
214795930|NCT04832113|OTHER|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
214795931|NCT04832113|OTHER|conventional management|Dietary and hydratation advices according to the recommendations
214795932|NCT00376571|PROCEDURE|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
214795933|NCT01807871|DRUG|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
214795934|NCT01807871|DRUG|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
214795935|NCT04232462|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
214795936|NCT00751946|BEHAVIORAL|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
214795937|NCT00751946|BEHAVIORAL|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
214795938|NCT05131906|DEVICE|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
214795939|NCT05017584|DRUG|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
214795940|NCT00698685|DRUG|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
214795941|NCT00698685|BIOLOGICAL|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
214795942|NCT00698685|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
214795943|NCT00940056|PROCEDURE|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
214795944|NCT00940056|DRUG|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
214795945|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
214795946|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
214795947|NCT04314739|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
214795948|NCT04314739|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
214795949|NCT03891719|PROCEDURE|Unilateral cleft lip rhinoplasty|"* Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
214795950|NCT04242771|BEHAVIORAL|Mindfulness|Subjects practice mindfulness before bedtime
214795951|NCT05567380|OTHER|Observation|Observation of Rheumatoid arthritis disease response to JAK inhibitors and TNF inhibitors after definite timepoints from the initialization of treatment in comparison to the current standard of care of therapy with conventional DMARDs.
215031053|NCT04480866|DEVICE|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
215031054|NCT00057148|PROCEDURE|massage treatment|
214795952|NCT06046027|DEVICE|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
214795953|NCT02540356|BIOLOGICAL|BAX69 Single-Route Arm|Intraperitoneal (IP) only
214795954|NCT02540356|BIOLOGICAL|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
214795955|NCT03056274|DRUG|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
214795956|NCT03056274|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
214795957|NCT05889871|DRUG|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
214795958|NCT00855842|DEVICE|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
214795959|NCT02978326|DRUG|SAGE-217 15/20 mg Oral Solution|SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
214795960|NCT02978326|DRUG|Placebo|SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
214795961|NCT02978326|DRUG|SAGE 217 30 mg Capsules|SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
214795962|NCT03317613|DRUG|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
214795963|NCT06159270|OTHER|Blood sample|Venuous blood sampling
214795964|NCT03920137|BEHAVIORAL|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
214795965|NCT03920137|BEHAVIORAL|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
214795966|NCT03920137|DEVICE|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
214795967|NCT00617526|DRUG|RDEA806 400 mg|
214795968|NCT00617526|DRUG|Placebo|Placebo
214795969|NCT00617526|DRUG|RDEA806 1000 mg|
214795970|NCT00617526|DRUG|RDEA806 600 mg|
214795971|NCT00617526|DRUG|RDEA806 800 mg|
214795972|NCT01048437|BEHAVIORAL|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
214795973|NCT01048437|BEHAVIORAL|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
214795974|NCT04730505|DEVICE|MyHOPE™ for Multiple Myeloma|The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.
214795975|NCT04730505|DEVICE|MyHope HCP Portal|Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
214795976|NCT04894994|DRUG|FLX475|Tablet
214795977|NCT04894994|DRUG|Ipilimumab|IV infusion
214795978|NCT03588325|DIAGNOSTIC_TEST|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
214795979|NCT03607006|PROCEDURE|Patient specific PEEK sheets|Computer aided sheet design
214795980|NCT03607006|PROCEDURE|Autogenous bone shell|autogenous retromolar/chin bone graft
214795981|NCT02566135|DEVICE|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
214795982|NCT02566135|DEVICE|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
214795983|NCT03945565|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
214795984|NCT03074526|OTHER|Amniotic Fluid|Amniotic Fluid
214795985|NCT03074526|OTHER|Saline Placebo|Saline Placebo
214795986|NCT03994445|BEHAVIORAL|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
215031055|NCT02499614|DRUG|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
215031056|NCT03999476|DEVICE|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
214795987|NCT02454270|DRUG|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
214795988|NCT02454270|DRUG|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
214795989|NCT03539315|BEHAVIORAL|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
214795990|NCT06022133|BEHAVIORAL|Dietary sodium restriction|Selfemployed dietary sodium restriction
214795991|NCT05753657|DRUG|Pioglitazone|hyperinsulinemia and hyperglycemia
214795992|NCT02509000|OTHER|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
214795993|NCT02763111|DRUG|BCD-085|
214795994|NCT02763111|OTHER|Placebo|
214795995|NCT01344408|PROCEDURE|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
214795996|NCT02703077|PROCEDURE|Spyglass|Endoscopic direct view of the bile ducts
214795997|NCT02703077|PROCEDURE|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
214795998|NCT02703077|PROCEDURE|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
214795999|NCT02703077|PROCEDURE|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
214796000|NCT00951288|DIETARY_SUPPLEMENT|Saffron|Saffron 20 mg/day supplementation
214796001|NCT00951288|DIETARY_SUPPLEMENT|Placebo|Placebo
214796002|NCT03841032|DRUG|Coppertone, BAY1183345|Lotion, for 4 weeks
214796003|NCT04217408|DEVICE|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
214796004|NCT03050632|BEHAVIORAL|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
214796005|NCT03050632|BEHAVIORAL|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
214796006|NCT02597543|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
214796007|NCT02597543|DRUG|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
214796008|NCT02597543|PROCEDURE|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
214796009|NCT04104568|BEHAVIORAL|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
214796010|NCT04104568|OTHER|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
215031057|NCT03999476|DEVICE|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
215031058|NCT01943227|OTHER|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
214796011|NCT06428448|COMBINATION_PRODUCT|REMEDY Spectrum IM Spacer Nail|"The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.~The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools."
214796012|NCT02832609|OTHER|Supine|measurements after 30 minutes in complete supine position
214796013|NCT00593879|DRUG|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
214796014|NCT02752945|OTHER|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
214796015|NCT02752945|OTHER|Usual care|Usual care afforded by local CAMHS services
214796016|NCT02959905|BIOLOGICAL|TSA-CTL|Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
214796017|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
214796018|NCT02959905|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.
214796019|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
214796020|NCT01411995|DRUG|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
214796021|NCT01411995|DRUG|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
214796022|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
214796023|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
214796024|NCT01937364|DRUG|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
214796025|NCT01937364|DRUG|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
214796026|NCT03715270|DEVICE|Image surgical area|Image surgical area
214796027|NCT01099384|BEHAVIORAL|Written self-help materials|Written materials to help adolescents stop tobacco use
214796028|NCT01099384|BEHAVIORAL|Group behavioral counseling|group behavioral counseling (2 day weekend program)
214796029|NCT04685421|DRUG|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
214796030|NCT01443806|DRUG|Oseltamivir|75 mg, one time
214796031|NCT01832805|OTHER|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
214796032|NCT05058742|DEVICE|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
214796033|NCT03133442|DEVICE|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
214796034|NCT01790620|OTHER|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
214796035|NCT01790620|OTHER|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
214796036|NCT00803842|DRUG|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
214796037|NCT04104646|DRUG|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
214796038|NCT04104646|DRUG|Morphine|Oral morphine administration at starting dose of 0.07 mg/kg q4
214796039|NCT04104646|DRUG|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
214796040|NCT04104646|DRUG|Morphine matched placebo|Oral morphine matched placebo administration
214796041|NCT00858000|OTHER|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
214796042|NCT04570566|PROCEDURE|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
214796043|NCT00284297|PROCEDURE|History taken and clinical examination|History is taken and clinical examination is followed
214796044|NCT02974153|BIOLOGICAL|ALD403 (Eptinezumab)|
214796045|NCT02974153|BIOLOGICAL|Placebo|
214796046|NCT05330507|OTHER|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
214796047|NCT03742531|DRUG|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
214796048|NCT01108900|DRUG|sildenafil|tables, 25,50,100 mg, on demand, 1 month
214796049|NCT01919879|DRUG|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
214796050|NCT01919879|DRUG|Cetuximab|Cetuximab administered intravenously
214796051|NCT02277769|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
214796052|NCT02277769|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
214796053|NCT06328283|OTHER|measure of Glutamine synthetase and BCLFAF1|compare Glutamine synthetase and BCLFAF1 in cases and controls
214796054|NCT03841383|DIAGNOSTIC_TEST|Echo stress dipyridamole|Echo stress dipyridamole
214796055|NCT03932266|DRUG|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
214796056|NCT03932266|DRUG|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
214796057|NCT03932266|DRUG|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
214796058|NCT03932266|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
214796059|NCT03556371|DRUG|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
214796060|NCT03556371|DRUG|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
214796061|NCT06469879|DRUG|TQB2450+Anlotinib|"TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week."
214796062|NCT06469879|DRUG|TQB2450 placebo + Anlotinib placebo|No drug substance is contained
214796063|NCT00391690|DRUG|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
214796064|NCT04458077|BEHAVIORAL|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
214796065|NCT00000359|BEHAVIORAL|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
214796066|NCT00000359|BEHAVIORAL|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
214796067|NCT00000359|BEHAVIORAL|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
214796068|NCT00000359|BEHAVIORAL|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
214796069|NCT00000359|BEHAVIORAL|ShamManeuver|Passive movement of the head
214796070|NCT03818958|OTHER|blood sampling|blood sampling
214796071|NCT05914519|PROCEDURE|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
214796072|NCT05914519|PROCEDURE|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
214796073|NCT00870909|PROCEDURE|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
214796074|NCT00870909|PROCEDURE|sham tDCS|sham condition as delivered by the stimulator
214796075|NCT01305083|DRUG|Udenafil|Placebo-control
214796076|NCT01305083|DRUG|Placebo|Placebo
214796077|NCT04258241|PROCEDURE|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
214796078|NCT04258241|PROCEDURE|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
214796079|NCT04258241|DEVICE|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
214796080|NCT04258241|DRUG|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
214796081|NCT04258241|DRUG|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
214796082|NCT01144884|OTHER|Procedure (education and exercise)|education/exercise
214796083|NCT02779816|DEVICE|Pen device|Adaptive pen device
214796084|NCT03885102|BEHAVIORAL|Intradialytic exercise intervention|50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
214796085|NCT03885102|BEHAVIORAL|Usual Care|Usual care with no exercise intervention or health literacy counselling
214796086|NCT03358459|OTHER|non|non
214796087|NCT03232203|DRUG|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
214796088|NCT05925790|DIAGNOSTIC_TEST|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described \[Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527\].
214796089|NCT05925790|DIAGNOSTIC_TEST|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
214796090|NCT00496184|DRUG|Nifedipine cream topical application|
214796091|NCT06085482|DRUG|LY3502970|Administered orally
214796092|NCT06085482|DRUG|[14C]-LY3502970|Administered IV
214796093|NCT03504852|DRUG|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
214796094|NCT00727454|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
214796095|NCT00727454|DEVICE|No treatment|No treatment
214796096|NCT01097356|DIETARY_SUPPLEMENT|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
214796097|NCT03262298|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
214796098|NCT02452645|BEHAVIORAL|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
214796099|NCT02452645|BEHAVIORAL|Comparison Group|Written materials, videos, books, and telephone counseling.
214796100|NCT00046709|DRUG|Smoked Marijuana|
214796101|NCT02677909|DEVICE|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
214796102|NCT02928848|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
214796103|NCT00015106|DRUG|Lamotrigine|
214796104|NCT03850509|DRUG|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
214796105|NCT03850509|DRUG|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
214796106|NCT03147170|DIAGNOSTIC_TEST|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
214796107|NCT06545136|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
214796108|NCT00969332|DRUG|Omegaven|0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
214796109|NCT05997056|DRUG|nab-sirolimus|Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion
214796110|NCT00582309|PROCEDURE|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
214796111|NCT00582309|PROCEDURE|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving \>80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
214796112|NCT00582309|PROCEDURE|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
214796113|NCT05152641|DRUG|BGE-117, 4mg|BGE-117, 4mg Capsules
214796114|NCT05152641|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous Sulfate, 325mg Tablets
214796115|NCT05152641|OTHER|Matching Placebo|Matching Placebo to BGE-117 Capsules
214796116|NCT05152641|DRUG|BGE-117, 12mg|BGE-117, 12mg Capsules
214796117|NCT01391182|OTHER|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
214796118|NCT01391182|OTHER|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
214796119|NCT01565083|DRUG|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
214796120|NCT01565083|DRUG|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
214796121|NCT01565083|DRUG|Vinorelbine|A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
214796122|NCT05297747|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
214796123|NCT05297747|DIAGNOSTIC_TEST|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
214796124|NCT01058421|PROCEDURE|intensive physical therapy|four week course of daily intensive physical therapy
214796125|NCT01058421|PROCEDURE|control group|four weeks of routine physical therapy
214796126|NCT05729633|OTHER|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
214796127|NCT06294171|DEVICE|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
214796128|NCT05434403|DEVICE|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
214796129|NCT05434403|DEVICE|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
214796130|NCT04771819|DEVICE|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
214796131|NCT01104857|PROCEDURE|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
214796132|NCT01104857|PROCEDURE|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
214796133|NCT03750474|DIAGNOSTIC_TEST|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
214796134|NCT00004812|BEHAVIORAL|Exercise|
214796135|NCT05269654|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
214796136|NCT05269654|OTHER|Normal Saline|Sham Comparator
214796137|NCT01050231|DEVICE|Functional/ Multi-joints activities|Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
214796138|NCT01050231|DEVICE|Individual Joint Training|Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
214796139|NCT03859609|PROCEDURE|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
214796140|NCT01824251|DRUG|NPB-01|
214796141|NCT03812068|BEHAVIORAL|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
214796142|NCT03812068|BEHAVIORAL|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
214796143|NCT00215982|DRUG|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
214796144|NCT00215982|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
214796145|NCT00215982|DRUG|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
214796146|NCT05657093|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
214796147|NCT05657093|COMBINATION_PRODUCT|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
214796148|NCT05128188|OTHER|No intervention will be given in this study|No intervention will be given in this study
214796149|NCT05705583|OTHER|Other: Blood and Urine Collection|Blood and Urine Collection
214796150|NCT02304575|OTHER|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
214796151|NCT02304575|OTHER|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
214796152|NCT00455533|DRUG|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
214796153|NCT00455533|DRUG|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
214796154|NCT00455533|DRUG|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
214796155|NCT00455533|DRUG|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
214796156|NCT00600626|DRUG|biphasic insulin aspart|
214796157|NCT00600626|DRUG|insulin NPH|
214796158|NCT00600626|DRUG|insulin aspart|
214796159|NCT03594877|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
214796160|NCT00129779|BEHAVIORAL|Intermediate care package|
214796161|NCT02785172|DRUG|IDP-118 Vehicle Lotion|Vehicle
214796162|NCT02785172|DRUG|IDP-118 Vehicle Cream|Vehicle
214796163|NCT02785172|DRUG|IDP-118 Lotion|Lotion
214796164|NCT02785172|DRUG|Ultravate Cream|Cream
214796165|NCT00901368|DRUG|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
214796166|NCT00901368|DRUG|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
214796167|NCT00800059|RADIATION|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
214796168|NCT05077852|DIAGNOSTIC_TEST|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
214796169|NCT06528717|PROCEDURE|Carotid graft interposition|In patients with extensive atherosclerotic carotid disease, when endarterectomy isn't feasible, replacement of the carotid artery with a graft is needed. Graft interposition can be performed either by end-to-end proximal and distal anastomoses in the undiseased common and internal carotid artery with ligation of the external carotid artery, or by side-to-end proximal anastomosis on the origin of the internal carotid artery and end-to-end distal anastomosis on the internal carotid artery with flow preservation in the external carotid artery.
214796170|NCT06527963|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
214796171|NCT02576990|BIOLOGICAL|Pembrolizumab|IV infusion
214796172|NCT04638985|BIOLOGICAL|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
214796173|NCT04638985|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
214796174|NCT04638985|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
214796175|NCT04638985|BIOLOGICAL|MMR|MMR at the age of 18 month old
214796176|NCT06375928|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
214796177|NCT06375928|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
214796178|NCT06375928|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
214796179|NCT00912418|BIOLOGICAL|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
214796180|NCT04147728|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
214796181|NCT04147728|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
214796182|NCT06526845|OTHER|Video-Conference based rehabilitation|"All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
214796183|NCT06526845|OTHER|Home-Based rehabilitation|"Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
214796184|NCT06529198|DEVICE|NeuroGyn Genital Neuromodulation System|Genital Neuromodulation
214796185|NCT04224090|DIAGNOSTIC_TEST|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
214796186|NCT05017233|DEVICE|Spectral CT|Using Spectral CT to scan Breast
214796187|NCT02702206|DRUG|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
214796188|NCT02702206|DRUG|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
214796189|NCT02702206|DRUG|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
214796190|NCT02768142|OTHER|Natural cesarean delivery|Natural cesarean delivery
214796191|NCT02768142|OTHER|Standard cesarean delivery|Standard cesarean delivery
214796192|NCT02758366|DRUG|Doxorubicin|
214796193|NCT04621942|OTHER|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
215031059|NCT01943227|OTHER|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
215031060|NCT02676180|OTHER|Group|
215031061|NCT01096004|DRUG|AZD4017|oral suspension, 1200mg, once daily, for 10 days
215031062|NCT01096004|DRUG|Placebo|
214796194|NCT04621942|OTHER|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
214796195|NCT04119661|DEVICE|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
214796196|NCT04119661|DEVICE|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
214796197|NCT02938494|DRUG|IDP-123 Lotion|Lotion
214796198|NCT02938494|DRUG|Tazorac Cream|Cream
214796199|NCT02938494|DRUG|Vehicle Lotion|Lotion
214796200|NCT02938494|DRUG|Vehicle Cream|Cream
214796201|NCT01760122|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
214796202|NCT01760122|DRUG|Pegasys|sc, qw, 48 weeks.
214796203|NCT04450290|DEVICE|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
214796204|NCT04330300|DRUG|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
214796205|NCT04330300|DRUG|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
214796206|NCT04330300|DRUG|ACE inhibitor|Anti-hypertensive (Control Arm)
214796207|NCT04330300|DRUG|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
214796208|NCT05024071|DEVICE|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
214796209|NCT05024071|DEVICE|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
214796210|NCT04650100|PROCEDURE|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
214796211|NCT06113796|OTHER|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
214796212|NCT00762671|DRUG|Ebselen|150 mg BID for 2 weeks
214796213|NCT00762671|DRUG|Placebo|Placebo 1 po BID for 2 weeks
214796214|NCT04900233|OTHER|surgery|emergency surgery
214796215|NCT02907008|OTHER|Polysomnography|
214796216|NCT02415959|DRUG|Creon IR|
214796217|NCT02415959|DRUG|Creon® (DR/GR)|
214796218|NCT04433481|DRUG|Dabigatran|T. Dabigatran 150 mg twice a day
214796219|NCT04433481|OTHER|Placebo|placebo
214796220|NCT02676219|OTHER|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
214796221|NCT02676219|OTHER|Water|
214796222|NCT01881399|DEVICE|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
214796223|NCT01881399|OTHER|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
214796224|NCT01881399|PROCEDURE|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
214796225|NCT03281421|OTHER|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
214796226|NCT05728632|DRUG|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
214796227|NCT05728632|DRUG|Placebo|Placebo, capsule, once daily, for 12 months
214796228|NCT02484820|DEVICE|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
214796229|NCT00911859|DRUG|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
214796230|NCT00911859|DRUG|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
214796231|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
214796232|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
214796233|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
214796234|NCT00911859|DRUG|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
214796235|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
214796236|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
214796237|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
214796238|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
214796239|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
214796240|NCT05781659|PROCEDURE|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
214796241|NCT05781659|PROCEDURE|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
214796242|NCT00021502|DRUG|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
214796243|NCT02495597|OTHER|no intervention - just observational|
214796244|NCT04730557|BEHAVIORAL|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
214796245|NCT01048333|DRUG|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
214796246|NCT01048333|DRUG|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
214796247|NCT01048333|DRUG|Placebo|Placebo Diskus and Placebo Turbuhaler
214796248|NCT01396044|OTHER|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
214796249|NCT01396044|OTHER|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
214796250|NCT01403883|BEHAVIORAL|Standard Care|Psychological \& enterostomal therapy clinics on demand only
214796251|NCT01403883|BEHAVIORAL|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
214796252|NCT04784117|OTHER|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
214796253|NCT01314755|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
214796254|NCT01314755|DIETARY_SUPPLEMENT|An iso-caloric, iso-nitrogenous control feed|
214796255|NCT05652621|DIETARY_SUPPLEMENT|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
214796256|NCT00564174|DRUG|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
214796257|NCT00564174|DRUG|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
214796258|NCT04582227|DEVICE|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
214796259|NCT00003860|BIOLOGICAL|filgrastim|
214796260|NCT00003860|DRUG|carboplatin|
214796261|NCT00003860|DRUG|etoposide|
214796262|NCT00003860|DRUG|ifosfamide|
214796263|NCT00003860|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214796264|NCT05892757|DRUG|Atogepant|Oral Tablet
214796265|NCT05892757|DRUG|Ubrogepant|Oral Tablet
214796266|NCT04571723|BEHAVIORAL|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
214796267|NCT04571723|BEHAVIORAL|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
214796268|NCT00851045|DRUG|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
214796269|NCT00851045|DRUG|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
214796270|NCT00851045|DRUG|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
214796271|NCT00851045|DRUG|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
214796272|NCT00851045|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
214796273|NCT00851045|DRUG|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
214796274|NCT00851045|DRUG|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
214796275|NCT00359229|DRUG|Zolpidem|Administration of Zolpidem 5mg
214796276|NCT00101972|BIOLOGICAL|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
214796277|NCT01880099|DRUG|placebo|placebo compared to 8mg of Galantamine
214796278|NCT01880099|DRUG|Galantamine 8mg|8mg of galantamine compared to placebo
214796279|NCT01880099|DRUG|Galantamine 16mg|16mg of galantamine compared to placebo
214796280|NCT00955747|DRUG|Tagatose|powder; 15 grams three times daily; one year
214796281|NCT00955747|DRUG|Sugar Substitute Splenda|1.5 g powder tid
214796282|NCT00711503|DRUG|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
214796283|NCT00711503|DRUG|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
214796284|NCT05647083|OTHER|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
214796285|NCT01909583|OTHER|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
214796286|NCT03623256|DRUG|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
214796287|NCT03623256|DRUG|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
214796288|NCT03623256|DRUG|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
214796289|NCT03623256|DRUG|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
214796290|NCT02610049|BEHAVIORAL|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson \& Chard (11/2010)
214796291|NCT02610049|BEHAVIORAL|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson \& Chard (11/2010)
214796292|NCT02610049|BEHAVIORAL|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson \& Chard (1/2010) CPT + Art Therapy of mixed individual techniques
214796293|NCT03562403|DEVICE|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
214796294|NCT00539539|OTHER|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
214796295|NCT03349606|DRUG|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
214796296|NCT03349606|RADIATION|[C-11]FLB 457|PET radiotracer
214796297|NCT00634179|DRUG|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
214796298|NCT00634179|BIOLOGICAL|Rituximab|Rituximab 375 mg/m²
214796299|NCT00634179|DRUG|Doxorubicin|Doxorubicin 50 mg/m²
214796300|NCT00634179|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m²
214796301|NCT00634179|DRUG|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
214796302|NCT00634179|DRUG|Prednisone|Prednisone 100 mg/day given orally on days 1-5
214796303|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.
214796304|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic spoon grasper|Hysteroscopic endometrial biopsy performed through the spoon grasper.
214796305|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic alligator grasper|Hysteroscopic endometrial biopsy performed through the alligator grasper.
214796306|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
214796307|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
214796308|NCT01858714|BEHAVIORAL|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
214796309|NCT01858714|BEHAVIORAL|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
214796310|NCT01858714|BEHAVIORAL|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
214796311|NCT05571709|OTHER|Exercise training|Resistance training of the lower limbs
214796312|NCT05571709|BEHAVIORAL|Questionnaire|Physical activity questionnaire
214796313|NCT05571709|PROCEDURE|Percutaneous muscle biopsy|Muscle biopsy of the vastus lateralis (m. quadriceps)
214796314|NCT05571709|PROCEDURE|Blood sample|Venous blood sample
214796315|NCT04784481|DRUG|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
214796316|NCT02231320|DRUG|Berodual® Respimat® - inhaler|
214796317|NCT04654403|DRUG|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
214796318|NCT03419195|OTHER|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
214796319|NCT02627027|DRUG|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
214796320|NCT02627027|DRUG|CKD-395 0.25/750mg|oral administration
214796321|NCT03441542|BEHAVIORAL|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
214796322|NCT03441542|BEHAVIORAL|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
214796323|NCT03800069|DEVICE|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
214796324|NCT04503798|BEHAVIORAL|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
214796325|NCT04464044|DEVICE|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
214796326|NCT00767325|DRUG|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
214796327|NCT00767325|DRUG|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
214796328|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
214796329|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
214796330|NCT02002156|BIOLOGICAL|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
214796331|NCT03538756|DEVICE|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
214796332|NCT03982758|OTHER|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
214796333|NCT03982758|OTHER|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
214796334|NCT01987804|DRUG|Oxytocin 100 i.u.|
214796335|NCT01987804|DRUG|Oxytocin 400 i.u.|
214796336|NCT01987804|DRUG|Placebo|
214796337|NCT04973956|OTHER|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
214796338|NCT04973956|OTHER|Control|No intervention
214796339|NCT06016855|PROCEDURE|Tumor Debulking|Undergo surgical debulking
214796340|NCT06016855|DRUG|Lutetium Lu 177 Dotatate|Given by IV
214796341|NCT06016855|PROCEDURE|Computed Tomography|Undergo Computed Tomography
214796342|NCT06016855|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
214796343|NCT06016855|DRUG|Copper Cu 64 Dotatate|Given by IV
214796344|NCT06016855|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
214796345|NCT03064633|DRUG|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
214796346|NCT03064633|DRUG|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
214796347|NCT03064633|DRUG|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
214796348|NCT02542306|DRUG|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
214796349|NCT00752856|DRUG|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
214796350|NCT00752856|DRUG|Atripla|Atripla 1 tab once a day
214796351|NCT03136692|BEHAVIORAL|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
214796352|NCT03131999|DRUG|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
214796353|NCT03131999|DRUG|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
214796354|NCT02402868|DRUG|Ketamine and saline|Ketamine intravenous and intranasal
214796355|NCT02260492|DRUG|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
214796356|NCT02260492|DRUG|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
214796357|NCT02260492|DRUG|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
214796358|NCT01323998|DRUG|5ARI|Dutasteride or Finasteride
214796359|NCT01323998|DRUG|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
214796360|NCT01898910|PROCEDURE|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
214796361|NCT01898910|PROCEDURE|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
214796362|NCT01898910|DRUG|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
214796363|NCT04295395|DEVICE|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
215031063|NCT03859219|DRUG|Rozanolixizumab|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
215031064|NCT03859219|DRUG|Placebo|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
215031065|NCT03463655|DIAGNOSTIC_TEST|cirrhotic albumin|Ascites puncture
215031066|NCT03463655|DIAGNOSTIC_TEST|serum albumin|blood punctures
215031067|NCT03372616|DIAGNOSTIC_TEST|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
214796364|NCT06547593|BEHAVIORAL|multifaceted nutrition intervention|"In this group, a 3-month multifaceted nutrition intervention will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: WeChat groups will be established to record the dietary status of the research subjects. The research subjects will be asked to keep a dietary diary and take photos of their diet daily. Trained researchers will record their daily diet and provide timely feedback to the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks. The content will include basic knowledge of frailty, prevention and treatment guidance, health outcomes, medication management, and healthy behaviors."
214796365|NCT06547593|BEHAVIORAL|Nutritional and Exercise Combined Intervention|To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
214796366|NCT06547593|BEHAVIORAL|Control Group|The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.
214796367|NCT04366479|BEHAVIORAL|Multistage Fitness Test|Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
214796368|NCT00317954|DRUG|Spironolactone|
214796369|NCT05937113|BIOLOGICAL|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
214796370|NCT06544577|DRUG|ELacestrant|345 mg/day once daily oral dosing
214796371|NCT00197756|DIETARY_SUPPLEMENT|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
214796372|NCT00197756|DIETARY_SUPPLEMENT|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
214796373|NCT00197756|DIETARY_SUPPLEMENT|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
214796374|NCT00197756|OTHER|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
214796375|NCT02550756|DRUG|CTNX-4975|
214796376|NCT00102869|DRUG|levodopa|100mg levodopa per day over 10 days/ treatment phase
214796377|NCT02989142|BEHAVIORAL|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
214796378|NCT00894907|OTHER|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI \>12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP\>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP\>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP\>65mmHg (MAP: Mean Arterial Pressure); IAPP \>60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
214796379|NCT00894907|OTHER|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP \>65mmHg;IAPP \>60mmHg"
214796380|NCT00838877|DRUG|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
214796381|NCT00838877|DRUG|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
214796382|NCT05653713|DRUG|CSL324|Single intravenous (IV) dose of CSL324
214796383|NCT05653713|DRUG|Placebo|IV dose of 0.9% saline
214796384|NCT06357026|DEVICE|Percutaneous Ventricular Assist System（Phigine Medical）|Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.
214796385|NCT06357026|DEVICE|intra-aortic balloon pump (IABP)|IABP provides intraoperative circulatory support during high-risk PCI.
214796386|NCT01503723|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
214796387|NCT03731481|BEHAVIORAL|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
214796388|NCT04085081|OTHER|E-mail|Receive brief motivational text or email messages
214796389|NCT04085081|BEHAVIORAL|Exercise Intervention|Receive personalized walking program plus strength exercises
214796390|NCT04085081|OTHER|Quality-of-Life Assessment|Ancillary studies
214796391|NCT04085081|OTHER|Questionnaire Administration|Ancillary studies
214796392|NCT04085081|BEHAVIORAL|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
214796393|NCT04085081|OTHER|Text Message|Receive brief motivational text or email messages
214796394|NCT05809674|DEVICE|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
214796395|NCT00996736|DRUG|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
214796396|NCT00996736|DRUG|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
214796397|NCT01412138|OTHER|genetic analysis|"1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
214796398|NCT02688608|DRUG|Pembrolizumab|200 mg IV once every 3 weeks
214796399|NCT01729702|OTHER|blood sample collection|
214796400|NCT03577236|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
214796401|NCT03863275|DEVICE|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
214796402|NCT03863275|OTHER|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
214796403|NCT04065893|PROCEDURE|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
214796404|NCT04065893|DRUG|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
214796405|NCT02456909|DEVICE|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
214796406|NCT02456909|DEVICE|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
214796407|NCT02456909|DRUG|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
214796408|NCT01250158|DEVICE|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
214796409|NCT04464135|OTHER|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
214796410|NCT04464135|OTHER|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
214796411|NCT04604639|DIAGNOSTIC_TEST|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
214796412|NCT06354244|DEVICE|Electroacupuncture of 2 sessions per week|Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.
214796413|NCT06354244|DEVICE|Electroacupuncture of 3 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
214796414|NCT06354244|DEVICE|Electroacupuncture of 4 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
214796415|NCT04203680|DRUG|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
214796416|NCT04203680|DRUG|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
214796417|NCT02367495|DEVICE|PCB|PCB with Citrate-based excipient
214796418|NCT03923595|OTHER|Adherence intervention research|dedicated management
214796419|NCT06087809|BEHAVIORAL|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
214796420|NCT06087809|BEHAVIORAL|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
214796421|NCT06463964|DIAGNOSTIC_TEST|Serum Creatinine|Laborataries for prediction of AKi in patients with ADHF
214796422|NCT01497938|DEVICE|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
214796423|NCT01497938|DEVICE|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
214796424|NCT02210403|DEVICE|transcranial direct current stimulation (tDCS)|
214796425|NCT05895253|DEVICE|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
214796426|NCT00024453|BIOLOGICAL|teicoplanin|
214796427|NCT04810819|DRUG|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
214796428|NCT04810819|DRUG|Placebo|Placebo
214796429|NCT00365352|DRUG|XP13512 600MG|XP13512 600MG ONCE DAILY
214796430|NCT00365352|DRUG|XP13512 1200MG|XP13512 1200MG ONCE DAILY
214796431|NCT00365352|DRUG|PLACEBO|PLACEBO ONCE DAILY
214796432|NCT04258670|OTHER|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)
214796433|NCT00235859|DRUG|adalimumab|
214796434|NCT00235859|DRUG|methotrexate|
214796435|NCT05895084|BEHAVIORAL|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
214796436|NCT00190554|DRUG|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
214796437|NCT00190554|DRUG|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
214796438|NCT04371978|DRUG|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
214796439|NCT01914315|BEHAVIORAL|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
214796440|NCT01914315|OTHER|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
214796441|NCT02546908|OTHER|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
214796442|NCT02368405|BEHAVIORAL|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
214796443|NCT02368405|BEHAVIORAL|Eat Smart, Live Better|Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
214796444|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
214796445|NCT02218359|DRUG|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
214796446|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
214796447|NCT01680185|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
214796448|NCT01680185|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
214796449|NCT01680185|OTHER|Standard of care|all covered above
214796450|NCT01983956|BEHAVIORAL|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
214796451|NCT02322528|DRUG|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
214796452|NCT02201498|PROCEDURE|Pulpotomies with Formocresol/OZE and Biodentine|
214796453|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
214796454|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
214796455|NCT05147051|DRUG|Meglumine Sodium Succinate|500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
214796456|NCT05147051|DRUG|Placebo|Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
214796457|NCT02331537|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
214796458|NCT04578743|DEVICE|Graded Exercise Therapy: ClearPlay(TM)|ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
214796459|NCT03070249|BEHAVIORAL|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
214796460|NCT03801161|BIOLOGICAL|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP \>5 mg/L in infants within 24 hours of immunization.
214796461|NCT04143113|OTHER|Decision Aid|Shared decision making tool
214796462|NCT03562442|BEHAVIORAL|Smoking cessation|Smoking cessation with or without professional / medical support
214796463|NCT02224456|DRUG|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
214796464|NCT04059601|DIAGNOSTIC_TEST|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
214796465|NCT04059601|DIAGNOSTIC_TEST|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
214796466|NCT05411770|DEVICE|Thoracic kyphosis and lumbar lordosis angle assessment|Thoracic kyphosis and lumbar lordosis angle assessment was performed with the reliable Baseline Bubble Inclinometer®.
214796467|NCT05411770|DEVICE|Temporomandibular range of motion|TMJ range of motion, maximum mouth opening amount (MAAM), right and left lateral movements of the mandible (laterotrusion), anterior movement of the mandible (protrusion), and backward movement of the mandible (retrusion) were measured with a millimetric ruler, while the adolescent was seated on a chair.
214796468|NCT05411770|DEVICE|Measuring the cervical joint range of motion|Cervical joint flexion, extension, lateral flexion and rotation ranges of motion were measured with a universal goniometer while the adolescent was sitting in a chair.
215031068|NCT03372616|DIAGNOSTIC_TEST|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
214796469|NCT05411770|DEVICE|Craniovertebral angle measurement|Head posture of the adolescent was evaluated by craniovertebral angle (CVA) method. Adolescents sat on a chair with back support in an upright position and turned sideways to the worker. The pivot point was accepted as the seventh cervical vertebra, and the angle between the head (tragus) and the horizontal plane was measured with a goniometer and recorded in degrees.
214796470|NCT05411770|DEVICE|Tragus-to-wall distance measurement|Tragus-to-wall distance was measured using a tape measure and recorded in cm.
214796471|NCT05411770|DEVICE|Scoliosis angle assessment|Scoliosis angle assessment was done with a scoliometer.
214796472|NCT00178581|DRUG|Glutamine|
214796473|NCT03665181|OTHER|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
214796474|NCT02815969|OTHER|vena punction|vena punction and urine collection
214796475|NCT00439790|PROCEDURE|Microneurography|Microneurography
214796476|NCT01644890|DRUG|NK105|IV, Weekly
214796477|NCT01644890|DRUG|Paclitaxel|IV, Weekly
214796478|NCT00214279|DRUG|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
214796479|NCT00238069|DEVICE|CPAP machine as a result of sleep study|
214796480|NCT03482063|DIETARY_SUPPLEMENT|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
214796481|NCT03482063|OTHER|Placebo|riboflavin (2.2mg)
214796482|NCT05889338|DRUG|adalimumab and methotrexate|Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
214796483|NCT01462214|DRUG|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
214796484|NCT02596503|DRUG|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
214796485|NCT02596503|DRUG|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
214796486|NCT02596503|OTHER|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
214796487|NCT05780541|DRUG|PF-07304814|PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
214796488|NCT05780541|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
214796489|NCT05780541|BIOLOGICAL|Remdesivir|Antiviral agent
214796490|NCT06162923|BEHAVIORAL|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
214796491|NCT06162923|BEHAVIORAL|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
214796492|NCT00252980|BEHAVIORAL|Psychotherapy|
214796493|NCT00620490|DRUG|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
214796494|NCT00620490|OTHER|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
214796495|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
214796496|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
214796497|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
214796498|NCT01418157|DRUG|Acetazolamide|125 mg twice daily until 4380 meters altitude
214796499|NCT01418157|DRUG|Placebo|Twice daily
214796500|NCT02761980|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
214796501|NCT02761980|DRUG|Ibuprofen 250 mg|Ibuprofen 250 mg
214796502|NCT02761980|DRUG|Acetaminophen 500 mg|1 APAP 500 mg caplet
214796503|NCT02761980|DRUG|Placebo|Placebo tablet
214796504|NCT01806922|BEHAVIORAL|Yoga|
214796505|NCT03400930|OTHER|Severe Acute Malnutrition|
214796506|NCT05404035|BEHAVIORAL|Family Connections for relatives of people with eating disorders and personality disorders|"The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment."
214796507|NCT05404035|BEHAVIORAL|Optimized Treatment As Usual|"Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs."
214796508|NCT04820803|OTHER|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
214796509|NCT04820803|OTHER|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
214796510|NCT04640103|OTHER|No interventions|No interventions
215031069|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
214796511|NCT05891990|PROCEDURE|immediate implant augmented with sticky tooth|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~* Finally, the flap will be repositioned and sutured."
214796512|NCT05891990|PROCEDURE|immediate implant augmented with autogenous tooth graft|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~* Finally, the flap will be repositioned and sutured."
214796513|NCT04303988|DRUG|SHR-1316|IV
214796514|NCT04303988|DRUG|Bevacizumab|IV
214796515|NCT04303988|DRUG|Cisplatin/Carboplatin|IV
214796516|NCT00613470|DRUG|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5."
214796517|NCT01130688|DRUG|Zileuton|Imatinib combined with Zileuton
214796518|NCT03976713|DRUG|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
214796519|NCT03976713|DRUG|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
214796520|NCT03976713|DRUG|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
214796521|NCT02427685|DEVICE|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
214796522|NCT00101582|DRUG|Placebo|
214796523|NCT00101582|DRUG|palifermin|
214796524|NCT00101582|DRUG|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
214796525|NCT00101582|RADIATION|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
214796526|NCT03370068|OTHER|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
214796527|NCT03370068|OTHER|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
214796528|NCT06486480|PROCEDURE|Using robot assisted endoscopy to clear intraventricular hemorrhage|More advanced surgical auxiliary instruments are used to improve surgical accuracy
214796529|NCT00056160|DRUG|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
214796530|NCT00056160|DRUG|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
214796531|NCT04898296|OTHER|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
214796532|NCT04898296|OTHER|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
214796533|NCT01551095|DEVICE|PEGJ tube|The self-propelled PEGJ feeding tube
214796534|NCT05436002|DEVICE|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
214796535|NCT02199548|OTHER|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
214796536|NCT03382002|DIAGNOSTIC_TEST|TCL|evaluation of oxidative status
214796537|NCT05268432|PROCEDURE|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
214796538|NCT04882332|OTHER|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
214796539|NCT04882332|OTHER|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
215031070|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
215031071|NCT02341274|DRUG|Tacrolimus|Bioequivalence study
214796540|NCT03528200|OTHER|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
214796541|NCT01436032|DRUG|N1539|IV
214796542|NCT01436032|DRUG|N1539|IV
214796543|NCT01436032|DRUG|N1539|IV
214796544|NCT01436032|DRUG|Ketorolac Tromethamine|IV
214796545|NCT01436032|DRUG|Placebo|IV
214796546|NCT05532332|DRUG|Fluoxetine 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
214796547|NCT05532332|DRUG|Prozac® 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
214796548|NCT03519828|OTHER|No intervention has been conducted|It is an observational study, and no intervention has been conducted
214796549|NCT02441972|DRUG|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
214796550|NCT03207581|BEHAVIORAL|Professional Coaching|Professional, individualized coaching
214796551|NCT04329208|DEVICE|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
214796552|NCT00868400|DIETARY_SUPPLEMENT|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
214796553|NCT00868400|DIETARY_SUPPLEMENT|flavored water|will be given in doses equal to those of high-carbohydrate beverage
214796554|NCT06451861|DRUG|Chidamide|Induction Therapy
214796555|NCT06451861|DRUG|Venetoclax|Induction Therapy
214796556|NCT06451861|DRUG|azacitidine|Induction Therapy
214796557|NCT06451861|DRUG|Anthracyclines or anthraquinones|Induction Therapy
214796558|NCT06451861|DRUG|cytarabine|Induction Therapy
214796559|NCT01452451|DRUG|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
214796560|NCT01452451|DRUG|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
214796561|NCT04347746|BEHAVIORAL|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
214796562|NCT04347746|BEHAVIORAL|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
214796563|NCT03093324|DRUG|ALKS 8700|Administered as specified in the treatment arm.
214796564|NCT03093324|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
214796565|NCT04629404|DRUG|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
214796566|NCT04629404|DRUG|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
214796567|NCT01139255|BEHAVIORAL|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
214796568|NCT01501799|DRUG|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
214796569|NCT01501799|DRUG|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
214796570|NCT01501799|DRUG|Placebo (Vehicle Gel)|Vehicle Gel
214796571|NCT04579328|BEHAVIORAL|Exposure to Growth Mats|see arm/group descriptions for description of intervention
214796572|NCT04119349|BEHAVIORAL|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
214796573|NCT01959256|BEHAVIORAL|Visual perceptual learning|24 times of training for visual perceptual learning
214796574|NCT01998321|OTHER|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production
214796575|NCT01998321|OTHER|conventional technique for TKA|
214796576|NCT06543264|DEVICE|Cryotherapy|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
214796577|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
214796578|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
214796579|NCT04583579|DEVICE|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
214796580|NCT04583579|DEVICE|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
214796581|NCT04583579|DEVICE|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
214796582|NCT06366256|BEHAVIORAL|Traditional ultrasound biofeedback|"Participants use a B-mode ultrasound device to view their tongue movement on a screen. The participant sees the ultrasound image of their tongue moving in sagittal plane on the screen. The speech-language pathologist working with the participant also views participant's tongue movement and provides verbal instruction on how the participant should move their tongue to produce a perceptually correct r sound in simple syllables (CV, VC), as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
214796583|NCT06366256|BEHAVIORAL|Simplified ultrasound biofeedback|"Participants use a B-mode ultrasound device that captures the movement of their tongue and software that transforms the movement of their tongue into gamified objects on a screen. The participant sees a game object (a character) move on the screen towards goals; the movement of the game object represents the movement of the tongue and the goals are representative of tongue movements that correlate with an acoustic percept of accuracy. The speech-language pathologist working with the participant views the movement of the game object and provides verbal instruction on how the participant should move the game character in order to reach the goals when saying simple syllable words (CV, VC) as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
214796584|NCT00071552|DRUG|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
214796585|NCT00071552|DRUG|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
214796586|NCT03561259|DRUG|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
214796587|NCT03561259|DRUG|131-MIBG + Vorinostat|Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
214796588|NCT00278200|BIOLOGICAL|Inactivated EBV-infected vaccine|
214796589|NCT01142037|DIETARY_SUPPLEMENT|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
214796590|NCT02505854|DIETARY_SUPPLEMENT|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
214796591|NCT02505854|DIETARY_SUPPLEMENT|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
214796592|NCT02505854|DIETARY_SUPPLEMENT|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
214796593|NCT00976664|DEVICE|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
214796594|NCT00976664|DEVICE|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
214796595|NCT04330248|DRUG|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
214796596|NCT04330248|DRUG|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
214796597|NCT02174939|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
214796598|NCT02174939|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
214796599|NCT01005836|BEHAVIORAL|Cognitive behavioral therapy for youth anxiety|
214796600|NCT01005836|OTHER|Usual clinic care|
214796601|NCT01005836|BEHAVIORAL|Cognitive behavioral treatment for youth depression|
214796602|NCT01915056|OTHER|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
214796603|NCT03949556|OTHER|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
214796604|NCT02935959|DRUG|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
214796605|NCT02935959|DRUG|nebulized Dexmedetomidine|
214796606|NCT02935959|DRUG|nebulized midazolam|
214796607|NCT00968383|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
214796608|NCT00968383|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
214796609|NCT00968383|DRUG|Statins|Participants will receive statins.
214796610|NCT00968383|DRUG|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
214796611|NCT00968383|PROCEDURE|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
214796612|NCT00759447|DEVICE|Genesis and Gemini|3 dimensional breast mammography system
214796613|NCT00759447|DEVICE|Investigational 3D Mammography system|3 dimensional breast mammography system
214796614|NCT04584268|BEHAVIORAL|mindfulness|in person and smart phone application mindfulness practice
214796615|NCT04584268|OTHER|standard medical education|standard medical education / control
214796616|NCT03407859|BIOLOGICAL|Sequential Treatment With different CART|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
214796617|NCT01442909|DRUG|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
214796618|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
214796619|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
214796620|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
214796621|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
214796622|NCT01903486|DRUG|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
214796623|NCT00720486|BEHAVIORAL|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
214796624|NCT00720486|BEHAVIORAL|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
214796625|NCT02304120|OTHER|Proprioceptive postural training|
214796626|NCT02304120|OTHER|Treadmill training|
214796627|NCT02304120|OTHER|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
214796628|NCT05480397|OTHER|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~* Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~* Group (3): Will receive (cryotherapy and conventional physical therapy )"
214796629|NCT01001065|PROCEDURE|Vascular ultrasound|RI ist predictive for arteriosclerosis
214796630|NCT00390312|DRUG|Intranasal Placebo|Intranasal placebo
214796631|NCT00390312|DRUG|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
214796632|NCT00390312|DRUG|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
214796633|NCT00390312|DRUG|Intravenous morphine|Intravenous morphine 7.5 mg
214796634|NCT00390312|DRUG|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
214796635|NCT00390312|DRUG|Oral placebo|Oral placebo
214796636|NCT00390312|DRUG|Intravenous placebo|Intravenous placebo
214796637|NCT05785455|OTHER|COGMO Intervention|Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy
214796638|NCT05785455|OTHER|Usual Care|Usual Primary Care health education and treatment for patients with chronic neck pain
214796639|NCT00135707|DRUG|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
214796640|NCT00135707|DRUG|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
214796641|NCT00100165|DRUG|Placebo|Placebo by mouth twice a day for 4 weeks
214796642|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
214796643|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 75 mg|3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
214796644|NCT02042391|DRUG|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
214796645|NCT02042391|DRUG|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
214796646|NCT02042391|DRUG|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
214796647|NCT02042391|DRUG|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
214796648|NCT02287168|PROCEDURE|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
214796649|NCT02287168|PROCEDURE|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
214796650|NCT02287168|PROCEDURE|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
214796651|NCT02939274|DRUG|Verteporfin|
214796652|NCT02939274|DEVICE|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
214796653|NCT00421174|DRUG|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
214796654|NCT00421174|DRUG|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
214796655|NCT03688230|DRUG|abituzumab|1000 mg IV
214796656|NCT03688230|COMBINATION_PRODUCT|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
214796657|NCT05263648|OTHER|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
214796658|NCT00003696|DRUG|carboplatin|
214796659|NCT00003696|DRUG|cyclophosphamide|
214796660|NCT00003696|DRUG|doxorubicin hydrochloride|
214796661|NCT00003696|DRUG|etoposide|
214796662|NCT00003696|DRUG|paclitaxel|
214796663|NCT00000563|DRUG|dexamethasone|
214796664|NCT02524379|DRUG|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
214796665|NCT01986036|DIETARY_SUPPLEMENT|Protein|Milk-Protein
214796666|NCT01986036|DIETARY_SUPPLEMENT|Calcium|Soluble calcium powder.
214796667|NCT01986036|DIETARY_SUPPLEMENT|Porridge-based breakfast.|Oats and water.
214796668|NCT01829464|DRUG|Placebo|TAK-875 placebo-matching tablets
214796669|NCT01829464|DRUG|TAK-875|TAK-875 tablets
214796670|NCT01829464|DRUG|TAK-875|TAK-875 tablets
214796671|NCT02743702|OTHER|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~* supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~* lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~* sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~* diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~* in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~* exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
214796672|NCT02743702|OTHER|USUAL THERAPIES|
214796673|NCT02229890|DRUG|alteplase|
214796674|NCT02295709|PROCEDURE|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
214796675|NCT02295709|PROCEDURE|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
214796676|NCT02295709|DRUG|Dexamethasone|One of the most efficient steroids
214796677|NCT02295709|DEVICE|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
214796678|NCT02295709|RADIATION|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
214796679|NCT02270788|DRUG|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
214796680|NCT02270788|DRUG|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
214796681|NCT02270788|DRUG|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
214796682|NCT04872907|DEVICE|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
214796683|NCT04872907|DEVICE|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
214796684|NCT04872907|DRUG|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
214796685|NCT01904500|DRUG|Pre-operative cefazolin|
214796686|NCT02046928|DRUG|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
214796687|NCT01947777|DRUG|IPI-145|25 mg oral capsule
214796688|NCT01947777|DRUG|Rifampin|2x 300 mg oral capsule
214796689|NCT02207309|DRUG|Pazopanib|
214796690|NCT02207309|DRUG|Placebo (for Pazopanib)|
214796691|NCT04172389|PROCEDURE|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
214796692|NCT01855724|DRUG|Gemcitabine-Pazopanib|
214796693|NCT03473782|OTHER|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
214796694|NCT03473782|OTHER|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
214796695|NCT00898482|OTHER|This is a non-intervention study for all groups.|This is a non-intervention study.
214796696|NCT00898482|OTHER|study of socioeconomic and demographic variables|Non-intervention study.
214796697|NCT01204580|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
214796698|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
214796699|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
214796700|NCT00617448|PROCEDURE|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
214796701|NCT00617448|PROCEDURE|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
214796702|NCT03763110|DEVICE|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
214796703|NCT03763110|DRUG|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
214796704|NCT00043836|DRUG|ALT-711|
214796705|NCT04648475|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
214796706|NCT03377400|DRUG|Durvalumab|concurrent radiotherapy
214796707|NCT05927285|DIAGNOSTIC_TEST|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
214796708|NCT05927285|OTHER|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
214796709|NCT02228382|DRUG|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
214796710|NCT03665103|OTHER|Laser-assisted ICSI|Laser opening of the zona pellucida.
214647006|NCT06915532|BEHAVIORAL|Pain Neurophysiology Education|"The program used for PNE was based on a brochure written in the Tunisian dialect with simple, patient-accessible language. The brochure includes different sections: definition of pain, origin of pain, types of pain, components of pain, role of nervous system in pain modulation and pain management. Thus, all main concepts of the neurophysiology of pain were explained and discussed using visual presentation.~At the end of the sessions, a test was provided to the patient to assess their understanding of the brochure's content.~At the follow-up session a month later, the main ideas taught were reinforced and any questions were answered."
214657034|NCT05247411|OTHER|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
214796711|NCT02337465|DEVICE|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
214796712|NCT02337465|RADIATION|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
214796713|NCT05744973|OTHER|No intervention|This is an observational study
214796714|NCT05637281|DRUG|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
214796715|NCT05637281|OTHER|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
214796716|NCT04605510|OTHER|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
214796717|NCT05883410|OTHER|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
214796718|NCT05883410|OTHER|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
214796719|NCT05883410|OTHER|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
214796720|NCT01925755|OTHER|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
214796721|NCT06461208|DRUG|Encapsulated FMT|Encapsulated Faecal Microbiota Transplant
214796722|NCT06461208|OTHER|Placebo|The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
214796723|NCT05549284|DRUG|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
214796724|NCT05632848|DRUG|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
214796725|NCT01819636|OTHER|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
214796726|NCT00356200|DRUG|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
214796727|NCT00356200|DRUG|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
214796728|NCT02470559|BIOLOGICAL|Aldesleukin|Given SC
214796729|NCT02470559|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV and IP
214796730|NCT02470559|OTHER|Laboratory Biomarker Analysis|Correlative studies
214796731|NCT02470559|BIOLOGICAL|Sargramostim|Given SC
214796732|NCT00344552|DRUG|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
214796733|NCT04072588|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
214796734|NCT02012309|BIOLOGICAL|PCV-13|
214796735|NCT02012309|BIOLOGICAL|PPSV-23|
214796736|NCT01625637|BEHAVIORAL|AAT-experiment|This AAT condition trains kids to avoid cigarettes
214796737|NCT01625637|BEHAVIORAL|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
214796738|NCT04120428|OTHER|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
214796739|NCT05780879|DRUG|Venetoclax|Venetoclax administered orally once daily on days 3-16.
214796740|NCT05780879|DRUG|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
214796741|NCT04073147|DRUG|Venetoclax|Venetoclax per os
214796742|NCT04073147|DRUG|Obinutuzumab|ObintuzumabIV
214796743|NCT00812253|DRUG|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
214796744|NCT00812253|DRUG|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
214796745|NCT04289545|DIETARY_SUPPLEMENT|Functional bread|Postprandial effects of bread containing galactomannan
214796746|NCT02035709|DRUG|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
214796747|NCT05176977|BEHAVIORAL|Peer Support-Whole Health Coaching|Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
214796748|NCT02382666|DRUG|Rolapitant|
214796749|NCT01365429|DEVICE|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
214796750|NCT04613830|DRUG|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
214647007|NCT06915532|PROCEDURE|conventional rehabilitation|"Conventional reeducation focused the first week on analgesic approach including:~* Education and lifestyle: Emphasizing weight management, autonomy in chronic low back pain management, and encouragement of physical activity.~* Massage and electrotherapy: To alleviate pain, enhance circulation, and relax muscles.~* Pelvic and lumbar movement awareness: Exercises focused on improving the control of pelvic movements.~* Breathing exercises: Breathing techniques to reduce tension and improve awareness.~Then in week 2 and beyond, physiotherapist continued analgesic work and physical training:~* Joint mobility and muscle flexibility: Exercises target mobility improvement, muscle strengthening, and stretching, with emphasis on posture control and lumbar mobility.~* Muscle strengthening: Focused on abdominal and spinal muscles, promoting spinal stability and improving trunk control.~* Proprioceptive rehabilitation: Enhancing lumbar-pelvic vigilance to stabilize the spine and prevent further ve"
214647008|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
214647009|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
214647010|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
214647011|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
214647012|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
214647013|NCT02115230|PROCEDURE|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
214647014|NCT06909435|OTHER|PEEK dental bar|"the master stone cast is scanned with external desktop scanner to produce an STL (Standard Tesellation Language) file for a virtual model using the CAD/CAM software (Medit 500i.). The design of the multiunit abutment and bar (Rhein Bar )was selected from the library of the CAD software. The bar dimensions were selected according to the study bar design .~After the data acquisition, the STL file was imported to the CAM part of the CAD/CAM system to mill PEEK bar from biological high-performance polymer (Bio-HPP) (BreCAM. BioHPP, Bredent GmbH \& Co.KG, Senden, Germany) block PEEK type. Multi-unit abutments were screwed to the implants and the PEEK bar was screwed to the abutments ."
214647015|NCT06909435|OTHER|Metal bar attachment|Co-Cr metal bar group, in the master cast , the multiunit abutment were attached to the implant analogues and plastic abutments were adjusted , prepared and then wax pattern coping was customized on each abutment and was connected to a preformed castable bar 2.4mm Height, (Rhein 83) The bar was placed to be away from the anterior ridge by about 2-3 mm for proper hygiene measures. The wax pattern was then sprued and casted into cobalt- chromium alloy.
214647016|NCT06912217|DEVICE|robotic rehabilitation|It is planned to provide a robotic rehabilitation program for patients in the robotic group, in addition to conventional rehabilitation for 4 weeks, with 30 minutes, 3 days a week, focusing only on their dominant upper extremities.
214647017|NCT06912217|DEVICE|Functional Electrical Stimulation|In the FES group, an upper extremity FES bicycle program (ADI) will be applied to the dominant upper extremity and hand, three days a week for 4 weeks.
214647018|NCT06912217|OTHER|occupational therapy|In the occupational therapy group, patients will receive the planned treatment in addition to conventional rehabilitation for 4 weeks, three days a week, for 30 minutes.
214647019|NCT00874211|PROCEDURE|assessment of therapy complications|By dental and medical assessments.
214647020|NCT03883516|OTHER|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
214647021|NCT03883516|OTHER|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
214647022|NCT03883516|OTHER|No Pre-briefing|no instruction of the study participants prior to the simulation training
214647023|NCT06912074|DRUG|Induction chemoimmunotherapy|All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.
214647024|NCT06912074|RADIATION|Hypofractionated Radiation Therapy|"All patients will receive hypofractionated radiotherapy once daily, five days per week, followed by a boost. Three weeks after the completion of the first phase of hypofractionated radiotherapy, tumor response and cardiopulmonary function will be evaluated. For patients who achieve a partial response, have no deep esophageal ulcers on endoscopy, and have cardiopulmonary function tolerating the radiotherapy boost, a second phase of radiotherapy will be planned using a new CT simulation and radiotherapy design.~First Phase of Radiotherapy: Total dose of 2500 cGy in 5 fractions (500 cGy per fraction) Second Phase of Radiotherapy: Total dose of 2500 cGy in 10 fractions (250 cGy per fraction) The interval between the two phases of radiotherapy will be 28 days."
214647025|NCT06912074|RADIATION|Conventional Fractionated Radiation Therapy|Patients will receive a total dose of 5000 cGy in 25 fractions, with 200 cGy per fraction.
214647026|NCT06912074|DRUG|Concurrent Chemotherapy|Capecitabine oral administration, 1000 mg/m², twice daily
214647027|NCT06910644|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of 0.5 μg/kg/h.
214647028|NCT06910644|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5mg/kg/h.
214647029|NCT06910644|DRUG|Isotonic saline|Patients will receive intravenous isotonic saline 0.9% in the same volume and manner as the study drugs.
214647030|NCT01218607|DRUG|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
214647031|NCT01218607|DRUG|Placebo|Placebo will be taken twice daily for 16 weeks
214647032|NCT06913712|OTHER|Weight loss without pharmacotherapy|The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.
214647033|NCT06913959|DIAGNOSTIC_TEST|Prospective|Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research
214647034|NCT06917573|DRUG|Cemiplimab|"Patients will receive Cemiplimab administered by IV infusion over 30 minutes every 28 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a high affinity hinge-stabilized IgG4P human antibody to the PD-1receptor (PDCD1, CD279) that blocks PD 1/PD L1 mediated T cell inhibition. Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.~Route of administration: Intravenous infusion."
214647035|NCT06917573|DRUG|Carboplatin|"Patients will receive Carboplatin administered by IV infusion for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin.~Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion."
214647036|NCT06917573|DRUG|Paclitaxel|"Patients will receive Paclitaxel administered by IV infusion for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20- epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately).~The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
214647037|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation
214647038|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation of localized intermediate-risk prostate cancer
214647039|NCT06915428|BEHAVIORAL|Care coordination|"Research team members will serve as research assistants and will also function as perinatal care coordinators.~In the care coordination role, team members will provide emotional support, liaise with clinical staff, and execute regularly scheduled check-ins with each study participant. Team members also assist with helping participants with logistics, obtaining and remembering to take prescribed medications, and other similar related activities. Participants receive access to contact the research assistant / care coordinator by text, email, phone, or through the electronic medical record participant portal.~\- Per protocol, the research staff will meet in person with participants at least twice (visit 1, visit 2) during pregnancy and once postpartum (0-10 weeks after delivery, for most participants).~Research staff may also meet in person with participants prior to visit 1 for recruitment/enrollment purposes."
214647040|NCT06915428|BEHAVIORAL|Electronic massage|"Participant is given the option to receive a 15-minute electronic massage / relaxation session in clinic via (a) a specialized massage chair or (b) a massage pad that is placed on top of a standard recliner chair.~* the electronic massages provide gentle massages and are safe for most people to use throughout pregnancy.~* participants are always be in control of the massage experience and will be given instructions on how to stop the massage at any time.~* participants are advised to consult the primary obstetric provider before using the massage chair regarding any specific concerns or questions~* during the session, participants may view relaxation videos (from free, publicly available sites online).~  * participants may choose to sign up for massage(s) at any obstetric visit in the clinic between visit 1 and delivery."
214796751|NCT04613830|DRUG|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
214796752|NCT05822401|BEHAVIORAL|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
214796753|NCT05822401|BEHAVIORAL|Usual care (control)|Will continue their work as usual
214796754|NCT00280267|DRUG|Testosterone gel|
214796755|NCT04682041|DIETARY_SUPPLEMENT|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
214796756|NCT04682041|OTHER|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
214796757|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
214796758|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
214796759|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
214796760|NCT02531984|DRUG|Azithromycin|
214796761|NCT00095381|DRUG|forodesine hydrochloride (BCX-1777)|
214796762|NCT03082781|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
214796763|NCT03082781|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
214796764|NCT03651323|DEVICE|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
214796765|NCT00039611|DRUG|FOLFOX regimen|
214796766|NCT00039611|DRUG|fluorouracil|
214796767|NCT00039611|DRUG|leucovorin calcium|
214796768|NCT00039611|DRUG|oxaliplatin|
214796769|NCT01911494|BEHAVIORAL|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
214796770|NCT01911494|DEVICE|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
214796771|NCT01911494|DRUG|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
214796772|NCT01911494|DRUG|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
214796773|NCT01241968|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
214796774|NCT01241968|DEVICE|Placebo|Placebo
214796775|NCT06436196|DEVICE|Video Laryngoscope|Use of Video laryngoscope to secure airway
214796776|NCT06436196|DEVICE|Direct laryngoscope|Macintosh or Miller's laryngoscopes used to secure paediatric airways
214796777|NCT03679741|DEVICE|CONTROL Lens|Acuvue OASYS
214796778|NCT03679741|DEVICE|TEST Lens|senofilcon A
214796779|NCT01906541|GENETIC|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
214796780|NCT01117610|DRUG|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
214796781|NCT01117610|DRUG|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
214796782|NCT03935269|DEVICE|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
214796783|NCT03935269|PROCEDURE|Stress management therapy|Undergo Cereset research office intervention
214796784|NCT03935269|OTHER|Questionnaire administration|Ancillary studies
214796785|NCT03935269|OTHER|Quality of Life Assessment|Ancillary studies
214796786|NCT05380635|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
214796787|NCT03711409|OTHER|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
214796788|NCT03711409|OTHER|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
214796789|NCT00726700|BIOLOGICAL|pegfilgrastim|Given subcutaneously
214796790|NCT00726700|BIOLOGICAL|rituximab|Given IV
214796791|NCT00726700|DRUG|cyclophosphamide|Given IV
214796792|NCT00726700|DRUG|doxorubicin hydrochloride|Given IV
214796793|NCT00726700|DRUG|prednisone|Given orally
214796794|NCT00726700|DRUG|vincristine sulfate|Given IV
214796795|NCT04834245|PROCEDURE|Hydrogel/nano silver-based dressing|compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
214796796|NCT06496763|DEVICE|Vision-700|OCT machines used for diagnostic purposes
214796797|NCT01774474|DRUG|Bromfenac|
214796798|NCT01774474|DRUG|Dexamethasone|
214796799|NCT01774474|DRUG|Bevacizumab|
214796800|NCT01774474|DRUG|Triamcinolone Acetonide|
214796801|NCT00719966|DRUG|anastrozole|Patients receive aromatase inhibition therapy.
214796802|NCT00719966|DRUG|exemestane|Patients receive aromatase inhibition therapy.
214796803|NCT00719966|DRUG|letrozole|Patients receive aromatase inhibition therapy.
214796804|NCT00719966|PROCEDURE|assessment of therapy complications|Endothelial function is measured
214796805|NCT05994222|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
214796806|NCT01263158|OTHER|Expectancy of standard oxytocin treatment|
215031072|NCT06376955|OTHER|High intensity interval exercise|HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.
214796807|NCT01390363|OTHER|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
214796808|NCT01390363|OTHER|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
214796809|NCT00012714|BEHAVIORAL|Case management services|
214796810|NCT00904020|DRUG|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
214796811|NCT03627936|DRUG|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
214796812|NCT03627936|DRUG|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
214796813|NCT02030184|DRUG|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
214796814|NCT00231868|DRUG|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
214796815|NCT00231868|PROCEDURE|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
214796816|NCT00231868|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
214796817|NCT02863302|OTHER|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
214796818|NCT00346086|DRUG|AIC (Amb a 1 Immunostimulatory Conjugate)|
214796819|NCT05253560|DIAGNOSTIC_TEST|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
214796820|NCT04981899|DRUG|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
214796821|NCT04981899|DRUG|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
214796822|NCT04981899|DRUG|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
214796823|NCT04981899|DRUG|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
214796824|NCT02627742|DEVICE|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
214796825|NCT03988270|OTHER|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
214796826|NCT05412407|OTHER|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
214796827|NCT00747188|BEHAVIORAL|PBL|
214796828|NCT05102279|DIETARY_SUPPLEMENT|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
214796829|NCT01261078|DRUG|Placebo|intrathecal 8 mg of bupivacaine only
214796830|NCT01261078|DRUG|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
214796831|NCT01261078|DRUG|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
214796832|NCT01261078|DRUG|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
214796833|NCT01261078|DRUG|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
214796834|NCT01645306|DRUG|Revacept|single intravenous injection
214796835|NCT01645306|DRUG|Placebo|single intravenous injection
214796836|NCT02584140|BEHAVIORAL|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
214796837|NCT02584140|BEHAVIORAL|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
214796838|NCT02584140|DRUG|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
215031073|NCT06376955|OTHER|Focused ultrasound|Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
215031074|NCT00856557|BEHAVIORAL|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
215031075|NCT00239915|DRUG|Pagoclone|
215031076|NCT06101420|DRUG|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
214796839|NCT05241236|DEVICE|Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer|Subjects diagnosed by a transperineal fusion or random transperineal or random transrectal prostate biopsy. Laser treatment plan generated by biopsy results +/- MRI is uploaded into the device. In procedure suite, a transperineal anesthetic block is conducted following by Bianco - USPTO PCT/US18/24404. On lithotomy a transrectal ultrasound probe is advanced, the prostate scanned. The images are acquired by fusion device. Co-registration is performed by surgeon delimiting boundaries of prostate. Medical device delivers real-time fusion guidance outlining prostate contours, ablation goals and laser introduce location. Surgeon executes plan or adjust as needed. Surgeon activates laser device, performs ablation monitored by medical device in real-time. The fusion device will deliver great perspective between the ablation areas and critical anatomical landmarks such as: NVB, membranous urethra, etc. Patient is dismissed to the recovery room and discharged afterwards
214796840|NCT05180006|DRUG|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
214796841|NCT05180006|DRUG|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
214796842|NCT05180006|DRUG|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
214796843|NCT05180006|DRUG|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
214796844|NCT04259177|OTHER|Scale|This test is divided into 3 sections: neurological examination, developmental motor boundary stones and behavioral status, and consists of a total of 37 items. The first part consists of 26 items such as cranial nerve functions, posture, quality, amount of movements, muscle tone, reflex and reactions. The second part evaluates motor development boundary stones consisting of 8 items. The third part refers to the behavioral condition consisting of 3 items. These items can be easily scored. It can be rated as optimal or inadequate. Each item is scored separately (as 0, 1, 2, 3) and the final total score is calculated. The total score ranges from 0-78. The total score shows the global optimal scores.
214796845|NCT02204371|DRUG|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
214796846|NCT02204371|DRUG|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
214796847|NCT00425815|DRUG|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
214796848|NCT00425815|OTHER|Placebo|Placebo comparison
214796849|NCT03097042|PROCEDURE|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
214796850|NCT03097042|PROCEDURE|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
214796851|NCT05150509|DIAGNOSTIC_TEST|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
214796852|NCT03972566|DRUG|INOMAX|INOMAX + PBM
214796853|NCT04351009|PROCEDURE|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
214796854|NCT04581005|BEHAVIORAL|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
214796855|NCT03196999|BEHAVIORAL|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
214796856|NCT03196999|BEHAVIORAL|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
214796857|NCT03196999|BEHAVIORAL|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
214796858|NCT05638503|OTHER|Left ventricular hypertrophy|Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
214796859|NCT05638503|OTHER|Left ventricular non-hypertrophy|Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
214796860|NCT00120900|DRUG|GW406381|
214796861|NCT01093209|DEVICE|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
214796862|NCT03706989|PROCEDURE|EEG|EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
214796863|NCT03706989|GENETIC|Apolipoprotein genotype|APOE genotyping will be performed for each patient
214796864|NCT03706989|BIOLOGICAL|Serum NfL measurements|5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
214796865|NCT03706989|OTHER|Preoperative neurocognitive evaluation|Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
214796866|NCT01159548|DRUG|Promethazine|
214796867|NCT01159548|DRUG|Promethazine|
214796868|NCT00906425|DEVICE|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
214796869|NCT02339766|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
214796870|NCT02339766|PROCEDURE|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
214796871|NCT02339766|DRUG|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
214796872|NCT02339766|DRUG|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
215031560|NCT03255395|DEVICE|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
215031561|NCT02397720|DRUG|Azacitidine|Given SC or IV
215031562|NCT02397720|DRUG|Ipilimumab|
214647041|NCT06915428|BEHAVIORAL|support gift #1|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 14+0 and 23+6 weeks gestation at time of routine prenatal appointment"
214647042|NCT06915428|BEHAVIORAL|Support gift #2|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 18+0 and 27+6 weeks gestation at time of routine prenatal appointment"
214647043|NCT06915428|BEHAVIORAL|Support gift #3|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 22+0 and 29+6 weeks gestation at time of routine prenatal appointment"
214647044|NCT06915428|BEHAVIORAL|Support gift #4|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 26+0 and 33+6 weeks gestation at time of routine prenatal appointment"
214647045|NCT06915428|BEHAVIORAL|Additional PTBCARE+ support|"Additional benefits / support items and support elements are provided to some participants on an as needed basis, per study protocol.~* Information / details intentionally withheld and not made public in order to preserve the scientific validity of the study and protect the rights of the research participants~* participant eligibility for additional resources as a part of the PTBCARE+ program will be determined by the research staff on the day of Visit 1 after initial set of surveys are completed, and is per protocol"
214647046|NCT06915428|BEHAVIORAL|Stress reduction toolkit - Visit 1 (V1)|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include:~Tote bag with the following stress reduction items or similar:~* eye mask~* set of pocket index cards, printed back and front, on a variety of topics that influence pregnancy health, ranging from physical to emotional/mental~* water bottles~* small notebook~* pill minder case~* magnet and business card for Health Resources and Services Administration (HRSA) national maternal mental health hotline~* log in codes for electronic resources~* initial handouts with self care plan, introduction to stress reduction toolkit, etc."
214647047|NCT06915428|BEHAVIORAL|PTBCARE+ mobile application (app) and website|"Comprehensive, study-specific app that is available as a website or as a downloadable application that includes personalized, interactive modules and resources~* no study related materials are available without a password~* goal is to collate reputable sources of information to make investigating things online easier~* includes optional educational modules for participants~* also includes option of entering stress, well-being, blood sugar, blood pressure, etc. values with option to easily download recorded values for patient's clinical team~* available online (computer/laptop), tablet, or smart phone. can be downloaded as a progressive web application (PWA) to a local device and used without internet access~* Electronic access to the PTBCARE+ website will continue through 10 weeks postpartum unless the participant delivered \<16+0 weeks gestation in which case access will continue through 4 weeks postpartum"
214647048|NCT06915428|BEHAVIORAL|Sleep, meditation, and Wellness app|"* complimentary one-year subscription to Aura - an 'all-in-one' wellbeing app that contains an enormous library of meditations, stories, breath work, work wellness, music, sounds, and more!~* Participants can access this app as needed throughout pregnancy and beyond, for up to one year after the date of enrollment"
214647049|NCT06915428|BEHAVIORAL|Emergency low blood sugar kit|"Pouch contains:~* printed index card with information about signs and symptoms of low blood sugar~* printed index card with information about what to do if blood sugar is low~* 2-3 non-perishable, individually wrapped over the counter candy / glucose-raising options; use for low blood sugar treatment is described on the card~Only participants who have a diagnosis of diabetes mellitus or glucose intolerance AND have been prescribed an oral medication for blood sugar control or have been prescribed insulin are eligible to receive this.~Each participant can receive a maximum of two kits during pregnancy; first at enrollment, and the other at visit 2 or until delivery"
214796873|NCT05559996|DEVICE|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
214796874|NCT00725439|DRUG|Talarozole|Oral Dose 1.0 mg once daily
214796875|NCT06078163|OTHER|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
214796876|NCT06078163|OTHER|rehabilitation|rehabilitation protocol lasting 20 sessions.
214796877|NCT00325533|BEHAVIORAL|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
214796878|NCT00325533|OTHER|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
214796879|NCT04602104|BIOLOGICAL|low dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
214796880|NCT04602104|BIOLOGICAL|medium dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
214796881|NCT04602104|BIOLOGICAL|high dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
214796882|NCT04602104|BIOLOGICAL|Dosage 1of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
214796883|NCT04602104|BIOLOGICAL|Dosage 2 of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
215031563|NCT02397720|DRUG|Venetoclax|Given Orally
215031564|NCT02397720|DRUG|Nivolumab|Given IV
214796884|NCT04602104|BIOLOGICAL|No hMSC-derived exosomes|basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
214796885|NCT03855475|BEHAVIORAL|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
214796886|NCT03855475|BEHAVIORAL|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
214796887|NCT04682275|OTHER|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
214796888|NCT00368966|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
214796889|NCT00368966|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|
214796890|NCT02866175|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
214796891|NCT02866175|DRUG|Clopidogrel|Clopidogrel 75 mg once-daily
214796892|NCT02866175|DRUG|Prasugrel|prasugrel 5mg or 10 mg once-daily
214796893|NCT02866175|DRUG|Ticagrelor|ticagrelor 90 mg twice-daily
214796894|NCT02866175|DRUG|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
214796895|NCT06460714|OTHER|Shock wave therapy, stretching and orthosis|Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
214796896|NCT06460714|OTHER|Stretching, strengthening and orthosis|In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
214796897|NCT00004096|DRUG|carboplatin|
214796898|NCT00004096|DRUG|vinorelbine ditartrate|
214796899|NCT01694485|BIOLOGICAL|Abrilumab|Administered by subcutaneous injection.
214796900|NCT01694485|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
214796901|NCT01595009|DRUG|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
214796902|NCT05608356|BIOLOGICAL|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
214796903|NCT05608356|DRUG|Sham Injection|Sham injection as a placebo injection
214796904|NCT03987152|DRUG|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
214796905|NCT03486977|PROCEDURE|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
214796906|NCT00506909|DRUG|Oxytocin|20 IU BID or 40 IU BID
214796907|NCT00506909|DRUG|Placebo|20 IU BID or 40 IU BID
214796908|NCT03129269|PROCEDURE|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
214796909|NCT02724683|DEVICE|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
214796910|NCT02724683|BEHAVIORAL|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
214796911|NCT02724683|BEHAVIORAL|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
214796912|NCT02724683|DEVICE|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
214796913|NCT02724683|OTHER|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
214796914|NCT00436358|OTHER|Not applicable: none|Please refer to the detailed description section
214796915|NCT00662025|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
214796916|NCT00662025|DRUG|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
214796917|NCT01919632|BEHAVIORAL|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
214796918|NCT00029679|DRUG|Gingko biloba|
214796919|NCT00029679|DRUG|Borage oil|
214796920|NCT00528242|DRUG|SLx-2101|
214796921|NCT00528242|DRUG|Placebo|
214796922|NCT00000391|DRUG|Peptide T|
214796923|NCT02010762|DRUG|Vitamin D|25.000 IU oral drops
214796924|NCT02010762|DRUG|Placebo|placebo oral drops
214796925|NCT05400876|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
214796926|NCT05400876|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
214796927|NCT04631770|PROCEDURE|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
214796928|NCT04631770|PROCEDURE|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
214796929|NCT01165671|RADIATION|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
214796930|NCT01165671|RADIATION|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
214796931|NCT03179345|DRUG|Gabapentin|
214796932|NCT03179345|DRUG|Pregabalin|
214796933|NCT03179345|OTHER|Placebo|
214796934|NCT05521750|PROCEDURE|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
214796935|NCT02925065|OTHER|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
214796936|NCT05575414|BEHAVIORAL|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
214796937|NCT05575414|BEHAVIORAL|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
214796938|NCT00820625|PROCEDURE|pulmonary vein isolation|common pulmonary vein isolation procedure
214796939|NCT00820625|PROCEDURE|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
214796940|NCT00095290|DRUG|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
214796941|NCT00095290|DRUG|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
214796942|NCT04873674|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
214796943|NCT04873674|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
214796944|NCT03824522|BIOLOGICAL|ADYNOVATE|Pegylated recombinant human factor VIII
214796945|NCT02623790|OTHER|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
214796946|NCT02623790|OTHER|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
214796947|NCT02623790|OTHER|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
214796948|NCT06449079|OTHER|Machine learning|Analysis of data with machine learning methods
214796949|NCT02300025|DRUG|cobimetinib|single oral 10-mg dose of cobimetinib
214796950|NCT05921058|DRUG|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
214796951|NCT05921058|DRUG|Placebo|NaCl 0,9% infusion
214796952|NCT00626925|DRUG|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
214796953|NCT00626925|DRUG|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
214796954|NCT01000740|GENETIC|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
214796955|NCT01000740|GENETIC|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
215031565|NCT07006883|OTHER|Therapeutic exercise|Therapeutic exercise focused on muscle strengthening, balance, and functional performance.
214647050|NCT06915428|BEHAVIORAL|Low dose aspirin (LDA)|"* Bottle of 90-100 pills (depending on manufacturer)~* Provided at Visit 1 (after randomization)~* Patients who received a bottle of low-dose aspirin at Visit 1 are offered a 2nd bottle at Visit 2.~All patients whose provider recommends or prescribes either 81mg or 162mg of LDA during pregnancy are offered LDA as described herein. LDA must be on the patient's med list or specific notes from the patient's prenatal provider must explicitly note that it is recommended the patient take LDA in pregnancy for it to be offered. Individuals who are receiving LDA due to participation in another study are not eligible to receive LDA from PTBCARE+~Please note that this is listed as a behavioral intervention rather than drug intervention because the rational behind providing this over the counter medication is to help make the participant's life easier, and the focus is not on the efficacy of LDA. As such, it is being provided as a behavioral intervention."
214647051|NCT06915428|BEHAVIORAL|Visit #2 Stress Reduction Toolkit|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include the following stress reduction items or similar:~1. Frame + ultrasound photo + certificate of achievement!~   * Picture from anatomy ultrasound (or other subsequent ultrasound) is downloaded, printed, and placed in frame.~  * Certificate of achievement is printed and placed on other side of frame with ultrasound photo~2. other small items including stickers, printed index cards with supportive messaging, etc."
214647052|NCT06916182|OTHER|MRI sequence|This sequence is a 2D spin-echo sequence for the generation of synthetic maps
214657035|NCT00596544|BEHAVIORAL|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
214657036|NCT00596544|BEHAVIORAL|questionnaires|Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
214657037|NCT04007614|OTHER|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
214657038|NCT00021294|DRUG|eflornithine|
214657039|NCT00021294|DRUG|triamcinolone|
214657040|NCT05137938|DRUG|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
214657041|NCT02760628|BEHAVIORAL|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
214657042|NCT02760628|BEHAVIORAL|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
214657043|NCT03152292|OTHER|Real-world, non-interventional|N/A - non-interventional
214657044|NCT05329116|DRUG|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
214657045|NCT05329116|BIOLOGICAL|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
214657046|NCT01549990|DRUG|Sevoflurane|maintenance of general anesthesia with sevoflurane
214657047|NCT01549990|DRUG|desflurane|maintenance of general anesthesia with desflurane
214657048|NCT00267735|BEHAVIORAL|Use of Computerized Decision Aid on Childbirth|
214657049|NCT03058484|BEHAVIORAL|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
214657050|NCT02594501|DEVICE|COBRA PzF|
214657051|NCT02594501|DEVICE|Drug Eluting Stent|
214657052|NCT03205579|OTHER|Video group|Using video for educate cancer pain patients
214657053|NCT03205579|OTHER|conventional group|Face to face cancer pain education by trained nurse
214657054|NCT03723447|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
214796956|NCT01606566|DRUG|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
214796957|NCT00780026|DRUG|insulin|bolus or infusion 80 to 110 mg/dl
214796958|NCT01142843|DRUG|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
214796959|NCT02320357|DRUG|Treatment by clopidogrel|Peripheral blood will be obtained during the study
214796960|NCT05067257|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
214796961|NCT05067257|DRUG|Placebo|Vehicle solution
214796962|NCT00897897|DEVICE|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
214796963|NCT04665076|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
214796964|NCT04665076|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
214796965|NCT04665076|PROCEDURE|Leukapheresis|Leukapheresis
214796966|NCT00102362|BEHAVIORAL|Behavior Therapy|
214796967|NCT01696591|BIOLOGICAL|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
214796968|NCT01076803|DRUG|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
214796969|NCT02959775|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
214796970|NCT02959775|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
214796971|NCT01215942|DRUG|LY2127399|Administered Subcutaneously
214796972|NCT01966042|PROCEDURE|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
214796973|NCT01966042|PROCEDURE|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
214796974|NCT01966042|PROCEDURE|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
214796975|NCT01966042|BIOLOGICAL|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
214796976|NCT02678910|PROCEDURE|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
214796977|NCT02625831|OTHER|Biological analysis|"Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies"
214796978|NCT01220349|DEVICE|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
214796979|NCT03960320|OTHER|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
214796980|NCT03522948|BEHAVIORAL|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
214796981|NCT01798069|BEHAVIORAL|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
214796982|NCT01798069|BEHAVIORAL|reading medical publication workshops|
214796983|NCT00930865|DRUG|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
214796984|NCT00930865|DRUG|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
214796985|NCT03866850|BEHAVIORAL|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
214796986|NCT03305055|DRUG|ketamine|Information included in arm descriptions
214796987|NCT03305055|DRUG|Fentanyl|Information included in arm descriptions
214796988|NCT04181450|OTHER|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., \& Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
214796989|NCT03198013|DRUG|Prednisolone|Specified dose on specified days
214796990|NCT03198013|DRUG|BMS-791826|Specified dose on specified days
214796991|NCT03198013|DRUG|Placebo|Specified dose on specified days
214647053|NCT06917300|DEVICE|Virtual Reality|The VR group will be exposed to a unified 15-minute VR video via phone using a VR device and goggles after receiving routine standard care. A 360˚ video with an immersive audio-visual environment describing pre-operative and post-operative experience on the day of the surgery will be provided, by which they can get accustomed to the environment and procedures associated with the surgery. Background audio will be provided through headsets, and the video will be directed by a neurosurgeon filmed using a Max 360 action VR camera. In the video, actors, neurosurgeons, and nurses will re-enact a typical day for a mock patient undergoing surgery, plus routine post-operative care, including the post-operative immediate recovery room and rehabilitation care by neurosurgeons, psychologists, and physiotherapists in the ward. Patients are allowed to move around freely so that they can experience all aspects of the virtual space, and are encouraged to ask questions at the end.
214647054|NCT06916026|PROCEDURE|Xenograft|Gap distance grafting using xenograft
214647055|NCT06916026|PROCEDURE|Xenograft mixed with HAM gel.|Gap distance grafting using xenograft mixed with HAM gel.
214647056|NCT06916247|BEHAVIORAL|Complex care management program|Intensive outpatient care management program that includes contact from nurses and case managers to help coordinate care, detect clinical red flags, and reduce overall unplanned acute care utilization.
214647057|NCT06917105|DRUG|CD33/CD123/CLL-1 CAR-T Cells|"Part A: Dose Escalation Phase. Follows a 3+3 dose escalation design with four predefined dose cohorts: 0.2×10⁶, 0.5×10⁶, 1×10⁶, and 2×10⁶ CAR-positive cells/kg.Anticipated enrollment: 12-24 subjects.Primary objectives: Assess safety, tolerability, and determine MTD.Dose-limiting toxicity (DLT) observation period: 28 days post-infusion.~Part B: Dose Expansion Phase.Enrolls 21 additional subjects to receive CAR-T cell infusion at the recommended Phase 2 dose (RP2D) established in Part A.Primary objective: Further evaluate therapeutic efficacy."
214647058|NCT06915688|DRUG|Doxycycline|Doxycycline will be given to COPD group 1
214647059|NCT06915688|DRUG|Levofloxacin|Levofloxacin given to copd patients
214647060|NCT06916962|BEHAVIORAL|Intervention|"Intervention participants will receive cash transfers on the condition of their participation in peer-led TB support meetings (TB Clubs).~Two monthly TB Club meetings will be held in each participating district. Each will aim to provide enhanced education about the TB treatment process, as well as to improve treatment engagement and adherence, foster social support and mitigate TB-related stigma.~Participants will be eligible for a maximum of three cash transfers, amounting to a total of 3,000,000 VND. The first payment of 1,000,000 VND will be made after a participant joins one TB Club, the second payment will be completed after attending a second TB Club, and the third payment will be provided after attendance at their 6th TB Club."
214647061|NCT06915792|DRUG|Labetalol|Labetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg/day as needed for blood pressure control.
214647062|NCT06915792|DRUG|Nifedipine|Nifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg/day as needed for blood pressure control.
214647063|NCT06916260|DEVICE|Red Light (PDT)|The intervention is a non invasive and safe practice. By delivering low level wavelength red light to the front part of the head, it can increase blood flow in the area treated and improve functioning of the associated regions, potentially improving symptoms.
214647064|NCT06916260|DEVICE|Placebo|The intervention is a non invasive and safe practice. Participants will be wearing a helmet that delivered low level light therapy to the brain, and use it for the same amount of time as the treatment group. These participants will however, not receive the actual light and receive a placebo, so the helmet will be off. This is done to control of any potential positive effects of the therapy.
214647065|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for two cycles (days1-4, and days 11-14).
214647066|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for three cycles (days1-4, days 11-14, and days 21-24).
214647067|NCT06915519|DIAGNOSTIC_TEST|measure motor strength and perfusion index|measurements of the motor strength and perfusion index in the blocked hand to predict the successfulness of the supraclavicular block at 0, 5, 10 and 15 min post blockage.
214657055|NCT03723447|DRUG|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
214657056|NCT02000609|DRUG|CHF 1535 NEXThaler 800/48|
214657057|NCT02000609|DRUG|CHF 1535 NEXThaler 200/12|
214657058|NCT02000609|DRUG|CHF 1535 NEXThaler PLACEBO|
214796992|NCT01802879|DRUG|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
214647068|NCT06917417|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
214647069|NCT06917274|DIETARY_SUPPLEMENT|Banana|A banana is consumed pre-exercise in order to prevent hypoglycemia
214647070|NCT06917274|OTHER|No banana|No banana is consumed pre-exercise
214647071|NCT06915103|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A pelvic MRI with and without contrast was performed for evaluation of the ovary.
214647072|NCT06915103|PROCEDURE|Salpingo-oophorectomy|Salpingo-oophorectomy procedure was performed on the left ovary.
214796993|NCT04845061|DRUG|Nebivolol Tablets|cardio selective beta-1 blocker
214796994|NCT05572411|OTHER|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
214796995|NCT02829671|OTHER|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
214647073|NCT06915623|DRUG|Innovative Gel application|Innovative gel application: Gel is applied as an adjunct treatment to cleaning and scaling.
214647074|NCT06915623|PROCEDURE|Mechanical Debridement|Cleaning and scaling of the implant.
214647075|NCT06917053|DEVICE|Ultrasound (including contrast enhanced ultrasound)|Ultrasound measures: contrast enhanced ultrasound (CEUS) of the kidney, venous excess ultrasound (VExUS), echocardiography
214647076|NCT06917053|DEVICE|Sublingual incident dark field videomicroscopy|Sublingual incident dark field (IDF) videomicroscopy
214796996|NCT04384172|DEVICE|Tibial e-stim|For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
214796997|NCT04384172|DEVICE|Genital e-stim|For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
214796998|NCT01105650|DRUG|Fludarabine|Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
214796999|NCT01105650|DRUG|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
214647077|NCT06917053|DEVICE|Urinary oxygen tension.|Continuous urinary oxygen tension
214647078|NCT04971005|DRUG|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
214647079|NCT04971005|DRUG|Ocrelizumab|600 mg every 6 months continuously
214647080|NCT04971005|DRUG|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
214647081|NCT06917092|DRUG|QL1706 combined with chemotherapy ± Bevacizumab|"* Drug: QL1706: 5 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first.~* Drug: Chemotherapy: physician's choice chemotherapy for 3-6 cycles.~* Drug: Bevacizumab (optional): 15 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first."
214647082|NCT00910156|DEVICE|Airtraq laryngoscope|Airtraq intubation
214647083|NCT00910156|DEVICE|Glidescope laryngoscope|glidescope intubation
214647084|NCT00910156|DEVICE|Macintosh laryngoscope|Macintosh intubation
214647085|NCT03641560|DRUG|Enzalutamide|Enzalutamide was administered orally
214647086|NCT03641560|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
214647087|NCT04704934|DRUG|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
214647088|NCT04704934|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
214647089|NCT04704934|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
214647090|NCT05142709|DRUG|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
214647091|NCT03371368|PROCEDURE|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
214647092|NCT03371368|PROCEDURE|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
214647093|NCT03371368|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
214647094|NCT05847686|OTHER|Counseling|Participate in therapy visits
214647095|NCT05847686|DRUG|Psilocybin|Given PO
214647096|NCT05847686|OTHER|Questionnaire Administration|Ancillary studies
214647097|NCT06353113|BEHAVIORAL|Down Dog Prenatal Yoga App|"The Down Dog prenatal yoga app launched in 2015 and was designed to align with the changes a pregnant body goes through in each trimester. Users can select a practice by trimester, which will offer modification cues to work with a changing body during pregnancy. Users can also customize their experience by boosting things like Heartburn or Pubic Symphysis so they can continue to practice yoga and omit poses that might be uncomfortable. The app also utilizes user feedback, to continuously implement new practices to better their app for user interface.~All of the prenatal yoga classes were created by a certified and experienced prenatal yoga instructor who has a 200hr yoga certification through Pure Yoga (New York), 80hr prenatal yoga certification through Prenatal Yoga Center (New Yoga), and is Trauma Informed Yoga certified through Exhale to Inhale (New York)."
214647098|NCT03494868|DIETARY_SUPPLEMENT|Carbohydrate Drink|2 - 12 oz drinks
214647099|NCT05947513|DRUG|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
214647100|NCT05947513|RADIATION|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
214647101|NCT05263076|OTHER|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
214657059|NCT02000609|DRUG|CHF 1535 pMDI 200/12|
214657060|NCT02000609|DRUG|CHF1535 pMDI 800/48|
214657061|NCT02862769|DRUG|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
214657062|NCT02862769|DRUG|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
214657063|NCT03733652|DRUG|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
214657064|NCT00864240|DRUG|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
214657065|NCT00691665|DRUG|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
214657066|NCT00691665|DRUG|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
214657067|NCT00533962|DRUG|Anterior Juxtascleral Depot of Anecortave Acetate|
214657068|NCT01492010|DIETARY_SUPPLEMENT|whey protein|25 g whey protein
214657069|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
214657070|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
214657071|NCT01865292|DRUG|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
214657072|NCT01865292|DRUG|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
214797000|NCT01105650|DRUG|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
214797001|NCT01105650|BIOLOGICAL|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.
214797002|NCT01105650|DRUG|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
214797003|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
214797004|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
214797005|NCT01105650|DRUG|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
214797006|NCT02180308|DEVICE|PET/MRI|Simultaneous PET/MRI (3T system)
214797007|NCT00263107|PROCEDURE|telerounding versus bedside rounding|
214797008|NCT00193778|PROCEDURE|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
214797009|NCT00193778|OTHER|No Loco-regional treatment|This group will not receive any loco-regional treatment
214797010|NCT01047345|BIOLOGICAL|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
214797011|NCT01047345|BIOLOGICAL|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
214797012|NCT01948505|DRUG|Intravenous acetaminophen|
214797013|NCT01948505|DRUG|Placebo for IV acetaminophen|
214797014|NCT02368847|DEVICE|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
214797015|NCT02368847|DEVICE|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
214797016|NCT00865553|BEHAVIORAL|computer-assisted smoking cessation intervention|
214797017|NCT00865553|OTHER|cancer prevention|
214797018|NCT00865553|OTHER|educational intervention|
214797019|NCT00865553|OTHER|survey administration|
214797020|NCT02520271|BEHAVIORAL|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
214797021|NCT02520271|BEHAVIORAL|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
214797022|NCT01601509|DRUG|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
215031077|NCT01432444|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
214797023|NCT01601509|DRUG|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
214797024|NCT03565809|OTHER|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
214797025|NCT02116803|DRUG|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
214797026|NCT02116803|DRUG|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
214797027|NCT04256265|DRUG|Risdiplam|Risdiplam will be administered orally once daily
214797028|NCT01060592|DEVICE|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
214797029|NCT00280436|DRUG|GW679769|
214797030|NCT05613699|BEHAVIORAL|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
214797031|NCT05613699|BEHAVIORAL|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
214797032|NCT05613699|BEHAVIORAL|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
214797033|NCT00322478|BEHAVIORAL|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
214797034|NCT00322478|BEHAVIORAL|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
214797035|NCT00322478|BEHAVIORAL|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
214797036|NCT03112057|DIAGNOSTIC_TEST|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
214797037|NCT01974895|BIOLOGICAL|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
214797038|NCT01974895|BIOLOGICAL|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
214797039|NCT02805803|OTHER|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
214797040|NCT04324008|DEVICE|Constic|Flowable resin composite
214797041|NCT04324008|DEVICE|G-ænial Universal Flo|Flowable resin composite
214797042|NCT04324008|DEVICE|Tetric N-Flow (self-etch)|Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
214797043|NCT04324008|DEVICE|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Tetric N-Bond Universal, etch\&rinse mode)
214797044|NCT02811809|DRUG|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
214797045|NCT02811809|DRUG|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
214797046|NCT01566071|OTHER|Assessment of drive abilities|
214797047|NCT01566318|BEHAVIORAL|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
214797048|NCT02779036|PROCEDURE|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
214797049|NCT02779036|PROCEDURE|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
214797050|NCT02217865|BEHAVIORAL|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
214797051|NCT02217865|BEHAVIORAL|Questionnaire|Questionnaire completion asking general health and demographic questions.
214797052|NCT02217865|BEHAVIORAL|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
214797053|NCT02217865|BEHAVIORAL|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
214797054|NCT00699504|DRUG|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
214797055|NCT00699504|DRUG|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
214797056|NCT00699504|DRUG|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
214797057|NCT00699504|DRUG|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
214797058|NCT00699504|DRUG|placebo|placebo IV and oral
214797059|NCT02763722|OTHER|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
214797061|NCT01072942|DRUG|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
214797062|NCT01072942|DRUG|Placebo|Placebo TID for 10 days
214797063|NCT00160212|DRUG|Daglutril|
214797064|NCT01984242|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
214797065|NCT01984242|DRUG|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
214797066|NCT01984242|DRUG|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
214797067|NCT05531409|BEHAVIORAL|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
214797068|NCT01357603|BIOLOGICAL|Glargine|dosage form: Subcutaneous injection
214797069|NCT01346852|DRUG|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
214797070|NCT02070185|BEHAVIORAL|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
214797071|NCT02070185|BEHAVIORAL|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
214797072|NCT02473211|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
214797073|NCT02473211|DRUG|Daclatasvir|Daclatasvir 60mg tablet administered once daily
214797074|NCT06346210|PROCEDURE|Tracheostomy|Surgery for tracheostomy
214797075|NCT04543136|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
214797076|NCT04543136|DEVICE|New intermittent Variant 1 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
214797077|NCT04543136|DEVICE|New intermittent Variant 2 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
214797078|NCT03806036|DRUG|Vitamin D|300.000 I.U single dose of VIT D IM injection
214657073|NCT03505268|BEHAVIORAL|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
214657074|NCT00006120|DRUG|docetaxel|
214657075|NCT00006120|DRUG|paclitaxel|
214657076|NCT05468970|OTHER|NO Intervention|NO Intervention
214657077|NCT05595525|DEVICE|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
214657078|NCT05595525|DEVICE|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
214657079|NCT03048630|BEHAVIORAL|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
214657080|NCT00476099|DRUG|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
214657081|NCT00476099|DRUG|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
214657082|NCT00476099|DRUG|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
214657083|NCT00152633|DRUG|Losartan|
214657084|NCT00152633|DRUG|Metoprolol|
214657085|NCT00152633|DRUG|Losartan|Treatment with Losartan
214657086|NCT05555004|OTHER|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
214657087|NCT05555004|OTHER|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
214657088|NCT04586491|COMBINATION_PRODUCT|Oral care protocol|Oral care protocol
214657089|NCT04417257|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
214657090|NCT04417257|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
214657091|NCT04453111|BIOLOGICAL|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
214657092|NCT04453111|BIOLOGICAL|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
214657093|NCT04453111|DRUG|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
214657094|NCT05379751|PROCEDURE|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
214657095|NCT05567523|DRUG|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
214657096|NCT05567523|DRUG|Normal saline|normal saline
214657097|NCT05567523|DRUG|Midazolam|midazolam
214657098|NCT05963503|OTHER|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
214657099|NCT05886361|OTHER|No intervention involved|No intervention involved
214657100|NCT02100384|PROCEDURE|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
214657101|NCT04421326|OTHER|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
214657102|NCT00003688|BIOLOGICAL|dactinomycin|
214657103|NCT01422330|DRUG|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
214657104|NCT00098787|BIOLOGICAL|bevacizumab|Given IV
214657105|NCT00098787|DRUG|fluorouracil|Given IV
214657106|NCT00098787|DRUG|irinotecan hydrochloride|Given IV
214657107|NCT00098787|DRUG|leucovorin calcium|Given IV
214657108|NCT00098787|DRUG|Oxaliplatin|Given IV
214657109|NCT04427254|DRUG|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
214657110|NCT03827161|DIETARY_SUPPLEMENT|Glucosamine|Given PO
214657111|NCT03827161|OTHER|Placebo|Given PO
214657112|NCT01834404|DRUG|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
214657113|NCT01834404|DRUG|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
214657114|NCT03501862|BEHAVIORAL|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
214657115|NCT03501862|BEHAVIORAL|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
214657116|NCT02203149|DRUG|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
214657117|NCT02203149|DRUG|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
214657118|NCT02203149|DRUG|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
214657119|NCT02203149|DRUG|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
214657120|NCT01360996|DRUG|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
214657121|NCT01766648|DEVICE|Far Cortical locking screw fixation|Standard screw fixation
214657122|NCT01766648|DEVICE|Standard screw fixation|
214657123|NCT04125537|BEHAVIORAL|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
214657124|NCT01454076|DRUG|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
214657125|NCT01454076|DRUG|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
214657126|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
214657127|NCT01454076|DRUG|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
214657128|NCT01454076|DRUG|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
214657129|NCT01454076|DRUG|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
214797079|NCT03806036|DRUG|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
214797080|NCT04433390|DRUG|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
214797081|NCT04433390|DRUG|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
214797082|NCT03820583|PROCEDURE|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
215031078|NCT02301897|DRUG|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
214657130|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
214657131|NCT05054855|BEHAVIORAL|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
214657132|NCT04964258|DRUG|TAK-105-a|TAK-105-a subcutaneous solution.
214657133|NCT04964258|DRUG|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
214657134|NCT01361256|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
215031079|NCT02301897|DRUG|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
215031080|NCT02675400|DRUG|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
214797083|NCT00585780|DRUG|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
214797084|NCT00585780|DRUG|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
214797085|NCT04079907|DIETARY_SUPPLEMENT|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
214797086|NCT04079907|DIETARY_SUPPLEMENT|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
214797087|NCT03465566|DIAGNOSTIC_TEST|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
214797088|NCT03050593|DIAGNOSTIC_TEST|MRI scan, Echo scan|
214797089|NCT05079009|DEVICE|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
214797090|NCT05137080|DRUG|Dexamethasone|24mg dexamethasone
214797091|NCT05137080|DRUG|Isotonic saline|Isotonic saline
214797092|NCT04844177|OTHER|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
214797093|NCT05710978|OTHER|Work Protocol|Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
214797094|NCT06355739|DEVICE|CAR T cell injection|intravenous injection
214797095|NCT04468256|OTHER|COVID-19 experience surveys|Serial online surveys recording experiences of the COVID-19 pandemic.
214797096|NCT03360201|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
214797097|NCT04648293|DEVICE|Starling|Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
214797098|NCT00151294|DRUG|escitalopram oxalate antidepressant|
214797099|NCT00947427|DRUG|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
214797100|NCT00947427|DRUG|Placebo|Placebo subcutaneous injections
214797101|NCT06452810|DIETARY_SUPPLEMENT|Experimental: Sahajan Golden Glow Balm|Participants will apply the Sahajan Golden Glow Balm twice daily (morning and night) to the periorbital area following the specified instructions.
214797102|NCT01372787|PROCEDURE|Assessment of Therapy Complications|Ancillary studies
214797103|NCT01372787|OTHER|Medical Chart Review|Ancillary studies
214657135|NCT01361256|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
214797104|NCT01372787|OTHER|Quality-of-Life Assessment|Ancillary studies
214797105|NCT01372787|OTHER|Questionnaire Administration|Ancillary studies
214797106|NCT04059666|OTHER|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
214797107|NCT04059666|OTHER|Control|Cow's milk-based Infant Formula
214797108|NCT02958657|OTHER|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
214797109|NCT00865709|DRUG|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
214797110|NCT00865709|DRUG|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
214797111|NCT00429923|DRUG|Difluprednate|
214797112|NCT00429923|DRUG|Difluprednate|
214797113|NCT00429923|DRUG|Placebo|
214797114|NCT00365261|DRUG|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
214797115|NCT00365261|DRUG|Placebo|placebo 2 to 3 mg po at bedtime
214797116|NCT05024461|DIAGNOSTIC_TEST|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~* Pre-analytical particularities and analytical particularities~* Cycle threeshold~* Demographic variables~* Clinical variables~* Clinical criteria~* Questionnaire on the perception of the 2 sampling methods"
214797117|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
214797118|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
214797119|NCT00697775|BIOLOGICAL|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
214797120|NCT04292106|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
214797121|NCT04292106|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
214797122|NCT00991198|DRUG|Topical oxygen|0.5% concentration of Topical oxygen
214797123|NCT00991198|DRUG|Topical oxygen|0.25% concentration topical oxygen
214797124|NCT00991198|DRUG|placebo|no O2
214797125|NCT01456611|DRUG|Diclofenac|Diclofenac Sodium Gel 1%
214797126|NCT01456611|DRUG|Placebo|Placebo Topical Gel
214797127|NCT01978678|DRUG|Pulmicort|ACQ and FeNO
214797128|NCT01041781|DRUG|carboplatin|Given IV
214797129|NCT01041781|DRUG|celecoxib|Given orally
214797130|NCT01041781|DRUG|gemcitabine hydrochloride|Given IV
214797131|NCT01041781|DRUG|pemetrexed disodium|Given IV
214797132|NCT01041781|OTHER|placebo|Given orally
214797133|NCT04516850|GENETIC|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
214797134|NCT04516850|GENETIC|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
214797135|NCT05237596|DRUG|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
214797136|NCT00257296|OTHER|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
214797137|NCT00257296|OTHER|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
214797138|NCT02276677|DRUG|Oxytocin|Single dose, intranasal
214797139|NCT02276677|DRUG|Placebo|Single dose, intranasal
214797140|NCT02204969|DIETARY_SUPPLEMENT|Lithia water|"* Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
215031081|NCT02675400|BEHAVIORAL|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
215031082|NCT02675400|DRUG|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
214797141|NCT02204969|DEVICE|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
214797142|NCT03025607|DEVICE|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
214797143|NCT01448083|OTHER|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
214797144|NCT02534779|OTHER|Placebo Vaginal Insert|Placebo insert
214797145|NCT00119613|DRUG|placebo|placebo
214797146|NCT00119613|DRUG|darbepoetin alfa|darbepoetin alfa
214797147|NCT04509609|OTHER|Exon 3 truncating mutation|Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
214797148|NCT04509609|OTHER|Any other mutation in SGBC gene|Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
214797149|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
214797150|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
214797151|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
214797152|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
214797153|NCT02133755|DRUG|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
214797154|NCT00896818|GENETIC|DNA analysis|
214797155|NCT00896818|GENETIC|genetic linkage analysis|
214797156|NCT00896818|GENETIC|loss of heterozygosity analysis|
214797157|NCT00896818|GENETIC|polymorphism analysis|
214797158|NCT00896818|OTHER|laboratory biomarker analysis|
214797159|NCT00896818|OTHER|medical chart review|
214797160|NCT00896818|OTHER|questionnaire administration|
214797161|NCT03158337|BEHAVIORAL|Aerobic exercise|
214797162|NCT02701075|DEVICE|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
214797163|NCT02701075|DEVICE|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
214797164|NCT00545558|DRUG|Efavirenz|600 mg tablet taken orally daily
214797165|NCT00545558|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
214797166|NCT02629874|DRUG|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
214797167|NCT02629874|DRUG|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
214797168|NCT02629874|DRUG|Placebo|
214797169|NCT02687009|DRUG|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
214797170|NCT03345316|DRUG|FFI-1010|Intravenous single dosing
214797171|NCT00662129|BIOLOGICAL|bevacizumab|
214797172|NCT00662129|DRUG|gemcitabine hydrochloride|
214797173|NCT00662129|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214797174|NCT03643419|PROCEDURE|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
214797175|NCT03643419|DEVICE|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
214797176|NCT02248077|DEVICE|AutoloGel|
214797177|NCT02248077|OTHER|Usual and Customary Care (UCC)|
215031083|NCT02179034|DRUG|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
215031084|NCT02179034|OTHER|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
215031085|NCT02179034|OTHER|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
215031086|NCT01347814|DRUG|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
215031087|NCT01347814|DRUG|Placebo|Homeopathic (Sugar) pill-Placebo
214797178|NCT05854758|OTHER|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
214797179|NCT05854758|OTHER|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
214797180|NCT04534647|DIAGNOSTIC_TEST|different serum and urine biomarkers|urine exosomes and serum biomarkers
214797181|NCT03325647|DRUG|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
214797182|NCT03325647|DRUG|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
214797183|NCT02520115|DRUG|Dexamethasone|Given PO
214797184|NCT02520115|OTHER|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
214797185|NCT02520115|DRUG|Valproic Acid|Given PO
214797186|NCT00880282|BIOLOGICAL|cixutumumab|Given IV
214797187|NCT00880282|DRUG|temsirolimus|Given IV
214797188|NCT00880282|OTHER|pharmacological study|Correlative studies
214797189|NCT00880282|OTHER|laboratory biomarker analysis|Correlative studies
214797190|NCT02494726|OTHER|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
214797191|NCT03348709|DIETARY_SUPPLEMENT|Isoosmolar|48 hours, 800 ml per 24 hours
214797192|NCT03348709|DIETARY_SUPPLEMENT|Hyperosmolar|48 hours, 800 ml per 24 hours
214797193|NCT01091025|OTHER|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
214797194|NCT02153736|BEHAVIORAL|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
214797195|NCT00767507|DRUG|cangrelor|
214797196|NCT00767507|OTHER|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
214797197|NCT02848703|DEVICE|Magnetic Resonance Imaging (MRI)|
214797198|NCT02848703|DEVICE|phosphorus-31 Magnetic Resonance Spectroscopy|
214797199|NCT02848703|DEVICE|sodium-23 MRI|
214797200|NCT05566093|PROCEDURE|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
214797201|NCT05566093|PROCEDURE|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
214657136|NCT01311778|DRUG|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
214657137|NCT01311778|DRUG|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
214657138|NCT00895063|BEHAVIORAL|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
214657139|NCT02836561|OTHER|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
214657140|NCT00817271|DRUG|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
214657141|NCT00817271|DRUG|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
214657142|NCT00211406|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
214657143|NCT03182530|DEVICE|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
214657144|NCT03182530|DEVICE|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
214657145|NCT03182530|DEVICE|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
214657146|NCT02190734|OTHER|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
214657147|NCT02190734|OTHER|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
214657148|NCT02190734|OTHER|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
214657149|NCT04077333|PROCEDURE|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
214657150|NCT01504503|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
214657151|NCT01504503|DRUG|Aricept|Aricept 10 mg Tablets
214657152|NCT01478958|DIETARY_SUPPLEMENT|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
214657153|NCT01478958|DIETARY_SUPPLEMENT|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
214657154|NCT01478958|DIETARY_SUPPLEMENT|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
214657155|NCT06351202|OTHER|Abdominal massage|An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
214657156|NCT01274221|DRUG|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
214657157|NCT01274221|OTHER|Placebo|1 capsule per day for one week of the double-blind crossover phase
214657158|NCT04003129|OTHER|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
214657159|NCT05213871|OTHER|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
214657160|NCT05213871|OTHER|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
214657161|NCT05213871|OTHER|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
214657162|NCT04352920|OTHER|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
214657163|NCT03603743|BEHAVIORAL|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
214657164|NCT06162455|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
214657165|NCT06162455|DRUG|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
214657166|NCT02646904|DRUG|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
214657167|NCT02646904|DRUG|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
214657168|NCT02290210|DRUG|URC102 0.25mg|
214657169|NCT02290210|DRUG|URC102 0.5mg|
214657170|NCT02290210|DRUG|URC102 1.0mg|
214657171|NCT02290210|DRUG|URC102 2.0mg|
214657172|NCT02290210|DRUG|placebo|
214657173|NCT04941326|OTHER|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
214657174|NCT04941326|OTHER|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
214657175|NCT04941326|OTHER|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
214657176|NCT04941326|OTHER|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
214657177|NCT04941326|OTHER|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
214657178|NCT02516930|BEHAVIORAL|crowdsourced video|video promoting condom use
214657179|NCT02516930|BEHAVIORAL|social marketing video|
214657180|NCT06016543|PROCEDURE|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
214797202|NCT04452578|PROCEDURE|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
214797203|NCT05638425|RADIATION|Radiotherapy combined with PD-1 inhibitors|Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
214797204|NCT03744260|DIAGNOSTIC_TEST|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
214797205|NCT04559295|BIOLOGICAL|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
214797206|NCT01097161|BEHAVIORAL|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
214797207|NCT03580343|DRUG|tofacitinib|tofacitinib extended release, 11mg, daily, oral
214797208|NCT05436158|OTHER|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
214797209|NCT04473079|DIETARY_SUPPLEMENT|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
214797210|NCT04473079|DIETARY_SUPPLEMENT|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
214797211|NCT02099461|DRUG|Denosumab|Single sucutaneous dose
214797212|NCT02099461|PROCEDURE|Percutaneous core needle breast biopsy|
214797213|NCT00663910|DRUG|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
214797214|NCT00663910|PROCEDURE|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
214797215|NCT00663910|PROCEDURE|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
214797216|NCT00663910|PROCEDURE|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
214797217|NCT03511352|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
215031088|NCT03283241|DEVICE|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
214797218|NCT03511352|BEHAVIORAL|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
214797219|NCT00809809|DRUG|Zicam (Ionic zinc)|33mmol/l of ionic zinc
214797220|NCT00809809|DRUG|placebo|placebo swab
214797221|NCT04253548|BEHAVIORAL|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
214797222|NCT02849925|DRUG|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
214797223|NCT01854788|OTHER|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
214797224|NCT01854788|OTHER|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
214797225|NCT01854788|OTHER|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
214797226|NCT03730324|DIAGNOSTIC_TEST|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
214797227|NCT03730324|DIAGNOSTIC_TEST|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
214797228|NCT03503357|OTHER|IFT Testing1|Command List A
214797229|NCT03503357|OTHER|IFT Testing 2|Command List B
214797230|NCT03503357|OTHER|IFT Testing 3|Command List C
214797231|NCT03503357|OTHER|IFT Testing 4|Command List D
214797232|NCT04712435|DRUG|N-acetylcysteine|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
214797233|NCT04712435|DRUG|Placebo|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
214797234|NCT01555619|DEVICE|CRT-D System|Implantation of a CRT-D System
214797235|NCT05612386|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
214797236|NCT01533168|GENETIC|cytogenetic analysis|
214797237|NCT01533168|GENETIC|nucleic acid sequencing|
214797238|NCT01533168|OTHER|diagnostic laboratory biomarker analysis|
214797239|NCT01533168|OTHER|laboratory biomarker analysis|
214797240|NCT01533168|OTHER|medical chart review|
214797241|NCT04906603|DEVICE|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
214797242|NCT05987046|BEHAVIORAL|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
214797243|NCT04317625|DIAGNOSTIC_TEST|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
214797244|NCT05912686|DRUG|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
214797245|NCT05912686|DRUG|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
214797246|NCT01123486|DRUG|hydromorphone|hydromorphone 0.02 mg/kg
214797247|NCT00720122|DRUG|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
214797248|NCT02202018|OTHER|Active KT intervention|"1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
214797249|NCT00907842|DEVICE|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
214797250|NCT04976959|DRUG|High Fiber supplement|The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
214797251|NCT03862599|DEVICE|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
214797252|NCT03862599|OTHER|Standard care|Cialis and vacuum pump
214797253|NCT05731154|OTHER|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
214797254|NCT01371578|DRUG|GS-5885 tablet|30 mg active tablet
214797255|NCT01371578|DRUG|GS-9451 tablet|two active 100 mg tablets
214657181|NCT03464669|OTHER|Prenatal education|Observational study : natural distribution of participants between groups
214657182|NCT01587742|DRUG|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
214657183|NCT02305563|DRUG|BMS-936564|
214657184|NCT02305563|DRUG|Cytarabine|
214657185|NCT00834015|OTHER|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
214657186|NCT04901156|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
214657187|NCT04901156|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
214657188|NCT04901156|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
214657189|NCT01459978|OTHER|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
214657190|NCT02968355|OTHER|Observational study|Observational study
214657191|NCT01364987|DRUG|ASP015K|oral
214657192|NCT01364987|DRUG|Mycophenolate Mofetil|oral
214657193|NCT02581709|BEHAVIORAL|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
214657194|NCT02193789|PROCEDURE|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
214657195|NCT02193789|DEVICE|Covered Self-expandable Metallic Stents|
214657196|NCT05079438|DRUG|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
214657197|NCT00036114|DRUG|aripiprazole|
214657198|NCT04439890|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
214657199|NCT04439890|DRUG|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
214657200|NCT04439890|DRUG|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
214657201|NCT04439890|DRUG|Placebo|Placebo
214657202|NCT01068561|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
214657203|NCT03034941|DRUG|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
214657204|NCT03034941|DRUG|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
214797256|NCT01371578|BIOLOGICAL|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
214797257|NCT01371578|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
214797258|NCT03917628|DRUG|SCT630|SCT630 single s.c. injection
214797259|NCT03917628|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
214797260|NCT00822198|DEVICE|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
214797261|NCT05420428|DEVICE|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
214797262|NCT05420428|DEVICE|endotracheal intubation|under general anesthesia, patients received endotracheal intubation
214797263|NCT03231839|BEHAVIORAL|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
214797264|NCT03231839|BEHAVIORAL|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
214797265|NCT03231839|BEHAVIORAL|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
214797266|NCT06179966|OTHER|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
214797267|NCT06179966|OTHER|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
214797268|NCT04038970|BIOLOGICAL|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
214797269|NCT04038970|BIOLOGICAL|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
214797270|NCT04038970|BIOLOGICAL|Placebo|Solution, intravenous, Placebo
214797271|NCT04038970|COMBINATION_PRODUCT|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
214797272|NCT02564913|OTHER|clinical evaluation|
214797273|NCT01604421|PROCEDURE|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
214797274|NCT01604421|PROCEDURE|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
214797275|NCT01485913|OTHER|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
214797276|NCT05151835|DEVICE|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console \[SGC\], a Patient Side Robot \[PSR\], and a Vision Cart \[VCT\], and is used with an endoscope, Surgical Instruments \[SGI\], and Accessories \[ACC\]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
214797277|NCT02579096|DRUG|allopurinol capsule, 100-800 mg by mouth once daily|Patients will be up-titrated up to the dose required to reach target uric acid levels.
214797278|NCT02579096|DRUG|febuxostat tablet 40-120 mg by mouth once daily|Patients will be up-titrated to the dose required to reach target uric acid levels.
214797279|NCT02579096|DRUG|Placebo, vehicle control (febuxostat-shaped)|Placebo tablets resembling febuxostat will be given with allopurinol.
214797280|NCT02579096|DRUG|Placebo, vehicle control (allopurinol-shaped)|Placebo capsules resembling allopurinol will be given with febuxostat.
214797281|NCT06544343|OTHER|Remote Monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
214797282|NCT06544343|OTHER|On site monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
214797283|NCT05854654|DIAGNOSTIC_TEST|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
214797284|NCT06544434|DEVICE|Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)|MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
214797285|NCT06544434|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
214797286|NCT01876186|DRUG|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
214797287|NCT01876186|DRUG|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
214797288|NCT05882474|DEVICE|PaCO2|Level of partial pressure of carbon dioxide
214797289|NCT05265325|DRUG|AND017 capsules TIW|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
214797290|NCT05265325|DRUG|AND017 capsules QW|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
214797291|NCT05265325|DRUG|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
214797292|NCT01361126|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX\_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
214797293|NCT00940368|DIETARY_SUPPLEMENT|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
214797294|NCT02447900|DEVICE|BioXmark|
214797295|NCT00624481|DRUG|Teriparatide|20ug subcutaneous injection daily for 24 weeks
214797296|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
214797297|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
214797298|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
214797299|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
214797300|NCT03834675|DIAGNOSTIC_TEST|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
214797301|NCT05478993|DRUG|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
214797302|NCT00663871|DIETARY_SUPPLEMENT|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
214797303|NCT00663871|DIETARY_SUPPLEMENT|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
214797304|NCT03303638|BEHAVIORAL|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
214797305|NCT05655936|BEHAVIORAL|Heart Health Doula Intervention Program|The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
214797306|NCT05655936|BEHAVIORAL|Usual Care|Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
215031089|NCT03283241|DEVICE|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
215031090|NCT04191226|DIAGNOSTIC_TEST|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
214797307|NCT01721525|DRUG|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects \> 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
214797308|NCT01394458|OTHER|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
214797309|NCT01394458|DRUG|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
214797310|NCT02742181|DRUG|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
214797311|NCT02742181|OTHER|Control Group|Standard postoperative care
214797312|NCT04240483|OTHER|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
214797313|NCT04240483|OTHER|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
214797314|NCT06364800|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
214797315|NCT06364800|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
214797316|NCT06364800|DRUG|targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
214797317|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
214797318|NCT06033066|BEHAVIORAL|Financial Incentives|Small financial incentive or prize incentive
214797319|NCT06033066|BEHAVIORAL|Message|Message inviting participant to enroll
214797320|NCT00974142|DRUG|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
214797321|NCT00974142|DRUG|Placebo|Fifteen patients will receive will receive placebo.
214797322|NCT02081326|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
214797323|NCT02081326|BIOLOGICAL|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
214797324|NCT03712657|COMBINATION_PRODUCT|ERAS|"1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging."
214797325|NCT02259751|DRUG|KUC 7483 CL|
214797326|NCT02259751|DRUG|Placebo|
214797327|NCT00944970|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
214797328|NCT00944970|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
214797329|NCT02957656|BIOLOGICAL|H7N9 pLAIV|10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
214797330|NCT02957656|BIOLOGICAL|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
214797331|NCT02957656|BIOLOGICAL|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
214797332|NCT01813656|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
214797333|NCT01813656|DRUG|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
214797334|NCT05111470|OTHER|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
214797335|NCT00002387|DRUG|Indinavir sulfate|
214797336|NCT00002387|DRUG|Efavirenz|
215031091|NCT03770702|DRUG|Angiotensin receptor blockers|Candesartan
215031092|NCT03770702|DRUG|Statins|Atorvastatin
214797337|NCT02946385|BIOLOGICAL|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY\_ 0\_2 Group, ABCWY\_ 0\_2\_6 Group and ABCWY\_ 0\_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
214797338|NCT02946385|BIOLOGICAL|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B\_0\_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
214797339|NCT05123456|PROCEDURE|Radiography|Comparative X-ray of the single knee at 30 ° flexion.
214797340|NCT00564525|DRUG|Amitriptyline|Medication taken for 4 weeks
214797341|NCT00564525|DRUG|Placebo|Medication taken for 4 weeks
214797342|NCT02206204|DRUG|selexipag|
214797343|NCT02206204|DRUG|placebo for selexipag|
214797344|NCT02206204|DRUG|moxifloxacin|
214797345|NCT02206204|DRUG|moxifloxacin-matching placebo|
214797346|NCT05108623|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
214797347|NCT05108623|DRUG|Approved ICIs|Nivolumab and pembrolizumab
214797348|NCT03810430|BEHAVIORAL|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
214797349|NCT03839706|DEVICE|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
214797350|NCT01583777|DRUG|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
214797351|NCT02717247|DEVICE|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
214797352|NCT02717247|DEVICE|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
214797353|NCT00006250|DRUG|chlorambucil|
214797354|NCT00006250|DRUG|dexamethasone|
214797355|NCT00006250|DRUG|fludarabine phosphate|
214797356|NCT00006250|DRUG|mitoxantrone hydrochloride|
214797357|NCT01643837|OTHER|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
214797358|NCT01643837|OTHER|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
214797359|NCT01060670|DEVICE|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
214797360|NCT01060670|OTHER|Conventional Wound Therapy|Conventional Wound Therapy
214797361|NCT02333370|DRUG|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
214797362|NCT02333370|DRUG|Letrozole|25mg
214797363|NCT02333370|DRUG|Tamoxifen|20 mg
214797364|NCT02333370|DRUG|Fulvestrant|500 mg
214797365|NCT02333370|DRUG|goserelin|
214797366|NCT04442776|BEHAVIORAL|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
214797367|NCT04714658|OTHER|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~1. st group collective workshop : allow the patient to better understand autoimmune~2. nd workshop : fatigue and techniques that enable its best management.~3. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
214797368|NCT00488748|DEVICE|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
214797369|NCT00488748|DEVICE|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
214797370|NCT05942703|OTHER|saliva samples|Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
214797371|NCT01366508|OTHER|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
214797372|NCT01366508|OTHER|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
214797373|NCT01581970|DRUG|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
214797374|NCT01581970|DRUG|Cetuximab|The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
214797375|NCT02062047|PROCEDURE|FMSRP|FMSRP in a maximum of 24 hours.
214797376|NCT02062047|DRUG|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
214797377|NCT02062047|PROCEDURE|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
214797378|NCT02062047|OTHER|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
214797379|NCT01190683|DRUG|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
214797380|NCT01190683|DRUG|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
214797381|NCT01190683|DRUG|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
214797382|NCT01190683|OTHER|lactose placebo|similar number of granules and tablets as active group
214797383|NCT01190683|OTHER|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
214797384|NCT03432247|BEHAVIORAL|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
215031093|NCT03497377|DRUG|18F-DCFPyL Injection|
215031094|NCT03497377|DRUG|18F-NaF|
215031095|NCT01831908|OTHER|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
214797385|NCT03432247|BEHAVIORAL|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
214797386|NCT00159302|PROCEDURE|Induced Sputum|
214797387|NCT00159302|PROCEDURE|Exhaled Nitric Oxide|
214797388|NCT00159302|PROCEDURE|Nasal Nitric Oxide|
214797389|NCT00159302|PROCEDURE|Blood Tests|
214797390|NCT00159302|PROCEDURE|24hr Urine Samples|
214797391|NCT00159302|PROCEDURE|Exhaled Breath Condensate|
214797392|NCT00159302|PROCEDURE|Spirometry|
214797393|NCT01016028|BEHAVIORAL|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
214797394|NCT01016028|BEHAVIORAL|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
214797395|NCT01016028|BEHAVIORAL|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
214797396|NCT02915679|OTHER|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling"
214797397|NCT01319656|BEHAVIORAL|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
214797398|NCT01584661|BEHAVIORAL|Dietary recommendations|
214797399|NCT05344183|DEVICE|Low-level laser|A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
214797400|NCT00275483|DEVICE|Vital-band (R)|
214797401|NCT02105376|DEVICE|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
214797402|NCT01827722|DRUG|Ozurdex|Intravitreal injection of Ozurdex
214797403|NCT01827722|DRUG|Ranibizumab|Intravitreal Injection of Ranibizumab
214797404|NCT01827722|DRUG|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
214797405|NCT00487344|PROCEDURE|Non-Personalized Meal Planning|
214797406|NCT00487344|PROCEDURE|Personalized Meal Planning and Dietetic Consultation|
214797407|NCT05210023|OTHER|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
214797408|NCT05210023|OTHER|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
214797409|NCT06041464|OTHER|cell culture|isolation of cell culture
214797410|NCT04100499|DEVICE|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
214797411|NCT00133770|DRUG|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
214797412|NCT01812421|OTHER|Hypertension Health Education Protocol (HHEP)|
214797413|NCT01183000|PROCEDURE|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
214797414|NCT03085446|BEHAVIORAL|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
214797415|NCT03085446|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
214797416|NCT06036758|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14 Test|Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
214797417|NCT00721877|DRUG|resveratrol|Given orally
214797418|NCT00721877|OTHER|pharmacological study|Correlative studies
214797419|NCT00721877|OTHER|laboratory biomarker analysis|Correlative studies
214797420|NCT03513393|DRUG|velpatasvir|Test 1
214797421|NCT03513393|DRUG|velpatasvir|Test 2
214797422|NCT03513393|DRUG|velpatasvir|Reference
214797423|NCT04592354|DIETARY_SUPPLEMENT|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
214797424|NCT02512354|OTHER|Sample of a fragment of fetal tissue|
214797425|NCT02512354|OTHER|Parent's blood samples|
214797426|NCT02616692|DRUG|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
214647102|NCT06083220|BEHAVIORAL|Smart Start - School Readiness Program|Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
214797427|NCT04963348|OTHER|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
214797428|NCT05063461|DEVICE|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
214797429|NCT05063461|PROCEDURE|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
214797430|NCT02574052|BEHAVIORAL|participants' food choices|just recorded the participants' food choices in the school cafeteria
214797431|NCT02574052|BEHAVIORAL|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
214797432|NCT02574052|BEHAVIORAL|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
214797433|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
214797434|NCT01309009|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
214797435|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
214797436|NCT01636856|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
214797437|NCT01636856|BEHAVIORAL|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
214797438|NCT03519256|BIOLOGICAL|Nivolumab|Specified dose on specified days
214797439|NCT03519256|BIOLOGICAL|BCG|Specified dose on specified days
214797440|NCT03519256|DRUG|BMS-986205|Specified dose on specified days
214797441|NCT04126356|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
214797442|NCT04828161|DRUG|ensovibep|IV on day 1 only.
214797443|NCT04828161|DRUG|Placebo|IV on day 1 only.
214797444|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
214797445|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
214797446|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
214797447|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
214797448|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
214797449|NCT03185897|OTHER|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
215031096|NCT05606107|DRUG|Tofacitinib|Tofacitinib combined with other csDMARDs, but no glucocorticoids.
215031097|NCT05606107|DRUG|Glucocorticoid|Glucocorticoid
215031566|NCT07006883|OTHER|Yoga therapeutic exercise|Yoga is a mind-body practice that integrates physical postures, breathing techniques, and mindfulness with the aim of improving physical function, balance, strength, mobility, and psychological well-being. I
214797450|NCT04222036|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
214797451|NCT04222036|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
214797452|NCT04222036|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
214797453|NCT06205719|DRUG|ciprofol|sedation
214797454|NCT06205719|DRUG|Remazolam|sedation
214797455|NCT06205719|DRUG|Flumazenil|antagonism
214797456|NCT06205719|DRUG|Remifentanil|2ug/kg Remifentanil
214797457|NCT01246375|DEVICE|Dual energy X-ray absorptiometry|Device which measures bone density
214797458|NCT04488575|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbe
214797459|NCT04488575|DRUG|Placebo|Placebo oral capsule
214797460|NCT03250533|DEVICE|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
214797461|NCT03250533|DEVICE|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
214797462|NCT06029036|DRUG|Darolutamide+ADT|"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"
214797463|NCT01224132|DRUG|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
214797464|NCT02234609|DEVICE|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
214797465|NCT03386422|BEHAVIORAL|MSC|Mindfulness and Self-Compassion training
214797466|NCT03386422|BEHAVIORAL|CBT|Cognitive-behavioural techniques training
214797467|NCT02458638|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
214797468|NCT04194866|OTHER|receiving operation during the day or at night|120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
214797469|NCT01274416|BEHAVIORAL|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
214797470|NCT01274416|BEHAVIORAL|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
214797471|NCT04316273|OTHER|colonic surgery|resection of duplicated colon
214797472|NCT04496635|OTHER|Implementation of a bundle of care|
215031567|NCT06674343|DRUG|Furmonertinib|Furmonertinib 160mg, once daily, orally. Other Names: AST2818
214797473|NCT06153121|OTHER|Physical performance test - Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST)|The test is performed in a pushup position with the hands placed 91.4 cm apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
214647103|NCT05523973|OTHER|Lingual Endurance Training|Participants will participate in 3 training sessions per day for 8 weeks. Some participants will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session. Other participants will complete effortful swallows during their 3rd training session. These participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva.
214647104|NCT05892614|DRUG|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
214647105|NCT05892614|DRUG|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
214647106|NCT05892614|DRUG|Placebo|IV infusion over approximately 60 minutes every 4 weeks
214647107|NCT05707884|OTHER|critical care management|The different sedation methods result in considerable differences in terms of set-up costs and the management of the patient, which will be examined in a direct comparison.
214647108|NCT01806311|DRUG|Candesartan32mg|
214647109|NCT01806311|DRUG|Amlodipine10mg|
214647110|NCT06270784|PROCEDURE|Traditional Extraction|Participants in this group will undergo traditional extraction method. This method involves uncovering the impacted tooth and extracting the tooth with or without dividing it.
214647111|NCT06270784|PROCEDURE|Orthodontic Extraction|"Participants in this group will undergo orthodontic extraction method. In this method, a two-stage surgical procedure will be performed. In the first operation, the impacted tooth will be uncovered, and then a button will be placed on the tooth. For anchorage purposes, orthodontic mini screws will be placed in the mandibular ramus or zygomaticomaxillary buttress area. Elastics and/or ligature wires fixed to the button will be attached to the mini screw to provide force for the traction of the tooth.~Patients will be called for check-up appointments every two weeks, and the movement of the impacted tooth will be monitored with panoramic x-rays. The second operation will be planned when the tooth moves away from the inferior alveolar nerve. In the second operation, the tooth will be extracted in a similar way to the traditional extraction group."
214647112|NCT04528771|DRUG|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
214647113|NCT04528771|DRUG|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
214647114|NCT05959720|DRUG|Prednisone|60 mg/m2 D1 to D21
214647115|NCT05959720|DRUG|Vincristin|1.5 mg/m2 D1, D8, D15 and D22
214647116|NCT05959720|DRUG|Daunorubicin|40 mg/m2 D1, D8, D15 and D22
214647117|NCT05959720|DRUG|Peg-asparaginase|2000 UI/m2 D12 and D26
214647118|NCT05959720|DRUG|Intrathecal Suspension|MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
214647119|NCT05959720|DRUG|Cyclophosphamide|1000 mg/m2 D36 and D64
214647120|NCT05959720|DRUG|Cytarabine|75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
214647121|NCT05959720|DRUG|Mercaptopurine|30 mg/m2 D36 to D63 and D1 to D56 of consolidation
214647122|NCT05959720|DRUG|Methotrexate|3.000 mg/m2 D8, D22, D36 and D50
214647123|NCT05959720|DRUG|Doxorubicin|30 mg/m2 D1 and D22
214647124|NCT05227105|BEHAVIORAL|Physical Activity|Physical activity will be encouraged up to an amount of 150 minutes per week.
214647125|NCT05227105|BEHAVIORAL|Delayed intervention|Physical activity will be encouraged at the end of the trial.
214647126|NCT05663580|DRUG|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
214647127|NCT06437509|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214647128|NCT06437509|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
214647129|NCT06777420|OTHER|Question prompt list|The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.
214647130|NCT05617833|COMBINATION_PRODUCT|MLT+EPO|Melatonin component will be a daily dose of 30 mg/kg enteral administered in the evening in a split dose given at cares/feedings. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr subcutaneously or intravenously) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday subcutaneously or intravenously) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.
214647131|NCT05617833|OTHER|Placebo|Placebo enteral and IV
214647132|NCT04259125|DIAGNOSTIC_TEST|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
214647133|NCT04259125|OTHER|Survey|Regarding epilepsy and development.
215031568|NCT06675851|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
214797474|NCT06153121|OTHER|Physical performance test - modified Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a pushup position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
214797475|NCT06153121|OTHER|Physical performance test - Seated Seated Single Arm Shot Put Test (SSASPT)|Set up requires that the subject is placed in a seated position with their back against the wall, and a 2kg medicine ball held in a shot put position. When ready, the subject will perform a shot put motion to project the medicine ball as far as possible. The average of three trials is recorded for each arm.
214797476|NCT06153121|OTHER|Physical performance test - Upper Limb Rotation Test (ULRT)|Participants starts in a modified (on elbows) push-up position. Participants are positioned next to a wall in order to allow the shoulder, the elbow epicondyle, the greater trochanter and the lateral malleolus of the ankle to touch the wall. Participants are asked to perform a trunk rotation, coupled with an external rotation of the shoulder in a 90°-90° position (90° abduction, 90° external rotation) touching the tape placed vertically on the wall as quickly as possible for 15 s. Finally, three 15-s test trials were performed, with 45 s rest between each trial.
214797477|NCT06153121|OTHER|Physical performance test - Shoulder endurance test (SET)|Participants were instructed to stand up straight with their back against a wall. The tested arm was placed in a 90°forward flexion holding a 1-m long thera-band® fixed at shoulder height on a graduated stick. Participants were asked to pull the thera-band® from the starting position 90°forward flexion-to a 90° external rotation and 90° abduction (90°90°position) at an alternated cadence given by a metronome. Males are asked to pull a green thera-band (2.1 kg) and females a red thera-band (1.7 kg). Repetitions are performed until the participant is fatigued.
214797478|NCT06153121|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm perpendicular to the floor. A bar on a stick is adjusted for each patient and fixed at the point that the participant's shoulder reaches 90° of horizontal abduction, the point at which the participant was to hold the arm at the top of the arc of motion for 1 second. The participant held a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg). Starting with the arm perpendicular to the floor, the participant horizontally abducted his arm to 90 degrees at a cadence of 30 beats per minute. Repetitions are performed until the participant is fatigued.
214797479|NCT06153121|OTHER|Analytical test - Shoulder Strength|shoulder external rotation and internal rotation measured with a hand held dynanometer
214797480|NCT06153121|OTHER|Analytical test - Hand Grip Strength|Hand grip strength measured with a JAMAR Hand Dynamometer
214797481|NCT06153121|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
214797482|NCT06153121|OTHER|PROM - Kerlan-Jobe Orthopedic Clinic Shoulder and Elbow Score (KJOC-SES)|The KJOC-SES survey is composed of ten 10-point questions to evaluate specifically the performance of overhead athletes, with the highest performance score of 100.
214797483|NCT06153121|OTHER|PROM - Competitive State Anxiety Inventory-2 (CSAI-2)|The Competitive State Anxiety Inventory scale contains 27 items. It a psychometric scale that asks the volunteer to rate, on a 4-point Likert scale, their coping skills for sports performance.
214797484|NCT06153121|OTHER|PROM - General elf-efficacy scale (GSES).|The GSES measures (10 statements) how a person deals with stressors/difficult situations in life. The scale is about a person's self-confidence that his or her actions are responsible for successful outcomes or, in other words, that one has control over challenging demands imposed by the environment.
214797485|NCT01908127|BEHAVIORAL|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
214797486|NCT01908127|BEHAVIORAL|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
214797487|NCT01908127|DRUG|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
214797488|NCT01908127|PROCEDURE|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
214797489|NCT04617665|OTHER|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
214797490|NCT04617665|OTHER|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
214797491|NCT05116020|OTHER|Usual chiropractic care|Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
214797492|NCT02296580|DEVICE|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
214797493|NCT02215694|DIETARY_SUPPLEMENT|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
214797494|NCT02215694|DIETARY_SUPPLEMENT|placebo|2g of powder daily without probiotics
214797495|NCT03408366|PROCEDURE|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
214797496|NCT03408366|OTHER|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
214797497|NCT03408366|OTHER|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
214797498|NCT03495648|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
214797499|NCT04409665|DRUG|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
214797500|NCT04409665|DRUG|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
214797501|NCT01290939|BIOLOGICAL|bevacizumab|
214797502|NCT01290939|DRUG|lomustine|
214797503|NCT01290939|GENETIC|DNA methylation analysis|
214797504|NCT01290939|OTHER|laboratory biomarker analysis|
214797505|NCT01290939|PROCEDURE|cognitive assessment|
214797506|NCT01290939|PROCEDURE|quality-of-life assessment|
214797507|NCT04177264|PROCEDURE|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
214797508|NCT04177264|PROCEDURE|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
214797509|NCT04177264|PROCEDURE|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
214797510|NCT04177264|PROCEDURE|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
214797511|NCT04177264|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
214797512|NCT04177264|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
214797513|NCT06141096|DRUG|MB07133|Evaluate the effectiveness and safety of different doses of MB07133
214797514|NCT00154024|DRUG|atorvastatin|
214797515|NCT00154024|DRUG|irbesartan|
214797516|NCT05197712|BIOLOGICAL|25 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
214797517|NCT05197712|BIOLOGICAL|50 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
214797518|NCT00600795|OTHER|CSF collection|CSF collection at time of VPS insertion
214797519|NCT05056181|OTHER|Physical Activity|Physical activity
214797520|NCT06126081|DEVICE|LBBP+GDMT|LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
214797521|NCT06126081|DRUG|GDMT|GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
214797522|NCT01479881|DRUG|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
214797523|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
214797524|NCT01479881|DRUG|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
214797525|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
214797526|NCT00648323|DRUG|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
214797527|NCT05209646|DIETARY_SUPPLEMENT|Bee honey|patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
214797528|NCT03528408|DRUG|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
214797529|NCT03528408|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
214797530|NCT03711955|OTHER|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
214797531|NCT05760664|OTHER|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
214797532|NCT05760664|OTHER|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
214797533|NCT05760664|OTHER|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
214797534|NCT02236338|PROCEDURE|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
214797535|NCT02236338|DEVICE|ClosureFAST radiofrequency catheter|
214797536|NCT02236338|DEVICE|EVLT 980nm diode laser system|
214797537|NCT00399113|DRUG|188Re-PTI-6D2|monoclonal antibody
214797538|NCT05095064|DRUG|Onivyde® + 5-FULV|Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
214797539|NCT01645384|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
215031569|NCT06675851|DRUG|Cipralex (escitalopram)|Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
214797540|NCT02966379|DEVICE|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point"
214797541|NCT02577159|DRUG|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
214797542|NCT01202006|OTHER|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
214797543|NCT03169959|DRUG|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
214797544|NCT03169959|DRUG|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
214797545|NCT03169959|DRUG|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
214797546|NCT03169959|DRUG|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
214797547|NCT03169959|DRUG|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
214797548|NCT03169959|DRUG|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
214797549|NCT02659852|PROCEDURE|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
214797550|NCT02659852|PROCEDURE|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
214797551|NCT01521442|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
214797552|NCT01521442|BEHAVIORAL|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
214797553|NCT00949299|DRUG|buprenorphine|intradermal injection
214797554|NCT06454006|DEVICE|Placebo PBMT-sMF|Placebo, without therapeutic dose.
214797555|NCT06454006|DEVICE|Active PBMT-sMF|Active with a dose of 31.50 J per site.
214797556|NCT00006052|DRUG|imatinib mesylate|
215031098|NCT04608058|BEHAVIORAL|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
215031099|NCT04608058|BEHAVIORAL|Routine training|The control group received the clinics' routine training include face to face class education.
214647134|NCT05734989|DIAGNOSTIC_TEST|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
214647135|NCT05734989|DIAGNOSTIC_TEST|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
214647136|NCT05734989|BEHAVIORAL|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
214797557|NCT04184037|BEHAVIORAL|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR\_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
214797558|NCT01918878|DRUG|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
214797559|NCT03129477|PROCEDURE|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
214797560|NCT03093454|DRUG|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
214797561|NCT00278694|DRUG|Oxaliplatin|
214797562|NCT00278694|DRUG|Chemoradiation|
214797563|NCT00278694|DRUG|5-FU|
214797564|NCT00278694|RADIATION|Preoperative chemoradiation|
214797565|NCT00278694|PROCEDURE|Pelvic surgery|
214797566|NCT00278694|DRUG|Neoadjuvant oxaliplatin|
214797567|NCT05522010|PROCEDURE|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
214797568|NCT02353130|DRUG|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
214797569|NCT04540497|DRUG|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
214797570|NCT04540497|OTHER|Placebo|Placebo
214797571|NCT02850068|DEVICE|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
214797572|NCT06547580|OTHER|Group-based PFMT|Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.
214797573|NCT06547580|OTHER|Individualized PFMT|Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
214797574|NCT04325074|OTHER|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
214797575|NCT04325074|OTHER|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
214797576|NCT04325074|OTHER|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
215031100|NCT02666053|DRUG|BMS-663068|BMS-663068
214797577|NCT03845920|COMBINATION_PRODUCT|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
214797578|NCT01681030|BIOLOGICAL|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
214797579|NCT01681030|BIOLOGICAL|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
214797580|NCT01681030|OTHER|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
214797581|NCT04566835|OTHER|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
214797582|NCT04566835|BEHAVIORAL|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
214797583|NCT00760058|DEVICE|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
214797584|NCT00760058|DEVICE|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
214797585|NCT00760058|DEVICE|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
214797586|NCT03996603|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
214797587|NCT00003584|DRUG|estramustine phosphate sodium|
214797588|NCT00003584|DRUG|prednisone|
214797589|NCT00003584|DRUG|vinorelbine tartrate|
214797590|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 1472 mcg, single dose
214797591|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 736 mcg, single dose
214797592|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 368 mcg, single dose
214797593|NCT00783406|DRUG|Placebo|Placebo
214797594|NCT01269970|OTHER|18-FDG-PET-CT|
214797595|NCT00197275|BIOLOGICAL|Hib-MenAC mixed with Tritanrix™-HepB|
214797596|NCT01390883|DRUG|Fondaparinux Sodium|
214797597|NCT05273619|DRUG|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
214797598|NCT05273619|DRUG|Placebo|4 tablets twice a day
214797599|NCT02707536|PROCEDURE|Socket grafting with PRF|Extraction with socket grafting using PRF.
214797600|NCT02707536|PROCEDURE|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
214797601|NCT04448665|DIAGNOSTIC_TEST|microbiological investigation|a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
214797602|NCT04700449|DRUG|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
214797603|NCT04700449|DRUG|Double-Blind Placebo|Placebo capsule oral administration
214797604|NCT04700449|DRUG|Open-label CBP-307|0.2 mg capsule oral administration
214797605|NCT04700449|DRUG|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
214797606|NCT03738332|DEVICE|Low-Level Laser|Low-level laser therapy
214797607|NCT01521559|PROCEDURE|Macular Laser Photocoagulation|
214797608|NCT01521559|DRUG|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
214797609|NCT03543956|BEHAVIORAL|Questionnaire|Questionnaire
214797610|NCT00027807|BIOLOGICAL|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
214797611|NCT00027807|BIOLOGICAL|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
214797612|NCT00027807|BIOLOGICAL|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
214797613|NCT06408909|BEHAVIORAL|Clinical Pharmacist Intervention Group|Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
214797614|NCT03558477|DRUG|YYD601 1|YYD601 1
214797615|NCT03558477|DRUG|YYD601 2|YYD601 2
214797616|NCT03558477|DRUG|YYD601 3|YYD601 3
214797617|NCT03558477|DRUG|Nexium|Nexium
214797618|NCT01190969|DIETARY_SUPPLEMENT|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
214797619|NCT00356798|BIOLOGICAL|an inactivated whole virion H5N1 vaccine, adjuvanted|
214797620|NCT06483945|DEVICE|Dexcom CGM G6/G6 Pro/G7|Dexcom CGM G6/G6 Pro/G7 device
214797621|NCT06003920|BEHAVIORAL|Process group|The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
214797622|NCT00315874|DRUG|Buprenorphine transdermal delivery system|
214797623|NCT04360031|DRUG|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
214797624|NCT04154748|DEVICE|Argon Plasma Coagulation 90W power|
214797625|NCT04154748|DEVICE|Argon Plasma Coagulation 60W power|
214797626|NCT04154748|DRUG|Omeprazole 120 mg|
214797627|NCT04154748|DRUG|Omeprazole 40 mg|
214797628|NCT02407444|OTHER|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
214797629|NCT02407444|OTHER|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
214797630|NCT03996486|DRUG|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
214797631|NCT03726463|PROCEDURE|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
214797632|NCT01521195|DEVICE|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
214797633|NCT03382366|DIAGNOSTIC_TEST|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
214797634|NCT04749602|DRUG|Nivolumab|40 mg of the nivolumab will be used intrapleurally (once).
214797635|NCT00275002|DRUG|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
214797636|NCT00275002|DRUG|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
214797637|NCT01627275|BIOLOGICAL|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
214797638|NCT06123507|BEHAVIORAL|Student practitioner perspective-taking intervention|This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
214797639|NCT05198804|DRUG|ZN-c3|ZN-c3 will be administered.
214797640|NCT05198804|DRUG|Niraparib|Niraparib will be administered.
214797641|NCT03408379|OTHER|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~* A Tissue sample will be taken during the surgery~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
214797642|NCT04567602|DRUG|PAH medication|There will be no specific interventions.
214797643|NCT05431881|PROCEDURE|Binaural beat|Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.
214797644|NCT05431881|PROCEDURE|Silent|Apply a wave file which is created in silence.
214797645|NCT02494765|DEVICE|I-gel TM|Airway management with I-gel
214797646|NCT02494765|DEVICE|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
214797647|NCT06250595|OTHER|Collection of clinical and laboratory data from EHR.|Observational sutdy
214797648|NCT02909140|DRUG|Topical phenylephrine 2.5%|
214797649|NCT02909140|DRUG|Topical cyclopentolate 1%|
214797650|NCT02909140|DRUG|Intracameral Lidocaine 1%|
214797651|NCT02909140|DRUG|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
214797652|NCT02580630|BEHAVIORAL|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
214797653|NCT02580630|OTHER|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
214797654|NCT02580630|DRUG|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
214797655|NCT02580630|DRUG|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
214797656|NCT01964664|BEHAVIORAL|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
214797657|NCT01964664|BEHAVIORAL|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
214797658|NCT03318692|PROCEDURE|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
214797659|NCT03318692|PROCEDURE|CT|CT of operated area is performed within 7 days of surgery
214797660|NCT05557786|DEVICE|Transcranial Alternating Current Stimulation|Cerebellar Transcranial Alternating Current Stimulation（tACS）
214797661|NCT04607239|PROCEDURE|Telemonitoring|"* A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check."
214797662|NCT04607239|PROCEDURE|Usual Care without Telemonitoring|"* Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
214797663|NCT04790084|OTHER|no intervention|no intervention
214797664|NCT03363295|DRUG|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
214797665|NCT02624843|DRUG|Benzyl Alcohol Lotion 5%|White topical lotion
214797666|NCT02624843|DRUG|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
214797667|NCT02624843|DRUG|Placebo|White topical lotion
214797668|NCT00972881|BIOLOGICAL|cetuximab|
214797669|NCT00972881|DRUG|capecitabine|
214797670|NCT00972881|DRUG|irinotecan hydrochloride|
214797671|NCT00972881|PROCEDURE|neoadjuvant therapy|
214797672|NCT00972881|PROCEDURE|therapeutic conventional surgery|
214797673|NCT00972881|RADIATION|radiation therapy|
214797674|NCT00576381|DRUG|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
214797675|NCT01747850|BEHAVIORAL|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
214797676|NCT01747850|DRUG|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
214797677|NCT01747850|DRUG|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
214797678|NCT04357275|OTHER|ICU treatment|ICU treatment according to standard of care
214797679|NCT01031537|BIOLOGICAL|FSME-IMMUN 0.5ml Baxter|Vaccine
214797680|NCT05123937|OTHER|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
214797681|NCT05123937|OTHER|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
214797682|NCT06236737|OTHER|Sensorimotor Exercise|The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.
214797683|NCT06236737|OTHER|Yoga Exercise|A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
214797684|NCT00099528|DRUG|REN-1654|
214797685|NCT02132247|DRUG|Diclofenac hydroxyethylpyrrolidine|
214797686|NCT02932254|DRUG|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
214797687|NCT02932254|DRUG|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
214797688|NCT01189825|BEHAVIORAL|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
214797689|NCT00658398|BEHAVIORAL|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
214797690|NCT00437242|DRUG|Odiparcil|
214797691|NCT06109103|PROCEDURE|telerehabilitation-based motor imagery training|"Motor imagery is defined as the mental thinking of a movement without actual movement being revealed. Many of the currently available physiotherapy and rehabilitation approaches are designed to stimulate damaged motor neural connections through neuroplasticity.~based on real movements. Studies have shown that similar brain regions are activated during motor imagery and real movement. By repeatedly visualizing the same movement, people can improve their motor activity skills such as lifting weights, playing the piano or performing surgery. These findings suggest that motor imagery provides motor learning by strengthening synaptic connections depending on activity."
214797692|NCT06109103|PROCEDURE|telerehabilitation-based physiotheraphy training|The telerehabilitation application will be carried out by video conference method, one of the image-based telerehabilitation technologies. The telerehabilitation-based physiotherapy program will be administered to both Group 1 and Group 2 children by a physiotherapist experienced in the physiotherapy of neuromuscular diseases, excluding the researchers who performed the randomization and evaluations.
214797693|NCT02404948|OTHER|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
214797694|NCT04736992|OTHER|No intervention involved|No intervention involved
214797695|NCT00359086|DRUG|MGCD0103|MGCD0103 given orally three times per week
214797696|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
214797697|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
214797698|NCT00348010|DRUG|Tramadol HCl ER|
214797699|NCT04910490|OTHER|No interventions - retrospective data collection|No new/additional patients will be enrolled within this project.
214797700|NCT05111821|PROCEDURE|Magnetic Resonance Imaging (MRI)|Quantification of iron will be performed through Magnetic Resonance Imaging
214797701|NCT05111821|DRUG|Deferiprone treatment|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
214797702|NCT01913990|DRUG|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
214797703|NCT01913990|OTHER|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
214797704|NCT04858100|PROCEDURE|Surgical excision of the lesion|"The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case."
214797705|NCT04858100|OTHER|Wait and see approach|"The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression."
214797706|NCT04332978|DRUG|Fluticasone Propionate|
214797707|NCT04596956|DRUG|sodium bicarbonate Ringer injection|Used in surgery
214797708|NCT04596956|DRUG|Lactated Ringer's solution|Used in surgery
214797709|NCT01079637|PROCEDURE|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
214797710|NCT01079637|PROCEDURE|Cast treatment|Cast treatment
214797711|NCT02750761|DRUG|Tedizolid Phosphate (IV)|200 mg/vial powder for injection
214797712|NCT02750761|DRUG|Tedizolid Phosphate (oral suspension)|Powder for oral suspension 20 mg/mL following reconstitution
214797713|NCT02715947|DRUG|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
214797714|NCT01451853|DRUG|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
214797715|NCT01451853|DRUG|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
214797716|NCT01451853|DRUG|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
214797717|NCT01451853|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
214797718|NCT05875818|DIAGNOSTIC_TEST|In-clinic Rehabilitation|Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
214797719|NCT05875818|DIAGNOSTIC_TEST|Tele-rehabilitation|Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
214797720|NCT02498548|BEHAVIORAL|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
214797721|NCT00795665|DRUG|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
214797722|NCT00795665|DRUG|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
214797723|NCT01270750|DRUG|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
214797724|NCT05184049|DRUG|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
214797725|NCT05184049|DRUG|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
214797726|NCT03784664|DIAGNOSTIC_TEST|Arterial blood gas|arterial blood sample with puncture of the radial artery
214797727|NCT03784664|DIAGNOSTIC_TEST|Veinous blood gas|veinous blood sample using peripheral venepuncture
214797728|NCT04908566|DRUG|PD-1 antibody combined with FOLFIRINOX regimen|Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
214797729|NCT04908566|DRUG|PD-1 antibody combined with SOX program|"Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles."
214797730|NCT00279721|PROCEDURE|IMRT|
214797731|NCT03256799|DRUG|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
214797732|NCT02354586|DRUG|Niraparib|
214797733|NCT05004428|OTHER|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
214797734|NCT01208558|BEHAVIORAL|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
214797735|NCT01208558|BEHAVIORAL|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
214797736|NCT01208558|BEHAVIORAL|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
214797737|NCT04207281|DIETARY_SUPPLEMENT|Raw Honey|Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
214797738|NCT04207281|DIETARY_SUPPLEMENT|Comparator|Honey comparator(1.5 tablespoons) administered for 7 days
214797739|NCT00634907|GENETIC|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
214797740|NCT00634907|OTHER|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
214797741|NCT06157307|DEVICE|Aortic compression|Aortic compression with four different methods on each participants
214797742|NCT01243554|BEHAVIORAL|Exercise|Exercise training at the hospital
214797743|NCT01787136|DRUG|Dextromethorphan|added on therapy
214797744|NCT00633282|BEHAVIORAL|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
214797745|NCT00633282|DRUG|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
214797746|NCT00633282|DRUG|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
214797747|NCT06227975|DRUG|[14C]-BMS-986368|Specified dose on specified days
214797748|NCT01158365|DRUG|LACTIC ACID (Dermacid)|Route of administration: local
214797749|NCT01158365|DRUG|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
214797750|NCT04963426|BEHAVIORAL|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
214797751|NCT04963426|OTHER|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
214797752|NCT03439163|DEVICE|MRI scan|All participants underwent the MRI scan
214797753|NCT02309125|PROCEDURE|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
214797754|NCT02309125|PROCEDURE|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
214797755|NCT02031848|OTHER|Diet Intervention|
214797756|NCT02031848|OTHER|Assessments and Diet Intake|
214797757|NCT03256110|BEHAVIORAL|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
214797758|NCT01747603|OTHER|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
214797759|NCT00752323|DRUG|aminolevulinic acid|Given orally
214797760|NCT00752323|PROCEDURE|Surgical Resection|Surgical resection - 6 biopsies from 3 fluorescent regions
214797761|NCT05852548|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
214797762|NCT03653195|OTHER|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
214797763|NCT05586425|BEHAVIORAL|Emotion Regulation Skills + Treatment as Usual|ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.
214797764|NCT05586425|BEHAVIORAL|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
214797765|NCT00536900|BEHAVIORAL|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
214797766|NCT00536900|BEHAVIORAL|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
214797767|NCT06046664|DIAGNOSTIC_TEST|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
214797768|NCT00766207|OTHER|Clinical decision support|multi-faceted decision support
214797769|NCT00766207|OTHER|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
214797770|NCT01495377|DRUG|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
214797771|NCT01495377|DRUG|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
214797772|NCT01495377|DRUG|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
214797773|NCT01495377|DEVICE|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
214797774|NCT04779619|OTHER|Online self-report questionnaire completion|After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
214797775|NCT05865639|BEHAVIORAL|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
214797776|NCT05865639|BEHAVIORAL|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
214797777|NCT03791749|OTHER|Breastfeeding Support|12-minute simple technique
214797778|NCT02551497|DRUG|CNV1014802|
214797779|NCT02503943|DRUG|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
214797780|NCT02503943|DRUG|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
214797781|NCT02503943|DRUG|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
214797782|NCT05717153|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214797783|NCT05717153|PROCEDURE|Computed Tomography|Undergo CT
214797784|NCT05717153|DRUG|Eflornithine|Given PO
214797785|NCT05717153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214797786|NCT05717153|DRUG|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Given PO
214797787|NCT05717153|PROCEDURE|Resection|Undergo surgical resection
214797788|NCT05717153|DEVICE|Microdialysis|Undergo Microdialysis
214797789|NCT05717153|PROCEDURE|Placement|Undergo placement of catheters
214797790|NCT05364827|DIAGNOSTIC_TEST|CTCA|CTCA performed in intervention arm patients prior to CTO PCI
214797791|NCT05389943|DRUG|Oral administration of vitamin D3|the effect of oral supplement in postmenopausal women.
214797792|NCT05389943|DRUG|Vitamin D3 50000 UNT Oral Capsule|In postmenopausal women with BMD less than 32 ng/ml
214797793|NCT05389943|DIETARY_SUPPLEMENT|milk, Dietary and life style modifications.|Postmenopausal women with BMD greater than 32 ng/ml
214797794|NCT03487055|BIOLOGICAL|TK006|Subcutaneous injection in the upper arm
214797795|NCT05770752|PROCEDURE|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
214797796|NCT02210715|DRUG|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
214797797|NCT02210715|OTHER|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
214797798|NCT05757011|PROCEDURE|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
214797799|NCT03332693|OTHER|Exercise|Leg weight raising
214797800|NCT03332693|OTHER|No exercise|Volunteers will not participate in exercise
214797801|NCT06837311|DEVICE|Ecological Momentary Assessment (EMA)|Daily ecological momentary assessment (EMA), in addition to treatment as usual (TAU) using apTeleCare eHealth device. Daily surveys includes questions reflecting all Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 symptom criteria for Depression, Generalized Anxiety Disorder, Post-Traumatic Symptom Disorder, evaluations of substance use (including dietary items at risk) as well as of two symptoms predictive of relapse (craving and loss of control), medication compliance and physical activity
214797802|NCT06837311|BIOLOGICAL|Biological assessment|Routine Biological assessment and of substance use
214797803|NCT06837311|BEHAVIORAL|Psychological examination and Substance Use symptomatology|Substance use symptomatology ; Neuropsychiatric symptomatology ; Functional outcomes ; Neurologic and Cardiovascular outcomes
214797804|NCT06837311|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU)
214797805|NCT06837311|DIAGNOSTIC_TEST|Expired carbon monoxide (CO)|Expired carbon monoxide (CO) measurement
214797806|NCT03319420|DRUG|LO2A eye drops|Sodium hyaluronate
214797807|NCT03319420|DRUG|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
214797808|NCT04955262|BIOLOGICAL|Bempegaldesleukin (NKTR-214)|Specified dose on specified days
214797809|NCT04955262|BIOLOGICAL|Nivolumab|Specified dose on specified days
214797810|NCT04955262|DRUG|⁸⁹Zr-Df-IAB22M2C|Specified dose on specified days
214797811|NCT01208012|DRUG|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
214797812|NCT05045118|OTHER|Digital Structured Patient Education Material|Participants of home-based Cardiac Rehabilitation Program that are included in this research will be provided with a digital Structured Patient Education Material at the beginning of the program, and will be followed up for 12 weeks duration
214797813|NCT04216043|DIETARY_SUPPLEMENT|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
214797814|NCT04216043|DIETARY_SUPPLEMENT|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
214797815|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
214797816|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
214797817|NCT00189709|DRUG|Micafungin|IV
214797818|NCT00189709|DRUG|fluconazole|IV
214797819|NCT04155983|DRUG|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
214797820|NCT00838318|BEHAVIORAL|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
214797821|NCT04693065|OTHER|ponseti|Standard of care, treatment by ponseti method
214797822|NCT04902274|OTHER|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
214797823|NCT04902274|OTHER|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
214797824|NCT04902274|OTHER|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
214797825|NCT03613350|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
214797826|NCT04104958|GENETIC|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
214797827|NCT02780557|BEHAVIORAL|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
214797828|NCT02780557|BEHAVIORAL|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
214797829|NCT01164943|PROCEDURE|Stimulation with human FSH|Human FSH
214797830|NCT01164943|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
214797831|NCT02598102|DRUG|Diclofenac sodium|Diclofenac for pain relief
214797832|NCT02598102|DRUG|Placebo|Placebo for comparison
214797833|NCT05220670|OTHER|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
214797834|NCT05220670|OTHER|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
214797835|NCT06375590|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid stenosis with the Navitor platform
214797836|NCT02583542|DRUG|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
214797837|NCT02583542|DRUG|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
214797838|NCT05214742|OTHER|Diagnostic Test|Molecular diagnosis carried out in the context of care
214797839|NCT01474278|DRUG|Placebo|Single dose
214797840|NCT01474278|DRUG|RO5028442|Single dose
214797841|NCT00002315|DRUG|Netivudine|
214797842|NCT00002315|DRUG|Acyclovir|
214797843|NCT05252481|DEVICE|Active tDCS|Eight sessions of transcranial current direct stimulation
214797844|NCT05252481|DEVICE|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
214797845|NCT02259712|OTHER|Hypopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
214797846|NCT02259712|BEHAVIORAL|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
214647137|NCT03915145|OTHER|Kinesio tape application|Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
214647138|NCT03915145|OTHER|Sham Kinesio tape application|Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
214647139|NCT03915145|OTHER|No intervention|The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
214647140|NCT02326519|OTHER|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
214647141|NCT00352534|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
214647142|NCT00352534|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214647143|NCT00352534|PROCEDURE|Chest Radiography|Undergo chest X-ray
214647144|NCT00352534|PROCEDURE|Computed Tomography|Undergo CT
214647145|NCT00352534|BIOLOGICAL|Dactinomycin|Given IV
214647146|NCT00352534|DRUG|Doxorubicin Hydrochloride|Given IV
214647147|NCT00352534|PROCEDURE|Echocardiography Test|Undergo echocardiography
214647148|NCT00352534|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214647149|NCT00352534|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214647150|NCT00352534|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214647151|NCT00352534|DRUG|Vincristine Sulfate|Given IV
214647152|NCT01836679|DRUG|Chidamide|Given orally
214647153|NCT01836679|DRUG|Paclitaxel|Given IV
214647154|NCT01836679|DRUG|Carboplatin|Given IV
214647155|NCT01836679|DRUG|Placebo|Given orally
214647156|NCT00408863|DRUG|tibolone|tibolone 2.5 mg/day
214647157|NCT00408863|DRUG|placebo|
214647158|NCT02304198|DRUG|Udenafil|Udenafil 50mg tablet
214647159|NCT01602341|DRUG|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
214647160|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
214647161|NCT01602341|DRUG|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
214647162|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
214647163|NCT01402245|BIOLOGICAL|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
214647164|NCT01402245|BIOLOGICAL|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
214647165|NCT04183985|DEVICE|Total knee arthroplasty prosthesis|In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
214647166|NCT05480969|OTHER|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
214647167|NCT06265142|PROCEDURE|Bladder catheterization|Participant will undergo the standard bladder catheterization for urine collection
214647168|NCT06265142|PROCEDURE|clean catch urine via bladder massage technique|Participant will undergo clean catch urine via bladder massage technique
214647169|NCT05046288|OTHER|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
214797847|NCT02259712|OTHER|Pelvic-perineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
214797848|NCT02259712|OTHER|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
214797849|NCT02224391|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
214797850|NCT02224391|OTHER|Laboratory Biomarker Analysis|Correlative studies
214797851|NCT02224391|DRUG|Nicotine Patch|Given via transdermal patch
214797852|NCT02224391|OTHER|Questionnaire Administration|Ancillary studies
214797853|NCT02224391|OTHER|Sham Intervention|Undergo sham training
214797854|NCT04879420|DRUG|Teriparatide|Teriparatide dispensing claim is used as the reference group.
214797855|NCT04879420|DRUG|Risedronate|Risedronate dispensing claim is used as the exposure group.
214797856|NCT00379457|BIOLOGICAL|dactinomycin|
214797857|NCT00379457|DRUG|carboplatin|
214797858|NCT00379457|DRUG|cyclophosphamide|
214797859|NCT00379457|DRUG|doxorubicin hydrochloride|
214797860|NCT00379457|DRUG|etoposide|
214797861|NCT00379457|DRUG|ifosfamide|
214797862|NCT00379457|DRUG|topotecan hydrochloride|
214797863|NCT00379457|DRUG|vincristine sulfate|
214797864|NCT00379457|DRUG|vinorelbine tartrate|
214797865|NCT00379457|PROCEDURE|conventional surgery|
214797866|NCT00379457|RADIATION|radiation therapy|
214797867|NCT03718455|DEVICE|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
214797868|NCT05743218|OTHER|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
214797869|NCT00084084|DRUG|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
214797870|NCT02617108|DEVICE|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
214797871|NCT06484946|OTHER|aquatic occupational therapy|Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
214797872|NCT01933295|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
214797873|NCT01933295|BEHAVIORAL|Sleep Education|
214797874|NCT01933295|BEHAVIORAL|Sleep Restriction Therapy|
214797875|NCT00108732|DRUG|Bicalutamide|Given orally
214797876|NCT00108732|DRUG|Goserelin Acetate|Given SC
214797877|NCT00108732|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
214797878|NCT00108732|BIOLOGICAL|Recombinant Vaccinia-TRICOM Vaccine|Given SC
214797879|NCT00108732|BIOLOGICAL|Sargramostim|Given SC
214797880|NCT02779309|PROCEDURE|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
214797881|NCT06545383|OTHER|Dynamic Neuromuscular Stabilization Exercises|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally DNS exercises will be performed in 40-minute sessions, 2 days a week for 6 weeks.
214797882|NCT06545383|OTHER|Exercise|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally, the control group will be asked to walk at moderate intensity for 40 minutes, 2 days a week, for 6 weeks.
214797883|NCT05427097|DEVICE|Helical® patches|Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
214797884|NCT04084756|BEHAVIORAL|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
214797885|NCT04084756|BEHAVIORAL|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
214797886|NCT00820456|OTHER|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
214797887|NCT02354300|DEVICE|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
214797888|NCT00991588|PROCEDURE|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
214797889|NCT00041509|DRUG|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
214797890|NCT00041509|DRUG|Placebo|matching placebo, oral, BID for 28 days
214797891|NCT06158321|DEVICE|M1 or DLPFC sham stimulation|Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.
214797892|NCT06158321|DEVICE|M1 rTMS|The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.
214797893|NCT06158321|DEVICE|DLPFC rTMS|The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
214797894|NCT04809246|OTHER|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
214797895|NCT00261196|DRUG|Collagenase|Anterior shoulder capsule injection
214797896|NCT02259556|BIOLOGICAL|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
214797897|NCT02573909|DRUG|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
214797898|NCT02573909|DRUG|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
214797899|NCT05713591|BEHAVIORAL|Transition care model|The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
214797900|NCT04229849|DRUG|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
214797901|NCT04229849|DRUG|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
214797902|NCT03963570|BEHAVIORAL|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
214797903|NCT03963570|BEHAVIORAL|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
214797904|NCT00642538|DRUG|MKC253 Inhalation Powder|Inhalation Powder, prandial
214797905|NCT00642538|DRUG|Technosphere Inhalation Powder|Inhalation Powder, prandial
214797906|NCT00642538|DRUG|subcutaneous injection|10µg Exenatide, prandial
214797907|NCT03644095|DRUG|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
214797908|NCT03644095|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
214797909|NCT03080181|DRUG|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
214797910|NCT03902275|OTHER|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
214797911|NCT03902275|OTHER|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
214797912|NCT03640156|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
214797913|NCT03640156|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
214797914|NCT02398877|OTHER|stress|
214797915|NCT04332302|OTHER|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
214797916|NCT04153253|DRUG|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
214797917|NCT04153253|PROCEDURE|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
214797918|NCT03772639|OTHER|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
214797919|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
214797920|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
214797921|NCT00440596|BEHAVIORAL|Mindfulness based stress reduction|8 weeks group MBSR
214797922|NCT00440596|BEHAVIORAL|Progressive Muscle Relaxation|8 weeks PMR in group format
214797923|NCT03922477|DRUG|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
214797924|NCT03922477|DRUG|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
214797925|NCT03318770|DRUG|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
214797926|NCT00879242|DRUG|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
214797927|NCT06484101|PROCEDURE|Exercise|3 x 30 seconds of supramaximal exercise
214797928|NCT01004770|DRUG|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
214797929|NCT01004770|DRUG|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
214797930|NCT02277652|DEVICE|The Miller Laryngoscope|Direct laryngoscopy
214797931|NCT02277652|DEVICE|The Bonfils intubation fibrescope|Optical laryngoscopy
214797932|NCT02277652|DEVICE|The GlideScope Ranger|Videolaryngoscopy
214797933|NCT02277652|DEVICE|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
214797934|NCT00001564|DRUG|EF-1 Peptide|
214797935|NCT00001564|DRUG|EF-2 Peptide|
214797936|NCT00001564|DRUG|PXFK Peptide|
214797937|NCT00001564|DRUG|E7 Peptide|
214797938|NCT00001564|DRUG|IL-2|
214797939|NCT00001564|DRUG|IL-4|
214797940|NCT00001564|DRUG|GM-CSF|
214797941|NCT00001564|DRUG|CD40 Ligand|
214797942|NCT01938976|BEHAVIORAL|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
214797943|NCT06111456|OTHER|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
214797944|NCT06111456|OTHER|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
214797945|NCT03105609|DEVICE|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
214797946|NCT03246542|DIAGNOSTIC_TEST|shistocytes percentage|
214797947|NCT06301802|PROCEDURE|CIC|clean intermittent catheterization
214797948|NCT06301802|DRUG|Anticholinergic|antimuscarinic once daily
214797949|NCT02272868|BIOLOGICAL|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
214797950|NCT02272868|DRUG|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
214797951|NCT02272868|DRUG|rifaximin+omeprazole+miralax|
214797952|NCT01820871|OTHER|Self-Management Using Smartphone Application for Type2 DM|
214797953|NCT01820871|OTHER|self-management using booklet for management type 2 DM|
214797954|NCT03795103|DEVICE|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
214797955|NCT03795103|OTHER|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
214797956|NCT03795103|OTHER|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
214797957|NCT04736264|OTHER|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
214797958|NCT04736264|OTHER|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
214797959|NCT04736264|OTHER|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
214797960|NCT05618171|DIAGNOSTIC_TEST|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
214797961|NCT02309749|OTHER|CAP|
214797962|NCT03317236|DRUG|Quetiapine|A fixed 50 mg exteded release formulation.
214797963|NCT00040378|DRUG|alphatocopherol|400 IU daily
214797964|NCT00040378|DRUG|Selenium|200mcg daily
214797965|NCT00040378|DRUG|Placebo replacement for vitamin E|1 placebo pill daily
214797966|NCT00040378|DRUG|Placebo replacement for Selenium|1 placebo pill daily
214797967|NCT03845933|PROCEDURE|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
214797968|NCT00719290|PROCEDURE|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
214797969|NCT00719290|PROCEDURE|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
214797970|NCT06352320|BIOLOGICAL|Diagnosis of HCM|Hypertrophic cardiomyopathy (HCM) is defined as the presence of increased LV wall thickness (with or without RV hypertrophy) or mass that is not solely explained by abnormal loading conditions.
214797971|NCT06352320|BIOLOGICAL|Diagnosis of DCM|Dilated cardiomyopathy (DCM) is defined as the presence of LV dilatation and global or regional systolic dysfunction unexplained solely by abnormal loading conditions (e.g. hypertension, valve disease, CHD) or CAD.Very rarely, LV dilatation can occur with normal ejection fraction (EF) in the absence of athletic remodelling or other environmental factors; this is not in itself a cardiomyopathy, but may represent an early manifestation of DCM. The preferred term for this is isolated left ventricular dilatation. Right ventricular dilatation and dysfunction may be present but are not necessary for the diagnosis.
214797972|NCT06352320|BIOLOGICAL|Diagnosis of ARVC|Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined as the presence of predominantly RV dilatation and/or dysfunction in the presence of histological involvement and/or electrocardiographic abnormalities in accordance with published criteria.
214797973|NCT06352320|BIOLOGICAL|Diagnosis of NDLVC|The NDLVC phenotype is defined as the presence of non-ischaemic LV scarring or fatty replacement regardless of the presence of global or regional wall motion abnormalities (RWMAs), or isolated global LV hypokinesia without scarring.
214797974|NCT06352320|BIOLOGICAL|Diagnosis of RCM|Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness.Restrictive cardiomyopathy commonly presents as biatrial enlargement. Left ventricular systolic function can be preserved, but it is rare for contractility to be completely normal. Restrictive pathophysiology may not be present throughout the natural history, but only at an initial stage (with an evolution towards a hypokinetic-dilated phase). Restrictive physiology can also occur in patients with end-stage hypertrophic and dilated cardiomyopathy; the preferred terms are 'hypertrophic' or 'dilated cardiomyopathy with restrictive physiology'. Restrictive ventricular physiology can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic function
214797975|NCT06352320|BIOLOGICAL|Diagnosis of LVNC|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickerendocardial layer. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope. Left ventricular non-compaction has also been used to describe an acquired and sometimes transient phenomenon of excessive LV trabeculation (e.g. in athletes, during pregnancy, or following vigorous activity)that must reflect increased prominence of an otherwise normal myocardial architecture, given that cardiomyocytes are terminally differentiated and the formation of new cardiac structures is impossible.The Task Force does not consider LVNC to be a cardiomyopathy in the general sense.
214797976|NCT00508560|BEHAVIORAL|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
214797977|NCT00508560|BEHAVIORAL|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
214797978|NCT00858195|DRUG|Indomethacin 75mg Extended-Release Capsules, Sandoz|
214797979|NCT00858195|DRUG|Indocin 75mg SR Capsules|
214797980|NCT03475784|DRUG|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
214797981|NCT03475784|DRUG|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
214797982|NCT01485536|DRUG|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
214797983|NCT02381977|OTHER|No intervention|
214797984|NCT01093937|DRUG|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
214797985|NCT00859664|OTHER|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
214797986|NCT01000896|DRUG|AZD0530|film coated tablet, PO, daily
214797987|NCT01000896|DRUG|Carboplatin|intravenous, 3 weeks
214797988|NCT01000896|DRUG|paclitaxel|intravenous, 3 weeks
214797989|NCT04359641|DEVICE|CoMET Display|Display and presentation of predictive monitoring score CoMET
214797990|NCT02771015|DEVICE|Mepilex Border®|randomization
214797991|NCT02771015|DEVICE|Cosmopor steril®|randomization
215031101|NCT01734044|DRUG|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
215031102|NCT01734044|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
215031103|NCT02246491|OTHER|A-T iPS cell line|Reprogramming A-T patients iPS cell line
214797992|NCT02626949|BEHAVIORAL|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
214797993|NCT02626949|BEHAVIORAL|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
214797994|NCT02940743|BEHAVIORAL|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
214797995|NCT02940743|BEHAVIORAL|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
214797996|NCT02940743|BEHAVIORAL|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
214797997|NCT01117883|OTHER|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
214797998|NCT01839084|DRUG|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
214797999|NCT01839084|DRUG|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
214798000|NCT01161641|DRUG|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
214798001|NCT01161641|DRUG|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
214798002|NCT01161641|DRUG|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
214798003|NCT03112356|DRUG|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
214798004|NCT00793845|DRUG|Cyclophosphamide|First HDCT
214798005|NCT00793845|DRUG|Etoposide|First HDCT
214798006|NCT00793845|DRUG|Carboplatin|First HDCT
214798007|NCT00793845|DRUG|Thiotepa|Second HDCT
214798008|NCT00793845|DRUG|Melphalan|Second HDCT
214798009|NCT00793845|RADIATION|Total body irradiation|Second HDCT
214798010|NCT06412133|BEHAVIORAL|photography|This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
214798011|NCT00050661|DRUG|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
214798012|NCT00050661|DEVICE|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
215031104|NCT02246491|OTHER|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
215031105|NCT00890500|DRUG|Fludarabine|30mg/m2/day IV x 6 days
215031106|NCT00890500|DRUG|Melphalan|100 mg/m2/day IV x 1 day
215031107|NCT00890500|DRUG|Antithymocyte Globulin|1mg/kg/day x 4 days
215031108|NCT00890500|DRUG|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
214798013|NCT03805828|OTHER|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
214798014|NCT06399770|DEVICE|Muscle ultrasound|Role of muscle ultrasound in LGMD
214798015|NCT04476082|OTHER|No intervention - observational study only|No intervention - observational study only
214798016|NCT02275364|DEVICE|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
214798017|NCT02275364|DEVICE|Placebo strip|Placebo strip
214798018|NCT02275364|OTHER|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
214798019|NCT04683822|OTHER|Telerehabilitation|Patients will attend telerehabilitation sessions
214798020|NCT03177603|DRUG|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
214798021|NCT05070156|BIOLOGICAL|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
214798022|NCT05070156|BIOLOGICAL|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
214798023|NCT05070156|BIOLOGICAL|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
214798024|NCT06544876|BEHAVIORAL|sit-to-stand|test for balance during movement from sitting to standing
214798025|NCT06544876|BEHAVIORAL|stand to sit|test for balance during movement from standing to sitting
214798026|NCT06544876|BEHAVIORAL|standing perturbation|test for balance recovery following perturbation
214798027|NCT06544876|OTHER|MRI of sciatic nerve|measure of peripheral nerve diameter
214798028|NCT00939445|PROCEDURE|Online HDF|Online HDF
214798029|NCT00939445|PROCEDURE|Short Daily Hemodialysis|Short Daily Hemodialysis
214798030|NCT06380946|BIOLOGICAL|iPRF|iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
214798031|NCT02593981|DIETARY_SUPPLEMENT|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
214798032|NCT02593981|DIETARY_SUPPLEMENT|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
214798033|NCT06318858|DIETARY_SUPPLEMENT|Iron supplement|Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
214798034|NCT04094870|DRUG|Sertraline|daily SSRI (Sertraline 25mg)
214798035|NCT04094870|BEHAVIORAL|Interpersonal therapy|11 sessions over a 24-week period
214798036|NCT04263870|DRUG|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
214798037|NCT01798745|DRUG|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
214798038|NCT01798745|OTHER|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
214798039|NCT00669578|DRUG|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
214798040|NCT03384745|DRUG|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
214798041|NCT03384745|DRUG|Placebo|Placebo contains no active drug.
214798042|NCT03384745|DRUG|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
214798043|NCT03480828|DIAGNOSTIC_TEST|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
214798044|NCT01484821|DEVICE|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
214798045|NCT04695405|GENETIC|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
214798046|NCT01924390|DEVICE|Mineralized freeze-dried bone allograft alone|
214647170|NCT00388947|DEVICE|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
214647171|NCT03038308|DRUG|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
214647172|NCT02343484|DRUG|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
214647173|NCT02343484|DRUG|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
214647174|NCT04187092|OTHER|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
214647175|NCT04187092|OTHER|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
214647176|NCT00278876|DRUG|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
214647177|NCT00565994|PROCEDURE|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
214647178|NCT01903265|DRUG|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
214647179|NCT01903265|DRUG|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
214647180|NCT03607279|PROCEDURE|NGAL|
214647181|NCT03712826|DRUG|Anti-TNF Drug|Crohn patient with antiTNF treatment
214647182|NCT03712826|DRUG|Ustekinumab|Crohn disease with ustekinumab treatment
214647183|NCT02303431|DRUG|Edoxaban low dose|Edoxaban low dose
214647184|NCT02303431|DRUG|Edoxaban high dose|Edoxaban high dose
214647185|NCT04175145|OTHER|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
214647186|NCT01777763|DRUG|Posaconazole 200 mg|
214647187|NCT01777763|DRUG|Posaconazole 300 mg|
214647188|NCT04887571|OTHER|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
214647189|NCT05228366|OTHER|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
214798047|NCT01924390|DEVICE|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
214798048|NCT02984683|DRUG|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
214798049|NCT02646345|PROCEDURE|Surgical checklist|Use of the World Health Organization Surgical checklist
214798050|NCT05960851|DRUG|LY3871801|Administered orally.
214798051|NCT05960851|DRUG|Placebo|Administered orally.
214798052|NCT04050488|DRUG|Zinc Sulfate|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
214798053|NCT04050488|DRUG|Placebos|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
214798054|NCT02992405|BEHAVIORAL|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
214798055|NCT02992405|BEHAVIORAL|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
214798056|NCT01877759|BIOLOGICAL|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
214798057|NCT00654485|DRUG|Rosuvastatin|
214798058|NCT00654485|DRUG|Atorvastatin|
214798059|NCT01351142|OTHER|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
214798060|NCT05764889|OTHER|wrapped with the Flexible Sleeve Penis Protection Device|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
214798061|NCT05764889|OTHER|wrapped with traditional gauze|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
214798062|NCT05391399|DEVICE|Interlocking detachable coils system|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
214798063|NCT05391399|DEVICE|Interlock Fibered IDC Occlusion System|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
214798064|NCT04648059|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
214798065|NCT05548933|PROCEDURE|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
214798066|NCT02739984|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection with an automated mini doser
214798067|NCT02739984|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
214798068|NCT02419638|DRUG|Rebif (IFN β-1a subcutaneous three times per week)|
214798069|NCT02419638|DRUG|Tecifdera (dimethyl fumarate)|
214798070|NCT05213078|OTHER|Educational Intervention|Receive teaching intervention
214798071|NCT05213078|OTHER|Quality-of-Life Assessment|Ancillary studies
214798072|NCT05213078|OTHER|Questionnaire Administration|Ancillary studies
214798073|NCT02233790|DRUG|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
214798074|NCT02233790|DRUG|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
214798075|NCT03342703|DIAGNOSTIC_TEST|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
214798076|NCT03880279|BIOLOGICAL|TAC01-CD19|Dose-escalating cohorts plus expansion groups
214798077|NCT00200031|DEVICE|Interstim therapy|
214798078|NCT04950283|DIAGNOSTIC_TEST|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
214798079|NCT01499121|DRUG|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop \> grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
214798080|NCT01847183|BEHAVIORAL|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
214798081|NCT01015430|DRUG|Placebo (for RO4917523 ascending doses)|Placebo daily po
214798082|NCT01015430|DRUG|Placebo (for RO4917523 fixed dose)|Placebo daily po
214798083|NCT01015430|DRUG|RO4917523|RO4917523 ascending doses daily po
214798084|NCT01015430|DRUG|RO4917523|RO4917523 fixed dose daily po
214798085|NCT05169164|OTHER|No intervention, observational|No intervention, observational
214798086|NCT03008460|DRUG|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
214798087|NCT03008460|DRUG|Klean-Prep®|Oral solution taken the evening before the colonoscopy
214798088|NCT04479657|DRUG|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
214798089|NCT04479657|DRUG|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
214798090|NCT04555525|DRUG|sarecycline|sarecycline tablet
214798091|NCT04555525|DIETARY_SUPPLEMENT|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
214798092|NCT06382181|BEHAVIORAL|Music therapy for community-dwelling individuals with unwanted loneliness|Music therapy workshops were implemented. The enjoyment and expression of feelings were encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. There was one session per week. Total 12 sessions.
214798093|NCT06382181|BEHAVIORAL|Health education for community-dwelling individuals with unwanted loneliness|Twelve health education workshops were carried out. They included group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others.
214798094|NCT06382181|BEHAVIORAL|Physical exercise for community-dwelling individuals with unwanted loneliness|This intervention was implemented with 2 group sessions each week for 13 weeks. It included physical exercise adapted to the physical conditions of each participant.
214798095|NCT04986696|DEVICE|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
214798096|NCT02153047|BEHAVIORAL|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
214798097|NCT04947579|DRUG|CC-99677|Oral
214798098|NCT04947579|OTHER|Placebo|Oral
214798099|NCT05720533|DRUG|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
214798100|NCT02381509|DEVICE|IVC Filter|
214798101|NCT04223050|DRUG|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
214798102|NCT00046813|DRUG|Nicotine patch|
214798103|NCT04272021|DRUG|Methylphenidate|standard therapy for ADHD
214798104|NCT05796609|OTHER|Driving under the influence of alcohol|"Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
214798105|NCT05796609|OTHER|Driving under the influence of a placebo|"Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
214798106|NCT03769480|OTHER|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
214798107|NCT04915807|DRUG|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
214798108|NCT04915807|DRUG|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
214647190|NCT05228366|OTHER|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
214647191|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
214647192|NCT03242954|OTHER|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
214647193|NCT03242954|OTHER|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
214647194|NCT03242954|OTHER|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
214647195|NCT04690699|BIOLOGICAL|Lerapolturev|Lerapolturev administered via intravesical instillation once
214647196|NCT04690699|OTHER|5% DDM|5% DDM and saline washes
214647197|NCT00646295|DEVICE|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
214647198|NCT06958367|DRUG|Dexmedetomidine|the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.
214647199|NCT06958367|DRUG|Normal Saline (Placebo)|Group (B): the control group will receive an infusion of an equivalent volume of a 0.9% saline for the same duration
214647200|NCT01781221|DEVICE|Alpha-Bio's GRAFT Natural Bovine Bone|
214647201|NCT01781221|DEVICE|Bio-Oss xenograft|
214647202|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
214647203|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
214647204|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
214647205|NCT06434831|DEVICE|Medical device for SNM: Interstim II, Interstim micro|ANI will be used during the SNM (2 hours)
214647206|NCT04444232|OTHER|Media Intervention|View an educational video
214647207|NCT04444232|OTHER|Survey Administration|Complete survey
214647208|NCT03072693|PROCEDURE|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
214798109|NCT01575054|BIOLOGICAL|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
214798110|NCT01575054|DRUG|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
214798111|NCT01566409|DRUG|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
214798112|NCT01566409|OTHER|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
214798113|NCT05777213|BIOLOGICAL|Secretome|The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
214798114|NCT04666766|DEVICE|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
214798115|NCT04897698|DIETARY_SUPPLEMENT|LB001|Probiotics
214798116|NCT00395707|DRUG|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
214798117|NCT00395707|DRUG|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
214798118|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
214798119|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.5mg/0.05 ml
214798120|NCT02958215|DRUG|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
214798121|NCT02958215|OTHER|Placebo|5 ml normal saline will be given before spinal anesthesia
214798122|NCT04689074|OTHER|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
214798123|NCT04689074|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214647209|NCT03072693|PROCEDURE|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
214647210|NCT03194984|DRUG|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
214647211|NCT03194984|DRUG|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
214647212|NCT04620486|OTHER|Epic Best Practice Alert|This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
214647213|NCT02266680|BEHAVIORAL|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
214647214|NCT00872950|DRUG|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
214647215|NCT04285385|OTHER|Lavender aromatherapy|0.10 ml of lavender essential oil
214647216|NCT04285385|OTHER|Sham aromatherapy|0.10 ml of mineral oil
214647217|NCT06207266|BEHAVIORAL|emotion intelligence program|The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
214647218|NCT03969875|DEVICE|Interscalene catheter|rescue catheters attached to a PCA pump
214647219|NCT03969875|DRUG|Liposomal bupivacaine|10 cc
214647220|NCT03969875|DRUG|Dexamethasone|1 cc of 4mg
214647221|NCT03969875|DRUG|Bupivacaine|0.5% bupivacaine
214647222|NCT04278885|DRUG|Lanadelumab|300mg Lanadelumab s.c. administration every 2 weeks
214647223|NCT03964584|OTHER|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
214647224|NCT06461598|DRUG|Chemotherapy|All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
214647225|NCT00589641|BEHAVIORAL|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
214647226|NCT00589641|BEHAVIORAL|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
214647227|NCT03743831|DEVICE|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
214647228|NCT03743831|DEVICE|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
214647229|NCT05845359|DRUG|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
214647230|NCT01749384|BIOLOGICAL|Bevacizumab|Given IV
214647231|NCT01749384|OTHER|Laboratory Biomarker Analysis|Correlative studies
214647232|NCT01749384|OTHER|Pharmacological Study|Correlative studies
214647233|NCT01749384|DRUG|Tivantinib|Given PO
214647234|NCT02155933|OTHER|Blood sampling|Blood sampling for later hormone measurements
214798124|NCT04689074|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214798125|NCT04474938|DRUG|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
214798126|NCT04474938|DRUG|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
214798127|NCT04474938|DRUG|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
214798128|NCT00764309|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
214798129|NCT05370521|DRUG|Tildacerfont|Oral tablet formulation taken once daily.
214798130|NCT05370521|DRUG|Placebo|Non-active dosage form taken once daily.
214798131|NCT03502642|DEVICE|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
214798132|NCT03502642|PROCEDURE|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
214798133|NCT03502642|DRUG|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
214798134|NCT03502642|DRUG|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
214798135|NCT03502642|DRUG|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
214798136|NCT04165538|PROCEDURE|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of \> 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
214798137|NCT01152203|DRUG|Bendamustine|Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
214798138|NCT01152203|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
214798139|NCT04511390|DEVICE|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
214798140|NCT05153122|DEVICE|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
214798141|NCT02893748|DEVICE|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
214798142|NCT02893748|PROCEDURE|Colonoscopy|Screening colonoscopy as per standard of care.
214798143|NCT02893748|DRUG|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
214798144|NCT01575678|DRUG|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
214798145|NCT01575678|DRUG|Lactose|blinded capsule 1/day, oral use, for 4 weeks
214798146|NCT04659109|DRUG|glenzocimab|IV administration as a sterile product
214798147|NCT04659109|DRUG|Placebo|IV administration
214798148|NCT05443243|PROCEDURE|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
214798149|NCT01179490|DRUG|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
214798150|NCT01179490|DRUG|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
214798151|NCT00097695|DRUG|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
214798152|NCT00097695|DRUG|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
214798153|NCT00001683|DRUG|COL-3|
214798154|NCT02676154|DRUG|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
214798155|NCT03958825|PROCEDURE|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
214798156|NCT03958825|PROCEDURE|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
214798157|NCT00428415|DRUG|Tesofensine|
214798158|NCT03363581|BEHAVIORAL|Food Preference|Buffet meal to assess food preference
214798159|NCT05200858|DEVICE|TENS - high-dose|Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
214798160|NCT05200858|DEVICE|TENS - low-dose|Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
214798161|NCT07036991|DRUG|Evolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe|PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe
214798162|NCT07036991|DRUG|Rosuvastatin/Atorvastatin ± Ezetimibe|Rosuvastatin/atorvastatin ± ezetimibe
214798163|NCT04054024|DRUG|Erenumab|140 mg Erenumab
214798164|NCT04054024|DRUG|Placebos|Saline
214798165|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
214798166|NCT01463540|DEVICE|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
214798167|NCT01463540|DEVICE|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
214798168|NCT06148909|OTHER|Small Talk Motivational Interviewing|Combining small talks and skills on Motivational Interviewing in the smoking cessation services
214798169|NCT00110968|DRUG|Itopride hydrochloride|
214798170|NCT05216536|OTHER|No intervention|No intervention
214798171|NCT05172375|BEHAVIORAL|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
214798172|NCT05769530|DRUG|Nalbuphine，dexmedetomidine|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
214798173|NCT02929979|BEHAVIORAL|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
214798174|NCT02929979|BEHAVIORAL|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
214798175|NCT04762056|OTHER|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
214798176|NCT05833386|PROCEDURE|Ureteral access sheath placement during flexible ureteroscope for renal stones|Ureteral access sheath placement during flexible ureteroscope
214798177|NCT00805558|DRUG|moxifloxacin|400 mg moxifloxacin once daily for 7 days
214798178|NCT00805558|DRUG|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
214798179|NCT00160407|DRUG|Orlistat (Xenical)|
214798180|NCT00160407|BEHAVIORAL|1400 kcal diet (30% fat)|
214798181|NCT00584298|DRUG|SMS995|
214798182|NCT00584298|DRUG|Placebo|
214798183|NCT05067361|PROCEDURE|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
214798184|NCT05067361|PROCEDURE|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
214798185|NCT01361802|DRUG|Ambroxol Spray|low dose Ambroxol Spray
214798186|NCT01361802|DRUG|Ambroxol Spray|medium dose Ambroxol Spray
214798187|NCT01361802|DRUG|Ambroxol Spray|high dose Ambroxol Spray
214798188|NCT01361802|DRUG|Placebo Spray|Placebo Spray
214798189|NCT01691508|DRUG|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
214798190|NCT01691508|DRUG|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
214798191|NCT01691508|DRUG|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
214798192|NCT03700944|OTHER|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
214798193|NCT02472678|OTHER|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
214798194|NCT02472678|OTHER|Standard care|The control group will receive standard care.
214798195|NCT01752348|OTHER|Endotoxin, US standard reference E.coli|
214798196|NCT04125628|BEHAVIORAL|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
214798197|NCT04125628|BEHAVIORAL|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
214798198|NCT05639842|OTHER|Pain in competitive athletes with physical disabilities. Techniques for its management, support received and perceived difficulties.|A total of 413 athletes with physical disabilities participated in the study, 157 Spanish athletes and 260 Latin American athletes. The athletes were contacted through different sports federations, Paralympic Committees and sports teams of people with disabilities.For the distribution of the questionnaire, the researcher made an initial telephone contact with the Spanish Paralympic Committee and the Spanish Sports Federation for People with Physical Disabilities, to explain the objectives of the study and ask for their collaboration in the dissemination. Subsequently, the information was officially sent to them by email.
214798199|NCT00026936|PROCEDURE|Radiotherapy|
214798200|NCT05022836|DIAGNOSTIC_TEST|four-limb blood pressure measurements|Four-limb blood pressures were measured by certificated nurses at admission.
214798201|NCT02322047|DRUG|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
214798202|NCT02322047|DRUG|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
214798203|NCT02322047|DRUG|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
214798204|NCT02322047|DRUG|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
214798205|NCT01596647|DRUG|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
214798206|NCT01596647|DRUG|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
214798207|NCT01596647|DRUG|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
214798208|NCT01596647|DRUG|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
214798209|NCT01596647|DRUG|TKI258|dovitinib, 5 days on / 2 days off dose schedule
214798210|NCT02213796|DRUG|Meropenem|
214798211|NCT01350063|DRUG|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
214798212|NCT01350063|DEVICE|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
214798213|NCT01350063|OTHER|No intervention|
214798214|NCT03830645|BIOLOGICAL|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
214798215|NCT00003145|DRUG|Fludarabine Phosphate|Given IV
214798216|NCT00003145|RADIATION|Total-Body Irradiation|Undergo TBI
214798217|NCT00003145|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
214798218|NCT00003145|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214798219|NCT00003145|DRUG|Cyclosporine|Given PO or IV
214798220|NCT00003145|DRUG|Mycophenolate Mofetil|Given PO or IV
214798221|NCT00003145|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
214798222|NCT00003145|OTHER|Laboratory Biomarker Analysis|Correlative studies
214798223|NCT03491449|PROCEDURE|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
214798224|NCT03491449|PROCEDURE|Group B|Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
214798225|NCT00836836|OTHER|Modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
214798226|NCT06009913|OTHER|online teaching|teaching of subject was done using online system only
214798227|NCT06009913|OTHER|In class teaching|subjects were explained in normal class room
214798228|NCT00175357|DRUG|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
214798229|NCT00175357|DRUG|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
214798230|NCT02207231|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
214798231|NCT02207231|DRUG|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
214798232|NCT02207231|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
214798233|NCT02207231|DRUG|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
214798234|NCT02954757|PROCEDURE|HIFU treatment|High intensity focused ultrasound
214798235|NCT01897974|OTHER|Survey|Families complete survey to measure medication compliance.
214798236|NCT04516525|DEVICE|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
214798237|NCT04928261|DRUG|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
214798238|NCT00185523|PROCEDURE|Allogeneic hematopoietic cell transplantation|
214798239|NCT03020121|PROCEDURE|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
214798240|NCT00326079|DEVICE|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
214798241|NCT03990675|PROCEDURE|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
214798242|NCT05166330|DRUG|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
214798243|NCT05166330|DRUG|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
214798244|NCT01456182|DRUG|AFX-2|Dose level 1
214798245|NCT01456182|DRUG|AFX-2|Dose level 2
214798246|NCT01456182|DRUG|AFX-2|Dose level 3
214798247|NCT01456182|DRUG|AFX-2|Dose level 4
214798248|NCT01456182|DRUG|AFX-2|Dose level 5
214798249|NCT03937063|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
214798250|NCT04241159|BIOLOGICAL|Allogeneic Young Plasma|"The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks."
214798251|NCT02258256|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
214798252|NCT02369809|DRUG|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
214798253|NCT04489407|DEVICE|Remote Photoplethysmography (rPPG) vital sign acquisition|Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
214798254|NCT04637997|DEVICE|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
214798255|NCT04637997|DEVICE|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
214798256|NCT00409994|DRUG|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
214798257|NCT04957108|OTHER|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
214798258|NCT01150487|PROCEDURE|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
214798259|NCT01150487|PROCEDURE|lymph node collection|An Iliac lymph node collection.
214798260|NCT05326464|DRUG|Tofacitinib 10mg|10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
214798261|NCT05005949|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter System|Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
214798262|NCT03462940|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
214798263|NCT02276196|DRUG|Lixisenatide|GLP-1 receptor agonist
214798264|NCT02276196|DRUG|Insulin glulisine|Insulin analogue
214798265|NCT04954950|OTHER|no intervention|no intervention
214798266|NCT01290263|DRUG|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
214798267|NCT01290263|DRUG|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
214798268|NCT03735602|BEHAVIORAL|perceptual training|orientation discrimination task
214798269|NCT05102175|OTHER|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
214798270|NCT03501875|RADIATION|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
214798271|NCT01083875|DRUG|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
214798272|NCT01083875|DRUG|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
214798273|NCT00998699|DRUG|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
214798274|NCT00998699|DRUG|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
214798275|NCT00698906|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
214798276|NCT00698906|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214798277|NCT05231109|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
214798278|NCT02889185|DEVICE|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
214798279|NCT02375009|PROCEDURE|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
214798280|NCT03492359|DEVICE|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
214798281|NCT03492359|DEVICE|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
214798282|NCT03492359|DEVICE|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
214798283|NCT02586259|DRUG|budesonide MMX®|
214798284|NCT00995137|BIOLOGICAL|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
214798285|NCT01315145|PROCEDURE|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
214798286|NCT01315145|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
214798287|NCT03312062|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
214798288|NCT04518774|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
215031109|NCT00890500|DRUG|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
214798289|NCT06409962|OTHER|Technological combination|The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
214798290|NCT03392974|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
214798291|NCT01963039|DEVICE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
214798292|NCT01963039|PROCEDURE|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
214798293|NCT03006016|DRUG|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
214798294|NCT03006016|OTHER|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
214798295|NCT02879279|DEVICE|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
214798296|NCT02879279|OTHER|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
214798297|NCT00996190|DRUG|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
214798298|NCT02933281|BIOLOGICAL|MTBVAC|Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU
214798299|NCT02933281|BIOLOGICAL|BCG|BCG 5 x 10\^5 CFU
214798300|NCT03942523|BEHAVIORAL|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
214798301|NCT05014308|PROCEDURE|Piezoelectric Alveolar Decortication, fibrotomy|
214798302|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
214798303|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
214798304|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
214798305|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
214798306|NCT04535908|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
214798307|NCT03365323|OTHER|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
214798308|NCT03365323|OTHER|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
214798309|NCT03643666|DRUG|dexamethasone|before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
214798310|NCT03643666|DRUG|magnesium sulphate|patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
214798311|NCT03643666|DRUG|Placebo (saline)|before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
214798312|NCT04601584|BIOLOGICAL|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798313|NCT04601584|BIOLOGICAL|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798314|NCT04601584|BIOLOGICAL|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798315|NCT04601584|BIOLOGICAL|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798316|NCT04601584|BIOLOGICAL|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798317|NCT04601584|BIOLOGICAL|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
214798318|NCT02675543|DEVICE|Vitreous Tamponade with Silicone Oil|
214798319|NCT03211559|OTHER|Exercise|clinical pilates on mat
214798320|NCT01751152|DRUG|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
214798321|NCT01751152|DRUG|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
214798322|NCT04815642|RADIATION|radiotherapy|Hypofractionated radiotherapy concomitantly with weekly boost
214798323|NCT02309099|DEVICE|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
214798324|NCT02016300|DEVICE|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
214798325|NCT02016300|DEVICE|Non-Bracing|Microfracture performed with no post-operative unloader bracing
214798326|NCT05495542|OTHER|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects \[5\]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered \[6\]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory \[7\]
214798327|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA fingerstick point of care assay|Xpert® HBV DNA point of care assay from finger-stick whole blood
214798328|NCT04289428|DIAGNOSTIC_TEST|Point of Care ALT|Point of Care ALT from finger-stick whole blood
214798329|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA point of care assay from dried blood spot|Xpert® HBV DNA point of care assay from dried blood spot
214798330|NCT06115005|BIOLOGICAL|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
214798331|NCT02103283|DRUG|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
214798332|NCT00665041|DRUG|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
214798333|NCT06291688|BEHAVIORAL|Mobile healthcare education game|Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.
214798334|NCT06291688|BEHAVIORAL|Mobile healthcare education application|Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
214798335|NCT06165744|DEVICE|UNITY Vitreoretinal Cataract System|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY TOTAL PLUS Combined Procedure Pak, and additional devices as needed to complete surgery
214798336|NCT06165744|PROCEDURE|Posterior segment surgery in the operating room with or without simultaneous cataract surgery|Posterior segment surgery involves removal of the vitreous (i.e., vitrectomy) followed by additional interventions as needed. Cataract surgery involves removal of the crystalline lens (which is often cloudy).
214798337|NCT06211491|OTHER|Urodynamic test|Urodynamic testing is performed using saline solution at the same temperature as body temperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min, respectively.
214798338|NCT01096927|DRUG|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
214798339|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose
214798340|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
214798341|NCT01056874|DRUG|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
214798342|NCT04788680|OTHER|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
214798343|NCT04788680|OTHER|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
214798344|NCT04788680|OTHER|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
214798345|NCT04788680|OTHER|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
214798346|NCT04997694|PROCEDURE|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
214798347|NCT04524065|OTHER|Early rehabilitation protocol for children hospitalized in the PICU|The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
214798348|NCT05456529|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
214798349|NCT02687048|BEHAVIORAL|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
214798350|NCT02687048|BEHAVIORAL|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
214798351|NCT00392639|PROCEDURE|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
214798352|NCT01496040|DRUG|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
214798353|NCT03901014|OTHER|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
214798354|NCT03901014|OTHER|Very low carbohydrate diet|Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
214798355|NCT04384549|BIOLOGICAL|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
214798356|NCT04384549|OTHER|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
214798357|NCT01785836|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
214798358|NCT01785836|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
214798359|NCT01785836|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
214798360|NCT01785836|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
214798361|NCT03622866|DEVICE|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
214798362|NCT03622866|DEVICE|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
214798363|NCT04726202|OTHER|Standard procedure|Coding of cases follows the standard procedures established at the hospital
214798364|NCT04726202|OTHER|precoding|"Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report."
214798365|NCT02786238|BEHAVIORAL|Standard Behavioral Treatment (SBT)|See description of treatment arm.
214798366|NCT02786238|BEHAVIORAL|Acceptance-Based Treatment (ABT)|See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
214798367|NCT03130764|DRUG|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
214798368|NCT03130764|DRUG|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
214798369|NCT01631864|DRUG|LCZ696|LCZ696 was provided as 400 mg tablets.
214798370|NCT01631864|DRUG|amlodipine|amlodipine was provided as 5 mg tablets.
214798371|NCT01631864|DRUG|Placebo|Matching placebo to LCZ696 and amlodipine.
214798372|NCT05366959|OTHER|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
214798373|NCT05366959|OTHER|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
214798374|NCT05366959|OTHER|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
214798375|NCT05366959|OTHER|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
214798376|NCT02815852|OTHER|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women \<40 years the typical imaging presentation pattern of malignancies observed in women\> 40 years are confirmed.
214798377|NCT00265733|DRUG|capecitabine|
214798378|NCT00265733|DRUG|paclitaxel poliglumex|
214798379|NCT00861809|DRUG|GSK962040 25 mg|25 mg
214798380|NCT00861809|DRUG|Placebo|placebo comparator
214798381|NCT00861809|DRUG|GSK962040 50 mg|50 mg
214798382|NCT00861809|DRUG|GSK962040 1250 mg|125 mg
214798383|NCT00583700|DRUG|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
214798384|NCT00583700|DRUG|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
214798385|NCT03443778|DRUG|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
214798386|NCT03443778|DRUG|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
214798387|NCT03443778|DRUG|Nacl 0,9 %|Injectable Solution
214798388|NCT03338361|BEHAVIORAL|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
214798389|NCT03338361|BEHAVIORAL|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
214798390|NCT03338361|BEHAVIORAL|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
214798391|NCT03338361|BEHAVIORAL|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
214798392|NCT00890877|DRUG|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
215031570|NCT03006315|DEVICE|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
215031571|NCT03006315|BEHAVIORAL|Mobile Health quality of life assessements|
214798393|NCT03238677|BEHAVIORAL|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
214798394|NCT03238677|BEHAVIORAL|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
214798395|NCT03238677|BEHAVIORAL|Distributed Practice|2 sessions per week for 10 weeks
214798396|NCT03238677|BEHAVIORAL|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
214798397|NCT03650777|OTHER|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
214798398|NCT03834805|OTHER|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
214798399|NCT00011297|DRUG|gabapentin (Neurontin)|
214798400|NCT00011297|DRUG|lorazepam (Ativan)|
214798401|NCT03602768|BEHAVIORAL|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
214798402|NCT03602768|BEHAVIORAL|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
214798403|NCT03602768|BEHAVIORAL|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
214798404|NCT04217720|DRUG|SNS-301|SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
214798405|NCT00724568|DRUG|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
214798406|NCT00724568|DRUG|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
214798407|NCT00724568|DRUG|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
214798408|NCT00724568|DRUG|Doxil|Patients will be treated with Doxil on day 4.
214798409|NCT02841774|DRUG|Pravastatin|40mg daily (Weeks 2 - 14)
214798410|NCT02841774|DRUG|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
214798411|NCT00066131|PROCEDURE|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
214798412|NCT00066131|PROCEDURE|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
214798413|NCT05700591|DRUG|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
214798414|NCT05700591|DRUG|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
214798415|NCT01242280|DEVICE|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
214798416|NCT01242280|DEVICE|Tamponade|Sengstaken-Blakemore tube
214798417|NCT00073294|BEHAVIORAL|diet|
214798418|NCT01456481|DRUG|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
214798419|NCT01456481|DRUG|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
214798420|NCT01434966|OTHER|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
214798421|NCT01434966|OTHER|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
214798422|NCT01434966|OTHER|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
214798423|NCT05153265|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
214798424|NCT05471674|DRUG|Nivolumab|3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
214798425|NCT05471674|PROCEDURE|Hepatectomy|Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
214798426|NCT05539820|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
214798427|NCT03824626|DIAGNOSTIC_TEST|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
214798428|NCT03409757|DRUG|Velphoro|4 weeks
214798429|NCT03409757|OTHER|saliva collection|2 samples
214798430|NCT03409757|OTHER|Supragingival biofilm collection|2 samples
214798431|NCT03409757|OTHER|stool collection|2 samples
214798432|NCT03409757|OTHER|blood collection|2 samples
214798433|NCT03305029|DRUG|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
215031572|NCT04767048|PROCEDURE|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
214798434|NCT02433665|DRUG|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
214798435|NCT02433665|DEVICE|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
214798436|NCT05948748|PROCEDURE|foot surgery|minimally invasive osteoarticular foot surgery
214798437|NCT00757601|DRUG|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
214798438|NCT00757601|DRUG|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
214798439|NCT01868841|DRUG|AdreView|10 millicurie of AdreView (123I-mIBG)
214798440|NCT01868841|OTHER|Single Photon Emission Computed Tomography|
214798441|NCT01552096|DRUG|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
214798442|NCT00527423|DRUG|VEGF Trap Eye|Intravitreal injection
214798443|NCT04502342|COMBINATION_PRODUCT|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
214798444|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
214798445|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
214798446|NCT04112485|PROCEDURE|Microdiscectomy|
214798447|NCT04774432|OTHER|GM-CSF group|GM-CSF added to CAPA and maturation medium
214798448|NCT04774432|OTHER|Control group|GM-CSF will not be added to CAPA and maturation medium
214798449|NCT05592509|DIETARY_SUPPLEMENT|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
214798450|NCT01957488|DEVICE|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
214798451|NCT01957488|DEVICE|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
214798452|NCT01957488|DEVICE|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
214798453|NCT03104322|OTHER|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
214798454|NCT03104322|OTHER|usual care|usual care
214798455|NCT03405207|DRUG|Vitamin D3 50000 UNT Oral Capsule|Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
214798456|NCT03405207|DRUG|Placebo oral capsule|identical as active drug providing by pharmaceutical company unless it is placebo
214798457|NCT01439165|BIOLOGICAL|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
214798458|NCT01439165|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
214798459|NCT05233280|OTHER|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
214798460|NCT01223807|OTHER|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
214798461|NCT00442910|DRUG|3% SPL7013 Gel (VivaGel)|3% vaginal gel
214798462|NCT00442910|DRUG|Placebo Gel|Placebo for SPL7013 gel
214798463|NCT00442910|DRUG|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
214798464|NCT02101541|PROCEDURE|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
214798465|NCT03499938|DEVICE|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
214798466|NCT02439398|BIOLOGICAL|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
214798467|NCT02439398|OTHER|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
214798468|NCT06291948|BIOLOGICAL|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose
214798469|NCT06291948|BIOLOGICAL|Adalimumab Richmond [Test Product]|A single subcutaneous dose
214798470|NCT02274298|BEHAVIORAL|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
214798471|NCT00623103|DRUG|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
214798472|NCT00623103|DRUG|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
214798473|NCT04784000|DRUG|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
214798474|NCT04784000|DRUG|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
214798475|NCT04784000|DRUG|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
214798476|NCT04784000|DRUG|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
214798477|NCT06196684|PROCEDURE|Mitral allograft implantation|Tricuspid valve replacement with mitral valve allograft
214798478|NCT02401282|BEHAVIORAL|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
214798479|NCT02401282|BEHAVIORAL|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
214798480|NCT04021069|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
214798481|NCT00376948|DIETARY_SUPPLEMENT|genistein|
214798482|NCT00376948|DRUG|erlotinib hydrochloride|
214798483|NCT00376948|DRUG|gemcitabine hydrochloride|
214798484|NCT03236857|DRUG|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
214798485|NCT03236857|DRUG|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
214798486|NCT02468739|DRUG|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
214798487|NCT02468739|DRUG|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
214798488|NCT06364722|OTHER|Acupuncture treatment|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
214798489|NCT06364722|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
214798490|NCT00688064|DRUG|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
214798491|NCT00688064|DRUG|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
214798492|NCT01138072|DRUG|GSK2248761|200mg once daily
214798493|NCT01138072|DRUG|Simvastatin|20 mg Simvastatin single dose
214798494|NCT01138072|DRUG|Atorvastatin|20 mg atorvastatin single dose
214798495|NCT01138072|DRUG|Rosuvastatin|10 mg rosuvastatin single dose
214798496|NCT01985802|OTHER|Pacing|
214798497|NCT05867355|PROCEDURE|surgical fixation|compare implant removal rates between surgical fixation techniques.
214798498|NCT05334849|DEVICE|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
214798499|NCT00001849|DRUG|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
214798500|NCT00001849|DRUG|18F-DOPA|18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
214798501|NCT00001849|DEVICE|CT scan|CT scan of chest, abdomen, neck and /or pelvis
214798502|NCT00001849|DEVICE|MRI|MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis
214798503|NCT00001849|DRUG|18-FDG|FDG PET scan of body
214798504|NCT02276313|DEVICE|Passeo-18 Lux|Endovascular Therapy
214798505|NCT00605449|DRUG|GSK376501|
214798506|NCT05936749|GENETIC|Pre-implantation genetic testing|
214798507|NCT00442936|DRUG|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
214798508|NCT00442936|DRUG|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
214798509|NCT00442936|DRUG|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
214798510|NCT00442936|DRUG|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
214798511|NCT00442936|DRUG|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
214798512|NCT00442936|DRUG|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
214798513|NCT00442936|DRUG|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
214798514|NCT03955536|OTHER|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
214798515|NCT03955536|OTHER|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
214798516|NCT03955536|OTHER|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~\- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
214798517|NCT00063206|DRUG|DVS-233 SR|
214798518|NCT00008736|DRUG|metoclopramide|
214798519|NCT05201690|DRUG|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
214798520|NCT05201690|DRUG|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
214798521|NCT05201690|DRUG|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
214798522|NCT01449266|DRUG|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
214798523|NCT00732290|DRUG|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
214798524|NCT00732290|DRUG|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
214798525|NCT05524103|DRUG|ALMB-0166|A single dose of ALMB-0166 injection.
214798526|NCT03400384|OTHER|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
214798527|NCT03273244|DEVICE|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
214798528|NCT01375881|DRUG|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
214798529|NCT00343759|DRUG|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
214798530|NCT02433678|DRUG|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
214798531|NCT02433678|DRUG|Placebo|
214798532|NCT02152878|DEVICE|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
214798533|NCT02152878|DEVICE|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
214798534|NCT00277745|DEVICE|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
214798535|NCT02083315|DRUG|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
214798536|NCT02083315|DRUG|TRV130 3 mg|TRV130 3 mg IV x 1 dose
214798537|NCT02083315|DRUG|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
214798538|NCT02083315|DRUG|Morphine 10 mg|Morphine 10 mg IV x 1 dose
214798539|NCT02083315|DRUG|Placebo|Dextrose 5% in water IV x 1 dose
214798540|NCT01024738|DRUG|Fluoride|Brush half mouth twice daily for four days.
214798541|NCT01024738|DRUG|Triclosan, fluoride|Brush twice daily
214798542|NCT01024738|DRUG|Chlorhexidine Gluconate|Rinse mouth twice a day
214798543|NCT06189378|OTHER|Inclusion of patient-provided pictures into blood pressure diaries|Patient-provided pictures with positive meaning were included into blood pressure diaries
214798544|NCT06189378|OTHER|Conventional blood pressure diary|Conventional blood pressure diary
214798545|NCT04103177|OTHER|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
214798546|NCT04076501|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
214798547|NCT04076501|PROCEDURE|Sham room air|Room air applied via mask
214798548|NCT05641597|OTHER|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
214798549|NCT05641597|OTHER|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
214798550|NCT05641597|OTHER|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
214798551|NCT05641597|OTHER|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
214798552|NCT00118105|BIOLOGICAL|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
214798553|NCT00118105|DRUG|capecitabine|Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
214798554|NCT00118105|DRUG|oxaliplatin|130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4
214798555|NCT00118105|PROCEDURE|conventional surgery|Resection
214798556|NCT01506947|DRUG|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
214798557|NCT01506947|DRUG|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
214798558|NCT00677196|DEVICE|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
214798559|NCT00677196|DEVICE|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
214798560|NCT04179045|DEVICE|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
214798561|NCT01421706|DRUG|Sibutramine-clopidogrel|Sibutramine-clopidogrel
214798562|NCT01421706|DRUG|sibutramine-Clarithromycin|sibutramine-Clarithromycin
214798563|NCT02820922|PROCEDURE|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
214647235|NCT04952623|OTHER|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
214647236|NCT04547322|OTHER|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
214647237|NCT02327260|BEHAVIORAL|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
214647238|NCT02327260|BEHAVIORAL|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
214647239|NCT06024525|DEVICE|Paclitaxel-Coated Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
214647240|NCT06024525|DEVICE|Paclitaxel-Releasing Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
214647241|NCT02987894|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
214647242|NCT04548557|BIOLOGICAL|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
214647243|NCT05133830|DRUG|Obeticholic acid|OCA will be administered
214647244|NCT05133830|DRUG|Linerixibat|Linerixibat will be administered
214647245|NCT03502330|DRUG|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
214647246|NCT03502330|DRUG|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
214647247|NCT03502330|DRUG|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
214647248|NCT06337435|OTHER|multi-looped wire|using multi-looped wire as a retainer
214647249|NCT04213404|DRUG|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
214647250|NCT04213404|DRUG|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
214647251|NCT02265484|DRUG|Lactulose+Rifaximin +Bromocriptine|
214647252|NCT03233932|DRUG|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
214647253|NCT03233932|DRUG|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
214647254|NCT00548548|DRUG|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
214798564|NCT03131180|OTHER|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
214798565|NCT04782648|PROCEDURE|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
214798566|NCT04540640|DEVICE|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
214798567|NCT00496444|DRUG|Azacitidine|Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
214798568|NCT00496444|DRUG|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
214798569|NCT00257712|DRUG|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
214798570|NCT01648010|DEVICE|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
214798571|NCT01648010|DEVICE|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
214798572|NCT03282838|DRUG|DFN-15 (fasted)|DFN-15 administered to fasted subjects
214798573|NCT03282838|DRUG|DFN-15 (fed)|DFN-15 administered to fed subjects
214798574|NCT03282838|DRUG|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
214798575|NCT01700621|BIOLOGICAL|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
214798576|NCT01700621|BIOLOGICAL|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
214798577|NCT03923764|DIETARY_SUPPLEMENT|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
214798578|NCT03923764|OTHER|Habitual Diet|Patients continue their usual diet
214798579|NCT02499666|PROCEDURE|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
214798580|NCT02499666|DEVICE|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
214798581|NCT02499666|DRUG|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
214798582|NCT02166697|DRUG|candesartan cilexetil|candesartan cilexetil tablets
214798583|NCT04566809|OTHER|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
214798584|NCT04566809|OTHER|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
214798585|NCT00939653|DRUG|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
214798586|NCT00939653|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
214798587|NCT00939653|DRUG|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
214798588|NCT00939653|DRUG|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.
214798589|NCT00939653|DRUG|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age"
214798590|NCT00515645|OTHER|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
214798591|NCT00569062|DRUG|GW856553X|GW856553X 7.5mg BID for 6 weeks
214798592|NCT00569062|OTHER|Placebo|Placebo to match GW856553X
214798593|NCT06497322|OTHER|Exercise intervention - High intensity interval training on a cycle-ergometer|The experimental group starts with 5 minutes of unloaded cycling, followed by 3 × 3-minute HIIT training sequences alternating between: i) 30 seconds at 90% of maximal PO (70 rpm for 30 seconds) and ii) 30 seconds of light pedaling at 20% of PO). Recent work suggests that this high-intensity approach to aerobic exercise is feasible and safe, even during acute oncology treatment. The HIIT sequences are interspersed with two 3-minute cycling sessions at moderate intensity. The training session will be concluded with a 5-minute cool-down by cycling (light pedaling) and stretching. This protocol will be performed twice a week throughout the study, and all patients who reach an 80% adherence threshold for the exercise intervention will be included in the final analysis.
214798594|NCT01311804|PROCEDURE|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
214798595|NCT01311804|PROCEDURE|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
214798596|NCT03622658|BIOLOGICAL|Placebo|Placebo solution for subcutaneous injection.
214798597|NCT03622658|BIOLOGICAL|Namilumab|Namilumab solution for subcutaneous injection
214798598|NCT02720510|DRUG|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
214798599|NCT02720510|DRUG|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
214798600|NCT02720510|DRUG|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
214798601|NCT02720510|DRUG|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
214798602|NCT02865408|DIETARY_SUPPLEMENT|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
214798603|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
214798604|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
214798605|NCT00983710|BEHAVIORAL|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
214798606|NCT00983710|BEHAVIORAL|Usual care|Booklet on coping with localized prostate cancer
214798607|NCT02869646|PROCEDURE|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
214798608|NCT02869646|PROCEDURE|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
214798609|NCT05585996|BIOLOGICAL|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
214798610|NCT02063295|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
214798611|NCT02063295|DRUG|ZGN-440 for injectable suspension|
214798612|NCT01992055|BEHAVIORAL|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
214798613|NCT01992055|BEHAVIORAL|Education & relaxation training|The Education \& Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
214798614|NCT03003338|DRUG|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
214798615|NCT03003338|DRUG|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
214798616|NCT02780336|OTHER|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
214798617|NCT05043636|DEVICE|Vagus|Cardiovascular autonomic neuropathy (Vagus) both resting heart rate variability and cardiovascular reflex tests The examination consists of 4 measures, all aimed at measuring heart rate. Measurements are taken for 5 minutes rest, change of position from lying to standing position, during deep breathing and by Valsalva (by breathing in a mouthpiece with a 40 mmHg resistance).
214798618|NCT05043636|DEVICE|HeartsTrends|• Cardiovascular autonomic neuropathy (HeartTrends®) measurers 60-minutes heart rate variability via a chest belt electrode (a Holter monitor) and an external data acquisition device.
214798619|NCT05043636|DEVICE|Sudoscan|Peripheral small-fiber sympathetic function (Sudoscan), measuring sudomotor function by electrochemical skin conductance in hands and feet
214798620|NCT05043636|DEVICE|UllMeter|• Pressure pain sensitivity of the chest bone is recorded (with a device which has the size and shape as a pen)during rest as a measure for sympathetic autonomic activity of the brain (UllMeter®) (www.stressmeter.org)
214798621|NCT05043636|DEVICE|DPN-check|Nerve conduction velocity and amplitude of the Sural nerves by DPN-check
214798622|NCT05043636|DEVICE|Rolltemp|Cold and warm sense of foot and lower leg
214798623|NCT05043636|DEVICE|Dexcom G6 Device|"Insertion of continuous glucose monitor ( The Dexcom G6 Device)~After 10 days in the study the patient will return the glucose monitor and diary by prepaid mail.~Glycemic variability and hypoglycemia duration will be calculated from CGM data. Glycemic variability will be assessed by standard deviation (SD) and Coefficient of Variance (CV). We define normo-glycemic range as sensor glucose between 4.0 and 10.0 mmol/L. Hypoglycemia will be defined in two ranges as SG ≤3.9 mmol/L or SG ≤3.0 mmol/L). An episode of hypoglycemia will be defined as at least 15 minutes with SG below 3.9 mmol/L or 3.0 mmol/L, respectively. CGM recordings with less than 72 hours of data will be excluded from analysis."
214798624|NCT04005664|DRUG|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
214798625|NCT03886090|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
214798626|NCT03886090|BEHAVIORAL|rest|Seated rest following motor skill practice
214798627|NCT03886090|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
214798628|NCT01719406|BEHAVIORAL|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
214798629|NCT02834000|DEVICE|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
214798630|NCT03140007|DEVICE|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
214798631|NCT03140007|DEVICE|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
214798632|NCT05944107|OTHER|Activated Clotting Time measurements combined with heparin concentration monitoring|In the HC group, the initial heparin dose is calculated using the HepCon HMS Plus . Except for ACT, heparin concentration is measured to maintain target heparin levels during CPB. The protamine dose for reversal is computed based on actual measured heparin levels using the device. ACT is also performed in all instances.
214798633|NCT05944107|OTHER|Activated Clotting Time|The target ACT for procedures other than Coronary Artery Bypass Grafting (CABG) is 400s when Minimally Invasive Extracorporeal Circulation is used. A bolus of 300 International Units(IU)/kg heparin are administered to reach this target and initiate cardiopulmonary bypass (CPB). Repeated ACT measurements guide further heparin dose to maintain adequate anticoagulation. Then, at the end of the CPB, 0.75 mg of protamine are administered for every 100IU of the initial heparin bolus.
214798634|NCT01504737|OTHER|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
214798635|NCT01504737|OTHER|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
214798636|NCT02585700|BIOLOGICAL|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
214798637|NCT02585700|OTHER|Placebo|0.5 mL of phosphate buffered saline
214798638|NCT05685979|PROCEDURE|Robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
214798639|NCT02841826|OTHER|IUD|
214798640|NCT02841826|OTHER|Uterine sounding|
214798641|NCT02841826|RADIATION|Transvaginal ultrasound|
214798642|NCT03104205|BEHAVIORAL|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
214798643|NCT01618266|DRUG|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
214798644|NCT02985151|DEVICE|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
214798645|NCT02226796|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
214798646|NCT04735419|OTHER|No intervention|No intervention
214798647|NCT00195299|DRUG|Temsirolimus|
214798648|NCT00450996|DRUG|Topical Steroids|
214798649|NCT05391009|DIAGNOSTIC_TEST|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
214798650|NCT05391009|DIAGNOSTIC_TEST|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
214798651|NCT03341065|DEVICE|exoskeleton type robot|
214798652|NCT03341065|DEVICE|end-effector type robot|
214798653|NCT05396820|OTHER|Experimental pain|Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
214798654|NCT04669665|DRUG|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
214798655|NCT04669665|DRUG|Placebo|Intranasal placebo
214798656|NCT04669665|OTHER|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
214798657|NCT04669665|DEVICE|Intranasal device|Device to deliver intranasal solution
214798658|NCT04744740|DEVICE|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
214798659|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
214798660|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
214798661|NCT00762957|DRUG|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
214798662|NCT03422926|BEHAVIORAL|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
214798663|NCT04664842|OTHER|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
214798664|NCT04664842|OTHER|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
214798665|NCT00317499|OTHER|Placebo|Placebo
214798666|NCT00317499|DRUG|Etanercept|Etanercept
214798667|NCT00625807|BEHAVIORAL|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
214798668|NCT00625807|BEHAVIORAL|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
214798669|NCT02473978|DEVICE|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
214798670|NCT00007878|DRUG|bortezomib|Given IV
214798671|NCT00007878|DRUG|fluorouracil|Given IV
214798672|NCT00007878|DRUG|leucovorin calcium|Given IV
214798673|NCT00007878|OTHER|pharmacological study|Correlative studies
214798674|NCT00007878|OTHER|laboratory biomarker analysis|Correlative studies
214798675|NCT04550195|DRUG|BMS-986337|Specified Dose on Specified Days
214798676|NCT04550195|OTHER|BMS-986337 Placebo|Specified Dose on Specified Days
214798677|NCT04550195|BIOLOGICAL|Famotidine|Specified Dose on Specified Days
214798678|NCT04342923|OTHER|No intervention|Blood analysis
215031573|NCT04767048|PROCEDURE|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
214798679|NCT01346423|BEHAVIORAL|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
214798680|NCT01346423|BEHAVIORAL|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
214798681|NCT00116935|DRUG|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
214798682|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
214798683|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
214798684|NCT02022813|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
214798685|NCT03997747|OTHER|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
214798686|NCT02870712|PROCEDURE|Suture of perineum|suture of the tear to obtain hemostasis
214798687|NCT02870712|PROCEDURE|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
215031574|NCT07009691|DIETARY_SUPPLEMENT|Hydrogen water which is prepared from an OTC supplement.|The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.
214647255|NCT00548548|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
214647256|NCT00548548|DRUG|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
214647257|NCT00548548|DRUG|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
214647258|NCT00548548|DRUG|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
214647259|NCT02664116|DRUG|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
214647260|NCT02664116|DRUG|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
214647261|NCT02128126|DRUG|ISA101/ISA101b|Four dose levels ISA101/ISA101b
214647262|NCT05714904|DRUG|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
214647263|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
214647264|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
214647265|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
214647266|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
214798688|NCT04400526|BEHAVIORAL|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
214798689|NCT04400526|BEHAVIORAL|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
214798690|NCT04400526|BEHAVIORAL|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
214798691|NCT05498246|PROCEDURE|laparoscopic partial nephrectomy|Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
214798692|NCT05050786|DEVICE|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
214798693|NCT05050786|OTHER|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
214798694|NCT01784042|DRUG|Placebo|placebo
214798695|NCT01784042|DRUG|Lovaza|
214798696|NCT01784042|OTHER|Dietary energy restriction|
214798697|NCT03317197|DRUG|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
214798698|NCT03317197|DRUG|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
214798699|NCT03317197|DRUG|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
214798700|NCT03317197|DRUG|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
214798701|NCT04861545|OTHER|Soy|"Isolated soy protein food sources are foods that include isolated soy protein in different forms and matrix (e.g. soy beverage and meat analogue).~Non-isolated soy protein food sources of soy protein are foods made with soy (e.g. Tofu, tempeh, edamame)."
214798702|NCT05265182|PROCEDURE|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
214798703|NCT04702620|DEVICE|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
214798704|NCT04716660|OTHER|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
214798705|NCT04510701|OTHER|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
214798706|NCT04708795|DRUG|AP701|Preparation of Cannabis flowers (Cannabis flos)
214798707|NCT02187042|OTHER|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
214798708|NCT02187042|OTHER|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
214798709|NCT00670956|DRUG|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
214798710|NCT00670956|DRUG|Placebo|PLACEBO: IM x 2 doses 24 hours apart
214798711|NCT04965571|GENETIC|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
214798712|NCT05029583|OTHER|routine screening|routine screening for advanced NASH
214798713|NCT05029583|OTHER|physician-driven screening|physician-driven screening for advanced NASH
214798714|NCT02044783|BEHAVIORAL|Behavioral Counseling|
214798715|NCT05795491|DEVICE|Blue Light Emitting Diode Therapy|Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
214798716|NCT05795491|DRUG|Azole Antifungal|Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
214798717|NCT01876862|OTHER|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
214798718|NCT01938118|BEHAVIORAL|Obesity Prevention Group|
214798719|NCT01938118|BEHAVIORAL|Injury Prevention Group|
214798720|NCT04040010|DIETARY_SUPPLEMENT|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
214798721|NCT03843203|DEVICE|Transcranial Direct Current Stimulation - tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
214798722|NCT03712553|BEHAVIORAL|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
214798723|NCT03712553|BEHAVIORAL|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
214798724|NCT03712553|BEHAVIORAL|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
214798725|NCT03712553|BEHAVIORAL|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
214798726|NCT00536575|DRUG|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
214798727|NCT00536575|DRUG|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
214798728|NCT04012697|BEHAVIORAL|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
214647267|NCT01447238|DEVICE|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
214647268|NCT00956930|RADIATION|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
214647269|NCT00956930|DRUG|Doxorubicin|75mg fixed dose
214647270|NCT00734084|DEVICE|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
214647271|NCT02313740|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
214798729|NCT03219398|PROCEDURE|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
214798730|NCT00424658|PROCEDURE|SAHS diagnosis|
214798731|NCT00794183|DEVICE|CRT device settings|Comparision of A-V delay settings
214798732|NCT04774081|DEVICE|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
214798733|NCT04337996|DIAGNOSTIC_TEST|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
214798734|NCT02010411|DRUG|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
214798735|NCT06165900|DRUG|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
214798736|NCT06165900|DRUG|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
214798737|NCT00790959|BEHAVIORAL|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
214798738|NCT00790959|OTHER|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
214798739|NCT03734497|OTHER|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
214798740|NCT03734497|OTHER|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
214798741|NCT03734497|OTHER|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
214798742|NCT04488640|PROCEDURE|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
214798743|NCT05964634|DIAGNOSTIC_TEST|OCT imaging|Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy.
214798744|NCT02532010|DRUG|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
214798745|NCT02532010|DRUG|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
214798746|NCT02532010|DRUG|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
214798747|NCT04373577|PROCEDURE|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
214798748|NCT04373577|PROCEDURE|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
214798749|NCT01065103|PROCEDURE|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
214798750|NCT01147952|BEHAVIORAL|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
214798751|NCT04137822|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
214798752|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
214798753|NCT03357783|OTHER|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
214798754|NCT04928651|DRUG|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
214798755|NCT00809042|DRUG|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
214798756|NCT00809042|DRUG|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
214798757|NCT00809042|DRUG|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
214798758|NCT00809042|DRUG|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
214647272|NCT03617705|DEVICE|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
214798759|NCT01380028|DRUG|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
214798760|NCT01380028|DRUG|placebo|placebo
214798761|NCT00788957|DRUG|Panitumumab|Panitumumab for intravenous infusion
214798762|NCT00788957|DRUG|Ganitumab|Ganitumab for intravenous infusion
214647273|NCT03617705|DEVICE|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
214798763|NCT00788957|DRUG|Rilotumumab|Rilotumumab for intravenous infusion
214647274|NCT03617705|DEVICE|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
214798764|NCT00788957|DRUG|Placebo|Placebo intravenous infusion
214798765|NCT03387098|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
214798766|NCT03387098|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214798767|NCT03387098|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214798768|NCT03387098|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
214798769|NCT03387098|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
214798770|NCT03387098|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
214798771|NCT03387098|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
214798772|NCT03387098|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214647275|NCT04399382|DRUG|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
214647276|NCT04997239|BIOLOGICAL|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
214647277|NCT04997239|BIOLOGICAL|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
214798773|NCT03387098|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214798774|NCT03387098|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214798775|NCT03387098|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214798776|NCT03387098|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214798777|NCT03387098|DRUG|lovaza|Omega-3-acid ethyl esters
214798778|NCT03387098|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214798779|NCT03387098|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214798780|NCT05067049|DEVICE|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
214798781|NCT05067049|DEVICE|Unconnected arm|Follow-up visits with the pysicians as usual
214798782|NCT03276975|DRUG|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
214798783|NCT01811043|BEHAVIORAL|Guided Meditation|
214798784|NCT01811043|BEHAVIORAL|Music|
214798785|NCT01811043|BEHAVIORAL|Supportive Dialogue|
214798786|NCT01349556|DRUG|Tretinoin|tretinoin 0.025% cream
214798787|NCT06348836|OTHER|Exercise|Description of exercises are noted in the arms/groups descriptions
214798788|NCT05197166|OTHER|Acute Clinical Settings|Acute clinical settings, like hospitals, where students are exposed to normal daily shift activities, involving prolonged walking and standing positions.
214798789|NCT04498923|DRUG|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
214798790|NCT02029209|DRUG|Anlotinib|Anlotinib QD
214798791|NCT02029209|DRUG|Placebo Capsule|Placebo capsule QD
214798792|NCT06285721|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
214798793|NCT06285721|DEVICE|Sham transcranial alternating current stimulation (tACS)|Sham-tACS is a form of non-effective stimulation which can mimic the subjective sensation of active tACS treatment. During sham-tACS, the device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.The sham-tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
214798794|NCT01282996|OTHER|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
214798795|NCT00918567|DRUG|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
214798796|NCT00918567|BEHAVIORAL|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
214798797|NCT06482463|BIOLOGICAL|CSF sample|an additional CSF sample of 1 ml is taken from the external ventriculostomy
214798798|NCT02581800|OTHER|App group|
214798799|NCT00021658|PROCEDURE|Pesticide application procedures|
214798800|NCT00128557|DIETARY_SUPPLEMENT|vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)|Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
214798801|NCT05596708|DRUG|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
214798802|NCT00653536|DEVICE|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
214798803|NCT03411005|DIETARY_SUPPLEMENT|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
214798804|NCT02294071|DRUG|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
214798805|NCT02294071|DRUG|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
214647278|NCT03502187|BEHAVIORAL|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
214647279|NCT03502187|DEVICE|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
214647280|NCT03502187|BEHAVIORAL|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
214647281|NCT01061008|OTHER|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
214647282|NCT01061008|OTHER|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
214647283|NCT01492673|DRUG|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
214647284|NCT02908100|DRUG|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
214647285|NCT02908100|DRUG|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
214798806|NCT00738166|OTHER|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
214798807|NCT00738166|OTHER|Diet (organic or conventional)|organic or conventional diet
214798808|NCT00000406|PROCEDURE|Progressive resistance exercise|
214798809|NCT01055223|DRUG|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
214647286|NCT02970695|DEVICE|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
214647287|NCT02970695|DEVICE|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
214647288|NCT04088409|DRUG|Baricitinib|Administered orally
214647289|NCT04088409|DRUG|Adalimumab|Administered SC
214647290|NCT02181933|DRUG|Nevirapine|
214647291|NCT02181933|DRUG|Zidovudine (ZDV)|
214647292|NCT02181933|DRUG|Lamivudine (3TC)|
214647293|NCT05182047|DRUG|Butamirate citrate|Butamirate citrate syrup will be administered orally.
214647294|NCT05182047|DRUG|Sinecod|Sinecod syrup will be administered orally.
214647295|NCT05573971|OTHER|with verbal encouragement|Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
214647296|NCT02065739|DRUG|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
214647297|NCT02065739|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
214647298|NCT00400400|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
214647299|NCT00400400|DRUG|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
214647300|NCT00400400|DRUG|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
214647301|NCT00400400|DRUG|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
214647302|NCT06522776|BEHAVIORAL|Cognitive behavioral therapy|The investigator adapted the manual of psychological intervention based on Cognitive Behavioral Therapy (CBT) which previously was validated in patients with chronic kidney disease. Patients received CBT using a model of six modules, with a time of 60 minutes for each weekly session. For each module, a skill acquisition criterion was used, to know if the participants were putting the techniques into practice in their daily lives and to know if it was pertinent to move on to the next module. Modules were adapted to the needs of each participant. In consequence, the number of sessions was different for each patient. All participants had a follow-up session one month after they finished the psychological therapy. Additionally, a daily self-record of symptoms perception and a short questionnaire on the usefulness of each technique used were sent daily to the participants via a phone text message.
214647303|NCT05561790|BEHAVIORAL|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
214647304|NCT02743247|DRUG|Tacrolimus|
214647305|NCT02743247|DRUG|Mycophenolate mofetil|
214647306|NCT05322213|DRUG|THC|2-Week, once daily, flexible dose, inhaled THC
214647307|NCT05322213|DRUG|Placebo|2-Week, once daily, flexible dose, inhaled placebo
214647308|NCT01497977|DRUG|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
214647309|NCT01497977|DRUG|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
214647310|NCT00949156|PROCEDURE|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
214647311|NCT05698667|DIAGNOSTIC_TEST|Transoral ultrasound|Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)
214647312|NCT05698667|DIAGNOSTIC_TEST|Transcervical ultrasound|The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.
214647313|NCT00627237|BEHAVIORAL|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
214798810|NCT01055223|DRUG|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
214798811|NCT01055223|DRUG|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
214798812|NCT01017783|BEHAVIORAL|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
214798813|NCT01017783|BEHAVIORAL|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
214798814|NCT01017783|BEHAVIORAL|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
214798815|NCT03587207|BIOLOGICAL|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
214798816|NCT03587207|BIOLOGICAL|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group, rMenBOMV+ACWY\_D Group and rMenBOMV Group
214798817|NCT03587207|BIOLOGICAL|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group and rMenBOMV+ACWY\_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
214798818|NCT02568384|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
214798819|NCT01473966|DIETARY_SUPPLEMENT|coffee|patients will receive a cup of coffee at room temperature orally twice daily
214798820|NCT01473966|DIETARY_SUPPLEMENT|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
214798821|NCT00966953|DRUG|Fluoride|Brush twice daily
214798822|NCT00966953|DRUG|Triclosan/Fluoride toothpaste|Brush twice daily
214798823|NCT00966953|DRUG|Fluoride|Brush twice daily
214798824|NCT00966953|DRUG|Fluoride|Brush twice daily
214798825|NCT00966953|OTHER|antibacterial plant extract|Brush twice daily
214798826|NCT03283709|DEVICE|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
214798827|NCT03283709|DEVICE|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
214798828|NCT00950157|OTHER|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
214798829|NCT00796510|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
214798830|NCT00796510|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
214798831|NCT06266988|DRUG|Sacubitril and Valsartan Tablets 97mg/103mg|Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
214798832|NCT06266988|DRUG|Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)|Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
214647314|NCT00627237|BEHAVIORAL|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
214647315|NCT03417271|DEVICE|Deep brain stimulation|The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
214647316|NCT04205890|DRUG|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
214647317|NCT00570102|DIETARY_SUPPLEMENT|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
214798833|NCT04111744|OTHER|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
214798834|NCT04111744|OTHER|Optimal medical therapy|Standard medication for stable CAD
214798835|NCT02799602|DRUG|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
214798836|NCT02799602|DRUG|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
214798837|NCT02799602|DRUG|Docetaxel|As prescribed by the treating physician.
214798838|NCT02799602|DRUG|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
214798839|NCT03619031|OTHER|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
214798840|NCT03619031|OTHER|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
214798841|NCT03619031|OTHER|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
214798842|NCT00744809|DRUG|TMC278; Moxifloxacin; Efavirenz|
214798843|NCT02651441|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
214798844|NCT02651441|DRUG|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
214798845|NCT02651441|BIOLOGICAL|D-CIK|8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
214798846|NCT01734772|DRUG|dabigatran etexilate|multiple doses of dabigatran
214798847|NCT01734772|DRUG|dabigatran etexilate|medium dose dabigatran
214798848|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
214798849|NCT01734772|DRUG|ticagrelor|multiple doses of ticagrelor
214798850|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
214798851|NCT01734772|DRUG|dabigatran etexilate|single dose of dabigatran
214798852|NCT01968252|OTHER|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
214798853|NCT03455166|DIAGNOSTIC_TEST|Serum Markers|Serum Markers
214798854|NCT01938950|OTHER|Aerobic Exercise|
214798855|NCT01938950|OTHER|Resistance Exercise|
214798856|NCT01938950|OTHER|Aerobic and Resistance Exercise|
214798857|NCT03532321|OTHER|NA : non interventional study|NA : non interventional study
214798858|NCT00899964|BEHAVIORAL|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
214798859|NCT02627911|DEVICE|Diabeloop System|Insulin delivery
214798860|NCT02627911|DEVICE|Continuous Glucose Monitoring|
214798861|NCT02627911|DEVICE|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
214798862|NCT02627911|DIETARY_SUPPLEMENT|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
214798863|NCT02281578|BEHAVIORAL|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
214798864|NCT02281578|BEHAVIORAL|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
214798865|NCT04255459|OTHER|Moist Snuff|Moist Snuff product
214798866|NCT04255459|OTHER|Camel Snus|Camel Snus product
214798867|NCT04255459|OTHER|Cigarettes|Cigarette product
214798868|NCT04255459|OTHER|No tobacco usage|No tobacco usage
214798869|NCT04984018|DRUG|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
214798870|NCT02217722|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
214798871|NCT02217722|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
214798872|NCT05998213|OTHER|Fecal microbiota transplant|Frozen FMT via duodenal tube (2 times) and enemas (4 times)
214798873|NCT03641898|PROCEDURE|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.
214798874|NCT03641898|DIAGNOSTIC_TEST|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
214798875|NCT00673491|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
214798876|NCT04275687|RADIATION|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost."
214798877|NCT04275687|DRUG|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
214798878|NCT00329602|DRUG|Placebo|Matching Placebo
214798879|NCT00329602|DRUG|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
214798880|NCT04436692|BEHAVIORAL|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
214798881|NCT01781039|DEVICE|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (\> 50% of the time), and 100 persons reporting little difficulty HIN (\< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
214798882|NCT01600495|OTHER|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
214798883|NCT04297852|DIETARY_SUPPLEMENT|Vegan drink|Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
214798884|NCT04297852|DIETARY_SUPPLEMENT|Control|Placebo drink Dose: 500 mL a day
214798885|NCT02097121|BIOLOGICAL|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
214798886|NCT00661999|BIOLOGICAL|darbepoetin alfa|Given by injection
214798887|NCT00661999|DIETARY_SUPPLEMENT|ferrous sulfate|Given by mouth
214798888|NCT00661999|DRUG|sodium ferric gluconate complex in sucrose|Given by IV
214798889|NCT00661999|OTHER|placebo|Given by mouth
214798890|NCT03066999|PROCEDURE|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
214798891|NCT03066999|DEVICE|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
214798892|NCT06015048|DRUG|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
214798893|NCT06015048|DRUG|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
214798894|NCT00510510|DRUG|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
214798895|NCT00510510|DRUG|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
214798896|NCT00510510|DRUG|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
214798897|NCT00219830|BEHAVIORAL|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
214798898|NCT03595657|BIOLOGICAL|CS1001|monoclonal antibody
214798899|NCT02294812|BEHAVIORAL|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
214798900|NCT00210548|DRUG|paliperidone palmitate|
214798901|NCT01197963|PROCEDURE|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
214798902|NCT01197963|DIETARY_SUPPLEMENT|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
214798903|NCT03758833|DIAGNOSTIC_TEST|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
214798904|NCT03758833|PROCEDURE|Single embryo transfer|Transfer of single embryo
214798905|NCT03758833|PROCEDURE|Double embryo tranfer|Transfer of two embryos
214798906|NCT00414947|DRUG|Vildagliptin (LAF237)|
214798907|NCT02113306|DEVICE|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
214798908|NCT02113306|DEVICE|sham stimulation|electrodes will be put upside down
214798909|NCT03992287|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
214798910|NCT03992287|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214798911|NCT02739542|DRUG|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
214798912|NCT02739542|DRUG|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
214798913|NCT02042911|DRUG|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
214798914|NCT04765033|DRUG|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
214798915|NCT04656977|OTHER|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
214798916|NCT04656977|OTHER|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
214798917|NCT01547195|PROCEDURE|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
214798918|NCT01547195|PROCEDURE|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
214798919|NCT02202174|DEVICE|Supraglottic Airway Device|
214798920|NCT03714295|OTHER|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
214798921|NCT04322071|OTHER|Interview|Qualitative interviews only
214798922|NCT03481309|DEVICE|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
214798923|NCT03481309|DEVICE|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
214798924|NCT03481309|DEVICE|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
214798925|NCT03501680|DRUG|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
214798926|NCT03501680|DEVICE|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
214798927|NCT05013671|OTHER|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
214798928|NCT05013671|OTHER|balance|compare the balance of residents with BPPV with residents without BPPV
214798929|NCT03951948|OTHER|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
214798930|NCT04516148|DRUG|Cefazolin|Dosing per hospital policy
214798931|NCT04516148|DRUG|Clindamycin|Dosing per hospital policy
214798932|NCT00721058|OTHER|CT-scan|A pre-operative CT-scan will be made
214798933|NCT02946099|PROCEDURE|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
214798934|NCT02946099|PROCEDURE|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
214798935|NCT01729130|PROCEDURE|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
214798936|NCT03400306|DRUG|Veliparib, capsule|capsule; 50 mg or 100 mg
214798937|NCT03400306|DRUG|Veliparib, tablet|tablet; 400 mg
214798938|NCT03400306|DRUG|Carboplatin|Intravenous
214798939|NCT03400306|DRUG|Paclitaxel|Intravenous
214798940|NCT02346201|DRUG|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
214798941|NCT02346201|DRUG|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
214798942|NCT04758936|DRUG|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
214798943|NCT04758936|DRUG|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
214798944|NCT00698100|BIOLOGICAL|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
215031575|NCT07010731|OTHER|Social support|After adopting the questioner from Oslo-3 -item social support scale, it was translated in to local language (Amharic) and then back to English by another language expert. The data was collected through face-to-face interviews with three BSc nurses. It was supervised by one MSc nurse
214798945|NCT00698100|BIOLOGICAL|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
214798946|NCT04951388|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
214798947|NCT04951388|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
214798948|NCT03504111|PROCEDURE|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
214798949|NCT03504111|PROCEDURE|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
214798950|NCT03832465|DRUG|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
214798951|NCT03832465|DRUG|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
214798952|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
214798953|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
214798954|NCT01836419|PROCEDURE|classic LMA insertion|
214798955|NCT03708211|DRUG|TAK-931 PIC|TAK-931 PICs.
214798956|NCT03708211|DRUG|TAK-931 Tablet|TAK-931 Tablets.
214798957|NCT03708211|DRUG|Esomeprazole|Esomeprazole Tablets.
214798958|NCT04986228|OTHER|Digital aftercare|The intervention group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge. These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.
214798959|NCT04986228|OTHER|TAU|The control group will receive the regular follow-up consultations in the clinic (treatment-as-usual, TAU). This includes at least one consultation with the case-leading therapist from the previous inpatient stay about 6 weeks after discharge. The assessment consisting of questionnaires at multiple time points about different topics is the same as in the intervention group.
214798960|NCT01134523|DRUG|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
214798961|NCT01134523|DRUG|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
214798962|NCT04876898|OTHER|prospective cohort in high body mass index patient with covid 19|A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels
214798963|NCT01508936|DRUG|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
214798964|NCT01508936|DRUG|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
214798965|NCT02401126|DIETARY_SUPPLEMENT|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
214798966|NCT02401126|DIETARY_SUPPLEMENT|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
214798967|NCT03164148|DEVICE|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
214798968|NCT00462982|DRUG|sunitinib malate|
214798969|NCT00679367|DRUG|dexamethasone|40 mg once weekly
214798970|NCT00679367|DRUG|lenalidomide|10 mg/day D1-21
214798971|NCT00679367|DRUG|melphalan|5 mg/m2 D1-4
214798972|NCT01180595|DEVICE|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
214798973|NCT01180595|DEVICE|Trabecular Metal Monoblock Tibial Total Knee Component|
214798974|NCT06211426|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
214798975|NCT06211426|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214798976|NCT04843670|PROCEDURE|duodenopancreatectomy|resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
214798977|NCT00436878|BEHAVIORAL|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
214798978|NCT02109133|PROCEDURE|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
214798979|NCT02109133|PROCEDURE|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
214798980|NCT02109133|DRUG|Rocuronium|
214798981|NCT02109133|DRUG|Sugammadex|
214798982|NCT02109133|DRUG|Atracurium|
214798983|NCT02109133|DRUG|Neostigmine|
214798984|NCT00409578|DRUG|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
214798985|NCT00409578|DRUG|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
214798986|NCT00409578|DRUG|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
214798987|NCT00409578|DRUG|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
214798988|NCT00922779|DRUG|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
214798989|NCT00922779|DRUG|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
214798990|NCT02249884|DRUG|Urea Dose A|Urea cream for topical use.
214798991|NCT02249884|DRUG|Urea Dose B|Urea cream for topical use.
214798992|NCT02249884|DRUG|Urea Dose C|Urea cream for topical use.
214798993|NCT02249884|DRUG|Chamomile Dose A|Chamomile gel for topical use.
214798994|NCT02249884|DRUG|Chamomile Dose B|Chamomile gel for topical use.
214798995|NCT02249884|DRUG|Chamomile Dose C|Chamomile gel for topical use.
214798996|NCT01737177|DRUG|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~\- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
214798997|NCT07036250|DRUG|U32 CAR-T|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
214798998|NCT02448771|DRUG|Palbociclib|
214798999|NCT02448771|DRUG|Bazedoxifene|
214799000|NCT05241535|DRUG|MT-7117|oral
214799001|NCT05241535|DRUG|moxifloxacin|oral
214799002|NCT05241535|DRUG|Placebo|oral
214799003|NCT06394102|OTHER|The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.|A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
214799004|NCT00004584|DRUG|Atazanavir|
214799005|NCT00004584|DRUG|Ritonavir|
214799006|NCT00004584|DRUG|Saquinavir|
214799007|NCT03604887|DIAGNOSTIC_TEST|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
214799008|NCT02328781|DEVICE|Drug-eluting stent|
214799009|NCT03559764|BIOLOGICAL|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
214799010|NCT07076056|DRUG|DW1026C1|Sitagliptin 100mg+Empagliflozin 10mg
214799011|NCT07076056|DRUG|DW1026C2|Sitagliptin 100mg+Empagliflozin 25mg
214799012|NCT07076056|DRUG|DW1026S|Sitagliptin 100mg
215031576|NCT07009912|DEVICE|Total Knee Arthroplasty|Robotic-assisted primary total knee arthroplasty, evaluating updated features for the Zimmer Biomet ROSA® Knee System, v1.5.
214799013|NCT01147120|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
214799014|NCT01147120|PROCEDURE|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
214799015|NCT00002637|BIOLOGICAL|aldesleukin|
214799016|NCT00002637|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
214799017|NCT00002637|BIOLOGICAL|recombinant interferon gamma|
214799018|NCT00161278|DRUG|Carboplatin|
214799019|NCT00161278|DRUG|Paclitaxel|
214799020|NCT00161278|PROCEDURE|Gene expression profiling (analysis) of tumor samples|
214799021|NCT00770315|BIOLOGICAL|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
214799022|NCT00770315|BIOLOGICAL|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
214799023|NCT02683187|DRUG|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
214799024|NCT02683187|DRUG|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
214799025|NCT02585258|DRUG|Prednisolone|1 capsule containing a tablet of 5 mg prednisolone/ day
214799026|NCT02585258|DRUG|Placebo|1 capsule containing a placebo tablet / day
214799027|NCT04740385|DIAGNOSTIC_TEST|Lung auscultation|auscultation of air entry through chest wal
214799028|NCT04740385|DEVICE|Fiberoptic bronchoscopy|Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
214799029|NCT04740385|DEVICE|Lung Ultrasound|real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
214799030|NCT00287027|DRUG|Risperdal Long Acting Injectable Antipsychotic Medication|
214799031|NCT04017013|PROCEDURE|Epidural Analgesia|"The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
214799032|NCT04017013|DRUG|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
214799033|NCT05054868|DRUG|Oxycodone|Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).
214799034|NCT05054868|DRUG|Ketorolac|Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
214799035|NCT05390346|BEHAVIORAL|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
214799036|NCT05364957|DEVICE|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
214799037|NCT05364957|PROCEDURE|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
214799038|NCT05364957|PROCEDURE|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
214799039|NCT03165448|DIAGNOSTIC_TEST|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
214799040|NCT03165448|DIAGNOSTIC_TEST|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
214799041|NCT03165448|DIAGNOSTIC_TEST|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
214799042|NCT03165448|DIAGNOSTIC_TEST|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
214799043|NCT04908748|DRUG|Esflurbiprofen Hydrogel Patch|Esflurbiprofen is a cyclooxygenase (COX) inhibitor
214799044|NCT04654104|OTHER|check immune check points|we will evaluate the expression of immune check points
214799045|NCT04639596|BEHAVIORAL|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
214799046|NCT04121390|BEHAVIORAL|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
214799047|NCT00999869|DRUG|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
214799048|NCT00999869|DRUG|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
214799049|NCT00102908|DRUG|Zoledronate|Zoledronate infusion
214799050|NCT00102908|DRUG|Zoledronate placebo|Zoledronate placebo infusion
214799051|NCT03702621|DRUG|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
214799052|NCT03702621|DRUG|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
214799053|NCT02422823|DRUG|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
214799054|NCT02422823|DRUG|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
214799055|NCT02422823|DRUG|Epinephrine|
214799056|NCT06440655|DEVICE|Platelet rich plasma|Subjects were treated by Platelet rich plasma in each side of head (Left or right)
214799057|NCT06440655|DEVICE|Platelet rich fibrin|Subjects were treated by Platelet rich fibrin in each side of head (Left or right)
214799058|NCT04359238|BEHAVIORAL|Individualized excercise|The participants in the intervention group carry out regularly endurance and strength exercises.
214799059|NCT00650936|DEVICE|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
214799060|NCT02464566|BEHAVIORAL|Intensive lifestyle intervention|
214799061|NCT02464566|OTHER|Health Education|
214799062|NCT03194464|OTHER|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
214799063|NCT01764438|PROCEDURE|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
214799064|NCT01055964|DRUG|Tacrolimus|
214647318|NCT00570102|DIETARY_SUPPLEMENT|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
214799065|NCT02791100|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
214799066|NCT04322175|DRUG|Meloxicam|Meloxicam Eye Drops
214799067|NCT03103100|DRUG|1% Lidocaine|10 mL of 1% lidocaine
214799068|NCT03103100|DRUG|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
214799069|NCT03103100|DRUG|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
214799070|NCT00842842|PROCEDURE|tack fixation of mesh|tack fixation of mesh
214799071|NCT00842842|PROCEDURE|glue fixation of mesh|glue fixation of mesh
214799072|NCT01079442|OTHER|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
214799073|NCT01079442|OTHER|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
214799074|NCT00003399|DRUG|carmustine|
214799075|NCT00003399|DRUG|cisplatin|
214799076|NCT00003399|DRUG|cyclophosphamide|
214799077|NCT00003399|DRUG|dexamethasone|
214799078|NCT00003399|DRUG|etoposide|
214799079|NCT00003399|DRUG|melphalan|
214799080|NCT00003399|DRUG|paclitaxel|
214799081|NCT00003399|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214799082|NCT06330870|PROCEDURE|WGS/TME evaluation|WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
214799083|NCT05219227|OTHER|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~1. Static abdominal exercises:~2. Dynamic abdominal exercises:~   * Hip shrugging exercise from crook lying position:~  * Lateral flexion of the trunk from crook lying position:~  * Antero-posterior flexion of the trunk from crook lying position:"
214799084|NCT06411366|GENETIC|Follistatin plasmid|Follistatin-344 plasmid
214799085|NCT02192736|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
214799086|NCT05707000|OTHER|group A concentric muscle training|"One set of each of the following exercises will completed during each session:~* leg press,~* knee flexion,~* knee extension,~* Quad drills For each set, 12 repetitions will be performed at a resistance load of 60% of the one-repetition maximum (1RM) for that exercise. The exercises will be performed 2 times a week for 6 weeks."
214799087|NCT05707000|OTHER|Group B fascilitatory kinesiotaping|Kinesiotaping is applied on the anterior thigh (quadriceps) region starting at 1/5 of the distance between anterosuperior iliac spine (ASIS) and tibia tuberosity. The tape is applied with 20% tension of the tape. The tape was tensioned from proximal region of mid quadriceps down to tibia tuberosity and, once it reached the knee, the tape was divided in the middle allowing it to circle the joint
214799088|NCT06001632|DIETARY_SUPPLEMENT|krill oil (SuperbaBoostTM)|4 g/day of Krill oil supplements (LC n-3 PUFAs) (1g capsule containing 191mg EPA, 94mg DHA and 78mg choline).
214799089|NCT06001632|DIETARY_SUPPLEMENT|4g/day of mixed vegetable oil|vegetable oil capsules (mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
214799090|NCT02606500|DRUG|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years."
214647319|NCT00212043|DRUG|carboplatin and gemcitabine|
214647320|NCT01474694|OTHER|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
214647321|NCT01150084|OTHER|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
214647322|NCT01150084|OTHER|delayed treatment|to start at week 10
214799091|NCT00623207|DRUG|Atropine|I.V Atropine 0.5mg up to 2 mg
214799092|NCT02470507|OTHER|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
214799093|NCT00436007|BIOLOGICAL|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
214799094|NCT00436007|BIOLOGICAL|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
214799095|NCT00436007|BIOLOGICAL|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
214799096|NCT00436007|BIOLOGICAL|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
214799097|NCT00436007|BIOLOGICAL|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
214799098|NCT04927533|OTHER|Ronnie Gardiner Method|"The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants."
214799099|NCT04552613|DRUG|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
214799100|NCT04552613|DRUG|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
214799101|NCT02972398|DRUG|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
214799102|NCT02972398|DRUG|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
214799103|NCT06433453|DRUG|Indomethacin 50 MG|The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
214799104|NCT06433453|PROCEDURE|Transvaginal ultrasound scans|Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
214799105|NCT06433453|DIAGNOSTIC_TEST|Finger prick blood test|Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
214799106|NCT06433453|DIAGNOSTIC_TEST|Urine test|Early morning urine tests to assay reproductive hormones
214799107|NCT04293666|DIETARY_SUPPLEMENT|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
214799108|NCT04293666|DIETARY_SUPPLEMENT|placebo|Maltodextrin, same calorie as kefir, 200ml/day
214799109|NCT02984436|PROCEDURE|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
214799110|NCT02984436|BEHAVIORAL|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
214799111|NCT02445664|BEHAVIORAL|Educational video|Video: Information on osteoporosis and alendronate treatment.
214799112|NCT00810368|DRUG|Carnosine|500mg Carnosine x2 daily
214799113|NCT00810368|DRUG|Placebo|Microcrystalline cellulose placebo tablets x2 daily
214799114|NCT03331042|DRUG|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
214799115|NCT03331042|DRUG|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
214799116|NCT03331042|DRUG|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
214799117|NCT03331042|DRUG|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
214799118|NCT02329756|DRUG|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
214799119|NCT02329756|DRUG|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
214799120|NCT06167538|OTHER|Decannulation|From the 1st of September 2021, the investigators started to perform decannulation earlier after admission to the Department of Brain Injury. Before attempting to decannulate a patient, several factors were considered and assessed by the patient's treating team: patient's level of consciousness, hemodynamical stability, need for and frequency of salivary aspiration, cough strength and respiration frequency. Patients could not be under treatment for pneumonia and simultaneously have respiratory instability at the time of decannulation.
214799121|NCT01567930|DRUG|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
214647323|NCT01424735|DRUG|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
214647324|NCT00501475|DRUG|NAC Bicarbonate|
214647325|NCT01292655|DRUG|BMS-906024|
214647326|NCT02611401|BEHAVIORAL|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
214647327|NCT02611401|BEHAVIORAL|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
214647328|NCT01017510|DEVICE|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
214647329|NCT01017510|DEVICE|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
214647330|NCT04853628|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
214647331|NCT04853628|BEHAVIORAL|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
214647332|NCT02946801|DRUG|Essential oils|
214647333|NCT02946801|DRUG|Essential oils without alcohol|
214647334|NCT02946801|DRUG|Sterile water|
214647335|NCT03817372|DEVICE|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
214647336|NCT03817372|DEVICE|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
214647337|NCT04047901|OTHER|exercise training|Patients undergo 16 weeks of physical training
214647338|NCT00189462|DRUG|Montelukast|
214647339|NCT00189462|DRUG|Placebo|
214647340|NCT00553163|BEHAVIORAL|Gut focussed hypnotherapy|Gut focussed hypnotherapy
214647341|NCT00553163|BEHAVIORAL|Control educational sessions|Control educational sessions
214647342|NCT05641701|DEVICE|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
214647343|NCT05641701|DEVICE|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
214647344|NCT01262625|DEVICE|CCTA|Complete diagnostic CCTA per protocol specifications.
214647345|NCT01262625|DEVICE|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
214647346|NCT00827190|DRUG|ILS-920|
214647347|NCT00110942|DRUG|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
214647348|NCT00110942|OTHER|Placebo|SC placebo injection Q4W for 3 doses
214647349|NCT03089957|DRUG|Ulinastatin|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
214647350|NCT03089957|OTHER|Usual care|Usual care in ICU.
214647351|NCT02789657|DRUG|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
214647352|NCT02789657|DRUG|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
214647353|NCT02789657|DRUG|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
214647354|NCT02789657|DRUG|carboplatin|AUC 2 administered weekly with no planned treatment breaks
214647355|NCT02789657|PROCEDURE|Breast surgery|breast conserving or mastectomy
214647356|NCT02789657|DRUG|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
214647357|NCT01075880|DRUG|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
214647358|NCT04681404|PROCEDURE|Knee Arthroplasty|Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL
214647359|NCT05647330|DRUG|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
214799122|NCT00825227|DRUG|Armodafinil 150 mg/day|"* 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
214799123|NCT00825227|DRUG|Placebo,|"* placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
214799124|NCT00826774|BEHAVIORAL|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
214799125|NCT00826774|BEHAVIORAL|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
214799126|NCT00826774|BEHAVIORAL|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
214799127|NCT00602329|BIOLOGICAL|bevacizumab|Given IV
214799128|NCT00602329|DRUG|fluorouracil|Given IV
214799129|NCT00602329|DRUG|leucovorin calcium|Given IV
214799130|NCT00602329|DRUG|oxaliplatin|Given IV
214799131|NCT04418726|OTHER|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
214799132|NCT04503330|PROCEDURE|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
214799133|NCT05425667|OTHER|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
214799134|NCT00929539|DRUG|JTT-130|Tablets
214799135|NCT00929539|DRUG|JTT-130 Placebo|Tablets
214799136|NCT05385068|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
214799137|NCT05258864|BEHAVIORAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
214799138|NCT04913896|DRUG|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
214799139|NCT03228095|DIAGNOSTIC_TEST|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
214799140|NCT03228095|DIAGNOSTIC_TEST|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
214799141|NCT03228095|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
214799142|NCT03228095|PROCEDURE|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
214799143|NCT03228095|PROCEDURE|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
214799144|NCT03228095|DIAGNOSTIC_TEST|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
214799145|NCT03228095|PROCEDURE|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
214799146|NCT03228095|DIAGNOSTIC_TEST|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
214799147|NCT02096419|DRUG|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
214799148|NCT03272139|DRUG|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
214799149|NCT03272139|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
214799150|NCT00720096|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
214799151|NCT00720096|DRUG|Topotecan|"1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
214799152|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
214799153|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
214799154|NCT05423808|OTHER|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
214799155|NCT05423808|DEVICE|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
214799156|NCT00919308|OTHER|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
214799157|NCT03694990|OTHER|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
214799158|NCT02524223|OTHER|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
214799159|NCT02524223|OTHER|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
214799160|NCT02524223|OTHER|systematic HPV Status in newborns in case of pregnancy|
214799161|NCT01568164|DEVICE|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
214799162|NCT01297049|BEHAVIORAL|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
214799163|NCT00005938|DRUG|exatecan mesylate|
214799164|NCT00776503|DRUG|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
214799165|NCT00521170|DRUG|Levocetirizine|
214799166|NCT04690270|DRUG|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
214799167|NCT01292109|DRUG|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
214799168|NCT00524459|DRUG|docetaxel|
214799169|NCT00524459|DRUG|pegylated liposomal doxorubicin hydrochloride|
214799170|NCT00524459|PROCEDURE|conventional surgery|
214799171|NCT00524459|PROCEDURE|neoadjuvant therapy|
214799172|NCT00925314|BIOLOGICAL|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
214799173|NCT04039542|OTHER|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
214799174|NCT03165552|OTHER|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
214799175|NCT04371250|OTHER|Survey and Questionnaire|Resilience and Loneliness questionnaires
214799176|NCT06101836|OTHER|Training intervention|Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
214799177|NCT02428699|OTHER|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
214799178|NCT02428699|OTHER|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
214799179|NCT01690442|BEHAVIORAL|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
214799180|NCT01690442|BEHAVIORAL|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
214799181|NCT04277533|DIAGNOSTIC_TEST|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
214799182|NCT03231475|DRUG|SPH1188-11|qd.po
214799183|NCT04173013|BIOLOGICAL|Uromune|2 sprays of solution once daily for a total of 3 months.
214799184|NCT02047266|PROCEDURE|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
214799185|NCT02047266|PROCEDURE|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time\>250seconds).
215031577|NCT07011290|OTHER|Self-paced Walking (W) training sessions|Participants will partake in 2 sessions of self-paced walking (W), each composed by 3x14 min periods interspersed by 2 min breaks, in which the participants will walk at a self-selected speed (without running) along a 38x18 m course.
214799186|NCT02047266|PROCEDURE|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time\>450seconds).
214799187|NCT02047266|DEVICE|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
214799188|NCT02047266|DEVICE|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
214799189|NCT03951337|DRUG|64Cu-ATSM|64 Cu-ATSM PET/CT scan
214799190|NCT02295397|OTHER|food|food provocation, skin testing, blood sampling
214799191|NCT03459937|BEHAVIORAL|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
214799192|NCT03459937|BEHAVIORAL|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
214799193|NCT05435001|DEVICE|Holter ECG Monitoring|Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
214799194|NCT05898568|DEVICE|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
214799195|NCT05898568|BEHAVIORAL|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
214799196|NCT03672110|DRUG|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
214799197|NCT00252356|DRUG|SR58611A|
214647360|NCT06420310|OTHER|exposure to pesticides|based on work exposures to pesticides
214647361|NCT04316169|DRUG|Abemaciclib|150 mg b.i.d
214647362|NCT04316169|DRUG|Hydroxychloroquine 200 mg|Dose level: 200 mg b.i.d.
214647363|NCT04316169|DRUG|Faslodex|Cohort B will receive Faslodex.
214647364|NCT04316169|DRUG|Anastrazole|Cohort A will receive anastrazole or letrozole.
214647365|NCT04316169|DRUG|Letrozole|Cohort A will receive anastrazole or letrozole.
214647366|NCT04316169|DRUG|Hydroxychloroquine 400 mg|Dose level: 400 mg. b.i.d.
214647367|NCT04316169|DRUG|Hydroxychloroquine 600 mg|Dose level: 600 mg b.i.d.
214647368|NCT01214044|DRUG|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
214647369|NCT01589484|DEVICE|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
214647370|NCT04049019|DIAGNOSTIC_TEST|Urine collection through a collecting device (Uridome®) for maximum 1 week|"The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night."
214647371|NCT04049019|DIAGNOSTIC_TEST|Urine collection|"The child will collect:~* Urine at bedtime.~* First morning voided volume"
214647372|NCT02471157|OTHER|Observation|
214647373|NCT04040361|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
214647374|NCT04040361|DRUG|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
214647375|NCT04040361|PROCEDURE|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
214647376|NCT03174210|DEVICE|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
214647377|NCT03174210|DEVICE|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
214647378|NCT01450176|DRUG|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
214647379|NCT01450176|DRUG|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
214647380|NCT02772757|BEHAVIORAL|standard hearing aid fitting|standard hearing aid, face-to-face fitting
214647381|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using average RECDs
214647382|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using measured RECDs
214647383|NCT03104842|DRUG|Isatuximab|Antibody Intravenous
214647384|NCT03104842|DRUG|Carfilzomib|Intravenous
214647385|NCT03104842|DRUG|Lenalidomide|Capsel
214647386|NCT03104842|DRUG|Dexamethasone|Capsel
214647387|NCT04911010|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
214647388|NCT00464204|DRUG|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
214647389|NCT00464204|DRUG|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
214647390|NCT00384241|BEHAVIORAL|Induced Stress|Participation in an active coping task by playing a video game against another participant.
214647391|NCT00384241|PROCEDURE|Buccal Swab|One Buccal swab collected from each parent
214647392|NCT03839108|OTHER|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
214647393|NCT03839108|DRUG|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
214799198|NCT00539877|DRUG|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
214799199|NCT00631033|DRUG|Placebo|
214799200|NCT00631033|DRUG|Diazoxide|
214799201|NCT00631033|DRUG|Metformin + Diazoxide|
214799202|NCT06434285|OTHER|Questionnaire development|Cognitive interviewing group will be run to inform questionnaire development.
214799203|NCT00530010|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
214799204|NCT05754047|DIAGNOSTIC_TEST|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
214799205|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
214799206|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
214799207|NCT03203915|DIETARY_SUPPLEMENT|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
214799208|NCT02697903|DIETARY_SUPPLEMENT|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
214799209|NCT02697903|DIETARY_SUPPLEMENT|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
214799210|NCT05108038|DRUG|CKD-382, D860, D027|QD, PO for 7days
214799211|NCT03689790|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
214799212|NCT03689790|PROCEDURE|gastric bypass|gastric bypass
214799213|NCT04611698|DEVICE|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
214799214|NCT05019066|DIETARY_SUPPLEMENT|Herbal Supplementation|A proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa.
214799215|NCT05318651|DEVICE|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
214799216|NCT05223582|DRUG|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
214799217|NCT05223582|DRUG|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
214799218|NCT05223582|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
214799219|NCT05223582|DRUG|Androgen deprivation therapy|Patients would get medical castration.
214799220|NCT05223582|PROCEDURE|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
214799221|NCT03209882|DEVICE|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
214799222|NCT03209882|DEVICE|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
214799223|NCT05252130|DEVICE|NoaScope|Smart digital stethoscope
214799224|NCT03637582|DRUG|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
214799225|NCT03637582|OTHER|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
214799226|NCT01574248|DRUG|icatibant|Subcutaneous at time 0 and 6 hours
214799227|NCT01574248|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
214799228|NCT04647604|DRUG|Omegaven®|A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
214799229|NCT04647604|DRUG|Sodium chloride|intravenously administered 2 mL/kg/day
214799230|NCT06200701|BEHAVIORAL|Job Crafting program|The training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
214799231|NCT00493272|DRUG|Fibrinogen|Fibrinogen behandling
214799232|NCT02922868|DEVICE|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
214799233|NCT02922868|DEVICE|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
214799234|NCT01781286|BEHAVIORAL|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
214799235|NCT01781286|BEHAVIORAL|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
214799236|NCT00995410|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
214799237|NCT02415023|DRUG|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
214799238|NCT03594123|DRUG|Brexpiprazole|2 or 3 mg tablet
214799239|NCT03594123|DRUG|Brexpiprazole|0.5 to 3 mg tablet
214799240|NCT04855981|OTHER|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
214799241|NCT04855981|OTHER|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
214799242|NCT04855981|OTHER|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
214799243|NCT00146523|DRUG|Mifepristone|
214799244|NCT00146523|DRUG|placebo|
214799245|NCT04123210|DIETARY_SUPPLEMENT|Vitamin A supplement|
214799246|NCT04123210|DIETARY_SUPPLEMENT|Placebo|
214799247|NCT04240938|PROCEDURE|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
214799248|NCT03393650|OTHER|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
214799249|NCT03393650|OTHER|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
214799250|NCT06179238|OTHER|Education|Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.
214799251|NCT06179238|OTHER|without patient education|without patient education
214799252|NCT01144936|DRUG|VX-985 or matching placebo|low dose
214799253|NCT01144936|DRUG|VX-985 or matching placebo|high dose
214799254|NCT01144936|DRUG|VX-985 or matching placebo|dose TBD
214799255|NCT00864864|DRUG|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
214799256|NCT00093990|DRUG|Tipifarnib;Zarnestra; R115777|
214799257|NCT03597490|COMBINATION_PRODUCT|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
214799258|NCT05681208|BEHAVIORAL|Motivational interview|"Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week."
214799259|NCT03970564|DIAGNOSTIC_TEST|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
214799260|NCT03365375|BEHAVIORAL|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
214799261|NCT03365375|OTHER|Usual Care Referral|Referral to PCP or Psychiatry
214799262|NCT02483975|DRUG|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
214799263|NCT02483975|DRUG|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
214799264|NCT02483975|DRUG|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
214799265|NCT02483975|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
214799266|NCT04912349|PROCEDURE|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
214799267|NCT04912349|PROCEDURE|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
214799268|NCT00508170|BEHAVIORAL|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
214799269|NCT02716870|OTHER|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
214799270|NCT04172870|DIAGNOSTIC_TEST|Molecular analysis|RT- PCR
214799271|NCT05554770|DIAGNOSTIC_TEST|Examinations in a TRV chair|Positional tests (Dix-Hallpike and SRT) traditionally used to diagnose BPPV uwith a TRV chair.
214799272|NCT04138732|BEHAVIORAL|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
214799273|NCT03683407|OTHER|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
214799274|NCT05896956|OTHER|no interventions|no interventions
214799275|NCT02317237|PROCEDURE|Local anesthesia|Conscious sedation
214799276|NCT01578837|DIETARY_SUPPLEMENT|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
214799277|NCT01578837|DIETARY_SUPPLEMENT|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
214799278|NCT05532085|OTHER|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
214799279|NCT05532085|OTHER|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
214799280|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
214799281|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
214799282|NCT02381171|DEVICE|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
214799283|NCT02381171|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
214799284|NCT02381171|DEVICE|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
214799285|NCT02381171|DEVICE|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
214799286|NCT05332015|OTHER|Hypotonic (distilled) water|orally given daily two liters of distilled water
214799287|NCT05332015|OTHER|Normal water|orally given daily two liters of normal water
214799288|NCT06301698|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
214799289|NCT06301698|PROCEDURE|Injection|the patients in the observation group were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214799290|NCT06301698|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214799291|NCT02747745|BEHAVIORAL|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
214799292|NCT06440564|PROCEDURE|Er:YAG Laser irradiation|The presented DALIR procedure differs in so far from a standard treatment that after exposure all accessible metal implant surfaces and the adjacent soft tissue is irradiated manually with the Er:YAG laser all over line-by-line with an intended overlap of approximately 10% at constant spot diameter.
214799293|NCT03992196|DRUG|Rotigotine 1 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).
214799294|NCT03992196|DRUG|Rotigotine 2 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).
214799295|NCT03992196|DRUG|Rotigotine 3 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
214799296|NCT05283044|BIOLOGICAL|biopsy liquid|Patient performs a blood test at treatment baseline
214799297|NCT06182020|DEVICE|Peripheral functional magnetic stimulation (ISKRA MEDICAL TESLA Former prestige Magneto therapy)|The peripheral functional magnetic stimulation will be conducted 30 minutes a session, 2 sessions per week, for consecutive 8 weeks. The stimulation will be placed over bilateral forearm flexor muscles and bilateral thighs over rectus femoris muscles.
214799298|NCT06182020|DIETARY_SUPPLEMENT|Nutritional supplementation (ENSURE HIGH CALCIUM)|"The nutritional supplementation includes 7 cans of ENSURE HIGH CALCIUM per week for 8 consecutive weeks."
214799299|NCT06182020|BEHAVIORAL|Education|The education includes a DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
214799300|NCT02684578|DRUG|Metformin|
214799301|NCT05919966|OTHER|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
214799302|NCT01485965|DRUG|SEN0014196|100 mg, immediate release tablets, once daily administration
214799303|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
214799304|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
214799305|NCT05786573|OTHER|Placebo|Placebo
214799306|NCT05060627|DRUG|Belantamab mafodotin|"In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
214799307|NCT05060627|DRUG|Carfilzomib|"In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
214799308|NCT05060627|DRUG|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
214799309|NCT06056869|DRUG|hyoscine butylbromide|will be given during first stage of labor intravenously
214799310|NCT06056869|OTHER|normal saline|placebo
214799311|NCT03942965|DEVICE|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
214799312|NCT02758665|DRUG|ibrutinib|
214799313|NCT02758665|DRUG|obinutuzumab|
214799314|NCT02758665|DRUG|venetoclax|
214799315|NCT06229925|DEVICE|Experimental Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.
214799316|NCT06229925|DEVICE|Sham Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
214799317|NCT01505530|DRUG|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
214799318|NCT01505530|DRUG|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
214799319|NCT01505530|DRUG|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
214799320|NCT04475965|OTHER|Isometric exercise for shoulder external rotators|The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
214799321|NCT03879239|DEVICE|Vibrating capsule|Vibrating Capsule administered 5 times per week
214799322|NCT04352361|DRUG|TVB-2640|TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
214799323|NCT04352361|DRUG|Placebo|Oral, matching number of placebo Tablets with active arm.
214799324|NCT04043845|DRUG|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
214799325|NCT04043845|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
214799326|NCT06038357|BEHAVIORAL|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
214799327|NCT06038357|OTHER|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
214799328|NCT03420066|OTHER|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
214799329|NCT03887195|OTHER|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
214799330|NCT02492958|BIOLOGICAL|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
214799331|NCT02492958|BIOLOGICAL|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
214799332|NCT02586831|DRUG|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
214799333|NCT02586831|DRUG|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
214799334|NCT02586831|DRUG|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
214799335|NCT02586831|DRUG|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
214799336|NCT02586831|OTHER|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
214799337|NCT02586831|OTHER|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
214799338|NCT02586831|OTHER|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
214799339|NCT02586831|OTHER|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
214799340|NCT00404274|DRUG|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
214799341|NCT00404274|DRUG|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
214799342|NCT03707873|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
214799343|NCT01875575|DIETARY_SUPPLEMENT|Placebo|
214799344|NCT01875575|DIETARY_SUPPLEMENT|Glucose 25g|
214799345|NCT01875575|DIETARY_SUPPLEMENT|Glucose 10g|
214799346|NCT03086772|BEHAVIORAL|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
214799347|NCT03086772|BEHAVIORAL|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
214799348|NCT01193608|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
214799349|NCT01193608|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
214799350|NCT01193608|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
214799351|NCT01193608|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
214799352|NCT01193608|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
214799353|NCT01193608|OTHER|Placebo|Placebo, IV
214799354|NCT00266409|DRUG|Niravam|
214799355|NCT00266409|DRUG|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
214799356|NCT04041765|DRUG|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
214799357|NCT05813587|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
214799358|NCT05813587|OTHER|Normal saline|Normal saline
214799359|NCT05128357|OTHER|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
214799360|NCT00712010|OTHER|Whey protein native|Whey protein native against the 6 other arms
214799361|NCT00712010|OTHER|Whey protein microgels|Whey protein microgels versus the six other arms
214799362|NCT00712010|OTHER|Hydrolyzed whey protein|versus the six other arms
214799363|NCT00712010|OTHER|Casein native|versus the six other arms
214799364|NCT00712010|OTHER|Hydrolyzed casein|versus the six other arms
214799365|NCT00712010|OTHER|Total milk protein native|versus the six other arms
214799366|NCT00712010|OTHER|Hydrolyzed milk protein|versus the six other arms
214799367|NCT04282538|DEVICE|Active rTMS|4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
214799368|NCT04282538|DEVICE|Sham rTMS|4-week (5 days per week) sham rTMS
214799369|NCT04282538|DEVICE|Active tDCS|4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
214799370|NCT04282538|DEVICE|Sham tDCS|4-week (5 days per week) sham tDCS
214799371|NCT04282538|OTHER|Walking training|4-week (5 days per week) walking training
214799372|NCT04282538|OTHER|Cognition training|4-week (5 days per week) cognition training
214799373|NCT02238223|DRUG|Alesion®|
214799374|NCT00409019|DRUG|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
214799375|NCT00409019|DRUG|Adefovir|
214799376|NCT00409019|DRUG|Tenofovir|
214799377|NCT04956419|DRUG|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
214799378|NCT04956419|DRUG|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
214799379|NCT03724006|BEHAVIORAL|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
214799380|NCT03849599|BIOLOGICAL|PRV-300|Treatment
214799381|NCT03849599|BIOLOGICAL|Placebo|Control
214799382|NCT00009711|PROCEDURE|management of therapy complications|
214799383|NCT00584766|PROCEDURE|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
214799384|NCT04842110|DEVICE|Experimental: eonTM FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
214799385|NCT04113343|DRUG|Remimazolam|Remimazolam via oral administration
214799386|NCT04113343|OTHER|Alcohol|Alcohol
214799387|NCT04549064|DIAGNOSTIC_TEST|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
214799388|NCT03879200|OTHER|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
214799389|NCT03138070|DRUG|BYL719|BYL719 400 mg daily by mouth continue for 14 days
214799390|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
214799391|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
214799392|NCT05909267|DRUG|L-dopa/Carbidopa|Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
214799393|NCT05909267|DRUG|Placebo|Patients and healthy controls will receive one time administration of Placebo.
214799394|NCT04787302|DRUG|CVL-231|Cohort 1: 30mg dose of CVL-231
214799395|NCT04787302|DRUG|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
214799396|NCT04787302|DRUG|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
214647394|NCT03235687|DIAGNOSTIC_TEST|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
214647395|NCT04698525|DRUG|Valproate Sodium|Comparison between two actives
214647396|NCT04698525|DRUG|Memantine|Memantine
214647397|NCT00546923|DRUG|Venlafaxine XR|
214647398|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
214647399|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
214647400|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
214647401|NCT02086331|BEHAVIORAL|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
214647402|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|
214647403|NCT02848937|DEVICE|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca\_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
214647404|NCT02848937|DEVICE|Bath with citrate and Ca_eq|bath with citrate and Ca\_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
214647405|NCT03869814|OTHER|Blood Draw|Blood Draw
214647406|NCT04219228|DIAGNOSTIC_TEST|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
214647407|NCT04219228|DEVICE|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
214647408|NCT05707923|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
214647409|NCT05431296|DEVICE|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
214647410|NCT00159094|DRUG|Doxil and Vinorelbine|
214647411|NCT03329378|DRUG|Docetaxel|Docetaxel 75mg/m2 IV, day 1
214647412|NCT03329378|DRUG|Carboplatin|Carboplatin AUC 6 IV, day 1
214647413|NCT03329378|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
214647414|NCT03329378|DRUG|Pertuzumab|Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
214647415|NCT03329378|DRUG|Pegfilgrastim|Pegfilgrastim 6mg SC, day 2 Cycled as per arm
214647416|NCT03329378|DRUG|Trastuzumab|Trastuzumab 6mg/kg every 21 days to complete 1 year
214799397|NCT04487210|BIOLOGICAL|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
214799398|NCT01801670|PROCEDURE|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
214799399|NCT01801670|PROCEDURE|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
214799400|NCT04111770|DEVICE|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
214799401|NCT04111770|DEVICE|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
214799402|NCT04491409|OTHER|Best Practice|Undergo standard of care
214799403|NCT04491409|OTHER|Medical Chart Review|Medical charts reviewed
214799404|NCT02806921|DEVICE|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
214799405|NCT01609764|BEHAVIORAL|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
214799406|NCT01493479|DRUG|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
214799407|NCT01493479|DRUG|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial."
214799408|NCT02327000|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
214799409|NCT02327000|DRUG|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
214799410|NCT00635154|BIOLOGICAL|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
214799411|NCT00635154|DRUG|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
214799412|NCT02563756|PROCEDURE|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
214799413|NCT02563756|PROCEDURE|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
214799414|NCT04159909|DEVICE|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
214799415|NCT04159909|DEVICE|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
214799416|NCT04390828|BEHAVIORAL|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
214799417|NCT04122430|OTHER|Review of Health Information|
214799418|NCT06403865|DRUG|Cabotegravir, Rilpivirine Drug Combination|Treatment switch to CAB+RPV LA
214799419|NCT05362448|DEVICE|Frequency|First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
214799420|NCT04908826|PROCEDURE|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
214799421|NCT01474226|DIETARY_SUPPLEMENT|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
214799422|NCT01474226|DIETARY_SUPPLEMENT|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
214799423|NCT03922438|PROCEDURE|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
214799424|NCT01399736|PROCEDURE|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
214647417|NCT03329378|DRUG|Paclitaxel|Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
214647418|NCT03329378|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 IV day 1
214647419|NCT03329378|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 IV day 1
214647420|NCT03329378|DRUG|Paclitaxel|80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
214647421|NCT05313542|BEHAVIORAL|Physical Activity|Physical Activity in the format of Self-defence Training
214647422|NCT05728788|DRUG|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
214647423|NCT00510276|DRUG|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
214647424|NCT00510276|DRUG|Placebo|twice a day, by mouth for 12 weeks
214647425|NCT05490706|BEHAVIORAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
214647426|NCT05490706|BEHAVIORAL|Walking|Performing a 30 minute minute walk after dinner at home
214647427|NCT02577263|OTHER|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
214647428|NCT03176316|DRUG|Naloxone|Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
214647429|NCT01451619|DRUG|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
214647430|NCT01451619|DRUG|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
214647431|NCT04566367|DIAGNOSTIC_TEST|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
214647432|NCT03209284|PROCEDURE|transcrestal sinus floor elevation|augmentation procedure with xenograft
214647433|NCT06343779|DRUG|Deucrictibant, Placebo|Deucrictibant Soft Capsules for Oral Use
214647434|NCT01349140|DRUG|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
214647435|NCT05375279|PROCEDURE|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
214647436|NCT04291144|RADIATION|PET-CT using FEOBV|We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
214647437|NCT04291144|RADIATION|MRI-scan|All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
214647438|NCT04291144|DIAGNOSTIC_TEST|Cognitive assessment|Full neuropsychometric examination including tests in 5 cognitive domains.
214799425|NCT01399736|PROCEDURE|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
214799426|NCT05399264|BEHAVIORAL|Auditory-working memory training program|"The AT-WMT program is comprised of 1,200 daily used sentences either created or selected from newspapers, books, TV programs and magazines by the research assistants. The sentences are political-, cultural-, and religious-neutral sentences. Each of them contains 10 words. Noise was recorded from the upper and lower decks of a bus, in a café, a Chinese restaurant, an MTR (the Mass Transit Railway) carriage, and from a street.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
214799427|NCT05399264|BEHAVIORAL|Auditory training program|During the training, an adaptive speech-in-noise perception task will be administered. Specifically, the sentences in a sentence set will be presented binaurally using a headphone at a level the listeners felt is comfortable. The trainees are expected to immediately repeat each noise-masked sentence after hearing it. If they cannot repeat the sentence, then the sound intensity of the noise will be automatically decreased (step size = 2 dB) until the sentence can be correctly repeated. If the sentence can be repeated at the first attempt, then the intensity of the noise will be automatically increased by 2 dB in the next sentence. To provide feedback, the targeted sentence will be replaced by an asterisk and only shown after clicking the sentence.
214799428|NCT05399264|BEHAVIORAL|Mindfulness training program|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training.
214799429|NCT03500484|DRUG|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
214799430|NCT01952249|DRUG|Demcizumab|administered intravenously
214799431|NCT01952249|DRUG|Taxol|administered intravenously
214799432|NCT04344418|DEVICE|Nurse-performed Focused cardiac ultrasound (FoCUS)|A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
214799433|NCT04344418|OTHER|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
214799434|NCT04509479|PROCEDURE|Valve replacement|Description of valve replacements
214799435|NCT05701202|DIETARY_SUPPLEMENT|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
214799436|NCT05701202|DIETARY_SUPPLEMENT|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
214799437|NCT01046123|RADIATION|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
214799438|NCT03947138|BIOLOGICAL|GC3107|BCG Vaccine
214799439|NCT03947138|BIOLOGICAL|Intradermal BCG SSI inj.|BCG Vaccine
214799440|NCT02639949|BEHAVIORAL|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
214799441|NCT02639949|BEHAVIORAL|Standard Care|
214799442|NCT02795104|BEHAVIORAL|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
214799443|NCT02795104|BEHAVIORAL|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
214647439|NCT04291144|DIAGNOSTIC_TEST|Clinical assessment|Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
214647440|NCT01349647|BIOLOGICAL|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
214647441|NCT01349647|BIOLOGICAL|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
214647442|NCT03472508|DRUG|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
214647443|NCT03472508|DRUG|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
214799444|NCT02795104|BEHAVIORAL|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
214799445|NCT02128048|DEVICE|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
214799446|NCT04677062|DRUG|GV-328|Patients with GV-328 treatment
214799447|NCT05946148|DRUG|Empagliflozin|Empagliflozin 10mg daily, as add-on to previous treatment regimen.
214799448|NCT05946148|DRUG|Dulaglutide|Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
214799449|NCT05946148|DRUG|Control Rx|Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
214799450|NCT01255475|DRUG|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
214799451|NCT01255475|DRUG|Placebo|Patients will receive placebo
214799452|NCT04547946|DRUG|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
214799453|NCT02090829|DRUG|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
214799454|NCT02090829|OTHER|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
214799455|NCT04634448|PROCEDURE|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
214799456|NCT04634448|DIAGNOSTIC_TEST|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
214799457|NCT01788956|DEVICE|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
214799458|NCT01788956|DEVICE|Co-Oximeter|
214799459|NCT03372538|PROCEDURE|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
214799460|NCT03106584|DIETARY_SUPPLEMENT|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
214799461|NCT03106584|DIETARY_SUPPLEMENT|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
214799462|NCT01166542|BIOLOGICAL|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
214799463|NCT01166542|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
214799464|NCT01166542|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
214799465|NCT01166542|DRUG|Placebo|Placebo
214799466|NCT04892979|OTHER|Cardiopulmonary exercise (centre-based)|Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale \[10\], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
214647444|NCT03472508|DRUG|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
214647445|NCT02119520|DRUG|Platelet rich fibrin +Atorvastatin|
214647446|NCT02119520|DRUG|Platelet rich fibrin|
214647447|NCT02119520|PROCEDURE|open flap debridement|
214647448|NCT04320524|DEVICE|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
214647449|NCT03486392|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
214647450|NCT03486392|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
214647451|NCT03486392|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
214647452|NCT03486392|DRUG|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
214647453|NCT03486392|DRUG|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
214647454|NCT00923117|DRUG|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
214647455|NCT01028625|BEHAVIORAL|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
214799467|NCT04892979|OTHER|Cardiopulmonary exercise (online-based)|Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
214799468|NCT05063409|OTHER|Treatment|Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
214799469|NCT01856088|DEVICE|Inspiron Stent|stent implantation
214799470|NCT01856088|DEVICE|Biomatrix Flex Stent|stent implantation
214799471|NCT01932840|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
214799472|NCT03044548|OTHER|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
214799473|NCT04462263|DRUG|HTL0014242|Solid suspension capsule
214799474|NCT05310370|GENETIC|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
214799475|NCT00394056|DRUG|Vestipitant|NK1 receptor antagonist
214799476|NCT00394056|DRUG|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
214799477|NCT00394056|OTHER|Placebo|Placebo
214799478|NCT00109109|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
214799479|NCT02983708|BIOLOGICAL|Peripheral blood mononuclear cells (mPBMC)|
214799480|NCT02983708|DRUG|G-CSF|
214799481|NCT02983708|DRUG|Placebo|
214799482|NCT04888910|OTHER|observational|observation of biomarkers in different asthma groups
214799483|NCT03729310|DEVICE|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
214647456|NCT01028625|OTHER|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
214647457|NCT00024427|DRUG|fluorouracil|High dose 5-FU
214647458|NCT00024427|DRUG|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
214647459|NCT00024427|DRUG|triacetyluridine|6 grams (12 tablets)
214647460|NCT00355316|OTHER|Blood draw|
214647461|NCT01440335|DRUG|Oral R,R'-Fenoterol|
214647462|NCT01440335|DRUG|Oral Racemic Fenoterol|
214799484|NCT03729310|DRUG|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
214799485|NCT03729310|DEVICE|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
214799486|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months.
214799487|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
214799488|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months
214799489|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
214799490|NCT01722981|PROCEDURE|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
214799491|NCT03150602|DRUG|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
214799492|NCT00025896|DRUG|recombinant human acid alpha-glucosidase (rhGAA)|
214799493|NCT00620009|BEHAVIORAL|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
214799494|NCT00046267|DRUG|Niacin|
214799495|NCT01048320|DRUG|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
214647463|NCT05797714|DRUG|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 144 weeks
214647464|NCT04420364|OTHER|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
214647465|NCT02803957|DEVICE|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
214647466|NCT02803957|DEVICE|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
214647467|NCT02862691|DRUG|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
214647468|NCT02862691|DRUG|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
214647469|NCT05077488|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Sterile gel in disposable syringe
214647470|NCT04856514|BEHAVIORAL|PEERS|16 week telehealth intervention; parallel teen and parent/caregiver groups; 90 minutes each week.
214647471|NCT04371367|BIOLOGICAL|avdoralimab|intravenous administration of avdoralimab
214647472|NCT04371367|OTHER|Placebo|intravenous administration of placebo
214647473|NCT01736956|PROCEDURE|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
214647474|NCT00313573|PROCEDURE|management of therapy complications|
214647475|NCT00313573|PROCEDURE|pain therapy|
214647476|NCT00313573|PROCEDURE|psychosocial assessment and care|
214647477|NCT00313573|PROCEDURE|quality-of-life assessment|
214647478|NCT00428402|BEHAVIORAL|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
214647479|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
214647480|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
214647481|NCT03784183|OTHER|Cognitive Stimulation (CS)|CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
214647482|NCT05729893|OTHER|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
214647483|NCT00679458|DRUG|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
214647484|NCT00679458|DRUG|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
214647485|NCT01731678|PROCEDURE|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
214647486|NCT00720148|DRUG|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
214647487|NCT00866099|OTHER|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
214647488|NCT01225341|DRUG|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
214647489|NCT01225341|OTHER|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
214647490|NCT02224898|BEHAVIORAL|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
214647491|NCT04960085|DEVICE|echocardiography|philips IE33
214647492|NCT03557567|DIAGNOSTIC_TEST|NGS molecular screening|
214647493|NCT00207467|BEHAVIORAL|Patient-delivered partner treatment|
214647494|NCT00207467|BEHAVIORAL|Booklet-enhanced partner referral|
214647495|NCT01175798|DRUG|Cholecalciferol|50,000 IU PO weekly x 6 weeks
214647496|NCT00430170|DRUG|Dipyridamole|Dipyridamole 2x200mg 7day per os
214647497|NCT00430170|DRUG|caffeine|caffeine 4mg/kg iv
214799496|NCT01048320|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
214799497|NCT01048320|DRUG|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
214799498|NCT02840409|DRUG|Vinblastine|
214799499|NCT02840409|DRUG|Bevacizumab|
214799500|NCT05427656|RADIATION|[18F] TRACK|We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.
214799501|NCT05427656|DEVICE|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
214799502|NCT03174756|DRUG|Hypochlorous Acid|Mouthwashes of antiplaque agents
214799503|NCT03174756|DRUG|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
214799504|NCT03174756|OTHER|Placebo|Sterile water as placebo
214799505|NCT04570904|BIOLOGICAL|Influenza vaccination at different time points|All HCWs will receive the seasonal influenza vaccine but at two different time points.
214799506|NCT04887142|OTHER|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
214799507|NCT01762085|PROCEDURE|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
214799508|NCT03265080|BIOLOGICAL|ADXS-NEO|Intravenous infusion
214799509|NCT03265080|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214799510|NCT05380271|DRUG|sequential DEB-BACE and Arotinib and Tirelizumab|DEB-BACE+Arotinib + Tirelizumab
214799511|NCT05380271|DRUG|DEB-BACE alone|DEB-BACE alone
214799512|NCT00757809|DRUG|neratinib|HKI-272
214799513|NCT04265365|DEVICE|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799514|NCT04265365|DEVICE|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799515|NCT04265365|DEVICE|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799516|NCT04265365|DEVICE|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799517|NCT04265365|DEVICE|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799518|NCT04265365|DEVICE|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
214799519|NCT04265365|DEVICE|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214799520|NCT04265365|DEVICE|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
214799521|NCT01709760|DRUG|Methotrexate|Methotrexate 15-25 mg/week
214799522|NCT01709760|DRUG|ENIA11|ENIA11 25 mg, sc twice weekly
214799523|NCT01709760|DRUG|Placebo|Placebo, sc twice weekly
214799524|NCT03397862|DRUG|Donepezil TDS|Donepezil patch
214799525|NCT03397862|DRUG|Vehicle TDS|Placebo patch
214799526|NCT00481780|DEVICE|plain balloon angioplasty|
214799527|NCT00481780|DEVICE|cutting balloon angioplasty|
214799528|NCT03553160|OTHER|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
214799529|NCT05540509|BEHAVIORAL|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
214799530|NCT05540509|BEHAVIORAL|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
214799531|NCT02193438|OTHER|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
214799532|NCT02193438|OTHER|Placebo|Tomato juice intake
214799533|NCT02844153|OTHER|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
214799534|NCT02026453|OTHER|Pharmacist obtains admission medication history|
214799535|NCT02026453|OTHER|Pharmacy technician obtains admission medication history|
214799536|NCT00554151|DEVICE|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
214799537|NCT04971551|DRUG|Jaktinib Hydrochloride Tablets|Oral on an empty stomach
214799538|NCT04963192|DEVICE|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
214799539|NCT04963192|DEVICE|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
214799540|NCT04963192|OTHER|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
214799541|NCT04963192|DEVICE|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
214799542|NCT04963192|DEVICE|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
214799543|NCT04963192|DEVICE|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
214799544|NCT04963192|DEVICE|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
214799545|NCT04963192|DEVICE|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
214799546|NCT04963192|OTHER|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
214799547|NCT04963192|OTHER|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
214799548|NCT04963192|OTHER|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
214799549|NCT04963192|OTHER|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
214799550|NCT04963192|OTHER|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
214799551|NCT01089647|DRUG|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
214799552|NCT01089647|DRUG|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
214799553|NCT00995553|BEHAVIORAL|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
214799554|NCT00995553|BEHAVIORAL|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
214799555|NCT06277193|DIAGNOSTIC_TEST|valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
214799556|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
214799557|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
214799558|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
214799559|NCT05892978|OTHER|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
214799560|NCT03840057|DRUG|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
214799561|NCT03840057|DRUG|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
214799562|NCT03840057|DRUG|Sodium chloride 0.9%|Normal saline is used as a placebo control.
214799563|NCT02652026|PROCEDURE|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
214799564|NCT02652026|PROCEDURE|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
214799565|NCT00927810|DRUG|Canakinumab|
214799566|NCT05276284|COMBINATION_PRODUCT|Atezolizumab, 6-mercaptopurine, 6-thioguanine|Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
214799567|NCT03920657|DRUG|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
214799568|NCT02334059|DRUG|Ketamine|Ketamine infusion plus placebo infusion of normal saline
214799569|NCT02334059|DRUG|Ketamine plus magnesium|Ketamine plus magnesium infusion
214799570|NCT02334059|OTHER|Placebo|2 placebo infusions
214799571|NCT03784261|DRUG|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
214799572|NCT03784261|DRUG|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
214799573|NCT03784261|DRUG|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
214799574|NCT00314691|GENETIC|Blood samples|
214799575|NCT00006156|OTHER|Control|No injection of FSH
214799576|NCT00006156|DRUG|Drug: FSH|FSH Stimulation Test
214799577|NCT00198029|DEVICE|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
214799578|NCT01520948|BEHAVIORAL|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
214799579|NCT01520948|BEHAVIORAL|Behavioral control|Mirrored star drawing
214799580|NCT04820868|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
214799581|NCT06321081|DRUG|irinotecan, cetuximab, envafolimab|rechallenge treatment
214799582|NCT01961908|DRUG|Proellex|
214799583|NCT03651674|DEVICE|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
214799584|NCT03651674|DRUG|Drug treatment|Patients only have antipsychotic drugs
214799585|NCT00546390|DEVICE|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
214799586|NCT03538236|DEVICE|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
214799587|NCT03538236|BEHAVIORAL|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
214799588|NCT03785236|RADIATION|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
214799589|NCT02991547|OTHER|Observational|
214799590|NCT04287881|GENETIC|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
214799591|NCT03682952|DRUG|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
214799592|NCT03682952|DRUG|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
214799593|NCT04716738|DIAGNOSTIC_TEST|Blood analyses and coprological|We will take a blood and stool sample
214799594|NCT03695926|DRUG|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
214799595|NCT00537147|BIOLOGICAL|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
214799596|NCT00537147|BIOLOGICAL|Placebo|Placebo for WN/DEN4delta30 vaccine
214799597|NCT01626079|DEVICE|MitraClip System|Percutaneous mitral valve repair using MitraClip System
214799598|NCT03466957|OTHER|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
214799599|NCT01215448|DIETARY_SUPPLEMENT|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
214799600|NCT01589536|OTHER|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
214799601|NCT04947956|DRUG|Camrelizumab|The camrelizumab-based treatment will be determined by the investigator.
214799602|NCT05083598|OTHER|6 Minute walking test|The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
214799603|NCT05083598|OTHER|Frailty questionaires|Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
214799604|NCT00006264|BIOLOGICAL|aldesleukin|
214799605|NCT00006264|DRUG|ganciclovir|
214799606|NCT00006264|DRUG|zidovudine|
214799607|NCT03648944|OTHER|Accelerated Rehabillitation|
214799608|NCT03648944|OTHER|Non-Accelerated Rehabillitation|
214799609|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
214799610|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
214799611|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
214799612|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
214799613|NCT00559481|DRUG|dexamethasone|
214799614|NCT00559481|DRUG|ketoconazole|
214799615|NCT00559481|DRUG|therapeutic hydrocortisone|
214799616|NCT00559481|PROCEDURE|pharmacological study|
214799617|NCT02519413|DRUG|dimethyl fumarate|delayed release capsules
214799618|NCT05602688|DIETARY_SUPPLEMENT|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
214799619|NCT05602688|DIETARY_SUPPLEMENT|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
214799620|NCT01709032|DRUG|Deferasirox and deferiprone|
214799621|NCT00448578|DRUG|Quetiapine Fumarate|
214799622|NCT00448578|DRUG|Lithium|
214799623|NCT01457053|DRUG|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
214799624|NCT01457053|OTHER|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
214799625|NCT02253797|DRUG|14C-Tipranavir|
214799626|NCT02253797|DRUG|Tipranavir|
214799627|NCT02253797|DRUG|Ritonavir|
214799628|NCT01743157|DRUG|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
214799629|NCT01184196|DRUG|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
214799630|NCT01184196|DRUG|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
214799631|NCT00814463|BEHAVIORAL|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
214799632|NCT00814463|BEHAVIORAL|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
214799633|NCT00814463|PROCEDURE|MRI|MRI done every 3 months for the length of the study.
214799634|NCT00814463|RADIATION|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
214799635|NCT01713309|DRUG|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
214799636|NCT00624871|DRUG|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
214799637|NCT00624871|DRUG|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
214799638|NCT00624871|DRUG|Placebo|
214799639|NCT03982433|BEHAVIORAL|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
214799640|NCT04832230|OTHER|Hearing test|"The hearing test is composed of several examinations:~* pure tone audiogram~* otoscopy~* tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
214799641|NCT04832230|OTHER|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
214799642|NCT04832230|OTHER|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
214799643|NCT04832230|OTHER|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
214799644|NCT04832230|OTHER|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
214799645|NCT04832230|OTHER|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
214799646|NCT04832230|OTHER|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
214799647|NCT04832230|BIOLOGICAL|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
214799648|NCT01548872|DRUG|HTK solution|50 ml/kg bolus in 2 minutes
214799649|NCT01548872|DRUG|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
214799650|NCT02686216|DRUG|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
214799651|NCT00098709|DEVICE|Fetal pulse oximeter|
214799652|NCT02369042|DEVICE|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
214799653|NCT00439764|BEHAVIORAL|General health talk|Routine clinical practice and talk on general health
214799654|NCT00439764|BEHAVIORAL|Handout of The Back Book|Talk on health of the back and handout of The Back Book
214799655|NCT00439764|BEHAVIORAL|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
214799656|NCT00368277|DRUG|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
214799657|NCT00368277|DRUG|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
214799658|NCT00368277|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
214799659|NCT00368277|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
214799660|NCT01951846|DRUG|BIBF 1120|
214799661|NCT00984295|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
214799662|NCT00984295|BIOLOGICAL|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
214799663|NCT00984295|BIOLOGICAL|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
214799664|NCT00984295|BIOLOGICAL|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
214799665|NCT00984295|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
214799666|NCT01072110|PROCEDURE|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
214799667|NCT01072110|PROCEDURE|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
214799668|NCT06495814|DRUG|1/bag of Jinlida granules, 3 times/day, taken with hot water.|All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.
214799669|NCT04799158|DRUG|Vonoprazan|Orally via capsules
214799670|NCT04799158|DRUG|Placebo|Orally via capsules
214799671|NCT04137679|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
214799672|NCT04137679|PROCEDURE|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
214799673|NCT03075137|DEVICE|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
214799674|NCT06544993|DRUG|Meso-botox|Micro-Botox, is a highly diluted Botulinum toxin type A
214799675|NCT01698996|PROCEDURE|Packing vs No Packing|
214799676|NCT03117673|OTHER|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
214799677|NCT01441271|PROCEDURE|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.
214799678|NCT01441271|PROCEDURE|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
214799679|NCT05662553|PROCEDURE|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
214799680|NCT05662553|PROCEDURE|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
214799681|NCT05555459|PROCEDURE|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
214799682|NCT03028272|OTHER|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
214799683|NCT03028272|OTHER|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
214799684|NCT02762097|PROCEDURE|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
214799685|NCT02762097|PROCEDURE|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
214799686|NCT02762097|DRUG|normal saline|Normal saline would be injected into uterine cavity to delineate defects
214799687|NCT03978403|DRUG|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
214799688|NCT03978403|DRUG|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
214799689|NCT03978403|DRUG|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
214799690|NCT03978403|DRUG|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose
214799691|NCT02524990|BEHAVIORAL|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
214799692|NCT00857636|BEHAVIORAL|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
214799693|NCT02746952|BIOLOGICAL|UCART19|
214799694|NCT02697409|BEHAVIORAL|Education Against Tobacco intervention|
214799695|NCT00143819|DRUG|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
214799696|NCT00143819|DRUG|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
214799697|NCT03416595|DIETARY_SUPPLEMENT|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
214799698|NCT03416595|DIETARY_SUPPLEMENT|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
214799699|NCT01131858|DRUG|Vigantol|Vigantol 4000IU/day
214799700|NCT01131858|DRUG|Placebo|Placebo
214799701|NCT06496269|OTHER|No intervention|No intervention
214799702|NCT04812106|OTHER|No Intervention|No Intervention
214799703|NCT05345132|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
214799704|NCT05345132|DRUG|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
214799705|NCT01291303|PROCEDURE|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
214799706|NCT01291303|PROCEDURE|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
214799707|NCT02359604|DRUG|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
214799708|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
214799709|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
214799710|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
214799711|NCT05011500|RADIATION|Radiotherapy with Closed Mask|Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.
214799712|NCT05011500|RADIATION|Radiotherapy with Open Mask and Surface Scanning|Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
214799713|NCT05011500|RADIATION|Radiotherapy with No Mask|Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
214799714|NCT02535507|DRUG|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
214799715|NCT04105881|DIETARY_SUPPLEMENT|Investigation|Cross sectional intervention
214799716|NCT02556242|OTHER|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
214799717|NCT02556242|OTHER|Generalised Indoor residual spraying|IRS is carried out as normally practiced
214799718|NCT03918798|DRUG|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
214799719|NCT03918798|DRUG|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
214799720|NCT00914667|DRUG|warfarin|Single Dose Warfarin 25 mg on Day 1
214799721|NCT00914667|DRUG|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
214799722|NCT06309706|OTHER|No intervention|Just observation
214799723|NCT04351295|DRUG|Favipiravir|Favipiravir
214799724|NCT04351295|DRUG|Chloroquine|chloroquine oral tablets
214647498|NCT01112332|DEVICE|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
214647499|NCT00888355|DRUG|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
214799725|NCT06166472|DRUG|AK132|IV infusion, specified dose on specified days.
214799726|NCT01729936|BEHAVIORAL|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
214799727|NCT03680170|BEHAVIORAL|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
214799728|NCT03680170|BEHAVIORAL|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
214799729|NCT03776032|DRUG|Darbepoetin alfa|Administered by subcutaneous injection once a week
214647500|NCT00888355|DRUG|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
214647501|NCT05713864|DEVICE|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
214647502|NCT05713864|DEVICE|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
214799730|NCT03776032|DRUG|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
214799731|NCT00569426|DEVICE|NovoFine® needle 6 mm|
214799732|NCT00569426|DEVICE|NovoFine® needle 8 mm|
214799733|NCT05132413|DRUG|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
214647503|NCT06166628|PROCEDURE|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
214647504|NCT06166628|PROCEDURE|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
214647505|NCT06166628|PROCEDURE|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
214647506|NCT04432363|DEVICE|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
214647507|NCT00002309|DRUG|Azithromycin|
214647508|NCT00222027|PROCEDURE|Collection of treatment-stratefying prognostic factors|
214647509|NCT01940614|OTHER|Water deprivation test|Classical water deprivation test alone
214647510|NCT01940614|OTHER|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
214647511|NCT01940614|OTHER|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
214647512|NCT00148746|DRUG|Pimecrolimus|
214647513|NCT00148746|DRUG|Tacrolimus|
214647514|NCT00148746|DRUG|Prednisolone|
214647515|NCT00148746|DRUG|Ciclosporin A|
214647516|NCT00148746|DRUG|Dermatop|
214647517|NCT04664348|OTHER|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
214647518|NCT04664348|OTHER|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
214647519|NCT05527457|DRUG|BAY2586116|160 μg BAY2586116 nasal spray application
214647520|NCT05527457|DRUG|Placebo|Placebo (saline) nasal spray application
214647521|NCT03524573|PROCEDURE|Appendectomy|Appendectomy is the surgical removal of the appendix.
214647522|NCT05050760|DRUG|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
214647523|NCT05050760|DRUG|DCF|DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
214647524|NCT00085280|DRUG|erlotinib hydrochloride|Given orally
214799734|NCT05132413|DRUG|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
214647525|NCT00085280|OTHER|laboratory biomarker analysis|Correlative studies
214647526|NCT00880360|DRUG|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
214647527|NCT03983499|BEHAVIORAL|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
214647528|NCT01684462|BIOLOGICAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
214647529|NCT01684462|DRUG|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
214647530|NCT02538172|OTHER|T-Track® CMV assay|
214647531|NCT01551693|DRUG|STA-9090|
214647532|NCT00138021|DEVICE|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk \& Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
214647533|NCT02841410|OTHER|Magnetic Resonance Imaging|
214647534|NCT00971126|DRUG|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
214647535|NCT05009901|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600 mg daily for 8 weeks
214647536|NCT05009901|DRUG|Placebo|Placebo one tablet daily for 8 weeks
214647537|NCT01271140|DRUG|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
214647538|NCT01310335|DEVICE|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
214647539|NCT01420484|OTHER|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
214647540|NCT04435223|BIOLOGICAL|biological assays in particular on the lipid metabolism|bioassays carried out on samples already collected and conserved
214647541|NCT06077084|OTHER|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
214647542|NCT02736032|PROCEDURE|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
214799735|NCT05132413|DRUG|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
214799736|NCT05977257|DEVICE|VitaFlow® Transcatheter Aortic Valve Replacement System|This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
214799737|NCT02898649|DEVICE|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
214799738|NCT03425864|PROCEDURE|connective tissue graft|patient will receive immediate implant and connective tissue graft
214799739|NCT03425864|DEVICE|immediate implant|patient will receive immediate implant with connective tissue graft.
214799740|NCT01298856|PROCEDURE|hydrotherapy|hydrotherapy and ankle taping and land-based
214799741|NCT01157390|OTHER|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage \& frequency: Fed as need Duration: at least 3 months
214799742|NCT01157390|OTHER|Breast feeding|Breast feeding
214799743|NCT00766688|DRUG|AVE5530|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
214799744|NCT00766688|DRUG|Placebo|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
214799745|NCT01790568|DRUG|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
214799746|NCT01790568|DRUG|Tacrolimus|
214799747|NCT01790568|DRUG|Methotrexate|
214799748|NCT01938482|DRUG|0.3% GSK1940029 gel|Will be supplied as gel for topical application
214799749|NCT01938482|DRUG|1% GSK1940029 gel|Will be supplied as gel for topical application
214799750|NCT01938482|DRUG|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
214799751|NCT00186706|DRUG|Selenium|
214799752|NCT00654264|PROCEDURE|Water immersion|Subjects will sit in tub for four hours.
214799753|NCT04790851|BIOLOGICAL|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
214799754|NCT04790851|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
214799755|NCT04790851|BIOLOGICAL|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
214799756|NCT03958890|DRUG|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
214799757|NCT03958890|DRUG|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
214799758|NCT02994056|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214799759|NCT02994056|DRUG|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
214799760|NCT01701284|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
214799761|NCT04107493|DEVICE|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
214799762|NCT04107493|DEVICE|Mobi|ResMed's variant of POC
215031578|NCT07011290|OTHER|Brisk walking (BW) training sessions|Participants will partake in 2 sessions of brisk walking (BW), each composed by 3x14 min periods, interspersed by 2 min breaks, in which the participants will follow a designated instructor who will dictate the walking speed along a 38x18 m course, thus ensuring that the speed of the walking corresponds to a brisk walking speed.
214799763|NCT02686840|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214799764|NCT02686840|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
214799765|NCT05793736|DEVICE|Biofeedback training|The intervention lasts 5 weeks, twice a week, each session lasts 45 minutes in which HRV (Heart Rate Variability) is detected, through plethysmographic sensors placed on the finger or earlobe during assigned tasks. During tasks that involve progressively more complex phases, they allow the person to receive immediate feedback on the video screen.
214799766|NCT05793736|DRUG|Treatment as usual|The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
214799767|NCT01925313|DRUG|CJ-30044|20.51mg a day,PO,QD
214799768|NCT01925313|DRUG|TALION TAB. 10mg|10mg a day,PO,BID
214799769|NCT02199509|DRUG|Levetiracetam|Anticonvulsant
214799770|NCT04025034|PROCEDURE|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
214799771|NCT04018625|BEHAVIORAL|SMART Mom|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
214799772|NCT04018625|BEHAVIORAL|Mama Support|Participants will be enrolled in an 8-week time and attention matched, process-based support group.
214799773|NCT04131361|OTHER|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
214799774|NCT03726190|PROCEDURE|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
214799775|NCT06173245|PROCEDURE|Intravitreal injection of ranibizumab|"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."
214799776|NCT03294356|OTHER|FT210771|An electronic cigarette
214799777|NCT03294356|OTHER|FT210751|An electronic cigarette
214799778|NCT03294356|OTHER|6T30134157764|An electronic cigarette
214799779|NCT03294356|OTHER|G41A7C071|An electronic cigarette
214799780|NCT03294356|OTHER|M011161212|An electronic cigarette
214799781|NCT03294356|OTHER|FT21002|A combustible cigarette
214799782|NCT01231061|RADIATION|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
214799783|NCT01231061|RADIATION|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
214799784|NCT06313047|DRUG|Doxorubicin|each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
214799785|NCT05875688|OTHER|Cementation Technique A|"* Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration."
214799786|NCT05875688|OTHER|Cementation Technique B|"* Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place."
214799787|NCT05875688|OTHER|Cementation Technique C|"* The utilisation of an appropriate quantity of cement.~* The mitigation of cement waste.~* Prolonged retention of dental crowns."
214799788|NCT01775215|RADIATION|Cardiac I123-MIBG Scintigraphy|
214799789|NCT01775215|OTHER|Cardiac MRI|
214799790|NCT01775215|OTHER|Stress and rest Echocardiogram|
214799791|NCT01775215|OTHER|High Sensitivity Troponin I|
214799792|NCT01775215|OTHER|Brain Natriuretic Peptide|
214799793|NCT04094194|OTHER|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
214799794|NCT03309956|DEVICE|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
214799795|NCT03309956|DEVICE|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
214799796|NCT04935775|OTHER|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
214799797|NCT02525328|OTHER|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
214799798|NCT02768298|DRUG|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
214799799|NCT02768298|DRUG|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
214799800|NCT02768298|DRUG|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
214799801|NCT02768298|DRUG|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
214799802|NCT01693783|BIOLOGICAL|Ipilimumab|Given IV
214799803|NCT01693783|OTHER|Laboratory Biomarker Analysis|Correlative studies
214799804|NCT04267666|DEVICE|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
214799805|NCT04267666|OTHER|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
214799806|NCT04455659|DEVICE|Trans-cutaneous Electrical Nerve Stimulation|TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
214799807|NCT04455659|PROCEDURE|Conventional physical therapy exercise|physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
214799808|NCT04059211|DIAGNOSTIC_TEST|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
214799809|NCT00260780|BEHAVIORAL|The MISTERS Intervention for Post Jail Release Men|
214799810|NCT02557607|DEVICE|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
214799811|NCT01975805|OTHER|Chlorhexidine Gluconate|
214799812|NCT01975805|OTHER|Povidone Iodine|
214799813|NCT01168505|DRUG|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
214799814|NCT05707299|PROCEDURE|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
214799815|NCT01779622|OTHER|Mixed meal|Ingestion of mixed meal
214799816|NCT00905125|BIOLOGICAL|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
214799817|NCT00905125|BIOLOGICAL|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
214799818|NCT01192646|BEHAVIORAL|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
214799819|NCT02078063|DRUG|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
214799820|NCT02078063|DRUG|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
214799821|NCT02929693|DRUG|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
214799822|NCT02929693|DRUG|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
214799823|NCT02929693|DRUG|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
214799824|NCT06871176|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be administered intravenously using the recommended activity for adults which is up to 150 MBq (4 mCi) fixed dose. There is no weight adaption recommended in the literature.
214799825|NCT04603937|DRUG|KSI-301|Intravitreal Injection
214799826|NCT04603937|DRUG|Aflibercept|Intravitreal Injection
214799827|NCT04603937|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214799828|NCT04823000|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
214799829|NCT02518685|DEVICE|TransPyloric Shuttle|
214799830|NCT02518685|DEVICE|Sham procedure|
214799831|NCT02518685|BEHAVIORAL|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
214799832|NCT01932034|DEVICE|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
214799833|NCT01922349|DRUG|BI 113608|Medium dose (Multiple dosing)
214799834|NCT01922349|DRUG|Placebo|Placebo (Multiple dosing)
214799835|NCT01922349|DRUG|BI 113608|Low dose (Multiple dosing)
214799836|NCT01922349|DRUG|Placebo|Placebo (Single dosing)
214799837|NCT01922349|DRUG|BI 113608|High dose (Single dosing)
214799838|NCT01922349|DRUG|BI 113608|Medium dose (Single dosing)
214799839|NCT01922349|DRUG|BI 113608|Low dose (Single dosing)
214799840|NCT01922349|DRUG|BI 113608|High dose (Multiple dosing)
214799841|NCT01611090|DRUG|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
214799842|NCT01611090|DRUG|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
214799843|NCT01611090|DRUG|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
214799844|NCT01611090|DRUG|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
214799845|NCT03136783|OTHER|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
214799846|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
214647543|NCT02736032|PROCEDURE|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
214647544|NCT02736032|DRUG|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
214647545|NCT02736032|DRUG|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
214647546|NCT02736032|DRUG|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
214647547|NCT02730156|OTHER|Altitude exposure|Altitude exposure
214647548|NCT01631669|DRUG|Celecoxib|200 mg Q 12 hours orally
214647549|NCT01893567|DRUG|Clobex Spray|
214647550|NCT04934930|DRUG|Bendamustin|Chemotherapy
214647551|NCT04934930|DRUG|Obinutuzumab|Immunotherapy
214647552|NCT03891550|DRUG|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
214647553|NCT02015169|DRUG|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
214799847|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
214799848|NCT06078488|OTHER|Individualized and Protocolized Nutritional Care Bundle|"Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks."
214799849|NCT06078488|OTHER|Optimized Standard Care|Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
214799850|NCT03618979|BIOLOGICAL|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
214799851|NCT03618979|BIOLOGICAL|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
215031110|NCT06272604|BEHAVIORAL|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
215031111|NCT02354521|OTHER|NO INTERVENTIONS|
215031112|NCT02884453|DRUG|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
215031113|NCT06375148|OTHER|Enteral nutrition|prone position ventilation
214799852|NCT03618979|BIOLOGICAL|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
214799853|NCT04476732|OTHER|Paraben-free skincare product|Paraben-free lotion will be applied twice a day for one week.
214799854|NCT04476732|OTHER|Paraben-containing skincare product|Paraben-containing lotion will be applied twice a day for one week.
214799855|NCT02398461|DRUG|rHIgM22|Administered via IV infusion
214799856|NCT02398461|DRUG|Placebo|
214799857|NCT00212095|DRUG|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
214799858|NCT00213811|BEHAVIORAL|clinical, biological, and radiological|
214799859|NCT03735758|DRUG|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
214799860|NCT01919190|DRUG|EXPAREL|TAP with EXPAREL
214799861|NCT01919190|DRUG|Placebo|Placebo
214799862|NCT04808089|OTHER|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
214799863|NCT04808089|OTHER|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
214799864|NCT03467568|DIETARY_SUPPLEMENT|Sodium Chloride|300mg sodium chloride will be provided in a capsule
214799865|NCT03467568|OTHER|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
214799866|NCT03467568|DIETARY_SUPPLEMENT|Water|Twice during the morning a drink of 150ml of water will be consumed
214799867|NCT03467568|BIOLOGICAL|No water consumed|No water will be consumed during the monring
214799868|NCT03803410|PROCEDURE|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
214799869|NCT05497414|BEHAVIORAL|Sleep deprivation|Overnight sleep deprivation.
214799870|NCT04879810|PROCEDURE|Sigmoidoscopy and biopsy, blood work|Flexible tube up lower colon, blood draws, quality of life questionnaires
214799871|NCT05224895|PROCEDURE|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
214799872|NCT05140096|DRUG|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
214799873|NCT05140096|DRUG|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
214799874|NCT05140096|DRUG|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
214799875|NCT00655642|DRUG|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
214799876|NCT00655642|DRUG|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
214799877|NCT00655642|DRUG|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
214799878|NCT00655642|DRUG|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
214799879|NCT04396028|OTHER|data collection|retrospective data collection
214799880|NCT05450770|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
214799881|NCT03244774|DRUG|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
214799882|NCT03244774|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
214799883|NCT01545076|BIOLOGICAL|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
214799884|NCT01545076|BIOLOGICAL|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
214799885|NCT01545076|BIOLOGICAL|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
214799886|NCT01545076|BIOLOGICAL|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
214799887|NCT02518113|DRUG|LY3039478|Administered orally
214799888|NCT02518113|DRUG|Dexamethasone|Administered orally
214799889|NCT02518113|DRUG|Placebo|Administered orally
214799890|NCT00797108|DRUG|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
214799891|NCT00797108|DRUG|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
214799892|NCT00797108|DRUG|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
214799893|NCT02270736|DRUG|NT 201 Placebo|NT 201 placebo matching injection.
214799894|NCT02270736|DRUG|NT 201|NT 201 injection.
214799895|NCT02349165|PROCEDURE|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
214799896|NCT02349165|DRUG|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
214799897|NCT02349165|DRUG|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
214799898|NCT05241184|DIAGNOSTIC_TEST|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
214799899|NCT05395000|BEHAVIORAL|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
214799900|NCT05395000|BEHAVIORAL|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
214799901|NCT05395000|BEHAVIORAL|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
214799902|NCT05625256|DEVICE|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
214799903|NCT03423888|DEVICE|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
214799904|NCT02134756|DRUG|NutraStem Active|
214799905|NCT02134756|DRUG|NutraStem Placebo|
214799906|NCT03958032|OTHER|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
214799907|NCT00098488|DRUG|tanespimycin|Given IV
214799908|NCT00098488|BIOLOGICAL|rituximab|Given IV
214799909|NCT04471207|DEVICE|Therapist Guided Prolonged Exposure with BioWare Device|"Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
214799910|NCT04471207|DEVICE|Record Only Prolonged Exposure with BioWare Device|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
214799911|NCT04066309|DEVICE|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
214799912|NCT04066309|DEVICE|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
214799913|NCT04066309|DEVICE|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
214799914|NCT04066309|DEVICE|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
214799915|NCT00952783|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
214799916|NCT02538445|OTHER|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
214799917|NCT02538445|OTHER|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
214799918|NCT02538445|OTHER|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
214799919|NCT02538445|OTHER|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
214799920|NCT03230851|DRUG|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
214799921|NCT03230851|DRUG|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
214799922|NCT03230851|DRUG|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
214799923|NCT03230851|DRUG|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
214799924|NCT03230851|DRUG|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
214799925|NCT03230851|DRUG|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
214799926|NCT03230851|DRUG|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
214799927|NCT01667783|PROCEDURE|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
214799928|NCT01667783|BEHAVIORAL|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
214799929|NCT01667783|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
214799930|NCT02188797|BEHAVIORAL|Group MI risk reduction program|
214799931|NCT02792205|OTHER|Non interventional study|no intervention
214799932|NCT05588856|OTHER|In depth Interview|In depth Interviews
214799933|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
214799934|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluzone)|
214799935|NCT02320942|OTHER|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
214799936|NCT00769106|BIOLOGICAL|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
214799937|NCT00561730|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
214799938|NCT01210729|DEVICE|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
214799939|NCT03233620|OTHER|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
214799940|NCT06120127|RADIATION|SBRT|postoperative SBRT of liver lesions
214799941|NCT06120127|DRUG|Chemotherapy|XELOX/FOLFOX/FOLFIRI
214799942|NCT06120127|DRUG|PD-1 antibody|Sintilimab (200mg d1，q3w)
214799943|NCT00376220|DRUG|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
214799944|NCT00376220|OTHER|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
214799945|NCT04347291|BEHAVIORAL|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
214799946|NCT04347291|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
214799947|NCT00678366|PROCEDURE|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
214799948|NCT00678366|PROCEDURE|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
214799949|NCT00269048|DRUG|SB-480848|SB-480848
214799950|NCT00269048|DRUG|placebo|placebo
214799951|NCT01640496|DRUG|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
214799952|NCT01640496|OTHER|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
214799953|NCT00067236|DRUG|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
214799954|NCT00067236|DRUG|Placebo tablet|placebo tablet, twice a day for 90 days
214799955|NCT04167566|COMBINATION_PRODUCT|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
214799956|NCT00919464|DEVICE|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
214799957|NCT00919464|DEVICE|Compartmental fracture pressure monitoring|
214799958|NCT00919464|DEVICE|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
214799959|NCT01672190|OTHER|Yoga Therapy Program|
214799960|NCT00682084|PROCEDURE|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
214799961|NCT00000775|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
214799962|NCT02313103|DRUG|lofexidine HCl|400 micrograms
214799963|NCT05560464|DRUG|VX-548|Tablets for oral administration.
214799964|NCT05251103|OTHER|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
214799965|NCT01098721|DRUG|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
214799966|NCT05865600|OTHER|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.
214799967|NCT05865600|DIAGNOSTIC_TEST|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
214799968|NCT05865600|DIAGNOSTIC_TEST|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
214799969|NCT05865600|OTHER|Standard of care|Standard of care
214799970|NCT03427970|BEHAVIORAL|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
214799971|NCT03427970|BEHAVIORAL|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
214799972|NCT00531206|DRUG|Tipranavir|
214799973|NCT00531206|DRUG|Ritonavir|low dose
214799974|NCT05976399|OTHER|Connective Tissue Massage|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
214799975|NCT05976399|OTHER|Manual Lymph Drainage|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
214799976|NCT01878370|OTHER|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
214799977|NCT01878370|OTHER|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
214799978|NCT00253032|DEVICE|PRIMA|
214799979|NCT05975970|DEVICE|MyoTrain AR|MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.
214799980|NCT05975970|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
214799981|NCT05420506|DEVICE|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
214799982|NCT02635100|OTHER|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
214799983|NCT05422547|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
214799984|NCT02301247|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
214799985|NCT02301247|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
214799986|NCT00802451|DRUG|Mesalamine|
214799987|NCT02397733|RADIATION|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
214799988|NCT02397733|RADIATION|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
214799989|NCT05209945|PROCEDURE|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
214799990|NCT02659722|DEVICE|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
214799991|NCT00017784|DRUG|Valganciclovir|
214799992|NCT04765709|COMBINATION_PRODUCT|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
214799993|NCT04765709|COMBINATION_PRODUCT|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
214799994|NCT04765709|BIOLOGICAL|durvalumab|Consolidation treatment with durvalumab
214799995|NCT06066502|OTHER|Precision ventilation|The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.
214799996|NCT06066502|OTHER|Guided usual care ventilation|The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
214799997|NCT00552331|DEVICE|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
214799998|NCT00552331|DEVICE|LISS|treatment of distal femur fractures with less invasive stabilization systems
214799999|NCT02715869|DRUG|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
214800000|NCT02715869|PROCEDURE|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
215031114|NCT06062303|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
215031115|NCT04243486|DRUG|UHE-105|Topical shampoo containing active drug
215031116|NCT04243486|DRUG|Vehicle|Topical shampoo containing no active drug
215031117|NCT03716596|RADIATION|SBRT|SBRT radiation dose is 40-50 Gy in total.
215031118|NCT03716596|DRUG|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
214800001|NCT05897580|BEHAVIORAL|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
214800002|NCT05897580|BEHAVIORAL|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
214800003|NCT06254248|DRUG|Systemic therapy|"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."
214800004|NCT03818048|DRUG|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
214800005|NCT03818048|DRUG|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
214800006|NCT03714165|DIAGNOSTIC_TEST|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
214800007|NCT03273322|DRUG|Rivaroxaban 10 mg qd|10mg qd
214800008|NCT03273322|DRUG|Rivaroxaban 15 mg qd|15mg qd
214800009|NCT03273322|DRUG|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
214800010|NCT00012857|DRUG|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
214800011|NCT02907996|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
214800012|NCT00048646|DRUG|IV Progesterone|
214800013|NCT00920140|DRUG|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
214800014|NCT00920140|DRUG|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
214800015|NCT03735446|DRUG|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
214800016|NCT03735446|DRUG|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
214800017|NCT03735446|DRUG|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
214800018|NCT03735446|DRUG|Cytarabine|Standard chemotherapy (anti-metabolite)
214800019|NCT03876613|BEHAVIORAL|Different music types|the type of music that reduces anxiety best and most effectively.
214800020|NCT01124149|DRUG|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
214800021|NCT06256536|DRUG|GZR18|0.6 mg-30 mg
214800022|NCT06256536|OTHER|Placebo|administered the same volume as GZR18
214800023|NCT01278849|DRUG|ASA404|
214800024|NCT04375254|OTHER|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
214800025|NCT03875157|BIOLOGICAL|IBI318|0.3 mg intravenous infusion, C1D1 and afterwards Q2W
214800026|NCT03875157|BIOLOGICAL|IBI318|1 mg intravenous infusion, C1D1 and afterwards Q2W
214800027|NCT03875157|BIOLOGICAL|IBI318|3 mg intravenous infusion, C1D1 and afterwards Q2W
214800028|NCT03875157|BIOLOGICAL|IBI318|10 mg intravenous infusion, C1D1 and afterwards Q2W
214800029|NCT03875157|BIOLOGICAL|IBI318|30 mg intravenous infusion, C1D1 and afterwards Q2W
214800030|NCT03875157|BIOLOGICAL|IBI318|100 mg intravenous infusion, C1D1 and afterwards Q2W
214800031|NCT03875157|BIOLOGICAL|IBI318|300 mg intravenous infusion, C1D1 and afterwards Q2W
214800032|NCT03875157|BIOLOGICAL|IBI318|600 mg intravenous infusion, C1D1 and afterwards Q2W
214800033|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
214800034|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
214800035|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion Q3W
214800036|NCT05680233|DRUG|OA-235i (4 mg)|3 participants will receive 4 mg as a single subcutaneous dose
214800037|NCT05680233|DRUG|OA-235i (8 mg)|3 participants will receive 8 mg as a single subcutaneous dose
214800038|NCT05680233|DRUG|OA-235i (16 mg)|3 participants will receive 16 mg as a single subcutaneous dose
214800039|NCT05680233|DRUG|OA-235i (30 mg)|3 participants will receive 30 mg as a single subcutaneous dose
214800040|NCT05680233|DRUG|OA-235i (40 mg)|3 participants will receive 40 mg as a single subcutaneous dose
214800041|NCT05680233|DRUG|OA-235i or placebo|9 participants will receive a daily subcutaneous dose of OA-235i or placebo for 7 consecutive days
214800042|NCT00796900|DRUG|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
214800043|NCT00796900|DRUG|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
214800044|NCT01644500|DRUG|Dulaglutide|Administered SC
214800045|NCT01644500|DRUG|Glimepiride|Administered orally
214800046|NCT01644500|DRUG|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
214800047|NCT01644500|DRUG|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
214800048|NCT00891475|PROCEDURE|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
214800049|NCT00891475|PROCEDURE|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
214800050|NCT00891475|DRUG|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
214800051|NCT02773836|OTHER|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
214800052|NCT06206356|DEVICE|PNS Injectrode F1|The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
214800053|NCT02153398|DRUG|D961H sachet 10 mg|
214800054|NCT02153398|DRUG|D961H capsule 10mg|
214800055|NCT02153398|DRUG|D961H capsule 20 mg|
214800056|NCT01234636|DIETARY_SUPPLEMENT|Placebo oil|Placebo oil of 4g/day
214800057|NCT03828045|DRUG|Apremilast|Apremilast
214800058|NCT00721409|DRUG|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
214800059|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
214800060|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
214800061|NCT04508998|DIAGNOSTIC_TEST|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
214800062|NCT04508998|DIAGNOSTIC_TEST|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
214800063|NCT04450745|BEHAVIORAL|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
214800064|NCT04450745|BEHAVIORAL|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
214800065|NCT00216398|DRUG|Lanreotide (Autogel formulation)|
214800066|NCT03174119|DEVICE|Light therapy - active|Active light will be used for one week, as compared to placebo light.
214800067|NCT03174119|DEVICE|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
214800068|NCT03528668|DEVICE|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
214800069|NCT02402166|DRUG|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
214800070|NCT01073995|DRUG|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
214800071|NCT05420051|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.
214800072|NCT05420051|BEHAVIORAL|Motivational Interviewing|The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
214800073|NCT04844840|DRUG|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
214800074|NCT04844840|OTHER|Placebo|Saline
214800075|NCT03923036|DRUG|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
214800076|NCT00789425|DIETARY_SUPPLEMENT|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
214800077|NCT00789425|DIETARY_SUPPLEMENT|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
214800078|NCT01138683|PROCEDURE|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
214800079|NCT01138683|DRUG|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
214800080|NCT05190263|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
214800081|NCT00006106|DRUG|cisplatin|
214800082|NCT00006106|DRUG|fluorouracil|
214800083|NCT00006106|DRUG|ONYX-015|
214800084|NCT02635243|DRUG|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214800085|NCT02635243|DRUG|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214800086|NCT02635243|DRUG|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
214800087|NCT03931642|DRUG|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
214800088|NCT03931642|DRUG|Blinatumomab|Blinatumomab by continuous vein infusion
214800089|NCT01536626|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
214800090|NCT04014322|OTHER|E-cigarette|"All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)"
214800091|NCT03510559|DRUG|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
214800092|NCT03510559|DRUG|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
214800093|NCT01989728|PROCEDURE|psychiatric examination and feedback|
214800094|NCT05137756|OTHER|no intervention|no intervention
215031119|NCT04923997|BEHAVIORAL|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
214800095|NCT05984771|DIETARY_SUPPLEMENT|Epineuron|Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)
214800096|NCT05984771|OTHER|Placebo group|Usual care
214800097|NCT03614195|DEVICE|MCDTT|The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.
214800098|NCT03614195|DEVICE|MDTT|The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.
214800099|NCT03614195|DEVICE|CDTT|The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
214800100|NCT02068482|DRUG|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
214800101|NCT05137678|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
214800102|NCT00002899|PROCEDURE|adjuvant therapy|
214800103|NCT00002899|RADIATION|radiation therapy|
214800104|NCT00002899|RADIATION|stereotactic radiosurgery|
214800105|NCT05333523|RADIATION|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~1. Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~2. Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~3. Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
214800106|NCT05333523|RADIATION|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
214800107|NCT00418470|PROCEDURE|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
214800108|NCT00418470|PROCEDURE|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
214800109|NCT00487227|DRUG|caffeine|
214800110|NCT00487227|DRUG|Placebo|
214800111|NCT05140447|OTHER|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
214800112|NCT03767088|DEVICE|WB-EMS|whole body electromyostimulation
214800113|NCT03767088|OTHER|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
214800114|NCT01239251|OTHER|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
214800115|NCT01690936|DIETARY_SUPPLEMENT|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
214800116|NCT05608512|OTHER|interview|The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
214800117|NCT01879839|DIETARY_SUPPLEMENT|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
214800118|NCT03270007|DRUG|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
214800119|NCT02550223|PROCEDURE|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
214800120|NCT01879280|PROCEDURE|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
214800121|NCT01879280|PROCEDURE|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
214800122|NCT00060866|DRUG|Propranolol|
214800123|NCT04518176|PROCEDURE|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
214800124|NCT04518176|DRUG|Oxytocin|20 units by slow intravenous drip injection
214800125|NCT00322491|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
214800126|NCT05586022|PROCEDURE|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
214800127|NCT01400425|DRUG|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
214800128|NCT00846625|DRUG|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
214800129|NCT00846625|DRUG|ranibizumab|Intravitreal injection, 0.5 mg
214800130|NCT03239522|DRUG|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
214800131|NCT03239522|DRUG|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
214800132|NCT03239522|DRUG|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
214800133|NCT01362725|DEVICE|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
214800134|NCT03652701|OTHER|Hair Up|Herbal topical
214800135|NCT03652701|OTHER|Placebo|Placebo
214800136|NCT04494659|DRUG|Famitinib capsule|single dose and co-administrated with Rifampicin capsule
214800137|NCT04494659|DRUG|Rifampicin capsule|repeated doses of Rifampicin capsule
214800138|NCT06850688|DEVICE|Remote monitoring platform|"EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training.~Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge"
214800139|NCT06278142|OTHER|Internet Based Intervention - GUIDED|In the expert-supported application, each participant will be sent a folder to be shared by the user and the guide via Google Drive, and the user is expected to perform the application in the folder. A module is added to the folder every Monday and the participant is asked to complete the relevant module until Friday of the same week. In the following two days, a feedback message is provided by the expert, taking into account the user's responses.
214800140|NCT06278142|OTHER|Internet Based Intervention - WİTHOUT GUİDANCE|The developed implementation plan is communicated to the participants without expert support and their participation is ensured. A common folder will be created with the participants accepted to the study and in the group without expert support, and the process is managed by transmitting the module to the user via the folder every Monday.
214800141|NCT03325530|BEHAVIORAL|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
214800142|NCT04663360|OTHER|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
214800143|NCT05266248|OTHER|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
214800144|NCT01151748|PROCEDURE|Intra-arterial infusion of chemotherapy|
214800145|NCT04709848|OTHER|None - standard of care|Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
214800146|NCT01424722|DEVICE|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
214800147|NCT05428722|BEHAVIORAL|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
214800148|NCT00442806|DRUG|Injection of ADRC's|ADRC's are injected
214800149|NCT00442806|OTHER|Injection of Placebo|Placebo is injected
214800150|NCT05641909|DRUG|Remifentanil|Remifentanil
214800151|NCT05641909|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
214800152|NCT00818883|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
214800153|NCT00818883|DRUG|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
214800154|NCT01556009|DRUG|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
214800155|NCT01556009|DRUG|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
214800156|NCT00048048|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
214800157|NCT04630938|DRUG|Morphine Sulfate|intrathecal morphine will be added to anaesthetics
214800158|NCT04630938|DRUG|morphine+lidocaine|local anesthetic will be infused intravenously
214800159|NCT04630938|DRUG|Saline|intravenous saline infusion
214800160|NCT04051970|DRUG|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
214800161|NCT00973700|BIOLOGICAL|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
214800162|NCT00973700|BIOLOGICAL|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
214800163|NCT04924309|OTHER|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
214800164|NCT02637193|DRUG|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
214800165|NCT02637193|DRUG|Moxifloxacin|400 mg single dose moxifloxacin
214800166|NCT02637193|DRUG|Drug - placebo|Placebo administered for 16 days
215031120|NCT00478257|DEVICE|bright white light|Intervention: Bright white light administered for 30 minutes each morning
215031121|NCT00478257|DEVICE|comparator red light treatment|dim red light administered for 30 minutes every morning
215031122|NCT01920113|DRUG|Dexmedetomidine - remifentanil group|
214800167|NCT05976971|OTHER|7T MRI|Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
214800168|NCT03168074|DRUG|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
214800169|NCT04122105|DRUG|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
214800170|NCT05664256|OTHER|Build capacity of canteen|"The investigators will conduct 1 day orientation training to the school nurse, principal and canteen managers of the facilities.~Different sessions on basic nutrition concept, healthy eating, healthy cooking practices including purchasing and serving will be conducted.~The investigators will develop training manuals: training curriculum, facilitators guide, and participants guide, aligning with policy contents."
214800171|NCT05664256|OTHER|Information, Education and Communication materials|Posters showing healthy plate model will be displayed on the canteen walls. The fact sheet on healthy eating will be distributed to all the public facilities and make it available at the entrance/ gate of the canteen.
214800172|NCT05664256|OTHER|Monitoring visit|A monitoring team from each municipality will be formed. The monitoring plan will be prepared with the team. At least one monitoring visit from the municipality government with onsite feedback will be done.
214800173|NCT05295771|PROCEDURE|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
214800174|NCT00314171|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
214800175|NCT00314171|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
214800176|NCT03576391|BEHAVIORAL|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
214800177|NCT03576391|BEHAVIORAL|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
214800178|NCT03576391|BEHAVIORAL|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
214800179|NCT03576391|BEHAVIORAL|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
214800180|NCT03978884|DRUG|Losartan 50Mg Tab|Take 1 tab daily
214800181|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
214800182|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
214800183|NCT03978884|DRUG|Amlodipine 5mg|Take 1 tablet daily
214800184|NCT01901055|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
214800185|NCT01901055|DEVICE|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
214800186|NCT01901055|BEHAVIORAL|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
214800187|NCT00731159|BIOLOGICAL|sperm capacitation|sperm capacitation measured at Bar Ilan University
214800188|NCT00731159|OTHER|biologic|sperm synthesis of G-actine to F-actine
214800189|NCT00731159|OTHER|sperm capacitation|sperm synthesis of G-actine to F-actine
214800190|NCT03864588|DRUG|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
214800191|NCT00140257|DRUG|Escitalopram|
214800192|NCT02983448|DEVICE|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
214800193|NCT04059796|DEVICE|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
214800194|NCT04059796|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
214800195|NCT01586741|PROCEDURE|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
215031123|NCT01920113|DRUG|Propofol - remifentanil group|
214800196|NCT04919421|DRUG|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
214800197|NCT04919421|DEVICE|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
214800198|NCT01346332|DEVICE|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
214800199|NCT05412498|BEHAVIORAL|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
214800200|NCT05412498|BEHAVIORAL|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
214800201|NCT00197951|DRUG|Treatment of psychiatric symptoms associated to alcoholism|
214800202|NCT05292742|DRUG|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
214800203|NCT05292742|DRUG|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
214800204|NCT03202225|DEVICE|constrained polyethylene|constrained polyethylene insert
214800205|NCT00479622|DRUG|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
214800206|NCT00525590|DRUG|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
214800207|NCT00331890|DRUG|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
214800208|NCT00331890|DRUG|Placebo|As active drug
214800209|NCT00622609|DRUG|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
214800210|NCT00622609|DRUG|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
214800211|NCT05704556|DRUG|VX-548|Tablets for oral administration.
214800212|NCT01781065|DEVICE|transcranial direct current stimulation|
214800213|NCT00783666|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
214800214|NCT02663596|DRUG|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
214800215|NCT00717457|DRUG|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
214800216|NCT00717457|DRUG|taspoglutide|10mg once weekly
214800217|NCT00717457|DRUG|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
214800218|NCT03763500|OTHER|Internet-based education|A six-step Internet-based patient education.
214800219|NCT00948675|DRUG|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
214800220|NCT00948675|DRUG|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
214800221|NCT00948675|DRUG|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
214800222|NCT00948675|BIOLOGICAL|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
214800223|NCT02296775|BIOLOGICAL|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
214800224|NCT02296775|BIOLOGICAL|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
214800225|NCT02296775|BIOLOGICAL|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
214800226|NCT04465942|DRUG|(chemo)immunotherapy|Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
214800227|NCT00593281|DRUG|Hylenex|Add Hylenex to SC injection of Morphine
215031124|NCT06419881|BEHAVIORAL|Tele-drama therapy|A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy
214800228|NCT04751110|OTHER|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
214800229|NCT00866242|BIOLOGICAL|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
214800230|NCT00001052|BIOLOGICAL|Aluminum hydroxide|
214800231|NCT00001052|BIOLOGICAL|QS-21|
214800232|NCT00001052|BIOLOGICAL|rgp120/HIV-1MN|
214800233|NCT02625948|DRUG|Tranexamic Acid|
214800234|NCT02497456|BEHAVIORAL|Follow-up counselling|
214800235|NCT03392298|DRUG|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
214800236|NCT02776709|PROCEDURE|ERCP with cholangioscopy|
214800237|NCT00600925|DRUG|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
214800238|NCT03333226|PROCEDURE|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
214800239|NCT01431924|DRUG|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
214800240|NCT01431924|DRUG|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
214800241|NCT01562496|BEHAVIORAL|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
214800242|NCT04750187|OTHER|Hypo-pressive abdominal exercise intervention|An 8-week hypo-pressive abdominal exercise program
214800243|NCT05449977|DIAGNOSTIC_TEST|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
214800244|NCT02502253|DRUG|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
214800245|NCT00770510|DRUG|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
214800246|NCT00770510|DRUG|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
214800247|NCT00770510|DRUG|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
214800248|NCT00770510|DRUG|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
214800249|NCT00770510|DRUG|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
214800250|NCT03056781|BEHAVIORAL|social interaction|Participants will engage in a social interaction with another person
214800251|NCT03056781|BEHAVIORAL|food consumption|Participants will be offered food stuffs to eat/drink
214800252|NCT04188821|PROCEDURE|breast drain removal|"Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care."
214800253|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
214800254|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
214800255|NCT00571428|DRUG|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
214800256|NCT05718778|DRUG|Piamprimab (AK105)|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
214800257|NCT02192346|DRUG|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
214800258|NCT02192346|DRUG|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
214800259|NCT02192346|DRUG|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
214800260|NCT02192346|DRUG|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
214800261|NCT02192346|DRUG|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
214800262|NCT02192346|DRUG|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
214800263|NCT02192346|DRUG|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
214800264|NCT02192346|DRUG|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
214800265|NCT02192346|DRUG|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
214800266|NCT04087395|DEVICE|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
214800267|NCT04087395|DEVICE|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
214800268|NCT02864758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
214800269|NCT02864758|DRUG|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
214800270|NCT02864758|DRUG|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
214800271|NCT05127577|OTHER|Abdominal massage|Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
214800272|NCT03716141|OTHER|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
214800273|NCT03716141|OTHER|Conventional Saline dressing|saline dressing of diabetic wounds will be done
214800274|NCT03057249|OTHER|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
214800275|NCT05655832|DEVICE|Vivalink wearable device|a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
214800276|NCT02192099|DRUG|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
214800277|NCT00628199|PROCEDURE|Improving the scientific process of human cell reprogramming|
214800278|NCT02348385|DRUG|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
214800279|NCT00379756|DRUG|LEVITRA (vardenafil)|active comparator
214800280|NCT00379756|DRUG|placebo|placebo comparator
214800281|NCT01170286|BIOLOGICAL|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
215031125|NCT06419881|OTHER|Usual Care|This arm continued to receive the routine activities provided by Uniper Care
214800282|NCT01170286|BIOLOGICAL|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
214800283|NCT06486116|BEHAVIORAL|Task Specific Physical Therapy Home Program|Home exercise program based on specific findings from physical therapy evaluations.
214800284|NCT01432977|DRUG|paracetamol /droperidol|
214800285|NCT01432977|DRUG|paracetamol / ondansetron|
214800286|NCT02796664|DIETARY_SUPPLEMENT|Ginseng|Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
214800287|NCT02796664|DIETARY_SUPPLEMENT|Placebo|Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
214800288|NCT03388307|PROCEDURE|unilateral laminotomy|minimally invasive technique
214800289|NCT03388307|PROCEDURE|decompressive laminectomy|classic surgery
214800290|NCT01305070|DEVICE|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
214800291|NCT01305070|DEVICE|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
214800292|NCT02679001|DRUG|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
214800293|NCT03463278|DIAGNOSTIC_TEST|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
214800294|NCT02246478|DRUG|TAS-205|"* Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
214800295|NCT02246478|DRUG|Placebo|"* Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
214800296|NCT05007288|OTHER|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
214800297|NCT05007288|OTHER|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
214800298|NCT00998023|DEVICE|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
214800299|NCT00998023|DEVICE|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
214800300|NCT00711464|DRUG|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
214800301|NCT02309827|DRUG|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
214800302|NCT06250010|DIAGNOSTIC_TEST|tissue samples (healthy and tumor taken from the same patient) and tissue samples (decidualized endometrium and trophoblast taken from it patient)|Correlation between the immuno-score results of each patient with his prognosis, in terms disease-free survival, overall survival, relapse-free survival, disease-specific survival cancer, distant and/or local free survival, to validate their potential role independent in the progression of endometrial cancer; later, for a better characterization of the various ones risk classes, we will combine our immuno-score with the already known risk factors, included in the ESMO-ESGO-ESTRO classification and in the biomolecular classification of endometrial cancer, to investigate whether the Microenvironmental immunological factors in endometrial cancer could allow better stratification of patients in risk classes.
214800303|NCT04645615|DEVICE|Cardioblate surgical ablation system|This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214800304|NCT04645615|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214800305|NCT01096420|PROCEDURE|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
214800306|NCT01096420|DRUG|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
214800307|NCT03453125|BEHAVIORAL|Spanish modified Story Memory Technique (mSMT)|
214800308|NCT05207280|COMBINATION_PRODUCT|Noradrenaline plus Terlipressin|Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
214800309|NCT04671641|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
214800310|NCT02090608|DRUG|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
215031126|NCT05503277|DEVICE|LTSD|measuring seal pressure
214800311|NCT05475353|BEHAVIORAL|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
214800312|NCT05475353|PROCEDURE|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
214800313|NCT02115646|DEVICE|fractionated carbon dioxide laser|patients will have serial laser treatments
214800314|NCT02805322|DEVICE|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
214800315|NCT02805322|DEVICE|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
214800316|NCT02805322|DEVICE|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
214800317|NCT04112030|DIAGNOSTIC_TEST|Digital image analysis|
214800318|NCT02079753|DEVICE|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
214800319|NCT02079753|DEVICE|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
214800320|NCT01531205|DRUG|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
214800321|NCT01531205|DRUG|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m\^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
214800322|NCT01531205|DRUG|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
214800323|NCT01531205|DRUG|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
214800324|NCT01531205|DRUG|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m\^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
214800325|NCT02632136|DRUG|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
214800326|NCT02632136|DRUG|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
214800327|NCT02800798|OTHER|Preeclampsia positive|
214800328|NCT05316675|DRUG|Isotretinoin|isotretinoin 13-cis-retinoic acid), derived from vitamin A
214800329|NCT02252731|DRUG|Warfarin|Oral
214800330|NCT02252731|DRUG|FG-4592|Oral
214800331|NCT05277727|DIETARY_SUPPLEMENT|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
214800332|NCT05277727|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily with food (morning and evening).
214800333|NCT02081521|BEHAVIORAL|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
214800334|NCT04345978|BEHAVIORAL|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
214800335|NCT05742581|OTHER|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
214800336|NCT05042336|DRUG|camrelizumab/lenvatinib combined with TACE|"Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w"
214800337|NCT00013546|DRUG|TMTDS|
214800338|NCT03629158|BEHAVIORAL|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
214800339|NCT00174642|DRUG|Insulin Glargine|One daily injection in the evening. 100 U/ml
214800340|NCT00174642|DRUG|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
214800341|NCT00174642|DRUG|Metformin|At same dosages as the previous treatment
214800342|NCT00174642|DRUG|insulin secretagogue|sulfonylurea or glinide
214800343|NCT00669630|BEHAVIORAL|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
214800344|NCT03629574|PROCEDURE|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
214800345|NCT04905342|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
214800346|NCT04905342|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
214800347|NCT03463356|BEHAVIORAL|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
214800348|NCT00339768|DRUG|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
214800349|NCT02001558|DRUG|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
214800350|NCT02001558|OTHER|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
214800351|NCT02483637|DEVICE|RejuvenAir|Device: RejuvenAir
214800352|NCT00136201|DRUG|tigecycline|
214800353|NCT04128007|DRUG|Roflumilast foam 0.3%|experimental
214800354|NCT04128007|DRUG|Vehicle foam|experimental
214800355|NCT02371525|BEHAVIORAL|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
214800356|NCT05152719|BEHAVIORAL|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
214800357|NCT01106963|PROCEDURE|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
214800358|NCT00322907|DRUG|Cotrifazid vs mefloquine or quinine+SP|
214800359|NCT02493244|OTHER|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
214800360|NCT04117607|OTHER|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
214647554|NCT03484715|BEHAVIORAL|Physical Activity Intervention|A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
214647555|NCT03447626|DEVICE|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
214647556|NCT02978482|DRUG|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
214647557|NCT02978482|DRUG|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
214800361|NCT04117607|DRUG|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
214800362|NCT04117607|DRUG|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
214800363|NCT00532337|DRUG|ONO-5334|Placebo - 24/mos.
214800364|NCT00532337|DRUG|ONO-5334|100mg QD /24 months
214800365|NCT00532337|DRUG|ONO-5334|50mg BID /24 mos.
214800366|NCT00532337|DRUG|ONO-5334|300mg QD /24 mos.
214800367|NCT00532337|DRUG|ONO-5334|Alendronate 70mg once weekly / 24 mos
214800368|NCT02200900|OTHER|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
215031127|NCT05503277|DEVICE|i-gel|measuring seal pressure
214647558|NCT00155480|PROCEDURE|computed tomography|
214647559|NCT03387631|DRUG|Artemether-Lumefantrine|
214647560|NCT01390792|DRUG|Zanamivir hydrate|
214647561|NCT04897867|DEVICE|CoolSculpting® Elite System with CoolSculpting® Elite applicators|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
214800369|NCT02200900|OTHER|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
214800370|NCT02200900|OTHER|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
214800371|NCT02200900|OTHER|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
214800372|NCT02250560|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
214800373|NCT04252469|OTHER|Oral care|oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
214800374|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
214800375|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
214800376|NCT03605043|OTHER|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
214800377|NCT00257153|DEVICE|Coronary thrombus aspiration catheter|
214800378|NCT02594462|DRUG|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
214800379|NCT05928780|DRUG|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
214800380|NCT05928780|DRUG|A2:SG|SG 10mg/kg d1, 8
214800381|NCT05928780|DRUG|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
214800382|NCT05928780|DRUG|B2:SG|SG 10mg/kg， d1, 8
214800383|NCT05928780|DRUG|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
214800384|NCT05928780|DRUG|C2:SG|SG 10mg/kg d1, 8
214800385|NCT05928780|DRUG|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
214800386|NCT05928780|DRUG|D2:SG|SG 10mg/kg d1, 8
214800387|NCT02852564|DRUG|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
214800388|NCT04506242|DRUG|SHR-1210|PD-1
214800389|NCT04506242|DRUG|Apatinib|VEGFR2
214800390|NCT00459888|DEVICE|PolarCath Peripheral Dilatation System (Boston Scientific)|
214800391|NCT02024087|DRUG|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
214800392|NCT03536338|OTHER|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
214800393|NCT03536338|OTHER|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
214800394|NCT01550211|DEVICE|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
214800395|NCT00007436|DRUG|Tenofovir disoproxil fumarate|
214800396|NCT02236507|DEVICE|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
214800397|NCT01861366|OTHER|A one year multifaceted implementation strategy|
214800398|NCT01861366|OTHER|A three hour lecture about the guidelines|
214800399|NCT03195985|OTHER|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
214800400|NCT03195985|OTHER|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
214800401|NCT03083171|DRUG|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
214800402|NCT03083171|DRUG|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
214800403|NCT03083171|DRUG|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
214800404|NCT00950807|DRUG|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
214800405|NCT00950807|DRUG|Placebo|Inactive/ excipients only
214800406|NCT00950807|DRUG|GSK573179|GSK573179 investigational drug
214800407|NCT01587222|DRUG|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
214800408|NCT01587222|DRUG|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
214800409|NCT01587222|DRUG|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
214800410|NCT05432011|PROCEDURE|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
215031128|NCT00809822|DRUG|NPB-01|Intravenous immunoglobulin
215031129|NCT00809822|DRUG|Placebo|Physiological saline
214800411|NCT05432011|PROCEDURE|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
214800412|NCT05432011|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
214800413|NCT03652077|DRUG|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
214800414|NCT00337077|DRUG|eribulin mesylate|Given IV
214800415|NCT05413603|PROCEDURE|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
214800416|NCT05413603|PROCEDURE|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
214800417|NCT03395106|BEHAVIORAL|Parent source|Having a parent feature prominently in a news story
214800418|NCT03395106|BEHAVIORAL|Doctor source|Having a doctor feature prominently in a news story
214800419|NCT03395106|BEHAVIORAL|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
214800420|NCT03395106|BEHAVIORAL|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
214800421|NCT02129348|DRUG|Lithium|
214800422|NCT02129348|DRUG|Placebo|
214800423|NCT01033162|BEHAVIORAL|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~* Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~* Reduce patients' negative affect and increase their emotional well being~* Improve patients' sense of social support~* Improve patients' health self-efficacy~* Improve patients' ratings of experience with cancer specialty care services~* Improve patients' health related quality of life (HRQL)~* Improve clinicians' ratings of quality of patient contacts~* Reduce healthcare utilization and costs (obtained via the EMR)"
214800424|NCT00154180|DRUG|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
214800425|NCT00154180|DRUG|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
214800426|NCT00154180|DRUG|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
214800427|NCT00154180|DRUG|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
214800428|NCT00154180|DRUG|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
214800429|NCT02327195|DRUG|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
214800430|NCT02327195|DRUG|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
214800431|NCT01775319|DIETARY_SUPPLEMENT|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
214800432|NCT01775319|DIETARY_SUPPLEMENT|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
214800433|NCT01775319|DIETARY_SUPPLEMENT|Placebo|
214800434|NCT01264224|DRUG|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
214800435|NCT04351204|RADIATION|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
214800436|NCT04195997|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.
214800437|NCT04195997|DRUG|Heparin|heparin during left atrial appendage occlusion.
214800438|NCT04312906|OTHER|no intervention|No intervention
214800439|NCT03509103|OTHER|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
214800440|NCT05554822|DRUG|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
214800441|NCT05554822|DRUG|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
214800442|NCT05657496|DRUG|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
214800443|NCT05657496|BIOLOGICAL|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
214800444|NCT00665730|DEVICE|Sepraspray|
214800445|NCT04339465|BEHAVIORAL|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
214800446|NCT04339465|BEHAVIORAL|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
214800447|NCT00540501|DRUG|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
214800448|NCT01433666|DRUG|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
214800449|NCT01433666|DRUG|Placebo|Acute intervention: single administration, capsulated form.
214800450|NCT01433666|DRUG|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
214800451|NCT02019940|DRUG|Riluzole|
214800452|NCT01598701|DRUG|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
214800453|NCT01598701|DRUG|Placebo|100 mL 0.9% Sodium Chloride
214800454|NCT01434121|DRUG|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
214800455|NCT01434121|DRUG|Placebo|
214800456|NCT06547944|DRUG|Zanubrutinib|160mg bid/d, from C1 to CR and MRD-negative or C24
214800457|NCT06547944|DRUG|Lenalidomide|From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
214800458|NCT06547944|DRUG|Obinutuzumab|1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
214800459|NCT01409486|OTHER|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
214800460|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
214800461|NCT00074906|DRUG|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
214800462|NCT02989688|DIETARY_SUPPLEMENT|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
214800463|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
214800464|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
214800465|NCT02223000|DRUG|BIBV 308 SE solution|
214800466|NCT02223000|DRUG|BIBV 308 SE capsule 1|
214800467|NCT02223000|DRUG|BIBV 308 SE capsule 2|
214800468|NCT02349893|DEVICE|RFA treatment|RFA treatment using CelonProSleep plus system
214800469|NCT04944537|OTHER|No Intervention|No Intervention
214800470|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 0cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
214800471|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 40cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
214800472|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 60cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
214800473|NCT01459328|RADIATION|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days"
214800474|NCT01459328|RADIATION|Radiotherapy|"Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
214800475|NCT06114251|DIAGNOSTIC_TEST|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
214800476|NCT05498805|RADIATION|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
214800477|NCT04548453|DEVICE|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
214800478|NCT06497153|PROCEDURE|lung ultrasound|lung ultrasound repeated according to protocol during the stay in the paediatric intensive care unit
214800479|NCT01415778|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
214800480|NCT01415778|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
215031130|NCT03931330|DEVICE|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
214800481|NCT06257745|OTHER|Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019|Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
214800482|NCT03328780|DEVICE|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
214800483|NCT02305823|DRUG|Aripiprazole|
214800484|NCT02305823|DRUG|Quetiapine|
214800485|NCT02305823|DRUG|Ziprasidone|
214800486|NCT01888081|DRUG|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
214800487|NCT01888081|RADIATION|Ionizing Radiation|
214800488|NCT05873023|OTHER|Chewing gum|chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
214800489|NCT02107690|PROCEDURE|Low temperature lidocaine injection|4 °C
214800490|NCT02107690|PROCEDURE|Room temperature lidocaine injection|20 °C
214800491|NCT02107690|PROCEDURE|Body temperature lidocaine injection|37 °C
214800492|NCT02665143|DRUG|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
214800493|NCT05629884|OTHER|COPERIA-REHAB|"After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week)."
214800494|NCT05754008|BEHAVIORAL|AURORA Care Strategy|Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
214800495|NCT04170309|DRUG|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
214800496|NCT02430870|DRUG|TAK-648|TAK-648 solution
214800497|NCT02430870|DRUG|Placebo|TAK-648 placebo-matching solution
214800498|NCT02770963|PROCEDURE|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
214800499|NCT02770963|PROCEDURE|Sham acupuncture|"Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
214800500|NCT01958463|PROCEDURE|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
214800501|NCT04697511|DRUG|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
214800502|NCT04697511|DRUG|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
214800503|NCT03635359|DIAGNOSTIC_TEST|blood test|analysis of cell-free DNA in maternal plasma
214800504|NCT02175706|DEVICE|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
214800505|NCT02175706|DEVICE|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
214800506|NCT03973983|PROCEDURE|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
214800507|NCT03973983|PROCEDURE|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
214800508|NCT04945876|BEHAVIORAL|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
214800509|NCT06325579|DEVICE|Immersive Virtual Reality for Dysphagia Treatment|Patients wore a VR headset while undergoing their rehabilitation session
214800510|NCT02767193|BIOLOGICAL|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
214800511|NCT02767193|BIOLOGICAL|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG\_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
214800512|NCT02767193|BIOLOGICAL|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
214800513|NCT02767193|BIOLOGICAL|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG\_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
214800514|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
214800515|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
214800516|NCT02560350|OTHER|no intervention|no intervention
214800517|NCT05951569|DEVICE|Community-Derived Open-Source Automated Insulin Delivery Loop System|The Loop System consists of an insulin pump and a Dexcom CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
214800518|NCT01265784|DRUG|TP-434|
214800519|NCT01265784|DRUG|Ertapenem|
214800520|NCT01265784|DRUG|Placebo|Administered IV to maintain the blind.
214800521|NCT01619826|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
214800522|NCT01619826|BEHAVIORAL|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
214800523|NCT03777137|BEHAVIORAL|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
214800524|NCT03846713|PROCEDURE|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
214800525|NCT03846713|PROCEDURE|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
214800526|NCT06203275|DRUG|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
214800527|NCT06203275|DRUG|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
214800528|NCT05694091|OTHER|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
214800529|NCT00796822|DRUG|Pentoxifylline|400 mg three times a day for 8 weeks
214800530|NCT00796822|DRUG|Placebo|One pill three times a day for 8 weeks
214800531|NCT05722509|PROCEDURE|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
214800532|NCT05722509|PROCEDURE|"Only Exodontia Group"|Third molar exodontia without associated surgery.
214800533|NCT01820377|BEHAVIORAL|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
214800534|NCT00519142|DRUG|placebo for mitiglinide|three times a day with meals
214800535|NCT00519142|DRUG|mitiglinide|three times a day with meals
214800536|NCT00519142|DRUG|mitiglinide|two times a day with meals
214800537|NCT06207409|BEHAVIORAL|PARTS-SUD|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
214800538|NCT04955379|DEVICE|EQ103|Ophthalmic Refractometer with a measurement and background channel
214800539|NCT05607914|PROCEDURE|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
214800540|NCT05607914|PROCEDURE|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
214800541|NCT02583503|RADIATION|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
214800542|NCT00446732|DEVICE|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
214800543|NCT05342857|DRUG|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T\&E criteria in Taiwan local consensus
214800544|NCT02603952|DRUG|Oseltamivir|75 mg capsules orally BID from Day 1 to Day 5.
214800545|NCT02603952|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
214800546|NCT02603952|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
214800547|NCT06452160|DRUG|BGC515|Capsules for oral administration
214800548|NCT05564832|DRUG|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
214800549|NCT01887626|DRUG|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
214800550|NCT01887626|DRUG|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
214800551|NCT01887626|DRUG|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
214800552|NCT00429806|DRUG|DHEA|DHEA
214800553|NCT00429806|DRUG|Placebo|Placebo
214800554|NCT01701726|OTHER|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
214800555|NCT01701726|OTHER|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
214800556|NCT05480722|OTHER|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
214800557|NCT05480722|OTHER|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
214800558|NCT02512913|BEHAVIORAL|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
214800559|NCT01870661|DEVICE|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
214800560|NCT01870661|DEVICE|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
214800561|NCT01911975|DRUG|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
214800562|NCT01911975|DRUG|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
214800563|NCT02698800|DEVICE|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
214800564|NCT02698800|DEVICE|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
214800565|NCT02624570|DRUG|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
214800566|NCT04646109|DRUG|Ivermectin|"Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions."
214800567|NCT05240677|PROCEDURE|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
214800568|NCT01679821|OTHER|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
214800569|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
214800570|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
214800571|NCT06286969|PROCEDURE|acupuncture|The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.
214800572|NCT04066166|DIAGNOSTIC_TEST|Palpation|All healthy subjects palpated
214800573|NCT01607645|DRUG|decitabine|Given IV
214800574|NCT01607645|DRUG|idarubicin|Given IV
214800575|NCT01607645|DRUG|cytarabine|Given IV
214800576|NCT01610258|OTHER|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
215031131|NCT03412929|DEVICE|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
214800577|NCT01809613|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
214800578|NCT03139968|DEVICE|(sham) radiation absorbing drape (RADPAD®)|
214800579|NCT04641481|BIOLOGICAL|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
214800580|NCT04641481|BIOLOGICAL|Placebo|Placebo (PBS+Alum, without antigen)
214800581|NCT05521763|BEHAVIORAL|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
214800582|NCT01867242|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
214800583|NCT01867242|OTHER|Snus|Winterchill or Robust flavors
214800584|NCT01683617|BEHAVIORAL|Coping skills and relaxation training with new technologies|
214800585|NCT01683617|BEHAVIORAL|Traditional coping skills and relaxation training|
214800586|NCT02133339|DRUG|TRN-157|
214800587|NCT02133339|DRUG|Placebo|
214800588|NCT03339349|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
214800589|NCT02494713|DRUG|Degarelix|Subcutaneous injection, once/month for 4 months
214800590|NCT02494713|DRUG|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
214800591|NCT02494713|DRUG|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
214800592|NCT02494713|DRUG|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
214800593|NCT02494713|DRUG|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
214800594|NCT00218179|OTHER|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
214800595|NCT03475927|OTHER|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
214800596|NCT02324998|DRUG|Olaparib|PARP Inhibitor
214800597|NCT02324998|DRUG|Degarelix|Gonadotrophin releasing hormone blocker
214800598|NCT00034125|DRUG|LY353381|
214800599|NCT00034125|DRUG|tamoxifen|
214800600|NCT04554654|DIAGNOSTIC_TEST|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
214800601|NCT05525195|PROCEDURE|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
214800602|NCT03094910|DIAGNOSTIC_TEST|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
214800603|NCT03094910|DIAGNOSTIC_TEST|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
214800604|NCT03094910|DIAGNOSTIC_TEST|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
214800605|NCT03094910|DIAGNOSTIC_TEST|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
214800606|NCT03094910|DIAGNOSTIC_TEST|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
214800607|NCT03094910|DIAGNOSTIC_TEST|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
214800608|NCT06132646|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
214800609|NCT04068142|OTHER|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
214800610|NCT01434836|OTHER|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
214800611|NCT01434836|OTHER|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
214800612|NCT01661270|DRUG|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
214800613|NCT01661270|DRUG|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
214800614|NCT03301675|OTHER|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
214800615|NCT04811768|PROCEDURE|Maxillary sinus augmentation|The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
214800616|NCT03184441|DEVICE|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
214800617|NCT04652570|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
214800618|NCT05736081|DRUG|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
214800619|NCT00264810|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
214800620|NCT00264810|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
214800621|NCT06192251|BEHAVIORAL|Lifestyle Medicine|Education and support for lifestyle modification to improve health conditions
214800622|NCT05496075|DRUG|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
214800623|NCT05496075|DRUG|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
214800624|NCT00968370|OTHER|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
214800625|NCT00968370|OTHER|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
214800626|NCT01206842|OTHER|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
215031132|NCT03962647|DIETARY_SUPPLEMENT|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
214800627|NCT05991739|BEHAVIORAL|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
214800628|NCT05717699|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
214800629|NCT05778409|BIOLOGICAL|Cordyceps cicadae extract|500mg/ day for one month
214800630|NCT05202704|PROCEDURE|Procedure/Surgery: Experimental: Hidden conditioning + Positive Expectation|Patients will be submitted to quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectations about the treatment by means of a workshop. Immediately after the first session of manipulative therapy, participants will be submitted again to the QST but now the heat pain threshold of the hidden conditioning group will be surreptitiously downgraded (the intense noxious stimulus will be downgraded to the moderate stimulus - individually obtained during the QST) as a mean to conditioning patients to believe that spinal manipulative therapy promoted pain relief. Patients will be invited to report the pain intensity perceived just after the QST (second test - conditioning procedure). The objective of questioning the pain intensity after the conditioning test is a procedure check to ensure that the conditioning procedure worked.
214800631|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Positive Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate whether the positive instructions will show any effect.
214800632|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Neutral Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce neutral expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate/confirm the effect of neutral instructions.
214800633|NCT05202704|PROCEDURE|Spinal Manipulative Therapy|All the groups recruited in the study will receive five sessions of Spinal Manipulative Therapy. The intervention will be performed with the patient in the supine position. The clinician-researcher will passively lean over the patient to the side to be manipulated and ask the patient to place their hands behind their head. The researcher will then passively rotate the patient on the side to be manipulated and perform a posterior and inferior thrust on the opposite anterosuperior spine. The patients will receive 4 maneuvers (twice towards right side and twice towards left side).
214800634|NCT00863525|DRUG|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
214800635|NCT00863525|DRUG|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
214800636|NCT00783757|DEVICE|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
214800637|NCT01512381|DEVICE|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
214800638|NCT01512381|DEVICE|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
214800639|NCT04052867|DRUG|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
214800640|NCT04052867|DRUG|Normal saline|An equivalent volume of normal saline is given
214800641|NCT02289768|DRUG|5-fluorouracil/salicylic acid|
214800642|NCT02289768|DRUG|Vehicle|
214800643|NCT00169936|DEVICE|Magnetocardiograph|
214800644|NCT01264952|PROCEDURE|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
214800645|NCT05324735|DRUG|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
214800646|NCT05324735|DRUG|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
214800647|NCT04098536|BEHAVIORAL|Diesel exhaust|Exposure to diesel exhaust fumes
214800648|NCT00044226|DRUG|ML-04A|
214800649|NCT01002690|DRUG|Etoricoxib|90 mg/day orally for 10-13 days
214800650|NCT00145938|DRUG|sildenafil|
214800651|NCT00543686|DRUG|Montelukast|Intake of Montelukast
214800652|NCT00543686|DRUG|Fluticasone|Intake of Fluticasone
214800653|NCT02093689|DRUG|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
215031133|NCT03962647|DRUG|Letrozole|2.5 mg taken once daily by mouth
215031134|NCT00818194|DRUG|extended release tacrolimus|oral
215031135|NCT00818194|DRUG|cyclosporine A microemulsion|oral
214800654|NCT02093689|DRUG|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
214800655|NCT02093689|DRUG|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
214800656|NCT01079676|DRUG|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
214800657|NCT01079676|DRUG|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
214800658|NCT05038813|DRUG|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
214800659|NCT00570271|OTHER|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
214800660|NCT00570271|OTHER|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
214800661|NCT00570271|OTHER|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
214800662|NCT00570271|OTHER|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
214800663|NCT00570271|OTHER|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
214800664|NCT00570271|OTHER|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
214800665|NCT04634409|DRUG|Bamlanivimab|Administered IV.
214800666|NCT04634409|DRUG|Etesevimab|Administered IV.
214800667|NCT04634409|DRUG|Placebo|Administered IV.
214800668|NCT04634409|DRUG|VIR-7831|Administered IV.
214800669|NCT04634409|DRUG|Bebtelovimab|Administered IV.
214800670|NCT03633890|DRUG|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
214800671|NCT03633890|DRUG|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
214800672|NCT00664781|DRUG|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
214800673|NCT00664781|GENETIC|protein expression analysis|
214800674|NCT00664781|GENETIC|western blotting|
214800675|NCT00664781|OTHER|immunohistochemistry staining method|
214800676|NCT00664781|OTHER|liquid chromatography|
214800677|NCT00664781|OTHER|mass spectrometry|
214800678|NCT00664781|OTHER|pharmacological study|
214800679|NCT01402908|DRUG|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
214800680|NCT01402908|OTHER|Placebo|Lactose lyophilized powder
215031136|NCT06052553|DEVICE|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
214800681|NCT04002700|DRUG|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
214800682|NCT04002700|DRUG|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
214800683|NCT04002700|DRUG|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
214800684|NCT03111043|DIAGNOSTIC_TEST|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
214800685|NCT04251390|DEVICE|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
215031137|NCT04897568|OTHER|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
215031579|NCT07011290|OTHER|Recreational running team handball (RTH) training sessions|"Recreational running team handball (RTH):~Participants will partake in 2 sessions of recreational team handball matches (RTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
214800686|NCT06240390|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
214800687|NCT06240390|DRUG|pharmacological treatment by Opioids|Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
214800688|NCT02328690|OTHER|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
214800689|NCT06111703|BEHAVIORAL|Knowledge assessment|Knowledge, Attitude and Practice Survey
214800690|NCT03371290|OTHER|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
214800691|NCT03371290|OTHER|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
214800692|NCT01739790|DRUG|N-Acetylcysteine|1800 mg twice daily for 8 weeks
214800693|NCT01739790|DRUG|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
214800694|NCT04296903|DEVICE|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
214800695|NCT04790448|DRUG|Cetuximab|Route of administration: Intravenous
214800696|NCT04790448|DRUG|Irinotecan|Route of administration: Intravenous
214800697|NCT04790448|DRUG|Vemurafenib|Route of administration: Oral
214800698|NCT04000217|BEHAVIORAL|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
214800699|NCT04000217|BEHAVIORAL|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
214800700|NCT04578158|DRUG|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
214800701|NCT04578158|DIETARY_SUPPLEMENT|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
214800702|NCT02315690|DRUG|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
214800703|NCT02315690|PROCEDURE|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
214800704|NCT04354532|PROCEDURE|Laparoscopic Banded Sleeve Gastrectomy|The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
214647562|NCT05242770|OTHER|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
214647563|NCT05242770|OTHER|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
214647564|NCT05242770|OTHER|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
214647565|NCT05242770|OTHER|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
214647566|NCT05242770|OTHER|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
214647567|NCT01825031|DRUG|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
214647568|NCT01825031|DRUG|Fluconazole|100mg once daily for 12 weeks
214647569|NCT01825031|DRUG|Azithromycin|500mg once daily for 5 days
214647570|NCT01825031|DRUG|Albendazole|a single dose 400mg
214647571|NCT01825031|DRUG|Isoniazid|300mg taken immediately in combination with cotrimoxazole
214647572|NCT01825031|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
214647573|NCT01568203|DRUG|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
214647574|NCT01568203|DRUG|Placebo|Matching placebo control for AMG 579 at each dose level
214647575|NCT03957967|OTHER|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
214647576|NCT01486030|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
214647577|NCT02251912|DRUG|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
214647578|NCT02251912|DRUG|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
214647579|NCT04171739|DRUG|Itraconazole oral solution|200 mg once daily on Days 6 to 15
214647580|NCT04171739|DRUG|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
214647581|NCT04171739|DRUG|Olorofim|Single oral dose on Days 1 and 11
214647582|NCT02515149|DEVICE|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
214647583|NCT01645267|PROCEDURE|Hydroxyapatite|Use of artifical bonegraft material
214647584|NCT06388902|DRUG|BR115 for injection|BR115 for injection will be administered by subcutaneous injection, two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data.
214647585|NCT01107444|DRUG|Docetaxel|Administered intravenously
214647586|NCT01107444|DRUG|LY2181308|Administered intravenously
214647587|NCT00961987|OTHER|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
214647588|NCT00961987|OTHER|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
214647589|NCT04588103|OTHER|Heat therapy|Lower limb warm water immersion (42 degrees C)
214647590|NCT04588103|OTHER|Exercise training|Moderate-intensity cycling exercise (\~40-59% VO2 reserve)
214647591|NCT01750255|OTHER|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
214647592|NCT01750255|OTHER|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
214647593|NCT03851692|OTHER|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
214647594|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
214647595|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
214647596|NCT05949307|DEVICE|acupuncture|acupuncture
214647597|NCT05949307|DEVICE|laser acupuncture|laser acupuncture
214647598|NCT05949307|DEVICE|Sham-laser acupuncture|Sham-laser acupuncture
214800705|NCT02592161|DRUG|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
214800706|NCT02581345|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
214800707|NCT02581345|BIOLOGICAL|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
214800708|NCT00316745|DRUG|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
214800709|NCT00316745|DRUG|TS-1|S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)
214800710|NCT00316745|DRUG|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
214800711|NCT00316745|DRUG|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
214800712|NCT00316745|DRUG|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
214800713|NCT02101346|DIETARY_SUPPLEMENT|Mixed High Fat Diet|Healthy, Round 1
214800714|NCT02101346|DIETARY_SUPPLEMENT|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
214800715|NCT02101346|DIETARY_SUPPLEMENT|Monounsaturated fat diet|Healthy, Round 1
214800716|NCT02101346|DIETARY_SUPPLEMENT|Polyunsaturated fat diet|Healthy, Round 1
214800717|NCT02101346|DIETARY_SUPPLEMENT|Triolein 13C|Healthy, Round 2
214800718|NCT02101346|DIETARY_SUPPLEMENT|Low fat|Healthy, Round 1
214800719|NCT02122796|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
214800720|NCT03830125|DRUG|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
214800721|NCT03830125|DRUG|Placebo group|Placebo matched to BBT-877, oral capsule
214800722|NCT03830125|DRUG|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
214800723|NCT00003422|DRUG|fluorouracil|
214800724|NCT00003422|DRUG|leucovorin calcium|
214800725|NCT00003422|PROCEDURE|adjuvant therapy|
214800726|NCT00003422|PROCEDURE|conventional surgery|
214800727|NCT00003422|PROCEDURE|neoadjuvant therapy|
214800728|NCT00003422|RADIATION|radiation therapy|
214800729|NCT00041808|DRUG|MTC-DOX for Injection|
214800730|NCT00041808|PROCEDURE|Chemotherapy|
214800731|NCT00969800|DEVICE|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
214800732|NCT00969800|DEVICE|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
214464474|NCT05868343|OTHER|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
214800733|NCT05285085|DRUG|Statin|Statin use
214800734|NCT02445456|DRUG|Sienna+ injection|Endoscopic injection of magnetic tracer
214800735|NCT02445456|OTHER|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
214800736|NCT02445456|PROCEDURE|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
214800737|NCT02445456|DEVICE|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
214800738|NCT01393678|DRUG|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
214800739|NCT01393678|DRUG|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
214800740|NCT06144671|DRUG|GT201|Autologous tumor infiltrating lymphocyte injection
214800741|NCT01408199|DRUG|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
214800742|NCT03025594|DRUG|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
214800743|NCT03025594|DRUG|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
214800744|NCT04768179|DRUG|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
214800745|NCT00881556|DRUG|Palifermin|60 mcg/kg/day for 6 days
214800746|NCT00881556|DRUG|Fludarabine|30 mg/m2 IV x 1 for 6 days
214800747|NCT00881556|DRUG|Busulfan|4 mg/kg/day IV divided BID for 4 days
214800748|NCT00881556|DRUG|Lorazepam|0.02-0.05 mg/kg for 5 days
214800749|NCT00881556|DRUG|Alemtuzumab|20 mg/m2 IV for 5 days
214800750|NCT00881556|DRUG|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
214800751|NCT00077948|DRUG|Enoximone|Enoximone administered orally
214800752|NCT00077948|DRUG|Metoprolol succinate|Metoprolol succinate administered orally
214800753|NCT00077948|DRUG|Placebo to match enoximone|Placebo to match match enoximone administered orally
214800754|NCT00077948|DRUG|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
214800755|NCT04511273|DRUG|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
214800756|NCT00590395|DRUG|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
214800757|NCT02279797|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
214647599|NCT06213428|BIOLOGICAL|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
214647600|NCT06213428|OTHER|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
214647601|NCT00439582|DIETARY_SUPPLEMENT|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
214647602|NCT00439582|DIETARY_SUPPLEMENT|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
214647603|NCT00000321|DRUG|Desipramine|
214647604|NCT04139876|PROCEDURE|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
214657205|NCT02901171|BEHAVIORAL|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
214800758|NCT02885077|DEVICE|High-intensity IMT + combined exercise|
214800759|NCT04761965|DIAGNOSTIC_TEST|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
215031580|NCT07011290|OTHER|Recreational walking team handball (WTH) training sessions|"Recreational walking team handball (WTH):~Participants will partake in 2 sessions of recreational walking team handball matches (WTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
215031581|NCT06678581|DRUG|SAP-001|Solid Oral Tablet
215031582|NCT06678581|DRUG|Placebo|Solid Oral Tablet
214657206|NCT02901171|BEHAVIORAL|ACT group treatment|
214657207|NCT02901171|BEHAVIORAL|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
214657208|NCT00378118|OTHER|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
214657209|NCT00378118|OTHER|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
214657210|NCT06583343|DRUG|OnabotulinumtoxinA|Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
214657211|NCT06583343|OTHER|Conventional Physical Therapy|Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
214657212|NCT05143021|OTHER|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
214657213|NCT05506943|DRUG|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
214657214|NCT05506943|DRUG|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
214657215|NCT02132442|DIETARY_SUPPLEMENT|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
214657216|NCT02617355|DEVICE|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
214657217|NCT02617355|DEVICE|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
214657218|NCT02617355|DEVICE|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
214657219|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
214657220|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
214657221|NCT02823158|PROCEDURE|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS."
214657222|NCT02823158|PROCEDURE|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
214657223|NCT00243997|BEHAVIORAL|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
214657224|NCT06230354|DRUG|Tezepelumab|Tezepelumab subcutaneous injection
214657225|NCT06230354|DRUG|Placebo|Placebo subcutaneous injection
214657226|NCT01639326|DRUG|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
214657227|NCT01639326|DRUG|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
214657228|NCT01926626|DRUG|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
214657229|NCT01926626|DRUG|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
214657230|NCT05203250|RADIATION|Heavy-ion therapy (hadrontherapy)|Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.
214657231|NCT03146364|DEVICE|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
214657232|NCT04743050|DRUG|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
214657233|NCT04743050|DIAGNOSTIC_TEST|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
214657234|NCT02607215|DRUG|Vinorelbine|25 mg/m2, D1, D8
214657235|NCT02607215|DRUG|DDP|75 mg/m2, D1
214657236|NCT04391140|OTHER|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
214800760|NCT03272048|BEHAVIORAL|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, \& Rudd, 2011; Jin, Khazem, \& Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, \& Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
214800761|NCT03354026|DRUG|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
214800762|NCT03354026|DRUG|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
214800763|NCT03354026|DRUG|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
214800764|NCT01244126|DRUG|Intranasal fentanyl|2mcg/kg fentanyl IN
214800765|NCT01244126|DRUG|morphine IM|0.1 mg/kg morphine IM for postop pain
214800766|NCT01244126|DRUG|IV morphine|0.1 mg/kg morphine IV
214800767|NCT02853279|BEHAVIORAL|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗\_peak- 〖WR〗\_LT )+ 〖WR〗\_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
214800768|NCT02853279|BEHAVIORAL|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
214800769|NCT06799260|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|500 mg/kg body weight of the KME supplement
214800770|NCT06799260|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo drink
214800771|NCT06799260|DEVICE|iTBS|iTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
214800772|NCT06799260|DEVICE|cTBS|cTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
214800773|NCT01451762|DRUG|.9 normal saline|.9 normal saline administered before surgery.
214800774|NCT01451762|DRUG|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
214800775|NCT01451762|DRUG|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
214800776|NCT02346097|DEVICE|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
214800777|NCT00245609|DRUG|Pregabalin|
214800778|NCT00245609|DRUG|Alprazolam|
214800779|NCT00245609|DRUG|Placebo|
214800780|NCT04978649|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
214800781|NCT04978649|DRUG|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
214800782|NCT01771965|BEHAVIORAL|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
214800783|NCT02696070|DEVICE|Provant Therapy System|
214800784|NCT03986177|BEHAVIORAL|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager"
214800785|NCT01921920|DRUG|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
214800786|NCT00907998|DRUG|APL180|
214800787|NCT00907998|DRUG|APL180|
214800788|NCT00907998|DRUG|Placebo|
214800789|NCT02435225|BEHAVIORAL|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
214800790|NCT04697498|PROCEDURE|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
214800791|NCT04697498|PROCEDURE|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
214800792|NCT01653626|OTHER|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
214800793|NCT00863746|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
214800794|NCT00863746|DRUG|Placebo|Placebo - 2 tablets twice daily (BID)
214800795|NCT04461808|DIAGNOSTIC_TEST|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
214800796|NCT04461808|DIAGNOSTIC_TEST|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
214800797|NCT05589896|OTHER|Ossium HPC Marrow, Bone Marrow Transplant|Hematopoetic Cell Transplantation
214800798|NCT05589896|OTHER|Pre-transplant conditioning - Myeloablative (MAC)|Regimen A or Regimen B
214800799|NCT05589896|OTHER|Pre-transplant conditioning - Reduced Intensity (RIC)|Regimen C or Regimen D
214800800|NCT05589896|OTHER|Post-transplant treatment|Post-transplant treatment
214800801|NCT02048111|BIOLOGICAL|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
214800802|NCT00323349|PROCEDURE|Oral Glucose Tolerance Testing|
214800803|NCT00323349|BEHAVIORAL|Education tailored to learning style preferences|
214800804|NCT01544361|OTHER|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
214800805|NCT01544361|BIOLOGICAL|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
214800806|NCT01544361|BIOLOGICAL|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
214800807|NCT01544361|BIOLOGICAL|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
214800808|NCT01544361|BIOLOGICAL|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
214800809|NCT06309901|OTHER|Exercise|"Home exercises were applied in 3 progressive phases.~1st phase: postoperative 0-4. week, 2nd phase: 5-12. week, 3rd phase 12-15. week.~In the 1st phase, ice application, strengthening for the hip, knee and ankle, and walking exercises were applied. 90 degrees knee flexion range of movement (ROM) was targeted.~In the 2nd phase, the resistance of the strengthening exercises was increased and closed kinetic chain exercises were added. Weight bearing, step climbing and balance exercises were performed. Full ROM targeted in the knee.~In the 3rd phase, pain-free full ROM was targeted, and progressive strengthening, balance and agility exercises for sports and recreational activities were applied."
214800810|NCT06309901|OTHER|Fascial Distortion Model|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of FDM technique were applied.~In this study, trigger band technique was chosen to apply around the knee. Interventions were made directly to the skin in the form of medial, lateral, anterior, posterior techniques of the knee and posterior and lateral techniques of the thigh. The techniques was made after the exercises."
215031583|NCT06678568|OTHER|telemedicine follow-up in 3rd week|Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
214800811|NCT06309901|OTHER|Instrument Assisted Soft Tissue Mobilisation|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of IASTM technique were applied.~In this study, the Graston technique was chosen to apply IASTM around the knee. Technique was applied with using stainless steel and ultrasound gel to around the knee, m. quadriceps, m. hamstring, iliotibial band and medial thigh. The technique was performed for at least 2 minutes in each region."
214800812|NCT01475448|OTHER|Long distance training|Long distance training during four months, 3 times per week
214800813|NCT01475448|OTHER|Walking training|Walking training during four months, three times per week
214800814|NCT06213844|DRUG|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
214800815|NCT06213844|DRUG|Placebo|Single dose of Placebo, administered subcutaneously on Day 1
214800816|NCT03065582|OTHER|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
214800817|NCT03065582|OTHER|Topical Product B|topical application of product A without topical antioxidants
214800818|NCT03065582|OTHER|Topical Product C|Topical application of antioxidants only
214800819|NCT03065582|OTHER|Control|No product applied
214800820|NCT00862979|DRUG|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
214800821|NCT00862979|DRUG|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
214800822|NCT00862979|DRUG|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
214800823|NCT00862979|DRUG|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
214800824|NCT00862979|DRUG|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
214800825|NCT00862979|DRUG|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
214800826|NCT06008457|DEVICE|Labcorp COVID-19+Flu+RSV Test Home Collection Kit|The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
214800827|NCT06630676|BEHAVIORAL|Control|Brief 4-slide presentation without a separate session for questions and answers
214800828|NCT06630676|BEHAVIORAL|Education|Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
214800829|NCT00218530|DRUG|Lofexidine|
214800830|NCT00679640|DRUG|Candesartan|Oral tablets
214800831|NCT06162793|BEHAVIORAL|RehaPlus+|24-week eHealth intervention
214800832|NCT05673642|OTHER|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
214800836|NCT01382433|PROCEDURE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
214800837|NCT01382433|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
214800838|NCT01382433|BEHAVIORAL|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
214800839|NCT02058056|RADIATION|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
214800840|NCT05699356|OTHER|Non Surgical treatment|Non Surgical
214800841|NCT05699356|PROCEDURE|laparoscopic drilling|Surgical intervension
214800842|NCT05699356|BEHAVIORAL|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
214800843|NCT05699356|PROCEDURE|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
214800844|NCT03129919|DEVICE|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
214800845|NCT03129919|DEVICE|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
214800846|NCT00248638|DRUG|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
214800847|NCT00248638|DRUG|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
214800848|NCT05037123|DRUG|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
214800849|NCT05037123|DRUG|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
214800850|NCT05037123|OTHER|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
214800851|NCT05084742|DEVICE|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
214800852|NCT02980887|OTHER|No Intervention|There is no intervention in this observational study
214800853|NCT05561413|BEHAVIORAL|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
214800854|NCT05561413|BEHAVIORAL|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
214800855|NCT03928782|RADIATION|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
214800856|NCT05118906|DRUG|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
214800857|NCT05118906|DRUG|Placebo|2 tablets of placebo per day
214800858|NCT05426720|OTHER|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
214800859|NCT01578174|DRUG|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
214800860|NCT01578174|DRUG|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
214800861|NCT04055363|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
214800862|NCT05387902|DEVICE|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
214800863|NCT05719870|BEHAVIORAL|Educational training|The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
214800864|NCT01367275|DRUG|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
214800865|NCT01367275|DRUG|Irinotecan|180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
214800866|NCT03852199|OTHER|Test protocol for proprioceptive force sense in case group|"* The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~* Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
214800867|NCT00750659|DRUG|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
214800868|NCT03378700|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
214800869|NCT03378700|OTHER|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
214800870|NCT06376032|DEVICE|EndeavorOTC®|EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
214800871|NCT03631524|DEVICE|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
214800872|NCT02495324|DRUG|Placebo|2 weeks of placebo PO daily
214800873|NCT02495324|DRUG|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
214800874|NCT02495324|DRUG|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
214800875|NCT02495324|DRUG|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
214800876|NCT00139321|DEVICE|Force platform and electromyography|
214800877|NCT03403764|OTHER|Wellness Intention|
214800878|NCT04933513|BEHAVIORAL|pre DBS patients responding to the DBS-PS scale|we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
214800879|NCT04236765|OTHER|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
214800880|NCT01059500|DEVICE|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP \>5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP\>20% consider empiric anticoagulation with heparin if no contraindications.
214800881|NCT03913000|DRUG|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
214800882|NCT00502775|DRUG|fluticasone furoate, fexofenadine|
214800883|NCT06237075|DEVICE|transcranial direct current stimulation|2-milliamp stimulation for 5\~15 min
214800884|NCT02127606|DEVICE|Vibration with tilt-table standing|
214800885|NCT06444074|BEHAVIORAL|Patient Activation through Conversations (PACT) Program|Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
214800886|NCT06444074|BEHAVIORAL|Usual Care|Routine Chronic Disease care
214800887|NCT04483700|DRUG|Filgotinib|Tablets administered orally once daily
214800888|NCT04483700|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
214800889|NCT05611034|DRUG|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
214800890|NCT03012477|DRUG|Cisplatin|chemotherapy
214800891|NCT03012477|DRUG|AZD1775|Wee1 tyrosine kinase inhibitor
214800892|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
214800893|NCT01208480|DRUG|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
214800894|NCT06370663|RADIATION|Radiotherapy|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
214800895|NCT06370663|DRUG|HAIC (GEMOX)|Hepatic Arterial Infusion Chemotherapy (GEMOX)
214800896|NCT06370663|DRUG|Chemotherapy|Chemotherapy (Gesitabine)
214800897|NCT05671484|OTHER|Transversalis Fascial Plane Block|Patients will receive ultrasound-guided transversalis fascial plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
214800898|NCT05671484|OTHER|Quadratus Lumborum Plane Block|Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
214800899|NCT05848986|OTHER|Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
214800900|NCT00287118|DRUG|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
214800901|NCT01398384|DRUG|Nitric Oxide|MI size at 48-72 hours
214800902|NCT01398384|DRUG|MI size at 48-72 hours|Placebo gas
214800903|NCT02474264|OTHER|Endothelial function assessment|reactive hyperemia index
214800904|NCT02474264|OTHER|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
214800905|NCT02474264|OTHER|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
214800906|NCT00262600|DRUG|warfarin|once a day
214800907|NCT00262600|DRUG|Dabigatran dose 1|twice daily
214800908|NCT00262600|DRUG|Dabigatran dose 2|twice a day
214800909|NCT04713059|GENETIC|FGFR2|Mutation of FGFR2
214800910|NCT06799117|OTHER|EMBED CDS|"EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.~Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)"
214800911|NCT06799117|OTHER|Nurse prompt to complete COWS|Nurse prompt to complete COWS
214800912|NCT06799117|OTHER|Provider Prompt|Provider Prompt to use EMBED: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community. Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)
214800913|NCT06799117|OTHER|Patient facing materials|Provider prompt to give patient customized discharge instructions directing patient to resources matched to their needs.
214800914|NCT06799117|OTHER|Optimized EMBED|CDS following Optimization Phase, Stage 2: Rapid serialized testing
215031138|NCT06186518|OTHER|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
214800915|NCT06799117|OTHER|Name of Intervention|Intervention to be informed by results during Evaluation Phase, Stage 1 and will involve refinement of user interface and workflows for the EMBED CDS: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.
214800916|NCT05473052|BEHAVIORAL|Preoperative home-based exercise training|"1\) Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity:Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week~2\) Weekly telephone supervision: A physical therapist carried out weekly telephone calls with all participants to monitor adverse events, give positive reinforcement and recommend strategies to overcome barriers that arise during the exercise program."
214800917|NCT01817556|DRUG|Stillen Tab.|
214800918|NCT01817556|DRUG|Mucosta Tab.|
214800919|NCT06327815|DRUG|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets|10 mg Dapagliflozin/1000 mg Metformin HCl extended-release
214800920|NCT06327815|DRUG|Dapagliflozin tablets and Metformin HCl extended-release tablets|Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
214800921|NCT02222428|DRUG|BI 1744 CL/BI 54903 XX FDC|
214800922|NCT02222428|DRUG|BI 54903 XX|
214800923|NCT02222428|DRUG|BI 1744 CL|
214800924|NCT05334771|DEVICE|Dual band pure tune audiometer|Orbiter 922 Tympanometry
214800925|NCT06365645|BEHAVIORAL|M.Bapp|Please see experimental group description.
214800926|NCT06365645|BEHAVIORAL|App-based parenting education|Please see active comparator group description.
214800927|NCT02280629|DRUG|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
214800928|NCT02280629|DRUG|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
214800929|NCT02280629|DRUG|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
214800930|NCT05733572|DRUG|CHF6467|drug eyedrops
214800931|NCT05733572|DRUG|Placebo|placebo eyedrops
214800932|NCT05663281|DIAGNOSTIC_TEST|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
214800933|NCT03238066|RADIATION|Brachytherapy|HDR/PDR brachytherapy
214800934|NCT03238066|OTHER|Hyperthermia|Interstitial hyperthermia
214800935|NCT03747822|PROCEDURE|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
214800936|NCT03089112|DRUG|HGP1607|Take it once per period
214800937|NCT03089112|DRUG|HGP1501|Take it once per period
214800938|NCT03089112|DRUG|HGP1607+HGP1501|Take it once per period
214800939|NCT03196024|BEHAVIORAL|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
214800940|NCT03196024|BEHAVIORAL|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
214800941|NCT00988923|OTHER|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
214800942|NCT00988923|OTHER|No intervention|the intervention tool was switched in off, only bolus was activated
214800943|NCT00003123|DRUG|amifostine trihydrate|
214800944|NCT04511559|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.
214800945|NCT04511559|DIAGNOSTIC_TEST|tissue DNA Methylation Sequencing|Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
214800946|NCT03304600|DEVICE|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
214800947|NCT03304600|DEVICE|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
214800948|NCT01574170|OTHER|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
214800949|NCT00926406|DRUG|lead chelation therapy|Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
214800950|NCT04799600|OTHER|BRESCİA-COVİD Respiratory Severity Scale|KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
214800951|NCT01385033|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
214800952|NCT02798484|DEVICE|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
214800953|NCT02906709|DRUG|Omarigliptin|Omarigliptin, 25 mg orally once weekly
214800954|NCT02906709|DRUG|Placebo|Placebo to omarigliptin orally once weekly
214800955|NCT02906709|BIOLOGICAL|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
214800956|NCT05649176|OTHER|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
214800957|NCT05649176|OTHER|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
214800958|NCT00726960|DRUG|aprepitant|Oral, 125 mg once daily for one week
214800959|NCT00726960|DRUG|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
214800960|NCT00000880|DRUG|Cyclosporine|
214800961|NCT05057715|BIOLOGICAL|VCN-01|Intravenous administration of VCN-01
214800962|NCT05057715|BIOLOGICAL|huCART-meso Cells|Intravenous administration of huCART-meso cells
214800963|NCT05227820|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
214800964|NCT05478226|OTHER|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
214800965|NCT06173336|PROCEDURE|gastric per-oral endoscopic myotomy (G-POEM)|Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
214800966|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
214800967|NCT04860492|DIETARY_SUPPLEMENT|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
214800968|NCT00763022|DRUG|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
214800969|NCT00763022|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
214800970|NCT00763022|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
214800971|NCT04428567|BEHAVIORAL|Dual-Task Treadmill exercise + Cognitive Training|The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
214800972|NCT00825708|DEVICE|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
214800973|NCT00825708|DEVICE|shamTMS|sham TMS session
214800974|NCT03215108|DEVICE|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
214800975|NCT03913806|DRUG|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
214800976|NCT06484218|PROCEDURE|conventional endodontic treatment|The conventional access cavity was prepared under the microscope through the incisal edge as this approach facilitates straight-line access. A high-speed contra-angle handpiece, associated with a long surgical bur 010 (Meisinger, CO, USA), was used until the dentin was exposed, which is in general 3 to 4 millimeters from the incisal edge. Then, the ultrasonic tip ED5 (woodpecker-DTE, Guilin, China) was marked with a stopper according to the calcification level viewed on the preoperative CBCT and then used gently at the stopper level until the canal was found.
214800977|NCT06484218|PROCEDURE|Guided endodontic treatment|In all cases, digital and clinical protocols were followed according to the method reported by Zehnder et al. and Connert et al. The guide was replaced, and the access cavity precisely drilled using the EG6 drill, mounted on a low-speed contra-angle handpiece. With every 3 mm of progression, the cavity was rinsed, and the head of the bur was cleaned until reaching the canal. The irrigation was done to avoid overheating the dentine and the accumulation of dentine debris
214800978|NCT04669236|BEHAVIORAL|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
214800979|NCT04911959|DRUG|Lenvatinib|Lenvatinib is taken orally.
214800980|NCT04911959|PROCEDURE|TACE|TACE treatment once.
214800981|NCT06139237|OTHER|High-protein supplement|High protein supplement 200 mL
214800982|NCT06139237|OTHER|Balanced supplement|Balanced supplement 200 mL
214800983|NCT02334371|RADIATION|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
214800984|NCT05042856|PROCEDURE|PanOptix IOL implantation|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
214800985|NCT02886078|PROCEDURE|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
214800986|NCT02886078|PROCEDURE|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
214800987|NCT03770923|DRUG|Rupatadine|Rupatadine 10 mg daily
214800988|NCT03770923|DRUG|Montelukast|Montelukast 10 mg daily
214800989|NCT02136095|PROCEDURE|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
214800990|NCT04915092|DEVICE|CoSIE app|"The app is a mobile phone application compatible with both iOS and Android operating system. Parents are able to register their children and to keep track of their weight status and activities. The app include five themes: child development, physical activity, healthy food, critical situations, BMI.~Push notification on healthy behaviours, on important event taking place in the province of Reggio Emilia, on food advices based on seasonality and on party tips are constantly delivered by the app."
214800991|NCT04022148|BIOLOGICAL|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
214800992|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
214800993|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
214800994|NCT01608581|OTHER|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
214800995|NCT05456074|OTHER|Data collection|Retrospective data collection
214800996|NCT00902876|DEVICE|Mucograft|Collagen Matrix for soft tissue regeneration
214800997|NCT00902876|PROCEDURE|Coronally advanced flap (CAF)|
214800998|NCT05003648|DRUG|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
214800999|NCT05003648|DRUG|Placebo|Matching placebo
214801000|NCT04848948|BEHAVIORAL|Calory Restriction (F.X. Mayr & VLCD)|"VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution."
214801001|NCT04848948|BEHAVIORAL|Biofeedback|Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
214801002|NCT04940455|OTHER|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
214801003|NCT01052090|DRUG|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
214801004|NCT02512666|DEVICE|AM4113-N5UT Dino-Lite|
214801005|NCT02295956|BEHAVIORAL|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
214801006|NCT02295956|OTHER|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
214801007|NCT02295956|OTHER|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
214801008|NCT02295956|BEHAVIORAL|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
214801009|NCT02295956|OTHER|Booklet|Exercise instructional booklet given to all participants describing all exercises.
214801010|NCT02304588|BIOLOGICAL|Mesenchymal stem cells|10-20 x 10\^6 cells/20mL
214801011|NCT00004825|DRUG|recombinant human insulin-like growth factor I|
214801012|NCT05901948|OTHER|Classification|Novel Asherman Scoring Classification
214801013|NCT00082563|DRUG|Azithromycin/Chloroquine|
214801014|NCT00082563|DRUG|Chloroquine|
214801015|NCT05885139|DEVICE|Exopulse Mollii Suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
214801016|NCT05885139|DEVICE|Sham Exopulse Mollii Suit|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
214801017|NCT05993156|DEVICE|modified Fixed twinblock|modified fixed twin block functional appliance, with cemented bands on the first molars
214801018|NCT05993156|DEVICE|removable twin block|Conventional Removable Clark twin block myofunctional appliance
214801019|NCT03943056|DRUG|BIIB091|Administered as specified in the treatment arm.
214801020|NCT03943056|DRUG|Placebo|Administered as specified in the treatment arm.
214801021|NCT04569682|DEVICE|LifePort transrenal artery perfusion|transrenal artery perfusion group
214801022|NCT04569682|DEVICE|LifePort transrenal vein perfusion|transrenal vein perfusion group
214801023|NCT05130892|DRUG|Colchicine|1 tablet (0.5mg) / time, once a day
214801024|NCT05130892|DRUG|Tranilast|1 capsule (0.1g) / time, 3 times a day
214801025|NCT05130892|DRUG|Oridonin|2 tablets (0.5g) / time, 3 times a day;
214801026|NCT03795363|DRUG|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
214801027|NCT00405314|DEVICE|Continuous positive airway pressure ventilation mask|
214801028|NCT05323864|BIOLOGICAL|Hypoxia|Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
214801029|NCT05293990|RADIATION|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
214801030|NCT01232270|DRUG|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
214801031|NCT01661452|OTHER|Referral to counseling services if desired|
214801032|NCT06367452|DRUG|Sodium alginate + sodium bicarbonate + magaldrate + simeticone|Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
214801033|NCT04035642|RADIATION|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
215031139|NCT06186518|OTHER|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
214801034|NCT04035642|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
214801035|NCT04035642|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
214801036|NCT04035642|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
214801037|NCT03561142|RADIATION|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
214801038|NCT03561142|DRUG|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
214801039|NCT03561142|OTHER|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
214801040|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
214801041|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
214801042|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
214801043|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
214801044|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
214801045|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
214801046|NCT02288832|OTHER|-self-collected vaginal samples|
214801047|NCT02288832|DRUG|zithromax|
214801048|NCT02288832|OTHER|usual practices|
214801049|NCT05749133|BIOLOGICAL|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based."
214801050|NCT00650000|DRUG|Modafinil Tablets 200 mg|200mg, single dose fasting
214801051|NCT00650000|DRUG|Provigil® Tablets 200 mg|200mg, single dose fasting
214801052|NCT02412215|PROCEDURE|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
214801053|NCT02412215|DEVICE|NanoFlex toric Intraocular Lens|
214801054|NCT05518487|BIOLOGICAL|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
214801055|NCT02802371|BEHAVIORAL|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
214801056|NCT02802371|OTHER|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
214801057|NCT03831451|BEHAVIORAL|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
214801058|NCT03831451|BEHAVIORAL|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
214801059|NCT01931033|DRUG|Intranasal Oxytocin|
214801060|NCT04270305|OTHER|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
214801061|NCT04270305|OTHER|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
215031140|NCT02878395|PROCEDURE|Ileocolic resection|
214801062|NCT00305045|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
214801063|NCT05956197|OTHER|No intervention|No intervention. This is a cohort study
214801064|NCT02052609|DRUG|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
214801065|NCT02052609|DRUG|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
214801066|NCT03130205|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
214801067|NCT03130205|RADIATION|Computed Tomography|Computed Tomography
214801068|NCT03130205|RADIATION|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
214801069|NCT03130205|PROCEDURE|Phlebotomy|3 EDTA tubes drawn from peripheral vein
214801070|NCT03130205|GENETIC|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
214801071|NCT02752776|DRUG|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
214801072|NCT00194740|DRUG|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
214801073|NCT00194740|DRUG|Vinorelbine|27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
214801074|NCT00194740|DRUG|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
214801075|NCT02419677|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
214801076|NCT02419677|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
214801077|NCT05577585|DRUG|Ketamine 50 MG/ML Blinded|See also Arm description
214801078|NCT05577585|DRUG|Midazolam|See also Arm description
214801079|NCT05577585|DRUG|Ketamine 50 MG/ML Open Label|Open Label Follow Up (up to 8 Infusions)
214801080|NCT05577585|OTHER|Treatment as Usual (TAU)|Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.
214801081|NCT04209972|DEVICE|Precision Ultra-High-Resolution CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
214801082|NCT04209972|DEVICE|Genesis high-end CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
214801083|NCT01399164|OTHER|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
214801084|NCT03967249|DRUG|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
214801085|NCT03967249|DRUG|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
214801086|NCT03714100|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
214801087|NCT05234437|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
214801088|NCT01946165|DRUG|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
214801089|NCT01946165|DRUG|Prednisone|5 mg by mouth once daily for each 28 day cycle.
214801090|NCT01946165|DRUG|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
214801091|NCT01946165|DRUG|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
214801092|NCT05226910|DEVICE|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
214801093|NCT05226910|DEVICE|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
214801094|NCT02824900|DEVICE|Vibration stimuli to neck muscles|
214801095|NCT02824900|DEVICE|Vibration stimuli to hand|
214801096|NCT02824900|BEHAVIORAL|conventional physiotherapy|
214801097|NCT02141100|DRUG|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
214801098|NCT00816959|DRUG|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
214801099|NCT00816959|DRUG|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
214801100|NCT01127542|DRUG|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
214801101|NCT04620174|OTHER|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
214801102|NCT04620174|OTHER|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
214801103|NCT01179919|DRUG|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
214801104|NCT00806156|DRUG|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
214801105|NCT00806156|DRUG|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
214801106|NCT00417690|DRUG|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
214801107|NCT00417690|DRUG|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
214801108|NCT02106065|BEHAVIORAL|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
214801109|NCT02106065|OTHER|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
214801110|NCT03186066|DEVICE|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
214801111|NCT03186066|PROCEDURE|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
214801112|NCT05278806|OTHER|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
214801113|NCT05278806|OTHER|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
214801114|NCT00599209|OTHER|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
214801115|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
214801116|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
214801117|NCT00337571|DRUG|Aripiprazole|Tablets, Oral, once daily, 8 weeks
214801118|NCT00337571|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
214801119|NCT03934073|OTHER|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
214801120|NCT03934073|OTHER|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
214801121|NCT03934073|OTHER|CONTROLE|Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
214801122|NCT04330937|DIETARY_SUPPLEMENT|dietetics|90 days of consumption
214801123|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP|"1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0"
214801124|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP; MVA ME-TRAP|"1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)"
214801125|NCT01286038|DRUG|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
214801126|NCT04662892|DRUG|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
214801127|NCT00414401|BEHAVIORAL|Clinical Reminder|
214801128|NCT00469625|DRUG|paricalcitol (initial dose 1 mcg orally per day)|
214801129|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
215031141|NCT05718739|DEVICE|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
214801130|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
214801131|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
214801132|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
214801133|NCT02060006|DRUG|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
214801134|NCT05458609|DRUG|Lemborexant 10 mg|10 mg of Lemborexant
214801135|NCT05458609|DRUG|Naltrexone|50 mg of Naltrexone
214801136|NCT04108325|DRUG|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
214801137|NCT05028842|OTHER|No intervention|None.This is an observational study
214801138|NCT01634906|DRUG|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
214801139|NCT04555928|OTHER|No intervention|This is a prospective cohort (survey) study. It has no intervention.
214801140|NCT04884893|DRUG|Nitrous Oxide|50% nitrous oxide
214801141|NCT06149936|DEVICE|excimer light|Excimer laser using high-dose monochromatic UV radiation
214801142|NCT03783208|DRUG|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
214801143|NCT03783208|OTHER|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
214801144|NCT01969357|DRUG|Placebo|Tablets(n=4),once daily for 84 days
214801145|NCT01969357|DRUG|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
214801146|NCT01969357|DRUG|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
214801147|NCT01969357|DRUG|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
214801148|NCT01969357|DRUG|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
214801149|NCT02554864|DRUG|lidocaine|Local anesthetic
214801150|NCT02554864|DRUG|ropivacaine|Local anesthetic
214801151|NCT02045121|DEVICE|Indwelling Pleural Catheter|
214801152|NCT02045121|PROCEDURE|Talc Pleurodesis|
214801153|NCT01767064|OTHER|Posted commitment letter|
214801154|NCT05941221|PROCEDURE|pericapsular nerve group (PENG) block|patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
214801155|NCT02636400|OTHER|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
214801156|NCT03312257|COMBINATION_PRODUCT|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
214801157|NCT00449150|DRUG|Cetrorelix 78 mg + 78 mg|
214801158|NCT00449150|DRUG|Cetrorelix 78 mg + 52 mg|
214801159|NCT00449150|DRUG|Placebo|
214801160|NCT01673958|OTHER|Exercise|Comparison between stair descending and stair ascending training
215031142|NCT02474173|OTHER|Laboratory Biomarker Analysis|Correlative studies
214801161|NCT02674334|DEVICE|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
214801162|NCT02674334|DEVICE|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
214801163|NCT03552757|DRUG|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
214801164|NCT03552757|DRUG|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
214801165|NCT03552757|DRUG|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
214801166|NCT03552757|DRUG|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
214801167|NCT06111911|DIAGNOSTIC_TEST|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
214801168|NCT04182971|OTHER|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
214801169|NCT04182971|OTHER|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
214801170|NCT04182971|OTHER|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
214801171|NCT05621265|BEHAVIORAL|Automated Text messaging|daily text message
214801172|NCT04558554|OTHER|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
214801173|NCT03765632|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
214801174|NCT03765632|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
214801175|NCT03765632|DRUG|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
214801176|NCT04905433|BEHAVIORAL|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
214801177|NCT04905433|BEHAVIORAL|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
214801178|NCT00543478|DRUG|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
214801179|NCT00543478|DRUG|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
214801180|NCT04362397|BEHAVIORAL|FoCo|This is an attention, care and self-care training.
214801181|NCT04362397|BEHAVIORAL|No intervention|This is a waiting list
214801182|NCT00005842|BIOLOGICAL|trastuzumab|
214801183|NCT00005842|DRUG|tipifarnib|
214801184|NCT04655599|DRUG|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
214801185|NCT04655599|DRUG|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
214801186|NCT02660242|DRUG|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
214801187|NCT02660242|OTHER|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
214801188|NCT02660242|OTHER|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
214801189|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214801190|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214801191|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214801192|NCT03977051|BEHAVIORAL|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
214801193|NCT01124851|DRUG|ABT-652|See arm description for details
214801194|NCT01124851|DRUG|Placebo|See arm description for details
214801195|NCT01282151|DRUG|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
214801196|NCT01282151|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
214801197|NCT03194581|DEVICE|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
214801198|NCT03236181|OTHER|SFA|High saturated fatty acid/SFA oil source
214801199|NCT03236181|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
214801200|NCT03236181|OTHER|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
214801201|NCT03236181|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
214801202|NCT02064595|PROCEDURE|External fixator|Treatment with external fixation
214801203|NCT02064595|PROCEDURE|Intramedullary nail|Fracture treated with intramedullary nail
214801204|NCT01345019|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
214801205|NCT01345019|DRUG|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
214801206|NCT01345019|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
214801207|NCT01345019|DRUG|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
214801208|NCT01345019|DRUG|Denosumab (for the open-label treatment phase)|Administered by subcutaneous injection once every 4 weeks.
214801209|NCT01706471|DRUG|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
214801210|NCT01706471|DRUG|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
214801211|NCT02834611|DRUG|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
214801212|NCT02992171|BEHAVIORAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
214801213|NCT00971893|DRUG|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
214801214|NCT05556109|DIAGNOSTIC_TEST|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
214801215|NCT04558307|DIAGNOSTIC_TEST|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
214801216|NCT04558307|OTHER|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
214801217|NCT01818856|DRUG|Ritonavir withdrawal, atazanavir 200 mg/12h|
214801218|NCT01818856|DRUG|Telaprevir interactions|
214801219|NCT00235456|PROCEDURE|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
215031143|NCT02474173|DRUG|Onalespib|Given IV
215031144|NCT02474173|DRUG|Paclitaxel|Given IV
214801220|NCT00235456|PROCEDURE|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
214801221|NCT05369871|DEVICE|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
214801222|NCT05369871|DEVICE|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
214801223|NCT00526968|DRUG|EVT 101|8 mg capsule, single oral dose
214801224|NCT00526968|DRUG|EVT 101|15 mg capsule, single oral dose
214801225|NCT00526968|DRUG|placebo|Placebo capsule, single oral dose
214801226|NCT02778919|DRUG|KLH-2109|
214801227|NCT02778919|DRUG|Placebo|
214801228|NCT02778919|DRUG|Leuprorelin acetate|
214801229|NCT04999553|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
214801230|NCT04999553|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
214801231|NCT04999553|DEVICE|Low Frequency Right (LFR)|Low Frequency Right (LFR)
214801232|NCT05834283|OTHER|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
214801233|NCT05834283|OTHER|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
214801234|NCT00000619|PROCEDURE|catheterization, Swan-Ganz|
214801235|NCT05830019|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
214801236|NCT01651702|DEVICE|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
214801237|NCT01651702|DEVICE|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
214801238|NCT04462458|DEVICE|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
214801239|NCT03830164|DRUG|Atorvastatin|Given PO
214801240|NCT03830164|DRUG|Pentoxifylline|Given PO
214801241|NCT03830164|DIETARY_SUPPLEMENT|Vitamin E Compound|Given PO
214801242|NCT04330807|OTHER|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
214801243|NCT04330807|OTHER|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
214801244|NCT00000462|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214801245|NCT00000462|PROCEDURE|coronary artery bypass|
214801246|NCT05261685|PROCEDURE|Single-step transepithelial PRK|Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
214801247|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
214801248|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
214801249|NCT00674999|DRUG|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
214801250|NCT03382756|DIETARY_SUPPLEMENT|High fat diet|A diet consisting of more than 900kcal and 35% of fat
214801251|NCT03382756|DRUG|CKD-337|Test Drug
214801252|NCT05823207|OTHER|sage essential oil|It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
214801253|NCT05867576|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
214801254|NCT03931876|DRUG|Placebos|Single ascending dose administration
214801255|NCT03931876|DRUG|AV-006|Single ascending dose administration
214801256|NCT00388180|DRUG|GW501516|
214801257|NCT00388180|DRUG|GW590735|
214801258|NCT00386009|DRUG|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
214801259|NCT00386009|DRUG|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
214801260|NCT00594347|BIOLOGICAL|Pneumo 23|Vaccine (Pneumo 23)
214801261|NCT00594347|BIOLOGICAL|Prevnar|Vaccine (Prevnar)
214801262|NCT01375322|DRUG|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
214801263|NCT01375322|DRUG|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
214801264|NCT01013025|PROCEDURE|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
214801265|NCT00531375|DEVICE|Silicone hydrogel contact lens|
214801266|NCT03491436|DEVICE|iHealth Align|remote monitor glucometer
214801267|NCT04031300|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
214801268|NCT01637038|OTHER|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
214801269|NCT00194103|BEHAVIORAL|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
214801270|NCT00194103|BEHAVIORAL|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
214801271|NCT06145815|PROCEDURE|Arthroscopic rotator cuff repair|Patients underwent an arthroscopic repair for rotator cuff lesions
214801272|NCT05575271|PROCEDURE|Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network|The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
214801273|NCT05960864|DRUG|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
214801274|NCT05003011|DEVICE|Cardiospire|Non-invasive hemodynamic monitoring
214801275|NCT05488197|OTHER|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
214801276|NCT02292745|RADIATION|stereotactic radiotherapy|
214801277|NCT04933825|BIOLOGICAL|ET-02|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
214801278|NCT05169554|DRUG|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
214801279|NCT05169554|DRUG|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
214801280|NCT01460797|OTHER|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
214801281|NCT06801093|BEHAVIORAL|Digital psychosocial tool|Wysa is a digital psychosocial tool that provides AI conversational chatbot support. The conversational agent acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT), mindfulness, and motivational intervention. Participants can progressively work through learning different skills and practice them in their daily life. The app also provides a repository of tools to manage problems and SOS resources for high distress.
214801282|NCT00004579|BIOLOGICAL|gp160 MN/LAI-2|
214801283|NCT00004579|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
215031145|NCT02474173|OTHER|Pharmacological Study|Correlative studies
214801284|NCT04026126|BEHAVIORAL|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
214801285|NCT00219323|DRUG|Omalizumab|
214801286|NCT04761731|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
214801287|NCT01127022|DIETARY_SUPPLEMENT|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
214801288|NCT01127022|DIETARY_SUPPLEMENT|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
214801289|NCT01492400|DRUG|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
214801290|NCT01492400|DRUG|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
214801291|NCT00604500|DRUG|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
214801292|NCT00804661|DEVICE|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
214801293|NCT05283005|PROCEDURE|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
214801294|NCT00878397|DEVICE|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
214801295|NCT01622998|DRUG|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
214801296|NCT01622998|DRUG|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
214801297|NCT02597998|DRUG|14C-BI 409306|
214801298|NCT00113347|DRUG|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
214801299|NCT00113347|DRUG|Docetaxel|15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
214801300|NCT00113347|RADIATION|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
214801301|NCT00320112|BEHAVIORAL|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
214801302|NCT00320112|BEHAVIORAL|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
214801303|NCT00320112|BEHAVIORAL|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
214801304|NCT04929626|DRUG|Magnesium Sulfate 500 mg/ml+ ventolin|3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
214801305|NCT04929626|DRUG|Ventolin|it will be given to control group in nebulized form after every 20 min in 1st hour
214801306|NCT03748082|DRUG|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
214801307|NCT03748082|DIAGNOSTIC_TEST|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
214801308|NCT03748082|PROCEDURE|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
215031146|NCT03947619|DEVICE|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
215031147|NCT05076110|DRUG|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
214801309|NCT05767385|PROCEDURE|Single Arm|"* Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
214801310|NCT05767385|PROCEDURE|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
214801311|NCT02045927|OTHER|sedation monitoring with RASS score|
214801312|NCT02045927|OTHER|sedation monitoring with BIS-Guided monitoring|
214801313|NCT02844803|DRUG|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
214801314|NCT02844803|DRUG|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
214801315|NCT02502110|DRUG|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
214801316|NCT02899338|DRUG|BI695501 Prefilled syringe|
214801317|NCT02899338|DRUG|BI695501Autoinjector|
214801318|NCT06370221|BEHAVIORAL|The effect of psoriatic Arthritis|to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.
214801319|NCT04296149|DRUG|Y90-DOTA-Tyr3-Octreotide|Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
214801320|NCT00822874|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
214801321|NCT04980001|BEHAVIORAL|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
214801322|NCT00811668|DEVICE|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
214801323|NCT00811668|DEVICE|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
214801324|NCT02353169|DRUG|Dexmedetomidine|
214801325|NCT02353169|DRUG|Saline|
214801326|NCT01021150|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
214801327|NCT01021150|DRUG|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
214801328|NCT02508961|BEHAVIORAL|Exercise|web-based physio exercise programme
214801329|NCT05881096|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
214801330|NCT05881096|OTHER|Sham Control|Practice of movement task without START
214801331|NCT00906347|DRUG|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
214801332|NCT00906347|DRUG|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
214801333|NCT03825900|DEVICE|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
214801334|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
214801335|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
214801336|NCT01584921|DRUG|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
214801337|NCT00980603|DRUG|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
214801338|NCT00980603|DRUG|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
214801339|NCT00980603|DRUG|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
214801340|NCT02933866|DRUG|DSXS topical|topical treatment
214801341|NCT02933866|DRUG|Vehicle topical|topical treatment
214801342|NCT04127409|OTHER|Control Chicken-meat|
214801343|NCT04127409|OTHER|Control Eggs|
214801344|NCT04127409|OTHER|Omega-3-PUFA Enriched Chicken-meat|
214801345|NCT04127409|OTHER|Omega-3PUFA Enriched Eggs|
214801346|NCT04480411|BEHAVIORAL|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
214801347|NCT00005910|PROCEDURE|Intraoperative ultrasound|
214801348|NCT00577460|DRUG|Pramipexole|Pramipexole ER 0.375 -4.5 mg
214801349|NCT00577460|DRUG|Placebo|Placebo tablets identical to Pramipexole ER tablets
214801350|NCT05894863|DEVICE|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
214801351|NCT04591626|DRUG|Dulaglutide|Administered SC
214801352|NCT04591626|DRUG|Placebo|Administered SC
214801353|NCT04591626|DRUG|Insulin Glargine|Administered SC
214801354|NCT02672553|DEVICE|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
214801355|NCT02672553|DEVICE|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
214801356|NCT03777033|DRUG|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
214801357|NCT00615784|DRUG|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
214801358|NCT01107002|PROCEDURE|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
214801359|NCT01353300|GENETIC|DNA analysis|
214801360|NCT01353300|GENETIC|cytogenetic analysis|
214801361|NCT01353300|GENETIC|gene expression analysis|
214801362|NCT01353300|GENETIC|gene rearrangement analysis|
214801363|NCT01353300|GENETIC|mutation analysis|
214801364|NCT01353300|GENETIC|polymerase chain reaction|
214801365|NCT01353300|GENETIC|polymorphism analysis|
214801366|NCT01353300|OTHER|laboratory biomarker analysis|
214801367|NCT01353300|OTHER|medical chart review|
214801368|NCT01482156|DRUG|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
214801369|NCT02986009|BEHAVIORAL|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
214801370|NCT02986009|BEHAVIORAL|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
214801371|NCT00182091|DRUG|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
214801372|NCT00182091|DRUG|Saline|To maintain study-subject blinding, doses were sham adjusted.
214801373|NCT05197907|PROCEDURE|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
214801374|NCT05197907|PROCEDURE|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
214801375|NCT02608853|OTHER|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
214801376|NCT03246295|OTHER|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
214801377|NCT04872322|DRUG|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
214801378|NCT04872322|DRUG|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
214801379|NCT04872322|DRUG|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
214801380|NCT04872322|DRUG|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
214801381|NCT04872322|PROCEDURE|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
214801382|NCT00372788|DRUG|AZD6244|oral vial
214801383|NCT00372788|DRUG|Pemetrexed|oral
214801384|NCT03349671|PROCEDURE|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
214801385|NCT00981305|DRUG|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
214801386|NCT00981305|DRUG|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
214801387|NCT03194035|BIOLOGICAL|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
214801388|NCT01487733|GENETIC|gene expression analysis|
214801389|NCT01487733|GENETIC|in situ hybridization|
214801390|NCT01487733|OTHER|immunohistochemistry staining method|
214801391|NCT01487733|OTHER|laboratory biomarker analysis|
214801392|NCT00801190|OTHER|HES (130/0.4)|33 ml/kg i.v. during surgery
214801393|NCT00801190|OTHER|Ringer's Lactate|33 ml/kg i.v.
214801394|NCT06683508|DRUG|LY3549492|Administered orally
214801395|NCT06683508|DRUG|Placebo|Administered orally
214801396|NCT00231296|DEVICE|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
214801397|NCT00231296|DRUG|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
214801398|NCT04029675|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
214801399|NCT02405195|PROCEDURE|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
214801400|NCT07027657|DEVICE|Treatment with BTL-699-2|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
214801401|NCT07027657|DEVICE|Treatment with BTL-699-2 (sham)|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.
214801402|NCT04962685|OTHER|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
214801403|NCT01615081|OTHER|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
214801404|NCT03746353|PROCEDURE|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
214801405|NCT00565305|BEHAVIORAL|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
214801406|NCT00565305|RADIATION|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
214801407|NCT01261884|BEHAVIORAL|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
214801408|NCT01261884|BEHAVIORAL|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
214801409|NCT07035756|DEVICE|Arterial Pressure Monitoring Set Fixation Device|A newly developed fixation device designed to securely stabilize the arterial pressure monitoring set, improving patient comfort and reducing device displacement during the postoperative period in patients undergoing coronary artery bypass graft surgery.
214801410|NCT04595136|DRUG|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
214801411|NCT04595136|DRUG|normal saline|0.9% NS via nebulization
214801412|NCT02765321|BEHAVIORAL|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
214801413|NCT06884943|BEHAVIORAL|AI-guided maintenance training with visual-acoustic biofeedback|"Participants will complete AI-guided practice in the home setting in which they will interact with a web interface of the staRt web-based software for speech practice. The staRt software will present words to practice and show a real-time visual display of the acoustic signal of speech (biofeedback). On select trials, feedback will be provided by a classifier for children's r sounds, PERCEPT. Research assistants will join sessions to facilitate but will not provide direct clinical guidance to participants."
214801414|NCT06884943|BEHAVIORAL|Treatment as Usual (TAU)|Participants will return to their regular community-based care. This may consist of treatment in the school setting or by a private SLP; participants who were not previously receiving treatment may return to a no-treatment condition. Data will be collected from parents/guardians to determine the frequency of treatment, if any, received during this phase.
214801415|NCT05263232|OTHER|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
214801416|NCT06266377|OTHER|Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder|"The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0)."
214801417|NCT06266377|OTHER|Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder|A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
214801418|NCT06130358|OTHER|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
214801419|NCT06130358|OTHER|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
214801420|NCT00522457|DRUG|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
214801421|NCT04738747|BEHAVIORAL|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
214801422|NCT02962128|DIETARY_SUPPLEMENT|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high \[10% energy\] LA-containing diet for 12 weeks.
214801423|NCT02962128|DIETARY_SUPPLEMENT|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low \[2.5% energy\] LA-containing diet for 12 weeks.
214801424|NCT01691248|DRUG|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
214801425|NCT01691248|DRUG|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
214801426|NCT05308043|DIAGNOSTIC_TEST|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
214801427|NCT01740700|DEVICE|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
214801428|NCT02863575|DRUG|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
214801429|NCT02863575|DRUG|Ibuprofen|Ibuprofen capsule
214801430|NCT02863575|DRUG|Placebo|Placebo treatment
214801431|NCT07056036|DEVICE|ActiveTreatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
214801432|NCT07056036|DEVICE|Sham Treatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will se to 5% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
214801433|NCT03176550|DEVICE|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
215031148|NCT05076110|DRUG|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
214801434|NCT07064746|DIAGNOSTIC_TEST|¹²³I-MIBG SPECT/CT|Patients take Lugol's iodine 2 days and on the day of injection for thyroid blockade. ¹²³I-MIBG (3-5 MBq/kg; max 370 MBq) is given IV. Whole-body planar imaging is performed 24 h post-injection, then focused SPECT/CT of any suspicious areas with low-dose CT; children are sedated only if motion control is required.
214801435|NCT07064746|DIAGNOSTIC_TEST|SSTR PET|Patients receive an intravenous bolus of 68Ga-DOTA-TATE (1.8-2.2 MBq/kg, max 200 MBq). After a 45-60 min uptake phase, a low-dose whole-body PET/CT or PET/MRI (skull base-mid-thigh) is acquired for \~20 min; MRI or CT provides attenuation correction. Sedation used when required.
214801436|NCT00993616|DRUG|belinostat|Given IV
214801437|NCT00993616|DRUG|carboplatin|Given IV
214801438|NCT04125654|DEVICE|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
214801439|NCT06899646|DEVICE|Treatment with BTL-699-2|Four transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 5 to 10 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
214801440|NCT01907009|DRUG|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
214801441|NCT01907009|DRUG|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
214801442|NCT01572766|OTHER|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
214801443|NCT05600374|DEVICE|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
214801444|NCT07076147|OTHER|Non-Interventional Study|Non-interventional study
214801445|NCT07076108|DRUG|Normal regimen of treatment of anemia|Patients were on normal regimen of treatment of anemia.
214801446|NCT07076108|DRUG|Vitamin C|Patients were on 250 mg oral vitamin C daily for 3 months.
214801447|NCT07076108|DRUG|Vitamin C|Patients were on 500 mg oral vitamin C daily for 3 months.
214801448|NCT07076082|DRUG|Clopidogrel (Plavix) Pharmacogenetic Test Reagents|Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
214801449|NCT07076095|DRUG|IBB0979|bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor
214801450|NCT07076095|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
214801451|NCT01640769|PROCEDURE|4D Model guided delivery of cardiac pacing leads|4D model-guided placement of LV and RV leads to optimal myocardial targets, as derived from pre-procedural Cardiac MRI
214801452|NCT01640769|PROCEDURE|Standard CRT lead delivery|Standard lead delivery
214801453|NCT02358980|DEVICE|KIDNEY therapy|
214801454|NCT04637438|OTHER|Fecal Microbiota Transplantation|FMT via colonoscopy
214801455|NCT04637438|OTHER|Placebo|Water infusion via colonoscopy
214801456|NCT03457909|DEVICE|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
214801457|NCT06481800|OTHER|Progressive muscle relaxation (PMR)|patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
214801458|NCT06481800|OTHER|cnotrol group|Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests
214801459|NCT06481800|OTHER|Manual lymphatic drainage (MLD)|Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
214801460|NCT04611035|DEVICE|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
214801461|NCT06504472|DIETARY_SUPPLEMENT|ProstaThrive™ Supplement|Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.
214801462|NCT06504472|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
214801463|NCT03533946|DRUG|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.
214801464|NCT06776003|PROCEDURE|Vertebroplasty|Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy
214801465|NCT06776003|PROCEDURE|Sham Vertebroplasty|A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
214801466|NCT05293223|BIOLOGICAL|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
214801467|NCT04702425|DRUG|VOB560|Powder for concentrate for solution for infusion
214801468|NCT04702425|DRUG|MIK665|Concentrate for solution for infusion
214801469|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
214801470|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
214801471|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
214801472|NCT05826925|OTHER|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
215031149|NCT05076110|DRUG|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
215031150|NCT05076110|DRUG|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
215031151|NCT05076110|DRUG|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
215031152|NCT06527430|PROCEDURE|4 mg bupivacaine|Spinal anesthesia was applied to the patients with 4 mg bupivacaine in the lateral decubitus position.
215031153|NCT06527430|PROCEDURE|6 mg bupivacaine|Spinal anesthesia was applied to the patients with 6 mg bupivacaine in the lateral decubitus position.
214801473|NCT03630718|BEHAVIORAL|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
214801474|NCT03630718|BEHAVIORAL|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
214801475|NCT06779981|OTHER|Nasopharyngeal swabs|Completion of an electronic Diary (eDiary) and collection of nasopharyngeal swabs in case the subject experiences ILI symptoms
214801476|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
214801477|NCT04104126|OTHER|Standard of Care Physical Therapy|Will receive standard of care physical therapy
214801478|NCT04104126|OTHER|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
214801479|NCT05820737|DIETARY_SUPPLEMENT|EF2001|One capsule to be consumed once a day
214801480|NCT05820737|DIETARY_SUPPLEMENT|beLP1|One capsule to be consumed once a day
214801481|NCT05820737|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed once a day
214801482|NCT01639508|DRUG|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
214801483|NCT06186037|DRUG|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
214801484|NCT06186037|DRUG|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
214801485|NCT06784648|BIOLOGICAL|pembrolizumab (KEYTRUDA®)|fixed dose 200mg
214801486|NCT06784648|BIOLOGICAL|BI-1607|Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles
214801487|NCT06784648|BIOLOGICAL|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles
214801488|NCT06784973|DRUG|Obeldesivir|Administered orally
214801489|NCT06784973|DRUG|Obeldesivir Placebo|Administered orally
214801490|NCT06132113|DRUG|BI 764532|BI 764532
214801491|NCT06132113|DRUG|Carboplatin|Standard of care
214801492|NCT06132113|DRUG|Etoposide|Standard of care
214801493|NCT06132113|DRUG|Cisplatin|Standard of care
214801494|NCT06830785|BEHAVIORAL|rhythmic auditory stimulation incorporated in upper-limb movement training|Rhythmic auditory stimulation will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
214801495|NCT06830785|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
214801496|NCT03317847|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
214801497|NCT03317847|DRUG|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
214801499|NCT03815942|BIOLOGICAL|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
214801500|NCT03815942|DRUG|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
214801501|NCT05094180|OTHER|Face-to-face appointment|Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).
215031154|NCT05141149|DRUG|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
214801502|NCT05094180|OTHER|Remote consultation (telephone or video consultation mode)|"Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment.~In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. .~In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference."
214801503|NCT04249154|DRUG|Eligard|Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
214801504|NCT02602184|DRUG|AR/101|
214801505|NCT02602184|DRUG|Placebo|
214801506|NCT00295178|DRUG|Daptomycin|
214801507|NCT00295178|DRUG|Vancomycin|
214801508|NCT00442845|DRUG|Atorvastatin (Lipitor)|
214801509|NCT00311961|DRUG|Intravenous prednisolone|
214801510|NCT00311961|DRUG|Oral prednisolone|
214801511|NCT02704351|PROCEDURE|Surgery|Sugammadex to reverse neuromuscular blockade
214801512|NCT05147077|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group."
214801513|NCT02785913|OTHER|Laboratory Biomarker Analysis|Correlative studies
214801514|NCT02785913|DRUG|Taselisib|Given PO
214801515|NCT03745859|DEVICE|Fraxinus VBN system|Open source planning tool for bronchoscopy
214801516|NCT03717064|DRUG|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
214801517|NCT03717064|DRUG|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
214801518|NCT03852706|OTHER|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
214801519|NCT03852706|OTHER|Treatment as usual|Treatment-as-usual
214801520|NCT01298570|DRUG|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
214801521|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
214801522|NCT01298570|DRUG|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
214801523|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
214801524|NCT06955715|OTHER|Pasteurized Donor Human Milk|This is a single arm study in which all participants will receive pasteurized donor human milk sourced from the Norther Star Mother's Milk Bank (Calgary, AB, Canada)
214801525|NCT06178081|OTHER|Periodontal Healthy|Non surgical periodontal therapy
214801526|NCT03787459|DRUG|Arbidol|Oseltamivir plus Arbidol will be administrated from Days 1-7.
214801527|NCT03787459|DRUG|Placebos|Oseltamivir plus placebos will be administrated from Days 1-7.
214801528|NCT02841709|DRUG|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
214801529|NCT02841709|DRUG|Placebo|Capsules for oral administration matching the ACT-541468 capsules
214801530|NCT01929109|DRUG|LY2409021|Administered orally
214801531|NCT01292161|DRUG|Silymarin|Tab 210 mg, 630 mg, daily, six months.
214801532|NCT03508713|DRUG|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
214801533|NCT02354742|OTHER|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
214801534|NCT02354742|OTHER|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
214801535|NCT02391064|BEHAVIORAL|Cognitive evaluation|"* Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test"
214801536|NCT02391064|BEHAVIORAL|Expanded Disability Status Scale (EDSS) score|\- EDSS score
214801537|NCT04894513|OTHER|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
214801538|NCT04894513|OTHER|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
214801539|NCT00076102|DRUG|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
214801540|NCT04696419|OTHER|Different intensities of contact to dogs|Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
214801541|NCT00482521|DRUG|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
214801542|NCT02702960|PROCEDURE|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for \>3 wks
214801543|NCT02702960|RADIATION|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
214801544|NCT02702960|PROCEDURE|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
214801545|NCT02702960|DRUG|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
214801546|NCT02702960|DRUG|Mesna|administered on Days 3 and 4 with PTCy
214801547|NCT02702960|DRUG|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
214801548|NCT02702960|DRUG|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
214801549|NCT02702960|DRUG|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
214801550|NCT02702960|DRUG|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
214801551|NCT02702960|DRUG|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
214801552|NCT02702960|DRUG|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
214801553|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 low dose
214801554|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
214801555|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
214801556|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
214801557|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
214801558|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
214801559|NCT03893539|DEVICE|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
214801560|NCT06369805|OTHER|there is no intervention|there is no intervention
214801561|NCT04480788|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
214801562|NCT00788125|DRUG|carboplatin|
214801563|NCT00788125|DRUG|dasatinib|
214801564|NCT00788125|DRUG|etoposide phosphate|
214801565|NCT00788125|DRUG|ifosfamide|
214801566|NCT00788125|GENETIC|microarray analysis|
214801567|NCT00788125|GENETIC|western blotting|
214801568|NCT00788125|OTHER|immunohistochemistry staining method|
214801569|NCT00788125|OTHER|laboratory biomarker analysis|
214801570|NCT00788125|PROCEDURE|therapeutic conventional surgery|
214801571|NCT00788125|RADIATION|radiation therapy|
214801572|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
214801573|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
214801574|NCT01674530|DRUG|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
214801575|NCT04667078|DRUG|Cangrelor|administration of cangrolor by iv befor thrombectomy
214801576|NCT04667078|OTHER|best medical management|used yhe best medical management
214801577|NCT03920007|DRUG|ATSN-101|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
214801578|NCT03920007|DRUG|ATSN-101 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
214801579|NCT03920007|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
214801580|NCT03920007|DRUG|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
214801581|NCT03920007|DRUG|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
214801582|NCT03920007|DRUG|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
214801583|NCT01669538|DRUG|Galantamine|
214801584|NCT01669538|DRUG|Placebo|
214801585|NCT03581448|BEHAVIORAL|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
214801586|NCT05510648|OTHER|high-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
214801587|NCT05510648|OTHER|sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
214801588|NCT05787639|DRUG|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
214801589|NCT03611894|OTHER|radiological comparison|comparison between clinical and radiological characteristics
214801590|NCT03102580|OTHER|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
214801591|NCT00411866|DRUG|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
214801592|NCT00411866|DRUG|Ketoconazole|Ketoconazole will be available as 200mg tablets.
214801593|NCT02528760|DRUG|Metaclopramide|23\. Metoclopromide to be given 10mg iv 8 hourly
214801594|NCT02528760|DRUG|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
214801595|NCT02528760|OTHER|Placebo|
214801596|NCT01621022|DRUG|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
214801597|NCT01621022|DRUG|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
214801598|NCT01621022|DRUG|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
214801599|NCT01936922|DEVICE|GaitAid®|Provides visual and auditory cues for walking.
214801600|NCT02515422|DRUG|Ketamine|Subcutaneous infiltration of ketamine
214801601|NCT02515422|DRUG|Bupivacaine|Subcutaneous infiltration of bupivacaine
214801602|NCT02515422|DRUG|Placebo (0.9% saline solution)|
214801603|NCT00005939|RADIATION|brachytherapy|
214801604|NCT00005939|RADIATION|phosphorus P32|
214801605|NCT03900624|DRUG|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
214801606|NCT01076972|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
214801607|NCT01056796|DEVICE|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
214801608|NCT05261464|DRUG|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
214801609|NCT05261464|DRUG|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
214801610|NCT05261464|DRUG|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
214801611|NCT03252964|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
214801612|NCT03252964|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
214801613|NCT03252964|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
214801614|NCT06202716|DRUG|Cadonilimab plus CapeOX chemotherapy|Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
214801615|NCT01075581|DRUG|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
214801616|NCT01075581|DRUG|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
214801617|NCT00148681|DRUG|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
214801618|NCT00148681|DRUG|Navelbine|Intravenously every week for 12 weeks
214801619|NCT00148681|DRUG|Doxorubicin|Every 3 weeks for 12 weeks
214801620|NCT00148681|DRUG|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
214801621|NCT00148681|DRUG|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
214801622|NCT00424203|DRUG|AC regimen|
214801623|NCT00424203|DRUG|cyclophosphamide|
214801624|NCT00424203|DRUG|doxorubicin hydrochloride|
214801625|NCT00424203|PROCEDURE|adjuvant therapy|
214801626|NCT00424203|PROCEDURE|cognitive assessment|
214801627|NCT00424203|PROCEDURE|management of therapy complications|
214801628|NCT00424203|PROCEDURE|psychosocial assessment and care|
214801629|NCT00424203|PROCEDURE|quality-of-life assessment|
214801630|NCT02154308|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
214801631|NCT01843608|OTHER|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
214801632|NCT05567614|RADIATION|Liver Fibroscan|Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
214801633|NCT00872079|DEVICE|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
214801634|NCT02445300|OTHER|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
214801635|NCT02445300|OTHER|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
214801636|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
214801637|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
214801638|NCT03022773|OTHER|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
214801639|NCT02700464|DEVICE|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
214801640|NCT02700464|PROCEDURE|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
214801641|NCT01273337|BIOLOGICAL|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
214801642|NCT01273337|PROCEDURE|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
214801643|NCT01491009|DRUG|Remifentanil|IV infusion
214801644|NCT01491009|DRUG|Midazolam|IV infusion
214801645|NCT03228693|PROCEDURE|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
214801646|NCT03228693|PROCEDURE|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
214801647|NCT01465477|BIOLOGICAL|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
214801648|NCT01465477|BIOLOGICAL|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
214801649|NCT02139553|PROCEDURE|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
214801650|NCT03769285|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
214801651|NCT03769285|DRUG|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
214801652|NCT03146247|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
214801653|NCT03189888|DEVICE|apheresis|
214801654|NCT00951925|OTHER|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
214801655|NCT00890981|PROCEDURE|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
214801656|NCT00890981|PROCEDURE|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
214801657|NCT00890981|BIOLOGICAL|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
214801658|NCT00890981|DRUG|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
214801659|NCT00283699|DRUG|albendazole|Active drug or placebo dosed bid p o for 8days
214801660|NCT00283699|OTHER|placebo|an inactive substance
214801661|NCT01188707|DRUG|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
214801662|NCT06451445|DEVICE|Irreversible Electroporation (NanoKnife)|Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
214801663|NCT03149861|PROCEDURE|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
214801664|NCT03149861|PROCEDURE|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
214801665|NCT00663559|DRUG|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
214801666|NCT04438356|COMBINATION_PRODUCT|M-Health|The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
214801667|NCT00449878|DRUG|Liprotamase|Administered orally
214801668|NCT00449878|DRUG|Placebo|Administered orally
214801669|NCT01751347|DRUG|Bupivacaine|Local anesthetics
214801670|NCT01751347|DRUG|Lidocaine|Local anesthetics
214801671|NCT02237183|DRUG|Iloprost|Given via inhalation
214801672|NCT02237183|OTHER|Placebo Administration|Given via inhalation
214801673|NCT02237183|OTHER|Quality-of-Life Assessment|Ancillary studies
214801674|NCT02237183|OTHER|Questionnaire Administration|Ancillary studies
214801675|NCT05346055|BEHAVIORAL|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
214801676|NCT00090038|DRUG|rituximab|Dose, schedule,and duration specified in protocol
214801677|NCT05262621|OTHER|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
214801678|NCT05262621|OTHER|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
214801679|NCT02745977|OTHER|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
214801680|NCT03820921|DIAGNOSTIC_TEST|EUS-FNB|"EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA)."
215031155|NCT05141149|DRUG|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
215031156|NCT03157128|DRUG|LOXO-292|Oral LOXO-292
215031157|NCT06165107|OTHER|No intervention|No intervention
215031158|NCT06257277|DRUG|GBCAs|GBCAs are given per routine clinical practice.
215031159|NCT06067516|OTHER|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
214801681|NCT03820921|OTHER|Immunohistochemistry|IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
214801682|NCT00000949|DRUG|Aldesleukin|
214801683|NCT06172842|DIAGNOSTIC_TEST|Echocardiography|Multi-modality echocardiography
214801684|NCT00676871|DRUG|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
214801685|NCT00676871|DRUG|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
214801686|NCT00676871|DRUG|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
214801687|NCT00676871|DRUG|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
214801688|NCT00676871|DRUG|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
214801689|NCT00676871|DRUG|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
214801690|NCT00676871|DRUG|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
214801691|NCT01860248|DRUG|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
214801692|NCT01860248|DRUG|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
214801693|NCT02019810|DRUG|Norepinephrine|
214801694|NCT02019810|DRUG|Dobutamine and norepinephrine|
214801695|NCT01195714|DRUG|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
214801696|NCT00689013|OTHER|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
214801697|NCT00689013|OTHER|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
214801698|NCT00689013|OTHER|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
214801699|NCT05368623|DIAGNOSTIC_TEST|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
214801700|NCT05368623|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
214801701|NCT05368623|DRUG|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
214801702|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
214801703|NCT00977106|DRUG|placebo|single iv infusion
214801704|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
214801705|NCT00059852|DRUG|erlotinib hydrochloride|
214801706|NCT00059852|DRUG|gemcitabine hydrochloride|
214801707|NCT03577509|DRUG|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
214801708|NCT01573065|BEHAVIORAL|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
214801709|NCT03505853|DRUG|Givosiran|single dose of givosiran by subcutaneous (sc) injection
214801710|NCT03505853|DRUG|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
214801711|NCT03190577|GENETIC|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
214801712|NCT02973893|BIOLOGICAL|Placebo|Placebo
214801713|NCT02973893|BIOLOGICAL|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
214801714|NCT02973893|BIOLOGICAL|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
214801715|NCT03204526|DEVICE|deep brain stimulation|
214801716|NCT05473169|DEVICE|Videofluoroscopy|Swallowing assessment
214801717|NCT05904808|DRUG|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
214801718|NCT05904808|DRUG|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
214801719|NCT05904808|DRUG|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
214801720|NCT01626664|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
214801721|NCT01626664|DRUG|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
214801722|NCT01626664|DRUG|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
214801723|NCT01626664|DRUG|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
214801724|NCT02747615|OTHER|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
214801725|NCT02747615|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
214801726|NCT02747615|OTHER|transfused only allogeneic blood.|
214801727|NCT03388320|DEVICE|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
214801728|NCT01949194|DRUG|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
214801729|NCT06261229|BEHAVIORAL|Intermittent fasting|The participant will consume food about/ within 8-hour per day
214801730|NCT06261229|BEHAVIORAL|Intermittent fasting + Behavioral economic|The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week
214801731|NCT06261229|BEHAVIORAL|Intensive Lifestyle Modification|Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
215031160|NCT01179880|DRUG|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
215031161|NCT01179880|DRUG|Placebo|Matching placebo for each step
214801732|NCT06369948|PROCEDURE|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed with the patient in the supine position. A linear high-frequency ultrasound probe (GE LOGIQ/P7 ultrasound, korea/ L6-12RS probe) is initially placed in a transverse plane over the anterior inferior iliac spine (AIIS); the probe is turned slightly medial until the hyperechoic continuous shadow of the iliopubic eminence (IPE). The target will be the plane between the psoas tendon and pubic ramus. The skin puncture site will be anesthetized using lidocaine 2% after skin disinfection and draping. A 22-gauge, 100 mm echogenic needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, 25 mL of the local anesthetic solution (bupivacaine 0.5%) was injected in 5 mL increments while observing for adequate fluid spread in this plane.
214801733|NCT06369948|PROCEDURE|elective hip hemiarthroplasty without receiving a PENG block.|elective hip hemiarthroplasty without receiving a PENG block.
214801734|NCT06369948|DRUG|bupivacaine 0.5% injection|bupivacaine 0.5% injection
214801735|NCT02319148|DRUG|itraconazole|itraconazole dosed at 200 mg
214801736|NCT02319148|DRUG|diltiazem|diltiazem dosed at 240 mg
214801737|NCT02319148|DRUG|SR verapamil|SR verapamil dosed at 240 mg
214801738|NCT02319148|DRUG|PF-00489791|PF-00489791 20 mg single dose administration
214801739|NCT06399822|DIAGNOSTIC_TEST|Nail capillaroscopy|"The intervention studied as part of the project is capillaroscopy. This examination consists of visualizing the capillaries located at the base of the nail using a device called a capillaroscope. This device magnifies the image of the capillaries to clearly visualize them. Capillaries are the smallest blood vessels, which allow the passage of only one red blood cell at a time. At the nail bed, they form a network of loops and are aligned next to each other. This alignment allows them to be viewed over their entire length. Researchers have described abnormalities in capillaries that are associated with certain diseases involving microvascular damage.~The results of capillaroscopy will be reported qualitatively, for all eight long fingers examined."
214801740|NCT02583204|DEVICE|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
214801741|NCT02583204|OTHER|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
214801742|NCT04223440|OTHER|MRI|MRI on both shoulder
214801743|NCT04223440|OTHER|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
214801744|NCT01029938|PROCEDURE|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
214801745|NCT01029938|PROCEDURE|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
214801746|NCT02230007|DRUG|MEOPA|3 sessions of reeducation using MEOPA
214801747|NCT03500861|OTHER|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
214801748|NCT03437083|DRUG|Eribulin mesylate|intravenous infusion
214801749|NCT03313609|BEHAVIORAL|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
214801750|NCT03618953|BIOLOGICAL|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
214801751|NCT03618953|BIOLOGICAL|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
214801752|NCT03618953|BIOLOGICAL|Atezolizumab|monoclonal antibody; checkpoint inhibitor
214801753|NCT05692999|DRUG|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
214801754|NCT05692999|DRUG|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m\^2 Q3W
214801755|NCT05692999|DRUG|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
214801756|NCT02359331|PROCEDURE|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
214801757|NCT02359331|DRUG|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
214801758|NCT02359331|DRUG|Metronidazole|
214801759|NCT02359331|DRUG|Tetracycline|
214801760|NCT02359331|DRUG|tripotassium dicitrate bismuthate|
214801761|NCT02359331|DRUG|7 days tailored therapy Proton Pump Inhibitor|
214801762|NCT02359331|DRUG|Moxifloxacin|
214801763|NCT02359331|DRUG|Amoxicillin|
214801764|NCT03533465|BEHAVIORAL|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
214801765|NCT02314338|OTHER|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
214801766|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
214801767|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
214801768|NCT02402348|DRUG|Metformin|
214801769|NCT02931474|DRUG|Tesamorelin|Growth Hormone-Releasing
214801770|NCT02931474|OTHER|Placebo|
214801771|NCT03727568|PROCEDURE|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
214801772|NCT04271722|OTHER|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
214801773|NCT04260204|PROCEDURE|Pediatric cardiac surgery|
214801774|NCT02268669|OTHER|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
214801775|NCT04219501|OTHER|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
214801776|NCT02388763|DEVICE|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
214801777|NCT02388763|DEVICE|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
214801778|NCT00309972|DRUG|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
214801779|NCT00309972|DRUG|Experimental arm (CON):|concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
214801780|NCT05360316|DEVICE|ESWT|extracorporeal shock wave therapy
214801781|NCT05505812|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
214801782|NCT04277910|DRUG|MT2004|MT2004 oral capsules
214801783|NCT04277910|DRUG|Placebo|Placebo oral capsules
214801784|NCT01434108|DRUG|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
214801785|NCT06357338|OTHER|no intervention|No intervention
214801786|NCT02305966|PROCEDURE|surgery|All patients will receive a Delta XTEND reverse shoulder implant
214801787|NCT02305966|DEVICE|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
214801788|NCT01153984|DRUG|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
214801789|NCT02460159|DRUG|EZ 10 mg/Atorva 20 mg FDC|
214801790|NCT02460159|DRUG|EZ 10 mg/Atorva 10 mg FDC|
214801791|NCT05522270|PROCEDURE|revitalization by concentrated growth factor|modified platelet concentrate
214801792|NCT03489759|DEVICE|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
214801793|NCT03489759|DEVICE|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
214801794|NCT03916952|DIAGNOSTIC_TEST|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
214801795|NCT05339100|DRUG|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
214801796|NCT05339100|DEVICE|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
214801797|NCT05339100|DEVICE|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
214801798|NCT05375175|OTHER|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
214801799|NCT05375175|OTHER|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
214801800|NCT02268032|DRUG|DHEA|DHEA 2.2 g in vaginal ring
214801801|NCT02268032|DRUG|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
214801802|NCT02268032|DRUG|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
214801803|NCT06253676|BEHAVIORAL|Problem Management Plus (PM+)|Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
214801804|NCT04519437|DRUG|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
214801805|NCT04519437|DRUG|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
214801806|NCT06374615|DIAGNOSTIC_TEST|IgG and IgM search for specific Tick-Borne Patogens|"Ticks will be classified based on morphological characteristics by microscopy observation.~For TBP detection by molecular test, Nucleic acid extraction will be performed on ticks lysate or blood using kits MagMAX TM Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific) on MagEX STARlet platform from Hamilton. Species identification by molecular method will be performed by Sanger sequencing for Rickettsiae and Babesia, and Multi-Locus Sequence Typing will be used to characterize Borrelia.~Serum samples collected throughout the study will be tested to assess any seroconversions during the follow-up period.~Samples will be tested for the presence of specific IgG and IgM for the following TBPs: TBEV, R. typhi. R. conorii, Borrelia spp, Anaplasma, Ehrlichia and Babesia."
214801807|NCT01449071|BIOLOGICAL|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
214801808|NCT01449071|BIOLOGICAL|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
214801809|NCT01449071|BIOLOGICAL|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
214801810|NCT01449071|BIOLOGICAL|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
214801811|NCT01449071|BIOLOGICAL|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
214801812|NCT02603783|OTHER|Capsaicin|capsaicin 1,5 mg
214801813|NCT02603783|OTHER|Placebo|0,9% saline 75 ml
214801814|NCT02003053|DEVICE|Inspiratory Muscle Trainer|
214801815|NCT05884853|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
214801816|NCT05126056|OTHER|Plant stanol ester|Product with active ingredient vs product without active ingredient
214801817|NCT05126056|OTHER|Placebo|Placebo
214801818|NCT04084483|DRUG|K-161|K-161 alternate dosage
214801819|NCT04084483|OTHER|Placebo (Vehicle)|Placebo solution
214801820|NCT02029105|BIOLOGICAL|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
214801821|NCT05887297|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
214801822|NCT02194998|DRUG|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
214801823|NCT02194998|DRUG|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
214801824|NCT02194998|DRUG|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
214801825|NCT01362998|DRUG|Preservative free morphine|3mg given epidurally during the Cesarean section.
214801826|NCT01362998|DRUG|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
214801827|NCT01458405|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
214801828|NCT01458405|DRUG|Placebo|Single, blinded, intracoronary infusion of a placebo solution
214801829|NCT05402852|DRUG|EuBone ® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
214801830|NCT05402852|DRUG|placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
214801831|NCT00000941|DRUG|Pravastatin sodium|
214801832|NCT00000941|DRUG|Simvastatin|
214801833|NCT00000941|DRUG|Atorvastatin calcium|
214801834|NCT00000941|DRUG|Ritonavir|
214801835|NCT00000941|DRUG|Nelfinavir mesylate|
214801836|NCT00000941|DRUG|Saquinavir|
214801837|NCT01190748|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
214801838|NCT01190748|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
214801839|NCT01454466|PROCEDURE|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
214801840|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
214801841|NCT03873701|DIAGNOSTIC_TEST|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
214801842|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
214801843|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
214801844|NCT03479736|DRUG|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
214801845|NCT03479736|DRUG|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
214801846|NCT03479736|OTHER|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
215031162|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
214801847|NCT03259581|COMBINATION_PRODUCT|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
214801848|NCT02497781|DRUG|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
214801849|NCT02497781|DRUG|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
214801850|NCT01910766|DRUG|Coenzyme Q10|no more details
214801851|NCT01910766|DRUG|clomiphene citrate|
214801852|NCT04568681|DEVICE|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
215031163|NCT05026723|BEHAVIORAL|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
215031164|NCT05026723|BEHAVIORAL|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
214801853|NCT04524039|DEVICE|intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.
214801854|NCT04524039|DEVICE|sham intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
214801855|NCT00386113|BIOLOGICAL|Fluarix and adjuvanted influenza vaccine|
214801856|NCT02709356|DIETARY_SUPPLEMENT|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
214801857|NCT02709356|DIETARY_SUPPLEMENT|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
214801858|NCT02236130|PROCEDURE|Regional block|Single shot peripheral nerve block
214801859|NCT02236130|PROCEDURE|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
214801860|NCT02236130|DRUG|Local Anesthetic Ropivacaine|0.5% Ropivacaine
214801861|NCT02236130|DRUG|Opioids Morphine|Morphine
214801862|NCT02236130|DRUG|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
214801863|NCT00981786|DRUG|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
214801864|NCT00981786|DRUG|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
214801865|NCT03162666|DEVICE|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
214801866|NCT05127993|DEVICE|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
214801867|NCT00780520|DIETARY_SUPPLEMENT|alanine-glutamine infusion|
214801868|NCT06227065|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
214801869|NCT06227065|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
214801870|NCT06227065|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
214801871|NCT06227065|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
214801872|NCT01697020|DRUG|Mercaptopurine 20mg/ml oral suspension|50mg
214801873|NCT01697020|DRUG|Mercaptopurine 50mg tablet|50mg
214801874|NCT03082274|DIAGNOSTIC_TEST|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
214801875|NCT03082274|DIAGNOSTIC_TEST|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
214801876|NCT00454636|DRUG|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
214801877|NCT00454636|DRUG|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
214801878|NCT00454636|DRUG|Epirubicin|50 mg/m2/day, IV, every 3 weeks
214801879|NCT00454636|DRUG|Cisplatin|60 mg/m2/day, IV, every 3 weeks
214801880|NCT00454636|DRUG|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
214801881|NCT00454636|DRUG|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
214801882|NCT00454636|DRUG|Docetaxel|60 mg/m2/day, IV, every 3 weeks
214801883|NCT00454636|DRUG|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
214801884|NCT02177084|DEVICE|PTNS|
214801885|NCT03812081|DEVICE|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
214801886|NCT03812081|DEVICE|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
214801887|NCT01400113|DRUG|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
214801888|NCT01400113|DRUG|Placebo|Placebo Sublingual Tablet, single-dose
214801889|NCT01437865|DRUG|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
214801890|NCT04175496|OTHER|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
214801891|NCT04175496|OTHER|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
214801892|NCT04175496|OTHER|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
214801893|NCT04175496|OTHER|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
214801894|NCT04175496|OTHER|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
214801895|NCT03554096|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
214801896|NCT04076358|BEHAVIORAL|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
214801897|NCT00209118|DRUG|paroxetine|
214801898|NCT00003096|GENETIC|DNA ploidy analysis|
214801899|NCT00003096|GENETIC|comparative genomic hybridization|
214801900|NCT00003096|GENETIC|cytogenetic analysis|
214801901|NCT00003096|GENETIC|fluorescence in situ hybridization|
214801902|NCT01095510|BIOLOGICAL|CINRYZE|
214801903|NCT05483322|DRUG|LAM-002A|25mg capsules
214801904|NCT05376046|BIOLOGICAL|Erythrocytic parameters and thrombin generation assay measurement|Erythrocytic parameters and thrombin generation assay measurement
214801905|NCT01025037|DEVICE|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
214801906|NCT00414297|DEVICE|ECP Therapy|application of ECP Therapy to CAD Patients
214801907|NCT04371809|OTHER|DNA methylome|Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
214801908|NCT02356471|DEVICE|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
214801909|NCT02356471|OTHER|Questionnaire Administration|Ancillary studies
214801910|NCT02356471|OTHER|Quality-of-Life Assessment|Ancillary studies
214801911|NCT01890915|OTHER|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
214801912|NCT03363074|DEVICE|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
214801913|NCT03363074|DEVICE|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
214801914|NCT03856970|DRUG|Microgestin®|30 μg/1500 μg tablets for oral administration
214801915|NCT03856970|DRUG|Levothyroxine|600 μg tablets for oral administration
214801916|NCT03856970|DRUG|Glyburide|5 mg tablets for oral administration
214801917|NCT03856970|DRUG|Digoxin|0.25 mg tablets for oral administration
214801918|NCT03856970|DRUG|IW-3718|500-mg film-coated tablets for oral administration
214801919|NCT04078451|PROCEDURE|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
214801920|NCT04191564|PROCEDURE|low perfusion state|reduce SAP below 100 mmHg
214801921|NCT04191564|PROCEDURE|normal perfusion state|maintain SAP above 100 mmHg
214801922|NCT02895529|DRUG|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
214801923|NCT02895529|DRUG|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
214801924|NCT05431868|OTHER|AT LISA tri 839MP (Carl Zeiss Meditec AG)|This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
214801925|NCT05815069|DIAGNOSTIC_TEST|[18F]AlF-NOTA-pentixather PET/CT|The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
214801926|NCT05528016|PROCEDURE|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
214801927|NCT00927147|RADIATION|BNCT|Boronophenylalanine infusion followed by neutron irradiation
214801928|NCT00927147|DRUG|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
214801929|NCT00861445|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
214801930|NCT00861445|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
214801931|NCT02386033|DRUG|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
214801932|NCT02386033|DRUG|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
214801933|NCT05043233|DRUG|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
214801934|NCT03361371|DEVICE|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
214801935|NCT03361371|DEVICE|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
214801936|NCT00756288|PROCEDURE|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
214801937|NCT00756288|PROCEDURE|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
214801938|NCT05329805|BEHAVIORAL|job crafting intervention|the participated nurses will receive session about job crafting followed by activity related to job crafting
214801939|NCT02632877|DRUG|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
215031165|NCT06252077|DIETARY_SUPPLEMENT|very low ketogenic diet|1 month of active phase of very low ketogenic diet
215031166|NCT05687578|DIAGNOSTIC_TEST|Measurements Only|This is an observational study only using biospecimen and imaging-based measurements only
214801940|NCT02632877|DRUG|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
214801941|NCT05701683|DRUG|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
214801942|NCT02114697|DRUG|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
214801943|NCT02114697|BEHAVIORAL|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
214801944|NCT05903365|OTHER|Blood sampling|Additional blood samples at J100, M6, M12, M24
214801945|NCT00991848|DRUG|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
214801946|NCT01624519|PROCEDURE|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
214801947|NCT00006864|BIOLOGICAL|aldesleukin|
214801948|NCT04897802|DRUG|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
214801949|NCT04897802|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
214801950|NCT05842538|DEVICE|Triathlon|Total knee arthroplasty
214801951|NCT05478148|DEVICE|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
214801952|NCT05981625|OTHER|Giomer varnish containing surface pre-reacted glass fillers|"Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity"
214801953|NCT05438797|DRUG|Adoptive TIL-TCM transfer therapy|Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
214801954|NCT02471469|DRUG|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
214801955|NCT05561400|DEVICE|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
214801956|NCT05561400|OTHER|Placebo|sham tDCS to the right cerebellum
214801957|NCT04085770|DRUG|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
214801958|NCT04670432|DRUG|Hydroxyethylrutoside|500 mg film-coated tablet
214801959|NCT00079170|DIETARY_SUPPLEMENT|garlic|
214801960|NCT00079170|DRUG|docetaxel|
214801961|NCT03732170|DEVICE|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
214801962|NCT03732170|DEVICE|AH plus® sealer|The participant will be treated with AH plus® sealer.
214801963|NCT02521207|DRUG|Ibuprofen|
214801964|NCT02714309|DIETARY_SUPPLEMENT|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
214801965|NCT02714309|OTHER|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
214801966|NCT02714309|OTHER|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
214801967|NCT02714309|OTHER|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
214801968|NCT04238156|OTHER|Hypopressive abdominal exercises|Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
214801969|NCT00424489|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
214801970|NCT00424489|DRUG|Cyclophosphamide|
214801971|NCT00424489|DRUG|ATG (rabbit)|
214801972|NCT00424489|DRUG|Mesna|
214801973|NCT00424489|DRUG|Methylprednisolone|
214801974|NCT00424489|DRUG|G-CSF|
214801975|NCT00345410|DRUG|AVE1625 B|
214801976|NCT03614520|OTHER|Administration of olive oil|25 mL of extra virgin olive oil
214801977|NCT03614520|OTHER|Administration of red wine|150 mL or Red Wine
214801978|NCT03614520|OTHER|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
214801979|NCT03614520|OTHER|Water|Mineral water will be given as placebo
214801980|NCT03614520|OTHER|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
214801981|NCT03614520|OTHER|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
214801982|NCT03614520|OTHER|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
214801983|NCT01632709|DRUG|Bupivacaine|one injection of 10ml of .25%
214801984|NCT01632709|DRUG|Placebo|Dry needling
214801985|NCT00321542|OTHER|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
214801986|NCT03825809|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
214801987|NCT03825809|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
214801988|NCT03825809|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
214801989|NCT03825809|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
214801990|NCT03825809|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
214801991|NCT03825809|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
214801992|NCT02351726|DEVICE|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
214801993|NCT05921890|DRUG|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
214801994|NCT01856153|DIETARY_SUPPLEMENT|Before meal|
214801995|NCT01856153|DIETARY_SUPPLEMENT|With Meal|
214801996|NCT01856153|DIETARY_SUPPLEMENT|After meal|
214801997|NCT02921477|DRUG|bosutinib|
214801998|NCT00982553|DRUG|Ribavirin|800mg once daily
214801999|NCT00982553|DRUG|Raltegravir|400mg twice daily
214802000|NCT01432795|DEVICE|Gliding aids for medical compression stockings|"Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)"
214802001|NCT05960526|DRUG|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
214802002|NCT05960526|DRUG|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
214802003|NCT00925626|PROCEDURE|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
214802004|NCT00925626|PROCEDURE|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
214802005|NCT00114426|DEVICE|non-invasive mechanical ventilation|
214802006|NCT04315857|OTHER|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
214802007|NCT00072124|DRUG|cisplatin|
214802008|NCT00072124|DRUG|dacarbazine|
214802009|NCT00072124|PROCEDURE|conventional surgery|
214802010|NCT05530681|DIAGNOSTIC_TEST|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
214802011|NCT05530681|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
214802012|NCT05154721|DEVICE|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
214802013|NCT05154721|DEVICE|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
214802014|NCT00921193|DEVICE|Radiation Therapy Positioning System (RTPS)|
214802015|NCT03151018|DEVICE|Resolute Onyx|
214802016|NCT00719316|DRUG|Aliskiren|Aliskiren 300mg per day for 6 weeks
214802017|NCT00639990|OTHER|PEEP|Application of positive end expiratory pressure
214802018|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
214802019|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
214802020|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
214802021|NCT01718639|DEVICE|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
214802022|NCT01718639|DEVICE|IQP-LH-101 liquid|Oral medical device in the form of a liquid
214802023|NCT01718639|OTHER|Placebo|
214802024|NCT00710229|DRUG|Ranibizumab|intravitreal injection
214802025|NCT00710229|DRUG|Bevacizumab|intravitreal injection
214802026|NCT00394108|PROCEDURE|Determination of neuropsychological status|
214802027|NCT01189123|BIOLOGICAL|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
214802028|NCT01189123|BIOLOGICAL|fluzone by sanofi pasteur|standard dose fluzone
214802029|NCT05801263|DIAGNOSTIC_TEST|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
214802030|NCT01076452|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
214802031|NCT00860405|DRUG|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
214802032|NCT00860405|DRUG|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
214802033|NCT00010647|PROCEDURE|Acupuncture|
214802034|NCT00005006|DRUG|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
214802035|NCT00005006|DRUG|Alendronate|Alendronate 70mg/week
214802036|NCT00005006|DRUG|Teriparatide|Teriparatide 20mcg/day
214802037|NCT00537225|BEHAVIORAL|exercise|tailored multifactor CVD risk reduction
214802038|NCT05493176|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
214802039|NCT01141465|DRUG|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
214802040|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
214802041|NCT01141465|DRUG|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
214802042|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
214802043|NCT01141465|DRUG|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
214802044|NCT01141465|DRUG|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
214802045|NCT01901666|DRUG|Growth Hormone|"All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
214802046|NCT04230083|DRUG|Dienogest 2.0 mg Test Drug|Bioequivalence
214802047|NCT04230083|DRUG|Dienogest 2.0 mg Reference Product|Bioequivalence
214802048|NCT04320173|DRUG|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
214802049|NCT04320173|DRUG|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
214802050|NCT04320173|DRUG|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
214802051|NCT04705142|DRUG|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
214802052|NCT01282359|OTHER|Clinical practice group|Clinical practice group will not receive any specific education
214802053|NCT01282359|OTHER|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
214802054|NCT01282359|OTHER|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
214802055|NCT04854148|OTHER|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
214802056|NCT02465567|DRUG|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
214802057|NCT02465567|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
214802058|NCT02465567|DRUG|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
214802059|NCT02465567|DRUG|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
214802060|NCT00242346|DRUG|candesartan cilexetil|
214802061|NCT06356675|DRUG|Tislelizumab|200mg iv D1 Q3W
214802062|NCT06356675|DRUG|Anlotinib|Anlotinib 12mg D1-12 Q3W
214802063|NCT02651636|DRUG|myo-inositol,alpha-lipoic acid and folic acid|
214802064|NCT04553575|BIOLOGICAL|serology|biological blood samples withdrawn at 6, 12 and 24 months
214802065|NCT05020548|OTHER|peak inspiratory pressure 10 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 10 cmH2O
214802066|NCT05020548|OTHER|peak inspiratory pressure 15 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 15 cmH2O
214802067|NCT05020548|OTHER|peak inspiratory pressure 20 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 20 cmH2O
214802068|NCT02234466|DRUG|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
214802069|NCT02234466|DRUG|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
214802070|NCT02234466|OTHER|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
214802071|NCT04527809|DEVICE|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
214802072|NCT04527809|DEVICE|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
214802073|NCT04556214|PROCEDURE|Liver Transplant|Liver Transplant
214802074|NCT05037149|DRUG|STP707|STP707 Powder for Injection
214802075|NCT01900509|DRUG|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
214802076|NCT01900509|DRUG|Clofarabine|Route of administration: IV days 1-5.
214802077|NCT01900509|DRUG|Etoposide|Route of administration: IV days 1-5.
214802078|NCT01900509|DRUG|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
214802079|NCT01900509|DRUG|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
214802080|NCT03531021|BEHAVIORAL|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
214802081|NCT03629925|DRUG|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
214802082|NCT03629925|DRUG|Gemcitabine|1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
214802083|NCT03629925|DRUG|Cisplatin|75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
214802084|NCT03629925|DRUG|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
214802085|NCT03629925|DRUG|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
214802086|NCT05177627|OTHER|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~* educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~* drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~* classroom lessons on philosophies and theories on communication and trust~* small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
214802087|NCT05177627|OTHER|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~\- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
214802088|NCT05177627|OTHER|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~\- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~* attendance of clinical internship~* analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
214802089|NCT03141203|DRUG|Romidepsin|10mg vial for Injection
214802090|NCT03141203|DRUG|Carfilzomib|60mg vial for injection
214802091|NCT03712722|OTHER|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
214802092|NCT03378466|DRUG|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
214802093|NCT03378466|OTHER|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
214802094|NCT01074554|DRUG|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
214802095|NCT01074554|DRUG|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
214802096|NCT00497796|DRUG|maribavir|100mg twice a day for 14 weeks.
214802097|NCT00497796|DRUG|ganciclovir|1000mg three times per day for 14 weeks.
214802098|NCT02184130|OTHER|transcranial magnetic stimulation and motion stimuli|
214802099|NCT03056248|DRUG|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
214802100|NCT03056248|DRUG|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
214802101|NCT02590861|PROCEDURE|Dental implant|All participants will receive the same intervention, this is a single group study.
214802102|NCT04284488|DRUG|APG-1387 for Injection|APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.
214802103|NCT04284488|DRUG|Toripalimab|240 mg toripalimab IV on Day 1 of each 21-Day Cycle
214802104|NCT01807637|DEVICE|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
214802105|NCT05203393|DEVICE|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
214802106|NCT00150007|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214802107|NCT01282047|DRUG|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
214802108|NCT01238237|DRUG|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
214802109|NCT02771548|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
214802110|NCT04418388|DRUG|PBK-1801|Administered orally
214802111|NCT04418388|DRUG|PBK-1801|Administered orally
214802112|NCT04418388|DRUG|PBK-1801|Administered orally
214802113|NCT04614961|OTHER|Lifestyle therapy - individual|Individual therapy
214802114|NCT04614961|OTHER|Lifestyle therapy - group|Group therapy
214802115|NCT04614961|OTHER|Medical therapy|Medical therapy
214802116|NCT04614961|PROCEDURE|Bariatric surgery|Surgical and endoscopic therapy
214802117|NCT04338126|DRUG|Tranexamic acid|previously described
214802118|NCT04338126|DRUG|Placebo oral tablet|previously described
214802119|NCT03773848|PROCEDURE|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
214802120|NCT06487676|PROCEDURE|Toe transfer|Toe-to-hand transfer
214802121|NCT06487676|PROCEDURE|Replantation|Finger or thumb replantation after amputation
214802122|NCT02645526|OTHER|Woolen cap|
214802123|NCT02361047|BEHAVIORAL|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
214802124|NCT04860219|DIETARY_SUPPLEMENT|Lactoferrin|7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
214802125|NCT04276883|DRUG|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
214802126|NCT04276883|DRUG|Placebo Film|Placebo Film for BXCL501
214802127|NCT00973193|DRUG|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
214802128|NCT03043924|DRUG|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
214802129|NCT03043924|DRUG|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
214802130|NCT01184560|DRUG|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
215031584|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
214802131|NCT01184560|DRUG|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
214802132|NCT02918994|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
214802133|NCT04842045|DRUG|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
214802134|NCT04038060|BEHAVIORAL|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
214802135|NCT04038060|BEHAVIORAL|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
214802136|NCT04038060|BEHAVIORAL|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
214802137|NCT04038060|BEHAVIORAL|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
214802138|NCT02301676|BEHAVIORAL|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
214802139|NCT02301676|DRUG|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
214802140|NCT02301676|DRUG|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
214802141|NCT02301676|DEVICE|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
214802142|NCT05627427|DRUG|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
214802143|NCT05627427|DRUG|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
214802144|NCT04133376|OTHER|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
214802145|NCT04133376|OTHER|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
214802146|NCT02366780|PROCEDURE|Pump|Breast milk expression using manually or using an electric pump
214802147|NCT02556944|DEVICE|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
214802148|NCT02707848|OTHER|No intervention|
214802149|NCT05251025|OTHER|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
214802150|NCT05251025|OTHER|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
214802151|NCT05999669|OTHER|GLASS staging|use the Global Limb Anatomic Staging System (GLASS) to evaluate its correlation with clinical outcomes after revascularization
214802152|NCT02116712|DRUG|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
214802153|NCT00946803|BEHAVIORAL|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
214802154|NCT01876706|DEVICE|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
214802155|NCT03178500|DRUG|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
214802156|NCT00628888|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
214802157|NCT02648607|DEVICE|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
214802158|NCT01743378|PROCEDURE|TAP Block Ropivacaine 0,75 %|
214802159|NCT01743378|PROCEDURE|TAP Block Saline 0,9 %|
214802160|NCT04211493|BEHAVIORAL|whole-body-workout|20 minutes whole-body-workout
214802161|NCT04211493|DEVICE|EMS|Electromyostimulation-intensity 5 (muscle stimulation)
214802162|NCT04211493|DEVICE|EMS-Placebo|Electromyostimulation-intensity 1 (no muscle stimulation)
214802163|NCT00821028|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
214802164|NCT05899478|DEVICE|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
214802165|NCT05899478|DEVICE|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
214802166|NCT00201305|DRUG|Gemcitabine+5FU+Leucovorin|
214802167|NCT01674582|OTHER|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
214802168|NCT01351688|DRUG|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
214802169|NCT04590378|OTHER|intensive care unit admission ratio|intensive care unit admission ratio
214802170|NCT01825993|DRUG|L-BUPIVACAINE ; MORPHINE|
214802171|NCT01825993|DRUG|MORPHINE|
214802172|NCT01509300|BIOLOGICAL|anti-thymocyte globulin|On days -10 to -9
214802173|NCT01509300|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
214802174|NCT01509300|RADIATION|Total body irradiation|2Gy D-6 to D-4
214802175|NCT01509300|DRUG|Fludarabine|30mg/M2 once daily IV on days -8 to -4
214802176|NCT01509300|DRUG|cyclophosphamide|60 mg/kg IV on day-3 and -2
214802177|NCT01509300|DRUG|Tacrolimus|begin on 0
214802178|NCT01509300|DRUG|Mycophenolate mofetil|begin on 0
214802179|NCT01509300|DRUG|Rituximab|375mg/m2 on day +21
214802180|NCT02936856|DEVICE|Hepatic Arteriography|
214802181|NCT02293083|DRUG|trigger point injection|
214802182|NCT05711771|BEHAVIORAL|medication therapy management|Patients receive medication therapy management within the primary care office
214802183|NCT06295653|PROCEDURE|implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane|assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
214802184|NCT06495905|PROCEDURE|transbronchoscopic interventional debridement|"1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement"
214802185|NCT02339233|DEVICE|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
214802186|NCT04326998|PROCEDURE|solvent|using solvent (GuttaClear) in procedure
214802187|NCT04326998|PROCEDURE|non-solvent|non-solvent
214802188|NCT02962297|DRUG|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
214802189|NCT02962297|DRUG|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
214802190|NCT03006445|DRUG|FYU-981|
214802191|NCT02550574|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
214802192|NCT02550574|PROCEDURE|Wound Closure with 5-0 Vicryl Sutures|
214802193|NCT01541280|DRUG|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
214802194|NCT01541280|OTHER|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of \>grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
214802195|NCT01543880|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
214802196|NCT02347501|DRUG|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
214802197|NCT02157220|DEVICE|Fixed bearing prosthesis|
214802198|NCT02157220|DEVICE|Mobile bearing prosthesis|
214802199|NCT00765648|DRUG|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
214802200|NCT00765648|DRUG|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
214802201|NCT02401386|BEHAVIORAL|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
214802202|NCT03165968|DEVICE|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
214802203|NCT06354504|PROCEDURE|Non-surgical periodontal treatment|Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
214802204|NCT04364568|RADIATION|Magnetic Resonance Imaging|IRM Sequences T1, T2, FLAIR, T2\*, Cerebral Blood Flow (CBF) et mean diffusivity (MD)
214802205|NCT05233163|DRUG|Empagliflozin|Empagliflozin 10 mg oral daily for 12 weeks
214802206|NCT06192134|DEVICE|CPM device|CPM brace
214802207|NCT04745546|DEVICE|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
214802208|NCT03131310|OTHER|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
214802209|NCT02601495|BEHAVIORAL|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
214802210|NCT01282606|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
214802211|NCT01097408|DRUG|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
214802212|NCT01097408|DRUG|Placebo comparator|Placebo capsules
214802213|NCT01370408|DRUG|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
214802214|NCT01370408|DRUG|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
214802215|NCT01370408|DRUG|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
214802216|NCT02931318|BEHAVIORAL|Nevsehir|The data of the study were collected with the questionnaire
214802217|NCT00239421|DRUG|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
214802218|NCT00239421|DRUG|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
214802219|NCT06021821|OTHER|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
214802220|NCT06021821|OTHER|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
214802221|NCT06006364|OTHER|Survey|"The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire"
214802222|NCT02120443|DEVICE|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
214802223|NCT00188864|DRUG|dexamethasone|
214802224|NCT00605709|DRUG|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
214802225|NCT02958709|DRUG|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
214802226|NCT02958709|DRUG|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
214802227|NCT02958709|DRUG|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
214802228|NCT00138060|DRUG|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
214802229|NCT00138060|DRUG|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
214802230|NCT03202576|DEVICE|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
214802231|NCT00005576|BIOLOGICAL|monoclonal antibody Ch14.18|Given IV
214802232|NCT00005576|DRUG|isotretinoin|Given orally
215031167|NCT01722643|BEHAVIORAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
214802233|NCT00005576|BIOLOGICAL|aldesleukin|Given IV
214802234|NCT00005576|BIOLOGICAL|sargramostim|Given IV
214802235|NCT04439396|DRUG|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
214802236|NCT04439396|OTHER|Saline|saline fluid injection
214802237|NCT02285738|DRUG|Aspirin|81mg/day for 4 weeks
214802238|NCT02285738|DRUG|Simvastatin|Daily dose of Simvastatin for 4 weeks
214802239|NCT02285738|OTHER|Observation|participants will be observed for thrombotic evens for 4 weeks
214802240|NCT01909076|BEHAVIORAL|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
214802241|NCT01909076|BEHAVIORAL|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
214802242|NCT01909076|BEHAVIORAL|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
214802243|NCT01909076|BEHAVIORAL|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
214802244|NCT01909076|BEHAVIORAL|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
214802245|NCT04963491|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
214802246|NCT04963491|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
214802247|NCT05546359|DRUG|Amisulpride Injection|Dose finding treatment for continuation to phase 3
214802248|NCT05546359|DRUG|Dexamethasone|Standard of care treatment
214802249|NCT00119886|DRUG|Botulinum toxin|
214802250|NCT04448223|DRUG|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
214802251|NCT04448223|DRUG|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
214802252|NCT04283084|DEVICE|Virtual Reality Based Balance and Coordination Exercises|With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
214802253|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
214802254|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
214802255|NCT04055337|PROCEDURE|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
214802256|NCT02780687|DRUG|Afatinib|
214802257|NCT05586009|DRUG|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
214802258|NCT01062256|DRUG|Placebo|One placebo tablet administered orally as a single dose
214802259|NCT01062256|DRUG|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
214802260|NCT01062256|OTHER|Buckwheat Honey|10 mL administered orally as a single dose
214802261|NCT03246100|BEHAVIORAL|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
214802262|NCT03038737|OTHER|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
214802263|NCT03038737|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
214802264|NCT03157856|OTHER|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
214802265|NCT03049488|BIOLOGICAL|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
214802266|NCT03049488|OTHER|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
214802267|NCT00137397|DRUG|Tolterodine ER|
214802268|NCT00137397|DRUG|Placebo|
214802269|NCT05723822|DEVICE|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
214802270|NCT05182489|DEVICE|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
214802271|NCT05182489|DEVICE|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
214802272|NCT02165228|BEHAVIORAL|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
214802273|NCT02165228|BEHAVIORAL|Nutrition Enhancement|Nutrition education class and behavioral intervention
214802274|NCT06544018|GENETIC|Genetic analysis of NLRP3|Blood test for genetic analysis of NLRP3
214802275|NCT06544018|DEVICE|Circadian rhythm measurement|Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
214802276|NCT06544018|BIOLOGICAL|Saliva sampling|Saliva sampling for salivary melatonin determination
214802277|NCT06544018|OTHER|Questionnaire|Questionnaire to determine chronotype
214802278|NCT06544018|OTHER|AIDAI score|Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
214802279|NCT06544018|BIOLOGICAL|Blood sampling|"1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways"
214802280|NCT02729376|DRUG|galeterone|
214802281|NCT00208026|DRUG|Pimecrolimus 1% Cream|Open label single arm
214802282|NCT02221765|DRUG|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
214802283|NCT02221765|DRUG|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
214802284|NCT03967730|COMBINATION_PRODUCT|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
214802285|NCT01028469|DEVICE|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
214802286|NCT04551638|OTHER|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
214802287|NCT00891293|DRUG|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
214802288|NCT04180345|OTHER|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
214802289|NCT00896285|OTHER|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
214802290|NCT00896285|OTHER|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
214802291|NCT00896285|OTHER|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
214802292|NCT00896285|OTHER|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
214802293|NCT03806777|DRUG|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
214802294|NCT01790204|DIETARY_SUPPLEMENT|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
214802295|NCT00442390|DRUG|hydrocortisone substitution therapy versus withdrawal|
214802296|NCT03194412|DIETARY_SUPPLEMENT|Diet /nutritional|"• Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
214802297|NCT03194412|BEHAVIORAL|Physical activity|"* Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises."
214802298|NCT03194412|COMBINATION_PRODUCT|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
214802299|NCT03194412|BEHAVIORAL|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
214802300|NCT00679965|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
214802301|NCT00679965|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
214802302|NCT00679965|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
214802303|NCT00679965|DRUG|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
214802304|NCT02274129|DEVICE|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
214802305|NCT04978766|BEHAVIORAL|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
214802306|NCT05732766|BIOLOGICAL|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
214802307|NCT05512026|DEVICE|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
214802308|NCT05890157|OTHER|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
214802309|NCT01448057|DRUG|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
214802310|NCT01448057|DRUG|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
214802311|NCT05335408|DEVICE|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
214802312|NCT05335408|DEVICE|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
214802313|NCT03124966|DEVICE|Pulse Oximeter sensor|
214802314|NCT05065879|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
214802315|NCT00159965|DRUG|sertraline|flexible dose sertraline
214802316|NCT00159965|DRUG|placebo|flexible dose placebo
214802317|NCT01310049|DRUG|LEO 32731|"* Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days"
214802318|NCT02607319|DRUG|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
214802319|NCT02507375|DRUG|Erlotinib|Erlotinib will be administered as oral tablets.
214802320|NCT02507375|DRUG|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
214802321|NCT07037550|BEHAVIORAL|Strength-based intervention|"The Strength-based intervention incorporates 8-week Ambassador-led strength-based intervention including:~1. a strength-based assessment to the patient-participant and caregiver done by the Social Worker,~2. Ambassador-assisted preparation of the strength-based biography,~3. four Ambassador-led workshops, the workshop will be delivered in group of 6-8 participants by at least 2 Ambassadors, and~4. one Social Worker-led zoom video conference delivered to the caregivers."
214802322|NCT03093506|DRUG|Low-dose rhEpo|60IU/kg/week
214802323|NCT03093506|DRUG|Micro-dose rhEpo|20IU/kg/week
214802324|NCT03093506|OTHER|Placebo Control|Saline
214802325|NCT02300090|DEVICE|Test Group|Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
214802326|NCT02300090|OTHER|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
214802327|NCT06387186|DRUG|Leucine-Enriched Essential Amino Acid powder|Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
214802328|NCT05004194|PROCEDURE|Vestibular Caloric Stimulation|Irrigation of the right external ear canal
214802329|NCT05594472|DRUG|Ozonated olive oil|Topical treatment will be applied for 5 consecutive days on the erosions.
214802330|NCT05594472|DRUG|Topical garamycin cream|Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
214802331|NCT02777528|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
214802332|NCT02777528|PROCEDURE|Revascularization Procedure|Revascularization procedure of the great vessel
214802333|NCT06245265|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|In this study, 15 periodontitis patients with RA, 15 healthy individuals with RA, 15 systemic healthy periodontitis patients and 15 systemic periodontally healthy individuals will be included. ANGPTL-4 biomarker and other biomarkers (MMP-13, TNF-α, IL-6) that have not been previously analysed in the serum and saliva of both RA and periodontitis patients will be evaluated before and 3 months after COPT. Clinical parameters (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), biochemical evaluations of serum, saliva and gingival samples will be performed and correlated with clinical parameters at baseline and 3 months after COPT in all individuals with periodontitis included in the study.
214802334|NCT05165381|DEVICE|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
214802335|NCT02400047|DRUG|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
214802336|NCT02400047|DRUG|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
214802337|NCT02400047|DRUG|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
214802338|NCT05172622|DRUG|JP-2266|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
214802339|NCT05172622|DRUG|JP-2266 Placebo|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
214802340|NCT00453362|OTHER|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
214802341|NCT00453362|OTHER|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
214802342|NCT00453362|DRUG|erlotinib HCl|Tablets taken orally 150 mg/day.
214802343|NCT05281822|OTHER|The stress management training|The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
214802344|NCT04885296|DEVICE|TRP-200|JJVC Investigational Contact Lens
214802345|NCT04885296|DEVICE|JJVC Marketed Contact Lens|ACUVUE Oasys 1-Day
214802346|NCT05941403|BEHAVIORAL|Enhanced Produce Prescription Implementation|Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
214802347|NCT05467683|BEHAVIORAL|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
214802348|NCT03718234|DRUG|Subcutaneous hydrocortisone|Pulsatile subcutaneous hydrocortisone administered in 8 doses per day via SQ infusion pump for 6 weeks
214802349|NCT05395533|DRUG|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection|The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.
214802350|NCT00384852|DRUG|rhBMP-2/CPM|
214802351|NCT02203448|DEVICE|Facet Wedge spinal system|
214802352|NCT01027143|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
215031168|NCT01722643|BEHAVIORAL|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
214802353|NCT01027143|DRUG|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
214802354|NCT03730597|DEVICE|reverse shoulder arthroplasty|prosthesis implantation
214802355|NCT04344847|PROCEDURE|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
214802356|NCT06327022|OTHER|Social media-based electronic bibliotherapy|Eight weekly sessions of bibliotherapy are delivered via their daily social media.
214802357|NCT06327022|OTHER|Usual care|The routine services provided by community centers
214802358|NCT02357732|DRUG|Nivolumab|
214802359|NCT02357732|DRUG|Trametinib|
214802360|NCT02357732|DRUG|Dabrafenib|
214802361|NCT02146261|DRUG|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
214802362|NCT02146261|DRUG|Placebo|Subcutaneous administration of placebo
214802363|NCT05942612|DRUG|SHR-2001|Subcutaneous injection, single dose or multiple doses.
214802364|NCT05942612|DRUG|Placebo|Subcutaneous injection, single dose or multiple doses.
214802365|NCT04272632|DRUG|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
214802366|NCT04272632|DRUG|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
214802367|NCT04272632|DRUG|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
214802368|NCT04079088|DRUG|Placebo|Administered as specified in the treatment arm.
214802369|NCT04079088|DRUG|BIIB061|Administered as specified in the treatment arm.
214802370|NCT04079088|BIOLOGICAL|Interferon-beta1|Stable dose as prescribed by the physician.
214802371|NCT04079088|DRUG|Glatiramer acetate|Stable dose as prescribed by the physician.
214802372|NCT05863949|DIETARY_SUPPLEMENT|vitamin D +/- calcium|vitamin D 1000iU daily +/- calcium 500mg BID daily
214802373|NCT05863949|OTHER|Placebo|placebo pill x3 daily
214802374|NCT03882320|PROCEDURE|Patient Controlled Analgesia (PCA)|Patient Controlled Analgesia (PCA)
214802375|NCT02564263|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
214802376|NCT02564263|DRUG|paclitaxel|80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
214802377|NCT02564263|DRUG|docetaxel|75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle
214802378|NCT02564263|DRUG|irinotecan|180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
214802379|NCT02310165|PROCEDURE|Z-tract Insertion Technique|
214802380|NCT02310165|PROCEDURE|Coaxial Insertion Technique|
214802381|NCT02252562|DEVICE|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
214802382|NCT05803746|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
214802383|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D3|a single oral dose of vitamin D3
214802384|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D2|a single oral dose of vitamin D2
214802385|NCT01675557|DIETARY_SUPPLEMENT|Placebo|a single oral dose of placebo
214802386|NCT04797130|DEVICE|Hospital Fit 2.0|HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
214802387|NCT05106166|BEHAVIORAL|Occupational Therapy|occupational therapy sessions are based on the joint attention
214802388|NCT00751465|BEHAVIORAL|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
214802389|NCT00751465|BEHAVIORAL|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
214802390|NCT02048865|DRUG|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
214802391|NCT02048865|DRUG|Placebo drug|placebo drug 2.5mg BID for 6 months
214802392|NCT02735174|DEVICE|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
214802393|NCT02735174|OTHER|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
214802394|NCT02735174|BEHAVIORAL|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
214802395|NCT02735174|OTHER|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
214802396|NCT00001221|DRUG|Growth Hormone (Humatrope)|
214802397|NCT01087970|DRUG|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
214802398|NCT01087970|DRUG|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
214802399|NCT01087970|DRUG|Carboplatin|Administered intravenously, for a maximum of 6 cycles
214802400|NCT01087970|DRUG|Cisplatin|Administered intravenously, for a maximum of 6 cycles
214802401|NCT03026270|OTHER|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
214802402|NCT06389409|OTHER|Observation of testicular cancer patients|Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
214802403|NCT04023409|OTHER|NA: no intervention|NA: no intervention
214802404|NCT00264797|DRUG|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
214802405|NCT00264797|DRUG|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
214802406|NCT06196060|BEHAVIORAL|Visual perspective taking training|Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.
214802407|NCT06196060|BEHAVIORAL|Block building training|Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.
214802408|NCT06196060|BEHAVIORAL|Thought-bubble training|Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.
214802409|NCT06196060|BEHAVIORAL|Treatment as usual|Participants will continue to receive treatment as usual during the trial.
214802410|NCT01689480|OTHER|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
214802411|NCT01474564|OTHER|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
214802412|NCT05485909|OTHER|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
214802413|NCT05485909|DRUG|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
214802414|NCT02000856|DIETARY_SUPPLEMENT|Beetroot juice|
214802415|NCT03027661|DRUG|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
214802416|NCT03027661|DRUG|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
214802417|NCT03756857|PROCEDURE|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
214802418|NCT03756857|PROCEDURE|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
214802419|NCT01307098|DRUG|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
214802420|NCT01307098|DRUG|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
214802421|NCT01307098|DRUG|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
214802422|NCT01520051|DRUG|Mepolizumab|3 monthly intravenous infusions of 750 mg
214802423|NCT01520051|DRUG|Placebo|3 monthly intravenous infusions with saline
214802424|NCT05640453|DRUG|Pregabalin|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
214802425|NCT05640453|DRUG|Dexmedetomidine|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
214802426|NCT03816371|OTHER|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
214802427|NCT02636907|DRUG|BI 695501 Autoinjector|
214802428|NCT02636907|DRUG|BI 695501 Prefilled syringe|
214802429|NCT03048162|DRUG|sodium chloride|500 ml of 0.9% isotonic sodium chloride
214802430|NCT03048162|DRUG|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
214802431|NCT03048162|DRUG|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
214802432|NCT00003666|DRUG|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
214802433|NCT00762086|DEVICE|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
214802434|NCT00762086|OTHER|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
214802435|NCT01252069|DRUG|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
214802436|NCT01252069|DRUG|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
214802437|NCT03996512|OTHER|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
214802438|NCT00000866|BIOLOGICAL|MN rgp120/HIV-1|
214802439|NCT00000866|BIOLOGICAL|TBC-3B Vaccine|
214802440|NCT05909124|DEVICE|MCE|underwent MCE examination
214802441|NCT02596334|DRUG|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
214802442|NCT02596334|DRUG|dolutegravir|
214802443|NCT06193395|OTHER|Questionnaire|No intervention, only clinical testing of questionnaire
214802444|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
214802445|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
214802446|NCT03375593|DRUG|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
214802447|NCT03375593|DRUG|Acetaminophen 500Mg Tab|tablet
214802448|NCT03375593|DRUG|Ibuprofen 600 mg tab|tablet
214802449|NCT03902171|DEVICE|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
214802450|NCT00866593|DRUG|Generic Escitalopram|10mg/d or 20mg/d
214802451|NCT00866593|DRUG|Innovator Escitalopram|10mg/d or 20mg/d
214802452|NCT01737671|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
214802453|NCT01737671|DRUG|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
214802454|NCT01737671|DRUG|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
214802455|NCT04791553|DRUG|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
214802456|NCT06447883|BEHAVIORAL|Lifestyle modification program|The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
214802457|NCT00043381|DRUG|decitabine (5-aza-2'deoxycytidine)|
214802458|NCT04308577|OTHER|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
214802459|NCT06441435|DIETARY_SUPPLEMENT|Low protein diet with AC-134|Low protein diet combined with AC-134 Dosage: 2 capsules,three times/day
214802460|NCT06441435|OTHER|Standard treatment|Low protein diet
214802461|NCT04931667|DRUG|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
214802462|NCT03107468|OTHER|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
214802463|NCT03107468|OTHER|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
214802464|NCT04856345|OTHER|Walking with music with synchronisation|Walking with music than one can synch to
214802465|NCT04856345|OTHER|Walking with music without synchronisation|Walking with music than one cannot synch to
214802466|NCT04856345|OTHER|walking without music|Walking without music
214802467|NCT00708019|BEHAVIORAL|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls \[total time 12.3 hours\]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls \[8.0 hours\]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
214802468|NCT02116049|BEHAVIORAL|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
214802469|NCT02116049|BEHAVIORAL|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
214802470|NCT01135641|DRUG|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
214802471|NCT01135641|DRUG|Ciclosporine|
214802472|NCT01135641|DRUG|Corticosteroids|
214802473|NCT01215890|DRUG|risedronate|
214802474|NCT01215890|DRUG|placebo|
214802475|NCT02272764|DRUG|Itraconazole|Administered orally in a crossover design
214802476|NCT02272764|DRUG|ALKS 5461|Administered sublingually in a crossover design
214802477|NCT01272752|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
214802478|NCT01272752|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
214802479|NCT02232100|BEHAVIORAL|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
214802480|NCT02232100|BEHAVIORAL|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
214802481|NCT00460304|DRUG|pramlintide|
214802482|NCT00460304|PROCEDURE|continuous glucose monitoring|
214802483|NCT00526786|DEVICE|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
214802484|NCT05198050|DRUG|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
214802485|NCT05198050|DRUG|Misoprostol Tabets|a synthetic prostaglandin medication
214802486|NCT05198050|DRUG|Placebo tablets|Placebo tables with a similar appearance to letrozole
214802487|NCT03598439|BIOLOGICAL|Standard IIV4|Standard inactivated influenza vaccine
214802488|NCT03598439|BIOLOGICAL|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
214802489|NCT03598439|BIOLOGICAL|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
214802490|NCT01652001|DRUG|Malic Acid|Oral spray for application into the oral cavity
214802491|NCT01652001|OTHER|Placebo|Oral spray for application into the oral cavity
214802492|NCT03928197|BEHAVIORAL|Tilt Test|Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
214802493|NCT03928197|DEVICE|Inbody S10|Bio-electrical impedance measurement every 5 minutes
214802494|NCT03928197|DEVICE|Tape measurements|Every 5 minutes, circumference of every leg is measured using a tape measure
214802495|NCT03928197|DEVICE|SOMNOtouchTMNIBP, Vivisol, Belgium|Continous measurement of blood pressure, heart rate and saturation
214802496|NCT05101174|BEHAVIORAL|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
214802497|NCT05101174|BEHAVIORAL|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
214802498|NCT03597334|BEHAVIORAL|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
214802499|NCT00803803|DRUG|Pilocarpine Concentration|Varying concentration 0.5 to 8%
214802500|NCT00803803|DRUG|Pilocarpine Frequency|1 to 4 times daily
214802501|NCT03027830|DEVICE|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
214802502|NCT03027830|DEVICE|Conventional|Other diagnostic devices (including FFR and angiography)
214802503|NCT02067364|DEVICE|Fit & Function test|
214802504|NCT01666470|OTHER|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
214802505|NCT01271530|OTHER|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
214802506|NCT00500474|PROCEDURE|endolymphatic sac drainage with steroids|
214802507|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
214802508|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine|
214802509|NCT01815073|BIOLOGICAL|live attenuated JE vaccine|
214802510|NCT06360627|RADIATION|Computed Tomography|Computed Tomography CHEST
214802511|NCT06115889|BEHAVIORAL|Smart Taiko Drumming|Participants will play drumming with the developed Smart Taiko Drumming System for 30-45 minutes three times per week for 16 weeks, in addition to usual care.
214802512|NCT05013112|DRUG|SGLT2 inhibitor|Empagliflozin 20mg once daily from discharge
214802513|NCT05013112|DRUG|Metformin|Metformin 500mg twice daily from discharge
214802514|NCT05013112|OTHER|Placebo|Placebo group
214802515|NCT05210738|DEVICE|Single incision sling|Single incision sling is used to treat occult SUI
214802516|NCT05210738|DRUG|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
214802517|NCT03354221|DEVICE|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
214802518|NCT03354221|OTHER|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
214802519|NCT03354221|OTHER|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
214802520|NCT03354221|OTHER|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
214802521|NCT01822600|DRUG|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
214802522|NCT01822600|DRUG|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
214802523|NCT00002132|DRUG|Itraconazole|
214802524|NCT00002132|DRUG|Fluconazole|
214802525|NCT00183807|DRUG|irinotecan, cisplatin, celecoxib|
214802526|NCT02921737|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
214802527|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
214802528|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
214802529|NCT04836000|OTHER|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
214802530|NCT05723809|DEVICE|Percussive Therapy Device|Same as group description
214802531|NCT05723809|BEHAVIORAL|Physical Therapy|Same as group description
214802532|NCT01826383|BEHAVIORAL|Active-Video|This group will watch an active-video with pain management strategies for parents
214802533|NCT01826383|BEHAVIORAL|Placebo Video|This group will watch a placebo-video describing immunization generally.
214802534|NCT04164745|DRUG|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
214802535|NCT04164745|BIOLOGICAL|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
214802536|NCT00422747|DRUG|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
214802537|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
214802538|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (40 mg/ml) with needles|Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
214802539|NCT00986297|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
214802540|NCT03472365|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214802541|NCT03472365|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
214802542|NCT03472365|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
214802543|NCT03472365|DRUG|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
214802544|NCT03593980|DIETARY_SUPPLEMENT|Cranberry juice|400ml cranberry juice
214802545|NCT05332925|DRUG|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
214802546|NCT01728922|DIETARY_SUPPLEMENT|5000IU vitamin D|Vigantol Oil
214802547|NCT01728922|DIETARY_SUPPLEMENT|10000IU vitamin D|Vigantol Oil
214802548|NCT01728922|OTHER|Placebo|Placebo Oil
214802549|NCT06341322|BEHAVIORAL|Standard letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, based on the current invite letter.
214802550|NCT06341322|BEHAVIORAL|Behaviorally informed letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, with incorporates severally behaviorally informed components, including an active choice prompt, social norm, call to action, chunking and simplification.
214802551|NCT06341322|BEHAVIORAL|Home testing colorectal cancer kit|The home testing kit is included with the reminder letter, instead of the usual process of responding to the letter to order the kit
214802552|NCT06427057|DRUG|Cadonilimab plus chemotherapy|AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）
214802553|NCT06427057|DRUG|Cadonilimab plus TKI|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)
214802554|NCT03769844|DRUG|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
214802555|NCT01944267|PROCEDURE|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
215031169|NCT05423613|PROCEDURE|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
215031170|NCT04639726|DIETARY_SUPPLEMENT|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
214802556|NCT01944267|PROCEDURE|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
214802557|NCT01944267|PROCEDURE|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
214802558|NCT01787058|OTHER|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
214802559|NCT03006419|DRUG|Basiliximab|Standard induction therapy
214802560|NCT03006419|DRUG|Thymoglobulin|Induction therapy
214802561|NCT03883906|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
214802562|NCT03063814|BEHAVIORAL|APP|See arm description
214802563|NCT03063814|BEHAVIORAL|PHY|see arm description
214802564|NCT02367638|BIOLOGICAL|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
214802565|NCT02367638|BIOLOGICAL|VARIVAX|VARIVAX is administered by subcutaneous injection
214802566|NCT03237364|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
214802567|NCT00242021|BEHAVIORAL|Fatty acid composition of a margarine (spread)|
214802568|NCT04659421|DRUG|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
214802569|NCT03982485|DRUG|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
214802570|NCT03982485|DRUG|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
214802571|NCT03982485|DRUG|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
214802572|NCT03982485|PROCEDURE|Surgery|Surgery
214802573|NCT00486837|DRUG|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
214802574|NCT03239509|PROCEDURE|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
214802575|NCT03239509|PROCEDURE|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
214802576|NCT01037283|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
214802577|NCT02468778|DEVICE|HeartMate PHP|The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
214802578|NCT02468778|DEVICE|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
215031171|NCT04639726|OTHER|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
215031172|NCT06802809|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247 (Crispact®)|Crispact® is a probiotic food supplement containing Lactobacillus crispatus M247.
214802579|NCT00660647|DRUG|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
214802580|NCT00660647|DRUG|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
214802581|NCT01197339|BEHAVIORAL|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
214802582|NCT01197339|BEHAVIORAL|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
214802583|NCT01197339|BEHAVIORAL|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
214802584|NCT01197339|BEHAVIORAL|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
214802585|NCT01197339|BEHAVIORAL|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
214802586|NCT05240222|BEHAVIORAL|Pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
214802587|NCT05240222|OTHER|Sham comparator|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
214802588|NCT00858923|DEVICE|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
214802589|NCT05070260|DRUG|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
214802590|NCT05070260|DRUG|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
214802591|NCT00350246|PROCEDURE|Laser Refractive Surgery|
214802592|NCT00743548|DEVICE|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
214802593|NCT00743548|DEVICE|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
214802594|NCT00147030|PROCEDURE|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
214802595|NCT00262964|DRUG|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
214802596|NCT00262964|DRUG|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
215031173|NCT06802809|OTHER|Placebo|The placebo does not contain the active probiotic strain and consists of inactive excipients.
215031174|NCT00023595|PROCEDURE|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
215031175|NCT00023595|DRUG|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
214802597|NCT00262964|DRUG|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
215031176|NCT00023595|PROCEDURE|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
215031177|NCT01472185|DRUG|Ranolazine|Ranolazine tablets administered orally twice daily.
215031178|NCT01472185|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily.
214802598|NCT02307734|BEHAVIORAL|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
214802599|NCT02307734|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
214802600|NCT01155986|DRUG|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
214802601|NCT01155986|DRUG|Placebo topical plaster|Topical hydrogel plaster
214802602|NCT00920764|DRUG|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
214802603|NCT00920764|DRUG|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
214802604|NCT00920764|DRUG|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
214802605|NCT00920764|DRUG|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
214802606|NCT04057144|BEHAVIORAL|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
214802607|NCT04057144|BEHAVIORAL|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
214802608|NCT04057144|BEHAVIORAL|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
214802609|NCT02590159|DEVICE|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
214802610|NCT02552342|DRUG|methylprednisolone|
214802611|NCT02552342|DRUG|Normal saline|
214802612|NCT03916497|DIAGNOSTIC_TEST|Quantiferon CMV|Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
214802613|NCT02134080|DRUG|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
214802614|NCT02134080|DRUG|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
214802615|NCT06302374|BIOLOGICAL|GR2001|intramuscular injection
214802616|NCT06302374|BIOLOGICAL|Placebo|intramuscular injection
214802617|NCT06302374|BIOLOGICAL|HTIG|intramuscular injection
214802618|NCT06302374|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
214802619|NCT01258725|PROCEDURE|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI\<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
215031179|NCT01472185|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
214802620|NCT06195618|BIOLOGICAL|Peptide (neoantigen) pulsed autologous Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses, one weekly after surgery.
214802621|NCT02303808|DEVICE|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
214802622|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
214802623|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
214802624|NCT04559854|BEHAVIORAL|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
214802625|NCT04617327|RADIATION|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is \<3 mm in any dimension, or rotation is \<3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
215031180|NCT01472185|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
215031181|NCT03941561|DRUG|S-1 for 9 months|S-1 for 9 months after D2 resection
214802626|NCT04483102|DEVICE|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
214802627|NCT04483102|PROCEDURE|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
214802628|NCT03130699|BEHAVIORAL|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
214802629|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
214802630|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
214802631|NCT00741871|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
214802632|NCT01199861|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
214802633|NCT01199861|DRUG|Placebo|Matching placebo capsules for oral administration.
214802634|NCT01199861|BIOLOGICAL|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
214802635|NCT01199861|BIOLOGICAL|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
214802636|NCT04551885|DRUG|FT516|Experimental Interventional Therapy
214802637|NCT04551885|DRUG|Avelumab|Monoclonal antibody
214802638|NCT04551885|DRUG|Cyclophosphamide|Lympho-conditioning agent
214802639|NCT04551885|DRUG|Fludarabine|Lympho-conditioning agent
214802640|NCT04551885|DRUG|IL-2|Biologic response modifier
214802641|NCT00843609|DEVICE|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
214802642|NCT05055921|DEVICE|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|"The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.~Other Names:~* Unpinning Termination Therapy~* Multi-stage therapy~* Multi-stage electrotherapy~* MultiPulse Therapy"
214802643|NCT06075654|OTHER|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
214802644|NCT02370407|DEVICE|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
214802645|NCT02370407|DEVICE|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
214802646|NCT04574193|DEVICE|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
214802647|NCT04574193|OTHER|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
214802648|NCT06307028|BEHAVIORAL|SISTA-P Intervention|This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
214802649|NCT00669864|DRUG|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
214802650|NCT00669864|DRUG|metformin|Tablets, 1000 - 2000 mg daily
214802651|NCT04996238|PROCEDURE|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
214802652|NCT00718679|DRUG|IVN201|Intralymphativ injection of the study drug
214802653|NCT00718679|DRUG|Placebo|
215031182|NCT03941561|DRUG|S-1 for 1 year|S-1 for 1 year after D2 resection
214802654|NCT02899390|BEHAVIORAL|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
214802655|NCT03670238|DEVICE|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
214802656|NCT03670238|DEVICE|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
214802657|NCT02602379|OTHER|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
214802658|NCT04260503|OTHER|Monitoring of the gut-microbiome and ultrasound elasticity.|The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
214802659|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome before and after operation.
214802660|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome along with the disease progress.
214802661|NCT04260503|OTHER|Monitoring of the gut-microbiome.|The investigator will investigate the alteration of gut-microbiome according to the normal development.
214802662|NCT00212069|DRUG|gemcitabine, carboplatin|
214802663|NCT02623088|OTHER|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
214802664|NCT05274711|OTHER|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
214802665|NCT05274711|OTHER|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
214802666|NCT00450307|BIOLOGICAL|monoclonal antibody 3F8|
214802667|NCT00450307|BIOLOGICAL|sargramostim|
214802668|NCT03186911|BEHAVIORAL|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
214802669|NCT00140517|DRUG|sulphadoxine-pyrimethamine|
214802670|NCT00140517|DRUG|chloroquine|
214802671|NCT06343948|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214802672|NCT06343948|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
214802673|NCT06343948|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
214802674|NCT06343948|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
214802675|NCT06343948|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
214802676|NCT04442906|DRUG|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
214802677|NCT04442906|DRUG|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
214802678|NCT04442906|DRUG|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
214802679|NCT01326403|DRUG|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
214802680|NCT05864976|DEVICE|Support Vector Machine|Machine learning algorithm
214802681|NCT02437149|BEHAVIORAL|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
214802682|NCT02437149|BEHAVIORAL|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
214802683|NCT02437149|BEHAVIORAL|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
215031183|NCT06337214|BEHAVIORAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
215031184|NCT04240509|DRUG|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
215031185|NCT01074346|DRUG|Interferon-β-1a|Interferon-β-1a according to the standard practice
214802684|NCT01241942|DEVICE|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
214802685|NCT01241942|OTHER|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
214802686|NCT05742529|PROCEDURE|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
214802687|NCT05742529|PROCEDURE|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
214802688|NCT04259229|OTHER|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
214802689|NCT04259229|OTHER|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
214802690|NCT00462852|DRUG|dalteparin|
214802691|NCT00462852|DRUG|gemcitabine hydrochloride|
214802692|NCT00462852|OTHER|diagnostic laboratory biomarker analysis|
214802693|NCT03743480|OTHER|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
214802694|NCT06063135|OTHER|Physical Exercise Intervention|Two strength training session per week and one endurance training session per week
214802695|NCT05946993|OTHER|Physiotherapy|participant will have 2 x 1h exercise classes per week with a physiotherapist, who will develop individualized plans based on medical history and scan reviews. Participants will be progressively guided through the programme, incrementally increasing in intensity or with modifications based on symptomatic presentation. This will be based on their baseline strength and cardiovascular fitness testing and grounded on evidence-based protocols previously demonstrating an effect in this patient population. Individualised tailored exercise programme which includes strength and conditioning.
214802696|NCT05946993|OTHER|Dietitian Support|The main goal of the nutritional intervention is to improve the diet quality of each patient using a standardized nutrition assessment, offering evidence-based diet group education and developing personalized nutrition goals. Participants will be progressively guided through the nutrition education programme; with modifications to the individual's usual diet, thereby recognizing personal eating patterns and preferences, which form the basis for individualized dietary counselling. The dietary counselling identifies the type, amount, and frequency of feeding and specifies the caloric/protein level to attain, together with any restrictions and limited or increased individual dietary components.
215031186|NCT00823797|DRUG|Bendamustine Hydrochloride|Given IV
215031187|NCT00823797|OTHER|Quality-of-Life Assessment|Ancillary studies
215031188|NCT06315998|DEVICE|Magnetocardiography|Magnetocardiography
215031189|NCT02507726|DEVICE|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
215031190|NCT00748774|BEHAVIORAL|Questionnaire|Two questionnaires taking about 10 minutes to complete.
214802697|NCT05946993|OTHER|Nursing and Psychosocial|Nursing, Psycho-oncology, pastoral care and social work-led sessions to inform participants on items including diagnosis shock, acceptance, coping with relationship changes with their partner and their roles, fear of uncertainty and the future, medication management, masculinity (male values being strong, capable, independent), practical management of bills, and household tasks. There will be an inclusion of practical information sessions including health systems information and managing side effects such as urinary symptoms, hot flushes, penile shortening, and loss of body hair.
214802698|NCT00535106|DEVICE|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
214802699|NCT00535106|DEVICE|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
214802700|NCT00535106|OTHER|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
214802701|NCT04552704|BIOLOGICAL|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
214802702|NCT04552704|DRUG|Placebo Administration|Given IV
214802703|NCT02099500|PROCEDURE|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
214802704|NCT02099500|OTHER|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
214802705|NCT02385097|DRUG|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
214802706|NCT02385097|DRUG|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
214802707|NCT01303978|DRUG|APD421|Single dose
214802708|NCT03441581|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
214802709|NCT03473314|DRUG|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
214802710|NCT00680121|DRUG|Benfotiamine|Benfotiamine 600 mg
214802711|NCT00680121|DRUG|Placebo|Placebo
214802712|NCT01822548|DRUG|Vildagliptin|100 mg daily
214802713|NCT01822548|DRUG|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
214802714|NCT01822548|DRUG|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
214802715|NCT03229655|PROCEDURE|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
214802716|NCT02809183|DRUG|Placebo|oral suspension
214802717|NCT02809183|DRUG|TRC101|oral suspension
214802718|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
214802719|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
214802720|NCT02545998|OTHER|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
214802721|NCT05187026|OTHER|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
214802722|NCT02942966|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
214802723|NCT03091946|OTHER|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
214802724|NCT03091946|OTHER|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
214802725|NCT04782726|OTHER|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
214802726|NCT04782726|OTHER|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
214802727|NCT03909659|BEHAVIORAL|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
214802728|NCT00858910|OTHER|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
214802729|NCT00858910|OTHER|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home."
214802730|NCT05802966|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
214802731|NCT03118466|DRUG|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
214802732|NCT03118466|DRUG|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
214802733|NCT03118466|DRUG|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
214802734|NCT03118466|DRUG|Mitoxantrone|It interfere with cell reproduction
214802735|NCT03401710|DRUG|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
214802736|NCT02534948|BEHAVIORAL|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
214802737|NCT01341366|OTHER|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
214802738|NCT01341366|OTHER|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
214802739|NCT05295758|BEHAVIORAL|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
214802740|NCT05722600|OTHER|Grape juice|Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
214802741|NCT05722600|OTHER|Placebo drink|Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
214802742|NCT01328730|DEVICE|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
214802743|NCT01328730|DEVICE|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
214802744|NCT02678195|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
214802745|NCT02678195|DRUG|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
214802746|NCT03955770|COMBINATION_PRODUCT|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).
214802747|NCT03955770|COMBINATION_PRODUCT|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
214802748|NCT05090657|COMBINATION_PRODUCT|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
214802749|NCT04366609|DRUG|Methylphenidate|Treatment with methylphenidate through dose escalation
214802750|NCT05282888|OTHER|blood sample|in order to develop a diagnostic assay using an innovative technology by imaging flow cytometry to identify red blood cell morphological anomalies in the diagnosis flowchart of anemia.
214802751|NCT00854321|DRUG|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
214802752|NCT00854321|DRUG|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
214802753|NCT03319056|OTHER|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
214802754|NCT05078008|PROCEDURE|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
214802755|NCT05078008|PROCEDURE|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
214802756|NCT02463149|BEHAVIORAL|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
214802757|NCT00696449|DRUG|Adapalene|All Subjects will treat the face once daily in the evening.
214802758|NCT00696449|BEHAVIORAL|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
214802759|NCT00696449|BEHAVIORAL|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
214802760|NCT00696449|BEHAVIORAL|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
214802761|NCT00696449|BEHAVIORAL|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
214802762|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
214802763|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
214802764|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
214802765|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
214802766|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
214802767|NCT06004102|OTHER|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
214802768|NCT01623622|DRUG|HC-58|once or more / week
214802769|NCT01623622|DRUG|Placebo|once or more / week
214802770|NCT06272409|DRUG|DEP114|DEP114 oral solution
214802771|NCT06272409|DRUG|Desloratadine 0.5 MG/ML|Desloratadine oral solution
214802772|NCT00265304|DRUG|Ketoprofen|
214802773|NCT02572310|DEVICE|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
214802774|NCT01402037|DRUG|Glucose|Glucose 20% intravenous
214802775|NCT01402037|DEVICE|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
214802776|NCT03472729|OTHER|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
214802777|NCT05047406|DIETARY_SUPPLEMENT|Bacillus clausii Probiotic liquid|mini bottles for oral administration containing 2 million spores of Bacillus clausii
214802778|NCT04826809|DEVICE|N95 mask|Standard 1870 N95 one time use mask
214802779|NCT04826809|DEVICE|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
214802780|NCT04826809|DEVICE|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
214802781|NCT04154033|DRUG|Naltrexone|Topical naltrexone cream (1%)
214802782|NCT04154033|OTHER|Placebo Cream|Topical placebo cream
214802783|NCT04195165|BEHAVIORAL|SIT|For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.
214802784|NCT04195165|BEHAVIORAL|ACTIVE|For the ACTIVE+EX condition, the subject will be asked to take \>10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.
214802785|NCT04195165|BEHAVIORAL|EX|The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
214802786|NCT04835922|PROCEDURE|Intercostal Nerve Block|: Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)
214802787|NCT04835922|PROCEDURE|Peritract Infiltration|At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
214802788|NCT01820026|DRUG|Imipenem|second line therapy
214802789|NCT01820026|DRUG|Vancomycin|Second line therapy
214802790|NCT01820026|DRUG|azithromycin|Second line therapy
214802791|NCT01820026|DRUG|Cefotaxime|Standard antibiotic therapy
214802792|NCT01820026|DRUG|Amoxicillin|Standard therapy
214802793|NCT01493908|DRUG|High price|Acetaminophen label as high price
214802794|NCT01493908|DRUG|Low price|Acetaminophen label as low price
214802795|NCT01493908|DRUG|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
214802796|NCT01493908|DRUG|No price|acetaminophen. No price - price issue not introduced to participants.
214802797|NCT01493908|DRUG|Free of charge|Acetaminophen. participants aware the product is free of charge
214802798|NCT04528420|OTHER|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
214802799|NCT05238493|DRUG|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
214802800|NCT05238493|DRUG|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
214802801|NCT04173754|PROCEDURE|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
214802802|NCT00003313|BIOLOGICAL|filgrastim|
214802803|NCT00003313|DRUG|amifostine trihydrate|
214802804|NCT00003313|DRUG|carboplatin|
214802805|NCT00003313|DRUG|paclitaxel|
214802806|NCT00003313|RADIATION|radiation therapy|
214802807|NCT01211548|OTHER|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
214802808|NCT02789033|DRUG|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
214802809|NCT02789033|DRUG|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
214802810|NCT02789033|DRUG|Placebo|placebo
214802811|NCT05328713|DIAGNOSTIC_TEST|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
214802812|NCT03437356|OTHER|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm
214802813|NCT03437356|DRUG|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, \>70kg, except 80 mg OD if female \>70 years or Cr \>1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
214802814|NCT04504513|DRUG|Trilaciclib|"Trilaciclib is a highly potent, selective, and reversible cyclin-dependent kinase 4/6 inhibitor administered intravenously prior to chemotherapy for chemotherapy-induced myelosuppression (CIM).~In patients being treated for SCLC, trilaciclib transiently maintains G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thus protecting the cells from damage by cytotoxic chemotherapy (myelopreservation). This can reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions."
214802815|NCT04028453|OTHER|Survey|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
214802816|NCT00006166|PROCEDURE|Transjugular intrahepatic portasystemic shunts (TIPS)|
214802817|NCT00006166|PROCEDURE|Total paracentecis (TP)|
214802818|NCT00301756|DRUG|Belinostat|Given IV
214802819|NCT00301756|OTHER|Laboratory Biomarker Analysis|Correlative studies
214802820|NCT04567342|OTHER|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
214802821|NCT04567342|OTHER|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
214802822|NCT04567342|OTHER|No personal contact attempt|No personal contact attempts will be made.
214802823|NCT04567342|OTHER|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
214802824|NCT06158269|DRUG|DVRd|The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
214802825|NCT04304963|OTHER|NO intervention - observational study|NO intervention - observational study
214802826|NCT06970613|BEHAVIORAL|Watching cartoons|While watching the cartoons, local anesthesia will be applied and restorative treatments will be completed.
214802827|NCT06970613|BEHAVIORAL|Robot cat|Local anesthesia will be applied with the robot cat in their lap during the treatment and their restorative treatments will be completed.
214802828|NCT02206659|DRUG|Telmisartan|
214802829|NCT02206659|DRUG|Placebo|
214802830|NCT04871737|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
214802831|NCT05559268|DRUG|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
214802832|NCT05559268|DRUG|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
214802833|NCT00249275|DEVICE|spectacles|
214802834|NCT01539109|BEHAVIORAL|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
214802835|NCT01539109|PROCEDURE|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
214802836|NCT01539109|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
214802837|NCT00431548|DRUG|100% O2|
214802838|NCT04182009|DEVICE|Omron NE-U17 Ultrasonic nebuliser|The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.
214802839|NCT04182009|DEVICE|Akita Jet Inhalation System|The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
214802840|NCT02028936|OTHER|Grape juice R@isol|
214802841|NCT02028936|OTHER|Commercially-available grape juice|
214802842|NCT00002595|DRUG|toremifene|
214802843|NCT00002595|PROCEDURE|conventional surgery|
214802844|NCT06134778|OTHER|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
214802845|NCT01208064|DRUG|pazopanib hydrochloride|
214802846|NCT01208064|OTHER|laboratory biomarker analysis|
214802847|NCT01208064|OTHER|pharmacogenomic studies|
214802848|NCT01208064|OTHER|pharmacological study|
214802849|NCT01208064|PROCEDURE|quality-of-life assessment|
214802850|NCT01840371|DRUG|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation"
214802851|NCT01840371|DRUG|Experimental sedation|"Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation"
214802852|NCT00290056|DRUG|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
214802853|NCT02923947|DRUG|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
214802854|NCT02070237|DRUG|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
214802855|NCT02183064|DRUG|Meloxicam|
214802856|NCT02183064|DRUG|NSAID|
214802857|NCT06032351|OTHER|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
214802858|NCT06032351|OTHER|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
214802859|NCT00597194|PROCEDURE|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
214802860|NCT04770623|DRUG|Docetaxel|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
214802861|NCT04770623|DRUG|Irinotecan|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
214802862|NCT02014181|DIETARY_SUPPLEMENT|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
214802863|NCT00158119|BEHAVIORAL|InVEST (Increased Velocity Exercise Specific to Task)|
214802864|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
214802865|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
214802866|NCT03415906|COMBINATION_PRODUCT|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
214802867|NCT03415906|DRUG|valsartan|Angiotensin receptor inhibition alone
214802868|NCT00004109|DRUG|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
214802869|NCT00004109|RADIATION|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
214802870|NCT00978900|DIETARY_SUPPLEMENT|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
214802871|NCT00978900|DIETARY_SUPPLEMENT|Water|
214802872|NCT03510364|BEHAVIORAL|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
214802873|NCT01891292|DRUG|Enalapril|0.25-0.35 mg/kg/day
214802874|NCT01891292|DRUG|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
214802875|NCT06355245|DIAGNOSTIC_TEST|Blood sampling|Collection of blood samples
214802876|NCT01570465|OTHER|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
214802877|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
214802878|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
214802879|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
214802880|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
214802881|NCT05639634|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
214802882|NCT05639634|OTHER|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
214802883|NCT05639634|DIETARY_SUPPLEMENT|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
214802884|NCT01226797|DRUG|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
214802885|NCT01226797|DRUG|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
214802886|NCT04917978|DIAGNOSTIC_TEST|Hematological Phenotype Analysis|Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio- Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).
214802887|NCT05718609|DRUG|Rabeprazole|proton-pump inhibitor (PPI)
214802888|NCT05718609|DRUG|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
214802889|NCT05718609|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214802890|NCT05718609|DRUG|Furazolidone|Antibiotic for H. pylori eradication
214802891|NCT05718609|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
214802892|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
214802893|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
214802894|NCT05504603|DRUG|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
214802895|NCT05504603|DRUG|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
214802896|NCT01206257|DRUG|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
214802897|NCT04117841|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
214802898|NCT00208286|DEVICE|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
214802899|NCT00208286|DEVICE|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
214802900|NCT02219945|OTHER|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
214802901|NCT00715442|DRUG|Sunitinib|50 mg by mouth daily for 28 consecutive days
214802902|NCT00715442|PROCEDURE|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
214802903|NCT06115265|BEHAVIORAL|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
214802904|NCT06115265|BEHAVIORAL|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
214802905|NCT03752541|BIOLOGICAL|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
214802906|NCT04512768|BEHAVIORAL|Transdiagnostic Internet-delivered Cognitive Behaviour Therapy|All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
214802907|NCT04512768|BEHAVIORAL|Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia|A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
214802908|NCT06379009|OTHER|Training|12 week home-based training program
214802909|NCT05557565|DRUG|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
214802910|NCT03262974|DIAGNOSTIC_TEST|PCR|PCR
214802911|NCT03262974|DIAGNOSTIC_TEST|HPLC-UV|HPLC-UV
214802912|NCT05287984|DRUG|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
214802913|NCT05287984|DRUG|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
214802914|NCT03089203|BIOLOGICAL|CART-PSMA-TGFβRDN cells|autologous CAR T cells
214802915|NCT03089203|DRUG|Cyclophosphamide|300 mg/m2/day given over 3 days
214802916|NCT03089203|DRUG|Fludarabine|30 mg/m2/day given over 3 days
214802917|NCT01302314|BEHAVIORAL|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
214802918|NCT06543524|OTHER|Care of premature infants|No intervention was performed
214802919|NCT00284102|PROCEDURE|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
214802920|NCT04538040|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
214802921|NCT02215174|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
214802922|NCT04016636|OTHER|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
214802923|NCT04812587|BEHAVIORAL|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
214802924|NCT03051685|DRUG|DFN-15 Dose 1|
214802925|NCT03051685|DRUG|DFN-15 Dose 2|
214802926|NCT03051685|DRUG|DFN-15 Dose 3|
214802927|NCT03051685|DRUG|Active Comparator|
214802928|NCT02161874|DEVICE|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
214802929|NCT02161874|DEVICE|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
214802930|NCT01376128|DRUG|Paroxetine|
214802931|NCT04089683|OTHER|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
214802932|NCT03203148|DIAGNOSTIC_TEST|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
214802933|NCT03137563|OTHER|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
214802934|NCT03979248|DRUG|BMS-986165|Specified dose on specified days.
214802935|NCT03979248|DRUG|Rabeprazole|Specified dose on specified days.
214802936|NCT03623048|OTHER|chlorhexidine|antibacterial and anti-inflammatory mouthwash
214802937|NCT03623048|OTHER|saline|anti-inflammatory cleansing mouthwash
214802938|NCT03623048|OTHER|Propolis extract|antibacterial mouthwash
214802939|NCT03623048|OTHER|pomegranate extract|antibacterial mouthwash
214802940|NCT04232150|DRUG|single-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
214802941|NCT04232150|DRUG|Double-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
214802942|NCT04232150|PROCEDURE|spinal anesthesia with no sedation.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
214802943|NCT00870922|PROCEDURE|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
214802944|NCT01946347|OTHER|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
214802945|NCT01946347|OTHER|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
214802946|NCT01506830|PROCEDURE|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
214802947|NCT01506830|PROCEDURE|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
214802948|NCT01606306|DRUG|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
214802949|NCT01606306|DRUG|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
214802950|NCT01606306|DRUG|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
214802951|NCT06249399|OTHER|Aerobic Exercise|Aerobic Exercise training will be provided three days a week, 45 minutes a day, for 12 weeks. Patients will be subjected to submaximal aerobic exercise with rhythmic movements without equipment via video conference accompanied by a physiotherapist.
214802952|NCT06249399|BEHAVIORAL|Behavioral Treatment Program|Behavioral Treatment Program will be completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.
214802953|NCT02761096|DEVICE|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
214802954|NCT02761096|OTHER|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
214802955|NCT01107236|DRUG|IW-6118|Single dose
214802956|NCT01107236|DRUG|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
214802957|NCT01107236|DRUG|Naproxen Sodium|Single dose
214802958|NCT02740608|DEVICE|OrganOx metra|Normothermic Machine Liver Perfusion
214802959|NCT02898623|OTHER|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
214802960|NCT05290181|OTHER|A support program with pilates exercise and whatsapp text message|Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
214802961|NCT03314025|DRUG|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
214802962|NCT03314025|DRUG|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
214802963|NCT03314025|DEVICE|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
214802964|NCT04641936|OTHER|No intervention required|No intervention required
214802965|NCT01512043|BEHAVIORAL|Breathing control|Practice of device guided breathing control twice a day for four weeks.
214802966|NCT03676803|OTHER|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
214802967|NCT03676803|OTHER|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
214802968|NCT06298656|OTHER|No intervention|It is an observational study.
214802969|NCT02319928|PROCEDURE|Colonoscopy|
214802970|NCT00055783|BIOLOGICAL|apolizumab|
214802971|NCT01581957|OTHER|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
214802972|NCT01581957|OTHER|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
214802973|NCT02537756|BEHAVIORAL|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
214802974|NCT01849042|DRUG|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
214802975|NCT01849042|DRUG|donepezil|
214802976|NCT02968485|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
214802977|NCT03080649|DEVICE|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
214802978|NCT03080649|DEVICE|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
214802979|NCT02253979|DEVICE|Standard double lumen tube|Endotracheal left side double lumen tube
214802980|NCT02253979|DEVICE|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
214802981|NCT05814458|DEVICE|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
214802982|NCT05814458|DEVICE|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
214802983|NCT00841100|DRUG|Kuvan|20mg/kg by mouth once daily
214802984|NCT00841100|OTHER|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
214802985|NCT01355081|DRUG|Vortioxetine|Vortioxetine tablets
214802986|NCT01355081|DRUG|Placebo|Vortioxetine placebo
214802987|NCT00001805|DRUG|Rituximab|
214802988|NCT00165399|DRUG|Docetaxel|Given intravenously on day 2 of four three-week cycles
214802989|NCT00165399|DRUG|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
214802990|NCT00165399|DRUG|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
214802991|NCT00165399|DRUG|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
214802992|NCT03493100|DIETARY_SUPPLEMENT|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
214802993|NCT03493100|OTHER|Usual care|The control group will receive treatment according to usual care.
214802994|NCT04895111|DIAGNOSTIC_TEST|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
214802995|NCT02467621|DRUG|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
214802996|NCT02467621|OTHER|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
214802997|NCT05231642|OTHER|Nutritional Interventional|Individualised postprandial glucose and vascular risk responses
214802998|NCT00205049|DRUG|pentoxifylline|daily dosing
214802999|NCT04770961|PROCEDURE|Erector spinae plane catheter with 0.5% Ropivacaine|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.
214803000|NCT04770961|PROCEDURE|Erector spinae plane catheter with saline|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
214803001|NCT05847699|OTHER|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
214803002|NCT03319498|OTHER|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
214803003|NCT03319498|OTHER|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
214803004|NCT04803357|DEVICE|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
214803005|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
214803006|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
214803007|NCT05209841|DRUG|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
214803008|NCT05209841|DRUG|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
214803009|NCT03526965|OTHER|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
214803010|NCT03526965|DRUG|Usual care|Intervention included pain medications and exercise movements for neck.
214803011|NCT00315549|DRUG|Telithromycin|
214803012|NCT00315549|DRUG|Penicillin|
214803013|NCT04782609|DRUG|Icapamespib|to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.
214803014|NCT04930081|BEHAVIORAL|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
214803015|NCT04353908|PROCEDURE|Rehabilitation|The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks
214803016|NCT04353908|PROCEDURE|Collagen Injection|With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
214803017|NCT03301909|DEVICE|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
214803018|NCT03301909|DRUG|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
214803019|NCT04323670|DEVICE|"Selectra 3D guiding catheter"|His lead measurements
214803020|NCT03438448|OTHER|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
214803021|NCT01046253|DRUG|Lansoprazole|30 mg Delayed-Release Capsules
214803022|NCT01046253|DRUG|Prevacid®|30 mg Delayed-Release Capsule
214803023|NCT02914795|OTHER|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
214803024|NCT01271439|DRUG|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
214803025|NCT05131126|PROCEDURE|Latarjet method|This operation consists of fixing a bone graft
214803026|NCT05131126|OTHER|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
214803027|NCT04081480|DRUG|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
214803028|NCT06101121|DEVICE|Lubri-Cream|Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
214803029|NCT03703063|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
214803030|NCT03703063|DRUG|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
214803031|NCT03703063|DRUG|Onivyde|Administered by intravenous infusion over 90 minutes.
214803032|NCT03703063|DRUG|Leucovorin|Administered by intravenous infusion over 30 minutes.
214803033|NCT03703063|DRUG|5-fu|Administered by intravenous infusion over 46 hours.
214803034|NCT02339909|BEHAVIORAL|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
214803035|NCT02339909|BEHAVIORAL|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
214803036|NCT02339909|BEHAVIORAL|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
214803037|NCT02703610|DRUG|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
214803038|NCT02703610|DRUG|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
214803039|NCT00855283|DRUG|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
214803040|NCT00855283|DRUG|IN NEO|40 mg Neostigmine via intranasal administration
214803041|NCT00855283|DRUG|IN NEO|60 mg Neostigmine via intranasal administration
214803042|NCT00855283|DRUG|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
214803043|NCT00855283|DRUG|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
214803044|NCT03086356|DRUG|Dabigatran etexilate|Days 1-4 and Day 8-11
214803045|NCT03086356|DRUG|Idarucizumab|Day 11
214803046|NCT03536624|BEHAVIORAL|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
214803047|NCT05112328|DRUG|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
214803048|NCT05112328|DRUG|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
214803049|NCT03202758|DRUG|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
214803050|NCT01365962|GENETIC|gene expression analysis|
214803051|NCT01365962|OTHER|immunohistochemistry staining method|
214803052|NCT01365962|OTHER|laboratory biomarker analysis|
214803053|NCT01365962|OTHER|mass spectrometry|
214803054|NCT01994525|BIOLOGICAL|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
214803055|NCT01994525|BIOLOGICAL|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
214803056|NCT01994525|OTHER|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
214803057|NCT02449876|OTHER|Neuroscience Education|"The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
214803058|NCT00060905|DRUG|Divalproex Sodium (Depakote ER)|
214803059|NCT04183231|DRUG|Anti-caries varnish|topical tooth varnish
214803060|NCT00860028|DRUG|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
214803061|NCT00860028|DRUG|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
214803062|NCT05803915|DRUG|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
214803063|NCT03029520|OTHER|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
214803064|NCT03029520|OTHER|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
214803065|NCT00677911|BEHAVIORAL|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
214803066|NCT06347757|PROCEDURE|Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy|laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).
214803067|NCT02687256|DEVICE|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
214803068|NCT02687256|DEVICE|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
214803069|NCT02687256|DRUG|Heparin|
214803070|NCT03389386|DIAGNOSTIC_TEST|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
214803071|NCT03389386|OTHER|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
214803072|NCT03389386|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
214803073|NCT00483496|DRUG|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
214803074|NCT00483496|DRUG|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
214803075|NCT00483496|DRUG|bisoctrizole 10% alone (formula RV3131A-MV1237)|
214803076|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
214803077|NCT00483496|DRUG|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
214803078|NCT00483496|DRUG|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
214803079|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
214803080|NCT00483496|DRUG|V0096 CR vehicle (formula RV3131A-MV1197)|
214803081|NCT02559583|OTHER|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
214803082|NCT02559583|OTHER|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
214803083|NCT02559583|OTHER|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
214803084|NCT06056388|DEVICE|Straumann BLX implant|Implant system with a deep fixture thread depth.
214803085|NCT06056388|DEVICE|Straumann BLT implant|Implant system with a regular fixture thread depth.
214803086|NCT02159105|DEVICE|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
214803087|NCT01658943|DRUG|Akt Inhibitor MK2206|Given PO
214803088|NCT01658943|DRUG|Fluorouracil|Given IV
214803089|NCT01658943|DRUG|Oxaliplatin|Given IV
214803090|NCT01658943|DRUG|Selumetinib|Given PO
214803091|NCT06455020|PROCEDURE|Catheter ablation|Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission
214803092|NCT06455020|PROCEDURE|Stepped-care strategies|Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
214803093|NCT06824701|DRUG|Tazemetostat|Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.
214803094|NCT06824701|DRUG|Zanubrutinib|Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
214803095|NCT06824701|DRUG|Rituximab|Rituximab or a biosimilar will be administered intravenously per standard of care.
214803096|NCT06824701|DRUG|Obinutuzumab|Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.
214803097|NCT05159635|DEVICE|Active Living programme and wearable technical aids|attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
214803098|NCT05159635|DEVICE|Wearable technical aids|apply wearable technical aids for 8 weeks.
214803099|NCT02625545|DEVICE|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
214803100|NCT01911195|DRUG|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
214803101|NCT01911195|OTHER|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
214803102|NCT03190486|OTHER|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
214803103|NCT00663221|DIETARY_SUPPLEMENT|Anthocyans, Calcium and Vitamin D|
214803104|NCT00663221|DIETARY_SUPPLEMENT|placebo|
214803105|NCT00699322|DRUG|Sitagliptin|100mg P.O. per day for 1month
214803106|NCT00699322|DRUG|Glimepiride|2mg P.O. per day for 1 month
214803107|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
214803108|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
214803109|NCT05312125|PROCEDURE|backward downhill walking|Children in the intervention group will take backward downhill walking program plus to routine physiotherapy.
214803110|NCT05312125|PROCEDURE|routine physiotherapy|Children in one of the groups will take routine physiotherapy programme
214803111|NCT03673059|DRUG|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
214803112|NCT03673059|OTHER|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
214803113|NCT05487833|BIOLOGICAL|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
214803114|NCT05487833|OTHER|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
214803115|NCT03392571|DRUG|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
214803116|NCT04437693|DRUG|Hydroxychloroquine|The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
214647605|NCT04139876|PROCEDURE|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
214803117|NCT03144687|DRUG|Itacitinib|Itacitinib self-administered orally once daily .
214803118|NCT03144687|DRUG|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
214803119|NCT06298435|PROCEDURE|Intermittent Positive pressure ventilation|Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
214803120|NCT04525807|DIAGNOSTIC_TEST|Multi-omics|Use multi-omics to analyze
214803121|NCT05015556|PROCEDURE|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
214803122|NCT00922532|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
214803123|NCT00922532|DRUG|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
215031191|NCT02731482|OTHER|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~* Aerobic training in stepping training.~* Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~* Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
214803124|NCT01054599|DRUG|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
214803125|NCT01054599|OTHER|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
214803126|NCT01054599|DRUG|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
214803127|NCT00001090|BIOLOGICAL|APL 400-047|
214803128|NCT00001090|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214803129|NCT00001090|DRUG|Sargramostim|
214803130|NCT01075139|BEHAVIORAL|Brief Motivational Intervention|30 minute one-on-one meeting
214803131|NCT01075139|BEHAVIORAL|Educational information|Educational handouts/brochures
214803132|NCT01564433|PROCEDURE|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
214803133|NCT01564433|PROCEDURE|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
214803134|NCT01966081|OTHER|Blood sample|
214803135|NCT01966081|OTHER|tissue samples from abdominal subcutaneous adipose|
214803136|NCT00475020|DRUG|Busulfan|Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days
214803137|NCT00475020|DRUG|Fludarabine|40 mg/m\^2 by vein daily over 1 hour x 4 days
214803138|NCT00475020|DRUG|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
214803139|NCT03218592|DRUG|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
214803140|NCT03218592|DRUG|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
214803141|NCT03218592|DRUG|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
214803142|NCT02492399|PROCEDURE|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
214803143|NCT02492399|PROCEDURE|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
214803144|NCT02514174|DRUG|Afatinib|afatinib starting at 30 mg daily dose
214803145|NCT01669109|BEHAVIORAL|Hatha yoga|
214803146|NCT05654909|PROCEDURE|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
214803147|NCT05612438|DEVICE|RADIX 2 Stent|RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis \> 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.
214803148|NCT05155800|DEVICE|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
215031192|NCT02731482|OTHER|Control Group|"* The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~* Participants will not receive any supervised physical training.~* Once a week, patients will receive a phone call to provide support and general advice."
215031193|NCT05226338|DRUG|D-0502|Formulation 1 Formulation 2 Formulation 3
214803149|NCT05320263|PROCEDURE|Contact aspiration Thrombectomy|"The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature."
214803150|NCT05320263|PROCEDURE|Stent retriever thrombectomy|The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
214803151|NCT02419352|DRUG|Sugammadex|
214803152|NCT02419352|DRUG|Neostigmine/atropine|
214803153|NCT04523649|DEVICE|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
214803154|NCT04302948|OTHER|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
214803155|NCT00001765|DEVICE|Nexell Isolex with T-cell Depletion|
214803156|NCT00001765|DEVICE|Baxter isolex 300i|
214803157|NCT03059862|DIETARY_SUPPLEMENT|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
214803158|NCT03059862|DIETARY_SUPPLEMENT|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
214803159|NCT02170688|DRUG|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
214803160|NCT02170688|OTHER|Weight calculation|
214803161|NCT02725307|DEVICE|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
214803162|NCT06345248|PROCEDURE|US-TAP|regional block team under ultrasound guidance
214803163|NCT06345248|PROCEDURE|LAPTAP|performed TAP block under direct visualization with the laparoscope
214803164|NCT01894178|DEVICE|Parker Flex-Tip® tracheal tube|
214803165|NCT01894178|DEVICE|Portex® Tracheal Tube|
214803166|NCT06344338|DEVICE|tDCS stimulation|In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation
214803167|NCT06344338|DEVICE|TDCS sham-stimulation|TDCS sham-stimulation
214803168|NCT04426799|OTHER|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
214803169|NCT06312371|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
214803170|NCT06312371|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
214803171|NCT05481307|DRUG|RLD2202|Take it once a day per period
214803172|NCT05481307|DRUG|RLD2203|Take it once a day per period
214803173|NCT01217086|DRUG|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
214803174|NCT04807621|BIOLOGICAL|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
214803175|NCT04807621|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
214803176|NCT01490944|DRUG|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
214803177|NCT01490944|DRUG|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
214803178|NCT05829148|DRUG|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
214803179|NCT05829148|DRUG|Melatonin|Melatonin
214803180|NCT05829148|DRUG|Pregabalin|Pregabalin
214803181|NCT05829148|DRUG|Placebo|Placebo
214803182|NCT05039502|OTHER|Protaper Universal Retreatment|D1-D2-D3 Retreatment files were used in 500 rpm and 3 Ncm with X-Smart endomotor
214803183|NCT05039502|OTHER|Reciproc|R25 retratment files were used with X-Smart endomotor in reciprocal motion
214803184|NCT05039502|OTHER|XP-Endo finisher R|XP-Endo finisher r file were used in 1000 rpm 1 Ncm with X-Smart endomotor
214803185|NCT03377881|PROCEDURE|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.
214803186|NCT03377881|PROCEDURE|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
214803187|NCT06234670|OTHER|No intervertion|This study is a retrospective observational study without intervention.
214803188|NCT00079807|DRUG|Alpha-Lipoic Acid|
214803189|NCT03043547|DRUG|nal-IRI|nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
214803190|NCT03043547|DRUG|5-FU|5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)
214803191|NCT03043547|DRUG|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
214803192|NCT01624376|DRUG|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
214803193|NCT01624376|DRUG|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
214803194|NCT06526962|DEVICE|5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser|Outpatient hysteroscopic polypectomy
214803195|NCT00263965|DRUG|Tesaglitazar|
214803196|NCT00263965|DRUG|Metformin|
214803197|NCT00263965|BEHAVIORAL|Dietary and lifestyle modification counseling|
214803198|NCT05886426|DIAGNOSTIC_TEST|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
214803199|NCT02084004|DRUG|Bifidobacterium viable pharmaceutics|
214803200|NCT02084004|DRUG|Berberine Hydrochloride|
214803201|NCT00543309|DRUG|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
214803202|NCT00543309|DRUG|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
214803203|NCT00543309|DRUG|placebo|Placebo bolus on CPB, then placebo infusion
214803204|NCT01524653|DRUG|Rosuvastatin|20 mg po od
214803205|NCT01524653|DRUG|Placebo|20 mg po od
214803206|NCT04541719|DRUG|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
214803207|NCT04541719|DRUG|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
214803208|NCT06437431|DRUG|glenzocimab|Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.
214803209|NCT06437431|DRUG|placebo|Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
214803210|NCT00349947|BEHAVIORAL|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
214803211|NCT02148302|DEVICE|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
214803212|NCT03281109|DIAGNOSTIC_TEST|diagnosis|diagnosis with ELISA
215031194|NCT03104920|PROCEDURE|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
214803213|NCT02947009|BEHAVIORAL|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
214803214|NCT03937453|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
214803215|NCT04107870|BEHAVIORAL|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
214803216|NCT04107870|BEHAVIORAL|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
214803217|NCT03582332|DRUG|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
214803218|NCT03582332|DRUG|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
214803219|NCT03582332|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
214803220|NCT03582332|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
214803221|NCT00369590|BIOLOGICAL|ziv-aflibercept|Given IV
214803222|NCT00369590|OTHER|pharmacological study|correlative studies
214803223|NCT00369590|OTHER|laboratory biomarker analysis|correlative studies
214803224|NCT00637390|DRUG|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
214803225|NCT02220868|DRUG|Sofosbuvir, Ribavirin, and Stribild|
214803226|NCT03409601|OTHER|100% Portion Size|Meal portion size at baseline
214803227|NCT03409601|OTHER|125% Portion Size|Meal portion size 125% of baseline
214803228|NCT03409601|OTHER|150% Portion Size|Meal portion size 150% of baseline
214803229|NCT03409601|OTHER|175% Portion Size|Meal portion size 175% of baseline
214803230|NCT01828996|DEVICE|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
214803231|NCT01828996|DEVICE|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
214803232|NCT03542422|DRUG|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
214803233|NCT04500509|DRUG|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
214803234|NCT04500509|DRUG|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
214803235|NCT06348693|OTHER|cell isolation from tumor biopsies and biomarker investigation|cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
214803236|NCT03974256|OTHER|Training in the use of the automaton|2 days training on automaton use
214803237|NCT00023309|DRUG|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
214803238|NCT00023309|DRUG|Adefovir alone|Adefovir (10 mg/day)
214803239|NCT04744909|DEVICE|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
214803240|NCT04132856|OTHER|Psychosocial Navigator|Services of psychosocial navigator
214803241|NCT04132856|OTHER|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
214803242|NCT01215409|DRUG|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
214803243|NCT03289156|BEHAVIORAL|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
214803244|NCT03289156|BEHAVIORAL|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
214803245|NCT05457101|OTHER|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
214803246|NCT01246830|RADIATION|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
214803247|NCT01246830|RADIATION|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
214803248|NCT03247556|DRUG|Placebo|Placebo was administered once daily
214803249|NCT03247556|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to Placebo
214803250|NCT03247556|DRUG|600mg SPN-812|600mg SPN-812 was administered once daily and compared to Placebo
214803251|NCT00845156|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
215031195|NCT03104920|PROCEDURE|Traditional treatment|A traditional perioperative management for HCC.
214647606|NCT00028990|DRUG|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
214647607|NCT00028990|DRUG|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
214647608|NCT05993637|OTHER|Examination of propriception|application of the tests used in proprioception assessment to patients by a physiotherapist
214647609|NCT06322875|PROCEDURE|Recombinant type III humanized collagen solution for injection|Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
214647610|NCT06322875|OTHER|SkinCeuticals recombinant humanized collagen (RHC) serum|Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face
214647611|NCT06322875|OTHER|Regular face cream smear|Subjects received Regular face cream smear application on the whole face
214647612|NCT03091309|OTHER|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
214647613|NCT03091309|BEHAVIORAL|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
214647614|NCT03091309|BEHAVIORAL|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
214647615|NCT03091309|BEHAVIORAL|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
214647616|NCT03091309|OTHER|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence \[self-reported using the 5 item Medication Adherence Report Scale (MARS-5)\] and IBD related disease activated \[self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity\].
214647617|NCT03091309|OTHER|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
214803252|NCT02946762|OTHER|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
214803253|NCT06143722|RADIATION|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
214803254|NCT06143722|RADIATION|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
214803255|NCT04493723|PROCEDURE|Surgery|To collect tumour tissue
214803256|NCT04493723|PROCEDURE|Venepuncture|To collect blood samples
214803257|NCT06316921|PROCEDURE|Epidural patient-controlled analgesia|Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery
214803258|NCT06316921|PROCEDURE|Standard postoperative pain management|Standard of care for postoperative pain after lumber spine surgery
214803259|NCT00843323|OTHER|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
214803260|NCT00795015|DRUG|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
214803261|NCT00795015|DRUG|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
214803262|NCT01203878|DRUG|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
214803263|NCT01203878|DRUG|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
214803264|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
214803265|NCT03701256|PROCEDURE|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
214803266|NCT03701256|DRUG|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
214803267|NCT05537051|DRUG|PM1021, PM8001|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
214803268|NCT06179056|DIAGNOSTIC_TEST|assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.|"Microbiological samples were collected from all patients for:~1. Isolation of C. acnes~2. Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~3. Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine"
214803269|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
214803270|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
214803271|NCT01071122|DRUG|Valsartan|Valsartan 160mg, Once daily
214803272|NCT03952143|DRUG|LY900014|Administered SC
214803273|NCT03952143|DRUG|Insulin Lispro|Administered SC
214803274|NCT03952143|DRUG|Insulin Glargine|Administered SC
214803275|NCT03952143|DRUG|Insulin Degludec|Administered SC
214803276|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
214803277|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
214803278|NCT01476085|RADIATION|ML10|\[18F\]ML10 radioligand apoptosis biomarker
214803279|NCT00431600|OTHER|100% Oxygen|100% Oxygen- breathing over 30 minutes
214803280|NCT03606278|OTHER|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
214803281|NCT03606278|OTHER|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
214803282|NCT04615793|OTHER|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
214803283|NCT03653260|DRUG|Lidocaine (Zingo)|0.5 mg lidocaine, 20 bar pressure
214803284|NCT03653260|DRUG|Placebo|Placebo injector, 20 Bar pressure, empty injector
214803285|NCT01019603|DRUG|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
214803286|NCT01019603|DRUG|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
214803287|NCT06562413|DRUG|MAbs|Monthly or quarterly mAbs administration
214803288|NCT01866319|BIOLOGICAL|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
214803289|NCT01866319|BIOLOGICAL|Ipilimumab|3 mg/kg IV Q3W.
214803290|NCT05053165|DRUG|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
214803291|NCT05053165|DRUG|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
214803292|NCT05053165|DRUG|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
214803293|NCT04684901|OTHER|AlloWrap® Amniotic Membrane|AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
214803294|NCT00056134|BIOLOGICAL|Dendritic cell vaccine plus denileukin difitox|
214803295|NCT01661114|DRUG|Gemcitabine|
214803296|NCT01661114|DRUG|5-FU|
214803297|NCT01661114|DRUG|Cisplatin|
214803298|NCT00661596|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
214803299|NCT00661596|DRUG|Placebo|Matching placebo
214803300|NCT06495983|DEVICE|dynamic microdialysis sampling|Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
214803301|NCT00035581|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
214803302|NCT04421508|COMBINATION_PRODUCT|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
214803303|NCT04421508|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
214803304|NCT00091052|BIOLOGICAL|sargramostim|
214803305|NCT00091052|RADIATION|radiation therapy|
214803306|NCT03141099|OTHER|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
214803307|NCT03141099|OTHER|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
214803308|NCT03141099|OTHER|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
214803309|NCT03141099|OTHER|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
214803310|NCT03980483|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
214803311|NCT03980483|DRUG|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
214803312|NCT03980483|DRUG|Placebo|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
214803313|NCT03980483|DRUG|Placebo|Placebo cap (containing lactose) to be administered orally.
214803314|NCT04559607|DRUG|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
214803315|NCT04559607|DEVICE|TACE|TACE if necessary
214803316|NCT04559607|DRUG|Apatinib|Apatinib: 250m, po, QD
214803317|NCT06343168|OTHER|prevalence of frailty|determine the prevalence of frailty
214803318|NCT04922424|DRUG|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
214803319|NCT04922424|OTHER|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
214803320|NCT04433910|DRUG|Convalesscent Plasma|Transfusion
214803321|NCT01164813|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
214803322|NCT01164813|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
214803323|NCT04495049|DEVICE|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
214803324|NCT06222749|DRUG|Intranasal oxytocin administration|24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
214803325|NCT06222749|DRUG|Intranasal placebo administration|Nasal spray solution; Placebo will be administered as the placebo controlled condition.
214803326|NCT02612636|OTHER|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
214803327|NCT02612636|OTHER|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
214803328|NCT00784849|DRUG|Methylene blue|1 mC1
214803329|NCT00322933|PROCEDURE|renal replacement therapy (intermittent or continuous)|
214803330|NCT01009398|OTHER|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
214803331|NCT06114706|BEHAVIORAL|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
214803332|NCT06114706|BEHAVIORAL|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
214803333|NCT06114706|BEHAVIORAL|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
214803334|NCT04622709|DRUG|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
214803335|NCT00760266|DRUG|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
214803336|NCT00760266|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
214803337|NCT02066675|DRUG|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
214803338|NCT00216437|DRUG|Capecitabine (Xeloda)|
214803339|NCT02684552|DEVICE|Non invasive ventilation|Training on treadmill with Non invasive ventilation
214803340|NCT02684552|DEVICE|Oxygen|Training on treadmill with oxygen
214803341|NCT03249064|DIAGNOSTIC_TEST|CD 91 levels|
214803342|NCT03249064|DIAGNOSTIC_TEST|Tregs|
214803343|NCT00001025|DRUG|Zidovudine|
214803344|NCT00001025|DRUG|Didanosine|
214803345|NCT03080090|BEHAVIORAL|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
214803346|NCT03080090|BEHAVIORAL|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
214803347|NCT03316729|DRUG|DS-9231|DS-9231 in saline solution for intravenous infusion
214803348|NCT03316729|DRUG|Placebo|Placebo is matching saline solution for intravenous infusion
214803349|NCT01625026|DRUG|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
214803350|NCT01625026|DRUG|Placebo|Placebo to obeticholic acid
214803351|NCT04346706|DEVICE|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
214803352|NCT04346706|DEVICE|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
214803353|NCT04815902|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
214803354|NCT04815902|DRUG|Losartan|12.5 mg oral Losartan taken for 30 days total.
214803355|NCT04815902|DRUG|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
214803356|NCT04815902|DRUG|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
214803357|NCT01893957|PROCEDURE|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
215031585|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
215031586|NCT06682000|DRUG|DWC202404, DWC202314|\- 2 tablet, Oral, Once a day
215031587|NCT06682000|DRUG|DWC202404, DWC202314P|\- 2 tablet, Oral, Once a day
214803358|NCT01893957|PROCEDURE|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
214803359|NCT01893957|DEVICE|Neurodyn High Volt Model (IBRAMED)|
214803360|NCT01225146|DRUG|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
214803361|NCT01715038|DIETARY_SUPPLEMENT|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
214803362|NCT01715038|DIETARY_SUPPLEMENT|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
214803363|NCT01715038|DIETARY_SUPPLEMENT|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
214803364|NCT01715038|DIETARY_SUPPLEMENT|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
214803365|NCT01132976|BEHAVIORAL|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
214803366|NCT01132976|BEHAVIORAL|Treatment as usual|No specific motivational interview
214803367|NCT01976130|PROCEDURE|Bronchoscopy|
214803368|NCT01997203|DRUG|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
214803369|NCT02283775|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
214803370|NCT02283775|DRUG|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
214803371|NCT02283775|DRUG|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
214803372|NCT06090149|DEVICE|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
214803373|NCT06090149|DEVICE|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
214803374|NCT02396875|PROCEDURE|Blood sampling and exercise protocol pre and post CRT implant|
214803375|NCT02396875|PROCEDURE|Peripheral blood sampling|
214803376|NCT02396875|PROCEDURE|Central blood sampling pre and post CRT implant|
214803377|NCT02396875|PROCEDURE|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
214803378|NCT01697878|PROCEDURE|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
214803379|NCT01697878|PROCEDURE|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
214803380|NCT05163951|PROCEDURE|Trabeculectomy|trabeculectomy
214803381|NCT05163951|PROCEDURE|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
214803382|NCT02799797|PROCEDURE|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
214803383|NCT02799797|PROCEDURE|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
214803384|NCT02799797|DEVICE|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
214803385|NCT02799797|DEVICE|PAJUNK Contiplex S Catheter|
214803386|NCT02799797|DRUG|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
214803387|NCT02799797|DRUG|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
214803388|NCT00003797|BIOLOGICAL|trastuzumab|
214803389|NCT00003797|DRUG|gemcitabine hydrochloride|
214803390|NCT03358849|BIOLOGICAL|Natural killer cell|Patients who received natural killer cell injection
214803391|NCT02238145|DRUG|Atrovent® Inhaletten|
214803392|NCT02566824|BEHAVIORAL|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q\&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
214803393|NCT02566824|BEHAVIORAL|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
214803394|NCT02566824|OTHER|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
214803395|NCT02566824|DRUG|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
214803396|NCT04876378|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214803397|NCT04876378|OTHER|Questionnaire Administration|Complete questionnaires
214803398|NCT02754401|OTHER|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
214803399|NCT02754401|OTHER|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
214803400|NCT03884166|DIAGNOSTIC_TEST|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
214803401|NCT04408404|PROCEDURE|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
214803402|NCT03492580|DRUG|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
214803403|NCT03492580|DRUG|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
214803404|NCT03492580|DRUG|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
214803405|NCT03492580|DRUG|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
214803406|NCT03492580|DRUG|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
214803407|NCT03492580|DRUG|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
214803408|NCT03492580|DRUG|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
214803409|NCT03492580|DRUG|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
214803410|NCT03492580|DRUG|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
214803411|NCT03249584|DEVICE|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
214803412|NCT06176287|PROCEDURE|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
214803413|NCT06176287|PROCEDURE|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
214803414|NCT02898909|DEVICE|nuclear lens fragmentation in 8 pieces|
214803415|NCT02898909|DEVICE|nuclear lens fragmentation in 16 pieces|
214803416|NCT05727137|PROCEDURE|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
214803417|NCT05727137|PROCEDURE|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
214803418|NCT02392793|DRUG|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
214803419|NCT02392793|DRUG|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
214803420|NCT02392793|DRUG|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
214803421|NCT02392793|DRUG|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.
214803422|NCT02392793|DRUG|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
214803423|NCT01345045|DRUG|ABT-639|ABT-639 Twice Daily for six weeks.
214803424|NCT01345045|DRUG|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
214803425|NCT01345045|DRUG|Placebo|Placebo twice daily for 6 weeks.
214803426|NCT04353791|DRUG|OST-122|Active dose
214803427|NCT04353791|DRUG|Placebo|Placebo
214803428|NCT00620048|BIOLOGICAL|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
214803429|NCT02191891|DRUG|Xentuzumab|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
214803430|NCT02191891|DRUG|Afatinib|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
214803431|NCT04370665|DEVICE|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
214803432|NCT01864330|DEVICE|Thealoz Duo®|Eye Drops
214803433|NCT01864330|DEVICE|Hyabak®|Eye Drops
214803434|NCT01864330|DEVICE|Hydrabak®|Eye Drops
214803435|NCT02693210|DRUG|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
214803436|NCT02693210|DRUG|Methotrexate|Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks
214803437|NCT02693210|OTHER|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
214803438|NCT02693210|OTHER|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
214803439|NCT02693210|OTHER|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
214803440|NCT02693210|DRUG|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
214803441|NCT01826123|DEVICE|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
214803442|NCT01826123|DEVICE|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
214803443|NCT06311942|DRUG|HAIC plus PD-1 inhibitors plus lenvatinib|Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
214803444|NCT06311942|DRUG|PD-1 inhibitors plus lenvatinib|The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
214803445|NCT02884232|PROCEDURE|Nasofibroscopy|
214803446|NCT05527678|OTHER|Questionnaires|Written or by phone
214803447|NCT05395247|OTHER|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
214803448|NCT00006734|BIOLOGICAL|filgrastim|Given IV
214803449|NCT00006734|DRUG|cyclophosphamide|Given IV
214803450|NCT00006734|DRUG|doxorubicin hydrochloride|Given IV
214803451|NCT00006734|DRUG|etoposide|Given IV
214803452|NCT00006734|DRUG|ifosfamide|Given IV
215031588|NCT06683248|OTHER|Investigate sleep deprivation|"Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor"
214803453|NCT00006734|DRUG|vincristine sulfate|Given IV
214803454|NCT00006734|PROCEDURE|adjuvant therapy|
214803455|NCT00006734|PROCEDURE|conventional surgery|
214803456|NCT00006734|PROCEDURE|neoadjuvant therapy|
214803457|NCT00006734|RADIATION|brachytherapy|
214803458|NCT00006734|RADIATION|radiation therapy|
214803459|NCT04004312|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
214803460|NCT04829227|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214803461|NCT04394676|PROCEDURE|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
214803462|NCT00487500|DEVICE|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
214803463|NCT01221376|DRUG|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
214803464|NCT02351466|OTHER|Observational|
214803465|NCT01522664|DRUG|DEDN6526A|Multiple ascending doses
214803466|NCT03223233|OTHER|procalcitonin level|serum procalcitonin level will be measured in both groups.
214803467|NCT06091878|OTHER|Observation|Observational study, no intervention
214803468|NCT03729297|DRUG|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
214803469|NCT04019678|PROCEDURE|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
214803470|NCT02687074|DEVICE|HFNC|patients treated with high flow nasal cannula
214803471|NCT02687074|DEVICE|NIV|patients treated with noninvasive ventilation
214803472|NCT04550065|BEHAVIORAL|Digital game|A digital family game with theme-based mini games (epidemic prevention, exercise, diet, communication and parenting)
214803473|NCT01973348|DEVICE|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
214803474|NCT01973348|DEVICE|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
214803475|NCT01973348|DEVICE|2-hour patching|2-hour patching for moderate amblyopia
214803476|NCT01973348|DEVICE|6-hour patching|6-hour patching for severe amblyopia
214803477|NCT00714740|DRUG|acetazolamide|acetazolamide 2 times 250mg per day
214803478|NCT04934917|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
214803479|NCT03356821|BIOLOGICAL|Mesenchymal Stem Cells|One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
214803480|NCT00874237|DRUG|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
214803481|NCT00874237|DRUG|Inhaled placebo|Inhaled Staccato placebo single dose
214803482|NCT00874237|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg
214803483|NCT00874237|DRUG|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
214803484|NCT02724800|BEHAVIORAL|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
214803485|NCT02724800|BEHAVIORAL|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
214803486|NCT01162226|BEHAVIORAL|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
214803487|NCT02355431|DRUG|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
214803488|NCT02355431|DRUG|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
214803489|NCT02355431|DRUG|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
214803490|NCT03129425|BEHAVIORAL|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
214803491|NCT03129425|OTHER|General Educational Program|5 sessions in groups of 15-20 people
214803492|NCT03077516|DEVICE|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
214803493|NCT01139437|BIOLOGICAL|Standard Dose HPIV2 Vaccine|10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
214803494|NCT01139437|BIOLOGICAL|Low dose HPIV2 vaccine|10\^5 TCID50 administered in a single dose
214803495|NCT01139437|OTHER|Placebo|Matched placebo
214803496|NCT01257009|DRUG|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
214803497|NCT06213688|OTHER|blood sampling|blood sampling at inclusion
214803498|NCT06213688|OTHER|urine sampling|urine sampling at inclusion
214803499|NCT03912337|DRUG|Placebo|Placebo once every 4 weeks. SC injection.
214803500|NCT03912337|DRUG|Erenumab|Erenumab once every 4 weeks. SC injection.
214803501|NCT03752528|DIAGNOSTIC_TEST|Blood sample collection|Determination of buprenorphine and norbuprenorphine plasma concentrations
214803502|NCT03752528|DIAGNOSTIC_TEST|Urine sample collection|Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
214803503|NCT06391983|OTHER|resistance training (elastic band)|The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.
214803504|NCT00721747|DRUG|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
214803505|NCT05857098|OTHER|Local Field potential recording|Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
214803506|NCT04196452|DRUG|Ipilimumab|Specified dose on specified days
214803507|NCT06631157|DEVICE|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
214803508|NCT04739020|DIAGNOSTIC_TEST|Resp-Aer-Meter|Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.
214803509|NCT04739020|DIAGNOSTIC_TEST|Spirometry|Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.
214803510|NCT04739020|DIAGNOSTIC_TEST|Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations|Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).
214803511|NCT03736382|OTHER|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
214803512|NCT03736382|OTHER|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
214803513|NCT03736382|OTHER|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
214803514|NCT01112280|DEVICE|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
214803515|NCT01772030|OTHER|Use of the Achieve catheter followed by ICE-guided mapping catheter|
214803516|NCT06328348|DIETARY_SUPPLEMENT|supplementation|group receiving a course of Black Cohosh, Soy Isoflavones, and SDG Lignans
214803517|NCT06328348|OTHER|placebo|placebo
214803518|NCT00414765|DRUG|Aldesleukin|
214803519|NCT02458469|DRUG|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
214803520|NCT02458469|DRUG|Trazodone|100 mg dose before bed-time
214803521|NCT02458469|DRUG|Placebo|One placebo pill before bed-time
214803522|NCT03682159|OTHER|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
214803523|NCT04795154|OTHER|Yoga excercise|Yoga exercise in pre-eclampsia \>20 weeks of pregnancy woman, treatment number was 4 times.
214803524|NCT02524197|DRUG|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
214803525|NCT02524197|DRUG|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
214803526|NCT02524197|DRUG|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
214803527|NCT02524197|DRUG|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
214803528|NCT06470880|DRUG|Adaptive Therapy|A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.
214803529|NCT06470880|DRUG|Standard of Care|Encorafenib and binimetinib delivered to UK standard of care.
214803530|NCT02156739|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
214803531|NCT02156739|DRUG|Gadobutrol|Given IV
214803532|NCT02156739|DRUG|Gadoxetate Disodium|Given IV
214803533|NCT05461547|DIAGNOSTIC_TEST|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
214803534|NCT05461547|OTHER|Usual Care|Usual care to decide diagnosis and treatment
214803535|NCT02468024|PROCEDURE|Lung Surgery|Sublobar Lung Resection
214803536|NCT02468024|RADIATION|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
214803537|NCT01081730|BIOLOGICAL|anti-TNF biologics|as prescribed
214803538|NCT01081730|OTHER|general population|non-treated cohort
214803539|NCT01081730|BIOLOGICAL|non-anti-TNF biologics|as prescribed
214803540|NCT01081730|BIOLOGICAL|ustekinumab|as prescribed
214803541|NCT01081730|DRUG|systemic non-biological treatments|as prescribed
214803542|NCT06002971|DEVICE|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
214803543|NCT03259763|DEVICE|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
214803544|NCT03259763|DEVICE|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
214803545|NCT05660642|DRUG|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
214803546|NCT00917033|DEVICE|GlideScope|Orotracheal intubation
214803547|NCT00917033|DEVICE|Macintosh direct laryngoscope|Orotracheal intubation
214803548|NCT00661505|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
214803549|NCT04534283|DRUG|Abemaciclib|Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
214803550|NCT04534283|DRUG|LY3214996|Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
214803551|NCT06542081|BEHAVIORAL|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
214803552|NCT04544371|DEVICE|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
214803553|NCT04544371|PROCEDURE|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
214803554|NCT00965653|DRUG|folic acid|\>/= 5 mg po weekly
214803555|NCT00965653|DRUG|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
214803556|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
214803557|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
214803558|NCT03561883|DRUG|IW-3718|oral tablet
214803559|NCT03561883|DRUG|placebo|oral tablet
214803560|NCT03561883|DRUG|Standard-dose PPIs QD|background therapy
214803561|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
214803562|NCT00524758|DEVICE|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
214803563|NCT00524758|DRUG|MMC in Trabeculectomy|MMC in Trabeculectomy
214803564|NCT02854280|BIOLOGICAL|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
214803565|NCT02854280|BIOLOGICAL|Isolated contractions of the quadriceps|Until exhaustion
214803566|NCT01283919|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
214803567|NCT02256007|OTHER|Paper and Pencil Assessments|Videogame Assessments
214803568|NCT06275191|BEHAVIORAL|Multicomponent intervention|The multicomponent intervention consists of (1) a single 45-60-minute academic detailing session with provider participants, plus (2) provision of patient post-extraction instruction materials and (3) provision of blister-packaged acetaminophen and ibuprofen for distribution to adolescent/young adult patients after tooth extraction in the course of clinical practice
214803569|NCT06275191|OTHER|Usual care|No intervention.
214803570|NCT06077565|OTHER|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
214803571|NCT06077565|OTHER|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
214803572|NCT06077565|OTHER|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
214803573|NCT05245695|OTHER|Observational study, no intervention|Observational study, no intervention
214803574|NCT04968249|OTHER|Observational|Observational Cohort to understand risk factors for early COPD.
214803575|NCT04675177|DRUG|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
214803576|NCT04675177|PROCEDURE|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
214803577|NCT00528281|DRUG|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
214803578|NCT00528281|DRUG|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
214803579|NCT04615156|DRUG|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
214803580|NCT04407819|RADIATION|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
214803581|NCT04963309|OTHER|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
214803582|NCT04820608|DEVICE|Cross-linking|Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
214803583|NCT04598243|DIETARY_SUPPLEMENT|Smart Energy System|A nutritional /herbal combination
214803584|NCT04010799|DRUG|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
214803585|NCT04010799|DRUG|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
214803586|NCT03558308|BEHAVIORAL|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
214803587|NCT03558308|OTHER|Sham computerized gaming|Sham training with generally stimulating computer-games
214803588|NCT03199157|DRUG|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
214803589|NCT05524688|DIETARY_SUPPLEMENT|Beta-glucan|2, 250 mg capsules of beta-glucan per day
214803590|NCT05524688|DIETARY_SUPPLEMENT|Placebo|2, 250 mg capsules of cellulose
214803591|NCT00618163|DRUG|Meloxicam|
214803592|NCT04085666|DRUG|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
214803593|NCT04085666|OTHER|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
214803594|NCT03879356|DRUG|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
214803595|NCT04604704|DRUG|Naltrexone|Naltrexone at 4.5 mg/day
214803596|NCT04604704|DIETARY_SUPPLEMENT|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
214803597|NCT00177593|BEHAVIORAL|behavioral weight loss|
214803598|NCT02200965|OTHER|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
214803599|NCT04870190|DRUG|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
214803600|NCT04870190|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
214803601|NCT02178826|DEVICE|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
214803602|NCT02178826|DEVICE|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
214803603|NCT03778905|OTHER|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
214803604|NCT03320304|DEVICE|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
214803605|NCT05921214|BEHAVIORAL|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
214803606|NCT01188746|BEHAVIORAL|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
214803607|NCT06093425|DRUG|TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
214803608|NCT06093425|DRUG|Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
214803609|NCT04141033|DIAGNOSTIC_TEST|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
214803610|NCT05455073|DIETARY_SUPPLEMENT|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
214803611|NCT05455073|COMBINATION_PRODUCT|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
214803612|NCT05455073|COMBINATION_PRODUCT|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
214803613|NCT05455073|BEHAVIORAL|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
214803614|NCT05455073|BEHAVIORAL|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
214803615|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
214803616|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
214803617|NCT01318499|OTHER|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
214803618|NCT00352261|DRUG|Esomeprazole|
214803619|NCT00352261|DRUG|Lansoprazole|
214803620|NCT06230081|DRUG|Ropivacain 5 mg/ml + Clonidine|Drug used in the block
214803621|NCT03905486|DRUG|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
214803622|NCT03905486|DRUG|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
214803623|NCT02589223|OTHER|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
214803624|NCT02589223|OTHER|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
214803625|NCT00455351|DRUG|Vorinostat|Increasing dosing, phase I
214803626|NCT00849459|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
214803627|NCT00284674|DEVICE|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
214803628|NCT03494322|DRUG|Avelumab|Avelumab 10 mg/kg given IV
214803629|NCT03494322|DRUG|Cetuximab|"Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in."
214803630|NCT01988922|DRUG|ketamine|0.4 mg/kg oral racemic ketamine
214803631|NCT05745805|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
214803632|NCT03938922|DRUG|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
214803633|NCT05039190|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
214803634|NCT05039190|DRUG|Placebo|Placebo Injection
214803635|NCT05161611|DRUG|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
214803636|NCT05161611|OTHER|Placebo|10 mg of normal saline will be given to neonates per day
214803637|NCT05161611|OTHER|Phototherapy|Neonates will be put under phototherapy
214803638|NCT01641445|DRUG|Topiramate|Topiramate (200 mg daily)
214803639|NCT01641445|DRUG|Placebo|"Matching placebo capusules (sugar pills"
214803640|NCT01974141|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
214803641|NCT01974141|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
214803642|NCT05328141|OTHER|Bread and butter|A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
214803643|NCT05328141|OTHER|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
214803644|NCT05328141|OTHER|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
214803645|NCT01780415|OTHER|blastocoele aspiration|
214803646|NCT01264120|BEHAVIORAL|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
214803647|NCT01128686|OTHER|No intervention|This study is retrospective chart review
214803648|NCT06144710|DRUG|SG301 SC Injection|Subcutaneous injection every two weeks
214803649|NCT06144710|DRUG|SG301 SC Placebo|Subcutaneous injection every two weeks
214803650|NCT06522958|DIETARY_SUPPLEMENT|High Dissolving Transitional Food|Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
214803651|NCT05935098|DRUG|BGB-A3055|Administered intravenously
214803652|NCT05935098|DRUG|Tislelizumab|Administered intravenously
214803653|NCT05935098|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214803654|NCT04656353|BEHAVIORAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
214803655|NCT04656353|BEHAVIORAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
214803656|NCT04977336|DRUG|VX-548|Tablets for oral administration.
214803657|NCT04977336|DRUG|HB/APAP|Capsules for oral administration.
214803658|NCT04977336|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
214803659|NCT04977336|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
214803660|NCT05344898|PROCEDURE|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
214803661|NCT05344898|PROCEDURE|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
214803662|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
214803663|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
214803664|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
214803665|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
214803666|NCT03393858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
214803667|NCT03393858|BIOLOGICAL|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
214803668|NCT03393858|DEVICE|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
214803669|NCT01347710|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
214803670|NCT01347710|DRUG|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
214803671|NCT03385746|OTHER|polyamide|metal reinforced polyamide denture base material
214803672|NCT03385746|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
214803673|NCT05150236|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.
214803674|NCT05150236|DRUG|Ipilimumab|Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.
214803675|NCT05150236|DRUG|Nivolumab|Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
214803676|NCT03541681|PROCEDURE|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
214803677|NCT03541681|PROCEDURE|Anesthetic Injections|0,5 ml Bupivacain
214803678|NCT04757415|OTHER|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
214803679|NCT04757415|OTHER|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
214803680|NCT01968382|DRUG|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
214803681|NCT01968382|DRUG|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
214803682|NCT04018261|DRUG|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
214803683|NCT00023283|DRUG|Buprenorphine|"1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
214803684|NCT00551005|DRUG|celecoxib|
214803685|NCT00551005|DRUG|etoposide|
214803686|NCT00551005|OTHER|immunoenzyme technique|
214803687|NCT00551005|OTHER|laboratory biomarker analysis|
214803688|NCT01004172|DRUG|carboplatin|
214803689|NCT01004172|DRUG|bevacizumab|
214803690|NCT01004172|DRUG|herceptin|
214803691|NCT01904786|DRUG|Melatonin|
214803692|NCT01904786|DRUG|placebo|
214803693|NCT05720572|DRUG|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
214803694|NCT05720572|DRUG|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
214803695|NCT02471066|DEVICE|rTMS|"* Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
214803696|NCT00913107|DRUG|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days."
214803697|NCT00913107|DRUG|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days."
214803698|NCT00950872|DEVICE|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
214803699|NCT06364670|PROCEDURE|acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
214803700|NCT01434342|DRUG|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
214803701|NCT05876195|BIOLOGICAL|Keyhole-Limpet Hemocyanin|Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)
214803702|NCT05876195|DRUG|Saline|Placebo intervention.
214803703|NCT05876195|DRUG|Montanide ISA 51 VG|Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant
214803704|NCT05876195|DRUG|Alhydrogel|Alhydrogel is a vaccine adjuvant
214803705|NCT00970281|DRUG|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
214803706|NCT00970281|DRUG|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
214803707|NCT00408902|DRUG|tandutinib|Given orally, 500 mg bid daily
214803708|NCT00408902|OTHER|laboratory biomarker analysis|Correlative studies
214803709|NCT03696381|OTHER|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
214803710|NCT03696381|OTHER|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
214803711|NCT04500522|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
214803712|NCT04500522|DRUG|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
214803713|NCT01032369|OTHER|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
214803714|NCT01032369|OTHER|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
214803715|NCT03874130|DRUG|Scopolamine|IV Scopolamine
214803716|NCT00192608|DRUG|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
214803717|NCT00192608|DRUG|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
214803718|NCT00113425|DEVICE|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
214803719|NCT05151406|OTHER|educational program|The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
214803720|NCT06317246|GENETIC|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
214803721|NCT02187978|OTHER|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
214803722|NCT02187978|OTHER|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
214803723|NCT01139164|DRUG|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
214803724|NCT01139164|DRUG|Regimen B|Other malignancies not addressed in A or C
214803725|NCT01139164|DRUG|Regimen C|B-Cell Lymphomas
214803726|NCT01406678|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
214803727|NCT01406678|PROCEDURE|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
214803728|NCT01406678|DRUG|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
214803729|NCT02003183|RADIATION|[F-18]FDDNP|Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
214803730|NCT06497387|BIOLOGICAL|PRG-1801|PRG-1801 (BCMA-targeting CAR-T Cells)
214803731|NCT01933607|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
214803732|NCT04531228|PROCEDURE|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
214803733|NCT00878995|DRUG|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
214803734|NCT00878995|DRUG|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
214803735|NCT02847806|BIOLOGICAL|Estradiol (Insulin sensitivity)|
214803736|NCT02847806|BIOLOGICAL|Testosterone (Insulin sensitivity)|
214803737|NCT03104738|OTHER|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
214803738|NCT01737190|OTHER|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
214803739|NCT04586621|DEVICE|Atoldys/ Lexilens - SHAM|Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
214803740|NCT04586621|DEVICE|SHAM- Atoldys/ Lexilens|SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
214803741|NCT01148082|PROCEDURE|Self administered Surveys|
214803742|NCT01148082|PROCEDURE|Interviews|
214803743|NCT01759290|DEVICE|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
214803744|NCT01353495|DEVICE|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
214803745|NCT01353495|OTHER|Wound Debridement|Wounds debrided in both arms of study
214803746|NCT03605238|BIOLOGICAL|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
214803747|NCT04641559|OTHER|Personalized nutrition group|"A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI."
214803748|NCT04641559|OTHER|Personalized Plan group|Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
214803749|NCT04641559|OTHER|Control group|The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
214803750|NCT00191932|DRUG|Duloxetine|
214803751|NCT02291900|PROCEDURE|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
214803752|NCT01722448|DIETARY_SUPPLEMENT|Choline|4 capsules with 480 mg choline per day
214803753|NCT01722448|DIETARY_SUPPLEMENT|Placebo|
214803754|NCT03338972|BIOLOGICAL|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Given IV
214803755|NCT03338972|DRUG|Cyclophosphamide|Given IV
214803756|NCT03338972|DRUG|Fludarabine|Given IV
214803757|NCT03338972|PROCEDURE|Leukapheresis|Undergo leukapheresis
214803758|NCT02068040|DIETARY_SUPPLEMENT|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
214803759|NCT02480764|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
214803760|NCT02480764|DRUG|Valsartan|Valsartan 80 mg capsules
214803761|NCT02480764|DRUG|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
214803762|NCT02480764|DRUG|Valsartan Placebo|Valsartan placebo-matching capsules
214803763|NCT03629249|DRUG|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
214803764|NCT03629249|DRUG|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
214803765|NCT03629249|DRUG|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
214803766|NCT00847548|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
214803767|NCT00847548|BEHAVIORAL|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
214803768|NCT04588753|OTHER|active isolated stretch|"Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
214803769|NCT04588753|OTHER|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2\. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
214803770|NCT01767428|DRUG|Paracetamol|500 mg immediate release paracetamol formulations
214803771|NCT01621165|DRUG|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
214803772|NCT01621165|DRUG|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
214803773|NCT02385396|DIETARY_SUPPLEMENT|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
215031196|NCT02264366|BEHAVIORAL|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
215031197|NCT02266771|DEVICE|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
214803774|NCT03365726|DIAGNOSTIC_TEST|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
214803775|NCT05084001|DRUG|silver diamine fluoride|topical application of the agent on tooth surface
214803776|NCT05084001|DRUG|sodium fluoride varnish|topical application of the agent on tooth surface
214803777|NCT05084001|OTHER|tonic water|topical application of tonic water on tooth surface
214803778|NCT04227639|PROCEDURE|T-piece trial|T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
214803779|NCT04227639|PROCEDURE|Pressure-support trial|Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
214803780|NCT05128981|BEHAVIORAL|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
214803781|NCT02767310|DRUG|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
214803782|NCT02767310|DRUG|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
214803783|NCT04807270|OTHER|Intra-articular T-LAB / PRP KIT injection|Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
214803784|NCT04807270|OTHER|Intra-articular T-LAB / PRP INJECTION SYRINGE injection|Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
214803785|NCT04807270|OTHER|Intra-articular SALINE injection|Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
214803786|NCT06139224|DIETARY_SUPPLEMENT|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
214803787|NCT05483153|BEHAVIORAL|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
214803788|NCT03963206|DRUG|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
214803789|NCT03931239|BIOLOGICAL|Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval|An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
214803790|NCT01853553|DRUG|Spironolactone|Blood pressure medication.
214803791|NCT01853553|DRUG|Sugar pill|Placebo.
214803792|NCT05432193|DRUG|[Ga-68]-PNT6555|\[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
214803793|NCT05432193|DRUG|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
214803794|NCT02068248|DIETARY_SUPPLEMENT|Soluble Fibre|
214803795|NCT05326659|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
214803796|NCT05326659|DRUG|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
214803797|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
214803798|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
214803799|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
214803800|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
214803801|NCT02968888|OTHER|Strength training|
214803802|NCT02968888|DIETARY_SUPPLEMENT|Milk 1%|
214803803|NCT02968888|DIETARY_SUPPLEMENT|Whey protein concentrate 80|
214803804|NCT02968888|DIETARY_SUPPLEMENT|Native whey|
214803805|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
214803806|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
214803807|NCT06033482|PROCEDURE|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
214803808|NCT01674556|DRUG|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
214803809|NCT01150747|DRUG|ceftriaxone|250mg IM once
214803810|NCT01150747|DRUG|Azithromycin|1 gm once
214803811|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
214803812|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
214803813|NCT04426409|DRUG|tarivid ointment|Vaseline ointment is applied to both noses.
214803814|NCT01242865|BEHAVIORAL|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
214803815|NCT00234429|DRUG|Gefitinib, raltitrexed|
214803816|NCT01475474|DEVICE|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
214803817|NCT01030965|DRUG|GSK573719 125mcg|125mcg once-daily
214803818|NCT01030965|DRUG|GSK573719 250mcg|250mcg once-daily
214803819|NCT01030965|DRUG|GSK573719 500mcg|500mcg once-daily
214803820|NCT01030965|DRUG|Placebo|once-daily
214803821|NCT02029937|DRUG|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
214803822|NCT05563909|OTHER|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
214803823|NCT05563909|OTHER|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
214803824|NCT05563909|OTHER|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
214803825|NCT06121037|PROCEDURE|proximal ultrasound-guided GON radiofrequency ablation|proximal GON radiofrequency
214803826|NCT06121037|PROCEDURE|distal ultrasound-guided GON radiofrequency ablation|distal GON radiofrequency
214803827|NCT02090439|DRUG|Silodosin|
214803828|NCT01333527|PROCEDURE|No Sling|Early range of motion
214803829|NCT01333527|PROCEDURE|Sling|Patients will use the sling for 6 weeks, as per usual care
214803830|NCT02097290|DEVICE|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
215031198|NCT02266771|DEVICE|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
214803831|NCT05277389|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
214803832|NCT05277389|OTHER|Sham Control|Practice of Movement task without START
214803833|NCT06081647|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
214803834|NCT06081647|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
215031199|NCT00007774|DRUG|Haloperidol|
215031200|NCT00007774|DRUG|Olanzapine|
214803835|NCT01868009|DEVICE|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
214803836|NCT01868009|DEVICE|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
214803837|NCT01276782|DRUG|Levothyroxine|It is FDA approved drug for thyroid disease
214803838|NCT06004609|DEVICE|Low-level laser therapy (LLLT)|Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
214803839|NCT06004609|OTHER|Conventional physical therapy|Conventional physical therapy will be applied three time each week, for 12 weeks
214803840|NCT00156949|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
214803841|NCT01570699|GENETIC|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
214803842|NCT00926744|BEHAVIORAL|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
214803843|NCT06268522|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement: (MORE) group|Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
214803844|NCT06268522|BEHAVIORAL|Psychoeducation|Education on the neurobiology of pain, healthy eating, diet, sleep and stress
214803845|NCT06597149|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
214803846|NCT05468229|DRUG|Dorzagliatin|single oral dose of dorzagliatin 50 mg
214803847|NCT05468229|DRUG|Placebo|Matching placebo
214803848|NCT01395953|DRUG|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
214803849|NCT01395953|DRUG|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
214803850|NCT00743197|DRUG|Aspirin|Aspirin 81 mg daily
214803851|NCT00743197|DRUG|Lisinopril|Lisinopril 10 mg every night
214803852|NCT00743197|DRUG|Simvastatin|Simvastatin 20 mg every night
214803853|NCT00743197|DRUG|Lovaza|Lovaza 1 gram daily
214803854|NCT00743197|BEHAVIORAL|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
214803855|NCT03208426|DRUG|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
214803856|NCT03208426|DRUG|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
214803857|NCT03208426|DRUG|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
214803858|NCT03208426|DRUG|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
214803859|NCT03208426|DRUG|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
214803860|NCT03208426|DRUG|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
214803861|NCT03208426|DRUG|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
214803862|NCT03208426|DRUG|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
214803863|NCT03887689|BEHAVIORAL|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
214803864|NCT00794079|DIETARY_SUPPLEMENT|omega-3 fatty acids|4 grams per day for 8 weeks
214803865|NCT00794079|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 8 weeks
214803866|NCT03114956|PROCEDURE|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
214803867|NCT03114956|PROCEDURE|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
214803868|NCT03114956|PROCEDURE|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
214803869|NCT03114956|PROCEDURE|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
214803870|NCT03970772|DRUG|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
215031201|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
214803871|NCT03970772|OTHER|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
214803872|NCT02184728|DEVICE|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
214803873|NCT01478620|DRUG|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
214803874|NCT02139514|BEHAVIORAL|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
214803875|NCT00313885|DRUG|eplivanserin (SR46349)|oral administration
214803876|NCT00313885|DRUG|placebo|oral administration
214803877|NCT00152165|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
214803878|NCT01255371|DRUG|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
214803879|NCT01255371|DRUG|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
214803880|NCT02057848|OTHER|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
214803881|NCT02057848|OTHER|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
214803882|NCT02057848|OTHER|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
214803883|NCT00672854|DRUG|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
214803884|NCT00672854|DRUG|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
214803885|NCT01627366|OTHER|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
214803886|NCT03383744|DIETARY_SUPPLEMENT|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
214803887|NCT04644133|OTHER|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
214803888|NCT04644133|OTHER|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
214803889|NCT05249907|OTHER|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
214803890|NCT04291066|DRUG|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
214803891|NCT01649622|DRUG|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
214803892|NCT02215577|PROCEDURE|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
214803893|NCT02215577|PROCEDURE|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
214803894|NCT02487784|PROCEDURE|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
215031202|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
215031203|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
215031204|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)
214803895|NCT02487784|PROCEDURE|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
214803896|NCT06073249|OTHER|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
214803897|NCT06073249|OTHER|Tibial Nerve Stimulation|The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
214803898|NCT02380183|DEVICE|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
214803899|NCT00322400|DRUG|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
214803900|NCT00322400|DRUG|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
214803901|NCT00322400|DRUG|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
214803902|NCT02130466|BIOLOGICAL|Pembrolizumab|IV infusion
214803903|NCT02130466|DRUG|Dabrafenib|oral capsule
214803904|NCT02130466|DRUG|Trametinib|oral tablet
214803905|NCT02130466|DRUG|Placebo|IV infusion
214803906|NCT02924480|PROCEDURE|Cystectomy|
214803907|NCT02924480|DRUG|Lidocaine|Patients will receive lidocaine infusion during surgery
214803908|NCT02924480|DRUG|Saline|Patients will receive saline infusion during surgery
214803909|NCT01963364|DIETARY_SUPPLEMENT|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
214803910|NCT01963364|DIETARY_SUPPLEMENT|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
214803911|NCT00458900|DRUG|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
214803912|NCT05337709|OTHER|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
214803913|NCT03423225|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
214803914|NCT05810766|OTHER|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
214803915|NCT05810766|OTHER|conventional physical therapy|Hot pack for 15 minutes
214803916|NCT03287700|OTHER|No intervention|No intervention will be administered to any group in this observational study.
214803917|NCT03307239|OTHER|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
214803918|NCT03307239|OTHER|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
214803919|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
214803920|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
214803921|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 1|TEST
214803922|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 2|CONTROL
214803923|NCT05825300|BEHAVIORAL|Email message|Email message encourages patients to donate blood
214803924|NCT05825300|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
214803925|NCT02473809|DRUG|Liraglutide|Once daily
214803926|NCT02473809|DRUG|Placebo|Once daily
214803927|NCT02403700|DEVICE|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
214803928|NCT04659538|DEVICE|CAPTIS Embolic Protection device|The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
214803929|NCT01834053|BIOLOGICAL|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
214803930|NCT02837965|DRUG|treatment with topical superpotent corticosteroid therapy|
214803931|NCT02837965|DRUG|treatment with systemic therapy (methotrexate)|
214803932|NCT02837965|DRUG|treatment systemic therapy (prednisone)|
214803933|NCT02837965|DRUG|treatment with systemic therapy (prednisone)|
214803934|NCT02837965|DRUG|treatment with systemic therapy (doxycycline)|
214803935|NCT02073630|OTHER|active cerebellar stimulation|
214803936|NCT02073630|OTHER|sham cerebellar stimulation|
214803937|NCT03876561|PROCEDURE|Pelvic floor prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
214803938|NCT00938210|PROCEDURE|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
214803939|NCT00605748|PROCEDURE|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
214803940|NCT00605748|PROCEDURE|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
214803941|NCT04825938|DRUG|Toripalimab , Carboplatin, Nab-paclitaxel|Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
214803942|NCT05544448|OTHER|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
214803943|NCT01567956|DRUG|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
214803944|NCT01567956|DRUG|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
214803945|NCT01411332|RADIATION|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
214803946|NCT01411332|RADIATION|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
214803947|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
214803948|NCT00469586|DRUG|metformin|Tablets, 2000 mg/day.
214803949|NCT00469586|DRUG|glimepiride|Tablets, 4 mg/day.
215031205|NCT05931822|OTHER|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
215031206|NCT05931822|OTHER|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
214803950|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
214803951|NCT03231670|PROCEDURE|Blood sampling|5ml blood will be taken in addition to standard sampling
214803952|NCT01229020|OTHER|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
214803953|NCT04617769|BEHAVIORAL|Psychoeducation|psychoeducational materials on trauma and safety behaviors
214803954|NCT04617769|BEHAVIORAL|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
214803955|NCT02952248|DRUG|BI 754091|
214803956|NCT03346564|BEHAVIORAL|Ritual training program|Ritual training program including education and demonstration
214803957|NCT03346564|BEHAVIORAL|Routine care|
214803958|NCT03396133|DIAGNOSTIC_TEST|Snap|screen, transmission, and analysis ECG automated
214803959|NCT03057262|DEVICE|Repositioning splint|Application of repositioning splint in the study group.
214803960|NCT05432843|DRUG|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
214803961|NCT05432843|DRUG|Placebo|Patients receive a treatment with placebo for 8 weeks
214803962|NCT04431271|PROCEDURE|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
214803963|NCT04757090|DRUG|89Zr-trastuzumab|"-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure."
214803964|NCT02787278|DRUG|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
214803965|NCT02787278|DRUG|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
214803966|NCT02787278|DRUG|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
214803967|NCT03680898|DEVICE|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
214803968|NCT02218164|DRUG|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
214803969|NCT02218164|DRUG|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
214803970|NCT02218164|DRUG|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
214803971|NCT03043378|BEHAVIORAL|Questionnaires|Participants complete three questionnaires at consultation visit.
214803972|NCT03709862|DIAGNOSTIC_TEST|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
214803973|NCT01471522|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
214803974|NCT01471522|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
214803975|NCT01471522|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
214803976|NCT01471522|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
214803977|NCT01471522|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
214803978|NCT04183881|DRUG|Brodalumab 210mg SC|210 mg, subcutaneous dosing, every 2 weeks
214803979|NCT06683638|DRUG|Doxycycline 200mg daily for 14 days|Doxycycline will be taken as a single dose of 200mg daily, rather than the current CDC-recommended 100mg twice daily regimen for early syphilis. The duration will still be 14 days of therapy.
214803980|NCT01190293|DRUG|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
214803981|NCT04469153|OTHER|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
214803982|NCT05670171|PROCEDURE|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
214803983|NCT05670171|PROCEDURE|Stent Angioplasty|Nickel-titanium self-expanding bare stent
214803984|NCT07035574|OTHER|Conventional Denture Teeth|Complete dentures fabricated using conventional techniques with prefabricated acrylic denture teeth.
214803985|NCT07035574|OTHER|3D Printed Denture Teeth|Complete dentures fabricated using additive manufacturing techniques with advanced resin materials.
214803986|NCT06450002|OTHER|physical therapy|Tens and Hot packs for 20 minutes, ultrasound for 5 minutes on the back and back exercise in form of bridging exercise and core stability exercise
214803987|NCT02078700|OTHER|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
214803988|NCT06818487|DRUG|Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
214803989|NCT06818487|DRUG|Sodium Hyaluronate|Participants received 0.1% sodium hyaluronate eye drop
214803990|NCT06818487|DRUG|1/2Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 5 g per time for a duration of 4 weeks.
214803991|NCT06818487|DRUG|Placebo|Participants will receive the following placebo Chinese herbal granules, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
214803992|NCT06904508|BEHAVIORAL|Facing Your Fears (FYF) Intervention: A CBT Focused Group Treatment for Autistic Youth with Anxiety|FYF is an outpatient, multi-family, evidence-based CBT group treatment for children and adolescents ages 8-14 with average intellectual abilities, and a primary co-occurring anxiety diagnosis (social, generalized, separation anxiety, or specific phobia).
214803993|NCT06907966|BEHAVIORAL|Engaging Families home practice app|"The intervention is a smartphone application (or app) that was developed to support caregiver home practice of intervention skills. The app was designed to support caregivers participating in the Bridges program, an evidence-based, family-based preventive intervention. Features of the app were developed to help caregivers overcome common barriers to practicing intervention skills at home."
214803994|NCT06907966|OTHER|Scheduling app|The Cozi Family Organizer is a smartphone application that will be given to caregivers randomized to the active control group. Cozi is a highly rated family organization app with features that include a family calendar, to do list, shopping list, and daily agenda. Cozi is available on Android and iPhone devices.
214803995|NCT06241430|DEVICE|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
214803996|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
214803997|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
214803998|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
214803999|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
214804000|NCT06797726|BEHAVIORAL|Cognitive behavioral therapy|Session 1: Functional analysis, motivational approach and psycho-education (advantages/disadvantages of consumption ; effect of addiction on mental disorders and interaction ADHD/behavioral addiction) Session 2: Follow-up to psycho-education session 1, treatment plan Session 3: ADHD: compensation strategies; reducing distractibility distractibility Session 4: ADHD: calendar and organization worksheet Session 5: ADHD: mood disorders and emotions Session 6: Recognizing and managing emotions Session 7: Analysis of functional elements in addictive disorder addictive disorders in patients with ADHD Session 8: Risk situations, psycho-education (emotions) Session 9: Managing craving; analysis of the functional elements of of addiction Session 10: Relapse and relapse prevention, problem solving and social pressure
214804001|NCT06916858|DEVICE|home sleep test|Apnealink air
214804002|NCT01459874|BEHAVIORAL|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
214804003|NCT04124861|DRUG|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
214804004|NCT05271539|DRUG|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
214804005|NCT05271539|DRUG|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
214804006|NCT05687058|DRUG|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session at home.
214804007|NCT05687058|DRUG|Empagliflozin 10 mg daily dosing|Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
214804008|NCT03724149|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
214804009|NCT03724149|DRUG|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
214804010|NCT01279525|DEVICE|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
214804011|NCT03157622|BEHAVIORAL|Exposure in vivo|10 sessions based on an individualized fear hierarchy
214804012|NCT03157622|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
214804013|NCT01284439|DRUG|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
214804014|NCT01284439|DRUG|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
214804015|NCT01718938|DRUG|velusetrag dose 1|
214804016|NCT01718938|DRUG|velusetrag dose 2|
214804017|NCT01718938|DRUG|velusetrag dose 3|
214804018|NCT01718938|DRUG|placebo|
214804019|NCT02673580|OTHER|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
214804020|NCT02673580|OTHER|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
214804021|NCT04947748|OTHER|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
214804022|NCT05395858|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
214804023|NCT03165058|DIAGNOSTIC_TEST|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
214804024|NCT05240196|OTHER|music|playing binaural or non-binaural music
214804025|NCT03413046|DIAGNOSTIC_TEST|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
214804026|NCT01130623|DRUG|Pazopanib (GW786034)|
214804027|NCT03171155|DEVICE|XPro System|Implantation of the XPro System
214804028|NCT00583258|DRUG|Alfuzosin (Xatral)|10 mg PO once a day
214804029|NCT00583258|DRUG|Placebo Alfuzosin|10 mg PO once a day
214804030|NCT00444145|DRUG|Prevacid|30 mg bid for 3 months
214804031|NCT00444145|PROCEDURE|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
214804032|NCT03267745|DIETARY_SUPPLEMENT|Amino Acid|23.7 g amino acid 3 times daily for 28 days
214804033|NCT03267745|DEVICE|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
214804034|NCT03267745|OTHER|Placebo|Excipient-matched placebo 3 times daily for 28 days
214804035|NCT04814745|DRUG|intrathecal infusion|morphine 150 mcg will be used by intrathecal administration
214804036|NCT04814745|DRUG|Intravenous Infusion|tramadol administration
214804037|NCT04814745|DRUG|Ropivacaine injection|bilateral transversus abdominis plane block by using ropivacaine 80 mg
214804038|NCT01195298|DRUG|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
214804039|NCT00775177|DRUG|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
214804040|NCT04872257|DRUG|Oral Vitamin D|Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
214804041|NCT04872257|PROCEDURE|NB-UVB Phototherapy|NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
214804042|NCT04872257|DRUG|Placebo|Administered orally daily for 6 months
214804043|NCT03208543|DEVICE|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
214804044|NCT00991445|PROCEDURE|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
214804045|NCT00991445|PROCEDURE|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
214804046|NCT01781598|DEVICE|Total knee arthroplasty (TKA) (Smith &Nephew®)|
214804047|NCT03229005|PROCEDURE|implant insertion|during surgery soft tissues will be measured
214804048|NCT03229005|PROCEDURE|operculectomy|during second surgery soft tissues will be measured again
214804049|NCT03229005|PROCEDURE|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
214804050|NCT02510547|PROCEDURE|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
214804051|NCT02510547|PROCEDURE|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
214804052|NCT05046548|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
214804053|NCT05046548|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
214804054|NCT00002725|DRUG|bryostatin 1|
214804055|NCT00002725|DRUG|chemotherapy|
214804056|NCT04281563|OTHER|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
214804057|NCT03155048|DRUG|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
214804058|NCT03155048|DRUG|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
214804059|NCT05192330|DEVICE|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
214804060|NCT05192330|BEHAVIORAL|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
214804061|NCT05008822|OTHER|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
214804062|NCT05008822|OTHER|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
214804063|NCT03474510|DRUG|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
214804064|NCT03474510|OTHER|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
214804065|NCT00465881|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
214804066|NCT01861210|BEHAVIORAL|Couples Voluntary HIV Counseling and Testing|
214804067|NCT01861210|BEHAVIORAL|Individual Counseling and Testing|
214804068|NCT03106610|DRUG|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
214804069|NCT03106610|BEHAVIORAL|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
214804070|NCT01374919|DRUG|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
214804071|NCT02812849|DRUG|Cu-64 DOTATATE|
214804072|NCT05717036|DEVICE|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
214804073|NCT02680626|DRUG|Magnesium Sulfate|Given via transversus abdominis plane block
214804074|NCT02680626|DRUG|Ropivacaine|Given via transversus abdominis plane block
214804075|NCT05647031|OTHER|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
214804076|NCT02977026|BEHAVIORAL|CYD|
214804077|NCT02977026|BEHAVIORAL|AHC|
214804078|NCT00090857|DRUG|Letrozole|
214804079|NCT00090857|OTHER|Placebo|
214804080|NCT05851131|OTHER|Approach to Diagnosis and Treatment of Osteoporosis Questionnaire|"The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report."
214804081|NCT06219473|DRUG|Fascia lata membrane|novel allogenic derived acellular matrix produced from human fascia lata allograft
214804082|NCT06219473|DRUG|Platlet Rich fibrin membrane|Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
214804083|NCT06219473|DRUG|subepithelial connective tissue graft|The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
214804084|NCT05097326|DRUG|Mifepristone|Mifepristone 200mg taken orally
214804085|NCT05097326|DRUG|Misoprostol|Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
214804086|NCT01553838|DEVICE|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
214804087|NCT06158516|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
214804088|NCT06158516|DRUG|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
214804089|NCT02060110|DEVICE|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
214804090|NCT02060110|DEVICE|MADIT-CRT ICD ONLY ARM|
214804091|NCT06264024|PROCEDURE|Corneal collagen cross linking (CXL)|Use of Avedro Inc. KXL 1 system to stop progression of keratoconus
214804092|NCT06264024|PROCEDURE|Transepithelial phototherapeutic keratectomy (t-PTK)|Use Alcon Wavelight 500, excimer laser to remove the epithelium and some of the stroma over apex
214804093|NCT03299296|DRUG|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
214804094|NCT03299296|DRUG|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
214804095|NCT03192696|DEVICE|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
214804096|NCT00653471|DEVICE|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
214804097|NCT00653471|DEVICE|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
214804098|NCT00653471|DEVICE|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
214804099|NCT04671888|OTHER|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
214804100|NCT05325047|PROCEDURE|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
214804101|NCT02684344|DRUG|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
214804102|NCT02684344|OTHER|Education|Education about signs and symptoms of urinary retention
214804103|NCT02143765|DRUG|Mitiglinide|three times a day, orally, for 12 weeks
214804104|NCT02143765|DRUG|Acarbose|three times a day, orally, for 12 weeks
214804105|NCT04529746|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
214804106|NCT03480425|DIAGNOSTIC_TEST|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
214804107|NCT02486822|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
214804108|NCT02486822|DRUG|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
214804109|NCT02486822|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
214804110|NCT03970122|DRUG|GFB-887|IMP
214804111|NCT03970122|DRUG|Placebo|Matching
214804112|NCT06011122|PROCEDURE|Distal radius fracture ORIF with a specific volar plate|Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
214804113|NCT02956772|DRUG|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
214804114|NCT02956772|DRUG|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
214804115|NCT05687630|OTHER|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
214804116|NCT03100630|DRUG|RO7239361|Specified dose on specified days
214804117|NCT04810416|OTHER|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
214804118|NCT04810416|OTHER|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
214804119|NCT04810416|OTHER|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
214804120|NCT04810416|OTHER|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
214804121|NCT00266006|DRUG|eptacog alfa (activated)|
214804122|NCT06381609|BEHAVIORAL|Quality life questionnaire AQoLS|Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
214804123|NCT06381609|BEHAVIORAL|Quality life questionnaire Euroqol EQ-5D-5L|Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
214804124|NCT06381609|OTHER|Peer support consultations|"For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.~Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up"
214804125|NCT01471847|DRUG|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
214804126|NCT01471847|DRUG|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
214804127|NCT02793453|OTHER|periodontal smears|
214804128|NCT05017298|BIOLOGICAL|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
214804129|NCT01386047|OTHER|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
214804130|NCT05868447|PROCEDURE|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
214804131|NCT02244034|PROCEDURE|hypothermia|
214804132|NCT02456779|OTHER|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
214804133|NCT02456779|OTHER|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
214804134|NCT02456779|OTHER|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
214804135|NCT02548637|PROCEDURE|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
214804136|NCT06443307|DRUG|Irinotecan Liposome|The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
214804137|NCT02424188|OTHER|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
214804138|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
214804139|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
214804140|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
214804141|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
214804142|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
214804143|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
214804144|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
214804145|NCT03846388|DIAGNOSTIC_TEST|follicular stimulating hormone|in the serum of our patients
214804146|NCT03846388|DIAGNOSTIC_TEST|Anti-mullerian hormone|in the serum of our patients
214804147|NCT03846388|RADIATION|Basal antral follicle count|by ultrasound
214804148|NCT02622945|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
214804149|NCT02622945|DEVICE|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
214804150|NCT00630305|DEVICE|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
214804151|NCT00630305|DEVICE|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
214804152|NCT00630305|DEVICE|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
214804153|NCT04949698|DEVICE|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
214804154|NCT06223347|DIAGNOSTIC_TEST|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
214804155|NCT05901857|DIAGNOSTIC_TEST|convolutional neural network|A deep learning model for dental age classification from panoramic images
214804156|NCT04949620|BEHAVIORAL|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
214804157|NCT04949620|BEHAVIORAL|Online parenting program|The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
214804158|NCT04902157|DIAGNOSTIC_TEST|Cycle threshold|cycle threshold number
214804159|NCT00467220|BEHAVIORAL|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
214804160|NCT05294094|BEHAVIORAL|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
214804161|NCT05294094|BEHAVIORAL|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
214804162|NCT00404131|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
214804163|NCT03339856|DEVICE|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
214804164|NCT04500470|DRUG|Ketoprofen + INH|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
214804165|NCT04500470|DRUG|Ketoprofen + placebo|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
214804166|NCT01494506|DRUG|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"
214804167|NCT01494506|DRUG|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
214804168|NCT01494506|DRUG|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
214804169|NCT00236457|DRUG|risperidone|
214804170|NCT04639765|OTHER|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
214804171|NCT04639765|OTHER|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
214804172|NCT04639765|OTHER|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
214804173|NCT04639765|OTHER|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
214804174|NCT04639765|OTHER|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
214804175|NCT04639765|OTHER|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
214804176|NCT05701670|BEHAVIORAL|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
214804177|NCT00186290|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
214804178|NCT01979341|PROCEDURE|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
214804179|NCT02753842|DEVICE|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
214804180|NCT00075543|DRUG|docetaxel|
214804181|NCT00075543|DRUG|oxaliplatin|
214804182|NCT03596190|DIAGNOSTIC_TEST|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
214804183|NCT02627209|OTHER|spectrophotometric assay|measurement of enzyme activity in the serum
214804184|NCT02627209|OTHER|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
214804185|NCT03659656|BEHAVIORAL|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
214804186|NCT03659656|DEVICE|Fitbit usage|The participants will have a Fitbit to use for 3 months.
214804187|NCT02303548|DRUG|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
214804188|NCT02303548|DRUG|Normal saline|Placebo
214804189|NCT02019056|DRUG|Placebo /bid P.O|
214804190|NCT02019056|DRUG|MG-1|
214804191|NCT02019056|DRUG|MG-2 : MG1000mg, Placebo /bid P.O|
214804192|NCT02019056|DRUG|metadoxine|
214804193|NCT05526950|DEVICE|Device: CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
214804194|NCT05216081|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
214804195|NCT01311908|PROCEDURE|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
214804196|NCT02359981|BEHAVIORAL|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
214804197|NCT02359981|BEHAVIORAL|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
214804198|NCT02359981|DEVICE|Smartphone|An Android Smartphone with operating system version higher than 2.2
214804199|NCT04172454|BIOLOGICAL|AK104|AK104, 6mg/kg, Q2W
214804200|NCT02576353|DRUG|Fentanyl|Fentanyl Sublingual Spray (FSS)
214804201|NCT02576353|DRUG|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
214804202|NCT01149629|DRUG|Droxidopa|One capsule containing 300 mg droxidopa, given once
214804203|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
214804204|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
214804205|NCT02393482|DRUG|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
214804206|NCT02393482|DRUG|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
214804207|NCT02393482|DRUG|Add back therapy 1 (tibolone)|tibolone 5 mg/die
214804208|NCT02393482|DRUG|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
214804209|NCT05525026|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
214804210|NCT05034653|OTHER|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
214804211|NCT05034653|OTHER|Healthy Plate|Quarter-quarter-half meal concept
214804212|NCT00715065|PROCEDURE|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
214804213|NCT01845363|DRUG|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
214804214|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab."
214804215|NCT02321384|DRUG|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
214804216|NCT02321384|DRUG|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
214804217|NCT02321384|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
214804218|NCT02321384|DRUG|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
214804219|NCT06000280|PROCEDURE|Trabeculectomy surgery|The Trabeculectomy aims to create a permanent drainage outflow channel for the aqueous humor, connecting the anterior chamber to the sub-Tenon's space, using mitomycin C consisted of opening the conjunctival base of the fornix and applying mitomycin C 0.4 mg/ml for 2 minutes. The trabeculectomy techniques require controlled outflow of aqueous humor through a sclerostomy and a partial-thickness scleral flap to form a subconjunctival bleb. The protected strength of the flap, with or without sutures, and the strength of the episcleral tissue determine the final IOP.
214804220|NCT02472522|DRUG|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
214804221|NCT02472522|OTHER|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
214804222|NCT05035355|PROCEDURE|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
214804223|NCT01785368|OTHER|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
214804224|NCT01785368|OTHER|Baseline observation|During this period of the study, baseline data will be collected.
214804225|NCT03359434|DEVICE|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
214804226|NCT03359434|DEVICE|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
214804227|NCT01421030|PROCEDURE|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
214804228|NCT04916652|RADIATION|MRI|MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).
214804229|NCT03100903|DRUG|BI 655130|single dose
214804230|NCT05193279|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
214804231|NCT06834230|DRUG|Dotinurad|Start at 0.5 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (2 mg once daily).
214804232|NCT06834230|DRUG|Febuxostat|Start at 10 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (40 mg once daily).
214804233|NCT04788836|OTHER|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
214804234|NCT04788836|OTHER|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
214804235|NCT04888221|DRUG|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
214804236|NCT04888221|DRUG|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
214804237|NCT00433147|DRUG|Afegostat tartrate|
214804238|NCT00517647|DRUG|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
214804239|NCT02821247|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
214804240|NCT01882647|DRUG|000-0551 Lotion|
214804241|NCT01882647|DRUG|Vehicle Lotion|
214804242|NCT01887262|DEVICE|BCM-guided fluid management|
214804243|NCT01887262|PROCEDURE|Fluid management based on the clinical information alone|
214804244|NCT00002166|DRUG|Nevirapine|
214804245|NCT05550519|OTHER|Entecavir (ETV)|ETV will continue throughout screening and will be stopped at baseline.
214804246|NCT05550519|OTHER|Tenofovir Disoproxil Fumarate (TDF)|TDF will continue throughout screening and will be stopped at baseline.
214804247|NCT05550519|OTHER|Tenofovir Alafenamide (TAF)|TAF will continue throughout screening and will be stopped at baseline.
214804248|NCT05880056|DRUG|Nerkardou (5 mg) & (10 mg)|Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
214804249|NCT00614289|DEVICE|Epikeia Coatings|Topical skin coating
214804250|NCT02405325|BEHAVIORAL|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
214804251|NCT06203522|PROCEDURE|Data collection of successful completion of MRI|age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
214804252|NCT01609322|BEHAVIORAL|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
214804253|NCT01609322|BEHAVIORAL|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
214804254|NCT04681703|BEHAVIORAL|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
214804255|NCT05218798|DIAGNOSTIC_TEST|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial"
214804256|NCT02493270|BEHAVIORAL|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
214804257|NCT02493270|PROCEDURE|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
214804258|NCT03399526|DRUG|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
214804259|NCT03399526|DRUG|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
214804260|NCT03399526|DRUG|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
214804261|NCT03399526|DRUG|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
214804262|NCT03399526|DRUG|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
214804263|NCT03413631|BEHAVIORAL|Prenatal mentalization intervention|
214804264|NCT03413631|OTHER|Prenatal obstetric treatment as usual|
214804265|NCT04760067|OTHER|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
214804266|NCT03311646|OTHER|Normal nicotine content cigarettes (NNC, Baseline)|Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
214804267|NCT03311646|OTHER|Very low nicotine content (VLNC)|Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
214804268|NCT02439008|PROCEDURE|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~* Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
214804269|NCT02439008|PROCEDURE|Blood samples collection during radiotherapy|"* Sample T1: within 15 minutes after the administration of the first fraction,~* Sample T2: within 15 minutes after the administration of the second fraction,~* Sample T3: within 15 minutes after the administration of the third fraction"
214804270|NCT02439008|PROCEDURE|Blood samples collection after radiotherapy|"* Sample T4: one week after the end of the radiotherapy,~* Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
214804271|NCT02439008|RADIATION|Radiotherapy|
214804272|NCT04638166|OTHER|Mineral water|Drinking mineral water for 12 weeks
214804273|NCT04638166|OTHER|Plain water|Drinking plain water for 12 weeks
214804274|NCT01492361|DRUG|AMR101|Parallel Assignment
214804275|NCT01492361|DRUG|Placebo|Parallel Assignment
214804276|NCT01492361|DRUG|Statin therapy|Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
214804277|NCT03460197|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
214804278|NCT00093925|DRUG|clevidipine|
214804279|NCT00093925|DRUG|nicardipine|
214804280|NCT05912322|DIETARY_SUPPLEMENT|Black chokeberry juice|100ml black chokeberry juice/day
214804281|NCT04776655|DRUG|Bevacizumab|"This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
214804282|NCT04776655|DRUG|Cetuximab|"This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
214804283|NCT04776655|DRUG|5-FU|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
214804284|NCT04776655|DRUG|Irinotecan|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
214804285|NCT04776655|DRUG|Calcium levofolinate|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
214804286|NCT01034319|BEHAVIORAL|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
214804287|NCT01034319|BEHAVIORAL|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
214804288|NCT00125424|DRUG|AQUAVAN® (fospropofol disodium) Injection|
214804289|NCT00125424|DRUG|Midazolam HCl|
214804290|NCT03444038|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214804291|NCT04812756|BEHAVIORAL|Step-2-It - text messaging program|participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
214804292|NCT01347788|DRUG|cabozantinib|Cabozantinib PO QD
214804293|NCT05759975|DEVICE|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
214804294|NCT05759975|DEVICE|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
214804295|NCT02523105|DEVICE|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
214804296|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
214804297|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
214804298|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
214804299|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
214804300|NCT01752257|DRUG|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
214804301|NCT02837822|DEVICE|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
214804302|NCT02837822|PROCEDURE|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
214804303|NCT03765502|DEVICE|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
214804304|NCT03765502|DEVICE|GEK|Used to administer glucagon intramuscularly (IM)
214804305|NCT03765502|DRUG|IM Glucagon|Administered IM via GEK
214804306|NCT00683020|BEHAVIORAL|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
214804307|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy|"the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
214804308|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel|"The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
214804309|NCT01465295|DEVICE|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
214804310|NCT03323125|OTHER|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
214804311|NCT01220830|DEVICE|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
215031589|NCT06682598|OTHER|Multicomponent physical exercise training|The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
214804312|NCT04048148|DEVICE|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
214804313|NCT05474248|BEHAVIORAL|Experimental group|Diaphragmatic Breathing Training
214804314|NCT03064022|OTHER|Growth|Some preterm infants grow at higher rates than others
214804315|NCT02716025|PROCEDURE|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
214804316|NCT04090892|PROCEDURE|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
214804317|NCT03814343|DRUG|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
214804318|NCT03814343|DRUG|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
214804319|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
214804320|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
214804321|NCT05353764|OTHER|scalp nerve block combined with intercostal nerve block using 0.5% ropivacaine|Participants randomized to the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine, which was performed exclusively by an attending anesthesiologist.An attending anesthesiologist will select the site of SNB based on the surgical incision site. Scalp nerve was blocked including greater occipital nerve (2-3ml), superficial temporal nerve (2-3ml), trochlear nerve (2-3ml) and supraorbital nerve (2-3ml). The total volume in scalp nerve block will not exceed 10 ml.Ultrasound-guided unilateral ICNB will be performed at the level of T4-T5 next to the sternum.10-15ml of 0.5% ropivacaine will be injected into the intercostal spaces where incision locates after negative aspiration.
214804322|NCT01272336|DRUG|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
214804323|NCT01272336|OTHER|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
214804324|NCT03156764|OTHER|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
214804325|NCT02015000|PROCEDURE|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
214804326|NCT02171052|DRUG|Dabigatran etexilate|
214804327|NCT02171052|DRUG|Digoxin|
214804328|NCT01220206|DRUG|Placebo|2 placebo capsules daily
214804329|NCT01220206|DRUG|One POMx capsule daily|One POMx capsule, one placebo capsule daily
214804330|NCT01220206|DRUG|2 POMx Capsules|2 POMx Capsules daily
214804331|NCT04809675|DEVICE|Hard occlusal splint|Use of a hard occlusal splint at times they considered helpful.
214804332|NCT04809675|DEVICE|Flexible customized mouthguard|Use of a flexible customized mouthguard at times they considered helpful.
214804333|NCT00004099|DRUG|cisplatin|
214804334|NCT00004099|DRUG|fluorouracil|
214804335|NCT00004099|DRUG|leucovorin calcium|
214804336|NCT00004099|PROCEDURE|neoadjuvant therapy|
214804337|NCT03919942|OTHER|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
214804338|NCT03919942|OTHER|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
214804339|NCT03919942|OTHER|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
214804340|NCT00728949|BIOLOGICAL|IMC-A12 (cixutumumab)|10 mg/kg I.V.
214804341|NCT00728949|DRUG|tamoxifen|Daily 20 mg, oral
214804342|NCT00728949|DRUG|Anastrozole|Daily 1 mg, oral
214804343|NCT00728949|DRUG|Letrozole|Daily 2.5 mg, oral
214804344|NCT00728949|DRUG|Exemestane|Daily 25 mg, oral
214804345|NCT00728949|DRUG|Fulvestrant|Monthly 250 mg, intramuscularly
214804346|NCT05527756|OTHER|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
214804347|NCT05527756|OTHER|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
214804348|NCT00989352|DRUG|Methotrexate|3g/m² i.v. max. 9 times
214804349|NCT00989352|DRUG|Lomustine|110 mg/m² p.o., max. 3 times
214804350|NCT00989352|DRUG|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
214804351|NCT00989352|DRUG|Rituximab|375 mg/m² i.v., max. 10 times
214804352|NCT01346085|DRUG|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
214804353|NCT03127137|DRUG|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
214804354|NCT03127137|DRUG|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
214804355|NCT03658837|PROCEDURE|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
214804356|NCT02885337|OTHER|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
214804357|NCT02885337|OTHER|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
214804358|NCT01550588|DEVICE|Device closure|PFO Amplatzer device closure
214804359|NCT01550588|DRUG|Standard medical treatment|Standard Medical management using anti-coagulant therapy
214804360|NCT00405678|BEHAVIORAL|Exercise Training|Subjects receiving chemo with exercise training
214804361|NCT00405678|BEHAVIORAL|Chemo only|Subjects receiving chemo only
214804362|NCT02695732|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
214804363|NCT02695732|DEVICE|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
214804364|NCT02037997|DRUG|docetaxel|docetaxel 75mg/m2 ivgtt D1
214804365|NCT02037997|DRUG|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
214804366|NCT02037997|DRUG|Erlotinib|Erlotinib 150mg qd
214804367|NCT01513083|DRUG|trastuzumab emtansine|Multiple intravenous doses
214804368|NCT03031054|PROCEDURE|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
214804369|NCT03031054|PROCEDURE|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
214804370|NCT05806710|DIETARY_SUPPLEMENT|GourMed© meal|patients receive GourMed© meal as lunch for 7 consecutive days
214804371|NCT01870180|DEVICE|EyeBag|fabric bag of beads which can be heated in a microwave
214804372|NCT01870180|OTHER|Placebo|
215031207|NCT03517605|OTHER|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
214804373|NCT01249664|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
214804374|NCT01249664|PROCEDURE|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
214804375|NCT01684969|DRUG|Haloperidol|0.5 mg iv x one dose
214804376|NCT01684969|DRUG|Placebo|0.5 mg iv , one dose
214804377|NCT05844722|BEHAVIORAL|Mindfulness-based intervention therapy|Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
214804378|NCT05844722|OTHER|usual care|Usual care means received standard multidisciplinary stroke care
214804379|NCT01682083|DRUG|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
214804380|NCT01682083|DRUG|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
214804381|NCT01682083|DRUG|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
214804382|NCT04331665|DRUG|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
214804383|NCT04813705|RADIATION|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
214804384|NCT04813705|RADIATION|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
214804385|NCT04813705|DRUG|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
214804386|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
214804387|NCT03968796|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
214804388|NCT03968796|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
214804389|NCT03968796|OTHER|Kinesio Taping|
214804390|NCT03968796|OTHER|Sham Kinesio Taping|
214804391|NCT03433430|DEVICE|truSculpt|Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
214804392|NCT05782647|DEVICE|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
215031590|NCT06689527|DRUG|Vamorolone|Days 3 to 14: 6 mg/kg vamorolone once daily.
214804393|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
214804394|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
214804395|NCT02255708|OTHER|Proprioceptive Neuromuscular Facilitation - PNF|
214804396|NCT03415802|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
214804397|NCT01425060|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
214804398|NCT01425060|OTHER|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
214804399|NCT05606393|OTHER|virtual reality speech training|virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software
214804400|NCT05606393|OTHER|traditional speech therapy|traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
214804401|NCT00006174|DRUG|Letrozole|
214804402|NCT03368508|BEHAVIORAL|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
214804403|NCT03368508|BEHAVIORAL|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
214804404|NCT04718506|BEHAVIORAL|Exercise|Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises \[squat, bench press, deadlift and bench pull\]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
214804405|NCT04718506|BEHAVIORAL|Inspiratory muscle training|Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
214804406|NCT04718506|BEHAVIORAL|Controls|Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
214804407|NCT01594203|OTHER|F18-FGD PET/CT|
214804408|NCT01378039|DRUG|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
214804409|NCT03291548|DIETARY_SUPPLEMENT|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
214804410|NCT03291548|DIETARY_SUPPLEMENT|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
214804411|NCT06126848|DEVICE|Ambient sensor system|Main study: A contactless non-intrusive ambient sensor system including infrared motion sensors combined with a contactless Emfit bed sensor will be installed in the home of single living study patients by using a commercially available System (Domo Health®, Lausanne) after informed consent has been obtained. Sensor data are prospectively followed over 3-6 months for predefined indicators of health deterioration. If indicators for health deterioration are present, patients will be called in to the hospital for cardiology consult by the study team including blood analysis for follow-up of BNP values and if necessary, therapy adaption.
214804412|NCT05194748|OTHER|No intervention, observational only|No intervention, observational only
214804413|NCT01470560|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
214804414|NCT01470560|BEHAVIORAL|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
214804415|NCT05319665|DEVICE|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
214804416|NCT05833581|OTHER|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
214804417|NCT03601663|BEHAVIORAL|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
214804418|NCT03601663|BEHAVIORAL|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
214804419|NCT03601663|BEHAVIORAL|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
214804420|NCT06110039|OTHER|Cervicothoracic Junction Mobilization|The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.
214804421|NCT06110039|OTHER|Upper Thoracic Spine Manipulation:|The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
214804422|NCT05149118|PROCEDURE|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
214804423|NCT04212949|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
214804424|NCT04212949|DRUG|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
214804425|NCT00921336|DRUG|KW-2450|Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
214804426|NCT05086523|DEVICE|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
214804427|NCT05086523|DEVICE|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
214804428|NCT05488613|DRUG|Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
214804429|NCT05133609|BIOLOGICAL|ChAdOx1 nCoV-19 vaccine (AZD1222)|ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
214804430|NCT04173936|BEHAVIORAL|tai chi|12-week community-based tai chi program
214804431|NCT04251611|OTHER|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
214804432|NCT05515926|PROCEDURE|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
214804433|NCT05515926|PROCEDURE|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
214804434|NCT05141864|BIOLOGICAL|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
214804435|NCT05141864|DRUG|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
214804436|NCT05141864|OTHER|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
214804437|NCT00738803|PROCEDURE|Total hip replacement|Total hip replacement typically preformed for hip arthritis
214804438|NCT01659203|RADIATION|IG-IMPT|Daily, Monday-Friday for about 6 weeks
214804439|NCT01659203|RADIATION|IG IMRT|Daily, Monday-Friday for about 6 weeks
214804440|NCT01239121|OTHER|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
214804441|NCT01239121|OTHER|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
214804442|NCT02802436|PROCEDURE|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
214804443|NCT03299400|DEVICE|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
214804444|NCT00237549|PROCEDURE|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
214804445|NCT04392271|DRUG|LY3372689|Administered orally.
214804446|NCT04392271|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered intravenously (IV).
214804447|NCT03259100|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
214804448|NCT04180007|DRUG|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
214804449|NCT04666909|DIAGNOSTIC_TEST|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP \> 135 mm Hg or DBP \> 85 mmHg (based on the average of 3 BP readings); or average SBP \> 130 mm Hg or DBP \> 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
214804450|NCT01014728|DRUG|propofol|100-200mcg/kg/min by infusion
214804451|NCT01014728|DRUG|sevoflurane|1-3% of sevoflurane (expired)
215031208|NCT01146821|DIETARY_SUPPLEMENT|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care
214804452|NCT01856309|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
214804453|NCT01856309|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
214804454|NCT01856309|DRUG|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
214804455|NCT01075711|DRUG|Prednisone|According to SPC
214804456|NCT06023147|PROCEDURE|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
214804457|NCT04946877|DIAGNOSTIC_TEST|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
214804458|NCT01050647|DRUG|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
214804459|NCT01050647|OTHER|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
214804460|NCT00220337|DRUG|Lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
214804461|NCT00944697|DRUG|Oxycodone Naloxone|Oxycodone Naloxone tablets
214804462|NCT00944697|DRUG|Placebo tablets|Placebo Oxycodone Naloxone tablets
214804463|NCT01022047|DRUG|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
214804464|NCT01022047|DRUG|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
214804465|NCT01284205|BIOLOGICAL|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
214804466|NCT01284205|BIOLOGICAL|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
214804467|NCT04926883|OTHER|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
214804471|NCT01273181|BIOLOGICAL|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
214804472|NCT01273181|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
214804473|NCT01273181|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
214804474|NCT01273181|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
214804475|NCT01056770|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
214804476|NCT05995470|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for drinkers with psychological distress
214804477|NCT05995470|BEHAVIORAL|Monthly health education|General health information and sharing sessions
214804478|NCT04172649|OTHER|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
214804479|NCT04172649|OTHER|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
214804480|NCT02803242|OTHER|Patient Reported Outcomes|
214804481|NCT00186108|DRUG|Oral Triamcinalone|
214804482|NCT06025448|PROCEDURE|BIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).
214804483|NCT06025448|PROCEDURE|MIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).
214804484|NCT06012903|OTHER|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
214804485|NCT06012903|OTHER|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
214804486|NCT06012903|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
214804487|NCT06012903|OTHER|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
214804488|NCT06012903|OTHER|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
214804489|NCT03657160|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
214804490|NCT03657160|DRUG|Vedolizumab|Vedolizumab IV infusion.
214804491|NCT04452734|PROCEDURE|Platelet Rich Plasma (PRP)|PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
214804492|NCT04452734|PROCEDURE|Surgical Extraction|Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
214804493|NCT00488865|DEVICE|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
214804494|NCT04366141|DEVICE|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
214804495|NCT00002260|DRUG|Alovudine|
214804496|NCT03806062|DRUG|domperidone|10 mg domperidone 3 times a day after meals
214804497|NCT03806062|DEVICE|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
214804498|NCT03806062|DEVICE|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
214804499|NCT03682562|DIAGNOSTIC_TEST|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
214804500|NCT02629757|DRUG|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
214804501|NCT05991726|OTHER|Other: Survey|Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
214804502|NCT04525248|PROCEDURE|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
214804503|NCT04525248|PROCEDURE|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
214804504|NCT02462330|DRUG|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
214804505|NCT02462330|DRUG|Placebo comparator|injections of human albumin
214804506|NCT03006965|DRUG|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
214804507|NCT03006965|DRUG|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
214804508|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
214804509|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
214804510|NCT04280757|PROCEDURE|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
214804511|NCT05696639|PROCEDURE|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
214804512|NCT00507234|DRUG|formoterol fumarate inhalation solution|
215031591|NCT06689527|DRUG|Midazolam|Day 1 and 14: Single doses of 2.5 mg midazolam
214804513|NCT04922112|DIAGNOSTIC_TEST|Obstructive sleep apnea testing|"* Functional Outcomes of Sleep Questionnaire (FOSQ-10)~* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)~* Epworth Sleepiness Scale (ESS)~* Adult Comorbidity Evaluation (ACE 27)~* University of Washington Quality of Life Questionnaire (UW-QOL)~* Chronic Pain Assessment Questionnaire"
214804514|NCT02749513|DRUG|Itraconazole|
214804515|NCT02161913|BEHAVIORAL|Multi-Family Group Treatment|
214804516|NCT02161913|BEHAVIORAL|SCI Education Control Group|
214804517|NCT03157388|DRUG|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
214804518|NCT03263637|DRUG|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
214804519|NCT02512978|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
214804520|NCT04909437|DIETARY_SUPPLEMENT|Mycobiotic|2 sachet/day, 21 days, oral
214804521|NCT04909437|DIETARY_SUPPLEMENT|Placebo|2 sachet/day, 21 days, oral
214804522|NCT02520505|DRUG|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
214804523|NCT02520505|BEHAVIORAL|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
214804524|NCT02520505|PROCEDURE|Intrauterine Insemination|Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
214804525|NCT06394505|OTHER|Data Collection Tools|"Safety Climate Scale: Since a customized safety climate perception measurement tool for nurses could not be found in the literature, the Safety Climate Scale (SAS), developed by Choudry et al. in 2009 and adapted to Turkish by Türen et al. in 2014, was used on healthcare workers and electronics industry workers. The scale consists of two subscales: 10 items evaluating the management's perspective and rules (YÖBAK) and 4 items evaluating colleagues and safety training (İAGE). Participants rate the statements in the scale between strongly agree (five points) and strongly disagree (one point). The total score of the scale is calculated by taking the average of the item scores, and as the average gets closer to five, the safety climate improves, and as it gets closer to one, it gets worse. The Cronbach Alpha reliability coefficient of the scale was determined as 0.93 in the study conducted by Türen et al., and in this study it was calculated as 0.82."
214804526|NCT01118247|PROCEDURE|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
214804527|NCT03677648|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
214804528|NCT03677648|DRUG|Placebos|Placebos
214804529|NCT05459727|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
214804530|NCT05459727|PROCEDURE|Control periodontal treatment|Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
214804531|NCT03268109|OTHER|assessment of cognitive impairment|Measure of Global Deficit Score
214804532|NCT01922648|PROCEDURE|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
214804533|NCT01101230|OTHER|Almonds|1.5 oz almonds/day
214804534|NCT04586088|DRUG|Apatinib plus Camrelizumab|Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
214804535|NCT04638153|BIOLOGICAL|Recifercept|Recifercept
214804536|NCT02707653|DRUG|Misoprostol|400 mcg sublingual misoprostol
214804537|NCT00002549|BIOLOGICAL|filgrastim|
214804538|NCT00002549|DRUG|busulfan|
214804539|NCT00002549|DRUG|cyclophosphamide|
214804540|NCT00002549|DRUG|cytarabine|
214804541|NCT00002549|DRUG|daunorubicin hydrochloride|
214804542|NCT00002549|DRUG|etoposide|
214804543|NCT00002549|DRUG|idarubicin|
214804544|NCT00002549|DRUG|mesna|
214804545|NCT00002549|DRUG|mitoxantrone hydrochloride|
214804546|NCT00002549|PROCEDURE|allogeneic bone marrow transplantation|
214804547|NCT00002549|PROCEDURE|autologous bone marrow transplantation|
214804548|NCT00002549|PROCEDURE|peripheral blood stem cell transplantation|
214804549|NCT00002549|RADIATION|radiation therapy|
214804550|NCT00270959|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
214804551|NCT00270959|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
214804552|NCT00270959|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
214804553|NCT00270959|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
214804554|NCT02829970|BEHAVIORAL|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).
214804555|NCT02829970|BEHAVIORAL|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
214804556|NCT04006171|DIAGNOSTIC_TEST|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
214804557|NCT01440283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
214804558|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
214804559|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
214804560|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
214804561|NCT05915403|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire|diagnostic tests
214804562|NCT05577845|DRUG|Ramosetron|Ramosetron, 4 weeks
214804563|NCT03599505|PROCEDURE|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
214804564|NCT06155630|OTHER|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
214804565|NCT02624557|DRUG|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
214804566|NCT05288127|DRUG|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
214804567|NCT03206866|DIAGNOSTIC_TEST|serum regucalcin antibody|serum regucalcin antibody
214804568|NCT00171821|DRUG|Deferasirox|
214804569|NCT00902109|DEVICE|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
214804570|NCT00902109|DEVICE|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
214804571|NCT00902109|DEVICE|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
214804572|NCT05165056|DEVICE|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
214804573|NCT05110677|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
214804574|NCT04386759|OTHER|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
214804575|NCT03447860|BEHAVIORAL|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
214804576|NCT03447860|BEHAVIORAL|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
214804577|NCT01974648|DRUG|propofol|
214804578|NCT01974648|DRUG|propofol and remifentanil|
214804579|NCT03850639|BEHAVIORAL|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
214804580|NCT04154579|BEHAVIORAL|HeRe We Arts|Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
214804581|NCT04154579|BEHAVIORAL|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
214804582|NCT01064570|DRUG|all-trans retinoic acid (ATRA)|
214804583|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
214804584|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
214804585|NCT00106548|DRUG|Placebo|iv / month
214804586|NCT00106548|DRUG|Methotrexate|10-25mg/week
214804587|NCT00537030|DRUG|Asparaginase|Given IM
214804588|NCT00537030|OTHER|Laboratory Biomarker Analysis|Correlative studies
214804589|NCT00537030|OTHER|Pharmacological Study|Correlative studies
214804590|NCT06383572|DRUG|Cyclophosphamide|Given by IV
214804591|NCT06383572|DRUG|Fludarabine phosphate|Given by IV
214804592|NCT06383572|DRUG|Decitabine|Given by IV
214804593|NCT06383572|DRUG|Dexamethasone|Given by mouth
214804594|NCT06354270|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
214804595|NCT06354270|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
214804596|NCT06137183|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
214804597|NCT06137183|DRUG|Placebo|Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
214804598|NCT03092856|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
214804599|NCT03092856|DRUG|Axitinib|Given PO
214804600|NCT03092856|OTHER|Laboratory Biomarker Analysis|Correlative studies
214804601|NCT03092856|OTHER|Placebo|Given IV
215031209|NCT01146821|DIETARY_SUPPLEMENT|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
214804602|NCT02736656|DRUG|SPN-812|"Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months.~Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months."
214804603|NCT06436781|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
214804604|NCT06436781|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
214804605|NCT06106555|BEHAVIORAL|Dialectibal Behaviour Therapy|Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
214804606|NCT05432232|DEVICE|HistoSonics Investigational System|The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
214804607|NCT01939197|DRUG|ABT-450/r/ABT-267|tablet
214804608|NCT01939197|DRUG|ABT-333|tablet
214804609|NCT01939197|DRUG|ribavirin|tablet
214804610|NCT04738032|OTHER|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
214804611|NCT00643877|PROCEDURE|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
214804612|NCT00643877|PROCEDURE|surgery|radical surgery only
214804613|NCT01834963|DRUG|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
214804614|NCT01834963|DRUG|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
214804615|NCT00004376|DRUG|guanfacine|
214804616|NCT01536223|DRUG|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
214804617|NCT01536223|DRUG|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
214804618|NCT02126865|DRUG|Placebo to BI 1060469|tablet
214804619|NCT02126865|DRUG|BI 1060469 Healthy|tablet
214804620|NCT02126865|DRUG|Placebo to BI 1060469 asthmatics|tablet
214804621|NCT02126865|DRUG|BI 1060469 asthmatics|tablet
214804622|NCT00182806|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
214804623|NCT00182806|DRUG|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
214804624|NCT01316653|BEHAVIORAL|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
214804625|NCT01316653|BEHAVIORAL|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
214804626|NCT02451605|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
214804627|NCT02451605|PROCEDURE|Total knee replacement surgery.|Total knee replacement surgery.
214804628|NCT03992859|PROCEDURE|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
214804629|NCT02231645|DEVICE|STN DBS|The DBS device is turned on and off by the physician.
214804630|NCT03159156|BEHAVIORAL|Applied Tension|Described above.
214804631|NCT03159156|BEHAVIORAL|Respiration Control|Described above.
214804632|NCT03159156|BEHAVIORAL|Applied Tension/Respiration Control|Described above.
214804633|NCT03847558|DIAGNOSTIC_TEST|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
214804634|NCT00005778|DRUG|High-dose immunoablative therapy|"1. High dose cyclophosphamide for 4 days.~2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
214804635|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
214804636|NCT04232605|OTHER|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
214804637|NCT04232605|OTHER|Placebo|Receive intravenous infusion saline
214804638|NCT00745095|DRUG|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
214804639|NCT06495762|OTHER|e-health assesment|This study is purely observational and does not forsee any intervention but only observational assesment of parents' wellbeing
214804640|NCT04351178|BEHAVIORAL|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
214804641|NCT04351178|BEHAVIORAL|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
214804642|NCT04925024|BIOLOGICAL|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
214804643|NCT04757259|DRUG|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams \[mg\] twice daily \[BID\]).
214804644|NCT01891409|DEVICE|Male circumcision using the Shang Ring device|
214804645|NCT03288766|PROCEDURE|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
214804646|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
214804647|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
214804648|NCT00958243|BIOLOGICAL|Placebo|Placebo
214804649|NCT06114407|DRUG|Baricitinib 2mg|Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
214804650|NCT06114407|DRUG|Tofacitinib 5 mg|Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
214804651|NCT05628636|DRUG|AC-OLE-01-VA|formulation of tricaprilin
214804652|NCT04016532|DIETARY_SUPPLEMENT|Personalized dietary management at home|"Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions"
214804653|NCT06170268|OTHER|Routine Care Documentation|Routine Care Documentation
214804654|NCT04916938|BEHAVIORAL|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
214804655|NCT04916938|BEHAVIORAL|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
214804656|NCT04916938|BEHAVIORAL|Interview|History and perception of the mother's issues.
214804657|NCT04916938|BEHAVIORAL|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
214804658|NCT00298870|DRUG|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
214804659|NCT00298870|DRUG|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
214804660|NCT06217172|DEVICE|RHEUPP App|RHEUPP App; Monthly RAPID3 response; General recommendations for managing Flare through App and Social Monitor for appropriate orientation; 3 month consultation by telehealth.
214804661|NCT06217172|OTHER|Usual Follow-up|Usual Care in Rheumatoid Arthritis Ambulatory Service
214804662|NCT02636816|DRUG|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
214804663|NCT05265806|DRUG|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
214804664|NCT05265806|DRUG|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
214804665|NCT05265806|DRUG|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
214804666|NCT03481205|DEVICE|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
214804667|NCT03571048|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
214804668|NCT03571048|BEHAVIORAL|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
214804669|NCT02679183|DIETARY_SUPPLEMENT|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
214804670|NCT02679183|OTHER|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
214804671|NCT00963209|DRUG|tamoxifen citrate|
214804672|NCT00963209|OTHER|laboratory biomarker analysis|
214804673|NCT00963209|OTHER|pharmacological study|
214804674|NCT01143857|DRUG|Varenicline|Varenicline 2.0 mg/day or Placebo
214804675|NCT00058292|BIOLOGICAL|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
214804676|NCT00058292|BIOLOGICAL|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
214804677|NCT00058292|DRUG|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
214804678|NCT00058292|DRUG|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
214804679|NCT00058292|DRUG|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
214804680|NCT00058292|DRUG|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
214804681|NCT00058292|PROCEDURE|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
214804682|NCT00058292|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
214804683|NCT04029610|PROCEDURE|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
214804684|NCT04029610|DRUG|lidocaine and adrenalin|lidocaine and adrenalin
214804685|NCT04029610|DRUG|lidocaine and arterial blockage|lidocaine and arterial blockage
214804686|NCT00162123|DRUG|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
214804687|NCT00188656|PROCEDURE|CT thorax|
214804688|NCT02173236|OTHER|platform-switched implants|
214804689|NCT02173236|OTHER|platform-matched implant|
214804690|NCT00534703|GENETIC|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
214804691|NCT00534703|DRUG|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
214804692|NCT00582400|DRUG|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
214804693|NCT02161848|OTHER|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
214804694|NCT05436756|OTHER|Biological sampling and collection|"* Biological sampling and collection:~  * whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~ * urine: 1 bottle of 30ml~* Freezing of serum after centrifugation~* Storage~* Collection of clinico-biological data on a dedicated eCRF"
214804695|NCT03257085|OTHER|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
214804696|NCT03257085|OTHER|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
214804697|NCT01936948|PROCEDURE|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
214804698|NCT06232252|DRUG|BI 765423|BI 765423
214804699|NCT06232252|DRUG|Placebo matching BI 765423|Placebo matching BI 765423
214804700|NCT02007122|OTHER|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
214804701|NCT02007122|OTHER|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
214804702|NCT02968186|BEHAVIORAL|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
214804703|NCT02781727|DRUG|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
214804704|NCT02781727|DRUG|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
214804705|NCT02327130|DEVICE|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
214804706|NCT06431594|DRUG|GSK5733584|GSK5733584 will be administered
214804707|NCT00003706|DRUG|pemetrexed disodium|
214804708|NCT01624766|BIOLOGICAL|Anakinra|Given SC
214804709|NCT01624766|BIOLOGICAL|Denosumab|Given SC
214804710|NCT01624766|DRUG|Everolimus|Given PO
214804711|NCT00495326|DRUG|Nevirapine based therapy|"* Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
214804712|NCT00495326|DRUG|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
214804713|NCT00495326|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"* Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase."
214804714|NCT05188937|PROCEDURE|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
214804715|NCT05256628|OTHER|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
214804716|NCT05256628|OTHER|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
214804717|NCT03055949|BEHAVIORAL|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
214804718|NCT02363790|PROCEDURE|LVHR PFC|Information included in arm description
214804719|NCT02363790|PROCEDURE|Bridging LVHR|Information included in arm description
214804720|NCT00417209|DRUG|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
214804721|NCT00417209|DRUG|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
214804722|NCT00417209|DRUG|Capecitabine|administered orally from Day 1 to Day 14 q3w
214804723|NCT01973049|DRUG|Daclatasvir|
214804724|NCT01973049|DRUG|Asunaprevir|
214804725|NCT01973049|DRUG|BMS-791325|
214804726|NCT01973049|DRUG|Ribavirin|
214804727|NCT01973049|DRUG|Placebo matching Ribavirin|
214804728|NCT04374084|OTHER|Moxibustion plus Cupping|"Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes."
214804729|NCT00406848|DRUG|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
214804730|NCT00406848|DRUG|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
214804731|NCT00276757|DRUG|leucovorin calcium|
214804732|NCT00276757|DRUG|methotrexate|
214804733|NCT00276757|DRUG|prednisolone|
214804734|NCT00276757|DRUG|vinblastine sulfate|
214804735|NCT00352690|DRUG|Paclitaxel poliglumex|
214804736|NCT00352690|DRUG|Carboplatin|
214804737|NCT00352690|RADIATION|External beam radiation therapy|
214804738|NCT05427383|DRUG|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
214804739|NCT05427383|DRUG|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
214804740|NCT05427383|DRUG|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
214804741|NCT05427383|DRUG|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
214804742|NCT04008784|DRUG|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
214804743|NCT04008784|DRUG|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
214804744|NCT05962879|BEHAVIORAL|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
214804745|NCT02589171|DEVICE|Neo Close Abdominal Closure|Neo Close Abdominal Closure
214804746|NCT02589171|DEVICE|Carter Thomason Device|Carter Thomason Device
214804747|NCT00448175|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
214804748|NCT00448175|DRUG|Tolterodine|
214804749|NCT04325100|BEHAVIORAL|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
214804750|NCT04325100|BEHAVIORAL|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
214804751|NCT05116670|OTHER||this is an observation study, no intervention is needed
214804752|NCT03657056|DEVICE|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
214804753|NCT03407365|BEHAVIORAL|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
214804754|NCT03407365|BEHAVIORAL|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
214804755|NCT03947242|DRUG|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
214804756|NCT01678547|DEVICE|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
214804757|NCT01678547|DEVICE|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
214804758|NCT01678547|OTHER|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
214804759|NCT03806803|BIOLOGICAL|Lyophilized fecal microbiota transplant|15 capsules
214804760|NCT03806803|BIOLOGICAL|Lyophilized sterile fecal filtrate|15 capsules
214804761|NCT01798836|PROCEDURE|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
214804762|NCT01798836|PROCEDURE|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
214804763|NCT02701114|PROCEDURE|Proximal Adductor Canal Block|Continuous Nerve Block
214804764|NCT02701114|PROCEDURE|Distal Adductor Canal Block|Continuous Nerve Block
214804765|NCT01113606|OTHER|Obagi New-Derm System|
214804766|NCT01113606|OTHER|Standard of Care|
215031210|NCT04486677|BEHAVIORAL|Caring Cards Group|Group of Veteran card-makers.
215031211|NCT04486677|BEHAVIORAL|Caring Cards Recipients|Group of Veteran card-recipients.
215031592|NCT03968042|DRUG|Nerve Growth Factor|Intramuscular injection for 2 weeks
214804767|NCT02719522|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
214804768|NCT02566278|OTHER|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
214804769|NCT00425256|DRUG|Bremelanotide|
214804770|NCT00351845|BEHAVIORAL|Low carbohydrate diet (behavior)|
214804771|NCT03788265|DEVICE|Lipogems|harvest and inject micro-fragment adipose tissue
214804772|NCT02134522|DEVICE|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
214804773|NCT03424291|DRUG|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
214804774|NCT04582721|OTHER|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~* 1\) CON-SCS with Subcutaneous stimulation~* 2\) HF-SCS~* 3\) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
214804775|NCT04627376|OTHER|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
214804776|NCT00252551|PROCEDURE|Osteosynthesis|
214804777|NCT00252551|PROCEDURE|Simple surgery|Surgery without device
214804778|NCT05920954|PROCEDURE|ERCP|Repeat ERCP
214804779|NCT06149780|DEVICE|Patients treated with laser|Patients treated with laser with topical steroid Patients treated with laser with vehicle
214804780|NCT03264664|DRUG|E7386|Oral immediate release tablets.
214804781|NCT00855556|GENETIC|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~1. Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~2. Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~3. No fasting, activity or medication restrictions are required prior to or following blood collection.~4. Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
215031593|NCT03968042|DRUG|Edaravone|Intravenous injection for 2 weeks
215031594|NCT03968042|DRUG|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
215031595|NCT06695689|DRUG|LM303|Treatment with LM303 injection
214804782|NCT01170442|DRUG|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
214804783|NCT01170442|DRUG|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
214804784|NCT01170442|DRUG|Placebo|placebo orally, daily for six months
214804785|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
214804786|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
214804787|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan + exercise group|Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
214804788|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan group|Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
214804789|NCT05052164|BEHAVIORAL|Active Comparator: Celiac controls group|Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
214804790|NCT03883607|DRUG|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
214804791|NCT03883607|DRUG|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
214804792|NCT05554653|DIETARY_SUPPLEMENT|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
214804793|NCT05554653|DIETARY_SUPPLEMENT|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
214804794|NCT04209920|DEVICE|CAD-CAM milled PMMA crown|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
214804795|NCT04209920|OTHER|Cast metal coping using nickel chromium alloy|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
214804796|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
214804797|NCT02527096|DRUG|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
214804798|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
214804799|NCT03491358|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
214804800|NCT03491358|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
214804801|NCT04025879|BIOLOGICAL|Nivolumab|Specified dose on specified days
214804802|NCT04025879|DRUG|Carboplatin|Specified dose on specified days
214804803|NCT04025879|DRUG|Cisplatin|Specified dose on specified days
214804804|NCT04025879|DRUG|Paclitaxel|Specified dose on specified days
214804805|NCT04025879|DRUG|Pemetrexed|Specified dose on specified days
214804806|NCT04025879|DRUG|Placebo|Specified dose on specified days
214804807|NCT04025879|DRUG|Docetaxel|Specified dose on specified days
214804808|NCT01198236|DRUG|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1\*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells\> 0.5\*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
214804809|NCT02888171|DRUG|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
214804810|NCT02888171|DRUG|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
214804811|NCT01136642|DRUG|Nicotrol|
214804812|NCT00254111|DEVICE|Ultra Probe Laser System|
214804813|NCT04192500|BIOLOGICAL|OVX836|One single administration intramuscularly at Day 1.
214804814|NCT04192500|BIOLOGICAL|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
214804815|NCT04882293|DRUG|Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose|1 tablet once a day, 20 mg /160 mg, Orally
214804816|NCT04882293|DRUG|Atorvastatin (Lipitor ®)|1 tablet once a day, 20 mg, Orally
214804817|NCT02419690|BEHAVIORAL|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
214804818|NCT05026866|DRUG|Donanemab|Administered intravenously
214804819|NCT05026866|DRUG|Placebo|Administered intravenously
214804820|NCT06497101|BEHAVIORAL|Temperament Based Therapy with Support (TBT-S)|Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
214804821|NCT03941223|PROCEDURE|PECSII and paravertebral blocks|Regional anesthesia for mastectomy outcomes
214804822|NCT05370183|PROCEDURE|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
214804823|NCT05370183|PROCEDURE|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
214804824|NCT03577964|DIAGNOSTIC_TEST|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
214804825|NCT05189184|DRUG|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
214804826|NCT02051309|DRUG|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
214804827|NCT02051309|DRUG|Placebo|
214804828|NCT00163449|DRUG|Ciclesonide|Efficacy and Safety of Ciclesonide
214804829|NCT00163449|DRUG|Placebo|Placebo
214804830|NCT01677078|DEVICE|Neuronavigation system|Neuronavigation
214804831|NCT01677078|DEVICE|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
214804832|NCT03654196|DRUG|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
214804833|NCT03654196|DRUG|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
214804834|NCT00592098|DRUG|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
214804835|NCT00592098|DRUG|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
214804836|NCT03805438|DRUG|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
214804837|NCT00610090|DEVICE|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
214804838|NCT01174134|OTHER|Nutritional beverage|
214804839|NCT00366899|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
214804840|NCT00366899|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
214804841|NCT03163875|OTHER|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
214804842|NCT05922449|PROCEDURE|Thoracic Paravertebral Block|Patients randomly assigned to PV group will be placed in lateral position, and punctured using the out of plane technique guided by ultrasound (Shenzhen Huasheng Navi low-frequency convex array probe). 15 ml of 0.5% ropivacaine was administered to the T4 and T7 thoracic paravertebral spaces respectively, for a total of 30 ml. After injection, the pleura of the punctured segment and adjacent segments could be obviously moved down. Upon successful puncture, the patient was transferred to the supine position. After 5, 10, and 15 minutes, the range of sensory blockage was tested at T3\~T8 to cover the surgical area.
214804843|NCT03968549|DIETARY_SUPPLEMENT|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
214804844|NCT03968549|OTHER|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
214804845|NCT01619800|DEVICE|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
214804846|NCT01619800|DEVICE|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
214804847|NCT05390437|DIETARY_SUPPLEMENT|Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination|4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
214804848|NCT05390437|DIETARY_SUPPLEMENT|Ready to use theraputic food (RUTF) and Starch (placebo)|Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
214804849|NCT05289713|PROCEDURE|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
214804850|NCT02539485|OTHER|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
214804851|NCT04583852|OTHER|AIVÍA, Ultra-Brightening Spot Micro-needle Patch|a dissolving micro-needle patch, contains active ingredients
214804852|NCT04583852|OTHER|Placebo Micro-needle Patch|matching placebo will be provided as a dissolving micro-needle patch
214804853|NCT02927509|DRUG|TNF alpha blockers|
214804854|NCT02429271|DRUG|Ticagrelor|
214804855|NCT02429271|DRUG|Clopidogrel|
214804856|NCT02429271|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
214804857|NCT02429271|PROCEDURE|Coronary Angiography|
214804858|NCT01255878|DEVICE|occlusal stabilization splint|
214804859|NCT01255878|DRUG|Gabapentine|100 mg(1 capsule)three times per day for two months
214804860|NCT02707978|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214804861|NCT01186588|DRUG|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
214804862|NCT03416777|BEHAVIORAL|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
214804863|NCT03416777|DIETARY_SUPPLEMENT|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
214804864|NCT03416777|BEHAVIORAL|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
214804865|NCT00994253|DRUG|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
214804866|NCT00994253|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
214804867|NCT01110447|DRUG|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
214804868|NCT01110447|OTHER|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
214804869|NCT02352298|DEVICE|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
214804870|NCT02352298|DEVICE|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
214804871|NCT00419770|DRUG|deferasirox|20 mg/kg enterally per day
214804872|NCT00419770|DRUG|Placebo|
214804873|NCT00419770|DRUG|Liposomal amphotericin B|
214804874|NCT03456570|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
214804875|NCT03456570|DRUG|Placebo Oral Tablet|oral tablets twice daily
214804876|NCT04175548|OTHER|Data extraction from medical files|Data extraction from medical files
214804877|NCT00005948|BIOLOGICAL|aldesleukin|
214804878|NCT00005948|BIOLOGICAL|recombinant interferon alfa|
214804879|NCT00005948|BIOLOGICAL|sargramostim|
214804880|NCT00005948|DRUG|busulfan|
214804881|NCT00005948|PROCEDURE|peripheral blood stem cell transplantation|
214804882|NCT04840251|OTHER|Well-being review and rehabiliation|"For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~* how they are~* what they can do for themselves~* what it is challenging for them to do~* how active they are~* if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes."
214804883|NCT04840251|OTHER|Qualitative Interviews|Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
214804884|NCT05651230|DIETARY_SUPPLEMENT|Rhamnan sulfate|A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
214804885|NCT06148090|DIAGNOSTIC_TEST|clobetasol decreasing measurement|"At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month"
214804886|NCT05121233|DRUG|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
214804887|NCT05121233|DRUG|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
214804888|NCT01627457|DEVICE|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
214804889|NCT01412580|OTHER|observational follow-up|observational follow-up
214804890|NCT05411692|OTHER|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
214804891|NCT05411692|OTHER|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
214804892|NCT05411692|OTHER|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
214804893|NCT02848326|DRUG|Atogepant|Atogepant capsule.
214804894|NCT02848326|DRUG|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
214804895|NCT01705769|OTHER|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
214804896|NCT01705769|OTHER|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
214804897|NCT01705769|OTHER|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
214804898|NCT03119480|DEVICE|electronic alerts|electronic alerts for AKI
214804899|NCT00927992|OTHER|Epidemiological Non interventional|Epidemiological Non interventional
214804900|NCT05023005|OTHER|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
214804901|NCT02857270|DRUG|LY3214996|Administered orally
214804902|NCT02857270|DRUG|Midazolam|Administered orally
214804903|NCT02857270|DRUG|Abemaciclib|Administered orally
214804904|NCT02857270|DRUG|Nab-paclitaxel|Administered IV
214804905|NCT02857270|DRUG|Gemcitabine|Administered IV
214804906|NCT02857270|DRUG|Encorafenib|Administered orally
214804907|NCT02857270|DRUG|Cetuximab|Administered IV
214804908|NCT01636570|DRUG|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
214804909|NCT01636570|DRUG|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
214804910|NCT04220151|GENETIC|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
214804911|NCT03973177|DRUG|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
214804912|NCT03973177|DRUG|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
214804913|NCT02446626|PROCEDURE|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
214804914|NCT02446626|PROCEDURE|Blood draw|Peripheral blood draws will be performed.
214804915|NCT02446626|DEVICE|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
214804916|NCT05007795|DIAGNOSTIC_TEST|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
214804917|NCT04526210|DRUG|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
214804918|NCT04526210|DRUG|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
214804919|NCT05471817|DRUG|Elinzanetant (BAY3427080)|Capsule, oral, single dose
214804920|NCT05471817|DRUG|Dabigatran etexilate|Capsule, oral, single dose
214804921|NCT06248450|OTHER|Medical yoga|Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.
214804922|NCT00812734|PROCEDURE|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
214804923|NCT00957814|BEHAVIORAL|Nutritional education|Systematic nutritional orientation program
214804924|NCT03341481|OTHER|Femaltiker|Patient had taken twice a day the product
214804925|NCT03341481|OTHER|Placebo|Patient had taken twice a day the placebo
214804926|NCT05710341|DIETARY_SUPPLEMENT|Water with added nitrate|Water with added nitrate
214804927|NCT05710341|DIETARY_SUPPLEMENT|Water without added nitrate|Water without added nitrate
214804928|NCT04334590|PROCEDURE|Cleft Lip/Nose Repair without PSIO|Standard of care surgical repair of cleft lip/nose without PSIO.
214804929|NCT04334590|PROCEDURE|Presurgical Infant Orthopedic Therapy|Standard of care surgical repair of cleft lip/nose with PSIO.
214804930|NCT05031884|DEVICE|MGIR3-US|MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
214804931|NCT05853484|OTHER|Bimodal lifestyle program|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
214804932|NCT01975207|BEHAVIORAL|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
214804933|NCT01975207|BEHAVIORAL|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
214804934|NCT01975207|BEHAVIORAL|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
214804935|NCT01781637|DRUG|Omalizumab|subcutaneous injection
214804936|NCT01781637|DRUG|placebo|subcutaneous injection
214804937|NCT05706337|DRUG|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
214804938|NCT05706337|DRUG|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
214804939|NCT05554809|OTHER|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
214804940|NCT01308593|DEVICE|Juvederm XC|Filler
214804941|NCT01308593|DRUG|Botox|26 units dosed one time
214804942|NCT06083337|DEVICE|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
214804943|NCT02804737|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
214804944|NCT02999178|DRUG|Nintedanib|
214804945|NCT02999178|DRUG|Placebo|
214804946|NCT00002889|DRUG|flutamide|
214804947|NCT00002889|DRUG|goserelin|
214804948|NCT00002889|DRUG|leuprolide acetate|
214804949|NCT00002889|RADIATION|low-LET photon therapy|
214804950|NCT03746093|DIETARY_SUPPLEMENT|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
214804951|NCT03746093|DIETARY_SUPPLEMENT|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
214804952|NCT04983706|PROCEDURE|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
214804953|NCT00458848|DRUG|asparaginase|
214804954|NCT00458848|DRUG|daunorubicin hydrochloride|
214804955|NCT00458848|DRUG|etoposide|
214804956|NCT00458848|DRUG|idarubicin|
214804957|NCT00458848|DRUG|imatinib mesylate|
214804958|NCT00458848|DRUG|mercaptopurine|
214804959|NCT00458848|DRUG|methotrexate|
214804960|NCT00458848|DRUG|methylprednisolone|
214804961|NCT00458848|DRUG|mitoxantrone hydrochloride|
214804962|NCT00458848|DRUG|prednisone|
214804963|NCT00458848|DRUG|vincristine sulfate|
214804964|NCT00458848|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214804965|NCT00458848|PROCEDURE|autologous hematopoietic stem cell transplantation|
214804966|NCT00458848|PROCEDURE|peripheral blood stem cell transplantation|
214804967|NCT00458848|RADIATION|radiation therapy|
215031212|NCT01809431|BEHAVIORAL|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
215031213|NCT02130037|BEHAVIORAL|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
215031214|NCT02130037|OTHER|psychotherapy|standard psychotherapy for eating disorders
214804968|NCT02837757|OTHER|Biological samples|blood and tumor tissue samples
214804969|NCT03914066|BEHAVIORAL|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
214804970|NCT00917657|PROCEDURE|Photorefractive keratectomy|
214804971|NCT05405725|BIOLOGICAL|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
214804972|NCT05405725|BIOLOGICAL|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
214804973|NCT00277381|BEHAVIORAL|Automated feedback regarding drug adherence|
214804974|NCT01483352|DEVICE|Accu-Chek DiaPort|
214804975|NCT00331526|BIOLOGICAL|aldesleukin|
214804976|NCT00331526|BIOLOGICAL|therapeutic autologous lymphocytes|
214804977|NCT00331526|PROCEDURE|adjuvant therapy|
214804978|NCT00331526|PROCEDURE|conventional surgery|
214804979|NCT00416481|BEHAVIORAL|quality of life questionnaires|
214804980|NCT04205942|DEVICE|Argon Plasma Jet|Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
214804981|NCT04205942|DEVICE|Placebo|Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
214804982|NCT01658293|BEHAVIORAL|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
214804983|NCT01658293|BEHAVIORAL|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
214804984|NCT03596372|DRUG|BAY1834942|"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."
214804985|NCT00396526|DRUG|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
214804986|NCT04114448|OTHER|Therapeutic exercise|Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
214804987|NCT04114448|OTHER|Usual physical therapy care|Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
214804988|NCT04112082|BEHAVIORAL|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
214804989|NCT04112082|OTHER|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
214804990|NCT02506582|DIETARY_SUPPLEMENT|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
214804991|NCT02506582|DIETARY_SUPPLEMENT|placebo|40 g powdered rice flour
214804992|NCT01909557|DRUG|Acetyl-L-carnitine|
214804993|NCT01909557|DRUG|placebo|
214804994|NCT05885165|BEHAVIORAL|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
214804995|NCT05885165|BEHAVIORAL|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
214804996|NCT05561426|OTHER|Ad libitum breakfast and dinner meals for 12 days|Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
214804997|NCT04165148|DEVICE|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
214804998|NCT04165148|DEVICE|conventional laparoscopy|conventional laparoscopy
214804999|NCT04165148|OTHER|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
214805000|NCT04165148|OTHER|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
214805001|NCT04165148|OTHER|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
214805002|NCT00983684|DEVICE|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
214805003|NCT00983684|RADIATION|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
214805004|NCT00913705|DRUG|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
214805005|NCT00913705|DRUG|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
214805006|NCT00913705|PROCEDURE|Surgery|Surgery
214805007|NCT04048005|DIAGNOSTIC_TEST|Fractional flow reserve|
214805008|NCT01001845|DRUG|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
214805009|NCT01001845|DRUG|vit E|200 mg twice daily for 3 weeks
214805010|NCT01001845|DRUG|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
214805011|NCT01288131|DRUG|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
214805012|NCT01288131|DRUG|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
214805013|NCT01400022|OTHER|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
214805014|NCT01400022|OTHER|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
214805015|NCT05682118|PROCEDURE|roadmap|"FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg."
214805016|NCT05682118|PROCEDURE|iFR/FFR|Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
214805017|NCT02137993|DRUG|A-prexa|A-prexa 5-20 mg for 6 weeks
214805018|NCT02137993|DRUG|Zyprexa|Zyprexa 5-20 mg for 6 weeks
214805019|NCT03469297|DEVICE|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
214805020|NCT00448097|DRUG|cetuximab|No verifiable data available, PI relocated
214805021|NCT00448097|DRUG|docetaxel|No verifiable data available, PI relocated
214805022|NCT03100305|OTHER|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
214805023|NCT02195245|DEVICE|memsorb|
214805024|NCT02086188|DRUG|Mirabegron|see detailed information in associated Arm Description
214805025|NCT02086188|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
214805026|NCT01701024|DRUG|ACYC|ACYC active, topically applied to the face for 12 weeks
214805027|NCT01701024|DRUG|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
214805028|NCT05257746|PROCEDURE|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
214805029|NCT05019469|DEVICE|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
214805030|NCT04910126|DRUG|Camrelizumab|Camrelizumab 200mg q3w up to 2 years
214805031|NCT04910126|DRUG|Adriamycin|adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
214805032|NCT00448695|PROCEDURE|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
214805033|NCT02188641|OTHER|Diet|
214805034|NCT02188641|OTHER|Exercise|
214805035|NCT02188641|OTHER|Diet and Exercise|
214805036|NCT02188641|OTHER|Healthy Lifestyle (Control) Group|
214805037|NCT05525871|DIETARY_SUPPLEMENT|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
214805038|NCT05525871|DIETARY_SUPPLEMENT|Control product|Fruit puree
214805039|NCT03571893|BEHAVIORAL|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
214805040|NCT03571893|BEHAVIORAL|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
214805041|NCT03471078|DRUG|Avatrombopag|Oral avatrombopag tablet
214805042|NCT03471078|DRUG|Placebo Oral Tablet|Placebo comparator tablet
214805043|NCT01058278|PROCEDURE|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
214805044|NCT01504698|PROCEDURE|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
214805045|NCT01504698|PROCEDURE|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
214805046|NCT01638988|DRUG|Metformin|"1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
214805047|NCT01638988|DRUG|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
214805048|NCT04697745|DRUG|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
214805049|NCT04697745|DRUG|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
214805050|NCT05498480|BIOLOGICAL|Relatlimab|Specified dose on specified days
214805051|NCT05498480|BIOLOGICAL|Nivolumab|Specified dose on specified days
214805052|NCT02473640|DRUG|SYN-004|
214805053|NCT02473640|DRUG|Esomeprazole|
214805054|NCT02473640|DRUG|Ceftriaxone|
214805055|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
214805056|NCT02609139|DRUG|PF-06650833|100mg modified release tablet administered under fasted conditions
214805057|NCT02609139|DRUG|PF-06650833|20mg modified release tablet administered under fasted conditions
214805058|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
214805059|NCT02609139|DRUG|PF-06650833|100mg modified released tablet administered with high fat meal food intake
214805060|NCT02609139|DRUG|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
214805061|NCT01556308|PROCEDURE|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
214805062|NCT04437862|DEVICE|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
214805063|NCT02012244|DRUG|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
214805064|NCT02012244|DRUG|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
214805065|NCT04206644|OTHER|biological analysis|biological analysis of the Concentration of CCL18
214805066|NCT02127281|DEVICE|Prevena|Device will be applied at end of procedure over closed incision.
214805067|NCT00153803|DRUG|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
214805068|NCT00153803|DRUG|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
214805069|NCT05119439|DRUG|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
214805070|NCT00038675|DRUG|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
214805071|NCT00138515|DRUG|vildagliptin|
214805072|NCT00587470|DRUG|Candesartan|Maximum vasodilation.
214805073|NCT00587470|DRUG|atacand|maximum vasodilation
214805074|NCT00587470|DRUG|Placebo|Placebo
214805075|NCT03292653|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
214805076|NCT03292653|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
214805077|NCT04155281|OTHER|urine analysis|New Psychoactive Substances research in urine at admission in unit care
214805078|NCT06157710|BEHAVIORAL|Digital intervention through modules|"* Introduction~* Goal Setting Techniques~* Motivation~* Barriers to Action~* Managing Maladaptive Thoughts and Beliefs~* Value Clarification~* Moving Forward"
214805079|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months) and more one avaliation with an interval of 12 months at 24 months."
214805080|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
214805081|NCT04720664|DRUG|SM-88|"* SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~* Methoxsalen, One 10 mg capsule taken orally once daily.~* Phenytoin, One 50 mg tablet taken orally once daily.~* Sirolimus, One 0.5 mg tablet taken orally once daily."
214805082|NCT02223741|OTHER|Korean medical treatment|acupuncture and herbal drugs
214805083|NCT04507711|DRUG|0 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
214805084|NCT04507711|DRUG|1 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
214805085|NCT04507711|DRUG|10 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
214805086|NCT04507711|DRUG|100 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
214805087|NCT06485869|OTHER|Measure the improvement in quality of life|Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire
214805088|NCT06485869|OTHER|Measure the level of satisfaction of patients and nursing staff|Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.
214805089|NCT06485869|OTHER|Measurement of anxiety and pain|Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)
214805090|NCT06485869|OTHER|Measurement of depressive state|Depressive State is measured by HAD score
214805091|NCT06485869|OTHER|measuring fatigue levels|Fatigue levels is measured by Visual Analogue Scale (VAS).
214805092|NCT06485869|OTHER|measurement of acute nausea and vomiting|acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)
214805093|NCT00384917|DRUG|Ketoconazole|
214805094|NCT05321316|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
214805095|NCT05317052|BEHAVIORAL|Massage group|Massage and music therapy
214805096|NCT06027879|BIOLOGICAL|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
214805097|NCT05628675|OTHER|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
214805098|NCT03927066|OTHER|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
214805099|NCT04486066|BEHAVIORAL|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
214805100|NCT04486066|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
214805101|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
214805102|NCT02811523|DRUG|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
214805103|NCT00898508|GENETIC|gene expression analysis|
214805104|NCT00898508|GENETIC|mutation analysis|
214805105|NCT00898508|GENETIC|proteomic profiling|
214805106|NCT00898508|GENETIC|reverse transcriptase-polymerase chain reaction|
214805107|NCT00898508|OTHER|fluorescent antibody technique|
214805108|NCT00898508|OTHER|immunohistochemistry staining method|
214805109|NCT00898508|OTHER|laboratory biomarker analysis|
214805110|NCT00898508|OTHER|liquid chromatography|
214805111|NCT00898508|OTHER|mass spectrometry|
214805112|NCT00898508|OTHER|medical chart review|
214805113|NCT00898508|PROCEDURE|quality-of-life assessment|
214805114|NCT06569615|OTHER|shock wave therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks."
214805115|NCT06569615|OTHER|LASER Therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
214805116|NCT06569615|OTHER|Cryotherapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
214805117|NCT06569615|OTHER|Exercises|The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
214805118|NCT05876156|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
214805119|NCT05876156|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
214805120|NCT05818137|BIOLOGICAL|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
214805121|NCT04925089|OTHER|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
214805122|NCT01699607|DRUG|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
214805123|NCT01035528|DRUG|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
214805124|NCT01035528|DRUG|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
214805125|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
214805126|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
214805127|NCT05632640|OTHER|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
214805128|NCT05632640|DEVICE|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
214805129|NCT05118178|DIAGNOSTIC_TEST|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
214805130|NCT06352437|DRUG|BI 3034701|BI 3034701
214805131|NCT06352437|DRUG|Placebo matching BI 3034701|Placebo matching BI 3034701
214805132|NCT01113268|OTHER|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
214805133|NCT01491581|DIETARY_SUPPLEMENT|food bar|milk based food bar enriched with micronutrients
214805134|NCT05631366|BEHAVIORAL|Alcohol Avoidance Training|Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
214805135|NCT01648166|OTHER|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
214805136|NCT00883090|BIOLOGICAL|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
214805137|NCT01683175|DRUG|Erlotinib|
214805138|NCT01683175|DRUG|cis-platinum|
214805139|NCT01683175|DRUG|Vinorelbine|
214805140|NCT02444403|BEHAVIORAL|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
214805141|NCT02467036|BEHAVIORAL|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
214805142|NCT03344510|DEVICE|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
214805143|NCT03344510|OTHER|Control|One injection will be administered without the kinetic anesthesia device.
214805144|NCT01074710|DRUG|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
214805145|NCT01074710|DRUG|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
214805146|NCT03535168|DRUG|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
214805147|NCT03535168|DRUG|Matching placebo|Matching placebo for BAY1902607
214805148|NCT03535168|DRUG|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
214805149|NCT05676866|PROCEDURE|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
214805150|NCT03862248|DRUG|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
214805151|NCT03862248|DRUG|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
214805152|NCT03862248|DRUG|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
214805153|NCT01475838|DRUG|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
214805154|NCT01475838|DRUG|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
214805155|NCT01475838|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
214805156|NCT01475838|DRUG|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
214805157|NCT00048568|DRUG|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
214805158|NCT00048568|DRUG|Methotrexate|Tablets, Oral, \>= 15 mg, weekly, 1 year
214805159|NCT00048568|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
214805160|NCT00098878|DRUG|carboplatin|
214805161|NCT03831048|DEVICE|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
214805162|NCT03831048|OTHER|Cold Storage|Active comparator intervention
214805163|NCT04083859|OTHER|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
214805164|NCT04083859|OTHER|Lung health video|Web-based video about guideline recommended exercise for lung health
214805165|NCT03576846|OTHER|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
214805166|NCT03576846|OTHER|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
214805167|NCT06545201|BIOLOGICAL|RE001 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
214805168|NCT00560235|DRUG|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
214805169|NCT01365650|DRUG|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
214805170|NCT01365650|DRUG|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
214805171|NCT01365650|DRUG|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
214805172|NCT04677764|OTHER|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
214805173|NCT04677764|OTHER|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
214805174|NCT01806090|DRUG|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
214805175|NCT01806090|OTHER|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
214805176|NCT01595503|PROCEDURE|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
214805177|NCT01595503|PROCEDURE|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
214805178|NCT06139003|DEVICE|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
214805179|NCT06139003|DEVICE|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
214805180|NCT03827109|BEHAVIORAL|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
214805181|NCT03827109|BEHAVIORAL|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
214805182|NCT03827109|BEHAVIORAL|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
214805183|NCT03827109|BEHAVIORAL|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
214805184|NCT03827109|BEHAVIORAL|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
214805185|NCT03827109|BEHAVIORAL|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
214805186|NCT01110265|BEHAVIORAL|attention training|
214805187|NCT01110265|BEHAVIORAL|placebo training|
214805188|NCT01245166|DRUG|Acarbose|Acarbose 50 mg, per orem, thrice daily
214805189|NCT01245166|DRUG|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
214805190|NCT00996320|OTHER|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
214805191|NCT05123690|DEVICE|Neurofeedback|A device that assists in training patients in relaxing.
214805192|NCT00852436|DRUG|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
214805193|NCT00852436|DRUG|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
214805194|NCT00055978|DRUG|celecoxib|Given orally. 400mg twice daily for 6 months.
214805195|NCT00055978|OTHER|placebo|Given orally
214805196|NCT04461665|OTHER|vitamin D|vitamin D supplement 10 μg daily for 2 months
214805197|NCT05938556|BEHAVIORAL|hybrid asynchronous-synchronous group coaching program|A hybrid asynchronous-synchronous program. The synchronous part has two weekly recorded live group coaching calls for four months. The asynchronous consist of 1) on-demand replies to recorded coaching calls, 2) Self-coaching through weekly self-study modules and worksheets, and 3) written Ask A Coach. Content modified per needs of APPs by a physician, a certified coach, and an APP who is also a Co-I. The curriculum has weekly themes that build. Month-1 consists of 1) Introduction to the Model, 2) How to Feel Better, 3) Defining Your Purpose, and 4) Living Your Purpose. Month-2 consists of 1) Growth Mindset, 2) Welcoming Feedback and Assessment Bias, 3) Feeling Valued and Belonging, and 4) How to Deal with Hidden Expectations. Month-3 consists of 1) Imposter Syndrome, 2) Perfectionism, 3) Approval Addiction, and 4) How to Change Your Thoughts. Month-4 consists of 1) How to deal with Ambiguity, 2) Confidence, 3) Self-Appreciation and Self-Compassion, and 4) Celebrate the New You.
214805198|NCT05938556|OTHER|treatment as usual group (TAU)|The treatment as usual group will consist of any structural or programmatic interventions, resources, lectures, curriculum, etc. offered at the participants' hospital of employment. Thus, this active control is designed to represent a best-case alternative to group coaching, making it a more rigorous form of control. Participants randomly assigned to TAU will also continue any structural or programmatic interventions or resources they were previously participating in.
214805199|NCT05871736|OTHER|Turkish version of Child Engagement in Daily Life Measure V2|Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.
214805200|NCT02069626|PROCEDURE|compression time of the laparoscopic linear stapler|
214805201|NCT00758849|DRUG|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
214805202|NCT00758849|DRUG|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
214805203|NCT06004726|OTHER|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~* Orientation about Training Programme using PowerPoint slides~* Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~* Distribution of informational booklet on basics about substance abuse~Module 2:~* Role play to develop a positive attitude towards the prevention of substance abuse.~* Case-based scenario to increase resistance to peer pressure.~* Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
214805204|NCT02009800|BIOLOGICAL|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
214805205|NCT00318994|DRUG|Meropenem|
214805206|NCT03408626|DRUG|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
214805207|NCT03408626|DEVICE|conventional rotary|traditional rotary method
214805208|NCT01315249|DRUG|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
214805209|NCT01315249|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
214805210|NCT01315249|DRUG|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
214805211|NCT01315249|DRUG|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
214805212|NCT05825495|DRUG|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
214805213|NCT05825495|OTHER|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
214805214|NCT04648358|DRUG|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
214805215|NCT04648358|DRUG|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
214805216|NCT02392364|DRUG|Intravitreal Aflibercept Injection|
214805217|NCT04033952|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
214805218|NCT04818242|DEVICE|Dexcom G6 CGM with GTS|CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to \< 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) \> 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
214805219|NCT04818242|DIAGNOSTIC_TEST|POC Blood Glucose Test + Blinded CGM|Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between \<80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
214805220|NCT02475915|DRUG|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
214805221|NCT02475915|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
214805222|NCT02475915|DRUG|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
214805223|NCT02475915|DRUG|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
214805224|NCT02475915|DRUG|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
214805225|NCT02475915|DRUG|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
214805226|NCT02475915|DRUG|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
214805227|NCT02256085|DEVICE|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
214805228|NCT02256085|DEVICE|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
214805229|NCT02256085|DEVICE|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
214805230|NCT04533607|BEHAVIORAL|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
214805231|NCT04069637|COMBINATION_PRODUCT|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
214805232|NCT00584311|OTHER|MRI and Ultrasound|MRI and US of the joint
214805233|NCT02511405|DRUG|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
214805234|NCT02511405|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
214805235|NCT04988061|OTHER|counselling|Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
214805236|NCT00290147|BIOLOGICAL|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
214805237|NCT01740661|OTHER|Cryotherapy|The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
214805238|NCT01740661|OTHER|Control|The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
214805239|NCT05080751|BEHAVIORAL|Eating Behaviors|Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
214805240|NCT03227445|DEVICE|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
214805241|NCT03227445|DEVICE|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
214805242|NCT03227445|DEVICE|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
214805243|NCT03227445|OTHER|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
214805244|NCT02287545|PROCEDURE|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
214805245|NCT04480398|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
214805246|NCT06441396|OTHER|Telerehabilitation|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. The individuals in this group were made to do the exercises together online via the WhatsApp program. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The main program consists of 15 calisthenic exercises involving the lower extremity, upper extremity and trunk large muscle groups. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The number of repetitions of each exercise started with 10 and was increased by 5 repetitions every two weeks until it reached 20 repetitions.
214805247|NCT06441396|OTHER|Video-based rehabilitation (VTR)|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. Participants were asked to exercise by watching these videos. In addition, these individuals were interviewed once a week to check the progress of the exercise program. Video images were sent to the intervention group for informational purposes, and the individuals in this group were made to do the exercises together online via the WhatsApp program.
214805248|NCT04200482|BEHAVIORAL|One Diet and Physical Activity Session|Attend 1 remote diet and physical activity session
214805249|NCT04200482|OTHER|Electronic (e) Health (eHealth) Communication Intervention|Receive eHealth communication intervention
214805250|NCT04200482|BEHAVIORAL|Twelve Diet and Physical Activity Group Sessions|Attend 12 remote diet and physical activity sessions in 6 months
214805251|NCT04200482|OTHER|Questionnaire Administration|Ancillary studies
214805252|NCT04200482|OTHER|Quality-of-Life Assessment|Ancillary studies
214805253|NCT02835482|PROCEDURE|Femtolaser surgery|
214805254|NCT02835482|PROCEDURE|Phacoemulsification|
214805255|NCT01977469|BEHAVIORAL|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
214805256|NCT01977469|BEHAVIORAL|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
214805257|NCT01977469|BEHAVIORAL|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
214805258|NCT05558891|BEHAVIORAL|THRIVE|Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).
214805259|NCT05558891|BEHAVIORAL|Usual Care|Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
214805260|NCT02025465|DRUG|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
214805261|NCT02025465|DRUG|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
214805262|NCT01880073|DEVICE|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
214805263|NCT00755196|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
214805264|NCT00755196|DRUG|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
214805265|NCT01532622|DIETARY_SUPPLEMENT|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
214805266|NCT01532622|OTHER|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
214805267|NCT02745522|DRUG|Oxytocin|
214805268|NCT02745522|DRUG|Placebo|
214805269|NCT04878146|PROCEDURE|Sacro-spinous fixation|Uterine cervix will be attached to the sacro-spinous ligament
214805270|NCT04878146|PROCEDURE|Subtotal hysterectomy|Done on both arms
214805271|NCT04878146|PROCEDURE|Sacrocolpopexy|Uterine cervix is attached to sacral promontory with two synthetic meshes
214805272|NCT04670913|DRUG|Camrelizumab|A human anti-PD-1 monoclonal antibody
214805273|NCT04670913|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
214805274|NCT00677118|DRUG|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
214805275|NCT00677118|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
214805276|NCT04366336|PROCEDURE|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
214805277|NCT04366336|PROCEDURE|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
214805278|NCT02845895|OTHER|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
214805279|NCT02845895|OTHER|Classic strategy|Classic organization with the training of the department team
214805280|NCT04734964|BEHAVIORAL|exercise training|Exercise training session for 45 minutes.
214805281|NCT03757364|DRUG|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
214805282|NCT00002579|DRUG|CMF regimen|
214805283|NCT00002579|DRUG|cyclophosphamide|
214805284|NCT00002579|DRUG|fluorouracil|
214805285|NCT00002579|DRUG|methotrexate|
214805286|NCT00002579|DRUG|tamoxifen citrate|
214805287|NCT00002579|PROCEDURE|conventional surgery|
214805288|NCT00002579|RADIATION|radiation therapy|
214805289|NCT02933775|GENETIC|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
214805290|NCT02933775|DRUG|Fludarabine|30 mg/m\^2/day×4 days
214805291|NCT02933775|DRUG|Cyclophosphamide|500 mg/m\^2/day×2 days
214805292|NCT03802370|PROCEDURE|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
214805293|NCT03925870|DRUG|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
215031215|NCT01526200|PROCEDURE|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
214805294|NCT01703832|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
214805295|NCT04238442|DEVICE|A&D TM-2657W oscillometric device|Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
214805296|NCT02925442|PROCEDURE|t-RFA|standard thermal genicular radiofrequency ablation
214805297|NCT02925442|PROCEDURE|C-RFA|Cooled radiofrequency ablation
214805298|NCT02925442|PROCEDURE|Control|Simulated radiofrequency ablation for placebo controlled group
214805299|NCT01991470|DEVICE|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
214805300|NCT05696470|DEVICE|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
214805301|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
214805302|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
214805303|NCT00771537|BEHAVIORAL|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
214805304|NCT03365037|DRUG|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
214805305|NCT03365037|DRUG|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
214805306|NCT03858712|OTHER|Active Care Team Alert|"2\) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
214805307|NCT03858712|OTHER|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
214805308|NCT00088062|DRUG|STA-5326|
214805309|NCT06233266|DRUG|Ticagrelor-Test product|Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
214805310|NCT06233266|DRUG|Ticagrelor-Reference product|Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
214805311|NCT05653596|BEHAVIORAL|Virtual reality-based cognitive intervention|This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
214805312|NCT04605107|DRUG|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
214805313|NCT04605107|DRUG|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
214805314|NCT00353353|PROCEDURE|consumption of fortified bread|
214805315|NCT06235398|BIOLOGICAL|Hematopoietic stem-cell transplantation|Upfront related donor transplantation
214805316|NCT03213886|DRUG|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
214805317|NCT04509180|PROCEDURE|Catheter ablation|Endovascular approach
214805318|NCT04509180|PROCEDURE|Convergent procedure|Surgical and endovascular approach
214805319|NCT00566800|DRUG|erlotinib hydrochloride|
214464475|NCT05868343|OTHER|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
214805320|NCT00566800|OTHER|laboratory biomarker analysis|
214464476|NCT04746105|DRUG|TS-142|Subjects received single-dose of 10 mg of TS-142 (oral tablet)
214464477|NCT04746105|DRUG|Dose-matched Placebo to TS-142|Subjects received single-dose matched placebo to TS-142 (oral tablet)
214805321|NCT00566800|PROCEDURE|biopsy|
214805322|NCT04457999|DEVICE|Lipiflow Thermal pulsation|Single vectored thermal pulsation treatment for dry eye
214805323|NCT05425888|OTHER|Hemophilia group|Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
214805324|NCT01206153|DRUG|metformin|
214805325|NCT03678038|DRUG|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
214805326|NCT03678038|DRUG|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
214805327|NCT00020826|OTHER|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
214805328|NCT02175264|GENETIC|Blood sample|
214805329|NCT02154321|DEVICE|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
214805330|NCT02151032|BEHAVIORAL|Booklet|Participants read a booklet about colorectal cancer screening tests.
214805331|NCT02151032|BEHAVIORAL|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
214805332|NCT02151032|BEHAVIORAL|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
214805333|NCT02151032|BEHAVIORAL|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
214805334|NCT02151032|BEHAVIORAL|Questionnaires|Questionnaire completion before and after viewing the program.
215031216|NCT04584723|OTHER|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
214805335|NCT01659307|DRUG|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
214805336|NCT01659307|DRUG|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
214805337|NCT01659307|DRUG|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
214805338|NCT00197210|BIOLOGICAL|Rotavirus|
214805339|NCT04366232|DRUG|Anakinra alone (stages 2b/3)|Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
214805340|NCT04366232|DRUG|Anakinra and Ruxolitinib (overcome stage 3)|Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
214805341|NCT04366232|OTHER|Standard of care|Routine clinical care for Covid-19
214805342|NCT04182152|DEVICE|Indocyanine green (ICG)|Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
214805343|NCT04182152|DEVICE|Electromagnetic navigation bronchoscopy|Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
214805344|NCT04182152|DEVICE|Hook wire|Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
214805345|NCT04360993|RADIATION|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
214805346|NCT02080923|BEHAVIORAL|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
214805347|NCT05549856|PROCEDURE|Wet suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). Before puncturing the lesion, flush the needle with 5ml saline, then use a 10 ml syringe in order to replacing the column of air with fluid. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
214805348|NCT05549856|PROCEDURE|Dry suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). The stylet is removed and a 10 ml air-filled pre-vacuum syringe is attached. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
214805349|NCT04113239|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
214805350|NCT04113239|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
214805351|NCT05502978|BEHAVIORAL|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
214805352|NCT00623779|DRUG|AZD0837|ER formulation
214805353|NCT00623779|DRUG|Aspirin|Oral form
214805354|NCT02297451|PROCEDURE|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
214805355|NCT01696097|BEHAVIORAL|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
214805356|NCT02829268|DRUG|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
214805357|NCT02977520|PROCEDURE|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
214805358|NCT02019290|DRUG|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
214805359|NCT02019290|DRUG|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
214805360|NCT02768064|DEVICE|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
214805361|NCT00898079|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214805362|NCT04208503|DIAGNOSTIC_TEST|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
214464478|NCT05427812|DRUG|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
214464479|NCT05427812|DRUG|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
214464480|NCT05662189|DRUG|68Ga-exendin-4|68Ga-exendin4 PET-CT scan
214805363|NCT03097900|DRUG|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
214805364|NCT03097900|OTHER|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
214805365|NCT01434693|BIOLOGICAL|Trichuris suis ova|single dose
214805366|NCT01434693|OTHER|Placebo|
214805367|NCT01393288|DRUG|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
214805368|NCT01393288|DRUG|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
214805369|NCT01393288|DRUG|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
214805370|NCT00444197|BEHAVIORAL|Mentoring and violence prevention curriculum with parental monitoring|
214805371|NCT06247657|DRUG|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
214805372|NCT03138330|OTHER|this study is observational, it is not an intervention|
214805373|NCT03755609|DRUG|Oxycodone|0.1 mg/kg intravenously
214805374|NCT03755609|DRUG|fentanyl|1ug/kg intravenously
214805375|NCT03248362|DEVICE|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
214805376|NCT03248362|DEVICE|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
214805377|NCT02330848|DIETARY_SUPPLEMENT|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
214805378|NCT02330848|DIETARY_SUPPLEMENT|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
214805379|NCT03316001|OTHER|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
214805380|NCT00376922|PROCEDURE|music therapy|music played for patient during bone marrow biopsy collection
214805381|NCT00440557|DRUG|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
214805382|NCT00440557|DRUG|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
214805383|NCT00440557|DRUG|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
214805384|NCT05267366|DRUG|PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed|PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
214805385|NCT00539266|BIOLOGICAL|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
214805386|NCT00539266|BIOLOGICAL|placebo|40 IM injections (calf muscle) of placebo suspension
214805387|NCT05856903|DIAGNOSTIC_TEST|ACT|"ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers"
214805388|NCT02865564|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|
214805389|NCT02865564|DIETARY_SUPPLEMENT|Placebo|
214805390|NCT02865564|DRUG|ampicillin and gentamicin|
214805391|NCT00377390|BIOLOGICAL|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
214805392|NCT01388270|DEVICE|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
214805393|NCT04999670|PROCEDURE|Fascial closure method during caesarean section via pfannenstiel incision.|Comparison of three different methods of fascial closure.
214805394|NCT00254956|DRUG|ciclesonide (XRP1526)|
214805395|NCT04763005|BEHAVIORAL|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
214805396|NCT04763005|BEHAVIORAL|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
214805397|NCT02869425|DRUG|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
214805398|NCT02869425|DRUG|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
214805399|NCT03827863|DEVICE|TTE|TTE to detect the heart function
214805400|NCT03229018|DIAGNOSTIC_TEST|Voxel size|200 μm and 300 μm Voxel Sizes
214805401|NCT01683032|DRUG|MPH|a capsule containing 20 mg
214805402|NCT04173650|DRUG|AGLE-102|Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations
214805403|NCT02514655|DEVICE|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
214805404|NCT02514655|OTHER|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
214805405|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from TIMP microbiome project will be analyzed with NGS techniques.
214805406|NCT06525831|DIAGNOSTIC_TEST|MR-elastography exam|Imaging acquisition
214805407|NCT06525831|DIAGNOSTIC_TEST|Ultrasound exam|Imaging acquisition
214805408|NCT06181825|BEHAVIORAL|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
214805409|NCT05602519|DRUG|propofol, rocuronium and fentanyl|In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
214805410|NCT05783284|DEVICE|Holocare Studio 2 (HS2)|3D HV
214805411|NCT00988624|DRUG|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
214805412|NCT00988624|DRUG|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
214805413|NCT00988624|DRUG|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
214805414|NCT00988624|DRUG|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
214805415|NCT00988624|DRUG|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
214805416|NCT02226458|DRUG|EPI-743|
214805417|NCT02450981|DRUG|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
214805418|NCT00721604|DRUG|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
214805419|NCT01918800|BEHAVIORAL|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
214805420|NCT01918800|BEHAVIORAL|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
214805421|NCT03960970|DRUG|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
214805422|NCT03960970|DRUG|Mefoxin 2g|Standard Prophylaxis
214805423|NCT02609464|DEVICE|Interrupted Knotted Sutures|
214805424|NCT02609464|DEVICE|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
214805425|NCT04285749|DRUG|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
214805426|NCT04285749|OTHER|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
214805427|NCT04285749|OTHER|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
214805428|NCT02601482|BEHAVIORAL|CON|
214805429|NCT02601482|BEHAVIORAL|IW-60|
214805430|NCT02601482|BEHAVIORAL|IW-45|
214805431|NCT02409472|OTHER|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
214805432|NCT03122522|DRUG|ipilimumab|ipilimumab 3mg/kg
214805433|NCT03122522|DRUG|nivolumab|nivolumab 1mg/kg
214805434|NCT03828942|DRUG|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
214805435|NCT03432845|OTHER|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
214805436|NCT05856045|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week."
214805437|NCT05856045|OTHER|PBBT (pertubation based balance training)|"Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week."
214464481|NCT05662189|OTHER|mixed meal test|before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
214464482|NCT06377982|BIOLOGICAL|hUCB|hUCB
214464483|NCT06532370|BEHAVIORAL|Contingency Managment|"If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. great job!). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
214805438|NCT05856045|OTHER|PNF and PBBT intervention group|proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
214805439|NCT03116386|OTHER|run-in period|observational time i.e. baseline situation
214805440|NCT03116386|DEVICE|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
214805441|NCT03116386|DEVICE|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
214805442|NCT01378975|DRUG|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
214805443|NCT06640192|DRUG|Standardised triple antiretroviral therapy|patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.
214805444|NCT06640192|DRUG|High doses Triple therapy antiretroviral drugs|dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
214805445|NCT04663152|BEHAVIORAL|INSTACARE|CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
214805446|NCT05969197|OTHER|Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
214805447|NCT05969197|OTHER|Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
214805448|NCT05857332|DRUG|SG1906|Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
214805449|NCT04659681|DIAGNOSTIC_TEST|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
214805450|NCT04659681|DIAGNOSTIC_TEST|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
214805451|NCT02281942|BEHAVIORAL|Yoga|
214805452|NCT02281942|BEHAVIORAL|Education|
214805453|NCT02032368|PROCEDURE|transarterial chemoembolization (TACE)|
214805454|NCT02097446|DEVICE|Guardix-FL|
214805455|NCT02097446|DEVICE|Interceed|
215031217|NCT04547387|DEVICE|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
215031218|NCT05755750|DRUG|Genipin|Intratendinous genipin injection
214805456|NCT03010748|DEVICE|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
214805457|NCT03435198|DIAGNOSTIC_TEST|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
214805458|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
214805459|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
214805460|NCT03054103|DRUG|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
214805461|NCT03486613|OTHER|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
214805462|NCT03486613|OTHER|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
214805463|NCT03708913|DEVICE|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
214805464|NCT02343120|DRUG|Zanubrutinib|Oral administration by capsule
214805465|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
214805466|NCT01369277|DRUG|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
214805467|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
214805468|NCT03947580|OTHER|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
214805469|NCT03947580|OTHER|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
214805470|NCT03947580|OTHER|Use of no pad|Description is not needed
214805471|NCT05985330|OTHER|Measurement of FeNO|Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
214805472|NCT00347503|DRUG|ketorolac 0.4%, bromfenac 0.09%|
214805473|NCT01872143|DEVICE|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
214805474|NCT00413556|BIOLOGICAL|ALK Grass tablet|
214805475|NCT01986582|DRUG|Oxymetazoline|Intranasal application
214805476|NCT01986582|OTHER|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
214805477|NCT01986582|OTHER|Placebo (lactose powder)|Intranasal application
214805478|NCT00018447|DRUG|PTH 1-34|
214464484|NCT04890171|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
214464485|NCT04890171|PROCEDURE|Surgery|Gastrectomy with lymph node dissection by a surgeon
214805479|NCT00018447|DRUG|MFPSR-fluoride|
214464486|NCT05204797|PROCEDURE|Robot-assisted UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
214805480|NCT01136538|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
214805481|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field|
214805482|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field Placebo Sham|
214805483|NCT06404307|BEHAVIORAL|Self-administration|patients will self administer their antimicrobial treatment
214464487|NCT05204797|PROCEDURE|Standard technique UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
214464488|NCT05168280|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
214464489|NCT05168280|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
214464490|NCT02601053|OTHER|Dull movie|A dull movie (duration approximately 90 minutes)
214464491|NCT02601053|OTHER|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
214805484|NCT03266237|DRUG|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
214805485|NCT05903326|OTHER|Dexmedetomidine|this was an observational study only based on a change of practice
214805486|NCT05343637|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
214805487|NCT03120117|PROCEDURE|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
214805488|NCT06672081|PROCEDURE|Early Catheter-Interventional Treatment|Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
214805489|NCT06672081|DRUG|Conventional care|reperfusion treatment
214805490|NCT03375242|DRUG|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
214805491|NCT06259435|BEHAVIORAL|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
214805492|NCT06259435|BEHAVIORAL|Usual diet|Subjects will follow time-restricted eating of the usual diet
214805493|NCT04121455|DRUG|Olaptesed pegol|Olaptesed pegol continuous i.v. administration
214805494|NCT04121455|RADIATION|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
214805495|NCT04121455|DRUG|Bevacizumab|Bevacizumab every 2 weeks i.v. infusion
214805496|NCT04121455|DRUG|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
214805497|NCT04121455|DRUG|Temozolomide (TMZ)|oral treatment according to current SPC
214805498|NCT05135442|DRUG|Bortezomib Injection|Bortezomib should be administered immediately after each plasma exchange, and the interval between the next plasma exchange is\> 24h. Plasma exchange continued until the patient's platelet count was \>100×109/L for 2 consecutive days, and then changed to once every other day for a total of two times and then stopped.
214805499|NCT04819971|DRUG|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
214805500|NCT04819971|DRUG|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
214805501|NCT04819971|DRUG|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
214805502|NCT04819971|DRUG|S1|S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
214805503|NCT04819971|DRUG|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
214805504|NCT05190510|OTHER|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
214805505|NCT05190510|PROCEDURE|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
214805506|NCT05190510|OTHER|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
214805507|NCT00922597|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
214805508|NCT03034226|OTHER|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
214464492|NCT02601053|OTHER|Heart rate measurement|Heart rate measurement using a actiheart device
214464493|NCT06460389|DIAGNOSTIC_TEST|Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
214805509|NCT01088126|PROCEDURE|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
214805510|NCT03254251|BEHAVIORAL|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
214805511|NCT04608643|DIAGNOSTIC_TEST|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
214805512|NCT02401334|DEVICE|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
214464494|NCT05986682|DRUG|Blenrep|Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
214464495|NCT03769155|BIOLOGICAL|Ipilimumab|Given IV
214464496|NCT03769155|BIOLOGICAL|Nivolumab|Given IV
214805513|NCT03688373|BEHAVIORAL|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
214805514|NCT04566159|BEHAVIORAL|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
214805515|NCT04566159|OTHER|Standard Care|Standard tobacco treatment care offered by the inpatient care
214805516|NCT00368953|DEVICE|Yukon Choice stent system|coronary stent implantation
214805517|NCT00368953|DEVICE|Taxus Liberté stent system|coronary stent implantation
214805518|NCT04713696|OTHER|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
214805519|NCT04713696|OTHER|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
214805520|NCT05441202|DEVICE|transdermal therapy|transdermal therapy with Chinese medicine
214805521|NCT02282436|OTHER|No specific intervention for this study|No specific intervention for this study
214805522|NCT04627506|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
214805523|NCT00221507|BEHAVIORAL|Reminder-Recall-Outreach|
214805524|NCT00221507|BEHAVIORAL|Case Management|
214805525|NCT00221507|BEHAVIORAL|Patient Navigator|
214805526|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by Experts|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. To generate diagnostic results of pCLE, two pCLE experts dignosed independent. Any discrepancies are then resolved by a third expert.
214805527|NCT06981819|DIAGNOSTIC_TEST|magnifying endoscopy with blue laser imaging|Magnifying Endoscopy with Blue Laser Imaging (ME-BLI) is an advanced endoscopic imaging technique that combines high-resolution magnification with laser-enhanced visualization to improve the detection and characterization of gastrointestinal (GI) mucosal lesions. Developed by Fujifilm, BLI utilizes specific laser wavelengths to enhance surface and vascular patterns, making it particularly useful for diagnosing early-stage cancers and precancerous conditions in the stomach, colon, and esophagus. To generate diagnostic results of ME-BLI, two ME-BLI experts dignosed independent. Any discrepancies are then resolved by a third expert.
214805528|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by trainees|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. The diagnosis results of CLE trainees are generated by each trainee themselves.
214805529|NCT01874951|DRUG|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
214805530|NCT01874951|DRUG|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
214805531|NCT01230151|DEVICE|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
214805532|NCT01230151|DEVICE|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
214805533|NCT04375293|OTHER|Microbiome swabs|Swabs for analysis of microbiome
214805534|NCT01880333|OTHER|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
214805535|NCT06665178|DRUG|Sacituzumab Govitecan|Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
214805536|NCT05635279|OTHER||
214805537|NCT06597214|DEVICE|AVACore Technologies, Inc. warmUP Sleeve|AVAcore Technologies's warmUP (WU-20) Temperature Management System was developed based on work with the Aquarius Medical Acrotherm device and prior human hypothermic subject data showing a rewarming rate of \~1ºC in 5 minutes when heat and vacuum application was tested. AVAcore Technologies received FDA acceptance of its Section 510(k) premarket notification for the warmUP (vH1) Temperature Management System in 2005. This product was used on over 100 patients in the US in 2005-2006 timeframe.
214805538|NCT06597214|DEVICE|Arizant Healthcare Bair Hugger®|The Arizant Healthcare Bair Hugger® Temperature Management System proposed for use in this study is a 'forced air' system providing convective warming via the circulation of warmed air through a specially designed blanket which is placed over a portion of the patient's body. This product has been in use in the US for over 20 years in a majority of hospitals.
214805539|NCT02236715|DRUG|Atrovent®|
214805540|NCT05059522|DRUG|Avelumab|oral
214805541|NCT05059522|DRUG|Lorlatanib|oral
214464497|NCT03769155|BIOLOGICAL|VX15/2503|Given IV
214464498|NCT03769155|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
214805542|NCT05059522|DRUG|Talazoparib|oral
214805543|NCT05059522|DRUG|Pemetrexed|IV (intravenous) infusion
214805544|NCT05059522|DRUG|Axitinib|oral
214805545|NCT05059522|DRUG|CMP 001|IT (intratumoral) or SC (subcutaneous)
214805546|NCT05059522|DRUG|Utomilumab|IV infusion
214805547|NCT05059522|DRUG|PF04518600|IV infusion
214805548|NCT03544138|DEVICE|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
214805549|NCT01540175|OTHER|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
214805550|NCT06614517|OTHER|Birdwatching Intervention|Description: Participants will attend three birdwatching sessions, where they will enjoy direct contact with nature in selected environments such as forests and farms. These outings will be guided by an expert, who will also introduce participants to the use of binoculars and tools for identifying the birds observed during the excursions. During the outings, participants will learn the body scan technique, which will help them focus on physical sensations without making judgments. This exercise will encourage them to pay attention to details such as muscle tension, temperature, or surface contact, allowing them to be more present and connected to their surroundings during the birdwatching sessions. In addition to the in-person outings, participants will receive digital materials via WhatsApp to complement the intervention.Birdwatching Intervention
214805553|NCT03704220|DRUG|Warfarin|Removal of anticoagulation with warfarin
214805554|NCT03268668|OTHER|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
214805555|NCT02851290|PROCEDURE|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
214805556|NCT02851290|PROCEDURE|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
214805557|NCT01766778|DRUG|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
214805558|NCT01766778|DRUG|Metformin|Metformin maximum tolerance dose
214805559|NCT04359095|DRUG|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
214805560|NCT04359095|DRUG|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
214805561|NCT04359095|DRUG|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
214805562|NCT04359095|OTHER|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
214805563|NCT05658367|PROCEDURE|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
214805564|NCT05658367|PROCEDURE|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
214805565|NCT05658367|PROCEDURE|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
214805566|NCT03537781|BEHAVIORAL|Food labelling versus no food labelling|Food labelling availability and satiety status
214805567|NCT02728037|PROCEDURE|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
214805568|NCT02728037|PROCEDURE|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
214805569|NCT02728037|DRUG|lidocaine|
214805570|NCT02728037|DRUG|magnesium sulfate, bicarbonate, dextrose.|
214805571|NCT04130256|DEVICE|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
214805572|NCT03863678|OTHER|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
214805573|NCT03863678|OTHER|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
214805574|NCT01853306|DRUG|Veliparib|veliparib
214805575|NCT06544668|OTHER|Breast cancer patients with bone metastasis|This study is an observational study
214805576|NCT06544668|OTHER|Breast cancer patients without bone metastasis|This study is an observational study
214805577|NCT01104662|DRUG|Vancomycin|
214805578|NCT01104662|DRUG|Daptomycin|
214805579|NCT01104662|DRUG|Semi-Synthetic Penicillin|
214805580|NCT05561114|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
214805581|NCT05561114|OTHER|Control|Standard Endoscopic Dilation
214805582|NCT00556127|DRUG|Rituximab|375 mg/m2 on day 1
214805583|NCT00556127|DRUG|Epirubicin|110 mg/m2 on day 3
214805584|NCT00556127|DRUG|Cyclophosphamide|1200 mg/m2 on day 3
214805585|NCT00556127|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
214805586|NCT00556127|DRUG|Prednisone|40 mg/m2 from day 1 to 5
214805587|NCT00556127|DRUG|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
214805588|NCT00556127|DRUG|Mitoxantrone|8 mg/m2 for 3-day
214805589|NCT00556127|DRUG|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
214805590|NCT00556127|DRUG|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
214805591|NCT00556127|DRUG|Carmustine BCNU|300 mg/m2 on day -7
214805592|NCT00556127|DRUG|Etoposide|100 mg/m2/12 hours
214805593|NCT00556127|DRUG|Melphalan|140 mg/m2 on day -2
214805594|NCT00556127|RADIATION|Radiotherapy|Involved Field Radiotherapy (IF-RT)
214805595|NCT00556127|PROCEDURE|PBSC reinfusion|ASCT
214805596|NCT06546410|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
214805597|NCT06483581|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
214805598|NCT06483581|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
214805599|NCT02453425|OTHER|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
214805600|NCT02453425|OTHER|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
214805601|NCT02453425|OTHER|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
214805602|NCT05733195|OTHER|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
214805603|NCT03797755|RADIATION|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
214805604|NCT02511509|DEVICE|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
214805605|NCT02511509|DEVICE|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
214805606|NCT05337956|PROCEDURE|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
214805607|NCT02756325|DEVICE|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
214805608|NCT03267056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
214805609|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
214805610|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
214805611|NCT04623736|BEHAVIORAL|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
214805612|NCT04190290|OTHER|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
214805613|NCT04190290|DIAGNOSTIC_TEST|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
214805614|NCT05742633|OTHER|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
214805615|NCT05742633|OTHER|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
214464499|NCT06393595|DIAGNOSTIC_TEST|surface enhanced Raman Spectroscopy|"Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation."
214805616|NCT04238767|DRUG|Dolutegravir|Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
214805617|NCT04813809|DEVICE|BARRIER EasyWarm|Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
214805618|NCT04620109|DRUG|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
214805619|NCT04620109|DRUG|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
214805620|NCT00280371|DRUG|Formoterol Fumarate|
214805621|NCT04297228|BEHAVIORAL|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
214805622|NCT02710201|BEHAVIORAL|Descriptive Social Norm|
214805623|NCT02710201|BEHAVIORAL|Descriptive-plus-Injunctive Social Norm|
214805624|NCT04281706|DRUG|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
214805625|NCT04885127|OTHER|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
214805626|NCT07020728|BEHAVIORAL|Solo: Unmasked Speech Stimuli|Speech stimuli recorded using non-moving speakers and mics. No masking sources present. No BSS applied to multi-channel recordings. Very high output QoS values.
214805627|NCT07020728|BEHAVIORAL|Raw: Fully masked speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. No speech separation or extraction methods applied to multi-channel recordings. Very low output QoS values.
214805628|NCT07020728|BEHAVIORAL|StatScrub: Extracted Speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Very high output QoS values.
214805629|NCT07020728|BEHAVIORAL|SlideSpch: Scrubbed Speech emitted from linearly moving speaker stimuli|Speech stimuli recorded using linearly moving speech source and stationary masking sources and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Moderately high output QoS values.
214805630|NCT07020728|BEHAVIORAL|SlideNoise: Speech Scrubbed from linearly moving and stationary noise stimuli|Mixed speech and noise sources recorded using a stationary speech source, a stationary noise source, and a linearly moving noise source. A valid source hypothesis of the speech source is used to extract the speech source. High output QoS values.
214805631|NCT07020728|BEHAVIORAL|SlideMic: Stationary sources scrubbed from a linearly moving mic stimuli|Mixed speech and noise sources recorded using all stationary sources, and a linearly moving microphone (mic 1). Joint ACES scrubbing of both noise sources is used to reduce the response of Mic 1 to a residue of speech. Low output QoS values.
214805632|NCT07013682|BIOLOGICAL|PRF as adjunct to non-surgical mechanical debridement|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, the PRF will be inserted in all pockets of the allocated side of the jaw in all pockets ≥ 5 mm.
214805633|NCT07013682|BIOLOGICAL|Control, non-surgical mechanical debridement alone|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, an empty sy will be inserted in all pockets of the allocated control side of the jaw in all pockets ≥ 5 mm.
214805634|NCT07027553|BEHAVIORAL|Mobile health exercise programme|8 week personalised exercise intervention. Delivered and monitored via mobile health technology
214805635|NCT07027553|OTHER|Lifestyle maintenance|Continue current lifestyle
214805636|NCT07036094|OTHER|Manual breast milk expression|"Manual breast milk expression: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was suckling from one breast, milk was expressed from the other breast, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes.~The mothers' food records were analyzed for 3 days before the milk sample was taken and on the day the milk sample was taken."
214805637|NCT07037095|DIAGNOSTIC_TEST|Ankle plantar flexion test:|Ankle plantarflexion is valid test used to assess for gastrocnemius muscle strain . Patient is asked to actively plantarflex the foot against resistance while examiner Observe ,this action activates the gastrocnemius muscle .The reliability for ankle plantar flexion is 0.81 to 0.99. If the patient reports pain in the region of gastrocnemius, the test is positive. If there is no pain , weakness or difficulty performing plantarflexion then suggest that test is negative.
214464500|NCT04044768|GENETIC|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
214805638|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + Postural Correction Exercises|Physiotherapy exercises of Shoulder and Neck Strengthening + Postural Correction Exercises for shoulder and neck pain
214805639|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + soft tissue mobilization|Physiotherapy exercises of Shoulder and Neck Strengthening + soft tissue mobilization Exercises for shoulder and neck pain
214805640|NCT02158936|DRUG|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
214805641|NCT02158936|DRUG|Azacitidine|Subcutaneous Injection (IV if local standard)
214805642|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets
214464501|NCT06265922|DEVICE|High frequency repetitive transcranial magnetic stimulation|High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.
214805643|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets will be supplied
215031596|NCT06695975|BEHAVIORAL|Occupational self-analysis|"Occupational self analysis program is delivered in group sessions, each session lasting 45 minutes, twice a week. Also Individual sessions are held throughout the program with each participant, with the intention of clarifying certain concepts and resolving specific difficulties that were occurring.The thematic modules worked are 5; occupation-health and difficulty, occupational balance, adaptation strategies to difficulties, social relationships and knowing other realities.~The methodological strategies used to structure the program were the Model of Human Occupation (MOHO) and the See-Judge-Act methodology"
214805644|NCT06887530|OTHER|Hand-10 questionnaire and ABILHAND-kids questionnaire|"Children and their parents included in the study will be informed about the purpose of the study and the evaluations to be made and will be asked to sign a written consent form. The questions in the data collection form will be asked to individuals in a face-to-face interview. The manual skills classification system, Hand-10 questionnaire and ABILHAND-kids questionnaire will be used.~While validating the Hand10 questionnaire in children with cerebral palsy, it was planned to use the ABILHAND-kids scale, which has been previously validated for reliability and validity in cerebral palsy. It was also planned to use the hand function classification system in the evaluations. The Hand-10 questionnaire will be filled out by the child himself. The ABILHAND-kids questionnaire will be filled out by the parent. An expert will record the manuel ability system according to the hand skills."
214805645|NCT06925373|OTHER|Indoor Air Purification|An indoor air purifier with a dual HEPA/activated carbon filter, a usage tracker, and an indoor air quality monitor will be installed in public housing residences.
214805646|NCT06925373|OTHER|Neighborhood Improvements|Improved built environment (green space, sidewalks, street lights) and social environment (educational and workforce development programs, wrap-around social services, Internet access).
214805647|NCT06925373|OTHER|Housing Improvements|High-quality public housing
214805648|NCT00135395|DRUG|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
214805649|NCT00135395|DRUG|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
214805650|NCT02295878|DIETARY_SUPPLEMENT|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
214464502|NCT06265922|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
214805651|NCT02295878|DIETARY_SUPPLEMENT|Placebo|
214805652|NCT04751578|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
214805653|NCT01706926|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
214805654|NCT01706926|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
214805655|NCT01706926|BIOLOGICAL|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
214805656|NCT01706926|OTHER|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
214805657|NCT00814099|BEHAVIORAL|Team approach to sedation management|"The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance"
214805658|NCT00814099|BEHAVIORAL|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
214805659|NCT02665013|BEHAVIORAL|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
214805660|NCT02665013|BEHAVIORAL|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
214805661|NCT00073177|DRUG|Roflumilast|
214805662|NCT03101878|DRUG|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
214805663|NCT03101878|DRUG|Placebo|Saline .9%
214805664|NCT02958111|DRUG|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
214805665|NCT04271826|PROCEDURE|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
214805666|NCT01218165|DIETARY_SUPPLEMENT|Probiotic drink|This group receives a probiotic drink daily for 6 week.
214805667|NCT01218165|OTHER|Control Group|without intervention
214805668|NCT00414466|DRUG|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
214805669|NCT00000566|PROCEDURE|ventilation-perfusion ratio|
214805670|NCT00000566|PROCEDURE|angiography|
214805671|NCT02637232|OTHER|Mirvaso® / Onreltea TM|
214805672|NCT00304447|DRUG|Mylotarg|
214805673|NCT02092922|DRUG|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
214805674|NCT02092922|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
214805675|NCT03814239|OTHER|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was \>15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained \>15%, administration of noradrenaline infusion was considered.
214805676|NCT05081258|PROCEDURE|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
214805677|NCT05081258|PROCEDURE|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
214805678|NCT01382290|PROCEDURE|MRI|
214805679|NCT03416647|PROCEDURE|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
214805680|NCT02248597|DRUG|fludarabine phosphate|Given IV
214805681|NCT02248597|DRUG|busulfan|Given IV
214805682|NCT02248597|DRUG|cyclophosphamide|Given IV
214805683|NCT02248597|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
214805684|NCT02248597|DRUG|tacrolimus|
214805685|NCT02248597|DRUG|mycophenolate mofetil|
214805686|NCT03127904|PROCEDURE|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
214805687|NCT03127904|PROCEDURE|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
214805688|NCT01269801|DRUG|onabotulinumtoxinA|"* Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
215031597|NCT06695208|DRUG|Biodentine|biodentine used in socket preservation
215031598|NCT06631534|DRUG|Dexmedetomidine|Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
215031599|NCT06631534|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline (placebo)
214805689|NCT01269801|DRUG|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
214805690|NCT01124929|DRUG|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
214805691|NCT01124929|DRUG|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
214805692|NCT03212222|OTHER|Peek Acuity|Cell phone application for visual acuity screening
214805693|NCT03212222|OTHER|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
214805694|NCT02648620|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
214805695|NCT02648620|PROCEDURE|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
214805696|NCT02715622|PROCEDURE|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
214805697|NCT05760872|OTHER|Placing esophageal probe|Placing an esophageal probe through the mouth
214805698|NCT02395822|BIOLOGICAL|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
214805699|NCT02975141|DRUG|Afatinib 30Mg Tab|Study Drug
214805700|NCT02975141|DRUG|Afatinib 40Mg Tab|Study Drug
214805701|NCT02975141|DRUG|Gemzar|Chemotherapy Backbone
214805702|NCT02975141|DRUG|Abraxane|Chemotherapy Backbone
214805703|NCT06218680|DRUG|Propofol|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
214805704|NCT06218680|DRUG|Normal saline|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
214805705|NCT04177290|DRUG|Sintilimab (M1b)|Intravenous infusion
214805706|NCT04177290|DRUG|Sintilimab (approved)|Intravenous infusion
214805707|NCT05369247|OTHER|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
214805708|NCT05369247|OTHER|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
214805709|NCT02937701|BIOLOGICAL|ABP 710|Administered by intravenous infusion
214805710|NCT02937701|BIOLOGICAL|Infliximab|Administered by intravenous infusion
214805711|NCT04793347|DEVICE|shock master (shock waves device)|device produces shock waves
214805712|NCT00076947|BIOLOGICAL|EnvPro|
214805713|NCT02757248|DRUG|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
214805714|NCT02757248|DRUG|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
214805715|NCT01533298|DRUG|CombiflexOmega peri|intravenously over 3 days infusion
214805716|NCT01533298|DRUG|SmofKabiven peripheral|intravenously over 3 days infusion
214805717|NCT04088422|PROCEDURE|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
214805718|NCT03753425|PROCEDURE|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
214805719|NCT04786080|BEHAVIORAL|Parent Positive|"Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~1. structured advice, support and tips for parents~2. facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~3. access to carefully selected high-quality, evidence-based online parenting resources."
214805720|NCT02042365|PROCEDURE|ERAS (Enhanced recovery after surgery)|
214805721|NCT03048526|DEVICE|NovaTears®|Topical eye drops for lubrication of the ocular surface
214805722|NCT03048526|DEVICE|Hydrabak®|Eye drops
214805723|NCT01295372|DRUG|Zicronapine|7.5 mg/day; orally
214805724|NCT01295372|DRUG|Risperidone|5 mg/day; orally
214805725|NCT00840138|PROCEDURE|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
214805726|NCT02683083|BIOLOGICAL|[131I]-SGMIB Anti-HER2 VHH1|
214805727|NCT05290311|BEHAVIORAL|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
214805728|NCT03401996|DEVICE|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
214805729|NCT03422211|OTHER|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
215031600|NCT06688253|DRUG|IV efgartigimod|IV efgartigimod
215031601|NCT06687850|BEHAVIORAL|animal assisted therapy|The canine was included in therapy sessions to determine the effect of the canine on prosocial behavior and emotional regulation in autistic children with varying verbality.
215031602|NCT06690450|DRUG|Venofer® 200 mg|A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
214805730|NCT01564511|DEVICE|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
214805731|NCT01564511|OTHER|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
214805732|NCT03288883|DEVICE|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
214805733|NCT03288883|DEVICE|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
214805734|NCT05523271|DIAGNOSTIC_TEST|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
214805735|NCT00164892|DRUG|Oral Vioxx (Rofecoxib)|
214805736|NCT03149653|DRUG|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
214805737|NCT03149653|DRUG|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
214805738|NCT03149653|DRUG|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
214805739|NCT03149653|DRUG|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
214805740|NCT03149653|DRUG|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
214805741|NCT03149653|DRUG|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
214805742|NCT03733197|BEHAVIORAL|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
214805743|NCT03733197|BEHAVIORAL|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
214805744|NCT02108119|DIETARY_SUPPLEMENT|Probiotics|
214805745|NCT02108119|DIETARY_SUPPLEMENT|Control placebo|
214805746|NCT03290326|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
214805747|NCT05086835|OTHER|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
214805748|NCT05086835|OTHER|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
214805749|NCT06074289|BEHAVIORAL|Family connections program|Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
214805750|NCT04370639|DEVICE|AccuFlow sensor|AccuFlow sensor will be worn and survey completed
214805751|NCT04370639|OTHER|Survey|Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
214805752|NCT04277390|OTHER|clinical intervention for microbial analysis and MIR155 as biomarker|Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
214805753|NCT00001018|DRUG|Letrazuril|
214805754|NCT03422653|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
214805755|NCT03422653|DRUG|Placebo|IV medication delivered three times/week
214805756|NCT02769715|DEVICE|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
214805757|NCT02769715|OTHER|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
214805758|NCT03265522|BEHAVIORAL|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
214805759|NCT03265522|BEHAVIORAL|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
214805760|NCT03265522|BEHAVIORAL|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
214805761|NCT01101022|DRUG|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
214805762|NCT01101022|OTHER|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
214805763|NCT01519661|DRUG|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
214805764|NCT01139047|DRUG|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
214805765|NCT01139047|DRUG|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
214805766|NCT03864575|DRUG|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
214805767|NCT01941095|DRUG|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805768|NCT01941095|DRUG|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805769|NCT01941095|DRUG|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805770|NCT01941095|DRUG|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805771|NCT01941095|DRUG|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805772|NCT01941095|DRUG|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
214805773|NCT01941095|DRUG|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
215031603|NCT06690450|DRUG|Venofer® 100 mg|A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
214805774|NCT01924858|DRUG|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
214805775|NCT01924858|DRUG|[18F]GSK2647544 IV bolus|\[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
214805776|NCT01724502|BEHAVIORAL|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO\_2 max determination, exercise periods and muscle biopsies.
214805777|NCT04734184|DIAGNOSTIC_TEST|DCFPyL|Single dose injection
214805778|NCT01183585|DRUG|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
214805779|NCT02463695|PROCEDURE|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
214805780|NCT00726739|BIOLOGICAL|aldesleukin|IL-2 Alone - administer 10 x 10\^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
214805781|NCT00726739|BIOLOGICAL|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI \[1 x 10\^7, 5-μm silica spheres\]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
214805782|NCT00724542|DRUG|Voglibose tablets|0.2mg Tid
214805783|NCT03625856|DIETARY_SUPPLEMENT|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
214805784|NCT03625856|DIETARY_SUPPLEMENT|Placebo|Starch 1500 mg
214805785|NCT02918877|DRUG|Sevoflurane|Volatile Anesthetic
214805786|NCT02918877|DRUG|Propofol|Intravenous Anesthetic
214805787|NCT00079625|DRUG|Th2/Tc2 Cells|
214805788|NCT03047226|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
214805789|NCT01714648|DRUG|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
214805790|NCT05341232|BEHAVIORAL|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
214805791|NCT05341232|BEHAVIORAL|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
214805792|NCT05341232|BEHAVIORAL|Board Games|Participants will play board games with each other.
214805793|NCT00625911|DRUG|morphine|intravenous patient controlled analgesia, standard protocol
214805794|NCT00625911|DRUG|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
214805795|NCT03527745|DRUG|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
214805796|NCT03527745|DRUG|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
214805797|NCT03527745|DRUG|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
214805798|NCT03527745|DRUG|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
214805799|NCT03527745|DRUG|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
214805800|NCT04699422|PROCEDURE|Serratus anterior plane block|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
214805801|NCT04699422|DRUG|PCIA with Piritramide|A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
214805802|NCT04066361|OTHER|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
214805803|NCT04066361|OTHER|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
214805804|NCT01161667|DRUG|naratriptan hydrochloride|2.5 mg tablet
214805805|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
214805806|NCT01188837|OTHER|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
214805807|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
214805808|NCT05960409|PROCEDURE|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
214805809|NCT06850090|COMBINATION_PRODUCT|TAS-102|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Concurrent administration of TAS-102 at a dose of 35 mg/m² twice daily at the 1st, 3rd and 5th week of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 85 mg/m² on day 1 combined with TAS-102 at 35 mg/m² twice daily from day 1 to day 5, repeated every 14 days for a total of 6 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy:~Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)."
214805810|NCT06850090|COMBINATION_PRODUCT|Capecitabine|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Capecitabine administered orally at a dose of 825 mg/m² twice daily on days of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 130 mg/m² on day 1 combined with capecitabine at 1000 mg/m² twice daily from day 1 to day 14, repeated every 21 days for a total of 4 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy: Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)"
214805811|NCT05956678|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
214805812|NCT05956678|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
214805813|NCT04833998|DRUG|Extremecare|The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
214805814|NCT04833998|DRUG|Placebo|Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
214805815|NCT05065645|DRUG|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
214805816|NCT05065645|DRUG|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
214805817|NCT00000588|DRUG|Chelation therapy|After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
214805818|NCT00000588|OTHER|Placebo|Placebo given at same time points as the Intervetnion for each clinical condition.
214805819|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
214805820|NCT01309945|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
214805821|NCT01309945|DRUG|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
214805822|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
214805823|NCT01309945|DRUG|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
214805824|NCT06038539|BIOLOGICAL|PERT-IJS plus trastuzumab, carboplatin and docetaxel|PERT-IJS is a monoclonal antibody, which has been developed by Biocon Biologics (earlier in collaboration with Viatris) as a proposed biosimilar to European Union (EU)-approved and United States (US) licensed Perjeta.
214805825|NCT06038539|BIOLOGICAL|Perjeta plus trastuzumab, carboplatin and docetaxel|EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).
214805826|NCT01762748|DRUG|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
214805827|NCT02480465|DRUG|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
214805828|NCT02480465|DRUG|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
214805829|NCT00581646|BEHAVIORAL|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
214805830|NCT01604850|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
214805831|NCT01604850|DRUG|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
214805832|NCT01604850|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
214805833|NCT01604850|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
214805834|NCT01185808|BIOLOGICAL|Vitamin D|Vitamin D 5000IU/day for 6 weeks
214805835|NCT01247259|DRUG|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
214805836|NCT02270970|BIOLOGICAL|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
214805837|NCT00243932|DRUG|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
214805838|NCT00243932|DRUG|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
214805839|NCT05167357|BIOLOGICAL|COVID19|"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."
214805840|NCT00166842|DRUG|sirolimus, cyclosporine, tacrolimus|
214805841|NCT04095871|OTHER|Observational study|No intervention, patients record the time of CISC
214805842|NCT02529280|BEHAVIORAL|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
214805843|NCT04549844|DRUG|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
214805844|NCT06521983|OTHER|Whole body vibration|Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine
214805845|NCT00867542|OTHER|no intervention|no intervention
214805846|NCT03002597|DEVICE|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
214805847|NCT05992805|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
214805848|NCT01381705|BIOLOGICAL|rituximab|
214805849|NCT01381705|GENETIC|DNA analysis|
214805850|NCT01381705|GENETIC|gene expression analysis|
214805851|NCT01381705|GENETIC|polymorphism analysis|
214805852|NCT01381705|OTHER|laboratory biomarker analysis|
214805853|NCT01381705|OTHER|medical chart review|
214805854|NCT01741844|DRUG|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
214805855|NCT02410928|DEVICE|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
214805856|NCT02410928|DEVICE|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
214805857|NCT02410928|DEVICE|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
214805858|NCT03981341|DRUG|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
214805859|NCT03236207|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
214805860|NCT03236207|OTHER|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
214805861|NCT02030353|BEHAVIORAL|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
214805862|NCT02030353|BEHAVIORAL|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
214805863|NCT00894283|DRUG|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
214805864|NCT00894283|DRUG|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
214805865|NCT05778448|DEVICE|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
214805866|NCT03105830|DRUG|iv paracetamol|iv paracetamol
214805867|NCT03962673|RADIATION|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
214805868|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
214805869|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
214805870|NCT01470482|PROCEDURE|No use of tourniquet|Tourniquet is not applied i 25 pts
214805871|NCT01470482|PROCEDURE|Tourniquet|Use of tourniquet
214805872|NCT04714294|DRUG|HPP737 or placebo|HPP737 or placebo will be randomized to assign to subjects
214805873|NCT00890526|OTHER|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from \~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
214805874|NCT00890526|OTHER|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
214805875|NCT00890526|OTHER|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
214805876|NCT00890526|OTHER|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
214805877|NCT00890422|BIOLOGICAL|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
214805878|NCT04314869|PROCEDURE|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
214805879|NCT00162669|DRUG|bevacizumab|
214805880|NCT03136666|DRUG|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
214805881|NCT00849901|DRUG|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
214805882|NCT00849901|DRUG|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
214805883|NCT00849901|DRUG|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
214805884|NCT00709566|BEHAVIORAL|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
214805885|NCT00709566|BEHAVIORAL|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
214805886|NCT00437658|DRUG|Elagolix|Provided as tablets for oral administration
214805887|NCT00437658|DRUG|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
214805888|NCT00437658|DRUG|Placebo to Elagolix|Matching placebo tablets for oral administration
214805889|NCT00437658|DRUG|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
214805890|NCT02068105|DRUG|ALKS 5461|Sublingual tablet
214805891|NCT02068105|DRUG|Placebo|Sublingual tablet
214805892|NCT04641130|OTHER|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
214805893|NCT01568476|PROCEDURE|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
214805894|NCT01568476|PROCEDURE|Interneural|Sciatic nerve blockade at the site of bifurcation
214805895|NCT05372926|DEVICE|high flow nasal canulae|high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.
214805896|NCT05372926|DEVICE|Ventury mask|Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.
214805897|NCT00213304|BIOLOGICAL|varicella vaccine (VARIVAX)|
214805898|NCT03953950|DRUG|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
214805899|NCT03953950|DRUG|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
214805900|NCT02276339|OTHER|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
214805901|NCT01126125|DIETARY_SUPPLEMENT|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
214805902|NCT02188953|DRUG|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
214805903|NCT02188953|DRUG|Calcium carbonate placebo|
214805904|NCT01469767|DRUG|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
214805905|NCT02254174|DRUG|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
214805906|NCT02254174|DRUG|Serevent® Diskus®|
214805907|NCT02254174|DRUG|Spiriva®|
214805908|NCT00770445|DRUG|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
214805909|NCT00770445|DRUG|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
214805910|NCT00770445|DRUG|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
214805911|NCT04751734|BIOLOGICAL|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
214805912|NCT01219322|DRUG|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
214805913|NCT01219322|DRUG|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
214805914|NCT01413581|DRUG|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
214805915|NCT01413581|DRUG|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
214805916|NCT04407806|DEVICE|Continous Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
214805917|NCT04407806|DEVICE|Intermittent Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
214805918|NCT04017156|PROCEDURE|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
214805919|NCT02513056|OTHER|MRI|MRI
214805920|NCT00161356|DRUG|Ambisome|5mg/kg IV - one time dose during liver transplant
214805921|NCT00161356|PROCEDURE|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
214805922|NCT04713709|COMBINATION_PRODUCT|Nasus Pharma FMXIN001|A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
214805923|NCT04713709|COMBINATION_PRODUCT|Nasal Naloxone liquid spray|A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
214805924|NCT02465697|BEHAVIORAL|Reappraisal Training|
214805925|NCT06561750|OTHER|Rooibos tea|Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water
214805926|NCT06561750|OTHER|Control|Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea
214805927|NCT06139588|DEVICE|acellular dermal matrix implant for breast reconstruction|acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
214805928|NCT00318383|BIOLOGICAL|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
214805929|NCT00318383|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
214805930|NCT03495622|BEHAVIORAL|Motivational Interviewing/Text messaging|"The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial"
214805931|NCT00857935|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
214805932|NCT00857935|DRUG|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
215031219|NCT00635050|DRUG|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
214805933|NCT02137135|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
214805934|NCT02137135|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
214805935|NCT02137135|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
214805936|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
214805937|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
214805938|NCT01498003|DRUG|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
214805939|NCT01498003|DRUG|normal saline solution|same use as tirofiban
214805940|NCT01433497|DRUG|Masitinib|
214805941|NCT01433497|DRUG|Placebo|
214805942|NCT00431197|DRUG|Ketoconazole, Dexamethesone, Androgel,GnRH|
214805943|NCT02731157|DRUG|Rejuvesol|
214805944|NCT02731157|PROCEDURE|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
214805945|NCT02495558|OTHER|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
214805946|NCT00389636|DEVICE|TheraGauze|TheraGauze
214805947|NCT00389636|DRUG|Regranex|Regranex + TheraGauze
214805948|NCT01407536|DEVICE|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
214805949|NCT03955757|BEHAVIORAL|Boot Camp Translation|Communities in the intervention arm will participate in the Boot Camp translation process, where stakeholders will come together to develop and implement locally relevant materials to promote adolescent vaccination.
214805950|NCT03955757|OTHER|Control|No intervention. Communities will continue to behave as usual.
214805951|NCT05954650|BEHAVIORAL|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
214805952|NCT00430079|DRUG|etanidazole|Given IV
214805953|NCT00430079|PROCEDURE|conventional surgery|Undergo surgery
214464503|NCT06052865|BEHAVIORAL|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
214805954|NCT00430079|OTHER|pharmacological study|Correlative studies
214805955|NCT00430079|OTHER|laboratory biomarker analysis|Correlative studies
214805956|NCT01807208|OTHER|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
214805957|NCT04450043|BEHAVIORAL|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
214805958|NCT04450043|BEHAVIORAL|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
214805959|NCT04450043|BEHAVIORAL|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
214805960|NCT04804800|OTHER|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
214805961|NCT04804800|OTHER|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
214805962|NCT04978532|OTHER|Guided Imagery|The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
214805963|NCT04978532|OTHER|Control Group|No intervention was made in the children.
214805964|NCT05618470|DRUG|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
215031220|NCT06013852|DIAGNOSTIC_TEST|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
215031221|NCT04544631|OTHER|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
214805965|NCT05618470|DRUG|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
214805966|NCT05614570|DEVICE|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
214805967|NCT05614570|OTHER|SCAT5|The Sport Concussion Assessment Tool version 5
214805968|NCT01051193|DRUG|Oxcarbazepine|
214805969|NCT01783171|DRUG|Akt Inhibitor MK2206|Given PO
214805970|NCT01783171|DRUG|Dinaciclib|Given IV
214805971|NCT01783171|OTHER|Laboratory Biomarker Analysis|Correlative studies
214805972|NCT01783171|OTHER|Pharmacological Study|Correlative studies
214805973|NCT01309607|DRUG|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously"
214805974|NCT05303909|DRUG|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
214805975|NCT05303909|DRUG|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
214805976|NCT01611389|DEVICE|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
214805977|NCT01611389|DEVICE|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
214805978|NCT01987271|DEVICE|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
214805979|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
214805980|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
214805981|NCT03270293|DEVICE|Profhilo|
214805982|NCT03287609|DRUG|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
214805983|NCT03287609|DRUG|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
214805984|NCT04985422|BEHAVIORAL|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
214805985|NCT04985422|BEHAVIORAL|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
214805986|NCT00832377|DRUG|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
214805987|NCT04558151|BEHAVIORAL|preoperative inspiratory muscle training|Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
214805988|NCT02513797|DEVICE|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
214805989|NCT02513797|DEVICE|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
214805990|NCT05689463|BIOLOGICAL|characterisation of immunoglobulin subclasses|For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed
214805991|NCT04043065|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
214805992|NCT04043065|OTHER|Placebo|Saline
214805993|NCT01561274|DRUG|2 ml bupivacaine|2 ml bupivacaine
215031222|NCT05699057|BEHAVIORAL|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
214805994|NCT01561274|DRUG|1.5 ml bupivicaine.|1.5 ml bupivicaine.
214805995|NCT04345965|PROCEDURE|Endovascular procedure|Endovascular therapies for erectile dysfunction
214805996|NCT05494567|DRUG|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
214805997|NCT05494567|DRUG|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
214805998|NCT05494567|DRUG|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
215031223|NCT06489509|DEVICE|Positive End Expiratory Pressure 5 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
215031224|NCT06489509|DEVICE|Positive End Expiratory Pressure 10 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
215031225|NCT00725855|DRUG|MEM 3454|1 mg dose
215031226|NCT00725855|DRUG|MEM 3454|5 mg dose
214805999|NCT04480073|PROCEDURE|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
214806000|NCT00213421|DRUG|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
214806001|NCT01881321|BEHAVIORAL|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
214806002|NCT01390337|DRUG|AC220|Oral Liquid
214806003|NCT01390337|DRUG|daunorubicin|Intravenous Infusion
214806004|NCT01390337|DRUG|cytarabine|Intravenous Infusion
214806005|NCT05108571|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
214806006|NCT05108571|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
214806007|NCT00122629|DRUG|peg-interferon alfa-2b|
214806008|NCT00122629|DRUG|ribavirin|
214806009|NCT00122629|DRUG|amantadine|
214806010|NCT01449630|DRUG|LY3031207|Administered orally
214806011|NCT01449630|DRUG|Placebo|Administered orally
214806012|NCT01449630|DRUG|Celecoxib|Administered orally
214806013|NCT01888263|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
214806014|NCT04692610|BEHAVIORAL|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
214806015|NCT04692610|BEHAVIORAL|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
214806016|NCT04692610|BEHAVIORAL|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
214806017|NCT04692610|BEHAVIORAL|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
214806018|NCT02016612|DEVICE|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
214806019|NCT02854579|BIOLOGICAL|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
214806020|NCT02854579|BIOLOGICAL|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
214806021|NCT02854579|BIOLOGICAL|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
214806022|NCT04064632|DRUG|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
214806023|NCT03256942|DEVICE|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
214806024|NCT04097600|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
214806025|NCT04250662|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
214806026|NCT04250662|DEVICE|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
214806027|NCT04250662|DEVICE|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
214806028|NCT04250662|DEVICE|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
214806029|NCT03799029|OTHER|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
214806030|NCT01735630|DRUG|ELND005|
214806031|NCT01735630|DRUG|Placebo|
215031227|NCT00725855|DRUG|MEM 3454|15 mg dose
214806032|NCT04203030|BEHAVIORAL|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
214806033|NCT01820923|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
214806034|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
214806035|NCT01820923|DEVICE|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
214806036|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
214806037|NCT03621579|PROCEDURE|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
214806038|NCT03099538|DRUG|Ixekizumab|Subcutaneous injection
214806039|NCT06266052|PROCEDURE|Triangular Flap|Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
214806040|NCT06266052|PROCEDURE|Berwick Flap|Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
214806041|NCT06266052|PROCEDURE|Saurez Flap|In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
214806042|NCT06266052|PROCEDURE|Heitz Flap|Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
214806043|NCT05090332|OTHER|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
214806044|NCT05090332|OTHER|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
214806045|NCT01067885|DEVICE|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
214806046|NCT03044171|DEVICE|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
214806047|NCT03044171|DRUG|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
214806048|NCT03044171|DRUG|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
215031228|NCT00725855|DRUG|MEM 3454|50 mg dose
215031229|NCT00725855|DRUG|Placebo for MEM 3454|Placebo dose
215031230|NCT00176748|DRUG|AG 6013736|5 mg po bid
214806049|NCT05964777|DEVICE|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.
214806050|NCT01276730|DRUG|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
214806051|NCT01276730|DRUG|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
214806052|NCT05738525|DEVICE|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
214806053|NCT02102425|PROCEDURE|Patients with or without bandage over exit site|
214806054|NCT04067102|DRUG|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
214806055|NCT04067102|DRUG|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
214806056|NCT04901377|COMBINATION_PRODUCT|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
214806057|NCT05879549|OTHER|Closed Chain Exercise Group|Closed Chain Exercise Group
214806058|NCT05879549|OTHER|Proprioceptive Exercise Group|Proprioceptive Exercise Group
214806059|NCT06415201|OTHER|Interactive Artificial Intelligence|scenario based AI to assess, classify, explain and conduct supportive interviews
214806060|NCT02096718|DRUG|Afatinib healthy|
214806061|NCT02096718|DRUG|Afatinib severe renally impaired|
214806062|NCT02096718|DRUG|Afatinib moderate renally impaired|
214806063|NCT02818439|OTHER|evaluation of frailty|
214806064|NCT03062046|DEVICE|RF ablation|RF ablation
214806065|NCT04448886|DRUG|Pembrolizumab|(iv) fixed dose, administered once per cycle
214806066|NCT04448886|DRUG|Sacituzumab Govitecan|(iv) fixed dose, administered twice per cycle
214806067|NCT04997993|DRUG|Leflunomide|Leflunomide, 20-50mg PO daily
214806068|NCT06234189|DEVICE|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|30 minutes without DIMS and 30 minutes with DIMS
214806069|NCT06577779|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
214806070|NCT06340802|DEVICE|VNS Treatment|Vagus nerve stimulation is started 2-week after the implantation
214806071|NCT03143400|DRUG|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
214806072|NCT01173770|DRUG|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
214806073|NCT01173770|DRUG|ADC3680B|ADC3680B or Placebo for 7 days
214806074|NCT01173770|DRUG|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
214806075|NCT03205553|PROCEDURE|SoC Staged Silo Closure|Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
215031231|NCT00672035|BIOLOGICAL|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
215031232|NCT00759395|DRUG|AZD2327|Tablet, Oral, Daily
215031233|NCT00759395|DRUG|Placebo|Tablet, Oral, Daily
215031234|NCT03728686|OTHER|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
215031235|NCT01233947|DRUG|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
214806076|NCT03205553|DRUG|Peritoneal Dialysis Solution/Dextrose 1.5%|Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
214806077|NCT02001948|DRUG|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
214806078|NCT02001948|DRUG|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
214464504|NCT06052865|BEHAVIORAL|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
214806079|NCT02001948|DEVICE|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
214806080|NCT02001948|DRUG|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
214806081|NCT03009448|OTHER|Interview|Each subject will be interviewed using a semi constructed interview.
214806082|NCT02461771|DRUG|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
214806083|NCT03752788|BEHAVIORAL|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
214806084|NCT03752788|BEHAVIORAL|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
214806085|NCT05777707|DRUG|PD-1 blockade|PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
214806086|NCT05777707|DRUG|Albumin paclitaxel|Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
214806087|NCT05777707|DRUG|Carboplatin/Nedaplatin|Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
214806088|NCT04096703|PROCEDURE|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is \> 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
214806089|NCT04191980|OTHER|Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists|"The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95\_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes"
214806090|NCT00383890|DRUG|Dexmedetomidine HCL Injection|
214806091|NCT00383890|DRUG|Placebo|
214806092|NCT03366909|BEHAVIORAL|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
214806093|NCT03366909|BEHAVIORAL|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
215031236|NCT01233947|DRUG|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
214806094|NCT00154414|DRUG|liraglutide|
214806095|NCT05258942|OTHER|Observational|Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.
214806096|NCT03436680|OTHER|Best Practice|Receive standard of care
214806097|NCT03436680|BEHAVIORAL|Neurofeedback|Complete neurofeedback training sessions
214806098|NCT03436680|OTHER|Quality-of-Life Assessment|Ancillary studies
214806099|NCT03436680|OTHER|Questionnaire Administration|Ancillary studies
214806100|NCT02980978|BEHAVIORAL|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
214806101|NCT02602925|OTHER|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
214806102|NCT02602925|OTHER|Usual care|Usual care
214806103|NCT01968265|DRUG|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
214806104|NCT01968265|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
214806105|NCT02222766|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
214806106|NCT02222766|BEHAVIORAL|Control|Minimal attention control- 9 weekly mailed information on general child development
214806107|NCT04471675|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
214806108|NCT01941030|DEVICE|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
214806109|NCT01941030|DEVICE|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
214464505|NCT06052865|OTHER|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
214464506|NCT06076187|OTHER|Dual isotope protein digestibility method|Dual isotope method
214806110|NCT04047095|DIETARY_SUPPLEMENT|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
214806111|NCT04047095|DIETARY_SUPPLEMENT|Normal daily meal|Normal daily meal (75-80 g protein)
214806112|NCT03210636|DEVICE|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
214806113|NCT00281125|DRUG|PTK787 and Pemetrexed with or without Cisplatin|
214806114|NCT00148564|DRUG|olanzapine|treatment with either Olanzapine or Ziprasidone
214806115|NCT00148564|DRUG|Ziprasidone|treatment with either Olanzapine or Ziprasidone
214806116|NCT03980288|DRUG|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
214806117|NCT02384174|DIETARY_SUPPLEMENT|Resistant starch|
214806118|NCT02384174|DIETARY_SUPPLEMENT|Dietary fibre (arabinogalactan, gum guar, pectin)|
214806119|NCT01835678|DRUG|Linagliptin|orally 5 mg/d for 4 weeks
214806120|NCT01835678|DRUG|Placebo|orally once a day for 4 weeks
214806121|NCT01502943|DRUG|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
214806122|NCT01502943|DRUG|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
214806123|NCT01502943|DRUG|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
214806124|NCT01502943|DRUG|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
214806125|NCT01502943|DRUG|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
214806126|NCT01345149|BEHAVIORAL|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
214806127|NCT00275353|BEHAVIORAL|Individualized Symptom Education|
214806128|NCT03635125|DRUG|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
214806129|NCT03635125|DRUG|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
214806130|NCT03635125|OTHER|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
214806131|NCT05048992|OTHER|ELDOA method|group A will receive
214806132|NCT05048992|OTHER|Post-facilitation stretching|Group B will receive
214806133|NCT05654779|BIOLOGICAL|LCAR-AMDR Cells Product|Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
214806134|NCT06032533|DEVICE|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
214806135|NCT06032533|DEVICE|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
214806136|NCT00547677|RADIATION|stereotactic radiosurgery|
214806137|NCT05077566|OTHER|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
214806138|NCT05077566|OTHER|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
214806139|NCT04438057|BIOLOGICAL|CCP|Randomized open label study to receive 2:1 CCP to standard of care
214806140|NCT00193622|DRUG|Bevacizumab|
214806141|NCT00193622|DRUG|Erlotinib|
214806142|NCT05352360|DIAGNOSTIC_TEST|Pilates Exercises|Exercises with Kinesio Taping
214806143|NCT05352360|DIAGNOSTIC_TEST|Muscle Energy Technique|Exercises with Kinesio Taping
214806144|NCT05823090|DEVICE|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
214806145|NCT01340430|DRUG|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
214806146|NCT02721264|BIOLOGICAL|Fecal Microbiota Transplant|
214806147|NCT02721264|OTHER|Standard Medical Treatment|
214806148|NCT04835246|DEVICE|Spectra IMDx system|The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
214806149|NCT03663803|BEHAVIORAL|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
214806150|NCT02930005|DRUG|Meclofenamic acid|
214806151|NCT02930005|DRUG|Pentosan polysulfate sodium|
214806152|NCT01054534|PROCEDURE|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
214806153|NCT05431166|BEHAVIORAL|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
214806154|NCT05431166|BEHAVIORAL|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
214806155|NCT01293422|DRUG|Rifampicin|Rifampicin 600 mg daily for a week
214806156|NCT04362891|PROCEDURE|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
214806157|NCT01524718|RADIATION|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
214806158|NCT04587557|BEHAVIORAL|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
214806159|NCT04587557|BEHAVIORAL|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
214806160|NCT04587557|OTHER|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
214806161|NCT04587557|OTHER|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
214806162|NCT00138385|BIOLOGICAL|FluMist|
214806163|NCT00138385|BIOLOGICAL|Fluzone|
214806164|NCT04347837|DEVICE|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
214806165|NCT00933751|DEVICE|Central vein catheterization|Blood samplings from IVC catheter
214806166|NCT02945215|DRUG|IBI301|IBI301 375mg/㎡
214806167|NCT02945215|DRUG|Rituximab|Rituximab 375mg/㎡
214806168|NCT03033420|DEVICE|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
214806169|NCT02125266|DRUG|V404|Sustained Release
214806170|NCT01288664|DRUG|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
214806171|NCT01313416|BIOLOGICAL|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
214806172|NCT01313416|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
214806173|NCT00487669|DRUG|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
214806174|NCT01895296|DRUG|Pasireotide|somatostatin analogue pasireotide
214806175|NCT01895296|DRUG|Placebo|placebo s.c.
214806176|NCT04012632|OTHER|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
214806177|NCT01806805|DRUG|zonegran|
214806178|NCT01806805|DRUG|placebo|
214806179|NCT00822926|DRUG|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
214806180|NCT00822926|DRUG|Saline|Subcutaneous injection of saline into scar tissue
214806181|NCT01765530|DEVICE|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
214806182|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
214806183|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
214806184|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
214806185|NCT01930461|BIOLOGICAL|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
214806186|NCT01540032|BEHAVIORAL|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
214806187|NCT01540032|BEHAVIORAL|Normal diet|Patients will eat their usual diet.
214806188|NCT03776903|OTHER|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
214806189|NCT00486083|DRUG|Atomoxetine Hydrochloride|
214806190|NCT00486083|DRUG|Methylphenidate Hydrochloride|
214806191|NCT01124396|DRUG|DSP-3025|
214806192|NCT01124396|DRUG|Placebo|
214806193|NCT02304432|DRUG|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
214806194|NCT02304432|DRUG|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
214806195|NCT02304432|DRUG|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
214806196|NCT06347042|OTHER|qigong exercise + routine medical treatment +Anti-inflammatory diet|1\. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.
214806197|NCT06347042|OTHER|routine medical treatment +Anti-inflammatory diet only|"1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment"
214806198|NCT01636609|DRUG|Azacitidine|Given IV or SC
214806199|NCT01636609|DRUG|Cytarabine|Given SC
214806200|NCT01636609|DRUG|Tosedostat|Given PO
214806201|NCT00948519|DEVICE|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
214806202|NCT00948519|DEVICE|Laser only|same only without ICG
214806203|NCT05786222|BEHAVIORAL|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator \[a trained CSH employee\] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
214806204|NCT03239145|DRUG|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
214806205|NCT03239145|DRUG|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
214806206|NCT04536805|DRUG|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
214806207|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
214806208|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
214806209|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
214806210|NCT00098371|DRUG|alvocidib|
214806211|NCT01314742|DRUG|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
214806212|NCT01314742|OTHER|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
214806213|NCT03767192|DEVICE|Active Stimulation|SPG stimulation and standard of care
214806214|NCT03767192|DEVICE|Sham Stimulation|Sham SPG stimulation and standard of care
214806215|NCT00003898|DIETARY_SUPPLEMENT|glutamine|Oral
214806216|NCT02268500|BIOLOGICAL|Influenza vaccine|Influenza vaccine
214806217|NCT02141256|DIETARY_SUPPLEMENT|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
214806218|NCT06037200|DEVICE|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
214806219|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 NODAGA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
214806220|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
214806221|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTATATE PET/CT|All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
214806222|NCT02348268|OTHER|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
214806223|NCT02348268|OTHER|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
214806224|NCT02348268|DEVICE|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
214806225|NCT01993875|DRUG|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
214806226|NCT01993875|DRUG|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
214806227|NCT02534493|DEVICE|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
214806228|NCT04578470|DRUG|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
214464507|NCT06225063|OTHER|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
214806229|NCT04578470|DRUG|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
214806230|NCT00002027|DRUG|Diclazuril|
214806231|NCT05060900|PROCEDURE|Ligament Reconstruction with Allograft Ligament|Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
214806232|NCT01662466|DRUG|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
214806233|NCT01662466|DIETARY_SUPPLEMENT|DHEA|DHEA 25mg tid
214806234|NCT01662466|DRUG|Placebo|Carrier cream without added testosterone in the identical type of pump
214806235|NCT02158832|DEVICE|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current \>sensation threshold \& maintained at a level that is comfortable/painless \& does not elicit skeletal muscle contractions (\~5mA, \<10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', \~15⁰ perpendicular to the skin, \~15⁰ lateral to the midline. Depth: \~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' \~15⁰ perpendicular to the skin, \~15⁰ medial. Depth: \~1.5 cm (secure anchorage)."
214806236|NCT05765565|DEVICE|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
214806237|NCT05765565|DEVICE|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
214806238|NCT05310565|PROCEDURE|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
214806239|NCT01023074|BEHAVIORAL|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
214806240|NCT01023074|OTHER|MS: Control Activity|MS group not receiving auditory training, doing control activity
214806241|NCT01521988|PROCEDURE|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
214806242|NCT01521988|PROCEDURE|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
214806243|NCT03415997|DRUG|Iohexol|Iodinated contrast media
214806244|NCT05327166|OTHER|ED-LINC|The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
214806245|NCT03125200|DRUG|ADCT-502|Intravenous Infusion
214806246|NCT00301769|DRUG|SJG-136|Given IV
214806247|NCT03811080|DRUG|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
214806248|NCT03811080|DRUG|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
214806249|NCT03811080|DRUG|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
214806250|NCT00028691|DRUG|chlorambucil|
214806251|NCT00028691|RADIATION|radiation therapy|
214806252|NCT00910364|OTHER|Exercise|Exercise
214806253|NCT00119379|DRUG|NucleomaxX|NucleomaxX 36 grams TID every other day
214806254|NCT00119379|DRUG|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
214806255|NCT01575223|DEVICE|NeilMed sinus rinse|High volume saline irrigation
214806256|NCT01575223|DEVICE|Salinex|Low volume saline irrigation
214806257|NCT01038791|DEVICE|heated humidification|temperature 35°
214806258|NCT01038791|DEVICE|heat and moisture exchanger|single patient device
214806259|NCT01038791|DEVICE|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
214806260|NCT01938586|OTHER|Steri-Strip|
214806261|NCT01938586|OTHER|Superficial sutures|
214806262|NCT03236753|PROCEDURE|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
214806263|NCT03236753|PROCEDURE|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
214806264|NCT02227121|DEVICE|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
214806265|NCT03236766|OTHER|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
214806266|NCT06143865|OTHER|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
214806267|NCT03929367|DRUG|Oxytocin|Single IV administration of oxytocin
214806268|NCT02120053|DEVICE|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
214806269|NCT02120053|DEVICE|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
214806270|NCT03354104|DEVICE|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
214806271|NCT03354104|DEVICE|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
214806272|NCT00411203|DRUG|Tamoxifen Citrate|
214806273|NCT00411203|DRUG|Placebo|
214806274|NCT00636896|DRUG|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
214806275|NCT00636896|DRUG|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
214806276|NCT00733616|DRUG|DOX: Docetaxel, oxaliplatin, Capecitabine|"* Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
214806277|NCT03061734|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
214806278|NCT03061734|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
214806279|NCT03061734|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
214806280|NCT03061734|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
214806281|NCT03061734|DRUG|Matching Placebo|Two Placebo capsules
214806282|NCT06880588|BEHAVIORAL|Brief Infant Sleep Questionnaire|"The Brief Infant Sleep Questionnaire will be used to assess sleep. Infant sleep problems are among the most common problems presented to healthcare professionals. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood. This questionnaire has been translated into Turkish and assessed sleep environment and sleep problems in infants. It consists of 33 items, is based on parent reports of infant or toddler sleep patterns and is used to validate the data. It is associated with daily records and parent reports of sleep. Its sensitivity in documenting developmental sleep trends is well established"
214806283|NCT06880588|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of Sensory Function in Infants is frequently used to evaluate the sensory processing
214806284|NCT06880588|BEHAVIORAL|Peabody Motor Development Scale-2|It was planned to use the Peabody Motor Development Scale-2 to evaluate motor development. The Peabody Motor Development Scale-2 was designed to determine developmental delays in children aged 0-72 months.
214806285|NCT05686759|BIOLOGICAL|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
214806286|NCT05686759|BIOLOGICAL|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
214806287|NCT05618119|DRUG|[18F]MC225|\[18F\]MC225 PET scan
214806288|NCT04279639|BEHAVIORAL|qigong|Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.
214806289|NCT05811156|BEHAVIORAL|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
214806290|NCT00905853|PROCEDURE|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
214806291|NCT00905853|DRUG|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
214806292|NCT01517256|BEHAVIORAL|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
214806293|NCT01517256|OTHER|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
214806294|NCT03418441|OTHER|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
214806295|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
214806296|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
214806297|NCT03664973|PROCEDURE|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
214806298|NCT00002005|DRUG|CD4 Antigens|
214806299|NCT05546827|PROCEDURE|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
214806300|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
214806301|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
214806302|NCT06988514|OTHER|Standardized stool collection from healthy volunteers|The only interventions are clinical examination, dietary restrictions and samples collection (stool, and urine for the pregnancy tests (when applicable).
214806303|NCT05647213|BIOLOGICAL|iPSC-CL|Autologous IPSCL
214806304|NCT03069274|BEHAVIORAL|Intervention|General nutritional recommendations, change drinking habits
214806305|NCT03069274|BEHAVIORAL|General nutritional recommendations|Only general nutritional recommendations were given
214806306|NCT01706536|DRUG|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
214464508|NCT06225063|OTHER|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
214806307|NCT01706536|DRUG|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
214806308|NCT01706536|DRUG|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
214806309|NCT01706536|DRUG|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
214806310|NCT01706536|DRUG|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
214806311|NCT02519322|BIOLOGICAL|Ipilimumab|Given IV
214806312|NCT02519322|OTHER|Laboratory Biomarker Analysis|Correlative studies
214806313|NCT02519322|BIOLOGICAL|Nivolumab|Given IV
214806314|NCT02519322|BIOLOGICAL|Relatlimab|Given IV
214806315|NCT02519322|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214806316|NCT06241378|DEVICE|perineometer device for physiotherapy|measuring the vaginal pressure for stress urinary incontinence patients
214806317|NCT04190693|DRUG|IMCY-0098 or placebo|Long-term follow-up
214806318|NCT06112535|DEVICE|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
214806319|NCT02459704|PROCEDURE|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
214806320|NCT02459704|DEVICE|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
214806321|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
214806322|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
214806323|NCT00006259|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
214806324|NCT02226328|DRUG|Propofol sedation|
214806325|NCT02226328|DRUG|Midazolam and Fentanyl sedation|
214806326|NCT00101543|DEVICE|Electrical Stimulation with Intramuscular Electrodes|
214806327|NCT00101543|PROCEDURE|Body Weight Supported Treadmill Training|
214806328|NCT03759821|BEHAVIORAL|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
214806329|NCT03759821|BEHAVIORAL|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
214806330|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
214806331|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
214806332|NCT01813461|DRUG|14C-labeled prodrug isavuconazonium sulfate|oral
214806333|NCT00993187|DRUG|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
214806334|NCT00993187|DRUG|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
214806335|NCT00993187|DRUG|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
214806336|NCT00993187|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
214806337|NCT00245713|DRUG|levetiracetam|
214806338|NCT00683293|PROCEDURE|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
214806339|NCT00683293|PROCEDURE|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
214806340|NCT01630980|OTHER|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
214806341|NCT03741595|BEHAVIORAL|Item spacing|Spatial proximity of items to one another
214806342|NCT00274326|DRUG|SR121463B|
214806343|NCT00681720|DRUG|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
214806344|NCT00681720|DRUG|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
214806345|NCT03262012|DRUG|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
214806346|NCT03262012|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
214806347|NCT03262012|DRUG|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
214806348|NCT03262012|DRUG|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
214806349|NCT03057392|OTHER|immersion|participants will sit in a 34-35C while receive dialysis
214806350|NCT03057392|OTHER|sham session|dialysis while sitting in the dialysis chair
214806351|NCT03494595|PROCEDURE|Pediatric Liver transplantation|Pediatric Liver transplantation
214806352|NCT01762358|OTHER|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
214806353|NCT01762358|OTHER|Physiotherapy|Twelve times standardized Physiotherapy
214806354|NCT00003148|BIOLOGICAL|aldesleukin|
215031604|NCT06132789|BIOLOGICAL|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
214806355|NCT01469546|DRUG|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST \[Response Evaluation Criteria In Solid Tumors\] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
214806356|NCT03154658|DRUG|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
214806357|NCT04987164|DIETARY_SUPPLEMENT|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
214806358|NCT00046865|PROCEDURE|acupressure therapy|
214806359|NCT00046865|PROCEDURE|management of therapy complications|
214464509|NCT01574274|DRUG|SC-PEG|11 doses Intravenously over one hour
214806360|NCT00046865|PROCEDURE|nausea and vomiting therapy|
214806361|NCT05814848|DRUG|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
214806362|NCT05978427|PROCEDURE|interscalene block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.
214806363|NCT05978427|PROCEDURE|superior trunk block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
214806364|NCT03321565|OTHER|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
214806365|NCT02079532|DRUG|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
214806366|NCT04175951|DEVICE|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
214806367|NCT06337006|PROCEDURE|Placement of the laryngeal mask airway|Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
214806368|NCT02924948|PROCEDURE|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
214806369|NCT06446180|DRUG|SsK12@Lip@GSH|SsK12@Lip@GSH powder contained 1×10\^9 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
214806370|NCT02716129|DRUG|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
214806371|NCT02716129|DRUG|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
214806372|NCT06028607|DIETARY_SUPPLEMENT|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
214806373|NCT03947515|PROCEDURE|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
214806374|NCT03947515|OTHER|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
214806375|NCT03947515|OTHER|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
214806376|NCT02498964|OTHER|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
214806377|NCT00605930|DIETARY_SUPPLEMENT|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
214806378|NCT00605930|DIETARY_SUPPLEMENT|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
214806379|NCT01247948|PROCEDURE|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
214806380|NCT01247948|PROCEDURE|traditional spine surgery|traditional spine surgery without navigation assist
214806381|NCT01513070|DRUG|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
214806382|NCT01513070|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
214806383|NCT01513070|DRUG|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
214806384|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
214806385|NCT01513070|DRUG|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
214806386|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
214806387|NCT05134792|DRUG|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
214806388|NCT01223612|DRUG|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
214806389|NCT01223612|PROCEDURE|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
214464510|NCT01574274|DRUG|Oncaspar|16 doses Intravenously over one hour
214806390|NCT04785937|DIAGNOSTIC_TEST|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
214806391|NCT02393040|OTHER|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
214806392|NCT07024654|DRUG|Doxycycline Injection|Injection of doxycycline as a sclerosing agent into the genicular artery region under ultrasound guidance for the purpose of evaluating its effectiveness in reducing knee pain.
214806393|NCT07027319|OTHER|Parenting Education|The intervention group will receive 8 sessions of Triple P (positive parenting training).
214806394|NCT07027670|DRUG|5-Aminolevulinic Acid hydrochloride (5-ALA)|5-ALA: supplied for oral administration as a dark green, opaque, size 0, hypromellose (HPMC) capsule containing drug alone at a dosage strength of 75mg (58.7mg as 5-ALA). There are no excipients.
214806395|NCT07027670|OTHER|Placebo|Supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing 125mg lactose. The capsule shells are of non-animal origin, and are comprised of HPMC, titanium dioxide, and a copper complex of chlorophyllins.
214806396|NCT07027670|DRUG|Sodium ferrous citrate (SFC)|SFC: supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing drug alone at a dosage strength 118mg (12.5mg as Fe). There are no excipients.
214806397|NCT03953170|DRUG|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
214806398|NCT03953170|DRUG|Placebo|Placebo
214806399|NCT01924130|OTHER|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
214806400|NCT01924130|BEHAVIORAL|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
214806401|NCT01924130|BEHAVIORAL|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
214806402|NCT01924130|BEHAVIORAL|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
214806403|NCT07029308|PROCEDURE|Modified poco-poco exercise program as the home-based therapy (Intervention)|Patient will do the exercise at home 5 days/week and supervised via zoom application. Supervised via Zoom will be conducted every week. The instructor will monitor the exercise movement of the participants, if there is any mistake the instructor will pause the session and correct it immediately. The monitoring will also be done by researcher assistant to collect attendance, help ensure correct movement and operational problem. The intensity of the exercise will be evaluated and adjusted every 4 weeks.
214806404|NCT07028840|OTHER|Physiotherapy|10 sessions over 2 weeks, including TENS, cold therapy, ultrasound, and exercise therapy, 5 sessions per week.
214806405|NCT07028840|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|4 sessions total, applied 2 times per week for 2 weeks.
214806406|NCT07028840|DEVICE|High-Intensity Laser Therapy (HILT)|4 sessions total, applied 2 times per week for 2 weeks.
214806407|NCT06625307|DRUG|NNC0537-1482|Administered via subcutaneous route
214806408|NCT06625307|DRUG|Placebo|Administered via subcutaneous route
214806409|NCT07025915|DRUG|[14C]SSS17|single oral dose
214806410|NCT03328793|BEHAVIORAL|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
214806411|NCT03328793|BEHAVIORAL|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
214806412|NCT03328793|BEHAVIORAL|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
214806413|NCT03328793|OTHER|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
214806414|NCT03328793|OTHER|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
214806415|NCT03328793|OTHER|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
214806416|NCT06707896|DRUG|TCR1020-CD8 T cells|TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.
214806417|NCT06709599|OTHER|Three-Week Strength and Conditioning Program|Athletes train six days a week for three weeks, totaling approximately 15 hours of training per week. Training includes circuit training, weightlifting, technique drills, and sparring, designed to mimic typical MMA preparation.
214806418|NCT07029048|OTHER|Standard Post-COVID Rehabilitation Program|This standardized rehabilitation intervention includes a 14-day inpatient course comprising physiotherapy, therapeutic exercises, massage, and respiratory gymnastics. The program is delivered equally to all participants regardless of cognitive status and is intended to promote post-viral recovery in patients recently discharged following COVID-19 pneumonia. No specific cognitive therapy or pharmacological treatment is administered during the rehabilitation period. The intervention is used as background care, not as an experimental variable.
214806419|NCT07028320|DRUG|SAL056 (56.5μg)|Administered by subcutaneous injection once a week during treatment phase
214806420|NCT07028320|DRUG|Alendronate|70 mg tablet taken once a week during treatment phase
214806421|NCT07035262|OTHER|serum metabolites|serum metabolites before and after colorectal cancer surgery
214806422|NCT07036029|DRUG|NAL ER|Oral tablets
214806423|NCT07036029|DRUG|Placebo|Oral tablets
214806424|NCT07036172|DRUG|HDM1702|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
214806425|NCT07036172|DRUG|Wegovy ®|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
214806426|NCT07037576|PROCEDURE|Breast Reconstruction Surgery|Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy
214806427|NCT07037355|COMBINATION_PRODUCT|Handgrip Strength and Hand-Eye Coordination Assessment|Children underwent standardized testing to assess functional recovery post-healing of distal radius greenstick fractures.
214806428|NCT07037290|DIAGNOSTIC_TEST|Ankle proprioceptive neuromuscualar facilitation technique|Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic technique that uses sensory input to enhance muscle function and improve flexibility. For the ankle, PNF techniques can be used to increase range of motion, improve balance and stability, and reduce pain associated with ankle injuries.
214806429|NCT07037290|DIAGNOSTIC_TEST|Foot core exercises along with conventional physiotherapy|This Group will be given foot core exercises which includes heel raise, toe curls, foot doming, toe spreading, balancing board, and tennis ball roll under foot along with conventional therapy which includes ultrasound, plantar fascia stretching and Achilles stretching.
214806430|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with lymphatic taping|Participants will receive a supervised, moderate-to-vigorous intensity resistance training program designed specifically for pregnant women, The resistance training will involve the use of light barbells (1-10 lbs) and weight plates (2.5-10 lbs), targeting all major muscle groups through 50-80 repetitions per muscle group over 3-5 minutes, with short rest intervals. Exercises will be performed at a self-rated intensity level considered moderate to vigorous, following the Borg scale for perceived exertion. The training program is based on the BodyPump format but modified to suit pregnancy-related safety considerations.
214806431|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with compression Bandage|Participants in will receive progressive resistance exercise same as Group B and also receive thecompression bandaging as the primary intervention for the management of lower-limb oedema during pregnancy. The compression bandage will be applied in a multi-layered manner, beginning from the base of the toes and extending proximally to below the knee, ensuring graded pressure with higher compression distally and gradually reducing proximally to support venous and lymphatic return. Prior to each application, participants will be asked to lie in a supine position with their legs elevated for 15-20 minutes to reduce pre-existing swelling.
214806432|NCT07036341|OTHER|Protein-enriched diet|A protein intake of 1.5 g/kg bodyweight/day. This will be obtained by consuming protein-rich and protein-enriched foods.
214806433|NCT07036341|OTHER|Progressive resistance exercise|The intervention group will perform resistance training during three non-consecutive days with a minimum of 48 hours between the sessions. Subjects will continue the resistance training after discharge for 2 times a week, also with a minimum of 48 hours between sessions until the study period of 3 months is completed. All sessions will be supervised by physiotherapists.
214806434|NCT07036393|OTHER|Acupuncture|"Cholecystectomy involves a procedure where patients' spines are kept in position and skin around the acupoints is disinfected with 75% alcohol. Acupuncture treatment is given when patients return to units within 2 hours after surgery. The needles are inserted using disposable sterile needles and manipulated to induce a sense of De qi (soreness, numbness, distension, or heaviness). Gastrectomy involves daily acupuncture sessions for 5 consecutive days, starting on postoperative day 1. The needles are inserted perpendicular to the acupoints in the extremities to a depth of approximately 20 mm from the skin surface."
214806435|NCT07036393|OTHER|Transcutaneous electrical nerve stimulation|Patients will receive a transcutaneous electrical nerve stimulation unit (ENNRAF) for up to 48 hours post-surgery, with instructions to self-titrate intensity for pain relief. Postoperative stimulation will be 20-40 milliampere and pulse width 5
214806436|NCT07036393|OTHER|drugs|analgesics and nonsteroidal anti-inflammatory drugs
214806437|NCT07035847|PROCEDURE|Echocardiography guided TAVR|Echocardiography guided TAVR
214806438|NCT07036978|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
214806439|NCT07035483|PROCEDURE|bariatric surgery|This is a prospective observational study evaluating the metabolic and tissue-level effects of bariatric surgery in obese individuals. The intervention includes either laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB), performed according to standard clinical guidelines. No experimental procedures are added beyond routine care. Skeletal muscle quality and visceral fat distribution are assessed using MRI and clinical biomarkers at multiple postoperative time points (baseline, 3 months, 12 months, and annually up to 5 years). A healthy control group undergoes baseline evaluation only, without surgical intervention.
214806440|NCT07037407|PROCEDURE|IOS|Intra oral scanning
214806441|NCT07037407|PROCEDURE|WTI|window technique Impression
214806442|NCT06126393|DIAGNOSTIC_TEST|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
214806443|NCT01085045|DRUG|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
214806444|NCT01085045|DRUG|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
214806445|NCT01085045|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
214806446|NCT01085045|DRUG|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
214806447|NCT01085045|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
214806448|NCT01085045|DRUG|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
214806449|NCT00714103|DRUG|8-Chloro-Adenosine|45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
214806450|NCT00202982|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
214806451|NCT00202982|DRUG|glatiramer acetate 40 mg|glatiramer acetate 40 mg
214806452|NCT04462926|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
214806453|NCT00234078|DRUG|0.5% OPC-12759|
214806454|NCT00234078|DRUG|1% OPC-12759|
214806455|NCT00234078|DRUG|2% OPC-12759|
214806456|NCT00234078|DRUG|placebo|
214806457|NCT05859386|BEHAVIORAL|Mindfulness maintenance program|"1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
214806458|NCT05531422|DRUG|Inhaled fentanyl aerosol|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
214806459|NCT05531422|DRUG|Placebo|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
214806460|NCT03202277|BEHAVIORAL|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
214806461|NCT03202277|BEHAVIORAL|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
214806462|NCT01464970|PROCEDURE|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
214806463|NCT01464970|PROCEDURE|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
214806464|NCT01464970|PROCEDURE|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
214806465|NCT01464970|PROCEDURE|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
214806466|NCT02683967|PROCEDURE|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
214806467|NCT00633399|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
214806468|NCT00633399|DRUG|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
214806469|NCT05745870|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
214806470|NCT01137539|DEVICE|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
214806471|NCT06038019|DIAGNOSTIC_TEST|Oral food challenge|Patients will undergo oral food challenge with increasing amounts of food allergen
214806472|NCT00637117|BIOLOGICAL|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
214806473|NCT03558945|BIOLOGICAL|Personalized neoantigen vaccine|Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
214806474|NCT02833389|DRUG|Placebo|UTTR1147A matching placebo will be administered SC.
214806475|NCT02833389|DRUG|UTTR1147A|UTTR1147A will be administered SC.
214806476|NCT01781325|DEVICE|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
214806477|NCT05060926|PROCEDURE|Awake prone positioning|Awake prone position as long as possible according to the patients' tolerance
214806478|NCT02994810|OTHER|Breastfeeding guidance|Breastfeeding guidance
214806479|NCT03199547|DRUG|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
214806480|NCT03199547|DRUG|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
214806481|NCT05439109|DEVICE|Topographical landmark technique of endotracheal tube placement|An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.
214806482|NCT05439109|DEVICE|Intubation guide mark technique of endotracheal tube placement|An endotracheal tube will be placed in this group by using the intubation guide mark.
214806483|NCT00985894|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
214806484|NCT00985894|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
214806485|NCT01521533|DRUG|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
214806486|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
214806487|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
214806488|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
214806489|NCT03067818|PROCEDURE|Unaffected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to unaffected hemisphere site prior to practice
214806490|NCT03067818|PROCEDURE|Affected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to affected hemisphere site prior to practice
214806491|NCT03067818|PROCEDURE|Control Transcranial Magnetic Stimulation|Non-invasive brain stimulation to control site prior to practice
214806492|NCT02282189|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
214806493|NCT00947908|BIOLOGICAL|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
214806494|NCT04900584|OTHER|Checklist|Checklist of guideline-based treatment before discharge
214806495|NCT04900584|OTHER|Education|Heart failure education before discharge
214806496|NCT04900584|OTHER|Telephone monitoring|Telephone monitoring after discharge
214806497|NCT04598984|DIAGNOSTIC_TEST|serum adipokines|Level of serum adipokines will be measured with flow cytometry
214806498|NCT03169348|DRUG|sofosbuvir daclatasvir|oral tablets
214806499|NCT03169348|DRUG|Ledipasvir/sofosbuvir|oral tablets
214806500|NCT04549584|DIAGNOSTIC_TEST|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
214806501|NCT03368755|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
214806502|NCT03368755|DIAGNOSTIC_TEST|Respiratory Muscle Strength and Endurance|CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
214806503|NCT01139034|DEVICE|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
214806504|NCT02172105|DRUG|BI 1744 CL|
214806505|NCT02172105|DRUG|Placebo|
214806506|NCT01537861|DRUG|Filgrastim|
214806507|NCT01537861|DRUG|Bortezomib|
214806508|NCT01537861|DRUG|Carfilzomib|
214806509|NCT01537861|DRUG|Dexamethasone|
214806510|NCT01537861|DRUG|Cyclophosphamide|
214806511|NCT01537861|DRUG|Thalidomide|
214806512|NCT01537861|DRUG|Lenalidomide|
214806513|NCT01537861|DRUG|Pomalidomide|
214806514|NCT00003040|PROCEDURE|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
214806515|NCT00003040|RADIATION|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
214806516|NCT00219297|DRUG|Patupilone|
214806517|NCT04126811|DRUG|Apatinib Mesylate, Pirarubicin, Ifosfamide|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
214806518|NCT04126811|DRUG|Apatinib Mesylate|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
214806519|NCT04126811|DRUG|Pirarubicin, Ifosfamide|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
214806520|NCT00464165|DRUG|rimonabant|
214806521|NCT04455633|DRUG|LX9211|Oral Tablets
214806522|NCT04455633|DRUG|LX9211 Matching Placebo|Oral Tablets
214806523|NCT00379548|BEHAVIORAL|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
214806524|NCT05357157|OTHER|Electroacupuncture|Subjects will be administered electroacupuncture as described in the electroacupuncture group description
214806525|NCT05357157|DIETARY_SUPPLEMENT|Nutrition|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
214806526|NCT05357157|DIETARY_SUPPLEMENT|Dietary supplement|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
214806527|NCT06543966|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
214806528|NCT06543966|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds
214806529|NCT02532764|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
214806530|NCT02532764|DRUG|Placebo|Normal Saline
214806531|NCT04177381|PROCEDURE|Cesarean section|"1. Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~2. The fascia will be then incised sharply at the midline~3. The transversalis fascia and pre peritoneal fat will be dissected carefully~4. The peritoneum will be then incised.~5. Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~6. Delivery of the Fetus and placenta.~7. Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
214806532|NCT04177381|PROCEDURE|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
214806533|NCT04177381|DEVICE|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
214806534|NCT04456361|BIOLOGICAL|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
214806535|NCT00706745|DIETARY_SUPPLEMENT|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
214806536|NCT00706745|DIETARY_SUPPLEMENT|placebo|identical placebo capsules.
214806537|NCT06130735|BEHAVIORAL|Cognitive Computerized Training|Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
214806538|NCT03946501|OTHER|Data collection|
214806539|NCT03282136|DRUG|Incretin Effect|The patients will receive incretins therapy.
214806540|NCT03282136|DEVICE|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
214806541|NCT03282136|DRUG|SGLT-2 inhibitor|The patients will receive SGLT2i therapy.
214806542|NCT05159206|PROCEDURE|CT group|This group will do a preoperative CT scan for templating. The same scan is then used for per-operative navigation. After surgery, a postoperative CT will validate the templating/navigation, and then subsequent CT scans (postoperative, 3 months, 1 and 2 years) will be done to measure prosthetic migration over time.
214806543|NCT04245826|OTHER|Change in LCSBs Intake|Effect of changing LCSBs intake
214806544|NCT04245826|OTHER|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
214806545|NCT03988127|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
214806546|NCT01717976|BEHAVIORAL|DISPO ED|primary care based nurse telephone support
214806547|NCT05806203|DEVICE|Low intensity shockwave treatment to pelvic floor region plus typical physical therapy|Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes
214806548|NCT05806203|DEVICE|Sham shockwave treatment plus typical physical therapy|Inactive dose of shockwave treatment
214806549|NCT04986332|BEHAVIORAL|Physical activity program|24-weeks moderate-intensity physical activity program
214806550|NCT04986332|OTHER|Global therapeutic remodeling|Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
214806551|NCT00483899|DRUG|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
214806552|NCT00483899|DRUG|Placebo|Placebo matching GW870086X will be administered by subjects
214806553|NCT05666752|DIETARY_SUPPLEMENT|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
214806554|NCT05666752|DIETARY_SUPPLEMENT|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
214806555|NCT05052138|OTHER|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
214806556|NCT01027780|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
214806557|NCT00115882|BEHAVIORAL|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
214806558|NCT01416766|OTHER|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
214806559|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
214806560|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
214806561|NCT03097120|DRUG|placebo tablets|two placebo tablets daily
214806562|NCT02631629|OTHER|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
214806563|NCT02631629|OTHER|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
214806564|NCT00308529|DRUG|irinotecan|
214806565|NCT00308529|DRUG|carboplatin|
214806566|NCT00308529|DRUG|bevacizumab|
214806567|NCT00308529|PROCEDURE|Radiation Therapy|
214806568|NCT06395857|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
214806569|NCT01008657|PROCEDURE|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
214806570|NCT05352386|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
214806571|NCT03201302|OTHER|School physical education class|Children participated only in school physical education classes only.
214806572|NCT03201302|OTHER|Taekwondo|Children participated only in taekwondo training only.
214806573|NCT03201302|OTHER|Martial arts|Children participated only in martial arts training only.
214806574|NCT03201302|OTHER|Climbing|Children participated only in climbing training only.
214806575|NCT03201302|OTHER|Volleyball|Children participated only in volleyball training only.
214806576|NCT03201302|OTHER|Artistic gymnastics|Children participated only in artistic gymnastics training only.
214806577|NCT03201302|OTHER|Swimming|Children participated only in swimming training only.
214806578|NCT03201302|OTHER|Dance|Children participated only in dance training only.
214806579|NCT03201302|OTHER|Basketball|Children participated only in basketball training only.
214806580|NCT03201302|OTHER|Wrestling|Children participated only in wrestling training only.
214806581|NCT03201302|OTHER|Football (soccer)|Children participated only in football (soccer) training only.
214806582|NCT03201302|OTHER|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
214806583|NCT03201302|OTHER|Track and field|Children participated only in track and field training only.
214806584|NCT03201302|OTHER|Tennis|Children participated only in tennis training only.
214806585|NCT03201302|OTHER|Combination of activities 1|Children participated in two weight-bearing activities.
214806586|NCT03201302|OTHER|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
214806587|NCT03538587|BEHAVIORAL|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
214806588|NCT03538587|BEHAVIORAL|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
214806589|NCT02827409|PROCEDURE|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
214806590|NCT02827409|PROCEDURE|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
214806591|NCT00893256|DRUG|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
214806592|NCT00893256|DRUG|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
214806593|NCT00893256|DRUG|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
214806594|NCT00893256|DRUG|Placebo|Placebo: once daily
214806595|NCT05911607|PROCEDURE|Low power laser|Phototherapy for extraction sockets using two different lasers.
214806596|NCT03305237|OTHER|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
214806597|NCT03305237|OTHER|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
214806598|NCT05666583|OTHER|Art therapy|The intervention group is the group in which art therapy is applied. They receive chemotherapy.
214806599|NCT01802697|DRUG|IdeS|
214806600|NCT01802697|DRUG|Placebo|
214806601|NCT00421005|DRUG|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
214806602|NCT04560881|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
214806603|NCT04560881|BIOLOGICAL|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
214806604|NCT03742102|DRUG|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
214806605|NCT03742102|DRUG|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
214806606|NCT03742102|DRUG|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
214806607|NCT03742102|DRUG|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
214806608|NCT03742102|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
214806609|NCT03742102|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
214806610|NCT05405998|OTHER|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~1. before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~2. after the installation of the pump following the above mentioned hospitalization."
214806611|NCT04635618|BEHAVIORAL|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
214806612|NCT04635618|BEHAVIORAL|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
214806613|NCT04635618|BEHAVIORAL|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
214806614|NCT00232336|DRUG|quetiapine|
214806615|NCT01187862|DRUG|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
214806616|NCT04465188|PROCEDURE|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
214806617|NCT04002388|BEHAVIORAL|activity monitor group|will receive a FitBit and will be asked to wear this for one year
214806618|NCT04002388|BEHAVIORAL|usual care group|will NOT receive a FitBit
214806619|NCT06297889|BEHAVIORAL|core strength training 1-6weeks|Behaviour: core strength training intervention for 1-6 weeks. Experimental: The experimental group performed core strength training during weeks 1-3. Subjects were first provided with basic information, familiarised with the content of the first phase of core strength training and watched a core strength video to understand its importance. The initial intervention was designed to ensure that subjects were proficient in core strength training, including warm-up and stretching patterns. During weeks 4-6, subjects will be supervised and assisted and a test will be organised at the end of week 6. Variables related to physical fitness and skills were recorded to assess whether core strength training improved physical fitness and skills.
214806620|NCT06297889|BEHAVIORAL|core strength training 7-12weeks|"Behaviour: core strength training intervention #7-12 weeks#.~Experimental: Weeks 7-9 were the experimental group:~Continued to warm up before each training session. The training content will increase in difficulty during this phase, and the supervisor should explain the training content and watch videos of the movements prior to training and prepare the training equipment in advance to protect the athlete from injury. Weeks 10-12: This is an advanced stage, requiring equipment and difficult movements to complete, please supervisors to arrange personnel to do a good job of protection to ensure that the subjects can complete the training tasks. A test will be conducted the day after Week 12 to measure the athlete's physical fitness and skills."
214806621|NCT02789306|PROCEDURE|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
214806622|NCT00727571|OTHER|Observations|This is a non-interventional, observational study; no investigational product is being used
214806623|NCT02831569|DRUG|Loxoprofen sodium|
214806624|NCT02831569|DRUG|Methocarbamol|
214806625|NCT03164772|DRUG|Durvalumab|anti-PD-L1
214806626|NCT03164772|DRUG|Tremelimumab|anti-CTLA-4
214806627|NCT03164772|BIOLOGICAL|BI 1361849|mRNA Vaccine
214806628|NCT03164772|DEVICE|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
214806629|NCT03034083|BEHAVIORAL|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
214806630|NCT01889836|BIOLOGICAL|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
214806631|NCT01889836|BIOLOGICAL|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
214806632|NCT00947258|OTHER|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
214806633|NCT04682002|OTHER|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
214806634|NCT04682002|OTHER|Usual care|Administration of routine care based on international guidelines
214806635|NCT04682002|OTHER|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
214806636|NCT04682002|OTHER|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
214806637|NCT04682002|OTHER|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
214806638|NCT04682002|OTHER|Coaching|There will be five personalized coaching sessions during the pregnancy.
214806639|NCT00527800|DRUG|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
214806640|NCT00527800|DRUG|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
214806641|NCT00527800|DRUG|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
214806642|NCT04449484|DRUG|MEDI1341|Intravenous infusion over 60 minutes
214806643|NCT04449484|OTHER|Placebo|Intravenous infusion over 60 minutes
214806644|NCT01453075|DRUG|Valacyclovir|Valacyclovir 1.5 mg po bid
214806645|NCT01453075|DRUG|Placebo|Matching placebo twice daily
214806646|NCT01909869|DEVICE|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
214806647|NCT04099888|DRUG|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
214806648|NCT04099888|DRUG|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
214806649|NCT01373970|DRUG|Placebo|Placebo, one tablet daily for 12 weeks
214806650|NCT01373970|DRUG|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
214806651|NCT06261853|RADIATION|3D-CBCT|CBCT provides a three-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. CBCT radiation doses are typically in the range of 60 microSv.
214806652|NCT06261853|RADIATION|2D-OPG|An OPG provides a two-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. OPG radiation doses are typically in the range of 20 microSv.
214806653|NCT05739045|DRUG|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
214806654|NCT04538170|BEHAVIORAL|pain after surgery|
214806655|NCT00144625|DRUG|MRA(Tocilizumab)|8mg/kg/4weeks
214806656|NCT00637299|OTHER|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
214806657|NCT00637299|OTHER|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
214806658|NCT02850770|BEHAVIORAL|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
214806659|NCT02850770|BEHAVIORAL|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
214806660|NCT02850770|BEHAVIORAL|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
214806661|NCT02857842|DRUG|Prednisolone|
214806662|NCT00051025|DRUG|ONTAK|
214806663|NCT01357278|PROCEDURE|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
214806664|NCT04118478|BEHAVIORAL|multi-component phased training program|The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
214806665|NCT06350656|OTHER|Clinical data collection|Post-retrieval from the medical record
214806666|NCT06350656|OTHER|Therapeutic data collection|Post-retrieval from the medical record
214806667|NCT06350656|OTHER|IntraCranial Pression (ICP) values collection|Post-retrieval of ICP values from the monitor
214806668|NCT04234100|OTHER|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
214806669|NCT02589964|DIETARY_SUPPLEMENT|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
214806670|NCT02589964|OTHER|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
214806671|NCT02171754|DRUG|BIBW 2992|
214806672|NCT02171754|DRUG|Ritonavir|
214806673|NCT03369860|BEHAVIORAL|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
214806674|NCT01213901|PROCEDURE|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
214806675|NCT02400957|OTHER|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
214806676|NCT02400957|OTHER|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
214806677|NCT02769637|DRUG|PPI treatment|PPI treatment or no PPI treatment
214806678|NCT05487274|PROCEDURE|Total Shoulder Arthroplasty + augmented glenoid component|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components. A prosthetic component is also implanted to correct for the amount of bone loss in the shoulder and restore stability.
214806679|NCT05487274|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
214806680|NCT06091007|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
214806681|NCT05047107|OTHER|No intervention|Non-interventional study
214806682|NCT00274937|DRUG|Amifostine|Given subcutaneously
214806683|NCT00274937|DRUG|Cisplatin|Given IV
214806684|NCT00274937|DRUG|Fluorouracil|Given IV
214806685|NCT00274937|OTHER|Laboratory Biomarker Analysis|Correlative studies
214806686|NCT00274937|RADIATION|Radiation Therapy|Undergo radiotherapy
214806687|NCT01097993|OTHER|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
214806688|NCT01097993|OTHER|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
214806689|NCT02189941|DRUG|Deferiprone sustained-release|Deferiprone sustained-release tablets
214806690|NCT02189941|DRUG|Deferiprone immediate-release|Deferiprone immediate-release tablets
214806691|NCT00538421|DRUG|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
214806692|NCT00538421|DRUG|Sevoflurane|0,7-1,5 MAC
214806693|NCT04526964|BEHAVIORAL|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
214806694|NCT01652079|DRUG|CRLX101|q 14 days
214806695|NCT00163605|DEVICE|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
214806696|NCT00778505|DRUG|Propofol|closed-loop administration using bispectral index as the controller
214806697|NCT00778505|DRUG|remifentanil|closed-loop administration using bispectral index as the controller
214806698|NCT00778505|DRUG|Propofol|manual administration according bispectral index values
214806699|NCT00778505|DRUG|Remifentanil|manual administration according bispectral index values
214806700|NCT05596877|BEHAVIORAL|Music therapy|Performing music therapy during a course of pulmonary rehabilitation (25 mins)
214806701|NCT00445003|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
214806702|NCT00445003|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
214806703|NCT00445003|BEHAVIORAL|Sham injection|Sham injection at baseline and 4 weeks
214806704|NCT00445003|PROCEDURE|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
214806705|NCT03222817|BEHAVIORAL|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
214806706|NCT03672604|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
214806707|NCT02027909|DEVICE|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
214806708|NCT05371444|BEHAVIORAL|Training with restriction of the DoF|The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
214806709|NCT05371444|BEHAVIORAL|Training without restriction of the DoF|The intrevention is based in the training of the upper extremity movements without the restriction of DoF
214806710|NCT01883271|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
214806711|NCT01883271|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
214806712|NCT06412549|BEHAVIORAL|Health care practices and routines|"The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team."
214806713|NCT02923635|PROCEDURE|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
214806714|NCT02923635|PROCEDURE|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
214806715|NCT04280263|DRUG|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
214806716|NCT04280263|DRUG|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
214464511|NCT04174391|BEHAVIORAL|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
214806717|NCT06366906|DIAGNOSTIC_TEST|The Resnet50 deep learning (DL) model|The predictive capability of the above Resnet50 deep learning (DL) model was validated in the test set. Based on the AUC and ACC, the best prediction model was identified. To explore the robust of the selected model, ROC analysis was performed the in the external validation set. Moreover, the Log-rank test was applied to evaluate the prognostic value of the model.
214806718|NCT00429234|DRUG|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
214806719|NCT00429234|DRUG|Gemcitabine|Starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
214806720|NCT01471093|DRUG|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
214806721|NCT01471093|DRUG|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
214806722|NCT04234256|OTHER|Static stretching exercise|Standing quadriceps stretch, Gastrocnemius stretch, Standing split, Adductor stretch, Half kneeling groin stretch, Hamstring stretch on the bench, Prayer squat, Seated adductor and hamstring stretch, Hurdle seat, Seated glute stretch, Lying glute stretch, Seated groin abduction, Soleus stretch, Half kneeling quad stretch, Split hamstring stretch
214806723|NCT04234256|OTHER|Dynamic stretching exercise|Downward dog to runner's lunge, Dynamic squat stretch, Crescent to hamstring stretch, Half kneeling hamstring stretch, Side to side lunge with reach, Standing calf and hamstring stretch, Hurdles, Side to side lunge with step, IT band stretch, Walking quad stretch, Swing the leg forward and back, Swing the leg cross, Knee pull, Standing quat stretch, Standing gluteus stretch
214806724|NCT03460951|DIAGNOSTIC_TEST|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
214806725|NCT00604877|BEHAVIORAL|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
214806726|NCT00604877|BEHAVIORAL|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
214806727|NCT04606420|BEHAVIORAL|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds \& nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
214806728|NCT04892511|OTHER|Adjusted medication|"In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~* Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~* Patients with TICI 2c-3: systolic blood pressure \<140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered."
214806729|NCT02475954|BEHAVIORAL|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
214806730|NCT02475954|OTHER|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
214806731|NCT00383656|DRUG|GnRH|75 ng/kg GnRH IV
214806732|NCT00383656|DEVICE|Pump|portable, infusion pump for GnRH
214806733|NCT04714307|DIAGNOSTIC_TEST|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
214806734|NCT04714307|DIAGNOSTIC_TEST|Cognitive Testing|"Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test"
214806735|NCT04714307|DIAGNOSTIC_TEST|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
214806736|NCT04714307|DIAGNOSTIC_TEST|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
214806737|NCT04714307|DIAGNOSTIC_TEST|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
214806738|NCT04714307|DIAGNOSTIC_TEST|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
214806739|NCT02932878|DRUG|DSXS topical|topical treatment
214806740|NCT01974297|DRUG|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
214806741|NCT01974297|DRUG|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
214806742|NCT03656783|DRUG|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
214806743|NCT03503578|DRUG|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
214806744|NCT03503578|DRUG|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
214806745|NCT02337309|DRUG|SF1126|SF1126 in IV form with be given to patients on this study.
214806746|NCT05376007|BEHAVIORAL|Serious game 'Broodles'|The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson \& Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
214806747|NCT03675828|BEHAVIORAL|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
214806748|NCT01918397|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
214806749|NCT01918397|DRUG|Optimized background regimen (OBR)|"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
214806750|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
214806751|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
214806752|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
214806753|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
214806754|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
214806755|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
214806756|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
214806757|NCT00864097|OTHER|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
214806758|NCT01961973|PROCEDURE|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
214806759|NCT01961973|PROCEDURE|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
214806760|NCT02700750|DEVICE|OCT exam|OCT exam
214806761|NCT00620022|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214806762|NCT00620022|DRUG|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214806763|NCT05194839|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
214806764|NCT05194839|DRUG|Placebo|Matching placebo
214806765|NCT04135027|OTHER|no interventions|no interventions
214806766|NCT05414760|DEVICE|Womed Leaf|Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
214806767|NCT00233194|PROCEDURE|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
214806768|NCT02911662|DRUG|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
214806769|NCT02911662|DRUG|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
214806770|NCT02775565|DEVICE|AngioVac|
214806771|NCT01207986|RADIATION|Low dose computed tomography (CT)|
214806772|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
214806773|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
214806774|NCT05286957|DRUG|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
214806775|NCT03682263|BEHAVIORAL|Full Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
214806776|NCT03682263|BEHAVIORAL|Basic Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
214806777|NCT01279902|DRUG|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
214806778|NCT04463602|DRUG|Desidustat|100 mg once daily
214806779|NCT04463602|OTHER|Standard of Care|Standard of care as per local authority
214806780|NCT05342285|DIAGNOSTIC_TEST|Flow mediated dilation|flow mediated dilation in brachial artery
214806781|NCT03156062|DRUG|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
214806782|NCT06354166|PROCEDURE|Unscheduled hospital admissions|Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
214806783|NCT01677962|BIOLOGICAL|Poly-ICLC|
214806784|NCT01677962|BIOLOGICAL|dendritic cell|
214806785|NCT00527657|DRUG|Lomustine|Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.
214806786|NCT00527657|DRUG|Temozolomide|75 mg/m\^2 by mouth daily on Days 1 to 42.
214806787|NCT00527657|DRUG|Thalidomide|200 mg/m\^2 by mouth daily.
214806788|NCT03904966|DEVICE|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
214806789|NCT03904966|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
214464512|NCT04174391|BEHAVIORAL|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
214464513|NCT05089019|DRUG|Selpercatinib|Administered orally
214806790|NCT00076934|DRUG|RG2077 (CTLA4-IgG4m)|RG2077
214806791|NCT00842595|DRUG|rituximab|6 courses every 28 days
214806792|NCT00842595|DRUG|vinorelbine|6 courses every 28 days
214806793|NCT00842595|DRUG|ifosfamide|6 courses every 28 days
214806794|NCT00842595|DRUG|Mitoxantrone|6 courses every 28 days
214464514|NCT06307951|OTHER|No intervention|No intervention
214806795|NCT00842595|DRUG|Prednisone|6 courses every 28 days
214806796|NCT03462524|PROCEDURE|Esophagectomy|FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
214806797|NCT00262223|BEHAVIORAL|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
214806798|NCT00262223|DRUG|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
214806799|NCT00262223|DRUG|Pill placebo|
214806800|NCT03828734|DEVICE|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
214806801|NCT03828734|DEVICE|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
214806802|NCT03828734|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
214806803|NCT02476799|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
214806804|NCT02476799|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
214806805|NCT02476799|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
214806806|NCT02476799|DRUG|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
214806807|NCT01804270|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
214806808|NCT00816569|DEVICE|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
214806809|NCT02260830|DRUG|Lu AF11167|
214806810|NCT04464330|OTHER|no intervention|This is an observation study, with no intervention
214806811|NCT00724230|DRUG|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
214806812|NCT00724230|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
214806813|NCT01428830|PROCEDURE|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
214806814|NCT01428830|PROCEDURE|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
214806815|NCT00978822|DRUG|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
214806816|NCT00815763|DRUG|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
214806817|NCT00815763|DRUG|placebo|infusion placebo once a day and continued for 14 day
214806818|NCT00270322|DRUG|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
214806819|NCT00270322|DRUG|Morphine sulphate|
214806820|NCT03152981|DRUG|Desflurane|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
214806821|NCT03152981|DRUG|propofol|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
214806822|NCT03152981|DRUG|remifentanil|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
214806823|NCT04231838|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
214806824|NCT04231838|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
214806825|NCT02603224|DRUG|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
214806826|NCT02603224|DRUG|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
214806827|NCT03507335|DEVICE|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
214806828|NCT01406418|BIOLOGICAL|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
214806829|NCT01406418|BIOLOGICAL|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
214806830|NCT01406418|BIOLOGICAL|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
214806831|NCT01406418|BIOLOGICAL|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
214806832|NCT01406418|BIOLOGICAL|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
214806833|NCT01406418|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion
214806834|NCT00000221|DRUG|Buprenorphine|
214806835|NCT02932696|OTHER|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
214806836|NCT00233597|DRUG|ferumoxytol or oral iron|
214806837|NCT03894605|DEVICE|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
214806838|NCT01856205|DRUG|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
214806839|NCT06073548|OTHER|Questionnaires and interviews|Patients wiill be asked to fulfill questionnaires at inclusion and 6 months after. An interview will be offered to a sub-sample of patients (approximately 20 patients).
214806840|NCT04937348|DIAGNOSTIC_TEST|Acquisition and analysis of milk samples|"In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits."
214806841|NCT04937348|DIAGNOSTIC_TEST|Collection, preparation and analysis of mother's blood samples.|Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.
214806842|NCT04937348|DIAGNOSTIC_TEST|Body composition assessment|The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
214806843|NCT04937348|OTHER|Anthropometric measurements|"Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis."
214806844|NCT01230580|DRUG|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
214806845|NCT01230580|DRUG|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
214806846|NCT06048146|DRUG|Experimental: FOLFOXIRI and Lateral lymph node dissection|Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
214806847|NCT06048146|DRUG|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
214806848|NCT05908266|OTHER|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
214806849|NCT05908266|OTHER|Disease Assessment|Disease stage assessed by trained professionals
214806850|NCT03079050|DRUG|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
214806851|NCT05820958|OTHER|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~* face and chest; 4 types of movements 10reps each;~* upper extremity; 4 types of movements, 10 reps each (left and right separately);~* abdomen; 2 types of movements, 10 reps each;~* lower extremity; 3 types of movements, 10 reps each (left and right separately);~* back; 2 types of movements, 10 reps each;~* final integration; 3 types of movements, 10 reps each."
214806852|NCT05502484|BEHAVIORAL|Integrative Dialectical Behavioural Therapy (DBT)|8 weeks outpatient pre-treatment DBT followed by integrative, inpatient DBT of 40 weeks, using standard DBT, augmented with an experience-oriented, body-oriented skills training based on DBT-principles by trained DBT-therapists, and a follow-up phase of 12 weeks outpatient aftercare (maximal 8 sessions individual DBT and 4 booster sessions) and 12 weeks no DBT. The inpatient treatment takes place in a living environment that is based on the principles of DBT and takes into account several aspects of autism.
214806853|NCT04109417|PROCEDURE|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
214806854|NCT04109417|PROCEDURE|osteotomy site following the surgical intervention was left empty|
214806855|NCT02696694|OTHER|Progesterone 25-75|Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
214806856|NCT02696694|OTHER|Progesterone <25, >75|Impact of serum progesterone concentrations (\<25, \>75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
214806857|NCT05908864|DRUG|Magnesium sulfate|Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
214806858|NCT03694782|BEHAVIORAL|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
214806859|NCT03694782|BEHAVIORAL|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
214806860|NCT03694782|BEHAVIORAL|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
214806861|NCT02006160|DRUG|dalfampridine|10 mg bid
214806862|NCT02006160|DRUG|placebo|10 mg bid
214806863|NCT03452501|DRUG|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
214806864|NCT03393728|DRUG|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
214806865|NCT01066182|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
214806866|NCT01066182|DIETARY_SUPPLEMENT|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
214806867|NCT01354860|OTHER|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
214806868|NCT01354860|OTHER|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
214806869|NCT00972218|BIOLOGICAL|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
214806870|NCT05879471|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
214806871|NCT01328093|DRUG|LY2140023|Administered orally
214806872|NCT01328093|DRUG|Aripiprazole|Administered orally
214806873|NCT01133353|DRUG|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
214806874|NCT01133353|DRUG|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
214806875|NCT01162603|DEVICE|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
214806876|NCT01162603|DRUG|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
214806877|NCT01162603|DRUG|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
214806878|NCT05488834|OTHER|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
214806879|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
214806880|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
214806881|NCT05075798|OTHER|No intervention,|pure observational study
214806882|NCT04667494|COMBINATION_PRODUCT|Sonotherapy|Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion
214806883|NCT05932524|DRUG|Baricitinib 2 MG|Baricitinib 2 mg q.d., p.o., for 6 consecutive months.
214806884|NCT05932524|DRUG|Dexamethasone|Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)
214806885|NCT02017119|DRUG|Comparison between Lactulose and Lactulose-Paraffin|
214806886|NCT02997150|DRUG|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
214806887|NCT01060618|OTHER|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
214806888|NCT04180709|DEVICE|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
214806889|NCT00369447|PROCEDURE|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
214806890|NCT00369447|BIOLOGICAL|nimotuzumab|weekly dose until disease progression
214806891|NCT02576249|DRUG|Ropivacaine|4cc 0.5% ropivacaine
214806892|NCT02576249|DRUG|Normal saline|4cc of sterile normal saline (0.9%)
214806893|NCT02576249|DRUG|Methylprednisolone|1cc 40mg methylprednisolone
214806894|NCT02417636|OTHER|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
214806895|NCT03490721|OTHER|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
214806896|NCT05150964|DEVICE|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
214806897|NCT05083299|DRUG|Sarpogrelate|Anpl-one SR
214806898|NCT01975064|DRUG|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
214806899|NCT01975064|DRUG|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
214806900|NCT02567838|DRUG|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
214806901|NCT02567838|DRUG|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
214806902|NCT04085107|BEHAVIORAL|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
214806903|NCT05866497|DIAGNOSTIC_TEST|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
214806904|NCT05866497|DIAGNOSTIC_TEST|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
214806905|NCT01723995|RADIATION|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
214806906|NCT03661528|DRUG|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
214806907|NCT03661528|DRUG|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
214806908|NCT01132963|OTHER|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
214806909|NCT01132963|OTHER|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
214806910|NCT01464866|OTHER|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
214806911|NCT01464866|OTHER|Hospital food|Typical hospital food given daily at meals
214806912|NCT00193284|DRUG|Gefitinib|
214806913|NCT00193284|DRUG|Docetaxel|
214806914|NCT00193284|DRUG|Carboplatin|
214806915|NCT00193284|DRUG|Fluorouracil|
214806916|NCT02879682|PROCEDURE|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
214806917|NCT02879682|PROCEDURE|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
214806918|NCT01220076|DRUG|tamoxifen|
214806919|NCT02979015|DRUG|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214806920|NCT02979015|DRUG|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214806921|NCT05948891|DRUG|Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)|observational, prospective, multicentric, international, cohort study
214806922|NCT05313425|OTHER|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
214806923|NCT02178722|DRUG|MK-3475|IV infusion
214806924|NCT02178722|DRUG|INCB024360|Oral daily dosing
214806925|NCT00949312|GENETIC|RNA marker analysis of lymph node and primary tumors|
214806926|NCT00949312|GENETIC|microarray profiling of primary tumors|
214806927|NCT00949312|GENETIC|reverse transcriptase-polymerase chain reaction of lymph node specimens|
214806928|NCT00949312|OTHER|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
214806929|NCT00949312|PROCEDURE|regional lymph node dissection|
214806930|NCT00949312|OTHER|lymph node staining for H&E and pancytokeratin IHC|
214806931|NCT02995057|DEVICE|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
214806932|NCT03195374|OTHER|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
214806933|NCT04247308|OTHER|Sensory Stimulation|Auditory, tactile, visual, vestibular and oro motor stimulation
214806934|NCT04247308|OTHER|Movement therapy|Passive range of movements, antigravity movements in prone and supine
214806935|NCT04247308|OTHER|Routine hospital care|Maintaining the vitals
214806936|NCT03553823|PROCEDURE|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
214806937|NCT03340727|DRUG|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
214806938|NCT03340727|DRUG|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
214806939|NCT04043884|OTHER|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
214806940|NCT04043884|OTHER|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
214806941|NCT04901221|DEVICE|Extrusion arch|one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
214806942|NCT03733509|PROCEDURE|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
214806943|NCT03733509|PROCEDURE|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
214806944|NCT03733509|PROCEDURE|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
214806945|NCT03733509|PROCEDURE|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
214806946|NCT02183688|DRUG|Low dose ASA|
214806947|NCT02183688|DRUG|High dose ASA|
214806948|NCT02183688|DRUG|Low dose paracetamol|
214806949|NCT02183688|DRUG|High dose paracetamol|
214806950|NCT02183688|DRUG|Caffeine|
214806951|NCT02183688|DRUG|Placebo|
214806952|NCT03643328|BIOLOGICAL|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
214806953|NCT03643328|BIOLOGICAL|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
214806954|NCT02555111|DRUG|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
214806955|NCT04999709|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
214806956|NCT06484647|PROCEDURE|Percutaneous Coronary Intervention|"Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique."
214806957|NCT03563105|DEVICE|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
214806958|NCT00721305|DRUG|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
214806959|NCT00721305|OTHER|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
214806960|NCT03601962|DIETARY_SUPPLEMENT|Aqualief|400mg oral mucoadesive tablets
214806961|NCT03601962|OTHER|Placebo|400mg Placebo oral mucoadesive tablets
214806962|NCT04712071|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
214806963|NCT03682900|OTHER|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
214806964|NCT03682900|OTHER|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
214806965|NCT05589818|DRUG|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
214806966|NCT06032299|PROCEDURE|Single Distal Femur Implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
214806967|NCT06032299|PROCEDURE|Dual Distal Femur Implant|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
214806968|NCT02546167|BIOLOGICAL|CART-BCMA|
214806969|NCT03348943|BEHAVIORAL|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
214806970|NCT03348943|BEHAVIORAL|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
214806971|NCT03348943|BEHAVIORAL|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
214806972|NCT03348943|BEHAVIORAL|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
214806973|NCT00716495|BIOLOGICAL|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
214806974|NCT05891977|OTHER|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
214806975|NCT05891977|OTHER|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
214806976|NCT03665649|PROCEDURE|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
214806977|NCT01582672|DRUG|Standard Treatment|Standard treatment for Renal Cell Carcinoma
214806978|NCT01582672|BIOLOGICAL|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
214806979|NCT05617703|DRUG|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
214806980|NCT01756937|DRUG|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
214806981|NCT01756937|DRUG|Placebo|1 capsule once daily for 24 weeks
214806982|NCT00258271|BIOLOGICAL|filgrastim|
214806983|NCT00258271|DRUG|cladribine|
214806984|NCT00258271|DRUG|cytarabine|
214806985|NCT00258271|DRUG|imatinib mesylate|
214806986|NCT04448678|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group descriptions\]
214806987|NCT04448678|OTHER|Usual Care|\[See arm/group descriptions\]
215031237|NCT02290912|BEHAVIORAL|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
215031238|NCT04233892|DRUG|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
214806988|NCT01024439|PROCEDURE|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
214806989|NCT01024439|PROCEDURE|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
214806990|NCT03414749|PROCEDURE|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
214806991|NCT03414749|PROCEDURE|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
214806992|NCT05886543|BEHAVIORAL|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
214806993|NCT05886543|BEHAVIORAL|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
214806994|NCT01483508|OTHER|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]
214806995|NCT01483508|OTHER|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]
214806996|NCT01483508|OTHER|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
214806997|NCT01962337|DRUG|FPA008|Infusion
214806998|NCT01962337|DRUG|Placebo|Infusion
214806999|NCT04908332|BEHAVIORAL|Kangaroo Baby Massage|The Kangaroo Baby Massage is an intervention that arose from nursing practice in 1996. It is a therapy that does not require an incubator, fuses massage, kangaroo position and music. KBM is available on video
214807000|NCT05689762|BEHAVIORAL|Healthy lifestyle counseling and E-health support|Promotion of healthy lifestyle behaviors through counseling and access to E-health platform
214807001|NCT01793194|OTHER|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
214807002|NCT05003635|DEVICE|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
214807003|NCT04292561|DRUG|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
214807004|NCT04292561|DRUG|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
214807005|NCT06545149|DIETARY_SUPPLEMENT|BioNutri AR-1,|intervention with fermented and nutritionally balanced food twice a day
214807006|NCT02011204|DEVICE|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
214807007|NCT05936710|DEVICE|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
214807008|NCT05936710|DEVICE|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
214807009|NCT03005522|DRUG|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
214807010|NCT03005522|DRUG|Placebo Oral Capsule|dosed with placebo
214807011|NCT00319358|DIETARY_SUPPLEMENT|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
214807012|NCT00319358|DIETARY_SUPPLEMENT|Placebo|placebo
214807013|NCT05352087|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
214807014|NCT04185935|OTHER|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
214807015|NCT04185935|OTHER|Questionnaire Administration|Ancillary studies
214807016|NCT00322803|DRUG|ELB139|
214807017|NCT03991494|DRUG|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
214807018|NCT00970697|DRUG|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
214807019|NCT00970697|DRUG|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
214807020|NCT06015126|DRUG|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
214807021|NCT01312922|DRUG|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
214807022|NCT01312922|DRUG|Citalopram|oral once daily administration
214807023|NCT01312922|DRUG|Pipamperone|oral once daily administration
214807024|NCT04898062|DEVICE|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
214807025|NCT01937390|DRUG|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
214807026|NCT01937390|DRUG|Indacterol 300 µg|inhalation powder
214807027|NCT01937390|DRUG|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
214807028|NCT01937390|DRUG|Indacterol 150 µg|inhalation powder
214807029|NCT00515203|DRUG|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
214807030|NCT00515203|DRUG|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
214807031|NCT05879328|PROCEDURE|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
214807032|NCT01439893|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
214807033|NCT01439893|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
214807034|NCT03559387|DRUG|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
214807035|NCT03559387|DRUG|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
214807036|NCT01569152|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
214807037|NCT01569152|DRUG|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
214807038|NCT01569152|DRUG|Methotrexate|MTX dosed at the stable dose receive upon study entry
214807039|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
214807040|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
214807041|NCT05324982|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
214807042|NCT05324982|DRUG|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
214807043|NCT06246032|OTHER|Modified feeding Protocol|"Initiation of feeding (fixed): 10cc/kg~Advancement based on birthweight (fixed):~\<750g: 15cc/kg/d 750-999g: 20cc/kg/d 1000-1249g: 25cc/kg/d 1250-1499g: 25cc/kg/d 1500-1749g: 35cc/kg/d 1750-2000g: 35cc/kg/d~Starting Human milk fortification when feed reach at 70cc/kg/d"
214807044|NCT05331664|PROCEDURE|Pars plana vitrectomy|Standard of care surgery
214807045|NCT05331664|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
214807046|NCT05331664|DRUG|Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin|Antibiotic eye drop 4 times per day for 1 week after surgery
214807047|NCT05331664|DRUG|Prednisolone 1%|Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
214807048|NCT05331664|DRUG|Atropine 1%|Eye drop daily for 1 week after surgery
214807049|NCT06203314|OTHER|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
214807050|NCT05451836|OTHER|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
214807051|NCT05451836|OTHER|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
214807052|NCT02126306|DRUG|Beta Glucosylceramide|Beta Glucosylceramide
214807053|NCT02126306|DRUG|Placebo|normal saline
214807054|NCT03686358|PROCEDURE|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~* Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~* Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~* Identification of prognostic factors"
214807055|NCT00191009|DRUG|atomoxetine hydrochloride|
214807056|NCT00191009|DRUG|placebo|
214807057|NCT06673706|OTHER|Front-of-package label|Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group
214807058|NCT07008885|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) :~starting dose: 5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg.~If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg.~Phase 2 : dose of RP2D."
214807059|NCT07008885|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
214807060|NCT07008885|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
214807061|NCT02098993|DRUG|Unfractionated heparin|
214807062|NCT05282654|BEHAVIORAL|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
214807063|NCT00522613|BEHAVIORAL|Recovery Group Project|Recovery Group Workbook \& Group Sessions
215031239|NCT04233892|DRUG|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
215031240|NCT04233892|DRUG|Estrogen|Patients will receive regular estrogen therapy
215031241|NCT00086515|DRUG|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
215031242|NCT00086515|DRUG|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
215031243|NCT00086515|DRUG|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
215031244|NCT00086515|DRUG|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
215031245|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
214807064|NCT02845258|PROCEDURE|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
214807065|NCT03167671|DEVICE|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
214807066|NCT03167671|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
214807067|NCT00662766|DIETARY_SUPPLEMENT|black currant seed press residue|Black currant seed press residue, baked into bread
214807068|NCT00662766|DIETARY_SUPPLEMENT|Bread without black currant seed press residues|Same bread but without seeds
214807069|NCT00662766|DIETARY_SUPPLEMENT|Baseline data|No supplement was administered.
214807070|NCT01623128|BEHAVIORAL|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
214807071|NCT02920996|DRUG|Merestinib|Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
214807072|NCT00154102|DRUG|Cetuximab|Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
214647618|NCT05503381|PROCEDURE|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
214807073|NCT00154102|DRUG|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
214807074|NCT03772496|DIAGNOSTIC_TEST|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
214807075|NCT03772496|DIAGNOSTIC_TEST|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
214807076|NCT00463606|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
214807077|NCT00463606|DRUG|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
214807078|NCT00463606|DRUG|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
214807079|NCT00628160|DRUG|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
214647619|NCT01133171|BEHAVIORAL|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
214647620|NCT01133171|BEHAVIORAL|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
214647621|NCT06439368|DRUG|Dezocine|At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
214647622|NCT00997009|DRUG|paclitaxel|175 mg/m2 IV day 1, every 21 days
214647623|NCT00997009|DRUG|carboplatin|AUC 5 IV day 1 every 21 days
214647624|NCT00997009|DRUG|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
214647625|NCT02526550|BIOLOGICAL|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
214647626|NCT02526550|BIOLOGICAL|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
214647627|NCT05740228|DEVICE|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
214647628|NCT05740228|DEVICE|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
214647629|NCT05740228|DEVICE|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
214647630|NCT03875950|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
214647631|NCT03969888|DRUG|ABBV-3067|Tablet taken orally.
214647632|NCT03969888|DRUG|Placebo ABBV-3067|Tablet taken orally.
214647633|NCT03969888|DRUG|ABBV-2222|Capsule taken orally.
214647634|NCT03969888|DRUG|Placebo ABBV-2222|Capsule taken orally.
214647635|NCT01260454|DRUG|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
214647636|NCT06175858|DIAGNOSTIC_TEST|CMR|We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
214647637|NCT05776849|OTHER|flipped classroom|Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.
214647638|NCT05461638|PROCEDURE|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
214807080|NCT00628160|DRUG|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
214807081|NCT02593851|DRUG|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
214807082|NCT02593851|DRUG|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
214807083|NCT04351516|DRUG|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
214807084|NCT04351516|OTHER|Placebo|Placebo: Film Coated Tablette
214807085|NCT01081717|DRUG|systemic non-biological treatments|as prescribed
214807086|NCT01081717|BIOLOGICAL|anti-TNF biologics|as prescribed
214807087|NCT01081717|BIOLOGICAL|golimumab|as prescribed
214807088|NCT01081717|BIOLOGICAL|non-anti-TNF biologics|as prescribed
214807089|NCT01081717|OTHER|general population|non-treated cohort
214807090|NCT06266962|DRUG|1% Atropine drops|Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
214807091|NCT06266962|DRUG|Epinephrine|Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
214807092|NCT06101225|OTHER|MindRegulation Intervention|The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
214807093|NCT06101225|OTHER|Relaxation|The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
214807094|NCT06101225|OTHER|Waiting List Control Group|No Intervention.
214807095|NCT00789984|DEVICE|noncontact specular microscopy|
214807096|NCT05791032|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
214807097|NCT03654625|BEHAVIORAL|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
214807098|NCT03654625|BEHAVIORAL|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
214807099|NCT03654625|BEHAVIORAL|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
214807100|NCT02228174|DEVICE|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
214807101|NCT05865197|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
214807102|NCT00401804|DRUG|Dexamethasone, Bortezomib, Doxorubicin|
214807103|NCT01427023|DEVICE|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
214807104|NCT02373332|OTHER|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
214807105|NCT01732978|BEHAVIORAL|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
214807106|NCT03863730|DIETARY_SUPPLEMENT|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
214807107|NCT03863730|DIETARY_SUPPLEMENT|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
214807108|NCT00438828|DRUG|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
214807109|NCT05266430|OTHER|Standard of Care|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
214807110|NCT05266430|DRUG|AU-011|Previously received
214807111|NCT03109132|DEVICE|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
214807112|NCT03109132|DEVICE|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
214807113|NCT03109132|DEVICE|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
214807114|NCT03109132|DEVICE|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
214807115|NCT03109132|DEVICE|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
214807116|NCT03109132|DEVICE|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
214807117|NCT02688257|OTHER|MRI|Functional magnetic resonance imaging
214807118|NCT02688257|OTHER|Ultrasound|Optoacoustic imaging
214807119|NCT02682602|DEVICE|DePuy Synthes total hip arthroplasty|
214807120|NCT02682602|RADIATION|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
214807121|NCT02682602|RADIATION|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
214807122|NCT00922909|BEHAVIORAL|Simon task|Reaction time task
214807123|NCT05982860|BEHAVIORAL|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries \& sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
214807124|NCT00113789|OTHER|PI Discretion|PI Discretion
214807125|NCT02366949|DRUG|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 \> (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
215031246|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
214807126|NCT02366949|DRUG|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
214807127|NCT07003399|OTHER|Diaphragmatic Ultrasound and EMG Assessment|Non-invasive assessment of diaphragmatic morphofunction and respiratory drive using ultrasound imaging and diaphragm electromyography (EMG). This evaluation will be performed once per participant without any therapeutic intervention.
214807128|NCT03476980|PROCEDURE|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
214807129|NCT03476980|PROCEDURE|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
214807130|NCT05047003|DIAGNOSTIC_TEST|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
214807131|NCT01342328|OTHER|Normal saline infusion|Normal saline infusion
214807132|NCT01342328|DRUG|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
214807133|NCT01342328|DRUG|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
214807134|NCT03544632|DRUG|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
214807135|NCT07009002|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) : starting dose:~5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg. If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg. Phase 2 : dose of RP2D."
214807136|NCT07009002|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
214807137|NCT07009002|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
215031247|NCT02041273|DRUG|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
214807138|NCT02753335|BEHAVIORAL|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
214807139|NCT02753335|BEHAVIORAL|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
214807140|NCT05551078|BIOLOGICAL|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
214807141|NCT06627738|RADIATION|Cyberknife irradiation|Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
214807142|NCT06631547|DRUG|Progesterone|Hormonal treatment
214807143|NCT06631547|DRUG|The usual head trauma care|the basic treatment
214807144|NCT07025395|BEHAVIORAL|- Core Training Protocol|This structured training intervention incorporates progressive core exercises designed to enhance neuromuscular activation, balance, and muscle hypertrophy. Participants perform eight exercise triads per session, progressing from core stability drills to high-intensity power movements over eight weeks.
214807145|NCT07025395|BEHAVIORAL|Control Group Core Routine|Control group participants engage in general core activation exercises twice per week, without progressive intensity or specialized neuromuscular adaptation.
214807146|NCT07029321|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises for 12 weeks
214807147|NCT07027800|DIETARY_SUPPLEMENT|Creatine Monohydrate|20 gram loading of creatine monohdyrate for 5 days, followed by 5 grams per day for 6 weeks
214807148|NCT07027800|DIETARY_SUPPLEMENT|Placebo|20 grams daily of non-caloric placebo + 5 grams daily non-caloric placebo for 6 weeks
214807149|NCT07029516|OTHER|Cosmetic patch containing urea applicated daily for 3 months|Daily application of the patch on toes, 3 months treatment
214807150|NCT07029516|OTHER|Placebo patch application|Daily application of a placebo patch on toes for a 3 months treatment
214807151|NCT07030725|DRUG|Menthol Gel|Menthol (5% L-menthol) will be applied to the anterior thorax.
214807152|NCT07030725|DRUG|Sham|Sham gel applied to the anterior thorax.
214807153|NCT07030725|BEHAVIORAL|Time control|No gel applied to anterior thorax.
214807154|NCT07035392|DRUG|Adebrelimab|Adebrelimab 1200mg，ivgtt，D1，Q3W
214807155|NCT07035392|DRUG|chemotherapy|"Queue A (lung squamous cell carcinoma patients):~Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W~Queue B (lung adenocarcinoma patients):~Pemetrexed 500 mg/m2, ivgtt，D1，Q3W Carboplatin AUC=5, D1，Q3W"
214807156|NCT07036289|PROCEDURE|Mechanical Treatment|manual quadrant scaling and root planing followed by dental prophylaxis within 4 weekly sections and oral hygiene instructions
214807157|NCT07035366|PROCEDURE|stabled resection|diaphragmatic plication of sever eventration by stabled resection
215031248|NCT00506766|BEHAVIORAL|Bladder Health Class consisting of 6 weekly group sessions|1 time
215031249|NCT00506766|BEHAVIORAL|Practice PFMT and BT|As needed for 4 years
215031250|NCT00506766|BEHAVIORAL|Clinic examination for pelvic muscle function|1/year for 4 years
215031251|NCT00506766|BEHAVIORAL|Record keeping in 3-day voiding diary|Every 6 months for 4 years
214807158|NCT07035366|PROCEDURE|running sutures|plication of diaphragmatic eventration by running sutures
214807159|NCT07035210|BEHAVIORAL|Group and 1:1 occupational therapy sessions|Patients will be educated on the goal setting process and setting self-directed goals aimed at occupations they identified as important in both group and 1:1 treatment sessions.
214807160|NCT07037329|DIAGNOSTIC_TEST|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a non-invasive electrotherapy technique used to manage pain and modulate physiological responses such as blood pressure. In this study, patients in Group 1 received TENS therapy as the primary intervention.
214807161|NCT07037329|DIAGNOSTIC_TEST|Electrical Muscle Stimulation (EMS)|EMS is a form of electrotherapy that causes muscle contractions through electrical impulses delivered via surface electrodes. In this study, patients in Group 2 received EMS therapy to investigate its effect on hemodynamic parameters in individuals with hypertension.
214807162|NCT07037394|DRUG|Probiotic plus lactulose|Probiotic and lactulose will be administered per the dose and schedule specified in the arms.
214807163|NCT07037394|DRUG|Rifaximin plus lactulose|Rifaximin and lactulose will be administered per the dose and schedule specified in the arms.
214807164|NCT07037394|DRUG|L-ornithine-L-aspartate plus latulose|LOLA and lactulose will be administered per the dose and schedule specified in the arms.
214807165|NCT07037394|DRUG|Lactulose|Lactulose will be administered per the dose and schedule specified in the arms.
214807166|NCT07037160|COMBINATION_PRODUCT|Kegel exercises|Kegel exercises, also known as pelvic floor exercises, involve contracting and relaxing the muscles of the pelvic floor to strengthen them. These exercises can help improve urinary and fecal continence, potentially enhance sexual function, and are recommended for both men and women.
214807167|NCT07037160|COMBINATION_PRODUCT|Kegel exercises with Foam Rolling|Foam rolling can be a helpful tool to prepare for or complement Kegel exercises by releasing tension in surrounding muscles and improving overall pelvic floor function. Foam rolling can help address tight muscles in the hips and lower back that can contribute to pelvic floor dysfunction. By releasing these tight areas, foam rolling can allow for better engagement and control of the pelvic floor muscles during Kegel exercises.
214807168|NCT07035743|OTHER|Exercise|5 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
214807169|NCT07035743|OTHER|Exercise|15 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
214807170|NCT07037524|RADIATION|Radiation Therapy|Low single-dose wholw-heart radiotherapy
214807171|NCT07036016|DRUG|EGFR-TKI|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib
214807172|NCT07036016|DRUG|PD-1/PD-L1 inhibitor|ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
214807173|NCT07036016|DRUG|EGFR-TKI combined with PD-1/PD-L1|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib combined with ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
214807174|NCT07035834|DRUG|Gliflozin|Our study will enroll non diabetic patients affected by chronic kidney disease secondary to lupus nephritis and ANCA associated vasculitis. Other studies have so far investigated only diabetic patients affected by the above mentioned diseases.
214807175|NCT07037485|OTHER|Renal resistive index|"It will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or inter-lobar artery will be localized, and three successive Doppler measurements at different positions in the kidney (high, middle, and low) will be performed. The average value for each kidney will be taken.~The renal resistive index will be calculated as follows:~(systolic peak flow velocity - diastolic minimum flow velocity)/systolic peak flow velocity"
214807176|NCT07037485|OTHER|Renal Artery Pulsatility Index|"It will be measured using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney, the interlobular artery will be located using color Doppler mode, and the velocity of the interlobular arteries will be assessed in one or two kidneys.~The Renal Artery Pulsatility Index (RAPI) will be calculated as follows:~RAPI = \[(peak systolic velocity) - (end diastolic velocity)\] /average velocity"
214807177|NCT07037485|OTHER|Urinary oxygen tension (PUO2)|Urinary oxygen tension (PUO2) will be measured preoperatively (baseline), postoperatively just after intensive care unit admission, 12 hours after surgery, and then once daily for 7 days.
214807178|NCT07036471|BEHAVIORAL|myCare Start|The service consists of two 10-minute, semi-structured and tailored consultations delivered by community pharmacists during the first 6 weeks of a patient initiating a new long-term medication, followed by tailored feedback to the patient's physician.
214807179|NCT07037537|PROCEDURE|Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation|Laparoscopic assisted mastectomy with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch, immediate one-step breast reconstruction and simultaneous autologous fat transplantation
214807180|NCT07036432|DEVICE|Endosign|"The intervention involves the EndoSign® Cell collection device (Cyted Ltd), a non-endoscopic method for esophageal sampling.~Patients swallow a gelatine/HPMC capsule containing a sponge attached to a string. After \~7 minutes in the stomach for dissolution and sponge expansion, a trained nurse withdraws the sponge via the string, collecting cells. Optional throat anesthetic is offered.~It can be performed without sedation in an outpatient clinic setting by a nurse. Samples undergo central analysis for TFF3, atypia, and p53, differing from standard biopsy histopathology. This study specifically evaluates its feasibility, acceptability, and nurse-led implementation in Swedish hospitals for Barrett's surveillance."
214807181|NCT07035509|BIOLOGICAL|Pharmaceutical fresh frozen plasma|OCTAPLAS LG® has been registered with INVIMA in Colombia for five years and is used as a plasma replacement in cardiac surgery, hematologic diseases, or intensive care settings where blood bank plasma is unavailable
214807182|NCT07035509|DRUG|Normal Saline|Bolus dose of 10 mL/kg normal saline (NS) (max. 500 mL) administered over \<15 minutes.
214807183|NCT07035509|DRUG|Ringer lactate (RL)|Bolus dose of 10 mL/kg Ringer's lactate (max. 500 mL) administered over \<15 minutes.
214807184|NCT07036640|OTHER|Heat exposure|Heat exposure during exercise
214807185|NCT07036367|DRUG|Sublingual Melatonin|Participants in this group received 3 mg of sublingual melatonin, administered 60 minutes before cataract surgery. The melatonin was given in the form of a rapidly dissolving sublingual tablet to enhance bioavailability and ensure consistent preoperative absorption. The goal of the intervention was to reduce preoperative anxiety, improve sedation level, and stabilize hemodynamic parameters. The melatonin tablets were indistinguishable in appearance from the placebo and were prepared and dispensed by a pharmacy technician not involved in data collection or patient care
214807186|NCT07036367|DRUG|Sublingual Placebo|Participants in this group received an identical-appearing sublingual placebo tablet containing inert ingredients, administered 60 minutes before cataract surgery. The placebo was visually indistinguishable from the melatonin tablets and was used to maintain double blinding in the trial. Tablets were prepared by the pharmacy team to ensure concealment and eliminate bias. This group was designed to serve as a control to evaluate the effectiveness of sublingual melatonin on anxiety and sedation levels in elderly patients
214807187|NCT07037472|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventioanl US imaging
214807188|NCT07037472|DRUG|Drug treatment|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventional US imaging. The histopathological biopsy results before and after treatment are combined as indicators for evaluating therapeutic efficacy and predicting treatment outcomes.
214807189|NCT07037563|OTHER|An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia|It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.
214807190|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched with mushrooms|Patients will receive the MeD personalized plan plus commercial mushrooms
214807191|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched the Lebanese herbal mixture Za'atar|Patients will receive the MeD personalized plan plus natural products/extracts of endemic plants (olive oil, herbs like Lebanese Za'atar).
214807192|NCT07035704|DIETARY_SUPPLEMENT|MeD Diet + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)|Patients will receive counselling and personalized dietary strategy aimed at increasing the adherence to Mediterranean diet by means of use of visual communication (e.g., comics, cartoons, videos) and digital tools (i.e., games, apps), including a physical activity program with a personal trainer + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)
214807193|NCT07036302|PROCEDURE|35% TCA combined with croton oil peel|3 sections every 30 days of 35% TCA combined with croton oil peel
214807194|NCT07036302|PROCEDURE|Isolate 35% TCA peel|3 sections every 30 days of isolate 35% TCA peel
214807195|NCT07036302|RADIATION|Erbium-YAG laser|3 sections every 30 days of Er-YAG laser
214807196|NCT07036302|RADIATION|Neodymium -YAG laser Q-switched|3 sections every 30 days of ND-YAG laser
214807197|NCT07036263|OTHER|Oculomotor therapy|"Oculomotor therapy will follow and adapt the protocol for treating convergence insufficiency (CI). Procedures will be organized progressively, from easiest to most difficult. Gross convergence techniques: (1) Brock String: A 1.5-2 m cord with colored beads; the patient focuses on each bead to train binocular fusion, observing the X shape of the cord. (2) Barillé Chart: A card with paired images for each eye; the patient merges the images into one using convergence and sensory fusion. Accommodative techniques: (1) Eccentric Circles: Printed circles with eccentric marks; viewed through filters to train motor and sensory fusion by aligning them into a single 3D image. (2) Opaque Lifesaver Cards: Cards with figures on an opaque background, used with red-green filters to stimulate convergence and fixation by reducing peripheral stimuli and enhancing visual attention."
214807198|NCT07036263|OTHER|No Treatment Added|Participants in the control group will not receive any type of treatment for a period of five weeks. After this period, they will be re-evaluated
214807199|NCT07035418|BEHAVIORAL|Clinical Decision-Making Scenarios and Preferences Assessment|Participants complete a socio-demographic questionnaire and decision-making preferences scale, including hypothetical clinical scenarios, to identify their preferred decision-making role (active, collaborative, or passive) and the influence of providers or family. Delivered electronically via secure link; reminders sent as needed.
214807200|NCT07037199|DRUG|SHR-A1811 + dalpiciclib+ endocrine therapy|sequential SHR-A1811 followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors)
214807201|NCT07036770|DIAGNOSTIC_TEST|Coronary CT scan using photon-counting CT|A dedicated cardiac UHR PCCT will be conducted within a maximum of 24 hours in ACS subjects and 72 hours in CCS subjects prior to the invasive CAG. Additionally, patients are also eligible for inclusion in case no PCCT is conducted prior to CAG, as long as no PCI is performed during the initial CAG. In these cases, the PCCT must be conducted within 24 hours for ACS patients and within 72 hours for CCS patients.
214807202|NCT07037602|OTHER|Sexual Health Education|After the Personal Information Form, Sexual Myths Scale and Sexual Self-Awareness Scale are applied as a pre-test to all women, sexual health training will be given to the women in the experimental group. The training will be given in 4 sessions over 2 weeks. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.
214807203|NCT07037602|OTHER|No Interventions|No intervention will be made.
214807204|NCT07036601|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
214807205|NCT07036601|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
214807206|NCT07035444|DIETARY_SUPPLEMENT|L-Carnitine 4g|500ml enteral nutrition solution containing 4g of L-carnitine
214807207|NCT07035444|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition was given 500 ml per day for a total of 84 days.
214807208|NCT07036276|BEHAVIORAL|Co-adapted intervention|An existing co-created intervention will be adapted by researchers and 7th and 8th grade pupils and teachers during 3 to 5 design sessions in both co-adaptation intervention schools.
214807209|NCT07036276|BEHAVIORAL|Standard intervention|The existing co-created intervention will be implemented in the standard intervention schools. So, adolescents and school staff from the standard intervention schools will not be involved in adapting the intervention.
214807210|NCT07036926|OTHER|Artificial Intelligence Video Education Arm|A novel, AI-generated, interactive peri-operative video education program. AI videos will be personalized using medical record chart data, specifically the patient's name, surgery date, and past medical history.
214807211|NCT07036315|OTHER|Music intervention|Participants will be asked to select different music clips based on meaning, enjoyment and preference.
214807212|NCT07037342|OTHER|Manual acupuncture|Manual acupuncture on acupoint (ST32, ST34, ST36, SP10) the needles will be inserted perpendicularly for 20 minutes.
214807213|NCT07037342|OTHER|Electro acupuncture|Electro acupuncture on acupoint (ST32, ST34, ST36, and SP10) for 20 minutes.
214807214|NCT07037342|OTHER|Sham acupuncture|Is a needle insertion at wrong points or non-points (locations that are not known acupuncture points)
214807215|NCT06719375|DEVICE|Gait Analysis Using IMU Sensor|Inertial Measurement Unit (IMU) sensor-based 3D gait analysis to assess spasticity and gait impairment. This intervention aims to provide quantitative data on gait parameters in DCM patients before and after surgery.
214807216|NCT07035496|OTHER|Benson's relaxation exercise|The Benson's relaxation exercise is based on the principle of choosing a word that is meaningful to the individual and focusing on it, breathing deeply and relaxing all the muscles in the body.The Benson relaxation exercise is a simple and easy-to-learn method.
214807217|NCT07036809|DIAGNOSTIC_TEST|Antithrombin III|quantitative measurement(%)
214807218|NCT07036809|DIAGNOSTIC_TEST|Protein C|quantitative measurement(%)
214807219|NCT07036809|DIAGNOSTIC_TEST|Protein S|quantitative measurement(%)
214807220|NCT07036809|DIAGNOSTIC_TEST|D-dimer|quantitative measurement( ug/ml)
214807221|NCT07036809|DIAGNOSTIC_TEST|Flow cytometry immunophenotyping|Flow cytometry immunophenotyping
214807222|NCT07036965|DEVICE|CardiPulse|abc
214807223|NCT07036965|DEVICE|FaraPulse|bcd
214807224|NCT07037186|DEVICE|Electroencephalogram|All patients will receive intraoperative electroencephalography monitorization during general anesthesia.
214807225|NCT07036861|DRUG|Ibuprofen 2%|Reformulated Ibuprofen 2% oral suspension (Berlin-Chemie AG)
214807226|NCT07036861|DRUG|Ibuprofen 4%|Reformulated Ibuprofen 4% oral suspension (Berlin-Chemie AG)
214807227|NCT07036861|DRUG|Ibuprofen 4%|Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension (Polish brand name)
214807228|NCT06723041|PROCEDURE|Acupressure Therapy|Undergo true acupressure
214807229|NCT06723041|PROCEDURE|Acupressure Therapy - placebo|Undergo sham acupressure
214807230|NCT06723041|PROCEDURE|Acupressure Therapy - self-administered|Undergo self-administered acupressure
214807231|NCT06723041|OTHER|Health Promotion and Education|Receive educational handouts
214807232|NCT06723041|OTHER|Survey Administration|Ancillary studies
214807233|NCT01432171|DRUG|Lacosamide|Given PO
214807234|NCT01432171|OTHER|Placebo|Given PO
214807235|NCT06739083|OTHER|e-mentoring program|The e-mentoring program is planned to last four weeks to facilitate the adaptation process of newly recruited nurses in intensive care units via the e-mentoring website.
214807236|NCT06036511|DRUG|Ketamine Hydrochloride|"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."
214807237|NCT06802315|RADIATION|Intensity modulated total marrow irradiation|"See Treatment Regimen"
214807238|NCT06802315|DRUG|Cyclophosphamide (CTX)|This study will determine the safety of the combination of Total Marrow Irradiation (TMI) and Post-Transplant Cyclophosphamide using a myeloablative fludarabine and iv targeted busulfan (Flu/Bu4) conditioning regimen.
214807239|NCT06802315|DRUG|Fludarabine (Fludara)|chemotherapy conditioning
214807240|NCT06802315|DRUG|Busulfan (conditioning for ALLO Transplant)|chemotherapy conditioning
214807241|NCT06241573|DRUG|Spesolimab|Spesolimab
214807242|NCT02426957|BEHAVIORAL|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
214807243|NCT06768476|BIOLOGICAL|CART123 Cells|1.3x10\^8 CART123 cells
214807244|NCT06768476|DRUG|Ruxolitinib 10 MG Oral Tablet|Twice Daily
214807245|NCT06768476|DRUG|Ruxolitinib 5 MG|Twice Daily
214807246|NCT06855563|OTHER|No treatment given|No treatment given
214807247|NCT05768269|OTHER|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
214807248|NCT05819398|DRUG|Spesolimab Formulation 1|Spesolimab Formulation 1
214807249|NCT05819398|DRUG|Spesolimab Formulation 2|Spesolimab Formulation 2
214807250|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
214807251|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
214807255|NCT06927869|OTHER|designed physical therapy , pully system exercise|Participants assigned to the intervention group will engage in a specially designed physical therapy program focusing on pulley system exercises. The program is scheduled to occur three times per week, which is frequent enough to potentially induce meaningful improvements while allowing adequate rest between sessions to prevent fatigue and overtraining
214807256|NCT06105047|BEHAVIORAL|Cognitive tests|". Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task~* quiz : Geneva Music Induced Checklist, GMIAC, Coutinho \& Scherer, 2017"
214807257|NCT03248063|DRUG|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
214807258|NCT03248063|DRUG|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
214807259|NCT05423210|COMBINATION_PRODUCT|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
214807260|NCT06630247|DRUG|XL495|oral doses of XL495
214807261|NCT06630247|DRUG|ADC cytotoxic agents|intravenous infusion of anti-cancer combination agent
214807263|NCT06903403|OTHER|Front-of-package label|Participants will see packaged food and beverage items displayed with labels as specified by their assigned group
214807264|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
214807265|NCT04709809|DEVICE|Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating|Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
214807266|NCT06929429|PROCEDURE|Bilateral Sphenopalatine Ganglion Block|A bilateral sphenopalatine ganglion block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine. The local anesthetic will be applied intranasally with a cotton-tipped applicator placed parallel to the zygomatic arch and advanced to the posterior nasal cavity. The applicator will remain in place for 15 minutes.
214807267|NCT06929429|PROCEDURE|Bilateral Infraorbital Nerve Block|A bilateral infraorbital nerve block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine per side. The block will be guided by linear ultrasound to identify the infraorbital foramen and administered with a 22G needle around the nerve. A 15-minute absorption period will be allowed before the surgical procedure begins.
214807268|NCT06648252|BEHAVIORAL|Healing Minds Biofeedback and Breathing Practices Intervention|The study participant will attend ten weekly Healing Minds sessions at the Hoskinson Health and Wellness Clinic. The parent (s) or guardian will accompany the study participant and follow along with the cues during the weekly session. Each session will be approximately 60 minutes. The principal investigator/pediatrician or trained and certified health care or research staff member will deliver the intervention. Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
214807269|NCT06818461|OTHER|Corvis St Before and after lasik, PRK, CXL|corneal biomechanics measurment using corvis St
214807270|NCT04655248|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
214807271|NCT06909357|OTHER|Quitline Treatment (QT)|Tobacco Free Florida Quitline. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
214807272|NCT06909357|OTHER|App-based Treatment (mHealth)|Fully automated digitally-delivered smoking cessation intervention targeted to cancer patients. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
214807273|NCT02754622|OTHER|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
214807274|NCT05928845|DIAGNOSTIC_TEST|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
214807275|NCT03732846|DRUG|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
214807276|NCT04137393|COMBINATION_PRODUCT|brushing|mechanical and chemical plaque removal
214807277|NCT05620225|DEVICE|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
214807278|NCT05620225|DEVICE|Sham and CMM|Sham and CMM
214807279|NCT00936169|PROCEDURE|IVUS optimised DES implantation|Ivus optimised stent implantation
214807280|NCT00936169|PROCEDURE|angiographically guided DES implantation|angiographically guided DES implantation
214807281|NCT02874300|OTHER|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
214807282|NCT02874300|OTHER|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
214807283|NCT05810753|BEHAVIORAL|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
214807284|NCT02950207|GENETIC|miRNA|miRNA extraction
214807285|NCT00416520|DRUG|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
214807286|NCT00416520|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
214807287|NCT00416520|DRUG|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
214807288|NCT05752994|OTHER|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
214807289|NCT05752994|OTHER|Home program|Home program
214807290|NCT04921462|PROCEDURE|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
214807291|NCT01798732|PROCEDURE|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
214807292|NCT04441970|PROCEDURE|Neutral position|The cuff pressure will be recorded at the neutral head position.
214807293|NCT04441970|PROCEDURE|Head extension position|The cuff pressure will be recorded at the head extension position.
214807294|NCT04441970|PROCEDURE|Head flexion position|The cuff pressure will be recorded at the head flexion position.
214807295|NCT04441970|PROCEDURE|Head rotation position|The cuff pressure will be recorded at the head rotation position.
214807296|NCT01633047|OTHER|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
214807297|NCT01633047|OTHER|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
214807298|NCT02620670|BEHAVIORAL|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
214807299|NCT01029470|DRUG|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
214807300|NCT03499847|BEHAVIORAL|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
214807301|NCT03499847|BEHAVIORAL|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
214807302|NCT02735122|DRUG|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
214807303|NCT02735122|DRUG|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
214807304|NCT02735122|DRUG|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
214807305|NCT02735122|DRUG|Placebo Tablet|2 placebo tablets
214807306|NCT02735122|DRUG|Placebo Caplet|2 placebo caplets
214807307|NCT02735122|DRUG|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
214807308|NCT04608253|DIAGNOSTIC_TEST|11C-choline PET/CT|11C-choline PET/CT
214807309|NCT03348423|DRUG|DEX-IN|IN Dexmedetomidine + IV placebo
214807310|NCT03348423|DRUG|Fentanyl|IN Placebo + IV Fentanyl
214807311|NCT03348423|DRUG|Placebo|IN Placebo + IV Placebo
214807312|NCT05636241|OTHER|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
214807313|NCT05636241|OTHER|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
214807314|NCT01917838|BEHAVIORAL|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
214807315|NCT06485999|PROCEDURE|Biologically Oriented Preparation Technique|It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
214807316|NCT03626649|DEVICE|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~* DiamondTemp Ablation Catheter~  o Unidirectional and Bidirectional models~* DiamondTemp Catheter-to RFG Cable~* DiamondTemp GenConnect Cable~* DiamondTemp FASTR Generator with Footswitch~* DiamondTemp Irrigation Pump~* DiamondTemp Irrigation Tubing Set"
214807317|NCT03619408|DRUG|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
214807318|NCT01559324|DEVICE|ECT|Bifrontal ECT, low dosage
214807319|NCT01559324|DEVICE|ECT|Right unilateral electrode position, high dosage
214807320|NCT06344624|BEHAVIORAL|CBT group|Brief cognitive behavioral therapy
214807321|NCT06344624|BEHAVIORAL|Laughter group|Laughter yoga therapy
214807322|NCT05621941|BEHAVIORAL|Game-Supported Goal Management Training|The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
214807323|NCT05621941|BEHAVIORAL|Information Group|In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
214807324|NCT02325141|PROCEDURE|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
214807325|NCT00003528|DRUG|raltitrexed|Given IV
214807326|NCT02125370|OTHER|Qualitative and survey|
214807327|NCT04298177|DEVICE|Atrial fibrillation ablation using the QDOT® catheter|Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.
214807328|NCT04298177|PROCEDURE|Standard atrial fibrillation ablation|Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.
214807329|NCT03423849|DRUG|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
214807330|NCT03423849|DRUG|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
214807331|NCT03423849|DRUG|Cisplatin|25mg/m2,day 1,every 3 weeks
214807332|NCT03423849|DRUG|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
214807333|NCT00060749|DRUG|Docosahexaenoic Acid (DHA) Dietary Supplement|
214807334|NCT00496548|PROCEDURE|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
214807335|NCT00496548|PROCEDURE|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
214807336|NCT05054348|BIOLOGICAL|IO-108|IO-108 given as monotherapy
214807337|NCT05054348|BIOLOGICAL|IO-108 + pembrolizumab combination therapy|IO-108 and fixed dose pembrolizumab combination therapy
214807338|NCT05054348|BIOLOGICAL|IO-108 + cemiplimab combination therapy|IO-108 and fixed dose cemiplimab combination therapy
214807339|NCT03269409|OTHER|Lactated Ringers|Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
214807340|NCT03269409|DEVICE|The Celution 800/GP System (Cytori Therapeutics)|The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
214807341|NCT03269409|BIOLOGICAL|Adipose Derived Regenerative Cells (ADRC)|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
214807342|NCT05033834|OTHER|covid-19 vaccines registered in Egypt|Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
214807343|NCT00373217|BIOLOGICAL|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
214807344|NCT00373217|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally or subcutaneously
214807345|NCT00373217|DRUG|carboplatin|Given IV
214807346|NCT00373217|DRUG|paclitaxel|Given IV
214807347|NCT00373217|PROCEDURE|conventional surgery|Patients undergo primary optimal cytoreductive surgery
214807348|NCT02808702|BEHAVIORAL|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
214807349|NCT06278545|DRUG|modified FOLFORINOX|"One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours"
214807350|NCT06278545|DRUG|Modified FOLFOX|"One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours"
214807351|NCT03726866|DRUG|Sequence 1|D326, D337 or CKD-828 for 9 days
214807352|NCT03726866|DRUG|Sequence 2|D326, D337 or CKD-828 for 9 days
214807353|NCT03726866|DRUG|Sequence 3|D326, D337 or CKD-828 for 9 days
214807354|NCT03726866|DRUG|Sequence 4|D326, D337 or CKD-828 for 9 days
214807355|NCT03726866|DRUG|Sequence 5|D326, D337 or CKD-828 for 9 days
214807356|NCT03726866|DRUG|Sequence 6|D326, D337 or CKD-828 for 9 days
214807357|NCT05059249|PROCEDURE|Hot Pack|Superficial Heating
214807358|NCT05059249|PROCEDURE|Manual Traction|Manual Traction for 10 minutes
214807359|NCT05059249|PROCEDURE|Mechanical Traction|Mechanical Traction for 10 minutes
214807360|NCT05059249|PROCEDURE|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
214807361|NCT05059249|PROCEDURE|TENS|TENS for 10 minutes with hot pack
214807362|NCT01759277|DRUG|Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
214807363|NCT01759277|DRUG|Experimental: Adductor Canal perineural local anesthetic infusion|The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
214807364|NCT01542190|DRUG|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
214807365|NCT00528905|DRUG|AZD3480|oral capsule
214807366|NCT05115357|PROCEDURE|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
214807367|NCT05115357|PROCEDURE|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
214807368|NCT02489526|DRUG|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
214807369|NCT02489526|DRUG|Placebo|Placebo group will receive the corresponding amount of placebo.
214807370|NCT04411966|DIAGNOSTIC_TEST|18F-fluorothymidine|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
214807371|NCT03329326|OTHER|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
214807372|NCT04040426|OTHER|Human split thickness skin allograft|Application of a fenestrated human skin graft
214807373|NCT04040426|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
214807374|NCT04040426|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
214807375|NCT04040426|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
214807376|NCT04953676|PROCEDURE|round tunnel technique|Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill
214807377|NCT04953676|PROCEDURE|flat tunnel technique|Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
214807378|NCT03374462|BEHAVIORAL|Telemedicine Intervention|Home-based telemedicine visits
214807379|NCT01659580|DRUG|T89 high dose|225mg bid
214807380|NCT01659580|DRUG|T89 Low dose|150mg bid
214807381|NCT01659580|DRUG|Sanqi+Bingpian|225 mg bid
214807382|NCT01659580|DRUG|Placebo|225mg bid
214807383|NCT04527575|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
214807384|NCT04527575|OTHER|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
214807385|NCT01532141|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
214807386|NCT01532141|DRUG|Rasagiline|1 mg rasagiline (single-dose)
214807387|NCT02857322|OTHER|Accompanying patient's specific perioperative|
214807388|NCT04249973|OTHER|Collection of urine and feces|Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
214807389|NCT04071444|OTHER|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
214807390|NCT04015232|COMBINATION_PRODUCT|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
214807391|NCT04015232|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
214807392|NCT01512407|PROCEDURE|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
214807393|NCT06261892|DIAGNOSTIC_TEST|Collect HPV DNA from urine|Use a sample collector to collect urine
214807394|NCT05381623|PROCEDURE|Simplified suture-less approach|Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.
214807395|NCT05381623|PROCEDURE|Application of hemostatic sponges and compressive sutures|Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
214807396|NCT02925364|RADIATION|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
214807397|NCT03328260|DEVICE|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
214807398|NCT02859662|PROCEDURE|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
214807399|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose
214807400|NCT00936871|DRUG|Placebo|Placebo single dose
214807401|NCT00936871|DRUG|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
214807402|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
214807403|NCT00936871|DRUG|Placebo|Placebo single dose
214807404|NCT00936871|DRUG|Moxifloxacin|Moxifloxacin 400 mg single dose
214807405|NCT03581422|DRUG|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
214807406|NCT00012948|PROCEDURE|Telephone Care|
214807407|NCT03146130|BIOLOGICAL|Variation of behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
214807408|NCT01591122|DRUG|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
214807409|NCT01591122|DRUG|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
214807410|NCT03943238|BIOLOGICAL|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of \>10 x10\^6 cells /Kg, 100 x 10\^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10\^6/Kg.
214807411|NCT02152566|DEVICE|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
214807412|NCT01297348|DRUG|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
214807413|NCT01297348|DRUG|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
214807414|NCT00711360|DEVICE|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
214807415|NCT00518830|OTHER|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
214807416|NCT00518830|OTHER|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
214807417|NCT05343078|DRUG|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
214807418|NCT02066207|DRUG|Fenofibrate|
214807419|NCT02066207|DRUG|Atorvastatin|
214807420|NCT01846585|BEHAVIORAL|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
214807421|NCT01846585|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
214807422|NCT02495415|DRUG|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
214807423|NCT02226185|DRUG|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
214807424|NCT02226185|DRUG|placebo|supplement of placebo two times per day for 2-3 years
214807425|NCT01541891|DRUG|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
214807426|NCT01541891|DRUG|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
214807427|NCT05998265|DEVICE|FeetMe rehabilitation|Home based rehabilitation program with real time biofeedback using a connected device
214807428|NCT05998265|OTHER|Physiotherapy|Conventional physiotherapy as prescribed by the neurologists
214807429|NCT01748630|DRUG|dexmedetomidine|
214807430|NCT01748630|DRUG|Midazolam|
214807431|NCT01748630|DRUG|fentanyl|
214807432|NCT04487132|BEHAVIORAL|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
214807433|NCT04487132|BEHAVIORAL|Recess or lunch time activities|group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
214647639|NCT05461638|PROCEDURE|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
214647640|NCT04747925|OTHER|Mulligan two leg rotation core muscle strengthning exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
214647641|NCT04747925|OTHER|mulligan bent leg raise technique, core muscle strengthning exercises|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
214647642|NCT01357369|PROCEDURE|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
214807434|NCT04865952|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
214807435|NCT04865952|OTHER|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
214807436|NCT00115128|DRUG|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
214807437|NCT01160926|DRUG|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
214807438|NCT01160926|DRUG|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
214807439|NCT02373319|BEHAVIORAL|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
214807440|NCT02373319|BEHAVIORAL|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
214807441|NCT02373319|BEHAVIORAL|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
214807442|NCT02373319|BEHAVIORAL|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
214807443|NCT03824119|DRUG|Ibuprofen 600 mg|Standard postpartum care (including administration of NSAIDs)
214807444|NCT03824119|OTHER|Standard Postpartum Care without NSAIDs|NSAID administration will be withheld from this group.
214807445|NCT02925247|BEHAVIORAL|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
214807446|NCT00319345|DRUG|Mannitol, Sodium-Lactate|
214807447|NCT03290820|RADIATION|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
214807448|NCT03290820|DRUG|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
214807449|NCT03290820|DRUG|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
214807450|NCT04465864|DRUG|Intracanalicular Dexamethasone, 0.4 mg insert|Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
214807451|NCT02109692|OTHER|blood sample|dosage of miRNA
214807452|NCT03798262|OTHER|Gluten|Tereos
214807453|NCT03798262|OTHER|Placebo|Whey protein from Nestlé Healthy Science
214807454|NCT01645839|DRUG|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
214807455|NCT04821401|DIETARY_SUPPLEMENT|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
214807456|NCT04821401|DIETARY_SUPPLEMENT|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
214807457|NCT00380198|DRUG|Apadenoson|
214807458|NCT05746897|DRUG|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
214807459|NCT05746897|DRUG|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
214807460|NCT04799314|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy
214807461|NCT01223820|DRUG|Capsaicin|5x nasal application in one day, 1 hour between each application
214807462|NCT03827291|DRUG|Exparel|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
214807463|NCT03827291|OTHER|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia
214807464|NCT01036360|OTHER|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
214807465|NCT02482090|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
214807466|NCT02482090|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
214807467|NCT02482090|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
214807468|NCT02482090|DRUG|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
214807469|NCT02136290|BEHAVIORAL|Prepackaged meals|Portion-controlled prepackaged meals
214807470|NCT02136290|BEHAVIORAL|Usual Care|Usual care dietary counseling
214807471|NCT00954395|OTHER|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
214807472|NCT05630586|DRUG|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
214807473|NCT05630586|OTHER|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
214807474|NCT04907838|DRUG|Insulin clamp|Continous infusion insulin + glucose
214807475|NCT04907838|DRUG|BQ123|Continuous infusion of Insulin + glucose + BQ123
214807476|NCT04907838|DRUG|BQ123 + BQ788|Continous infusion of insulin + glucose + BQ123 + BQ788
214807477|NCT02536950|DEVICE|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
214807478|NCT02536950|DEVICE|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
214807479|NCT01516983|DRUG|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
214807480|NCT01516983|RADIATION|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
214807481|NCT06416826|DEVICE|Vibroacoustic Therapy System - VTS 1000|Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
214807482|NCT03748303|DRUG|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
214807483|NCT02334722|DRUG|Levetiracetam|
214807484|NCT01118936|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
214807485|NCT01118936|DIETARY_SUPPLEMENT|Placebo|3 tablets of placebo daily for 12 weeks
214807486|NCT00911235|DRUG|Fesoterodine|Single 8 mg oral dose of fesoterodine
214807487|NCT00911235|DRUG|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
214807488|NCT04175366|OTHER|Shared Decision Making|Shared Decision Making including adapted decision aid.
214807489|NCT02305225|BEHAVIORAL|Sleep Deprivation|
214807490|NCT00856388|DRUG|fludarabine phosphate|Given IV
214807491|NCT00856388|DRUG|melphalan|Given IV
214807492|NCT00856388|RADIATION|total-body irradiation|Undergo total-body irradiation
214807493|NCT00856388|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
214807494|NCT00856388|BIOLOGICAL|anti-thymocyte globulin|Given IV
214807495|NCT03527017|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
214807496|NCT03527017|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
214807497|NCT03644147|DRUG|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
214807498|NCT01880034|OTHER|Lipid Emulsion Survey|
214807499|NCT04403880|OTHER|Sample collection|"* Optional nasal specimen(s)~* Blood collection"
214807500|NCT00643578|DRUG|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
214807501|NCT00643578|DRUG|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
214807502|NCT00643578|DEVICE|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
214807503|NCT03998865|DEVICE|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
214807504|NCT00281866|DRUG|erlotinib hydrochloride|
214807505|NCT06246474|PROCEDURE|physical therapy program|Arm Description: Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
214807506|NCT01617668|DRUG|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
214807507|NCT01617668|DRUG|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
214807508|NCT04504396|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
214807509|NCT04504396|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
214807510|NCT02017964|DRUG|Carboplatin|Given IV
214807511|NCT02017964|OTHER|Cognitive Assessment|Optional ancillary studies
214807512|NCT02017964|DRUG|Cyclophosphamide|Given IV
214807513|NCT02017964|DRUG|Etoposide|Given IV
214807514|NCT02017964|OTHER|Laboratory Biomarker Analysis|Correlative studies
214807515|NCT02017964|DRUG|Methotrexate|Given IV
214807516|NCT02017964|DRUG|Vincristine Sulfate|Given IV
214807517|NCT01867723|OTHER|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
214807518|NCT00925769|DRUG|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
214807519|NCT00925769|DRUG|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
214807520|NCT00925769|DRUG|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
214807521|NCT00406913|DRUG|mupirocin ointment|
214807522|NCT00406913|OTHER|SOC sterilization|
214807523|NCT02005536|BIOLOGICAL|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
214807524|NCT03450564|BEHAVIORAL|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
214807525|NCT03450564|BEHAVIORAL|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
214807526|NCT03450564|OTHER|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
214807527|NCT06484933|BEHAVIORAL|Focus groups of health professionals and users of primary care|"2 phases of Focus Group will be organized :~* the participants of the first 4 Focus Groups will propose an operational definition of the notion of a professional team in primary care (validation by consensus based on the definitions in the literature)~* 12 subsequent Focus Groups will be organized in 12 primary care teams to describe the ways in which risks are managed in primary care"
214807528|NCT04590300|OTHER|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
214807529|NCT00686959|DRUG|Pemetrexed|infusion over 10 minutes
214807530|NCT00686959|DRUG|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
214807531|NCT00686959|DRUG|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
214807532|NCT00686959|DRUG|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
214807533|NCT00686959|DRUG|Paclitaxel|administered as a 3-hour infusion
214807534|NCT00686959|DRUG|Carboplatin|administered per local practice guidelines over 30 minutes
214807535|NCT00686959|RADIATION|Thoracic Radiation Therapy (TRT)|
214807536|NCT02303678|DRUG|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
214807537|NCT00759928|DRUG|Erlotinib|150 mg once daily by mouth
214807538|NCT00759928|DRUG|Sorafenib|400 mg twice daily by mouth
214807539|NCT06127498|BIOLOGICAL|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
214647643|NCT00184145|OTHER|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
214647644|NCT00184145|OTHER|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
214647645|NCT02899143|DRUG|Antibiotic|Targeted antimicrobial therapy
214647646|NCT00280761|DRUG|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
214647647|NCT00280761|DRUG|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
214647648|NCT00280761|PROCEDURE|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
214647649|NCT00280761|RADIATION|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
214647650|NCT05434039|OTHER|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
214647651|NCT05434039|OTHER|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
214647652|NCT05434039|OTHER|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
214647653|NCT00609596|DRUG|GI198745|
214647654|NCT01518595|DRUG|bosentan|pts. will receive bosentan for 3 months
214647655|NCT01518595|DRUG|Placebo|pts. will receive placebo for 3 months
214647656|NCT05505266|OTHER|observational|observational
214647657|NCT02530931|DRUG|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
214647658|NCT01121380|DRUG|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
214647659|NCT01121380|DRUG|1021|1021
214647660|NCT06539546|OTHER|Yttria stabilized multilayered (YML) zirconia restorations|Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties
214647661|NCT06539546|OTHER|Lithium disilicate restorations|Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
214647662|NCT03963609|RADIATION|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
214647663|NCT00214123|RADIATION|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
214647664|NCT01814163|DRUG|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
214647665|NCT02570269|PROCEDURE|AuraGain|Fiberoptic Intubation
214647666|NCT02570269|PROCEDURE|Slotted Guedeltubus|Fiberoptic Intubation
214647667|NCT06438081|COMBINATION_PRODUCT|Cook double-balloon catheter|To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
214647668|NCT03287128|DRUG|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
214647669|NCT04880187|DRUG|AXA1125|AXA1125 administered BID with or without food
214647670|NCT04880187|DRUG|Placebo|Matching Placebo administered BID with or without food
214807540|NCT06127498|OTHER|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
214807541|NCT03202914|BEHAVIORAL|Usual protein and phosphorus diet|Diet intervention
214807542|NCT03202914|BEHAVIORAL|Low protein and phosphorus diet|Diet intervention
214807543|NCT03202914|BEHAVIORAL|Very low protein and phosphorus|Diet intervention
214807544|NCT05328804|DRUG|rhTPO|subcutaneous injection
214807545|NCT05328804|DRUG|Herombopag|Orally by mouth
214807546|NCT02625558|DRUG|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
214807547|NCT02625558|DRUG|Placebo|Placebo given three times a day
214807548|NCT06342076|PROCEDURE|Patients undergoing subcostal transversus abdominis plane block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a subcostal transversus abdominis plane block in addition to the posterior transversus abdominis plane block to a group of patients who underwent surgery with a midline incision due to major gynecological cancer.
214807549|NCT06342076|PROCEDURE|Patients undergoing rectus sheat block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a rectus sheath block in addition to the posterior transversus abdominis plane block to a group of patients who were operated on through a midline incision due to major gynecological cancer.
214807550|NCT00150462|DRUG|Carfilzomib|Administered as an IV bolus dose
214807551|NCT00150462|DRUG|Dexamethasone|Administered orally prior to carfilzomib
214807552|NCT01212874|DRUG|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
214807553|NCT01212874|DRUG|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
214807554|NCT01872546|DRUG|HUMIRA 40mg|
214807555|NCT02166138|PROCEDURE|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
214807556|NCT03589534|DIAGNOSTIC_TEST|home pregnancy test|Each participant will use 4 different home pregnancy tests
214807557|NCT02654912|DRUG|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
214807558|NCT01444443|DEVICE|Closed-loop control|Blood glucose controlled by algorithm
214807559|NCT01444443|OTHER|Open-loop control|Blood glucose controlled by patient
214807560|NCT04564482|RADIATION|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
214807561|NCT04564482|RADIATION|SCPRT|25 Gy in 5 Gy fractions over 5 working days
214807562|NCT04564482|RADIATION|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
214647671|NCT05030688|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
214807563|NCT04564482|DIAGNOSTIC_TEST|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
214647672|NCT03240146|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
214807564|NCT01196052|DRUG|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
214807565|NCT01908725|DRUG|Lamazym|ERT, i.v. infusions weekly
214807566|NCT03037372|DRUG|ART, Atorvastatin|ART, Atorvastatin
214807567|NCT03037372|DRUG|ART, Rosuvastatin|ART, Rosuvastatin
214807568|NCT03037372|DRUG|ART, No statin|ART, No statin
214807569|NCT03037372|DRUG|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
214807570|NCT04225663|BEHAVIORAL|Guided Meditation|Participants will meditate in response to the guidance provided by a trained meditation coach in person.
214807571|NCT00828035|PROCEDURE|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
214807572|NCT02381210|DEVICE|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
214807573|NCT03512366|PROCEDURE|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
214807574|NCT03512366|PROCEDURE|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
214807575|NCT01572948|DRUG|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
214807576|NCT01572948|DRUG|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
214807577|NCT03603314|DRUG|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
214807578|NCT03603314|OTHER|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
214807579|NCT03603314|DRUG|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
214807580|NCT05468021|OTHER|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
214807581|NCT02598479|OTHER|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
214807582|NCT05687864|DIAGNOSTIC_TEST|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
214807583|NCT05037006|DRUG|Sevoflurane - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
214807584|NCT05037006|DRUG|Sevoflurane - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
214807585|NCT05037006|DRUG|Sevoflurane - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
214807586|NCT05037006|DRUG|TIVA - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
214807587|NCT05037006|DRUG|TIVA - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
214807588|NCT05037006|DRUG|TIVA - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
214807589|NCT03450070|DEVICE|Light Therapy Mask Cream|test panel
214807590|NCT03608215|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
214807591|NCT03608215|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
214807592|NCT03737578|OTHER|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
214807593|NCT05137483|OTHER|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
214807594|NCT00002361|DRUG|Indinavir sulfate|
214807595|NCT00002361|DRUG|Ritonavir|
214807596|NCT04259528|DEVICE|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
214807597|NCT02588677|DRUG|Masitinib (4.5)|4.5 mg/kg/day
214807598|NCT02588677|DRUG|Riluzole|
214807599|NCT02588677|DRUG|Placebo|
214807600|NCT02588677|DRUG|Masitinib (3.0)|3 mg/kg/day
214807601|NCT01876576|OTHER|Clear liquids|Clear liquids
214807602|NCT01876576|OTHER|Low residue breakfast and lunch|Low residue
214807603|NCT06383962|DEVICE|Synergy cervical spine disc replacement|motion preservation disc
214807604|NCT02389491|DIETARY_SUPPLEMENT|normal density formula (Necocate)|In control group,there are 32 infants
214807605|NCT02389491|DIETARY_SUPPLEMENT|high density formula(Infatrini)|In intervention group,there are 32 infants
214807606|NCT01388465|BEHAVIORAL|Mobile phone text messaging|Daily assessment followed by feedback
214807607|NCT01450462|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
214807608|NCT01450462|DIETARY_SUPPLEMENT|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
214807609|NCT03820466|DRUG|Aspirin|Once daily application of platelet inhibiting medication
214807610|NCT03820466|DRUG|Atorvastatin|Once daily application of lipid lowering medication
214807611|NCT03820466|DRUG|Placebo Aspirin|Once daily application of placebo
214807612|NCT03820466|DRUG|Placebo Atorvastatin|Once daily application of placebo
214807613|NCT03657329|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
214807614|NCT01941966|DRUG|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
214807615|NCT01941966|DRUG|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
214807616|NCT01941966|RADIATION|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
214807617|NCT01582126|OTHER|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
214807618|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
214807619|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
214807620|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
214807621|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
214807622|NCT05354648|PROCEDURE|Hypoxic-hyperoxic preconditioning|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
214807623|NCT05354648|PROCEDURE|Placebo|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
214807624|NCT00716248|DRUG|bucillamine|bucillamine 100 mg, twice a day
214807625|NCT00716248|DRUG|methotrexate|methotrexate 6 mg or more per week
214807626|NCT01926548|DRUG|CJ Imatinib mesylate tablet|
214807627|NCT01926548|DRUG|Gleevec film-coated tablet 2 x 100mg|
214807628|NCT01208363|DIETARY_SUPPLEMENT|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
214807629|NCT01903317|OTHER|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
214807630|NCT01903317|OTHER|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
214807631|NCT01903317|OTHER|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
214807632|NCT05061290|OTHER|Control Porridge|Maize porridge containing 54Fe as iron sulfate
214807633|NCT05061290|OTHER|Reference Porridge A|Maize porridge counting 58Fe as iron sulfate with ascorbic acid
214807634|NCT05061290|OTHER|Test Porridge B|Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
214807635|NCT05061290|OTHER|Test Porridge C|Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
214807636|NCT05061290|OTHER|Test Porridge D|Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
214807637|NCT04274114|DRUG|L Glutamine|Powder
214807638|NCT04274114|DRUG|Placebos|Powder
214807639|NCT02491346|PROCEDURE|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
214807640|NCT02491346|PROCEDURE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
214807641|NCT06318702|OTHER|Education|is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
214807642|NCT04181190|DIAGNOSTIC_TEST|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
214807643|NCT04181190|DIAGNOSTIC_TEST|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
214807644|NCT04181190|DIAGNOSTIC_TEST|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
214807645|NCT04181190|DIAGNOSTIC_TEST|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
214807646|NCT00968552|PROCEDURE|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
214807647|NCT06089538|DIAGNOSTIC_TEST|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
214807648|NCT03607097|PROCEDURE|Secondary prevention program for drug related problems|The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
214807649|NCT01346397|DRUG|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
214807650|NCT00516880|DRUG|rosiglitazone|
214807651|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
214807652|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
214807653|NCT05000619|BEHAVIORAL|Outreach mailer|Postcard or letter
214807654|NCT05000619|BEHAVIORAL|Humor/Salience|Funny cartoon
214807655|NCT05000619|BEHAVIORAL|Doctor's authority|Letter from a doctor
214807656|NCT05000619|BEHAVIORAL|Information|Information about benefits of the appointment
214807657|NCT01829308|BEHAVIORAL|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
214807658|NCT01829308|BEHAVIORAL|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
214807659|NCT04407962|BEHAVIORAL|SMS group|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
214807660|NCT03232008|DIETARY_SUPPLEMENT|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
214807661|NCT03232008|DIETARY_SUPPLEMENT|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
214807662|NCT01720264|DRUG|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
214807663|NCT04738084|BEHAVIORAL|Meru Health Program|Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
214807664|NCT01980732|DRUG|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
214807665|NCT00877032|BIOLOGICAL|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
214807666|NCT00877032|BIOLOGICAL|Placebo|intravenous, single dose with experimental dose.
214807667|NCT00306371|DEVICE|1450nm diode laser|
214807668|NCT00924326|DRUG|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
214807669|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
214807670|NCT00924326|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
214807671|NCT00924326|DRUG|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
214807672|NCT00924326|DRUG|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
214807673|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
214807674|NCT00662740|DRUG|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
214807675|NCT00662740|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
214807676|NCT00662740|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
214807677|NCT00662740|DRUG|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
214807678|NCT00662740|DRUG|Tiotropium (Spiriva®)|Tiotropium, Spiriva®
214807679|NCT06077526|BEHAVIORAL|P.E.A.K. Rx|Pain Education + Physical Activity Group Based Intervention
214807680|NCT06077526|OTHER|Usual Care|Participants will receive the community hospital's usual care.
214807681|NCT05598658|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
214807682|NCT05598658|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
214807683|NCT06031792|PROCEDURE|Piezo endodontic surgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex, the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth using piezotome. apical preparation will be performed and Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament suture will be applied. Finally, Post-operative parallel Digital view.
214807684|NCT06031792|PROCEDURE|Conventional endodontic surgery|After the soft tissue curettage and exposure of the root apex, the osteotomy will be performed using a conventional surgical handpiece. The same steps will be followed to prepare and restore the root, as well as to reposition the flap.
214807685|NCT02072486|OTHER|Laboratory Biomarker Analysis|Correlative studies
214807686|NCT02072486|DRUG|Sorafenib Tosylate|Given PO
214807687|NCT00615069|DEVICE|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
214807688|NCT03749369|DRUG|Salvadora Persica Root|Salvadora Persica Gel
214807689|NCT03749369|PROCEDURE|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
214807690|NCT02148484|BEHAVIORAL|Prolonged Exposure for Adolescents|
214807691|NCT02148484|BEHAVIORAL|Client Centered Therapy|
214807692|NCT06215352|OTHER|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
214807693|NCT00669942|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
214807694|NCT00669942|DRUG|Placebo|Placebo to AIN457
214807695|NCT01929642|DRUG|Sirolimus|
214807696|NCT01929642|DRUG|Everolimus|
214807697|NCT00375700|DIETARY_SUPPLEMENT|Nutritional Supplement|
214807698|NCT02636959|OTHER|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
214807699|NCT04136899|OTHER|Dukes scale|collection of questionnaires
214807700|NCT01988909|DRUG|WR 279,396|Paromomycin + Gentamicin Topical Cream
214807701|NCT00000961|DRUG|Anti-HIV Immune Serum Globulin (Human)|
214807702|NCT00000961|DRUG|Zidovudine|
214807703|NCT02008305|DEVICE|protocol of optimization ALARA|
214807704|NCT02008305|DEVICE|protocol of optimization Philips|
214807705|NCT00354198|DRUG|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
214807706|NCT00354198|DRUG|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
214807707|NCT04022798|OTHER|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
214807708|NCT04389320|DRUG|Hydroxychloroquine|assess its role in the coarse of covid 19 virus infection
214807709|NCT04056182|DRUG|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
214807710|NCT02786030|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
214807711|NCT02786030|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
214807712|NCT02301325|BEHAVIORAL|Smoking research cigarettes with or without NRT|
214807713|NCT01708824|BEHAVIORAL|Dietary|"Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily"
214807714|NCT01708824|BEHAVIORAL|Physical activity|"Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
214807715|NCT00259012|DRUG|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
214807716|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
214807717|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
214807718|NCT02916290|DRUG|Fuzhenghuayu|
214807719|NCT02916290|DRUG|UDCA|
214807720|NCT06214364|DEVICE|Active Transcranial Direct Current Stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
214807721|NCT06214364|DEVICE|Sham Transcranial Direct Current Stimulation|"The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
214807722|NCT02226952|DRUG|BILN 2061 W, low dose|
214807723|NCT02226952|DRUG|BILN 2061 W, medium dose|
214807724|NCT02226952|DRUG|BILN 2061 W, high dose|
214807725|NCT02226952|DRUG|Placebo|
214807726|NCT02312700|BEHAVIORAL|Interactive empowerment tool|
214807727|NCT03533270|PROCEDURE|Urethroplasty|Surgical repair of Urethral injury
214807728|NCT03027115|DRUG|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
214807729|NCT01612871|DRUG|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
214807730|NCT04267627|BEHAVIORAL|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
214807731|NCT05532527|DRUG|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
214807732|NCT00882180|DRUG|ALN-VSP02|IV infusion administered every two weeks
214807733|NCT02167165|DRUG|Digoxin Injection|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
214807734|NCT03148886|OTHER|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
214807735|NCT02828917|DEVICE|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
214807736|NCT03803800|OTHER|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
214807737|NCT03803800|OTHER|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
214807738|NCT03803800|DIETARY_SUPPLEMENT|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
214807739|NCT06405009|OTHER|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
214807740|NCT01646788|DEVICE|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
214807741|NCT05807932|DRUG|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
214807742|NCT05807932|DRUG|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
214807743|NCT05807932|DRUG|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
214807744|NCT05807932|DRUG|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
214807745|NCT05807932|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
214807746|NCT01245907|BEHAVIORAL|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
214807747|NCT03843593|BEHAVIORAL|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
214807748|NCT03843593|BEHAVIORAL|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
214807749|NCT03843593|BEHAVIORAL|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
214807750|NCT03843593|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
214807751|NCT03843593|BEHAVIORAL|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].
214807752|NCT03843593|BEHAVIORAL|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
214807753|NCT00581971|DRUG|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
214807754|NCT00581971|DRUG|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
214807755|NCT00581971|DRUG|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
214807756|NCT00581971|RADIATION|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
214807757|NCT05232877|OTHER|SHAM tDCS|The control group will follow cognitive training with a combined sham tDCS. Intervention will last for 4-week with 3 sessions per week (12 sessions).
214807758|NCT05232877|OTHER|tDCS|The intervention group will follow sessions of tDCS combined with a simultaneous cognitive training on tablet
214807759|NCT01804777|DRUG|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
214807760|NCT01804777|DRUG|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
214807761|NCT01954264|PROCEDURE|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
214807762|NCT01954264|OTHER|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
214807763|NCT05868564|DEVICE|Atherectomy+Drug-coated balloon|Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group
214807764|NCT05868564|DEVICE|Drug-coated balloon|drug-coated balloon only in the active comparator group.
214807765|NCT04713137|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water.
214807766|NCT04713137|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
214807767|NCT04713137|DIETARY_SUPPLEMENT|Sucralose|0.0558g sucralose dissolved in 300mL tap water.
214807768|NCT04713137|DIETARY_SUPPLEMENT|Water|300mL tap water.
214807769|NCT01390233|DRUG|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
214807770|NCT01390233|DEVICE|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
214807771|NCT01390233|OTHER|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
214807772|NCT01496183|DRUG|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
214807773|NCT01496183|DRUG|Placebo|Placebo capsule administered orally at bedtime for 14 days
214807774|NCT04258150|DRUG|Nivolumab|6 mg/kg IV q4w
214807775|NCT04258150|DRUG|Ipilimumab|1 mg/kg IV twice q6w
214807776|NCT04258150|DRUG|Tocilizumab|8 mg/kg IV q4w
214807777|NCT04258150|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
214807778|NCT02479893|PROCEDURE|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
214807779|NCT00743964|DRUG|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
214807780|NCT00743964|DRUG|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
214807781|NCT03787030|DRUG|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
214807782|NCT03787030|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
214807783|NCT03002077|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
214807784|NCT04539470|DRUG|Efmarodocokin Alfa|Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
214807785|NCT03325426|DEVICE|FitBit|Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
214807786|NCT01240291|DIETARY_SUPPLEMENT|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
214807787|NCT01240291|DIETARY_SUPPLEMENT|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
214807788|NCT05482893|DRUG|Spevatamig (PT886)|Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
214807789|NCT05482893|DRUG|Paclitaxel|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C1
214807790|NCT05482893|DRUG|Gemcitabine|Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: Cohort C2
214807791|NCT05482893|DRUG|Abraxane|Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: Cohort C2
214807792|NCT05482893|DRUG|KEYTRUDA® (pembrolizumab)|Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D: Cohort D2, D3 and D4.
214807793|NCT05482893|DRUG|Oxaliplatin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
214807794|NCT05482893|DRUG|Leucovorin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
214807795|NCT05482893|DRUG|Fluorouracil|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
214807796|NCT05482893|DRUG|Capecitabine|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
214807797|NCT05482893|DRUG|FOLFIRINOX|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C3
214807798|NCT03435796|GENETIC|Gene-modified (GM) T cell therapy|No investigational product will be administered
214807799|NCT00738868|BIOLOGICAL|cetuximab|
214807800|NCT00738868|RADIATION|stereotactic body radiation therapy|
214807801|NCT06293872|DEVICE|12*2 mm length miniscrew|"Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots"
214807802|NCT06336733|DRUG|ANAKINRA|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
214807803|NCT00045877|DRUG|Recombinant Human Interleukin-2 and Rituximab|
214807804|NCT01243996|DRUG|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
214807805|NCT06196242|DIAGNOSTIC_TEST|MRI and CT scan|"An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes."
214807806|NCT01599338|DRUG|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
214807807|NCT03803865|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
214807808|NCT03803865|BEHAVIORAL|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
214807809|NCT01148095|DRUG|AZD2516|Oral, single, daily, 11 days
214807810|NCT01148095|DRUG|Placebo|
214807811|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
214807812|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
214807813|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
214807814|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
214807815|NCT05898919|OTHER|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
214807816|NCT05898919|OTHER|Sham acupuncture|Participants will receive sham acupuncture at sham points.
214807817|NCT05898919|DRUG|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
214807818|NCT04701619|OTHER|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
214807819|NCT04887077|DEVICE|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
214807820|NCT04887077|BEHAVIORAL|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
214807821|NCT04342481|OTHER|Educational Screening tool|Educational Screening tool
214807822|NCT01635322|DEVICE|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
214807823|NCT06343805|DRUG|AJ1-11095|Type II JAK2 Inhibitor
214807824|NCT04659915|DRUG|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
214807825|NCT04659915|DRUG|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
214807826|NCT05293054|OTHER|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
214807827|NCT00071136|DRUG|pemetrexed|
214807828|NCT00071136|DRUG|gemcitabine|
214807829|NCT00169195|DRUG|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
214807830|NCT03267628|PROCEDURE|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
214807831|NCT03267628|PROCEDURE|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
214807832|NCT03267628|PROCEDURE|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
214807833|NCT03267628|PROCEDURE|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
214807834|NCT00486109|DEVICE|I-Port(TM) Injection Port|
214807835|NCT01819623|OTHER|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
214807836|NCT04862078|DIAGNOSTIC_TEST|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
214807837|NCT04862078|DIAGNOSTIC_TEST|Usual care|standard follow-up according to the institutional practice
214807838|NCT03699644|DEVICE|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
214807839|NCT03699644|DEVICE|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
214807840|NCT03699644|DEVICE|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
214807841|NCT03699644|DIAGNOSTIC_TEST|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
214807842|NCT03699644|DEVICE|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
214807843|NCT02625454|DRUG|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
214807844|NCT02625454|DRUG|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
214807845|NCT03221374|BEHAVIORAL|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
214807846|NCT04597086|OTHER|Best Practice|Receive standard of care
214807847|NCT04597086|PROCEDURE|Bright White Light Therapy|Receive BWLT
214807848|NCT04597086|OTHER|Survey Administration|Ancillary studies
214807849|NCT00018252|BEHAVIORAL|exercise|
214807850|NCT05679648|DIAGNOSTIC_TEST|ultrasonography|studying degree of steatosis
214807851|NCT02567968|DRUG|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
214807852|NCT02567968|DRUG|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
214807853|NCT01301573|BIOLOGICAL|rAAV-GAD|
214807854|NCT00014105|DRUG|carboplatin|
214807855|NCT00014105|DRUG|temozolomide|
214807856|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties|All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
214807857|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse|All children in the control group will consume on daily basis vegetable and fruit mousse for six months
214807858|NCT05140070|BEHAVIORAL|Dietary and physical activity counselling|All children in the study will obtain 4 dietary and physical activity advice during the course of the study
214807859|NCT02522806|PROCEDURE|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
214807860|NCT03818230|OTHER|None (observational study)|None (observational study)
214807861|NCT05877170|DIETARY_SUPPLEMENT|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
214807862|NCT05877170|DRUG|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
214807863|NCT00473356|DIETARY_SUPPLEMENT|receive amino acid supplement|Receive amino acid supplement
214807864|NCT04281992|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
214807865|NCT06063005|PROCEDURE|Translocation ILM Flap|After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
214807866|NCT06063005|PROCEDURE|ILM Peeling|After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
214807867|NCT01245322|DRUG|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
214647673|NCT04915040|BEHAVIORAL|Behavioral Activation for Depression|Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate \& (b) gather feasibility data for home-based Behavioral Activation + Caregiver
214647674|NCT01859247|DEVICE|rTMS|
214647675|NCT01625520|DRUG|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
214647676|NCT04340973|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
214647677|NCT01282229|DEVICE|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
214647678|NCT02629562|BIOLOGICAL|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
214647679|NCT02635971|PROCEDURE|Transcatheter arterial infusion|
214647680|NCT02635971|PROCEDURE|Intravenous chemotherapy|
214647681|NCT02635971|DRUG|Gemcitabine|
214647682|NCT02635971|DRUG|Oxaliplatin|
214647683|NCT00116766|DEVICE|anti-mosquito plant use|
214647684|NCT04345666|DRUG|Testosterone cypionate|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
214647685|NCT04345666|DRUG|Placebos|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
214647686|NCT04146922|OTHER|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
214647687|NCT04146922|OTHER|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
214647688|NCT04515966|DRUG|Methylprednisolone Injection [Solu-Medrol]|A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
214647689|NCT04515966|DEVICE|wrist splint|A standard wrist splint
214647690|NCT04909684|DRUG|Pembrolizumab|The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
214647691|NCT03775876|PROCEDURE|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
214647692|NCT03775876|PROCEDURE|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
214647693|NCT03775876|DRUG|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
214647694|NCT03775876|DRUG|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
214647695|NCT03775876|DIAGNOSTIC_TEST|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
214647696|NCT05346614|BEHAVIORAL|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
214647697|NCT05936320|BEHAVIORAL|Information leaflets with illustrations about hearing aid functions|The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
214647698|NCT05936320|BEHAVIORAL|Information leaflets with only text about hearing aid functions|The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
214647699|NCT00713362|PROCEDURE|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
214807868|NCT05627141|OTHER|Photobiomodulation; Cryotherapy, Massage|"Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session."
214807869|NCT00336479|DRUG|Telaprevir|tablet
214807870|NCT00336479|DRUG|Ribavirin|tablet
214807871|NCT00336479|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
214807872|NCT00336479|OTHER|Placebo|matching placebo tablet
214807873|NCT00377871|DEVICE|biological heart valve prosthesis|Two heart valve designs
214807874|NCT01479439|DRUG|Losartan|Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months
214807875|NCT02365207|DRUG|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
214807876|NCT01924078|DRUG|Capecitabine|metronomic use: capecitabine 500mg/tid
214807877|NCT01924078|DRUG|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
214807878|NCT01541150|BEHAVIORAL|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
214807879|NCT01722877|DEVICE|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
214807880|NCT03299907|DIAGNOSTIC_TEST|Spirometry|
214807881|NCT01395030|DIAGNOSTIC_TEST|Computed Tomography|Undergo FCH PET/CT
214807882|NCT01395030|DRUG|18F-fluoromethylcholine|Undergo FCH PET/CT
214807883|NCT01395030|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo FCH PET/CT
214807884|NCT02079766|DRUG|florbetapir F 18|370 megabecquerel (MBq) IV single-dose
214807885|NCT02079766|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
214807886|NCT05836805|DRUG|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
214807887|NCT06165562|PROCEDURE|PSV|Pressure support ventilation applied from the start of subcutaneous suture until extubation.
214807888|NCT06165562|PROCEDURE|Intermittent Manual Assistance|Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.
214807889|NCT06165562|PROCEDURE|EEG-Guidance|Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64
214807890|NCT06165562|PROCEDURE|Obey Command|Extubation criteria include obeying commands (eye-opening or handgrip).
214807891|NCT06165562|PROCEDURE|Spontaneous Respiration|"Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min"
214807892|NCT05273866|OTHER|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
214807893|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
214807894|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
214807895|NCT02265783|DEVICE|Nellcor USB Pulse Oximeter Monitor Interface Cable|Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
214807896|NCT03379103|DRUG|Sevoflurane|Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
214807897|NCT03379103|DRUG|Propofol|Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
214807898|NCT01658228|DRUG|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
214807899|NCT01658228|DRUG|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
214807900|NCT01658228|DRUG|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
214807901|NCT01658228|DRUG|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
214807902|NCT05299047|OTHER|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
214807903|NCT05299047|OTHER|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
214807904|NCT02406898|DEVICE|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
214807905|NCT01852435|DRUG|R-CEOP-70|
214807906|NCT01852435|DRUG|R-CEOP-90|
214807907|NCT01852435|DRUG|R-CHOP-50|
214807908|NCT05067647|DEVICE|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
214807909|NCT02874586|OTHER|Plasma exchange combination of immunosuppressive regimens|
214807910|NCT01884740|DRUG|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
214807911|NCT02348983|BEHAVIORAL|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
214807912|NCT00002654|DRUG|chemotherapy|
214807913|NCT00002654|DRUG|cisplatin|
214807914|NCT00002654|RADIATION|low-LET cobalt-60 gamma ray therapy|
214807915|NCT00002654|RADIATION|low-LET electron therapy|
214807916|NCT00002654|RADIATION|low-LET photon therapy|
214807917|NCT04341285|PROCEDURE|ECMO Implantation|Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
214807918|NCT00791947|DRUG|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
214807919|NCT02904837|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
214807920|NCT02904837|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
214807921|NCT02461823|DEVICE|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
214807922|NCT02461823|DEVICE|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
214807923|NCT00857623|DRUG|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
214807924|NCT00857623|DRUG|Placebo|Capsule, once daily
214807925|NCT04785677|BEHAVIORAL|Resiliency in Stressful Experiences (RISE) Program|The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
214807926|NCT00493831|DRUG|nicotine polacrilex, transdermal system or inhaler|on label use of Nicotine replacement therapy (NRT)
214807927|NCT04193566|DRUG|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information\_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
214807928|NCT02463513|DIETARY_SUPPLEMENT|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
214807929|NCT02463513|DIETARY_SUPPLEMENT|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
214807930|NCT02463513|DIETARY_SUPPLEMENT|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
214807931|NCT06062771|DEVICE|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
214807932|NCT06062771|DEVICE|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
214807933|NCT02545946|DEVICE|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I\&D
214807934|NCT02545946|OTHER|traditional I&D with or without packing|abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
214807935|NCT01106326|BEHAVIORAL|Intervention|"Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
214807936|NCT04792749|DRUG|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
214807937|NCT00050856|DRUG|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
214807938|NCT03741348|PROCEDURE|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
214807939|NCT03741348|PROCEDURE|control|in control group, Erector Spinae Plane Block will not be done
214807940|NCT05425147|OTHER|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
214807941|NCT01799681|BEHAVIORAL|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
214807942|NCT01799681|BEHAVIORAL|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
214807943|NCT01447563|DRUG|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
214807944|NCT01447563|DRUG|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
214807945|NCT02696681|BEHAVIORAL|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
214807946|NCT01278056|DRUG|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
214807947|NCT00870870|DRUG|Gemcitabine|"1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]"
214807948|NCT00870870|DRUG|Cisplatin|"75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]"
214807949|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]"
214807950|NCT00870870|BIOLOGICAL|Cetuximab|"400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]"
214807951|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
214807952|NCT00870870|BIOLOGICAL|Cetuximab|"500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
214807953|NCT00870870|DRUG|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin"
214807954|NCT01210456|DRUG|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
214807955|NCT04438005|DRUG|ICP-022|ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
214807956|NCT05017857|DEVICE|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
214807957|NCT05017857|BEHAVIORAL|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
214807958|NCT04468802|OTHER|Case fatality rate|Mortality rate caused by SARS CoV-2
214807959|NCT03104166|DEVICE|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
214807960|NCT03104166|DEVICE|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
214807961|NCT03117569|DRUG|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
214807962|NCT05602064|DRUG|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
214807963|NCT05602064|DRUG|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
214807964|NCT05602064|OTHER|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
214647700|NCT00713362|PROCEDURE|chest tube drainage|Chest tube drainage for pneumothroax
214647701|NCT00757731|DRUG|milnacipran|hard capsule
214647702|NCT00757731|DRUG|Placebo|hard capsule
214647703|NCT02758535|DEVICE|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
214647704|NCT02758535|DEVICE|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
214647705|NCT00769119|DRUG|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
214647706|NCT00769119|DRUG|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
214647707|NCT02481635|DRUG|Gemcitabine|
214647708|NCT02481635|DRUG|Nab-paclitaxel|
214647709|NCT02481635|RADIATION|Radiation Therapy|
214647710|NCT02481635|PROCEDURE|Surgical Resection|
214647711|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel|
214647712|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel (Reference)|
214647713|NCT02525549|DRUG|Placebo gel|
214647714|NCT04167475|DIETARY_SUPPLEMENT|Probiotic capsule|Each probiotic capsule contains 1 x 10\^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
214647715|NCT04167475|DIETARY_SUPPLEMENT|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
214647716|NCT01578031|DEVICE|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
214647717|NCT01578031|OTHER|Usual Care|Usual care.
214647718|NCT06549088|DEVICE|Spatial Frequency Domain Imaging|Resected lung tissue will be removed from the surgical field and labeled with sutures per standard of care. The specimen will then be immediately analyzed using two SFDI devices in the operating room using sterile technique. Each specimen will be recorded up to three times to ensure at least one high fidelity recording is captured. The SFDI data will be analyzed and compared to the official pathology report from the electronic medical record.
214647719|NCT05642910|DRUG|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
214647720|NCT05642910|DRUG|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
214647721|NCT03094195|DRUG|EMA401|EMA401
214647722|NCT03094195|DRUG|Placebo|Placebo
214647723|NCT02238847|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
214647724|NCT03632980|DEVICE|"Ablatherm Foc/Dyn or Focal One HIFU treatment"|"Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application."
214647725|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
214647726|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
214647727|NCT01961115|DRUG|Epacadostat|Given PO
214647728|NCT01961115|BIOLOGICAL|MELITAC 12.1 Peptide Vaccine|Given ID/SC
214647729|NCT03693248|DRUG|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
214647730|NCT00529737|PROCEDURE|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
214647731|NCT00529737|PROCEDURE|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
214647732|NCT00003063|BIOLOGICAL|recombinant interferon alfa|
214647733|NCT00003063|DRUG|fluorouracil|
214647734|NCT00003063|DRUG|leucovorin calcium|
214647735|NCT00003063|DRUG|levamisole hydrochloride|
214647736|NCT00360399|DRUG|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
214647737|NCT00360399|DRUG|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
214647738|NCT00360399|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
214647739|NCT06439030|BEHAVIORAL|Recovery program|The practices included in the program are: Cinema Film Screening and Emotion/Thought Sharing, Laughter Yoga Practice, Stress Coping Techniques Training, Progressive Relaxation, Loss/Mourning Process Training, Expressive Art Therapy Practice, Healthy Lifestyle Behaviors Training.
214647740|NCT02670603|DRUG|EVONAIL® solution|
214647741|NCT02613455|PROCEDURE|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
214647742|NCT02613455|DRUG|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
214647743|NCT02613455|DRUG|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
214647744|NCT05112510|OTHER|Observing whether developing distant metastasis or recurrence|The study is a observational study and has no intervention.
214647745|NCT01902732|DEVICE|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
214647746|NCT02315924|OTHER|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
214647747|NCT02315924|OTHER|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
214647748|NCT03987204|DRUG|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
214647749|NCT03894345|DRUG|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
214647750|NCT02628860|DRUG|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
214647751|NCT05965674|PROCEDURE|Sacral Erector Spinae Plane Block|The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
214647752|NCT03845387|DRUG|KDT-3594|oral administration, dose titration
214647753|NCT03845387|DRUG|Pramipexole|ER formulation, oral administration, dose titration
214647754|NCT00018954|DRUG|asparaginase|
214647755|NCT00018954|DRUG|cyclophosphamide|
214647756|NCT00018954|DRUG|cytarabine|
214647757|NCT00018954|DRUG|daunorubicin hydrochloride|
214647758|NCT00018954|DRUG|doxorubicin hydrochloride|
214647759|NCT00018954|DRUG|etoposide|
214647760|NCT00018954|DRUG|ifosfamide|
214647761|NCT00018954|DRUG|mercaptopurine|
214647762|NCT00018954|DRUG|methotrexate|
214647763|NCT00018954|DRUG|prednisone|
214647764|NCT00018954|DRUG|vincristine sulfate|
214647765|NCT00018954|PROCEDURE|conventional surgery|
214647766|NCT00018954|RADIATION|radiation therapy|
214647767|NCT02858427|BEHAVIORAL|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
214647768|NCT02858427|BEHAVIORAL|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
214647769|NCT02858427|BEHAVIORAL|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
214647770|NCT02858427|BEHAVIORAL|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
214647771|NCT02440581|DRUG|Alendronate|
214647772|NCT02440581|DRUG|Teriparatide|
214647773|NCT02440581|DRUG|Cinacalcet|
214647774|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
214647775|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
214647776|NCT00611494|DRUG|MMF|Gradual optimization of drug dosage, as clinically tolerated.
214647777|NCT00611494|DRUG|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
214647778|NCT04097327|OTHER|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
214647779|NCT05190952|DRUG|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
214647780|NCT05190952|DRUG|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
214807965|NCT00555230|DRUG|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
214807966|NCT00555230|DRUG|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
214807967|NCT06291792|OTHER|telerehabilitation otago exercise program|telerehabilitation otago exercise program
214807968|NCT06291792|OTHER|face to face otago exercise program|face to face otago exercise program
214807969|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback|See information included in arm/group descriptions.
214807970|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Biofeedback|See information included in arm/group descriptions.
214807971|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback|See information included in arm/group descriptions.
214807972|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback|See information included in arm/group descriptions.
214807973|NCT02803398|OTHER|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann \& Rauscher).
214807974|NCT00006370|RADIATION|yttrium Y 90-edotreotide|
214807975|NCT04675580|BEHAVIORAL|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
214807976|NCT02059746|OTHER|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
214807977|NCT06252025|COMBINATION_PRODUCT|Memo-gration|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
214807978|NCT06252025|OTHER|Picture reminiscence therapy|Picture reminiscence therapy
214807979|NCT03858257|DEVICE|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
214807980|NCT03858257|DEVICE|Standard oxygenation|Supplemental oxygen through a facemask.
214807981|NCT02123979|DRUG|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
214807982|NCT00709553|DRUG|midazolam|
214807983|NCT00709553|DRUG|ZD4054|ZD4054 10 mg od
214807984|NCT00694551|BIOLOGICAL|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
214807985|NCT00694551|DRUG|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
214807986|NCT03231956|DEVICE|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
214807987|NCT01614730|DEVICE|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
214647781|NCT05190952|DRUG|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
214647782|NCT05526027|DIAGNOSTIC_TEST|CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement|cf supra
214647783|NCT01515033|OTHER|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
214647784|NCT03828487|DEVICE|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
214647785|NCT03828487|DEVICE|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
214647786|NCT05792514|OTHER|stong,stamp,pyms|STRONG(screening tool for risk of nutritional status and growth) STAMP(screening tool assessment of malnutrition in pediatrics) PYMS
214647787|NCT05706935|DIAGNOSTIC_TEST|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
214647788|NCT04230447|OTHER|No intervention|No intervention
214647789|NCT03430986|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.
214647790|NCT03430986|OTHER|No-treatment control|No treatment during the control period.
214647791|NCT02190019|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
214647792|NCT03478384|BEHAVIORAL|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
214647793|NCT05104047|OTHER|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
214807988|NCT01614730|DEVICE|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
214807989|NCT00059865|DRUG|gemcitabine hydrochloride|
214807990|NCT00059865|DRUG|pemetrexed disodium|
214807991|NCT06992674|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
214807992|NCT06992674|DRUG|Placebo|Take 75mg qd of placebo
214807993|NCT05005156|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
214807994|NCT05069636|OTHER|Lymphatic OMM|Patients receive lymphatic myofascial release and thoracic pump techniques.
214807995|NCT05069636|OTHER|Light Touch|Patients receive a series of light touch techniques.
214807996|NCT04164771|OTHER|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
215031252|NCT03185026|BEHAVIORAL|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~1. Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~2. Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~3. and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5\) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
215031253|NCT03185026|OTHER|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
214647794|NCT05104047|OTHER|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
214647795|NCT05104047|OTHER|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
214647796|NCT04193930|DRUG|Letrozole|Oral tablet letrozole 2,5 mg/twice daily for 5 days
214647797|NCT04193930|DRUG|Menotropins|150 IU of highly purified menotropins intramuscular
214647798|NCT04193930|DRUG|recombinant Follicular stimulating hormone|recombinant Follicular stimulating hormone 300- 400 IU
214647799|NCT01232478|BEHAVIORAL|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
214647800|NCT04228848|OTHER|new triple hop test|New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
214647801|NCT03871478|DRUG|Lidocaine|See Arm Description
214647802|NCT03871478|DRUG|Bupivacaine|See Arm Description
214647803|NCT03871478|DRUG|Lidocaine and Bupivacaine|See Arm Description
214647804|NCT00067210|DEVICE|Head and Neck Cooling System|
214647805|NCT00003414|BIOLOGICAL|aldesleukin|
214647806|NCT00003414|BIOLOGICAL|recombinant interferon gamma|
214647807|NCT00003414|DRUG|busulfan|
214647808|NCT00003414|DRUG|cyclophosphamide|
214647809|NCT00003414|DRUG|cyclosporine|
214647810|NCT00003414|PROCEDURE|peripheral blood stem cell transplantation|
214647811|NCT00003414|RADIATION|radiation therapy|
214647812|NCT05775328|OTHER|Intense pulsed light|Already described in the arm/group description
214647813|NCT02022826|DEVICE|SmartPill Monitoring System|
214647814|NCT04590456|OTHER|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
214647815|NCT05152381|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214647816|NCT00706017|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214647817|NCT03540186|DIETARY_SUPPLEMENT|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
214647818|NCT03540186|PROCEDURE|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
214647819|NCT01962779|OTHER|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
214647820|NCT06477692|DRUG|ENI using IMRT with or without chemotherapy|This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
214647821|NCT06477692|RADIATION|INRT|INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
214647822|NCT06477692|RADIATION|ENI|ENI using IMRT with or without chemotherapy
214647823|NCT05607901|DRUG|Tacrolimus ointment|tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares
214647824|NCT05607901|DRUG|Hydrocortisone 1% cream|Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
215031254|NCT00382226|DRUG|Azopt|
215031255|NCT01331655|DRUG|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
214647825|NCT04077905|DRUG|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
214647826|NCT04077905|DRUG|Etoposide|100mg/m² ivgtt on day 1
214647827|NCT04077905|DRUG|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
214647828|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 0|"Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses."
214647829|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose -1|"Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
214647830|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 1|"Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
214647831|NCT05939037|DRUG|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
214647832|NCT04736654|OTHER|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
214647833|NCT02282683|DRUG|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
214647834|NCT01078805|DRUG|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
214647835|NCT03608917|DRUG|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
214647836|NCT03608917|DEVICE|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
214647837|NCT03608917|DRUG|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
214647838|NCT05920967|DRUG|Dexamethasone Palmitate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
214807997|NCT03187002|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
214807998|NCT03187002|DRUG|Moderate IV Sedation|IV sedation with fentanyl and versed
214807999|NCT03187002|OTHER|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
214808000|NCT03187002|OTHER|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
214808001|NCT03734965|DEVICE|AWAKEN INTUBATION|Intubation
214808002|NCT05822518|DIETARY_SUPPLEMENT|Neo-mune powder (otsuka pharmaceutical)|"* Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~* Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
214808003|NCT05822518|DRUG|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
214808004|NCT04989036|PROCEDURE|pulpotomy|Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
214808005|NCT01245790|DRUG|fostamatinib|Oral tablets, single dose
214808006|NCT06114004|DRUG|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
214808007|NCT06114004|DRUG|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
214808008|NCT01695551|OTHER|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
214808009|NCT01226069|DRUG|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
214808010|NCT01226069|DRUG|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
214808011|NCT01226069|OTHER|No application|No application
214808012|NCT04851301|BEHAVIORAL|Active Virtual Reality|Participants will be assigned to an immersive VR environment.
214808013|NCT04851301|BEHAVIORAL|sham Virtual Reality|Participants will be assigned to a sham VR environment without the immersive experience.
214808014|NCT04851301|OTHER|No Intervention|Participants will experience tonic pain tolerance tests without exposure to any environments.
214808015|NCT04851301|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
214647839|NCT05920967|DRUG|Dexamethasone Sodium Phosphate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
214808016|NCT04851301|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
214808017|NCT04851301|OTHER|Natural history|Participants will not be provided Naloxone or Saline.
214808018|NCT00216502|DRUG|galantamine hydrobromide|
214808019|NCT06159803|BEHAVIORAL|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
214808020|NCT01096290|DRUG|lubiprostone|24mcg BID, capsule, oral 30days
214808021|NCT01096290|DRUG|Matched placebo|Twice daily for 30days, oral
214808022|NCT00357448|BIOLOGICAL|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
214808023|NCT00357448|PROCEDURE|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
214808024|NCT00357448|OTHER|laboratory biomarker analysis|Correlative studies
214808025|NCT00357448|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214647840|NCT03911726|RADIATION|Single PET/MR-measurement|A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
214647841|NCT05107817|OTHER|Exercise intervention|A ball catching and throwing exercise.
214647842|NCT01609842|OTHER|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
214647843|NCT06419933|OTHER|The SuperKids Program|The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
214647844|NCT02910245|DRUG|Mercaptopurine (Purinethol)|
214647845|NCT02910245|DRUG|Placebo|
214647846|NCT02910245|DRUG|Mesalamine|
214647847|NCT02910245|DRUG|Prednisone|
214647848|NCT05767723|DRUG|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
214647849|NCT05767723|DRUG|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
214647850|NCT04936074|PROCEDURE|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
214647851|NCT04936074|PROCEDURE|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
214647852|NCT04147351|DRUG|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
214647853|NCT04023955|BEHAVIORAL|Twitter|Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
214647854|NCT02715687|DRUG|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
214647855|NCT02715687|DRUG|Placebo|Will receive 30 days treatment with oral placebo of 200mg
214647856|NCT01893333|PROCEDURE|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
214647857|NCT01136343|OTHER|lifestyle modified project|education, counseling
214647858|NCT05558332|BEHAVIORAL|Youth-Nominated Support Teams for CHR|"Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk."
214647859|NCT02474329|OTHER|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.
214647860|NCT02474329|DEVICE|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
214647861|NCT04743180|DEVICE|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
214647862|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
214647863|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
214808026|NCT00357448|OTHER|flow cytometry|Correlative studies
214808027|NCT05697471|DRUG|Dienogest|Dienogest 2 mg per day
214808028|NCT05697471|DRUG|Danazol|Danzol 200MG per day
214808029|NCT00385684|DRUG|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
214808030|NCT00385684|DRUG|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
214808031|NCT00385684|DRUG|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
214808032|NCT03220867|DRUG|Risperidone: Xian Risperdal (test)|Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.
214808033|NCT03220867|DRUG|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
214808034|NCT07003074|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
214808035|NCT07003074|DRUG|Docetaxel combined + Trastuzumab +Pertuzumab|Positive control.
214808036|NCT02801877|BEHAVIORAL|IntelliCare|
214808037|NCT02801877|BEHAVIORAL|Hub App with the Recommender System|
214808038|NCT02801877|BEHAVIORAL|Coaching|
214808039|NCT04008979|DRUG|Aspirin|Aspirin - lipid complex
214808040|NCT00591630|DRUG|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
214808041|NCT00591630|DRUG|Carmustine|300 mg/m\^2 by vein.
214808042|NCT00591630|DRUG|Etoposide|200 mg/m\^2 by vein every 12 hours.
214808043|NCT00591630|DRUG|Cytarabine|200 mg/m\^2 by vein every 12 hours.
214808044|NCT00591630|DRUG|Melphalan|140 mg/m\^2 by vein.
214808045|NCT00591630|DRUG|Rituximab|"Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
214808046|NCT00591630|PROCEDURE|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
214808047|NCT00331578|DEVICE|Excel drug-eluting coronary artery stent|
214808048|NCT07028996|DEVICE|Daily use of the PEASY urine collection device for 5 days|"The PEASY device features a non-adhesive attachment system to the penis, unlike penile sheaths which are used for the same indications and whose attachment system is based on an adhesive system. Fixation of the PEASY device to the penis involves the use of a clamp on the foreskin. The clamp has a certain elasticity and has been developed to be atraumatic.~The medical device comprises a glans cup which covers the urinary meatus. This cup therefore rests on the glans."
214808049|NCT07028996|OTHER|Daily collection of patient feedback using a visual analog scale (0-100)|Daily collection of patient feedback using a visual analog scale (0-100) and any suggestions for improving the device during an open interview at the end of the test period.
214808050|NCT03815838|DIAGNOSTIC_TEST|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
214808051|NCT07036380|DRUG|MP0317 + Gemcitabine + Cisplatine + Durvalumab|"* MP0317: 3 mg/kg IV(intraveinous), day 1, every 3 weeks for a maximum of 5 administrations~* Immuno-chemotherapy (ICT): cycle 1-5~  * Durvalumab 1500 mg IV, day 8 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 8 and 15 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 8 and 15 every 3 weeks~* Immuno-chemotherapy (ICT): cycle 6-8~  * Durvalumab 1500 mg IV every 3 weeks~ * Gemcitabine 1000 mg/m² at day 1, 8 every 21 days~ * Cisplatin 25 mg/m² at day 1, 8 every 21 days~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
214808052|NCT07036380|PROCEDURE|CT-Scan|at baseline, every 6 weeks (± 1 week) for the first 24 weeks and then every 8 weeks until progression, at end of treatment visit, At each follow-up visit : Only for patients who have not progressed during treatment phase
214808053|NCT07036380|DRUG|Gemcitabine + Cisplatin + Durvalumab|"* Immuno-chemotherapy (ICT) for 8 cycles :~  * Durvalumab 1500 mg IV, day 1 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 1 and 8 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 1 and 8 every 3 weeks~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
214808054|NCT07035899|DRUG|Caesarean Section|Cesarean section was performed as routine surgical procedure
214808055|NCT07035561|DRUG|Rituximab (Mabthera)|"In Chronic hypersensitivity pneumonitis patients with no improvement in lung function (deterioration in their FVC% predicted more than or equal 5%) after a minimum of 6 months treatment including antigen avoidance and immunosuppressive therapy. Rituximab will be administered by an intravenous infusion.~* Two doses of Rituximab will be given, the first dose at day 0 and the second dose at day 15, 1 gram of Rituximab will be given in each dose.~* Patients will be given acetaminophen and antihistamine before each infusion.~* Rituximab will be diluted in an infusion bag of either 0.9% sodium chloride or 5% dextrose.~* No other drugs will be mixed with it, and patients will be closely monitored for any infusion reactions."
214808056|NCT07037654|DRUG|ondansetron lingual film|8 mg of the lingual film form of ondansetron, given 15 minutes before spinal anesthesia
214808057|NCT07037654|DRUG|Placebo|a placebo lingual film form, given 15 minutes before spinal anesthesia
214808058|NCT07036354|OTHER|Human-Animal Interaction|HAI - participants spend a specific amount of time with a therapy dog in a controlled environment.
214808059|NCT07036354|OTHER|General Health Education|GHE - participants will be educated on strategies to assist in managing general and academic anxiety.
214808060|NCT07036237|DRUG|Tramadol group|Drug used as final irrigant
214808061|NCT07036237|DRUG|Dexamethasone Group|drug used as a final irrigant
214808062|NCT07037251|OTHER|there is no intervention|there is no intervention only observation
214808063|NCT07037212|BEHAVIORAL|Intensive Medical Nutrition Therapy (MNT)|Participants will receive individualized intensive medical nutrition therapy (MNT) with weekly dietary counseling and follow-ups for 12 weeks. The intervention focuses on improving glycemic control, reducing systemic inflammation, and enhancing gut barrier function.
214808064|NCT07037212|BEHAVIORAL|Standard Dietary Counseling|Participants will receive standard dietary advice in a single counseling session at baseline. No further dietary intervention will be provided.
214808065|NCT07035301|DRUG|Normal Saline (Placebo)|During anesthesia induction, an equal volume of normal saline was used instead of rocuronium for anesthesia.
214808066|NCT07035301|DRUG|Lidocaine Intravenous Infusion|Lidocaine was administered at a dose of 0.5mg/kg for the induction of anesthesia.
214808067|NCT07035301|DRUG|Remimazolam Tosilate|Remimazolam was administered at a dose of 0.2 mg/kg for the induction of anesthesia.
214808068|NCT07035301|DRUG|Remifentanil|Remifentanil was administered at a dose of 3 micrograms per kilogram for the induction of anesthesia.
214808069|NCT07035301|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium was administered at a dose of 0.15mg/kg for the induction of anesthesia.
214808070|NCT07035860|RADIATION|Carbon ion radiotherapy|Patients will receive platinum-based doublet chemotherapy and immunotherapy, followed by carbon iron radiotherapy and immunotherapy. The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
214808071|NCT07035860|DRUG|Chemotherapy|platinum-based doublet chemotherapy
214808072|NCT07035860|DRUG|Immunotherapy|The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
214808073|NCT07036939|PROCEDURE|Immediate LVA|Bilateral cervical lymphatic-venous anastomosis (LVA) performed within 2 weeks after baseline assessments.
214808074|NCT07036939|PROCEDURE|Delayed LVA|Identical LVA procedure performed at 6 months (±2 weeks) post-baseline
215031256|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
215031257|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
214808075|NCT07035639|BEHAVIORAL|The Baduanjin intervention was designed following traditional Chinese health preservation principles and conducted under the guidance of certified instructors. The training sessions were led by nation|The Baduanjin group received training guided by national-level social sports instructors certified by the Institute of Sports Medicine, General Administration of Sport of China. The intervention consisted of Baduanjin training 4 times per week for 8 consecutive weeks, with a total duration (including warm-up and breaks) of ≥30 minutes per session. The training protocol included 16 minutes of Baduanjin exercise, a 2-minute break, and an additional 16 minutes of Baduanjin exercise.
214808076|NCT07035964|DIETARY_SUPPLEMENT|human lactoferrin|effera human lactoferrin
214808077|NCT07035964|DIETARY_SUPPLEMENT|Placebo|Placebo Control
214808078|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine.
214808079|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine.
214808080|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) and Oscillatory Positive Expiratory Pressure (OPEP) group|Patients with bronchiectasis using ACT and OPEP simultaneously
214808081|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) group|Patients will receive only ACBT for airway clearance.
214808082|NCT06876207|DEVICE|Tandem t:slim X2 with Control-IQ technology|Control-IQ is one of the second-generation AID technologies currently available worldwide and is approved for people \> 6 years. Control-IQ can predict glucose levels 30 minutes in advance and automatically adjust basal insulin delivery, providing corrective boluses if needed. The system can prevent hypoglycemia by suspending insulin delivery if glucose is predicted to drop below 70 mg/dl (8). Additionally, the device offers specific settings for circumstances such as sleep or exercise. When the exercise mode is activated, the system temporarily raises the minimum glucose target from 112.5 to 140 mg/dl to minimize the risk of hypoglycemia, a common effect of physical activity.
214808083|NCT07037069|COMBINATION_PRODUCT|Desensitization Training|Participants in this group received desensitization training aimed at reducing hypersensitivity and pain perception through progressive exposure to different tactile stimuli. Use of soft and coarse textures (cotton, wool, Velcro, brush). Rubbing, tapping, rolling over the affected wrist and hand.
214808084|NCT07037069|COMBINATION_PRODUCT|Graded Motor Imagery (GMI)|Training Sample Size: 20 participants Participants underwent a progressive 3-phase motor training program designed to target cortical reorganization and improve movement without provoking pain. Phases: Laterality Recognition - identifying left/right hand images (Recognise™ app or cards). Explicit Motor Imagery - visualizing wrist movements without actual motion. Mirror Therapy - using a mirror box to simulate movement of the affected wrist. Sessions: 30-45 minutes/day, 5 times/week, for 4 weeks.
214808085|NCT07037368|BEHAVIORAL|Impact of Delivery Mode|investigates the impact of delivery mode vaginal delivery versus cesarean section on the prevalence and severity of three postpartum musculoskeletal complications: coccydynia, pelvic girdle pain (PGP), and rectus diastasis (RD). Conducted on postpartum females
214808086|NCT07037173|COMBINATION_PRODUCT|Kinesiology Taping|Elastic therapeutic tape applied over the SiJ region using a standardized protocol. Therapy sessions were supervised and conducted at a rehabilitation center three times per week for six weeks.
214808087|NCT07037173|COMBINATION_PRODUCT|Yoga Therapy|A structured yoga program including asanas, pranayama, and mindfulness practices focused on enhancing flexibility, core strength, and posture. conducted at a yoga center
214808088|NCT07037667|OTHER|Pilates exercises|Single leg lifts:The participant is in supine lying position with knees bent and feet parallel and hip-width apart. Head, neck and shoulders totally relaxed and arm extended and relaxed beside the body. Then the participant is asked to inhale first without moving her leg then exhale while bringing one leg up towards chest , drawing her pelvic floor and abdominals up and in like gently tightening a belt and maintaining 90 degrees angle at the knee and then put her leg down while inhaling. One leg circle:The participant is in supine lying position with one leg raised towards the ceiling and the other leg on the floor and both knees slightly bent.Then the participant is asked to inhale first without moving her leg and to make sure to use the abdominal muscles to try to maintain a neutral pelvis while doing the exercise then makes a small circle while exhaling and inhale when she completes the circle and reaches the starting position.
214808089|NCT07037667|OTHER|Dietary recommendations|Dietary recommendations as healthy snacks that are rich in magnesium and vitamin B-6.
214808090|NCT07036731|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
214808091|NCT07036913|DIAGNOSTIC_TEST|somatocognitive therapy|In somatocognitive therapy which includes drawing( three days prior to menustration in first two months and the first day of menustration in third month) and music(in the first 12 hours of menustration)along with TENS(thirty minutes on abdominal region, upon the onset of dysmonarrhea).
214808092|NCT07036913|COMBINATION_PRODUCT|Stretching exercises|Stretching exercises of abdominal, lumbar or pelvic region will be performed as a treatment. Frequency:15 minutes;three times per week.
214808093|NCT06713590|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
214808094|NCT07035717|OTHER|Patient interview|A semi-structured interview with five questions will be conducted, with audio recording, which will later be transcribed verbatim.
214808095|NCT07037030|BEHAVIORAL|Guided deep breathing|Children will complete a brief, 5-minute, deep breathing intervention using the Domi tool to help maintain a 5-second breath pace
214808096|NCT07036575|BEHAVIORAL|Standard Visual Health Education|Participants receive conventional eye health education using standard visual materials, explained by an instructor.
214808097|NCT07036575|BEHAVIORAL|Easy-Read Instructor-Guided Education|Participants receive Easy-Read health education through 16 simplified images with instructor-guided explanation using plain language and pictorial content.
214808098|NCT07036575|BEHAVIORAL|Easy-Read Audio-Based Self-Learning|Participants use a voice-assisted pen device to self-learn Easy-Read materials (16 images) with audio explanations, without additional teacher guidance.
215031258|NCT04986150|OTHER|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
215031259|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
214808099|NCT07035808|COMBINATION_PRODUCT|2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy|The enrolled patients first receive 2 cycles of combined drug induction therapy: paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706, every 3 weeks for 2 cycles; After induction therapy, synchronous radiotherapy and chemotherapy combined with immunotherapy: extracorporeal irradiation+post loading radiotherapy+synchronous chemotherapy+immunotherapy. During radiotherapy, single agent cisplatin/carboplatin treatment for 5 courses per week+QL1706 treatment every 3 weeks for 3 courses; After the end of radiotherapy and chemotherapy, immune maintenance therapy will be administered for six months: treatment with QL1706 every 3 weeks for 9 courses, followed by a follow-up period until the end of radiotherapy for 2 years or death.
214808100|NCT07037108|COMBINATION_PRODUCT|Reflexology + Generalized Stretching|Participants in Group 1 received a combination of foot reflexology and generalized stretching exercises. focusing on specific reflex points related to the endocrine, nervous, and reproductive systems. Each reflexology session lasted for 20 minutes, conducted three times per week for 6 weeks.
214808101|NCT07037108|COMBINATION_PRODUCT|Stretching Only|Generalized Stretching Only Method: Generalized Stretching Exercises Details: Participants in Group 2 received only generalized stretching exercises without any reflexology treatment. The stretching protocol included exercises for major muscle groups such as the neck, shoulders, back, hips, hamstrings, and calves. Each session will last for 20-25 minutes, which included a 5-minute warm-up, 15-20 minutes of static stretching, and a 5-minute cool-down.
214808102|NCT07036055|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.
214808103|NCT07036055|DEVICE|Sham Stimulation|Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.
214808104|NCT07036055|BEHAVIORAL|Mindfulness Training|Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.
214808105|NCT07035314|PROCEDURE|Dexamethasone|1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and paracetamol.
214808106|NCT07035314|DRUG|NSAIDs|2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.
214808107|NCT07035314|DRUG|Control (Standard treatment)|3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsillectomy medications in our department.
214808108|NCT07036887|DIAGNOSTIC_TEST|First Rib Mobilization + Respiratory Physiotherapy|Patients were given post isometric relaxation for restricted first rib in sitting position and therefore the affected elevated first rib, opposite foot of therapist was placed on the table and patient non affected arm is 'dropped' on the therapist flexed knee. The practitioner's conjointly flexes the elbow on the non-affected side placed anterior to shoulder with the hand supporting the patient facet of head. Then therapist makes contact with the tubercle of the first rib with fingers or thumb of affected side (patient) disposing of available soft tissue. slack as steady force is applied in inferior direction. The therapist eases his flexed leg and uses his supported hand to encourage patient's neck into a side flexion and rotation to affected side thus unloading the scalene tension thereon side and encourage the first rib to move anteriorly and inferiorly
214808109|NCT07036887|COMBINATION_PRODUCT|Scalene Muscle Energy Technique (MET) + Respiratory Physiotherapy|MET for the scalene muscle, the participants were made to lie supine with a cushion or towel under the upper thoracic area. The PT placed his hand on the side of the participant's face/forehead to resist the isometric contraction and the other hand on the sternum. The participants were asked to perform the action of the anterior scalene muscle against PT resistance and hold it for 7-8 seconds followed by relaxation. (42) Along with the same respiratory physiotherapy protocol used in Group A. The treatment protocol was given for three sessions per week for four weeks
214808110|NCT07035912|COMBINATION_PRODUCT|PIONEER Protocol|"* Oral nutritive stimulus with every feed (minimum 5mL)~* Esophageal stimulation with up to 15 stimulations given at least 5 times per week with stimulation catheter~* High resolution esophageal manometry as much as weekly if feasible throughout protocol~* Parent biofeedback (during manometry studies) and education on at least a weekly basis with focus on their participation in oral feeding"
214808111|NCT07035782|DEVICE|temperature monitoring|Core temperature will be measured in the distal esophagus. The esophageal probe will be inserted after intubation to the depth from the upper incisors recommended by Bloch et al,1 specifically one-quarter of the patient's height plus 4.5 cm.
214808112|NCT07035782|DRUG|Sevoflurane|Anesthesia induction will be standardized for all participants., the children will undergo inhalational induction using 8% sevoflurane with a fresh gas flow of 5 L/min in 100% oxygen. Once children loses consciousness, the sevoflurane concentration will be reduced to 3%-5% and then maintained as close as possible to 1.2 MAC, age-adjusted
214808113|NCT07036497|DRUG|Vitamin B12|Vitamin B12 treatment was initiated in male patients with vitamin B12 deficiency due to anemia etiology.
214808114|NCT07037693|DIAGNOSTIC_TEST|Comprehensive complication index (CCI)|Comprehensive complication index (CCI)
214808115|NCT07037693|DIAGNOSTIC_TEST|Clavien-Dindo-Classification (CDC)|Clavien-Dindo-Classification (CDC)
214808116|NCT05280132|PROCEDURE|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
214808117|NCT05280132|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
214808118|NCT03559023|PROCEDURE|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
214808119|NCT03559023|PROCEDURE|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
214808120|NCT03559023|PROCEDURE|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
214808121|NCT03559023|PROCEDURE|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
214808122|NCT06894355|OTHER|hydrotherapy|hydrotherapy in addition to physical therapy
214808123|NCT06894355|OTHER|control group|regular physical therapy treatments
214808124|NCT06751043|OTHER|Fasting|"Process: Fasting pre-procedure~Tube feeding will be stopped at least 8 hours before the patient's scheduled surgery or procedure time."
214808125|NCT06751043|OTHER|Not fasting|"Process: Not fasting pre-procedure~Tube feeding will be continued until patient transfer to the operating room/procedure area."
214808126|NCT06795893|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index,compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022,respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
214808127|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
214808128|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
214808129|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
214808130|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
214808131|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
214808132|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed
214808133|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
214808134|NCT04201171|DEVICE|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
214808135|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
214808136|NCT02924038|BIOLOGICAL|IMA950|IMA950 vaccine
214808137|NCT02924038|BIOLOGICAL|poly-ICLC|poly-ICLC vaccine
214808138|NCT02924038|BIOLOGICAL|Varlilumab|Intravenous solution
214808139|NCT01845662|OTHER|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
214808140|NCT03601637|DRUG|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
214808141|NCT03601637|DRUG|IVA|FDC granules (LUM/IVA).
214808142|NCT03797547|OTHER|AFLIBERCEPT|Patients will be treated following a real life protocol and according to the French recommendation
214808143|NCT01854008|OTHER|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut\_publica/itineraris/index"
214808144|NCT01854008|OTHER|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
214808145|NCT05107323|BEHAVIORAL|Compassionate Mind Training for Teachers|Compassionate Mind Training for Teachers is a biopsychosocial evidence-based approach that aims to foster compassion, affect regulation, prosocial qualities and wellbeing in teachers.
214808146|NCT04756752|OTHER|Fit and Vitaal program|Intervention type: training
214808147|NCT03318471|DRUG|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
214808148|NCT03318471|DRUG|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
214808149|NCT03003871|DEVICE|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
214808150|NCT03003871|DEVICE|Manual toothbrush|Oral-B® Pro-Health All-In-One
214808151|NCT03003871|OTHER|Toothpaste|Colgate Maximum Cavity Protection®
214808152|NCT03003871|OTHER|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
214808153|NCT00206583|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
214808154|NCT05689905|DIAGNOSTIC_TEST|HLA typing of the children|The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
214808155|NCT02877147|OTHER|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
214808156|NCT05343143|DEVICE|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
214808157|NCT04715477|BEHAVIORAL|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
214808158|NCT03172351|DEVICE|EDoF1|extended depth of focus IOL - EDoF1
214808159|NCT03172351|DEVICE|Monofocal|Monofocal IOL
214808160|NCT03172351|DEVICE|EDoF2|Comparison EDoF2 IOL
214808161|NCT03326180|DRUG|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
214808162|NCT03326180|DRUG|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
214808163|NCT00479258|DRUG|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
214808164|NCT00479258|DRUG|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
214808165|NCT01008878|BEHAVIORAL|interdisciplinary intervention|
214808166|NCT03838393|OTHER|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
214808167|NCT01860105|DRUG|MDCO-157|intravenous administration
214808168|NCT01860105|DRUG|PLAVIX|oral administration
214808169|NCT03141398|DIAGNOSTIC_TEST|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
214808170|NCT03141398|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
214808171|NCT03141398|DIAGNOSTIC_TEST|T2* MRI of the Pancreas|MRI \[Magnetic resonance imaging\] of the pancreas which is safe and takes around 30 minutes.
214808172|NCT02942953|DEVICE|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
214808173|NCT03073330|DIAGNOSTIC_TEST|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
214808174|NCT03073330|DIAGNOSTIC_TEST|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
214808175|NCT02403791|DEVICE|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
214808176|NCT02403791|DEVICE|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
214808177|NCT06410222|PROCEDURE|Recurrence after undergo spinal cord stimulation|"1. To investigate the pain relief and recurrence of patients with herpes zoster neuralgia after spinal cord stimulation treatment.~2. To analyze the risk factors related to recurrence after spinal cord stimulation treatment in patients with herpes zoster neuralgia, and build a recurrence prediction model."
214808178|NCT06366581|DIAGNOSTIC_TEST|Transcriptomic analysis|high-throughput sequencing technology
214808179|NCT01662284|DRUG|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
214808180|NCT04826679|DRUG|Camrelizumab, nab-paclitaxel, cisplatin|"Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
214808181|NCT01012635|OTHER|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
214808182|NCT01012635|OTHER|Meditation|"Meditation: focus on a single word (one) for the entire session."
214808183|NCT01012635|OTHER|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
214808184|NCT01012635|OTHER|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
214808185|NCT02452164|OTHER|Teaching|
214808186|NCT02452164|DEVICE|(CellScopeOTO)|
214808187|NCT04715152|DRUG|ACB group|Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
214808188|NCT04715152|DRUG|IA group|Patients will receive intra-articular bupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline
214808189|NCT02407275|OTHER|Biological sample|
214808190|NCT05187949|OTHER|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
214808191|NCT05512442|PROCEDURE|the centric relation|All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.
214808192|NCT01630733|DRUG|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
214808193|NCT01630733|DRUG|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
214808194|NCT04471610|OTHER|Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day|Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
214808195|NCT03261310|DRUG|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
214808196|NCT01820208|DRUG|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
214808197|NCT01820208|DRUG|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
214808198|NCT02088463|PROCEDURE|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
214808199|NCT02088463|PROCEDURE|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
214808200|NCT02088463|DEVICE|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
214808201|NCT00793663|DRUG|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
214808202|NCT00793663|DRUG|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
214808203|NCT00793663|DRUG|Dexamethasone|Intravenous use, 4 mg, single shot
214808204|NCT00793663|DRUG|NaCl|Intravenous use; single shot
214808205|NCT00793663|DRUG|Ondansetron|Intravenous use; 4 mg; single shot
214808206|NCT00793663|DRUG|NaCl|Intravenous use; single shot
214808207|NCT05388318|BEHAVIORAL|Prolonged nightly fasting|14 hour nightly fast from caloric food and beverage; followed by 10 hour eating window. 8-week intervention duration.
214808208|NCT05388318|BEHAVIORAL|Health Education Control|Weekly health education video viewing related to general health topics
214808209|NCT00005877|DRUG|rubitecan|
214808210|NCT05349695|DEVICE|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
214808211|NCT00420303|DRUG|Etanercept|50 mg injection once weekly
214808212|NCT00420303|OTHER|Placebo|placebo
214808213|NCT00739947|OTHER|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
214808214|NCT05729594|DRUG|Bimatoprost Ophthalmic|eyedrops
214808215|NCT04891120|DIAGNOSTIC_TEST|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
214808216|NCT05289674|DIETARY_SUPPLEMENT|High Calorie Formula|The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
214808217|NCT01446094|DRUG|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
214808218|NCT00247195|BEHAVIORAL|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
214808219|NCT06196515|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
214808220|NCT06196515|DRUG|nano calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
214808221|NCT03627780|DIAGNOSTIC_TEST|DNA extraction|DNA will be extracted from white cells
214808222|NCT00081848|DRUG|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
214808223|NCT00081848|DRUG|rF-CEA(6D)/TRICOM|
214808224|NCT00081848|DRUG|Recombinant Fowlpox-GM-CSF|
214808225|NCT00081848|DRUG|Celecoxib|
214808226|NCT00312039|DRUG|Elvucitabine|Elvucitabine 10 mg QD for 14days
214808227|NCT00312039|DRUG|Lamivudine|Lamivudine 300 mg QD for 14 days
214808228|NCT05088577|DIETARY_SUPPLEMENT|Whole egg|Daily consumption of two whole eggs during 8 weeks
214808229|NCT05088577|DIETARY_SUPPLEMENT|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
214808230|NCT05088577|DIETARY_SUPPLEMENT|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
214808231|NCT05383794|OTHER|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
214808232|NCT06242613|PROCEDURE|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
214808233|NCT06242613|PROCEDURE|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
214808234|NCT02264106|DRUG|Lefradafiban tablet|
214808235|NCT02264106|DRUG|Lefradafiban double chamber sachet|
214808236|NCT02264106|DRUG|Pantoprazole|
214808237|NCT04177368|DIETARY_SUPPLEMENT|Theragran 60ml|history,examination and biochemical values
214808238|NCT00885456|BEHAVIORAL|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
214808239|NCT00885456|BEHAVIORAL|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
214808240|NCT04660656|DIAGNOSTIC_TEST|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
214808241|NCT02149745|PROCEDURE|Calling the patient's name|calling the patient's name during anesthesia reversal
214808242|NCT02149745|PROCEDURE|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
214808243|NCT00000229|DRUG|Buprenorphine|
214808244|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
214808245|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
214808246|NCT02772289|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
214647864|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
214647865|NCT05833672|DRUG|Terelizumab|q3w Terelizumab 200mg on day 1 of each cycle
214647866|NCT05833672|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
214647867|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
214647868|NCT03186989|DRUG|IONIS MAPTRx|IONIS MAPTRx injections.
214647869|NCT03186989|OTHER|Placebo|Artificial CSF injections.
214647870|NCT06143527|BIOLOGICAL|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214647871|NCT00599495|PROCEDURE|allogeneic HSCT|dose-reduced conditioning regimen
214647872|NCT06028659|OTHER|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
214647873|NCT06028659|OTHER|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
214647874|NCT03570112|DRUG|SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg|sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
214647875|NCT01811147|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
214647876|NCT00891826|DIETARY_SUPPLEMENT|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
214647877|NCT00891826|DIETARY_SUPPLEMENT|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
214647878|NCT03657615|DEVICE|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
214647879|NCT03341676|DRUG|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
214647880|NCT03341676|DRUG|Placebo|Sodium Chloride 0.9% w/v solution for injection
214647881|NCT02630160|DRUG|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
214647882|NCT02630160|OTHER|Physiological Saline|Intraarticular infusion physiological serum
214647883|NCT01550497|OTHER|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
214647884|NCT01195337|BEHAVIORAL|PA Prescription Plan|Exercise program and instructions.
214647885|NCT01195337|DEVICE|Pedometer|Step monitor for individual PA progress.
214647886|NCT01195337|BEHAVIORAL|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
214647887|NCT05539846|PROCEDURE|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
214647888|NCT06106594|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
214647889|NCT03475043|BEHAVIORAL|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
214647890|NCT06865170|PROCEDURE|25 gauge needle|This intervention will observe patients post-procedural pain using a 25 gauge needle
214647891|NCT06865170|PROCEDURE|22 gauge needle|This intervention will observe patients post-procedural pain using a 22 gauge needle
214647892|NCT06865170|PROCEDURE|+/- Ethyl Chloride Topical Aerosol Anesthetic|This intervention will observe patients post-procedural pain when using topical ethyl chloride spray. This will be compared to a placebo spray which will utilize isopropyl alcohol.
214647893|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
214647894|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
214808247|NCT02639741|DRUG|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
214808248|NCT02639741|DRUG|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
214808249|NCT02639741|OTHER|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
214808250|NCT05817916|PROCEDURE|ESP block|ESP block: ultrasound guided erector spina plane block
214808251|NCT05817916|PROCEDURE|LP block|LP block: ultrasound guided lumbar plexus block
214808252|NCT02565095|PROCEDURE|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
214808253|NCT01064349|DRUG|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
214808254|NCT02215161|DRUG|Selinexor|Given PO
214808255|NCT05020847|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml
214808256|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 with CMV|Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
214808257|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 without CMV|Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
214808258|NCT05129098|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
214808259|NCT05129098|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
214808260|NCT05914103|PROCEDURE|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
214808261|NCT04602507|DRUG|Ivermectin|Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
214808262|NCT04602507|OTHER|Placebo|Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
214808263|NCT02621775|BEHAVIORAL|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
214808264|NCT02621775|BEHAVIORAL|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
214808265|NCT02621775|OTHER|Waiting list|The patients are followed by their General Practitioners without change in treatment .
214808266|NCT02164838|DRUG|Axitinib|
214808267|NCT02822781|OTHER|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
214808268|NCT04168463|DEVICE|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
214808269|NCT01979081|OTHER|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
214808270|NCT06545253|DIAGNOSTIC_TEST|microRNAs analysis|Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
214808271|NCT03621748|PROCEDURE|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
214808272|NCT03621748|PROCEDURE|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
214808273|NCT03488342|PROCEDURE|Repair for primary inguinal hernia|Repair for primary inguinal hernia
214808274|NCT02465658|OTHER|Medical records were reviewed.|retrospective study
214808275|NCT01029353|PROCEDURE|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
214808276|NCT01029353|PROCEDURE|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
214808277|NCT01900730|DRUG|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
214808278|NCT01900730|DRUG|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
214808279|NCT01900730|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
214808280|NCT01900730|BEHAVIORAL|Pill Diary|Patient given a pill diary to record the time each dose taken.
214808281|NCT01900730|BEHAVIORAL|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
214808282|NCT00936260|DRUG|alendronate|several duration of treatment
214808283|NCT03728296|BIOLOGICAL|islet body|Transplanting islet bodies under the diaphragm
214808284|NCT05558930|DEVICE|iTBS stimulation|standard iTBS burst pattern:3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals. 600 pulses on both side of cerebellar with an interval of 5 minutes.
214808285|NCT05558930|DEVICE|sham stimulation|Participants receive a sound stimulation with the same pattern with iTBS stimulation,but without magnetic field
214808286|NCT01520909|DRUG|Eltrombopag|Thrombopoietin receptor agonist
214808287|NCT01520909|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
215031260|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
215031261|NCT01188187|DRUG|Custirsen|
215031262|NCT01188187|DRUG|Docetaxel|
214808288|NCT06390501|DRUG|Semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks, 0.1 mg semaglutide once weekly for four weeks, 1.7 mg semaglutide once weekly for four weeks followed by 2.4 mg semaglutide once weekly for eight weeks
214808289|NCT06390501|DRUG|Placebo|Solution for subcutaneous (s.c. - under the skin) injection
214808290|NCT03918486|DEVICE|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
214808291|NCT02792426|DRUG|Research ENDS S-TA-U001|
214808292|NCT02792426|DRUG|Nicorette Inhalator|
214808293|NCT00650793|DRUG|Extended Release OROS® Paliperidone|
214808294|NCT04383431|PROCEDURE|PACK-CXL|Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.
214808295|NCT02942264|DRUG|Zotiraciclib (TG02)|"Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study."
214808296|NCT02942264|DRUG|Temozolomide (TMZ)|"Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design."
214808297|NCT05167981|OTHER|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
214808298|NCT05935631|DIETARY_SUPPLEMENT|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
214647895|NCT06916936|OTHER|Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter|"Peanut Butter (PB) Group: Participants in this group will receive a daily snack consisting of a personalized portion of smooth peanut butter (Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). The amount of peanut butter will be limited to 16g per two crackers, but additional crackers will be provided if the personalized portion exceeds this limit"
214647896|NCT06916936|OTHER|Cadbury Milk Chocolate Spread|"Control (CTL) Group: Participants in this group will receive a daily snack consisting of an isocaloric amount of a nut-free, vegetable oil-based chocolate spread (Cadbury Milk Chocolate) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). Similar to the peanut butter group, the chocolate spread will be limited to 16g per two crackers, with additional crackers provided if needed."
214808299|NCT06221319|OTHER|sacral erectör spinae plane group|sacral erectör spinae plane will be applied to patients in Group S
214808300|NCT05664919|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
214808301|NCT06337721|BEHAVIORAL|SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction)|This behavioral group intervention will consist of multiple group sessions to reduce AUDs and alcohol-related harms in Pacific Islander young adults. It will infuse culturally resonant narratives, language, and elements into existing evidence-based strategies.
214808302|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
214808303|NCT00989274|BIOLOGICAL|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
214808304|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
214808305|NCT00485394|DRUG|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
214808306|NCT00485394|DRUG|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
214808307|NCT00485394|DRUG|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
214808308|NCT03977649|DRUG|erenumab|erenumab 140 mg sc every 4 weeks
214808309|NCT03977649|DRUG|placebo|placebo sc every 4 weeks
214808310|NCT00003064|BIOLOGICAL|filgrastim|
214808311|NCT00003064|DRUG|carboplatin|
214808312|NCT00003064|DRUG|etoposide phosphate|
214808313|NCT00003064|DRUG|paclitaxel|
214808314|NCT00003064|DRUG|thiotepa|
214808315|NCT00003064|DRUG|topotecan hydrochloride|
214808316|NCT00003064|PROCEDURE|peripheral blood stem cell transplantation|
214808317|NCT05855785|BEHAVIORAL|dual task exercise|8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
214808318|NCT05855785|BEHAVIORAL|home exercise|60-minute light intensity home exercise, 4 times a week for 8 weeks
214808319|NCT02401607|OTHER|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
215031263|NCT01188187|DRUG|Prednisone|
214808320|NCT02997800|DRUG|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
215031264|NCT01188187|DRUG|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
215031265|NCT00049543|DRUG|gefitinib|Given PO
214647897|NCT06916442|DIAGNOSTIC_TEST|PET/CT Imaging with GZMB-targeted tracer|Intravenous administration of GZMB-targeted tracer (150-200 MBq), followed by whole-body PET/CT scan 30\~60 minutes post-injection.
214647898|NCT06916975|DRUG|Adebrelimab|Adebrelimab: 1200mg，iv，d1，q3w；
214647899|NCT06916975|DRUG|AG|Gemcitabine: 1000 mg/m² ，iv，d1、d8，q3w； Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；
214647900|NCT06916416|DRUG|Pembrolizumab|6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy
214647901|NCT06916208|DIETARY_SUPPLEMENT|capsinoid supplementation|Adolescents in the experimental group will receive active capsules containing dihydrocapsiate (bought from Ajinomoto® (Ajinomoto Health \& Nutrition North America, Inc., Japan) 3 times per day, representing 9mg/day all through the duration of the 4-week multidimensional care program.
214647902|NCT06916208|OTHER|Control group (placebo)|Regular multidimensional care 4-week program
214647903|NCT06916299|DIAGNOSTIC_TEST|dental casts|"At the end of the planned expansion, an 8-month retention period was expected. At this time, the expansion device was removed, and impressions were taken in both groups (T1).~At 12-month follow-up (T2), new impressions were taken in both groups to evaluate, at dental level, the relapse in the short term. Fig 1"
214647904|NCT06916299|DEVICE|tooth-borne expander insertion|tooth-borne expander delivery.
214647905|NCT06916299|PROCEDURE|miniscrew and bone-borne expander insertion|Insertion of the paramedian miniscrews in a totally guided procedure, and after was delivered the tooth-borne expander
214647906|NCT06916377|BEHAVIORAL|Edutainment Content: Norms Campaign|Soap opera that challenges harmful norms that condone IPV, targeting the belief that violence is an acceptable way to assert control or maintain reputation.
214647907|NCT06916377|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|CBT-based skills for stress management and non-violent conflict resolution.
214647908|NCT06916377|BEHAVIORAL|Edutainment Content: Placebo Campaign|Soap opera that features unrelated non-violent content
214647909|NCT05255328|DIETARY_SUPPLEMENT|Glutamine oral supplement|12-18 g /day of glutamine supplementation
214647910|NCT03371797|DRUG|Valsartan, Amlodipine -|"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."
214647911|NCT00865020|DRUG|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
214647912|NCT00865020|DRUG|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
214647913|NCT00865020|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
214647914|NCT00865020|DRUG|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
214647915|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
214647916|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
214647917|NCT06333145|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
214647918|NCT06960174|DEVICE|Virtual reality|If the participant is assigned to the intervention group a 3D virtual model will be constructed. For the intervention group the CT + VR will be reviewed during preoperative planning.
214647919|NCT06961149|PROCEDURE|Chromoendoscopy with indigo carmine solution spray|Patients will undergo chromoendoscopy with spraying indigo carmine.
214647920|NCT06961149|PROCEDURE|Linked-color imaging endoscopy|Patients will undergo Linked-color imaging endoscopy.
214808321|NCT02997800|DRUG|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
214808322|NCT02997800|DRUG|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
214808323|NCT02997800|OTHER|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
214808324|NCT02997800|OTHER|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
214808325|NCT04866524|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
214808326|NCT04866524|OTHER|Physical development and General Health|Physical development and General health examination
214808327|NCT04866524|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
214808328|NCT06094517|OTHER|Interview|Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
214808329|NCT03162315|PROCEDURE|Freeze all|
214808330|NCT02572921|BEHAVIORAL|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
214808331|NCT02572921|BEHAVIORAL|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
214808332|NCT03684538|OTHER|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
214808333|NCT03684538|OTHER|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
214808334|NCT03684538|OTHER|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
214808335|NCT03684538|OTHER|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
214808336|NCT02535611|DRUG|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
214808337|NCT02535611|DRUG|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
214808338|NCT02507427|DEVICE|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
214808339|NCT05393960|OTHER|Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program.|Manual therapy, mobility exercise therapy and a home-based self-stretching program. Manual mobilization postero-anterior glides at lumber facets joints, Transverse glides at spinous process \& Posterior-anterior glides at SI joint. Glides will be performed 3 times with 5 repetitions. Mobility exercise therapy.
215031266|NCT00049543|OTHER|placebo|Given PO
215031267|NCT00049543|OTHER|laboratory biomarker analysis|Correlative studies
215031268|NCT00236041|DRUG|ACTIQ®|
215031269|NCT03045952|PROCEDURE|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
215031270|NCT02714751|BEHAVIORAL|Daily asynchronies information|
215031271|NCT06565182|OTHER|Exercise|The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
215031272|NCT03321942|DRUG|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
214808340|NCT05393960|OTHER|home based self strechings program only.|Home based self-stretching program includes 3 repetitions of 15 seconds duration stretch (with 20 seconds rest between each repetition). Repeat stretching exercises twice a day for 3 alternate days for 1 week. Piriformis stretch: in supine crook lying, placing the lateral side of the foot over the contralateral knee and pulling towards the chest with the hands. Quadriceps stretch: stand on your left leg, one knee touching the other, hold a chair or the wall to keep you steady if needed, grab your right foot, using your right hand, and pull it towards your butt. Hamstring stretch: To stretch the right leg, sit on the ground with the left leg bent at the knee with the foot facing inward. This is called the butterfly position. Extend the right leg, keeping it slightly bent at the knee. Bend forward at the waist, making sure to keep the back straight.
214808341|NCT00242866|DRUG|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
214808342|NCT00242866|OTHER|Placebo|Placebo to Match GW274150
214808343|NCT06059326|DRUG|HSK7653 10 mg|Tablet, HSK7653 10 mg Q2W, 12 weeks
214808344|NCT06059326|DRUG|HSK7653 25 mg|Tablet, HSK7653 25 mg Q2W, 12 weeks
214808345|NCT06059326|DRUG|HSK7653 50 mg|Tablet, HSK7653 50 mg Q2W, 12 weeks
214808346|NCT06059326|DRUG|Placebo|Tablet, 0 mg Q2W, 12 weeks
214808347|NCT02458482|DEVICE|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
214808348|NCT02458482|DRUG|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
214808349|NCT05809765|OTHER|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
214808350|NCT01631565|BEHAVIORAL|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
214808351|NCT01631565|BEHAVIORAL|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
214808352|NCT01631565|BEHAVIORAL|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
214808353|NCT02199392|DRUG|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
214808354|NCT03200067|BEHAVIORAL|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
214808355|NCT01367340|BEHAVIORAL|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
214808356|NCT01367340|BEHAVIORAL|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
214808357|NCT00016419|BIOLOGICAL|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
214808358|NCT00016419|DRUG|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
214808359|NCT00595608|DRUG|Sterimar Spray|Post-op nasal spray, three times a day
214808360|NCT00595608|DRUG|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
214808361|NCT01297036|DRUG|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
214808362|NCT01297036|DRUG|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
214808363|NCT01357707|GENETIC|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
214808364|NCT00125307|DRUG|tacrolimus|
214808365|NCT05091385|BIOLOGICAL|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
214808366|NCT03681509|DRUG|Pramipexole|Pramipexole
214808367|NCT03681509|DRUG|Placebo|Lactose placebo capsule
214808368|NCT04522609|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session."
214808369|NCT02835261|OTHER|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
214808370|NCT00569374|DRUG|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
214808371|NCT04382937|DRUG|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
214808372|NCT04382937|DRUG|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
214808373|NCT02448927|DEVICE|balloon aortic valvuloplasty|
214808374|NCT02448927|DEVICE|Transcatheter Aortic Valve Implantation|
214808375|NCT00002349|DRUG|Stavudine|
214808376|NCT04896164|DRUG|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
214808377|NCT04896164|OTHER|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
214808378|NCT03004300|PROCEDURE|Rapid maxillary expansion|Device
214808379|NCT03004300|PROCEDURE|Adenotonsillectomy|Surgery
214808380|NCT00740493|DRUG|warfarin|18 months of warfarin therapy
214808381|NCT00740493|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy
214808382|NCT02992678|DRUG|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
214808383|NCT02992678|DRUG|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
214808384|NCT04574648|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
214808385|NCT05425381|BEHAVIORAL|Enhanced version of Interconnected Systems Framework|"* District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~* Detailed memoranda of understanding between schools and collaborating mental health centers~* Community mental health clinicians meaningfully participate in MTSS teams~* Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~* Universal screening of students' social, emotional, behavioral, and academic functioning~* Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~* Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~* Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~* A Community of Practice (Wenger, 2010) among the ISFE schools"
214808386|NCT05425381|BEHAVIORAL|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"* PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai \& Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~* SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
214808387|NCT00172055|DRUG|Zoledronic acid|
214808388|NCT05567874|OTHER|Nosocomial SARS-COV 2 Infection proportion|Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
214808389|NCT05561335|DEVICE|hearing aid -novel program|novel microphone configuration
214808390|NCT05561335|DEVICE|hearing aid - standard program|standard microphone configuration
214808391|NCT01743326|PROCEDURE|Radio Frequency Denervation|
214808392|NCT01743326|PROCEDURE|Local Anesthesia|
214808393|NCT03232437|DEVICE|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
214808394|NCT02554370|BEHAVIORAL|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
214808395|NCT02679053|BEHAVIORAL|Aerobic exercise|
214808396|NCT02679053|BEHAVIORAL|Placebo control|
214808397|NCT03366805|BEHAVIORAL|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
215031273|NCT03321942|DRUG|Control group|Conventional treatment were used to treat patients with chronic renal failure.
215031274|NCT00541424|PROCEDURE|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
215031275|NCT02480049|DRUG|Asmakast|1 tablet contains 10 mg of montelukast
215031276|NCT02480049|DRUG|Singulair|1 tablet contains 10 mg of montelukast
214808398|NCT03366805|BEHAVIORAL|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
214808399|NCT00535951|DRUG|LBH589|
214808400|NCT00064753|DRUG|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
214808401|NCT00064753|DEVICE|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
214808402|NCT03333291|DIETARY_SUPPLEMENT|fecal suspension|helathy donor fecal suspension administered by duodenal scope
214808403|NCT03389438|BIOLOGICAL|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
214808404|NCT03436225|DRUG|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
214808405|NCT03436225|DRUG|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
214808406|NCT03436225|DRUG|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
214808407|NCT03436225|DRUG|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
214808408|NCT04455581|DRUG|SHR-1209|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
214808409|NCT00784823|DRUG|Bortezomib 1 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
214808410|NCT00784823|DRUG|Bortezomib 1.3 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
214808411|NCT00784823|DRUG|Bortezomib 1.6 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
214808412|NCT00784823|DRUG|Melphalan|"* Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight"
214808413|NCT05088252|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
214808414|NCT05088252|DRUG|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
214808415|NCT00130988|BEHAVIORAL|DEPENAS cognitive and behavioural techniques|
214808416|NCT01194609|BIOLOGICAL|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
214808417|NCT01194609|RADIATION|Low dose radiation|20cGy whole body radiation every three weeks for three times
214808418|NCT03834870|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
214808419|NCT00841178|PROCEDURE|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
214808420|NCT00841178|PROCEDURE|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
214808421|NCT02550678|BIOLOGICAL|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
214808422|NCT02550678|DRUG|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
214808423|NCT02857088|BEHAVIORAL|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
214808424|NCT02857088|BEHAVIORAL|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
214808425|NCT02857088|BEHAVIORAL|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
214808426|NCT00004907|DRUG|busulfan|
214808427|NCT00004907|DRUG|cyclophosphamide|
214808428|NCT00004907|DRUG|etoposide|
214808429|NCT00004907|PROCEDURE|allogeneic bone marrow transplantation|
214808430|NCT00004907|PROCEDURE|bone marrow ablation with stem cell support|
214808431|NCT00004907|PROCEDURE|peripheral blood stem cell transplantation|
214808432|NCT00004907|RADIATION|radiation therapy|
214808433|NCT03205254|OTHER|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
214808434|NCT03205254|OTHER|Fast food diet|four days of participant-scaled isocaloric fast food meals
214808435|NCT04348162|OTHER|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
214808436|NCT01544127|BEHAVIORAL|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
214808437|NCT01544127|BEHAVIORAL|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
214808438|NCT01544127|OTHER|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
214808439|NCT04083846|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
214808440|NCT04083846|DRUG|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
214808441|NCT04083846|DRUG|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
214808442|NCT02870920|DRUG|Tremelimumab|
214808443|NCT02870920|DRUG|Durvalumab|
214808444|NCT02870920|OTHER|Best Supportive Care|
214808445|NCT00533273|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
214808446|NCT03619746|BEHAVIORAL|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
214808447|NCT05160350|DRUG|Probiotic|Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
214808448|NCT01799330|PROCEDURE|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
214808449|NCT01799330|OTHER|Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
214808450|NCT04053348|PROCEDURE|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
214808451|NCT04507425|OTHER|Standard of Care - Nasal Cannula|Standard of care. Flexible tube to provide extra oxygen when patients need a little help, but are not in respiratory distress.
214808452|NCT04507425|OTHER|High-flow nasal cannula|Same as nasal cannula, except the oxygen is heated or humidified and the flow is stronger, pushing air into the lungs to help keep the airway open.
214808453|NCT04507425|OTHER|HFNC plus non-invasive ventilation|This method uses HFNC as described above and adds noninvasive ventilation which is similar to CPAP machine and uses a mask rather than having to intubate (putting a tube down your throat to keep your airway from collapsing).
214808454|NCT03343730|DIAGNOSTIC_TEST|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
214808455|NCT03343730|DIAGNOSTIC_TEST|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
214808456|NCT04414072|PROCEDURE|sleeve gastrectomy with loop bipartition|operations to decrease weight
214808457|NCT00533663|PROCEDURE|Healing Touch|every other week (during their infusion)
214808458|NCT00533663|OTHER|Standard care|Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
214808459|NCT00533663|PROCEDURE|guided relaxation|
214808460|NCT05205759|DRUG|Bamlanivimab Etesevimab|Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
214808461|NCT05205759|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
214808462|NCT05205759|DRUG|Casirivimab-Imdevimab|Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
214808463|NCT04175964|BEHAVIORAL|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
214808464|NCT04175964|COMBINATION_PRODUCT|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
214808465|NCT04175964|BEHAVIORAL|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
214808466|NCT00363506|BEHAVIORAL|Serotona Plus and dietary behavior management|
214808467|NCT03088670|DRUG|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
214808468|NCT03088670|DRUG|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
214808469|NCT03088670|DRUG|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
214808470|NCT00768742|DEVICE|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
214808471|NCT02914600|DRUG|Filgotinib|Tablet administered orally once a day
214808472|NCT02914600|DRUG|Placebo|Tablet administered orally once a day
214808473|NCT02433106|OTHER|GAA 15|Neuromuscular injury prevention training
214808474|NCT02433106|OTHER|Control|Usual training
214808475|NCT00454909|BIOLOGICAL|Meningococcal vaccine 134612|Single dose intramuscular injection.
214808476|NCT00454909|BIOLOGICAL|Menactra®|Single dose intramuscular injection.
214808477|NCT05553197|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
214808478|NCT05553197|OTHER|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
214808479|NCT03991260|DIAGNOSTIC_TEST|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
214808480|NCT02457520|DRUG|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
214808481|NCT01087476|DRUG|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
214808482|NCT03064880|OTHER|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change \< 10% and maintained for 20 minutes
214808483|NCT05606562|PROCEDURE|Dental care|Participants will be offered free dental care
214808484|NCT03923465|PROCEDURE|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
214808485|NCT03923465|DEVICE|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
214647921|NCT04837417|DIAGNOSTIC_TEST|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
214647922|NCT05231213|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
214647923|NCT05231213|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
214808486|NCT03923465|DEVICE|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
214808487|NCT02107092|DRUG|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
214808488|NCT01292330|PROCEDURE|nutritional support before operation|nutritional support before operation for more than 4 days
214808489|NCT02581748|DRUG|HLX02|
214647924|NCT05900115|BEHAVIORAL|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
214647925|NCT05900115|BEHAVIORAL|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
214647926|NCT05906394|PROCEDURE|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
214647927|NCT02796573|BEHAVIORAL|cognitive behavioural therapy|
214647928|NCT03782454|DIAGNOSTIC_TEST|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
214647929|NCT00619502|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
214647930|NCT04993625|PROCEDURE|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
214647931|NCT01812902|PROCEDURE|Radical Prostatectomy|
214647932|NCT00771472|DRUG|vorinostat|Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
214808490|NCT02581748|DRUG|Herceptin|
214808491|NCT02703948|DEVICE|Restylane Silk with Lidocaine|
214808492|NCT03522675|DEVICE|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
214808493|NCT02149888|DRUG|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
214808494|NCT01586611|DRUG|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
214808495|NCT01586611|DRUG|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
214808496|NCT00707161|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
214808497|NCT00707161|DRUG|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
214808498|NCT00707161|PROCEDURE|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
214808499|NCT05280262|DIAGNOSTIC_TEST|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
214808500|NCT04877080|BIOLOGICAL|Fast Dual CAR-T Injection|Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA. A single infusion of CART cells will be administered intravenously.
214808501|NCT02763865|DEVICE|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
214808502|NCT02763865|DEVICE|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
214808503|NCT02758691|DRUG|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
214808504|NCT02758691|DRUG|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
214808505|NCT02076022|DEVICE|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
214808506|NCT02076022|PROCEDURE|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
214808507|NCT00312663|BIOLOGICAL|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
214808508|NCT05404386|OTHER|Training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence.|After the participants enrolled in the study, a training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence will be given to the participants.
214808509|NCT05404386|OTHER|3 months follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test (baseline), intermediate follow-up test (6th week), and post-test (12th week).
214808510|NCT05404386|BEHAVIORAL|"Mobile application which named as My Fighting with Incontinence"|"The mobile application My Fighting with Incontinence aims to reduce incontinence symptoms of women with UI, ensure compliance with Kegel exercises, increase health belief and quality of life regarding UI and kegel exercises, and also allow researchers to be included in the awareness and management process."
214808511|NCT05956366|BEHAVIORAL|Family-based treatment|Open-end family therapy ad modum The Maudsley model
214808512|NCT04927208|OTHER|exercise and nutritional support|"resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks"
214808513|NCT03808064|BEHAVIORAL|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
214808514|NCT05266521|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
214808515|NCT05275179|OTHER|Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
214808516|NCT03241784|BIOLOGICAL|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
214808517|NCT03241784|BIOLOGICAL|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
214808518|NCT04005859|DRUG|Exparel|"2\. Liposomal bupivacaine TAP block (experimental arm)~1. Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~2. A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~3. The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~4. Adhesive tapes will be applied at the level of the TAP block puncture sites."
214808519|NCT04005859|DRUG|IV Lidocaine|"1\. Intravenous Lidocaine infusion (control arm, current standard of care)~1. 100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~2. 1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~3. Adhesive tapes will be applied at the presumed level of TAP block puncture sites."
214808520|NCT03067207|BEHAVIORAL|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
214808521|NCT02832752|PROCEDURE|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is \< 60 minutes, and from emergency department (ED) arrival to ECMO flows \< 30 minutes.
214808522|NCT03341585|OTHER|expiration lente prolongée|l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
214808523|NCT00819507|DRUG|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
214808524|NCT00535054|DRUG|Tears Again|Liposome Eye Spray
214808525|NCT01259583|PROCEDURE|CO2|CO2 insufflation
214808526|NCT01259583|PROCEDURE|Warm water|warm water irrigation
214808527|NCT02052947|RADIATION|SPECT-DaTscan|"* Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~* LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
214808528|NCT03265977|BIOLOGICAL|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
214808529|NCT03265977|OTHER|Placebo|Normal saline
214808530|NCT05430698|DRUG|PD-1antibody plus GEMOX|"1. PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~3. Three weeks is a course of treatment,a total of 6-8 courses."
214808531|NCT01789905|DRUG|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
214808532|NCT03331497|PROCEDURE|Tonsillotomy|About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
214808533|NCT03250286|DEVICE|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
214808534|NCT03250286|DEVICE|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
214808535|NCT02661295|DRUG|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and \< 50% and ferritin ≥ 200 and \< 500 ng/ml after a 2 week wash out period.
214808536|NCT06272331|OTHER|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink
214808537|NCT06272331|OTHER|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
214808538|NCT06272331|OTHER|Cow's milk|Ingestion of cow's milk
214808539|NCT02829762|OTHER|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
214808540|NCT01364194|DRUG|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
214808541|NCT01364194|DRUG|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
214808542|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
214808543|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
214808544|NCT02722980|DIETARY_SUPPLEMENT|Placebo|The intervention consists of capsules containing placebo.
214808545|NCT02722980|DIETARY_SUPPLEMENT|: Probiotic capsules|The intervention consists of capsules containing probiotics.
214808546|NCT05567965|OTHER|Home care intervention|The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
214808547|NCT05345236|DRUG|Aflibercept|Intravitreal (IVT) injection
214808548|NCT01434147|DRUG|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
214808549|NCT01790347|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week."
214808550|NCT03702894|DRUG|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
214808551|NCT03702894|DRUG|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
214808552|NCT01603862|PROCEDURE|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
214808553|NCT01545830|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
214808554|NCT04037839|OTHER|Questionnaire|"Medical records of children aged 0-18 years who were prescribed a HFNC device at Schneider Children's between 2014-2018 for use in the home setting will be reviewed retrospectively. As part of the telephone consent process, parents will be offered to opt out at the beginning of the interview."
214808555|NCT01013467|BEHAVIORAL|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
214808556|NCT01376167|DRUG|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
214808557|NCT01376167|DRUG|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
214808558|NCT01376167|DRUG|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
214808559|NCT01376167|DRUG|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
214808560|NCT01376167|DRUG|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
214808561|NCT01376167|DRUG|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
214808562|NCT01376167|DRUG|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
214808563|NCT01376167|DRUG|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
214808564|NCT01376167|DRUG|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
214808565|NCT01376167|DRUG|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
214808566|NCT01376167|DRUG|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
214808567|NCT03064334|PROCEDURE|Total Knee Arthroplasty|surgical knee joints Arthroplasty
214808568|NCT04591717|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
214808569|NCT01826409|DIETARY_SUPPLEMENT|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
214808570|NCT01826409|DIETARY_SUPPLEMENT|Placebo|Placebo 2.7g/day for 4 weeks
214808571|NCT03541941|DRUG|Exparel|Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
214808572|NCT03541941|DRUG|Bupivacaine Hcl 0.25% Inj|Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
214808573|NCT03541941|DRUG|Placebo|Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
214808574|NCT04060823|OTHER|Easy Breathing program|Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
214808575|NCT05796310|DIAGNOSTIC_TEST|Salivary collection|Collection of saliva via swab for miRNA processing
214808576|NCT05796310|DIAGNOSTIC_TEST|eye-tracking recorder|Administration of eye-tracking session recording Saccadic Eye Movements, fixation duration and pupillary response.
214808577|NCT05796310|DIAGNOSTIC_TEST|neuropsychological assessment|Administration of neuropsychological tests and collected patient medical history
214808578|NCT04255719|PROCEDURE|DBS|Unilateral DBS for treatment of patients with PD
214808579|NCT05622461|BEHAVIORAL|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
214808580|NCT00193141|DRUG|Paclitaxel|
214808581|NCT00193141|DRUG|Carboplatin|
214808582|NCT00193141|DRUG|5-Fluorouracil|
214808583|NCT02099981|DRUG|Aminoguanidine|
214808584|NCT06238986|OTHER|Non-Interventional Study|Non-interventional study
214808585|NCT00802100|DRUG|Olanzapine|Daily tablets of 10 to 30 mg
214808586|NCT00802100|DRUG|Perphenazine|Daily tablets of 8 to 24 mg
214808587|NCT00802100|DRUG|Aripiprazole|Daily tablets of 10 to 30 mg
214808588|NCT00802100|DRUG|Metformin|Daily tablets of 850 to 2550 mg
214808589|NCT00802100|DRUG|Simvastatin|Daily tablets of 20 to 40 mg
214808590|NCT00802100|DRUG|Benztropine|Daily tablets of 1 to 2 mg
214808591|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
214808592|NCT02576925|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
214808593|NCT06139783|PROCEDURE|Exercise and dietary recommendations|Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
214808594|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
214808595|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
214808596|NCT06319963|DRUG|Two IM injections Lenti-HPV-07|two Lenti-HPV-07 intramuscular injections one month apart
214808597|NCT06319963|DRUG|One IM injection Lenti-HPV-07|a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
214808598|NCT01229852|DEVICE|DSF-rTMS|Effective Transcranial Magnetic Stimulation
214808599|NCT02688556|DRUG|cyclosporine|
214808600|NCT02688556|DRUG|vehicle of OTX-101|
214808601|NCT02952495|BEHAVIORAL|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
214808602|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
214808603|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
214808604|NCT01955590|BEHAVIORAL|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
214808605|NCT01955590|BEHAVIORAL|EMDR|8-12 sessions of manualized EMDR
214808606|NCT01955590|BEHAVIORAL|Treatment as usual|8-12 sessions of treatment of usual
214808607|NCT02403752|BEHAVIORAL|Paired PLIE Program|Integrative exercise as described above
214808608|NCT02849652|BEHAVIORAL|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
214808609|NCT02849652|BEHAVIORAL|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
214808610|NCT00565448|DRUG|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
214808611|NCT00565448|DRUG|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
214808612|NCT00565448|DRUG|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
214808613|NCT06039982|OTHER|no intervention|no intervention
214808614|NCT00472290|DRUG|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
214808615|NCT01325675|BEHAVIORAL|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
214808616|NCT00777829|DRUG|zolpidem|Participants will receive one dose of 10 mg before each nap.
214808617|NCT00777829|DRUG|Placebo|Participants will receive a dose of placebo before each nap.
214808618|NCT02472288|DEVICE|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
214808619|NCT02472288|DEVICE|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
214808620|NCT01575509|OTHER|Berry product|Sugar infused dried lingonberry
214808621|NCT01575509|OTHER|Bread product|Brown bread
214808622|NCT01575509|OTHER|Bread product|Whole grain bread
214808623|NCT01575509|OTHER|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
214808624|NCT01575509|OTHER|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
214808625|NCT04834037|BEHAVIORAL|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
214808626|NCT02877056|PROCEDURE|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
214808627|NCT03344445|OTHER|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
214808628|NCT05223556|DEVICE|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
214808629|NCT05223556|DEVICE|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
214808630|NCT00692653|BEHAVIORAL|P4|Tailored online decision support system for prostate cancer treatment decision making
214808631|NCT00370006|BIOLOGICAL|Towne CMV vaccine|
214808632|NCT03139019|BEHAVIORAL|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
214808633|NCT03139019|BEHAVIORAL|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
214808634|NCT03139019|BEHAVIORAL|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
214808635|NCT06206395|DEVICE|Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging|"2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment."
214808636|NCT02359305|DRUG|Acetaminophen|Acetaminophen given by IV
214808637|NCT02359305|DRUG|Acetaminophen|Acetaminophen suppository given rectally
214808638|NCT01890382|DIETARY_SUPPLEMENT|Whey protein|30 g in total; twice a day (morning and evening)
214808639|NCT01890382|DIETARY_SUPPLEMENT|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
214808640|NCT01890382|DIETARY_SUPPLEMENT|leucine supplementation|7.5 g/d in total; three times per day
214808641|NCT01890382|DIETARY_SUPPLEMENT|soy protein|30 g in total; twice a day
214808642|NCT01890382|DIETARY_SUPPLEMENT|creatine|6.0 g in total; twice a day
214808643|NCT01890382|DIETARY_SUPPLEMENT|placebo|
214808644|NCT03719222|OTHER|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
214808645|NCT01157091|DRUG|pazopanib hydrochloride|Given orally
214808646|NCT01157091|OTHER|laboratory biomarker analysis|Correlative studies
214808647|NCT01157091|OTHER|immunologic technique|Correlative studies
214808648|NCT05189405|DEVICE|INVOcell IVC|Embryo development in intravaginal incubation
214808649|NCT06001034|DEVICE|Occlusion training|Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
214808650|NCT02242292|DRUG|Hyoscine butylbromide|
214808651|NCT02242292|DRUG|Placebo|
214808652|NCT04856449|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.
214808653|NCT04856449|BEHAVIORAL|EMDR|EMDR sessions will be conducted to reprocess trauma-related memories.
214808654|NCT04526496|DRUG|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
214808655|NCT04526496|DRUG|Placebo, single dose|Placebo matched to FTP-198, oral suspension
214808656|NCT04526496|DRUG|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
214808657|NCT04526496|DRUG|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
214808658|NCT02995070|PROCEDURE|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
214808659|NCT02995070|DEVICE|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
214808660|NCT02995070|DEVICE|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
214808661|NCT04299178|DEVICE|X-PLO2R POC|Portable Oxygen Concentrator (POC)
214808662|NCT00582088|BIOLOGICAL|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
214808663|NCT00013351|PROCEDURE|Prevention of Falls|
214808664|NCT05719090|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
214808665|NCT02016170|DRUG|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
214808666|NCT02016170|DRUG|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
214808667|NCT02016170|DRUG|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
214808668|NCT00302952|DRUG|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
214808669|NCT00302952|DRUG|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
214808670|NCT04764565|DIETARY_SUPPLEMENT|Nuun Instant|Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
214808671|NCT04764565|OTHER|Water|water
214808672|NCT04764565|DIETARY_SUPPLEMENT|Nuun Electrolyte|Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
214808673|NCT02501057|BEHAVIORAL|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
214808674|NCT02501057|BEHAVIORAL|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
214808675|NCT02501057|BEHAVIORAL|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
214808676|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 1 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
214808677|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 2 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
214808678|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection placebo combined with Linezolid|After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
214808679|NCT04845165|OTHER|Biopsy|Biopsy of subcutaneous adipose tissue
214808680|NCT00429000|DEVICE|thermospot|
214808681|NCT03627585|DEVICE|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
214808682|NCT01692405|DEVICE|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
214808683|NCT01692405|PROCEDURE|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
214808684|NCT02597101|DRUG|Metformin|background drug
214808685|NCT02597101|DRUG|saxagliptin|background drug
214808686|NCT02597101|DRUG|AZD9668|study drug
214808687|NCT02597101|DRUG|placebo|placebo for AZD9668 to be added to background drugs
214808688|NCT01900080|OTHER|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
214808689|NCT01900080|OTHER|Standard ART Initiation|Standard ART Initiation
214808690|NCT01900080|OTHER|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count \>500 cells/mm3 (CD4 count within 7 days of HIV test)
214808691|NCT01900080|OTHER|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count \>500 cells/mm3
214808692|NCT04599699|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
214808693|NCT01092351|DRUG|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
214808694|NCT06496035|DEVICE|Blood Flow Restriction with low load exercise|Cuff/tourniquet will be applied to proximal leg at hip crease and inflated to 60-80% of limb occlusion pressure to decrease venous blood flow in the limb while performing exercise.
214808695|NCT06496035|OTHER|Therapeutic Exercise|Exercise performed at appropriate load as guided by physical therapist
214808696|NCT01066806|BEHAVIORAL|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
214808697|NCT01066806|OTHER|observation|observe normal dairy intake
214808698|NCT00985257|DEVICE|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
214808699|NCT02373098|DRUG|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
214808700|NCT05983874|BIOLOGICAL|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|100µg Month 0 and Month 3
214808701|NCT02077270|PROCEDURE|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
214808702|NCT02177981|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
214808703|NCT02177981|PROCEDURE|Control|The cuff will be placed around the arm but not inflated.
214808704|NCT05451030|DEVICE|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
214808705|NCT05070286|BEHAVIORAL|Observational Study.|Semi-structured interviews.
214808706|NCT01486121|OTHER|Therapy strategy|Sedation \& mechanical ventilation
214808707|NCT03666585|OTHER|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
214808708|NCT03666585|OTHER|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
214808709|NCT00473486|DRUG|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
214808710|NCT00473486|DRUG|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
215031277|NCT01489137|DRUG|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
214647933|NCT00412477|BIOLOGICAL|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
214647934|NCT01909284|DEVICE|Acupuncture|"* BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~* Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
214647935|NCT01909284|PROCEDURE|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
214647936|NCT03185689|BEHAVIORAL|Effectiveness of an intensified DSME in T2D adult patients|
214647937|NCT00845195|DRUG|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
214647938|NCT00845195|DRUG|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
214647939|NCT01420510|DRUG|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
214647940|NCT01420510|DRUG|Placebo vaginal gel|Application of a placebo vaginal gel
214647941|NCT00880750|DRUG|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
214647942|NCT00880750|DRUG|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
214647943|NCT02285179|DRUG|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
214647944|NCT02285179|DRUG|Tamoxifen|daily dose of 20 mg
214647945|NCT03890809|DRUG|BMS-986165|Oral administration
214647946|NCT05682014|BEHAVIORAL|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
214647947|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic retrosigmoid minimally invasive vestibular neurectomy
214647948|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic tenotomy of middle ear muscles
214647949|NCT00483327|DRUG|Megestrol Acetate|
214647950|NCT00239031|DRUG|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
214647951|NCT02087332|DRUG|Prolonged release Torasemide (Britomar)|
214647952|NCT02087332|DRUG|Torasemide (Diuver)|
214647953|NCT01184690|PROCEDURE|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
214647954|NCT01184690|PROCEDURE|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
214647955|NCT04120558|OTHER|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
214647956|NCT04120558|OTHER|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
214808711|NCT05728385|DIETARY_SUPPLEMENT|Modified Specific carbohydrate diet for 3 months|"All children at the start of the study will be subjected to:~1. Full history taking including demographic and medical history~2. Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~3. Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~4. At the beginning of the study and at the end~   1. The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~  2. Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~  3. Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score"
214808712|NCT04166032|DEVICE|Alertgy non-invasive continuous glucose monitoring device (ANICGM)|Alertgy non-invasive continuous glucose monitoring device (ANICGM)
214808713|NCT05826262|PROCEDURE|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
214808714|NCT02008565|DRUG|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
214808715|NCT02008565|DRUG|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
214808716|NCT02008565|BEHAVIORAL|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
214808717|NCT02008565|BEHAVIORAL|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
214808718|NCT04414605|DRUG|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
214808719|NCT04414605|DRUG|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
214808720|NCT02923388|DRUG|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
214808721|NCT02923388|DRUG|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
214808722|NCT02923388|DRUG|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
214808723|NCT02923388|DRUG|Placebo pill|Placebo pill orally thrice daily for 5 weeks
214808724|NCT06360913|DIAGNOSTIC_TEST|High resolution mass spectrometry|Metabolomics study
214808725|NCT05921955|DEVICE|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
214808726|NCT04305782|DEVICE|Release/Relock Socket - In Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.
214808727|NCT04305782|DEVICE|Release/Relock Socket - Out of Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.
215031278|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
214808728|NCT04305782|DEVICE|Release/Relock Socket & Control|The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
214808729|NCT00391105|DRUG|Remifentanil|
214808730|NCT04091256|OTHER|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
214808731|NCT01740219|BEHAVIORAL|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
214808732|NCT01740219|BEHAVIORAL|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
214808733|NCT02420444|BIOLOGICAL|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
214808734|NCT02420444|BIOLOGICAL|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
214808735|NCT02420444|BIOLOGICAL|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
214808736|NCT04095247|DEVICE|Vagus nerv stimulator|pulse triggered autostimulation
214808737|NCT02763085|DEVICE|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
214808738|NCT00801970|BEHAVIORAL|Psychological Treatment|15 weekly therapy sessions.
214808739|NCT00801970|BEHAVIORAL|Group Therapy|3 months of weekly group therapy sessions.
214808740|NCT02193178|DEVICE|comfilcon A Toric|Contact lenses
214808741|NCT04759885|DRUG|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
214808742|NCT04759885|DRUG|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
214808743|NCT04759885|DRUG|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
214808744|NCT04759885|DRUG|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
214808745|NCT04759885|DRUG|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
214808746|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK|horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror
214808747|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK|horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
214808748|NCT03435081|DRUG|Baricitinib|Administered orally
214808749|NCT03435081|DRUG|Placebo|Administered orally
214808750|NCT00420238|DRUG|Etanercept (Enbrel)|50 mg injection once weekly
214808751|NCT00420238|OTHER|Placebo|placebo
214808752|NCT05247658|OTHER|Therapeutic lens alone|Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
214808753|NCT05247658|OTHER|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
214808754|NCT05214560|DEVICE|Spinal needle|Insertion of a spinal needle to perform the neuraxial procedure.
214808755|NCT04734665|DRUG|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
214808756|NCT05764044|DRUG|cisplatin, gemcitabine|Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.
214808757|NCT05764044|OTHER|Follow-up|Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
214808758|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program|Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
214808759|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise|Passive knee flexion-extension movements + Incremental cycle ergometer exercise
214808760|NCT03916094|DRUG|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
214808761|NCT01850420|DRUG|IMC-1|
214808762|NCT04662996|BIOLOGICAL|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
214808763|NCT00886171|BEHAVIORAL|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
214808764|NCT00886171|BEHAVIORAL|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
214808765|NCT02748161|PROCEDURE|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
214808766|NCT03639311|DRUG|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
214808767|NCT03639311|DRUG|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
214808768|NCT03639311|DRUG|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
214808769|NCT03639311|DRUG|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
214808770|NCT00185705|DRUG|Telmisartan|
214808771|NCT04624412|OTHER|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down"
214808772|NCT04624412|OTHER|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down"
214808773|NCT01101802|DRUG|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
214808774|NCT01101802|DRUG|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
214808775|NCT01190163|DRUG|Dinoprostone|
214808776|NCT01190163|DRUG|Oxytocin|
214808777|NCT00032903|DRUG|Gimatecan® (ST 1481)|
214808778|NCT06080321|OTHER|WhatsApp reminders|"Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
214808779|NCT06080321|OTHER|Instagram reminders|"Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
215031279|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
214808780|NCT06080321|OTHER|Phone calls|"Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
214808781|NCT06080321|OTHER|Application alerts|"Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
214808782|NCT00054106|DRUG|buserelin|
214808783|NCT00054106|DRUG|custirsen sodium|
214808784|NCT00054106|DRUG|flutamide|
214808785|NCT00054106|PROCEDURE|conventional surgery|
214808786|NCT00054106|PROCEDURE|neoadjuvant therapy|
214808787|NCT04734288|DIETARY_SUPPLEMENT|Vit.D3 5000 IU, Immune Active|"The subjects will receive monthly (for either 3 or 6 months):~1. Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.~2. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.~3. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire."
214808788|NCT05297032|DIETARY_SUPPLEMENT|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
214808789|NCT02615847|DRUG|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
214808790|NCT02155205|DRUG|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
214808791|NCT02155205|DRUG|Placebo|Matching placebo
214808792|NCT02155205|DRUG|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
214808793|NCT00493142|OTHER|Exercise|
214808794|NCT00493142|OTHER|Usual care|
214808795|NCT05449249|PROCEDURE|Long-term fasting|The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
214808796|NCT03151057|DRUG|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
214808797|NCT03151057|DRUG|Placebo Oral Tablet|placebo
214808798|NCT02717390|BEHAVIORAL|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
214808799|NCT02717390|BEHAVIORAL|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
214808800|NCT00699491|BIOLOGICAL|Cixutumumab|Given IV
214808801|NCT00699491|OTHER|Laboratory Biomarker Analysis|Correlative studies
214808802|NCT00699491|OTHER|Pharmacological Study|Correlative studies
214808803|NCT00699491|DRUG|Temsirolimus|Given IV
214808804|NCT03018249|DRUG|Entinostat|Given PO
214808805|NCT03018249|PROCEDURE|Hysterectomy|Undergo hysterectomy
214808806|NCT03018249|OTHER|Laboratory Biomarker Analysis|Correlative studies
214808807|NCT03018249|DRUG|Medroxyprogesterone Acetate|Given IM
214808808|NCT01886326|OTHER|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
214808809|NCT01891266|PROCEDURE|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
214808810|NCT01891266|PROCEDURE|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
214808811|NCT00338481|DRUG|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
214808812|NCT00338481|DRUG|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
214808813|NCT05493930|OTHER|The hospital where the treatment is performed|
214808814|NCT03943433|PROCEDURE|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
214808815|NCT03943433|PROCEDURE|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
214808816|NCT02342054|RADIATION|MRI-TRUS fusion guided Single Frac HDR|
214808817|NCT00128154|DRUG|Chromium picolinate|
214808818|NCT03832257|OTHER|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
214808819|NCT03832257|OTHER|Matched Non-Participating Facilities|Matched Non-Participating Facilities
214808820|NCT03168633|BEHAVIORAL|web-based DM2 information pages|"Each email will include information on one of the following topics:~1. The importance of physical activity~2. Correct nutrition~3. The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
214808821|NCT01596166|DRUG|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
214808822|NCT01596166|DRUG|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
214808823|NCT02378571|BEHAVIORAL|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
214808824|NCT01114022|DEVICE|Experimental 1|oeso pharyngeal device
214808825|NCT01114022|DEVICE|Experimental|oeso pharyngeal device
214808826|NCT01114022|DEVICE|experimental 3|oeso pharyngeal device
214808827|NCT01114022|DEVICE|Active comparator|oeso pharyngeal device
214808828|NCT01194492|RADIATION|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
214808829|NCT04758260|DIETARY_SUPPLEMENT|Antioxidant|Oral antioxidant oral intake in the 3 months prior to inclusion in the study
214808830|NCT04881968|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
214808831|NCT01054027|DRUG|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
214808832|NCT00254644|PROCEDURE|Morphological and functional MRI|one time
214808833|NCT04067180|OTHER|allogeneic stem cell transplantation with a haplo-identical family donor graft|"The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil."
214808834|NCT04067180|OTHER|allogeneic stem cell transplantation with a matched unrelated donor graft|"Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied."
214808835|NCT04607863|DIAGNOSTIC_TEST|Case control|Is a case-control research
214808836|NCT00304083|BIOLOGICAL|filgrastim|Given subcutaneously
214808837|NCT00304083|DRUG|doxorubicin hydrochloride|Given IV
214808838|NCT00304083|DRUG|etoposide|Given IV
214808839|NCT00304083|DRUG|ifosfamide|Given IV
214808840|NCT00304083|PROCEDURE|conventional surgery|Patients undergo surgery
214808841|NCT00304083|RADIATION|radiation therapy|Patients undergo radiotherapy
214808842|NCT01589783|OTHER|completion of a questionnaire|Completion of a questionnaire
214808843|NCT01589783|OTHER|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
214808844|NCT02144753|DIETARY_SUPPLEMENT|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
214808845|NCT02144753|DRUG|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
214808846|NCT04616066|OTHER|Dates|The effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
214808847|NCT04616066|OTHER|Raisins|The effect of raisins phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
214808848|NCT05292651|PROCEDURE|PCI|percutaneous coronary intervention
214808849|NCT06237023|OTHER|epidemyolojical|The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
214808850|NCT00715702|DRUG|AZD5672|100 mg oral single dose
214808851|NCT02287675|DRUG|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
214808852|NCT02287675|DRUG|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
214808853|NCT01134848|DRUG|Morphine|10mg IM
214808854|NCT01134848|DRUG|Neostigmine|1mg IM
214808855|NCT01134848|DRUG|0.9% saline|0.1 ml/kg
214808856|NCT01134848|DRUG|Secretin|1 unit/kg IV
214808857|NCT01134848|DRUG|0.9% saline|1ml IM
214808858|NCT05470972|DRUG|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
214808859|NCT06035315|DIETARY_SUPPLEMENT|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
214647957|NCT04217343|DIAGNOSTIC_TEST|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
214647958|NCT01746251|DRUG|Afatinib|
214647959|NCT00249574|DRUG|Buprenorphine/naloxone|Human subjects HIV, HCV
214647960|NCT00249574|DRUG|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
214647961|NCT00670007|BIOLOGICAL|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
214647962|NCT00618722|DRUG|Deoxycholic Acid Injection|
214808860|NCT03966365|DRUG|PRO-122|"* PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic."
214647963|NCT00618722|DRUG|Placebo|
214647964|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
214808861|NCT03966365|DRUG|Krytantek Ofteno®|"* \- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* \- Route of administration: topical ophthalmic."
214808862|NCT03961425|BEHAVIORAL|NO CO2|Traditional mechanical Deairing
214808863|NCT03961425|DEVICE|CO2 Cannula|NON specific, low cost delivery system
214808864|NCT03961425|DEVICE|CO2 Cardia|Specific Commercial CO2 Diffuser
214808865|NCT03227497|DIETARY_SUPPLEMENT|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
214808866|NCT05939180|DRUG|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
214808867|NCT05939180|DRUG|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
214808868|NCT02578953|DRUG|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
215031280|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
215031281|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
215031282|NCT02053155|BEHAVIORAL|Computer based patient education|
214647965|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
214647966|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
214647967|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
214647968|NCT05825248|OTHER|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
214647969|NCT05825248|OTHER|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
214647970|NCT05949008|DRUG|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
214647971|NCT05949008|DRUG|Placebo|Matching placebo will be provided as 1000 mg capsules
214647972|NCT00624221|PROCEDURE|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
214647973|NCT04785612|BIOLOGICAL|RSVPreF|A single dose of 120 mcg RSVpreF for intramuscular injection
214647974|NCT04785612|OTHER|Placebo|A single Placebo dose for intramuscular injection to match experimental vaccine
214647975|NCT06957769|OTHER|heat stress|"Heat stress (exposure) will be quantified using validated environmental heat stress indices, including the Universal Thermal Climate Index (UTCI), Wet Bulb Globe Temperature (WBGT) and heat index (HI). The former two indices integrate four key environmental parameters, ambient temperature, relative humidity, solar radiation, and wind speed, to provide a quantified measure of thermal stress. The heat index represents the apparent temperature or how hot it feels to the human body when air temperature is combined with relative humidity.~Indoor heat exposure will be assessed using wearable temperature and humidity loggers, while outdoor environmental data, including temperature, humidity, radiation, and wind speed, will be captured using Kestrel WBGT devices installed in the study area."
214647976|NCT05192187|OTHER|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ"
214647977|NCT00200057|DEVICE|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
214647978|NCT01235676|BEHAVIORAL|diet|calorie restriction to reduce weight gain
214647979|NCT01235676|BEHAVIORAL|Exercise|Exercise to reduce weight gain
214647980|NCT01533727|DRUG|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
214647981|NCT01533727|DRUG|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
214647982|NCT03048955|DEVICE|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
214647983|NCT03048955|PROCEDURE|Direct decompression Surgery|A surgical procedure - the control
214647984|NCT02243384|PROCEDURE|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
214647985|NCT02243384|PROCEDURE|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
214647986|NCT00510705|OTHER|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
214647987|NCT00510705|OTHER|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
214808869|NCT02578953|DRUG|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
214808870|NCT01044732|DEVICE|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
214808871|NCT03918278|BIOLOGICAL|MK-0482|IV infusion
214808872|NCT03918278|BIOLOGICAL|pembrolizumab|IV infusion
214808873|NCT03918278|DRUG|Paclitaxel|IV infusion
214808874|NCT03918278|DRUG|Nab-paclitaxel|IV infusion
214808875|NCT03918278|DRUG|Gemcitabine|IV infusion
214808876|NCT03918278|DRUG|Carboplatin|IV infusion
214808877|NCT03918278|DRUG|Pemetrexed|IV infusion
214808878|NCT00769041|DRUG|moxifloxacin|400mg
214808879|NCT00769041|DRUG|avanafil|100mg single dose
214808880|NCT00769041|DRUG|avanafil|800mg single dose
214808881|NCT00769041|DRUG|sugar pill|single dose
214808882|NCT04137211|BEHAVIORAL|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
214808883|NCT04137211|BEHAVIORAL|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
214808884|NCT04137211|BEHAVIORAL|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
214808885|NCT00003961|BIOLOGICAL|sargramostim|
214808886|NCT04510077|BEHAVIORAL|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
214808887|NCT04510077|OTHER|Survey Administration|Ancillary studies
214808888|NCT02425579|DRUG|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
214808889|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
214808890|NCT02425579|DRUG|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
214647988|NCT00510705|OTHER|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
214647989|NCT04968418|DEVICE|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
214647990|NCT03575026|BEHAVIORAL|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
214647991|NCT03575026|BEHAVIORAL|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
214647992|NCT00227201|BEHAVIORAL|Self-affirmation intervention|
214647993|NCT06122402|OTHER|SECURE Care Bundle|The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including CHG dressing and silicone based remover.
214647994|NCT06122402|PROCEDURE|Standart Care|It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
214647995|NCT00778830|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
214647996|NCT00778830|DRUG|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
214647997|NCT00778830|DRUG|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
214647998|NCT03752125|DIETARY_SUPPLEMENT|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
214647999|NCT03752125|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
214648000|NCT04323371|DIAGNOSTIC_TEST|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
214648001|NCT00061711|DRUG|Hormone Replacement Therapy|
214648002|NCT00061711|DRUG|Cimicifuga racemosa (Black Cohosh)|
214648003|NCT00061711|DRUG|Multibotanical phytoestrogen formula|
214648004|NCT01241500|DRUG|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
214648005|NCT02151825|DIETARY_SUPPLEMENT|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
214648006|NCT02151825|OTHER|Placebo|3 capsules of Maltodextrin per day
214648007|NCT05020379|PROCEDURE|Perioperative and postoperative multimodal analgesia|"Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day."
214808891|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
214808892|NCT00081783|DRUG|Xcellerated T Cells|
214808893|NCT03455348|OTHER|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
214808894|NCT00258947|BIOLOGICAL|Smallpox vaccine, LISTER strain, from chick embryo cells|
214808895|NCT00899028|GENETIC|comparative genomic hybridization|
214808896|NCT00899028|GENETIC|fluorescence in situ hybridization|
214808897|NCT00899028|GENETIC|gene expression analysis|
214808898|NCT00899028|GENETIC|microarray analysis|
214808899|NCT00899028|GENETIC|protein expression analysis|
214808900|NCT00899028|OTHER|immunohistochemistry staining method|
214808901|NCT00899028|OTHER|laboratory biomarker analysis|
214808902|NCT00899028|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
214808903|NCT00899028|OTHER|medical chart review|
214808904|NCT00899028|PROCEDURE|diagnostic bronchoscopy|
214808905|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
214808906|NCT05666349|DRUG|Niraparib|100 mg, 200 mg, or 300mg oral niraparib once daily.
214808907|NCT05666349|RADIATION|Re-irradiation (re-RT)|Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.
214808908|NCT01523899|DEVICE|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
214808909|NCT01523899|DIAGNOSTIC_TEST|Standard culture|
214808910|NCT05412732|OTHER|prospective biomedical research study|A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
214808911|NCT05411809|DRUG|drug adjuvant therapy|The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
214808912|NCT00824265|DRUG|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
214808913|NCT00824265|DRUG|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
214808914|NCT01195259|DRUG|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
214808915|NCT04752748|DRUG|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48."
214808916|NCT03917771|OTHER|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
214808917|NCT03917771|OTHER|Usual follow-up|Usual follow-up carried out in GO consultation
214808918|NCT05249413|PROCEDURE|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
214808919|NCT01624220|RADIATION|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
214808920|NCT01624220|RADIATION|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
214808921|NCT01624220|PROCEDURE|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
214808922|NCT01624220|BEHAVIORAL|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
214808923|NCT03556566|BIOLOGICAL|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
214808924|NCT05245643|DEVICE|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
214808925|NCT00002012|DRUG|Interferon alfa-n3|
214808926|NCT01740609|DRUG|Placebo|Placebo
214808927|NCT01740609|BIOLOGICAL|PF-06342674 Dose A|Single SC Dose
214808928|NCT01740609|BIOLOGICAL|PF-06342674 Dose B|Single SC Dose
214808929|NCT01740609|BIOLOGICAL|PF-06342674 Dose C|Single SC Dose
214808930|NCT01740609|BIOLOGICAL|PF-06342674 Dose D|Single SC Dose
214808931|NCT01740609|BIOLOGICAL|PF-06342674 Dose E|Single SC Dose
214808932|NCT01740609|BIOLOGICAL|PF-06342674 Dose F|Single IV Dose
214808933|NCT01740609|BIOLOGICAL|PF-06342674 Dose G|Single SC Dose
214808934|NCT01740609|BIOLOGICAL|PF-06342674 Dose H|Single IV Dose
214808935|NCT01740609|BIOLOGICAL|PF-06342674 Dose I|Single SC Dose
214808936|NCT01740609|BIOLOGICAL|PF-06342674 Dose J|Single IV Dose
214808937|NCT01471366|DIETARY_SUPPLEMENT|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
214808938|NCT01471366|DIETARY_SUPPLEMENT|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
214808939|NCT01471366|DIETARY_SUPPLEMENT|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
214808940|NCT01471366|DIETARY_SUPPLEMENT|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
214808941|NCT00912353|DRUG|AZD7268|Single Oral
214808942|NCT00912353|DRUG|Placebo|Single Oral
214808943|NCT01402947|DRUG|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
214808944|NCT01402947|DRUG|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
214808945|NCT03634709|BEHAVIORAL|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
214808946|NCT03716011|DEVICE|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
214808947|NCT06756607|OTHER|SUPPORT toolkit|The SUPPORT toolkit comprises of the SUPPORT CT website and interaction with a SUPPORT navigator.
214808948|NCT06930703|DRUG|Cannabidiol|Cannabidiol (CBD) twice daily taken orally for 4-weeks
214808949|NCT06930703|DRUG|Placebo|Placebo equivalent twice daily taken orally for 4-weeks
214808950|NCT02417805|PROCEDURE|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
214808951|NCT02836847|PROCEDURE|biological test|mutation and signal pathway activation status analysis
214808952|NCT02836847|DRUG|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
214808953|NCT02836847|DRUG|Cetuximab|
214808954|NCT02836847|DRUG|Trastuzumab|
214808955|NCT02836847|DRUG|Gefitinib|
214808956|NCT02836847|DRUG|Lapatinib|
214808957|NCT02836847|DRUG|Everolimus|
214808958|NCT02836847|DRUG|Sorafenib|
214808959|NCT02836847|DRUG|Crizotinib|
214808960|NCT00756080|DRUG|citrulline|0.06 G/kg three times/day during 7 days
214808961|NCT00756080|DRUG|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
214808962|NCT00868010|DRUG|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
214808963|NCT00868010|DRUG|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
214808964|NCT00218205|DRUG|Epirubicin|
214808965|NCT00218205|DRUG|Estramustine Phosphate|
214808966|NCT00218205|DRUG|Celecoxib|
214808967|NCT06202196|PROCEDURE|Risk prevention session|"The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS)."
214808968|NCT06202196|PROCEDURE|Usual Therapeutic Patient Education (TPE) management|The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
214808969|NCT00115726|DRUG|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
214808970|NCT00115726|DRUG|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
214808971|NCT03859466|DEVICE|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
214808972|NCT01497652|DRUG|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
214808973|NCT01497652|DRUG|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
214808974|NCT01248247|DRUG|Erlotinib|150 mg by mouth each day of a 28 day cycle.
214808975|NCT01248247|DRUG|AZD6244|100 mg by mouth daily of a 28 day cycle.
214808976|NCT01248247|DRUG|MK-2206|100 mg by mouth every week of a 28 day cycle.
214808977|NCT01248247|DRUG|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
214808978|NCT01248247|DRUG|Erlotinib|150 mg by mouth daily of a 28 day cycle.
214808979|NCT01248247|DRUG|MK-2206|135 mg by mouth every week of a 28 day cycle.
214808980|NCT03164889|DRUG|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
214808981|NCT03164889|DRUG|Entecavir|Antiviral drug for hepatitis b virus (HBV)
214808982|NCT05872217|OTHER|conventional upper extremity therapeutic program|"• This group will receive conventional UE therapeutic program for 60 minutes each session including:~* Exercises based on neurodevelopment technique .~* Gentle manual stretching for tight muscles of the affected UE from proximal to distal segments for 5minutes.~* Weight-bearing exercises for 10minutes for UE from prone lying, side sitting and quadriped position.~* Strengthening exercises for 10 minutes for muscles of UE as push-up from prone lying position, quadriped position, 3 point exercise, walk on hand, climbing, hanging on a bar, squeeze stress balls, cutting usescissors to strengthen hand .~* Goal directed training for 10 minutes the child will practice specific tasks that are needed for everyday life and which they find a challenge like (3 daily tasks as cleaning mirror, dressing and undressing, using pen and ruler to draw shapes, brushing teeth .~* Fine motor activities as reach, grasp, carry and release activities."
214808983|NCT05872217|OTHER|full immersive VRapeutic software gaming technology|• Children in this group will receive the same conventional UE therapeutic program as control group for 60 minutes in addition to virtual reality session using VRapeutic software gaming technology, Archeeko module (figure 3) for 30 min/3 sessions/week for 8 weeks
214808984|NCT00736970|DRUG|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
214808985|NCT00736970|DRUG|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
214808986|NCT03962023|OTHER|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
214808987|NCT03363503|DRUG|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
214808988|NCT03363503|DRUG|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
214808989|NCT02214264|BEHAVIORAL|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
214808990|NCT02214264|BEHAVIORAL|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
214808991|NCT02214264|BEHAVIORAL|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
214808992|NCT02214264|BEHAVIORAL|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
214808993|NCT01231490|DRUG|Placebo|Placebo
214808994|NCT01231490|DRUG|Naproxen|Capsule
214808995|NCT02341261|BEHAVIORAL|Standard Care Counseling|
214808996|NCT02341261|BEHAVIORAL|Supervised Exercise and Counseling|
214808997|NCT05088005|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
214808998|NCT05940909|DRUG|Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet|"Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine."
214808999|NCT03456947|DRUG|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
214809000|NCT02126137|DRUG|Ezetimibe|
214809001|NCT02185872|OTHER|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
214809002|NCT02185872|OTHER|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
214809003|NCT02236494|BEHAVIORAL|Brief Negotiated Interview|As per arm
214809004|NCT02236494|BEHAVIORAL|General Health Information|As per arm (this is the active comparator)
214809005|NCT01108094|DRUG|Itraconazole|"* Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
214809006|NCT02822820|DEVICE|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
214809007|NCT02822820|DEVICE|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
214809008|NCT05254301|OTHER|Intervention group|This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance \& follow-up, low-threshold activities, homebased functional training \& better follow-up guidance afterwards).
214809009|NCT01796886|OTHER|pupillometry data|
214809010|NCT03412357|PROCEDURE|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
214809011|NCT03412357|PROCEDURE|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
214809012|NCT04349917|DRUG|Methylphenidate|A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
214809013|NCT04349917|OTHER|Placebo|A matching placebo pill will be administered on the placebo day.
214809014|NCT02992938|DRUG|Acetazolamide|
214809015|NCT02992938|DRUG|Placebo Oral Tablet|
214809016|NCT01287910|OTHER|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
214809017|NCT00705536|DRUG|Humalog|
214809018|NCT00705536|DRUG|Humulin-R|
214809019|NCT00705536|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
214809020|NCT01861379|PROCEDURE|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
214809021|NCT01382641|DEVICE|Hoya AF-1 IOL|The patients will be assessed for three months
214809022|NCT01382641|DEVICE|Revital vision|The patients will be assessed for three months.
214809023|NCT04188106|DRUG|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
214809024|NCT04188106|DRUG|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
214809025|NCT05221242|PROCEDURE|Conventional Resin Cement vs Preheated Resin Composite|For this study, variolink esthetic resin cement will be used to bond ceramic partial laminate veneers in one side of the maxillary anterior teeth (left or right upper incisors and canines), while, the other side will receive ceramic partial laminate veneers bonded with a preheated resin composite
214809026|NCT05125419|DIAGNOSTIC_TEST|Homocysteine level|diagnostic test
214809027|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 1|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets."
214809028|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 2|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets."
214809029|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 3|"The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets."
214809030|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 4|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets."
214809031|NCT01113424|DRUG|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
214809032|NCT01113424|DRUG|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
214809033|NCT05926570|DRUG|Cinacalcet|calcimimetic
214809034|NCT01356693|DRUG|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
214809035|NCT01356693|DRUG|Placebo|Placebo with mimicking characteristics of experimental drug
214809036|NCT00441467|DRUG|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
214809037|NCT00322166|OTHER|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
214809038|NCT00322166|OTHER|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
214809039|NCT00322166|OTHER|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
214809040|NCT02289963|DRUG|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
214809041|NCT02289963|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
214809042|NCT02289963|DRUG|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
214809043|NCT04140318|DRUG|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
214809044|NCT04140318|DRUG|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
214809045|NCT03514420|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx solution for SC injection.
214809046|NCT00269776|DRUG|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
214809047|NCT00269776|DRUG|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
214809048|NCT00269776|DRUG|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
214809049|NCT00410865|GENETIC|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
214809050|NCT01042522|BIOLOGICAL|Bleomycin Sulfate|Given IV
214809051|NCT01042522|DRUG|Carboplatin|Given IV
214809052|NCT01042522|DRUG|Cisplatin|Given IV
214809053|NCT01042522|DRUG|Etoposide Phosphate|Given IV
214809054|NCT01042522|OTHER|Laboratory Biomarker Analysis|Correlative studies
214809055|NCT01042522|DRUG|Paclitaxel|Given IV
214809056|NCT00675935|OTHER|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
214809057|NCT06217224|OTHER|Preventive photobiomodulation Therapy (PBMT)|The application of preventive TLBP will be performed with a laser device containing an aluminum phosphide and indium gallium diode (InGaAlP) emitting radiation in the red region of the electromagnetic spectrum (660 nm) with a power of 100mW and a beam area of 0.03 cm2 . An energy of 1J/point and an energy density of 33.3 J/cm2/point were determined, which will be applied punctually, with a distance between the points of 1cm, for 10s per point, totaling 9 points per region.
214809058|NCT00549718|DRUG|Lurasidone HCl|Once daily
214809059|NCT02372149|DRUG|10% intravenous immunoglobulin (IVIg)|
214809060|NCT02372149|DRUG|0.9% sodium chloride|
214809061|NCT04742283|DRUG|DE-126 Ophthalmic Solution 0.002% QD|DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
214809062|NCT04742283|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution BID (morning and evening)
214809063|NCT04783051|DRUG|Sulfadoxine pyrimethamine|Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine
214809064|NCT04783051|DRUG|Pyramax|Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
214809065|NCT01641068|OTHER|Cognitive Intervention|Participate in memory and thinking skills workshop
214809066|NCT01641068|OTHER|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
214809067|NCT01641068|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
214809068|NCT01641068|OTHER|Memory Intervention|Participate in memory and thinking skills workshop
214809069|NCT01641068|OTHER|Quality-of-Life Assessment|Ancillary studies
214809070|NCT01641068|OTHER|Questionnaire Administration|Ancillary studies
214809071|NCT02545205|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
214809072|NCT02545205|OTHER|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
214809073|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
214809074|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
214809075|NCT01825447|DRUG|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
214809076|NCT01825447|DRUG|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
214809077|NCT01825447|DRUG|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
214809078|NCT06036498|DEVICE|Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography|We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
214809079|NCT01507051|DRUG|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
214809080|NCT01507051|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
214809081|NCT01507051|DRUG|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
214809082|NCT01507051|DRUG|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
214809083|NCT00371722|PROCEDURE|Appendectomy|
214809084|NCT01675622|DRUG|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
214809085|NCT01675622|DRUG|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
214809086|NCT03004105|DRUG|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
214809087|NCT03004105|DRUG|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
214809088|NCT03004105|BEHAVIORAL|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
214809089|NCT03016858|PROCEDURE|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
214809090|NCT04132622|DRUG|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
214809091|NCT04132622|DRUG|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
214809092|NCT04609722|OTHER|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
214809093|NCT04127656|OTHER|Amino Acid-Based Experimental Study Formula|Amino Acid-Based Formula; fed ad libitum
214809094|NCT04032977|DEVICE|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
214809095|NCT04032977|DEVICE|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
214809096|NCT01086254|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
214809097|NCT01086254|DRUG|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
214809098|NCT01086254|DRUG|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
214809099|NCT04282954|DRUG|JP-1366|JP-1366, QD
214809100|NCT04282954|DRUG|JP-1366 placebo|JP-1366 placebo, QD
214809101|NCT04282954|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, QD
214809102|NCT04282954|DRUG|Esomeprazole placebo|Esomeprazole placebo, QD
214809103|NCT03377894|PROCEDURE|blunt uterine incision expansion|blunt uterine incision expansion
214809104|NCT03377894|PROCEDURE|sharp uterine incision expansion|sharp uterine incision expansion
214809105|NCT03018717|OTHER|Telemonitoring Constant|telemedicine of Constant
214809106|NCT03018717|OTHER|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
214809107|NCT04262934|DRUG|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
214809108|NCT04262934|OTHER|No vitamin D administration|No vitamin D administration
214809109|NCT03871361|DRUG|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly
214809110|NCT02909478|DRUG|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
214809111|NCT02909478|DRUG|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
214809112|NCT06161961|DEVICE|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
214809113|NCT02880761|PROCEDURE|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
214809114|NCT00817661|DIETARY_SUPPLEMENT|Vitamin A|10000 IU Vitamin A or placebo per week
214809115|NCT00817661|DIETARY_SUPPLEMENT|Placebo|10000 IU Vitamin A or placebo per week
214809116|NCT03808805|DRUG|Aprepitant 80 mg|oral therapy - daily dose - 14 days
214809117|NCT03808805|DRUG|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
214809118|NCT03808805|DRUG|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
214809119|NCT03808805|DRUG|Placebo of Aprepitant|oral therapy - daily dose - 14 days
214809120|NCT03203876|BIOLOGICAL|Lirilumab|Specified dose on specified days
214809121|NCT03203876|BIOLOGICAL|Nivolumab|Specified dose on specified days
214809122|NCT03203876|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214809123|NCT01134094|PROCEDURE|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
214809124|NCT01134094|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
214809125|NCT05705180|BIOLOGICAL|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
214809126|NCT06440499|DIAGNOSTIC_TEST|US|Us
214809127|NCT01688934|DRUG|V116517 50-mg tablets|Taken orally twice daily
214809128|NCT01688934|DRUG|V116517 30-mg tablets|Taken orally twice daily
214809129|NCT01688934|DRUG|Naproxen 500-mg capsules|Taken orally twice daily
214809130|NCT01688934|DRUG|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
214809131|NCT00356785|BEHAVIORAL|health education|
214809132|NCT00356785|BEHAVIORAL|food supplementation|
214809133|NCT00356785|BEHAVIORAL|food supplementation combined with physical activity program|
214809134|NCT02442934|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
214809135|NCT02442934|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
214809136|NCT02442934|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
214809137|NCT03597256|DEVICE|Restylane Defyne|Intradermal injection
214809138|NCT06370754|DRUG|JS001|240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
214809139|NCT06370754|DRUG|JS004|200 mg by IV infusion Q3W, given on cycle day 1.
214809140|NCT06370754|DRUG|JS007|3mg/kg by IV infusion Q3W, given on cycle day 1.
214809141|NCT06370754|DRUG|JS015|600mg by IV infusion Q3W, given on cycle day 1.
214809142|NCT06370754|DRUG|Irinotecan Liposome Injection|60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
214809143|NCT06370754|DRUG|5-Fluorouracil (5-FU)|2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
214809144|NCT06370754|DRUG|Leucovorin (LV)|400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
214809145|NCT06370754|DRUG|Nab paclitaxel|125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
214809146|NCT06370754|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
214809147|NCT04167267|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
214809148|NCT04167267|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
214809149|NCT05612867|DIETARY_SUPPLEMENT|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
214809150|NCT04306133|PROCEDURE|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
214809151|NCT04306133|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
214809152|NCT02943447|DRUG|Cilofexor|Tablet(s) administered orally once daily, with food
214809153|NCT02943447|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily, with food
214809154|NCT04092751|DRUG|PRA|Single oral 20-mg dose of PRA on Day 1 AM
214809155|NCT04092751|DRUG|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
214809156|NCT02106156|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
214809157|NCT02106156|DRUG|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
214809158|NCT01907334|DRUG|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
214809159|NCT01907334|DRUG|Flovent Diskus 100 µg|Flovent Diskus 100 µg
214809160|NCT01907334|DRUG|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
214809161|NCT01907334|DRUG|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
214809162|NCT05636319|BIOLOGICAL|ABO1020|Vaccine
214809163|NCT05636319|BIOLOGICAL|Placebo|Placebo
214809164|NCT02345941|OTHER|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
214809165|NCT02345941|OTHER|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
214809166|NCT03826745|OTHER|Plasma/Urine|Plasma of normal male and female normotensive, hypertensive, and/or resistant hypertensive subjects.
214809167|NCT03751345|BEHAVIORAL|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
214809168|NCT04138745|OTHER|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
214809169|NCT02485977|DEVICE|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
214809170|NCT00409162|DEVICE|Eraser TM device, with washing fluid|
214809171|NCT03059966|PROCEDURE|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
214809172|NCT03059966|BIOLOGICAL|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
214809173|NCT03224494|DEVICE|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
214809174|NCT03224494|OTHER|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
214809175|NCT03224494|OTHER|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
214809176|NCT06161623|BEHAVIORAL|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
214809177|NCT06559735|DEVICE|CereVu Device|Observational, non-invasive measurements
214809178|NCT00377416|GENETIC|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
214809179|NCT00581139|BEHAVIORAL|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
214809180|NCT00581139|DRUG|Midazolam|0.5 mg/kg oral midazolam
214809181|NCT00581139|BEHAVIORAL|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
214809182|NCT00581139|OTHER|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
214809183|NCT04638179|OTHER|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
214809184|NCT01332864|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
214809185|NCT01332864|PROCEDURE|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
214809186|NCT03545828|DIAGNOSTIC_TEST|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
214809187|NCT02080845|DIETARY_SUPPLEMENT|no caffeine|
214809188|NCT02080845|DIETARY_SUPPLEMENT|high caffeine|
214809189|NCT02080845|DIETARY_SUPPLEMENT|no theobromine|
214809190|NCT02080845|DIETARY_SUPPLEMENT|low theobromine|
214809191|NCT02080845|DIETARY_SUPPLEMENT|high theobromine|
214809192|NCT02982356|PROCEDURE|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16\~24 weeks, 24\~27+6 weeks,\>28weeks
214809193|NCT02982356|DRUG|Potassium Chloride|
214809194|NCT04320420|OTHER|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
214809195|NCT03633474|BIOLOGICAL|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
214809196|NCT03633474|OTHER|PBS only|Sterile PBS only containing no bacteria
214809197|NCT01887691|DRUG|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
214809198|NCT01996527|DEVICE|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
214809199|NCT01996527|DEVICE|CEST-MRI|Undergo CEST-MRI
214809200|NCT01996527|DEVICE|DW-MRI|Undergo DWI-MRI
214809201|NCT01996527|DEVICE|DCE-MRI|Undergo DCE-MRI
214809202|NCT01996527|DEVICE|DSC-MRI|Undergo DSC-MRI
214809203|NCT01996527|DRUG|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
214809204|NCT06328491|DRUG|Erdafitinib|Protein Kinase Inhibitor
214809205|NCT05017480|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
214809206|NCT05017480|DRUG|Placebo|subcutaneous(SC) injection
214809207|NCT01136382|DRUG|budesonide|pMDI, inhalation, bid, 6 weeks
214809208|NCT01136382|DRUG|placebo|pMDI, inhalation, bid, 6 weeks
214809209|NCT00963482|BEHAVIORAL|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
214809210|NCT00963482|BEHAVIORAL|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
214809211|NCT01794039|DRUG|Dexamethasone|Given PO
214809212|NCT01794039|DRUG|Lenalidomide|Given PO
214809213|NCT01794039|DRUG|Pomalidomide|Given PO
214809214|NCT03521765|OTHER|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
214809215|NCT00000310|DRUG|Risperidone|
214809216|NCT04915053|DIETARY_SUPPLEMENT|ABG+ Black Garlin|Daily tablet intake during three months
214809217|NCT04915053|DIETARY_SUPPLEMENT|Crystalline Cellulose|Daily tablet intake during three months
214809218|NCT02885285|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
214809219|NCT02885285|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
214809220|NCT02885285|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
214809221|NCT02885285|OTHER|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
214809222|NCT00027053|DRUG|Trazodone|50 to 150 mg qhs
214809223|NCT00027053|DRUG|Placebo|
214809224|NCT01992991|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
214809225|NCT05167760|DRUG|Apraclonidine|1-2 drops per eye every 8 hours for 2 weeks
214809226|NCT02071303|DRUG|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
214809227|NCT02071303|DRUG|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
214809228|NCT02071303|DRUG|Placebo|A placebo will be given to 70 women before the procedure.
214809229|NCT06093802|DIAGNOSTIC_TEST|Drug-induced Sleep Endoscopy findings (identified obstruction sites)|As described above
214809230|NCT02548234|OTHER|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
214809231|NCT02548234|OTHER|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
214809232|NCT02063841|DEVICE|lead-free protective drape containing bismuth and antimony (RADPAD®)|
214809233|NCT02063841|DEVICE|sterile identical sham drape|
214809234|NCT00485472|DRUG|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
214809235|NCT00485472|OTHER|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
214809236|NCT05767619|DIAGNOSTIC_TEST|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
214809237|NCT05767619|DIAGNOSTIC_TEST|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
214809238|NCT02455492|OTHER|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
214809239|NCT00403715|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
214809240|NCT01789385|DRUG|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
214809241|NCT06561399|COMBINATION_PRODUCT|TACE, Lenvatinib combination with Sintilimab sequential radiotherapy|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team
214809242|NCT00437138|BEHAVIORAL|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
214809243|NCT01274988|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
214809244|NCT01274988|OTHER|methadone maintenance treatment|methadone maintenance treatment
214809245|NCT02889848|OTHER|Saline|Saline injection
214809246|NCT02889848|DRUG|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
214809247|NCT02658045|DEVICE|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
214809248|NCT02658045|DEVICE|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
214809249|NCT00416845|DRUG|FTY720|
214809250|NCT00088829|DRUG|paclitaxel|subjects will receive paclitaxel neoadjuvantly
214809251|NCT00088829|GENETIC|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
214809252|NCT00088829|PROCEDURE|biopsy|All subjects will have a biopsy to collect tissue
214809253|NCT00088829|PROCEDURE|neoadjuvant therapy|paclitaxel is given neoadjuvantly
214809254|NCT00088829|DRUG|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
214809255|NCT02711449|DRUG|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
214809256|NCT02711449|DRUG|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
214809257|NCT01194648|OTHER|questionnaire administration|
214809258|NCT01194648|PROCEDURE|assessment of therapy complications|
214809259|NCT01194648|PROCEDURE|high-intensity focused ultrasound ablation|
214809260|NCT01194648|PROCEDURE|multiparametric magnetic resonance imaging|
214809261|NCT01194648|PROCEDURE|quality-of-life assessment|
214809262|NCT01194648|PROCEDURE|transperineal prostate biopsy|
214809263|NCT01194648|PROCEDURE|transrectal prostate biopsy|
214809264|NCT04438239|OTHER|none, this study is observational|none, this study is observational
214809265|NCT00633594|DRUG|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
214809266|NCT00633594|DRUG|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
214809267|NCT00633594|DRUG|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
214809268|NCT06627699|DEVICE|Total Knee Arthroplasty|Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
214809269|NCT01358344|DRUG|Pantoprazole|40 mg delayed-release tablet administered orally in the morning of Days 1-7
214809270|NCT01358344|DRUG|SCH 530348 (high percentage)|2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
214809271|NCT01358344|DRUG|SCH 530348 (standard percentage)|2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
214809272|NCT06293196|OTHER|acupressure|Massage acupoints and non-acupoint areas around the eyes.
214809273|NCT01887548|OTHER|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
214809274|NCT03535896|OTHER|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
214809275|NCT03535896|DRUG|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
214809276|NCT06062277|DRUG|Colchicine 0.5 MG|one oral tablet daily for 30 days
214809277|NCT01209793|BIOLOGICAL|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
214809278|NCT04207983|COMBINATION_PRODUCT|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
214809279|NCT02851771|OTHER|Nasopharyngeal Swab|
214809280|NCT05539339|OTHER|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
214809281|NCT03029663|PROCEDURE|Transurethral resection of the bladder tumour|
214809282|NCT05781282|DEVICE|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
214809283|NCT03682068|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214809284|NCT03682068|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
214809285|NCT03682068|DRUG|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
214809286|NCT03682068|DRUG|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
214809287|NCT06486246|PROCEDURE|Adductor canal block|Injection of the local anesthetic prior to the surgery, either in the the adductor canal or in the genicular nerves by the anesthesiologist under ultrasound guidance.
214809288|NCT06547190|BEHAVIORAL|High AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The High AGEs diet was cooked for example by baking and grilling.
214809289|NCT06547190|BEHAVIORAL|Low AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The low AGEs diet was cooked for example by steaming and boiling.
214809290|NCT05749172|OTHER|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
214809291|NCT05749172|OTHER|Controlled group|Two hours of parkour training for two days a week.
214809292|NCT01444703|OTHER|licorice solution|licorice (0.5 g)
214809293|NCT01444703|OTHER|sugar solution|sugar (5 g).
214809294|NCT05585957|DIAGNOSTIC_TEST|INTERLEUKIN 6|role of interleukin 6 in the diagnosis of neonatal sepsis in comparison with the routine diagnostic markers of neonatal sepsis
214809295|NCT04900090|OTHER|Epidemiological study|"* Clinical phenotypic assessment and neurosensory measures~* Biological, genetic and metabolomic evaluation~* Questionnaires (quality of life, gout, life habit, comorbidities)~* Morphological evaluation by Dual-energy CT scan"
214809296|NCT02767232|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
214809297|NCT02767232|DRUG|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
214809298|NCT02091882|DRUG|Placebo|Oral placebo-embedded IEM tablet.
214809299|NCT02091882|COMBINATION_PRODUCT|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
214809300|NCT05737992|OTHER|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
214809301|NCT00813046|BIOLOGICAL|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
214809302|NCT04287426|DRUG|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
214809303|NCT04287426|DRUG|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
214809304|NCT02788448|DEVICE|VIVASURE CLOSURE DEVICE|Large hole closure device
214809305|NCT01191320|DRUG|Placebo|Placebo capsule 1x daily for 3 months
214809306|NCT01191320|DRUG|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
214809307|NCT02208726|OTHER|Sucrose pillules|Unmedicated sucrose pillules
214809308|NCT02208726|OTHER|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
214809309|NCT03560544|BEHAVIORAL|Breaking up sitting|"A three-part behaviour change intervention, including:~1. Supportive organisational culture and knowledge of consequence of prolonged sitting~2. Environmental Modification~3. Behavioural Changes"
214809310|NCT06096740|BEHAVIORAL|Cognitive Processing Therapy|"Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms."
214648008|NCT05020379|PROCEDURE|ESP Block|Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
214809311|NCT05227625|BEHAVIORAL|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
214809312|NCT05227625|BEHAVIORAL|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
214809313|NCT04788238|BEHAVIORAL|Dual-Task Zumba Gold|Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
214809314|NCT03160352|OTHER|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
214809315|NCT00365300|DRUG|pantoprazole|
214809316|NCT00365300|DRUG|Placebo|
214809317|NCT03832400|BIOLOGICAL|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
214809318|NCT03832400|DRUG|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
214809319|NCT04915352|DRUG|Nasal provocation test - 725 Dermatophagoides Pteronyssinus|"3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months"
214809320|NCT04915352|OTHER|Negative control|Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
214809321|NCT02896361|DEVICE|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
214809322|NCT03818945|DRUG|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
214809323|NCT03818945|DRUG|Sodium fluoride varnish|5% sodium fluoride \[22,600 ppm F-\]
214809324|NCT00302705|DRUG|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
214809325|NCT00302705|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
214809326|NCT00302705|PROCEDURE|Missing one dose|Patients skip the dose the second day of monitoring
214809327|NCT05116228|DRUG|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
214809328|NCT05116228|DRUG|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
214809329|NCT03503448|PROCEDURE|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
214809330|NCT03503448|PROCEDURE|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
214809331|NCT00556049|DRUG|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
214809332|NCT00556049|DRUG|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
214809333|NCT00954915|BIOLOGICAL|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
214648009|NCT01536444|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
214648010|NCT05148026|DRUG|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
214648011|NCT05148026|DRUG|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
214648012|NCT03198143|DRUG|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
214648013|NCT03198143|DRUG|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
214648014|NCT00594477|RADIATION|IMRT|
214648015|NCT04836949|DEVICE|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
214648016|NCT04836949|DEVICE|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
214648017|NCT03156803|BEHAVIORAL|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
214809334|NCT05852847|DRUG|Baricitinib 2 MG [Olumiant]|Oral baricitinib was given at a dose of 2 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
214809335|NCT05852847|DRUG|Danazol|Danazol was given at a dose of 200 mg bid for 6 months
214809336|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
214809337|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
214809338|NCT01287013|DEVICE|Cone-beam computed tomography (CT)|Imaging
214809339|NCT01287013|DEVICE|Conventional Computed Tomography (CT)|Imaging
214809340|NCT05146596|DEVICE|use low level light therapy,The Dr.Tai's energy cap|30 minutes each time, three times a week, a total of 12 times.
214809341|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
214809342|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
214809343|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
214809344|NCT03673488|DEVICE|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
214809345|NCT01832701|OTHER|Coffee|coffee versus placebo
214809346|NCT01832701|OTHER|Placebo comparator|maltodextrine with caffeine
214809347|NCT03021720|PROCEDURE|Arterial access|Location of arterial puncture
214809348|NCT01179048|DRUG|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
214809349|NCT01179048|DRUG|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
214809350|NCT04343690|BEHAVIORAL|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
214809351|NCT06113653|OTHER|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
214809352|NCT04131751|DIAGNOSTIC_TEST|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
214809353|NCT02109042|DRUG|Blosozumab|Administered subcutaneously
214809354|NCT01511939|DRUG|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
215031283|NCT04192708|PROCEDURE|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
214809355|NCT04489264|DRUG|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
214809356|NCT04568408|DEVICE|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
214809357|NCT03203447|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
214809358|NCT03203447|DRUG|suprachoroidal sham|sham suprachoroidal procedure
214809359|NCT03203447|DRUG|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
214809360|NCT02987491|BEHAVIORAL|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
214809361|NCT00324168|DRUG|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
214809362|NCT00324168|DRUG|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
214648018|NCT03840876|DEVICE|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
214648019|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
214648020|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
214648021|NCT02135536|BIOLOGICAL|NGM282|NGM282
214648022|NCT01891643|DRUG|Lenalidomide|
214648023|NCT01891643|DRUG|Dexamethasone|
214648024|NCT01891643|BIOLOGICAL|Elotuzumab|
214648025|NCT00004165|BIOLOGICAL|filgrastim|
214648026|NCT00004165|DRUG|melphalan|
214648027|NCT00004165|PROCEDURE|peripheral blood stem cell transplantation|
214648028|NCT06956638|OTHER|Non-interventional|Non-interventional study
214648029|NCT06957639|OTHER|Standard physiotherapy intervention and home exercises|Various physical agents such as electrotherapy, hotpack (warm compress) and ultrasound therapy will be used within the standard physiotherapy intervention. These approaches are effective methods to reduce pain, relax muscles and accelerate healing. Home exercises are daily neck exercises recommended by a specialist physiotherapist.
214648030|NCT06957639|OTHER|Trigger point therapy and home exercises|Trigger point therapy is a common method used in patients with myofascial pain syndrome. This method involves manually releasing trigger points. Approaches such as pressure applications and stretching techniques are used. Muscle functions are improved by loosening painful muscle knots. Muscle flexibility and endurance are increased with home exercises.
214648031|NCT06957639|OTHER|Kinesiology Taping therapy and home exercises|"Kinesiology taping is an elastic band technique used for pain management and muscle activity support. It accelerates healing by increasing blood circulation. It supports and protects the muscles in the neck and shoulder area.~It provides supportive stabilization without restricting joint movements. It facilitates movement by reducing pain. It targets muscle strengthening and mobilization with home exercises"
214648032|NCT06957639|OTHER|Cervical - Scapular Mobilization and home exercises|Cervical and scapular mobilization includes manual therapy techniques aimed at increasing the range of motion of the joints in the spine and shoulder area. Mobilization is applied to the cervical spine and shoulder joints. Relaxation is provided in the muscles around the shoulder and neck. Cervical and scapular stability is improved. Postural disorders are corrected and range of motion is increased. Sustainability of mobilization is ensured with home exercises.
214648033|NCT03983681|BEHAVIORAL|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
214648034|NCT03983681|BEHAVIORAL|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
214648035|NCT06155175|DRUG|NSAIDs|The exposure to NSAIDs: NSAIDs was used at least once within the first day after surgery
214648036|NCT05038683|BEHAVIORAL|Holbæk Obesity Treatment|"Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
214648037|NCT05038683|BEHAVIORAL|Conventional Obesity Treatment|"Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
214648038|NCT04494009|DRUG|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
214648039|NCT04751396|OTHER|Best Practice|Receive standard educational information
214648040|NCT04751396|OTHER|Educational Intervention|Navigate educational tool
214648041|NCT04751396|OTHER|Interview|Participate in interview
214648042|NCT04751396|OTHER|Questionnaire Administration|Complete questionnaire
214648043|NCT04751396|OTHER|Survey Administration|Complete surveys
214648044|NCT05839210|BEHAVIORAL|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
214648045|NCT05839210|BEHAVIORAL|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
214809363|NCT00324168|DRUG|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
214809364|NCT04140188|DIAGNOSTIC_TEST|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
214809365|NCT05966571|PROCEDURE|Ovary Biopsie|Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
214809366|NCT03171493|BIOLOGICAL|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
214809367|NCT01192230|DRUG|Endostatins|7.5mg/m2 qd \*14d,q3w
214809368|NCT01192230|DRUG|Docetaxel|75mg/m2 D1, q3w,4-6cycles
214809369|NCT00662571|DRUG|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
214809370|NCT01836341|DRUG|Afatinib|
214809371|NCT01836341|DRUG|Cisplatin|
214809372|NCT01836341|DRUG|Carboplatin|
214809373|NCT01836341|DRUG|Pemetrexed|
214809374|NCT01836341|RADIATION|Radiation therapy|
214809375|NCT04990817|OTHER|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
214809376|NCT04990817|OTHER|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
214809377|NCT03649841|DRUG|Antiandrogen Therapy|Undergo ADT
214809378|NCT03649841|DRUG|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
214809379|NCT03649841|DRUG|Prednisone|Undergo Prednisone Treatment SOC
214809380|NCT03649841|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
214809381|NCT05847205|DRUG|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
214809382|NCT02134405|DRUG|Rebamipide|Rebamipide 100mg tid
214809383|NCT02134405|DRUG|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
214809384|NCT02134405|DRUG|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
214809385|NCT03497897|DRUG|LYS006 20 mg|LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
214809386|NCT03497897|DRUG|LYS006 2 mg|LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
214809387|NCT03497897|DRUG|Placebo|Matching placebo, capsules, oral administration, BID, for 12 weeks
214809388|NCT03839303|DEVICE|Infra-zygomatic Mini Implant Supported Appliance|"1. leveling and alignment of the four maxillary incisors~2. infra zygomatic mini-implant will be placed bilaterally~3. wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~4. a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~5. orthopedic force will be delivered from the mini-implants to the wire frame work"
214809389|NCT03839303|DEVICE|high pull head gear|"1. acrylic maxillary splint is made with flying tubes~2. high pull head gear is adapted to be inserted in the flying tubes"
214809390|NCT02291562|DRUG|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
214809391|NCT02291562|DRUG|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
214809392|NCT02291562|DRUG|placebo|placebo (capsule, once) oral intake
214809393|NCT01529060|DRUG|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
214809394|NCT01529060|DRUG|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
214809395|NCT00914394|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
214809396|NCT00914394|DRUG|Phenylephrine|1µg/kg/min, infusion period 20 minutes
214809397|NCT00914394|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
214809398|NCT00914394|DEVICE|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
214809399|NCT00914394|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
214809400|NCT00914394|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
214809401|NCT04603209|RADIATION|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
214809402|NCT00060307|DRUG|erlotinib hydrochloride|Given orally
214809403|NCT00060307|OTHER|laboratory biomarker analysis|Correlative studies
214809404|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
214809405|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
214809406|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
214809407|NCT04329988|OTHER|questionnaire|A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
214809408|NCT03663478|DRUG|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
214809409|NCT03663478|DRUG|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
214809410|NCT02903888|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
214809411|NCT00126906|DRUG|Monthly sulfadoxine/pyrimethamine|
214809412|NCT00126906|DRUG|2-dose sulfadoxine/pyrimethamine|
214809413|NCT02962934|OTHER|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
214809414|NCT02962934|OTHER|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
214809415|NCT03764709|DEVICE|Vital signs wireless monitoring system|WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
214809416|NCT00528606|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
214809417|NCT00528606|BIOLOGICAL|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
214809418|NCT02841488|PROCEDURE|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
214809419|NCT02841488|DRUG|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
214809420|NCT02841488|DRUG|Ropivacaine|
214809421|NCT02841488|DEVICE|Perineural catheter|
214809422|NCT00020397|BIOLOGICAL|NY-ESO-1 peptide vaccine|
214809423|NCT00020397|BIOLOGICAL|aldesleukin|
214809424|NCT01538251|DRUG|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
214809425|NCT01538251|DRUG|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
214809426|NCT03735251|OTHER|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
214809427|NCT02332148|DRUG|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
214809428|NCT02332148|DRUG|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
214809429|NCT04470180|BEHAVIORAL|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
214809430|NCT04470180|BEHAVIORAL|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
214809431|NCT04452656|PROCEDURE|bilateral erector spinae block|"An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12."
214809432|NCT05173207|DIAGNOSTIC_TEST|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
214809433|NCT00874887|DRUG|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
214809434|NCT00874887|DRUG|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
214809435|NCT00783861|DRUG|Lactic Acid|Lactic Acid (Dermacyd Femina)
214809436|NCT04503993|OTHER|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
214809437|NCT02047071|DEVICE|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
214809438|NCT01643005|BEHAVIORAL|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
214809439|NCT01643005|BEHAVIORAL|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
214809440|NCT01604694|PROCEDURE|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
214809441|NCT05813340|PROCEDURE|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
214809442|NCT06083389|BEHAVIORAL|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
214809443|NCT06083389|DEVICE|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
214809444|NCT06294080|OTHER|Dance|Exercise intervention
214809445|NCT06294080|OTHER|Tai Chi|Exercise intervention
214809446|NCT02335840|OTHER|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
214809447|NCT02335840|OTHER|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
214809448|NCT02335840|OTHER|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
214809449|NCT02335840|OTHER|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
214809450|NCT00959660|BEHAVIORAL|Exercise|walking, treadmill and bicycle exercise
214809451|NCT00959660|DIETARY_SUPPLEMENT|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
214809452|NCT00959660|BEHAVIORAL|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
214809453|NCT00959660|OTHER|Attention Control|control group- continue their previously randomized life style
214809454|NCT04299594|OTHER|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
214809455|NCT05212766|BIOLOGICAL|COVID infection|Infections with COVID 19
214809456|NCT05212766|BIOLOGICAL|COVID vaccination|Vaccination against COVID 19
214809457|NCT05212766|DIAGNOSTIC_TEST|Oral examination|Assessment of oral and periodontal health status
214809458|NCT00142662|BEHAVIORAL|diet|
214809459|NCT00142662|BEHAVIORAL|financial incentives|
214809460|NCT02600286|DRUG|EllaOne|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
214809461|NCT02600286|DRUG|EllaOne placebo|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
214809462|NCT05565664|DRUG|Ketamine hydrochloride|"Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
214809463|NCT05565664|DRUG|Magnesium sulfate|"A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
214809464|NCT05336708|OTHER|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
214809465|NCT05336708|OTHER|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
214809466|NCT01805583|OTHER|Acceptance and Commitment Therapy (ACT)|
214809467|NCT01805583|OTHER|workplace intervention (WPI)|
214809468|NCT04768309|OTHER|Ex vivo exploration of the effect of a probiotic over precursor indole production|Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
214809469|NCT00771485|DRUG|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
214809470|NCT00771485|DRUG|Marketed Bowel Cleanser|Marketed bowel cleanser
214809471|NCT06324682|DEVICE|Cardiac pacing - Conventional RV pacing|Implantation of devices for cardiac pacing/defibrillation
214809472|NCT06324682|DEVICE|Cardiac pacing - Conduction System Pacing|Implantation of devices for cardiac pacing/defibrillation
214809473|NCT06324682|DEVICE|Cardiac pacing - Cardiac resynchronization therapy (pacing - CRTP - or defibrillation - CRTD)|Implantation of devices for cardiac pacing/defibrillation
214809474|NCT06324682|DEVICE|Cardiac pacing - Epicardial pacing|Implantation of devices for cardiac pacing/defibrillation
214809475|NCT06324682|DEVICE|Cardiac pacing - Leadless pacing|Implantation of devices for cardiac pacing/defibrillation
214809476|NCT05179681|OTHER|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
214809477|NCT02158182|DRUG|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
214809478|NCT02158182|DRUG|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
214809479|NCT02158182|DRUG|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
214809480|NCT02158182|DRUG|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
214809481|NCT00000190|PROCEDURE|Parotid Gland|
214809482|NCT02775357|BEHAVIORAL|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
214809483|NCT02775357|BEHAVIORAL|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
214809484|NCT05508659|DRUG|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
214809485|NCT05508659|DRUG|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
214809486|NCT04065035|OTHER|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
214809487|NCT04065035|OTHER|Body Cleanser|Body cleanser to be used by study participants
214809488|NCT04065035|OTHER|Sunscreen|Sunscreen to be applied after application of moisturizer
214809489|NCT04065035|OTHER|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
214809490|NCT03478397|OTHER|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
214809491|NCT00486395|DEVICE|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
214809492|NCT00486395|DEVICE|Mechanical ventilation|Volume guarantee strategy
214809493|NCT02664103|DRUG|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
214809494|NCT03850795|DRUG|HC-1119|oral once daily 80 mg
214809495|NCT03850795|DRUG|Enzalutamide|oral once daily 160 mg
214809496|NCT03893318|DRUG|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
214809497|NCT03893318|DRUG|Placebos|Saline
214809498|NCT04664621|DIAGNOSTIC_TEST|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
214809499|NCT02188303|DRUG|LY2944876|Administered SC
214809500|NCT02188303|DRUG|Placebo|Administered SC
214809501|NCT01945164|DRUG|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
214809502|NCT04206332|DRUG|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
214809503|NCT04206332|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
214809504|NCT03059628|OTHER|Personalized Normative Feedback|"This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking."
214809505|NCT03059628|OTHER|Brief Therapeutic Intervention|BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
214809506|NCT03059628|OTHER|Evaluation questionnaire|The patient have to fill the same evaluation questionnaire at J0, M6 and M12
214809507|NCT01618097|BEHAVIORAL|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
214809508|NCT01618097|BEHAVIORAL|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
214809509|NCT02110953|COMBINATION_PRODUCT|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
214809510|NCT02110953|PROCEDURE|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
214809511|NCT06201650|DIAGNOSTIC_TEST|Neurofilament light chain|Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
214648046|NCT05839210|BEHAVIORAL|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
214648047|NCT04858477|OTHER|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
214648048|NCT04858477|DEVICE|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
214648049|NCT02863068|DRUG|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
214648050|NCT02863068|OTHER|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
214648051|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
214648052|NCT04259853|PROCEDURE|PCI|Revascularization on non culprit vessel
214648053|NCT06045988|DEVICE|Non-Contact Sleep Quality Monitor System|Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
214648054|NCT06208488|DRUG|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
214648055|NCT06208488|DRUG|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
214648056|NCT02312024|DEVICE|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
214648057|NCT01583179|DRUG|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
214648058|NCT00522067|BIOLOGICAL|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
214648059|NCT01246206|DRUG|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
214648060|NCT00699179|DRUG|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
214648061|NCT03347149|DEVICE|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
214648062|NCT01211912|DRUG|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
214648063|NCT01211912|DRUG|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
214648064|NCT01429571|OTHER|No intervention|No intervention
214648065|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
214648066|NCT05630963|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
214648067|NCT05630963|DRUG|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
214648068|NCT05330208|DRUG|SHR-1816|SHR-1816
214648069|NCT05330208|DRUG|Placebo|Placebo
214648070|NCT06434311|DIAGNOSTIC_TEST|3 meter Backward Test|evaluation
214648071|NCT02965716|BIOLOGICAL|Pembrolizumab|Given IV
214648072|NCT02965716|BIOLOGICAL|Talimogene Laherparepvec|Given IL
214648073|NCT06530433|DEVICE|CPRCard + TCPR Link App and Web|Application that allows responder to perform CPR with two-way audio communication and one-way video streaming to SCDF Dispatcher
214648074|NCT06530433|DEVICE|CPRCard Only|Control arm with standard care of procedure that Bystander using CPRCard only
214648075|NCT06231745|DRUG|Methotrexate|Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
214648076|NCT06231745|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
214648077|NCT05588635|OTHER|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
214648078|NCT04047797|DRUG|Ixazomib|Given by mouth
214648079|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
214648080|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
214648081|NCT03523351|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
214648082|NCT03523351|DRUG|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
214648083|NCT01009957|DRUG|Everolimus|0.75 mg x 2 / day
214648084|NCT02013843|BEHAVIORAL|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
214648085|NCT05933538|DRUG|Cariprazine|The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.
214648086|NCT05933538|COMBINATION_PRODUCT|Treatment as usual|Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
214648087|NCT02633683|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
214648088|NCT06099782|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
214809512|NCT04052503|BEHAVIORAL|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
214809513|NCT03289884|OTHER|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
214809514|NCT03289884|OTHER|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
214809515|NCT03289884|OTHER|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
214809516|NCT03289884|OTHER|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
214809517|NCT03289884|OTHER|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
214809518|NCT00061321|DRUG|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
214809519|NCT05570084|DRUG|Silodosin|Cap silodosin for medical expulsion therapy
214809520|NCT05570084|DRUG|Tamsulosin|Cap tamsulosin
214809521|NCT05246293|DRUG|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
214809522|NCT05688306|DRUG|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
214809523|NCT02485522|OTHER|No Intervention|No intervention
214809524|NCT02278835|OTHER|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
214809525|NCT02278835|DEVICE|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
214809526|NCT02278835|DEVICE|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
214809527|NCT02278835|DEVICE|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
214809528|NCT04360694|PROCEDURE|Incremental hemodialysis|95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
214809529|NCT04360694|PROCEDURE|Conventional hemodialysis|95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
214648089|NCT06099782|BIOLOGICAL|Pembrolizumab|Administered via IV infusion
214809530|NCT04805411|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
214809531|NCT04805411|BIOLOGICAL|Placebo|Placebo
214809532|NCT00734019|DEVICE|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
214809533|NCT05096780|OTHER|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
214809534|NCT03824691|DRUG|Cabozantinib|cabozantinib 40 mg orally once daily
214809535|NCT03824691|DRUG|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
214809536|NCT00695162|OTHER|quiet|no noise
214809537|NCT00695162|OTHER|non-speech noise|noise without speech
214648090|NCT03020862|DIETARY_SUPPLEMENT|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
214648091|NCT02277717|DRUG|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
214648092|NCT06399926|DRUG|Pemetrexed injection|Group 1（20mg）:induction stage is 20 mg per 24 hours for 72 hours, every 2 weeks; consolidation stage is 20mg per 24 hours for 72 hours, every 3 weeks.
214809538|NCT00695162|OTHER|speech noise|noise with speech present
214809539|NCT03318796|DEVICE|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB \& SB
214809540|NCT00193037|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin
214809541|NCT00193037|DRUG|Docetaxel|Docetaxel
214809542|NCT03336411|BEHAVIORAL|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
214809543|NCT03336411|BEHAVIORAL|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
214809544|NCT00858156|DRUG|BG9928|Oral 75 mg single dose
214809545|NCT02438878|BEHAVIORAL|Baby Behavior|
214809546|NCT01346163|DRUG|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
214809547|NCT01346163|OTHER|Placebo|Placebo will be used as a comparator to the active arm.
214809548|NCT03428594|BIOLOGICAL|CKD-11101|
214809549|NCT03428594|BIOLOGICAL|NESP|
214809550|NCT02197195|DIETARY_SUPPLEMENT|Chocolate Milk|
214809551|NCT02197195|DIETARY_SUPPLEMENT|Fruit Drink|
214809552|NCT02197195|BEHAVIORAL|Exercise|
214809553|NCT00041496|DRUG|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
214809554|NCT00041496|OTHER|Placebo|Placebo to match SB-207266
214809555|NCT03380819|DIAGNOSTIC_TEST|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
214809556|NCT03405402|PROCEDURE|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
214809557|NCT04942756|DEVICE|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
214809558|NCT04942756|DEVICE|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
214809559|NCT01716793|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics."
214809560|NCT01716793|OTHER|Autologous transplantation|"* In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling."
214809561|NCT01716793|OTHER|Allogeneic HLA-identical sibling transplantation|"* Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
214809562|NCT01716793|OTHER|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
214809563|NCT00912288|DRUG|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
214809564|NCT00912288|DRUG|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
214809565|NCT02506309|DEVICE|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
214809566|NCT02506309|DEVICE|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
214809567|NCT03021538|DEVICE|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
214809568|NCT03021538|DEVICE|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
214809569|NCT04115280|DIAGNOSTIC_TEST|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
214809570|NCT03061526|OTHER|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
214809571|NCT02562365|DRUG|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
214809572|NCT00893464|DRUG|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
214809573|NCT00050778|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
214809574|NCT00050778|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).
214809575|NCT00050778|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
214809576|NCT03933956|DRUG|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
214809577|NCT00999037|DRUG|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
214809578|NCT00999037|OTHER|Placebo|1 inert tablet tid x 12 weeks
214809579|NCT01371162|DRUG|RO5428029|Multiple ascending doses
214809580|NCT01371162|DRUG|placebo|multiple doses
214809581|NCT01498848|DIETARY_SUPPLEMENT|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
214809582|NCT00403039|DRUG|Ranibizumab (Lucentis )|
214809583|NCT01275586|DRUG|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
214809584|NCT02472184|PROCEDURE|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
214809585|NCT02472184|PROCEDURE|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
214809586|NCT04873310|OTHER|Triple P online with professional support|The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
214809587|NCT04873310|OTHER|Triple P online without professional support|The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
214809588|NCT02865746|DRUG|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
214809589|NCT02865746|DRUG|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
214809590|NCT01787708|PROCEDURE|Red light|
214809591|NCT03098108|RADIATION|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
214809592|NCT01359566|DRUG|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
214809593|NCT01359566|DRUG|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
214809594|NCT01359566|DRUG|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
214648093|NCT06399926|DRUG|Pemetrexed|Group 2（30mg）:induction stage is 30 mg D1，every week.Consolidation stage is 30 mg D1,every 3 weeks.
214648094|NCT01125280|PROCEDURE|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
214648095|NCT03363633|DRUG|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
214648096|NCT03363633|DEVICE|Compression|20-30 mmHg compression stockings
214648097|NCT03723187|OTHER|normal saline|experimental group use normal saline sealing tube
214809595|NCT01359566|DRUG|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
214809596|NCT01126736|DRUG|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
214809597|NCT01126736|DRUG|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
214809598|NCT01126736|DRUG|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
214809599|NCT06284538|DEVICE|NOVA.EMOSTOP RE-EPITHELIZING|RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
215031284|NCT04192708|PROCEDURE|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
214648098|NCT03723187|OTHER|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
214648099|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
214648100|NCT03266835|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
214648101|NCT04714515|DRUG|Montelukast|An FDA approved medicine to treat asthmatic patients
214648102|NCT04714515|DRUG|Hydroxychloroquine|An FDA approved antiarthritis drug
214648103|NCT04714515|DRUG|Ivermectin|An FDA approved anti-parasitic medicine
214648104|NCT02441790|BEHAVIORAL|Early Active Range of Motion|3-9 days
214648105|NCT02441790|BEHAVIORAL|Standard Immobilization|21-27 days
214648106|NCT05234580|DRUG|PA9159 nasal spray solution, 10 μg once daily for 14 days|PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
214648107|NCT05234580|DRUG|PA9159 nasal spray solution, 20 μg once daily for 14 days|PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
214648108|NCT05234580|DRUG|PA9159 nasal spray solution, 40 μg once daily for 14 days|PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
214648109|NCT05234580|DRUG|Placebo nasal spray solution without PA9159, once daily for 14 days|Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
214648110|NCT06170996|BEHAVIORAL|Internet-based behavioral parent training (I-BPT)|Internet-based behavioural parent training in a group format, 8 sessions over 2 months, delivered by a systematically trained and supervised therapist.
214648111|NCT06350214|BEHAVIORAL|physical activity and nutrition assessment|Assessment of the physical activity and nutrition condition of cancer survivors.
214648112|NCT00176293|DRUG|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, \& 5 of each 28-day cycle
214648113|NCT00176293|DRUG|doxorubicin|Doxorubicin 50mg/m\^2 I.V. on day 5
214648114|NCT00926692|OTHER|Blood draw|Subject will have blood draw.
214648115|NCT04931953|OTHER|Intermittent theta burst stimulation (iTBS)|The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
214648116|NCT04931953|OTHER|Sham Intermittent theta burst stimulation (iTBS)|The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
214648117|NCT03903380|OTHER|Manual Therapy and Usual care exercise protocol for neck pain|Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
214648118|NCT03903380|OTHER|Manual Therapy and Augmented reality exercise protocol|Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
214648119|NCT01327742|DEVICE|Relay Thoracic Stent-Graft|Device implant
214648120|NCT02638636|BEHAVIORAL|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
214648121|NCT00945360|DRUG|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
214648122|NCT01322022|BEHAVIORAL|ParentTraining|5 sessions of individual parent training
214648123|NCT01322022|OTHER|Parent Education|Parent Education to control for time and attention
214648124|NCT04051957|DRUG|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
214648125|NCT04051957|DRUG|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
214648126|NCT01929057|PROCEDURE|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
214648127|NCT01929057|PROCEDURE|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
214648128|NCT01097629|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214648129|NCT01097629|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214648130|NCT01097629|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214648131|NCT00221884|PROCEDURE|Ultrasound|
214648132|NCT06273254|DRUG|Sacubitril and Valsartan Tablets 49mg/51mg|Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
214648133|NCT06273254|DRUG|Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)|Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
214648134|NCT06526702|DEVICE|High-flux hemodialysis|FX CorDiax 100 dialyzer
214648135|NCT06526702|DEVICE|Post-dilution hemodiafiltration|FX CorDiax 1000 dialyzer
214648136|NCT03168984|DRUG|UCB0942|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
214648137|NCT03168984|OTHER|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
214648138|NCT01867229|OTHER|observational|standard of care fore patients with non metastatic breast cancer
214648139|NCT05422066|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
214648140|NCT05422066|DRUG|Rituximab|Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
214648141|NCT05422066|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
214648142|NCT05422066|DRUG|Doxorubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
214648143|NCT05422066|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
214648144|NCT05422066|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
214648145|NCT05197803|DEVICE|Hearing aid|Participants will complete testing aided and unaided. The hearing aids have been fit to compensate for their hearing loss.
214648146|NCT00132041|DEVICE|radiofrequency ablation|
214648147|NCT06133660|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy and Silicone oil removal to distinguish subjects
214648148|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
214648149|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
214648150|NCT05429086|DRUG|Remimazolam combined propofol|Remimazolam combined propofol
214648151|NCT05429086|DRUG|Remimazolam|remimazolam only
214648152|NCT05429086|DRUG|Propofol|propofol only
214648153|NCT01483430|DRUG|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
214648154|NCT01483430|DRUG|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
214648155|NCT01483430|DRUG|Placebo|1 capsule/day (starch), Duration: 8 weeks
214648156|NCT02658422|DRUG|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
214648157|NCT02658422|DRUG|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
214648158|NCT03609619|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
214648159|NCT03609619|DRUG|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
214648160|NCT05495204|DRUG|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
214648161|NCT01171820|DEVICE|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
214648162|NCT01171820|DEVICE|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
214648163|NCT01567098|PROCEDURE|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
214648164|NCT01358032|BEHAVIORAL|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) \& 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
214648165|NCT02592889|DEVICE|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
214648166|NCT01081756|DRUG|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
214648167|NCT01081756|DRUG|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
214648168|NCT03817203|OTHER|Kinesio tape application|Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
214648169|NCT03817203|OTHER|Sham tape application|Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
214648170|NCT00956943|DRUG|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
214648171|NCT00956943|DRUG|placebo|placebo patch
214648172|NCT02186184|DEVICE|Orthokeratology|
214648173|NCT02186184|DEVICE|Spectacle|
214648174|NCT04552171|BEHAVIORAL|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
214648175|NCT02613208|DRUG|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
214648176|NCT02613208|DRUG|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
214648177|NCT01208129|DRUG|NAB001|nail lacquer, once daily, 52 weeks
214648178|NCT01208129|DRUG|Placebo control|nail lacquer, once daily, 52 weeks
214648179|NCT02663895|DRUG|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
214648180|NCT03064672|DEVICE|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
214648181|NCT03057366|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
214648182|NCT03057366|DRUG|[14C]-Pevonedistat|\[14C\]-Pevonedistat intravenous infusion.
214648183|NCT03057366|DRUG|Docetaxel|Docetaxel intravenous infusion.
214648184|NCT03057366|DRUG|Carboplatin|Carboplatin intravenous infusion.
214648185|NCT03057366|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
214648186|NCT02208245|DEVICE|Ultrasound: Axillary block|Ultrasound guided axillary block
214648187|NCT02208245|DEVICE|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
214648188|NCT02208245|DRUG|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
214648189|NCT00247104|DRUG|Cranberries - Vaccinium macrocarpon|
214648190|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
214648191|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
214648192|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
214648193|NCT00191672|DRUG|Gemcitabine|
214648194|NCT00191672|DRUG|Paclitaxel|
214648195|NCT00191672|DRUG|Docetaxel|
214648196|NCT04956900|DRUG|Aurase Wound gel|Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
214648197|NCT01126255|DRUG|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
214648198|NCT01126255|DRUG|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
214648199|NCT02321293|DIETARY_SUPPLEMENT|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
214648200|NCT02321293|DRUG|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
214648201|NCT02321293|DRUG|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
214648202|NCT05529563|PROCEDURE|LSG|LSG
214648203|NCT05636631|DEVICE|Chest ultrasound|chest ultrasound as a non invasive, low cost \& bedside device for differentiation \& follow up of lung congestion \& pneumonia
214809600|NCT01270919|DEVICE|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
214809601|NCT04932252|DRUG|A4368 or placebo tablet|orally administered
214809602|NCT03538405|OTHER|Supporting cushions|Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
214809603|NCT03538405|OTHER|Harmonic techniques|Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
214809604|NCT02039362|DRUG|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
214809605|NCT06061666|OTHER|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
214809606|NCT02778165|OTHER|MyCaRe (my cardiac recovery Android application)|Android application \& Fitbit Inspire 2 activity monitor
214809607|NCT02210390|BEHAVIORAL|Psycho education|Psycho-education Sessions will be offered weekly basis
214809608|NCT04349735|OTHER|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
214809609|NCT04869787|DEVICE|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
214809610|NCT01450085|OTHER|GeneXpert|Point of care GeneXpert
214809611|NCT01450085|OTHER|LED Microscopy|Point of care LED Microscopy
214809612|NCT01675232|OTHER|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
214809613|NCT01675232|OTHER|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
214809614|NCT03056937|OTHER|Bariatric surgery|evaluations pre and post bariatric surgery.
214809615|NCT03056937|OTHER|Control|without intervention, it will be performed only evaluations
214809616|NCT05110209|OTHER|Aflibercept|intravitreal injection
214809617|NCT05110209|OTHER|Ranibizumab|intravitreal injection
214809618|NCT05110209|OTHER|Bevacizumab|intravitreal injection
214809619|NCT01453556|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
214809620|NCT00813293|DRUG|Sorafenib|
214809621|NCT00813293|PROCEDURE|radiofrequency ablation|
214809622|NCT04074174|DRUG|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
214809623|NCT04074174|DRUG|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
214809624|NCT04074174|DRUG|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
214809625|NCT06075173|DIAGNOSTIC_TEST|Resting full-cycle ration (RFR) measurments|RFR and FFR measurements in main vessel and side branch lesions
214809626|NCT01303848|OTHER|Blood Sampling|Blood Sampling over 24 hours
214809627|NCT02867930|DRUG|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
214809628|NCT02867930|DRUG|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
214809629|NCT05194722|BEHAVIORAL|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
214809630|NCT02883335|OTHER|Observational registry|
214809631|NCT04819633|OTHER|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
214809632|NCT05293847|BEHAVIORAL|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
214809633|NCT01500876|RADIATION|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
214809634|NCT05070676|DIAGNOSTIC_TEST|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
214809635|NCT00257673|DRUG|MEM 1003|30 mg twice a day
214809636|NCT00257673|DRUG|MEM 1003|90 mg MEM 1003 twice a day
214809637|NCT00257673|DRUG|Placebo for MEM 1003|Placebo twice a day
214809638|NCT03429920|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
214809639|NCT03429920|DIETARY_SUPPLEMENT|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
214809640|NCT02006173|DRUG|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
214809641|NCT02006173|DRUG|Normal Saline|
214648204|NCT03324204|OTHER|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
214648205|NCT03324204|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
214648206|NCT00237679|BEHAVIORAL|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
214648207|NCT00237679|BEHAVIORAL|Unstimulated|No current is generated.
214648208|NCT05855304|OTHER|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
214648209|NCT05855304|OTHER|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
214648210|NCT02312804|DRUG|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
214648211|NCT02312804|DRUG|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
214648212|NCT02312804|DRUG|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
214648213|NCT01182038|DEVICE|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
214648214|NCT05749757|DEVICE|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
214648215|NCT05749757|DEVICE|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
214648216|NCT01750814|BIOLOGICAL|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
214648217|NCT01750814|BIOLOGICAL|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
214648218|NCT05102526|BEHAVIORAL|"Experimental: Young Millie prevention program, active teachers"|"Prevention program: Young Mili, in collaboration with the teacher"
214648219|NCT05102526|BEHAVIORAL|"Prevention program: Young Mili, non active teachers"|"Prevention program: Young Mili, without the participation of the teacher"
214648220|NCT03805126|BEHAVIORAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
214648221|NCT03805126|BEHAVIORAL|Usual Care|Usual care includes consultation with a social worker and a community health worker.
214648222|NCT05335889|DEVICE|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
214648223|NCT05335889|DEVICE|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
214648224|NCT01496157|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
214648225|NCT02507479|DRUG|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
214648226|NCT00067756|DRUG|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
214648227|NCT04224935|PROCEDURE|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
214648228|NCT01734876|BEHAVIORAL|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
214648229|NCT01734876|BEHAVIORAL|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
214648230|NCT03757884|BEHAVIORAL|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
214648231|NCT03757884|BEHAVIORAL|Diagnostic Checklist|Checklist reminder for diagnosis
214648232|NCT03757884|BEHAVIORAL|Noise cancelling headphones|Noise cancelling headphones
214648233|NCT03757884|BEHAVIORAL|Privacy tablescreen|Privacy Tablescreen
214648234|NCT03757884|BEHAVIORAL|Diagnostic assistance application|Diagnostic assistance application
214648235|NCT01424592|DEVICE|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
214648236|NCT04288024|BEHAVIORAL|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
214648237|NCT02984800|OTHER|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
214648238|NCT02984800|OTHER|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
214648239|NCT02984800|OTHER|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
214648240|NCT02151344|BIOLOGICAL|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
214648241|NCT02151344|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
214648242|NCT03443167|BEHAVIORAL|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
214648243|NCT03443167|BEHAVIORAL|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
214648244|NCT05136274|DRUG|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
214648245|NCT04172090|OTHER|Control|Normal physical activity and standard energy intake
214648246|NCT04172090|OTHER|SIT+E|Reduced physical activity and standard energy intake
214809642|NCT00282048|DRUG|AG-013736 (axitinib)|AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
214809643|NCT02649803|BEHAVIORAL|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
214809644|NCT01002638|OTHER|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
214809645|NCT01002638|PROCEDURE|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
214809646|NCT04349592|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
214809647|NCT04349592|DRUG|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
214809648|NCT04349592|OTHER|Placebo Tablet|Oral, one tablet three times a day for 7 days
214809649|NCT04349592|OTHER|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
214809650|NCT04869722|BEHAVIORAL|Liquid Model|Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
214809651|NCT04869722|BEHAVIORAL|Solid Model|Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
214809652|NCT06340139|OTHER|conventional treatment|conventional treatment with Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage
214809653|NCT06340139|OTHER|experimental treatment|1 being a fixation point and phase 2 including head and eye movements
214809654|NCT00388544|BEHAVIORAL|Activity matched to interest|Recreational activities are tailored to subject's style of interest
214809655|NCT00388544|BEHAVIORAL|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
214809656|NCT00388544|BEHAVIORAL|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
214648247|NCT04172090|OTHER|SIT=E|Reduced physical activity and reduced energy intake
214809657|NCT05326841|DRUG|Vitamin D3|cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks
214809658|NCT02038608|DEVICE|PET|
214809659|NCT00599664|DRUG|OMS201|OMS201 irrigation solution during surgery
214809660|NCT00599664|DRUG|Vehicle|Vehicle irrigation solution during surgery
214809661|NCT04879888|BIOLOGICAL|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
214809662|NCT00122577|DRUG|Tenofovir|
214809663|NCT00122577|DRUG|Atazanavir|
214809664|NCT00122577|DRUG|Ritonavir|
214809665|NCT00122798|PROCEDURE|Stroke treatment|
214809666|NCT01536405|BIOLOGICAL|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
214648248|NCT03283202|DRUG|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
214648249|NCT03283202|DRUG|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
214648250|NCT03283202|DRUG|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
214809667|NCT01536405|BIOLOGICAL|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
214809668|NCT04517162|DRUG|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
214809669|NCT00817960|DRUG|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
214809670|NCT00003674|DRUG|dalteparin|
214809671|NCT00003674|DRUG|standard therapy|
214809672|NCT01530620|DRUG|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
214809673|NCT01530620|DRUG|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
214809674|NCT06323876|DIAGNOSTIC_TEST|HRCT|High resolution computed tomography (HRCT) scan is a medical imaging technique used to obtain detailed internal images of the body. HRCT images will be obtained at 0 and 12 months.
214809675|NCT06323876|DIAGNOSTIC_TEST|Blood Draw|During blood draw, someone uses a needle to take blood from a vein, usually in your arm.
214809676|NCT00301366|DRUG|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
214809677|NCT03212573|COMBINATION_PRODUCT|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
214809678|NCT03212573|COMBINATION_PRODUCT|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
214809679|NCT01510730|DRUG|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
214809680|NCT05037422|PROCEDURE|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
214809681|NCT01371786|DRUG|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
214809682|NCT01371786|DRUG|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
214809683|NCT02549092|DRUG|Optimized Medical Treatment|Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.
214809684|NCT02549092|DRUG|Levodopa-Carbidopa Intestinal Gel|
214809685|NCT02549092|DEVICE|Nasojejunal (NJ) tube|optional prior to PEG-J placement
214809686|NCT02549092|DEVICE|Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube|
214809687|NCT04988763|OTHER|Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose
214809688|NCT04540523|BEHAVIORAL|Exergaming intervention group|In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
214809689|NCT04540523|BEHAVIORAL|Traditional physical activity comparison|Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
214809690|NCT03463369|BIOLOGICAL|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
214809691|NCT03463369|BIOLOGICAL|Placebo|Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
214809692|NCT03463369|DRUG|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
214809693|NCT00838149|DIETARY_SUPPLEMENT|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
214809694|NCT00838149|DIETARY_SUPPLEMENT|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
214809695|NCT02170311|DRUG|Z-213|
214809696|NCT04128943|OTHER|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
214809697|NCT04128943|OTHER|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
214809698|NCT04128943|OTHER|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
214809699|NCT04128943|OTHER|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
214809700|NCT02511782|DEVICE|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
214809701|NCT01623726|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
214809702|NCT03627091|DRUG|Ontamalimab|SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
214809703|NCT03627091|OTHER|Placebo|SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
214809704|NCT01695720|PROCEDURE|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
214809705|NCT01723748|DRUG|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
214809706|NCT05375604|DRUG|CDK-004|ASO-STAT6 exosome administered Intravenously
214809707|NCT05398718|DRUG|Sotrovimab|collect local clinical evidence for sotrovimab effect in the real-life setting
214809708|NCT00450190|DEVICE|Saizen® E-Device|Saizen® (recombinant human growth hormone \[r-hGH\]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
214809709|NCT00518518|DRUG|Staloral 300|Staloral 300
214809710|NCT00518518|DRUG|placebo|placebo
214809711|NCT02324725|DRUG|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
214809712|NCT01357863|DRUG|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
214809713|NCT01757600|OTHER|Microperimetry|
214809714|NCT01447615|BEHAVIORAL|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
214809715|NCT01447615|BEHAVIORAL|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
214809716|NCT01447615|OTHER|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
214809717|NCT00196651|DRUG|IL-2|
214809718|NCT00196651|BIOLOGICAL|LIPO-6T|
214809719|NCT00196651|BIOLOGICAL|ALVAC VIH 1433|
214809720|NCT03611608|DRUG|LY3316531|Administered IV
214809721|NCT03611608|DRUG|Placebo|Administered IV
214809722|NCT03679377|DEVICE|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
214809723|NCT01866449|DRUG|Cabazitaxel|
214809724|NCT01671514|DIETARY_SUPPLEMENT|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
214809725|NCT01671514|OTHER|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
214809726|NCT02158494|DEVICE|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
214809727|NCT02158494|DEVICE|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
214809728|NCT05293353|OTHER|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
214809729|NCT06245278|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|A total of 60 individuals, 15 with IBD and periodontitis, 15 with IBD and periodontal health, 15 with systemic health and periodontitis, and 15 with systemic and periodontal health, will be included in the study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and serum, saliva and gingival samples will be obtained from all individuals. Individuals with periodontitis will receive non-surgical periodontal treatment in half jaws within 2 weeks. Clinical measurements, serum and saliva sample collection will be repeated 3 months after the treatment. Biomarker levels in serum and saliva samples will be analysed by ELISA.
214809730|NCT06812403|DEVICE|the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
214809731|NCT03968718|BEHAVIORAL|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
214809732|NCT01844219|PROCEDURE|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
214809733|NCT02392897|BEHAVIORAL|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
214809734|NCT02392897|BEHAVIORAL|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
214809735|NCT06075667|DRUG|Tirzepatide|Administered SC
214809736|NCT06075667|DRUG|Placebo|Administered SC
214809737|NCT03865654|OTHER|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
214809738|NCT05536518|BEHAVIORAL|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
214809739|NCT06373705|DEVICE|Cardiac simulator|A computer software cardiac simulator for surgical planning in complex Congenital Heart Disease (CHD) pediatric patients.
214809740|NCT03872999|OTHER|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
214809741|NCT03660839|DRUG|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
214809742|NCT03660839|DRUG|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
214809743|NCT01702584|PROCEDURE|stent assisted embolization|stent assisted embolization and anti-thrombotic management
214809744|NCT01809171|DRUG|Vitamin D3|ampoule
214809745|NCT01809171|DRUG|Placebo|ampoule
214809746|NCT03540056|DIAGNOSTIC_TEST|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
214809747|NCT01582607|DRUG|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
214809748|NCT01582607|DRUG|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
214809749|NCT01582607|DRUG|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
214809750|NCT01582607|DRUG|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
214809751|NCT01582607|DRUG|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
214809752|NCT01582607|DRUG|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
214809753|NCT02161965|DRUG|Rivaroxaban|20mg or 15mg
214648251|NCT03283202|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
214648252|NCT03283202|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
214648253|NCT02626676|OTHER|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
214648254|NCT05821361|DRUG|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
214648255|NCT04474327|DRUG|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
214648256|NCT05034640|PROCEDURE|Conventional multiport thoracoscopic surgery|Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
214648257|NCT05034640|PROCEDURE|Single port site thoracoscopic surgery|Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
214648258|NCT05030714|DIAGNOSTIC_TEST|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
214648259|NCT03793439|DRUG|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
214648260|NCT03793439|DIAGNOSTIC_TEST|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
214648261|NCT03793439|GENETIC|RNA Sequencing|RNA sequencing test at baseline and week 16
214648262|NCT03793439|DIAGNOSTIC_TEST|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
214648263|NCT03793439|DRUG|Corticosteroid|Taper corticosteroids starting at week 4
214648264|NCT03793439|DRUG|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
214648265|NCT04261530|BEHAVIORAL|Self-hypnosis/self-care|
214648266|NCT04261530|BEHAVIORAL|Music/self-care|
214648267|NCT04261530|BEHAVIORAL|Self-care|
214648268|NCT04261530|BEHAVIORAL|Psycho-education|
214648269|NCT02131857|BEHAVIORAL|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
214648270|NCT02472847|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
214809754|NCT02161965|DRUG|Fluindione|
214809755|NCT02161965|DRUG|Warfarin|
214809756|NCT01967108|OTHER|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
214809757|NCT04361266|DEVICE|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
214809758|NCT04361266|PROCEDURE|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
214809759|NCT01989091|DEVICE|B-Lock|Antimicrobial Catheter Lock Solution
214809760|NCT01989091|DRUG|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
214809761|NCT03897998|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
214809762|NCT03897998|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
214809763|NCT05084781|PROCEDURE|Coblation Debridement (FLOW90)|bipolar radiofrequency energy
214809764|NCT02602041|OTHER|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
214809765|NCT00202319|PROCEDURE|Sedation management protocol|
214809766|NCT02744352|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
214809767|NCT02744352|DRUG|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
214809768|NCT04149964|DRUG|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
214809769|NCT04149964|DRUG|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
214809770|NCT04149964|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
214809771|NCT04149964|DRUG|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
214809772|NCT04753437|DRUG|Clarithromycin|Clarithromycin tablets.
214809773|NCT04753437|DRUG|Amoxicillin|Amoxicillin capsules.
214809774|NCT04753437|DRUG|Bismuth potassium citrate|Bismuth potassium citrate tablets.
214809775|NCT04753437|DRUG|Esomeprazole|Esomeprazole tablets.
214809776|NCT04753437|DRUG|Vonoprazan|Vonoprazan tablets.
214809777|NCT05763238|OTHER|INTERVENTION GROUP|"Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup"
214809778|NCT05763238|OTHER|CONTROL GROUP|"Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup"
214809779|NCT04175379|OTHER|group 40|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
214809780|NCT04175379|OTHER|group 50|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
214809781|NCT04175379|OTHER|group 60|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
214809782|NCT04168788|OTHER|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
214809783|NCT01189669|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
214809784|NCT01189669|DIETARY_SUPPLEMENT|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
214809785|NCT01655628|DRUG|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
214809786|NCT01655628|DRUG|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
214809787|NCT03392909|DRUG|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
214809788|NCT03096821|DRUG|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
214809789|NCT03325114|DRUG|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
214809790|NCT03382457|DEVICE|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
214809791|NCT06949202|OTHER|breating exercises|diaphragmatic breathing
214809792|NCT05018416|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
214809793|NCT00633256|DRUG|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
214809794|NCT00633256|DRUG|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
214809795|NCT05240495|BEHAVIORAL|Internet-based Cognitive-behavioural therapy|Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.
214809796|NCT05240495|BEHAVIORAL|Work-focused Cognitive-behavioural therapy|The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
214809797|NCT04472078|DIAGNOSTIC_TEST|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
214809798|NCT00139178|DRUG|Different HAART regimens|
214809799|NCT02785003|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
214809800|NCT02785003|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
214809801|NCT02785003|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
214809802|NCT02785003|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
214809803|NCT02785003|DRUG|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
214809804|NCT00881088|DRUG|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
214809805|NCT00881088|DRUG|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
214809806|NCT05391685|OTHER|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
214809807|NCT05197322|DRUG|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
214809808|NCT00003114|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
214809809|NCT00003114|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
214809810|NCT00003114|DRUG|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
214809811|NCT00003114|DRUG|lomustine|Patients receive oral lomustine on day 1.
214809812|NCT00003114|DRUG|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
214809813|NCT00003114|RADIATION|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
214809814|NCT03744364|DRUG|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
214809815|NCT03744364|DRUG|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
214809816|NCT04003350|DRUG|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
214809817|NCT04003350|DRUG|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
214809818|NCT04003350|DRUG|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
214809819|NCT04003350|DRUG|Meloxicam|Meloxicam 15 mg as need once per day
214809820|NCT04003350|DRUG|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
214809821|NCT04003350|DRUG|Metaxalone|Metaxalone 800mg TID
214809822|NCT04003350|DRUG|Esomeprazole 20mg|Esomeprazole 20mg daily
214809823|NCT05961423|PROCEDURE|Robotic surgery|The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
214809824|NCT01972165|PROCEDURE|Mini-incision carpal tunnel release|
214809825|NCT01972165|PROCEDURE|Endoscopic carpal tunnel release|
214809826|NCT03776422|BEHAVIORAL|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
214809827|NCT00318812|DRUG|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
214809828|NCT00318812|DRUG|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
214809829|NCT06163079|BEHAVIORAL|No intervention|No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
214809830|NCT00630149|DRUG|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
214809831|NCT01822483|DRUG|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
214809832|NCT01822483|DRUG|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg\*h ml-1.
214809833|NCT01049607|PROCEDURE|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
214809834|NCT01049607|PROCEDURE|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
214809835|NCT02424097|DRUG|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~\- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
214809836|NCT02424097|DRUG|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
214809837|NCT05792072|DEVICE|rTMS|High-frequency rTMS
214809838|NCT05792072|DEVICE|Sham rTMS|sham rTMS
214809839|NCT04486794|DEVICE|Restylane®|Hyaluronic acid
214809840|NCT02093494|DEVICE|Initial Specimen Diversion Device (ISDD)|
214809841|NCT02093494|PROCEDURE|Lab standard practice (LSP)|
214809842|NCT02093494|DEVICE|Peripheral Intravenous Catheters (PIVC)|
214809843|NCT00080951|DRUG|fluorouracil|
214809844|NCT00080951|DRUG|irinotecan hydrochloride|
214809845|NCT00080951|DRUG|leucovorin calcium|
214809846|NCT00080951|DRUG|oxaliplatin|
214809847|NCT02311361|BIOLOGICAL|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
214809848|NCT02311361|BIOLOGICAL|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
214809849|NCT02311361|RADIATION|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
214809850|NCT05046860|DRUG|Dalbavancin|"The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg."
214809851|NCT02072577|BEHAVIORAL|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
214809852|NCT06559670|OTHER|Blood sampling|\- Collection and analysis of blood samples
214809853|NCT05074472|DRUG|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
214809854|NCT03387072|OTHER|Non interventional study|mental stress test and Blood (or salivary) sample
214809855|NCT01978743|DRUG|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
214809856|NCT01107093|DRUG|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
214809857|NCT01107093|DRUG|Placebo|single oral dose
214809858|NCT00745420|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
214809859|NCT06534996|DRUG|SCD-2101|Tradictional Chinese Medicine formula (SCD-2101)
214809860|NCT02653664|BEHAVIORAL|PsychoEducation|Condition #1
214809861|NCT02653664|BEHAVIORAL|Self-Hypnosis Training|Condition #2
214809862|NCT02653664|BEHAVIORAL|Mindfulness Meditation|Condition #3
214809863|NCT04991779|DIAGNOSTIC_TEST|AI-assisted cEEG detection tool|"This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association."
214809864|NCT01548677|DRUG|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
214809865|NCT04657770|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
214809866|NCT04707040|OTHER|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
214809867|NCT01886768|DEVICE|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
214809868|NCT01886768|DEVICE|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
214809869|NCT01805934|DRUG|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
214809870|NCT01805934|DRUG|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
214809871|NCT03071029|BEHAVIORAL|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
214809872|NCT00929929|DIETARY_SUPPLEMENT|L-leucine.|10 g of leucine per day, during 12 weeks.
214809873|NCT00929929|DIETARY_SUPPLEMENT|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
214809874|NCT00929929|BEHAVIORAL|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
214809875|NCT02529592|BIOLOGICAL|Endotoxin|
214809876|NCT02529592|BIOLOGICAL|Placebo|
214809877|NCT02064088|DRUG|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
214809878|NCT02064088|DRUG|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
214809879|NCT06334445|BEHAVIORAL|Control group|Wearables/sensors and ePsycHeart App
214809880|NCT06334445|BEHAVIORAL|Intervention group|Wearables/sensors and ePsycHeart App and eHealtHeart
214809881|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
214809882|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
214809883|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
214809884|NCT00746798|BIOLOGICAL|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
214809885|NCT03157362|OTHER|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
214648271|NCT02472847|DRUG|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
214648272|NCT03561233|DRUG|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
214648273|NCT00221364|DRUG|Mass treatment with oral azithromycin to an entire village|
214648274|NCT00623831|BIOLOGICAL|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
214648275|NCT01348230|OTHER|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
214648276|NCT02562625|DRUG|Pembrolizumab|Powder solution for infusion
214648277|NCT02562625|RADIATION|Radiotherapy|24Gy
214648278|NCT00700856|DRUG|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
214648279|NCT00700856|DRUG|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
214648280|NCT02377102|PROCEDURE|Physical Therapy|12 weeks of supervised physical therapy.
214809886|NCT03157362|OTHER|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
214809887|NCT03157362|OTHER|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
214809888|NCT03157362|OTHER|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
214809889|NCT00112645|BIOLOGICAL|anti-thymocyte globulin|
214809890|NCT00112645|DRUG|busulfan|
214809891|NCT00112645|DRUG|cyclosporine|
214809892|NCT00112645|DRUG|melphalan|
214809893|NCT00112645|DRUG|methotrexate|
214809894|NCT00112645|DRUG|methylprednisolone|
214809895|NCT00112645|PROCEDURE|allogeneic bone marrow transplantation|
214809896|NCT00112645|PROCEDURE|peripheral blood stem cell transplantation|
214809897|NCT00112645|PROCEDURE|umbilical cord blood transplantation|
214809898|NCT03121443|OTHER|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
214809899|NCT01502566|BEHAVIORAL|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
214809900|NCT03655106|DEVICE|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
214809901|NCT03655106|DEVICE|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
214809902|NCT05113056|DEVICE|Acutus Medical Pulsed Field Ablation System|All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
214809903|NCT00503152|DRUG|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214809904|NCT00503152|DRUG|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214809905|NCT00503152|DRUG|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214809906|NCT02298465|PROCEDURE|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
214809907|NCT02298465|PROCEDURE|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
214809908|NCT02298465|DEVICE|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
214809909|NCT05575180|DRUG|Acetazolamide 250Mg Tab|Oral acetazolamide
214809910|NCT05575180|DRUG|Methazolamide Pill|Oral Methazolamide
214809911|NCT05575180|DRUG|Placebo|Oral placebo
214809912|NCT04043871|DIAGNOSTIC_TEST|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
214809913|NCT00156247|DRUG|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
214809914|NCT06217653|BEHAVIORAL|mother baby yoga|"Yoga Video Content Plan~* Mood Regulation: Abdominal/Belly Breathing~* Warm Touch from the Heart~* Chair Posture~* Bucket Wrapping~* Bukka Bukka (Heart)~* Vortex Generation~* Fertile Falls~* One Hand Two Hands~* Tiny Stretches~* Here and Now Awareness~* Dolphin Pose Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes."
214809915|NCT01163760|DEVICE|etafilcon A|daily disposable contact lens
214809916|NCT01163760|DEVICE|ocufilcon D|daily disposable contact lens
214809917|NCT02104960|OTHER|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
214809918|NCT02104960|OTHER|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
214809919|NCT02104960|OTHER|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
214809920|NCT04433871|OTHER|No intervention, observational|No intervention, observational
214809921|NCT03334825|OTHER|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
214809922|NCT03334825|OTHER|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
214809923|NCT01423760|BIOLOGICAL|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
214809924|NCT01423760|OTHER|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
214809925|NCT01353469|DRUG|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
214809926|NCT01353469|DRUG|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
214809927|NCT04697017|OTHER|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
214809928|NCT05703048|DRUG|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
214809929|NCT05703048|DRUG|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
214809930|NCT01367457|OTHER|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
214809931|NCT00151047|DRUG|Capecitabine|
214809932|NCT00151047|DRUG|Docetaxel|
214809933|NCT02170506|DEVICE|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
214809934|NCT04257474|BEHAVIORAL|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
214809935|NCT04257474|BEHAVIORAL|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
214809936|NCT01249222|PROCEDURE|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
214809937|NCT01249222|OTHER|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
214809938|NCT02160925|OTHER|Preoperative 99mTc-Sestamibi SPECT/CT|
214809939|NCT01882257|DEVICE|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
214809940|NCT01882257|DEVICE|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
214809941|NCT05168670|COMBINATION_PRODUCT|Protection of eyes with tinted soft scleral eye shields|In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids
214809942|NCT04152174|PROCEDURE|Combined extracorporeal blood purification|Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
214809943|NCT04152174|PROCEDURE|CRRT|Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
214809944|NCT00162474|DRUG|Warfarin|
214809945|NCT00162474|DRUG|Phenytoin|
214809946|NCT04468503|OTHER|Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional|In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
214809947|NCT03116659|DRUG|Doxycycline|Doxycycline 100 mg PO BID x 14 days
214809948|NCT03116659|DRUG|Imiquimod|up to 2 packs 3/ week x 28 days
214809949|NCT04446559|PROCEDURE|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
214809950|NCT00822822|BEHAVIORAL|First Questionnaire|Complete questionnaire before completing health history
214809951|NCT00822822|BEHAVIORAL|Health History|Complete electronic health history
214809952|NCT00822822|BEHAVIORAL|Second Questionnaire|Complete questionnaire after completing electronic health history
214809953|NCT01336322|DRUG|Metformin|Metformin 850 mg bid
214809954|NCT01336322|DRUG|Sitagliptin|Sitagliptin 100 mg qd
214809955|NCT01336322|DRUG|Sitagliptin + Metformin|sitagliptin 100mg + metformin 850mg
214809956|NCT05000658|DRUG|Dexamethasone phosphate|HSC injection of 4mL
214809957|NCT06181175|DRUG|PEAPROSTIL 600 + Tamsulosin 0.4 mg|PEAPROSTIL 600 mg one sachet oral daily+ Tamsulosin 0.4 mg one tablet oral daily
214809958|NCT06181175|DRUG|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg one tablet oral daily
214809959|NCT06181175|DRUG|PEAPROSTIL 600 mg|PEAPROSTIL 600 mg one sachet oral daily
214809960|NCT02058498|BEHAVIORAL|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
214809961|NCT00483626|DRUG|oral sildenafil|
214809962|NCT00487565|DEVICE|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
214809963|NCT01163825|DRUG|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
214809964|NCT04128826|OTHER|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
214809965|NCT02548403|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
214809966|NCT02548403|DRUG|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
214809967|NCT00304603|OTHER|No intervention|No treatment was given to the patients as this is an observational study.
214809968|NCT02209441|DRUG|Phase I Dose-finding Study of Sorafenib Study|
214809969|NCT01901705|DRUG|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
214809970|NCT01901705|DRUG|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
214809971|NCT04982094|BEHAVIORAL|Mental Health First Aid and Relationship Building Training|"Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
214809972|NCT04982094|BEHAVIORAL|Mental Health First Aid|"Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
214809973|NCT04792450|DEVICE|Thermography|Measure Temperature using Thermal Camera
214809974|NCT04792450|DEVICE|Tympanic Thermometer|Measure Temperature using Tympanic Thermometer
214809975|NCT04792450|DEVICE|Forehead Thermometer|Measure Temperature using Forehead Temperature
214809976|NCT04792450|DEVICE|62 Max + Infra-red thermometer|Measure Temperature using 62 Max + Infra-red thermometer
214809977|NCT02011295|PROCEDURE|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
214809978|NCT02011295|OTHER|Bone Marrow Aspirate injection|
214809979|NCT04222881|PROCEDURE|AVF anastomosis|Type of arteriovenous anastomosis
214809980|NCT04881435|DEVICE|Hydrogen gas therapy|Hydrogen gas therapy three times one day for 5 days
214809981|NCT04628117|DIETARY_SUPPLEMENT|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
214809982|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results."
214809983|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results."
214809984|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results."
214809985|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
214809986|NCT03171285|OTHER|Less than 35 years old|Clinical and laboratory evaluations
214809987|NCT03171285|OTHER|Greater than or equal to 35 years|Clinical and laboratory evaluations
214809988|NCT03950336|DIETARY_SUPPLEMENT|Prebiotics|Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks
214809989|NCT03950336|OTHER|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
214809990|NCT03950336|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
214809991|NCT03950336|OTHER|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
214809992|NCT05215535|RADIATION|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
214809993|NCT05215535|RADIATION|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
214809994|NCT03220802|DIETARY_SUPPLEMENT|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
214809995|NCT02537093|BEHAVIORAL|Psychiatric Consultation|
214809996|NCT06562452|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
214809997|NCT01233622|DRUG|Vildagliptin|
214809998|NCT01233622|DRUG|Placebo|
214809999|NCT01893008|OTHER|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
214810000|NCT05602103|DRUG|use of anticancer drugs in monotherapy or in combination therapy|Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
214810001|NCT06310460|PROCEDURE|Papillectomy|Papillectomy prior to bile duct cannulation during ERCP
214810002|NCT03690960|PROCEDURE|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
214810003|NCT03690960|PROCEDURE|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
214810004|NCT05019560|DRUG|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
214810005|NCT05019560|DRUG|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
214810006|NCT04013425|PROCEDURE|Ice Cream Cone Technique|Guided bone regeneration
214810007|NCT02376348|BEHAVIORAL|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
214810008|NCT04883801|DIAGNOSTIC_TEST|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
214810009|NCT02994186|PROCEDURE|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
214648281|NCT00948961|BIOLOGICAL|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
214648282|NCT00948961|BIOLOGICAL|CDX-1401|
214648283|NCT00948961|BIOLOGICAL|Resiquimod|
214648284|NCT00948961|BIOLOGICAL|poly-ICLC|
214648285|NCT01468649|DEVICE|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
214648286|NCT00270894|DRUG|epirubicin|epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
214648287|NCT00270894|DRUG|cyclophosphamide|cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
214648288|NCT00270894|DRUG|docetaxel|docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
214648289|NCT00270894|DRUG|trastuzumab|trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
214648290|NCT02773329|OTHER|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
214648291|NCT02773329|OTHER|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
214648292|NCT03933943|DRUG|LY3361237|Administered SC
214648293|NCT03933943|DRUG|Placebo|Administered SC
214648294|NCT03724448|DRUG|aleozen|treatment with herbal medicine
214648295|NCT03724448|DRUG|Placebo Oral Tablet|No aleozen treatment
214810010|NCT02994186|OTHER|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
214810011|NCT02020707|BIOLOGICAL|Bevacizumab|Given IV
214810012|NCT02020707|OTHER|Laboratory Biomarker Analysis|Correlative studies
214810013|NCT02020707|DRUG|Nab-paclitaxel|Given IV
214810014|NCT02020707|OTHER|Pharmacological Study|Correlative studies
214810015|NCT03151278|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
214810016|NCT03151278|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
214810017|NCT03615300|DIAGNOSTIC_TEST|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
214810018|NCT01643707|BEHAVIORAL|Evidence based guidelines and tools|Education, guidelines, tools
214810019|NCT02183571|DRUG|Merck Glucophage® high dose|Part I: Treatment A
214810020|NCT02183571|DRUG|BMS Glucophage® high dose|Part I: Treatment B
214810021|NCT02183571|DRUG|Merck Glucophage® low dose|Part II: Treatment C
214810022|NCT02183571|DRUG|BMS Glucophage® low dose|Part II: Treatment D
214810023|NCT01391793|DRUG|Placebo|Twice daily for 3 days
214810024|NCT01391793|DRUG|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
214810025|NCT01666730|DRUG|metformin hydrochloride|Given PO
214810026|NCT01666730|DRUG|oxaliplatin|Given IV
214810027|NCT01666730|DRUG|leucovorin calcium|Given IV
214810028|NCT01666730|DRUG|fluorouracil|Given IV
214810029|NCT01666730|OTHER|laboratory biomarker analysis|Correlative studies
214810030|NCT04335578|DRUG|Zampilimab|Participants will receive zampilimab (UCB7858) at pre-specified time-points.
214810031|NCT04335578|DRUG|Placebo|Participants will receive matching placebo (PBO) at pre-specified time-points.
214810032|NCT05290194|RADIATION|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
214810033|NCT05290194|DRUG|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
214810034|NCT05290194|DRUG|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
214810035|NCT05702567|DEVICE|RF + PFMT|"During each session the patient is lying face up, with knees bent and feet resting on the stretcher.~Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency. The device is started at 15% intensity and adapting to a 10-point Likert scale, at point 3 or 4 of intensity.~At the same time that the radiofrequency is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are three:~* 10 fast contractions of one second each, with 10 seconds of rest.~* 5 seconds of sustained contraction and 10 seconds of rest.~* 10 seconds of contraction maintained with 10 seconds of rest.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
214810036|NCT05702567|OTHER|PFMT + Placebo RF|"The intervention is exactly the same as the group RF + PFMT, unlike the non-functioning of the RF in the patients belonging to this group.~The patient is lying face up, with knees bent and feet resting on the stretcher. Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency, the device is started at 15% intensity, but in this case, the program does not work or apply radiofrequency to the patients.~At the same time, that the radiofrequency's probe is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are the three named in the Radiofrequency + PFMT.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
214810037|NCT00758186|PROCEDURE|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
214810038|NCT00758186|PROCEDURE|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
214810039|NCT02087904|BIOLOGICAL|ABT-981|
214810040|NCT02087904|OTHER|Placebo|
214810041|NCT02186730|BEHAVIORAL|Stressbusters|cCBT
214810042|NCT02186730|BEHAVIORAL|Websites|Self help websites
214810043|NCT01327963|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
214810044|NCT01823965|DRUG|ranibizumab|
214810045|NCT03705065|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
214810046|NCT04258982|OTHER|no intervention|no intervention
214810047|NCT02743130|DIETARY_SUPPLEMENT|Blackcurrant Nectar|Consumption of a single dose (300 ml)
214810048|NCT02743130|DIETARY_SUPPLEMENT|Lingonberry Nectar|Consumption of a single dose (300 ml)
214810049|NCT02743130|DIETARY_SUPPLEMENT|Reference|Consumption of a single dose (300 ml)
214810050|NCT01389102|DRUG|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
214810051|NCT01389102|DRUG|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
214810052|NCT01389102|DRUG|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
214810053|NCT01389102|DRUG|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
214810054|NCT01389102|DRUG|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
214810055|NCT01389102|DRUG|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
214810056|NCT01493752|DIETARY_SUPPLEMENT|beetroot juice|250mls daily beetroot juice
214810057|NCT04903600|DIETARY_SUPPLEMENT|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
214810058|NCT04903600|DIETARY_SUPPLEMENT|Placebo|Eat 16 g for once, and twice a day
214810059|NCT02910037|DEVICE|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
214810060|NCT00436553|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
214810061|NCT00436553|DRUG|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
214810062|NCT00436553|DRUG|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
214810063|NCT00436553|DRUG|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
214810064|NCT02379247|DRUG|BYL-719 (alpelisib)|Oral PI3K inhibitor
214810065|NCT02379247|DRUG|Nab-paclitaxel|IV taxane
214810066|NCT03867994|DRUG|Atorvastatin|
214810067|NCT03867994|DRUG|Carvedilol|
214810068|NCT03867994|DRUG|saline|
214810069|NCT01563965|DIETARY_SUPPLEMENT|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
214810070|NCT01563965|OTHER|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
214810071|NCT01174680|PROCEDURE|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
214810072|NCT01056965|DRUG|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
214810073|NCT01056965|DRUG|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
214810074|NCT00000957|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214810075|NCT04135820|DRUG|BPI-7711|BPI-7711 180 mg
214810076|NCT02770625|DRUG|ISU302|60 U/kg given intravenously
214810077|NCT03192930|OTHER|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
214810078|NCT01474668|DRUG|GDC-0941|Single oral dose\\n \\n\\n\\n\\n
214810079|NCT03203863|DIAGNOSTIC_TEST|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
214810080|NCT02437279|PROCEDURE|Surgery of the tumor|
214810081|NCT02437279|DRUG|Infusion with ipilimumab 3 mg/kg q3wks|
214810082|NCT02437279|DRUG|Infusion with nivolumab 1 mg/kg q3wks|
214810083|NCT00944203|DRUG|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
214810084|NCT02549651|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
214810085|NCT02549651|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
214810086|NCT02549651|DRUG|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
214810087|NCT04556240|DEVICE|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
214810088|NCT02698982|DEVICE|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
214810089|NCT02698982|PROCEDURE|moderate risk surgery|
214810090|NCT01361048|DRUG|oral metronidazole|2 gm oral once
214810091|NCT01361048|DRUG|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
214810092|NCT01361048|DRUG|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
214810093|NCT04625348|DEVICE|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
214810094|NCT04625348|OTHER|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
214810095|NCT02620930|DEVICE|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
214810096|NCT00558857|DEVICE|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
214810097|NCT02550340|OTHER|acute alcohol intake|Smart phone based ECG recording
214810098|NCT01020734|BIOLOGICAL|anti-thymocyte globulin|
214810099|NCT01020734|DRUG|busulfan|
214810100|NCT01020734|DRUG|cyclophosphamide|
214810101|NCT01020734|DRUG|cyclosporine|
214810102|NCT01020734|DRUG|fludarabine phosphate|
214810103|NCT01020734|DRUG|methotrexate|
214810104|NCT01020734|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214810105|NCT01661686|DEVICE|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
214810106|NCT01661686|DEVICE|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
214810107|NCT04766281|DIETARY_SUPPLEMENT|MLC901|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
214810108|NCT04766281|GENETIC|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
214810109|NCT01550900|DRUG|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
214810110|NCT01550900|OTHER|Placebo|Placebo tablets by mouth 1 time a day.
214810111|NCT01985893|DRUG|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
214810112|NCT05934071|DRUG|SGLT2 inhibitor|optimization of the medical therapy for heart failure with reduced ejection fraction with SGLT2 inhibitor, according to clinical guidelines
214810113|NCT04391062|DRUG|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
214810114|NCT04391062|DEVICE|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
214810115|NCT00206544|DRUG|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
214810116|NCT00206544|DRUG|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
214810117|NCT00206544|OTHER|placebo|adjunctive placebo daily in oral capsule
214810118|NCT06129227|BEHAVIORAL|Dual-task training|This group will receive 30 min of dual-task exercise training and 30 min of stretching exercises in each session. The dual-task component involves walking activities performed in conjunction with cognitive activities. For the stretching exercise component, no cognitive load will be added.
214810119|NCT06129227|BEHAVIORAL|Single-task training|This group will undergo 30 min of single-task mobility training and another 30 min of single-task cognitive activities. The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately. No extra cognitive load will be imposed during the mobility exercises. No additional motor demand will be imposed during the cognitive exercises, as the participants will be sitting.
214810120|NCT06129227|BEHAVIORAL|Control group|This group will undergo 30 min of stretching exercises (same as the dual-task group) and another 30 min of upper limb strengthening exercises performed primarily in the sitting or lying position. No cognitive load will be added.
214810121|NCT00428857|PROCEDURE|non invasive ventilation|non invasive ventilation
214810122|NCT03411330|DRUG|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
214810123|NCT03411330|DRUG|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
214810124|NCT03411330|DRUG|Bupivacaine|bupivacaine (0.5%)
214810125|NCT01873586|PROCEDURE|Posterolateral Fusion|
214810126|NCT05440903|BEHAVIORAL|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
214810127|NCT05440903|BEHAVIORAL|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
214810128|NCT00531856|DRUG|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
214810129|NCT00531856|DRUG|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
214810130|NCT00531856|DRUG|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
214810131|NCT00531856|DRUG|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
214810132|NCT00531856|DRUG|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
214810133|NCT01559220|DEVICE|Deep Brain Stimulation|Implanted device
214810134|NCT00190814|DRUG|duloxetine|
214810135|NCT00190814|DRUG|placebo|
214810136|NCT01327690|BEHAVIORAL|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
214810137|NCT01327690|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
214810138|NCT05320679|OTHER|Implementation of Questionnaire|Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
214810139|NCT02171637|DRUG|BIBW 2992|escalating doses
214810140|NCT04269460|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
214810141|NCT06119841|PROCEDURE|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
214810142|NCT06119841|PROCEDURE|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
214648296|NCT01067820|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
214648297|NCT01067820|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
214648298|NCT05422729|BEHAVIORAL|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
214648299|NCT05422729|BEHAVIORAL|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
214810143|NCT06303726|PROCEDURE|ACL reconstruction single bundle|We will do surgery of ACL reconstruction with patellar ligament.
214810144|NCT06303726|PROCEDURE|ACL reconstruction double bundle|We will do surgery of ACL reconstruction with hamstring ligament.
214810145|NCT01933373|PROCEDURE|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
214648300|NCT04022486|OTHER|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
214648301|NCT02285400|PROCEDURE|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
214648302|NCT03285815|DEVICE|Proton Therapy|
214648303|NCT02669693|DIETARY_SUPPLEMENT|bread without olives|
214648304|NCT02669693|DIETARY_SUPPLEMENT|bread with olives|
214648305|NCT02707770|OTHER|Pulmonary Rehabilitation|
214648306|NCT05619965|DRUG|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
214648307|NCT05619965|DEVICE|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
214648308|NCT05619965|DEVICE|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
214648309|NCT05802030|OTHER|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
214648310|NCT05802030|OTHER|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
214648311|NCT00976430|PROCEDURE|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
214648312|NCT03088969|OTHER|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
214648313|NCT02163070|DIETARY_SUPPLEMENT|whey drink,|consumption of 220 milliliters of whey drink three times a week,
214648314|NCT02163070|DIETARY_SUPPLEMENT|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
214648315|NCT02163070|DIETARY_SUPPLEMENT|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
214648316|NCT03026387|BEHAVIORAL|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory."
214648317|NCT01091961|PROCEDURE|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
214648318|NCT05130177|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
214648319|NCT05130177|DRUG|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
214648320|NCT05737693|DRUG|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
214648321|NCT05737693|DRUG|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
214648322|NCT02172651|DRUG|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
214648323|NCT02172651|DRUG|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
214648324|NCT03384108|OTHER|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
214810146|NCT01933373|PROCEDURE|Dor|Anterior partial fundoplication plus myotomy.
214810147|NCT00624065|DRUG|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
214810148|NCT00624065|DRUG|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
214810149|NCT00696020|DRUG|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
214810150|NCT00696020|DRUG|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
214810151|NCT00696020|DEVICE|Respimat® Inhaler|
214810152|NCT01467765|OTHER|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
214810153|NCT04195022|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
214810154|NCT04195022|PROCEDURE|Dental Restoration with Bulk fill resin composite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with bulk fill resin composite.
214810155|NCT01237522|DRUG|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
214810156|NCT01387022|DRUG|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
214810157|NCT05311501|OTHER|Non-surgical periodontal treatment|Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
214810158|NCT01972204|BEHAVIORAL|Intensive adherence instruction|Instruction with educational brochure
214810159|NCT01972204|BEHAVIORAL|Control|Instruction as per usual practice
214810160|NCT05122286|PROCEDURE|Bailout angioplasty|Use balloons or stents for bailout angioplasty
214810161|NCT05122286|PROCEDURE|Standard therapy|Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
214810162|NCT03636763|DRUG|data report|"the information gliptin exposure will be reported"
214810163|NCT02462317|DRUG|botulinum A toxin|botulinum toxin injection
214810164|NCT02462317|DRUG|Baclofen|baclofen oral tablet
214810165|NCT02462317|DRUG|Placebo toxin|placebo injection
214810166|NCT02462317|DRUG|placebo baclofen|placebo oral tablet
214810167|NCT01352663|BIOLOGICAL|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
214810168|NCT01352663|BIOLOGICAL|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
214810169|NCT02426710|DEVICE|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
214810170|NCT01165086|OTHER|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
214810171|NCT05841316|DRUG|Sugammadex|"During the surgery, the desired level of neuromuscular block will be deep and followed by post-tetanic-count (PTC) of 1 to 3 in every 5 minutes. 0.3-1mg/kg/h rocuronium will be infused to ensure PTC of 1 to 3.~At the end of the surgery, 0,6 mg sugammadex will be given as a bolus in the first patient of the study. The duration between the completion of sugammadex injection and the first measurement of Train-of-four ratio (TOFR) of 0.4 will be recorded.~If the TOFR is achieved to 0.4 after sugammadex bolus of 0,6 mg/kg in 5 minutes, the result of reversal will be evaluated as positive. The consecutive patient will be given the same or decreased dose of sugammadex by 0,2 mg/kg according to the randomisation scheme.~If the patient fails to recover from deep neuromuscular block to superficial block in 5 minutes after a given dose of sugammadex, the consecutive patient will be administered increased dose of sugammadex by 0,2 mg/kg."
214810172|NCT04441463|BIOLOGICAL|Blood sampling for tryptase analysis|"3 bloods test~* One blood sample taking from the mother's vein punction, during the delivery.~* One blood sample tanking from umbilical cord.~* One blood sample taking from the baby in day 3 of life, during the Guthrie test."
214810173|NCT00601302|DRUG|Amlodipine|
214810174|NCT04048369|DIAGNOSTIC_TEST|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
214810175|NCT06062914|DRUG|oral nutritional supplements|Only ONS was used as enteral nutrition
214810176|NCT00524264|DRUG|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
214810177|NCT05165823|BEHAVIORAL|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
214810178|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
214810179|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
214810180|NCT01577303|BEHAVIORAL|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
214810181|NCT01577303|BEHAVIORAL|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
214810182|NCT01577303|BEHAVIORAL|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
214810183|NCT01577303|BEHAVIORAL|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
214810184|NCT04058288|DEVICE|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
214810185|NCT01987011|BIOLOGICAL|MG1109|
214810186|NCT01987011|BIOLOGICAL|Placebo|
214810187|NCT04772807|DEVICE|Kinocardiograph|Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
214810188|NCT06121193|BEHAVIORAL|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
214810189|NCT06121193|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
214810190|NCT01868971|DEVICE|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
214810191|NCT00097383|DRUG|ALIMTA plus Epirubicin|
214810192|NCT03080597|DEVICE|PrEP Smart app|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart."
214810193|NCT04321850|DRUG|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
214810194|NCT04321850|DRUG|Placebo oral tablet|The tablets were manufactured specifically for this study.
214810195|NCT01292720|DRUG|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
214810196|NCT01292720|DRUG|Placebo|Placebo in matching volumes
214810197|NCT03639662|OTHER|sophrology sessions|"Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
214648325|NCT03384108|OTHER|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
214648326|NCT03754660|DRUG|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
214648327|NCT00605267|DRUG|Tamoxifen|20 mg once daily oral dose
214648328|NCT00605267|DRUG|Anastrazole (Arimidex)|1 mg once daily oral dose
214648329|NCT00605267|DRUG|Goserelin acetate (Zoladex)|3.6mg/month depot injection
214648330|NCT02939131|BEHAVIORAL|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
214648331|NCT02939131|BEHAVIORAL|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
214648332|NCT03995719|OTHER|Preoperative education|65 patients were instructed to a preoperative stoma-education program
214648333|NCT03995719|OTHER|Postoperative education|73 patients, receiving the same information in postoperative period.
214648334|NCT06959823|DEVICE|Multisensory Pediatric Support Device (MSPSD)|Child-friendly multisensory device providing audio-visual distraction during invasive procedures.
214648335|NCT06960291|BEHAVIORAL|Group Exercise Classes|Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.
214648336|NCT06960863|RADIATION|fibroscan|Liver fibrosis and steatosis can be staged using Dimensional ultrasound TE (transient elastography).
214648337|NCT06959836|DEVICE|VIVERE Bovine Pericardial Bioprosthetic Valve|Replacement of the native valve or bioprosthesis
214648338|NCT02983487|PROCEDURE|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
214648339|NCT02983487|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
214648340|NCT00896467|OTHER|questionnaire administration|
214648341|NCT00896467|PROCEDURE|psychosocial assessment and care|
214648342|NCT00896467|PROCEDURE|quality-of-life assessment|
214648343|NCT01425385|OTHER|Near infrared spectroscopy monitoring|This is an observational study without interventions
214648344|NCT01425385|OTHER|Autoregulation monitoring|There are no interventions in this observational study
214648345|NCT00437216|DRUG|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
214648346|NCT00437216|DRUG|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
214648347|NCT03129308|DIAGNOSTIC_TEST|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
214648348|NCT04782167|BEHAVIORAL|BRACE|"Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1\) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
214648349|NCT04782167|BEHAVIORAL|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
214648350|NCT00360347|DRUG|C.E.R.A.|
214810198|NCT02360462|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
214810199|NCT02360462|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
214810200|NCT01759901|PROCEDURE|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
214810201|NCT05351918|OTHER|acupuncture|Acupuncture points are punctured with needles.
214810202|NCT00886275|DRUG|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
214810203|NCT00886275|DRUG|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
214810204|NCT00886275|DRUG|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
214810205|NCT02494544|DEVICE|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker
214810206|NCT02494544|DEVICE|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
214810207|NCT03982862|DRUG|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
214810208|NCT03982862|DRUG|Lidocaine|0.1ml 2% Xylocaine
214810209|NCT03982862|DRUG|Botulinum toxin A|4U Botox® diluted to 0.1 ml
214810210|NCT00287092|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
214810211|NCT00287092|BIOLOGICAL|Infanrix® -IPV+Hib|0.5 mL, IM
214810212|NCT05526573|DEVICE|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
214810213|NCT06217614|OTHER|(Manuka honey-green tea)|"Manuka honey is a natural honey, and green tea are herbs Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. Green tea plus ginger mouthwash was prepared by adding 50% green tea extract and 50% ginger extract. After extraction, the extract was filtered and taker to the vacuum evaporator to remove the solvent.~The mouthwash was prepared by adding 3 gm of each extract, 0.12 gm sodium saccharin, and one liter distilled water, then every 20 ml of Manuka honey were added in 100 ml of (green tea and ginger solution). Finally, the mixture was stirred vigorously until all the particles were dissolved. Thereafter the obtained mixture was filtered. The mouthwash then filled in sterilized amber color bottles of 250 ml each.~According to similar studies performed in this field, the patients used a 20ml of (Manuka honey-green tea- ginger) mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out"
214810214|NCT00103623|DRUG|Plenaxis|
214810215|NCT02356302|DEVICE|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
214648351|NCT01249235|PROCEDURE|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
214648352|NCT03775707|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214648353|NCT03775707|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214648354|NCT01451593|DRUG|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
214648355|NCT01451593|DRUG|Placebo|placebo identical in appearance to active IMP (phenytoin)
214810216|NCT02356302|DEVICE|MK-2048 IVR|Contains 30 mg MK-2048.
214810217|NCT02356302|DEVICE|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
214810218|NCT02356302|DEVICE|Placebo IVR|
214810219|NCT01273779|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
214810220|NCT01273779|DRUG|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
214810221|NCT03252509|PROCEDURE|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
214810222|NCT05757245|GENETIC|GMCN-508A Drug Product|Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.
214810223|NCT03959683|DEVICE|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
214810224|NCT03959683|DEVICE|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
214810225|NCT05026671|PROCEDURE|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
214810226|NCT05026671|PROCEDURE|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
214810227|NCT05026671|PROCEDURE|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
214810228|NCT05026671|PROCEDURE|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
214810229|NCT00002905|DRUG|cyclophosphamide|
214810230|NCT00002905|DRUG|didanosine|
214810231|NCT00002905|DRUG|doxorubicin hydrochloride|
214810232|NCT00002905|DRUG|etoposide|
214810233|NCT00002905|DRUG|mitoxantrone hydrochloride|
214810234|NCT00002905|DRUG|prednimustine|
214810235|NCT00002905|DRUG|zidovudine|
214810236|NCT06305897|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
214810237|NCT06305897|DEVICE|CRYONOVE (EC+05_1osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
214810238|NCT06305897|DEVICE|CRYONOVE (EC+05_2osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
214810239|NCT00904345|DRUG|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
214810240|NCT00904345|RADIATION|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
214810241|NCT03352518|DEVICE|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
214810242|NCT02495467|DRUG|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
214810243|NCT02495467|DRUG|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
214810244|NCT02848742|DEVICE|Dermal Cooling System|Dermal cryotherapy
214810245|NCT06486129|PROCEDURE|Noninvasive ventilation volume targetted|he aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (BiPAP) on cardiac parameters and myocardial biomarkers in patients with OHS
214810246|NCT02976662|PROCEDURE|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
214810247|NCT01779544|OTHER|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
214810248|NCT01779544|OTHER|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
214810249|NCT05683665|DEVICE|scintigraphy DaTSCAN|DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
214810250|NCT04770857|OTHER|Visual analogue scale|Post procedural pain assessment using the visual analogue scale (VAS) will be performed in patients undergoing ERCP
214810251|NCT01536574|DRUG|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
214810252|NCT01392430|OTHER|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
214810253|NCT05184426|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
214810254|NCT05184426|DIAGNOSTIC_TEST|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
214810255|NCT05184426|DIAGNOSTIC_TEST|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
214810256|NCT05184426|DIAGNOSTIC_TEST|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
214810257|NCT04970420|OTHER|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).|In this study, individual training, training via mobile application and telephone counseling will be given to the experimental group. During the meetings, attention will be paid to the pandemic rules.
214810258|NCT04970420|OTHER|Control group|Individual training, mobile application and telephone counseling will be given to the control group after the study data is collected.
214810259|NCT05668520|DIAGNOSTIC_TEST|Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system|"Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference"
214810260|NCT02605148|DIETARY_SUPPLEMENT|Gluten free diet|Gluten free diet during 18 months.
214810261|NCT02605148|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Omega 3 fatty acid
214810262|NCT02605148|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 800 U/day
214810263|NCT02605148|DIETARY_SUPPLEMENT|Probiotics|Probiotics
214810264|NCT05293886|OTHER|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
214810265|NCT05293886|OTHER|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
214810266|NCT00526734|BIOLOGICAL|filgrastim|
214810267|NCT00526734|BIOLOGICAL|pegfilgrastim|
214810268|NCT00526734|DRUG|melphalan|
214810269|NCT00526734|PROCEDURE|autologous hematopoietic stem cell transplantation|
214810270|NCT01319123|DEVICE|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
214810271|NCT02646865|BEHAVIORAL|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
214810272|NCT02646865|BEHAVIORAL|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol
214810273|NCT00656305|DEVICE|ExAblate MRfFUS|MR guided focused ultrasound.
214810274|NCT00656305|DEVICE|Sham|sham comparator
214810275|NCT01262469|DRUG|lapatinib + capecitabine|"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."
214810276|NCT04710381|DRUG|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
214810277|NCT01667627|DIETARY_SUPPLEMENT|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
214810278|NCT01667627|OTHER|Placebo|Identical placebo
214810279|NCT01139320|GENETIC|DNA analysis|
214810280|NCT01139320|GENETIC|polymerase chain reaction|
214810281|NCT01139320|OTHER|laboratory biomarker analysis|
214810282|NCT01139320|OTHER|pharmacological study|
214810283|NCT02193165|DRUG|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
214810284|NCT02193165|DRUG|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
214810285|NCT02193165|DRUG|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
214810286|NCT05439148|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
214810287|NCT01778517|OTHER|Group Psychotherapy|
214810288|NCT01778517|OTHER|Cognitive behavior therapy based on self help|
214810289|NCT01125137|PROCEDURE|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
214810290|NCT05069961|PROCEDURE|ESPB|Ropivacaine is injected near the nerves in the back
214810291|NCT05069961|PROCEDURE|TEA|Bupivacaine is injected into the space around the spinal cord.
214810292|NCT01486147|BEHAVIORAL|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
214810293|NCT01486147|BEHAVIORAL|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
214810294|NCT00202605|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
214810295|NCT04658745|DEVICE|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
214810296|NCT04658745|BEHAVIORAL|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
214810297|NCT04658745|DEVICE|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
214810298|NCT04658745|BEHAVIORAL|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
214810299|NCT03203980|OTHER|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
214810300|NCT01498120|DRUG|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day"
214810301|NCT04058080|OTHER|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
214810302|NCT04058080|OTHER|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
214810303|NCT01173692|DRUG|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
214810304|NCT01173692|DRUG|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
214810305|NCT05857085|DRUG|Semaglutide Pen Injector [Ozempic]|GLP 1 agonist
214810306|NCT05857085|DRUG|Empagliflozin 10 MG|SGLT 2 inhibitor
214810307|NCT05658783|OTHER|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
214810308|NCT00616408|DRUG|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
214810309|NCT04222790|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
214810310|NCT04222790|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
214810311|NCT05672264|OTHER|Whole-Body Electromyostimulation|Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.
214810312|NCT05672264|OTHER|Physiotherapy|Six standardised physiotherapy sessions (20 min each)
214810313|NCT02783352|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
214810314|NCT02783352|PROCEDURE|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
214810315|NCT00845715|OTHER|Early motion|Early referral to physical therapy for range of motion (2 days post)
214810316|NCT00845715|OTHER|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
214810317|NCT03785301|DEVICE|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
214810318|NCT05200663|DRUG|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
214810319|NCT05200663|DRUG|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
214810320|NCT01842750|DEVICE|Endorectal Balloon insertion|
214810321|NCT00678639|OTHER|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
214810322|NCT04603092|BEHAVIORAL|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
214810323|NCT03090932|OTHER|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
214810324|NCT02096510|DRUG|Solu-Cortef|administration by pump for minimum 2 weeks
214810325|NCT02096510|DRUG|Cortef|tablet treatment 2 ro 3 times per day for 14 days
214810326|NCT02469805|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
214810327|NCT02469805|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
214810328|NCT02469805|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
214810329|NCT02469805|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
214810330|NCT02469805|DEVICE|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
214810331|NCT03609983|OTHER|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
214810332|NCT03609983|OTHER|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
214810333|NCT04360447|DEVICE|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
214810334|NCT04360447|OTHER|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
214810335|NCT00986245|DRUG|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
214810336|NCT06558162|BEHAVIORAL|Mindfetalness|"They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks."
214810337|NCT06558162|BEHAVIORAL|Sadovsky|"They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month"
214810338|NCT00132262|BEHAVIORAL|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
214810339|NCT00132262|BEHAVIORAL|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
214810340|NCT01629381|DRUG|Rivaroxaban|10 mg os once daily for 1 week
214810341|NCT01629381|DRUG|placebo|10 mg os once daily for 1 week
214810342|NCT05519800|DIETARY_SUPPLEMENT|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
214810343|NCT05519800|DIETARY_SUPPLEMENT|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
214810344|NCT03235388|OTHER|Audit filters|Institutional implementation of audit filters
214648356|NCT06250387|PROCEDURE|Endobronchial ultrasound transbronchial cryobiopsy|"Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy"
214648357|NCT04925492|RADIATION|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
214648358|NCT04925492|DRUG|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
214648359|NCT01718184|PROCEDURE|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
214648360|NCT01718184|PROCEDURE|Sulcoflex intraocular lens implantation|
214648361|NCT05063812|OTHER|Observational|All these patients have been enrolled in the COVID-19 remote patient monitoring program
214648362|NCT02720757|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
214648363|NCT00788905|DEVICE|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
214648364|NCT02048345|DRUG|Suspension Fasted State|
214648365|NCT02048345|DRUG|Suspension Fed State|
214648366|NCT02048345|DRUG|Solution Fasted State|
214648367|NCT02048345|DRUG|Solution Fed State|
214648368|NCT02606552|DRUG|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
214648369|NCT02606552|DRUG|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
214648370|NCT02606552|DEVICE|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
214648371|NCT04324645|OTHER|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
214648372|NCT00883493|DRUG|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
214648373|NCT00883493|DRUG|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
214648374|NCT00531193|DRUG|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
214648375|NCT00531193|OTHER|[11C]SCH442416|11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
214648376|NCT04324177|OTHER|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
214648377|NCT05959473|DEVICE|Idylla EGFR_IUO/3.20 Mutation Test|Clinical Performance Study Protocol for Idylla EGFR\_IUO/3.20 Mutation Test The EGFR\_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.
214648378|NCT01699139|DEVICE|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
214648379|NCT01699139|DEVICE|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
214648380|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
214648381|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
214648382|NCT01084551|DRUG|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
214648383|NCT00423059|DRUG|bevacizumab|
214648384|NCT01583478|BIOLOGICAL|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
214648385|NCT02556567|OTHER|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
214648386|NCT04688294|DRUG|Sacubitril-Valsartan|30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
214648387|NCT04688294|DRUG|Valsartan|30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
214648388|NCT05674474|DRUG|Vorasidenib|Administered orally as tablets.
214648389|NCT00463476|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
214648390|NCT01061931|PROCEDURE|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
214810345|NCT02816788|BEHAVIORAL|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
214810346|NCT03846765|DRUG|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
214810347|NCT03846765|DRUG|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
214810348|NCT01214850|BIOLOGICAL|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
214810349|NCT01214850|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
214810350|NCT01214850|BIOLOGICAL|Japanese Encephalitis vaccine|
214810351|NCT00021463|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
214810352|NCT00021463|DRUG|Abacavir sulfate|
214810353|NCT00021463|DRUG|Efavirenz|
214810354|NCT00021463|DRUG|Nevirapine|
214810355|NCT02824484|BEHAVIORAL|GWDP|"In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
214810356|NCT02824484|BEHAVIORAL|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
214810357|NCT03664908|OTHER|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
214810358|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
214810359|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
214810360|NCT04478019|DRUG|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
214810361|NCT01416246|PROCEDURE|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is \< or = to 50 and/or age \> 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
214810362|NCT04038710|DRUG|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
214810363|NCT01863745|DRUG|nilotinib|Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
214810364|NCT00193609|DRUG|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
214810365|NCT00193609|DRUG|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
214810366|NCT03956264|DEVICE|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
214810367|NCT03956264|DRUG|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
214810368|NCT04680364|OTHER|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
214810369|NCT01214226|DRUG|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
214810370|NCT01214226|DRUG|placebo|prolonged-release tablets 3 time per day for 1 month
214810371|NCT01965522|DRUG|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
214810372|NCT01965522|DRUG|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
214810373|NCT01965522|DRUG|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
214810374|NCT01965522|DRUG|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
214810375|NCT00854308|DRUG|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
214810376|NCT00854308|DRUG|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
214810377|NCT00854308|DRUG|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
214810378|NCT05928481|OTHER|Simulation-based postpartum bleeding management training|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
214810379|NCT01642511|RADIATION|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
214810380|NCT01642511|PROCEDURE|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
214810381|NCT01642511|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
214810382|NCT01642511|DEVICE|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
214810383|NCT01642511|PROCEDURE|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
214810384|NCT01642511|PROCEDURE|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
214810385|NCT00076050|DIETARY_SUPPLEMENT|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
214810386|NCT00076050|DIETARY_SUPPLEMENT|Placebo|Placebo soy isoflavones
214810387|NCT01180569|DRUG|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
214810388|NCT04806308|BEHAVIORAL|Otolaryngology stretching micro-breaks (OSMB)|Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
214810389|NCT03518281|DIETARY_SUPPLEMENT|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing \>50% Beta Glucan
214810390|NCT03518281|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
214810391|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
214810392|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
214810393|NCT00003332|DRUG|cisplatin|
214810394|NCT00003332|DRUG|gemcitabine hydrochloride|
214810395|NCT00003332|PROCEDURE|surgical procedure|
214810396|NCT00003332|RADIATION|radiation therapy|
214810397|NCT00167739|DRUG|Quinine plus sulfadoxine-pyrimethamine|
214810398|NCT04817709|OTHER|Educational Intervention|Review workbook
214810399|NCT04817709|OTHER|Usual Care|Receive educational materials
214810400|NCT04817709|OTHER|Media Intervention|Watch video
214810401|NCT04817709|OTHER|Medical Chart Review|Review of medical records
214810402|NCT04817709|OTHER|Questionnaire Administration|Complete questionnaires
214810403|NCT04514393|DRUG|Methotrexate|Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
214810404|NCT04514393|DRUG|Ibrutinib|Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
214810405|NCT04514393|DRUG|Temozolomide|Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
214810406|NCT00610363|BIOLOGICAL|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
214810407|NCT00610363|OTHER|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
214810408|NCT03048500|OTHER|Laboratory Biomarker Analysis|Correlative studies
214810409|NCT03048500|DRUG|Metformin Hydrochloride|Given PO
214810410|NCT03048500|BIOLOGICAL|Nivolumab|Given IV
214810411|NCT02324803|DRUG|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
214810412|NCT01461850|DRUG|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
214810413|NCT01461850|PROCEDURE|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
214810414|NCT04723602|BIOLOGICAL|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
214810415|NCT04723602|BIOLOGICAL|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
214810416|NCT05439824|BIOLOGICAL|SYS6006 20 μg|SARS-CoV-2 mRNA Vaccine
214810417|NCT05439824|BIOLOGICAL|SYS6006 30 μg|SARS-CoV-2 mRNA Vaccine
214810418|NCT05439824|BIOLOGICAL|Placebo|Placebo
214810419|NCT00724191|PROCEDURE|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
214810420|NCT01171963|BIOLOGICAL|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
214810421|NCT01171963|BIOLOGICAL|Placebo|Oral administration
214810422|NCT01171963|BIOLOGICAL|Infanrix™|Intramuscular administration
214810423|NCT01171963|BIOLOGICAL|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
214810424|NCT00957151|DRUG|Creon|
214810425|NCT00439075|PROCEDURE|CPAP|
214810426|NCT00439075|DRUG|standard treatment|
214810427|NCT05664464|DRUG|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
214810428|NCT05664464|DRUG|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
214810429|NCT05664464|DRUG|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
214810430|NCT05664464|DRUG|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
214810431|NCT05664464|RADIATION|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
214810432|NCT03807141|OTHER|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
214810433|NCT03113006|PROCEDURE|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
214810434|NCT01751594|BEHAVIORAL|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
214810435|NCT01751594|BEHAVIORAL|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
214810436|NCT03876054|DEVICE|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
214810437|NCT03876054|DEVICE|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
214810438|NCT02866188|DEVICE|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
214810439|NCT05517681|OTHER|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
214810440|NCT05517681|DRUG|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
214810441|NCT06280690|DRUG|SGM-101|SGM-101 is cea-targeted fluorescent dye
214810442|NCT03079271|DRUG|Lacrisert, 5 Mg Ophthalmic Insert|
214810443|NCT00665821|BEHAVIORAL|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
214810444|NCT00665821|BEHAVIORAL|General health education|General health education: a booklet describing general norms for maintaining good health
214810445|NCT03587649|DRUG|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
214810446|NCT03435705|BEHAVIORAL|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
214810447|NCT00804063|PROCEDURE|drawing blood sample|fasting blood sample
214810448|NCT03963063|PROCEDURE|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2"
214648391|NCT06228612|DEVICE|vacuum therapy|vacuum therapy :all patients were informed about initial suction sensation and possible appearance of bruising at the application site. Basic vacuum therapy equipment (cangexia, China) was utilized including a manual suction pump, plastic cups of 40 mm diameter with rolled edge, and anti-septic tools.
214648392|NCT06228612|DEVICE|maxillary stabilization splint (MSS)|maxillary stabilization splint (MSS): was constructed for each patient from hard, heat-cured clear acrylic resin and fitted to the maxillary teeth. On the mounted master casts, the vertical dimension was adjusted to provide 3 mm of vertical space between the closest opposing cusps of the maxillary and mandibular teeth.
214648393|NCT06228612|DEVICE|vacuum therapy VT and maxillary stabilization splint (MSS)|vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
214648394|NCT00215007|DRUG|Levofloxacin|
214648395|NCT03360760|DRUG|Doxorubicin|60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
214648396|NCT03360760|DRUG|Cisplatin|100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
214648397|NCT03360760|DRUG|Methotrexate|High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
214648398|NCT03360760|DRUG|Ifosfamide|12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
214648399|NCT03360760|PROCEDURE|definitive surgery|Including limb-sparing procedure and amputation
214648400|NCT03360760|OTHER|pre surgical chemotherapy|chemotherapy that given before definitive surgery
214648401|NCT02120755|BIOLOGICAL|AmnioClear™ Human Allograft Amniotic Membrane|
214648402|NCT05504200|OTHER|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
214648403|NCT01484067|DEVICE|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
214648404|NCT00988247|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
214648405|NCT00988247|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
214648406|NCT03948932|DEVICE|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
214648407|NCT03948932|DEVICE|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
214648408|NCT01633957|OTHER|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
214648409|NCT01633957|OTHER|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
214648410|NCT04120922|OTHER|calcium carbonate|See arm description
214648411|NCT04120922|OTHER|sevelamer carbonate|See arm description
214648412|NCT01067131|BIOLOGICAL|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
214648413|NCT01067131|BIOLOGICAL|PEV7C9|capsule intravaginal application contains excipient only
214648414|NCT01067131|BIOLOGICAL|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
214648415|NCT01067131|BIOLOGICAL|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
214648416|NCT00289913|BIOLOGICAL|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
214648417|NCT00289913|BIOLOGICAL|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
214648418|NCT00289913|BIOLOGICAL|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
214810449|NCT03963063|PROCEDURE|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg"
214810450|NCT03252353|DRUG|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
214810451|NCT03252353|DRUG|Matching placebo|Matching placebo capsules
214810452|NCT03220919|OTHER|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
214810453|NCT03220919|OTHER|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, \>10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, \> 20 mmol/L."
214810454|NCT06325189|OTHER|Aerobic Interval Training|Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
214810455|NCT00467662|DRUG|Acyclovir 5%|
214810456|NCT00467662|DRUG|Docosanol 10%|
214810457|NCT00467662|DEVICE|Superlysine gel|
214810458|NCT00626548|DRUG|ZD4054|10 mg once daily oral dose
214810459|NCT00626548|DRUG|Palcebo|Matching Plcebo oral tablet once daily
214810460|NCT00048581|DRUG|Abatacept|Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
214810461|NCT00048581|DRUG|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
214810462|NCT00048581|DRUG|Abatacept|Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
214810463|NCT02706236|DRUG|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
214810464|NCT02706236|DRUG|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
214810465|NCT02719249|OTHER|Dried blood spot test|
214810466|NCT00499642|DRUG|Lecozotan SR|
214810467|NCT00499642|DRUG|Moxifloxacin|
214810468|NCT04219566|DEVICE|VeNS|Non-invasive electrical vestibular nerve stimulation
214810469|NCT04219566|DEVICE|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
214810470|NCT04619810|OTHER|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
214810471|NCT01059903|DRUG|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
214810472|NCT02344784|DEVICE|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
214810473|NCT02344784|DRUG|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
214810474|NCT03095222|DRUG|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
214810475|NCT03095222|DRUG|Opioids|Standard of care for pain management.
214810476|NCT05805657|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
214810477|NCT05805657|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
214810478|NCT05805657|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
214810479|NCT00085696|DRUG|VELCADE and rituximab|
214810480|NCT04063358|DRUG|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
214810481|NCT02243930|DEVICE|Disposable distal attachment|
214810482|NCT03230149|DIAGNOSTIC_TEST|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
214810483|NCT03206619|OTHER|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
214810484|NCT01616602|OTHER|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
214810485|NCT01616602|OTHER|Standard Position|The traditional left-lateral decubitus position
214810486|NCT00385593|DRUG|Symbicort (budesonide/formoterol) Turbuhaler|
214810487|NCT00385593|DRUG|Conventional treatment|
214810488|NCT06150027|OTHER|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
214810489|NCT00381537|DRUG|phenobarbitone|
214810490|NCT00381537|DRUG|carbamazepine|
214810491|NCT06282809|DEVICE|HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy|Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
214810492|NCT02551445|BEHAVIORAL|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
214810493|NCT00168883|DRUG|Carboplatin|
214810494|NCT00168883|DRUG|Paclitaxel|
214810495|NCT00168883|DRUG|Vinorelbine|
214810496|NCT03829098|OTHER|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
214810497|NCT03416764|DEVICE|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
214810498|NCT01270048|DRUG|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
214810499|NCT01270048|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
214810500|NCT04007133|OTHER|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
214810501|NCT03487107|DRUG|SOF|400 mg tablet administered orally once daily
214810502|NCT03487107|DRUG|DAG181|100 mg capsule administered orally once daily
214810503|NCT03992586|OTHER|Wearing pink glasses|Wearing pink-colored lenses
214810504|NCT03992586|OTHER|Wearing clear glasses|Wearing clear glasses
214810505|NCT02344992|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
214810506|NCT02344992|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
214810507|NCT02873910|DIETARY_SUPPLEMENT|IQP-AS-119|
214810508|NCT02873910|DIETARY_SUPPLEMENT|Placebo|
214810509|NCT01734291|BEHAVIORAL|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
214810510|NCT03979703|OTHER|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
214810511|NCT00214422|RADIATION|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
214810512|NCT06287905|DRUG|Prazosin Oral Tablet|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
214810513|NCT05717257|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
214810514|NCT00319735|PROCEDURE|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
214810515|NCT00319735|PROCEDURE|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
214810516|NCT00319735|PROCEDURE|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
214810517|NCT03929393|BEHAVIORAL|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
214810518|NCT03929393|OTHER|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
214810519|NCT03576040|DEVICE|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
214810520|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
214810521|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
214810522|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
214810523|NCT04165096|DRUG|diphenhydramine|PO
214810524|NCT04165096|DRUG|acetaminophen|PO
214810525|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
214810526|NCT04763161|PROCEDURE|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
214810527|NCT04763161|PROCEDURE|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
214810528|NCT04912739|BEHAVIORAL|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
214810529|NCT00958178|DRUG|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
214810530|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
214810531|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
214810532|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
214810533|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
214810534|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
214810535|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
214810536|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
214810537|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
214810538|NCT00969566|DRUG|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
214810539|NCT06375408|DEVICE|Real transcranial alternating electrical stimulation|The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
214810540|NCT06375408|DEVICE|Sham transcranial alternating electrical stimulation|The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
214810541|NCT03820713|PROCEDURE|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
214810542|NCT03820713|PROCEDURE|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
214810543|NCT02530762|OTHER|Novel Fiber|novel fiber supplemented beverage provided in one serving
214810544|NCT02530762|OTHER|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
214810545|NCT02530762|OTHER|Negative Control|No added fiber beverage
214810546|NCT03394209|DRUG|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
214810547|NCT03394209|DRUG|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
214810548|NCT03420300|DRUG|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
214810549|NCT03030196|DRUG|Denosumab|NaCl 0.9% injection is used as placebo
214810550|NCT05055349|OTHER|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
214810551|NCT04355455|DRUG|Citalopram|40 mg citalopram intravenously
214810552|NCT04355455|DRUG|Placebo|Saline solution
214810553|NCT04633109|PROCEDURE|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
214648419|NCT04173741|OTHER|USG measurement|IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
214648420|NCT01989130|DEVICE|Roche AMPLICOR CT/NG|
214648421|NCT01989130|DEVICE|Cepheid Xpert CT/NG Test|
214810554|NCT04633109|DIAGNOSTIC_TEST|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
214648422|NCT01124565|DRUG|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
214648423|NCT04568850|DIAGNOSTIC_TEST|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
214648424|NCT00563147|DRUG|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
214648425|NCT02530645|BEHAVIORAL|OnTrack|
214648426|NCT02530645|BEHAVIORAL|Treatment as Usual|
214648427|NCT02530645|BEHAVIORAL|Brief Motivational Interviewing|
214648428|NCT04381208|DIAGNOSTIC_TEST|Complete clinical examination|Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)
214648429|NCT02538302|DRUG|Minirin|Minirin 5 to 10 mg daily for 6 months
214648430|NCT02538302|DRUG|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
214648431|NCT01169779|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214648432|NCT01169779|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214648433|NCT01169779|DEVICE|Pen auto-injector|
214648434|NCT01169779|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
214648435|NCT01169779|DRUG|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
214648436|NCT03512548|DRUG|Relacorilant 350mg|Relacorilant 350mg
214648437|NCT03512548|DRUG|Itraconazole|Itraconazole 200 mg
214648438|NCT03512548|DRUG|Relacorilant 300mg|Relacorilant 300mg
214648439|NCT02141893|BEHAVIORAL|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
214648440|NCT02141893|BEHAVIORAL|CALMA|Family Education Intervention on management of pediatric asthma
214648441|NCT04111614|DRUG|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
214648442|NCT04111614|DRUG|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
214648443|NCT01284790|DEVICE|Cochlear implants|
214648444|NCT02779205|PROCEDURE|adipose tissue sample|adipose tissue sample
214648445|NCT00715130|BEHAVIORAL|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
214648446|NCT03261115|PROCEDURE|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
214648447|NCT02024971|DRUG|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
214648448|NCT06396650|DEVICE|Home-based training|"1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another."
214648449|NCT06396650|DEVICE|Lab-based training|In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
214648450|NCT03922854|OTHER|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
214648451|NCT03479047|DIAGNOSTIC_TEST|assess diaphragmatic displacement (DD) using ultrasonography|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
214648452|NCT01384682|DRUG|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
214648453|NCT02615457|DRUG|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
214648454|NCT00003665|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|
214648455|NCT00003665|BIOLOGICAL|gp100 antigen|
214648456|NCT00003665|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214648457|NCT00003665|BIOLOGICAL|tyrosinase peptide|
214648458|NCT06267963|DRUG|Oral [14C]PF-07220060|A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
214648459|NCT06267963|DRUG|Oral PF-07220060|A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.
214648460|NCT06267963|DRUG|IV [14C] PF-07220060|A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
214648461|NCT00087373|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
214648462|NCT00087373|OTHER|laboratory biomarker analysis|Correlative studies
214648463|NCT05863715|BEHAVIORAL|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
214648464|NCT01726088|DRUG|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
214648465|NCT04338490|DEVICE|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
214648466|NCT04139122|DRUG|SJP-0132|SJP-0132 is administered as an eye drop
214648467|NCT04139122|DRUG|Placebo|Placebo is administered as an eye drop
214648468|NCT04009928|DEVICE|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
214648469|NCT04009928|DEVICE|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
214648470|NCT05906277|DIAGNOSTIC_TEST|Biopsy|Liquid biopsy, re-biopsy, tissue biopsy
214648471|NCT01245088|DRUG|chondroitin sulfate|400 mg orally three times daily for 8 weeks
214648472|NCT03568877|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
214648473|NCT03568877|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
214648474|NCT04121845|DEVICE|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
214648475|NCT04121845|OTHER|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
214648476|NCT04613726|DRUG|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
214648477|NCT04613726|DRUG|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
214648478|NCT04613726|DRUG|Saline|Control group consisted of patients receiving IV 10 ml normal saline
214648479|NCT05689619|DIETARY_SUPPLEMENT|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
214648480|NCT05689619|OTHER|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
214648481|NCT05305807|OTHER|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
214648482|NCT06405672|PROCEDURE|Endotracheal tube with stylet|The obese patients who will be intubated with stylet in laparoscopic sleeve gastrectomy
214648483|NCT06405672|PROCEDURE|Endotracheal tube alone|The obese patients who will be intubated without stylet in laparoscopic sleeve gastrectomy
214648484|NCT02455401|DRUG|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
214648485|NCT02455401|DRUG|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
214648486|NCT02455401|DRUG|No remifentanil|Intervention: no remifentanil will be administrated
214648487|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
214648488|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
214648489|NCT00035204|DRUG|galantamine|
214648490|NCT04058587|DRUG|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
214648491|NCT02274610|DRUG|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
214648492|NCT02274610|DRUG|Taxotere|Docetaxel
214648493|NCT00052390|BIOLOGICAL|bevacizumab|
214648494|NCT00052390|DRUG|doxorubicin hydrochloride|
214648495|NCT03501966|DRUG|Acetazolamide|Medical therapy including diet
214648496|NCT03501966|PROCEDURE|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
214648497|NCT03501966|PROCEDURE|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
214648498|NCT00849667|DRUG|Farletuzumab|Farletuzumab IV infusion.
214648499|NCT00849667|DRUG|Carboplatin|Carboplatin IV infusion.
214810555|NCT04633109|DIAGNOSTIC_TEST|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
214648500|NCT00849667|DRUG|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
214648501|NCT00849667|DRUG|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
214648502|NCT04827641|OTHER|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
214648503|NCT01821495|BIOLOGICAL|DC-CIK|
214648504|NCT01821495|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
214648505|NCT03153839|BEHAVIORAL|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
214648506|NCT00046787|DRUG|OSI-211 (Liposomal Lurtotecan)|
214648507|NCT00424970|DRUG|acetazolamide|
214648508|NCT03228563|OTHER|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
214648509|NCT02198248|DRUG|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
214648510|NCT02198248|DRUG|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
214648511|NCT03973476|OTHER|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
214648512|NCT05568589|OTHER|Preoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
214810556|NCT04633109|DIAGNOSTIC_TEST|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
214810557|NCT04633109|DIAGNOSTIC_TEST|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
214810558|NCT04633109|DIAGNOSTIC_TEST|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
214810559|NCT04633109|OTHER|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
214810560|NCT04633109|OTHER|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
214810561|NCT05813028|OTHER|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
214810562|NCT05789238|BEHAVIORAL|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
214810563|NCT05789238|BEHAVIORAL|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
214810564|NCT06158451|COMBINATION_PRODUCT|Zinc oxide propolis|"Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached."
214810565|NCT06158451|COMBINATION_PRODUCT|Modified triple antibiotic paste|"Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~* After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~* The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency"
214810566|NCT04349605|BEHAVIORAL|Meditation|Meditation involves guided breathing and mindfulness training.
214810567|NCT04349605|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
214810568|NCT03948347|DRUG|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
214810569|NCT02041169|OTHER|Subsequent walking performance|Subsequent walking performance
214810570|NCT00465764|OTHER|Alternate protein infant formula|Feed as per HCP directions
214810571|NCT00465764|OTHER|Standard infant formula|Feed as per HCP directions
214810572|NCT03380754|DIETARY_SUPPLEMENT|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
214810573|NCT03380754|OTHER|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
214810574|NCT02012153|BIOLOGICAL|Mesenchymal Stromal Cells|
214810575|NCT05614960|OTHER|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
214810576|NCT00500487|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
214810577|NCT00500487|BEHAVIORAL|HIV Prevention Skills|12-session group intervention including sexual health skills training.
214810578|NCT00500487|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of health topics.
214810579|NCT04205201|DRUG|Drugs, Investigational|To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
214810580|NCT05566015|OTHER|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
214810581|NCT03447678|DRUG|Pembrolizumab|humanized antibody used in cancer immunotherapy
214810582|NCT01929122|DIETARY_SUPPLEMENT|Placebo-Control Meals and Snacks|
214810583|NCT01929122|DIETARY_SUPPLEMENT|Cooked Navy Bean Powder Meals and Snacks|
214810584|NCT01929122|DIETARY_SUPPLEMENT|Rice Bran Meals and Snacks|
214810585|NCT02164279|OTHER|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)
214810586|NCT03280797|PROCEDURE|Blood sample|2ml blood taken into TruCulture tube
214810587|NCT04150627|OTHER|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
214810588|NCT05859841|OTHER|Music listening|Music listening under instruction by music therapist, min 3 hours daily
214810589|NCT05859841|OTHER|Control|Standard treatment, care and rehabilitation
214810590|NCT03750097|BEHAVIORAL|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
214810591|NCT03750097|BEHAVIORAL|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
214810592|NCT03750097|BEHAVIORAL|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
214810593|NCT03012178|PROCEDURE|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
214810594|NCT00480350|BEHAVIORAL|rice based food supplement|
214810595|NCT03731598|PROCEDURE|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
214810596|NCT03306160|OTHER|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
214810597|NCT06234163|BEHAVIORAL|Assigned intervention|"Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition."
214810598|NCT02628834|OTHER|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
214810599|NCT02628834|OTHER|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
214810600|NCT02140060|DRUG|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
214810601|NCT02140060|DRUG|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
214810602|NCT02140060|DRUG|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
214810603|NCT02140060|DRUG|Brinzolamide 1% ophthalmic suspension AZOPT®|
214810604|NCT02140060|DRUG|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
214810605|NCT02140060|DRUG|Travoprost solution vehicle|Inactive ingredients used for masking purposes
214810606|NCT02140060|DRUG|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
214810607|NCT04849520|DEVICE|High flow nasal cannula|Oxygen supplement via high flow nasal cannula at a rate of 2 liters/kg/min
214810608|NCT04849520|DEVICE|Buccal oxygenation|Oxygen supplement intra-orally via oral Ring-Adair-Elwyn endotracheal tube connected to oxygen at a rate of 0.5 liters/kg/min
214810609|NCT01856426|DRUG|EDP239|
214810610|NCT01856426|DRUG|Placebo|
214810611|NCT00862550|OTHER|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
214810612|NCT07036757|OTHER|Meal Kit and Nutrition Education|Meal kits contain ingredients for 3 meals designed for 4 servings, along with nutrition education materials, recipes, and information on how to store and prepare the meals. Weekly educational content focused on healthy eating, food security, and meal planning will be provided, either via print materials or through an online platform (e.g., email or app-based resources).
214810613|NCT07035223|DRUG|4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-fr|Group D: patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-free normal saline, 0.5 ml will be withdrawn)
214810614|NCT07035223|DRUG|fentanyl|Group F:patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
214810615|NCT07037264|DEVICE|Non-ablative fractional laser treatment|The entire scar area is sealed with local anesthetic for 60 minutes before laser treatment. Give the study side 1565 nm non-ablative fractional laser treatment, spot diameter 10～16 mm, energy 40～45 mJ/cm2, spot density 150～200/cm2,1\~2passes.
214810616|NCT07036107|DEVICE|ABLE Exoskeleton|Participants will receive a 24-session rehabilitation treatment program with the ABLE Exoskeleton, 3 times a week for up to 8 weeks
214810617|NCT07036107|OTHER|Conventional therapy|"Participants will receive a 24-session conventional therapy program for gait rehabilitation, 3 times a week for up to 8 weeks.~Conventional therapy includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers)."
214810618|NCT07035613|DRUG|BXD treatment|The BXD extract was obtained from Sun Ten Pharmaceutical Company and is manufactured according to the standard procedures outlined in the Taiwan Herbal Pharmacopeia IV. The extract is produced using a fixed herbal composition and ratio based on the traditional BXD formula to yield a concentrated powder. The administration of BXD in this study follows the dosage and usage guidelines specified in the Pharmacopeia.
214810619|NCT07035587|OTHER|Serial Blood Sampling for Molecular Profiling|Cancer patients will undergo serial peripheral blood sampling at baseline (prior to surgery or chemotherapy), after treatment, and during follow-up visits. Blood samples will be analyzed for circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), RNA, and protein biomarkers. The purpose is to detect variant allele frequency (VAF) and evaluate its relationship with tumor dynamics and treatment outcomes, including recurrence and survival.
214810620|NCT07035587|OTHER|One-Time Blood Sampling for Molecular Profiling|Control participants, including individuals with asymptomatic gallstones, benign polyps, or those undergoing health screening, will provide a one-time peripheral blood sample. The sample will be analyzed for cfDNA, RNA, and protein biomarkers and used as a baseline reference to compare molecular characteristics between non-cancer and cancer groups.
214810621|NCT07037147|COMBINATION_PRODUCT|instrument assistance soft tissue mobilisation|In this group instrument assistance soft tissue mobilisation will be given followed by conventional therapy. IASTM will be given by using IASTM tool M2T blade. In this process patient will be asked to sit in a chair by resting its forearm in front of the table.
214810622|NCT07037147|COMBINATION_PRODUCT|Bowen technique|In this group Bowen technique will be given after the basic conventional therapy. For this technique patient will be asked to lie in a prone position where the neck of the patient will be supported with the help of a small pillow. Therapist thumb will be placed on the affected side of the muscle.
214810623|NCT07036133|DRUG|Pralatrexate Injection|Pralatrexate will be administered based on Child-Pugh Classification of liver impairment
214810624|NCT07035236|PROCEDURE|maxillary sinus lifting|The schneiderian membrane will be tented using titanium mesh.
214810625|NCT07035236|PROCEDURE|Maxillary sinus lifting|The Schneiderian membrane will be elevated using bone screws
214810626|NCT07036588|DEVICE|Modified Transanal Drainage Tube|Patients with rectal adenocarcinoma will undergo elective laparoscopic/robotic low anterior resection. After the anastomosis is completed and the air leak test is confirmed to be negative, a modified TDT (occlusive balloon catheter) will be inserted. The balloon will be placed 5 cm above the anastomosis and filled under laparoscopic visualization (approximately 25 ml) to slightly dilate the intestinal lumen and occlude the intestinal cavity (under laparoscopic monitoring to ensure it does not affect the blood supply of the intestine). The external part of the tube will be sutured to the perianal skin and further secured with a 3M transparent dressing on the outside. It will be connected to a drainage bag (with an inner diameter greater than 8 mm) and left in place for 7 days, or until the drainage function is lost due to obvious defecation around the anal tube, at which point the catheter will be removed.
214810627|NCT07036510|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye.
214810628|NCT07036510|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
214810629|NCT03098277|OTHER|Accelerometer|Wear Microsoft Band 2
214810630|NCT03098277|OTHER|Laboratory Biomarker Analysis|Correlative studies
214810631|NCT03098277|OTHER|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
214810632|NCT03098277|BEHAVIORAL|Telephone-Based Intervention|Complete PRO questionnaires
214810633|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
214810634|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
214810635|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
214810636|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
214810637|NCT00047606|DRUG|IOP Lowering Medications|
214810638|NCT05380024|DRUG|Ensartinib|Ensartinib 225mg QD 8 weeks
214810639|NCT05843279|PROCEDURE|Myofunctional therapy|In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
214810640|NCT00161564|DRUG|Rituximab|
214810641|NCT03762564|DRUG|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
214810642|NCT03762564|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
214810643|NCT04385771|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
214810644|NCT04385771|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
214810645|NCT06118970|OTHER|Neuropsychological tasks and self-report questionnaires|Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.
214810646|NCT03196570|BEHAVIORAL|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
214810647|NCT03196570|BEHAVIORAL|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
214810648|NCT03280394|DIAGNOSTIC_TEST|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
214810649|NCT02157636|DRUG|CPI-0610|
214810650|NCT03557632|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|As above.
214810651|NCT03557632|BEHAVIORAL|Relapse Prevention Drug Education|As above.
214810652|NCT04074915|OTHER|Placebo mouth rinse|Normal saline
214810653|NCT04074915|DRUG|Chlorhexidine mouth rinse|Chlorhexidine gluconate
214810654|NCT04074915|DRUG|Test group|Chamomile mouth rinse
214810655|NCT00465439|DRUG|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
214810656|NCT03067753|DRUG|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
214810657|NCT03067753|DRUG|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
214810658|NCT03067753|DRUG|Prednisolone|
214810659|NCT05278325|OTHER|Telephone intervention|Two planned phone call between clinical controls
214810660|NCT02158572|DRUG|AG200-15|Transdermal contraceptive delivery system
214810661|NCT05236634|DRUG|Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
214810662|NCT05236634|DRUG|Alpha Blockers|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
214810663|NCT05236634|DRUG|Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
214810664|NCT03670485|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214810665|NCT04013919|DRUG|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
214810666|NCT04013919|DRUG|Single insulin injections|Basal insulin injections only
214810667|NCT06317454|DIAGNOSTIC_TEST|Blood and saliva analysis|Phenotyping and genotyping characterization using blood and saliva
214810668|NCT04394962|DEVICE|Virtual reality|Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
214810669|NCT04503603|DRUG|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
214810670|NCT04503603|OTHER|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
214810671|NCT05163743|DIETARY_SUPPLEMENT|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
214810672|NCT05093309|BEHAVIORAL|Educational Webinar|At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
214810673|NCT05093309|BEHAVIORAL|Resources|After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
214810674|NCT05093309|BEHAVIORAL|Reminders|Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
214810675|NCT03306394|DRUG|Trifluridine/Tipiracil hydrochloride (S95005)|
214810676|NCT00120198|DRUG|CDOP plus rituximab|
214810677|NCT02807987|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
214810678|NCT04863768|DIAGNOSTIC_TEST|Gene panel|comprehensive cancer gene panel targeting regions in 37 clinically relevant cancer genes in FFPE tumor tissue blocks
214810679|NCT04318821|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
214810680|NCT04230525|DIAGNOSTIC_TEST|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
214810681|NCT06140264|OTHER|Acupuncture dry needle|The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
214810682|NCT01735409|DRUG|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
214810683|NCT01735409|DRUG|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
214810684|NCT01735409|DRUG|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
214810685|NCT00343278|DRUG|Valaciclovir Hydrochloride|
214810686|NCT04901962|DEVICE|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
214810687|NCT03888794|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
214810688|NCT01814462|DEVICE|6 months CPAP|
214810689|NCT00800709|DRUG|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
214810690|NCT02970656|BEHAVIORAL|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
214810691|NCT03611478|DIETARY_SUPPLEMENT|Probiotic formulation|Probiotic capsule
214810692|NCT03611478|DIETARY_SUPPLEMENT|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
214810693|NCT05008640|DEVICE|TrueLoo™|TrueLoo™ is an Internet-connected, smart toilet seat that uses computer vision technology to log and capture daily bowel movements and urinations. This data is then categorized by physical excreta characteristics to train and develop machine learning algorithms that are intended to eventually identify significant changes in stool and urine in real-time.
214810694|NCT00511069|DRUG|Bortezomib|
214810695|NCT06248853|OTHER|Garston technique|the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot
214810696|NCT06248853|OTHER|exercise program|the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
214810697|NCT04416230|BEHAVIORAL|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
214810698|NCT04416230|BEHAVIORAL|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
214810699|NCT03866330|BIOLOGICAL|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
214810700|NCT00275730|DRUG|indometacine (drug) effect on ocular blood flow|
214810701|NCT02746484|OTHER|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
214810702|NCT02746484|OTHER|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
214810703|NCT02042664|DRUG|BYETTA treatment|
214810704|NCT02042664|DRUG|Metformine|
214810705|NCT03084822|BEHAVIORAL|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
214810706|NCT03478748|OTHER|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
214810707|NCT02575222|DRUG|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
214810708|NCT04249271|OTHER|serum sampling|repeated serum sampling during pregnancy and thereafter
214810709|NCT02676024|DEVICE|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
214810710|NCT02676024|DEVICE|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
214810711|NCT02676024|DEVICE|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
214810712|NCT04529863|DRUG|Tocilizumab|Tocilizumab claim is used as the reference group.
214810713|NCT04529863|DRUG|Abatacept|Abatacept claim is used as the exposure group.
214810714|NCT03217903|DIAGNOSTIC_TEST|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
214810715|NCT01366079|PROCEDURE|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
214810716|NCT01366079|PROCEDURE|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
214810717|NCT05220683|DEVICE|digital marking system|Verion or Callisto, digital marking system
214810718|NCT02898168|DEVICE|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
214810719|NCT02898168|OTHER|Control|Conventional rehabilitation therapy and gait training without WA.
214810720|NCT00763763|DRUG|Imatinib mesylate|imatinib 600 mg/day for 2 years
214810721|NCT00763763|DRUG|Interferon|45 micrograms per week during 2 years
214810722|NCT00763763|DRUG|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
214810723|NCT00763763|DRUG|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
214810724|NCT05673317|OTHER|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
214810725|NCT03860415|DIETARY_SUPPLEMENT|Vivomixx|Two months of 2 sachets vivomixx each morning and 2 sachets each night. Each sachet of viviomixx contains 450 billion live bacteria.
214810726|NCT03860415|DIETARY_SUPPLEMENT|Placebo|Two months of 2 sachets placebo each morning and 2 sachets each night. Each sachet of placebo contains 450 billion live bacteria.
214810727|NCT01108029|DRUG|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
214810728|NCT01108029|DRUG|placebo|2 tablets of placebo 1 time a day in the morning
214810729|NCT00939718|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
214810730|NCT02589808|DEVICE|Full TTE|Full transthoracic echocardiogram, with Doppler.
214810731|NCT02589808|DEVICE|GE Vscan|Handheld echo.
214810732|NCT01114048|DRUG|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
214810733|NCT05463822|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
214810734|NCT04036539|PROCEDURE|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
214810735|NCT05934825|BIOLOGICAL|Injectable suspension of allogeneic adult mesenchymal stem cells|Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).
214810736|NCT05934825|OTHER|Placebo|The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.
214810737|NCT02209285|BEHAVIORAL|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
214810738|NCT04926805|DEVICE|CPAP with Mask A|CPAP mask
214810739|NCT04926805|DEVICE|CPAP with Mask B|CPAP mask
214810740|NCT05050071|DRUG|Allium Sativum|Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
214810741|NCT05050071|DEVICE|Polymerase chain reaction|Change in the bacterial load in response to different treatment procedures
214810742|NCT02195193|OTHER|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
214810743|NCT02388971|DRUG|MLN1202|MLN1202 solution
214810744|NCT02388971|DRUG|Placebo|MLN1202 placebo-matching solution
214810745|NCT04028440|BIOLOGICAL|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
214810746|NCT06264960|BEHAVIORAL|Music therapy|After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
214810747|NCT06264960|BEHAVIORAL|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
214810748|NCT01608269|DRUG|Abacavir/Lamivudine|one tablet once a day
214810749|NCT05420896|OTHER|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
214810750|NCT05361330|DRUG|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
214810751|NCT05361330|DRUG|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
214810752|NCT00705003|DRUG|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
214810753|NCT00705003|DRUG|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
214810754|NCT00705003|DRUG|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
214810755|NCT01626287|OTHER|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
214810756|NCT01626287|OTHER|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
214810757|NCT04675372|DRUG|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
214810758|NCT04675372|DRUG|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
214810759|NCT06563336|OTHER|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick."
214810760|NCT06563336|OTHER|conventional occupational training|This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
214810761|NCT01668264|PROCEDURE|Echocardiograph|
214810762|NCT01668264|PROCEDURE|Magnetic Resonance Imaging (MRI)|
214810763|NCT06046430|OTHER|Assessment|The same assessments will be made to participants in both groups.
214810764|NCT02539589|BEHAVIORAL|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
214810765|NCT02539589|BEHAVIORAL|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
214810766|NCT06423066|DIAGNOSTIC_TEST|Pleural ultrasound|Patients who examine pleural ultrasound preoperatively.
214810767|NCT03505463|OTHER|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
214810768|NCT03505463|OTHER|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
214810769|NCT03505463|OTHER|Clinical examination|Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
215031285|NCT04192708|PROCEDURE|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
215031286|NCT06332157|DRUG|Remimazolam besylate|In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
214810770|NCT01848301|DEVICE|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
214810771|NCT01848301|DRUG|Acetylcholine|Infusion in the coronary artery to study endothelial function
214810772|NCT01848301|PROCEDURE|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
214810773|NCT04839367|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
214810774|NCT01056861|DRUG|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
214810775|NCT01416753|DEVICE|UCR|BVM-based regulation of ultrafiltration and conductivity
214810776|NCT01416753|DEVICE|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
214810777|NCT01302496|BIOLOGICAL|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
214810778|NCT01171690|DRUG|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
214810779|NCT01038856|DRUG|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
214810780|NCT04872075|OTHER|Concert|People attending a concert in a closed area, with a mask
214810781|NCT04872075|DIAGNOSTIC_TEST|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
214810782|NCT04872075|DIAGNOSTIC_TEST|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
214810783|NCT06199297|DRUG|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
214810784|NCT06199297|DRUG|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
214810785|NCT06199297|PROCEDURE|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
214810786|NCT02689297|OTHER|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
214810787|NCT02689297|OTHER|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
214810788|NCT00905658|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
214810789|NCT00905658|PROCEDURE|standard follow-up care|Patients undergo standard monitoring
214810790|NCT05439252|BEHAVIORAL|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
214810791|NCT01568762|DRUG|VAK694|Intravenous infusion
215031287|NCT06332157|DRUG|Propofol Injection Emulsion|In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
215031288|NCT00706173|DRUG|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
215031289|NCT00706173|DRUG|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
214810792|NCT01568762|DRUG|VAK694 placebo|Intravenous infusion
214810793|NCT01568762|DRUG|QAX576|Intravenous infusion
214810794|NCT01568762|DRUG|QAX576 placebo|Intravenous infusion
214810795|NCT02953223|OTHER|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
214810796|NCT03135236|BEHAVIORAL|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
214810797|NCT04466111|DEVICE|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
214810798|NCT01317927|DRUG|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
214810799|NCT02886468|OTHER|skin ultrasound|
214810800|NCT00182442|DRUG|Olanzapine & Quetiapine|
214810801|NCT02830022|OTHER|physiological explorations|
214810802|NCT02263092|BEHAVIORAL|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
214810803|NCT02263092|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
214810804|NCT02263092|BEHAVIORAL|Rest|15 or 30 minutes seat without move the legs
214810805|NCT00105196|DRUG|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
214810806|NCT00105196|DRUG|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
214810807|NCT05034055|DRUG|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
214810808|NCT03025880|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
214810809|NCT03025880|DRUG|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
214810810|NCT01123681|DEVICE|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
215031290|NCT00767780|DEVICE|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
215031291|NCT05325684|DRUG|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
214810811|NCT04343066|DEVICE|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
214810812|NCT05287438|DIAGNOSTIC_TEST|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
214810813|NCT05287438|DIAGNOSTIC_TEST|Standard Culture|Standard of care culture and sensitivity
214810814|NCT04127045|PROCEDURE|IMN-Group|Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
214810815|NCT04127045|PROCEDURE|HA-Group|In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
214810816|NCT05642494|DEVICE|SDF|Silver Diamine Fluoride 38% (Applied bianually)
214810817|NCT05642494|DEVICE|NaF|Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
214810818|NCT00595062|RADIATION|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
214810819|NCT03047265|DRUG|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
214810820|NCT03047265|DRUG|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
215031292|NCT06083454|DRUG|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
214810821|NCT01202448|PROCEDURE|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
214810822|NCT04857125|OTHER|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
214810823|NCT04857125|OTHER|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
214810824|NCT01631422|DRUG|RO4602522|Single radiolabeled dose
214810825|NCT01382719|DRUG|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
214810826|NCT02731365|DEVICE|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
214810827|NCT02015390|PROCEDURE|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
214810828|NCT02015390|PROCEDURE|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
214810829|NCT04350970|OTHER|High flow nasal therapy|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
214810830|NCT04350970|OTHER|Non-invasive ventilation|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
214810831|NCT04350970|OTHER|Control|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
214810832|NCT01535859|DRUG|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
214810833|NCT01535859|DRUG|Placebo|1 tablet daily for 8 days.
214810834|NCT04158570|PROCEDURE|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~* Guy's scoring system (GSS).~* Seoul renal stone complexity scoring system (S-ReSC).~* S.T.O.N.E. nephrolithometry scoring system.~* CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
214810835|NCT00998556|DRUG|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
214810836|NCT03855332|DRUG|Sildenafil|See above
214810837|NCT03855332|DRUG|Cilostazol|See above
214810838|NCT03855332|DRUG|Placebo|Overencapsulated placebo
214810839|NCT01285037|DRUG|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
214810840|NCT01285037|DRUG|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
215031293|NCT06083454|DRUG|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
215031294|NCT06083454|PROCEDURE|Surgery (SOC)|Surgery SOC
215031295|NCT03088033|DEVICE|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
214810841|NCT01285037|DRUG|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
214810842|NCT01285037|DRUG|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
214810843|NCT01285037|DRUG|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
214810844|NCT02683837|DRUG|Remifentanil|
214810845|NCT02683837|DEVICE|Pupillometry|Pupillary diameter measured every 5 minutes
214810846|NCT02683837|DRUG|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
214810847|NCT00194753|DRUG|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
214810848|NCT00194753|DRUG|Doxorubicin|24 mg/m2 IV weekly x 12
214810849|NCT00194753|DRUG|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
214810850|NCT00194753|DRUG|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
214810851|NCT05975853|OTHER|Binaural beat music group (BBM group)|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
214810852|NCT05975853|OTHER|Control group|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
214810853|NCT01914497|DEVICE|Acutus Medical System Mapping|
214810854|NCT00987805|DIETARY_SUPPLEMENT|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
214810855|NCT00987805|DIETARY_SUPPLEMENT|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
214810856|NCT04107454|DEVICE|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
214810857|NCT04107454|DEVICE|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
214810858|NCT04857697|PROCEDURE|Biopsy|Undergo biopsy
214810859|NCT04857697|PROCEDURE|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
214810860|NCT04857697|DRUG|Probiotic|Given PO
214810861|NCT04857697|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214810862|NCT04925817|OTHER|Electronic Health Record Review|Medical record reviewed
214810863|NCT04925817|PROCEDURE|Ultrasound Microvessel Imaging|Undergo 3D ultrasound microvessel imaging
214810864|NCT02819934|DRUG|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
214810865|NCT04031131|DRUG|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
214810866|NCT04031131|OTHER|KY Gel|Lubricant Gel
214810867|NCT02193880|DEVICE|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
214810868|NCT02544594|DEVICE|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
214810869|NCT01510262|BEHAVIORAL|Tailored Socio-Contextual Intervention|"1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard."
214810870|NCT01510262|BEHAVIORAL|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
214810871|NCT03136380|DRUG|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
215031296|NCT03088033|OTHER|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
215031297|NCT00375258|DRUG|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
214810872|NCT03136380|DRUG|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
214810873|NCT02951962|DRUG|Twynsta 80/5mg|Hypertension
214810874|NCT02951962|DRUG|Crestor 20mg|Hyperlipidemia
214810875|NCT03548389|OTHER|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
214810876|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
214810877|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
214810878|NCT01924091|DRUG|Dapivirine gel|
214810879|NCT01924091|DRUG|Dapivirine film|
214810880|NCT02208492|DRUG|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
214810881|NCT02208492|DRUG|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
214810882|NCT04753710|DRUG|Ocular gel|Instillation
215031298|NCT00375258|DRUG|Sodium Chloride 0.9%|Visual matched placebo
214810883|NCT03110302|BEHAVIORAL|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
214810884|NCT03535207|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
214810885|NCT03554707|GENETIC|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
214810886|NCT03554707|RADIATION|Radiation|Standard radiation plan
214810887|NCT03554707|DRUG|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
214810888|NCT03554707|DRUG|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
214810889|NCT03554707|DRUG|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
214810890|NCT03514771|DEVICE|Fraxel DUAL 1550/1927|
214810891|NCT03514771|DRUG|oral isotretinoin|oral isotretinoin
214810892|NCT03514771|DRUG|oral valacyclovir|Oral valacyclovir
214810893|NCT00672178|RADIATION|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
214810894|NCT00553280|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
214810895|NCT03874871|PROCEDURE|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
214810896|NCT03874871|PROCEDURE|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
214810897|NCT05738382|DRUG|BG2109|oral administration once daily
214810898|NCT05738382|DRUG|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
214810899|NCT05506462|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
214810900|NCT06406491|DEVICE|active microprocessor-controlled knee|Active microprocessor-controlled knees are motorized prosthesis, actively supporting the users while walking, getting up, and climbing stairs.
214810901|NCT00864591|PROCEDURE|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
214810902|NCT00864591|PROCEDURE|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
214810903|NCT01423526|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
214810904|NCT01423526|DRUG|Placebo|Placebo tablets, oral administration, single administrations
214810905|NCT02794974|OTHER|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
214810906|NCT02794974|OTHER|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
214810907|NCT02794974|OTHER|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
214810908|NCT04969757|DEVICE|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
214810909|NCT02164448|DRUG|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
214810910|NCT02164448|DRUG|the control group|saline infusion from induction of anesthesia to end of surgery
214810911|NCT05477030|DEVICE|Medtronic MiniMed 780G with SmartGuard activation|Insulin pump implemented with alghoritm for automatic modulation of insulin delivery (to increase time in glucose range 70-180 mg/dl)
214810912|NCT05477030|DEVICE|Medtronic MiniMed 780G without SmartGuard activation|Insulin pump implemented with alghoritm for low glucose insulin suspension (to reduce hypoglycemia rate)
214810913|NCT03983564|OTHER|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
214810914|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
214810915|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
214810916|NCT01743547|OTHER|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
214810917|NCT02996682|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214810918|NCT02996682|DRUG|RBV|Capsules administered orally in a divided daily dose
214810919|NCT04334174|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
214810920|NCT03488667|DRUG|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
214810921|NCT03488667|DRUG|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
214810922|NCT05165680|COMBINATION_PRODUCT|combination of aerobic exercise and healthy diet|"The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks"
214810923|NCT02587962|DRUG|Birinapant|Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
214810924|NCT02587962|DRUG|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
214810925|NCT03184480|DRUG|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
214810926|NCT04990180|BEHAVIORAL|Shared Decision Making Intervention|Decision coaching will be provided to the Pulmonary Rehabilitation Specialists to provide the skills needed to facilitate shared decision making between themselves and patients (and carers). The patient decision aid will be an informational booklet which describes the available Pulmonary Rehabilitation options at the University Hospitals of Leicester. It will detail the risks and benefits of each option and provide interactive sections to engage patients with the content, guide them through it, encourage them to attribute personal meaning and preference to each one so they can make an informed and values-based decision about PR.
214810927|NCT02167620|DRUG|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
214810928|NCT02167620|DRUG|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
214810929|NCT00000966|DRUG|Azithromycin|
214810930|NCT00000966|DRUG|Pyrimethamine|
214810931|NCT00000966|DRUG|Leucovorin calcium|
214810932|NCT00425672|BIOLOGICAL|ONTAK|Given IV
214810933|NCT00425672|OTHER|flow cytometry|Correlative studies
214810934|NCT00425672|OTHER|immunohistochemistry staining method|Correlative studies
214810935|NCT00425672|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214810936|NCT00425672|OTHER|laboratory biomarker analysis|Correlative studies
214810937|NCT00425672|GENETIC|protein expression analysis|Correlative studies
214810938|NCT05298267|DEVICE|Do Not Disturb While Driving|Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
214810939|NCT04423263|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
214810940|NCT04423263|PROCEDURE|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
214810941|NCT00086996|DRUG|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
214810942|NCT00086996|DRUG|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
214810943|NCT00086996|PROCEDURE|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
214810944|NCT00086996|RADIATION|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
214810945|NCT05959681|DEVICE|Compression garment with Vari-pad microdots ink-printed on inside.|Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
214810946|NCT02983110|PROCEDURE|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
214810947|NCT02983110|PROCEDURE|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
214810948|NCT02983110|PROCEDURE|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
214810949|NCT00184600|DRUG|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
214810950|NCT00184600|DRUG|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
214810951|NCT00184600|DRUG|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
214810952|NCT04000100|PROCEDURE|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
214810953|NCT04742478|PROCEDURE|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
214810954|NCT04898361|PROCEDURE|PFO closure|Interventional closure of a patent foramen oval preceded by an electrophysiological study
214810955|NCT05681247|DRUG|ezetimibe tablet|The subjects randomly received single oral administration of ezetimibe tablet 10 mg
214810956|NCT05681247|DRUG|ezetimibe tablet(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
214810957|NCT01758627|DRUG|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
214810958|NCT04300673|PROCEDURE|Radio guided surgery (RGS) using Indium-labelled PSMA|Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
214810959|NCT05884762|OTHER|electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist."
214810960|NCT05884762|OTHER|SHAM electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the SHAM group, the visual feedback and haptic feedback are randomly generated"
214810961|NCT00001862|DRUG|Enbrel|
214810962|NCT02964260|DRUG|Chemotherapy drug|Doxorubicin/Platinum agents
214810963|NCT02964260|DRUG|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
214810964|NCT02964260|PROCEDURE|Simultaneously|1-3 days
214810965|NCT02964260|PROCEDURE|Sequentially|1 month
214810966|NCT02964260|DEVICE|Ablation|Radiofrequency ablation/Microwave ablation
214810967|NCT05831462|DRUG|Ticagrelor 60mg|Standard vs Low dose ticagrelor in post PPCI patients
214810968|NCT03871920|OTHER|physical therapy treatment|any treatment chosen by treating physiotherapist
214810969|NCT04104165|DEVICE|Foley Catheter|Foley catheter used for treatment of urinary retention
214810970|NCT03929822|DIAGNOSTIC_TEST|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
214810971|NCT03257722|DRUG|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
214810972|NCT03257722|DRUG|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
214810973|NCT04274686|DEVICE|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
214810974|NCT04274686|OTHER|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
214810975|NCT02326610|DRUG|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
214810976|NCT00489112|DRUG|Alfuzocine XL 10 mg once a day|
214810977|NCT05445310|DRUG|Furmonertinib|Furmonertinib 80mg/d
214810978|NCT02738723|RADIATION|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
214810979|NCT02738723|RADIATION|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
214810980|NCT02738723|DRUG|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
214810981|NCT00376623|DRUG|BI 2536|Intravenous Infusion
214810982|NCT05899855|OTHER|No intervention|No intervention
214810983|NCT04920708|DRUG|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
214810984|NCT04920708|DRUG|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
214810985|NCT04920708|DRUG|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
214810986|NCT04920708|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
214810987|NCT00034684|DRUG|Farnesyl Protein Transferase Inhibitor|
214810988|NCT00949585|OTHER|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
214810989|NCT02561793|DRUG|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
214810990|NCT02561793|DRUG|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
214810991|NCT01004237|DRUG|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
214810992|NCT01482377|DRUG|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
214810993|NCT01482377|DRUG|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.
214810994|NCT01482377|DRUG|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
214810995|NCT01482377|DRUG|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
214810996|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
214810997|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
214810998|NCT00286754|BEHAVIORAL|UC|Usual Care
214810999|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
214811000|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
214811001|NCT00286754|BEHAVIORAL|UC|Usual Care
214811002|NCT02651753|DRUG|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
214811003|NCT02651753|DRUG|CKD-337|Test Drug: CKD-337
214811004|NCT02409953|OTHER|Lying in a bath during 2 hours|
214811005|NCT02409953|OTHER|Lying in a bed during 2 hours|
214811006|NCT02625077|PROCEDURE|Laparoscopic gastroesophageal valvuloplasty|
214811007|NCT02625077|PROCEDURE|Laparoscopic Toupet fundoplication|
214811008|NCT02646397|DRUG|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
214811009|NCT02646397|DRUG|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
214811010|NCT02646397|DRUG|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
214811011|NCT02719223|DEVICE|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
214811012|NCT02712827|PROCEDURE|Progrip|Self-fixating mesh
214811013|NCT02712827|PROCEDURE|Non-Progrip|Non self-fixating mesh with the use of glue
214811014|NCT00492960|DRUG|larazotide acetate|gelatin capsules
214811015|NCT00492960|DRUG|placebo|gelatin capsules
214811016|NCT00492960|DIETARY_SUPPLEMENT|900 mg gluten|gelatin capsules
214811017|NCT06326762|OTHER|comparaison|description indicate
214811018|NCT02867280|DRUG|Sorafenib|red round tablet
214811019|NCT03543462|DEVICE|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
214811020|NCT04351074|PROCEDURE|LIFT|ligation of the intersphincteric fistula track
214811021|NCT04351074|PROCEDURE|fistulectomy|excision of the fistulous track with its internal and external orifices
214811022|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind+|Virtual Reality Exposure Self-Therapy led by a participant
214811023|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind|Treatment with Virtual Reality Exposure Therapy led by a therapist
214811024|NCT03895957|BEHAVIORAL|Cognitive Behavioral Therapy|Standard treatment for social phobia led by a therapist
214811025|NCT00015626|DRUG|Metformin|
214811026|NCT00015626|PROCEDURE|skin biopsy|
214811027|NCT00015626|BEHAVIORAL|diet and exercise|
214811028|NCT00015626|DRUG|pioglitazone|
214811029|NCT00015626|DRUG|rosiglitazone|
214811030|NCT01579357|OTHER|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
214811031|NCT01911520|DRUG|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
214811032|NCT01911520|DRUG|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
214811033|NCT01911520|PROCEDURE|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
214811034|NCT01911520|PROCEDURE|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
214811035|NCT03274830|DEVICE|aneXys|150 patients with the aneXys cup
214811036|NCT01273974|BIOLOGICAL|intradermal influenza vaccine|0.25ml ,intradermal
214811037|NCT01273974|BIOLOGICAL|intramuscular influenza vaccine|0.5ml,intramuscular
214811038|NCT04050930|OTHER|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
214811039|NCT03694665|OTHER|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
214811040|NCT05731674|OTHER|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
214811041|NCT06302686|DEVICE|engAGE system|The experimental group use the engAGE system at both healthcare organization and home. At the healthcare organization, the subject interacts with Pepper robot. The interaction is supervised by the formal caregivers and includes the following activities: dialoguing with the robot, storytelling, drama play, cognitive and physical games. This interaction is planned to last about 1 hour twice a week for 6 months. At home, the older user interacts with the tablet supervised by the informal caregiver. The user plays cognitive and physical games installed on MEMAS app. This activity is performed for 0.5 hour, every day for 6 months. Throughout the whole period of experimentation, the older user wears the smartwatch that measures his/her physiological parameters and the steps. Any activity performed by the seniors is assigned by formal caregiver and can be personalized taking into account the user's abilities, lifestyle, and social interactions.
214811042|NCT06302686|OTHER|Group practicing with only the support of a booklet|To the control group will be given a booklet containing information and activities on well-being to do at home.
214811043|NCT00550563|DIETARY_SUPPLEMENT|cholecalciferol|Oral
214811044|NCT00550563|GENETIC|polymerase chain reaction|companion study
214811045|NCT00550563|GENETIC|polymorphism analysis|companion study
214811046|NCT00550563|GENETIC|protein expression analysis|companion study
214811047|NCT00550563|GENETIC|reverse transcriptase-polymerase chain reaction|companion study
214811048|NCT00550563|GENETIC|western blotting|companion study
214811049|NCT00550563|OTHER|high performance liquid chromatography|companion study
214811050|NCT00550563|OTHER|laboratory biomarker analysis|companion study
214811051|NCT00550563|OTHER|pharmacological study|companion study
214811052|NCT00550563|PROCEDURE|adjuvant therapy|Additional therapy
214811053|NCT00550563|PROCEDURE|immunoscintigraphy|additional testing
214811054|NCT04336696|PROCEDURE|Total thyroidectomy and central neck dissection|
214811055|NCT03957239|OTHER|Cranberry Beverage|The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
214811056|NCT03957239|OTHER|Control Beverage|The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
214811057|NCT00910663|DRUG|Mycophenolate Mofetil|250 mg Capsule
214811058|NCT00910663|DRUG|CellCept®|250 mg Capsule
214811059|NCT02865850|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214811060|NCT02865850|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
214811061|NCT00215410|DRUG|Formoterol Fumarate|
214811062|NCT01960569|DRUG|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
214811063|NCT01960569|OTHER|Placebo assigned to arm 2|
214811064|NCT02726581|BIOLOGICAL|Nivolumab|Specified dose on specified days, IV (intravenous)
214811065|NCT02726581|BIOLOGICAL|Elotuzumab|Specified dose on specified days, IV
214811066|NCT02726581|DRUG|Pomalidomide|Specified dose on specified days, PO (by mouth)
214811067|NCT02726581|DRUG|Dexamethasone|Specified dose on specified days, PO
214811068|NCT02024646|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
214811069|NCT02024646|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
214811070|NCT02024646|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
214811071|NCT00552669|DRUG|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
214811072|NCT00552669|DEVICE|Drug Eluting stent|Any Drug eluting stent
214811073|NCT01090713|DRUG|lisdexamfetamine|oral; 20-70mg/day
214811074|NCT01090713|DRUG|Placebo control|20-70mg; oral
214811075|NCT01844375|DIETARY_SUPPLEMENT|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
214811076|NCT01844375|OTHER|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
214811077|NCT00176306|DRUG|Levofloxacin 750 mg IV|PK in obesity
214811078|NCT01593007|OTHER|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
214811079|NCT01593007|OTHER|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
214811080|NCT03347032|PROCEDURE|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
214811081|NCT03347032|PROCEDURE|Control|Serial inflations and deflations as detailed in the arm/group descriptions
214811082|NCT02634437|DRUG|Ulipristal acetate|
214811083|NCT04649411|DRUG|ferric citrate|oral tablets
214811084|NCT04649411|DRUG|standard of care|administered per the approved label and at the Investigator's discretion
214811085|NCT03352271|PROCEDURE|Individualized Incremental hemodialysis|Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
214811086|NCT03352271|PROCEDURE|Conventional thrice weekly hemodialysis|Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
214811087|NCT03879915|PROCEDURE|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
214811088|NCT01772537|DRUG|Propofol|Intravenous anesthetic
214811089|NCT01772537|DRUG|isoflurane|
214811090|NCT06292871|BEHAVIORAL|Additional GDM management through social media|Usual care provided by a diabetes nurse educator and dietitian. Additional educational resources for dietary management care received, and for any queries to be addressed by dietitian via social media platform from baseline to one-month follow-up visit.
214811091|NCT06292871|BEHAVIORAL|Usual care|Usual care provided by a diabetes nurse educator and dietitian.
214811092|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
214811093|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
214811094|NCT01689792|DRUG|MOVIPREP|
214811095|NCT01689792|DRUG|CitraFleet|
214811096|NCT01394562|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
214811097|NCT01394562|OTHER|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
214811098|NCT03983057|DRUG|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
214811099|NCT03143920|COMBINATION_PRODUCT|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
214811100|NCT04186182|BEHAVIORAL|CICI - Feasibility trial study group|The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
214811101|NCT00760448|DRUG|insulin detemir|
214811102|NCT00760448|DRUG|insulin NPH|
214811103|NCT03735030|DRUG|Human hCG 10'000 IU|A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
214811104|NCT03735030|DRUG|Recombinant hCG 6'500 IU|A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
214811105|NCT04455230|GENETIC|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
214811106|NCT01263704|DRUG|Cyclophosphamide|150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
214811107|NCT01263704|DRUG|Fludarabine|12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
214811108|NCT01263704|DRUG|Rituximab|375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
214811109|NCT05634772|DEVICE|dormia basket|Use of dormia basket in management of proximal stent migration
214811110|NCT05634772|DEVICE|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
214811111|NCT04000386|OTHER|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
214811112|NCT04000386|OTHER|placebo socks|placebo socks were given to subjects for 2 weeks
214811113|NCT04720638|OTHER|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
214811114|NCT04720638|OTHER|Conventional resin composite restoration|Microhybrid resin composite
214811115|NCT00413764|DRUG|tibolone|tibolone (2.5 mg) over 24 weeks
214811116|NCT00413764|DRUG|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
214811117|NCT03020615|DRUG|Hydroxyurea|Given orally once daily.
214811118|NCT01704677|PROCEDURE|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
214811119|NCT01704677|BEHAVIORAL|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
214811120|NCT02336854|DRUG|Tacrobell tab. 2mg|
214811121|NCT02336854|DRUG|Prograf cap. 2mg|
214811122|NCT05357898|BIOLOGICAL|SQZ-eAPC-HPV|Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.
214811123|NCT05357898|BIOLOGICAL|Pembrolizumab|programmed cell death 1 (PD-1) blocking antibody
214811124|NCT00724477|DRUG|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
214811125|NCT00357201|DRUG|Food supplement (T1675)|
214811126|NCT04953832|BEHAVIORAL|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
214811127|NCT01590420|DEVICE|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
214811128|NCT02903901|DRUG|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
214811129|NCT02903901|DRUG|Placebo|10 mg liquid placebo at 7 pm for 1 week
214811130|NCT03247920|DRUG|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
214811131|NCT03247920|DRUG|Antibiotics|Intravenous antibiotic therapy following local protocol
214811132|NCT03060694|OTHER|diabetes|"1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
214811133|NCT00252720|DRUG|candesartan|32 mg oral tablet
214811134|NCT04458701|DEVICE|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
214811135|NCT01415557|OTHER|Non-Fortified Control Product|Non-Fortified Control Beverage
214811136|NCT01415557|OTHER|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
214811137|NCT03851965|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
214811138|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
214811139|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
214811140|NCT02627066|BEHAVIORAL|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
214811141|NCT02627066|BEHAVIORAL|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
214811142|NCT01310920|OTHER|observation|genotyping
214811143|NCT06346730|DEVICE|Virtual reality glasses to intervention group|experimental and control ,a randomized pretest-posttest study to examine
214811144|NCT05901922|BEHAVIORAL|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
214811145|NCT03962686|DRUG|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
214811146|NCT01942863|PROCEDURE|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
214811147|NCT01942863|PROCEDURE|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
214811148|NCT01942863|OTHER|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
214811149|NCT01760408|OTHER|all patients on Home Parenteral Nutrition|
214811150|NCT00189956|BIOLOGICAL|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
214811151|NCT02977260|OTHER|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
214811152|NCT02977260|OTHER|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
214811153|NCT02977260|OTHER|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
214811154|NCT02977260|OTHER|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
214811155|NCT00723476|BEHAVIORAL|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
214811156|NCT00723476|BEHAVIORAL|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
214811157|NCT02330380|DRUG|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
214811158|NCT02330380|DRUG|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
214811159|NCT02330380|DRUG|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
214811160|NCT02330380|DRUG|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
214811161|NCT02330380|DRUG|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
214811162|NCT02330380|OTHER|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
214811163|NCT02330380|OTHER|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
214811164|NCT01838720|PROCEDURE|zero ischemia laparoscopic RFA assisted TE|
214811165|NCT01838720|PROCEDURE|ischemia|conventional laparoscopic partial nephrectomy
214811166|NCT02325531|OTHER|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
214811167|NCT02325531|OTHER|Medium support|"Same as provided to the low support arm, PLUS~* STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~* ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 \& 3."
214811168|NCT02325531|OTHER|High support|"Same as provided to the low and medium support arms, PLUS~\- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
214811169|NCT02325531|OTHER|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
214811170|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
214811171|NCT04007640|RADIATION|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
214811172|NCT04007640|PROCEDURE|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
214811173|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
214811174|NCT03872674|BIOLOGICAL|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
214811175|NCT02514122|DRUG|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
214811176|NCT02514122|DRUG|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
214811177|NCT04739566|DRUG|Dabrafenib|Given PO twice daily
214811178|NCT04739566|DRUG|Trametinib|Given PO once daily
214811179|NCT04809961|OTHER|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
214811180|NCT04340011|OTHER|Colposcopy|prospective resident education for colposcopy
214811181|NCT02365454|DEVICE|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
214811182|NCT00054626|DRUG|cisplatin|
214811183|NCT00054626|DRUG|gemcitabine hydrochloride|
214811184|NCT00054626|PROCEDURE|adjuvant therapy|
214811185|NCT00159848|BEHAVIORAL|Treatment Optimization Program (educational material)|
214811186|NCT00319930|DRUG|CNF1010 (17-AAG)|
214811187|NCT04417933|DEVICE|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
214811188|NCT03611374|PROCEDURE|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
214811189|NCT05195762|DRUG|NFX-179 Gel 1.50%|"Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi."
214811190|NCT01188135|BEHAVIORAL|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
214811191|NCT00112463|DRUG|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
214811192|NCT03287310|DRUG|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
214811193|NCT03287310|DRUG|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
214811194|NCT03287310|DRUG|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
214811195|NCT01118312|DRUG|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day for 6 months
214811196|NCT01118312|OTHER|Placebo|Intranasal placebo spray
214811197|NCT03544008|OTHER|The use of AXIOS in Endoscopic transmural drainage|
214811198|NCT01703975|OTHER|Training in pairs (Dyad training)|
214811199|NCT00307697|PROCEDURE|receipt of copy of psychiatic assessment letter|
214811200|NCT05880576|DEVICE|Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy|Infants will have monitoring three times a day with resonance Raman spectroscopy device during arch watch period. They will have continuous monitoring with pulse oximetry and near infrared spectroscopy. They will have intermittent blood pressure monitoring.
214811201|NCT02810886|DRUG|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
214811202|NCT01854463|DRUG|Vitamin D3|2000IU per day
214811203|NCT01854463|DRUG|placebo|elemental calcium 200mg per day per 24 weeks
214811204|NCT05907421|BEHAVIORAL|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
214811205|NCT01507337|DRUG|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
214811206|NCT06018532|DEVICE|PRESAGE CARE|PRESAGE Care informations from the application will be processed by the PRESAGE Care algorithm in real time, and may generate alerts indicating an increased risk of hospitalization or emergency department visits within 7 to 14 days. These alerts will be transmitted to a Care Manager platform, who will analyse the situation, initiate the healthcare intervention and coordinate its implementation. In practice, a care manager (coordinating nurse) will process the alert and carry out an initial assessment of the beneficiary's situation, using the information feedback platform, then by telephone, contacting the older adults beneficiary and the relative. The care manager may or may not implement preventive measures. If necessary, the patient may be offered an outpatient medical consultation, a home visit, a consultation with his or her GP and/or social or paramedical interventions.
214811207|NCT03506386|OTHER|No Intervention|As it was an observational study, no intervention was administered.
214811208|NCT05454553|OTHER|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
214811209|NCT05735925|DIAGNOSTIC_TEST|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
214811210|NCT01390493|BEHAVIORAL|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
214811211|NCT05417425|COMBINATION_PRODUCT|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
214811212|NCT06426056|RADIATION|radiotherapy|Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
214811213|NCT06426056|DRUG|Nab paclitaxel|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
214811214|NCT06426056|DRUG|Cisplatin|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
214811215|NCT02543671|OTHER|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
214811216|NCT02543671|OTHER|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
214811217|NCT02512393|DEVICE|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
214811218|NCT02512393|DEVICE|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
214811219|NCT04723810|DRUG|Indocyanine Green|The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
214811220|NCT04109469|DEVICE|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
214811221|NCT04400123|DRUG|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
214811222|NCT03527147|DRUG|AZD9150|AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
214811223|NCT03527147|DRUG|Acalabrutinib|Acalabrutinib will be administered orally twice daily (bid).
214811224|NCT03527147|DRUG|AZD6738|AZD6738 will be administered orally twice daily (bid).
214811225|NCT03527147|DRUG|Hu5F9-G4|HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
214811226|NCT03527147|DRUG|Rituximab|Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
214811227|NCT03527147|DRUG|AZD5153|AZD5153 will be administered orally once per day (qd).
214811228|NCT03264898|DEVICE|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
214811229|NCT03901768|DRUG|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
214811230|NCT03901768|DRUG|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
214811231|NCT03901768|DRUG|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
214811232|NCT02140398|PROCEDURE|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
214811233|NCT03212339|OTHER|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
214811234|NCT04862429|OTHER|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
214811235|NCT04862429|OTHER|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
214811236|NCT00860223|DRUG|Digoxin|
214811237|NCT00860223|DRUG|Neratinib|HKI-272
214811238|NCT02419456|DRUG|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
214811239|NCT02419456|DRUG|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
214811240|NCT05436509|BIOLOGICAL|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
214811241|NCT00735904|DRUG|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
214811242|NCT00735904|DRUG|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
214811243|NCT00735904|DRUG|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
214811244|NCT02841800|DEVICE|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
214811245|NCT01233505|DRUG|veliparib|Given PO
214811246|NCT01233505|DRUG|capecitabine|Given PO
214811247|NCT01233505|DRUG|oxaliplatin|Given IV
214811248|NCT01233505|OTHER|pharmacological study|Correlative studies
214811249|NCT01233505|OTHER|laboratory biomarker analysis|Correlative studies
214811250|NCT02808065|DRUG|Tacrolimus|Administered dose were individualized according to their own prescription
214811251|NCT02808065|DRUG|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
214811252|NCT03687515|DRUG|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
214811253|NCT03687515|DRUG|budesonide|nasal spray 256μg BID
214811254|NCT03687515|DRUG|Prednisone|oral prednisone 24mg QD
214811255|NCT03613259|DRUG|Fluorothymidine F-18|Given IV
214811256|NCT03613259|OTHER|Laboratory Biomarker Analysis|Correlative studies
214811257|NCT03613259|PROCEDURE|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
214811258|NCT01390844|DRUG|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
214811259|NCT01390844|DRUG|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
214811260|NCT01390844|DRUG|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
214811261|NCT01390844|DRUG|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
214811262|NCT01390844|DRUG|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
214811263|NCT02543554|PROCEDURE|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
214811264|NCT04605861|DRUG|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
214811265|NCT04605861|DRUG|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
214811266|NCT02042846|DEVICE|SportWelding Fiji Anchor|
214811267|NCT01316445|DRUG|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
214811268|NCT03205241|DIETARY_SUPPLEMENT|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
214811269|NCT03205241|DIETARY_SUPPLEMENT|Placebo|Olive oil capsules
214811270|NCT02495545|PROCEDURE|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
214811271|NCT02495545|PROCEDURE|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
214811272|NCT00490594|DEVICE|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
214811273|NCT00547781|PROCEDURE|PGD|
214811274|NCT04792944|DRUG|Urokinase|Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
214811275|NCT04792944|PROCEDURE|Endovascular treatment|Aneurysm treatment through endovascular methods
214811276|NCT04792944|PROCEDURE|Clipping|Surgical clipping of brain aneurysms
214811277|NCT04792944|PROCEDURE|External ventricular drain|Insertion of an external ventricular drain to treat acute hydrocephalus
214811278|NCT00378690|DRUG|leuprorelin acetate|LHRH antagonist
214811279|NCT04932837|BIOLOGICAL|Blood and Saliva collection|Serological, viral RNA and antigenic test
214811280|NCT03204539|DRUG|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
214811281|NCT04520464|DIAGNOSTIC_TEST|Cervical samples for identification of HR-HPV DNA via real-time PCTR.|Identification of HR-HPV DNA via real-time PCTR.
214811282|NCT01624064|DRUG|Enalapril|2.5-20 mg/day
214811283|NCT01624064|DRUG|Calcium Supplement|Calcium 2.5-20 mg/day
214811284|NCT04350580|DRUG|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
214811285|NCT04350580|DRUG|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
214811286|NCT04853459|PROCEDURE|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
214811287|NCT02456948|DRUG|Minocycline|6 weeks 200mg/day Minocycline add-on
214811288|NCT02456948|DRUG|Placebo|6 weeks Placebo add-on
214811289|NCT05093205|DRUG|PF-06882961|Tablets
214811290|NCT05093205|DRUG|Atorvastatin|Tablets
214811291|NCT05093205|DRUG|Midazolam|Syrup
214811292|NCT05093205|DRUG|Levonorgestrel & Ethinyl Estradiol|Tablet
214811293|NCT06475924|DIAGNOSTIC_TEST|Caesarean scar defect evlauation by ultraosund|"Women will be examined in the lithotomy position with an empty bladder. The uterus will be examined in a standardized way excluding causes of abnormal uterine bleeding or pelvic pain (myoma, polyp, pelvic inflammatory disease, adenomyosis).~Upon detection of the SCD, the following will be measured:~In the midsagittal plane: the depth (the vertical distance between the base and apex of the defect), width (the length of the widest gap along the cervicoisthmic canal), residual myometrial thickness (RMT) overlying the defect, and the adjacent myometrial thickness fundal to the defect.~In the transverse plane: the length of the defect.~The uterine position will be classified as anteverted or retroverted.~Clinical symptoms of the patients will be reviewed such as :Postmenstrual spotting, Abnormal uterine bleeding, Pain, Secondary infertility."
214811294|NCT01698476|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
214811295|NCT01698476|DRUG|Placebo tablets|
214811296|NCT00048126|DRUG|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
214811297|NCT00048126|DRUG|capecitabine [Xeloda]|1000mg po bid
214811298|NCT00818337|DRUG|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
214811299|NCT03361228|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
214811300|NCT03361228|DRUG|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
214811301|NCT03361228|DRUG|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
214811302|NCT01274364|OTHER|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
214811303|NCT01274364|OTHER|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
214811304|NCT00005856|DRUG|oxaliplatin|Given IV
214811305|NCT00005856|OTHER|pharmacological study|Correlative studies
214811306|NCT05822232|DEVICE|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
214811307|NCT05822232|DEVICE|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
214811308|NCT05822232|DEVICE|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
214811309|NCT04862702|DEVICE|mechanical instrumentation using rotary file system|the mechanical preparation will be performed using rotary file system
214811310|NCT02328443|DRUG|Midazolam|
214811311|NCT02328443|DRUG|itraconazole|
214811312|NCT02328443|DRUG|rifampicin|
214811313|NCT03123237|DIAGNOSTIC_TEST|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.
214811314|NCT01123265|DRUG|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
214811315|NCT01123265|DRUG|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
214811316|NCT00360360|DRUG|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
214811317|NCT00360360|DRUG|carboplatin|Carboplatin AUC 6.0 IV Day 1
214811318|NCT00360360|DRUG|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
214811319|NCT00360360|DRUG|erlotinib|Erlotinib 150 mg by mouth daily
214811320|NCT06327607|OTHER|Control Group|Standard care for breast cancer
214811321|NCT06327607|OTHER|Psychosexological intervention|The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.
214811322|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
214811323|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
214811324|NCT00401778|DRUG|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
214811325|NCT00141466|BEHAVIORAL|Education for professionals|
214811326|NCT00141466|BEHAVIORAL|Distribution of educational materials|
214811327|NCT00141466|BEHAVIORAL|Feedback for professionals|
214811328|NCT00141466|BEHAVIORAL|Reminders for professionals|
214811329|NCT00720330|DRUG|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
214811330|NCT00720330|DRUG|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
214811331|NCT00720330|OTHER|placebo|placebo
214811332|NCT03571880|DEVICE|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
214811333|NCT03693430|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
214811334|NCT03693430|DRUG|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
214811335|NCT02702817|DRUG|Naproxen|pale blue oval tablets
214811336|NCT02702817|DRUG|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
214811337|NCT01578694|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
214811338|NCT04132908|DIETARY_SUPPLEMENT|Dietary Supplement: nutraceutical|Subjects will consume two capsules at breakfast and dinner for ten weeks.
214811339|NCT04132908|DIETARY_SUPPLEMENT|Placebo|Subjects will consume two capsules at breakfast and dinner for ten weeks.
214811340|NCT03365115|DRUG|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
214811341|NCT03365115|DRUG|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
214811342|NCT00945165|BEHAVIORAL|Exercise intervention|various exercise characteristics
214811343|NCT00945165|BEHAVIORAL|No exercise|No exercise control period
214811344|NCT02045550|DRUG|Prospan Syrup|2.5 ml twice daily for 4 weeks
214811345|NCT01890239|OTHER|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
214811346|NCT05267405|OTHER|no interventions, only observation|no interventions, only observation
214811347|NCT01719731|BEHAVIORAL|Education|This group will receive the psychoeducation
214811348|NCT01719731|BEHAVIORAL|Non-Education|This group will not receive the psychoeducation
214811349|NCT05633485|OTHER|Animation-Supported Education|Expert support was received for the design and preparation of animation videos.
214811350|NCT01988974|BEHAVIORAL|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
214811351|NCT01988974|BEHAVIORAL|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
214811352|NCT00401947|DRUG|ACH-0137171|
214811353|NCT05605301|DRUG|Oral 2-Deoxy-D-Glucose (2DG)|2DG will be formulated as an solid dosage form and administered orally.
214811354|NCT01746329|OTHER|Tea|Oral intake of tea containing 75 grams of glucose
214811355|NCT01746329|OTHER|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
214811356|NCT01746329|OTHER|Placebo|Oral intake of 75 grams of glucose in water
214811357|NCT03430830|DRUG|Ravidasvir 50mg|50mg, Tablet
214811358|NCT03430830|DRUG|Ravidasvir 200mg|200mg, Tablet
214811359|NCT04589195|BEHAVIORAL|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
214811360|NCT00816504|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
214811361|NCT00003630|DRUG|arsenic trioxide|
214811362|NCT03583593|DIETARY_SUPPLEMENT|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
214811363|NCT03583593|DIETARY_SUPPLEMENT|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
214811364|NCT03163680|DRUG|Omeprazole 40 MG|Omperazole 40 mg twice daily
214811365|NCT00887263|DRUG|Budesonide|3 mg TID
214811366|NCT00887263|DRUG|Placebo|0 mg TID
214811367|NCT00362765|DRUG|Fenofibrate|160 mg
214811368|NCT00362765|DRUG|Metformin|2000 mg
214811369|NCT00362765|DRUG|Placebo|Placebo
214811370|NCT04844489|OTHER|Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19|"Blood samples at:~* D0 (the day of the injection of the SARS-CoV-2 vaccine),~* during the 2nd injection as part of the national vaccination campaign (on D28)~* during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~* then to M1, M6 and M12 of the last injection"
214811371|NCT04185909|DEVICE|Renuvion Dermal System|The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
214811372|NCT04035603|DRUG|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
214811373|NCT04035603|DRUG|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
214811374|NCT04035603|BEHAVIORAL|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
214811375|NCT04035603|DRUG|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
214811376|NCT01395186|PROCEDURE|varicocelectomy|varicocelectomy for painful varicocele
214811377|NCT03983486|OTHER|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
214811378|NCT01417078|DRUG|Diazepam|single-dose; dosage in mg, based on patient body weight
214811379|NCT04458649|DEVICE|Dexcom continuous glucose monitor|Measurement of interstitial glucose
214811380|NCT05493007|PROCEDURE|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
214811381|NCT05493007|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
214811382|NCT02518581|PROCEDURE|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
214811383|NCT05677698|OTHER|Lemon oil|Lemon oil with massage
214811384|NCT05677698|OTHER|peppermint oil|peppermint oil with massage
214811385|NCT05677698|OTHER|Almond oil|Almond oil massage
214811386|NCT04078048|DIETARY_SUPPLEMENT|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
214811387|NCT00002064|DRUG|Pyrimethamine|
214811388|NCT00002064|DRUG|Clindamycin|
214811389|NCT00535808|DRUG|nitroprusside|Administration of nitroprusside
214811390|NCT00535808|DRUG|nitroglycerine|Administration of nitroglycerine
214811391|NCT00535808|DRUG|sevoflurane|Administration of Sevoflurane
214811392|NCT02769208|DEVICE|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
214811393|NCT05703308|BIOLOGICAL|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
214811394|NCT00000482|DRUG|estrogen|
214811395|NCT00000482|DRUG|clofibrate clofibrate|
214811396|NCT00000482|DRUG|dextrothyroxine sodium|
214811397|NCT00000482|DRUG|niacin|
214811398|NCT03895684|DRUG|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
214811399|NCT01709474|DRUG|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
214811400|NCT01709474|DRUG|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
214811401|NCT01934673|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
214811402|NCT01874756|DRUG|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
214811403|NCT01874756|DRUG|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
214811404|NCT01874756|DRUG|Placebo|6 placebo capsules daily for 8 weeks
214811405|NCT01874756|DRUG|LY500307 25mg|LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
214811406|NCT05306470|PROCEDURE|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
214811407|NCT05306470|PROCEDURE|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
214811408|NCT01049893|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
214811409|NCT05448430|DEVICE|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
214811410|NCT02485808|OTHER|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
214811411|NCT02485808|PROCEDURE|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
214811412|NCT02485808|OTHER|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
214811413|NCT02485808|OTHER|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
214811414|NCT03458871|DEVICE|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
214811415|NCT00191295|DRUG|Atomoxetine|
214811416|NCT00191295|DRUG|Placebo|
214811417|NCT02501005|PROCEDURE|VT ablation|Catheter ablation of ventricular tachycardia
214811418|NCT00308022|DEVICE|High Frequency Percussive Ventilation|
214811419|NCT01007500|DRUG|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
214811420|NCT01007500|DRUG|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
214811421|NCT00000132|DRUG|Betaxolol|
214811422|NCT00000132|PROCEDURE|Argon Laser Trabeculoplasty|
214811423|NCT04981938|PROCEDURE|Lobectomy with pulmonary artery reconstruction|"Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space~Subgroups : different types of pulmonary artery reconstruction such as :~* Tangential vascular reconstruction with direct suture~* Circumferential resection and end-to-end anastomosis~* bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch"
214811424|NCT00002994|BIOLOGICAL|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
214811425|NCT00002994|BIOLOGICAL|rhuMAb|90 min IV infusion day 7 of each cycle
214648513|NCT05568589|OTHER|Intraoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
214648514|NCT05568589|OTHER|Non Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
214811426|NCT01223365|DRUG|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
214811427|NCT00839605|DRUG|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
214648515|NCT03628027|DEVICE|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
214648516|NCT01316393|OTHER|XER2020|mucoprotective product
214648517|NCT01785355|OTHER|Dental treatment|"1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions."
214648518|NCT05631912|BIOLOGICAL|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10\^6 cells/kg) ,dose 2 (3×10\^6 cells/kg) ,dose 3 (1×10\^7 cells/kg); Phase 2 : Appropriate dose
214648519|NCT05631912|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
214648520|NCT05631912|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
214648521|NCT05110079|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
214648522|NCT00947284|DRUG|nalbuphine plus naloxone|single dose administered intravenously
214648523|NCT00947284|DRUG|nalbuphine plus saline|single dose administered intravenously
214648524|NCT00947284|DRUG|naloxone plus saline|single dose administered intravenously
214648525|NCT04015830|OTHER|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
214648526|NCT02185937|DIETARY_SUPPLEMENT|cola|imatinib intake with coca-cola
214648527|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
214648528|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
214648529|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
214648530|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
214648531|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
214648532|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
214648533|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
214811428|NCT02738242|DEVICE|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
214811429|NCT04499170|OTHER|Muscular Energy Technique G1|Group of older (G1) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
214811430|NCT04499170|OTHER|Muscular Energy Technique G2|Group of young people (G2) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
214811431|NCT04558905|OTHER|Face-to-face medical visits|Face-to-face medical visits
214811432|NCT04558905|OTHER|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
214811433|NCT03567174|OTHER|Integrated care van (ICV)|Structural service delivery intervention
214811434|NCT00380445|DRUG|Vildagliptin|
214811435|NCT02005705|OTHER|Outpatient Management of Low-risk Patients|"* Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30"
214811436|NCT02005705|OTHER|Inpatient Management of Low-risk Patients|"* Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30"
214811437|NCT02644434|PROCEDURE|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.~Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
214648534|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
214648535|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
214648536|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
214648537|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
214648538|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
214648539|NCT02909621|DIETARY_SUPPLEMENT|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
214811438|NCT02644434|PROCEDURE|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
214811439|NCT03153930|BEHAVIORAL|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
214811440|NCT03153930|BEHAVIORAL|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
214811441|NCT03243630|DRUG|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
214811442|NCT03243630|DRUG|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
214648540|NCT02909621|OTHER|PLACEBO|
214811443|NCT03243630|DRUG|green apple|green apple will be added to the menthol flavor
214811444|NCT03243630|DRUG|green apple and menthol|menthol and green apple will be the active intervention
214811445|NCT04061005|PROCEDURE|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
214811446|NCT04061005|PROCEDURE|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
214648541|NCT04863963|PROCEDURE|Milligan Morgan|Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
214648542|NCT04627909|OTHER|Robot|The patient interacts with a robot
214648543|NCT04627909|OTHER|Medical Personnel|The patient interacts with medical personnel
214648544|NCT04627909|OTHER|Caregiver|The patient interacts with the caregiver
214648545|NCT06111989|BEHAVIORAL|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
214648546|NCT06111989|BEHAVIORAL|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
214648547|NCT02714114|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
214648548|NCT02714114|OTHER|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
214648549|NCT05874531|DIAGNOSTIC_TEST|End-expiratory occlusion test|15 seconds end-expiratory occlusion
214648550|NCT04272567|DRUG|Norepinephrine|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
214648551|NCT04272567|DRUG|Normal saline|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
214648552|NCT00649103|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
214648553|NCT00649103|DRUG|Accupril® Tablets 40 mg|40mg, single dose fasting
214648554|NCT01880411|BIOLOGICAL|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
214648555|NCT00836550|BEHAVIORAL|Video|The participants saw a 6 minute video
214811447|NCT04061005|PROCEDURE|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
214811448|NCT00229645|DRUG|Quetiapine Fumarate (Seroquel®)|
214811449|NCT00279357|PROCEDURE|Narrow Band Imaging|
214811450|NCT02845739|OTHER|Kidney transplanted patients|
214811451|NCT07035600|PROCEDURE|Targeted leaderled training program|"Training program:~After inclusion and consent the patients are instructed through an online group training program consisting of specific training of levator, abdominal, quadriceps (all portions), and gluteal muscles as well as endurance training. They are given information about WHO recommendations about physical activity. The patients are asked to sign up for two specific training occasions per week where no group will be larger than 10 patients. Group based exercise sessions consist of 45-minute supervised online zoom exercise sessions. Apart from the supervised sessions patients are encouraged to perform one functional training session, unsupervised, as well as follow the WHO recommendation for aerobic exercise"
214811452|NCT07035600|PROCEDURE|Control arm with WHO recommendation on physical activity|Training will be in accordance with WHO recommendations of 30 min aerobic physical activity five times per week (150 min per week) plus strength sessions twice weekly. The patients will be individually adviced on how to perform the training at inclusion in the trial. This is considered standard care and will not include any on-line supervision, but will include a coaching/reminder by a phone call from a research nurse/short message service (by choice of the patient) at regular intervals before and after surgery
214811453|NCT06781853|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being.
214811454|NCT05363111|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
214811455|NCT05363111|BIOLOGICAL|Daratumumab|Given IV
214811456|NCT05363111|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
214811457|NCT06263348|DRUG|Dorzagliatin tablets|During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
214811458|NCT04010331|DIETARY_SUPPLEMENT|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
214811459|NCT04010331|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
214811460|NCT00567177|DRUG|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
214811461|NCT00803764|DRUG|Naproxen Tablets, 500 mg|
214811462|NCT01727271|DRUG|Tenofovir|
214811463|NCT01727271|BIOLOGICAL|Pegylated interferon alpha-2b|
214811464|NCT04587778|DRUG|Ketamine Hydrochloride|intravenous infusion
214811465|NCT04587778|DRUG|Esketamine|intravenous infusion
214811466|NCT04587778|DRUG|Placebo|intravenous infusion
214811467|NCT04587778|DRUG|Pilot study II: Esketamine|intravenous infusion
214811468|NCT04587778|DRUG|Pilot study II: Placebo|intravenous infusion
214811469|NCT05172219|BEHAVIORAL|Physician Sent Outreach with Embedded Asynchronous Care in Portal Message|PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
214811470|NCT05172219|BEHAVIORAL|Physician Sent Outreach without Embedded Asynchronous Care in Portal Message|Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
214811471|NCT05172219|BEHAVIORAL|System Sent Outreach with Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
214811472|NCT05172219|BEHAVIORAL|System Sent Outreach without Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
214811473|NCT04487262|PROCEDURE|Cardiac surgery|Elective open heart surgery
214811474|NCT01722474|DEVICE|ASI Device|
214811475|NCT03991026|BEHAVIORAL|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
214811476|NCT01415700|DEVICE|Functional electrical stimulator|The stimulator is surgically implanted
214811477|NCT01415700|DEVICE|feet orthosis|feet orthosis specifically mold
214811478|NCT00081952|DRUG|L-norleucine|
214811479|NCT01387737|DRUG|TA-7284-Low|TA-7284-Low
214811480|NCT01387737|DRUG|TA-7284-High|TA-7284-High
214811481|NCT00911898|DRUG|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
214811482|NCT05437744|OTHER|Cyanoacrylate glue|8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.
214811483|NCT05437744|OTHER|Platelet-rich fibrin (PRF)|8 sockets that will be treated by immediate implant placement and sealed by PRF.
214811484|NCT01360970|BIOLOGICAL|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
214811485|NCT06131502|DEVICE|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
214811486|NCT01316549|DRUG|Fludarabine|Given as injection
214811487|NCT02173418|DRUG|Phrenic nerve block with Ropivacaine|
214811488|NCT02173418|DRUG|Phrenic nerve block with saline|
214811489|NCT00060918|DRUG|carvedilol|
214811490|NCT00060918|DRUG|metoprolol|
214811491|NCT00085150|BIOLOGICAL|LMB-2 immunotoxin|
214811492|NCT02817841|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
214811493|NCT02985593|DRUG|KHK4083|
214811494|NCT02985593|DRUG|Placebo|
214811495|NCT04373278|OTHER|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
214811496|NCT00934934|OTHER|Normal Saline|Normal Saline
214811497|NCT00934934|DRUG|anidulafungin|TBA
214811498|NCT06043843|COMBINATION_PRODUCT|Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram|"1. Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing~   1. Fasting and exemptions~  2. Self-monitoring of blood glucose~  3. Acute diabetes complications and treatment~  4. Ramadan nutritional plan~  5. Safe physical activity You will be taught to record~   <!-- -->~   1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan.~2. Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction \< 8% 30% 8 to 10% 15% \> 10% None~2\) Glucose monitoring~1. up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week~2. uploaded into an online portal for data collection, without remote monitoring."
214648556|NCT00836550|BEHAVIORAL|in-person HIV pre-test counseling|
214648557|NCT04278807|PROCEDURE|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
214648558|NCT04610476|DRUG|Prednisolone|Prednisolone oral 1-5 mg/day
214648559|NCT04610476|DRUG|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
214648560|NCT04610476|DRUG|Leflunomide|Leflunomide oral 20 mg/day
214648561|NCT04610476|DRUG|Methotrexate|Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
214648562|NCT04610476|DRUG|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
214648563|NCT04610476|DRUG|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
214648564|NCT04610476|DRUG|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
214648565|NCT04610476|DRUG|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
214648566|NCT04610476|DRUG|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
214648567|NCT04610476|DRUG|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
214648568|NCT04610476|DRUG|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
214648569|NCT04610476|DRUG|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
214648570|NCT04610476|DRUG|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
214648571|NCT04610476|DRUG|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
214648572|NCT04610476|DRUG|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
214648573|NCT04039997|DEVICE|CPRMeter|teaching resuscitation with application of cpr feedback device
214648574|NCT04039997|OTHER|Manual chest compression|Manual chest compression
214811499|NCT02087514|PROCEDURE|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
214811500|NCT02087514|OTHER|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks"
214811501|NCT02236247|DRUG|ivabradine|5 mg oral twice daily
214811502|NCT02236247|DRUG|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
214811503|NCT00062790|DRUG|Dutasteride|
214811504|NCT01546766|DEVICE|Pupillometry testing.|
214811505|NCT04572659|OTHER|Group psychosocial intervention|Several couples attended a total of six group psychotherapy sessions conducted by a psychologist. Between 4 and 7 couples were treated in each group session.
214811506|NCT04572659|OTHER|Couple psychosocial intervention|The couple attended a total of six psychotherapy sessions conducted by a psychologist. Each couple was attended particularly.
214811507|NCT03941925|DIETARY_SUPPLEMENT|Prebiotic fructans|Prebiotic group receiving the prebiotic fructans in two doses during the 4-week intervention period.
214811508|NCT03941925|DIETARY_SUPPLEMENT|Non-prebiotic maltodextrin|Placebo group receiving the non-prebiotic maltodextrin in two doses during the 4-week intervention period.
214811509|NCT01393366|OTHER|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
214811510|NCT01393366|OTHER|Usual Practice|None, only usual practice.
214811511|NCT03175718|OTHER|Incisional Negative Pressure Wound Therapy (INPWT)|A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.
214811512|NCT03175718|OTHER|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
214811513|NCT00928525|DRUG|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
214811514|NCT01746017|DRUG|Placebo|Administered orally as capsules
214811515|NCT01746017|DRUG|LY2922470|Administered orally as capsules
214811516|NCT00899483|DRUG|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
214811517|NCT00397488|DRUG|sunitinib malate|
214811518|NCT04171570|PROCEDURE|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
214811519|NCT01458561|DEVICE|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
214811520|NCT01458561|DEVICE|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
214811521|NCT05113147|OTHER|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
214811522|NCT01215981|BIOLOGICAL|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
214811523|NCT01215981|BIOLOGICAL|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
214811524|NCT00659763|OTHER|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
214811525|NCT00659763|OTHER|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
214811526|NCT03075761|DEVICE|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
214811527|NCT03075761|BEHAVIORAL|30-minute education session|
214811528|NCT05378724|DEVICE|Hospital Fit 2.0, HFITAPP0, release 05, Maastricht Instruments B.V., the Netherlands|Hospital Fit consists of a smartphone app combined to the MOX accelerometer. Hospital Fit provides patients and physiotherapists direct feedback on patients' physical activity behavior. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. Hospital Fit also gives patients insight into their own recovery process. During every treament, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
214811529|NCT00722124|DRUG|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
214811530|NCT00722124|DRUG|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
214811531|NCT00722124|OTHER|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
214811532|NCT02069158|DRUG|PF-05212384|iv administrartion
214811533|NCT02069158|DRUG|Paclitaxel|iv administration
214811534|NCT02069158|DRUG|Carboplatin|iv administration
214811535|NCT01224535|DIETARY_SUPPLEMENT|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
214811536|NCT02821897|PROCEDURE|Target-controlled intravenous anaesthesia|
214811537|NCT02821897|PROCEDURE|Total anaesthesia|
214811538|NCT04551261|DRUG|GLS4|It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
214811539|NCT04551261|DRUG|RTV|"1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human."
214811540|NCT04551261|DRUG|TAF|It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
214811541|NCT00840632|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
214811542|NCT00840632|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
214811543|NCT01294787|DRUG|indacaterol and glycopyrronium bromide (QVA149)|
214811544|NCT01294787|DRUG|placebo|
214811545|NCT01294787|DRUG|tiotropium|
214811546|NCT04816253|DRUG|Normal saline|Normal saline irrigation and No other drug placed after extraction
214811547|NCT04816253|DRUG|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
214811548|NCT04816253|DRUG|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
214811549|NCT04816253|DRUG|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
214811550|NCT00006682|DRUG|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
214811551|NCT00006682|DRUG|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
214811552|NCT03978923|DEVICE|preparation of the implant site with Piezosurgery vs drill|"The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0."
214811553|NCT04908098|DEVICE|diode laser|It is the application of the laser tip parallel to the inner surface of the periodontal pocket
214811554|NCT04908098|PROCEDURE|scaling - root planning|Scaling is the removal of calculus and other deposits in the root of the tooth.Root planning is the removal of necrotic cementum on the tooth root surface. Scaler and gracey curettes are used for these operations.
214811555|NCT01725529|DRUG|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
214811556|NCT01725529|DRUG|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
214811557|NCT01725529|DRUG|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
214811558|NCT01725529|DRUG|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
214811559|NCT00789230|PROCEDURE|primary suture closure|primary suture closure of hernia
214811560|NCT00789230|DEVICE|mesh enforced closure|mesh enforced closure of hernia
214839810|NCT03399006|DEVICE|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
214811561|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
214811562|NCT04927013|BEHAVIORAL|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
214811563|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
214811564|NCT04927013|BEHAVIORAL|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
214811565|NCT02656186|DIETARY_SUPPLEMENT|Pre-intervention|First 2-weeks : keeping routine dietary habit
214811566|NCT02656186|DIETARY_SUPPLEMENT|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
214811567|NCT01948258|DEVICE|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
214811568|NCT04234334|OTHER|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
214811569|NCT04234334|OTHER|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
214811570|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
214811571|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
214811572|NCT04019951|DIETARY_SUPPLEMENT|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
214811573|NCT00070915|BEHAVIORAL|Tai chi|
214811574|NCT00070915|BEHAVIORAL|Mindfulness-based Stress Reduction program|
214811575|NCT00070915|PROCEDURE|Therapeutic massage|
214811576|NCT01452815|DRUG|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
214811577|NCT01452815|DRUG|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
214811578|NCT01452815|DRUG|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
214811579|NCT01304823|DIETARY_SUPPLEMENT|lactisole|flavoring agent/sweet taste antagonist
214811580|NCT01304823|OTHER|mixed liquid meal|Ensure Plus
214811581|NCT01730638|DRUG|• TF2 and 68 Ga-IMP-288|
214811582|NCT03502889|PROCEDURE|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
214811583|NCT03502889|PROCEDURE|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
214811584|NCT03502889|DRUG|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
214811585|NCT03502889|DEVICE|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
214811586|NCT05157477|BEHAVIORAL|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
214811587|NCT02046746|OTHER|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
214811588|NCT02381834|PROCEDURE|Bladder stimulation technique|
214811589|NCT02286817|DRUG|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
214811590|NCT04095117|PROCEDURE|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
214811591|NCT00004359|DRUG|methoxsalen|
214811592|NCT01094067|DRUG|ACT-050089|5 mg/h intravenously, Tezosentan
214811593|NCT01094067|OTHER|Placebo|Matching placebo
214811594|NCT04355104|BEHAVIORAL|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
214811595|NCT04355104|BEHAVIORAL|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
214811596|NCT02380989|DEVICE|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
214811597|NCT02380989|DEVICE|Placebo|
214811598|NCT01012934|DRUG|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
214811599|NCT01012934|DRUG|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
214811600|NCT06558656|DRUG|NTQ5082 capsule|"Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle."
214811601|NCT02262377|BEHAVIORAL|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
214811602|NCT05697419|BEHAVIORAL|deep breathing, muscle relaxation, and mindfulness|5-10-minute group sessions will be administered to DPT students teaching them the NIH recommended strategies of deep breathing, muscle relaxation or mindfulness.
214811603|NCT00878878|DRUG|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
214811604|NCT00878878|DRUG|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
214811605|NCT02071797|DEVICE|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
214811606|NCT05710562|OTHER|Name not applicable|In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
214811607|NCT02227186|OTHER|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
214811608|NCT01239862|OTHER|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
214811609|NCT05729529|OTHER|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
214811610|NCT05729529|DRUG|Placebo|Placebo oral gel used on tongue
214811611|NCT04164589|DEVICE|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
214811612|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on saturated fat.
214811613|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
214811614|NCT01721681|BIOLOGICAL|FACTOR X|
214811615|NCT04466553|DEVICE|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
214811616|NCT01395563|BEHAVIORAL|strength training|strength training, high intensity, twice up to 3 times per week
214811617|NCT05344872|OTHER|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
214811618|NCT04712422|OTHER|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
214811619|NCT04712422|OTHER|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
214811620|NCT01830569|BEHAVIORAL|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
214811621|NCT01830569|OTHER|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
214811622|NCT05316922|DRUG|Levothyroxine|Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
214811623|NCT01771705|OTHER|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
214811624|NCT04221425|PROCEDURE|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
214811625|NCT04221425|PROCEDURE|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
214811626|NCT04365309|DRUG|Aspirin 100mg|on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
214811627|NCT06424145|DIAGNOSTIC_TEST|Superior radial artery|Upper radial artery, 1 ml of lidocaine
214811628|NCT06424145|DIAGNOSTIC_TEST|Right side of radial artery|Right side of the radial artery,1ml of lidocaine
214811629|NCT00063856|BIOLOGICAL|Wetvax (APSV)|
214811630|NCT00723528|DRUG|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
214811631|NCT00723528|DRUG|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
214811632|NCT00723528|DRUG|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
214811633|NCT00723528|DRUG|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
214811634|NCT00723528|DRUG|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
214811635|NCT00723528|DRUG|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
214811636|NCT00723528|DRUG|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
214811637|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
214811638|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
214811639|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
214811640|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
214811641|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
214811642|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
214811643|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
214811644|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
214811645|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
214811646|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
214811647|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
214811648|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
214811649|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
214811650|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
214811651|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
214811652|NCT04626856|BIOLOGICAL|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
214811653|NCT04626856|BIOLOGICAL|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
214811654|NCT04719949|BEHAVIORAL|Behavioral Activation (BA) Therapy|Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.
214811655|NCT04719949|BEHAVIORAL|Problem Solving Therapy (PST)|Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
214811656|NCT04832399|DRUG|Natalizumab|As described in the treatment arm.
214811657|NCT02779894|OTHER|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
214811658|NCT00406068|DRUG|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
214811659|NCT02961309|DRUG|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
214811660|NCT00164671|BEHAVIORAL|POWER|
214811661|NCT05564897|DRUG|H101, Camrelizumab|Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10\*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
214811662|NCT00822497|BEHAVIORAL|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
214811663|NCT00822497|BEHAVIORAL|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
214811664|NCT00021528|DRUG|citalopram|
214811665|NCT00021528|DRUG|BuproprionSR|
214811666|NCT00021528|DRUG|buspirone|
214811667|NCT00021528|DRUG|Lithium|
214811668|NCT00021528|DRUG|mirtazapine|
214811669|NCT00021528|DRUG|nortriptyline|
214811670|NCT00021528|DRUG|sertraline|
214811671|NCT00021528|DRUG|tranylcypromine|
214811672|NCT00021528|DRUG|VenlafaxineXR|
214811673|NCT00021528|BEHAVIORAL|Cognitive Therapy|
214811674|NCT00021528|DRUG|T3 (Triiodothyronine)|
214811675|NCT01993030|DEVICE|HQ® Matrix Medical Wound Dressing|
214811676|NCT01993030|DEVICE|Sidaiyi® wound dressing|
214811677|NCT00698230|DRUG|INCB013739|INCB013739 5 mg QD tablet
214811678|NCT00698230|DRUG|INCB013739|INCB013739 15 mg QD tablet
214811679|NCT00698230|DRUG|INCB013739|INCB013739 50 mg QD tablet
214811680|NCT00698230|DRUG|INCB013739|INCB013739 100 mg QD tablet
214811681|NCT00698230|DRUG|INCB013739|INCB013739 200 mg QD
214811682|NCT00698230|DRUG|Placebo comparator matching INCB013739|Orally once daily tablet
214811683|NCT00698230|DRUG|Metformin|
214811684|NCT03785548|OTHER|Usage of a mirror|using a mirror during the pelvic examination
214811685|NCT01710657|DRUG|Lacosamide 50 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
214811686|NCT01710657|DRUG|Lacosamide 100 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use"
214811687|NCT01710657|DRUG|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
214811688|NCT00881322|DIETARY_SUPPLEMENT|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
214811689|NCT00881322|DIETARY_SUPPLEMENT|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD\&C yellow #5 Lake, FD\&C blue #1 Lake, FD\&C red #46 Lake and vegetable capsule"
214811690|NCT04196322|OTHER|observational study|observational study
214811691|NCT02187562|DRUG|Meloxicam|
214811692|NCT02187562|DRUG|Aspirin|
214811693|NCT03921294|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
214811694|NCT02601794|BEHAVIORAL|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
214811695|NCT05865691|OTHER|biomarker assay|blood sample on the day of inclusion
214811696|NCT01868529|DRUG|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
214648575|NCT04581720|DEVICE|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
214648576|NCT02250209|DRUG|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
214648577|NCT02250209|DRUG|Capecitabine|"Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
214648578|NCT02250209|DRUG|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
214648579|NCT01369121|DRUG|XERECEPT|BID dosing, subcutaneous for 1 year
214648580|NCT02130414|DRUG|Sandimmun® IV|2 mg/kg IV
214648581|NCT02130414|DRUG|CyCol® capsules|37.5 mg CyCol® capsules
214648582|NCT00531960|DRUG|Erlotinib|150 mg, PO, daily
214648583|NCT00531960|DRUG|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
214648584|NCT00531960|DRUG|Standard platinum-based chemotherapy|At the discretion of the investigator
214648585|NCT06301178|DRUG|Cholecalciferol|Vitamin D has various critical regulatory roles, including inflammatory control, cellular proliferation and differentiation, and wound healing regulation.
214648586|NCT01500057|DEVICE|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
214648587|NCT01500057|DEVICE|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
214648588|NCT00806104|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
214648589|NCT00806104|DIETARY_SUPPLEMENT|Maltodextrins|Dietary supplementation for 4 weeks
214811697|NCT01868529|DRUG|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
214811698|NCT02404662|OTHER|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
214811699|NCT02404662|OTHER|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
214811700|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
214811701|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
214811702|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
214811703|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
214811704|NCT00535860|DRUG|Teriparatide|Daily for 96 days
214811705|NCT01033565|DRUG|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
214811706|NCT04828720|DRUG|ozonated oil|All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
214811707|NCT03222765|DRUG|Placebo, metformin, linagliptin, linagliptin + metformin|
214811708|NCT05778422|DRUG|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
214811709|NCT05778422|PROCEDURE|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
214811710|NCT04769622|PROCEDURE|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
214811711|NCT04769622|OTHER|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~* adherence to Mediterranean Diet;~* sleep quality;~* physical activity;~* perceived stress."
214811712|NCT01452022|DEVICE|Inductigraft|Synthetic bone graft
214811713|NCT04993664|DRUG|Pelacarsen (TQJ230)|The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
214811714|NCT04993664|DRUG|Placebo|The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
214811715|NCT01591785|DRUG|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
214811716|NCT01591785|DRUG|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
214811717|NCT06340256|OTHER|Continuous spinal anesthesia|The Catheter will be then fed over the needle into the intrathecal space and Inserted 3cm cephalad into the subarachnoid space.The spinal needle and the modified Tuohy needle will be then removed, and a Luer connector and A filter previously filled with the anesthetic solution will be attached to the Catheter (priming volume 0.6ml). Plain bupivacaine 0.5% in 20ml vials will Be used CSA group received 1 ml(5 mg) of plain bupivacaine (0.5%) Together with fentanyl l25μg injected via the catheter at a rate of 0.2ml/15s. The level of the resulting sensory blockade will be tested using pin prick.
214811718|NCT06340256|OTHER|Continuous epidural anesthesia|The needle is advanced until the epidural space is identified by the loss-of-resistance technique, and then a 20G catheter is inserted 3 cm cephalad into the epidural space. a test dose of 3ml of 2% lignocaine with adrenaline (1:200000) will be injected into the catheter. Three minutes later, 10 ml of plain bupivacaine (0.5%) together with fentanyl l50μg will be injected via the catheter.
214811719|NCT05275985|DIAGNOSTIC_TEST|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
214811720|NCT03322709|PROCEDURE|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
214811721|NCT01672515|DEVICE|RIPC group|
214811722|NCT01672515|DEVICE|Control group|
214811723|NCT03827044|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
214811724|NCT01215266|DRUG|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
214811725|NCT01215266|DRUG|Placebo|Day 3-21 2x2 800 mg(milligram) daily
214811726|NCT00595166|DEVICE|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
214811727|NCT01095692|PROCEDURE|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
214811728|NCT01095692|PROCEDURE|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
214811729|NCT06377657|BEHAVIORAL|Exercise|The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino
214811730|NCT06377657|DIETARY_SUPPLEMENT|Aloe vera|Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
214811731|NCT06491524|DEVICE|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone <2cm|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
214811732|NCT00358449|DRUG|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
214811733|NCT01998217|DRUG|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
214811734|NCT01998217|DRUG|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
214811735|NCT02222805|PROCEDURE|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
214811736|NCT02222805|PROCEDURE|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
214811737|NCT00641420|PROCEDURE|Fractionated Laser Resurfacing|
214811738|NCT03958422|DRUG|cardiomyopeptidin|The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
214811739|NCT01523730|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
214839811|NCT02991352|DEVICE|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
214839812|NCT05202288|BIOLOGICAL|Ervebo|Administration of r-VSV-ZEBOV vaccine
214839813|NCT05202288|DRUG|Inmazeb|Administration of Inmazeb
214811740|NCT01523730|DEVICE|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
214811741|NCT05318157|DRUG|AIT drops|Once a day
214811742|NCT05318157|DRUG|Clarityne, Rhinocort and Emedastine Difumarate Eye Drops|The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
214811743|NCT05174325|DRUG|Sintilimab + chemotherapy|Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
214811744|NCT01458002|OTHER|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
214811745|NCT01458002|OTHER|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
214811746|NCT00546897|DRUG|Lenalidomide|
214811747|NCT00242060|PROCEDURE|MRI|
214811748|NCT04769648|DRUG|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
214811749|NCT04769648|DRUG|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
214811750|NCT00987948|DRUG|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
214811751|NCT05099822|DRUG|CC-97489|Specified dose on specified days
214811752|NCT05099822|OTHER|Placebo|Specified dose on specified days
214811753|NCT02440308|DRUG|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is \[4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl\]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
214811754|NCT02440308|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|
214811755|NCT02440308|PROCEDURE|Positron Emission Tomography (PET) scan|
214811756|NCT03370549|BEHAVIORAL|AWARE intervention|Group psychotherapy for Asian-American women
214811757|NCT01585259|DRUG|Anfibatide|Snake venom
214811758|NCT01585259|DRUG|Placebo|Saline
214811759|NCT01221922|DEVICE|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
214811760|NCT00374335|PROCEDURE|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
214811761|NCT00374335|OTHER|Dermatologic Examination|Complete dermatologic examination
214839814|NCT05762887|OTHER|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
214648590|NCT06460571|OTHER|Standard Cardiac rehabilitation with Delorme technique|Aerobic training will be provided three alternate days a week at 60-70% of maximum heart rate for eight weeks. Resistance training for 3 sets and 10 repetitions (10 lifts with 50%of 10RM, then 75% of 10RM and will progress to 100% of 10RM) will involve seven exercises (abdominal curl ups, bicep curls, triceps extension, back extension, leg curls, side leg raises and knee extensions).
214811762|NCT05119270|DEVICE|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|"The LenSx laser (Alcon Laboratories Inc., USA) automates key steps in the procedure including capsulorhexis, incision making and phaco. The Frequency Domain - Optical Coherence Tomography (FD-OCT) optical imaging system provides high-resolution, real-time visualization of ocular structures and their dimensions. The device sends the results to the interface which programs the laser and indicates the exact location, size and depth of the desired incisions.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
214811763|NCT05119270|PROCEDURE|Standard phacoemulsification with the Active Sentry handpiece|"Phacoemulsification is done by using the Active Sentry handpiece to allow for a better control of the intraocular pressure throughout the surgery.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
214811764|NCT05119270|PROCEDURE|Standard phacoemulsification with the OZil handpiece|"Phacoemulsification is done by using the traditional OZil handpiece that allows rotational movement of the phaco tip.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
214811765|NCT02259270|OTHER|Record review|Record review. No intervention with patient or physician. No effect on outcome.
214811766|NCT02259270|OTHER|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
214811767|NCT01375660|DRUG|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
214811768|NCT01375660|DRUG|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
214811769|NCT00737490|OTHER|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
214648591|NCT06460571|OTHER|standard cardiac rehabilitation|The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique. The control group will not perform any specific training but will be given a diet chart to follow
214648592|NCT04088448|DRUG|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
214811770|NCT00737490|OTHER|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
214811771|NCT02685462|DRUG|Rosuvastatin|
214811772|NCT02685462|DRUG|Atorvastatin|
214811773|NCT02685462|DRUG|Simvastatin|
214811774|NCT02685462|DRUG|Digoxin|
214811775|NCT02685462|DRUG|Caffeine|
214839815|NCT05762887|OTHER|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
214648593|NCT04088448|DRUG|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
214648594|NCT02606994|DRUG|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
214648595|NCT02606994|DRUG|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
214648596|NCT02606994|DRUG|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
214648597|NCT00703313|DRUG|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
214648598|NCT00703313|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
214648599|NCT00703313|DRUG|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
214648600|NCT02392260|DEVICE|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
214648601|NCT04719351|BEHAVIORAL|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
214648602|NCT00686816|DIETARY_SUPPLEMENT|Low calorie diet|low calorie diet
214648603|NCT00686816|DIETARY_SUPPLEMENT|Olestra|low calorie Olestra diet
214648604|NCT00503165|BIOLOGICAL|Menitorix (MenC and Hib conjugate)|
214648605|NCT05928975|OTHER|MT+ PNE with MI|"The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process."
214648606|NCT05928975|OTHER|MT|"Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE."
214648607|NCT05928975|OTHER|Control|The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
214648608|NCT00701714|DRUG|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
214648609|NCT00701714|DRUG|ERYPO|Solution for injection (s.c.)
214648610|NCT01147614|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
214648611|NCT01147614|BEHAVIORAL|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
214648612|NCT00456313|DRUG|FLIXOTIDE and SERETIDE|comparator
214648613|NCT02005120|DRUG|Bevacizumab|Intrapleural administration of bevacizumab
214648614|NCT02005120|DRUG|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
214648615|NCT06121414|DEVICE|laserpuncture|laserpuncture use continous wave,dose 2 Joule, 785nm, 50mw
214648616|NCT06121414|DEVICE|Sham Laserpuncture|Sham laser using laserpuncture in off condition
214648617|NCT05560737|BEHAVIORAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
214648618|NCT04873492|OTHER|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
214648619|NCT05429879|OTHER|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
214648620|NCT05429879|OTHER|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
214811776|NCT06314022|OTHER|Mobile application for colonoscopy preparation instructions|The APP will also consider the comorbidities and drugs of each patient. It can be adapted to the different types of laxative (4, 2 or 1 litre) and notify the need to discontinue anticoagulant and/or antiplatelet treatments by contacting with the primary care physician. Additionally, the application may ask short questions to the patient to control the laxative intake instruction. The user must confirm the appointment 48 hours in advance.
214811777|NCT00496964|DRUG|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
214811778|NCT00496964|DRUG|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
214811779|NCT04775745|DRUG|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
214811780|NCT04775745|DRUG|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
214811781|NCT04264130|DRUG|Artesunate-Pyronaridine|Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
214811782|NCT04264130|DRUG|Artemether-Lumefantrine|subjects received artemether-lumefantrine according to their body weight twice per day for three days.
214811783|NCT04264130|DRUG|Artefenomel-Ferroquine|Subject received a single dose of artefenomel-ferroquine according to their body weight
214811784|NCT02642367|DEVICE|McGrath videolaryngoscope|without use of stylet
214811785|NCT02642367|DEVICE|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
214811786|NCT02642367|DRUG|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
214811787|NCT04383366|DEVICE|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
214811788|NCT04383366|DEVICE|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
214811789|NCT04383366|DEVICE|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
214811790|NCT01162694|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
214811791|NCT01162694|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
214811792|NCT00469417|DRUG|Metvix® cream|
214811793|NCT00469417|PROCEDURE|Hand held liquid nitrogen spray cryotherapy|
214811794|NCT01038947|BIOLOGICAL|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
214811795|NCT03799653|OTHER|No intervention|This is a prospective observational study, and there is no intervention.
214811796|NCT04012112|DEVICE|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
214811797|NCT05730166|OTHER|Mechanical Conditioning stimulus|Mechanical stimulus on the upper trapezius of the non-dominant side.
214811798|NCT00909610|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
214811799|NCT00909610|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
214811800|NCT03585790|DEVICE|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
214811801|NCT03585790|DEVICE|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
214811802|NCT06279338|DRUG|Azacitidine Injection|On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
214811803|NCT03013634|DRUG|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
214811804|NCT03013634|DRUG|Normal saline|Equal volume normal saline substitute for dexmedetomidine
214811805|NCT02337218|DEVICE|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
214811806|NCT02054845|BEHAVIORAL|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~1. Body scan~2. Psychoeducation~3. Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~4. Body Awareness Training~5. Exposure training (imaginary exposure to induce response fluctuations)~6. Training in cueing techniques to overcome problems with initiation and freezing~7. Visual Feedback training~8. Relaxation techniques"
214811807|NCT02054845|OTHER|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
214811808|NCT05327491|DRUG|Sotorasib|Oral Tablet
214811809|NCT04073394|BEHAVIORAL|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
214811810|NCT04073394|BEHAVIORAL|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
214811811|NCT03660384|PROCEDURE|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
214811812|NCT03660384|PROCEDURE|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
214811813|NCT04908007|OTHER|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
214811814|NCT04908007|OTHER|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
214811815|NCT04908007|OTHER|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
214811816|NCT04908007|OTHER|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
214811817|NCT04135235|DRUG|TAF|Propofol tenofovir fumarate
214811818|NCT04135235|DRUG|TDF|Dipirofurate fumarate tenofovir
214811819|NCT01074879|DIETARY_SUPPLEMENT|Whey protein|Dietary supplement after training
214811820|NCT01074879|DIETARY_SUPPLEMENT|Milk protein|Dietary supplement after training
214811821|NCT01074879|DIETARY_SUPPLEMENT|Carbohydrates|Dietary supplement after training
214811822|NCT03756259|BEHAVIORAL|Mobile Health (mHealth) for Pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
214811823|NCT02753959|OTHER|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
214811824|NCT02753959|OTHER|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
214811825|NCT02142556|DRUG|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
214811826|NCT05316428|DRUG|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
214811827|NCT05316428|OTHER|alcohol|0.5 g/kg alcohol
214811828|NCT05316428|DRUG|TPN171H tablet|10 mg TPN171H tablet QD
214811829|NCT04555889|DEVICE|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
214811830|NCT01868191|DRUG|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
214811831|NCT01868191|DRUG|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
214811832|NCT01138540|OTHER|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
214811833|NCT02095782|DRUG|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
214811834|NCT04362020|OTHER|Distal radial access|Distal radial access and No anticoagulation
214811835|NCT04362020|OTHER|Distal radial access|Distal radial access and ACT-guided anticoagulation
214811836|NCT01418586|DRUG|Torrent's Alfuzosin Extended Release Tablet|
214811837|NCT05974163|DIAGNOSTIC_TEST|radiomic of CT|Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.
214811838|NCT05217225|PROCEDURE|Simple restorative treatment|Simple Occlusal Cavity class I then followed by final restoration
214811839|NCT03427164|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
214811840|NCT02957318|DIETARY_SUPPLEMENT|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
214811841|NCT02957318|DIETARY_SUPPLEMENT|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
214811842|NCT02957318|DIETARY_SUPPLEMENT|Placebo|Low-fiber control
214811843|NCT01297179|DRUG|Mirabegron|Oral
214811844|NCT01297179|DRUG|Minidril|Oral
214811845|NCT01297179|DRUG|Placebo|Oral
214811846|NCT05076253|DRUG|Ivermectin|Ivermectin plus standard care
214811847|NCT05076253|DRUG|Placebo|Standard care
214811848|NCT04106193|OTHER|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
214811849|NCT04106193|OTHER|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
214811850|NCT04106193|OTHER|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
214811851|NCT04957953|OTHER|Patient's consent|Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
214811852|NCT04957953|OTHER|Inclusion form|"This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate."
214811853|NCT04957953|OTHER|Adverse reaction report form.|One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
214811854|NCT04957953|DIAGNOSTIC_TEST|Follow-up report form.|In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
214811855|NCT00270777|DRUG|adrenaline, promethazine, hydrocortisone|
214811856|NCT02897791|BEHAVIORAL|written evaluations|answering questions about pictures and stories
214811857|NCT02380560|DEVICE|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
214811858|NCT03598101|DEVICE|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
214811859|NCT01725958|DIETARY_SUPPLEMENT|Nutritional supplement and protein shakes|
214811860|NCT04019834|DRUG|regional nerve block with local anesthesia of bupivacaine with steroid|Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
214811861|NCT04019834|OTHER|Placebo regional nerveblock with normal saline|Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
214811862|NCT04547517|OTHER|Evaluation of Counselling competencies|To complete a set of questionnaires
214811863|NCT02005419|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214811864|NCT02005419|DRUG|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214811865|NCT02005419|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214811866|NCT06407206|OTHER|Sub occipital muscle inhibition technique and conventional therapy|Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
214811867|NCT06407206|OTHER|conventional therapy|Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
214811868|NCT04513587|BEHAVIORAL|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
214811869|NCT04513587|BEHAVIORAL|Control|Treatment as usual
214811870|NCT04433611|DRUG|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
214811871|NCT04433611|DRUG|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
214811872|NCT04535830|DEVICE|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
214811873|NCT01082523|OTHER|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
214811874|NCT01274039|DRUG|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
214811875|NCT03187522|DEVICE|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
214811876|NCT03031184|DRUG|Mirtazapine|
214811877|NCT03031184|OTHER|Placebo|
214811878|NCT05038293|DEVICE|Automated mouthpiece-based toothbrush|One-time use during study visit.
214811879|NCT05038293|DEVICE|Manual toothbrush|One-time use during study visit.
214811880|NCT02163837|DRUG|rifaximine|
214811881|NCT02708693|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
214811882|NCT02708693|DEVICE|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
214811883|NCT02708693|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
214811884|NCT02887339|OTHER|Training Website|Additional training website can be found at gtextraing.org
214811885|NCT02887339|OTHER|Control|Standard training given by OPOs and GTEx staff
214811886|NCT04166734|DRUG|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
214811887|NCT04166734|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
214811888|NCT06042335|DEVICE|DAISe EZ|DAISe Thrombectomy System for mechanical thrombectomy
214811889|NCT01627158|DRUG|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
214811890|NCT01627158|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler
214811891|NCT01627158|DRUG|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
214811892|NCT01627158|DRUG|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
214811893|NCT02339558|OTHER|Laboratory Biomarker Analysis|Correlative studies
214811894|NCT02339558|BIOLOGICAL|Nivolumab|Given IV
214811895|NCT03587493|OTHER|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
214811896|NCT02259283|DEVICE|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
214811897|NCT00906477|PROCEDURE|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
214811898|NCT04043377|DRUG|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
214811899|NCT02697747|OTHER|Education|Educational intervention in the use of ultrasound to identify landmarks
214811900|NCT05310591|DRUG|Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )|"Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
214811901|NCT05310591|DRUG|Nivolumab starting at day -1|"It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
214811902|NCT01185691|DEVICE|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
214811903|NCT00645762|DEVICE|RS-Series Rhinosinusitis Treatment System|Single arm
214811904|NCT00645762|DEVICE|FinESS Balloon|
214811905|NCT04253366|DEVICE|Clinical investigation device class IIa not marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
214811906|NCT01247701|DRUG|Busulfan|Busulfan dosing will be as follows: Patients \< 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \> 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
214811907|NCT01247701|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
214811908|NCT01247701|DRUG|Fludarabine|Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients \> 10 kg: 40 mg/m\^2.
214811909|NCT01247701|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
214811910|NCT04533269|OTHER|Arnica montana, Ledum palustre|Homeopathic
214811911|NCT01795872|PROCEDURE|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
214811912|NCT04166630|DEVICE|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
214811913|NCT04351425|DEVICE|Weaning to crib|We weaned the infants into two groups. Group A, 1.6 kg
214811914|NCT04351425|DEVICE|Weaning from incubator|We weaned the infants into two groups. group B, 1.4 kg
214811915|NCT04747535|DEVICE|Auto-CPAP|AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
214811916|NCT04747535|DEVICE|CPAP since before|A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
214811917|NCT01628835|BEHAVIORAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
214811918|NCT01628835|BEHAVIORAL|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
214811919|NCT00001135|DRUG|Nevirapine|
214811920|NCT04574102|DEVICE|Omega Refractive Capsule with FDA approved Intraocular Lens|Omega Refractive Capsule with FDA approved Intraocular Lens
214811921|NCT04574102|DEVICE|FDA approved Intraocular lens|FDA approved Intraocular lens
214811922|NCT04579770|DIETARY_SUPPLEMENT|Ketone ester|75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.
214811923|NCT04579770|OTHER|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
214811924|NCT04579770|OTHER|Placebo|Placebo
214811925|NCT05176015|DEVICE|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
214811926|NCT05176015|DIAGNOSTIC_TEST|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
214811927|NCT03397251|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
214811928|NCT03696745|OTHER|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
214811929|NCT03696745|DRUG|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
214811930|NCT00096447|DRUG|lapatinib ditosylate|
214811931|NCT00002662|DRUG|docetaxel|
214811932|NCT00002662|DRUG|paclitaxel|
214811933|NCT05522361|DRUG|Risdiplam|administered to participants per product label insert
214811934|NCT04510545|DIAGNOSTIC_TEST|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
214811935|NCT03827356|DEVICE|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
214811936|NCT04292873|OTHER|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
214811937|NCT00834743|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
214811938|NCT00834743|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
214811939|NCT04995783|DIAGNOSTIC_TEST|Coral FRS test|A novel clinical test to predict autoimmune medication response
214811940|NCT04470791|BIOLOGICAL|F(ab)2 antivenom therapy (antivipmyn®).|Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
214811941|NCT04470791|PROCEDURE|Local cryotherapy.|Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
214811942|NCT04088760|DRUG|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
214811943|NCT03964662|DEVICE|WeReha|Rehabilitation of stroke patients with the device WeReha
214811944|NCT04855058|OTHER|online survey(or phone survey)|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over google survey(or the phone survey) for patients.
214811945|NCT00607230|BIOLOGICAL|BCG|BCG vaccination at 0 and 4 weeks
214811946|NCT00607230|BIOLOGICAL|Saline|Saline vaccination at 0 and 4 weeks
214811947|NCT05702424|DRUG|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
214811948|NCT00764777|DEVICE|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
214811949|NCT02434055|DEVICE|AVERT PLUS|
214811950|NCT02460653|DEVICE|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
214811951|NCT04091971|DRUG|Ketamine|"Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks)."
214811952|NCT03734263|DRUG|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
214811953|NCT03016650|DRUG|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
214811954|NCT03016650|DRUG|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
214811955|NCT02507128|DRUG|liraglutide|Liraglutide were taken 30 min before PCI.
214811956|NCT02507128|DRUG|placebo|Placebo were taken 30 min before PCI.
214811957|NCT05600322|DRUG|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
214811958|NCT05600322|DEVICE|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
214811959|NCT06437691|PROCEDURE|Self-Expandable Metallic Stent Placement|
214811960|NCT06626555|DRUG|Letermovir|Letermovir 480mg PO once daily
214811961|NCT03867721|DEVICE|Ventilator|Comparison of two ventilators for mouthpiece ventilation
214811962|NCT05186571|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
214811963|NCT00004314|DRUG|aminomidazole carboxamide riboside|
214811964|NCT04206410|DIETARY_SUPPLEMENT|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
214811965|NCT04206410|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
214811966|NCT05427643|PROCEDURE|study group|dental implant procedure under local anesthesia
214811967|NCT05427643|PROCEDURE|control group|dental implant procedure under local anesthesia
214811968|NCT04949932|OTHER|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
214811969|NCT04949932|OTHER|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
214811970|NCT00649753|PROCEDURE|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
214811971|NCT00649753|PROCEDURE|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
214811972|NCT00649753|PROCEDURE|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
214811973|NCT03661047|DRUG|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
214811974|NCT02898545|DEVICE|SEEQ monitor|An external cardiac rhythm monitor
214811975|NCT05479630|OTHER|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
214811976|NCT04336930|DIAGNOSTIC_TEST|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
214811977|NCT03038048|PROCEDURE|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
214811978|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
214811979|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
214811980|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
214811981|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
214811982|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
214811983|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
214811984|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214811985|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
214811986|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
214811987|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
214811988|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
214811989|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
214811990|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
214811991|NCT05813548|OTHER|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
214811992|NCT05813548|OTHER|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
214811993|NCT01878825|BIOLOGICAL|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
214811994|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
214811995|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
214811996|NCT00216463|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
214811997|NCT00216463|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
214811998|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
214811999|NCT05542108|BEHAVIORAL|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
214812000|NCT05542108|BEHAVIORAL|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
214812001|NCT00006495|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214812002|NCT00006495|BIOLOGICAL|HIV-1 Immunogen|
214812003|NCT02472366|DRUG|ILUVIEN|
214812004|NCT02728102|PROCEDURE|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
214812005|NCT02728102|PROCEDURE|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
214812006|NCT02728102|DRUG|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
214812007|NCT02728102|PROCEDURE|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
214812008|NCT02728102|BIOLOGICAL|Myeloma vaccine|The target dose is 3 x 10\^6 fusion cells per vaccine. A minimum of 3 x 10\^6 total fusion cells will be required to proceed with vaccine administration. Patients who have \<3 x 10\^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
214812009|NCT02728102|DRUG|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
214812010|NCT02728102|DRUG|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
214812011|NCT03739749|PROCEDURE|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
214812012|NCT00830232|DEVICE|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
214812013|NCT00830232|DEVICE|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
214812014|NCT02419937|DRUG|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
214812015|NCT02419937|DRUG|Placebo|Saline injection
214812016|NCT02924883|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
214812017|NCT02924883|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
214812018|NCT02924883|OTHER|Placebo|Placebo matched to atezolizumab
214812019|NCT03142360|DRUG|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
214812020|NCT01182415|PROCEDURE|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
214812021|NCT01182415|DRUG|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
214812022|NCT00941837|DIETARY_SUPPLEMENT|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
214812023|NCT04843878|DIAGNOSTIC_TEST|COVID Detect|The study is determining the efficacy of a new rapid COVID testing method.
214812024|NCT04386278|DEVICE|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
214812025|NCT04386278|DEVICE|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
214812026|NCT04386278|DEVICE|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
214812027|NCT04386278|DEVICE|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
214812028|NCT04386278|DEVICE|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
214812029|NCT04386278|DEVICE|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
214812030|NCT04386278|DEVICE|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
214812031|NCT04386278|DEVICE|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
214812032|NCT01135927|DRUG|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
214812033|NCT01135927|DRUG|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
214812034|NCT02535494|OTHER|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
214812035|NCT01725698|DRUG|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
214812036|NCT04044326|PROCEDURE|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
214812037|NCT05479110|BEHAVIORAL|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
214812038|NCT05479110|OTHER|case studies|active control: case studies(text)
214812039|NCT00481520|DRUG|SAM-531|
214812040|NCT00481520|OTHER|placebo|
214812041|NCT01981720|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
214812042|NCT05009225|OTHER|Comprehensive ED AF management tool|Managing atrial fibrillation (AF) patients in the emergency department (ED) is complex, often requiring many separate decisions: How to best reduce the heart rate? Should emergency physicians attempt cardioversion? If so, how? Does this patient need stroke prevention? The investigators' CDSS provides emergency physicians with a one-stop, evidence-based resource that addresses all aspects of ED AF management.
214812043|NCT03685565|PROCEDURE|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
214812044|NCT03685565|PROCEDURE|Dermabond|Laceration repaired with Dermabond
214812045|NCT05101044|BEHAVIORAL|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
214812046|NCT00148772|DRUG|Erlotinib (Tarceva)|
214812047|NCT03717350|DRUG|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
214812048|NCT03717350|DRUG|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
214812049|NCT03828058|DRUG|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
214812050|NCT03828058|DRUG|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
214812051|NCT01488786|DEVICE|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
214812052|NCT02830386|DEVICE|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
214812053|NCT02522234|BIOLOGICAL|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
214812054|NCT02522234|BIOLOGICAL|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
214812055|NCT03447717|DEVICE|ActiGait|implanted device for peroneal nerve stimulation
214812056|NCT00659321|DRUG|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
214812057|NCT00659321|DRUG|placebo|16 weeks treatment with placebo
214812058|NCT02605395|DRUG|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
214812059|NCT02605395|DRUG|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
214812060|NCT03875755|DIETARY_SUPPLEMENT|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
214812061|NCT03875755|OTHER|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
214812062|NCT02738190|DRUG|Albumin|Albumin 5% added to blood priming solution
214812063|NCT02738190|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
214812064|NCT01813006|DRUG|Omega-3|
214812065|NCT01813006|DRUG|placebo|
214812066|NCT01423006|PROCEDURE|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
214812067|NCT00149500|BEHAVIORAL|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
214812068|NCT00398515|DRUG|lenalidomide|Given orally
214812069|NCT00398515|DRUG|temsirolimus|Given IV
214812070|NCT00398515|OTHER|pharmacological study|Correlative studies
214812071|NCT00398515|OTHER|laboratory biomarker analysis|Correlative studies
214812072|NCT00553228|BIOLOGICAL|Tdap|0.5 mL IM once at visit #2
214812073|NCT00553228|BIOLOGICAL|Td|0.5 mL IM once at visit #2
214812074|NCT00278980|DRUG|C-peptide|
214812075|NCT00004562|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
214812076|NCT00004562|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
214812077|NCT00004562|PROCEDURE|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
214812078|NCT00004562|DRUG|ACE Inhibitors|Participants will receive ACE inhibitors.
214812079|NCT00567762|DRUG|FK506|Opthalmic suspension
214812080|NCT00567762|DRUG|placebo|placebo eye drops
214812081|NCT02770820|BIOLOGICAL|Aldesleukin|Given SC
214812082|NCT02770820|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
214812083|NCT02770820|OTHER|Laboratory Biomarker Analysis|Correlative studies
214812084|NCT01652794|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214812085|NCT01652794|DRUG|carboplatin|Given IV
214812086|NCT01652794|DRUG|gemcitabine hydrochloride|Given IV
214812087|NCT01652794|OTHER|laboratory biomarker analysis|Optional correlative studies
214812088|NCT01652794|OTHER|pharmacogenomic studies|Optional correlative studies
214812089|NCT05700565|OTHER|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
214812090|NCT05700565|OTHER|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
214812091|NCT04165239|DRUG|KH176|Oral administration of 50 mg KH176 twice daily
214812092|NCT04165239|DRUG|KH176|Oral administration of 100 mg KH176 twice daily
214812093|NCT04165239|DRUG|Placebo|Oral administration of matching placebo twice daily
214812094|NCT02648334|DEVICE|IN.PACT drug coated balloon|
214812095|NCT02648334|DEVICE|Lutonix drug coated balloon|
214812096|NCT04395417|DRUG|Hyaluronic Acid|Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
214812097|NCT04395417|BIOLOGICAL|Prolotherapy|Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
214812098|NCT01532297|DEVICE|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
214812099|NCT01532297|DEVICE|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
214812100|NCT03310697|OTHER|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
214812101|NCT03310697|OTHER|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
214812102|NCT03525860|PROCEDURE|Acupuncture|"The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~."
214812103|NCT01773330|PROCEDURE|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
214812104|NCT01773330|DIETARY_SUPPLEMENT|Gatorade|The patient will be given Gatorade to drink at various times during the study.
214812105|NCT01773330|OTHER|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
214812106|NCT01773330|OTHER|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
214812107|NCT01773330|PROCEDURE|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
214812108|NCT01773330|PROCEDURE|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
214812109|NCT02336165|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
214812110|NCT02336165|RADIATION|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
214812111|NCT02336165|BIOLOGICAL|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
214812112|NCT05223426|OTHER|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
214812113|NCT05223426|OTHER|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
214812114|NCT00378131|DRUG|RC-1291|
214812115|NCT00378131|DRUG|placebo|
214812116|NCT01054586|DRUG|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
214812117|NCT01054586|DRUG|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
214812118|NCT01054586|DRUG|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
214812119|NCT01054586|DRUG|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
214812120|NCT01054586|DRUG|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
214812121|NCT01762618|BEHAVIORAL|Cognitive Behavioral Therapy Group|Therapy Groups
214812122|NCT02134964|DRUG|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
214812123|NCT02134964|DRUG|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
214812124|NCT04542603|DRUG|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
214812125|NCT02841033|DRUG|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
214812126|NCT03195491|BIOLOGICAL|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
214812127|NCT05213273|BEHAVIORAL|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
214812128|NCT03182114|OTHER|supine position|the patient will be placed in regular supine position after spinal anesthesia
214812129|NCT03182114|OTHER|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
214812130|NCT03182114|DRUG|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
214812131|NCT03357003|OTHER|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
214812132|NCT05188742|DRUG|mirabegron|mirabegron 50mg QD
214812133|NCT05188742|PROCEDURE|TTNS|transcutaneous tibial nerve stimulation
214812134|NCT03499171|DRUG|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
214812135|NCT03499171|DRUG|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
214812136|NCT03292354|OTHER|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
214812137|NCT01777347|DRUG|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
214812138|NCT01777347|DRUG|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
214812139|NCT02613260|BEHAVIORAL|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
214812140|NCT04859920|OTHER|Questionnaires|QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data
214812141|NCT04859920|OTHER|Collection of clinical data and treatments|clinical data and treatments
214812142|NCT05332496|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
214812143|NCT05332496|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
214812144|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
214812145|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
214812146|NCT06180512|DIETARY_SUPPLEMENT|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
214812147|NCT01314417|DRUG|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
214812148|NCT00938106|RADIATION|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
214812149|NCT05707507|OTHER|Place of treatment|Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
214812150|NCT03735485|OTHER|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
214812151|NCT03735485|OTHER|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
214812152|NCT03735485|OTHER|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
214812153|NCT05136183|DEVICE|HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)|"* If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization."
214812154|NCT01828697|DRUG|Low dose nadroparin|"Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily"
214812155|NCT01828697|DRUG|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily."
214812156|NCT01828697|DRUG|Low dose enoxaparin|"Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily"
214812157|NCT01828697|DRUG|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily."
214812158|NCT01828697|DRUG|Low dose dalteparin|"Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily"
214812159|NCT01828697|DRUG|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily."
214812160|NCT01828697|DRUG|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily"
214812161|NCT01828697|DRUG|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily."
214812162|NCT01683682|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
214812163|NCT01683682|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
214812164|NCT01683682|DRUG|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
214812165|NCT04125576|DIAGNOSTIC_TEST|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
214812166|NCT03387176|OTHER|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
214812167|NCT04239872|DRUG|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
214812168|NCT04239872|DRUG|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
214812169|NCT06362772|RADIATION|Iodine-125 brachytherapy|"In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions."
214812170|NCT04690166|OTHER|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
214812171|NCT00714090|OTHER|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
214812172|NCT00714090|OTHER|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
214812173|NCT00714090|OTHER|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
214812174|NCT06218108|DIAGNOSTIC_TEST|Taulí-T1 versus conventional classifications|All the slides of each case will be reviewed, selecting the one that contains the most invasive section, and this will be digitized to take measurements in micrometers with greater precision. To measure the degree of infiltration, the measurement of residual healthy submucosa (hrSB) will be used, which is the distance between the point of greatest infiltration and the muscularis propria. The total thickness of the submucosa in the tumor area will also be measured, taking as a reference the muscularis of the mucosa or, in its absence, the surface of the lesion, to calculate the percentage of infiltration of the submucosa. This percentage will be calculated as the inverse percentage of invasion with respect to the hrSB: (total thickness of the submucosa - hrSB / total thickness of the submucosa) x 100. The qualitative categories will be obtained: sm1 (\< 33.3%), sm2 (33.3% - 66.6%) and sm3 (\> 66.6%). Measurements will be also taken in micrometers for the conventional classifications.
214812175|NCT02819323|DRUG|PEG-ELS|polyethylene glycol based bowel preparation
214812176|NCT02819323|DRUG|BLI800|BLI800 bowel preparation
214812177|NCT03644264|DRUG|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
214812178|NCT03644264|DRUG|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
214812179|NCT05984251|DRUG|CCX168|Administered orally.
214812180|NCT05984251|DRUG|Placebo|Administered orally.
214812181|NCT00962611|DRUG|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
214812182|NCT01067183|BEHAVIORAL|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
214812183|NCT03115177|DRUG|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
214812184|NCT03115177|DRUG|Cefazolin|
214812185|NCT00648947|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
214812186|NCT00648947|DRUG|Plavix® Tablets 75 mg|75mg, single dose fasting
214812187|NCT05084677|COMBINATION_PRODUCT|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
214812188|NCT03957447|OTHER|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
214812189|NCT01583127|BEHAVIORAL|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
214812190|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in stroke group|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
214812191|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in healthy group|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
214812192|NCT00004694|DRUG|heparin|
214812193|NCT00747162|DEVICE|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
214812194|NCT00747162|DEVICE|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
214812195|NCT06562855|GENETIC|Peripheral blood sampling|
214812196|NCT03065374|BIOLOGICAL|IMM-529|IMM-529
214812197|NCT03065374|OTHER|Placebo|Matching placebo
214812198|NCT02642835|PROCEDURE|vaginal wall mesh|retrospective review of case series
214812199|NCT00704821|DRUG|PTC299|Oral
214812200|NCT00704821|DRUG|Docetaxel|Intravenous infusion
214812201|NCT04826718|OTHER|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
214812202|NCT05660655|DRUG|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
214812203|NCT05660655|DRUG|Baricitinib 2 MG|baricitinib 4mg once daily in group A
214812204|NCT02420210|DRUG|Bendamustine Hydrochloride|Given IV
214812205|NCT02420210|BIOLOGICAL|Obinutuzumab|Given IV
214812206|NCT02420210|DRUG|Dexamethasone|Given PO
214812207|NCT02420210|OTHER|Quality-of-Life Assessment|Ancillary studies
214812208|NCT02420210|OTHER|Laboratory Biomarker Analysis|Correlative studies
214812209|NCT01185821|DRUG|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
214812210|NCT01167205|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin 20mg for 12 weeks
214812211|NCT00296647|DRUG|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
214812212|NCT00296647|DRUG|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
214812213|NCT00296647|DRUG|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
214812214|NCT00296647|DRUG|bupropion|dosage according to prescription directions: 12 weeks
214812215|NCT00296647|DRUG|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
214812216|NCT00296647|DRUG|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
214812217|NCT01985347|DEVICE|CPAP|Continuous positive airway pressure( CPAP)
214812218|NCT01947218|PROCEDURE|bronchial biopsies|
214812219|NCT01947218|OTHER|Determination of CO in exhaled air|
214812220|NCT00510172|DRUG|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
214812221|NCT00510172|DRUG|Placebo|NaCL 0,9%
214812222|NCT04811794|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
214812223|NCT04811794|OTHER|Personal history|Personal history on diagnosis, treatment, and socioeconomic factors
214812224|NCT03781739|DRUG|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
214812225|NCT03097107|DRUG|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
214812226|NCT03097107|DRUG|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
214812227|NCT03097107|DRUG|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
214812228|NCT03097107|DRUG|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
214812229|NCT03969693|RADIATION|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
214812230|NCT02074605|BIOLOGICAL|Interferon alpha|
214812231|NCT05856604|BEHAVIORAL|Music Therapy|"Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017)."
214812232|NCT05856604|BEHAVIORAL|Storytelling|"Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation."
214812233|NCT03677622|DRUG|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
214812234|NCT03539003|DRUG|sevoflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
214812235|NCT03539003|DRUG|desflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
214812236|NCT03539003|DRUG|propofol and remifentanil|anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
214812237|NCT05875597|OTHER|Physical therapy exercise programme|Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
214812238|NCT00940693|DRUG|duloxetine|60 mg capsule once per day for 6 weeks
214812239|NCT00940693|DRUG|placebo|one capsule of placebo taken one a day for 6 weeks
214812240|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
214812241|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
214812242|NCT01565096|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
214812243|NCT01565096|DRUG|Glimepiride|Glimepiride at individual dose
214812244|NCT02519491|OTHER|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
214812245|NCT02519491|OTHER|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
214812246|NCT03423056|OTHER|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
214812247|NCT06368037|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
214812248|NCT05564819|DRUG|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
214812249|NCT05564819|DRUG|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
214812250|NCT02590185|DRUG|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg"
214812251|NCT02608502|BIOLOGICAL|RSV-F Vaccine|
214812252|NCT02608502|BIOLOGICAL|Phosphate Buffer Placebo|
214812253|NCT06051240|DRUG|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
214812254|NCT06051240|DRUG|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
214812255|NCT06346223|BEHAVIORAL|Mindfulness and psychoeducation|The single-session mindfulness intervention includes a 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit. All of the teaching contents will be closely related to dementia caregiving and delivered by a mindfulness teacher who has received 40 hours training in dementia caregiving. A weekly mindfulness practice reminder will be sent to the participants through SMS for 8 weeks. The caregivers will also be provided with access to a social media online platform for sharing their practice experience with their classmates online. The interventionist will address their difficulties and challenges via the platform to reinforce skill mastery.
214812256|NCT06346223|BEHAVIORAL|Psychoeducation|The caregivers in the control group will receive brief education on dementia with the same group size and of the same duration (90-minutes) as the sessions in the intervention arm. The nurse will deliver brief education (15 minutes) on dementia in the session, followed by group sharing and discussion on their daily caregiving experience. The caregivers in the control group will be provided with a toolkit with education materials about the common health problems of older adults and also be given access to a social media platform in which they can communicate and share their caregiving experiences with classmates.
214812257|NCT01234103|BEHAVIORAL|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
214812258|NCT00048958|GENETIC|cytogenetic analysis|
214812259|NCT04058223|DEVICE|Hemorrhoidopexy|stapled hemorrhoidopexy
214812260|NCT05411536|OTHER|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order."
214812261|NCT05313698|DIAGNOSTIC_TEST|No intervention|cross-sectional study/psychometric study
214812262|NCT04714047|OTHER|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
214839816|NCT00867854|OTHER|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
214839817|NCT00096239|DRUG|CP-547,632|
214839818|NCT02343965|OTHER|Touch-massage|
214812263|NCT04714047|OTHER|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
214812264|NCT04714047|OTHER|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
214839819|NCT01774630|DRUG|Nilotinib|300 mg/twice a day
214839820|NCT03858127|OTHER|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
214839821|NCT03858127|OTHER|Examination of genitalia|Examination of genitalia
214839822|NCT03858127|OTHER|Video messaging|Short video of infant recorded at home by the parents
214839823|NCT06616727|DRUG|SNC109|SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
214839824|NCT01688882|DRUG|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
214812265|NCT04714047|OTHER|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
214812266|NCT00854100|DRUG|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
214812267|NCT00854100|DRUG|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
214812268|NCT00854100|DRUG|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
214812269|NCT05250245|DRUG|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
214812270|NCT05250245|OTHER|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
214812271|NCT06981754|DRUG|Dexamethasone palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
214812272|NCT06981754|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
214812273|NCT02398071|DEVICE|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
214812274|NCT04500353|OTHER|Face mask application for CPAP and/or PPV delivery|Face mask application for CPAP and/or PPV delivery
214812275|NCT03079128|BEHAVIORAL|Intervention|Weight Watchers Intervention
214812276|NCT06146153|DIAGNOSTIC_TEST|digital impression|intra oral scanning
214812277|NCT05639062|BEHAVIORAL|Narrative-based card game|This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
214812278|NCT02209480|BEHAVIORAL|Alexander Technique|
214812279|NCT02209480|DEVICE|Heat pad application|
214812280|NCT02209480|BEHAVIORAL|guided imagery|
214812281|NCT02359474|DRUG|Trabectedin|
214839825|NCT01688882|DRUG|Placebo|Placebo will be used to control for normal variability in disease severity.
214839826|NCT01676129|PROCEDURE|Nocipoint Therapy|
214839827|NCT01676129|PROCEDURE|Physical Therapy|
214839828|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
214839829|NCT03259789|DRUG|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
214839830|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
214812282|NCT02359474|GENETIC|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
214812283|NCT01064128|PROCEDURE|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
214812284|NCT01064128|PROCEDURE|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
214812285|NCT01520623|OTHER|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
214812286|NCT05063500|DRUG|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
214812287|NCT05063500|DRUG|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
214812288|NCT00827853|PROCEDURE|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
214812289|NCT00827853|PROCEDURE|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
214812290|NCT00731926|DIETARY_SUPPLEMENT|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
214812291|NCT00731926|DIETARY_SUPPLEMENT|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
214812292|NCT00731926|OTHER|placebo|twice a day for 1 month
214812293|NCT02296515|PROCEDURE|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
214812294|NCT07035873|BEHAVIORAL|Remote Programming|Use of the Advanced Bionics Target CI remote programming software to complete behavioral measurements of cochlear implant function and programming via telehealth.
214812295|NCT07035873|DIAGNOSTIC_TEST|Remote Speech Perception|Use of digital audio streaming (DAS) through a proprietary platform to complete remote speech perception testing of performance with cochlear implants via telehealth.
214812296|NCT02435043|OTHER|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
214812297|NCT02435043|OTHER|standard management after stroke|standard management after stroke is individualised.
214812298|NCT02040376|DRUG|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
214812299|NCT02040376|DRUG|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
214812300|NCT04041843|DRUG|Apixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
214812301|NCT03552081|OTHER|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
214812302|NCT01950637|BEHAVIORAL|No treatment given|Completion of 90-item online questionnaire.
214812303|NCT01950637|BEHAVIORAL|survey|Completion of 58-item online questionnarie.
214812304|NCT04414917|DRUG|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
214839831|NCT05038891|DIAGNOSTIC_TEST|Digital Cervical Exam|Standard Digital Cervical Exam by an experienced OB provider
214839832|NCT05038891|DIAGNOSTIC_TEST|Transperineal Ultrasound|Self-administered transperineal ultrasound after instruction by a health care professional
214839833|NCT05038891|DIAGNOSTIC_TEST|Transvaginal Ultrasound|Self-administered transvaginal ultrasound after instruction by a health care professional
214839834|NCT01143831|DIETARY_SUPPLEMENT|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
214812305|NCT04414917|DEVICE|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
214812306|NCT03137108|DEVICE|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
214812307|NCT02982408|DIETARY_SUPPLEMENT|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
214812308|NCT02982408|BEHAVIORAL|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
214812309|NCT02982408|BEHAVIORAL|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
214812310|NCT05518890|OTHER|Diet Only|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
214812311|NCT05518890|OTHER|Diet plus Exercise|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
214812312|NCT03659006|BIOLOGICAL|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
214812313|NCT01616381|DRUG|Sildenafil|PDE-5 Inhibitor
214812314|NCT01616381|DRUG|Placebo|Placebo for sildenafil 40mg x 3 daily
214812315|NCT06031766|DIETARY_SUPPLEMENT|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
214812316|NCT03828981|PROCEDURE|fast-track recovery program|"Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain."
214812317|NCT00239278|DRUG|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
214812318|NCT00239278|DRUG|prednisolone, 30 mg once daily and placebo|
214812319|NCT03421834|PROCEDURE|Catheter ablation of ventricular tachycardia|Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.
214812320|NCT03421834|DRUG|Optimal medical treatment|Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
214812321|NCT04298918|DRUG|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
214812322|NCT04298918|DRUG|Venetoclax|Participants will receive oral venetoclax.
214812323|NCT04298918|DRUG|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
214812324|NCT02464553|OTHER|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
214812325|NCT02606708|RADIATION|Accelerated intensity modulated radiation therapy (AIMRT)|
214812326|NCT00349843|DEVICE|Soft contact lens|
214812327|NCT00349843|DRUG|Marketed soft lens multipurpose disinfection regimen|
214812328|NCT03701191|PROCEDURE|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
214812329|NCT00426647|DRUG|Buprenorphine|
214812330|NCT00426647|DRUG|Tramadol|
214812331|NCT06265298|PROCEDURE|Conjunctival reconstruction|Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
214812332|NCT02110277|DEVICE|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
214812333|NCT04198090|BEHAVIORAL|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
214812334|NCT04874389|DIAGNOSTIC_TEST|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
214812335|NCT06421870|DRUG|Dapagliflozin 10mg Tab|Patients will be given dapagliflozin 10 mg once daily
214812336|NCT06421870|DRUG|Pentoxifylline 400 MG|Patients will be given pentoxyifylline 400 mg twice daily
214812337|NCT00000294|DRUG|Carvedilol|
214812338|NCT01604902|OTHER|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
214812339|NCT00953498|DRUG|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
214812340|NCT00953498|DRUG|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
214812341|NCT00674505|DEVICE|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
214812342|NCT05617222|OTHER|Bed rest|5 days of strict bed rest
214812343|NCT05617222|OTHER|Neuromuscular electrical stimulation|Unilateral neuromuscular electrical stimulation (m. Quadriceps)
214812344|NCT02109354|BIOLOGICAL|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
214812345|NCT02109354|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
214812346|NCT02109354|BIOLOGICAL|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
214812347|NCT02109354|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
214812348|NCT02109354|BIOLOGICAL|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
214812349|NCT02109354|BIOLOGICAL|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
214812350|NCT02109354|BIOLOGICAL|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
214812351|NCT02109354|BIOLOGICAL|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
214812352|NCT00382694|DRUG|Fludarabine|
214812353|NCT00893386|PROCEDURE|LV Lead Extraction|Removal of a LV lead using any tools \& techniques.
214812354|NCT05867095|PROCEDURE|Surgical navigation|Patients will be operated with assistance of a navigation system
214812355|NCT05867095|PROCEDURE|Conventional|Patients will be operated using the conventional technique
214812356|NCT00158171|DRUG|Nicotine Replacement Therapies|Nicotine gum 2 \& 4 mg dependent on baseline smoking rate
214812357|NCT00158171|DRUG|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
214812358|NCT00158171|DIETARY_SUPPLEMENT|Folic Acid|400 mg
214812359|NCT04057222|OTHER|No intervention|Only propose water and wait for need to void
214812360|NCT05087524|DIAGNOSTIC_TEST|BinaxNOW Ag Card|A nasal swab specimen is collected from the participant, 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The participant sample is inserted into the test card through the bottom hole of the swab well, and firmly pushed upwards until the swab tip is visible through the top hole. The swab is rotated 3 times clockwise and the card is closed, bringing the extracted sample into contact with the test strip. Test results are interpreted visually at 15 minutes based on the presence or absence of visually detectable pink/purple colored lines.
214812361|NCT03878719|DRUG|binimetinib|taken orally
214812362|NCT03878719|DRUG|encorafenib|taken orally
214812363|NCT03979079|RADIATION|external beam radiation therapy|
214812364|NCT03204266|DRUG|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
214812365|NCT03204266|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
214812366|NCT02945891|DEVICE|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
214812367|NCT02436057|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
214812368|NCT00002804|BIOLOGICAL|filgrastim|
214812369|NCT00002804|DRUG|doxorubicin hydrochloride|
214812370|NCT00002804|DRUG|ifosfamide|
214812371|NCT00002804|DRUG|mesna|
214812372|NCT00002804|DRUG|vincristine sulfate|
214812373|NCT00002804|PROCEDURE|conventional surgery|
214812374|NCT00002804|RADIATION|brachytherapy|
214812375|NCT00002804|RADIATION|low-LET cobalt-60 gamma ray therapy|
214812376|NCT00002804|RADIATION|low-LET electron therapy|
214812377|NCT00002804|RADIATION|low-LET photon therapy|
214812378|NCT05599438|OTHER|No intervention|No intervention
214812379|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
214812380|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
214812381|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
214812382|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
214812383|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
214812384|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
214812385|NCT06254677|OTHER|Retrospective review of histological features|Correlate histopathology characteristics of acute kidney injury with molecular signatures, kidney function and aetiology of acute kidney injury to derive clinically validated scoring system for acute kidney injury and acute tubular injury
214812386|NCT03350347|DRUG|Molidustat (BAY85-3934)|Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
214812387|NCT03350347|DRUG|Darbepoetin alfa|Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
214812388|NCT00846274|BIOLOGICAL|SK Antithrombin III|
214812389|NCT01029522|DRUG|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
214812390|NCT01029522|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
214812391|NCT03135743|OTHER|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
214812392|NCT03447262|DRUG|VX-659/TEZ/IVA|Fixed-dose combination tablets for oral administration qd in the morning.
214812393|NCT03447262|DRUG|IVA|IVA tablet qd in the evening.
214812394|NCT05986448|BEHAVIORAL|Tai-chi exercise|Traditional Chinese Tai Chi Movement
214812395|NCT03786965|OTHER|On-pump CABG|On-pump CABG
214812396|NCT03786965|OTHER|Off-pump CABG|Off-pump CABG
214812397|NCT03786965|OTHER|Pump-assisted CABG|Pump-assisted CABG
214812398|NCT03786965|OTHER|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
214812399|NCT03786965|OTHER|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
214812400|NCT03933748|DRUG|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
214812401|NCT00938834|OTHER|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
214812402|NCT00830206|OTHER|Azithromycin|Oral Suspension
214812403|NCT00830206|DRUG|Zithromax®|Oral Suspension
214812404|NCT05306639|OTHER|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
214812405|NCT06327243|OTHER|Elastic tape ( kinesio tape)|This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.
214812406|NCT06327243|OTHER|Sham Taping|Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
214812407|NCT03848286|DRUG|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
214812408|NCT03197285|OTHER|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
214812409|NCT03197285|OTHER|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
214812410|NCT03174847|PROCEDURE|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
214812411|NCT03174847|DRUG|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
214812412|NCT03934047|DRUG|Tranexamic Acid 100 MG/ML|Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
214812413|NCT05852886|DEVICE|Enable Oral Hygiene System (EOHS)|The Enable Oral Hygiene System (EOHS) is a manual toothbrush comprised of a handle and shaft with multiple surfaces of synthetic bristles extending off of the shaft at one end.
214812414|NCT03269838|DIAGNOSTIC_TEST|ECG|Primary Percutaneous coronary intervention
214812415|NCT03562091|OTHER|Data collection|The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).
214812416|NCT00328926|DRUG|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
214812417|NCT00328926|DRUG|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
214812418|NCT00328926|DRUG|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
214812419|NCT00328926|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
214812420|NCT00328926|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
214812421|NCT04123548|BIOLOGICAL|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
214812422|NCT03192722|DEVICE|Colored near reading glasses|Participants are provided with colored near vision glasses.
214812423|NCT03192722|DEVICE|Lighting as determined by LuxIQ/2 or OttLite Cobra|Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
214812424|NCT00002053|DRUG|Pentamidine isethionate|
214812425|NCT01171989|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, one dose.
214812426|NCT01171989|BIOLOGICAL|Infanrix hexa™|Intramuscular, one dose.
214812427|NCT01171989|BIOLOGICAL|Menjugate™|Intramuscular, one dose.
214812428|NCT01171989|BIOLOGICAL|NeisVac-C™|Intramuscular, one dose.
214812429|NCT01171989|BIOLOGICAL|Synflorix™|Intramuscular, one dose.
214812430|NCT00418184|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
214812431|NCT00418184|OTHER|Colored cellulose tainted with fishy odor|as arm 1
214812432|NCT02296008|DEVICE|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
214812433|NCT00309881|BIOLOGICAL|rituximab|
214812434|NCT00309881|DRUG|cyclophosphamide|
214812435|NCT00309881|DRUG|doxorubicin hydrochloride|
214812436|NCT00309881|DRUG|prednisone|
214812437|NCT00309881|DRUG|vincristine sulfate|
214812438|NCT03744481|OTHER|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
214812439|NCT02376777|OTHER|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
214812440|NCT04989491|DRUG|Rituximab|One single dose of rituximab intravenously (IV)
214812441|NCT04989491|OTHER|control group|No treatment
214812442|NCT05056974|BIOLOGICAL|UB-421|10 mg/kg, weekly UB-421 during the 8-week
214812443|NCT05056974|DRUG|chidamide|10 mg/dose, twice a week for 8 weeks
214812444|NCT01933360|DRUG|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
214812445|NCT01933360|DRUG|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
214812446|NCT01933360|DRUG|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
214812447|NCT01933360|DRUG|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
214812448|NCT01933360|DRUG|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
214812449|NCT01933360|DRUG|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
214812450|NCT01933360|DRUG|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
214812451|NCT01933360|DRUG|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
214812452|NCT04690101|OTHER|none, this is an observational study|none, this is an observational study
214812453|NCT02875769|PROCEDURE|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
214812454|NCT02875769|DRUG|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
214812455|NCT02875769|DRUG|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
214812456|NCT02875769|OTHER|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
214812457|NCT02875769|OTHER|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
214812458|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, fructooligosaccharides, inulin|"The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
214812459|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin|"The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
214812460|NCT03601819|DRUG|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
214812461|NCT02300103|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214812462|NCT02300103|DRUG|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214812463|NCT01015625|PROCEDURE|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
214812464|NCT01015625|PROCEDURE|Surgery on Demand|if necessary local therapy on demand
214812465|NCT01479738|PROCEDURE|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
214812466|NCT02424266|DEVICE|None invasive imaging of the tear film (AdOM)|White light tomography imaging
214812467|NCT00175617|DRUG|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
214812468|NCT00175617|DRUG|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
214812469|NCT04966455|DIETARY_SUPPLEMENT|Raisins|Daily supplementation of 50 g of rainsins for 3 months
214812470|NCT01256684|DRUG|Placebo|Placebo vaginal suppository
214812471|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
214812472|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
214812473|NCT05209009|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
214812474|NCT05209009|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
214812475|NCT02993991|DRUG|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
214812476|NCT02993991|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
214812477|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214812478|NCT01121276|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214812479|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214812480|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214812481|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214812482|NCT03314298|DRUG|testosterone anastrozole|subcutaneous testosterone and anastrozole
214812483|NCT02674477|DEVICE|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
214812484|NCT02674477|OTHER|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
214812485|NCT00006027|DRUG|cisplatin|
214812486|NCT00006027|DRUG|paclitaxel|
214812487|NCT00006027|PROCEDURE|adjuvant therapy|
214812488|NCT00006027|RADIATION|radiation therapy|
214812489|NCT00720265|DRUG|Prograf|oral
214812490|NCT00720265|DRUG|MR4|oral
214812491|NCT01414972|DRUG|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
214812492|NCT01414972|DRUG|placebo|1 cap placebo/day for 3 month
214812493|NCT01386593|DRUG|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
214812494|NCT01386593|DRUG|"Basel Cocktail"|
214812495|NCT01386593|DRUG|Basel cocktail + Rifampicin|
214812496|NCT04138147|PROCEDURE|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
214812497|NCT04138147|PROCEDURE|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
214812498|NCT03482427|BEHAVIORAL|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
214812499|NCT05595694|OTHER|No intervention|This is a retrospective review of 1320 patients in our database who underwent elective primary and revision TJA in Queen Mary Hospital, Hong Kong from from January 2018 to December 2021. No intervention was involved.
214812500|NCT00006226|DRUG|thalidomide|Given PO
214812501|NCT00006226|OTHER|laboratory biomarker analysis|Correlative studies
214812502|NCT04622657|OTHER|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
214812503|NCT01532674|DEVICE|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~* Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~* Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~* All the periodontal pockets will be treated subgingivally~* Elimination of the photosensitive by irrigation"
214812504|NCT01532674|PROCEDURE|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~\* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
214812505|NCT04459585|DRUG|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
214812506|NCT04459585|DRUG|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
214812507|NCT01814930|BEHAVIORAL|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
214812508|NCT06011538|OTHER|On-line, multi-media information on a specifically designed website for Same Day Discharge following Laparoscopic Hysterectomy|A patient educational website that provides clear, easily accessible, patient friendly information explaining what SDD after laparoscopic hysterectomy is, why SDD may be beneficial and what to expect from decision for surgery, through to the admission to hospital and immediate, short and long term recovery.
214812509|NCT02098876|DEVICE|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
214812510|NCT02098876|DEVICE|Xience Xpedition everolimus eluting stent|PCI with Xience stent
214812511|NCT02098876|DEVICE|Optical Coherence Tomography (OCT)|Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
214812512|NCT02098876|DEVICE|Intravascular Ultrasound (IVUS)|Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
214812513|NCT00641394|BEHAVIORAL|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
214812514|NCT00641394|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
214812515|NCT01159860|PROCEDURE|cryosurgery|freezing of lesion with liquid nitrogen
214812516|NCT01159860|PROCEDURE|Curettage|the lesion will be anesthetized and destroyed with a curette.
214812517|NCT05481840|DEVICE|Continence material with sensor|"Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care."
214812518|NCT01707134|DRUG|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
214812519|NCT01707134|DRUG|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
214812520|NCT01707134|DRUG|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
214812521|NCT01765114|DRUG|PEG-Formulation|
214812522|NCT04764214|DRUG|3rd generation EGFR-TKI|Osimertinib will be administered orally at the dose of 80 mg once daily.
214812523|NCT04764214|RADIATION|Consolidative SRT|Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SRT until disease progression or intolerable toxicity.
214812524|NCT00940810|PROCEDURE|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
214812525|NCT00940810|PROCEDURE|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
214812526|NCT02809469|DRUG|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
214812527|NCT02345395|PROCEDURE|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
214812528|NCT05237310|DEVICE|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
214812529|NCT05237310|DEVICE|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
214812530|NCT05237310|DEVICE|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
214812531|NCT01061866|DRUG|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
214812532|NCT00002911|DRUG|marimastat|
214812533|NCT02099747|DRUG|hATG|
214812534|NCT02099747|DRUG|CsA|
214812535|NCT02099747|DRUG|Eltrombopag|
214812536|NCT03086473|DRUG|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
214812537|NCT03086473|DRUG|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
214812538|NCT03857295|OTHER|No interventions|No intervention
214812539|NCT04566848|DIAGNOSTIC_TEST|Flow cytometric analysis|Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
214812540|NCT04270448|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
214812541|NCT03515967|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
214812542|NCT02598882|DEVICE|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
214812543|NCT02598882|DEVICE|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
214812544|NCT01330186|OTHER|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
214812545|NCT01216839|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
214812546|NCT01185886|GENETIC|gene expression analysis|
214812547|NCT01185886|GENETIC|mutation analysis|
214812548|NCT01185886|GENETIC|polymorphism analysis|
214812549|NCT01185886|OTHER|biologic sample preservation procedure|
214812550|NCT01185886|OTHER|laboratory biomarker analysis|
214812551|NCT01185886|OTHER|pharmacogenomic studies|
214812552|NCT06362486|OTHER|Severity of infection, time of infection.|Severity of infection, time of infection.
214812553|NCT06362486|OTHER|Mental health assessment|Mental health assessment
214812554|NCT06362486|OTHER|biological|Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
214812555|NCT00772941|DRUG|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
214812556|NCT06231784|DEVICE|LUMINA IOL|A standard technique of phacoemulsification was performed followed by implantation of the Lumina in the sulcus plane of the eye by using a standard disposable injector system with an adapted, proprietary, AkkoLens butterfly cartridge.
214812557|NCT00637741|DEVICE|Everflex 200|
214812558|NCT03949179|DEVICE|The Low Back Pain and Disability Drivers Management (PDDM) model|The Low Back Pain and Disability Drivers Management (PDDM) model aims to identify the domains influencing pain and disability to guide clinical decisions. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers (i.e., somatic, inflammatory or mixed pain), 2) nervous system dysfunction (NSD) drivers (i.e., sensitization of the peripheral and/or central nervous system), 3) comorbidity drivers (i.e., physical and/or mental health comorbidities), 4) cognitive-emotional drivers (i.e., maladaptive cognitions and/or behaviors) and 5) contextual drivers (i.e., occupational-related and social environmental contextual drivers). This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.
214812559|NCT04786184|BEHAVIORAL|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
214812560|NCT04786184|BEHAVIORAL|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
214812561|NCT00830700|OTHER|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
214812562|NCT00834756|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
214812563|NCT00834756|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
214812564|NCT05638971|DEVICE|ivWatch|The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
214812565|NCT05026567|DRUG|2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)|Intramuscular injection
214812566|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh|Intramuscular injection
214812567|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area|Intramuscular injection
214812568|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh|Intramuscular injection
214812569|NCT01026363|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
214812570|NCT01026363|DRUG|Calcitriol|0.25 mcg tablet once daily for 14 days
214812571|NCT03676686|DEVICE|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
214812572|NCT05178095|DEVICE|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
214812573|NCT05178095|DEVICE|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
214812574|NCT04818892|DIAGNOSTIC_TEST|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
214812575|NCT05839834|DIAGNOSTIC_TEST|Blood test|RNA sequencing of peripheral blood cells
214812576|NCT03675269|OTHER|HBOT|Standard practice
214812577|NCT03675269|BEHAVIORAL|Standard wound care|Standard wound care
214812578|NCT00505570|DEVICE|AMPLATZER® PFO Occluder Device|PFO device closure
214812579|NCT03861845|DEVICE|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
214812580|NCT03861845|DEVICE|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
214812581|NCT03861845|DEVICE|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
214812582|NCT03861845|BEHAVIORAL|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
214812583|NCT03861845|BEHAVIORAL|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
214812584|NCT04543760|OTHER|Prone position|prone positioning in spontaneous ventilation
214812585|NCT04543760|OTHER|Supine position|supine positiong in spontaneous ventilation
214812586|NCT02251886|OTHER|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
214812587|NCT02251886|OTHER|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
214812588|NCT00191204|DRUG|Duloxetine|
214812589|NCT00687063|DRUG|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
214812590|NCT06561737|OTHER|Video|For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
214812591|NCT04044261|PROCEDURE|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
214812592|NCT05209347|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
214812593|NCT06215976|DRUG|Metformin Hydrochloride 500 MG|Metformin 500mg tablets twice daily
214812594|NCT06278844|DEVICE|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.
214812595|NCT06278844|DEVICE|Right ventricular apical pacing|This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
214812596|NCT02443220|DEVICE|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
214812597|NCT02443220|DEVICE|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
214812598|NCT02443220|DEVICE|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
214812599|NCT04535076|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
214812600|NCT04535076|PROCEDURE|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
214812601|NCT02209194|DEVICE|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
214812602|NCT02426762|PROCEDURE|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~* 4-5 trocar-produced incisions (5/10mm, minor incision)~* 1 sample-retrieval incision (4-5cm, small incision)"
214812603|NCT02426762|DEVICE|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
214812604|NCT04060147|DRUG|Cilofexor|Tablets administered orally once daily
214812605|NCT00578552|DRUG|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
214812606|NCT00578552|DRUG|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
214812607|NCT00578552|DRUG|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
214812608|NCT06092658|OTHER|No Intervention|no intervention
214812609|NCT02057458|DRUG|Sildenafil (Acute-1 hour)|Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
214812610|NCT02057458|DRUG|Sildenafil (Subchronic-4 weeks)|Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
214812611|NCT02057458|DRUG|Placebo|Sugar pill designed to mimic the sildenafil treatment
214812612|NCT02149693|OTHER|high-fidelity simulation and teamwork training|
214812613|NCT02149693|OTHER|traditional resuscitation training|
214812614|NCT03767361|BIOLOGICAL|packed red blood cells transfusion|packed red blood cells transfusion
214812615|NCT01534520|DRUG|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
214812616|NCT01534520|DRUG|Placebo|KY Jelly
214812617|NCT02960594|BIOLOGICAL|INO-1400|
214812618|NCT02960594|BIOLOGICAL|INO-9012|
214812619|NCT02960594|BIOLOGICAL|INO-1401|
214812620|NCT05288881|BIOLOGICAL|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
214812621|NCT05288881|DRUG|Placebo|Participants will receive matching placebo administered by IV infusion.
214812622|NCT05601674|OTHER|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
214812623|NCT05601674|OTHER|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
214812624|NCT00100620|DRUG|Zoledronic Acid|
214812625|NCT05642286|DEVICE|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
214812626|NCT01334307|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
214812627|NCT01334307|DEVICE|Control|Standard of Care
214812628|NCT01783561|DRUG|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
214812629|NCT06464120|OTHER|Increasing load strength training|The Smith machine was used to intervene with athletes by employing an incremental load approach.
214812630|NCT06464120|OTHER|Constant load strength training|The Smith machine was used to intervene with athletes by employing a constant load approach.
214812631|NCT00439491|BEHAVIORAL|Hypocaloric diet|
214812632|NCT05086562|OTHER|observation study|observation study
214812633|NCT00125086|DEVICE|autologous platelet gel|
214812634|NCT04391621|PROCEDURE|Autologous Adipose Derived stem cell transplantation|Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
214812635|NCT04391621|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
214812636|NCT02147925|DRUG|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
214812637|NCT02147925|DRUG|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
214812638|NCT02147925|DRUG|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
214812639|NCT03955237|PROCEDURE|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
214812640|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|10 mEq/day
214812641|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|300 mEq/day
214812642|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|150 mEq/day dietary sodium
214812643|NCT02979353|BEHAVIORAL|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
214812644|NCT04991090|RADIATION|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
214812645|NCT02192047|OTHER|Palm Olein|8 weeks
214812646|NCT02192047|OTHER|IE Palm olein|8 weeks
214812647|NCT02192047|OTHER|IE soybean oil-based|8 weeks
214812648|NCT05319990|DRUG|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
214812649|NCT05319990|DRUG|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
214812650|NCT04346927|OTHER|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
214812651|NCT04346927|OTHER|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
214812652|NCT04784598|OTHER|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
214812653|NCT02816905|DRUG|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
214812654|NCT02816905|DRUG|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
214812655|NCT02816905|DRUG|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
214812656|NCT00760110|DEVICE|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
214812657|NCT02582541|PROCEDURE|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
214812658|NCT02582541|PROCEDURE|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
214812659|NCT01099943|OTHER|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
214812660|NCT03337997|PROCEDURE|Irreversible Electroporation|Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
214812661|NCT03608722|OTHER|SLUMS|A pen and paper screening tool of cognitive impairment
214812662|NCT03608722|OTHER|MMSE|A pen and paper screening tool of cognitive impairment
214812663|NCT03608722|OTHER|MoCA|A pen and paper screening tool for cognitive impairment
214812664|NCT03608722|DEVICE|BrainCheck|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
214812665|NCT00086762|BEHAVIORAL|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
214812666|NCT00086762|BEHAVIORAL|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
214812667|NCT00086762|BEHAVIORAL|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
214812668|NCT00086762|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
214812669|NCT04231084|DRUG|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
214812670|NCT04231084|DRUG|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
214812671|NCT01079988|DRUG|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
214812672|NCT01079988|DRUG|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
214812673|NCT01079988|DRUG|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
214812674|NCT01079988|DRUG|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
214812675|NCT01079988|DRUG|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
214812676|NCT00585689|DRUG|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
214812677|NCT00585689|DRUG|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
214812678|NCT00585689|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
214812679|NCT00585689|PROCEDURE|Radical Cystectomy|
214812680|NCT00385346|BEHAVIORAL|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
214812681|NCT01324193|DIETARY_SUPPLEMENT|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
214812682|NCT03375853|BEHAVIORAL|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
214812683|NCT03375853|BEHAVIORAL|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
214812684|NCT02704182|DEVICE|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
214812685|NCT02704182|DEVICE|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
214812686|NCT02479503|PROCEDURE|Antibiotic prophylaxis in adult heart transplantation|
214812687|NCT02853682|BIOLOGICAL|plasma|assesment of glycocalyx protein
214812688|NCT04873011|DRUG|Quinine Hydrochloride|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion
214812689|NCT04873011|DRUG|Placebo|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
214812690|NCT01042886|BEHAVIORAL|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
214812691|NCT01042886|BEHAVIORAL|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
214812692|NCT02121886|PROCEDURE|venous reconstruction with the parietal peritoneum|
214812693|NCT04189250|DEVICE|Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments|The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
214812694|NCT02560194|PROCEDURE|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
214812695|NCT02560194|OTHER|Fecal occult blood test|Test for hemoglobin in faeces
214812696|NCT00550537|DRUG|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
214812697|NCT00550537|DRUG|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
214812698|NCT00550537|DRUG|erlotinib hydrochloride|150 mg taken by mouth daily
214812699|NCT00550537|DRUG|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
214812700|NCT00550537|GENETIC|gene expression analysis|Blood and tissue collection.
214812701|NCT00550537|GENETIC|protein expression analysis|Blood and tissue collection.
214812702|NCT00550537|GENETIC|proteomic profiling|Blood and tissue collection.
214812703|NCT00550537|OTHER|laboratory biomarker analysis|Blood and tissue collection.
214812704|NCT00003647|DRUG|allovectin-7|
214812705|NCT00003647|DRUG|allovectin-7/dacarbazine|
214812706|NCT00003647|DRUG|dacarbazine|
214812707|NCT00260039|BIOLOGICAL|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
214812708|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
214812709|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
214812710|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
214812711|NCT01705301|DEVICE|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
214812712|NCT00003186|DRUG|isosulfan blue|
214812713|NCT00003186|PROCEDURE|lymphangiography|
214812714|NCT00003186|PROCEDURE|sentinel lymph node biopsy|
214812715|NCT05269901|GENETIC|SLC7A11, GPX4, P53|Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
214812716|NCT00268905|DRUG|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
214812717|NCT00268905|DRUG|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
214812718|NCT00268905|DRUG|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
214812719|NCT04520386|DRUG|OMT-111|Pre-filled Syringe
214812720|NCT01540760|DRUG|MCAF5352A|Multiple ascending doses
214812721|NCT01540760|DRUG|Placebo|Matching MCAF5352A, multiple doses
214812722|NCT05565053|PROCEDURE|Bilateral thoracal erector spinae plane block|Bilateral upper thoracal erector spinae plane block with ultrasound
214812723|NCT05565053|PROCEDURE|Trapezius muscle trigger point injection|Trapezius muscle trigger point injection
214812724|NCT03827174|OTHER|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
214812725|NCT03827174|BEHAVIORAL|Behaviour Change Ability Program|"1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation and problem-solving.~3. Patient-specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work"
214812726|NCT04093037|DIAGNOSTIC_TEST|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
214812727|NCT04093037|DIAGNOSTIC_TEST|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
214812728|NCT04093037|DIAGNOSTIC_TEST|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
214812729|NCT04093037|DIAGNOSTIC_TEST|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
214812730|NCT04093037|DIAGNOSTIC_TEST|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
214812731|NCT00617305|DRUG|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
214812732|NCT00617305|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
214812733|NCT00617305|DRUG|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
214812734|NCT00617305|DRUG|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
214812735|NCT01853566|DRUG|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
214812736|NCT04355468|DRUG|Opioid Anesthesia|Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
214812737|NCT04355468|DRUG|Opioid Free Anaesthesia|"Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1."
214812738|NCT02380807|DEVICE|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
214812739|NCT02380807|OTHER|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
214812740|NCT04934618|DRUG|Carelizumab Combined With Irinotecan and Apatinib|Three-drug regimen was used in second-line treatment of Advanced gastric cancer
214812741|NCT02170922|DRUG|BIBR 1048 MS tablet|
214812742|NCT02170922|DRUG|BIBR 1048 MS solution|
214812743|NCT05228626|DRUG|COVIDEX|COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
214812744|NCT02900443|DRUG|Mycophenolate mofetil|
214812745|NCT02900443|DRUG|Azathioprine|
214812746|NCT03289286|OTHER|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~* Completion of questionnaires using an electronic tool,~* Telephone follow-up if necessary between the nurse and the patient."
214812747|NCT05552833|OTHER|High intensity interval training|Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
214812748|NCT02130856|DEVICE|Neonatal kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
214812749|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
214812750|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
214812751|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
214812752|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
214812753|NCT03459807|DRUG|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
214812754|NCT03459807|PROCEDURE|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
214812755|NCT02109250|DRUG|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
214812756|NCT01044485|DRUG|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
214812757|NCT01044485|DRUG|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
214812758|NCT04728763|OTHER|Protein profile|Analysis of the protein content by proteomics of bronchoalveolar lavage
214812759|NCT00449592|DRUG|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
214812760|NCT00449592|DRUG|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
214812761|NCT02409979|OTHER|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
214812762|NCT02409979|OTHER|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
214812763|NCT02409979|OTHER|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
214812764|NCT02002754|DRUG|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
214812765|NCT05020925|DRUG|SHR-1701|Intravenous (IV) on Day 1 of each cycle
214812766|NCT05020925|DRUG|Famitinib|Famitinib, po, qd
214812767|NCT01746485|DRUG|UT-15C|
214812768|NCT01122147|DRUG|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
214812769|NCT01122147|DRUG|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
214812770|NCT03575234|DRUG|Cyclophosphamide|Given IV
214812771|NCT03575234|BIOLOGICAL|IRX-2|Given SC
214812772|NCT03575234|BIOLOGICAL|Nivolumab|Given IV
214812773|NCT03575234|PROCEDURE|Surgery|Undergo surgery
214812774|NCT04660747|DRUG|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
214812775|NCT03764748|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
214812776|NCT06561022|DRUG|Fluzoparib|Fluzoparib
214812777|NCT06561022|DRUG|Everolimus|Everolimus
214812778|NCT06561022|DRUG|Fulvestrant|Fulvestrant
214812779|NCT06561022|DRUG|Abemaciclib|Abemaciclib
214812780|NCT06562023|OTHER|Botulinum Toxin Type A|Patients will receive BTA injection within a period of 5 days after primary closure.
214812781|NCT06562023|OTHER|Mesotherapy|Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
214812782|NCT04443660|OTHER|Blood test|Blood samples taken to test levels of autophagy and apoptosis
214812783|NCT00275600|DRUG|Vitamin E, Evening Oil of Primrose, and Placebo|
214812784|NCT04510285|DRUG|Trastuzumab|Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
214812785|NCT04510285|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
214812786|NCT02745951|OTHER|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
214812787|NCT02745951|OTHER|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
214812788|NCT00083785|DRUG|Talaporfin sodium (LS11)|
214812789|NCT00083785|DEVICE|LED-based light infusion device|
214812790|NCT00083785|DEVICE|Light emitting diodes (LED)|
214812791|NCT00083785|PROCEDURE|Photodynamic therapy|
214812792|NCT00083785|PROCEDURE|Phototherapy|
214812793|NCT00083785|PROCEDURE|Chemotherapy|
214812794|NCT04486196|DEVICE|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
214812795|NCT04486196|PROCEDURE|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
214812796|NCT00379600|DRUG|rosiglitazone XR|
214812797|NCT06082258|OTHER|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
214812798|NCT06082258|OTHER|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
214812799|NCT01406795|DEVICE|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
214812800|NCT05372666|OTHER|Standard white bread|Bread to be consumed within 10 minutes after 10h fasting
214812801|NCT05372666|OTHER|Experimental white bread|Bread to be consumed within 10 minutes after 10h fasting
214812802|NCT05372666|OTHER|Standard High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
214812803|NCT05372666|OTHER|Experimental High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
214812804|NCT00821834|DRUG|clopidogrel (SR25990)|"Form: tablets~Route: oral"
214812805|NCT00821834|DRUG|ticlopidine|"Form: tablets~Route: oral"
214812806|NCT00821834|DRUG|Placebo|"Form: tablets~Route: oral"
214812807|NCT01384838|BEHAVIORAL|Counseling|Nutritional, lifestyle and sports counseling
214812808|NCT01384838|BEHAVIORAL|physical activity|counseling and controlled physical activity
214812809|NCT03119935|DEVICE|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
214812810|NCT03119935|DEVICE|Ambu bag|Participants ventilated the simulated patients by ambu bag
214812811|NCT00000804|DRUG|Indinavir sulfate|
214812812|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
214812813|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
214812814|NCT04702178|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
214812815|NCT04702178|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
214812816|NCT05124574|OTHER|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"* nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~* Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~* Sampling of amniotic fluid in case of cesarean section~* Sampling of the placenta for histological and virological study."
214812817|NCT05124574|OTHER|Samples concern newborns of SARS-COV-2 + mothers at birth|"* In the birth room:~  * Collection of gastric fluid (PCR SARS-COV-2),~ * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~* In the newborn at D3 of life:~  \- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~* In symptomatic newborns:~  * 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~ * nasopharyngeal PCR,"
214812818|NCT05978479|OTHER|Teach-Back Method|No intervention will be given to the patients in the control group.
214812819|NCT00950625|DRUG|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
214812820|NCT00950625|DRUG|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
214812821|NCT00683202|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
214812822|NCT00683202|DRUG|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
214812823|NCT05094713|OTHER|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
214812824|NCT05094713|OTHER|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
214812825|NCT03902028|OTHER|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
214812826|NCT04691830|BEHAVIORAL|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
214812827|NCT04691830|BEHAVIORAL|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
214812828|NCT04774757|PROCEDURE|Para-aortic lymph node dissection|Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
214812829|NCT05480657|BIOLOGICAL|AT-1501 IV Infusion|Investigational study drug
214812830|NCT05480657|BIOLOGICAL|Isolated cadaveric islet cells|Infusion of human cadaveric islet cells into the portal vein
214812831|NCT02563808|OTHER|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
214812832|NCT02563808|OTHER|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
214812833|NCT03897088|DRUG|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
214812834|NCT03897088|DRUG|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
214812835|NCT02048306|BEHAVIORAL|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
214812836|NCT02048306|BEHAVIORAL|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
214812837|NCT00237003|BEHAVIORAL|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
214812838|NCT01475396|BEHAVIORAL|exercise|
214812839|NCT04473807|DRUG|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
214812840|NCT05526118|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
214812841|NCT03971825|DRUG|CC-92252|CC-92252
214812842|NCT03971825|OTHER|Placebo|Placebo
214812843|NCT00855738|DRUG|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"* Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d"
214812844|NCT02745925|DRUG|Ibuprofen|
214812845|NCT05829122|PROCEDURE|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
214812846|NCT02215083|DIETARY_SUPPLEMENT|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
214812847|NCT00992771|DRUG|varenicline|up to 1mg BID for 8 weeks
214812848|NCT00992771|DRUG|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
214812849|NCT03097783|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
214812850|NCT06320977|OTHER|Static Stretching|"The static stretching protocol will include the following muscle groups of the dominant lower limb:~* Gastrocnemius - Participants will assume a bipedal position facing a wall. Then, the leg that is not being stretched will be placed forward, with the knee in semi-flexion, and the leg that is being stretched, behind, with the knee in full extension. Instructions will be given in order to keep the calcaneus on the floor;~* Tibialis anterior - Participants will be facing a wall, with the entire foot in touch with the ground and toes pointing forward. Then, they will secure themselves to a handrail and project the hips back.~These stretchings will be held in a position where the participants refer discomfort, and will be maintained for 30 seconds or 90 seconds according to the condition."
214812851|NCT04046211|DRUG|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
214812852|NCT00993252|PROCEDURE|CT Scan|CT scan
214812853|NCT02751398|DRUG|Dapagliflozin 10mg|
214812854|NCT02751398|DRUG|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
214812855|NCT04864548|BIOLOGICAL|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
214812856|NCT01205295|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
214812857|NCT02329678|PROCEDURE|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
214812858|NCT03904303|DRUG|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
214812859|NCT02392000|DEVICE|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
214812860|NCT02392000|BEHAVIORAL|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
214812861|NCT04047147|OTHER|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
214812862|NCT04047147|OTHER|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
214812863|NCT00204139|PROCEDURE|Routine midtrimester pregnany ultrasound scan|
214812864|NCT00540020|OTHER|Rehabilitation|
214812865|NCT00761020|DRUG|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
214812866|NCT00761020|OTHER|Control|No Intervention
214812867|NCT04384978|BEHAVIORAL|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
214812868|NCT04384978|BEHAVIORAL|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
214812869|NCT02218905|BEHAVIORAL|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
214812870|NCT03725605|COMBINATION_PRODUCT|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
214812871|NCT02023853|PROCEDURE|ultrasonic|
214812872|NCT02023853|PROCEDURE|erythritol|
214812873|NCT02023853|DRUG|metronidazole gel|
214812874|NCT05463653|DEVICE|Experimental|A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
214812875|NCT02281305|DRUG|Colchicine|
214812876|NCT04057872|PROCEDURE|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
214812877|NCT03555305|DRUG|Insulin Glargine|Administered SC
214812878|NCT03555305|DRUG|Lantus|Administered SC
214812879|NCT01944800|DRUG|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
214812880|NCT01944800|DRUG|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg
214812881|NCT00925054|DRUG|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
214812882|NCT00925054|DRUG|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
214812883|NCT00925054|DRUG|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
214812884|NCT00925054|DRUG|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
214812885|NCT00925054|DRUG|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
214812886|NCT01638377|DRUG|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
214812887|NCT01638377|DRUG|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
214812888|NCT06387771|DRUG|Tolcapone|Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
214812889|NCT03286465|DEVICE|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
214812890|NCT03286465|DEVICE|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
214812891|NCT02478190|OTHER|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
214812892|NCT02478190|OTHER|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
214812893|NCT03586726|DRUG|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
214812894|NCT03586726|DRUG|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
214812895|NCT05833594|DIETARY_SUPPLEMENT|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs|The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
214812896|NCT04470557|DIAGNOSTIC_TEST|D-dimer,CBC.ESR,CRP,|Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.
214812897|NCT04470557|DIAGNOSTIC_TEST|Liver function tests ,serum ferritin and PCR for COVID-19 .|"Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),"
214812898|NCT04302662|DRUG|MS1819-SD|Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
214812899|NCT00000171|DRUG|Melatonin|
214812900|NCT00512421|PROCEDURE|computer-assisted surgery|
214812901|NCT05403684|OTHER|High-volume breastmilk|Preterm infants will be given high-volume breastmilk
214812902|NCT00965185|DRUG|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
214812903|NCT00965185|DRUG|Placebo|Placebo
214812904|NCT00766168|OTHER|HDS HI 1.54; pahrifocon A|Contact Lens
214812905|NCT00766168|DEVICE|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
214812906|NCT02209922|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
214812907|NCT02209922|DEVICE|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
214812908|NCT06105034|PROCEDURE|interventional techniques, the severity of placental invasion, and various placental positions and suture techniques|Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
214812909|NCT04888572|RADIATION|Peri-Apical X-ray|"Using a PCP UNC 15 Hu Friedy® periodontal probe and a gentle horizontal sweeping motion through the peri-implant tunnel or sulcus the examiner will assess bleeding on probing, the main factor in determining peri-implant inflammation and subsequently possible peri-implantitis. Then, using the same instrument, the author will examine whether there is an increase in the values of pocket depths compared to the initial values, highlighting an installation of peri-implant disease. Radiographically, evidence of bone loss after healing through taking a digital x-ray that will be viewed on DBSWIN® software will help authors make a diagnosis of peri-implantitis as well. It will be required that the digital film be perfectly parallel to the axis of the implant and the X-ray tube perpendicular to them in order to have an orthogonal radiograph."
214812910|NCT03226054|BEHAVIORAL|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
214812911|NCT01718886|DEVICE|Obalon Gastric Balloon|
214812912|NCT00781586|DIETARY_SUPPLEMENT|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
214812913|NCT00781586|DRUG|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
214812914|NCT00781586|DRUG|Placebo|Placebo 1 tablet at 1st visit
214812915|NCT02937415|PROCEDURE|Breath carbon monoxide|Breath carbon monoxide measurement.
214812916|NCT02937415|PROCEDURE|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
214812917|NCT02937415|PROCEDURE|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
214812918|NCT03520517|DRUG|BHV-0223|BHV-0223, 40 mg BID
214812919|NCT02803450|PROCEDURE|Epidural needle|Medication administration via epidural needle.
214812920|NCT02803450|PROCEDURE|Catheter Administration|Medication administration via epidural catheter.
214812921|NCT02803450|PROCEDURE|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
214812922|NCT02161445|DEVICE|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
214812923|NCT06124235|COMBINATION_PRODUCT|Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles|"insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position."
214812924|NCT06124235|COMBINATION_PRODUCT|Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles|Non-coated orthodontic miniscrews
214812925|NCT01840735|DRUG|GS-5737|
214812926|NCT01840735|DRUG|Placebo|
214812927|NCT05499572|DEVICE|Inhalation maneuver with placebo Inbrija and placebo Cyclops|Patients perform the inhalation maneuvers with placebo inhalers (Inbrija and Cyclops) during a Parkinson's off episode.
214812928|NCT04453748|OTHER|Complex diagnostic panel|Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
214812929|NCT05669768|DRUG|Pamiparib/Tamoxifen|Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
214812930|NCT00059371|PROCEDURE|male circumcision|
214812931|NCT00622232|GENETIC|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
214812932|NCT04316312|DEVICE|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
214812933|NCT00323193|BEHAVIORAL|MOVE!|group based psychoeducation, motivation and support
214812934|NCT01491880|BEHAVIORAL|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
214812935|NCT01491880|BEHAVIORAL|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
214812936|NCT01779323|OTHER|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
214812937|NCT03132727|OTHER|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
214812938|NCT04332627|DRUG|Sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
214812939|NCT04332627|DRUG|Neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
214812940|NCT03708835|OTHER|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
214812941|NCT02100228|DRUG|Apixaban|Oral, 2.5 or 5 mg BID
214812942|NCT02100228|DRUG|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
214812943|NCT01051505|DRUG|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
214812944|NCT01051505|DRUG|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
214812945|NCT05834231|DRUG|Memantine|oral
214812946|NCT05834231|DRUG|Placebo|oral
214812947|NCT05552781|DRUG|H002 capsule|Small molecule, Capsule
214812948|NCT03148808|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
214812949|NCT00291057|DRUG|MALG|30 minute application
214812950|NCT03180866|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
214812951|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
214812952|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
214812953|NCT02879877|DRUG|UCB7858|
214812954|NCT02879877|DRUG|Placebo|
214812955|NCT01307722|OTHER|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
214812956|NCT05057650|DIETARY_SUPPLEMENT|Vegan diet|Provide
214812957|NCT04395677|DRUG|AB-106|"Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD"
214812958|NCT00062283|DRUG|L-alanosine|
214812959|NCT01320696|BIOLOGICAL|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
214812960|NCT01837862|DRUG|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
214812961|NCT01837862|DRUG|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients \< 12kg: 0.05 mg/kg; for patient \> 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
214812962|NCT01837862|DRUG|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
214812963|NCT01837862|DRUG|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
214812964|NCT01837862|DRUG|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
214812965|NCT01837862|DRUG|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
214812966|NCT02878109|DEVICE|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
214812967|NCT02878109|DEVICE|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
214812968|NCT04339894|OTHER|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
214812969|NCT03992066|DRUG|Vadadustat|oral 150 mg tablet
214812970|NCT03992066|DRUG|Darbepoetin alfa|solution intravenous injection
214812971|NCT03992066|DRUG|Epoetin alfa|solution for intravenous injection
214812972|NCT01821144|BEHAVIORAL|Salt reduction|Salt reduction
214812973|NCT01821144|OTHER|Control|No salt awareness education
214812974|NCT04181853|OTHER|exercise|aerobic exercise
214812975|NCT00322465|DRUG|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
214812976|NCT00322465|OTHER|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
214812977|NCT00322465|DRUG|Doxycycline|100 mg orally, twice daily for 7 days.
214812978|NCT00322465|DRUG|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
214812979|NCT02815319|DRUG|Dexamethasone|Steroid prophylaxis
214812980|NCT04795609|OTHER|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening."
214812981|NCT01073657|OTHER|Supported Education|Rehabilitation counseling using peers to achieve educational goals
214812982|NCT01073657|OTHER|General Peer Support|Matched peer support for any personal goal other than education
214812983|NCT01790581|BEHAVIORAL|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
214812984|NCT01790581|BEHAVIORAL|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
214812985|NCT03255148|DRUG|Oxytocin|Syntocinon nasal spray
214812986|NCT03255148|DRUG|Placebo|Placebo nasal spray
214812987|NCT03909516|DEVICE|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
214812988|NCT01975688|DRUG|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
214812989|NCT04350086|DRUG|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
214812990|NCT01459003|OTHER|beauty care|beauty care performed before each chemo cycle
214812991|NCT00183794|DRUG|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
214812992|NCT00584922|PROCEDURE|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
214812993|NCT01228409|DRUG|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
214812994|NCT04004676|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
214812995|NCT04004676|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
214812996|NCT03486990|DRUG|TIMP-GLIA|intravenous infusion.
214812997|NCT05285020|OTHER|Alter G|"It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions)."
214812998|NCT05285020|OTHER|Parallel bars and Scale|It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
214812999|NCT05285020|OTHER|Standard rehabilitation protocol|It is the hospital's standard protocol for that injuries once a day for two weeks.
214813000|NCT04960488|PROCEDURE|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
214813001|NCT02216071|DRUG|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
214813002|NCT02216071|DRUG|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
214813003|NCT05277753|BIOLOGICAL|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
214813004|NCT01934621|BEHAVIORAL|Strategy Training|
214813005|NCT01934621|BEHAVIORAL|Attention Control|
214813006|NCT00385125|DRUG|Bendamustine|
214813007|NCT00385125|DRUG|Rituximab|
214813008|NCT00252811|DRUG|Gefitinib|
214813009|NCT02069665|OTHER|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
214813010|NCT02069665|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
214813011|NCT02069665|DRUG|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
214813012|NCT02069665|DRUG|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
214813013|NCT02069665|DRUG|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
214813014|NCT02069665|DRUG|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
214813015|NCT02069665|DRUG|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
214813016|NCT02069665|DRUG|Ibuprofen Suspension|taken under prescription
214813017|NCT02069665|DRUG|salbutamol|taken under prescription
214813018|NCT03328936|OTHER|Laboratory Biomarker Analysis|Correlative studies
214813019|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
214813020|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
214813021|NCT03328936|OTHER|Pharmacological Study|Correlative studies
214813024|NCT03104101|COMBINATION_PRODUCT|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
214813025|NCT03104101|DEVICE|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
214813026|NCT00389064|DRUG|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
214813027|NCT00389064|DRUG|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
214813028|NCT02917902|OTHER|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
214813029|NCT02512952|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
214813030|NCT02512952|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
214813031|NCT02512952|PROCEDURE|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
214813032|NCT05608161|DIAGNOSTIC_TEST|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
214813033|NCT00762307|DEVICE|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
214813034|NCT02478957|DRUG|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
214813035|NCT02478957|DRUG|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
214813036|NCT00336622|DEVICE|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
214813037|NCT04995822|DEVICE|hip arthroplasty|Hip prosthesis surgery
214813038|NCT02264054|DRUG|[14C]talsaclidine, oral|
214813039|NCT02264054|DRUG|[14C]talsaclidine, iv|
214813040|NCT05589311|OTHER|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
214813041|NCT05589311|OTHER|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
214813042|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
214648621|NCT03825913|BEHAVIORAL|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
215031299|NCT02692027|OTHER|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
214648622|NCT03825913|BEHAVIORAL|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
214648623|NCT03806426|DRUG|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
214648624|NCT03806426|DRUG|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
214648625|NCT04744974|BEHAVIORAL|Diet intervention|Participants will be given dietician counseling on their assigned diet
214648626|NCT00586365|DRUG|Naproxen|500 mg Naproxen twice a day for two weeks
214648627|NCT00888667|OTHER|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
214648628|NCT05831982|OTHER|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
214648629|NCT05831982|OTHER|Standard training|Training as usual when discharged with a rehabilitation plan.
214648630|NCT02273245|RADIATION|Thoracic aortogram CT|With and without contrast dye
214648631|NCT05593848|PROCEDURE|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
214648632|NCT05593848|PROCEDURE|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
214648633|NCT00521781|DRUG|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
214648634|NCT00521781|DRUG|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
214648635|NCT00521781|DRUG|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
214648636|NCT03415555|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
214648637|NCT03415555|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
214648638|NCT03415555|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
214648639|NCT03415555|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
214648640|NCT00948740|DRUG|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
214648641|NCT04550026|OTHER|HTP inhalation|Sham inhalation for 30 minutes
214648642|NCT04061083|DEVICE|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
214648643|NCT04061083|DEVICE|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
214648644|NCT00224666|DEVICE|Cortex stimulation|
214648645|NCT06395844|DRUG|METR-NK cell(Metabolic Remodeling Nature Killer Cells)|The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
214648646|NCT05916872|OTHER|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
214648647|NCT05916872|OTHER|control group|Patients will receive conventional therapy.
214648648|NCT01510327|DEVICE|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
214648649|NCT01510327|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
214648650|NCT01510327|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
214648651|NCT00131846|DRUG|Thiazide diuretics|Any dosage, frequency, and duration
214648652|NCT00131846|DRUG|No diuretics|Any antihypertensive regimen other than diuretics
214648653|NCT00252330|DRUG|SR58611A|
214813043|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
214813044|NCT01701128|OTHER|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
214813045|NCT05122208|DRUG|Famotidine Tablets|160 mg/day Famotidine
214813046|NCT01820793|DRUG|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
214813047|NCT04972656|DRUG|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
214813048|NCT04972656|DRUG|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
214813049|NCT06215079|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that modulates the cortical excitability of the targeted motor area. While single-pulse TMS is generally used to explore the functioning of the brain, repetitive TMS is employed to induce lasting changes in brain activity. High-frequency rTMS leads to an increase in excitability in the motor cortex, whereas low-frequency application results in inhibition of motor cortical excitability. Theta-burst stimulation (TBS) is a form of rTMS that can be delivered continuously (cTBS) or intermittently (iTBS), thus modulating the excitability of corticospinal neurons beneath the stimulation area to either decrease or increase. rTMS is a growing research area in pain management, proven to be a safe and well-tolerated method. Studies have shown that rTMS applied to the motor cortex is a promising treatment method for chronic pain
214813050|NCT06215079|DEVICE|Sham transcranial magnetic stimulation|Patients in the control group will receive sham transcranial magnetic stimulation with sham coil for 35 minutes a day, 5 sessions in total, together with conventional rehabilitation.
214813051|NCT06215079|DEVICE|conventional rehabilitation program|Patients will receive 5 minutes of continuous ultrasound (1MHz, 2W/cm2, 1:4)), followed by a 20-minute contrast bath, and 15 minutes of TENS (frequency: 100 Hz; pulse duration: 50-100 ms; and amplitude adjusted to avoid discomfort or muscle contraction to the patient).
214813052|NCT05586256|RADIATION|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
214813053|NCT02395003|OTHER|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
214813054|NCT04347642|PROCEDURE|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
214813055|NCT04347642|PROCEDURE|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
214813056|NCT01900236|BEHAVIORAL|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
214813057|NCT02449707|PROCEDURE|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
214813058|NCT02449707|DEVICE|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
214813059|NCT02449707|DEVICE|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
214813060|NCT02449707|DEVICE|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
214813061|NCT02449707|DEVICE|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
214648654|NCT02816957|DRUG|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
214648655|NCT00859859|DEVICE|Vagus Nerve Stimulation|"1. Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~2. Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
214648656|NCT04387097|DRUG|remifentanil|postoperative drip-infusion of remifentanil
214648657|NCT03188952|DIAGNOSTIC_TEST|International Caries Classification and Management System|Caries assessment and management system
214648658|NCT03335540|BIOLOGICAL|Nivolumab|Specified dose on specified day
214648659|NCT03335540|BIOLOGICAL|Relatlimab|Specified dose on specified day
214648660|NCT03335540|BIOLOGICAL|Cabiralizumab|Specified dose on specified day
214648661|NCT03335540|BIOLOGICAL|Ipilimumab|Specified dose on specified day
214648662|NCT03335540|DRUG|IDO1 Inhibitor|Specified dose on specified day
214648663|NCT03335540|RADIATION|Radiation Therapy|Specified dose on specified day
214648664|NCT05600075|DRUG|microneedling with topical glycolic acid 35%.|15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
214648665|NCT05600075|DRUG|microneedling with topical human insulin solution.|15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
214648666|NCT05392452|DEVICE|CamAPS HX|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
214648667|NCT05392452|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
214648668|NCT05613530|BEHAVIORAL|MAX NEONAT|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
214648669|NCT05613530|BEHAVIORAL|standard of care|no cognitive aid but poster/paper only
214648670|NCT05990855|COMBINATION_PRODUCT|eCBTi-obj|eCBTi based on objective sleep measures recorded by the Muse S headband.
214648671|NCT05990855|BEHAVIORAL|eCBTi-subj|eCBTi based on standard subjective sleep measures recorded on the sleep diary.
214813062|NCT02449707|PROCEDURE|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
214813063|NCT02449707|PROCEDURE|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
214813064|NCT04770883|BEHAVIORAL|Internet based cognitive behavioral therapy.|Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.
214813065|NCT04770883|DIETARY_SUPPLEMENT|Low FODMAP diet therapy|Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.
214813066|NCT01371409|OTHER|continuous theta burst stimulation|80% active motor threshold, 600 pulses
214813067|NCT03451201|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
214813068|NCT03451201|BEHAVIORAL|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
214813069|NCT03451201|OTHER|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
214813070|NCT02613156|PROCEDURE|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
214813071|NCT02992093|OTHER|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
214813072|NCT03438253|PROCEDURE|spinal anaesthesia|
214813073|NCT04235881|BEHAVIORAL|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
214813074|NCT04235881|BEHAVIORAL|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
214813075|NCT02658604|OTHER|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
214813076|NCT02779543|DEVICE|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
214813077|NCT02779543|DEVICE|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
214813078|NCT02779543|DEVICE|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
214813079|NCT04875793|DIAGNOSTIC_TEST|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
214813080|NCT03291925|PROCEDURE|Selective invasive angiography based on CT/CCTA imaging.|
214813081|NCT03291925|PROCEDURE|Procedure/Surgery: Invasive angiography|
214813082|NCT03133364|OTHER|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
214813083|NCT05522062|PROCEDURE|surgical treatment for humerus shaft fracture|surgical treatment for humerus shaft fracture
214813084|NCT03965858|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
214813085|NCT03965858|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
214813086|NCT03965858|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
214813087|NCT03965858|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
214813088|NCT01552447|OTHER|EpiFix|Dehydrated placental tissue
214813089|NCT01552447|OTHER|Compression Therapy|Compression bandaging
214813090|NCT02629094|DRUG|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
214813091|NCT00006194|BEHAVIORAL|Exercise|
214813092|NCT05340010|DRUG|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
214813093|NCT06433141|PROCEDURE|treatment option for primary second molar|final restoration for primary second molars
214813094|NCT00135941|DRUG|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
214813095|NCT00135941|DRUG|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
214813096|NCT05741437|DRUG|CKD-378, QD, PO Drug: D745, D150, QD, PO|Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
214813097|NCT03148704|DRUG|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
214813098|NCT02648880|BEHAVIORAL|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
214813099|NCT02648880|OTHER|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
214813100|NCT04607720|PROCEDURE|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
214813101|NCT04607720|PROCEDURE|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
214813102|NCT03004820|DEVICE|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
214813103|NCT03707912|DRUG|Anaferon|Oral administration.
214813104|NCT03707912|DRUG|Placebo|Oral administration.
214813105|NCT06433674|DRUG|Zinc Sulfate|The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
214813106|NCT06433674|OTHER|Sterile Water|The placebo group with will receive a similar amount of sterile water in a colored syringe
214813107|NCT01678066|DEVICE|Bilateral cardiac output|
214813108|NCT01617954|DEVICE|MammaPrint|All subjects
214813109|NCT04024007|DIAGNOSTIC_TEST|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
214813110|NCT02960568|DRUG|Primaquine|30 mg oral primaquine one time
214813111|NCT02745899|DIETARY_SUPPLEMENT|Cow milk|Ingestion of 240 ml cow milk
214813112|NCT02745899|DIETARY_SUPPLEMENT|Soy milk|Ingestion of 240 ml soy milk
214813113|NCT07035652|OTHER|XH-S004 20 mg, 40 mg or 60 mg|Administered once per day for 140 days.
214813114|NCT07035652|OTHER|Placebo|Administered once per day for 140 days.
214813115|NCT07037017|BEHAVIORAL|Cognitive-Behavioral Therapy|Manualized 12-week CBT protocol focused on reducing body image disturbance, distorted beliefs about food and appearance, and avoidance behaviors in individuals with anorexia nervosa. The intervention incorporates psychoeducation, cognitive restructuring, emotional regulation, food exposure, and body image work.
214813116|NCT07035353|DRUG|T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.|The treatment plan will be recommended to the subject by the treating physician in accordance with current clinical practice guidelines and clinical practice, and the patient's decision to receive T-DXd (DS8201) should precede enrollment in this study. The strategy for administering a particular treatment to a subject is not determined a priori by the trial protocol, but should be in accordance with current clinical practice. Because of the non-interventional nature of this study, this study does not alter or interfere with the patient's actual current medical practice.
214813117|NCT07035522|OTHER|Ozone therapy|The study also aims to analyze the efficacy of ozone therapy in participants affected by endometriosis, enriching the knowledge base in the field of women's health/gynecology. The expected results will contribute to improving current therapeutic approaches, informing clinical decisions and encouraging future research. Understanding the technique and its clinical applicability will help health professionals to offer personalized and effective treatments. In addition, the insights obtained can direct new investigations, such as the optimization of protocols or the exploration of innovative therapeutic combinations for even more satisfactory results. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it may be possible that one of the approaches demonstrates a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of these participants will improve and i
214813118|NCT04590443|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
214813119|NCT06304701|DIAGNOSTIC_TEST|Cognitive and writing tests|"* Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing"
214813120|NCT06944145|DRUG|raloxifene|Participants in the Finasteride + Raloxifene Combination Therapy Arm will receive both Finasteride and Raloxifene as their intervention.
214813121|NCT06944145|DRUG|Finasteride|"Participants in the Finasteride Monotherapy arm will receive only Finasteride as their standard-of-care intervention.~Participants in the Finasteride + Raloxifene Combination Therapy arm will receive both Finasteride and Raloxifene as the study intervention."
214813122|NCT02486445|DRUG|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
214813123|NCT03267381|OTHER|Blood draw (before surgery)|Blood will be drawn before surgery
214813124|NCT03267381|OTHER|Blood draw (every 3 months)|Blood will be drawn every 3 months
214813125|NCT03267381|OTHER|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
214813126|NCT03006705|DRUG|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
214813127|NCT03006705|DRUG|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
214813128|NCT03006705|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
214813129|NCT03006705|DRUG|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
214813130|NCT03006705|DRUG|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
214813131|NCT03036085|DRUG|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
214813132|NCT03036085|DRUG|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
214813133|NCT03036085|DRUG|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
214813134|NCT03036085|DRUG|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
214813135|NCT00276848|DRUG|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
214813136|NCT00276848|DRUG|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
214813137|NCT04354974|BEHAVIORAL|Evaluation|Evaluation of a cognitive remediation program for mood disorders
214813138|NCT01148030|DRUG|3M Skin and Nasal Antiseptic|Intra-nasal dosing
214813139|NCT02562378|DRUG|Trastuzumab and non-pegylated liposomal doxorubicin|"3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV"
214813140|NCT00858793|PROCEDURE|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
214813141|NCT02152397|BEHAVIORAL|Therapist-led brief intervention (TBI)|
214813142|NCT06427161|PROCEDURE|LLLT application|The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.
214813143|NCT06427161|PROCEDURE|dextrose injection|25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
214813144|NCT04899089|BEHAVIORAL|Cognitive Training|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
214813145|NCT04899089|BEHAVIORAL|Trivia Training|The computerized trivia training asks participants to answer general questions related to pop culture, science, geography, etc. Participants can use online sources to search for answers and will be provided feedback on their accuracy.
214813146|NCT01104025|DRUG|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
214813147|NCT01104025|DRUG|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
214813148|NCT01104025|DRUG|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
214813149|NCT01104025|DRUG|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
214813150|NCT01104025|DRUG|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
214648672|NCT01078766|OTHER|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
214648673|NCT00865215|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
214648674|NCT00865215|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
214648675|NCT01567644|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
214648676|NCT05435820|DEVICE|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
214648677|NCT03172689|DEVICE|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
214648678|NCT00544934|DRUG|GLY-230|125, 250 0r 375 mg bid for 14 days
214648679|NCT00544934|OTHER|Placebo|No drug administered
214813151|NCT02372747|PROCEDURE|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
214813152|NCT02372747|PROCEDURE|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
214813153|NCT05401786|DRUG|Ipilimumab|Anti-CTLA-4
214813154|NCT05401786|DRUG|Cemiplimab|PD-1 inhibition
214813155|NCT05401786|RADIATION|SBRT|Stereotactic Body Radiotherapy
214813156|NCT03979768|OTHER|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
214813157|NCT05267093|PROCEDURE|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
214813158|NCT05267093|PROCEDURE|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
214813159|NCT04002024|OTHER|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
214813160|NCT04002024|OTHER|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
214813161|NCT06385236|BIOLOGICAL|Dupilumab|"Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training."
214813162|NCT06385236|BIOLOGICAL|Benralizumab|"Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training."
214813163|NCT03757845|OTHER|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
214813164|NCT03914365|PROCEDURE|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
214813165|NCT05679024|DRUG|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
214813166|NCT02053454|DRUG|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
214813167|NCT02053454|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214813168|NCT00460733|DRUG|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
214813169|NCT00460733|DRUG|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
214813170|NCT05413096|COMBINATION_PRODUCT|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
214813171|NCT05413096|OTHER|placebo|placebo
214813172|NCT03528187|OTHER|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
214813173|NCT03528187|OTHER|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
214813174|NCT01368991|DEVICE|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
214813175|NCT01368991|PROCEDURE|Conventional closure|conventional closure, no kryptonite applied
214813176|NCT06409377|DRUG|Precedex 200 MCG in 2 ML Injection|Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
214813177|NCT06409377|OTHER|C group:|Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
214813178|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
214813179|NCT01811953|DRUG|Metformin|oral administration
214813180|NCT01811953|DRUG|Empagliflozin|low dose of Empagliflozin oral administration
214813181|NCT01811953|DRUG|Empagliflozin/Metformin|low dose of Empagliflozin
214813182|NCT01811953|DRUG|Metformin|oral administration
214813183|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
214813184|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
214813185|NCT01811953|DRUG|Metformin|oral administration
214813186|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
214648680|NCT03541421|OTHER|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
214648681|NCT04171609|BEHAVIORAL|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
214648682|NCT00737139|PROCEDURE|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
214648683|NCT00737139|PROCEDURE|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
214648684|NCT06098638|OTHER|Nutritional recommendation and Faradic stimulation program|proper maternal nutrition and fluid intake during breast-feeding per day for 12 weeks and2 sessions per week, each session 20 minutes, for 12 weeks. Frequency of 65 Hz, and width pulse 300 ms, with contraction time 10 sec and relaxation time 10 sec
214648685|NCT06098638|OTHER|aerobic and resisted exercise for 12 weeks|Each woman in group (B) participated in a moderate exercise program (aerobic+resistive), 3 days/week, for 12 weeks. The session began with 15 minutes of aerobic exercise on a bicycle ergometer, at 60% of heart rate reserve (HRR), with HRR estimated (220-age-resting heart rate). Then, the participant was performed 15 minutes of resistive exercise (two sets of 8-12 repetitions at 75% of one repetition maximum (1-RM) for basic core exercises in the form of hip lifts, knee extension and flexion, crunches, shoulder flexion and extension, elbow flexion and extension with resistance
214648686|NCT05549115|DRUG|clarithromycin-sensitive(first-line)|esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
214648687|NCT05549115|DRUG|clarithromycin-resistant(first-line)|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
214648688|NCT05549115|DRUG|empirical therapy group first-line|esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
214648689|NCT05549115|DRUG|levofloxacin-sensitive(rescue treatment)|esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
214648690|NCT05549115|DRUG|levofloxacin-resistant(rescue treatment)|esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
214648691|NCT05549115|DRUG|empirical therapy group rescue treatment|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
214648692|NCT03726684|DEVICE|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
214648693|NCT03274921|DIAGNOSTIC_TEST|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
214648694|NCT02476318|DEVICE|ArterX Vascular Sealant|
214648695|NCT00417586|DEVICE|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
214648696|NCT00692367|BEHAVIORAL|Physical Activity|1\. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
214648697|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
214648698|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
214648699|NCT01486199|OTHER|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
214648700|NCT02803073|DRUG|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
214648701|NCT02803073|DRUG|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
214648702|NCT00459069|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
214648703|NCT02509091|DRUG|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
214648704|NCT01263041|DRUG|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
214648705|NCT01263041|DRUG|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
214648706|NCT00844467|BIOLOGICAL|serotypes and resistance|screening patients with invasive pneumococci
214648707|NCT06549244|DIAGNOSTIC_TEST|Maximum Inspiratory Pressure monitoring|Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day
214648708|NCT04759300|DEVICE|C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS
214648709|NCT04759300|DEVICE|C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
214648710|NCT01539980|DEVICE|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
214648711|NCT04941144|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
214648712|NCT00845988|DRUG|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
214648713|NCT04591054|DEVICE|Extended Vision IOL|Vivity IOL implantation following cataract extraction
214648714|NCT04591054|DEVICE|Neutral Aspheric Monofocal IOL|enVista IOL implantation following cataract extraction
214648715|NCT02705898|BEHAVIORAL|LPA+Fitbit|
214648716|NCT02705898|BEHAVIORAL|HEC|
214648717|NCT03883269|DRUG|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
214648718|NCT03883269|DRUG|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
214648719|NCT03883269|DRUG|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
214648720|NCT05490797|OTHER|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
214648721|NCT05490797|OTHER|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
214648722|NCT02647073|DEVICE|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
214648723|NCT01660217|OTHER|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
214648724|NCT03005626|OTHER|Therapeutic education|
214648725|NCT03005626|OTHER|Standard follow-up|
214648726|NCT00392028|DRUG|ertapenem|
214648727|NCT01172015|OTHER|blood samples|
214648728|NCT06915740|OTHER|Exercise|virtual rehabilitation, including endurance exercise, strength training, breathing exercises, patient education, dietary advice
214648729|NCT03820245|DIETARY_SUPPLEMENT|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
214648730|NCT03820245|DIETARY_SUPPLEMENT|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
214648731|NCT03820245|DIETARY_SUPPLEMENT|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
214648732|NCT03820245|DIETARY_SUPPLEMENT|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
214648733|NCT01400932|DRUG|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
214648734|NCT01400932|DRUG|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
214648735|NCT01554787|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
214648736|NCT01554787|OTHER|Placebo|at a rate of 2.8g three times per day
214648737|NCT04646148|BEHAVIORAL|Yoga classes|All participants are invited to attend weekly yoga classes.
214648738|NCT02653950|PROCEDURE|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
214648739|NCT02653950|PROCEDURE|Traditional septoplasty|septoplasty under direct vision
214648740|NCT04689230|PROCEDURE|upper eyelid blepharoplasty|upper eyelid blepharoplasty
214648741|NCT00352703|DRUG|Kepivance (Palifermin)|
214648742|NCT02566720|DRUG|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
214648743|NCT02566720|PROCEDURE|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
214648744|NCT03346330|DRUG|TRK-750|TRK-750 capsule
214648745|NCT03346330|DRUG|Placebo|Placebo capsule
214648746|NCT04899635|OTHER|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
214648747|NCT03244059|BIOLOGICAL|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
214648748|NCT03244059|DRUG|Placebo|An identically appearing placebo infusion.
214648749|NCT02457234|BEHAVIORAL|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
214648750|NCT04222829|PROCEDURE|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
214648751|NCT04321811|OTHER|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
214648752|NCT02235506|PROCEDURE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
214648753|NCT02235506|PROCEDURE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
214648754|NCT02235506|DEVICE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
214648755|NCT02235506|DEVICE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
214648756|NCT05184907|BEHAVIORAL|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
214648757|NCT05184907|OTHER|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
214648758|NCT02103686|DRUG|Lyrica|
214648759|NCT02103686|DRUG|Experimental drug|sustained release formulation of pregabalin
214648760|NCT02103686|DIETARY_SUPPLEMENT|High fat meal|
214648761|NCT02103686|DIETARY_SUPPLEMENT|fasted|
214648762|NCT02201758|DIETARY_SUPPLEMENT|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
214648763|NCT02201758|OTHER|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
214648764|NCT00138216|DRUG|irinotecan hydrochloride|
214648765|NCT00138216|DRUG|temozolomide|
214648766|NCT00138216|DRUG|vincristine sulfate|
214648767|NCT03993717|BIOLOGICAL|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
214648768|NCT04781075|OTHER|Pain Scale|Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
214648769|NCT04781075|DRUG|Exparel Injectable Product|Given at the beginning of the surgery for post-operative pain management
214648770|NCT04781075|DRUG|Bupivacaine Injection|Given at the beginning of the surgery for post-operative pain management
214648771|NCT04974788|OTHER|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
214648772|NCT04974788|OTHER|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
214648773|NCT04974788|OTHER|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
214648774|NCT05121402|DRUG|TLL018|a TYK2/JAK1 inhibitor
214648775|NCT05121402|OTHER|Placebo|a TLL018 Placebo
214813187|NCT05937451|OTHER|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
214813188|NCT03579303|OTHER|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
214813189|NCT04741477|DRUG|CBD|CBD will be topically applied
214813190|NCT04741477|DRUG|THC|THC will be topically applied
214813191|NCT04741477|DRUG|Placebo|a placebo product (without cannabinoids) will be topically applied
214813192|NCT02007733|OTHER|Serial Weights|We will collect serial weights on all children enrolled in this study.
214813193|NCT02007733|OTHER|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
214813194|NCT02007733|OTHER|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
214813195|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
214813196|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
214813197|NCT04970368|PROCEDURE|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
214813198|NCT04970368|PROCEDURE|Selective staging|Intraoperative consultation (IOC)
214813199|NCT04132011|DRUG|Extended Release Opioid Formulation, Shortened Intervals|Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
214813200|NCT04132011|DRUG|Extended Release Opioid Formulation, Standard intervals|Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
214813201|NCT04132011|DRUG|Placebo oral tablet|Lactose pill manufactured to mimic extended release opioid formulation
214813202|NCT04115332|BIOLOGICAL|bio-feedback training|The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
214813203|NCT03500003|OTHER|Acute milk intake|Food matrix: milk
214813204|NCT03500003|OTHER|Acute Yogurt intake|Food matrix: yogurt
214813205|NCT00281749|PROCEDURE|TELEPHONE CALL|
214813206|NCT05338047|DRUG|Pegfilgrastim|Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
214813207|NCT03523039|DEVICE|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
214813208|NCT00371839|PROCEDURE|Audiological Evaluation|Tests of hearing, cognition, and speech perception
214813209|NCT06315530|DRUG|Telitacicept+SOC|160mg once a week for 48 weeks
214813210|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
214813211|NCT00401089|DRUG|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
214813212|NCT03966560|DRUG|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
214813213|NCT03966560|DRUG|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
214813214|NCT03966560|DRUG|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
214813215|NCT03966560|DRUG|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
214813216|NCT03966560|DRUG|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
214813217|NCT03966560|DRUG|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
214813218|NCT00152035|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
214813219|NCT01003002|DRUG|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
214813220|NCT03408119|DIETARY_SUPPLEMENT|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
214813221|NCT03408119|DIETARY_SUPPLEMENT|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
214813222|NCT03000296|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
214813223|NCT00006365|RADIATION|brachytherapy|
214813224|NCT00006365|RADIATION|iodine I 125|
214813225|NCT00006365|RADIATION|radiation therapy|
214839835|NCT04972331|PROCEDURE|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
214839836|NCT04972331|PROCEDURE|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.
214839837|NCT04972331|OTHER|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
214839838|NCT01071031|BIOLOGICAL|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
214839839|NCT01071031|BIOLOGICAL|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
214839840|NCT01071031|BIOLOGICAL|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
214839841|NCT02546050|DRUG|Metformin|
214839842|NCT01279382|BEHAVIORAL|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
214839843|NCT01279382|BEHAVIORAL|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
214839844|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
214839845|NCT01879631|PROCEDURE|radial keratotomy|
214839846|NCT03901157|DIETARY_SUPPLEMENT|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
214839847|NCT03901157|DIETARY_SUPPLEMENT|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
214813226|NCT05312827|BEHAVIORAL|Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
214813227|NCT02360982|BEHAVIORAL|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
214813228|NCT02360982|BEHAVIORAL|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
214813229|NCT01523626|OTHER|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
214813230|NCT01523626|OTHER|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
214813231|NCT03437304|BIOLOGICAL|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
214813232|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
214813233|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
214813234|NCT03437304|BIOLOGICAL|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
214813235|NCT03437304|DRUG|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
214813236|NCT03437304|BIOLOGICAL|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
214813237|NCT02713022|DEVICE|DEXA Scan|
214813238|NCT02713022|BEHAVIORAL|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
214813239|NCT01049334|DRUG|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
214813240|NCT01049334|DRUG|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
214813241|NCT05309941|OTHER|Internal Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
214813242|NCT05309941|OTHER|External Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
214813243|NCT05701930|BEHAVIORAL|symptom management|pecha kucha training
214813244|NCT02991404|PROCEDURE|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
214813245|NCT02991404|PROCEDURE|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
214813246|NCT02991404|DRUG|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
214813247|NCT02991404|DRUG|Continuous infusion|Continuous infusion of 0.125% bupivacaine
214813248|NCT04751669|DIETARY_SUPPLEMENT|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
214813249|NCT04751669|DIETARY_SUPPLEMENT|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
214813250|NCT01175616|DRUG|Creatine|Oral Creatine 5 grams daily.
214813251|NCT00003939|DRUG|trabectedin|
214813252|NCT00396279|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
214813253|NCT00396279|DIETARY_SUPPLEMENT|Calcium/Vitamin D|
214813254|NCT04825808|OTHER|usual care|according to recommendations
214813255|NCT04285359|PROCEDURE|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
214813256|NCT00517530|DRUG|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
214813257|NCT03026348|BIOLOGICAL|RSV F Vaccine with Aluminum Phosphate Adjuvant|
214813258|NCT03026348|BIOLOGICAL|RSV F Vaccine|
214813259|NCT03026348|BIOLOGICAL|Matrix-M1 Adjuvant|
214813260|NCT03026348|OTHER|Phosphate Buffer|
214813261|NCT00667095|DRUG|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
214813262|NCT00667095|DRUG|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
214813263|NCT01900964|PROCEDURE|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
214813264|NCT01900964|PROCEDURE|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
214813265|NCT01194388|DEVICE|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
214813266|NCT02967107|PROCEDURE|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
214813267|NCT02967107|PROCEDURE|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
214813268|NCT01050088|DIETARY_SUPPLEMENT|sucrose solution|5cc 5% sucrose solution P/O
214813269|NCT01050088|DIETARY_SUPPLEMENT|Saline|5cc saline p/o
214813270|NCT00242788|DRUG|Gefitinib and capecitabine|
214813271|NCT01199848|DIETARY_SUPPLEMENT|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
214813272|NCT01199848|DIETARY_SUPPLEMENT|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
214813273|NCT01199848|DIETARY_SUPPLEMENT|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
214813274|NCT01199848|DIETARY_SUPPLEMENT|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
214813275|NCT01199848|DIETARY_SUPPLEMENT|Placebonofiber|Placebo without Fiber
214813276|NCT03598374|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
214813277|NCT03598374|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
214813278|NCT03598374|BEHAVIORAL|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
214813279|NCT00126932|DEVICE|SonoPrep|
214813280|NCT01349374|OTHER|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
214813281|NCT04680962|BIOLOGICAL|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
214813282|NCT04680962|BIOLOGICAL|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
214813283|NCT04680962|BIOLOGICAL|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
214813284|NCT05983562|DIETARY_SUPPLEMENT|Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
214813285|NCT05983562|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
214813286|NCT04914962|OTHER|glazed zirconium lithium silicate|monolithic glazed crown
214813287|NCT04914962|OTHER|polished zirconium lithium silicate|monolithic polishedcrowns
214813288|NCT02371343|DIETARY_SUPPLEMENT|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
214813289|NCT02371343|DIETARY_SUPPLEMENT|Sunflower Oil|
214813290|NCT02514941|DRUG|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
214813291|NCT02514941|DRUG|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
214813292|NCT02514941|DRUG|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
214813293|NCT02514941|PROCEDURE|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
214813294|NCT02514941|PROCEDURE|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
214813295|NCT02514941|PROCEDURE|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
214813296|NCT01832259|DRUG|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
214813297|NCT01832259|OTHER|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
214813298|NCT06281340|OTHER|Manual therapy|Each session will last approximately 50-60 minutes. Each session is composed of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to the criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy.
214813299|NCT06281340|OTHER|Placebo manual therapy|Each session will last approximately 50-60 minutes. Each session consists of the placebo application of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy. In the techniques there will be no joint sliding, manipulations or myofascial inductions, being the only stimulus the contact of the physiotherapist with his hands and the pressure exerted with these, on the ankle.
214813300|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
214813301|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
214813302|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
214813303|NCT04854330|DIETARY_SUPPLEMENT|Ketone monoesters|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml.
214813304|NCT04854330|DIETARY_SUPPLEMENT|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
214813305|NCT00833339|DRUG|mifepristone|600 mg/day x 1 week
214813306|NCT00833339|DRUG|placebo|placebo
214813307|NCT05652543|BIOLOGICAL|SCTV01E|Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
214813308|NCT05652543|BIOLOGICAL|Placebo (normal saline)|Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
214813309|NCT04109521|OTHER|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
214813310|NCT00927303|DEVICE|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
214813311|NCT00927303|DEVICE|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
214813312|NCT00004905|BIOLOGICAL|filgrastim|
214813313|NCT00004905|BIOLOGICAL|recombinant interferon alfa|
214813314|NCT00004905|DRUG|cyclophosphamide|
214813315|NCT00004905|DRUG|cytarabine|
214813316|NCT00004905|DRUG|etoposide|
214813317|NCT00004905|DRUG|idarubicin|
214813318|NCT00004905|PROCEDURE|peripheral blood stem cell transplantation|
214813319|NCT00004905|RADIATION|radiation therapy|
214813320|NCT01334645|OTHER|Copeptin|"Patients with hyponatremia \< 135 mmol/L or troponin \> 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
214813321|NCT04781205|GENETIC|Mutation arrays, NGS panels, GWAS, WES, WGS,|DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
214813322|NCT04781205|DEVICE|wearable monitors|test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
214813323|NCT02296177|BEHAVIORAL|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
214813324|NCT00029198|PROCEDURE|massage|15 massage given tid
214813325|NCT00029198|PROCEDURE|Sham massage|non-massage touch
214813326|NCT03195205|DIAGNOSTIC_TEST|OraQuick HCV Rapid Antibody Test|HCV Screening
214813327|NCT06392594|GENETIC|xpert MTB , XDR assay|To determine how accurate Xpert MTB/RIF and XDR for diagnosis of pulmonary TB and Rifampicin resistance
214813328|NCT00532974|BIOLOGICAL|EP1090|Low dose
214813329|NCT00532974|BIOLOGICAL|EP1090|High dose
214813330|NCT05719922|OTHER|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
214813331|NCT00688363|PROCEDURE|weekly blood glucose profile|once daily self-control of urinary-glucose
214813332|NCT00688363|PROCEDURE|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
214813333|NCT00688363|PROCEDURE|no blood-glucose self-control|once daily self-control of urinary-glucose
214813334|NCT00905346|DRUG|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
214813335|NCT00905346|DRUG|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
214813336|NCT00905346|OTHER|Applesauce|Applesauce
214813337|NCT01948414|PROCEDURE|electroencephalography|
214813338|NCT01948414|BIOLOGICAL|Blood sampling|
214813339|NCT01948414|BEHAVIORAL|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
214813340|NCT03351335|DEVICE|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
214813341|NCT03928691|DRUG|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
214813342|NCT05632874|BEHAVIORAL|relaxing breathing exercise|"Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients."
214813343|NCT04913376|DEVICE|Hilotherapy|Constant cooling device for hands and feet.
214813344|NCT00946374|DRUG|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
214813345|NCT00946374|DRUG|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( \> 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
214813346|NCT00946374|OTHER|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
214813347|NCT00301691|BEHAVIORAL|behavioral dietary intervention|
214813348|NCT00301691|OTHER|educational intervention|
214813349|NCT00301691|OTHER|preventative dietary intervention|
214813350|NCT01699191|DIETARY_SUPPLEMENT|Probiotic|
214813351|NCT01699191|DIETARY_SUPPLEMENT|Placebo|
214813352|NCT00731744|PROCEDURE|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
214813353|NCT05757908|DRUG|Long-Acting Beta Agonist|The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
214813354|NCT04391933|DIAGNOSTIC_TEST|MRI 3 tesla|MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
214813355|NCT00089193|BIOLOGICAL|incomplete Freund's adjuvant|
214813356|NCT00089193|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
214813357|NCT00089193|BIOLOGICAL|sargramostim|
214813358|NCT05225597|PROCEDURE|Intracameral administration of epinephrine and carbachol during cataract surgery|All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
214813359|NCT01980693|DEVICE|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
214813360|NCT03723993|DEVICE|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
214813361|NCT03723993|DEVICE|Non inflated cuff|non inflated cuff around the arm for the control group
214813362|NCT03191474|BEHAVIORAL|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
214813363|NCT06046846|DEVICE|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
214813364|NCT04082858|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
214813365|NCT04082858|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
214813366|NCT05197634|OTHER|Not Applicable (observation)|Questionnaire
214813367|NCT02071108|DEVICE|Shockwave Lithoplasty System|
214813368|NCT03790345|DRUG|Pyridoxine|Adjuvant daily treatment with 200mg of pyridoxine
214813369|NCT03790345|DRUG|Cobalamin|Adjuvant daily treatment with 2mg of cobalamin
214813370|NCT03790345|DRUG|Placebo Oral Tablet|Adjuvant daily treatment with placebo
214813371|NCT03770598|BEHAVIORAL|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
214813372|NCT03770598|BEHAVIORAL|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
214813373|NCT03770598|BEHAVIORAL|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
214813374|NCT03770598|BEHAVIORAL|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
214813375|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
214813376|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
214813377|NCT01623362|OTHER|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
214813378|NCT01623362|OTHER|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
214813379|NCT01623362|OTHER|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
214813380|NCT00183521|BEHAVIORAL|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
214813381|NCT00183521|BEHAVIORAL|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
214813382|NCT00183521|BEHAVIORAL|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
214813383|NCT04767477|OTHER|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
214813384|NCT04767477|OTHER|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
214813385|NCT01751048|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
214813386|NCT01751048|BIOLOGICAL|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
214813387|NCT01751048|BIOLOGICAL|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
214813388|NCT01751048|DRUG|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
214813389|NCT05410301|DEVICE|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
214813390|NCT05410301|DRUG|Lomustine|Chemotherapy drug
214813391|NCT05410301|DRUG|Bevacizumab|Chemotherapy and targeted therapy drug
214813392|NCT00773422|DRUG|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
214813393|NCT00773422|DRUG|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
214813394|NCT00773422|DRUG|placebo|placebo
214813395|NCT00977522|DRUG|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
214813396|NCT00977522|DRUG|Placebo|Placebo tablet BID
214813397|NCT05034757|OTHER|HA only|HA injection only
214813398|NCT05034757|OTHER|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
214813399|NCT05034757|OTHER|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
214813400|NCT04786626|DIAGNOSTIC_TEST|Ultrasound evaluation|After vaginal, all patients were followed by traditional 2D US scanning and Doppler velocimetry on Days: 0, 2, 30, 60 and 90. Authors evaluated: scar diameter and Doppler velocimetry and resistance index (RI) of the uterine arteries, at their ascending branch
214813401|NCT06407622|OTHER|Foot Reflexology|In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
214813402|NCT03194139|DRUG|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
214813403|NCT03194139|DRUG|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
214813404|NCT03194139|DRUG|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
214813405|NCT04742790|DIAGNOSTIC_TEST|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
214813406|NCT04742790|DIAGNOSTIC_TEST|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
214813407|NCT04742790|DIAGNOSTIC_TEST|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero \& Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
214813408|NCT04742790|DIAGNOSTIC_TEST|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
214839848|NCT02898701|BEHAVIORAL|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
214813409|NCT04742790|DIAGNOSTIC_TEST|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter \[variation coefficient of pupillary dilation, VCPD, Charier et al. 2017\]), light-evoked speed of pupil constriction \[maximum pupil constriction velocity, PCV, Connely et al., 2014\]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
214813410|NCT04742790|DIAGNOSTIC_TEST|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
214813411|NCT04742790|DIAGNOSTIC_TEST|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
214813412|NCT04742790|DIAGNOSTIC_TEST|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
214813413|NCT04742790|DIAGNOSTIC_TEST|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
214813414|NCT04742790|OTHER|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
214813415|NCT05985317|PROCEDURE|Collagen membrane over BMAC/bovine graft in sinus lift|Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
214813416|NCT05985317|PROCEDURE|PRF membrane over BMAC/bovine graft in sinus lift|PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
214813417|NCT05318365|DRUG|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
214813418|NCT05318365|BEHAVIORAL|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
214813419|NCT05612724|DEVICE|Testing for SARS CoV2 Antigen|Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
214813420|NCT06280183|OTHER|Functional Inspiratory Muscle Training|Inspiratory muscle training is a technique that combines aerobic training with inspiratory muscle training. will be applied simultaneously with aerobic exercise. Participants will work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP.
214813421|NCT06280183|OTHER|Aerobic+Resistive Exercise Traning|Aerobic exercise is planned at 60-85% of the Maximum Heart Rate on a cycle ergometer for 30-40 minutes. Resistive exercise will cover all major muscle groups. The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles, and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body, abdominal, and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM).
214813422|NCT00139711|DRUG|Irinotecan|
214813423|NCT00139711|DRUG|Docetaxel|
214813424|NCT00747097|DRUG|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
214813425|NCT05417230|DRUG|RC48-ADC|2.5mg/kg, IV, d1, every 2 weeks;
214813426|NCT05417230|DRUG|Envafolimab|200mg, SC, d1, every 2 weeks;
214813427|NCT04123808|DEVICE|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
214813428|NCT03112863|DRUG|Bakuchiol|This group will receive bakuchiol
214813429|NCT03112863|DRUG|Retinol|This group will receive retinol
214813430|NCT04000815|DIAGNOSTIC_TEST|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
214813431|NCT00239577|BIOLOGICAL|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
214813432|NCT00239577|BIOLOGICAL|Placebo|Placebo
214813433|NCT06118047|DRUG|Crisaborole Ointment|Crisaborole ointment to be applied twice daily.
214813434|NCT06118047|DRUG|Cetuximab|Cetuximab
214813435|NCT02778451|OTHER|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
214813436|NCT02631772|DRUG|Sofosbuvir/Ledipasvir x 12 weeks|
214813437|NCT02631772|DRUG|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
214813438|NCT03622801|DRUG|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
214813439|NCT02811666|DEVICE|Assessment of sarcopenia by CT-Scan|
214813440|NCT02811666|DEVICE|hand gauge|
214813441|NCT03143686|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
214813442|NCT00439634|DRUG|AVE1625|oral administration
214813443|NCT00439634|DRUG|placebo|oral administration
214813444|NCT01488058|OTHER|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
214813445|NCT01488058|OTHER|Waitlist Control|Waitlist will receive iCBT at week 11
214813446|NCT01931007|DRUG|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
214813447|NCT01931007|DRUG|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
214813448|NCT03988803|DRUG|BI 425809|Film coated tablet
214813449|NCT03988803|DRUG|Memantine|Film coated tablet
214813450|NCT02736721|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
214813451|NCT03863002|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
214813452|NCT05595590|DRUG|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
214813453|NCT05595590|RADIATION|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
214813454|NCT00112190|DRUG|Itopride Hydrochloride|100 mg tid
214813455|NCT00112190|DRUG|itopride|100 mg three times daily
214813456|NCT01021670|DRUG|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
214813457|NCT01021670|OTHER|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
214813458|NCT00840099|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
214813459|NCT00840099|DRUG|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
214813460|NCT03021018|DRUG|Brivaracetam|"* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous"
214813461|NCT03021018|DRUG|Lorazepam|"* Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous"
214813462|NCT02778815|OTHER|Kindness for Mums|
214813463|NCT00001085|DRUG|Amprenavir|
214813464|NCT00001085|DRUG|Lamivudine|
214813465|NCT00001085|DRUG|Zidovudine|
214813466|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
214813467|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
214813468|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
214839849|NCT00267358|DRUG|RC-1291 HCl|
214839850|NCT00267358|DRUG|Placebo|
214813469|NCT01032083|DRUG|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
214813470|NCT01032083|DRUG|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
214813471|NCT01885052|BEHAVIORAL|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
214813472|NCT01885052|BEHAVIORAL|Low Contact|
214813473|NCT04533893|OTHER|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
214813474|NCT02193971|DEVICE|BS-DES (Biostable polymer drug-eluting stent)|
214813475|NCT02193971|DEVICE|BD-DES (Biodegradable polymer drug-eluting stent)|
214813476|NCT02193971|DRUG|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
214813477|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
214813478|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
214813479|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
214813480|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
214813481|NCT03251430|PROCEDURE|gastrectomy|Distal gastrectomy, Total gastrectomy
214813482|NCT00706186|DRUG|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
214813483|NCT05963035|DRUG|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
214813484|NCT05118412|OTHER|Lucerne protein concentrate shake|At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
214813485|NCT05118412|OTHER|Whey protein concentrate shake|At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
214813486|NCT06267703|OTHER|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
214813487|NCT05234502|OTHER|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
214813488|NCT05234502|OTHER|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
214813489|NCT02621996|DEVICE|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
214813490|NCT02621996|DEVICE|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
214813491|NCT00095108|DRUG|Recombinant Human Interleukin-21|
214813492|NCT03205774|BEHAVIORAL|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
214813493|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% BID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
214813494|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% QID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
214813495|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% Six times per day|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
214813496|NCT05951192|DRUG|Daprodustat|Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
214813497|NCT03909620|DIAGNOSTIC_TEST|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
214813498|NCT00068991|BEHAVIORAL|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
214813499|NCT00068991|BEHAVIORAL|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
214813500|NCT00068991|BEHAVIORAL|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
214813501|NCT00204074|DRUG|17-beta-estradiol (drug)|
214813502|NCT01971060|DEVICE|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
214813503|NCT01319162|OTHER|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
214813504|NCT04064892|BEHAVIORAL|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, \& Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
214813505|NCT06279286|DRUG|HS-10506|HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
214813506|NCT06279286|DRUG|Placebo|Placebo, placebo tablets matching the HS-10506 tablets
214813507|NCT03944330|DIETARY_SUPPLEMENT|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
214813508|NCT00557050|OTHER|Training|10-week eccentric hamstring muscle training
214813509|NCT02670772|DRUG|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
214813510|NCT02670772|DRUG|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
214813511|NCT04757792|OTHER|File inquiry|Data extraction out of file registry
214813512|NCT04760704|BIOLOGICAL|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
214813513|NCT03342157|DRUG|senna/docusate|Stimulant laxative
214813514|NCT02269657|DEVICE|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
214813515|NCT02196766|OTHER|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
214813516|NCT02196766|OTHER|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
214813517|NCT01888822|DRUG|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
214813518|NCT01888822|DRUG|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
214813519|NCT01888822|DRUG|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
214813520|NCT00620074|DRUG|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
214813521|NCT00620074|DRUG|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
214813522|NCT04798144|DEVICE|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
214813523|NCT04798144|DEVICE|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
214813524|NCT03836560|DRUG|Nicotine patch|nicotine patch given for 8 weeks
214813525|NCT03836560|DRUG|Nicotine gum|nicotine gum given as requested
214813526|NCT00309101|DRUG|tacrolimus|Oral
214813527|NCT01796730|DRUG|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
214813528|NCT01796730|DRUG|Placebo|
214813529|NCT01239017|BIOLOGICAL|REGN475|
214813530|NCT01239017|OTHER|Placebo|
214813531|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
214813532|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
214813533|NCT03362710|DIAGNOSTIC_TEST|simplified tools|"1. Skin temperature on the back of the foot with infra-red thermometry~2. Toe saturometry~3. ABI with an automatic sphygmomanometry~4. Skin Recoloration time at the foot"
214813534|NCT02723981|DEVICE|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
214813535|NCT02723981|DRUG|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
214813536|NCT02723981|DEVICE|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
214813537|NCT02723981|DRUG|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
214813538|NCT01665586|DRUG|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
214813539|NCT03251534|PROCEDURE|Centromedullary nailing|
214813540|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
214813541|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% \[3,18 \]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) \[41\]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
214813542|NCT05931315|DIETARY_SUPPLEMENT|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
214813543|NCT05931315|DIETARY_SUPPLEMENT|Placebo|One capsule to be taken immediately post-dinner / with dinner
214813544|NCT02615028|OTHER|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
214813545|NCT03037671|DEVICE|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
214813546|NCT06563011|OTHER|Counselling|Tailored Dietary Counselling
214813547|NCT00958451|DRUG|Paricalcitol|"1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
214813548|NCT00958451|DRUG|Ergocalciferol|"1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
214813549|NCT00477945|DRUG|clofarabine|"Cohort N Clofarabine (mg/m2/day)~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
214813550|NCT04294303|OTHER|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
214813551|NCT04294303|OTHER|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
214813552|NCT03450057|DRUG|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
214813553|NCT00933530|DRUG|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
214813554|NCT00933530|DRUG|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
214813555|NCT05721586|OTHER|Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR|The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR
214813556|NCT05721586|OTHER|Fluoride varnish (DURAFLOR|A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
214813557|NCT03024086|DRUG|DWJ1252|DWJ1252 and Placebo of Gasmotin
214813558|NCT03024086|DRUG|Gasmotin|Gasmotin and Placebo of DWJ1252
214813559|NCT01838941|DRUG|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children \> 30 kg, in 4 divided doses (3 g at meal time and bed time)."
214813560|NCT03584919|DRUG|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
214813561|NCT03584919|DRUG|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
214813562|NCT03584919|OTHER|control subjects|no intervention
214813563|NCT02822235|OTHER|No Intervention|
214813564|NCT01346735|OTHER|No intervention|
214813565|NCT03214952|DRUG|Vonoprazan|Vonoprazan tablets
214813566|NCT06067243|DIAGNOSTIC_TEST|T2 mapping 3T MRI + hip arthroscopy|"1. 3T MRI~2. hip arthroscopy"
214813567|NCT05365932|DEVICE|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
214813568|NCT00005785|DRUG|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
214813569|NCT03596294|DRUG|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
214813570|NCT03596294|DRUG|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
214813571|NCT03596294|OTHER|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
214813572|NCT05952544|DRUG|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
214813573|NCT05952544|OTHER|low protein diet|patients were on low protein diet only
214813574|NCT02968992|DRUG|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
214813575|NCT02968992|OTHER|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
214813576|NCT02056691|PROCEDURE|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
214813577|NCT02056691|PROCEDURE|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
214813578|NCT02246166|DRUG|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
214813579|NCT02246166|OTHER|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
214813580|NCT00000925|DRUG|Optimune oral nutritional supplement|
214813581|NCT04455139|DRUG|Topotecan|intravitreal or intra-arterial administration of topotecan
214813582|NCT04455139|DRUG|Melphalan|intravitreal or intra-arterial administration of topotecan
214813583|NCT01811758|BEHAVIORAL|Culturally Specific CBT|
214813584|NCT01811758|BEHAVIORAL|Standard CBT|
214813585|NCT01950715|DEVICE|sacral nerve stimulation|Sacral nerve stimulation
214813586|NCT02140580|DEVICE|Minimally invasive surfactant therapy|Active Comparator
214813587|NCT02140580|OTHER|Continuation on CPAP|Sham Comparator
214813588|NCT03144050|DEVICE|SFDI Imaging|Imaging with SFDI device
214813589|NCT04039334|OTHER|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
214813590|NCT04039334|OTHER|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
214813591|NCT03992222|DEVICE|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
214813592|NCT03769896|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
214813593|NCT03769896|DRUG|Placebo|capsule, corn starch, daily basis
214813594|NCT00938795|OTHER|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
214813595|NCT00938795|OTHER|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
214813596|NCT02603003|DRUG|JinFuKang|po.tid.30ml
214813597|NCT02603003|DRUG|Cisplatin|According to the individual patient's condition
214813598|NCT02603003|DRUG|Pemetrexed|According to the individual patient's condition
214813599|NCT05194059|BEHAVIORAL|Home-based physical activity|Participants will follow a personalized activity pacing program
214813600|NCT00268879|DRUG|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
214839851|NCT05550792|DEVICE|optimizer smart|The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
214813601|NCT04739475|PROCEDURE|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
214813602|NCT04927091|OTHER|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
214813605|NCT00974935|DRUG|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
214813606|NCT00974935|BIOLOGICAL|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
214813607|NCT05472350|DRUG|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
214813608|NCT05472350|OTHER|Placebo|placebo is 0.9% normal saline
214813609|NCT02200224|OTHER|Rapid Testing|
214813610|NCT02054117|OTHER|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
214813611|NCT01960920|OTHER|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
214813612|NCT01960920|OTHER|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
214813613|NCT01960920|OTHER|Clean air|No pollution and no filter mask
214813614|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
214813615|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
214813616|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
214813617|NCT01515592|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
214813618|NCT00377260|DRUG|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
214813619|NCT00377260|DRUG|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
214813620|NCT00490204|DRUG|Cetirizine|
214813621|NCT00829530|DRUG|Ramipril 10 mg capsule|1 x 10 mg
214813622|NCT00829530|DRUG|Altace® 10 mg capsule|1 x 10 mg
214813623|NCT02510118|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
214813624|NCT02510118|DRUG|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
214813625|NCT02510118|DRUG|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
214813626|NCT02510118|DRUG|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
214813627|NCT04354493|DEVICE|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
214813628|NCT00959153|DEVICE|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
214813629|NCT01320254|DRUG|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
214813630|NCT01320254|DRUG|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
214813631|NCT05839613|DIAGNOSTIC_TEST|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
214813632|NCT01200043|OTHER|fructose restriction diet|fruits and vegetables only
214813633|NCT00840866|DRUG|cefprozil|500 mg Tablet
214813634|NCT00840866|DRUG|Cefzil®|500 mg Tablet
214813635|NCT03804749|DRUG|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
214813636|NCT03804749|OTHER|placebo|Placebo is 0.9% sodium chloride injection.
214813637|NCT04343794|DEVICE|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
214813638|NCT05399446|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
214813639|NCT05399446|BEHAVIORAL|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
214813640|NCT01110122|DIETARY_SUPPLEMENT|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
214813641|NCT04112823|DRUG|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
214813642|NCT04112823|DRUG|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
214813643|NCT04373096|DEVICE|current IPAC-UHN PPE|"* Fit-tested N95 mask~* Open face shield~* Double extended-cuff"
214813644|NCT04373096|DEVICE|modified IPAC-UHN PPE|"* Fit-tested N95 mask~* Hood~* Double extended-cuff gloves"
214813645|NCT01260389|BEHAVIORAL|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
214813646|NCT06627010|OTHER|description|study of file
214813647|NCT01770938|DEVICE|Effective light-emitting diode therapy|
214813648|NCT01770938|DEVICE|Placebo light-emitting diode therapy|
214813649|NCT01410630|DIAGNOSTIC_TEST|FLT-PET/CT|Standard of Care
214813650|NCT01410630|DIAGNOSTIC_TEST|FDG-PET/CT|Standard of Care
214813651|NCT01410630|DRUG|FLT|5 mCi IV
214813652|NCT00625443|DRUG|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
214813653|NCT00625443|DRUG|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
214813654|NCT00625443|DRUG|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
214813655|NCT04327375|OTHER|Observational|Observational
214813656|NCT01437501|DRUG|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
214813657|NCT01437501|DRUG|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
214813658|NCT06197529|OTHER|Homeostatic Plasticity|Anodal tDCS S1/M1
214813659|NCT06197529|DRUG|Topical alone (Capsaicin 8% Patch)|4x4 patch
214813660|NCT06197529|OTHER|Placebo Patch|4x4 patch
214813661|NCT06197529|OTHER|Homeostatic Plasticity (Sham)|sham Homeostatic Plasticity protocol over S1
214813662|NCT01168557|DEVICE|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
214813663|NCT02742935|BIOLOGICAL|camrelizumab|A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)
214813664|NCT04121364|DEVICE|Tetranite|Dental Adhesive for increased implant stability
214813665|NCT01729377|OTHER|Interview|
214813666|NCT03169205|OTHER|observation registry|observation registry
214813667|NCT00223197|DRUG|Pregnenolone|
214813668|NCT05070611|DEVICE|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
214813669|NCT01846845|DEVICE|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
214813670|NCT01846845|DEVICE|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
214813671|NCT00165594|DRUG|E7070|
214813672|NCT01159132|DRUG|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
214813673|NCT00946166|DRUG|simvastatin|40 mg daily in the evening for a maximum of 14 days
214813674|NCT00946166|DRUG|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
214813675|NCT01386294|DRUG|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
214813676|NCT01386294|DRUG|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
214813677|NCT02678286|DRUG|N1539|
214813678|NCT02678286|DRUG|Intravenous Placebo|
214813679|NCT00280904|DEVICE|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
214813680|NCT03232372|DEVICE|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
214813681|NCT03232372|DEVICE|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
214813682|NCT03232372|DEVICE|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
214813683|NCT00234286|BEHAVIORAL|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
214813684|NCT01422538|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
214813685|NCT01422538|DRUG|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
214813686|NCT01422538|OTHER|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
214813687|NCT02220166|DIETARY_SUPPLEMENT|Triticum monococcum|
214813688|NCT02527278|PROCEDURE|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
214813689|NCT02527278|PROCEDURE|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
214813690|NCT02853162|RADIATION|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
214813691|NCT02697331|DRUG|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
214813692|NCT02697331|OTHER|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
214813693|NCT05412173|DRUG|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
214813694|NCT03214822|DIETARY_SUPPLEMENT|H2MF|As described in the Experimental Arm description.
214813695|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
214813696|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode|"Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam."
214813697|NCT05724810|DEVICE|Active deep transcranial magnetic stimulation (dTMS)|"First, the investigators will find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
214813698|NCT05724810|DEVICE|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
214813699|NCT04484493|DRUG|mometasone furoate nasal spray|dose of 2 puff in each nostril (100 µg once daily each nostril).
214813700|NCT03723395|DRUG|tucatinib|300mg dose, orally administered
214813701|NCT03723395|DRUG|itraconazole|200mg dose
214813702|NCT03723395|DRUG|rifampin|600mg dose
214813703|NCT03723395|DRUG|gemfibrozil|600mg tablets
214813704|NCT03723395|DRUG|repaglinide|1mg dose
214813705|NCT03723395|DRUG|tolbutamide|500mg dose
214813706|NCT03723395|DRUG|midazolam|2mg dose
214813707|NCT03723395|DRUG|digoxin|0.5 mg dose
214813708|NCT04337320|OTHER|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
214813709|NCT01841866|OTHER|LMA removal|
214813710|NCT02965326|PROCEDURE|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
214813711|NCT00381225|PROCEDURE|Ultra-sound guided radio-frequency ablation|
214813712|NCT03446248|DEVICE|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
214813713|NCT03446248|DEVICE|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
214813714|NCT00010205|DRUG|benzoylphenylurea|Given orally
214813715|NCT00010205|OTHER|pharmacological study|Correlative studies
214813716|NCT05253105|DRUG|TAB006|Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
214813717|NCT05253105|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
214813718|NCT01861262|DEVICE|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
214813719|NCT01789294|DRUG|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
214813720|NCT01789294|BEHAVIORAL|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
214813721|NCT04202874|PROCEDURE|Surgeon-administered transversus abdominis plane (TAP)|Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.
214813722|NCT04960163|OTHER|No intervention|No intervention
214813723|NCT02496416|BEHAVIORAL|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
214813724|NCT02496416|BEHAVIORAL|Stretching Program|The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
214813725|NCT03388203|DIAGNOSTIC_TEST|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
214813726|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214813727|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214813728|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214813729|NCT01278732|OTHER|no intervention performed|no intervention is performed
214813730|NCT04807374|DEVICE|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
214813731|NCT05223894|BIOLOGICAL|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
214813732|NCT05223894|OTHER|Control|Coronary artery bypass grafting surgery only.
214813733|NCT02062580|BIOLOGICAL|BCG|
214813734|NCT05267691|PROCEDURE|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
214813735|NCT05764980|BEHAVIORAL|visual function evaluation|visual function evaluation
214813736|NCT03173391|DRUG|HMS5552|BID Oral administration
214813737|NCT03173391|DRUG|Placebo|BID Oral administration
214813738|NCT03079765|BEHAVIORAL|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
214813739|NCT03079765|BEHAVIORAL|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
214813740|NCT05704426|DEVICE|Impulse Dynamics Optimizer Device|The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
214813741|NCT04624620|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
214813742|NCT02481830|DRUG|Nivolumab|
214813743|NCT02481830|DRUG|Topotecan|
214813744|NCT02481830|DRUG|Amrubicin|
214813745|NCT00290030|DRUG|Alfuzosin|
214813746|NCT04997122|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
214813747|NCT04997122|OTHER|High oleic acid sunflower oil|Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
214813748|NCT03678844|BEHAVIORAL|Taekwondo practice|The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
214813749|NCT03678844|OTHER|CONTROL|The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
214813750|NCT05858463|OTHER|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
214813751|NCT06420986|PROCEDURE|Open Hemorrhoidectomy|Surgical treatment of Hemorrhoids. Removal of hemorrohids leaving the wounds open. Surgical technique described by Milligan Morgan
214813752|NCT06420986|PROCEDURE|Transanal Hemorrhoidal Dearterialization|Surgical treatment of Hemorrhoids. This operation involves no excision. The hemorrhoidal arteries are ligated and the hemorrhoial prolapse is treated by a suture mucopexi. Described by Rato
214813753|NCT01747317|DEVICE|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
214813754|NCT04597463|PROCEDURE|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
214813755|NCT01464112|DRUG|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
214813756|NCT04627038|DRUG|LY3556050|LY3556050 Given orally
214813757|NCT04627038|DRUG|Placebo|Placebo Given orally
214813758|NCT05607264|OTHER|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
214813759|NCT05607264|OTHER|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
214813760|NCT05607264|OTHER|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
214813761|NCT03254771|OTHER|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
214813762|NCT04512092|BEHAVIORAL|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
214813763|NCT02061891|PROCEDURE|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
214813764|NCT02061891|PROCEDURE|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
214813765|NCT00783367|DRUG|Lenalidomide|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study
214813766|NCT00783367|DRUG|Dexamethasone|Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;
214813767|NCT00783367|DRUG|Rituximab|Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
214813768|NCT03921463|OTHER||This is an observational study
214813769|NCT04490941|OTHER|Ophthalmologist-delivered health education|The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
214813770|NCT04490941|OTHER|Usual care|Usual care follows standard procedure on diabetes management similar to the routine service provision.
214813771|NCT01773590|OTHER|Rhinovirus Infection|
214813772|NCT01591447|DRUG|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
214813773|NCT01591447|DRUG|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
214813774|NCT03407781|DRUG|68Ga-BBN-IRDye800CW|PET/NIR fluorescent imaging-guided surgery
214813775|NCT05088343|DRUG|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
214813776|NCT05088343|DRUG|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
214813777|NCT04920929|DEVICE|Hydrophilic Biomaterial|PICC made out of a Hydrophilic Biomaterial
214813778|NCT04920929|DEVICE|Thermoplastic Polyurethane|PICC made out of a thermoplastic polyurethane material
214813779|NCT02465320|DRUG|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
214813780|NCT02465320|DRUG|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
214813781|NCT03956862|DRUG|GB001|film-coated oral tablet
214813782|NCT03956862|DRUG|Placebo|film-coated oral tablet
214813783|NCT00040391|DRUG|Investigational drug|
214813784|NCT00040391|DRUG|Irinotecan|
214813785|NCT00040391|DRUG|5-fluorouracil|
214813786|NCT00040391|DRUG|Leucovorin|
214813787|NCT05732857|DEVICE|valveless trocar|the valveless trocar will be used instead of the standard trocar - these trocars are used for insufflation of carbon dioxide into the abdomen
214813788|NCT05732857|DEVICE|standard trocar|standard trocar, usually camera port for robotic surgery
214813789|NCT06627725|BEHAVIORAL|Patient-Family Communication|Patient-Family Communication
214813790|NCT05079425|DRUG|NXC736|Oral administration
214813791|NCT05079425|DRUG|Placebo|Oral administration
214813792|NCT06123130|DEVICE|Vectorcardiography (VECG)|Patients enrolled will undergo diagnostic ECG recording: three sets of simultaneous 30s recordings with the investigational device AIMIGo and a standard 12L ECG.
214813793|NCT02975622|PROCEDURE|Central venous catheterization|Ultrasound guided central venous catheterization
214813794|NCT00410774|BIOLOGICAL|bevacizumab|
214813795|NCT00410774|DRUG|gemcitabine hydrochloride|
214813796|NCT00410774|PROCEDURE|adjuvant therapy|
214813797|NCT04737486|DRUG|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
214813798|NCT04737486|OTHER|Placebo|D-PBS
214813799|NCT03974438|PROCEDURE|Superficial dry needling / Acupunture|Se arm-description.
214813800|NCT06317103|DEVICE|WADYMED endo|"Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)"
214813801|NCT06317103|OTHER|Control group (the endoscopists)|"Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists"
214813802|NCT01331187|PROCEDURE|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
214813803|NCT01331187|OTHER|Usual care|No intervention, except for usual care (goal-directed diagnostics)
214813804|NCT01363765|OTHER|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
214813805|NCT01363765|OTHER|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
214813806|NCT02451267|OTHER|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
214813807|NCT02451267|OTHER|physical therapy treatment|neck exercise strengthening program with neck massage
214813808|NCT02045563|OTHER|prise de sang|
214813809|NCT02045563|OTHER|magnetic resonance imaging and magnetic resonance spectroscopy|
214813810|NCT00422214|DRUG|Quetiapine fumarate (Seroquel) SR|
214813811|NCT01691456|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
214813812|NCT02086747|DRUG|Acetaminophen|100 ml iv, 4 times a day for 72 hours
214813813|NCT02086747|DRUG|Isotonic|100 ml iv, 4 times a day for 72 hours
214813814|NCT02527382|PROCEDURE|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
214813815|NCT03816072|DRUG|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
214813816|NCT03816072|OTHER|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).
214813817|NCT03816072|DRUG|Propofol|Propofol
214813818|NCT03816072|DRUG|Sevoflurane|Sevoflurane
214813819|NCT03502395|DRUG|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
214813820|NCT03502395|DRUG|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
214813821|NCT04055805|BEHAVIORAL|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
214813822|NCT04671368|DIAGNOSTIC_TEST|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
214813823|NCT04671368|DIAGNOSTIC_TEST|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
214813824|NCT04671368|DIAGNOSTIC_TEST|Gold Standard|Firstly, the two expert pathologist(\>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(\>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
214813825|NCT04889586|DEVICE|EMG-biofeedback armband (REMO)|After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
214813826|NCT00397787|DRUG|sunitinib malate|Given PO
214813827|NCT03553979|BEHAVIORAL|Stress management program (SM)|Participants follow the SM program.
214813828|NCT03553979|BEHAVIORAL|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
214813829|NCT05043103|COMBINATION_PRODUCT|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
214813830|NCT04822259|DEVICE|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
214813831|NCT04822259|DEVICE|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
214813832|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
214813833|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
214813834|NCT03023150|OTHER|Ischemic Preconditioning|
214813835|NCT03023150|OTHER|Sham|
214813836|NCT03180606|OTHER|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
214813837|NCT02967159|DRUG|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
214813838|NCT02967159|DRUG|AZD7594|Treatment B: AZD7594 440 μg via DPI
214813839|NCT02967159|DRUG|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
214813840|NCT02967159|DRUG|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
214813841|NCT02308722|RADIATION|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV\_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV\_R) 10Gy/# (total dose 50Gy)"
214813842|NCT06078072|PROCEDURE|Biomaterials augmented with mesenchymal stem/stromal cells|Combined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate)
214813843|NCT01938066|DEVICE|Procellera|bioelectric wound dressing
214813844|NCT01938066|DEVICE|negative pressure therapy|
214813845|NCT04228744|DEVICE|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
214813846|NCT03295474|OTHER|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
214813847|NCT06141317|BIOLOGICAL|PASC transplantation (25 million PASCs/patient)|3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
214813848|NCT06141317|BIOLOGICAL|Control|0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
214813849|NCT04018339|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
214813850|NCT04018339|DRUG|Placebo|Capsules containing an inert placebo
214813851|NCT02848924|OTHER|No intervention|
214813852|NCT02731534|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
214813853|NCT02731534|DRUG|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
214813854|NCT01123694|OTHER|Survey Study|Survey regarding quality of life
214813855|NCT00155545|BEHAVIORAL|Motion analysis of patients|
214813856|NCT01565876|DEVICE|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
214813857|NCT02601560|BIOLOGICAL|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
214813858|NCT02601560|BIOLOGICAL|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
214813859|NCT02601560|BIOLOGICAL|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
214813860|NCT04294108|OTHER|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
214813861|NCT02146495|DEVICE|Simultaneous EEG and fMRI recordings|
214813862|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial|Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology
214813863|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial|Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.
214813864|NCT01714570|DRUG|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
214813865|NCT01714570|DRUG|Imipenem|0.5g q6h, 5-10 days
214813866|NCT02563197|DEVICE|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
214813867|NCT02766075|BEHAVIORAL|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
214813868|NCT01295853|PROCEDURE|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
214813869|NCT01295853|PROCEDURE|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
214813870|NCT03262688|DRUG|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
214813871|NCT03262688|DRUG|Bupivacaine HCl infiltration|Infiltration of the surgical site
214813872|NCT03637153|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214813873|NCT03637153|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214813874|NCT03607032|DEVICE|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
214813875|NCT03607032|OTHER|usual treatment|medical aerosol session followed by aspiration or not, as required
214813876|NCT04836078|PROCEDURE|open flap subgingival debridement|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
214813877|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly
214813878|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly
214813879|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (III); injected subgingivally with placebo chitosan 2% gel weekly
214813880|NCT00359489|DEVICE|cardiac echosonography|
214813881|NCT03500692|DEVICE|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
214813882|NCT04913909|DIETARY_SUPPLEMENT|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
214813883|NCT00591643|PROCEDURE|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
214813884|NCT00591643|RADIATION|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
214813885|NCT04714268|PROCEDURE|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
214813886|NCT02822248|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-64-R84-070)
214813887|NCT02162069|DEVICE|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
214813888|NCT03066453|DRUG|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
214813889|NCT03066453|DRUG|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
214813890|NCT01376102|DRUG|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214813891|NCT05269381|DRUG|Cyclophosphamide|Given IV
214813892|NCT05269381|BIOLOGICAL|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
214813893|NCT05269381|BIOLOGICAL|Pembrolizumab|Given IV
214813894|NCT05269381|BIOLOGICAL|Sargramostim|Given SC
214813895|NCT04791670|OTHER|survey study|The surveys will include general data, the type of electronic devices in possession and the purpose of use. eHealth literacy will be assessed with the eHeals questionnaire. Platform's ease of use will be assessed with the System Usability Scale, and participants´ opinion about the digital path utility with six questions. These items will be answered with a Likert-scale. Finally, we added an open question for qualitative analysis.
214813896|NCT01880593|DRUG|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
214813897|NCT01880593|DRUG|Ketamine|
214813898|NCT01880593|DRUG|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
214813899|NCT04191993|DEVICE|Total hip arthroplasty|Surgical intervention designed to replace arthritic joint with artificial implant
214813900|NCT02272777|DRUG|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
214813901|NCT02272777|DRUG|Nilotinib|Nilotinib 300mg BID or 400mg QD
214813902|NCT02066922|DEVICE|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
214813903|NCT02066922|DEVICE|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
214813904|NCT02066922|DEVICE|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
214813905|NCT05275205|DRUG|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
214813906|NCT05275205|DRUG|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
214813907|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
214813908|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
214813909|NCT03338660|BIOLOGICAL|Placebo|Subjects will receive infusion placebo (saline).
214813910|NCT00440297|BIOLOGICAL|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
214813911|NCT00440297|BIOLOGICAL|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
214813912|NCT02058797|BEHAVIORAL|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
214813913|NCT02058797|BEHAVIORAL|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
214813914|NCT01397630|DRUG|Oxytocin|Accelerated Oxytocin Titration
214813915|NCT04181905|OTHER|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
214813916|NCT05539222|OTHER|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
214813917|NCT05675215|DIAGNOSTIC_TEST|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer \& Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks \& Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun \& Kempenaers, 2007)."
214813918|NCT01925092|DRUG|mifepristone|tablets
214813919|NCT05065229|DEVICE|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
214813920|NCT02934347|PROCEDURE|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
214813921|NCT00050297|DRUG|YM598|
214813922|NCT00431691|DRUG|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
214813923|NCT00431691|DRUG|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
214813924|NCT00431691|DRUG|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
214813925|NCT00431691|DRUG|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
214813926|NCT02686333|OTHER|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
214813927|NCT02039908|DRUG|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
214813928|NCT01833052|DEVICE|TAVI (Medtronic CoreValve)|
214813929|NCT01833052|DEVICE|Claret-Filter|
214813930|NCT03622138|OTHER|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
214813931|NCT07036328|DEVICE|repetitive transcranial magnetic stimulation|20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus
214813932|NCT07036328|DEVICE|sham repetitive transcranial magnetic stimulation|20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus
214813933|NCT07035977|RADIATION|Participants will receive a 1/6 views undersampling lung CBCT scan.|Participants will receive a 1/6 views undersampling lung CBCT scan. And the CBCT images will be reconstructed by DeepSparseCBCT model for further analysis.
214813934|NCT07037511|DRUG|Salbutamol|Meter-dose inhaler of salbutamol performed using large-volume spacer
214813935|NCT07037511|DRUG|Placebo|Meter-dose inhaler of placebo performed using large-volume spacer
214813936|NCT07037225|OTHER|Fluid challenge during one-lung ventilation (OLV) in the lateral decubitus position|During OLV, a lung recruitment maneuver will be performed, followed by measurements of CPI, CI, SVI, and MAP. A fluid challenge using 250 mL of normal saline (0.9% NaCl) will be administered. Hemodynamic parameters will be recorded at 2 and 5 minutes post-infusion. Patients will be classified as responders (SVI and MAP increase ≥10%) or non-responders. Changes in CPI will also be recorded accordingly.
214813937|NCT07037225|DEVICE|Hemodynamic monitoring|Invasive hemodynamic monitoring will be performed using the HemoSphere device (Edwards Lifesciences).
214813938|NCT06717750|DRUG|CSCJC3456 tablet|"* Phase Ia: Single and Multiple Dose Escalation.~  1. Dosage form: tablet.~ 2. Dosage: 7 dose groups, 5 mg, 15 mg, 30 mg, 45 mg, 60 mg, 80 mg, 100 mg.~ 3. Frequency: once daily (tentative), or twice daily and other options (adjusted based on the results of the preliminary trials).~ 4. Duration: 5 mg(days 1-28; 28 days per cycle), other groups (days 1-14; 21 days per cycle) .~* Phase Ib: Cohort Expansion. Dosage and dosing regimen: according to the recommended dosage and dosing cycle from the Phase Ia study."
214813939|NCT03309709|DRUG|subcutaneous progesterone|25mg daily for 7 days
214813940|NCT01802320|DRUG|Akt Inhibitor MK2206|Given PO
214813941|NCT01802320|OTHER|Laboratory Biomarker Analysis|Correlative studies
214813942|NCT01802320|OTHER|Pharmacological Study|Correlative studies
214813943|NCT01256892|PROCEDURE|induction of labour|
214813944|NCT04475861|DIETARY_SUPPLEMENT|L-arginine supplements and nutritional supports|The enrolled subjects will then be randomized into two groups. The subjects will receive either L-arginine (the study group) or another amino acid supplement (the control group), with 60 patients in each group. All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
214813945|NCT04201353|BEHAVIORAL|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
214813946|NCT04690881|BEHAVIORAL|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
214813947|NCT01832350|DRUG|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
214813948|NCT01066143|DRUG|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
214813949|NCT05162664|OTHER|Pressure pain thresholds|PPT will be performed firstly at the anterior tibial muscle halfway between the most superior attachment to the tibia and its tendon in the upper one third of the muscle belly (13) and secondly at the middle of the temporalis muscle (12), using a digital algometer (Wagner FPX 50) with a 1 cm2 rubber tip. The pressure algometer will apply a perpendicular increasing pressure (1kg/s) at the different test locations until the participant reports the first feeling of pain. The PPT of 4 series of ascending stimulus intensities, with an inter-stimulus interval (ISI) of 20sec between the different stimuli and an ISI of 60sec between the 2 locations, will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated.
214813950|NCT05162664|OTHER|Thermal detection and pain thresholds|The thermal tests will be performed unilateral at tibial anterior, thenar and the forehead, using a TSA-2 (Neuro Sensory Analyzer, MEDOC). At first cold and heat detection thresholds will be measured. The patient will be asked to indicate when they feel a change in temperature. Afterwards the patient will be asked to indicate when the stimulus becomes painful to determine the cold and heat pain thresholds. The thresholds of 4 series of stimuli will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated for every location. The subject will push a button when the thresholds are reached. The baseline temperature will be 32°C and the stimuli will increase with 1°C/s (14).
214813951|NCT05162664|OTHER|Temporal summation|The temporal summation will be assessed at the thenar eminence (19,20) using a ramp and hold protocol with the TSA-2 (Neuro Sensory Analyzer, MEDOC). Heat stimuli will be applied for a duration of 15sec. The stimulus temperature will increase from a baseline temperature of 35°C for 9sec at a sensitivity-adjusted rate of about 1,5°C/s until the HTP 5/10 of the thenar is reached. Afterwards the temperature will remain steady for the next 6 seconds. The maximal pain rating should be 50 ± 10 NRS. Subjects rate the pain intensity at the end of the ramp (9sec) and at the end of the hold procedure (15sec) using the NRS. Afterwards the ramp and hold aftersensations are measured. The subjects have to rate the pain intensity every 5sec for 30sec after the termination of the heat stimulus.
214813952|NCT05162664|OTHER|Conditioned pain modulation|CPM will be assessed by comparing heat pain thresholds and pressure pain thresholds before and after giving a conditioning stimulus at a pain free distant zone by using a second thermode of the TSA-2 (17). The conditioning stimulus (HPT 4/10 (18) at the TA) will be applied for 120 seconds. The first test stimulus will be applied at the forehead 30 seconds after the start of the conditioning stimulus (17). The HPT will be measured twice with an ISI of 20 seconds. Immediately after the end of the application of the conditioning stimulus (120 seconds), the HPT at the forehead will be measured again twice, with an ISI of 20 seconds. Afterwards, there will be 10 minutes of rest to avoid bias.
214813953|NCT00520988|BEHAVIORAL|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
214813954|NCT00804960|DRUG|Letrozole|1\) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
214813955|NCT00804960|DRUG|Std IVF Protocol|2\) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
214813956|NCT04192162|OTHER|Mud therapy application|Aplication the mud pack therapy from 20 minutes
214813957|NCT04192162|OTHER|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
214813958|NCT04192162|OTHER|Hygienic water|Exercise in hygienic water
214813959|NCT06219044|PROCEDURE|laparoscopic endometrioma laser vaporization|laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
214813960|NCT06071299|BEHAVIORAL|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
214813961|NCT06071299|BEHAVIORAL|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
214813962|NCT05376319|DRUG|Obinutuzumab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
214813963|NCT05376319|DRUG|Rituximab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
214813964|NCT03421717|DEVICE|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
214813965|NCT06017635|OTHER|Exposure factors|"1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
214813966|NCT00942968|DRUG|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
214813967|NCT06558981|RADIATION|Radiotherapy|Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
214813968|NCT06558981|OTHER|radioiodine treatment|RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
214813969|NCT02856347|OTHER|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
214813970|NCT03405454|DRUG|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
214813971|NCT03405454|DRUG|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
214813972|NCT01686451|DRUG|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
214813973|NCT01686451|DRUG|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
214813974|NCT02470247|OTHER|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
214813975|NCT02470247|OTHER|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
214813976|NCT01466166|BIOLOGICAL|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
214813977|NCT03733158|DEVICE|the standard Bougie stylet for difficult intubation|intubation with the standard Bougie stylet for difficult intubation and endotracheal tube 7.0 internal diameter
214813978|NCT03733158|DEVICE|The new Flexible Tip Bougie catheter|intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
214813979|NCT00834535|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
214813980|NCT00834535|DRUG|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
214813981|NCT01163435|DRUG|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
214813982|NCT01163435|DRUG|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
214813983|NCT01163435|DRUG|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
214813984|NCT01163435|DRUG|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
214813985|NCT05302128|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
214813986|NCT02681939|DRUG|Tulsi(Ocimum sanctum Linn.) capsules|
214813987|NCT01340495|RADIATION|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
214813988|NCT04621552|DEVICE|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
214813989|NCT05996926|DIAGNOSTIC_TEST|Three-Dimensional Transvaginal Ultrasound (3D TVS)|"In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~Procedure: A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches."
214813990|NCT05996926|DIAGNOSTIC_TEST|Saline-Infused Sonography (Sonohystrography)|The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
214813991|NCT05883215|OTHER|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
214813992|NCT05883215|OTHER|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
214813993|NCT05883215|OTHER|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
214813994|NCT05883215|OTHER|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
214813995|NCT02055963|DRUG|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
214813996|NCT02055963|DRUG|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
214813997|NCT02055963|BEHAVIORAL|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
214813998|NCT01268787|BIOLOGICAL|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
214813999|NCT02131363|DEVICE|Ingrowing Toenail Treatment Kit|detailed in arm description
214814000|NCT01762605|OTHER|Supportive Care|
214814001|NCT01762605|PROCEDURE|Cast|
214814002|NCT06092125|DEVICE|PET/MR|PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
214814003|NCT06413290|OTHER|PIFP block group|Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery
214814004|NCT06413290|OTHER|Control group|No intervention
214814005|NCT02273622|DIETARY_SUPPLEMENT|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
214814006|NCT02273622|DIETARY_SUPPLEMENT|placebo|
214814007|NCT00812266|DRUG|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
214814008|NCT00812266|DRUG|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
214814009|NCT06036082|OTHER|Conventional physical therapy|"* Standing with feet together .~* Step standing .~* High step standing and trying to keep balanced.~* Single leg stance unilateral standing with assistance.~* Standing on a declined surface by using wedge.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
214814010|NCT00667862|DRUG|Panobinostat|
214814011|NCT06054581|BEHAVIORAL|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
214814012|NCT01819597|PROCEDURE|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
214814013|NCT02495857|DEVICE|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
214814014|NCT02495857|DEVICE|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
214814015|NCT02495857|DEVICE|Placebo|0.9% sodium chloride, sterile
214814016|NCT04816838|DRUG|Osimertinib|"\* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~\- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)"
214814017|NCT04905017|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricusupid valve using Trisol System in a transcatheter approach
214814018|NCT03439982|BIOLOGICAL|FMT|FMT processed from routinely screened donors
214814019|NCT01253590|BEHAVIORAL|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
214814020|NCT05229445|DEVICE|continuous glucose monitor based insulin bolus calculator|Participants will use the bolus calculator with meals to calculate their insulin bolus doses
214814021|NCT03518905|DEVICE|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
214814022|NCT03518905|PROCEDURE|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
214814023|NCT03821545|OTHER|Lidocaine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
214814024|NCT03821545|OTHER|Ketamine|Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
214814025|NCT03821545|OTHER|Lidocaine and Ketamine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
214814026|NCT03821545|OTHER|Placebo (0.9% NaCl)|Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
214814027|NCT02010320|OTHER|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
214814028|NCT02010320|OTHER|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
214814029|NCT00654030|DRUG|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
214814030|NCT05886101|BEHAVIORAL|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
214814031|NCT03301948|OTHER|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
214814032|NCT03301948|OTHER|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
214814033|NCT01435265|BEHAVIORAL|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
214814034|NCT01435265|BEHAVIORAL|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
214814035|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferal|400 IU/day
214814036|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferol|800 IU/day D3
214814037|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with \>= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves \> 60% of mucosa and extends to the lower third of mucosa."
214814038|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R\&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
214814039|NCT05238181|DIAGNOSTIC_TEST|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
214814040|NCT01082926|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given intratumorally
214814041|NCT01082926|BIOLOGICAL|aldesleukin|Given intratumorally
214814042|NCT01082926|OTHER|laboratory biomarker analysis|Optional correlative studies
214814043|NCT01082926|PROCEDURE|positron emission tomography|Optional correlative studies
214814044|NCT03396120|DIAGNOSTIC_TEST|Pulmonary function test|forced vital capacity and diffusing capacity
214814045|NCT04605094|BIOLOGICAL|Benralizumab|Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
214814046|NCT04605094|BIOLOGICAL|Placebo / Benralizumab|Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
214814047|NCT06200220|DRUG|Venetoclax|Observational study
214814048|NCT02724462|BEHAVIORAL|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
214814049|NCT02724462|BEHAVIORAL|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
214814050|NCT01900691|DEVICE|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
214814051|NCT04113265|DEVICE|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
214814052|NCT00979303|DEVICE|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
214814053|NCT06391606|DIETARY_SUPPLEMENT|Coenzyme Q10|2 pills/day of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)
214814054|NCT06391606|OTHER|Placebo|2 pills/day
214814055|NCT00891800|DEVICE|Brachytherapy|SIR-Sphere contains radiation of Y-90.
214814056|NCT00891800|DEVICE|SIR-Sphere|Brachytherapy Radiation seeds
214814057|NCT06378242|DRUG|Disitamab Vedotin for injection|Intravesical instiliations into the bladder
214814058|NCT00242970|DEVICE|3-Dimensional Color Scanning|Color imaging of the face and neck.
214814059|NCT04403997|PROCEDURE|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
214814060|NCT04111263|DIETARY_SUPPLEMENT|FP|Fiber and polyphenol blend
214814061|NCT04111263|DIETARY_SUPPLEMENT|Placebo|Matched placebo
214814062|NCT04111263|OTHER|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
214814063|NCT04111263|OTHER|Sea level|Sea level environment in altitude chamber
214814064|NCT01975623|DEVICE|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
214814065|NCT01026623|BIOLOGICAL|Cixutumumab|Given IV
214814066|NCT01026623|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214814067|NCT01026623|DRUG|Temsirolimus|Given IV
214814068|NCT06560515|DRUG|Vaginal Dinoprostone|induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
214814069|NCT00008515|DRUG|Fluocinolone|
214814070|NCT03481998|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214814071|NCT03481998|DRUG|Letrozole or anastrozole or Fulvestrant|Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
214814072|NCT03423680|DRUG|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
214814073|NCT03423680|DRUG|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
214814074|NCT06020924|OTHER|No intervention|This study is a retrospective observational study without intervention.
214814075|NCT03548519|BEHAVIORAL|OCAT-only|online-contingent Attention Training without prior psychoeducation
214814076|NCT03548519|BEHAVIORAL|OCAT-sham|Placebo version of Online contingent Attention Training without prior psychoeducation
214814077|NCT03548519|BEHAVIORAL|OCAT-combo|Online contingent Attention Training with prior psychoeducation
214814078|NCT03169595|PROCEDURE|Surgery|Patients affected by epithelioid hemangioma treated with surgery
214814079|NCT04847323|DEVICE|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
214814080|NCT04847323|DEVICE|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
214814081|NCT02035306|OTHER|non invasive co-oximetry haemaglobin measurement|
214814082|NCT06000709|DRUG|6% aqueous phenol|1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
214814083|NCT06000709|DRUG|MethylPREDNISolone 40 MG|40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance
214814084|NCT06000709|DRUG|Intraarticular Knee Placebo|Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
214814085|NCT06000709|DRUG|Genicular Nerve Placebo|1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
214814086|NCT04794283|OTHER|Breast milk|Milk substitute given during the first 24h
214814087|NCT05105945|PROCEDURE|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
214814088|NCT05105945|PROCEDURE|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
214814089|NCT05796869|BEHAVIORAL|Assigned Interventions|The laughter therapy session will be administered to the application group face to face for 25-30 minutes once a week for 2 months by a researcher with a laughter therapy certificate. In the laughter therapy session, introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, maintaining the rhythm with music, turning laughter that starts like a child's play into reality and meditation practices will be carried out.
214814090|NCT00054301|PROCEDURE|adjuvant therapy|
214814091|NCT00054301|PROCEDURE|conventional surgery|Patients undergo excisional biopsy or surgery.
214814092|NCT00054301|RADIATION|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
214814093|NCT02584439|DRUG|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
214814094|NCT02584439|DRUG|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
214814095|NCT00770822|DEVICE|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
214814096|NCT00770822|DEVICE|Brachytherapy|Standard of care
214814097|NCT00184522|DRUG|Aflurax|
214814098|NCT00184522|DRUG|esomeprazole|
214814099|NCT01644058|PROCEDURE|Immediate loading|
214814100|NCT06392438|DRUG|CycloSPORINE Ophthalmic|Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
214814101|NCT06392438|PROCEDURE|Intense Pulsed Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
214814102|NCT06392438|PROCEDURE|Sham Intense Pulse Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
214814103|NCT04721795|DRUG|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
214814104|NCT04721795|DRUG|Standard anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
214814105|NCT00530725|PROCEDURE|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
214814106|NCT00530725|OTHER|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
214814107|NCT00944424|DRUG|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
214814108|NCT00944424|DRUG|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
214814109|NCT00561834|DRUG|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
214814110|NCT05609539|DEVICE|Endovascular Aortic Repair (EVAR)|"Techniques for delivery and deployment of the standard device have been well described by different papers, but for the prototype some attention is required.~Once the device was advanced at the level of the lowest RA the C-Arm has been moved to correct the parallax effect and positioned orthogonally to the origin of the artery. This procedure permits perfectly matching the scallop with the artery takeoff.~A selective angiogram was performed to assure the patency of the lower RA. After the deployment of the main body proper iliac extensions were delivered to completely exclude the aneurysm as standard practice."
214814111|NCT05001022|DRUG|ALG-020572|Single or multiple doses of ALG-020572
214814112|NCT05001022|DRUG|Placebo|Single or multiple doses of Placebo
214814113|NCT05648721|OTHER|Datos mobile health application|The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.
214814114|NCT05648721|OTHER|Regular follow-up|Regular follow-up according to the local clinic protocol
214814115|NCT06376656|BEHAVIORAL|Cognitive stimulation|"The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions."
214814116|NCT06376656|BEHAVIORAL|Physical activity|"The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period."
214814117|NCT05290961|OTHER||The study is an observational trial, which don't have any intervention.
214814118|NCT06225609|PROCEDURE|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
214814119|NCT06225609|PROCEDURE|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
214814120|NCT02128997|DEVICE|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
214814121|NCT01419093|OTHER|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
214814122|NCT03644693|DIETARY_SUPPLEMENT|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
214814123|NCT03644693|DIETARY_SUPPLEMENT|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
214814124|NCT00520923|DRUG|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
214814125|NCT00520923|DRUG|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
214814126|NCT00520923|DRUG|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
214814127|NCT00520923|DRUG|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
214814128|NCT00520923|DRUG|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
214814129|NCT00520923|DRUG|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
214814130|NCT00520923|DRUG|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
214814131|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
214814132|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
214814133|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
214814134|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
214814135|NCT01969747|DRUG|Empagliflozin medium|Empagliflozin medium
214814136|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
214814137|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
214814138|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
214814139|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
214814140|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
214814141|NCT01969747|DRUG|Empagliflozin low|Empagliflozin low
214814142|NCT01969747|DRUG|Empagliflozin high|Empagliflozin high
214814143|NCT06380023|DEVICE|Enclosure barrier|Surgical mask \& Enclosure tent compared with open suction
214814144|NCT02061917|OTHER|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
214814145|NCT02061917|OTHER|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
214814146|NCT02061917|OTHER|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
214814147|NCT06009471|OTHER|Routine treatment in Neurology|Routine treatment in Neurology department, including drug treatment,etc.
214814148|NCT06009471|DEVICE|Routine treatment in Neurology and rTMS|Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
214814149|NCT06110377|PROCEDURE|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
214814150|NCT06110377|PROCEDURE|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
214814151|NCT01232647|DRUG|Phylloquinone|1.0 mg daily of vitamin K1
214814152|NCT01232647|DRUG|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
214814153|NCT01232647|DRUG|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
214814154|NCT03430869|DRUG|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
214814155|NCT03430869|DRUG|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
214814156|NCT00651586|DRUG|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
214814157|NCT00651586|DRUG|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
214814158|NCT02372266|OTHER|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
214814159|NCT02372266|OTHER|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
214814160|NCT03125135|DEVICE|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
214814161|NCT02987439|OTHER|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
214814162|NCT02659358|DEVICE|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
214814163|NCT02393417|BIOLOGICAL|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
214814164|NCT02393417|OTHER|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
214814165|NCT00725517|DRUG|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
214814166|NCT02203058|OTHER|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
214814167|NCT02203058|OTHER|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
214814168|NCT01305018|DIETARY_SUPPLEMENT|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
214814169|NCT01305018|DIETARY_SUPPLEMENT|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
214814170|NCT01305018|DIETARY_SUPPLEMENT|Placebo|14 g of alanine per day during 9 days
214814171|NCT00264394|BEHAVIORAL|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
214814172|NCT00264394|BEHAVIORAL|Guidelines|provision of guidelines for CHD risk factor management only
214814173|NCT00002062|DRUG|Spiramycin|
214814174|NCT03394235|DEVICE|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
214814175|NCT02422264|BIOLOGICAL|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
214814176|NCT02422264|DRUG|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
214814177|NCT06558864|PROCEDURE|Subiculum RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform Subiculum RF-TC.
214814178|NCT05291702|PROCEDURE|PCNL|Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
214814179|NCT03475303|BEHAVIORAL|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
214814180|NCT04444479|OTHER|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
214814181|NCT04444479|OTHER|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
214814182|NCT00603187|DRUG|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
214814183|NCT02386618|PROCEDURE|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
214814184|NCT01203332|BEHAVIORAL|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
214814185|NCT01543217|OTHER|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
214814186|NCT01543217|OTHER|Ususal care|Routine respiratory care.
214814187|NCT01503736|DRUG|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
214814188|NCT01503736|DRUG|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
214814189|NCT01503736|DRUG|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
214814190|NCT00025818|DRUG|Ophthalmic Emulsion|
214814191|NCT05364853|BEHAVIORAL|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
214814192|NCT05364853|BEHAVIORAL|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
214814193|NCT00859534|DRUG|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
214814194|NCT03874715|DRUG|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
214814195|NCT03874715|DRUG|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
214814196|NCT03874715|DRUG|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
214814197|NCT04904120|DRUG|[203Pb]VMT01|Diagnostic imaging radiopharmaceutical; by intravenous infusion
214814198|NCT04904120|DRUG|[68Ga]VMT02|Diagnostic imaging radiopharmaceutical; by intravenous infusion
214814199|NCT00273026|DRUG|salmeterol xinafoate/fluticasone propionate|
214814200|NCT00875550|DRUG|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
214814201|NCT00875550|DRUG|Midazolam|Rescue medication for sedation according to UMSS scores
214814202|NCT00875550|DRUG|Fentanyl|Rescue medication for pain based on UMSS scores
214814203|NCT00875550|DRUG|Morphine|Rescue medication for pain based on UMSS scores.
214814204|NCT05217524|DEVICE|Galaxy BIA watch|Digital multifunction watch
214814205|NCT02344732|DRUG|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
214814206|NCT02344732|DRUG|Homatropine 2% eye drops thrice daily|
214814207|NCT02344732|DRUG|Oxygen gas|
214814208|NCT05971420|OTHER|VR activity-based|VR games activities were chosen for simulated cognitive-motor training in the VR group. The VR training modules for this study included fire drill, walking exercise, balancing game activities and community shopping practices. These training modules involved dual task components; the participant was expected to train up his/her physical and cognitive motor performances in an 8-week VR activity-based program. VR group participants received 2-sessions per week, 16 training sessions in total.
214814209|NCT05971420|OTHER|Exercise-based (Baduanjin)|The exercise group used a traditional Chinese Qigong Baduanjin exercise incorporating with a fall prevention education strategy.
214814210|NCT02648074|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
214814211|NCT02648074|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
214814212|NCT02656368|DEVICE|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
214814213|NCT00186355|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
214814214|NCT05115123|DRUG|Duloxetine|60 mg duloxetine
214814215|NCT05115123|DRUG|Placebo|Placebo
214814216|NCT00769964|DRUG|VA111913 TS / placebo|
214814217|NCT03590808|BIOLOGICAL|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
214814218|NCT01273350|DEVICE|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
214814219|NCT04074655|DEVICE|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
214814220|NCT00045422|BIOLOGICAL|recombinant interferon alfa|
214814221|NCT00045422|DRUG|imatinib mesylate|
214814222|NCT01880853|OTHER|mammography|participants were screened by mammography alone every year
214814223|NCT01880853|OTHER|ultrasound|participants were screened by ultrasound alone every year
214814224|NCT01880853|OTHER|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
214814225|NCT06395194|DRUG|Cardiac outcomes on treatment with valsartan|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
214814226|NCT06395194|DRUG|Cardiac outcomes on treatment with amlodipine|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
214814227|NCT02527109|DRUG|Nifedipine|
214814228|NCT01826058|RADIATION|Stereotactic body radiation therapy|
214814229|NCT06515054|BEHAVIORAL|wall squat|self-learnt wall squat exercise to be conducted for totally 24 weeks
214814230|NCT06515054|BEHAVIORAL|passive stretching|time-matched passive stretching exercise to be conducted for totally 24 weeks
214814231|NCT00851877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
214814232|NCT00851877|DRUG|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
214814233|NCT00851877|DRUG|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
214814234|NCT00851877|RADIATION|intensity-modulated radiation therapy|intensity-modulated radiation therapy
214814235|NCT00836667|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
214814236|NCT00836667|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
214814237|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
214814238|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
214814239|NCT05457231|OTHER|specific feedback based on an in-depth assessment tool for communication skills training|In addition to the specific feedback based on an in-depth assessment tool, four strategies modified from common strategies in the previous studies were incorporated into the intervention protocol, including lecture, patient interview, brief feedback, and self-reflection
214814240|NCT06558669|OTHER|Fresh Sugarcane juice|Fresh sugarcane juice in different doses will be given to liver patients for 90 days
214814241|NCT03977272|DRUG|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
214814242|NCT03977272|DRUG|Chemotherapy|modified-FOLFIRINOX
214814243|NCT06502340|DIAGNOSTIC_TEST|high sensitive troponin I|high-sensitive Troponin I levels
214814244|NCT05402358|OTHER|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
214814245|NCT04102319|DIAGNOSTIC_TEST|serum hepcidin|it is a serum marker
214814246|NCT02412384|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
214814247|NCT02412384|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
214814248|NCT06199219|OTHER|Sexual counseling, based on the extended (EX-PLISSIT)|"The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved (Taylor and Davis 2006; Punjani and Papathanasoglu, 2019)."
214814249|NCT05458583|PROCEDURE|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
214814250|NCT05458583|PROCEDURE|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
214814251|NCT05458583|PROCEDURE|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
214814252|NCT05458583|PROCEDURE|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
214814253|NCT04093245|BEHAVIORAL|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
214814254|NCT04093245|BEHAVIORAL|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
214814255|NCT04093245|BEHAVIORAL|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
214814256|NCT04093245|BEHAVIORAL|medical follow-up appointment|a planned follow-up appointment with their family physician
214814257|NCT04093245|BEHAVIORAL|follow-up phone call|a systematic follow-up phone call for discharged patients
214814258|NCT04093245|OTHER|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
214814259|NCT04093245|OTHER|Telemonitoring service|access to a community-based telemonitoring service
215031300|NCT02692027|OTHER|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
215031301|NCT00319007|DRUG|Sulindac (drug)|
214814260|NCT02753231|BEHAVIORAL|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214814261|NCT02753231|BEHAVIORAL|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214814262|NCT02753231|BEHAVIORAL|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214814263|NCT02753231|BEHAVIORAL|Conventional physical activity program|One Physical Education sessions / week
214814264|NCT03114748|OTHER|EEG|
214814265|NCT03114748|OTHER|DBS switched OFF and ON|
214814266|NCT00573066|DRUG|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
214814267|NCT01034358|BIOLOGICAL|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
214814268|NCT04574219|OTHER|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
214814269|NCT02473718|OTHER|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
214814270|NCT02473718|DEVICE|Ultrasound|
214814271|NCT05332002|DRUG|Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)|"This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric"
214814272|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5mL oral dose
214814273|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
214814274|NCT02950805|DRUG|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
214814275|NCT02950805|DRUG|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
214814276|NCT03701594|OTHER|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
214814277|NCT03701594|OTHER|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
214814278|NCT03701594|OTHER|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
214814279|NCT02350231|DRUG|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
214814280|NCT02350231|DRUG|Tonics group|Those patients will receive only tonics
214814281|NCT05278221|DEVICE|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
214814282|NCT01526694|DRUG|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
214814283|NCT01526694|DRUG|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
214814284|NCT01526694|DRUG|Dexamethasone|It's a corticosteroid.
214814285|NCT02069080|DRUG|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
214814286|NCT02430272|DRUG|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
215031302|NCT00319007|DRUG|VSL#3 (probiotic)|
215031303|NCT00319007|DRUG|Inulin (probiotic)|
215031304|NCT01048957|BEHAVIORAL|Real Time Feedback Training|
214814287|NCT06486623|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
214814288|NCT06486623|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
214814289|NCT03992118|BEHAVIORAL|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
214814290|NCT05643911|PROCEDURE|HFNC|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes.
214814291|NCT05643911|PROCEDURE|NIV|Patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance.
214814292|NCT04882163|DRUG|CC-220|CC-220
214814293|NCT04882163|DRUG|Polatuzumab vedotin|Polatuzumab vedotin
214814294|NCT04882163|DRUG|Rituximab|Rituximab
214814295|NCT04882163|DRUG|Tafasitamab|Tafasitamab
214814296|NCT04882163|DRUG|Gemcitabine|Gemcitabine
214814297|NCT04882163|DRUG|Cisplatin|Cisplatin
214814298|NCT04882163|DRUG|Dexamethasone|Dexamethasone
214814299|NCT04882163|DRUG|Bendamustine|Bendamustine
214814300|NCT04882163|DRUG|Lenalidomide|Lenalidomide
214814301|NCT03190239|DRUG|Apatinib|Apatinib 250mg qd
214814302|NCT03190239|DRUG|Pemetrexed|Pemetrexed 500mg/m2 qm
214814303|NCT01534663|DRUG|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
214814304|NCT01534663|DRUG|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
214814305|NCT02598063|DRUG|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
214814306|NCT02598063|DRUG|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
214814307|NCT02598063|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
214814308|NCT00627016|DRUG|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
214814309|NCT00627016|DRUG|Placebo|1 capsule, orally, once daily for 4 weeks
214814310|NCT06411847|BEHAVIORAL|Virtual appointments|This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
214814311|NCT05402137|BEHAVIORAL|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
214814312|NCT05620511|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
214814313|NCT04476511|DRUG|Cholecalciferol|tablet containing 30.000IU cholecalciferol
214814314|NCT04480983|DEVICE|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
214814315|NCT00295477|GENETIC|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
214814316|NCT00052377|BIOLOGICAL|aldesleukin|Given SC
214814317|NCT00052377|BIOLOGICAL|recombinant interleukin-12|Given SC
214814318|NCT00052377|OTHER|laboratory biomarker analysis|Correlative studies
215031305|NCT06218602|DRUG|Fecal Microbiota Transplantation|Given by PO
215031306|NCT06218602|PROCEDURE|Chemotherapy|Given by Infusion
214814319|NCT06203951|DIAGNOSTIC_TEST|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
214814320|NCT04767347|OTHER|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
214814321|NCT04767347|OTHER|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
214814322|NCT04767347|OTHER|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
214814323|NCT04767347|OTHER|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
214814324|NCT04767347|OTHER|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
214814325|NCT04767347|OTHER|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
214814326|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
214814327|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
214814328|NCT05999253|PROCEDURE|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia."
214814329|NCT05999253|PROCEDURE|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia"
214814330|NCT02565160|PROCEDURE|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
214814331|NCT02565160|PROCEDURE|Joint irrigation washout|Procedural washout for treatment purposes
214814332|NCT02565160|PROCEDURE|Total Joint Arthroplasty|
214814333|NCT02565160|PROCEDURE|Revision Joint Arthroplasty|
214814334|NCT03107091|DRUG|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
214814335|NCT05464394|DRUG|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
214814336|NCT05464394|DRUG|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
214814337|NCT05266313|BEHAVIORAL|Oncosexology program|Thematic workshops throughout the year
214814338|NCT03786341|DEVICE|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
214814339|NCT03839719|PROCEDURE|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
214814340|NCT03839719|PROCEDURE|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
214814341|NCT03839719|PROCEDURE|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
214814342|NCT05579535|OTHER|gait training exercises|walking exercises in different directions
214814343|NCT04277403|RADIATION|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
214814344|NCT04277403|RADIATION|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
214814345|NCT00949143|OTHER|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
214814346|NCT00949143|OTHER|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
214814347|NCT02069535|BIOLOGICAL|AVANZ Cupressus|AVANZ Cupressus
214814348|NCT05507619|OTHER|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
214814349|NCT05507619|OTHER|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
214814350|NCT02778230|DIETARY_SUPPLEMENT|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
214814351|NCT02778230|DIETARY_SUPPLEMENT|Control|Snacks (2 baked goods) without fiber fortification.
214814352|NCT04567186|DEVICE|Investigational senofilcon A C3 Multifocal Lens|TEST
214814353|NCT04567186|DEVICE|delefilcon A Multifocal Lens|Dailies Total 1® Multifocal Contact Lens
214814354|NCT05451446|DIETARY_SUPPLEMENT|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
214814355|NCT05451446|OTHER|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
214814356|NCT05451446|OTHER|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
214814357|NCT05506280|PROCEDURE|blood prolactin levels|The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
214814358|NCT03095846|PROCEDURE|Cooling|Individualized cooling protocol
214814359|NCT04161365|PROCEDURE|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
214814360|NCT04161365|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
214814361|NCT01707420|DRUG|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
214814362|NCT01707420|DRUG|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
214814363|NCT06189274|OTHER|Anatomy-Based Electrode Array Selection|Use of pre-operative imaging to select the appropriate length electrode vs standard of care
214814364|NCT06189274|OTHER|Standard of Care Electrode Array Selection|Use of standard of care electrode which is the FLEX 28 electrode
214814365|NCT03124420|DRUG|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
214814366|NCT03124420|DRUG|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
214814367|NCT03124420|DRUG|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
214814368|NCT04277026|BEHAVIORAL|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
214814369|NCT06349967|DRUG|Nab-paclitaxel Combined With Cadonilimab (AK104)|Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
214814370|NCT02293668|DRUG|FSH 225IU and hMG 225IU|
214814371|NCT02293668|DRUG|FSH 150IU and hMG 150IU|
214814372|NCT02293668|DRUG|Letrozole 5mg and hMG 150IU|
214814373|NCT02175238|DRUG|BI 691751 fasted|single dose BI 691751 in fasted state
214814374|NCT02175238|DRUG|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
214814375|NCT03586700|DRUG|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
214814376|NCT03586700|RADIATION|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
215031307|NCT06218602|PROCEDURE|CAR-T Therapy|Given by Infusion
214814377|NCT03586700|DRUG|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
214814378|NCT03885362|DEVICE|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
214814379|NCT06095076|DIAGNOSTIC_TEST|Skin swabbing|Skin swabbing will be performed on CVC insertion site before CVC placement (baseline), and then every 3 days (or when dressing is changed) while CVC is in place, then at ICU discharge. Bacterial metagenomics using bacterial DNA extraction, 16S PCR amplification and Nanopore sequencing will allow for description of cutaneous microbiota and diversity evaluation through Shannon index. Evolution of alpha-diversity will be evaluated through time-series data analysis: comparison of Shannon index at various time points with baseline Shanonn index (before CVC placement). Standard microbiologic culture of skin swabbing will be performed.
214814380|NCT06095076|OTHER|Data collection|General patient characteristics and informations relative to CVC infection and treatment will be collected.
214814381|NCT01305226|DRUG|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
214814382|NCT01305226|DRUG|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
214814383|NCT05486780|BEHAVIORAL|Digital Window|For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
215031308|NCT03485157|BIOLOGICAL|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
214814384|NCT01167530|DRUG|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
214814385|NCT01185548|DRUG|Tolbutamide|Administered orally
214814386|NCT01185548|DRUG|Tasisulam|Administered intravenously
215031309|NCT03485157|DRUG|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
215031310|NCT05808712|OTHER|validation|Translation and validation design
215031311|NCT05871060|DIETARY_SUPPLEMENT|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
215031312|NCT05871060|DIETARY_SUPPLEMENT|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
214814387|NCT03245086|DEVICE|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
214814388|NCT03245086|PROCEDURE|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
214814389|NCT02330068|DRUG|citalopram|Cases
214814390|NCT05321446|DEVICE|GoHand(TM)|The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
214814391|NCT01798212|PROCEDURE|endoscopic full thickness plication|
215031313|NCT05871060|DIETARY_SUPPLEMENT|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
214814392|NCT02266264|DRUG|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
214814393|NCT04840264|DRUG|Docetaxel|25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
214814394|NCT04840264|DRUG|Oxaliplatin|85 mg/msquare metre, D1, D15, repeat every 4 weeks.
214814395|NCT04840264|DRUG|Fluorouracil|1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
214814396|NCT05723900|DRUG|Castor oil|"Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil"
214814397|NCT05723900|DRUG|Formocresol|Group II treated with formocresol
214814398|NCT06128811|DEVICE|Rubber Dam Isolation|Rubber dam isolation will be placed using a proper size dental clamp on the first permanent molar after topical anesthesia application.
214814399|NCT06128811|DEVICE|DryShieled isolation|For the DryShieled isolation, a pedo-size mouthpiece will be utilized with all the participants.
214814400|NCT06128811|OTHER|fissure sealant|After proper isolation, fissure sealant (Conseal-F TM SDI) will be applied following the manufacturer's instructions, and the quality of the applied fissure sealant will be checked with an explorer. An additional layer will be applied if any deficiency is detected
214814401|NCT01247545|PROCEDURE|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
214814402|NCT01247545|PROCEDURE|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
214814403|NCT03546777|DEVICE|magnetic resonance imaging|magnetic resonance imaging of shoulder
214814404|NCT02466594|DEVICE|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
215031314|NCT04892589|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
215031315|NCT00422487|DRUG|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
215031316|NCT00422487|DRUG|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
215031317|NCT00422487|DRUG|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
215031318|NCT00422487|DRUG|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
214814405|NCT04476329|DRUG|Regorafenib 40 MG|Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).
214814406|NCT05622422|BEHAVIORAL|EMPOWER-BKP|The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially at the first session and then again at the seventh session. The intervention will be provided in seven sessions the first three will be face-to-face at a community center and then the last four sessions will be through video conferencing and will be facilitated by three researchers. The participants will be invited to a focus group interview in week nine in order to collect quantitative data. Once the sessions are finished both qualitative and quantitative data will be collected and then analyzed.
214814407|NCT01743508|PROCEDURE|Misoprostol treatment by midwife|Misoprostol treatment by midwife
214814408|NCT02865356|DRUG|Cyclosporine 5% solution|topical solution
214814409|NCT02865356|DRUG|Placebo|topical vehicle solution
214814410|NCT03744715|DRUG|Poziotinib|Poziotinib
214814411|NCT03322111|DIAGNOSTIC_TEST|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
214814412|NCT00715377|DRUG|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
214814413|NCT03109977|DRUG|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
214814414|NCT04667091|OTHER|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
214814415|NCT02218580|OTHER|Massage therapy|
214814416|NCT02218580|OTHER|Standard care|
214814417|NCT02331394|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
215031319|NCT00422487|DRUG|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
215031320|NCT00422487|DRUG|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
214814418|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
214814419|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
214814420|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
214814421|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
214814422|NCT04444557|OTHER|Beck Depression Inventory (BDI)|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
214814423|NCT01313273|DRUG|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
214814424|NCT01313273|DRUG|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
214814425|NCT00344110|DRUG|Aliskiren|
214814426|NCT03687736|BIOLOGICAL|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
214814427|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
214814428|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
214814429|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
214814430|NCT03613337|OTHER|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
214814431|NCT04163354|PROCEDURE|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
215031321|NCT00422487|DRUG|Placebo for MBX-2044|Placebo Intervention
215031322|NCT02386241|OTHER|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
215031323|NCT02710032|BEHAVIORAL|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
215031324|NCT02710032|BEHAVIORAL|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
214814432|NCT04163354|PROCEDURE|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
214814433|NCT06132074|BEHAVIORAL|School sessions on consent, reciprocity and sexual violence|The intervention consists of a 120-minute workshop led by a representative from Uppsala Tjej- och Transjour and aims to reduce the vulnerability and prevalence of sexual harassment, sexual violence and to counteract men's violence against women and violence in close relationships by raising awareness among pupils, school staff and guardians about sexual health among young people. The workshop covers areas of consent, reciprocity and sexual violence. The participants will do several valuation based and discussion based exercises regarding these topics and discuss issues, legality, and norms during the time.
214814434|NCT05492630|DRUG|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
214814435|NCT05492630|DRUG|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
214814436|NCT01037023|DRUG|Topotecan|patients administrated Topotecan according to the prescribing information
214814437|NCT05319938|PROCEDURE|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
214839852|NCT05997940|DRUG|PENG block|The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
214814438|NCT05319938|PROCEDURE|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
214814439|NCT05319938|PROCEDURE|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
214814440|NCT03122990|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
214814441|NCT03122990|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
214814442|NCT02608788|DRUG|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
214814443|NCT02608788|DRUG|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
214814444|NCT02608788|DRUG|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
214814445|NCT02608788|DRUG|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
214814446|NCT00148837|DRUG|Peg-interferon alpha 2b (drug)|
214814447|NCT00148837|DRUG|Ribavirin (drug)|
214814448|NCT00148837|DRUG|Prazosin (drug)|
214814449|NCT06025188|OTHER|training set|LASSO regression analysis, Logistic regression analysis, Nomogram
214814450|NCT04593628|BEHAVIORAL|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
214814451|NCT03227198|BIOLOGICAL|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
214814452|NCT03227198|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
214814453|NCT05382377|BIOLOGICAL|KD-025|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
214814454|NCT03800251|DIETARY_SUPPLEMENT|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
214814455|NCT02459951|OTHER|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
214814456|NCT02133105|DRUG|Levosimendan|
214814457|NCT02133105|DRUG|Dobutamine|
214814458|NCT03128905|DRUG|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
214814459|NCT03128905|DRUG|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
214814460|NCT00798447|DRUG|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
214814461|NCT00798447|DRUG|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
214814462|NCT06132698|DRUG|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
214814463|NCT03995420|BEHAVIORAL|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
214814464|NCT03995420|OTHER|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
214814465|NCT05005494|DRUG|Magnesium sulfate IV|Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)
214814466|NCT05005494|DRUG|Placebo|Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)
214814467|NCT05566860|PROCEDURE|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
214814468|NCT05566860|PROCEDURE|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
214814469|NCT05566860|PROCEDURE|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
214814470|NCT05566860|PROCEDURE|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI\>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
214814471|NCT05566860|PROCEDURE|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
214814472|NCT01043380|DRUG|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
214814473|NCT01043380|DRUG|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
214814474|NCT00481338|PROCEDURE|X-rays|X-rays (hip and knee) every 2 years
214814475|NCT00481338|BIOLOGICAL|biological samples|biological sample (blood and urine) every 2 years
214814476|NCT00481338|OTHER|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
214814477|NCT01936194|DIETARY_SUPPLEMENT|DHA+EPA|
214814478|NCT01936194|DIETARY_SUPPLEMENT|High Olive Oil|
214814479|NCT01936194|DIETARY_SUPPLEMENT|DHA|
214814480|NCT04455126|DRUG|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
214814481|NCT05038657|DRUG|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
214814482|NCT02694731|BEHAVIORAL|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
214814483|NCT02406625|BEHAVIORAL|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
214814484|NCT00102440|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
214814485|NCT00102440|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
214814486|NCT00102440|DRUG|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
214814487|NCT03337386|DIAGNOSTIC_TEST|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
214814488|NCT03337386|DIAGNOSTIC_TEST|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
214814489|NCT03337386|DIAGNOSTIC_TEST|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
214814490|NCT05218486|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
214814491|NCT06035107|DIAGNOSTIC_TEST|Radar blood pressure device|The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
214814492|NCT05151588|DRUG|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
214814493|NCT05151588|DRUG|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
214814494|NCT05151588|DRUG|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
214814495|NCT05151588|DRUG|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
214814496|NCT05151588|PROCEDURE|Surgery|Radical surgery
214814497|NCT05151588|OTHER|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
214814498|NCT03251911|DRUG|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
214814499|NCT02255097|BIOLOGICAL|pembrolizumab|
214814500|NCT04694391|GENETIC|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
214814501|NCT03918174|DEVICE|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
214814502|NCT03918174|OTHER|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
214814503|NCT03207880|DEVICE|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
214814504|NCT00074230|BIOLOGICAL|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
214814505|NCT04471272|PROCEDURE|RFA using gradual RF energy delivery mode with Octopus electrodes|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
214814506|NCT03985267|BEHAVIORAL|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
214814507|NCT01880814|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
214814508|NCT01880814|BEHAVIORAL|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
214814509|NCT02883413|BEHAVIORAL|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
214814510|NCT02883413|BEHAVIORAL|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
214814511|NCT01268085|OTHER|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
214814512|NCT01268085|OTHER|Control|Control with no inverention
214814513|NCT02294253|DRUG|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
214814514|NCT06358053|DRUG|CRTE7A2-01 TCR-T cell therapy|Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell
214814515|NCT01808794|DEVICE|Mucograft|Mucograft Collagen Matrix
214814516|NCT01808794|DEVICE|Dynamatrix|Dynamatrix
214814517|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
214814518|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
214814519|NCT00544180|DRUG|Risedronate|
214814520|NCT04278391|DRUG|DWJ1421|1 tablet administered in fasting condition
214814521|NCT04278391|DRUG|DWC201903|1 tablet administered in fasting condition
214814522|NCT01745120|GENETIC|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
214814523|NCT00852462|BEHAVIORAL|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
214814524|NCT00914420|DEVICE|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
214814525|NCT00914420|DEVICE|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
214814526|NCT04784520|DRUG|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
214814527|NCT04089592|DRUG|Dexmedetomidine|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
214814528|NCT04089592|DRUG|Fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline
214814529|NCT02129426|DRUG|Ketamine|Sedation medication
214814530|NCT02129426|DRUG|Midazolam|Sedation medication
214814531|NCT02129426|DRUG|Dexmedetomidine|Sedation medication
214814532|NCT05258474|DRUG|controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)|single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
214814533|NCT05258474|DRUG|Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
214814534|NCT05258474|DRUG|Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)|single- and multiple-ascending dose (SAD/MAD)
214814535|NCT05258474|DRUG|Placebo Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
214814536|NCT00509730|PROCEDURE|Urodynamics|
214839853|NCT03710044|DRUG|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
214814537|NCT05527548|DRUG|Alendronate (ALN)|The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
214814538|NCT01526330|DRUG|YH14618|A mg/disc
214814539|NCT01526330|DRUG|YH14618|B mg/disc
214814540|NCT01526330|DRUG|YH14618|C mg/disc
214814541|NCT01526330|DRUG|Placebo|0mg/disc
214814542|NCT06225622|DRUG|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
214814543|NCT06225622|DRUG|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
214814544|NCT06225622|DRUG|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
214814545|NCT06225622|DRUG|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
214814546|NCT06225622|DRUG|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
214814547|NCT06225622|DRUG|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
214814548|NCT03961230|DRUG|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
214814549|NCT03961230|DRUG|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
214814550|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
214814551|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
214814552|NCT04366401|BEHAVIORAL|Conventional Dietary Advice|"The education content in the control group will be centered on the acquisition of knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Culinary techniques: conservation of properties of the diet.~* \- Feeding in particular situations."
214814553|NCT04366401|BEHAVIORAL|Prebiotic/Probiotic Dietary Modulation|"The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Description and justification of prescribed prebiotic and probiotic diet.~* \- Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* \- Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* \- Feeding in particular situations."
214814554|NCT02059863|BEHAVIORAL|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
214814555|NCT02468284|DRUG|degarelix|
215031325|NCT00265122|DRUG|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
215031326|NCT00265122|DRUG|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
215031327|NCT00265122|DRUG|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
214814556|NCT04656223|COMBINATION_PRODUCT|MF/IND/GLY plus sensor system|"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
214814557|NCT04656223|DRUG|FDC therapy|There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
214814558|NCT02038621|DRUG|Paclitaxel|
214814559|NCT02038621|DRUG|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
214814560|NCT03609866|PROCEDURE|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
214814561|NCT03609866|PROCEDURE|inferior limb passive mobilization|it will be performed a passive mobilization technique on the patient
214814562|NCT00579670|DRUG|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
214814563|NCT03414593|DRUG|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
214814564|NCT04438707|OTHER|Pilates Method combined with Therapeutic exercice.|Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
214814565|NCT04438707|OTHER|Therapeutic exercise|Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
214814566|NCT00440453|OTHER|Nutritional therapy|Nutritional therapy by dietician
214814567|NCT04365153|DRUG|Canakinumab Injection 600mg|Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
214814568|NCT04365153|DRUG|Canakinumab Injection 300mg|Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
214814569|NCT04365153|DRUG|Placebos|250 mL of 5% dextrose infused IV over 2 hours
214814570|NCT00850174|DRUG|Oxcarbazepine|600 mg Tablet
214814571|NCT00850174|DRUG|Trileptal®|600 mg Tablet
214814572|NCT00635492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214814573|NCT00635492|DRUG|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
214814574|NCT01900626|DRUG|epidural catheter|epidural catheter with 0.3% ropivacaine
214814575|NCT03026374|BEHAVIORAL|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
215031328|NCT00265122|DRUG|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
214814576|NCT03968601|OTHER|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
214814577|NCT04549272|OTHER|No interventions|No interventions - observational study
214814578|NCT06368869|OTHER|Livento press veneers luted with dual cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bifix QM dual cured cement
214814579|NCT06368869|OTHER|Livento press veneers luted with light cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bisco choice 2 light cured cement
215031329|NCT01429688|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
214814580|NCT06368869|OTHER|Celtra duo veneers luted with dual cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted using Bifix QM dual cured cement
214814581|NCT06368869|OTHER|Celtra duo veneers luted with light cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted Bisco choice 2 light cured cement
214814582|NCT02881255|DEVICE|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
214814583|NCT06558721|OTHER|Conventional rehabilitation|Lower extremity conventional rehabilitation in stroke patients
214814584|NCT06558721|OTHER|Mirror therapy|Mirror therapy of the lower extremity in stroke patients
214814585|NCT06558721|DEVICE|Bicycle ergometer with functional electric stimulation|Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
214814586|NCT03239990|BEHAVIORAL|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
214814587|NCT01702987|DIETARY_SUPPLEMENT|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
214814588|NCT01702987|DIETARY_SUPPLEMENT|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
214814589|NCT01702987|DRUG|statin|statin was given for 1 month to 21 patients
214814590|NCT00006051|DRUG|cisplatin|
214814591|NCT00006051|DRUG|fluorouracil|
214814592|NCT00006051|RADIATION|radiation therapy|
214814593|NCT03247933|DEVICE|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
214814594|NCT04992611|BEHAVIORAL|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
215031330|NCT01146145|DRUG|Ketamine|intravenous morphine titration combined to ketamine
214814595|NCT04992611|BEHAVIORAL|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
214814596|NCT06189833|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
214814597|NCT06189833|DRUG|Bortezomib|Bortezomib will be administered via a subcutaneous injection (SC)
214814598|NCT06189833|DRUG|Lenalidomide|Lenalidomide will be administered orally
214814599|NCT06189833|DRUG|Dexamethasone|Dexamethasone will be administered orally
214814600|NCT06013293|PROCEDURE|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
214814601|NCT06013293|PROCEDURE|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
214814602|NCT03235128|DIAGNOSTIC_TEST|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
214814603|NCT01736878|DRUG|Sorafenib|
214814604|NCT00318045|DEVICE|Eyeglass lenses|
214814605|NCT02895373|DRUG|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
214814606|NCT02895373|DRUG|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
214814607|NCT02078791|DRUG|Botox infiltration|botox cervical infiltration in a group
214814608|NCT02078791|BEHAVIORAL|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
214814609|NCT02078791|OTHER|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
214814610|NCT05350891|PROCEDURE|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
214814611|NCT04813692|PROCEDURE|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
214814612|NCT04813692|PROCEDURE|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
214814613|NCT04813692|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
214814614|NCT01650974|DEVICE|HFNOT|high flow nasal oxygen therapy
214814615|NCT02004535|PROCEDURE|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
214814616|NCT00622414|BIOLOGICAL|ziv-aflibercept|Given IV
214814617|NCT02307981|OTHER|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
214814618|NCT02350621|PROCEDURE|ACDF|
214814619|NCT02350621|PROCEDURE|minimal invasive Posterior Cervical Foraminotomy|
214814620|NCT02017223|DEVICE|Knowme Device Wear|
214814621|NCT06022237|DRUG|Ibandronate|Ibandronate 150 mg once monthly.
214814622|NCT06022237|DRUG|Calcium|Calcium 500 mg twice daily
214814623|NCT06022237|DRUG|Vitamin D3|Vitamin D3 - 1000 IU daily
214814624|NCT03666728|DRUG|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
214814625|NCT03666728|DRUG|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
214814626|NCT04100733|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
214814627|NCT04100733|DIAGNOSTIC_TEST|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
214814628|NCT01223105|PROCEDURE|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
214814629|NCT01223105|PROCEDURE|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
214814630|NCT02210182|DRUG|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
214814631|NCT02210182|OTHER|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
214814632|NCT04123769|DRUG|Hydronidone|First take Hydronidone capsule, single-dose and then Multiple-dose
214814633|NCT02167386|BEHAVIORAL|Enhanced PrEP Adherence|
214814634|NCT02167386|BEHAVIORAL|Standard PrEP Adherence|
214814635|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
214814636|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
214814637|NCT05388266|OTHER|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
214814638|NCT04035395|OTHER|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
214814639|NCT04035395|OTHER|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
214814640|NCT04035395|OTHER|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
214814641|NCT04035395|OTHER|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
214814642|NCT04035395|OTHER|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
214814643|NCT04263649|DEVICE|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
214814644|NCT04910178|DRUG|Empagliflozin 25 MG|tablets to be taken orally once a day
214814645|NCT04910178|DRUG|Ursodeoxycholic acid|tablets to be taken orally twice a day
214814646|NCT04910178|DRUG|Pentoxifylline 400 MG|tablets to be taken orally twice a day
214814647|NCT04910178|OTHER|placebo|just starch tablets without any active agents
214814648|NCT01982318|DRUG|VitroGro® ECM|
214814649|NCT01982318|DRUG|Dulbecco's Phosphate Buffered Saline|
214814650|NCT03834376|DRUG|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.
214814651|NCT00233415|DEVICE|Stereotactic Radiosurgery (Cyberknife)|
214814652|NCT03546283|DRUG|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
214814653|NCT03546283|DRUG|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
214814654|NCT04503174|DEVICE|t:slim X2 pump with Control-IQ technology|Real-world use
214814655|NCT04836598|OTHER|laparoscopic cholecystectomy|A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
214814656|NCT03392454|PROCEDURE|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
214814657|NCT03392454|PROCEDURE|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
214814658|NCT05615454|DEVICE|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
214814659|NCT05615454|DEVICE|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
214814660|NCT02127463|DRUG|MC-1101|Topically, two times a day, morning and bedtime
214814661|NCT02127463|DRUG|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
214814662|NCT05169710|DRUG|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
214814663|NCT05169710|DRUG|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
214814664|NCT05169710|DRUG|Placebo|Placebo tablet (supplied in two tablets)
214814665|NCT04660864|DEVICE|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
214839854|NCT05776381|OTHER|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
214839855|NCT00005858|BIOLOGICAL|LMB-9 immunotoxin|
214814666|NCT06563258|DEVICE|Biodex Balance Training|"Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise."
214814667|NCT06563258|DEVICE|A vibration device|WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
214814668|NCT06563258|OTHER|traditional exercises|"1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)"
214814669|NCT00910052|DEVICE|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
214814670|NCT00221299|DRUG|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
214814671|NCT00221299|DRUG|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
214814672|NCT05687552|DEVICE|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
214814673|NCT06421337|DEVICE|BraiN20(R)|"SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove."
214814674|NCT02828033|DRUG|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
214814675|NCT00346385|DRUG|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
214814676|NCT02729714|DRUG|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
214814677|NCT02729714|DRUG|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
214814678|NCT01633450|OTHER|Zinc biofortified rice|1.12 mg zinc per meal
214814679|NCT01633450|OTHER|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
214814680|NCT06350955|DRUG|Iron isomaltoside|single dose of 500 mg iron isomaltoside
214814681|NCT06350955|DRUG|Iron Carboxymaltose|single dose of 500 mg ferric carboxymaltose
214814682|NCT00223925|DRUG|Maribavir|
214814683|NCT00223925|DRUG|Placebo|
214814684|NCT05250843|PROCEDURE|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
214814685|NCT05250843|DRUG|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
214839856|NCT02104869|BIOLOGICAL|Trivalent influenza vaccine (inactivated and fragmented).|
214814686|NCT05250843|DRUG|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
214814687|NCT05250843|PROCEDURE|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
214814688|NCT02897414|OTHER|Surveillance of state medical examiner databases|
214814689|NCT00199277|DRUG|i.v. iron sucrose|
214814690|NCT00199277|DRUG|Oral iron|
214814691|NCT03853954|DEVICE|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
214814692|NCT00892892|DRUG|Rilmenidine|1 mg Rilmenidine per day versus
214814693|NCT00892892|DRUG|Nitrendipine|20 mg Nitrendipine per day
214814694|NCT03713333|DIAGNOSTIC_TEST|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~* Handheld imaging - focused echocardiographic examination (Butterfly IQ)~* Smartphone iECG for cardiac rhythm assessments (Alivecor)~* Blood Pressure (CloudDX)~* Oxygen Saturation (CloudDX)~* Weight (CloudDX)~* Point-of-Care Genetic Testing (Phosphorous)"
214814695|NCT03579095|DIETARY_SUPPLEMENT|Cereboost|200mg Cereboost and Maltodextrin capsules
214814696|NCT03579095|DIETARY_SUPPLEMENT|Placebo|200mg Maltodextrin capsules
214814697|NCT00693628|DEVICE|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
214814698|NCT01774435|DRUG|EN3342|
214814699|NCT05733884|OTHER|soft contact lens|soft contact lens
214814700|NCT05451069|DIAGNOSTIC_TEST|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
214814701|NCT03347435|GENETIC|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
214814702|NCT03347435|OTHER|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
214814703|NCT01288352|OTHER|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
214814704|NCT02640183|DRUG|EMLA|
214814705|NCT02640183|OTHER|Placebo|
214814706|NCT04504526|DRUG|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
214814707|NCT03396523|DRUG|Losartan|administration of losartan (50 mg) (oral)
214814708|NCT03396523|DRUG|Placebo Oral Tablet|administration of placebo (oral)
214814709|NCT02092805|PROCEDURE|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
214814710|NCT02092805|PROCEDURE|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
214814711|NCT03343795|DRUG|oral progesterone|daily
214814712|NCT03343795|DRUG|intramuscular progesterone|every week
214814713|NCT06327191|OTHER|No intervention as the study is observational.|No intervention as the study is observational.
214814714|NCT02812732|BEHAVIORAL|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
214814715|NCT04192006|DEVICE|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
214814716|NCT00846495|DRUG|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
214814717|NCT00846495|DRUG|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
214814718|NCT01686438|BEHAVIORAL|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
214814719|NCT05841225|BEHAVIORAL|Food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
214814720|NCT05841225|BEHAVIORAL|Non-food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
214814721|NCT01759940|DRUG|ropivacaine 0,375%|
214814722|NCT01759940|DRUG|ropivacaine 0,75%|
214839857|NCT00889252|DEVICE|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
214839858|NCT00889252|DEVICE|contact lens|Placebo contact lens
214839859|NCT02416934|DRUG|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
214839860|NCT02416934|DRUG|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
214814723|NCT04561622|BEHAVIORAL|Emotional Stroop Task|"Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too."
214814724|NCT04791150|OTHER|Fill in a form|Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs
214814725|NCT06213506|BIOLOGICAL|Measles and Rubella vaccine|Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
214814726|NCT06213506|BIOLOGICAL|Yellow Fever vaccine|Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
214814727|NCT06213506|BIOLOGICAL|Pentavalent vaccine|Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
214814728|NCT06213506|BIOLOGICAL|Pneumococcal vaccine|Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
214814729|NCT06213506|BIOLOGICAL|Inactivated polio vaccine|Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
214814730|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose C|-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Dose C and Infants\_6W\_Dose C\_2 groups.
214814731|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose B|-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose B and Infants\_6W\_Dose B\_2 groups.
214814732|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose A|3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose A and Infants\_6W\_Dose A\_2 groups.
214839861|NCT06096350|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
214839862|NCT06096350|DIAGNOSTIC_TEST|hematochemical analysis|Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
214814733|NCT06213506|BIOLOGICAL|MenACWY|-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B, Infants\_6W\_Control C and Infants\_6W\_Control\_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
214814734|NCT06213506|COMBINATION_PRODUCT|DTPa-HBV-IPV+Hib|1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.
214814735|NCT06213506|DRUG|Placebo|1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.
214814736|NCT03815669|PROCEDURE|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
214814737|NCT04937101|DRUG|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
214814738|NCT05596279|DIAGNOSTIC_TEST|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
214814739|NCT05596279|DIAGNOSTIC_TEST|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
214814740|NCT02431494|DEVICE|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
214814741|NCT02431494|DEVICE|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
214814742|NCT02431494|DEVICE|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
214814743|NCT01889719|BIOLOGICAL|MVA-CMDR|injections of MVA-CMDR vaccine
214814744|NCT03743753|OTHER|Experimental|The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
214814745|NCT00000194|DRUG|Cycloserine|
214814746|NCT02134834|DRUG|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
214814747|NCT02134834|DRUG|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
214814748|NCT00803491|OTHER|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
214814749|NCT00803491|OTHER|Traditional rheumatology care.|Individually base.
214814750|NCT01083277|DEVICE|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
214814751|NCT01083277|OTHER|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
214814752|NCT02541149|PROCEDURE|blood sample|
214814753|NCT06551584|DRUG|ORCA-T|On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
214814754|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
214814755|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
214814756|NCT06358820|DRUG|Amino acid peritoneal dialysis solution|Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
214814757|NCT04815954|PROCEDURE|Urinary catheter removal|Removal of urinary catheter which was placed during kidney transplantation.
214814758|NCT06101238|DIETARY_SUPPLEMENT|supplementation with low dose elemental iron|65mg daily
214814759|NCT05627739|DRUG|Mycophenolate Mofetil|Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
214814760|NCT02773134|OTHER|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
214814761|NCT02773134|OTHER|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
214814762|NCT02640521|BEHAVIORAL|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
214814763|NCT03708991|DIAGNOSTIC_TEST|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
214814764|NCT03708991|DIAGNOSTIC_TEST|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
214814765|NCT00005591|BIOLOGICAL|cetuximab|
214814766|NCT00005591|DRUG|gemcitabine hydrochloride|
214814767|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
214814768|NCT02728856|OTHER|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
214814769|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
214814770|NCT03183037|PROCEDURE|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
214814771|NCT03183037|PROCEDURE|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
214814772|NCT03183037|OTHER|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
214814773|NCT03183037|BEHAVIORAL|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
214814774|NCT01124175|DRUG|Losartan|100 mg Tablets
214814775|NCT01124175|DRUG|Cozaar®|100 mg Tablets
214814776|NCT05839470|DRUG|cadonilimab|Cadonilimab (6mg/kg, iv, Q2W, Day1)
214814777|NCT05839470|DRUG|irinotecan|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1
214814778|NCT05839470|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² iv continue for 2 hours,
214814779|NCT05839470|DRUG|leucovorin or levoleucovorin|leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
214814780|NCT05839470|DRUG|5-FU|5-FU 2400 mg/m² cont. inf. 46h
214814781|NCT04456842|OTHER|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
214814782|NCT00486863|DRUG|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
214814783|NCT00486863|OTHER|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
214814784|NCT03040648|DEVICE|DSA|DSA was used for detection of intravascular injection
214814785|NCT03040648|DEVICE|RTF|RTF was used for detection of intravascular injection
214814786|NCT00039286|PROCEDURE|positron emission tomography|
214814787|NCT00039286|PROCEDURE|radionuclide imaging|
214814788|NCT00039286|RADIATION|fludeoxyglucose F 18|
214814789|NCT04330534|DRUG|BCX9930|BCX9930 capsules for oral administration
214814790|NCT04330534|DRUG|Placebo|placebo to match BCX9930 capsules for oral administration
214814791|NCT00501397|DRUG|ketoconazole|
214814792|NCT00501397|DRUG|GSK189075|
214814793|NCT00355797|DEVICE|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
214814794|NCT00355797|DEVICE|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
214814795|NCT00355797|DEVICE|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
214814796|NCT00218257|DRUG|Progesterone|200mg progesterone twice daily
214814797|NCT00218257|OTHER|Placebo|placebo
214814798|NCT01400087|DEVICE|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
214814799|NCT04630834|DRUG|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
214814800|NCT04630834|DRUG|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
214814801|NCT04630834|DRUG|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
214814802|NCT03296722|BEHAVIORAL|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
214814803|NCT04408586|DRUG|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
214814804|NCT04408586|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
214814805|NCT04408586|OTHER|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
214814806|NCT05329922|BEHAVIORAL|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
214814807|NCT04625153|BIOLOGICAL|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
214814808|NCT04625153|BIOLOGICAL|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
214814809|NCT05905718|OTHER|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
214814810|NCT05954741|OTHER|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
214814811|NCT05954741|OTHER|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
214814812|NCT05954741|OTHER|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
214814813|NCT00462345|DRUG|rituximab|1000 mg i.v. on Days 1 and 15
214814814|NCT00462345|DRUG|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
214814815|NCT00462345|DRUG|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
214814816|NCT00462345|DIETARY_SUPPLEMENT|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
214814817|NCT02060747|BEHAVIORAL|Coordinator-based post fracture program|
214814818|NCT06561906|OTHER|Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing|Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
214814819|NCT04274374|DIETARY_SUPPLEMENT|Gluten-Free Diet|Dietary supplement without gluten
214814820|NCT04274374|DIETARY_SUPPLEMENT|Gluten Diet|Dietary supplement with gluten
214814821|NCT05013463|DRUG|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
214814822|NCT05013463|DRUG|Indapamide Pill|Oral Indapamide, 2.5 mg OD
214814823|NCT04904718|DEVICE|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
214814824|NCT04053296|OTHER|Observational study|We follow up the results of patients.
214814825|NCT06485531|OTHER|Pranamaya|Pranamaya
214814826|NCT06485531|OTHER|Pursed Lips Breathing|Pursed Lips Breathing
214814827|NCT01067963|BEHAVIORAL|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
214814828|NCT01067963|BEHAVIORAL|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
214839863|NCT06096350|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
214814829|NCT06626815|BEHAVIORAL|Lateral Kangaroo Position|Newborns in the lateral kangaroo position group will be positioned diagonally on their mothers chests, with their heads placed between the mothers breast and collarbone.
214814830|NCT06626815|BEHAVIORAL|Reverse Kangaroo Position|Newborns in the reverse kangaroo position group will be positioned vertically with their backs in contact with the mothers chest.
214814831|NCT01079585|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
214814832|NCT05146492|PROCEDURE|MRI|MRI with gadolinium contrast media injection
214814833|NCT04501003|DEVICE|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
214814834|NCT00428298|DRUG|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
214814835|NCT00428298|DRUG|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
214814836|NCT06345053|BEHAVIORAL|Narrative Exposure Therapy|The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
214814837|NCT00070291|DRUG|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
214814838|NCT04336605|OTHER|Age & Development|Age, sex, pubertal onset and development
214814839|NCT04336605|OTHER|Socioeconomy|Family structure and economy
214814840|NCT04336605|OTHER|Traumatic Events|Violence and other traumatic events
214814841|NCT04336605|OTHER|Psychosocial conditions|Family/social support
214814842|NCT04336605|OTHER|Lifestyle|Physical activity, BMI, nutrition, smoking …
214814843|NCT04336605|OTHER|Chronic conditions|I.e. Epilepsy or juvenile rheumatoid arthritis ...
214814844|NCT04336605|OTHER|Somatic symptoms|Headache, pain, sleep disturbances ...
214814845|NCT04336605|OTHER|Psychological symptoms|PTSS, anxiety, depressive symptoms \& loneliness ...
214814846|NCT04336605|OTHER|Non-prescription analgesics|Non-prescription analgesics
214814847|NCT04336605|OTHER|Prescription drugs|Analgetic, sedative \& anxiolytic medication
214814848|NCT01783535|DRUG|vincristine|Given via minibag/gravity flow.
214814849|NCT01783535|DRUG|topotecan|Given IV over 30 minutes.
214814850|NCT01783535|DRUG|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is \>2,000/µL on one occasion after the expected nadir.
214814851|NCT01783535|DRUG|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is \>2,000/µL on one occasion after the expected nadir.
214814852|NCT01783535|DRUG|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
214814853|NCT01783535|OTHER|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
214814854|NCT01783535|DRUG|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
214814855|NCT01783535|DRUG|cyclophosphamide|Given IV.
214814856|NCT01783535|DRUG|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
214814857|NCT01783535|DRUG|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
214814858|NCT01783535|PROCEDURE|enucleation|Eye removal due to advanced disease in Strata C and D participants.
214814859|NCT01783535|RADIATION|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
214814860|NCT00507117|DRUG|Lunesta|Lunesta 3mg prior to PSG
215031331|NCT04582591|DRUG|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
214814861|NCT00507117|DRUG|Placebo control|matching placebo
214814862|NCT01174225|DEVICE|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
214814863|NCT01174225|DEVICE|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
214814864|NCT02821728|DIETARY_SUPPLEMENT|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
214814865|NCT02821728|OTHER|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
214814866|NCT03491072|DEVICE|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
214814867|NCT03491072|DRUG|Fentanyl|Patients will receive IV fentanyl
214814868|NCT03217539|DIAGNOSTIC_TEST|Imaging|
214814869|NCT00777972|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
214814870|NCT03547622|DRUG|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
214814871|NCT03547622|DRUG|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
214814872|NCT00520130|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
214814873|NCT00520130|DRUG|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
214814874|NCT00520130|DRUG|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
214814875|NCT00520130|DRUG|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
214814876|NCT00520130|DRUG|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
214814877|NCT00520130|DRUG|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
214814878|NCT00520130|DRUG|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
214814879|NCT00520130|BIOLOGICAL|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
214814880|NCT02028715|DRUG|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
214814881|NCT02028715|DRUG|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
214814882|NCT02018263|DRUG|Cocaine hydrochloride|
214814883|NCT02018263|BEHAVIORAL|Exercise|
214814884|NCT02018263|DRUG|Nicotine|
214814885|NCT05392621|BEHAVIORAL|Yoga|A single Hatha yoga session designed to support stress management.
214814886|NCT05392621|BEHAVIORAL|Deep Breathing|A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.
214814887|NCT05392621|BEHAVIORAL|Progressive Muscle Relaxation|A single session of progressive muscle relaxation designed to elicit relaxation.
214814888|NCT05392621|BEHAVIORAL|Quiet sitting|A single session of quiet sitting.
214814889|NCT05058638|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
214814890|NCT00820326|DRUG|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
214814891|NCT00820326|DRUG|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
214814892|NCT05077124|DEVICE|CytoSorb|Sorbent hemoperfusion system
214814893|NCT03487224|DEVICE|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
214814894|NCT04915755|DRUG|Niraparib|Niraparib will be administered.
214814895|NCT04915755|DRUG|Placebo|Matching placebo will be administered
214814896|NCT06501040|OTHER|Web-based Educational Intervention|View web-based educational video
214814897|NCT06501040|OTHER|Questionnaire Administration|Pre video baseline survey and a post video educational survey
214814898|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
214814899|NCT04049669|DRUG|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
214814900|NCT04049669|RADIATION|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
214814901|NCT04049669|RADIATION|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine).
214814902|NCT04049669|DRUG|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
214814903|NCT04049669|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
214814904|NCT04049669|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
214814905|NCT04049669|DRUG|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
214814906|NCT04189614|DRUG|Cofetuzumab Pelidotin|Intravenous (IV) infusion
214814907|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
214814908|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
214814909|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
214814910|NCT05654103|DEVICE|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
214814911|NCT05654103|PROCEDURE|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
214814912|NCT05946083|DIETARY_SUPPLEMENT|Inulin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
214814913|NCT05946083|DIETARY_SUPPLEMENT|Maltodextrin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
214814914|NCT04725773|DEVICE|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
214814915|NCT06427252|DRUG|HIPEC|In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
214814916|NCT06427252|DRUG|Systemic therapy|"1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;"
214814917|NCT06026098|BEHAVIORAL|Artificial Intelligence|Participants will use the Artificial Intelligence assistance tool for case reports.
214814918|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
214814919|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
214814920|NCT01942746|DIETARY_SUPPLEMENT|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
214814921|NCT01942746|DIETARY_SUPPLEMENT|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
214814922|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
214814923|NCT03660020|DRUG|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
214814924|NCT03660020|DRUG|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
214814925|NCT03638739|OTHER|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
214814926|NCT02467205|OTHER|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
214814927|NCT05358860|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214814928|NCT04758130|OTHER|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
214814929|NCT03408691|DIETARY_SUPPLEMENT|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
214814930|NCT03408691|OTHER|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
214814931|NCT00875030|DRUG|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
214814932|NCT00875030|DRUG|Arsuamoon|single dose 50 mg arsuamoon tablet
214814933|NCT05488808|DEVICE|repetitive Transcranial Magnetic Stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
214814934|NCT04381962|DRUG|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
214814935|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
214814936|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
214814937|NCT01516996|DRUG|docetaxel and cisplatin|"* The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
214814938|NCT01516996|RADIATION|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times"
214814939|NCT01516996|BIOLOGICAL|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13\~14 weeks
214814940|NCT01069536|DRUG|metoclopramide 10 mg|
214814941|NCT02059070|DRUG|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
214814942|NCT02059070|DRUG|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
214814943|NCT00657332|PROCEDURE|blood sample draw|
214814944|NCT00657332|PROCEDURE|urine sample|
214814945|NCT01552499|OTHER|Standard of care|
214814946|NCT01552499|OTHER|Applications of EpiFix|
214814947|NCT01954394|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
214814948|NCT01954394|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
214814949|NCT01980823|DRUG|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
214814950|NCT01980823|DRUG|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
214814951|NCT01980823|PROCEDURE|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
214814952|NCT04089735|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
214814953|NCT04089735|DRUG|APP13007, 0.1%|APP13007 eye drop, 0.1%
214814954|NCT04089735|DRUG|APP13007 Placebo, 0.05%|APP13007 placebo eyedrop, 0.05%
214814955|NCT04089735|DRUG|APP13007 Placebo, 0.1%|APP13007 placebo eyedrop, 0.1%
214814956|NCT01601145|DIETARY_SUPPLEMENT|consumption of lozenges|Each subject two lozenges a day for 6 weeks
214814957|NCT01959750|BEHAVIORAL|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
214814958|NCT04295122|DEVICE|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
214814959|NCT03429634|PROCEDURE|Balloon-Stent Kissing technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
214814960|NCT03429634|PROCEDURE|Jailed Wire technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
214814961|NCT02974556|PROCEDURE|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
214814962|NCT02974556|PROCEDURE|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
214814963|NCT02974556|DRUG|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
214814964|NCT02973685|PROCEDURE|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
214814965|NCT02973685|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
214814966|NCT02973685|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
214814967|NCT02973685|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
214814968|NCT00752297|DRUG|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
214814969|NCT00752297|DRUG|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
214814970|NCT03483194|DEVICE|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
214814971|NCT03483194|DRUG|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
214814972|NCT03829891|DRUG|Beinaglutide|"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
214814973|NCT03829891|DRUG|glargine|"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
214814974|NCT06458491|DEVICE|Evolution of urinary symptoms|Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
214814975|NCT01439880|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214814976|NCT01439880|OTHER|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
214814977|NCT05497362|DEVICE|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
214814978|NCT05497362|DEVICE|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
214814979|NCT02956460|DEVICE|fanfilcon A|contact lens
214814980|NCT02956460|DEVICE|senofilcon A|contact lens
214814981|NCT02598089|BIOLOGICAL|Trivalent Seasonal Influenza Vaccine|
214814982|NCT02598089|OTHER|Placebo|0.5 mL of phosphate buffered saline
214814983|NCT00834067|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
214814984|NCT00834067|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
214814985|NCT01072890|DRUG|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
214814986|NCT05281341|DRUG|Growth Hormone|In GH groups (Group 4A \& 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B \& 3B) will receive only standard COS without GH supplementation
214814987|NCT04129346|BEHAVIORAL|Fit2ThriveMB App|The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
214814988|NCT04129346|BEHAVIORAL|Fitbit|The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
214814989|NCT04129346|BEHAVIORAL|Physical Activity Coaching Calls|Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
214814990|NCT04129346|BEHAVIORAL|Healthy Living Coaching Calls|Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
214814991|NCT04129346|BEHAVIORAL|Cancer.net app|Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
214814992|NCT05474365|OTHER|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
214814993|NCT00003484|DRUG|carmustine|
214814994|NCT00003484|DRUG|irinotecan hydrochloride|
214814995|NCT00003484|PROCEDURE|surgical procedure|
214814996|NCT00003484|RADIATION|iodine I 131 monoclonal antibody 81C6|
214814997|NCT04740632|BEHAVIORAL|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
214814998|NCT03501147|OTHER|Resistance training|15 minutes of resistance training during work every day
214814999|NCT03465839|BEHAVIORAL|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
214815000|NCT03465839|BEHAVIORAL|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
214815001|NCT01888523|BEHAVIORAL|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
214815002|NCT01888523|BEHAVIORAL|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
214815003|NCT03429959|DEVICE|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
214815004|NCT03429959|DEVICE|SIGVARIS Cotton|SIGVARIS Cotton
214815005|NCT05443386|PROCEDURE|colorectal surgery|we have included several types of colorectal surgery procedures, in emergency conditions
214815006|NCT04559386|OTHER|Survey|Questionnaire
214839864|NCT06096350|DIAGNOSTIC_TEST|nutritional assessment, MNA,|nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
214839865|NCT06096350|DIAGNOSTIC_TEST|stool sampling|stool will be collected at T0 and at T1
214839866|NCT06096350|DIAGNOSTIC_TEST|urine sampling|the first morning urine will be collected at T0 and at T1
214815007|NCT03562962|BEHAVIORAL|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle \& Linnerooth, 2000; Kohlenberg \& Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg \& Tsai, 1991).
214815008|NCT06539273|DRUG|Exosome Complex, RNA|A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
214815009|NCT02332863|DEVICE|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
214815010|NCT02332863|DEVICE|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
214815011|NCT06040723|DEVICE|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
214815012|NCT01533805|OTHER|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
214815013|NCT01533805|OTHER|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
214815014|NCT00861406|DRUG|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
214815015|NCT00861406|DRUG|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
214815016|NCT00276133|DRUG|Effects of atorvastatin versus probucol on small dense LDL|
214815017|NCT02553564|OTHER|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment"
214815018|NCT00717405|DRUG|Standard chemotherapy|As prescribed
214815019|NCT00717405|DRUG|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
214815020|NCT00717405|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
214815021|NCT01517321|DRUG|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
214815022|NCT01517321|DRUG|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
214815023|NCT02184260|DRUG|Metamizole|
214815024|NCT02184260|DRUG|Placebo|
214815025|NCT02197260|DRUG|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
214815026|NCT01305681|DEVICE|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
214815027|NCT06009146|DEVICE|Endovascular treatment|Endovascular treatment for infrapopliteal arterial disease.
214815028|NCT03018834|DRUG|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
214815029|NCT03018834|DRUG|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
214815030|NCT04107675|DRUG|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
214815031|NCT04107675|DRUG|Liposomal Placebo|Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
214815032|NCT03314870|GENETIC|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
214815033|NCT06254781|DRUG|Luspatercept|Erythroid Maturation Agent
214815034|NCT05053763|DRUG|Remimazolam|The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
214815035|NCT00359905|DRUG|Silodosin|8 mg daily for 12 weeks
214815036|NCT00359905|DRUG|Tamsulosin|0.4 mg daily for 12 weeks
214815037|NCT00359905|DRUG|Placebo|once daily for 12 weeks
214815038|NCT00407394|DRUG|Amoxycillin|
214815039|NCT03464240|DIETARY_SUPPLEMENT|Glucose|glucose drink
214815040|NCT03464240|DIETARY_SUPPLEMENT|Water|control
214815041|NCT01513486|BEHAVIORAL|immobilization|
214815042|NCT00904553|RADIATION|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
214815043|NCT03572777|DRUG|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
214815044|NCT03572777|DRUG|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
214815045|NCT03572777|DRUG|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
214815046|NCT03572777|DRUG|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
214815047|NCT03572777|DRUG|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
214815048|NCT03572777|DRUG|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
214815049|NCT03572777|DRUG|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
214815050|NCT03572777|DRUG|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
214815051|NCT03999684|DRUG|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
214815052|NCT05655845|OTHER|bowel function score(BFS) questionnaire survey|A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
214815053|NCT00836056|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
214815054|NCT00836056|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
214815055|NCT02569073|DRUG|Dronabinol|Dronabinol 5 mg, every other night, orally
214815056|NCT02569073|DRUG|Placebo|Placebo--no drug
214815057|NCT01851577|BEHAVIORAL|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
214815058|NCT01851577|BEHAVIORAL|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
214815059|NCT04033471|DRUG|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
214815060|NCT04078932|BEHAVIORAL|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
214815061|NCT03170323|DRUG|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
214815062|NCT03170323|DRUG|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
214815063|NCT05857891|DRUG|Human erythropoietin injection|Each subject in the test group received 40000iu of human erythropoietin intravenously
214815064|NCT05857891|DRUG|0.9%NaCl|Each subject in the control group was injected with an equal volume of 0.9%NaCl
214815065|NCT00507663|DRUG|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
214815066|NCT01209390|DEVICE|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
214815067|NCT03892694|DEVICE|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
214815068|NCT03892694|OTHER|Sham|Sham control procedure
214815069|NCT00501345|DRUG|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
214815070|NCT05084066|OTHER|Repeated remote ischemic preconditioning|"An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention."
214815071|NCT05084066|OTHER|Simulation of repeated remote ischemic preconditioning (sham)|The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.
214815072|NCT00306462|DRUG|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.
214815073|NCT00306462|DRUG|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
214815074|NCT01887145|PROCEDURE|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
214839867|NCT06096350|DEVICE|indirect calorimetry analysis|indirect calorimetry analysis with K5 (COSMED, Italy) during six minute walk test or timed up and go test.
214839868|NCT02111122|DRUG|Sodium Oxybate|
214839869|NCT02111122|DRUG|Placebo|
214839870|NCT01514123|DRUG|VGX-100|VGX-100 will be administered by IV infusion once every week
214839871|NCT01514123|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
214815075|NCT01887145|PROCEDURE|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
214815076|NCT02291263|BIOLOGICAL|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
214815077|NCT02291263|BIOLOGICAL|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
214815078|NCT02291263|BIOLOGICAL|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
214815079|NCT05297630|OTHER|Evaluation of the evolution of biological markers from the biobank.|The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
214815080|NCT02321566|DEVICE|Epidural Motor Cortex Stimulation|
214815081|NCT02670057|PROCEDURE|Transnasal SPG block|
214815082|NCT04148391|DRUG|Placebo Oral Capsule|Matching placebo capsules.
214815083|NCT04148391|DRUG|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
214815084|NCT00522886|DRUG|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
214815085|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
214815086|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
214815087|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
214815088|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
214815089|NCT04987619|DIETARY_SUPPLEMENT|Beetroot juice|Subjects will drink juice 120 minutes before each visit
214815090|NCT04987619|OTHER|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
214815091|NCT04593134|BEHAVIORAL|exercise group|"exercise education: A 12-week regimen of homebased walking exercises, include moderate intensity for 40 min, three times a week.~We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the heart rate reserve, as determined by the Karvonen method, or 13-14 on the RPE.~Exercise education:~Weekly telephone or mobile application LINE consultations concerning exercise.we discussed whether participants' exercise fulfilled the prescribed intensity, duration, frequency and whether the participants experienced any adverse effects."
214815092|NCT05585866|DRUG|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
214815093|NCT01802086|DRUG|Emla-cream|Topical anaesthetic
214815094|NCT01802086|DRUG|Miniderm cream|Topical
214815095|NCT02648347|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214815096|NCT02648347|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
214815097|NCT01639222|DRUG|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
214815098|NCT01639222|OTHER|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
214815099|NCT03546842|BIOLOGICAL|9vHPV vaccine|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
214815100|NCT04772105|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
214815101|NCT04772105|DRUG|4.0mg of BAT5906|Specification: 4.0mg of BAT5906
214815102|NCT04025450|DRUG|Chidamide+VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
214815103|NCT04025450|DRUG|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
214815104|NCT00214097|RADIATION|Radiotherapy|Daily radiation to prescribed dose
214815105|NCT01268709|DRUG|Doxepin|
214815106|NCT01268709|DRUG|Nortriptyline|
214815107|NCT01268709|DRUG|placebo|
214815108|NCT01884519|BIOLOGICAL|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
214815109|NCT04977245|OTHER|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
214815110|NCT04977245|OTHER|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
214815111|NCT05241808|BEHAVIORAL|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
214815112|NCT01870856|DEVICE|Spectacles|Per participant's habitual prescription
214815113|NCT01870856|DEVICE|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
214815114|NCT01870856|DEVICE|Etafilcon A contact lenses|Hydrogel single vision contact lenses
214815115|NCT03872505|DRUG|Durvalumab|IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
214815116|NCT03872505|RADIATION|Radiation Therapy|The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
214815117|NCT03872505|DRUG|Carboplatin|IV administration weekly for 12 weeks
214815118|NCT03872505|DRUG|Paclitaxel|IV administration every week for 12 weeks
214815119|NCT02352259|PROCEDURE|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
214815120|NCT02352259|DEVICE|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
214815121|NCT02352259|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
214815122|NCT05286203|DEVICE|Metagenomic Deep Sequencing (MDS)|MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.
214815123|NCT05286203|DIAGNOSTIC_TEST|Standard of Care (SOC)|SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
214815124|NCT00658762|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
214815125|NCT00658762|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
214815126|NCT00658762|DRUG|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
214815127|NCT00658762|DRUG|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
214815128|NCT05333159|DRUG|SGLT2 inhibitor|dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
214815129|NCT02258620|DRUG|dinitrate isosorbide|dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat
214815130|NCT02258620|DRUG|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
214815131|NCT05514860|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
214815132|NCT05514860|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
214815133|NCT01265056|DRUG|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
214815134|NCT01265056|DRUG|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
214815135|NCT01229618|DRUG|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
214815136|NCT04887766|DEVICE|GS300|Gelesis300 hydrogel in gelatin capsules
214815137|NCT04887766|DEVICE|Placebo|Placebo capsules
214815138|NCT01794715|PROCEDURE|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
214815139|NCT01732172|OTHER|Sperm sample|Sperm sample
214815140|NCT01416584|BEHAVIORAL|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
214815141|NCT01416584|BEHAVIORAL|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
214815142|NCT01387633|OTHER|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
214815143|NCT01387633|OTHER|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
214815144|NCT03698981|BEHAVIORAL|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
214815145|NCT05757765|OTHER|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
214815146|NCT05757765|OTHER|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
214815147|NCT00362024|DRUG|MK0952|
214815148|NCT00362024|DRUG|Comparator: Placebo|
214815149|NCT01650350|DRUG|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
214815150|NCT00064974|DRUG|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
214815151|NCT03117296|OTHER|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
214815152|NCT03117296|OTHER|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
214815153|NCT03117296|OTHER|OT post procedure|PT and OT Daily until goals met or patient discharge.
214815154|NCT03117296|OTHER|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
214815155|NCT03384602|OTHER|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
214815156|NCT03384602|OTHER|home exercise strength program|simple strength exercise program to perform individually at home
214815157|NCT03859102|DIETARY_SUPPLEMENT|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
214815158|NCT03859102|DRUG|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
214815159|NCT03859102|DRUG|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
214815160|NCT03859102|DRUG|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
214815161|NCT03859102|DRUG|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
214815162|NCT03859102|DRUG|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
214815163|NCT03859102|DRUG|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
214815164|NCT03859102|DRUG|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
214815165|NCT03859102|DRUG|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
214815166|NCT03859102|DRUG|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
214815167|NCT03859102|DRUG|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
214815168|NCT03859102|PROCEDURE|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
214815169|NCT03859102|PROCEDURE|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
214815170|NCT03859102|OTHER|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
214815171|NCT01638741|BEHAVIORAL|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
214815172|NCT05166148|OTHER|Session (a)|Eccentric cycling
214815173|NCT05166148|OTHER|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
214815174|NCT05166148|OTHER|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
214815175|NCT02082392|DRUG|Escitalopram|
214815176|NCT02082392|DRUG|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
214815177|NCT05643976|BEHAVIORAL|KardioPAC Mobile Application|"Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, \& a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable."
214815178|NCT05643976|OTHER|Standard of Care|During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
214815179|NCT01356849|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
214815180|NCT01356849|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
214815181|NCT02799108|DEVICE|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
214815182|NCT02799108|DEVICE|fMRI|fMRI acquisition under the same stimulation conditions
214815183|NCT00833937|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
214815184|NCT00833937|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
214815185|NCT04092647|DRUG|Ashwagandha|Ashwagandha 350 mg po BID
214815186|NCT04092647|DRUG|Placebo|Placebo 350 mg po BID
214815187|NCT04290845|BEHAVIORAL|Relief-Hybrid|A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
214815189|NCT04419311|DEVICE|Vanguard® Knee System|Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
214815190|NCT04425447|DRUG|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
214815191|NCT04425447|DRUG|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
214815192|NCT04425447|DRUG|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
214815193|NCT04133623|DRUG|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
214815194|NCT04133623|DRUG|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
214815195|NCT05239819|BEHAVIORAL|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
214815196|NCT05239819|BEHAVIORAL|Regulated care and education|Regulated care and education will be applied
214815197|NCT01458808|OTHER|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
214815198|NCT01458808|OTHER|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
214815199|NCT03283943|RADIATION|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
214815200|NCT03283943|DRUG|Durvalumab|Durvalumab 1500 mg IV every 28 days
214815201|NCT03211403|DRUG|SHR4640|SHR4640 or placebo once daily for a week
214815202|NCT01306630|DRUG|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
214815203|NCT01939717|OTHER|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
214815204|NCT03536130|DEVICE|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
214815205|NCT04773470|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
214815206|NCT00465270|DEVICE|AMPLATZER PFO Occluder|patent foramen ovale closure device
214815207|NCT00465270|OTHER|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
214815208|NCT02004509|DRUG|Anticoagulant|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
214815209|NCT00913406|OTHER|Lutein fortification|
214815210|NCT00913406|OTHER|Standard formula|
214815211|NCT04589091|OTHER|Refractive surgery|Refractive surgery for correction of error of refraction
214815212|NCT03696394|DEVICE|BioCartilage® Micronized Cartilage Matrix|BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
214815213|NCT03233724|DRUG|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
214815214|NCT03233724|DRUG|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
214815215|NCT03233724|DRUG|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
214815216|NCT00807196|DRUG|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
214815217|NCT00807196|DRUG|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
214815218|NCT00807196|DRUG|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
214815219|NCT00807196|DRUG|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
214815220|NCT00807196|OTHER|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
214815221|NCT01448902|DRUG|OC000459|OC000459 200mg bid for 8 days
214815222|NCT01448902|DRUG|Placebo|Placebo bid for 8 days
214815223|NCT03509545|DRUG|CHF Patients: ER Torsemide 40 mg|ER Torsemide 40mg given once daily to CHF patients
214815224|NCT03509545|DRUG|CHF Patients: Furosemide 40 mg|Stable CHF patients taking twice-daily 40 mg Furosemide
214815225|NCT00314990|DRUG|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
214815226|NCT04967794|OTHER|Teleorientation and Tooth Brushing Orientation|Guide children in toothbrushing with a preventive purpose during the COVID-19 pandemic
214815227|NCT06144385|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
214815228|NCT01467791|OTHER|Observation|Observe patients
214815229|NCT03135834|BIOLOGICAL|MenABCWY|N meningitidis group A, B, C, W, and Y vaccine
214815230|NCT03135834|BIOLOGICAL|Saline|Placebo
214815231|NCT03135834|BIOLOGICAL|rLP2086|Bivalent recombinant lipoprotein 2086 vaccine
214815232|NCT03135834|BIOLOGICAL|MenACWY-CRM|meningococcal group A, C, W-135, and Y conjugate vaccine
214815233|NCT01045161|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
214815234|NCT01045161|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
214815235|NCT05878483|DEVICE|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
214815236|NCT05114447|OTHER|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
214815237|NCT05114447|OTHER|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
214815238|NCT04531605|BEHAVIORAL|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
214815239|NCT00304733|DEVICE|cast vs. shoe|
214815240|NCT00688571|DEVICE|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
214815241|NCT00046527|DRUG|ABI-007|
214815242|NCT04484545|DIAGNOSTIC_TEST|Prognostic score|Validation of scores of systemic inflammatory response
214815243|NCT01964092|BEHAVIORAL|Individual Placement and Support|
214815244|NCT01964092|BEHAVIORAL|Ordinary employment schemes|
214815245|NCT02605928|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
214815246|NCT05210062|OTHER|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
214815247|NCT01165905|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
214815248|NCT01165905|DRUG|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
214815249|NCT04874545|DRUG|Propofol|Total intravenous inhalational anesthesia
214815250|NCT02313064|DRUG|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
214815251|NCT02313064|DRUG|CXA-10 placebo|
214815252|NCT05649228|DRUG|Capsaicin 0.1% Cream|A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
214815253|NCT05649228|DRUG|Capsaicin Palmitate 0.25% Cream|A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
214815254|NCT05649228|DRUG|Placebo Cream|A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
214815255|NCT04236401|PROCEDURE|electrosurgery will be used for abdominal incision|electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also
214815256|NCT04236401|PROCEDURE|scalpel will be used for abdominal incision|scalpel will be used for abdominal wall incision and thread will be used for haemostsis
214815257|NCT04168346|DRUG|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
214815258|NCT04168346|DRUG|Placebos|NaCl 0.9% infusion
214815259|NCT01089699|BEHAVIORAL|online support group|online support group
214815260|NCT01089699|BEHAVIORAL|online support group|online support group
214815261|NCT01089699|BEHAVIORAL|home study support materials|self-study materials
214815262|NCT00030446|DRUG|carboplatin|
214815263|NCT00030446|DRUG|erlotinib hydrochloride|
214815264|NCT02752126|RADIATION|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
214815265|NCT02752126|RADIATION|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
214815266|NCT06366477|DEVICE|Vibration stimulation combined with task-oriented training|Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
214815267|NCT01417390|DRUG|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
214815268|NCT01417390|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
214815269|NCT02612337|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
214815270|NCT02612337|DRUG|Placebo|Single intratympanic injection of placebo
214815271|NCT03727100|COMBINATION_PRODUCT|Clonidine Micropellets|Injection
214815272|NCT03727100|OTHER|Sham|Injection
214815273|NCT05376683|DEVICE|Curate.AI|Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI
214815274|NCT05376683|BEHAVIORAL|Telemonitoring|Patients will report their blood pressure to a telemonitoring health platform
214815275|NCT05372406|OTHER|• no intervention|• no intervention
214815276|NCT00000697|DRUG|Foscarnet sodium|
214815277|NCT02124122|BIOLOGICAL|Lactobacillus reuteri|Probiotic
214815278|NCT02124122|BIOLOGICAL|Placebo|Placebo
214815279|NCT05334173|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
214815280|NCT03726151|BEHAVIORAL|Parent Reminders|Automated, system-generated mailed or text message reminders
214815281|NCT03726151|BEHAVIORAL|Multicomponent clinic-system strategies|"1. Workflow modifications to reduce missed opportunities for vaccination~2. Provider- and clinic-level audit and feedback~3. Provider \& staff training on workflow modifications and communication strategies"
214815282|NCT03726151|BEHAVIORAL|Combined Condition|Parent reminders and multicomponent clinic-system strategies
214815283|NCT02613000|OTHER|No intervention|
214815284|NCT04473170|BIOLOGICAL|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
214815285|NCT04473170|DRUG|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
214815286|NCT04668105|OTHER|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
214815287|NCT04668105|OTHER|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
214815288|NCT02726425|BEHAVIORAL|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
214815289|NCT05801497|PROCEDURE|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
214815290|NCT03661593|OTHER|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
214815291|NCT03521856|BEHAVIORAL|shoulder exercise|Exercises performed 3 times a week for 12 weeks
214815292|NCT03521856|BEHAVIORAL|education|
214815293|NCT05245357|BEHAVIORAL|Lentil|Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.
214815294|NCT05245357|BEHAVIORAL|Control|Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
214815295|NCT01851733|DEVICE|MRI-guided Laser Heat Ablation (MLA)|
214815296|NCT01851733|DRUG|Doxorubicin|
214815297|NCT01851733|OTHER|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
214815298|NCT01851733|DEVICE|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
214815299|NCT00901745|DRUG|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
214815300|NCT00901745|DRUG|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
214815301|NCT05314023|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
214815302|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -B|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
214815303|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -A|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
214815304|NCT00002047|DRUG|Zidovudine|
214815305|NCT03300934|DEVICE|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
214815306|NCT00799656|DRUG|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
214815307|NCT00799656|DRUG|placebo|oral administration once daily for 28 days
214815308|NCT02242201|DRUG|PNB Bupivacaine|Infusion
214815309|NCT02242201|DRUG|PAI Ropivacaine|Injection
214815310|NCT02242201|DRUG|PAI liposomal bupivacaine|Injection
214815311|NCT02242201|DRUG|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
214815312|NCT02242201|DRUG|Ketorolac|Injection, 30 mg
214815313|NCT00098826|DRUG|ispinesib|Given IV
214815314|NCT00098826|OTHER|laboratory biomarker analysis|Correlative studies
214815315|NCT00098826|OTHER|pharmacological study|Correlative studies
214815316|NCT00011570|DEVICE|Bladder & Bowel Control|
214815317|NCT00017953|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
214815318|NCT00017953|BEHAVIORAL|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
214815319|NCT02374853|DRUG|Vancomycin|Topical prophylactic antibiotic
214815320|NCT02374853|OTHER|No Vancomycin|Placebo: Sterile water. No Vancomycin.
214815321|NCT00122785|DRUG|dexamethasone|
214815322|NCT05844553|DEVICE|Measurement of inhaled measuring hydrogen peroxide in exhaled breath|Participant exhales in to device
214815323|NCT00152685|DRUG|human serum albumin|
214815324|NCT01802853|DRUG|RO6811135|Single subcutaneous dose
214815325|NCT01802853|DRUG|RO6811135|Single intravenous dose
214815326|NCT05283070|OTHER|Questionnaires, physical tests, and heart rate variability measures|"The 2MWT will be conducted in an unobstructed hallway with patients being asked to walk at moderate intensity (brisk walk) for the duration of the activity (2 minutes). The amount of distance in metres will be recorded.~The EMLi movement consists of pushing a 2kg weighted ball from the chest level forward, and then raising the ball overhead, before returning it to the starting position (Figure 1). The number of repetitions done at moderate intensity will be recorded after 60 seconds.~HRV and questionnaires previously listed"
214815327|NCT03038009|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
214815328|NCT03313349|BEHAVIORAL|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
214815329|NCT02356354|PROCEDURE|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
214815330|NCT00408070|DRUG|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
214815331|NCT00408070|DRUG|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
214815332|NCT00408070|DRUG|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
214815333|NCT02269995|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
214815334|NCT00931697|DRUG|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
214815335|NCT00931697|DRUG|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
214815336|NCT00931697|DRUG|Placebo|Over-encapsulated placebo to maintain blinding
214815337|NCT02281084|DRUG|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
214815338|NCT02281084|DRUG|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
214815339|NCT00590408|DIETARY_SUPPLEMENT|coenzyme Q10|60mg capsule twice daily for 12 weeks
214815340|NCT00590408|DIETARY_SUPPLEMENT|matching placebo|matching placebo capsule twice daily for 12 weeks
214815341|NCT00346814|DRUG|intravitreal injection|
214815342|NCT03902496|OTHER|HIT-6 Questionnaire|Headache Impact Test
214815343|NCT03902496|DEVICE|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
214815344|NCT03902496|DEVICE|Sham Spectacles|Sham
214815345|NCT01895205|DRUG|Iron isomaltoside 1000|
214815346|NCT01895205|DRUG|Red blood cell transfusion|
214815347|NCT01374750|DRUG|Sirolimus|Sirolimus
214815348|NCT01374750|DRUG|m-TOR inhibitor free|calcineurin inhibitors
214815349|NCT02351154|OTHER|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
214815350|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell|Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
214815351|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
214815352|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
214815353|NCT04699149|OTHER|Transcranial magnetic stimulation|Non-invasive brain stimulation
214815354|NCT04699149|OTHER|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
214815355|NCT04023539|DIETARY_SUPPLEMENT|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
214815356|NCT04023539|OTHER|Placebo|Placebo capsules
214815357|NCT04048317|DRUG|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
214815358|NCT04048317|DRUG|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
214815359|NCT06176326|OTHER|Ethics Education Program in Nursing|In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
214815360|NCT03938402|OTHER|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
214815361|NCT02957097|DRUG|Gabapentin|Medication used for management of neuropathic pain conditions
214815362|NCT02957097|DRUG|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
214815363|NCT05378360|BIOLOGICAL|DWP708|Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
214815364|NCT02946125|COMBINATION_PRODUCT|MDD-administered EYN-1601|Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
214815365|NCT02946125|DRUG|Phenylephrine 2.5% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
214815366|NCT02946125|DRUG|Phenylephrine 10% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
214815367|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
214815368|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
214815369|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
214815370|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
214815371|NCT05910632|BEHAVIORAL|Eccentrically strengthened resistance exercise|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with high intensity (ever 10 on the OMNI-RES Scale).
214815372|NCT05910632|BEHAVIORAL|Traditional resistance training|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8-12 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with moderate and high intensities (6 to 10 on the OMNI-RES scale).
214815373|NCT03648658|DRUG|Paracetamol 120Mg/5mL Oral Suspension|The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
214815374|NCT00962260|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
214815375|NCT01697696|DRUG|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
214815376|NCT01697696|DRUG|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
214815377|NCT01697696|DRUG|Placebo|Placebo to match QAB149
214815378|NCT02464709|DRUG|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
214815379|NCT02464709|DRUG|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
214815380|NCT03608878|BIOLOGICAL|adagloxad simolenin/OBI-821|"Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration."
214815381|NCT03608878|PROCEDURE|TACE|Transarterial chemoembolization
214815382|NCT04764916|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
214815383|NCT04764916|DRUG|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
214815384|NCT01050803|BEHAVIORAL|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
214815385|NCT01050803|BEHAVIORAL|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
214815386|NCT01424644|BIOLOGICAL|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
214815387|NCT01424644|BIOLOGICAL|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
214815388|NCT01935440|BEHAVIORAL|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
214815389|NCT01935440|BEHAVIORAL|Prevention & Testing Control|7 group sessions
214815390|NCT01350765|BEHAVIORAL|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
214815391|NCT01350765|BEHAVIORAL|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
214815392|NCT05226169|DRUG|Ferinject|"* Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~* Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin \< 100 ng/mL or TSAT \< 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
214815393|NCT05226169|OTHER|Conservative management|"* Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~* If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
214815394|NCT06623643|DIAGNOSTIC_TEST|The investigation of melatonin and cortisol levels in the saliva|In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
214815395|NCT01629069|BEHAVIORAL|Mindfulness based Resilience Training|6 weekly group sessions
214815396|NCT00662753|DEVICE|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
214815397|NCT00662753|OTHER|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
214815398|NCT02041871|DIETARY_SUPPLEMENT|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
214815399|NCT02041871|DIETARY_SUPPLEMENT|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
214815400|NCT05593965|DEVICE|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
214815401|NCT05593965|DEVICE|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
214815402|NCT05593965|DEVICE|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
214815403|NCT01061125|OTHER|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
214815404|NCT05396430|DEVICE|Urinary catheter|Duration of planned urinary cathterization following cesarean delivery
214815405|NCT04125706|DRUG|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
214815406|NCT04125706|DRUG|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
214815407|NCT03437148|DEVICE|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
214815408|NCT03437148|DEVICE|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
214815409|NCT01077596|DRUG|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
214815410|NCT01077596|DRUG|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
214815411|NCT01077596|DRUG|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
214815412|NCT01077596|DRUG|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
214815413|NCT01091090|BEHAVIORAL|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
214815414|NCT01091090|BEHAVIORAL|Control|Treatment as usual
214815415|NCT05400148|DRUG|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)
214815416|NCT03422770|DIAGNOSTIC_TEST|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
214815417|NCT03422770|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
214815418|NCT03422770|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
214815419|NCT03422770|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
214815420|NCT03422770|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
214815421|NCT03585530|DRUG|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
214815422|NCT04732195|DEVICE|Pilocarpine microneedle patch|Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
214815423|NCT04732195|DEVICE|Pilocarpine Iontophoresis|Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
214815424|NCT03110003|DRUG|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
215031332|NCT04744584|OTHER|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
214815425|NCT03110003|DRUG|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
214815426|NCT02372630|DRUG|Linagliptin|5 mg daily oral tablets of linagliptin
214815427|NCT02372630|DRUG|Placebo|matching placebo giving orally daily
214815428|NCT02623543|DEVICE|OrthoK|
214815429|NCT00534443|PROCEDURE|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
214815430|NCT01852617|BEHAVIORAL|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
214815431|NCT02947230|OTHER|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
214815432|NCT00167505|BEHAVIORAL|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
214815433|NCT00167505|BEHAVIORAL|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
214815434|NCT03619005|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
214815435|NCT03619005|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
214815436|NCT02911597|DRUG|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
214815437|NCT04460105|DRUG|Lanadelumab|Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
214815438|NCT04460105|OTHER|Placebo|Participants will receive placebo matching IV infusion on Day 1 and Day 4.
214815439|NCT01690494|BEHAVIORAL|PACT|Couple-based behavioral HIV/STI preventive intervention
214815440|NCT01690494|BEHAVIORAL|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
214815441|NCT03751605|PROCEDURE|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
214815442|NCT05914857|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
214815443|NCT05914857|BEHAVIORAL|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
214815444|NCT05076305|OTHER|No specific intervention; cases are retrospective and patients have already been treated.|To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
214815445|NCT04408144|DRUG|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
214815446|NCT02024932|DRUG|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
214815447|NCT02024932|DRUG|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
214815448|NCT00847678|BIOLOGICAL|Efungumab (Mycograb)|
214815449|NCT00847678|BIOLOGICAL|placebo|
214815450|NCT00847678|BIOLOGICAL|Amphotericin B|
214815451|NCT00847678|BIOLOGICAL|5 flucytosine|
214815452|NCT02445339|DRUG|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
214815453|NCT05986357|DIAGNOSTIC_TEST|maternal serum C reactive protein|maternal serum high sensitivity C reactive protein
214815454|NCT05986357|DIAGNOSTIC_TEST|total leucocytic count levels|total leucocytic count levels
214815455|NCT05986357|DIAGNOSTIC_TEST|differential leucocytic count levels|differential leucocytic count levels
214815456|NCT01454544|BIOLOGICAL|AIT Tablet|1 tablet per day in 12 months
214815457|NCT00383097|GENETIC|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
214815458|NCT00383097|GENETIC|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
214815459|NCT05693597|DRUG|Imtenan Oil|Cold Press Oil
214815460|NCT05693597|DRUG|Baraka Capsules|Soft Gelatin Capsules
214815461|NCT03020641|PROCEDURE|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
214815462|NCT03020641|PROCEDURE|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
214815463|NCT01442857|RADIATION|MRI|High resolution MRI of the brachial plexus
214815464|NCT04314505|DRUG|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
214815465|NCT04314505|DRUG|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
214815466|NCT03041025|DRUG|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
214815467|NCT03041025|DRUG|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
214815468|NCT05397093|BIOLOGICAL|ITIL-306|ITIL-306 is a cell therapy product derived from a participant's own TILs and contains a unique molecule designed to increase TIL activity when it encounters FOLR1 on the tumor. A portion of the participant's tumor is surgically removed to make a personalized ITIL-306 product. Once ITIL-306 has been made, the participant is treated with 3 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by 2 days of rest then a single infusion of ITIL-306.
214815469|NCT01033305|DRUG|CyCol™|Orally, once per day for 4 weeks
214815470|NCT01033305|DRUG|Placebo|Orally, once per day for 4 weeks
214815471|NCT01875315|OTHER|Diagnostic Cardiac Imaging|
214815472|NCT03388671|PROCEDURE|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
214815473|NCT03388671|PROCEDURE|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
214815474|NCT03388671|DRUG|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
214815475|NCT03962348|BEHAVIORAL|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
214815476|NCT00938171|PROCEDURE|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
214815477|NCT00938171|PROCEDURE|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
214815478|NCT02409693|PROCEDURE|Myringotomy with tube insertion|
214815479|NCT01670890|DRUG|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
214815480|NCT01670890|DRUG|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
214815481|NCT02963259|DEVICE|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
214815482|NCT05016063|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
214815483|NCT05016063|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
214815484|NCT05016063|BIOLOGICAL|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
214815485|NCT02533362|DRUG|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
214815486|NCT00731705|PROCEDURE|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
214815487|NCT04513730|OTHER|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
214815488|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
214815489|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
214815490|NCT01436422|BIOLOGICAL|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
214815491|NCT05900934|OTHER|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
214815492|NCT05900934|OTHER|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
214815493|NCT01448798|PROCEDURE|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
214815494|NCT01448798|PROCEDURE|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
214815495|NCT00939003|BIOLOGICAL|Adalimumab|40 mg every other week up to Week 12
214815496|NCT00939003|BIOLOGICAL|Placebo|Placebo every other week up to Week 12
214815497|NCT00939003|BIOLOGICAL|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
214815498|NCT05087134|DRUG|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
214815499|NCT00757874|DRUG|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
214815500|NCT00757874|DRUG|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
214815501|NCT01885455|OTHER|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
214815502|NCT01885455|OTHER|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
214815503|NCT03584139|DEVICE|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
214815504|NCT03584139|DEVICE|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
214815505|NCT01612520|BEHAVIORAL|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
214815506|NCT05357417|DRUG|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
214815507|NCT05357417|DRUG|Bevacizumab|15mg/kg, day 1
214815508|NCT00226317|DRUG|Aripiprazole|
214815509|NCT00932880|DRUG|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
214815510|NCT00932880|DRUG|Norvasc|10 mg dose (Pfizer, USA)
214815511|NCT02131129|DEVICE|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
214815512|NCT02131129|DEVICE|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
214815513|NCT00727961|DRUG|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
214815514|NCT01848340|DRUG|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
214815515|NCT01848340|DRUG|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
214815516|NCT01848340|DRUG|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
214815517|NCT03386019|OTHER|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
214815518|NCT03386019|OTHER|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
214815519|NCT03386019|OTHER|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
214815520|NCT01467622|PROCEDURE|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
214815521|NCT02865122|DRUG|NTRA-9620|Oral daily dose
214815522|NCT02865122|DRUG|Placebo|Oral daily dose
214815523|NCT00278018|PROCEDURE|Immunotherapy treatment for solid tumors|
214815524|NCT04357639|OTHER|No intervention|No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
214815525|NCT05330754|DIETARY_SUPPLEMENT|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
214815526|NCT02388620|DRUG|LEE011|400 mg
214815527|NCT03552250|BEHAVIORAL|Parenting for Lifelong Health for Young Children|In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
214815528|NCT04549883|OTHER|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
214815529|NCT02152683|DEVICE|Renova|Low- Intensity Shockwave
214815530|NCT06041061|BIOLOGICAL|Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
214815531|NCT06041061|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
214815532|NCT05984420|DEVICE|LimpiAD 2,5% plus cream|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
214815533|NCT05984420|OTHER|Vehicle|"Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component."
214815534|NCT05984420|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
214815535|NCT02978586|DEVICE|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
214815536|NCT02012920|DRUG|Seviteronel: given orally once daily in 28 day cycles|
214815537|NCT03462654|BEHAVIORAL|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
214815538|NCT03462654|BEHAVIORAL|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
214815539|NCT00058955|DRUG|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
214815540|NCT06123533|OTHER|No intervention|There is no intervention.
214815541|NCT03697798|BIOLOGICAL|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
214815542|NCT03488186|DRUG|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
214815543|NCT02404194|BEHAVIORAL|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
214815544|NCT02404194|BEHAVIORAL|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
214815545|NCT01721850|OTHER|control formula|commercial stage 1 infant formula
214815546|NCT01721850|OTHER|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
214815547|NCT01721850|OTHER|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
214815548|NCT03497247|BEHAVIORAL|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
214815549|NCT04478786|OTHER|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
214815550|NCT01757886|OTHER|Biomarkers to analyze both intracoronary thrombi as blood|
214815551|NCT03568565|BEHAVIORAL|ePREP Program|see arm descriptions
214815552|NCT03568565|BEHAVIORAL|OurRelationship Program|see arm descriptions
214815553|NCT05815056|DEVICE|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
214815554|NCT05815056|DRUG|drug intervention|using sufentanyl 5mg intravenously during the surgery
214815555|NCT03951363|BEHAVIORAL|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
214815556|NCT04729881|OTHER|Conventional Rehabiliation Group|Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise
214815557|NCT04729881|OTHER|Spesific Exercise Group|Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise
214815558|NCT04729881|OTHER|Control group|No intervention will be aplied
214815559|NCT04906772|DRUG|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
214815560|NCT04906772|DRUG|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
214815561|NCT02435823|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
214815562|NCT00229281|BEHAVIORAL|Group therapy|
214815563|NCT00831428|OTHER|no intervention|this is a screening study, not an interventional study
214815564|NCT01502254|OTHER|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
214815565|NCT05130554|PROCEDURE|XEN45 gel stent implantation|The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
214815566|NCT02105103|DEVICE|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
214815567|NCT02187354|DRUG|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment \& no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) \& 28μg/day for the escalated dose after dose step should not be exceeded.
214815568|NCT02187354|OTHER|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
214815569|NCT03851250|DRUG|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
214815570|NCT03851250|DRUG|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
214815571|NCT04005677|DIAGNOSTIC_TEST|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
214815572|NCT00911781|OTHER|No intervention|We are only asking for photographs from parents.
214815573|NCT03871166|OTHER|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~\[Time Frame: 01/2007 - 12/2018\]"
214815574|NCT04270721|BEHAVIORAL|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
214815575|NCT00915694|DRUG|nelfinavir mesylate|
214815576|NCT00915694|DRUG|temozolomide|
214815577|NCT00915694|PROCEDURE|adjuvant therapy|
214815578|NCT00915694|RADIATION|radiation therapy|
214815579|NCT01421277|DRUG|Statin Therapy|Investigator's choice of any statin.
214815580|NCT00477347|DEVICE|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
214815581|NCT00477347|DEVICE|Manual administration|intraoperative manual administration of propofol and remifentanil
214815582|NCT03989648|OTHER|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
214815583|NCT03989648|OTHER|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
214815584|NCT04907370|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
214815585|NCT04907370|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
214815586|NCT04907370|DRUG|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
214815587|NCT04907370|DRUG|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
214815588|NCT04907370|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
214815589|NCT05974293|DRUG|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
214815590|NCT05974293|DRUG|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
214815591|NCT04062045|DRUG|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
214815592|NCT04062045|DRUG|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
214815593|NCT01530880|DRUG|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
214815594|NCT01530880|DRUG|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
214815595|NCT05594420|PROCEDURE|Mitral valve replacement|Mitral valve replacement through median sternotomy and minimally invasive approach
214815596|NCT02232776|DRUG|Losartan|Dose of Losartan : 0.7mg/kg once daily.
214815597|NCT01212848|DEVICE|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
214815598|NCT01212848|DEVICE|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
214815599|NCT02713425|DEVICE|Entertaining Video Game|Children between 7 \& 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
214815600|NCT02053857|DIETARY_SUPPLEMENT|RUTF|
214815601|NCT02053857|DIETARY_SUPPLEMENT|RUTF-P|
214815602|NCT02053857|DRUG|Amoxicillin|
214815603|NCT06559566|PROCEDURE|USG|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
214815604|NCT06559566|PROCEDURE|BCT|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
214815605|NCT04229121|OTHER|nonintervention|nonintervention
214815606|NCT01646554|DRUG|Modified FOLFOX6|
214815607|NCT01646554|BIOLOGICAL|Aflibercept|Targeted therapy
214815608|NCT01646554|PROCEDURE|Surgery|
214815609|NCT03663322|PROCEDURE|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
214815610|NCT03663322|PROCEDURE|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
214815611|NCT04362566|DRUG|Bupivacaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
214815612|NCT04362566|OTHER|Placebo Saline|Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
214815613|NCT04484883|OTHER|Observational|Observational
214815614|NCT03253003|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
214815615|NCT05044364|DRUG|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
214815616|NCT01015703|BIOLOGICAL|CoVaccine HT|intramuscular injection, dose escalation
214815617|NCT02896010|OTHER|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
214815618|NCT02896010|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
214815619|NCT03227835|OTHER|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR \>29mL/min/1.73m2
214815620|NCT04582019|DEVICE|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
214815621|NCT05893290|OTHER|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
214815622|NCT05893290|OTHER|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
214815623|NCT02581553|DRUG|lesinurad/allopurinol 200/300 FDC tablets|
214815624|NCT02581553|DRUG|lesinurad 200 mg|
214815625|NCT02581553|DRUG|allopurinol 300 mg|
214815626|NCT02581553|DRUG|lesinurad/allopurinol 200/200 FDC tablets|
214815627|NCT02581553|DRUG|allopurinol 200 mg|
214815628|NCT05347719|BEHAVIORAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
214815629|NCT04784338|BEHAVIORAL|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
214815630|NCT04784338|BEHAVIORAL|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
214815631|NCT01613872|OTHER|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
214815632|NCT00042874|DRUG|alvocidib|Given IV
214815633|NCT00042874|DRUG|irinotecan hydrochloride|Given IV
214815634|NCT00042874|DRUG|fluorouracil|Given IV
214815635|NCT00042874|DRUG|leucovorin calcium|Given IV
214815636|NCT00042874|OTHER|laboratory biomarker analysis|Correlative studies
214815637|NCT03512925|OTHER|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
214815638|NCT03316963|DRUG|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
214815639|NCT01793558|PROCEDURE|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
214815640|NCT00834418|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
214815641|NCT00834418|DRUG|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
214815642|NCT02540603|DEVICE|F&P Jupiter Full Face Mask|Investigative F\&P Jupiter full face mask to be used for OSA therapy
214815643|NCT04303884|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
214815644|NCT01705574|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
214815645|NCT01705574|DRUG|ATV|300 mg capsule administered orally with food once daily
214815646|NCT01705574|DRUG|RTV|100 mg tablet administered orally with food once daily
214815647|NCT01705574|DRUG|FTC/TDF|200/300 mg tablet administered orally with food once daily
214815648|NCT01705574|DRUG|E/C/F/TDF Placebo|Tablet administered orally with food once daily
214815649|NCT01705574|DRUG|ATV Placebo|Tablet administered orally with food once daily
214815650|NCT01705574|DRUG|RTV Placebo|Capsule administered orally with food once daily
214815651|NCT01705574|DRUG|FTC/TDF Placebo|Tablet administered orally with food once daily
214815652|NCT01705574|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
214815653|NCT06457308|BIOLOGICAL|Physical training of agility|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training,
214815654|NCT06457308|BIOLOGICAL|Physical training of resistance|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars
214815655|NCT03049215|DEVICE|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
214815656|NCT03049215|DEVICE|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
214815657|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
214815658|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
214815659|NCT03939364|DRUG|SBS-101|Isotretinoin Oral-Adhesive Film
214815660|NCT03939364|DRUG|Placebo|Placebo
214815661|NCT00975494|DRUG|Sildenafil|
214815662|NCT00975494|DRUG|Placebo|
214815663|NCT05065346|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214815664|NCT01313949|OTHER|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
214815665|NCT06061146|DRUG|Arm A|anti-PD-1 immunotherapy
214815666|NCT06061146|DRUG|Arm A|chemotherapy
214815667|NCT06061146|RADIATION|Arm A|Radiation Concurrent Radiation, 1.8Gy/f, 28f
214815668|NCT06061146|DRUG|Arm B|chemotherapy
214815669|NCT06061146|RADIATION|Arm B|Radiation Concurrent Radiation, 1.8Gy/f, 28f
214815670|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
214815671|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
214815672|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
214815673|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
214815674|NCT03804762|PROCEDURE|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
214815675|NCT02815527|OTHER|Fresubin intensive|Enteral nutrition containing a high protein concentration
214815676|NCT02171793|DRUG|BI 1744 CL|
214815677|NCT02171793|DRUG|Placebo|
214815678|NCT00614471|DRUG|Entecavir|0.5mg po daily for 24 weeks
214815679|NCT00614471|DRUG|Entecavir|0.5mg po daily from week 13 to week 36
214815680|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
214815681|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
214815682|NCT00300911|DRUG|Rosiglitazone(drug), cardiac adverse effects|
214815683|NCT00089661|DRUG|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
214815684|NCT00089661|DRUG|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
214815685|NCT04826653|OTHER|Suture removal|Suture removal after coronally advanced flap plus a connective tissue graft
214815686|NCT01273805|DRUG|Hydroxychloroquine|
214815687|NCT00444847|DEVICE|Hyperbaric chamber|
214815688|NCT03493347|BEHAVIORAL|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
214815689|NCT03959605|GENETIC|blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism
214815690|NCT03959605|DIAGNOSTIC_TEST|Ophtalmological examination|measurement of visual acuity, OCT and OCTA
214815691|NCT02647944|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
214815692|NCT02647944|DRUG|Placebo|
214815693|NCT00941174|DRUG|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
214815694|NCT05340140|DIAGNOSTIC_TEST|deep learning model|deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
214815695|NCT03101540|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
214815696|NCT04400617|BEHAVIORAL|Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.|The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.
214815697|NCT03596944|DRUG|Statin|Prescribed with statins for primary prevention
214815698|NCT01246076|DRUG|Lenalidomide|
214815699|NCT04525365|PROCEDURE|Pleural aspiration|Pleural aspiration
214815700|NCT02246322|DEVICE|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
214815701|NCT02246322|DEVICE|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
214815702|NCT02760368|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
214815703|NCT02760368|DRUG|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
214815704|NCT01700244|DEVICE|Pacemaker implant|
214815705|NCT03375463|DRUG|Tirzepatide|Administered SC
214815706|NCT03375463|DRUG|Tirzepatide|Administered IV
214815707|NCT03375463|DRUG|Placebo|Administered SC
214815708|NCT03375463|DRUG|Tirzepatide|Administered IV
214815709|NCT00022386|BIOLOGICAL|epoetin alfa|
214815710|NCT00022386|PROCEDURE|quality-of-life assessment|
214815711|NCT04909190|PROCEDURE|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
214815712|NCT01602419|OTHER|Patients using Wilate as standard of care|Patients with von Willebrand Disease using Wilate for a period of 2 years.
214815713|NCT01792635|DRUG|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
214815714|NCT01792635|DRUG|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
214815715|NCT00800137|DRUG|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. \> 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
214815716|NCT00800137|DRUG|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
214815717|NCT03974685|DRUG|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
214815718|NCT00569153|DRUG|TAK-700|"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning"
214815719|NCT02062489|DRUG|Tamoxifen|20 mg(2#)/day, PO, daily
214815720|NCT02062489|DRUG|Placebo|2#/day, PO, daily
214815721|NCT05824325|DRUG|SHR-A1811|HER2 ADC
214815722|NCT05824325|DRUG|TROP2 ADC|TROP2 ADC
214815723|NCT02139839|OTHER|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
214815724|NCT02139839|DRUG|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
214815725|NCT01860521|PROCEDURE|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
214815726|NCT01860521|PROCEDURE|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
214815727|NCT01860521|PROCEDURE|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
214815728|NCT01860521|DRUG|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
214815729|NCT01860521|DEVICE|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
214815730|NCT01860521|DEVICE|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
214815731|NCT01860521|DRUG|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
214815732|NCT02431221|DRUG|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
214815733|NCT02431221|DRUG|Placebo|
214815734|NCT05963321|DEVICE|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
214815735|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
214815736|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
214815737|NCT03970421|OTHER|Observation|Check clinical status at different time intervals during 3 months
214815738|NCT03045250|DEVICE|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
214815739|NCT03045250|PROCEDURE|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
214815740|NCT03045250|PROCEDURE|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
214815741|NCT03045250|OTHER|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
214815742|NCT00904423|DRUG|Vitamin D|up to 2400 mg; oral tablet
214815743|NCT00478179|DRUG|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
214815744|NCT05063903|OTHER|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
214815745|NCT00629590|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
214815746|NCT04396015|DIETARY_SUPPLEMENT|Bulletproof Brain Octane|Medium chain triglyceride oil (MCT)
214815747|NCT04396015|DIETARY_SUPPLEMENT|Placebo|Placebo (olive) oil
214815748|NCT02902211|DEVICE|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
214815749|NCT02902211|OTHER|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
214815750|NCT02498847|BEHAVIORAL|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication"
214815751|NCT05075447|BEHAVIORAL|Emotion Control Treatment Program|Intervention programs include Child Training and Training in real scenes
214815752|NCT03144505|BEHAVIORAL|MCT combined with RT Group|
214815753|NCT03144505|BEHAVIORAL|HIIT combined with RT Group|
214815754|NCT03025945|DRUG|Nepafenac 0.3%|
214815755|NCT03025945|DRUG|Saline Solution|
214815756|NCT00438945|DRUG|Eprosartan|
214815757|NCT01513174|DRUG|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
214815758|NCT01513174|DRUG|Olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
214815759|NCT01158274|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214815760|NCT01158274|DRUG|capecitabine|Given orally
214815761|NCT01158274|OTHER|laboratory biomarker analysis|Correlative studies
214815762|NCT00704691|DRUG|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
214815763|NCT01046474|BEHAVIORAL|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
214815764|NCT02413320|DRUG|Paclitaxel|
214815765|NCT02413320|DRUG|Carboplatin|
214815766|NCT02413320|DRUG|Doxorubicin|
214815767|NCT02413320|DRUG|Cyclophosphamide|
214815768|NCT02413320|DRUG|Docetaxel|
214815769|NCT04492774|COMBINATION_PRODUCT|Goldic serum|epidural injections
214815770|NCT04492774|DRUG|Steroid injections|epidural injections
214815771|NCT04492774|PROCEDURE|Manual therapy|Veno-lymphatic drainage
214815772|NCT04195360|OTHER|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
214815773|NCT05203562|PROCEDURE|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
214815774|NCT05203562|DRUG|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
214815775|NCT01922180|RADIATION|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
214815776|NCT04131374|BEHAVIORAL|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
214815777|NCT03476265|DEVICE|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
214815778|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
214815779|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
214815780|NCT04368520|OTHER|Placebo|Hypromellose capsules, given daily for 3 months
214815781|NCT04374448|PROCEDURE|Sinonasal Benign or Malignant Tumor Resection|During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.
214815782|NCT04374448|PROCEDURE|Skull Base Surgery (Assessment of Nasoseptal Flap)|In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.
214815783|NCT04374448|PROCEDURE|Endoscopic Sinus Surgery|During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.
214815784|NCT04374448|PROCEDURE|Posterior Epistaxis Management (SPA Ligation)|During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
214815785|NCT00335348|DRUG|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
214815786|NCT00335348|DRUG|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
214815787|NCT02096991|OTHER|Can 1|drink the beverage in a can and a glass bottle
214815788|NCT02096991|OTHER|Can 2|Consume two canned beverage
214815789|NCT02096991|OTHER|Glass|consume two glass bottled beverage
214815790|NCT04312165|DEVICE|Duramesh Laparotomy Closure|Closure of midline laparotomy incision with experimental suture
214815791|NCT04312165|DEVICE|Conventional suture closure|Closure of midline laparotomy incision with standard suture
214815792|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|"In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W"
214815793|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|In Phase II study, eligible patients receive the dose determined in phase Ib cohort.
214815794|NCT01844674|DRUG|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast \>/= 10 hours.
214815795|NCT01844674|DRUG|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
214815796|NCT00190840|DRUG|pemetrexed|
214815797|NCT00485667|DRUG|SKY0402|Subects received either 300mg or 450mg
214815798|NCT00485667|DRUG|Moxifloxacin 400mg|
214815799|NCT00485667|DRUG|Placebo injection|
214815800|NCT00485667|DRUG|Placebo tablet|
214815801|NCT03134586|OTHER|Diagnostic imaging|
214815802|NCT04395586|OTHER|Culture|Culture
214815803|NCT06056817|DEVICE|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
214815804|NCT05030363|DRUG|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
214815805|NCT03001063|OTHER|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
214815806|NCT03001063|OTHER|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
214815807|NCT04701541|DEVICE|Diaphragmatic Ultrasound|Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
214815808|NCT02130518|DRUG|Auriclosene Irrigation Solution, 0.2%|
214815809|NCT02130518|DRUG|Auriclosene Vehicle Solution|
214815810|NCT00995241|DRUG|Raltegravir|Raltegravir 800 mg / 24 hours.
214815811|NCT04511910|PROCEDURE|Early Laparoscopic Cholecystectomy|
214815812|NCT00019812|BIOLOGICAL|trastuzumab|
214815813|NCT00019812|DRUG|paclitaxel|
214815814|NCT00451412|DRUG|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
214815815|NCT00451412|DRUG|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
214815816|NCT00626184|DRUG|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
214815817|NCT03617523|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214815818|NCT03617523|BIOLOGICAL|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214815819|NCT03617523|BIOLOGICAL|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214815820|NCT00421850|BEHAVIORAL|UNITED Planned Care|
214815821|NCT02408302|DRUG|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
214815822|NCT05206318|DRUG|Topical Cysteamine|Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
214815823|NCT05206318|DRUG|Topical Vehicle Control|Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
214815824|NCT04691895|OTHER|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
214815825|NCT00900718|DEVICE|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
214815826|NCT00900718|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
214815827|NCT05497921|DEVICE|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
214815828|NCT02682784|DRUG|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
214815829|NCT02682784|DRUG|Placebo|
214815830|NCT01074203|DRUG|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
214815831|NCT00801164|DRUG|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
214815832|NCT00801164|DRUG|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
214815833|NCT05994859|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.
214815834|NCT00327379|DRUG|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
214815835|NCT00327379|DRUG|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
214815836|NCT04146987|PROCEDURE|Rotator cuff repair surgery|Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
214815837|NCT05333809|DRUG|Pembrolizumab|an anti-PD-1 monoclonal antibody
214815838|NCT05333809|DRUG|Disitamab vedotin|HER2-ADC
214815839|NCT01344707|DRUG|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
214815840|NCT06151678|OTHER|Pain Education|Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
214815841|NCT03137251|DEVICE|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
214815842|NCT03137251|DEVICE|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
214815843|NCT03137251|DEVICE|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
214815844|NCT05287061|BEHAVIORAL|Multicomponent Psychological Program (MPP)|"Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive."
214815845|NCT04606628|OTHER|Eggshell membrane (ESM)|The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.
214815846|NCT04606628|OTHER|Placebo|The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks
214815847|NCT05029297|DRUG|Capsaicin|
214815848|NCT05910853|DIAGNOSTIC_TEST|Specimen Donation|Blood donation
214815849|NCT03671447|OTHER|ICU Usual Care|The control condition delivered at ICU is usual care.
214815850|NCT03671447|BEHAVIORAL|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
214815851|NCT04353063|BEHAVIORAL|Multidisciplinary care with a personalized care|During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
214815852|NCT00467363|DRUG|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
214815853|NCT00467363|DIETARY_SUPPLEMENT|Folic acid|400micrograms of folic acid.
214815854|NCT04839276|COMBINATION_PRODUCT|Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat|Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
214815855|NCT04839276|PROCEDURE|Injection Laryngoplasty with Autologous Fat|Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
214815856|NCT00002880|DRUG|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
214815857|NCT04962594|OTHER|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
214815858|NCT04962594|OTHER|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
214815859|NCT04962594|OTHER|Breast feeding (BF)|Exclusive breast feeding up to 4 months
214815860|NCT06156644|DEVICE|PFA|Ablation to treat trail fibrillation
214815861|NCT04533594|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
214815862|NCT00609960|BEHAVIORAL|clowns present|clowns present during the proccess of induction of anesthesia
214815863|NCT00609960|DRUG|midazolam|midazolam
214815864|NCT02938962|DRUG|Tranexamic Acid|
214815865|NCT05305430|DEVICE|Synergy Cervical Disc System|motion preservation disc
214815866|NCT00056667|BEHAVIORAL|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
214815867|NCT00056667|BEHAVIORAL|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
215031333|NCT04744584|OTHER|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
214815868|NCT00056667|OTHER|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
214815869|NCT03883412|OTHER|Exercise|16 weeks of treatment
214815870|NCT03883412|DRUG|Liraglutide|16 weeks of Liraglutide
214815871|NCT04146766|COMBINATION_PRODUCT|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
214815872|NCT02288195|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
214815873|NCT02288195|DRUG|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
214815874|NCT02288195|RADIATION|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
214815875|NCT04461379|BIOLOGICAL|BCG vaccine|A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
214815876|NCT04461379|OTHER|Placebo|A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
214815877|NCT03892408|DEVICE|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
214815878|NCT04055584|DIAGNOSTIC_TEST|Sputum|DNA extraction and perform a diversity of molecular diagnostic tests
214815879|NCT05070052|BEHAVIORAL|cognitive behavioral therapy|9 sessions of CBT weekly treatment in group setting
214815880|NCT05070052|BEHAVIORAL|mindfulness-based cognitive therapy|9 sessions of MBCT weekly treatment in group setting
214815881|NCT00051233|PROCEDURE|World Wide Web-Based Psychoeducation|
214815882|NCT00000885|DRUG|Indinavir sulfate|
214815883|NCT00000885|DRUG|Abacavir sulfate|
214815884|NCT00000885|DRUG|Nelfinavir mesylate|
214815885|NCT00000885|DRUG|Efavirenz|
214815886|NCT00000885|DRUG|Levocarnitine|
214815887|NCT00000885|DRUG|Adefovir dipivoxil|
214815888|NCT00000885|DRUG|Lamivudine|
214815889|NCT00000885|DRUG|Stavudine|
214815890|NCT00000885|DRUG|Zidovudine|
214815891|NCT00000885|DRUG|Didanosine|
214815892|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
214815893|NCT05506007|DRUG|DA-5216-R|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
214815894|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
214815895|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
214815896|NCT03667183|OTHER|Pilates|Specific postures in movement according to Pilates guidelines.
214815897|NCT03727828|DIAGNOSTIC_TEST|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
214815898|NCT05419661|OTHER|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
214815899|NCT04865653|DRUG|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
214815900|NCT04865653|DRUG|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
214815901|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
214815902|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
214815903|NCT04865653|OTHER|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
214815904|NCT04327453|DEVICE|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
214815905|NCT04327453|DEVICE|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
214815906|NCT04327453|DEVICE|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
214815907|NCT03738605|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
214815908|NCT03383354|OTHER|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
214815909|NCT05408897|DIAGNOSTIC_TEST|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
214815910|NCT02757105|DRUG|BEKINDA|
214815911|NCT02757105|DRUG|Placebo|
214815912|NCT01564238|OTHER|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
214815913|NCT01564238|OTHER|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
214815914|NCT01401647|DRUG|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
214815915|NCT01401647|DRUG|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
214815916|NCT01401647|OTHER|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
214815917|NCT01599728|DRUG|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
214815918|NCT03597243|OTHER|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
214815919|NCT00546988|BIOLOGICAL|allogeneic stem cell transplant|
214815920|NCT00471419|DRUG|Rimexolone|
214815921|NCT02554032|PROCEDURE|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
214815922|NCT02554032|PROCEDURE|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
214815923|NCT01457716|DRUG|Budesonide|Single inhalation
214815924|NCT01457716|DRUG|Formoterol|Single inhalation
214815925|NCT01457716|DEVICE|Easyhaler|Inhaler device
214815926|NCT01457716|DEVICE|Turbohaler Forte|Inhaler device
214815927|NCT04156919|BEHAVIORAL|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
214815928|NCT04156919|OTHER|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
214815929|NCT01862627|PROCEDURE|Optical coherence tomography|
214815930|NCT03034694|OTHER|teledermatology consult|teledermatology consult
214815931|NCT03034694|OTHER|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
214815932|NCT00752973|DRUG|MALG (malathion) Treatment|MALG applied for 30 minutes
214815933|NCT01935076|BEHAVIORAL|Neonatal exposure to maternal obesity|
214815934|NCT05428020|DEVICE|Indwelling foley catheter|short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
214815935|NCT05428020|OTHER|No foley catheter|No foley catheter is placed for surgery
214815936|NCT03502148|DRUG|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
214815937|NCT04230330|DRUG|IV Nivolumab|240mg every 2 weeks.
214815938|NCT04230330|DRUG|IV Nivolumab|Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
214815939|NCT04230330|DRUG|IV Gemcitabine|800mg/m2 on Days 1 and 8 every 21 days
214815940|NCT04230330|DRUG|IV Cisplatin|20mg/m2 on Day 1 to 4 every 21 days
214815941|NCT04230330|DRUG|IV/PO Dexamethasone|10mg on Days 1 to 4 every 21 days
214815942|NCT04230330|DRUG|IV L-asparaginase|6000 Units/m2 on Days 2 to 8 every 21 days
214815943|NCT03600480|DRUG|NNC0174-0833|Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
214815944|NCT03600480|DRUG|Semaglutide|Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
214815945|NCT03600480|DRUG|Placebo (NNC0174-0833)|Participants will receive once weekly injections of NNC0174-0833 matched placebo.
214815946|NCT00473330|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
214815947|NCT00473330|DRUG|Sham injection|
214815948|NCT02261857|DEVICE|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
214815949|NCT03888430|PROCEDURE|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
214815950|NCT01975948|OTHER|Mental Health Practice Support Program|"1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
214815951|NCT01975948|OTHER|Treatment as Usual|Physicians manage patients with depression as usual
214815952|NCT01675765|BIOLOGICAL|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
214815953|NCT01675765|BIOLOGICAL|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
214815954|NCT04807439|DEVICE|SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries \>3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
214815955|NCT01152840|DRUG|RAD001|"RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn."
214815956|NCT01111864|DIETARY_SUPPLEMENT|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
214815957|NCT01111864|DIETARY_SUPPLEMENT|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
214815958|NCT05253950|OTHER|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
214815959|NCT00260650|BEHAVIORAL|Heart PACT Program|patient activation intervention
214815960|NCT04325724|OTHER|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
214815961|NCT04325724|OTHER|Dermatological evaluation|treatment and evaluation
214815962|NCT04325724|OTHER|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
214815963|NCT04325724|OTHER|para clinical data|biological data, medical imaging data
214815964|NCT04325724|OTHER|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
214815965|NCT02834663|DRUG|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
214815966|NCT02986386|PROCEDURE|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
214815967|NCT02986386|PROCEDURE|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
214815968|NCT04215510|PROCEDURE|endonasal endoscopic surgery|143 patients will undergo endonasal endoscopic surgery
214815969|NCT04215510|RADIATION|radiation therapy(IMRT)|143 patients will undergo radiation therapy.
214815970|NCT04887818|DRUG|2% Diltiazem ointment with 1.5% lidocaine|3 g of topical 2% diltiazem ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
214815971|NCT04887818|DRUG|0.3% Nifedipine ointment with 1.5% lidocaine|3 g of topical 0.3% nifedipine ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
214815972|NCT01181700|DRUG|Treatment A|PF-00241939 300 ug using inhaler A
214815973|NCT01181700|DRUG|Treatment B|PF-00241939 300 ug using inhaler A
214815974|NCT01181700|DRUG|Treatment C|PF-00241939 300 ug using inhaler A
214815975|NCT01181700|DRUG|Treatment D|PF-00241939 300 ug using inhaler B
214815976|NCT01181700|DRUG|Treatment E|PF-00241939 300 ug using inhaler B
214815977|NCT01181700|DRUG|Treatment F|PF-00241939 300 ug using inhaler B
214815978|NCT01181700|DRUG|Treatment G|PF-00241939 300 ug using inhaler B
214815979|NCT04596007|DRUG|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
214815980|NCT04596007|DRUG|Placebo|placebo
214815981|NCT02356978|DEVICE|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
214815982|NCT02356978|DEVICE|DRAP|
214815983|NCT02020915|PROCEDURE|lateral sphincterotomy|
214815984|NCT02020915|PROCEDURE|ultrasound guided lateral sphincterotomy|
214815985|NCT05844605|PROCEDURE|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
214815986|NCT05377931|DIAGNOSTIC_TEST|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
214815987|NCT05377931|DIAGNOSTIC_TEST|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
214815988|NCT02305394|DRUG|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
214815989|NCT02305394|DRUG|propofol and normal saline|propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
214815990|NCT05537129|PROCEDURE|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
214815991|NCT06403930|DEVICE|Maxillary Obturator|Maxillary obturators are prosthetic devices used to close maxillary defects resulting from surgical removal of part or all of the maxilla bone due to conditions like tumors or congenital anomalies. They separate the oral and nasal cavities, restore speech, swallowing, and mastication functions, provide facial support, and improve aesthetics and quality of life.
214815992|NCT05113693|DRUG|CKD-393|QD, PO
214815993|NCT05113693|DRUG|CKD-501, D759, H053|QD, PO
214815994|NCT05479383|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
214815995|NCT06560814|DRUG|Cabergoline plus timed intercourse|Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
214815996|NCT06560814|DRUG|Dydrogesterone plus timed intercourse|Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
214815997|NCT05163132|DEVICE|Shearwave elastography|Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis
214815998|NCT03335761|DEVICE|InterStim Therapy|Device Programming
214815999|NCT01723397|DRUG|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
214816000|NCT01723397|OTHER|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
214816001|NCT01723397|BIOLOGICAL|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
214816002|NCT02329197|DRUG|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
214816003|NCT05853666|BEHAVIORAL|CNH+|CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery \[evidence-based parent targeted education platform\]; Vicarious Experience \[observing other families similar to them succeeding in a task i.e., videos and photos\]; Verbal Persuasion \[in-person/virtual medical rounds and provision of social support\]; and Physiological States \[notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway\]).
214816004|NCT02449265|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
214816005|NCT02449265|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15\~18 fractions of 2 Gy 5 days per week for partial response (PR)."
214816006|NCT02449265|DRUG|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
214816007|NCT02449265|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
214816008|NCT02449265|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy.
214816009|NCT02449265|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy.
214816010|NCT03548675|DRUG|TCA treatment|All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
214816011|NCT02196675|DEVICE|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
214816012|NCT03225456|DRUG|Syntocinon|Intra-nasal oxytocin
214816013|NCT03225456|DRUG|Placebos|Intra-nasal placebo
214816014|NCT02711852|DRUG|Duvelisib|Administered as oral capsules
214816015|NCT00537979|DRUG|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
214816016|NCT00537979|DRUG|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
214816017|NCT02009163|DRUG|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
214816018|NCT02009163|OTHER|Placebo|Placebo capsule once per day (double-blind period)
214816019|NCT05952986|DRUG|FB825 or Placebo in subcutaneous route|FB825 or placebo solution for SC injection
214816020|NCT05952986|DRUG|FB825 in intravenous route|FB825 solution for IV infusion
214816021|NCT00652288|DRUG|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
214816022|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given separately
214816023|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
214816024|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given separately
214816025|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
214816026|NCT02453386|DRUG|tozadenant|
214816027|NCT02453386|DRUG|placebo|
214816028|NCT01817985|DRUG|GS-5816|
214816029|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention without motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks.. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks
214816030|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention with motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online and will also apply motivational strategies based on self-determination theory. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
214816031|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention without motivational strategies|Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
214816032|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention with motivational strategies|"Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional who will also apply motivational strategies. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center.~The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks."
214816033|NCT01547377|DIETARY_SUPPLEMENT|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
214816034|NCT01547377|OTHER|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
214816035|NCT03401086|OTHER|Kinesio Taping|Kinesio Taping
214816036|NCT01559428|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
214816037|NCT01559428|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
214816038|NCT01559428|DIETARY_SUPPLEMENT|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
214816039|NCT06559748|DEVICE|transcranial magnetic thetaburst stimulation （TBS）|TBS group: iTBS was administered to stimulate RMFC, 80-100% RMT, 10 times a course, twice a day, for a total of 5 days; Conventional drugs group: pantoprazole 40 mg orally once a day; itopride 50 mg orally three times a day; treatment for 4 weeks. （Standard medication regimen）
214816040|NCT02755714|DRUG|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
214816041|NCT00833586|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
214816042|NCT00833586|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
214816043|NCT06037772|OTHER|subcutaneous injection administration game|The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
214816044|NCT06037772|OTHER|control group|only
214816045|NCT05344053|OTHER|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
214816046|NCT05344053|OTHER|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
214816047|NCT00802763|DEVICE|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
214816048|NCT01304641|OTHER|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
214816049|NCT01304641|OTHER|Simvastatin Initiators|Retrospective database analysis no intervention performed.
214816050|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
214816051|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
214816052|NCT04544787|BIOLOGICAL|Placebo|sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)
214816053|NCT05599074|DEVICE|extrusion arch|A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
214816054|NCT01514617|PROCEDURE|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
214816055|NCT04395222|DRUG|Tocilizumab|Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
214816056|NCT04395222|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
214816057|NCT04395222|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.
214816058|NCT04395222|DRUG|Anti-thymocyte globulin (rabbit)|Anti-thymocyte globulin (ATG) 1.5 mg/kg
214816059|NCT04395222|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
214816060|NCT02155465|DRUG|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
214816061|NCT02155465|DRUG|Erlotinib|Erlotinib 150mg PO QD
214816062|NCT01453465|OTHER|Laboratory Biomarker Analysis|Correlative studies
214816063|NCT05437549|PROCEDURE|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
214816064|NCT03360305|BEHAVIORAL|GAPcare intervention|Subjects will receive PT and pharmacist evaluation. PT will help determine whether subject may benefit from doing exercises to improve strength or balance. PT may also supply subject with an assist device. A pharmacist will ask patient about any medication they are taking and will make recommendations on how their medication could be changed to prevent falls. Pharmacists will communicate this information to subject's doctors. Subjects will receive a fall calendar for home, where they will record any falls they have after their discharge from the ED. They will receive a phone call at home asking about any recent falls and health care interactions. Study personnel will call subjects every 2 weeks for 6 months. Subjects may receive a referral for outpatient or home-based physical and occupational therapy at the end of the visit.
214816065|NCT02388191|DRUG|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
214816066|NCT02388191|OTHER|Placebo tablet|
214816067|NCT02234661|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
214816068|NCT03127826|PROCEDURE|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~\- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~\- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, \& graded exposure"
214816069|NCT03127826|PROCEDURE|Usual Care|Usual care at the general practitioner's discretion
214816070|NCT03494894|DIAGNOSTIC_TEST|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
214816071|NCT00057239|DRUG|Radafaxine|
214816072|NCT00584025|DRUG|levetiracetam|100 - 500mg IV q 15 min
214816073|NCT00584025|DRUG|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
214816074|NCT03301363|DEVICE|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
214816075|NCT03047317|BIOLOGICAL|MABp1|Single dose of intravenous MABp1
214816076|NCT03805815|DEVICE|tunable crack sensor|blood pressure monitoring via crack sensor
214816077|NCT02363634|DIETARY_SUPPLEMENT|magnesium threonate|nutritional product
214816078|NCT02559063|BEHAVIORAL|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
214816079|NCT02559063|BEHAVIORAL|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
214816080|NCT02830516|OTHER|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
214816081|NCT03686033|DRUG|Placebo|Participants will receive E2082-matched placebo tablets orally.
214816082|NCT03686033|DRUG|E2082|Participants will receive E2082 tablets orally.
214816083|NCT03197883|OTHER|Test Product|Restoring lipid balm
214816084|NCT03197883|OTHER|Cleanser|Moisturizing facial cleanser
214816085|NCT03197883|OTHER|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
214816086|NCT00433225|DRUG|Prednisolone Acetate|
214816087|NCT00433225|DRUG|Ketorolac 0.4%|
214816088|NCT00433225|DRUG|Gatifloxacin 0.3%|
214816089|NCT00807794|DRUG|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
214816090|NCT00807794|DRUG|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
214816091|NCT00807794|DRUG|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
214816092|NCT00807794|DRUG|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
214816093|NCT00807794|DRUG|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
214816094|NCT02371486|PROCEDURE|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
214816095|NCT02371486|PROCEDURE|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
214816096|NCT02371486|PROCEDURE|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
214816097|NCT02371486|PROCEDURE|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
214816098|NCT00163514|DRUG|Ciclesonide|
214816099|NCT03677492|OTHER|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
214816100|NCT01299363|BEHAVIORAL|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
214816101|NCT06561724|DIETARY_SUPPLEMENT|Biscuits maltodextrin|Biscuits includes maltodextrin
214816102|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics tartoufa inulin|Biscuits prebiotics
214816103|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics chicory inulin|Biscuits prebiotics
214816104|NCT00858845|DRUG|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
214816105|NCT00858845|OTHER|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
214816106|NCT06533345|BEHAVIORAL|Behavior Change Coaching|Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
214816107|NCT06533345|BEHAVIORAL|Nutrition|Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
214816108|NCT06533345|OTHER|Autonomic Recalibration|Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
214816109|NCT06533345|PROCEDURE|Dry Needling|An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
214816110|NCT06533345|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
214816111|NCT06533345|BEHAVIORAL|Counseling Psychology|Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
214816112|NCT06533345|OTHER|Multiple Treatments|"Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description."
214816113|NCT04841317|COMBINATION_PRODUCT|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
214816114|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
214816115|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
214816116|NCT02596100|DRUG|Betrixaban|
214816117|NCT04916548|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
214816118|NCT00987103|DRUG|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
214816119|NCT01353664|DRUG|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
214816120|NCT01643135|DRUG|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
214816121|NCT01643135|DRUG|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
214816122|NCT05259241|DIAGNOSTIC_TEST|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
214816123|NCT03549364|BEHAVIORAL|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
214816124|NCT03233386|BEHAVIORAL|Mantente REAL|substance abuse prevention curriculum for adolescents
214816125|NCT01114893|DRUG|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
214816126|NCT01114893|DRUG|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
214816127|NCT01114893|DRUG|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
214816128|NCT04086030|OTHER|Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
214816129|NCT04086030|OTHER|Sham Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
214816130|NCT02866422|OTHER|No Intervention|Observational Study: No intervention
214816131|NCT04857008|DEVICE|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
214816132|NCT05212363|DEVICE|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
214816133|NCT05212363|BEHAVIORAL|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
214816134|NCT01592578|PROCEDURE|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
214816135|NCT01592578|PROCEDURE|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
214816136|NCT00556790|PROCEDURE|Standard Care|standard fluid regime, delayed feeding
214816137|NCT00556790|PROCEDURE|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
214816138|NCT03642548|DRUG|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
214816139|NCT03642548|DRUG|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
214816140|NCT00465010|BEHAVIORAL|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
214816141|NCT01085825|PROCEDURE|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
214816142|NCT00830401|PROCEDURE|Treatment of predefined abnormality by hysteroscopic surgery|"* Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint"
214816143|NCT00830401|DRUG|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
214816144|NCT03922906|DEVICE|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
214816145|NCT03193177|OTHER|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
214816146|NCT05383222|BEHAVIORAL|Technical task|Simulated insertion of a central venous catheter
214816147|NCT05383222|BEHAVIORAL|Administrative task|Requesting a battery of investigations on the EPR
214816148|NCT02160210|DEVICE|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
214816149|NCT00314886|DRUG|Diet|
214816150|NCT02089997|DRUG|Sodium Risedronate|Sodium risedronate tablets
214816151|NCT04004091|BIOLOGICAL|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
214816152|NCT01855932|BEHAVIORAL|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
214816153|NCT02441309|DRUG|Mifamurtide|
214816154|NCT02441309|DRUG|Ifosfamide|
214816155|NCT01916408|DRUG|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
214816156|NCT01916408|DRUG|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
214816157|NCT05704881|DIAGNOSTIC_TEST|End-Tidal CO2 measurement during COPD exacerbation|The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
214816158|NCT01950611|DRUG|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
214816159|NCT00415363|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
214816160|NCT00415363|DRUG|placebo|oral, daily
214816161|NCT01850173|DEVICE|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
214816162|NCT02132663|OTHER|Control: Marketed routine infant formula|
214816163|NCT02132663|OTHER|An investigational infant formula containing an alternate source of DHA|
214816164|NCT03382548|DRUG|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
214816165|NCT03382548|DRUG|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
214816166|NCT02939729|OTHER|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
214816167|NCT02939729|DEVICE|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
214816168|NCT02939729|OTHER|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
214816169|NCT01967485|OTHER|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
214816170|NCT01967485|OTHER|Treatment as usual|Children will receive stimulant treatment for ADHD.
214816171|NCT05106465|DEVICE|Konectom platform|Administered as specified in the treatment arm.
214816172|NCT05420805|DIETARY_SUPPLEMENT|ALAC, inulin, FOS, and sodium butyrate|Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
214816173|NCT05420805|DIETARY_SUPPLEMENT|Sodium butyrate and zinc oxide|Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
214816174|NCT02183415|DRUG|BI 1356 BS, low dose|
214816175|NCT02183415|DRUG|BI 1356 BS, medium dose|
214816176|NCT02183415|DRUG|BI 1356 BS, high dose|
214816177|NCT02183415|DRUG|Placebo|
214816178|NCT04036422|DEVICE|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
214816179|NCT04036422|OTHER|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
214816180|NCT04036422|OTHER|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
214816181|NCT02592226|PROCEDURE|Anesthesia: alveolar recruitment maneuver|
214816182|NCT02592226|PROCEDURE|Anesthesia: standardized|
214816183|NCT02444715|BEHAVIORAL|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
214816184|NCT02444715|BEHAVIORAL|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
214816185|NCT03863418|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|PROBIOTIC
214816186|NCT03863418|OTHER|placebo|placebo
214816187|NCT01944930|DEVICE|Laparoscopic narrow band imaging|
214816188|NCT01944930|DEVICE|Standard white-light laparoscopy|
214816189|NCT05277779|DIAGNOSTIC_TEST|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
214816190|NCT02216006|PROCEDURE|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214816191|NCT02216006|PROCEDURE|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214816192|NCT03257956|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214816193|NCT03257956|DEVICE|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
214816194|NCT00095212|DRUG|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
214816195|NCT00095212|DRUG|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
214816196|NCT05345665|OTHER|Echography|Neuronal blockade anesthesia for elective surgery of the hand was performed with an only echography.
214816197|NCT05345665|OTHER|Echography and neurostimulation|Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.
214816198|NCT05345665|OTHER|Echography, neurostimulation and active mobilization|Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.
214816199|NCT02496546|DRUG|LEO 32731 cream|Applied for 3 weeks
214816200|NCT02496546|DRUG|LEO 32731 cream vehicle|Applied for 3 weeks
214816201|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 1
214816202|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 11
214816203|NCT01613040|DRUG|RO4917838|Multiple daily low doses of RO4917838 for 10 days
214816204|NCT01613040|DRUG|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
214816205|NCT01613040|DRUG|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
214816206|NCT04829045|DEVICE|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
214816207|NCT04829045|OTHER|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
214816208|NCT00175487|PROCEDURE|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
214816209|NCT04513379|DRUG|Efavirenz 600mg|EFV 600 mg per day given orally
214816210|NCT04513379|DRUG|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
214816211|NCT06402539|BEHAVIORAL|family-centered empowerment program|The intervention will be carried out face to face in the Orthopedics and Traumatology outpatient clinic, and some interviews will be held by phone. The first interview is on the day the patient will be approved in the anesthesia department, the second interview is when the patient is admitted to the ward, the third interview is after the surgery and the fourth interview is in the ward on the day of discharge, the fifth interview is by phone 1 week after discharge, the sixth interview is at the outpatient clinic when the patient comes for a check-up 2 weeks after discharge, and the seventh interview is at the time of discharge. The eighth interview will be held by phone in the 3rd week after discharge, and the eighth interview will be held in the outpatient clinic in the 4th week after discharge.
214816212|NCT04301791|OTHER|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
214816213|NCT02335658|DRUG|DSP-5423P|40-80mg/day
214816214|NCT01804803|PROCEDURE|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
214816215|NCT01804803|PROCEDURE|Use of regular glucometer|
214816216|NCT06329947|DRUG|Surufatinib 250mg/d qd once daily|mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
214816217|NCT03133533|PROCEDURE|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
214816218|NCT03133533|PROCEDURE|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
214816219|NCT05341622|BEHAVIORAL|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
214816220|NCT05341622|BEHAVIORAL|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
214816221|NCT05341622|BEHAVIORAL|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
214816222|NCT05341622|BEHAVIORAL|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
214816223|NCT05341622|BEHAVIORAL|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
214816224|NCT05341622|BEHAVIORAL|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
214816225|NCT00215319|DEVICE|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
214816226|NCT00921622|DIETARY_SUPPLEMENT|Vitamin D|1000 IU twice daily for up to 10 days
214816227|NCT00921622|DIETARY_SUPPLEMENT|Vitamin C|500 mg twice daily for up to 10 days
214816228|NCT02726230|BEHAVIORAL|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
214816229|NCT01169883|BEHAVIORAL|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
214816230|NCT01169883|BEHAVIORAL|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
214816231|NCT01169883|BEHAVIORAL|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
214816232|NCT01169883|BEHAVIORAL|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
214816233|NCT01169883|BEHAVIORAL|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
214816234|NCT02771353|RADIATION|WT_vDIBH|
214816235|NCT02771353|RADIATION|VMAT_FB|
214816236|NCT02947243|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
214816237|NCT02947243|DRUG|Morphine|As per unit's protocol
214816238|NCT00001748|PROCEDURE|Peripheral blood progenitor cell transplant|
214816239|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae|granule
214816240|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix|granule
214816241|NCT02658084|DRUG|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
214816242|NCT02658084|DRUG|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
214816243|NCT01173042|DIETARY_SUPPLEMENT|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
214816244|NCT01173042|DIETARY_SUPPLEMENT|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
214816245|NCT01173042|DIETARY_SUPPLEMENT|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
214816246|NCT02071875|DEVICE|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
214816247|NCT02305758|DRUG|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
214816248|NCT02305758|DRUG|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
214816249|NCT02305758|DRUG|Modified FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
214816250|NCT02305758|DRUG|FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
214816251|NCT02305758|DRUG|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
214816252|NCT02305758|DRUG|Fluorouracil infusion|2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
214816253|NCT01954680|BEHAVIORAL|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
214816254|NCT01954680|BEHAVIORAL|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
214816255|NCT02661529|PROCEDURE|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
214816256|NCT02661529|PROCEDURE|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
214816257|NCT02661529|OTHER|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
214816258|NCT02661529|OTHER|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
214816259|NCT01678638|PROCEDURE|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
214816260|NCT01678638|PROCEDURE|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
214816261|NCT03732443|DIAGNOSTIC_TEST|FAM-CAM|Family Confusion Assessment Method
214816262|NCT02325271|OTHER|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
214816263|NCT01379664|DRUG|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
214816264|NCT01379664|DRUG|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
214816265|NCT02032888|DRUG|Daclatasvir|
214816266|NCT02032888|DRUG|Sofosbuvir|
214816267|NCT00824148|DEVICE|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
214816268|NCT00824148|OTHER|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
214816269|NCT01767298|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
214816270|NCT01767298|DRUG|Valsartan|Valsartan alone
214816271|NCT01767298|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
214816272|NCT03502161|DEVICE|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
214816273|NCT01506466|OTHER|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
214816274|NCT00577668|DRUG|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
214816275|NCT02852980|OTHER|gestational diabetes women|No intervention.
214816276|NCT04494867|DEVICE|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
214816277|NCT04494867|OTHER|Standard of Care|Standard temperature management and treatment
214816278|NCT03613922|OTHER|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
214816279|NCT03613922|OTHER|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
214816280|NCT04511507|PROCEDURE|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
214816281|NCT03550625|DIAGNOSTIC_TEST|Computer program|No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
214816282|NCT03616106|OTHER|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
214816283|NCT00430196|DRUG|BOTOX®|
214816284|NCT00430196|DRUG|Zanaflex®|
214816285|NCT02804204|DRUG|Anti-TNF|
214816286|NCT02548897|DEVICE|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
214816287|NCT02548897|OTHER|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
214816288|NCT02298322|DEVICE|CoolSculpting System|
214816289|NCT02218411|OTHER|Exercise training|Exercises routine based on the Otago exercise programme
214816290|NCT00360997|BEHAVIORAL|Conventional UK physical therapy|
214816291|NCT00360997|PROCEDURE|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation \& Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
214816292|NCT03206177|DRUG|Galunisertib|Galunisertib 150mg po BID day 4-17
214816293|NCT03206177|DRUG|Paclitaxel|IV Day 1: Paclitaxel 175 mg/m2 over 3 hours
214816294|NCT03206177|DRUG|Carboplatin|IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
214816295|NCT02750124|DEVICE|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
214816296|NCT02750124|OTHER|Routine practice|The standard, annual renewed invitation to cervical screening.
214816297|NCT05354479|DRUG|Paracetamol|babies will get expressed breast milk along with paracatamol for pain relief
214816298|NCT03365297|DRUG|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
214816299|NCT01069926|DRUG|AZD1656|Single dose oral tablet
214816300|NCT02877186|OTHER|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
214816301|NCT02877186|OTHER|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
214816302|NCT01835093|DRUG|Tipepidine Hibenzate|
214816303|NCT04236960|BIOLOGICAL|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
214816304|NCT04953234|DEVICE|NovoTTF-100L|Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
214816305|NCT01472393|DIETARY_SUPPLEMENT|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
214816306|NCT01472393|DIETARY_SUPPLEMENT|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
214816307|NCT00055315|BEHAVIORAL|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
214816308|NCT00055315|BEHAVIORAL|Treatment As Usual (TAU)|
214816309|NCT02458586|DIETARY_SUPPLEMENT|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
214816310|NCT00091260|DRUG|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
214816311|NCT00091260|DRUG|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
214816312|NCT02744820|DRUG|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
214816313|NCT02744820|OTHER|Placebo|Matching doses by oral route, once a day, 28 days
214816314|NCT01713465|OTHER|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
214816315|NCT02828709|DEVICE|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
214816316|NCT00191022|DRUG|LY686017|
214816317|NCT00191022|DRUG|paroxetine|
214816318|NCT00191022|DRUG|placebo|
214816319|NCT05128812|DIETARY_SUPPLEMENT|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
214816320|NCT04008498|DIAGNOSTIC_TEST|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
214816321|NCT04611789|DRUG|LY3832479|Administered subcutaneously
214816322|NCT04611789|DRUG|Placebo|Administered subcutaneously
214816323|NCT02359617|DRUG|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
214816324|NCT02359617|DEVICE|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
214816325|NCT02466880|DEVICE|Telemedicine|A diabetes self-management and education program delivered via telemedicine
214816326|NCT02466880|OTHER|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
214816327|NCT01549080|DRUG|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
214816328|NCT04320147|DEVICE|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
214816329|NCT05551780|DEVICE|SoundBite Crossing System|Use of the SoundBite Crossing System to cross calcified chronic total occlusions
214816330|NCT03338075|RADIATION|fractionated stereotactic radiotherapy|The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
214816331|NCT04985474|OTHER|questionnaires|
214816332|NCT03880266|DRUG|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
214816333|NCT03880266|DRUG|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
214816334|NCT04011345|DIETARY_SUPPLEMENT|Folic Acid Supplement|1 milligram folic acid
214816335|NCT04011345|DIETARY_SUPPLEMENT|Placebo|Placebo
214816336|NCT02492568|DRUG|pembrolizumab|
214816337|NCT02492568|RADIATION|Stereotactic Body Radiation Therapy|
214816338|NCT00118547|BEHAVIORAL|In home monitoring with feedback|Behavioral counseling
214816339|NCT00873639|DRUG|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
214816340|NCT00873639|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
214816341|NCT03161405|DRUG|TAK-906 Maleate|TAK-906 capsule
214816342|NCT03161405|DRUG|Itraconazole|Itraconazole solution
214816343|NCT04567147|DIETARY_SUPPLEMENT|Probiotic|Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).
214816344|NCT04567147|DIETARY_SUPPLEMENT|Placebo|Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
214816345|NCT01173263|OTHER|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
214816346|NCT01173263|OTHER|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
214816347|NCT01173263|OTHER|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
214816348|NCT03498391|DRUG|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
214816349|NCT03498391|DRUG|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
214816350|NCT01194791|DRUG|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
214816351|NCT01194791|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
214816352|NCT01194791|DRUG|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
214816353|NCT01492894|DRUG|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
214816354|NCT01492894|DRUG|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
214816355|NCT05957003|PROCEDURE|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
214816356|NCT05957003|PROCEDURE|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
214816357|NCT00837486|DEVICE|Reclaim™ DBS System|
214816358|NCT00361751|DRUG|fenofibrate|
214816359|NCT03024515|DRUG|opioids titration|Standard Practice Arm
214816360|NCT03024515|DRUG|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
214816361|NCT02655679|DRUG|VTP-38543|VTP-38543 topical cream
214816362|NCT02655679|OTHER|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
214816363|NCT02655679|OTHER|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
214816364|NCT03105453|OTHER|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
214816365|NCT01577381|BIOLOGICAL|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
214816366|NCT01577381|BIOLOGICAL|Placebo|Intravenous, 11 doses, 30 minute infusion
214816367|NCT02186821|DRUG|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
214816368|NCT06461091|RADIATION|TMI|Observing the efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating adult acute lymphoblastic leukemia with a conditioning regimen including total marrow irradiation (TMI) in individuals aged 16 years and older: Primary Exploratory Endpoint: Event-free survival at 1 year post allogeneic hematopoietic stem cell transplantation (EFS).
214816369|NCT00497263|DEVICE|Niti CAR|
214816370|NCT00194454|BEHAVIORAL|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
214816371|NCT00194454|OTHER|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
214816372|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
214816373|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
214816374|NCT03372187|BEHAVIORAL|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
214816375|NCT04589910|DIAGNOSTIC_TEST|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
214816376|NCT01789177|DEVICE|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
214816377|NCT01789177|OTHER|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
214816378|NCT01549353|BEHAVIORAL|gum chewing|
214816379|NCT04189848|DRUG|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
214816380|NCT04189848|DRUG|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
214816381|NCT01745783|OTHER|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
214816382|NCT01745783|OTHER|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
214816383|NCT03201523|OTHER|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
214816384|NCT06000449|BEHAVIORAL|Center M|Digital mental health platform. Screening and prevention activities will be provided through the Center M platform, telehealth group mindfulness sessions, and digitally delivered home practice materials.
214816385|NCT06000449|BEHAVIORAL|Treatment as Usual|Paper screening and PD handout.
214816386|NCT05674513|DRUG|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
214816387|NCT05349513|OTHER|ESSME questionnaire|The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
214816388|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
214816389|NCT00819741|DRUG|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
214816390|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
214816391|NCT07036185|DRUG|KJ015 Injection (Subcutaneous Injection)|KJ015 is administered via subcutaneous injection, with the dosing frequency set at either Q3W.
214816392|NCT07035821|DRUG|Olanzapine Tablets|Oral olanzapine tablets
214816393|NCT07035821|DRUG|Placebo|Oral placebo
214816394|NCT00119015|DRUG|Placebo|
214816395|NCT00119015|DRUG|Montelukast|
214816396|NCT00119015|DRUG|Fluticasone propionate|
214816397|NCT03301285|DRUG|Zoledronic Acid|Treatment of osteoporosis
214816398|NCT03227302|PROCEDURE|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
214816399|NCT03227302|PROCEDURE|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
214816400|NCT03227302|PROCEDURE|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
214816401|NCT01313780|DRUG|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
214816402|NCT01313780|DRUG|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
214816403|NCT00889109|OTHER|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
214816404|NCT04799028|OTHER|Traditional cow's milk|Fortified cow's milk
214816405|NCT04799028|OTHER|Experimental milk|Milk with synbiotics and fat blend
214816406|NCT04799028|OTHER|Habitual diet|Habitual diet
214816407|NCT06945380|OTHER|Best Practice, Comparator Program|Receive access to a comparator program
214816408|NCT06945380|OTHER|Best Practice, Usual Care|Receive usual care
214816409|NCT06945380|OTHER|Internet-Based Intervention|Receive access to the PNR program
214816410|NCT06945380|PROCEDURE|Massage Therapy|Perform the relaxation massage techniques
214816411|NCT06945380|OTHER|Survey Administration|Complete surveys to assess CIPN symptoms, overall well-being and quality of life, and caregiver reaction and attitudes
214816412|NCT04439656|DIAGNOSTIC_TEST|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
214816413|NCT03023956|PROCEDURE|Locking plates were used for proximal humeral fractures.|
214816414|NCT05301361|DRUG|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
214816415|NCT05995275|BIOLOGICAL|mRNA-1769|Sterile liquid for injection
214816416|NCT05995275|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
214816417|NCT05782478|DIAGNOSTIC_TEST|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
214816418|NCT04248543|DEVICE|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
214816419|NCT05790538|PROCEDURE|Assessment of Therapy Complications|Complete clinic assessments
214816420|NCT05790538|OTHER|Electronic Health Record Review|Medical records are reviewed
214816421|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear SmartSocks
214816422|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
214816423|NCT05790538|OTHER|Survey Administration|Complete survey
214816424|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
214816425|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
214816426|NCT03179904|DRUG|Anastrozole|Given PO
214816427|NCT03179904|DRUG|Denifanstat|Given PO
214816428|NCT03179904|DRUG|Exemestane|Given PO
214816429|NCT03179904|DRUG|Fulvestrant|Given IM
214816430|NCT03179904|PROCEDURE|Echocardiography|Undergo ECHO
214816431|NCT03179904|DRUG|Letrozole|Given PO
214816432|NCT03179904|DRUG|Paclitaxel|Given IV
214816433|NCT03179904|BIOLOGICAL|Trastuzumab|Given IV
214816434|NCT03179904|PROCEDURE|Computed Tomography|Undergo CT
214816435|NCT03179904|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214816436|NCT03179904|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214816437|NCT03179904|PROCEDURE|Biopsy|Undergo biopsy
214816438|NCT05637814|DIAGNOSTIC_TEST|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
214816439|NCT00716066|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214816440|NCT00716066|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
214816441|NCT00716066|DRUG|Carmustine|Given IV
214816442|NCT00716066|DRUG|Cytarabine|Given IV
214816443|NCT00716066|DRUG|Etoposide|Given IV
214816444|NCT00716066|OTHER|Laboratory Biomarker Analysis|Correlative studies
214816445|NCT00716066|DRUG|Melphalan|Given IV
214816446|NCT00716066|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
214816447|NCT00716066|DRUG|Prednisone|Given PO
214816448|NCT00716066|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
214816449|NCT06783179|OTHER|Non-Interventional Study|Non-interventional study
214816450|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
214816451|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214816452|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
214816453|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
214816454|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
214816455|NCT06056895|DRUG|Tuparstobart|Given IV
214816456|NCT06056895|DRUG|Verzistobart|Given IV
214816457|NCT03963739|OTHER|Interview|Undergo interview
214816458|NCT03963739|OTHER|Questionnaire Administration|Ancillary studies
214816459|NCT06321562|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye
214816460|NCT06321562|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
214816461|NCT06154304|DRUG|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
214816462|NCT06154304|DRUG|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
214816463|NCT06154304|DRUG|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
214816464|NCT06154304|DRUG|Placebo|Placebo
214816465|NCT03235739|DRUG|Naloxegol 25 MG|Oral Naloxegol 25 MG
214816466|NCT03235739|DRUG|Placebo|matching oral placebo
214816467|NCT03797872|DRUG|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
214816468|NCT03797872|DRUG|Sulfasalazine|Sulfasalazine up to 3g daily po
214816469|NCT03797872|DRUG|Leflunomide|Leflunomide 10-20mg daily po
214816470|NCT03797872|DRUG|Methylprednisolone|For IA or IM injection 20-120mg
214816471|NCT03797872|DRUG|Triamcinolone|For IA or IM injection 20-120mg
214816472|NCT03616730|DIAGNOSTIC_TEST|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
214816473|NCT02299453|BEHAVIORAL|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
214816474|NCT06242145|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214816475|NCT06242145|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214816476|NCT06163430|DRUG|TERN-701|TERN-701 orally QD
214816477|NCT00834522|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
214816478|NCT00834522|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
214816479|NCT01982981|OTHER|water provision|perception behavioral change at the beginning and at the end of the intervention
214816480|NCT01982981|OTHER|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
214816481|NCT05681130|OTHER|questionaire|two questionaires for each group
214816482|NCT01424124|DRUG|YHD001 dose level 1|Tablet, three times daily / 8 weeks
214816483|NCT01424124|DRUG|YHD001 dose level 2|Tablet, three times daily / 8 weeks
214816484|NCT01424124|DRUG|Singulair|Tablet, one times daily / 8 weeks
214816485|NCT01424124|DRUG|Placebo|Tablet, one times daily / 7 days
214816486|NCT00834249|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
214816487|NCT00834249|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
214816488|NCT02758496|OTHER|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
214816489|NCT04354285|OTHER|Observational|Observational
214816490|NCT03702322|BEHAVIORAL|Voice therapy: respiratory|Abdominal voice onset
214816491|NCT03702322|BEHAVIORAL|Voice therapy: glottal closure|Pulling/pushing task
214816492|NCT03702322|BEHAVIORAL|Voice therapy: loud|Assertive task
214816493|NCT03702322|BEHAVIORAL|Voice therapy: Semiocclusion|Semi-occluded vocal tract
214816494|NCT02779803|PROCEDURE|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
214816495|NCT01343303|DRUG|Placebo|Placebo tablet/capsule every 12 hours for 21 days
214816496|NCT01343303|DRUG|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
214816497|NCT01343303|DRUG|Naproxen|500 mg capsule every 12 hours for 21 days
214816498|NCT01343303|DRUG|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
214816499|NCT00111397|PROCEDURE|Cytokine therapy|
214816500|NCT00111397|DRUG|Interferon Gamma, GM-CSF|
214816501|NCT03630471|BEHAVIORAL|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
214816502|NCT03630471|BEHAVIORAL|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
214816503|NCT02256683|DRUG|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
214816504|NCT02256683|DRUG|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
214816505|NCT03289845|DEVICE|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
214816506|NCT01163461|BEHAVIORAL|speech therapy|individuals will receive 60 hours of behavioral speech therapy
214816507|NCT02146105|OTHER|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
214816508|NCT05215483|BEHAVIORAL|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
214816509|NCT05215483|BEHAVIORAL|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
214816510|NCT05215483|BEHAVIORAL|LFT available|LFT availability: Enough lateral flow tests available at home
214816511|NCT05215483|BEHAVIORAL|No LFT available|LFT availability: No lateral flow tests available at home
214816512|NCT00034905|DRUG|quetiapine fumarate vs risperidone|
214816513|NCT04414228|DEVICE|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
214816514|NCT04414228|DEVICE|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
214816515|NCT03832530|BEHAVIORAL|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
214816516|NCT05770648|DEVICE|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
214816517|NCT05770648|OTHER|The guidelines guide medication|The guidelines guide medication
214816518|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #1|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
214816519|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #2|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
214816520|NCT00844922|DRUG|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
214816521|NCT00844922|DRUG|Placebo|Placebo
214816522|NCT04089917|DEVICE|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
214816523|NCT05832411|DEVICE|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
214816524|NCT02476994|DRUG|Clinolipid|
214816525|NCT02476994|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
214816526|NCT05671965|DIETARY_SUPPLEMENT|Xylitol|33.5g xylitol dissolved in 300mL tap water.
214816527|NCT05671965|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
214816528|NCT05671965|DIETARY_SUPPLEMENT|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
214816529|NCT05671965|DIETARY_SUPPLEMENT|Water|300mL tap water.
214816530|NCT06146972|DRUG|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
214816531|NCT05859425|DEVICE|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
214816532|NCT05859425|OTHER|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
214816533|NCT01649011|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
214816534|NCT01649011|BEHAVIORAL|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
214816535|NCT05025345|DEVICE|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
214816536|NCT05025345|DEVICE|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
214816537|NCT04383574|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
214816538|NCT04383574|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
214816539|NCT04383574|BIOLOGICAL|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
214816540|NCT04383574|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
214816541|NCT06133920|OTHER|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
214816542|NCT06133920|OTHER|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
214816543|NCT02226289|DRUG|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
214816544|NCT06559020|BEHAVIORAL|Kangroo mother care|Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
214816545|NCT00128791|DRUG|Nitroprusside|
214816546|NCT04776226|DRUG|Citalopram|Antidepressant use in patients with depression
214816547|NCT05034094|OTHER|VEMP recording|"* Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~* The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
214816548|NCT00766701|PROCEDURE|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
214816549|NCT00850148|PROCEDURE|Anwar|Anwar surgical method
214816550|NCT00850148|PROCEDURE|Melles|Melles surgical method
214816551|NCT04195230|BEHAVIORAL|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
214816552|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
214816553|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
214816554|NCT01964053|BEHAVIORAL|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
214816555|NCT01964053|BEHAVIORAL|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
214816556|NCT00077077|DRUG|DJ-927|
214816557|NCT00077077|DRUG|capecitabine|
214816558|NCT04854798|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
214816559|NCT00350753|DRUG|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
214816560|NCT00833209|PROCEDURE|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
214816561|NCT00833209|PROCEDURE|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
214816562|NCT00833209|PROCEDURE|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
214816563|NCT03442491|PROCEDURE|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
214816564|NCT04020952|OTHER|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
214816565|NCT04020952|OTHER|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
214816566|NCT04020952|OTHER|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
214816567|NCT05454683|DIETARY_SUPPLEMENT|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
214816568|NCT05454683|OTHER|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
214816569|NCT00003291|GENETIC|cytogenetic analysis|
214816570|NCT00003291|GENETIC|mutation analysis|
214816571|NCT00003291|OTHER|laboratory biomarker analysis|
214816572|NCT01956591|DRUG|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
214816573|NCT01558635|DEVICE|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
214816574|NCT01558635|PROCEDURE|Mitral Valve surgery|Classic mitral valve surgery was performed
214816575|NCT01558635|DEVICE|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
214816576|NCT01558635|PROCEDURE|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
214816577|NCT01045018|DRUG|Placebo|placebo 400 mg
214816578|NCT01045018|DRUG|Mesalamine|
214816579|NCT01045018|DRUG|Mesalamine|
214816580|NCT04215718|PROCEDURE|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\\0 sutures
214816581|NCT04215718|PROCEDURE|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
214816582|NCT02300935|DRUG|trametinib|
214816583|NCT02300935|DRUG|nab-paclitaxel|
214816584|NCT06561659|BEHAVIORAL|Exercise Condition|Already described in the arm description
214816585|NCT06561659|BEHAVIORAL|Relaxation Control Condition|Already described in the arm description
214816586|NCT00041015|DRUG|cisplatin|
214816587|NCT00041015|DRUG|etoposide|
214816588|NCT00041015|DRUG|topotecan hydrochloride|
214816589|NCT03699020|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
214816590|NCT03699020|OTHER|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
214816591|NCT03995030|DIAGNOSTIC_TEST|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
214816592|NCT04971668|OTHER|Aromatherapy|Three drops of the designated blend aromatherapy (ginger \& lavender) will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
214816593|NCT04971668|OTHER|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
214816594|NCT04971668|OTHER|Controlled|Patients will inhale deeply with inert gauze and simulate like chewing gum for 5 minutes.
214816595|NCT04867252|DRUG|Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)|51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
214816596|NCT04867252|DRUG|Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)|51 Patients with PCOS receiving Metformin and Pioglitazone 500 mg and 15 mg BD daily respectively
214816597|NCT04233320|DEVICE|silicone cream containing Allium Cepa extract|silicone cream containing Allium Cepa extract contains 10% of Allium cepa bulb extract.
214816598|NCT04233320|DEVICE|Commercial scar gel|Commercial scar gel is a topical silicone gel. It contains cyclic and polymeric siloxanes and Vitamin C ester.
214816599|NCT00470769|PROCEDURE|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
214816600|NCT03861065|PROCEDURE|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
214816601|NCT03861065|PROCEDURE|Historical Wound Closure|Participants wounds are left partially open to heal.
214816602|NCT02246920|DRUG|Fluticasone propionate|50 mcg/actuation Nasal Spray
214816603|NCT02246920|DRUG|Flonase®|50 mcg/actuation Nasal Spray
214816604|NCT02246920|DRUG|Placebo|Inactive Nasal Spray
214816605|NCT03642769|OTHER|Fluid administration|Fluid administration of bolus and maintenance fluids
214816606|NCT00197769|BIOLOGICAL|9 valent pneumococcal con jugate vaccine|
214816607|NCT04860804|DRUG|Aspirin and Ketamine|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
214816608|NCT04860804|DRUG|Oral Ketamine|Proprietary oral formulation of 0.5mg/kg of ketamine
214816609|NCT04572386|OTHER|light cure 3m single bond universal bond|light -cure universal bond
214816610|NCT04572386|OTHER|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
214816611|NCT06133725|PROCEDURE|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
214816612|NCT01115465|DEVICE|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
214816613|NCT05066438|BEHAVIORAL|Antenatal hand expression|Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
214816614|NCT00448019|DRUG|Fludarabine|25 mg/m\^2 IV over 30 minutes daily for 3 days
214816615|NCT00448019|DRUG|Cyclophosphamide|250 mg/m\^2 IV over 30 minutes daily for 3 days
214816616|NCT00448019|DRUG|Rituximab|375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.
214816617|NCT00448019|DRUG|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
214816618|NCT01433718|PROCEDURE|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
214816619|NCT02543203|BIOLOGICAL|Reconnect|Topical Essential Oils mixture and aromatic method
214816620|NCT02543203|BIOLOGICAL|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
214816621|NCT00996788|DRUG|Rebamipide|Rebamipide 100 mg tid for 28 days
214816622|NCT02297932|BEHAVIORAL|Strength training|Participants will engage in a home-based strength training program.
214816623|NCT02297932|BEHAVIORAL|Stretching|Participants will engage in a home-based stretching training program
214816624|NCT06370507|DEVICE|Electrical impedance tomography assessment of ventilation distribution in course of sedation/general anesthesia for pediatric surgery|Assessment of ventilation distribution through electrical impedance tomography in pediatric patients subjected to sedation or general anesthesia for surgery
214816625|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
214816626|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
214816627|NCT05044221|OTHER|Former ICU patient and caregiver workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
214816628|NCT05044221|OTHER|Health care professional workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
214816629|NCT03048812|DEVICE|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
214816630|NCT03048812|DEVICE|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
214816631|NCT02077465|DRUG|Andecaliximab|400 mg andecaliximab administered intravenously
214816632|NCT02077465|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
214816633|NCT00115843|DEVICE|Mobile Cardiac Outpatient Telemetry|
214816634|NCT02776878|DRUG|dasatinib|
214816635|NCT04738071|DEVICE|PFO closure|PFO closure after stroke or transient ischemic attack
214816636|NCT05494671|PROCEDURE|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
214816637|NCT01853657|OTHER|Virological monitoring|
214816638|NCT01286922|OTHER|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
214816639|NCT05528744|OTHER|Observational Study|No intervention. This is an observational study
214816640|NCT05528744|OTHER|Sample collection only|Collection of blood and/or skin samples.
214816641|NCT06263972|DEVICE|Direct Stimulation Prefrontal Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.
214816642|NCT06263972|DEVICE|Shame cortex stimulation|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.
214816643|NCT06263972|DEVICE|Direct Stimulation to Motor Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.
214816644|NCT06263972|BEHAVIORAL|erobic physical activity|Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
214816645|NCT05770063|DIETARY_SUPPLEMENT|amino acid tablet|multiple essential amino acids supplements
214464515|NCT03587272|DRUG|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
214816646|NCT04471363|BEHAVIORAL|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
214816647|NCT01827163|DRUG|Paclitaxel|
214816648|NCT01827163|DRUG|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
214816649|NCT01827163|DRUG|Lapatinib|
214816650|NCT01827163|DRUG|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
214816651|NCT04448106|BIOLOGICAL|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
214816652|NCT01875952|DRUG|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
214816653|NCT02120937|BEHAVIORAL|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
214816654|NCT06459271|OTHER|Managing Cancer And Living Meaningfully (CALM)|Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.
214816655|NCT03215693|DRUG|X-396 capsule|225mg once daily
214816656|NCT02193061|BIOLOGICAL|Rotarix|
214816657|NCT02193061|BIOLOGICAL|RotaTeq|
214816658|NCT03075553|OTHER|Laboratory Biomarker Analysis|Correlative studies
214816659|NCT03075553|BIOLOGICAL|Nivolumab|Given IV
214816660|NCT00938951|OTHER|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
214816661|NCT00272597|DRUG|Risperidone|See Detailed Description.
214816662|NCT00719745|DRUG|Prograf|oral
214816663|NCT00719745|DRUG|MR4|oral
214816664|NCT03620747|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"
214816665|NCT05033847|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
214816666|NCT05033847|BIOLOGICAL|COVID-19 vaccine (Vero cells)|Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
214816667|NCT04534166|OTHER|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
214816668|NCT02514330|OTHER|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
214816669|NCT02514330|OTHER|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
214816670|NCT03050944|OTHER|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
214816671|NCT01661855|DRUG|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
214816672|NCT01661855|DRUG|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
214816673|NCT02514876|DEVICE|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
214816674|NCT02714062|DRUG|Placebo|po once daily
214816675|NCT02714062|DRUG|VI-0521 Mid Dose|po once daily
214464516|NCT06279416|PROCEDURE|fiberoptic intubation|awake nasal fiberoptic intubation
214816676|NCT02714062|DRUG|VI-0521 Top Dose|po once daily
214816677|NCT03106662|BIOLOGICAL|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.
214816678|NCT03106662|DRUG|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
214816679|NCT02294604|DEVICE|ethyl alcochol, chlorhexidine and moisturizers|
214816680|NCT02294604|DEVICE|chlorhexidine|
214816681|NCT02294604|DEVICE|povidone-iodine|
214816682|NCT01780870|DIETARY_SUPPLEMENT|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
214816683|NCT04587570|PROCEDURE|Infiltration with PRP|Infiltration with 1.5 ml PRP
214816684|NCT04587570|PROCEDURE|Infiltration with Fat|Infiltration with 1.5 ml Fat
214816685|NCT04587570|PROCEDURE|Infiltration with PRP and Fat|Infiltration with 0.75 ml PRP and 0.75 ml Fat
214816686|NCT04587570|PROCEDURE|Infiltration with NaCl|Infiltration with 1.5 ml NaCl
214816687|NCT05479487|DRUG|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
214816688|NCT05479487|DRUG|Fluzoparib Monotherapy|Fluzoparib 150mg bid
214816689|NCT05516056|OTHER|ERAS clinical pathway|Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
214816690|NCT00059306|DRUG|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
214816691|NCT00059306|DRUG|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
214816692|NCT00059306|OTHER|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
214816693|NCT00059306|OTHER|placebo|an inactive substance
214816694|NCT04504240|DRUG|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
214816695|NCT06627140|DIAGNOSTIC_TEST|Diagnostic procedures|Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
214816696|NCT05218772|OTHER|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
214816697|NCT06029686|DEVICE|Stanford Glove|The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
214816698|NCT03082872|DEVICE|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
214816699|NCT03082872|DEVICE|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
214816700|NCT00820586|PROCEDURE|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
214816701|NCT02355886|DRUG|Gabapentin|Given PO
214816702|NCT02355886|OTHER|Placebo|Given PO
214816703|NCT02355886|OTHER|Questionnaire Administration|Ancillary studies
214816704|NCT02135263|DRUG|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
214816705|NCT02135263|DRUG|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
214816706|NCT04303663|PROCEDURE|Fibular Plate|ORIF with Plating
214816707|NCT04303663|PROCEDURE|Fibular Nail|CRIF +/- ORIF with Fibular nail
214816708|NCT01200810|OTHER|placebo|Given orally
214816709|NCT01200810|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214816710|NCT01200810|DRUG|bicalutamide|Given orally
214816711|NCT02081612|BEHAVIORAL|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
214816712|NCT02081612|PROCEDURE|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
214816713|NCT05570981|DIAGNOSTIC_TEST|Laryngeal sensitivity testing|Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
214816714|NCT00365846|DRUG|Campath-1H|
214816715|NCT00614250|DRUG|AVE0657|capsules once a day at bedtime
214816716|NCT00614250|DRUG|placebo|capsules once a day at bedtime
214816717|NCT02477202|DEVICE|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
214816718|NCT00208819|DRUG|risperidone|
214464517|NCT06279416|PROCEDURE|laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
214816719|NCT00208819|DRUG|quetiapine|
214816720|NCT00208819|DRUG|olanzapine|
214816721|NCT00208819|DRUG|divalproex|
214816722|NCT03976635|DEVICE|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
214464518|NCT06279416|PROCEDURE|videolaryngoscopy|awake intubation with videolaryngoscopy
214816723|NCT03976635|DEVICE|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
214816724|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using modular dual mobility cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
214816725|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using conventional acetabular cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
214816726|NCT05422521|OTHER|blood samples and 18FDG PET-CT exams|"* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
214816727|NCT04344106|PROCEDURE|Prone positioning|The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.
214816728|NCT01666899|PROCEDURE|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
214816729|NCT00904215|DRUG|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
214816730|NCT00501488|DRUG|rosiglitazone|
214816731|NCT01855685|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
214816732|NCT01621893|PROCEDURE|Subchondroplasty|
214816733|NCT03890471|BEHAVIORAL|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
214816734|NCT01939756|DEVICE|Intravesical baobab oil|Intravesical baobab oil
214816735|NCT01538888|PROCEDURE|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
214816736|NCT02570009|BEHAVIORAL|TEAMS (Talking about Eating, Activity, Mutual Support)|
214816737|NCT02570009|BEHAVIORAL|Need Support Training|
214816738|NCT01318551|DRUG|BAY85-3934|single dose, 20 mg
214816739|NCT01318551|DRUG|BAY85-3934|single dose, 40 mg (optional)
214816740|NCT01318551|DRUG|BAY85-3934|single dose, 80 mg (optional)
214816741|NCT02322983|BEHAVIORAL|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
214816742|NCT00960297|DRUG|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
214816743|NCT00960297|DRUG|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
214816744|NCT00960297|DRUG|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
214816745|NCT02008097|DEVICE|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
214816746|NCT05763147|DEVICE|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
214816747|NCT01033877|BIOLOGICAL|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
214816748|NCT01033877|BIOLOGICAL|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d)
214816749|NCT01299454|DRUG|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
214816750|NCT06628102|DIAGNOSTIC_TEST|Chest CT Scan|Chest CT Scan
214816751|NCT03149874|DRUG|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
214816752|NCT03149874|DRUG|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
214816753|NCT03214276|DIETARY_SUPPLEMENT|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
214816754|NCT03214276|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
214816755|NCT03309774|DIAGNOSTIC_TEST|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)"
214816756|NCT03309774|DIAGNOSTIC_TEST|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
214816757|NCT03309774|DIAGNOSTIC_TEST|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
214816758|NCT03309774|OTHER|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
214816759|NCT01208727|PROCEDURE|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
214816760|NCT01891994|DRUG|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
214816761|NCT03965091|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm description.
214816762|NCT03965091|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
214816763|NCT03559491|DRUG|Intravitreal injection|Long term release steroid injection
214816764|NCT04215822|DIAGNOSTIC_TEST|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
214816765|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
214816766|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
214816767|NCT04678141|OTHER|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
214816768|NCT01355133|BIOLOGICAL|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
214816769|NCT00982397|DEVICE|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
214816770|NCT00982397|DEVICE|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
214816771|NCT04435353|DEVICE|VibroLUNG|Lungs intensive therapy
214816772|NCT05015114|OTHER|Sarcopenia Assessment|Sarcopenia Assessment
214816773|NCT00303940|DRUG|carboplatin|
214816774|NCT00303940|DRUG|talabostat mesylate|
214816775|NCT00303940|DRUG|temozolomide|
214816776|NCT00303940|OTHER|pharmacological study|
214816777|NCT01871662|DRUG|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
214816778|NCT01871662|DRUG|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
214816779|NCT01871662|DRUG|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
214816780|NCT04167410|OTHER|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
214816781|NCT01333332|DRUG|Capecitabine|Capecitabine
214816782|NCT01333332|RADIATION|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
214816783|NCT02363803|DRUG|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
214816784|NCT02363803|DRUG|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
214816785|NCT01912898|DEVICE|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
214816786|NCT01477476|DRUG|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
214816787|NCT01477476|OTHER|Placebo Comparator|A placebo will be given to 7 subjects.
214816788|NCT03140631|DRUG|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
214816789|NCT01152827|DRUG|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn"
214816790|NCT03774680|DRUG|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
214816791|NCT03774680|DRUG|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
214816792|NCT02372305|BIOLOGICAL|FlexHD|Patients will be randomized to receive FlexHD.
214816793|NCT02372305|BIOLOGICAL|Alloderm|Patient will be randomized to receive Alloderm.
214816794|NCT03324178|BEHAVIORAL|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
214816795|NCT03324178|BEHAVIORAL|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
214816796|NCT02169115|DRUG|Omalizumab|150mg, s.c., every 4 weeks
214816797|NCT02169115|DRUG|Omalizumab|300mg, s.c., every 4 weeks
214816798|NCT02169115|DRUG|Placebo|Placebo, s.c., every 4 weeks
214816799|NCT04509063|BEHAVIORAL|Information about hypothetical mammography screening without benefits|We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
214816800|NCT05970653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
214816801|NCT05970653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214816802|NCT02159950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214816803|NCT02159950|BIOLOGICAL|Sipuleucel-T|Given IV
214816804|NCT02159950|DRUG|Tasquinimod|Given PO
215031334|NCT00770393|PROCEDURE|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
215031335|NCT00770393|PROCEDURE|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~\- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
215031336|NCT02873728|PROCEDURE|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
215031337|NCT02873728|OTHER|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
215031338|NCT05509660|BEHAVIORAL|PUMA+|Transdiagnostic CBT
215031339|NCT05509660|BEHAVIORAL|PUMA|Transdiagnostic CBT
215031340|NCT03198403|DRUG|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
215031341|NCT00608062|DRUG|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
215031342|NCT00608062|DRUG|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
215031343|NCT00608062|DRUG|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
215031344|NCT04349683|DRUG|Jinshuibao|6 capsules at a time, 3 times a day (tid).
215031345|NCT04349683|DRUG|Placebo|6 capsules at a time, 3 times a day (tid).
215031346|NCT02695277|DEVICE|AtriCure Bipolar System|
215031347|NCT02695277|DEVICE|Standard Endocardial Ablation with Catheter|
215031348|NCT02695277|DEVICE|AtriClip® PRO LAA Exclusion System|
215031349|NCT02695277|DEVICE|Endocardial Ablation with Catheter|
215031350|NCT02695277|DEVICE|Repeated Endocardial ablation(s)|
215031351|NCT01728103|DEVICE|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
215031352|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
215031353|NCT05205616|DEVICE|Reciprocating saw|See above description
215031354|NCT01324973|BEHAVIORAL|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
215031355|NCT05430438|OTHER|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
215031356|NCT05430438|OTHER|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
215031357|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
215031358|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
215031359|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
215031360|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
215031361|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
215031362|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
214816805|NCT03325192|DRUG|Rapid pleurodesis protocol|"* The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
214816806|NCT03325192|OTHER|Placebo|"* The pleural space will be evacuated completely through the newly placed IPC~* Only placebo (normal saline) will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
214816807|NCT00003659|BIOLOGICAL|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
214816808|NCT00003659|BIOLOGICAL|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
214816809|NCT00003659|DRUG|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
214816810|NCT00003659|DRUG|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
214816811|NCT00925860|PROCEDURE|non positive pressure mechanical ventilatory support|
214816812|NCT05324098|OTHER|STAND-T platform|Internet-based intervention comprised of evidence-based, patient materials and resources
214816813|NCT05324098|OTHER|Survey Administration|Satisfaction and follow-up surveys will be administered to participants
214816814|NCT05324098|OTHER|Text Messages|Participants will receive periodic text messages
214816815|NCT03515694|DRUG|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
214816816|NCT05915091|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
214816817|NCT05915091|OTHER|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
214816818|NCT02237820|DRUG|Dexamethasone|6 mg/day of Oral Dexamethasone
214816819|NCT02237820|DRUG|Prednisone|40 mg/day of Oral Prednisone
214816820|NCT02177422|DRUG|Telmisartan|telmisartan 80 mg once daily
214816821|NCT02177422|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
214816822|NCT00987740|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
214816823|NCT06167122|PROCEDURE|Craniofacial reconstruction|"Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted."
214816824|NCT04906148|OTHER|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
214816825|NCT04906148|OTHER|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
214816826|NCT05221021|DRUG|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
214816827|NCT05221021|DRUG|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
214816828|NCT01312844|DRUG|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
214816829|NCT04946864|DRUG|APG-2575|APG2575 monotherapy
214816830|NCT04946864|DRUG|Palbociclib|combination APG2575+pablociclib
214816831|NCT05691322|DIAGNOSTIC_TEST|transvaginal ultrasound|Transvaginal ultrasound for endometriosis diagnosis (UBESS)
215031363|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
215031364|NCT04720001|DRUG|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
215031365|NCT04720001|DEVICE|PET|PET Scan for brain imaging
215031366|NCT02040909|DRUG|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
215031367|NCT02215473|DRUG|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
214816832|NCT05691322|DIAGNOSTIC_TEST|MRI|MRI for endometriosis diagnosis (Enzian classification)
214816833|NCT03413839|BEHAVIORAL|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
214816834|NCT03413839|BEHAVIORAL|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
214816835|NCT00503477|DRUG|AZD2171|oral tablet
214816836|NCT06015984|BEHAVIORAL|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
214816837|NCT03588923|DRUG|SH229|tablet, oral, 400 mg once daily for 3 days
214816838|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
214816839|NCT03588923|DRUG|SH229|tablet, oral, 600 mg once daily for 3 days
214816840|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
214816841|NCT03588923|DRUG|SH229|tablet, oral, 800 mg once daily for 3 days
214816842|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
214816843|NCT02714465|OTHER|hyperbaric oxygen therapy|hyperbaric oxygen therapy
214816844|NCT06559813|BEHAVIORAL|Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
214816845|NCT06558617|DIAGNOSTIC_TEST|SARC-F Questionnaire|The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
214816846|NCT06558617|DIAGNOSTIC_TEST|Calf Circumference Measurement|Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
214816847|NCT06558617|DIAGNOSTIC_TEST|SARC-CalF Questionnaire|This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
214816848|NCT00209781|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
214816849|NCT00209781|DEVICE|ITNs|
214816850|NCT02648438|DRUG|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
214816851|NCT02648438|DRUG|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
214816852|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
214816853|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
214816854|NCT02648438|DRUG|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
214816855|NCT00709254|DRUG|i.v. fentanyl|single dose, 200 ug
214816856|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
214816857|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
214816858|NCT03138967|DRUG|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
214816859|NCT03138967|DRUG|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
214816860|NCT03138967|DRUG|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
214816861|NCT03138967|DRUG|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
214816862|NCT03590795|OTHER|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
214816863|NCT04400890|DRUG|Resveratrol|Resveratrol vs placebo given for 15 days.
214816864|NCT04400890|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 100,000 IU given on day one.
214816865|NCT01414933|OTHER|Biopsy|Breast metastases biopsy
214816866|NCT00836849|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
214816867|NCT00836849|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
214816868|NCT04892823|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214816869|NCT04892823|OTHER|Electronic Health Record Review|Review of medical records
214816870|NCT04892823|OTHER|Questionnaire Administration|Complete questionnaires
214816871|NCT01585792|DRUG|TAK-875|
214816872|NCT01585792|DRUG|TAK-875|
214816873|NCT01585792|DRUG|Glimepiride|
214816874|NCT01585792|DRUG|Placebo|
214816875|NCT06112626|BEHAVIORAL|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
215031368|NCT02215473|PROCEDURE|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
214816876|NCT04697368|DEVICE|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
214816877|NCT04697368|OTHER|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
214816878|NCT06261528|DEVICE|Light therapy|Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
214816879|NCT04915248|DRUG|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
214816880|NCT04915248|DRUG|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
214816881|NCT04915248|DRUG|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
214816882|NCT05661097|PROCEDURE|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
214816883|NCT03925532|BIOLOGICAL|Denosumab|Given SC
214816884|NCT03467399|DEVICE|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
214816885|NCT05350787|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
214816886|NCT06851936|BEHAVIORAL|Nicotine cessation program|All participants will complete a nicotine cessation program designed by Area Health Education Center (AHEC). The focus is on known tobacco cessation techniques and motivations to quit with additional focuses on cancer survivors and caregivers. The program consists of 4 sessions (each session is approximately 60 minutes long) that will be delivered by a Tobacco Treatment Specialist by either videoconference or by telephone. Dyad enrollees (i.e., cancer survivors and their caregiver/family member) will complete sessions together. Participants will also be eligible for free nicotine replacement therapy while on study if medically appropriate.
214816887|NCT06173401|RADIATION|Single-fraction spine SRS|Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)
214816888|NCT06173401|RADIATION|Multi-fraction spine SRS|Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
214816889|NCT04018365|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
214816890|NCT02258074|DRUG|Nicotinamide|
214816891|NCT02258074|DRUG|Lanthanum Carbonate|
214816892|NCT02258074|DRUG|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
214816893|NCT02258074|DRUG|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
214816894|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
214816895|NCT06561997|DEVICE|Robot-assisted|received percutaneous pedicle screw fixation (PPSF) with robotic assistance
214816896|NCT06561997|DEVICE|Free-hand|received percutaneous pedicle screw fixation (PPSF) without robotic assistance
214816897|NCT04904861|BEHAVIORAL|Videoconference intervention group|A short face-to-face dyadic group workshop focused on increasing maternal sensitivity was adapted to be carried out virtually by videoconference. The intervention considers 4 sessions, with a weekly frequency, with a minimum of 3 and a maximum of 6 dyads per group led by a monitor (psychologist). The activities are protocolized in a manual and are designed to be carried out by the mother with the baby under one year of age. .
214816898|NCT04904861|OTHER|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks) in addition to the usual care in their primary care center
214816899|NCT04577846|DRUG|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
214816900|NCT04577846|DRUG|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
214816901|NCT03835715|DRUG|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
214816902|NCT00723710|BIOLOGICAL|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
214816903|NCT04405570|DRUG|Molnupiravir 200 mg|Oral capsule of molnupiravir
214816904|NCT04405570|DRUG|Molnupiravir 400 mg|Oral capsule of molnupiravir
214464519|NCT03626766|BEHAVIORAL|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
214464520|NCT03626766|BEHAVIORAL|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
214816905|NCT04405570|DRUG|Molnupiravir 800 mg|Oral capsule of molnupiravir
214816906|NCT04405570|DRUG|Placebo (PBO)|placebo oral capsule
214816907|NCT01003054|DRUG|Busulfan|130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
214816908|NCT01003054|DRUG|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
214816909|NCT01003054|DRUG|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.
214816910|NCT01003054|PROCEDURE|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
214816911|NCT03625661|DRUG|Ferinject|Ferinject 50mg/ml, one injection
215031369|NCT04692779|OTHER|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
215031370|NCT01955863|PROCEDURE|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
214816912|NCT05358405|OTHER|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
214816913|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 0.5%|0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
214816914|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 1.0%|1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
214816915|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, Placebo|Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
214816916|NCT03522363|OTHER|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
215031371|NCT01955863|PROCEDURE|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
214464521|NCT03626766|BEHAVIORAL|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
214464522|NCT05720416|DIETARY_SUPPLEMENT|protein supplementation|protein supplementation for 16 weeks
214816917|NCT04499963|DRUG|Theracurmin HP|The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
214816918|NCT03144453|DRUG|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
214816919|NCT03144453|DRUG|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
214816920|NCT04000464|BEHAVIORAL|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
214816921|NCT05222477|BEHAVIORAL|pelvic floor exercise|pelvic floor exercises(intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
214816922|NCT05222477|BEHAVIORAL|Abdominal muscles exercise|abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
214816923|NCT03503422|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for back pain|"Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
215031372|NCT01955863|PROCEDURE|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
215031373|NCT00802906|DEVICE|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
215031374|NCT00802906|DRUG|bevacizumab|1.5 mg initial intravitreal injection
214816924|NCT03503422|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for back pain|"Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively"
214816925|NCT06064799|DIAGNOSTIC_TEST|miRNA-223 & -214 detection|miRNA-223 \& -214 detection in GCF samples by PCR kits
214816926|NCT00144014|DRUG|V10153|Single acute intravenous bolus dose up to 10 mg/kg
214816927|NCT05854186|BEHAVIORAL|Telehealth solution: video conferencing|Telehealth solution: video conferencing
214816928|NCT02411552|BEHAVIORAL|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
214816929|NCT04054232|OTHER|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~1. Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~2. What peripheral artery disease is and why diagnosis may be important~3. Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~4. The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
214816930|NCT03444090|PROCEDURE|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
214816931|NCT00868413|DRUG|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
214816932|NCT00868413|DRUG|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
214816933|NCT00868413|DRUG|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
214816934|NCT00693290|OTHER|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
214816935|NCT01208337|DRUG|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
214816936|NCT02399917|DRUG|Azacitidine|Given SC or IV
214816937|NCT02399917|BIOLOGICAL|Lirilumab|Given IV
214816938|NCT05186662|OTHER|patient education|patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
214816939|NCT05186662|OTHER|patient education|Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
214816940|NCT05048004|PROCEDURE|QMODE intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
214816941|NCT05048004|PROCEDURE|QMODE+ intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
214816942|NCT00365534|PROCEDURE|MEI|
214816943|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
214816944|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
214816945|NCT01639092|DRUG|Entecavir|Entecavir 1 mg daily Oral
214816946|NCT05593991|OTHER|Elevated heels|"Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer."
214816947|NCT06562699|OTHER|Hot Matcha brew|"* Hot matcha brew will be prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 30 mL of hot water (75 ̊C). The first step will be to massage the matcha powder with a small amount of water until a smooth paste forms, then additional 50 mL of hot water will be added to dilute down the concentration. The matcha will then be vigorously shaken in a lidded jar.~* After 5 minutes of the acidic attack, participants will be instructed to swish 25 mL of matcha tea 34 times then swallow, and saliva samples will be collected (T2).~* Then saliva will be collected after 10 (T3), 20 (T4), 30 (T5), and 40 (T6) minutes."
214816948|NCT06562699|OTHER|Water|Water (elano) at 13 ̊C swished 34 times then swallowed.
214816949|NCT06562699|OTHER|Cold matcha brew|25 mL of cold matcha brew prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 80 mL of cold water (13 ̊C) swished 34 times then swallowed.
214816950|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy|the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer
214816951|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection|the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer
214816952|NCT02107300|DRUG|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
214816953|NCT02107300|DRUG|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
214816954|NCT03663179|DEVICE|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
214816955|NCT03663179|DEVICE|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
214816956|NCT04785456|DEVICE|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
214816957|NCT04785456|DEVICE|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
214816958|NCT03513822|DRUG|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
214816959|NCT03513822|DRUG|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
214816960|NCT03513822|DRUG|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
214816961|NCT06469671|DEVICE|The system based on real - time artificial intelligence - assisted for colonoscopy|"Russian medical decision support system based on artificial intelligence ArtInCol"
214816962|NCT05792774|DRUG|Bupivacain|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
214816963|NCT05792774|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
214816964|NCT00134394|DRUG|Etanercept plus tacrolimus|
214816965|NCT02152332|DRUG|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
214816966|NCT02152332|DRUG|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
214816967|NCT02152332|DRUG|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
214816968|NCT02152332|DRUG|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
214816969|NCT02152332|DRUG|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
214816970|NCT03226522|DRUG|AXS-05|AXS-05
214816971|NCT03226522|DRUG|Bupropion|Bupropion
214816972|NCT03226522|DRUG|Placebo|Placebo
214816973|NCT04988464|BEHAVIORAL|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
214816974|NCT04988464|BEHAVIORAL|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
214816975|NCT02972047|BEHAVIORAL|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
214816976|NCT02972047|BEHAVIORAL|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
214816977|NCT02319980|PROCEDURE|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
214816978|NCT00068731|DIETARY_SUPPLEMENT|lycopene|
214816979|NCT05996510|DEVICE|ultrasound|Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
214816980|NCT01336660|BIOLOGICAL|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
214816981|NCT01336660|OTHER|Intensive care support plus placebo|Intensive care support as needed plus placebo
214816982|NCT04729660|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
214816983|NCT03113786|OTHER|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
214816984|NCT03113786|OTHER|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
214816985|NCT00984126|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
214816986|NCT00984126|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
214816987|NCT01001208|DRUG|Methotrexate|Methotrexate tablets over-encapsulated for blinding
214816988|NCT01001208|DRUG|Etanercept|1 mL for subcutaneous injection
214816989|NCT01001208|DRUG|Placebo|Matching placebo to methotrexate capsules
214816990|NCT02927119|DIETARY_SUPPLEMENT|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
214816991|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
214816992|NCT04591405|BIOLOGICAL|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
214816993|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
214816994|NCT04591405|BIOLOGICAL|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
214816995|NCT04068441|OTHER|no intervention|No intervention
214816996|NCT04472156|PROCEDURE|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
214816997|NCT04286802|DEVICE|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
214816998|NCT04286802|BEHAVIORAL|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
214816999|NCT04886973|OTHER|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
214817000|NCT00818545|DRUG|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
214817001|NCT00818545|DRUG|placebo|
214817002|NCT01199718|DRUG|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
214817003|NCT04550585|OTHER|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
214817004|NCT04550585|OTHER|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
214817005|NCT04550585|OTHER|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
214817006|NCT04550585|OTHER|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
214817007|NCT04550585|OTHER|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
214817008|NCT04550585|OTHER|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
214817009|NCT01463761|DEVICE|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
214817010|NCT01518439|DEVICE|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
214817011|NCT01518439|DEVICE|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
214817012|NCT01518439|DEVICE|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
214817013|NCT01518439|DEVICE|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
214817014|NCT01518439|OTHER|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
214817015|NCT01864174|DRUG|Metformin XR|
214817016|NCT01864174|DRUG|Metformin IR|
214817017|NCT01864174|DRUG|Placebo matching with Metformin XR|
214817018|NCT01864174|DRUG|Placebo matching with Metformin IR|
214817019|NCT02739997|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
214817020|NCT02739997|DRUG|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
214817021|NCT03555747|OTHER|Canine distalization|GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
214817022|NCT04059965|OTHER|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
214817023|NCT04059965|OTHER|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
214817024|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
214817025|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
214817026|NCT02078986|OTHER|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
214817027|NCT02078986|OTHER|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
214817028|NCT05132933|PROCEDURE|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
214817029|NCT00133822|DRUG|Sertraline and Risperidone|
214817030|NCT03719898|DRUG|Brigatinib|Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
214817031|NCT03783793|BEHAVIORAL|Mindfulness Training App|Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
214817032|NCT03783793|BEHAVIORAL|Cognitive Training With 2048|The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
214817033|NCT00731978|PROCEDURE|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
214817034|NCT03749512|DIAGNOSTIC_TEST|Complete blood count|During routine preoperative blood test complete blood count is taken.
214817035|NCT03749512|OTHER|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
214817036|NCT00798954|DEVICE|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
214817037|NCT00798954|DEVICE|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
214817038|NCT02158663|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS Device
214817039|NCT02290171|BEHAVIORAL|Activity groups|Children attend to activity groups weekly during the intervention periode.
214817040|NCT02290171|BEHAVIORAL|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
214817041|NCT02290171|BEHAVIORAL|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
214817042|NCT02813018|PROCEDURE|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
214817043|NCT02813018|PROCEDURE|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
214817044|NCT01286090|DRUG|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
214817045|NCT01286090|DRUG|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
214817046|NCT01769183|DRUG|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
214464523|NCT05720416|BEHAVIORAL|muscle strength training|muscle strength training for 16 weeks
214464524|NCT05720416|OTHER|usual care|no intervention
214817047|NCT00770718|DRUG|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
214817048|NCT00770718|DRUG|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is \>1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
214817049|NCT00770718|BIOLOGICAL|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is \>4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to \>1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
214817050|NCT01184183|PROCEDURE|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
214817051|NCT03892863|DEVICE|active repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
214817052|NCT03892863|DEVICE|sham repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
214817053|NCT00251030|DRUG|Nelfinavir and Omeprazole|
214817054|NCT00007852|BIOLOGICAL|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
214817055|NCT00007852|DRUG|carmustine|BCNU 300 mg/M2 IV day -6
214817056|NCT00007852|DRUG|cytarabine|100 mg/m2 on days -5 through -2
214817057|NCT00007852|DRUG|etoposide|100mg/M2 BID on days -5 through -2
214817058|NCT00007852|DRUG|melphalan|140 mg/m2 IV on day -1
214817059|NCT00007852|PROCEDURE|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
214817060|NCT03216577|OTHER|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
214817061|NCT04309981|BIOLOGICAL|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
214817062|NCT05082779|DRUG|CS0159|Tablets administered orally
214817063|NCT00498381|DEVICE|CPAP|
214817064|NCT03525522|DEVICE|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
214817065|NCT03525522|DRUG|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
214817066|NCT04308850|DRUG|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
214817067|NCT00749177|OTHER|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
214817068|NCT00741858|PROCEDURE|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
214817069|NCT00741858|PROCEDURE|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
214817070|NCT02603055|BIOLOGICAL|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
214817071|NCT02603055|BIOLOGICAL|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
214817072|NCT01305122|BEHAVIORAL|neurocognitive tests|"* inclusion~* 1 year~* 3 years~* 5 years"
214817073|NCT04943029|DRUG|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
214817074|NCT04943029|DRUG|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
214817075|NCT04943029|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
214817076|NCT04943029|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
214817077|NCT02241434|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
214817078|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
214817079|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
214817080|NCT01852747|PROCEDURE|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
214817081|NCT05388305|BIOLOGICAL|CAR--γδT cells|Biological: CAR-γδT; Drug:
214817082|NCT03552393|DRUG|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
214817083|NCT02308475|DEVICE|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
214817084|NCT03141047|OTHER|Lifespan Integration|A protocol based psychological treatment method
214817085|NCT04039594|DEVICE|VA ECMO|VA ECMO for cardiopulmonary support
214817086|NCT03328676|DRUG|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
214817087|NCT03328676|DRUG|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
214817088|NCT02414152|DRUG|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
214817089|NCT03305263|DRUG|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
214817090|NCT03305263|DRUG|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
214817091|NCT03488147|DRUG|Esomeprazole|20 mg esomeprazole tablet
214817092|NCT03488147|DRUG|Placebo Oral Tablet|resembling esomeprazole tablet
214817093|NCT02105779|OTHER|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
214817094|NCT02105779|OTHER|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
214817095|NCT04418310|PROCEDURE|Lay open and curettage|Lay open and curettage
214817096|NCT04418310|PROCEDURE|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
214817097|NCT00473863|PROCEDURE|Coronary Computed Tomographic Angiography|CCTA will be performed
214817098|NCT06456918|PROCEDURE|Quality of Recovery 15 questionnaire|return to daily life after surgery according to the patient's baseline or social norms
214817099|NCT00725803|DRUG|GS-9450|GS-9450 capsules administered orally once daily
214817100|NCT00725803|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
214817101|NCT01689311|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214817102|NCT01689311|DRUG|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214464526|NCT01593917|DEVICE|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
214464527|NCT04978506|DRUG|BI 1569912|BI 1569912
214464528|NCT04978506|DRUG|Placebo|Placebo
214817103|NCT01689311|DRUG|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214817104|NCT01689311|DRUG|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
214817105|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
214817106|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
214817107|NCT00019591|BIOLOGICAL|aldesleukin|
214817108|NCT00019591|BIOLOGICAL|ras peptide cancer vaccine|
214817109|NCT00019591|PROCEDURE|adjuvant therapy|
214817110|NCT02601625|DRUG|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
214817111|NCT02601625|DRUG|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
214817112|NCT02601625|DRUG|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
214817113|NCT02601625|DRUG|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
214817114|NCT02601625|DRUG|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
214817115|NCT02601625|DRUG|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
214817116|NCT02285894|OTHER|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
214817117|NCT05640544|OTHER|Sound and light stimulation in Gamma band|"We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients."
214817118|NCT01828528|PROCEDURE|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
214817119|NCT00560443|DRUG|ketorolac|0,5 mg/kg per os one time
214817120|NCT00560443|DRUG|tramadol|2,5 mg/ kg per os in one dose
214817121|NCT01926821|DRUG|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
214817122|NCT02284490|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
214817123|NCT01683474|DEVICE|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
214817124|NCT03037697|OTHER|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
214817125|NCT03037697|OTHER|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
214817126|NCT00359281|DRUG|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
214817127|NCT00359281|DRUG|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
214817128|NCT00359281|DRUG|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
214817129|NCT00359281|DRUG|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
214817130|NCT00359281|DRUG|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
214817131|NCT00359281|DRUG|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
214817132|NCT00448903|DRUG|Bemiparin|Bemiparin sodium
214817133|NCT00448903|DRUG|Placebo|Sodium Chloride 0,9%
214817134|NCT05672433|DIETARY_SUPPLEMENT|Placebo|Capsule without cafestol twice daily
214817135|NCT05672433|DIETARY_SUPPLEMENT|Cafestol|Capsule with 6 mg cafestol twice daily
214817136|NCT04609917|PROCEDURE|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
214817137|NCT00407147|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
214817138|NCT01111045|DRUG|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
214817139|NCT01111045|DRUG|Placebo|Placebo
214817140|NCT06103058|OTHER|Cross sectional|Cross sectional
214817141|NCT04887415|BEHAVIORAL|Respiratory Strength Training (RST) Program|Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
214817142|NCT06268665|DRUG|Tart Cherry Juice|Given PO
214817143|NCT06561867|DRUG|Ticagrelor 90 MG|Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
214817144|NCT06561867|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214817145|NCT05363059|DRUG|Hypoglycemic drugs|drug
214817146|NCT05363059|PROCEDURE|Bariatric surgery|surgery
214817147|NCT04567082|DIAGNOSTIC_TEST|Examination of saliva|Collection of saliva samples
214817148|NCT05895383|DRUG|Nitrous oxide|Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
214817149|NCT01415986|DRUG|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
214817150|NCT01415986|DEVICE|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
214817151|NCT03932058|DRUG|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
214817152|NCT01116362|PROCEDURE|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
214817153|NCT01116362|PROCEDURE|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
214817154|NCT04016415|BEHAVIORAL|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
214464529|NCT05553145|DIAGNOSTIC_TEST|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
214817155|NCT04016415|BEHAVIORAL|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
214817156|NCT03069586|PROCEDURE|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
214817157|NCT03069586|PROCEDURE|No pulmonary recruitment|At the end of surgery no intervention was completed
214817158|NCT00707408|DRUG|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
214817159|NCT03792477|BIOLOGICAL|Test formulation|A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
214817160|NCT03792477|BIOLOGICAL|Reference formulation|A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
214817161|NCT00308048|DRUG|Pegylated Interferon alfa 2b and ribavirin|
214817162|NCT02364063|OTHER|urotherapy with or without pharmacotherapy|Individualized
214817163|NCT01557712|DRUG|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
214817164|NCT01557712|DRUG|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
214817165|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
214817166|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
214817167|NCT01681745|DEVICE|Cryo-Touch III|
214817168|NCT02767921|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214817169|NCT02767921|OTHER|Laboratory Biomarker Analysis|Correlative studies
214817170|NCT02767921|PROCEDURE|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
214817171|NCT02767921|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214817172|NCT02767921|PROCEDURE|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
214817173|NCT04444505|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
214817174|NCT02456714|DRUG|FOLFIRINOX|
214817175|NCT01701492|OTHER|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
214817176|NCT01701492|OTHER|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
214817177|NCT00840411|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
214817178|NCT00840411|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
214817179|NCT04031001|DEVICE|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
214817180|NCT02804945|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.
214817181|NCT01983761|DRUG|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
214817182|NCT01983761|DRUG|Fludarabine, Melphalan, ATG (Reduced Intensity)|
214817183|NCT00464048|PROCEDURE|controlled physical exercise|
214817184|NCT01488630|OTHER|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
214817185|NCT05926479|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
214817186|NCT05926479|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
214817187|NCT05926479|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
214817188|NCT01372579|DRUG|eribulin mesylate|Given IV
214817189|NCT01372579|DRUG|carboplatin|Given IV
214817190|NCT01372579|PROCEDURE|biopsy|Correlative studies
214817191|NCT05813678|DRUG|Pegvaliase|This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).
214817192|NCT02666300|OTHER|TaperGuard ETT|tracheal intubation with TaperGuard ETT
214817193|NCT06560580|DRUG|3% Diquafosol Sodium Eye Drops|Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
214817194|NCT06560086|DRUG|Ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
214817195|NCT06560086|DRUG|Luteinizing Hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
214817196|NCT06561100|BEHAVIORAL|Sub-symptomatic Adaptable Exercise Treatment (SAET)|Each workout will be structured in a similar format. The first 5 minutes will be devoted to stretching and warm up exercises. Then the next 20 minute segment devoted to light to moderate aerobic exercise. The second 20 minutes of each exercise session will be composed of a series of 5 predetermined exercises that rotate every day. Each workout will have one or two alternatives that the patient can complete either for modification to accommodate a physical limitation or to optimize preference. Resistance training each day will include multi-joint functional movements along with stability work. The last five minutes of the session will include more mobility work, and/or cooling down.
214817197|NCT06561100|BEHAVIORAL|Stretching Control Group (SCG)|Each workout will be 50-60 minutes long and participants are instructed to not do any other type of exercise that may elevate their heart rate. Modifications will be available for stretches that may be too advanced for the individual.
214817198|NCT00002345|DRUG|Megestrol acetate|
214817199|NCT05782634|DEVICE|immediate satellite implant with immediate loading|"Infiltration anesthesia will be administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 . Injection to control pain and bleeding for hemostasis.~Dental extraction will be done with minimal force to avoid trauma to the bone. Flab will be released, different drilling sizes will be used to attain the final drill size of the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, a satellite implant device is attached to the implant's abutment placed on the buccal and palatal plates of bone and retention between the abutment and microplate will help in neglecting the lateral destructive forces . sutures will be done . Impression will be taken for immediate loading with the final crown. Cone beam will be done."
214817200|NCT01424293|DEVICE|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
214817201|NCT01424293|DEVICE|The SPY® Intraoperative Imaging System|
214817202|NCT05729061|DEVICE|Assist-Knee|Investigational prosthetic knee-ankle device
214817203|NCT05729061|DEVICE|Prosthetic Knee|Commercially available prosthetic knee devices
214817204|NCT05729061|DEVICE|Prosthetic Ankle|Commercially available prosthetic ankle devices
214817205|NCT05729061|DEVICE|Prosthetic Foot|Commercially available prosthetic foot devices
214817206|NCT05729061|DEVICE|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
214817207|NCT02003547|DRUG|AMA0076|
214817208|NCT02003547|DRUG|Placebo|
214817209|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Active|
214817210|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Sham|
214817211|NCT05123495|BEHAVIORAL|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
214817212|NCT05123495|BEHAVIORAL|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
214817213|NCT02609295|DIETARY_SUPPLEMENT|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
214817214|NCT02609295|DIETARY_SUPPLEMENT|ALA group|1.2 g (two capsules) of perilla oil
214817215|NCT04915534|DEVICE|Ambu® AuraGain™ Laryngeal Mask (LM)|Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
214817216|NCT00227136|DRUG|5-Hydroxy-Tryptamine|
214817217|NCT00175058|DEVICE|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
214817218|NCT01642342|OTHER|laboratory biomarker analysis|Correlative studies
214817219|NCT01642342|OTHER|pharmacological study|Correlative studies
214817220|NCT01642342|BIOLOGICAL|recombinant albumin fusion protein sEphB4-HSA|Given IV
214817221|NCT04495647|OTHER|Whole-Body Electromyostimulation|"Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention."
214817222|NCT03373162|DRUG|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
214817223|NCT00127946|PROCEDURE|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
214817224|NCT00576056|DRUG|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
214817225|NCT00576056|DRUG|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
214817226|NCT01854047|DRUG|Dupilumab|Solution for injection, Subcutaneous injection
214817227|NCT01854047|DRUG|placebo|Solution for injection, Subcutaneous injection
214817228|NCT01854047|DRUG|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
214817229|NCT01854047|DRUG|Salbutamol/albuterol|Oral inhalation as needed
214817230|NCT01854047|DRUG|Levosalbutamol/levalbuterol|Oral inhalation as needed
214817231|NCT05645367|OTHER|No intervention|This is a post-hoc analysis of a cross-sectional study.
214817232|NCT06628336|DEVICE|HARMONY EVOLUTION|It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.
214817233|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games|Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.
214817234|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games|Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
214817235|NCT04852380|PROCEDURE|PRP injections|The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
214817236|NCT00907413|PROCEDURE|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
214817237|NCT00907413|PROCEDURE|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
214817238|NCT04517019|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
214817239|NCT01764347|PROCEDURE|therapeutic conventional surgery|Undergo robotic radical prostatectomy
214817240|NCT01764347|PROCEDURE|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
214817241|NCT01764347|PROCEDURE|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
214817242|NCT02416726|DEVICE|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
214817243|NCT06562738|DRUG|Hetrombopag|Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
214817244|NCT04920877|OTHER|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
214817245|NCT01653353|BEHAVIORAL|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
214817246|NCT00437853|DRUG|Anastrozole|
214817247|NCT01051570|DRUG|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
214817248|NCT01051570|DRUG|RAD 001|5 mg orally starting on Day 2 then continuous
214817249|NCT01051570|DRUG|prednisone|5 mg orally twice a day starting on Day 1 then continuous
214817250|NCT01051570|OTHER|laboratory biomarker analysis|Samples will be collected from archival tissue.
214817251|NCT01051570|OTHER|pharmacological study|Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
214817252|NCT04322500|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
214817253|NCT04322500|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
214817254|NCT00614952|DEVICE|PSG (polysomnography)|POLYSOMNOGRAPHY
214817255|NCT00614952|OTHER|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
214817256|NCT02989233|OTHER|Non-surgical periodontal treatment|Scaling and oral hygiene instructions with brochure, model or video
214817257|NCT01930227|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
214817258|NCT01930227|OTHER|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
214817259|NCT02864615|RADIATION|SBRT|Dose and schedule will be depended on metastases location.
214817260|NCT03592953|OTHER|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
214817261|NCT01232426|PROCEDURE|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
214817262|NCT01232426|DEVICE|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
214817263|NCT01141426|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
214817264|NCT01141426|BEHAVIORAL|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
214817265|NCT03620175|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
214817266|NCT05948683|DRUG|MDMA|The stimulant MDMA
214817267|NCT05948683|DRUG|Placebo|Dextrose
214817268|NCT04894097|DEVICE|magnetic therapy|High intensity low frequency magnetic therapy
214817269|NCT06785350|DRUG|0.012%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.5ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.012%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
214817270|NCT06785350|DRUG|0.009%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.375ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.009%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
214817271|NCT06785350|DRUG|0.006%diprospan+0.5ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.25ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.006%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
214817272|NCT06785350|DRUG|0.003%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.125ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.003%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
214817273|NCT06785350|DRUG|0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 15 ml of ropivacaine will be diluted to 30 ml with in 0.9% NaCl, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
214817274|NCT04366791|RADIATION|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
214817275|NCT06847087|OTHER|Self-questionnaire|Assessment of the inadequacy between dietary and medicinal calcium intake by the Fardellone self-questionnaire and the patient's clinical record
214817276|NCT02847650|DRUG|Placebo|
214817277|NCT02847650|DRUG|PF-06649751|
214817278|NCT00333645|DRUG|Caspofungin|
214817279|NCT04551976|BEHAVIORAL|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
214817280|NCT03734718|DRUG|GIP|Infusion of Glucose-dependent insulinotropic peptide
214817281|NCT06111170|DEVICE|Compression dressing|Application of dressing
214817282|NCT02432976|DRUG|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
214817283|NCT02432976|DRUG|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
214817284|NCT03818581|DRUG|Suvorexant|10-mg or 20-mg Suvorexant capsules
214817285|NCT03818581|OTHER|Placebo|Matching placebo capsules
214817286|NCT04722458|OTHER|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
214817287|NCT04722458|OTHER|IPSS|International Prostate Symptom Score
214817288|NCT04722458|OTHER|UDI-6|Urogenital Distress Inventory
214817289|NCT03084250|DRUG|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
214817290|NCT03084250|DRUG|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
214817291|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
214464530|NCT05006157|DEVICE|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
214817292|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
214817293|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
214817294|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
214817295|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
214817296|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
214817297|NCT02775045|OTHER|Observation Period|8 week observational period
214817298|NCT03825328|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
214817299|NCT03825328|DRUG|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
214817300|NCT03825328|DRUG|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
214817301|NCT03825328|DRUG|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
214817302|NCT01383694|DRUG|Piperine|
214817303|NCT00500591|BEHAVIORAL|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
214817304|NCT02935517|BIOLOGICAL|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
214817305|NCT02767791|OTHER|Acupuncture|Acupuncture
214817306|NCT02767791|OTHER|Auriculotherapy|Auriculotherapy
214817307|NCT02517294|DEVICE|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
214817308|NCT02517294|DEVICE|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
214817309|NCT03777826|OTHER|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
214817310|NCT05370417|OTHER|Use of fluoride toothpaste|The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
214817311|NCT05370417|RADIATION|Photobiomodulation|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point."
214817312|NCT05370417|PROCEDURE|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
214817313|NCT05370417|PROCEDURE|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
214817314|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
214817315|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
214817316|NCT05726526|DEVICE|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
214817317|NCT05802680|DEVICE|Transcranial photobiomodulation|Administration of Sham or 1064 (+/- 50) nanometers tPBM
214817318|NCT05802680|DEVICE|Sham transcranial photobiomodulation|Sham treatment
214817319|NCT06161558|DRUG|Erlotinib|Small-molecule tyrosine kinase inhibitor targeting EGFR
214817320|NCT06161558|DRUG|Lenvatinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
214817321|NCT06161558|DRUG|Axitinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
214817322|NCT06508411|OTHER|Pain screening|exploration of the relationship between pain and sexual health
214817323|NCT02096211|DEVICE|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
214817324|NCT05095519|DRUG|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
214817325|NCT01281501|DRUG|Normal saline|10 ml of 0.9% sodium chloride solution
214817326|NCT01281501|DRUG|Pantoprazole|80 mg of intravenous pantoprazole
214817327|NCT01281501|DRUG|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
214817328|NCT01281501|DRUG|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
214817329|NCT02667405|PROCEDURE|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
214817330|NCT02667405|PROCEDURE|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
214817331|NCT01202422|DRUG|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
214817332|NCT01202422|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
214817333|NCT01202422|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
214817334|NCT01619930|BEHAVIORAL|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
214464531|NCT05856344|DEVICE|Spherical tip noncompliant balloon|The main difference of this experimental balloon is the spherical tip, other parameters are consistent with regular noncompliant balloons.
214464532|NCT05856344|DEVICE|Regular noncompliant balloon|The balloon is designed as tapered-tip.
214817335|NCT01619930|BEHAVIORAL|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
214817336|NCT01619930|BEHAVIORAL|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
214817337|NCT01619930|BEHAVIORAL|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
214817338|NCT06031857|OTHER|kinesio tape|kinesio tape was applied over the specific muscle of rotator cuff
214817339|NCT06031857|OTHER|Dry needling|dry needling was applied over the affected muscles
214817340|NCT05278481|BEHAVIORAL|Reward Message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
214817341|NCT05278481|BEHAVIORAL|Reward Message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
214817342|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
214817343|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
214817344|NCT05278481|BEHAVIORAL|Social norms message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
214817345|NCT05278481|BEHAVIORAL|Social norms message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
214817346|NCT02494479|DRUG|Prurisol|50mg tablet
214817347|NCT02494479|DRUG|Placebo|Sugar pill designed to match Purisol tablet
214817348|NCT01038661|DRUG|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
214817349|NCT01038661|DRUG|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
214817350|NCT01038661|OTHER|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
214817351|NCT01807793|BEHAVIORAL|Psychoeducation|
214817352|NCT00941811|DRUG|Imiquimod|Local Imiquimod three times weekly for 16 weeks
214817353|NCT05385601|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
214817354|NCT05644340|PROCEDURE|Speed 8 (Fast balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
214817355|NCT05644340|PROCEDURE|Speed 4 (Medium speed balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
214464533|NCT06029075|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
214464534|NCT06029075|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
214817356|NCT02102165|PROCEDURE|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
214817357|NCT05378217|DIAGNOSTIC_TEST|AMR LFIA Assay|AMR LFIA will be performed in parallel to routine testing on appropriate sample types retrieved from routine testing : Blood, urine, BronchoAlveolar Lavage (BAL), Tracheal Aspirate (TA), Rectal swab
214817358|NCT04206358|BIOLOGICAL|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
214817359|NCT03569059|DEVICE|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
214817360|NCT03569059|BEHAVIORAL|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
214817361|NCT03569059|DEVICE|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
214817362|NCT00519194|DEVICE|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
214817363|NCT00519194|PROCEDURE|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
214817364|NCT03165994|DRUG|APX005M|APX005M IV infusion
214817365|NCT03165994|RADIATION|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
214817366|NCT03165994|DRUG|Paclitaxel|Paclitaxel IV infusion
214817367|NCT03165994|DRUG|Carboplatin|Carboplatin IV infusion
214817368|NCT03165994|PROCEDURE|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-17
214817369|NCT00716690|PROCEDURE|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
214817370|NCT00002318|DRUG|Doxorubicin hydrochloride (liposomal)|
214464535|NCT06029075|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
214817371|NCT00002318|DRUG|Bleomycin sulfate|
214817372|NCT00002318|DRUG|Vincristine sulfate|
214817373|NCT00002318|DRUG|Doxorubicin hydrochloride|
214817374|NCT02996591|PROCEDURE|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
214817375|NCT02996591|PROCEDURE|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
214817376|NCT02996591|DRUG|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
214817377|NCT02996591|PROCEDURE|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
214817378|NCT02996591|PROCEDURE|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
214817379|NCT04564560|PROCEDURE|Endovascular aortic repair with Zenith Alpha Spiral-Z®|The Zenith Alpha Spiral-Z® stent graft may have an increased risk of thrombosis. The intervention in this study is to assess the extent and degree of thrombosis in patients treated with the Zenith Alpha Spiral-Z® during endovascular repair of aortic aneurysm
214817380|NCT05934643|DEVICE|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
214817381|NCT05934643|OTHER|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
214817382|NCT02597660|DRUG|Somatropin|Active drug
214817383|NCT02597660|DRUG|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
214817384|NCT02597660|OTHER|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
214817385|NCT02597660|PROCEDURE|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
214817386|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
214817387|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
214817388|NCT04833504|BIOLOGICAL|CD19 CAR-T Expressing IL7 and CCL19|A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19
214817389|NCT00152646|DRUG|placebo, aspirine, clopidogrel|
214817390|NCT00144534|DRUG|MRA (Tocilizumab)|8mg/kg/4 weeks
214817391|NCT03911258|PROCEDURE|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
214817392|NCT04576234|DIETARY_SUPPLEMENT|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
214817393|NCT02816996|PROCEDURE|Hand-holding|Subject will have their hand held.
214817394|NCT02816996|PROCEDURE|Stress Ball|Subject will be given a stress ball to hold.
214817395|NCT00047099|DRUG|cyclophosphamide|
214817396|NCT00047099|DRUG|docetaxel|
214817397|NCT00047099|DRUG|epirubicin hydrochloride|
214817398|NCT00047099|DRUG|fluorouracil|
214817399|NCT00047099|DRUG|goserelin acetate|
214817400|NCT00047099|DRUG|tamoxifen citrate|
214817401|NCT00047099|PROCEDURE|adjuvant therapy|
214817402|NCT00047099|RADIATION|radiation therapy|
214817403|NCT00665470|DRUG|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
214817404|NCT05368870|PROCEDURE|Carlevale implantation|Vitrectomy and Carlevale implantation
214817405|NCT02003833|DEVICE|Poly-L-lactic acid|Sculptra injections
214817406|NCT02003833|DEVICE|Placebo comparator|saline injections
214817407|NCT00738049|DRUG|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
214817408|NCT03565133|DIETARY_SUPPLEMENT|Quinine sham feeding quinine|Oral sham feeding with quinine
214817409|NCT03565133|DIETARY_SUPPLEMENT|Gastric quinine|A gastric capsule containing quinine
214817410|NCT03565133|DIETARY_SUPPLEMENT|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
214817411|NCT03565133|DIETARY_SUPPLEMENT|Gastric placebo|A gastric capsule containing placebo (cellulose)
214817412|NCT03141671|DRUG|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
214817413|NCT03141671|DRUG|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
214817414|NCT03141671|RADIATION|Salvage radiation|Radiation
214817415|NCT03141671|DRUG|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
214817416|NCT03141671|DRUG|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
214817417|NCT03141671|DRUG|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
214817418|NCT00461786|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
214817419|NCT00934050|DRUG|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
214817420|NCT03974035|DRUG|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
214817421|NCT02816450|BEHAVIORAL|Water Intake|
214817422|NCT01133470|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
214817423|NCT05885971|DIAGNOSTIC_TEST|Administration of the SCOFF-F and EDE-Q questionnaires|The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
214817424|NCT01457300|OTHER|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
214817425|NCT03400020|OTHER|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
214817426|NCT03400020|OTHER|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
214817427|NCT00835991|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
214817428|NCT00835991|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
214817429|NCT02561520|BIOLOGICAL|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
214817430|NCT02561520|BIOLOGICAL|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
214817431|NCT00315562|PROCEDURE|carotid endarterectomy|
214817432|NCT02553044|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
214817433|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
214817434|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
214817435|NCT02149420|DRUG|VAY736|
214817436|NCT02149420|DRUG|Placebo|
214817437|NCT05422391|DIETARY_SUPPLEMENT|3 day caloric restriction/metabolic reset|Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
214817438|NCT00833157|DRUG|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
214817439|NCT00833157|DRUG|ibuprofen|Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
214817440|NCT00833157|DRUG|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
214817441|NCT04205123|GENETIC|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
214817442|NCT06801418|DRUG|Adagrasib|Specified dose on specified days
214464536|NCT05713383|BEHAVIORAL|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
214817443|NCT03167515|DEVICE|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
214817444|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
214817445|NCT05886660|DRUG|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
214817446|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
214464537|NCT04043156|RADIATION|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
214464538|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging
214817447|NCT05886660|DRUG|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
214817448|NCT00991965|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
214817449|NCT03612960|DRUG|Very low nicotine content cigarettes|Very low nicotine content cigarettes
214817450|NCT03612960|DRUG|Normal nicotine content cigarettes|Normal nicotine content cigarettes
214817451|NCT03197415|OTHER|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
214817452|NCT05824481|DRUG|Cadonilimab|Injectable solution
214817453|NCT05824481|DRUG|Lenvatinib|Capsule
214817454|NCT06795087|OTHER|Opioid Medication Disposal Education|Education on opioid medication disposal will be provided in the form of a pamphlet created by Atrium Health based on FDA resources and will be given to all participants at discharge (cystectomy, nephrectomy, prostatectomy) beginning in the second year, approximately 13 months from when the first participant is enrolled or until a minimum of 100 evaluable participants are enrolled in the pre-education cohort, whichever occurs last.
214817455|NCT06559722|DRUG|Insulin Degludec/liraglutide Injection|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
214817456|NCT06559722|DRUG|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
214817457|NCT03574558|DEVICE|MD-Logic Switch Advisor|Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
214817458|NCT00854659|DRUG|ABT-102|BID tablets, 7 days of treatment
214817459|NCT00854659|DRUG|Placebo|BID tablets, 7 days of treatment
214817460|NCT03536091|DIAGNOSTIC_TEST|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
214817461|NCT00784472|DRUG|oxycodone|intravenous according to patients weight, pn.
214817462|NCT00784472|DRUG|morphine|intravenous administration according to patients weight, pn.
214817463|NCT02378935|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
214817464|NCT02378935|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
214817465|NCT02378935|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214817466|NCT01022463|DRUG|Ivabradine|Ivabradine 5 mg BId for 4 weeks
214817467|NCT01022463|DRUG|Atenolol|50 mg od for 4 weeks
214817468|NCT00271752|PROCEDURE|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
214817469|NCT02649621|BIOLOGICAL|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
214817470|NCT00272779|DRUG|ATV|300mg Oral capsules for 96 weeks
214817471|NCT00272779|DRUG|RTV|100mg Oral Capsules for 96 weeks
214817472|NCT00272779|DRUG|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
214817473|NCT00272779|DRUG|LPV|400 mg (3 133mg capsules) BID for 96 weeks
214817474|NCT05901870|OTHER|Questionnaire administration|All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
214817475|NCT06560099|DRUG|Oxytocin|will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
214817476|NCT00561015|DRUG|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
214817477|NCT00561015|DRUG|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
214817478|NCT00561015|DRUG|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
214817479|NCT04700787|DRUG|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
214817480|NCT00003015|DRUG|carboplatin|
214817481|NCT00003015|DRUG|vincristine sulfate|
214817482|NCT00003015|PROCEDURE|conventional surgery|
214817483|NCT00003015|RADIATION|radiation therapy|
214817484|NCT03616535|OTHER|Cognitive training|The investigators will provide participants with tablets to play brain games.
214817485|NCT03616535|OTHER|Exercise training|The investigators will provide participants with foot peddlers.
214817486|NCT03616535|OTHER|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
214817487|NCT02440711|DEVICE|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
214817488|NCT02440711|DEVICE|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
214817489|NCT01980771|BEHAVIORAL|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
214817490|NCT01980771|BEHAVIORAL|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
214817491|NCT02373397|DEVICE|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
214817492|NCT02373397|DEVICE|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
214817493|NCT04084197|DRUG|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
214817494|NCT04084197|DRUG|HIP1801|Tamsulosin 0.4mg
214817495|NCT04185493|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
214817496|NCT01442753|BEHAVIORAL|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
214817497|NCT02277847|DRUG|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
214817498|NCT02277847|DRUG|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
214817499|NCT01375920|DRUG|Metyrapone|500 milligrams to be taken twice a day orally
214817500|NCT01375920|DRUG|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
214817501|NCT01631331|DRUG|vismodegib|Given PO
214817502|NCT01631331|PROCEDURE|Mohs surgery|Undergo Mohs surgery
214817503|NCT04297891|OTHER|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
214817504|NCT04297891|OTHER|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
214817505|NCT04297891|OTHER|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
214817506|NCT04297891|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
214817507|NCT03199872|BIOLOGICAL|RV001V|Sc injection
214817508|NCT01196572|PROCEDURE|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
214817509|NCT02311686|DIETARY_SUPPLEMENT|10 g ethanol|Alcohol single oral dose
214817510|NCT02311686|DIETARY_SUPPLEMENT|20 g ethanol|Alcohol single oral dose
214817511|NCT02311686|DIETARY_SUPPLEMENT|40 g ethanol|Alcohol single oral dose
214817512|NCT02311686|DIETARY_SUPPLEMENT|60 g ethanol|Alcohol single oral dose
214817513|NCT02311686|DIETARY_SUPPLEMENT|80 g ethanol|Alcohol single oral dose
214817514|NCT00366925|DEVICE|Adacolumn®|
214817515|NCT05232786|OTHER|No treatment given|No treatment given
214817516|NCT00163657|DRUG|Daclizumub|anti-rejection drug
214817517|NCT00163657|DRUG|Tacrolimus|anti rejection drug
214817518|NCT00163657|DRUG|Cyclosporine|anti rejection drug
214817519|NCT00163657|DRUG|MMF|anti rejection drug
214817520|NCT05022381|PROCEDURE|Radiofrequency thermal coagulation of articular branches of femoral and obturator nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Patients who do not have any complications after the procedure and who are mobilized are discharged in the 2nd hour.
214817521|NCT04741217|OTHER|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
214817522|NCT04490005|OTHER|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
214817523|NCT03647293|PROCEDURE|Ultrasound Guided Central Catheter Insertion|
214817524|NCT03647293|PROCEDURE|Peripherally Inserted Central Catheter|
214817525|NCT03935880|DEVICE|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
214817526|NCT03935880|PROCEDURE|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
214817527|NCT04738539|DRUG|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
214817528|NCT04738539|DIAGNOSTIC_TEST|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
214817529|NCT01607918|DRUG|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
214817530|NCT01607918|DRUG|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
214817531|NCT02563561|DRUG|Apaziquone|One dose of apaziquone administered by intravesical administration
214817532|NCT02563561|OTHER|Placebo|Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
214817533|NCT02129894|DEVICE|abdominal Binder|placement of abdominal binder
214817534|NCT03531294|DRUG|Aflibercept Injection|intravitreal 2mg aflibercept injection
214817535|NCT04485767|BEHAVIORAL|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
214817536|NCT04485767|BEHAVIORAL|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
214817537|NCT04559503|OTHER|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
214817538|NCT05283850|DRUG|High Calcium, Low Sodium (HCLS) Crystalloid Therapy|Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
214817539|NCT05283850|DRUG|High Calcium, High Sodium (HCHS) Crystalloid Therapy|Normal saline IV drip and 1g IV bolus Calcium Chloride.
214817540|NCT03047343|OTHER|Retrospective data extraction in medical files|Retrospective data extraction in medical files
214817541|NCT03532035|DRUG|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
214817542|NCT03532035|DRUG|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
214817543|NCT04347018|DEVICE|BRIUS|This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion
214817544|NCT01859858|DIETARY_SUPPLEMENT|curcumin|
214817545|NCT01859858|DRUG|Irinotecan|
214817546|NCT02221921|DEVICE|MicroPort's Transcatheter Aortic Valve and Delivery System|
214817547|NCT03122535|DEVICE|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
214817548|NCT03122535|DEVICE|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
214817549|NCT01191996|BIOLOGICAL|MIS416|MIS416 intravenously every week
214464539|NCT06402955|DRUG|ketamine hydrochloride|There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.
214817550|NCT02718326|DRUG|Intravitreal aflibercept injection [IAI]|
214817551|NCT02718326|DRUG|Sham|
214817552|NCT00387686|DRUG|rhBMP-2/CPM|
214817553|NCT00387686|DRUG|rhBMP-2/CPM|
214817554|NCT00387686|DRUG|rhBMP-2/CPM|
214817555|NCT00387686|DRUG|rhBMP-2/CPM|
214817556|NCT05084625|OTHER|Digitized support|Access to information about the disease, treatment, side effects and self-care
214817557|NCT05350917|DRUG|Tislelizumab|"Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
214817558|NCT05624034|DEVICE|Electrogastrography|Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
214817559|NCT02646124|DRUG|Naproxen|Naproxen 500mg by mouth two times a day, #20
214817560|NCT02646124|DRUG|Placebo|28 placebo capsules
214817561|NCT02646124|DRUG|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
214817562|NCT04343196|RADIATION|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
214817563|NCT06368219|DRUG|ketamine- midazolam versus ketamine- propofol|"* Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg)~* Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)"
214817564|NCT00840398|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
214817565|NCT00840398|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
214817566|NCT02255292|DRUG|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
214817567|NCT06238791|OTHER|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
214817568|NCT03040362|DRUG|[14C]-lasmiditan|\[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
214817569|NCT00151229|OTHER|target blood pressure|
214817570|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
214817571|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
214817572|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
214817573|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
214817574|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
214817575|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
214817576|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
214817577|NCT02703194|DRUG|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
214817578|NCT02703194|DRUG|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
214817579|NCT02844660|BIOLOGICAL|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
214817580|NCT02844660|OTHER|Standard of Care|moist wound therapy and offloading
214817581|NCT05790772|BEHAVIORAL|Vigorous Exercise|50 minutes of running on a treadmill
214817582|NCT06008704|DIAGNOSTIC_TEST|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
214817583|NCT06008704|DIAGNOSTIC_TEST|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
214817584|NCT06008704|DIAGNOSTIC_TEST|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
214817585|NCT06008704|DIAGNOSTIC_TEST|Thermotest|The thermotest is performed to assess the pain perception threshold
214817586|NCT06008704|DIAGNOSTIC_TEST|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
214817587|NCT06008704|DIAGNOSTIC_TEST|[18F]-MPPF PET scan|The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
214817588|NCT03965169|PROCEDURE|Prone spinal surgery|spinal surgery in prone position under general anesthesia
214817589|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
214817590|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
214817591|NCT06302335|DRUG|Povidone-iodine|Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
214817592|NCT06302335|DRUG|Saline solution|Application of saline solution to the surgical wound of patients submitted to colorectal resections.
214817593|NCT02525458|DEVICE|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
214817594|NCT02525458|DEVICE|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
214817595|NCT05829421|OTHER|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
214817596|NCT03154047|DRUG|NEOD001|humanized monoclonal antibody
214817597|NCT05831449|DRUG|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
214817598|NCT05831449|DRUG|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
214817599|NCT05831449|DRUG|Placebo|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
214817600|NCT00857454|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
214817601|NCT05824897|OTHER|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
214817602|NCT01997983|DEVICE|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
214817603|NCT04244097|DRUG|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
214817604|NCT04244097|DRUG|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
214817605|NCT05647005|OTHER|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
214817606|NCT05647005|OTHER|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
214817607|NCT00992147|DRUG|Adipocell|autologous cultured adipocytes (ANTG-adip)
214817608|NCT06434753|DRUG|Zinc Acexamate|"The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.~The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose)."
214817609|NCT02436005|DEVICE|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
214817610|NCT02436005|DEVICE|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
214817611|NCT03407677|DEVICE|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
214817612|NCT03166345|OTHER|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
214817613|NCT04030845|PROCEDURE|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
214817614|NCT04030845|PROCEDURE|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
214817615|NCT01720147|DRUG|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
214817616|NCT02193763|PROCEDURE|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
214817617|NCT04736186|DRUG|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
214817618|NCT04736186|DRUG|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
214817619|NCT04736186|DRUG|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
214817620|NCT00573443|DRUG|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
214817621|NCT00573443|DRUG|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
214817622|NCT00573443|DRUG|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
214817623|NCT03975075|BEHAVIORAL|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
214817624|NCT03975075|BEHAVIORAL|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
214817625|NCT04599998|DIAGNOSTIC_TEST|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
214817626|NCT00849576|DRUG|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
214817627|NCT00849576|DRUG|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
214817628|NCT00849576|DRUG|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
214817629|NCT00849576|DRUG|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
214817630|NCT05236348|DEVICE|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
214817631|NCT06523842|OTHER|questionnaire|cronell questionnaire for assessment muscloskeletal discomfort in sedentary and standing workers males and females
214817632|NCT00804856|DRUG|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
214817633|NCT00804856|DRUG|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
215031375|NCT02011529|OTHER|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
214464540|NCT04068623|OTHER|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
214817634|NCT05193461|PROCEDURE|Pulsed mood radiofrequency on dorsal root ganglion|3\) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
214817635|NCT00418561|BIOLOGICAL|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
214817636|NCT00418561|BIOLOGICAL|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
214817637|NCT00418561|BIOLOGICAL|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
214817638|NCT01796171|DRUG|10 MBq/kg Betalutin|
214817639|NCT01796171|DRUG|15 MBq/kg Betalutin|
214817640|NCT01796171|DRUG|20 MBq/kg Betalutin|
214817641|NCT01796171|DRUG|40 mg lilotomab|
214817642|NCT01796171|DRUG|100 mg/m2 lilotomab|
214817643|NCT01796171|DRUG|60 mg/m2 lilotomab|
214817644|NCT01796171|DRUG|Rituximab|
214817645|NCT01796171|DRUG|12.5 mBq/kg Betalutin|
214817646|NCT01036009|OTHER|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
214817647|NCT00829309|DRUG|Pravastatin|80 mg Tablet
214817648|NCT00829309|DRUG|Pravastatin|80 mg Tablets
214817649|NCT05597982|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
214817650|NCT05597982|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
214817651|NCT05569291|DEVICE|Automated Coaching Program (ACP)|A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
214817652|NCT05569291|OTHER|Manual Coaching Program (MCP)|A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
214817653|NCT04999501|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
214817654|NCT03651739|DEVICE|Knee Connect|An electronic goniometer with smart phone application
214817655|NCT04278261|PROCEDURE|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
214817656|NCT04278261|PROCEDURE|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
214817657|NCT00404183|DRUG|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
214817658|NCT00404183|DRUG|Placebo|2 tablets BID
214817659|NCT02322593|DRUG|TAS-118 plus Oxaliplatin|
214817660|NCT02322593|DRUG|S-1 plus Cisplatin|
214817661|NCT00042783|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
214817662|NCT00042783|BIOLOGICAL|SB-AS02B adjuvant|
214817663|NCT04834128|DRUG|TCB008|administration of gamma delta T cells by IV bolus injection
214817664|NCT01683045|DEVICE|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
214817665|NCT05149066|BEHAVIORAL|#KindGirlsInACTion|9-session weekly cognitive-behavioural intervention to promote psychological well-being and prevent body image and eating-related disordered behaviours.
214817666|NCT03950362|DRUG|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
214817667|NCT03950362|DEVICE|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
214817668|NCT00455312|DRUG|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
214817669|NCT00455312|DRUG|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
214817670|NCT00455312|DRUG|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
214817671|NCT00455312|PROCEDURE|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
214817672|NCT00455312|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
214817673|NCT00455312|DRUG|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
214817674|NCT00455312|DRUG|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
214817675|NCT05636735|OTHER|data collection|evaluation of self -confidence
214817676|NCT03763435|BEHAVIORAL|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
214817677|NCT06342830|DRUG|nanocurcumin gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of nanocurcumin gel until shown fill the canal under magnification and by using lentulospirals
214817678|NCT06342830|DRUG|Curcumin Gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of curcumin gel until shown fill the canal under magnification and by using lentulospirals
214817679|NCT06342830|DRUG|Ciprofloxacin 500 mg +ibuprofen 400mg|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
214817680|NCT06342830|DRUG|Metapaste [calcium hydroxide paste (control group)]|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
214817681|NCT05637125|OTHER|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
214817682|NCT05637125|OTHER|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
214817683|NCT02641444|PROCEDURE|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
214817684|NCT02641444|PROCEDURE|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
214464541|NCT05673772|RADIATION|short-course radiotherapy|25 Gy in 5 fractions for 5 days
214464542|NCT05673772|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
214464543|NCT05673772|RADIATION|Chemoradiotherapy|45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
214464544|NCT05673772|PROCEDURE|TME surgery|TME surgery
214817685|NCT02641444|PROCEDURE|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
214817686|NCT06028204|DRUG|Biologic Agent|Biologic group will have biological agent commenced if considered necessary as part of routine care.
214817687|NCT06560801|DRUG|Dapagliflozin 10mg Tab|Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
214817688|NCT06485804|OTHER|Smartphone application guided exercises|"Participants in the intervention group will use a smartphone application to execute a self-rehabilitation program. The app will integrate:~* Basic information about neck pain and ergonomic advice.~* A series of evaluation questions on pain and function.~* Appropriate sets of exercises with videos and instructions.~* Daily reminders.~* Evaluation reports providing feedback and adherence."
214817689|NCT06095401|OTHER|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
214817690|NCT06095401|OTHER|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
214817691|NCT01342939|OTHER|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
214817692|NCT01342939|OTHER|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
214817693|NCT01342939|DIETARY_SUPPLEMENT|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
214817694|NCT01342939|OTHER|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
214817695|NCT01342939|OTHER|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
214817696|NCT00164463|DRUG|Moxifloxacin|400 mg po qd 5/7 days per week
214817697|NCT00164463|DRUG|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
214817698|NCT02030223|PROCEDURE|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
214817699|NCT06561516|PROCEDURE|Arm I (Red ginseng)|"Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test."
214817700|NCT01693523|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day).
214817701|NCT01693523|OTHER|Placebo|Matching placebo capsules by mouth twice a day.
214817702|NCT01693523|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
214817703|NCT06094023|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
214817704|NCT06094023|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours.
214817705|NCT05187481|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
214464545|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
214464546|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
214817706|NCT05187481|DRUG|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
214817707|NCT02736123|DRUG|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
214817708|NCT02736123|DRUG|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
214817709|NCT02765724|DRUG|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
214817710|NCT06115317|OTHER|Prism|Prism
214817711|NCT06115317|OTHER|Sham|Sham
214817712|NCT03343535|DEVICE|OCS Lung Preservation|OCS Lung Preservation
214817713|NCT03059979|DRUG|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
214817714|NCT03059979|OTHER|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
214817715|NCT02134379|DEVICE|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
214817716|NCT00085293|DRUG|Decitabine|Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
214464547|NCT05099302|OTHER|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
214817717|NCT00085293|RADIATION|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
214817718|NCT00085293|BIOLOGICAL|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
214817719|NCT00085293|RADIATION|Fludeoxyglucose F 18|Optional correlative studies
214817720|NCT00085293|PROCEDURE|Positron emission tomography|Optional correlative studies
214817721|NCT00006218|DRUG|triapine|
214817722|NCT05464836|DRUG|CB-103|Given by PO
214817723|NCT05464836|DRUG|Venetoclax|Given by PO
214464548|NCT03216057|DIETARY_SUPPLEMENT|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
214817724|NCT06407505|OTHER|Acupressure group|LI4 acupressure applied group.
214817725|NCT06407505|OTHER|Placebo group|Group where acupressure was applied to an area 1.5 cm away at the LI4 acupressure point
214817726|NCT04919005|OTHER|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
214817727|NCT02419339|PROCEDURE|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
214817728|NCT02659150|DRUG|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
214817729|NCT02729090|OTHER|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
214817730|NCT02729090|OTHER|Device: treadmill Train_Comb_aerobic|Device: treadmill Train\_Comb\_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train\_Comb\_aerobic
214817731|NCT06218524|DRUG|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
214817732|NCT06218524|DRUG|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
215031376|NCT04798820|OTHER|Dietary education(nutritional counselling)|Dietary education provided to gastrectomy patients by dietitian.
214817733|NCT06015035|DRUG|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
214817734|NCT02984696|DRUG|1 mg of transdermal estradiol daily and 10mg of oral MPA|
214817735|NCT03904381|DRUG|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
214817736|NCT03904381|PROCEDURE|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
214817737|NCT03904381|PROCEDURE|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
214817738|NCT01215279|DRUG|AZD2423|100 mg oral treatment once daily for 28 days
214817739|NCT01215279|DRUG|Placebo to AZD2423|Oral treatment once daily for 28 days
214817740|NCT06150807|DEVICE|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
214817741|NCT06560983|OTHER|The investigators are planning to do a observational cohort study, hence won't be doing any intervention.|The investigators won't be doing any intervention since this is an observational study.
214817742|NCT01724515|OTHER|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
214817743|NCT05795504|OTHER|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
214648776|NCT04217395|BEHAVIORAL|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
214648777|NCT01276821|DRUG|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
214817744|NCT05795504|OTHER|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
214817745|NCT05795504|DIETARY_SUPPLEMENT|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
214817746|NCT05345249|DRUG|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
214817747|NCT05345249|DRUG|Sodium chloride|Placebo comparator
214817748|NCT00270582|DRUG|Taxotere, Cisplatin, Gemcitabine|
214817749|NCT05244720|DIAGNOSTIC_TEST|Fibroscan|A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
214817750|NCT05244720|DIAGNOSTIC_TEST|Blood samples|Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
214817751|NCT03510923|OTHER|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
214648778|NCT01276821|DRUG|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
214648779|NCT03136939|OTHER|No intervention|No intervention
214648780|NCT00430118|DRUG|asparaginase|
214648781|NCT00430118|DRUG|cyclophosphamide|
214648782|NCT00430118|DRUG|cytarabine|
214648783|NCT00430118|DRUG|daunorubicin hydrochloride|
214648784|NCT00430118|DRUG|dexamethasone|
214648785|NCT00430118|DRUG|doxorubicin hydrochloride|
214648786|NCT00430118|DRUG|etoposide|
214648787|NCT00430118|DRUG|ifosfamide|
214648788|NCT00430118|DRUG|mercaptopurine|
214648789|NCT00430118|DRUG|methotrexate|
214648790|NCT00430118|DRUG|prednisone|
214648791|NCT00430118|DRUG|thioguanine|
214648792|NCT00430118|DRUG|vincristine sulfate|
214648793|NCT00430118|DRUG|vindesine|
214648794|NCT00430118|RADIATION|radiation therapy|
214464549|NCT03216057|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
214648795|NCT00320970|DRUG|Candesartan|
214648796|NCT00868387|OTHER|energy-restricted, CHO-restricted diet|carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
214648797|NCT00868387|OTHER|energy-restricted, CHO-rich diet|carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
214648798|NCT05432544|DRUG|SHR-1918|Ascending dose
214648799|NCT05432544|DRUG|SHR-1918 placebo|Ascending dose
214648800|NCT04275700|PROCEDURE|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
214464550|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
214464551|NCT04564742|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
214464552|NCT04564742|DRUG|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
214464553|NCT05194540|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
214648801|NCT06800053|BEHAVIORAL|FOCUS ON US|"This intervention will include 5 sessions cover 5 core content areas, represented by the acronym FOCUS. Family involvement (F) Outlook and meaning (O) Coping effectiveness (C) Uncertainty reduction (U) Symptom management (S) Content from every area is presented in the 3 longer in-depth sessions and reinforced in the 2 shorter check-in sessions. FOCUS encourages participants to work as a team, communicate openly, and support one another, and uses skill building (e.g., stress reduction techniques, healthy behaviors), education (e.g., symptom trajectories, information gathering), and problem-solving therapy to address here-and-now issues that impact QOL. The intervention is flexible, allowing more attention to be spent on issues relevant to particular patients/caregivers."
214648802|NCT06582147|OTHER|Implementation of social determinants of health screening and referral|WE CARE is a relatively simple, low-intensity intervention that has two key components: (1) screening individuals using the WE CARE SDOH Screener for unmet social needs, and (2) providing individuals who have unmet social needs with SDOH Community Resource sheets
214648803|NCT01431183|BEHAVIORAL|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
214648804|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
214648805|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
214648806|NCT01323205|DRUG|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
214648807|NCT01323205|DRUG|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
214648808|NCT00770055|OTHER|medical chart review|
214648809|NCT00770055|OTHER|questionnaire administration|
214648810|NCT00770055|OTHER|survey administration|
214648811|NCT00770055|PROCEDURE|psychosocial assessment and care|
214648812|NCT00182104|DRUG|Warfarin vs ASA|
214648813|NCT04066868|OTHER|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
214648814|NCT04066868|OTHER|CTCAE rating|CTCAE Ratings are conducted by clinicians
214648815|NCT04066868|OTHER|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
214648816|NCT01964404|DRUG|Marijuana|Smoked plant with THC
214648817|NCT01964404|DRUG|Dronabinol|Capsule with THC
214648818|NCT01964404|DRUG|Placebo|Capsule with no active ingredient
214648819|NCT03162848|BEHAVIORAL|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
214648820|NCT03986255|PROCEDURE|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
214648821|NCT04126824|DRUG|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
214648822|NCT04126824|DRUG|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
214648823|NCT04126824|OTHER|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
214648824|NCT00434525|PROCEDURE|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
214648825|NCT00434525|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
214648826|NCT00556426|DEVICE|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
214648827|NCT00372879|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800IU bid
214464554|NCT05644028|BEHAVIORAL|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
214464555|NCT04929743|DEVICE|BTI Implant|Placement of dental implants of 5.5 vs \>6.5 mm length
214464556|NCT05992870|RADIATION|Neoadjuvant radiotherapy|"In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment."
214464557|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
214464558|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
214464559|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
214464560|NCT04096170|DRUG|IV lidocaine|Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
214464561|NCT04096170|DRUG|Placebo|o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
214464562|NCT05694013|DEVICE|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
214464563|NCT05694013|DRUG|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
214464564|NCT05694013|OTHER|Local SOC support|Participants will receive local SOC support
214464565|NCT06055075|DRUG|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
214464566|NCT06055075|DRUG|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
214464567|NCT06055075|DRUG|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
214648828|NCT00217919|BEHAVIORAL|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
214648829|NCT00486447|DEVICE|64 Channel VCT|cardiac CT angiography exam
214648830|NCT00932516|BEHAVIORAL|South Beach Diet™ with South Beach Diet™ Products|
214648831|NCT00932516|BEHAVIORAL|South Beach Diet™|
214648832|NCT00932516|BEHAVIORAL|Calorie restricted diet with South Beach Diet™ Products|
214648833|NCT00932516|BEHAVIORAL|Calorie Restricted Diet|
214648834|NCT01299727|BIOLOGICAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
214648835|NCT01299727|BIOLOGICAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
214648836|NCT01299727|BIOLOGICAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
214648837|NCT02055404|DEVICE|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
214648838|NCT02055404|DEVICE|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
214648839|NCT02247089|OTHER|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
214648840|NCT02247089|OTHER|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
214648841|NCT01773655|OTHER|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
214648842|NCT04297462|DRUG|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
214648843|NCT04297462|DRUG|Oseltamivir 7 days|Active comparator
214648844|NCT00537433|OTHER|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
214648845|NCT00341614|BEHAVIORAL|3-month Exercise Training and Diet Education|
214648846|NCT02529033|DEVICE|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
214648847|NCT00955058|DRUG|OCP|Daily For 3 months
214648848|NCT01523483|DRUG|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
214648849|NCT01523483|DRUG|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
214648850|NCT02690909|DEVICE|Redy™ Renal Denervation System|Renal Denervation System
214648851|NCT05770128|PROCEDURE|laparoscope|subserosal manipulation of gallbladder with laparoscope .
214648852|NCT03611439|DIETARY_SUPPLEMENT|ReBuilder|8-component botanical dietary supplement
214648853|NCT03611439|DIETARY_SUPPLEMENT|Placebo|Inactive Placebo Capsule
214817752|NCT03510923|OTHER|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
214817753|NCT00274781|DRUG|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
214817754|NCT00274781|DRUG|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
214817755|NCT03264339|BEHAVIORAL|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
214817756|NCT00134485|DRUG|torcetrapib/atorvastatin|
214817757|NCT00134485|DRUG|atorvastatin|
214817758|NCT05312216|DRUG|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
214648854|NCT04583371|OTHER|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
214648855|NCT00441792|DRUG|Etomidate|Etomidate at induction dose based on weight
214648856|NCT00441792|DRUG|midazolam|Midazolam at induction dose based on weight
214648857|NCT05428150|DRUG|Esbriet 267 MG Oral Capsule|Reference Formulation
214648858|NCT05428150|DRUG|EXCL-100, 600 MG Oral Tablet|Test Formulation
214817759|NCT01726205|DRUG|Pregabalin and normal saline infusion, PRG|
214817760|NCT01726205|DRUG|Pregabalin and ropivacaine 02% infusion|
214817761|NCT01726205|DRUG|Placebo drug, normal saline infusion|
214817762|NCT01846923|BIOLOGICAL|PCV13|
214817763|NCT00352820|BEHAVIORAL|Interview|Recorded face-to-face session.
214817764|NCT00352820|BEHAVIORAL|Questionnaire|Written survey lasting approximately 30 minutes.
214464568|NCT06530030|DRUG|efanesoctocog alfa|All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
214464569|NCT06465641|DRUG|Methylphenidate Hydrochloride|Methylphenidate hydrochloride in capsules
214464570|NCT06465641|DRUG|Placebo|Microcrystalline cellulose in capsules
214464571|NCT05341726|BEHAVIORAL|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
214464572|NCT05341726|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
214648859|NCT03544112|BEHAVIORAL|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
214648860|NCT03544112|DRUG|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
214648861|NCT00638937|DRUG|saracatinib|Given PO
214648862|NCT05695326|BEHAVIORAL|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
214648863|NCT05114083|OTHER|symptom assessment|symptom assessment
214648864|NCT03062657|DEVICE|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
214648865|NCT01191112|OTHER|Peptide based enteral formula|Sole source nutrition as per HCP
214648866|NCT03585855|OTHER|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
214648867|NCT04874857|OTHER|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
214648868|NCT04874857|OTHER|Baby oil|Massage application
214648869|NCT01739426|DEVICE|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
214648870|NCT00457340|DRUG|Atorvastatin 80mg|
214464573|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
214464574|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
214464575|NCT06382675|DEVICE|Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2|230 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
214464576|NCT04174157|OTHER|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
214464577|NCT04174157|DRUG|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
214817765|NCT05478395|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
214817766|NCT00485771|DRUG|Olanzapine|
214817767|NCT00485771|DRUG|Fluoxetine|
214817768|NCT00485771|DRUG|Lamotrigine|
214817769|NCT02533479|OTHER|Caloric restriction|three alternate days weekly along 4 weeks.
214817770|NCT01196260|DRUG|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
214817771|NCT01922765|DRUG|amoxicillin, clarithromycin, metronidazole, rabeprazole|
214464578|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
214648871|NCT06091644|DEVICE|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
214648872|NCT03649152|DRUG|Propagermanium|Immediate release capsule
214648873|NCT03649152|DRUG|Placebo|Placebo capsule
214648874|NCT02091180|DRUG|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
214648875|NCT02091180|DRUG|Control|Saline infusion
214648876|NCT04354428|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
214648877|NCT04354428|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
214648878|NCT04354428|DRUG|Azithromycin|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
214648879|NCT04354428|DRUG|Folic Acid|Eligible participants in a household will receive folic acid and an additional intervention drug
214648880|NCT04354428|DRUG|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]|Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
214648881|NCT03872492|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively."
214648882|NCT00289640|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
214648883|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
214648884|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
214648885|NCT05835869|DIAGNOSTIC_TEST|Optical coherence tomography angiography and pattern electroretinogram|Optical coherence tomography angiography is an infrared eye scan that analyzes retinal vascularization and anatomy
214648886|NCT03893045|DRUG|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
214648887|NCT03893045|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
214648888|NCT02510079|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
214648889|NCT00041678|DRUG|aripiprazole|
214648890|NCT05489445|DEVICE|KODEX - EPD|A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
214648891|NCT00301171|DRUG|Inhaled Fluticasone|
214648892|NCT03880201|PROCEDURE|ultrasound guided supraclavicular block|"The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves."
214648893|NCT03880201|DEVICE|Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)|Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
214648894|NCT00579813|DRUG|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
214648895|NCT04217369|DEVICE|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
214648896|NCT01854346|BEHAVIORAL|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
214648897|NCT01810679|DEVICE|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
214648898|NCT00362973|OTHER|laboratory biomarker analysis|
214648899|NCT00362973|PROCEDURE|needle biopsy|
214648900|NCT00362973|PROCEDURE|positron emission tomography|
214648901|NCT00362973|PROCEDURE|radionuclide imaging|
214648902|NCT00362973|RADIATION|fludeoxyglucose F 18|
214648903|NCT02006771|OTHER|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
214648904|NCT02006771|OTHER|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
214648905|NCT02006771|OTHER|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
214648906|NCT02006771|OTHER|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
214648907|NCT04977206|OTHER|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
214648908|NCT02495727|BEHAVIORAL|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
214648909|NCT02495727|BEHAVIORAL|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
214648910|NCT02495727|BEHAVIORAL|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
214648911|NCT05183919|OTHER|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
214648912|NCT01338467|DEVICE|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
214648913|NCT01573312|DRUG|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
214648914|NCT01573312|BIOLOGICAL|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
214648915|NCT02894229|BEHAVIORAL|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
214648916|NCT02894229|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
214464579|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
214464580|NCT05270408|DEVICE|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
214464581|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
214464582|NCT03767621|OTHER|Indication of revascularization|Device: iFR/FFR
214464583|NCT06044090|DRUG|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
214464584|NCT06044090|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
214464585|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
214464586|NCT04910152|DRUG|BRD4 Inhibitor PLX51107|Given PO
214464587|NCT02465268|BIOLOGICAL|pp65-shLAMP DC with GM-CSF|
214464588|NCT02465268|BIOLOGICAL|unpulsed PBMC and saline|
214464589|NCT02465268|DRUG|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
214464590|NCT02465268|DRUG|Saline|
214464591|NCT02465268|BIOLOGICAL|pp65-flLAMP DC with GM-CSF|
214464592|NCT04014335|DRUG|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
214464593|NCT05974852|OTHER|Ocrelizumab|Non-interventional
214464594|NCT05449743|OTHER|Spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
214464595|NCT03532282|BEHAVIORAL|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
214464596|NCT03532282|BEHAVIORAL|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm (checklist). Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
214464597|NCT04035434|BIOLOGICAL|CTX110|CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
214464598|NCT02378350|DEVICE|Hemodialysis treatment (no specific device is defined)|
214464599|NCT02378350|DRUG|Peritoneal Dialysis treatment (no specific drug is defined)|
214464600|NCT05793541|BEHAVIORAL|Phone call|A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call. This intervention occurs at High Risk only.
214464601|NCT05793541|BEHAVIORAL|Text messaging|A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction. This intervention occurs at High Risk only.
214464602|NCT05793541|BEHAVIORAL|Automated interactive smartphone-based tool|An automated interactive, smartphone-based tool that will (a) (at High Risk only) guide the participant through a risk assessment and (b) (at High and Medium/Low Risk) present recommendation to use and a review of the safety plan.
214464603|NCT05793541|BEHAVIORAL|Non-interactive pop-up messages|Automated non-interactive, static pop-up messages that recommend use of the safety plan or its components (Medium/Low Risk only).
214464604|NCT02744677|DEVICE|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position
214464605|NCT02744677|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
214464606|NCT02744677|DEVICE|SAPIEN 3 Ultra RESILIA THV|SAPIEN 3 Ultra RESILIA THV in the pulmonic position
214464607|NCT05802615|BEHAVIORAL|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
214464608|NCT05802615|OTHER|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
214464609|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
214464610|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
214464613|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
214464614|NCT05348993|DRUG|Placebo|placebo
214464615|NCT03705715|DRUG|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|\[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
214464616|NCT03705715|OTHER|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
214817772|NCT06559423|DEVICE|non-ablative Er:YAG laser and high intensity Tesla magnetic stimulation (HITS)|Patients will initially undergo three monthly intravaginal treatments with the Er:YAG laser. Six weeks after the final laser treatment, patients will receive six sessions of magnetic stimulation. During these sessions, patients will sit on a specialized chair that generates a therapeutic magnetic field.
214464617|NCT01501955|DEVICE|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
214464618|NCT01501955|DEVICE|Stanmore|Stanmore hip prosthesis
214464619|NCT05982314|BIOLOGICAL|Gamma-PN3|Experimental whole-cell pneumococcal vaccine
214464620|NCT05982314|BIOLOGICAL|Pneumovax-23|Licensed pneumococcal vaccine
214464621|NCT05982314|BIOLOGICAL|Prevenar-13|Licensed pneumococcal vaccine
214464622|NCT05982314|BIOLOGICAL|Placebo|Saline placebo
214464623|NCT05259085|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
214464624|NCT02993159|DRUG|Afimoxifene|Applied to the breast
214464625|NCT02993159|OTHER|Laboratory Biomarker Analysis|Correlative studies
214464626|NCT02993159|OTHER|Placebo|Given PO
214464627|NCT02993159|OTHER|Placebo|Applied to the breast
214464628|NCT02993159|DRUG|Tamoxifen Citrate|Given PO
214464629|NCT06136728|DRUG|Dalfampridine 10 MG [Ampyra]|Dalfampridine (10 mg) every 12 hours for 6 weeks.
214464630|NCT06136728|BEHAVIORAL|Physical therapy|Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
214464631|NCT06136728|OTHER|Dalfampridine plus physical therapy|Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
214464632|NCT05219500|DRUG|FPI-2265|Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
214817773|NCT05342597|DRUG|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
214464633|NCT05387954|PROCEDURE|Transcatheter PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
214464634|NCT05387954|DRUG|Oral Anticoagulant, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
214648917|NCT05758090|PROCEDURE|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.
214648918|NCT05758090|PROCEDURE|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
214648919|NCT03494556|OTHER|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
214648920|NCT01705847|DRUG|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
214648921|NCT05086601|PROCEDURE|colorectal cancer surgery|Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
214648922|NCT01879410|DRUG|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
214648923|NCT01879410|DRUG|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
214648924|NCT01879410|DRUG|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
214648925|NCT01879410|DRUG|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
214648926|NCT05632679|OTHER|personalized music intervention|participants who are randomly selected to this group will choose three set of music they prefer among the available selection of instrumental music in the application
214648927|NCT05632679|OTHER|selected audio book|participants who are randomly selected to this group will choose one audio book they prefer among the available selection of audio books on the tablet
214648928|NCT04754789|DRUG|Atorvastatin|preloading with high dose statins (atorvastatin 80mg) with loading dose of dual antiplatelet( asprine 300 mg and ticagrelor 180 mg) pre-primary PCI
214648929|NCT04754789|DRUG|Aspirin|Loading dose of dual antiplatelet (asprine 300 mg and ticagrelor 180 mg)
214648930|NCT02649634|BEHAVIORAL|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
214648931|NCT02649634|BEHAVIORAL|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
214648932|NCT02774993|DRUG|Doxycycline|
214648933|NCT02774993|DRUG|placebo|
214648934|NCT05223595|DRUG|Gentuximab|Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
214648935|NCT02080052|DEVICE|Robot-assisted prostate biopsy|
214648936|NCT01911026|OTHER|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
214464635|NCT05387954|DRUG|Antiplatelet therapy|Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
214464636|NCT02895464|OTHER|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
214464637|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
214464638|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
214464639|NCT05357430|DRUG|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
214464640|NCT04240054|DRUG|Bortezomib|Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
214464641|NCT04240054|DRUG|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
214464642|NCT04240054|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
214464643|NCT04240054|DRUG|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
214464644|NCT05039788|OTHER|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
214464645|NCT06097910|PROCEDURE|Watchful waiting|Conduct thoracic computed tomography scans every 12 months. The decision regarding surgery is based on the surgeon's evaluation of radiologic follow-up. The reference resection criteria encompass: a) Any lesion that progresses to a tumor diameter larger than 2cm or has CTR greater than 0.25. b) Clinical Tumor, node, metastasis (TNM) stage upstaging.
214464646|NCT05653453|DEVICE|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
214648937|NCT02524431|OTHER|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
214648938|NCT03498157|BEHAVIORAL|Exercise|The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
214648939|NCT03498157|BEHAVIORAL|Prehabilitation Education|Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey
214648940|NCT05999825|BIOLOGICAL|Sm-p80 + GLA-SE Vaccine|30 μg Sm-p80 + 5 μg GLA-SE
214648941|NCT05999825|OTHER|Placebo|0.9% Sterile Normal Saline
214648942|NCT05999825|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
214648943|NCT00453466|BEHAVIORAL|EBW group intervention to empower battered women|
214648944|NCT06119880|DRUG|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
214648945|NCT06119880|OTHER|Routine treatment plan|Routine treatment plan without PERT
214648946|NCT05274126|BEHAVIORAL|Patient group/Passvers|"Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness."
214648947|NCT01262183|DRUG|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
214648948|NCT01262183|DRUG|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
214648949|NCT02616913|OTHER|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
214648950|NCT02616913|OTHER|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
214648951|NCT02616913|OTHER|Placebo|Each subject consumes placebo in one of 3 treatment periods
214648952|NCT01777672|BEHAVIORAL|Dietary and oral hygiene recommendations|
214648953|NCT01777672|DIETARY_SUPPLEMENT|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
214648954|NCT01777672|DEVICE|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
214648955|NCT01777672|DEVICE|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
214648956|NCT04963829|BIOLOGICAL|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
214648957|NCT04963829|BIOLOGICAL|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
214648958|NCT04963829|BIOLOGICAL|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
214648959|NCT01012492|DRUG|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
214648960|NCT05779163|DRUG|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
214648961|NCT00874198|PROCEDURE|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system \[pressure settings: 30 - 200 mmH20\]
214648962|NCT01676285|DRUG|Metoprolol succinate|
214648963|NCT01676285|DRUG|placebo|
214648964|NCT01200745|DRUG|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
214648965|NCT05460585|DEVICE|Cerebral oximetry using Rheopatch|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
214648966|NCT05460585|DEVICE|Cerebral oximetry using NIRO-200NX|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
214648967|NCT02009241|OTHER|Pulmonary Rehabilitation|
214648968|NCT05859477|DRUG|Nivolumab|360 mg, i.v., every 3 weeks
214648969|NCT05859477|DRUG|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
214648970|NCT05859477|DRUG|Oxaliplatin|130 mg/m², i.v., day 1, every 3 weeks
214648971|NCT01361516|OTHER|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
214648972|NCT03603041|DIETARY_SUPPLEMENT|Whey protein|Participants in the protein arms will receive whey protein daily for 16 weeks.
214648973|NCT03603041|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
214648974|NCT02153762|DRUG|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
214648975|NCT02153762|DRUG|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
214648976|NCT02337803|BEHAVIORAL|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
214648977|NCT02337803|BEHAVIORAL|Usual Care|Will continue daily physical activity and complete surveys online
214648978|NCT04525963|OTHER|Preoperative visit of the operating room nurse and patient education|The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
214817774|NCT01054898|BEHAVIORAL|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
214648979|NCT02419027|DIETARY_SUPPLEMENT|GI Flora|
214648980|NCT02419027|DIETARY_SUPPLEMENT|Placebo|
214648981|NCT00626743|DRUG|SK3530 100mg, Placebo, Amlodipine|
214648982|NCT04660188|OTHER|Multidisciplinary collaborative care arm|Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
214648983|NCT05951283|DEVICE|Hybrid Closed Loop Insulin Pump|As above
214648984|NCT01361763|DRUG|Dabigatran|110 mg twice daily
214648985|NCT01361763|DRUG|Antiplatelets|100mg once a day
214648986|NCT00165009|DEVICE|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
214648987|NCT01486862|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
214648988|NCT06282328|DIAGNOSTIC_TEST|HIV test|Bedside rapid capillary HIV test
214648989|NCT05449457|OTHER|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
214648990|NCT06544278|DIETARY_SUPPLEMENT|probiotic product|During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
214648991|NCT06544278|DIETARY_SUPPLEMENT|Maltodextrin|During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
214648992|NCT02964156|OTHER|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
214648993|NCT02964156|OTHER|No intervention|No intervention
214648994|NCT01902940|OTHER|Natural History|Assessment of natural history in IBM and CCFDN
214648995|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
214648996|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
214648997|NCT03691415|DRUG|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
214648998|NCT00634231|BIOLOGICAL|AdV-tk|
214648999|NCT00634231|DRUG|valacyclovir|
214649000|NCT00634231|RADIATION|Radiation|
214649001|NCT02644408|DRUG|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
214649002|NCT02644408|RADIATION|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
214649003|NCT02644408|OTHER|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
214649004|NCT05329675|DIETARY_SUPPLEMENT|Sinphar Lipucan Capsule|oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
214649005|NCT00569257|DRUG|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
214649006|NCT03720457|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
214649007|NCT03002974|DRUG|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
214649008|NCT03002974|DRUG|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
214649009|NCT03002974|DRUG|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
214649010|NCT03002974|DRUG|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
214649011|NCT05373238|PROCEDURE|Early discharge|Early discharge
214649012|NCT02211261|BIOLOGICAL|PF-06293620|subcutaneous, single dose 0.3 mg/kg
214649013|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
214649014|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
214649015|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
214649016|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 3 mg/kg
214649017|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
214649018|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 6 mg/kg
214649019|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
214649020|NCT02211261|BIOLOGICAL|PF-06293620|Intravenous infusion single dose 1 mg/kg
214649021|NCT02211261|BIOLOGICAL|Placebo|Intravenous infusion normal saline single dose
214649022|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
214817775|NCT01054898|BEHAVIORAL|usual community services|standard care for abused women in the community
214817776|NCT05239832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214464647|NCT05653453|DRUG|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
214464648|NCT04082650|DRUG|vitamin D|4000IU per day
214464649|NCT04082650|OTHER|Placebo|The same doses with vitamin D
214464650|NCT05172999|DEVICE|levonorgestrel-releasing intrauterine system|Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
214464651|NCT05172999|DRUG|Polyethylene Glycol Loxenatide|Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
214649023|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
214649024|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
214649025|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
214649026|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
214649027|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
214649028|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
214649029|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
214649030|NCT01037673|PROCEDURE|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
214649031|NCT01037673|PROCEDURE|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
214649032|NCT00887757|DRUG|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
214649033|NCT00887757|DRUG|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
214649034|NCT05452967|OTHER|Distraction technique|The post operative pediatric patients will be given mobile phone in recovery for plying games and watching cartoons and with the help of this distraction technique will assess that routine rescue analgesia is needed or not
214649035|NCT01737931|DRUG|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
214649036|NCT01737931|DRUG|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
214649037|NCT00382837|DRUG|Epratuzumab|
214649038|NCT00124345|DEVICE|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
214649039|NCT02521155|BEHAVIORAL|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
214649040|NCT02288884|DEVICE|Acticoat PostOp|
214649041|NCT02288884|DEVICE|OpSite PostOp|
214649042|NCT02405533|DIETARY_SUPPLEMENT|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
214649043|NCT02405533|OTHER|Placebo|Placebo supplementation x 12 months
214649044|NCT04069663|OTHER|No interventional study|Retrospective data analysis
214649045|NCT04779151|DRUG|Dostarlimab|Substance: immunoglobulin G4 (IgG4) humanized monoclonal antibody (mAb) that binds with high affinity to PD-1 Manufacturer: Tesaro Inc. Dose: 500 mg every 21 days for the first 4 cycles, followed by 1,000 mg every 42 days cycle (ie, Q6W)
214649046|NCT04779151|DRUG|Niraparib|Substance: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) Manufacturer: Tesaro Inc. Dose: Flat-fixed dose (if \<77kg or platelets \<150,000 μL: 200mg; if \>/=77kg and platelets \>/= 150,000μL: 300mg)
214649047|NCT02351232|DRUG|Liraglutide|
214649048|NCT02351232|DRUG|Placebo|
214649049|NCT06000358|PROCEDURE|Bronchoscopic cryotherapy|The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.
214649050|NCT06000358|DRUG|Pembrolizumab|As a standard of care, patients will receive pembrolizumab.
214649051|NCT06000358|DRUG|Platinum based chemotherapy|As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.
214649052|NCT01454804|DRUG|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
214649053|NCT01454804|DRUG|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
214649054|NCT01454804|DRUG|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
214649055|NCT01454804|DRUG|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
214649056|NCT01693172|BEHAVIORAL|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
214649057|NCT02775032|BEHAVIORAL|Advance care planning conversations between patients and their GP|
214464652|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
214464653|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
214464654|NCT06208514|BEHAVIORAL|Brief pain exposure therapy (BPET)|"Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol (fibromyalgia participants only will complete the daily logs), and 7 for days post-treatment.~Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study."
214464655|NCT06460038|DRUG|Tenapanor|Inhibitor of NHE3
214464656|NCT06460038|DRUG|Placebo|Placebo drug
214464657|NCT04440982|DRUG|LUM015|LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
214464658|NCT04440982|DEVICE|Lum Imaging System|UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
214464659|NCT03482557|DEVICE|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
214464660|NCT03482557|DEVICE|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
214464661|NCT06803758|DIAGNOSTIC_TEST|Teicoplanin Allergy Testing using autologous serum|"In addition to performing teicoplanin allergy skin testing using standard recommended Teicoplanin concentration, we will perform skin testing using autologous serum, the supernatant which is obtained via centrifugation. Skin testing ( skin prick test and intradermal test) will be performed with these additional samples:~1. STpre: Teicoplanin added to blood sample pre-centrigufation.~2. STpost: Teicoplanin added to supernatant post-centrigufation.~3. ST0: Supernatant with no additives ( serum negative control)"
214464662|NCT06802822|DRUG|Prevention of Allosensitization|This study evaluates the impact of two different durations of immunosuppressive therapy on kidney transplant patients who return to dialysis after a failed transplant. One group will continue immunosuppressive therapy for two years, while the other will stop the therapy six months after starting dialysis. The goal is to determine if continuing immunosuppression can reduce the risk of allosensitization and improve outcomes, compared to stopping the therapy earlier.
214464663|NCT06799091|DEVICE|Low frequency TENS|Low TENS group participated in twelve sessions of electrical stimulation with low frequency (TENS, 10 Hz/200 μs) was applied with self-adhesive electrodes (size 9 × 5 cm,), in the paravertebral ganglionar region (from T1 to L2). The sessions took place at the same time of the day, lasted 30 min, in an acclimatized room (23 °C) and the intensity of the current was delivered at sensory-level intensity, adjusted every 5 min by the sensory threshold, during the 30 min as tolerated by each subject, but without motor contraction or pain reported by the subject.
214464664|NCT06798441|OTHER|Brush Only|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. Subjects will record their twice daily product usage on a subject diary.
214464665|NCT06798441|OTHER|Brush / Rinse (Jolly Rancher Prototype)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
214464666|NCT06798441|OTHER|Brush / Rinse (LISTERINE® Total Care Zero Alcohol)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
214464667|NCT06802419|OTHER|Continuous adductor canal block|Patients will receive continuous adductor canal block.
214817777|NCT04794140|PROCEDURE|different number of passes|Each patient's operation process is the same, that is, after obtaining enough specimens for diagnosis by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique, additional three passes are performed. One of which is randomly selected as the one pass group, and the other two passes automatically as the two pass group. Please refer to the literature for EUS-FNB wet technique (Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.)
214817778|NCT05598476|OTHER|5kg bag|a 5 kg bag is applied on the chest for 2 hours
214817779|NCT04314362|DRUG|AZR-MD-001 ointment/semi-solid drug|AZR-MD-001 (1.0%) and suitable excipient
214817780|NCT04377009|DEVICE|Sleep Healthy Using the Internet (SHUTi)|Cognitive behavioral therapy delivered via internet-guided program customized for military service members
214464668|NCT06802419|OTHER|Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule|Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee
214464669|NCT06798896|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
214464670|NCT06798896|DRUG|Placebo|Placebo, bid
214464671|NCT06027086|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
214817781|NCT04377009|OTHER|Education Control Program|Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
214817782|NCT03004209|DRUG|Erythropoietin|three times per a week 100IU / k
214464672|NCT06027086|DRUG|DRP-104|"Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration."
214464673|NCT04701671|BEHAVIORAL|Observational (not including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
214464674|NCT04701671|BEHAVIORAL|Observational (including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
214464675|NCT06803017|BEHAVIORAL|combination of exercise and sport with fast-tempo music|Fast-tempo music selected by the researcher with exercise training and sports training
214464676|NCT06803017|BEHAVIORAL|combination of exercise and sport with slow-temp music|Slow-tempo music selected by the researcher with exercise training and sports training
214464677|NCT06803017|BEHAVIORAL|combination of exercise and sport with no music|Exercise training and sports training without music
214464678|NCT06803784|GENETIC|Genetic: whole genome sequencing|Genetic: whole genome sequencing PD Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
214464679|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~AD Partecipants will be assessed for disease progression:~* assessment of cognitive disorders (MMSE, MOCA test, clock test);~* assessment of language disorders;~* current drug therapy (and possible start date of treatment);~* date of onset of cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate AD genes"
214464680|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~ALS/FTD Partecipants will be assessed for disease progression:~* clinical classification according to El Escorial - revised;~* assessment of cognitive disorders (and classification according to Strong criteria, 2017);~* assessment of language disorders;~* ongoing pharmacological therapy (and possible start date of treatment);~* date of onset of motor and cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate ALS/FTD genes"
214464681|NCT02596802|DEVICE|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
214464682|NCT06801158|DRUG|use of anticancer drugs in monotherapy or in combination therapy|ICSRs involving antineoplastic or immunomodulating agents were included.
214464683|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation
214464684|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation + training with WBVE|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation + 24 sessions (2 sessions per day) of 30 minutes each of training on a vibration platform (WBVE)
214464685|NCT05553301|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
214464686|NCT05553301|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
214464687|NCT05553301|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
214464688|NCT05553301|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
214817783|NCT01334632|PROCEDURE|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
214817784|NCT01334632|PROCEDURE|PCA morphine|Postoperative with iv self-administration of morphine
214817785|NCT01364532|PROCEDURE|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
214817786|NCT01364532|PROCEDURE|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
214649058|NCT03909958|OTHER|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm\*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
214649059|NCT03909958|BEHAVIORAL|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
214649060|NCT01814787|OTHER|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI \> 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
214649061|NCT02242500|PROCEDURE|Coronally Advanced Flap|
214649062|NCT02242500|DEVICE|Mucograft|
214649063|NCT00481845|DRUG|Vandetanib|300 mg daily
214649064|NCT00481845|DRUG|Anastrozole|1 mg daily
214649065|NCT05708391|DRUG|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
214649066|NCT05708391|RADIATION|Radiotherapy|Radiotherapy
214649067|NCT04625777|BEHAVIORAL|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
214817787|NCT04638452|BEHAVIORAL|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
214817788|NCT04638452|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
214817789|NCT05132985|DRUG|Icotinib|125mg 1tt(Take 1 tablet 3 times a day) orally.
214817790|NCT05132985|DRUG|Cisplatin|75 mg/m2 (IV，Q3W)
214817791|NCT05132985|DRUG|Carboplatin|AUC 5 (IV, Q3W)
214817792|NCT05132985|DRUG|Pemetrexed|500 mg/m2 (IV, Q3W)
214649068|NCT04625777|BEHAVIORAL|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
214649069|NCT04625777|BEHAVIORAL|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
214649070|NCT06226363|DRUG|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
214649071|NCT02594436|DRUG|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
214649072|NCT00031031|DRUG|Kanglaite Injection (KLT)|
214649073|NCT02849639|OTHER|Placebo|Participants will receive educational materials, but will not receive MTM.
214649074|NCT02849639|OTHER|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
214649075|NCT02849639|DRUG|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
214649076|NCT01958645|DRUG|MEDI8111|MEDI8111 lyophilisate for solution for infusion
214649077|NCT01958645|OTHER|Placebo|Placebo for MEDI8111 saline solution for infusion
214649078|NCT00531804|DRUG|gantenerumab|Administered iv at escalating doses (7 cohorts)
214649079|NCT01006070|PROCEDURE|kyphoplasty|surgical kyphoplasty
214649080|NCT03183128|BIOLOGICAL|SER-109|"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
214649081|NCT03183128|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
214649082|NCT00004433|DRUG|pergolide|
214649083|NCT05039060|DIETARY_SUPPLEMENT|Modified MAC diet (3-weeks)|"* Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis"
214649084|NCT04326530|DEVICE|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
214649085|NCT04326530|OTHER|Other assessments|"* Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit."
214649086|NCT00363792|DRUG|Glyceryl trinitrate, azetazolamide|
214649087|NCT01772667|PROCEDURE|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
214649088|NCT01171651|DRUG|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
214649089|NCT00389584|DRUG|irinotecan hydrochloride|
214649090|NCT00389584|PROCEDURE|cognitive assessment|
214649091|NCT00389584|PROCEDURE|management of therapy complications|
214649092|NCT00389584|RADIATION|radiation therapy|
214649093|NCT03737162|PROCEDURE|Stent implantation of subclavian artery|Stent implantation of subclavian artery
214817793|NCT03884088|OTHER|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
214649094|NCT01023984|PROCEDURE|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
214649095|NCT01023984|PROCEDURE|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
214649096|NCT03773302|DRUG|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
214649097|NCT03773302|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
214649098|NCT03773302|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
214817794|NCT02148497|PROCEDURE|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
214817795|NCT03544411|BIOLOGICAL|olive oil|the intervention consist of 15 ml / day of olive oil
214817796|NCT03544411|BIOLOGICAL|bran oil|the intervention consist of 15 ml / day of bran oil
214817797|NCT05162222|DRUG|Danicamtiv|Specified dose on specified days
214817798|NCT05162222|DRUG|Itraconazole|Specified dose on specified days
214817799|NCT05162222|DRUG|Diltiazem|Specified dose on specified days
214817800|NCT00471523|DRUG|Clomiphene citrate|
214817801|NCT00471523|DRUG|Metformin|
214817802|NCT04560738|DRUG|[14C]-CC-92480|Oral
214817803|NCT05442021|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
214817804|NCT05442021|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
214817805|NCT03397056|OTHER|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
214817806|NCT05244798|DRUG|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
214817807|NCT05244798|RADIATION|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
214817808|NCT05244798|DRUG|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
214649099|NCT05641532|BEHAVIORAL|Physical activity behavioral intervention in persons newly diagnosed with MS|"1. The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~2. The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (\~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~3. The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program."
214817809|NCT02360761|PROCEDURE|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
214817810|NCT02360761|PROCEDURE|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
214817811|NCT03284476|OTHER|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
214817812|NCT03174080|RADIATION|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
214649100|NCT04289896|OTHER|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
214649101|NCT04855994|PROCEDURE|paravertebral block|The investigators performed Paravertebral block to that patient group for postoperative analgesia
214649102|NCT04855994|PROCEDURE|pectoral block|The investigators performed pectoral block to that patient group for postoperative analgesia
214817813|NCT04819594|OTHER|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
214649103|NCT00380562|BEHAVIORAL|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
214649104|NCT02417389|DRUG|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
214649105|NCT02417389|DRUG|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
214649106|NCT03729882|PROCEDURE|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
214649107|NCT03729882|PROCEDURE|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
214649108|NCT03850197|DEVICE|EarPopper|"The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
214649109|NCT03850197|DEVICE|Tympanometry|The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.
214649110|NCT03850197|DEVICE|Tubomanometry|"Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
214649111|NCT04747015|DRUG|Oxytocin|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation
214649112|NCT04747015|DRUG|Oxytocin|5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
214649113|NCT04747015|PROCEDURE|cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
214649114|NCT05421910|DEVICE|robotic training combined with electrical stimulation|Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
214649115|NCT05202145|DRUG|ALXN2050|Oral tablet.
214649116|NCT05202145|DRUG|Cyclosporine|Oral capsule.
214649117|NCT05202145|DRUG|Tacrolimus|Oral capsule.
214649118|NCT05202145|DRUG|MMF|Oral tablet.
214649119|NCT06312891|DRUG|Ivabradine|heart rate lowering therapy
214649120|NCT01303055|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
214649121|NCT01303055|DRUG|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
214649122|NCT01647737|DIETARY_SUPPLEMENT|MighTeaFlow|4-6 times daily
214649123|NCT01647737|DIETARY_SUPPLEMENT|Xylitol|4-6 times daily
214649124|NCT00330187|DRUG|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
214649125|NCT00330187|BEHAVIORAL|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
214649126|NCT00330187|OTHER|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
214649127|NCT03258814|BEHAVIORAL|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
214649128|NCT03258814|BEHAVIORAL|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
214649129|NCT00271388|DEVICE|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
214649130|NCT03681444|OTHER|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
214649131|NCT03681444|OTHER|Clear fluid diet|"Patients will be provided with~* Plain water~* Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~* Soup broth (bouillon or consommé)~* Clear sodas, such as ginger ale and Sprite~* Gelatin (Jell-O)~* Tea or coffee with no cream or milk added~* Sports drinks that don't have color"
214649132|NCT03681444|OTHER|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
214649133|NCT03681444|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
214649134|NCT04805086|BIOLOGICAL|MON002|Autologous monocytes
214649135|NCT01234155|BEHAVIORAL|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
214649136|NCT01234155|BEHAVIORAL|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
214649137|NCT01413958|DRUG|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
214649138|NCT01413958|DRUG|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
214649139|NCT01413958|DRUG|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
214649140|NCT02817672|BEHAVIORAL|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
214649141|NCT02817672|BEHAVIORAL|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
214649142|NCT05603429|DIAGNOSTIC_TEST|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
214649143|NCT02153502|DRUG|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
214649144|NCT02153502|DRUG|Placebo|Placebo capsules administered twice a day over a 10-week period
214649145|NCT01900002|OTHER|Laboratory Biomarker Analysis|Correlative studies
214649146|NCT01900002|OTHER|Quality-of-Life Assessment|Ancillary studies
214649147|NCT01900002|DRUG|Sorafenib|Given PO
214649148|NCT01900002|DRUG|Sorafenib Tosylate|Given PO
214649149|NCT01900002|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
214649150|NCT00754156|DEVICE|ABRA Abdominal Closure System|ABRA Abdominal Closure System
214649151|NCT00754156|DEVICE|V.A.C. Therapy|V.A.C. Therapy Alone
214817814|NCT03950089|DEVICE|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
214649152|NCT00754156|DEVICE|KCI ABThera|KCI ABThera
214649153|NCT04475328|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
214649154|NCT04475328|DRUG|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
214649155|NCT04475328|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
214649156|NCT03604315|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214649157|NCT03604315|PROCEDURE|Computed Tomography|Undergo \[18F\]FTT PET/CT
214649158|NCT03604315|RADIATION|Fludeoxyglucose F-18|Given IV
214649159|NCT03604315|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
214649160|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214649161|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET/CT
214649162|NCT00030069|DRUG|Calcitriol|
214649163|NCT00030069|DRUG|Dexamethasone|
214817815|NCT05881525|BIOLOGICAL|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
214817816|NCT05881525|DRUG|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
214649164|NCT03262415|DEVICE|LabPatch Continuous Glucose Monitoring (CGM)|"1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~3. A wire that connects the chip to a laptop that continuously captures glucose data."
214649165|NCT04869800|DRUG|CKD-398|Test Drug
214649166|NCT04869800|DRUG|CKD-501, D745|Reference Drug
214649167|NCT06177366|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
214649168|NCT06151561|DRUG|AGN-151586|Intramuscular Injection
214649169|NCT06151561|DRUG|Placebo|Intramuscular Injection
214649170|NCT03382509|DRUG|[14C]BI 1467335|Once Daily
214649171|NCT03382509|DRUG|BI 1467335|Twice Daily
214649172|NCT01751971|DRUG|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
214649173|NCT01751971|OTHER|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
214649174|NCT00453401|DRUG|NB-001|
214649175|NCT00167258|BEHAVIORAL|Voucher Reinforcement|
214649176|NCT00167258|BEHAVIORAL|Extra Counseling Services|
214649177|NCT00167258|BEHAVIORAL|Voucher Reinforcement + Extra Counseling Services|
214649178|NCT04881123|DRUG|SER150|Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
214649179|NCT04881123|DRUG|Placebo|Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
214649180|NCT01974609|DRUG|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
214649181|NCT01974609|DRUG|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
214649182|NCT06002503|DRUG|Venezuelan Equine Encephalitis DNA Vaccine|Venezuelan Equine Encephalitis DNA Vaccine Candidate
214649183|NCT06002503|DEVICE|PharmaJet Stratis Needle-free Injection System|Intramuscular Needle-free Injection System (Jet Injector)
214649184|NCT06002503|DEVICE|PharmaJet Tropis Needle-free Injection System|Intradermal Needle-free Injection System (Jet Injector)
214649185|NCT02022449|BEHAVIORAL|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
214817817|NCT05881525|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214817818|NCT05881525|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214817819|NCT05881525|DRUG|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214817820|NCT03003091|OTHER|Needs-based patient education|
214817821|NCT03003091|OTHER|Traditional patient education|
214817822|NCT01177020|OTHER|Biological specimen|Biological specimen taken from placenta
214817823|NCT03680248|DIETARY_SUPPLEMENT|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
214817824|NCT03680248|DIETARY_SUPPLEMENT|Fasting|Subjects will fast throughout the experiment.
214817825|NCT03680248|DIETARY_SUPPLEMENT|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
214817826|NCT03680248|DIETARY_SUPPLEMENT|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
214817827|NCT03680248|DIETARY_SUPPLEMENT|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
214817828|NCT03680248|DIETARY_SUPPLEMENT|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
214817829|NCT00431730|PROCEDURE|flicker light stimulation|
214649186|NCT02606578|OTHER|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (\~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
214649187|NCT04749069|DIAGNOSTIC_TEST|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
214649188|NCT03221218|OTHER|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
214649189|NCT04810702|OTHER|no intervention|no intervention
214649190|NCT06435702|DRUG|Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
214649191|NCT06435702|DRUG|androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
214649192|NCT02820467|DEVICE|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
214649193|NCT03921996|PROCEDURE|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
214649194|NCT03921996|PROCEDURE|Radical prostatectomy (RP) only|Radical prostatectomy
214649195|NCT02682680|DRUG|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
214649196|NCT02682680|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
214649197|NCT01332448|DRUG|Orlistat 120|Orlistat 120mg tid
214649198|NCT01332448|DRUG|Orlistat 60|Orlistat 60mg tid
214649199|NCT05772637|PROCEDURE|Repeated cystometries with bladder sensations assessment|A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
214649200|NCT00206921|DEVICE|Pulsed dye laser|
214649201|NCT00206921|DEVICE|Intense pulsed light|
214649202|NCT01130129|OTHER|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
214649203|NCT04297358|DRUG|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
214649204|NCT02475889|PROCEDURE|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
214649205|NCT02475889|PROCEDURE|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
214649206|NCT05721066|DIAGNOSTIC_TEST|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
214649207|NCT05721066|DIAGNOSTIC_TEST|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
214649208|NCT05721066|OTHER|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
214649209|NCT00000943|BIOLOGICAL|Tetanus Toxoid Vaccine|
214649210|NCT00000943|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
214649211|NCT00000943|BIOLOGICAL|HIV-1 Immunogen|
214649212|NCT00000943|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
214649213|NCT03209219|DRUG|Interferon Alfa-2A|3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
214649214|NCT03209219|DRUG|Cyclosporine Pill|100mg， oral, bid
214649215|NCT05888974|DIAGNOSTIC_TEST|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
214649216|NCT03295214|DRUG|Acetaminophen|Acetaminophen given for pain relief
214649217|NCT00899340|GENETIC|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
214649218|NCT00899340|GENETIC|microarray analysis|microarray analysis
214649219|NCT00899340|GENETIC|protein expression analysis|protein expression analysis
214649220|NCT00899340|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
214649221|NCT00899340|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214649222|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
214649223|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
214649224|NCT00905957|PROCEDURE|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
214649225|NCT00905957|PROCEDURE|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
214649226|NCT05086042|DIAGNOSTIC_TEST|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
214649227|NCT01286493|BIOLOGICAL|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
214649228|NCT02905734|DRUG|Nicotine patch|Single administration of an active treatment (nicotine patch)
214649229|NCT02905734|OTHER|placebo patch|Single administration of a placebo treatment
214649230|NCT00135629|BIOLOGICAL|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
214649231|NCT00135629|OTHER|Placebo Injection|Placebo Injection
214649232|NCT00135629|PROCEDURE|Venepuncture: 100ml blood sample taken on 12 separate visits|Venepuncture: 100ml blood sample taken on 12 separate visits
214649233|NCT01470677|DRUG|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
214649234|NCT01261559|DEVICE|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
214649235|NCT03869255|PROCEDURE|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
214649236|NCT02935309|DRUG|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
214649237|NCT02935309|DRUG|Capecitabine|Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
214649238|NCT02935309|RADIATION|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
214649239|NCT02773966|RADIATION|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
214649240|NCT02773966|RADIATION|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
214649241|NCT05700266|DRUG|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
214649242|NCT05700266|DRUG|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
214649243|NCT05700266|DRUG|Aspirin|Aspirin (100mg once a day for 1 year)
214649244|NCT05700266|OTHER|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
214649245|NCT00224536|PROCEDURE|Intracoronary bone marrow cell transfer|
214649246|NCT04772248|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
214649247|NCT04772248|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
214649248|NCT03785054|DRUG|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
214649249|NCT03785054|DRUG|Placebo oral capsule|Placebo treatment
214649250|NCT04597476|DIETARY_SUPPLEMENT|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
214649251|NCT04597476|OTHER|Placebo( Potato starch)|Potato starch 4.4gram
214649252|NCT03680937|OTHER|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
214649253|NCT03680937|OTHER|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
214649254|NCT00963326|OTHER|laboratory biomarker analysis|
214649255|NCT02601573|DRUG|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
214649256|NCT02601573|DRUG|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
214649257|NCT02601573|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
214649258|NCT02601573|DRUG|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
214649259|NCT05222633|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
214649260|NCT05222633|DRUG|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
214649261|NCT05222633|DRUG|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
214649262|NCT00746499|DRUG|Raltegravir|400mg raltegravir BID x 7 days
214649263|NCT01052857|PROCEDURE|acupuncture|acupuncture application
214649264|NCT04569838|DRUG|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
214649265|NCT02921425|BEHAVIORAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
214649266|NCT00564993|DRUG|Dobutamin|10\&20 µg/kg/min
214649267|NCT04671836|DRUG|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
214649268|NCT04671836|DRUG|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
214649269|NCT06078657|DRUG|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
214649270|NCT04049825|DRUG|OPB-111077|OPB-111077+bendamustine
214649271|NCT04049825|DRUG|OPB-111077|OPB-111077+rituximab+bendamustine
214649272|NCT05816681|DRUG|DWJ1230|Daewoong Pharmaceutical
214649273|NCT05816681|DRUG|DWB2001|Daewoong Bio
214649274|NCT02627040|DEVICE|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
214649275|NCT02627040|DEVICE|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
214649276|NCT05064657|PROCEDURE|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
214649277|NCT00899093|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214649278|NCT00899093|OTHER|Laboratory Biomarker Analysis|Correlative studies
214817830|NCT02516839|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
214649279|NCT03403400|BEHAVIORAL|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
214649280|NCT03403400|BEHAVIORAL|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
214649281|NCT02036229|DRUG|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
214649282|NCT00643149|DRUG|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
214649283|NCT00643149|DRUG|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
214649284|NCT01396369|DRUG|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
214649285|NCT01396369|DRUG|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
214649286|NCT00016458|DRUG|anti-thymocyte globulin|
214649287|NCT00016458|DRUG|cyclophosphamide|
214649288|NCT05158855|DIETARY_SUPPLEMENT|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
214649289|NCT04358757|PROCEDURE|Elective cesarean delivery|scheduled cesarean delivery for maternal / obstetric indications
214649290|NCT01124825|DEVICE|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
214649291|NCT01124825|DEVICE|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
214649292|NCT00989989|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
214649293|NCT00989989|PROCEDURE|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
214649294|NCT00989989|DRUG|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
214649295|NCT00989989|PROCEDURE|Sham laser photocoagulation|Sham laser treatment administered at day 1.
214649296|NCT00166387|PROCEDURE|Blood draw|A single blood draw.
214649297|NCT04706884|DEVICE|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
214649298|NCT05568771|OTHER|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
214649299|NCT03979976|DRUG|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
214649300|NCT01384292|DRUG|NKTR-118|12.5 mg oral tablet once daily
214649301|NCT01384292|DRUG|NKTR-118|25 mg oral tablet once daily
214649302|NCT01384292|DRUG|Placebo|Oral treatment
214649303|NCT02122627|DRUG|Vitamin D|Colecalciferol 16.800 IU per week
214649304|NCT02122627|DRUG|Placebo|
214649305|NCT04391725|PROCEDURE|Periapical surgery with guided tissue regeneration|periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
214649306|NCT04391725|PROCEDURE|Periapical surgery without anyguided tissue regeneration|periapical surgery will be done followed by flap closure
214649307|NCT03378908|BEHAVIORAL|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
214649308|NCT00243659|BIOLOGICAL|ReFacto AF|
214649309|NCT02342405|OTHER|80% oxygen|
214649310|NCT02342405|OTHER|30% oxygen|
214649311|NCT00002909|DRUG|chemotherapy|
214649312|NCT00002909|DRUG|oral sodium phenylbutyrate|
214649313|NCT01975168|DEVICE|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
214649314|NCT03310970|DRUG|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
214649315|NCT03310970|DRUG|Lidocaine hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
214649316|NCT03310970|DRUG|Lidoderm 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
214649317|NCT01964235|DRUG|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
214817831|NCT02516839|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
214649318|NCT01964235|DRUG|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
214649319|NCT04446364|OTHER|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
214649320|NCT04446364|OTHER|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
214649321|NCT00755833|DRUG|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
214649322|NCT01770600|OTHER|placebo|placebo pill administered daily for 5 days
214649323|NCT01770600|DRUG|Riperidone|1 mg risperidone administered orally for 5 days
214649324|NCT04992975|OTHER|MRI at 7T|MRI at 7T
214649325|NCT01273064|DRUG|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
214649326|NCT01273064|DRUG|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
214649327|NCT01273064|DRUG|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
214649328|NCT01273064|DRUG|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
214649329|NCT03987087|RADIATION|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
214649330|NCT03987087|DRUG|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
214649331|NCT06384092|OTHER|Test Sun Protection Cream|Apply directly on the designated site till absorbed.
214649332|NCT06384092|OTHER|Benchmark Sun Protection Cream|Apply directly on the designated site till absorbed.
214649333|NCT00383045|DRUG|Buprenorphine/Subutex|
214649334|NCT00383045|DRUG|Naltrexone|
214649335|NCT00383045|PROCEDURE|Drug counseling|
214649336|NCT04545255|DEVICE|Shockwave treatment|ED 1000 shockwave generator
214649337|NCT04635865|DEVICE|3D-printed patient-specific plate|"We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder."
214649338|NCT04635865|DEVICE|Conventional commercial reconstruction plate|Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.\[
214649339|NCT05272865|DRUG|Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator|Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
214649340|NCT03043833|BEHAVIORAL|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~* Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~* Lesson 2 presents different strategies to generate realistic cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~* Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
214649341|NCT03984058|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
214649342|NCT05789095|OTHER|Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)|"Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation."
214649343|NCT04973943|DIAGNOSTIC_TEST|Donor-derived cell Free DNA|Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously
214649344|NCT02859909|BIOLOGICAL|BT595|
215031377|NCT06551727|OTHER|Intervention group|"After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database."
215031378|NCT06551727|OTHER|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
215031379|NCT02816112|DRUG|Ciprofloxacin|Antibiotic
215031380|NCT02816112|DRUG|Neupogen|Granulocyte-colony stimulating factor
215031381|NCT01460615|DRUG|Hydrocortisone|
215031382|NCT03843073|DEVICE|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
215031383|NCT03889535|DEVICE|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
215031384|NCT03889535|DEVICE|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
215031385|NCT00087035|DRUG|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
215031386|NCT00087035|DRUG|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
215031387|NCT06537687|OTHER|Control|A standardized handout on HPV and vaccine education will be given
215031388|NCT06537687|OTHER|Intervention|A video about HPV and vaccines on a tablet provided by a research assistant
215031389|NCT04708847|DRUG|GYM329|GYM329 subcutaneous injection
215031390|NCT04708847|DRUG|Placebo|Placebo subcutaneous injection
215031391|NCT05823441|DRUG|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
215031392|NCT05823441|DRUG|Placebo|Volunteers inhale 24 units of placebo spray
215031393|NCT05823441|BEHAVIORAL|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
215031394|NCT05823441|BEHAVIORAL|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
215031395|NCT03085953|BEHAVIORAL|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
215031396|NCT03085953|OTHER|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
215031397|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
215031398|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
215031399|NCT00663260|DRUG|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
215031400|NCT03361631|DRUG|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
214649345|NCT03448588|DIAGNOSTIC_TEST|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
214649346|NCT00128466|DRUG|gentamicin|
214649347|NCT00128466|DRUG|streptomycin|
214649348|NCT02906072|BEHAVIORAL|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
214649349|NCT02906072|BEHAVIORAL|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
214649350|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
214649351|NCT02851914|DRUG|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
214649352|NCT02851914|DRUG|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
214649353|NCT02240043|OTHER|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
214649354|NCT02979210|OTHER|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
214649355|NCT02979210|OTHER|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
214649356|NCT00291551|DEVICE|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
214649357|NCT04494932|PROCEDURE|Self-Locking Tenotomy|Self-locking Tenotomy describes the surgical procedure that will be performed to treat SLAP tears.
214649358|NCT04494932|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat SLAP tears.
214649359|NCT04666038|DRUG|Pirtobrutinib|Oral Pirtobrutinib
214649360|NCT04666038|DRUG|Idelalisib|Oral
214649361|NCT04666038|DRUG|Bendamustine|IV
214649362|NCT04666038|DRUG|Rituximab|IV
214649363|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214649364|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214649365|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214649366|NCT00406146|DRUG|amodiaquine+artesunate/artemether-lumefantrine|
214649367|NCT00006070|DRUG|etanercept (Enbrel)|
214649368|NCT05558150|DRUG|Ilaprazole|Ilaprazole 10mg
214649369|NCT05558150|DRUG|Aceclofenac|Aceclofenac 100mg
214649370|NCT01635790|DRUG|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
214649371|NCT01635790|DRUG|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
214649372|NCT04955561|OTHER|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
214649373|NCT04955561|OTHER|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
214649374|NCT04955561|OTHER|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
214649375|NCT06469060|DRUG|neoadjuvant anti-PD-1 with DOC chemotherapy|"Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1\. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle."
214649376|NCT05154695|DEVICE|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
214649377|NCT05154695|DEVICE|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
214649378|NCT05154695|DRUG|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
214649379|NCT00168961|DIETARY_SUPPLEMENT|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
214649380|NCT04690010|PROCEDURE|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
214649381|NCT04690010|PROCEDURE|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
214649382|NCT06215833|DRUG|Propofol|All children will undergo anesthesia via Propofol bolus injection in induction then Propofol infusion in maintenance of anesthesia and will be given after total recovery, Cetal suppositories as postoperative analgesia
214649383|NCT06215833|DRUG|Sevoflurane|All children will undergo anesthesia via Sevoflurane will be given during induction then through maintenance of anesthesia and will be given after total recovery, Cetal suppositories as post operative analgesia
214649384|NCT02049047|DRUG|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
214649385|NCT03400800|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
214649386|NCT03400800|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
214817832|NCT02516839|BEHAVIORAL|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
214817833|NCT02516839|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
214817834|NCT00202722|DRUG|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
214817835|NCT02606825|OTHER|Registry of AML patients > 60 years|
214817836|NCT04138186|DEVICE|2.0g G-PUR®, oral administration|tid for 12 weeks
214817837|NCT04138186|DEVICE|Placebo, oral administration|tid for 12 weeks
214817838|NCT03916263|DRUG|Metformin|Traditional care including diet, exercise and metformin
214817839|NCT03916263|OTHER|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
214817840|NCT03916263|OTHER|Video Dietary Instruction|Participant receives video dietary instruction
214817841|NCT03354286|BEHAVIORAL|Developmental & Technological Demands|Education and training related to use of CGM in this age group
214817842|NCT03354286|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
214817843|NCT03354286|BEHAVIORAL|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
214817844|NCT03354286|BEHAVIORAL|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
214817845|NCT03354286|BEHAVIORAL|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
214817846|NCT02576938|DRUG|Baricitinib|Administered orally
214817847|NCT02576938|DRUG|Placebo|Administered orally
214649387|NCT03280160|DRUG|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
214649388|NCT02025296|DEVICE|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
214649389|NCT03073473|DIAGNOSTIC_TEST|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
214649390|NCT00002162|DRUG|Saquinavir|
214649391|NCT00002162|DRUG|Lamivudine|
214649392|NCT00002162|DRUG|Stavudine|
214649393|NCT00002162|DRUG|Zidovudine|
214649394|NCT00002162|DRUG|Zalcitabine|
214649395|NCT00002162|DRUG|Didanosine|
214649396|NCT02000947|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
214649397|NCT02000947|DRUG|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
214649398|NCT02000947|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
214649399|NCT04986787|DEVICE|tACS|a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms
214649400|NCT04986787|DEVICE|TMS|a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain, it will be specifically cerebellar stimulation
214649401|NCT04986787|DEVICE|TIS|temporal interference stimulation targeted to striatum, a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms deep in the brain
214649402|NCT03897543|DRUG|ABX196|ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
214817848|NCT02576938|DRUG|Triamcinolone (Optional)|Administered topically
214649403|NCT04901039|OTHER|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
214649404|NCT04901039|OTHER|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
214649405|NCT04901039|OTHER|Peripheral venous pressure|Assessment of peripheral venous pressure
214649406|NCT04901039|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging
214649407|NCT04901039|OTHER|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
214649408|NCT03219073|DEVICE|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
214649409|NCT03219073|DEVICE|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
214649410|NCT03887130|DRUG|oral vinorelbine|Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles
214649411|NCT03887130|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
214649412|NCT03887130|DRUG|Gemcitabine 1250 mg/m²|Gemcitabine 1250 mg/m² on day 1 \& day 8
214649413|NCT03887130|DRUG|Gemcitabine 1000 mg/m²|Gemcitabine: 1000 mg/m² on day 1 \& 8
214649414|NCT03887130|DRUG|Paclitaxel|Paclitaxel 175 mg/m² on day 1
214649415|NCT03887130|DRUG|Docetaxel|Docetaxel 75 mg/m² on day 1
214649416|NCT03611426|DRUG|rhThrombin ( Topical )|Active Substance
214649417|NCT03611426|DRUG|placebo|saline solution
214649418|NCT02926703|OTHER|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
214649419|NCT01709188|BEHAVIORAL|Musical Dual Task Training|
214649420|NCT01709188|BEHAVIORAL|Walking and Talking|
214649421|NCT04082663|DEVICE|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
214649422|NCT06314464|DEVICE|Praxis|Praxis' gaze stabilization exercises are delivered via the tablet-based VestAid software that uses the tablet camera to automatically assess compliance in the conduct of vestibulo-ocular reflex exercises. The smooth pursuit, saccade, agility, and dual tasking exercises are delivered in the form of military-themed mixed reality games using the HTC Vive Focus 3 headset.
214649423|NCT06314464|BEHAVIORAL|Supervised cardiovascular exercise|The supervised cardiovascular exercise does not incorporate gaze stabilization exercises (vestibulo-ocular reflex exercises) or smooth pursuit, saccade, agility, and dual tasking exercises.
214649424|NCT03215563|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
214649425|NCT03215563|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
214649426|NCT05591495|PROCEDURE|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
214649427|NCT01291602|DRUG|NXL104|IV Solution
214649428|NCT01291602|DRUG|CAZ104|IV Solution
214649429|NCT01291602|DRUG|Placebo|IV saline
214649430|NCT05796986|PROCEDURE|Endovascular procedure of treatment of wide neck saccular cerebral aneurysm|Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
214649431|NCT00705263|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214649432|NCT00705263|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214817849|NCT03500341|DEVICE|INVSENSOR00014|Noninvasive pulse oximeter sensor
214649433|NCT03799510|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
214649434|NCT03799510|DRUG|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
214649435|NCT04958538|DRUG|Methotrexate|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
214649436|NCT01752023|DRUG|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
214649437|NCT01752023|DRUG|Cisplatin + Gemcitabine|Active Comparator
214649438|NCT01755663|DRUG|Ivabradine and Metoprolol|
214649439|NCT02921451|DEVICE|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
214649440|NCT01207830|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
214649441|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given standard of care nutritional supplementation
214649442|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
214649443|NCT02445833|BEHAVIORAL|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
214649444|NCT02899156|DRUG|Flumazenil|
214649445|NCT02899156|DRUG|Placebo|0.9% normal saline
214817850|NCT01377779|DRUG|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
214649446|NCT00909155|DRUG|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
214649447|NCT00909155|DRUG|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
214817851|NCT01377779|DRUG|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
214649448|NCT03787914|PROCEDURE|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
214649449|NCT00000733|DRUG|Ribavirin|
214649450|NCT04749381|COMBINATION_PRODUCT|acupoint with TCM|The acupoint application was made of traditional Chinese medicine (TCM), and the therapeutic effect was produced through the stimulation of TCM drugs and acupoints.
214817852|NCT01275469|DRUG|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
214649451|NCT04749381|COMBINATION_PRODUCT|acupoint with placebo|The placebo acupoint application was made of black beans and honey, which shares the similar shape and smell of the experiment group, applied at the same acupoints.
214649452|NCT05187832|DRUG|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
214649453|NCT05809141|DIAGNOSTIC_TEST|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
214649454|NCT00823641|DRUG|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
214649455|NCT02629731|DEVICE|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
214649456|NCT02269358|DRUG|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
214649457|NCT00787787|DRUG|sunitinib malate|Given PO
214649458|NCT00787787|DRUG|capecitabine|Given PO
214649459|NCT04210271|BEHAVIORAL|Buddy self-testing condition|
214649460|NCT04210271|BEHAVIORAL|Control self-screening condition|
214649461|NCT02452502|DEVICE|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
214649462|NCT01412957|OTHER|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
214649463|NCT01412957|DRUG|Panitumumab|Administered intravenously
214649464|NCT05011591|OTHER|Swimming economy|Detailed in arm's section
214649465|NCT02965157|BIOLOGICAL|CART20|
214649466|NCT03885778|DRUG|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
214649467|NCT06584916|DRUG|Orforglipron|Administered orally
214649468|NCT06584916|DRUG|Placebo|Administered orally
214649469|NCT04722991|DRUG|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
214649470|NCT04722991|OTHER|Placebo|Oral dose of matching placebo
214649471|NCT02084277|DEVICE|Self-ligating brackets (SLB)|
214649472|NCT02084277|DEVICE|Conventional brackets (CB)|
214649473|NCT03063580|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
214649474|NCT03063580|DRUG|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
214817853|NCT01275469|DRUG|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
214817854|NCT02104908|PROCEDURE|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
214817855|NCT02104908|PROCEDURE|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
214817856|NCT06093932|DRUG|Songling Xuemaikang Capsules|3 capsules at a time, three times a day, duration: 12 weeks
214649475|NCT05583942|DEVICE|trascutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
214649476|NCT05583942|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
214649477|NCT01889849|DRUG|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
214649478|NCT01889849|DRUG|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
214649479|NCT06538701|PROCEDURE|Anterolateral advancement pharyngoplasty|Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
214649480|NCT01163071|DRUG|ABI-011|ABI-011
214649481|NCT01113970|DRUG|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
214649482|NCT05065398|DRUG|HLX208|450mg bid, take orally
214649483|NCT01648231|DRUG|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
214649484|NCT01648231|DRUG|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
214649485|NCT01648231|DRUG|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
214649486|NCT05105178|OTHER|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
214649487|NCT05105178|OTHER|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
214649488|NCT01370460|DRUG|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
214649489|NCT01370460|DRUG|Placebo|100mL 0.9% sterile saline
214649490|NCT00002744|DRUG|asparaginase|
214649491|NCT00002744|DRUG|cyclophosphamide|
214649492|NCT00002744|DRUG|cytarabine|
214649493|NCT00002744|DRUG|daunorubicin hydrochloride|
214649494|NCT00002744|DRUG|dexamethasone|
214649495|NCT00002744|DRUG|doxorubicin hydrochloride|
214649496|NCT00002744|DRUG|mercaptopurine|
214649497|NCT00002744|DRUG|methotrexate|
214649498|NCT00002744|DRUG|pegaspargase|
214649499|NCT00002744|DRUG|prednisone|
214649500|NCT00002744|DRUG|therapeutic hydrocortisone|
214649501|NCT00002744|DRUG|thioguanine|
214649502|NCT00002744|DRUG|vincristine sulfate|
214649503|NCT00002744|RADIATION|low-LET cobalt-60 gamma ray therapy|
214649504|NCT00002744|RADIATION|low-LET photon therapy|
214649505|NCT02576314|DRUG|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
214649506|NCT02576314|DRUG|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"
214649507|NCT05902000|DEVICE|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
214649508|NCT05902000|PROCEDURE|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
214649509|NCT05902000|DRUG|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
214649510|NCT05902000|DRUG|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
214649511|NCT05927883|BEHAVIORAL|Indigenously Adapted Cognitive Behavioral Therapy|IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
214649512|NCT04928534|DIAGNOSTIC_TEST|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
214649513|NCT05906420|DIAGNOSTIC_TEST|ASTRAL prognostic score|ASTRAL prognostic score
214649514|NCT02246621|DRUG|Abemaciclib|Administered orally
214649515|NCT02246621|DRUG|Anastrozole|Administered orally
214649516|NCT02246621|DRUG|Letrozole|Administered orally
214649517|NCT02246621|DRUG|Placebo|Administered orally
214649518|NCT03131817|DEVICE|Activa PC+S Prefrontal|
214817857|NCT06093932|BEHAVIORAL|Lifestyle intervention|everyday, duration: 12 weeks
214817858|NCT06093932|DRUG|Placebo|3 capsules at a time, three times a day, duration: 12 weeks
214817859|NCT03055637|PROCEDURE|Furlow double opposing z-plasty|\* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
214817860|NCT03055637|PROCEDURE|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
214649519|NCT02435355|BEHAVIORAL|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
214649520|NCT05308316|OTHER|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
214649521|NCT03152682|DIETARY_SUPPLEMENT|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
214649522|NCT03152682|OTHER|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
214649523|NCT05219188|RADIATION|3.7 mS, CT radiation|Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
214649524|NCT04465929|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
214649525|NCT01583374|DRUG|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
214649526|NCT01583374|DRUG|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
214649527|NCT01583374|DRUG|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
214649528|NCT00393575|BEHAVIORAL|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
214649529|NCT01265524|DRUG|CLP|Oral administration
214649530|NCT01265524|DRUG|Placebo|Oral administration
214649531|NCT02905175|PROCEDURE|blood sample|
214649532|NCT02905175|PROCEDURE|synovial tissue|synoviocytes from synovial tissue
214817861|NCT03650985|PROCEDURE|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
214817862|NCT01010932|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
214817863|NCT01010932|OTHER|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
214817864|NCT03545451|DEVICE|Videogames|Videogames
214817865|NCT04481815|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
214817866|NCT04481815|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
214817867|NCT04481815|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
214817868|NCT00838630|DRUG|Cilostazol 100 mg tablets|1 x 100 mg
214817869|NCT00838630|DRUG|Pletal® 100 mg tablets|1 x 100 mg
214649533|NCT03771742|PROCEDURE|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
214649534|NCT03771742|PROCEDURE|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
214649535|NCT00783588|BIOLOGICAL|ISF35|Subjects participating in this study will receive up to two doses of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
214649536|NCT03349814|PROCEDURE|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
214649537|NCT03349814|PROCEDURE|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
214649538|NCT00460343|OTHER|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
214649539|NCT00460343|OTHER|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
214649540|NCT02504229|BIOLOGICAL|autologous dendritic cells co-cultured with cytokine-induced killer cells|
214649541|NCT02504229|DRUG|Gimeracil and Oteracil Porassium Capsules|
214649542|NCT02504229|DRUG|Oxaliplatin|
214649543|NCT03741166|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
214649544|NCT00808041|DEVICE|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
214649545|NCT05622539|COMBINATION_PRODUCT|CONVENTIONAL ACUTE STROKE MANAGEMENT|Conventional treatment for acute stroke patients, with or without reperfusion treatments
214649546|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
214649547|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
214649548|NCT05025215|BEHAVIORAL|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
214649549|NCT05025215|BEHAVIORAL|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
214649550|NCT06810375|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|preoperative erector spinae block with bupivacaine (Marcaine®)
214649551|NCT06810375|DRUG|Intercostal nerve block|intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)
214649552|NCT01604005|RADIATION|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
214649553|NCT02281591|DRUG|BIA 2-093|Tablets containing 900 mg
214649554|NCT02281591|DRUG|S-licarbazepine|capsules containing 225 mg
214649555|NCT02281591|DRUG|R-licarbazepine|capsules containing 225 mg
214649556|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
214649557|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
214649558|NCT05400187|BEHAVIORAL|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
214649559|NCT06703554|OTHER|Sage Oil Mouthwash|Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
214649560|NCT06703554|BIOLOGICAL|Chlorohexidine Mouthwash|0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
214649561|NCT03227809|BEHAVIORAL|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
214649562|NCT03227809|BEHAVIORAL|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
214649563|NCT06899919|DEVICE|Treatment with light compression systeme during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)|Treatment with light compression system during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)
214649564|NCT06899919|DEVICE|Light compression system of the mixed leg ulcer stage C6 / C6r of the CEAP classification|Etiological treatment of mixed leg ulcer stage C6 / C6r of the CEAP classification
214649565|NCT04768127|OTHER|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
214649566|NCT04768127|OTHER|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
214649567|NCT06916169|DRUG|AG2304|AG2304, Single-dose Oral Administration
214649568|NCT06916169|DRUG|AG23041 and AG23042|AG23041/AG23042, Single-dose Oral Administration
214649569|NCT06916117|DRUG|Neoadjuvant Chemotherapy (NACT)|"Neoadjuvant chemotherapy:~The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.~Concurrent chemoradiotherapy:~Radical dose to the pelvic concurrent with cisplatin.~Consolidative immunotherapy:~Following the completion of chemoradiotherapy, Sintilimab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total of 6 cycles, starting 3-4 weeks after chemoradiotherapy."
214649570|NCT06935266|BIOLOGICAL|TAK-881|TAK-881 SC injection.
214649571|NCT06935266|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
214649572|NCT06936592|DRUG|Ascorbic acid|Ascorbic acid induce gingival healing
214649573|NCT00379860|DRUG|LXR-623|
214649574|NCT05630157|BEHAVIORAL|Unplugged plus gambling component|12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
214649575|NCT03822481|BEHAVIORAL|Mindful Construal Diary|A Mindful Eating Intervention
214649576|NCT05018858|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214649577|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
214649578|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
214649579|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
214649580|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
214649581|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
214649582|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
214649583|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
214649584|NCT03561402|DRUG|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
214649585|NCT06401863|OTHER|Shared Decision Making Tool|EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
214649586|NCT04610658|DRUG|Nivolumab|Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
214649587|NCT04610658|DRUG|Ipilimumab|Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
214649588|NCT04610658|DRUG|Lurbinectedin|Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)
214649589|NCT01097772|DEVICE|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
214649590|NCT02644226|OTHER|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
214649591|NCT02644226|OTHER|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
214649592|NCT01542645|DRUG|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
214649593|NCT01542645|DRUG|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
215031401|NCT01399645|DRUG|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
215031402|NCT06199752|DIETARY_SUPPLEMENT|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
215031403|NCT01799135|OTHER|DCE-MRI scan|
215031404|NCT01799135|RADIATION|Stereotactic Body Radiation Therapy|
215031405|NCT01799135|OTHER|4D-CT scan|
215031406|NCT05781451|DRUG|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
214817870|NCT04487691|BIOLOGICAL|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (\~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
214817871|NCT04487691|OTHER|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
214649594|NCT04644848|DIAGNOSTIC_TEST|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~* Round shape.~* Cortical thickness \> 3 mm~* Eccentric cortical thickness.~* Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
214649595|NCT04644848|PROCEDURE|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
214649596|NCT04644848|DIAGNOSTIC_TEST|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
214649597|NCT04644848|PROCEDURE|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
214649598|NCT02842931|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
214649599|NCT02842931|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
214649600|NCT02842931|DRUG|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
214649601|NCT02842931|DRUG|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
214649602|NCT05589142|BEHAVIORAL|Time Restricted Eating|Eating calories only during a specific feeding window.
214817872|NCT00448591|DRUG|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
214817873|NCT00448591|DRUG|Taxane-based chemotherapy|As prescribed
215031407|NCT02678377|DRUG|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
214649603|NCT01878630|DEVICE|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~\- electronic patient record (eHealth connect 2.0, T-Systems International)"
214649604|NCT01878630|OTHER|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
214649605|NCT04091893|BEHAVIORAL|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
214649606|NCT04091893|BEHAVIORAL|Art Rx|Individuals in this group participate in a specialized tour of an art museum
214649607|NCT04091893|BEHAVIORAL|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
214649608|NCT01224548|OTHER|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
214649609|NCT01224548|OTHER|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
214649610|NCT02714179|DRUG|Paracetamol was given intravenously in both group at different times|
214649611|NCT05693584|OTHER|distraction|diverting the patient's attention with virtual reality glasses
215031408|NCT02678377|DRUG|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
214649612|NCT01930786|DRUG|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
214649613|NCT00030082|DRUG|isolated perfusion|
214649614|NCT00030082|DRUG|melphalan|
214649615|NCT06055634|GENETIC|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
214649616|NCT02299193|BEHAVIORAL|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
214649617|NCT02299193|BEHAVIORAL|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
214649618|NCT00006417|PROCEDURE|Stem cell transplantation|
214649619|NCT02456584|DRUG|DMPA 150|injectable contraceptive
214649620|NCT02456584|DRUG|DMPA 300|injectable contraceptive
214649621|NCT02456584|DRUG|DMPA 104|injectable contraceptive
214649622|NCT03652909|DEVICE|Ascending Hearing Technologies device|Personal Sound Amplification Device
214649623|NCT04924127|DIAGNOSTIC_TEST|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
214649624|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
214649625|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
214649626|NCT02591615|DRUG|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
214649627|NCT02591615|DRUG|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
214649628|NCT02591615|DRUG|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
214649629|NCT02591615|DRUG|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
214649630|NCT03282747|BEHAVIORAL|no intervention|no intervention
214649631|NCT05424172|BEHAVIORAL|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
214649632|NCT05424172|BEHAVIORAL|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
214649633|NCT05424172|BEHAVIORAL|Stage-II, Groups 1a/2a: E-Coaching 1x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
214649634|NCT05424172|BEHAVIORAL|Stage-II, Groups 1b/2b: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
214649635|NCT06377566|DRUG|Brentuximab vedotin|Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle
214649636|NCT06377566|DRUG|Doxorubicin|Doxorubicin 25 mg/m\^2 IV
214649637|NCT06377566|DRUG|Vinblastine|Vinblastine 6 mg/m\^2 IV
214649638|NCT06377566|DRUG|Dacarbazine|Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle
214649639|NCT06377566|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV (flat) on day 1
214649640|NCT06377566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV (days 1 an
214649641|NCT06377566|DRUG|Vinorelbine|Vinblastine 6 mg/m\^2 IV
214649642|NCT06377566|DIAGNOSTIC_TEST|FDG-PET/CT scan|After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
214649643|NCT04188197|OTHER|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
214649644|NCT02107703|DRUG|Abemaciclib|Administered Orally
214649645|NCT02107703|DRUG|Fulvestrant|Administered IM
214649646|NCT02107703|DRUG|Placebo|Administered Orally
214649647|NCT01711242|DRUG|Capecitabine|
214649648|NCT01711242|DRUG|Oxaliplatin|
214649649|NCT01711242|RADIATION|Radiotherapy|
214649650|NCT06490861|DEVICE|Paragit|Sleeve to quantify symptoms
214649651|NCT04068857|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
214649652|NCT00770848|DRUG|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
214649653|NCT00770848|DRUG|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
214649654|NCT00770848|DRUG|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
214649655|NCT00770848|DRUG|Placebo|Placebo
214649656|NCT00770848|DRUG|Prednisone|5 mg orally BID
214649657|NCT03320655|OTHER|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
214649658|NCT03320655|OTHER|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
214649659|NCT02862314|BIOLOGICAL|Blood sample|
214649660|NCT00000979|DRUG|Zidovudine|
214649661|NCT00000979|DRUG|Didanosine|
214649662|NCT02933918|OTHER|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
214649663|NCT04574999|DRUG|Estriol|Gel for vaginal application
214649664|NCT04574999|OTHER|Placebo|Gel for vaginal application
214649665|NCT00192374|BIOLOGICAL|CAIV-T, Liquid|
214649666|NCT06075225|DRUG|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
214649667|NCT03631927|OTHER|Observation|Observation
214649668|NCT00746174|DRUG|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
214649669|NCT00746174|DRUG|Placebo|Placebo 1 tablet PO daily for 16 weeks
214649670|NCT03717376|OTHER|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
214649671|NCT03411395|DIETARY_SUPPLEMENT|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
214649672|NCT03411395|OTHER|Placebo drink|Placebo water with carbonation and aroma
214649673|NCT05739773|OTHER|five-element music therapy|music therapy
214649674|NCT02427282|DEVICE|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
214649675|NCT02427282|DEVICE|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
214649676|NCT02681666|DIETARY_SUPPLEMENT|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
214649677|NCT02681666|BEHAVIORAL|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
214649678|NCT04092842|DEVICE|Silicone prosthesis|Silicone prosthesis
214649679|NCT04092842|PROCEDURE|Usual practice|Usual surgery
214649680|NCT02948361|OTHER|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
214649681|NCT00008385|OTHER|placebo|Given orally
214649682|NCT00008385|DRUG|selenium|Given orally
214649683|NCT00398112|DRUG|sunitinib malate|Given orally
214649684|NCT00398112|OTHER|pharmacological study|Correlative studies
214649685|NCT00398112|OTHER|laboratory biomarker analysis|Correlative studies
214649686|NCT00595231|DRUG|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
214649687|NCT00595231|DRUG|Placebo|0 mg tablets
214649688|NCT02519114|PROCEDURE|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
214649689|NCT01823809|DEVICE|adenosine stress Cardiac Magnetic Resonance Imaging|
214649690|NCT00365989|DEVICE|ExAblate Enhanced Sonication|
214649691|NCT02318095|DRUG|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
214649692|NCT02318095|RADIATION|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
214649693|NCT02318095|OTHER|Sugical resection|Surgical resection of the pancreas post radiation therapy
214649694|NCT02318095|DRUG|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
214649695|NCT00686127|DRUG|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
214649696|NCT00686127|DRUG|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
214649697|NCT04852640|PROCEDURE|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
214649698|NCT04852640|PROCEDURE|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
214649699|NCT06441877|OTHER|No intervention|There is no intervention, this is an observationnal study.
214649700|NCT00066690|DRUG|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
214649701|NCT00066690|OTHER|Laboratory Biomarker Analysis|Correlative studies
214649702|NCT00066690|PROCEDURE|Oophorectomy|Undergo bilateral surgical oophorectomy
214649703|NCT00066690|OTHER|Quality-of-Life Assessment|Ancillary studies
214649704|NCT00066690|RADIATION|Radiation Therapy|Undergo ovarian irradiation
214649705|NCT00066690|DRUG|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
214649706|NCT00066690|DRUG|Triptorelin|3.75 mg by im injection q28 days for 5 years
214649707|NCT05421611|BIOLOGICAL|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
214817874|NCT02503527|OTHER|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
214817875|NCT02503527|OTHER|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
214817876|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
214649708|NCT05421611|BIOLOGICAL|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
214649709|NCT05337735|DRUG|XmAb20717|Given by vein (IV)
214649710|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
214649711|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
214649712|NCT04953871|DRUG|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
214649713|NCT05356767|PROCEDURE|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
214649714|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
214649715|NCT03580616|DRUG|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
214649716|NCT03706365|DRUG|Abemaciclib|Administered orally.
214649717|NCT03706365|DRUG|Placebo|Administered orally.
214649718|NCT03706365|DRUG|Abiraterone acetate|Administered orally.
214649719|NCT03706365|DRUG|Prednisone|Administered orally.
214649720|NCT05046028|DIETARY_SUPPLEMENT|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
214649721|NCT05046028|DIETARY_SUPPLEMENT|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
214817877|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
214649722|NCT05046028|DIETARY_SUPPLEMENT|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
214649723|NCT06428890|DIETARY_SUPPLEMENT|Grape Seed Extract|dietary supplements that rich in polyphenolic compounds
214649724|NCT06428890|DIETARY_SUPPLEMENT|Placebo|Starch
214649725|NCT02162862|BEHAVIORAL|Behavioral Counseling|
214649726|NCT02162862|DRUG|bupropion-SR|
214817878|NCT06626776|PROCEDURE|lateral sinus lift with using allograft and collagen membrane|sinus floor elevation with placing allograft and collagen membrane
214817879|NCT06626776|PROCEDURE|lateral sinus lift with using exteneded platelet rich fibrin|sinus floor elevation with placing eprf
214649727|NCT02594488|DEVICE|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
214649728|NCT03116113|BIOLOGICAL|BIIB112|Administered as specified in the treatment arm.
214649729|NCT06286423|DRUG|Colchicine 0.6 mg|Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
214817880|NCT01619891|DIETARY_SUPPLEMENT|Vitamin D|100mcg per day
214649730|NCT06286423|DRUG|Control/Placebo group|Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
214649731|NCT01286584|DRUG|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
214649732|NCT01286584|DRUG|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
214817881|NCT01890057|DRUG|Sugammadex|The dose of sugammadex
214649733|NCT06358014|DRUG|Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs|In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
214649734|NCT06358014|DRUG|SSRIs|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
214649735|NCT02200484|BEHAVIORAL|Combined parent training and obesity prevention program|
214649736|NCT02200484|BEHAVIORAL|Wellness program (active contact control)|
214649737|NCT03857789|OTHER|Questionnaire|A 40 question frailty questionnaire.
214649738|NCT00006227|DRUG|Paclitaxel|Given IV
214649739|NCT05495048|PROCEDURE|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
214649740|NCT05495048|PROCEDURE|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
214649741|NCT04426305|OTHER|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
214649742|NCT04426305|OTHER|care as usual|care as usual is provided by professional primary care provider
214649743|NCT02159807|DRUG|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
214649744|NCT02159807|DRUG|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
214649745|NCT02319902|DEVICE|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
214649746|NCT02319902|DEVICE|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
214649747|NCT05195528|DRUG|Vonoprazan|Orally via capsule
214649748|NCT05195528|DRUG|Placebo|Orally via capsule
214649749|NCT03892837|PROCEDURE|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
214649750|NCT03892837|PROCEDURE|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
214649751|NCT04856592|DEVICE|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
214649752|NCT04856592|DEVICE|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
214649753|NCT01485978|DRUG|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
214649754|NCT01485978|DRUG|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
214649755|NCT01485978|DRUG|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
214649756|NCT05312957|OTHER|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
214649757|NCT01100489|RADIATION|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
214649758|NCT01100489|OTHER|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
214649759|NCT01100489|PROCEDURE|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
214649760|NCT00930202|DRUG|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
214649761|NCT01552902|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
214649762|NCT01552902|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
214649763|NCT01552902|DRUG|Placebo|Daily oral dosing in the AM for 6 weeks
214649764|NCT00878124|DIETARY_SUPPLEMENT|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
214649765|NCT00878124|OTHER|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
214649766|NCT00722293|DRUG|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
214649767|NCT00722293|DRUG|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
214649768|NCT00722293|DRUG|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
214649769|NCT06411093|COMBINATION_PRODUCT|Kinesiology tape wrapping|Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months
214649770|NCT06411093|DRUG|Conventional treatment including silver nitrate cauterization|Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
214649771|NCT00452803|DRUG|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
214649772|NCT00452803|DRUG|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
214649773|NCT00452803|RADIATION|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
214649774|NCT02828176|PROCEDURE|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
214649775|NCT02828176|PROCEDURE|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
214649776|NCT02828176|PROCEDURE|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
214649777|NCT02828176|PROCEDURE|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
214649778|NCT05130008|OTHER|Digitally-enabled CHW Care|Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
214649779|NCT05130008|BEHAVIORAL|Usual CHW Care|Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
214649780|NCT03742778|BEHAVIORAL|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
214649781|NCT03742778|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
214649782|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
214649783|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
214649784|NCT02588456|BIOLOGICAL|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
214649785|NCT03006783|PROCEDURE|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
214649786|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
214649787|NCT05136833|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
214649788|NCT05136833|BIOLOGICAL|Placebo|Normal saline will be used as a placebo.
214649789|NCT02487108|DRUG|TV-46763|TV-46763 will be administered per dose and schedule specified in the arm description.
214649790|NCT02487108|DRUG|Placebo|Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
214649791|NCT04848077|BEHAVIORAL|Step count increase with the use of a motivational smartphone application|All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
214649792|NCT06960148|DRUG|CSPR Toothpaste|a commercially available 8% arginine toothpaste
214649793|NCT06960148|DRUG|Colgate Dental Cream Toothpaste|a commercially available fluoride toothpaste
214649794|NCT06960746|BEHAVIORAL|lifestyle changing plus CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group (CPAP will be applied in this group that will contain 20 males, CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks plus lifestyle changes that will contain 3-session per-week 40-minute treadmill exercising and low-caloric/dietary 12-week restriction.
214649795|NCT06960746|OTHER|CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group. in this group CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks
214817882|NCT01631383|DRUG|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
214649796|NCT06960785|DEVICE|MEL90 excimer laser - PRESBYOND|"Participants will undergo laser eye surgery in both eyes using the PRESBYOND method. First, a thin flap is created on the surface of the eye using a femtosecond laser. Then, a second laser (excimer laser) reshapes the cornea to improve vision at near, intermediate, and far distances.~The treatment is similar to monovision techniques, where one eye is mainly corrected for distance and the other for near vision. However, PRESBYOND differs by adjusting the depth of focus in each eye individually, allowing the brain to better combine the two images in the intermediate range-this area is called the Blend Zone. This approach helps preserve natural binocular (3D) vision, contrast sensitivity, and depth perception. Most patients adapt well and quickly to this type of correction. The procedure is customized based on each patient's age and eye characteristics."
214649797|NCT06960005|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|Participants will engage in one-hour exercise sessions twice weekly for 26 weeks: one day of RYMA training and one day of ADL-based training
214649798|NCT06960278|PROCEDURE|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.
214649799|NCT06960278|PROCEDURE|Control|The dimensions of the lesion were measured by oral medicine specialists using a flexible ruler
214649800|NCT06960278|DEVICE|ALUMSTONE|alum administration via adhesive patches on the healing process of aphthous ulcers
214649801|NCT06960161|DEVICE|Phototherapy|Phototherapy
214649802|NCT06960044|PROCEDURE|Procalcitonin-guided antibiotic management|After the randomization, PCT plasma concentration will be dosed and repeated every 24 hours and antimicrobial treatment will be withdrawn as soon as the PCT value will decrease \> 80% of peak value or will fall below 0.25 ng/mL. Patients with a normal baseline PCT value (below 0.25 ng/mL) will start the antimicrobial therapy, as clinically appropriate and PCT plasma concentration will be repeated every 24 hours, as indicated in the protocol. The antimicrobial agents will be managed according to the clinical and radiological evolution of the LRTI.
214649803|NCT06960044|PROCEDURE|Standard of care|Patients assigned to the control group will be treated according to the best standard of care and PCT will not be evaluated for the whole duration of the study.
214649804|NCT06960876|PROCEDURE|Therapeutic Ultrasound|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This Group will additionally receive a therapeutic Ultrasound over the maxillary sinus.
214649805|NCT06960876|PROCEDURE|Sinus Massage|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will additionally receive, sinus massage (pressure \& milking)
214649806|NCT06960876|PROCEDURE|Control group|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will not receive any other adjunct physical therapy treatment (control group)
214649807|NCT06960304|OTHER|Physical exercise program|Evaluation of AVF maturation using clinical and ultrasound criteria, after applying a structured physical exercise program.
214649808|NCT06959719|PROCEDURE|Air Entrainment - intentional introduction of the atmospheric air into the pleural space.|This intervention is distinct in that it uses a standard 3-way tap, already present in routine pleural drainage procedures, to intentionally introduce atmospheric air into the pleural space in a controlled and repeatable manner. Unlike other studies where air entrainment may occur incidentally or as part of more invasive procedures, this method specifically utilises precise manipulation of the tap handle to allow intermittent air entry, aiming to reduce negative intrapleural pressure and associated pain during fluid drainage. Air entry is carefully controlled, can be repeated up to five times per procedure, and does not interfere with fluid drainage or introduce additional equipment or complexity.
214649809|NCT06960343|PROCEDURE|magnetic resonance imaging (MRI)|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and an MRI of the operated shoulder will also be performed.
214649810|NCT06960343|OTHER|VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and a clinical evaluation will be performed using the following measurements and scores: VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction.
214649811|NCT06959875|BEHAVIORAL|High-Fidelity Simulation-Based Therapeutic Communication Training|This intervention involves a structured, high-fidelity simulation scenario in a clinical skills lab setting using mannequins and standardized patients. The scenario focuses on communication with a patient experiencing perinatal loss. The session includes pre-briefing, simulation, and debriefing components.
214649812|NCT06959875|BEHAVIORAL|Paper-Pencil Simulation-Based Therapeutic Communication Training|This intervention utilizes a written clinical case scenario related to perinatal loss. Students read the scenario and write appropriate therapeutic communication responses, followed by group discussion and instructor feedback. The focus is on reflection and theoretical integration.
214649813|NCT06960200|DEVICE|Phototherapy|Non-surgical laser therapy (phototherapy)
214649814|NCT06960837|BEHAVIORAL|ultrasound simulation training case-based workshop during resident sim days|Using the CAE Vimedix ultrasound simulator or standardized patient, a patient stem will be read or video shown to an individual participant. The participant will have 10 minutes to discuss the scenario and scan the simulator/patient. Participants will verbalize their findings and receive additional information, including diagnostic tests or point-of-care ultrasound (POCUS) videos, as they proceed through the case. They will be scored using a standardized rubric. For Objective Structured Clinical Exam (OSCE) testing, two independent raters, both with ultrasound fellowship training, one known to the participants and one unknown to the participants, will observe and rate the participant on a simulated POCUS case using the already published OSCE tool. The rater will read a brief standardized stem, and the participant will have 10 minutes to complete the station.
214649815|NCT06960356|OTHER|detect post-traumatic stress disorder|recommendation for follow-up by a professional specializing in child development and/or a complementary medical consultation
214649816|NCT06960733|DEVICE|Winged plastic stent|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention winged stents were used.
214649817|NCT06960733|DEVICE|Standard plastic stents|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention standard plastic stents were used.
214649818|NCT06960798|OTHER|Bio-specimen Collection|Tissue samples will be taken from existing archived collections and sent for further analysis.
214649819|NCT06960798|OTHER|Blood Draw|Blood samples will be collected within the first year of enrollment.
214649820|NCT06961045|PROCEDURE|Guided Inferior Alveolar Nerve Lateralization with Simultaneous Implant Placement|All patients will be operated on under general anesthesia. A para-crestal incision will be done and a mucoperiosteal flap will be reflected exposing the alveolar ridge and the buccal cortex. The surgical guide will be fitted and fixed in place and the outline of the window will be drawn by the aid of the surgical guide using the piezotome then the guide will be removed. Once the osteotomy is completed the bone window will be mobilized for exposure of the neurovascular bundle. The diamond tips will be used for removal of any remaining bone around the nerve. The neurovascular bundle will be dissected and retracted properly. a surgical guide will be inserted for implant osteotomy. The bone block which was removed for the buccal window will be crushed to be particulates and will be mixed with autologous fibrin glue for preparation of sticky bone, the sticky bone will be packed gently in the window area around the neurovascular bundle then will be covered by platelet rich fibrin.
214817883|NCT01631383|DRUG|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
214649821|NCT06959797|DEVICE|Closed loop|Ypsomed pump (Ypsomed), CamAPS HX application activated, Android smartphone. Freestyle 3 sensors (Abbott)
214817884|NCT03375047|DRUG|MRT5005|Nebulization of MRT5005
214817885|NCT03375047|DRUG|Normal saline|Normal Saline for Inhalation
214649822|NCT06959797|DEVICE|Open loop|Ypsomed pump (Ypsomed). Android smartphone. Freestyle 3 sensors (Abbott)
214817886|NCT02865005|DRUG|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
214817887|NCT02865005|OTHER|Placebo|Topical Gel
214817888|NCT02865005|DRUG|Dapsone 5.0% Gel (Allergan)|Topical Gel
214649823|NCT06960551|OTHER|ınfertility group|"Before starting the project, the couples in the experimental group will be informed about the mobile application. The women will use the mobile application weekly for 3 months.~4 times for at least 15 minutes each. To create motivation for use, women in the experimental group will be asked to motivational notification will be sent via the mobile application."
214817889|NCT05183503|DIAGNOSTIC_TEST|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
214649824|NCT06960551|OTHER|control group|Women in the control group will not receive any intervention. After collecting the post-test data in the project, the principle of benefit and equality Taking this into account, women and their husbands participating in the control group will be given the opportunity to use the mobile application free of charge for three months.
214649825|NCT01808352|OTHER|Observational|HPTN 073 is an observational study in MSM in the United States
214649826|NCT05926219|BEHAVIORAL|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
214649827|NCT01254669|BEHAVIORAL|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
214649828|NCT01571063|DRUG|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
214649829|NCT01571063|DRUG|Placebo|Placebo Tbl. p.o.
214649830|NCT00600171|DRUG|GW642444M|GW642444M
214649831|NCT00600171|DRUG|Placebo|Placebo mulit-dose dry powder inhaler
214649832|NCT02367521|COMBINATION_PRODUCT|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
214649833|NCT02367521|DEVICE|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
214649834|NCT02104414|DRUG|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
214649835|NCT02104414|DRUG|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
214649836|NCT02104414|DRUG|Normal Saline|30mL Normal Saline
214649837|NCT00891514|BEHAVIORAL|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
214649838|NCT00891514|BEHAVIORAL|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
214649839|NCT00469612|DEVICE|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
214649840|NCT00542191|DRUG|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
214649841|NCT00542191|PROCEDURE|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
214649842|NCT00542191|RADIATION|Radiotherapy|Standard of care RADIATION THERAPY as indicated
214649843|NCT01596179|BEHAVIORAL|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
214649844|NCT01596179|BEHAVIORAL|Internet access|a netbook computer with internet access is provided to participants on the control arm.
214649845|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
214649846|NCT04888481|DRUG|68Ga-HA-DOTATATE|Tracer injection
214649847|NCT00970606|DRUG|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
214649848|NCT00970606|DRUG|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
214649849|NCT00103012|DRUG|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
214649850|NCT00103012|DRUG|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
214649851|NCT00103012|DRUG|Panax ginseng|Panax ginseng 500 mg twice daily
214817890|NCT03590782|OTHER|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
214817891|NCT04533295|DEVICE|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
214817892|NCT04533295|DEVICE|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
214649852|NCT00430755|DEVICE|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
214649853|NCT00430755|PROCEDURE|physician taken history|Convential history taking by physicians
214649854|NCT00430755|OTHER|Computer-assisted history taking|
214649855|NCT03258892|OTHER|Educational Intervention|Receive STG
214649856|NCT03258892|OTHER|Quality-of-Life Assessment|Ancillary studies
214649857|NCT03258892|OTHER|Survey Administration|Ancillary studies
214649858|NCT02300493|BEHAVIORAL|Experimental|Asked to weigh themselves
214649859|NCT01790490|DRUG|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
214649860|NCT01790490|DRUG|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
214649861|NCT01790490|DRUG|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
214649862|NCT05470127|DEVICE|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
214649863|NCT05261269|DRUG|DAN-222|Administered IV every week to subjects
214649864|NCT05261269|DRUG|Niraparib|Administered orally once daily
214649865|NCT05167786|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
214649866|NCT05167786|DEVICE|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
214649867|NCT05167786|OTHER|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
214649868|NCT00847327|BEHAVIORAL|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
214649869|NCT00847327|BEHAVIORAL|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
214649870|NCT05276661|DIETARY_SUPPLEMENT|TAC/Collagen gel|Apply it twice per day for 4 weeks
214649871|NCT05276661|DIETARY_SUPPLEMENT|placebo lotion|Apply it twice per day for 4 weeks
214649872|NCT02932787|DEVICE|Height-adjustable workstation|
214649873|NCT00250510|BEHAVIORAL|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
214649874|NCT04024800|BIOLOGICAL|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in \> 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
214649875|NCT04024800|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
214649876|NCT01621685|BIOLOGICAL|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
214649877|NCT01721499|BEHAVIORAL|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
214649878|NCT01721499|BEHAVIORAL|Mindfulness Intervention|
214649879|NCT01944709|BIOLOGICAL|Dendritic cell application|
214649880|NCT03904797|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|"Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team."
214649881|NCT06549361|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
214649882|NCT04684420|DRUG|Glucophage® XR RM Test|Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
214649883|NCT04684420|DRUG|Glucophage® XR Reference|Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
214649884|NCT00450944|BIOLOGICAL|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
214649885|NCT05997355|DRUG|Gabapentin 600Mg Tab|A single preoperative dose of gabapentin 600mg
214649886|NCT03346174|OTHER|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
214649887|NCT03346174|OTHER|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
214649888|NCT00008190|BIOLOGICAL|aldesleukin|
214649889|NCT00008190|BIOLOGICAL|filgrastim|
214649890|NCT00008190|DRUG|busulfan|
214649891|NCT00008190|DRUG|cyclophosphamide|
214649892|NCT00008190|DRUG|etoposide|
214649893|NCT00008190|DRUG|melphalan|
214649894|NCT00008190|PROCEDURE|peripheral blood stem cell transplantation|
214649895|NCT00254410|DRUG|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
214649896|NCT00254410|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
214649897|NCT00254410|DRUG|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
214649898|NCT00254410|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
214649899|NCT00254410|DRUG|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
214649900|NCT03728387|OTHER|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
214649901|NCT00739284|DEVICE|nephrostomy tube and ureteral stent|
214649902|NCT04329221|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
214649903|NCT04329221|DRUG|Vaseline|Placebo
214649904|NCT04329221|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
214649905|NCT00166855|PROCEDURE|dynamic MRI and bone marrow sampling|
214649906|NCT03480802|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
214649907|NCT03480802|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
214649908|NCT03480802|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
214649909|NCT03015103|DEVICE|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
214649910|NCT02243228|DRUG|GM-CSF|
214649911|NCT03281642|OTHER|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
214649912|NCT00635973|DRUG|Gefitinib (Iressa)|Iressa
214649913|NCT05427578|OTHER|fNIRS measurement|measurement using functional near-infrared spectroscopy
214649914|NCT01690845|DEVICE|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
214649915|NCT03115996|DRUG|REGN3918|Intravenous (IV) or Subcutaneous (SC)
214649916|NCT03115996|DRUG|Placebo|Matching Placebo
214649917|NCT03358914|OTHER|No intervention|Completion of surveys
214649918|NCT03822884|DRUG|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
214649919|NCT02620904|DRUG|Mifepristone|
214649920|NCT02620904|DRUG|placebo|
214649921|NCT02633371|DRUG|Oxybutynin 3% gel|
214649922|NCT01742260|PROCEDURE|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
214649923|NCT02557178|BEHAVIORAL|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
214649924|NCT01202461|PROCEDURE|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
214649925|NCT03990870|OTHER|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
214649926|NCT03990870|OTHER|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
214649927|NCT05222321|OTHER|Sensory-Play Based (SenPlay) Intervention|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
214649928|NCT05222321|OTHER|Spontaneous, Free Play|Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
214649929|NCT03420560|BEHAVIORAL|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
214649930|NCT05395221|OTHER|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
214649931|NCT05850845|DEVICE|Microscopic hyperspectral imaging system|CTX for idiopathic membranous nephropathy
214649932|NCT04351802|DIAGNOSTIC_TEST|Lung ultrasound|Focused lung ultrasound examination
214649933|NCT00126165|PROCEDURE|radiotherapy|
214649934|NCT01214486|DRUG|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
214649935|NCT01989221|DRUG|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
214649936|NCT03454373|BEHAVIORAL|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
214649937|NCT00976144|DRUG|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
214649938|NCT05450614|OTHER|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
214649939|NCT05450614|BEHAVIORAL|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
214649940|NCT05996796|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
214649941|NCT05996796|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
214649942|NCT02308644|DRUG|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
214649943|NCT00789633|DRUG|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
214649944|NCT00789633|DRUG|Placebo|Matching placebo given orally twice daily
214649945|NCT00789633|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
214649946|NCT02144779|BEHAVIORAL|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
214649947|NCT02144779|BEHAVIORAL|Usual Care|usual hospital care, not assigned to palliative care team
214649948|NCT03354689|RADIATION|Scintigraphy|Scintigraphy
214649949|NCT00917436|DRUG|Thiocolchicoside|
214649950|NCT06001567|DRUG|Avatrombopag|Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
214649951|NCT01762514|DRUG|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
214649952|NCT01762514|DRUG|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
214649953|NCT02834910|OTHER|collection of bacterial sample|
214649954|NCT05731921|BEHAVIORAL|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
214649955|NCT02970617|OTHER|Memory Intervention|Ring bell after final radiation treatment
214649956|NCT02970617|OTHER|Questionnaire Administration|Ancillary studies
214649957|NCT02970617|RADIATION|Radiation therapy|Radiation therapy with or without chemotherapy
214649958|NCT01279057|DRUG|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
214649959|NCT01279057|DRUG|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
214649960|NCT01279057|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
214649961|NCT00670826|DEVICE|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
214649962|NCT00670826|DEVICE|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
214649963|NCT00967265|BEHAVIORAL|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
214649964|NCT00967265|OTHER|Usual care|Usual care
214649965|NCT01196442|OTHER|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
214649966|NCT01196442|OTHER|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
214649967|NCT06130332|DRUG|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
214649968|NCT06130332|PROCEDURE|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
214649969|NCT00287742|DRUG|risperidone|
214649970|NCT01736904|DRUG|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
214649971|NCT01736904|DRUG|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
214649972|NCT03949907|OTHER|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
214649973|NCT03949907|OTHER|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
214649974|NCT01427309|BIOLOGICAL|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
214649975|NCT01427309|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
214649976|NCT05140057|COMBINATION_PRODUCT|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
214649977|NCT02750059|DRUG|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
214649978|NCT02750059|DRUG|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
214649979|NCT03644628|PROCEDURE|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
214649980|NCT01362582|DRUG|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
214649981|NCT02508155|BIOLOGICAL|MEDI7352 for IV infusion|MEDI7352 for IV infusion
214649982|NCT02508155|BIOLOGICAL|Placebo for IV infusion|IV Placebo infusion
214649983|NCT02508155|BIOLOGICAL|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
214649984|NCT02508155|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
214649985|NCT01068444|DRUG|Pioglitazone|"1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months"
214649986|NCT01068444|DRUG|placebo|placebo 30 mg/d for 6 months
214649987|NCT01835184|DRUG|cabozantinib-s-malate|Given PO
214649988|NCT01835184|DRUG|vemurafenib|Given PO
214649989|NCT01835184|OTHER|laboratory biomarker analysis|Correlative studies
214649990|NCT01835184|OTHER|pharmacological study|Correlative studies
214649991|NCT01935895|BEHAVIORAL|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
214649992|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
214649993|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
214649994|NCT06391645|DRUG|Nerve Growth Factor|intravenously injection
214649995|NCT04232826|BIOLOGICAL|single dose of CNCT19|"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
214649996|NCT03445702|DRUG|Metformin|Metformin 1000mg once
214649997|NCT03445702|DRUG|Placebo|Sugar pill manufactured to mimic metformin 1000mg
214649998|NCT00002113|DRUG|Flucytosine|
214649999|NCT00002113|DRUG|Fluconazole|
214817893|NCT02375386|PROCEDURE|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
214650000|NCT03168516|DEVICE|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
214650001|NCT04726332|DRUG|XL102|oral doses of XL102
214650002|NCT04726332|DRUG|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
214650003|NCT04726332|DRUG|Abiraterone|abiraterone 1000 mg administered orally once daily.
214650004|NCT04726332|DRUG|Prednisone|prednisone 5 mg administered orally twice daily.
214650005|NCT05464017|DEVICE|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
214650006|NCT03374280|DRUG|pemetrexed/cisplatin intercalating gefitinib|
214650007|NCT03374280|DRUG|pemetrexed/cisplatin|
214650008|NCT04030078|OTHER|Survey|Questionnaire-based survey
214650009|NCT00849017|BIOLOGICAL|albiglutide|albiglutide weekly injection
214650010|NCT00849017|BIOLOGICAL|albiglutide uptitration|albiglutide uptitration at week 12
214650011|NCT00849017|BIOLOGICAL|placebo|matching albiglutide placebo weekly injection
214650012|NCT04681092|BIOLOGICAL|AKS-452|s.c. or i.m. vaccination
214650013|NCT02022605|DEVICE|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
214650014|NCT02022605|OTHER|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
214650015|NCT01941589|DRUG|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
214650016|NCT01941589|DRUG|corticosteroids only|IV corticosteroids only
214650017|NCT01767402|BIOLOGICAL|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
214650018|NCT01767402|BIOLOGICAL|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
214650019|NCT01767402|BIOLOGICAL|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
214650020|NCT05905796|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
214650021|NCT01604746|BIOLOGICAL|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
214650022|NCT02571348|PROCEDURE|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
214650023|NCT05655117|OTHER|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
214650024|NCT02844855|BEHAVIORAL|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
214650025|NCT04279197|DRUG|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
214650026|NCT04279197|DRUG|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
214650027|NCT04279197|DRUG|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
214650028|NCT04279197|OTHER|respiratory function rehabilitation training|Health exercise, once a day
214650029|NCT05327699|DRUG|Ketamine|A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
214650030|NCT05327699|OTHER|Placebo|A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
214650031|NCT01841619|DRUG|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
214650032|NCT04807894|DRUG|Vaginal Cream with Applicator|Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
214650033|NCT06960122|PROCEDURE|Fecal Microbiota Transplant (FMT)|One course of fecal microbiota transplantation (FMT) was administered in addition to standard therapy.
214650034|NCT06960122|OTHER|Standard Therapy|Standard Therapy Alone
214650035|NCT06959784|DRUG|semaglutide|The semaglutide intervention group received semaglutide (0.25 mg qw initially, increased to 0.5 mg qw after four weeks) for 24 weeks (6 months).
214650036|NCT06959784|DRUG|Metformin|The metformin control group was treated with metformin (gradually increasing to 1g bid) for 24 weeks (6 months)
214650037|NCT03962309|OTHER|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
214650038|NCT01695421|PROCEDURE|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
214650039|NCT01695421|PROCEDURE|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
214650040|NCT01695421|PROCEDURE|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
214650041|NCT01695421|PROCEDURE|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
214650042|NCT03625388|DRUG|Dasatinib|Film coated tablet contains dasatinib monohydrate
214650043|NCT00511043|DRUG|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
214650044|NCT04119570|BEHAVIORAL|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
214650045|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214650046|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
214650047|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
214650048|NCT00544830|DRUG|Bicalutamide|Given PO
214650049|NCT00544830|DRUG|Goserelin Acetate|Given SC
214650050|NCT00544830|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214650051|NCT00544830|OTHER|Laboratory Biomarker Analysis|Correlative studies
214650052|NCT00544830|DRUG|Leuprolide Acetate|Given via injection
214650053|NCT04933123|DEVICE|indirect restorative treatment with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
214650054|NCT06325007|DIETARY_SUPPLEMENT|Induction of labor|The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
214650055|NCT01548261|PROCEDURE|Donating oral mucosal cells|Donating oral mucosal cells
214650056|NCT05242822|DRUG|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
214650057|NCT05536375|OTHER|Exhaled breath condensate collection and blood draw|"Venepuncture- 10mls of blood to be collected~and~Exhaled breath condensate (EBC) collection method- this involved breathing in and out through a disposable device (akin to breathing onto cold glass to produce condensate) with an external cooler device. The R Tube starter kit is a complete disposable EBC collection kit and It has been used in many research clinical investigations."
214650058|NCT06542640|DEVICE|Mb-rt-fMRI-NFB|The MRI and TMS interventions described below will yield measures of change in the targeted brain regions in post- relative to pre- intervention comparisons. These change measures will be compared relative to changes in the sham/control group and the HC group. Furthermore, they will be compared to HC to assess improvement or normalization of brain function in the targeted brain regions. In addition, the investigators will examine treatment effects on traditional biomarkers that are likely to be impacted by such interventions: ERP, NP and NLP measures. Here, mindfulness meditation practiced during a real-time fMRI NFB session will be used to bring connectivity changes to brain structures involved in positive psychiatric symptoms (e.g. attenuated psychotic symptoms) in order to to reduce them.
214650059|NCT06542640|DEVICE|Sham mb-rt-fMRI-NFB|Individuals with CHR who are randomly assigned to this arm will receive mb-rt-fMRI-NFB, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
214650060|NCT06542640|DEVICE|rTMS|In previous work, the investigators used a multivariate pattern analysis to identify functional connectivity correlates of negative symptom severity in a schizophrenia (SZ) group. DLPFC-cerebellum hypo-connectivity was strongly correlated with negative symptoms. In a separate SZ cohort, the investigators used rTMS targeting the cerebellum to manipulate this circuit. The rTMS-induced increase in functional connectivity in a cerebellar-midbrain-DLPFC circuit was strongly linked to negative symptom severity reduction. Furthermore, individuals varied in the degree of change in functional connectivity in response to rTMS. This variation strongly predicted variation in post-rTMS symptom severity. The investigators predict that rTMS based intervention, but not sham rTMS, will similarly impact the cerebellar-midbrain-dorsolateral prefrontal cortex (DLPFC) network in the CHR group receiving real but not sham rTMS.
214650061|NCT06542640|DEVICE|Sham rTMS|Individuals with CHR who are randomly assigned to this arm will receive rTMS, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
214650062|NCT05254418|DRUG|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
214650063|NCT05579717|BEHAVIORAL|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
214650064|NCT01320605|BIOLOGICAL|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
214650065|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
214650066|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
214650067|NCT06213909|OTHER|This is a retrospective analysis of health data from inpatient record, no intervention was designed|This is a retrospective analysis of health data from inpatient record, no intervention was designed
214650068|NCT05547698|PROCEDURE|Off-pump lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
214650069|NCT05547698|PROCEDURE|Venoarterial ECMO lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
214650070|NCT03247634|BEHAVIORAL|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
214650071|NCT01538485|DRUG|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
214650072|NCT00983411|OTHER|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
214650073|NCT06499922|PROCEDURE|SURGICAL EXCISION|surgical excision of low grade glioma
214650074|NCT00955773|DRUG|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
214650075|NCT03931304|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
214650076|NCT02940067|OTHER|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
214650077|NCT01111305|DRUG|Reslizumab|
214650078|NCT01111305|DRUG|Diethylcarbamazine|
214650079|NCT01111305|OTHER|Placebo|
214650080|NCT03624946|BIOLOGICAL|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
214650081|NCT03624946|OTHER|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
214650082|NCT02909894|OTHER|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
214650083|NCT02909894|OTHER|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
214650084|NCT00379951|DRUG|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
214650085|NCT00818376|OTHER|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
214650086|NCT04856657|DEVICE|Transcranial alternating current stimulation|The tACS will be applied with a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (25 cm²) applied to the back of the head. The anode will be located at Oz and the cathode will be located at Cz.
214650087|NCT06075381|COMBINATION_PRODUCT|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
214650088|NCT06075381|PROCEDURE|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
214650089|NCT03992144|DRUG|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
214650090|NCT03992144|DRUG|metronidazole 400mg|400mg of metronidazole an hour before extraction
214650091|NCT03992144|DRUG|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
214650092|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
214650093|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
214650094|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
214650095|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
214650096|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
214650097|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt|Intake of yoghurt during 4 weeks
214650098|NCT03711604|DRUG|Tenalisib|BID Orally
214650099|NCT01869348|BEHAVIORAL|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
214650100|NCT00130715|DEVICE|Seprafilm Bioresorbable Membrane|
214650101|NCT00624520|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
214650102|NCT00624520|OTHER|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
214650103|NCT02688348|OTHER|Quality-of-Life Assessment|Ancillary studies
214650104|NCT02688348|OTHER|Questionnaire Administration|Ancillary studies
214650105|NCT04905667|DRUG|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
214650106|NCT04905667|DRUG|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
214650107|NCT00370201|DRUG|colchicine|
214650108|NCT00216723|DRUG|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
214650109|NCT03075163|PROCEDURE|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
214650110|NCT03075163|DRUG|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
214650111|NCT05460039|OTHER|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
214650112|NCT02865382|PROCEDURE|white light was used for colonoscopy withdrawal|
214650113|NCT02865382|PROCEDURE|OE mode was used for colonoscopy withdrawal|
214650114|NCT01925209|DRUG|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
214650115|NCT01925209|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
214650116|NCT05774327|OTHER|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
214650117|NCT05774327|OTHER|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
214650118|NCT02796755|DRUG|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
214650119|NCT02796755|DRUG|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
214650120|NCT05014477|PROCEDURE|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
214650121|NCT02318758|DRUG|UT-15C|sustained release oral treprostinil
214650122|NCT02318758|OTHER|ethanol|Absolut 100 vodka
214650123|NCT00397332|DRUG|Alefacept|IM Alefacept
214650124|NCT05640401|DEVICE|Endoscopy guided by mixed reality (HoloLens2TM) (HXtend™ software)|"Included expert gastrointestinal endoscopists performing diagnostic procedures with mixed reality guidance. All the procedures will be performed by using the HoloLens2TM (Microsoft, Redmond, WA, USA), an ergonomic self-contained holographic device.~HoloLens2TM (Microsoft, Redmond, WA, USA) uses HXtend™ developed software (mdconsgroup, Guayaquil, Ecuador) installed and running on Windows holographic OS. The monitors signals are replicated into holograms by an app developed with the unity Software package (Version 2022.1.22, Unity Technologies, San Francisco, CA, USA).~After each procedure, the researchers will evaluate the device performance along with the acceptance and experience of the endoscopists using this technology."
214650125|NCT01487369|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
214650126|NCT05119803|DEVICE|Spinal Mouse (IDIAG M360 )|This device is an electronic computer-aided measuring december that measures the range of motion of the spine, evaluates the angle and shape of the spine in the sagittal and frontal planes. The device provides data to the computer via Bluetooth, and the measured curvatures are displayed on the computer screen. The method has no medical risks or dangers. The device has two rotating wheels that follow the spinous protrusions of the spine, and the distance and angle measurements are transferred from the device to the computer.
214650127|NCT05119803|OTHER|Nine Hole Peg Test|The nine-hole peg test is a simple, fast and manual skill test that has been proven to be valid and reliable in measuring upper limb function in Parkinson's patients. While the patient is sitting, he is asked to insert nine sticks into the holes of the test box with nine holes one by one as fast as possible and remove them back when he is finished
214650128|NCT04704622|DRUG|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
214650129|NCT04704622|DRUG|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
214650130|NCT04704622|DRUG|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
214650131|NCT05764148|BEHAVIORAL|behavioral activation|"Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions."
214650132|NCT00675025|DRUG|Donepezil hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
214650133|NCT01361841|DRUG|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
214650134|NCT01361841|DRUG|travoprost, latanoprost and bimatoprost|one drop once a day for life
214650135|NCT01561651|OTHER|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
214650136|NCT00110994|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
214650137|NCT00110994|DRUG|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
214650138|NCT00110994|DRUG|Dacarbazine|Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
214650139|NCT00150098|BEHAVIORAL|Enhanced HIV risk reduction and HIV vaccine education|
214650140|NCT06160401|DRUG|Singletine|Singletine orally administered
214650141|NCT06160401|DRUG|Placebo|Placebo orally administered
214650142|NCT01845545|OTHER|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
214650143|NCT00294944|DRUG|Idazoxan|
214650144|NCT02002702|DRUG|Serelaxin|Intravenous infusion
214650145|NCT02002702|DRUG|Placebo|Placebo
214650146|NCT01845714|PROCEDURE|Corneal Cross Linking|
214650147|NCT01845714|PROCEDURE|Corneal Cross Linking combined with topoguided PRK|
214650148|NCT06485193|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of archived diagnostic tissue samples.
214650149|NCT06028633|DRUG|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
214650150|NCT06028633|DRUG|lenvatinib|lenvatinib 8mg taken orally every day
214650151|NCT06028633|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
214650152|NCT01672931|OTHER|Oocyte Measurement|
214650153|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
214650154|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
214650155|NCT05177055|OTHER|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
214650156|NCT00080847|BIOLOGICAL|oblimersen sodium|Given IV
214650157|NCT00080847|BIOLOGICAL|rituximab|Given IV
214650158|NCT00080847|DRUG|cyclophosphamide|Given IV
214650159|NCT00080847|DRUG|doxorubicin hydrochloride|Given IV
214650160|NCT00080847|DRUG|vincristine sulfate|Given IV
214650161|NCT00080847|DRUG|prednisone|Given orally
214650162|NCT00080847|OTHER|laboratory biomarker analysis|Correlative studies
214650163|NCT00460980|BEHAVIORAL|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
214650164|NCT00953394|DRUG|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
214650165|NCT01804231|OTHER|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
214650166|NCT00974220|DRUG|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
214650167|NCT00974220|DRUG|normal saline (placebo)|single dose, 0.9% saline solution
214650168|NCT03806244|OTHER|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
214650169|NCT00004899|BIOLOGICAL|filgrastim|
214650170|NCT00004899|DRUG|busulfan|
214650171|NCT00004899|DRUG|etoposide|
214650172|NCT00004899|PROCEDURE|autologous bone marrow transplantation|
214650173|NCT02135380|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
214650174|NCT02135380|BIOLOGICAL|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
214650175|NCT02135380|OTHER|Control|Standard Therapy
214650176|NCT04399083|DIETARY_SUPPLEMENT|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
214650177|NCT05351658|DEVICE|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
214650178|NCT01176916|DRUG|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
214650179|NCT02363075|DRUG|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
214650180|NCT02363075|DRUG|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
214650181|NCT03891147|OTHER|Electro-acupuncture|
214650182|NCT03158220|BIOLOGICAL|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
214650183|NCT01896960|DRUG|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
214650184|NCT02299960|DEVICE|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
214650185|NCT02299960|DEVICE|NICOM|Non-invasive measurement of cardiac output
214650186|NCT00622895|DRUG|fludarabine phosphate|Given IV
214650187|NCT00622895|DRUG|Mycophenolic Acid|Given PO
214650188|NCT00622895|DRUG|tacrolimus|Given PO
214650189|NCT00622895|RADIATION|total-body irradiation|Undergo TBI
214650190|NCT00622895|PROCEDURE|bone marrow transplantation|Undergo transplantation
214650191|NCT00622895|PROCEDURE|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
214650192|NCT00622895|PROCEDURE|quality-of-life assessment|Ancillary studies
214650193|NCT00622895|OTHER|laboratory biomarker analysis|Correlative studies
214650194|NCT00622895|OTHER|flow cytometry|Correlative studies
214650195|NCT00622895|PROCEDURE|biopsy|Punch biopsy of skin involved with scleroderma
214650196|NCT01959165|DRUG|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
214650197|NCT01959165|DRUG|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
214650198|NCT01959165|DRUG|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
214650199|NCT01959165|DRUG|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
214650200|NCT01745809|PROCEDURE|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
214650201|NCT06454526|BEHAVIORAL|Mindfulness Based Program|Mindfulness Based Program is an 8-week program with a total of 25 hours. The program, which consists of lectures, meditation and sharing areas, consists of the following topics: Six Senses and Pleasure, Mindfulness and Mind, Get Out of the Head and Enter the Body, Compassion, Meeting Challenges, Stress Reactions and Healing, Retreat Silence Day, Neuroplasticity and the Changing Brain and Wise Living.
214650202|NCT03686969|DRUG|Octanorm|Octanorm 0.5g/kg/week
214650203|NCT03686969|OTHER|Placebo|Placebo
214650204|NCT02381379|DRUG|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
214650205|NCT05742555|OTHER|Virtual reality intervention|After the relatives of the patients included in the experimental group are informed about the study, they will be asked to fill in the Participant Information Form, Nottingham Health Profile (NSP) and Warwick-Edinburgh Mental Well-Being Scale (WEMIOÖ) after obtaining their permission. The virtual reality intervention will be applied to the caregivers at a suitable time of the day (when the patient's care and treatment is not intensive, the caregiver wishes). Different nature scenes (sea, forest, stream) with different types of music (classical music, nature sounds, relaxing music) will be watched for 10 minutes, 3 days a week. The application will be made for 4 weeks. At the end of this period, they will be asked to fill the NSP and WEMİOÖ again as a final test.
214650206|NCT01740180|OTHER|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
214650207|NCT01044563|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
214650208|NCT01044563|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
214650209|NCT05004545|DRUG|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
214650210|NCT00560755|BIOLOGICAL|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
214650211|NCT00848120|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
214650212|NCT04500704|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214650213|NCT04500704|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
214650214|NCT03174145|BEHAVIORAL|Positive behaviour|Information about T4P1010 treatment
214650215|NCT03174145|DRUG|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
214650216|NCT03174145|GENETIC|Pharmacogenetic|Blood sample of 10 millilitres maximum
214650217|NCT03174145|OTHER|Questionnaires and diary completion|Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
214650218|NCT02344225|DRUG|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
214650219|NCT02344225|DRUG|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
214650220|NCT02344225|DRUG|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
214650221|NCT01515228|DEVICE|Xience Prime|everolimus-eluting stent implantation
214650222|NCT01515228|DEVICE|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
214650223|NCT00093613|DRUG|sorafenib tosylate|Given PO
214650224|NCT00093613|OTHER|pharmacological study|Correlative studies
214650225|NCT01119547|OTHER|Exercise in a group|The patient do their individual exercise program in a group.
214650226|NCT01119547|OTHER|Home exercise|The patient exercise their individual program at home during 6 v.
214650227|NCT01988090|DRUG|800 IU Vitamin D Supplement|Standard Dose
214650228|NCT01988090|DRUG|50,000 IU Vitamin D supplement|High Dose
214650229|NCT01734317|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer.
214650230|NCT04870671|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)|Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
214650231|NCT01083667|DRUG|Pyrimethamine|Open Label, dose escalating,
214650232|NCT02581254|DEVICE|Thin Wire Snare|
214650233|NCT02581254|DEVICE|Thick Wire Snare|
214650234|NCT05078125|DEVICE|Holter monitoring|24 hours Holter monitoring
214650235|NCT02039739|DEVICE|Orsiro™ Drug Eluting Stent group|
214650236|NCT06960486|PROCEDURE|Bedside ultrasound-guided real-time biliary drainage|Bedside ultrasound-guided real-time biliary drainage by emergency surgeon in the frail and high risk elderly patients with severe acute suppurative infection of biliary tract
214650237|NCT06960486|PROCEDURE|traditional appointment ultrasound|Traditional appointment ultrasound
214650238|NCT03497845|BIOLOGICAL|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650239|NCT03497845|BIOLOGICAL|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650240|NCT03497845|BIOLOGICAL|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650241|NCT03497845|BIOLOGICAL|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650242|NCT03497845|BIOLOGICAL|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650243|NCT03497845|BIOLOGICAL|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650244|NCT03497845|BIOLOGICAL|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
214650245|NCT06960772|BEHAVIORAL|Flow Ball Intervention|"Participants receive an intensive intervention using the Flow Ball device over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
214650246|NCT06960772|BEHAVIORAL|Straw Phonation Intervention|"Participants receive an intensive intervention using a straw over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
214650247|NCT06960772|BEHAVIORAL|Sham Intervention|"Participants receive an intensive intervention over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach' The sham intervention uses breathing exercises through the Flow Ball, no phonation will be involved."
214650248|NCT01817816|PROCEDURE|Botox_A|
214650249|NCT01817816|PROCEDURE|Botox_B|
214650250|NCT00927563|DRUG|Tolcapone|pill, 100-300mg/day for 8 weeks
214650251|NCT04764552|DIETARY_SUPPLEMENT|Yeahhh Baby Ointment|The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
214650252|NCT04764552|OTHER|Coconut oil ointment|Coconut oil ointment with a little olive oil.
214650253|NCT06364995|BEHAVIORAL|Volleyball|Volleyball Specialised Physical Education Intervention is a step-by-step approach to teaching the intervention. Each lesson was conducted as a Warm-up (10 minutes), Basic contents of the PE lesson (25 minutes), and Cool-down (5 minutes). From the learning of basic skills in the first session to the final Combination Practice underhand service, receive, service, pass, spiking, and block, from the simple to the difficult, the intensity of the training is from weak to strong, Allowing participants to build upon a solid foundation toward mastering intricate volleyball maneuvers. Intensity modulation is key to this intervention; training intensity evolves from moderate to vigorous, aligning with the increasing complexity of skills and the physical demand required to execute them proficiently. The curriculum is thoughtfully designed to transition from basic skill execution to complex gameplay, with each lesson introducing new skills or refining existing ones.
214650254|NCT06364995|BEHAVIORAL|Traditional Physical Education|Participants participating in the control group will attend traditional physical education classes following the established physical education syllabus. Participants in the control group will attend four 40-minute classes per week over ten weeks. Each session will consist of a warm-up (10 minutes), the basics of PE (25 minutes), and a cool-down (5 minutes). The duration and intensity of the experimental and control groups were the same, which allowed for a better comparison.
214650255|NCT00516594|PROCEDURE|Diet with polyfructans and viscous fibers or soy protein|
214650256|NCT03566329|DRUG|Magnesium sulphate|Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
214650257|NCT03566329|DRUG|Lidocaine Hydrochloride|lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
214650258|NCT03566329|DRUG|Normal saline|Normal saline infusion with the same rate of infusion as the study drugs
214650259|NCT04208425|BEHAVIORAL|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
214650260|NCT04208425|BEHAVIORAL|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
214650261|NCT04112680|BEHAVIORAL|Debunking Misinformation through Audio Dramas|The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
214650262|NCT04112680|BEHAVIORAL|Control group audio jingles|The control group will receive audio jingles about exclusive breastfeeding
214650263|NCT05891067|BEHAVIORAL|SterkWerk|Classroom-based intervention program
214650264|NCT05891067|BEHAVIORAL|Treatment-as-usual|Active control group
214650265|NCT01774422|DEVICE|Extracorporeal CO2 removal device|
214650266|NCT00412776|DRUG|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
214650267|NCT04920773|OTHER|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
214650268|NCT04920773|OTHER|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
214650269|NCT03135249|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
214650270|NCT00862095|DRUG|Placebo|Every month for 3 months
214650271|NCT00862095|DRUG|Propranolol|target does 80 mg per day for 3 months
214650272|NCT00862095|DRUG|Amitriptyline|Target does of 50 mg per day for 3 months
214650273|NCT00862095|DRUG|Topiramate|Target dose 100 mg a day for 3 months
214817894|NCT02375386|PROCEDURE|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
214817895|NCT02375386|PROCEDURE|fMRI|Both groups will receive an fMRI.
214650274|NCT04114305|BEHAVIORAL|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
214650275|NCT01784796|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
214817896|NCT02375386|BEHAVIORAL|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
214650276|NCT01784796|BEHAVIORAL|Health Education Program|8 week Health Education Program
214817897|NCT02375386|OTHER|Questionnaires|Both groups will receive Questionnaires
214817898|NCT02375386|BEHAVIORAL|Physical Impairment|Both groups will receive testing on physical impairment.
214817899|NCT00919230|DRUG|Ferrous sulphate tablets|200mg twice daily for four weeks
214817900|NCT00298350|DRUG|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
214817901|NCT05494203|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
214650277|NCT01129193|OTHER|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
214650278|NCT01129193|OTHER|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
214650279|NCT01129193|OTHER|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
214650280|NCT01129193|DRUG|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
214650281|NCT03120832|BIOLOGICAL|PAN-301-1|
214650282|NCT05884320|DRUG|Sacituzumab Govitecan|Given by IV (vein)
214650283|NCT00003400|BIOLOGICAL|filgrastim|
214650284|NCT00003400|DRUG|carmustine|
214650285|NCT00003400|DRUG|cisplatin|
214650286|NCT00003400|DRUG|melphalan|
214650287|NCT00003400|DRUG|vinorelbine tartrate|
214650288|NCT00003400|PROCEDURE|peripheral blood stem cell transplantation|
214650289|NCT00413959|DRUG|VELCADE®|1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
214650290|NCT00413959|DRUG|Rituximab|375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
214650291|NCT00413959|DRUG|Cyclophosphamide|400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
214650292|NCT00413959|DRUG|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
214650293|NCT03057795|DRUG|Brentuximab Vedotin|Given IV
214650294|NCT03057795|OTHER|Laboratory Biomarker Analysis|Correlative studies
214650295|NCT03057795|BIOLOGICAL|Nivolumab|Given IV
214650296|NCT01531842|PROCEDURE|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
214650297|NCT04523532|OTHER|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
214650298|NCT01508741|DIETARY_SUPPLEMENT|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
214650299|NCT01508741|DIETARY_SUPPLEMENT|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
214650300|NCT00963950|PROCEDURE|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
214650301|NCT00963950|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
214650302|NCT01893749|BEHAVIORAL|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
214650303|NCT06021249|PROCEDURE|Traditional ventilation strategies|"1. Tidal volume：10ml/kg predicted body weight（PBW）；~2. 0 cm H2O positive end expiratory pressure（PEEP）；~3. negative pressure extubation"
214650304|NCT06021249|PROCEDURE|Traditional lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. Ventilator-controlled recruitment manoeuvre；~4. CPAP；~5. negative pressure extubation"
214650305|NCT06021249|PROCEDURE|Innovative lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. positive pressure extubation；~4. postoperative breathing training"
214650306|NCT06021249|PROCEDURE|Lung-protective ventilation|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；"
214650307|NCT06021249|PROCEDURE|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
214650308|NCT06021249|PROCEDURE|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
214650309|NCT06021249|PROCEDURE|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
214650310|NCT06076629|OTHER|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
214650311|NCT06076629|OTHER|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
214650312|NCT04343651|DRUG|Placebo|Placebo
214650313|NCT04343651|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
214650314|NCT02987855|PROCEDURE|Lipoaspiration|Closed syringe harvesting subdermal fat
214650315|NCT02987855|PROCEDURE|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
214650316|NCT02987855|PROCEDURE|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
214650317|NCT05886725|OTHER|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
214650318|NCT05917288|BIOLOGICAL|Belimumab|Belimumab will be administered
214650319|NCT05917288|DRUG|Standard of care|Standard of care will be administered
214650320|NCT05585242|BEHAVIORAL|Infertility ACTion Program|Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
214650321|NCT04849871|RADIATION|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
214650322|NCT05829512|OTHER|Validity and reliability study|Face-to-face questionnaire study
214650323|NCT04186455|DEVICE|proseal|laryngeal mask proseal
214650324|NCT04186455|DEVICE|baska-mask|laryngeal mask baska-mask
214650325|NCT03913156|OTHER|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
214817902|NCT06133933|DEVICE|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
214817903|NCT04280120|OTHER|Neural Mobilisation|Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.
214817904|NCT04280120|OTHER|Massage therapy|Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
214650326|NCT03789227|PROCEDURE|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
214650327|NCT04788524|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
214650328|NCT04152824|BEHAVIORAL|Resilience-Supportive Leadership Training (RESULT)|Platoon leaders receive a 90-minute, in-person training addressing supportive supervisor behaviors and resilience
214650329|NCT01943565|DRUG|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
214650330|NCT01943565|DRUG|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
214650331|NCT01943565|DRUG|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
214650332|NCT01943565|DRUG|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
214650333|NCT05204043|OTHER|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
214650334|NCT05204043|OTHER|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
214650335|NCT05204043|OTHER|Questionnaires|"* State Trait Anxiety Inventory (STAI)~* Pain assessment - Visual Analogic Scale (from 0 to 10)."
214650336|NCT04941196|DRUG|Anplag (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
214650337|NCT04941196|DRUG|Brilinta (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
214650338|NCT04785365|OTHER|Biological: ATL001|No investigational product will be administered
214650339|NCT01292057|DRUG|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
214817905|NCT04280120|DIAGNOSTIC_TEST|Faradic electrical stimulation|Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
214650340|NCT01292057|DRUG|Placebo|Placebo to match active drug Aripiprazole for 8 days
214650341|NCT02711280|DRUG|Sevoflurane|
214650342|NCT02711280|DRUG|Propofol|
214650343|NCT00287625|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation
214650344|NCT01526083|OTHER|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
214650345|NCT01526083|OTHER|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
214650346|NCT01538238|DRUG|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
214650347|NCT00384787|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
214650348|NCT00384787|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
214650349|NCT02254031|DRUG|bivatuzumab mertansine|
214650350|NCT01034995|DRUG|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
214650351|NCT01034995|DRUG|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
214650352|NCT01034995|DRUG|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
214650353|NCT03440593|OTHER|Caloric delivery will target results of IC measurement.|The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
214650354|NCT01459614|DRUG|Gemcitabine|IV on Days 4 and 11
214650355|NCT01459614|DRUG|Taxotere|IV on Days 4 and 11
214650356|NCT01459614|DRUG|Xeloda|orally, twice a day Days 1-14
214650357|NCT01459614|DRUG|Cisplatin|IV Days 4 and 11
214650358|NCT04451707|OTHER|non-cholera Vibrio infection|Epidemiology of patients diagnosed with non-cholera Vibrio infection
214650359|NCT02587338|DEVICE|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anodal, right cathodal
214650360|NCT02587338|DEVICE|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
214650361|NCT01187537|PROCEDURE|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
214650362|NCT01506882|DRUG|Levetiracetam (LEV)|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use"
214650363|NCT06536738|PROCEDURE|esophageal repair|The surgery confirmed a secondary esophageal fistula following the anterior cervical surgery. The procedure involved trimming the esophageal tissue around the fistula and repairing the fistula.
214650364|NCT02402855|OTHER|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
214650365|NCT02402855|OTHER|Interview with a sociologist|For a sub-group of 40 womens
214650366|NCT02402855|OTHER|No intervention|
214650367|NCT01448200|DRUG|PPI-668|capsules
214650368|NCT01448200|DRUG|Placebo|capsules
214650369|NCT01602588|DRUG|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
214650370|NCT01602588|RADIATION|Radiotherapy|Short Course radiotherapy
214817906|NCT04280120|OTHER|Exercises|Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
214817907|NCT03700411|DRUG|Morphine|Morphine intravenous
214817908|NCT03700411|DRUG|Piritramid|Piritramid intravenous
214817909|NCT03700411|DRUG|Epidural|Perioperative epidural analgesia
214650371|NCT01758510|GENETIC|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.
214650372|NCT05079360|DRUG|Sabizabulin|32mg each day by mouth
214650373|NCT05079360|DRUG|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
214650374|NCT04800731|OTHER|observation no intervention|no intervention
214650375|NCT02436603|BEHAVIORAL|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
214650376|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (8 mg/m^2)|
214650377|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2)|
214650378|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
214650379|NCT01302808|COMBINATION_PRODUCT|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
214650380|NCT00273000|DRUG|GLP-2|
214817910|NCT04065867|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
214817911|NCT01517854|DRUG|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
214650381|NCT00488787|DRUG|intranasal ketamine|low dose
214650382|NCT00488787|DRUG|intranasal ketamine|medium dose
214650383|NCT00488787|DRUG|intranasal ketamine|high dose
214650384|NCT00488787|DRUG|placebo|placebo
214817912|NCT01517854|DRUG|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
214817913|NCT02688023|DRUG|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
214817914|NCT02045472|DRUG|VIS410|
214817915|NCT02045472|DRUG|Placebo|
214817916|NCT05137184|DRUG|Methoxyflurane|Inhalation of Methoxyflurane
214817917|NCT05137184|DRUG|Fentanyl|Intranasal Fentanyl
214817918|NCT05137184|DRUG|Morphine hydrochloride|Intravenous Morphine
214817919|NCT01289262|PROCEDURE|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
214817920|NCT01289262|PROCEDURE|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
214817921|NCT00838279|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
214817922|NCT00838279|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
214817923|NCT00838136|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
214817924|NCT00838136|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
214817925|NCT03380845|DEVICE|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
214817926|NCT03380845|DEVICE|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
214817927|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
214650385|NCT03281980|OTHER|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
214650386|NCT03281980|OTHER|Government Intervention (UCT+HE)|fgbfgjhgykghilk
214650387|NCT06053008|OTHER|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
214817928|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
214817929|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
214817930|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
214650388|NCT05873985|OTHER|Dynamic tape on experimental group|"The dynamic taping application was carried out in 2 stages. Three I-shaped tapes were cut. In the first stage, the person was asked to perform scapular retraction, and in this position, the tape was placed by applying medium tension to the anterior part of the other deltoid muscle, passing from the anterior part of the deltoid muscle to the upper thoracic region. In the second stage, the participant was asked to do scapular retraction and depression, and while maintaining this position, medium tension was applied to the lower thoracic vertebra starting from the anterior part of the deltoid muscle and the acromion and tape was applied. Afterward, this process was applied on the other side"
214650389|NCT05873985|OTHER|Sham tape on placebo group|"Sham taping was performed in 2 stages. Three I-shaped tapes were cut. Participants were asked to stand in the comfortable position they used during the day. The first tape was adhered from the starting point of the spine of the scapula with the acromion to the junction of the spine of the scapula and the acromion on the other side without any tension. The other two tapes, starting from the beginning and ending points of the first tape, were adhered to the lower thoracic region without any tension"
214817931|NCT04092023|OTHER|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
214817932|NCT01434953|BEHAVIORAL|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
214817933|NCT01434953|BEHAVIORAL|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
214817934|NCT01449383|DIETARY_SUPPLEMENT|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
214817935|NCT01449383|DIETARY_SUPPLEMENT|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
214817936|NCT01250912|DRUG|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128\_128 matrix) will be acquired beginning 15 minutes after tracer injection.
214817937|NCT06225921|DRUG|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
214817938|NCT06225921|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
214817939|NCT06225921|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
214817940|NCT03899077|DRUG|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
214817941|NCT03899077|DRUG|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
214817942|NCT03899077|DRUG|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
214817943|NCT03899077|DRUG|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
214817944|NCT03899077|DRUG|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
214650390|NCT00821678|OTHER|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
214650391|NCT04863274|DRUG|atorvastatin|"Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre."
214650392|NCT02225548|DRUG|Selegiline|
214650393|NCT02225548|DRUG|Tadalafil|
214650394|NCT01439438|DRUG|Topiramate coated tablet|Test formulation
214650395|NCT01439438|DRUG|Topamax® coated tablet|Reference formulation
214650396|NCT02243501|BEHAVIORAL|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
214650397|NCT06915415|BEHAVIORAL|Animal-assisted therapy|One group had a live therapy canine included in therapy sessions who was trained to provide comfort measures and promote interaction with autistic children. He is a certified therapy and service dog and knows over 50 commands and is certified in 10 autism service dog tasks. Participants played with him at the beginning of the session. They could choose to play fetch or hide and seek. Participants could say commands to make him do tricks and give him a treat as a reward. The canine would lay at participants' feet while the therapist was working on a skill in the clinic room. The canine would alert to the onset of anxiety and provide comfort measures. Participants could also cue the canine to provide comfort measures or could brush his fur and give him water as a prosocial behavior. Participants ended sessions with either fetch, soccer, or hide and seek.
214650398|NCT06915415|BEHAVIORAL|Behavioral therapy|One group had a toy plush dog included in therapy sessions. The therapist would incorporate the toy plush dog in the seated portion of the session to practice social skills. Participants could brush the toy plush dog, pet it, and hold it during sessions.
214650399|NCT06917638|PROCEDURE|implant placment|"* Crestal incision followed by full thickness mucoperiosteal flap elevation.~* Drilling of the implant according to the manufacturer's instructions to reach the final drill corresponding to the implant size.~* Allocation concealment will be broken at this point to assign the patient into one of two groups:~Control Group: osteotomy preparation the same diameter of the implant. Intervention: oversized drilling:Osteotomy preparations will include an extra drill,(0.2mm) wider than the diameter of the implant.~* A smart peg will then be attached to the implant, to measure its stability using Ostell and three readings will be recorded:occlusal buccal and lingual reading.~* A healing collar will then be place over the implant, then simple intrerupted suture~* A standardized digital periapical radiograph will be taken using a radiographic holder and a custom-made radiographic stent to determine the initial crestal bone level."
214650400|NCT06916871|OTHER|The control group will benefit from awareness|During hospitalization in rehabilitation, doctors and nursing staff will transmit information in a linear manner, i.e. explain, possibly argue and answer the patient's questions on topics such as interpreting blood sugar levels, explaining treatment, good practices in terms of diet, physical activity, etc. at the patient's bedside in an unstructured manner based on interactions between patient and caregivers. There is therefore no standard frequency, number of specific sessions, or topics addressed systematically.
214650401|NCT06916871|OTHER|The experimental group will benefit from structured education which will be carried out by the diabetes nurse|During hospitalization in rehabilitation, the experimental group will benefit from structured education which will be carried out by the diabetes nurse at a rate of 3 sessions for patients on oral anti-diabetics and 5 sessions for patients on insulin.
214650402|NCT06912672|DIAGNOSTIC_TEST|Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer|The study aims to evaluate the diagnostic performance of the EPIPROBE TAGMe DNA Methylation Detection Kit for the detection of urothelial cancer. This assay utilizes targeted DNA methylation analysis to identify specific epigenetic alterations associated with urothelial malignancies. The performance of the kit will be assessed in terms of sensitivity, specificity, and overall diagnostic accuracy using clinical urine samples from a patient population with hematuria.
214650403|NCT06912880|PROCEDURE|trans obturator tape surgery|Trans-obturator technique is a more beneficial and a less invasive procedure in treatment of SUI when compared with other techiniques. In this technique, a synthetic mesh tape, which is passing bilaterally through the obturator foramen, is placed underneath the mid part of the urethra.
214650404|NCT06917391|BEHAVIORAL|Wendyverse VR food marketing experience|"In the Wendyverse VR application (app) participants can order from a Wendy's restaurant, play games, meet with others who may be visiting the Wendyverse, and access codes that can be used to obtain free food at physical restaurants."
214650405|NCT06917391|BEHAVIORAL|Nikeland VR non-food marketing experience|In Nikeland VR app, participants can play sports, try on apparel, and engage with celebrity athletes.
214650406|NCT06915064|DEVICE|Low- level laser- photobiomodulation therapy|Three patients (30%) received treatment on the left side and seven (70%) on the right side. The treatment was carried out using the EPIC X laser (BIOLASE®), which uses a solid-state diode as a semiconductor source of invisible infrared radiation. The therapy was applied to the masticatory muscles (temporal, masseter, internal pterygoid), to trigger points discovered on palpation and to the intra-articular area of the TMJ (posterior portion through the external ear, superior portion and anterior portion). All patients included in the study underwent four sessions of PBMT-LLL for four consecutive weeks. T
214650407|NCT06917157|DRUG|Administration of antibiotics prophylactically at the time of membrane rupture|"Participants will receive the antibiotic regimen:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
214650408|NCT06917157|DRUG|Administration of antibiotics non-prophylactically at 22 weeks|"Participants will receive latency antibiotics starting 22 weeks 0 days:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
214650409|NCT06917625|DIAGNOSTIC_TEST|Imaging|The participants will be assessed with a brain MRI and will performed a neurophysiological test to evaluate executive functions
214650410|NCT06917430|OTHER|No intervention|No intervention.
214650411|NCT06917144|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stimulation sessions were performed using a YINGCHI M-100 Ultimate device with liquid-cooled figure-8 coils.~Patients attended 10-minute sessions daily for 10 consecutive working days. For rTMS, stimulation was delivered at an excitatory frequency of 10 Hz, targeting the M1, contralateral to the side of pain in the facial region.~Each session consisted of the following steps.~* 10 series: 60 pulses per series (600 pulses in total).~* Rest intervals: 60 seconds between series.~* Intensity: 70% of the resting motor threshold (RMT). RMT was determined using single-pulse stimulation over the M1 region controlling the abductor pollicis brevis muscle, localized via neuronavigation. The threshold was de-fined as the lowest stimulator intensity producing a motor-evoked potential amplitude \>50 µV in at least 5 of 10 trials."
214650412|NCT06917144|DEVICE|Sham Stimulation|"Sham Stimulation:~The same device and protocol used for intervention protocol with Repetitive Transcranial Magnetic Stimulation were used for sham stimulation, but no active stimulation was delivered. The equipment produced identical sounds and appearances, thereby ensuring blinding."
214650413|NCT06917209|OTHER|CBT-CD psychotherapy|9 weekly sessions of CBT-CD psychotherapy
214650414|NCT06916403|DRUG|Intravenous Ketamine Infusions|Ketamine will be slowly infused with the routine target dose 1.5-2 mg/kg over 3-4 hours.
214220973|NCT02741518|BIOLOGICAL|Fecal Microbiota Transplantation|This is pre-screened fecal material that has been encapsulated
214220974|NCT02741518|OTHER|Placebo|These are capsules that have no fecal material in them.
214220975|NCT03168958|DRUG|Methadone|Methadone will be provided at induction of anesthesia
214220976|NCT03168958|DRUG|Saline|Saline will be administered at induction of anesthesia
214220977|NCT01464281|DRUG|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
214220978|NCT05722444|OTHER|Nighttime Feminine Product|"During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak"
214220979|NCT01710540|OTHER|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214220980|NCT01710540|OTHER|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214220981|NCT02439359|DRUG|CF-301|Dose escalation
214220982|NCT02439359|DRUG|Placebo|
214650415|NCT06935526|OTHER|The mobile training program and telephone follow-ups|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. All sections were shared with the intervention group. After the pre-test, intervention group patients could log in to M-ICDEP anytime using their email and password, accessing content repeatedly during the three-month follow-up. The researcher conducted telephone follow-ups in the second, fifth, and eighth weeks, evaluating patients using the Telephone Calls Monitoring Form. The information given to the patients during the telephone conversation was continued within the limited of the training program prepared within the scope of M-ICDEP.
214220983|NCT00129844|DRUG|Motexafin Gadolinium|
214220984|NCT03817047|BEHAVIORAL|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
214220985|NCT03817047|BEHAVIORAL|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
214220986|NCT03817047|BEHAVIORAL|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
214220987|NCT03817047|BEHAVIORAL|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
214220988|NCT06348290|DRUG|JMKX001899|Oral
214220989|NCT06348290|DRUG|Itraconazole|Oral
214220990|NCT06348290|DRUG|Midazolam|Oral
214220991|NCT06348290|DRUG|Rifampin|Oral
214220992|NCT06348290|DRUG|dextromethorphan|Oral
214220993|NCT06348290|DRUG|Rosuvastatin|Oral
214220994|NCT06348290|DRUG|digoxin|Oral
214220995|NCT05186415|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
214220996|NCT00062231|DRUG|amoxicillin-clavulanate potassium|
214220997|NCT00062231|DRUG|ciprofloxacin|
214220998|NCT00062231|DRUG|moxifloxacin hydrochloride|
214220999|NCT00062231|PROCEDURE|management of therapy complications|
214221000|NCT02249637|PROCEDURE|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
214221001|NCT05401058|DRUG|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
214221002|NCT05401058|DRUG|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
214221003|NCT01139008|DRUG|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
214221004|NCT01139008|DRUG|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
214221005|NCT04546984|DRUG|HEC96719|Part 2：Mulltiple doses up to 10 days
214221006|NCT02785770|DRUG|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
214221007|NCT02785770|DRUG|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
214221008|NCT02785770|DRUG|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
214221009|NCT03154229|OTHER|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
214221010|NCT03154229|OTHER|Paper-based decision-support|WHO guidelines presented on paper
214221011|NCT03154229|OTHER|Pre-Assessment of practices|Observation of baseline clinical practice.
214221012|NCT00347620|DEVICE|spectacles|
214221013|NCT00347620|PROCEDURE|Cataract Surgery|
214221014|NCT03488511|OTHER|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
214221015|NCT02452827|OTHER|Biomechanical parameters|
214221016|NCT02452827|OTHER|MRI|MRI of cervical spine
214221017|NCT04567901|OTHER|Death|Mortality group
214221018|NCT04567901|OTHER|Survive|Survival group
214221019|NCT05880290|PROCEDURE|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
214221020|NCT04951661|DEVICE|Virtual Reality|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
214221021|NCT03968939|DRUG|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
214221022|NCT03968939|DIETARY_SUPPLEMENT|Melatonin|Oral Melatonin, 3 mg
214221023|NCT03968939|BEHAVIORAL|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
214221024|NCT01624311|OTHER|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
214221025|NCT01624311|OTHER|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
214221026|NCT05331859|DRUG|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
214221027|NCT05331859|DRUG|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
214221028|NCT05331859|DRUG|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
214221029|NCT00505778|DRUG|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
214221030|NCT00505778|DRUG|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
214221031|NCT00116298|DRUG|stavudine, efavirenz, lamivudine|
214221032|NCT04249232|DRUG|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
214221033|NCT04249232|DRUG|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
214221034|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
214221035|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
214221036|NCT04642001|RADIATION|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
214221037|NCT04642001|COMBINATION_PRODUCT|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
214221038|NCT04140578|DRUG|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
214221039|NCT03690752|DEVICE|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
214221040|NCT03690752|DEVICE|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
214221041|NCT02766556|DRUG|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
214221042|NCT02766556|PROCEDURE|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
214221043|NCT02766556|DRUG|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
214221044|NCT04282746|DRUG|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
214221045|NCT00229424|DRUG|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
214221046|NCT00229424|DRUG|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
214221047|NCT00229424|OTHER|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
214221048|NCT01056302|PROCEDURE|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
214221049|NCT05324761|DRUG|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
214221050|NCT05324761|DRUG|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
214221051|NCT04384081|DRUG|BI 456906|Solution for injection
214221052|NCT04384081|DRUG|Placebo|Solution for injection
214221053|NCT02558647|BEHAVIORAL|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
214221054|NCT02558647|BEHAVIORAL|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
214650416|NCT06935526|OTHER|Only a two-page summary section of M-ICDEP|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. Only a two-page summary section were shared with the control group. After the pre-test, control group patients could log in to M-ICDEP anytime using their email and password, accessing the summary section repeatedly during the three-month follow-up. Routine outpatient follow-up was continued for the control group without any other intervention.
214221055|NCT05380479|DRUG|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
214221056|NCT05380479|DRUG|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
214221057|NCT02136069|DRUG|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
214221058|NCT02136069|DRUG|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
214221059|NCT02136069|OTHER|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
214221060|NCT02136069|OTHER|Placebo (Injection)|Administered by SC injection Q4W until Week 52
214221061|NCT05627323|BIOLOGICAL|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
214221062|NCT03547024|DRUG|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
214221063|NCT03547024|DRUG|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
214221064|NCT03547024|DRUG|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
214221065|NCT03547024|DRUG|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
214221066|NCT01871740|DRUG|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
214221067|NCT01871740|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
214221068|NCT03571685|BEHAVIORAL|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
214221069|NCT01092546|DRUG|[18F]Flutemetamol|All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
214221070|NCT05407662|OTHER|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
214221071|NCT03171467|PROCEDURE|Salpingectomy|
214221072|NCT05724511|DRUG|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
214221073|NCT05861349|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
214221074|NCT05861349|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
214221075|NCT03338127|DIAGNOSTIC_TEST|renal function test|2 ml blood sample to be investigated for renal function test
214221076|NCT01698034|BEHAVIORAL|Volunteering|Weekly volunteering with elementary school children in after school programs
214221077|NCT06116513|DEVICE|S53P4 bioactive glass granules|During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
214221078|NCT01667419|DRUG|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
214221079|NCT01667419|DRUG|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
214221080|NCT03799042|DEVICE|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
214221081|NCT03799042|BEHAVIORAL|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
214221082|NCT01094145|OTHER|Deep brain stimulation|DBS in the Nucleus basalis Meynert
214221083|NCT02328365|OTHER|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
214221084|NCT05048524|DRUG|S-1, leucovorin, oxaliplatin and gemcitabine|"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day"
214221085|NCT05200234|DRUG|Nattokinase|Nattokinase + standard treatment
214221086|NCT05200234|DRUG|Placebo|Placebo+ standard treatment
214221087|NCT05376033|OTHER|root canal filling with Ceraseal sealer|root canal filling with Ceraseal sealer
214221088|NCT03364270|DRUG|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
214221089|NCT04364984|DRUG|Angiotensin converting enzyme inhibitor|routine drug intake
214221090|NCT04364984|DRUG|Angiotensin Receptor Blockers|routine drug intake
214221091|NCT04364984|DRUG|Direct renin inhibitor|routine drug intake
214221092|NCT01051154|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
214221093|NCT01051154|DIETARY_SUPPLEMENT|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
214221094|NCT04404400|DRUG|Investigational products administration|"Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
214221095|NCT04404400|DRUG|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
214221096|NCT05967507|DEVICE|Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
214221097|NCT05967507|DEVICE|High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
214221098|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
214221099|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
214221100|NCT03511807|OTHER|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
214221101|NCT03511807|OTHER|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
214221102|NCT00122551|PROCEDURE|Intermittent antiretroviral therapy|
214221103|NCT06338137|DEVICE|Holmium Yag laser|Use two laser energy low and high to reach the optimal setting for stone dusting
214221104|NCT01941186|OTHER|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
214221105|NCT00261261|BEHAVIORAL|ADVANCE|
214221106|NCT00261261|DRUG|Midazolam|
214221107|NCT00261261|PROCEDURE|Parental presence|
214221108|NCT01765257|DRUG|AZILECT®|
214221109|NCT01765257|DRUG|Placebo|
214221110|NCT02918513|BEHAVIORAL|Wellness Element 1 - Exercise|1\. Daily wellness element focusing on Exercise; adherence documented online daily
214221111|NCT02918513|BEHAVIORAL|Wellness Element 2 - Mindfulness|2\. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
214221112|NCT02918513|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|3\. Daily wellness element focusing on sleep hygiene; adherence documented online daily
214221113|NCT02918513|BEHAVIORAL|Wellness Element 4 - Social Connectedness|4\. Daily wellness element focusing on Social Connectedness; adherence documented online daily
214221114|NCT02918513|BEHAVIORAL|Wellness Element 5 - Nutrition|5\. Daily wellness element focusing on Nutrition; adherence documented online daily
214221115|NCT02918513|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|6\. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
214221116|NCT02918513|BEHAVIORAL|Wellness Element 7 - Motivational Messages|7\. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
214221117|NCT04607317|BEHAVIORAL|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
214221118|NCT04607317|BEHAVIORAL|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
214221119|NCT04607317|BEHAVIORAL|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
214221120|NCT00158418|PROCEDURE|Cemented Humeral Stem|
214221121|NCT00158418|PROCEDURE|Uncemented Humeral Stem|
214221122|NCT00742144|DRUG|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
214221123|NCT01125696|DRUG|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
214221124|NCT01125696|DRUG|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
214221125|NCT04737304|DRUG|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
214221126|NCT02252796|RADIATION|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
214221127|NCT02252796|DRUG|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
214221128|NCT02252796|DRUG|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
214221129|NCT02252796|RADIATION|Image-guided IMRT|Given during chemo-radiation phase
214221130|NCT03314922|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
214221131|NCT04551872|BEHAVIORAL|Digital weight loss intervention|Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
214221132|NCT02290678|BEHAVIORAL|Adventure-based Programming|
214221133|NCT05002075|OTHER|m-health cardiac rehabilitation|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California). This app includes a patient-facing iOS and Android compatible smartphone app and an integrated hospital-facing online dashboard for remote monitoring and care coordination by a trained coach
214221134|NCT04335019|OTHER|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
214221135|NCT06045702|PROCEDURE|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
214221136|NCT06259370|BEHAVIORAL|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
214221137|NCT04380519|DRUG|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
214221138|NCT04380519|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
214221139|NCT04380519|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
214221140|NCT05417763|DEVICE|Randomized physiological measurements by the two systems|To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
214221141|NCT03005899|DRUG|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
214221142|NCT03005899|DRUG|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
214221143|NCT04300166|DEVICE|Telemedicine & Humidification|Wireless control of CPAP usage, adherence, leakage and humidifier usage
214221144|NCT04173494|DRUG|Momelotinib|Momelotinib tablets will be self-administered orally once daily
214221145|NCT04173494|DRUG|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
214221146|NCT04173494|DRUG|Danazol|Danazol capsules will be self-administered orally twice daily
214221147|NCT04173494|DRUG|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
214221148|NCT02474069|DRUG|Secukinumab|
214221149|NCT04518579|PROCEDURE|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
214221150|NCT03656380|DRUG|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
214221151|NCT03656380|DRUG|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
214221152|NCT03656380|OTHER|Placebo|Saline subcutaneous injection
214221153|NCT04078256|OTHER|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
214221154|NCT04078256|OTHER|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
214221155|NCT01623050|DEVICE|SinuSys Dilation System|Sinuplasty
214221156|NCT04287270|OTHER|Assesment|Evaluations which explained in the arms section will be made as described.
214221157|NCT00393861|DRUG|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
214221158|NCT03294564|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
214221159|NCT03294564|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
214221160|NCT04812262|DRUG|DD01|The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
214221161|NCT04812262|DRUG|Placebo|Placebo drug of DD01, administered in a 1mL volume for injection
214221162|NCT03347955|PROCEDURE|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
214221163|NCT03347955|PROCEDURE|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
214221164|NCT06492863|GENETIC|FT-003|Administered via intraocular injection.
214221165|NCT01251341|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
214221166|NCT01251341|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
214221167|NCT01251341|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
214221168|NCT03405961|DEVICE|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
214221169|NCT02837107|DIETARY_SUPPLEMENT|Mind Master|80ml Mind Master / day for 8 weeks
214221170|NCT02837107|DIETARY_SUPPLEMENT|Placebo|80ml a look-alike Placebo / day for 8 weeks
214221171|NCT01600534|BEHAVIORAL|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
214221172|NCT02803983|PROCEDURE|Pediatric hip plate|Children were treated with pediatric hip plate.
214221173|NCT02803983|PROCEDURE|Cannulated screw|Children were treated with cannulated screw.
214221174|NCT02236936|DIETARY_SUPPLEMENT|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
214221175|NCT02236936|DIETARY_SUPPLEMENT|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
214221176|NCT02236936|BIOLOGICAL|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
214221177|NCT02236936|DRUG|Cisplatin|Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
214221178|NCT02236936|RADIATION|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
214221179|NCT00271284|DRUG|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
214221180|NCT00271284|DRUG|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
214221181|NCT02556528|BEHAVIORAL|Health Coaching|
214221182|NCT06159218|DEVICE|CEST - coiled oesophageal string test|All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
214221183|NCT06531785|DEVICE|chest ultrasound|Lung ultrasound to early diagnose ILD among rheumatoid arthritis patients
214221184|NCT05228691|OTHER|Evaluation and Education|A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
214221185|NCT00349050|DEVICE|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
214221186|NCT00349050|PROCEDURE|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
214221187|NCT05149235|OTHER|early mobilization group|Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).
214221188|NCT05149235|DEVICE|physio adventure|The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.
214221189|NCT05149235|OTHER|placebo|Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
214221190|NCT04135287|DRUG|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
214221191|NCT02499133|OTHER|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
214221192|NCT04073524|OTHER|Nature-Body-Mind-Community|The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
214221193|NCT04073524|OTHER|Treatment as usual|Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
214221194|NCT03399396|BEHAVIORAL|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
214221195|NCT00985699|GENETIC|polymorphism analysis|
214221196|NCT00985699|OTHER|laboratory biomarker analysis|
214221197|NCT00985699|OTHER|pharmacogenomic studies|
214221198|NCT02857634|DEVICE|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
214221199|NCT06361836|BIOLOGICAL|SBT777101|Experimental treatment
214221200|NCT03452163|DEVICE|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
214221201|NCT03452163|DEVICE|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
214221202|NCT00855881|DRUG|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
214221203|NCT02379663|DRUG|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
214221204|NCT02379663|DRUG|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
214221205|NCT02379663|OTHER|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
214221206|NCT02321670|PROCEDURE|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
214221207|NCT02321670|PROCEDURE|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
214221208|NCT03632486|OTHER|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines."
214221209|NCT01103193|DRUG|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
214221210|NCT01103193|DRUG|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
214221211|NCT04944199|OTHER|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
214221212|NCT02156934|BIOLOGICAL|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
214221213|NCT00433134|BEHAVIORAL|Adherence|
214221214|NCT04468152|BEHAVIORAL|Dietary habits and intake|Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
214221215|NCT00210912|DRUG|topiramate|
214221216|NCT02902562|PROCEDURE|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
214221217|NCT02902562|PROCEDURE|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
214221218|NCT06406543|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|an oral solution of vitamin D in a refined olive oil solution
214221219|NCT01388335|DRUG|warfarin|Administered orally
214221220|NCT01388335|DRUG|enzastaurin|Administered orally
214221221|NCT02829801|BEHAVIORAL|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
214221222|NCT02829801|BEHAVIORAL|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
214221223|NCT01688349|OTHER|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
214221224|NCT02752282|OTHER|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
214221225|NCT02752282|OTHER|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
214221226|NCT04638361|OTHER|Questionnaires|To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
214221227|NCT06433492|DEVICE|Intra-articular injection|Three doses of intra-articular injection administered in weekely intervals.
214221228|NCT03808259|DRUG|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
214221229|NCT03808259|DRUG|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
214221230|NCT03808259|DRUG|Placebo|Participants will receive matching placebo.
214221231|NCT02931773|DEVICE|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
214221232|NCT02389153|BEHAVIORAL|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
214221233|NCT01612832|DRUG|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
214221234|NCT01612832|OTHER|Control|pain treatment as customary in the department
214221235|NCT03446404|DIAGNOSTIC_TEST|Standing Computed Tomography|Provides weight bearing 3D view of knees.
214221236|NCT00520806|DRUG|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
214221237|NCT00520806|DRUG|Placebo|Intravenous infusion for 48 h
214221238|NCT03193827|DEVICE|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
214650417|NCT04876352|OTHER|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
214650418|NCT04876352|OTHER|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
214650419|NCT04876352|OTHER|No intervention|Only baseline evaluations, without longitudinal assessment
214650420|NCT05632354|DRUG|Osivelotor|Osivelotor
214221239|NCT03193827|DEVICE|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
214221240|NCT01753648|DEVICE|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
214221241|NCT01753648|OTHER|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
214221242|NCT01753648|OTHER|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
214221243|NCT01367951|PROCEDURE|Surgical fixation|"* The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
214221244|NCT04038021|BEHAVIORAL|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
214221245|NCT04038021|BEHAVIORAL|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
214221246|NCT01805791|DRUG|HMPL-004 1800 mg/day|Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
214221247|NCT01805791|DRUG|Placebo|Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
214221248|NCT01805791|DRUG|HMPL-004 2400 mg/day|Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
214221249|NCT00518089|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
214221250|NCT00518089|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
214221251|NCT04413617|DRUG|PF-06650833|400 mg
214221252|NCT04413617|DRUG|PF-06651600|100 mg
214221253|NCT04413617|DRUG|Tofacitinib|11 mg
214221254|NCT02019485|DRUG|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
214221255|NCT02019485|DRUG|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
214221256|NCT03112577|DRUG|REGN3500|Intravenous (IV) use
214221257|NCT03112577|DRUG|Dupilumab|Subcutaneous (SC) use
214221258|NCT03112577|DRUG|Placebo|Matching placebo
214221259|NCT03112577|DRUG|Fluticasone propionate|Inhalation use
214221260|NCT04721301|COMBINATION_PRODUCT|Nivolumab plus Ipilimumab plus Maraviroc|In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
214221261|NCT05739201|PROCEDURE|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
214221262|NCT05739201|PROCEDURE|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
214221263|NCT05739201|PROCEDURE|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
214221264|NCT06425835|OTHER|VR device|"The VR device consists of a pair of VR glasses with a video previously chosen and installed. Patient preparation must be done before initiating the protocol.~The first step is to choose patient candidates for VR who are understanding and interested. Guardian approval is required; then it is necessary to explain the principle, the stages and the benefits of the care.~The intensity of pain is calculated according to the visual analog scale before, during the procedure and 30 minutes after as well as the max VAS during the procedure, the 'Children Fear Scale', the satisfaction score and any adverse effects are noted."
214221265|NCT04379622|OTHER|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
214221266|NCT00641368|BEHAVIORAL|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
214221267|NCT00641368|OTHER|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
214221268|NCT04205383|OTHER|biological analyses|The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.
214221269|NCT05680688|OTHER|Manual Therapy|"* Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
214221270|NCT04106076|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
214650421|NCT03148730|DEVICE|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
214650422|NCT00439855|DRUG|Enoxaparin i.v.|
214650423|NCT00439855|DRUG|unfractionated heparin|
214221271|NCT04162860|DEVICE|Eso-SPONGE® device|Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
214650424|NCT05145465|OTHER|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
214650425|NCT04824378|OTHER|No Intervention.|No Intervention.Only learn ICG image features of different label groups
214650426|NCT04920409|OTHER|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
214650427|NCT04920409|OTHER|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
214650428|NCT00102310|DRUG|YM443|
214650429|NCT01239407|BEHAVIORAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2\. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3\. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
214650430|NCT05494307|DRUG|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
214650431|NCT05494307|DRUG|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
214650432|NCT05742984|DRUG|linaprazan glurate 25 mg QD|"The subjects will receive 25 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
214650433|NCT05742984|DRUG|linaprazan glurate 50 mg QD|"The subjects will receive 50 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
214650434|NCT05742984|DRUG|linaprazan glurate 75 mg QD|"The subjects will receive 75 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
214650435|NCT05742984|DRUG|linaprazan glurate 25 mg BID|The subjects will receive 25 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
214650436|NCT05742984|DRUG|linaprazan glurate 50 mg BID|The subjects will receive 50 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
214650437|NCT05742984|DRUG|linaprazan glurate 75 mg BID|The subjects will receive 75 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
214650438|NCT00379340|RADIATION|3-Dimensional Conformal Radiation Therapy|
214221272|NCT02801019|OTHER|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
214221273|NCT02801019|OTHER|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
214650439|NCT00379340|PROCEDURE|Conventional Surgery|
214221274|NCT02657408|DRUG|BI 1026706|
214221275|NCT02657408|DRUG|Placebo|
214221276|NCT00863213|PROCEDURE|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
214221277|NCT00863213|DRUG|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
214650440|NCT00379340|DRUG|Cyclophosphamide|Given IV
214650441|NCT00379340|BIOLOGICAL|Dactinomycin|Given IV
214650442|NCT00379340|DRUG|Doxorubicin Hydrochloride|Given IV
214650443|NCT00379340|DRUG|Etoposide|Given IV
214650444|NCT00379340|DRUG|Vincristine Sulfate Liposome|Given IV
214221278|NCT01693978|BEHAVIORAL|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007)."
214650445|NCT06351293|DEVICE|Defyne Treatment in Nasolabial Fold|Defyne will be injected into left or right nasolabial fold, per randomization.
214650446|NCT06351293|DEVICE|RHA3 Treatment in Nasolabial Fold|RHA3 will be injected into left or right nasolabial fold, per randomization.
214650447|NCT04801758|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
214650448|NCT05587881|BIOLOGICAL|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
214650449|NCT05587881|BIOLOGICAL|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
214650450|NCT02064764|DEVICE|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
214650451|NCT02064764|DEVICE|Arctic Front Advance™ Cardiac Cryoablation System|
214650452|NCT06473636|BEHAVIORAL|Mindfulness training|The mindfulness training program consisted of four 45-minute lessons, conducted once a week. After each lesson, participants were required to complete daily homework, which included the mindfulness exercises learned during that week for at least 30 minutes. The mindfulness training program was based on Kabat-Zinn's Mindfulness-Based Stress Reduction and Williams' Mindfulness-Based Cognitive Therapy. Additionally, specific contents of cancer-related mindfulness training were incorporated into this program, such as Anti-cancer Self-healing Power: 8 Lessons in Mindfulness-based Stress Reduction.
214650453|NCT05812911|PROCEDURE|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
214650454|NCT05812911|PROCEDURE|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
214650455|NCT05812911|PROCEDURE|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
214650456|NCT06079502|DEVICE|Neuromuscular Electrical Stimulation|A supervised program of intradialytic NMES of the quadriceps and calf muscles of both lower limbs with different phases, types and current intensity. The electrical stimulation program will included (total time, intensity, contraction-relaxation phase time): a toning program in the first two weeks.
214650457|NCT06079502|OTHER|resistive training program|"Part one: Warming up for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~Part two: The main part is the resistive training for quadriceps and calf muscles from supine position using weights in the form of sand bags for 20 min.~Part three: Cooling down for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~The training parameters:~The exercise training will be done during the first 2 hours of HD session using free leg weights. The patient will assume a supine lying position on the treatment plinth and perform the exercises for every lower limb separately while the other limb will be supported on the plinth by therapist or the patient himself. Resistance will be placed at the malleoli level in the distal third of the leg."
214650458|NCT03089567|DRUG|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
214221279|NCT01693978|BEHAVIORAL|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
214221280|NCT02471326|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
214221281|NCT05805319|OTHER|increasing total fiber intake|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
214221282|NCT03866876|OTHER|Eucapnic pH|Collection of Biological marker (proposed by Racinet): eucapnic pH
214221283|NCT03162367|BIOLOGICAL|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
214221284|NCT03162367|DRUG|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
214650459|NCT03089567|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
214650460|NCT06960226|OTHER|Music Listening|Participants listen to selected instrumental music excerpts presented via headphones during designated experimental trials.
214221285|NCT00324961|DRUG|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
214221286|NCT04193644|BEHAVIORAL|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
214221287|NCT04193644|BEHAVIORAL|Walking training|Walking training with moderate intensity
214221288|NCT02487017|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
214650461|NCT06960226|OTHER|Silence Control|Participants experience periods of silence with no music presented via headphones during designated control trials. This serves as the auditory control condition compared to Music Listening.
214650462|NCT06960226|OTHER|Active Sensorimotor Synchronization|Participants actively synchronize movements (such as foot tapping and/or head nodding) by timing them with the rhythm of the presented music or with a pacing stimulus provided during silent trials.
214650463|NCT06960226|OTHER|Passive Control Task|Participants remain still and do not perform specific instructed synchronized movements during designated control trials. This serves as the motor task control condition compared to Active Sensorimotor Synchronization.
214650464|NCT06960889|OTHER|radiotherapy|Definitive radiotherapy or radiotherapy-based combined modality therapy
214650465|NCT06960889|DRUG|Immunotherapy|Immune checkpoint inhibitors as monotherapy or in combination with other therapies
214650466|NCT06960889|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Radical esophagectomy with or without neoadjuvant/adjuvant therapy
214650467|NCT06960512|BEHAVIORAL|Precision Lifestyle Intervention (PLI) group|"1. Device Application: Participants in the intervention group will wear the GX-01S continuous glucose monitoring system, with data transmitted in real-time to a secure cloud platform.~2. Multidisciplinary Management: A specialized team (health managers, nutritionists, endocrinologists, and Counselor) will analyze glucose fluctuations, dietary patterns, sleep health, physical activity and to formulate personalized adjustment plans. Modifications may include meal timing optimization, sleep duration regulation, and exercise frequency adaptations.~3. Telehealth Follow-up: Participants will receive structured guidance via telephone/telemedicine consultations throughout the 28-day intervention period. Type 2 Diabetes Mellitus (T2DM) patient compliance will be systematically monitored and documented.~4. Tailored Recommendations: Evidence-based lifestyle recommendations will be provided post-intervention, informed by quantitative biomarker data and adherence metrics collected."
214650468|NCT05019131|BEHAVIORAL|Training|trainings to reduce conscious bias and stress
214650469|NCT05019131|BEHAVIORAL|Peer support and mentorship|facilitated peer and mentorship opportunities
214650470|NCT05019131|BEHAVIORAL|Leadership engagement|Engaged leadership at the county and facility levels
214650471|NCT05019131|BEHAVIORAL|Embedded champions|Facilitate local champions to promote intervention
214650472|NCT05791292|OTHER|Evaluation|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
214650473|NCT05723432|DRUG|KD6001|KD6001 will be administered intravenously.
214221289|NCT02487017|BIOLOGICAL|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
214221290|NCT01819532|PROCEDURE|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
214221291|NCT01819532|PROCEDURE|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
214221292|NCT01839669|DEVICE|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
214221293|NCT01839669|PROCEDURE|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
214221294|NCT01839669|DEVICE|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
214221295|NCT02397629|OTHER|This study has no intervention|
214221296|NCT04655651|OTHER|No intervention|There is no intervention for both groups.
214650474|NCT05723432|DRUG|Toripalimab|Toripalimab will be administered intravenously.
214650475|NCT05220839|PROCEDURE|Type of cerclage procedure Mc Donald|Patients who underwent Mc Donald cervical cerclage will be calculated the area of cervical cerclage area
214650476|NCT05378009|BEHAVIORAL|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
214650477|NCT05378009|BEHAVIORAL|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
214650478|NCT01703000|DEVICE|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
214650479|NCT03514082|DEVICE|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
214650480|NCT04139083|PROCEDURE|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
214650481|NCT04139083|PROCEDURE|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
214650482|NCT00352248|PROCEDURE|Tongue Acupuncture (Procedure)|
214221297|NCT00333099|DIETARY_SUPPLEMENT|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
214221298|NCT00333099|OTHER|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
214221299|NCT01719744|DRUG|ENMD-2076|
214221300|NCT05298449|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
214221301|NCT05298449|DRUG|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
214221302|NCT01148992|DRUG|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
214221303|NCT01148992|DRUG|Placebo|0mg
214221304|NCT05870696|DIAGNOSTIC_TEST|PrecogColo Dx test|the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer
214221305|NCT00781573|DRUG|Clopidogrel|Clopidogrel, 75 mg QD, for one year
214221306|NCT03545971|DRUG|IBI310|IBI310 is anti CTLA-4 antibody
214221307|NCT03545971|DRUG|Sintilimab|PD-1 monoclonal antibody
214221308|NCT03617016|DRUG|Domperidone|Participants will receive domperidone tablets orally.
214221309|NCT03617016|DRUG|Placebo|Participants will receive matching placebo to domperidone tablets orally.
214221310|NCT05300919|OTHER|Measurement based care|Measurement-based care based on arm.
214221311|NCT05475574|OTHER|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
214221312|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
214221313|NCT03649997|DRUG|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
214221314|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
214221315|NCT05854784|DRUG|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
214221316|NCT04463108|OTHER|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
214221317|NCT05710627|DEVICE|TENEX|Use of TENEX device for sectioning of the gluteus medius and ITB tendons.
214221318|NCT03646396|DRUG|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
214221319|NCT06121544|DIAGNOSTIC_TEST|Plasma tau|Plasma levels of different p-tau and np-tau species
214221320|NCT06121544|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|Plasma levels of Ab42/Ab40 ratio
214221321|NCT06121544|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|Positron emission tomography (PET) imaging of amyloid-β plaques
214221322|NCT06121544|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
214221323|NCT06121544|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Different MRI sequences relevant for brain imaging
214221324|NCT06491914|DRUG|Aflibercept 8 mg|Administered by intravitreal (IVT) injection
214221325|NCT03629951|DRUG|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
214221326|NCT03162627|DRUG|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
214221327|NCT03162627|DRUG|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
214221328|NCT03954574|DIAGNOSTIC_TEST|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
214221329|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
214221330|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
214221331|NCT03977181|BEHAVIORAL|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
214221332|NCT03977181|BEHAVIORAL|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
214221333|NCT03795870|DIETARY_SUPPLEMENT|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
214221334|NCT03795870|DIETARY_SUPPLEMENT|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
214221335|NCT04960124|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
214221336|NCT03963258|DEVICE|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
214221337|NCT03963258|OTHER|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
214221338|NCT04059159|DEVICE|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
214221339|NCT03350672|DRUG|FTC/TAF|Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
214221341|NCT04571697|DRUG|Methotrexate|No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
214221342|NCT04571697|DRUG|Anti-TNF|No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
214221343|NCT04342325|BIOLOGICAL|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
214221344|NCT00003278|DRUG|dexamethasone|
214221345|NCT00003278|RADIATION|radiation therapy|
214221346|NCT00000716|DRUG|Zidovudine|
214221347|NCT04145661|DEVICE|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
214221348|NCT04145661|DEVICE|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
214221349|NCT03369262|DRUG|OBE022|Oral
214221350|NCT03369262|DRUG|Placebos|Oral
214221351|NCT03369262|DRUG|Atosiban|I.V.
214221352|NCT03879161|DEVICE|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
214221353|NCT05927155|DRUG|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
214221354|NCT05927155|DRUG|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
214221355|NCT05694416|DRUG|Etoposide Plus Cisplatin|Etoposide Plus Cisplatin ivdrip d1-5
214221356|NCT04348916|BIOLOGICAL|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
214221357|NCT04348916|BIOLOGICAL|pembrolizumab|Anti-PD-1 monoclonal antibody
214221358|NCT03454360|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
214221359|NCT04298671|BEHAVIORAL|Yoga-Pilates|As above
214221360|NCT01749189|DIETARY_SUPPLEMENT|Blend|22 grams of protein/day
214221361|NCT01749189|DIETARY_SUPPLEMENT|Whey|22 grams of protein/day
214221362|NCT01749189|DIETARY_SUPPLEMENT|Placebo|22 grams of carbohydrate/day
214221363|NCT02457143|BEHAVIORAL|Letter|
214221364|NCT02457143|BEHAVIORAL|Phone call|
214221365|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
214221366|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
214221367|NCT02853058|RADIATION|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
214221368|NCT02853058|RADIATION|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
214221369|NCT01247272|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
214221370|NCT01247272|DRUG|PROZAC WEEKLY®|90 mg Capsules
214221371|NCT02781259|PROCEDURE|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
214221372|NCT02781259|DRUG|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
214221373|NCT02781259|DEVICE|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
214221374|NCT06299332|DEVICE|Device treatment|20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit
214221375|NCT05019911|DEVICE|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
214221376|NCT05019911|DEVICE|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
214221377|NCT01436929|DRUG|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
214221378|NCT01436929|DRUG|Placebo|Placebo 1tab bid
214221379|NCT03815266|DIAGNOSTIC_TEST|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
214221380|NCT03815266|DIAGNOSTIC_TEST|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
214221381|NCT03815266|DIAGNOSTIC_TEST|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
214650483|NCT01113320|DRUG|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
214650484|NCT01113320|DRUG|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
214650485|NCT00021983|BIOLOGICAL|BL22 immunotoxin|
214650486|NCT06960265|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"Targeting: The left dorsolateral prefrontal cortex (DLPFC) will be the target for treatment.~Equipment: rTMS will be delivered using a Magstim super rapid magnetic stimulator with a 70-mm air-cooled figure-eight-shaped coil. Resting Motor Threshold (rMT) Measurement: rMT is determined through visual twitch responses in the contralateral hand, identifying the minimal intensity needed to elicit thumb movement in 50% of trials.~rTMS will be administered at a frequency of 15Hz, with each pulse at 100% rMT intensity. Sessions include 60 pulses per train, with a 26-second inter-train pause, across 40 trains, totaling 2400 pulses over a 20-minute session."
214650487|NCT06960265|DEVICE|sham for repetitive Transcranial Magnetic Stimulation|The sham group will undergo a placebo procedure using the same rTMS parameters but with a figure-of-eight sham coil, following precedents set by studies on cocaine use disorder treatment (Terraneo et al., 2016).
214221382|NCT03815266|DIAGNOSTIC_TEST|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
214221383|NCT03815266|DIAGNOSTIC_TEST|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
214221384|NCT03815266|DIAGNOSTIC_TEST|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
214221385|NCT03815266|DIAGNOSTIC_TEST|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
214221386|NCT03815266|DIAGNOSTIC_TEST|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
214221387|NCT00052117|DRUG|capravirine|
214221388|NCT00052117|DRUG|Kaletra|
214221389|NCT00052117|DRUG|2 NRTIs|
214221390|NCT04240548|RADIATION|Regional Nodal Irradiation|
214221391|NCT01349400|OTHER|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
214221392|NCT01349400|PROCEDURE|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
214221393|NCT04837378|OTHER|Abdominal Massage|The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
214221394|NCT04837378|OTHER|In-bed Exercise|In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
214221395|NCT00549003|DEVICE|Rapid Diagnostic Test for P. falciparum malaria|
214221396|NCT05741619|OTHER|Long-term outcome|Autonomy, physical examination, behavioural disorders
214650488|NCT02348099|OTHER|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
214650489|NCT05413811|DRUG|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
214221397|NCT04650529|DEVICE|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
214221398|NCT00223080|BIOLOGICAL|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
214221399|NCT00223080|OTHER|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
214221400|NCT05440552|DIAGNOSTIC_TEST|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
214221401|NCT05440552|DIAGNOSTIC_TEST|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
214221402|NCT03098004|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
214221403|NCT03237286|DRUG|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
214650490|NCT05413811|DRUG|Placebo|Intravaginal topical placebo cream
214221404|NCT03237286|BEHAVIORAL|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
214221405|NCT04105504|DRUG|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
214221406|NCT04105504|DRUG|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
214221407|NCT06265662|BEHAVIORAL|A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand|The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
214221408|NCT04618848|DIAGNOSTIC_TEST|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
214221409|NCT03193593|DRUG|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
214221410|NCT03193593|DRUG|EB-001|Single injection of EB-001 into Pectoralis Muscle
214221411|NCT02877771|DEVICE|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
214221412|NCT00316043|BEHAVIORAL|Written information for parents|
214221413|NCT00316043|BEHAVIORAL|Distance learning package for General Practitioners|
214221414|NCT00316043|BEHAVIORAL|Distance learning package for practice assistants|
214221415|NCT05852613|DEVICE|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
214221416|NCT05852613|COMBINATION_PRODUCT|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
214221417|NCT04286048|OTHER|Weight implement|"The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement."
214221418|NCT04588467|OTHER|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
214221419|NCT04588467|PROCEDURE|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
214221420|NCT00253162|DRUG|risperidone|
214221421|NCT05454072|PROCEDURE|Sinonasal Microbiota Transfer|Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
214221422|NCT05454072|PROCEDURE|Sham Sinonasal Microbiota Transfer|Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
214221423|NCT00948441|DRUG|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
214221424|NCT00948441|OTHER|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
214221425|NCT05102032|PROCEDURE|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
214221426|NCT05102032|PROCEDURE|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
214221427|NCT00056797|BIOLOGICAL|ALVAC HIV vaccine (vCP1452)|
214221428|NCT00056797|DRUG|Interleukin-2|
214221429|NCT04074408|PROCEDURE|stereotactic surgery|stereotactic aspiration surgery
214221430|NCT04074408|BIOLOGICAL|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
214221431|NCT04074408|BIOLOGICAL|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
214221432|NCT00456391|PROCEDURE|Medical history|
214221433|NCT00456391|PROCEDURE|Brain CT scan|
214221434|NCT03313817|DEVICE|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
214221435|NCT00186134|BEHAVIORAL|physical activity|
214221436|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
214221437|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
214221438|NCT02578758|OTHER|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
214221439|NCT00110721|DRUG|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
214221440|NCT02797613|BEHAVIORAL|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
214221441|NCT02121080|DRUG|REGN2222(SAR438584)|
214221442|NCT02121080|DRUG|placebo|
214221443|NCT00438568|DRUG|Regular Insulin|administered intra-nasally twice a day for 16 weeks
214221444|NCT00438568|DRUG|Placebo|administered intra-nasally twice a day for 16 weeks
214221445|NCT05006001|DRUG|Colchicine and NSAID|Colchicine and nonsteroidal anti-inflammatory drug combination therapy
214221446|NCT02879188|OTHER|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
214221447|NCT02879188|OTHER|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
214221448|NCT05111730|DEVICE|The Shock wave Therapy.|Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
214221449|NCT00002076|DRUG|Fluconazole|
214221450|NCT05048966|BEHAVIORAL|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
214221451|NCT05048966|BEHAVIORAL|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
214221452|NCT00947882|DRUG|Placebo|Mannitol 50 mg/mL solution
214221453|NCT00947882|DRUG|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
214221454|NCT00947882|DRUG|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
214221455|NCT00947882|DRUG|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
214221456|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|"Group A:~1. Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~2. Treatment will focus on the patient's needs and in accordance with the physicians requests.~3. Three months post initial treatment re-assessment will be conducted."
214221457|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
214221458|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
214221459|NCT02949791|PROCEDURE|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
214221460|NCT02949791|OTHER|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
214221461|NCT02949791|OTHER|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
214221462|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
214221463|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
214221464|NCT03629496|OTHER|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
214221465|NCT05381857|OTHER|Human Biological Samples|Blood, urine, nasal swab, fecal samples
214221466|NCT04274946|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
214221467|NCT00327197|DRUG|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
214221468|NCT00327197|PROCEDURE|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
214221469|NCT02888938|OTHER|pelvic radiography|
214221470|NCT02888938|OTHER|pelvic MRI|
214221471|NCT02888938|OTHER|pelvic CT-scan|
214221472|NCT03736642|BIOLOGICAL|blood sampling|12 ml sample
214221473|NCT03736642|OTHER|stool sampling|20 g sample
214221474|NCT03736642|OTHER|urine sampling|18 ml sample
214221475|NCT03736642|DIAGNOSTIC_TEST|neuropsychological tests|"* Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale"
214221476|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
214221477|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
214221478|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
214221479|NCT02640196|DEVICE|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
214221480|NCT02640196|DEVICE|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
214221481|NCT02640196|DEVICE|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
214221482|NCT02640196|DEVICE|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
214221483|NCT01396057|DRUG|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
214221484|NCT01396057|OTHER|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
214221485|NCT01396057|OTHER|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
214221486|NCT02685137|DRUG|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
214221487|NCT02685137|OTHER|Sham Injection|nothing
214221488|NCT03290924|BEHAVIORAL|Low dose high frequency health worker training approach|"* Two 4-day training sessions for skilled birth attendants~* 1-day peer practice coordinator training after first training session~* Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~* SMS reminder messages and quizzes~* Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~* Health information officer training~* Data collection and use training~* Supply of simulators, newborn resuscitation equipment, and delivery sets"
214221489|NCT03290924|BEHAVIORAL|Active Comparison|Training on data collection and reporting
214221490|NCT02174822|DRUG|AVP-786|
214221491|NCT02174822|DRUG|Paroxetine|
214221492|NCT02174822|DRUG|Duloxetine|
214221493|NCT04449263|DEVICE|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
214221494|NCT04449263|DEVICE|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
214221495|NCT04449263|DEVICE|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
214221496|NCT06175949|DRUG|HRS-7085 Tablets|HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
214221497|NCT06175949|DRUG|HRS-7085 simulant|PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
214650491|NCT06509841|OTHER|Electro-acupuncture at the Jiaji points|Adopting treatments for the group that received electro-acupuncture at the Jiaji points, including: ① electro-acupuncture at the Jiaji points with continuous treatment for 8 weeks.
214650492|NCT06509841|OTHER|Electro-acupuncture at the scalp points|Adopting treatments for the group that received electro-acupuncture at the Scalp points, including: ① electro-acupuncture at the Scalp points with continuous treatment for 8 weeks.
214221498|NCT03282214|BEHAVIORAL|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
214221499|NCT00888719|DRUG|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
214221500|NCT00888719|DRUG|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
214221501|NCT00888719|DRUG|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
214221502|NCT05895474|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
214221503|NCT03368690|DIETARY_SUPPLEMENT|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
214221504|NCT03368690|OTHER|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
214221505|NCT04370119|DIAGNOSTIC_TEST|Nasal swab|SARS-CoV-2 PCR
214221506|NCT04370119|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
214221507|NCT03497013|DEVICE|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
214221508|NCT03497013|DEVICE|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
214221509|NCT05418543|PROCEDURE|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
214221510|NCT02194374|PROCEDURE|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
214221511|NCT02194374|DRUG|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
214221512|NCT02194374|DRUG|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
214221513|NCT02194374|DRUG|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
214221514|NCT02194374|DRUG|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
214221515|NCT03037580|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
214221516|NCT03037580|DRUG|Placebo|Placebo (sugar pill) for TID oral administration
214221517|NCT00152269|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
214221518|NCT00152269|DRUG|Asoprisnil|25mg Tablet, oral Daily for 12 months
214221519|NCT00152269|DRUG|Placebo|Placebo, Tablet, oral Daily for 12 months
214221520|NCT02327663|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
214221521|NCT02087423|DRUG|MEDI4736|MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
214221522|NCT04235296|BIOLOGICAL|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
214221523|NCT04235296|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
214221524|NCT04609644|OTHER|Digital Tools for Asthma Self-Management|Please see description of active study arm.
214221525|NCT02246465|DRUG|RXI-109|
214221526|NCT00026169|DRUG|imatinib mesylate|Given orally
214221527|NCT00026169|OTHER|laboratory biomarker analysis|Correlative studies
214221528|NCT00026169|OTHER|pharmacological study|Correlative studies
214221529|NCT00000921|DRUG|Prednisone|
214221530|NCT02470000|DEVICE|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
214221531|NCT02470000|DEVICE|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
214221532|NCT02470000|OTHER|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
214221533|NCT06017037|DRUG|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
214221534|NCT06017037|DRUG|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
214221535|NCT03500224|DRUG|[14C]-TAK-954|\[14C\]-TAK-954 intravenous infusion.
214221536|NCT04181125|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
214221537|NCT04181125|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
214221538|NCT00268853|DRUG|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
214221539|NCT00268853|DRUG|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
214221540|NCT00713297|BEHAVIORAL|satisfaction questionnaire|Satisfaction questionnaire
214221541|NCT01167244|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
214221542|NCT00500214|PROCEDURE|elective ilioinguinal nerve excision|
214221543|NCT01324401|DRUG|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
214221544|NCT01885585|DRUG|Apixaban|
214221545|NCT03574181|OTHER|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
214221546|NCT05969847|RADIATION|split-course hypofraction radiotherapy|After reaching a cumulative radiotherapy dose of 25Gy in the entire pelvic cavity (PTV1), the treatment field was subsequently narrowed to solely focus on the primary tumor (PTV2), with a total dose of 35Gy administered. All patients will undergo fractionated radiotherapy, following a regimen of 7Gy per fraction, delivered every 3 weeks for five cycles.
214221547|NCT05969847|DRUG|CAPOX|Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
214221548|NCT05969847|DRUG|Envafolimab|Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
214221549|NCT05969847|PROCEDURE|Local excision|Local full-thickness resection is employed for patients with clinical complete response (cCR) or near-clinical complete response (ncCR) following TNT.
214221550|NCT03233321|OTHER|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
214221551|NCT03233321|OTHER|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
214221552|NCT00522899|BEHAVIORAL|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
214221553|NCT00522899|BEHAVIORAL|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
214221554|NCT00522899|BEHAVIORAL|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
214221555|NCT00522899|BEHAVIORAL|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
214221556|NCT04121585|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
214221557|NCT01586130|OTHER|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
214221558|NCT04021693|OTHER|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
214221559|NCT01122121|DRUG|Leuprorelin SR|Leuprorelin SR injection
214221560|NCT01122121|RADIATION|Radiotherapy|Radiotherapy 70 +/- 4 Gy
214221561|NCT01122121|DRUG|Flutamide|Flutamide tablets
214221562|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
214221563|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
214221564|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
214221565|NCT01708902|DRUG|Metformin 500mg|Metformin 500mg BID
214221566|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
214221567|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
214221568|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
214221569|NCT01708902|DRUG|Metformin 1000mg|Metformin 1000mg BID
214221570|NCT00725062|BIOLOGICAL|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10\^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10\^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10\^7 CD4+CD25 cells/kg
214221571|NCT00725062|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
214221572|NCT00224640|DRUG|Iron chelating intervention|Iron chelating intervention
214221573|NCT03699215|DRUG|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
214221574|NCT03699215|DRUG|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
214221575|NCT02879201|PROCEDURE|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
214650493|NCT05049538|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214650494|NCT05049538|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
214221576|NCT06326333|PROCEDURE|Combined parasternal block and serratus anterior plane block|"The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally."
214221577|NCT00422682|DRUG|bsi-201 + topotecan|21 day cycle
214221578|NCT00422682|DRUG|bsi-201 + temozolomide|28 day cycle
214221579|NCT00422682|DRUG|bsi-201 + gemcitabine|28 day cycle
214221580|NCT00422682|DRUG|bsi-201 + carboplatin/paclitaxel|21 day cycle
214221581|NCT02921334|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
214221582|NCT01779258|DRUG|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
214221583|NCT01779258|DEVICE|Atopiclair®|1 application in the morning, in the afternoon and in the evening
214221584|NCT01779258|DRUG|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
214221585|NCT01779258|DRUG|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
214221586|NCT04803240|DEVICE|Thealoz Duo|Non applicable
214221587|NCT01281332|DEVICE|Menopod|The mechanism of action of the device will not be revealed in advance.
214221588|NCT01281332|DEVICE|Inactive device|
214221589|NCT05306808|OTHER|physiotherapy class|The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
214221590|NCT00442364|DRUG|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
214221591|NCT00442364|PROCEDURE|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
214221592|NCT00357279|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
214221593|NCT00357279|DRUG|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
214221594|NCT00217178|DRUG|Vitamins: Folic acid, B6, B12|
214221595|NCT00530816|DRUG|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
214221596|NCT01573234|DEVICE|MySkin patch|Hydrogel and polyurethane film
214221597|NCT01573234|DEVICE|Gauze and Patch|Traditional Dressing
214221598|NCT00003206|DRUG|carboplatin|
214221599|NCT00003206|DRUG|paclitaxel|
214221600|NCT04801056|DRUG|TB006|TB006 monoclonal antibody
214221601|NCT04801056|OTHER|Placebo|Placebo i.v. infusion
214221602|NCT03791944|DEVICE|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
214221603|NCT03791944|DEVICE|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
214221604|NCT03791944|DEVICE|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
214221605|NCT03791944|DEVICE|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
214221606|NCT04473287|OTHER|reflexology practice|Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
214221607|NCT04834089|BIOLOGICAL|AntiSARS-CoV-2 Serum|Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
214221608|NCT04834089|OTHER|Placebo|Saline solution Administration Route: Intravenous
214221609|NCT05094778|PROCEDURE|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
214221610|NCT05444595|BEHAVIORAL|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
214221611|NCT05444595|BEHAVIORAL|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
214221612|NCT05430633|PROCEDURE|Appendectomy|Appendectomy - laparoscopic or open
214221613|NCT02922478|RADIATION|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
214650495|NCT05049538|OTHER|Pap Smear|Undergo Pap smear
214650496|NCT06118385|DRUG|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
214221614|NCT02922478|PROCEDURE|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
214221615|NCT02922478|RADIATION|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
214221616|NCT02922478|PROCEDURE|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
214221617|NCT00800254|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
214221618|NCT00800254|OTHER|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
214221619|NCT03399201|PROCEDURE|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
214221620|NCT03399201|PROCEDURE|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
214221621|NCT03399201|DIAGNOSTIC_TEST|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
214221622|NCT06230211|OTHER|Music Therapy|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
214221623|NCT06230211|OTHER|Maternal Voice|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
214221624|NCT01388985|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
214221625|NCT01057589|DRUG|Pemetrexed|"Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
214221626|NCT01057589|DRUG|Cetuximab|"Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
214221627|NCT01057589|DRUG|Cisplatin|Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
214221628|NCT01057589|DIETARY_SUPPLEMENT|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
214221629|NCT01057589|DIETARY_SUPPLEMENT|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
214221630|NCT03761368|PROCEDURE|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
214221631|NCT03761368|PROCEDURE|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
214221632|NCT05533229|DRUG|Fentanyl|The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
214221633|NCT05533229|DRUG|Morphine|The trial aims to study the quality of anesthesia, perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
214221634|NCT01643096|OTHER|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
214221635|NCT01643096|OTHER|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
214650497|NCT06118385|DRUG|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
214221636|NCT00543530|DRUG|MK0831|
214221637|NCT02224001|PROCEDURE|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
214221638|NCT01454817|BEHAVIORAL|Quality of life|Improving Quality of Life
214221639|NCT01240824|DRUG|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
214221640|NCT03636516|DEVICE|SWL|extracorporeal shockwave lithotripsy apply
214221641|NCT00457457|DRUG|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
214221642|NCT00457457|DRUG|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
214221643|NCT02507167|DIETARY_SUPPLEMENT|mixed meal|250 ml Fortimel compact (chocolate)
214221644|NCT02507167|DRUG|Rifampin|oral rifampin administration (600 mg EREMFAT®)
214221645|NCT03835364|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
214221646|NCT00464191|DRUG|escitalopram|
214221647|NCT04066231|DEVICE|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
214650498|NCT04526106|DRUG|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
214650499|NCT05317221|OTHER|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
214650500|NCT05815498|BIOLOGICAL|mRNA-1283.222|Sterile liquid for injection
214650501|NCT05815498|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
214650502|NCT05815498|BIOLOGICAL|mRNA-1283.815|Sterile liquid for injection
214650503|NCT05815498|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
214221648|NCT04066231|DRUG|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
214221649|NCT04129281|PROCEDURE|Surgery|Surgery acconding to clinical practice
214221650|NCT02587273|DRUG|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
214221651|NCT06147388|DIAGNOSTIC_TEST|Colposcopy|No surgery, observation
214221652|NCT00899431|DRUG|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
214221653|NCT00899431|DRUG|Fludarabine|30 mg/m\^2 intravenously daily on days -5, -4, -3.
214221654|NCT00899431|DRUG|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
214221655|NCT00899431|DRUG|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
214221656|NCT00899431|PROCEDURE|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
214221657|NCT00899431|DRUG|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
214221658|NCT00899431|DRUG|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
214221659|NCT01193504|DRUG|Pred Forte|Pred Forte BID for 4 weeks postop
214221660|NCT01193504|DRUG|Lotemax|Lotemax BID for 4 weeks postop.
214221661|NCT04440904|DEVICE|CT workstation (Syngo Via VB10B, Siemens, Germany)|Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
214221662|NCT04867096|OTHER|Physical activity|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
214221663|NCT04483648|OTHER|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
214221664|NCT05131724|OTHER|Treadmill training with virtual reality|The virtual environment will be composed of obstacles, different paths, and narrow and deviated corridors. Walking through this environment will require the infant to coordinate walking behaviour and adjust the length, height, and width of steps to negotiate the obstacles on the television screen placed at the infant's eye level in front of the treadmill. The speed, orientation, size, frequency of appearance, and shape of the obstacles will be manipulated according to individual performance following a standardized protocol. The virtual system will provide visual and auditory feedback on the success or failure of the activity to enhance motor learning. In addition, the characteristics of the environment (e.g., visibility, configuration, and distractions) will be adjusted to increase the complexity of the training.
214650504|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
214221665|NCT05131724|OTHER|Treadmill training|The RAM870A of the Medisoft treadmill will be used. Two treadmill training sessions will be held before the onset of the intervention to familiarize the children with the equipment. During these two sessions, the treadmill training and speed will be set according to the following procedures: the ground walking speed of each child will be determined through the baseline 6MWT, then the training velocity will be set at 50% of the maximum ground speed established during the 6MWT and increased gradually based on the tolerance of each child (i.e., no complaint of fatigue, heart rate not exceeding 70% of the maximum heart rate, and a lack of gait shuffling, buckling or dragging steps more than 5 seconds during walking).
214221666|NCT05438472|OTHER|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
214650505|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
214650506|NCT06498921|OTHER|Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel|No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.
214221667|NCT05933252|OTHER|Augmented reality (AR)|an app on an iPad every 15 minutes
214221668|NCT04313361|OTHER|No intervention|No drug will be administered as part of this study.
214221669|NCT03478826|OTHER|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
214221670|NCT03478826|OTHER|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
214650507|NCT01323478|DRUG|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
214221671|NCT03478826|OTHER|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
214221672|NCT03462693|OTHER|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
214221673|NCT00238355|DRUG|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
214221674|NCT00238355|DRUG|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
214221675|NCT05036330|OTHER|Clinical Evaluation|Undergo speech and swallow evaluation
214221676|NCT05036330|PROCEDURE|Physical Examination|Undergo examination of TEP and laryngectomy stoma
214221677|NCT05036330|OTHER|Quality-of-Life Assessment|Complete questionnaires
214221678|NCT05036330|OTHER|Questionnaire Administration|Complete questionnaires
214221679|NCT04770181|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
214221680|NCT04770181|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
214221681|NCT02902146|DEVICE|Bougie|
214221682|NCT02902146|DEVICE|Endotracheal tube|
214221683|NCT01441232|DRUG|LX4211|400 mg of LX4211 administered as two 200 mg tablets
214221684|NCT01441232|DRUG|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
214221685|NCT03389958|OTHER|Counseling and provision of contraception|Provider training, availability of contraceptive methods
214221686|NCT01906606|BEHAVIORAL|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
214221687|NCT02038361|GENETIC|blood draw|
214221688|NCT03304249|BEHAVIORAL|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
214221689|NCT03304249|OTHER|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
214221690|NCT01253577|DEVICE|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
214221691|NCT01253577|DEVICE|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
214221692|NCT00334113|BEHAVIORAL|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
214221693|NCT03697889|DRUG|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
214221694|NCT03697889|DRUG|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
214221695|NCT03204240|OTHER|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
214221696|NCT01866085|PROCEDURE|AdVance® sling procedure|
214221697|NCT01866085|PROCEDURE|ARGUS Sling procedure|
214221698|NCT06218498|DEVICE|ablative fractional 2940-nm Er: YAG laser|Ablative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
214221699|NCT06218498|DEVICE|non-ablative fractional 1565nm|Non-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
214221700|NCT06218498|DRUG|5% Minoxidil|topical 5% minoxidil, 1 ml, twice daily
214221701|NCT04189224|DEVICE|JJV Investigational Multifocal Contact Lens|TEST
214221702|NCT04189224|DEVICE|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
214221703|NCT02509026|BIOLOGICAL|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
214221704|NCT00159887|DRUG|Sildenafil citrate|
214221705|NCT01539460|PROCEDURE|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
214221706|NCT01469611|BIOLOGICAL|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
214221707|NCT04078906|OTHER|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
214221708|NCT04963868|PROCEDURE|Stent removed by the novel strategy|The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；
214221709|NCT04963868|PROCEDURE|Stent removed by the conventional strategy|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
214221710|NCT04652037|DEVICE|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
214221711|NCT00692263|DRUG|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
214221712|NCT00692263|DRUG|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
214221713|NCT00692263|DRUG|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
214221714|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
214221715|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
214221716|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
214221717|NCT03265652|DEVICE|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
214221718|NCT03265652|DEVICE|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
214221719|NCT03546205|DRUG|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
214221720|NCT05163275|DIAGNOSTIC_TEST|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
214221721|NCT04643613|DIETARY_SUPPLEMENT|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
214221722|NCT04185051|DRUG|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
214221723|NCT04185051|DRUG|Placebo|Participants will receive matching placebo oral capsules.
214221724|NCT05533866|COMBINATION_PRODUCT|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
214221725|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
214221726|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
214221727|NCT03089918|DRUG|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
214221728|NCT00721968|DEVICE|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
214221729|NCT00721968|PROCEDURE|cataract surgery alone|Cataract surgery alone
214221730|NCT03174938|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
214221731|NCT03174938|DIAGNOSTIC_TEST|[18F]-RO6958948|PET imaging of Tau aggregates
214221732|NCT03174938|DIAGNOSTIC_TEST|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
214221733|NCT03174938|DIAGNOSTIC_TEST|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
214221734|NCT03593954|DRUG|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
214650508|NCT06386510|PROCEDURE|Strength training|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.
214650509|NCT06386510|PROCEDURE|Cranial nerve non-invasive neuromodulation|For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
214221735|NCT03593954|DRUG|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
214221736|NCT04198714|PROCEDURE|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
214221737|NCT01064947|DRUG|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
214221738|NCT05348213|DRUG|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
214221739|NCT05348213|DRUG|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
214221740|NCT05348213|DRUG|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
214221741|NCT05348213|DRUG|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
214221742|NCT05348213|DRUG|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
214221743|NCT02970942|DRUG|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
214221744|NCT02970942|DRUG|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
214221745|NCT06651905|DRUG|Dexmedetomidine|The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
214221746|NCT06651905|DRUG|Superior laryngeal nerve block|The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
214221747|NCT00508196|OTHER|RVP-min|DDD pacing with long AV delay
214221748|NCT00508196|OTHER|RVP-max|DDD pacing with short AV delay
214221749|NCT06655025|DRUG|Dexmedetomidine|Dexmedetomidine infusion during open heart surgery
214221750|NCT06654115|DEVICE|Wireless Physiologic Monitoring|YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
214221751|NCT00169065|DRUG|Clozapine|
214221752|NCT00169065|DRUG|Olanzapine|
214221753|NCT06444191|DRUG|Rilzabrutinib|Rilzabrutinib tablet(s) administered orally
214221754|NCT04761328|BEHAVIORAL|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
214221755|NCT06592937|OTHER|Invasive ventilation|Invasive ventilation and respiratory support
214221756|NCT04282330|DIAGNOSTIC_TEST|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
214221757|NCT02529553|DRUG|LY3076226|Administered IV
214221758|NCT06591078|OTHER|electropuncture|"The needle was retained for 30 minutes. During the retention period, the needle was lifted and twisted for 3 times with even small amplitude every 10 minutes, and the complement method was performed for 3 times. No manipulation before the needle, cotton ball press directly out of the needle.~④ Frequency, course and time: Start at the same time as immunotherapy, and complete 1-2 times of electroacupuncture treatment per week; Electroacupuncture was performed 4 times per 28 days. The number of electroacupuncture treatment cycles and the number of immunotherapy courses should be consistent."
214221759|NCT04549545|DEVICE|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
214221760|NCT04549545|DEVICE|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
214221761|NCT04478942|DRUG|Misoprostol Oral Product|Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.
214221762|NCT04478942|DRUG|Intravenous Oxytocin|Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
214221763|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
214221764|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
214650510|NCT02411448|DRUG|Ramucirumab|Administered IV.
214221765|NCT04554914|BIOLOGICAL|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
214221766|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
214221767|NCT05886413|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application, the investigators will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery. The investigators will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
214650511|NCT02411448|DRUG|Placebo|Administered IV.
214650512|NCT02411448|DRUG|Erlotinib|Administered orally.
214650513|NCT02411448|DRUG|Gefitinib|Administered orally.
214221768|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
214221769|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
214221770|NCT05475483|DRUG|Placebo capsules|Treatment was blind for the whole duration of the study.
214221771|NCT05475483|DRUG|SOM3355 200 mg capsules|Treatment was blind for the whole duration of the study.
214221772|NCT05475483|DRUG|SOM3355 300 mg capsules|Treatment was blind for the whole duration of the study.
214221773|NCT06015152|DRUG|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|\[ARAZLO\]
214221774|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
214221775|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
214221776|NCT01006291|DRUG|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
214221777|NCT03969784|OTHER|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
214221778|NCT02102204|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
214221779|NCT01597167|DIETARY_SUPPLEMENT|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
214221780|NCT02130791|BEHAVIORAL|Sleep|
214221781|NCT00202475|PROCEDURE|eythrocytapheresis|machinal collection of erythrocytes
214221782|NCT00202475|PROCEDURE|whole blood collection|collection of whole blood
214221783|NCT04628910|OTHER|Simulated Flotation Therapy|"The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions."
214221784|NCT04628910|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
214221785|NCT05661188|DRUG|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
214221786|NCT00234754|PROCEDURE|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
214221787|NCT01865552|BIOLOGICAL|SB4|SC administration
214650514|NCT02411448|DRUG|Osimertinib|Administered orally.
214221788|NCT01865552|BIOLOGICAL|EU sourced Enbrel|SC administration
214221789|NCT01865552|BIOLOGICAL|US sourced Enbrel|SC administration
214221790|NCT05957471|DRUG|Drug: BC3195 for Injection|BC3195 via intravenous(IV).
214221791|NCT03114540|DRUG|GBT440|Oral
214221792|NCT03079102|DRUG|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
214221793|NCT03079102|DRUG|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
214221794|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
214221795|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
214221796|NCT01440192|BIOLOGICAL|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
214221797|NCT05289518|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
214221798|NCT05289518|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
214221799|NCT02052492|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
214221800|NCT03716167|DEVICE|Summus Laser|infrared laser treatment
214221801|NCT03716167|DEVICE|Summus Laser Sham|non-infrared light
214221802|NCT02923921|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus FOLFOX
214650515|NCT05052268|DRUG|XTX202|XTX202 Monotherapy
214650516|NCT02689323|DEVICE|repeated transcranial magnetic stimulation|
214650517|NCT06325501|DRUG|Misoprostol 200mcg Tab|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
214221803|NCT02923921|DRUG|FOLFOX|FOLFOX Alone
214221804|NCT04230135|DEVICE|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
214221805|NCT04177576|BIOLOGICAL|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
214221806|NCT04860778|DIETARY_SUPPLEMENT|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
214221807|NCT00778843|DIETARY_SUPPLEMENT|Viusid|Viusid, three oral sachets daily during 24 weeks
214221808|NCT00778843|OTHER|Placebo|Placebo three oral sachets daily during 24 weeks
214221809|NCT00479687|DEVICE|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
214221810|NCT00479687|DEVICE|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
214221811|NCT01474239|DRUG|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
214221812|NCT01474239|DRUG|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
214221813|NCT04708314|DRUG|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
214221814|NCT04591678|DRUG|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
214221815|NCT01282619|DRUG|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
214221816|NCT01282619|DRUG|huperzine A|Tablet, 200µg twice a day, 24 weeks
214221817|NCT01282619|DRUG|Placebo|placebo orally twice a day
214221818|NCT01715012|BIOLOGICAL|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
214221819|NCT01715012|DRUG|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
214221820|NCT03192371|BIOLOGICAL|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
214221821|NCT04415671|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
214221822|NCT04415671|OTHER|Placebo|Placebo
214221823|NCT04458090|BEHAVIORAL|A decision aid for patients considering Hospice care.|A 12 page booklet and 17 min video describing hospice care
214221824|NCT02120183|BEHAVIORAL|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
214221825|NCT02175199|DEVICE|Lotrafilcon B contact lenses with color printing|
214221826|NCT02175199|DEVICE|Phemfilcon A contact lenses with color printing|
214221827|NCT06126211|DEVICE|Assessment|"The hand grip strength of each individuals was measured by the Electronic Camry Dynamometer (Model EH101, Zhongs-han Camry Electronic Co. Ltd. China: 90 kg capacity, 356 g weight) and Jamar Hydraulic Hand Grip Dynamometer (Model J00105, Lafayette Instrument Com-pany. USA: 90 kg capacity, 727 g weight). The assessments of the upper extremity were performed bilaterally.~Camry Electronic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Camry Electronic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left).~Jamar Hydraulic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Jamar Hydraulic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left)."
214221828|NCT01257061|DRUG|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
214221829|NCT01257061|DRUG|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
214221830|NCT00459732|DIETARY_SUPPLEMENT|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
214221831|NCT00459732|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
214221832|NCT04502173|DEVICE|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
214221833|NCT02789930|OTHER|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
214221834|NCT06291818|DEVICE|temporary magnetic system for tarsorrhaphy (MST)|cutting-edge technology has produced smaller magnets with stronger magnetic fields, prompting experts to revisit the use of magnets to facilitate eyelid closure
214650518|NCT06325501|DRUG|Oxytocin|after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
214650519|NCT05873218|DRUG|Ephedrine|The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
214650520|NCT05873218|DRUG|Normal Saline Placebo|Placebo will be administered at matching rate.
214221835|NCT01017380|DRUG|Celecoxib|celecoxib 400 mg 1 cap before surgery
214221836|NCT01017380|DRUG|etoricoxib|120 mg 1 tab before surgery
214221837|NCT00045461|DRUG|carboplatin|
214221838|NCT00045461|DRUG|ifosfamide|
214221839|NCT00045461|PROCEDURE|hyperthermia treatment|
214221840|NCT00935922|DIETARY_SUPPLEMENT|Flaxseed|Flaxseed omega-3 fatty acids and lignans
214221841|NCT01322841|OTHER|CHICA Diagnosis Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
214221842|NCT01322841|OTHER|CHICA Placebo|This was CHICA without the screening module
214221843|NCT01095198|DEVICE|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
214650521|NCT02735629|DRUG|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
214650522|NCT02735629|DRUG|CX1739 - 600 mg|CX1739 - 600 mg
214650523|NCT02735629|DRUG|CX1739 - 900 mg|CX1739 - 900 mg
214650524|NCT02735629|DRUG|Placebo|Placebo to 300 mg CX1739
214221844|NCT01095198|OTHER|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
214221845|NCT00283335|DRUG|gemfibrozil|
214221846|NCT00283335|OTHER|Placebo|Matching placebo tablets taken once per day
214221847|NCT05633017|COMBINATION_PRODUCT|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
214221848|NCT02817425|DRUG|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
214221849|NCT02817425|DRUG|SOX|S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
214221850|NCT02817425|DRUG|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
214221851|NCT01401660|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
214221852|NCT03983317|DEVICE|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
214221853|NCT03991897|DIETARY_SUPPLEMENT|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
214221854|NCT03991897|DIETARY_SUPPLEMENT|Isocaloric diet|Patients will follow an isocaloric diet
214221855|NCT03991897|DIETARY_SUPPLEMENT|Ketone ester supplementation|25g of a ketone monoester, ingested 3 times a day for a period of 12 weeks. Ingestion is separated from a meal and interspersed by at least 4 hours to ensure maximal available ketone bodies circulating in the blood.
214221856|NCT02904213|BIOLOGICAL|ComBe Five (Liquid)|
214221857|NCT02998957|DEVICE|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
214221858|NCT02998957|DEVICE|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
214221859|NCT03205449|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
214221860|NCT03205449|OTHER|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
214221861|NCT03565952|OTHER|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
214221862|NCT03565952|OTHER|Control group|The control group does not receive treatment
214221863|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
214221864|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
214221865|NCT03595995|BIOLOGICAL|UB-621|Monoclonal antibody by SC injection
214221866|NCT03595995|OTHER|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
214221867|NCT00323011|DRUG|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
214221868|NCT04480970|DEVICE|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
214221869|NCT01349049|DRUG|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
214221870|NCT01349049|DRUG|PLX3397|The drug product is available in capsule form, to be taken orally.
214221871|NCT03140215|DEVICE|laryngeal mask insertion (Baska)|
214221872|NCT03140215|DEVICE|laryngeal mask insertion (I-gel )|
214221873|NCT05350696|DRUG|Erector Spinae plane block (plain pubivicaine)|"The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance."
214221874|NCT05350696|DRUG|Intravenous morphine group|patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
214221875|NCT06092944|PROCEDURE|Catheterization|Before the operation,the patient was placed in the left lateral position.The catheter（soft tip epidural catheter 20-gauge-100 cm） was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level。
214221876|NCT06092944|PROCEDURE|Single nerve block|Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
214221877|NCT06092944|PROCEDURE|Continuous nerve block|After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
214221878|NCT06092944|PROCEDURE|PCIA|After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min
214221879|NCT02384798|OTHER|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
214221880|NCT02384798|OTHER|interval training|interval training
214221881|NCT01170533|DRUG|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
214221882|NCT03647813|RADIATION|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
214221883|NCT03647813|RADIATION|Placebo|The same laser protocol was followed but with the device switched off.
214221884|NCT02933450|DRUG|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
214221885|NCT05212545|DIETARY_SUPPLEMENT|Placebo|maltodextrin taken daily for 4 weeks with water
214221886|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
214221887|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
214221888|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
214221889|NCT00732446|DRUG|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
214221890|NCT00732446|DRUG|Moxifloxacin|moxifloxacin 0,5% qid and
214221891|NCT00732446|DRUG|Dexamethasone|dexamethasone 0,1% qid
214221892|NCT02810444|BIOLOGICAL|IgG Next Generation (BT595)|
214221893|NCT03414892|DRUG|Globalagliatin Hydrochloride|once daily, oral
214221894|NCT03414892|DRUG|Placebo|once daily, oral
214221895|NCT00948220|DRUG|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
214221896|NCT02381483|OTHER|Cold exposure|
214221897|NCT00345644|DRUG|risedronate|risedronate sodium 35 mg tablets (once a week dose)
214221898|NCT00345644|DRUG|risedronate placebo|placebo for risedronate tablets (once a week dose)
214221899|NCT02506985|DRUG|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
214221900|NCT02506985|DRUG|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
214650525|NCT05728879|COMBINATION_PRODUCT|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
214650526|NCT03399266|DEVICE|Double Balloon catheter for induction of labor|With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
214221901|NCT01373671|DEVICE|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
214221902|NCT00344578|DEVICE|Restor IOL|
214221903|NCT00369291|BIOLOGICAL|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
214221904|NCT00369291|BIOLOGICAL|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
214221905|NCT00001068|DRUG|Lamivudine|
214221906|NCT05173116|OTHER|Medical Outcomes Study Short Form 36 (SF 36)|completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
214221907|NCT05173116|OTHER|observationnal study|data collection
214221908|NCT04702919|OTHER|Registration|Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.
214221909|NCT04702919|OTHER|Auditive oddball task|Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
214221910|NCT05091775|DRUG|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
214650527|NCT05056844|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CESM
214221911|NCT01320137|PROCEDURE|Blood withdrawal|Blood sampling
214221912|NCT02934100|DEVICE|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
214650528|NCT05056844|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
214650529|NCT05056844|DRUG|Iodinated Contrast Agent|Given iodine-based contrast agent IV
214650530|NCT05056844|OTHER|Questionnaire Administration|Ancillary studies
214650531|NCT02686294|DRUG|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
214650532|NCT02686294|DRUG|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
214221913|NCT02934100|DEVICE|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
214221914|NCT02934100|DEVICE|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
214221915|NCT02934100|DEVICE|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
214221916|NCT02859870|DEVICE|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
214221917|NCT04455152|BEHAVIORAL|self-control|avoiding eating sweets as a way of building self-control strength
214221918|NCT01882608|OTHER|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
214221919|NCT00199303|DRUG|pre-operatively followed by 30 mg three times per day after surgery|
214221920|NCT00262938|BEHAVIORAL|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
214221921|NCT00262938|OTHER|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
214221922|NCT00262938|OTHER|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
214221923|NCT00262938|OTHER|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
214221924|NCT00262938|PROCEDURE|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
214221925|NCT06458816|DEVICE|Non-Invasive Knee Joint Distraction|Non-invasive Distraction device
214221926|NCT06458816|PROCEDURE|Manual Joint Distraction|no device. manual distraction.
214221927|NCT04995367|DEVICE|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
214221928|NCT00373893|DRUG|Lidoderm Patch|
214221929|NCT01146743|PROCEDURE|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
214221930|NCT01146743|PROCEDURE|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
214221931|NCT02643134|PROCEDURE|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
214221932|NCT02643134|DEVICE|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
214221933|NCT02756416|DEVICE|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
214221934|NCT02756416|DEVICE|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
214221935|NCT02756416|DEVICE|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
214221936|NCT03049241|OTHER|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
214221937|NCT04880291|DRUG|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
214221938|NCT04880291|DRUG|Placebo|Matched placebo
214221939|NCT06201806|OTHER|Test food breakfast with NCS or witout NCS|"Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups."
214221940|NCT04259619|DEVICE|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)\^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
214221941|NCT04259619|DEVICE|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
214221942|NCT05220475|DEVICE|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
214221943|NCT05220475|DEVICE|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
214221944|NCT02433951|OTHER|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
214221945|NCT04785469|OTHER|Low-load eccentric training|"* Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
214221946|NCT04785469|OTHER|Usual care|"* Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + \[0.002x6-Minute walk work (6MWW)\]. \[Sex: female = 0; male:1\] \[6MWW = 6-Minute walk distance x weight in kg\].~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
214221947|NCT02299583|OTHER|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
214221948|NCT01112449|OTHER|Placebo|no active medication
214221949|NCT01112449|DIETARY_SUPPLEMENT|selenomethionine|200 µg/day of selenomethionine (SM)
214221950|NCT01112449|DIETARY_SUPPLEMENT|low dose selenized-yeast|200 µg/day of SY
214221951|NCT01112449|DIETARY_SUPPLEMENT|high dose selenized-yeast|285 µg/day of SY
214221952|NCT00484757|DRUG|Orexine A|
214221953|NCT01454141|OTHER|Cognitive Control Training|Three sessions of CCT.
214221954|NCT01454141|OTHER|Peripheral Vision Task|Three sessions of PVT.
214221955|NCT04078646|OTHER|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
214221956|NCT04078646|OTHER|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
214221957|NCT04078646|OTHER|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
214221958|NCT00568165|PROCEDURE|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
214221959|NCT00568165|PROCEDURE|Standard care|Standard care
214221960|NCT04494997|OTHER|Survey Questionnaire|"This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent."
214221961|NCT05439213|DRUG|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
214221962|NCT05439213|DRUG|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
214221963|NCT02881567|DRUG|Daclizumab|High yield formulation
214221964|NCT03010488|BEHAVIORAL|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
214221965|NCT03010488|BEHAVIORAL|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
214221966|NCT03010488|DEVICE|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
214221967|NCT03544762|DRUG|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
214221968|NCT03378713|DRUG|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
214221969|NCT03378713|DRUG|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
214221970|NCT03378713|DRUG|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
214221971|NCT01335737|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4 times/week
214221972|NCT01335737|BEHAVIORAL|Wait list|wait list control condition
214221973|NCT01290913|DRUG|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
214221974|NCT01563653|PROCEDURE|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
214221975|NCT02078960|DRUG|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
214221976|NCT00472680|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
214221977|NCT00472680|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
214221978|NCT00472680|BEHAVIORAL|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
214221979|NCT04316403|PROCEDURE|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
214221980|NCT04129437|DRUG|Ibuprofen|Weight based ibuprofen dosing
214221981|NCT04129437|PROCEDURE|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
214221982|NCT04313413|OTHER|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
214221983|NCT00522938|DRUG|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
214221984|NCT00522938|DRUG|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
214221985|NCT03284541|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
214221986|NCT03284541|BEHAVIORAL|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
214221987|NCT00888186|DRUG|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
214221988|NCT05412446|DRUG|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
214650533|NCT01551979|DEVICE|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
214221989|NCT03457064|BEHAVIORAL|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
214650534|NCT04233515|DRUG|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
214650535|NCT03720132|PROCEDURE|Extensive flushing of the port catheter|The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
214650536|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
214650537|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
214221990|NCT01737593|DRUG|Acetaminophen|
214221991|NCT04595890|DEVICE|Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)|Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
214221992|NCT04595890|OTHER|Saline injection|Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
214221993|NCT02173509|OTHER|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
214221994|NCT03278353|OTHER|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
214221995|NCT03278353|OTHER|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
214221996|NCT00951197|OTHER|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
214221997|NCT05905978|PROCEDURE|Corneal donors predisposed by CXL|Corneal donors predisposed by CXL and DALK procedure was conducted in patients
214221998|NCT05905978|PROCEDURE|Corneal donors stored in corneal storage media|Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
214221999|NCT00413985|DRUG|Nutrient-enriched human milk|
214222000|NCT04156633|DIAGNOSTIC_TEST|conventional identification method: biochemical profiling or MALDI-TOF MS|Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
214222001|NCT04156633|DIAGNOSTIC_TEST|new identification method: Biofire FilmArray© BCID panel|The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
214222002|NCT04156633|DIAGNOSTIC_TEST|new identification method: metagenomic WGS|shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
214222003|NCT00975689|DRUG|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
214222004|NCT02155478|DEVICE|ISERT 250 (HOYA, Japan): a standard IOL|
214222005|NCT02155478|DEVICE|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
214222006|NCT04335136|DRUG|RhACE2 APN01|Patients will be treated with APN01 intravenously twice daily (BID).
214222007|NCT04335136|DRUG|Physiological saline solution|Patients will be treated with placebo intravenously twice daily (BID).
214222008|NCT04380246|OTHER|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
214222009|NCT06098742|DRUG|Antareit|A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
214222010|NCT01361204|DIETARY_SUPPLEMENT|Theanine|Taking 4 tablets of theanine two times daily for 16 days
214222011|NCT04011358|OTHER|Sleeping Monitor|to evaluate obstructive sleep apnea
214222012|NCT05867771|DRUG|PM1022|PM1022 Injection
214222013|NCT06027645|BEHAVIORAL|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
214222014|NCT02250729|OTHER|intradermal pholcodine allergy test in cases|
214222015|NCT02250729|OTHER|Blood sampling|
214222016|NCT00787618|DRUG|50 mg Proellex|Single dose
214222017|NCT05046327|DRUG|Avatrombopag 20 mg Oral Tablet|Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
214222018|NCT02536417|DRUG|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
214650538|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
214650539|NCT05302687|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
214222019|NCT02536417|DRUG|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
214222020|NCT03181646|DRUG|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
214222021|NCT05086029|DIAGNOSTIC_TEST|Superb Microvascular Imaging|Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
214222022|NCT04995458|PROCEDURE|composite-ceramic|To assess the clinical performance of composite-ceramic crowns
214222023|NCT04995458|PROCEDURE|Monolithic zirconia|To assess the clinical performance of monolithic z¡irconia crowns
214222024|NCT02584556|DRUG|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
214222025|NCT02584556|DRUG|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
214222026|NCT03966339|DRUG|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
214222027|NCT02949479|BEHAVIORAL|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
214222028|NCT06111118|DEVICE|ThermaCare HeatWraps|ThermaCare HeatWraps application
214222029|NCT03763097|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
214222030|NCT04653597|PROCEDURE|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order
214222031|NCT04653597|PROCEDURE|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
214222032|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
214222033|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
214222034|NCT01334619|PROCEDURE|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
214222035|NCT03885167|OTHER|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
214222036|NCT02649751|DRUG|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
214222037|NCT02649751|DRUG|Placebo|The placebo treatment is lactose capsule.
214222038|NCT02340351|DEVICE|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
214222039|NCT02340351|PROCEDURE|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
214222040|NCT01305577|DRUG|Deoxycholic acid injection|
214222041|NCT01305577|DRUG|Placebo|Phosphate buffered saline placebo for injection
214222042|NCT04726540|OTHER|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
214222043|NCT05151029|DEVICE|Elastography|new dignostic tool
214222044|NCT00718653|DIETARY_SUPPLEMENT|Lutein|Lutein (12 mg/d)
214222045|NCT00718653|DIETARY_SUPPLEMENT|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
214222046|NCT03928977|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
214650540|NCT05302687|DIETARY_SUPPLEMENT|placebo|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
214650541|NCT05306132|DRUG|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
214650542|NCT01826708|BIOLOGICAL|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
214222047|NCT00796978|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
214222048|NCT00796978|OTHER|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
214222049|NCT00796978|PROCEDURE|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
214222050|NCT00796978|PROCEDURE|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
214222051|NCT02750241|BEHAVIORAL|Active video game-based intervention|"* Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~* Participate in self-paced home sessions~* Monitor daily, weekly, and monthly steps using Wii Fit Meter~* Feedback on physical activity and physical function"
214222052|NCT02750241|BEHAVIORAL|Pedometer|"* Attend 3 monthly UTMB Breast Cancer Support Group Sessions~* Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~* Feedback on physical activity and physical function"
214222053|NCT02059096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
214222054|NCT02967341|OTHER|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
214222055|NCT00257270|DRUG|gabapentin|
214222056|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
214222057|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
214222058|NCT04655937|OTHER|Acceptance and Commitment Therapy|9 x two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
214222059|NCT03253341|BEHAVIORAL|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
214222060|NCT03253341|BEHAVIORAL|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
214222061|NCT00914108|BEHAVIORAL|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
214222062|NCT02364336|DRUG|Peginterferon alfa-2a|
214222063|NCT05787548|BEHAVIORAL|Contact information|Information on how to contact Geisinger if the patient needs care
214222064|NCT05787548|BEHAVIORAL|Urgent care map|A map of the patient's nearest Geisinger urgent care location, with information about urgent care
214222065|NCT05787548|BEHAVIORAL|Self-triage chart|A chart demonstrating what to do in response to several common conditions where the patient might be compelled to visit the ED
214222066|NCT03333772|BEHAVIORAL|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
214222067|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
214222068|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
214222069|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of breast milk|Daily oral consumption of breast milk
214222070|NCT05819255|OTHER|Non-Interventional|"This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs.~The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology."
214222071|NCT05246514|DRUG|Trastuzumab deruxtecan|administered as an IV infusion
214222072|NCT02910986|BEHAVIORAL|Written educational brochure|Written educational brochure about breast density
214650543|NCT02780193|DRUG|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
214222073|NCT02910986|BEHAVIORAL|Promotora interaction|Promotora education about breast density
214222074|NCT05377229|DEVICE|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
214222075|NCT06331013|RADIATION|CyberKnife ultra-hypofractionated SBRT|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
214222076|NCT04856085|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214222077|NCT04856085|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
214222078|NCT04856085|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
214222079|NCT02592096|DRUG|0.1% Pazufloxacin Mesilate Ear Drops|
214222080|NCT02592096|DRUG|0.3% Pazufloxacin Mesilate Ear Drops|
214222081|NCT02592096|DRUG|0.5% Pazufloxacin Mesilate Ear Drops|
214222082|NCT02592096|DRUG|Pazufloxacin mesilate injection|
214222083|NCT02897856|DRUG|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
214222084|NCT02897856|DRUG|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
214222086|NCT04756908|DEVICE|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
214222087|NCT04856839|DIAGNOSTIC_TEST|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
214222088|NCT01068600|DRUG|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
214222089|NCT01068600|DRUG|Placebo to indacaterol|Once daily via SDDPI
214222090|NCT02575690|DIETARY_SUPPLEMENT|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
214222091|NCT02575690|OTHER|Placebo|Individuals receive a placebo daily, for 3 months.
214222092|NCT03715049|PROCEDURE|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
214222093|NCT06061757|DEVICE|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
214222094|NCT03386916|PROCEDURE|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
214222095|NCT02928016|OTHER|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222096|NCT02928016|OTHER|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222097|NCT02928016|OTHER|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222098|NCT02928016|OTHER|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222099|NCT02928016|OTHER|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222100|NCT02928016|OTHER|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
214222101|NCT01727024|DRUG|Tiotropium|Tiotropium via Respimat® device once a day
214222102|NCT01727024|DRUG|Indacaterol|Indacaterol via Breezhaler® device once a day
214222103|NCT06131060|OTHER|Progressive eccentric exercises|This include progressive eccentric exercises thrice a week for 6 weeks.
214222104|NCT06131060|OTHER|Bodyweight exercises|This include bodyweight exercises thrice a week for 6 weeks
214222105|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
214222106|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
214222107|NCT04296838|DRUG|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
214222108|NCT05525481|DRUG|Tamoxifen|Hormone therapy
214222109|NCT03345290|DEVICE|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
214222110|NCT03345290|DEVICE|Central blood pressure measurement|Central blood pressure measurement
214222111|NCT03345290|OTHER|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
214222112|NCT05970354|DRUG|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
214222113|NCT05970354|DRUG|VersaPro Cream Base for Compounding|Placebo
214222114|NCT02167139|DRUG|Humira (adalimumab)|
214222115|NCT02167139|DRUG|SB5 (proposed biosimilar to adalimumab)|
214222116|NCT01406613|OTHER|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
214222117|NCT00357669|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
214222118|NCT00357669|DRUG|Brivaracetam 50 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
214222119|NCT00357669|OTHER|Placebo|"* Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use"
214650544|NCT04041115|DIETARY_SUPPLEMENT|Non-alcoholic beer|Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
214222120|NCT05634668|OTHER|Interviewing sheet|"1. . Interviewing sheet: It was designed by the researchers and used to obtain subjects' sociodemographic data; their age, menopausal age, gravidity, parity, BMI, residency, occupation, education level, hot flashes, sweating, and daily habits.~2. . Menopause specific quality of life questionnaire (MENQOL): MENQOL was designed by Hilditch and used to assess the presence of menopausal symptoms, its severity, and the degree to which they adversely affect women's life. It consisted of 29 items categorized into four domains~3. . Pittsburgh Sleep Quality Index (PSQI): The PSQI was a self-report scale consisting of 7 components and 19 questions. PSQI studies quality of sleep in the recent month."
214222121|NCT05055206|DIAGNOSTIC_TEST|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
214222122|NCT03637439|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
214222123|NCT03637439|OTHER|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
214222124|NCT02885116|DEVICE|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
214222125|NCT02885116|DEVICE|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
214222126|NCT00480467|DRUG|SAM-315|
214222127|NCT01553370|OTHER|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
214222128|NCT01553370|OTHER|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
214222129|NCT05391490|GENETIC|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
214650545|NCT04041115|OTHER|control|Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
214222130|NCT00989872|DRUG|EDP-322|
214222131|NCT00488553|BEHAVIORAL|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
214222132|NCT05322668|DEVICE|Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)|"All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~* Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~* Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin"
214222133|NCT05398913|DRUG|Rimonabant|Rimonabant
214222134|NCT04286906|OTHER|Questionnaire|MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
214222135|NCT04165421|BEHAVIORAL|Family intervention group|Education and Family conversations
214222136|NCT02806583|OTHER|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
214222137|NCT00597324|PROCEDURE|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
214222138|NCT02912858|DEVICE|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
214222139|NCT05768607|PROCEDURE|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
214222140|NCT05768607|PROCEDURE|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
214222141|NCT05768607|PROCEDURE|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
214222142|NCT05915598|OTHER|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
214222143|NCT05915598|OTHER|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
214222144|NCT02893956|PROCEDURE|echocardiography with postural support|
214222145|NCT02893956|PROCEDURE|echocardiography with standard condition (usual)|
214222146|NCT00860548|DRUG|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
214222147|NCT05268913|DIAGNOSTIC_TEST|MRI scan|Participants will undertake a magnetic resonance imaging scan.
214222148|NCT05268913|BIOLOGICAL|Blood test|Participants will undertake a fasting blood test.
214222149|NCT05870943|PROCEDURE|Hybrid Argon Plasma Coagulation|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach.
214222150|NCT05870943|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
214222151|NCT00329797|DIETARY_SUPPLEMENT|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
214222152|NCT00329797|DIETARY_SUPPLEMENT|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
214650546|NCT01590173|DRUG|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
214222153|NCT00329797|RADIATION|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
214222154|NCT00329797|DRUG|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
214222155|NCT00329797|DIETARY_SUPPLEMENT|Vitamin D|400 IU (10μg), orally each day for 3 years.
214222156|NCT02644876|DRUG|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
214222157|NCT02644876|DRUG|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
214222158|NCT02219867|DRUG|Ketamine|Drug (including placebo)
214222159|NCT06178601|DRUG|RC48-ADC|RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
214222160|NCT06178601|DRUG|AK104|AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
214222161|NCT03220906|OTHER|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
214222162|NCT02084121|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
214222163|NCT00161343|BEHAVIORAL|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
214222164|NCT06518018|RADIATION|HDR brachytherapy (30Gy single fraction)|Study Group receives a novel triple combination therapy for advanced NSCLC in the second-line setting. The treatment begins with a single fraction of high-dose rate (HDR) brachytherapy, delivering 30 Gy locally to the tumor site. This is followed within 1-3 days by systemic therapy, combining immunotherapy and chemotherapy , both administered intravenously.
214222165|NCT06518018|DRUG|Immunotherapy|Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
214222166|NCT05751603|DRUG|sugammadex|sugammadex is administered just after extubation
214222167|NCT03615443|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
214222168|NCT00653926|DRUG|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
214222169|NCT00653926|DRUG|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
214222170|NCT03370432|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
214222171|NCT01405144|DRUG|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
214222172|NCT01405144|PROCEDURE|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
214222173|NCT01206218|DRUG|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
214222174|NCT01206218|DRUG|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
214222175|NCT05270252|OTHER|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright \& Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
214222176|NCT05429385|DRUG|HLX70|Single-dose, intravenous infusion
214222177|NCT05429385|DRUG|Placebo|Single-dose, intravenous infusion
214222178|NCT06227104|DEVICE|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
214222179|NCT00073476|DRUG|traxiprodil (CP-101,606)|
214222180|NCT05196321|OTHER|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
214222181|NCT02659891|BIOLOGICAL|IVIg|
214222182|NCT02659891|OTHER|Placebo|
214222183|NCT01430052|DRUG|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
214222184|NCT01430052|DRUG|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
214222185|NCT04911608|OTHER|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
214222186|NCT04911608|OTHER|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
214222187|NCT01385527|BEHAVIORAL|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
214222188|NCT01385527|DRUG|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
214222189|NCT04976543|DRUG|nadroparin calcium-warfarin sequential anticoagulation|The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
214222190|NCT01858935|DRUG|ND-L02-s0201 Injection|Single IV infusion.
214222191|NCT01858935|DRUG|Placebo|Single IV infusion.
214222192|NCT00272103|DRUG|Itopride (drug)|
214222193|NCT05317741|DRUG|IA-14069|Subjects received IA-14069 tablet orally on Day 1.
214222194|NCT05317741|DRUG|Placebo|Subjects received matching placebo tablet orally on Day 1.
214222195|NCT01575626|DRUG|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
214222196|NCT01508806|DRUG|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
214222197|NCT03327103|BEHAVIORAL|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
214222198|NCT06020989|DRUG|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
214222199|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
214222200|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
214222201|NCT04656327|OTHER|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
214222202|NCT02211170|DRUG|BIBR 796 BS, low dose|
214222203|NCT02211170|DRUG|BIBR 796 BS, high dose|
214222204|NCT02211170|DRUG|Placebo|
214222205|NCT02211170|DRUG|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
214222206|NCT03985969|DRUG|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
214222207|NCT03985969|DRUG|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
214222208|NCT00104520|DRUG|AZLI 75 mg two times a day (BID)/three times a day (TID)|
214222209|NCT00104520|DRUG|Placebo two times a day (BID)/three times a day (TID)|
214222210|NCT06140030|BEHAVIORAL|Mindfulness training|Mindfulness-training mobile health application
214222211|NCT01862237|OTHER|Intervention|"* blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery."
214222212|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP)|"Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions."
214222213|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)|Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
214222214|NCT03830619|DIAGNOSTIC_TEST|collect samples|collect serum samples and clinical features
214222215|NCT01151904|DRUG|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
214222216|NCT01151904|DRUG|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
214222217|NCT01026324|DRUG|dinaciclib|Given IV
214222218|NCT01026324|OTHER|pharmacological study|Correlative studies
214222219|NCT01026324|OTHER|laboratory biomarker analysis|Correlative studies
214222220|NCT01311141|DRUG|doripenem|doripenem once i.v.500mg
214222221|NCT06176911|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
214222222|NCT06176911|DRUG|Danazol|200 mg twice daily.
214222223|NCT03358264|DIETARY_SUPPLEMENT|L-citrulline|Amino acid supplement
214222224|NCT05188053|DRUG|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
214222225|NCT05188053|DRUG|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
214222226|NCT05405686|DRUG|Lutropin alfa|addition of recombinant luteinizing hormone
214222227|NCT05405686|DRUG|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
214222228|NCT05405686|DIAGNOSTIC_TEST|Endometrial biopsy|pipelle de cornier biopsy
214222229|NCT03182569|DEVICE|FLEXIBLE CATHETER|
214222230|NCT03182569|DEVICE|hourly rigid needle puncture|
214222231|NCT00238641|DRUG|Botulinum Toxin type B|
214222232|NCT00794313|DRUG|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
214222233|NCT00794313|DRUG|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
214222234|NCT00794313|DRUG|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
214222235|NCT05895019|DRUG|Propofol|Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
214222236|NCT02344524|DEVICE|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
214222237|NCT02447302|DRUG|Etrasimod|
214650547|NCT01590173|DRUG|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
214222238|NCT02447302|DRUG|Placebo|
214222239|NCT00752804|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
214222240|NCT00752804|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
214222241|NCT00752804|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
214222242|NCT01901250|DIETARY_SUPPLEMENT|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
214222243|NCT01901250|DIETARY_SUPPLEMENT|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
214222244|NCT01901250|BEHAVIORAL|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
214222245|NCT01901250|DEVICE|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
214222246|NCT01901250|DEVICE|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
214222247|NCT03672890|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
214222248|NCT04401683|DEVICE|Home-based rehabilitation with a digital biofeedback system|"Participants in the experimental group will perform a 12-week digital exercise program, to be performed independently at home using the SWORD Phoenix® medical device, under remote monitoring from a physical therapist.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
214222249|NCT04401683|OTHER|Conventional home-based rehabilitation|"Participants in the control group will benefit from a 12-week home-based rehabilitation program, consisting of 12 face-to-face sessions (1 per week) with a physical therapist, complemented by additional non-supervised sessions. Both supervised and unsupervised sessions will follow the same set of exercises defined for the experimental group.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
214222250|NCT00006100|BIOLOGICAL|aldesleukin|
214222251|NCT00006100|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
214222252|NCT00006100|DRUG|fludarabine phosphate|
214222253|NCT00006100|PROCEDURE|peripheral blood stem cell transplantation|
214222254|NCT00284453|PROCEDURE|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
214222255|NCT00463723|DRUG|FK506 0.06% (eye drops)|
214222256|NCT03111641|DIAGNOSTIC_TEST|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
214650548|NCT01016379|GENETIC|DNA analysis|
214222257|NCT03892304|OTHER|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
214222258|NCT04341519|BEHAVIORAL|PTSD|"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days"
214222259|NCT04341519|BEHAVIORAL|Burnout|Symptoms of burnout as assessed by the Maslash Burnout Inventory
214222260|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention handbook
214222261|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention research nurse coaching
214222262|NCT03686007|OTHER|Informational Intervention|Receive ASCO print materials
214222263|NCT03686007|OTHER|Informational Intervention|Receive CRA assistance
214222264|NCT03686007|OTHER|Media Intervention|View the MSM intervention videos
214222265|NCT03686007|OTHER|Media Intervention|View American Cancer Society (ACS) videos
214222266|NCT01867697|DRUG|Cetuximab|
214222267|NCT01867697|DRUG|Irinotecan|
214222268|NCT01867697|DRUG|Oxaliplatin|
214222269|NCT01867697|DRUG|Folinic Acid|
214222270|NCT01867697|DRUG|Calcium Carbonate|
214222271|NCT02752581|DEVICE|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
214222272|NCT02752581|DEVICE|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
214222273|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
214222274|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
214222275|NCT00614068|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
214222276|NCT00614068|BEHAVIORAL|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
214222277|NCT00152919|DRUG|Meloxicam|
214222278|NCT00687141|DRUG|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
214222279|NCT00687141|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
214222280|NCT04787536|PROCEDURE|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
214222281|NCT04927624|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
214222282|NCT04927624|PROCEDURE|quoadratus lumborum block|quoadratus lumborum block
214222283|NCT04619771|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
214222284|NCT04522830|DRUG|BTL-TML-COVID|"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
214222285|NCT04522830|DRUG|Placebo|"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
214222286|NCT05779618|OTHER|no intervention|observational study, all data collected are binary
214222287|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
214222288|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
214222289|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
214222290|NCT05961007|DRUG|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
214222291|NCT01456897|DRUG|OPC-34712|orally administered once daily
214650549|NCT01016379|OTHER|biologic sample preservation procedure|
214650550|NCT01016379|OTHER|laboratory biomarker analysis|
214222292|NCT06057727|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
214222293|NCT06057727|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
214222294|NCT06057727|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
214222295|NCT06057727|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
214222296|NCT00493051|BIOLOGICAL|GAM501|Ad5PDGF-B formulated in a collagen gel
214222297|NCT00493051|BIOLOGICAL|Placebo|Collagen gel
214222298|NCT00493051|OTHER|Standard of care|moist dressing changes daily
214222299|NCT03304938|DRUG|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
214222300|NCT03304938|DRUG|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
214222301|NCT00930072|DRUG|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
214222302|NCT01396070|DRUG|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
214222303|NCT01561313|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
214222304|NCT03722004|BIOLOGICAL|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
214222305|NCT03722004|BIOLOGICAL|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
214222306|NCT03722004|BIOLOGICAL|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
214222307|NCT01810536|DEVICE|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
214222308|NCT01810536|DEVICE|Venturi mask|
214222309|NCT02377739|OTHER|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
214222310|NCT04254913|DRUG|MT-1186|Suspension
214222311|NCT02045641|PROCEDURE|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
214222312|NCT04621149|OTHER|chlorine dioxide|chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
214650551|NCT06157385|BEHAVIORAL|Culinary Medicine|The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.
214650552|NCT06157385|BEHAVIORAL|Control|The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
214650553|NCT02701673|DRUG|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
214650554|NCT02701673|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
214222313|NCT04621149|DIETARY_SUPPLEMENT|zinc acetate|zinc acetate lozenges have been suggested to have antiviral properties
214222314|NCT04621149|DRUG|Famotidine|famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
214650555|NCT02701673|DRUG|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
214222315|NCT04621149|OTHER|placebo|filtered water
214222316|NCT04621149|DIETARY_SUPPLEMENT|lactoferrin, green tea extract|lactoferrin and green tea extract are dietary supplements
214222317|NCT04464018|OTHER|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
214222318|NCT02695420|DRUG|25 mg Omecamtiv Mecarbil|oral tablet
214222319|NCT02695420|DRUG|Placebo|oral tablet
214222320|NCT02695420|DRUG|37.5 mg Omecamtiv Mecarbil|oral tablet
214222321|NCT02695420|DRUG|50 mg Omecamtiv Mecarbil|oral tablet
214222322|NCT04655170|DRUG|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
214650556|NCT02701673|DRUG|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
214650557|NCT02701673|DRUG|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
214650558|NCT02701673|DRUG|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
214650559|NCT02701673|DRUG|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
214222323|NCT04655170|DRUG|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
214222324|NCT03881215|PROCEDURE|Platelet Rich Plasma|Platelet Rich Plasma
214222325|NCT03881215|PROCEDURE|intra-uterine balloon|intra-uterine balloon
214222326|NCT04535453|BIOLOGICAL|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
214222327|NCT04535453|OTHER|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
214222328|NCT03412240|PROCEDURE|Induced pacing of the heart|Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
214222329|NCT00416039|DRUG|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
214222330|NCT00416039|DRUG|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
214222331|NCT01911962|PROCEDURE|transvaginal laparoscopic surgery|
214222332|NCT00695929|DRUG|Levosimendan|Intravenous injection
214222333|NCT00695929|DRUG|Milrinone|Intravenous injection
214222334|NCT03843008|DIETARY_SUPPLEMENT|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
214222335|NCT01245569|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
214222336|NCT01245569|DRUG|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
214222337|NCT05507112|DRUG|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
214222338|NCT05507112|DRUG|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
214222339|NCT05507112|RADIATION|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
214222340|NCT00916929|DEVICE|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
214222341|NCT02929407|DRUG|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
214222342|NCT02929407|DRUG|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
214222343|NCT06259656|DIAGNOSTIC_TEST|COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)|Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
214222344|NCT05721599|BEHAVIORAL|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
214222345|NCT02413151|BEHAVIORAL|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
214222346|NCT02413151|DEVICE|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
214222347|NCT00002618|BIOLOGICAL|filgrastim|
214222348|NCT00002618|DRUG|cytarabine|
214222349|NCT00002618|DRUG|doxorubicin hydrochloride|
214222350|NCT00002618|DRUG|leucovorin calcium|
214222351|NCT00002618|DRUG|mercaptopurine|
214222352|NCT00002618|DRUG|methotrexate|
214222353|NCT00002618|DRUG|prednisone|
214222354|NCT00002618|DRUG|vincristine sulfate|
214222355|NCT00002618|RADIATION|low-LET cobalt-60 gamma ray therapy|
214222356|NCT00002618|RADIATION|low-LET electron therapy|
214222357|NCT00002618|RADIATION|low-LET photon therapy|
214222358|NCT03156296|DRUG|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
214222359|NCT03156296|DRUG|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
214222360|NCT01236976|DEVICE|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
214222361|NCT01236976|DEVICE|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
214650560|NCT02701673|DRUG|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
214650561|NCT02701673|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
214650562|NCT06182735|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
214650563|NCT03118193|OTHER|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
214650564|NCT03118193|BIOLOGICAL|blood test|one sample of 4mL
214222362|NCT01236976|OTHER|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
214222363|NCT01236976|OTHER|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
214222364|NCT01360736|BEHAVIORAL|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
214222365|NCT00982059|OTHER|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
214222366|NCT01286909|DIETARY_SUPPLEMENT|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
214222367|NCT00850421|DRUG|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
214222368|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
214222369|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
214222370|NCT02442804|DIETARY_SUPPLEMENT|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
214222371|NCT02442804|OTHER|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
214222372|NCT02464280|OTHER|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
214222373|NCT02464280|OTHER|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
214222374|NCT02464280|OTHER|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
214222375|NCT02036853|DRUG|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
214222376|NCT01755819|DEVICE|Biocomposite interference screw|
214222377|NCT01755819|DEVICE|Extracortical ACL Tightrope fixation|
214222378|NCT04269798|OTHER|Traditional Treatment|conventional rehabilitation program for lower limb, balance and gait training
214222379|NCT05493800|DRUG|MIT-001|Corresponding dose of MIT-001 IV injection during 0.5\~1hr
214222380|NCT05493800|DRUG|normal saline|normal saline IV injection
214222381|NCT02375334|OTHER|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
214222382|NCT00254930|DRUG|risperidone|
214222383|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLE494
214222384|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLF497
214222385|NCT01035411|DRUG|AZD9668|2 x 30 mg tablet variant 1
214222386|NCT03783715|DRUG|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
214222387|NCT01742286|DRUG|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
214222388|NCT03200886|DEVICE|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
214222389|NCT03200886|DRUG|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
214222390|NCT04335734|PROCEDURE|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
214222391|NCT04335734|PROCEDURE|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
214650565|NCT03118193|BIOLOGICAL|Collection of faeces|Collection of faeces by patient at home - optional
214222392|NCT05155189|BIOLOGICAL|C-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
214222393|NCT05155189|DRUG|Lenvatinib|Tyrosine kinase inhibitors
214222394|NCT05155189|DRUG|PD-1(L1) monoclonal antibody|Immune checkpoint inhibitors, ICIs
214222395|NCT01890252|DEVICE|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
214650566|NCT03118193|DEVICE|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
214650567|NCT02483741|BIOLOGICAL|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
214222396|NCT01890252|DRUG|saline solution|saline solution of 5% NaCl
214222397|NCT01452100|DRUG|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
214222398|NCT01452100|OTHER|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
214222399|NCT00163254|DRUG|abciximab|
214222400|NCT00163254|DEVICE|stent and drug eluting stent|
214222401|NCT06153719|OTHER|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
214222402|NCT01305980|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
214222403|NCT02633020|BIOLOGICAL|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
214222404|NCT02633020|BIOLOGICAL|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
214222405|NCT04174326|BEHAVIORAL|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
214222406|NCT01649206|PROCEDURE|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
214222407|NCT04306796|DEVICE|3D printed splints|3D printed made to measure splints
214222408|NCT04306796|DEVICE|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
214222409|NCT06373133|DRUG|SHR-8068|1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w
214222410|NCT06373133|DRUG|Adebrelimab|1200mg, ivgtt, d1, q3w
214222411|NCT06373133|DRUG|BP102|7.5mg/kg, ivgtt, d1, q3w
214222412|NCT05611333|BEHAVIORAL|Physician-Led Remote Exercise Program Intervention|The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
214222413|NCT01136785|DEVICE|active CPAP Therapy|7 days of active CPAP therapy
214222414|NCT01136785|DEVICE|sham CPAP therapy|7 days of sham CPAP therapy
214222415|NCT03423199|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214222416|NCT03423199|DRUG|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214222417|NCT03423199|DRUG|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
214650568|NCT04067518|BIOLOGICAL|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days
214222418|NCT03423199|DRUG|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
214222419|NCT01461109|DRUG|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
214222420|NCT02850471|DEVICE|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
214222421|NCT05842356|BEHAVIORAL|Communication Technique 2|A new communication technique.
214222422|NCT03435783|BEHAVIORAL|Brief Electronic Intervention|The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
214222423|NCT03435783|BEHAVIORAL|Attention-Matched Control|Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
214222424|NCT02954172|DRUG|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
214222425|NCT02954172|DRUG|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
214222426|NCT00853567|DRUG|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
214222427|NCT00853567|OTHER|placebo|Placebo
214222428|NCT00388817|BEHAVIORAL|Pharmacist intervention|
214222429|NCT01235078|DEVICE|EZ-IO|powered intraosseous vascular access system
214222430|NCT06870071|OTHER|Control group|IV paracetamol (1 g, 3×1) and IV dexketoprofen (50 mg, 2×1)
214222431|NCT06870071|OTHER|Quadro iliac plane block|40 mL of 0.25% bupivacaine
214222432|NCT06614166|OTHER|SBD111 Probiotic Medical Food|Medical food comprised of probiotics and prebiotic fibers
214222433|NCT06614166|OTHER|SBD121 Probiotic Medical Food|Probiotic medical food comprised of three lactic acid bacteria and one bacillus
214222434|NCT01545505|BEHAVIORAL|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
214222435|NCT05073146|OTHER|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
214222436|NCT06671405|DRUG|AZD0780|Dose 1 and Dose 2
214222437|NCT06671405|DRUG|Itraconazole|"* Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration)."
214222438|NCT06671405|DRUG|Carbamazepine|"* Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only)."
214222439|NCT06671405|DRUG|Midazolam|"* Period 1 (midazolam administration only).~* Period 3 (AZD0780 + midazolam administration)."
214222440|NCT06671405|DRUG|Ethinyl estradiol/levonorgestrel|"* Period 1 (EE and LNG administration only).~* Period 3 (AZD0780 + EE and LNG administration)."
214222441|NCT06748443|BEHAVIORAL|Support intervention for the use of Knee Control+|Coaches will be offered a smorgasbord of support interventions that they can choose from depending on their specific needs: physical and digital workshops before and during the study, site visits to their team, digital programme material, leaflets and social media posts. Fitness coaches will be responsible for physical workshops to train the football coaches.
214222442|NCT06748443|OTHER|Information about Knee Control+|Coaches receive information about injuries in football and the efficacy of injury prevention exercise programmes at a pre-season digital workshop, and guided to access the Knee Control+ programme from the Swedish Football Association website.
214222443|NCT05552196|DRUG|Ponesimod|Ponesimod tablet will be administered orally.
214222444|NCT05552196|DRUG|Carbamazepine|Carbamazepine tablet will be administered orally.
214222445|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
214222446|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
214222447|NCT00982423|DRUG|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
214222448|NCT04842591|DIAGNOSTIC_TEST|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
214222449|NCT06925490|DRUG|Metapex|Pulpectomy using Metapex
214222450|NCT06925490|DRUG|3Mixtatin|pulpotomy treatment when applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
214222451|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
214222452|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
214222453|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
214222454|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
214222455|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
214222456|NCT06919926|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
214222457|NCT06919926|DRUG|Placebo|placebo capsule
214650569|NCT02771522|DEVICE|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black \& white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
214222458|NCT02712047|DRUG|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
214222459|NCT02712047|DRUG|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
214222460|NCT02712047|DRUG|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
214222461|NCT06924294|OTHER|observation of renal affection in patients with liver cirrhosis|"* CBC~* Liver function test~* kidney function test (serum creatinine, BUN, eGFR (EPI equation and MDRD equation) ,~* Prothrombin time and concentration, INR,~* Serum electrolytes~* Urine analysis."
214650570|NCT01555229|DEVICE|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
214650571|NCT01555229|DEVICE|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
214222462|NCT02536053|PROCEDURE|Limb salvage|
214222463|NCT05167071|DRUG|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
214222464|NCT05167071|DRUG|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
214222465|NCT05167071|DRUG|Tislelizumab|Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.
214222466|NCT06940206|DIAGNOSTIC_TEST|Multidirectional Isometric Assessment of the Hip|Participants perform isometric tests (flexion, extension, ABD, ADD) to assess isometric hip strength at different basic movements over two sessions. Data is collected to evaluate the reliability and validity of these tests for swimmers.
214222467|NCT06941428|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a cognitive-behavioral individual intervention for children aged 3 to 18 years with trauma exposure and related mental health sequelae.TF-CBT core components include psychoeducation, relaxation skills, affective regulation skills, cognitive coping skills, construction of a trauma narrative to facilitate imaginal exposure and cognitive processing of the traumatic events, and in vivo exposure to trauma reminders. TF-CBT is hypothesized to operate on specific mechanisms that influence improvements in clinical outcomes.
214222468|NCT06941428|BEHAVIORAL|School-Adapted TF-CBT (S-TF)|S-TF is a version of Trauma-Focused Cognitive Behavioral Therapy modified for delivery by providers in the education sector. Although modifications will be determined by Study 1 activities, we anticipate that S-TF might modify treatment pacing, session length, or content sequencing. Regardless, the core functions of TF-CBT will be retained in the S-TF redesign.
214222469|NCT06937918|DEVICE|The AFM and Eadyn - guided resuscitation group|A fluid challenge using a stroke volume change prediction (∆SVpredict) and Eadyn guide. If the ∆SVpredict is more than 10%, isotonic crystalloid of 500 ml will be administered in 30 minutes, and the machine's response will be awaited. If ∆SVpredict is still more than 10%, continuous fluid loading was reapplied until SVV was less than 10% (fluid therapy will be stopped if ∆SVpredict is less than 10%) and dynamic arterial elastance (EAdyn) reaches the goal of 0.8-1.0 along with a vasopressor will be administered and titrated every 10 minutes until the target MAP \> 65 mmHg is reached. After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed
214222470|NCT06937918|OTHER|The standard care for septic shock|"The standard of care group will be treated according to according to septic shock guidelines 2021; In brief A vasopressor with optimal ideal fluid (at least 30 ml/kg) will be given to achieve the hemodynamic target (MAP ≥ 65 mm Hg) by fluid challenge technique guided by MAP and central venous pressure (CVP) changes after fluid challenge. Fluid-responsive tests can be used as a subsidiary, depending on the attending physician. Early Norepinephrine (NE) infusion can be used with a standard dose of 0.05 mcg/k/min and titrated at the rate of 0.01-0.02 mcg/kg/min every 10 min until 0.25 mcg/kg/min was achieved; then, the second line vasopressor will be added and adjusted to the target of vasopressor. Hydrocortisone can be given according to septic shock guidelines.~After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed"
214222471|NCT00212368|DRUG|Zinc acetate|
214222472|NCT01885741|DEVICE|IPBS|
214222473|NCT06943157|OTHER|No intervention|This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.
214222474|NCT06947850|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|Oxervate (cenegermin-bkbj) is commonly used to treat neurotrophic keratitis
214222475|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|1% chocolate milk
214222476|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|pea-based beverage
214222477|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|almond-based beverage
214222478|NCT06944314|PROCEDURE|Diagnostic procedures|Diagnostic Flexible Cystoscopy
214222479|NCT06944314|PROCEDURE|Flexible Cystoscopy|Diagnostic Flexible Cystoscopy
214222480|NCT06946407|DRUG|Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation|"Pre-induction Therapy (R-M regimen):~Cycle 1-2 (C1-C2):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2~Induction Therapy (R-MT regimen):~Cycle 3-6 (C3-C6):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2 Thiotepa (T): 30 mg/m² IV over 30 minutes, on Day 3~Consolidation Therapy (EA regimen):~Cycle 7-8 (C7-C8):~Etoposide (E): 5 mg/kg IV, every 12 hours on Days 1 and 2 Cytarabine (A): 2.0 g/m² IV over 2 hours, every 12 hours on Days 3 and 4"
214222481|NCT06946771|DIAGNOSTIC_TEST|Advanced MRI parameters for the diagnosis of prostate cancer|This study aims to use time-dependent DWI (td-DWI) to fit and calculate quantitative information such as cellularity, cell diameter, intracellular volume fraction and cell density; use the chemical exchange saturation transfer (CEST) sequence to saturate hydrogen protons (hydroxyl (-OH), amide (-NH) and amine (-NH2) groups) in specific metabolites in the body by applying frequency-selective saturation pulses to non-invasively reflect metabolic information in the human body for the diagnosis of prostate cancer and to evaluate its diagnostic accuracy compared with traditional multi-parameter magnetic resonance imaging.
214222482|NCT06946888|BEHAVIORAL|Acupressure|Participants in this group will receive instruction on how to perform self-acupressure targeting two specific acupoints on the hands: Shenmen and Neiguan. The acupressure protocol includes pressing each acupoint approximately 15 times (about 30 seconds), with a total of four acupoints per session (both hands), for approximately 2 minutes per session. Pressure should be applied until a sensation of soreness, numbness, fullness, or slight pain is felt (equivalent to about 3 kg of pressure). Participants are asked to perform self-acupressure twice daily (once in the afternoon and once before bedtime, adjustable based on personal schedule) for a total of 2 weeks. They will record their practice using a daily log and continue to complete psychological and emotional outcome questionnaires weekly over a 2-month follow-up period.
214222483|NCT06947109|DRUG|Placebo|Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.
214222484|NCT06947109|DRUG|AK111|The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.
214222485|NCT06947187|OTHER|Pre-bunking video|\~3 minutes educational video to improve vaccine literacy and vaccine confidence
214222486|NCT06947187|OTHER|Video on safe disposal of medication|\~3 minutes educational video on safe disposal of medication
214222487|NCT06946173|DIETARY_SUPPLEMENT|health program|"Health children their age between 6-12 years bone and live in Gharbia governorate.~\- Legal pre mission will be taken from each school movement system to assess over weight among there school children.~\- The children and their family included in the study will be able to follow program of health intervention to prevent obesity.~Materials and methods:~1. Each children will be subjected to full history talking , clinical examination, growth assessment; weight height and body mass index (BMI) for age percentile ( Egyptians growth charts)~2. Laboratory investigation will be done which include lipid profile, serum cholesterol, triglycerides, LDL and hemoglobin level~3. Child history will be taken which include personal history~4. Dietary history of the child which include eating habits"
214222488|NCT06947629|DIAGNOSTIC_TEST|Intraoperative Frozen Section|"Intraoperative Frozen Section analysis which will include the following steps:~\- The specimen will undergo both gross and microscopic examination:~1. Gross examination: Evaluation of nodular features including, multiplicity, size, outlines, color and consistency.~2. Microscopic examination: Assessment of capsular pattern, capsular invasion, thickness of capsule, vascular invasion and number of invaded vessels and the presence or absence of papillary structures."
214222489|NCT06946940|DRUG|Cannabis Oil (5% THC/5% CBD)|Cannabis oil containing a balanced formulation of 5% tetrahydrocannabinol (THC) and 5% cannabidiol (CBD). Administered sublingually over a three-month period, starting with a six-week titration phase to optimize dosing, followed by maintenance.
214222490|NCT06946940|DRUG|Sham Cannabis Oil|Placebo oil visually and chemically matched to the active cannabis oil but devoid of active cannabinoids (THC/CBD). Administered sublingually over three months, mirroring the active arm's titration and maintenance schedule.
214222491|NCT06946329|BEHAVIORAL|Aquatic Exercise|Supervised WATERinMOTION sessions (60 mins, 3x/week) in heated pool. Focus on progressive resistance and mobility exercises.
214222492|NCT06946329|BEHAVIORAL|Land-Based Rehabilitation|Matched frequency/duration land-based program emphasizing core stabilization and low-impact aerobics.
214222493|NCT06946589|DRUG|Carbetocin|A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section
214222494|NCT06946212|DRUG|Dexmedetomidine|In Dexmedetomidine group: patients received an intravenous dose of dexmedetomidine at 1 mcg/kg over 10 min in 100 mL normal saline followed by continous infusion of dexmedetomidine at 0.2mcg/kg/h up to 0.7mcg/kg/hr till reaching Ramsay sedation score 2-3
214222495|NCT06946212|DRUG|Ketamine plus Midazolam|In Ketamine Midazolam group: patients received midazolam 0.02 mg /kg IV then 2 minutes later take ketamine 0.25 mg/kg IV and we will repeated this mixture till reaching Ramsay sedation score 2-3
214222496|NCT06947902|DEVICE|High flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (2L/kg per min with max of 45L)
214222497|NCT06947902|DEVICE|Low Flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (0.5L/kg per min with max of 5L)
214222498|NCT06947525|OTHER|Manual pressure|Before the procedure in the manual pressure group, the vein entry area will be pressed with the right hand thumb for 10 seconds. The pressure will be applied until the nail bed turns white.
214222499|NCT06947525|OTHER|Shotblocker|In the Shotblocker group, the shotblocker will be placed 2 cm above the vein entry point and will remain throughout the procedure.
214222500|NCT06947655|DEVICE|VBM Tourniquet|Perioperative VBM-Tourniquet Application with a fixation pressure of 15mmHg.
214222501|NCT06947655|DEVICE|Adaptive Cuff|Perioperative Delfi-Tourniquet Application with a fixation pressure of 15mmHg.
214222502|NCT06947746|BIOLOGICAL|hiSCs|hiSCs are derived from human induced pluripotent stem cells and exhibit immunomodulatory properties.
214222503|NCT06946901|COMBINATION_PRODUCT|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy|"* HIPEC (cisplatin 70mg/m², Day 1,3 post-surgery), 1 cycle；~* Systemic AG chemotherapy (nab-paclitaxel 125mg/m²+ gemcitabine 1000mg/m², initiated, Day 1,8,15, q4 week), 4 cycles"
214222504|NCT06947772|BEHAVIORAL|Skill building education|This intervention includes two session. theoretical and practical. In theroretical patient will be teahc about self-care of AVF and in oracticla session they learn how to monitor their AVF. monitoring have three part. inspection, palpation and auscultation
214222505|NCT06946693|PROCEDURE|To evaluate the color stability and surface roughness of implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing in mandibular posterior region.|Subjects with single stage implant placement and early non-functional loading with implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing.
214222506|NCT06947564|DIAGNOSTIC_TEST|CMR|Coronary microvascular function was assessed using contrast-enhanced CMR after PCI.
214222507|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
214222508|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
214222509|NCT06946485|BIOLOGICAL|Universal CAR-T (CHT101)|Universal CAR-T (CHT101) cell therpy
214222510|NCT06947226|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
214222511|NCT06947226|DRUG|Other anti-cancer therapy|Subjects will receive other anticancer therapy as per protocol
214222512|NCT06946069|RADIATION|NB-UVB twice weekly|Standard phototherapy without additional systemic treatment.
214222513|NCT06946069|OTHER|NB-UVB + dexamethasone (2.5-3 mg/week)|Combination therapy to enhance immunosuppression and repigmentation.
214222514|NCT06945939|PROCEDURE|Fixation of Pott's fracture b and c|Assessment of syndesmotic injury via X-ray, CT, ultrasound and intraoperative
214222515|NCT06946147|OTHER||
214222516|NCT06946667|OTHER|the UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
214222517|NCT06946667|OTHER|the Non-UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
214222518|NCT06947148|OTHER|Comprehensive post hospital management based on digital health intervention(DHI)|Based on the routine HF management of standard of care (SOC), the intervention group will carry out comprehensive post hospital management based on DHI, including cognitive behavioral therapy, digital self-monitoring and ReDS™ technology, etc.
214222519|NCT06947863|OTHER|thermal cure|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The thermal treatment used hot, chlorinated and sodium water. Every day, the patients received 4 out of the 5 following treatments: underwater showers (15 minutes), shower-massage (10 minutes), hydromassage (20 minutes), swimming pool rehabilitation (20 minutes) and application of heated peloid (15 minutes).
214222520|NCT06947863|OTHER|dry rehabilitation|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The physical rehabilitation treatment was delivered in dry and included an analgesic physiotherapy based on electrotherapy (30 minutes) and muscle strengthening, as well as group rehabilitation.
214222521|NCT06946251|DEVICE|Transcutaneous Diaphragm Stimulation|"In the ICU, TEDS is administered by a physiotherapist once daily for 20 minutes, five days a week, as part of the routine treatment protocol. The stimulation is delivered using the LGT-231 model device from the LONGEST brand.~A transcutaneous current with a frequency of 30-50 Hz and a pulse width of 300-400 microseconds is applied to the diaphragm. The stimulation intensity is increased until visible muscle contraction is achieved."
214222522|NCT06496750|DRUG|Ketamine Hydrochloride|Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
214222523|NCT06496750|DRUG|Midazolam Hydrochloride|Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
214222524|NCT06590051|DRUG|UPLIZNA|
214222525|NCT05286749|PROCEDURE|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
214222526|NCT05286749|DEVICE|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
214222527|NCT05286749|DIAGNOSTIC_TEST|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
214222528|NCT01395524|DRUG|NKTR-118|12.5 mg oral tablet once daily
214222529|NCT01395524|DRUG|NKTR-118|25 mg oral tablet once daily
214222530|NCT01395524|DRUG|Placebo|Oral tablet intake once daily
214222531|NCT04427332|OTHER|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
214222532|NCT03425474|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
214222533|NCT03425474|DRUG|Propofol|Initial dose plus supplemental doses as necessary
214222534|NCT00644891|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
214222535|NCT00644891|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
214222536|NCT01657461|DRUG|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
214222537|NCT01657461|DEVICE|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
214222538|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
214222539|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
214222540|NCT05772351|DRUG|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
214222541|NCT01317459|BEHAVIORAL|Guided self-determination|Group counselling
214222542|NCT01303224|DRUG|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
214222543|NCT01303224|DRUG|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
214222544|NCT01303224|DRUG|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
214222545|NCT01303224|DRUG|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
214222546|NCT03796520|DIAGNOSTIC_TEST|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age \> 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
214222547|NCT05310175|DEVICE|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
214222548|NCT05310175|DEVICE|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
214222549|NCT05133531|DRUG|Ravulizumab|Administered Intravenous (IV) per the protocol
214222550|NCT05133531|DRUG|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
214222551|NCT05133531|DRUG|Cemdisiran|Administered SC per the protocol
214222552|NCT05133531|DRUG|Eculizumab|Administered IV per the protocol
214650572|NCT01419132|DRUG|Furosemide|125-250 mg furosemide bid
214650573|NCT01419132|DRUG|Furosemide|125-250 mf furosemide bid
214650574|NCT06549010|DIAGNOSTIC_TEST|Perimetric test|This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.
214650575|NCT00995254|BEHAVIORAL|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
214650576|NCT00010231|DIETARY_SUPPLEMENT|calcitriol|
214650577|NCT00010231|DRUG|dexamethasone|
214650578|NCT03281785|OTHER|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
214650579|NCT03281785|OTHER|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
214650580|NCT03281785|OTHER|Pressure support mode (PS)|Pressure support mode (PS)
214650581|NCT01577238|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
214650582|NCT01577238|DRUG|Placebo|Vaginal gel, daily for 7 days
214650583|NCT05083455|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
214650584|NCT05083455|DRUG|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
214650585|NCT05655377|DEVICE|FitMi PD|Exercise using the motion sensing devices and a tablet computer
214650586|NCT01256177|DRUG|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
214650587|NCT01256177|DRUG|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
214650588|NCT05845346|OTHER|Electrotherapy-Transcutaneous Electrical Stimulation (TENS)|Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
214650589|NCT05845346|OTHER|Massage therapy|Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.
214650590|NCT05845346|OTHER|Stretching exercises|Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.
214650591|NCT05845346|OTHER|Ischaemic Compression Technique|Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
214650592|NCT00000855|DRUG|Zidovudine|
214650593|NCT01110395|DIAGNOSTIC_TEST|MR Spectroscopy|MR spectroscopy of myocardial
214650594|NCT00113594|DRUG|Olanzapine|
214650595|NCT00442403|DRUG|chloroquine|
214650596|NCT00442403|DRUG|dehydroepiandrosterone sulphate|
214650597|NCT02493569|PROCEDURE|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
214650598|NCT00275431|DRUG|AT-101|Oral
214650599|NCT01933841|DEVICE|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
214650600|NCT01933841|PROCEDURE|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
214650601|NCT00793767|DRUG|erythropoietin|bolus of 400 IU/kg
214650602|NCT00793767|DRUG|placebo (saline)|i.v
214650603|NCT01743833|OTHER|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
214650604|NCT01743833|OTHER|Scapular High Velocity, Low Amplitude Thrust Maneuver|
214650605|NCT03966326|DRUG|sevoflurane and fentanil|Patients will receive standard general anesthesia
214650606|NCT03966326|DRUG|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
214650607|NCT00505947|DRUG|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
214650608|NCT00505947|DRUG|placebo|placebo 5 mg/Kg body weight by intravenous infusion
214650609|NCT00001676|DRUG|SQ Fludarabine|
214650610|NCT02024984|DRUG|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
214222553|NCT04058132|DRUG|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo\[4,3-d\]pyrimidin-5-yl)-4- ethoxyphenyl\]sulfonyl\]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
214222554|NCT04058132|DEVICE|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
214222555|NCT04058132|OTHER|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
214222556|NCT04058132|OTHER|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
214222557|NCT04058132|DRUG|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
214222558|NCT04058132|PROCEDURE|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
214222559|NCT04058132|OTHER|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
214222560|NCT01574183|DRUG|Vilazodone|up to 40 mg capsule daily
214222561|NCT01574183|DRUG|Placebo|up to 40 mg capsule daily
214222562|NCT01426841|RADIATION|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
214222563|NCT04299932|PROCEDURE|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
214222564|NCT04299932|PROCEDURE|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
214222565|NCT02609113|DEVICE|Strong Magnetic Wristband|
214222566|NCT02609113|DEVICE|Weaker Magnetic Wristband|
214222567|NCT00609531|DRUG|Citalopram|Pill, 5-20mg once a day for twelve weeks
214222568|NCT00609531|DRUG|Placebo|Placebo pill once a day for twelve weeks
214222569|NCT05094388|OTHER|Admitted to intensive care units|Admitted to intensive care units
214650611|NCT04909528|DEVICE|Low-level tragus stimulation|Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
214650612|NCT04909528|DEVICE|Sham stimulation|Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
214650613|NCT00553462|DRUG|carboplatin|
214650614|NCT00553462|DRUG|erlotinib hydrochloride|
214650615|NCT00553462|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214650616|NCT00553462|RADIATION|radiation therapy|
214650617|NCT02451787|DIETARY_SUPPLEMENT|Vitamin D|2400 units per day for 3 months
214650618|NCT03871894|OTHER|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
214650619|NCT03871894|OTHER|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
214650620|NCT02700178|OTHER|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
214650621|NCT01781455|DRUG|BBI503|
214650622|NCT00983567|OTHER|teen web|Min web
214650623|NCT01728779|DRUG|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
214650624|NCT01728779|RADIATION|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
214650625|NCT05730595|PROCEDURE|lymph node dissection|The extent of lymph node dissection varies between groups
214650626|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
214650627|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
214650628|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
214650629|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
214650630|NCT00814385|BIOLOGICAL|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
214650631|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
214650632|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
214650633|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
214650634|NCT00814385|BIOLOGICAL|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
214650635|NCT03981159|OTHER|Physical training|Physical training for three months, twice per week (60 minutes per session).
214650636|NCT03843476|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
214650637|NCT02204631|OTHER|Head and Neck Educational Handbook|
214650638|NCT05759884|DRUG|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
214650639|NCT05759884|RADIATION|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
214650640|NCT04082208|DEVICE|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
214650641|NCT04082208|DEVICE|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
214650642|NCT06416163|OTHER|Prospective|Collection of prospective data all ready available for participant
214650643|NCT04822545|OTHER|referral to comprehensive weight management clinic|"Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience."
214650644|NCT02698098|DRUG|Methadone|
214650645|NCT02492633|BEHAVIORAL|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
214222570|NCT01744535|BEHAVIORAL|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
214222571|NCT01744535|BEHAVIORAL|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
214222572|NCT01744535|BEHAVIORAL|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
214222573|NCT06313385|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG)|The ICG will be injected intravenously and being assessed with Near-infrared (NIR) camera FLUORO4000XL 20 cm above the flap and fluorescence intensity counted with application called ImageJ
214222574|NCT06313385|DIAGNOSTIC_TEST|Temperature|Portable thermal imaging camera called Forward-looking infrared (FLIR) ONE® was used to assess flap and normal skin temperature. The FLIR ONE® device was place in perpendicular manner from the skin. The images were attained in two points of times which is direct temperature and after cold challenge test.
214222575|NCT06313385|DIAGNOSTIC_TEST|Transcutaneous oxygen and carbon dioxide pressure|The partial transcutaneous pressure is measured in flap using transcutaneous monitor (TCM) Combi probe. The probe should be cleaned using alcohol pads before use. After 5-10 minutes, the TCM 4 machine monitor should show stable transcutaneous oxygen and carbon dioxide pressure from the flap
214222576|NCT06313385|DIAGNOSTIC_TEST|Histopathology|A part of tissue from free flap is acquired and stored in 10% formalin tube. Later on, the tissue was colored with hematoxylin-eosin, neutrophile count, necrosis volume, and vessel proliferation will be assessed
214222577|NCT06313385|DIAGNOSTIC_TEST|Hypoxia inducible factor-1 (HIF-1) alpha|Peripheral tissue from distal free flap (0,5 x 0,5 cm in size) is obtained and stored in tube with dry ice. The tissue is assessed with human HIF - 1 Alpha Enzyme-Linked Immunosorbent Assay (ELISA) kit ab171577.
214222578|NCT06226389|PROCEDURE|4 different bulk-fill composite|Posterior cavities either class 1/2
214222579|NCT06213103|PROCEDURE|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
214222580|NCT06213103|PROCEDURE|Control cohort|Collection of 6 blood tubes at the inclusion visit.
214222581|NCT00295880|PROCEDURE|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
214222582|NCT00843284|DRUG|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
214222583|NCT02558413|DRUG|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
214222584|NCT02558413|DRUG|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
214222585|NCT02064413|DEVICE|ESS310 (BAY1454032)|
214222586|NCT03563924|OTHER|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
214222587|NCT03980691|BIOLOGICAL|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
214222588|NCT01984658|BIOLOGICAL|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
214222589|NCT03742466|DRUG|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
214222590|NCT03742466|DRUG|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
214222591|NCT01757249|DRUG|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
214650646|NCT02492633|BEHAVIORAL|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~1. A web-based smoking cessation intervention via Facebook~2. Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~3. A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
214650647|NCT00241332|DRUG|fentanyl|
214222592|NCT05150899|DRUG|Tamsulosin Hcl 0.4Mg Cap|alpha blocker
214222593|NCT05150899|DRUG|fexofenadine 180 mg Oral tablet|antihistaminic
214222594|NCT02830685|DEVICE|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
214650648|NCT04106154|BEHAVIORAL|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
214650649|NCT00065143|DRUG|clofarabine|
214650650|NCT00065143|DRUG|Ara-C|
214222595|NCT02830685|DEVICE|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
214222596|NCT02269579|DRUG|CPX-351|
214222597|NCT01794143|DRUG|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
214222598|NCT01794143|DRUG|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
214222599|NCT01794143|DRUG|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
214222600|NCT01794143|DRUG|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
214222601|NCT06478394|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
214222602|NCT03257449|DIETARY_SUPPLEMENT|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
214222603|NCT01437904|PROCEDURE|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
214222604|NCT01437904|PROCEDURE|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
214222605|NCT00547443|DRUG|carboplatin|Given IV
214222606|NCT00547443|DRUG|paclitaxel|Given IV
214222607|NCT00547443|DRUG|sorafenib tosylate|Given orally
214222608|NCT00547443|RADIATION|radiation therapy|Given 5 days a week for 7.5 weeks
214222609|NCT00250328|DEVICE|LapCAC Laparoscopic Compression Anastomosis Clip|
214222610|NCT04183543|DEVICE|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
214222611|NCT04183543|DEVICE|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
214222612|NCT03291366|DRUG|UCMSCC|infusion of aUCMSC and conventional therapy
214222613|NCT03291366|DRUG|conventional treatment|conventional treatment
214222614|NCT03344770|DEVICE|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
214222615|NCT03344770|DEVICE|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
214222616|NCT04344964|OTHER|None - NA|Observational study
214222617|NCT03933891|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
214222618|NCT03060122|DEVICE|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
214222619|NCT03060122|DEVICE|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
214222620|NCT03060122|DEVICE|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
214222621|NCT02061839|OTHER|Sunscream with visible light protection|
214222622|NCT02061839|OTHER|Sunscream|
214222623|NCT05480111|DRUG|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
214222624|NCT05480111|DRUG|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
214222625|NCT05480111|DRUG|Sham Local|20 mls of normal saline given at incision site
214222626|NCT05480111|DRUG|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
214222627|NCT02988284|OTHER|No intervention|
214222628|NCT02803346|OTHER|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
214222629|NCT04851405|BEHAVIORAL|Otago Exercise Programme+ (OEP+)|"Physiotherapists (PTs) will receive OEP and BAP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 phone calls).~Older adults will have access to the OEP app."
214222630|NCT04851405|BEHAVIORAL|Otago Exercise Programme (OEP)|PTs will receive OEP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 follow-up phone calls).
214222631|NCT02814500|DRUG|DP-R212|Investigational product is prescribed to all of randomized subjects
214222632|NCT02814500|DRUG|Amlodipine|Investigational product is prescribed to all of randomized subjects
214222633|NCT02814500|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
214222634|NCT04980742|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution
214222635|NCT02560545|DRUG|Cannabis oil|Cannabis oil 20% THC
214222636|NCT03263949|OTHER|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
214650651|NCT05265767|BIOLOGICAL|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
214222637|NCT05090774|BEHAVIORAL|Adapted Otago Exercise Program (OEP)|A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
214222638|NCT02767349|DRUG|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
214222639|NCT02122757|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
214222640|NCT02122757|DEVICE|sham Cefaly tDCS|2mA during 30sec
214222641|NCT01761162|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
214222642|NCT01761162|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
214222643|NCT05730803|OTHER|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
214222644|NCT01856218|DRUG|UX003|
214222645|NCT06010043|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
214222646|NCT06010043|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
214222647|NCT03718091|DRUG|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
214222648|NCT02490670|DRUG|Cephalexin|Administered orally
214222649|NCT03443583|OTHER|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
214222650|NCT02358291|PROCEDURE|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
214222651|NCT02358291|PROCEDURE|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
214222652|NCT02358291|PROCEDURE|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
214222653|NCT05172583|BEHAVIORAL|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU. These are orientation in time, space, and place, accompaniment of the family for two hours in the morning and two hours in the afternoon, physical therapy once a day according to the patient's condition, medication with conscious sedation, and progressive reduction analgesics. opioids and benzodiazepines.
214222654|NCT05172583|BEHAVIORAL|Interventions to reduce delirium based on DSM and scientific evidence|The interventions are designed from the structure of the Dynamic Symptoms Model (DSM), taking into account the antecedents of delirium, physiological such as the medical condition of mechanical ventilation and pain, and drug treatment with sedatives and analgesics; the psychological, social, and spiritual antecedents with stimulation in the values, life experience, personality and spirituality, and the environmental antecedents with an adaptation of the physical conditions of the ICU. In addition, previous experience with identification and care of concomitant symptoms such as fear, confusion, restlessness, loneliness, and discomfort, and with the measurement and classification of the trajectory of delirium when it occurs, will also be considered. The interventions follow the scientific evidence, mainly from the ABCDEF bundle. All interventions are non-pharmacological.
214222655|NCT03117452|BEHAVIORAL|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
214222656|NCT01717053|DRUG|Abiraterone acetate|1000 mg orally once a day for 6 months.
214222657|NCT01717053|DRUG|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
214222658|NCT01717053|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
214222659|NCT01717053|DRUG|Prednisone|5 mg tablet once daily for 6 months.
214222660|NCT01460511|DRUG|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
214222661|NCT01460511|DRUG|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
214222662|NCT02160899|DRUG|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
214222663|NCT02160899|DRUG|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
214222664|NCT03856281|DEVICE|Intermittent Pneumatic Compression|Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
214222665|NCT01714791|OTHER|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
214650652|NCT01545960|OTHER|not applicable in this study|No actual interventions will be administered for this study.
214222666|NCT01714791|OTHER|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques."
214222667|NCT01039129|PROCEDURE|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
214222668|NCT01039129|PROCEDURE|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
214222669|NCT01039129|PROCEDURE|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
214222670|NCT01531855|OTHER|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
214222671|NCT00250198|DRUG|STA-5326|
214222672|NCT02398006|OTHER|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
214222673|NCT02398006|OTHER|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
214222674|NCT02492607|OTHER|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
214222675|NCT02492607|DEVICE|digital mammography|annual mammography
214222676|NCT02492607|RADIATION|radiotherapy|according local policy
214222677|NCT00770575|DRUG|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
214222678|NCT00770575|DRUG|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
214222679|NCT04939350|OTHER|questionnaire|patients will complete a vaccination questionnaire
214222680|NCT00232791|DEVICE|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
214222681|NCT00232791|DEVICE|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
214222682|NCT02453815|PROCEDURE|non-cardiac surgery|all surgical procedures except cardiac
214222683|NCT02453815|OTHER|arterial catheter|arterial catheter
214222684|NCT05180396|OTHER|Questionnaires|Application of a study based questionnaire described in the protocol
214222685|NCT03776370|PROCEDURE|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
214222686|NCT03776370|PROCEDURE|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
214222687|NCT01793870|DRUG|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
214222688|NCT01793870|DRUG|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
214222689|NCT01793870|DRUG|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
214222690|NCT02501187|PROCEDURE|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
214222691|NCT02501187|PROCEDURE|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
214222692|NCT02501187|PROCEDURE|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
214222693|NCT04643145|PROCEDURE|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
214222694|NCT05344196|BEHAVIORAL|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
214222695|NCT00526916|DRUG|[C-11]PBR28|
214222696|NCT05761717|DRUG|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
214222697|NCT03855826|DRUG|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
214222698|NCT03855826|DRUG|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
214222699|NCT01876940|DEVICE|air-Q, followed by fiberoptic intubation|
214222700|NCT01876940|DEVICE|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
214222701|NCT01009372|BEHAVIORAL|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
214222702|NCT00798759|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
214222703|NCT00798759|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
214650653|NCT00968422|DRUG|ABT-384|3 escalating doses will be administered daily for 21 days
214650654|NCT00968422|DRUG|Matching placebo to ABT-384|Doses will be administered daily for 21 days
214222704|NCT05410756|DIAGNOSTIC_TEST|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
214222705|NCT03372759|PROCEDURE|airtamponade|airtamponade is applicated in the study group air
214222706|NCT03372759|PROCEDURE|saline|saline is left in the study Group saline
214222707|NCT04273880|DRUG|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
214222708|NCT04273880|DRUG|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
214222709|NCT01677429|DEVICE|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
214222710|NCT01677429|DEVICE|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
214222711|NCT01677429|BEHAVIORAL|Cognitive Behavioral Therapy|For the treatment of panic disorder
214222712|NCT06471283|OTHER|physical activity|Exercising physical activity during dialysis
214222713|NCT01429025|BIOLOGICAL|rituximab|IV
214222714|NCT01429025|DRUG|bendamustine|IV
214222715|NCT01429025|DRUG|lenalidomide|PO
214222716|NCT00740935|BIOLOGICAL|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
214222717|NCT05350956|DRUG|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
214222718|NCT05350956|DRUG|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
214222719|NCT04331743|DRUG|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
214222720|NCT04208113|BEHAVIORAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
214222721|NCT03599232|OTHER|Formative objective structured clinical examination (OSCE)|
214222722|NCT05481957|DRUG|Vortioxetine|5-10mg for 16 weeks
214222723|NCT05481957|DRUG|valprote|500\~1000mg for 16 weeks
214222724|NCT04540510|DEVICE|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
214222725|NCT04540510|OTHER|Standard care|Standard pneumonia care
214222726|NCT01371279|DEVICE|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
214222727|NCT05423353|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
214222728|NCT05423353|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
214222729|NCT03704753|DRUG|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
214222730|NCT03704753|DRUG|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
214222731|NCT01976039|OTHER|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
214222732|NCT02903459|OTHER|Transversal Study so there is no intervention|
214222733|NCT04156542|BEHAVIORAL|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
214222734|NCT04518995|DRUG|CTP-543 matching placebo|Administered as tablets.
214222735|NCT04518995|DRUG|CTP-543|Administered as tablets.
214222736|NCT04518995|DRUG|CTP-543|Administered as tablets.
214222737|NCT00561860|DEVICE|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
214222738|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
214222739|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
214222740|NCT05950152|DRUG|Meloxicam Injection 30mg|meloxicam injection 30mg every 24 hours for up to 2 dose
214222741|NCT05950152|DRUG|Meloxicam Injection 60mg|meloxicam injection 60mg every 24 hours for up to 2 dose
214222742|NCT05950152|DRUG|Nacl 0.9%|IV Placebo every 24 hours for up to 2 doses
214222743|NCT00904410|OTHER|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
214222744|NCT04397666|DIAGNOSTIC_TEST|conjunctival RT PCR|conjunctival sample in covid-19 patients
214222745|NCT05987176|DRUG|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
214222746|NCT05226455|DRUG|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
214222747|NCT02714972|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
214222748|NCT01600144|OTHER|digital mammography|data collection
214222749|NCT05424289|DEVICE|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
214222750|NCT04190888|OTHER|No intervention|No intervention - observational study
214222751|NCT01310205|DRUG|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
214222752|NCT01278940|BIOLOGICAL|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
214222753|NCT01278940|PROCEDURE|IL-2|IL-2 were administrated by intranodal injection
214222754|NCT00222664|BIOLOGICAL|Hep-V Vax|
214222755|NCT02891070|DRUG|FS VH S/D 500 s-apr|
214222756|NCT02891070|DEVICE|DuraSeal Dural Sealant|
214222757|NCT02697344|DRUG|Dexamethasone|Given PO
214222758|NCT02697344|OTHER|Laboratory Biomarker Analysis|Correlative studies
214222759|NCT02697344|DRUG|Lenalidomide|Given PO
214222760|NCT02697344|OTHER|Pharmacological Study|Correlative studies
214222761|NCT02697344|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
214222762|NCT02945709|BEHAVIORAL|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
214222763|NCT02945709|BEHAVIORAL|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
214222764|NCT02945709|BEHAVIORAL|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
214222765|NCT03336437|DRUG|Estradiol vaginal ring|Estradiol 2mg vaginal ring
214222766|NCT03336437|OTHER|Placebo vaginal ring|Silicone vaginal ring without any active estradiol
214222767|NCT00085176|PROCEDURE|management of therapy complications|
214222768|NCT00085176|PROCEDURE|psychosocial assessment and care|
214222769|NCT00002271|DRUG|Alovudine|
214222770|NCT04491604|BIOLOGICAL|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
214222771|NCT04491604|OTHER|Placebo|Matching masked inactive topical gel
214222772|NCT04509349|DEVICE|transcranial Altering Current Stimulation|The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
214222773|NCT04509349|DEVICE|Sham tACS|2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
214222774|NCT01585506|OTHER|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
214222775|NCT01585506|OTHER|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
214222776|NCT02934503|BIOLOGICAL|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
214222777|NCT02934503|DRUG|Cisplatin|75 mg/m2
214222778|NCT02934503|DRUG|Carboplatin|AUC 6
214222779|NCT02934503|DRUG|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
214222780|NCT02934503|RADIATION|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
214222781|NCT04248491|DEVICE|BTL Emsella chair|Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
214222782|NCT00003560|DRUG|carboplatin|
214222783|NCT00003560|DRUG|docetaxel|
214222784|NCT03799302|BEHAVIORAL|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
214222785|NCT06438510|PROCEDURE|Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)|All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
214222786|NCT04228029|DEVICE|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
214222787|NCT04228029|DRUG|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
214222788|NCT00675467|BEHAVIORAL|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
214222789|NCT00675467|BEHAVIORAL|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
214222790|NCT01227135|DRUG|hydroxychloroquine|
214222791|NCT01227135|DRUG|imatinib mesylate|
214222792|NCT01227135|GENETIC|cytogenetic analysis|
214222793|NCT01227135|GENETIC|polymerase chain reaction|
214222794|NCT01227135|OTHER|laboratory biomarker analysis|
214222795|NCT01227135|OTHER|pharmacological study|
214222796|NCT00587496|DRUG|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
214222797|NCT00587496|DRUG|placebo|lactose placebo capsule, six per day for 30 days
214222798|NCT00587496|DRUG|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
214222799|NCT01701232|BIOLOGICAL|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
214222800|NCT06471192|PROCEDURE|PPCI|PPCI for patients of STEMI to assess thrombus burden
214222801|NCT02058524|BIOLOGICAL|fecal microbiota transplantation|
214222802|NCT02870478|DRUG|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
214222803|NCT03073837|OTHER|Rhinovirus Challenge|Challenge with HRV-16 virus
214222804|NCT05136950|PROCEDURE|Secondary in-the-bag IOL fixation|The experimental group with secondary IOL fixated in the capsular bag
214222805|NCT05136950|PROCEDURE|Secondary ciliary sulcus IOL fixation|The control group with secondary IOL fixated in the ciliary sulcus
214222806|NCT02995824|OTHER|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) \[lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)\] \[Group 1\] versus other ART regimens including boosted PI or NNRTIs \[Group 2\] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
214222807|NCT03747666|PROCEDURE|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
214222808|NCT02809040|OTHER|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
214222809|NCT02809040|OTHER|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
214222810|NCT02873351|DRUG|carbidopa-levodopa 25-100 mg|included in arm description
214222811|NCT02873351|DRUG|placebo for carbidopa-levodopa 25-100 mg|included in arm description
214222812|NCT05035602|OTHER|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
214222813|NCT00741845|DRUG|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
214222814|NCT01944852|DRUG|Icodextrin|
214222815|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
214222816|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
214222817|NCT03890042|DRUG|Dienogest group|VISANNE 2MG Tablet once daily
214222818|NCT03890042|DRUG|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
214222819|NCT03890042|RADIATION|Ultrasound|ultrasound assessment of uterine volume
214222820|NCT03890042|OTHER|visual analogue scale|visual analogue scale for assessment of pain
214222821|NCT02597478|DRUG|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
214222822|NCT02597478|PROCEDURE|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
214222823|NCT02597478|BEHAVIORAL|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
214222824|NCT02597478|BEHAVIORAL|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
214650655|NCT04398732|DRUG|Enbrel|As provided in real world practice
214650656|NCT02113670|OTHER|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
214650657|NCT00002623|DRUG|carboplatin|
214650658|NCT00002623|DRUG|cisplatin|
214650659|NCT00002623|PROCEDURE|conventional surgery|
214650660|NCT00002623|RADIATION|radiation therapy|
214650661|NCT02395991|DRUG|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
214650662|NCT02395991|OTHER|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
214650663|NCT01724957|PROCEDURE|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
214650664|NCT01596257|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
214650665|NCT01596257|DEVICE|CliniMACS|
214650666|NCT00936988|DRUG|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
214650667|NCT05501626|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
214650668|NCT05501626|DEVICE|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
214650669|NCT04019366|OTHER|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
214650670|NCT04019366|OTHER|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
214650671|NCT02274337|DRUG|AC0010|patients take avitinib orally once per day at different dose
214650672|NCT06487546|DIETARY_SUPPLEMENT|Ergothioneine|This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.
214650673|NCT06454084|DRUG|Acetylcholine Chloride|Vasodilator solution
214650674|NCT03599180|DEVICE|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
214650675|NCT06526780|PROCEDURE|Bronchscopy|Bronchscopy in critical ill children with airway diseases
214650676|NCT00237133|DRUG|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
214650677|NCT02714478|DEVICE|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
214650678|NCT02714478|DEVICE|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
214222825|NCT02597478|BEHAVIORAL|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
214222826|NCT01536067|BIOLOGICAL|ofatumumab|Given IV
214650679|NCT02876692|DEVICE|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
214650680|NCT02427113|OTHER|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
214650681|NCT02427113|OTHER|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
214650682|NCT01570244|DRUG|levonorgestrel|multiple doses
214650683|NCT01570244|DRUG|Ethinylestradiol|multiple doses
214650684|NCT01570244|DRUG|levonorgestrel|multiple doses
214650685|NCT01570244|DRUG|BI 201335|multiple doses
214650686|NCT01570244|DRUG|Ethinylestradiol|multiple doses
214650687|NCT06201052|OTHER|Exercise test|Beep Test for measuring aerobic power
214650688|NCT00050102|DRUG|MDX-010 (CTLA-4)|
214650689|NCT00826735|BEHAVIORAL|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
214650690|NCT02266108|BEHAVIORAL|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
214650691|NCT03623789|DRUG|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
214650692|NCT03623789|DRUG|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
214650693|NCT03623789|DRUG|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
214650694|NCT05146141|OTHER|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
214650695|NCT04225325|COMBINATION_PRODUCT|SYMTUZA|DESCOVY+REZOLSTA
214650696|NCT04225325|COMBINATION_PRODUCT|DESCOVY+DOLUTEGRAVIR|DESCOVY+DOLUTEGRAVIR
214650697|NCT04225325|COMBINATION_PRODUCT|SYMTUZA+DOLUTEGRAVIR|DESCOVY+REZOLSTA+DTG
214222827|NCT01536067|DRUG|bortezomib|Given SC
214222828|NCT01536067|OTHER|laboratory biomarker analysis|Correlative studies
214222829|NCT03005015|DRUG|Lenvatinib|
214222830|NCT03005015|DRUG|Doxorubicin|
214222831|NCT01652469|DRUG|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
214222832|NCT01652469|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
214222833|NCT01402102|DIETARY_SUPPLEMENT|Aged garlic powder|Aged garlic powder(6.0g/day)
214222834|NCT01402102|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder(6.0g/day)
214222835|NCT03264729|OTHER|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
214222836|NCT03264729|OTHER|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
214222837|NCT03264729|OTHER|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
214222838|NCT06050824|DRUG|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
214222839|NCT05873907|DRUG|AMG 592|Administered as SC injection
214222840|NCT05873907|OTHER|Placebo|Administered as SC injection
214222841|NCT00522769|BEHAVIORAL|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
214222842|NCT05043142|DIAGNOSTIC_TEST|ELISA test for the antibodies to COVID-2019.|Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.
214222843|NCT02324634|DEVICE|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
214222844|NCT00967824|OTHER|informational intervention|
214222845|NCT00967824|OTHER|questionnaire administration|
214222846|NCT00967824|OTHER|survey administration|
214222847|NCT02922686|DRUG|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
214222848|NCT02922686|DRUG|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
214222849|NCT02922686|DRUG|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
214222850|NCT00000303|DRUG|Baclofen|
214222851|NCT02809222|OTHER|Samples|Blood samples
214222852|NCT02809222|OTHER|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
214222853|NCT05895526|PROCEDURE|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
214222854|NCT02408757|PROCEDURE|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
214222855|NCT00905645|DEVICE|Silimed Gel-Filled Mammary Implant|
214222856|NCT02511223|DRUG|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
214222857|NCT01731938|BIOLOGICAL|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
214222858|NCT01731938|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
214650698|NCT05617521|DEVICE|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
214650699|NCT05617521|DEVICE|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
214650700|NCT01598376|PROCEDURE|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
214650701|NCT01598376|PROCEDURE|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
214650702|NCT00455117|DRUG|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
214650703|NCT04917770|DRUG|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
214650704|NCT02840331|DRUG|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
214650705|NCT02840331|DEVICE|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
214650706|NCT03860948|DRUG|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
214650707|NCT03860948|DRUG|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
214650708|NCT03241446|DRUG|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
214650709|NCT02673333|DRUG|Pembrolizumab|
214650710|NCT06373874|BEHAVIORAL|Heel blood collection in a newborn simulation model|"The person who will take heel blood in the newborn simulation model can prepare the materials.~Firstly, the blood sample can fill in all the information on the filter paper. Knows where the baby's face should be. It can determine the area where a heel blood sample can be taken.It can gently warm the heel area for a few minutes. The area can be cleaned with alcoholic preparation (cotton/swab, etc.). He can squeeze the heel with his thumb and index finger in front. The other 3 fingers can be rubbed at the back. May stroke the heel three times. The heel can be pierced once with a lancet at a suitable location. He can relax his hand. He can wipe away the first drop of blood. It can create a large thick drop of blood to be collected on filter paper. It can make the drop fill the entire ring on the filter paper with one touch. After the procedure is completed, the heel can be pressed."
214650711|NCT05510960|OTHER|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
214650712|NCT02898480|PROCEDURE|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
214650713|NCT01884792|OTHER|Sitting OGTT|
214650714|NCT01884792|OTHER|Standing OGTT|
214650715|NCT01884792|OTHER|Sitting CGM|
214650716|NCT01884792|OTHER|Standing CGM|
214650717|NCT00131807|PROCEDURE|Blood Pressure Measurement|
214650718|NCT00131807|PROCEDURE|Questionnaire|
214650719|NCT05003557|OTHER|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~* concerning the current health situation~* the SF 36~* the IPQ-R questionnaire"
214650720|NCT04142645|DEVICE|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
214650721|NCT00129064|BEHAVIORAL|Electronic referral system|
214650722|NCT01509625|DRUG|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
214650723|NCT02318784|DRUG|Carfilzomib|
214650724|NCT00934102|DEVICE|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
214650725|NCT00934102|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
214650726|NCT00934102|DEVICE|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
214650727|NCT01219842|PROCEDURE|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
214650728|NCT01219842|OTHER|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
214650729|NCT00766792|PROCEDURE|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
214650730|NCT00766792|PROCEDURE|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
214650731|NCT01361347|DIETARY_SUPPLEMENT|milk|milk for milk allergic children (1:25 dilution, whole milk)
214650732|NCT02673255|BIOLOGICAL|Tetanus and Diphtheria (Td) Vaccine|
214650733|NCT00792298|DRUG|Suvorexant|oral tablet taken before bedtime
214650734|NCT00792298|DRUG|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
214650735|NCT04737148|OTHER|Mortality scores|Revised Baux, BOBI and FLAMES scores
214650736|NCT01590342|DRUG|Diclofenac|Diclofenac 75 mg, two doses
214650737|NCT01590342|DRUG|Placebo|Placebo, two doses
214650738|NCT01405092|DEVICE|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
214650739|NCT01405092|DEVICE|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
214650740|NCT03719235|OTHER|CBCT|ultra-low dose CBCT
214650741|NCT01812642|DRUG|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
214222859|NCT03020940|DRUG|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
214222860|NCT04931888|BEHAVIORAL|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
214222861|NCT03968133|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
214222862|NCT03968133|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
214222863|NCT03701035|BEHAVIORAL|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
214222864|NCT03701035|BEHAVIORAL|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
214222865|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
214222866|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
214222867|NCT00960726|DRUG|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
214222868|NCT05946356|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
214222869|NCT05657574|DRUG|D377|oral, once daily, 8 weeks
214222870|NCT05657574|DRUG|CKD-331|oral, once daily, 8 weeks
214222871|NCT05657574|DRUG|D086|oral, once daily, 8 weeks
214222872|NCT05657574|DRUG|Placebo (for D377)|oral, once daily, 8 weeks
214222873|NCT05657574|DRUG|Placebo (for CKD-331)|oral, once daily, 8 weeks
214222874|NCT05657574|DRUG|Placebo (for D086)|oral, once daily, 8 weeks
214222875|NCT04709133|PROCEDURE|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
214222876|NCT05573269|DIETARY_SUPPLEMENT|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
214222877|NCT05573269|OTHER|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
214222878|NCT06121999|BEHAVIORAL|Standard of care acceptance-based behavioral weight loss program|Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.
214222879|NCT06121999|BEHAVIORAL|Occupational therapy dietary and lifestyle modifications|Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
214222880|NCT06704633|DRUG|Sacubitril / Valsartan Oral Tablet|A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
214222881|NCT00778661|DRUG|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
214222882|NCT05395273|DEVICE|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
214222883|NCT04538144|OTHER|Hot and Humid Trial|Individuals will be exposed to a simulated heat wave (hot and humid) condition.
214222884|NCT04538144|OTHER|Hot and Dry Trial|Individuals will be exposed to a simulated heat wave (hot and dry) condition.
214222885|NCT05612932|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
214222886|NCT05612932|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
214222887|NCT05140876|BEHAVIORAL|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
214222888|NCT03422328|DRUG|macitentan|macitentan 10 mg, film-coated tablet, oral use
214222889|NCT02350478|DRUG|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
214222890|NCT02350478|DRUG|Placebo|The subject will receive placebo orally once daily for 12 weeks.
214222891|NCT02185495|BEHAVIORAL|Observer nodule detection|Radiologists will detect the nodules.
214222892|NCT02185495|DEVICE|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
214222893|NCT04550598|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
214222894|NCT04550598|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
214222895|NCT05571566|OTHER|Educational Book|An educational book with information about appendicitis for patients, parents and caregivers
214222896|NCT05704569|DIAGNOSTIC_TEST|measurement of multiple biomarkers|All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
214222897|NCT04132271|OTHER|Personalized diet|Modified texture and volumen diet according to the OD specifications
214222898|NCT04132271|OTHER|Control|Nutritional Recommendations according to the OD specifications
214222899|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
214222900|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
214222901|NCT06143930|OTHER|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
214222902|NCT06143930|OTHER|strengthening ex|Therapeutic strengthening training program for lower extremities.
214222903|NCT06153303|BEHAVIORAL|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
214222904|NCT00771953|DRUG|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
214222905|NCT00771953|DRUG|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
214222906|NCT00771953|DRUG|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
214222907|NCT05520554|OTHER|Development of the Telerehabilitation Satisfaction Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
214222908|NCT02288455|DEVICE|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
214222909|NCT05211583|DIAGNOSTIC_TEST|Serum progesterone levels|In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
214222910|NCT01254708|DRUG|Ambisome ®|liposomal amphotericin B
214222911|NCT01254708|DRUG|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
214222912|NCT05944484|BEHAVIORAL|low caloric diet, ultrasound cavitation,Kegel exercises|"* low caloric diet (800-1200) calories/day,). According to each patient, diet contained (carbohydrate protein, fats, minerals, vitamins). 50 to 55% of total calories are carbohydrates, 10 to 15% of total calories protein. Fat limited to less than about 28% of daily total calories .Women took 1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman allowed to change the types of food to avoid boarding.~* ultrasound cavitation emits low-frequency ultrasound 40 khz for 30 minutes on abdomen twice/ week with 3 days apart for 12 weeks.~kegel exercise: Each woman in the study took the same Kegel exercise program performed the Kegel exercise for 12 weeks (3 sessions per week)"
214222913|NCT04174404|OTHER|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
214222914|NCT04174404|OTHER|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
214222915|NCT02014701|PROCEDURE|Echocardiogram|"1. Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~2. Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
214222916|NCT01787721|PROCEDURE|Ankle manipulation|
214222917|NCT01787721|OTHER|Sham manipulation|
214222918|NCT03328208|OTHER|Comfort Talk® app|Test app
214222919|NCT03328208|OTHER|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
214222920|NCT01179113|DRUG|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
214222921|NCT01179113|DRUG|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
214222922|NCT04875000|OTHER|Remineralizing agent I application|Application of UltraEZ remineralizing agent to the bleached teeth
214222923|NCT04875000|OTHER|Remineralizing agent II application|Application of 2.5% arginine solution to the bleached teeth
214222924|NCT04875000|OTHER|Remineralizing agent III application|Application of 2.5% nano-hydroxyapatite solution to the bleached teeth
214222925|NCT05680441|OTHER|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
214222926|NCT04729023|PROCEDURE|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
214222927|NCT04729023|PROCEDURE|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
214222928|NCT00006117|DRUG|gemcitabine hydrochloride|
214222929|NCT00006117|DRUG|oxaliplatin|
214650742|NCT01812642|OTHER|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
214650743|NCT04093648|GENETIC|TEGAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10\^7/m2 DL2: 3x10\^7/m2 DL3: 1x10\^8/m2 DL4: 3x10\^8/m2 DL5: 1x10\^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214650744|NCT04093648|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
214650745|NCT04093648|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
214650746|NCT03855501|OTHER|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
214650747|NCT03855501|OTHER|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
214650748|NCT05688462|OTHER|Data Collection|This is an observational prospective cohort study. Children admitted to ten identified PICUs in the UK with severe TBI with a clinical need for ICP and ABP monitoring will be included for data collection. The database will contain routinely monitored physiological parameters during management of PTBI in PICU. Without disturbing the routine care and management of these patients, investigators aim to collect this data continuously in a bedside laptop equipped with the study software (ICM+, Cambridge Enterprise Ltd, Cambridge, UK). Alongside these physiological parameters, investigators will also collect relevant clinical and demographic data (details below) and follow these patients for up to 12 months post ictus to assess neuro-psychological outcome.
214650749|NCT01564706|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
214650750|NCT01393977|PROCEDURE|rehabilitation of limb function|only receive rehabilitation of limb function
214222930|NCT05214261|OTHER|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
214222931|NCT01206088|DRUG|nilotinib|administration of nilotinib as 2nd line
214222932|NCT01984528|BIOLOGICAL|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
214222933|NCT04707300|DRUG|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
214222934|NCT05819853|DRUG|Semaglutide Injectable Product (Wegovy and/or Ozempic)|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
214222935|NCT05009459|BEHAVIORAL|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
214222936|NCT06156384|DEVICE|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
214222937|NCT05605444|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
214222938|NCT05667454|DRUG|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
214222939|NCT05667454|DRUG|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
214222940|NCT04988841|DRUG|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
214222941|NCT04988841|DRUG|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
214222942|NCT04988841|DRUG|Nivolumab|AntiPD1 ( immunothérapy)
214222943|NCT04988841|DRUG|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
214222944|NCT04988841|DRUG|Normacol|hypertonic enema solution
214650751|NCT01393977|PROCEDURE|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
214650752|NCT01770327|BEHAVIORAL|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
214650753|NCT03670459|OTHER|Cawthorne Cooksey exercises|Eye movements and head movements
214650754|NCT03670459|OTHER|Vestibular habituation exercises|Move from a sitting position to flat on the back
214650755|NCT03670459|OTHER|Balance exercises|Weight Shift Forward and Back
214222945|NCT04988841|DRUG|Placebo of Maat013|expérimental drug placebo of MaaT013
214222946|NCT04458259|DRUG|PF-07265807|Given 2 weeks on/1 week off
214222947|NCT04458259|DRUG|Sasanlimab|Given SC Q3W
214222948|NCT04458259|DRUG|Axitinib|Dosed per package label starting with 5 mg PO BID
214222949|NCT02722304|BIOLOGICAL|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
214222950|NCT02722304|BIOLOGICAL|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
214222951|NCT02722304|BIOLOGICAL|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
214222952|NCT02722304|BIOLOGICAL|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
214650756|NCT02388295|DRUG|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
214650757|NCT02388295|DRUG|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
214650758|NCT04007159|OTHER|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
214650759|NCT04007159|OTHER|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
214222953|NCT02722304|BIOLOGICAL|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
214222954|NCT03018262|DEVICE|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
214222955|NCT03018262|DEVICE|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
214222956|NCT03018262|DEVICE|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
214222957|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
214222958|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
214222959|NCT00157482|DRUG|Ezetimibe|
214222960|NCT00157482|DRUG|Simvastatin|
214222961|NCT02232568|BEHAVIORAL|Feedback|
214222962|NCT06708299|DRUG|CardiolRx|The intervention will be administered orally (via syringe) with food twice daily.
214222963|NCT01013103|DRUG|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
214222964|NCT01013103|DRUG|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
214222965|NCT02644109|DIETARY_SUPPLEMENT|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
214222966|NCT02644109|DIETARY_SUPPLEMENT|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
214817945|NCT05822479|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg intramuscular (IM) meperidine was administered in the ward."
214222971|NCT01038999|BIOLOGICAL|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
214222972|NCT02127957|OTHER|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
214222973|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
214222974|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
214222975|NCT05827536|DIETARY_SUPPLEMENT|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
214222976|NCT05827536|DIETARY_SUPPLEMENT|Standard of Care|Protein substitute
214222977|NCT01519869|DRUG|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
214222978|NCT03023813|OTHER|Intervention|Written material provided.
214650760|NCT04007159|OTHER|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
214222979|NCT00838084|DRUG|LY2811376|Oral capsules
214222980|NCT00838084|DRUG|Placebo|Oral capsules
214650761|NCT04007159|OTHER|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
214650762|NCT01963481|DRUG|Exemestane|
214650763|NCT01963481|DRUG|Cyclophosphamide|
214222981|NCT00577798|PROCEDURE|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
214222982|NCT06382376|PROCEDURE|Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group|Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group
214222983|NCT02230319|OTHER|Cryotherapy|
214222984|NCT02230319|DRUG|Paclitaxel|
214222985|NCT02433080|BEHAVIORAL|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
214222986|NCT06193122|DEVICE|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
214222987|NCT05304533|DRUG|MYK-224|Specified dose on specified days
214650764|NCT04239326|DIAGNOSTIC_TEST|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
214222988|NCT05304533|DRUG|Itraconazole|Specified dose on specified days
214222989|NCT05304533|DRUG|Verapamil|Specified dose on specified days
214222990|NCT02188901|OTHER|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) \[GE healthcare\]
214222991|NCT05996302|BEHAVIORAL|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
214222992|NCT04530136|DRUG|Ruconest|Patients will be randomized to Ruconest or Standard of Care
214222993|NCT06522542|DRUG|systematic therapy|All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
214222994|NCT03415711|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billion sachets
214222995|NCT03415711|DRUG|Mesalamine|Mesalamine 2.4 g/day in once daily administration.
214222996|NCT03415711|DRUG|Placebo|sachets with maltose, cornstarch and dioxide
214650765|NCT04258579|BEHAVIORAL|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
214650766|NCT03718247|OTHER|Modified Atkins diet|High fat low carbohydrate diet.
214650767|NCT03746691|DRUG|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
214650768|NCT03746691|DRUG|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
214222997|NCT04121793|DEVICE|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
214222998|NCT01537614|DRUG|COLIMYCINE inhalation|2 MILLION UI
214222999|NCT01537614|DRUG|COLIMYCINE injectable|2 MILLIONS UI
214223000|NCT03561467|OTHER|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
214223001|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
214223002|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral dose
214223003|NCT03174600|OTHER|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
214223004|NCT03546452|DIAGNOSTIC_TEST|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
214223005|NCT03351283|OTHER|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
214223006|NCT03351283|OTHER|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
214223007|NCT04240132|OTHER|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
214223008|NCT00980967|OTHER|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
214223009|NCT01387542|DRUG|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
214223010|NCT00870519|DRUG|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
214223011|NCT00870519|DRUG|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
214223012|NCT03601117|DEVICE|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
214223013|NCT03601117|DEVICE|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
214223014|NCT01010867|DRUG|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10\^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
214223015|NCT00773318|PROCEDURE|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
214223016|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
214223017|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
214223018|NCT04023734|BEHAVIORAL|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
214223019|NCT04023734|BEHAVIORAL|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
214223020|NCT04023734|BEHAVIORAL|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
214223021|NCT04023734|BEHAVIORAL|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
214223022|NCT04023734|BEHAVIORAL|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
214223023|NCT04775628|PROCEDURE|Inferior glide humerus in GH joint|Supine inferior glide GH joint
214223024|NCT06159426|OTHER|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
214223025|NCT00884741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
214223026|NCT00884741|BIOLOGICAL|Bevacizumab|Given IV
214223027|NCT00884741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
214223028|NCT00884741|OTHER|Laboratory Biomarker Analysis|Correlative studies
214223029|NCT00884741|OTHER|Placebo|Given IV
214223030|NCT00884741|OTHER|Quality-of-Life Assessment|Ancillary studies
214223031|NCT00884741|DRUG|Temozolomide|Given orally
214223032|NCT02052999|DRUG|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
214223033|NCT02052999|OTHER|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
214223034|NCT02052999|DRUG|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
214223035|NCT05438303|DRUG|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
214223036|NCT05438303|DRUG|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
214650769|NCT05606926|OTHER|physical therapy program|Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
214650770|NCT05606926|OTHER|whole body vibration (without extra weight vest)|9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.
214650771|NCT05606926|OTHER|whole body vibration (with weight vest)|The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
214650772|NCT04924426|PROCEDURE|TTC immersion|TTC immersion
214223037|NCT05438303|DRUG|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
214223038|NCT05438303|DRUG|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
214223039|NCT05438303|DRUG|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
214223040|NCT01475149|OTHER|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
214223041|NCT04655989|DEVICE|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
214223042|NCT02659241|DRUG|Adavosertib|Given PO
214223043|NCT02659241|OTHER|Laboratory Biomarker Analysis|Correlative studies
214223044|NCT05808361|OTHER|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
214223045|NCT05808361|OTHER|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
214223046|NCT01638182|DIETARY_SUPPLEMENT|Placebo|27 participants received for three months 1 placebo capsule per day
214223047|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
214223048|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
214223049|NCT06314828|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
214223050|NCT01233232|DRUG|Placebo|Oral dose bid
214223051|NCT01233232|DRUG|AZD5069 50mg|Oral dose bid
214223052|NCT01233232|DRUG|AZD5069 80mg|Oral dose bid
214223053|NCT05522491|DRUG|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
214223054|NCT02762370|DRUG|FX006 32 mg|Single 5 mL IA injection
214223055|NCT02762370|DRUG|TCA IR 40 mg|Single 1 mL IA injection
214223056|NCT00029770|PROCEDURE|Chiropractic spinal manipulation|
214223057|NCT00029770|DRUG|Acetaminophen|
214223058|NCT00029770|BEHAVIORAL|Self-care|
214223059|NCT00029770|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
214223060|NCT00029770|DRUG|Tylenol with codeine|
214223061|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
214223062|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
214223063|NCT00528697|DRUG|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
214223064|NCT00528697|DRUG|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
214223065|NCT00528697|DRUG|placebo|Subject will take a tablet once daily for 8 weeks
214223066|NCT02917122|DEVICE|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
214223067|NCT02917122|DRUG|Sertraline|Patients will take Sertraline.
214223068|NCT02917122|DEVICE|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
214223069|NCT00900952|OTHER|Clinical record review|
214223070|NCT04239378|PROCEDURE|socket preservation|Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
214223071|NCT03297905|BEHAVIORAL|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
214223072|NCT03297905|BEHAVIORAL|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
214223073|NCT01224990|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
214223074|NCT00125528|DRUG|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
214223075|NCT00125528|DRUG|placebo|placebo bid
214223076|NCT02543060|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
214223077|NCT02543060|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
214223078|NCT00101452|DRUG|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
214223079|NCT00101452|DRUG|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
214223080|NCT00101452|DRUG|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
214223081|NCT04282408|DEVICE|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
214223082|NCT04696614|BEHAVIORAL|exercise|intervention groups provided different sequential modality of exercise
214223083|NCT02105181|DEVICE|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
214223084|NCT04001959|PROCEDURE|Silver Diamine Fluoride with Potassium Iodide|Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
214223085|NCT02901678|DEVICE|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
214223086|NCT00499590|DRUG|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
214223087|NCT00499590|DRUG|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
214223088|NCT00000776|DRUG|Flucytosine|
214223089|NCT00000776|DRUG|Fluconazole|
214223090|NCT00000776|DRUG|Amphotericin B|
214223091|NCT00000776|DRUG|Dexamethasone|
214223092|NCT05661851|DRUG|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
214223093|NCT05661851|DRUG|Blink® Tears eye Drops|Control Product
214223094|NCT01212341|BIOLOGICAL|Allogeneic NK cells|
214223095|NCT01014910|OTHER|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
214223096|NCT01014910|DEVICE|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
214223097|NCT00583076|DRUG|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
214223098|NCT04146636|DIAGNOSTIC_TEST|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
214223099|NCT04583241|OTHER|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
214223100|NCT04583241|OTHER|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
214223101|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
214650773|NCT05432531|DRUG|Anti JAK1,2|Induction of remission of active lupus nephritis
214650774|NCT05432531|DRUG|Cyclophosphamid|Induction of remission of active lupus nephritis
214650775|NCT02456246|PROCEDURE|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
214650776|NCT02076165|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
214650777|NCT02076165|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
214223102|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
214223103|NCT04583241|OTHER|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
214223104|NCT01689493|BEHAVIORAL|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
214223105|NCT00409357|DRUG|SL77.0499-10 (alfuzosin hydrochloride)|
214223106|NCT05740878|DIETARY_SUPPLEMENT|immunonutrients oral nutritional supplements|1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
214223107|NCT05740878|DIETARY_SUPPLEMENT|standard oral nutritional supplements|1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
214650778|NCT04578002|OTHER|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
214650779|NCT00834054|PROCEDURE|Double-lung transplantation|Double-lung transplanted patients
214650780|NCT03844009|OTHER|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
214650781|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
214650782|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PG)|5.0 grams of PGX
214650783|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX|7.5 grams of PGX
214650784|NCT00801814|DIETARY_SUPPLEMENT|Control|0g of PGX
214650785|NCT00801814|DIETARY_SUPPLEMENT|Second Control|0g of PGX
214650786|NCT04477226|DIAGNOSTIC_TEST|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
214650787|NCT02509559|DRUG|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
214650788|NCT02509559|DRUG|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
214650789|NCT02509559|DEVICE|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
214650790|NCT02509559|DEVICE|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
214650791|NCT02509559|DEVICE|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
214650792|NCT02509559|DEVICE|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
214650793|NCT02509559|DEVICE|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
214650794|NCT02509559|PROCEDURE|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
214650795|NCT01242644|DEVICE|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
214650796|NCT01242644|DEVICE|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
214650797|NCT01242644|DRUG|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
214650798|NCT00345670|BIOLOGICAL|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
214650799|NCT00345670|BIOLOGICAL|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
214650800|NCT00345670|BIOLOGICAL|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
214650801|NCT05699655|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
214650802|NCT05699655|DRUG|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
214650803|NCT05699655|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
214650804|NCT05699655|DRUG|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
214650805|NCT01187992|DRUG|Atorvastatin|80 mg/day
214650806|NCT03631576|BIOLOGICAL|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
214650807|NCT03290339|PROCEDURE|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
214650808|NCT04025593|DRUG|Cyclophosphamide|750mg/m2 day 1
214650809|NCT04025593|DRUG|Rituximab|375mg/m2 day 0
214650810|NCT04025593|DRUG|Doxorubicin|50mg/m2 day 1
214650811|NCT04025593|DRUG|Vincristine|1.4mg/m2, max 2mg day 1
214650812|NCT04025593|DRUG|Prednisone|60mg/m2, max 100mg day 1-5
214650813|NCT04025593|DRUG|Ibrutinib|420mg/day qd
214650814|NCT04025593|DRUG|Lenalidomide|25mg day1-10
214650815|NCT04025593|DRUG|chidamide|20mg day 1,4,8,11
214650816|NCT04025593|DRUG|decitabine|decitabine 10mg/m2 day-5 to day-1
214650817|NCT02867397|DRUG|Teysuno (S1) in combination with epirubicin and oxaliplatin|
214650818|NCT00157833|DRUG|Artekin / Coartemther|
214650819|NCT00240760|DRUG|Memantine Hydrochloride|
214650820|NCT03026582|DEVICE|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
214650821|NCT05423405|OTHER|Acupressure|selected acupoint pressure
214650822|NCT02543138|DEVICE|Trocar|Closed thoracostomy using the new trocar
214650823|NCT03466892|OTHER|Questionnaires and computer paradigm|Patients will complete different scales and also the visual probe task. First, we hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, we hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).
214650824|NCT04688203|DRUG|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
214223108|NCT03039946|DEVICE|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
214223109|NCT03039946|OTHER|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
214223110|NCT02503137|DRUG|Topical SM04554 solution|
214223111|NCT02503137|DRUG|Topical Vehicle solution|
214223112|NCT04662515|PROCEDURE|Type of surgery|surgical or non-surgical extraction one or more teeth
214223113|NCT04662515|DRUG|Dabigatran|
214223114|NCT04662515|DRUG|Rivaroxaban|
214223115|NCT04662515|DRUG|Apixaban|
214223116|NCT04662515|DRUG|Edoxaban|
214223117|NCT04662515|DRUG|Warfarin|
214223118|NCT03564704|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
214223119|NCT03564704|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
214223120|NCT03564704|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
214223121|NCT03564704|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
214223122|NCT03564704|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
214223123|NCT03564704|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
214223124|NCT03564704|DRUG|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
214223125|NCT03564704|DRUG|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
214223126|NCT03564704|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
214223127|NCT03564704|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
214223128|NCT03564704|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
214223129|NCT03564704|PROCEDURE|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
214223130|NCT03564704|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
214223131|NCT03564704|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
214223132|NCT03564704|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
214223133|NCT03564704|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
214223134|NCT03564704|DIAGNOSTIC_TEST|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
214223135|NCT03564704|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
214223136|NCT03564704|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
214223137|NCT03564704|DRUG|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
214223138|NCT03564704|DIAGNOSTIC_TEST|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
214223139|NCT00600977|DRUG|Doxorubicine|9mg/m² J1 J4 2 COURSES
214223140|NCT00600977|DRUG|Doxorubicine pegylated|40 MG/M² J1 2 courses
214223141|NCT03050229|DRUG|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
214223142|NCT03050229|DRUG|Placebo|Placebo once daily before or after breakfast
214223143|NCT05499299|BEHAVIORAL|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
214223144|NCT04357223|DRUG|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
214223145|NCT04357223|DRUG|Placebo|Placebo
214223146|NCT00612807|BEHAVIORAL|Weekly marital therapy|Weekly marital therapy for 6 months.
214223147|NCT00612807|DRUG|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
214223148|NCT04063306|OTHER|none of intervention was given|this is an observational survey and no intervention is given
214223149|NCT06129617|DEVICE|Hemodialysis|5 treatments with hemodialysis on day 1, 2, 3, 5 and 7
214223150|NCT06129617|DEVICE|ADVOS|5 treatments with ADVOS on day 1, 2, 3, 5 and 7
214223151|NCT01192685|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
214223152|NCT01192685|DEVICE|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
214223153|NCT02408159|DRUG|Varicella Zoster Vaccine|
214223154|NCT02408159|DRUG|Placebo|
214223155|NCT05539300|DIAGNOSTIC_TEST|PSMA-PET/CT response evaluation|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
214223156|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of lower mean BP
214223157|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
214223158|NCT01580501|DRUG|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
214223159|NCT04506138|DRUG|Camrelizumab|Camrelizumab 200mg D1, D22
214223160|NCT04506138|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
214223161|NCT04506138|DRUG|Carboplatin|Carboplatin AUC5 D1, D22
214223162|NCT06086340|DRUG|Palbociclib|Palbociclib with an aromatase inhibitor therapy
214223163|NCT06086340|DRUG|Aromatase Inhibitor|Aromatase Inhibitor Therapy
214223164|NCT06112886|OTHER|There was no intervention in this study|There was no intervention in this study
214223165|NCT02162199|DRUG|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
214223166|NCT02162199|DRUG|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
214223167|NCT02252939|RADIATION|X-Ray|X-ray as part of standard care
214223168|NCT05266833|BEHAVIORAL|Slow diaphragmatic breathing|"The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session."
214223169|NCT02223494|DRUG|Terbogrel|
214223170|NCT01237769|DRUG|Vitamin D3|2200 IU/day
214223171|NCT01237769|BEHAVIORAL|Lifestyle advice|Diet and exercise
214223172|NCT05179590|OTHER|Quality of Dream|"Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia."
214223173|NCT04673396|DRUG|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
214223174|NCT04673396|DRUG|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
214223175|NCT02029898|DRUG|Remifentanil|
214223176|NCT02029898|DRUG|sodium chloride 0,9%|
214223177|NCT00633204|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
214223178|NCT00580671|BEHAVIORAL|MET/CBT|Weekly Individual Counseling Sessions
214223179|NCT00580671|BEHAVIORAL|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
214223180|NCT00580671|BEHAVIORAL|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
214223181|NCT02738385|BEHAVIORAL|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214223182|NCT02738385|BEHAVIORAL|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214223183|NCT00858104|PROCEDURE|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
214223184|NCT05611190|DIAGNOSTIC_TEST|CT-FFR|CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
214223185|NCT05611190|DIAGNOSTIC_TEST|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice.
214223186|NCT03220321|OTHER|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
214223187|NCT03220321|OTHER|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
214223188|NCT01710813|BIOLOGICAL|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
214223189|NCT01170572|OTHER|No intervention|No intervention
214223190|NCT04411563|OTHER|Taking biological samples|Taking blood samples for biochemical and epigenetic analysis
214223191|NCT03248791|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
214223192|NCT03248791|DRUG|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
214650825|NCT04688203|DRUG|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
214650826|NCT01767584|DRUG|Cephalexin 1g tablets|Reference product
214223193|NCT03248791|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
214223194|NCT03829423|DIAGNOSTIC_TEST|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
214650827|NCT01767584|DRUG|Cephalexin 1g tablets|Test product
214223195|NCT00870584|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
214223196|NCT00870584|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
214223197|NCT03913338|PROCEDURE|LasikXtra|By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
214223198|NCT03913338|PROCEDURE|LASIK|Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
214223199|NCT04824651|BIOLOGICAL|COVID-19 vaccine|Vaccination done as part of France's COVID-19 Vaccination Campaign
214223200|NCT01497366|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
214223201|NCT01497366|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
214223202|NCT01497366|DRUG|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg"
214223203|NCT03800420|DRUG|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
214223204|NCT03800420|DRUG|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
214223205|NCT00001062|DRUG|Ganciclovir|
214223206|NCT02152917|DRUG|Tranexamic acid|
214223207|NCT02152917|DRUG|Floseal®|
214223208|NCT04409860|RADIATION|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
214223209|NCT04409860|DRUG|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
214223210|NCT03911102|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
214223211|NCT01886989|DIETARY_SUPPLEMENT|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
214223212|NCT02014337|DRUG|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
214223213|NCT00746512|DRUG|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
214223214|NCT00746512|DRUG|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
214223215|NCT00746512|DRUG|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
214223216|NCT00746512|DRUG|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
214223217|NCT00419445|DRUG|GTS21/Placebo|
214223218|NCT02117557|PROCEDURE|Single incision laparoscopic surgery|
214223219|NCT02117557|PROCEDURE|Conventional laparoscopic surgery|
214223220|NCT00961909|DRUG|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
214223221|NCT00961909|DRUG|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
214223222|NCT00961909|DRUG|metformin|stable dose
214223223|NCT00961909|DRUG|placebo|sc once weekly for 4 weeks
214223224|NCT03499535|BEHAVIORAL|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
214223225|NCT03499535|BEHAVIORAL|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
214223226|NCT03499535|BEHAVIORAL|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
214223227|NCT03499535|BEHAVIORAL|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
214223228|NCT03499535|BEHAVIORAL|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
214223229|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
214223230|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
214223231|NCT01449799|DRUG|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
214223232|NCT01449799|DRUG|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
214223233|NCT01449799|DRUG|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
214650828|NCT00640094|DRUG|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
214223234|NCT01449799|DRUG|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
214223235|NCT03258528|BEHAVIORAL|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
214223236|NCT05693961|DEVICE|CART-I plus|CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
214223237|NCT06144580|OTHER|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
214223238|NCT02745080|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
214223239|NCT02745080|BIOLOGICAL|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
214223240|NCT06233370|BEHAVIORAL|Moderate intensity walking exercise|For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
214223241|NCT03216824|OTHER|Dressing|A dressing is maintained on the CVAD exit site.
214223242|NCT03216824|OTHER|No-Dressing|The CVAD exit site is not covered with a dressing.
214223243|NCT02860429|DRUG|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
214223244|NCT02860429|DRUG|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
214223245|NCT01453062|DRUG|Arzerra|Treatment with Arzerra
214223246|NCT00106899|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scans
214223247|NCT00106899|PROCEDURE|Positron Emission Tomography (PET)|PET scans
214223248|NCT00106899|PROCEDURE|Lumbar Puncture (LP)|collection of cerebrospinal fluid
214223249|NCT04234412|PROCEDURE|umbilical cord blood stem cell implantation for osteoarthritis treatment|"The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface."
214223250|NCT02093195|DRUG|Bosentan|
214223251|NCT02093195|DRUG|Symbicort turbuhaler|
214223252|NCT01821560|DRUG|Baclofen|
214223253|NCT01821560|DRUG|placebo|
214223254|NCT02182388|DRUG|Placebo|
214223255|NCT02182388|DRUG|BI 207127 NA powder for solution|
214223256|NCT02182388|DRUG|BI 207127 NA tablet|
214223257|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
214223258|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
214223259|NCT04562051|OTHER|prophylaxis regimen|All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
214223260|NCT06076967|BEHAVIORAL|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
214223261|NCT06076967|BEHAVIORAL|Services-As-Usual|Services-As-Usual includes the standard support services provided by universities
214223262|NCT03196362|DRUG|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
214223263|NCT03196362|DRUG|Placebo Oral Tablet|One tablet of placebo will be given twice daily
214223264|NCT04306484|DIAGNOSTIC_TEST|FDOPA-TEP|FDOPA-TEP performed as part of the normal management of a suspected brain tumour
214223265|NCT04107025|OTHER|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
214223266|NCT01892839|OTHER|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
214223267|NCT01892839|OTHER|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
214223268|NCT04291989|DEVICE|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
214223269|NCT05513209|PROCEDURE|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
214223270|NCT05513209|PROCEDURE|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
214223271|NCT00268255|DRUG|gefitinib|
214223272|NCT00268255|PROCEDURE|adjuvant therapy|
214223273|NCT00268255|PROCEDURE|enzyme inhibitor therapy|
214223274|NCT00268255|PROCEDURE|neoadjuvant therapy|
214223275|NCT00268255|PROCEDURE|protein tyrosine kinase inhibitor therapy|
214223276|NCT00268255|PROCEDURE|radiation therapy|
214223277|NCT00268255|PROCEDURE|radiosensitization|
214223278|NCT01338298|DRUG|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
214223279|NCT01338298|DRUG|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
214223280|NCT06216925|BEHAVIORAL|#BabyLetsMove|Description of #BabyLetsMove
214223281|NCT06216925|BEHAVIORAL|WIC Antenatal Care|Description
214223282|NCT03719196|OTHER|Reading glass|Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
214223283|NCT05037175|BEHAVIORAL|CPT-Text|CPT is a 12-session (13 modules), trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one. Brief synchronous messaging sessions can be arranged
214223284|NCT05037175|BEHAVIORAL|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy. Brief synchronous messaging sessions can be arranged.
214223285|NCT05037175|BEHAVIORAL|Retention Incentive|Participants will be told at baseline that they can earn free or discounted therapy for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
214223286|NCT05037175|BEHAVIORAL|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
214223287|NCT05741008|RADIATION|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
214223288|NCT05301608|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
214223289|NCT05301608|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
214223290|NCT06228768|OTHER|Acupressure|9 acupoints will be stimulated for 3 minutes per point
214223291|NCT06228768|OTHER|Acupressure|9 areas will be stimulated for 3 minutes per point
214223292|NCT06414291|OTHER|Plain Water|Plain water without calories, sweetener, or electolytes
214223293|NCT06414291|OTHER|Liquid IV Hydration Multiplier|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
214223294|NCT06414291|OTHER|Liquid IV Sugar Free|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
214223295|NCT05847530|DEVICE|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
214223296|NCT05847530|DEVICE|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
214223297|NCT05407818|DRUG|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
214223298|NCT05716542|OTHER|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
214223299|NCT06516055|DRUG|S1B-408|Medication with multiple monoamine activities
214223300|NCT04966481|DRUG|Palbociclib|Administered on an outpatient basis
214223301|NCT04966481|DRUG|Cetuximab|Given intravenously over approximately 60 minutes
214223302|NCT06102499|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
214223303|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
214223304|NCT05920135|DRUG|BBT-207|BBT-207 given orally alone
214223305|NCT03313011|DIAGNOSTIC_TEST|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
214223306|NCT05601544|DEVICE|ACUVUE OASYS 1-Day|Sphere CONTROL
214223307|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day|Sphere TEST
214223308|NCT05601544|DEVICE|ACUVUE OASYS Multifocal|Multifocal CONTROL
214223309|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day Multifocal|Multifocal TEST
214223310|NCT05601544|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|Toric CONTROL
214650829|NCT00728065|DIETARY_SUPPLEMENT|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
214650830|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
214650831|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
214650832|NCT00728065|DIETARY_SUPPLEMENT|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
214650833|NCT00728065|DIETARY_SUPPLEMENT|Rice milk|Rice milk containing 50g of available carbohydrates
214650834|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
214650835|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
214650836|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
214650837|NCT05835414|DEVICE|Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)|Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
214223311|NCT05601544|DEVICE|senofilcon A based contact lens (toric) with new UV/HEV filter|Toric TEST
214223312|NCT06108583|BEHAVIORAL|TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder|The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
214223313|NCT04940039|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
214650838|NCT05394038|OTHER|None，observational study.|observational study
214650839|NCT05527990|DEVICE|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
214650840|NCT00914381|BEHAVIORAL|Behavioral therapy|
214650841|NCT04340050|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
214650842|NCT01950819|BIOLOGICAL|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
214650843|NCT01950819|DRUG|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
214650844|NCT01950819|DRUG|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
214650845|NCT01950819|DRUG|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
214223314|NCT04940039|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
214223315|NCT04940039|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
214650846|NCT04134494|DEVICE|Ablative Fractional 2940 nm Laser|"* Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
214650847|NCT02537041|PROCEDURE|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
214223316|NCT04940039|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
214223317|NCT04940039|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
214223318|NCT04940039|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
214223319|NCT04940039|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
214223320|NCT04940039|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
214650848|NCT02537041|PROCEDURE|MRI|
214650849|NCT01152606|DRUG|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
214650850|NCT01710930|OTHER|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
214650851|NCT04008732|DRUG|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
214650852|NCT04008732|DRUG|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
214650853|NCT04008732|DRUG|Nitro Pohl|to be dosed intravenously in Part 2 of the study
214650854|NCT06110052|OTHER|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
214650855|NCT00119340|DRUG|cyclosporine|
214650856|NCT00119340|DRUG|fludarabine phosphate|
214650857|NCT00119340|DRUG|mycophenolate mofetil|
214650858|NCT00119340|PROCEDURE|peripheral blood stem cell transplantation|
214650859|NCT00119340|RADIATION|radiation therapy|
214650860|NCT00183846|DRUG|irinotecan|
214650861|NCT00183846|PROCEDURE|radiation therapy|
214650862|NCT02976155|OTHER|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
214650863|NCT01096914|PROCEDURE|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
214650864|NCT01096914|PROCEDURE|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
214650865|NCT00781365|OTHER|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
214650866|NCT01784835|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
214650867|NCT01784835|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
214650868|NCT01114789|OTHER|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
214650869|NCT05479903|PROCEDURE|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
214650870|NCT05479903|BEHAVIORAL|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
214650871|NCT05479903|BEHAVIORAL|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
214650872|NCT05479903|BEHAVIORAL|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
214650873|NCT05479903|OTHER|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
214650874|NCT01474590|DRUG|Epiduo/Tactuo|topical to the face, once daily in the evening
214650875|NCT01474590|OTHER|vehicle gel|topical to the face, once daily in the evening
214223321|NCT04940039|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
214223322|NCT00081874|DRUG|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
214223323|NCT06228599|OTHER|Treatment Plan|A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
214223324|NCT06322576|DRUG|177Lu-PNT2002|"10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires."
214223325|NCT02491632|DRUG|Dexamethasone|Given PO
214223326|NCT02491632|BEHAVIORAL|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
214223327|NCT02491632|OTHER|Laboratory Biomarker Analysis|Correlative studies
214223328|NCT02491632|OTHER|Quality-of-Life Assessment|Ancillary studies
214223329|NCT02491632|OTHER|Questionnaire Administration|Ancillary studies
214650876|NCT01474590|DRUG|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
214650877|NCT01474590|DRUG|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
214650878|NCT01708031|OTHER|physiological signals|
214650879|NCT00756548|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
214650880|NCT00756548|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
214650881|NCT01086436|BIOLOGICAL|Rotarix ™|Oral, single dose
214650882|NCT01086436|BIOLOGICAL|Placebo|Oral, single dose
214650883|NCT00456690|OTHER|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
214650884|NCT05734729|DEVICE|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
214650885|NCT05734729|DEVICE|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
214650886|NCT00102089|BIOLOGICAL|VRC-HIVADV014-00-VP booster|
214650887|NCT00102089|DRUG|VRC-HIVADV014-00-VP|
214650888|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
214650889|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
214650890|NCT04586985|DRUG|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
214650891|NCT04586985|DRUG|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
214650892|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
214650893|NCT05554120|OTHER|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
214650894|NCT02505529|OTHER|Resistance Exercise Training|Behavioral interventions of resistance exercise
214650895|NCT02505529|OTHER|Mental Imagery|Behavioral intervention of mental imagery
214650896|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
214650897|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
214650898|NCT00000655|DRUG|Atovaquone|
214223330|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
214650899|NCT00000655|DRUG|Sulfamethoxazole-Trimethoprim|
214650900|NCT01756456|DRUG|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
214650901|NCT01756456|DRUG|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
214650902|NCT01756456|OTHER|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
214650903|NCT01618760|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
214650904|NCT01618760|DRUG|Risperidone|1 mg tablet once a day
214650905|NCT00198692|BEHAVIORAL|self-management|
214223331|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
214223332|NCT00328107|BIOLOGICAL|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
214650906|NCT05804799|DIAGNOSTIC_TEST|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
214650907|NCT01573910|DRUG|Moxifloxacin ophthalmic solution, 0.5%|
214650908|NCT01573910|DRUG|Ofloxacin ophthalmic solution, 0.3%|
214650909|NCT03830216|DEVICE|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
214223333|NCT02117297|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
214223334|NCT06221826|DRUG|Mexidol|Neurocytoprotector
214650910|NCT03830216|DEVICE|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
214650911|NCT00124280|DRUG|RAD001|
214650912|NCT06355882|PROCEDURE|Anesthetic infiltration|Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
214650913|NCT01649947|DRUG|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
214650914|NCT01649947|DRUG|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
214650915|NCT01649947|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
214650916|NCT01649947|DRUG|Bevacizumab|"Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
214650917|NCT01920802|DRUG|olanzapine|5mg BID up to 4 weeks
214650918|NCT01920802|DRUG|iloperidone|6 mg BID up to 4 weeks
214650919|NCT01920802|DRUG|Placebo|BID up to 4 weeks
214223335|NCT06124508|BEHAVIORAL|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
214223336|NCT06124508|BEHAVIORAL|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
214223337|NCT06124508|BEHAVIORAL|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
214223338|NCT04254549|DRUG|Rifaximin|550 mg by mouth three times daily for 14 days
214223339|NCT04254549|DRUG|Placebo|By mouth three times daily for 14 days
214223342|NCT02773082|DEVICE|Reclaim™ DBS Therapy|DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
214223343|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
214223344|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
214223345|NCT06853587|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
214223346|NCT06853587|OTHER|Current prescribing guidelines/recommendations|SSRI dosing based on current prescribing guidelines/recommendations
214223347|NCT06654804|DRUG|Perflutren lipid|Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
214223348|NCT03120897|DEVICE|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
214223349|NCT06170047|BEHAVIORAL|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
214223350|NCT06170047|OTHER|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
214223351|NCT06173518|BIOLOGICAL|AUTO1|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
214223352|NCT06767774|DRUG|Combination therapy|"* pitavastatin 4mg~* ezetimibe 10mg"
214223353|NCT06767774|DRUG|High intensity statin monotherapy|rosuvastatin 20mg
214223354|NCT06015282|BIOLOGICAL|Investigational aQIVc|Investigational Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214223355|NCT06015282|BIOLOGICAL|licensed QIVr|Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
214223356|NCT06015282|BIOLOGICAL|licensed aQIV|Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
214223357|NCT06760507|OTHER|Adapted Family History Screening Program|The intervention includes four key steps designed to enhance the family health screening process. Before the visit, clinics will engage in community outreach using tools such as social media, events, and promotional materials to raise awareness and drive appointment scheduling through the updated GA CORE website 2.0. During the visit, the intervention streamlines the screening process by embedding reminders into workflows and simplifying results communication and documentation. Patients receive theory-based communication materials about their results. After the visit, follow-ups are automated using the updated website 2.0, consolidating data tracking and incorporating risk-stratified communication strategies to encourage appropriate cancer screening behaviors.
214223358|NCT06795191|DRUG|Triptorelin Mesylate|22.5 mg in a prefilled, ready-to-use, long-acting formulation
214223359|NCT05436327|BEHAVIORAL|Geriatric Assessment|Clinical staff receive (a) training in GA and workflow management strategies (\<60 minutes) at baseline, (b) monthly facilitation and technical support calls (15-30 minutes) for 12 months, and (c) a group-based quarterly call for 12 months. For 12 months, clinical staff implement GA strategies during visits with older adult (65+) patients planning to receive new chemotherapy regimen and their care partners/caregivers.
214223360|NCT02910700|DRUG|Binimetinib|Given PO
214223361|NCT02910700|DRUG|Dabrafenib|Given PO
214223362|NCT02910700|DRUG|Encorafenib|Given PO
214223363|NCT02910700|OTHER|Laboratory Biomarker Analysis|Correlative studies
214223364|NCT02910700|BIOLOGICAL|Nivolumab|Given IV
214223365|NCT02910700|OTHER|Pharmacological Study|Correlative studies
214223366|NCT02910700|DRUG|Trametinib|Given PO
214223367|NCT06003049|DRUG|OnabotulinumtoxinA|BOTOX injection series
214223368|NCT06003049|OTHER|Placebo|Placebo injection series
214223369|NCT04083612|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
214223370|NCT04083612|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
214223371|NCT06493279|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13vg (3ml), 6E13vg(6ml), and 1.2E14 vg(12ml) per person sequentially.
214223372|NCT05290571|OTHER|Modified Otago Exercise Program with music|Our study attempts to establish a new home-based exercise option incorporating mOEP with video, music and lyrics. Our new approach shares the same aims with Exergames and video-supported methods - to increase the exercise motivation of elderlies, hence their physical performance. Based on the video-supported approach in one previous study, we add in the component of music therapy. Music-based exercise interventions could produce positive outcomes on both physical, such as gait, balance and fall risk and level of physical activities and psychological, including exercise adherence, perceived exertion, thus extending exercise duration. However, exact mechanisms have not been revealed and it may be limited by personal preferences on music. In our video, the music we chose is of brisk rhythm, slightly delightful melody and higher pitch, which all help to shape a cheerful and relaxing atmosphere for the elderlies.
214223373|NCT05290571|OTHER|Modified Otago Exercise Program|Otago Exercise Program (OEP) was developed by Otago Medical School in New Zealand as a tailor-made home-based fall prevention program to improve the balance performance of community-dwelling elderlies over 1 year. It comprises of 3 main components: 5 lower limb strengthening, 12 balance retraining and walking exercises. In the original program, the intensity was set as moderate with up to 4 difficulty levels for strengthening and balance exercises, in terms of ankle cuff weights and number of repetitions, and level of support respectively. It also stated that the frequency was at least 3 times a week for the former two exercises and at least 2 times per week for walking exercises; while the total duration was expected to make up to an hour, including 30-minute walking exercises.
214223374|NCT00895206|DRUG|individual adapted immunosuppression|individual adapted immunosuppression
214223375|NCT00895206|DRUG|golden standard therapy|golden standard therapy
214223376|NCT03390114|BEHAVIORAL|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
214223377|NCT03036215|BEHAVIORAL|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
214223378|NCT00566384|DRUG|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
214223379|NCT00566384|DRUG|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
214223380|NCT05194371|RADIATION|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
214223381|NCT00498771|BEHAVIORAL|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
214223382|NCT03180632|DRUG|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
214223383|NCT03180632|OTHER|Placebo|Patient receive one of two tablet of Placebo according to body weight
214223384|NCT06326983|DRUG|Dexmedetomidine|Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
214223385|NCT06326983|DRUG|Acetaminophen|Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
214223386|NCT06326983|DRUG|Ketorolac|Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
214223387|NCT06326983|DRUG|Morphine|Morphine (0.1mg/kg given intravenously at induction of anesthesia)
214223388|NCT01732601|BEHAVIORAL|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
214223389|NCT01732601|BEHAVIORAL|Standard Care|Treatment at step-down facilities
214223390|NCT00788177|DRUG|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
214223391|NCT03664349|DEVICE|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
214223392|NCT03792828|DRUG|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
214223393|NCT03637088|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
214223394|NCT03637088|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
214223395|NCT00474279|DRUG|Orally active growth hormone secretagogue (MK-677)|
214650920|NCT05123235|BEHAVIORAL|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
214650921|NCT04266535|DEVICE|Target controlled infusion|Target controlled infusion vs manually controlled infusion
214650922|NCT06545357|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
214650923|NCT04187235|PROCEDURE|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
214650924|NCT02591264|OTHER|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
214650925|NCT05535647|DRUG|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
214650926|NCT05535647|DRUG|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
214650927|NCT05833802|OTHER|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
214650928|NCT00616135|PROCEDURE|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
214650929|NCT03284450|OTHER|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
214650930|NCT03284450|OTHER|SSRS|The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
214650931|NCT06072014|OTHER|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
214650932|NCT04244370|DEVICE|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
214650933|NCT00002948|BIOLOGICAL|filgrastim|
214650934|NCT00002948|DRUG|topotecan hydrochloride|
214650935|NCT00002948|PROCEDURE|bone marrow ablation with stem cell support|
214650936|NCT00002948|PROCEDURE|peripheral blood stem cell transplantation|
214650937|NCT04687319|BIOLOGICAL|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
214650938|NCT01912755|DRUG|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
214650939|NCT01912755|DRUG|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
214650940|NCT03071783|DEVICE|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
214650941|NCT05779709|OTHER|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
214650942|NCT05779709|OTHER|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
214650943|NCT05011084|DEVICE|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
214650944|NCT05011084|OTHER|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
214650945|NCT02054182|DRUG|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
214650946|NCT01526525|DRUG|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
214650947|NCT01526525|DRUG|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
214223396|NCT00271713|DRUG|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
214223397|NCT00271713|DRUG|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
214223398|NCT03500445|DRUG|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1"
214650948|NCT01526525|DRUG|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
214650949|NCT01526525|DRUG|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
214650950|NCT01526525|PROCEDURE|sedation|If the patient had sedation score \>2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
214650951|NCT01526525|PROCEDURE|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
214650952|NCT01526525|DRUG|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
214650953|NCT01526525|DRUG|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
214650954|NCT06120257|PROCEDURE|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
214223399|NCT03500445|DRUG|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
214223400|NCT03500445|DRUG|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
214223401|NCT03500445|DRUG|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
214223402|NCT01541683|OTHER|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
214223403|NCT01541683|OTHER|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
214223404|NCT00648050|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
214223405|NCT00648050|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
214223406|NCT06308705|DIAGNOSTIC_TEST|InBios Strongy Detect TM IgG ELISA|The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies to Strongyloides recombinant antigens NIE and SsIR in serum. It consists of an enzymatically amplified sandwich-type immunoassay. Positive and negative control samples are provided in the kit. The test will be run and interpreted according to the manufacturer's instruction. The results are expressed as OD and nOD. Clinical interpretation of the results will be done by analysis of the Receiver Operating Characteristics (ROC) curve generated using data from confirmed positive and confirmed negative samples.
214223407|NCT01505764|DRUG|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
214223408|NCT01505764|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
214650955|NCT06120257|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
214650956|NCT06120257|PROCEDURE|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
214650957|NCT03325179|OTHER|Thread-embedding Therapy|
214223409|NCT01670305|PROCEDURE|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
214223410|NCT01670305|PROCEDURE|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
214223411|NCT01670305|PROCEDURE|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
214223412|NCT01670305|PROCEDURE|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
214223413|NCT01670305|PROCEDURE|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
214223414|NCT02773953|DEVICE|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
214223415|NCT02773953|DEVICE|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
214223416|NCT01256294|DRUG|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
214223417|NCT01256294|DRUG|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
214223418|NCT04030156|PROCEDURE|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
214223419|NCT04681352|DEVICE|Octave-Ultherapy treatment|Micro-focused ultrasound delivered below the surface of the skin.
214223420|NCT06335745|BEHAVIORAL|PediCARE Intervention|A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
214223421|NCT03517345|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
214223422|NCT03517345|DIETARY_SUPPLEMENT|Control|The only yogurt consumed as 200 g/d without prebiotic.
214223423|NCT03625843|BEHAVIORAL|Mindfulness exercises|
214223424|NCT04952155|DRUG|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
214650958|NCT01905475|DRUG|POL6326|
214650959|NCT01905475|DRUG|Placebo|
214650960|NCT03527576|DRUG|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
214650961|NCT03527576|DRUG|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
214650962|NCT01998542|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
214650963|NCT01998542|BIOLOGICAL|CRCL|autologous tumor-derived chaperone protein mixture
214650964|NCT01998542|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
214650965|NCT00001757|DRUG|Voriconazole|
214650966|NCT00612599|DRUG|biphasic insulin aspart|
214650967|NCT01850615|DRUG|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
214650968|NCT01850615|DRUG|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
214223425|NCT03220451|PROCEDURE|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
214223426|NCT02603666|DEVICE|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
214223427|NCT01643772|DRUG|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
214223428|NCT03293901|BEHAVIORAL|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
214223429|NCT05466370|BIOLOGICAL|Transfusion of Allogeneic Blood|Transfusion of Allogeneic Blood
214223430|NCT04866745|DEVICE|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
214223431|NCT04866745|DEVICE|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
214223432|NCT04866745|DEVICE|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
214223433|NCT03140059|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
214223434|NCT03140059|PROCEDURE|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
214223435|NCT00004040|BIOLOGICAL|recombinant interferon alfa|
214223436|NCT00004040|BIOLOGICAL|rituximab|
214223437|NCT04195542|OTHER|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
214223438|NCT03982134|DRUG|PDR001|PDR001 is a humanized IgG4 antibody
214223439|NCT03982134|DRUG|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
214223440|NCT03649308|DEVICE|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
214223441|NCT03649308|PROCEDURE|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
214223442|NCT04314791|DEVICE|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
214650969|NCT04968444|OTHER|Physiotherapy|"Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation"
214223443|NCT05554562|OTHER|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
214223444|NCT00979667|DRUG|Oseltamivir|75 mg twice daily for 5 days
214223445|NCT00979667|DRUG|Zanamivir|10 mg twice daily for 5 days
214223446|NCT00979667|DRUG|Placebo of Oseltamivir|twice daily for 5 days
214223447|NCT00771862|PROCEDURE|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
214223448|NCT02338882|DEVICE|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
214223449|NCT02338882|DEVICE|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
214223450|NCT01328405|DEVICE|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
214650970|NCT04968444|OTHER|Back Pain Workshop|Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
214650971|NCT04920240|BEHAVIORAL|cleaning and disinfection mode for surfaces with high frequency contact|According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
214650972|NCT04920240|BEHAVIORAL|Routine procedure|clean the high frequency contact surface like other surfaces
214650973|NCT00608855|OTHER|questionnaire administration|
214650974|NCT00608855|PROCEDURE|cryosurgery|
214650975|NCT00608855|PROCEDURE|pain therapy|
214650976|NCT00608855|PROCEDURE|quality-of-life assessment|
214223451|NCT03495609|DRUG|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
214650977|NCT05257512|DRUG|SY-3505|The third-generation ALK TKI
214650978|NCT02829879|DRUG|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
214650979|NCT02829879|DRUG|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
214223452|NCT05366400|DIAGNOSTIC_TEST|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
214223453|NCT01293227|PROCEDURE|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
214223454|NCT00639743|DRUG|placebo ( group B)|placebo ( group B)
214223455|NCT00639743|DRUG|tenecteplase (group A)|tenecteplase (group A)
214223456|NCT04745949|DRUG|Brentuximab Vedotin|Given IV
214223457|NCT04745949|DRUG|Cyclophosphamide|Given IV
214223458|NCT04745949|DRUG|Doxorubicin|Given IV
214223459|NCT04745949|BIOLOGICAL|Nivolumab|Given IV
214223460|NCT04745949|DRUG|Prednisone|Given PO
214223461|NCT04745949|OTHER|Quality-of-Life Assessment|Ancillary studies
214223462|NCT04745949|BIOLOGICAL|Rituximab|Given IV
214223463|NCT06052449|BEHAVIORAL|Social determinants of health screening assessment and referral process|Unite Us is an electronic SDoH screening and referral tool assessing: (1) financial resource strain; (2) housing stability; (3) transportation needs; and (4) food insecurity. Upon completion, the Unite Us platform identifies a list of geographically-tailored resources to connect the individual in need. A staff member will administer the SDoH screening and referral tool, review the results with the participant, and use the geographically-tailored resources to make SDoH-related referrals.
214223464|NCT06052449|BEHAVIORAL|Current practice - Community-based lunch cancer screening (LungTalk)|The current practice during community events is to offer LungTalk. LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled LCS knowledge and health beliefs (p \< 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% Confidence Interval (CI), 1.03, 3.85, p = 0.03.
214223465|NCT04838977|BEHAVIORAL|RESET|Therapy
214223466|NCT06454682|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13 vg/person, 6E13 vg/person, and 1.2E14 vg/person sequentially.
214223467|NCT06128538|DEVICE|Auricular acupuncture|we will implement 12 weeks of BFA. These sessions will be done every other week (total of 6 sessions over 12 weeks). During these sessions, Dr. Quinlan (Co-I) and another BFA-trained provider (Dr. Wilbur or Dr. Butler; also research team members) will perform the group BFA protocol with all 20 participants. During this 12-week acupuncture phase, participants will receive the same SMS messages twice a week to collect pain intensity scores. The group BFA protocol involves taking vitals for all patients (similar to a regular medical visit) and placing all 10 acupuncture needles (5 in each ear) while the patient remains seated in a chair. Once the acupuncture needles are placed, the patient will be asked to move around and remain in the room for 30 minutes (for any questions or medical concerns.
214223468|NCT06128538|BEHAVIORAL|Visual Analog Scale for Pain|During the first 12 weeks of the trial, the research manager will collect weekly pain scores using the visual analog scale (pain scale 1-10). During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect pain scores using the visual analog scale at each acupuncture session immediately before and 30 minutes after the acupuncture protocol by the research team, and then twice a week thereafter.
214223469|NCT06128538|BEHAVIORAL|Roland-Morris Disability Questionnaire|During the first 12 weeks of the trial, the research manager will collect weekly Roland -Morris Disability questionnaire data. During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect disability scores using the Roland-Morris Disability Questionnaire at each acupuncture session (6 sessions in total).
214223470|NCT00786370|DRUG|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
214223471|NCT00786370|DRUG|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
214223472|NCT00786370|DRUG|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
214223473|NCT03323424|RADIATION|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
214223474|NCT03323424|OTHER|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
214223475|NCT05433285|BIOLOGICAL|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
214223476|NCT05433285|BIOLOGICAL|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
214650980|NCT03135912|DRUG|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
214650981|NCT03135912|DRUG|Placebo|Dosage method of SESC 01, without active ingredients.
214223477|NCT01145092|BEHAVIORAL|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
214223478|NCT04734899|OTHER|Exercise program|Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg
214223479|NCT04734899|OTHER|Foot core training|Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
214223480|NCT05518318|DRUG|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
214223481|NCT05518318|DRUG|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
214223482|NCT02492932|DEVICE|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
214223483|NCT00152100|PROCEDURE|Stem cell transplant|
214223484|NCT00152100|DRUG|Filgrastim, Alemtuzumab|
214223485|NCT00152100|DEVICE|Miltenyi CliniMACS|
214223486|NCT03065972|PROCEDURE|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
214223487|NCT03065972|DEVICE|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
214223488|NCT04903743|DRUG|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
214223489|NCT04903743|DRUG|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
214223490|NCT05648032|COMBINATION_PRODUCT|lyophilized platelet (30ng) and triamcinolone acetonide 10mg|Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
214223491|NCT05648032|OTHER|lyophilized platelet (30ng)|Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
214223492|NCT05648032|DRUG|triamcinolone acetonide 10mg|Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
214223493|NCT06032325|DIAGNOSTIC_TEST|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
214223494|NCT04780919|DEVICE|BTL-6000 FSWT|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.
214223495|NCT04780919|DEVICE|BTL-6000 FSWT with sham applicator|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
214650982|NCT03135912|DRUG|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
214223496|NCT05435443|DEVICE|PowerBreathe and PEP Therosold tools|"Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM."
214223497|NCT01076439|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
214223498|NCT01076439|DRUG|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
214223499|NCT01076439|DRUG|Saline Nasal Spray|Placebo
214223500|NCT03247452|OTHER|One-day Low fiber diet|One-day low fiber diet before colonoscopy
214223501|NCT03247452|OTHER|Three-day low fiber diet|Three days low fiber diet before colonoscopy
214223502|NCT03247452|DRUG|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
214223503|NCT03074019|DIETARY_SUPPLEMENT|Xylooligosaccacharide|XOS95 powder
214223504|NCT03074019|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder
214223505|NCT05715112|PROCEDURE|Graded Motor Imagery|GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
214223506|NCT05132322|BEHAVIORAL|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
214223507|NCT05132322|BEHAVIORAL|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
214223508|NCT05132322|BEHAVIORAL|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
214650983|NCT01227967|DRUG|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
214223509|NCT05132322|BEHAVIORAL|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
214223510|NCT04280237|OTHER|Blood samples|Blood samples
214223511|NCT02314637|DRUG|Teneligliptin|Teneligliptin for 52 weeks
214223512|NCT02314637|DRUG|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
214223513|NCT04126278|DRUG|Barbotage|Administered as per standard of care
214223514|NCT04126278|DRUG|Dexamethasone|4 mg of dexamethasone
214223515|NCT00448318|PROCEDURE|Music Therapy|
214223516|NCT00724867|BIOLOGICAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
214223517|NCT00724867|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
214223518|NCT03663660|OTHER|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
214223519|NCT04133129|BEHAVIORAL|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
214223520|NCT04133129|BEHAVIORAL|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
214223521|NCT05233241|OTHER|in vitro Allergological test Allergological skin tests|"In vitro allergological tests: lymphocyte transformation test, measurement of CD154 membrane expression, ELISPOT-IFNgammma Allergological skin tests (patch tests, prick tests and intradermal tests with European standardised method) in case of negative in vitro tests."
214223522|NCT00213538|DRUG|Response to anakinra associated with methotrexate|
214223523|NCT00389987|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
214223524|NCT00389987|DRUG|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
214223525|NCT02999438|DEVICE|Actigraph to check activity levels at home|
214223526|NCT00207064|DRUG|quetiapine|flexible doses according to the clinical condition
214223527|NCT02663713|DRUG|Ticagrelor|Ticagrelor 60mg twice daily
214223528|NCT02663713|DRUG|Clopidogrel|Clopidogrel 75 mg once daily
214223529|NCT00922948|PROCEDURE|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
214223530|NCT00922948|PROCEDURE|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
214223531|NCT01221935|OTHER|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
214223532|NCT01221935|OTHER|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
214223533|NCT01221935|OTHER|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
214223534|NCT01221935|OTHER|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
214223535|NCT02302612|BEHAVIORAL|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
214223536|NCT02302612|OTHER|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
214223537|NCT03189238|BIOLOGICAL|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
214223538|NCT00373113|DRUG|Capecitabine|1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
214223539|NCT00373113|DRUG|Sunitinib malate|37.5 mg daily, continuous dosing
214223540|NCT00494247|DEVICE|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
214223541|NCT00856232|BIOLOGICAL|Medical Air|Compressed medical air
214223542|NCT00856232|BIOLOGICAL|Oxygen|Medical Oxygen
214223543|NCT02239549|DEVICE|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
214223544|NCT02239549|DEVICE|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
214223545|NCT03241030|DRUG|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
214223546|NCT03241030|OTHER|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
214223547|NCT03241030|DRUG|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
214650984|NCT01227967|DRUG|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
214223548|NCT03241030|DRUG|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
214223549|NCT01373541|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
214223550|NCT01373541|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
214223551|NCT04215302|DEVICE|laryngeal mask|the size of laryngeal mask given to the patient was based on patient's weight measurement
214223552|NCT03828578|PROCEDURE|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
214223553|NCT05490550|BEHAVIORAL|COAST-enhanced CBTI|Participants will receive CBTI delivered through the COAST platform by one of NOCTEM's certified and licensed COAST clinician. Communication between the participant and licensed clinician will occur primarily through COAST's HIPAA-compliant text messaging, but clinicians and patients may elect to connect via telephone calls or HIPAA-compliant secure videoconference if needed.
214223554|NCT05490550|BEHAVIORAL|Military Treatment Facility Insomnia Care As Usual|Participants will receive the insomnia care offered at their site following current delivery practices (i.e., face-to-face or virtual; individual or group format). During the treatment phase, participants randomized to ICAU will be instructed to communicate with their clinicians as needed, according to standard procedures in place.
214223555|NCT05126251|DRUG|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
214223556|NCT05126251|BEHAVIORAL|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
214223557|NCT04504552|DRUG|Avelumab|Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
214223558|NCT04352972|DEVICE|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
214223559|NCT04352972|OTHER|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
214223560|NCT02969148|PROCEDURE|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
214223561|NCT02969148|PROCEDURE|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
214223562|NCT03078140|DIETARY_SUPPLEMENT|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
214223563|NCT03078140|DIETARY_SUPPLEMENT|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
214223564|NCT02902341|DIETARY_SUPPLEMENT|Nutrition Therapy|Nutrition based on measured caloric needs.
214223565|NCT02902341|DIETARY_SUPPLEMENT|Control|Standard protocol nutrition based on calculated caloric needs.
214223566|NCT02265588|BEHAVIORAL|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
214223567|NCT01863836|PROCEDURE|Fluoroscopy|
214223568|NCT01863836|PROCEDURE|Radial EBUS-guided biopsy|
214223569|NCT04466202|OTHER|Music with Structured Verbal Training|Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
214223570|NCT02117622|DRUG|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
214223571|NCT06297772|DRUG|Decitabine|decitabine 20mg/m2 per day for consecutive 5 days
214223572|NCT06297772|DRUG|Fludarabine Injection|fludarabine 30mg/m2 per day for consecutive 5 days
214223573|NCT06297772|DRUG|Busulfan Injection|Busulfan 3.2mg/kg per day for consecutive 4 days
214223574|NCT02150434|DEVICE|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
214223575|NCT02150434|DRUG|Compressed air|compressed air delivered at a fixed flow of 2 L/min
214223576|NCT02150434|DRUG|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
214223577|NCT06055543|DIETARY_SUPPLEMENT|Fortimel|2 bottles/day of the high energy ONS
214223578|NCT00124046|PROCEDURE|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
214223579|NCT00124046|PROCEDURE|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
214223580|NCT00621062|PROCEDURE|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
214650985|NCT00430144|DRUG|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
214223581|NCT00621062|PROCEDURE|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
214223582|NCT00621062|PROCEDURE|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
214223583|NCT00621062|PROCEDURE|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
214223584|NCT02683603|DRUG|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
214223585|NCT02683603|DRUG|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
214223586|NCT02683603|DRUG|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
214223587|NCT02683603|DRUG|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
214223588|NCT02683603|DRUG|AS colistin and imipenem|IV imipenem 1 g three times per day.
214223589|NCT02683603|DRUG|IV colistin and imipenem|IV imipenem 1 g three times per day
214223590|NCT05688124|DRUG|IBI351|IBI351 is administered orally
214223591|NCT05688124|DRUG|Esomeprazole|Esomeprazole is administered orally
214223592|NCT00621348|DRUG|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
214223593|NCT00621348|DRUG|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
214223594|NCT00621348|DRUG|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
214223595|NCT03671850|BIOLOGICAL|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
214223596|NCT03671850|OTHER|Placebo|Peripheral blood mononuclear cell, PBMC
214223597|NCT06122311|DRUG|N Acetylcysteine|N-acetylcysteine sachets 600 mg twice daily
214223598|NCT01785992|DRUG|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
214223599|NCT05949502|DRUG|Beautifil II LS (Low-Shrinkage)|low shrinkage bioactive material Giomer
214223600|NCT05949502|DRUG|3M Filtek Z250 XT Universal|Universal Nano-hybrid composite
214223601|NCT04170985|OTHER|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
214223602|NCT06278818|BEHAVIORAL|Cognitive Telerehabilitation|Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.
214223603|NCT06278818|OTHER|Control Condition|This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
214223604|NCT05254847|DRUG|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
214223605|NCT04313140|DIAGNOSTIC_TEST|Diagnostic test|"The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~* Cinicial MRI (50 minutes)~* Research MRI (Phosphorus Spectroscopy, Sodium Imaging)"
214223606|NCT04013061|OTHER|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
214223607|NCT02715440|DRUG|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
214223608|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (A&B)|An app-based, evidence-based positive psychology intervention focusing on two modules: (A) Awareness \& Positivity and (B) Meaning and Accomplishment
214223609|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (C&D)|An app-based, evidence-based positive psychology intervention focusing on two modules: (C) Rapport \& Conflict Management and (D) Compassion \& Leadership
214223610|NCT05086614|DRUG|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
214223611|NCT02042716|OTHER|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
214223612|NCT05941871|OTHER|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
214223613|NCT05941871|OTHER|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
214223614|NCT03120351|DRUG|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
214223615|NCT03120351|DRUG|Placebo patch|2\) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
214223616|NCT04668027|DIAGNOSTIC_TEST|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
214223617|NCT04668027|DIAGNOSTIC_TEST|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
214223618|NCT04668027|DIAGNOSTIC_TEST|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
214223619|NCT01438736|DRUG|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
214223620|NCT01438736|DRUG|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
214223621|NCT00617799|BIOLOGICAL|aldesleukin|
214223622|NCT00617799|GENETIC|gene expression analysis|
214223623|NCT00617799|GENETIC|mutation analysis|
214223624|NCT00617799|OTHER|flow cytometry|
214223625|NCT01507064|DRUG|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
214223626|NCT01507064|PROCEDURE|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
214223627|NCT03421769|PROCEDURE|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
214223628|NCT03421769|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
214223629|NCT04765228|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
214650986|NCT04840121|DIAGNOSTIC_TEST|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
214223630|NCT04765228|DRUG|Anlotinib|Anlotinib
214223631|NCT01256190|BIOLOGICAL|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
214223632|NCT01256190|DEVICE|Gelatin sponge|absorbable gelatin sponge for topical use
214223633|NCT06273696|DEVICE|ShangRing|The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
214223634|NCT00576329|DRUG|Ketorolac|Topical use before surgery
214223635|NCT03846518|DEVICE|Hyrax|Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
214223636|NCT03846518|DEVICE|mini Hyrax|Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
214650987|NCT00004373|DRUG|alprazolam|
214650988|NCT04522492|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
214650989|NCT04522492|OTHER|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
214223637|NCT02834793|DRUG|Placebo|Participants will receive matching placebo in Randomization phase.
214223638|NCT02834793|DRUG|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
214223639|NCT05622253|COMBINATION_PRODUCT|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
214223640|NCT03458013|BEHAVIORAL|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
214223641|NCT03811236|OTHER|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
214223642|NCT06173115|DEVICE|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
214223643|NCT01523977|DRUG|Everolimus|Orally, daily days 1-32 per assigned dose level
214223644|NCT01523977|DRUG|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
214223645|NCT01523977|DRUG|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
214223646|NCT01523977|DRUG|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
214223647|NCT01523977|DRUG|Doxorubicin|30 mg/m2 IV on days 4 and 5
214223648|NCT01523977|DRUG|Dexrazoxane|300 mg/m2 IV on days 4 and 5
214223649|NCT03961698|DRUG|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
214223650|NCT03961698|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
214223651|NCT03961698|DRUG|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
214650990|NCT01275014|DRUG|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
214223652|NCT03961698|DRUG|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
214223653|NCT01049009|DRUG|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
214223654|NCT01049009|DRUG|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
214223655|NCT03843671|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy
214223656|NCT03843671|DEVICE|Hyperbaric chamber|Hyperbaric chamber
214223657|NCT05374915|COMBINATION_PRODUCT|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
214223658|NCT02423902|BIOLOGICAL|Ad-RTS-hIL-12|Approximately 1.0x10\^12 viral particles (vp) per injection
214223659|NCT02423902|DRUG|Veledimex|7 oral doses of veledimex
214223660|NCT06783868|DEVICE|Catheter Ablation|Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.
214223661|NCT06783868|DRUG|Market-approved AVNB, OAC and AAD|Used per protocol for the duration of the trial.
214223662|NCT00622440|DRUG|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
214223663|NCT00622440|DRUG|Placebo|Placebo twice daily for 48 weeks.
214650991|NCT01275014|DRUG|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
214650992|NCT00443508|DRUG|adding Certican to therapy|
214650993|NCT00443508|DRUG|reducing Tacrolimus|
214650994|NCT01763164|DRUG|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
214650995|NCT01763164|DRUG|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
214650996|NCT00998439|DEVICE|SeQuent® Please|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
214223664|NCT05475730|PROCEDURE|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
214223665|NCT06157840|DEVICE|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
214223666|NCT06157840|DEVICE|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
214223667|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
214223668|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
214223669|NCT04580667|OTHER|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
214223670|NCT06291727|DRUG|Mepivacaine|Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
214223671|NCT06291727|DRUG|Bupivacaine|Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
214223672|NCT06023667|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
214223673|NCT05052736|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
214223674|NCT05822609|DRUG|Semaglutide|1.0 mg
214223675|NCT05822609|OTHER|Placebo|Placebo
214223676|NCT06564636|DEVICE|CATALYSTEM|CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
214223677|NCT04915950|DRUG|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
214223678|NCT04915950|DRUG|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
214223679|NCT05315414|DEVICE|PrimeTaper EV implant|Tapered dental implant developed by Dentsply Sirona
214223680|NCT06376045|DRUG|Rocatinlimab|Rocatinlimab will be administered by SC injection.
214223681|NCT06376045|DRUG|Placebo|Placebo will be administered by SC injection.
214223682|NCT05770609|DRUG|SPH3127 Tablets with Dose A|See Arm description
214223683|NCT05770609|DRUG|SPH3127 Tablets with Dose B|See Arm description
214223684|NCT05770609|DRUG|SPH3127 Tablets placebo|See Arm description
214223685|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB)|Rhomboid Intercostal Block (RIB) A regional anesthesia technique administered under ultrasound guidance for postoperative pain relief. This will be used as the sole intervention in Arm 1.
214223686|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB) + Serratus Anterior Plane Block (SAPB)|A combination of two regional anesthesia techniques, Rhomboid Intercostal Block (RIB) and Serratus Anterior Plane Block (SAPB),(THE SAPB will received within 24 hours after RIB) administered under ultrasound guidance. SAPB targets the lateral cutaneous branches of the thoracic nerves, complementing the pain relief provided by RIB. This combination is used in Arm 2 to enhance postoperative analgesia.
214223687|NCT04781309|DRUG|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
214223688|NCT01786772|OTHER|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
214223689|NCT01786772|OTHER|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
214223690|NCT00354276|DRUG|cytarabine|
214223691|NCT00354276|DRUG|laromustine|
214223692|NCT05416710|DIAGNOSTIC_TEST|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
214223693|NCT03777891|COMBINATION_PRODUCT|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
214223694|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25ug + spacer|
214223695|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25 ug|
214223696|NCT02829190|DEVICE|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
214223697|NCT04195893|DEVICE|somofilcon A|Contact Lens
214223698|NCT04195893|DEVICE|etafilcon A|Contact Lens
214223699|NCT02873117|OTHER|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
214223700|NCT01999517|DRUG|Intravenous Nitroglycerin|
214223701|NCT01999517|DRUG|IV Fluids|
214223702|NCT04846413|OTHER|Speech task|Speech task which consists of a sustained emission of the vowel /e/.
214223703|NCT06248775|BEHAVIORAL|Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)|During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
214223704|NCT01551511|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
214223705|NCT01551511|DRUG|Placebo|Identical step-up approach to the Namisol arm.
214223706|NCT02739971|BEHAVIORAL|Low AGEs diet|Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
214223707|NCT02739971|BEHAVIORAL|Standard of care dietary guidance for Type 2 diabetes|Oral and written instructions for standard of care dietary guidance for type 2 diabetes
214223708|NCT00880971|RADIATION|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
214223709|NCT03689686|DEVICE|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP"
214223710|NCT00775008|BEHAVIORAL|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
214223711|NCT05526404|OTHER|Dieta mobile application|Mobile application that functions on mobile phones and allows for tracking of symptoms, dietary intake, and stool characteristics using logs and pictures. Users of the application track symptoms by completing questionnaires regarding stool frequency, consistency, and mental status changes. Users can track dietary intake and stool characteristics by taking time-stamped photos of all dietary intake and bowel movements.
214223712|NCT00973869|DIETARY_SUPPLEMENT|curcumin|
214223713|NCT00973869|OTHER|high performance liquid chromatography|
214223714|NCT00973869|OTHER|laboratory biomarker analysis|
214223715|NCT00973869|OTHER|pharmacological study|
214223716|NCT00973869|PROCEDURE|diagnostic endoscopic procedure|
214223717|NCT00973869|PROCEDURE|therapeutic conventional surgery|
214223718|NCT00541801|DEVICE|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
214223719|NCT04241055|BEHAVIORAL|Values affirmation exercise|In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
214223720|NCT04241055|BEHAVIORAL|Active control exercise|In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
214223721|NCT01731418|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, \& Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
214223722|NCT01731418|OTHER|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
214223723|NCT05764707|DRUG|Acetaminophen|Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
214223724|NCT05764707|DRUG|Placebo|Patients will received 1000mg of normal saline within 30 minutes of skin closure.
214223725|NCT05353504|DIETARY_SUPPLEMENT|Inulin|28g/day delivered in 2 sachets throughout the day with main meals
214223726|NCT05353504|BEHAVIORAL|Lifestyle intervention|weekly educational sessions to improve individual's eating behaviour
214223727|NCT05353504|DIETARY_SUPPLEMENT|Placebo|equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
214223728|NCT05658315|OTHER|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
214223729|NCT01694407|DRUG|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
214223730|NCT01694407|DRUG|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
214223731|NCT01694407|DRUG|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
214223732|NCT01694407|DRUG|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
214223733|NCT01802073|DRUG|Oral Vancomycin|
214223734|NCT00003690|DRUG|alvocidib|
214223735|NCT00003690|DRUG|carboplatin|
214223736|NCT00003690|DRUG|cisplatin|
214223737|NCT05571319|DRUG|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
214223738|NCT00616538|DEVICE|Epiceram(r)|Topical barrier repair emulsion cream
214223739|NCT00616538|DRUG|Fluticasone Propionate 0.05%|Topical mid-strength steroid
214223740|NCT05171062|DRUG|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
214223741|NCT05171062|DRUG|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
214223742|NCT00332722|PROCEDURE|Cervical facet joint nerve blocks|
214223743|NCT06007365|DEVICE|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
214223744|NCT01940172|DRUG|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
214223745|NCT01940172|DRUG|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
214223746|NCT03223519|DRUG|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
214223747|NCT03223519|DRUG|Placebo|Powder for oral solution administered TID for 3 days
214223748|NCT03223519|DRUG|Ibuprofen|Powder for oral solution administered TID for 3 days
214223749|NCT03223519|DRUG|Magnesium|Powder for oral solution administered TID for 3 days
214223750|NCT03223519|DRUG|Vitamin C|Powder for oral solution administered TID for 3 days
214223751|NCT03735524|OTHER|Exercise|Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
214223752|NCT00000156|DEVICE|Goggles|
214223753|NCT00000156|PROCEDURE|Ambient Light Reduction|
214223754|NCT03883841|DRUG|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
214223755|NCT04303039|DRUG|ABP-671|ABP-671 Tablet 1.0 mg
214223756|NCT05709938|DRUG|Glargine and regular insulin versus NPH and regular insulin|"Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening."
214223757|NCT01421355|DRUG|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
214223758|NCT01697618|DRUG|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
214223759|NCT01697618|DRUG|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
214223760|NCT01229696|PROCEDURE|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
214223761|NCT01229696|PROCEDURE|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
214223762|NCT01929499|BIOLOGICAL|cytokine-induced killer cells|
214223763|NCT02123472|DRUG|Cephalexin|Administered Orally
214223764|NCT01852396|PROCEDURE|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
214817946|NCT05822479|OTHER|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg IM meperidine was administered in the ward."
214223765|NCT00811096|DRUG|Tinidazole|2gms, p.o. q.d. for 5 days
214223766|NCT00811096|DRUG|chloroquine|
214223767|NCT00918736|DRUG|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
214223768|NCT02049606|DRUG|LAYLA tablet|1 Tablet twice a day
214223769|NCT02049606|DRUG|CENATONE tablet|2 Tablets once a day
214223770|NCT02802267|DRUG|Inecalcitol|vitamin D receptor agonist
214223771|NCT02802267|DRUG|Placebo Oral Tablet|placebo
214223772|NCT03142711|OTHER|No Medical Intervention|Validation of phone ePRO
214223773|NCT04096976|OTHER|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
214223774|NCT02907632|DRUG|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
214223775|NCT02907632|DRUG|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
214223776|NCT02292836|OTHER|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
214817947|NCT02175602|DRUG|Escitalopram|10 milligrams administered each morning
214223777|NCT03463642|DIETARY_SUPPLEMENT|vitamin D3|100,000IU
214223778|NCT03463642|DIETARY_SUPPLEMENT|Pill|Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
214223779|NCT03463642|DIETARY_SUPPLEMENT|orange syrup|100 drops orange syrup
214223780|NCT03463642|OTHER|mineral oil|Paraffinum Liquidum,Isopropyl Palmitate,Parfum
214223781|NCT03463642|DIETARY_SUPPLEMENT|Penetrator|Tangerine essential oil (10ml)
214223782|NCT04279418|DIETARY_SUPPLEMENT|Mixed functional foods supplementation|In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
214223783|NCT04279418|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
214223784|NCT01474018|DRUG|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
214223785|NCT03825861|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
214223786|NCT01137604|DRUG|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
214223787|NCT01137604|DRUG|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
214223788|NCT02149667|DEVICE|total hip arthroplasty implant|
214223789|NCT03138980|BEHAVIORAL|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
214223790|NCT03688256|DEVICE|Obalon Balloon System|6 month Obalon Intragastric Balloons
214223791|NCT06282133|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
214223792|NCT05352633|DRUG|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
214223793|NCT05352633|DRUG|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
214223794|NCT01057641|PROCEDURE|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
214223795|NCT01057641|OTHER|physiotherapy|physiotherapy
214223796|NCT04022395|DIAGNOSTIC_TEST|stress cardiac MRI|pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
214223797|NCT04919980|DEVICE|Innovalve MR system|Innovalve MR system
214223798|NCT05437250|DRUG|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
214650997|NCT00998439|DEVICE|SeQuent® II|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
214817948|NCT02175602|DRUG|Sertraline|50 milligrams administered each morning
214223799|NCT00137072|DRUG|Viagra (Sildenafil Citrate) 100 mg|
214223800|NCT06529081|RADIATION|Palliative Radiotherapy|Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).
214223801|NCT06529081|RADIATION|Radical/Ablative Radiotherapy|Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
214223802|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.
214223803|NCT05247788|BEHAVIORAL|Performance feedback training|This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).
214223804|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training for controls|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
214223805|NCT00923611|DRUG|Fimasartan|
214223806|NCT01297491|DRUG|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
214223807|NCT02462915|DEVICE|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
214223808|NCT02462915|DEVICE|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
214223809|NCT02462915|DRUG|lidocaine, propofol, fentanyl and cisatracurium|
214223810|NCT02864654|PROCEDURE|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
214223811|NCT02864654|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
214223812|NCT02864654|PROCEDURE|Liposuction|
214223813|NCT02511106|DRUG|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
214223814|NCT02511106|DRUG|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
214223815|NCT02511106|DRUG|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
214223816|NCT05178719|DEVICE|PMA-zeolite|given for a total period of 4 years
214223817|NCT02741973|OTHER|Yoga|
214223818|NCT02741973|OTHER|School sport|
214223819|NCT06332417|OTHER|Ba-Duan-Jin Based Deep Breathing Exercises|"Pressing Up to the Heavens: Deep inhales while raising arms, promoting lung expansion.~Drawing the Bow to Shoot the Eagle: Stretching exercises to improve flexibility and posture."
214223820|NCT06332417|OTHER|FET (Forced Expiratory Technique)|The forced expiratory technique sometimes referred to as a 'huff', is used to help force secretions (phlegm) up the throat so it can be removed via the mouth without the pain of coughing.
214223821|NCT03399929|OTHER|Post Acute Rehabiltation|
214223822|NCT01455636|OTHER|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
214223823|NCT01455636|DIETARY_SUPPLEMENT|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
214223824|NCT01455636|OTHER|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
214223825|NCT01455636|DIETARY_SUPPLEMENT|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
214650998|NCT05106530|DIAGNOSTIC_TEST|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
214650999|NCT04928014|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
214651000|NCT02924701|OTHER|Blood samples, fibroscan and questionaires|
214651001|NCT02618369|DEVICE|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
214223826|NCT00947167|DRUG|pertuzumab|840 mg, 420 mg, iv
214223827|NCT00947167|DRUG|erlotinib|150 mg, PO
214223828|NCT00664001|DIETARY_SUPPLEMENT|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
214223829|NCT00664001|DIETARY_SUPPLEMENT|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
214223830|NCT05099263|DEVICE|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
214223831|NCT01838980|DEVICE|Motus GI Clean-Up Device|
214223832|NCT05613062|DRUG|Modified Huang-Lian-Jie-Du Decoction (MHLJDD)|Chinese medicine granules for 12 weeks twice daily
214223833|NCT05613062|DRUG|Placebo|Placebo granules for 12 weeks twice daily
214223834|NCT02895867|OTHER|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
214223835|NCT02895867|OTHER|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
214223836|NCT02895867|OTHER|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
214223837|NCT06424314|DIAGNOSTIC_TEST|Monitoring of respiratory mechanics parameters|Physiologic recording instrumentation measure maximal transdiaphragmatic pressure，twitch diaphragmatic pressure and maximal diaphragmatic electromyography
214223838|NCT00344487|DRUG|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
214223839|NCT03764293|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
214223840|NCT03764293|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
214223841|NCT03764293|DRUG|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
214223842|NCT03094507|DRUG|Tivicay|50 mg once daily
214223843|NCT03094507|DRUG|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
214223844|NCT06638216|OTHER|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
214223845|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
214223846|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
214223847|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
214223848|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
214817949|NCT02175602|DRUG|DCV 3DAA FDC|Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
214223853|NCT05065424|DRUG|IV Atropine and Fentanyl Premedication Arm|"Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
214223854|NCT05065424|DRUG|IV Normal Saline Placebo Arm|"Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
214223855|NCT06795139|BEHAVIORAL|Trial Enrollment Diversity Dashboard Behavioral|A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
214223856|NCT04616677|DRUG|JNJ-42847922|JNJ-42847922 tablet will be administered orally.
214223857|NCT06541210|OTHER|Community Health Service|Access CoLLab Learning Health System to use any of the services
214223858|NCT06541210|OTHER|Questionnaire Administration|Ancillary studies
214223859|NCT03679754|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
214223860|NCT03679754|DRUG|veledimex|"* 20mg/day~* 15 oral daily doses of veledimex"
214223861|NCT04013659|OTHER|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
214223862|NCT04469335|DEVICE|mobile neurofeedback|"to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain\_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well."
214223863|NCT04469335|DEVICE|Sham mobile neurofeedback|"It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study."
214223864|NCT04469335|DEVICE|medication + mobile neurofeedback|The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
214223865|NCT04469335|DEVICE|medication + Sham mobile neurofeedback|The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
214223866|NCT01262820|DRUG|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
214223867|NCT01933685|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
214223868|NCT01933685|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
214223869|NCT02784067|DRUG|Sucraid|Study drug
214223870|NCT02784067|DRUG|Placebo|Sucraid placebo
214223871|NCT04836780|DRUG|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
214223872|NCT01614483|OTHER|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
214223873|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
214223874|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
214651002|NCT00295269|DRUG|Mythylprednisolone|
214651003|NCT01201213|DRUG|local anaesthetic injection|Single bolus of drug for pain relief in early labour
214651004|NCT06199167|BEHAVIORAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
214223875|NCT04500262|DEVICE|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
214223876|NCT04500262|DEVICE|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
214223877|NCT00711477|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
214223878|NCT00711477|DRUG|Placebo|
214223879|NCT00711477|OTHER|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
214223880|NCT05028244|DIAGNOSTIC_TEST|venous ultrasound of lower extremity|Patients are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compression and doppler flow evaluation
214223881|NCT02605265|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
214223882|NCT02605265|DRUG|Capecitabine|
214223883|NCT02605265|DRUG|Irinotecan|
214223884|NCT02605265|DRUG|Oxaliplatin|
214223885|NCT03043105|DRUG|Thalidomide, cyclophosphamide and prednisone|"* Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
214223886|NCT01895621|PROCEDURE|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
214223887|NCT01895621|DIETARY_SUPPLEMENT|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
214223888|NCT03308721|DRUG|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
214223889|NCT03308721|DRUG|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
214223890|NCT02949895|DRUG|BMS-986012|
214223891|NCT02949895|DRUG|Cisplatin|
214223892|NCT02949895|DRUG|Etoposide|
214223893|NCT01640834|DRUG|LY2409021|Administered orally
214223894|NCT01640834|DRUG|Placebo|Administered orally
214223895|NCT01640834|DRUG|Glucagon|Administered via intramuscular injection
214223896|NCT03722277|OTHER|Variable load training|Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
214223897|NCT03722277|OTHER|Conventional strength training|Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
214223898|NCT03060161|BEHAVIORAL|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
214223899|NCT02198118|OTHER|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
214223900|NCT00013156|PROCEDURE|Effectiveness of Lung Reduction Therapy|
214223901|NCT02717806|BEHAVIORAL|PATHway|Patients will use the PATHway platform for 6 months
214223902|NCT01430169|BIOLOGICAL|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
214651005|NCT06199167|BEHAVIORAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
214651006|NCT03458169|DEVICE|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
214651007|NCT03458169|DEVICE|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
214223903|NCT05750771|DEVICE|DES|Second-generation drug-eluting stents
214223904|NCT05750771|DEVICE|DCB|Drug-coated balloon with paclitaxel as drug coating
214223905|NCT01626937|OTHER|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
214223906|NCT01626937|OTHER|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
214223907|NCT01119079|OTHER|Normal Saline|10ml Normal Saline instilled in the epidural space
214223908|NCT01119079|PROCEDURE|Administration of epidural anesthesia for labor|Standard procedure
214223909|NCT01490489|OTHER|blood sample and doppler Ultrasound of uterine arteries|"* 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
214223910|NCT02916537|DRUG|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
214223911|NCT02916537|PROCEDURE|Prostatectomy|Radical prostatectomy with lymph node dissection
214223912|NCT05518747|DIETARY_SUPPLEMENT|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
214223913|NCT05518747|DIETARY_SUPPLEMENT|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
214223914|NCT06120829|PROCEDURE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
214223915|NCT06120829|DEVICE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
214223916|NCT06120829|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy
214223917|NCT03241147|DRUG|Lu AF35700|Single dose, 10 mg film coated tablet
214223918|NCT00637702|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
214223919|NCT03827915|DEVICE|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
214223920|NCT04521049|DRUG|Saxagliptin 5mg|Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
214223921|NCT05933239|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
214223922|NCT00145977|DRUG|Alendronate|alendronate 70 mg once weekly
214223923|NCT00145977|DIETARY_SUPPLEMENT|Calcium Citrate|600 mg of calcium citrate
214223924|NCT00145977|DIETARY_SUPPLEMENT|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
214223925|NCT00849095|DRUG|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
214223926|NCT00849095|DRUG|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
214223927|NCT00849095|DRUG|placebo|bid inhaled placebo
214223928|NCT00849095|DRUG|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
214223929|NCT06205186|BEHAVIORAL|Army Health|A whole health mobile application for Soldiers
214223930|NCT02202083|OTHER|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
214223931|NCT01567839|PROCEDURE|Mandibular buccal Infiltration injection|
214223932|NCT02966054|BEHAVIORAL|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
214223933|NCT00749853|DRUG|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
214223934|NCT00749853|DRUG|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
214223935|NCT04512612|DIAGNOSTIC_TEST|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
214223936|NCT04512612|DIAGNOSTIC_TEST|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
214223937|NCT04215497|OTHER|PSSE|"Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home."
214651008|NCT03458169|DEVICE|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
214651009|NCT00526201|BEHAVIORAL|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
214651010|NCT00526201|BEHAVIORAL|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
214223938|NCT06386016|OTHER|artificial intelligence-based stethoscope|artificial intelligence-based stethoscope
214223939|NCT00275548|DRUG|Pegasys|135-180 micrograms administered sc once weekly
214223940|NCT00275548|DRUG|Copegus|400-1200 mg/day for 48 weeks
214223941|NCT03790033|DRUG|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
214223942|NCT03790033|DRUG|Placebo|placebo granule
214223943|NCT00757471|PROCEDURE|Brillant Blue|Membrane Peeling with Brillant Blue
214223944|NCT00757471|PROCEDURE|Indocyanine Green|Membrane Peeling with indocyanine Green
214223945|NCT02645019|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
214223946|NCT02645019|DEVICE|Cuffed LMA|Cuffed laryngeal mask airway.
214223947|NCT04994002|DRUG|CERC-006|Oral solution
214223948|NCT00705549|DRUG|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
214223949|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
214223950|NCT00705549|DRUG|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
214223951|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
214223952|NCT00705549|DRUG|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
214223953|NCT00705549|DRUG|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
214223954|NCT02816385|PROCEDURE|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
214223955|NCT02816385|PROCEDURE|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
214223956|NCT00782834|DRUG|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
214223957|NCT05879094|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
214223958|NCT05415917|DRUG|Gemcitabine and Capecitabine|"A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."
214223959|NCT02452515|DRUG|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
214223960|NCT02452515|DRUG|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
214223961|NCT02452515|DRUG|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
214223962|NCT02452515|DRUG|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
214223963|NCT02452515|DRUG|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
214223964|NCT03521440|BEHAVIORAL|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
214223965|NCT03521440|BEHAVIORAL|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
214223966|NCT02657785|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
214223967|NCT06327841|OTHER|sesame oil|15min of oil pulling with 15ml sesame oil for 8 weeks
214223968|NCT06327841|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
214223969|NCT04059588|DRUG|2141 V-11|intratumoral injection of 2141-V11
214223970|NCT02055118|BIOLOGICAL|idursulfase-IT|10mg
214223971|NCT02055118|OTHER|No IT treatment|Standard of Care
214223972|NCT05901389|DRUG|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
214223973|NCT05901389|DRUG|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
214223974|NCT04828317|OTHER|Pork Challenge|Double blind oral challenges comparing wild-type and alpha-gal free pork.
214223975|NCT05828056|DEVICE|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
214651011|NCT05383690|DEVICE|LED bright light treatment device|Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
214223976|NCT04239612|BEHAVIORAL|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
214223977|NCT02281383|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|
214223978|NCT01215097|DRUG|Linagliptin|once a day
214223979|NCT01215097|DRUG|placebo|once a day
214223980|NCT05838898|DEVICE|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
214651012|NCT05241158|BEHAVIORAL|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
214651013|NCT05241158|BEHAVIORAL|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
214651014|NCT04727541|DRUG|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
214223981|NCT02570048|DEVICE|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
214223982|NCT03497312|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
214223983|NCT00000426|DRUG|Calcium supplement|
214223984|NCT02758483|OTHER|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
214223985|NCT02758483|OTHER|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
214223986|NCT02633696|DRUG|silybin phosphatidylcholine|
214223987|NCT02633696|DRUG|Legalón SIL|
214223988|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
214223989|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
214651015|NCT04929990|BEHAVIORAL|Respiratory muscle training|Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
214651016|NCT01972321|OTHER|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
214817950|NCT02175602|DRUG|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
214223990|NCT01605630|BEHAVIORAL|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
214223991|NCT01605630|BEHAVIORAL|Control|standard of care
214223992|NCT02709382|DRUG|Cefepime and Tazobactam combination|
214223993|NCT00004005|DRUG|fluorouracil|
214223994|NCT00004005|DRUG|irinotecan hydrochloride|
214223995|NCT00004005|DRUG|leucovorin calcium|
214223996|NCT00004005|PROCEDURE|conventional surgery|
214223997|NCT00004005|RADIATION|radiation therapy|
214223998|NCT00888199|DEVICE|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
214223999|NCT01924416|BEHAVIORAL|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
214224000|NCT01924416|BEHAVIORAL|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
214224001|NCT06210360|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14 day cycle
214224002|NCT06210360|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14 day cycle
214224003|NCT06210360|DRUG|5-FU|2400 mg/m² continuous IV infusion in 46 h
214224004|NCT06210360|DRUG|LV|400 mg/m² on Day 1 of a 14 day cycle
214224005|NCT02515721|DEVICE|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
214224006|NCT02515721|DEVICE|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
214224007|NCT05315895|OTHER|natural aging process|To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.
214224008|NCT00310661|DRUG|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
214651017|NCT01972321|BEHAVIORAL|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
214224009|NCT00310661|OTHER|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
214224010|NCT00515268|DRUG|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
214224011|NCT00515268|DRUG|Placebo|Subjects will receive placebo inhaler.
214224012|NCT00538811|DRUG|interferon alpha-2b, ribavirin, interferon-gamma,|
214224013|NCT00538811|DRUG|interferon alpha-2b, ribavirin, amantadine|
214224014|NCT03323567|DRUG|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
214817951|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
214224015|NCT03323567|DRUG|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
214224016|NCT03323567|DRUG|Saline Solution, Hypertonic|intramuscular Saline injection
214224017|NCT00051662|DRUG|efalizumab|
214224018|NCT01710319|OTHER|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
214224019|NCT03723967|DRUG|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
214224020|NCT03476005|BEHAVIORAL|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
214224021|NCT02106819|BEHAVIORAL|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
214224022|NCT02106819|PROCEDURE|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
214224023|NCT01221311|DEVICE|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
214224024|NCT01221311|DEVICE|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
214224025|NCT05744440|DRUG|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
214224026|NCT00314002|DEVICE|Mechanical Thrombectomy|
214224027|NCT01717924|PROCEDURE|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
214224028|NCT01717924|PROCEDURE|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
214224029|NCT05184829|OTHER|selective lymph node dissection|selective lymph node dissection
214224030|NCT05184829|OTHER|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
214224031|NCT02560025|DRUG|Alisertib|
214224032|NCT02560025|DRUG|Cytarabine|
214224033|NCT02560025|DRUG|Idarubicin|
214224034|NCT02560025|DRUG|Daunorubicin|Can be used in place of idarubicin
214224035|NCT02703337|DRUG|LY900014|Administered subcutaneously (SC)
214224036|NCT02703337|DRUG|Insulin Lispro|Administered SC
214224037|NCT04208607|PROCEDURE|Bronchoscopy|Role of bronchoscopy in diagnosis of bronchiectasis
214224038|NCT05069870|DRUG|SKLB1028|SKLB1028, capsule, oral
214224039|NCT05069870|DRUG|Itraconazole|Itraconazole, capsule, oral
214224040|NCT05069870|DRUG|Gemfibrozil|Gemfibrozil, capsule, oral
214224041|NCT05069870|DRUG|Rifampicin|Rifampicin, capsule, oral
214224042|NCT02897570|DIETARY_SUPPLEMENT|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
214224043|NCT02897570|DIETARY_SUPPLEMENT|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
214224044|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
214224045|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
214224046|NCT02897570|DEVICE|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
214224047|NCT02897570|DEVICE|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
214224048|NCT01859520|PROCEDURE|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
214224049|NCT04371588|OTHER|No Response to Train of Four Stimulation|No response is observed during Train of Four stimulation monitoring during surgery
214224050|NCT04371588|OTHER|1-2 Response to Train of Four Stimulation|1 to 2 response is observed during Train of Four stimulation monitoring during surgery
214224051|NCT02879006|DRUG|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
214224052|NCT02879006|DRUG|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
214224053|NCT02879006|DRUG|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
214224054|NCT02879006|DRUG|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
214224055|NCT04458480|COMBINATION_PRODUCT|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
214224056|NCT00064064|DRUG|gemcitabine hydrochloride|
214224057|NCT00064064|DRUG|triapine|
214224058|NCT01256632|DRUG|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
214224059|NCT03407716|DRUG|American Ginseng|Given PO
214224060|NCT03407716|OTHER|Laboratory Biomarker Analysis|Correlative studies
214224061|NCT03407716|OTHER|Placebo|Given PO
214224062|NCT03407716|OTHER|Questionnaire Administration|Correlative studies
214224063|NCT06032013|OTHER|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information"
214224064|NCT01751945|BEHAVIORAL|EmONC package|"The EmONC package consists of:~1. Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~2. Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~3. Community mobilisation"
214224065|NCT04155242|DIAGNOSTIC_TEST|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
214224066|NCT04155242|DIAGNOSTIC_TEST|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
214651018|NCT01972321|OTHER|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
214224067|NCT04155242|DIAGNOSTIC_TEST|Oesophagogastroduodenoscopy|"* Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
214224068|NCT00282308|DRUG|Rituximab|Rituximab was supplied in single-use vials.
214224069|NCT00282308|DRUG|Methotrexate|
214224070|NCT00282308|DRUG|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
214224071|NCT00282308|BIOLOGICAL|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
214224072|NCT00282308|BIOLOGICAL|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
214224073|NCT00282308|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
214224074|NCT00282308|BIOLOGICAL|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
214224075|NCT00329524|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
214224076|NCT03229694|DRUG|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
214224077|NCT03229694|DRUG|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
214224078|NCT02184052|DRUG|Meloxicam|7.5 mg or 15 mg
214224079|NCT01234935|DRUG|dasatinib|Given orally
214224080|NCT01234935|DRUG|gemcitabine hydrochloride|Given IV
214224081|NCT01234935|OTHER|laboratory biomarker analysis|Correlative studies
214224082|NCT01234935|GENETIC|mutation analysis|Correlative studies
214224083|NCT01234935|GENETIC|nucleic acid sequencing|Correlative studies
214224084|NCT01234935|OTHER|immunohistochemistry staining method|Correlative studies
214224085|NCT04479371|DRUG|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
214224086|NCT04479371|DRUG|Bupivacaine|Standard bupivacaine
214224087|NCT06518434|DRUG|Medical Cannabis|Medical cannabis oil three times daily
214224088|NCT02243462|DEVICE|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
214224089|NCT02243462|OTHER|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
214224090|NCT04965038|DRUG|Tenecteplase (until trial protocol V04: Alteplase)|Intravenous thrombolysis within 4.5 hours of symptom onset
214224091|NCT04239625|DRUG|ALK-001|Oral administration of a pill for up to 24 months
214224092|NCT04665089|DRUG|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
214224093|NCT06577831|DIAGNOSTIC_TEST|dynamic MRI|"* MRI sequences will be performed for patients and healthy volunteers i~* Vaginal and rectal tagging will be performed using a water-based ultrasound gel.~* The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe.~* MRI sequences.~* Data analysis and interpretation."
214224094|NCT04126161|PROCEDURE|CT|standard of care CT prior to primary hip replacement
214224095|NCT04126161|DEVICE|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
214224096|NCT06273202|OTHER|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
214224097|NCT06486168|PROCEDURE|NIVATS|Non-Intubated Video-Assisted Thoracic Surgery (NIVATS) is the least invasive approach available. It is part of an optimal Enhanced Recovery After Surgery (ERAS) pathway and allows for expanding surgical indications in patients with poor cardio-pulmonary function.
214224098|NCT05743946|DRUG|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be for 28 days, and otherwise identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
214224099|NCT06115148|OTHER|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
214224100|NCT06115148|OTHER|Fasting|Water will be consumed as described during the Fasting Arm.
214224101|NCT05073432|OTHER|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
214224102|NCT04063098|OTHER|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
214224103|NCT04286373|DEVICE|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
214224104|NCT04286373|DEVICE|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
214224105|NCT04280029|DEVICE|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
214224106|NCT04280029|DEVICE|Control|POBA or FDA-approved -limus DES
214224107|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
214224108|NCT06157151|BIOLOGICAL|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
214224109|NCT06157151|DRUG|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
214224110|NCT03878615|PROCEDURE|elective surgery, according to deprtement routine|none, descriptive study
214224111|NCT01001325|BIOLOGICAL|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
214224112|NCT01001325|BIOLOGICAL|Normal saline|0.5 mL intramuscular
214224113|NCT05133037|DEVICE|GE MR Scanner|"3T GE MR 750 systems MR scanner~Scanners run compatible software so pulse sequences and reconstructions can easily be supported on all systems. Reconstruction servers are networked to all scanners for reconstruction and data archiving. 3T scanner is equipped with state-of-the-art gradient systems (at least 40 mT/m Gradients / 150 mT/m/ms slew rates) and 16 or more receive channels. 3T scanner includes an assortment of RF coils including quadrature and phased-array coils designed to image brain, spine, neurovascular, torso, pelvis, cardiac, knee, foot/ankle, and hand/wrist. 3T system has several sizes of 16-channel wrap coils that are excellent for scans using parallel imaging."
214224114|NCT05408078|DEVICE|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
214224115|NCT05408078|OTHER|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
214224116|NCT04226196|DEVICE|Implantation of an intraocular lens|Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
214224117|NCT05571332|DRUG|Avatrombopag 20 MG Oral Tablet|p-ATG and CsA in combination with Avatrombopag to treat
214224118|NCT05780983|BEHAVIORAL|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
214224119|NCT03028519|DRUG|Vitamin D3|Vitamin D3
214224120|NCT01584440|DRUG|AVP-923-20|AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
214651019|NCT06218927|OTHER|QoL monitoring|QoL questionnaire
214651020|NCT05878028|COMBINATION_PRODUCT|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
214651021|NCT03557021|DIAGNOSTIC_TEST|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
214651022|NCT03384329|DRUG|Resveratrol Pill|Resveratrol 500 mg
214651023|NCT03384329|DRUG|Placebos|Placebo Pills
214651024|NCT01167608|OTHER|No Intervention. This is a cross-sectional survey study.|No intervention.
214224121|NCT01584440|DRUG|Placebo|Placebo capsule
214224122|NCT01584440|DRUG|AVP-923-30|AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
214224123|NCT06453486|RADIATION|High dose radiation therapy|"High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:~* 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.~* 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.~* 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.~These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist."
214224124|NCT05512000|BEHAVIORAL|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
214224125|NCT05512000|BEHAVIORAL|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
214224126|NCT05512000|BEHAVIORAL|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
214224127|NCT05512000|BEHAVIORAL|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
214224128|NCT05512000|BEHAVIORAL|No teaching control|The words in this set are not taught, only assessed.
214224129|NCT03390283|OTHER|Survey Administration|Complete online survey
214224130|NCT02759367|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
214224131|NCT05770323|DIAGNOSTIC_TEST|Uric acid level|Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
214224132|NCT06022523|DIAGNOSTIC_TEST|Data acquisition using DT-400 pulse oximetry system|Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
214224133|NCT04947982|OTHER|carbon dioxide|carbon dioxide insufflation pressure
214224134|NCT00531427|DRUG|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
214224135|NCT00531427|DRUG|Placebo|transdermal system (placebo) applied for 7-day wear
214651025|NCT04186611|OTHER|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
214651026|NCT00190060|DRUG|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
214651027|NCT00190060|DRUG|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
214224136|NCT00166413|DRUG|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
214651028|NCT06543771|DIAGNOSTIC_TEST|Safety Test ABO and ABTest Card®|Pre transfusional control with the Safety Test ABO device (reference device) and the ABTest Card® device (comparator).
214651029|NCT05740774|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
214651030|NCT03670030|DRUG|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
214651031|NCT03119012|DRUG|Clopidogrel|75mg/day
214651032|NCT03119012|DRUG|Ticagrelor|120mg/day
214651033|NCT03119012|DRUG|Aspirin|100mg/day
214651034|NCT01745757|DRUG|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
214224137|NCT06217016|PROCEDURE|ICCAUT|In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
214224138|NCT06217016|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
214224139|NCT00495898|DEVICE|CYPHER sirolimus-eluting stent|drug-eluting stent
214224140|NCT00495898|DEVICE|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
214224141|NCT03990519|DRUG|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
214224142|NCT03990519|DRUG|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
214651035|NCT01745757|DRUG|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
214651036|NCT06231017|DRUG|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
214651037|NCT06041555|OTHER|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
214651038|NCT02109237|PROCEDURE|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
214224143|NCT02510677|OTHER|myocardial perfusion scintigraphy|
214224144|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
214224145|NCT00773604|DEVICE|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
214224146|NCT06378216|DIAGNOSTIC_TEST|neurocognitive evaluations|clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
214224147|NCT06662383|DRUG|Retatrutide|Administered SC
214224148|NCT06662383|DRUG|Tirzepatide|Administered SC
214224149|NCT06655038|BEHAVIORAL|Advocacy coalition|"* set up a task force composed of school stakeholders (students, teachers, educators, principle,...). These stakeholders will meet 4 times a year to improve the implementation and enforcement of TFSP through rules that are accepted, adopted and to which all school actors adhere.~* share of good practices in implementation with the other schools of the intervention arm through a sharing platform and two annual meetings.~* support to reffer nicotine-dependant students and staff members to smoking cessation programs.~* support in the implementation of TFSP and in getting all school actors on board, by the research team, but also by local health promotion partners."
214224150|NCT06655038|BEHAVIORAL|Feedback|Feedback on the basis of the audit and the surveys
214224151|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education|Participants randomized to receive the Mediterranean Diet Nutrition Education will receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits, which will be created by the PI and Co-I's of the study (who are comprised of Professors who are either Registered Dietitian credentialed or have experience with creating nutrition/physical activity programs), including an explanation of the principles and components of a Mediterranean dietary pattern and its benefits, guidance on recommended intake of various food groups, budget-friendly strategies for incorporation, supporting resources (educational materials and online tools), and techniques for overcoming barriers to following a Mediterranean dietary pattern. Additional educational materials will be provided to participants through computer or web-based sources.
214224152|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education with Baked White Potato|Participants randomized to receive the Mediterranean Diet Nutrition Education with Baked White Potatoes will similarly receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits (same as the Mediterranean Diet Nutrition Education group). They will also receive will 100 g roasted white russet potatoes with the skin and will be asked to consume the regimen as a part of their meals (breakfast, lunch, dinner) or as a snack throughout the day to contribute to a balanced meal plan. The baked white potato regimen will be pre-portioned (in 100g amounts), stored in the freezer and given in freezer-microwave safe containers. The baked white potato regimen is approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat . In order to increase participants' compliance, they will be informed of a variety of ways to consume the baked white potato regimen.
214224153|NCT04516954|BIOLOGICAL|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
214224154|NCT00273793|BEHAVIORAL|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
214224155|NCT03524729|DEVICE|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
214224156|NCT03524729|DEVICE|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
214224157|NCT03524729|DEVICE|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
214224158|NCT02230124|DEVICE|MRE|
214224159|NCT01548833|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
214224160|NCT01548833|DEVICE|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
214224161|NCT01548833|DEVICE|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
214224162|NCT06463158|DEVICE|Family Room Application|The Family Room application is a point of care tool that guides families on contributing to patient participant care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful care giving. Importantly, family caregiver participants receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
214224163|NCT01740453|DRUG|ropivacaine 2 mg/ml|single
214224164|NCT05190744|DRUG|PB|1000mg twice daily (BID). The dose of PB inducing the maximal increase in urine osmolality will be continued for up to four weeks providing that no side effects are observed including clinical and laboratory surveillance.
214224165|NCT06595134|OTHER|Non Interventional|Screening (Day -7 to Day -1) Visit 1 (Day 0) Visit 2 (Month 3 +/- 7 days) Visit 3 (Month 6 +/- 7 days) Visit 4 (Month 12 +/- 7 days) Visit 5 (Month 24 +/- 7 days) Visit 6 (Month 60 +/- 30 days; end of study)
214224166|NCT01955460|BIOLOGICAL|Aldesleukin|Given IV
214224167|NCT01955460|DRUG|Cyclophosphamide|Given IV
214224168|NCT01955460|DRUG|Fludarabine Phosphate|Given IV
214651039|NCT04205435|BIOLOGICAL|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
214651040|NCT02321969|DIETARY_SUPPLEMENT|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
214224169|NCT01955460|OTHER|Laboratory Biomarker Analysis|Correlative studies
214224170|NCT01955460|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
214224171|NCT01955460|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
214224172|NCT06864481|OTHER|Blood samples|one Blood sample (20 ml)
214224173|NCT02626624|DEVICE|Implantation of the CarboClear Pedicle Screw System|
214224174|NCT06704841|BEHAVIORAL|Music in combination with mindfulness|Participants will attend two in-person sessions per week over two consecutive weeks. Each session will be up to one hour in duration. During each session, participants will engage in a 20-minute guided meditation while listening to instrumental music.
214651041|NCT03284190|PROCEDURE|Surgery|Surgery
214224175|NCT06708468|OTHER|Exercise|The intervention includes 12-day personalized exercise program set in a rehabilitation center, followed by a three-month digital intervention and then a second 12-day personalized exercise program in a rehabilitation center.
214224176|NCT06708468|OTHER|Usual Care|Usual care includes appointments at hospitals and in the community health system according to what has been recommended to that individual
214224177|NCT06718972|OTHER|Not applicable- observational study|This is a retrospective and observational study. Not Applicable
214224178|NCT05348278|DRUG|Urea cream|apply 10% urea cream at both hands and feet twice daily
214224179|NCT06888388|PROCEDURE|Nipple Sparing Mastectomy (NSM)|Nipple sparing mastectomy (NSM) is a surgical procedure which removes all macroscopic breast glandular tissue while retaining the skin as well as the nipple areola complex.
214224180|NCT06888388|PROCEDURE|Skin-Sparing Mastectomy (SSM)|Skin sparing mastectomy (SSM) is a procedure that removes the nipple and areola complex along with all visible macroscopic breast glandular tissue.
214224181|NCT06888388|PROCEDURE|Total (Simple) Mastectomy|Total (Simple) Mastectomy is a traditional mastectomy approach that removes the breast glandular tissue with a large overlying area of skin including the nipple and areola complex to allow for flat closure.
214224182|NCT06721936|COMBINATION_PRODUCT|Multimodal pelviperineal physioterapy group|"The multimodal PPT protocol includes:~Pelvic Floor Muscle Training (PFMT): This component includes techniques to raise awareness of the pelvic floor, incorporating both manual and instrumental intravaginal techniques.~Non-Ablative Radiofrequency Therapy (Model: RNG, INDIBA): Applied during all eight sessions, with each session lasting 25 minutes.~Therapeutic Pelvic Health Education: Designed to empower participants with knowledge about their condition and the pelvic-perineal area. This educational intervention aims to enhance understanding, promote self-care, and encourage behaviours that alleviate symptoms associated with GSM"
214224183|NCT06721936|DEVICE|Laser CO2 Therapy group|"The fractional laser application will be delivery with the following probes:~90° Probe for Incontinence: Maximum power of 40W; 360° Probe for Vaginal Atrophy: Maximum power of 40W and Right-Angle Probe for Vulvar Atrophy: Maximum power of 24W."
214224184|NCT02464046|DRUG|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
214224185|NCT02464046|DRUG|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
214224186|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
214224187|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
214224188|NCT01258322|DRUG|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
214224189|NCT02269189|DRUG|BIIL 284 BS, high dose|
214224190|NCT02269189|DRUG|BIIL 284 BS, low dose|
214224191|NCT02269189|DRUG|Placebo|
214224192|NCT04075812|DEVICE|Neuromuscular Stimulator|
214224193|NCT00373568|DRUG|miltefosine: 2.5 mg/kg/day for 42 days|
214224194|NCT02657473|DRUG|tobramycin inhalation solution|
214224195|NCT02657473|DRUG|Saline 0.9% inhalation solution|
214224196|NCT00283634|DRUG|erlotinib and bortezomib|
214224197|NCT05025319|RADIATION|X-ray image|Bedside x-ray at intensive unit.
214224198|NCT00122980|PROCEDURE|Red Cell Transfusions|Red Blood Cell Transfusions
214224199|NCT00122980|PROCEDURE|Iron Chelation|Iron Chelation Therapy
214224200|NCT00122980|DRUG|Hydroxyurea|Hydroxyurea
214651042|NCT02678429|DEVICE|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
214224201|NCT00122980|PROCEDURE|Phlebotomy|Phlebotomy
214224202|NCT01124864|DRUG|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
214224203|NCT01243242|DRUG|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
214224204|NCT00005642|DRUG|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
214224205|NCT00380653|DRUG|sapacitabine|
214224206|NCT05103852|PROCEDURE|Cardiac MRI|vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
214224207|NCT00002069|DRUG|Ditiocarb sodium|
214224208|NCT05295667|DIAGNOSTIC_TEST|Doppler measurement in combination with amniotic fluid volume|Ultrasonographic evaluation
214224209|NCT01156064|DEVICE|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
214224210|NCT01156064|DEVICE|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
214224211|NCT01511120|DRUG|Tetraspan|
214224212|NCT01511120|DRUG|acetated Ringer's solution|
214817952|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
214817953|NCT03410784|DRUG|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
214224213|NCT01037764|PROCEDURE|alloHCT|"\[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
214224214|NCT00973817|BIOLOGICAL|ELAD plus standard of care treatment|Use of ELAD plus standard of care
214224215|NCT00973817|OTHER|Standard of care|Standard of care in the treatment of AOCH will be administered
214224216|NCT05011201|DEVICE|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
214224217|NCT05011201|DEVICE|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
214224218|NCT06317545|OTHER|Mulligan Taping|Mulligan taping involves the application of tape to the lateral aspect of the elbow to offload stress during movement of the extensor tendons.
214224219|NCT00700388|DEVICE|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
214224220|NCT00700388|PROCEDURE|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
214224221|NCT04581707|DEVICE|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
214224222|NCT04581707|DEVICE|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
214224223|NCT03618355|DRUG|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
214224224|NCT03629275|COMBINATION_PRODUCT|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
214224225|NCT03629275|DRUG|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
214224226|NCT03387527|BEHAVIORAL|Prostate cancer decision aid|Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
214224227|NCT04825470|PROCEDURE|Liver Transplantation|Liver Transplantation
214224228|NCT04009564|DIETARY_SUPPLEMENT|Date coffee|45 g of date seeds coffee in 280 ml of water
214224229|NCT04009564|DIETARY_SUPPLEMENT|Normal coffee|6 g of normal coffee in 280ml of water
214224230|NCT04009564|DIETARY_SUPPLEMENT|Placebo|water, food colouring and coffee flavouring
214224231|NCT00749710|PROCEDURE|clopidogrel|ORIF - surgical treatment
214224232|NCT00749710|PROCEDURE|no antiaggregant therapy|ORIF - surgical treatment
214224233|NCT06153004|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
214224234|NCT06153004|DRUG|Antidepressant medication (ADM)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
214224235|NCT03896256|DRUG|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
214224236|NCT03135418|DEVICE|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
214224237|NCT03135418|DEVICE|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
214224238|NCT03553992|BEHAVIORAL|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
214224239|NCT03553992|BEHAVIORAL|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
214224240|NCT00724711|DRUG|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
214224241|NCT00724711|DRUG|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
214224242|NCT06321380|BEHAVIORAL|Complex span task|"The intervention consists in a computerized working memory task. This task follows the design of a complex span task, involving alternation between memorization and processing steps.~For each trial, participants have to memorize French words. These words are sequentially displayed on the screen. Between each word, participants perform a processing task consisting in a spatial location task: They have to determine if a shape is at the top or at the bottom of the screen. After each processing episode, participants have a free time (i.e., available time to maintain information in WM). At the end of each trial, participants perform an orally immediate recall. This experimental task involves several conditions in order to manipulate the opportunities for the spontaneous use of refreshing and elaborative strategies."
214224243|NCT06321380|DIAGNOSTIC_TEST|Clinical neuropsychological assessment|"As part of routine care, participants in the patient group undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions. The investigators hypothesize correlations between working memory performance during the experimental task and the results of neuropsychological tests. Thus, the investigators consider the results to several French versions of neuropsychological tests:~* MMSE (Mini-Mental State Examination)~* Digit Span Backward subtest (WAIS-IV)~* Stroop Test~* Trail Making Test (TMT)~* Rappel Libre - Rappel Indicé à 16 items or GERIA-12~* Category fluences~* Instrumental Activities of Daily Living and ADL ."
214224244|NCT06321380|DIAGNOSTIC_TEST|Clinical neurospychological assessement|"Participants in the control group undergo 2 tests clinical that evaluate cognitive functioning.~The investigators consider the results to French versions of these neuropsychological tests:~* MMSE (Mini-Mental State Examination; )~* Digit Span Backward subtest (WAIS-IV)"
214224245|NCT01945710|DRUG|Eribulin-LF|
214224246|NCT00647569|PROCEDURE|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
214224247|NCT00647569|PROCEDURE|Conventional facial closure|The abdominal facia is closed with with continuous running suture
214224248|NCT00747734|DRUG|MNRP1685A|Escalating intravenous dose
214224249|NCT00375609|DRUG|Betrixaban|Capsule
214224250|NCT00375609|DRUG|Enoxaparin|Administered subcutaneously
214224251|NCT05208840|DRUG|Ocrelizumab|Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
214224252|NCT01368562|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
214224253|NCT05402605|PROCEDURE|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
214224254|NCT05402605|PROCEDURE|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
214224255|NCT00000724|DRUG|Trimetrexate glucuronate|
214224256|NCT00000724|DRUG|Leucovorin calcium|
214224257|NCT03457441|OTHER|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
214224258|NCT03457441|DEVICE|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
214224259|NCT05330715|OTHER|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
214224260|NCT03201081|OTHER|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
214224261|NCT05864092|OTHER|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
214224262|NCT05111301|DEVICE|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
214224263|NCT05154305|BEHAVIORAL|multidisciplinary intervention|"* individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
214817954|NCT03410784|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
214817955|NCT03410784|DRUG|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
214817956|NCT06253403|BEHAVIORAL|psychotherapy|psychotherapy related to sexual intervention
214224264|NCT00985920|DRUG|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
214224265|NCT00985920|DRUG|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
214224266|NCT00940667|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
214224267|NCT00940667|DRUG|Amlodipine|amlodipine 5mg q.d.
214224268|NCT01974739|DRUG|Hydrochloorthiazide|
214224269|NCT01974739|DRUG|placebo|
214224270|NCT03348189|OTHER|Pulse Oximeter|Pulse Oximeter
214224271|NCT05207943|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
214224272|NCT05207943|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
214224273|NCT02216110|PROCEDURE|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
214224274|NCT04685161|PROCEDURE|Surgical extrusion|Invasive treatment option for fractured tooth
214224275|NCT04685161|DEVICE|Fibre post|Easy approach for treatment
214224276|NCT02346773|DIETARY_SUPPLEMENT|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
214224277|NCT02346773|OTHER|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
214224278|NCT05828004|BEHAVIORAL|Whole-Course Multidisciplinary Care Intervention|On the basis of standard treatment, all patients were evaluated by senior practice nurses in the Department of Oncology in person at the time of enrollment (before radiotherapy) and once every week during radiotherapy, and once in person/over the phone at 1, 2, 3, and 6 months after radiotherapy.
214224279|NCT02050542|PROCEDURE|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
214224280|NCT02050542|PROCEDURE|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
214224281|NCT00558688|PROCEDURE|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
214224282|NCT03610100|DRUG|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
214224283|NCT03610100|DRUG|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
214224284|NCT06243523|BEHAVIORAL|The stress management psychoeducation program based on Neuman's Systems Model|The stress management psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care. The first session includes the meeting and introduction of the psychoeducation program. The second session includes the adaptation process to the intensive care unit. The third, fourth and fifth sessions include methods of coping with stress. The sixth session includes evaluation and termination of the psychoeducational program. Quantitative data of the research will be collected with the pre-action and post-action Psychological Distress Scale and the Stress Coping Styles Scale. Qualitative data of the research will be collected through semi-structured individual in-depth interviews conducted after the action.
214224285|NCT02835053|OTHER|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
214224286|NCT04989153|DIAGNOSTIC_TEST|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
214224287|NCT00328302|DRUG|Candesartan|
214224288|NCT00328302|DRUG|Placebo|
214224289|NCT00167297|DRUG|Atomoxetine|
214224290|NCT02935829|OTHER|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214817957|NCT04882150|DRUG|BMS-986196|Specified dose on specified days
214224291|NCT02935829|OTHER|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214224292|NCT02935829|OTHER|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214224293|NCT02935829|OTHER|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214224294|NCT02935829|OTHER|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
214224295|NCT02935829|OTHER|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
214224296|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
214224297|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
214224298|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
214224299|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
214224300|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
214224301|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of Placebo IV
214224302|NCT02226679|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
214224303|NCT05911594|DRUG|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
214224304|NCT05911594|PROCEDURE|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
214224305|NCT05911594|DRUG|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
214651043|NCT06374758|OTHER|The Accelerate model of care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
214651044|NCT06374758|DRUG|bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg|Same as above, it is the same intervetion
214651045|NCT02848196|RADIATION|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
214224306|NCT05911594|COMBINATION_PRODUCT|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
214224307|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
214224308|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
214224309|NCT00738621|DRUG|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
214224310|NCT00738621|DRUG|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
214224311|NCT04978454|BIOLOGICAL|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
214224312|NCT04978454|OTHER|Placebo|Sucrose phosphate glutamate (SPG) inoculum
214224313|NCT05212870|OTHER|assessment of cognitive level, pain catastrophe, physical activity level and quality of life|assessment of cognitive level, pain catastrophe, physical activity level and quality of life
214224314|NCT02812017|BEHAVIORAL|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
214817958|NCT04882150|OTHER|Placebo|Specified dose on specified days
214224315|NCT02812017|OTHER|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
214224316|NCT00358540|DRUG|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
214224317|NCT00130975|DRUG|Candesartan|
214224318|NCT02245425|OTHER|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
214224319|NCT02245425|OTHER|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
214224320|NCT04540016|DRUG|[14C]HSK7653|25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
214224321|NCT03583385|DRUG|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
214224322|NCT03583385|DRUG|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
214224323|NCT00095940|DRUG|lapatinib ditosylate|Given orally
214224324|NCT00095940|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214224325|NCT00095940|OTHER|laboratory biomarker analysis|Correlative studies
214224326|NCT00095940|OTHER|pharmacological study|Correlative studies
214224327|NCT00095940|PROCEDURE|positron emission tomography|Correlative studies
214224328|NCT00095940|PROCEDURE|magnetic resonance imaging|Correlative studies
214224329|NCT02852616|BEHAVIORAL|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
214224330|NCT03029988|DRUG|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
214224331|NCT03029988|PROCEDURE|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
214224332|NCT05189353|OTHER|Ghrelin|Ghrelin infusion
214224333|NCT05189353|OTHER|Placebo|Saline infusion
214224334|NCT01540955|BEHAVIORAL|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
214224335|NCT02586649|DRUG|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
214224336|NCT02586649|DRUG|Placebo|Placebo is a non-active inhalation capsule .
214224337|NCT00001113|DRUG|Interferon alfa-2a|
214224338|NCT00001113|DRUG|Zidovudine|
214224339|NCT00001113|DRUG|Interferon alfa-n1|
214224340|NCT03539549|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
214224341|NCT03303508|DIAGNOSTIC_TEST|anti-ds DNA|venous blood samples
214224342|NCT04602871|DIAGNOSTIC_TEST|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
214224343|NCT05003297|OTHER|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
214224344|NCT02713074|DRUG|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
214224345|NCT02713074|DRUG|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
214224346|NCT02864862|DEVICE|Immediate implant|
214224347|NCT02864862|BIOLOGICAL|SCTG|
214224348|NCT02864862|BIOLOGICAL|ADM|
214224349|NCT02091557|DRUG|GnRH-analogue|
214224350|NCT03841630|DRUG|LY3437943|Administered subcutaneously (SC)
214224351|NCT03841630|DRUG|Placebo|Administered SC
214224352|NCT03702881|DEVICE|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
214224353|NCT03702881|DEVICE|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
214224354|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
214224355|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
214224356|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
214224357|NCT04645719|OTHER|Lactate ringer group|General anesthesia only
214224358|NCT04645719|DRUG|Magnesium sulfate dose through real weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight
214224359|NCT04645719|DRUG|Magnesium sulfate dose through corrected ideal weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
214224360|NCT00783484|DRUG|PF-03716539|PF-03716539 10 mg oral solution, single dose
214224361|NCT00783484|DRUG|PF-03716539|PF-03716539 25 mg oral solution, single dose
214224362|NCT00783484|DRUG|PF-03716539|PF-03716539 3 mg oral solution, single dose
214224363|NCT00783484|OTHER|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
214224364|NCT00783484|DRUG|PF-03716539|PF-03716539 100 mg oral solution, single dose
214224365|NCT00783484|DRUG|PF-03716539|PF-03716539 200 mg oral solution, single dose
214224366|NCT00783484|DRUG|PF-03716539|PF-03716539 50 mg oral solution, single dose
214224367|NCT00783484|OTHER|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
214224368|NCT00783484|DRUG|Midazolam|Midazolam 1 mg IV, single dose
214224369|NCT00783484|DRUG|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
214224370|NCT00783484|DRUG|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
214224371|NCT00783484|DRUG|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
214224372|NCT00783484|DRUG|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
214224373|NCT00783484|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
214224374|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
214224375|NCT00783484|DRUG|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
214224376|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
214224377|NCT00473733|PROCEDURE|GLP receptors expression|
214224378|NCT00473733|PROCEDURE|ESOPHAGOGASTRODUODENOSCOPY|
214224379|NCT03514810|COMBINATION_PRODUCT|Combined Sertraline & Ketoprofen|The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.
214224380|NCT03514810|OTHER|Interleukins in MDD after treatment|Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
214224381|NCT05646017|DEVICE|Intermittenly scanned continuous glucose monitoring|Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
214224382|NCT04294056|DRUG|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
214224383|NCT04294056|DRUG|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
214651046|NCT02788864|DRUG|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
214651047|NCT02788864|DRUG|Placebo|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
214651048|NCT01647607|BEHAVIORAL|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
214224384|NCT02527044|PROCEDURE|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
214224385|NCT03304158|BEHAVIORAL|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
214224386|NCT06110832|BEHAVIORAL|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
214651049|NCT01647607|BEHAVIORAL|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
214651050|NCT00047658|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
214224387|NCT02206971|OTHER|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
214224388|NCT03935568|DRUG|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
214224389|NCT03935568|DRUG|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
214224390|NCT03935568|DRUG|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
214224391|NCT03935568|DRUG|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
214224392|NCT06310720|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
214224393|NCT04323787|OTHER|observational|No Intervention
214224394|NCT04693234|BIOLOGICAL|Tislelizumab|200 mg administered intravenously once every 3 weeks on day 1 of each cycle
214224395|NCT04693234|BIOLOGICAL|Ociperlimab|900 mg administered intravenously once every 3 weeks on day 1 of each cycle
214224396|NCT05283577|OTHER|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
214224397|NCT05283577|OTHER|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
214224398|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
214224399|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
214224400|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
214224401|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
214224402|NCT06958107|OTHER|Non-Metastatic and Resectable|"Blood Draw Timepoints:~* Before any treatment begins~* After Neo-adjuvant therapy (only if you receive this type of therapy)~* After local surgery~* After Adjuvant therapy (only if you receive this type of therapy)~* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
214224403|NCT06958107|OTHER|Metastatic and Un-resectable|"Blood Draw Timepoints:~* Before any treatment begins~* During standard of care disease evaluation visits for up to 24 months"
214224404|NCT06958107|OTHER|No evidence of disease, under surveillance|"Blood Draw Timepoints:~* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
214224405|NCT06958107|OTHER|ALT or WDLS|"Blood Draw Timepoints:~• Collect once after surgery (up to six weeks after surgery)"
214224406|NCT06743282|BEHAVIORAL|Waitlist|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete baseline questionnaires.
214224407|NCT06743282|BEHAVIORAL|Senyo App|Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
214224408|NCT06743282|BEHAVIORAL|Follow-up|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
214224409|NCT06499025|BIOLOGICAL|targeted AML1-ETO neoantigen cytotoxic T cells (CTL)|After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.
214224410|NCT06499025|DRUG|Cyclophosphamide injection|Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion
214224411|NCT06499025|DRUG|Decitabine Injection|Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion
214224412|NCT06499025|DRUG|Liposome mitoxantrone|Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion
214224413|NCT06377254|BEHAVIORAL|Decreased Physical Activity|Physical activity levels will be decreased
214224414|NCT06377254|BEHAVIORAL|Increased Physical activity|Physical activity levels will be increased
214224415|NCT04540198|BEHAVIORAL|GamePlan4Care|GamePlan4Care; Experimental
214224416|NCT04540198|BEHAVIORAL|Resources4Care|R4C; Active Comparator
214224417|NCT04607850|BIOLOGICAL|ChAdOx1-HPV|Trial vaccine
214224418|NCT04607850|BIOLOGICAL|MVA-HPV|Trial vaccine
214224419|NCT04607850|BIOLOGICAL|Placebo|Saline placebo vaccine
214224420|NCT05650632|DRUG|ABBV-383|Intravenous Infusion
214224421|NCT05028309|OTHER|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
214224422|NCT06074549|DEVICE|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
214224423|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
214224424|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
214224425|NCT01620931|DRUG|Placebo|Single doses, iv or sc
214224426|NCT01620931|DRUG|RO5469754|Single ascending doses, iv or sc
214224427|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
214224428|NCT00311129|DRUG|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
214224429|NCT00311129|DRUG|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
214224430|NCT01655004|DRUG|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
214224431|NCT01696604|DRUG|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
214224432|NCT01696604|DRUG|Placebo|Matching placebo capsules will be available.
214224433|NCT02888119|DEVICE|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
214224434|NCT04764331|DEVICE|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
214224435|NCT06182397|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.
214224436|NCT06182397|DEVICE|Placebo balloon angioplasty|For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
214224437|NCT04582253|DIAGNOSTIC_TEST|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
214224438|NCT05573386|DRUG|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
214224439|NCT05573386|DRUG|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
214224440|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
214224441|NCT05491512|DIAGNOSTIC_TEST|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
214224442|NCT05491512|RADIATION|Radiation|Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
214224443|NCT05491512|DRUG|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
214224444|NCT05491512|DRUG|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
214224445|NCT05491512|DRUG|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
214817959|NCT02477787|BIOLOGICAL|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
214224448|NCT05793567|DIAGNOSTIC_TEST|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
214224449|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
214651051|NCT05788939|OTHER|Planned Visual Education Based on Health Belief Model|"The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~."
214651052|NCT00855114|DRUG|everolimus|5 mg/day x 7 days by mouth
214651053|NCT00855114|PROCEDURE|therapeutic conventional surgery|Definitive excision of breast cancer tissue
214651054|NCT01920360|OTHER|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
214651055|NCT01920360|OTHER|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
214224450|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
214224451|NCT06535607|BIOLOGICAL|Volrustomig|IV Infusion
214224452|NCT06535607|DRUG|Cisplatin|IV Infusion
214224453|NCT06535607|DRUG|Carboplatin|IV Infusion
214224454|NCT06535607|DRUG|Paclitaxel|IV Infusion
214224455|NCT03646123|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion
214224456|NCT03646123|DRUG|doxorubicin|25 mg/m\^2 by IV infusion
214224457|NCT03646123|DRUG|vinblastine|6 mg/m\^2 by IV infusion
214224458|NCT03646123|DRUG|dacarbazine|375 mg/m\^2 by IV infusion
214224459|NCT03646123|DRUG|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
214224460|NCT03646123|DRUG|nivolumab|240 mg by IV infusion
214224461|NCT01775072|GENETIC|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, \& others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection \& research biopsies."
214224462|NCT01775072|GENETIC|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk"
214224463|NCT06567769|DRUG|GC1130A|ICV injection
214224464|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
214224465|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
214224466|NCT03133416|OTHER|PRP preparation|
214224467|NCT03133416|DEVICE|Physiotherapy|
214224468|NCT03133416|OTHER|PRP and physiotherapy|
214224469|NCT02209532|DEVICE|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
214224470|NCT02989428|PROCEDURE|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
214224471|NCT04049149|OTHER|Biogenetic explanation and endocrinologist intensive managment|"* JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires"
214224472|NCT04049149|OTHER|Usual care management|"* JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires"
214224473|NCT01034748|DRUG|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
214224474|NCT00001378|DRUG|fenretinide|
214224475|NCT02865707|DIETARY_SUPPLEMENT|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
214224476|NCT02865707|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
214224477|NCT01345357|DRUG|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
214224478|NCT01345357|DRUG|Gemcitabine|Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
214224479|NCT01345357|DRUG|Cisplatin|Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
214224480|NCT04820140|PROCEDURE|Lymphatic drainage|Lymphatic drainage
214224481|NCT01961726|BIOLOGICAL|Placebo|Coronary Sinus Delivery
214224482|NCT01961726|BIOLOGICAL|30 mg dose of JVS-100|Coronary Sinus Delivery
214224483|NCT01961726|BIOLOGICAL|45 mg dose of JVS-100|Coronary Sinus Delivery
214224484|NCT02567604|BEHAVIORAL|Focus Groups|at least three focus groups lasting approximately one hour
214224485|NCT00229515|OTHER|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
214224486|NCT00229515|OTHER|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
214224487|NCT00229515|OTHER|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
214224488|NCT00229515|OTHER|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
214224489|NCT02857348|BEHAVIORAL|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
214224490|NCT02857348|BEHAVIORAL|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
214224491|NCT04036292|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
214224492|NCT04036292|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
214224493|NCT04346355|DRUG|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
214224494|NCT03462511|BEHAVIORAL|HABIT Intervention|Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
214224495|NCT03462511|OTHER|Standard of Care|Standard of care used to treat patients with SCD
214224496|NCT03462511|OTHER|Education materials|Education materials provided to all patients enrolled in the trial
214224497|NCT00042471|DRUG|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
214224498|NCT05506228|OTHER|No intervention|
214224499|NCT02428283|DRUG|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
214224500|NCT02428283|DRUG|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
214224501|NCT02428283|DRUG|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
214224502|NCT03826368|DIETARY_SUPPLEMENT|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
214224503|NCT01702493|DRUG|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
214224504|NCT01702493|DRUG|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
214224505|NCT01702493|DRUG|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
214224506|NCT01702493|DRUG|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
214224507|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
214224508|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
214224509|NCT04705493|OTHER|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
214224510|NCT02925416|DRUG|Oritavancin|Administered intravenously
214224511|NCT02925416|DRUG|Placebo (D5W)|Administered intravenously
214224512|NCT03595228|BIOLOGICAL|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
214224513|NCT01298908|PROCEDURE|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
214224514|NCT01298908|PROCEDURE|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
214224515|NCT01298908|PROCEDURE|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
214224516|NCT02811874|BEHAVIORAL|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
214224517|NCT02811874|BEHAVIORAL|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
214224518|NCT03716154|RADIATION|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
214224519|NCT02711241|DRUG|Dipyrone|1 gram by slow IV infusion
214224520|NCT02711241|DRUG|Papaverine|80 mg by slow intravenous infusion
214224521|NCT02036151|DRUG|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
214224522|NCT02036151|DRUG|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
214224523|NCT06533995|DEVICE|Visuprime|Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
214224524|NCT06533995|OTHER|Placebo|placebo eyedrop isotonic buffered saline solution
214224525|NCT01415414|DRUG|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
214224526|NCT01757990|DIETARY_SUPPLEMENT|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
214224527|NCT00200356|DRUG|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
214224528|NCT00200356|DRUG|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
214224529|NCT05985460|DEVICE|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
214224530|NCT05985460|DEVICE|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
214224531|NCT02900989|BEHAVIORAL|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
214224532|NCT06154577|DIAGNOSTIC_TEST|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
214224533|NCT01022008|DEVICE|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
214224534|NCT03495856|BEHAVIORAL|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
214224535|NCT06119750|DEVICE|NS Solution|This will be administered via skin patch.
214224536|NCT06119750|OTHER|Normal Saline|This will be administered via skin patch.
214224537|NCT06119750|OTHER|SLS|This will be administered via skin patch.
214224538|NCT00770419|OTHER|medical chart review|
214224539|NCT00770419|OTHER|questionnaire administration|
214224540|NCT00770419|PROCEDURE|psychosocial assessment and care|
214224541|NCT02619162|DRUG|Nintedanib|Tablets of 100 mg. or 150 mg.
214224542|NCT02619162|DRUG|Letrozole|Tablet of 2.5 mg.
214224543|NCT01860183|DRUG|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
214224544|NCT04598191|DRUG|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
214224545|NCT04598191|DRUG|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
214224546|NCT00966914|DRUG|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
214224547|NCT00966914|DRUG|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
214224548|NCT01965574|PROCEDURE|Trendelenburg position|
214224549|NCT03219658|BEHAVIORAL|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
214224550|NCT02675556|DRUG|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
214224551|NCT02675556|DRUG|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
214224552|NCT00965965|BEHAVIORAL|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
214224553|NCT00965965|BEHAVIORAL|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
214224554|NCT05395793|OTHER|Support Group|Support Group with moderator
214224555|NCT05456685|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
214224556|NCT05456685|DRUG|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
214224557|NCT03273218|DEVICE|Tiger catheter|
214224558|NCT03273218|DEVICE|Judkins catheter|
214224559|NCT02691871|DRUG|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
214224560|NCT02691871|DRUG|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
214224561|NCT02691871|DRUG|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
214224562|NCT04522700|PROCEDURE|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
214224563|NCT03534479|DRUG|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
214224564|NCT02797002|OTHER|Assessment|
214224565|NCT05187273|BEHAVIORAL|Elastance Group|Fluids are given based on dynamic elastane value
214224566|NCT03998839|OTHER|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
214224567|NCT00830908|DEVICE|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
214224568|NCT00435045|DRUG|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
214224569|NCT00435045|DRUG|atorvastatin|atorvastatin + placebo
214224570|NCT03316495|BEHAVIORAL|PAMPHLET|EXPOSURE TO PAMPHLETS
214224571|NCT05075005|OTHER|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
214224572|NCT05075005|OTHER|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
214224573|NCT04145518|DRUG|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
214224574|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
214224575|NCT02874703|OTHER|Cardiac MRI/MRS|
214224576|NCT06354816|DRUG|Xylocaine 10% pump spray|"First volunteers will undergo insertion of PIVC into the vessel of dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Lidocaine spray 10 % serves as a local anesthesia is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
214651056|NCT01920360|OTHER|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
214651057|NCT05952700|DEVICE|inContAlert|InContAlert is a non-invasive sensor technology to measure the bladder filling level for incontinence patients. The device is fixed about 2cm above the pubic bone using a patch or strap and does not require surgery. The data collected from the patient is analyzed using deep learning algorithms. The bladder filling level determined in this way is then displayed on an app.
214224577|NCT06354816|DRUG|Saline solution isotonic 0.9% NaCl|"First volunteers will undergo insertion of PIVC into the vessel at dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Physiological saline solution serves as a placebo and is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
214224578|NCT01050517|DRUG|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
214224579|NCT01050517|DRUG|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
214224580|NCT00312195|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
214651058|NCT00702078|BEHAVIORAL|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
214651059|NCT00702078|BEHAVIORAL|usual care|follow-up according to todays best practice
214651060|NCT01897480|BIOLOGICAL|LY2875358|Administered IV
214651061|NCT01897480|DRUG|Erlotinib|Administered Orally
214651062|NCT02745561|DRUG|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
214224581|NCT00312195|DRUG|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
214224582|NCT01956721|PROCEDURE|Exercise training,|
214224583|NCT01956721|PROCEDURE|Muscle biopsy|
214224584|NCT03152929|DRUG|Paravertebral Block|20-30 mL 0.5% Ropivacaine
214224585|NCT03152929|DRUG|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
214224586|NCT05044299|DEVICE|Isoped|Isoped is a mechanical device allowing movement of lower extremities in a forward and backward motion, with phone-based app to control resistance load
214224587|NCT03276091|BEHAVIORAL|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
214224588|NCT01015638|DRUG|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
214224589|NCT01015638|DRUG|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
214224590|NCT02578303|OTHER|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
214224591|NCT04741126|OTHER|Manually assisted cough technique|Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
214224592|NCT04734561|OTHER|Inspiratory muscle training group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
214224593|NCT04734561|OTHER|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
214224594|NCT04734561|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
214224595|NCT04734561|OTHER|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
214224596|NCT04477278|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
214224597|NCT04477278|BEHAVIORAL|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
214224598|NCT04296448|DEVICE|Cellscope|Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
214224599|NCT05646849|OTHER|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
214224600|NCT00000176|DRUG|Estrogen|
214224601|NCT00000176|DRUG|Estrogen and Progesterone|
214224602|NCT00662467|DRUG|aspirin + clopidogrel|Dual therapy
214224603|NCT00662467|DRUG|aspirin + clopidogrel + warfarin|Triple therapy
214224604|NCT03739125|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
214224605|NCT03739125|DRUG|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
214224606|NCT01569893|OTHER|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
214224607|NCT06464978|DEVICE|Stapler Reinforcement Patch|Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
214224608|NCT06464978|DEVICE|Standard Stapler|Participants in this group will receive gastrojejunostomy with the use of Standard Stapler
214224609|NCT04752098|DIAGNOSTIC_TEST|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
214224610|NCT04033393|OTHER|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
214224611|NCT04033393|OTHER|Treadmill training|Participants in the control group will receive treadmill training
214224612|NCT02181725|BEHAVIORAL|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
214224613|NCT02181725|BEHAVIORAL|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
214224614|NCT00021801|PROCEDURE|Islet Cell Transplantation|
214224615|NCT05755061|BEHAVIORAL|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
214224616|NCT05755061|BEHAVIORAL|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
214224617|NCT00540410|DRUG|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
214224618|NCT00540410|DRUG|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
214224619|NCT05843669|DRUG|Guafenesin tablets|During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
214224620|NCT06455579|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for community healthcare providers (BTS-HP)|The sleep health education program includes 6 educational modules on different topics related to sleep health: (1) Basics of Sleep, 2) Sleep and Development, 3) Sleep Health, 4) Consequences of Deficient Sleep, 5) Sleep Health Disparities, and 6) Sleep Screening and Evaluation.
214224621|NCT03732781|DRUG|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
214224622|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
214224623|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
214224624|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
214224625|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
214224626|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
214224627|NCT02503657|DRUG|MN-001|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
214224628|NCT02503657|DRUG|Matching Placebo|Excipients of MN-001/tipelukast
214224629|NCT05989893|BEHAVIORAL|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
214224630|NCT01703754|GENETIC|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
214224631|NCT01703754|DRUG|Palifosfamide|Small molecule chemotherapy, IV administration
214224632|NCT03492567|BIOLOGICAL|Blood test|Blood draw (max 15 ml)
214224633|NCT04950816|BEHAVIORAL|tailored MBI (.b)|The session will include brief didactic presentations, videos, and mindfulness practice followed by inquiry. We anticipate that sessions will take place twice a week. Sessions will be held on site at the Covenant House Texas (CHT) shelter in a quiet, designated learning space to ease access to sessions for the participants and to assure access to shelter staff (e.g., social workers and case managers) and services (e.g., food and shelter). CHT has onsite, weekday clinical and mental health care and established protocols for accessing needed resources 24/7. Selection criteria for the interventionist include maintaining a personal mindfulness practice for at least two years, trained in .b, and prior experience working with high-risk youth. The interventionist will receive additional training in Trauma-Informed Care as well as study procedures.
214224634|NCT04950816|BEHAVIORAL|attention control condition|Participants will receive no training in MBI or meditation. Topics covered may include physical activity, nutrition, managing weight, understanding adolescence, personal care, avoiding tobacco, alcohol, and drugs though this will be finalized in YR-1 with the HYWG and advisory panel. The HT program will be led by a positive adult instructor with training in health education or a related field and experience working with YEH.
214224635|NCT00964171|DRUG|Efavirenz 600mg|
214224636|NCT05871450|BEHAVIORAL|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
214224637|NCT02834936|DRUG|pyrotinib|
214224638|NCT05997420|BEHAVIORAL|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
214224639|NCT05997420|BEHAVIORAL|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
214224640|NCT00652106|DRUG|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
214224641|NCT00652106|DRUG|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
214224642|NCT00652106|DRUG|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
214651063|NCT02745561|DRUG|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
214651064|NCT02745561|RADIATION|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
214651065|NCT05623293|DIAGNOSTIC_TEST|eye - Optcial coherence tomography|pre and postoperative
214224643|NCT04600271|DRUG|Crystalloid Solutions|exposure
214224644|NCT04600271|DRUG|Colloid Blood Volume Expanders|exposure
214224645|NCT04600271|OTHER|blood replacement|exposure
214224646|NCT04600271|DRUG|Diuretic|exposure
214224647|NCT04600271|DRUG|noradrenaline|exposure
214224648|NCT04600271|DRUG|Non-Steroidal Anti-Inflammatory Analgesics|exposure
214224649|NCT03016741|BIOLOGICAL|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
214224650|NCT03016741|DRUG|Prednisone|Given by mouth
214224651|NCT03016741|DRUG|Abiraterone Acetate|Given by mouth
214224652|NCT03016741|DRUG|Enzalutamide|Given by mouth
214224653|NCT05518773|OTHER|Observational|Observational
214224654|NCT06336642|BEHAVIORAL|SPOT-ON Early Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
214224655|NCT06336642|BEHAVIORAL|SPOT-ON Delayed Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
214224656|NCT05342441|PROCEDURE|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
214224657|NCT05342441|PROCEDURE|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
214224658|NCT05342441|PROCEDURE|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
214224659|NCT06532383|DRUG|PF-07940369|Bulk powder for extemporaneous preparation for oral solutions.
214224660|NCT06532383|DRUG|Placebo|Bulk powder for extemporaneous preparation for oral solutions
214224661|NCT05021237|RADIATION|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
214224662|NCT05757960|PROCEDURE|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
214224663|NCT05723679|OTHER|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
214224664|NCT05723679|OTHER|Room air gas mixture|Normal room air
214224665|NCT06803004|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
214224666|NCT06803004|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Senior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
214817960|NCT03801980|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
214817961|NCT03801980|DRUG|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
214224667|NCT06803004|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
214224668|NCT06803004|OTHER|AI-assisted junior sonographer measurement of DDH|Participants will receive visual cues from the DeepDDH system.
214224669|NCT04373317|DRUG|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
214224670|NCT04373317|DRUG|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate"
214224671|NCT04760769|DRUG|Tavapadon|Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
214224672|NCT06543355|DEVICE|Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol|The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
214224673|NCT03891446|DRUG|Bimatoprost SR|Intraocular implant
214224674|NCT03891446|OTHER|Standard of Care|Standard of care treatment based on investigator's judgement.
214224675|NCT06395948|DRUG|APG777|APG777 subcutaneous injection
214224676|NCT06395948|DRUG|Placebo|Matching placebo subcutaneous injection
214224677|NCT05487196|DRUG|Clonidine|Clonidine belongs to the drug classification of antihypertensives
214224678|NCT05487196|DRUG|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
214224679|NCT05487196|DRUG|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
214224680|NCT05487196|DRUG|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
214224681|NCT05461170|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214224682|NCT05461170|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
214224683|NCT05461170|DRUG|NRTI|NRTI given orally.
214224684|NCT06279195|DRUG|Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet|All participants will be instructed to take REL-CT.
214224685|NCT04728425|DRUG|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
214224686|NCT04728425|DRUG|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
214224687|NCT00042003|DRUG|decitabine (5-aza-2'deoxycytidine)|
214224688|NCT06292923|DRUG|Foralumab|"Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare."
214224689|NCT06292923|OTHER|Placebo|Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
214224690|NCT00802256|PROCEDURE|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
214224691|NCT05379998|OTHER|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
214224692|NCT05379998|OTHER|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
214224693|NCT06322030|DIETARY_SUPPLEMENT|FOCUS-15 Lifestyle Management Program|15 week weight management program
214224694|NCT06322030|BEHAVIORAL|Exercise Training|15 weeks of progressive exercise training
214224695|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
214224696|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
214224697|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
214224698|NCT03755778|DRUG|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
214224699|NCT03755778|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
214224700|NCT03755778|DRUG|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
214224701|NCT04376866|DRUG|Toripalimab|anti-PD-1 antibody
214224702|NCT02872935|DRUG|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
214224703|NCT02872935|DRUG|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
214224704|NCT03854877|BEHAVIORAL|Health behaviour intervention|The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
214224705|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
214224706|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
214224707|NCT06425692|BEHAVIORAL|Education|Education on basic palliative care via e-learning + webinar to deepen knowledge.
214224708|NCT02792829|DRUG|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
214224709|NCT03173001|DIAGNOSTIC_TEST|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
214224710|NCT00136188|DRUG|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
214224711|NCT02616796|BEHAVIORAL|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
214224712|NCT01518764|DIETARY_SUPPLEMENT|Red Wine Polyphenols 600mg/day|
214224713|NCT01518764|DIETARY_SUPPLEMENT|placebo|
214224714|NCT01500681|PROCEDURE|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
214224715|NCT02361632|DIETARY_SUPPLEMENT|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
214224716|NCT03059680|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
214224717|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
214224718|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
214224719|NCT00276523|BIOLOGICAL|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
214224720|NCT00276523|PROCEDURE|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
214224721|NCT00276523|PROCEDURE|Neoadjuvant therapy|
214224722|NCT03616301|DRUG|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
214224723|NCT03616301|DRUG|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
214224724|NCT01670916|DIETARY_SUPPLEMENT|probiotics|Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
214224725|NCT03714581|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
214224726|NCT05504642|DRUG|Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
214224727|NCT05504642|DRUG|Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
214651066|NCT02602223|DEVICE|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
214817962|NCT06288035|DRUG|Dexamethasone Oral|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
214224728|NCT05504642|PROCEDURE|Maintenance Treatment (Nivolumab/Ipilimumab)|For six months after Chemo-radio-immunotherapy, Nivolumab 3mg/kg every two weeks x12 (week +2, +4, +6, +8, +10, +12, +14, +16, +18, +20, +22, +24 (twelve applications), each application over 30 minutes and Ipilimumab every six weeks x4 (week +6,+12, +18, +24).
214224729|NCT05829044|DEVICE|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
214224730|NCT05829044|DEVICE|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
214224731|NCT02618499|DRUG|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
214224732|NCT04514380|OTHER|Carbohydrate fluid|400 mL carbohydrate fluid
214224733|NCT04514380|OTHER|Non-carbohydrate fluid|0 mL carbohydrate fluid
214224734|NCT02400983|DEVICE|Pacemaker, ICD|
214224735|NCT03834272|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device. Some patients may be imaged with an additional imaging device.
214224736|NCT05262829|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
214224737|NCT04413682|BEHAVIORAL|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
214224738|NCT04413682|BEHAVIORAL|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
214224739|NCT01812278|BEHAVIORAL|ACT|
214224740|NCT01812278|BEHAVIORAL|CBT|
214224741|NCT03966430|PROCEDURE|damage control surgery|"1. Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~2. ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~3. Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
214224742|NCT03966430|PROCEDURE|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~1. The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~2. After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~3. After the operation, re-laparotomy is performed on demand."
214224743|NCT03572127|OTHER|Diet|High protein diet derived from either animal or non-animal sources.
214224744|NCT04270370|DRUG|LY3478045|Administered orally.
214224745|NCT04270370|DRUG|Placebo|Administered orally.
214224746|NCT04270370|DRUG|Atorvastatin|Administered orally.
214224747|NCT00464971|DRUG|estradiol, 25 mcg|
214224748|NCT03382340|DRUG|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
214224749|NCT03218800|COMBINATION_PRODUCT|Ertapenem|"Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
214224750|NCT03464539|DIETARY_SUPPLEMENT|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
214224751|NCT02756429|OTHER|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
214817963|NCT06288035|DRUG|Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
214817964|NCT04306068|OTHER|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
214224755|NCT03622476|DRUG|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
214224756|NCT02714322|BIOLOGICAL|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
214224757|NCT02714322|BIOLOGICAL|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
214224758|NCT04922385|OTHER|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
214224759|NCT00897819|GENETIC|DNA methylation analysis|
214224760|NCT00897819|GENETIC|loss of heterozygosity analysis|
214224761|NCT00897819|GENETIC|microsatellite instability analysis|
214224762|NCT00897819|OTHER|laboratory biomarker analysis|
214224763|NCT02276417|OTHER|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
214224764|NCT02276417|OTHER|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
214224765|NCT02276417|OTHER|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
214224766|NCT02276417|OTHER|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
214224767|NCT02276417|OTHER|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
214224768|NCT02276417|OTHER|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
214224769|NCT02276417|OTHER|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
214224770|NCT02496052|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
214224771|NCT02496052|DEVICE|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
214224772|NCT02496052|DRUG|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
214224773|NCT03009396|DRUG|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
214224774|NCT00351858|DRUG|ertumaxomab|
214224775|NCT00530504|DEVICE|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
214224776|NCT00811486|DRUG|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
214224777|NCT00610480|DRUG|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
214224778|NCT00610480|DRUG|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
214224779|NCT02872285|DRUG|Drug: LYC-30937-EC|
214224780|NCT02872285|DRUG|Placebo|
214224781|NCT02024789|DRUG|Placebo|Orally twice daily, 26 weeks
214224782|NCT02024789|DRUG|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
214224783|NCT02024789|DRUG|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
214224784|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
214224785|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
214224786|NCT05477108|DRUG|Treatment A (BGF MDI HFO with oral activated charcoal)|Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
214224787|NCT05477108|DRUG|Treatment B (BGF MDI HFA with oral activated charcoal)|Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
214224788|NCT05854914|PROCEDURE|Use of hypnosis videos|Hypnosis on smartphone will be used to manage pain for emergent coelioscopy surgery of patients with acute and complicated appendicitis, with generalized peritonitis
214224789|NCT06054659|DEVICE|Real Time Continuous Glucose Monitoring (rt-CGM)|Participants randomized to rt-CGM will have CGM placed before hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will provide CGM devices, but subjects may use their glucometer for FBG testing as needed for CGM calibration.
214224790|NCT06054659|OTHER|Fingerstick blood glucose (FBG) monitoring|Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
214224791|NCT06054659|BEHAVIORAL|Diabetes Education|Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
214224792|NCT02660983|DRUG|Donepezil hydrochloride|
214224793|NCT02660983|DRUG|Donepezil matching placebo|
214224794|NCT02660983|DRUG|Donepezil hydrochloride|
214224795|NCT06077227|DEVICE|virtual reality therapy|6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
214224796|NCT06077227|OTHER|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
214224797|NCT03814304|OTHER|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
214224798|NCT03814304|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
214224799|NCT03759353|DIAGNOSTIC_TEST|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
214651067|NCT02602223|DEVICE|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
214651068|NCT01375764|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214651069|NCT01375764|DRUG|Ezetimibe|Administered orally once a day
214224800|NCT03759353|DRUG|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
214224801|NCT03759353|DRUG|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
214224802|NCT03759353|DIAGNOSTIC_TEST|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
214224803|NCT02358941|BEHAVIORAL|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
214224804|NCT02358941|BEHAVIORAL|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
214224805|NCT02083861|DEVICE|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
214224806|NCT03376295|DRUG|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
214224807|NCT03376295|DRUG|LABA and an ICS (LABA-ICS)|combinational drug
214224808|NCT03665519|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
214224809|NCT03665519|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
214224810|NCT05685251|OTHER|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
214224811|NCT05685251|OTHER|Home Blood Pressure Monitoring|Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
214651070|NCT01375764|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
214224812|NCT04164511|DIETARY_SUPPLEMENT|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
214224813|NCT06505837|DRUG|JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001sc and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001sc and pemetrexed maintenance therapy, and the cumulative treatment of JS001sc did not exceed 35 cycles (Each cycle is 21 days).
214224814|NCT06505837|DRUG|JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001 and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001 and pemetrexed maintenance therapy, and the cumulative treatment of JS001 did not exceed 35 cycles (Each cycle is 21 days).
214224815|NCT01966848|DEVICE|Wich prosthesis is used|
214224816|NCT04408781|PROCEDURE|Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
214224817|NCT00564668|DRUG|biphasic insulin aspart|
214224818|NCT03666715|DRUG|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
214224819|NCT03666715|DRUG|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
214224820|NCT05197062|DRUG|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
214224821|NCT02902601|DRUG|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
214224822|NCT02902601|DRUG|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
214224823|NCT02902601|OTHER|Placebo|Matching placebo to JNJ-54175446
214224824|NCT03809325|DRUG|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
214224825|NCT04303195|DRUG|NG101|Capsules
214224826|NCT04303195|DRUG|Placebo|Capsules
214224827|NCT06230523|DRUG|LY3841136|Administered SC.
214224828|NCT06230523|DRUG|Placebo|Administered SC.
214224829|NCT03155022|DEVICE|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
214224830|NCT03155022|DEVICE|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
214224831|NCT05556902|DEVICE|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
214224832|NCT04772989|DRUG|AB308|Administered intravenously (IV) as specified in the treatment arm
214224833|NCT04772989|DRUG|Zimberelimab|Administered IV as specified in the treatment arm
214224834|NCT06974786|DRUG|Elranatamab|Participants will receive step up dosing of Elranatamab subcutaneously in first cycle of consolidation followed by fixed dosing for 2 additional cycles and for 12 cycles in maintenance. Arm A participants will receive additional 12 cycles of Elranatamab monotherapy if they are MRD negative after Maintenance 1 for a total of 27 cycles. Cycles will be 28 days.
214224835|NCT06974786|DRUG|Daratumumab|Participants will be given 1800 mg of Daratumumab subcutaneously every 4 weeks for up a maximum of 26 cycles.
214224836|NCT06974786|DRUG|Lenalidomide|Participants will receive 10 mg of Lenalidomide daily by mouth for 21 days of each 28-day cycle for up to a maximum of 24 cycles.
214224837|NCT06974786|PROCEDURE|autologous stem cell transplantation|Participants will undergo ASCT as standard treatment following individual site's processes and practices.
214224838|NCT07127445|DIETARY_SUPPLEMENT|OEA supplement|The supplement contains OEA, ginger extract, and lavender essential oil as its active ingredients.
214224839|NCT06855043|DRUG|Calfactant|Participants will receive 3 daily doses of Calfactant (1.5ml/kg) administered intratracheally
214224840|NCT06855043|DRUG|Budesonide|Participants will receive 3 daily doses of Budesonide (0.25mg/kg) administered intratracheally.
214224841|NCT05171049|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
214224842|NCT05171049|DRUG|Apixaban|Apixaban 10 mg followed by 5 mg
214224843|NCT06523400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
214224844|NCT06523400|DRUG|Placebo|Matching Placebo
214224845|NCT06655155|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
214224846|NCT06655155|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
214224847|NCT06167473|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
214224848|NCT04562428|DRUG|Xiang Sha Liu Jun Zi Decoction dry powder|the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
214224849|NCT04562428|DRUG|XSLJZ Placebo|XSLJZ Placebo
214224850|NCT06060548|OTHER|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
214224851|NCT06843343|PROCEDURE|Intertransverse Process Block with 1.5% Lidocaine|For the ITP block, the needle will be advanced further into the intertransverse tissue complex between the T4 and T5 transverse processes, and local anesthetic will be injected just above the superior costotransverse ligament, under ultrasound guidance.
214224852|NCT06843343|PROCEDURE|Erector Spinae Plane Block with 1.5% Lidocaine|The ESP block will be performed by advancing the needle to the transverse process, under ultrasound guidance, with local anesthetic injected between the erector spinae muscle and the transverse process, targeting a caudad-cephalad spread.
214224853|NCT06843343|DRUG|1.5% Lidocaine|local anesthetic to be used in either the ITP and ESP block
214224854|NCT06812650|OTHER|Medical treatment|Patients will continue their routine medical treatment for gastroesophageal reflux disease.
214224855|NCT06812650|OTHER|Exercise|The exercise program will consist of diaphragmatic breathing exercises and progressive muscle relaxation exercises. Diaphragmatic breathing exercises will be performed for 8 weeks, 5 days a week, twice a day, for 15 minutes each time.
214224856|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine (IIV) at baseline|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
214224857|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 3-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
214224858|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine at Month 1|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
214224859|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 6-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
214224860|NCT06593119|BEHAVIORAL|Telemedicine management of Hypertension|TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care
214224861|NCT06593119|BEHAVIORAL|Usual Care|This includes usual clinic based HTN care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.
214224862|NCT04553133|DRUG|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
214224863|NCT04553133|DRUG|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
214224864|NCT04553133|DRUG|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
214224865|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
214224866|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
214224867|NCT04553133|DRUG|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
214224868|NCT04553133|DRUG|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
214224869|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
214224870|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
214224871|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
214224872|NCT01065454|DRUG|Placebo|Placebo three times a day
214224873|NCT06985485|DRUG|Blinatumomab and Inotuzumab Ozogamicin|Subjects who meet the study criteria during screening will receive induction therapy consisting of low-intensity chemotherapy combined with BiTE with or without TKIs. Regimen includes dexamethasone, vindesine, followed by blinatumomab dosed by body weight: pts ≥45 kg receive fixed dosing (9 µg/day days 1-7, 28 µg/day days 8-28), pts \<45 kg receive BSA-adjusted dosing (5 µg/m²/day days 1-7, 15 µg/m²/day days 8-28). Philadelphia chromosome-positive ALL pts receive second-generation TKIs, with subsequent switch to third-generation TKIs upon resistance. If morphologic remission is not achieved after initial therapy, a salvage cycle with InO will be administered. Post-remission consolidation chemotherapy includes high-dose methotrexate followed by sequential immunotherapy: BiTE (per weight-stratified dosing), then after a 2-week break, InO (0.8 mg/m² on day 1), followed by another 2-week break.This sequence is repeated for 4 cycles.
214224874|NCT05306548|PROCEDURE|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
214224875|NCT05306548|DRUG|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
214224876|NCT03391739|BIOLOGICAL|CART-19 cells|CART-19 cells treat
214224877|NCT05612139|DEVICE|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
214224878|NCT06819813|BEHAVIORAL|Feasibility/Efficacy Testing|This digital intervention will include elements of adapted cognitive-behavioral treatment for adolescent binge eating and weight control, with a focus on self-regulation and skills use.
214224879|NCT06988163|BEHAVIORAL|OACareTools+|OACareTools+ is a healthcare provider intervention that combines healthcare provider education, customized patient and clinical resources, and technical support from a national organization to facilitate provider counseling on and referral to as well as patient engagement in Walk With Ease. There are 2 main parts to this intervention: 1) Healthcare provider education: The study team will deliver the provider education and resources (including information about Walk With Ease and the established referral process/smartphrase) in a presentation providers at a weekly clinician meeting and in follow-up emails. 2) Implementation: Providers will use the resources to briefly counsel patients about physical activity and Walk With Ease and use the smartphrase to refer patients to Walk With Ease. Patients will register for and participate in the online Walk With Ease program. Patients and providers can seek assistance from the national organization as needed during these processes.
214224880|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
214224881|NCT06651242|OTHER|Routine care|Routine care
214224882|NCT06986928|OTHER|No intervention will be applied.|No intervention will be applied.
214224883|NCT06986928|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
214224884|NCT04133246|BEHAVIORAL|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
214224885|NCT04133246|BEHAVIORAL|Individual interview|Interview led by the psychologist about the patient's parenthood
214224886|NCT06855771|DRUG|BMS-986504|Specified dose on specified days
214224887|NCT06660277|DEVICE|Super High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is currently approved by Health Canada and available for use across Canada. This filter has larger pores than a high-flux dialyzer that allow for greater removal of potential toxins and wastes in the blood that would regularly be filtered out by healthy kidneys.
214224888|NCT06660277|DEVICE|High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is that is widely used across Canada for hemodialysis treatments.
214224889|NCT01601652|DRUG|Omegaven|1 g/kg/d iv infusion over 24h
214224890|NCT03839537|OTHER|Exposure measurement|"* 2 measurements per subject (in warm season and in cold season)~* Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
214224891|NCT03839537|OTHER|Spirometry test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will inhale and exhale in the device"
214224892|NCT03839537|DIAGNOSTIC_TEST|Exhaled carbon monoxide test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will exhale in the device"
214224893|NCT03839537|DIAGNOSTIC_TEST|Skin allergy test|\- Performed by a physician during the inclusion clinical examination
214224894|NCT03839537|DIAGNOSTIC_TEST|Spirometry test|\- Performed by a physician during the inclusion clinical examination
214224895|NCT03839537|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide Testing|\- Performed by a physician during the inclusion clinical examination
214224896|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
214224897|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
214224898|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
214224899|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
214224900|NCT00758199|DRUG|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
214224901|NCT00758199|DRUG|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
214224902|NCT00758199|DRUG|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
214224903|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
214224904|NCT06606860|DRUG|Placebo|Placebo tablet
214224905|NCT06984679|OTHER|Physical Evaluations in Children with Cystic Fibrosis|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in children and adolescents with cystic fibrosis. The data to be obtained through all these evaluations will be done face to face within 45-60 minutes.
214224906|NCT06984679|OTHER|Physical Evaluations in Healthy Children|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in healthy children and adolescents. The data to be obtained from all these assessments will be made face to face within 45-60 minutes.
214224907|NCT05688670|PROCEDURE|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
214224908|NCT05688670|PROCEDURE|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
214224909|NCT05688670|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
214224910|NCT06594393|DRUG|TCP-25 gel|Topical gel
214224911|NCT06594393|DRUG|Vehicle (placebo)|Placebo gel
214224912|NCT06853912|DRUG|Psilocybin 25 mg|Botanical drug product PEX010(25) contains the drug substance, PYEX, which is primarily composed of psilocybin (delivered in a capsule)
214224913|NCT06853912|DRUG|Maltodextrin (Placebo)|25 mg of Maltodextrin (delivered in a capsule)
214224914|NCT04321707|RADIATION|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
214651071|NCT04070482|OTHER|Tenofovir exposure in utero and during breastfeeding|Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
214651072|NCT04213755|DIAGNOSTIC_TEST|ROTEM|ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
214224915|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
214224916|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
214224921|NCT06991322|DEVICE|A-FLUX Reducer System|The VahatiCor A-FLUX Reducer System is an implantable, self-expanding dense-cell nitinol coronary sinus flow restrictor device pre-loaded into the A-FLUX Delivery Catheter.
214224922|NCT06354660|DRUG|Retatrutide|Administered SC.
214224923|NCT06354660|DRUG|Placebo|Administered SC.
214224924|NCT03159793|BEHAVIORAL|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
214224925|NCT03159793|BEHAVIORAL|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
214224926|NCT06997744|DEVICE|Low-frequency(2HZ) TENS|Participants receive transcutaneous electrical nerve stimulation (TENS) at a frequency of 2Hz. The stimulation is delivered using surface electrodes placed on the affected upper limb. Each session lasts 30 minutes and is conducted three times per week for a total of 8 weeks. Intensity is gradually increased from 1 mA to 3 mA during each session.
214224927|NCT06997744|DEVICE|High-frequency(100HZ) TENS|Participants receive TENS at a frequency of 100Hz using the same electrode placement and schedule as the 2Hz group. Sessions last 30 minutes, three times weekly for 8 weeks, with intensity increasing from 1 mA to 3 mA across the session. This group represents high-frequency stimulation.
214224928|NCT06997744|DEVICE|Placebo TENS|Participants use a TENS device identical in appearance to the active treatment units. The power light is on, but no electrical stimulation is delivered due to internal circuit disconnection. Sessions follow the same schedule and duration as the active groups.
214224929|NCT06996990|OTHER|Physical evaluations in Volleyball Players|This study will evaluate pain, fatigue, muscle strength, balance and quality of life in volleyball players. All these measurements will be completed in two sessions lasting 45-60 minutes.
214224932|NCT06342193|DEVICE|virtual reality group|This group will use virtual reality glasses as distraction during cystoscopy.
214224933|NCT00975897|BIOLOGICAL|bevacizumab|
214224934|NCT00975897|BIOLOGICAL|cetuximab|
214224935|NCT00975897|DRUG|fluorouracil|
214224936|NCT00975897|DRUG|irinotecan hydrochloride|
214224937|NCT00975897|DRUG|leucovorin calcium|
214224938|NCT00975897|DRUG|oxaliplatin|
214224939|NCT00975897|GENETIC|RNA analysis|
214224940|NCT00975897|GENETIC|cytogenetic analysis|
214224941|NCT00975897|GENETIC|fluorescence in situ hybridization|
214224942|NCT00975897|GENETIC|gene expression analysis|
214224943|NCT00975897|GENETIC|mutation analysis|
214224944|NCT00975897|GENETIC|protein expression analysis|
214224945|NCT00975897|OTHER|diagnostic laboratory biomarker analysis|
214224946|NCT00975897|OTHER|immunohistochemistry staining method|
214224947|NCT00975897|OTHER|questionnaire administration|
214224948|NCT00975897|PROCEDURE|cognitive assessment|
214224949|NCT07134361|PROCEDURE|Open Carpal Tunnel Release|All patients included in the cohort will undergo open carpal tunnel release as part of routine clinical care. The study does not assign the surgical procedure as an investigational intervention; however, it will observe clinical and ultrasonographic outcomes before and after surgery to assess prognostic factors.
214224950|NCT05437393|DEVICE|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
214224953|NCT06923436|BEHAVIORAL|Psychological Assessment|Collection of anamnestic and socio-demographic data, test administration repeated 4 months apart to monitor any changes
214224954|NCT06924151|PROCEDURE|surgical aortic valve replacement|SAVR
214224955|NCT06924151|PROCEDURE|Transcatheter aortic valve replacement|TAVR
214224956|NCT04307576|DRUG|Omitted Doxorubicin|Omission of IV Doxorubicin
214224957|NCT04307576|DRUG|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
214224958|NCT04307576|DRUG|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
214224959|NCT04307576|DRUG|Imatinib|p.o. Imatinib
214224960|NCT04307576|DRUG|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
214224961|NCT04307576|DRUG|Blinatumomab|IV Blinatumomab
214224962|NCT06728085|BEHAVIORAL|Baseline Assessment For Mother-Daughter Day HPV Campaign|"Pre-Implementation:~Identify, screen, and enroll mother-daughter dyads in the study to participate in the upcoming Mother-Daughter Day event on HPV vaccination and screening.~Complete baseline surveys with enrolled participants. Distribute reminder cards and send text messages to mother-daughter dyads who agree to participate in the mother-daughter day campaign."
214224963|NCT06728085|BEHAVIORAL|Implement Mother-Daugther Day HPV Campaign|"Tailor and adapt to context: Mother-Daughter Day campaigns will be tailored and adapted to the local contexts within the 18 LGA.~Trained community health workers will implement the tailored Mother-Daughter Campaign by providing education on cervical cancer control and educational materials on HPV vaccination and HPV screening.~Engage mothers and daughters with on-site access to services: This includes offer of onsite vaccinations to girls by study nurse as well as offer of onsite self-collection screening kits to mothers and caregivers in a private area, along with instructions on how to use and return the sample.~Distribute gift bags with HPV vaccination cards, follow-up reminders, and linkage cards for participants with positive test results, as community health workers continue to provide onsite support and assistance."
214224964|NCT06728085|BEHAVIORAL|Post-Implementation Follow-Up|"A follow-up invitation will be sent to participate in a consultative phone call with study health workers to review self-collection results.~Participants with positive HPV test results will be linked to follow-up care and treatment."
214224973|NCT06883045|OTHER|MyChildCMC app (an app designed to facilitate home monitoring of CMC's health status)|MyChildCMC is an app designed to support remote monitoring of CMC crosscutting symptoms to identify signs of CMC's health deterioration early to change their care early to avoid progression and prevent ED/hospital admissions. The app includes the following features: 1) automated reminders, 2) vital sign/symptom monitoring, 3) real-time feedback system, 4) automated and real-time summary reports with longitudinal graphs, 5) automated alerts to a care coordinator, and 6) clinic dashboard connecting patients to clinics and allowing access to patient data to support care coordination.
214224974|NCT01273753|OTHER|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
214224975|NCT03064061|DEVICE|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
214817965|NCT01575457|BEHAVIORAL|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
214817966|NCT03121716|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
214224978|NCT01784822|DEVICE|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
214224979|NCT06033092|DRUG|Tamoxifen 10 mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
214224980|NCT06033092|OTHER|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
214224981|NCT06033092|BEHAVIORAL|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
214224982|NCT03425253|DRUG|BELKYRA®|BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
214224983|NCT03425253|DEVICE|Juvéderm® VOLUMA™ with Lidocaine|Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
214224984|NCT06744920|DRUG|Remibrutinib (Blinded)|Remibrutinib (Blinded) active treatment
214224985|NCT06744920|OTHER|Placebo|Placebo
214224986|NCT06744920|DRUG|Remibrutinib (Open Label)|Remibrutinib (Open Label) active treatment
214224987|NCT03581916|DRUG|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
214224988|NCT07054216|OTHER|Probiotic|Given daily from 14 days of age until 9 months of age
214224989|NCT07054216|DIETARY_SUPPLEMENT|Placebo|Given daily from 14 days of age until 9 months of age
214224990|NCT07051538|DRUG|SHR-1139 Injections|SHR-1139 injections.
214224991|NCT07051538|DRUG|SHR-1139 Injections Placebo|SHR-1139 injections placebo
214224992|NCT07054385|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
214224993|NCT07054385|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
214224994|NCT03103477|OTHER|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
214224995|NCT04948983|OTHER|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
214224996|NCT04948983|OTHER|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
214224997|NCT04020861|DEVICE|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
214224998|NCT04020861|DEVICE|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
214224999|NCT04020861|DEVICE|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
214225000|NCT04020861|DEVICE|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
214225001|NCT06750536|DEVICE|MiniLung petite kit combined with the Xenios console|Veno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) treatment will be performed using the MiniLung petite kit combined with the Xenios console according to their intended use and local standards/requirements.
214225002|NCT06756113|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
214225003|NCT06756113|BEHAVIORAL|Usual Care|All patients in this study received regular nephrology care at National Cheng Kung University Hospital. Nephrologists conducted routine examinations and provided diagnoses based on test results. The patient's condition (e.g., changes in kidney function), treatment plan, prognosis, and risks were explained to both the patient and family members. The treatment plan included medication, monitoring blood pressure, dietary and exercise at home, and consultations with the Health Education Center for kidney care or nutrition advice.
214225004|NCT06763939|OTHER|RT00401-GO0046|Cosmetic care product
214225005|NCT06763939|OTHER|RT00401-GA0677|Placebo cosmetic care product
214225006|NCT07059650|DRUG|DZD8586+R-CHOP|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-CHOP (Rituximab: 375 mg/m2, IV, d1; Cyclophosphamide: 750 mg/m2, IV, d1; Doxorubicin: 50 mg/m2, IV, d1; Vincristine: 1.4 mg/m2, IV, d1; Prednisone: 100 mg, po, d1-5) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
214225007|NCT07059650|DRUG|DZD8586+R-GemOx|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-GemOx (Rituximab: 375 mg/m2, IV, d1; Gemcitabine: 1000 mg/m2, IV, d1; Oxaliplatin: 100 mg/m2, IV, d1) in a 21-day cycle for 8 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
214225008|NCT07059650|DRUG|DZD8586+BR|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with BR (Bendamustine: 90 mg/m2, IV, d1-d2; Rituximab: 375 mg/m2, IV, d1) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
214225009|NCT06757920|PROCEDURE|bronchoscopic argon plasma coagulation|Argon Plasma Cogulation for Debulking Endobronchial Carcinoid Using Fiberoptic Bronchoscopy
214225010|NCT06734065|BEHAVIORAL|ReDS-guided heart failure management program|"Remote dielectric sensing (ReDS) system (Sensible Medical Innovations Ltd., Netanya, Israel) is a novel electromagnetic energy-based technology that accurately quantifies changes in lung fluid concentration non-invasively.~Patients in the intervention group will receive a three-month, ReDS-guided heart failure management program in addition to usual care.~The program, led by nurses, will integrate algorithms for diuretic use, a structured follow-up schedule, and self-care support tailored to pulmonary fluid levels assessed by ReDS."
214225011|NCT05009979|DRUG|F18-FDG|Within approximately 2 weeks of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography/ computed tomography (PET/CT) scan, participants will be scanned with a fludeoxyglucose F 18 (18F-FDG) PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.
214225012|NCT05009979|DEVICE|MRI|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
214225013|NCT05009979|DEVICE|CT|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
214817967|NCT03121716|DRUG|Gemcitabine|gemcitabine
214817968|NCT03121716|DRUG|cis-platinum|cis-platinum
214817969|NCT02137330|DEVICE|Swallowable Obalon® Gastric Balloon|
214225014|NCT05009979|DRUG|F18-DCFPyL|Each subject will receive a single intravenous (IV) dose of piflufolastat F-18 (18F-DCFPyL) by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL positron emission tomography and computed tomography (PET/CT) imaging will consist of the 18F-DCFPyL injection, followed by approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/-10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.
214225015|NCT05009979|PROCEDURE|Tumor biopsy|Principal investigator discretion pre-treatment or during surgical resection.
214817970|NCT01393054|DRUG|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
214225016|NCT06751810|DIETARY_SUPPLEMENT|Food supplement|"The nutritional composition of the food supplement comprises:~sodium butyrate, inactivated Lactobacillus rhamnosus GG Perilla frutescens dry extract quercetin fructo-oligosaccharides Vitamin D3 omega 3 polyunsaturated acids sorbitol sucralose silicon dioxide aroma"
214225017|NCT06751810|OTHER|Placebo|Placebo
214225018|NCT05970978|DRUG|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
214225019|NCT05970978|DRUG|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
214225020|NCT07123025|PROCEDURE|Partial Pulpotomy in Moderate Pulpitis|"Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Moderate Pulpitis.~After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin."
214225021|NCT07123025|PROCEDURE|Partial Pulpotomy in Severe Pulpitis|Description: Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Severe Pulpitis. After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin
214225022|NCT07086261|OTHER|Spaced Retrieval Training|This study adopted a quasi-experimental research design with two groups of pre- and post-tests. The sample was recruited by convenient sampling. The experimental group used the time extraction training program to intervene and perform relevant water drinking training, 40 minutes each time, 3 times a week, for a total of 8 weeks of intervention measures, while the control group used routine care for general water drinking. Both groups collected pre-test data before the time extraction training intervention program activities in the first week, and conducted post-test data tracking and analysis in the 4th and 8th weeks after the intervention activities.
214225023|NCT07084883|DEVICE|No intervention.|No intervention. Evaluate the automated AMD screening software.
214225024|NCT06195631|BEHAVIORAL|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
214225025|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
214225026|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
214225027|NCT05566873|BEHAVIORAL|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
214225028|NCT05566873|BEHAVIORAL|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
214225029|NCT07136051|PROCEDURE|Ethcing|Etching: After polishing all teeth included in the study with a polishing brush, Vococid (Voca, Germany) etching gel will be applied to the surface and left for 15 seconds, then rinsed and dried.
214225030|NCT07136051|PROCEDURE|Deproteinization|The teeth randomly assigned to Group B will receive 5.25% NaOCl applied with a sterile cotton pellet for 60 seconds after acid etching, followed by rinsing and drying.
214225031|NCT07136051|PROCEDURE|Bonding|The teeth randomly assigned to Group C will receive Futurabond® M+ (Voco, Germany) applied with a brush following acid etching. After gently drying with air for 5 seconds, the bonding step will be completed by light-curing for 10 seconds.
214817971|NCT02247752|OTHER|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
214817972|NCT00803153|PROCEDURE|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
214817973|NCT04608149|DEVICE|Carpediem System|Continuous renal replacement therapy
214817974|NCT03623230|PROCEDURE|Ultrasound Guided Femoral Nerve Block|Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
214225032|NCT07136051|PROCEDURE|Application of resin-based fissure sealant|After completing the pretreatment steps for all groups, Grandio Seal (Voco GmbH, Germany) will be applied to the pits and fissures on the tooth surface and light-cured for 20 seconds. The procedure will be completed after checking the surface.
214225033|NCT06939647|DRUG|Treprostinil Palmitil|Treprostinil Palmitil Inhalation Powder
214225034|NCT07145814|DRUG|dexmedetomidine 0.3 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h, respectively, until 30 minutes before the end of the operation.
214225035|NCT07145814|DRUG|dexmedetomidine 0.5 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) high dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.5 µg/kg/h, respectively, until 30 minutes before the end of the operation.
214225036|NCT07145814|DRUG|0.9 % saline|Placebo group received an equivalent volume of 0.9% saline.
214225037|NCT07146633|BEHAVIORAL|A-EMDR|Participants in the treatment group will receive Autonomous Eye movement desensitization and reprocessing (A-EMDR) therapy delivered through an app on their device. Participants will be asked to complete 3 sessions per week for 4 consecutive weeks. During the treatment period, participants will also attend clinical sessions which will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol.
214225038|NCT07146633|OTHER|Treatment as Usual (TAU)|Participants are advised to continue seeking mental health care as usual and will be added to a waitlist for A-EMDR. They will also attend two clinical sessions. Sessions may last 15 to 60 minutes and will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol. Participants will continue to receive any usual healthcare services as per local standard of care. TAU and other medical appointments will be checked for attendance throughout the study period.
214225039|NCT07145346|DRUG|Suzetrigine (SUZ)|The intervention arm will receive oral suzetrigine (100 mg loading dose followed by 50 mg every 12 hours).
214225040|NCT07145346|DRUG|Placebo|The control arm will receive placebo capsules matched to suzetrigine for oral administration.
214225041|NCT07146009|PROCEDURE|Nerve Surgery|Patients undergoing prophylactic nerve surgery (RPNI) during second-stage implant exchange after tissue expander based breast reconstruction.
214225042|NCT07146009|OTHER|Standard of Care (Investigator Choice)|Patients receiving standard medical therapies for PMPS prevention (e.g., pharmacologic pain management, physical therapy).
214225043|NCT07145216|OTHER|Interfrential stimulation|The participant will be positioned in semi-Fowler's position. Interferential therapy was given using the quadripolar method. Two electrodes were placed on the lower abdomen just above the outer half of the inguinal ligament, and another two on the inner aspect of the thigh near the origin of the adductor muscle. At the first treatment session, every participant will be examined for pelvic floor contraction by the finger palpation method using sterilized gloves to ensure the correct position of the electrodes. It will be set with intensity up to the tolerable limit of subjects, carrier frequency of 2000Hz, vector 900, rhythmic sweep frequency of 10-100Hz, and duration 20 minutes. Interferential therapy will be applied for the treatment procedure of all women in both groups for 20 minutes, 3days per week for 8 weeks.
214225044|NCT07145216|OTHER|Knack pelvic floor training|"The knack technique (Fitz et al., 2021):~* The patient will be instructed to lie in supine lying position with flexed knees.~* Ask the patient to contract the pelvic floor muscles for 2-4 seconds and relax for 4 seconds for 15 repetitions with 3 sets before and during coughing or sneezing .~* Contract the PFM before and during all daily activities involving effort, before and during coughing, sneezing, laughing, walking up and down stairs, jumping, running, bending, lifting a weight from the floor, holding a child, pushing furniture to prevent urine leakage.~* Contract PFM and hold for 2-4 seconds, relax 4 seconds, with 3 sets of 15 repetitions."
214225045|NCT07146685|DRUG|Bupivacaine|We are comparing two concentrations of the same drug: 10 ml of 0.5% and 20 ml of 0.25%; We will use the same milligram dose (50 mg).
214225046|NCT07145060|DRUG|Yiqi Yangyin Formula|Yiqi Yangyin Formula,consists of seven Chinese herbal medicines（Table 1）: Rehmanniae Radix (Sheng Di Huang), Lilium brownii (Bai He), Adenophorae Radix (Nan Sha Shen), Fructus Hordei Germinatus (Sheng Mai Ya), Artemisia annua (Qing Hao), Cimicifuga foetida (Sheng Ma) , and Bupleurum chinense(Chai Hu)
214225047|NCT07145060|DRUG|Yiqi Yangyin Formula placebo|Yiqi Yangyin Formula placebo,has the same appearance, state, and taste as YQYYF, but contains 5% of the ingredients of Yiqi Yangyin Formula
214225048|NCT07145879|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL) and 0.012 mg epinephrine base. Excipients: Sodium metabisulfite, sodium chloride, water for injection.
214225049|NCT07145879|DRUG|Articaine 4% with epinephrine 1:100,000|Patients were received Infiltrative anesthesia with Articaine (Ultracain DS Forte, Sanofi Aventis İlaçları, Istanbul, Türkiye): Active ingredient: 40 mg articaine HCL and 0.012 mg epinephrine per 1 ml. Excipients: Sodium chloride, sodium metabisulfite, hydrochloric acid, water for injection
214225050|NCT07145879|PROCEDURE|Free gingival graft (FGG)|FGG surgery was performed around natural teeth and implants where keratinized gingival tissue was inadequate.
214651073|NCT05286606|BEHAVIORAL|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
214651074|NCT03436784|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
214225051|NCT07146412|BEHAVIORAL|Multimodal Lifestyle Intervention|The intervention supports adoption and maintenance of healthy behaviors including healthy nutrition The Mediterranean-DASH (Dietary Approaches to Stop Hypertension) Intervention for Neurodegenerative Delay, or MIND Diet), physical activity (150 min/week of moderate activity), stress management, weight management, and adherence to doctor-prescribed medical regimens. In addition, participants will be encouraged to participate regularly in social and learning activities, and to engage in cognitive training via Posit's BrainHQ web-based training tools (brainhq.com). Participants will be supported by telephone-based health coaching. Coaches will be currently licensed allied health providers such as Registered Dietitians. Using the combination of an individual's biological data (including genomics, blood, stool, saliva, etc.), activity data, behavioral data, and other incoming streams of health information, the coach will tailor the lifestyle intervention for each participant.
214225052|NCT07144891|GENETIC|Sperm DNA fragmentation|Estimation of sperm DFI level with sperm chromatin dispersion
214225053|NCT07145294|BIOLOGICAL|iEV|Intranasal administration of iEV, twice a week, 2 ml each time (at a concentration of 2×10¹⁰/ml), for 12 consecutive weeks.
214225054|NCT07145294|OTHER|Basic treatments|Basic treatments for cerebrovascular diseases such as antiplatelet aggregation, blood pressure control, blood glucose control, blood lipid control, and plaque stabilization.
214225055|NCT07146152|DEVICE|Patient Decision Aid|A Patient Decision Aid designed to help patients with CIN2 make informed decisions about wether they prefer operation (Loop Electrical Surgery) or active surveillance.
214225056|NCT07144917|DIAGNOSTIC_TEST|mHLA-DR analysis|"mHLA-DR analysis will be realized on Cyto-Chex® BCT anticoagulant tubes (5mL). Each sample will be transported and centralized at the Immunology Laboratory of Edouard Herriot Hospital and analyzed by flow cytometry.~Samples will be collected :~* The day of surgery before intervention~* The day of surgery after intervention~* At postoperative day one~* At postoperative day two~* At postoperative day three~* At postoperative day four~* At postoperative day five~* At postoperative day seven"
214225057|NCT07146217|DRUG|Likmez® (metronidazole) Oral Suspension|Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL
214225058|NCT07146386|DRUG|H077 sustained-release tablet|Subjects are administered one H077 sustained-release tablet (8 mg) orally once daily, along with one silodosin capsule (placebo) orally twice daily.
214225059|NCT07146386|DRUG|Silodosin capsules Control Group|Subjects are administered one Silodosin capsule (4 mg) twice daily, along with one H077 sustained-release tablet placebo once daily, orally.
214225060|NCT07146815|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
214225061|NCT07146815|DIAGNOSTIC_TEST|MRI PDFF|Performance of an MRI-PDFF to determine amount of liver steatosis.
214225062|NCT07145385|OTHER|multiplex digital PCR|multiplex digital PCR
214225063|NCT07146672|BIOLOGICAL|Super DC Vaccine|Super DC Cell Injection
214225064|NCT07145723|OTHER|Earkick app|"Participants will have a baseline visit followed by an 8-week home monitoring period (HMP) using the Earkick app.~The Earkick app will interact with a mental health chatbot. Participants will complete online surveys at the midpoint (4 weeks) and end (8 weeks) of the HMP. Participants will choose one mental health-related topic to focus on from weeks 1-4 and one physical health-related topic to focus on from weeks 5-8.~Additionally, participants will have a post-HMP interview over Zoom."
214225065|NCT07147140|DEVICE|dorsal root ganglion stimulation cessation|Treatment of DRGS will be stopped at home and physiological parameters will be monitored with bio wearables at home. physiological parameters will be monitored during a baseline period, before stopping DRGS. While DRGS is stopped. And during the period while the DRGS is turned back on.
214225066|NCT07146126|DRUG|PG-011 nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
214225067|NCT07146126|DRUG|Placebo|2 sprays in each nostril, twice daily for 14-day treatment period.
214225068|NCT07145424|OTHER|kinesio taping group|The original Kinesio Tape (Kinesio Tex Classic Tape) was used for taping by a physiotherapist with 15 years of experience in the field. The tape was cut into an I-shape and applied to the lower abdominal and lumbo-sacral regions where the participants experienced pain, 10 days prior to the anticipated start of menstruation (Figure 2). The tapes were renewed after four days. This procedure was performed three times and the total taping period was completed as 12 days. The tapes were removed on the third day of menstruation and all outcome measurements were performed again for the post intervention measurements
214225069|NCT07146321|DIETARY_SUPPLEMENT|multi-vitamin, multi-nutrient|A multi-vitamin, multi-nutrient combination of approved and/or GRAS ingredients
214225070|NCT07146321|DIETARY_SUPPLEMENT|Placebo|placebo
214651075|NCT03595280|BEHAVIORAL|Hookah tobacco risk messages|Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
214651076|NCT01238692|DRUG|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
214651077|NCT01238692|DRUG|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
214651078|NCT03417050|OTHER|No intervention will take place for this retrospective and observational study.|No intervention will take place for this retrospective and observational study.
214651079|NCT05042739|DIAGNOSTIC_TEST|CAARMS;SIPS; BSABS;|Comprehensive Assessment of At Risk Mental State (CAARMS); Structured Interview for Psychosis-Risk Syndrome (SIPS); Bonn Scale for the Assessment of Basic Symptoms (BSABS);
214651080|NCT01739751|DEVICE|pedometers|portable device that estimate the number of steps walked daily
214651081|NCT03246633|OTHER|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
214651082|NCT01501279|PROCEDURE|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
214225073|NCT07146360|BIOLOGICAL|Revelise (GENERIUM, Russia)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
214225074|NCT07146360|BIOLOGICAL|Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
214225075|NCT07145489|DEVICE|photobiomodulation|a hat with infrared lights will be worn for 30 minutes daily for 6 months
214225076|NCT07146048|DRUG|Secondary Prophylaxis|Continue standard of care with continued secondary antibiotic prophylaxis
214225077|NCT07145840|OTHER|Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)|Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum
214225078|NCT06946004|DEVICE|Normobaric oxygen therapy|Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for finalization and the decompression period.
214225079|NCT06946004|DEVICE|Normobaric oxygen therapy|Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide placebo intervention as the study comparator) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere).
214225080|NCT06947265|DRUG|L-Arginine|get 3 gm oral tablets of L-arginine
214225081|NCT06947265|DRUG|Tadalafil 5 mg|get 5 mg oral tadalafil for 8 weeks
214225082|NCT07146399|PROCEDURE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
214225083|NCT07146399|PROCEDURE|Sham (No Treatment)|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
214651083|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation in Whole Course of Treatment with ATDs|Moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken from ATDs treatment starting until 1 year after ATDs withdrawal.
214651084|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation During Maintenance Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded at the early course of ATDs treatment, and moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken when the ATDs dose is titrated down to a maintenance level until 1 year after ATDs withdrawal.
214651085|NCT06540469|DIETARY_SUPPLEMENT|Iodine Restriction in Whole Course of Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded from ATDs treatment starting until 1 year after ATDs withdrawal.
214651086|NCT06540469|DRUG|anti-Thyroid Drugs|Individualized methimazole (MMI)
214651087|NCT02658812|OTHER|Laboratory Biomarker Analysis|Correlative studies
214225084|NCT01039662|DIETARY_SUPPLEMENT|L-arabinose and indigestible dextrin|
214225085|NCT01039662|DIETARY_SUPPLEMENT|Placebo|
214225086|NCT04606329|DRUG|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
214225087|NCT04606329|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
214225088|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
214225089|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
214225090|NCT03093662|DEVICE|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
214651088|NCT02658812|BIOLOGICAL|Talimogene Laherparepvec|Given IT
214651089|NCT06095739|COMBINATION_PRODUCT|DA-OTC-002|"The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject"
214651090|NCT04506983|BIOLOGICAL|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.
214817975|NCT03623230|OTHER|Dressing|Only dressing will be applied to related area to protect blindness between groups
214817976|NCT03623230|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
214817977|NCT03623230|DRUG|Bupivacaine 0.125% Injectable Solution|Perineural Injection
214225091|NCT03093662|DEVICE|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
214225092|NCT02728492|DRUG|Quisinostat|
214225093|NCT02728492|DRUG|Paclitaxel|
214225094|NCT02728492|DRUG|Carboplatin|
214225095|NCT02728492|DRUG|Gemcitabine|
214225096|NCT02728492|DRUG|Cisplatin|
214225097|NCT04012164|BIOLOGICAL|blood sampling|5ml blood sampling
214225098|NCT04012164|BIOLOGICAL|stool collection|self stool collection (2g)
214225099|NCT04012164|OTHER|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
214225100|NCT04012164|OTHER|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
214225101|NCT02664948|PROCEDURE|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
214225102|NCT01934270|OTHER|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
214225103|NCT04122352|OTHER|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
214225104|NCT04122352|OTHER|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
214225105|NCT03329014|DRUG|Remimazolam|For induction and maintenance of sedation
214225106|NCT03329014|DRUG|Placebo|Control arm
214225107|NCT01048632|DRUG|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
214225108|NCT00036842|DRUG|arsenic trioxide|
214225109|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
214225110|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
214225111|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
214225112|NCT03844945|OTHER|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
214651091|NCT06335056|BEHAVIORAL|ProudMe|"ProudMe Tech: Regular human/computer interaction (3-5 times per week) to engage in SMART goal-setting, behavior monitoring, and self-reflection as assisted by AI-enabled feedback.~ProudMe Physical Education \[PE\]: 12 lessons to acquire knowledge, skill, and dispositions to improve physical activity, diet, screen-based sedentary behaviors.~ProudMe Cafeteria: Purposely enabling policy and environmental changes in school cafeteria (recognize areas of strengths and weaknesses; set goals and action plans; make changes to improve scores assessed by the Smarter Lunchroom Scorecard).~ProudMe Training: 4-hour implementation training + regular check-in and support (via motivational interviewing techniques)"
214651092|NCT06335056|BEHAVIORAL|Waitlist Control|The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the overall importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
214225113|NCT05636449|OTHER|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
214225114|NCT05636449|OTHER|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
214225115|NCT00632606|DRUG|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
214225116|NCT00632606|DRUG|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
214225117|NCT02871752|BEHAVIORAL|Health promotion|mindfulness-based stress reduction
214225118|NCT05654077|BIOLOGICAL|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。
214225119|NCT05654077|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
214225120|NCT05654077|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
214225121|NCT01947413|OTHER|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
214225122|NCT01947413|OTHER|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
214225123|NCT01947413|OTHER|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
214225124|NCT03159260|DEVICE|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
214817978|NCT03359356|DRUG|Dupilumab|A total of 24 doses
214817979|NCT03359356|DRUG|Placebo|A total of 24 doses
214225125|NCT03159260|OTHER|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
214225126|NCT03314571|OTHER|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
214225127|NCT03963271|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
214225128|NCT05194423|DEVICE|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
214225129|NCT02878187|DEVICE|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
214225130|NCT06166121|OTHER|ShenJu|One package per time, twice a day, 90 days of treatment
214225131|NCT06166121|OTHER|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
214225132|NCT01043939|OTHER|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
214225133|NCT01043939|OTHER|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
214225134|NCT01121809|DRUG|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
214225135|NCT01121809|DRUG|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
214225136|NCT00543959|DRUG|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
214225137|NCT00543959|DRUG|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
214225138|NCT00543959|DRUG|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
214225139|NCT01077921|DRUG|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
214225140|NCT01077921|DRUG|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
214225141|NCT05667077|DRUG|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
214225142|NCT04183361|DIAGNOSTIC_TEST|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2\. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
214225143|NCT05235490|OTHER|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~* Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading of tumor sample slides by pathologists~* Patients follow-up (imaging, clinical)~* Recurrence-free survival"
214225144|NCT04129151|DRUG|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
214225145|NCT04129151|DRUG|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
214225146|NCT00693082|DIETARY_SUPPLEMENT|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
214225147|NCT01437475|BIOLOGICAL|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
214651093|NCT03601286|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
214651094|NCT01512264|DEVICE|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
214651095|NCT04433507|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
214651096|NCT04433507|PROCEDURE|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
214225148|NCT02051933|DRUG|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
214225149|NCT02051933|DRUG|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
214225150|NCT05249478|PROCEDURE|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
214225151|NCT00147368|DRUG|intravenous (IV) arginine|
214225152|NCT05917431|COMBINATION_PRODUCT|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
214225153|NCT00748852|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
214225154|NCT01449942|BIOLOGICAL|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
214225155|NCT01449942|OTHER|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
214225156|NCT05019118|OTHER|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
214225157|NCT05019118|OTHER|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
214225158|NCT05019118|OTHER|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
214225159|NCT05019118|OTHER|Placebo milk|Conventional milk
214225160|NCT05019118|OTHER|Placebo yogur|Conventional yogur
214225161|NCT05019118|OTHER|Placebo fresh cheese|Conventional fresh cheese
214225162|NCT02509234|DRUG|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
214225163|NCT01779817|BEHAVIORAL|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
214225164|NCT04503187|BEHAVIORAL|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
214225165|NCT00974584|DRUG|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
214225166|NCT00974584|DRUG|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
214225167|NCT00974584|DRUG|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
214225168|NCT00974584|DRUG|cisplatin|Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
214225169|NCT00974584|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
214651097|NCT02758158|DEVICE|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
214225170|NCT00974584|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
214225171|NCT00407381|DRUG|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
214225172|NCT00407381|PROCEDURE|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
214225173|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
214225174|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
214225175|NCT02730195|DRUG|Pioglitazone|Given PO
214225176|NCT02730195|DRUG|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
214225177|NCT02265159|PROCEDURE|Focal Therapy Using High Intensity Focused Ultrasound|
214225178|NCT00906737|DEVICE|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
214225179|NCT00906737|OTHER|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
214225180|NCT01539044|DRUG|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
214225181|NCT01539044|DRUG|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
214225182|NCT06227598|OTHER|Procedure: Additional biopsies collection|Procedure: Additional biopsies collection We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
214225183|NCT00754221|DRUG|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
214225184|NCT01594801|DEVICE|InsuPad|Use of the InsuPad for at least 3 times a day.
214225185|NCT02763943|BEHAVIORAL|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
214225186|NCT01055652|DRUG|Dapagliflozin|10mg, oral, once daily
214225187|NCT03561532|OTHER|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
214225188|NCT03561532|OTHER|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
214225189|NCT03913416|DEVICE|3D printed model|Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
214225190|NCT03913416|OTHER|Control group|The control group is composed of patients operated with standard surgery
214225191|NCT05918211|DRUG|Udenafil|Active drug
214225192|NCT05918211|DRUG|Placebo|Matching Placebo
214225193|NCT04277923|DRUG|SMOFlipid|the lipid of all-in-one is less than 4g/kg.d
214225194|NCT04277923|DRUG|Lipofundin|the lipid of all-in-one is less than 4g/kg.d
214225195|NCT06071078|BEHAVIORAL|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
214225196|NCT03841916|DIAGNOSTIC_TEST|transvaginal ultrasound|transvaginal ultrasound to measure endometrial thickness
214225197|NCT00265148|DRUG|Rosiglitazone|Extended Release Tablets
214225198|NCT00265148|OTHER|Placebo|Placebo dummy to match
214225199|NCT02842554|OTHER|EPT|
214225200|NCT02842554|DRUG|Drug Placebo Administration|
214225201|NCT02842554|OTHER|C|No Intervention
214225202|NCT03101111|BIOLOGICAL|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
214225203|NCT03101111|BIOLOGICAL|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
214225204|NCT05525078|BEHAVIORAL|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
214651098|NCT01194440|DRUG|letrozole|Given orally
214651099|NCT01194440|DRUG|zoledronic acid|Given IV
214225205|NCT05525078|OTHER|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
214651100|NCT00584870|DRUG|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
214651101|NCT00584870|DRUG|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
214651102|NCT00584870|DRUG|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
214651103|NCT04058327|DIAGNOSTIC_TEST|neurophysiological tests, blood biomarkers.|Let the patients do neuropsychological tests and detect blood biomarkers.
214651104|NCT03299803|BEHAVIORAL|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
214651105|NCT02314507|OTHER|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
214651106|NCT02314507|OTHER|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
214651107|NCT00854828|PROCEDURE|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
214225206|NCT02524600|DEVICE|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
214225207|NCT02524600|DEVICE|scintigraphic imaging|
214225208|NCT01504906|DRUG|cyclosporine|Oral tablets, 600 mg , single dose
214225209|NCT01504906|DRUG|ticagrelor|Oral tablets, 180 mg, single dose
214225210|NCT00942994|DRUG|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
214225211|NCT00942994|DRUG|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
214225212|NCT03507387|DRUG|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
214225213|NCT03507387|DRUG|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
214225214|NCT03507387|DRUG|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
214225215|NCT06954051|OTHER|REThink Life|REThink Life is a therapeutic game developed by David and collaborators (2019) and it is composed of four levels, each training a different emotion regulation ability (emotion recognition, mindfulness, distinguishing between rational and irrational thoughts, and positive attention bias).
214225216|NCT06078943|DEVICE|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
214225217|NCT03914222|DEVICE|CardioSpire (Respirix) Device|Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
214225218|NCT04470076|DRUG|Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin|"① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy."
214225219|NCT04470076|PROCEDURE|Surgical treatment|The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
214225220|NCT04470076|DRUG|Adjuvant treatment:afatinib|The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
214225221|NCT00706303|BEHAVIORAL|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
214225222|NCT00296296|DRUG|Cyclosporin|Dose adjustment to pre-established targets
214225223|NCT00296296|DRUG|Tacrolimus|Dose adjustment to pre-established targets
214651108|NCT00854828|OTHER|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
214651109|NCT01239355|DRUG|Akt Inhibitor MK2206|Given PO
214651110|NCT01239355|OTHER|Laboratory Biomarker Analysis|Correlative studies
214651111|NCT02427347|OTHER|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
214651112|NCT02427347|OTHER|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
214651113|NCT00217165|DRUG|taurine|taurine 2mg BID po
214651114|NCT01232699|BEHAVIORAL|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
214651115|NCT01232699|BEHAVIORAL|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
214651116|NCT01232699|BEHAVIORAL|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
214651117|NCT02292212|DEVICE|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
214651118|NCT01966549|DRUG|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
214651119|NCT01966549|DRUG|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
214651120|NCT04957290|DRUG|NOX66|NOX66 800 mg daily (400 mg suppository twice daily \[BID\]).
214651121|NCT04957290|DRUG|NOX66|NOX66 1200 mg daily (600 mg suppository BID).
214225224|NCT00296296|BEHAVIORAL|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
214225225|NCT01874340|DRUG|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
214225226|NCT01874340|DRUG|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
214225227|NCT05390619|PROCEDURE|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
214225228|NCT05390619|PROCEDURE|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
214225229|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical creatine|
214225230|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical placebo|
214651122|NCT04957290|DRUG|NOX66|NOX66 1600 mg daily (800 mg suppository BID).
214225231|NCT03006861|DIETARY_SUPPLEMENT|21 g/d Oral creatine|
214225232|NCT03006861|DIETARY_SUPPLEMENT|21 g/d oral placebo|
214225233|NCT01504646|DIETARY_SUPPLEMENT|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
214225234|NCT01504646|DIETARY_SUPPLEMENT|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
214225235|NCT03736915|PROCEDURE|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
214225236|NCT03736915|OTHER|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
214225237|NCT03736915|OTHER|Questionnaires|Patient is asked to answer questionairres at the end of each injection
214225238|NCT01421472|DRUG|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
214225239|NCT01421472|DRUG|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
214225240|NCT03540836|DRUG|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
214225241|NCT03540836|DRUG|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
214225242|NCT03540836|DRUG|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
214225243|NCT01437306|DRUG|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
214225244|NCT06131099|OTHER|Dohsa hou exercises|Dohsa hou is a type of psychomotor therapy that helps improve psychological problems by using bodily movements, sensation and relaxation experience.
214225245|NCT06131099|OTHER|Standard treatment protocal|Standard treatment including soft tissue massage therapy, task specific training interventions, bicycle training and aerobic exercises.
214225246|NCT05274295|DEVICE|Diabetic leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
214225247|NCT00753246|DRUG|nimotuzumab|monoclonal antibody
214225248|NCT06337019|OTHER|Cohort observational|Cohort observational
214225249|NCT00263289|PROCEDURE|preprocedural fasting|
214225250|NCT02385422|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
214225251|NCT02385422|DRUG|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
214225252|NCT00641641|DRUG|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
214225253|NCT05948384|OTHER|PNF|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
214225254|NCT04521504|DEVICE|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
214225255|NCT00160472|PROCEDURE|removal of ovarian vessels|
214225256|NCT01068964|DRUG|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
214225257|NCT01068964|DRUG|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
214225258|NCT01758536|DRUG|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
214225259|NCT03264053|DEVICE|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
214225260|NCT03264053|PROCEDURE|Conventional immediate implantation|Conventional immediate implantation
214225261|NCT02553252|OTHER|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
214225262|NCT03486626|DRUG|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
214225263|NCT04249349|DEVICE|Assisted gait with a motorized ankle foot orthosis|The motorized ankle foot orthosis is a powered lower extremity assistance device with an actuated ankle joint. A novel control software has been design and implemented in this device, which allows precise joint movement and recording of data from training session.
214225264|NCT00040560|DRUG|111In-DAC|
214225265|NCT00040560|PROCEDURE|Diagnostic|
214225266|NCT01676779|BIOLOGICAL|Dendritic cell therapy|Dendritic cell therapy IV and ID
214225267|NCT01311024|BIOLOGICAL|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
214225268|NCT01311024|BIOLOGICAL|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
214225269|NCT02706964|DEVICE|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
214225270|NCT02706964|DEVICE|Magnetic resonance imaging|A brain MRI will be performed.
214225271|NCT02706964|DEVICE|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
214225272|NCT03630770|DRUG|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
214225273|NCT01523275|DRUG|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
214225274|NCT01523275|OTHER|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
214225275|NCT00170378|DRUG|Enoxaparin|
214225276|NCT02469545|DRUG|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
214225277|NCT02469545|DRUG|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
214225278|NCT02469545|DRUG|Escitalopram|5-20mg daily
214225279|NCT02469545|DRUG|Sertraline|50-100mg daily
214225280|NCT05409534|OTHER|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
214225281|NCT05409534|OTHER|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
214225282|NCT04870580|DIAGNOSTIC_TEST|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
214225283|NCT04327193|PROCEDURE|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
214225284|NCT04327193|PROCEDURE|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
214225285|NCT05222672|OTHER|His Bundle Pacing|Pacing of the His bundle
214225286|NCT02801266|BEHAVIORAL|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
214225287|NCT06173180|DEVICE|TOT|In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
214225288|NCT06173180|DEVICE|VACS-D|The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
214225289|NCT01788436|BEHAVIORAL|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT\_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT\_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
214225290|NCT01788436|BEHAVIORAL|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
214225291|NCT05526040|DIETARY_SUPPLEMENT|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
214225292|NCT05526040|DIETARY_SUPPLEMENT|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
214225293|NCT01206322|DRUG|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
214225294|NCT01206322|DRUG|Placebo|The acute effects of intranasal sterile saline.
214225295|NCT00689117|DRUG|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
214225296|NCT00689117|DRUG|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
214225297|NCT00689117|DRUG|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
214225298|NCT00689117|DRUG|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
214225299|NCT03260049|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy
214225300|NCT02794675|DRUG|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
214225301|NCT04170972|OTHER|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
214225302|NCT02463890|OTHER|Training|
214225303|NCT02463890|OTHER|Control|
214225304|NCT06044051|OTHER|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
214225305|NCT06044051|OTHER|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
214225306|NCT06044051|OTHER|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
214225307|NCT02828670|BIOLOGICAL|blood sample|
214225308|NCT02828670|PROCEDURE|spleen sample|
214225309|NCT02735135|DEVICE|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
214225310|NCT02735135|DEVICE|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
214225311|NCT02735135|DEVICE|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
214225312|NCT02735135|DEVICE|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
214225313|NCT00802113|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days
214225314|NCT00802113|DRUG|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
214225315|NCT00802113|DRUG|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
214225316|NCT03635658|PROCEDURE|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
214225317|NCT03635658|PROCEDURE|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
214225318|NCT03354507|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate. See arms.
214225319|NCT03924895|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
214225320|NCT03924895|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
214225321|NCT03924895|DRUG|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
214225322|NCT05701280|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
214225323|NCT05701280|OTHER|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
214225324|NCT03268070|DEVICE|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
214225325|NCT03268070|DEVICE|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
214225326|NCT03268070|DEVICE|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
214225327|NCT03268070|DEVICE|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
214225328|NCT03268070|DEVICE|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
214225329|NCT05477082|OTHER|Observational group|Includes blood draws and data collection only
214225330|NCT06547138|DEVICE|Prophylactic mesh|Prevention of incisional hernia after a prophylactic mesh in high-risk patients
214225331|NCT04748367|DEVICE|Virtual Reality Headset|Virtual Reality Headset running SILVER software
214651123|NCT04957290|DRUG|NOX66|NOX66 2400 mg daily (1200 mg suppository BID).
214225332|NCT04441541|OTHER|Treadmill with auditory feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
214225333|NCT04441541|OTHER|Treadmill with visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
214225334|NCT04441541|OTHER|Treadmill with auditory and visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
214225335|NCT04441541|OTHER|Treadmill training|Participants will receive training 3 times per week for 4 weeks (12 sessions).
214225336|NCT04709627|DEVICE|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
214225337|NCT01086358|DRUG|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
214225338|NCT01086358|DRUG|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
214225339|NCT04975230|BEHAVIORAL|Sleep Self-Management|Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
214651124|NCT04957290|DRUG|NOX66|NOX66 RP2D
214651125|NCT04957290|RADIATION|EBRT|The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.
214651126|NCT03418012|DEVICE|cervical pessary|Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
214225340|NCT03206788|DRUG|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
214225341|NCT03206788|DRUG|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
214225342|NCT06185751|BIOLOGICAL|WS-CART-CS1|-Subject will be hospitalized for 7 days
214225343|NCT06185751|DRUG|Lymphodepleting chemotherapy|"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"
214225344|NCT05903885|OTHER|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff.
214225345|NCT05903885|OTHER|On-site With Social Media Advertising Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff supplemented by exposure to targeted social media advertisements.
214225346|NCT06095596|DRUG|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
214225347|NCT06095596|DRUG|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
214225348|NCT03899805|DRUG|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
214225349|NCT03899805|DRUG|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
214225350|NCT03317405|DRUG|Endoxifen Hydrochloride|Apply to the skin
214225351|NCT03317405|OTHER|Placebo Administration|Apply to the skin
214225352|NCT03317405|OTHER|Questionnaire Administration|Ancillary studies
214225353|NCT01458041|DRUG|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
214225354|NCT06523699|DRUG|Recombinant glycosylated human interleukin-7|Provided by RevImmune
214225355|NCT06523699|DRUG|Melphalan|Standard of care
214225356|NCT06523699|PROCEDURE|Autologous hematopoietic cell transplant|Standard of care
214225357|NCT04024189|OTHER|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
214225358|NCT02835976|DRUG|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
214225359|NCT03633539|PROCEDURE|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
214225360|NCT03633539|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
214225361|NCT04201808|DRUG|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
214225362|NCT06067672|OTHER|Observations to investigate the current practices of communication and decision-making during Nurse-patient consultations|No intervention
214225363|NCT05536271|DRUG|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
214225364|NCT02291016|DRUG|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
214225365|NCT02291016|OTHER|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
214225366|NCT02825797|DRUG|3BNC117|Intravenous infusion of 3BNC117
214225367|NCT02825797|DRUG|10-1074|Intravenous infusion of 10-1074
214651127|NCT03418012|OTHER|Control-Group|Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
214651128|NCT03410511|OTHER|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
214225368|NCT02825797|OTHER|Analytical treatment interruption|Analytical treatment interruption
214225369|NCT02825797|DRUG|Placebo|Intravenous infusion of placebo (sterile saline)
214225370|NCT05986201|DEVICE|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
214225371|NCT03469778|DEVICE|Robotic Therapy|Robotic Therapy
214225372|NCT00732719|DEVICE|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
214225373|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225374|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225375|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225376|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225377|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225378|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
214225379|NCT02340637|BEHAVIORAL|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
214225380|NCT02340637|BEHAVIORAL|TAU|Treatment as usual
214225381|NCT05541796|DEVICE|Intraocular lens|"Tecnis Symfony Optiblue (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles."
214225382|NCT04489069|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
214225383|NCT04489069|DIAGNOSTIC_TEST|Clinical and Neuropsychological evaluations|Clinical interviews and neuropsychological tests (paper/pencil and computer based)
214225384|NCT04489069|DIAGNOSTIC_TEST|Drawing DNA sample|Saliva sample
214225385|NCT03635671|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
214225386|NCT05478031|DRUG|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
214225387|NCT05478031|DRUG|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
214225388|NCT05478031|DRUG|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
214225389|NCT01018810|DRUG|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
214225390|NCT01018810|DRUG|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
214225391|NCT01018810|DRUG|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
214225392|NCT01018810|DRUG|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
214225393|NCT01640314|BIOLOGICAL|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
214225394|NCT04618796|OTHER|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
214225395|NCT01237015|DEVICE|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
214225396|NCT04450381|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
214225397|NCT05659160|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
214225398|NCT03785223|DRUG|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
214225399|NCT03785223|DRUG|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
214225400|NCT02619916|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
214225401|NCT02619916|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
214651129|NCT03410511|OTHER|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
214651130|NCT03410511|OTHER|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
214225402|NCT00004368|DRUG|colchicine|
214225403|NCT03433612|OTHER|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
214651131|NCT03190408|OTHER|Fluids|Fluids Administered in Shock
214225404|NCT03433612|OTHER|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
214225405|NCT03084783|DRUG|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
214225406|NCT03157700|BEHAVIORAL|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
214225407|NCT05983081|PROCEDURE|Injection Treatment|Physical Therapy
214225408|NCT06405308|PROCEDURE|R-NOSES group|robotic natural orifice specimen extraction surgery
214225409|NCT06405308|PROCEDURE|R-TSES group|robotic transabdominal specimen extraction surgery
214225410|NCT04107389|BEHAVIORAL|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
214225411|NCT04107389|BEHAVIORAL|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
214225412|NCT06095648|OTHER|Dose of platelet transfusion|Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU
214225413|NCT00317278|OTHER|massage therapy|massage therapy to stable preterm infants
214225414|NCT00317278|OTHER|Sham|Sham (placebo) provided to the control group
214225415|NCT00708084|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
214225416|NCT00708084|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
214225417|NCT04335214|OTHER|one to one interview|one to one interviews with older people from moroccon origin in Belgium
214225418|NCT06192017|DIAGNOSTIC_TEST|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
214225419|NCT04435691|DRUG|Azacitidine|Given SC or IV
214225420|NCT04435691|BIOLOGICAL|Magrolimab|Given IV
214225421|NCT04435691|DRUG|Venetoclax|Given PO
214225422|NCT06370182|DEVICE|ANA Funnel Catheter|Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.
214225423|NCT06370182|DEVICE|Control|Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.
214225424|NCT05290064|OTHER|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
214225425|NCT05290064|OTHER|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
214225426|NCT05290064|OTHER|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
214225427|NCT05290064|OTHER|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
214225428|NCT02765009|DRUG|diuretics|Used to reduce fluid overload as evidenced by weight gain
214225429|NCT02765009|DRUG|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
214225430|NCT02765009|OTHER|fluid restriction|Used to reduce fluid overload
214225431|NCT02765009|DEVICE|renal replacement|Used to reduce fluid overload in patients with renal replacement
214225432|NCT06132139|DEVICE|VisAR|The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
214225433|NCT00173641|PROCEDURE|blood drawing|
214225434|NCT01989208|OTHER|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
214225435|NCT01989208|OTHER|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
214225436|NCT05251701|DEVICE|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
214225437|NCT05913193|OTHER|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
214225438|NCT04973436|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
214225439|NCT00566696|DEVICE|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
214225440|NCT00566696|PROCEDURE|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
214225441|NCT00566696|DRUG|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225442|NCT00566696|DRUG|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225443|NCT00566696|DRUG|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225444|NCT00566696|DRUG|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225445|NCT00566696|DRUG|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225446|NCT00566696|DRUG|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
214225447|NCT00566696|DRUG|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225448|NCT00566696|DRUG|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225449|NCT00566696|DRUG|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
214225450|NCT00566696|DRUG|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
214225451|NCT04309864|DEVICE|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
214225452|NCT04309864|DEVICE|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
214225453|NCT05737355|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
214225454|NCT05737355|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
214225455|NCT06338462|DEVICE|Chatbot|The chatbot is a WhatsApp-based, artificial-intelligence powered customer service agent adapted for TB outreach. The objective of the Chatbot is to facilitate information gathering, education, and support throughout TB contact evaluation, ensuring accessible assistance on-demand during and after contact tracing procedures. It operates in a secure data environment that includes end-to-end encryption and has been reviewed and approved by the data protection team within the information technology unit at the Cali Secretariat of Public Health (SoPH) for the study purposes.
214225456|NCT06338462|DIAGNOSTIC_TEST|Oral testing|Oral testing involves collection of a saliva sample or use of a nylon swab to collect material from the tongue and oral mucosa that is then tested with a molecular test for Mycobacterium tuberculosis
214225457|NCT05750446|DRUG|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
214225458|NCT05750446|OTHER|Placebo|Placebo
214225459|NCT00351429|DEVICE|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
214225460|NCT00010699|DRUG|Vitamin E|
214225461|NCT03048006|PROCEDURE|MRI with Dotarem|
214225462|NCT01321099|OTHER|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
214225463|NCT01321099|OTHER|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
214225464|NCT01321099|OTHER|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
214225465|NCT03867318|DRUG|Atorvastatin|Atorvastatin administered orally QD as 10 mg tablets.
214225466|NCT03867318|DRUG|Ezetimibe|Ezetimibe administered orally QD as 10 mg tablets
214225467|NCT03867318|DRUG|Placebo for Ezetimibe|Single placebo tablet administered orally QD
214225468|NCT03867318|DRUG|Placebo for Atorvastatin|Single placebo tablet administered orally QD
214225469|NCT01534897|DRUG|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
214225470|NCT06174688|DRUG|BOTOX|Intramuscular Injections
214225471|NCT06174688|DRUG|Placebo|Intramuscular Injections
214225472|NCT03783624|BEHAVIORAL|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
214225473|NCT03783624|BEHAVIORAL|Open label placebo|Ritual intake of 2 placebo capsules twice a day
214651132|NCT02893345|BEHAVIORAL|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
214225474|NCT02512029|DRUG|18F-AV-1451|
214225475|NCT00552747|DRUG|fenofibrate|fenofibrate 160 mg capsules qd
214225476|NCT00552747|DRUG|placebo|capsules placebo
214225477|NCT03573271|DEVICE|MCD|Micro-coring skin removal with automated coring device
214225478|NCT05367297|DIAGNOSTIC_TEST|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
214225479|NCT00466570|DRUG|gatifloxacin, moxifloxacin|
214225480|NCT06396104|OTHER|Mobilisation with movement|The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.
214225481|NCT06396104|OTHER|Sham mobilisation|While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
214225482|NCT04252976|BEHAVIORAL|Ethical Living|Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
214225483|NCT04252976|BEHAVIORAL|Yoga Exercises|Ujjaii breathing and simple yoga asanas
214225484|NCT04252976|BEHAVIORAL|Mantra Meditation|Meditation with mantras
214225485|NCT05701319|PROCEDURE|PCI|percutaneous coronary intervention
214225486|NCT05168111|DIAGNOSTIC_TEST|Detect the serum sample|Detect the serum sample
214225487|NCT05744804|DRUG|-group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg|receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
214225488|NCT05744804|DRUG|(acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
214225489|NCT04993157|DRUG|FIA586|FIA586 capsule
214225490|NCT00644982|DRUG|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
214225491|NCT00644982|DRUG|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
214225492|NCT04298476|PROCEDURE|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
214225493|NCT00132548|DRUG|Pyrimethamine/sulfadoxine|
214225494|NCT00132548|DRUG|Amodiaquine|
214225495|NCT00132548|DRUG|Artesunate|
214225496|NCT04180124|OTHER|Walking|"Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated."
214225497|NCT00452361|DRUG|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
214225498|NCT00452361|DRUG|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation"
214225499|NCT01472718|DEVICE|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
214225500|NCT01472718|DEVICE|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
214225501|NCT03116152|BIOLOGICAL|IBI308|IBI308 200mg Intravenous drip every three weeks；
214225502|NCT03116152|DRUG|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
214225503|NCT05949437|OTHER|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
214225504|NCT05949437|OTHER|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
214225505|NCT04802577|DIAGNOSTIC_TEST|FACT-F questionnaire|The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
214225506|NCT04802577|DIAGNOSTIC_TEST|Beck Depression Inventory|The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
214225507|NCT04802577|DIAGNOSTIC_TEST|Beck Anxiety Inventory|The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
214225508|NCT04802577|DIAGNOSTIC_TEST|Insomnia severity index.|The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
214225509|NCT04802577|OTHER|ESSPRI|The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
214225510|NCT04802577|OTHER|ESSDAI|Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
214225511|NCT04802577|OTHER|Pain Detect Questionnaire|The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
214225512|NCT03959397|DRUG|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
214225513|NCT00003749|PROCEDURE|adjuvant therapy|
214225514|NCT00003749|PROCEDURE|conventional surgery|
214225515|NCT00003749|RADIATION|brachytherapy|
214225516|NCT00003749|RADIATION|radiation therapy|
214225517|NCT03238014|DEVICE|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
214225518|NCT03945617|BEHAVIORAL|Unified Treatment Protocol|The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
214225519|NCT03179605|DRUG|DFD06|Apply twice per day for 15 days
214225520|NCT06517485|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
214225521|NCT00910299|DRUG|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
214225522|NCT00910299|DRUG|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
214225523|NCT00635999|BEHAVIORAL|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
214225524|NCT00635999|OTHER|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
214225525|NCT00635999|BEHAVIORAL|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
214651133|NCT02893345|OTHER|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
214651134|NCT02409238|DRUG|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
214225526|NCT05587686|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
214225527|NCT03849118|DIAGNOSTIC_TEST|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
214225528|NCT02163941|BEHAVIORAL|Compassion Training|
214225529|NCT05063448|BEHAVIORAL|DadSpace|A group educational support and mentoring program for perinatal fathers.
214225530|NCT02448641|BIOLOGICAL|SB623 Implant (2.5M)|2.5 million SB623 cells
214225531|NCT02448641|BIOLOGICAL|SB623 Implant (5.0M)|5 million SB623 cells
214225532|NCT02448641|PROCEDURE|Sham surgery|
214225533|NCT05861713|DRUG|Hydrating Cream|The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
214225534|NCT05170880|PROCEDURE|Primary endodontic treatment|Primary non surgical endodontic treatment will be provided to patients in treatment group.
214225535|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
214225536|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
214225537|NCT05213728|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
214225538|NCT04006275|DRUG|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
214225539|NCT04006275|DRUG|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
214225540|NCT00228553|DRUG|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
214225541|NCT05359367|DIAGNOSTIC_TEST|Observational|Laboratory movement analysis, navigated transcranial magnetic stimulation and clinical aspects of gait function and walking.
214225542|NCT04152564|PROCEDURE|levo-bupivacaine infusion via Thoracic epidural catheter|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
214225543|NCT04152564|PROCEDURE|levo-bupivacaine infusion via preperitoneal catheter|At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
214225544|NCT03492918|DRUG|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
214225545|NCT05081297|OTHER|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
214225546|NCT05367089|DRUG|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
214225547|NCT05367089|DEVICE|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
214225548|NCT00959725|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
214225549|NCT01608932|PROCEDURE|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
214225550|NCT06164990|OTHER|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
214817980|NCT03491579|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
214817981|NCT03491579|DRUG|Cladribine|Standard chemotherapy
214225551|NCT03292172|DRUG|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
214225552|NCT03292172|DRUG|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
214225553|NCT00536497|DRUG|GW842166X|
214651135|NCT02409238|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
214817982|NCT03491579|DRUG|Cytarabine|Standard chemotherapy
214225554|NCT02526030|DRUG|Aripiprazole|
214225555|NCT02526030|DRUG|Quetiapine|
214225556|NCT02526030|DRUG|Ziprasidone|
214225557|NCT02402660|DRUG|ALK-001|Daily, oral administration for 24 months
214225558|NCT02402660|DRUG|Placebo|Daily, oral administration for 24 months
214225559|NCT04516785|DIAGNOSTIC_TEST|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
214225560|NCT01017913|OTHER|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
214225561|NCT01017913|OTHER|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
214225562|NCT02185924|DRUG|Parecoxib|
214225563|NCT02185924|DRUG|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
214225564|NCT02185924|DRUG|N/S 0.9%|
214225565|NCT01898351|OTHER|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
214225566|NCT01656265|DRUG|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
214817983|NCT06619041|BEHAVIORAL|HealthyTogether|HealthyTogether is a brief (8-session), virtual, dyadic weight management intervention.
214225567|NCT02269540|DRUG|Sertraline|selective serotonin reuptake inhibitor
214225568|NCT02269540|DRUG|Citalopram|selective serotonin reuptake inhibitor
214225569|NCT02269540|DRUG|N-acetylcysteine (NAC)|natural health product
214225570|NCT02269540|DRUG|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
214225571|NCT00409370|DEVICE|SOMA safe enclosure|
214225572|NCT05368701|BEHAVIORAL|Volitional Help Sheet for self-harm|"The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents."
214225573|NCT01536392|DRUG|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
214225574|NCT01536392|DRUG|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
214225575|NCT01536392|BEHAVIORAL|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
214225576|NCT01536392|BEHAVIORAL|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
214225577|NCT03195309|DRUG|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
214225578|NCT03195309|DRUG|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
214225579|NCT00037089|DRUG|UFT (Tegafur/Uracil)|
214225580|NCT01012089|DRUG|Daptomycin|Daptomycin IV 5 mg/kg one time dose
214225581|NCT01269242|DRUG|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
214225582|NCT01269242|DRUG|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
214225583|NCT01269242|DRUG|placebo|bindarit-matching placebo tablets for 6 months.
214225584|NCT01895478|BEHAVIORAL|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
214225585|NCT02724397|DEVICE|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
214225586|NCT02724397|DEVICE|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
214225587|NCT00666484|DRUG|cyclophosphamide|
214225588|NCT00666484|DRUG|doxorubicin hydrochloride|
214225589|NCT00666484|DRUG|etoposide|
214225590|NCT00666484|DRUG|prednisolone|
214225591|NCT00666484|DRUG|procarbazine hydrochloride|
214225592|NCT00666484|DRUG|vincristine sulfate|
214225593|NCT00666484|RADIATION|radiation therapy|
214225594|NCT04813185|BEHAVIORAL|Bridging the Gap|"Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
214225595|NCT03944252|DRUG|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
214225596|NCT03944252|DRUG|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
214225597|NCT01196403|OTHER|questionnaire administration|
214225598|NCT01196403|PROCEDURE|quality-of-life assessment|
214225599|NCT01196403|PROCEDURE|robot-assisted laparoscopic surgery|
214225600|NCT01196403|PROCEDURE|therapeutic conventional surgery|
214225601|NCT01196403|PROCEDURE|therapeutic laparoscopic surgery|
214225602|NCT02259088|DRUG|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
214225603|NCT02259088|PROCEDURE|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
214225604|NCT02259088|DRUG|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
214225605|NCT02259088|PROCEDURE|Sham laser|Imitation of an active laser
214225606|NCT06343519|DEVICE|Echocardiography|Measuring echocardiographic parameters (cardiac index, speckle tracking, tissue Doppler indices)
214225607|NCT01918748|DEVICE|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
214225608|NCT00932828|DRUG|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
214225609|NCT05942235|OTHER|Education|Education
214225610|NCT05170932|PROCEDURE|CHX gel 2 % + 24% EDTA|The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
214225611|NCT04340271|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
214225612|NCT04340271|OTHER|conventional occupational therapy|Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
214651136|NCT02409238|BEHAVIORAL|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
214225613|NCT05434780|OTHER|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
214225614|NCT01033448|DRUG|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
214225615|NCT01033448|DRUG|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
214225616|NCT01818752|DRUG|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
214225617|NCT01818752|DRUG|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
214225618|NCT01818752|DRUG|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
214225619|NCT01818752|DRUG|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
214225620|NCT05360862|PROCEDURE|Prone positioning session|To perform respiratory measurements before, during and after a prone positioning session.
214225621|NCT03617224|RADIATION|TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
214225622|NCT03617224|DRUG|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
214225623|NCT01155128|BEHAVIORAL|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
214225624|NCT01324141|DRUG|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
214225625|NCT01324141|DRUG|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
214225626|NCT01324141|DRUG|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
214225627|NCT01324141|PROCEDURE|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
214225628|NCT05593562|DRUG|SPH3127|Oral 100 mg \[14 c\] SPH3127 mixed suspension
214225629|NCT00000955|DRUG|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
214225630|NCT04105491|DEVICE|IInvisalign® Aligners|Clear aligner orthodontic treatment
214225631|NCT03170180|DRUG|Sunitinib|sunitinib 37.5mg daily
214225632|NCT03170180|DRUG|Gefitinib|Gefitinib 250mg daily
214225633|NCT03170180|DRUG|Imatinib|Imatinib 400mg daily
214225634|NCT01983410|BEHAVIORAL|The risk assessment questionnaire|
214225635|NCT01983410|OTHER|Blood specimens|
214225636|NCT01983410|OTHER|tumor tissue samples will be requested|
214225637|NCT01358955|OTHER|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
214225638|NCT01358955|OTHER|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
214225639|NCT05210777|DEVICE|observation|no intervention
214225640|NCT05489133|BEHAVIORAL|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
214225641|NCT04462770|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
214225642|NCT04462770|DRUG|Placebo|Placebo will be administered as an oral solution.
214225643|NCT04784065|DEVICE|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
214225644|NCT05238922|DRUG|INCB0123667|25 mg tablets
214225645|NCT05238922|DRUG|Palbociclib|Palbociclib will be administered at protocol defined dose.
214225646|NCT05238922|DRUG|Bevacizumab|Bevacizumab will be administered at protocol defined dose.
214225647|NCT05238922|DRUG|Olaparib|Olaparib will be administered at protocol defined dose.
214225648|NCT05238922|DRUG|Paclitaxel|Paclitaxel will be administered at protocol defined dose.
214225649|NCT05238922|DRUG|Ribociclib|Ribociclib will be administered at protocol defined dose.
214225650|NCT05238922|DRUG|Fulvestrant|Fulvestrant will be administered at protocol defined dose.
214225651|NCT03049007|DIAGNOSTIC_TEST|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
214817984|NCT01823263|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
214817985|NCT01823263|PROCEDURE|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
214225654|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
214225655|NCT05692453|DIAGNOSTIC_TEST|Arterial blood gas with co-oximetry|1 mL blood sample for ABG-CoOx analysis to obtain co-oximetry measured arterial oxygen saturation (SaO2C) and standard ABG derived arterial oxygen saturation (SaO2S).
214225656|NCT03477539|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214225657|NCT03477539|BIOLOGICAL|Daratumumab|Given IV
214225658|NCT03477539|DRUG|Lenalidomide|Given PO
214225659|NCT06053242|DRUG|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
214225660|NCT06053242|OTHER|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
214817986|NCT01823263|PROCEDURE|Interference task|30-minute interference task
214817987|NCT01823263|BEHAVIORAL|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
214225663|NCT05322954|DRUG|Psilocybin|25mg orally followed by 25 mg or 50 mg orally
214225664|NCT03606499|DRUG|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
214225665|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
214225666|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
214817988|NCT01823263|BEHAVIORAL|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
214817989|NCT01823263|BEHAVIORAL|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
214817990|NCT01218867|BIOLOGICAL|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
214225667|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
214225668|NCT04703114|DIAGNOSTIC_TEST|Blood count|Blood count at each visit
214225669|NCT04703114|DIAGNOSTIC_TEST|Blood collection|Blood collection to understanding of the immunological profile at each visit
214225670|NCT04703114|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
214225671|NCT04703114|DIAGNOSTIC_TEST|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
214225672|NCT04703114|DIAGNOSTIC_TEST|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
214225673|NCT04703114|GENETIC|Genetic blood collection|Collection to further research at each visit
214225674|NCT04703114|OTHER|Data collection|Demographics, symptoms, biological constants
214225675|NCT01165216|DRUG|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
214225676|NCT01165216|DRUG|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
214225677|NCT01165216|DRUG|Paclitaxel|IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles
214225678|NCT01165216|DRUG|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
214225679|NCT00141791|DRUG|Etanercept|
214225680|NCT01962363|DRUG|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
214225681|NCT00167219|BIOLOGICAL|Stem Cell Transplant|Transplantation on Day 0.
214225682|NCT00167219|DRUG|Preparative Regimen|"* Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)"
214225683|NCT06412939|DEVICE|Agile Nail|Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
214225684|NCT04895735|BIOLOGICAL|Pembrolizumab|Given IV
214225685|NCT04895735|DRUG|Pemetrexed Disodium|Given IV
214225686|NCT04895735|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214225687|NCT04895735|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214225688|NCT04895735|PROCEDURE|Positron Emission Tomography|Undergo PET
214225689|NCT04895735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214225690|NCT04895735|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214225691|NCT04848792|DIETARY_SUPPLEMENT|Sulforaphane|Myrosinase-active whole broccoli sprout material
214225692|NCT04848792|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
214651137|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
214651138|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
214817991|NCT01218867|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
214817992|NCT01218867|BIOLOGICAL|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
214817993|NCT01218867|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
214817994|NCT01093963|DRUG|Lisdexamfetamine|oral; 20-70mg/day
214817995|NCT01093963|DRUG|Placebo|oral; 20-70mg/day
214817996|NCT04808557|OTHER|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
214817997|NCT04808557|OTHER|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair \& Protect for home oral hygiene for the following 30 days from the bonding procedure.
214225699|NCT06455319|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
214225700|NCT06455319|DRUG|verapamil extended release capsule|Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
214225701|NCT06455319|DRUG|Placebo|I.V. Saline
214225702|NCT05704244|DRUG|FE 999326|75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
214225703|NCT06230679|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
214817998|NCT03655535|DRUG|BTI320|Non-systemic galactomannan complex polysaccharide
214817999|NCT03655535|OTHER|Placebo|Placebo
214818000|NCT02100761|DRUG|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
214225704|NCT06230679|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
214225705|NCT06805838|DEVICE|Sotair|"The device is a durable plastic connector with a silicone flap inside it requiring no special handling. There are no patients involved, only a simulated lung that also requires no special handling. Adult Sotair® device has FDA clearance as a Class II device through the 510(k) pathway (K212905) for the intended use of Flow-limiting, safe, and optimal manual ventilation to minimize gastric insufflation."
214225706|NCT06199570|BEHAVIORAL|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a second coaching session, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a third coaching session, the stress management plan will be revisited for new concerns.
214225707|NCT06199570|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
214651139|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
214651140|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
214651141|NCT00896532|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
214651142|NCT00896532|DRUG|Alendronate|Administered orally once a week
214651143|NCT00896532|DRUG|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
214651144|NCT00896532|DRUG|Romosozumab|Administered by subcutaneous injection
214225708|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 of Dose A
214225709|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 at dose B
214225710|NCT05469360|DRUG|Matching placebo|A single intrathecal injection of matching placebo
214225711|NCT05469360|DRUG|NIO752|Multiple intrathecal injections of NIO752 of Dose A
214225712|NCT05469360|DRUG|NIO752|Two intrathecal injections of NIO752 at dose C
214225713|NCT05469360|DRUG|NIO752|Single intrathecal injection of NIO752 at dose C
214225714|NCT05469360|DRUG|Matching placebo|Two intrathecal injections of matching placebo
214225715|NCT06176183|PROCEDURE|Arthroscopic meniscus repair|"A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted."
214225716|NCT05738837|BEHAVIORAL|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships\&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
214225717|NCT05738837|BEHAVIORAL|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
214651145|NCT00896532|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
214651146|NCT00896532|DRUG|Placebo to Denosumab|Administered by subcutaneous injection Q6M
214651147|NCT00896532|DRUG|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
214651148|NCT01950832|OTHER|Investigating clinically normal patients with optic coherence tomography|
214651149|NCT03082560|DIAGNOSTIC_TEST|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
214651150|NCT04758962|BIOLOGICAL|1 µg CoV2 SAM (LNP)|2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
214651151|NCT02411747|BEHAVIORAL|Testing|
214651152|NCT02411747|BEHAVIORAL|Directed self-regulated simulation training|
214225718|NCT06795178|DRUG|FP-014|11.25 mg in a prefilled, ready-to-use, long-acting formulation
214225719|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
214225720|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
214225721|NCT06332092|DRUG|FID007|Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
214225722|NCT06421636|DRUG|REGN7999|Administered subcutaneous (SC)
214225723|NCT06421636|DRUG|Placebo|Administered SC
214225724|NCT02694458|OTHER|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
214225725|NCT02694458|OTHER|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
214225726|NCT04999449|DRUG|Scopolamine|Intranasal scopolamine at 0.2 mg or 0.4 mg
214225727|NCT04999449|DRUG|Placebo|Intranasal saline placebo
214225728|NCT05563363|OTHER|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
214225729|NCT05563363|OTHER|standard inpatient treatment|Inpatient treatment on addiction ward
214225730|NCT06040541|DRUG|RMC-9805|Oral Tablets
214225731|NCT06040541|DRUG|RMC-6236|Oral Tablets
214225732|NCT05365139|OTHER|Structured clinical diagnostic interview for PGD (PGD-I)|"Participants were administered the Structured clinical diagnostic interview for PGD (PGD-I) and screened with clinical interviews for PTSD, anxiety and depression. Whether the Aarhus PGD-scale should be answered before or after the interview was randomized.~The PGD-I and self-report scale were readministered to 50 participants 7-14 days after the initial administration."
214225733|NCT06227572|BEHAVIORAL|CATNAP MI|"Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence."
214225734|NCT06251206|BEHAVIORAL|ADL/Postoperative Instruction|This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.
214225735|NCT06251206|BEHAVIORAL|Postoperative Instruction|This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
214225736|NCT05672524|DRUG|Trastuzumab|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
214225737|NCT05672524|DRUG|Tucatinib|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
214225738|NCT06445166|DRUG|Propranolol Hydrochloride|"Dosing is as follows:~* Patients who weigh 40 to 59.9 kg:~  * 40 mg BID (target)~ * 20 mg BID (half the target)~* Patients who weigh ≥ 60 kg:~  * 60 mg BID (target)~ * 30 mg BID (half the target)"
214225739|NCT05744310|DEVICE|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
214225740|NCT05744310|DEVICE|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
214225741|NCT01595958|DRUG|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
214225742|NCT01595958|PROCEDURE|cardio-pulmonary resuscitation|usual care of cardiac arrest
214225743|NCT06729970|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
214225744|NCT06729970|DRUG|Lithium|Specified dose on specified days
214225745|NCT06729970|DRUG|Valproic Acid|Specified dose on specified days
214225746|NCT06729970|DRUG|Lamotrigine|Specified dose on specified days
214225747|NCT06457204|DRUG|Pramipexole manufactured in Ingelheim|1 tablet Sifrol® (pramipexole) manufactured in Ingelheim containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
214225748|NCT06457204|DRUG|Pramipexole manufactured in Ennigerloh|1 tablet Sifrol® (pramipexole) manufactured in Ennigerloh containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
214225749|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
214225750|NCT06644599|DEVICE|wireless monitoring|The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
214225751|NCT06853522|DRUG|exosomes derived from human umbilical cord mesenchymal stem cells|The corresponding exosome content of 60×10\^6 umbilical cord mesenchymal stem cells was given
214225752|NCT06853522|DRUG|saline +5% albumin|Equal amount of saline +5% albumin was given
214225753|NCT04066907|OTHER|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
214225754|NCT03124004|PROCEDURE|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
214225755|NCT06208943|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
214225756|NCT03727724|DRUG|Afatinib|Tablet
214225757|NCT03727724|DRUG|Cetuximab|Injection
214225758|NCT06546397|DRUG|17β-estradiol/dydrogesterone tablets|The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
214225759|NCT02035254|OTHER|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
214225760|NCT04007354|OTHER|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
214225761|NCT06981585|OTHER|Physical Evaluations of Patients with Chronic Kidney Failure|In this study, data from children and adolescents with chronic kidney disease will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.
214225762|NCT06981585|OTHER|Physical Evaluations of Healthy Children|In this study, data from healthy children and adolescents will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. Data obtained through all these assessments will be collected from participants face-to-face at once and for a maximum of approximately 1 hour.
214225763|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
214818001|NCT01474551|DRUG|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
214818002|NCT00488800|BIOLOGICAL|pneumococcal conjugate vaccine|
214225766|NCT06862219|DRUG|Enfortumab Vedotin|Intravenous Infusion
214225767|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
214225768|NCT05704595|OTHER|Initial hospitalization-based management strategy|Direct admission to the hospital
214225769|NCT06616987|DRUG|Sacituzumab Govitecan with pegfilgrastim|"▪ Sacituzumab Govitecan group~\- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9"
214225770|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
214225771|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
214225772|NCT06607783|DIAGNOSTIC_TEST|MRI|Standard MRI using phantom.
214225773|NCT06998355|OTHER|Registry|observational data collection
214225774|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
214225775|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
214225776|NCT00027989|DRUG|gemcitabine hydrochloride|
214225777|NCT00027989|DRUG|pegylated liposomal doxorubicin hydrochloride|
214225778|NCT04576871|DRUG|225Ac-J591|In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.
214225779|NCT05650073|OTHER|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
214225780|NCT05822908|DRUG|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
214225781|NCT02230228|DRUG|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
214225782|NCT05758935|OTHER|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
214225783|NCT06672861|OTHER|Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)|To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
214225784|NCT01808092|DRUG|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
214225785|NCT01808092|DRUG|meropenem (active comparator)|1000mg of Meropenem
214225786|NCT03520504|RADIATION|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
214818003|NCT01351220|BEHAVIORAL|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
214225791|NCT07008911|BEHAVIORAL|CardioHeartConnect|Participants in the CardioHeartConnect group engage in an eight-week digital cardiac rehabilitation program using the commercially available Peloton app. The intervention includes two daily modules (10-25 minutes total) on weekdays, focused on walking, strength, low-intensity cardio, yoga, pilates, and stretching. Modules progress in intensity over time. The program is delivered through the Ortus-iHealth platform, which prompts daily participation and integrates survey responses and smartwatch data. The intervention is designed to support physical activity, functional capacity, quality of life, and cardiovascular health among patients recovering from Transcatheter Aortic Valve Replacement (TAVR).
214225792|NCT07008911|BEHAVIORAL|CardioHeartEd|CardioHeartEd is the control condition in which participants receive weekly cardiac rehabilitation-related educational resources through the Ortus-iHealth platform for eight weeks. The content is created by the American College of Cardiology and is designed to promote cardiovascular health following TAVR. Participants also receive a smartwatch to wear for self-monitoring, but do not receive structured exercise content. The CHE group controls for access to technology and general education about heart health.
214225793|NCT07013903|OTHER|Standard rehabilitation plus cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
214225794|NCT07013903|OTHER|Standard rehabilitation only|same rehabilitation program than the experimental group but without hydrotherapy
214225795|NCT06682806|DRUG|PRT3789|PRT3789 is administered as an intravenous infusion once weekly for 3 weeks
214225796|NCT06682806|DRUG|pembrolizumab|Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
214225797|NCT05830084|DRUG|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
214225798|NCT03711695|DEVICE|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
214225799|NCT00658164|OTHER|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
214225800|NCT07018830|BEHAVIORAL|Behavioral Treatment|Participants will be provided 11, 60 - 90 minute group sessions. They will receive behavioral strategies to address each of the lifestyle behaviors. These strategies are based on the Social Cognitive Theory and Self Determination Theory. Topics will include, but are not limited to, self-monitoring, goal setting, social support, cues, problem solving, and relapse prevention. Groups may occur both in-person and virtually.
214225801|NCT05933850|BEHAVIORAL|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
214225802|NCT06331702|BIOLOGICAL|Vero cell-drived inactive Japanese encephalitis vaccine|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered in the deltoid area of lateral arm by intramuscular injection.
214225803|NCT06331702|BIOLOGICAL|Measles-Mumps-Rubella Vaccine|0.5ml for each dose (after dissolving), manufactured by Shanghai Institute of Biological Products CO., LTD, administered in the lower part of the deltoid area of lateral arm, by subcutaneous injection.
214225804|NCT02897661|PROCEDURE|WMT|Washed microbiota transplantation (WMT) through mid-gut
214225805|NCT02897661|DIETARY_SUPPLEMENT|EEN|Exclusive enteral nutrition (EEN) through feeding tube
214225806|NCT06867081|OTHER|The intervention will be the BRILLIANT Platform, an online platform which provides five Modules aimed at increasing coordination of care and direct rehabilitation time|The BRILLIANT Platform provides five Modules aimed at increasing coordination of care and direct rehabilitation time: 1) Standardized measures: provided consistently with scoring and reminders to complete assessments, across all stages of recovery and care settings to guide and evaluate treatment effectiveness of clinical outcomes, performance based outcomes, patient reported outcome measures; 2) Communication Module: clinicians can communicate together and with patient/family to clarify patient-related information and update colleagues for time sensitive information, synchronously and asynchronously; 3) Shared intervention goals and plan: personalized and dynamic care trajectory and intervention plan guided by standardized assessments, reminders, and evidence-based interventions recommendations to direct patients and caregivers to the right services and interventions at the right time based on clinical and social profile and best practices; and 2 other related topics.
214225807|NCT07025434|PROCEDURE|Hip Bump Manipulation|This technique is a high velocity low amplitude thrust (HVLAT) directly posterior to the greater trochanter which theorizes the quick stretch of the external rotator muscles and may improve a malpositioned femoral head within the acetabulum.
214225808|NCT07025434|PROCEDURE|Sham (No Treatment)|Iliac Crest Sham Manipulation
214225809|NCT07025226|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214225810|NCT07025226|DRUG|Dasatinib|Given PO
214225811|NCT07025226|DRUG|Fisetin|Given PO
214225812|NCT07025226|DRUG|Fluorodopa F 18|Undergo 18F-DOPA-PET scan
214225813|NCT07025226|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214225814|NCT07025226|OTHER|Patient Observation|Receive rest and take no treatment
214225815|NCT07025226|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET scan
214225816|NCT07025226|DRUG|Quercetin|Given PO
214225817|NCT07025226|DRUG|Temozolomide|Given PO
214651153|NCT02035826|BEHAVIORAL|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
214225818|NCT01762137|PROCEDURE|Flow Diversion|Endovascular flow diverter placement
214225819|NCT01762137|PROCEDURE|Coiling|Endovascular coil placement
214651154|NCT02149810|BEHAVIORAL|Automatic Self Transcending Meditation|as above
214651155|NCT01946815|DRUG|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
214651156|NCT00080197|DRUG|E7070|
214225823|NCT07028684|OTHER|Reflexology Massage|"Reflexology massage will be applied twice a week for 30 minutes per session, for a total of 10 sessions. The treatment will begin by relaxing the ankle with a few passive movements. Reflexology massage will be applied to the right foot first and then to the left foot.~Target Areas to be Applied to the Right Foot: Brain, Pineal, Hypophysis, Hypothalamus and Thalamus, Temples, Eye area and Optic nerve, Ear area, Middle ear and Balance point, Neck.~Other areas to be applied to the right foot: Thyroid and Parathyroid, Lung, Liver, Face area, Speech center and Thymus, Teeth, Diaphragm, Vertebra, Extremities.~Areas to be applied to the left foot: Kidney, Diaphragm, Intestines, Neck, Vertebra, Extremities.~The session is completed from the left foot by applying to the lymph inlet, lymph channel and diaphragm from both feet."
214225824|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
214225825|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
214225826|NCT06710938|DEVICE|The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system|The thoracoabdominal artery stent graft system is a mixed branch design with two inner branches for the visceral arteries and two outer branches for the bilateral renal arteries.
214225827|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 phonocardiogram (PCG) recording|Noninvasive acquisition of heart sound (phonocardiogram, PCG) recordings using the FDA (U.S. Food and Drug Administration)-cleared Eko CORE 500 digital stethoscope. At least four 15-second recordings are collected at standard auscultation sites (aortic, pulmonic, tricuspid, mitral). Recordings are used solely for investigational algorithm development and are not used for diagnostic or clinical decision-making.
214225828|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 three-lead electrocardiogram (ECG) recording|Noninvasive acquisition of three-lead electrocardiogram (ECG) signals using the FDA-cleared Eko CORE 500 digital stethoscope. Recordings are obtained simultaneously with PCG at auscultation sites. Data are used solely for investigational algorithm development and are not intended for diagnostic use.
214225829|NCT06714617|DRUG|BL-M17D1|The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks.
214225830|NCT06714006|DRUG|PYC-003|A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion
214225831|NCT07032558|DRUG|DW-1021|DW-1021 is a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), formulated as a controlled-release film-coated tablet. It is administered as a single oral dose with 150 mL of water under fasting conditions for the evaluation of pharmacokinetics in healthy adult male volunteers.
214225832|NCT07032558|DRUG|Pelubi CR + Zytram CR|The reference treatment consists of two separate controlled-release film-coated tablets: Pelubi CR (Pelubiprofen 45 mg) and Zytram CR (Tramadol HCl 75 mg). These are co-administered as a single oral dose with 150 mL of water under fasting conditions to compare the pharmacokinetic profile against the fixed-dose combination DW-1021.
214225834|NCT07037940|OTHER|OpenEvidence|Medical information platform which uses retrieval-augmented generation to access medical literature
214225835|NCT07037940|OTHER|GPT-4|A chatbot application developed that uses GPT-4, a large language model, to engage in conversational interactions with users.
214225836|NCT05065411|DRUG|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm \& Abemaciclib
214225837|NCT05065411|DRUG|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
214225838|NCT06719258|DEVICE|MR850|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
214225839|NCT06719258|DEVICE|FP950|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
214225840|NCT06500273|GENETIC|cemacabtagene ansegedleucel|An allogeneic CAR T cell therapy targeting CD19
214225841|NCT06500273|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214225842|NCT06500273|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214225843|NCT06500273|DEVICE|Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™|A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.
214225844|NCT06885281|DRUG|ZL-1310|drug ZL-1310
214225845|NCT07046429|DIETARY_SUPPLEMENT|Melatonin tablet 3 mg once daily|Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
214225846|NCT07046429|DIETARY_SUPPLEMENT|Thiamine|Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
214818004|NCT01351220|BEHAVIORAL|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
214225850|NCT07042607|OTHER|not appicable|no intervention
214225851|NCT06888011|BEHAVIORAL|Participants: iAmHealthy|Families will take part in an educational group program with parents and their children. These one-hour meetings will be focused on living healthy lifestyles and engaging in healthy habits as a family and will occur weekly for three months and monthly for three months. Each family will also have the opportunity to receive individual health coaching sessions every other week that will last approximately 30 minutes to address concerns and health behaviors specific to each pair. There will be additional opportunities to demonstrate and apply learned concepts.
214225852|NCT06888011|BEHAVIORAL|Participants: Newsletter|Families assigned to the newsletter control intervention will receive the AAP Healthy Children Newsletter (HealthyChildren.org) every month for six months.
214225853|NCT06888011|OTHER|Clinics: Healthy Clinics|Healthy Clinics is a clinic level intervention designed to improve provider office processes using a bundled intervention of provider prompts, skills training and intervention tools implemented with performance feedback. Each clinic receives Healthy Clinics at some point in the intervention.
214225854|NCT02415036|DEVICE|Delcath Hepatic Delivery System|
214225855|NCT02415036|DRUG|Melphalan|
214225856|NCT02553356|DRUG|PT2385|
214225857|NCT01909011|DEVICE|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
214225858|NCT01909011|DEVICE|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
214225859|NCT00695097|DRUG|Rituximab|Rituximab infusion on Day 1 and Day 15
214225860|NCT00695097|DRUG|No Rituximab|No Rituximab
214225861|NCT04994808|DRUG|Clofarabine|Given IV
214225862|NCT04994808|DRUG|Fludarabine|Given IV
214225863|NCT04994808|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214225864|NCT04994808|RADIATION|Total-Body Irradiation|Undergo TBI
214225865|NCT04994808|DRUG|Treosulfan|Given IV
214225866|NCT04994808|PROCEDURE|Echocardiography Test|Undergo ECHO
214225867|NCT04994808|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214225868|NCT04994808|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214225869|NCT04994808|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214225870|NCT04994808|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214225871|NCT04994808|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214225872|NCT07060508|BIOLOGICAL|Single dose of 1800 mg L9LS SC|A human monoclonal antibody to protect against Plasmodium falciparum.
214225873|NCT07060508|OTHER|Placebo|Normal saline
214225874|NCT07060209|DRUG|DW-1021|A fixed-dose combination controlled release film-coated tablet containing pelubiprofen 45 mg and tramadol 45.9 mg (salt form), administered as a single oral dose under fasting and fed conditions in a two-period, two-sequence crossover design. Each subject receives the intervention once under each condition with a 14-day washout period.
214225875|NCT05289037|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214225876|NCT05289037|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
214225877|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.1.529)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
214225878|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.351)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
214225879|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.1)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
214225880|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
214225881|NCT05289037|BIOLOGICAL|CoV2 preS dTM [B.1.351]|Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
214225882|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614|Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
214225883|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614+B.1.351|Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
214225884|NCT05289037|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
214225885|NCT05289037|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
214225886|NCT05289037|BIOLOGICAL|mRNA-1273.529|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
214225887|NCT05289037|BIOLOGICAL|mRNA-1273.617.2|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
214225888|NCT05289037|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
214225889|NCT06247995|DRUG|[68Ga]Ga-NeoB|68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
214225890|NCT06247995|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB is a radioligand therapy drug.
214225891|NCT06247995|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
214225892|NCT06250582|OTHER|virtual reality therapy|A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.
214225893|NCT06780137|BIOLOGICAL|Gocatamig|IV infusion
214225894|NCT06780137|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
214225895|NCT06780137|BIOLOGICAL|Durvalumab|IV infusion
214225896|NCT07073209|PROCEDURE|PENG Block Administration|"Policy for the PENG block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%~While these drugs are administered to participants, the intervention under evaluation is the PENG Block anesthesia technique."
214225897|NCT07073209|PROCEDURE|Femoral Block Administration|"Policy for the Femoral block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg~While these drugs are administered to participants, the intervention under evaluation is the Femoral Block anesthesia technique."
214225898|NCT07073209|DRUG|Bupivacaine , epinephrine Dexamethasone|30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%
214225899|NCT07076459|DRUG|HR091506 tablet|In each period under fed conditions, subjects received oral administration of either HR091506 tablet（T1）, HR091506 tablet（T2）, or HR091506 tablet（R）.
214225900|NCT05554354|DRUG|Binimetinib|Given PO
214225901|NCT05554354|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214225902|NCT05554354|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214225903|NCT05554354|PROCEDURE|Bone Scan|Undergo bone scan
214225904|NCT05554354|PROCEDURE|Computed Tomography|Undergo CT scan
214225905|NCT05554354|PROCEDURE|Echocardiography Test|Undergo ECHO
214225906|NCT05554354|DRUG|Fulvestrant|Given IM
214225907|NCT05554354|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214225908|NCT05554354|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214225909|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
214225910|NCT06811363|OTHER|Metabolic / prescribed diet|Instructed diet (400 mg Ca, 800 mg P, 100 mEq Na) and two liters of distilled water daily for three days (equilibration period), followed by a constant standardized meal with the same composition of Ca, P, and Na for one day. After 240hr urine sample collection patient fasted the preceding evening except for 300 ml of distilled water at 9 pm and 11 pm. On test days, 600 ml distilled water given and fasting blood obtained.
214225911|NCT06811363|OTHER|KCit Load (40 meq)|Potassium citrate load of 40meq will be given after fasting blood has been obtained
214225912|NCT06811363|DRUG|Anti-resorptive agents|Zoledronic acid or Denosumab (as prescribed by their physician)
214225913|NCT06811363|DRUG|Anabolic Agents|Romosozumab (as prescribed by their physician)
214818005|NCT04699799|OTHER|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
214818006|NCT05454111|PROCEDURE|Multiscale entropy-guided ablation plus PVI|The multiscale entropy is calculated based on intracardiac electrical signals, higher multiscale entropy value indicates closer to the core of rotors which maintains the persistent atrial fibrillation.
214818007|NCT05454111|PROCEDURE|CARTO-Finder-guided ablation plus PVI|CARTO-Finder-guided ablation plus PVI
214818008|NCT05530447|DRUG|Samelisant|Tablet
214818009|NCT03426241|OTHER|no intervention|this is cross-sectional study
214225920|NCT06568484|DRUG|Bedaquiline|"CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)"
214225921|NCT06568484|COMBINATION_PRODUCT|Isoniazid, rifapentine|"CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)"
214225922|NCT06568484|DRUG|Levofloxacin|"CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)"
214225923|NCT04453085|DRUG|JR-171|Intravenous (IV) infusion
214225924|NCT05141448|DEVICE|1-Day Acuvue Moist|Run-in Contact Lens
214225925|NCT05141448|DEVICE|EMO-118|Test Lens1
214225926|NCT05141448|DEVICE|EMO-114|Test Lens2
214225927|NCT05141448|DEVICE|MiSight® 1 day|Control Lens
214225928|NCT05429502|DRUG|Topotecan|Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
214225929|NCT05429502|DRUG|Temozolomide|Starting out dose of temozolomide for cohort A1 and A2 for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts, Cohort A3 and onwards, in Phase 1-Part A will initiate at 100mg/m2/day.
214225930|NCT05429502|DRUG|Ribociclib|Starting out dose of ribociclib for cohort A1 Phase 1-Part A: 200mg/m2/day. Starting out dose for Cohort A2 and A3 was 100mg/m2/day.
214225931|NCT07102147|BEHAVIORAL|High Touch Outreach|Gain-framed message, informational flyer, and direct request
214225932|NCT07127549|OTHER|Muscle strength, endurance and balance assessment|All participants were administered a demographic assessment form; the International Physical Activity Questionnaire-Short Form (IPAQ-SF) to assess physical activity level; the Pelvic Floor Distress Inventory (PFDI-20) and all of its subscales to evaluate the severity of symptoms associated with pelvic floor distress; urodynamic measurement; a pad test to assess the severity of UI; a perineometer device to evaluate pelvic floor muscle (PFM) strength; the Sahrmann five-level core stabilization test and the Stabilizer Pressure Biofeedback Unit to assess core muscle strength; McGill's Trunk Endurance Tests for core endurance; and the Y Balance Test to assess balance.
214225933|NCT07131540|DRUG|umbilical cord Mesenchymal Stem Cell|To test the safety and tolerability of ucMSC 1 million/kg will be given intra-venously once a week for 4 week in 10 ACLF patients. 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will be taken from ILBS cGMP facility and will be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
214225934|NCT07137091|OTHER|Gyrokinesis exercise|"1. Warm-Up:~   * Begin with gentle seated movements to prepare the body.~  * Focus on awakening the spine with small circles and undulating motions, coordinating with deep breathing.~2. Seated Exercises:~   * Perform a series of exercises on a stool or chair.~  * Emphasize spinal articulation, pelvic tilts, and side bends while maintaining rhythmic breathing.~3. Floor Work:~   * Transition to mat-based exercises focusing on core strength and flexibility.~  * Incorporate movements like leg lifts, spirals, and arching motions to engage different muscle groups.~4. Standing Series:~   * Conclude with standing exercises to enhance balance and full-body integration.~  * Use spiral movements and weight shifts to energize the body and improve posture."
214225935|NCT06931626|DRUG|NMS-03305293|Route of administration: Oral
214225936|NCT06931626|DRUG|Temozolomide|Route of administration: Oral Commercially available Temozolomide
214225937|NCT06412913|DEVICE|MJ-Flex The New Metaizeau Nail|Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
214225938|NCT06940375|OTHER|Abdominal ultrasound , Fibroscan and body composition analysis examination|Abdominal ultrasound and Fibroscan examinations were conducted to obtain LSM, CAP, and calculate the FAST score. Bioelectrical impedance analysis was performed to obtain the content of subcutaneous and visceral fat.
214225939|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast inducing no reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast without reactive hypoglycaemia at 90minutes
214225940|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast causing reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast causing reactive hypoglycaemia at 90 minutes
214225941|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
214225942|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
214225943|NCT07143656|BIOLOGICAL|Imaging and Clinical Reports|Inclusion of existing imaging data (MRI, EMG reports) and standard clinical documentation, where available.
214225944|NCT06945094|DEVICE|caIMR|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation"
214225945|NCT06945328|PROCEDURE|Upper endoscopy|All patients will do gastroscopy (upper endoscopy) within the first 24 hour of admission and specific elements of bleeding
214225946|NCT06943989|OTHER|Ozone Exposure|6.6 hour exposure to 0.07 ppm ozone while at rest
214225947|NCT06943989|OTHER|Clean air (0.0 ppm ozone)|6.6 hour exposure to clean air (0.00 ppm ozone) while at rest
214225948|NCT04254991|DIAGNOSTIC_TEST|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
214225949|NCT01217307|DRUG|Metformin|Metformin 500mg twice daily during 4 months
214225950|NCT01217307|DRUG|Placebo|Placebo twice daily during 4 months
214225951|NCT01868542|DRUG|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
214225952|NCT02205554|DRUG|Omnitram|Nine 20 mg doses administered every 6 hours
214225953|NCT02205554|DRUG|Tramadol|Nine 50 mg doses administered every 6 hours.
214225954|NCT02205554|DRUG|Placebo|Nine doses administered every 6 hours.
214225955|NCT03027544|RADIATION|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles."
214225957|NCT04240795|DIETARY_SUPPLEMENT|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
214225958|NCT03574519|BEHAVIORAL|Non-contingent incentives|Incentives are provided for participation
214225959|NCT03574519|BEHAVIORAL|Contingent incentives|Incentives are provided for attaining daily goals
214225960|NCT03574519|BEHAVIORAL|Weekly feedback|Text message feedback is delivered weekly summarizing the past week's progress
214225961|NCT03574519|BEHAVIORAL|Daily feedback|Text message feedback is delivered daily summarizing the current day's progress
214225962|NCT03085849|DRUG|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
214225963|NCT03085849|DRUG|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
214225964|NCT03085849|DRUG|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
214225965|NCT02206789|DRUG|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
214225966|NCT02206789|DRUG|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
214225967|NCT02711917|DRUG|MAC 0.5|0.5 MAC Sevoflurane
214225968|NCT02711917|DRUG|MAC 0.75|0.75 MAC Sevoflurane
214225969|NCT02711917|DRUG|MAC 1.0|1.0 MAC Sevoflurane
214225970|NCT02711917|DRUG|Propofol|Propofol consumption
214225971|NCT02711917|DRUG|Etomidate|Etomidate consumption
214225972|NCT02711917|DRUG|Rocuronium|Consumption of Rocuronium
214225973|NCT00073853|PROCEDURE|Autologous Incubated Macrophages (cell therapy)|
214225974|NCT03730792|BEHAVIORAL|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
214225975|NCT00003013|DRUG|CMF regimen|
214225976|NCT00003013|DRUG|cyclophosphamide|
214225977|NCT00003013|DRUG|doxorubicin hydrochloride|
214225978|NCT00003013|DRUG|fluorouracil|
214225979|NCT00003013|DRUG|methotrexate|
214225980|NCT00003013|DRUG|paclitaxel|
214225981|NCT00003013|DRUG|tamoxifen citrate|
214225982|NCT00003013|PROCEDURE|conventional surgery|
214225983|NCT00003013|RADIATION|radiation therapy|
214225984|NCT05317780|DRUG|rAAV9-CB6-AspA|This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
214225985|NCT02248675|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
214225986|NCT02248675|OTHER|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
214225987|NCT04404218|DIETARY_SUPPLEMENT|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
214225988|NCT04404218|OTHER|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
214225989|NCT01282970|DRUG|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
214225990|NCT01282970|DRUG|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
214225991|NCT02512627|BEHAVIORAL|Cognitive training|visuospatial, attention, memory, and executive abilities
214225992|NCT02512627|BEHAVIORAL|Physical exercise|endurance, balance, and mobility
214225993|NCT01024621|DEVICE|Endomicroscope|Pentax EC3870K, Tokyo, Japan
214225994|NCT01024621|DEVICE|Standard endoscopy|Pentax EG-2931 gastroscope
214225995|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
214225996|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
214225997|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
214225998|NCT00395057|DRUG|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
214225999|NCT05232370|DRUG|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
214226000|NCT05232370|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
214226001|NCT05011279|OTHER|Move Together app/Garmin Activity Tracker|"* The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time."
214226002|NCT02800876|OTHER|CT-acquisition|
214226003|NCT02634476|BEHAVIORAL|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
214226004|NCT02634476|BEHAVIORAL|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
214226005|NCT00813943|DRUG|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
214226006|NCT00813943|DRUG|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
214226007|NCT00813943|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
214226008|NCT00813943|RADIATION|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
214226009|NCT04153734|DRUG|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
214226010|NCT04153734|DRUG|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
214226011|NCT04153734|DRUG|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
214226012|NCT04153734|DRUG|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
214226013|NCT04153734|DRUG|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
214226014|NCT02529228|OTHER|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
214226015|NCT02529228|OTHER|Protein Composition|Consuming meals with higher or lower protein.
214226016|NCT00679445|DEVICE|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
214226017|NCT04742582|DIETARY_SUPPLEMENT|Preterm Infants - fed fermented formula|Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)
214226018|NCT04742582|OTHER|Preterm Infants - fed standard formula|Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)
214226019|NCT04742582|OTHER|Pre-term Infants - breastfed|Breastfeeding infants - Reference group
214226020|NCT02551991|DRUG|nal-IRI|
214226021|NCT02551991|DRUG|5 fluorouracil|
214226022|NCT02551991|DRUG|Leucovorin|
214226023|NCT02551991|DRUG|Oxaliplatin|
214226024|NCT03689309|PROCEDURE|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
214226025|NCT06343857|DIAGNOSTIC_TEST|self-assessment questionnaire|Completion of the anatomical site-specific self-assessment questionnaire.
214226026|NCT05676775|OTHER|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
214226027|NCT03540550|OTHER|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
214226028|NCT02909387|BEHAVIORAL|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
214226029|NCT04982601|OTHER|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
214226030|NCT00643721|OTHER|dehydration|dehydration to 3% and 5% loss of total body water
214226031|NCT00755638|BIOLOGICAL|ACE-031|single subcutaneous dose of ACE-031
214226032|NCT05197660|PROCEDURE|surgical procedures|number of hospital stays
214226033|NCT02224885|DEVICE|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
214226034|NCT00973297|OTHER|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
214226035|NCT05857696|OTHER|walking quantified analysis|Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
214226036|NCT01145586|DRUG|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
214226037|NCT01122056|OTHER|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
214651157|NCT00675597|DRUG|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
214651158|NCT03587532|DIAGNOSTIC_TEST|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
214226038|NCT01766258|DRUG|ODM-101 65mg Carbidopa|
214226039|NCT01766258|DRUG|ODM-101 105mg Carbidopa|
214226040|NCT01766258|DRUG|Stalevo|
214226041|NCT00673530|BEHAVIORAL|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
214226042|NCT00673530|BEHAVIORAL|care as usual|Unchanged treatment of hospital patients without interference by the study.
214226043|NCT06312124|BEHAVIORAL|Educational Module|Part 1 consists of an education module with premodule and postmodule assessment questionnaires.
214226044|NCT06312124|PROCEDURE|Salpingectomy|Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
214226045|NCT01515020|DRUG|vancomycin monotherapy|intravenous therapy by vancomycin
214226046|NCT01515020|DRUG|daptomycin monotherapy|intravenous therapy by daptomycin
214226047|NCT02780011|DRUG|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
214226048|NCT02780011|DRUG|Alsertib|Aurora A kinase inhibitor
214226049|NCT01567709|DRUG|Alisertib|Given PO
214226050|NCT01567709|OTHER|Laboratory Biomarker Analysis|Correlative studies
214226051|NCT01567709|OTHER|Pharmacological Study|Correlative studies
214226052|NCT01567709|DRUG|Vorinostat|Given PO
214226053|NCT04309097|BEHAVIORAL|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
214226054|NCT04309097|BEHAVIORAL|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
214226055|NCT05190926|BEHAVIORAL|Smart-Treatment for Anorexia Nervosa Recovery (STAR)|"Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes."
214226056|NCT05190926|BEHAVIORAL|Present-focused Anorexia Nervosa Coping Treatment (PACT)|Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
214226057|NCT05971706|DEVICE|Ozone therapy using a device (Ozone DTA Ozone Generator, Denta Tec Dental AS, Norway)|Ozone therapy procedures will be performed immediately after non-surgical periodontal treatment and three times (every third day) within one week using a device equipped with a periodontal tip according to equipment producer recommendations. The periodontal tip will be halted 1 mm short of the pocket depth. Ozone will be applied only to the pockets; which depth is equal to or greater than 5 mm. Ozone application time to the pockets will be 30 seconds at a fixed concentration of 2,100 ppm (80% oxygen) through a connected handpiece.
214226058|NCT05971706|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment consists of oral hygiene instructions, full mouth supragingival scaling using hand instruments, ultrasonic devices, polishing, and subgingival debridement under local anesthesia with sharp Gracey and Universal curettes and ultrasonic instruments in a single appointment.
214226059|NCT00984620|DRUG|BI 201335|BI 201335
214226060|NCT00984620|DRUG|BI 201335|BI 201335
214226061|NCT00984620|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
214226062|NCT00984620|DRUG|Ribavirin (RBV)|Ribavirin (RBV)
214226063|NCT05533580|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
214226064|NCT05533580|DRUG|Propofol|The control group was sedated with propofol.
214226065|NCT02262208|OTHER|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
214226066|NCT02262208|OTHER|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
214226067|NCT02262208|DEVICE|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
214226068|NCT05025436|DEVICE|Acupoint stimulation with low energy laser (Erger laser pen)|Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
214226069|NCT03346642|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
214226070|NCT03346642|DRUG|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
214226071|NCT03346642|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
214226072|NCT03209128|RADIATION|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
214226073|NCT01920685|OTHER|Anxiety intervention|
214226074|NCT05311813|DRUG|Enoxaparin, Hydroxychloroquine|To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
214226075|NCT02424578|DRUG|Diclofenac Capsules low dose|
214226076|NCT02424578|DRUG|Diclofenac Capsules high dose|
214226077|NCT03899467|DRUG|GT0918|anti-tumor activity
214226078|NCT01386866|DRUG|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
214226079|NCT03695770|OTHER|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
214226080|NCT02909608|OTHER|No interventions / observations only|This is an observational study only
214226081|NCT03684369|DEVICE|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
214226082|NCT06396910|DIAGNOSTIC_TEST|Spatial transcriptomics|Localize immune transcripts in the pulmonary lessions of sarcoidosis and tuberculosis patients. This is done in biopsies from pathological libraries.
214226083|NCT00254189|DRUG|Levonorgestrel|
214226084|NCT00254189|DRUG|Ethinyl Estradiol|
214226085|NCT01302145|DRUG|ASP1941|Tablet
214226086|NCT01302145|DRUG|Metformin|Tablet
214226087|NCT01302145|DRUG|Placebo|Tablet
214226088|NCT02581150|PROCEDURE|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
214226089|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin I
214226090|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin II
214226091|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula without Inulin
214226092|NCT05953233|OTHER|Active classroom HEPA cleaner|Commercially available portable HEPA cleaner
214226093|NCT05953233|OTHER|Sham classroom HEPA cleaner|Commercially available portable HEPA cleaner with filtration device removed
214226094|NCT00470834|DRUG|dutasteride|0.5mg dutasteride (Investigation Product)
214226095|NCT00470834|DRUG|placebo|making placebo
214226096|NCT00470834|DRUG|bicalutamide|50 mg Casodex or generic equivalent
214226097|NCT00244140|DRUG|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
214226098|NCT00244140|DRUG|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
214226099|NCT05260918|OTHER|Float-REST|Participants will utilize sensory deprivation tanks.
214226100|NCT05260918|OTHER|Nappod|Participants will utilize nappod.
214226101|NCT05152225|DIAGNOSTIC_TEST|Brain MRI|Brain MRI performed routinely in patients with EI
214226102|NCT05152225|DIAGNOSTIC_TEST|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
214226103|NCT05580445|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
214226104|NCT05580445|DRUG|Toripalimab|Programmed Death 1(PD-1) antibody
214226105|NCT05580445|DRUG|Gemcitabine|nucleoside inhibitor
214651159|NCT03587532|DIAGNOSTIC_TEST|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
214651160|NCT03587532|DIAGNOSTIC_TEST|Biological and pathological markers of ischemia|"* Systemic and local capillary lactate on blood samples~* Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~* Pathological analyses of the biopsies at 3 ROI"
214226106|NCT05192447|BEHAVIORAL|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
214226107|NCT05330104|BEHAVIORAL|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
214226108|NCT05682222|DRUG|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
214226109|NCT05682222|DRUG|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
214226110|NCT05682222|DRUG|Placebo oral capsule|Placebo.
214818010|NCT01762709|PROCEDURE|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
214226119|NCT05605951|OTHER|non-interventional study|observational study
214226120|NCT03541395|DRUG|GnRH antagonist|
214226121|NCT05428124|OTHER|In vitro fertilisation|In vitro fertilisation
214226122|NCT05922670|BEHAVIORAL|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
214226123|NCT01174433|DEVICE|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
214226124|NCT01538784|DRUG|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"
214651161|NCT02714166|OTHER|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
214226125|NCT05553834|COMBINATION_PRODUCT|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
214226126|NCT05357261|BEHAVIORAL|Wellness Check and Socialization|In-home delivery with opportunity for driver observation and interaction
214226127|NCT05357261|OTHER|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
214226128|NCT04255745|BEHAVIORAL|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
214226129|NCT05408637|DEVICE|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
214226130|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
214226131|NCT04509622|DRUG|Venetoclax|Tablet; Oral
214226132|NCT04509622|DRUG|Cytarabine|Subcutaneous Injection
214226133|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
214226134|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
214226135|NCT05025956|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
214226136|NCT05025956|DRUG|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
214226137|NCT00079365|DRUG|fluorouracil|
214226138|NCT00079365|DRUG|gemcitabine hydrochloride|
214226139|NCT00079365|RADIATION|brachytherapy|
214226140|NCT00079365|RADIATION|phosphorus P32|
214226141|NCT00079365|RADIATION|radiation therapy|
214226142|NCT06363942|OTHER|SAFE program (exercise intervention)|Participants will be asked to carry out the SAFE program with the help of a caregiver. Our healthcare professionals will visit them during the first week to explain to them and their caregivers how to perform the exercises correctly while using our website. All exercises will be performed using video capsules available on our website (https://safe-seniors.com/fr). The exercises are divided into 4 levels of difficulty: level 1 (light); level 2 (moderate); level 3 (moderate to vigorous); and level 4 (vigorous). Each level lasts 25 to 30 minutes and includes 5 exercise categories split into 5 videos: warm-up, strength, balance, flexibility, and endurance. The exercise intervention will include 3 sessions per week over 12 weeks.
214226143|NCT06331728|DRUG|IGNX001|IGNX001 given as a single subcutaneous dose on Day 1.
214226144|NCT06331728|DRUG|Placebo|Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
214226145|NCT05712707|DRUG|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
214226146|NCT05712707|DRUG|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
214226147|NCT05712707|OTHER|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
214226148|NCT05712707|OTHER|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
214226149|NCT02992444|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
214226150|NCT02992444|OTHER|Experimental adhesive strip|This is a strip of a newly developed adhesive.
214226151|NCT04975438|DRUG|GSK1070806|GSK1070806 will be administered
214226152|NCT04975438|DRUG|Placebo|Placebo will be administered
214226153|NCT06454409|DRUG|Azacitidine|Given IV
214226154|NCT06454409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214226155|NCT06454409|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214226156|NCT06454409|DRUG|Regorafenib|Given PO
214226157|NCT06454409|DRUG|Venetoclax|Given PO
214226158|NCT04856462|BEHAVIORAL|Education Support|Caregivers engage in a weekly video/teleconference support group with a skilled facilitator to discuss various strategies for managing caregiving stress, challenging behaviors, and personal self-care.
214226159|NCT05372718|DRUG|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
214226160|NCT05372718|PROCEDURE|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
214226161|NCT02693132|BEHAVIORAL|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
214226162|NCT02693132|BEHAVIORAL|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
214226163|NCT02693132|BEHAVIORAL|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
214226164|NCT05840757|DEVICE|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
214226165|NCT05743959|PROCEDURE|No intervention|No intervention
214226166|NCT03251313|COMBINATION_PRODUCT|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
214226167|NCT03251313|COMBINATION_PRODUCT|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
214226168|NCT03251313|COMBINATION_PRODUCT|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
214226169|NCT03251313|COMBINATION_PRODUCT|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
214226170|NCT04615832|DEVICE|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
214226171|NCT02213861|DRUG|SHAPE|topical gel
214226172|NCT00492128|DRUG|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
214226173|NCT04145232|BIOLOGICAL|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
214226174|NCT01276054|RADIATION|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
214226175|NCT01276054|DRUG|methylene blue|Given subcutaneously
214226176|NCT01276054|DRUG|indocyanine green solution|Given subcutaneously
214226177|NCT01276054|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
214226178|NCT01276054|PROCEDURE|axillary lymph node biopsy|Undergo axillary lymph node biopsy
214226179|NCT01276054|PROCEDURE|bioimpedance spectroscopy|Correlative studies
214226180|NCT01276054|PROCEDURE|quality-of-life assessment|Ancillary studies
214226181|NCT01276054|OTHER|lymphedema management|Undergo axillary reverse mapping
214226182|NCT05986396|DEVICE|INSPIRIS Resilia (model 11500A)|Aortic Valve
214226183|NCT00534482|BEHAVIORAL|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
214226184|NCT00534482|BEHAVIORAL|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
214226185|NCT00534482|BEHAVIORAL|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
214651162|NCT02714166|OTHER|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
214651163|NCT06192173|PROCEDURE|Percutaneous PFO closure|Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.
214651164|NCT01469559|DRUG|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
214651165|NCT01469559|DRUG|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
214226186|NCT00534482|BEHAVIORAL|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
214226187|NCT02640508|DRUG|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
214226188|NCT02640508|DRUG|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
214651166|NCT02104284|PROCEDURE|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
214226189|NCT02707575|DRUG|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
214226190|NCT03924856|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
214226191|NCT03924856|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
214226192|NCT03924856|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
214226193|NCT03924856|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
214226194|NCT03924856|DRUG|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
214226195|NCT05071768|BEHAVIORAL|Focused ACT|Brief acceptance and commitment therapy
214226196|NCT00932178|BEHAVIORAL|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
214226197|NCT02703441|OTHER|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
214226198|NCT03202615|DIETARY_SUPPLEMENT|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
214226199|NCT03202615|DRUG|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
214226200|NCT02776397|DIETARY_SUPPLEMENT|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
214226201|NCT02776397|OTHER|Placebo|Placebo arm
214226202|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^11 DRP/mL
214226203|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
214226204|NCT00126724|GENETIC|tgAAC94 placebo|placebo
214226205|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^12 DRP/mL tgAAC94
214226206|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
214226207|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^13 DRP/mL tgAAC94
214226208|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
214226209|NCT04780997|OTHER|Virtual Reality|Microsoft Xbox Kinect® was used for virtual reality exercises
214226210|NCT01168986|OTHER|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
214226211|NCT01168986|OTHER|Exercise|Participants perform an exercise to strengthen the deep neck flexors
214226212|NCT02842190|DEVICE|NIPPV|after ekstubation
214226213|NCT05405257|DRUG|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
214226214|NCT05405257|OTHER|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
214226215|NCT06584383|PROCEDURE|Exablate MRgFUS subthalamotomy|Exablate MRgFUS subthalamotomy for Parkinson's Disease
214226216|NCT06584383|DRUG|Best Medical Treatment|Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
214226217|NCT03791099|DRUG|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
214651167|NCT05401266|PROCEDURE|mild hypercapnia|Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
214651168|NCT00134628|PROCEDURE|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
214226218|NCT00220129|DRUG|Epirubicin, Cisplatin, Capecitabine|
214226219|NCT00220129|PROCEDURE|Surgical Resection|
214226220|NCT04267484|DEVICE|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
214226221|NCT04267484|OTHER|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
214226222|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
214226223|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
214226224|NCT01280877|DEVICE|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
214226225|NCT01280877|DEVICE|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
214226226|NCT03126318|DRUG|COR-001|Anti-inflammatory therapy
214226227|NCT03126318|DRUG|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
214651169|NCT00134628|PROCEDURE|Sham treatment|Normal air under pressure (1.1 ATA)
214651170|NCT00832897|PROCEDURE|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
214226233|NCT00776919|DRUG|clindamycin / benzoyl peroxide gel|Once a day application to the face
214226234|NCT00776919|DRUG|clindamycin gel|Once a day application to the face
214226235|NCT00776919|DRUG|BPO gel|Once a day application to the face
214226236|NCT00776919|DRUG|vehicle gel|Once a day application to the face
214226237|NCT01162837|DEVICE|BEAM device|A red/blue LED device for the treatment of acne
214226238|NCT02481128|PROCEDURE|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
214226239|NCT01739062|GENETIC|Genetic risk assessment|
214226240|NCT03453138|DEVICE|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
214226241|NCT03453138|DEVICE|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
214226242|NCT01794286|OTHER|Provider bulletins|
214226243|NCT01794286|OTHER|Trigger alerts|
214226244|NCT03803319|DIETARY_SUPPLEMENT|Fibre 1 (combined fibres)|Dietary fibre supplement
214226245|NCT03803319|DIETARY_SUPPLEMENT|Fibre 2 (natural fibres)|Dietary fibre supplement
214226246|NCT03803319|DIETARY_SUPPLEMENT|Dietary Supplement: placebo|Dietary supplement
214226247|NCT02745015|PROCEDURE|non-surgical periodontal treatment|full-mouth scaling and root planing
214226248|NCT00275340|OTHER|Peer Support|
214226249|NCT00004908|DRUG|cyclophosphamide|
214226250|NCT00004908|PROCEDURE|peripheral blood stem cell transplantation|
214226251|NCT00004908|RADIATION|radiation therapy|
214226252|NCT00002771|BIOLOGICAL|recombinant interferon alfa|
214226253|NCT00002771|DRUG|busulfan|
214226254|NCT00002771|DRUG|cytarabine|
214226255|NCT00002771|DRUG|hydroxyurea|
214226256|NCT00002771|DRUG|idarubicin|
214226257|NCT00002771|PROCEDURE|allogeneic bone marrow transplantation|
214226258|NCT00002771|PROCEDURE|autologous bone marrow transplantation|
214651171|NCT00759070|DRUG|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~\+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
214226259|NCT00002771|PROCEDURE|peripheral blood stem cell transplantation|
214226260|NCT00002771|RADIATION|radiation therapy|
214226261|NCT02672293|DRUG|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
214226262|NCT06443931|PROCEDURE|cryoablation of intercostal nerves|"Patients in the CryoINB group will undergo cryoablation of the intercostal nerves, at the end of surgery before weaning from CPB, using the ArtiCue device for 120 seconds at a temperature of -50°C to -70°C, in the intercostal spaces where the surgical approach is located, one intercostal space above and one below it. Cold leads to axonotmesis, in which the axon and myelin sheath are damaged, preventing the pain signal from traveling along the sensory nerve. However, the structural elements of the nerve are preserved, which promotes complete regeneration at a rate of 1-2 mm per day, thereby restoring normal function within several months."
214226263|NCT01469715|DEVICE|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
214226264|NCT03705013|OTHER|Cologuard|Observational
214226265|NCT00851227|DRUG|conivaptan hydrochloride|intravenous
214226266|NCT01966718|DRUG|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
214226267|NCT03305497|BEHAVIORAL|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
214226268|NCT04587609|BEHAVIORAL|Free Phone Mounts|Participants will receive free phone mounts
214226269|NCT04587609|BEHAVIORAL|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
214226270|NCT04587609|BEHAVIORAL|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
214226271|NCT04587609|BEHAVIORAL|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
214651172|NCT00759070|DRUG|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
214651173|NCT01014403|DRUG|enoxaparin|Enoxaparin 30 mg sq q 12 hours
214651174|NCT01014403|DRUG|placebo|vehicle
214651175|NCT03668574|OTHER|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
214651176|NCT03668574|OTHER|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
214226272|NCT04587609|BEHAVIORAL|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
214226273|NCT06291519|OTHER|Multi-sensory Stimulation Method-Mother Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated before vaccination.~2. nd stimulus (sense of touch),: The mother applied touch - a light massage for 5 min until the vaccination process. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The mother spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The mother made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
214226274|NCT06291519|OTHER|Multi-sensory Stimulation Method-Nurse Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated 5 min before vaccination.~2. nd stimulus (sense of touch),: The nurse applied touch - a light massage for 5 minutes until the vaccination. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The nurse spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The nurse made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
214226275|NCT06291519|OTHER|Breastfeeding Applied Group|"Multisensory stimulus method not applied:~The baby was breastfed by its mother for 20 minutes. Breastfeeding was stopped just before the vaccination."
214226276|NCT02865876|PROCEDURE|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
214226277|NCT04660916|DRUG|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
214226278|NCT00430976|BEHAVIORAL|Minds in Motion|
214226279|NCT00764764|PROCEDURE|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
214226280|NCT00764764|PROCEDURE|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
214226281|NCT02379637|DRUG|N-acetylcysteine|
214226282|NCT02379637|DRUG|Placebo|
214226283|NCT04045002|OTHER|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
214226284|NCT04759326|OTHER|Hippotherapy|Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
214226285|NCT04759326|OTHER|Conventional Neurorehabilitation|The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
214226286|NCT04454853|OTHER|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
214226287|NCT04454853|OTHER|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
214226288|NCT04454853|OTHER|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
214226289|NCT00665808|DRUG|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
214651177|NCT02500186|DRUG|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
214651178|NCT02500186|OTHER|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
214651179|NCT01629745|GENETIC|gene expression analysis|
214651180|NCT01629745|OTHER|flow cytometry|
214226290|NCT00665808|DRUG|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
214226291|NCT01110148|OTHER|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
214226292|NCT01110148|OTHER|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
214226293|NCT00862641|DRUG|Regadenoson|IV
214226294|NCT00862641|DRUG|Placebo|IV
214226295|NCT03795272|DRUG|Rucaparib|2:1 randomization to receive rucaparib/placebo twice daily for 24 month
214226296|NCT03795272|DRUG|Placebo|placebo
214226297|NCT00420043|DRUG|imatinib|
214226298|NCT05149521|OTHER|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
214226299|NCT00511368|DRUG|matching placebo|
214226300|NCT00511368|DRUG|Bevirimat|
214226301|NCT02176252|DRUG|AZD1722|
214226302|NCT02176252|DRUG|Placebo|
214226303|NCT00238342|GENETIC|proteomic profiling|
214226304|NCT00238342|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
214226305|NCT00238342|PROCEDURE|biopsy|
214226306|NCT05816499|DRUG|Cadonilimab|Given IV, 10mg/kg Q3W
214226307|NCT05816499|DRUG|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
214226308|NCT05816499|DRUG|Docetaxel|Given IV, 60-75mg/m2 Q3W
214226309|NCT04242641|BEHAVIORAL|WW|WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
214226310|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
214226311|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
214226312|NCT06143904|DRUG|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
214226313|NCT02365480|DRUG|Berberine Chloride|Given PO
214226314|NCT02365480|OTHER|Laboratory Biomarker Analysis|Correlative studies
214226315|NCT02365480|OTHER|Placebo Administration|Given PO
214226316|NCT03512938|PROCEDURE|Non-surgical periodontal therapy|Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
214226317|NCT03091348|DRUG|Testosterone|Testosterone cypionate injection
214226318|NCT02791763|DRUG|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
214226319|NCT02791763|DRUG|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
214226320|NCT02791763|DRUG|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
214226321|NCT02048319|DRUG|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
214226322|NCT02048319|PROCEDURE|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
214226323|NCT02048319|DRUG|Placebo|Saline solution, injected as placebo
214226324|NCT03617328|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214226325|NCT03617328|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
214226326|NCT03617328|DRUG|polyICLC|polyICLC, local adjuvant
214226327|NCT03617328|DRUG|CDX-1127|CDX-1127, anti-CD27 monoclonal antibody
214226328|NCT01716403|BIOLOGICAL|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
214226329|NCT02722018|DRUG|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
214226330|NCT02722018|DRUG|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
214226331|NCT02086513|DRUG|LDE225|Treatment with LDE225
214226332|NCT06035419|OTHER|education|breastfeeding education for migrant mothers
214226333|NCT03144934|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
214226334|NCT03144934|DRUG|Placebo|This is the placebo of GX-I7 described above.
214226335|NCT05243693|DRUG|Brentuximab vedotin|3 cycles of Brentuximab vedotin and DHAP
214226336|NCT04534686|BEHAVIORAL|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
214226337|NCT04534686|BEHAVIORAL|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
214226338|NCT00706342|DRUG|Fostamatinib Disodium / R935788|R935788 tablets
214226339|NCT03941704|DIETARY_SUPPLEMENT|Pulse-based diet|Low Glycemic Index
214226340|NCT03941704|DIETARY_SUPPLEMENT|Regular diet|Moderate Glycemic Index
214651181|NCT01629745|OTHER|laboratory biomarker analysis|
214226341|NCT01034670|DEVICE|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
214226342|NCT01034670|DEVICE|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
214226343|NCT01034670|DEVICE|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
214226344|NCT01034670|DRUG|fluorescent Peptide|microdosing; Topical through the endoscope
214226345|NCT01034670|DRUG|fluorescein|100 mcg topical
214226346|NCT01034670|DRUG|indocyanine green|100 mcg topical
214226347|NCT01284036|DRUG|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
214226348|NCT01319604|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
214226349|NCT01319604|DEVICE|Tonometer|Tonometric assessment of IOP
214226350|NCT04383418|DRUG|dexmedetomidine nasal spray|dexmedetomidine nasal spray
214226351|NCT04383418|DRUG|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
214226352|NCT00097604|DIETARY_SUPPLEMENT|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
214226353|NCT05282134|PROCEDURE|Wet cupping therapy|Wet cupping therapy is a bloodletting application done by cups on the skin
214226354|NCT05282134|PROCEDURE|Acupuncture|Acupuncture is a complementary application of TCM done by needles
214226355|NCT04762719|DRUG|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
214226356|NCT04762719|DIAGNOSTIC_TEST|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
214226357|NCT04692636|DIAGNOSTIC_TEST|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
214226358|NCT02254954|DRUG|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
214226359|NCT02001636|DRUG|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
214226360|NCT02001636|DRUG|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
214226361|NCT01630538|DRUG|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
214226362|NCT04492332|DIAGNOSTIC_TEST|standard lumbar puncture|Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
214226363|NCT00888043|DRUG|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose"
214226364|NCT02340871|GENETIC|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
214226365|NCT03899181|DEVICE|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
214226366|NCT03899181|OTHER|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
214226367|NCT01419197|DRUG|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change \> 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
214464689|NCT06802692|BEHAVIORAL|VR glasses and meditation music group|Starting 15 minutes before the ET procedure, participants in the VR glasses and meditation music group will be shown a video of the sea, underwater and forest with VR glasses and will be made to listen to meditation music. At the same time, meditation music will be played. When the ET procedure is completed, the video and meditation music will be stopped. After the procedure, the VR glasses will be disinfected with antiseptic spray before being used on another patient, and disposable ear pads will be placed on the headphones after each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be evaluated 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure, the application of VR glasses and listening to meditation music will be evaluated.
214226368|NCT01419197|DRUG|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
214226369|NCT01929811|DRUG|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
214226370|NCT01929811|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
214226371|NCT01929811|DRUG|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
214226372|NCT01929811|DRUG|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
214226373|NCT05726188|PROCEDURE|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
214226374|NCT05071248|DEVICE|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
214226375|NCT02465424|OTHER|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
214226376|NCT04858022|BEHAVIORAL|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
214226377|NCT04858022|OTHER|No treatment - waitlist|10-week period of no treatment
214226378|NCT01612806|DEVICE|PriMatrix|fetal bovine dermal scaffold
214226379|NCT01612806|DEVICE|PriMatrix Ag|fetal bovine dermal scaffold with Ag
214226380|NCT01612806|PROCEDURE|moist wound therapy|standard of care moist wound therapy
214226381|NCT03692819|DRUG|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
214226382|NCT03692819|DRUG|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
214226383|NCT03692819|DRUG|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
214226384|NCT03123406|DRUG|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
214226385|NCT05950386|OTHER|Lead exposure|The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
214226386|NCT03114319|DRUG|TNO155|TNO155 for oral administration
214226387|NCT03114319|DRUG|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
214651182|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
214226388|NCT02410343|DRUG|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
214226389|NCT02410343|DRUG|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
214226390|NCT06518395|OTHER|Questionnaire for The degree of knowledge and attitude.|Questionnaire for The degree of knowledge and attitude of Egyptian nurses regarding the emergency treatment of traumatic dental injuries
214226391|NCT05178797|OTHER|Kinesiology taping technique with exercise therapy|Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
214226392|NCT05178797|OTHER|Compression decongestive therapy|"It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma."
214651183|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
214651184|NCT06548139|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
214226393|NCT03892278|BEHAVIORAL|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
214226394|NCT03892278|BEHAVIORAL|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
214226395|NCT03892278|BEHAVIORAL|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
214226396|NCT00799214|DRUG|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
214226397|NCT00799214|DRUG|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
214226398|NCT00799214|DRUG|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
214226399|NCT02428478|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
214226400|NCT02428478|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
214226401|NCT02663934|BEHAVIORAL|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
214226402|NCT02663934|BEHAVIORAL|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
214226403|NCT06344897|OTHER|Kinesio taping|After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
214226404|NCT01563133|PROCEDURE|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
214226405|NCT01563133|DEVICE|nCLE|needle-based Confocal Laser Endomicroscopy
214226406|NCT04423341|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg BID for three months Placebo oral solution for three months
214226407|NCT05339997|OTHER|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
214226408|NCT02878798|DRUG|topiramate|Oral topiramate at a target dose of 50mg twice daily.
214226409|NCT02878798|OTHER|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
214226410|NCT02396472|BEHAVIORAL|Order by time and topic|
214226411|NCT02396472|BEHAVIORAL|Order by information relevance|
214226412|NCT02396472|BEHAVIORAL|Order by social relationship|
214226413|NCT02396472|BEHAVIORAL|Order by help giving|
214226414|NCT02396472|BEHAVIORAL|Order by self-disclosure|
214226415|NCT04952935|PROCEDURE|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
214226416|NCT04952935|PROCEDURE|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
214226417|NCT06081933|DRUG|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
214226418|NCT06081933|DRUG|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
214226419|NCT01110642|DRUG|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
214651185|NCT06548139|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
214651186|NCT03137615|PROCEDURE|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
214651187|NCT03137615|DRUG|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
214651188|NCT00364299|DEVICE|Automatic control of tracheal tube cuff pressure|
214226420|NCT03572608|OTHER|Acupuncture treatment|Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
214226421|NCT05589558|PROCEDURE|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
214226422|NCT06415500|DRUG|NK042|NK042 intraperitoneal infusion on Days 0,7 and 14.
214226423|NCT00246740|DRUG|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
214226424|NCT00246740|DRUG|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
214226425|NCT05519722|BEHAVIORAL|Expectation-focused online intervention|Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
214226426|NCT03153722|PROCEDURE|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
214226427|NCT02215980|DRUG|Lenalidomide|
214226428|NCT02215980|DRUG|Dexamethasone|
214226429|NCT06416579|OTHER|Schroth Exercise Group|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. The exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
214226430|NCT06416579|OTHER|Schroth Method Based Virtual Reality Group|During Schroth method-based virtual reality exercises, continuity in stabilization will be ensured by using external focus and muscular activation in positions appropriate to the Schroth method and in corrected posture. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Warm-up and cool-down will consist of aerobic games available in Nitendo wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis and Baseball will be included in the program. Progression will be made by difficulty level and positional in all games. The exercises will be made more difficult by side sitting, side sitting on a stool, sitting position, knight position, standing, sitting on a balance ball, standing on a soft floor, on a bosu ball and moving towards the balance board.
214226431|NCT06416579|OTHER|Control Group|Participants in the control group will be placed on a waiting list for 24 weeks. Participants will not receive any exercise intervention for 24 weeks and will be able to continue their routine physical activities.
214226432|NCT02236117|OTHER|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, \>80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
214226433|NCT01510769|DRUG|Lesinurad|Tablets, 400 mg once daily (QD)
214226434|NCT01510769|DRUG|Lesinurad|Tablets, 200 mg QD
214226435|NCT01510769|DRUG|Placebo|Tablets, Placebo QD
214226436|NCT01510769|DRUG|Febuxostat|80 mg
214464690|NCT06802692|BEHAVIORAL|Meditation music group|Meditation music group participants will listen to meditation music through headphones starting from 15 minutes before the ET procedure until the procedure is completed. When the ET procedure is completed, the meditation music will be stopped. After the procedure, disposable ear pads will be placed on the headphones for each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be assessed 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure and listening to meditation music will be assessed.
214651189|NCT00591695|PROCEDURE|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
214651190|NCT00591695|PROCEDURE|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
214226437|NCT06803628|OTHER|Point of care ultrasound|"OCCLUS-POCUS will include patients with suspected SBO, with low or moderate Gestalt probability who meet the inclusion criteria During the patient's visit to the ED, the investigating physician will present the study and the importance of evaluating the value of POCUS in the diagnosis of exclusion of SBO. Once oral non-opposition to the study has been obtained, the participation of the patient lasts 28 days.~POCUS is performed only for patients with low or moderate Gestalt probability. It will be performed by trained emergency physicians (EP) using a curvilinear probe . After POCUS realization, the EP will:~* determine if there is presence or absence of SBO.~* collect POCUS duration, difficulty and investigator's characteristics.~* Realization of CT which will be the gold standard for SBO presence or absence.~* The study protocol procedure ends when the report of the CT is available and the physician establish its diagnosis.~* The study ends at D28 with a phone call"
214226438|NCT03815318|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
214226439|NCT00964210|DRUG|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
214226440|NCT02230917|DRUG|Sotatercept|
214226441|NCT02230917|DRUG|Placebo|
214226442|NCT04388462|OTHER|Finite element analysis|Biomechanical study to describe micromotion
214226443|NCT05927337|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for managing Obesity|Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
214226444|NCT00335764|DRUG|sorafenib tosylate|given orally
214226445|NCT00335764|DRUG|erlotinib hydrochloride|given orally
214226446|NCT00335764|DRUG|tipifarnib|given orally
214226447|NCT00335764|DRUG|temsirolimus|IV administration
214226448|NCT01383148|BIOLOGICAL|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
214226449|NCT01383148|DRUG|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1"
214226450|NCT01442844|DEVICE|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
214226451|NCT00460291|DEVICE|Implantation of the ProVena vein graft during bypass surgery|
214226452|NCT02466659|DEVICE|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
214226453|NCT00363701|DRUG|esomeprazole|
214226454|NCT02937402|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
214226455|NCT02937402|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
214226456|NCT00744302|DRUG|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
214226457|NCT00929643|OTHER|no intervention|success of the initial empiric treatment
214226458|NCT02212184|OTHER|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
214464691|NCT06799663|OTHER|activity questionnaire|Physical activity questionnaire will be applied on children and adolescents to compare the effect of smart phone on physical fitness
214464692|NCT06799663|OTHER|Raven's Progressive Matrices test (RPM)|Raven's Progressive Matrices test will be applied on children and adolescents to compare the effect of smart phone on intelligence
214464693|NCT06799663|OTHER|Postural assessment software|Postural assessment software will be applied on children and adolescents to compare the effect of smart phone on posture
214464694|NCT06799104|OTHER|Pyramidal training|"Pyramidal training prescription:Mode of exercise: aerobic interval training. Intensity: ranging from 20-80% from THR. Duration: 40 minutes per session.Frequency: Three sessions per week for 12 weeks.~The course of the program will be 2 sets of pyramidal training with 10 minutes for rest between them. Each set will be 5 levels of incremental and 5 levels of decremental aerobic exercise and each level 2 minutes on a treadmill.~1. Level one: will be set as a 20% walking of Karvonen formula.~2. Level two: will be set as a 30% running of Karvonen formula.~3. Level three: will be set as a 50%running of Karvonen formula.~4. Level four: will be set as a 70% running of Karvonen formula.~5. Level five: will be set as a 80% running of Karvonen formula."
214464695|NCT06799104|OTHER|Mediterranean diet|"Mediterranean diet:~Meal Composition Main meals consumed daily should be a combination of three elements: cereals, vegetables and fruits, and a small quantity of legumes, beans or other (though not in every meal). Cereals in the form of bread, pasta, rice, couscous or bulgur (cracked wheat) should be consumed as one-two servings per meal. Vegetable consumption should amount to two or more servings per day, in raw form for at least one of the two main meals (lunch and dinner). Fruit should be considered as the primary form of dessert, with one-two servings per meal."
214226459|NCT02212184|OTHER|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
214226460|NCT05413174|BEHAVIORAL|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
214226461|NCT04541771|DRUG|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
214226462|NCT04541771|DRUG|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
214226463|NCT01980485|BEHAVIORAL|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
214226464|NCT01980485|BEHAVIORAL|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
214226465|NCT00375206|BIOLOGICAL|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
214226466|NCT02747472|DRUG|GIP-A|GIP receptor antagonist
214226467|NCT02747472|DRUG|GIP(1-42)|GIP receptor agonist
214226468|NCT02747472|OTHER|Saline|Placebo
214226469|NCT03929094|DRUG|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
214226470|NCT03929094|DRUG|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
214226471|NCT04636983|DRUG|BV100|Rifabutin IV
214226472|NCT04636983|DRUG|Placebo|Saline
214226473|NCT04039009|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
214226474|NCT05928546|DRUG|Quercetin|"Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket ."
214226475|NCT05928546|DEVICE|scaling and root planing|\- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
214226476|NCT04942977|DEVICE|telemonitoring|"The system consists of the following elements:~1. Professional website at the hospital, which allows:~   * To set up an individualised care plan~  * To establish the patient's risk profile and targets for improvement.~  * Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~  * Advise the patient on self-management strategies.~2. Mobile application software with the following functions:~   * Scheduled exercise sessions~  * Medication reminder~  * Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~  * Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~  * Training monitor: guides the patient in the performance of their exercise.~  * Access to certified health information for patients"
214226477|NCT04942977|OTHER|Centre-based cardiac rehabilitation|The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
214226478|NCT02750020|OTHER|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
214226479|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
214226480|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
214226481|NCT02685982|DEVICE|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
214651191|NCT03847285|OTHER|solid organ transplantation|solid organ transplantation: kidney, heart, pancreas, lung and liver transplantation
214226482|NCT00934440|DRUG|Bevacizumab|"* First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
214226483|NCT00934440|DRUG|Azacitidine|"* Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight"
214226484|NCT01700309|BEHAVIORAL|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
214226485|NCT00163917|DEVICE|Virtual reality relaxation|
214226486|NCT02141737|DRUG|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
214226487|NCT02141737|DRUG|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
214226488|NCT02141737|DRUG|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
214226489|NCT02141737|DRUG|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
214226490|NCT02141737|DRUG|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
214226491|NCT02141737|DRUG|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
214226492|NCT02172534|DRUG|Tiotropium bromide low|
214226493|NCT02172534|DRUG|Tiotropium bromide medium|
214226494|NCT02172534|DRUG|Tiotropium bromide high|
214226495|NCT02172534|DRUG|Placebo|
214226496|NCT04206241|DIAGNOSTIC_TEST|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
214226497|NCT02707263|DRUG|intravenous continuous infusion of heparin (IV UFH)|
214226498|NCT02707263|DRUG|Subcutaneous Heparin|
214226499|NCT01986556|DRUG|Lesinurad 400 mg (Site 1)|
214226500|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot A)|
214226501|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot B)|
214651192|NCT02276586|PROCEDURE|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
214226502|NCT00744042|BIOLOGICAL|asfotase alfa|
214226503|NCT00263185|DIETARY_SUPPLEMENT|Vitamin D|
214226504|NCT00263185|DIETARY_SUPPLEMENT|Calcium carbonate|
214226505|NCT00263185|DRUG|Vitamin D|
214651193|NCT02276586|PROCEDURE|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
214651194|NCT04178980|DRUG|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
214651195|NCT01015833|DRUG|Doxorubicin Hydrochloride|Given IV
214651196|NCT01015833|OTHER|Laboratory Biomarker Analysis|Correlative studies
214651197|NCT01015833|OTHER|Pharmacogenomic Study|Correlative studies
214651198|NCT01015833|DRUG|Sorafenib Tosylate|Given PO
214818011|NCT01762709|PROCEDURE|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
214226506|NCT00263185|OTHER|Placebo|
214226507|NCT05675488|DIAGNOSTIC_TEST|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
214226508|NCT00660686|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
214226509|NCT00660686|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
214226510|NCT01333930|OTHER|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
214226511|NCT01333930|OTHER|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
214226512|NCT06521905|DEVICE|intravascular lithotripsy|The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.
214226513|NCT06521905|DEVICE|high-pressure ballon|High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
214226514|NCT06516926|DRUG|SHR-4602|Intravenous infusion, cycle every 21 days;
214226515|NCT03849625|DRUG|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
214226516|NCT06462105|DRUG|Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection|"Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable."
214226517|NCT00339001|DRUG|erythropoietin and early iron supplements|
214226518|NCT04735484|DEVICE|Gait analysis|Collecting movement data whilst participants walk
214226519|NCT01029106|PROCEDURE|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
214226520|NCT06385782|OTHER|Antarctic environment|. According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.
214226521|NCT03048513|OTHER|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
214226522|NCT05376332|DEVICE|Sonomyographic Prosthesis|The sonomyographic system will include a custom-fitted test socket incorporating ultrasound transducers and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
214226523|NCT05376332|DEVICE|Myoelectric direct control prosthesis|The direct control system will include a custom-fitted test socket incorporating dual-site electrodes and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
214226524|NCT05376332|DEVICE|Myoelectric pattern recognition prosthesis|The pattern recognition system will include the subject's clinically-prescribed socket and commercially-available pattern recognition technology (IBT Sense). The pattern recognition system will not be fitted as part of this study, as subjects will already be trained users prior to enrolling in the study.
214226525|NCT00750152|DRUG|NAFT-500|topical cream application up to 4 weeks
214226526|NCT00750152|DRUG|Placebo|placebo cream applied for up to 4 weeks
214226527|NCT02862340|GENETIC|Genetic test|
214226528|NCT02125591|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
214226529|NCT02125591|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
214226530|NCT02057081|BEHAVIORAL|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
214226531|NCT02057081|BEHAVIORAL|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
214226532|NCT00912184|DEVICE|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
214226533|NCT00912184|DEVICE|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
214226534|NCT05386407|DIAGNOSTIC_TEST|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
214226535|NCT03859362|DRUG|Ertapenem Injection|1 g of ertapenem q24h, 30 min infusion
214226536|NCT04629066|BEHAVIORAL|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
214226537|NCT00003280|BIOLOGICAL|rituximab|
214226538|NCT00410098|BEHAVIORAL|Bikram Yoga|
214226539|NCT01877252|PROCEDURE|Surgical revascularization|
214226540|NCT01877252|PROCEDURE|Endovascular revascularization|
214226541|NCT01877252|OTHER|No vascular intervention|
214226542|NCT04228133|BEHAVIORAL|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
214818012|NCT01762709|PROCEDURE|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
214226543|NCT04228133|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
214226544|NCT06329895|DRUG|BAY2927088|Oral administration.
214651199|NCT01671280|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
214651200|NCT00996203|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
214651201|NCT00996203|DRUG|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
214651202|NCT01419431|PROCEDURE|Laparoscopic resection|Inflammatory response in laparoscopic surgery
214651203|NCT05815355|DIETARY_SUPPLEMENT|exclusive enteral nutrition treatment group|
214651204|NCT01439945|DRUG|magnesium oxide|Given PO
214651205|NCT01439945|OTHER|placebo|Given PO
214651206|NCT00981994|BEHAVIORAL|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
214651207|NCT03016780|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
214226545|NCT06329895|DRUG|Dabigatran etexilate|Oral administration.
214226546|NCT06329895|DRUG|Rosuvastatin|Oral administration.
214651208|NCT03016780|OTHER|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
214651209|NCT02730260|BEHAVIORAL|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
214226547|NCT01028300|DEVICE|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
214651210|NCT02730260|BEHAVIORAL|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
214651211|NCT04524845|DEVICE|Unloading brace|"Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain."
214651212|NCT04524845|DEVICE|Rebel Reliever (RR)|Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
214651213|NCT04524845|DEVICE|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France)
214651214|NCT02787772|PROCEDURE|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
214651215|NCT05231083|DEVICE|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
214651216|NCT00177515|BEHAVIORAL|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
214651217|NCT01468987|DRUG|LY2605541|
214651218|NCT01468987|DRUG|Insulin Glargine|
214651219|NCT01468987|DRUG|Insulin Lispro|
214651220|NCT03436173|DRUG|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
214651221|NCT03436173|OTHER|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
214226548|NCT00845091|BEHAVIORAL|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
214226549|NCT00845091|BEHAVIORAL|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
214226550|NCT02140593|DRUG|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
214651222|NCT02834949|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
214651223|NCT02834949|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
214226551|NCT02140593|DRUG|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
214226552|NCT03702413|PROCEDURE|Endovascular treatment|Acute thrombectomy
214226553|NCT03018483|DEVICE|Variable PSV|"Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician."
214226554|NCT03018483|DEVICE|Conventional PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
214226555|NCT03018483|DEVICE|Automated PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
214226556|NCT03018483|DEVICE|NAVA|NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
214226557|NCT05805618|BIOLOGICAL|Recombinant Norovirus Hexavalent Vaccine|To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17
214226558|NCT05805618|OTHER|Matching Placebo|matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
214226559|NCT03842020|OTHER|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: \[H0-H3\]; \[H5-H9\] and just before the next set \[H24\], depending if the child is or is not admitted to hospital
214226560|NCT02644616|DRUG|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
214226561|NCT02644616|DRUG|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
214226562|NCT01142804|BEHAVIORAL|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
214226563|NCT01214395|DRUG|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
214226564|NCT02238184|DRUG|Atrovent®|
214226565|NCT02238184|DRUG|Ventilat®|
214226566|NCT06067620|PROCEDURE|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.
214651224|NCT02834949|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
214651225|NCT05112796|PROCEDURE|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
214651226|NCT05112796|PROCEDURE|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
214226567|NCT06067620|PROCEDURE|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
214226568|NCT04166240|BEHAVIORAL|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series \[VBTS\] Collaborative supplemented with automated surveillance data on test results.
214226569|NCT00715910|BIOLOGICAL|Nimenrix|One dose, as intramuscular injection
214226570|NCT00715910|PROCEDURE|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
214651227|NCT05032950|DRUG|Midazolam|Midazolam administered as a single dose on Day 1
214651228|NCT05032950|DRUG|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
214651229|NCT05032950|DRUG|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
214226571|NCT04136782|DRUG|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
214226572|NCT04136782|DRUG|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
214226573|NCT03854994|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
214226574|NCT02034409|DEVICE|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
214226575|NCT02034409|DEVICE|Sham Comparator|20 minutes daily for 48 weeks
214226576|NCT04950478|OTHER|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
214226577|NCT02215018|DRUG|BI 44370 TA solution|
214226578|NCT02215018|DRUG|BI 44370 TA tablet|
214226579|NCT02215018|DRUG|Placebo solution|
214226580|NCT02215018|DRUG|Placebo tablet|
214226581|NCT05453149|BEHAVIORAL|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
214226582|NCT02335814|DRUG|FLX925|
214226583|NCT03365843|DEVICE|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
214226584|NCT03365843|OTHER|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
214226585|NCT00239135|DRUG|PEP005|
214226586|NCT05128708|PROCEDURE|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
214226587|NCT06072456|PROCEDURE|laparoscopic lateral suspension|Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
214226588|NCT06072456|PROCEDURE|laparoscopic pectopexy|Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
214226589|NCT06072456|PROCEDURE|Sacrospinous ligament fixation|Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
214226590|NCT05092360|BIOLOGICAL|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
214226591|NCT05092360|BIOLOGICAL|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
214226592|NCT05092360|BIOLOGICAL|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
214226593|NCT05092360|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
214226594|NCT05092360|DRUG|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
214226595|NCT05092360|DRUG|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
214226596|NCT05092360|DRUG|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
214226597|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
214226598|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
214226599|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
214226600|NCT06384781|BEHAVIORAL|Peer Support Checklist|Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
214226601|NCT06389799|DRUG|Pemigatinib|selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
214226602|NCT06389799|DRUG|Retifanlimab|PD-1 inhibitor, Intravenous infusion
214226603|NCT06449001|DRUG|Danicopan|Participants will receive danicopan on a weight-based dosing regimen.
214226604|NCT06151210|DRUG|DA-5219|1 tablet/day
214226605|NCT06151210|DRUG|Stillen® Tab|3 tablets/day
214226606|NCT06151210|DRUG|DA-5219 Placebo|1 tablet/day
214226607|NCT06151210|DRUG|Stillen® Tab Placebo|3 tablets/day
214226608|NCT05737342|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
214226609|NCT05737342|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
214226610|NCT06291623|DRUG|Glycyrrhizin|used as intracanal medication for one week
214226611|NCT04180540|DEVICE|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
214226612|NCT04180540|OTHER|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
214226613|NCT07131813|DRUG|Tofacitinib 5 mg BID and Triamcinolone ointment|Patients in the test group will get tofacitinib 5mg capsules twice daily as an add on to triamcinolone ointment
214226614|NCT07131813|DRUG|Placebo and Triamcinolone ointment|Patients in the control group will receive identical looking capsules as placebo with triamcinolone ointment
214226615|NCT07003451|DIAGNOSTIC_TEST|Calprotectin Level|Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score
214226616|NCT04242238|DRUG|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
214226617|NCT04242238|DRUG|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
214226618|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
214226619|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
214651230|NCT03257189|DEVICE|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
214651231|NCT03257189|DEVICE|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
214651232|NCT03257189|DEVICE|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
214226620|NCT06870760|OTHER|Monoclonal Gammopathy|Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.
214226621|NCT06870760|OTHER|Complete Blood Count with differential (CBC w/ diff)|Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.
214226622|NCT06870760|OTHER|Clonal hematopoiesis (CHIP)|Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.
214226623|NCT05576480|RADIATION|Short-course radiotherapy|5×5Gy in Week 1
214226624|NCT05576480|DRUG|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
214226625|NCT05576480|DRUG|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
214226626|NCT05576480|PROCEDURE|TME surgery|Patient will receive radical rectal cancer surgery
214651233|NCT03257189|OTHER|Activity classification|Visual annotation of subject posture and other activities used for reference
214651234|NCT06296121|DRUG|BCD-264|IV, 16 mg/kg
214651235|NCT06296121|DRUG|Darzalex|IV, 16 mg/kg
214651236|NCT00299988|DRUG|Intravenous Immunoglobulin|
214651237|NCT00299988|OTHER|Placebo|
214651238|NCT00005724|BEHAVIORAL|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
214651239|NCT00005724|OTHER|Minimal Intervention Group|Dietary Information pamphlets.
214651240|NCT00005724|BEHAVIORAL|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
214651241|NCT03132584|DRUG|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~\- Via IV Day 3"
214651242|NCT03132584|DRUG|Alemtuzumab|"* The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4"
214226627|NCT03332849|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
214651243|NCT01699256|BEHAVIORAL|Guideline implementation as usual|Newsletters and Invitation to Meetings
214651244|NCT01699256|BEHAVIORAL|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
214651245|NCT00354302|DIETARY_SUPPLEMENT|calcium carbonate|
214651246|NCT00354302|DIETARY_SUPPLEMENT|calcium citrate|
214651247|NCT00354302|DIETARY_SUPPLEMENT|cholecalciferol|
214651248|NCT00354302|DRUG|alendronate sodium|
214651249|NCT00354302|DRUG|calcium gluconate|
214651250|NCT00354302|DRUG|risedronate sodium|
214651251|NCT00354302|OTHER|laboratory biomarker analysis|
214226628|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
214226629|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
214226630|NCT07011524|BIOLOGICAL|CM512 injection|subcutaneous injection
214226631|NCT07011524|DRUG|Placebo|subcutaneous injection
214651252|NCT00354302|PROCEDURE|dual x-ray absorptometry|
214651253|NCT04452890|DIAGNOSTIC_TEST|Sonourethrography|Ultrasound of the urethra.
214651254|NCT01105390|BIOLOGICAL|rilotumumab|Given IV
214651255|NCT01105390|DRUG|cisplatin|Given IV
214651256|NCT01105390|DRUG|pemetrexed disodium|Given IV
214226632|NCT06687889|OTHER|Elastography Measurements|Elastography Measurements
214226633|NCT06687889|OTHER|Bone Mineral Density Measurement (DEXA)|Bone Mineral Density Measurement (DEXA)
214226634|NCT06687889|OTHER|Berg balance scale|Berg balance scale
214226635|NCT06687889|OTHER|Functional reach test|Functional reach test
214226636|NCT06687889|OTHER|Timed Up and Go Test|Timed Up and Go Test
214226637|NCT07017400|PROCEDURE|Local Anesthetic Injection|combination of regional blocks for TKA postoperative analgesia
214226638|NCT06520085|OTHER|interactive mHealth application for patients undergoing RSA|Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
214226639|NCT07033481|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules
214226640|NCT07033481|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
214226641|NCT07136610|BEHAVIORAL|SMART Tool|The intervention in this implementation study involves (1) integrating the SMART Tool into electronic health records (EPIC), (2) educating all NICU staff (about 850 nurses, lactation consultants, speech-language pathologists, and physicians), and (3) Quality improvement to reinforce learning.
214226642|NCT04469998|DRUG|AXR-270 Low Dose|AXR-270 Topical Eyelid Cream
214226643|NCT04469998|DRUG|AXR-270 High Dose|AXR-270 Topical Eyelid Cream
214226644|NCT04469998|DRUG|AXR-270 Vehicle|AXR-270 Topical Eyelid Cream Vehicle
214226645|NCT06704269|GENETIC|YTB323|CAR-T cell suspension for intravenous infusion
214226646|NCT06758245|PROCEDURE|femoral and anterior sciatic nerve block|First, in the supine position, the USG probe is placed below the inguinal crease. The femoral nerve is located lateral to the femoral artery, above the iliopsoas muscle. Once the needle tip reaches the nerve, simultaneous nerve stimulation is applied. Patellar movement is observed due to quadriceps muscle contraction upon needle placement. After a negative aspiration test, 20 ml of local anesthetic is injected.For the anterior sciatic block, while the patient was in the supine position, a convex ultrasound (USG) probe was placed transversely approximately 10 cm distal to the inguinal ligament. After visualizing the sciatic nerve as a hyperechoic flat structure, the nerve stimulator was set to 1-1.5 mA, 0.1 ms, and 1 Hz. Using an in-plane technique, the block needle was advanced. Upon reaching the sciatic nerve, when contractions in the calf, foot, or big toe continued at a current of 0.3-0.5 mA, 20 ml of 0.5% bupivacaine was administered following a negative aspiration test.
214226647|NCT06758245|PROCEDURE|femoral and popliteal sciatic nerve block|The ultrasound probe is placed transversely at the popliteal crease. The first structure seen is the popliteal artery. Just above and lateral to the artery, the tibial nerve appears as a hyperechoic, oval, and round structure. After identifying the tibial and peroneal nerves, the probe is moved proximally, and it is observed that the nerves join about 5-10 cm above the popliteal crease. The needle is advanced using an in-plane technique. After obtaining the first sciatic nerve stimulation, 20 cc of 0.5% bupivacaine is injected following a negative aspiration test.
214226648|NCT04614324|DEVICE|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
214226649|NCT06759350|DIETARY_SUPPLEMENT|Soy isoflavone supplement|2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.
214226650|NCT06759350|OTHER|Control (placebo) group|2 placebo capsules containing a multivitamin compound.
214226651|NCT06571773|PROCEDURE|intraoperative implantation of Capsular Tension Ring|The Capsular Tension Ring(ACPi-11; Bausch + Lomb, Rochester, New York, USA) is a device made of PMMA with blunt-tipped eyelets at its ends. It can be inserted at any point during cataract surgery, following the creation of a strong anterior capsulotomy via capsulorhexis
214226652|NCT06571773|PROCEDURE|none intraoperative implantation of CTR|the surgeon did a surgery without the intraoperative implantation of CTR
214226653|NCT05110937|OTHER|Blood sampling|Blood sampling
214226654|NCT07073157|DRUG|HRS-8427 injection plus furosemide|HRS-8427 injection plus furosemide
214226655|NCT07073157|DRUG|HRS-8427 injection plus metformin|HRS-8427 injection plus metformin
214651257|NCT01105390|OTHER|laboratory biomarker analysis|Correlative studies
214226656|NCT06930768|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
214226657|NCT06930768|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214226658|NCT05811897|BEHAVIORAL|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~* Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~* Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~* Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
214226659|NCT05811897|BEHAVIORAL|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
214226660|NCT04791540|DIAGNOSTIC_TEST|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
214226661|NCT04791540|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
214226662|NCT04791540|DIAGNOSTIC_TEST|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
214226663|NCT04791540|DIAGNOSTIC_TEST|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
214226664|NCT04791540|BIOLOGICAL|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
214226665|NCT04791540|BIOLOGICAL|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
214226666|NCT04791540|OTHER|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
214226667|NCT07132736|DEVICE|Hubbard tank|women will perform pelvic floor exercise and core stability exercise under water each session will be for 30 min
214226668|NCT07132736|OTHER|Mat on the ground|women will perform core stability exercise and pelvic floor exercise on the mat for 30 min
214651258|NCT01416363|DRUG|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
214651259|NCT01416363|DRUG|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
214651260|NCT01416363|DRUG|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
214651261|NCT05827757|BIOLOGICAL|autologous adipose-derived mesenchymal stem cell transplantation|Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90
214651262|NCT01111266|DEVICE|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
214226669|NCT07137754|OTHER|Advanced practice physiotherapy|Physiotherapists undergoing post-graduate education as advanced practice physiotherapists will independently diagnose, manage and discharge patients.
214651263|NCT03791333|OTHER|injury severity score|injury severity score of multi trauma patients
214651264|NCT06613633|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
214651265|NCT00109148|DRUG|MK0364|
214651266|NCT02159300|BEHAVIORAL|experience brain activity recording|Intervention: experience brain activity recording
214651267|NCT05111587|OTHER|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
214651268|NCT03596346|OTHER|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
214651269|NCT03596346|OTHER|Control product without added RI|2 snack bars daily containing 0 g of RI.
214651270|NCT02292771|DRUG|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
214226670|NCT07137754|OTHER|Usual Care|Nurses and physicians in the emergency department will diagnose, manage and discharge patients as usual
214226671|NCT07092501|BEHAVIORAL|Mentholated cigarette sampling|Participants will participate in five sampling trials (menthol cigarette, non-menthol cigarette, non-menthol cigarette mentholated with accessory 1, with accessory 2, and with accessory 3). They will be exposed to these trials in a randomized order. In each trial, participants will take four guided puffs from one cigarette. They will have a 20-minute washout period between trials. They will first complete subjective ratings for the product they just sampled. Then, during the washout period, participants will be instructed to rinse their mouth thoroughly with room-temperature water three times. Each rinse will last approximately 10 seconds, and participants will be guided to swish the water around all areas of the mouth before expectorating. A one-minute rest will follow each rinse to allow residual taste to dissipate. No food or drink will be allowed during this period.
214226672|NCT07092501|BEHAVIORAL|Hypothetical Policy Scenarios|Participants will complete the real Experimental Tobacco Marketplace consisting of one control trial and two menthol flavor restrictions (menthol cigarettes unavailable and both menthol cigarettes and menthol-flavored accessories unavailable). Participants will complete a total of 3 purchasing trials each for 7 days worth of products. In each trial, participants will buy tobacco products to use throughout the next 7 days. At the end of the session, the participant will randomly draw an individual purchasing trial and will receive all the products purchased at that trial to use over the next week. During the following 7 days, the participant is asked to use only the tobacco/nicotine products received during the study.
214226673|NCT07092501|BEHAVIORAL|Subjective value assessment|Participants will complete a hypothetical purchase task where the price of a variety of products will increase progressively during the task.
214226674|NCT07094555|BEHAVIORAL|Animal Assisted Practice|The animal-assisted intervention group initiated interaction with a goldfish in a portable aquarium during the preoperative period and accompanied them until they reached the operating room.
214226675|NCT07094555|BEHAVIORAL|Kaleidoscope|The kaleidoscope group was distracted with a kaleidoscope during the preoperative period and continued this intervention until they reached the operating room.
214226676|NCT06927713|OTHER|Bloodletting Acupuncture|Bloodletting was applied to the right hand ﬁrst and then the left hand in the order of Shaoshang (LU 11), Shangyang (LI 1), Zhongchong (PC 9), Guanchong (TE 1), Shaochong (HT 9) and Shaoze (SI 1).
214226677|NCT06927713|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical acupoint stimulation at hand twelve jing-well points.
214226678|NCT07094113|DRUG|AMG 410|Administered as an oral tablet.
214226679|NCT07094113|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion.
214226680|NCT07094113|DRUG|Panitumumab|Administered as an IV infusion.
214651271|NCT02292771|DRUG|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
214651272|NCT02292771|DRUG|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
214651273|NCT02292771|DRUG|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
214226681|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
214226682|NCT06820216|DRUG|Rectointercostal facial plane block using bupivacaine 0.25%|Ultrasound guided bilateral recto-intercostal facial plane block will be done after induction of general anesthesia using bupivacaine 0.25%. A linear ultrasound transducer Philips CX50 (5-14 MHz) will be placed 2-3 cm lateral and caudal to the xiphoid in the epigastric area. The rectus abdominis muscle and its insertion, 6th and 7th cartilage ribs will be visualized. The needle will be inserted between rectus abdominis muscle and the costal cartilages with an in-plane technique in a caudal-cranial way. Hydro-dissection will be performed with 5 ml saline for confirmation needle tip position, 20 ml of 0.25% bupivacaine will be injected, the same procedure will be then repeated with 20 ml 0.25% bupivacaine on the contra-lateral side (a total of 40 ml bilaterally).
214226683|NCT06820216|OTHER|No Intervention as a control|General anesthesia without performing any block.
214226684|NCT00001721|DRUG|Cholesterol Suspension|
214226685|NCT00001721|DRUG|CRH|
214226686|NCT00001721|DRUG|Cholesterol|
214226687|NCT06825403|BEHAVIORAL|Olfactory Memory Training|Participants will complete 48 OMT sessions at home lasting approximately 10 minutes each over 3 months.
214226688|NCT06825403|BEHAVIORAL|Visual Memory Training|Participants will complete 48 VMT sessions at home lasting approximately 10 minutes each over 3 months.
214226689|NCT06827028|OTHER|N/A, no intervention, participation in survey|N/A, no intervention, participation in survey
214226690|NCT04627285|DRUG|Lacosamide|"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
214226691|NCT05259839|DRUG|Etentamig|Intravenous (IV) Infusion
214226692|NCT05259839|DRUG|Dexamethasone|Oral; Tablet or IV Infusion
214226693|NCT05259839|DRUG|Lenalidomide|Oral; Capsule
214226694|NCT05259839|DRUG|Pomalidomide|Oral; Capsule
214226695|NCT05259839|DRUG|Daratumumab|Subcutaneous Injection (SC)
214226696|NCT06869564|OTHER|blood sampling|At the time of blood sampling for biological tests, 2 additional tubes of blood will be taken.
214226697|NCT06923800|BEHAVIORAL|Combined Exercise Program + A specific nutritional plan for individuals with IBS|60-minute sessions three times per week for 4 months, incorporating moderate aerobic, resistance, and flexibility exercises
214226698|NCT06923800|BEHAVIORAL|Aerobic Exercise + A specific nutritional plan for individuals with IBS|60-minute sessions, three times a week for 4 months, with low-impact, non-weight-bearing aerobic activities at 60-75% of max heart rate.
214226699|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
214226700|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
214226701|NCT07134387|OTHER|N/A, no intervention, participation in survey|"A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term BPD wherever feasible and instead employs a more general reference to lung problems."
214226702|NCT07123103|DRUG|XB371|Intravenous (IV) infusion.
214226703|NCT06934356|DEVICE|EEG|Participants will have scalp EEG recorded with the international 10-20 system sampled at 256Hz using EEG amplifiers for purposes of surface event related potential analysis
214226704|NCT06934356|DEVICE|Eye Tracking|An eye-tracking device may be used during the perceptual awareness task. Pupillary and gaze location measurements are recorded using either a ViewPoint\~VoltagePro.EyeLink 1000 Plus system, or Argus Science ETVision system. If using the ViewPoint\~VoltagePro system or the Argus Science ETVision system, participants will be asked to wear an eye tracker during the perceptual awareness task (similar to wearing sunglasses). If using the EyeLink 1000 Plus system, participants may be asked to place their head inside of a padded head-chin rest to stabilize head position
214226705|NCT06934356|DEVICE|Behavioral task|For the visual perceptual awareness task, the participant will be presented with barely perceptible visual stimuli. After a variable delay, the participant will be asked to report perception of each stimulus and identify its location.
214226706|NCT06936787|DRUG|IGT001|Study drugs
214226709|NCT06936618|DEVICE|Electrical Impedance Tomography (EIT), Enlight 2100|Patients will undergo ventilator adjustments using EIT-guided PEEP titration to optimize mechanical power and lung mechanics.
214651274|NCT06915558|PROCEDURE|Opioid-Free Anesthesia (OFA)|Opioid-free anesthesia using a multimodal approach, including dexmedetomidine, lidocaine, ketamine, and magnesium sulfate. No intraoperative opioids are administered.
214226710|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with physiological saline|Rectus sheath and ilioinguinal nerve block without local anaesthesia
214226711|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with local anaesthesia|Rectus sheath and ilioinguinal nerve block with local anaesthesia
214651275|NCT06915558|PROCEDURE|Opioid-Based Intravenous Anesthesia (OBA-IV)|Standard opioid-based intravenous anesthesia using propofol, remifentanil, and neuromuscular blockade.
214651276|NCT06915558|PROCEDURE|Opioid-Based Inhalational Anesthesia (OBA-Inh)|Standard opioid-based inhalational anesthesia using sevoflurane, remifentanil, and neuromuscular blockade.
214651277|NCT06916884|DRUG|Desloratadine / Betamethasone in fixed dose|1 tablet, once a day of 5 mg / 0.25 mg
214651278|NCT06916884|DRUG|Desloratadine|1 tablet, once a day of 5 mg
214651279|NCT00260520|DRUG|Dalteparin|
214226712|NCT06940921|RADIATION|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|"Radiation: Stereotactic Body Radiation Therapy (SBRT)~* Stereotactic Body Radiation Therapy (SBRT) will be performed first at a total dose of 20-50 Gy, delivered in 3-5 fractions of 6-10 Gy each. And the target area was specifically selected based on the location and size of the patient's tumor.~Radiation: low-dose radiotherapy (LDRT)~* Whole-abdominal low-dose radiotherapy will be initiated within 10 days of the end of SBRT with a total dose of 7-15 Gy at 0.5-2.0 Gy twice daily. And the target area included all suspicious tumor tissues and potential metastatic foci in the abdominal cavity."
214226713|NCT06940921|DRUG|Cadonilimab|· Cadonilimab: 6 mg/kg IV, D1, Q2W, until disease progression, death, toxicity intolerance or withdrawal of informed consent
214226714|NCT06942767|DRUG|QLS31905 for Injection|QLS31905 for Injection
214226715|NCT06942767|DRUG|QL2107 Injection|QL2107 Injection
214226716|NCT06942767|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
214226717|NCT06942767|DRUG|Capecitabine Tablets|Capecitabine Tablets
214226718|NCT07144176|DRUG|DWJ1511|Test drug: DWJ1511
214226719|NCT07144176|DRUG|DWC202501|Comparator: DWC202501
214226720|NCT06942637|BEHAVIORAL|INSPIRE (Integrated Network for Student Psychosocial Intervention, Resilience, and Education)|The INSPIRE intervention is an 8-week school-based program aimed at enhancing adolescent mental health, attitudes towards mental health and help-seeking behaviors, mental health literacy, resilience and addressing depression and anxiety. Trained school counsellors deliver this structured curriculum using comprehensive materials including lesson plans, activities, and visual aids. the program provides supplementary resources for both participating students and their parents .
214226721|NCT07145073|DEVICE|DC-Stimulator MC|Experimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
214226722|NCT07145073|DEVICE|DC-Stimulator MC|Sham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
214226723|NCT07146165|DEVICE|EndoTEM resection platform and technique|EndoTEM is a flexible transanally introduced port system that allows the insertion of a second instrument alongside the flexible endoscope. A curved rigid grasping instrument has been developed, with a 2 cm long tip that can be rotated and angled in all directions.
214226724|NCT07144930|OTHER|MCIT program|"The MCIT program combines motor and cognitive training, progressing independently with increasing difficulty.~* Motor training, based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks.~* Cognitive incorporative component, adapted from previous stroke studies, supports cognitive recovery and overall well-being. Training starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. Progression requires an 80% success rate; if not achieved, tasks are simplified by reducing memory span or providing additional guidance."
214226725|NCT07144930|OTHER|Motor training program|Based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. Progression is guided by core action goals (Table 2) and depends on stable vital signs, balance, and minimal assistance. If participants are unable to progress, simpler tasks are provided.
214226726|NCT07144787|OTHER|implant retained complete Overdenture|four implant retained complete Overdenture versus Fixed-detachable prosthesis
214226727|NCT07144787|OTHER|Fixed-detachable prosthesis|four implant retained complete Overdenture versus Fixed-detachable prosthesis.
214226728|NCT07145866|DRUG|varenicline|"Dosing of this FDA-approved medication will follow the below schedule, which follows the clinical standard:~0.5 mg once daily or 3 days, 0.5 mg twice daily for 4 days 1.0 mg twice daily for 11 weeks"
214226729|NCT07145866|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days.
214226730|NCT07145866|DEVICE|Transcranial Magnetic Stimulation Sham|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days. The sham setting will deliver no magnetic field to the brain but will deliver electrical current to the scalp to mimic the feel of active treatment.
214226731|NCT07145866|BEHAVIORAL|Nicotine Cessation Counseling|Each participant will receive 6 sessions of brief nicotine cessation counseling by a trained study staff member. This will be provided at the weekly follow-up visits, spread out throughout the study. This counseling, while not the main aim of the study, should help participants manage their expectations of quitting and provide support and quitting strategies throughout the process.
214651280|NCT06438822|COMBINATION_PRODUCT|Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil|cadonilimab at a dosage of 6 mg/kg on day 1 combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 2400 mg/m2 for 46 h every 2 weeks.
214651281|NCT06201910|OTHER|Observation of Blood loss|Retrospetive observation of bloodloss and RBC transfusions.
214651282|NCT05992467|BEHAVIORAL|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
214818013|NCT06366009|DEVICE|NaoX in-ear EEG system|EEG recordings will be carried out simultaneously using standard EEG equipment (full set of electrodes according to the 10-20 system extended by additional temporal electrodes T9/T10) and the NAOX in-ear EEG system device.
214818014|NCT03115242|OTHER|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
214226732|NCT07145021|BEHAVIORAL|Breathing Exercise Intervention|Participants will receive guided breathing exercise training conducted by a certified breathing coach. The intervention consists of weekly 40-minute sessions over a 6-week period, aimed at reducing test anxiety and improving academic performance. Participants will also maintain a breathing exercise log throughout the study.
214226733|NCT07145645|DRUG|Voltaren Topical Gel|Topical diclofenac emulgel (Voltaren) 11.6 mg/g. Dosing is based on weight bands: 25 kg: 2 grams/dose, ≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose. ATC code: M02A A15.
214226734|NCT07145645|DRUG|Ibuprofen Oral Suspension 100 mg/5mL|Children's Ibuprofen Oral suspension (Motrin) 100mg/5 mL . Dosing is 10 mg/kg to a maximum of 600mg.
214226735|NCT07145645|DRUG|ORA-Blend Oral Suspension|Oral Ibuprofen suspension (labelled as ibuprofen) given at 10 mg/kg to a maximum of 600mg each dose.
214226736|NCT07145645|DRUG|VersaPro Cream Base for Compounding|"Topical Versapro Cream emulgel (labeled as diclofenac diethylamine). Dose is based on the following weight bands: 25 kg: 2 grams/dose;~≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose."
214226737|NCT07146295|DRUG|Technetium (99mTc)|A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.
214226738|NCT07146295|DRUG|Indocyanine Green|Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.
214226739|NCT07146295|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.
214226740|NCT07146516|PROCEDURE|Prophylactic (non-invasive) Laser Retinopexy|Prophylactic laser retinopexy to prevent RD in participants with SS using the indirect ophthalmoscopy (IDO) to place approximately 1800 to 2400 moderate intensity burns to produce encircling grid pattern, placed one burn width apart from 2 MM anterior to the ora serrata, extending to and between the vortex vein ampullae.
214226741|NCT07145632|DEVICE|App-based education and training of inhalation technique|The use of MDI or DPI requires different inhalation techniques and flows, which makes correct inhalation technique more challenging if patient use different types of inhaler devices. Healthcare providers may assess inhalation technique by observation and in addition PIF may be measured by manual meter. However, this does not capture all relevant information about patient's ability to correctly inhale medication and handle prescribed inhaler(s) and do not give instant and automated feedback on the inhalation technique to user. For instance, DPI users should reached a sufficiently high PIF within the first 0.4 seconds \[18\] and MDI users inhalation time should exceed 4 seconds in adults (2-3 seconds in children) in order to optimize lung deposition of the aerosol during a low PIF \[19\]. The app-based inhalation medical device gives automated feedback on inspiratory flows that are specific DPI and MDI devices.
214226742|NCT07145151|DRUG|UBT251|UBT251 administered subcutaneously (SC) once a week.
214226743|NCT07145151|DRUG|Placebo|Placebo,SC,once a week for 48 weeks
214226744|NCT07145125|DRUG|Brentuximab-Vedotin associated with Bendamustine|Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine
214226745|NCT07146906|BIOLOGICAL|zigakibart|zigakibart 600 mg sc injections every second week for 104 weeks (2 years)
214226746|NCT07145463|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.
214226747|NCT07146022|DRUG|VDPHL01 QD|VDPHL01 Extended Release (ER) Tablet
214226748|NCT07146022|DRUG|Placebo|Placebo tablet
214226749|NCT07146022|DRUG|VDPHL01 BID|VDPHL01 Extended Release (ER) Tablet
214226750|NCT07146022|DRUG|Placebo|Placebo tablet
214226751|NCT07145658|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert colour matched power
214226752|NCT07145658|DIETARY_SUPPLEMENT|multivitamin|20-ingredient multivitamin
214226753|NCT07146256|OTHER|Non-interventional observational study|No intervention will be studied
214226754|NCT07146737|DIAGNOSTIC_TEST|Corneal tomography generation model after ICL surgery|The ICL procedures collected would be assessed by the corneal tomography generation model. The performance of the model would be assessed, including accuracy,AUC, sensitivity and specificity.
214226755|NCT07146451|OTHER|Self-administered parental questionnaire|A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment
214226756|NCT07146451|OTHER|A short psychological assessment performed online|"NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales.~Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD)."
214818015|NCT04497181|DEVICE|Coil embolization surgery|Embolization of aneurysms with various coils system
214818016|NCT03680222|PROCEDURE|Reversed Tracking Method|Reversed Tracking Method
214818017|NCT02433639|DRUG|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
214818018|NCT00071591|BEHAVIORAL|Functional Adaptation Skills Training (FAST)|
214226757|NCT07145593|DEVICE|Application tACS- 80 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (80 Hz).The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
214226758|NCT07145593|DEVICE|Application tACS -40 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at gamma frequencies (40 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
214226759|NCT07145593|DEVICE|Application TACS - (6-80 Hz)|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at theta- gamma coupling frequencies ( 6-80 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
214226760|NCT07145593|DEVICE|Application TACS- Individual Gamma Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at individual gamma frequencies . The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
214226761|NCT07145593|DEVICE|Application TACS- Sham|In this study, a single 20-min tACS session will be applied over the bilateral dorsolateral prefrontal cortex (DLPFC) in a sham application. The anodal surface electrode will be placed over the left DLPFC (F3 of the 10-20 system) and the cathodal electrode will be placed over the right DLPFC (F4).
214226762|NCT07145671|OTHER|Transition program|"Transition Consultation:~Pediatric HCP introduces the transition process to AYA and family. A contact person is assigned (ideally the AYA's trusted HCP), along with someone from the AYA's personal network. Key points are recorded in the Individualized Transition Plan (ITP).~Independent Visit:~AYA has a solo consultation (parents briefly step out). They complete the Ready Steady Go checklist. The ITP is updated, and concerns are discussed.~Joint Consultation:~Pediatric and adult HCPs meet with the AYA. A new adult contact is assigned, and the AYA picks a pediatric contact for feedback. Checklist is completed again.~Feedback Moment:~After transfer, the pediatric contact checks in. The checklist guides discussion; feedback is shared across teams, and follow-up arranged if needed."
214226763|NCT07145450|BIOLOGICAL|ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|"The cells will be gene edited and administered by a single IV infusion on Day 1.~Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy."
214226764|NCT07145450|BIOLOGICAL|ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.
214226765|NCT07145450|BIOLOGICAL|ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy
214226766|NCT07146139|DEVICE|MyPrEP Plus Package|Participants receiving the MyPrEP Plus Package will utilize the interactive MyPrEP website to learn about PrEP and the various kinds of PrEP available as well as information about Doxy-PEP. While on PrEP, participants will be able sign up for PrEPmate, a tool designed to support PrEP adherence.
214226767|NCT07146139|BEHAVIORAL|Standard of Care (SOC)|Participants in the control condition will receive PrEP support according to local standard of care while using the website pleaseprepme.org.
214226768|NCT07145606|BEHAVIORAL|Standard Rehabilitation|Standardized postoperative ACL rehabilitation only. Begins \~2 weeks after surgery; supervised \~3 sessions/week for 6 weeks. Includes progressive range of motion, quadriceps activation/strengthening, functional drills, and return-to-activity progressions delivered per protocol.
214226769|NCT07145606|BEHAVIORAL|Blood Flow Restriction (BFR) Training|Low-load resistance exercises performed with individualized limb occlusion pressure (LOP) determined each session; target %LOP per protocol. Progresses from isometric to dynamic open/closed-chain tasks. Delivered under supervision \~3 sessions/week for 6 weeks; monitoring of tolerance and adverse events per safety LOP.
214226770|NCT07145606|BEHAVIORAL|sEMG Biofeedback|Real-time surface electromyography biofeedback to optimize quadriceps recruitment during targeted tasks (e.g., isometric contractions, straight-leg raise, sit-to-stand, mini-squat, gait drills). Visual and/or auditory feedback with progressive targets. Supervised \~3 sessions/week for 6 weeks; outcome assessors remain blinded.
214226771|NCT07145684|BEHAVIORAL|A culturally tailored medical nutrition therapy|This MNT intervention combines evidence-based menu plans based on the 4A framework of food security with individual nutrition counseling and group diabetes education.
214226772|NCT06946719|OTHER|pulp lavage Octenidine|Use of Octenidine as a pulp irrigation solution in pulp capping for mature permanent teeth
214226773|NCT06946719|OTHER|pulp lavage NaOCl|Use of NaOCl as a pulp irrigation solution in pulp capping for mature permanent teeth
214226774|NCT06946979|OTHER|Spinal Manipulation|"Spinal Manipulation Therapy The treatment consists of two standardized steps: tendon adjustment techniques and bone-setting techniques.~The total duration for both steps is approximately 15 minutes, conducted three times per week for two consecutive weeks."
214226775|NCT06946979|OTHER|Medication|Patients in both groups will receive celecoxib (one tablet, twice daily) for two weeks, with detailed records maintained.
214226776|NCT06947239|PROCEDURE|Mirror therapy along with conventional therapy|"The experimental group will receive 20 minutes of conventional therapy followed by 20 minutes of mirror therapy training including 3 minutes of rest period between the interventions.~WEEK OF INTERVENTION:~TASK PERFORM IN FRONT OF MIRROR:~WEEK :1-2~ACTIVE SHOULDER ROM:~flexion, abduction, external-internal rotation movements of the intact extremity~Increase the number of repetition according to the patient progression~WEEK:3-4~ACTIVITIES TARGETING SHOULDER ROM:~Cleaning the mirror with a towel(internal rotation+ abduction)~Lifting a glass to drink ( flexion + abduction)~Holding a brush to comb hair (external rotation~WEEK:5-6~Overhead reaching~(pasting stickers on the~mirror)(internal rotation~/ abduction)~Lifting a bottle overhead.~( flexion/abduction)~Throwing a ball (external~rotation)~PROGRESSION OF TASK SPECIFIC MIRROR THERAPY:~WEEK: 1-2 Increase the number of repetition according to the patient progression WEEK:3-4 Add water in glass Transfer glass"
214818019|NCT04700254|OTHER|DASS questionnaire|The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
214226777|NCT06947239|PROCEDURE|Control Group|"Details: Weeks wise:~The control group will receive 20 mints of conventional therapy .~1. Heat pack \& TENS to alleviate pain for 15 minutes~2. Shoulder isometric exercises 10 reps~3. Active and passive Range of Motion exercises 10 reps each~4. Codman exercises 10 reps each~5. Wand exercises 10 reps each"
214226778|NCT06946563|DEVICE|Fetoscopic Neural Tube Defect Repair Devices|Fetoscopic NTD repair will be performed on enrolled participants. An incision will be made to gain exposure and access to the uterus. The amniotic cavity is entered using a needle to administer fetal anesthesia. Then, the initial trocar is inserted into the amniotic cavity. The major steps of the procedure are neural placode dissection, myofascial flaps creation, and closure of the neural tube defect.
214226779|NCT06947733|BEHAVIORAL|pre-class videos|This project aims to evaluate the impact of pre-class videos on enhancing ultrasound teaching effectiveness, particularly comparing videos shot with a first-person perspective (POV) to those shot with a face-to-face perspective.
214226780|NCT06947733|BEHAVIORAL|no pre-class videos|the control group (who will not watch any videos)
214226781|NCT06947200|OTHER|Fibromyalgia|no intervention
214226782|NCT06947122|BEHAVIORAL|Mindfulness based smartphone app|The Mindful Journey intervention includes (1) 14 foundational modules/lessons, (2) brief check-in surveys (3 times/day) via the app, (3) app-guided momentary mindfulness coaching (max 3 times/day), and (4) brief 5 to 10-minute phone-based check-in from a trained staff member, on a weekly basis. Occurring for approximately 8 weeks following enrollment visit
214226783|NCT06947330|PROCEDURE|Unilateral Erector Spinae group|On injecting 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine into the interfacial plane below erector spinae; a manifest linear pattern will be visualized uplifting the muscle.
214226784|NCT06947330|PROCEDURE|Unilateral Serratus Anterior group|Once the needle will be in perfect position, confirmed by hydro-dissection on injecting 2-3 ml of normal saline, then 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine.
214226785|NCT06946017|DIETARY_SUPPLEMENT|Fermented dairy protein with prebiotic fiber supplement|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The intervention product contains whey protein concentrate and a prebiotic fiber. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
214226786|NCT06946017|DIETARY_SUPPLEMENT|Control placebo|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The placebo product is calorically matched to the intervention product and the main ingredients are protein and carbohydrate. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
214226787|NCT06946849|RADIATION|radiotherapy|Radiotherapy
214226788|NCT06946849|DRUG|FOLFIRI or FOLFOX or Regorafenib|FOLFIRI or FOLFOX or Regorafenib
214226789|NCT06946342|BEHAVIORAL|"Aquatic Exercise Group"|"Structured WATERinMOTION aquatic exercise program (3x/week for 8 weeks) in a heated pool (30-32°C), including warm-up, aerobic conditioning, resistance training with water equipment (e.g., dumbbells, noodles), and cool-down. Sessions are group-based and led by certified instructors."
214226790|NCT06946342|BEHAVIORAL|"Land-Based Rehabilitation Group"|"60-minute land-based sessions (3x/week for 8 weeks), including core stabilization, low-impact aerobics, and stretching."
214226791|NCT06947057|PROCEDURE|Guided implant placement|The four types of fully guided surgical guides (bilateral tooth-supported guides, unilateral tooth-supported guides, mucosa-supported full arch guides and stackable guides)
214226792|NCT06947096|DIAGNOSTIC_TEST|Radiomics-Based AI Imaging Analysis|This intervention involves the development and application of a radiomics-based artificial intelligence (AI) model to analyze preoperative abdominal CT images of patients with gastric cancer. The AI algorithm extracts high-dimensional imaging features from the para-aortic region to predict the presence or absence of para-aortic lymph node metastasis (PALNM). This non-invasive method aims to assist clinicians in preoperative risk stratification and treatment planning. The model will be trained and validated using manually segmented lymph node regions and correlated with postoperative pathological findings to ensure accuracy and clinical relevance.
214226793|NCT06946381|PROCEDURE|Evar|Branch Evar with the e-liac device
214226794|NCT06946732|DEVICE|Acostream aspiration|The pulmonary thrombus removal by Acostream.
214226795|NCT06946420|RADIATION|SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy|This group of patients will first undergo radiotherapy on the primary pancreatic lesion and stereotactic treatment on the metastatic sites before being started on standard systemic therapy (chemotherapy)
214226796|NCT06946420|DRUG|Standard systemic therapy (chemotherapy) without RT/SBRT|This group of patients will undergo standard systemic therapy (chemotherapy drugs chosen by oncologist) without radiotherapy treatment
214226797|NCT06947070|PROCEDURE|To evaluate the surface topography and color stability of 3D printing provisional material.|Subjects with single stage implant placement followed by early non-functional loading with implant supported provisional restorations fabricated using 3D printing provisional material.
214226798|NCT06946459|OTHER|Exercise|Participants in the Hip Strength Exercise Training group performed structured hip strengthening exercises using resistance bands in addition to their regular handball and strength training programs. The training was implemented three times per week for 8 weeks, with one rest day between sessions, and was conducted before regular handball practices. The exercises focused on activating and strengthening the hip muscles through simple, well-structured movements. Resistance bands were chosen due to their portability, cost-effectiveness, and suitability for adolescent athletes. This method ensured a safe training environment, reduced the risk of overload, and allowed for proper execution and control of the exercises.
214226799|NCT06947590|DRUG|mavacamten|Patients in this group were treated with Mavacamten, starting at an initial dose of 2.5 mg, administered orally once daily. Subsequent doses were adjusted based on changes in pressure gradients and cardiac function observed during follow-up.
214226800|NCT06947798|BEHAVIORAL|motivational interviewing|motivational interviewing four times
214226801|NCT06947798|OTHER|Diet|A calorie-restricted diet was implemented in both the intervention and control groups.
214226802|NCT06947798|BEHAVIORAL|Physical exercise|A moderate-intensity aerobic exercise program, consisting of 30-minute sessions five days per week, was implemented in both groups
214226803|NCT07145970|OTHER|Neuropsychological assessment tests for spatial neglect|"Standardized administration of four paper-and-pencil tests designed to assess different forms of spatial neglect:~* Apples Cancellation Test (Birmingham Cognitive Screen) for egocentric and allocentric neglect,~* Simplified Comb and Razor Test for personal and motor neglect,~* Line Bisection Test (30 cm ruler, blind version) for tactile neglect,~* Dot Test for visual exploration.~The purpose is to establish normative reference scores in healthy French-speaking adults according to age, sex, and professional qualification. No therapeutic intervention or patient population is involved."
214226804|NCT06246006|OTHER|Gene sequencing|Next generation sequencing of candidate genes (JAK2, cMPL, CALR, ASXL1 and NF-E2)
214226805|NCT03034551|BEHAVIORAL|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
214226806|NCT03968640|DIETARY_SUPPLEMENT|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
214226807|NCT03968640|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
214226808|NCT04473235|BEHAVIORAL|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
214226809|NCT04473235|BEHAVIORAL|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
214226810|NCT06515808|DEVICE|Direct Laryngoscope|Patient receiving tracheal intubation with direct laryngoscope, GlideScope or Airway Scope
214226811|NCT03950921|BEHAVIORAL|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
214226812|NCT02809716|OTHER|Biomarker Analysis|Correlative studies
214226813|NCT02809716|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
214226814|NCT05910671|BEHAVIORAL|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
214226815|NCT05724693|DRUG|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
214226816|NCT01754402|DRUG|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
214226817|NCT01754402|DRUG|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
214226818|NCT01754402|DRUG|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
214226819|NCT03448484|DIETARY_SUPPLEMENT|Intervention (integrated package)|"Provided to all intervention households:~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* 8 birds of chicken (child consumes 1 egg/day)~* Vegetable seeds (red onion, indigenous managu and sukuma)~* Monthly trainings to all farmers on nutrition and WASH~* Micronutrient powder (MixMe, 1g sachet every third day)~* Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
214226820|NCT03448484|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~* Agricultural training (every 2 weeks on average) for all~* Free to enrol for the following products on credit:~  * Compost boosters~ * Cook stoves~ * Seeds (onions, maize, indigenous greens, beans)~ * Maize storage bags~ * Drying tarps~ * Trees~ * Solar lights~ * Fertilizer~ * Actellic dust (insecticide)~ * Re-usable sanitary pads"
214226821|NCT01282463|DRUG|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
214226822|NCT01282463|BIOLOGICAL|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
214226823|NCT01282463|BIOLOGICAL|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
214226824|NCT02726542|DRUG|somatropin|Norditropin (growth hormone) given by injection using a pen-device
214226825|NCT00086268|DRUG|zoledronic acid|
214226826|NCT00086268|DRUG|Taxotere|
214226827|NCT00086268|DRUG|Carboplatin|
214818020|NCT04700254|OTHER|EAT-26 questionnaire|The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
214226828|NCT03010371|BEHAVIORAL|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
214226829|NCT03010371|BEHAVIORAL|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
214226830|NCT03010371|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful."
214226831|NCT03522623|OTHER|Non-interventional study|Non-interventional study
214226832|NCT02594995|DRUG|NBP|
214226833|NCT01802164|DEVICE|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
214226834|NCT00391209|DRUG|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
214226835|NCT00391209|DRUG|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
214226836|NCT02069275|OTHER|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
214226837|NCT02069275|OTHER|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
214226838|NCT04830098|OTHER|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
214226839|NCT04830098|OTHER|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
214226840|NCT01221285|BIOLOGICAL|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
214226841|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
214226842|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
214226843|NCT02300636|OTHER|Training|Standard ACL rehabilitation
214226844|NCT05949034|DEVICE|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
214651283|NCT06957392|BEHAVIORAL|Systematic self-help training program for enhancing social reward|"Based on previous research, this study has made significant innovations and optimizations within the traditional framework of Acceptance and Commitment Therapy (ACT). We have specifically developed a systematic self-help training module aimed at enhancing social reward, which includes components such as social scenario experience, social skills training, and the improvement of social reward sensitivity.~A single-blind randomized controlled trial will be conducted, dividing IGD participants into two groups. The SRI group (Social Reward Intervention group) will receive a psychological self-help training program designed to improve social reward, while the other (Control group) will receive a course introducing general knowledge about Internet Gaming Disorder. Both groups will have identical learning durations and modalities. The self-help training consists of 8 sessions, delivered twice weekly through a blended online and offline learning format, lasting approximately one month."
214818021|NCT05099198|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference
214818022|NCT05099198|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference
214226845|NCT00301184|BIOLOGICAL|pGA2/JS7 DNA|DNA Vaccine
214226846|NCT00301184|BIOLOGICAL|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
214226847|NCT02872844|DEVICE|ICS AirCal3|Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
214226848|NCT06429553|PROCEDURE|Minimally invasive hematoma aspiration drainage combined with urokinase injection|Minimally invasive hematoma aspiration drainage combined with urokinase injection
214226849|NCT04865367|OTHER|Exposure to culture media|Exposure to culture media
214226850|NCT06013813|PROCEDURE|Radial Artery approach on percutaneous coronary intervention (PCI)|"* Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches."
214226851|NCT02031328|RADIATION|Stereotactic Ablative Radiation|
214226852|NCT02150694|PROCEDURE|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
214226853|NCT02150694|PROCEDURE|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
214226854|NCT02150694|OTHER|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
214226855|NCT02150694|OTHER|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
214226856|NCT01795768|DRUG|AZD 4547|
214226857|NCT00523263|DEVICE|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
214226858|NCT00523263|DEVICE|Human umbilical vein femoro-popliteal bypass|
214226859|NCT00608946|DIETARY_SUPPLEMENT|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
214226860|NCT00608946|DIETARY_SUPPLEMENT|placebo|placebo
214226861|NCT03007251|OTHER|"Eurythmy Therapy Movement R"|
214226862|NCT03007251|OTHER|"Eurythmy Therapy Movement L"|
214226863|NCT03007251|OTHER|"Eurythmy Therapy Movement B"|
214226864|NCT03007251|OTHER|Normal movements during walking or standing|
214226865|NCT02491944|DRUG|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
214226866|NCT02491944|DRUG|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
214226867|NCT06351384|DEVICE|miRNA detection test|miRNA sequencing based on Next-Generation Sequencing (NGS) technology
214226868|NCT01239992|DRUG|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
214226869|NCT05181280|OTHER|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
214226870|NCT05181280|OTHER|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
214226871|NCT01601600|DRUG|BYM338|BYM338
214226872|NCT01601600|DRUG|Placebo|BYM338 Placebo
214226873|NCT04698577|BEHAVIORAL|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
214226874|NCT04698577|BEHAVIORAL|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
214226875|NCT00334178|DRUG|Laxymig ER (drug)|
214226876|NCT04960839|RADIATION|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
214226877|NCT00849316|DRUG|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
214226878|NCT02689921|DRUG|Exemestane|Aromatase inhibitor
214226879|NCT02689921|DRUG|Letrozole|Aromatase inhibitor
214226880|NCT02689921|DRUG|Anastrozole|Aromatase inhibitor
214226881|NCT02689921|DRUG|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
214226882|NCT02689921|DRUG|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
214226883|NCT02689921|DRUG|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
214226884|NCT03645343|DEVICE|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
214226885|NCT03645343|DEVICE|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
214226886|NCT03496714|BEHAVIORAL|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
214226887|NCT03496714|BEHAVIORAL|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
214226888|NCT02165839|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
214226889|NCT02165839|BEHAVIORAL|Healthy Eating Education Learning (HEAL)|
214226890|NCT02775929|DRUG|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
214226891|NCT02775929|DRUG|ART|ART for HIV-1 infected partners
214226892|NCT04340219|OTHER|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
214226893|NCT03605602|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
214226894|NCT01126047|OTHER|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
214226895|NCT03873675|DIAGNOSTIC_TEST|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
214226896|NCT04544215|BIOLOGICAL|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
214226897|NCT04544215|BIOLOGICAL|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
214226898|NCT04544215|BIOLOGICAL|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
214226899|NCT04802629|DEVICE|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
214226900|NCT00866008|DRUG|Ovarian stimulation|"1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
214226901|NCT04582123|PROCEDURE|crossed pin configuration|comparison of two crossed pin fixation methods
214226902|NCT03861988|DRUG|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
214226903|NCT03861988|DRUG|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
214226904|NCT06074042|OTHER|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
214226905|NCT01300533|DRUG|BIND-014|
214226906|NCT00170001|DRUG|Nexium|40 mg bid dosing
214226907|NCT00170001|DRUG|Sugar Pill|40 mg BID
214226908|NCT00220779|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
214226909|NCT00220779|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|
214226910|NCT03331471|PROCEDURE|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
214226911|NCT03331471|PROCEDURE|conventional ventilation|conventional ventilation using the anesthesia machine
214226912|NCT06237192|DRUG|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
214226913|NCT00102401|BEHAVIORAL|Internet-based Dyspnea Self-Management Program|
214226914|NCT00102401|BEHAVIORAL|Face-to-face Dyspnea Self-Management Program|
214226915|NCT00210938|DRUG|Doripenem|
214226916|NCT03390101|DRUG|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
214226917|NCT03390101|DRUG|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
214226918|NCT03390101|DRUG|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
214226919|NCT03699969|RADIATION|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
214226920|NCT01701752|BIOLOGICAL|FP-01.1 + Placebo|
214226921|NCT01701752|BIOLOGICAL|FP-01.1 + TIV|
214226922|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + Placebo|
214226923|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + TIV|
214226924|NCT01701752|BIOLOGICAL|Adjuvant + TIV|
214226925|NCT01701752|BIOLOGICAL|Placebo + TIV|
214226926|NCT01701752|BIOLOGICAL|FP-01.1|
214226927|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant|
214226928|NCT01701752|OTHER|Placebo|
214226929|NCT04708171|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
214226930|NCT04708171|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
214226931|NCT04708171|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
214226932|NCT06371183|DEVICE|Colonoscope|Endoscopy for lower GIT
214226933|NCT00338975|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
214226934|NCT00338975|BEHAVIORAL|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
214226935|NCT00338975|BEHAVIORAL|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
214226936|NCT00338975|BEHAVIORAL|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
214226937|NCT00281658|DRUG|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
214226938|NCT00281658|DRUG|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
214226939|NCT00281658|DRUG|Placebo|Paclitaxel Matching Placebo
214226940|NCT04013243|DRUG|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
214226941|NCT04013243|DRUG|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
214226942|NCT02828891|DEVICE|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
214226943|NCT04054427|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
214226944|NCT00310453|BIOLOGICAL|ALK Grass tablet|
214226945|NCT03830905|DRUG|XC221|Participants will receive 200 mg XC221 once a day during 3 days
214226946|NCT03830905|DRUG|Placebo|Participants will receive Placebo once a day during 3 days
214226947|NCT06955481|PROCEDURE|Navigated Total Knee Arthroplasty|The OrthoPilot® Software Pheno4u TKA Level 1 is an application software for computer aided navigation of surgical instruments and serves (in combination with compatible hardware and compatible navigated instruments) as an optional aid for the surgeon during the preparation of the implant site for a compatible knee endoprosthesis.
214226948|NCT05741606|DRUG|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
214226949|NCT05741606|DRUG|Placebo|Placebo capsules
214226950|NCT02704143|OTHER|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
214226951|NCT01235598|OTHER|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
214226952|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
214226953|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
214226954|NCT02151773|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
214226955|NCT00395343|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
214226956|NCT00395343|DRUG|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
214226957|NCT05120063|DEVICE|SPS monoblock stem, Symbios|hip prosthesis
214226958|NCT05120063|DEVICE|Quadra-H, Medacta|hip prosthesis
214226959|NCT05120063|PROCEDURE|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
214226960|NCT05120063|PROCEDURE|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
214226961|NCT00917215|DEVICE|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
214226962|NCT01801345|OTHER|Fatigued|
214226963|NCT01801345|OTHER|Rested|
214226964|NCT03073551|OTHER|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
214226965|NCT02507960|DEVICE|The Gamma Pod|Immobilization of breast during radiation.
214226966|NCT02507960|DEVICE|CT simulation|See arm description
214226967|NCT01463007|RADIATION|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
214226968|NCT01463007|OTHER|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
214226969|NCT00387790|DRUG|motexafin gadolinium|Given IV
214226970|NCT00387790|RADIATION|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
214226971|NCT00102778|DRUG|GW873140|
214226972|NCT00102778|DRUG|Kaletra (lopinavir/ritonavir)|
214226973|NCT00458770|PROCEDURE|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
214226974|NCT00444678|DRUG|Cetuximab|500 mg/m2, IV every two weeks
214226975|NCT00444678|DRUG|Oxaliplatin|85 mg/m2, IV, q 2 weeks
214226976|NCT00444678|DRUG|Capecitabine|2500 mg, po bid x 7 days every two weeks
214226977|NCT06073483|DEVICE|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
214226978|NCT00472758|BIOLOGICAL|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
214226979|NCT00472758|OTHER|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
214226980|NCT06085456|DIAGNOSTIC_TEST|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
214226981|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
214226982|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
214226983|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
214226984|NCT01558128|DRUG|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
214226985|NCT01558128|PROCEDURE|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
214226986|NCT04193514|OTHER|Acceptance and Commitment Therapy|The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
214226987|NCT04321447|OTHER|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
214226988|NCT05132803|DRUG|HPV 16 TA-CIN|No dose escalation or reduction
214226989|NCT00985777|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
214226990|NCT01649453|DEVICE|Pathwork® Tissue of Origin Test|
214226991|NCT05607212|OTHER|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
214226992|NCT05607212|OTHER|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
214226993|NCT05607212|OTHER|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
214226994|NCT04955678|DRUG|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
214226995|NCT04955678|DRUG|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
214226996|NCT02551510|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique
214226997|NCT02551510|DEVICE|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
214651284|NCT06957392|BEHAVIORAL|general knowledge about Internet Gaming Disorder .|"A single-blind randomized controlled trial is conducted. 30 people, assigned to Control group, was provided with standard educational courses introducing general knowledge about Internet Gaming Disorder. Assessments including standardized scales, behavioral tests, and neuroimaging are conducted once before and once after the intervention.~During the course, participants will receive twice-weekly online guidance sessions totaling eight sessions. The entire intervention lasts approximately one month, with follow-up assessments conducted at 3, 6, and 12 months post-intervention."
214651285|NCT06090071|DEVICE|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
214651286|NCT06090071|DEVICE|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
214651287|NCT06090071|DRUG|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
214651288|NCT01559909|DEVICE|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
214226998|NCT06174142|DEVICE|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
214651289|NCT02384811|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
214651290|NCT03702725|DRUG|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
214651291|NCT03702725|DRUG|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
214651292|NCT03702725|DRUG|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
214651293|NCT01475734|BIOLOGICAL|albiglutide|subcutaneous injection
214226999|NCT06174142|DEVICE|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
214227000|NCT06174142|DEVICE|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
214227001|NCT03596541|DEVICE|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
214227002|NCT04352426|OTHER|Exercise Test|Tests were conducted to evaluate exercise capacity.
214227003|NCT00625664|DRUG|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
214227004|NCT00625664|DRUG|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
214227005|NCT00625664|DRUG|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
214227006|NCT02721394|BEHAVIORAL|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
214227007|NCT01718418|OTHER|test meal|
214227008|NCT01718418|OTHER|reference|
214227009|NCT00321581|DRUG|Cediranib, AZD2171, RECENTIN|
214227010|NCT04693052|OTHER|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
214227011|NCT03264118|PROCEDURE|Scaling and root planing|Furcation treatment by scaling and root planing
214227012|NCT03264118|DRUG|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
214227013|NCT05739084|RADIATION|pre-operative radiation|As per standard of care and institutional guidelines
214227014|NCT05739084|PROCEDURE|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
214227015|NCT05869357|OTHER|cream containing 2.5% sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
214227016|NCT05869357|OTHER|cream containing 5%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
214227017|NCT05869357|OTHER|cream containing 10%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
214227018|NCT05869357|OTHER|cream base|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
214227019|NCT04348968|DEVICE|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
214227020|NCT03014232|PROCEDURE|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
214227021|NCT03014232|PROCEDURE|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
214651294|NCT01475734|BIOLOGICAL|placebo|subcutaneous injection
214651295|NCT03069651|OTHER|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
214651296|NCT00486486|DRUG|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
214651297|NCT00486486|DRUG|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
214651298|NCT03906825|DIETARY_SUPPLEMENT|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
214651299|NCT03906825|DIETARY_SUPPLEMENT|placebo|placebo
214227022|NCT02150902|PROCEDURE|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF \>10g, FTI \> 500 g-sec and minimum ablation duration \>10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
214227023|NCT02150902|PROCEDURE|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
214227024|NCT00977301|DRUG|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
214227025|NCT00977301|DRUG|olanzapine|15 mg olanzapine single dose
214227026|NCT00977301|DRUG|olanzapine|10 mg olanzapine single dose
214227027|NCT03480464|BEHAVIORAL|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
214227028|NCT05896280|PROCEDURE|EST|Stones are taken by cutting the papillary sphincter
214227029|NCT05896280|PROCEDURE|ECPP|During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
214227030|NCT06435065|DRUG|Biodentine|DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
214227031|NCT06435065|DRUG|Mineral Tri-Oxide Aggregate|DIRECT PULP CAPPINGWILL BE DONE USING MTA
214227032|NCT06435065|DRUG|THERACAL LC|DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
214227033|NCT06435065|DRUG|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
214227034|NCT00858338|PROCEDURE|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
214227035|NCT00858338|DRUG|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
214227036|NCT00858338|PROCEDURE|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
214227037|NCT02779556|OTHER|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
214227038|NCT02779556|OTHER|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
214227039|NCT04631211|BIOLOGICAL|Thrombosomes|Human platelet derived lyophilized hemostatic
214227040|NCT04631211|BIOLOGICAL|Liquid Stored Platelets (LSP)|Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)
214227041|NCT01344525|PROCEDURE|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
214227042|NCT01344525|PROCEDURE|Gastric Banding|Gastric Banding
214227043|NCT01344525|PROCEDURE|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
214651300|NCT02265913|DRUG|Acyclovir 5 percent (Perrigo)|
214651301|NCT02265913|DRUG|Acyclovir 5 percent (Reference)|
214227044|NCT01344525|PROCEDURE|Roux-en-Y Bypass|Roux-en-Y Bypass
214227045|NCT02216604|BEHAVIORAL|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
214227046|NCT02223377|DRUG|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
214651302|NCT02265913|DRUG|Placebo cream|
214651303|NCT06386328|DRUG|CKD-378, QD, PO|CKD-378, QD, PO
214651304|NCT05539014|OTHER|Data collection|Prospectif data collection
214651305|NCT03990129|DRUG|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
214651306|NCT00376961|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 for cycles 1-6.
214651307|NCT00376961|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
214651308|NCT00376961|DRUG|cyclophosphamide|750 mg/m\^2 on day 1 of cycles 1-6.
214651309|NCT00376961|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 1 of cycles 1-6.
214651310|NCT00376961|DRUG|prednisone|100 mg on days 1-5 of cycles 1-6.
214227047|NCT02223377|DRUG|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
214227048|NCT00942526|DRUG|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
214227049|NCT00942526|OTHER|Water|perioperative gargling with water
214227050|NCT05808569|BEHAVIORAL|Test|A specific self-test composed by 16 questions , will be administered to BC patients undergoing adjuvant RT.
214227051|NCT03972943|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP treatment
214227052|NCT03972943|OTHER|Patient Observation|Undergo observation
214227053|NCT03972943|OTHER|Questionnaire Administration|Ancillary studies
214227054|NCT02901704|DEVICE|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
214227055|NCT02901704|PROCEDURE|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
214227056|NCT06110169|DEVICE|Anodal Transcranial Direct Current Stimulation (Anodal tDCS)|Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
214227057|NCT06110169|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of sham anodal tDCS
214227058|NCT00462397|DRUG|carboplatin|
214227059|NCT00462397|DRUG|cisplatin|
214227060|NCT00462397|DRUG|paclitaxel|
214227061|NCT00462397|PROCEDURE|neoadjuvant therapy|
214227062|NCT00462397|RADIATION|brachytherapy|
214227063|NCT00462397|RADIATION|radiation therapy|
214227064|NCT03139591|DRUG|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
214227065|NCT00846963|DRUG|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (\>33mmol/L) to the resolution of cholestasis (conjugated bilirubin \<34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
214227066|NCT00846963|DRUG|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
214227067|NCT04497051|DIAGNOSTIC_TEST|CT-DSA|CTA before and after embolization
214651311|NCT00376961|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 1 of cycles 1-6.
214651312|NCT02614846|DRUG|Hetrombopag Olamine|
214651313|NCT05237557|BEHAVIORAL|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
214651314|NCT03728088|OTHER|Rating scales concerning non-technical attributes|
214227068|NCT00221468|DRUG|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
214227069|NCT02086396|DIETARY_SUPPLEMENT|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
214227070|NCT02086396|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
214227071|NCT03236662|DRUG|(-)-Epicatechin|
214227072|NCT00194493|BEHAVIORAL|ESRA-C|Graphical summary of patient symptoms and quality of life
214227073|NCT03110770|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
214227074|NCT03110770|OTHER|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
214227075|NCT03616808|OTHER|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
214227076|NCT02948036|OTHER|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
214227077|NCT00892736|OTHER|Laboratory Biomarker Analysis|Correlative studies
214227078|NCT00892736|OTHER|Pharmacological Study|Correlative studies
214227079|NCT00892736|DRUG|Veliparib|Given PO
214227080|NCT00260962|DRUG|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
214227081|NCT00260962|BEHAVIORAL|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
214227082|NCT01623557|BIOLOGICAL|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.
214227083|NCT01623557|BIOLOGICAL|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.
214227084|NCT01623557|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
214227085|NCT05713149|OTHER|Surgical flap and anti-bacterial agents|Surgical flap and anti-bacterial agents
214227086|NCT01254162|DRUG|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
214227087|NCT03206281|DIAGNOSTIC_TEST|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
214227088|NCT01996839|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
214227089|NCT01996839|DRUG|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
214227090|NCT01996839|DRUG|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
214227091|NCT01996839|DRUG|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
214227092|NCT04494100|PROCEDURE|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
214227093|NCT04494100|PROCEDURE|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
214227094|NCT04494100|PROCEDURE|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
214227095|NCT04494100|DRUG|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
214227096|NCT04494100|DRUG|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
214227097|NCT02508558|OTHER|motion perception and locomotor operation performance measurements|
214227098|NCT02508558|OTHER|parabolic flight|
214227099|NCT00154089|DRUG|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
214227100|NCT00742833|DRUG|KUC-7483|
214227101|NCT00742833|DRUG|Placebo|
214227102|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
214227103|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
214227104|NCT02379130|BEHAVIORAL|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
214651315|NCT04256967|OTHER|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
214227105|NCT02379130|BEHAVIORAL|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
214227106|NCT03142685|DEVICE|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
214227107|NCT05873166|OTHER|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
214227108|NCT05873166|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
214227109|NCT02820532|DEVICE|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
214227110|NCT04356261|BEHAVIORAL|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
214227111|NCT00718588|DRUG|MTRX1011A|Subcutaneous and intravenous single and repeating dose
214227112|NCT02082340|BEHAVIORAL|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
214227113|NCT02082340|OTHER|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
214227114|NCT02082340|OTHER|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
214227115|NCT02082340|BEHAVIORAL|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
214227116|NCT02082340|BEHAVIORAL|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
214227117|NCT01814709|DRUG|GDC-0032|Oral doses of GDC-0032
214227118|NCT01814709|DRUG|Itraconazole|Oral doses of Itraconazole
214227119|NCT01814709|DRUG|Rifampin|Oral doses of Rifampin
214227120|NCT04613843|OTHER|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
214227121|NCT04613843|OTHER|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
214227122|NCT01625260|BIOLOGICAL|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
214227123|NCT01625260|DRUG|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
214227124|NCT02937584|DRUG|GP MDI (PT001) 14.4 μg|Glycopyrronium
214227125|NCT02937584|DRUG|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
214227126|NCT00838032|DRUG|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
214227127|NCT00838032|DRUG|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
214227128|NCT05987995|PROCEDURE|Endometrial injury|A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
214227129|NCT04329338|OTHER|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
214227130|NCT01855646|OTHER|Structured Sign Out Form|
214227131|NCT00003021|DRUG|bizelesin|
214227132|NCT01521312|DRUG|saxagliptin|5mg a day for 11-14 weeks
214227133|NCT01521312|OTHER|placebo pill|one tablet a day for 11-14 weeks
214227134|NCT04724122|OTHER|Observational / Assessment only|The results of this assessment will determine the needs for future interventions
214651316|NCT03109431|BEHAVIORAL|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
214227135|NCT00635219|DRUG|Placebo|capsules; daily; orally
214227136|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
214227137|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
214227138|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
214227139|NCT00635219|DRUG|Duloxetine|60 mg/day; encapsulated capsules; orally
214227140|NCT02646241|PROCEDURE|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
214227141|NCT02646241|PROCEDURE|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB \& unroofing biopsy.
214227142|NCT02535390|BEHAVIORAL|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
214227143|NCT02535390|BEHAVIORAL|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
214227144|NCT02575027|RADIATION|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
214227145|NCT02575027|OTHER|Questionnaire Administration|Ancillary studies
214227146|NCT02575027|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
214227147|NCT04721080|OTHER|Functional Outcome Measurements|Dyspnea Exercise capacity Quality of life assessment
214227148|NCT01755000|PROCEDURE|USCOM scan|
214227149|NCT01755000|PROCEDURE|Fluid Bolus|
214227150|NCT03903224|PROCEDURE|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
214227151|NCT03903224|PROCEDURE|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
214227152|NCT02323607|DRUG|Pacritinib|Given PO
214227153|NCT02323607|DRUG|Cytarabine|Given IV
214227154|NCT02323607|DRUG|Daunorubicin Hydrochloride|Given IV
214227155|NCT02323607|DRUG|Decitabine|Given IV
214227156|NCT02323607|OTHER|Laboratory Biomarker Analysis|Correlative studies
214227157|NCT02323607|OTHER|Pharmacological Study|Correlative studies
214227158|NCT00028652|BIOLOGICAL|interleukin-12 gene|
214227159|NCT00280384|DRUG|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
214227160|NCT00280384|DRUG|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
214227161|NCT04229407|DIETARY_SUPPLEMENT|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
214227162|NCT04229407|DIETARY_SUPPLEMENT|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
214227163|NCT00694148|DRUG|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
214227164|NCT04090801|DRUG|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
214227165|NCT04090801|DRUG|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
214227166|NCT04090801|OTHER|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
214227167|NCT00299429|PROCEDURE|Stenting and minimally invasive bypass surgery|
214227168|NCT00299429|PROCEDURE|PCI with DES|PCI with DES
214227169|NCT02456363|BIOLOGICAL|TNF alpha|Depending on patient need to use different TNF alpha
214227170|NCT02456363|DRUG|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
214227171|NCT06412614|OTHER|disease phenotype|evaluation of SSc phenotypes
214227172|NCT01223742|DIETARY_SUPPLEMENT|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
214227173|NCT01223742|DRUG|placebo|placebo twice per day
214227174|NCT01598129|GENETIC|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
214227175|NCT05615519|DIAGNOSTIC_TEST|A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.|Digital ruler of strabismus
214227176|NCT00591318|DRUG|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
214227177|NCT00591318|DRUG|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
214227178|NCT04431921|DIAGNOSTIC_TEST|Functional capacity|Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
214227179|NCT00572130|GENETIC|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
214227180|NCT00572130|GENETIC|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
214227181|NCT04308967|OTHER|balance exercises|Three-stage progressive balance exercises will be applied.
214227182|NCT02101710|DRUG|Elantan SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
214227183|NCT02101710|DRUG|Imdur SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
214227184|NCT00846950|DRUG|dexchlorpheniramine, lorazepam|
214227185|NCT02292069|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
214227186|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
214227187|NCT02462642|OTHER|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
214227188|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
214227189|NCT02462642|OTHER|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
214227190|NCT02685059|DRUG|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
214227191|NCT02685059|DRUG|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
214227192|NCT02685059|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
214227193|NCT02685059|DRUG|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
214227194|NCT02685059|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
214227195|NCT04042090|DEVICE|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
214227196|NCT02420015|DRUG|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
214227197|NCT02420015|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
214227198|NCT02420015|BEHAVIORAL|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
214227199|NCT02420015|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
214227200|NCT02420015|BEHAVIORAL|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
214227201|NCT02420015|BEHAVIORAL|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
214227202|NCT01835509|BEHAVIORAL|Intervention, Camp plus reunions|
214227203|NCT00669123|DRUG|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
214227204|NCT00669123|DRUG|Placebo|
214651317|NCT03109431|BEHAVIORAL|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
214651318|NCT03109431|BEHAVIORAL|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
214227205|NCT04074161|DRUG|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
214227206|NCT04074161|DRUG|Placebo (semaglutide)|Administered once weekly for 68 weeks
214227207|NCT04074161|DRUG|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
214651319|NCT01059448|DRUG|AMG 827|AMG 827 210 mg
214651320|NCT02267486|OTHER|Standard therapy of Alzheimer Dementia (AD)|
214227208|NCT04074161|DRUG|Placebo (liraglutide)|Administered once daily for 68 weeks
214227209|NCT02317744|DRUG|Naltrexone and bupropion combination|
214227210|NCT02317744|OTHER|Pill Placebo|
214227211|NCT03236155|DRUG|opioid pain pills|patient will receive their pain pill prescription
214227212|NCT01412489|DEVICE|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
214227213|NCT05067309|DRUG|Letrozole 2.5mg|Missed abortion received letrozole then misoprostol
214227214|NCT00155675|DRUG|GUSUIBU|
214227215|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
214227216|NCT05166837|DRUG|Placebo|Intravenous injection
214227217|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
214227218|NCT05166837|DRUG|Placebo|Intravenous injection
214227219|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
214227220|NCT05166837|DRUG|Placebo|Intravenous injection
214227221|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
214227222|NCT05166837|DRUG|Placebo|Intravenous injection
214227223|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
214227224|NCT05166837|DRUG|Placebo|Intravenous injection
214227225|NCT03890666|DRUG|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
214227226|NCT03890666|DRUG|albuterol|Standard of care albuterol-administering rescue inhaler
214227227|NCT01529138|DRUG|Axitinib|Combination treatment with temsirolimus and axitinib
214227228|NCT01529138|DRUG|Temsirolimus|Combination treatment with temsirolimus and axitinib
214227229|NCT04459208|DEVICE|Manta|plug-based vascular closure
214227230|NCT04459208|DEVICE|ProGlide|suture-based vascular closure
214227231|NCT02152280|DRUG|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
214227232|NCT02152280|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
214227233|NCT05830617|DEVICE|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
214227234|NCT05830617|DEVICE|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
214227235|NCT00586092|DRUG|bevacizumab, ABT-510|"* Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
214227236|NCT02368561|DRUG|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
214227237|NCT01639729|DRUG|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
214227238|NCT01639729|DRUG|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
214227239|NCT01639729|DRUG|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
214227240|NCT01639729|DRUG|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
214227241|NCT02373085|OTHER|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
214651321|NCT02267486|OTHER|Observation|
214651322|NCT04306874|DIETARY_SUPPLEMENT|Ensure Max Protein|Liquid shake with 30 g protein per serving
214651323|NCT04614792|DEVICE|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
214227242|NCT03629314|OTHER|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
214227243|NCT02607748|OTHER|18F-NaF PET and coronary CTA imaging|
214227244|NCT00607490|BEHAVIORAL|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
214227245|NCT00607490|BEHAVIORAL|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
214227246|NCT02120040|OTHER|evaluation of anxiety with psychosocial scales|
214227247|NCT02524613|OTHER|Pelvis CT scan|
214227248|NCT02166944|DRUG|tamoxifen 40 mg daily for one year|both arms with riluzole daily
214227249|NCT05642650|DEVICE|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
214227250|NCT04678076|DRUG|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
214227251|NCT04678076|DRUG|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
214227252|NCT03141996|OTHER|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
214227253|NCT03141996|OTHER|Standard of Care|Standard of care treatment
214227254|NCT03052426|DEVICE|Ergotron WorkFit - TL|A sit to stand work station.
214227255|NCT00907179|DRUG|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
214651324|NCT02179632|BEHAVIORAL|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
214651325|NCT05956457|BEHAVIORAL|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
214651326|NCT05956457|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
214651327|NCT01091350|DEVICE|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
214651328|NCT01091350|DEVICE|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
214227256|NCT00907179|DRUG|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
214227257|NCT05624333|OTHER|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
214227258|NCT05624333|OTHER|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
214227259|NCT00314587|PROCEDURE|1 or 2 elastic stable intramedullary nails|
214227260|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
214227261|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
214227262|NCT00077090|DRUG|hyperbaric oxygen|
214227263|NCT01093703|OTHER|Medication Adjustment|"1. Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~2. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~3. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~4. Awake SBP\>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
214227264|NCT02031965|BIOLOGICAL|oncolytic HSV-1716|Given IT
214227265|NCT02031965|DRUG|dexamethasone|Given IV
214227266|NCT02031965|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214227267|NCT02031965|OTHER|laboratory biomarker analysis|Correlative studies
214227268|NCT04699136|OTHER|6 minutes step test (ST6)|Performing a 6 minutes step test at different intervals and comparing with respect with the 6 minutes walk test and cardiac stress test
214227269|NCT03083990|BIOLOGICAL|IBI305(Bevacizumab Biosimilar)|3mg/kg, infusion in 90minutes
214227270|NCT03083990|DRUG|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
214227271|NCT03502356|DRUG|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
214227272|NCT03672097|DRUG|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
214227273|NCT05788471|OTHER|conventional Treatment|It consists of Superficial heat, Ultrasound therapy and stretching exercise to lumbrical muscles of the hand.
214227274|NCT05788471|OTHER|Neurodynamic mobilization|It is the mobilisation of the nervous system as an approach to physical treatment of pain. The treatment and or assessment relies on influencing pain physiology via the mechanical treatment of neural tissues and non-neural structures surrounding the nervous system.
214227275|NCT06287177|DRUG|Inclisiran|Injection
214227276|NCT06516419|DRUG|Concentrated secretome Injection 2mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
214227277|NCT06516419|DRUG|Tranexamic acid injection|"1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2\. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject"
214227278|NCT06516419|DRUG|Triple Combination Cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
214227279|NCT03120195|DEVICE|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
214227280|NCT03279562|DRUG|Nalmefene|Educational and behaviorally oriented drug counseling
214227281|NCT00512980|DRUG|prednisone|
214227282|NCT00512980|DRUG|vinblastine|
214227283|NCT00512980|DRUG|doxorubicin|
214227284|NCT00512980|DRUG|gemcitabine|
214227285|NCT04354597|DRUG|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
214227286|NCT03111862|DIAGNOSTIC_TEST|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
214227287|NCT02739685|DEVICE|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
214227288|NCT02739685|DEVICE|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
214227289|NCT01781299|DEVICE|AlloDerm RTU|
214227290|NCT01781299|DEVICE|SurgiMend PRS|
214227291|NCT04519242|PROCEDURE|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
214227292|NCT00146848|DEVICE|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
214227293|NCT01798849|DRUG|MK-8892|
214227294|NCT01798849|DRUG|Placebo for MK-8892|
214227295|NCT03211572|DRUG|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
214227296|NCT02436837|OTHER|sessions with virtual reality|sessions with virtual reality to improve the balance
214227297|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (LAX)
214227298|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (SAX)
214227299|NCT02657603|PROCEDURE|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
214227300|NCT02657603|PROCEDURE|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
214227301|NCT02636361|DRUG|LY900014|Administered subcutaneously (SC)
214227302|NCT02636361|DRUG|Insulin lispro (Humalog)|Administered SC
214227303|NCT02032238|DEVICE|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
214227304|NCT03277339|DRUG|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
214227305|NCT03277339|OTHER|Thermal cure|Thermal cure is realized for 3 weeks
214227306|NCT05318742|PROCEDURE|laser|Endolaser photocoagulation during PPV
214227307|NCT04404933|OTHER|Treatment algorithm for OIC|Treatment Algorithm for OIC
214227308|NCT04500561|DRUG|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
214227309|NCT01559740|DRUG|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
214227310|NCT01494623|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
214651329|NCT03429478|OTHER|Preoperative application of a bluetooth enabled Headphones.|A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
214227311|NCT05420259|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
214227312|NCT05420259|BEHAVIORAL|Standard Care|Standard Care
214227313|NCT03098615|DRUG|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
214227314|NCT03241719|DRUG|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
214227315|NCT01573052|DRUG|Chlordiazepoxide|25mg four times daily x 3 days then tapered over 3 days
214227316|NCT01573052|DRUG|Gabapentin|300mg four times daily x 3 days then tapered over 3 days
214227317|NCT01955629|DRUG|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
214227318|NCT01955629|DRUG|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
214227319|NCT01955629|DRUG|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
214227320|NCT01630993|OTHER|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
214227321|NCT03307655|OTHER|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
214227322|NCT03307655|OTHER|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
214227323|NCT04017845|DIAGNOSTIC_TEST|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
214651330|NCT03706703|DRUG|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
214651331|NCT03706703|DRUG|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
214651332|NCT03706703|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
214651333|NCT03706703|DRUG|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
214651334|NCT02911688|DRUG|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
214227324|NCT04017845|PROCEDURE|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
214227325|NCT04017845|PROCEDURE|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
214227326|NCT04017845|DIAGNOSTIC_TEST|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: \>10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
214227327|NCT04017845|DRUG|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
214227328|NCT04017845|DRUG|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
214227329|NCT05529095|DRUG|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
214227330|NCT05529095|DRUG|Placebo|Placebo (sugar pill)
214227331|NCT03158285|DRUG|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
214227332|NCT03158285|DRUG|Placebo|Participants will receive matching placebo as SC injection.
214227333|NCT02200640|DRUG|High dose of Micardis®, once daily|
214227334|NCT02200640|DRUG|Low dose of Micardis®, once daily|
214227335|NCT02200640|DRUG|Low dose of COZAAR®, once daily|
214227336|NCT02200640|DRUG|High dose of COZAAR®, once daily|
214227337|NCT02200640|DRUG|Placebo|
214227338|NCT04587765|BEHAVIORAL|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
214227339|NCT03601884|BEHAVIORAL|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
214227340|NCT03601884|OTHER|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
214651335|NCT02911688|DRUG|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
214651336|NCT00809328|DRUG|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
214651337|NCT04201717|PROCEDURE|laparoscopic assisted left colectomy (extracorporeal anastomosis group)|For patients in the control group, the surgeon uses wound edge protectors to exteriorize the colon through a small incision in the midline of the abdomen. A ruler and methylene blue solution are employed to mark the area for colon resection. This guarantees a 10-cm margin from the tumor. Guided by these markers, the marginal vessels and mesentery are divided outside the body. The method of anastomosis is at the surgeon's discretion. A side-to-side anastomosis (including antiperistaltic, isoperistaltic, or overlapping anastomosis) is recommended. Side-to-end or end-to-end anastomosis (sewn by hand or by inserting a circular stapler through the anus or proximal colon) is also allowed. After completing the anastomosis, the incision is sutured. An abdominal drainage tube is inserted at the end of the operation.
214227341|NCT02587377|OTHER|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
214227342|NCT03171181|OTHER|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
214227343|NCT02659397|DRUG|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
214227344|NCT02659397|DRUG|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
214227345|NCT02659397|DRUG|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
214227346|NCT01441362|PROCEDURE|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
214227347|NCT01441362|PROCEDURE|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
214227348|NCT04293744|DEVICE|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
214227349|NCT04293744|DEVICE|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
214227350|NCT05591235|DRUG|Metformin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
214227351|NCT05591235|DRUG|Dapagliflozin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
214227352|NCT05591235|DRUG|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
214227353|NCT03419585|DEVICE|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
214227354|NCT03419585|DEVICE|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
214227355|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
214227356|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
214227357|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
214227358|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
214227359|NCT02948517|OTHER|Time restricted feeding|Time restricted feeding
214227360|NCT04032509|OTHER|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
214227361|NCT03464175|DEVICE|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
214227362|NCT03464175|DEVICE|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
214227363|NCT03464175|DEVICE|Heated-humidified circuit|It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
214227364|NCT03464175|DEVICE|Dry ventilator circuit specific for aerosol therapy|Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
214227365|NCT03464175|DEVICE|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
214227366|NCT04620876|OTHER|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
214227367|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
214227368|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
214227369|NCT01642615|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
214227370|NCT04221776|OTHER|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
214227371|NCT04221776|OTHER|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
214227372|NCT03545425|PROCEDURE|Biofluid samplings|Blood and Urine
214227373|NCT01699867|DEVICE|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
214227374|NCT05673798|OTHER|initial chemotherapy response|Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
214227375|NCT02938715|OTHER|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
214227376|NCT05201664|PROCEDURE|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
214227377|NCT00796926|DRUG|Systane Ultra eyedrops|Four times a day
214227378|NCT00796926|DRUG|Refresh eye drops|Four times a day
214227379|NCT05825157|DEVICE|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
214227380|NCT03391245|DIAGNOSTIC_TEST|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
214227381|NCT02479646|BIOLOGICAL|MYL-1401H|
214227382|NCT02479646|BIOLOGICAL|EU-Neulasta|
214227383|NCT02479646|BIOLOGICAL|US-Neulasta|
214227384|NCT05291312|PROCEDURE|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
214227385|NCT04427982|BEHAVIORAL|dance|Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
214227386|NCT04427982|BEHAVIORAL|diabetes education|The dance classes will be followed by a brief diabetes education and discussion session.
214227387|NCT03593616|PROCEDURE|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
214227388|NCT02681354|OTHER|Biorescue training|
214227389|NCT04656535|DRUG|Zimberelimab|Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
214227390|NCT04656535|DRUG|Domvanalimab|Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
214227391|NCT04656535|DRUG|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
214227392|NCT00456170|PROCEDURE|Performing Vaginal hysterectomy with Harmonic Scalpel|
214227393|NCT00380380|DRUG|Vildagliptin|
214227394|NCT00624169|PROCEDURE|An optimized perioperative course|A number of interventions before, during and after surgery
214227395|NCT01750749|BIOLOGICAL|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
214227396|NCT01085006|DRUG|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
214227397|NCT01085006|DRUG|Normal saline|Tranexamic acid in cases, normal saline in controls
214227398|NCT04077788|OTHER|muscle energy technique|"Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms."
214227399|NCT02551549|DRUG|CD101 IV|antifungal
214227400|NCT02551549|DRUG|Placebo|Normal saline
214227401|NCT04046614|DRUG|nintedanib-nivolumab combination therapy|"Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease."
214227402|NCT01209013|DEVICE|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
214227403|NCT01209013|PROCEDURE|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
214227404|NCT01209013|PROCEDURE|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
214227405|NCT01209013|PROCEDURE|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
214227406|NCT01209013|PROCEDURE|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
214227407|NCT01209013|PROCEDURE|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
214227408|NCT01209013|PROCEDURE|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
214227409|NCT00006289|DRUG|Placebo|4 tabs b.i.d.
214227410|NCT00006289|DRUG|Neurotropin|4 tabs b.i.d.
214227411|NCT02873949|BIOLOGICAL|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
214227412|NCT02873949|BIOLOGICAL|Saliva samples (1ml)|
214227413|NCT02873949|OTHER|Etiologic treatment|education on oral hygiene, scaling and root planing
214227414|NCT02873949|OTHER|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
214227415|NCT02973438|DEVICE|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
214227416|NCT02973438|DEVICE|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
214227417|NCT06464783|OTHER|Comprehensive Corrective Exercise Program|"Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps)."
214227418|NCT06464783|OTHER|Thoracic Exercise Program|"Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)"
214227419|NCT02098668|OTHER|Fertility treatment|Fertility treatment
214227420|NCT04241419|BEHAVIORAL|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
214227421|NCT03211052|DRUG|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
214227422|NCT03211052|PROCEDURE|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
214227423|NCT06522594|DRUG|Esmolol|A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
214227424|NCT03807375|OTHER|CPAP preoxygenation|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
214227425|NCT02079272|OTHER|Helical tomotherapy for breast cancer|"1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy"
214651338|NCT04201717|PROCEDURE|total laparoscopic left colectomy (intracorporeal anastomosis group)|In the experimental group, the surgeon will use a 10-cm medical suture and methylene blue solution to mark the resection margin. The marginal vessels and mesentery will be divided inside the body. The proximal and distal colons are resected using a 60mm linear laparoscopic stapler. Side-to-side intracorporeal anastomotic techniques like anti-peristaltic, iso-peristaltic, or overlap methods will be applied. Once the anastomosis is completed, the specimen is retrieved. The surgeon can place the specimen in a sterile plastic bag for retrieval. Alternatively, the surgeon can use a disposable incision retraction fixator to protect the wound. An abdominal drainage tube is inserted.
214651339|NCT01327755|DIETARY_SUPPLEMENT|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
214651340|NCT01327755|OTHER|Placebo|Same number of pills, frequency, and duration as selenium intervention.
214651341|NCT04828863|BEHAVIORAL|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
214651342|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
214651343|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
214651344|NCT03286972|DEVICE|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
214651345|NCT00856310|BIOLOGICAL|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
214651346|NCT05288582|DEVICE|NovaTears|Over-the-counter eye drop
214227426|NCT03718780|OTHER|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~* 1\) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~* 2\) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
214227427|NCT03718780|OTHER|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
214227428|NCT03718780|OTHER|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
214227429|NCT04721587|DEVICE|Virtual Reality|"The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration"
214227430|NCT03817697|OTHER|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
214227431|NCT03013309|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
214227432|NCT03013309|OTHER|Treatment as usual|Treatment as usual
214227433|NCT00002272|DRUG|Foscarnet sodium|
214227434|NCT00501904|DRUG|Metformin|
214227435|NCT00539968|DRUG|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
214227436|NCT02465099|DEVICE|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
214227437|NCT02465099|DEVICE|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
214227438|NCT00582075|DRUG|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
214227439|NCT04359901|BIOLOGICAL|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
214227440|NCT03438071|OTHER|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
214227441|NCT01686997|PROCEDURE|Roux-en-Y Gastric Bypass|
214227442|NCT03726229|DEVICE|Cholate assay|Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
214651347|NCT02379325|BEHAVIORAL|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
214227443|NCT02983929|PROCEDURE|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
214227444|NCT06429735|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface
214227445|NCT06429735|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
214651348|NCT02379325|BEHAVIORAL|pamphlets material|Given pamphlets material on smoking and complication
214651349|NCT01678976|DRUG|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
214227446|NCT02252341|DIETARY_SUPPLEMENT|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
214227447|NCT00575146|DIETARY_SUPPLEMENT|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
214227448|NCT00690144|DEVICE|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
214651350|NCT01678976|DRUG|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
214651351|NCT05277974|DRUG|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
214651352|NCT04020744|OTHER|real-time fMRI based neurofeedback from the hippocampus|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
214651353|NCT04020744|OTHER|real-time fMRI based neurofeedback from another brain area|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
214227449|NCT04137939|DEVICE|smart exercise system|The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
214651354|NCT00907075|BEHAVIORAL|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
214227450|NCT00052624|BIOLOGICAL|transferrin-CRM107|
214651355|NCT00907075|BEHAVIORAL|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
214651356|NCT04116021|OTHER|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
214651357|NCT04116021|OTHER|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
214651358|NCT05876351|DRUG|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
214227451|NCT06248580|DIAGNOSTIC_TEST|Anti Delta|Anti Delta by ELISA
214227452|NCT02110459|DRUG|POL7080|Intravenous infusion
214227453|NCT02481349|OTHER|Best Practice|Undergo standard of care
214227454|NCT02481349|OTHER|Informational Intervention|Receive DVD for home practice
214227455|NCT02481349|OTHER|Quality-of-Life Assessment|Ancillary studies
214227456|NCT02481349|OTHER|Questionnaire Administration|Ancillary studies
214227457|NCT02481349|OTHER|Yoga|Complete couple-based Hatha yoga program
214227458|NCT00851162|BIOLOGICAL|Trinity multipotent stem cells|Enough to fill voids which vary in size
214227459|NCT00851162|BIOLOGICAL|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
214227460|NCT05448885|DRUG|Tislelizumab|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
214651359|NCT04782791|DRUG|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
214227461|NCT04410133|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
214227462|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
214227463|NCT05890755|OTHER|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
214651360|NCT04782791|DRUG|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
214227464|NCT03631888|DIAGNOSTIC_TEST|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
214227465|NCT03682380|DRUG|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
214227466|NCT03682380|DRUG|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
214227467|NCT04216797|DRUG|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
214227468|NCT05525858|DRUG|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
214227469|NCT05525858|DRUG|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
214227470|NCT05525858|DRUG|Erlotinib|"EGFR Exon 19 deletions in the region E746\_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
214227471|NCT05525858|DRUG|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
214227472|NCT05525858|DRUG|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215\_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775\_G776insSVMA, A775\_G776insYVMA (i.e.,Y772\_A775dup,M774\_A775insAYVME 770delinsEAYVM), G776\_V777 \> AVCV, G776\_V777 \> AVGCV, G776\_V777 \> VCV, G776\_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777\_G778insC, V777L, V777M, G778\_Y779insGSP, P780\_Y781insGSP (i.e.,G778\_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
214227473|NCT05525858|DRUG|Vemurafenib|BRAF\_V600E/D/K/R mutations
214227474|NCT05525858|DRUG|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
214227475|NCT05525858|DRUG|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
214227476|NCT05525858|DRUG|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
214227477|NCT06645496|OTHER|Evaluation of ehealth literacy|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO\_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
214227478|NCT04159298|DEVICE|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
214227479|NCT01229293|PROCEDURE|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
214227480|NCT01229293|PROCEDURE|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
214227481|NCT04423198|BEHAVIORAL|Cognitive Assessment|Self administered cognitive battery
214651361|NCT04782791|PROCEDURE|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
214227482|NCT04423198|BEHAVIORAL|Patient Reported Neurological Outcome Assessments|Standard neurocognitive and neuropsychological tests
214227483|NCT04423198|PROCEDURE|Blood Draw|Specimen collection of whole blood, serum, RNA
214227484|NCT04424953|DEVICE|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
214227485|NCT04424953|DEVICE|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
214227486|NCT03510741|DRUG|Sodium Benzoate|Sodium Benzoate will be administered at 1000mg daily
214227487|NCT03510741|DRUG|N-Acetylcysteine|N-Acetylcysteine 1000 mgs twice daily dose
214227488|NCT03510741|DRUG|Placebo|Placebo added to TAU
214227489|NCT03510741|DRUG|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
214227490|NCT06882356|DEVICE|AI-based glaucoma screening|AI analysis of fundus photographs to detect signs of glaucoma, added to AI-based diabetic eye disease screening performed for routine clinical care
214227491|NCT06882356|DEVICE|IOP measurement|Intraocular pressure measurement by Icare tonometer
214227492|NCT06882356|DEVICE|Virtual Reality Visual Field Testing|Virtual Reality Visual Field Testing by the Olleyes device for participants suspected of having glaucoma
214227493|NCT06746688|BIOLOGICAL|ES2B-C001|Vaccine; Administration with or without \[adjuvant\] every third week for a total of five vaccinations.
214227494|NCT06746688|OTHER|ISA 51 VD|Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.
214227495|NCT06646614|BEHAVIORAL|Group Advance Care Planning Education|Those assigned to the group ACP arm will receive usual care and the intervention which consists of 2 virtual or in-person sessions for a total of 2 hours by a trained community health worker/health educator. Sessions will introduce advanced care planning, help veterans discuss their goals of care with their care teams and learn how to discuss with their families and oncologist, and filing an advanced directive. Participants will be surveyed and interviewed at baseline and again at 8 months post-enrollment.
214227496|NCT07066709|COMBINATION_PRODUCT|FDG PET/MRI|Participants will undergo an FDG PET/MRI
214227497|NCT07070661|DEVICE|Fixed-Dose Radial Pressure Wave Therapy.|Radial pressure wave therapy will be delivered using the BTL-6000 device. Parameters such as frequency and pressure will remain constant throughout each session. Each participant will receive one session per week for three weeks. The treatment will follow a standardized protocol previously established in the literature and based on patient tolerance.
214227498|NCT07070661|DEVICE|Modulated-Dose Radial Pressure Wave Therapy.|The BTL-6000 device will be used to deliver therapy with dynamic modulation of frequency and/or pressure within each session, following a structured protocol aiming to optimize clinical response.
214818023|NCT02503293|DEVICE|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
214227499|NCT06806982|DRUG|VRN101099|Oral capsules
214227500|NCT06141473|DRUG|Frexalimab|SAR441344 Solution for IV infusion
214227501|NCT06141473|DRUG|Teriflunomide|Aubagio oral tablet
214227502|NCT06141473|DRUG|Placebo infusion|Solution for IV infusion
214227503|NCT06141473|DRUG|Placebo tablet|Oral tablet
214227504|NCT06141473|DRUG|MRI contrast-enhancing agents|IV, as per respective label
214227505|NCT06141473|DRUG|Cholestyramine|oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
214227506|NCT06141473|DRUG|Activated charcoal|oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
214227507|NCT07137546|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy ( FFLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at gallbladder fundus~* Peritoneum incised from infundibulum to fundus along liver bed~* Gallbladder dissected from fundus toward infundibulum~* Cystic artery and duct identified and divided last~* Critical view of safety achieved before vessel division"
214227508|NCT07137546|PROCEDURE|Classical Laparoscopic Cholecystectomy (CLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at Calot's triangle~* Critical view of safety achieved first~* Cystic artery and duct divided before gallbladder bed dissection~* Gallbladder dissected from liver bed"
214227509|NCT07099638|DRUG|Varenicline (VAR)|13 weeks of varenicline
214227510|NCT07099638|DRUG|Nicotine lozenge (NRT)|12 weeks of nicotine lozenges
214227511|NCT07099638|BEHAVIORAL|Smartphone intervention with adherence components (ADHERE)|Smartphone-based smoking cessation intervention with adherence components
214227512|NCT07099638|BEHAVIORAL|Smartphone intervention without adherence components (NO ADHERE)|Smartphone-based smoking cessation intervention without adherence components
214227513|NCT07099638|BEHAVIORAL|Telephone Counseling|Up to 6 telephone counseling sessions with a tobacco treatment specialist
214227514|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
214227515|NCT00336648|DRUG|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
214227516|NCT00336648|DRUG|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
214227517|NCT00336648|PROCEDURE|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
214227518|NCT07096024|DRUG|palbociclib plus fulvestrant|Patients treated with the combination of palbociclib and fulvestrant
214227519|NCT07096024|DRUG|fulvestrant|Patients treated with fulvestrant alone
214227521|NCT06556992|BEHAVIORAL|FIT Teens|This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
214227522|NCT07106788|DEVICE|Aveir DR Leadless Pacemaker Implant|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
214227523|NCT07106788|DEVICE|Single-chamber atrial Aveir patients|Patients will undergo a single chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right atrium
214227524|NCT07106788|DEVICE|Upgrades|Patients with an existing single-chamber leadless pacemaker will undergo a leadless pacemaker system implant wherein an additional leadless pacemaker will be implanted in either the right ventricle or right atrium to form a dual-chamber LP system.
214227525|NCT07106788|DEVICE|Roll-over|Patients with an existing active Aveir DR leadless pacemaker system are eligible to be rolled into the Aveir Japan PMS upon consent for ongoing follow-up.
214227526|NCT07109869|DRUG|Boric acid|Boric acid vaginal inserts consisting of 600 mg boric acid drug substance filled into white, opaque hypromellose capsules with no additional excipients included in the formulation. Each vaginal insert is sealed into a clear blister cavity.
214227527|NCT07109869|OTHER|Placebo|Placebo vaginal inserts containing anhydrous lactose and 1% magnesium stearate are also manufactured and filled into white, opaque hypromellose capsules. Packaged in clear blisters.
214227528|NCT06749067|BEHAVIORAL|Mindfulness Based Practices|Experiment 1 Group Intervention: In the first session preparation session; face-to-face meeting with the women in the experimental group and then general information about the definition, purpose and applications of the mindfulness-based practice will be given, and the lack of information about the practice, if any, will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Awareness Practice, women will be focused on the moment with a 3-minute breathing exercise and then continue with the raisin exercise.
214227529|NCT06749067|BEHAVIORAL|Occupational Practices|Experiment 2 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. Before starting the Busyness Practice, women will be asked to choose the practice that they can do within the scope of the busyness practice such as 'hand knitting, wood painting, charcoal, origami, bead work, jewellery design, painting tables with
214227530|NCT06749067|BEHAVIORAL|Mindfulness-Based Occupational Practice|Experiment 3 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Mindfulness-Based Engagement Practice, women will be focused on the moment with a 3-minute breathing exercise, followed by a raisin exercise.
214227531|NCT06915233|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|An autologous cellularized scaffold product being studied for the repair of symptomatic, single or multiple full-thickness cartilage defects of the talus with or without bone involvement in adults.
214227532|NCT06915233|PROCEDURE|Bone Marrow Stimulation|"A surgical awl or microdrill will be used to make multiple holes in the exposed base of the lesion. The microfracture procedure should result in holes that are approximately 3 to 4 mm apart.~When fat droplets can be seen coming from the marrow cavity, the appropriate depth (approximately 2 to 4 mm) has been reached.~The released marrow elements (including mesenchymal stem cells, growth factors, and other healing proteins) form a surgically induced clot that provides an enriched environment for new tissue formation."
214227533|NCT07118839|DRUG|Full Dose MDMA|3 MDMA dosing (Experimental) sessions: Session 1 - 80mg to 120mg MDMA HCl; Session 2 - 80mg to 180mg MDMA HCl; Session 3 - 80mg to 180mg MDMA HCl
214227534|NCT07118839|BEHAVIORAL|MDMA-AT|inner-directive psychotherapy will be conducted throughout the study; Lykos Therapeutics MDMA-AT Manual
214227535|NCT07118839|DRUG|Active Placebo Dose MDMA|3 MDMA dosing (Experimental) sessions in which participants will receive 40mg MDMA HCl max at each session.
214227536|NCT07117877|DRUG|Etoposide Capsules|50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle
214227537|NCT07117877|DRUG|Bevacizumab|7.5mg/kg, i.v, q3w
214227538|NCT07117877|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg, i.v., q3w
214227539|NCT07124494|PROCEDURE|Regional anethesia|This single-center, prospective, randomized controlled trial aims to compare the effects of three different postoperative analgesia techniques following spinal anesthesia in patients undergoing total knee arthroplasty (TKA). The study will assess the impact of combined spinal-epidural anesthesia, adductor canal block, and multimodal intravenous analgesia on postoperative knee range of motion (ROM). Secondary outcomes include patient satisfaction, opioid consumption, Oxford Knee Score (OKS), activity levels, and visual analog scale (VAS) pain scores.
214651362|NCT03339492|DEVICE|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
214651363|NCT01922921|BIOLOGICAL|HER-2/neu Intracellular Domain Protein|Given ID
214651364|NCT01922921|OTHER|Laboratory Biomarker Analysis|Correlative studies
214651365|NCT01922921|BIOLOGICAL|Pertuzumab|Given per standard of care
214227540|NCT05629676|BEHAVIORAL|BMT-VR|BMT-VR is a novel psychosocial intervention that addresses the supportive care needs of patients undergoing BMT. BMT-VR includes six sections focused on: 1) psychoeducation to help patients increase their awareness to stress and challenges that may accompany the BMT journey; 2) supportive psychotherapy strategies to help patients adjust to the intense BMT hospitalization; 3) psychosocial skill building to promote mindfulness, acceptance and gratitude while living with uncertainty; 4) psychoeducation to manage expectations and enhance preparedness for extended hospitalization; 5) psychosocial skill-building to promote effective coping; and 6) an overview of psychosocial skills grounded in cognitive behavior therapy, mindfulness, and positive psychology
214227541|NCT06938347|DRUG|Agitated Saline SoC|The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.
214227542|NCT06938347|DRUG|ASI-02|Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.
214227543|NCT06942481|BEHAVIORAL|Girls Invest|The Girls Invest intervention involved: 1) app-based trainings on topics related to financial literacy, gender equity, and health and 2) financial resources/incentives supporting girls' education/career.
214227544|NCT06942481|BEHAVIORAL|Waitlist control|Participants receive Girls Invest after they complete the 6 month follow-up survey.
214227545|NCT07144826|PROCEDURE|Biospecimen Collection|Undergo blood and vaginal sample collection
214227546|NCT07144826|DRUG|Placebo Administration|Given PO
214227547|NCT07144826|DIETARY_SUPPLEMENT|Probiotic|Given PO
214227548|NCT07144826|OTHER|Questionnaire Administration|Ancillary studies
214227549|NCT07146074|RADIATION|Preventive radiotherapy|Either conventional radiotherapy (single dose of 8 Gy) or Stereotactic Ablative Body Radiation (either 1x20 Gy, 2x12 Gy, 3x10 Gy or 5x8 Gy) will be delivered depending on the participant's prognostic outcome.
214227550|NCT07146074|DRUG|Systemic therapy (Standard of Care)/Observation|It concerns systemic therapy if applicable according to the standard of care or only observation.
214227551|NCT07146646|DRUG|Trifluridine/tipiracil|FTD/TPI will be taken by mouth on Days 1-5 of the 14-day treatment cycle. The starting does is 25mg/m2 twice per day.
214227552|NCT07146646|DRUG|Oxaliplatin|Oxaliplatin is given on Day 1 of each 14-day cycle. It is given intravenously (by IV) over 2 hours.
214227553|NCT07144982|BEHAVIORAL|Counselling session|Each enrolled parent received a single, standardized counselling session (\~15 minutes) delivered in the ambulatory unit by a certified tobacco counsellor. The session followed a fixed script and covered: (1) types of tobacco smoke exposure (primary, secondary and tertiary), (2) health consequences for children with emphasis on perioperative respiratory and anaesthetic risks, (3) practical measures to reduce household exposure (smoke-free home/car rules, behavioural strategies), and (4) brief advice on initial cessation steps and referral options. Structured handouts and signposting to support services were offered when appropriate.
214227554|NCT07145411|OTHER|Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)|The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
214227555|NCT07146919|DRUG|Bemarituzumab|"Part 1 Dose escalation part :~IV infusion, every 3 weeks with the dose :~DL1 = 15 mg/kg cycle 1 day 1, then 11 mg/kg thereafter from cycle 2 day 1 DL2 = 22 mg/kg cycle 1 day 1, then 15 mg/kg thereafter from cycle 2 day 1 DL3 = 30 mg/kg cycle 1 day 1, then 22 mg/kg thereafter from cycle 2 day 1~Part 2 Extension part :~IV infusion, every 3 weeks with the dose defined in the phase I dose escalation~Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first"
214227556|NCT07146919|DRUG|Bevacizumab|IV infusion, 15mg/kg, every 3 weeks. Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first
214227557|NCT07146607|BEHAVIORAL|Audiology text-message protocol|Florence is an interactive text messaging service, endorsed by NHS England, designed to improve clinical outcomes for patients. An audiology text-message protocol, delivered via Florence, will prepare, inform and support new NHS hearing aid users as they are prescribed, receive, and start to use their hearing aid(s).
214227558|NCT07145307|DEVICE|Sidekick|An app for adolescents used to plan, complete and evaluate exposure exercises completed between sessions at a children and adolescent mental health clinic (BUP)
214227559|NCT07145281|DRUG|Estradiol (E2)|"Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).~In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.~All participants are treatment-naive."
214227560|NCT07145281|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|"Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.~All participants are treatment-naive."
214227561|NCT07146035|DEVICE|CP369 Feasibility of a newly developed ostomy prototype (only one intervention)|The study is an open-label, single-arm, comparative study, investigating the feasibility of the prototype in subjects with ileostomy. The study is comparing the prototype exposed only to sweat (abdominal side) with the prototype exposed to sweat and output (peristomal side). Meaning, subjects are their own control.
214651366|NCT01922921|OTHER|Placebo|Given PO
214651367|NCT01922921|BIOLOGICAL|Polysaccharide-K|Given PO
214651368|NCT01922921|BIOLOGICAL|Trastuzumab|Given per standard of care
214651369|NCT01332708|BEHAVIORAL|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
214651370|NCT00709826|DRUG|gemcitabine|Gemcitabine: per package insert.
214651371|NCT00709826|DRUG|placebo|placebo: 100 mg tablets, 400 mg/day
214651372|NCT00709826|DRUG|Erlotinib|Erlotinib - per package insert.
214651373|NCT00709826|DRUG|apricoxib|apricoxib: 100mg tablets, given orally
214227562|NCT06946095|DRUG|Chinese patent medicine|This study aims to investigate whether the addition of Xinyue Capsule to conventional Western medical therapy significantly improves cardiac function and reduces the level of heart failure biomarker NT-proBNP in patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
214227563|NCT06946303|OTHER|Survey|Pre and post survey on confidence and knowledge of falls
214227564|NCT06946303|OTHER|Interview|Interview on the learning from the falls ambassador programme
214227565|NCT06946303|OTHER|Observation|Observation of falls ambassador workshops
214227566|NCT06947616|DRUG|Mild therapeutic hypothermia|Patients received mild therapeutic hypothermia (MTH) to 33°C for 24-36 h
214227567|NCT06946706|DIAGNOSTIC_TEST|hydrogen and methane breath testing|The hydrogen and methane breath testingt(HMBT) is a non-invasive method based on gas analysis of gut microbiota metabolomics.Normal human metabolic processes do not produce methane and hydrogen, and all methane and hydrogen in exhaled breath come from metabolites produced during the fermentation of substrates by gut microbiota. About 14-21% of the gas can diffuse through the intestinal mucosa to the bloodstream, circulate through the bloodstream to the alveoli, and be exhaled through gas exchange.Based on substrate properties, separate and measure methane and hydrogen concentrations from exhaled breath for non-invasive, convenient, and accurate diagnosis of microbial imbalance/small intestine bacterial overgrowth (SIBO)
214227568|NCT06947759|RADIATION|PET/MRI|"This single-center prospective observational study targets patients pathologically diagnosed with nasopharyngeal carcinoma (NPC) and clinically staged as cT3-4/N2-N3. Participants will first undergo standard whole-body 18F-FDG PET/CT, followed by localized 18F-FDG PET/MRI of the head and neck within 4 hours. Both imaging procedures will be performed according to standard clinical protocols to ensure data consistency and comparability.~PET/MRI data will be independently interpreted by an experienced nuclear medicine physician and a radiologist. The sensitivity, specificity, and staging accuracy for detecting distant metastases will be analyzed. In cases of disagreement, a third physician will mediate to reach a consensus.~The study team will also record the operational time, direct costs, and potential issues encountered during the examination process for both imaging modalities. All participants will be followed for at least one year to validate imaging results and assess correlation"
214227569|NCT06946264|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (albuterol sulfate 2.5mg/ 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
214227570|NCT06946264|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (sodium chloride 0.9% 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
214227571|NCT06947421|BEHAVIORAL|McKenzie Exercise|"Exercises will be performed in seated or supine positions, 15 repetitions per session, twice daily, for a total duration of 6 weeks. The program will begin with physiotherapist-supervised sessions and continue at home with guidance via a digital training manual. Weekly follow-up and progress will be ensured through individual exercise diaries. Participants missing two consecutive days of exercise will be excluded from the study. Includes:~* Cervical retraction in sitting and supine positions~* Cervical rotation to both sides~* Lateral flexion of the neck~* Combined chin rotation toward the shoulder"
214227572|NCT06947421|BEHAVIORAL|Standard Neck Exercise|"The protocol includes chin tucks, chin drop stretches, scapular retraction with resistance, and both unilateral and bilateral pectoral stretching. Exercises will be performed twice daily, 15 repetitions per session, over a period of 6 weeks. Exercise progression will be adapted biweekly based on participant tolerance. Includes:~* Chin tucks in supine with progressive hold durations~* Chin drop stretch in sitting with optional manual assistance~* Scapular retraction using theraband or weights~* Pectoral muscle stretching using doorway and seated techniques"
214227573|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
214227574|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214227575|NCT06946953|BIOLOGICAL|P63+ lung progenitors|"1. Patient Screening and Cell Collection:~   Eligible patients will undergo sample collection at the study center or authorized tertiary hospitals. The operator will collect samples via bronchial brushing from three healthy segments of the patient's 3-5 level bronchi. The samples will be transported to a cooperative production facility for isolation and preparation. The cell preparation cycle is approximately 4-8 weeks. Patients will bear the costs of this process.~2. Transplantation Therapy:~   Transplantation therapy will be conducted at Ruijin Hainan Hospital. The cell preparation will be administered via fiberoptic bronchoscopy to each lung segment, with one dose per patient. After infusion, patients are advised to remain hospitalized for 24-48 hours for observation.~3. Post-Treatment Follow-Up:~Patients are advised to return for examination and evaluation at 4 and 24 weeks post-treatment."
214227576|NCT06946121|DRUG|Lignocaine|50 women undergoing diagnostic outpatient office hysteroscopy proceeded by infusions of intrauterine lidocaine 2% and normal saline at room temperature.
214227577|NCT06946121|DRUG|Saline|50 women undergoing diagnostic outpatient office hysteroscopy using warmed normal saline distention medium.
214227578|NCT06946108|DIAGNOSTIC_TEST|Detection of Pancreatic Exocrine Function in Patients with Chronic Pancreatitis (CP)|For CP patients who are hospitalized, they are recruited to voluntarily preserve their feces for the detection of fecal elastase-1 (FE-1) so as to evaluate the pancreatic exocrine function.
214227579|NCT06947941|DRUG|KarXT|Specified dose on specified days
214227580|NCT06947941|DRUG|KarX-EC|Specified dose on specified days
214651374|NCT01258920|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
214227581|NCT06947941|DRUG|KarXT + KarX-EC Arm Matching Placebo|Specified dose on specified days
214227582|NCT06945991|OTHER|observation group|the observation group was additionally managed with an integrated nursing and medical approach.
214227583|NCT06945991|OTHER|control group|The control group received routine nursing care
214227584|NCT06946498|PROCEDURE|Local Anesthesia Thoracoscopy|"The patient is placed in a lateral decubitus, with the affected hemithorax upwards. Ensuring a venous line and full monitoring of vital functions. Mild sedation is given and a dose of Ceftriaxone is given 30 minutes before. Local anesthesia is injected in layers, starting from the skin and working up to the intercostal muscles, intercostal nerve, and periosteum of the rib.~Development of pneumothorax is done using a 16-gauge Boutin needle. 15 spontaneous breaths are sufficient to create a pneumothorax, and entry of rigid thoracoscope into the hemithorax through a 11-13 mm Trocar. Multiple biopsies from the parietal pleura are taken and pleurodesis is made according to operator judgment. A chest drain 20-22 G is placed and sutured.~A chest X-ray is performed 2-8 hours later after the patient is transferred to the ward. Chest drain is removed after 24h if fluid production is \<250ml and lung re-expansion."
214227585|NCT06946498|DEVICE|Pleuroscopy with Rigid Thoracoscope and Forceps biopsies|A video thoracoscope with an external light source, outer diameter 10 mm (Karl Storz), is inserted into the pleural cavity through a uniportal incision (1 - 1.5 cm) and complete inspection of the pleural cavity is performed. Parietal pleural biopsies are taken with a rigid 40 mm forceps (Karl Storz).
214227586|NCT06947889|OTHER|RAGT|Biofeedback based system development to enhance Robotic Assisted Gait Training in cerebral palsy pediatric patients
214227587|NCT06946628|DRUG|Group A (triple combination therapy group)|1\) Initiate with Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, if blood glucose is not controlled, adjust to Semaglutide 0.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd. If Semaglutide is well-tolerated, increase to 1 mg qw after 1 week; 3)If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
214227588|NCT06946628|DRUG|Group B (standard therapy group)|metformin-based treatment is recommended when not contraindicated. 1).Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After another month, if blood glucose remains uncontrolled, add Semaglutide 0.25 mg qw, then increase to 0.5 mg qw after 1 month. If well-tolerated, increase to 1.0 mg qw after 1 week; 4) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
214227589|NCT07146971|DRUG|OTC Drug for Atopic Dermatitis in Cream form|OTC Cosmetic Cream Formulation
214227590|NCT06947044|PROCEDURE|RBC transfusion strategy|RBC transfusion strategy to maintain a hemoglobin level of at least 110 g/L.
214227591|NCT07146269|DEVICE|tDCS|Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3/F4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.
214227592|NCT07146269|DEVICE|VR-based relaxation therapy|Nature exposure via a Virtual Reality (VR) headset, for 30 minutes daily concurrently to tDCS, Monday to Friday, for a total of 20 sessions.
214227593|NCT07146828|DEVICE|Binocular Wavefront Optometry Machine (BWFOM, Ai-Zhitong Medical Technology Co., Ltd., Zhejiang, China)|The 0.05 D refraction group had their infusion rates precisely calibrated using 0.05 D refraction by the Binocular Wavefront Optometry Machine
214227594|NCT07145320|OTHER|Oral Cryotherapy Group (Group 1)|Participants were educated about oral cryotherapy before their first chemotherapy cycle. Individually portioned ice bags (15 mL per cube) were prepared and provided free of charge for home use (6 bags per cycle). Patients were instructed to apply the ice intra-orally for 30 minutes at a time, 6-10 times daily, beginning at the start of Adriamycin infusion. A Cryotherapy Application Log Form was used to record date, start, and end times for each session.
214651375|NCT05395676|DEVICE|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
214651376|NCT01898156|DRUG|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
214651377|NCT05779085|OTHER|Dermocosmetic|Use of daily cleanser to treat facial acne
214651378|NCT00193830|PROCEDURE|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
214651379|NCT03502512|OTHER|Questionnaire Administration|Ancillary studies
214651380|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
214651381|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
214651382|NCT02103140|BEHAVIORAL|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
214227595|NCT07145320|OTHER|Chewing Gum Group (Group 2)|Patients received standardized, tasteless, single-use chewing gum (6 boxes per cycle) and were instructed to chew a piece for 20-30 minutes before and during chemotherapy infusion. A new piece was provided midway through the session. Usage was recorded in a Chewing Gum Application Log Form, capturing date and timing details.
214227596|NCT06947005|BEHAVIORAL|Intervention 1|The students in the serious game group were asked to download the drug applications serious game to their phones. They were asked to play the game for two weeks. The students continued to play the game at any time and as often as they wanted until they won at least one gold medal for each application. At the end of the 2nd week, a questionnaire form and VAS scale were applied to the students to evaluate the post-test data and their satisfaction levels with the game. The collected data were analysed to understand the different dimensions of game satisfaction and to assess overall satisfaction levels.
214651383|NCT02103140|BEHAVIORAL|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
214227597|NCT06947005|BEHAVIORAL|Intervention 2|A WhatsApp group was established to maintain communication with the students in the video-supported education group. After the pre-test data were collected, the students were introduced to the ed-puzzle web page where they could watch the application videos and were asked to register to the system. No fee was paid to register to the ed-puzzle web page. Students were given the opportunity to watch the videos on the ed-puzzle web page for 2 weeks and answer the questions. Each student was allowed to watch the videos at least once until they answered all the questions correctly. The number of videos watched was monitored by the researcher. At the end of the 2nd week, post-test data were collected from the students.
214227598|NCT06954064|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
214227599|NCT06955195|BEHAVIORAL|School-based intervention program on improving adolescent mental wellbeing|Students participating in the intervention program will attend the school talk and workshops about mental health. They are also required to organize whole-school activities to promote peer mental wellbeing at school. All attended students will be guided by registered social workers and trained research personnel throughout the intervention program.
214227600|NCT06955195|OTHER|Control-no treatment|Students participating at control group will not receive intervention program during the academic year compared with their counterparts in active comparator group. They will live and attend the class as usual at school. After the academic year, they will receive the intervention program on the alternative academic year.
214227601|NCT07145047|BIOLOGICAL|oncolytic virus|Intratumoral injection of oncolytic virus.
214227602|NCT07147088|DRUG|SHR-1701|SHR-1701 will be administered by IV, 1200mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214227603|NCT07147088|DRUG|Famitinib|Famitinib will be administered at 15 mg orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214227604|NCT07147088|PROCEDURE|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. SHR-1701 plus famitinib will be administered 1-3 days after cryoablation.
214227605|NCT07146841|PROCEDURE|Round window insertion|Insertion of the electrode array via the round window.
214227606|NCT07146841|PROCEDURE|Cochleostomy insertion|Insertion of the electrode array via cochleostomy.
214227607|NCT07146841|DEVICE|Lateral wall array|Lateral wall electrode array from Advanced Bionics.
214227608|NCT07146841|DEVICE|Periomodiolar electrode array|Perimodiolar MidScala electrode array from Advanced Bionics.
214227609|NCT07145177|DRUG|177Lu-PSMA-617|Given intravenously (IV)
214227610|NCT07145177|PROCEDURE|Ablation|Undergo ablation
214227611|NCT07145177|PROCEDURE|Trans-arterial chemoembolization (TACE)|Undergo TACE
214227612|NCT07145177|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
214651384|NCT05148884|DRUG|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
214227613|NCT07145177|PROCEDURE|Tumor Biopsy|Undergo biopsy
214651385|NCT05148884|DRUG|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
214227614|NCT07145177|OTHER|Questionnaire|Participant will complete questionnaire
214227615|NCT07145775|DRUG|sufentanil-ropivacaine combination|Epidural labor analgesia will be conducted using the sufentanil-ropivacaine combination (0.4 microgram/ml sufentanil + 0.072% ropivacaine).
214227616|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 1|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 1 (0.4 microgram/ml dexmedetomidine + 0.15 mg/ml esketamine + 0.036% ropivacaine).
214227617|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 2|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 2 (0.4 microgram/ml dexmedetomidine + 0.2 mg/ml esketamine + 0.036% ropivacaine).
214227618|NCT07144904|DRUG|Indocyanine Green (ICG)-Assisted Ureteral Identification|A temporary ureteral stent will be placed unilaterally (left or right) prior to robotic procedures in participants undergoing robot-assisted single-site surgery for advanced-stage endometriosis. Indocyanine green (ICG) will be administered through the stent to enable real-time fluorescence imaging for intraoperative ureter identification. The contralateral ureter will be identified using standard visualization techniques without ICG. Side allocation (ICG vs. control) will be determined by computer-generated block randomization.
214651386|NCT01993888|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|
214651387|NCT01993888|OTHER|Standard of Care (SoC)|
214651388|NCT01501903|PROCEDURE|Standard|FNA in a single plane
214651389|NCT01501903|PROCEDURE|Fanning|FNA in multiple planes
214651390|NCT00806221|DRUG|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
214227619|NCT07144904|PROCEDURE|Standard Ureteral Identification without ICG|Ureter identification will be performed using standard intraoperative visualization techniques without the use of indocyanine green (ICG) fluorescence imaging. This will be done on the contralateral side to the randomized ICG-assisted ureteral identification during robot-assisted single-site surgery for advanced-stage endometriosis.
214227620|NCT07146945|DRUG|S1-221|S1-221 will be administered orally to participants.
214227621|NCT07146945|DRUG|Placebo|Matching placebo will be administered orally to participants.
214227622|NCT07146945|DRUG|THC|A single dose of THC will be administered to participants orally.
214227623|NCT07145008|DRUG|Suprachoroidal triamcinolone acetonide injection|For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.
214227624|NCT07145853|OTHER|Mandala activity|"The application will last for 1-2 hours once a week for a total of 8 weeks.~For individuals aged 65 years and over who meet the inclusion criteria and are included in the intervention group, a mandala draft in A4 format (21.0 cm x 29.7 cm) consisting of 8 round patterns to be determined in advance, and a dry paint set consisting of 12 colors for ease of use will be used. Quality dry paint will be used to prevent allergies"
214227625|NCT07147010|DEVICE|MIB Breath Analyzer|"Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).~Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)~Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)."
214227626|NCT07145242|OTHER|Acupuncture|Intervention Description \* § Add details that will distinguish this intervention from other interventions in this or another clinical study.
214227627|NCT07145541|DEVICE|Aion Tempshield Device|The AION BIOSYSTEMS, INC. tempshield is a skin-applied, continuous temperature monitor. It is battery powered, communicates using Bluetooth LE to a smartphone, then to a clinician dashboard, and is designed to be worn continuously for up to 60 days. Its primary use is for patient monitoring in hospital or post-discharge from a healthcare facility. Through the tempshield system, clinicians can be notified if a patient's temperature exceeds a given threshold. The tempshield system is centered around a non-invasive temperature sensor placed against the patient's skin, in the pectoral region just below the collar bone. The temperature sensor is held in place with a silicone adhesive tape similar to a custom shaped piece of medical tape. The silicone adhesive tape is hypoallergenic.
214227628|NCT07146373|OTHER|Inspiratoty Muscle training|Participants will follow an IMT program through a threshold IMT device which consists of 5 set/6 breaths at 50-60% MIP for 3 months along with their usual physical and cogntive training
214227629|NCT07146373|OTHER|Usual Care|Physical and cognitive training
214227630|NCT07145749|BEHAVIORAL|Transtheoretical theory-based education|Transtheoretical theory-based education will be provided to individuals with substance use disorders face-to-face in 8 modes and each lesson will last 45 minutes. Weekly education stages of transtheoretical theory-based education: Week 1; Stage 1 (not thinking); Weeks 2 and 3, Stage 2 (Thinking/Intention); Weeks 4 and 5, Stage 3 (Preparation); Weeks 6 and 7, Stage 4 (taking action); Week 8, Stage 5 (Maintenance/Continuing).
214227631|NCT07145749|OTHER|Pre-test-after-test-re-test|Information Form, Sexual Risk Taking Scale, AIDS Knowledge Scale and AIDS Prevention Self-Efficacy Scale
214227632|NCT07146594|DRUG|Modified bismuth-containing eradication treatment|"After the confirmation of Helicobacter pylori infection, eligible patients whether first line or rescue therapy will be assigned to receive:~\- A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all medications taken for 14 days.~Esomeprazole will be given at least 30 minutes before meals every 12 hours. Antibiotics will be given after meals every 8 hours and bismuth subcitrate at least 2 hours far from meals every 12 hours."
214227633|NCT07144969|DIETARY_SUPPLEMENT|Honey|Group B patients were asked to eat one half tablespoon of natural honey every 4 hours
214227634|NCT07144969|DIETARY_SUPPLEMENT|gum chewing|Group A patients were asked to chew gum for 5 minutes every 4 hours
214227635|NCT07145554|OTHER|Focal extracorporeal schock wave therapy|Participants in this group will receive a total of 5 sessions of focal extracorporeal shock wave therapy. Each session will deliver 1000 pulses per cm² to the affected piriformis muscle.
214227636|NCT07145554|PROCEDURE|Steroid Injection|Participants in this group will receive a single injection of corticosteroid into the piriformis muscle.
214227637|NCT07147166|DEVICE|Brijjit® BP100-6 and BP-75|Brijjit® BP-100 and BP-75 are a non-invasive, flexible devices that acts as a force modulating tissue bridge (FMTB) to aid in wound healing. BP-100 and BP-75 simply refer to different sizes of the Brijjit device.
214227638|NCT07147166|OTHER|Control: Standard of care and normal wound dressing|The control chest side will receive only standard of care and normal wound dressing.
214227639|NCT07146087|BIOLOGICAL|MSC-Derived Exosomes|Purified, sterile, acellular extracellular vesicles (exosomes) isolated from culture supernatant of GLP-manufactured allogeneic human bone-marrow-derived MSCs. Release criteria include particle size distribution 30-150 nm (nanoparticle tracking analysis), particle count, sterility/endotoxin testing, mycoplasma negative, and predefined protein/marker profile (e.g., CD9/CD63/CD81 positive).
214227640|NCT07146087|BIOLOGICAL|Placebo (Normal Saline)|0.9% sodium chloride solution matched to the experimental product in volume, appearance, infusion set-up, and administration procedures.
214651391|NCT00832819|DRUG|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
214651392|NCT00832819|DRUG|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
214651393|NCT00832819|DRUG|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
214227641|NCT05552352|OTHER|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
214227642|NCT03703297|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214651394|NCT00832819|DRUG|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
214651395|NCT03606382|DIAGNOSTIC_TEST|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
214651396|NCT03606382|DIAGNOSTIC_TEST|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
214227643|NCT03703297|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
214227644|NCT03703297|OTHER|Placebo|Placebo IV (intravenous infusion)
214227645|NCT05887596|OTHER|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
214227646|NCT05148195|DRUG|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
214227647|NCT05148195|DRUG|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
214227648|NCT05148195|DRUG|Docetaxel|75mg/m2，Q3W
214227649|NCT05148195|DRUG|Irinotecan|180 mg/m2，Q2W
214227650|NCT05148195|DRUG|Leucovorin calcium|400mg/m2，Q2W
214227651|NCT05148195|DRUG|5-Fluorouridine|2400 mg/m2，Q2W
214227652|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
214227653|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
214227654|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
214227655|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
214227656|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
214227657|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
214651397|NCT03276741|DIETARY_SUPPLEMENT|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
214651398|NCT05028803|DRUG|sodium phenylbutyrate|same as arm/group
214227658|NCT04333303|OTHER|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
214227659|NCT01483339|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
214651399|NCT00851903|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
214651400|NCT00851903|DRUG|Sitagliptin|Oral administration. 100mg film-coated tablets.
214227660|NCT01483339|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
214227661|NCT06233669|OTHER|Analysis of Burnout|No intervention used.
214227662|NCT06023836|DEVICE|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
214227663|NCT06023836|PROCEDURE|Dry needling|Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
214227664|NCT01410617|PROCEDURE|hemodialysis|3 sessions hemodialysis before CABG
214227665|NCT04788368|PROCEDURE|Surgical resection|Surgical resection with either of the above mentioned techniques
214651401|NCT00851903|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
214651402|NCT06329934|BEHAVIORAL|Establishment of a hierarchical monitoring and management team|To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
214227666|NCT01888432|DRUG|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
214227667|NCT01888432|DRUG|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
214227668|NCT00000771|DRUG|Paromomycin sulfate|
214227669|NCT03054129|OTHER|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
214227670|NCT03054129|OTHER|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
214227671|NCT00130247|DRUG|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
214227672|NCT00130247|DRUG|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
214227673|NCT00130247|DRUG|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
214227674|NCT00130247|DRUG|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
214227675|NCT04278105|DEVICE|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
214227676|NCT04278105|DEVICE|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
214227677|NCT04278105|OTHER|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
214227678|NCT04486001|BIOLOGICAL|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
214227679|NCT01930331|DRUG|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
214227680|NCT01930331|DRUG|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
214227681|NCT05841173|DIETARY_SUPPLEMENT|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
214227682|NCT05841173|BEHAVIORAL|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
214227683|NCT05841173|OTHER|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
214227684|NCT05841173|BEHAVIORAL|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
214227685|NCT06185270|DIAGNOSTIC_TEST|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
214227686|NCT04608461|DRUG|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
214651403|NCT06329934|BEHAVIORAL|Assessment of pressure injury|Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
214651404|NCT06329934|BEHAVIORAL|Communication|Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
214227687|NCT01660958|DIETARY_SUPPLEMENT|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
214227688|NCT01660958|BEHAVIORAL|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
214227689|NCT05491460|DRUG|Apixaban 5 MG Tab|oral intake
214227690|NCT05491460|DRUG|Dabigatran 150 MG Tab|oral intake
214227691|NCT05491460|DRUG|Edoxaban 60Mg Tab|oral intake
214227692|NCT05491460|DRUG|Rivaroxaban 20 MG Tab|oral intake
214227693|NCT05637060|DRUG|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
214227694|NCT05637060|DRUG|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
214227695|NCT05498415|BEHAVIORAL|Education|Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.
214227696|NCT05498415|BEHAVIORAL|Health coaching|Participants will meet with a health coach weekly for 8 weeks
214227697|NCT05498415|BEHAVIORAL|Activity Monitor|Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
214227698|NCT00434239|DRUG|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
214227699|NCT04137445|OTHER|Baby Foods|Commercially available baby foods
214227700|NCT04137445|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
214227701|NCT03165604|OTHER|standard information|The participates will be given a standard information regarding the water drink before physical activity
214227702|NCT03165604|OTHER|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
214227703|NCT02889367|DRUG|Odalasvir 100 mg|Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.
214227704|NCT02889367|DRUG|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
214227705|NCT02889367|DRUG|Odalasvir 500 mg|Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.
214227706|NCT02889367|DRUG|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
214227707|NCT02604901|BEHAVIORAL|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
214227708|NCT02604901|BEHAVIORAL|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
214227709|NCT05363254|OTHER|Marlboro Gold Box|A combustible cigarette
214227710|NCT05363254|OTHER|Newport Box|A combustible cigarette
214227711|NCT05363254|OTHER|Non-combusted cigarette variant 42001401|A menthol flavor variant of a non-combusted cigarette (42001401)
214227712|NCT05363254|OTHER|Non-combusted cigarette variant 42001399|A menthol flavor variant of a non-combusted cigarette (42001399)
214227713|NCT05363254|OTHER|Non-combusted cigarette variant 40007386|A menthol flavor variant of a non-combusted cigarette (40007386)
214227714|NCT05363254|OTHER|Non-combusted cigarette variant 42001402|A non-menthol flavor variant of a non-combusted cigarette (42001402)
214227715|NCT06057961|OTHER|Art Therapy|8 meetings in 1 year
214227716|NCT01671579|PROCEDURE|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
214227717|NCT01671579|PROCEDURE|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
214227718|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Myo-inositol
214227719|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|N-Acetyl-Cysteine
214227720|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Folic Acid
214227721|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Selenium
214227722|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-arginine
214227723|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-carnitine
214227724|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Vitamin E
214227725|NCT02754700|OTHER|Neuromuscular Training|Standardized, comprehensive neuromuscular training
214227726|NCT02754700|OTHER|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
214227727|NCT02754700|OTHER|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
214227728|NCT02559700|BEHAVIORAL|Brain training programme|An online package of brain training programmes
214227729|NCT05998889|BEHAVIORAL|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
214227730|NCT05998889|BEHAVIORAL|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
214227731|NCT04671732|PROCEDURE|Fenestrated endovascular aortic aneurysm repair|Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.
214227732|NCT04671732|PROCEDURE|open repair of abdominal aortic aneurysm.|Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
214227733|NCT03636841|DEVICE|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
214227734|NCT03406091|DRUG|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
214227735|NCT05563870|PROCEDURE|Endoluminal radiofrequency ablation|Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
214227736|NCT05563870|PROCEDURE|Endoscopic biliary stenting|Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
214227737|NCT00106509|DRUG|tolevamer potassium-sodium (GT267-004)|
214227738|NCT01822314|DRUG|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
214227739|NCT01822314|DRUG|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
214227740|NCT05373069|PROCEDURE|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
214227741|NCT03648866|OTHER|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
214227742|NCT02702297|OTHER|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
214227743|NCT01957670|DEVICE|Lacrima medical Prototypes|
214227744|NCT02848729|DRUG|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
214227745|NCT02848729|DRUG|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
214227746|NCT02848729|DRUG|IV Morphine|Morphine for IV administration (0.125 mg/kg)
214227747|NCT02848729|DRUG|Placebo Tablets|Placebo tablets matching oral acetaminophen
214227748|NCT02848729|DRUG|Saline|Saline placebo matching IV acetaminophen
214227749|NCT04111562|PROCEDURE|Cranioplasty|Bone grafts
214227750|NCT01904773|DRUG|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
214227751|NCT00207324|DEVICE|Silver Leaf Dressing|
214227752|NCT06480162|PROCEDURE|Mechanical ventilation|After replacing the electrode, we'll monitor the EEG activity of the hippocampus and other cortex regions while weaning off mechanical ventilation.
214227753|NCT00791076|DRUG|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
214227754|NCT00791076|DRUG|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
214227755|NCT01106469|DRUG|JNJ-41443532|25mg tablet once daily
214227756|NCT01106469|DRUG|JNJ-41443532|250mg tablet once daily
214227757|NCT01106469|DRUG|JNJ-41443532|1500mg once daily (with 250mg tablets)
214227758|NCT01106469|DRUG|JNJ-41443532|100mg tablet once daily
214227759|NCT01106469|DRUG|JNJ-41443532|1000mg once daily (with 250mg tablets)
214227760|NCT01106469|DRUG|Placebo|Matching placebo
214227761|NCT01106469|DRUG|JNJ-41443532|500mg once daily (with 250mg tablets)
214227762|NCT05291468|RADIATION|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
214227763|NCT01464957|BEHAVIORAL|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
214227764|NCT01857596|DRUG|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
214227765|NCT04565327|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
214227766|NCT04565327|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
214227767|NCT01097200|DEVICE|Elevate mesh|The correction of the prolapse can be made by this new technique.
214227768|NCT01097200|DEVICE|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
214227769|NCT00773227|PROCEDURE|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
214227770|NCT03224559|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
214227771|NCT00606905|BIOLOGICAL|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
214227772|NCT00606905|OTHER|normal saline|equivalent volume of normal saline
214227773|NCT04753151|DRUG|Tranexamic acid|The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
214227774|NCT05925543|PROCEDURE|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
214227775|NCT03994029|DIETARY_SUPPLEMENT|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
214227776|NCT02933229|DEVICE|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
214227777|NCT02933229|DRUG|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
214227778|NCT02236182|DRUG|Ipratropium Bromide low dose|
214227779|NCT02236182|DRUG|Placebo|
214227780|NCT02236182|DRUG|Ipratropium Bromide high dose|
214651405|NCT06329934|BEHAVIORAL|Intervention for pressure ulcer|For patients with a Braden score of \>14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
214651406|NCT06329934|BEHAVIORAL|Rehabilitation training|After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
214227781|NCT05307913|OTHER|EIT-guided PEEP|PEEP setting according to EIT
214227782|NCT05307913|OTHER|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
214227783|NCT03700684|BEHAVIORAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
214227784|NCT03700684|DEVICE|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
214227785|NCT03700684|BEHAVIORAL|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
214227786|NCT05729867|PROCEDURE|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
214227787|NCT00227708|DRUG|docetaxel|
214227788|NCT00227708|PROCEDURE|quality-of-life assessment|
214227789|NCT03118908|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
214227790|NCT03118908|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
214227791|NCT03118908|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
214227792|NCT05779371|BEHAVIORAL|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
214227793|NCT03319745|BIOLOGICAL|Pembrolizumab|Given IV
214227794|NCT04143178|OTHER|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
214227795|NCT04143178|OTHER|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
214227796|NCT00870103|DRUG|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
214227797|NCT03872076|OTHER|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
214227798|NCT03872076|OTHER|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
214227799|NCT06078800|DRUG|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
214227800|NCT05356156|PROCEDURE|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
214227801|NCT05356156|PROCEDURE|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
214227802|NCT03830723|DRUG|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
214227803|NCT01523847|DRUG|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
214227804|NCT06466408|DIETARY_SUPPLEMENT|Supplementation Protocol|After the pre-test, the enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days. The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) instead until the end of the study. Participants returned to the laboratory each morning to receive the daily supplement, which was administered on-site. Following supplementation, participants reported their dinner intake to the researchers, ensuring compliance with the prescribed supplementation regimen.
214227805|NCT06466408|DIAGNOSTIC_TEST|Blood Lactate Test|The blood lactate was measured at five time points: before exercise, after the fourth and eighth bouts of exercise, and at 5 and 10 minutes after exercise. The blood lactate were analyzed using a Biosen Cline blood analysis system (EKF-diagnostic, Germany). Capillary blood samples of 10 μL were collected and added to red blood cell lysis reagent and stored at low temperature until analyzed. Prior to analysis, instrument standardization and test calibration were performed, and the coefficient of variation was determined to be ≤1.5%. The detection range for blood lactate was 0.5-40 mM
214227806|NCT06466408|DIAGNOSTIC_TEST|Training Impulse|In this study, the exercise load was represented by the TRIMP \[32\], which is calculated as the product of exercise intensity and duration. To accommodate the convenience of the experiment, two different TRIMP calculation methods were used, including % HRmax (objective) and RPE (subjective). At the end of each exercise bout (8 bouts in total) and during the recovery period before the next bout (7 bouts in total), participants were asked to report their RPE, and their heart rate was recorded. This process was repeated 8 times.
214227807|NCT06466408|DIAGNOSTIC_TEST|Exergaming HIIE Test|The sensor system utilized two Nintendo controllers: one mounted on the exercise ring and the other secured to the participant's thigh to enhance gameplay interaction. Through the Ring-Con, participants engaged in diverse physical activities such as weightlifting, yoga, and aerobic exercises. The fitness ring sensor accurately captures and integrates players' movements into the game. The gameplay involves unlocking levels and engaging in fitness challenges that are achieved through actual physical activities. It offers a wide range of exercise routines targeting various muscle groups and provides engaging gaming challenges. The exercise protocol included eight sets of 20-second high-effort exercises, interspersed with 30-second rest intervals, totaling 370 seconds of active exercise time. Specifically, the fitness game mode used was the Adventure Mode in 'Ring Fit Adventure,' comprising exercises targeting the pectoralis major, latissimus dorsi, deltoids, and quadriceps muscles.
214227808|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
214227809|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
214227810|NCT04858178|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
214227811|NCT04858178|DEVICE|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
214227812|NCT06093074|BEHAVIORAL|self-management program after traumatic injuries|The self-management support (SMS) program is manualized and will include eight weekly 2.5-hour sessions in groups of 5-7 participants. This feasibility trial will assess both face-to-face delivered program and a tele-health program via electronic devices. The tele-health intervention will be delivered with the same SMS content, frequency, and in-group mode.
214227813|NCT01827683|OTHER|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
214227814|NCT04307342|PROCEDURE|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
214227815|NCT02781740|DEVICE|Continous Positive Air Pressure Device|
214227816|NCT03095196|DEVICE|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
214227817|NCT03095196|DEVICE|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
214227818|NCT03095196|DRUG|HF drugs|full medical therapy to treat HF symptoms and its progression.
214227819|NCT00463021|DRUG|Hectorol (doxercalciferol capsules)|
214227820|NCT00463021|DRUG|Zemplar (paricalcitol injection)|
214227821|NCT03255629|DRUG|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
214227822|NCT03255629|DEVICE|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
214227823|NCT00977847|OTHER|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
214227824|NCT03189290|PROCEDURE|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
214227825|NCT00969982|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
214227826|NCT00969982|DRUG|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
214227827|NCT00859638|BEHAVIORAL|Physiotherapy|group self-management classes
214227828|NCT00859638|BEHAVIORAL|Occupational Therapy|group self-management classes
214227829|NCT00859638|BEHAVIORAL|Capacity Building|workshops and case reviews with primary health care team members
214227830|NCT01488123|BEHAVIORAL|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
214227831|NCT02826720|OTHER|No intervention was applied|No intervention was applied
214227832|NCT04800952|OTHER|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
214227833|NCT02910505|DEVICE|enLighten Laser|Laser for tattoo removal
214227834|NCT00745589|DRUG|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
214227835|NCT02969408|DRUG|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
214227836|NCT02762773|PROCEDURE|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
214227837|NCT02762773|PROCEDURE|control|Dissection of inferior and superior aspect of the rectus sheath
214227838|NCT00125125|DRUG|Fluvastatin|
214227839|NCT00322985|DRUG|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
214227840|NCT02694432|BEHAVIORAL|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
214227841|NCT02694432|BEHAVIORAL|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
214227842|NCT00539175|DEVICE|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
214227843|NCT00539175|DEVICE|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
214227844|NCT04375462|DEVICE|AspireAssist device|"Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment"
214227845|NCT04375462|DEVICE|Standard decompressive PEG tube|"Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment"
214227846|NCT04375462|OTHER|gastric outlet obstruction scoring system (GOOSS) questionnaire|"Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call"
214227847|NCT04375462|OTHER|Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire|"Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call"
214227848|NCT04375462|OTHER|Patient satisfaction and ease of use survey|"Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call"
214227849|NCT05354362|COMBINATION_PRODUCT|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
214227850|NCT00015834|DRUG|imatinib mesylate|Given PO
214227851|NCT00015834|DRUG|cytarabine|Given IV
214227852|NCT01767142|DEVICE|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214227853|NCT01331213|DRUG|Pregabalin|FDA approved medication (capsules) at 200mg dose.
214227854|NCT01331213|DRUG|Placebo|Placebo capsules
214227855|NCT06092918|RADIATION|EXTERNAL RADIOTHERAPY|EXTERNAL RADIOTHERAPY
214227856|NCT05693012|DIAGNOSTIC_TEST|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
214227857|NCT04442035|BEHAVIORAL|5-element music therapy|participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
214227858|NCT05637528|DIAGNOSTIC_TEST|MRI|Patients will undergo an MRI and mammography one year after MagTrace injections
214227859|NCT03671317|BEHAVIORAL|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
214227860|NCT03753945|DIAGNOSTIC_TEST|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
214227861|NCT02628080|DRUG|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
214227862|NCT04075734|BEHAVIORAL|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
214227863|NCT06520644|DEVICE|Wii-based interactive training program|include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension
214227864|NCT06520644|OTHER|Traditional physical therapy program|Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
214227865|NCT04708249|DIETARY_SUPPLEMENT|D-chiroinositol|Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
214227866|NCT04380272|DIAGNOSTIC_TEST|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
214227867|NCT05181189|DRUG|DAOIB+Omega-3|The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
214227868|NCT05181189|DRUG|DAOIB+Placebo|Placebo
214227869|NCT00397917|DRUG|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
214227870|NCT02250703|DRUG|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
214227871|NCT02250703|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
214227872|NCT04483401|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
214651407|NCT06329934|BEHAVIORAL|introduction of the current patient's condition to family members|timely introduction of the current patient's condition to family members to alleviate their concerns
214227873|NCT01672177|BEHAVIORAL|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
214227874|NCT00000722|DRUG|Pentamidine isethionate|
214227875|NCT02460601|DRUG|Qizhiweitong granule|
214227876|NCT05541536|OTHER|Consultation meeting|Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
214227877|NCT05541536|OTHER|Pamphlet|Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.
214227878|NCT05541536|OTHER|Usual Care|Study participants will not receive the general information pamphlet or consultation.
214227879|NCT05827198|OTHER|Low-sugar candies compared to regular sugar candies|Acute intake
214227880|NCT06174090|OTHER|Coronary bypass graft surgery video education|It includes information about surgical process and handling issues within the first few days of surgery.
214227881|NCT01776307|DRUG|BBI608|BBI608 is administered at 500 mg po bid continuously.
214227882|NCT01776307|DRUG|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
214227883|NCT01776307|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
214227884|NCT01776307|DRUG|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
214227885|NCT03615040|DRUG|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
214227886|NCT03615040|DRUG|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
214227887|NCT00945295|DRUG|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
214227888|NCT00945295|OTHER|Rehabilitation Therapy|Rehabilitation therapy
214227889|NCT02656225|DRUG|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
214227890|NCT02656225|DRUG|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
214227891|NCT00641511|DRUG|SYN117 (nepicastat)|120 mg per day
214227892|NCT00641511|DRUG|Placebo comparator|once per day placebo capsules
214227893|NCT02200809|DEVICE|MR-guided focal laser ablation|
214227894|NCT03502551|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
214227895|NCT05484544|DIAGNOSTIC_TEST|High sensitivity troponin T|Collection of hs-cTnT samples
214227896|NCT04430595|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
214227897|NCT03549832|DRUG|Sofosbuvir|Sofosbuvir 400 mg oral pills
214227898|NCT03549832|DRUG|Simeprevir|Simeprevir 150 mg oral pills
214227899|NCT03549832|DRUG|Daclatasvir|Daclatasvir 60 mg oral pills
214227900|NCT03549832|DRUG|Ribavirin|Ribavirin 200 mg oral pills
214227901|NCT03549832|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir oral pills
214227902|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 30μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
214227903|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 50μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
214227904|NCT04760743|OTHER|Normal Saline|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
214227905|NCT02205489|DRUG|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
214227906|NCT02205489|DRUG|cetirizine|Pharmaceutical form:tablet Route of administration: oral
214227907|NCT02205489|DRUG|ranitidine|Pharmaceutical form:tablet Route of administration: oral
214227908|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
214227909|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
214227910|NCT02205489|DRUG|aciclovir|Pharmaceutical form:tablet Route of administration: oral
214227911|NCT02205489|DRUG|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
214227912|NCT02205489|DRUG|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
214227913|NCT02205489|DRUG|paracetamol|Pharmaceutical form:tablet Route of administration: oral
214227914|NCT05366868|DRUG|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
214227915|NCT05366868|DRUG|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
214227916|NCT05366868|DRUG|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
214227917|NCT00239252|DRUG|Interferon alfacon-1|
214651408|NCT06329934|BEHAVIORAL|maintaining appropriate temperature and humidity in the ward|maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
214227918|NCT04769700|BEHAVIORAL|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
214227919|NCT04769700|BEHAVIORAL|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
214227920|NCT04769700|BEHAVIORAL|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
214227921|NCT04876300|OTHER|No intervention|All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
214227922|NCT03033550|BEHAVIORAL|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
214227923|NCT02546700|DRUG|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
214227924|NCT02546700|DRUG|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
214227925|NCT06376903|OTHER|Pilates exercise - pelvic floor exercise - home advices|"Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A)."
214227926|NCT03236324|DEVICE|ultrasound-guided nerve block|Transversalis fascia plane (TFP) block, ultrasound-guided
214227927|NCT03236324|DRUG|Saline|20 mL 0.9% saline administered on each side as bilateral TFP blocks
214227928|NCT03236324|DRUG|Bupivacaine-epinephrine|20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
214227929|NCT04696887|BEHAVIORAL|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
214227930|NCT04950296|OTHER|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
214227931|NCT04950296|OTHER|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
214227932|NCT04950296|OTHER|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
214227933|NCT04036370|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
214227934|NCT04036370|OTHER|Control group|Standard pain follow up and monitorization will be performed.
214227935|NCT05741554|OTHER|Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.|Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
214227936|NCT02737891|DRUG|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
214227937|NCT02737891|DRUG|Placebo|
214227938|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
214227939|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
214227940|NCT02073344|PROCEDURE|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
214227941|NCT02073344|OTHER|no intervention|no renal replacement therapy
214227942|NCT04133142|PROCEDURE|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
214227943|NCT01342237|DRUG|HDCT 1(TTC), HDCT2(MEC)|"1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
214227944|NCT05122702|DRUG|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
214227945|NCT05122702|OTHER|Placebo|Placebo granules, twice daily for 12 weeks.
214227946|NCT02895126|BEHAVIORAL|"Appui Parental program"|
214227947|NCT02895126|BEHAVIORAL|Regular parental support|
214227948|NCT00131053|DRUG|Methotrexate|
214227949|NCT00131053|DRUG|Prednisolone|
214227950|NCT00131053|DRUG|Dexamethasone|
214227951|NCT00131053|DRUG|Vincristine|
214227952|NCT00131053|DRUG|Pirarubicin|
214227953|NCT00131053|DRUG|Cyclophosphamide|
214227954|NCT00131053|DRUG|L-asparaginase|
214227955|NCT00131053|DRUG|Cytarabine|
214227956|NCT00131053|DRUG|Hydrocortisone|
214227957|NCT00131053|DRUG|Mercaptopurine|
214227958|NCT00077129|DRUG|carboplatin|
214227959|NCT00077129|DRUG|paclitaxel|
214227960|NCT04847336|OTHER|No intervention is planned|No intervention is planned
214227961|NCT06243562|OTHER|combined exercises and progressive muscle relaxation group|Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
214227962|NCT06243562|OTHER|combined exercises group|Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
214227963|NCT05145270|DIETARY_SUPPLEMENT|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
214227964|NCT05145270|DEVICE|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
214227965|NCT05145270|DRUG|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
214227966|NCT04145219|BIOLOGICAL|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
214227967|NCT04145219|OTHER|Placebo|For daily administration (1 tablet per day)
214227968|NCT04332861|OTHER|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers"
214227969|NCT03122951|DIAGNOSTIC_TEST|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
214227970|NCT03555019|DIETARY_SUPPLEMENT|Formulaid|Supplementation with ARA and DHA
214227971|NCT03555019|DIETARY_SUPPLEMENT|MCT-oil|Supplementation with medium chain fatty acids
214227972|NCT00010452|DRUG|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
214227973|NCT00226759|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
214227974|NCT00226759|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
214227975|NCT06341920|BEHAVIORAL|Experimental: BoneFit intervention|Exercise, nutrition and psychological support provided in 8 weeks prior to surgery
214227976|NCT06341920|BEHAVIORAL|Placebo Comparator: Control|Control group receive usual care (zero intervention)
214227977|NCT01518270|OTHER|No treatment|No treatment will be provided
214227978|NCT01098643|OTHER|computer-assisted intervention|
214227979|NCT01098643|OTHER|medical chart review|
214227980|NCT01098643|OTHER|questionnaire administration|
214227981|NCT01098643|OTHER|survey administration|
214227982|NCT04162691|DIAGNOSTIC_TEST|Tissue|Four 4-5 mm tissues of the thymoma
214227983|NCT00620529|DIETARY_SUPPLEMENT|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
214227984|NCT00620529|DIETARY_SUPPLEMENT|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
214227985|NCT00079027|DRUG|doxorubicin hydrochloride|
214227986|NCT00079027|PROCEDURE|hepatic artery embolization|
214227987|NCT03739021|DRUG|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
214227988|NCT03739021|DRUG|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
214227989|NCT02246413|BEHAVIORAL|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
214227990|NCT05241977|PROCEDURE|anterior supra scapular nerve block|nerve block for postoperative pain
214227991|NCT05826171|BEHAVIORAL|High-Intensity Aerobic Exercise Prior to Balance Training|20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
214227992|NCT05826171|BEHAVIORAL|Low-Intensity Exercise Prior to Balance Training|"20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components."
214227993|NCT03966638|PROCEDURE|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
214227994|NCT00918788|OTHER|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
214227995|NCT00918788|OTHER|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
214227996|NCT00918788|OTHER|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC).
214227997|NCT00918788|OTHER|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
214227998|NCT00918788|PROCEDURE|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
214227999|NCT00918788|PROCEDURE|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
214228000|NCT00918788|PROCEDURE|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
214228001|NCT05938205|DIETARY_SUPPLEMENT|AA-1|low dose aminoacids
214228002|NCT05938205|DIETARY_SUPPLEMENT|AA-2|high dose aminoacids
214228003|NCT05938205|BEHAVIORAL|Placebo|Nutritional Placebo
214228004|NCT05938205|BEHAVIORAL|Exe-H|high intensity physical exercise
214228005|NCT02371941|DRUG|oral cromolyn sodium|Oral cromolyn sodium
214228006|NCT02371941|DRUG|Placebo|Saline
214228007|NCT01788215|DRUG|doxycycline|200mg/day in divided doses of 100mg twice daily
214228008|NCT01788215|OTHER|Sugar Pill|1 pill twice a day
214228009|NCT02129088|DRUG|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
214228010|NCT02129088|DRUG|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
214228011|NCT04695808|BEHAVIORAL|yoga|Yoga practice will be done two days a week for 10 weeks.
214228012|NCT01950013|BEHAVIORAL|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
214228013|NCT01950013|BEHAVIORAL|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
214228014|NCT02751385|DRUG|Microgynon|
214228015|NCT02751385|DRUG|Nintedanib|
214228016|NCT02299791|OTHER|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~1. EHR tools to expedite identification~   a. EHR automated point-of-care alerts (Best Practice Alerts)~2. EHR tools to expedite prescribing~   1. EHR order sets~  2. EHR text shortcuts for notation~  3. patient education materials (handout, poster)~3. EHR-based outreach support tools a. EHR registries"
214228017|NCT02299791|OTHER|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
214228018|NCT04360382|OTHER|ERACS|Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
214228019|NCT04360382|OTHER|Regular care|Usual care for all cases subjected to cesarean section at our hospital.
214228020|NCT05525806|OTHER|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
214228021|NCT03334786|DRUG|FLX-787-ODT|Oral Disintegrating Tablet
214228022|NCT03584880|DEVICE|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
214228023|NCT03584880|DEVICE|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
214228024|NCT00710216|DRUG|Lamivudine|100 mg/day
214228025|NCT00710216|DRUG|Telbivudine|600 mg/day
214228026|NCT06532149|DRUG|Alectinib|Alectinib 600 mg/BID
214228027|NCT06532149|DRUG|Brigatinib|180 mg/daily
214228028|NCT06532149|DRUG|Lorlatinib 100 mg|100 mg/daily
214228029|NCT06532149|DRUG|Osimertinib|80 mg/daily
214228030|NCT06532149|DRUG|Sotorasib|960 mg/daily
214228031|NCT06532149|DRUG|Dabrafenib|150 mg/BID
214228032|NCT06532149|DRUG|Trametinib|2 mg/daily
214228033|NCT06532149|DRUG|Selpercatinib|160 mg/BID
214228034|NCT06532149|DRUG|Pembrolizumab|200 mg intravenous every 21 days
214228035|NCT06532149|DRUG|Cemiplimab|350 mg intravenous every 21 days
214228036|NCT06532149|DRUG|Nivolumab|240 mg intravenous every 14 days
214228037|NCT06532149|DRUG|Carboplatin|AUC4/AU5 intravenous every 21 days
214228038|NCT06532149|DRUG|Pemetrexed|500 mg/mq intravenous every 21 days
214228039|NCT06532149|DRUG|Paclitaxel|175 mg/mq intravenous every 21 days
214228040|NCT03163017|DEVICE|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
214228041|NCT03163017|DEVICE|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
214228042|NCT06240416|PROCEDURE|Low speed drilling without irrigation|Low-speed drilling (50 rpm) irrigation to perform the osteotomy
214228043|NCT06240416|PROCEDURE|High speed drilling with irrigation|High-speed drilling (800 rpm) irrigation to perform the osteotomy
214228044|NCT05625555|DRUG|Ketamine|IV Ketamine infusion 0.5mg/kg over 40 minutes
214228045|NCT05625555|DRUG|Midazolam|IV Midazolam infusion 30μg/kg over 40 minutes
214228046|NCT01099449|DRUG|calcium gluconate|Given IV
214228047|NCT01099449|DRUG|magnesium sulfate|Given IV
214228048|NCT01099449|OTHER|placebo|Given IV
214228049|NCT01099449|DRUG|oxaliplatin|
214228050|NCT03528499|OTHER|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
214228051|NCT03528499|OTHER|General Exercises|Strengthening and stretching exercises.
214228052|NCT02527772|DRUG|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
214228053|NCT02527772|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
214228054|NCT02451384|PROCEDURE|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
214228055|NCT02451384|PROCEDURE|no-touch surgery|
214228056|NCT02451384|PROCEDURE|laparoscopic surgery|
214228057|NCT00815555|OTHER|There is no intervention - this is an observational study|
214228058|NCT03272776|DEVICE|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
214228059|NCT01339520|BEHAVIORAL|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
214228060|NCT01339520|BEHAVIORAL|Control|Standard of care for diabetes subjects
214228061|NCT06060327|DRUG|Tranexamic acid|Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
214228062|NCT03535298|DRUG|Early Highly Effective Therapies Group|Highly Effective MS Therapy group of medications
214228063|NCT03535298|DRUG|Escalation Therapies Group|Escalation MS Therapy group of medications
214228064|NCT00612105|DRUG|Retigabine|150mg/day up to 900mg/day
214228065|NCT00612105|DRUG|Placebo|daily
214228066|NCT03803241|DRUG|CD133+ infusion|Infusion of cells cd133+
214228067|NCT03803241|OTHER|portal vein embolization|portal vein embolization
214228068|NCT00770159|DRUG|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
214228069|NCT00770159|DRUG|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
214228070|NCT01658306|PROCEDURE|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
214228071|NCT01658306|PROCEDURE|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
214228072|NCT04185116|DEVICE|3D Optic System (Olympus VISERA Elite II 3D)|"Use of the 3D Optic System Olympus VISERA Elite II 3D"
214228073|NCT04978103|DRUG|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
214228074|NCT03730090|DEVICE|zero flux skin termometer|Core temperature is monitored continously, non-invasively
214228075|NCT06033755|OTHER|Norwegian psychomotor physiotherapy|"The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months."
214228076|NCT03385772|PROCEDURE|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
214228077|NCT00900588|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
214651409|NCT06329934|BEHAVIORAL|careful observation of vital signs in patients|careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients
214651410|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg twice daily
214228078|NCT04915378|OTHER|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
214228079|NCT04915378|PROCEDURE|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
214228080|NCT04865900|DIAGNOSTIC_TEST|Laboratory Blood Tests|Blood tests to determine liver and kidney functioning, total blood count, and troponin levels
214228081|NCT04865900|DIAGNOSTIC_TEST|ECG|ECG to determine heart rate and functioning
214228082|NCT04865900|DIAGNOSTIC_TEST|PCR|PCR test to determine whether patient has Covid19
214228083|NCT04865900|DIAGNOSTIC_TEST|Antibody test|Antibody test to determine level of antibodies to Covid19
214228084|NCT04865900|DIAGNOSTIC_TEST|Echocardiography|If Troponin level elevated echocardiography to determine heart function
214228085|NCT04865900|DIAGNOSTIC_TEST|MRI|If Troponin level elevated MRI to determine heart function
214228086|NCT04408560|DRUG|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH
214228087|NCT04408560|OTHER|paracetamol (drug analgesic class1)|paracetamol (drug analgesic class1)
214228088|NCT00922727|BIOLOGICAL|L. reuteri|The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.
214228089|NCT00922727|BIOLOGICAL|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
214228090|NCT01238484|OTHER|Standard of care|shoe modification home stretching exercises
214228091|NCT01238484|DEVICE|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
214228092|NCT03386838|BIOLOGICAL|Nivolumab|Specified dose on specified days
214228093|NCT03386838|DRUG|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
214228094|NCT03386838|BIOLOGICAL|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
214228095|NCT03386838|DRUG|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
214228096|NCT03386838|DRUG|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
214228097|NCT03386838|DRUG|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
214228098|NCT05224804|BEHAVIORAL|knwoledge|Knowledge and Attitudes about ADRs Reporting
214228099|NCT02410889|OTHER|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
214651411|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg once daily
214651412|NCT00317044|DRUG|Placebo|Placebo twice daily
214651413|NCT02426814|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
214651414|NCT02426814|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
214651415|NCT04792866|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis
214651416|NCT03960528|PROCEDURE|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
214228100|NCT03794830|OTHER|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
214228101|NCT03794830|OTHER|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
214228102|NCT00829192|DRUG|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
214228103|NCT00829192|DRUG|Placebo|Placebo subcutaneous implant administered every 60 days
214228104|NCT03449641|DEVICE|Positive airway pressure (PAP)|Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
214228105|NCT01801267|PROCEDURE|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
214228106|NCT01801267|PROCEDURE|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
214228107|NCT03497351|DRUG|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
214228108|NCT03497351|DRUG|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
214228109|NCT01380626|PROCEDURE|exercise training|strength and endurance training, 5 time per week.
214228110|NCT00230867|DEVICE|iontophoretic acyclovir|
214228111|NCT00572767|DRUG|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
214228112|NCT00572767|OTHER|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
214228113|NCT05552417|OTHER|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
214228114|NCT00618085|BEHAVIORAL|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
214228115|NCT00618085|OTHER|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
214228116|NCT05926518|PROCEDURE|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
214228117|NCT00824733|DRUG|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
214228118|NCT00824733|DRUG|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
214228119|NCT00824733|OTHER|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
214228120|NCT01115322|DRUG|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228121|NCT01115322|DRUG|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228122|NCT01115322|DRUG|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228123|NCT01115322|DRUG|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
214228124|NCT01115322|DRUG|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228125|NCT01115322|DRUG|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228126|NCT01115322|DRUG|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
214228127|NCT01115322|DRUG|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214651417|NCT03960528|PROCEDURE|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
214651418|NCT03817671|OTHER|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
214651419|NCT03817671|OTHER|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
214228128|NCT01115322|DRUG|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
214228129|NCT02925949|BEHAVIORAL|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
214228130|NCT02925949|BEHAVIORAL|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
214228131|NCT00575484|DRUG|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
214228132|NCT00575484|DRUG|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
214228133|NCT02512835|OTHER|Community vital signs|We will present clinicians with information about their patients' communities
214228134|NCT02352285|DRUG|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
214228135|NCT02352285|DRUG|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
214228136|NCT00301613|DRUG|Mycophenolate mofetil|MMF,1.0g/d
214228137|NCT04179292|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
214228138|NCT04179292|OTHER|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
214228139|NCT05861817|DEVICE|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
214228140|NCT04944264|BEHAVIORAL|Stress Management and Resiliency Training (SMART) program|The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.
214228141|NCT00756535|PROCEDURE|Exercise training|Group-based exercise training 5 days a week during hospitalization
214228142|NCT00756535|PROCEDURE|usual treatment and rehabilitation|usual treatment and rehabilitation
214228143|NCT00651729|BIOLOGICAL|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
214228144|NCT00271505|DRUG|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
214228145|NCT00271505|DRUG|Carboplatin|AUC 6 IV every 3 weeks
214228146|NCT00271505|DRUG|Docetaxel|75 mg/m2 IV every 3 weeks
214228147|NCT00444561|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC administration
214228148|NCT02377661|DRUG|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
214228149|NCT04713397|DIAGNOSTIC_TEST|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
214228150|NCT03891238|DRUG|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
214228151|NCT05692336|OTHER|vestibular training|balance training in the form of vestibular training
214228152|NCT05692336|OTHER|dual task training|balance training in the form of dual task training
214228153|NCT04189185|PROCEDURE|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
214228154|NCT05379010|PROCEDURE|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
214228155|NCT04556383|DRUG|GB004|oral tablet
214228156|NCT04556383|DRUG|Placebo|oral tablet
214228157|NCT05675644|DRUG|Drospirenone-only pill|Single dose based on adaptive dose-finding design
214228158|NCT03811860|DIAGNOSTIC_TEST|Lithium level|The level of lithium in the serum
214228159|NCT03811860|DIAGNOSTIC_TEST|Serum Creatinine|The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
214228160|NCT03706248|OTHER|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
214228161|NCT00935246|DRUG|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
214228162|NCT01715441|DRUG|Sorafenib and irinotecan combination|
214228163|NCT01715441|DRUG|Sorafenib monotherapy|
214228164|NCT01715441|DRUG|Irinotecan monotherapy|
214228165|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
214228166|NCT00119678|DRUG|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
214228167|NCT00119678|DRUG|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
214228168|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
214228169|NCT01146457|DRUG|Morphine|Active dosage
214228170|NCT01146457|DRUG|Saline|Saline Control
214228171|NCT00004930|DRUG|doxorubicin hydrochloride|
214228172|NCT03309176|DRUG|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
214228173|NCT03309176|OTHER|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
214228174|NCT02692391|DRUG|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
214228175|NCT02692391|DRUG|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
214228176|NCT02720042|DEVICE|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
214228177|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
214228178|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
214228179|NCT05343767|OTHER|Metformin|A total dose of 2000 mg was administered per day.
214651420|NCT04271462|OTHER|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
214651421|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
214651422|NCT00006981|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
214228180|NCT03381976|OTHER|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
214228181|NCT03381976|OTHER|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
214228182|NCT01761240|DRUG|MORAb-066|MORAb-066 infusion.
214228183|NCT02356900|PROCEDURE|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
214228184|NCT02356900|PROCEDURE|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
214228185|NCT02356900|DRUG|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
214228186|NCT03479333|DEVICE|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
214228187|NCT03479333|DEVICE|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
214228188|NCT06171477|DEVICE|Ventilation 20-40-60|The respiratory rate during mechanical ventilation will be altered from 20 to 40 and finally to 60 breaths per minute.
214228189|NCT06171477|DEVICE|Ventilation 60-40-20|The respiratory rate during mechanical ventilation will be altered from 60 to 40 and finally to 20 breaths per minute.
214228190|NCT06171477|DEVICE|Ventilation 40-60-20|The respiratory rate during mechanical ventilation will be altered from 40 to 60 and finally to 20 breaths per minute.
214228191|NCT03894397|DEVICE|Electrical stimulation of the BNST|Electrical stimulation of the BNST
214228192|NCT00504530|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
214228193|NCT02009540|DRUG|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
214228194|NCT02009540|DRUG|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
214228195|NCT00509145|DRUG|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
214228196|NCT00509145|OTHER|Placebo|oral, once daily, capsule
214228197|NCT05981053|DIETARY_SUPPLEMENT|Wine enriched with Resveratrol|Wine enriched with Resveratrol
214228198|NCT01685151|DRUG|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
214228199|NCT01685151|DRUG|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
214228200|NCT01685151|DRUG|Placebo|Placebo
214228201|NCT03484793|OTHER|AESOP service system|Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
214228202|NCT00977119|OTHER|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
214228203|NCT00977119|OTHER|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
214228204|NCT05155254|DRUG|IO102-IO103|IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
214228205|NCT05155254|DRUG|Pembrolizumab|Pembrolizumab administered intravenously
214228206|NCT05391789|DRUG|Ulinastatin|Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
214228207|NCT05391789|DRUG|Placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
214228208|NCT03687944|OTHER|Validity and reliability|Test-retest method and concurrent validity
214228209|NCT04343105|PROCEDURE|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
214228210|NCT01994889|DRUG|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
214228211|NCT01994889|DRUG|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
214228212|NCT01994889|DRUG|Placebo|Placebo in soft gel capsules administered once a day for 30 months
214228213|NCT03632954|DEVICE|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
214228214|NCT01572987|DEVICE|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
214228215|NCT01572987|DEVICE|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
214228216|NCT03853278|BEHAVIORAL|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
214228217|NCT01307644|BEHAVIORAL|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
214228218|NCT01307644|BEHAVIORAL|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
214651423|NCT02208960|DEVICE|Neonatal Kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
214228219|NCT01307644|BEHAVIORAL|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
214228220|NCT02969655|DRUG|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
214228221|NCT02969655|DRUG|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
214228222|NCT02969655|DRUG|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
214228223|NCT02969655|DRUG|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
214228224|NCT02969655|DRUG|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
214228225|NCT02969655|DRUG|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
214228226|NCT04027478|DIETARY_SUPPLEMENT|FMD|fasting mimicking diet
214228227|NCT03767790|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
214228228|NCT00236704|DRUG|topiramate|
214228229|NCT06225869|BEHAVIORAL|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
214228230|NCT02600780|DRUG|Febuxostat|Comparison of two anti-hyperuricemic molecules
214228231|NCT02600780|DRUG|Allopurinol|Comparison of two anti-hyperuricemic molecules
214228232|NCT04491071|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7 (GAD 7)|test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.
214228233|NCT04491071|DIAGNOSTIC_TEST|Background questionnaire|questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
214228234|NCT04491071|DIAGNOSTIC_TEST|Impact of COVID-19 questionnaire|status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
214228235|NCT04491071|DIAGNOSTIC_TEST|Confinement and Communication During the COVID-19 Pandemic|know the experience of containment and isolation during the pandemic
214228236|NCT04491071|DIAGNOSTIC_TEST|Mental Health questionnaire|welfare effect
214228237|NCT04491071|DIAGNOSTIC_TEST|Patient Health Questionnaire (PHQ-9)|assess depression during the pandemic
214228238|NCT04491071|DIAGNOSTIC_TEST|Post Traumatic Stress Disorder questionnaire (PTSD-8)|Assessing the trauma of subjects during the pandemic
214228239|NCT04491071|DIAGNOSTIC_TEST|Experiences in Close Relationship Scale questionnaire (ECR-S)|Measuring social ties and attachment of subjects
214228240|NCT00161538|DEVICE|Pacing leads to be implanted according randomization.|
214228241|NCT00161538|DEVICE|Selection 9000 prevent AF an Diagnose AF|
214228242|NCT00136513|DRUG|SB-743921|
214228243|NCT02674204|DRUG|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
214228244|NCT02674204|DRUG|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
214228245|NCT00437008|DRUG|Benfotiamine 1050mg, 3 days|
214228246|NCT00437008|BEHAVIORAL|high-AGE vs. low-AGE meal|
214228247|NCT01748240|DRUG|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
214228248|NCT03229642|DEVICE|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
214228249|NCT03229642|DEVICE|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
214228250|NCT02911831|DRUG|Tranexamic Acid|
214228251|NCT02911831|DRUG|Sodium Chloride|
214228252|NCT00761644|DRUG|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
214228253|NCT00761644|DRUG|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
214228254|NCT00761644|DRUG|Temsirolimus|Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
214228255|NCT00351871|DRUG|PEG-Intron Plus REBETOL|
214228256|NCT06193109|OTHER||the patients with sepsis and septic shock were performed echocardiography for detecting right ventricular systolic function
214228257|NCT02779322|PROCEDURE|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
214228258|NCT02779322|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
214228259|NCT00256568|BEHAVIORAL|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
214228260|NCT00995059|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
214228261|NCT00995059|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
214228262|NCT00995059|DRUG|bortezomib|Given IV
214228263|NCT00995059|DRUG|melphalan|Given IV
214228264|NCT00995059|DRUG|anti-thymocyte globulin|Given IV
214228265|NCT00995059|DRUG|sirolimus|Given orally
214228266|NCT00995059|DRUG|tacrolimus|Given oral or IV
214228267|NCT00995059|RADIATION|total-body irradiation|Undergo total-body irradiation
214228268|NCT03111186|DRUG|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
214228269|NCT03111186|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
214228270|NCT03111186|DRUG|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
214228271|NCT05800301|BIOLOGICAL|Wharton's jelly derived mesenchymal stemcells|The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.
214228272|NCT05800301|DEVICE|Magnovision|Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
214228273|NCT04904224|DEVICE|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
214228274|NCT04904224|DEVICE|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
214228275|NCT03753113|DRUG|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
214228276|NCT03753113|DRUG|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
214228277|NCT01764139|PROCEDURE|Blood sampling|
214228278|NCT02586779|OTHER|whatsApp|whatsApp application will be used for consultations.
214228279|NCT02586779|OTHER|without whatsApp|whatsApp application will be not used for consultations.
214228280|NCT01516034|DEVICE|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
214228281|NCT02923440|BIOLOGICAL|blood sample|
214228282|NCT03485300|DIAGNOSTIC_TEST|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
214228283|NCT03485300|BEHAVIORAL|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
214228284|NCT03485300|DRUG|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
214228285|NCT00043797|DRUG|Lidorestat (IDD 676)|
214228286|NCT00466141|BEHAVIORAL|Increased Exercise for weight loss maintenance|
214228287|NCT00466141|BEHAVIORAL|Daily Self-weighing for weight loss maintenance|
214228288|NCT00466141|BEHAVIORAL|Education for weight loss maintenance|
214228289|NCT03149744|DEVICE|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
214228290|NCT01836978|OTHER|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
214228291|NCT03060551|PROCEDURE|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
214228292|NCT00178113|DRUG|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
214228293|NCT00178113|DRUG|- Certagen (multivitamins with minerals)|
214228294|NCT02613026|DRUG|Pirarubicin|
214228295|NCT02613026|DRUG|Docetaxel|
214228296|NCT02613026|DRUG|Cyclophosphamide|
214228297|NCT00864695|OTHER|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
214228298|NCT04735640|BEHAVIORAL|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
214228299|NCT04735640|BEHAVIORAL|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
214228300|NCT04346719|DEVICE|10 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
214228301|NCT04346719|DEVICE|20 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
214228302|NCT04346719|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
214228303|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C gummy|vitamin C
214228304|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C tablet|vitamin C
214228305|NCT00250146|BEHAVIORAL|Gluten (behaviour)|
214228306|NCT01415336|DRUG|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
214228307|NCT01415336|DRUG|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
214228308|NCT00171522|DRUG|Tegaserod and Polyethylene Glycol 3350|
214228309|NCT04716296|DRUG|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
214228310|NCT04716296|DRUG|Saline|Saline will be given for the second stage of the DBS surgery.
214228311|NCT01646489|DRUG|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
214228312|NCT01646489|DRUG|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
214228313|NCT05032469|OTHER|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
214228314|NCT01576068|OTHER|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
214228315|NCT02467426|DRUG|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
214228316|NCT04499352|DRUG|BI 754091|BI 754091
214228317|NCT04499352|DRUG|BI 836880|BI 836880
214228318|NCT01809639|DRUG|Progesterone|
214228319|NCT01809639|DRUG|Placebo|Standard placebo
214228320|NCT00814060|DRUG|neratinib|HKI-272
214228321|NCT03519191|BEHAVIORAL|Healthy Relationships Education (HRE)|Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
214228322|NCT03519191|BEHAVIORAL|HRE+Technology Bootcamp|HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
214228323|NCT02940314|DRUG|HIP1503|
214228324|NCT02940314|DRUG|HGP1103|
214228325|NCT04664699|DEVICE|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume"
214228326|NCT04664699|DEVICE|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
214228327|NCT00379301|PROCEDURE|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
214228328|NCT05388292|OTHER|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
214228329|NCT02047721|BEHAVIORAL|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
214228330|NCT02047721|BEHAVIORAL|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
214228331|NCT03336593|BIOLOGICAL|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
214228332|NCT03336593|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
214228333|NCT00611754|DRUG|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
214228334|NCT05514808|OTHER|Nutrition education modules|Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
214228335|NCT03101553|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
214228336|NCT03101553|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
214228337|NCT02414256|OTHER|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
214228338|NCT04273035|DRUG|Midazolam oral solution|Oral Buccolam
214228339|NCT04273035|DEVICE|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
214228340|NCT00392145|DRUG|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
214228341|NCT00392145|DRUG|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
214228342|NCT04962256|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
214228343|NCT00950677|DRUG|Byetta (exenatide)|exenatide 5 mcg subcutaneously
214228344|NCT00950677|DRUG|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
214228345|NCT03769584|OTHER|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
214228346|NCT03769584|OTHER|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
214228347|NCT00830778|PROCEDURE|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
214228348|NCT00830778|PROCEDURE|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
214228349|NCT04911985|DEVICE|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
214228350|NCT05993013|OTHER|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
214228351|NCT05090397|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
214228352|NCT05090397|DEVICE|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
214228353|NCT04580134|DRUG|clozapine|Biotype 1 and Biotype 2
214228354|NCT04580134|DRUG|risperidone|Biotype 1 and Biotype 2
214228355|NCT00062803|DRUG|SR34006|
214228356|NCT00062803|DRUG|(LMW)heparin|
214228357|NCT00062803|DRUG|Warfarin VKA|
214228358|NCT00062803|DRUG|Acenocoumarol VKA|
214228359|NCT02814994|BEHAVIORAL|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
214228360|NCT02814994|BEHAVIORAL|low tidal volume|ventilation ventilated with low tidal volume
214228361|NCT05219370|DRUG|Cannabis oil|administration of different cannabis oil types as compared with placebo
214228362|NCT05767268|DEVICE|Lokomat|gait rehabilitation
214228363|NCT01252225|DRUG|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
214651424|NCT02208960|BEHAVIORAL|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch"
214228364|NCT01252225|DRUG|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
214228365|NCT01252225|DRUG|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
214228366|NCT02145013|PROCEDURE|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
214228367|NCT02499757|DEVICE|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
214228368|NCT02499757|DEVICE|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
214228369|NCT02499757|DEVICE|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
214228370|NCT02499757|DEVICE|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
214228371|NCT00452192|DRUG|Telmisartan|telmisartan 80 mg daily over 2 weeks
214228372|NCT01525225|DRUG|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
214228373|NCT01525225|DRUG|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
214228374|NCT01525225|DRUG|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
214228375|NCT01525225|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
214228376|NCT01525225|DRUG|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
214228377|NCT06516523|PROCEDURE|PEMF and Control/Sham|Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
214228378|NCT06516523|DEVICE|PEMF and without PEMF|Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
214228379|NCT01783756|DRUG|lapatinib ditosylate|Given PO
214228380|NCT01783756|DRUG|everolimus|Given PO
214228381|NCT01783756|DRUG|capecitabine|Given PO
214228382|NCT01783756|OTHER|laboratory biomarker analysis|Correlative studies
214228383|NCT05878262|DRUG|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
214228384|NCT01575535|GENETIC|gene expression analysis|
214228385|NCT01575535|OTHER|flow cytometry|
214228386|NCT01575535|OTHER|fluorescence activated cell sorting|
214228387|NCT01575535|OTHER|laboratory biomarker analysis|
214228388|NCT01575535|OTHER|medical chart review|
214228389|NCT05972057|PROCEDURE|cardiac surgery|All cardiac surgery patients who met the inclusion criteria were included in the cardiac surgery department of Renji Hospital.
214228390|NCT04596059|OTHER|Frisolac Gold Intensive HA|Regular medical care
214228391|NCT03801057|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
214651425|NCT02649257|PROCEDURE|cataract surgery|
214228392|NCT03801057|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
214228393|NCT05974059|DRUG|Oxaliplatin|Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;
214228394|NCT05974059|DRUG|Capecitabine|Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
214228395|NCT05974059|DRUG|Cadonilimab|Cadonilimab 10 mg/kg, d1, Q3W
214228396|NCT02667353|PROCEDURE|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
214228397|NCT02667353|DRUG|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
214228398|NCT02667353|DRUG|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
214228399|NCT04297722|OTHER|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
214228400|NCT00363545|BIOLOGICAL|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
214228401|NCT00363545|BIOLOGICAL|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
214228402|NCT01315561|OTHER|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
214228403|NCT05685173|DRUG|Odronextamab|Odronextamab will be administered by IV infusion
214228404|NCT05685173|DRUG|REGN5837|REGN5837 will be administered by IV infusion
214228405|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
214228406|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
214228407|NCT00703248|PROCEDURE|Osteopathic Manipulative Treatments|"1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
214228408|NCT01379508|DRUG|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
214228409|NCT01379508|DRUG|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
214228410|NCT03225508|DIAGNOSTIC_TEST|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
214228411|NCT03225508|DIAGNOSTIC_TEST|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
214228412|NCT03225508|DIAGNOSTIC_TEST|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
214228413|NCT05227040|DEVICE|Nintendo Ring Fit Adventure Exergame|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
214228414|NCT05726084|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
214651426|NCT02649257|DEVICE|intraocular lens (MC 6125 AS)|
214651427|NCT02649257|DEVICE|capsular tension ring (CTR 13/11)|
214228415|NCT05726084|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
214228416|NCT05543993|DRUG|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
214228417|NCT01457352|DRUG|SPARC0921|
214228418|NCT01457352|DRUG|Placebo0921|
214651428|NCT04315467|DRUG|SGM-101|A one-time infusion of SGM-101
214651429|NCT04315467|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
214651430|NCT02051907|DEVICE|KAM1403 Gel|
214651431|NCT02051907|DEVICE|aloevera gel|
214651432|NCT00732173|BEHAVIORAL|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
214651433|NCT00732173|BEHAVIORAL|exercise intervention|Undergo SUCCEED lifestyle intervention
214651434|NCT00732173|OTHER|counseling intervention|Undergo SUCCEED lifestyle intervention
214228419|NCT00040300|DRUG|Racivir|
214228420|NCT03437616|BEHAVIORAL|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
214228421|NCT00529607|DRUG|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
214228422|NCT00529607|PROCEDURE|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
214228423|NCT00529607|PROCEDURE|cardiac MRI|before discharge and after 6 months
214228424|NCT00529607|PROCEDURE|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
214228425|NCT01562093|DRUG|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
214228426|NCT01562093|DRUG|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
214228427|NCT01589991|DRUG|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
214228428|NCT03230019|PROCEDURE|chest tube|VATS with chest tube placement
214228429|NCT03230019|PROCEDURE|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
214228430|NCT03230019|DEVICE|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
214228431|NCT02972567|DIETARY_SUPPLEMENT|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
214228432|NCT02972567|DIETARY_SUPPLEMENT|Control|Maltodextrin
214228433|NCT02537015|DRUG|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
214228434|NCT04279106|PROCEDURE|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214228435|NCT04279106|PROCEDURE|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214228436|NCT04279106|PROCEDURE|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214228437|NCT04279106|PROCEDURE|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214228438|NCT04168736|OTHER|Feasibility and Acceptability of Genetic Counseling Materials|"To determine the feasibility and acceptability of a communication aid in sharing genetic test results with family members.~To determine the utility of a communication aid in sharing information. To determine the impact of patient focused information sheets on patient knowledge of genetic testing."
214228439|NCT00201552|DRUG|Statin|
214228440|NCT03445949|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
214228441|NCT03445949|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
214228442|NCT03445949|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
214228443|NCT03445949|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
214228444|NCT04174365|DRUG|Brexpiprazole|Oral tablet; take once daily
214228445|NCT04174365|DRUG|Placebo|Administered orally daily for up to Week 8.
214228446|NCT06909773|BEHAVIORAL|Guideline education and implementation intervention|"The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：~1. Disease education~   * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.~  * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.~2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.~3. Follow-up management:the subjects will be followed up every 4 weeks."
214228447|NCT06914765|DEVICE|Endoscopic Sleeve Gastroplasty (ESG) Procedure|The ESG procedure will be performed under general anesthesia monitored by an anesthesiologist. The device that will be used is called the Apollo Endosurgery ESG System, which is the only FDA approved device for the reduction of stomach volume through endoscopic sleeve gastroplasty for adult patients with obesity. This device works by being attached to a standard upper endoscope and is inserted through the mouth and goes into the stomach. When in the stomach, the back and front wall of the stomach will be stitched together to reduce the size of the stomach and help decrease the amount of food a patient can eat and drink at one time before feeling full.
214228448|NCT06917001|DRUG|Resomelagon|Resomelagon 100mg, orally, once daily.
214228449|NCT06917001|DRUG|Placebo|Placebo
214228450|NCT06917001|OTHER|Standard Treatment|Hydration and symptomatic therapy as indicated for Dengue fever.
214228451|NCT06920030|DEVICE|Subcutaneous cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in a left thoracic subcutaneous pocket
214228452|NCT06920030|DEVICE|Infraclavicular pocket cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in the same infraclavicular pocket as the device itself
214228453|NCT06920030|DEVICE|Coronary Sinus cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a coronary sinus electrode
214228454|NCT06836869|PROCEDURE|Laparoscopic radical hysterectomy incorporating modified tumor-free techniques|"Thoroughly examine the pelvic and abdominal cavities. Coagulation of the fallopian tubes are recommanded at the beginning of the surgery. The use of uterine manipulator is prohibited. An 8-suture at the uterine fundus is recommended. Insert a trocar 3 cm above the pubic symphysis and suspend the uterus by pulling with a needle holder. Alternative methods are also acceptable. Perform pelvic lymphadenectomy. Conduct radical hysterectomy according to the Q-M classification type C. Before incising the vagina, the upper part of the vagina must be closed (using a cable tie or suture), or the vagina can be incised transvaginally after deflating the pneumoperitoneum. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity. The vaginal stump can be sutured either laparoscopically or transvaginally."
214228455|NCT06836869|PROCEDURE|Abdominal radical hysterectomy|At the onset of surgery, comprehensively explore the pelvic and abdominal cavities. If intraperitoneal metastases are identified, radical hysterectomy should be aborted. Perform pelvic lymphadenectomy. After lymph node resection, remove the lymph nodes from the surgical field promptly. Sentinel lymph node mapping and biopsy are not performed in this study. Perform radical hysterectomy according to type C of the Q-M classification. It can be accompanied by or without bilateral salpingo - oophorectomy. For patients who retain their ovaries, bilateral ovarian transposition can be carried out. Before incising the vagina, close the upper segment of the vagina and/or the vaginal stump. This can be achieved using instruments such as a large right - angle clamp or an auricular clamp. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity.
214228456|NCT07144865|DRUG|conbercept ophthalmic injection （0.5mg）|Participants were randomly assigned to receive intravitreal injections of either faricimab (IVF, n=4) or conbercept (IVC, n=4) based on a randomisation protocol. To establish a baseline comparison, FVMs were obtained from three treatment-naive patients who served as controls. All participants underwent surgery 4 days after the intravitreal anti-VEGF injections.
214228457|NCT07144865|DRUG|Faricimab|According to the randomization protocol, participants were randomly assigned to receive intravitreal injections of faricimab (IVF, n=4) or conbercept (IVC, n=4). To establish a baseline comparison, FVMs were obtained from three treatment-naïve patients as controls. All participants underwent surgery 4 days after intravitreal anti-VEGF injection.
214228458|NCT07146724|OTHER|Exercise|"The intervention consists of a pilates-based exercise program specifically designed to target hamstring flexibility, plantar pressure sensitivity, and dynamic balance.~Unlike general fitness-oriented pilates, this program includes a combination of mat-based and functional pilates movements adapted to improve posterior chain flexibility and sensory feedback in the lower extremities.~The protocol includes 3 sessions per week for 8 weeks - 1 session conducted face-to-face under physiotherapist supervision and 2 sessions as a monitored home exercise. Exercise progression is standardized, and all sessions follow a validated physiotherapy protocol tailored for university-aged individuals with clinically measured hamstring shortening."
214228459|NCT07145398|BEHAVIORAL|Mandala Coloring|Children hospitalized in the burn unit will participate in structured mandala coloring sessions. Each session will last approximately 30 minutes and will be conducted once daily for 7 consecutive days. Children will be provided with printed mandala patterns and coloring materials, and the sessions will be supervised by the research team. The purpose of the intervention is to reduce pain and stress levels and improve sleep quality in burn patients.
214228460|NCT07145398|OTHER|Control - Standard Care|Children in the control group will receive routine burn unit care without any additional interventions. No mandala coloring sessions will be provided.
214228461|NCT07145268|DRUG|Entecavir (ETV)|"Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months.(control group)"
214228462|NCT07145268|DRUG|Zinc (zinc sulphate)|"Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months."
214228463|NCT06944912|PROCEDURE|Transversalis fascia plane block and transversus abdominis plane block|20 ml local anesthetics for Transversus Abdominis Plane block and 10 ml local anesthetics for Trasnversalis fascia plane block
214228464|NCT06944912|PROCEDURE|Intrathecal Morphine|100 mcg morphine with local anesthetics injected intrathecally
214228465|NCT06947343|PROCEDURE|ACTION OBSERVATION THERAPY|functional AOT with visual feedback and physical training after watching a video 30mins session, 3times/week total 8weeks 3mins for observation phase, 2min for action execution Stage 1, sitting position (static and dynamic balance) exercises for trunk flexion, upper and lower trunk rotation multidirectional reaching to pick up any object from different directions, forward, lateral, and diagonal reaching Stage 2, sit to stand and stand to sit from sitting to standing, trunk flexed, hips and knees 90 degree flexed, feet behind knee, 15cm apart, then standing, trunk extension hips knees extend feet apart and vice vers 4phases of sit to stand, seat off, standing, seat on, sitting in sitting position dorsiflexion training, flexion extension training knee joint the right hand touches the left foot and viceversa pick up an object from floor stage3, standing balance weight shifting, front, back, sideways, left and right head and trunk movements in different directions while standing
214651435|NCT00732173|OTHER|educational intervention|Receive information
214651436|NCT00732173|OTHER|survey administration|Undergo SUCCEED lifestyle intervention
214651437|NCT05521737|PROCEDURE|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
214651438|NCT05521737|PROCEDURE|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
214651439|NCT06395493|PROCEDURE|Pilates Group|In this study, the participants in the Pilates group will undergo 2 sessions per week, for 12 consecutive weeks.
214651440|NCT06395493|PROCEDURE|Exercise Group|In this study, the participants in the Exercise group will undergo 2 sessions per week, for 12 consecutive weeks.
214228466|NCT06947343|PROCEDURE|MOTOR RELEARNING PROGRAM|Motor relearning program, interventional group B, based on task-oriented training 30mins, 3times/week total 8weeks stage 1, balanced sitting exercises for trunk flexion and rotation, feet and knees 15cm apart multidirectional reaching while seated forward, lateral and diagonal reaching to pick up any thing from different directions butt walking scooting on bed stage 2, standing up and sitting down transition from a seated position on a firm flat surface with no armrests to standing with an upright posture, upper body vertical and feet placed backward followed by sitting down by flexing hips,knees and ankle prerequisited of sit to stand, 4phases in sitting dorsiflexion training, flexion extension training of knee joint right hand touch to left foot and viceversa picking up objects from floor stage3, balanced standing weight shifting head and trunk movemnts while standing with feetapart standing unsupported with eyes closed multidirectional reaching
214228467|NCT06947603|PROCEDURE|inula viscosa extract|the topical gel of inula viscosa was applied to one side after the extraction of the impacted molar in each patient, while the other side was left without the application of any pharmaceutical substance after extraction
214228468|NCT06947603|PROCEDURE|no inula viscosa extract|the other side of patient was left without the application of inula viscosa extract after lower third molar extraction.
214228469|NCT07144943|RADIATION|For subjects on SSRIs: bone densitometry|"For subjects on SSRIs:~Bone densitometry is one of the additional examinations considered. This assessment is part of the routine monitoring for subjects on androgens."
214228470|NCT07145359|OTHER|Virtual Reality Intervention|This intervention is distinguished by its integration of a structured, nurse-led virtual reality (VR) protocol specifically designed for symptom management during hematopoietic stem cell transplantation (HSCT). Unlike general VR distraction methods used in oncology, this intervention employs video content created by the research team in accordance with Attention Restoration Theory (ART), offering five preselected nature-themed options tailored to patient preferences. Prior to the procedure, eligible patients are introduced to the intervention one day in advance and given the opportunity to trial the VR equipment, ask questions, and select their preferred video. During the infusion, VR is initiated exactly one minute before the stem cell procedure and ends at the 15th minute, as recommended by the literature. Symptom assessments are conducted immediately before and after the intervention using validated tools, including the Distress Thermometer, State Anxiety Inventory, and the Edmonto
214228471|NCT06947369|OTHER|Experimental Group|Within the scope of the research, the pregnant women in the experimental group will be given a training program based on Joyce Travelbee's human-to-human relations theory, one session per week for 30-45 minutes, for a total of five sessions, while the control group will continue their routine follow-up.
214228472|NCT06946277|DRUG|Preemptive Analgesia Of Dexmedetomidine|Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation
214228473|NCT06955130|DRUG|Glycerol|Subjects will receive an infusion of glycerol and glucagon.
214228474|NCT06955130|DRUG|Lactate|Subjects will receive an infusion of lactate and glucagon.
214228475|NCT06955130|DRUG|Glucose|Subjects will receive an infusion of glucose and glucagon.
214228476|NCT06947395|DIAGNOSTIC_TEST|PancreaSure|Serum-based biomarker test comprised of ELISA-based analyte readings of 4 protein biomarkers (ICAM-1, TIMP1, THSB1, and CTSD) and CA19-9 summed by a mathematical algorithm with associated coefficients where a pre-defined cutoff establishes a positive or negative detection of PDAC.
214228477|NCT07144852|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
214228478|NCT07144852|OTHER|Vehicle|Solution for topical use
214228479|NCT07144852|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.|BLU-U® blue light PDT illuminator
214228480|NCT07145697|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
214228481|NCT07146061|OTHER|no other intervention|This is a observational study.
214228482|NCT07145931|PROCEDURE|Neoadjuvant chemoimmunotherapy|"* Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.~* Surgical treatment is performed within 3 weeks after completing neoadjuvant therapy.~* Postoperative (chemo)radiotherapy is initiated 4-6 weeks after surgery.~* Following (chemo)radiotherapy, adjuvant immunotherapy (Tislelizumab 200mg) is administered every 3 weeks for a total of 8 cycles."
214228483|NCT07145931|DRUG|Tislelizumab Nab paclitaxel|Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.
214228484|NCT07144995|DRUG|Fruquintinib+Paclitaxel|(using IPD from the FRUTIGA trial, n=703) Fruquintinib：subjects received Fruquintinib orally, once daily for 3 wks on/ 1 wk off Paclitaxel：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
214228485|NCT07144995|DRUG|Ramucirumab+Paclitaxel|(using published AgD from RAINBOW-Asia, n=440) Ramucirumab：8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel ：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
214228486|NCT07144813|DEVICE|Neuspera Implantable Sacral Neuromodulation System|Stimulation of the Sacral Nerve.
214228487|NCT07145203|DEVICE|Meta Quest 2 VR headset|The VR intervention used a head-mounted VR headset with built-in headphones. Patients selected VR environments from a predefined list of four nature scenes (tropical beach, diving, forest, and snowy landscape) with relaxing music and nature sounds. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/) featured 360-degree immersive nature environments with standardized calming background audio. VR was applied during the colonoscopy procedure, with sessions lasting 15 to 30 minutes and discontinued if the patient reported nausea, dizziness, or requested removal.
214464696|NCT06111027|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
214651441|NCT06395493|PROCEDURE|Control Group|The participants in the control group, are those who either opt not to do the exercises or are on the waiting list for physiotherapy intervention. Therefore, they will not undergo any intervention for 12 consecutive weeks.
214228488|NCT07145788|OTHER|PhYoMind|This integrative intervention method includes some specific physiotherapy techniques, ( e. g. self proprioceptive neuromuscular facilitation, self nerve gliding, self mobility, post isometric relaxation techniques) yoga postures, left nostril breathing, humming bee breathing, mindfulness practices and home exercises. Each session will be 75 minutes and focus on different parts of the body and yoga postures will be selected according to these focused areas. For each week, a specific body area will be chosen as the focus. For example, the first week will focus on the hip area and lower extremities, the second week on the upper body and upper extremities, the third week on the core and anterior line of the body, and the fourth week on the back and posterior line of the body and this sequence will continue through the eighth week. In addition to these sessions, participants in this group will also apply home exercises (aerobic+strenghtening+streching) twice a week, 60 minutes per practice.
214228489|NCT07145788|OTHER|Exercise|The control group will receive only home exercises twice a week. Big muscle groups strengthening and stretching exercises and walking planned for the patient will be given as home exercise. The walking exercise will last 30 minutes at a moderately fast pace, depending on the subject's adaptation. The strengthening exercises will last 15 minutes and will consist of 3 sets of 12 repetitions of exercises with body weight and light weights, generally targeting the back extensor muscles, core stabilization muscles, shoulder region muscles in the upper extremity and hip and knee joint muscles in the lower extremity. The stretching exercises will last 15 minutes and will include neck muscles, pectoralis major/minor, erector spina, hamstrings, quadriceps femoris muscles 1-2 times for 30 seconds each. Participants will be taught face to face with a brochure when they come for the first assessment and will be asked to do HE at home.
214228490|NCT07147075|OTHER|REACH - Hypertension|The intervention is a skills training program for doctors that includes 3 self-paced on-line learning modules and 3 coaching sessions (one in-person and 2 virtual).
214228491|NCT07145762|PROCEDURE|Interventional Block|For patients who are offered interventional blocks as part of their standard of care, we will measure ANI as well as pressure pain threshold before, during, and after the block as well and at follow-up to assess correlation with treatment efficacy.
214228492|NCT07145892|DEVICE|Three-dimensional Digital Breast Tomosynthesis|Patients underwent three-dimensional digital breast tomosynthesis.
214228493|NCT07145892|DEVICE|Two-dimensional Digital Mammography|Patients underwent two-dimensional digital mammography
214228494|NCT07147049|DRUG|HL-1186|HL-1186 tablet for oral administration.
214228495|NCT07147049|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
214228496|NCT07145528|OTHER|Questionary with a case-report-form|Questionary with : Gender, Age, Marital Status, medical history, Socio-économic description, skills assessment test written by R-Shankland, AUDIT-C, fargestrom, HAD, CAST, EPICE, Stroop-Test, Trail making test, Rosenberg Test
214228497|NCT07146178|PROCEDURE|Enhanced Recovery After Surgery|"1. Before surgery~   * Sips of water until 6 AM on the day of surgery, followed by a 200 mL carbohydrate drink~  * Pre-emptive oral analgesics (celecoxib 200mg 1 cap + acetaminophen 650mg 2 tab)~2. During surgery~   * Total intravenous anesthesia~  * Local anesthetic infiltration at the laparoscopic port site for post-operative pain control~3. After surgery~   * Sips of water and a foley catheter removal on ward arrival~  * Soft meal 4 housr after surgery~  * General diet 8 hours after surgery"
214228498|NCT07146178|PROCEDURE|Usual Care|"1. Before surgery~   * Midnight NPO~  * No pre-emptive analgesics~2. During surgery~   * Balanced anesthesia~3. After surgery~   * Sips of water 8 hours after arrival in the ward~  * Foley catheter removal one day after the surgery~  * Soft meal after gas out~  * General diet after one soft meal"
214228499|NCT07145372|OTHER|Manual therapy|It includes 10 minutes of massage and myofascial release for the trapezius and neck extensors, 10 repetitions of occiput-atlas (C0-C1) joint mobilization, occiput-atlas joint manipulation, mobilization of each segment from C2 to C7 with 10 repetitions each, C2-C7 manipulation, cervicothoracic junction (C7-T1) manipulation, thoracic region (T2-T6) manipulation, and sacroiliac joint manipulation.
214228500|NCT07145372|OTHER|Diaphragmatic relaxation technique|It includes diaphragm manual release techniques and a diaphragmatic breathing exercise program
214228501|NCT07145372|OTHER|Shoulder ROM exercise|This group was given a home exercise program consisting of shoulder girdle range of motion (ROM) exercises that do not affect the cervical region.
214228502|NCT07145736|DRUG|Moxidectin|2 mg tablets
214228503|NCT07145736|DRUG|Ivermectin|3 mg tablets
214228504|NCT07144878|DIAGNOSTIC_TEST|Parasternal Intercostal Ultrasound and RSBI Assessment|Participants underwent ultrasonographic evaluation of the parasternal intercostal muscle using a high-frequency linear probe to measure thickness and the thickening fraction during respiration. In addition, the Rapid Shallow Breathing Index was calculated from ventilator-displayed values under standardized settings: pressure support equal to zero centimeters of water and positive end-expiratory pressure equal to zero centimeters of water. Both assessments were performed immediately prior to a spontaneous breathing trial to evaluate their predictive accuracy for successful weaning from mechanical ventilation.
214228505|NCT07146867|BEHAVIORAL|High intensity interval training (exercise)|One 30 minute session of high intensity interval training
214228506|NCT07146347|DRUG|GZR4 injection|GZR4 is a new ultra-long-acting insulin analog
214228507|NCT07145476|DEVICE|Robotic arm exoskeleton integrated with cognitively engaging serious games|A specific sequence of exercises including passive and active- assisted movements, unilateral and bilateral reaching tasks with visual feedback and bimanual symmetric and asymmetric coordination tasks.
214228508|NCT07145112|PROCEDURE|Laser interstitial thermal therapy|MRI guided laser
214228509|NCT07145112|DRUG|Lomustine|Given orally (PO)
214228510|NCT07145086|BEHAVIORAL|Voice therapy with vibration|Voice therapy with a novel vibration device will be delivered for five or eight weeks depending on group allocation. All participants will receive flow phonation voice therapy.
214228511|NCT07146711|DRUG|Tamsulosin (0.4 mg/j)|Multiple dose administration (7 days)
214228512|NCT07146711|DRUG|Omnic Ocas®,|Multiple dose administration (7 days)
214464697|NCT06803173|OTHER|No intervention|No intervention
214464698|NCT06536452|OTHER|Non-Interventional Study|Non-interventional study
214464699|NCT05798845|RADIATION|SBRT+LDRT|primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/2Fx, d1-2, d22-23 (2 cycles)
214464700|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d4, d24 (2 cycles)
214228513|NCT07146789|OTHER|occupational therapy combined with HomeGRASP program|To the present date there has been no trial combining conventional treatment with the GRASP programme as opposed to conventional treatment alone. Therefore, it is necessary to translate and adapt the materials transculturally so that it can be applied in Spain and verify the changes that occur in perceived quality of life and functionality of the affected upper limb as primary outcomes, as well as evaluating manipulative skills, use of the upper limb in ADLs and personal autonomy as secondary outcomes. All this, through the HomeGRASP programme as a complement to conventional rehabilitation in occupational therapy.
214228514|NCT07146789|OTHER|occupational therapy|It will consist solely of conventional occupational therapy treatment at the rehabilitation centre. The conventional treatment sessions will be based on: generally between 2-3 sessions a week lasting 45 minutes each at the rehabilitation centre you attend. The approaches to be used during the sessions will be based solely on mobilisations of the affected upper limb if necessary (maximum 10 minutes of the session), task-oriented training and training in ADLs.
214228516|NCT07147101|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg every 3 weeks
214228517|NCT07147101|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.
214228518|NCT07147101|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
214228519|NCT07147101|DRUG|Rivoceranib|Rivoceranib will be administered by oral 250 mg once daily.
214228520|NCT07147101|DRUG|Nivolumab|Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks
214228521|NCT07147101|DRUG|Ipilimumab|Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.
214228522|NCT03229343|OTHER|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
214228523|NCT05101213|BIOLOGICAL|Virus-specific Cytotoxic T-lymphocytes|Given IV
214228524|NCT04113551|DRUG|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
214228525|NCT04113551|DRUG|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
214228526|NCT04113551|DRUG|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
214228527|NCT04113551|DRUG|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
214228528|NCT03796026|DRUG|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
214228529|NCT03796026|DRUG|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
214228530|NCT02957968|DRUG|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
214228531|NCT02957968|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
214228532|NCT02957968|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
214228533|NCT02957968|DRUG|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
214228534|NCT02957968|DRUG|Decitabine|Given IV
214228535|NCT02957968|DRUG|Pembrolizumab|Given IV
214228536|NCT04731272|DRUG|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
214228537|NCT06507488|DRUG|Daphnetin Capsule|Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
214228538|NCT06507488|DRUG|Placebo|The placebo is a Daphnetin Capsule simulants
214228539|NCT04130308|OTHER|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
214228540|NCT00711178|PROCEDURE|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
214228541|NCT00660881|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
214228542|NCT02156271|DRUG|ramelteon|
214228543|NCT02156271|DRUG|placebo|
214228544|NCT00109590|DRUG|Didanosine, enteric-coated|once daily
214228545|NCT00109590|DRUG|Lopinavir/ritonavir|twice daily
214228546|NCT00109590|DRUG|Nevirapine|single-dose at the onset of labor
214228547|NCT00109590|DRUG|Zidovudine|twice daily
214228548|NCT03719534|PROCEDURE|haplo-HCT|HCT will be performed with a haploidentical donor
214228549|NCT03719534|PROCEDURE|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
214228550|NCT05952752|OTHER|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
214228551|NCT05952752|OTHER|Dexamethsone IV|4 mg IV dexamethasone
214228552|NCT06081322|DRUG|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
214228553|NCT01800175|DEVICE|Punctum Plug|
214228554|NCT04043624|DRUG|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
214228555|NCT04043624|DRUG|Saline|IV bolus of saline, followed by continuous infusion of saline
214228556|NCT05446831|DRUG|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
214228557|NCT00353470|BEHAVIORAL|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
214228558|NCT00353470|BEHAVIORAL|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
214228559|NCT00353470|BEHAVIORAL|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
214228560|NCT05790161|DRUG|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
214228561|NCT03650946|DIAGNOSTIC_TEST|Ga-68 PSMA PET|Ga-68 PSMA PET
214228562|NCT00409331|DRUG|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
214228563|NCT00409331|PROCEDURE|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
214228564|NCT01546272|DEVICE|Insorb resorbable staples|Subcutanous suture using resorbable staples
214228565|NCT01546272|DEVICE|Monocryl resorbable wire|Subcutanous suture using resorbable wire
214228566|NCT03989869|OTHER|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
214228567|NCT03712007|DEVICE|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
214228568|NCT03712007|DEVICE|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
214228569|NCT02793856|DRUG|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
214228570|NCT02793856|OTHER|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
214228571|NCT01511055|DRUG|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
214228572|NCT03487692|OTHER|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
214228573|NCT03487692|OTHER|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
214228574|NCT00480987|DRUG|Oxaliplatin|30 mg/m\^2 IV days 1-4
214228575|NCT00480987|DRUG|Fludarabine|30 mg/m\^2 IV days 2-6
214228576|NCT00480987|DRUG|Cytarabine|500 mg/m\^2 by IV continuous infusion days 2-6
214228577|NCT02879045|OTHER|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
214228578|NCT04590248|DRUG|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
214228579|NCT02697110|BEHAVIORAL|Edutainment based intervention|Edutainment intervention package
214228580|NCT01109056|DRUG|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
214228581|NCT01109056|DRUG|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
214228582|NCT02052414|DRUG|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
214228583|NCT01303003|DRUG|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
214228584|NCT01303003|PROCEDURE|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
214228585|NCT03759808|BEHAVIORAL|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
214228586|NCT03619811|DIAGNOSTIC_TEST|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
214228587|NCT05696028|DEVICE|Gamma counter|DTpA
214228588|NCT03263702|DEVICE|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
214228589|NCT05089422|PROCEDURE|Squint surgery|Lateral rectus recession and /or medial rectus resection
214228590|NCT03976804|OTHER|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
214228591|NCT03976804|OTHER|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
214228592|NCT03976804|OTHER|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
214228593|NCT00775047|OTHER|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
214228594|NCT00775047|OTHER|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
214228595|NCT01350193|DEVICE|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
214228596|NCT01350193|OTHER|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
214228597|NCT02527200|DRUG|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
214228598|NCT02527200|DRUG|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
214228599|NCT02349932|OTHER|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
214228600|NCT03464292|DRUG|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
214228601|NCT03464292|OTHER|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
214228602|NCT06365762|DRUG|EDTA Ophthalmic Solution 2.6%|
214228603|NCT06365762|DRUG|EDTA Ophthalmic Solution 1.3%|
214228604|NCT06365762|DRUG|Saline Solution (Placebo)|
214228605|NCT01734889|DRUG|Nitisinone|Oral suspension
214228606|NCT00966875|BIOLOGICAL|LY2439821|Subcutaneous
214228607|NCT00966875|DRUG|Placebo|Subcutaneous
214228608|NCT02263352|DRUG|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
214228609|NCT02263352|DEVICE|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
214228610|NCT02886403|OTHER|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
214228611|NCT02886403|OTHER|New adhesive strip|A newly developed adhesive strip
214228612|NCT02645838|BEHAVIORAL|Motivational interviewing|1\. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
214228613|NCT04602234|DIAGNOSTIC_TEST|Lung ultrasonography|Investigators performed lung ultrasonography on patients
214228614|NCT03505840|DIAGNOSTIC_TEST|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
214228615|NCT00851968|PROCEDURE|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
214228616|NCT00851968|PROCEDURE|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
214228617|NCT00851968|PROCEDURE|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
214228618|NCT03463005|OTHER|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
214228619|NCT03463005|PROCEDURE|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
214228620|NCT00288899|OTHER|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
214228621|NCT00288899|OTHER|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
214464701|NCT05798845|DRUG|Chemotherapy drug|Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
214464702|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d1, d22 (2 cycles)
214651442|NCT03320499|PROCEDURE|echo doppler at the bed|we practise the echo doppler at the patient 's bed
214651443|NCT03320499|PROCEDURE|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
214228622|NCT03923244|DIAGNOSTIC_TEST|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
214228623|NCT01788813|DRUG|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
214228624|NCT01788813|DRUG|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
214228625|NCT01680198|DRUG|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
214228626|NCT01680198|DRUG|placebo|
214228627|NCT00408941|DRUG|Propofol|
214228628|NCT00408941|DRUG|Prilocaine|
214228629|NCT03557840|DRUG|temocillin|Drug dosing and blood sampling as per the protocol
214228630|NCT02747433|DEVICE|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
214228631|NCT02747433|DEVICE|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
214228632|NCT04657666|DRUG|Nabiximols|oromucosal spray
214228633|NCT04657666|DRUG|Placebo|oromucosal spray
214228634|NCT02591498|BEHAVIORAL|Computerized cognitive training|
214228635|NCT02386189|BEHAVIORAL|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
214228636|NCT00291044|OTHER|testing for HSV 1 and 2 IgG type specific antibosy|
214228637|NCT05804617|PROCEDURE|Dome-type (Modified C-incision) manual morcellation|Morcellation performed by surgeon or trainee
214228638|NCT02654964|DRUG|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
214228639|NCT03223168|DEVICE|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
214228640|NCT04175990|DRUG|Dydrogesterone Pill|started from day 1 of menses till trigger day
214228641|NCT01651806|DRUG|Tranexamic Acid standard dose|Uniform 1 gram dosing
214228642|NCT01651806|DRUG|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
214228643|NCT01651806|DRUG|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
214228644|NCT01651806|DRUG|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
214228645|NCT01659554|DRUG|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
214228646|NCT01659554|DRUG|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
214228647|NCT01790243|DEVICE|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
214228648|NCT01790243|DEVICE|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
214228649|NCT00447070|DRUG|ATAZANAVIR|
214228650|NCT00121043|DEVICE|SimpleJectTM|
214228651|NCT00121043|DRUG|Kineret® (Anakinra)|
214228652|NCT01046435|PROCEDURE|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
214228653|NCT01046435|PROCEDURE|Two placebos|Two placebos 3 times a day for 7 days
214228654|NCT00043329|DRUG|Actimmune Registry|as administered by physician
214228655|NCT04120103|BEHAVIORAL|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
214228656|NCT04120103|OTHER|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
214651444|NCT04122599|DRUG|Melatonin|Melatonin for prevent post stroke delirium
214228657|NCT05863000|OTHER|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
214228658|NCT03870594|DIAGNOSTIC_TEST|glycated hemoglobin|hemoglobin A1c level in blood
214228659|NCT06163378|DEVICE|Rubato Life App|An algorithmically enhanced personalized music-based intervention
214228660|NCT02604329|DEVICE|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
214228661|NCT04510428|DRUG|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
214228662|NCT04510428|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
214228663|NCT04664764|DRUG|Degludec|Basal insulin comparison
214228664|NCT04664764|DRUG|Glargine|Basal insulin comparison
214228665|NCT04664764|DRUG|NPH insulin|Basal insulin comparison
214228666|NCT01222156|PROCEDURE|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
214228667|NCT01222156|DEVICE|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
214228668|NCT00551928|DRUG|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
214228669|NCT00551928|DRUG|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
214228670|NCT00551928|DRUG|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
214228671|NCT00551928|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
214228672|NCT03457779|DIETARY_SUPPLEMENT|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV"
214228673|NCT03946696|OTHER|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
214228674|NCT04813367|PROCEDURE|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
214228675|NCT03954340|DEVICE|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
214228676|NCT03922113|OTHER|Patient follow up|Patient follow up during one month
214228677|NCT05063071|DRUG|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
214228678|NCT01199367|DRUG|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
214228679|NCT02711228|BIOLOGICAL|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
214228680|NCT01022398|DRUG|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
214228681|NCT05962567|OTHER|Non surgical periodontal therapy|scaling and subgingival debridement
214228682|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
214228683|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
214228684|NCT02651909|OTHER|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
214228685|NCT03287206|BIOLOGICAL|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
214228686|NCT03287206|BIOLOGICAL|blood samples from parents|secondary controls for children's analyses
214228687|NCT02507037|DIETARY_SUPPLEMENT|gum+PEG|chew sugarless gum
214228688|NCT02507037|DRUG|polyethylene glycol|2L PEG
214228689|NCT01725659|OTHER|Motor Learning|training of the hemiplegic upper limb with motor learning
214228690|NCT01725659|OTHER|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
214228691|NCT01725659|OTHER|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
214651445|NCT05981066|DRUG|Neoantigen vaccine, I.M injection|Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
214228692|NCT05411627|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
214228693|NCT00450008|DRUG|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
214228694|NCT00450008|DRUG|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
214228695|NCT00450008|DRUG|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
214651446|NCT04847388|DRUG|Substance like alcohol, marijuana, etc.|Cohort study
214228696|NCT00564057|DRUG|candesartan|tablet 8-16 mg once daily, one year
214228697|NCT00564057|DRUG|lercanidipine|tablets 10-20 mg once daily, one year
214228698|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
214228699|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
214228700|NCT01004198|DRUG|Ringers Lactate solution|Ringers Lactate solution for Injection
214228701|NCT05367258|OTHER|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
214228702|NCT03963167|DRUG|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
214228703|NCT02126345|DEVICE|MASTER SL femoral stem and DELTA TT acetabular cup|
214228704|NCT01317550|DRUG|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
214228705|NCT01317550|OTHER|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
214228706|NCT01317550|DRUG|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
214228707|NCT01317550|BEHAVIORAL|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
214228708|NCT00121862|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
214228709|NCT06394362|OTHER|Bispectral index monitor|Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
214228710|NCT03287271|DRUG|VS-6063|"Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
214228711|NCT03287271|DRUG|Paclitaxel|"Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
214228712|NCT03287271|DRUG|Carboplatin|"Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
214228713|NCT06074731|DIAGNOSTIC_TEST|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
214651447|NCT02393911|DIETARY_SUPPLEMENT|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
214651448|NCT00267527|DRUG|CJC 1295|
214651449|NCT02357420|DRUG|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
214651450|NCT02357420|DRUG|Placebo|Placebo given subcutaneously for 12 weeks.
214651451|NCT00582517|DEVICE|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
214651452|NCT00582517|PROCEDURE|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
214651453|NCT05543590|DRUG|Plasmapheresis|5 sessions of plasma exchanges
214651454|NCT05543590|OTHER|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
214651455|NCT05543590|OTHER|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
214651456|NCT05543590|OTHER|PET scan|PET scan at baseline and M6
214651457|NCT05543590|OTHER|Cycle ergometer stress test|Cycle ergometer stress test at M6
214228714|NCT03359018|DRUG|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
214228715|NCT03359018|DRUG|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
214228716|NCT02065427|BEHAVIORAL|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
214228717|NCT04241978|OTHER|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
214228718|NCT04241978|OTHER|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
214228719|NCT00680238|DRUG|Human derived FSH|Customized for each patient
214228720|NCT00006233|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214228721|NCT00006233|DRUG|cyclosporine|
214228722|NCT00006233|DRUG|fludarabine phosphate|
214228723|NCT00006233|DRUG|mycophenolate mofetil|
214228724|NCT00006233|PROCEDURE|peripheral blood stem cell transplantation|
214228725|NCT00006233|RADIATION|radiation therapy|
214228726|NCT03179202|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
214228727|NCT04670250|DIAGNOSTIC_TEST|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
214228728|NCT06125470|BEHAVIORAL|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
214228729|NCT06125470|BEHAVIORAL|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
214228730|NCT06125470|BEHAVIORAL|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
214228731|NCT06125470|BEHAVIORAL|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
214228732|NCT06125470|BEHAVIORAL|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
214228733|NCT06125470|BEHAVIORAL|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
214228734|NCT05273502|BEHAVIORAL|Citizen Science intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
214228735|NCT01120782|DEVICE|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
214651458|NCT05543590|OTHER|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
214228736|NCT01120782|DEVICE|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
214651459|NCT05543590|OTHER|Medical consultations|Medical consultations
214228737|NCT03848299|OTHER|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
214228738|NCT04301310|DRUG|BMS-986235 (Treatment A)|Specified dose on specified days
214228739|NCT04301310|DRUG|Rifampin (Treatment B)|Specified dose on specified days
214228740|NCT03717428|DEVICE|Daily Weighing Group|The Experimental group will weigh themselves everyday
214228741|NCT03717428|DEVICE|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
214228742|NCT05291169|DEVICE|Omeza® OCM™|"Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial."
214228743|NCT02299739|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
214651460|NCT05401747|OTHER|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
214228744|NCT02299739|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
214228745|NCT02299739|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214228746|NCT02299739|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214228747|NCT02299739|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
214228748|NCT01147627|DRUG|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
214228749|NCT01147627|DRUG|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
214228750|NCT01147627|DRUG|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
214228751|NCT00000460|BEHAVIORAL|Low intensity exercise|
214228752|NCT00000460|BEHAVIORAL|High intensity exercise|
214228753|NCT00862420|DRUG|clopidogrel (SR25990)|oral administration (tablets)
214228754|NCT00862420|DRUG|ticlopidine|oral administration (tablets)
214228755|NCT05277948|OTHER|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
214228756|NCT05277948|OTHER|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
214228757|NCT02404090|RADIATION|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
214228758|NCT04059536|DEVICE|Roxwood Anchoring Catheters|Anchoring catheters
214228759|NCT04059536|DRUG|Acetylsalicylic Acid|Oral Tablet
214228760|NCT04059536|DRUG|Heparin|Intravenous Injection
214228761|NCT00640224|DRUG|rosiglitazone|4 mg daily for 6 months
214228762|NCT00640224|DRUG|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
214228763|NCT02535156|DRUG|Risperidone|1 mg Risperidone
214228764|NCT02535156|DRUG|Placebo|Lactose Placebo
214228765|NCT03613142|PROCEDURE|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
214228766|NCT03613142|PROCEDURE|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
214228767|NCT00461474|BEHAVIORAL|Shoulder strengthening exercises|
214228768|NCT00461474|BEHAVIORAL|Movement Optimization|
214228769|NCT05099367|DIAGNOSTIC_TEST|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
214228770|NCT05099367|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
214228771|NCT05099367|DIAGNOSTIC_TEST|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
214228772|NCT02011724|DEVICE|Apligraf|
214228773|NCT01343381|DRUG|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
214228774|NCT01343381|DRUG|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
214651461|NCT00928070|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg
214651462|NCT00928070|DRUG|Placebo|Placebo sham 4 mg and 8 mg
214228775|NCT02270372|BIOLOGICAL|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
214228776|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
214228777|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
214228778|NCT04655196|OTHER|SOLUS-D + weekly feedback by a coach|internet-based self-help
214228779|NCT04655196|OTHER|SOLUS-D + weekly automated messages|internet-based self-help
214228780|NCT04015375|DRUG|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
214228781|NCT04015375|DRUG|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
214228782|NCT04015375|OTHER|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
214228783|NCT05981781|PROCEDURE|ultrasound guided peng block in paediatric hip surgery|"On the supine position, under strict aseptic technique, a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed in the transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral artery, and femoral nerve. The probe will be then rotated, and aligned with the pubic ramus to visualize the AIIS, iliopubic eminence (IPE), femoral artery, psoas muscle, and the superior pubic ramus.~Under direct visualization, a needle will be advanced in-plane, lateral to medial between the psoas tendon and pubic ramus until the needle contacts the IPE. The needle will be slightly withdrawn, and following negative aspiration, 0.5 ml/kg of bupivacaine 0.25% will be injected."
214228784|NCT05981781|PROCEDURE|ultrasound guided caudal epidural block in paediatric hip surgery|On lateral decubitus position, under strict aseptic technique, the sacral hiatus will be visualized at the level of the sacral cornua by employing a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed transversely at the midline to obtain a transverse view of the two cornua, sacrococcygeal ligament, sacral bone, and sacral hiatus. At this level, the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and subsequently placed between the two cornua. A needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. (17) At this level, after confirming absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute while observing an ultrasound longitudinal image.
214228785|NCT01919281|BEHAVIORAL|strength training|
214228786|NCT01919281|BEHAVIORAL|interval training|
214228787|NCT05785819|DRUG|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
214228788|NCT05785819|DRUG|Placebo|Placebo matching VLX-1005
214228789|NCT01105546|DRUG|recombinant activated factor VII|90 µg/kg/day i.v.
214228790|NCT01105546|DRUG|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
214651463|NCT02480530|BEHAVIORAL|Individual Feedback|Patient gets feedback reports on adherence weekly.
214651464|NCT02480530|BEHAVIORAL|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
214651465|NCT03377920|DEVICE|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"* pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
214651466|NCT02415309|DRUG|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
214228791|NCT02870322|BEHAVIORAL|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
214228792|NCT02870322|BEHAVIORAL|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
214228793|NCT03438370|OTHER|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
214228794|NCT03438370|OTHER|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
214228795|NCT00017329|DRUG|bortezomib|
214228796|NCT03673397|BEHAVIORAL|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
214228797|NCT00845793|BEHAVIORAL|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
214228798|NCT01689194|DRUG|genexolPM + cisplatin|
214228799|NCT00583713|DRUG|BLI-800|BLI-800 oral solution (two doses)
214228800|NCT02849730|DEVICE|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
214228801|NCT04224688|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
214228802|NCT04224688|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
214228803|NCT01584544|DRUG|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
214228804|NCT01584544|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
214228805|NCT01584544|DRUG|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
214228806|NCT01584544|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
214228807|NCT01584544|DRUG|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
214651467|NCT02415309|DRUG|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
214651468|NCT02415309|OTHER|Placebo|40 patients will randomly receive a placebo/sugar pill
214228808|NCT06123234|DIETARY_SUPPLEMENT|Verum|Food supplement in single-dose vials
214228809|NCT06123234|OTHER|Placebo|Food supplement in single-dose vials
214228810|NCT00374829|BEHAVIORAL|An IT-based patient follow-up and reminder system|
214228811|NCT01024309|PROCEDURE|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
214228812|NCT01024309|PROCEDURE|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
214228813|NCT05160142|BEHAVIORAL|DICE|10-week culinary and nutrition education program for children with type I diabetes
214228814|NCT01745497|DRUG|Ferrous sulfate|3mg/kg liquid
214228815|NCT01745497|DRUG|Placebo|Equivalent volume of liquid with similar color and taste.
214228816|NCT04997356|BEHAVIORAL|Hostile Bias Modification Training|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.
214228817|NCT04997356|BEHAVIORAL|Other training|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
214228818|NCT04872140|DIETARY_SUPPLEMENT|Low phytate pea powder|Exercise performance with low phytate pea powder
214228819|NCT04872140|DIETARY_SUPPLEMENT|Regular pea powder|Exercise performance with regular pea powder
214228820|NCT04872140|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
214228821|NCT04382014|DIETARY_SUPPLEMENT|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
214228822|NCT06445452|BEHAVIORAL|Direct SNAP-Ed|Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
214228823|NCT01757158|RADIATION|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
214228824|NCT00561626|DIETARY_SUPPLEMENT|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
214228825|NCT00561626|DIETARY_SUPPLEMENT|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
214228826|NCT03725241|DIETARY_SUPPLEMENT|Glutathione Supplement|1000 mg/day Glutathione
214228827|NCT03725241|DIETARY_SUPPLEMENT|Placebo Supplement|Crystalline cellulose
214228828|NCT00450125|OTHER|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
214228829|NCT00450125|OTHER|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
214228830|NCT04264832|OTHER|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
214228831|NCT04636216|BEHAVIORAL|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
214818024|NCT02503293|DEVICE|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
214818025|NCT02305706|PROCEDURE|starting position in colonoscopy|
214228832|NCT02256397|OTHER|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
214228833|NCT02256397|OTHER|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
214228834|NCT02068898|DRUG|XS003|
214228835|NCT02068898|DRUG|Tasigna|
214228836|NCT03405233|PROCEDURE|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
214228837|NCT03405233|PROCEDURE|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
214228838|NCT03405233|PROCEDURE|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
214228839|NCT00165815|DRUG|ARICEPT|
214228840|NCT01988584|BIOLOGICAL|umbilical cord blood (hUCB) cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
214228841|NCT01988584|DRUG|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
214228842|NCT01988584|BIOLOGICAL|bone marrow derived mononuclear cells (BMMNCs)|Autologous stem cells from bone marrow harvest.
214228843|NCT04257188|PROCEDURE|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
214228844|NCT02113254|OTHER|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
214228845|NCT05271500|DEVICE|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
214228846|NCT03816709|DEVICE|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
214228847|NCT03232333|DEVICE|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
214228848|NCT01980589|DRUG|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
214228849|NCT01980589|DRUG|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
214228850|NCT01980589|DRUG|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
214228851|NCT00120757|DRUG|Alendronate|
214228852|NCT02641340|DRUG|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
214228853|NCT02641340|DRUG|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
214228854|NCT02074891|DRUG|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
214228855|NCT05120557|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
214228856|NCT05781880|OTHER|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
214228857|NCT03845439|OTHER|Lumbar puncture|Lumbar puncture
214228858|NCT00653432|DEVICE|Monovisc®|Intra-articular injection
214228859|NCT00653432|OTHER|Saline|0.9% Sterile Saline
214228860|NCT00308464|DRUG|PHA-794428|
214228861|NCT00567255|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
214228862|NCT00567255|DRUG|Placebo|
214228863|NCT00567255|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
214818026|NCT01921062|BEHAVIORAL|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
214228864|NCT01780220|DRUG|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
214228865|NCT05246865|DRUG|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
214228866|NCT05236868|DRUG|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
214228867|NCT02868827|DRUG|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
214228868|NCT02868827|OTHER|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
214228869|NCT05037578|BEHAVIORAL|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
214228870|NCT03430713|PROCEDURE|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
214228871|NCT01179685|PROCEDURE|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
214228872|NCT05680116|DEVICE|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
214228873|NCT05680116|OTHER|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
214228874|NCT05282745|OTHER|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
214228875|NCT04090775|DRUG|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
214228876|NCT04090775|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
214228877|NCT04090775|DRUG|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
214228878|NCT04090775|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
214228879|NCT00196092|DEVICE|Roll-in|Proctored entry.
214228880|NCT00196092|DEVICE|Surgical|Surgery
214228881|NCT00196092|DEVICE|Standard Risk|Standard Endovascular repair
214228882|NCT00196092|DEVICE|High Risk|High Risk Endovascular repair.
214228883|NCT00196092|DEVICE|Compassionate Use|Endovascular repair for compassionate use patients.
214228884|NCT00196092|DEVICE|Treatment for females|Endovascular repair in female patients
214228885|NCT00196092|DEVICE|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
214228886|NCT00196092|DEVICE|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
214228887|NCT03194737|DEVICE|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
214228888|NCT05246267|BIOLOGICAL|Dupilumab|Standard of care treatment with dupilumab
214228889|NCT01116778|BIOLOGICAL|eN-Lac®|One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
214228890|NCT01116778|OTHER|Placebo|One placebo capsule, once daily, po
214228891|NCT01088607|DRUG|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
214228892|NCT00255424|DRUG|ferumoxytol or oral iron|
214228893|NCT01692821|DRUG|100% oxygen breathing|100% oxygen breathing - 30 minutes
214228894|NCT01692821|DRUG|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
214228895|NCT01692821|DRUG|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
214228896|NCT03162900|DRUG|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
214651469|NCT06293703|PROCEDURE|Surgery|Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
214228897|NCT03162900|DRUG|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
214228898|NCT03162900|DRUG|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
214228899|NCT03162900|OTHER|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
214228900|NCT00911885|BEHAVIORAL|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
214228901|NCT00108368|DRUG|Risperidone|
214228902|NCT00108368|DRUG|Olanzapine|
214228903|NCT04276376|DRUG|Atezolizumab|Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
214228904|NCT04276376|DRUG|Rucaparib|Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
214228905|NCT00029510|DRUG|Magnesium|
214228906|NCT02166671|BIOLOGICAL|HBV booster vaccination 1dose|
214228907|NCT03207165|DRUG|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
214228908|NCT03207165|DRUG|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
214228909|NCT02942732|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
214228910|NCT05246085|DIAGNOSTIC_TEST|Cortisol level|Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
214651470|NCT05249946|OTHER|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
214228911|NCT01290796|DEVICE|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
214228912|NCT02753257|OTHER|Non-Interventional|Non-Interventional
214228913|NCT04765085|BEHAVIORAL|comprehensive behavioral intervention therapy (CBIT)|"Comprehensive behavioral intervention for tics is an extension of habit reversal training. It includes an expanded set of strategies, such as psycho-education about tic disorders, tic awareness training, competing response training, relaxation training, and functional analysis.~According to the CBIT treatment manual (translated by sun Jinhua and Xu Wen, the author were Douglas W. woods et al., Oxford University Press, New York). The treatments consisted of 8 sessions for 10 weeks The first two phases were 1.5 hours, the last six stages were 1 hour.The treatment process was regularly supervised by a treatment supervisor."
214228914|NCT04765085|DRUG|Aripiprazole 5Mg Oral Tablet|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
214228915|NCT02343549|DEVICE|NovoTTF100A|
214228916|NCT02343549|DRUG|Bevacizumab|
214228917|NCT02343549|DRUG|Temozolomide|
214228918|NCT00749112|DRUG|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
214228919|NCT03087617|DEVICE|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
214228920|NCT03087617|BEHAVIORAL|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
214228921|NCT03087617|OTHER|Usual Care|Usual Care for Lung Cancer Screening patients.
214228922|NCT01896206|DEVICE|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
214228923|NCT01040234|PROCEDURE|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
214228924|NCT02284841|DEVICE|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
214228925|NCT00132977|DEVICE|Cardiac Resynchronization Therapy|
214228926|NCT05483218|DEVICE|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
214228927|NCT05034822|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
214228928|NCT01090323|DRUG|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
214228929|NCT01766505|DRUG|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
214228930|NCT01766505|DRUG|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
214228931|NCT01864005|DRUG|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
214228932|NCT01864005|DRUG|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
214228933|NCT01717599|DRUG|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
214228934|NCT01717599|DRUG|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
214228935|NCT01082549|DRUG|gemcitabine/carboplatin|i.v.
214228936|NCT01082549|DRUG|gemcitabine/carboplatin plus Iniparib|i.v.
214228937|NCT03482934|DEVICE|sphygmomanometer|device used for measurement of brachial blood pressure
214228938|NCT03482934|DEVICE|mobilogragh|device used for measurement of central blood pressure
214228939|NCT03482934|DIAGNOSTIC_TEST|ECG|Electrocardiogram
214228940|NCT03482934|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
214228941|NCT04379128|OTHER|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
214228942|NCT00386919|PROCEDURE|CyberKnife|
214228943|NCT00763698|DEVICE|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
214228944|NCT02190565|DIETARY_SUPPLEMENT|Food supplement|Randomized double-blind, placebo-controlled
214228945|NCT06001359|OTHER|No intervention|No intervention
214228946|NCT04264624|DEVICE|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
214228947|NCT04264624|DEVICE|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
214228948|NCT03367468|OTHER|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
214228949|NCT03367468|OTHER|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
214228950|NCT03970915|DEVICE|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
214228951|NCT03970915|DEVICE|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
214228952|NCT02059291|DRUG|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
214228953|NCT02059291|DRUG|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
214228954|NCT00492713|OTHER|dark chocolate|dark chocolate
214228955|NCT00492713|OTHER|Milk chocolate 1|Milk chocolate 1
214228956|NCT00492713|OTHER|Milk chocolate 2|Milk chocolate 2
214228957|NCT05815979|BEHAVIORAL|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
214228958|NCT00213993|DRUG|antiperspirant|antiperspirant topically once daily to one foot
214228959|NCT01736761|DRUG|Darunavir, Ritonavir and Rilpivirine|
214228960|NCT01433289|DRUG|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
214228961|NCT01433289|DRUG|Placebo|
214228962|NCT03241368|DEVICE|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
214228963|NCT04902300|OTHER|Data collection|evaluation of internet addiction
214228964|NCT03463200|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
214228965|NCT03463200|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
214228966|NCT03463200|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
214228967|NCT01998568|OTHER|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
214228968|NCT06333600|DRUG|Topical minoxidil|Therapeutic intervention
214228969|NCT06333600|DRUG|Topical Vitamin D|Therapeutic intervention
214228970|NCT06333600|DRUG|Saline spray|placebo
214228971|NCT04708236|DRUG|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
214228972|NCT04708236|DRUG|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
214228973|NCT04708236|DRUG|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
214228974|NCT04708236|OTHER|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
214228975|NCT03820440|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
214228976|NCT03820440|DIAGNOSTIC_TEST|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
214228977|NCT04590833|BEHAVIORAL|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
214228978|NCT04590833|BEHAVIORAL|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
214228979|NCT04248283|DEVICE|Adjustable Continence Therapy for Women (ACT)|Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
214228980|NCT06531980|OTHER|Modi|"The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course."
214228981|NCT06531980|OTHER|Treatment as usual|Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
214228982|NCT02213406|DIETARY_SUPPLEMENT|yogurt|Subjects will receive yogurt with varying fat concentrations
214651471|NCT03539445|DRUG|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
214228983|NCT02130102|DEVICE|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
214228984|NCT02668471|PROCEDURE|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
214228985|NCT02668471|PROCEDURE|traditional method|Radial artery catheters will be placed by the palpation technique only.
214228986|NCT04493528|COMBINATION_PRODUCT|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
214228987|NCT04493528|COMBINATION_PRODUCT|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
214228988|NCT02278523|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
214228989|NCT02973880|DRUG|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
214228990|NCT02973880|DRUG|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
214228991|NCT02284932|OTHER|No specific intervention for this study|No specific intervention for this study
214228992|NCT00324259|DRUG|Estradiol|
214228993|NCT04382989|DEVICE|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
214228994|NCT05662800|DIAGNOSTIC_TEST|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
214228995|NCT05253391|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
214228996|NCT01425580|DRUG|liraglutide|1.8 mg s.c. (QD)
214228997|NCT01425580|DRUG|glimepiride|4 mg p.o. (QD)
214228998|NCT01425580|DRUG|Metformin|500 mg p.o. (BID)
214228999|NCT02482831|PROCEDURE|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
214229000|NCT03021993|DRUG|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
214229001|NCT03058328|OTHER|Cognitive testing, testing of heart rate variability and blood samples|No intervention. Registration of ECG, cognitive testing and blood sampling is performed in the perioperative period and during follow up.
214229002|NCT02313961|OTHER|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
214229003|NCT02310334|OTHER|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
214229004|NCT02310334|OTHER|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
214229005|NCT04229732|DEVICE|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
214229006|NCT04122651|PROCEDURE|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
214229007|NCT04122651|PROCEDURE|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
214229008|NCT05171556|OTHER|Cosmetic product|RV4942A is a face balm product
214229009|NCT00080899|DRUG|fenretinide|Given orally
214229010|NCT00080899|OTHER|laboratory biomarker analysis|Correlative studies
214229011|NCT01463085|OTHER|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
214229012|NCT02618070|OTHER|Yogurt|
214229013|NCT02215811|BIOLOGICAL|Mesenchymal stromal cells|
214229014|NCT01163227|DRUG|Placebo (single and multiple doses)|
214229015|NCT01163227|DRUG|AQW051 2 mg (single and multiple doses)|
214229016|NCT01163227|DRUG|AQW051 15mg (single and multiple doses)|
214229017|NCT01163227|DRUG|AQW051 100mg (single dose), and 50mg (multiple doses)|
214651472|NCT03539445|DRUG|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
214229018|NCT01462253|DRUG|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
214229019|NCT02065258|OTHER|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
214229020|NCT02065258|OTHER|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
214229021|NCT02824796|BEHAVIORAL|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
214229022|NCT02824796|BEHAVIORAL|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
214229023|NCT02106858|DRUG|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
214229024|NCT00882297|PROCEDURE|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
214229025|NCT01125488|DEVICE|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
214229026|NCT01125488|DRUG|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
214229027|NCT05243732|BEHAVIORAL|Mindful Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness."
214229028|NCT05243732|BEHAVIORAL|Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given"
214229029|NCT01481194|DRUG|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
214229030|NCT01481194|DRUG|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
214229031|NCT01481194|DRUG|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
214229032|NCT01481194|DRUG|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
214229033|NCT01481194|DRUG|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
214229034|NCT04551209|PROCEDURE|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
214229035|NCT03279640|DEVICE|rTMS on ipsilesional M1|
214229036|NCT03279640|DEVICE|tDCS on contralesional M1|
214229037|NCT03881527|DEVICE|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
214229038|NCT03881527|PROCEDURE|aortic valve replacement|Aortic valve replacement in a standard fashion
214229039|NCT04961411|PROCEDURE|operation or non-operative treatment|type of operation or if possible non-operative treatment
214229040|NCT00787267|DRUG|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
214229041|NCT04343235|DRUG|furosemide|five day course of furosemide 20mg QD
214229042|NCT04343235|DRUG|labetalol|200mg labetalol BID
214229043|NCT03455231|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
214229044|NCT00865280|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
214229045|NCT00865280|DRUG|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
214229046|NCT00865280|DRUG|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
214229047|NCT00874419|DRUG|erlotinib|erlotinib 150 mg oral, once a day
214229048|NCT00874419|DRUG|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
214229049|NCT04412785|DRUG|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
214229050|NCT03779490|DEVICE|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
214229051|NCT04901689|DRUG|Leronlimab|Leronlimab 700 mg
214229052|NCT04901689|DRUG|Placebo|Placebo
214229053|NCT01616693|DIETARY_SUPPLEMENT|Probiotic|A capsule that contains at least 1 x 10\^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
214229054|NCT01616693|DIETARY_SUPPLEMENT|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
214229055|NCT01616693|DIETARY_SUPPLEMENT|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
214229056|NCT01616693|DIETARY_SUPPLEMENT|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
214229057|NCT01616693|BIOLOGICAL|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
214229058|NCT01616693|BIOLOGICAL|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
214229059|NCT00117494|DRUG|Pravastatin|
214229060|NCT00117494|DRUG|Rosuvastatin|
214229061|NCT04863911|RADIATION|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
214229062|NCT05083832|PROCEDURE|Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block|Two different catheter techniques with same doses local anesthetic infusion
214229063|NCT04971317|BEHAVIORAL|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
214229064|NCT04971317|BEHAVIORAL|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
214229065|NCT04971317|BEHAVIORAL|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
214229066|NCT06019442|BEHAVIORAL|Brief alcohol intervention (Health4Her-Automated)|"Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content)."
214229067|NCT06019442|BEHAVIORAL|Lifestyle health promotion|"Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight)."
214229068|NCT06228677|PROCEDURE|Selective adrenal artery embolization|Percutaneous selective adrenal artery embolization in patients with primary aldosteronism
214229069|NCT04814199|OTHER|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
214229070|NCT06171841|OTHER|low-intensity resistance training|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions performed twice a week for 6 weeks.
214229071|NCT06171841|OTHER|high-intensity resistance training|4 sets of 10 repetitions of leg press exercise at 70-80% one-repetition maximum (weeks 1-3: 70%, weeks 4-6: 80%) in normoxic conditions performed twice a week for 6 weeks.
214651473|NCT02371850|DRUG|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
214651474|NCT01296048|DEVICE|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
214229072|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
214229073|NCT06171841|OTHER|low-intensity resistance training in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in hypoxia conditions (3500 meters above sea) performed twice a week for 6 weeks.
214229074|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normobaric hypoxia conditions (3500 meters above sea) with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
214229075|NCT00653939|DRUG|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
214651475|NCT01403909|DEVICE|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
214651476|NCT01403909|PROCEDURE|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
214651477|NCT00891995|DEVICE|Closed loop|Closed loop therapy for up to 4 to 6 days
214651478|NCT00891995|DEVICE|Home glucose monitoring|Standard diabetes management using a home glucose meter.
214651479|NCT00891995|DEVICE|Insulin pump|Insulin pump use for 2 years
214651480|NCT00891995|DEVICE|Continuous glucose monitor|Continuous glucose monitor use for 2 years
214229076|NCT00653939|DRUG|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
214229077|NCT00653939|DRUG|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
214229078|NCT00653939|DRUG|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
214229079|NCT03542032|OTHER|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
214229080|NCT05828537|DEVICE|endotracheal tube|pediatric extubation
214229081|NCT04110535|DRUG|Remimazolam|IV administration over 1 minute
214229082|NCT04110535|DRUG|Midazolam|IV administration over 1 minute
214229083|NCT04110535|OTHER|Saline|IV administration over 1 minute
214229084|NCT04090372|DEVICE|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
214229085|NCT01105767|DRUG|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
214229086|NCT01105767|OTHER|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
214229087|NCT02940041|PROCEDURE|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
214229088|NCT04786834|PROCEDURE|Vesico urethral anastomosis on chicken model|Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
214229089|NCT01443624|DRUG|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
214229090|NCT00743106|DRUG|Fenoldopam|Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours
214229091|NCT00743106|DRUG|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
214229092|NCT04772833|OTHER|Autopsy|The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
214229093|NCT03730142|DRUG|WXFL10030390|WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
214229094|NCT02840617|DRUG|Indocyanine Green (ICG)|
214229095|NCT04611490|PROCEDURE|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
214229096|NCT04771091|DIAGNOSTIC_TEST|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
214651481|NCT04755556|OTHER|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
214651482|NCT04755556|OTHER|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
214651483|NCT02054702|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
214651484|NCT02054702|DRUG|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
214651485|NCT05448118|DIAGNOSTIC_TEST|Virtual POC Toxicology Test|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
214651486|NCT00887458|DRUG|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
214651487|NCT00887458|DRUG|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
214229097|NCT05960630|PROCEDURE|MIRRORS Protocol|Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
214229098|NCT05960630|PROCEDURE|Standard Open Cytoreductive Surgery|Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
214229099|NCT00817596|DEVICE|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
214229100|NCT02282241|DRUG|Melatonin|
214229101|NCT02282241|OTHER|Placebo|
214229102|NCT00294619|DRUG|growth hormone|subcutaneous injection, once-weekly
214229103|NCT00274833|DRUG|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
214229104|NCT00274833|DRUG|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
214229105|NCT00274833|RADIATION|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
214229106|NCT02646371|BIOLOGICAL|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
214651488|NCT03180892|OTHER|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
214651489|NCT00501228|DRUG|Filgrastim|5 mg/kg ID Once Daily x 1 Week
214651490|NCT00393419|BEHAVIORAL|Comprehensive pharmacy care program|
214651491|NCT03448640|DRUG|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
214229107|NCT02646371|BIOLOGICAL|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
214229108|NCT00933556|DIETARY_SUPPLEMENT|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
214229109|NCT00933556|DIETARY_SUPPLEMENT|sugar pill (placebo)|placebo identical to the active product will be given
214229110|NCT04194385|PROCEDURE|Upper trunk block|Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .
214229111|NCT04194385|PROCEDURE|Costoclavicular block|Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
214229112|NCT04194385|PROCEDURE|Diaphragmatic function assessment|Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
214229113|NCT04194385|PROCEDURE|Cervical plexus blockade|Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
214229114|NCT01792544|OTHER|Statement|
214229115|NCT01792544|OTHER|No Statement|
214229116|NCT02290743|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
214229117|NCT00574236|DRUG|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
214229118|NCT05676268|PROCEDURE|Implant-supported fixed dental prostheses with cantilever extension|Healthy patients in need of replacement of missing teeth with dental implants supporting partial fixed dental prostheses with cantilever extensions
214229119|NCT01937429|DEVICE|Colonoscopy with blue Indigo Carmin®|
214229120|NCT01937429|DEVICE|Standard colonoscopy with insufflation of air|
214229121|NCT02874144|DRUG|AZ compound|40 mg three times daily po for 12 weeks
214229122|NCT02874144|OTHER|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
214229123|NCT02874144|DRUG|Intranasal corticosteroid|QD Nasal Spray
214229124|NCT02874144|DRUG|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
214229125|NCT06156709|PROCEDURE|Group I: Lower Volume with Higher Anaesthetic Concentration|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
214229126|NCT06156709|PROCEDURE|Group II: Higher Volume with LowerAnaesthetic Concentration|20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
214229127|NCT03370705|DRUG|Sulodexide|Sulodexide 250 ULS twice daily per oral route
214229128|NCT03370705|DRUG|Statin|Statin 20mg once daily per oral route,
214229129|NCT03370705|DRUG|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
214818027|NCT03129022|PROCEDURE|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
214229130|NCT03370705|DRUG|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
214229131|NCT03537300|BEHAVIORAL|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
214229132|NCT03537300|BEHAVIORAL|conventional exercises|conventional exercises
214229133|NCT03063047|OTHER|PD21871AA|A 100s size menthol cigarette.
214229134|NCT03063047|OTHER|PD21872AA|A 100s size menthol cigarette.
214229135|NCT04075253|BEHAVIORAL|VO2 peak testing|Exercise on treadmill starts with \~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
214229136|NCT00272025|DRUG|Escitalopram|10mg to 20mg tablet daily for 6 weeks
214229137|NCT00272025|DRUG|placebo|
214229138|NCT00486811|DRUG|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
214229139|NCT00486811|DRUG|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
214229140|NCT00486811|DRUG|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
214229141|NCT02369744|DRUG|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
214229142|NCT02369744|DRUG|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
214229143|NCT00924859|OTHER|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
214229144|NCT02659748|DIETARY_SUPPLEMENT|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
214229145|NCT02659748|DIETARY_SUPPLEMENT|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
214229146|NCT00003497|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
214229147|NCT03753789|DEVICE|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
214229148|NCT01146587|DEVICE|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
214229149|NCT01146587|DEVICE|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
214229150|NCT01146587|OTHER|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
214229151|NCT04273906|PROCEDURE|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
214229152|NCT04273906|PROCEDURE|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
214229153|NCT02975557|DRUG|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
214229154|NCT02975557|DRUG|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
214229155|NCT02975557|DRUG|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
214229156|NCT02928263|OTHER|Non-Interventional|Other
214229157|NCT02845167|OTHER|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
214229158|NCT05731349|OTHER|2018 Surviving Sepsis Campaign Hour-1 Bundle|"1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg"
214229159|NCT03361683|DEVICE|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
214229160|NCT03361683|DEVICE|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
214229161|NCT05149885|DEVICE|SenseGuard monitoring|All subjects that recruited to the study will undergo MCT as usual with the addition of SG measurement after each Methacholine dose and spirometry test.
214229162|NCT01821976|PROCEDURE|Ertl Procedure|
214229163|NCT01821976|PROCEDURE|Burgess Procedure|
214229164|NCT00597597|DRUG|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
214229165|NCT02249000|DEVICE|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
214229166|NCT02237222|OTHER|Gait rehabilitation|
214229167|NCT04650867|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
214651492|NCT03982550|BEHAVIORAL|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
214651493|NCT05859035|DEVICE|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
214818028|NCT02109263|PROCEDURE|saccharose versus breast-feeding|saccharose versus breast-feeding
214229168|NCT00139789|DRUG|Kemstro|
214229169|NCT02027090|DRUG|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
214229170|NCT02027090|DRUG|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
214229171|NCT05205889|BEHAVIORAL|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
214229172|NCT01032109|DRUG|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
214229173|NCT04287582|OTHER|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
214229174|NCT00601952|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
214229175|NCT00601952|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
214229176|NCT03050385|DEVICE|transcranial direct current stimulation|
214229177|NCT04119466|BEHAVIORAL|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
214229178|NCT00646269|BEHAVIORAL|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
214229179|NCT00646269|BEHAVIORAL|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
214229180|NCT00646269|BEHAVIORAL|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
214229181|NCT00646269|BEHAVIORAL|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
214229182|NCT03276455|GENETIC|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
214229183|NCT03882268|BEHAVIORAL|MIYCN interventions|"1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
214229184|NCT04334577|BIOLOGICAL|live attenuated zoster vaccine|subcutaneous injection
214229185|NCT04334577|BIOLOGICAL|placebo|subcutaneous injection
214229186|NCT03366519|PROCEDURE|clinical echography (CE)|clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
214229187|NCT02205840|DRUG|SI-614|1 drop in each eye
214229188|NCT02205840|DRUG|Vehicle|1 drop in each eye
214229189|NCT04240834|DRUG|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
214229190|NCT04240834|DRUG|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
214229191|NCT01785485|OTHER|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
214229192|NCT02878057|DRUG|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
214651494|NCT04285320|DRUG|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water"
214229193|NCT01192009|DIETARY_SUPPLEMENT|Leucine|7.2 g of leucine during 2 weeks
214229194|NCT01192009|DIETARY_SUPPLEMENT|Placebo|7.2 g of alanine during 2 weeks
214229195|NCT00946153|DRUG|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
214229196|NCT01030666|DRUG|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
214229197|NCT01030666|DRUG|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
214229198|NCT01030666|PROCEDURE|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
214229199|NCT01030666|BIOLOGICAL|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
214229200|NCT01030666|DRUG|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
214229201|NCT01030666|DRUG|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
214229202|NCT01030666|DRUG|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
214229203|NCT03904056|PROCEDURE|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
214229204|NCT03904056|PROCEDURE|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
214229205|NCT00003745|DRUG|topotecan hydrochloride|
214229206|NCT03675854|DRUG|Cefazolin|3 weeks
214229207|NCT02784639|OTHER|Plasma Analysis of circulating cell free DNA|
214229208|NCT02784639|OTHER|Tumor tissue analysis of circulating cell free DNA|
214229209|NCT05991544|BEHAVIORAL|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
214229210|NCT06173700|BEHAVIORAL|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
214229211|NCT01024725|OTHER|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
214229212|NCT06532240|DRUG|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
214229213|NCT06532240|DRUG|Placebo|An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
214229214|NCT02594020|PROCEDURE|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
214651495|NCT04285320|DRUG|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)"
214651496|NCT04375657|COMBINATION_PRODUCT|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
214651497|NCT04375657|COMBINATION_PRODUCT|Active Control|Metformin and DHEA
214229215|NCT02594020|PROCEDURE|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
214229216|NCT02594020|PROCEDURE|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
214229217|NCT00985829|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
214229218|NCT05956444|OTHER|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
214229219|NCT05956444|OTHER|Conventional Physiotherapy|Classical physiotherapy applications for balance.
214229220|NCT03698591|DEVICE|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
214229221|NCT03698591|DEVICE|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
214229222|NCT05373914|DRUG|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
214651498|NCT00421876|BEHAVIORAL|multifactorial continued educational - behavioural programme|
214229223|NCT05373914|DRUG|Control: Matching Placebo|Placebo - 250mg tablets (orally)
214229224|NCT02894268|DRUG|Doxycycline|Doxycycline 100g po bid
214229225|NCT02894268|DRUG|Furazolidone|Furazolidone 100mg po bid
214229226|NCT02894268|DRUG|Esomeprazole|Esomeprazole 20mg po bid
214229227|NCT02894268|DRUG|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
214229228|NCT02894268|DRUG|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
214229229|NCT05225805|DRUG|Lefamulin|Antibiotic
214229230|NCT06423274|DIAGNOSTIC_TEST|fundus photography|using artificial intelligence to identify diabetic retinopathy using fundus photography
214229231|NCT06423274|DIAGNOSTIC_TEST|optical coherence tomography|detect diabetic retinopathy and diabetic macular edema by optical coherence tomography
214229232|NCT06423274|DIAGNOSTIC_TEST|fundus fluorescence angiography|detect diabetic retinopathy by fundus fluorescence angiography
214229233|NCT02369172|DRUG|Bupropion|
214229234|NCT02369172|DRUG|ASP2151|
214229235|NCT04371458|DRUG|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
214229236|NCT06451198|DRUG|Indobufen|Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
214229237|NCT06451198|DRUG|Aspirin|Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
214229238|NCT06451198|DRUG|Ticagrelor|All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
214229239|NCT00831493|RADIATION|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
214229240|NCT00831493|DRUG|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
214229241|NCT04708457|OTHER|VV-ECMO|Early use of VV-ECMO in SARI patients.
214651499|NCT05931783|PROCEDURE|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
214229242|NCT01550848|DRUG|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
214229243|NCT04465838|OTHER|NIS|This is a non-interventional study (NIS).
214229244|NCT00620503|DRUG|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
214229245|NCT00620503|DRUG|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
214229246|NCT04452110|DIAGNOSTIC_TEST|Ultrasonography|Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
214229247|NCT02145650|OTHER|No Intervention|There is no intervention administered in this study.
214229248|NCT04185285|DEVICE|Percutaneous coronary intervention, stents|
214229249|NCT02371915|OTHER|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
214229250|NCT04367909|DRUG|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
214229251|NCT04367909|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
214229252|NCT04367909|DRUG|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
214229253|NCT04326426|DRUG|Tradipitant|Neurokinin-1 antagonist
214229254|NCT04326426|DRUG|Placebo|Matching placebo
214229255|NCT03400605|OTHER|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
214229256|NCT04578821|OTHER|Educational intervention|Educational intervention
214229257|NCT04529356|DEVICE|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
214229258|NCT04529356|DRUG|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
214229259|NCT00557856|DRUG|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
214651500|NCT05931783|PROCEDURE|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
214651501|NCT03812406|PROCEDURE|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
214229260|NCT00451347|DEVICE|Quadriceps strength training|
214229261|NCT00451347|DEVICE|Taping|
214229262|NCT00451347|DEVICE|Home exercise|
214229263|NCT02234895|DEVICE|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
214229264|NCT02234895|DEVICE|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
214229265|NCT02177149|DEVICE|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
214229266|NCT02177149|DEVICE|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
214229267|NCT05036421|DRUG|Empagliflozin 10 milligram|antihyperglycemic medication
214229268|NCT00726011|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
214229269|NCT03320577|BEHAVIORAL|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
214229270|NCT03320577|BEHAVIORAL|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
214229271|NCT03320577|BEHAVIORAL|Control|Log dinner times
214229272|NCT01763008|DRUG|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
214229273|NCT02726854|DRUG|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
214229274|NCT04120519|DRUG|thalidomide combined with dexamethasone and cyclophosphamide|TCD
214229275|NCT02400385|DRUG|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
214229276|NCT02400385|DRUG|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
214229277|NCT01675167|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
214229278|NCT01675167|DRUG|Placebo|Matching Placebo Buccal Film twice daily
214229279|NCT02326480|OTHER|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
214229280|NCT00625430|BIOLOGICAL|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
214229281|NCT02172417|DRUG|Cimetidine + Tiotropium|
214229282|NCT02172417|DRUG|Ranitidine + Tiotropium|
214229283|NCT02172417|DRUG|Tiotropium|
214229284|NCT03745885|DRUG|Supaglutide injection|Administered SC in the Supaglutide arms.
214229285|NCT03745885|DRUG|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
214229286|NCT02224248|BEHAVIORAL|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
214229287|NCT02224248|BEHAVIORAL|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
214229288|NCT03620461|DRUG|Gemcitabine - nabpaclitaxel|efficacy and safety
214229289|NCT05518578|DRUG|SPN-817|oral capsule
214229290|NCT05819489|DIAGNOSTIC_TEST|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
214229291|NCT00296205|DRUG|Cyclophosphamide|
214651502|NCT03812406|PROCEDURE|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
214651503|NCT00000981|DRUG|Fiacitabine|
214651504|NCT02304926|DRUG|Simvastatin|simvastatin (40 mg/day) for 4 weeks
214651505|NCT02304926|DRUG|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
214229292|NCT04874051|DEVICE|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
214229293|NCT04874051|OTHER|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
214229294|NCT01798108|RADIATION|Radium-223 dichloride (BAY88-8223)|\- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
214229295|NCT00512629|DRUG|Omegaven|Omegaven is a fish based intravenous fat emulsion
214229296|NCT00512629|DRUG|Intralipid|Intralipid is a plant based intravenous fat emulsion
214229297|NCT02277561|PROCEDURE|diffusion tensor imaging|Undergo VB-DTI
214229298|NCT02277561|RADIATION|whole-brain radiation therapy|Undergo WBRT
214229299|NCT02277561|RADIATION|stereotactic radiosurgery|Undergo SRS
214229300|NCT02277561|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
214229301|NCT02277561|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
214229302|NCT05364359|DIETARY_SUPPLEMENT|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
214229303|NCT05364359|OTHER|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
214229304|NCT06936631|PROCEDURE|Catheter replacement|"In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule.~The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results."
214229305|NCT06936631|PROCEDURE|Catheter retainment|In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule. The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results.
214229306|NCT07146204|DEVICE|Robotic-assisted percutaneous coronary intervention|Patients with coronary artery disease will be treated usiing the R-Star robotic system for a robotic-assisted percutaneous coronary intervention
214229307|NCT06943287|BEHAVIORAL|Pharmacist Intervention|If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
214229308|NCT06946134|OTHER|FIT SA|self-adhesive flowable giomer restorative material
214229309|NCT06946134|OTHER|Beautifil Flow Plus F00|Conventional flowable giomer restorative material
214229310|NCT01528267|OTHER|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
214229311|NCT01528267|OTHER|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
214229312|NCT06448767|DIETARY_SUPPLEMENT|Multispecies probiotics|Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.
214229313|NCT06448767|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotics.
214229314|NCT00449397|DRUG|Quetiapine Fumarate|
214229315|NCT03973528|DRUG|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
214229316|NCT01925131|DRUG|cyclophosphamide|Given IV
214229317|NCT01925131|DRUG|vincristine sulfate|Given IV
214229318|NCT01925131|DRUG|prednisone|Given PO
214651506|NCT02304926|DRUG|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
214229319|NCT01925131|BIOLOGICAL|inotuzumab ozogamicin|Given IV
214229320|NCT01925131|OTHER|laboratory biomarker analysis|Correlative studies
214229321|NCT05206084|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
214229322|NCT05206084|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
214651507|NCT00848744|DRUG|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
214651508|NCT00848744|DRUG|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
214651509|NCT02960282|PROCEDURE|Biospecimen Collection|Undergo collection of fecal specimens
214651510|NCT02960282|OTHER|Laboratory Biomarker Analysis|Correlative studies
214651511|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
214651512|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
214229323|NCT04876820|OTHER|Pharmacist intervention|"In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist.~An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done.~An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done.~An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done."
214229324|NCT04876820|OTHER|Standard of care|An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
214229325|NCT06540807|DEVICE|Colovac Colorectal Anastomosis Protection Device|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
214229326|NCT06540807|PROCEDURE|Stoma creation|Diverting loop ileostomy
214229327|NCT06080932|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
214229328|NCT06080932|OTHER|NIH Toolbox|IPAD-based assessments that examines cognitive function
214229329|NCT06080932|OTHER|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
214229330|NCT06080932|OTHER|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
214229331|NCT06080932|OTHER|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
214229332|NCT06080932|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
214229333|NCT06080932|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
214229334|NCT06080932|OTHER|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
214229335|NCT06080932|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
214229336|NCT06080932|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
214229337|NCT06080932|BEHAVIORAL|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
214229338|NCT06080932|BEHAVIORAL|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
214229339|NCT06080932|BEHAVIORAL|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
214229340|NCT00326573|BEHAVIORAL|Motivational Interviewing|
214229341|NCT03407300|DRUG|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
214229342|NCT03407300|DRUG|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
214229343|NCT05323058|DRUG|tulsi extract|4% topical oral spray
214229344|NCT05323058|DRUG|Benzydamine Hydrochloride|0.15% topical oral spray
214229345|NCT00000659|DRUG|CD4 Antigens|
214229346|NCT00000659|DRUG|Zidovudine|
214229347|NCT01410916|DRUG|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
214229348|NCT05621525|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
214229349|NCT03278067|OTHER|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
214229350|NCT04237142|DIAGNOSTIC_TEST|Vaginal secretions collection|Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
214229351|NCT04237142|DIAGNOSTIC_TEST|Blood sample|2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
214229352|NCT03007004|DRUG|Botulinum toxin type B (2500 units / vial)|BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
214229353|NCT03007004|DRUG|Physiological saline|Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
214229354|NCT05960292|PROCEDURE|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
214229355|NCT03572205|DIETARY_SUPPLEMENT|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
214229356|NCT03572205|DIETARY_SUPPLEMENT|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
214229357|NCT04215965|DRUG|Biphozyl (dialysate and replacement)|Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
214229358|NCT04215965|DRUG|Prismocal B22 (dialysate) + phoxilium (replacement)|solution with phosphate and calcium in CRRT with citratre-based antigoagulation
214229359|NCT01696929|DRUG|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
214229360|NCT04712240|DEVICE|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
214229361|NCT02711267|DRUG|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
214229362|NCT02711267|DRUG|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
214229363|NCT02711267|DRUG|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
214229364|NCT02711267|DRUG|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
214229365|NCT02711267|DRUG|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
214229366|NCT02711267|PROCEDURE|OFM|Sampling method for interstitial fluid
214229367|NCT02711267|DEVICE|OFM Probe|Sampling probe used during OFM
214229368|NCT02711267|DEVICE|OFM Pump|Pump used to operate OFM probes
214229369|NCT02782156|OTHER|Process evaluation|Adherence to screening and action algorithm
214229370|NCT01794338|DEVICE|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
214229371|NCT01794338|DEVICE|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
214229372|NCT00446680|DRUG|Mannitol|400mg BD for 6 months followed by a 6 month open label period
214229373|NCT00446680|DRUG|placebo|placebo BD for 6 months
214229374|NCT02522624|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
214229375|NCT05503745|OTHER|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
214229376|NCT05503745|OTHER|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
214229377|NCT03337828|OTHER|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
214229378|NCT03337828|OTHER|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
214229379|NCT05615025|DRUG|Sevoflurane|Anesthesia will be maintained by sevoflurane.
214229380|NCT05615025|DRUG|Propofol|Anesthesia will be maintained by propofol.
214229381|NCT05326854|OTHER|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
214229382|NCT02123251|BEHAVIORAL|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
214229383|NCT02672696|DEVICE|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
214229384|NCT03936231|OTHER|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
214229385|NCT05206656|DRUG|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
214229386|NCT05206656|DRUG|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
214229387|NCT04468529|DRUG|Recombinant human Neuregulin for injection|10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
214229388|NCT04468529|DRUG|Placebo|10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
214229389|NCT06199583|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound shear-wave elastography
214229390|NCT00956098|DRUG|oltipraz|60mg bid 90mg qd
214229391|NCT00956098|DRUG|placebo|
214229392|NCT04271618|OTHER|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
214229393|NCT04313647|BIOLOGICAL|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
214229394|NCT04313647|BIOLOGICAL|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
214229395|NCT04313647|BIOLOGICAL|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
214229396|NCT04313647|BIOLOGICAL|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
214229397|NCT04313647|BIOLOGICAL|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
214229398|NCT05012670|DRUG|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
214229399|NCT02176746|BIOLOGICAL|cancer stem cell vaccine|
214229400|NCT00458029|BEHAVIORAL|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
214229401|NCT05069701|DIAGNOSTIC_TEST|SVV test|SVV test will be done with virtual reality glasses.
214229402|NCT02825290|DRUG|Choriogonadotropin alfa|
214229403|NCT02825290|DRUG|Triptorelin acetate|
214229404|NCT00642889|DRUG|Safinamide|
214229405|NCT00642889|DRUG|Safinamide|
214229406|NCT00642889|DRUG|Placebo|
214229407|NCT02929043|OTHER|air puffs|
214229408|NCT05223153|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
214229409|NCT04672954|DRUG|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
214229410|NCT04672954|DRUG|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
214229411|NCT04672954|DRUG|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
214229412|NCT04672954|DRUG|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
214229413|NCT04672954|DRUG|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
214229414|NCT04743570|DRUG|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
214229415|NCT04743570|DRUG|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
214229416|NCT05269121|BIOLOGICAL|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
214229417|NCT00057980|DRUG|celecoxib|
214229418|NCT00057980|DRUG|epirubicin hydrochloride|
214229419|NCT02050178|DRUG|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
214229420|NCT03869801|PROCEDURE|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
214229421|NCT03869801|PROCEDURE|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
214229422|NCT03381742|DRUG|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
214229423|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
214229424|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
214229425|NCT03381742|DRUG|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
214229426|NCT02617485|DRUG|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
214651513|NCT04940234|BEHAVIORAL|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
214229427|NCT02617485|DRUG|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
214229428|NCT02617485|DRUG|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
214229429|NCT02617485|DRUG|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
214229430|NCT02617485|DRUG|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
214229431|NCT04613778|PROCEDURE|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
214229432|NCT02565134|DRUG|PAC-14028 cream 0.1%|Topical application
214229433|NCT02565134|DRUG|PAC-14028 cream 0.3%|Topical application
214229434|NCT02565134|DRUG|PAC-14028 cream 1.0%|Topical application
214229435|NCT02565134|DRUG|PAC-14028 cream vehicle|Topical application
214229436|NCT04443595|PROCEDURE|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
214229437|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
214229438|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
214229439|NCT05951465|DRUG|Propofol|propofol
214229440|NCT02298335|DRUG|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
214229441|NCT05150639|OTHER|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
214229442|NCT00617669|DRUG|Docetaxel|intravenous infusion given every three weeks
214229443|NCT00617669|DRUG|ZD4054|10 mg oral once daily dose
214229444|NCT00617669|DRUG|Placebo|placebo oral tablet once daily
214229445|NCT05184439|PROCEDURE|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
214229446|NCT02889744|DEVICE|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
214229447|NCT04369820|OTHER|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
214229448|NCT02648633|RADIATION|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
214651514|NCT02732067|OTHER|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
214651515|NCT03585140|OTHER|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
214229449|NCT02648633|DRUG|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
214229450|NCT02648633|DRUG|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
214229451|NCT02912143|OTHER|documentation only|
214229452|NCT03467100|DRUG|XEN901|Capsule filled with XEN901
214229453|NCT03467100|DRUG|Inert Ingredients Oral Product|Placebo capsule
214229454|NCT05469698|BEHAVIORAL|Tobacco Treatment Research Program Standard Care|Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
214229455|NCT06240767|BIOLOGICAL|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
214229456|NCT03680742|DEVICE|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
214229457|NCT06190054|DEVICE|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
214229458|NCT04023929|PROCEDURE|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
214229459|NCT03393533|PROCEDURE|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
214229460|NCT03393533|PROCEDURE|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
214229461|NCT00136383|DRUG|paroxetine versus duloxetine|
214229462|NCT00425178|DRUG|FGF-1|
214229463|NCT02384915|DRUG|prilocaine|
214229464|NCT02384915|DRUG|mepivacaine|
214229465|NCT02384915|PROCEDURE|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
214229466|NCT02384915|PROCEDURE|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
214229467|NCT02384915|DEVICE|Sonoplex, Pajunk|
214229468|NCT00586781|DEVICE|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
214651516|NCT03585140|OTHER|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
214651517|NCT03585140|DRUG|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
214651518|NCT03585140|DRUG|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
214651519|NCT05448625|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
214229469|NCT01533740|DRUG|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
214229470|NCT00035113|DRUG|epothilone b|
214229471|NCT05546203|OTHER|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
214229472|NCT05546203|DEVICE|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
214229473|NCT05546203|BEHAVIORAL|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
214229474|NCT04787419|OTHER|placebo|saccharum lactis
214229475|NCT04787419|COMBINATION_PRODUCT|probiotics|Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
214229476|NCT01446783|DRUG|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
214229477|NCT01446783|DRUG|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
214229478|NCT04028544|DRUG|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
214229479|NCT04028544|DRUG|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
214229480|NCT03478293|DEVICE|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
214229481|NCT00000679|DRUG|Zidovudine|
214229482|NCT00000679|DRUG|Zalcitabine|
214229483|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
214229484|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
214229485|NCT01060280|BEHAVIORAL|Education on active management|Routine clinical practice plus education on active management.
214229486|NCT01060280|OTHER|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
214229487|NCT01060280|OTHER|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
214229488|NCT01248104|DRUG|Tranexamic Acid|Infusion during cardiac surgery
214229489|NCT01248104|DRUG|Aminocaproic Acid|Infusion during cardiac surgery
214229490|NCT02129504|DEVICE|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
214229491|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
214229492|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
214651520|NCT04752202|BEHAVIORAL|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
214229493|NCT03736772|DRUG|LY3090106|Administered SC
214229494|NCT03736772|DRUG|Placebo|Administered SC
214229495|NCT04010578|DIETARY_SUPPLEMENT|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
214229496|NCT04010578|OTHER|Placebo|Patients will receive a placebo each day.
214229497|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
214229498|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
214229499|NCT02894502|BEHAVIORAL|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
214229500|NCT04944108|PROCEDURE|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
214229501|NCT04944108|PROCEDURE|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
214229502|NCT05813808|DIAGNOSTIC_TEST|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
214229503|NCT05901753|DEVICE|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
214229504|NCT05901753|DEVICE|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
214229505|NCT02494063|PROCEDURE|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
214229506|NCT02494063|PROCEDURE|At least unilateral systematic pelvic lymph node dissection|
214229507|NCT01008241|BEHAVIORAL|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
214229508|NCT02150538|DEVICE|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
214229509|NCT02150538|DEVICE|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
214229510|NCT03289624|BEHAVIORAL|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG \& PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, \& ending with a review of material, addressing questions, \& previewing the next session. Sessions titles are: Communication \& Health Education; Care Values; Care Preferences; Family, Friends, \& Community Resources; Taking care of yourself-taking care of each other; \& Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values \& preferences are supported when decisions have to be in the future."
214229511|NCT04605991|DRUG|LY900014|Administered SC
214229512|NCT04605991|DRUG|Insulin Glargine|Administered SC
214229513|NCT01410357|BEHAVIORAL|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
214229514|NCT00230555|BEHAVIORAL|professional support model|
214229515|NCT03590964|PROCEDURE|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
214229516|NCT03590964|PROCEDURE|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
214229517|NCT00615901|DRUG|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
214229518|NCT04958395|DIAGNOSTIC_TEST|FFR and d-FFR|Measure FFR and d-FFR
214229519|NCT03598114|BEHAVIORAL|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
214229520|NCT04734470|DIAGNOSTIC_TEST|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
214229521|NCT02842034|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
214229522|NCT05919836|PROCEDURE|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
214229523|NCT05919836|PROCEDURE|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
214229524|NCT05919836|PROCEDURE|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
214229525|NCT04972045|DRUG|CuminUP60®|4 capsules, 400 mg / capsule
214229526|NCT04972045|DRUG|Curcumin capsules|4 capsules, 400 mg / capsule
214229527|NCT04647981|OTHER|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
214229528|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
214229529|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
214229530|NCT03847441|DRUG|Calcipotriol|Calcipotriol ointment (0.005%)
214229531|NCT03847441|DEVICE|Narrow Band UVB|NB-UVB (311nm) phototherapy
214229532|NCT03847441|DIAGNOSTIC_TEST|vitamin D3 level|vitamin D3 (ng/ml)
214229533|NCT04395053|DRUG|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
214651521|NCT04752202|BEHAVIORAL|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
214651522|NCT05447702|DRUG|Camrelizumab|Intravenous (IV) infusion
214651523|NCT05447702|DRUG|Apatinib|po.
214651524|NCT05447702|DRUG|Nab-paclitaxel|IV infusion.
214651525|NCT05447702|DRUG|Epirubicin|IV infusion.
214651526|NCT05447702|DRUG|Cyclophosphamide|IV infusion.
214229534|NCT00224185|PROCEDURE|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
214229535|NCT00224185|PROCEDURE|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
214229536|NCT00224185|PROCEDURE|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
214229537|NCT02578719|DRUG|bupivacaine|marcaine %0.5 20 ml flacon
214229538|NCT02578719|DRUG|saline|%0.9 sodium chloride
214229539|NCT03351205|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
214229540|NCT03351205|PROCEDURE|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
214229541|NCT03351205|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
214229542|NCT03866395|DRUG|Ivabradine|Ivabradine 5 mg twice a day
214229543|NCT00950885|BIOLOGICAL|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
214229544|NCT00950885|BIOLOGICAL|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
214229545|NCT00950885|BIOLOGICAL|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
214229546|NCT03643978|OTHER|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
214229547|NCT05072613|OTHER|Malaria screening|Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
214229548|NCT01883076|BIOLOGICAL|autologous cell-based delivery|"autologous cells (derived from self)"
214229549|NCT03133741|OTHER|GIP-A|GIP-A (GIP receptor antagonist)
214229550|NCT03133741|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
214229551|NCT03133741|OTHER|Placebo|Saline (9mg/mL)
214229552|NCT03133741|OTHER|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
214229553|NCT03124927|DEVICE|DCI pulse oximeter sensor|
214229554|NCT02921464|OTHER|none - registry clinic followup only|
214229555|NCT06419530|OTHER|Probiotic formula capsule|The subjects take 4 capsules a day for 84 days.
214229556|NCT06419530|OTHER|placebo capsule|The subjects take 4 capsules a day for 84 days.
214229557|NCT06419530|OTHER|FMT capsule|The subjects take 4 capsules a day for 84 days.
214229558|NCT06531967|OTHER|No intervention|No intervention
214229559|NCT00614770|PROCEDURE|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
214229560|NCT00614770|PROCEDURE|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
214229561|NCT00614770|PROCEDURE|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
214229562|NCT03713905|DRUG|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
214229563|NCT05702346|BEHAVIORAL|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
214229564|NCT00361634|DRUG|Etanercept|
214229565|NCT00833417|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
214229566|NCT03330002|DEVICE|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
214229567|NCT03262311|OTHER|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
214229568|NCT04772326|OTHER|Questionnaire|Questionnaire
214229569|NCT05802953|OTHER|Physical assessments|Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
214229570|NCT05802953|OTHER|Questionnaire|General Health Questionnaire-28 and SF-36 will be apply.
214229571|NCT02114658|DRUG|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
214229572|NCT05076864|OTHER|No intervention|No intervention
214229573|NCT04263584|DRUG|Copanlisib|Copanlisib vials 60 mg
214229574|NCT04263584|DRUG|R-CHOP Chemotherapy|Immunochemotherapy
214229575|NCT00204555|DRUG|Imiquimod|
214229576|NCT04650451|BIOLOGICAL|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
214229577|NCT00960583|OTHER|Exercise program|24 group exercise sessions during 12 weeks
214229578|NCT00960583|OTHER|Routine follow-up|Advice to stay active
214229579|NCT02773784|OTHER|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
214229580|NCT01883453|DEVICE|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
214229581|NCT01883453|DEVICE|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
214229582|NCT02274909|OTHER|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
214229583|NCT04143464|BEHAVIORAL|Kyphosis-specific exercise class and kyphosis-specific exercise videos|"The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos."
214229584|NCT03725228|DRUG|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
214229585|NCT03725228|DRUG|Lidocaine|Lidocaine 1,5mg/kg/h
214229586|NCT00426452|DRUG|Vatalinib|
214229587|NCT00217659|DRUG|anastrozole|
214229588|NCT00217659|DRUG|goserelin acetate|
214229589|NCT05454917|DEVICE|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
214229590|NCT04113213|BEHAVIORAL|Lifestyle Prescription (LRx)|Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
214229591|NCT03986593|DEVICE|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
214229592|NCT03745599|DRUG|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
214229593|NCT03745599|DRUG|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
214229594|NCT03745599|DRUG|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
214229595|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 8 mg BID
214229596|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 3 mg BID
214229597|NCT00505076|DRUG|placebo|2 tablets placebo BID
214229598|NCT04641884|OTHER|Not concerned|Not concerned
214229599|NCT02661048|DEVICE|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
214229600|NCT01499706|BEHAVIORAL|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
214229601|NCT01499706|BEHAVIORAL|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
214229602|NCT02231099|PROCEDURE|Prolift + M|prolapse surgery with mesh
214229603|NCT02231099|PROCEDURE|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
214229604|NCT02303132|OTHER|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
214229605|NCT00133549|DRUG|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
214229606|NCT00133549|BIOLOGICAL|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
214229607|NCT00133549|BIOLOGICAL|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
214229608|NCT00421941|PROCEDURE|Tube feeding|
214229609|NCT02449746|BIOLOGICAL|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
214229610|NCT02449746|BIOLOGICAL|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
214229611|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
214229612|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Kindeva)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
214229613|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
214229614|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
214229615|NCT06247189|OTHER|ICOPE Monitoring|"At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program.~Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program"
214229616|NCT01917253|DEVICE|Standard Device for peripheral vein cannulation|
214229617|NCT01917253|DEVICE|Long Catheters for peripheral vein cannulation|
214229618|NCT02586441|DEVICE|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
214229619|NCT02586441|DRUG|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
214229620|NCT02586441|DRUG|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
214229621|NCT04845711|OTHER|Control group|patients will receive general anesthesia only.
214229622|NCT04845711|PROCEDURE|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
214229623|NCT04845711|PROCEDURE|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
214229624|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
214229625|NCT00647270|DRUG|Placebo|Pre-filled syringe. See arm for more detail
214229626|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
214229627|NCT01184950|OTHER|Trainer Curriculum|
214229628|NCT02215941|DRUG|TV-45070|TV-45070 8% ointment
214229629|NCT02215941|DRUG|Placebo|Placebo
214229630|NCT05520892|DRUG|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
214229631|NCT05862506|BEHAVIORAL|Daily Mile|The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
214229632|NCT01641419|DRUG|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
214229633|NCT01641419|DRUG|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
214229634|NCT01641419|DRUG|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
214229635|NCT04941170|DRUG|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
214229636|NCT04941170|DRUG|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
214229637|NCT03303664|OTHER|IMPROVE Protocol|Comprehensive pain management protocol
214229638|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion|Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.
214229639|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion [SKLICE]|Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.
214229640|NCT03337490|DRUG|Placebo 0% Lotion|Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
214229641|NCT00002845|BIOLOGICAL|aldesleukin|
214229642|NCT04076098|DRUG|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
214229643|NCT02468245|BEHAVIORAL|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
214229644|NCT02468245|BEHAVIORAL|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
214229645|NCT04606680|DEVICE|Heat application at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
214229646|NCT04606680|DEVICE|Medicated plaster at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
214229647|NCT04606680|DEVICE|Herb-partitioned moxibustion at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard\[18\]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
214229648|NCT02619383|DEVICE|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
214229649|NCT01466829|DRUG|Parathyroid hormone|100 microgram daily. S.c
214229650|NCT01466829|DRUG|Placebo|Placebo; saline injection.
214229651|NCT05884749|BEHAVIORAL|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
214229652|NCT05884749|BEHAVIORAL|Care as Usual (UC)|Participants in this group will receive care available typically in the community
214229653|NCT03373903|OTHER|Placebo|oral
214229654|NCT03373903|DRUG|BEZ235|oral
214229655|NCT03373903|DRUG|BEZ235 plus everolimus (RAD001)|Oral
214229656|NCT03133884|OTHER|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
214229657|NCT03133884|OTHER|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
214229658|NCT03835793|DIAGNOSTIC_TEST|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
214229659|NCT05056584|BIOLOGICAL|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
214229660|NCT05056584|BIOLOGICAL|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
214229661|NCT06043544|DEVICE|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
214229662|NCT06043544|DRUG|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
214229663|NCT02013258|DRUG|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
214229664|NCT02013258|OTHER|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
214229665|NCT01293071|OTHER|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
214229666|NCT02745145|DRUG|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
214229667|NCT02745145|DRUG|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
214229668|NCT02745145|DRUG|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
214229669|NCT02990624|RADIATION|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
214229670|NCT00277875|DRUG|ALT-711 (alagebrium chloride)|
214229671|NCT01379144|DRUG|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
214229672|NCT01379144|DRUG|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
214229673|NCT01379144|DRUG|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
214229674|NCT01379144|DRUG|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
214229675|NCT01733303|BEHAVIORAL|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
214229676|NCT04698096|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
214229677|NCT04698096|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214229678|NCT04698096|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214229679|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
214229680|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
214229681|NCT00232869|DEVICE|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
214229682|NCT00232869|DEVICE|bare-metal stent|SMART™ bare-metal stent
214229683|NCT01764191|OTHER|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
214229684|NCT04685239|DEVICE|dual mobility cup|The use of a Sunfit dual mobility cup
214229685|NCT04685239|DEVICE|unipolar cup|The use of a TMT cup
214229686|NCT05468073|DRUG|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
214229687|NCT05468073|DRUG|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
214229688|NCT04158843|PROCEDURE|Radical resection|Radical resection is performed, and the cutting edge is negative.
214229689|NCT04158843|RADIATION|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
214229690|NCT04158843|OTHER|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
214229691|NCT04663490|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
214229692|NCT02083549|OTHER|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
214229693|NCT02635932|DEVICE|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
214229694|NCT02635932|DEVICE|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
214229695|NCT05997394|OTHER|A prayer concert will be held for the participants.|Participants who are in the experimental group will be given a prayer audience.
214229696|NCT04583137|DRUG|Lidocain|Layngeal direct fiberoptic examination transnasaly
214229697|NCT02782858|DRUG|GNbAC1|Monthly IV repeated dose
214229698|NCT02782858|DRUG|Placebo|Monthly IV repeated dose
214229699|NCT01920672|BEHAVIORAL|Timed Planned Activity|
214229700|NCT01920672|BEHAVIORAL|Home Safety and Education Program|
214229701|NCT05620693|BIOLOGICAL|NY-ESO-1 TCR-T|NY-ESO-1 TCR-T treatment
214651527|NCT01639430|OTHER|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
214229702|NCT01490801|GENETIC|DNA analysis|
214229703|NCT01490801|GENETIC|RNA analysis|
214229704|NCT01490801|GENETIC|cytogenetic analysis|
214229705|NCT01490801|GENETIC|in situ hybridization|
214229706|NCT01490801|GENETIC|mutation analysis|
214229707|NCT01490801|GENETIC|polymerase chain reaction|
214229708|NCT01490801|GENETIC|western blotting|
214229709|NCT01490801|OTHER|flow cytometry|
214229710|NCT01490801|OTHER|immunohistochemistry staining method|
214229711|NCT01490801|OTHER|medical chart review|
214229712|NCT03149627|OTHER|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
214229713|NCT04233918|DRUG|Evinacumab|Part A: Single IV dose Part B \& C: IV dose Q4W
214229714|NCT00104598|DRUG|Bupropion|
214229715|NCT00104598|BEHAVIORAL|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
214229716|NCT06516445|RADIATION|SCRT|5×5Gy，5Gy/d，QD，D1-D5
214229717|NCT06516445|DRUG|Camrelizumab|200mg, D1, ivgtt, Q3W, C1-4
214229718|NCT06516445|DRUG|Fluzoparib|100mg, BID, PO, Q3W, C1-4
214229719|NCT06516445|DRUG|CAPEOX|Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
214229720|NCT03956238|BEHAVIORAL|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
214229721|NCT03956238|BEHAVIORAL|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
214229722|NCT03728283|PROCEDURE|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
214229723|NCT03728283|OTHER|Implant placement|Implants were placed following teh manufacturer's instructions
214229724|NCT00424541|DRUG|SPP100 (aliskiren)|
214229725|NCT02173093|BIOLOGICAL|IL-2|Given SC
214229726|NCT02173093|BIOLOGICAL|GD2Bi-aATC|Given IV
214229727|NCT02173093|BIOLOGICAL|GM-CSF|Given SC
214229728|NCT02173093|OTHER|laboratory evaluations of immune responses|Correlative studies
214229729|NCT04091607|OTHER|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
214229730|NCT00830895|DRUG|RAD001|RAD001 10mg/day
214229731|NCT00984113|DRUG|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
214229732|NCT02709538|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
214229733|NCT02709538|DRUG|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
214229734|NCT02709538|DRUG|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
214229735|NCT05543772|DRUG|Normal saline|participant will be given 500 ml normal saline through intravenous access. blood sample will be extracted before and after giving normal saline using same intravenous catheter
214229736|NCT00835211|DRUG|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
214229737|NCT00835211|DRUG|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
214229738|NCT00197548|DIETARY_SUPPLEMENT|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
214229739|NCT00197548|DIETARY_SUPPLEMENT|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
214229740|NCT02543749|BIOLOGICAL|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
214229741|NCT02160041|DRUG|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
214651528|NCT03291314|DRUG|Axitinib|1\. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
214229742|NCT02402998|DRUG|Eltrombopag|Eltrombopag 50 mg/daily.
214229743|NCT01403948|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
214229744|NCT00836121|PROCEDURE|right thoracotomy|complete surgical resection
214229745|NCT00019383|BIOLOGICAL|aldesleukin|
214229746|NCT00019383|BIOLOGICAL|incomplete Freund's adjuvant|
214229747|NCT00019383|BIOLOGICAL|sargramostim|
214229748|NCT00019383|BIOLOGICAL|tyrosinase peptide|
214229749|NCT00019383|BIOLOGICAL|tyrosinase-related protein-1|
214229750|NCT05253261|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
214229751|NCT05253261|PROCEDURE|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
214229752|NCT05253261|PROCEDURE|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
214229753|NCT05253261|DIAGNOSTIC_TEST|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
214229754|NCT05253261|PROCEDURE|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
214229755|NCT05498701|DRUG|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
214229756|NCT05498701|DRUG|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
214229757|NCT02451215|DEVICE|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
214229758|NCT00380042|DEVICE|Cortical Stimulation|Cortical stimulation of prefrontal cortex
214229759|NCT00380042|DEVICE|Sham|Sham stimulation
214229760|NCT03163797|DIAGNOSTIC_TEST|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
214229761|NCT02668211|DEVICE|PROFEMUR Preserve Classic Femoral Components|
214229762|NCT01906996|PROCEDURE|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
214229763|NCT01906996|PROCEDURE|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
214229764|NCT03868644|BEHAVIORAL|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
214229765|NCT03868644|BEHAVIORAL|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
214229766|NCT03472170|DIETARY_SUPPLEMENT|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
214229767|NCT03472170|OTHER|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
214229768|NCT02495038|DRUG|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
214229769|NCT02495038|DRUG|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
214229770|NCT04316832|BEHAVIORAL|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
214229771|NCT04316832|OTHER|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
214229772|NCT00006409|BEHAVIORAL|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
214229773|NCT04375540|PROCEDURE|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
214229774|NCT04375540|PROCEDURE|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
214229775|NCT05457621|OTHER|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
214229776|NCT04608539|DRUG|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
214229777|NCT04608539|DRUG|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
214229778|NCT04608539|DRUG|normal saline|Single-dose infusion (placebo), postoperative day 1
214229779|NCT00959400|DRUG|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
214229780|NCT02902484|DRUG|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
214229781|NCT02147119|PROCEDURE|Coronary angiography|
214229782|NCT05902650|DIAGNOSTIC_TEST|imaging|imaging
214229783|NCT02360683|OTHER|patients with Parkinson's disease|
214229784|NCT05661747|DEVICE|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
214651529|NCT03291314|DRUG|Avelumab|2\. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
214651530|NCT05987748|BEHAVIORAL|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
214229785|NCT03554811|DEVICE|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
214229786|NCT03554811|OTHER|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
214229787|NCT03587285|BIOLOGICAL|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
214229788|NCT03587285|BIOLOGICAL|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
214229789|NCT05214079|DEVICE|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
214229790|NCT00522132|DRUG|Artesunate|intravenous application
214229791|NCT04744090|DRUG|Roflumilast|"1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."
214229792|NCT04744090|DRUG|Placebo|Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
214229793|NCT00681356|DRUG|4975, 15 and 5 mg|Direct instillation into the surgical site
214229794|NCT00681356|DRUG|Placebo Comparator|Direct instillation into the surgical site
214229795|NCT00681356|DRUG|4975 - 5 mg|Direct instillation into the surgical site
214229796|NCT03665727|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
214229797|NCT03665727|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
214229798|NCT03665727|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
214229799|NCT06085885|DEVICE|Cochlear implant|Cochlear implant
214229800|NCT04117867|BEHAVIORAL|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
214229801|NCT04159753|DEVICE|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
214229802|NCT01763996|DRUG|Febuxostat|Febuxostat capsules
214229803|NCT01763996|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
214229804|NCT02280018|DRUG|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
214229805|NCT02280018|DRUG|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
214229806|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
214229807|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
214229808|NCT00728403|DIETARY_SUPPLEMENT|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
214229809|NCT02906605|DRUG|JNJ-809|JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
214229810|NCT02906605|DRUG|Apalutamide|Apalutamide 240 mg orally daily.
214229811|NCT06521528|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
214229812|NCT01649089|PROCEDURE|Conization|Undergo cone biopsy
214229813|NCT01649089|OTHER|Quality-of-Life Assessment|Ancillary studies
214229814|NCT01649089|OTHER|Questionnaire Administration|Ancillary studies
214229815|NCT01649089|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy
214229816|NCT01649089|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
214229817|NCT01266187|PROCEDURE|adjuvant surgery + FOLFOX + cetuximab|surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab
214229818|NCT01266187|PROCEDURE|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab"
214229819|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
214229820|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
214229821|NCT03619057|OTHER|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
214229822|NCT00993226|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
214229823|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
214229824|NCT00993226|DRUG|Bupivacaine HCl Treatment 1c|40 ml
214229825|NCT00993226|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
214229826|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
214229827|NCT00993226|DRUG|Bupivacaine HCl Treatment 2c|40 ml
214229828|NCT02379689|DRUG|Injectable placental tissue extract called BioDGenesis (Active Product)|
214229829|NCT02379689|DRUG|Placebo|
214229830|NCT05822765|DRUG|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
214229831|NCT05822765|DRUG|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
214229832|NCT03704636|DEVICE|INVSENSOR00028|Noninvasive pulse oximeter sensor
214229833|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
214229834|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
214229835|NCT00432549|DRUG|Almotriptan|
214229836|NCT00432549|DRUG|Topiramate|
214229837|NCT02989454|OTHER|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
214229838|NCT02345564|DEVICE|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
214229839|NCT05236088|DEVICE|Neuromuscular electrical stimulation application|It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
214229840|NCT05236088|DEVICE|Sham neuromuscular electrical stimulation application|Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
214229841|NCT00539188|DRUG|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
214229842|NCT00539188|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
214229843|NCT02670148|PROCEDURE|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
214229844|NCT01546623|DRUG|TAP-144-SR(6M)|
214229845|NCT01546623|DRUG|TAP-144-SR(3M)|
214229846|NCT04517890|DRUG|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
214229847|NCT04517890|DRUG|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
214229848|NCT05213819|OTHER|Carpal Tunnel Syndrome|
214229849|NCT01134705|DRUG|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
214229850|NCT01134705|DRUG|Placebo Nasal Aerosol|HFA Vehicle Aerosol
214229851|NCT06250361|OTHER|Questionnaire completion|A questionnaire will be completed by the participant and their gastroenterologist. Estimated completion time is 30 minutes for the patient, 10 minutes for the gastroenterologist.
214229852|NCT04784442|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
214229853|NCT04784442|DRUG|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
214229854|NCT04784442|DRUG|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
214229855|NCT04784442|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
214229856|NCT06197919|OTHER|postural exercises|"In this study forward head posture will be defined as CVA\<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Kendall et al's approach. The exercises involved~1. chin tucks ins~2. a chin drop in sitting~3. shoulder retraction~4. unilateral and bilateral pectoralis stretches Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form"
214229857|NCT06197919|OTHER|postural exercises with breathing exercises|"The postural exercise program consisted the exercises i.e chin tucks in, a chin drop in sitting, shoulder retraction. Participants were instructed to complete 3sets of 12repetitions of these exercises. This program was to be repeated 4times per week. They also returned for a consultation every 2weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12repetitions, 3times easily with correct form.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled diaphragmatic breathing, relaxation technique, deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, and segmental breathing techniques. exercise protocol will be continued for 6 weeks with and initial, after 3weeks and final assessment of pain and CVA."
214229858|NCT06244290|DRUG|Colgate SNF|toothpaste
214229859|NCT06244290|DRUG|Sensodyne Extra Whitening|toothpaste
214229860|NCT06244290|DRUG|Colgate Fluoride (CDC)|toothpaste
214229861|NCT04812847|DIAGNOSTIC_TEST|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
214229862|NCT01893034|PROCEDURE|Arthroscopic treatment of femoroacetabular impingement|
214229863|NCT01893034|OTHER|Physiotherapy and activity modification|
214229864|NCT00012597|PROCEDURE|Web-based telemedicine system for assessment of status of pressure ulcers|
214229865|NCT01912313|PROCEDURE|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
214229866|NCT00527241|BEHAVIORAL|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
214229867|NCT00508664|RADIATION|Radiation|Radiation start in week 11
214229868|NCT00508664|DRUG|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
214229869|NCT00508664|DRUG|Docetaxel|75 mg/m2 i.v. day 1 3 times
214229870|NCT00508664|DRUG|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
214229871|NCT00508664|DRUG|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
214229872|NCT03844204|DEVICE|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
214229873|NCT00054340|BIOLOGICAL|anti-thymocyte globulin|
214229874|NCT00054340|DRUG|busulfan|
214229875|NCT00054340|DRUG|cyclophosphamide|
214229876|NCT00054340|DRUG|cyclosporine|
214229877|NCT00054340|DRUG|methotrexate|
214229878|NCT00054340|PROCEDURE|allogeneic bone marrow transplantation|
214229879|NCT00054340|PROCEDURE|peripheral blood stem cell transplantation|
214229880|NCT02540278|BEHAVIORAL|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
214229881|NCT05249517|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a patient education approach that explains in detail the neurobiology, neurophysiology of pain, and the processing of pain by the nervous system in the management of chronic pain.
214229882|NCT05249517|OTHER|Progressive submaximal exercise program|It has been shown that the long-term results of the use of PNE in addition to physiotherapy are more effective in reducing pain and disability. It has been reported that progressive submaximal exercise program including cervicothoracic strengthening, endurance, flexibility, and coordination exercises has positive effects on chronic neck pain, related disability, quality of life and mood.
214229883|NCT03069105|OTHER|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
214229884|NCT00078169|BEHAVIORAL|Behavior Therapy|
214229885|NCT00930137|OTHER|isocaloric for week diet|"Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
214229886|NCT02037555|BIOLOGICAL|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
214229887|NCT02037555|OTHER|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
214229888|NCT00461071|BEHAVIORAL|Guided Self-help for Bulimia nervosa|bibliotherapy
214229889|NCT03035877|BEHAVIORAL|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
214229890|NCT03035877|BEHAVIORAL|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
214229891|NCT04109885|DRUG|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
214229892|NCT04109885|DRUG|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
214229893|NCT01061255|OTHER|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
214229894|NCT01212380|DRUG|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
214229895|NCT01212380|OTHER|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
214651531|NCT03240926|DEVICE|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
214229896|NCT01212380|OTHER|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
214229897|NCT01212380|OTHER|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
214229898|NCT01212380|OTHER|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
214229899|NCT00321126|DRUG|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
214229900|NCT02001753|DEVICE|CMR|
214229901|NCT01526824|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
214229902|NCT03812822|DEVICE|Insole|Custom-made insoles which support the foot at subtalar neutral position
214229903|NCT05466201|DRUG|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
214229904|NCT05466201|DRUG|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
214229905|NCT03873090|OTHER|SBRT|hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
214229906|NCT03137745|OTHER|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
214229907|NCT04520438|PROCEDURE|Leukocyte and platelet rich fibrin|L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
214229908|NCT04520438|PROCEDURE|Non-Surgical Periodontal treatment|The control group only received NSPT (scaling and root planing) in one treatment session.
214229909|NCT01590758|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
214229910|NCT01590758|DRUG|Topical placebo cream|14 days of treatment
214229911|NCT01590758|OTHER|Standard wound care|14 days of treatment
214229912|NCT01578850|DRUG|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
214229913|NCT01578850|DRUG|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
214229914|NCT03697915|DEVICE|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
214229915|NCT01232803|DRUG|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
214229916|NCT01232803|DRUG|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
214229917|NCT01232803|DRUG|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
214229918|NCT06071585|OTHER|Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis|We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
214229919|NCT04855084|OTHER|Monolithic FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
214229920|NCT04855084|OTHER|Monolithic FDPs: after adjustment|After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
214229921|NCT04855084|OTHER|Metal fused porcelain FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
214229922|NCT04855084|OTHER|Metal fused porcelain FDPs: after adjustment|After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
214229923|NCT06123351|DEVICE|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
214229924|NCT06123351|OTHER|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
214229925|NCT06123351|DEVICE|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
214651532|NCT01650090|DRUG|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
214229926|NCT06153680|DEVICE|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
214651533|NCT05085509|PROCEDURE|US guidance and MB staining|Ultrasound guidance and methylene blue staining
214229927|NCT02756806|DEVICE|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
214229928|NCT01806701|BEHAVIORAL|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
214229929|NCT00254345|PROCEDURE|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
214229930|NCT03089385|OTHER|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
214229931|NCT02562664|DRUG|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
214229932|NCT02562664|DRUG|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
214229933|NCT02562664|DRUG|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
214229934|NCT02717832|DRUG|hyperinsulinemic-euglycemic clamp|
214229935|NCT01041534|OTHER|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
214229936|NCT04408222|OTHER|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
214229937|NCT01189019|DRUG|ranibizumab|2mg intravitreal injection monthly
214229938|NCT01189019|DRUG|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
214229939|NCT00541814|DRUG|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
214229940|NCT02929498|DRUG|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
214229941|NCT02929498|DRUG|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
214229942|NCT03666364|OTHER|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
214229943|NCT00243165|BEHAVIORAL|Lifemel honey intake every day|
214229944|NCT02744040|DRUG|ART initiation at time of HIV diagnosis|Immediate ART initiation
214229945|NCT02744040|DRUG|ART at 24 weeks|ART initiation 24 weeks after enrollment
214229946|NCT01398917|PROCEDURE|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
214651534|NCT01755988|OTHER|Educational website (in addition to usual care).|
214229947|NCT01398917|PROCEDURE|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
214651535|NCT01755988|OTHER|Website and interactive platform with telemonitoring.|
214229948|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL|One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
214229949|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL|One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
214229950|NCT00096356|DIETARY_SUPPLEMENT|CoQ10 & Vitamin E|
214229951|NCT00096356|DIETARY_SUPPLEMENT|Placebo & Vitamin E|
214229952|NCT03820739|OTHER|Follow-up|No investigational vaccine will be administered during this study
214229953|NCT03820739|OTHER|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
214229954|NCT01008423|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
214651536|NCT06192979|DRUG|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
214651537|NCT06192979|DRUG|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
214651538|NCT06192979|DRUG|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
214229955|NCT01008423|DRUG|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
214229956|NCT05901844|DIAGNOSTIC_TEST|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
214229957|NCT02093052|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
214229958|NCT02093052|BEHAVIORAL|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
214229959|NCT04476004|OTHER|scapular-focused exercise|scapular-focused exercise
214229960|NCT04476004|OTHER|visual feedback|EMG visual feedback
214229961|NCT04103788|DIETARY_SUPPLEMENT|95% Curcuminoid Powder|1200 mg curcuminoids
214229962|NCT04103788|DIETARY_SUPPLEMENT|CurQ+|400 mg curcuminoids + coconut oil + polysorbate
214229963|NCT00967954|DRUG|antiandrogen therapy|
214229964|NCT00967954|DRUG|releasing hormone agonist therapy|
214229965|NCT00967954|GENETIC|DNA analysis|
214229966|NCT00967954|GENETIC|RNA analysis|
214229967|NCT00967954|GENETIC|comparative genomic hybridization|
214229968|NCT00967954|GENETIC|gene expression analysis|
214229969|NCT00967954|OTHER|laboratory biomarker analysis|
214229970|NCT00967954|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214229971|NCT00967954|PROCEDURE|magnetic resonance spectroscopic imaging|
214229972|NCT01522937|RADIATION|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
214651539|NCT06192979|DRUG|Venetoclax|All patients received venetoclax 400mg daily.
214651540|NCT03157531|DEVICE|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
214651541|NCT00250692|DRUG|Nitrous Oxide|
214229973|NCT05014633|OTHER|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
214229974|NCT02500940|DRUG|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
214229975|NCT02500940|DRUG|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
214229976|NCT02500940|RADIATION|Radiation therapy|Intensity-Modulated Radiation Therapy
214229977|NCT02500940|DRUG|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
214229978|NCT04580992|DRUG|Ajmaline|Ajmaline administration
214229979|NCT03288142|OTHER|Hypertension Coaching Application and Home Monitor|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
214229980|NCT03288142|OTHER|Control: Tracking Application and Home Monitor|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
214229981|NCT04599530|DEVICE|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
214229982|NCT00504972|DRUG|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
214229983|NCT05995067|OTHER|periodontitis challenge|control will be compared to diseased group suffering from periodontal disease.
214229984|NCT04332458|BEHAVIORAL|A focus group interview|this is a qualitative study using focus group interviewing.
214229985|NCT03903315|OTHER|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
214229986|NCT02917564|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
214229987|NCT02917564|OTHER|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
214229988|NCT03069729|OTHER|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
214229989|NCT01646333|BEHAVIORAL|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
214651542|NCT00331006|DRUG|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
214651543|NCT05131061|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
214229990|NCT01646333|BEHAVIORAL|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
214229991|NCT03269929|OTHER|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
214229992|NCT03269929|DRUG|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
214229993|NCT03062254|DRUG|radium-223 dichloride|6 doses of Radium-223
214229994|NCT05847985|DEVICE|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
214229995|NCT04052256|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
214229996|NCT01798160|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
214229997|NCT01798160|PROCEDURE|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
214229998|NCT05664568|DRUG|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
214229999|NCT05664568|DRUG|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
214230000|NCT05664568|OTHER|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
214230001|NCT04363788|PROCEDURE|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
214230002|NCT03147157|OTHER|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
214651544|NCT03804684|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
214651545|NCT03804684|DIAGNOSTIC_TEST|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
214230003|NCT02935283|PROCEDURE|MRI|MRI, fMRI, 1H MRS, DTI
214230004|NCT02935283|BEHAVIORAL|Behavioral|Battery of executive function tasks
214230005|NCT01250444|OTHER|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
214230006|NCT01316068|DRUG|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
214230007|NCT01316068|DRUG|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
214230008|NCT02102659|GENETIC|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
214230009|NCT02102659|GENETIC|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
214230010|NCT01622309|DIETARY_SUPPLEMENT|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
214230011|NCT01622309|OTHER|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
214230012|NCT00963118|DIETARY_SUPPLEMENT|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
214230013|NCT05772585|OTHER|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
214230014|NCT00084890|DRUG|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
214230015|NCT00084890|DRUG|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
214230016|NCT00934843|DRUG|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
214230017|NCT00934843|DRUG|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
214230018|NCT01831583|DEVICE|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
214230019|NCT01831583|DEVICE|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
214230020|NCT00123253|DRUG|TH9507|
214230021|NCT03456882|DRUG|RNS60|normal saline plus oxigen in nanobubble
214651546|NCT02542488|OTHER|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI \>35 kg/m2? A: Are you \>50 years old? N: Is your neck circumference \>40cm? G: Is your gender male?"
214651547|NCT02542488|DIAGNOSTIC_TEST|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
214230022|NCT01144299|BIOLOGICAL|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
214230023|NCT03225040|DRUG|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
214230024|NCT06408753|PROCEDURE|sterotatic body radiotherapy|checkpoint inhibitors with or without sterotatic body radiotherapy
214230025|NCT03353233|DRUG|Ropivacaine|Local anesthetic (numbing drug)
214230026|NCT03353233|PROCEDURE|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
214230027|NCT03353233|DRUG|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
214230028|NCT01800461|OTHER|OPC-Stroke|Occupational therapy coaching intervention
214230029|NCT01800461|OTHER|Usual care|Usual community care
214230030|NCT00183729|DRUG|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
214230031|NCT00183729|OTHER|Placebo|Placebo distribution is planned to mimic the active drug.
214230032|NCT01615276|DEVICE|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
214230033|NCT01615276|DEVICE|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
214230034|NCT00003076|DRUG|eflornithine|
214651548|NCT02542488|OTHER|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
214230035|NCT02739178|OTHER|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
214230036|NCT03512457|BEHAVIORAL|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
214230037|NCT03512457|BEHAVIORAL|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
214230038|NCT04049877|OTHER|None - Observational study|None - Observational study
214230039|NCT05509868|DRUG|PBK_L1704 0.35mg|The subject will receive PBK\_L1704 0.35mg/ml by PCA
214230040|NCT05509868|DRUG|PBK_L1704 0.5mg|The subject will receive PBK\_L1704 0.5mg/ml by PCA
214230041|NCT05509868|DRUG|Placebo|The subject will receive placebo by PCA
214230042|NCT02878161|DRUG|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
214230043|NCT02878161|BIOLOGICAL|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
214230044|NCT02878161|BIOLOGICAL|etanercept|Etanercept :hypodermic injection,25mg/twice a week
214230045|NCT02878161|BIOLOGICAL|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
214230046|NCT02878161|DRUG|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
214230047|NCT02878161|DRUG|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
214230048|NCT02878161|DRUG|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
214230049|NCT01785862|DRUG|Ibuprofen 25 mg|Lozenge, Oromucosal administration
214230050|NCT01785862|DRUG|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
214230051|NCT01624246|DRUG|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
214230052|NCT06478381|DRUG|L218CAR19|L218CAR19 is intravenously administered at three dose levels.
214230053|NCT01859546|BEHAVIORAL|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
214230054|NCT00846183|PROCEDURE|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
214230055|NCT03302182|DRUG|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
214230056|NCT03302182|DRUG|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
214230057|NCT00635076|OTHER|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
214230058|NCT00635076|DRUG|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
214230059|NCT02884713|DRUG|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
214230060|NCT02884713|DRUG|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
214651549|NCT03644290|BEHAVIORAL|Cognitive training|Five sessions of semantic strategy training and face-name association training
214651550|NCT03644290|BEHAVIORAL|Control Condition|Five sessions of active control information and education
214651551|NCT02736903|BEHAVIORAL|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
214651552|NCT02736903|BEHAVIORAL|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
214651553|NCT02052102|RADIATION|Radiation therapy|
214230061|NCT02884713|DRUG|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
214230062|NCT02207426|DRUG|Tobramycin|
214230063|NCT01774409|GENETIC|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
214230064|NCT04154813|DRUG|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
214230065|NCT04154813|DRUG|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
214230066|NCT04154813|BEHAVIORAL|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
214230067|NCT04154813|BEHAVIORAL|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
214230068|NCT00199043|DRUG|Allopurinol|
214230069|NCT00199043|DRUG|Rasburicase|
214230070|NCT03114852|DIAGNOSTIC_TEST|blood collection|They will have blood tested to renal genetic diseases
214230071|NCT05291715|DEVICE|Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)|Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
214230072|NCT05138952|BEHAVIORAL|Mindfulness Meditation|"30-day mediation program comprising:~1. Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~2. 10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
214230073|NCT04947085|DRUG|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
214230074|NCT04947085|DRUG|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
214230075|NCT03976648|DRUG|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
214230076|NCT02605460|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
214230077|NCT02605460|DRUG|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
214230078|NCT02605460|DRUG|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
214230079|NCT02605460|PROCEDURE|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
214230080|NCT02980575|OTHER|Music|
214230081|NCT02980575|OTHER|Exercise|
214230082|NCT03647891|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
214230083|NCT00243841|RADIATION|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
214230084|NCT01282580|DIETARY_SUPPLEMENT|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
214230085|NCT01282580|OTHER|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
214230086|NCT00285389|DRUG|Adriblastin|
214230087|NCT00285389|DRUG|dexamethasone|
214230088|NCT00285389|DRUG|Chlorambucil|
214230089|NCT00285389|DRUG|rituximab|
214230090|NCT00285389|DRUG|cyclophosphamide|
214651554|NCT06422182|DRUG|Bupivacain 25% (Erector Spinae Plane Block)|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
214651555|NCT06422182|DRUG|Morphine (Intravenous patient-controlled analgesia)|Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
214651556|NCT02780791|OTHER|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
214230091|NCT00285389|DRUG|alkeran|
214230092|NCT00285389|PROCEDURE|Total body irradiation (8Gy/4fr)|
214230093|NCT00285389|DRUG|vincristine|0,4 mg/day day 1 to day 4
214230094|NCT00115583|DRUG|Drug Infusion (BQ-123)|
214230095|NCT04947852|DEVICE|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
214230096|NCT04947852|DEVICE|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
214230097|NCT00881868|DRUG|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
214230098|NCT00881868|DRUG|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
214230099|NCT03079960|DEVICE|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
214230100|NCT01981551|DRUG|PF-03084014|Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
214230101|NCT03255083|DRUG|DS-1205c|DS-1205c 200 mg capsule
214230102|NCT03255083|DRUG|Osimertinib|Osimertinib 80 mg tablet
214230103|NCT01046409|OTHER|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
214230104|NCT00627952|DRUG|amlodipine 10 mg|amlodipine 10 mg once daily
214230105|NCT00627952|DRUG|manidipine 20 mg|manidipine 20 mg once daily
214230106|NCT00627952|DRUG|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
214230107|NCT00627952|DRUG|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
214651557|NCT02780791|OTHER|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
214651558|NCT05428709|BEHAVIORAL|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
214651559|NCT04024592|DEVICE|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
214651560|NCT03870841|DRUG|PC945|PC945, nebulized
214651561|NCT02718859|BIOLOGICAL|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
214651562|NCT02718859|PROCEDURE|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
214651563|NCT02937805|DEVICE|Moisturizing vaginal and vulvar sea buckthorn oil cream|
214230108|NCT04162561|BEHAVIORAL|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
214230109|NCT00439816|BEHAVIORAL|Group Visits|
214230110|NCT05926115|DIAGNOSTIC_TEST|Diagnostic Ultrasound|During the initial visit, a transvaginal or transabdominal pelvic ultrasonography will be performed in all participants, based on the sexual history and consent form by trained gynecologists who are part of study investigators. A transvaginal ultrasound is the accepted and validated method to assess the ovarian morphology in the study of patients with PCOS.
214230111|NCT05926115|DIAGNOSTIC_TEST|Venous puncture|After an overnight fast of at least 6 hours (ideally), a 18 ml sample of venous blood will be collected from each study participant (i.e., the basal fasting sample). About 12 ml of the venous blood will be collected in plain tubes for serum cryopreservation and subsequent analysis, and the remainder in plain tubes for immediate glucose estimation in serum.
214230112|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - low|
214230113|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - medium|
214230114|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - high|
214230115|NCT02264145|DRUG|Ethanolic Solution From Respimat®|
214230116|NCT04963985|DRUG|Tafamidis Pill|Oral
214230117|NCT04197219|DRUG|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
214230118|NCT04197219|DRUG|Axitinib|5 mg PO BID continuously
214230119|NCT01182844|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
214230120|NCT04247867|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
214230121|NCT04247867|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium and Inulin)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
214230122|NCT04247867|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
214230123|NCT00343941|DRUG|Tucaresol tablets 25 mg|
214230124|NCT05048576|BEHAVIORAL|Negative Reinforcement|"Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet."
214230125|NCT05048576|BEHAVIORAL|Positive Reinforcement|"Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job."
214230126|NCT05048576|BEHAVIORAL|Silence|No recordings will be played during this condition.
214230127|NCT05048576|BEHAVIORAL|Music|Participant's can choose their own music to play during this condition.
214230128|NCT02854930|OTHER|questioning|
214230129|NCT00960570|DRUG|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
214230130|NCT00960570|DRUG|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
214230131|NCT00960570|DRUG|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
214230132|NCT01451437|DRUG|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
214230133|NCT00602199|DRUG|ABT-510|
214230134|NCT00602199|OTHER|immunoenzyme technique|
214230135|NCT00602199|OTHER|immunohistochemistry staining method|
214230136|NCT00602199|OTHER|laboratory biomarker analysis|
214230137|NCT00602199|OTHER|pharmacological study|
214230138|NCT00602199|PROCEDURE|biopsy|
214230139|NCT02422199|DRUG|pyrotinib|
214230140|NCT02422199|DRUG|Lapatinib|
214230141|NCT02422199|DRUG|capecitabine|
214230142|NCT06811376|BEHAVIORAL|Spiritual Care Intervention #1|Experimental
214230143|NCT06811376|OTHER|Spiritual Care Intervention #2|Active Comparator
214230144|NCT06654531|DRUG|Dexmedetomidine|"Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2"
214230145|NCT00824837|OTHER|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
214230146|NCT00824837|OTHER|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
214230147|NCT02412813|DEVICE|LEGION OXINIUM|Investigational Group
214230148|NCT02412813|DEVICE|LEGION Cobalt Chrome|Control Group
214651564|NCT02937805|DEVICE|Moisturizing vaginal and vulvar cream|
214230149|NCT03254108|DRUG|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
214230150|NCT03254108|DRUG|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
214230151|NCT03254108|DRUG|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
214230152|NCT03254108|DRUG|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
214230153|NCT03254108|DRUG|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
214230154|NCT03459391|DRUG|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
214230155|NCT03459391|DRUG|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
214230156|NCT03459391|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
214230157|NCT00317291|PROCEDURE|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
214230158|NCT00317291|OTHER|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
214230159|NCT02631382|PROCEDURE|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
214230160|NCT05898997|BEHAVIORAL|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
214230161|NCT01661842|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
214230162|NCT01661842|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
214230163|NCT02397018|BIOLOGICAL|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
214230164|NCT00923949|DRUG|Pioglitazone|45 mg tablet daily by mouth for six weeks
214230165|NCT00490529|BIOLOGICAL|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
214230166|NCT00490529|BIOLOGICAL|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
214230167|NCT00490529|PROCEDURE|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
214230168|NCT00490529|PROCEDURE|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
214230169|NCT00490529|DRUG|Rituximab|375 mg/m² by infusion
214230170|NCT00490529|DRUG|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
214230171|NCT00490529|DRUG|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
214230172|NCT00490529|DRUG|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
214230173|NCT00862797|OTHER|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
214230174|NCT03254459|DRUG|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
214230175|NCT03254459|DRUG|Morphine|4 mg Intravenous Injection
214230176|NCT03254459|DRUG|Oxycodone Hydrochloride|10 mg tablet
214230177|NCT03254459|DRUG|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
214230178|NCT00265356|PROCEDURE|PET diagnostic imaging|PET diagnostic imaging
214230179|NCT02329340|BEHAVIORAL|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
214230180|NCT02329340|BEHAVIORAL|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
214230181|NCT00727441|BIOLOGICAL|GVAX pancreatic cancer vaccine|Given intradermally
214230182|NCT00727441|DRUG|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
214230183|NCT03038477|DRUG|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
214230184|NCT04837352|OTHER|Study of the role of sociocognitive factors|Questionnaires
214230185|NCT00535288|DRUG|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
214230186|NCT00535288|DRUG|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
214230187|NCT00004581|DRUG|Lopinavir/Ritonavir|
214230188|NCT00004581|DRUG|Nevirapine|
214230189|NCT06505733|BEHAVIORAL|postnatal attendant training|"Intervention Group: Training and counselling will be provided to the puerperant and companions before discharge in a quiet and stimulus-free environment using the Companion Training Guide. Research data will be collected three times: pre-test data, after the training and on the tenth day."
214230190|NCT00965640|DRUG|Botulinum Toxin - A injections|
214230191|NCT04549402|OTHER|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
214230192|NCT04549402|OTHER|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
214230193|NCT02480140|OTHER|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
214230194|NCT02480140|OTHER|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
214230195|NCT02480140|OTHER|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
214230196|NCT05279391|DRUG|Dexamethasone|Dexamethasone 6-8 mg once daily
214230197|NCT05279391|DRUG|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
214230198|NCT05279391|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
214230199|NCT05279391|DRUG|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
214230200|NCT05279391|DRUG|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
214230201|NCT05279391|DRUG|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
214230202|NCT02923024|BEHAVIORAL|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
214230203|NCT00745849|DRUG|esomeprazole|40mg by mouth twice daily
214230204|NCT00745849|DRUG|placebo|
214230205|NCT02102711|DIETARY_SUPPLEMENT|Vitamin A oral drops|
214230206|NCT00796887|DRUG|Extended-Release Niacin|500mg tablet once daily
214230207|NCT00796887|DRUG|Extended-Release Niacin|1000mg tablet once daily
214230208|NCT00796887|DRUG|Placebo|Placebo tablet once daily
214230209|NCT02776748|DRUG|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
214230210|NCT03861494|BEHAVIORAL|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
214230211|NCT03861494|BEHAVIORAL|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
214230212|NCT01413347|PROCEDURE|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
214230213|NCT01413347|PROCEDURE|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
214230214|NCT05090176|OTHER|povidone-soaked suture|suture soak with povidone solution for 3 mins
214230215|NCT05090176|OTHER|ordinary suture|suture no need to soak with povidone solution
214230216|NCT03176342|OTHER|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
214230217|NCT04308733|DEVICE|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
214230218|NCT06515535|DRUG|Topical tranexamic acid|Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%
214651565|NCT05264350|DEVICE|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
214651566|NCT05264350|DEVICE|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
214651567|NCT00109473|DRUG|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
214230219|NCT06515535|DRUG|Intravenous tranexamic acid|Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
214230220|NCT02333864|DEVICE|POGO® BGMS|SMBG
214230221|NCT04811300|OTHER|There is no intervention|There is no intervention
214230222|NCT01129583|DRUG|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
214230223|NCT01129583|DRUG|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
214230224|NCT02600871|DRUG|Provodine|
214230225|NCT02600871|PROCEDURE|Incision and Drainage|
214230226|NCT04492215|BEHAVIORAL|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
214230227|NCT03515291|BIOLOGICAL|iMP cells|Immunomodulatory progenitor cells
214230228|NCT03515291|OTHER|Control injection|Cell suspension solution
214230229|NCT02363023|PROCEDURE|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
214230230|NCT03537469|DEVICE|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
214230231|NCT03537469|DEVICE|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
214230232|NCT01263912|DIETARY_SUPPLEMENT|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
214230233|NCT01263912|DIETARY_SUPPLEMENT|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
214230234|NCT00003296|BIOLOGICAL|filgrastim|
214230235|NCT00003296|DRUG|pegylated liposomal doxorubicin hydrochloride|
214230236|NCT01466257|BIOLOGICAL|cetuximab|
214230237|NCT01466257|DRUG|cisplatin|
214230238|NCT01466257|GENETIC|DNA analysis|
214230239|NCT01466257|GENETIC|gene expression analysis|
214230240|NCT01466257|GENETIC|mutation analysis|
214230241|NCT01466257|OTHER|laboratory biomarker analysis|
214230242|NCT00083252|DRUG|talabostat (PT-100) tablets|
214230243|NCT00083252|DRUG|cisplatin|
214230244|NCT02604121|DEVICE|Orcellex® Rovers brush|transepithelial brushing
214230245|NCT04507373|DRUG|Simvastatin 40mg|40mg oral daily for 10 weeks
214230246|NCT04963842|BEHAVIORAL|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
214230247|NCT04259723|OTHER|VR during TAVI|Virtual Reality (VR) glasses
214230248|NCT00830869|DRUG|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
214230249|NCT01185431|DIETARY_SUPPLEMENT|Ficus carica (Fig paste)|Ficus carica paste 300g/day
214230250|NCT01185431|DIETARY_SUPPLEMENT|Placebo (Placebo paste)|Placebo composition 300g/day
214230251|NCT00972647|PROCEDURE|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
214230252|NCT05477472|DRUG|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
214230253|NCT03348592|DIETARY_SUPPLEMENT|Oligofructose-enriched inulin (p-inulin)|
214230254|NCT03348592|OTHER|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
214230255|NCT00690261|OTHER||No intervention in this study
214230256|NCT03745820|DRUG|BIIB104|Administered as specified in the treatment arm
214230257|NCT03745820|OTHER|Placebo|Administered as specified in the treatment arm
214230258|NCT04829578|OTHER|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
214230259|NCT01809587|DEVICE|IQP-PO-101|
214230260|NCT04140760|OTHER|Symprove|A liquid probiotic
214230261|NCT04140760|OTHER|Symprove placebo product|An inert placebo
214230262|NCT01324518|DRUG|ORM-12741|60mg twice a day
214230263|NCT01324518|DRUG|ORM-12741|200mg twice a day
214230264|NCT01324518|DRUG|Placebo for ORM-12741|Placebo twice a day
214230265|NCT02280798|PROCEDURE|Endometrial Biopsy|4 endometrial biopsy
214230266|NCT06151509|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214230267|NCT06151509|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214230268|NCT01604993|OTHER|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
214230269|NCT01604993|OTHER|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
214230270|NCT06235255|BEHAVIORAL|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
214230271|NCT06235255|BEHAVIORAL|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
214230272|NCT06235255|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
214651568|NCT00109473|DRUG|cortecosteroid|As prescribed by the referring gastroenterologist
214230273|NCT01561703|DRUG|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
214230274|NCT04583709|DEVICE|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
214230275|NCT00945906|BIOLOGICAL|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
214230276|NCT03402464|DRUG|Icotinib combined dihydroaremisinin|Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
214230277|NCT02936661|DRUG|Tranexamic Acid|
214230278|NCT02936661|DRUG|Placebo|
214230279|NCT00264459|BIOLOGICAL|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
214230280|NCT00264459|OTHER|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
214230281|NCT01579851|DRUG|Sugammadex|"sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations"
214230282|NCT05146947|DEVICE|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
214230283|NCT03141294|PROCEDURE|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
214230284|NCT02294968|OTHER|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
214230285|NCT04494568|DEVICE|HIFU treatment|HIFU Treatment of rectal endometriosis
214230286|NCT04087330|OTHER|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
214230287|NCT04087330|OTHER|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
214230288|NCT06390072|BEHAVIORAL|Self-Hypnosis|Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
214230289|NCT06390072|BEHAVIORAL|Ankle Education|Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
214230290|NCT04135586|OTHER|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
214230291|NCT04135586|OTHER|Control|Yoga + educational program
214230292|NCT03199443|DIAGNOSTIC_TEST|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
214230293|NCT03721029|DEVICE|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
214230294|NCT03721029|PROCEDURE|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
214230295|NCT00998218|DRUG|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
214230296|NCT00998218|DRUG|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
214230297|NCT04796870|OTHER|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
214230298|NCT03643536|OTHER|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
214230299|NCT00985036|PROCEDURE|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
214651569|NCT00047346|DRUG|erlotinib hydrochloride|Given PO
214230300|NCT04231552|DRUG|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
214230301|NCT02849353|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
214230302|NCT02849353|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214230303|NCT00797966|DRUG|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
214230304|NCT00797966|DRUG|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
214230305|NCT00797966|DRUG|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
214230306|NCT04280809|DEVICE|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
214230307|NCT04374227|PROCEDURE|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
214230308|NCT05504876|DRUG|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
214230309|NCT05504876|DRUG|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
214230310|NCT05504876|DRUG|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
214230311|NCT05551442|PROCEDURE|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
214230312|NCT05551442|DEVICE|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
214230313|NCT05937464|OTHER|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
214230314|NCT05937464|OTHER|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
214230315|NCT03859973|DRUG|BI 425809|Tablet
214230316|NCT03859973|DRUG|Placebo|Tablet
214230317|NCT04334395|PROCEDURE|primary tumor resection group|resection of cancer at colon
214230318|NCT01131013|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
214651570|NCT00047346|OTHER|pharmacological study|Correlative studies
214230319|NCT01131013|DRUG|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
214230320|NCT01131013|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
214230321|NCT00367783|DRUG|CP-741,952|
214230322|NCT00440791|DEVICE|PillCam Colon capsule endoscopy|
214230323|NCT01478048|BIOLOGICAL|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
214230324|NCT01478048|DRUG|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
214230325|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
214230326|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
214230327|NCT01478048|DRUG|Dexamethasone|Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
214230328|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
214230329|NCT00858572|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
214230330|NCT03897439|DRUG|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
214230331|NCT03897439|DRUG|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
214651571|NCT00047346|OTHER|laboratory biomarker analysis|Correlative studies
214651572|NCT00379327|PROCEDURE|Acupuncture|Acupuncture administered in last three weeks of pregnancy
214651573|NCT00379327|DEVICE|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
214230332|NCT03897439|DRUG|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
214230333|NCT04120298|BEHAVIORAL|Supervised exercise|An individualised exercise programme supervised by a trained instructor
214230334|NCT03584581|DIETARY_SUPPLEMENT|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
214230335|NCT03584581|DIETARY_SUPPLEMENT|Control|Placebo
214230336|NCT03278704|OTHER|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
214230337|NCT03278704|OTHER|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
214230338|NCT00150917|BEHAVIORAL|Supportive-Expressive Group Therapy|
214230339|NCT03897140|DIAGNOSTIC_TEST|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
214230340|NCT06069440|OTHER|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
214230341|NCT05975398|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
214230342|NCT05975398|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
214230343|NCT02576184|DEVICE|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
214651574|NCT04236544|BEHAVIORAL|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
214651575|NCT04236544|BEHAVIORAL|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
214818029|NCT02479633|OTHER|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
214230344|NCT02576184|DEVICE|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
214230345|NCT04605705|COMBINATION_PRODUCT|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
214230346|NCT02047344|DRUG|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
214230347|NCT00955201|BEHAVIORAL|Exercise|Structured aerobic exercise (treadmill).
214230348|NCT00955201|BEHAVIORAL|Exercise|Structured isokinetic strength exercise (dynameter).
214230349|NCT02486341|DRUG|Insulin|Continuous glucose monitoring system over 120-hour period.
214230350|NCT05293899|DIAGNOSTIC_TEST|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
214230351|NCT00565929|DRUG|Placebo|Sterile saline (0.9%).
214230352|NCT00565929|BIOLOGICAL|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
214230353|NCT03032380|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
214230354|NCT03032380|DRUG|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
214230355|NCT03032380|DRUG|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
214230356|NCT05109455|DIETARY_SUPPLEMENT|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
214230357|NCT05109455|DIETARY_SUPPLEMENT|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
214230358|NCT03933995|OTHER|no Intervention|no Intervention
214230359|NCT02639858|DRUG|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
214230360|NCT03310333|DRUG|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
214230361|NCT03310333|DEVICE|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
214230362|NCT01258569|DRUG|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
214230363|NCT01258569|DRUG|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
214230364|NCT01258569|DRUG|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
214230365|NCT03254576|OTHER|Functional MRI|
214230366|NCT01561898|DRUG|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
214230367|NCT03361644|BEHAVIORAL|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
214230368|NCT03361644|BEHAVIORAL|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
214230369|NCT05885178|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
214230370|NCT03957460|OTHER|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
214230371|NCT00294762|DRUG|Tarceva|oral tablet
214230372|NCT00294762|DRUG|carboplatin|IV
214230373|NCT00294762|DRUG|paclitaxel|IV
214230374|NCT03605628|OTHER|measuring tape|measurement of change in abdominal wall length \[cm\] during neuromuscular block with a measuring tape.
214230375|NCT03605628|OTHER|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
214230376|NCT03605628|OTHER|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~1. extremely poor conditions~2. poor conditions~3. acceptable conditions~4. good conditions~5. optimal conditions"
214230377|NCT04208971|OTHER|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
214230378|NCT05812560|OTHER|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
214230379|NCT02238080|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
214230380|NCT01738646|DRUG|Vorinostat|
214651576|NCT02544555|PROCEDURE|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
214818030|NCT01990391|DIETARY_SUPPLEMENT|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
214230381|NCT01738646|DRUG|Bevacizumab|
214230382|NCT04640662|BIOLOGICAL|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
214230383|NCT04640662|BIOLOGICAL|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
214230384|NCT06167811|OTHER|whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
214230385|NCT05904418|OTHER|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
214818031|NCT01990391|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
214818032|NCT03207503|PROCEDURE|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
214230386|NCT05904418|OTHER|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
214230387|NCT05904418|RADIATION|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
214230388|NCT04691414|GENETIC|NGS|next-generation sequencing on preexisting samples
214230389|NCT02299102|DEVICE|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
214230390|NCT02299102|DEVICE|OnControl Powered Ported Device|OnControl Powered Ported Device
214230391|NCT04304638|RADIATION|radiation or chemo-radiation|standard treatment for stage III lung cancer
214230392|NCT04304638|DRUG|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
214230393|NCT03222882|PROCEDURE|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
214230394|NCT00749567|DRUG|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
214230395|NCT00749567|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
214230396|NCT04351789|OTHER|Psychoeducational intervention|"The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital."
214230397|NCT03198325|OTHER|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values \>50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
214230398|NCT01712724|OTHER|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
214230399|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
214230400|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
214230401|NCT01707238|DEVICE|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
214230402|NCT01707238|DEVICE|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
214230403|NCT00682578|DRUG|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
214230404|NCT00682578|DRUG|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
214230405|NCT01945918|BEHAVIORAL|Self-management support education|Same as Arm Description
214230406|NCT01945918|BEHAVIORAL|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
214230407|NCT01945918|BEHAVIORAL|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
214230408|NCT01676636|DRUG|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
214230409|NCT01676636|DRUG|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
214230410|NCT01676636|DRUG|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
214230411|NCT01676636|DRUG|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
214230412|NCT05575050|PROCEDURE|Oral Procedure|Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
214230413|NCT04093024|DRUG|Nintedanib|Capsule
214230414|NCT04093024|DRUG|Placebo|Capsule
214230415|NCT03156387|PROCEDURE|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
214230416|NCT03156387|PROCEDURE|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
214230417|NCT04779788|DEVICE|I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)|An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
214230418|NCT04779788|DEVICE|Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)|Bare self-expanded metal stent
214230419|NCT00488306|DRUG|tigecycline|
214230420|NCT04694924|OTHER|standard of care|"No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician."
214230421|NCT02482038|DEVICE|geko|neuromuscular electrostimulator
214230422|NCT03234283|DEVICE|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
214230423|NCT05317117|DIAGNOSTIC_TEST|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
214230424|NCT05707039|OTHER|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
214230425|NCT05707039|OTHER|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
214230426|NCT00262054|DRUG|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
214230427|NCT00262054|DRUG|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
214230428|NCT02523144|DRUG|Chloral Hydrate|70mg/kg chloral hydrate
214230429|NCT02523144|DRUG|Dexmedetomidine|2mcg/kg
214230430|NCT02523144|DRUG|Dexmedetomidine|3mcg/kg
214230431|NCT02523144|DRUG|Placebo|Flavored placebo syrup
214230432|NCT00498290|PROCEDURE|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
214230433|NCT00498290|PROCEDURE|control|normal recovery protocol as usually
214230434|NCT00188383|DRUG|Amantadine|
214230435|NCT05594745|DRUG|Lifitegrast Ophthalmic|eyedrop
214230436|NCT05594745|DRUG|Systane Free|eyedrop
214230437|NCT05594745|DEVICE|Lipiflow|thermal pulsation
214230438|NCT00901732|DEVICE|Caphosol|Oral Mouth Rinse
214230439|NCT02855918|OTHER|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
214230440|NCT05996913|OTHER|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz \& Weertman, 1999).
214230441|NCT06144099|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
214230442|NCT06144099|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
214230443|NCT04626401|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
214230444|NCT02030899|PROCEDURE|Cage fusion|Randomized selection of surgery type
214230445|NCT02030899|PROCEDURE|Plate fusion|Randomized selection of surgery type
214230446|NCT05677685|DEVICE|VISUPRIME|twice daily
214230447|NCT05677685|DEVICE|Placebo|twice daily
214230448|NCT00335179|DRUG|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
214230449|NCT00335179|DRUG|Vehicle cream|Vehicle cream in 250 mg
214230450|NCT01450852|BEHAVIORAL|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
214230451|NCT02642224|BEHAVIORAL|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
214230452|NCT01566084|DRUG|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
214230453|NCT01566084|OTHER|placebo|Placebo tablets are administered to maintain the low sodium condition.
214230454|NCT05460091|DEVICE|PTech Device|High-frequency vibration device used on regular basis in orthodontics
214230455|NCT05460091|DEVICE|PTech Sham Device|sham device (does not vibrate)
214230456|NCT00474305|BEHAVIORAL|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
214230457|NCT00233454|DRUG|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
214230458|NCT06391632|DIAGNOSTIC_TEST|Revised Cardiac Risk Index|The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.
214230459|NCT02141477|DRUG|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
214230460|NCT02141477|DRUG|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
214230461|NCT00796445|DRUG|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
214230462|NCT00796445|DRUG|Placebo|IM solution, a course of 13 injections administered over 27 months
214230463|NCT02366091|DRUG|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
214230464|NCT02366091|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
214230465|NCT02366091|DRUG|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
214230466|NCT00644007|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
214230467|NCT00644007|DRUG|SK3530|SK3530 100 mg
214230468|NCT01787162|OTHER|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
214230469|NCT00190255|PROCEDURE|CY2PC9 genotyping|CY2PC9 genotyping
214230470|NCT01395290|DRUG|cholecalciferol|20.000 IU per week, oral
214230471|NCT06088602|PROCEDURE|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
214230472|NCT06088602|PROCEDURE|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
214230473|NCT02328053|PROCEDURE|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
214230474|NCT02328053|DRUG|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
214230475|NCT02568891|DIETARY_SUPPLEMENT|Probiotic|multispecies probiotic
214230476|NCT02568891|DIETARY_SUPPLEMENT|Placebo|matrix
214230477|NCT00234247|OTHER|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
214230478|NCT05378698|DRUG|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
214230479|NCT05403398|DIETARY_SUPPLEMENT|B. subtilis CU1|2 billion CFUs daily, for 4 weeks
214230480|NCT04355585|DRUG|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
214230481|NCT04355585|DRUG|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
214230482|NCT00322621|DRUG|Duloxetine|
214230483|NCT01743001|DRUG|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
214230484|NCT01743001|DRUG|Placebo|Macitentan-matching placebo oral tablet once daily
214230485|NCT04502680|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
214230486|NCT02961101|DRUG|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
214230487|NCT02961101|DRUG|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
214230488|NCT02961101|DRUG|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
214230489|NCT04218565|BIOLOGICAL|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
214230490|NCT03030846|OTHER|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
214230491|NCT03030846|OTHER|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
214230492|NCT01565343|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi)
214230493|NCT05763355|PROCEDURE|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
214230494|NCT01012674|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
214230495|NCT01012674|OTHER|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
214230496|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
214230497|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
214230498|NCT00352352|PROCEDURE|Tongue Acupuncture (Procedure)|
214230499|NCT01650870|DRUG|Crystalline Lactulose|
214230500|NCT03965000|OTHER|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
214230501|NCT06099080|DRUG|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
214230502|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
214230503|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
214230504|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
214230505|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
214230506|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
214230507|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
214230508|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
214230509|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
214230510|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
214230511|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
214230512|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
214230513|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
214230514|NCT01532193|OTHER|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
214230515|NCT05919706|BEHAVIORAL|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
214230516|NCT00093405|DRUG|tanespimycin|
214230517|NCT03495778|OTHER|Test Granola|50.5 Test Granola
214230518|NCT03495778|OTHER|Control Granola|54.3 Control Granola
214230519|NCT04243382|BIOLOGICAL|Autologous umbilical cord blood|Single infusion of autologous umbilical cord blood cells
214230520|NCT04243382|BIOLOGICAL|Placebo|Placebo
214230521|NCT00496600|DRUG|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
214230522|NCT00496600|DRUG|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
214230523|NCT04781933|DIETARY_SUPPLEMENT|Treatment with Combo|Treatment with Combo
214230524|NCT04781933|OTHER|Treatment with placebo|Treatment with placebo
214230525|NCT01018784|DRUG|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
214230526|NCT05401942|OTHER|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
214230527|NCT00749814|DIETARY_SUPPLEMENT|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
214230528|NCT00749814|OTHER|Placebo tablets|Placebo
214230529|NCT02057588|PROCEDURE|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
214230530|NCT02350764|DRUG|nivolumab|
214230531|NCT02350764|DRUG|pilimumab|
214230532|NCT04193462|OTHER|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
214230533|NCT04193462|OTHER|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
214230534|NCT05549921|BIOLOGICAL|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
214230535|NCT04529486|OTHER|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
214230536|NCT04302909|OTHER|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
214230537|NCT04302909|OTHER|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
214230538|NCT04302909|OTHER|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
214230539|NCT00327821|BEHAVIORAL|calorie controlled diet|
214230540|NCT00246545|BEHAVIORAL|exercise|
214230541|NCT03614052|DRUG|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
214230542|NCT03614052|DRUG|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
214230543|NCT02161692|DRUG|Cyclophosphamide|
214230544|NCT02161692|DRUG|Etoposide|
214230545|NCT02161692|DRUG|Cisplatin|
214230546|NCT02161692|DRUG|Bleomycin|
214230547|NCT02161692|DRUG|Carboplatin|High dose carboplatin
214230548|NCT03905044|OTHER|eyes with congenital cataracts|observation
214230549|NCT04475705|DRUG|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
214230550|NCT04475705|DRUG|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
214230551|NCT03859947|DEVICE|Heated humidiﬁed high-flow nasal cannula|Non-invasive ventilation with a nasal cannula
214230552|NCT01109732|OTHER|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
214230553|NCT03347370|DRUG|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
214230554|NCT03347370|DRUG|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
214230555|NCT03347370|DRUG|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
214230556|NCT03171753|DIAGNOSTIC_TEST|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
214230557|NCT03171753|DIAGNOSTIC_TEST|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
214230558|NCT03171753|DIAGNOSTIC_TEST|cardiac monitoring|the cardiac monitoring will be performed through study period
214230559|NCT03171753|DIAGNOSTIC_TEST|skin resistance|the skin resistance monitoring will be performed through study period
214230560|NCT03171753|DEVICE|Music listening|Listening prerecorded music through an individual headset for 30 min
214230561|NCT03171753|DEVICE|No sound|No sound through an individual headset for 30 min
214651577|NCT02544555|PROCEDURE|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
214230562|NCT01765959|OTHER|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
214230563|NCT01765959|OTHER|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
214230564|NCT05731011|OTHER|antioxidative stress|blood interventions
214230565|NCT05731011|DEVICE|electrotherapy|hotpack,Tens, ultrasound
214230566|NCT03531632|BIOLOGICAL|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
214230567|NCT03635450|BIOLOGICAL|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
214230568|NCT04704947|DRUG|nonselective beta blocker|nonselective beta blocker
214230569|NCT04704947|DRUG|cardio-selective beta blocker group|cardio-selective beta blocker group
214230570|NCT04704947|DRUG|alendronate sodium|alendronate sodium
214230571|NCT02888496|DRUG|tocilizumab|3 monthly IV infusions in PMR patients
214230572|NCT01645943|PROCEDURE|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
214230573|NCT02678559|OTHER|tee measurement|
214230574|NCT02678559|OTHER|flotrac measurement|
214230575|NCT02678559|OTHER|clearsight measurement|
214230576|NCT00619320|BEHAVIORAL|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
214230577|NCT01317108|DRUG|CMF Chemotherapy|
214230578|NCT00600119|DRUG|placebo|placebo, oral, once daily (QD)
214651578|NCT05926427|DRUG|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
214230579|NCT00600119|DRUG|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
214230580|NCT06215768|DRUG|Dexmedetomidine and Midazolam|"This will be a prospective, double-blind, randomized controlled study conducted between October 2023and June 2024 .~Patients aged( 2\_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg Or intravenous midazolam 0.1 mg /kg(Group A) or (Group B) over 10 minutes after induction of anesthesia. The primary outcome is the incidence of ED within 30 minutes after extubation. Other outcomes are the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs)."
214230581|NCT04444856|DRUG|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
214230582|NCT04444856|OTHER|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
214230583|NCT03927560|PROCEDURE|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
214230584|NCT04084119|OTHER|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
214230585|NCT04084119|OTHER|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
214230586|NCT01906944|DRUG|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
214230587|NCT01906944|DRUG|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
214651579|NCT05926427|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
214651580|NCT05926427|DRUG|Chemotherapy|Not specified, recommended regimen according to histopathologic type
214230588|NCT05738681|DRUG|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
214230589|NCT04381039|DEVICE|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
214651581|NCT01736046|RADIATION|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
214230590|NCT04772638|BEHAVIORAL|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
214230591|NCT04772638|OTHER|Wait list control|not an active intervention
214230592|NCT05592860|DEVICE|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
214230593|NCT05592860|BEHAVIORAL|Daily Diary|participants will use daily diary to record glucose level
214230594|NCT01081418|BEHAVIORAL|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
214230595|NCT00729469|DRUG|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
214230596|NCT00729469|DRUG|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
214230597|NCT02660840|DRUG|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230598|NCT02660840|DRUG|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230599|NCT02660840|DRUG|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230600|NCT02660840|DRUG|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230601|NCT02660840|DRUG|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230602|NCT02660840|DRUG|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
214230603|NCT03373227|DRUG|Envarsus|Patients will take once daily Envarsus
214230604|NCT02183740|BEHAVIORAL|Multifaceted educational program|
214230605|NCT00514852|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
214230606|NCT00514852|DRUG|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
214230607|NCT03504046|DEVICE|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
214230608|NCT01809093|BIOLOGICAL|Blood draw|3-4 tablespoons of blood will be drawn, one time.
214230609|NCT00655174|DRUG|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
214230610|NCT00655174|DRUG|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
214230611|NCT00655174|DRUG|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
214230612|NCT00213694|DRUG|docetaxel and celecoxib|
214230613|NCT03812237|OTHER|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
214230614|NCT02884505|DEVICE|Pupillometry|Measures pupillary dynamics in darkness and light conditions
214230615|NCT02884505|BEHAVIORAL|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
214230616|NCT02884505|OTHER|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
214230617|NCT02884505|BEHAVIORAL|Hypersomnia Severity Index|Self-report measure of hypersomnolence
214230618|NCT05606029|PROCEDURE|Cholecystectomy, extended cholecystectomy|Cholecystectomy and histopathological evaluation
214230619|NCT03711240|DRUG|bevacizumab|5mg/kg iv day 1 every 2 weeks
214230620|NCT03711240|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
214230621|NCT03711240|DRUG|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
214230622|NCT03711240|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
214230623|NCT03711240|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
214230624|NCT00740610|DRUG|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
214230625|NCT00740610|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
214230626|NCT05094518|BEHAVIORAL|Mobile phone reminders|Appointment reminders in the form of push notifications will be sent through HERA app.
214230627|NCT00206232|DRUG|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
214230628|NCT01270802|DRUG|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
214230629|NCT01270802|DRUG|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
214230630|NCT01270802|DRUG|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
214230631|NCT03662581|BEHAVIORAL|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care"
214230632|NCT01875679|OTHER|Comprehensive Surgical Coaching|
214230633|NCT01875679|OTHER|Conventional Surgical Training|Surgical training as per participant's residency program
214230634|NCT02807675|DRUG|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
214230635|NCT02807675|OTHER|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
214230636|NCT00909207|BEHAVIORAL|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
214230637|NCT02539056|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
214230638|NCT03666156|OTHER|No intervention|No Intervention
214230639|NCT00799851|DEVICE|Variceal band ligation|
214230640|NCT00799851|DRUG|cyanoacrylate injection|cyanoacrylate injection
214230641|NCT03608358|DRUG|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
214230642|NCT03608358|DRUG|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
214230643|NCT03608358|DRUG|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
214230644|NCT03608358|DRUG|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
214230645|NCT03608358|DRUG|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
214230646|NCT03608358|DRUG|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
214230647|NCT01066390|BIOLOGICAL|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
214230648|NCT04634305|PROCEDURE|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
214230649|NCT05667337|DEVICE|CLP-PEG-MPC|Implantation of a 500 um thick biosynthetic corneal implant utilizing DALK surgical technique
214230650|NCT05667337|PROCEDURE|Human donor cornea penetrating keratoplasty|Implantation of a human donor cornea graft utilizing PKP surgical technique
214230651|NCT00484744|DRUG|Acetaminophen|
214230652|NCT00484744|DRUG|Avicel (placebo)|
214651582|NCT03314506|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
214230653|NCT00484744|DRUG|Ibuprofen|
214230654|NCT01388556|BEHAVIORAL|Tango dancing|Twice weekly tango dance classes
214230655|NCT03363113|DRUG|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
214230656|NCT02226445|OTHER|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
214230657|NCT03284892|BEHAVIORAL|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
214230658|NCT05254145|DIAGNOSTIC_TEST|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
214230659|NCT06089785|DEVICE|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
214230660|NCT02744950|PROCEDURE|Pulley stitches|
214230661|NCT02744950|PROCEDURE|Intermediate Repair|
214230662|NCT04181814|DEVICE|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
214230663|NCT00811213|DEVICE|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
214230664|NCT00811213|DEVICE|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
214230665|NCT01246817|DRUG|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
214651583|NCT00238264|RADIATION|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
214651584|NCT05484193|DRUG|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
214651585|NCT05484193|DRUG|Progesterone|vaginal progesterone for luteal phase support
214651586|NCT04850560|BIOLOGICAL|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
214651587|NCT00065026|BEHAVIORAL|Physical activity opportunities for low-income women|
214651588|NCT02706938|OTHER|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
214230666|NCT05412589|DRUG|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
214230667|NCT00179491|BEHAVIORAL|Intercessory Prayer|14 days of intercessory prayer from 3 sites
214230668|NCT06334406|OTHER|Biological samples|"Blood samples will be collected at baseline, after the diagnostic TURBT, and D15 after the end of treatment in each cohort.~Tumor tissues will be collected at baseline for three patients."
214230669|NCT02535572|DEVICE|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
214230670|NCT02535572|DEVICE|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
214230671|NCT03685890|DRUG|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
214230672|NCT03685890|PROCEDURE|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
214230673|NCT03137667|OTHER|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
214230674|NCT04620798|BEHAVIORAL|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
214230675|NCT01297777|DRUG|Imatinib Mesylate|"* In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
214230676|NCT02872220|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214230677|NCT02872220|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214230678|NCT02872220|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
214230679|NCT02872220|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
214230680|NCT00022347|DRUG|canfosfamide hydrochloride|
214230681|NCT03030742|OTHER|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids"
214651589|NCT02706938|OTHER|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
214818033|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
214230682|NCT03948477|DRUG|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
214230683|NCT03948477|DRUG|Placebo|Matched placebo
214230684|NCT03027284|DRUG|Merestinib|Administered orally
214230685|NCT03027284|DRUG|Cisplatin|Administered IV
214230686|NCT03027284|DRUG|Gemcitabine|Administered IV
214230687|NCT00000590|DRUG|immunoglobulins|
214230688|NCT00128323|DRUG|Gentian violet 1% solution|
214230689|NCT00128323|DRUG|Gentian violet 0.00165% solution|
214230690|NCT00128323|DRUG|Nystatin solution|
214230691|NCT00002339|DRUG|Fluconazole|
214230692|NCT06208956|DRUG|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
214230693|NCT06208956|DRUG|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
214230694|NCT02929654|DEVICE|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
214230695|NCT02929654|DEVICE|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
214230696|NCT02929654|DEVICE|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
214230697|NCT03740815|PROCEDURE|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
214230698|NCT03740815|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
214230699|NCT03740815|PROCEDURE|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
214230700|NCT00005779|DRUG|Interleukin-12|
214230701|NCT00005779|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
214230702|NCT02969603|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
214230703|NCT02969603|OTHER|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
214230704|NCT03462901|PROCEDURE|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
214230705|NCT00568633|PROCEDURE|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
214230706|NCT00568633|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
214230707|NCT00568633|DRUG|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
214230708|NCT00568633|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
214230709|NCT00568633|RADIATION|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
214230710|NCT00568633|DRUG|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
214230711|NCT00568633|DRUG|Best standard care|"Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
214230712|NCT03673761|OTHER|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
214230713|NCT01960907|DEVICE|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
214230714|NCT04119271|OTHER|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
214230715|NCT00561548|PROCEDURE|rectosigmoïdal biopsies|rectosigmoïdal biopsies
214230716|NCT02084251|DRUG|PB-119|
214230717|NCT00003544|DRUG|irinotecan hydrochloride|
214230718|NCT00003544|PROCEDURE|surgical procedure|
214230719|NCT04583722|DIETARY_SUPPLEMENT|AX-olive oil-PP emulsion|single dose and plasma samples
214230720|NCT05648669|DRUG|Elagolix|200 mg tablet
214230721|NCT05648669|DRUG|Elagolix placebo|Elagolix-matched Placebo tablet
214230722|NCT00644085|DRUG|aspirin|oral administration of aspirin 100 mg
214651590|NCT05533749|DEVICE|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
214230723|NCT00644085|DRUG|placebo|oral administration of placebo
214230724|NCT02080819|DRUG|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
214230725|NCT05231096|OTHER|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.
214230726|NCT05231096|OTHER|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
214230727|NCT05231096|PROCEDURE|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
214230728|NCT05219916|PROCEDURE|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
214230729|NCT02943304|OTHER|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
214230730|NCT02078856|DRUG|A3384|
214651591|NCT04713943|DIETARY_SUPPLEMENT|>Your< Iron Syrup|Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
214651592|NCT04713943|OTHER|Placebo|Once daily dose of placebo syrup for 12 weeks
214230731|NCT02834754|DRUG|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
214230732|NCT02834754|DRUG|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
214230733|NCT06113679|DEVICE|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
214230734|NCT05266729|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
214230735|NCT05266729|DRUG|Placebo|Phosphate buffered saline placebo for injection
214230736|NCT00886678|DRUG|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
214230737|NCT00886678|DRUG|carboplatin|AUC=5,IV,q 21 days x 2 cycles
214230738|NCT00886678|RADIATION|thoracic radiation|66 Gy over 33 fractions
214230739|NCT00684541|BEHAVIORAL|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
214230740|NCT00684541|BEHAVIORAL|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
214230741|NCT00439738|DRUG|HCTZ + Amlodipine|"* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules"
214230742|NCT00439738|DRUG|Valsartan/HCTZ|"* 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules"
214230743|NCT00004845|DRUG|Rofecoxib|
214230744|NCT00004845|DRUG|Naproxen|
214230745|NCT02890641|GENETIC|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
214230746|NCT01094522|DRUG|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
214230747|NCT01094522|DRUG|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
214230748|NCT03774719|DEVICE|Hand-carried ultrasound|Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
214230749|NCT00402740|DEVICE|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
214230750|NCT00147836|DRUG|Human Insulin (Novolin-R, Novo Nordisk)|
214230751|NCT00147836|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
214230752|NCT00147836|OTHER|Pre-meal|
214230753|NCT00147836|DRUG|Novolin-R|
214230754|NCT00147836|DRUG|Human Insulin NPH (Novolin-N, Novo Nordisk)|
214230755|NCT00147836|DRUG|Gliclazide (Diamicron, Servier)|
214230756|NCT00147836|DRUG|Diamicron and Glucophage|
214230757|NCT05338424|OTHER|Sprint Interval Training (SIT)|Active arm-- exercise dictated by protocol
214230758|NCT00137891|DRUG|Modified Release rhTSH|
214230759|NCT04125953|DEVICE|Andullation|Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
214230760|NCT04125953|OTHER|Placebo|Placebo Andullation
214230761|NCT03869463|OTHER|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
214230762|NCT03869463|OTHER|Control|This group will not receive computerized cognitive training.
214230763|NCT01232036|DRUG|Glucophage 500mg|Single Oral Dose of
214230764|NCT01232036|DRUG|HL-018 500mg|Single Oral Dose of
214230765|NCT01232036|OTHER|No administration of Drug|
214230766|NCT05302336|DRUG|Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide|"All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide)."
214230767|NCT02046759|OTHER|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
214230768|NCT02046759|OTHER|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
214230769|NCT02740803|OTHER|Sodium fluoride toothpaste 1,450 ppmF|
214230770|NCT02740803|OTHER|sodium monofluorophosphate toothpaste 1,450 ppmF|
214230771|NCT02740803|OTHER|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
214230772|NCT02740803|OTHER|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
214230773|NCT02740803|OTHER|Amine fluoride toothpaste 1,400 ppmF|
214230774|NCT02740803|OTHER|Non-fluoridated toothpaste 0 ppmF|
214230775|NCT03291093|DRUG|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
214230776|NCT04241900|BEHAVIORAL|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
214230777|NCT05286645|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
214230778|NCT05286645|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214230779|NCT03754439|BEHAVIORAL|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
214230780|NCT00117052|DRUG|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
214230781|NCT03047824|DEVICE|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
214230782|NCT03047824|OTHER|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
214230783|NCT01295879|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
214230784|NCT04986358|OTHER|Follow up at 2 years|The patients will have a follow-up to carry out 2 years after their intervention in addition to their traditional care
214230785|NCT01185353|DRUG|LY3009104|Administered orally
214230786|NCT01185353|DRUG|Placebo|Administered orally
214230787|NCT01185353|DRUG|Methotrexate|Administered orally as background therapy
214230788|NCT04580641|OTHER|Questionnaire|A self-administered questionnaire will be completed by each study subject
214230789|NCT02569099|OTHER|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
214230790|NCT00294086|DRUG|valsartan 160 mg|
214230791|NCT00294086|DRUG|valsartan 160 mg BID|
214651593|NCT01838044|DRUG|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
214230792|NCT00638638|DRUG|Abciximab|"* Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min"
214230793|NCT00638638|DRUG|Abciximab placebo|"* Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min"
214230794|NCT05090319|DIAGNOSTIC_TEST|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
214230795|NCT05921045|OTHER|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
214230796|NCT05921045|OTHER|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
214230797|NCT03235232|DRUG|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
214230798|NCT03235232|DRUG|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
214230799|NCT01930578|OTHER|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
214230800|NCT01930578|OTHER|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
214230801|NCT01930578|OTHER|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
214230802|NCT02270944|BIOLOGICAL|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
214230803|NCT02270944|BIOLOGICAL|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
214230804|NCT05471713|OTHER|Autonomic dysfunction|Autonomic dysfunction
214230805|NCT00605956|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
214230806|NCT00605956|DRUG|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
214230807|NCT00605956|DRUG|Blank Patch|Blank Patch
214230808|NCT00095147|DRUG|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
214230809|NCT00095147|DRUG|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
214230810|NCT00095147|DRUG|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
214230811|NCT00095147|DRUG|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
214230812|NCT00095147|DRUG|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
214230813|NCT00001272|DRUG|taxol|
214230814|NCT01311167|DRUG|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
214230815|NCT01311167|DRUG|Placebo|Daily administration of 2 mg of placebo for 4 days
214230816|NCT02390791|OTHER|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
214651594|NCT01838044|DRUG|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
214651595|NCT00495157|BEHAVIORAL|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
214230817|NCT02390791|OTHER|treatment as usual standard portal|Standard version of myADHDportal.com web software
214230818|NCT01789398|DRUG|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
214230819|NCT03927378|DRUG|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
214230820|NCT03927378|DRUG|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
214230821|NCT01375075|DRUG|LY2484595|Administered orally
214230822|NCT01375075|DRUG|Placebo|Administered orally
214230823|NCT01375075|DRUG|Atorvastatin|Administered orally
214230824|NCT04891393|DIETARY_SUPPLEMENT|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
214230825|NCT04891393|DIETARY_SUPPLEMENT|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
214230826|NCT05216354|DRUG|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
214230827|NCT05681143|OTHER|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
214651596|NCT00495157|BEHAVIORAL|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
214651597|NCT00495157|BEHAVIORAL|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
214230828|NCT05681143|OTHER|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
214230829|NCT01011309|BIOLOGICAL|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
214230830|NCT01011309|DRUG|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
214230831|NCT05032924|COMBINATION_PRODUCT|PPR group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection
214230832|NCT05032924|COMBINATION_PRODUCT|PPR group without ESWT|PRP or HA injection only
214230833|NCT05032924|COMBINATION_PRODUCT|HA group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)
214230834|NCT05032924|COMBINATION_PRODUCT|HA group without ESWT|PRP or HA injection only
214230835|NCT05306119|OTHER|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
214230836|NCT05902052|OTHER|Care Protocol|Evaluation of patients' pain in the extubated period with the Visual Anolog Scale Active participation of the patient in pain reporting Regular questioning of the patient's pain Questioning pain at rest and movement Implementing nursing interventions in painful condition (VAS≤ 4)
214230837|NCT03893695|DRUG|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
214230838|NCT03858816|OTHER|Mixture probiotics|The mixture probiotics capsule
214230839|NCT03858816|OTHER|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
214230840|NCT04124679|OTHER|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
214230841|NCT01896791|PROCEDURE|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
214230842|NCT01896791|PROCEDURE|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
214230843|NCT05881070|BEHAVIORAL|Mobile-health self management|Mobile-health self management
214230844|NCT02298660|DRUG|BOTOX|"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
214230845|NCT02121613|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
214230846|NCT02121613|DRUG|Tamsulosine LP|Oral administration - 0.4 mg daily.
214230847|NCT02121613|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
214230848|NCT02121613|DRUG|Placebo matching Tamsulosine LP|Oral administration - daily.
214230849|NCT02122068|BEHAVIORAL|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
214230850|NCT02122068|BEHAVIORAL|Relaxation cd|
214230851|NCT02806141|DRUG|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
214230852|NCT02806141|DRUG|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
214230853|NCT06044597|DEVICE|SyncAV function on|CRT-D with SyncAV plus activated
214230854|NCT04064125|DRUG|FMX-101|
214230855|NCT05488821|DRUG|QLH11906|QLH11906 only
214230856|NCT00486655|PROCEDURE|NOTES-Assisted Cholecystectomy|
214230857|NCT03207035|PROCEDURE|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
214230858|NCT01625741|DRUG|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
214230859|NCT02862067|OTHER|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
214230860|NCT02439489|DRUG|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
214230861|NCT02439489|DRUG|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
214651598|NCT05191160|OTHER|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
214230862|NCT04847713|OTHER|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
214230863|NCT00554710|DRUG|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
214230864|NCT00554710|DRUG|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
214230865|NCT03833193|RADIATION|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
214464703|NCT02278744|RADIATION|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
214464704|NCT02278744|DEVICE|MRI and/or CT|
214651599|NCT05191160|OTHER|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
214230866|NCT03917407|DRUG|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
214230867|NCT03917407|DRUG|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
214230868|NCT05176171|PROCEDURE|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
214230869|NCT00299611|DRUG|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
214230870|NCT00299611|DRUG|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
214230871|NCT00299611|DRUG|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
214230872|NCT02082756|DRUG|Bifidobacterium viable pharmaceutics|
214230873|NCT02082756|DRUG|Berberine Hydrochloride|
214230874|NCT05072067|PROCEDURE|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
214230875|NCT04792242|DEVICE|cv line insertion|Svo2 and central venous pressure measurements
214230876|NCT04792242|DEVICE|Urinary catheter insertion|urine output measurement
214230877|NCT04792242|DEVICE|Arterial line|Arterial blood gases measurment
214230878|NCT03840434|DIAGNOSTIC_TEST|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
214230879|NCT04363541|DEVICE|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
214230880|NCT05085301|DIAGNOSTIC_TEST|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
214230881|NCT00755300|PROCEDURE|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
214230882|NCT05427877|DEVICE|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
214230883|NCT04312646|DEVICE|Elastography .|Performance of US, elastography
214230884|NCT05857865|BEHAVIORAL|SPYKids|SSIs will be tailored to the parent areas of primary concern as identified in the pre-questionnaire. Participants will meet with the parent coach in a virtual 90-minute session to discuss coping strategies relevant to the identified concerns. Content will be informed by the baseline questionnaire and include psychoeducation with an explanation of 1 or 2 skills to manage a primary mental health issue (e.g., Emotion Regulation, Distress Tolerance, Communication), a brief practice of the skills (as appropriate), and an action plan for the family to apply the skills at home. Families will also be provided with recommendations for relevant services from our family-focused resource list. Please note, the session length may be extended to 120 minutes if an interpreter is required in order to provide equal opportunity for understanding the session content.
214230885|NCT05857865|OTHER|Services as Usual (SAU)|Participants will receive links to the Manitoba 211 websites and a local organization's resource website with resources for adults and children. This resource is used to locate crisis, distress, and support phone lines, and counselling. Following completion of the 3-month survey, participants will receive a lab-developed comprehensive list of resources (also provided to participants in the SPYKids arm).
214230886|NCT00123669|DRUG|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
214230887|NCT03708393|DEVICE|Imagio (IUS+OA)|The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
214230888|NCT03708393|DEVICE|Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of the reader study
214230889|NCT03708393|DEVICE|Mammography|Mammography images as available per standard of care
214230890|NCT06341985|RADIATION|Exclusive radiotherapy|Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
214230891|NCT00990418|DRUG|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
214230892|NCT05261529|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
214464705|NCT06229951|DIETARY_SUPPLEMENT|Collagen|Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day
214464706|NCT06229951|OTHER|Placebo|Control patients will take placebo 2 tabs a day.
214230893|NCT05261529|BEHAVIORAL|Physical Exercise Program|Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
214230894|NCT03144609|PROCEDURE|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
214230895|NCT03144609|PROCEDURE|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
214230896|NCT03144609|PROCEDURE|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
214230897|NCT04985552|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
214230898|NCT04985552|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion. The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
214230899|NCT04985552|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
214230900|NCT01252732|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
214230901|NCT01252732|DRUG|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
214230902|NCT02220088|PROCEDURE|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214230903|NCT02220088|DRUG|Sorafenib|Accept sorafenib.
214230904|NCT03894007|DRUG|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
214230905|NCT03894007|DRUG|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
214230906|NCT03894007|DRUG|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
214230907|NCT03894007|DRUG|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
214230908|NCT03894007|DRUG|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
214230909|NCT03894007|DRUG|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
214230910|NCT03894007|DRUG|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
214230911|NCT03894007|DRUG|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
214230912|NCT03894007|DRUG|Paclitaxel|80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
214230913|NCT03219775|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
214230914|NCT01956916|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
214230915|NCT01956916|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
214230916|NCT00324597|DRUG|gemcitabine hydrochloride|
214230917|NCT00324597|DRUG|motesanib diphosphate|
214230918|NCT00324597|OTHER|pharmacological study|
214464707|NCT02474160|OTHER|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
214464708|NCT05148299|DRUG|Pegcetacoplan|20-cc glass vials-1080 mg
214464709|NCT04631926|BEHAVIORAL|Hip Muscle Exercise|Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
214464710|NCT06446960|DRUG|Lidocaine 20mg/ml|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
214464711|NCT06446960|DRUG|Levobupivacaine Hydrochloride 1.25 MG/ML|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
214464712|NCT06446960|DRUG|Sodium Chloride 0.9% Inj|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
214230919|NCT01305798|OTHER|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
214230920|NCT06335004|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients will undergo a magnetic resonance imaging for clinical purposes to which additional sequences. Post gadolinium research sequences will be acquired only if intravenous gadolinium needs to be administered for clinical purposes.
214230921|NCT03939741|BIOLOGICAL|SVF Containg Autologous Non Expanded ADSC|5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.
214230922|NCT00003496|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214230923|NCT03805113|DEVICE|Magnetotherapy device|Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
214230924|NCT03805113|DEVICE|Placebo|Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
214230925|NCT03219970|DRUG|Osimertinib|80mg oral daily
214230926|NCT03339154|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
214230927|NCT00457106|DRUG|Paroxetine|
214230928|NCT00457106|DRUG|Risperidone|
214230929|NCT00630383|BIOLOGICAL|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
214230930|NCT00630383|OTHER|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
214230931|NCT05738590|PROCEDURE|muscle biopsy|true cut needle biopsy
214230932|NCT03048383|DRUG|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
214230933|NCT03048383|DRUG|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
214230934|NCT03048383|DRUG|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
214230935|NCT05094310|DEVICE|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
214230936|NCT03472547|DRUG|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
214651600|NCT05191160|OTHER|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
214230937|NCT06435897|BIOLOGICAL|fetal MSCs combined with 4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
214230938|NCT03400267|DRUG|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
214230939|NCT03400267|DRUG|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
214230940|NCT06945913|BEHAVIORAL|Exercise|HIIT Group
214230941|NCT06946394|DRUG|Pegmolesatide|Pegmolesatide Injection: Specification 1mL: 4.0mg (National Medical Products Administration Approval No. H20230020), administered once every 4 weeks
214230942|NCT06946745|OTHER|tissue biopsy|By performing single-cell sequencing on tumor tissues at baseline and post-treatment (cycle 2) across all patients, we will conduct pseudotime trajectory analysis to study the differentiation dynamics of cellular populations.
214230943|NCT04148144|OTHER|No intervention included|No intervention included
214230944|NCT02635425|PROCEDURE|7 eggs collection|vaginal US
214651601|NCT04707638|OTHER|No intervention used|No intervention used
214651602|NCT05601245|OTHER|High voltage pulsed current|The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
214651603|NCT05601245|OTHER|Microcurrent therapy|The treatment session duration is 40 minutes.
214651604|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
214651605|NCT03824301|DEVICE|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
214651606|NCT03824301|DEVICE|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
214651607|NCT01982591|OTHER|laboratory biomarker analysis|Correlative studies
214651608|NCT01982591|OTHER|questionnaire administration|Ancillary studies
214818034|NCT02291250|DIETARY_SUPPLEMENT|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
214230945|NCT02635425|PROCEDURE|Full eggs collection|vaginal US
214230946|NCT04236141|DRUG|Polatuzumab Vedotin|Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
214230947|NCT04236141|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
214230948|NCT04236141|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
214230949|NCT04236141|DRUG|Placebo|Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
214230950|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
214230951|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
214230952|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
214230953|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
214230954|NCT03198065|PROCEDURE|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
214230955|NCT03198065|PROCEDURE|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
214230956|NCT01300013|DRUG|Placebo|48-hour infusion of placebo
214230957|NCT01300013|DRUG|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
214230958|NCT03395236|COMBINATION_PRODUCT|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
214230959|NCT00680641|DRUG|Simvastatin|40mg of Simvastatin once daily
214230960|NCT00680641|DRUG|Placebo|40mg of placebo once daily
214230961|NCT04304599|DEVICE|LoFric Elle|The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
214230962|NCT01948193|BIOLOGICAL|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
214230963|NCT00043342|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
214230964|NCT03130647|DEVICE|Focused ultrasound|Focused ultrasound
214230965|NCT01563614|RADIATION|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
214230966|NCT01563614|DRUG|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
214230967|NCT01563614|DRUG|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
214230968|NCT03116581|OTHER|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~* Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~* Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
214230969|NCT03116581|OTHER|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
214464713|NCT05627375|DRUG|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
214464714|NCT05627375|DRUG|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
214464715|NCT03841357|DRUG|Abatacept Injection|Supplied as a weekly injection via a pre-filled syringe
214464716|NCT03841357|OTHER|Usual Care|Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
214464717|NCT04992520|BIOLOGICAL|Shigella sonnei 53G|Shigella sonnei (S. sonnei) strain 53G (Lot 1794); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
214464718|NCT04992520|BIOLOGICAL|Shigella flexneri 2a 2457T|Shigella flexneri (S. flexneri) strain 2457T (Lot 1617); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
214464719|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
214230970|NCT03116581|OTHER|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
214230971|NCT02981459|DRUG|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
214230972|NCT01823588|BEHAVIORAL|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
214230973|NCT04675554|OTHER|Follow up of physical activity|participants will fill in the non-opposition form via the application and will complete, with their smartphone, a series of psychometric questionnaires. Participants will then use the mobile application for a period of 12 weeks during which time, physical activity data provided from participants smartphone will be gathered After 12 weeks, participants will complete again the same series of psychometric questionnaires.
214230974|NCT03276520|DIAGNOSTIC_TEST|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
214230975|NCT03276520|DIAGNOSTIC_TEST|ethanol|alcohol urine screening with ethanol
214230976|NCT00408044|PROCEDURE|cardiac surgery with sternotomy|
214230977|NCT05883384|OTHER|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
214230978|NCT02695160|BIOLOGICAL|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
214230979|NCT00545870|DRUG|bevacizumab|intravitreal application
214230980|NCT00545870|DRUG|Ranibizumab|intravitreal application
214230981|NCT03285022|PROCEDURE|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
214230982|NCT01685398|DRUG|0.5% timolol maleate eye drop|
214230983|NCT01685398|DRUG|Normal saline|
214230984|NCT02423967|BIOLOGICAL|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
214230985|NCT02423967|BIOLOGICAL|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
214230986|NCT04193618|PROCEDURE|Conservative surgery for placenta accretta|Uterine devasculrization and transverse compressing sutures before placental delivery
214230987|NCT03665025|OTHER|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
214230988|NCT02885571|DEVICE|SomnoDent Flex with DentiTrac|
214230989|NCT00423202|DRUG|ambrisentan|
214230990|NCT01681355|OTHER|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
214230991|NCT02081755|DRUG|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
214230992|NCT02081755|DRUG|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
214230993|NCT02081755|DRUG|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
214651609|NCT03465033|OTHER|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
214651610|NCT05596214|COMBINATION_PRODUCT|Curcumin-Berberine (coptis)|dietary supplement
214651611|NCT05596214|COMBINATION_PRODUCT|Placebo|Placebo
214230994|NCT02081755|DRUG|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
214230995|NCT02081755|DRUG|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
214230996|NCT02980952|OTHER|High-fat overfeeding|
214230997|NCT02980952|OTHER|Forearm immobilization|
214230998|NCT02043340|DRUG|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
214230999|NCT02043340|DEVICE|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
214651612|NCT04060615|PROCEDURE|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
214651613|NCT02612870|DEVICE|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
214231000|NCT02043340|PROCEDURE|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
214231001|NCT05396716|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
214231002|NCT02720107|DRUG|fingolimod|
214231003|NCT06022289|DRUG|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
214231004|NCT00225810|DRUG|Crohn's Disease|
214231005|NCT02649348|BEHAVIORAL|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
214231006|NCT04925154|BEHAVIORAL|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
214231007|NCT04348227|BEHAVIORAL|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
214231008|NCT02879331|PROCEDURE|10 coils in upper lobes|
214231009|NCT02879331|PROCEDURE|15 coils in upper and lower lobes|
214231010|NCT02879331|PROCEDURE|cycloergometry|
214231011|NCT00204438|DRUG|0.15mg desogestrel /0.03mg ethinyl estradiol|
214231012|NCT04868630|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
214231013|NCT03787381|DEVICE|Ultrasound|Vaginal ultrasound examination
214231014|NCT05449483|DRUG|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
214231015|NCT01049945|DRUG|bendamustine hydrochloride|Given IV
214231016|NCT01049945|DRUG|lenalidomide|Given orally
214231017|NCT01049945|DRUG|dexamethasone|Given orally or IV
214231018|NCT03660085|BEHAVIORAL|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
214231019|NCT06255366|DRUG|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
214231020|NCT06255366|DRUG|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
214231021|NCT06255366|DRUG|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
214231022|NCT01767831|BEHAVIORAL|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
214231023|NCT04704804|DIAGNOSTIC_TEST|Synthetic CT Scan|method of generating CT-synthetic image from MRI
214231024|NCT03283410|DRUG|Propofol|Propofol plasmatic concentration (Marsh)
214231025|NCT02210598|DEVICE|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
214231026|NCT02210598|DEVICE|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
214651614|NCT02612870|DEVICE|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
214651615|NCT02612870|DEVICE|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
214231027|NCT02210598|DRUG|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
214231028|NCT01594437|BIOLOGICAL|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
214231029|NCT01594437|BIOLOGICAL|Placebo|One or two doses administered by intravenous infusion.
214231030|NCT05184751|OTHER|colonoscopy|
214231031|NCT03674931|BEHAVIORAL|musical practice|Intensive weekly musical keyboard training over 12 months
214231032|NCT03674931|BEHAVIORAL|music education|Recreative weekly musical courses without practice over 12 months
214231033|NCT02697669|OTHER|18F-FDG PET|Imaging
214231034|NCT06484205|OTHER|WHO QualityRights e-training|WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.
214231035|NCT06484205|OTHER|Emotional intelligence e-training|This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
214231036|NCT03960450|DRUG|BOS-475|topical cream
214231037|NCT03960450|DRUG|Vehicle|topical cream
214231038|NCT05512468|DRUG|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
214231039|NCT05657522|DEVICE|Rapid molar intruder|The rapid molar intruder was applied.
214231040|NCT01528865|DRUG|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
214231041|NCT01528865|DRUG|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
214231042|NCT03878693|DRUG|Fomepizole|IV 4-MP.
214231043|NCT03878693|DRUG|APAP|Oral APAP
214231044|NCT00507728|DRUG|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
214231045|NCT00507728|DRUG|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
214231046|NCT00507728|DRUG|Placebo|Placebo by mouth for 12 weeks.
214231047|NCT00507728|BEHAVIORAL|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
214231048|NCT03121651|DEVICE|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
214231049|NCT04590742|DRUG|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
214231050|NCT04590742|DRUG|Placebo|Patient given 6 weeks of placebo tablet
214231051|NCT05779384|OTHER|It was an observational study|data collected concerning the incidence of exacerbations
214231052|NCT03188172|DRUG|Cyclophosphamide|Chemotherapy
214231053|NCT03188172|DRUG|Bortezomib|Chemotherapy
214231054|NCT03188172|DRUG|Lenalidomide|Chemotherapy
214231055|NCT03188172|DRUG|Daratumumab|Chemotherapy
214231056|NCT03188172|DRUG|Dexamethasone|Chemotherapy
214231057|NCT03188172|DRUG|Melphalan|Chemotherapy
214231058|NCT03188172|DRUG|Filgrastim|Haematopoietic agent for the stem cell harvest
214231059|NCT01337037|DEVICE|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
214231060|NCT01337037|PROCEDURE|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
214231061|NCT01337037|PROCEDURE|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
214231062|NCT01337037|PROCEDURE|Open lobectomy|standard lobectomy procedure by thoracotomy approach
214231063|NCT01964755|DRUG|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
214231064|NCT01964755|DRUG|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
214231065|NCT01964755|DRUG|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
214231066|NCT01964755|BIOLOGICAL|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
214231067|NCT01964755|DRUG|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
214231068|NCT01964755|DRUG|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
214231069|NCT04988191|DRUG|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
214231070|NCT04988191|DRUG|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
214231071|NCT04988191|DRUG|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
214231072|NCT01198613|BIOLOGICAL|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
214231073|NCT01198613|BIOLOGICAL|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
214231074|NCT02495571|OTHER|Cough Assessment in ALS Patients|"1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
214231075|NCT02845219|DRUG|semaglutide|Oral administration once daily alone or together with oral contraceptive.
214231076|NCT02845219|DRUG|SNAC|Oral administration once daily together with oral contraceptive.
214231077|NCT02845219|DRUG|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
214231078|NCT03599375|BIOLOGICAL|CD19-targeted CART cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
214651616|NCT02612870|DEVICE|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
214651617|NCT02612870|DEVICE|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
214651618|NCT00860470|DIETARY_SUPPLEMENT|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
214651619|NCT00860470|DIETARY_SUPPLEMENT|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
214231079|NCT06131164|OTHER|Diaphragmatic Breathing Exercise Group|The subjects in this group will perform Diaphragmatic Breathing Exercise Group
214231080|NCT06131164|OTHER|Thoracic Extension Exercise Group|The subjects in this group will perform Thoracic Extension Exercise Group
214231081|NCT01873612|PROCEDURE|Hypoxic ventilatory response|
214231082|NCT01873612|PROCEDURE|Hypercapnic ventilatory response|
214231083|NCT02356367|OTHER|telemonitoring|
214231084|NCT01710137|DRUG|Varenicline|
214231085|NCT01710137|DRUG|Placebo|
214231086|NCT01710137|BEHAVIORAL|Smoking Cessation Counseling|
214231087|NCT03007810|DRUG|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
214231088|NCT03007810|DRUG|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
214231089|NCT03251131|OTHER|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
214231090|NCT05045937|DRUG|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
214231091|NCT01275807|DEVICE|acupuncture|10 sessions of acupuncture
214231092|NCT01275807|OTHER|self care|physical exercice, diet, self help groups, psychological support
214231093|NCT00988650|OTHER|isocaloric diet|
214231094|NCT00988650|OTHER|free living conditions|
214231095|NCT01810614|OTHER|ADPKD Diet|Diet specifically designed for people with ADPKD
214231096|NCT00601042|OTHER|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
214231097|NCT00601042|OTHER|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
214231098|NCT03196492|OTHER|No intervention|No intervention
214231099|NCT04752644|BIOLOGICAL|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
214231100|NCT04752644|DRUG|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
214231101|NCT03035487|DEVICE|Ultrasound guided prostate exam using SOC ultrasound system|
214231102|NCT03035487|DEVICE|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
214231103|NCT03035487|DEVICE|High-resolution micro-ultrasound guided prostate biopsy|
214231104|NCT01332799|DRUG|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
214231105|NCT01332799|OTHER|Placebo|Sugar pill administered orally for 3 years.
214231106|NCT00629967|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
214231107|NCT00629967|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
214231108|NCT01198522|DRUG|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
214231109|NCT04347668|OTHER|Virtual Reality|VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
214231110|NCT04347668|OTHER|Usual Care|meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
214231111|NCT00178529|BEHAVIORAL|Psychoeducation, Counseling and Skill Training|
214231112|NCT00291213|DRUG|levetiracetam|
214231113|NCT00291213|DRUG|placebo|
214231114|NCT01909791|PROCEDURE|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
214231115|NCT01909791|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
214231116|NCT01909791|PROCEDURE|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
214231117|NCT01909791|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
214231118|NCT01268280|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
214231119|NCT01268280|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
214231120|NCT01268280|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
214231121|NCT00091325|DIETARY_SUPPLEMENT|defined green tea catechin extract|
214231122|NCT02908490|DRUG|Sildenafil|Sildenafil 50 mg once daily
214231123|NCT02908490|OTHER|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
214231124|NCT02168387|DEVICE|continuous high frequency oscillator (CHFO)|
214231125|NCT02168387|DRUG|Acetylcysteine|
214231126|NCT02168387|DRUG|dornase alfa|
214231127|NCT06450119|OTHER|walking training|The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
214231128|NCT06450119|OTHER|cognition training|The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
214231129|NCT03519542|DRUG|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
214231130|NCT02893579|BEHAVIORAL|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
214231131|NCT02893579|BEHAVIORAL|Delayed SR intervention|Activity tracking only for the first month
214231132|NCT00002289|DRUG|Thymopentin|
214231133|NCT03660670|BEHAVIORAL|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
214651620|NCT03689192|BIOLOGICAL|ARG1-18,19,20|300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
214231134|NCT03660670|BEHAVIORAL|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
214231135|NCT01936090|DRUG|Bortezomib|Given IV
214231136|NCT01936090|RADIATION|Total-Body Irradiation|Undergo TBI
214231137|NCT01936090|DRUG|Melphalan|Given IV
214231138|NCT01936090|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
214231139|NCT01936090|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214231140|NCT01936090|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214651621|NCT05851469|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
214651622|NCT02648386|PROCEDURE|Laparoscopic surgery|Completely resected rectal tumor.
214231141|NCT01936090|OTHER|Laboratory Biomarker Analysis|Correlative studies
214231142|NCT02730143|OTHER|Altitude exposure|Altitude exposure
214651623|NCT02648386|DEVICE|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
214231143|NCT01004276|OTHER|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
214231144|NCT05630391|DEVICE|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
214231145|NCT05630391|OTHER|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
214231146|NCT03676101|BIOLOGICAL|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
214231147|NCT03676101|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
214231148|NCT06079229|OTHER|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
214231149|NCT01588756|DRUG|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
214231150|NCT01588756|DRUG|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
214231151|NCT02505828|PROCEDURE|Articular punction, salivary samples, blood sample|
214231152|NCT03467152|DRUG|Irsenontrine|Oral hypromellose capsules.
214231153|NCT03467152|DRUG|Placebo|Oral hypromellose capsules.
214231154|NCT03395119|DRUG|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
214231155|NCT03395119|DIETARY_SUPPLEMENT|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
214231156|NCT03395119|DIETARY_SUPPLEMENT|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
214231157|NCT01236547|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214651624|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
214651625|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
214231158|NCT01236547|DRUG|Paclitaxel|Given IV
214231159|NCT01236547|DRUG|Pazopanib Hydrochloride|Given PO
214231160|NCT01236547|OTHER|Placebo Administration|Given PO
214231161|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
214231162|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
214231163|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
214231164|NCT00000144|PROCEDURE|Argon Laser Treatment|
214231165|NCT02117128|DRUG|Tranexamic acid|
214231166|NCT00715143|DEVICE|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
214231167|NCT05099224|BEHAVIORAL|Mindfulness meditation|similar to the information included in arm/group descriptions
214231168|NCT04250077|BEHAVIORAL|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
214231169|NCT04250077|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
214231170|NCT03069521|DEVICE|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
214231171|NCT00315757|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
214231172|NCT00315757|BIOLOGICAL|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
214231173|NCT00315757|DRUG|Bortezomib|1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
214231174|NCT05302453|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
214231175|NCT05373888|DEVICE|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)"
214231176|NCT00910624|DRUG|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
214231177|NCT00910624|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
214231178|NCT00910624|DRUG|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
214231179|NCT02653703|OTHER|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
214231180|NCT02653703|OTHER|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
214231181|NCT02880085|DRUG|Local anesthetic|local injection
214231182|NCT03775538|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
214651626|NCT05265650|DRUG|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
214231183|NCT03775538|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
214231184|NCT02226133|DEVICE|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
214231185|NCT05736029|OTHER|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
214231186|NCT04140227|DRUG|NOV03|100% Perfluorohexyloctane
214231187|NCT01713933|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
214231188|NCT00412373|DRUG|Placebo|for 6 weeks
214231189|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
214231190|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
214231191|NCT06505720|PROCEDURE|Arthroscopic management of acute pediatric septic hip infecion|Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection
214231192|NCT06505720|PROCEDURE|Open debridement of acute pediatric septic hip|surgical drainage and debridement of acute septic hip in children via classic lateral approach
214231193|NCT00423527|DRUG|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
214231194|NCT06257043|PROCEDURE|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
214231195|NCT01167387|DIETARY_SUPPLEMENT|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
214231196|NCT01167387|OTHER|water|The control group will receive plain water with the same volume and timing of treatment.
214231197|NCT03349398|PROCEDURE|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
214651627|NCT05265650|PROCEDURE|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
214651628|NCT01348802|BEHAVIORAL|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
214231198|NCT03349398|PROCEDURE|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
214231199|NCT00954096|DRUG|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
214231200|NCT03458715|DRUG|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
214231201|NCT03458715|DRUG|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
214231202|NCT02871882|RADIATION|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
214231203|NCT02871882|OTHER|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
214231204|NCT02871882|DRUG|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
214231205|NCT02871882|OTHER|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
214231206|NCT02113800|DRUG|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
214231207|NCT02248688|DEVICE|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
214231208|NCT02248688|PROCEDURE|Left Gastric Artery Embolization|
214651629|NCT01348802|BEHAVIORAL|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
214651630|NCT01079767|DRUG|temsirolimus|
214651631|NCT01662648|DRUG|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
214651632|NCT00220220|DRUG|olmesartan medoxomil|
214651633|NCT00220220|DRUG|amlodipine|
214231209|NCT04248959|BEHAVIORAL|Multimodal prehabilitation|"Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital"
214231210|NCT04097587|BEHAVIORAL|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
214231211|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
214231212|NCT00469170|DEVICE|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
214231213|NCT04022733|DRUG|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
214231214|NCT04022733|DRUG|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
214231215|NCT05778383|DIETARY_SUPPLEMENT|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
214231216|NCT04371874|DRUG|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
214231217|NCT04673110|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
214231218|NCT06059131|OTHER|KeenMind|320 mg/d (2 capsules/d) during 3 months
214231219|NCT06059131|OTHER|Placebo|320 mg/d (2 capsules/d) during 3 months
214231220|NCT05290376|PROCEDURE|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
214231221|NCT05290376|DEVICE|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
214231222|NCT03844711|OTHER|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"* Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
214231223|NCT03844711|OTHER|Inspiratory Muscle Training (IMT)|\- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
214231224|NCT03844711|OTHER|Conventional physiotherapy|\- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
214231225|NCT05441878|DRUG|20% albumin|Albumin arm for resuscitation fluid
214231226|NCT05441878|DRUG|Balanced salt solution|Only Balanced salt solution will be used.
214231227|NCT00076375|DRUG|Nanocrystalline silver cream (NPI)|
214231228|NCT00576680|DRUG|RAD001|Given orally once a day
214231229|NCT00576680|DRUG|Temozolomide|Taken orally once a day for one week followed by a one-week break period
214231230|NCT02816164|DRUG|Neupogen|Subcutaneous injections
214231231|NCT03652623|DRUG|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
214651634|NCT06249750|DRUG|Immunotherapy|Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
214231232|NCT00708253|DEVICE|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
214231233|NCT00708253|DEVICE|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
214231234|NCT05405088|OTHER|Questionnaires|Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
214231235|NCT04483388|OTHER|Training with Virtual Reality|Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
214231236|NCT04483388|OTHER|Conventional Training|"It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training)."
214231237|NCT02423369|PROCEDURE|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
214231238|NCT02423369|OTHER|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
214231239|NCT02423369|OTHER|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
214231240|NCT02855541|DEVICE|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
214231241|NCT01417013|OTHER|Systane Ultra|Lubricant Eye Drops
214231242|NCT01417013|OTHER|Optive|Lubricant eye drops
214231243|NCT01389661|BIOLOGICAL|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
214231244|NCT00033267|DRUG|temsirolimus|Given IV
214231245|NCT00422513|DRUG|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
214231246|NCT00422513|DRUG|Epoetin alfa|As prescribed, iv, 3 times weekly
214231247|NCT00637949|DEVICE|lumiracoxib|400 mg once daily, oral over 6 weeks
214231248|NCT00637949|DRUG|rofecoxib|25 mg, oral, daily over 6 weeks
214231249|NCT02086006|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
214231250|NCT03135119|BEHAVIORAL|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
214231251|NCT03135119|BEHAVIORAL|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
214231252|NCT01160419|DRUG|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
214231253|NCT01160419|DRUG|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
214231254|NCT01160419|DRUG|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
214231255|NCT01160419|DRUG|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
214231256|NCT03878433|DRUG|Glisodin|500 mg/day between 12 weeks
214231257|NCT03878433|OTHER|placebo|Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
214231258|NCT01158170|RADIATION|Prophylactic cranial irradiation|25GY/10fraction
214231259|NCT01158170|DRUG|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
214231260|NCT06065085|OTHER|mobile education|"The study was conducted as a randomized controlled trial with 134 individuals with hypertension (68 experimental, 66 controlled) who applied a university hospital. The data were collected by Patient Information Form, Healthy Lifestyle Behaviour Scale II, EQ-5D General Quality of Life Scale, Mindful Attention Awareness Scale and Percieved Stress Scale were used. An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application."
214231261|NCT01541397|DRUG|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
214231262|NCT03920644|DRUG|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
214231263|NCT03920644|DRUG|Scopolamine|IND, up to 6 administration of intranasal gel.
214231264|NCT03920644|DRUG|Placebo Patch|Placebo Patch, 1 patch behind the ear.
214231265|NCT03920644|DRUG|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
214231266|NCT00313183|DRUG|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
214231267|NCT02249897|DRUG|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
214231268|NCT02267317|DRUG|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
214231269|NCT02267317|DRUG|D5W|5% Dextrose Water = Vehicle
214231270|NCT00807560|BEHAVIORAL|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
214231271|NCT00807560|BEHAVIORAL|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
214231272|NCT02292914|PROCEDURE|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
214231273|NCT02292914|PROCEDURE|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
214231274|NCT00004913|DRUG|cisplatin|
214231275|NCT00004913|DRUG|docetaxel|
214231276|NCT00004913|DRUG|fluorouracil|
214231277|NCT00004913|DRUG|leucovorin calcium|
214231278|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy with Splenectomy|
214231279|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
214231280|NCT04727489|GENETIC|DNA from subjects will be stored in the biobank of our study.|Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
214231281|NCT00036608|DRUG|Entecavir|
214231282|NCT00837317|DIETARY_SUPPLEMENT|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
214231283|NCT02931669|OTHER|Qualitative Descriptive Study|
214231284|NCT01606917|OTHER|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
214231285|NCT05829785|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
214231286|NCT05473650|DIAGNOSTIC_TEST|CBC.with with differential Peripheral smear|determine spectrum of hematological disorders in childern with pancytopenia
214231287|NCT01689532|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
214231288|NCT01689532|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
214231289|NCT01689532|DRUG|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
214231290|NCT01363349|DRUG|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
214231291|NCT01363349|DRUG|Risperidone|
214231292|NCT02720029|DEVICE|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
214231293|NCT06180187|DEVICE|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
214231294|NCT06180187|DEVICE|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
214231295|NCT04169932|BIOLOGICAL|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
214231296|NCT02269085|DRUG|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I."
214231297|NCT02269085|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I."
214231298|NCT02269085|BEHAVIORAL|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
214231299|NCT03506230|BEHAVIORAL|Incentives|A bonus to buy their medications if they reduce their HBA1c
214231300|NCT01697280|BEHAVIORAL|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
214231301|NCT01697280|OTHER|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
214231302|NCT01697280|OTHER|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
214231303|NCT02366364|DRUG|Placebo|Single oral administration of placebo consumption on Day 1
214231304|NCT02366364|DRUG|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
214231305|NCT02366364|DRUG|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
214231306|NCT02366364|DRUG|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
214231307|NCT00324298|BIOLOGICAL|bleomycin sulfate|
214231308|NCT00324298|DRUG|cisplatin|
214231309|NCT00324298|DRUG|etoposide|
214231310|NCT00324298|PROCEDURE|management of therapy complications|
214231311|NCT00710125|DRUG|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
214231312|NCT01209182|DEVICE|Testing a new device (LS BioPath TOUCH) on excised tissue|Measurements are obtained with test device on excised tissue.
214231313|NCT03002467|OTHER|PESI score|
214231314|NCT00233883|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
214231315|NCT00233883|DRUG|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
214231316|NCT03238170|DEVICE|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
214231317|NCT02445547|OTHER|UC-MSCs by peripheral intravenous infusion|
214231318|NCT02445547|DRUG|received hormone maintenance therapy|
214231319|NCT00300547|PROCEDURE|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
214231320|NCT02208063|DRUG|Telavancin|
214231321|NCT02208063|DRUG|Vancomycin|
214231322|NCT02208063|DRUG|Daptomycin|
214231323|NCT02208063|DRUG|Synthetic penicillin|
214231324|NCT02208063|DRUG|Cefazolin|
214231325|NCT00579384|DRUG|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
214231326|NCT00579384|DRUG|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
214231327|NCT01608022|DRUG|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
214231328|NCT05767567|BEHAVIORAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
214231329|NCT05952128|DRUG|Fluzoparib+ Dalpiciclib|"Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390"
214231330|NCT00275132|DRUG|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
214231331|NCT00275132|DRUG|Matched placebo|Matched placebo PO daily
214231332|NCT00913458|DRUG|etanercept|
214231333|NCT02882750|OTHER|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
214231334|NCT02882750|OTHER|PS Q18|Patients Satisfaction Questionnaire
214231335|NCT02882750|OTHER|Decision Self-Efficacy Scale|Questionnaire
214231336|NCT06530472|OTHER|Monitoring|At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
214231337|NCT02844062|BIOLOGICAL|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
214231338|NCT02844062|DRUG|cyclophosphamide|250 mg/m\^2 d1-3
214231339|NCT02844062|DRUG|Fludarabine|25mg/m\^2 d1-3
214231340|NCT04595994|DRUG|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
214231341|NCT05439785|DEVICE|Dental floss/Interdental brush|Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
214231342|NCT01260675|DRUG|Buprenorphine HCl/Naloxone HCl|
214231343|NCT03569345|DRUG|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
214231344|NCT02583217|DRUG|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
214231345|NCT02583217|DRUG|remifentanyl|
214231346|NCT02583217|DRUG|propofol|
214231347|NCT02583217|DEVICE|laryngeal mask|
214231348|NCT02279407|DRUG|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
214231349|NCT02279407|DRUG|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
214231350|NCT02279407|DRUG|Dapagliflozin|10 mg administered as 10 mg tablet
214231351|NCT02279407|DRUG|Placebo|Placebo matching to dapagliflozin 10 mg
214651635|NCT06249750|DRUG|Targeted therapy|Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
214231352|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
214231353|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
214231354|NCT03756493|PROCEDURE|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
214231355|NCT00766753|BIOLOGICAL|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
214231356|NCT00766753|BIOLOGICAL|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
214231357|NCT00766753|BIOLOGICAL|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
214231358|NCT00186953|DRUG|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
214231359|NCT04516395|OTHER|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
214231360|NCT04516395|OTHER|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
214231361|NCT03216434|DIAGNOSTIC_TEST|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
214231362|NCT02760225|DRUG|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
214231363|NCT02760225|DEVICE|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
214231364|NCT04043741|OTHER|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
214231365|NCT04043741|OTHER|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~\+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
214231366|NCT01671878|OTHER|Reference Glucose|
214231367|NCT01671878|OTHER|Test Food 1 (Cereal)|
214231368|NCT01671878|OTHER|Test Food 2 (Biscuit)|
214231369|NCT01191567|PROCEDURE|VAC treatment|wound treatment with VAC-therapy
214231370|NCT01191567|PROCEDURE|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
214231371|NCT02998632|PROCEDURE|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
214231372|NCT02998632|PROCEDURE|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
214231373|NCT04109508|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
214231374|NCT05482750|OTHER|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
214231375|NCT05482750|OTHER|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
214231376|NCT04228159|DEVICE|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
214231377|NCT04228159|OTHER|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
214231378|NCT06126250|DEVICE|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
214231379|NCT06126250|DEVICE|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
214231380|NCT01335022|BEHAVIORAL|lecture|6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
214231381|NCT01585519|DIETARY_SUPPLEMENT|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
214231382|NCT03084380|BIOLOGICAL|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
214231383|NCT03084380|DRUG|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
214231384|NCT03084380|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
214231385|NCT02672527|DRUG|Trabectedin|
214231386|NCT02672527|DRUG|Dexamethasone|
214231387|NCT01964768|OTHER|Skin prick-test|
214231388|NCT02061319|BEHAVIORAL|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
214231389|NCT04579887|OTHER|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
214231390|NCT01816945|BEHAVIORAL|MOMBA web-based application|Web-based, interactive, social network application.
214231391|NCT00401180|DRUG|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
214231392|NCT00401180|DRUG|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
214231393|NCT01488513|DRUG|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
214231394|NCT06530979|DEVICE|Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter|The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
214231395|NCT02618213|DEVICE|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
214231396|NCT02618213|DEVICE|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
214464720|NCT06801561|PROCEDURE|Laser therapy|This group will be subjected to laser therapy. Er,Cr:YSGG will be used (Waterlase®, Biolase, USA) of a wavelength of 2780 nm at a power of 0.75 W using a frequency of 20 Hz and pulse duration of 140 µs. (33) Irradiation will be performed on the entire occlusal and at the hypomineralized areas. (34) The laser tip will pass in a uniform scanning motion steadily for 20 sec with relative isolation with 11% air and no water-cooling system. During the laser treatment, all safety measures will be followed.
214231397|NCT05324644|BEHAVIORAL|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
214231398|NCT05747040|DIAGNOSTIC_TEST|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
214231399|NCT04062136|COMBINATION_PRODUCT|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
214231400|NCT01155011|BEHAVIORAL|Physical Activity|"MIPARC will focus on 3 physical activity goals:~1. increasing walking behavior through gradually increasing step goals~2. increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~3. reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
214231401|NCT01155011|BEHAVIORAL|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
214231402|NCT01155011|BEHAVIORAL|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~1. health check~2. step goal check~3. barrier identification~4. problem solving~5. specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
214231403|NCT01155011|BEHAVIORAL|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
214231404|NCT01155011|BEHAVIORAL|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
214231405|NCT01155011|BEHAVIORAL|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
214231406|NCT01155011|BEHAVIORAL|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
214231407|NCT01155011|BEHAVIORAL|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
214231408|NCT01155011|BEHAVIORAL|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
214231409|NCT01155011|BEHAVIORAL|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
214231410|NCT00852514|DEVICE|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
214231411|NCT05537870|BEHAVIORAL|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
214231412|NCT05537870|BEHAVIORAL|case manager care|case manager care (usual care)
214231413|NCT02407652|BEHAVIORAL|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
214231414|NCT02407652|BEHAVIORAL|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
214231415|NCT00622271|BEHAVIORAL|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
214231416|NCT02149849|PROCEDURE|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
214231417|NCT01302977|PROCEDURE|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
214231418|NCT02721953|DIETARY_SUPPLEMENT|Butyrate|Butyrate
214231419|NCT02721953|OTHER|Placebo|Placebo
214231420|NCT04369261|DRUG|Synovian®|Synovian® Inj.
214231421|NCT02156245|OTHER|conventional rehabilitation program (including concentric cycle ergometer)|
214231422|NCT02156245|OTHER|cycling included into a conventional rehabilitation program|
214231423|NCT01517360|DRUG|Oxytocin|Oxytocin 40 IU, intranasal inhalation
214231424|NCT01517360|OTHER|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
214231425|NCT01517360|BEHAVIORAL|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
214231426|NCT04380064|PROCEDURE|ILM Peeling|ILM peeling performed during primary PPV for PDR
214231427|NCT04380064|PROCEDURE|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
214231428|NCT00613912|OTHER|Magnetic Resonance Imaging|"* Morphological sequences~* Arterial Spin Labelling (Perfusion)~* Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
214231429|NCT00422084|DRUG|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
214231430|NCT00422084|DRUG|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
214231431|NCT04368078|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop"
214231432|NCT03741387|OTHER|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
214231433|NCT03741387|OTHER|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
214231434|NCT00940472|DRUG|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
214231435|NCT00940472|DRUG|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
214231436|NCT05184010|DEVICE|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
214231437|NCT05184010|DEVICE|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
214231438|NCT04982003|OTHER|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
214231439|NCT05563155|DRUG|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
214231440|NCT05563155|DRUG|Placebo|Placebo tablet given on day 1 after surgery.
214231441|NCT03670420|OTHER|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
214231442|NCT06356428|OTHER|Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)|The PACRR comprises 20 items and 1 open ended item to assess physicians' attitudes and beliefs about CR and referral (includes instructions for scale completion to respondents). Response options were 1 = strongly disagree, 2 = agree, 3 = neutral, 4 = agree, and 5 = strongly agree. Five (5) items are reverse-scored to mitigate acquiescence bias (denoted with \*), such that higher scores reflect more positive atti- tudes toward CR and referral. A mean score is computed for the total (where at least 80% of items were completed; i.e., 15/19) scale and subscales.
214231443|NCT00146484|DRUG|Twice Daily versus Three Times Daily Insulin Injections|
214231444|NCT00915499|DEVICE|VPAP Adapt SV|Comparison of ASV and CPAP modes
214231445|NCT01944280|OTHER|massage|
214231446|NCT06049901|DRUG|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
214231447|NCT03774823|DEVICE|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
214231448|NCT03774823|DEVICE|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
214231449|NCT04571528|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
214231450|NCT04571528|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
214231451|NCT04571528|BEHAVIORAL|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
214231452|NCT02827656|DRUG|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
214231453|NCT02827656|DRUG|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
214231454|NCT01429909|DEVICE|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.
214231455|NCT00958438|DRUG|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
214231456|NCT00958438|DRUG|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
214231457|NCT00958438|DRUG|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
214231458|NCT04618510|DEVICE|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
214231459|NCT04618510|DEVICE|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
214231460|NCT00759564|DRUG|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
214231461|NCT05948865|DRUG|CPO301|Administered by intravenous injection
214231462|NCT04813003|OTHER|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
214231463|NCT01931215|OTHER|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
214231464|NCT01931215|OTHER|TAP-block with ropivacaine and clonidine|
214231465|NCT03550521|BEHAVIORAL|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
214231466|NCT01410344|DRUG|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
214231467|NCT01410344|DRUG|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
214231468|NCT01410344|DRUG|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
214231469|NCT01410344|DRUG|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
214231470|NCT02872506|DRUG|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
214231471|NCT02872506|PROCEDURE|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
214231472|NCT02788279|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
214231473|NCT02788279|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
214231474|NCT02788279|DRUG|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
214231476|NCT00386542|BIOLOGICAL|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
214231477|NCT00386542|DEVICE|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
214231478|NCT04801264|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
214231479|NCT04801264|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
214231480|NCT05451485|DIAGNOSTIC_TEST|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
214231481|NCT05451485|DIAGNOSTIC_TEST|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
214231482|NCT05451485|DIAGNOSTIC_TEST|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
214231483|NCT05451485|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
214231484|NCT05908006|DEVICE|Velacur|Imaging Procedures Comparison
214231485|NCT01599364|DRUG|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
214231486|NCT06212258|PROCEDURE|Abdominal Laparascopy|pneumoperitoneum
214231487|NCT03176017|PROCEDURE|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
214231488|NCT03176017|PROCEDURE|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
214231489|NCT05414734|DRUG|HHT120|Capsule, oral administration
214231490|NCT05414734|DRUG|Placebo|Capsule, oral administration
214231491|NCT01529775|DEVICE|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
214231492|NCT01529775|DEVICE|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
214231493|NCT03257709|PROCEDURE|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
214231494|NCT03257709|PROCEDURE|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
214231495|NCT03697135|BEHAVIORAL|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
214231496|NCT00737399|BEHAVIORAL|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
214231497|NCT02678494|OTHER|Neurofeedback training|
214231498|NCT03708887|DRUG|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
214231499|NCT03708887|DRUG|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
214231500|NCT03708887|DRUG|Control drug|Matching placebo capsules,3 g/d by mouth for 1 year
214231501|NCT01062178|DRUG|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
214231502|NCT05647278|DRUG|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
214231503|NCT05647278|DRUG|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
214231504|NCT00329849|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
214231505|NCT00329849|BIOLOGICAL|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
214231506|NCT03996369|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
214231507|NCT03996369|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
214231508|NCT05845697|OTHER|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
214231509|NCT05845697|OTHER|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
214231510|NCT04286997|DEVICE|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
214231511|NCT00349700|PROCEDURE|Compression: 2 weeks four layer bandages, then stockings|
214231512|NCT00349700|PROCEDURE|debridement|
214231513|NCT00349700|PROCEDURE|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
214231514|NCT02734901|DIETARY_SUPPLEMENT|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
214231515|NCT02734901|DIETARY_SUPPLEMENT|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
214231516|NCT02734901|DIETARY_SUPPLEMENT|Placebo|1x daily intake of 600 mL raspberry deprived supplement
214231517|NCT04751214|PROCEDURE|APPENDICECTOMY|
214231518|NCT02710162|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
214231519|NCT02710162|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
214231520|NCT02710162|DEVICE|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
214231521|NCT02710162|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
214231522|NCT02710162|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
214231523|NCT02710162|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
214231524|NCT02710162|OTHER|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
214231525|NCT02710162|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
214231526|NCT02710162|OTHER|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
214231527|NCT02710162|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
214231528|NCT02710162|OTHER|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
214231529|NCT02710162|OTHER|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
214231530|NCT03905252|OTHER|sample analysis|blood, Random urine sample and 24-hour urine samples
214231531|NCT00477516|PROCEDURE|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
214231532|NCT00445237|DEVICE|H1 and H2 deep TMS coils|
214231533|NCT00848562|DRUG|Nicorandil|Oral administration of nicorandil (15 mg/day)
214231534|NCT00005862|DRUG|semaxanib|
214231535|NCT00493857|DRUG|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
214231536|NCT00493857|DRUG|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
214231537|NCT04187287|OTHER|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
214231538|NCT04187287|OTHER|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
214231539|NCT04086498|OTHER|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
214231540|NCT04086498|OTHER|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
214231541|NCT04086498|OTHER|KD|The group received a plan for a low carbohydrate ketogenic diet
214231542|NCT00794898|BIOLOGICAL|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
214231543|NCT05062954|DIETARY_SUPPLEMENT|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
214231544|NCT05062954|DIETARY_SUPPLEMENT|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
214231545|NCT00793273|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
214231546|NCT04685174|DEVICE|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
214231547|NCT03391193|BIOLOGICAL|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
214231548|NCT03391193|BIOLOGICAL|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
214231549|NCT01757145|DRUG|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again)."
214231550|NCT03489746|OTHER|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
214231551|NCT03489746|OTHER|Standard care|Normal clinically indicated inhaled therapy
214231552|NCT04869501|DRUG|TJ004309|Antibody to CD73
214231553|NCT04869501|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
214231554|NCT03294577|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
214231555|NCT03294577|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
214231556|NCT03294577|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
214231557|NCT03294577|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
214231558|NCT02402725|DRUG|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
214231559|NCT00203814|DRUG|Sulfadoxine-pyrimethamine|
214231560|NCT00203814|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
214231561|NCT02238067|DRUG|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
214231562|NCT02238067|OTHER|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
214231563|NCT02942940|DEVICE|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
214231564|NCT02942940|OTHER|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
214231565|NCT05185011|DRUG|TPN171H|10 mg TPN171H tablets，single dose
214231566|NCT04653467|DRUG|GLPG4399 oral suspension|GLPG4399 for oral administration
214231567|NCT04653467|DRUG|GLPG4399 capsules|GLPG4399 for oral administration
214231568|NCT04653467|DRUG|Placebo|Placebo oral suspension
214231569|NCT00329446|DRUG|Quetiapine Fumarate|
214231570|NCT00329446|DRUG|Escitalopram oxylate|
214231571|NCT01566214|BEHAVIORAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
214231572|NCT02914028|PROCEDURE|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
214231573|NCT02914028|DRUG|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
214231574|NCT04821362|DEVICE|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
214231575|NCT04821362|DEVICE|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
214231576|NCT00781352|DRUG|nitrous oxide|65% nitrous oxide administered during surgery
214231577|NCT00781352|DRUG|nitrogen|Nitrogen administration during surgery
214231578|NCT01740505|BEHAVIORAL|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
214231579|NCT01740505|BEHAVIORAL|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
214231580|NCT01740505|BEHAVIORAL|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
214231589|NCT03761862|PROCEDURE|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
214231590|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
214231591|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
214231592|NCT02968537|BEHAVIORAL|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
214231593|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
214231594|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
214231595|NCT02968537|BEHAVIORAL|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
214231596|NCT00832624|DRUG|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
214231597|NCT06044701|OTHER|Hologram Distraction Technique|Hologram fan application during blood collection process
214231598|NCT06044701|OTHER|Bubble Machine Distraction Technique|Bubble machine application during blood collection
214231599|NCT04802122|DRUG|Sevoflurane inhalant product|Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
214231600|NCT04802122|DRUG|Propofol Fresenius|Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
214231601|NCT06234241|OTHER|Echocardiography|Echocardiography was performed in all enrolled populations.
214231602|NCT03614208|BEHAVIORAL|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
214231603|NCT03113890|GENETIC|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
214231604|NCT03113890|GENETIC|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
214231605|NCT03113890|OTHER|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
214231606|NCT02395172|DRUG|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
214231607|NCT02395172|DRUG|Docetaxel|Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
214231608|NCT02980913|DEVICE|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
214231609|NCT02980913|DEVICE|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
214231610|NCT00717236|DRUG|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
214651636|NCT06249750|DEVICE|Hyperthermia|"Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h."
214231611|NCT00717236|OTHER|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
214231612|NCT00194870|PROCEDURE|EEG|computer-assisted analysis of the digitally-recorded EEG signals
214231613|NCT00572754|PROCEDURE|Circumcision|Circumcision by tying a ligature around the foreskin.
214231614|NCT00475982|BEHAVIORAL|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
214231615|NCT00475982|OTHER|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
214231616|NCT02366884|DRUG|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
214231617|NCT02366884|DRUG|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
214231618|NCT02366884|DRUG|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
214231619|NCT01651962|DRUG|Terbutaline|
214231620|NCT01651962|DRUG|Fentanyl|
214231621|NCT01651962|DRUG|0.9% NaCl|
214231622|NCT02778113|DRUG|Nasal Glucagon|Administered intranasally.
214231623|NCT02778113|DRUG|Glucagon|Administered SC.
214231624|NCT00783198|BIOLOGICAL|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
214231625|NCT00783198|BIOLOGICAL|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
214231626|NCT00783198|BIOLOGICAL|Placebo|matching placebo sublingual tablets administered once daily
214231627|NCT06332872|DRUG|Oral Ivermectin|Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart
214231628|NCT06332872|DRUG|4% dimenticone liquid gel|topical formulation (liquid gel) only 1 application
214231629|NCT01318824|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
214231630|NCT01318824|PROCEDURE|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
214231631|NCT05716672|DRUG|Lazertinib|Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
214231632|NCT01629446|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
214231633|NCT00870376|OTHER|biomarkers|To define a biomarker or combination of overactive bladder syndrome
214231634|NCT01054833|PROCEDURE|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
214231635|NCT00946985|DRUG|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
214231636|NCT00946985|DRUG|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
214231637|NCT03268655|DIETARY_SUPPLEMENT|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
214231638|NCT03268655|OTHER|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
214231639|NCT04335305|DRUG|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
214231640|NCT04335305|BIOLOGICAL|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
214231641|NCT04832269|OTHER|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
214231642|NCT00523445|DRUG|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
214231643|NCT00523445|DRUG|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
214231644|NCT06394934|BEHAVIORAL|Healthscan App|Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
214231645|NCT03868527|OTHER|Data collection|Data collection for biostatistical analysis about hematological diseases
214231646|NCT05636800|DEVICE|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
214231647|NCT00166556|DRUG|Campath-1H and Tacrolimus|
214231648|NCT01037894|PROCEDURE|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
214231649|NCT01037894|PROCEDURE|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
214231650|NCT02956590|DRUG|Pitavastatin|Statin
214231651|NCT02956590|DRUG|Placebo|Placebo
214231652|NCT00926315|DRUG|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
214231653|NCT00926315|DRUG|Calcitriol|calcitriol 0.25 mcg PO bid
214231654|NCT03919097|OTHER|Medical Data extraction|Data extraction from the patient's Medical Files
214231655|NCT02919358|OTHER|Music|
214231656|NCT02919358|OTHER|No music.|This is the control group.
214231657|NCT04683601|OTHER|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
214231658|NCT00554281|DEVICE|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
214231659|NCT02766140|DRUG|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
214231660|NCT02766140|DRUG|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
214231661|NCT02585336|BEHAVIORAL|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
214231662|NCT01771341|DEVICE|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
214231663|NCT01771341|DEVICE|MAQUET SERVOi ventilator|Pressure Support
214231664|NCT04345367|DRUG|Abrocitinib 200 mg|Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
214231665|NCT04345367|COMBINATION_PRODUCT|Dupilumab 300 mg|Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
214231666|NCT00852371|DRUG|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
214231667|NCT00852371|DRUG|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
214231668|NCT00852371|DRUG|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
214231669|NCT00852371|OTHER|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
214231670|NCT00892801|DRUG|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
214231671|NCT00892801|RADIATION|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
214231672|NCT05282303|PROCEDURE|CABG operation|Efficacy of regional analgesia techniques in coronary artery bypass operations
214231673|NCT00796523|BEHAVIORAL|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
214231674|NCT00796523|BEHAVIORAL|control videotape|a videotape with general newborn care instructions
214231675|NCT04525885|DRUG|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
214231676|NCT04525885|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
214231677|NCT04525885|DRUG|Placebo|Placebo tablet administered orally BID
214231678|NCT04525885|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
214231679|NCT02252744|OTHER|No intervention|
214231680|NCT04707859|DIAGNOSTIC_TEST|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
214231681|NCT05912790|DEVICE|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
214231682|NCT01779791|DRUG|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
214231683|NCT05141877|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
214231684|NCT05141877|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
214231685|NCT02527577|DRUG|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
214231686|NCT02527577|DRUG|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
214231687|NCT00645437|DRUG|Levofloxacin|
214231688|NCT00947960|DRUG|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
214231689|NCT00947960|OTHER|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
214231690|NCT04586842|BEHAVIORAL|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
214231691|NCT04586842|BEHAVIORAL|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
214231692|NCT06427135|BEHAVIORAL|Exercise interventions|Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
214231693|NCT00168129|PROCEDURE|Helical tomotherapy|
214231694|NCT00637988|DRUG|Esomeprazole|40mg twice daily
214231695|NCT00637988|DRUG|Aspirin|
214231696|NCT00637988|DRUG|Rofecoxib|25mg once daily
214231697|NCT05650918|BIOLOGICAL|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
214231698|NCT05650918|BIOLOGICAL|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
214231699|NCT00571168|DRUG|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
214231700|NCT00571168|DRUG|Placebo|Placebo capsules on day 1-4
214231701|NCT02537288|DRUG|Fedovapagon|
214231702|NCT02537288|DRUG|Moxifloxacin|
214231703|NCT02537288|DRUG|Placebo (for fedovapagon)|
214231704|NCT04665869|BEHAVIORAL|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
214231705|NCT04665869|BEHAVIORAL|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
214231706|NCT03083444|DIAGNOSTIC_TEST|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
214231707|NCT05033405|BEHAVIORAL|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
214231708|NCT00677989|PROCEDURE|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
214231709|NCT00677989|PROCEDURE|Open appendectomy|open appendectomy: did appendectomy by laparotomy
214231710|NCT01612923|OTHER|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
214231711|NCT03208985|DRUG|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
214231712|NCT05363306|PROCEDURE|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
214231713|NCT00183417|BEHAVIORAL|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
214231714|NCT00183417|BEHAVIORAL|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
214231715|NCT00183417|BEHAVIORAL|Bibliotherapy|Participants will be given a book on how to increase their mood.
214231716|NCT01613170|DRUG|Toviaz|Toviaz 4mg daily
214231717|NCT01613170|DRUG|Premarin|Premarin cream 1 g per vagina twice weekly
214231718|NCT01613170|DRUG|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
214231719|NCT00753740|DRUG|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
214231720|NCT00753740|DRUG|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
214231721|NCT00753740|DRUG|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
214231722|NCT06471387|BEHAVIORAL|Flexiquit Smoking Cessation Intervention|Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
214231723|NCT00273533|DRUG|Ramipril|
214231724|NCT03027882|OTHER|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
214231725|NCT02968056|PROCEDURE|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
214231726|NCT03288233|DIAGNOSTIC_TEST|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
214231727|NCT01374100|BEHAVIORAL|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
214231728|NCT01374100|BEHAVIORAL|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
214231729|NCT04667884|DIETARY_SUPPLEMENT|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
214651637|NCT05394415|DRUG|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
214651638|NCT05394415|DRUG|Paclitaxel|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
214231730|NCT00496938|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
214231731|NCT02984930|DRUG|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
214231732|NCT02984930|DRUG|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
214231733|NCT02984930|PROCEDURE|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
214231734|NCT02453672|BIOLOGICAL|SB8|SB8, proposed bevacizumab biosimilar
214231735|NCT02453672|BIOLOGICAL|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
214231736|NCT02453672|BIOLOGICAL|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
214231737|NCT00170534|BEHAVIORAL|Behavior|
214231738|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
214231739|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
214231740|NCT04838080|BIOLOGICAL|Placebo|Two applications on Days 0 and 21
214231741|NCT05777291|DEVICE|Activity watch monitoring|Patients will be using activity devices during the study period
214231742|NCT05777291|DEVICE|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
214231743|NCT05777291|BEHAVIORAL|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
214231744|NCT00978757|DRUG|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
214231745|NCT00978757|OTHER|Placebo|saline solution
214231746|NCT04034667|OTHER|No intervention|No intervention
214231747|NCT01687725|DEVICE|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
214231748|NCT03586570|DRUG|Aprocitentan 25mg|Oral tablets in strength of 25 mg
214231749|NCT03586570|DRUG|Placebo|Oral tablets matching aprocitentan tablets
214231750|NCT05167006|OTHER|routine physical therapy|Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation. Consisting of many purposeful kinesthetic activities such as Graded pinch exercise, Bimanual placing cone, Arm bicycling, Shoulder curved arch, Double-curved arch, Block-stacking, Skateboard-supported arm sliding exercises on a tabletop, Putty kneading, Pegboard exercise, Picking up a ball and putting it into a basket, Plastic cone stacking. Therapists can offer passive, active-assistive, or active training, as deemed appropriate to the patient's ability
214231751|NCT05167006|OTHER|Perfetti's method|. Only one participant per therapist, with or without caregiver observation. Participant will be blindfolded during the exercises and asked to focus on sensing the position of the limb. The therapist will passively move the shoulder, elbow, wrist, or fing
214231752|NCT00093249|DRUG|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
214231753|NCT00093249|DRUG|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
214231754|NCT01039103|DRUG|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
214231755|NCT01039103|DRUG|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
214231756|NCT03989505|DIAGNOSTIC_TEST|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
214651639|NCT05394415|DRUG|Carboplatin|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
214231757|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
214231758|NCT02559492|DRUG|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
214231759|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
214231760|NCT02559492|DRUG|INCB050465|INCB050465 tablets will be administered orally once daily.
214231761|NCT01700387|DRUG|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
214231762|NCT01700387|DRUG|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
214231763|NCT01700387|DRUG|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
214231764|NCT01158001|BEHAVIORAL|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
214231765|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
214231766|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
214231767|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
214231768|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
214231769|NCT02974699|DIETARY_SUPPLEMENT|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
214231770|NCT02974699|DIETARY_SUPPLEMENT|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
214231771|NCT00895102|DRUG|ABT-333 Tablet|See Arm Description for more information.
214231772|NCT00895102|DRUG|Placebo|See Arm Description for more information.
214231773|NCT00895102|DRUG|ABT-333 Capsule|See arm description for more information
214231774|NCT00266786|DRUG|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
214231775|NCT00266786|DRUG|Intranasal Placebo|Intranasal Placebo
214231776|NCT02683590|DEVICE|Ceramic Implant|The replacement of the sternum by a ceramic implant
214231777|NCT05519592|DRUG|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
214231778|NCT05519592|DRUG|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
214231779|NCT05742308|BEHAVIORAL|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
214231780|NCT02551042|DRUG|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
214231781|NCT02551042|DRUG|0.9% sodium chloride|IV infusion
214231782|NCT05614856|DEVICE|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
214231783|NCT00685009|DRUG|Estrogen hormone therapy|Estrogen pill daily
214231784|NCT00685009|DRUG|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
214231785|NCT00685009|DRUG|Placebo|Placebo pill daily
214231786|NCT00182481|PROCEDURE|Induced sputum cell counts|
214231787|NCT00182481|DRUG|inhaled corticosteroids and other asthma drugs|
214231788|NCT05620121|PROCEDURE|Surgery for Incisional hernias|Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
214231789|NCT02459288|DRUG|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
214231790|NCT02459288|DRUG|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
214231791|NCT04387240|DRUG|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
214231792|NCT04387240|OTHER|placebo|placebo or sham drug will be given to the second arm
214231793|NCT00708487|OTHER|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
214231794|NCT02863536|DEVICE|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
214231795|NCT03603678|DRUG|BAY2253651|100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
214231796|NCT03603678|DRUG|Placebo|Matching Placebo dosing
214231797|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
214231798|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
214231799|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
214231800|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
214231801|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
214231802|NCT01031836|DRUG|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
214231803|NCT00137878|DRUG|TNFerade™|
214231804|NCT02602756|RADIATION|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
214231805|NCT05560308|DRUG|Trastuzumab Emtansine for Injection|3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
214231806|NCT05560308|DRUG|Pyrotinib Maleate Tablets|The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
214231807|NCT05055284|OTHER|Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.|Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
214231808|NCT05569460|OTHER|No intervention|No intervention
214231809|NCT01103024|BIOLOGICAL|AIN457|
214231810|NCT01103024|BIOLOGICAL|AIN457|
214231811|NCT01103024|BIOLOGICAL|AIN457|
214231812|NCT01103024|BIOLOGICAL|Placebo|
214231813|NCT04679415|DRUG|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
214231814|NCT04679415|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
214231815|NCT03137069|DRUG|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
214231816|NCT03137069|DRUG|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
214231817|NCT03730402|DRUG|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
214231818|NCT03730402|DRUG|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
214231819|NCT03730402|DRUG|Saline|placebo injection of saline
214231820|NCT04835675|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
214231821|NCT02908542|GENETIC|genetic analysis with massively parallel sequencing|
214231822|NCT03225859|BEHAVIORAL|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
214231823|NCT06315790|DRUG|Botulinum toxin A|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
214231824|NCT06315790|OTHER|Isotonic saline|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
214231825|NCT03876392|DIAGNOSTIC_TEST|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
214231826|NCT00038389|DRUG|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
214231827|NCT00336830|BEHAVIORAL|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
214231828|NCT00336830|BEHAVIORAL|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
214231829|NCT01788410|PROCEDURE|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
214231830|NCT01788410|DEVICE|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
214231831|NCT04740645|OTHER|NOCDURNA Cohort|Non intervention
214231832|NCT04740645|OTHER|LUTS Cohort|Non intervention
214231833|NCT02043899|DRUG|[124I]meta-Iodobenzylguanidine|Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
214231834|NCT03633240|OTHER|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
214231835|NCT03196609|BIOLOGICAL|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
214231836|NCT02108340|PROCEDURE|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
214231837|NCT06242353|DIAGNOSTIC_TEST|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
214231838|NCT01954927|DRUG|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
214231839|NCT01954927|DRUG|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
214231840|NCT03320824|DEVICE|New Dermal Filler|hyaluronic acid
214231841|NCT03320824|DEVICE|Device: FDA Approved Dermal Filler|hyaluronic acid
214231842|NCT00955305|BIOLOGICAL|Bevacizumab|Given IV
214231843|NCT00955305|DRUG|Carboplatin|Given IV
214231844|NCT00955305|BIOLOGICAL|Cixutumumab|Given IV
214231845|NCT00955305|DRUG|Paclitaxel|Given IV
214231846|NCT00491088|DEVICE|CPAP|CPAP for 12 weeks
214231847|NCT02270996|OTHER|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
214231848|NCT02606942|OTHER|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
214231849|NCT03387111|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
214231850|NCT03387111|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214231851|NCT03387111|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
214231852|NCT03387111|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214231853|NCT03387111|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
214231854|NCT03387111|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
214231855|NCT03387111|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
214231856|NCT03387111|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
214231857|NCT03387111|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
214231858|NCT03387111|DRUG|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
214231859|NCT03387111|DRUG|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
214231860|NCT03387111|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214231861|NCT03387111|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
214231862|NCT03387111|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
214231863|NCT03387111|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214231864|NCT03387111|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214231865|NCT03387111|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214231866|NCT03387111|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214231867|NCT03387111|DRUG|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
214231868|NCT03387111|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214231869|NCT03387111|BIOLOGICAL|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
214231870|NCT01180179|DRUG|Lansoprazole|30mg once daily
214231871|NCT01180179|DRUG|Famotidine|40mg once daily
214231872|NCT00594945|DRUG|Clonazepam|1 Dose
214231873|NCT00813540|BEHAVIORAL|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
214231874|NCT00813540|OTHER|Usual Care|Usual Care
214231875|NCT02108015|PROCEDURE|Brain Imaging (PET)|
214231876|NCT02108015|PROCEDURE|Aterial Line|
214231877|NCT02108015|PROCEDURE|Blood Sampling|
214231878|NCT00588159|DRUG|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
214231879|NCT00588159|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
214231880|NCT05909800|DRUG|Phenofibrate|Administred orally, once daily, for 12 months.
214231881|NCT05909800|DRUG|Placebo|Administred orally, once daily, for 12 months.
214231882|NCT03800394|OTHER|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
214231883|NCT02610504|DEVICE|Durolane|single injection of 3ml
214231884|NCT02735824|PROCEDURE|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
214231885|NCT02735824|PROCEDURE|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
214231886|NCT02735824|PROCEDURE|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
214231887|NCT03219710|DRUG|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
214231888|NCT03219710|DRUG|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
214231889|NCT03219710|DRUG|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
214231890|NCT03219710|DRUG|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
214231891|NCT00894959|BIOLOGICAL|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
214231892|NCT00894959|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
214231893|NCT00995033|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
214231894|NCT00995033|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
214231895|NCT00995033|DRUG|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
214231896|NCT02438358|DRUG|LUM015|
214231897|NCT02438358|DEVICE|LUM 2.6 Imaging Device|
214231898|NCT01801371|DRUG|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
214231899|NCT03698344|OTHER|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
214231900|NCT00949494|DEVICE|Synvisc|intra-articular, 3 weekly injections
214231901|NCT02856191|OTHER|Holter|
214231902|NCT06141356|DRUG|[18F]Florbetazine ([18F]92)|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
214231903|NCT06141356|DRUG|[11C]PIB|Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
214231904|NCT01335802|GENETIC||Genetic counseling
214231905|NCT01325337|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214231906|NCT01325337|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214231907|NCT01325337|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214231908|NCT01325337|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214231909|NCT01325337|DRUG|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
214231910|NCT04415242|OTHER|positioning|different positioning prior surgery
214231911|NCT04048733|DEVICE|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
214231912|NCT00362180|DRUG|mipomersen|200 mg subcutaneous injections
214231913|NCT00362180|DRUG|Placebo|subcutaneous injections
214231914|NCT03469869|OTHER|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
214231915|NCT02230969|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
214231916|NCT00107484|DRUG|ferumoxtran-10|
214231917|NCT00107484|PROCEDURE|magnetic resonance imaging|
214231918|NCT00107484|PROCEDURE|sentinel lymph node biopsy|
214231919|NCT00481975|DRUG|rimonabant (SR141716)|
214231920|NCT02006095|OTHER|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
214231921|NCT02006095|BEHAVIORAL|Neuropsychological testing|
214231922|NCT04195191|OTHER|ANM|communication intervention
214231923|NCT04195191|OTHER|Placebo|regular assistance in community pharmacies
214231924|NCT03483922|DIAGNOSTIC_TEST|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
214231925|NCT03246997|OTHER|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
214231926|NCT03246997|OTHER|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
214231927|NCT01237483|DRUG|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
214231928|NCT03930264|DRUG|Azathioprine 50Mg Tab|tablet
214231929|NCT03930264|DRUG|Azathioprine 10mg/mL oral suspension|oral suspension
214231930|NCT04441190|BEHAVIORAL|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
214231931|NCT04441190|BEHAVIORAL|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
214231932|NCT04441190|BEHAVIORAL|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
214231933|NCT04320641|OTHER|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
214231934|NCT04774211|DIAGNOSTIC_TEST|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
214231935|NCT01737229|DEVICE|Application of Biodentine™ (RD94), dentin substitute|
214231936|NCT05056428|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
214231937|NCT05128422|OTHER|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
214231938|NCT01007630|DRUG|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
214231939|NCT01007630|DRUG|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
214231940|NCT00307320|BEHAVIORAL|Relaxation Training|Relaxation techniques training
214231941|NCT02434471|DEVICE|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
214231942|NCT04451213|DIAGNOSTIC_TEST|MRI head|MRI head
214231943|NCT04625296|BEHAVIORAL|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
214231944|NCT04625296|BEHAVIORAL|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
214231945|NCT03667898|PROCEDURE|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
214231946|NCT03667898|PROCEDURE|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
214231947|NCT02575547|DRUG|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
214231948|NCT03663556|OTHER|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
214231949|NCT01696162|OTHER|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
214231950|NCT01696162|OTHER|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
214231951|NCT01696162|OTHER|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
214231952|NCT00439049|DRUG|modafinil|400 mg daily
214231953|NCT00439049|DRUG|d-amphetamine|60mg daily
214231954|NCT00439049|DRUG|L-Dopa|800/200mg daily
214231955|NCT00439049|DRUG|Naltrexone|50mg daily
214231956|NCT02811627|DRUG|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
214231957|NCT02811627|DEVICE|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
214231958|NCT02110602|OTHER|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
214231959|NCT02110602|OTHER|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
214231960|NCT00920010|OTHER|biologic sample preservation procedure|
214231961|NCT00720447|BIOLOGICAL|alemtuzumab|
214231962|NCT00720447|BIOLOGICAL|donor lymphocytes|
214231963|NCT00720447|DRUG|carmustine|
214231964|NCT00720447|DRUG|cytarabine|
214231965|NCT00720447|DRUG|etoposide|
214231966|NCT00720447|DRUG|melphalan|
214231967|NCT00720447|PROCEDURE|allogeneic bone marrow transplantation|
214231968|NCT00720447|PROCEDURE|peripheral blood stem cell transplantation|
214231969|NCT00369629|DRUG|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
214231970|NCT00369629|DRUG|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
214231971|NCT00855270|DRUG|Placebo|IV saline will be used as placebo for control
214231972|NCT00855270|DRUG|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
214231973|NCT06086262|DEVICE|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
214231974|NCT04193696|DRUG|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
214231975|NCT01436617|OTHER|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
214231976|NCT00874939|DRUG|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
214231977|NCT00874939|DRUG|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
214231978|NCT00874939|DRUG|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
214231979|NCT00874939|DRUG|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
214231980|NCT00874939|DRUG|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
214231981|NCT03560700|DIETARY_SUPPLEMENT|lactobacillus probiotic strain|Approved Dietary supplement
214651640|NCT05394415|RADIATION|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
214651641|NCT02928952|BEHAVIORAL|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
214231982|NCT03560700|OTHER|placebo|placebo comparator
214231983|NCT02204124|DEVICE|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
214231984|NCT02204124|DEVICE|Standard of care scissors, ligatures, clips, and sutures|
214231985|NCT02452788|OTHER|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
214231986|NCT01250496|DRUG|Aminophylline|75 mg of intravenous aminophylline
214231987|NCT01250496|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
214231988|NCT04495205|BIOLOGICAL|PRF under non-eugenol containing periodontal pack|Platelet Rich Fibrin under non-eugenol containing periodontal pack
214231989|NCT04495205|OTHER|Non-eugenol containing periodontal pack|Non-eugenol containing periodontal pack after gingival depigmentation
214231990|NCT03249662|PROCEDURE|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
214231991|NCT03249662|DRUG|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
214231992|NCT03011944|OTHER|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
214231993|NCT03886545|OTHER|Assessment of physical and functional capacities|Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
214231994|NCT01180218|PROCEDURE|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
214231995|NCT01180218|PROCEDURE|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
214231996|NCT04620213|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
214231997|NCT04620213|OTHER|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
214231998|NCT05014061|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
214231999|NCT05006300|OTHER|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
214232000|NCT00883688|DRUG|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
214232001|NCT00883688|DRUG|Lapatinib|Pills of 700 mg/m\^2/dose given orally 2 times each day.
214232002|NCT05278351|DRUG|Tislelizumab Combined With Cetuximab and Irinotecan|Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan
214232003|NCT05278351|DRUG|Third-line regimens|Trifluridinetipiracil or Regorafenib or Fruquintinib
214232004|NCT01656356|BIOLOGICAL|Avian Flu Vaccine|
214232005|NCT01656356|BIOLOGICAL|Placebo|
214232006|NCT00205270|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
214232007|NCT04732013|OTHER|No clinical intervention is planned; study is observational|No intervention
214232008|NCT02395432|DEVICE|orotracheal intubation|
214232009|NCT04610957|DRUG|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
214232010|NCT03071757|DRUG|ABBV-368|Intravenous infusion
214232011|NCT03071757|DRUG|ABBV-181|Intravenous infusion
214232012|NCT03532607|OTHER|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
214232013|NCT06224751|DIAGNOSTIC_TEST|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
214232014|NCT06224751|DIAGNOSTIC_TEST|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
214232015|NCT06224751|DIAGNOSTIC_TEST|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
214232016|NCT06224751|DIAGNOSTIC_TEST|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
214232017|NCT06224751|DIAGNOSTIC_TEST|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
214232018|NCT06224751|DIAGNOSTIC_TEST|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
214232019|NCT06224751|DIAGNOSTIC_TEST|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
214232020|NCT02907840|DEVICE|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
214232021|NCT03495583|OTHER|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
214232022|NCT03852680|PROCEDURE|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
214232023|NCT02382484|DEVICE|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
214651642|NCT05655585|OTHER|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
214232024|NCT02926521|DEVICE|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
214232025|NCT02926521|DEVICE|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
214232026|NCT05342038|DEVICE|T-02|Stent retriever
214232027|NCT03707028|DRUG|Rivoceranib|Film-coated tablet
214232028|NCT03707028|DRUG|Paclitaxel|Solution administered intravenously
214232029|NCT02211911|DRUG|Bisacodyl|
214232030|NCT02211911|DRUG|Sodium picosulfate|
214232031|NCT00732836|DRUG|HAI Abraxane|Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
214232032|NCT00732836|PROCEDURE|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
214232033|NCT00732836|DRUG|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
214232034|NCT01964040|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
214232035|NCT01075633|PROCEDURE|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
214232036|NCT01075633|PROCEDURE|Colonoscopy with sedation|Colonoscopy with sedation
214232037|NCT03466593|OTHER|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
214232038|NCT03466593|OTHER|Routine care|Preoperative information
214232039|NCT03466593|OTHER|Extra early mobilization|Mobilization the day of surgery
214232040|NCT03466593|OTHER|Standard mobilization|Mobilization the day after surgery
214232041|NCT00918931|DRUG|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
214232042|NCT00659347|DRUG|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
214232043|NCT00659347|DRUG|Placebo|Capsules,25 mg,BID,6weeks
214232044|NCT00318942|DRUG|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
214232045|NCT00318942|DRUG|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
214232046|NCT00318942|DRUG|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
214232047|NCT00318942|DRUG|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
214232048|NCT04453943|DEVICE|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
214232049|NCT04453943|DEVICE|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
214232050|NCT00755209|DRUG|tranexamic acid|Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
214232051|NCT00828438|DRUG|Lorcaserin 10mg|
214232052|NCT03751254|DEVICE|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
214232053|NCT00655915|OTHER|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
214232054|NCT06219798|DIAGNOSTIC_TEST|GFR|Exit of the study due to death, dialysis, or transplantation
214232055|NCT05748652|DEVICE|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
214232056|NCT05748652|OTHER|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
214232057|NCT01610375|OTHER|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
214232058|NCT05171452|BIOLOGICAL|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
214232059|NCT01471431|OTHER|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
214232060|NCT05594615|DRUG|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
214232061|NCT05594615|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
214232062|NCT05594615|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
214232063|NCT05594615|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
214232064|NCT01642875|OTHER|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
214232065|NCT01642875|OTHER|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
214232066|NCT00391183|PROCEDURE|Biliary stenting|ERCP and stenting
214232067|NCT00724321|DRUG|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
214232068|NCT04110652|OTHER|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
214651643|NCT05655585|OTHER|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
214651644|NCT02553837|BIOLOGICAL|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
214232069|NCT02723045|PROCEDURE|Open Lichtenstein Hernioplasty|
214232070|NCT02723045|PROCEDURE|Laparoscopic TEP Hernioplasty|
214232071|NCT00791973|DRUG|fluticasone furoate|2 puffs in each nostril once daily for 1 week
214232072|NCT00791973|DRUG|Placebo|2 puffs in each nostril once daily for 1 week
214232073|NCT04661761|DIAGNOSTIC_TEST|Paraffin Pellets from Aurosan GmbH|1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
214232074|NCT04661761|DIAGNOSTIC_TEST|Chewing wax from the Saliva-Check Buffer from GC Europe|1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
214232075|NCT05313776|OTHER|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
214232076|NCT03737227|RADIATION|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
214232077|NCT03978143|DRUG|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
214232078|NCT03978143|DRUG|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
214232079|NCT03978143|DRUG|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
214232080|NCT03978143|DRUG|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
214232081|NCT03978143|DRUG|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
214232082|NCT03978143|DRUG|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
214232083|NCT03978143|DRUG|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
214232084|NCT03978143|DRUG|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
214232085|NCT01503671|DRUG|Atorvastatin|Atorvastatin 40 mg/day
214232086|NCT01104376|DRUG|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
214651645|NCT00934076|DRUG|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
214232087|NCT01104376|DRUG|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
214232088|NCT04240678|OTHER|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
214232089|NCT02758379|DEVICE|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
214232090|NCT00541190|OTHER|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
214232091|NCT00732901|DRUG|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
214232092|NCT00732901|DRUG|Placebo|Once daily days 1-28
214232093|NCT01486043|DRUG|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
214232094|NCT02601807|DEVICE|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
214232095|NCT02601807|DEVICE|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
214232096|NCT04306991|DEVICE|Auscultation using an electronic stethoscope (EKO CORE 4)|"* Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography."
214232097|NCT00972140|DRUG|Formoterol|Formoterol-HFA pMDI 12µg twice daily
214232098|NCT00972140|DRUG|Formoterol|Formoterol-DPI 12 µg twice daily
214232099|NCT04227054|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
214232100|NCT03252340|DRUG|ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
214651646|NCT03406533|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
214651647|NCT03406533|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
214651648|NCT03406533|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
214232101|NCT04785690|DEVICE|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
214232102|NCT04785690|DEVICE|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
214232103|NCT05098262|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
214232104|NCT05098262|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
214232105|NCT03085914|DRUG|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
214232106|NCT03085914|DRUG|Pembrolizumab|Pembrolizumab
214232107|NCT03085914|DRUG|Oxaliplatin|Oxaliplatin
214232108|NCT03085914|DRUG|Leucovorin|Leucovorin
214232109|NCT03085914|DRUG|5-Fluorouracil|5-Fluorouracil
214232110|NCT03085914|DRUG|Gemcitabine|Gemcitabine
214232111|NCT03085914|DRUG|nab-Paclitaxel|nab-Paclitaxel
214232112|NCT03085914|DRUG|Carboplatin|Carboplatin
214232113|NCT03085914|DRUG|Paclitaxel|Paclitaxel
214232114|NCT03085914|DRUG|Pemetrexed|Pemetrexed
214232115|NCT03085914|DRUG|Cyclophosphamide|Cyclophosphamide
214232116|NCT03085914|DRUG|Carboplatin|Carboplatin
214232117|NCT03085914|DRUG|Cisplatin|Cisplatin
214232118|NCT03085914|DRUG|5-Fluorouracil|5-FU
214232119|NCT03085914|DRUG|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
214232120|NCT03816540|DEVICE|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
214232121|NCT04644315|DRUG|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
214232122|NCT05315908|OTHER|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
214232123|NCT05273073|DIETARY_SUPPLEMENT|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
214232124|NCT05273073|DIETARY_SUPPLEMENT|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
214232125|NCT01445548|DRUG|Sirolimus|
214232126|NCT04085939|OTHER|Online survey|Anonymous survey using the online survey tool, JotForm
214232127|NCT00182585|PROCEDURE|computer-based HIV, STD & Hepatitis Education|
214651649|NCT03406533|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
214651650|NCT03406533|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
214232128|NCT00182585|PROCEDURE|educator-delivered HIV, STD and Hepatitis education|
214232129|NCT00103233|BIOLOGICAL|trastuzumab|
214232130|NCT00103233|DRUG|vinorelbine tartrate|
214232131|NCT01217333|BEHAVIORAL|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
214232132|NCT01217333|BEHAVIORAL|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
214232133|NCT06370403|OTHER|Cooling of the head and neck|Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects
214232134|NCT06370403|OTHER|Heating of the head and neck|Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
214232135|NCT05839158|OTHER|HFMT cell suspension|Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
214232136|NCT05839158|OTHER|Mupirocin ointment|the Minoxidil ointment is evenly applied to the control group surface.
214232137|NCT04232618|DIAGNOSTIC_TEST|Multi-biomarker point-of-care test|Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
214232138|NCT04038216|PROCEDURE|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
214232139|NCT04038216|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
214651651|NCT03751111|DRUG|Naloxone|Naloxone at an sublingual dose of 0.4 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
214651652|NCT03751111|DRUG|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
214232140|NCT06157788|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging and clinical assessment|"* fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images"
214232141|NCT03415542|BEHAVIORAL|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
214232142|NCT03406741|BEHAVIORAL|psychometric evaluation|Wechsler type composite scales (WISC)
214232143|NCT03406741|BEHAVIORAL|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
214232144|NCT01876004|DRUG|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
214232145|NCT01876004|DRUG|Placebo|Prescribed Placebo IM (intramuscularly), single dose
214232146|NCT02867644|OTHER|standard care|Patients coming for preoperative breast assessment will have standard care.
214232147|NCT02867644|OTHER|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
214232148|NCT02861274|DEVICE|pacemaker|
214232149|NCT04497038|DRUG|Cabozantinib|Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
214232150|NCT04909983|DEVICE|DPLX-PT1|A polymer skin patch for occlusional therapy
214232151|NCT04909983|OTHER|Control arm|Standard of care
214232152|NCT02697149|RADIATION|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
214232153|NCT02697149|RADIATION|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
214232154|NCT03298971|OTHER|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
214232155|NCT01991613|DIETARY_SUPPLEMENT|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
214651653|NCT02628925|DEVICE|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
214651654|NCT00723957|DRUG|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
214651655|NCT00723957|DRUG|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m\^2
214651656|NCT00723957|DRUG|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
214232156|NCT04121663|DEVICE|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
214232157|NCT03287518|DIETARY_SUPPLEMENT|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
214232158|NCT03287518|DIETARY_SUPPLEMENT|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
214232159|NCT00773539|PROCEDURE|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
214232160|NCT00773539|PROCEDURE|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
214232161|NCT00773539|PROCEDURE|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
214232162|NCT01617746|DRUG|Ambrisentan|5mg od two weeks
214232163|NCT01617746|DRUG|Bosentan|62.5mg bd two weeks
214232164|NCT01617746|DRUG|Placebo|bd for two weeks
214232165|NCT00148707|DRUG|CT-2103 (Xyotax)|
214651657|NCT00807950|DRUG|Simvastatin|
214651658|NCT05814445|OTHER|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
214651659|NCT05814445|OTHER|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
214651660|NCT01007526|OTHER|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
214651661|NCT00706628|DRUG|BIBF 1120|
214651662|NCT00706628|DRUG|BIBW 2992|
214232166|NCT06193551|DEVICE|Ovitex LPR|Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
214232167|NCT02609867|DEVICE|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
214651663|NCT00706628|DRUG|Sequential BIBF 1120 + BIBW 2992|
214651664|NCT02235649|BEHAVIORAL|Social Cognition therapy ( Psychological Therapy)|
214232168|NCT02204475|DRUG|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
214232169|NCT02204475|DRUG|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
214232170|NCT02204475|DRUG|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
214232171|NCT02204475|DRUG|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
214232172|NCT05024110|OTHER|High intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
214232173|NCT05024110|OTHER|Moderate intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
214232174|NCT02637349|BEHAVIORAL|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
214232175|NCT02637349|BEHAVIORAL|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
214232176|NCT02944006|PROCEDURE|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
214232177|NCT03642132|DRUG|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
214232178|NCT03642132|DRUG|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
214232179|NCT03642132|DRUG|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
214232180|NCT04571671|OTHER|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
214232181|NCT03561688|DEVICE|Foot orthotics|Insoles for shoes
214232182|NCT03561688|DEVICE|Standard insole|Sham foot orthotic
214232183|NCT05916599|DEVICE|ultrasound|a device which is used in intensive care units,
214232184|NCT03145818|OTHER|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
214232185|NCT05366504|COMBINATION_PRODUCT|LiST + PRP intracorporeal injection|12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
214232186|NCT05366504|COMBINATION_PRODUCT|LiST + Placebo(normal saline intracorporeal injection)|All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
214232187|NCT05506241|DEVICE|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
214232188|NCT03632408|DRUG|Zopiclone|Oral, single dose, 7.5 mg
214232189|NCT03632408|BEHAVIORAL|hangover|as per subjects choice to consume alcohol
214232190|NCT03632408|DRUG|Placebo oral capsule|oral
214651665|NCT02866864|OTHER|Animal allergy +|Allergic symptom occurs when subject contact animal
214651666|NCT02866864|OTHER|Animal allergy -|Allergic symptom does not occur when subject contact animal
214651667|NCT01264939|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
214651668|NCT01264939|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
214232191|NCT00856414|BIOLOGICAL|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
214232192|NCT00367367|PROCEDURE|Hysteroscopy and Curettage|
214232193|NCT04508218|DIETARY_SUPPLEMENT|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
214651669|NCT01264939|DRUG|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
214651670|NCT01264939|DRUG|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
214651671|NCT01099228|OTHER|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
214232194|NCT04508218|OTHER|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
214232195|NCT04508218|OTHER|traditional burn care|ROM exercises, stretching, ADL activities and scar management
214232196|NCT01839604|DRUG|AZD9150|Intravenous infusion over 3 hours.
214232197|NCT05511077|OTHER|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
214232198|NCT04493892|BEHAVIORAL|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
214232199|NCT04782206|PROCEDURE|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
214232200|NCT04782206|PROCEDURE|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
214232201|NCT03300102|OTHER|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
214232202|NCT02812498|OTHER|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
214232203|NCT02812498|OTHER|Standard|Group of patients followed in a traditional way
214232204|NCT05867589|DRUG|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
214232205|NCT01128621|DRUG|GSK1292263|Tablet
214232206|NCT01128621|DRUG|GSK1292263 matching placebo|Tablet
214232207|NCT01128621|DRUG|Sitagliptin|Tablet
214232208|NCT03472846|DRUG|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
214232209|NCT03472846|DRUG|Teriparatide|osteoanabolic treatment with Forsteo
214232210|NCT04139889|DIAGNOSTIC_TEST|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
214232211|NCT03271645|BEHAVIORAL|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
214232212|NCT03271645|BEHAVIORAL|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
214232213|NCT03271645|BEHAVIORAL|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
214232214|NCT03271645|BEHAVIORAL|Face-to-face counselling|Face-to-face counselling
214651672|NCT01099228|OTHER|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
214232215|NCT00109603|DRUG|Tenofovir disoproxil fumarate|
214232216|NCT00511940|DRUG|acamprosate|999 mg/day - 2997 mg/day, oral
214232217|NCT00511940|OTHER|placebo|oral, placebo
214651673|NCT03181113|DRUG|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
214232218|NCT04405466|PROCEDURE|Blood sampling|Blood samples
214232219|NCT04405466|PROCEDURE|Throat swab|Throat swab
214232220|NCT02704390|DRUG|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
214232221|NCT02470988|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|
214232222|NCT02470988|BEHAVIORAL|CBASP Without DPI|
214232223|NCT00060359|DRUG|Carboplatin|Given IV
214651674|NCT03181113|DRUG|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
214651675|NCT03251326|DRUG|Nabilone|Nabilone capsules (4 mg)
214651676|NCT03251326|DRUG|Cannabis|Cigarettes (0.0 and 5.6% THC)
214651677|NCT03251326|DRUG|Propranolol|Propranolol capsules (40mg)
214651678|NCT03251326|DRUG|Placebo|Placebo capsules
214651679|NCT00003490|BIOLOGICAL|sargramostim|
214651680|NCT00003490|DRUG|cyclophosphamide|
214651681|NCT00003490|DRUG|prednisone|
214651682|NCT00003490|DRUG|vincristine sulfate|
214232224|NCT00060359|DRUG|Paclitaxel Poliglumex|Given IV
214232225|NCT00060359|OTHER|Pharmacological Study|Correlative studies
214232226|NCT03044600|OTHER|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
214232227|NCT03044600|OTHER|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
214232228|NCT03595618|DRUG|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
214232229|NCT03595618|DRUG|Placebo|Film-coated tablets of matching placebo for oral use.
214232230|NCT01291485|BEHAVIORAL|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
214232231|NCT04277806|BEHAVIORAL|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
214232232|NCT00027833|BIOLOGICAL|ALVAC-CEA-B7.1 vaccine|
214232233|NCT00027833|BIOLOGICAL|tetanus toxoid|
214232234|NCT00027833|DRUG|FOLFIRI regimen|
214232235|NCT00027833|DRUG|fluorouracil|
214232236|NCT00027833|DRUG|irinotecan hydrochloride|
214232237|NCT00027833|DRUG|leucovorin calcium|
214232238|NCT04617431|BEHAVIORAL|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
214232239|NCT02024178|PROCEDURE|Ultrasound Imaging|
214232240|NCT06148844|OTHER|interactive robot group|Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
214232241|NCT05239429|BEHAVIORAL|Transcendental Meditation Technique|Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
214232242|NCT00169858|BIOLOGICAL|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
214232243|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
214232244|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
214232245|NCT02776319|DEVICE|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
214232246|NCT02776319|DEVICE|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
214232247|NCT01253811|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
214232248|NCT00740376|DEVICE|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
214232249|NCT00740376|DEVICE|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
214232250|NCT01705067|DEVICE|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
214232251|NCT03381534|DEVICE|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
214232252|NCT03381534|DEVICE|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
214232253|NCT04311593|DIAGNOSTIC_TEST|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
214232254|NCT01221740|DRUG|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
214232255|NCT04652414|DRUG|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
214232256|NCT04652414|DRUG|Placebo|This is a matching placebo to prednisone.
214232257|NCT02835079|DRUG|Tamoxifen|
214651683|NCT01722461|DEVICE|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
214651684|NCT01722461|DEVICE|Sham treatment|Ulthera System delivering no ultrasound energy
214232258|NCT03547115|DRUG|voruciclib monotherapy|Voruciclib will be administered orally
214232259|NCT03547115|DRUG|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
214232260|NCT03010436|DRUG|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
214232261|NCT05052931|DRUG|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
214232262|NCT05929573|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
214232263|NCT05929573|DIAGNOSTIC_TEST|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
214232264|NCT01849744|DRUG|VS-4718|
214232265|NCT02540889|BEHAVIORAL|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
214232266|NCT02682979|OTHER|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
214232267|NCT01481532|DRUG|Crotoxin|Intra patient dose escalation
214232268|NCT02111278|OTHER|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
214232269|NCT02111278|OTHER|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
214232270|NCT02111278|OTHER|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
214232271|NCT04134546|PROCEDURE|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
214232272|NCT02858544|OTHER|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
214232273|NCT02858544|OTHER|ImPACT|Patient- completed computerized neurocognitive test battery
214232274|NCT00744354|DRUG|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
214232275|NCT00744354|DRUG|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
214232276|NCT00744354|DRUG|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
214232277|NCT06138223|OTHER|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
214232278|NCT06138223|OTHER|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
214232279|NCT05690867|OTHER|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
214232280|NCT05690867|OTHER|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
214232281|NCT04150367|DRUG|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
214651685|NCT04113811|DEVICE|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
214232282|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
214232283|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
214232284|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
214232285|NCT04150367|DRUG|Isoniazid|. Participants will get the dosage according to the instruction for use.
214232286|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
214232287|NCT00958997|DRUG|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
214232288|NCT00958997|BIOLOGICAL|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
214232289|NCT03498053|BEHAVIORAL|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
214232290|NCT03498053|BEHAVIORAL|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
214232291|NCT03498053|BEHAVIORAL|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
214232292|NCT02728973|OTHER|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
214232293|NCT03997227|PROCEDURE|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
214232294|NCT04267601|DRUG|Anagliptin|Anagliptin treatment for 24weeks
214232295|NCT01781273|OTHER|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
214232296|NCT01781273|OTHER|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
214232297|NCT01246908|DRUG|Placebo|Placebo administered twice per day for six weeks.
214232298|NCT01246908|DRUG|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
214232299|NCT03740984|OTHER|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
214232300|NCT01214057|DRUG|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
214651686|NCT02266433|DRUG|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
214651687|NCT02266433|DRUG|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
214651688|NCT03709563|DIETARY_SUPPLEMENT|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
214651689|NCT03709563|DIETARY_SUPPLEMENT|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
214651690|NCT04525703|BEHAVIORAL|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
214651691|NCT00268814|DRUG|Diacetylmorphine|Diacetylmorphine (i.v.), daily
214651692|NCT00268814|BEHAVIORAL|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
214651693|NCT00268814|DRUG|Methadone|Methadone (p.o.), daily
214232301|NCT01214057|DRUG|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
214232302|NCT03597646|DEVICE|Kinesio Tape|
214232303|NCT03597646|DEVICE|Threshold Inspiratory Muscle Trainer|
214232304|NCT00002317|DRUG|Trimetrexate glucuronate|
214232305|NCT00002317|DRUG|Leucovorin calcium|
214232306|NCT03373331|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
214232307|NCT03373331|BEHAVIORAL|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
214232308|NCT01811264|BEHAVIORAL|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
214232309|NCT05798468|OTHER|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
214232310|NCT05798468|OTHER|Control group|Traditional education will be carried out
214232311|NCT05253001|DEVICE|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
214232312|NCT03693729|DEVICE|HD-tDCS|Participants will complete a metamemory and memory task
214232313|NCT04787523|RADIATION|Radiotherapy|Patients have received neoadjuvant radiotherapy
214232314|NCT02316509|DRUG|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
214232315|NCT00006439|BEHAVIORAL|Counseling in the home|
214232316|NCT04987788|BEHAVIORAL|Motívate|The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.
214232317|NCT04987788|BEHAVIORAL|Video link|General health information video link
214232318|NCT02614469|DRUG|Inosine|Inosine, 1000 mg
214232319|NCT02149771|PROCEDURE|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
214232320|NCT02149771|DEVICE|endovascular stents implantation|Bare stents implant within portal vein.
214651694|NCT00268814|BEHAVIORAL|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
214651695|NCT01285349|BEHAVIORAL|Couple HIV/STI prevention intervention|
214651696|NCT01285349|BEHAVIORAL|Couple-based HIV/STI prevention|
214651697|NCT01285349|BEHAVIORAL|Individual HIV/STI prevention|
214232321|NCT02149771|PROCEDURE|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
214232322|NCT00520585|DRUG|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
214232323|NCT02958683|OTHER|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
214232324|NCT00357760|BIOLOGICAL|VEGF Trap|Given IV
214232325|NCT02043600|BEHAVIORAL|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
214232326|NCT02043600|BEHAVIORAL|Self-care|Self-care books are provided for self-directed use
214232327|NCT01246154|OTHER|EXERCISE TRAINING|EXERCISE TRAINING
214232328|NCT00001131|DRUG|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
214651698|NCT01285349|BEHAVIORAL|Couple Wellness Promotion|
214651699|NCT03609255|BEHAVIORAL|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
214232329|NCT00001131|DRUG|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
214651700|NCT03609255|BEHAVIORAL|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
214651701|NCT03609255|BEHAVIORAL|Control|An educational handout for sedentary behavior and weekly neutral topic videos
214651702|NCT01145560|DRUG|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
214651703|NCT01145560|DRUG|Placebo|Placebo
214651704|NCT04304456|OTHER|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
214651705|NCT00712348|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
214232330|NCT02473692|OTHER|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)"
214232331|NCT00021073|DRUG|alvocidib|Given IV
214651706|NCT04292600|DIAGNOSTIC_TEST|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
214232332|NCT00021073|DRUG|leucovorin calcium|Given IV
214232333|NCT00021073|DRUG|fluorouracil|Given IV
214232334|NCT00021073|DRUG|irinotecan hydrochloride|Given IV
214232335|NCT00593242|BIOLOGICAL|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
214232336|NCT00593242|OTHER|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
214232337|NCT04959071|PROCEDURE|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
214232338|NCT05377697|OTHER|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
214232339|NCT02802670|DRUG|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
214232340|NCT04272138|BEHAVIORAL|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
214232341|NCT04272138|BEHAVIORAL|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
214232342|NCT02299401|DRUG|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
214232343|NCT02299401|DEVICE|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
214232344|NCT04136444|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
214232345|NCT02766842|PROCEDURE|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
214232346|NCT02766842|PROCEDURE|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
214651707|NCT02820961|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDAC)
214651708|NCT02820961|DRUG|exemestane|Aromatase inhibitor
214651709|NCT03204344|DIETARY_SUPPLEMENT|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
214818035|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
214232347|NCT02766842|DEVICE|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
214232348|NCT02766842|DEVICE|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
214232349|NCT02726308|DRUG|Dexamethasone|5 mg I.V. Dexamethasone just before induction
214232350|NCT02726308|DRUG|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
214232351|NCT02726308|DRUG|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
214232352|NCT00115323|BEHAVIORAL|Problem Solving|Problem solving intervention
214232353|NCT00115323|BEHAVIORAL|Attention Control|Attention control intervention
214232354|NCT03480724|OTHER|Google Cardboard VRA|Intervention was randomized and shuffled.
214232355|NCT03480724|OTHER|Oculus Rift VRA|Intervention was randomized and shuffled.
214232356|NCT06401187|OTHER|Bar overdenture|use of bar attachments as retentive mean of denture
214232357|NCT06311318|PROCEDURE|lower eyelid massage|The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
214232358|NCT00616499|DRUG|gefitinib|
214232359|NCT00616499|PROCEDURE|neoadjuvant therapy|
214232360|NCT00616499|PROCEDURE|therapeutic conventional surgery|
214232361|NCT01133028|BEHAVIORAL|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
214232362|NCT01133028|BEHAVIORAL|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
214232363|NCT02010151|OTHER|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
214232364|NCT04040491|DRUG|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
214232365|NCT00839033|DEVICE|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
214232366|NCT00839033|DEVICE|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
214651710|NCT03204344|OTHER|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
214651711|NCT04819906|DRUG|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
214651712|NCT04819906|DRUG|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
214651713|NCT04819906|DRUG|Placebo|Five placebo tablets orally once
214651714|NCT04819906|DRUG|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
214651715|NCT00126971|DRUG|chlorproguanil-dapsone|
214232367|NCT01962961|DIETARY_SUPPLEMENT|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
214651716|NCT02057133|DRUG|LY2835219|Administered orally.
214651717|NCT02057133|DRUG|Letrozole|Administered orally.
214651718|NCT02057133|DRUG|Anastrozole|Administered orally.
214651719|NCT02057133|DRUG|Tamoxifen|Administered orally.
214651720|NCT02057133|DRUG|Exemestane|Administered orally.
214651721|NCT02057133|DRUG|Everolimus|Administered orally.
214651722|NCT02057133|DRUG|Trastuzumab|Administered IV infusion.
214232368|NCT01962961|DIETARY_SUPPLEMENT|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
214232369|NCT02184572|BIOLOGICAL|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
214232370|NCT02184572|BIOLOGICAL|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
214232371|NCT02184572|BIOLOGICAL|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
214232372|NCT02184572|BIOLOGICAL|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
214232373|NCT02184572|BIOLOGICAL|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
214232374|NCT01600625|DRUG|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
214232375|NCT04235010|DEVICE|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
214651723|NCT02057133|DRUG|LY3023414|Administered orally.
214651724|NCT02057133|DRUG|Fulvestrant|Administered IM.
214651725|NCT02057133|DRUG|Pertuzumab|Administered IV infusion.
214651726|NCT02057133|DRUG|Loperamide|Administered orally.
214232376|NCT04235010|DEVICE|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
214232377|NCT00451503|DEVICE|Middle Ear Implant|surgery
214232378|NCT02411864|OTHER|different low b-values distribution|
214232379|NCT03726996|DRUG|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
214232380|NCT00485797|DRUG|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
214232381|NCT01328444|DRUG|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
214232382|NCT01328444|DRUG|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
214232383|NCT01328444|DRUG|GSK 573719 125|125mcg
214232384|NCT01328444|DRUG|GSK 573719 62.5|62.5mcg
214232385|NCT01328444|DRUG|GW642444 25|25mcg
214232386|NCT01328444|DRUG|Plb|Comparator
214232387|NCT03180619|DRUG|TAF|Tablet administered orally once daily
214232388|NCT00700167|BIOLOGICAL|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
214232389|NCT00685256|OTHER|counseling intervention|subjects and parents will receive genetic counseling
214232390|NCT00685256|OTHER|educational intervention|subjects and parents will receive education re: genetic testing
214232391|NCT00685256|OTHER|survey administration|surveys will be administered to subjects and parents
214232392|NCT00685256|BEHAVIORAL|psychosocial assessment and care|psychosocial assessment and counseling will be provided
214232393|NCT00685256|BEHAVIORAL|supportive care|parents and children will be provided with supportive care
214232394|NCT04484571|DEVICE|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
214232395|NCT02743611|BIOLOGICAL|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
214651727|NCT02057133|DRUG|Endocrine therapy|Endocrine therapy administered orally.
214232396|NCT02743611|DRUG|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
214232397|NCT01583829|BEHAVIORAL|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
214232398|NCT01583829|BEHAVIORAL|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
214232399|NCT01583829|OTHER|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
214232400|NCT04732390|PROCEDURE|erector spinae block with bupivacaine|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
214232401|NCT04732390|PROCEDURE|erector spinae block with bupivacaine and magnesium sulphate|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
214232402|NCT04520529|OTHER|Biologic Samples|"* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research."
214232403|NCT03234569|PROCEDURE|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
214232404|NCT00002280|DRUG|Didanosine|
214232405|NCT02490345|DRUG|gabapentin|gabapentin usage as adjunctive treatment for pain control
214232406|NCT02490345|DRUG|Placebo|Identical placebo
214232407|NCT02895425|OTHER|Registry (No intervention)|
214232408|NCT02086032|DRUG|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
214232409|NCT02086032|DRUG|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
214232410|NCT02086032|DRUG|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
214232411|NCT04554056|DRUG|MW05|Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
214232412|NCT04554056|DRUG|PEG-rhG-CSF|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
214232413|NCT01675089|DRUG|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
214232414|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
214232415|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
214232416|NCT02058823|DRUG|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
214232417|NCT02058823|DRUG|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
214651728|NCT02278783|DRUG|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
214232418|NCT04471285|PROCEDURE|acupuncture|acupuncture
214232419|NCT04471285|PROCEDURE|Sham acupuncture|Sham acupuncture
214232420|NCT03995329|OTHER|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
214232421|NCT04933370|OTHER|Stimulation parameters|Different device stimulation parameters
214232422|NCT02587611|OTHER|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
214232423|NCT02587611|OTHER|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
214232424|NCT00436540|DRUG|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
214232425|NCT00436540|DRUG|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
214232426|NCT01610999|DRUG|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
214232427|NCT00357591|DEVICE|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
214232428|NCT00370045|DRUG|Bivalirudin with and without eptifibatide|
214232429|NCT02183753|OTHER|wood smoke|
214232430|NCT02183753|OTHER|clean air|
214232431|NCT05254977|DRUG|Standard Preparation|Any kind of intervention received to reduce adverse effects
214232432|NCT06221657|DRUG|Vemlidy|1 tablet once a day, oral administration
214232433|NCT06221657|DRUG|Virreal|1 tablet once a day, oral administration
214232434|NCT04704362|BEHAVIORAL|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
214232435|NCT04704362|BEHAVIORAL|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
214232436|NCT04929717|OTHER|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
214232437|NCT04929717|OTHER|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
214232438|NCT03683732|BEHAVIORAL|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
214232439|NCT00456443|PROCEDURE|Historical records|
214232440|NCT04215757|PROCEDURE|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
214232441|NCT01947062|DRUG|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
214232442|NCT01947062|DRUG|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
214232443|NCT06251401|BEHAVIORAL|In-person supervised cardiac rehabilitation|In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
214464721|NCT06801561|PROCEDURE|Glass ionomer sealant|This group will receive glass ionomer sealant. Conditioning of the surface will be done using polyacrylic acid (10%) conditioner for 20 seconds, then rinsed and dried. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
214464722|NCT05651308|BEHAVIORAL|Care coordination delivered based on perceived need|If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
214464723|NCT05651308|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
214464724|NCT05942287|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
214464725|NCT02532244|OTHER|sample collection|collection of blood
214464726|NCT03625167|OTHER|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
214464727|NCT05227222|DEVICE|PEP-device|PEP-device
214464728|NCT04465708|BEHAVIORAL|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
214464729|NCT03259360|BEHAVIORAL|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
214464730|NCT03259360|BEHAVIORAL|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
214464731|NCT04326010|DEVICE|Surgery|THA surgery
214464732|NCT05245682|DRUG|Tolinapant|Given PO
214464733|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
214232444|NCT06251401|BEHAVIORAL|Virtual cardiac rehabilitation|Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
214232445|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
214232446|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
214232447|NCT02931708|OTHER|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
214232448|NCT02086643|PROCEDURE|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
214232449|NCT00561977|BEHAVIORAL|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
214232450|NCT00561977|BEHAVIORAL|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
214232451|NCT00561977|BEHAVIORAL|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
214232452|NCT01064375|BIOLOGICAL|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
214232453|NCT01064375|DEVICE|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
214232454|NCT01064375|BIOLOGICAL|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
214232455|NCT01064375|DRUG|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
214232456|NCT00881543|DRUG|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
214232457|NCT00967980|PROCEDURE|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
214232458|NCT01644747|DEVICE|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
214232459|NCT05568940|DRUG|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
214232460|NCT02710955|DIETARY_SUPPLEMENT|Thickened infant formula|
214232461|NCT01621815|BEHAVIORAL|Video Game|Playing various video games: RPG, Race, FPS, Strategy
214232462|NCT02057328|DRUG|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
214232463|NCT02057328|DRUG|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
214651729|NCT00628186|DEVICE|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
214232464|NCT03675009|OTHER|Educational Programming|Green Cleaning educational programming to day care staff.
214232465|NCT02883257|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
214232466|NCT04285840|OTHER|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
214232467|NCT01352403|PROCEDURE|Roux-en-Y gastric bypass|
214232468|NCT01352403|BEHAVIORAL|Psychotherapy-enhanced lifestyle intervention|
214232469|NCT06409416|OTHER|Analysis of diagnostic biomarkers|The investigators will analyze TCP-biomarkers diagnostic by IHC, qRT-PCR and next-generation sequencing, in tumor and plasma samples of lung cancer patients.
214232470|NCT01494493|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
214232471|NCT01494493|PROCEDURE|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
214232472|NCT05622760|OTHER|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
214232473|NCT05622760|OTHER|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
214232474|NCT02385656|DRUG|Modafinil|200mg of modafinil daily for 4 weeks
214232475|NCT00852839|DRUG|Placebo|Placebo to match oromucosal formulation of 552-02
214232476|NCT00852839|DRUG|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
214232477|NCT00781885|DRUG|Beraprost sodium modified release|Tablets 60mcg
214232478|NCT02108678|BEHAVIORAL|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
214232479|NCT02108678|BEHAVIORAL|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
214651730|NCT00628186|DEVICE|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
214651731|NCT04640714|BEHAVIORAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
214232480|NCT04954651|BIOLOGICAL|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
214232481|NCT01755026|DRUG|cefazolin|2 gram dose for pre-operative prophylaxis
214232482|NCT01755026|DRUG|cefazolin|4 gram dose for pre-operative prophylaxis
214232483|NCT00194649|DRUG|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
214232484|NCT01629225|DRUG|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
214232485|NCT06121245|OTHER|Proton Pump inhibitor|A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)
214232486|NCT06121245|OTHER|Placebo|Placebo capsule
214232487|NCT00577616|PROCEDURE|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
214651732|NCT03904680|DRUG|Methotrexate|Methotrexate 2.5 mg tablet
214651733|NCT03904680|DRUG|Vitamin D|Vitamin D 200,000 IU ampules
214651734|NCT01541293|DRUG|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
214232488|NCT04802668|DEVICE|Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume|Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.
214232489|NCT04802668|BEHAVIORAL|spontaneous breathing and no spontaneous breathing|Data were recorded when patients had and did not have spontaneous breathing
214232490|NCT03712085|OTHER|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
214232491|NCT03712085|OTHER|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
214651735|NCT01541293|DRUG|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
214651736|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
214651737|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
214651738|NCT06274567|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
214232492|NCT03653559|BEHAVIORAL|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
214232493|NCT03653559|BEHAVIORAL|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
214232494|NCT06374043|DRUG|Dapagliflozin 10mg Tab|Oral administration
214232495|NCT06374043|DRUG|Placebo|Oral administration
214232496|NCT06374043|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken."
214232497|NCT06374043|DEVICE|Withings Body+|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 40 days."
214232498|NCT06374043|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 22 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, CRP, lipid profile, HbA1c, uric acid, glucose and NT-proBNP.
214232499|NCT06374043|DEVICE|MEMS (Medication Electronic Monitoring System) Cap|Medication will be provided in standard medicine bottles with the MEMS® (Medication Electronic Monitoring System) Cap (AARDEX Ltd, Union City, CA, USA), which is a customizable medication package which records and stores up to 4,000 dosing events. The cap fits on standard medicine bottles and with integrated microcircuits, the child-resistant MEMS® Cap records the date and time whenever a patient opens a vial. The stored information can be transferred at any time through the MEMS® Reader to the adherence software for immediate analysis and interpretation.
214232500|NCT06374043|BEHAVIORAL|Questionnaire: participants' perspectives toward remote data collection|Self-made questionnaires consisting of 6 multiple choice questions and 2 open questions will be used to assess patient experience and satisfaction to guide and inform future trials and use in clinical practice.
214818036|NCT02291250|DIETARY_SUPPLEMENT|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
214232501|NCT03031002|BEHAVIORAL|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
214232502|NCT02547961|BIOLOGICAL|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
214232503|NCT00167492|DRUG|Myfortic|720 mg by mouth every 12 hours
214232504|NCT03078829|DRUG|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
214232505|NCT00392379|DRUG|Nicotine Lozenges|Nicotine lozenges, 4 mg
214232506|NCT00392379|DRUG|Placebo lozenge|Placebo lozenge
214232507|NCT04231370|DRUG|Sintilimab|Sintilimab, 200mg, iv day1
214818037|NCT05819918|DRUG|Calcifediol|Subjects hospitalized with COVID-19 treated with calcifediol
214818038|NCT05819918|DRUG|Best available therapy|Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
214232508|NCT04231370|DRUG|Lenalidomide|25mg/d oral d1-14
214464734|NCT05724823|OTHER|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
214464735|NCT03720197|OTHER|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
214464736|NCT03720197|OTHER|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
214464737|NCT03720197|OTHER|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
214464738|NCT03720197|OTHER|Food questionnaire|24-hour food recall questionnaire
214464739|NCT03720197|OTHER|Pedometer|Participants will wear a podometer for 14 consecutives days
214464740|NCT03720197|OTHER|Waist circumference|Participants will be asked to measure their waist circumference
214464741|NCT03720197|OTHER|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
214464742|NCT03720197|OTHER|List of medications|Participants will be invited to send us their list of medications
214464743|NCT03720197|OTHER|Continuous glucose monitor|Participants will be invited to send us the latest report of their continuous glucose monitor
214464744|NCT05825677|DEVICE|tDCS actif|Active brain stimulation
214464745|NCT05825677|DEVICE|tDCS Sham|Sham brain stimulation
214464746|NCT04743167|PROCEDURE|Surgery|Laparoscopic treatment of endometriotic lesions
214464747|NCT04743167|PROCEDURE|IVF|Up to three completed cycles of IVF
214464748|NCT04880785|DRUG|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
214232509|NCT05728099|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
214232510|NCT05728099|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
214232511|NCT05516563|OTHER|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
214232512|NCT01757340|BEHAVIORAL|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
214232513|NCT01757340|BEHAVIORAL|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
214232514|NCT03071250|PROCEDURE|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
214232515|NCT04783558|BEHAVIORAL|Mobile-based NAS Caregiving Tool|The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
214232516|NCT04267900|DRUG|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
214232517|NCT02087007|DRUG|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
214232518|NCT02087007|DRUG|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
214232519|NCT03523598|OTHER|Placebo gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
214232520|NCT03523598|OTHER|Placebo Gel + Potassium Nitrate Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
214651739|NCT06274567|DEVICE|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
214651740|NCT00113243|DRUG|adult stem cells|
214651741|NCT04364919|BEHAVIORAL|aerobic exercise program|"The program incorporated modified yoga movements suitable for pregnant women. The DVD provides an illustration with the written caption, Please take enough water before exercise, and wear loose and comfortable clothes in a suitable environment. If you feel tired, stop exercising immediately. The DVD's narrator then says, Now you are ready to prepare a comfortable, solid chair with a chair back. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercises were developed as a progressive program in order to achieve the goals of strength-conditioning, moderate-intensity exercise (ACOG, 2015)."
214651742|NCT02094144|OTHER|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
214651743|NCT02094144|OTHER|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
214818039|NCT04519515|DEVICE|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
214818040|NCT06540716|DEVICE|Inspire System|Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
214232521|NCT03523598|OTHER|Potassium Nitrate Gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
214232522|NCT05807165|RADIATION|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
214232523|NCT05807165|RADIATION|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"* The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]"
214232524|NCT03233880|DRUG|Azithromycin 1gm|Azithromicin 1 gm oral single dose
214232525|NCT03233880|OTHER|PLACEBO|placebo
214232526|NCT00470509|DRUG|Adalimumab|2 subcutaneous injections on day 0 and 7
214232527|NCT00470509|DRUG|Placebos|2 subcutaneous injections on day 0 and 7
214232528|NCT00225264|DRUG|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
214232529|NCT00225264|DRUG|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
214232530|NCT02991664|OTHER|Equia Forte|Glass ionomer restorative system
214232531|NCT02991664|OTHER|G-aenial Posterior|Micro hybrid composite resin
214818041|NCT05456763|DIETARY_SUPPLEMENT|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
214232532|NCT01920646|OTHER|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
214232533|NCT04320758|OTHER|conventional preparation design|chamfer finish line
214232534|NCT04320758|OTHER|biologically oriented preparation technique|shoulder less preparation design
214232535|NCT00427115|BEHAVIORAL|Multimodal exercise and psychosocial program|
214232536|NCT01175681|PROCEDURE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
214232537|NCT01557634|PROCEDURE|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
214232538|NCT04033588|DEVICE|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
214232539|NCT04495608|DRUG|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
214232540|NCT04495608|DRUG|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
214232541|NCT00766350|DRUG|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
214232542|NCT00766350|DRUG|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
214232543|NCT04986956|DIETARY_SUPPLEMENT|Whole coffee cherry extract|200mg WCCE
214232544|NCT04986956|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to WCCE
214232545|NCT03041129|DIAGNOSTIC_TEST|oral glucose tolerance test|6 hours OGTT
214232546|NCT03041129|DIAGNOSTIC_TEST|MRI of liver|MRI of the liver and use of DIXON method
214232547|NCT04136847|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
214232548|NCT04105478|PROCEDURE|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
214232549|NCT04195776|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
214232550|NCT02973373|DEVICE|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
214232551|NCT02973373|OTHER|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
214232552|NCT05828641|PROCEDURE|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
214232553|NCT05828641|PROCEDURE|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
214232554|NCT02102373|DEVICE|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
214818042|NCT05456763|OTHER|placebo|placebo
214818043|NCT06452472|DEVICE|I-LIMB|Use of a multi-grip myoelectric hand prosthesis (I-LIMB after using a standard myoelectric prosthesis)
214232555|NCT02665403|OTHER|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
214232556|NCT02665403|OTHER|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
214232557|NCT00533754|PROCEDURE|drawing blood|
214232558|NCT04972643|DIETARY_SUPPLEMENT|EPA|EPA 2000mg Soft capsules
214232559|NCT04972643|DIETARY_SUPPLEMENT|DHA|DHA 2000mg Soft capsules
214232560|NCT04972643|DIETARY_SUPPLEMENT|Placebo|Placebo Soft capsules
214232561|NCT03678870|OTHER|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
214232562|NCT05712486|OTHER|High force hip Lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.
214232563|NCT05712486|OTHER|Placebo force hip lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
214232564|NCT03633877|DEVICE|DuraporeTM and Hy-Tape®|Medical tapes
214232565|NCT03104816|DRUG|Acetaminophen IV Soln 10 MG/ML|
214232566|NCT03104816|DRUG|Acetaminophen|
214232567|NCT03104816|DRUG|Hydromorphone|
214232568|NCT05783882|DRUG|Prolgolimab|250 mg Q3W
214232569|NCT01997112|DRUG|Paracetamol|
214232570|NCT01997112|DRUG|Placebo oral capsule|
214232571|NCT02550769|PROCEDURE|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
214232572|NCT02550769|PROCEDURE|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
214232573|NCT02303652|PROCEDURE|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
214232574|NCT02303652|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
214232575|NCT01055067|DRUG|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
214232576|NCT01159431|DEVICE|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
214232577|NCT01986699|PROCEDURE|Laparoscopic Assisted Polypectomy|
214232578|NCT06226857|DRUG|Cetuximab|FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles
214232579|NCT05229497|DRUG|AK112|IV infusion,Specified dose on specified days
214232580|NCT05229497|DRUG|AK117|IV infusion,Specified dose on specified days
214232581|NCT05229497|DRUG|Carboplatin|IV infusion,Specified dose on specified days
214232582|NCT05229497|DRUG|Cisplatin|IV infusion,Specified dose on specified days
214232583|NCT05229497|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
214232584|NCT00022646|DRUG|gemcitabine hydrochloride|
214232585|NCT00022646|DRUG|pemetrexed disodium|
214232586|NCT00538083|OTHER|Chocolate|74 grams of single dose solid dark chocolate versus placebo
214232587|NCT00538083|OTHER|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
214232588|NCT00538083|OTHER|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
214232589|NCT04349904|DIAGNOSTIC_TEST|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
214232590|NCT04643600|DRUG|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
214232591|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
214232592|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
214232593|NCT03777462|DRUG|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
214232594|NCT04320030|DRUG|[18F]-DPA-714 PET/CT scan|Pretherapeutic \[18F\]-DPA-714 PET/CT scan
214818044|NCT01301794|DIETARY_SUPPLEMENT|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
214232595|NCT06021860|DRUG|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
214232596|NCT00645450|DRUG|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
214232597|NCT00645450|DRUG|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
214232598|NCT04686058|DRUG|Propofol 10 MG/ML Injection|
214232599|NCT04686058|DRUG|Midazolam injection|
214232600|NCT04686058|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
214232601|NCT04686058|DEVICE|target controlled infusion pump|
214232602|NCT04686058|DEVICE|patient-controlled sedation pump|
214232603|NCT03645434|DRUG|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
214232604|NCT03645434|DRUG|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
214232605|NCT04646564|DRUG|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
214232606|NCT04646564|RADIATION|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
214232607|NCT00833664|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
214232608|NCT00833664|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
214232609|NCT06946199|BIOLOGICAL|cizutamig|Cizutamig will be dosed according to the assigned group.
214232610|NCT00434616|PROCEDURE|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
214232611|NCT00434616|BIOLOGICAL|saline injection|saline injections
214232612|NCT04842825|DRUG|Er Zhi Wan combined with Si Wu Tang|"The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days"
214232613|NCT04842825|DRUG|Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder|The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
214232614|NCT05197569|OTHER|thyme oil|Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
214232615|NCT03914963|BIOLOGICAL|Fibrin sealant hemipelvis|Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
214232616|NCT03914963|BIOLOGICAL|Control hemipelvis|Contralateral hemipelvis not treated with fibrin sealant
214232617|NCT00678743|DRUG|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
214232618|NCT03658876|DRUG|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
214232619|NCT03658876|DRUG|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
214232620|NCT00057343|DRUG|Zevalin (ibritumomab tiuxetan)|
214232621|NCT00057343|DRUG|Rituxan (rituximab)|
214232622|NCT01330017|DRUG|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
214232623|NCT01330017|DRUG|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
214232624|NCT01330017|DRUG|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
214232625|NCT06230601|OTHER|Cough Trick Method|During the Blood Collection Procedure in School-Age Children, one group will use the Cough Trick Method
214232626|NCT06230601|OTHER|Pinwheel Blowing method|Pinwheel Blowing method
214232627|NCT05827471|DIAGNOSTIC_TEST|Diagnosis of colon cancer|Clinical diagnosis results
214232628|NCT03453372|DEVICE|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
214232629|NCT03453372|OTHER|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
214818045|NCT01359696|DRUG|GDC-0425|Oral escalating dose
214818046|NCT01359696|DRUG|gemcitabine|Intravenous repeating dose
214232630|NCT03995251|DRUG|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
214232631|NCT03995251|DRUG|Standard Medical Treatment|Standard Medical Treatment
214232632|NCT03995251|OTHER|Exercise|Exercise
214232633|NCT01106092|BIOLOGICAL|GSK2036874A vaccine|Intramuscular, single dose
214232634|NCT01106092|BIOLOGICAL|Zilbrix™/Hib vaccine|Intramuscular, single dose
214232635|NCT01106092|BIOLOGICAL|Poliorix™|Intramuscular, single dose
214232636|NCT03834649|PROCEDURE|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
214232637|NCT03834649|PROCEDURE|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
214232638|NCT01030081|DRUG|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
214232639|NCT01030081|DRUG|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
214232640|NCT04427826|DRUG|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
214232641|NCT03117439|OTHER|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
214232642|NCT04124744|OTHER|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
214232643|NCT04124744|OTHER|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
214232644|NCT00843778|BIOLOGICAL|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
214232645|NCT02027129|OTHER|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
214232646|NCT01473368|DIETARY_SUPPLEMENT|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
214232647|NCT01473368|DRUG|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
214232648|NCT00998244|OTHER|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
214232649|NCT01850576|BEHAVIORAL|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
214232650|NCT03386045|RADIATION|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
214232651|NCT03386045|RADIATION|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)"
214232652|NCT05616689|OTHER|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
214232653|NCT02728713|PROCEDURE|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
214232654|NCT02728713|PROCEDURE|Sham/Placebo|A laying on of hands with no actual treatment being performed.
214232655|NCT04143308|OTHER|Simultaneous training of walking and cognitive group|"Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP"
214232656|NCT04143308|OTHER|Cognitive training group|"Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP"
214232657|NCT04143308|OTHER|Treatment as usual group|Keep treatment as usual
214232658|NCT02898285|BEHAVIORAL|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
214232659|NCT02898285|BEHAVIORAL|Individual sport condition|Participants will choose from a list of individual sports.
214232660|NCT02898285|BEHAVIORAL|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
214232661|NCT00003388|BIOLOGICAL|filgrastim|
214232662|NCT00003388|DRUG|cyclophosphamide|
214232663|NCT00003388|DRUG|cytarabine|
214232664|NCT00003388|DRUG|methotrexate|
214232665|NCT00003388|DRUG|pegylated liposomal doxorubicin hydrochloride|
214232666|NCT00003388|DRUG|prednisone|
214232667|NCT00003388|DRUG|vincristine sulfate|
214232668|NCT00003388|RADIATION|radiation therapy|
214232669|NCT04158193|OTHER|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
214232670|NCT04158193|OTHER|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
214232671|NCT04545970|COMBINATION_PRODUCT|Facial cleanser|Facial cleanser to be used by study participants
214232672|NCT04545970|COMBINATION_PRODUCT|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
214232673|NCT04545970|COMBINATION_PRODUCT|Sunscreen|Sunscreen to be applied after application of serum in the morning.
214232674|NCT03338959|BIOLOGICAL|Pembrolizumab|Given IV
214232675|NCT03338959|RADIATION|Radiation Therapy|Undergo radiation therapy
214232676|NCT00125346|DRUG|Tobramycin Inhalation Powder|
214232677|NCT05624047|BEHAVIORAL|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
214232678|NCT05624047|BEHAVIORAL|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
214232679|NCT05461378|DRUG|Evusheld|Participants who have received or plan to receive Evusheld.
214232680|NCT00361413|DRUG|Alefacept (AMEVIVE®)|Alefacept
214232681|NCT00361413|DRUG|control group|these patients will receive the same treatment as group A, without alefacept
214232682|NCT04718844|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
214232683|NCT04718844|DRUG|Placebo|Sodium chloride for s.c. injection
214232684|NCT04911374|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
214232685|NCT04911374|OTHER|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
214232686|NCT00813969|BIOLOGICAL|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
214232687|NCT02933671|PROCEDURE|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
214232688|NCT02933671|PROCEDURE|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
214232689|NCT02933671|DRUG|Ropivacaine|Local anesthetic (numbing drug)
214232690|NCT02933671|DRUG|Saline|Salt water placebo
214232691|NCT06210932|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum videos|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
214232692|NCT01744145|OTHER|Interventional 40-60|This group will receive the intervention aged 40-60
214232693|NCT01744145|OTHER|Interventional 60 and above|This group will receive the intervention aged 60 and above.
214232694|NCT04514783|DEVICE|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
214232695|NCT04514783|OTHER|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
214232696|NCT04076553|BEHAVIORAL|CBT|Participants will complete 12 sessions of CBT
214232697|NCT04076553|BEHAVIORAL|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
214232698|NCT03086564|BIOLOGICAL|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
214232699|NCT03086564|PROCEDURE|TACE|TACE solely in the first day of a clinical course.
214232700|NCT01915927|DRUG|MSC-AFP|
214232701|NCT00706498|DRUG|BI 2536|
214232702|NCT05883826|BEHAVIORAL|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
214232703|NCT03328182|DEVICE|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
214232704|NCT03938753|DEVICE|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
214232705|NCT00743236|PROCEDURE|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
214232706|NCT00743236|PROCEDURE|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
214232707|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
214232708|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
214232709|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
214232710|NCT03790423|DRUG|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
214232711|NCT03790423|OTHER|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
214232712|NCT00716833|DRUG|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
214232713|NCT00716833|DRUG|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
214232714|NCT00476671|PROCEDURE|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
214232715|NCT04601454|DEVICE|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
214232716|NCT02608333|BEHAVIORAL|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
214232717|NCT02608333|BEHAVIORAL|control group|"heteregenous as usual community intervention"
214232718|NCT01670578|BIOLOGICAL|PRP|
214232719|NCT01670578|DEVICE|Hyaluronic acid|
214232720|NCT04307875|DIAGNOSTIC_TEST|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
214232721|NCT04307875|DIAGNOSTIC_TEST|Blood glucose measurement|measuring blood glucose using standard measurement devices
214232722|NCT04307875|OTHER|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
214232723|NCT00762424|DRUG|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
214232724|NCT00762424|DRUG|placebo|cornstarch
214232725|NCT05010642|DEVICE|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
214232726|NCT02984072|DRUG|Menthol|Topical menthol in aqueous cream
214232727|NCT02984072|DRUG|Aqueous Cream|placebo
214232728|NCT01347580|DRUG|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
214232729|NCT01347580|DRUG|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
214232730|NCT01926327|BIOLOGICAL|PRP injection|Injection of PRP in patients with knee osteoarthritis.
214232731|NCT01926327|BIOLOGICAL|Placebo|
214232732|NCT00912665|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
214232733|NCT00912665|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
214232734|NCT00912665|OTHER|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
214232735|NCT00912665|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
214232736|NCT01650012|DRUG|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
214232737|NCT01650012|DRUG|Placebo|Placebo
214232738|NCT00390026|DRUG|Bevacizumab (Avastin)|
214232739|NCT00390026|DRUG|Verteporfin photodynamic therapy (PDT)|
214232740|NCT06251531|OTHER|Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)|The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
214232741|NCT01643031|DRUG|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
214232742|NCT01643031|DRUG|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
214232743|NCT04162782|PROCEDURE|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
214232744|NCT03134573|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
214232745|NCT03134573|DEVICE|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
214232746|NCT03134573|DEVICE|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
214232747|NCT01491438|PROCEDURE|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
214232748|NCT01491438|PROCEDURE|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
214232749|NCT02870933|BIOLOGICAL|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
214232750|NCT03554694|DIETARY_SUPPLEMENT|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
214232751|NCT03554694|DIETARY_SUPPLEMENT|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
214232752|NCT00003590|DRUG|hydroxyurea|20 mg/kg/day PO
214232753|NCT01542567|DRUG|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
214232754|NCT01542567|DRUG|Placebo|Placebo suppositories
214232755|NCT03129399|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
214232756|NCT03129399|DEVICE|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
214232757|NCT01697410|DRUG|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
214232758|NCT01697410|DRUG|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
214232759|NCT01425463|DRUG|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
214232760|NCT01425463|DRUG|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
214232761|NCT01425463|OTHER|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
214232762|NCT01425463|OTHER|Placebo to Polyferose|Administered orally with water.
214232763|NCT02224196|OTHER|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
214232764|NCT02224196|OTHER|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
214232765|NCT04176653|DRUG|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
214232766|NCT00205920|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
214651744|NCT05419895|BEHAVIORAL|Early Diagnostic Response Model (EDRM)|Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
214232767|NCT06518590|DEVICE|Cycle|Kettler upright bike Giro P:
214232768|NCT02862756|OTHER|diffusion-weighted MRI and clinical examination|
214232769|NCT03243708|BEHAVIORAL|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
214232770|NCT03613272|PROCEDURE|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
214232771|NCT03613272|PROCEDURE|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
214232772|NCT03573011|DIAGNOSTIC_TEST|[18F]PSMA-11|18F-PET imaging
214232773|NCT01009840|DRUG|IV busulfan|PK-directed dosing of IV busulfan for 4 days
214232774|NCT01009840|DRUG|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m\^2.
214232775|NCT01009840|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
214232776|NCT05009433|BEHAVIORAL|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
214651745|NCT00476580|BEHAVIORAL|Questionnaire|Questions to collect health information specific to Sri Lankans.
214651746|NCT03324360|DRUG|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
214651747|NCT03180775|OTHER|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
214232777|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
214232778|NCT05009433|BEHAVIORAL|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
214232779|NCT05009433|BEHAVIORAL|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
214232780|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
214232781|NCT05009433|BEHAVIORAL|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
214232782|NCT00853268|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
214232783|NCT00853268|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
214232784|NCT01596556|DRUG|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
214232785|NCT01596556|OTHER|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
214232786|NCT05940454|PROCEDURE|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
214232787|NCT04144127|BEHAVIORAL|Soccer|"* Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
214232788|NCT00732043|DIETARY_SUPPLEMENT|pomegranate extract|8 oz per day, 48 months
214232789|NCT00732043|DIETARY_SUPPLEMENT|pomegranate juice|8 oz per day, 48 months
214232790|NCT00732043|DIETARY_SUPPLEMENT|placebo|8 oz per day, 48 months
214232791|NCT00196183|PROCEDURE|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
214232792|NCT00196183|PROCEDURE|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
214232793|NCT00118521|PROCEDURE|Foot Orthotics|
214232794|NCT00118521|PROCEDURE|Physiotherapy|
214232795|NCT02719873|OTHER|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
214232796|NCT02117206|DRUG|L-arginine (L-arginine Veyron)|
214232797|NCT02117206|DRUG|Nacl|
214232798|NCT05172479|DIAGNOSTIC_TEST|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
214232799|NCT05172479|DIAGNOSTIC_TEST|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
214818047|NCT05323396|DRUG|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy or stool PCR) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with negative stool microscopy and negative stool PCR will not be administered treatment, thus will serve as controls."
214232800|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
214232801|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
214232802|NCT05172479|DIAGNOSTIC_TEST|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
214232803|NCT02528721|DEVICE|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
214232804|NCT01221454|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
214232805|NCT01221454|DRUG|Conserved therapy|Oral or intravenous administration
214232806|NCT00376714|DRUG|GSK233705|
214232807|NCT06257602|PROCEDURE|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
214232808|NCT02349308|DEVICE|CentrosFLO Long Term Hemodialysis Catheter|
214232809|NCT02799420|DEVICE|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
214232810|NCT02799420|DEVICE|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
214232811|NCT02218632|OTHER|lactose-free diet|standard diet
214232812|NCT02218632|DIETARY_SUPPLEMENT|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
214232813|NCT00052442|DRUG|pralatrexate|
214232814|NCT00321087|DRUG|T2000|Dose escalation from 600 to 1000 mg
214232815|NCT00321087|DRUG|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
214232816|NCT00321087|DRUG|T2000|Placebo followed by dose escalation from 600 to 1000
214232817|NCT05130671|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
214232818|NCT05130671|DIETARY_SUPPLEMENT|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
214232819|NCT06403488|DRUG|Letrozole 2.5mg|specific aromatase inhibitor
214232820|NCT02922699|DRUG|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
214232821|NCT02922699|DRUG|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
214232822|NCT04343924|OTHER|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
214232823|NCT04343924|OTHER|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
214232824|NCT00853216|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
214232825|NCT00853216|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
214232826|NCT02082938|DEVICE|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
214232827|NCT05324904|DRUG|Vitamin D|"\- Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
214232828|NCT05324904|DRUG|acyclovir|"-Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
214232829|NCT02891928|DEVICE|Rocker sole shoes|Measure of walk testing Measure of standing position
214232830|NCT02891928|DEVICE|Normal shoes|Measure of walk testing Measure of standing position
214232831|NCT00076453|DEVICE|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
214232832|NCT00076453|DEVICE|Standard orthotic shoe inserts|Neutral orthotic inserts
214232833|NCT02651129|OTHER|Noise measurement|We will be measuring noise levels in the operating room
214232834|NCT00941434|DIETARY_SUPPLEMENT|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
214232835|NCT00947791|DRUG|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
214232836|NCT00947791|DRUG|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
214232837|NCT01958489|DRUG|Evacetrapib|Administered orally
214232838|NCT01958489|DRUG|Pravastatin|Administered orally
214232839|NCT04226768|OTHER|"Enhanced Haematology Palliative Care (Fast-track) Group"|Early and proactive multidisciplinary care
214232840|NCT04226768|OTHER|Conventional Care|Conventional care and referral as indicated
214232841|NCT04276324|OTHER|Resistance training|Ten weeks of resistance training
214232842|NCT04276324|OTHER|Testing sessions|Testing sessions
214232843|NCT02561767|OTHER|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
214232844|NCT02561767|OTHER|Saline|Saline as placebo of MSCs
214232845|NCT02561767|DRUG|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
214232846|NCT02561767|DRUG|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
214232847|NCT00875693|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
214232848|NCT01208753|DRUG|GLPG0555|two different aqueous formulations
214232849|NCT01208753|DRUG|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
214232850|NCT01208753|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
214232851|NCT01717833|PROCEDURE|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
214232852|NCT01717833|PROCEDURE|Sham|Sham sessions of neuromuscular electrical stimulation
214232853|NCT04367051|DRUG|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
214232854|NCT04367051|DRUG|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
214232855|NCT00028145|BEHAVIORAL|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
214232856|NCT06277453|OTHER|surgery|radical gastric cancer surgery (R0) and D2 lymph node dissection
214232857|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
214232858|NCT01547559|DRUG|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
214232859|NCT01547559|DRUG|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
214232860|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
214232861|NCT01547559|DRUG|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
214232862|NCT04745260|DRUG|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
214232863|NCT04745260|DRUG|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
214232864|NCT02642055|BEHAVIORAL|Neuro+ Attention Training|Attention training program with Neuro+ software
214232865|NCT02642055|OTHER|Treatment as Usual|Continuation of current ADHD treatment
214232866|NCT02322853|DRUG|Tamoxifen|hormonotherapy
214232867|NCT02322853|DRUG|Ralimetinib (LY2228820 dimesylate)|
214232868|NCT04911192|PROCEDURE|mechanical fragmentation|patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy
214232869|NCT04911192|PROCEDURE|In Situ thrombolysis|Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
214232870|NCT00917644|DRUG|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
214232871|NCT00917644|GENETIC|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
214232872|NCT02338232|DRUG|Telmisartan|
214232873|NCT04769180|OTHER|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
214232874|NCT03081156|DRUG|Glycopyrrolate / Formoterol|Exercise Tolerance
214232875|NCT02500056|DEVICE|Optilene LP mesh|Lichtenstein hernioplasty
214232876|NCT02500056|DEVICE|Ultrapro mesh|Lichtenstein hernioplasty
214232877|NCT02045030|DRUG|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
214232878|NCT01832584|DIETARY_SUPPLEMENT|RGC|
214232879|NCT01832584|DIETARY_SUPPLEMENT|Placebo|
214232880|NCT05343533|DIETARY_SUPPLEMENT|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
214232881|NCT00864916|DRUG|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
214232882|NCT00864916|DRUG|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
214232883|NCT00864916|DRUG|Placebo|Participants will receive placebo three times per day for 48 weeks.
214232884|NCT04232332|DRUG|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
214232885|NCT04232332|DRUG|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
214232886|NCT04232332|DRUG|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
214232887|NCT02720354|OTHER|[11C]-DMDPA|
214232888|NCT03554343|DIAGNOSTIC_TEST|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
214232889|NCT02087267|PROCEDURE|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
214232890|NCT04716556|BIOLOGICAL|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
214232891|NCT05473078|OTHER|online anonymous exploratory study|online self-administered questionnary
214232892|NCT02331095|DRUG|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
214232893|NCT02331095|DRUG|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
214232894|NCT05464953|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
214232895|NCT05464953|DRUG|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
214232896|NCT00665314|DRUG|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
214232897|NCT00665314|DRUG|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
214232898|NCT01087736|DRUG|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
214232899|NCT01087736|OTHER|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
214232900|NCT01568528|DRUG|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
214232901|NCT01568528|DRUG|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
214232902|NCT01568528|OTHER|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
214232903|NCT04469829|DRUG|Secukinumab|standard doses of secukinumab for psoriasis
214232904|NCT04469829|DRUG|Methotrexate|Methotrexate 15 mg/week
214232905|NCT02727543|OTHER|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
214232906|NCT04649372|PROCEDURE|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
214232907|NCT01323855|DRUG|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
214232908|NCT06455267|DIETARY_SUPPLEMENT|Now Foods L-Ornithine Capsules|L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
214232909|NCT05446337|OTHER|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
214232910|NCT03970980|OTHER|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
214232911|NCT06163677|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
214232912|NCT02122783|DEVICE|ADR™ brace resistance|
214232913|NCT02122783|DEVICE|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
214232914|NCT00924040|DRUG|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
214232915|NCT04418401|DRUG|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
214232916|NCT04877509|BIOLOGICAL|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
214232917|NCT03449784|OTHER|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
214232918|NCT02783079|BEHAVIORAL|CBT|
214232919|NCT02783079|BEHAVIORAL|MBSR|
214232920|NCT02372227|DRUG|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
214232921|NCT01223443|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
214232922|NCT06492655|DRUG|CKD-383(Fed)|After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
214232923|NCT06492655|DRUG|CKD-383(Fasted)|After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
214232924|NCT01890629|DRUG|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
214232925|NCT03814421|DRUG|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
214232926|NCT04440605|PROCEDURE|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
214232927|NCT04570059|BEHAVIORAL|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
214232928|NCT01141062|DEVICE|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
214232929|NCT01579812|DRUG|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
214232930|NCT00678678|DEVICE|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
214232931|NCT00678678|DEVICE|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
214232932|NCT01101308|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
214232933|NCT01101308|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
214232934|NCT01695876|DRUG|AMG 357|Oral administration available in varying dose strength.
214232935|NCT01695876|DRUG|Placebo|Matching placebo to AMG 357 containing no active drug
214232936|NCT01528540|DRUG|Placebo|This group will include placebo.
214232937|NCT01528540|DRUG|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
214232938|NCT00338182|DRUG|AZD1152 part A|48-hour continuous intravenous infusion
214232939|NCT00338182|DRUG|AZD1152 part B|2-hour intravenous infusion
214232940|NCT01873521|PROCEDURE|Non invasive ventilation|
214232941|NCT02886208|BEHAVIORAL|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
214232942|NCT04634045|BEHAVIORAL|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
214232943|NCT00061412|BEHAVIORAL|Comprehensive program to improve reading and writing skills|
214232944|NCT01138176|PROCEDURE|Cooling|Reduction of rectal temperature to 33.5 C
214232945|NCT04308031|DRUG|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
214232946|NCT04308031|DRUG|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
214818048|NCT05675995|BEHAVIORAL|Qigong|6 sessions of combined external and internal qigong delivered in a group-based format once a week.
214232947|NCT04636853|BIOLOGICAL|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
214232948|NCT00957125|DRUG|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
214232949|NCT00957125|DRUG|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
214232950|NCT00957125|DRUG|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
214232951|NCT04458688|OTHER|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
214232952|NCT05168501|OTHER|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
214232953|NCT02400164|DEVICE|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
214232954|NCT06189235|OTHER|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
214232955|NCT02870023|OTHER|Balance training|
214232956|NCT02870023|OTHER|Strength training|
214232957|NCT05577273|DRUG|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
214232958|NCT04906915|DRUG|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
214232959|NCT00260364|DRUG|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
214232960|NCT00260364|DRUG|Capecitabine orally days 1 -21|
214232961|NCT00260364|DRUG|Erlotinib 100 mg orally days 1-28|
214232962|NCT00260364|DRUG|Bevacizumab 5 mg/kg intravenously every 2 weeks|
214232963|NCT01155882|PROCEDURE|Whipple at the Splenic Artery (WATSA)|
214232964|NCT05330078|DRUG|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
214232965|NCT05330078|DRUG|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
214818049|NCT03948503|PROCEDURE|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
214232966|NCT05627778|DRUG|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
214232967|NCT05627778|DRUG|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
214232968|NCT03785275|RADIATION|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
214232969|NCT03483129|BEHAVIORAL|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
214232970|NCT02664623|PROCEDURE|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
214232971|NCT02664623|PROCEDURE|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
214232972|NCT05053932|OTHER|blood collection|blood collection
214232973|NCT00266669|DRUG|Topical organogel with nitroglycerin|
214232974|NCT04630574|OTHER|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
214232975|NCT04630574|OTHER|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
214232976|NCT00002165|DRUG|Nelfinavir mesylate|
214232977|NCT04422275|DRUG|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
214232978|NCT04422275|BEHAVIORAL|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
214232979|NCT04422275|DRUG|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
214232980|NCT04422275|BEHAVIORAL|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
214232981|NCT01940978|DRUG|Methylphenidate ER|Watson generic, starting dose 18mg QD
214232982|NCT01940978|DRUG|Cyproheptadine|cyproheptadine hydrochloride
214232983|NCT02480946|DRUG|MBS2320|As described in the arm descriptions
214232984|NCT02480946|DRUG|Placebo|As described in the arm descriptions
214232985|NCT02480946|DRUG|Methotrexate|Background therapy as described in the arm descriptions
214818050|NCT03948503|PROCEDURE|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
214818051|NCT03002779|DRUG|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
214818052|NCT04562662|DEVICE|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
214818053|NCT01110005|OTHER|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
214232986|NCT04517279|BEHAVIORAL|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
214232987|NCT04517279|BEHAVIORAL|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
214232988|NCT05436873|DEVICE|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
214232989|NCT00253708|PROCEDURE|management of therapy complications|
214232990|NCT00253708|PROCEDURE|massage therapy|
214232991|NCT00253708|PROCEDURE|pain therapy|
214232992|NCT00253708|PROCEDURE|psychosocial assessment and care|
214232993|NCT00253708|PROCEDURE|quality-of-life assessment|
214232994|NCT00626470|PROCEDURE|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
214232995|NCT04644731|DEVICE|Aquadex™ System|Ultrafiltration for fluid removal
214232996|NCT05207189|BIOLOGICAL|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
214232997|NCT03290482|DIAGNOSTIC_TEST|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
214232998|NCT03290482|DEVICE|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
214232999|NCT03290482|DIAGNOSTIC_TEST|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
214233000|NCT04905498|BEHAVIORAL|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
214233001|NCT04905498|BEHAVIORAL|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
214233002|NCT01902771|BIOLOGICAL|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
214233003|NCT01902771|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
214233004|NCT01902771|OTHER|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
214233005|NCT01902771|PROCEDURE|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
214233006|NCT01937104|DRUG|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~\- adjust MAC to maintain BIS between 40-60"
214233007|NCT01937104|DRUG|Remifentanil|"Adjuvant continuous administration~\- adjust effect site concentration to maintain changes of vital sign below 20%"
214233008|NCT01937104|DEVICE|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
214233009|NCT01937104|PROCEDURE|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
214233010|NCT01937104|PROCEDURE|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
214233011|NCT01937104|PROCEDURE|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
214233012|NCT02282878|DIETARY_SUPPLEMENT|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
214233013|NCT04531774|BEHAVIORAL|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
214233014|NCT04531774|BEHAVIORAL|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
214233015|NCT05510271|OTHER|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
214233016|NCT05510271|OTHER|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
214233017|NCT02866955|DRUG|Estramustine|140mg/4 caps/day
214233018|NCT02866955|DRUG|Tamoxifen|20mg/day
214233019|NCT04805879|BIOLOGICAL|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
214233020|NCT04805879|BIOLOGICAL|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
214233021|NCT02599051|DEVICE|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
214233022|NCT02599051|DEVICE|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
214233023|NCT05275361|BEHAVIORAL|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
214233024|NCT02769897|BEHAVIORAL|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
214233025|NCT00311298|DIETARY_SUPPLEMENT|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
214233026|NCT00311298|DIETARY_SUPPLEMENT|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
214233027|NCT01845987|DRUG|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
214233028|NCT01845987|DRUG|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
214233029|NCT02143050|DRUG|Dabrafenib|
214233030|NCT02143050|DRUG|Trametinib|
214233031|NCT02143050|DRUG|Metformin|
214233032|NCT04626141|DRUG|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
214233033|NCT04626141|DRUG|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
214233034|NCT00497809|DRUG|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
214233035|NCT02976220|OTHER|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
214233036|NCT00869778|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
214233037|NCT00869778|OTHER|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
214233038|NCT02856152|DRUG|GDC-0276 capsule|Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
214233039|NCT02856152|DRUG|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
214233040|NCT03661879|DRUG|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
214233041|NCT03661879|DRUG|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
214233042|NCT03642704|DRUG|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~\- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
214233043|NCT03339297|DRUG|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
214233044|NCT03339297|DRUG|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
214233045|NCT00411580|BIOLOGICAL|CAD106|
214233046|NCT00411580|DRUG|Placebo|
214233047|NCT05705635|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
214233048|NCT05705635|DRUG|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
214233049|NCT04869748|OTHER|Perfetti method|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
214233050|NCT04869748|OTHER|passive stretching|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
214233051|NCT01274260|DRUG|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
214233052|NCT01274260|DRUG|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
214233053|NCT03997045|BEHAVIORAL|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
214233054|NCT02725489|BIOLOGICAL|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
214233055|NCT02725489|DRUG|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
214233056|NCT00574964|OTHER|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
214233057|NCT05026814|OTHER|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
214233058|NCT00603772|DRUG|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
214233059|NCT06181045|DRUG|LY3410738|Administered orally.
214233060|NCT06181045|DRUG|Placebo|Administered orally.
214233061|NCT00129298|DRUG|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
214233062|NCT02551796|PROCEDURE|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
214233063|NCT02551796|PROCEDURE|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
214233064|NCT02551796|PROCEDURE|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
214233065|NCT06076278|PROCEDURE|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
214233066|NCT02320201|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
214233067|NCT06068920|OTHER|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
214233068|NCT04341428|DRUG|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
214233069|NCT04341428|DRUG|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
214233070|NCT04341428|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
214233071|NCT04341428|DRUG|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
214233072|NCT05134532|DRUG|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
214233073|NCT03490812|DIAGNOSTIC_TEST|PET scan|Investigational PET scan as add-on to standard-of-care scan
214233074|NCT03490812|OTHER|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
214233075|NCT05073094|DRUG|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
214233076|NCT05073094|DRUG|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
214233077|NCT00406562|BIOLOGICAL|Boostrix|
214233078|NCT01962038|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
214233079|NCT01962038|BEHAVIORAL|Stretching Exercises|Gym and home based stretching exercises
214233080|NCT01962038|BEHAVIORAL|Cognitive Training|Group-based cognitive training
214233081|NCT05272436|DEVICE|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
214233082|NCT02575066|RADIATION|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
214233083|NCT02575066|DRUG|pazopanib|pazopanib QD 800 mg
214233084|NCT02804841|DIETARY_SUPPLEMENT|Cholecalciferol -Vitamin D3|
214233085|NCT02804841|OTHER|Placebo -gel capsule containing no vitamin D.|
214233086|NCT01794195|BEHAVIORAL|Diffusion tensor imaging and fibres tracking|
214233087|NCT04863183|BIOLOGICAL|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
214818054|NCT01110005|OTHER|Lactated Ringer's Solution (LR)|LR IV fluid
214233088|NCT04863183|DRUG|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
214233089|NCT01716962|OTHER|Infusion of 6% tetrastarch for a total of 500 ml|
214233090|NCT03051620|DRUG|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
214233091|NCT03540251|OTHER|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
214233092|NCT00393510|DRUG|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
214233093|NCT00393510|DRUG|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
214233094|NCT03077087|DEVICE|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
214233095|NCT04858971|OTHER|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
214233096|NCT00918060|DRUG|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
214233097|NCT02907476|BEHAVIORAL|Iyengar Yoga|
214233098|NCT02907476|BEHAVIORAL|Walking|
214233099|NCT04095676|PROCEDURE|VATS group|VATS procedure with drainage, including rinse with NaCl
214233100|NCT04095676|PROCEDURE|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
214233101|NCT02723487|DRUG|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
214233102|NCT02723487|DRUG|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
214233103|NCT02336126|BEHAVIORAL|Biopsychological intervention|
214233104|NCT01054183|DEVICE|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
214233105|NCT01054183|DEVICE|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
214233106|NCT02112045|DRUG|Granix|
214233107|NCT02112045|DRUG|High dose melphalan (HDR)|
214233108|NCT02112045|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|
214233109|NCT03774498|DRUG|Sensodyne repair and protect|NovaMin \& fluoride toothpaste
214233110|NCT04585971|DIAGNOSTIC_TEST|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
214233111|NCT04585061|DRUG|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
214233112|NCT04585061|DEVICE|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
214233113|NCT04585061|DIETARY_SUPPLEMENT|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
214233114|NCT03680118|DEVICE|autogenous rings with GBR and autogenous graft with ti-mesh|"* Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
214233115|NCT00443963|DRUG|Esomeprazole Magnesium|PPI compared to H2RA
214233116|NCT00513825|DRUG|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
214233117|NCT02052713|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
214233118|NCT02052713|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
214233119|NCT01661582|OTHER|CT/PET Myocardial Perfusion Imaging using O-15 water|
214233120|NCT01661582|OTHER|Coronary blood flow measured by doppler echocardiography|
214233121|NCT02524483|BEHAVIORAL|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
214233122|NCT02524483|BEHAVIORAL|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
214233123|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
214233124|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
214233125|NCT02775240|DRUG|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
214233126|NCT02775240|DRUG|Maribavir|200mg twice a day for 8 days
214233127|NCT02775240|DRUG|Dextromethorphan|30 mg oral dose
214233128|NCT05577520|PROCEDURE|Sinus floor augmentation|
214233129|NCT02614521|OTHER|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
214233130|NCT05965271|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
214233131|NCT00000973|DRUG|Pyrimethamine|
214233132|NCT00000973|DRUG|Leucovorin calcium|
214233133|NCT00000973|DRUG|Zidovudine|
214233134|NCT02859584|BIOLOGICAL|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
214233135|NCT00348608|DRUG|iodixanol|
214233136|NCT00973011|DRUG|FCFD4514S|Intravitreal escalating dose
214233137|NCT01819285|PROCEDURE|Immediate Orchiectomy or depot LHRH|
214233138|NCT01819285|PROCEDURE|Delayed Orchiectomy or depot LHRH|
214233139|NCT00977080|DRUG|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
214233140|NCT00977080|DRUG|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
214233141|NCT05076721|OTHER|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
214233142|NCT05076721|OTHER|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
214233143|NCT00686114|DRUG|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
214233144|NCT00686114|DRUG|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
214233145|NCT00686114|DRUG|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
214233146|NCT00686114|RADIATION|Radiotherapy|Enlarged field radiotherapy
214233147|NCT00686114|RADIATION|Radiotherapy|Conventional field radiotherapy
214233148|NCT06383312|DEVICE|Reflexologic Magnetic Insole Group|Reflexologic magnetic insole will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
214233149|NCT06383312|DEVICE|Orthopedic Insole Group|Orthopedic insole (sham) will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
214233150|NCT05617456|PROCEDURE|AF ablation|Patients with standard indications to AF ablation
214233151|NCT02992197|BIOLOGICAL|Rotarix, dose 1|Rotarix, dose 1
214233152|NCT02992197|BIOLOGICAL|Rotarix, dose 2|Rotarix, dose 2
214233153|NCT02992197|DRUG|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
214233154|NCT02571335|BEHAVIORAL|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
214233155|NCT02571335|BEHAVIORAL|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
214233156|NCT00441116|DRUG|Dutasteride 0.5mg oral tablets|Dutasteride
214233157|NCT03192358|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
214233158|NCT03192358|OTHER|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
214233159|NCT00578760|DRUG|aspirin|325mg ASA OD for the duration of the cisplatin
214233160|NCT00578760|DRUG|placebo|OD for course of cisplatin chemotherapy
214233161|NCT06046300|DIAGNOSTIC_TEST|Investigation of the relationship between trunk position sense and muscle activation, balance and quality of life in individuals with transtibial amputation.|It is aimed to investigate whether the trunk position sense, including the trunk right and left sides of the individuals with transtibial amputation, is affected and the relationship between trunk position sense and muscle activation, balance and quality of life.
214233162|NCT03658096|DEVICE|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
214233163|NCT01716416|DRUG|Pazopanib|
214233164|NCT01716416|DRUG|Cetuximab|
214233165|NCT00637780|DRUG|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
214233166|NCT01550653|DRUG|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
214233167|NCT01550653|DRUG|Placebo|
214233168|NCT01251536|DRUG|Dose escalation of cetuximab|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
214233169|NCT01251536|DRUG|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
214233170|NCT01205867|DRUG|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
214233171|NCT00401232|PROCEDURE|Blood Collection|Blood Collection
214233172|NCT00597896|DRUG|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
214233173|NCT05396599|DEVICE|Model DIU|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
214233174|NCT05396599|DEVICE|Model DFW|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
214233175|NCT05396599|DEVICE|Model ZCT|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
214233176|NCT02920099|OTHER|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
214233177|NCT03542396|BEHAVIORAL|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
214233178|NCT00796991|DRUG|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
214233179|NCT00796991|DRUG|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
214233180|NCT00796991|DRUG|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
214233181|NCT00796991|DRUG|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
214233182|NCT01411735|DRUG|Enalapril|2.5mg titrated up to 10mg twice daily
214233183|NCT01411735|DRUG|placebo|2.5mg titrated up to 10mg twice daily.
214233184|NCT06284824|DEVICE|Stryker Triathlon with MAKO Robotic-Arm|Implant is the Stryker Triathlon total knee arthroplasty and the robotic device is the MAKO robotic-arm
214233185|NCT06284824|DEVICE|DePuy Attune with VELYS Robotic-Assistance|Implant is the DePuy Attune total knee arthroplasty and the robotic device is the VELYS robotic-assistance
214233186|NCT04696211|OTHER|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
214651748|NCT03180775|DIETARY_SUPPLEMENT|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233187|NCT01765218|DRUG|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
214233188|NCT01765218|DRUG|Placebo|A placebo identical in appearance to the active agent (topiramate)
214651749|NCT03180775|DIETARY_SUPPLEMENT|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214818055|NCT04646213|BEHAVIORAL|Managing Cancer and Living Meaningfully (CALM) Therapy|6 sessions of individualized CALM therapy
214233189|NCT04305067|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
214233190|NCT00932061|OTHER|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
214233191|NCT00932061|OTHER|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
214233192|NCT06298942|PROCEDURE|natural band|to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
214233193|NCT06298942|PROCEDURE|silicone band|to use synesthetic band with sleeve gastrectomy
214233194|NCT06460740|OTHER|4-7-8 breathing technique|Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
214233195|NCT06460740|OTHER|Stationary Cycling|In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
214233196|NCT05783557|DRUG|Clevidipine Butyrate Injectable Emulsion|intravenous injection
214233197|NCT05783557|DRUG|Cleviprex®|intravenous injection
214233198|NCT01316198|DIETARY_SUPPLEMENT|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
214233199|NCT01316198|DIETARY_SUPPLEMENT|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
214233200|NCT06212037|DIAGNOSTIC_TEST|Point of Care Ultrasound|Point of Care Ultrasound will be performed on all subjects and their laryngeal air column width difference will be calculated. The patients will be followed after extubation and the presence/absence of post extubation stridor will be recorded.
214233201|NCT05364333|PROCEDURE|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
214233202|NCT02237534|DRUG|Lanthanum carbonate|
214233203|NCT02237534|DRUG|Calcium Carbonate|
214233204|NCT03909594|DRUG|Bupivacaine|Bupivacaine
214233205|NCT03909594|DRUG|Ketamine|Ketamine
214233206|NCT03148691|DRUG|A-101|Topical Solution
214233207|NCT00171834|DRUG|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
214233208|NCT01030640|OTHER|placebo|single dose of the drug formulation
214233209|NCT01030640|BIOLOGICAL|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
214233210|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
214233211|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
214233212|NCT05532293|DRUG|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
214233213|NCT05532293|OTHER|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
214233214|NCT05113238|PROCEDURE|Assisted gamete activation|compare two different assisted gamete activation protocols to improve ICSI outcome
214233215|NCT01336400|OTHER|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
214233216|NCT00115921|BEHAVIORAL|Provision of antimalarial treatment at home|
214233217|NCT03011021|DRUG|Liraglutide|Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
214233218|NCT03011021|BIOLOGICAL|UCB-Treg|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline
214233219|NCT03011021|DRUG|Insulin|Receive insulin following clinician's instruction.
214233220|NCT03878641|BEHAVIORAL|Children in Grade 1 to 5 with literacy and language needs|The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
214233221|NCT04359381|OTHER|kinesiotaping application|kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
214233222|NCT04359381|OTHER|Pilate exercises program|Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
214651750|NCT03180775|DIETARY_SUPPLEMENT|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233223|NCT02184624|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
214233224|NCT02184624|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
214233225|NCT02184624|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
214233226|NCT02184624|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
214233227|NCT02184624|DEVICE|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
214233228|NCT02184624|DEVICE|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
214233229|NCT05304780|BEHAVIORAL|needs-tailored nurse-led recovery program|The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
214233230|NCT03417713|DEVICE|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
214233231|NCT05977244|OTHER|HGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
214233232|NCT05977244|OTHER|LGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
214233233|NCT05977244|OTHER|HGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
214233234|NCT05977244|OTHER|LGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
214233235|NCT03952949|BEHAVIORAL|Default Option While Online Grocery Shopping|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age."
214233236|NCT03952949|BEHAVIORAL|Nutrition Education|"The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
214233237|NCT00886847|PROCEDURE|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
214233238|NCT06194045|DIETARY_SUPPLEMENT|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
214233239|NCT06194045|DIETARY_SUPPLEMENT|Placebo|2 x 1 g capsules containing corn oil
214233240|NCT00006050|DRUG|FOLFOX regimen|
214233241|NCT00006050|DRUG|fluorouracil|
214233242|NCT00006050|DRUG|isolated perfusion|
214233243|NCT00006050|DRUG|leucovorin calcium|
214233244|NCT00006050|DRUG|oxaliplatin|
214233245|NCT00651079|DRUG|GSK1247303|
214233246|NCT01294098|DRUG|Marcaine|0.75 cc/kg of 1/4% Marcaine
214233247|NCT02642497|DRUG|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
214233248|NCT02642497|DRUG|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
214233249|NCT02642497|DRUG|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
214233250|NCT05813223|DRUG|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
214233251|NCT02365233|DRUG|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
214233252|NCT02365233|DRUG|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
214233253|NCT02365233|DRUG|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
214233254|NCT02414529|DRUG|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
214233255|NCT02414529|DRUG|Placebo|
214233256|NCT03530709|OTHER|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
214233257|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
214233258|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
214233259|NCT00127270|BEHAVIORAL|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
214233260|NCT04375319|DEVICE|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
214233261|NCT00349115|DRUG|Thalidomide|
214233262|NCT04870697|BEHAVIORAL|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
214651751|NCT03180775|DIETARY_SUPPLEMENT|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214651752|NCT03180775|DIETARY_SUPPLEMENT|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233263|NCT04870697|OTHER|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
214233264|NCT00795119|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
214233265|NCT04504409|OTHER|Rehabilitation|Training
214651753|NCT03180775|DIETARY_SUPPLEMENT|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233266|NCT01978938|DRUG|Eravacycline|
214233267|NCT01978938|DRUG|Levofloxacin|
214233268|NCT00361933|DRUG|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
214233269|NCT06306872|DRUG|Sequence A ABSK-011|Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
214233270|NCT06306872|DRUG|Sequence B ABSK-011|Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
214233271|NCT03618290|DIAGNOSTIC_TEST|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
214233272|NCT04455490|OTHER|Self-control|We compared relevant scores of patients before and after surgery
214233273|NCT04395950|DRUG|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
214233274|NCT04395950|DRUG|Placebo|Placebo two tablets daily in the morning for 6 weeks
214233275|NCT04669418|DIAGNOSTIC_TEST|RNA expression signature|Whole transcriptome profiling using RNA sequencing
214233276|NCT02121665|DRUG|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
214233277|NCT02121665|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
214233278|NCT04453553|DIAGNOSTIC_TEST|Q16 testing|Nasal swab tested on a rapid near patient device
214233279|NCT04453553|DIAGNOSTIC_TEST|Nasopharyngeal swab and main laboratory|Standard of care testing
214233280|NCT00097149|PROCEDURE|Systematic pediatric care|
214233281|NCT05513118|DIAGNOSTIC_TEST|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
214233282|NCT00093665|DRUG|cisplatin|
214233283|NCT00093665|DRUG|fluorouracil|
214233284|NCT00093665|RADIATION|radiation therapy|
214233285|NCT04546828|DRUG|Gemcitabine, Cisplatin, and Nab-Paclitaxe|"* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days ."
214233286|NCT05735210|DEVICE|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
214233287|NCT05373056|BEHAVIORAL|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
214233288|NCT05373056|BEHAVIORAL|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
214233289|NCT03154892|PROCEDURE|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
214233290|NCT03154892|PROCEDURE|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
214233291|NCT00936728|OTHER|therapeutic nutritional supplementation|Given orally
214651754|NCT03180775|DIETARY_SUPPLEMENT|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233292|NCT00936728|DIETARY_SUPPLEMENT|white wine|Given orally
214233293|NCT00936728|OTHER|questionnaire administration|Ancillary studies
214233294|NCT03964558|DRUG|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
214233295|NCT02342418|DRUG|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
214233296|NCT04763681|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
214233297|NCT05163015|OTHER|Data collection|Description: quality of life assessment
214233298|NCT00428584|DRUG|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
214233299|NCT00428584|DRUG|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
214233300|NCT03540719|PROCEDURE|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
214233301|NCT05705089|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
214233302|NCT05705089|DRUG|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
214233303|NCT03199755|DRUG|ACT|Current approved drug for treating malaria
214233304|NCT03199755|DRUG|DLA1|Experimental drug treatment, single dose.
214233305|NCT03199755|DRUG|DLA2|Experimental drug treatment, doubled the dose of DLA1.
214233306|NCT00200343|DRUG|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
214233307|NCT00200343|DRUG|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
214233308|NCT00200343|DRUG|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
214233309|NCT03619967|DEVICE|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
214233310|NCT06267378|OTHER|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
214233311|NCT06086197|DRUG|Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin|"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."
214233312|NCT01348477|PROCEDURE|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
214233313|NCT00196846|DRUG|Goserelin|
214233314|NCT03002090|DIETARY_SUPPLEMENT|Iron trained|"1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
214233315|NCT03002090|DIETARY_SUPPLEMENT|Iron Untrained|1\. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
214233316|NCT03002090|DIETARY_SUPPLEMENT|BZKL Trained|"1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
214233317|NCT03002090|DIETARY_SUPPLEMENT|BZKL Untrained|1\. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
214233318|NCT03002090|DIETARY_SUPPLEMENT|Placebo Trained|1\. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
214233319|NCT03002090|DIETARY_SUPPLEMENT|Placebo Untrained|No intervention
214233320|NCT02158429|OTHER|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
214233321|NCT04424277|OTHER|diaphragm ultrasound|respiratory loading
214233322|NCT04926402|OTHER|Kangaroo Care Education Program|It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
214233323|NCT02065388|BEHAVIORAL|Standard of care dosing for warfarin|
214233324|NCT02065388|GENETIC|Genotype-guided dosingTaiwan algorithm for warfarin|
214233325|NCT02065388|GENETIC|Genotype-guided dosing IWPC algorithm for warfarin|
214233326|NCT02285062|DRUG|lenalidomide|
214233327|NCT02285062|DRUG|Placebo|
214233328|NCT02285062|DRUG|Rituximab|
214233329|NCT02285062|DRUG|Cyclophosphamide|
214233330|NCT02285062|DRUG|Doxorubicin|
214233331|NCT02285062|DRUG|prednisone|
214233332|NCT02285062|DRUG|vincristine|
214233333|NCT03714269|OTHER|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
214233334|NCT03714269|OTHER|measurement evaluated with an 2D ultrasound|"* simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
214233335|NCT03714269|OTHER|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
214651755|NCT03180775|DIETARY_SUPPLEMENT|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214651756|NCT03180775|DIETARY_SUPPLEMENT|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214233336|NCT00256971|PROCEDURE|meniscectomy|
214233337|NCT02323100|DRUG|Ravicti low dose|8 am, 4pm and midnight
214233338|NCT02323100|DRUG|Ravicti high dose|8 am, 4pm and midnight
214233339|NCT02323100|DRUG|Placebo|8 am, 4pm and midnight
214233340|NCT02885467|PROCEDURE|Total knee arthroplasty with Saphenous nerve burial|
214233341|NCT02885467|PROCEDURE|Standard total knee arthroplasty|
214233342|NCT03478436|DRUG|Doxycycline|Doxycycline 40 mg capsules
214233343|NCT05551247|DRUG|Envafolimab|300mg,sc,d3,Q3W;
214233344|NCT05551247|DRUG|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
214233345|NCT02753088|DRUG|BCD-063|
214233346|NCT02753088|DRUG|Copaxone-Teva|
214233347|NCT02753088|DRUG|Placebo|
214233348|NCT00763503|DRUG|CD 2027|3µg/g Oily Spray
214233349|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
214233350|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
214233351|NCT06363305|DIETARY_SUPPLEMENT|Dietary capsules|Daily doses of dietary capsaicin or placebo in capsule form
214233352|NCT00821509|BEHAVIORAL|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
214233353|NCT00821509|BEHAVIORAL|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
214233354|NCT02880696|BEHAVIORAL|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
214233355|NCT02880696|BEHAVIORAL|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
214233356|NCT02880696|DEVICE|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
214233357|NCT00473980|DRUG|Indomethacin, celecoxib, esomeprazole|
214233358|NCT04628377|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
214233359|NCT04049682|BEHAVIORAL|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
214233360|NCT03127098|BIOLOGICAL|ETBX-011|ETBX-011 immunization was administered by subcutaneous (SC) injection.
214233361|NCT03127098|BIOLOGICAL|ALT-803|ALT-803 was administered by SC injection.
214233362|NCT00150904|PROCEDURE|venous blood puncture|
214233363|NCT04064216|PROCEDURE|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
214233364|NCT04711161|DRUG|GRN-300|A salt-inducible kinase (SIK) inhibitor
214233365|NCT04711161|DRUG|Paclitaxel|Microtubule inhibitor
214233366|NCT05857280|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
214233367|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233368|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233369|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233370|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233371|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233372|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
214233373|NCT01227629|DRUG|warfarin|comparator
214233374|NCT01227629|DRUG|dabigatran without ASA|dose comparison
214233375|NCT01227629|DRUG|dabigatran without ASA|dose comparison
214233376|NCT01227629|DRUG|dabigatran without ASA|dose comparison
214233377|NCT03302364|DRUG|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
214233378|NCT00156156|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
214233379|NCT00156156|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
214233380|NCT03602560|DRUG|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
214233381|NCT03602560|DRUG|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
214233382|NCT03602560|DRUG|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
214233383|NCT06294743|PROCEDURE|Posterior tibial nerve neuroprolotherapy|Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
214233384|NCT06294743|DRUG|Acetaminophen 500Mg Tab|Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
214233385|NCT05354453|DRUG|BI 1839100|BI 1839100
214233386|NCT05354453|DRUG|Placebo|Placebo
214233387|NCT05354453|DRUG|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
214233388|NCT00222131|DRUG|Esomeprazole|Esomeprazole 40 mg QD
214233389|NCT00222131|OTHER|Placebo|Placebo
214233390|NCT03470727|DEVICE|Citrate dialysate|Change form acetate to citrate dialysate
214233391|NCT06131528|OTHER|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
214233392|NCT06131528|OTHER|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
214233393|NCT03387488|DEVICE|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
214233394|NCT00164476|BEHAVIORAL|Preventive Services Prevention Kit|
214233395|NCT00164476|BEHAVIORAL|peer mentors (control group)|
214233396|NCT05157828|OTHER|No intervention|No intervention
214233397|NCT00534599|DRUG|Placebo|oral
214233398|NCT00534599|DRUG|quetiapine fumarate XR|oral
214233399|NCT01588470|DRUG|pioglitazone|45 mg per day for 6 months
214233400|NCT04822805|DRUG|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
214233401|NCT05918198|DRUG|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)"
214233402|NCT03571698|DEVICE|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
214233403|NCT04796064|OTHER|low-intensity aerobic training|"A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~\- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes."
214233404|NCT00415298|DRUG|DACH polymer platinate AP5346|
214233405|NCT00415298|DRUG|oxaliplatin|
214233406|NCT00415298|GENETIC|gene expression analysis|
214233407|NCT00415298|OTHER|immunohistochemistry staining method|
214233408|NCT00415298|OTHER|pharmacological study|
214233409|NCT00415298|PROCEDURE|biopsy|
214233410|NCT04437121|OTHER|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
214233411|NCT00770380|BEHAVIORAL|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
214233412|NCT00770380|OTHER|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
214233413|NCT00600561|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction Intervention
214233414|NCT03865316|DEVICE|SedLine Vs Comparator Test Group|Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
214233415|NCT00060554|DRUG|fondaparinux sodium|
214233416|NCT00060554|DRUG|heparin|
214233417|NCT00060554|PROCEDURE|percutaneous coronary intervention (PCI)|
214233418|NCT00105768|BEHAVIORAL|Advisor-Teller Money Management-Substance Abuse Counselling|
214233419|NCT05030948|BEHAVIORAL|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
214233420|NCT06320925|DEVICE|Standard of Care Treatment|Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
214233421|NCT05552144|DEVICE|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
214233422|NCT04889976|DEVICE|Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). Active iBT consists of a smartphone app with an electronic therapist-avatar. The iBT sessions are delivered concomitantly to the tDCS sessions (the tDCS device connects via bluetooth to the participant's smartphone app).
214233423|NCT04889976|DEVICE|ptES-only: Active portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). The sham iBT sessions are delivered concomitantly to the active ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
214233424|NCT04889976|DEVICE|Double-sham: Sham portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|Sham ptES for this trial is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all transcranial direct current stimulation (tDCS) headset, with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining 28 1/2 minutes. The sham iBT sessions are delivered concomitantly to the sham ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
214233425|NCT05249218|OTHER|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
214233426|NCT05249218|OTHER|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
214233427|NCT05249218|OTHER|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
214233428|NCT05249218|OTHER|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
214233429|NCT04863027|RADIATION|Thoracic radiotherapy|Patients will have pre-treatment and post-treatment perfusion DECT for baseline and post-treatment lung function
214233430|NCT00910143|PROCEDURE|conventional rectal surgery|type of rectal surgery before the introduction of TME
214233431|NCT00910143|PROCEDURE|total mesorectal excision|total mesorectal excision
214233432|NCT02616146|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
214233433|NCT02616146|DRUG|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
214233434|NCT05202158|PROCEDURE|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
214233435|NCT05202158|PROCEDURE|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
214233436|NCT06191211|BEHAVIORAL|Motivational Interviewing, AIMS|Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.
214233437|NCT06191211|BEHAVIORAL|Facility engagement|A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
214233438|NCT04463511|OTHER|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
214233439|NCT04444206|PROCEDURE|Transvaginal ultrasound cervical length screening|Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
214233440|NCT01454310|DEVICE|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
214233441|NCT01454310|DEVICE|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
214233442|NCT04135170|COMBINATION_PRODUCT|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
214233443|NCT00257335|PROCEDURE|IMRT|
214651757|NCT03180775|DIETARY_SUPPLEMENT|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
214651758|NCT02452762|DRUG|Vitamin D3|
214651759|NCT02452762|DRUG|Placebo|
214651760|NCT02890680|PROCEDURE|Platelet-rich fibrin|
214651761|NCT02890680|PROCEDURE|Control group|
214651762|NCT03365193|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.
214651763|NCT00631137|DRUG|testosterone gel applied to skin|Application of testosterone gel
214651764|NCT00631137|DIETARY_SUPPLEMENT|whey powder protein|
214233444|NCT04364438|DEVICE|Electric Muscle Stimulation|EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.
214233445|NCT04364438|DEVICE|Transcutaneous Electric Nerve Stimulation|TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
214233446|NCT03678714|BEHAVIORAL|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
214233447|NCT03678714|BEHAVIORAL|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
214233448|NCT01599936|BIOLOGICAL|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
214233449|NCT00336856|DRUG|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
214233450|NCT00336856|DRUG|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
214233451|NCT03894722|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group.
214233452|NCT03894722|PROCEDURE|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
214233453|NCT03894722|PROCEDURE|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
214233454|NCT03894722|PROCEDURE|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
214651765|NCT04385173|DRUG|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
214651766|NCT04385173|DRUG|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
214651767|NCT03682120|BIOLOGICAL|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
214651768|NCT03682120|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
214233455|NCT04316975|OTHER|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
214233456|NCT04113369|DEVICE|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
214233457|NCT04113369|PROCEDURE|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
214233458|NCT04113369|DEVICE|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
214233459|NCT05049083|DRUG|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
214233460|NCT05049083|DRUG|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
214233461|NCT00842907|DRUG|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
214233462|NCT00842907|DRUG|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
214651769|NCT03682120|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
214651770|NCT01805947|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
214651771|NCT05488860|DRUG|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
214651772|NCT05488860|PROCEDURE|Piezoelectric drived microneedling|Piezoelectric drived microneedling
214651773|NCT05488860|DRUG|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
214651774|NCT03308188|BEHAVIORAL|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
214233463|NCT01452542|DRUG|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
214233464|NCT01452542|DRUG|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
214233465|NCT02906982|OTHER|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
214233466|NCT02906982|OTHER|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
214233467|NCT01627834|DRUG|Ropinirole|
214233468|NCT05146453|PROCEDURE|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
214233469|NCT05146453|OTHER|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
214233470|NCT02555501|OTHER|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
214233471|NCT02555501|RADIATION|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
214233472|NCT03626298|DRUG|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
214233473|NCT03626298|DRUG|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
214233474|NCT03626298|DRUG|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
214233475|NCT04044144|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
214233476|NCT02603796|OTHER|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
214233477|NCT04548492|OTHER|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
214233478|NCT01604278|DRUG|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
214233479|NCT01604278|DRUG|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
214651775|NCT01970163|OTHER|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
214233480|NCT05167383|DEVICE|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
214233481|NCT05167383|BEHAVIORAL|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
214233482|NCT02184455|BIOLOGICAL|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
214233483|NCT05832775|BIOLOGICAL|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
214233484|NCT05832775|BIOLOGICAL|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
214651776|NCT01970163|OTHER|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
214651777|NCT01970163|OTHER|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~* If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~* Hydrogels can also be used if the wound is in need of moisture.~* For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion."
214651778|NCT03092050|BEHAVIORAL|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
214233485|NCT00815178|BEHAVIORAL|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
214233486|NCT00815178|BEHAVIORAL|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
214233487|NCT03515954|PROCEDURE|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
214233488|NCT02955251|DRUG|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
214233489|NCT02955251|DRUG|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
214233490|NCT04367571|OTHER|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
214233491|NCT04367571|OTHER|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
214233492|NCT00672659|DRUG|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
214233493|NCT00672659|DRUG|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
214233494|NCT04062344|OTHER|Swab|Rectal swab before and after the drug provocation testing
214233495|NCT03841578|DIETARY_SUPPLEMENT|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
214233496|NCT00931840|DRUG|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
214233497|NCT01012219|DRUG|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
214233498|NCT01012219|DRUG|Comparator: aspirin|81 mg oral tablet once daily for 7 days
214233499|NCT01012219|DRUG|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
214233500|NCT01012219|DRUG|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
214233501|NCT01012219|DRUG|Comparator: placebo|placebo oral tablet once daily for 7 days
214233502|NCT02941536|DIAGNOSTIC_TEST|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
214233503|NCT00674596|DRUG|ramipril|ramipril 10 mg/day during 3 months
214651779|NCT03092050|BEHAVIORAL|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
214651780|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
214651781|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
214651782|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
214651783|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
214651784|NCT04935983|OTHER|High CHO|Diet with high carbohydrate content
214233504|NCT00603486|DEVICE|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
214233505|NCT04028271|DEVICE|Comfort-in injection system|local anesthesia during dental treatment
214233506|NCT04028271|OTHER|conventional injection with dental needle|for local anesthesia during dental treatment
214233507|NCT03690635|PROCEDURE|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
214651785|NCT04935983|OTHER|Low CHO|Diet with low carbohydrate content
214651786|NCT01881646|RADIATION|Positron emission tomography (PET) using [11C]PBR28|
214651787|NCT02254915|DEVICE|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
214651788|NCT02254915|DRUG|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
214233508|NCT03010644|OTHER|n/a - observational study|n/a - observational study
214233509|NCT01313741|DEVICE|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
214233510|NCT03322319|PROCEDURE|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
214233511|NCT05371847|OTHER|assessment for upper limb dysfunction|clinical assessments and questionnaires
214233512|NCT05371847|OTHER|retest assessment|For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
214233513|NCT03661567|RADIATION|chest radiation|split-course chest radiation
214233514|NCT03661567|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
214233515|NCT03661567|DRUG|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
214233516|NCT00970385|DRUG|CHOP21|"CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
214233517|NCT00970385|DRUG|VIP/ABVD|"VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D"
214233518|NCT00970385|RADIATION|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
214233519|NCT02171910|DRUG|Doxapram|
214233520|NCT02171910|DRUG|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
214233521|NCT00081094|PROCEDURE|18F-Fluorodeoxyglucose-PET (FDG-PET)|
214233522|NCT00081094|PROCEDURE|11Carbon-Acetate-PET|
214233523|NCT03663400|DIAGNOSTIC_TEST|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
214233524|NCT06084975|PROCEDURE|Splenic vessels preservation|preservation the splenic vessels
214233525|NCT03706547|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
214233526|NCT03706547|DRUG|Fludarabine|30mg/m2/d
214233527|NCT03706547|DRUG|Cyclophosphamide|300mg/m2/d
214233528|NCT02775019|DIETARY_SUPPLEMENT|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
214233529|NCT02775019|DIETARY_SUPPLEMENT|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
214233530|NCT01131819|DEVICE|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
214233531|NCT01593267|PROCEDURE|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
214233532|NCT01593267|PROCEDURE|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
214233533|NCT01491113|DRUG|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
214233534|NCT01491113|DRUG|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
214233535|NCT02980809|DRUG|Apatinib|
214233536|NCT02980809|DRUG|Topotecan|
214233537|NCT00950339|DRUG|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
214233538|NCT00950339|DRUG|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
214233539|NCT00950339|DRUG|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
214233540|NCT06418139|OTHER|No intervention|No intervention added by the study
214651789|NCT02147873|DRUG|birinapant|
214233541|NCT00712400|DRUG|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
214233542|NCT00712400|DRUG|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
214233543|NCT02706990|DEVICE|Physica KR|Kinematic retaining total knee implant
214233544|NCT02706990|DEVICE|Physica PS|Posterior stabilized total knee implant
214233545|NCT03680235|OTHER|Informational Intervention|Receive standard information about breastfeeding and pregnancy
214233546|NCT03680235|OTHER|Informational Intervention|Receive information about breastfeeding and cancer
214233547|NCT03680235|OTHER|Interview|Participate in focus groups
214233548|NCT03680235|OTHER|Survey Administration|Ancillary studies
214651790|NCT02147873|DRUG|Azacitidine|
214651791|NCT02147873|DRUG|Placebo|
214233549|NCT00511394|DRUG|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
214233550|NCT00511394|DRUG|Normal Saline|Infusion of 100 mL of Normal Saline
214233551|NCT00646854|DRUG|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
214233552|NCT00646854|DRUG|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
214233553|NCT05258188|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
214233554|NCT05258188|OTHER|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
214233555|NCT01956344|BEHAVIORAL|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
214233556|NCT02051699|PROCEDURE|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
214233557|NCT03908489|PROCEDURE|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
214233558|NCT03908489|PROCEDURE|vital pulpotomy using mta|mta vital pulpotomy
214233559|NCT00756912|DRUG|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
214233560|NCT05334056|DRUG|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
214233561|NCT02350751|DRUG|MEDI8852|
214233562|NCT02350751|DRUG|Placebo|
214233563|NCT00706576|DRUG|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
214233564|NCT04844710|COMBINATION_PRODUCT|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
214233565|NCT04844710|DRUG|standard care|standard care only
214233566|NCT02437227|DRUG|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
214651792|NCT00772447|DRUG|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
214651793|NCT00772447|DRUG|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~\- 1 g every 6 hours or 2 g every 8 hours"
214233567|NCT00522925|DRUG|PS433540|200mg capsule, once daily for 28 days
214233568|NCT00522925|DRUG|placebo|placebo capsule, once daily for 28 days
214233569|NCT00522925|DRUG|PS433540|500mg capsule, once daily for 28 days
214233570|NCT02666157|DRUG|Dabigatran etexilate|this drug is administered twice per day for the entire study period
214233571|NCT02666157|DRUG|Rivaroxaban|this drug is administered once per day for the entire study period
214233572|NCT02666157|DRUG|Apixaban|this drug is administered twice per day for the entire study period
214233573|NCT05382000|DIAGNOSTIC_TEST|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
214233574|NCT05633030|PROCEDURE|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
214233575|NCT04825730|DRUG|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
214233576|NCT01413932|DRUG|HT-2157|QD oral dosing
214233577|NCT01413932|DRUG|Placebo|QD oral dosing
214233578|NCT02396160|DIETARY_SUPPLEMENT|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
214233579|NCT02396160|OTHER|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
214233580|NCT03739229|BIOLOGICAL|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
214651794|NCT04485585|DRUG|BR9006-1|* Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
214233581|NCT03739229|BIOLOGICAL|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
214233582|NCT04290728|DEVICE|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
214233583|NCT04290728|OTHER|Apnea|Apnea without any application of oxygenation
214233584|NCT01444092|DRUG|Entocort|Entocort capsules, oral
214233585|NCT05999162|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
214233586|NCT00918008|GENETIC|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
214233587|NCT01037621|DRUG|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
214233588|NCT05170776|OTHER|Pilates and postural correction exercise|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
214233589|NCT05170776|OTHER|Pilates exercises|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1"
214233590|NCT05170776|OTHER|postural correction exercises|"postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period."
214233591|NCT03661476|BEHAVIORAL|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
214233592|NCT02080702|DEVICE|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
214233593|NCT03635580|OTHER|Negative control|Untreated-control group
214233594|NCT06420258|PROCEDURE|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
214233595|NCT01811667|DRUG|Sirolimus|
214233596|NCT01698307|OTHER|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
214233597|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
214233598|NCT01809470|BEHAVIORAL|FIFA2013|Playing FIFA2013 for 1 hour
214233599|NCT01809470|BEHAVIORAL|Call of Duty|Playing Call of Duty for 1 hour
214233600|NCT01809470|BEHAVIORAL|Watching TV|Watching TV for 1 hour
214233601|NCT06066229|OTHER|Questionnaire- Delphi method|Identify important evaluation criteria for lung transplant patients by rating each criterion
214233602|NCT05860270|DRUG|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
214233603|NCT05860270|DRUG|Placebo|Patients in the control group will receive placebo 2 capsules per day.
214233604|NCT00594425|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
214233605|NCT06089369|DRUG|Sintilimab (9 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
214233606|NCT06089369|DRUG|Sintilimab (18 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
214233607|NCT06089369|OTHER|Active surveillance|Active surveillance
214233608|NCT05532670|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
214651795|NCT04485585|DRUG|BR9006-2|"* Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose"
214651796|NCT01951677|DRUG|HBsAg|Standard hepatitis B vaccine antigen
214651797|NCT01951677|BIOLOGICAL|PreS HBsAg|preS hepatitis B surface antigen
214651798|NCT01951677|BIOLOGICAL|Advax-1(TM)|Adjuvant formulated with vaccine antigen
214651799|NCT01951677|BIOLOGICAL|Advax-2(TM)|Adjuvant formulated with vaccine antigen
214651800|NCT01951677|BIOLOGICAL|Advax-3(TM)|Adjuvant formulated with vaccine antigen
214651801|NCT01951677|BIOLOGICAL|Alum|Adjuvant formulated with vaccine antigen
214651802|NCT05300945|COMBINATION_PRODUCT|HIPEC|HIPEC after gastrectomy with D2 local lymph node dissection.
214651803|NCT03052803|DEVICE|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
214651804|NCT00180973|DRUG|Hydroxyurea|
214651805|NCT01957137|DEVICE|InterStim® (Device Programming)|
214651806|NCT03163420|DRUG|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
214651807|NCT03163420|OTHER|Placebo|Fructose
214651808|NCT04553107|BEHAVIORAL|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
214233609|NCT04269382|DEVICE|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
214233610|NCT02965092|GENETIC|Second generation CAR-T cells|
214233611|NCT01122264|DRUG|Tadalafil|Administered orally for 24 weeks.
214233612|NCT01122264|DRUG|Sildenafil Citrate|Administered orally for 24 weeks.
214233613|NCT03813368|PROCEDURE|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
214233614|NCT02085642|OTHER|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
214233615|NCT02085642|OTHER|Sham needle|Retractable needle with no skin puncture
214233616|NCT03209674|PROCEDURE|Cardiothoracic surgery|Cardiac or thoracic procedure
214233617|NCT00657410|DRUG|dexamethasone|
214233618|NCT00657410|DRUG|prednisone|
214233619|NCT00657410|PROCEDURE|quality-of-life assessment|
214233620|NCT01100957|PROCEDURE|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
214233621|NCT03005873|DRUG|TLC599 LD group|Single dose via intra-articular injection
214233622|NCT03005873|DRUG|Normal Saline|Single dose via intra-articular injection
214233623|NCT03005873|DRUG|TLC599 HD group|Single dose via intra-articular injection
214651809|NCT04553107|BEHAVIORAL|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
214651810|NCT01497262|DRUG|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
214651811|NCT00777179|DRUG|Vandetanib|Tablet, oral, daily
214233624|NCT00471809|DRUG|Budesonide + Salmeterol + Azithromycin|
214233625|NCT00471809|DRUG|Budesonide + Salmeterol + Montelukast|
214233626|NCT00471809|DRUG|Budesonide + Salmeterol + Placebo|
214233627|NCT04585009|DRUG|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
214233628|NCT04585009|DRUG|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
214233629|NCT04585009|DEVICE|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
214233630|NCT02558829|DRUG|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
214233631|NCT02558829|DRUG|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
214233632|NCT05320744|PROCEDURE|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
214651812|NCT00777179|DRUG|Placebo|Placebo
214233633|NCT04622800|OTHER|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
214233634|NCT00532675|DRUG|LBH589|PAN 5 mg and PAN 20 mg capsules
214233635|NCT00532675|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 5mg or 25 mg
214233636|NCT00097981|DRUG|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
214233637|NCT00097981|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
214233638|NCT00097981|DRUG|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
214233639|NCT04645277|DEVICE|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
214233640|NCT05814302|DRUG|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
214233641|NCT01337999|OTHER|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
214233642|NCT05588219|DRUG|Tislelizumab|Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
214233643|NCT05588219|DRUG|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
214233644|NCT04662827|DIETARY_SUPPLEMENT|Palmithylethanolamid|PEA 3x/d
214233645|NCT04662827|OTHER|placebo|placebo 3x/d
214233646|NCT00025727|DRUG|Lopinavir/Ritonavir|
214233647|NCT00025727|DRUG|Ritonavir|
214233648|NCT00025727|DRUG|GW433908|
214233649|NCT01031420|DRUG|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
214233650|NCT03956797|DEVICE|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
214233651|NCT05694221|DRUG|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
214233652|NCT05694221|DRUG|Digoxin|Oral Administration
214233653|NCT05694221|DRUG|Metformin|Oral Administration
214233654|NCT02368925|DEVICE|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
214233655|NCT00895011|DRUG|Placebo|One dose 30 minutes prior to initiation of sexual activity
214233656|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
214233657|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
214233658|NCT00312754|DRUG|Atazanavir|
214233659|NCT00641927|DRUG|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
214233660|NCT00641927|DRUG|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
214233661|NCT05506605|DRUG|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
214233662|NCT02713256|DRUG|CFZ533|CFZ533 intravenously over approximately one hour
214233663|NCT03516474|DEVICE|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
214233664|NCT02230527|DRUG|Ticagrelor|90mg twice a day by mouth
214651813|NCT04127201|BEHAVIORAL|en_línea|This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.
214651814|NCT04127201|BEHAVIORAL|Group therapy|This is a traditional behavioral weight control program
214651815|NCT02497001|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
214651816|NCT02497001|DRUG|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
214651817|NCT02497001|DRUG|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
214651818|NCT02497001|DRUG|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
214651819|NCT01656772|DEVICE|Vdrive Lasso navigation|Remote robotic Lasso navigation
214651820|NCT01656772|PROCEDURE|Manual Lasso navigation|Manually maneuver a Lasso catheter
214651821|NCT01415024|PROCEDURE|second LV lead in CRT|second LV lead in CRT
214651822|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
214651823|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
214651824|NCT01011348|DIETARY_SUPPLEMENT|Placebo|Three month period
214651825|NCT02737865|DRUG|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
214233665|NCT02230527|DRUG|Clopidogrel|75mg once a day by mouth
214233666|NCT04941443|DRUG|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
214233667|NCT04941443|DRUG|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
214233668|NCT03277820|DIETARY_SUPPLEMENT|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
214233669|NCT04461600|DRUG|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
214233670|NCT05605145|DIAGNOSTIC_TEST|PCR was used to detect pneumocystis in respiratory specimens|Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.
214233671|NCT05767476|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment"
214233672|NCT03810729|DIAGNOSTIC_TEST|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
214233673|NCT03810729|DIAGNOSTIC_TEST|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
214233674|NCT02376959|BEHAVIORAL|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
214233675|NCT01768884|DRUG|Nitric Oxide|
214233676|NCT01768884|DRUG|Placebo|
214233677|NCT02270853|DEVICE|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
214233678|NCT01613846|DRUG|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
214233679|NCT01613846|DRUG|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
214233680|NCT04848857|DRUG|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
214651826|NCT02737865|DEVICE|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
214651827|NCT05774340|DRUG|CM326|CM326 injection
214233681|NCT04848857|DRUG|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
214651828|NCT05774340|OTHER|Placebo|Placebo
214651829|NCT05587283|DRUG|Experimental: Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.
214233682|NCT00760799|PROCEDURE|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
214233683|NCT01779518|DRUG|Sofosbuvir|
214233684|NCT01779518|DRUG|Ribavirin|
214233685|NCT01779518|DRUG|Pegylated Interferon|
214233686|NCT01242813|DRUG|ACZ885|
214233687|NCT00332735|DRUG|spinal administration of articaine|
214233688|NCT00332735|DRUG|spinal administration of bupivacaine|
214233689|NCT00049985|DRUG|Darbepoetin Alfa|
214233690|NCT02458937|OTHER|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
214233691|NCT02458937|OTHER|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
214233692|NCT02458937|OTHER|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
214233693|NCT02447237|OTHER|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
214233694|NCT02766582|DRUG|Pembrolizumab|IV every 21 days at 200 mg
214233695|NCT02766582|DRUG|Carboplatin|IV every 21 days
214233696|NCT02766582|DRUG|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
214233697|NCT04319497|DEVICE|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
214233698|NCT04319497|DEVICE|Autorefraction|Five autorefraction measurements will be performed for all the patients included
214233699|NCT04319497|DEVICE|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
214233700|NCT03126552|BIOLOGICAL|Necator americanus L3 larvae|50 Necator americanus L3 larvae
214233701|NCT01910311|DRUG|Baricitinib|Administered orally
214233702|NCT01910311|DRUG|Rifampicin|Administered orally
214233703|NCT00228176|DRUG|Rimonabant|Tablet, oral administration
214233704|NCT00228176|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214233705|NCT04269083|OTHER|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
214233706|NCT00400036|BEHAVIORAL|Cod protein NCEP-diet|
214233707|NCT04098055|DEVICE|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
214233708|NCT04098055|DEVICE|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
214233709|NCT01106417|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
214233710|NCT01106417|DEVICE|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
214233711|NCT04232969|DRUG|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
214233712|NCT04504851|DRUG|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
214233713|NCT04504851|DRUG|Rifampicin|Rifampicin 10mg/kg
214233714|NCT04504851|DRUG|Isoniazid|Isoniazid 5mg/kg
214233715|NCT04504851|DRUG|Pyrazinamide|Pyrazinamide 25mg/kg
214233716|NCT04504851|DRUG|Ethambutol|Ethambutol 15mg/kg
214233717|NCT01369329|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
214233718|NCT01369329|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
214233719|NCT01369329|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
214233720|NCT01252667|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
214233721|NCT01252667|DRUG|Clofarabine|Given IV
214233722|NCT01252667|DRUG|Cyclosporine|Given PO
214233723|NCT01252667|OTHER|Laboratory Biomarker Analysis|Correlative studies
214233724|NCT01252667|DRUG|Mycophenolate Mofetil|Given PO
214233725|NCT01252667|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
214233726|NCT01252667|OTHER|Pharmacological Study|Optional correlative studies
214233727|NCT01252667|RADIATION|Total-Body Irradiation|Undergo TBI
214233728|NCT05955573|DIAGNOSTIC_TEST|xray|radiological description
214233729|NCT04403009|OTHER|no intervention|no intervention
214233730|NCT03851172|DRUG|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
214233731|NCT03851172|DRUG|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
214233732|NCT03851172|DRUG|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
214233733|NCT05307367|BEHAVIORAL|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
214233734|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
214233735|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
214233736|NCT06411171|DRUG|Pembrolizumab plus chemotherapy (FLOT)|The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
214233737|NCT01127789|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
214233738|NCT01836276|DRUG|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
214233739|NCT04532580|DEVICE|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
214233740|NCT01847131|DRUG|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
214233741|NCT01847131|DRUG|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
214233742|NCT05247528|DRUG|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
214233743|NCT05247528|DRUG|Placebo|Placebo Comparator
214233744|NCT03014882|DRUG|L-Carnitine and N-acetyl cysteine|
214233745|NCT04994470|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
214233746|NCT04994470|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
214233747|NCT00331552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214233748|NCT00331552|DRUG|cyclophosphamide|Given orally
214233749|NCT00331552|BIOLOGICAL|trastuzumab|Given IV
214233750|NCT05507788|DEVICE|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
214233751|NCT01708096|DIETARY_SUPPLEMENT|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
214233752|NCT01708096|DIETARY_SUPPLEMENT|Normal diet|normal diet 2 weeks before gastric by-pass
214233753|NCT00767182|OTHER|blood sample|biological markers evaluated : D-Dimer, sEPCR
214233754|NCT00072527|DRUG|carboplatin|IV
214233755|NCT00072527|DRUG|cisplatin|IV
214233756|NCT00072527|DRUG|etoposide|IV
214233757|NCT00072527|DRUG|irinotecan hydrochloride|IV
214233758|NCT00072527|RADIATION|radiation therapy|
214233759|NCT00223782|BEHAVIORAL|Gait Training with Feedback|
214233760|NCT00223782|BEHAVIORAL|Gait Training with no feedback|
214233761|NCT04664894|DRUG|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
214233762|NCT01413633|PROCEDURE|cholecystectomy|single incision laparoscopic cholecystectomy
214233763|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
214233764|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
214233765|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
214233766|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
214233767|NCT03611257|DIAGNOSTIC_TEST|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
214233768|NCT03611257|DIAGNOSTIC_TEST|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
214233769|NCT02204761|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
214233770|NCT02824406|DRUG|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
214233771|NCT03675906|OTHER|hypoalbuminemia|hypoalbuminemia and acute kidney injury
214233772|NCT01786070|DRUG|Budesonide|
214233773|NCT01786070|DRUG|placebo|
214233774|NCT01609829|PROCEDURE|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
214233775|NCT06519045|DEVICE|Intelligent Fingerprinting Drug Screening System|The Intelligent Fingerprinting Drug Screening System utilizes a single-use, rapid, non-invasive fingerprint sweat drug screening test intended for use with the Intelligent Fingerprinting DSR-Plus fluorescence reader. The Intelligent FingerprintingTM Fingerprint Collection Kit for Laboratory Analysis (i.e. confirmation test) provides a quantitative analytical result via laboratory-based liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is used to collect and measure drug mass in the full set of 10 fingerprints.
214233776|NCT02815722|DRUG|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
214233777|NCT02815722|DRUG|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
214233778|NCT02686008|DRUG|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
214233779|NCT02532699|DIETARY_SUPPLEMENT|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
214233780|NCT02532699|DIETARY_SUPPLEMENT|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
214233781|NCT04009811|DEVICE|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
214233782|NCT01620320|OTHER|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
214233783|NCT02198001|DRUG|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
214233784|NCT02198001|PROCEDURE|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
214233785|NCT04204551|BEHAVIORAL|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
214233786|NCT04204551|BEHAVIORAL|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
214233787|NCT02899572|PROCEDURE|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
214233788|NCT04958460|DRUG|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
214233789|NCT04958460|OTHER|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
214233790|NCT04414735|OTHER|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
214233791|NCT03687463|DRUG|Decitabine|Decitabine for injection
214233792|NCT03558880|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block was performed
214233793|NCT03558880|PROCEDURE|Tumescent Anesthesia|Tumescent Anesthesia was applied
214233794|NCT00692536|BEHAVIORAL|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
214233795|NCT00692536|BEHAVIORAL|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
214233796|NCT04287543|DRUG|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
214233797|NCT04287543|DRUG|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
214233798|NCT06277843|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
214233799|NCT04195971|DIAGNOSTIC_TEST|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
214233800|NCT02577887|DEVICE|Patients implanted with a St. Jude Medical pacemakers|
214651830|NCT05587283|DRUG|Experimental: Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.
214651831|NCT05587283|DRUG|Experimental: High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule, 5 x 10\^9 CFU/capsule with excipients.
214651832|NCT05587283|OTHER|Placebo Comparator: Low dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
214651833|NCT05587283|OTHER|Placebo Comparator: Medium dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
214651834|NCT05587283|OTHER|Placebo Comparator: High dose Placebo capsule|High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
214651835|NCT02947867|DRUG|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
214651836|NCT03898063|BEHAVIORAL|90 DAYS film|the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
214651837|NCT03898063|BEHAVIORAL|HIV pamphlet on disclosure|A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
214233801|NCT06146231|DEVICE|Motiva Flora® Tissue Expander|"This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant.~Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication.~To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study."
214233802|NCT02135003|OTHER|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
214233803|NCT03560518|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
214233804|NCT03560518|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
214233805|NCT01879644|BEHAVIORAL|NF|
214233806|NCT01879644|BEHAVIORAL|SM|
214233807|NCT01879644|BEHAVIORAL|PE|
214233808|NCT01879644|BEHAVIORAL|SU|
214233809|NCT01078818|DRUG|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
214233810|NCT01078818|DRUG|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
214233811|NCT01078818|DRUG|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
214233812|NCT02852187|DEVICE|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
214233813|NCT02852187|DEVICE|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
214233814|NCT04829084|BEHAVIORAL|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
214233815|NCT05468047|DRUG|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
214233816|NCT03014999|DEVICE|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
214233817|NCT03014999|DEVICE|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
214651838|NCT05610371|DRUG|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
214651839|NCT05610371|DRUG|Saline|The control group underwent hysteroscopy using a saline distension medium.
214651840|NCT04937010|PROCEDURE|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
214651841|NCT03706573|DRUG|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
214651842|NCT04392960|DRUG|[18F]Florbetaben|"Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
214651843|NCT03684135|OTHER|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
214651844|NCT02347904|DRUG|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
214651845|NCT03711903|DRUG|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
214651846|NCT03711903|DRUG|0.9% Sodium-chloride|normal saline
214233818|NCT03014999|DEVICE|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
214233819|NCT03338322|DEVICE|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
214233820|NCT03338322|DEVICE|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
214233821|NCT03356704|OTHER|no intervention|Observational study
214233822|NCT03782831|PROCEDURE|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
214233823|NCT03782831|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214233824|NCT03782831|DRUG|Placebos|intravenous injection every 2 weeks
214233825|NCT03708562|DEVICE|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
214233826|NCT05229861|BEHAVIORAL|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
214233827|NCT05229861|BEHAVIORAL|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
214233828|NCT06329128|OTHER|Experimental: Study Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization"
214233829|NCT06329128|OTHER|Active Comparator: Control Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary."
214233830|NCT02984943|DEVICE|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
214233831|NCT04155411|DRUG|Dasatinib|70 mg of Dasatinib orally daily for 12 months
214233832|NCT04575792|BEHAVIORAL|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
214233833|NCT04220593|OTHER|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
214233834|NCT01133990|DRUG|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
214233835|NCT01133990|DRUG|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
214233836|NCT01133990|DRUG|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
214233837|NCT04329689|OTHER|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
214233838|NCT04135105|OTHER|Normal hearing group|Observational
214233839|NCT05277337|BIOLOGICAL|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
214233840|NCT05277337|BIOLOGICAL|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
214233841|NCT03743077|BEHAVIORAL|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
214651847|NCT02949830|DRUG|Givosiran|Givosiran by subcutaneous (SC) injection.
214651848|NCT00054132|BIOLOGICAL|Bevacizumab|Given IV
214651849|NCT00054132|DRUG|Erlotinib Hydrochloride|Given PO
214233842|NCT05704127|OTHER|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
214233843|NCT05704127|OTHER|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
214233844|NCT03229174|DRUG|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
214233845|NCT03229174|DRUG|Placebo|Placebo (sugar pill)
214233846|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm bevel|Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
214233847|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm stair-step chamfer|Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
214233848|NCT00734955|DEVICE|49-channel optical spectrometer|
214233849|NCT00005866|DRUG|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
214233850|NCT00005866|DRUG|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
214233851|NCT00005866|DRUG|cyclosporine|both arms per published schedule
214233852|NCT00005866|DRUG|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
214233853|NCT00005866|PROCEDURE|allogeneic bone marrow transplantation|day 0
214233854|NCT00005866|RADIATION|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
214233855|NCT04182464|OTHER|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
214233856|NCT04182464|OTHER|Placebo|Cornstarch without significant physiological effects
214233857|NCT03271983|DRUG|Metronidazole gel 1|RLD gel
214233858|NCT03271983|DRUG|Metronidazole gel 2|generic gel
214651850|NCT00054132|OTHER|Laboratory Biomarker Analysis|Correlative studies
214651851|NCT06087757|DRUG|Open Label Clemastine with a blinded randomize withdrawal|Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
214233859|NCT03271983|DRUG|Metronidazole cream|generic cream
214233860|NCT01552798|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
214233861|NCT01552798|DRUG|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
214233862|NCT01552798|DRUG|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
214651852|NCT03955094|DEVICE|Intubation via AMBU® AURAGAIN™|Success rate of paediatric intubation through AMBU® AURAGAIN™
214233863|NCT05555173|DEVICE|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
214233864|NCT02052765|DEVICE|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
214233865|NCT05282056|DIAGNOSTIC_TEST|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
214233866|NCT00004082|DRUG|carboplatin|
214233867|NCT00004082|DRUG|docetaxel|
214233868|NCT00004082|DRUG|gemcitabine hydrochloride|
214233869|NCT00543244|DRUG|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
214233870|NCT02402738|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|
214233871|NCT02402738|BEHAVIORAL|Enhanced Treatment as Usual|
214233872|NCT02282345|OTHER|Laboratory Biomarker Analysis|Correlative studies
214233873|NCT02282345|DRUG|Talazoparib|Given PO
214233874|NCT04564768|BEHAVIORAL|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
214233875|NCT01185301|BIOLOGICAL|adalimumab|Pre-filled syringe every other week
214233876|NCT01185301|DRUG|methotrexate|weekly oral capsule dosing
214233877|NCT01319331|DRUG|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
214651853|NCT01290887|DRUG|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
214651854|NCT02920060|DRUG|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
214651855|NCT02920060|DRUG|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
214651856|NCT03316352|PROCEDURE|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
214233878|NCT05214053|DEVICE|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
214233879|NCT03529071|BEHAVIORAL|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
214233880|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
214233881|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
214233882|NCT02683746|DRUG|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
214233883|NCT02683746|DRUG|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
214233884|NCT01191216|DRUG|1-methyl-d-tryptophan|
214233885|NCT01191216|DRUG|docetaxel|
214233886|NCT01191216|OTHER|diagnostic laboratory biomarker analysis|
214233887|NCT01191216|OTHER|pharmacological study|
214233888|NCT06054204|DEVICE|lateral bony window|bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
214233889|NCT00023699|DRUG|gefitinib|
214233890|NCT04987944|DRUG|Zavegepant|150 mg BID
214233891|NCT04987944|DRUG|Placebo|Placebo matching active drug
214233892|NCT00088556|DRUG|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
214233893|NCT00088556|DRUG|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
214233894|NCT00088556|DRUG|paclitaxel|200 mg/m² Once every 3 weeks
214233895|NCT01663753|DEVICE|18F-FDG-PET|
214233896|NCT05306821|OTHER|Comprehensive electronic tool in the electronic medical chart|Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis
214233897|NCT05306821|OTHER|Educative sessions|Educative sessions on thromboprophylaxis
214233898|NCT05306821|OTHER|Pocket card|Pocket card (guide for thromboprophylaxis)
214233899|NCT05277480|DRUG|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
214233900|NCT05277480|DRUG|IE|ifosfamide ivgtt ; etoposide ivgtt .
214233901|NCT04563832|OTHER|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
214233902|NCT04563832|OTHER|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
214233903|NCT04924413|DRUG|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
214233904|NCT00401362|DRUG|SC Methylnaltrexone|Dose 1
214233905|NCT00401362|DRUG|SC Placebo|
214233906|NCT00401362|DRUG|SC Methylnaltrexone|Dose 2
214233907|NCT05205577|DEVICE|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
214651857|NCT03316352|PROCEDURE|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
214233908|NCT00790309|PROCEDURE|Weight loss surgery|Weight loss surgery
214651858|NCT03316352|DEVICE|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
214651859|NCT03316352|DRUG|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
214233909|NCT00790309|PROCEDURE|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
214233913|NCT05519293|DRUG|H002|Small molecule, Capsule
214233914|NCT02983097|DRUG|Rituximab|Rituximab 375 mg/m²
214233915|NCT02983097|DRUG|Cisplatin|Cisplatinum 100 mg / m²
214233916|NCT02983097|DRUG|Carboplatin|Carboplatinum AUC5
214233917|NCT02983097|DRUG|Dexamethasone|Dexamethasone 40 mg
214233918|NCT02983097|DRUG|Cytarabine|Cytarabine 2000 mg/m², administered twice
214233919|NCT02983097|DRUG|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
214233920|NCT02983097|DRUG|PegFilgrastim|PegFilgrastim 6 mg
214233921|NCT02983097|PROCEDURE|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
214233922|NCT00595374|DRUG|insulin detemir|
214233923|NCT00595374|DRUG|insulin NPH|
214233924|NCT00595374|DRUG|insulin aspart|
214233925|NCT00400296|DRUG|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
214233926|NCT05662709|PROCEDURE|Tooth extraction|Tooth extraction in the most atraumatic way
214233927|NCT05662709|PROCEDURE|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
214233928|NCT05535010|PROCEDURE|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
214233929|NCT05094973|DEVICE|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
214233930|NCT04272112|COMBINATION_PRODUCT|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
214233931|NCT04272112|COMBINATION_PRODUCT|BruxZir, Glidewell|Type: high translucent zirconia
214233932|NCT04272112|COMBINATION_PRODUCT|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
214233933|NCT05753579|BEHAVIORAL|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
214233934|NCT05753579|BEHAVIORAL|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
214233935|NCT00345332|DRUG|Botox|Injected
214233936|NCT00345332|DRUG|Placebo|Injected
214233937|NCT05585281|DRUG|Fluzoparib|Fluzoparib Orally twice daily
214233938|NCT05585281|BIOLOGICAL|QL1101|Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
214233939|NCT03096587|DEVICE|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
214233940|NCT03096587|DEVICE|ultrasonic activated irrigation|by Satelec,Acteon, France
214233941|NCT03409978|DEVICE|in-Motion app|mobile phone application for recording fidgety movements at home
214233942|NCT00499057|RADIATION|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
214233943|NCT02085031|PROCEDURE|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
214233944|NCT02085031|PROCEDURE|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
214233945|NCT02294760|DEVICE|Subsensory|The stimulation is set to 90% of the sensory threshold.
214233946|NCT02294760|DEVICE|OFF|The stimulation is turned OFF.
214233947|NCT01606657|PROCEDURE|Irrigation|The patient will receive irrigation as a part of their wound care
214233948|NCT01606657|OTHER|No Irrigation|The patient will not receive irrigation as part of their wound care
214233949|NCT04125264|DEVICE|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
214233950|NCT01781091|DEVICE|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
214233951|NCT01781091|DEVICE|Conventionals Modes|
214233952|NCT04012489|PROCEDURE|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
214233953|NCT04012489|PROCEDURE|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
214233954|NCT01329835|BEHAVIORAL|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
214233955|NCT01329835|OTHER|brochure|brochure given after randomization
214233956|NCT00105365|DEVICE|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
214233957|NCT00105365|OTHER|walking shoes|walking shoes
214651860|NCT05430269|OTHER|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
214233958|NCT01602133|PROCEDURE|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
214233959|NCT00128505|DRUG|Mifepristone|
214233960|NCT04121078|DRUG|TAK-906|TAK-906 capsule.
214233961|NCT04121078|DRUG|Rifampin|Rifampin infusion.
214233962|NCT02353143|DRUG|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
214233963|NCT05920083|OTHER|CPAP withdrawal|2 weeks of CPAP withdrawal
214233964|NCT00817128|PROCEDURE|PEPT|Pain Exposure Physical Therapy
214233965|NCT00817128|PROCEDURE|CBO standard|Standard therapy as defined in CBO guideline 2006
214651861|NCT05430269|OTHER|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
214651862|NCT01811511|DIETARY_SUPPLEMENT|Chungkookjang|
214651863|NCT01811511|DIETARY_SUPPLEMENT|Placebo|
214233966|NCT01981057|OTHER|Numeta|parenteral receipt prescribed with Numeta
214233967|NCT01981057|OTHER|Individual|parenteral receipt prescribed individually
214233968|NCT03040570|PROCEDURE|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
214233969|NCT03040570|PROCEDURE|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
214233970|NCT03751306|PROCEDURE|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
214233971|NCT03751306|PROCEDURE|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
214233972|NCT03751306|PROCEDURE|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
214233973|NCT02946931|DRUG|Prizbind®|Prizbind®
214233974|NCT04476173|DRUG|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
214233975|NCT04476173|DRUG|Morphine|ACS patients who received intravenous morphine as analgesic treatment
214233976|NCT05015985|OTHER|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
214233977|NCT05015985|OTHER|control group|music relaxation using a music playlist supply (control group)
214233978|NCT00126880|DRUG|AVX754|apricitabine, 600mg BID or 800mg BID
214233979|NCT00126880|DRUG|3TC|3TC, 150mg BID
214233980|NCT06409793|BEHAVIORAL|mHealth|A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
214233981|NCT05198544|DEVICE|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
214233982|NCT03288792|DEVICE|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
214233983|NCT02213133|DRUG|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
214233984|NCT03196388|DRUG|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
214233985|NCT02991989|BEHAVIORAL|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
214233986|NCT02991989|DIETARY_SUPPLEMENT|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
214233987|NCT06275633|DRUG|Levodopa|Medicine response
214651864|NCT02886299|DRUG|Fenofibrate|
214233988|NCT03121976|DEVICE|Ultrasound|Femoral catheter inserted using ultrasound only
214233989|NCT03121976|DEVICE|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
214233990|NCT02208687|BEHAVIORAL|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
214233991|NCT02208687|OTHER|Control group|Usual care
214233992|NCT04691947|BIOLOGICAL|ERUCOV-VAC|Vaccination on Day 0 and Day 21
214233993|NCT04691947|OTHER|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
214233994|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
214233995|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
214233996|NCT02012582|DRUG|VAS203|i.v. infusion
214233997|NCT02012582|DRUG|Saline|i.v. infusion
214651865|NCT02886299|DRUG|Simvastatin|
214651866|NCT01705015|BEHAVIORAL|direct feedback about exercise|
214233998|NCT01929941|DRUG|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
214233999|NCT01929941|DRUG|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
214234000|NCT01929941|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
214234001|NCT01929941|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
214234002|NCT00704275|DRUG|0.05% cyclosporin eye drop|bid dosage for 4 months
214234003|NCT00375401|DRUG|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
214234004|NCT00375401|DRUG|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
214234005|NCT00375401|DRUG|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
214234006|NCT00511225|DIETARY_SUPPLEMENT|cholecalciferol|10,000 IU weekly
214234007|NCT00511225|DIETARY_SUPPLEMENT|placebo|placebo capsule
214234008|NCT00865423|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
214234009|NCT00865423|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
214234010|NCT01374035|OTHER|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
214234011|NCT06405945|GENETIC|PCR and sequence|sequence the mutatation SNPs
214234012|NCT02480725|PROCEDURE|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
214234013|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 1|
214234014|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 2|
214234015|NCT01229917|OTHER|Standard fruit juice|
214234016|NCT01277003|DEVICE|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
214234017|NCT01277003|DEVICE|TENS|tow therapeutic points, each for 15 minutes
214234018|NCT06292611|DEVICE|Battery operated toothbrush|Device on extrinsic stain removal efficacy
214234019|NCT06292611|DEVICE|Manual toothbrush|Device on extrinsic stain removal efficacy
214234020|NCT00802815|DRUG|Etanercept|50 milligrams subcutaneously every week
214234021|NCT04244305|OTHER|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
214234022|NCT01883856|DEVICE|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
214234023|NCT01883856|DEVICE|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
214234024|NCT02673541|DEVICE|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
214234025|NCT02673541|DEVICE|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
214234026|NCT01426542|DRUG|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
214234027|NCT01426542|OTHER|No medication, but routine heart surgery|No medication, but routine heart surgery
214234028|NCT00557817|DRUG|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
214234029|NCT00557817|DRUG|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
214234030|NCT05947292|PROCEDURE|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
214234031|NCT00435253|BIOLOGICAL|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
214234032|NCT02816567|DRUG|propofol|
214234033|NCT02816567|DRUG|NMBA - cisatracurium|
214234034|NCT02816567|DRUG|placebo - isotonic saline serum|
214234035|NCT02816567|DRUG|sufentanil|
214234036|NCT02816567|PROCEDURE|laparoscopic surgery|
214234037|NCT04740905|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
214234038|NCT04740905|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
214234039|NCT04740905|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214234040|NCT02663726|OTHER|Yoga|10 weekly 75-min sessions of specialised yoga
214234041|NCT02663726|BEHAVIORAL|Written advice|Written advice about physical activity
214651867|NCT01705015|BEHAVIORAL|PLacebo|UCFit plus encouraged exercise
214234042|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
214234043|NCT02789319|DEVICE|Blood Glucose Meter Systems|
214234044|NCT00594724|PROCEDURE|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
214234045|NCT04316910|DRUG|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
214234046|NCT02700334|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
214234047|NCT02700334|DRUG|Placebo|one per day before breakfast during 12 weeks.
214234048|NCT04538209|RADIATION|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
214234049|NCT06192810|PROCEDURE|Laparoscopic/open adrenalectomy|
214234050|NCT01479283|DRUG|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
214234051|NCT01479283|DRUG|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
214234052|NCT03340103|DIETARY_SUPPLEMENT|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
214234053|NCT03340103|DRUG|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
214234054|NCT01368718|PROCEDURE|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
214234055|NCT03313661|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
214234056|NCT03313661|DRUG|Gliclazide|gliclazide (60-120 mg)
214234057|NCT00003798|DRUG|motexafin gadolinium|
214234058|NCT00003798|RADIATION|radiation therapy|
214234059|NCT01023477|DRUG|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
214234060|NCT01023477|DRUG|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
214234061|NCT01023477|PROCEDURE|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
214234062|NCT02412488|OTHER|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
214234063|NCT02817477|DRUG|Ketamine Hydrochloride|Delivered intranasally using an atomizer
214234064|NCT02817477|DRUG|Morphine|Delivered either as an IM injection or a slow IV bolus
214234065|NCT01989468|BIOLOGICAL|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
214234066|NCT01989468|BIOLOGICAL|Placebo|Secukinumab placebo provided in 1 mL autoinjector
214234067|NCT00742664|BEHAVIORAL|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
214234068|NCT00742664|BEHAVIORAL|Wait-list control|The subject will not receive active treatment during this interval.
214234069|NCT01634425|DEVICE|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
214234070|NCT02409108|DEVICE|Exatherm-TBH system|One treatment of Total Body Hyperthermia
214234071|NCT01402336|DRUG|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
214234072|NCT01402336|DRUG|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
214234073|NCT00289055|DEVICE|stent|Cordis SMART™ Nitinol Stent
214234074|NCT00289055|DEVICE|angioplasty|balloon angioplasty
214651868|NCT04058522|OTHER|Rotator cuff rehabilitation classes|
214234075|NCT01640327|BIOLOGICAL|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
214234076|NCT02864485|PROCEDURE|live donor liver transplantation|live donor liver transplantation
214234077|NCT01371370|OTHER|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
214234078|NCT01371370|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
214234079|NCT01371370|OTHER|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
214234080|NCT03222492|BIOLOGICAL|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
214234081|NCT03222492|BIOLOGICAL|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
214234082|NCT01797770|DRUG|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
214234083|NCT01797770|OTHER|No Preparation|No laxatives or bowel preparation
214234084|NCT03156647|DIAGNOSTIC_TEST|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
214234085|NCT01143805|DRUG|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
214234086|NCT01143805|DRUG|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
214234087|NCT02451371|DEVICE|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
214234088|NCT05587946|OTHER|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
214234089|NCT00447200|PROCEDURE|Esophagus Doppler monitoring|
214234090|NCT00447200|PROCEDURE|Fluid optimization|
214234091|NCT01891526|DRUG|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
214234092|NCT06515067|OTHER|back massage|back massage
214234093|NCT06515067|OTHER|no ıntervention|no ıntervention
214234094|NCT03396757|PROCEDURE|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
214234095|NCT03396757|PROCEDURE|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
214234096|NCT01190423|BEHAVIORAL|Family Based Therapy for young adults|Individual and Group Therapy Sessions
214234097|NCT04560244|DRUG|SHR1701|PD-L1 / TGF-β RII double antibody
214234098|NCT01229462|DRUG|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
214234099|NCT01229462|DRUG|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
214234100|NCT01229462|DRUG|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
214651869|NCT04058522|OTHER|Individual Physiotherapy|
214651870|NCT04058522|DRUG|Triamcinolone Injection|Subacromial Injection 40mg/1ml
214234101|NCT01229462|OTHER|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
214234102|NCT02830269|DEVICE|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
214234103|NCT03080077|DRUG|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
214651871|NCT01042444|DEVICE|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
214234104|NCT03080077|DRUG|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
214234105|NCT05313100|DRUG|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
214234106|NCT03134079|OTHER|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
214234107|NCT03134079|OTHER|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
214234108|NCT03134079|OTHER|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
214234109|NCT05121571|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214234110|NCT05121571|DRUG|Sorafenib|sorafenib 400mg bid
214234111|NCT01476202|DRUG|nicotine|nicotine in the form of a mouth strip, lozenge and gum
214234112|NCT06046157|OTHER|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
214234113|NCT06046157|OTHER|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
214234114|NCT02963844|OTHER|Inspiratory Muscle Training|
214234115|NCT02963844|OTHER|Inspiratory Muscle Training Sham|
214234116|NCT01906879|DRUG|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
214234117|NCT02189954|PROCEDURE|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
214234118|NCT02189954|PROCEDURE|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
214234119|NCT01861951|DRUG|Pazopanib|
214234120|NCT01861951|DRUG|Doxorubicin|
214234121|NCT06405620|OTHER|Assistance robot|the child controls the robot at his parent's home from his room
214234122|NCT02771691|OTHER|Mentalization-Based Group Therapy for Adolescents|
214234123|NCT06631053|OTHER|velocity-based FIT (VBFIT)|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week"
214234124|NCT06631053|OTHER|No Exercise|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study."
214234125|NCT03028454|DIETARY_SUPPLEMENT|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
214234126|NCT03028454|DIETARY_SUPPLEMENT|Placebo|Capsules containing rice flour powder.
214234127|NCT00065429|DRUG|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
214234128|NCT03515317|BEHAVIORAL|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
214234129|NCT03515317|BEHAVIORAL|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
214234130|NCT00355836|BEHAVIORAL|Mental Imagery|
214234131|NCT03208582|DRUG|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
214234132|NCT03208582|DIETARY_SUPPLEMENT|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
214234133|NCT01671943|DEVICE|Ice-Sense3TM|Ice-Sense Cryoprobe
214234134|NCT00002642|DRUG|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
214234135|NCT00002642|DRUG|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
214234136|NCT00002642|PROCEDURE|conventional surgery|surgery some time between weeks 9 and 12
214234137|NCT00002642|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
214234138|NCT01762020|DEVICE|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
214234139|NCT01762020|DRUG|Standard Preparation|standard creams
214234140|NCT06264388|DRUG|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
214234141|NCT06264388|DRUG|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
214234142|NCT05547009|OTHER|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
214234143|NCT05547009|OTHER|Face-to-face learning group|The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
214234144|NCT02084290|BEHAVIORAL|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
214234145|NCT00118495|DRUG|Non-prescription Zestra(TM): patented formulation|
214234146|NCT00331110|DEVICE|Laterally-Wedged Insole with Ankle Strapping|
214234147|NCT00331110|DEVICE|Laterally-Weged Insole|
214234148|NCT00243646|RADIATION|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
214234149|NCT00243646|DRUG|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
214234150|NCT00243646|DRUG|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
214234151|NCT00528541|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
214234152|NCT00528541|BIOLOGICAL|botulinum toxin type A|750 Units at Visit 1 (Day 1)
214234153|NCT02015221|DEVICE|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
214234154|NCT02015221|DEVICE|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
214234155|NCT01770444|OTHER|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)"
214234156|NCT01770444|OTHER|Conventional cardiac CT protocol|"Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)"
214234157|NCT01845623|DRUG|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
214234158|NCT01845623|DRUG|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
214234159|NCT01845623|OTHER|Placebo Concept 1|Placebo administered via the Concept 1 device.
214234160|NCT01845623|OTHER|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
214234161|NCT02896322|RADIATION|Partial breast irradiation with cyberknife|
214234162|NCT03158662|OTHER|Survey|Survey Study
214234163|NCT05387499|DRUG|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
214234164|NCT05387499|DRUG|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
214234165|NCT05387499|OTHER|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
214234166|NCT00995566|DRUG|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
214234167|NCT06134011|OTHER|Without any intervention|There were no special interventions for the two groups.
214234168|NCT01975857|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
214234169|NCT01975857|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
214234170|NCT03520127|DEVICE|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
214234171|NCT02434588|DEVICE|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
214234172|NCT05711303|DIETARY_SUPPLEMENT|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
214234173|NCT00174772|DRUG|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
214234174|NCT00174772|DRUG|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
214234175|NCT02375789|DEVICE|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
214234176|NCT02375789|DEVICE|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
214234177|NCT06401629|DIAGNOSTIC_TEST|NPRP criteria|Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
214234178|NCT06401629|DIAGNOSTIC_TEST|IADPSG criteria|The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
214234179|NCT06430827|DRUG|irinotecan hydrochloride liposome injection|rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
214234180|NCT06430827|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
214234181|NCT01576159|OTHER|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
214234182|NCT01576159|OTHER|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
214234183|NCT01576159|OTHER|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
214234184|NCT00223236|DRUG|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
214234185|NCT00223236|DRUG|Placebo|Placebo matching active medication in all other aspects.
214234186|NCT01763840|DRUG|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
214234187|NCT04429477|DEVICE|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
214651872|NCT04725279|PROCEDURE|Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home|The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
214651873|NCT03471325|PROCEDURE|Plaque disclosed with air flow|air polishing with prior plaque disclosing
214651874|NCT03471325|PROCEDURE|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
214651875|NCT03471325|PROCEDURE|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
214234188|NCT06335563|PROCEDURE|AR glasses-assisted pulmonary nodule puncture localization|Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
214234189|NCT06335563|PROCEDURE|CT-guided pulmonary nodule puncture localization|Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
214234190|NCT01181986|DRUG|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
214234191|NCT01181986|DRUG|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
214234192|NCT01181986|DRUG|Placebo SC|Placebo sc BID/10days
214234193|NCT01181986|DRUG|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
214234194|NCT01181986|DRUG|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
214234195|NCT02639416|DIETARY_SUPPLEMENT|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
214234196|NCT02639416|DIETARY_SUPPLEMENT|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
214234197|NCT02639416|OTHER|Standard management|Standard management with F-100 and/or RUTF
214234198|NCT06110637|OTHER|"hard shoes runners evaluation"|"The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
214234199|NCT06110637|OTHER|"Soft shoes runners evaluation"|"The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
214234200|NCT02549599|BEHAVIORAL|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
214234201|NCT02549599|BEHAVIORAL|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
214234202|NCT02549599|OTHER|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
214234203|NCT03720652|BEHAVIORAL|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~* Discovering Mindful Self-Compassion~* Practicing Mindfulness~* Practicing Lovingkindness~* Discovering your Compassionate Voice~* Living Deeply~* Meeting Difficult Emotions~* Exploring Challenging Relationships~* Embracing Your Life"
214234204|NCT03720652|BEHAVIORAL|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~* What is Self-Compassion~* Practicing Self-Compassion~* Discovering your Compassionate Voice~* Self-Compassion and Resilience~* Self-Compassion and Burnout~* Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
214234205|NCT03073733|BIOLOGICAL|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
214234206|NCT03073733|OTHER|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
214234207|NCT06436677|OTHER|molecular subtype based treatment|The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
214234208|NCT01454778|DRUG|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose"
214234209|NCT03254511|DRUG|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
214234210|NCT03254511|RADIATION|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
214234211|NCT03254511|DRUG|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
214234212|NCT01274689|OTHER|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
214234213|NCT00835731|DRUG|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
214234214|NCT00835731|DEVICE|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
214234215|NCT03558568|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
214234216|NCT00348881|BIOLOGICAL|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
214234217|NCT00348881|BIOLOGICAL|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
214234218|NCT00348881|BIOLOGICAL|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
214234219|NCT03428919|PROCEDURE|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
214234220|NCT03428919|PROCEDURE|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
214234221|NCT01407380|DRUG|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
214234222|NCT04084561|BEHAVIORAL|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (\~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (\~90%).
214234223|NCT04084561|BEHAVIORAL|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (\~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (\~10%).
214234224|NCT04084561|BEHAVIORAL|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
214234225|NCT04084561|BEHAVIORAL|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
214234226|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
214234227|NCT00900887|DRUG|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
214234228|NCT00900887|DRUG|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
214234229|NCT00900887|DRUG|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
214234230|NCT04184986|DIAGNOSTIC_TEST|dry blood test|screening test for Fabry disease
214234231|NCT04816409|OTHER|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~\- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
214234232|NCT04816409|OTHER|Neurodevelopmental therapy|"Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
214234233|NCT04650880|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation
214234234|NCT04650880|OTHER|Placebo|Placebo tablets with the same external appearance
214234235|NCT04090099|OTHER|Erector spina plane block|While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
214234236|NCT01221272|DRUG|Ranolazine|"* One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
214234237|NCT01221272|DRUG|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
214234238|NCT01221272|PROCEDURE|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
214234239|NCT01221272|BEHAVIORAL|Exercise|Treadmill stress test
214234240|NCT04839562|DRUG|Solriamfetol 75 MG|Daily oral consumption
214234241|NCT04839562|DRUG|Solriamfetol 150 MG|Daily oral consumption
214234242|NCT04839562|OTHER|Placebo|Placebo
214234243|NCT02099071|DRUG|ACT-389949 1 mg|
214234244|NCT02099071|DRUG|ACT-389949 5 mg|
214234245|NCT02099071|DRUG|ACT-389949 20 mg|
214234246|NCT02099071|DRUG|ACT-389949 50 mg|
214234247|NCT02099071|DRUG|ACT-389949 100 mg|
214234248|NCT02099071|DRUG|ACT-389949 200 mg|
214234249|NCT02099071|DRUG|ACT-389949 500 mg|
214234250|NCT02099071|DRUG|ACT-389949 1000 mg|
214234251|NCT02099071|DRUG|Placebo|
214234252|NCT03509415|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
214234253|NCT01761071|DRUG|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
214234254|NCT01761071|DRUG|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
214234255|NCT04486274|OTHER|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
214234256|NCT00828373|DRUG|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
214234257|NCT00828373|DRUG|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
214234258|NCT01246466|DEVICE|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
214234259|NCT05334095|DEVICE|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
214234260|NCT05334095|DEVICE|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
214234261|NCT04612296|GENETIC|Research genetic analysis|Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
214234262|NCT00693862|DRUG|levodopa, carbidopa, entacapone|
214651876|NCT03471325|PROCEDURE|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
214234263|NCT00693862|DRUG|levodopa, carbidopa|
214234264|NCT00877773|DRUG|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
214234265|NCT00562666|OTHER|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
214234266|NCT00140361|DRUG|Sulfadoxine-pyrimethamine|
214234267|NCT00140361|DRUG|sulfadoxine-pyrimethamine plus artesunate|
214234268|NCT00140361|DRUG|lumefantrine plus artemether|
214234269|NCT00140361|BEHAVIORAL|Sleeping under insecticide-treated bednet|
214234270|NCT01145638|DRUG|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
214234271|NCT01145638|DRUG|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
214234272|NCT03218683|DRUG|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
214234273|NCT03218683|DRUG|AZD5991 + Venetoclax|Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
214234274|NCT04995289|OTHER|Prone position on ECMO patient|blood gas analysis before and after PP
214234275|NCT00456807|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214234276|NCT00456807|BIOLOGICAL|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214234277|NCT00140543|DRUG|sirolimus versus mycophenolate mofetil|
214234278|NCT05876832|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
214234279|NCT05876832|DRUG|Salvage Chemotherapy|Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
214234280|NCT03033498|DRUG|ABBV-951|ABBV-951 administered by subcutaneous infusion.
214234281|NCT00003472|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214234282|NCT06328387|DRUG|Hydroxychloroquine|The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
214651877|NCT01795547|DRUG|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
214651878|NCT01795547|DRUG|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
214651879|NCT00578357|BEHAVIORAL|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
214234283|NCT06328387|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
214234284|NCT06328387|DRUG|Trastuzumab Deruxtecan|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
214234285|NCT00575341|DRUG|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
214234286|NCT00575341|DRUG|placebo|placebo, oral, once daily
214234287|NCT05188157|OTHER|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
214234288|NCT05188157|OTHER|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
214234289|NCT04424329|DIETARY_SUPPLEMENT|Fibers and probiotics|A blend of fibers and seven probiotics
214234290|NCT02974751|PROCEDURE|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
214234291|NCT01135667|DRUG|clopidogrel|clopidogrel 150 mg once daily for 30 days
214234292|NCT01135667|DRUG|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
214234293|NCT00347256|DRUG|cisplatin|
214234294|NCT00347256|PROCEDURE|targeted radiation therapy|
214234295|NCT00347256|PROCEDURE|tumor resection|
214234296|NCT00181636|DRUG|Galantamine-CR|
214234297|NCT01350544|BEHAVIORAL|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
214234298|NCT06090292|DEVICE|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
214234299|NCT06090292|DEVICE|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
214234300|NCT06090292|DEVICE|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
214651880|NCT00308451|DRUG|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
214651881|NCT06334588|DIAGNOSTIC_TEST|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist
214651882|NCT06334588|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
214234301|NCT06090292|DEVICE|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
214234302|NCT04592718|BEHAVIORAL|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
214234303|NCT04592718|BEHAVIORAL|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
214234304|NCT03940183|DRUG|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
214234305|NCT03940183|DRUG|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
214234306|NCT04246931|OTHER|No intervention (survey)|No intervention -\> survey at 1 timepoint
214234307|NCT01975324|DRUG|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
214651883|NCT06334588|OTHER|Clinical Scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
214651884|NCT06334588|GENETIC|Research of genetic anomalies|For the diagnosis of autism, patients benefit from a a genetic assessment. This is carried out as part of their care
214651885|NCT04234737|BEHAVIORAL|Hypnotherapy|Hypnotherapy
214651886|NCT03132402|DIAGNOSTIC_TEST|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
214651887|NCT03247621|BEHAVIORAL|Whatsapp|
214651888|NCT03247621|BEHAVIORAL|Article|
214651889|NCT03247621|BEHAVIORAL|No Phone|
214651890|NCT01779284|DRUG|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
214234308|NCT01975324|DRUG|Placebo|placebo (sugar pill) twice a day for two weeks
214234309|NCT01027390|BEHAVIORAL|physical training exercise|physical exercise training at the work site during work time
214234310|NCT03523923|BEHAVIORAL|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
214234311|NCT00546598|DEVICE|Total hip replacement/arthroplasty|Hip replacement
214234312|NCT00366067|DRUG|Phenytoin|
214234313|NCT02341937|OTHER|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
214234314|NCT01622634|BEHAVIORAL|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
214234315|NCT01622634|OTHER|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
214234316|NCT01622634|OTHER|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
214234317|NCT06081088|OTHER|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~1. Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~2. Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~3. Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
214234318|NCT06081088|OTHER|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
214234319|NCT06081088|OTHER|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
214234320|NCT03112954|DRUG|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
214234321|NCT03112954|DRUG|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
214234322|NCT04352153|DRUG|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
214234323|NCT04352153|DRUG|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
214234324|NCT05853731|DEVICE|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
214234325|NCT05853731|DEVICE|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
214234326|NCT04671472|DRUG|NPC-09|The drug will be administered by the oral route with the same manner
214651891|NCT01779284|DRUG|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
214651892|NCT02959814|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
214651893|NCT01428466|DRUG|GSK2585823|CLDM1%/BPO3%
214651894|NCT01428466|DRUG|Benzoyl peroxide 3%|Benzoyl peroxide 3%
214651895|NCT01428466|DRUG|Benzoyl peroxide 5%|Benzoyl peroxide 5%
214234327|NCT04671472|DRUG|NPC-09 placebo|The drug will be administered by the oral route with the same manner
214234328|NCT01373827|DEVICE|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
214234329|NCT04180384|DRUG|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
214234330|NCT00373438|PROCEDURE|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
214234331|NCT00445016|PROCEDURE|peripheral regional anesthesia|evaluation and description of adverse effects
214234332|NCT04549389|DEVICE|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
214234333|NCT01518738|BEHAVIORAL|breath attention training|4 week training
214234334|NCT01518738|BEHAVIORAL|working memory attention training|4 week training
214234335|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234336|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234337|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234338|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234339|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234340|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234341|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234342|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234343|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234344|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234345|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
214234346|NCT02723071|DRUG|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
214234347|NCT00538785|BIOLOGICAL|Motavizumab|15 mg/kg IM administered at monthly intervals
214234348|NCT00538785|BIOLOGICAL|Palivizumab|15 mg/kg IM administered at monthly intervals
214234349|NCT03483064|OTHER|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
214234350|NCT02310087|DIETARY_SUPPLEMENT|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
214234351|NCT02310087|OTHER|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
214234352|NCT04280770|PROCEDURE|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
214234353|NCT01378546|DRUG|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
214234354|NCT03452748|DEVICE|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
214234355|NCT00634738|PROCEDURE|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
214234356|NCT05410951|DIAGNOSTIC_TEST|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
214651896|NCT01428466|OTHER|Vehicle|placebo
214234357|NCT01057875|OTHER|caffeine|Starbuck's Grande Pike Roast coffee
214234358|NCT01057875|OTHER|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
214234359|NCT05008978|OTHER|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
214234360|NCT05008978|OTHER|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
214234361|NCT05008978|OTHER|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
214234362|NCT05008978|OTHER|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
214651897|NCT02116621|BEHAVIORAL|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
214651898|NCT02116621|DEVICE|smartphone|
214651899|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
214651900|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
214651901|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
214234363|NCT05008978|OTHER|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
214234364|NCT02667613|OTHER|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
214234365|NCT02667613|OTHER|Control|Usual customary care
214234366|NCT04321785|OTHER|Placebo|placebo capsule (mannitol)
214234367|NCT04321785|OTHER|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
214234368|NCT02878356|BEHAVIORAL|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
214651902|NCT02972320|DRUG|temozolomide|temozolomide maintain therapeutic
214234369|NCT02878356|BEHAVIORAL|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
214234370|NCT02878356|BEHAVIORAL|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
214234371|NCT01949701|BIOLOGICAL|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*0201restricted URLC10 peptides with adjuvant.
214234372|NCT05527938|OTHER|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
214234373|NCT05060809|DRUG|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
214234374|NCT04034797|OTHER|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
214234375|NCT04034797|OTHER|No photo|Usual management without photography teletransmission
214234376|NCT02891785|BEHAVIORAL|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
214234377|NCT04137510|DEVICE|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
214234378|NCT03549793|BEHAVIORAL|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
214234379|NCT03549793|BEHAVIORAL|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
214234380|NCT01812980|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
214234381|NCT05905614|DRUG|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
214234382|NCT05375773|OTHER|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
214234383|NCT03431272|DRUG|Lifitegrast|Eye drop
214234384|NCT04363398|OTHER|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
214234385|NCT04363398|OTHER|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
214234386|NCT03046277|OTHER|No intervention|No intervention
214234387|NCT03581890|OTHER|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories)."
214234388|NCT00815854|DIETARY_SUPPLEMENT|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
214234389|NCT00815854|OTHER|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
214234390|NCT01002820|DRUG|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
214234391|NCT01844167|PROCEDURE|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
214234392|NCT01844167|PROCEDURE|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
214234393|NCT01673347|BIOLOGICAL|Meniscal Allograft|Meniscal allograft
214234394|NCT03611842|OTHER|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
214651903|NCT04928183|OTHER|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to \~10%
214651904|NCT04928183|DRUG|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
214234395|NCT03086967|DEVICE|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
214234396|NCT04967495|PROCEDURE|TACE combined with lenvatinib and iodion-125 seeds brachytherapy|TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
214234397|NCT04967495|PROCEDURE|TACE combined with lenvatinib|TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
214234398|NCT05202938|DIAGNOSTIC_TEST|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
214234399|NCT05202938|DIAGNOSTIC_TEST|FDG PET scan|FDG venous injection and positron emission tomography scan.
214234400|NCT05202938|DIAGNOSTIC_TEST|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
214234401|NCT05202938|DIAGNOSTIC_TEST|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
214234402|NCT05202938|DIAGNOSTIC_TEST|Blood sampling|Collecting 20ml of venous blood.
214234403|NCT02408432|OTHER|Laboratory Biomarker Analysis|Correlative studies
214234404|NCT02408432|OTHER|Standard of Care|Undergo mesenchymal stem cell infusion
214234405|NCT02408432|DRUG|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
214234406|NCT05243173|OTHER|Sequencing|Laboratory analysis of samples
214234407|NCT00631761|OTHER|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
214234408|NCT00631761|OTHER|no intervention (usual resident activities)|usual activities
214234409|NCT02623231|DRUG|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
214234410|NCT02623231|DRUG|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
214651905|NCT04928183|DRUG|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
214651906|NCT00708370|OTHER|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
214651907|NCT00708370|OTHER|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
214234411|NCT00637143|DRUG|Tacrolimus|Oral
214234412|NCT00637143|DRUG|Cyclosporine|Oral
214234413|NCT01293578|OTHER|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
214234414|NCT02853799|OTHER|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
214234415|NCT02853799|DIETARY_SUPPLEMENT|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
214234416|NCT05059288|DEVICE|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
214234417|NCT05099029|BIOLOGICAL|EV71 vaccine|EV71 vaccine (\[1 μg total protein + adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
214234418|NCT05099029|BIOLOGICAL|Placebo|Placebo (\[ adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
214234419|NCT02744742|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
214234420|NCT02744742|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
214234421|NCT02744742|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
214234422|NCT02744742|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
214234423|NCT00560521|BEHAVIORAL|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
214234424|NCT05882721|DEVICE|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
214234425|NCT02761837|BEHAVIORAL|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
214234426|NCT02761837|BEHAVIORAL|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
214234427|NCT04396184|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
214818056|NCT00803686|DRUG|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
214234428|NCT06372743|OTHER|INTEGREAT-CKD Intervention|"The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status."
214234429|NCT00813176|DEVICE|Double Lumen Endotracheal Tube|
214234430|NCT00813176|DEVICE|Arndt Bronchial Blocker|
214234431|NCT03105544|OTHER|simulation-based training|As described under group descriptions
214234432|NCT05368454|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
214234433|NCT05368454|BEHAVIORAL|Standard of Care|All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
214234434|NCT03656471|DEVICE|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
214234435|NCT05323162|OTHER|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
214234436|NCT03211806|BEHAVIORAL|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
214234437|NCT03211806|DEVICE|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
214234438|NCT01934543|OTHER|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
214234439|NCT01934543|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
214234440|NCT02073266|PROCEDURE|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
214234441|NCT02617901|RADIATION|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
214234442|NCT01389362|DRUG|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
214234443|NCT01389362|DRUG|Placebo comparator|2 sachets to be taken daily
214234444|NCT00177047|PROCEDURE|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
214234445|NCT00177047|DRUG|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
214234446|NCT00177047|DRUG|Melphalan|Administered intravenously 200 mg/m\^2
214234447|NCT00177047|BIOLOGICAL|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
214234448|NCT02661178|DRUG|emodepside (BAY 44-4400)|
214234449|NCT02661178|DRUG|placebo|
214234450|NCT01010139|DRUG|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
214234451|NCT04834960|OTHER|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
214234452|NCT00014755|DRUG|anti-thymocyte globulin|
214234453|NCT00014755|DRUG|cyclophosphamide|
214234454|NCT00014755|DRUG|filgrastim|
214234455|NCT00014755|DRUG|prednisone|
214234456|NCT00014755|PROCEDURE|peripheral blood stem cell transplantation|
214234457|NCT00014755|PROCEDURE|irradiation|
214234458|NCT04643301|DRUG|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
214234459|NCT02426489|DEVICE|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
214234460|NCT03086031|BEHAVIORAL|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
214234461|NCT03086031|BEHAVIORAL|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
214818057|NCT00803686|DRUG|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
214234462|NCT03279627|OTHER|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
214234463|NCT01733212|DRUG|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
214234464|NCT01733212|DRUG|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
214234465|NCT02776618|PROCEDURE|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
214234466|NCT00650481|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
214234467|NCT00650481|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
214234468|NCT01566812|BEHAVIORAL|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
214234469|NCT01566812|BEHAVIORAL|Usual care|Usual care applied in the hospital
214234470|NCT03443557|OTHER|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
214234471|NCT04842032|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
214234472|NCT00443196|PROCEDURE|MiCK Assay|Physician determined treatment
214234473|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
214234474|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
214234475|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
214234476|NCT03999775|DIETARY_SUPPLEMENT|Calcium, vitamin D and bioactive collagen peptides supplement|
214234477|NCT03999775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|
214234478|NCT06102018|DIAGNOSTIC_TEST|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
214234479|NCT00775203|DRUG|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
214234480|NCT00775203|DRUG|Placebo|
214234481|NCT05062993|PROCEDURE|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
214234482|NCT00704522|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214234483|NCT00704522|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
214234484|NCT00704522|BEHAVIORAL|Patient assistance program|"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
214234485|NCT04191083|BEHAVIORAL|Motor imagery|This group will perform motor imagery training on motor learning of different motor tasks
214234486|NCT04191083|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
214234487|NCT04191083|BEHAVIORAL|Action observation|This group will perform action observation training on motor learning of various motor tasks.
214234488|NCT04191083|BEHAVIORAL|Placebo intervention|This group will watch a video of a landscape without the presence of people.
214234489|NCT03951168|BEHAVIORAL|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
214651908|NCT03056105|OTHER|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
214651909|NCT02312973|DRUG|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
214651910|NCT02312973|DRUG|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
214651911|NCT05996484|DRUG|Toripalimab|Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
214651912|NCT05996484|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
214651913|NCT05996484|DRUG|Albumin paclitaxel|Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
214651914|NCT05996484|DRUG|Cisplatin|Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
214234490|NCT03951168|BEHAVIORAL|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
214234491|NCT01373736|DRUG|123I-meta-iodobenzylguanidine|
214234492|NCT05792657|BEHAVIORAL|High dosage in-person exercise coaching|High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
214234493|NCT05792657|BEHAVIORAL|Medium dosage in-person exercise coaching.|Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
214234494|NCT05792657|BEHAVIORAL|Low dosage in-person exercise coaching|Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
214234495|NCT01306578|DRUG|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
214234496|NCT01306578|PROCEDURE|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
214234497|NCT02454361|DRUG|KBP-7072|KBP-7072
214234498|NCT02454361|DRUG|Placebo|Placebo
214234499|NCT04119518|DEVICE|CSEM Pulse Watch|Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
214234500|NCT04756336|DRUG|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
214234501|NCT01414348|BEHAVIORAL|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
214234502|NCT01414348|BEHAVIORAL|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
214234503|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.5%
214234504|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.2%
214234505|NCT00891540|DRUG|placebo|Isotonic NaCl
214234506|NCT02512484|PROCEDURE|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
214234507|NCT00508781|BEHAVIORAL|Multiphoton laser image in cutaneous pathology|
214234508|NCT03834558|OTHER|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
214234509|NCT01988701|OTHER|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
214234510|NCT04938297|DRUG|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
214234511|NCT04938297|DRUG|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
214234512|NCT04938297|DRUG|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
214234513|NCT05260541|DRUG|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
214234514|NCT05260541|DRUG|Placebo|Once daily oral treatment for 4 weeks
214234515|NCT05260541|DRUG|40 mg PRAX-114|Once daily oral treatment for 8 weeks
214234516|NCT00147550|DRUG|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
214234517|NCT05346822|PROCEDURE|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
214234518|NCT00547001|DRUG|Estradiol|1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
214234519|NCT02192424|DRUG|Metformin alone|
214234520|NCT02192424|DRUG|Metformin + Intermittent Insulin Therapy|
214234521|NCT01765309|PROCEDURE|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
214234522|NCT04925856|OTHER|blood sample|"•Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
214234523|NCT00537615|DRUG|PD 0332334|
214234524|NCT01336361|OTHER|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
214234525|NCT01849887|BIOLOGICAL|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
214234526|NCT01849887|DRUG|Placebo|Placebo
214234527|NCT03360864|OTHER|Education program|Patient will participate to a education program.
214234528|NCT04415970|OTHER|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
214651915|NCT01983644|DEVICE|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
214234529|NCT04415970|OTHER|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
214234530|NCT03163602|DRUG|Control group|Access flap and debridement
214234531|NCT03163602|DEVICE|Test group|Regenerative treatment
214234532|NCT04674540|OTHER|No Intervention|No Intervention
214234533|NCT02185976|OTHER|cartoon|5 different cartoons which will be recorded on a tablet PC.
214234534|NCT02024152|DRUG|JDP-205 IV high dose|
214234535|NCT02024152|DRUG|JDP-205 IV low dose|
214234536|NCT02024152|DRUG|JDP-205 IM|
214234537|NCT02024152|DRUG|Control: Zyrtec|
214234538|NCT00885820|DRUG|Tacrolimus|Oral
214234539|NCT00885820|DRUG|MMF|Oral
214234540|NCT00885820|DRUG|Corticosteroids (Prednisone)|Oral
214234541|NCT03355482|DRUG|Methylprednisolone|160mg IM at baseline
214234542|NCT03355482|DRUG|Placebos|IM saline injection at baseline
214234543|NCT04316702|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
214234544|NCT04316702|DRUG|Cymbalta / Lyrica - Drug treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
214234545|NCT05967039|OTHER|Physiotherapy|Physiotherapy in respiratory rehabilitation
214234546|NCT01970904|DRUG|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
214234547|NCT01970904|DRUG|Ribavirin|Ribavirin tablets of various strengths for oral administration
214234548|NCT01970904|DRUG|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
214234549|NCT03160547|OTHER|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
214234550|NCT03160547|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
214234551|NCT02122913|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
214234552|NCT04837326|OTHER|Heel Lance Blood Sampling in Facilitated Tucking Position|
214234553|NCT04837326|OTHER|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|
214234554|NCT04837326|OTHER|Heel Lance Blood Sampling Using White Noise|
214234555|NCT00062816|DRUG|ISIS 14803, peginterferon alfa, ribavirin|
214234556|NCT00353756|DRUG|C326, IL-6 Inhibitory Avimer protein|
214234557|NCT00146055|PROCEDURE|Reduced intensity conditioning with allogeneic transplant|
214234558|NCT02173262|DRUG|G-CSF|
214234559|NCT02173262|DRUG|Ciprofloxacin|
214234560|NCT00729391|BEHAVIORAL|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
214234561|NCT00729391|BEHAVIORAL|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
214234562|NCT00729391|BEHAVIORAL|VCT Only|Participants in this group will receive VCT only.
214234563|NCT05015413|DEVICE|Shockwave|Shock wave master 500 Germany
214234564|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
214234565|NCT01213576|DRUG|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
214234566|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
214234567|NCT01213576|DRUG|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
214234568|NCT01565304|BEHAVIORAL|POWER Through Choices|10-session group-based sexual education curriculum
214234569|NCT03844295|DEVICE|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
214234570|NCT03844295|DEVICE|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
214651916|NCT01983644|DEVICE|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
214234571|NCT02553954|PROCEDURE|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
214234572|NCT04645485|BIOLOGICAL|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
214234573|NCT05953441|OTHER|AI-powered doctor|AI-powered virtual doctor
214234574|NCT05953441|OTHER|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
214234575|NCT02901327|PROCEDURE|Lumbar Stabilisation Exercise|"McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
214234576|NCT02901327|PROCEDURE|treadmill walk exercise|"Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'"
214234577|NCT03916107|PROCEDURE|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
214234578|NCT03916107|PROCEDURE|Frontalis flap|Using frontal muscle flap to correct severe ptosis
214234579|NCT00157287|PROCEDURE|Evidence based weaning protocol|
214234580|NCT02779361|DIETARY_SUPPLEMENT|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*)."
214234581|NCT05614167|OTHER|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
214234582|NCT05651204|DIAGNOSTIC_TEST|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
214234583|NCT02700503|BEHAVIORAL|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
214234584|NCT06085976|DRUG|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
214234585|NCT06085976|OTHER|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
214234586|NCT01287182|DRUG|Ateronon|Ateronon daily for 3 months
214234587|NCT05176457|OTHER|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
214234588|NCT03341780|PROCEDURE|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
214234589|NCT00305461|DRUG|Ciclesonide|Effect of Ciclesonide on Quality of Life
214234590|NCT05242796|DEVICE|Low frequency magnetic therapy|
214234591|NCT05262062|OTHER|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2\. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3\. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4\. Once the position of ease was identified, it was held for 20 to 30 seconds."
214234592|NCT05262062|OTHER|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2\. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3\. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
214234593|NCT05262062|OTHER|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,~2. After MTrPs identification,~3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
214234594|NCT01520428|BEHAVIORAL|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
214234595|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
214234596|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Soda|Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
214234597|NCT04118257|DIETARY_SUPPLEMENT|Control: Water|Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
214234598|NCT04062903|BEHAVIORAL|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
214234599|NCT04062903|BEHAVIORAL|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
214234600|NCT01943253|DEVICE|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
214234601|NCT01943253|DEVICE|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
214234602|NCT05557825|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
214234603|NCT04677478|OTHER|Impact of respiratory isolation on quality of life|Semi-structured interviews
214234604|NCT00170690|DRUG|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
214234605|NCT00170690|DRUG|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
214234606|NCT04811534|BEHAVIORAL|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
214234607|NCT05428878|DIAGNOSTIC_TEST|ANS Watch|"1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type"
214234608|NCT00571402|BEHAVIORAL|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
214234609|NCT00571402|BEHAVIORAL|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
214234610|NCT03494491|DIETARY_SUPPLEMENT|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
214234611|NCT03494491|DIETARY_SUPPLEMENT|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
214234612|NCT02965768|DRUG|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
214234613|NCT00918996|PROCEDURE|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
214234614|NCT00277082|DRUG|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
214234615|NCT01073046|DEVICE|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
214234616|NCT00748020|PROCEDURE|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
214234617|NCT00748020|PROCEDURE|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
214234618|NCT01525901|DRUG|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
214234619|NCT01525901|DRUG|Normal saline|Saline solution will be administered for three months subcutaneously.
214234620|NCT00559182|DRUG|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
214234621|NCT00559182|DRUG|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
214234622|NCT00003959|BIOLOGICAL|ras peptide cancer vaccine|
214234623|NCT00003959|BIOLOGICAL|sargramostim|
214234624|NCT00641316|PROCEDURE|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
214234625|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
214234626|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
214234627|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
214234628|NCT02486627|DRUG|plazomicin|
214234629|NCT02486627|DRUG|meropenem|
214234630|NCT02486627|DRUG|levofloxacin (oral)|
214234631|NCT01722227|DRUG|Liraglutide|
214234632|NCT01722227|DRUG|Placebo|
214234633|NCT04590846|BEHAVIORAL|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
214234634|NCT04590846|BEHAVIORAL|General Health Course|General courses about health issues according to the curriculum of each primary school.
214234635|NCT01853488|RADIATION|DXA|Osteodensitometry
214234636|NCT01853488|RADIATION|pQCT|Osteodensitometry
214234637|NCT05984550|DRUG|NMN|"NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.~In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+."
214234638|NCT04083729|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
214234639|NCT05080244|DIETARY_SUPPLEMENT|Probiotics|2 strains 10x10\^9 UFC/capsule
214234640|NCT05080244|DIETARY_SUPPLEMENT|Placebo|Potato starch and magnesium stearate
214234641|NCT05330884|BIOLOGICAL|BCG vaccine|0.1ml BCg vaccine to be given intradermally
214234642|NCT05330884|DRUG|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
214818058|NCT00803686|DRUG|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
214234643|NCT06065111|OTHER|study tendon damage in osteogenesis imperfecta patients|"* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~* To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
214234644|NCT01597115|PROCEDURE|Duplex ultrasonography|
214234645|NCT01578824|OTHER|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
214234646|NCT01126671|DRUG|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
214234647|NCT00445588|DRUG|erlotinib hydrochloride|150mg Given orally once daily
214234648|NCT00445588|DRUG|sorafenib tosylate|400mg Given orally twice daily
214234649|NCT00445588|OTHER|pharmacological study|Correlative studies
214234650|NCT06171204|PROCEDURE|Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic
214234651|NCT03554486|DRUG|Fiasp|Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
214234652|NCT03554486|DRUG|Novolog|Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
214234653|NCT05796206|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
214234654|NCT05796206|DRUG|placebo|An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
214234655|NCT01182090|PROCEDURE|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
214234656|NCT01182090|PROCEDURE|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
214234657|NCT01509053|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
214234658|NCT01509053|DRUG|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
214234659|NCT04114617|OTHER|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
214234660|NCT04114617|OTHER|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
214234661|NCT04114617|COMBINATION_PRODUCT|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
214234662|NCT05078762|OTHER|Immersive Virtual Reality|Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
214234663|NCT01500499|GENETIC|gene expression analysis|
214234664|NCT01500499|GENETIC|gene rearrangement analysis|
214234665|NCT01500499|GENETIC|polymerase chain reaction|
214234666|NCT01500499|GENETIC|protein analysis|
214234667|NCT01500499|GENETIC|western blotting|
214234668|NCT01500499|OTHER|laboratory biomarker analysis|
214234669|NCT01500499|OTHER|mass spectrometry|
214234670|NCT01738477|BIOLOGICAL|Boostrix|Single dose intramuscular administration.
214234671|NCT00756262|BIOLOGICAL|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
214234672|NCT04291404|DEVICE|Virtual Reality Distraction|Distraction therapy using a Virtual Reality (VR) device
214234673|NCT05140824|DRUG|Placebo|0.9% sodium chloride solution
214234674|NCT05140824|BIOLOGICAL|TJ202 injection|TJ202 injection
214234675|NCT01915303|DRUG|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
214234676|NCT02925338|OTHER|QOL questionaire|Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
214234677|NCT05191914|DRUG|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
214234678|NCT02509117|DRUG|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
214234679|NCT02509117|DRUG|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
214234680|NCT02509117|DRUG|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
214234681|NCT02509117|DRUG|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
214234682|NCT02509117|DRUG|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
214234683|NCT02509117|DRUG|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
214234684|NCT04128813|DEVICE|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
214234685|NCT00568386|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
214234686|NCT00568386|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
214234687|NCT06327724|DRUG|Belimumab|Start of new treatment due to active disease
214234688|NCT06092268|DRUG|SHR-A2009 for injection ； Almonertinib Mesilate Tablets|"Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization."
214234689|NCT06092268|DRUG|SHR-A2009 for injection；Adebrelimab Injection|"Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy."
214234690|NCT03891797|OTHER|Cognitive Processing Therapy|Group-based psychotherapy.
214234691|NCT00548184|DRUG|Lapatinib|Monoclonal Antibody
214234692|NCT00548184|DRUG|Trastuzumab|Monoclonal Antibody
214234693|NCT00548184|DRUG|Endocrine|Hormonal Therapy
214234694|NCT04921813|OTHER|3 dimensional scoliosis exercise|Schroth exercises
214234695|NCT04921813|OTHER|Balance Exercise|Balance-coordination exercises
214234696|NCT04921813|OTHER|Brace treatment|Brace usage
214234697|NCT02601261|OTHER|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:~1. The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~2. The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~3. The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~4. The short questionnaire on critical events occurring during the day,~5. The short questionnaire with obstetric anamnesis."
214234698|NCT03228329|OTHER|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
214234699|NCT01279941|BEHAVIORAL|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
214234700|NCT03817086|BEHAVIORAL|Hand coordination and mental practice|"20 chronic (\>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
214234701|NCT03817086|BEHAVIORAL|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
214234702|NCT01846767|OTHER|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
214234703|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
214234704|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
214234705|NCT00636363|DEVICE|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
214234706|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 1|Description in the arm description
214234707|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 2|Description in the arm description
214234708|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 3|Description in the arm description
214234709|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 4|Description in the arm description
214234710|NCT02422368|DRUG|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
214234711|NCT02422368|DRUG|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
214234712|NCT05790278|OTHER|Survey|Completion of a Purpose in Life Survey
214234713|NCT01764919|RADIATION|[124I]FIAU|A single intravenous injection of 5 mCi\[124I\]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
214234714|NCT00280748|DRUG|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
214234715|NCT00280748|RADIATION|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
214234716|NCT00004042|BIOLOGICAL|monoclonal antibody F19|
214234717|NCT00004042|RADIATION|iodine I 131 monoclonal antibody F19|
214234718|NCT00029146|PROCEDURE|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
214234719|NCT00029146|DRUG|best medical therapy|best current practice medical therapy
214234720|NCT00005815|DRUG|temozolomide|
214234721|NCT00005815|DRUG|thalidomide|
214234722|NCT05979142|OTHER|community-based primary care program|See group description
214234723|NCT01040117|PROCEDURE|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
214234724|NCT01040117|PROCEDURE|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
214234725|NCT01775397|DRUG|Fidaxomicin|capsule
214234726|NCT01775397|DRUG|Vancomycin|capsule
214234727|NCT01775397|DRUG|Placebo|Capsule
214234728|NCT06266793|DEVICE|Holmium Laser|Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
214234729|NCT06266793|DEVICE|Thulium Laser|Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
214234730|NCT06393335|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
214234731|NCT00920803|DRUG|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
214234732|NCT00920803|DRUG|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
214234733|NCT05014737|OTHER|no intervention|this is an abservational study and no intervention will be involved
214234734|NCT05037435|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
214234735|NCT05037435|OTHER|Placebo|Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
214234736|NCT01433380|DRUG|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
214234737|NCT01433380|DRUG|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
214234738|NCT06523829|OTHER|GROUP GIVEN VIDEO TRAINING|Video-based training was given to this group.
214234739|NCT00272662|DRUG|peginesatide|
214234740|NCT02771613|OTHER|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
214234741|NCT02771613|OTHER|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
214234742|NCT02199717|DEVICE|Accelerometer|
214234743|NCT03567343|DIETARY_SUPPLEMENT|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
214234744|NCT03567343|OTHER|Control|Placebo
214234745|NCT00047645|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
214234746|NCT00907452|DRUG|melphalan-prednisone-thalidomide|
214234747|NCT00907452|DRUG|lenalidomide-dexamethasone|
214234748|NCT06515795|OTHER|Isometric exercise|In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
214234749|NCT04810689|DRUG|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
214234750|NCT04810689|OTHER|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
214234751|NCT04831632|DIAGNOSTIC_TEST|quantitative and qualitative iFOBTs|They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
214234752|NCT03267485|DEVICE|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
214818059|NCT00803686|DRUG|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
214818060|NCT00711386|DRUG|GSK706769|50mg, 100mg, 200mg, or 400mg
214818061|NCT00711386|OTHER|Placebo|Placebo
214234753|NCT04308200|OTHER|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
214234754|NCT04308200|OTHER|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
214234755|NCT03980353|OTHER|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
214234756|NCT00077467|DRUG|bortezomib|Given IV
214234757|NCT00077467|OTHER|pharmacological study|Correlative studies
214234758|NCT00077467|OTHER|laboratory biomarker analysis|Correlative studies
214234759|NCT00019994|BIOLOGICAL|MART-1 antigen|
214234760|NCT00019994|BIOLOGICAL|aldesleukin|
214234761|NCT00019994|BIOLOGICAL|gp100 antigen|
214234762|NCT00019994|BIOLOGICAL|incomplete Freund's adjuvant|
214234763|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
214234764|NCT04944680|BEHAVIORAL|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
214234765|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
214234766|NCT06431971|DRUG|Talineuren|Talineuren infusion weekly
214234767|NCT06431971|DRUG|Placebo|Placebo infusion weekly
214234768|NCT06114524|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
214234769|NCT01138917|DEVICE|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
214234770|NCT02104037|PROCEDURE|Lumbar puncture|
214234771|NCT02859805|OTHER|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
214234772|NCT00286598|BEHAVIORAL|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
214234773|NCT00795678|DRUG|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
214234774|NCT00795678|DRUG|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
214234775|NCT00795678|DRUG|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
214234776|NCT00795678|DRUG|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
214234777|NCT00795678|DRUG|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
214234778|NCT00795678|DRUG|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
214234779|NCT00795678|DRUG|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
214234780|NCT00795678|DRUG|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
214234781|NCT02890615|BEHAVIORAL|Depression self-care|Toolkit and coaching
214234782|NCT00825253|DRUG|biphasic insulin aspart 30|
214234783|NCT00825253|DRUG|biphasic human insulin 30|
214234784|NCT05382767|DRUG|CKDB-501A|Muscle Spasticity
214234785|NCT05382767|DRUG|Botox®|Muscle Spasticity
214234786|NCT04479319|DIAGNOSTIC_TEST|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
214234787|NCT03707275|DEVICE|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
214234788|NCT03707275|OTHER|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
214234789|NCT03007888|DRUG|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
214234790|NCT03007888|DRUG|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
214234791|NCT03841747|DRUG|Pembrolizumab|200 mg Pembrolizumab IV Q3W.
214234792|NCT03841747|DRUG|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
214234793|NCT01696682|PROCEDURE|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
214234794|NCT01696682|PROCEDURE|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
214234795|NCT01806662|DRUG|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
214651917|NCT04159883|OTHER|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
214234796|NCT01806662|OTHER|Placebo|Injection of placebo
214234797|NCT01479426|DIETARY_SUPPLEMENT|EFLA400|EFLA400(960mg/day)for 12 weeks
214234798|NCT01479426|DIETARY_SUPPLEMENT|Placebo|Placebo(960mg/day) for 12 weeks
214234799|NCT00043550|BEHAVIORAL|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
214234800|NCT00043550|DRUG|Sertraline|Participants will receive sertraline.
214234801|NCT00043550|DRUG|Pill Placebo|Participants will receive a pill placebo.
214234802|NCT00043550|DRUG|Venlafaxine|Participants will receive venlafaxine.
214234803|NCT03471624|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
214234804|NCT03259620|DRUG|CLS006|Furosemide Topical Gel
214234805|NCT03259620|DRUG|CLS006 Vehicle|Vehicle Topical Gel
214234806|NCT05282914|DRUG|administration of UI058|UI058 1Tab/day for 7days
214234807|NCT05282914|DRUG|administration of UIC202004|UIC202004 1Tab/day for 7days
214234808|NCT02967757|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
214234809|NCT04623125|BEHAVIORAL|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
214234810|NCT00827931|DRUG|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
214234811|NCT00827931|PROCEDURE|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
214234812|NCT01151943|OTHER|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
214234813|NCT01151943|OTHER|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
214234814|NCT04097951|DRUG|Combinations|Montelukast and Bepotastine Combination
214234815|NCT00129662|BEHAVIORAL|Pictorial action plan|
214234816|NCT02757417|DRUG|sodium fluorescein|
214234817|NCT02757417|DRUG|phenazopyridine|
214818062|NCT03348553|DIETARY_SUPPLEMENT|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
214818063|NCT03348553|DIETARY_SUPPLEMENT|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
214818064|NCT03348553|DIETARY_SUPPLEMENT|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
214234818|NCT01252693|DRUG|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
214234819|NCT01252693|DRUG|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
214234820|NCT02728427|DEVICE|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
214234821|NCT02728427|DEVICE|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
214234822|NCT00222716|BEHAVIORAL|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
214234823|NCT01418508|BEHAVIORAL|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
214234824|NCT01418508|BEHAVIORAL|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
214234825|NCT00300430|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
214234826|NCT00300430|DRUG|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
214234827|NCT00300430|DRUG|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
214234828|NCT04511377|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
214234829|NCT04511377|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
214234830|NCT00000791|DRUG|Glycovir|
214234831|NCT00000791|DRUG|Zidovudine|
214234832|NCT01917656|DRUG|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
214234833|NCT01917656|DRUG|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
214234834|NCT01917656|DRUG|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
214234835|NCT03849573|BEHAVIORAL|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
214234836|NCT03849573|BEHAVIORAL|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
214234837|NCT05143788|PROCEDURE|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
214234838|NCT05331417|DIAGNOSTIC_TEST|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
214234839|NCT02748382|OTHER|higher chloride crystalloid|Normal saline
214234840|NCT02748382|OTHER|higher chloride albumin|5% Octalbin
214234841|NCT02748382|OTHER|lower chloride crystalloid|Ringers Lactate
214234842|NCT02748382|OTHER|lower chloride albumin|5% Plasbumin
214651918|NCT04159883|OTHER|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
214651919|NCT05986942|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
214234843|NCT06333197|PROCEDURE|ORIF through transparotid approach|The Retromandibular Transparotid approach is a surgical method used to access structures in the parotid gland region by making an incision behind the mandible.
214234844|NCT06333197|PROCEDURE|ORIF through retroparotid approach|The Retromandibular Retroparotid approach, also known as the Modified Blair Incision, is a surgical technique used to access structures within the parotid gland region by creating an incision behind the mandible and extending it into the parotid region.
214234845|NCT03035474|OTHER|Digital Engagement|Patient engagement to improve self-management/medication adherence
214234846|NCT03035474|OTHER|Direct Engagement|Health system engagement to improve local QI programs
214651920|NCT05986942|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
214234847|NCT02081859|DEVICE|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
214234848|NCT02081859|OTHER|Conventional Criteria|
214234849|NCT05323825|DIETARY_SUPPLEMENT|Probiotic|Fermented milk product containing a probiotic
214234850|NCT05323825|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
214234851|NCT04066712|DRUG|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
214234852|NCT03444480|DRUG|Remimazolam Tosylate|Initial dose plus supplemental doses
214234853|NCT02444000|DRUG|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
214234854|NCT02444000|DRUG|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
214234855|NCT04565808|PROCEDURE|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
214234856|NCT04914260|OTHER|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
214234857|NCT03894371|DEVICE|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
214234858|NCT05547204|OTHER|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
214234859|NCT02560506|DEVICE|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
214234860|NCT01612845|PROCEDURE|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
214234861|NCT01612845|BIOLOGICAL|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
214234862|NCT00322972|DRUG|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
214234863|NCT04585503|DEVICE|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
214234864|NCT05086211|OTHER|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
214234865|NCT05086211|OTHER|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
214234866|NCT01870076|BEHAVIORAL|Healing Touch|
214234867|NCT01870076|BEHAVIORAL|Healing Touch, Sham|
214234868|NCT01870076|BEHAVIORAL|Control, Presence|
214234869|NCT00492063|BIOLOGICAL|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
214234870|NCT00492063|BIOLOGICAL|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
214818065|NCT03348553|DIETARY_SUPPLEMENT|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
214234871|NCT04160975|BEHAVIORAL|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
214234872|NCT05895916|BEHAVIORAL|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
214234873|NCT06491901|OTHER|PS was given according to lung ultrasound score|If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
214234874|NCT06491901|OTHER|PS was given according to clinical criteria|In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
214234875|NCT00181597|DRUG|Trilostane|Taken orally once a day for three days then twice daily thereafter.
214234876|NCT00181597|DRUG|Hydrocortisone|Taken orally with trilostane.
214234877|NCT05973721|BIOLOGICAL|phage|The treatment group was given one phage each time, once a day for two weeks
214234878|NCT01467219|PROCEDURE|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
214234879|NCT01467219|PROCEDURE|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
214234880|NCT01467219|PROCEDURE|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
214234881|NCT01467219|RADIATION|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
214234882|NCT05884801|DRUG|QLS1103|Oral dose
214234883|NCT00167856|DRUG|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
214234884|NCT01150669|OTHER|laboratory biomarker analysis|Samples are analyzed in laboratory studies
214234885|NCT02338908|OTHER|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
214234886|NCT02338908|OTHER|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
214234887|NCT00368290|DRUG|Modafinil|300mg a day for 8 weeks
214234888|NCT00368290|DRUG|placebo|placebo pills for 8 weeks
214234889|NCT00368290|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
214234890|NCT03810872|DRUG|Afatinib|Open label
214234891|NCT03810872|DRUG|Paclitaxel|Paclitaxel
214234892|NCT01143701|OTHER|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
214234893|NCT06491966|OTHER|observation|data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
214234894|NCT03310762|OTHER|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
214234895|NCT03310762|OTHER|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
214234896|NCT00123890|DRUG|GW873140|
214234897|NCT00948467|DRUG|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
214234898|NCT00510653|DRUG|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
214234899|NCT05349201|OTHER|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
214234900|NCT05349201|OTHER|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
214234901|NCT02990247|DEVICE|anharmonic morphological analysis of the respiratory signals (AMARS)|
214234902|NCT04268602|OTHER|local anesthetic injection|1% lidocaine
214234903|NCT02777320|DRUG|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
214234904|NCT02777320|DRUG|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
214234905|NCT02613273|BEHAVIORAL|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
214234906|NCT02613273|BEHAVIORAL|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
214234907|NCT02847572|PROCEDURE|Cataract Surgery|All patients wil be having intraocular lens surgery
214234908|NCT05143710|DIAGNOSTIC_TEST|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
214234909|NCT00003001|DRUG|fluorouracil|
214234910|NCT00003001|DRUG|gemcitabine hydrochloride|
214234911|NCT00003001|DRUG|leucovorin calcium|
214234912|NCT01444807|DRUG|sorafenib|sorafenib 400 mg bid
214234913|NCT04157673|BEHAVIORAL|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
214234914|NCT05471583|OTHER|Main group|no intervention; observational only
214234915|NCT00908739|GENETIC|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
214234916|NCT00908739|OTHER|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
214234917|NCT00908739|OTHER|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
214234918|NCT01467778|DEVICE|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
214234919|NCT01467778|DEVICE|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
214234920|NCT03513341|OTHER|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
214234921|NCT00949767|DRUG|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
214234922|NCT00949767|DRUG|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
214234923|NCT00949767|DRUG|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
214234924|NCT00949767|DRUG|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
214234925|NCT00949767|DRUG|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
214234926|NCT00949767|DRUG|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
214234927|NCT00949767|DRUG|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
214234928|NCT00949767|DRUG|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
214234929|NCT05337020|OTHER|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
214234930|NCT03417401|PROCEDURE|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
214234931|NCT03417401|DRUG|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
214234932|NCT01523470|DEVICE|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
214234933|NCT02312687|BIOLOGICAL|KRN23|solution for SC injection
214234934|NCT05632744|DEVICE|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
214234935|NCT00735059|DEVICE|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, \> 3 hours
214234936|NCT00735059|DEVICE|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, \> 3 hours
214234937|NCT04733794|PROCEDURE|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
214234938|NCT05138471|DEVICE|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
214234939|NCT05138471|DEVICE|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
214234940|NCT05138471|BEHAVIORAL|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
214234941|NCT00878436|DRUG|Panobinostat|
214234942|NCT00878436|DRUG|Bicalutamide|
214234943|NCT00535574|DRUG|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
214234944|NCT00535574|DRUG|bexarotene|75 mg/day 6 weeks
214234945|NCT02884700|BIOLOGICAL|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
214234946|NCT06371820|OTHER|ESPRESSO [The study has no intervention]|This study has no interventions.
214234947|NCT05793229|OTHER|observation|observation
214234948|NCT06051708|OTHER|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
214234949|NCT06051708|OTHER|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
214234950|NCT02133443|DEVICE|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
214234951|NCT02133443|DEVICE|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
214234952|NCT00716950|DRUG|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
214234953|NCT00716950|DRUG|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
214234954|NCT00409305|DRUG|Betahistine|
214234955|NCT00409305|BEHAVIORAL|Dietary counseling|
214234956|NCT02557477|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
214234957|NCT02557477|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules twice daily
214234958|NCT00217464|DRUG|fulvestrant|intramuscularly
214234959|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
214234960|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
214234961|NCT00169442|BIOLOGICAL|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
214234962|NCT00169442|BIOLOGICAL|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
214234963|NCT00169442|BIOLOGICAL|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
214234964|NCT01426789|DRUG|Placebo|Matching placebo to secukinumab I.V.
214234965|NCT01426789|DRUG|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
214234966|NCT04253509|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
214234967|NCT01765478|DRUG|HM71224 single ascending dose|
214234968|NCT01765478|DRUG|HM71224 food effect|
214234969|NCT01765478|DRUG|HM71224 Multiple ascending dose|
214234970|NCT01516333|OTHER|High GL 107|Three meals a day
214234971|NCT01516333|OTHER|Medium GL 76|Three meals a day
214234972|NCT01516333|OTHER|Medium GL 68|Three meals a day
214234973|NCT01516333|OTHER|Low GL 48|Three meals a day
214234974|NCT03067233|OTHER|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
214234975|NCT05328349|BEHAVIORAL|Education Program|After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
214234976|NCT01628185|PROCEDURE|Repositioning|pain assessment at baseline then following routine care repositioning in bed
214234977|NCT00123643|DRUG|rosiglitazone|
214234978|NCT00123643|DRUG|glyburide|
214234979|NCT02103296|PROCEDURE|Drawing admission labs from cord blood|
214234980|NCT02103296|PROCEDURE|Drawing admission labs from infant blood|
214234981|NCT02473146|DRUG|Gemtuzumab ozogamicin (GO)|
214234982|NCT00311584|DRUG|irinotecan hydrochloride|Given IV
214234983|NCT00311584|DRUG|temozolomide|Given IV
214234984|NCT02193906|OTHER|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
214234985|NCT02193906|OTHER|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
214234986|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
214234987|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
214234988|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
214234989|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
214234990|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
214234991|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
214234992|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
214234993|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
214234994|NCT02103153|DEVICE|Picosure Laser System|
214234995|NCT04953988|PROCEDURE|Robotic TKA|Robotic TKA
214234996|NCT04953988|PROCEDURE|Manual operation|Manual operation
214234997|NCT04918342|OTHER|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
214234998|NCT00371553|DRUG|SU011248 (Sunitinib)|
214234999|NCT05122598|DRUG|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
214235000|NCT05122598|DRUG|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
214235001|NCT03093584|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
214235002|NCT03093584|BEHAVIORAL|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
214235003|NCT04465136|DEVICE|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
214235004|NCT00477841|PROCEDURE|Esophageal stent placement|
214235005|NCT00477841|PROCEDURE|dysphagia scores|
214235006|NCT00477841|PROCEDURE|complications of therapy|
214235007|NCT00477841|PROCEDURE|survival time of therapy|
214235008|NCT02335671|PROCEDURE|Intra-operative Magnetic Resonance Imaging (MRI)|
214235009|NCT02335671|OTHER|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
214235010|NCT03053206|DRUG|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
214235011|NCT00668993|BEHAVIORAL|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
214235012|NCT05041608|PROCEDURE|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
214235013|NCT03355547|OTHER|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
214235014|NCT00167778|DEVICE|Transverse plane rotation adaptor pylon|Potential future practice
214235015|NCT00167778|DEVICE|Rigid pylon|Current clinical practice
214235016|NCT02654717|DRUG|DFD-07 Cream|
214235017|NCT02654717|DRUG|Placebo Cream|
214235018|NCT00799175|DRUG|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
214235019|NCT00799175|DRUG|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
214235020|NCT04187872|COMBINATION_PRODUCT|LITT + Pembrolizumab|Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
214235021|NCT02291653|DEVICE|McGrath|video-laryngoscopy
214235022|NCT02291653|DEVICE|MIL|direct-laryngoscopy
214235023|NCT02858817|DRUG|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
214235024|NCT02858817|BIOLOGICAL|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
214235025|NCT02858817|OTHER|NaCl 0,9%|0.9% NaCl solution for injection
214235026|NCT02572739|DEVICE|PICCO|measurements based on thermodilution
214651921|NCT03844867|DIETARY_SUPPLEMENT|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
214235027|NCT02572739|DEVICE|NICCOMO|measurements based on impedance
214651922|NCT00961961|DRUG|Lithium / Fluoxetine|Individualized Daily Dosage
214235028|NCT05233397|DRUG|Tocilizumab|For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
214235029|NCT06161896|DIAGNOSTIC_TEST|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
214235030|NCT05795478|DRUG|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
214235031|NCT05795478|DRUG|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
214235032|NCT05795478|DRUG|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
214235033|NCT05795478|DRUG|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
214651923|NCT00961961|DRUG|Lithium / Placebo|Individualized Daily Dosage
214818066|NCT05683730|OTHER|Intermittent caloric restriction|"Intermittente caloric restriction:~1. st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~2. nd month: restriction of 50% of the caloric intake 2 days per week~3. rd month: restriction of 60% of the caloric intake 2 days per week~4. th month: restriction of 75% of the caloric intake 2 days per week"
214651924|NCT04086732|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
214651925|NCT00652184|DRUG|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
214235034|NCT05481541|OTHER|written education|"Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group."
214235035|NCT04609007|BEHAVIORAL|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
214235036|NCT04609007|BEHAVIORAL|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
214235037|NCT03521102|DRUG|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
214235038|NCT03521102|DRUG|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
214235039|NCT01327183|PROCEDURE|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
214235040|NCT01327183|DRUG|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
214235041|NCT01327183|DRUG|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
214235042|NCT01327183|DRUG|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
214235043|NCT05001633|BEHAVIORAL|modified media content paradigm|media content
214235044|NCT05001633|BEHAVIORAL|control|media content experience
214235045|NCT00252252|DEVICE|VPAP non-invasive ventilator|
214235046|NCT00252252|DEVICE|AutoVPAP non-invasive ventilator|
214651926|NCT00652184|DRUG|placebo|placebo cream and placebo valaciclovir
214235047|NCT00483132|DRUG|interferon alpha 2a|
214235048|NCT05977738|DRUG|Pitavastatin calcium|Daily Pitavastatin administration
214235049|NCT04119375|BEHAVIORAL|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
214651927|NCT00652184|DRUG|valaciclovir|active valaciclovir
214651928|NCT04965740|DRUG|Cannabis|Recreational Cannabis
214651929|NCT02298114|DEVICE|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
214651930|NCT02298114|OTHER|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
214651931|NCT00796588|OTHER|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
214235050|NCT04119375|BEHAVIORAL|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
214235051|NCT04119375|BEHAVIORAL|SMS Reminder|Patients receive a single daily SMS message to take their medication.
214235052|NCT04119375|OTHER|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
214235053|NCT04676256|PROCEDURE|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
214235054|NCT06165458|OTHER|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
214235055|NCT06165458|OTHER|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
214235056|NCT06165458|OTHER|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
214235057|NCT06165458|OTHER|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
214235058|NCT01486082|OTHER|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
214651932|NCT00525577|DRUG|Placebo|Placebo tablet, once daily
214651933|NCT00525577|DRUG|AGI-1067|75 mg AGI-1067 tablet, once daily
214651934|NCT00525577|DRUG|AGI-1067|150 mg AGI-1067 Tablet, once daily
214651935|NCT02334150|DRUG|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
214235059|NCT05236387|DRUG|99m Tc-TM|Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
214235060|NCT05018351|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
214235061|NCT05018351|BEHAVIORAL|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
214235062|NCT00320957|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
214235063|NCT00042341|DRUG|clofarabine (IV formulation)|
214235064|NCT01371032|DEVICE|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
214235065|NCT01371032|DEVICE|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
214235066|NCT02327715|DRUG|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
214235067|NCT05541588|PROCEDURE|peripheral nerve block|ultrasound guided nerve block
214235068|NCT05358340|DIAGNOSTIC_TEST|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
214235069|NCT00612495|DRUG|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
214235070|NCT05365854|PROCEDURE|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
214235071|NCT04896970|OTHER|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
214235072|NCT02294942|DRUG|RANCAD|Extended-Release RANCAD
214235073|NCT03594942|DIAGNOSTIC_TEST|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
214651936|NCT02567526|BEHAVIORAL|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
214651937|NCT03863314|DEVICE|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
214235074|NCT04095533|OTHER|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
214235075|NCT04095533|OTHER|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
214235076|NCT01280201|DRUG|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
214235077|NCT04142879|DEVICE|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
214235078|NCT05240443|PROCEDURE|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
214235079|NCT05240443|OTHER|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
214651938|NCT03863314|OTHER|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
214818067|NCT01107366|PROCEDURE|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
214235080|NCT05315869|PROCEDURE|Appendectomy|Surgical procedure for removal of the appendix
214235081|NCT01659801|DEVICE|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
214235082|NCT03553966|PROCEDURE|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
214235083|NCT03553966|PROCEDURE|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
214235084|NCT03553966|DEVICE|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
214235085|NCT06001411|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
214235086|NCT06001411|BEHAVIORAL|control group|Patients in the control group (C group) received standard perioperative care without any prone position training.
214235087|NCT02302430|DRUG|Oxytocin|20 International Units Intranasal Oxytocin
214235088|NCT02302430|OTHER|Placebo comparator|Saline nasal spray
214235089|NCT01779076|PROCEDURE|30% oxygen|
214235090|NCT01779076|PROCEDURE|100% oxygen|
214235091|NCT04050020|BIOLOGICAL|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
214235092|NCT04050020|BIOLOGICAL|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
214235093|NCT05456282|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
214235094|NCT05456282|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
214235095|NCT02012868|PROCEDURE|bariatric surgery|
214235096|NCT00125398|DRUG|AQUAVAN (fospropofol disodium; GPI 15715 )|
214235097|NCT02776020|DEVICE|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
214235098|NCT00430183|DRUG|docetaxel|75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
214235099|NCT00430183|DRUG|LHRH agonist|Given intramuscularly
214651939|NCT04113967|OTHER|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
214651940|NCT03437447|DRUG|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
214651941|NCT03437447|DRUG|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
214235100|NCT00430183|PROCEDURE|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
214235101|NCT01578512|BEHAVIORAL|Face-to-Face|Face-to-Face behavioral weight loss
214235102|NCT01578512|BEHAVIORAL|Web-based|Web-based behavioral weight loss
214235103|NCT01578512|BEHAVIORAL|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
214235104|NCT01625533|PROCEDURE|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
214235105|NCT01625533|PROCEDURE|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
214235106|NCT02436980|DRUG|Tramadol|GROUP T
214235107|NCT02436980|DRUG|Midazolam|GROUP M
214235108|NCT05628259|BEHAVIORAL|Tele-Nursing based Motivational Interviewing|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
214235109|NCT06298344|DRUG|Thiamine|Daily Thiamine 100 mg in 28 days
214235110|NCT01097083|DRUG|Coriolus Versicolor|
214235111|NCT02542930|RADIATION|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
214235112|NCT02542930|DRUG|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
214235113|NCT05413434|OTHER|exercise|high-intensity interval training will be performed on the treadmill.
214235114|NCT05413434|DEVICE|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
214235115|NCT02592642|BEHAVIORAL|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
214235116|NCT02592642|BEHAVIORAL|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
214235117|NCT02592642|DEVICE|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
214235118|NCT02592642|DEVICE|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
214235119|NCT02592642|DEVICE|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
214235120|NCT02592642|DEVICE|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
214235121|NCT05726877|OTHER|ventilation strategy|Titrating positive end-expiratory pressure
214235122|NCT05930015|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
214235123|NCT05930015|BEHAVIORAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
214235124|NCT05930015|BEHAVIORAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
214235125|NCT01073371|DRUG|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
214235126|NCT05264948|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
214235127|NCT03099343|BEHAVIORAL|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
214651942|NCT06424496|OTHER|Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression|Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
214651943|NCT01352481|OTHER|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
214651944|NCT00145444|DRUG|olanzapine|
214651945|NCT00145444|DRUG|ziprasidone|
214651946|NCT03778437|PROCEDURE|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
214651947|NCT03778437|PROCEDURE|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
214651948|NCT03778437|PROCEDURE|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
214651949|NCT01322906|OTHER|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
214235128|NCT04951323|DRUG|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
214235129|NCT02199327|DRUG|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
214235130|NCT02199327|DRUG|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
214235131|NCT04288232|DRUG|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
214235132|NCT04446390|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
214235133|NCT04446390|OTHER|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
214235134|NCT05641389|OTHER|Monitoring|Participants will be monitored for alcohol use.
214235135|NCT02126748|OTHER|inhalation 4ml hypertonic saline 3% 3x/day|
214235136|NCT02126748|DEVICE|Intrapulmonary Percussive Ventilation|
214235137|NCT02126748|PROCEDURE|Assisted Autogenic Drainage|
214235138|NCT00216164|DRUG|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
214235139|NCT00216164|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
214235140|NCT01844479|DEVICE|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
214235141|NCT01844479|OTHER|Standard innersole|
214235142|NCT01976988|DRUG|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
214235143|NCT02208778|DRUG|Duloxetine|54 participants will be allocated for duloxetine treatment
214235144|NCT02208778|DRUG|Remifentanil|27 participants will be allocated to Remifentanil infusion
214235145|NCT02208778|DRUG|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
214235146|NCT02208778|DRUG|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
214235147|NCT04037878|PROCEDURE|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
214235148|NCT04037878|PROCEDURE|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
214235149|NCT04037878|DRUG|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
214235150|NCT01768429|BEHAVIORAL|Fatty fish|
214235151|NCT01768429|BEHAVIORAL|Lean Fish|
214235152|NCT01768429|BEHAVIORAL|Alpha-linolenic acid|
214235153|NCT01768429|BEHAVIORAL|Control|
214235154|NCT03746288|DRUG|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
214235155|NCT01741402|DEVICE|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
214235156|NCT01741402|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
214235157|NCT05395091|BIOLOGICAL|AVT03|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm received AVT03 60mg administered s.c. on Day 1 and at Month 6. At Month 12, subjects in the AVT03 arm received a third dose of AVT03 60 mg.
214235158|NCT05395091|BIOLOGICAL|Denosumab|"Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection.~Subjects in this arm received 60mg of commercially available US-Prolia, administered s.c on Day 1 and at Month 6. At Month 12, subjects in the Prolia treatment group were re-randomized in a 1:1 ratio to receive either:~* AVT03 60 mg administered s.c. on Day365.~* Prolia 60 mg administered s.c. on Day365."
214235159|NCT03534336|BEHAVIORAL|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
214235160|NCT03534336|BEHAVIORAL|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
214235161|NCT05019547|BEHAVIORAL|Determining Barriers and Facilitators of Physical Activity|Determining Barriers and Facilitators of Physical Activity
214235162|NCT05866848|OTHER|Placebo|Flour capsules as a placebo.
214235163|NCT05866848|OTHER|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
214235164|NCT05866848|OTHER|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
214235165|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg|
214235166|NCT02620163|DRUG|YH22162 40/5/12.5 mg|
214235167|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg|
214235168|NCT02620163|DRUG|YH22162 80/5/25 mg|
214235169|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg placebo|
214235170|NCT02620163|DRUG|YH22162 40/5/12.5 mg placebo|
214235171|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg placebo|
214235172|NCT02620163|DRUG|YH22162 80/5/25 mg placebo|
214235173|NCT01332461|DRUG|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
214235174|NCT01332461|DRUG|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
214235175|NCT01483417|PROCEDURE|Single incision Laparoscopic hysterectomy|SILS port
214235176|NCT01483417|PROCEDURE|Conventional laparoscopic hysterectomy|3-4 conventional ports
214235177|NCT00125606|PROCEDURE|conditioning for allogeneic HSCT|
214235178|NCT00313781|DRUG|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
214235179|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
214235180|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
214235181|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
214235182|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
214235183|NCT04260139|PROCEDURE|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~1. Proximal colon,~2. Ileum in cases with right hemicolectomy only,~3. Proximal border,~4. Tumor,~5. Distal border,~6. Total specimen,~7. Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
214235184|NCT00518960|DRUG|ProAlgaZyme|
214235185|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
214235186|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
214235187|NCT03354793|OTHER|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
214235188|NCT03354793|OTHER|Survey on first pregnancy|Obstetric complications were noted
214235189|NCT01090583|OTHER|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
214235190|NCT03288051|OTHER|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
214235191|NCT03288051|DRUG|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
214235192|NCT03288051|DRUG|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
214235193|NCT01074385|BEHAVIORAL|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
214235194|NCT01331252|OTHER|semi-recumbent|Patient rests in a semi-recumbent body position
214235195|NCT01331252|OTHER|supine|Patient rests in a supine position
214235196|NCT02753439|DRUG|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
214235197|NCT06272227|DRUG|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
214235198|NCT06272227|DRUG|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
214235199|NCT06272227|DRUG|Denosumab|denosumab
214235200|NCT05784285|BEHAVIORAL|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
214235201|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
214235202|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
214235203|NCT04849702|PROCEDURE|No intervention was compared|No intervention was compared
214235204|NCT00187603|BEHAVIORAL|tobacco cessation program|
214235205|NCT04083625|DRUG|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
214235206|NCT04083625|DRUG|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
214235207|NCT05515185|DRUG|KT095 CAR-T injection|Clearance of lymphocytes
214235208|NCT04139993|DRUG|Microbiota-based Formulation RBX7455|Given PO
214235209|NCT02508818|OTHER|Parabolic flight|
214235210|NCT02508818|OTHER|Cardiovascular measurements|
214235211|NCT00453414|DRUG|Iloprost Inhalation Solution (Ventavis)|
214235212|NCT02401425|DRUG|Letrozole|
214235213|NCT02401425|DRUG|Misoprostol|
214235214|NCT02401425|OTHER|Placebo|
214235215|NCT02957214|OTHER|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
214235216|NCT00433602|OTHER|clinical observation|
214235217|NCT00433602|PROCEDURE|management of therapy complications|
214235218|NCT00433602|PROCEDURE|ultrasound imaging|
214235219|NCT03079713|DEVICE|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
214235220|NCT03079713|DEVICE|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
214235221|NCT03079713|DEVICE|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
214235222|NCT02338570|DRUG|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
214235223|NCT00146432|PROCEDURE|Immunoadsorption of LPS, IL-6 and C5a|
214235224|NCT05297318|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
214235225|NCT05297318|OTHER|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
214235226|NCT00943449|DRUG|4SC-201|oral administration
214235227|NCT00943449|DRUG|Sorafenib|oral administration
214235228|NCT02767297|DRUG|FDL169|
214235229|NCT04123691|DEVICE|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
214235230|NCT00636350|DIETARY_SUPPLEMENT|Pepper|pepper carotenoids as meals
214235231|NCT04628455|DEVICE|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
214235232|NCT02236351|DEVICE|Pinch Patch/ flat Patch|
214235233|NCT00245167|PROCEDURE|Tracheal Aspirate Fluid|
214235234|NCT05089851|PROCEDURE|Onabotulinumtoxin A|Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
214235235|NCT05089851|COMBINATION_PRODUCT|Facial Cleanser|Facial Cleanser to be used by participants twice daily
214235236|NCT05089851|COMBINATION_PRODUCT|Facial Moisturizer|Bland moisturizer to be used by study participants after serum twice daily.
214651950|NCT01322906|OTHER|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
214235237|NCT05089851|COMBINATION_PRODUCT|Sunscreen|Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
214235238|NCT02690571|OTHER|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
214235239|NCT05067218|DEVICE|buzzy device|bee shaped with wings could be frozen.
214235240|NCT05067218|OTHER|Conventinal anasthesia|normal technique of injection
214235241|NCT00834080|DRUG|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
214235242|NCT05483829|BEHAVIORAL|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
214235243|NCT01416597|BIOLOGICAL|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
214235244|NCT05424770|OTHER|Education with crossword|Afterwards, crossword activities prepared by the researcher will be implemented and students will be actively involved in the process. The researcher will also include a collaborative learning environment where students can exchange information with each other. After the completion of each puzzle, the researcher will make the necessary checks and corrections.
214235245|NCT05668390|DRUG|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
214235246|NCT02671513|DRUG|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
214235247|NCT00185198|DRUG|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
214235248|NCT00185198|DRUG|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
214235249|NCT02431260|DRUG|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
214651951|NCT01322906|OTHER|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
214818068|NCT01107366|PROCEDURE|lupiae technique|"LUPIAE technique~Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:~1. surgical arch reconstruction with a Dacron multibranched surgical prothesis~2. endovascular implantation of a thoracic stent graft"
214235250|NCT04120311|DRUG|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
214235251|NCT05605938|DRUG|Tenoten for children|Oral administration
214235252|NCT05605938|DRUG|Placebo|Oral administration
214235253|NCT04204876|DIAGNOSTIC_TEST|Magnet Resonance Imaging (MRI)|MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
214235254|NCT04204876|DIAGNOSTIC_TEST|PET/CT analysis|Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
214235255|NCT00165802|DRUG|E7974|Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
214235256|NCT00795587|DRUG|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
214235257|NCT00321646|DRUG|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
214235258|NCT00321646|DRUG|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
214235259|NCT03450330|DRUG|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
214235260|NCT00827138|DRUG|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
214235261|NCT04548869|DRUG|CDX-0159|Administered intravenously
214235262|NCT03449524|DRUG|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
214235263|NCT03449524|DRUG|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
214235264|NCT03449524|OTHER|Placebo|Placebo
214235265|NCT05176132|OTHER|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
214235266|NCT05176132|OTHER|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
214235267|NCT05176132|OTHER|No intervention|Control groups (BMI 20-25 and BMI 25-30)
214235268|NCT05893953|DEVICE|immediately feedback device|Sitting in a standard chair with immediate feedback device
214235269|NCT05893953|DEVICE|Unstable chair|sitting in an unstable chair
214235270|NCT05893953|OTHER|Standard chair|Sitting in a standard chair
214235271|NCT03079544|COMBINATION_PRODUCT|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
214235272|NCT04559711|OTHER|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
214235273|NCT01037192|DRUG|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
214235274|NCT01037192|DRUG|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
214235275|NCT04772677|BEHAVIORAL|BEAM Mental Health and Parenting Program|The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
214235276|NCT00154323|DRUG|Oxcarbazepine|
214235277|NCT03853824|OTHER|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
214235278|NCT03853824|OTHER|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
214818069|NCT01333150|DRUG|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
214818070|NCT01333150|DRUG|Placebo|One single dose of placebo
214235279|NCT05734417|DIETARY_SUPPLEMENT|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
214235280|NCT05734417|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
214235281|NCT00877123|DRUG|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
214235282|NCT00877123|DRUG|Placebo|similar placebo once a month for three consecutive months
214235283|NCT03005210|DRUG|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
214235284|NCT03005210|DRUG|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
214235285|NCT03005210|DRUG|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
214235286|NCT02634190|OTHER|Thinprep® LBC|liquid based cytology
214235287|NCT02634190|OTHER|APTIMA® HPV Assay|in vitro diagnostic test
214235288|NCT02634190|OTHER|HR HC2® HPV DNA|in vitro diagnostic test
214235289|NCT02634190|OTHER|Colposcopy|Colposcopy
214235290|NCT05278598|PROCEDURE|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
214235291|NCT05278598|PROCEDURE|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
214235292|NCT05278598|PROCEDURE|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
214235293|NCT04955600|OTHER|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
214235294|NCT03205592|DIAGNOSTIC_TEST|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
214235295|NCT03601234|PROCEDURE|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
214235296|NCT03601234|PROCEDURE|laparoscopic surgery|the traditional surgery
214235297|NCT00287417|DEVICE|echography|
214235298|NCT00287417|OTHER|blood sample|
214235299|NCT05766358|BEHAVIORAL|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
214235300|NCT05766358|DRUG|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
214235301|NCT02234518|OTHER|High quantity fiber|The intervention type is food product
214235302|NCT02234518|OTHER|Low quantity fiber|The intervention type is food product
214235303|NCT02234518|OTHER|Placebo|
214235304|NCT04326101|OTHER|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
214235305|NCT02113397|DRUG|TOBI™ Podhaler™ 112 mg inhaled twice daily|
214235306|NCT02113397|DRUG|Colistimethate 75 mg inhaled two times daily|
214235307|NCT03068351|DRUG|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
214235308|NCT03068351|BIOLOGICAL|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
214235309|NCT03045224|DEVICE|PTA, balloon angioplasty, stent|
214235310|NCT04431674|DRUG|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
214235311|NCT05874167|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast"
214235312|NCT05049317|PROCEDURE|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
214235313|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Reference product
214235314|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Test product
214235315|NCT02917057|DRUG|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
214235316|NCT02917057|DRUG|basal insulin|basal insulin tretament in the customary clinical care in USA
214235317|NCT05887778|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
214235318|NCT05887778|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
214235319|NCT05887778|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
214235320|NCT02605291|OTHER|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
214235321|NCT02605291|OTHER|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
214235322|NCT02605291|OTHER|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
214235323|NCT02605291|OTHER|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
214235324|NCT02605291|OTHER|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
214235325|NCT04458324|DRUG|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
214235326|NCT04458324|DRUG|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
214235327|NCT04458324|DEVICE|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
214235328|NCT04458324|DEVICE|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
214235329|NCT04458324|OTHER|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
214235330|NCT03439683|OTHER|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
214235331|NCT02576145|BIOLOGICAL|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
214235332|NCT02576145|DRUG|Daclizumab|The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
214235333|NCT02576145|BIOLOGICAL|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
214235334|NCT05846607|DIETARY_SUPPLEMENT|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
214235335|NCT02660138|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214235336|NCT02660138|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214235337|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214235338|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214235339|NCT02889029|DEVICE|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
214235340|NCT04108117|PROCEDURE|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
214235341|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
214235342|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
214235343|NCT00308581|OTHER|Placebo|placebo administered 4-weekly in Active 1
214235344|NCT02894697|DEVICE|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
214235345|NCT02894697|DEVICE|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
214235346|NCT01247298|COMBINATION_PRODUCT|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
214235347|NCT02029378|DRUG|Eculizumab|
214235348|NCT00852488|PROCEDURE|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
214235349|NCT05299853|OTHER|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
214235350|NCT05299853|OTHER|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
214235351|NCT01552421|PROCEDURE|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
214235352|NCT00401687|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
214235353|NCT05061056|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
214235354|NCT05061056|OTHER|Russian current 20%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
214235355|NCT05061056|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
214235356|NCT05061056|OTHER|Aussie current 20%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
214235357|NCT01286961|DRUG|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
214235358|NCT00627575|DRUG|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
214235359|NCT00627575|DRUG|atorvastatin|Atorvastatin will available as 40 mg tablets.
214235360|NCT00627575|DRUG|phenytoin|Phenytoin will available as 100 mg capsules.
214235361|NCT01087788|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
214235362|NCT01087788|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
214235363|NCT01087788|OTHER|Placebo|Matching Placebo to CZP injection.
214235364|NCT00254267|DRUG|AMG 706|AMG 706 125mg, oral, once a day
214235365|NCT03131830|OTHER|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
214235366|NCT04805489|OTHER|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
214235367|NCT03235180|DRUG|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
214235368|NCT03235180|DEVICE|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
214235369|NCT03235180|DEVICE|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
214235370|NCT03235180|DEVICE|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
214235371|NCT05520164|OTHER|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
214235372|NCT04152993|DEVICE|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
214235373|NCT03893890|BIOLOGICAL|Previously Treated with EN3835|No treatment to be administered - Observational only
214235374|NCT06248047|PROCEDURE|uretheroplasty|4\. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
214235375|NCT01779219|DEVICE|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
214235376|NCT01779219|DEVICE|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
214235377|NCT00304213|DRUG|Testosterone|
214235378|NCT02386683|OTHER|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
214235379|NCT05907941|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
214235380|NCT05907941|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
214235381|NCT05907941|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
214235382|NCT00680394|DRUG|mifepristone|200 mg mifepristone
214235383|NCT00680394|DRUG|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
214235384|NCT00680394|DRUG|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
214235385|NCT00534313|DRUG|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
214235386|NCT00534313|DRUG|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
214235387|NCT00464880|DRUG|Aliskiren|
214235388|NCT01773447|PROCEDURE|Set-back suture|
214235389|NCT01773447|PROCEDURE|Vertical mattress suture|
214235390|NCT03665818|DEVICE|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
214235391|NCT02285036|BIOLOGICAL|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
214235392|NCT02285036|BIOLOGICAL|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
214235393|NCT04089800|OTHER|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
214235394|NCT04168632|OTHER|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
214235395|NCT02358356|DRUG|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
214235396|NCT02358356|DRUG|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
214235397|NCT02358356|DRUG|Temozolomide|temozolomide 75mg/m2 b.i.d.
214235398|NCT02521896|DEVICE|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
214235399|NCT02133703|BEHAVIORAL|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
214235400|NCT02133703|BEHAVIORAL|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
214235401|NCT02133703|BEHAVIORAL|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
214235402|NCT02133703|BEHAVIORAL|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
214235403|NCT02133703|BEHAVIORAL|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
214235404|NCT01642628|OTHER|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
214235405|NCT04880902|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
214235406|NCT02762227|DEVICE|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
214235407|NCT02762227|DEVICE|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
214235408|NCT02762227|PROCEDURE|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
214235409|NCT03438721|BEHAVIORAL|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
214235410|NCT03438721|BEHAVIORAL|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
214235411|NCT06472986|OTHER|Activity-based therapy and transcutaneous spinal cord stimulation|Activity Based Therapy (ABT) is a method of neuro-rehabilitation that incorporates a high intensity, long duration and effortful engagement from the individual receiving therapy, to garner improvements in sensory and motor function. The ABT constitutes 4 types of exercises including: cardio-fitness, resistance, postural/weightbearing and functional exercises. TransCutaneous Spinal Cord Stimulation (TCSCS) stimulates spinal networks in the cervical region to neuro-modulate the descending motor commands/motor intentions from the brain, which control the muscles. In tCSCS, electrical stimulation is delivered at a frequency of 30-50Hz at 500-1000µs between C3-C7. 12 sessions of ABT (4 weeks), followed by 28 sessions of ABT-TCSCS (7 weeks). Each session will last 1 hour and delivered 3 times per week.
214235412|NCT03725462|DEVICE|Cardioskin|Subjects have a monitoring with cardioskin and comparator
214235413|NCT03725462|DEVICE|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
214235414|NCT05738343|OTHER|dieta mediterranea|nutritional education or Mediterranean food scheme
214235415|NCT05045989|BEHAVIORAL|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
214235416|NCT03717272|DRUG|AEF0117|AEF0117 capsules
214235417|NCT03717272|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
214235418|NCT03337672|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
214235419|NCT03337672|DRUG|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
214235420|NCT05307198|DRUG|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
214235421|NCT05307198|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
214235422|NCT05307198|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
214235423|NCT05307198|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
214235424|NCT05903209|DEVICE|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
214235425|NCT02970682|DRUG|SFX-01|Stabilised Sulforaphane
214235426|NCT02970682|DRUG|Fulvestrant|Fulvestrant
214235427|NCT02970682|DRUG|Tamoxifen|Tamoxifen
214235428|NCT02970682|DRUG|Aromatase Inhibitors|
214235429|NCT02687867|DRUG|Dabigatran (Pradaxa)|As prescribed by treating physicians
214235430|NCT02687867|DRUG|Vitamin K antagonist|As prescribed by treating physicians
214235431|NCT01615497|BEHAVIORAL|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
214235432|NCT01615497|BEHAVIORAL|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
214235433|NCT01615497|BEHAVIORAL|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
214235434|NCT03772288|DRUG|TAK-659|Tablets.
214235435|NCT03772288|DRUG|NKTR-214|Intravenous infusion.
214235436|NCT04008927|DIAGNOSTIC_TEST|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
214235437|NCT04008927|DIAGNOSTIC_TEST|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.
214235438|NCT04008927|DRUG|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
214235439|NCT01905423|DRUG|Albendazole (annual)|Albendazole 400 mg pnce annually
214235440|NCT01905423|DRUG|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
214235441|NCT01905423|DRUG|Albendazole (semiannual)|Albendazole 400 mg twice annually
214235442|NCT01905423|DRUG|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
214235443|NCT04717830|DRUG|Gamezumab|solution for infusion
214235444|NCT05157802|BEHAVIORAL|Physical activity coaching|Physical activity coaching over 5 sessions
214235445|NCT03709576|DRUG|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
214235446|NCT03709576|PROCEDURE|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
214235447|NCT03709576|DRUG|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
214235448|NCT00726401|DRUG|COLD-fX|200mg BID for 4 weeks
214235449|NCT00726401|DRUG|Placebo|200mg BID for 4 weeks
214235450|NCT04370340|DEVICE|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
214235451|NCT00000803|DRUG|Delavirdine mesylate|
214235452|NCT00000803|DRUG|Zidovudine|
214235453|NCT00000803|DRUG|Didanosine|
214235454|NCT06421129|PROCEDURE|anal fistula surgery|anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
214235455|NCT05725759|BEHAVIORAL|Rehabilitation|Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
214235456|NCT01459289|OTHER|leaflet|
214235457|NCT01459289|OTHER|counseling and leaflet|
214235458|NCT04276909|COMBINATION_PRODUCT|LUM Imaging System|LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
214235459|NCT00882570|DRUG|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
214235460|NCT00882570|DRUG|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
214235461|NCT00930748|DEVICE|MR imaging with endorectal coil|MR imaging with endorectal coil
214235462|NCT00930748|DEVICE|MRI with endo-rectal coil|MRI with endo-rectal coil
214235463|NCT02518880|OTHER|Parabolic flight|
214235464|NCT02518880|OTHER|plasma volume measurements|
214235465|NCT04662970|DEVICE|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
214235466|NCT02593071|BIOLOGICAL|RSV-F Vaccine|
214235467|NCT02593071|BIOLOGICAL|Phosphate Buffer Placebo|
214235468|NCT02030431|DEVICE|Dynaloc|
214235469|NCT02030431|DEVICE|Cancellous screws|
214235470|NCT02727231|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
214235471|NCT02727231|DEVICE|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
214235472|NCT02996058|DRUG|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
214235473|NCT02996058|DRUG|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
214235474|NCT03365388|DRUG|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
214235475|NCT03365388|DRUG|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
214235476|NCT00263861|PROCEDURE|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
214235477|NCT00189774|DRUG|nateglinide|
214235478|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
214235479|NCT01947855|DRUG|Empagliflozin|Empagliflozin low dose
214235480|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
214235481|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
214235482|NCT01947855|DRUG|Empagliflozin|Empagliflozin high dose tablet once daily
214235483|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
214235484|NCT02595645|GENETIC|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
214235485|NCT06255678|DIAGNOSTIC_TEST|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
214235486|NCT01150344|DRUG|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
214235487|NCT01150344|DRUG|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
214235488|NCT02727530|OTHER|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
214235489|NCT02727530|OTHER|ADVICES|Advices for parents to improve the management of infant colic
214235490|NCT05783427|OTHER|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
214235491|NCT02631473|DRUG|50mg NANO-efavirenz|OD
214235492|NCT02631473|DRUG|400mg NANO-Lopinavir|BID
214235493|NCT02631473|DRUG|200mg NANO-Lopinavir|BID
214235494|NCT02631473|DRUG|100mg Ritonavir|BID
214235495|NCT02631473|DRUG|300mg NANO-Efavirenz|OD
214235496|NCT02631473|DRUG|600mg Sustiva|OD
214235497|NCT02631473|DRUG|200mg NANO-Efavirenz|OD
214235498|NCT02631473|DRUG|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
214235499|NCT02631473|DRUG|+/- 200mg NANO-Lopinavir|BID
214235500|NCT02631473|DRUG|+/- 200mg ritonavir NORVIR|BID
214235501|NCT02631473|DRUG|400mg Sustiva|
214235502|NCT03977311|DEVICE|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
214235503|NCT03977311|RADIATION|Radiation therapy|-Standard of Care
214235504|NCT00536211|BEHAVIORAL|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
214235505|NCT00536211|DRUG|Metformin|oral tablet, 1000 mg daily for 17 days
214235506|NCT03829800|DIETARY_SUPPLEMENT|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
214235507|NCT03829800|DIETARY_SUPPLEMENT|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
214235508|NCT03829800|DIETARY_SUPPLEMENT|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
214235509|NCT03829800|DIETARY_SUPPLEMENT|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
214235510|NCT01233518|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
214235511|NCT03798119|DRUG|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
214235512|NCT00436501|DRUG|docetaxel|25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
214235513|NCT00436501|BIOLOGICAL|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
214235514|NCT00436501|OTHER|laboratory biomarker analysis|Correlative studies
214235515|NCT00436501|OTHER|pharmacological study|Correlative studies
214235516|NCT04796181|DEVICE|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
214235517|NCT02615626|PROCEDURE|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
214235518|NCT00692354|DRUG|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
214235519|NCT03131427|DRUG|Standard of care|Standard of care according to the updated national and/or international guidelines
214235520|NCT03231683|DRUG|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
214235521|NCT03231683|DRUG|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
214235522|NCT03231683|DRUG|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
214235523|NCT03231683|DRUG|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
214235524|NCT00886652|OTHER|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
214235525|NCT01724554|DRUG|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
214235526|NCT02874170|OTHER|Spectroscopy magnetic resonance of phosphorus 31|
214235527|NCT04363151|OTHER|No intervention.|
214235528|NCT06448416|PROCEDURE|UBE|Patients with HDL were treated with UBE
214235529|NCT05424783|OTHER|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
214235530|NCT04641338|DRUG|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
214235531|NCT04641338|DRUG|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
214235532|NCT04641338|DRUG|Codeine|30 mg codeine every 6 hours if necessary.
214235533|NCT00714571|BEHAVIORAL|Mnemonic strategy training (MST)|
214235534|NCT00714571|BEHAVIORAL|Repeated exposure (XP)|
214235535|NCT00714571|BEHAVIORAL|Subtracting Cues training|
214235536|NCT04407572|OTHER|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
214235537|NCT06435559|OTHER|Neurotablet® and Neuropsychological evaluations|The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
214235538|NCT06435559|OTHER|Neuropsychological evaluations|Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
214235539|NCT03206164|OTHER|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
214235540|NCT00000939|DRUG|Hydroxyurea|
214235541|NCT00000939|DRUG|Efavirenz|
214235542|NCT00000939|DRUG|Stavudine|
214235543|NCT00000939|DRUG|Didanosine|
214235544|NCT02079818|DEVICE|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
214235545|NCT03011892|DRUG|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
214235546|NCT03011892|DRUG|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
214235547|NCT03011892|DRUG|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
214235548|NCT03011892|DRUG|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
214235549|NCT03011892|DRUG|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
214235550|NCT03011892|DRUG|Vehicle Cream BID|Vehicle cream BID
214235551|NCT02282293|DRUG|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
214235552|NCT02282293|DRUG|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
214235553|NCT01673152|DIETARY_SUPPLEMENT|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
214235554|NCT01673152|DIETARY_SUPPLEMENT|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
214235555|NCT06286176|BEHAVIORAL|Videos with breastfeeding education material and encouraging messages|Distributed videos aim to increase breastfeeding related knowledge and to receive support
214235556|NCT06286176|BEHAVIORAL|Whatsapp group|The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
214235557|NCT04514354|BEHAVIORAL|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
214235558|NCT03829878|DRUG|CP101|Orally administered donor derived full spectrum microbiota
214235559|NCT03829878|DRUG|Placebo|Placebo for CP101
214235560|NCT03381729|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
214235561|NCT03538171|DRUG|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
214235562|NCT03538171|DRUG|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214235563|NCT03538171|DRUG|Exemestane|Exemestane PO once daily on day 1-28.
214235564|NCT04879147|DIAGNOSTIC_TEST|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
214235565|NCT02688322|DRUG|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
214651952|NCT06353776|PROCEDURE|conjunctival biopsy after micropulse transscleral laser therapy|"During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed."
214651953|NCT01253603|DRUG|QAW039 capsules once daily for 28 days|
214651954|NCT01253603|DRUG|Placebo to QAW039 capsules once daily for 28 days|
214651955|NCT01253603|DRUG|Fluticasone propionate inhaler twice daily for 28 days|
214235566|NCT02787486|OTHER|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
214235567|NCT01587768|DRUG|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
214235568|NCT03758755|DEVICE|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
214235569|NCT03758755|OTHER|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
214235570|NCT04178278|DIAGNOSTIC_TEST|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
214651956|NCT02532348|OTHER|Blood samples|Blood samples
214651957|NCT02764541|DRUG|Letrozole|
214651958|NCT02764541|DRUG|Tamoxifen|
214651959|NCT02764541|DRUG|Palbociclib|
214651960|NCT02764541|DRUG|Endocrine Therapy|
214651961|NCT05253456|PROCEDURE|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
214651962|NCT00749190|DRUG|BI 10773|
214651963|NCT00749190|DRUG|placebo|
214651964|NCT00749190|DRUG|sitagliptin|
214651965|NCT04713761|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
214651966|NCT01652924|DEVICE|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
214651967|NCT01652924|DEVICE|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
214235571|NCT04178278|DIAGNOSTIC_TEST|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
214235572|NCT04178278|DIAGNOSTIC_TEST|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
214235573|NCT05429775|DRUG|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
214235574|NCT02817399|DEVICE|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
214235575|NCT02817399|DEVICE|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
214235576|NCT02817399|PROCEDURE|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
214235577|NCT01264601|BIOLOGICAL|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
214235578|NCT02365142|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
214235579|NCT02365142|BIOLOGICAL|Platelet Rich plasma (PRGF)|3 injections of PRGF
214235580|NCT00832039|DRUG|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
214235581|NCT00832039|DRUG|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
214235582|NCT00832039|PROCEDURE|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
214235583|NCT00030004|PROCEDURE|spinal manipulation|
214235584|NCT00030004|DRUG|midazolam|
214235585|NCT05397782|DEVICE|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
214235586|NCT02622906|DRUG|Pasireotide|60 mg per month of the Pasireotide during 6 months
214235587|NCT02622906|DRUG|Placebo|Vehicule injection per month during 6 months
214235588|NCT04204980|DRUG|Daratumumab dose escalation|\- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
214235589|NCT04204980|DRUG|Daratumumab full dose|\- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
214235590|NCT00006212|DRUG|cisplatin|
214235591|NCT00006212|DRUG|vinblastine sulfate|
214235592|NCT00006212|RADIATION|phosphorus P32|
214235593|NCT00006212|RADIATION|radiation therapy|
214235594|NCT01410851|OTHER|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
214235595|NCT02000908|DEVICE|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
214235596|NCT02000908|OTHER|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
214235597|NCT02000908|OTHER|Physiotherapy|Chiropractic massage and lymphedema treatment
214235598|NCT05367375|PROCEDURE|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
214235599|NCT06234332|OTHER|No Interventions|No intervention This is an observational study without any intervention
214235600|NCT01525992|BEHAVIORAL|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
214235601|NCT01525992|OTHER|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
214235602|NCT01924429|DRUG|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
214235603|NCT02680678|OTHER|Colloid Preload|preload infusion
214235604|NCT02680678|OTHER|colloid co-load|co-load infusion
214235605|NCT02680678|OTHER|Crystalloid preload|preload infusion
214235606|NCT02680678|OTHER|Crystalloid Co-load|co-load infusion
214235607|NCT01943357|BEHAVIORAL|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
214235608|NCT03443947|DEVICE|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
214235609|NCT03443947|PROCEDURE|control group|airway assessment after tongue protrusion
214651968|NCT03064464|OTHER|None Intervention|It is observational study, no interventios to any of the three study arms
214651969|NCT04957459|OTHER|No intervention|No intervention
214235610|NCT04612023|OTHER|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
214235611|NCT01699971|PROCEDURE|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
214235612|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
214235613|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
214235614|NCT06131671|OTHER|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
214235615|NCT05785481|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
214235616|NCT00384111|DRUG|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
214235617|NCT00384111|DRUG|R-CVP|Standard R-CVP
214235618|NCT01702181|DRUG|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
214235619|NCT01702181|DRUG|Tacrolimus|0.1% concentration of tacrolimus.
214235620|NCT01702181|DRUG|Placebo|
214235621|NCT01715597|DRUG|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
214235622|NCT01715597|DRUG|Normal saline|normal saline 500ml IV
214651970|NCT04706910|DRUG|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
214235623|NCT01779271|DRUG|Pelubiprofen|
214235624|NCT01779271|DRUG|Loxoprofen|
214235625|NCT00801307|DEVICE|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
214651971|NCT04706910|DRUG|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
214651972|NCT00570245|DRUG|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
214235626|NCT02643069|OTHER|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
214235627|NCT05599477|DEVICE|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
214235628|NCT00647829|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
214235629|NCT00647829|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
214235630|NCT00647829|DRUG|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
214235631|NCT05329038|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
214235632|NCT05053373|DEVICE|Electroacupuncture group|
214235633|NCT05053373|DEVICE|Sham electroacupuncture group|
214235634|NCT05053373|BEHAVIORAL|Pelvic floor muscle training|
214235635|NCT04204070|PROCEDURE|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
214235636|NCT04204070|PROCEDURE|APAD|APAD
214651973|NCT00570245|DRUG|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
214235637|NCT05653531|OTHER|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
214235638|NCT04796987|DIAGNOSTIC_TEST|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
214235639|NCT02101697|BEHAVIORAL|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
214235640|NCT03725423|DRUG|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
214235641|NCT04253886|DEVICE|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
214235642|NCT06177275|PROCEDURE|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
214235643|NCT06177275|PROCEDURE|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
214235644|NCT04130737|DEVICE|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
214235645|NCT00807573|DRUG|Paclitaxel|Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
214235646|NCT00807573|DRUG|Pemetrexed|Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
214235647|NCT00807573|DRUG|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
214235648|NCT00198887|PROCEDURE|Operations research|
214235649|NCT00168987|DRUG|oral nutritional supplement rich in eicosapentanoic acid|
214235650|NCT05503667|DRUG|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
214235651|NCT05503667|DRUG|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
214235652|NCT04392700|DRUG|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
214235653|NCT04392700|DRUG|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
214235654|NCT03314246|OTHER|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
214235655|NCT03314246|OTHER|Standard of care|Standard of care
214235656|NCT01419821|DRUG|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
214235657|NCT01419821|OTHER|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
214235658|NCT01706900|OTHER|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
214235659|NCT01706900|OTHER|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
214235660|NCT00266565|DRUG|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
214235661|NCT05918081|OTHER|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
214235662|NCT04516837|DRUG|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
214235663|NCT04516837|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
214235664|NCT05580094|OTHER|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
214235665|NCT05580094|OTHER|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
214235666|NCT03070743|PROCEDURE|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
214235667|NCT02434601|PROCEDURE|Treatment of Dentin Surface|"* Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
214235668|NCT02434601|PROCEDURE|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
214235669|NCT02434601|PROCEDURE|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
214235670|NCT01089361|DRUG|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
214235671|NCT01089361|DRUG|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
214235672|NCT04046588|DIAGNOSTIC_TEST|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
214235673|NCT04046588|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
214235674|NCT05313152|DRUG|TAVO103A|TAVO103A single ascending dose IV infusion.
214235675|NCT05313152|OTHER|Placebo|Placebo single ascending dose IV infusion.
214235676|NCT03612856|DRUG|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
214235677|NCT03612856|DRUG|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
214235678|NCT03612856|DRUG|placebo|Participants will receive a single dose of placebo.
214235679|NCT03993093|OTHER|CD4 cell count|CD4 cell count from treatment naive HIV patients
214235680|NCT05630300|DIAGNOSTIC_TEST|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
214235681|NCT05630300|DIAGNOSTIC_TEST|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
214235682|NCT00256477|BEHAVIORAL|Sudarshan KRIYA Breathing Technique|
214235683|NCT02900144|BEHAVIORAL|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
214235684|NCT02900144|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
214235685|NCT06022484|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
214235686|NCT03588962|BIOLOGICAL|In-stent restenosis|Patch tests for the metals applicated in each of the patients
214235687|NCT01513200|DRUG|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
214235688|NCT01513200|DRUG|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
214235689|NCT01513200|DRUG|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
214235690|NCT02485678|OTHER|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
214235691|NCT02485678|OTHER|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
214235692|NCT02485678|OTHER|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
214235693|NCT02284672|DRUG|Dexmedetomidine|
214235694|NCT02284672|DRUG|Normal saline|
214235695|NCT06012643|OTHER|The purpose of this systematic review of case reports and case series was to evaluate the spectrum of subperiosteal implants for severely atrophied jaws using digital technology.|An electronic and manual search was conducted in the PubMed, Scopus, and Google Scholar databases. Publications of case reports and series written in English without data restrictions
214235696|NCT04975529|BEHAVIORAL|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
214235697|NCT06391528|PROCEDURE|Transversalis Fascia Plane Block|application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
214235698|NCT00265928|DRUG|bortezomib|
214235699|NCT00265928|DRUG|rituximab|
214235700|NCT00265928|PROCEDURE|antibody therapy|
214235701|NCT00265928|PROCEDURE|biological therapy|
214235702|NCT00265928|PROCEDURE|enzyme inhibitor therapy|
214235703|NCT00265928|PROCEDURE|monoclonal antibody therapy|
214235704|NCT00718562|DRUG|AMN107|
214235705|NCT01164709|DRUG|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
214235706|NCT01164709|DRUG|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
214235707|NCT02012673|DEVICE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
214235708|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and two booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
214235709|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and one booster session|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
214235710|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) without booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
214235711|NCT02203175|DRUG|saline|Before the anesthesia induction, 5 ml isotonic saline
214235712|NCT02203175|DRUG|fentanyl|before the anesthesia induction 50 mcgr fentanyl
214235713|NCT02203175|DRUG|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
214235714|NCT04232293|DIAGNOSTIC_TEST|Blood tests|eLift and FibroMeter
214235715|NCT06367712|DRUG|Letrozole tablets|To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
214235716|NCT04463069|OTHER|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
214235717|NCT03583619|RADIATION|APBI|Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.
214235718|NCT03583619|RADIATION|WBI|Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
214235719|NCT02457104|PROCEDURE|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
214235720|NCT02457104|BEHAVIORAL|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
214235721|NCT01227174|DRUG|Propofol|Procedural sedation will be achieved using propofol
214235722|NCT01267357|OTHER|no intervention|
214235723|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by SpO2|Titration of fraction of inspired oxygen (FiO2) guided by SpO2
214235724|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
214235725|NCT00575393|DRUG|gold sodium thiomalate|
214235726|NCT00575393|GENETIC|gene expression analysis|
214235727|NCT00575393|OTHER|fluorine F 18 fluorothymidine|
214235728|NCT00575393|OTHER|mass spectrometry|
214235729|NCT00575393|OTHER|pharmacological study|
214235730|NCT03594240|DRUG|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
214235731|NCT03594240|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
214235732|NCT06329284|DIAGNOSTIC_TEST|ELISA|ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
214235733|NCT05668611|OTHER|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
214235734|NCT05668611|OTHER|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
214235735|NCT05668611|OTHER|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
214235736|NCT05668611|OTHER|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
214235737|NCT05668611|OTHER|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
214235738|NCT05668611|OTHER|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
214235739|NCT06179342|DIAGNOSTIC_TEST|Multiple-Breath-Washout|One additional diagnostic test is performed using the Multiple-Breath-Washout technology
214235740|NCT01900912|OTHER|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
214235741|NCT02491229|OTHER|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
214235742|NCT02491229|OTHER|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
214235743|NCT06276504|DRUG|Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection|Pembrolizumab administration at D0, M1 and M2
214235744|NCT02351427|DRUG|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
214235745|NCT02351427|DRUG|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
214235746|NCT03596749|DRUG|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
214235747|NCT01634191|DRUG|Apremilast|One oral 30 mg dose of apremilast
214235748|NCT00013702|DRUG|Adefovir|
214235749|NCT03736902|OTHER|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
214235750|NCT02154828|BEHAVIORAL|Integrative practices|
214235751|NCT00839176|DRUG|RX-10100|Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
214235752|NCT04037332|OTHER|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
214235753|NCT06434987|PROCEDURE|Retrograde Inferior Vena Cava Perfusion|Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.
214235754|NCT06434987|PROCEDURE|Antegrade cerebral perfusion|After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
214235755|NCT01155167|DRUG|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
214235756|NCT01155167|OTHER|Placebo|Placebo
214235757|NCT02243423|PROCEDURE|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
214651974|NCT01245673|BIOLOGICAL|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
214235758|NCT02243423|PROCEDURE|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
214235759|NCT02380768|DEVICE|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
214235760|NCT02380768|DEVICE|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
214235761|NCT00551304|DEVICE|Ardian Catheter|
214235762|NCT00286559|DRUG|SonoVue|
214235763|NCT00286559|DRUG|Optison|
214235764|NCT04482023|BEHAVIORAL|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
214235765|NCT00649597|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
214235766|NCT00649597|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
214235767|NCT00945828|BEHAVIORAL|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
214235768|NCT00945828|BEHAVIORAL|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
214235769|NCT03345966|DIAGNOSTIC_TEST|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
214235770|NCT02076425|BEHAVIORAL|PCIT-ED|
214235771|NCT03337789|DIETARY_SUPPLEMENT|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
214235772|NCT03337789|DIETARY_SUPPLEMENT|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
214235773|NCT04006600|PROCEDURE|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
214235774|NCT01428947|PROCEDURE|Arterial approach|Randomization to right radial or femoral approach
214235775|NCT04408378|OTHER|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
214235776|NCT04094415|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
214235777|NCT02070198|DRUG|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
214235778|NCT02070198|DRUG|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
214235779|NCT02070198|DRUG|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
214235780|NCT00118456|DRUG|AEE788|
214235781|NCT02230488|OTHER|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~\--------------------------------------------------------------------------------"
214235782|NCT06981429|BEHAVIORAL|Nourish to Flourish: The Power of Positive Food Parenting|This intervention focuses on increasing diet quality and parent use of positive food parenting practices with the goal of promoting healthy child growth). This will be a 12 - week, 12 session study. Sessions 1 and 12 will consist of collection baseline and post-intervention data. Sessions 2 - 11 will be a mix of online - group sessions and individual online or in - person sessions (based on participant preference). The group sessions are focused on principal investigator presentation of the intervention curriculum and group discussion. The individual sessions are focused on goal setting, coping planning, and working through individual situations with a trained coach.
214235783|NCT02691585|OTHER|Music Intervention|A raga will be played for 10 minutes \& data collected.
214651975|NCT01245673|OTHER|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.
214235784|NCT00970619|DEVICE|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
214235785|NCT03763513|DEVICE|ESWT|Extracorporeal Shock Wave Therapy=ESWT
214235786|NCT03763513|OTHER|Kinesiotaping Application|Kinesiotaping=KT (CT)
214235787|NCT00156936|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
214235788|NCT00156936|DRUG|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
214235789|NCT05158400|RADIATION|Ultrasound|Ultrasound examination on the hand
214235790|NCT05573815|DEVICE|BT-M01|Clinical decision support system for detecting brain metastasis
214235791|NCT02491359|DRUG|Carfilzomib|Given IV
214235792|NCT02491359|OTHER|Laboratory Biomarker Analysis|Correlative studies
214235793|NCT02491359|OTHER|Quality-of-Life Assessment|Ancillary studies
214235794|NCT02491359|OTHER|Questionnaire Administration|Ancillary studies
214235795|NCT03001271|DRUG|Angiotensin 1-7|
214235796|NCT03001271|OTHER|Placebo|
214235797|NCT02324127|DEVICE|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
214235798|NCT03754478|OTHER|Physical activity training|subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
214235799|NCT00000682|DRUG|Zidovudine|
214235800|NCT00000682|DRUG|Zalcitabine|
214235801|NCT05917782|BIOLOGICAL|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
214235802|NCT05917782|BIOLOGICAL|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|subcutaneous injection of 1 dose on Day 1
214235803|NCT05917782|BIOLOGICAL|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
214235804|NCT01962324|RADIATION|SIB Dose-Escalation Radiotherapy|
214235805|NCT02364401|DEVICE|Ablation|Catheter ablation for atrial fibrillation
214235806|NCT03703401|DIAGNOSTIC_TEST|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
214235807|NCT02880956|DRUG|ABBV-8E12|ABBV-8E12 solution for IV infusion
214235808|NCT02880956|DRUG|placebo for ABBV-8E12|placebo solution for intravenous (IV) infusion
214235809|NCT06476054|PROCEDURE|Optimal timing for laparoscopic cholecystectomy|To compare early and late cholecystectomy after cholecystostomy.
214235810|NCT06988644|DIAGNOSTIC_TEST|exhaled carbon monoxyde measurement|At the initial tobacco consultation: measurement of exhaled carbon monoxyde. At the tobaccology consultation at 12 months, measurement of the cessation rate: no tobacco smoked in the last 7 days (self-reported), confirmed by a measurement of exhaled carbon monoxyde \< 9 ppm.
214235811|NCT06426524|PROCEDURE|IGF-1 Gel|After degranulation of the defect, IGF-1 gel mixed with Hydroxyapatite graft will be placed in the defect.
214235812|NCT06426524|PROCEDURE|Hydroxyapatite|After degranulation of the defect, Hydroxyapatite graft will be placed in the defect.
214235813|NCT01128023|OTHER|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
214235814|NCT00853970|DRUG|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
214235815|NCT00853970|DRUG|Placebo Comparator|sterile ophthalmic solution
214235816|NCT05604378|PROCEDURE|Gastrectomy|All patients in our study underwent gastrectomy.
214235817|NCT05129033|DRUG|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
214235818|NCT05129033|DRUG|itraconazole|Anti-fungal medication to reduce fugal load.
214235819|NCT05129033|BIOLOGICAL|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
214235820|NCT05750199|OTHER|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
214235821|NCT05750199|OTHER|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
214235822|NCT00771589|DEVICE|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
214235823|NCT06994052|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous injection
214235824|NCT06993805|BEHAVIORAL|OPA|The Our Practice Advisory (OPA) intervention is a behavioral nudge integrated into the electronic health record system. It is designed to prompt providers to reconsider ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests if a similar test was performed within the previous 30 days. The OPA aligns with evidence-based guidelines to reduce unnecessary testing, improve resource utilization, and optimize patient care by enhancing clinical decision-making at the point of order entry.
214651976|NCT01245673|DRUG|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
214235825|NCT06995066|PROCEDURE|collagenase injection into the epidural space|"The Collagenase injection into the epidural space is a medical procedure for treating cervical disc herniation. Firstly, the patient is positioned, and the specific location of the epidural space at the affected cervical spine segment is accurately identified with the guidance of imaging devices like fluoroscopy or CT. After local anesthesia, a special puncture needle is inserted into the epidural space following the marked path. Once the needle is in the correct position, an appropriate amount of collagenase solution is slowly injected. After the operation, the patient needs to stay in the hospital for observation to monitor vital signs and neurological conditions. The patient should rest in bed for a certain period and then gradually engage in proper activities. Additionally, personalized rehabilitation treatment plans, including physical therapy and exercise, are usually required to help with recovery."
214235826|NCT06995573|DRUG|NSC001|rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
214235827|NCT06995573|OTHER|Placebo|matching placebo to NSC001
214235828|NCT06995001|DRUG|SHR-2173|SHR-2173 injection dose 1；
214235829|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 2 ；Pacebo dose 2
214235830|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 3 ；Pacebo dose 3
214235831|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 4 ；Pacebo dose 4
214235832|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 5 ；Pacebo dose 5
214235833|NCT03881761|BIOLOGICAL|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
214235834|NCT01688206|BIOLOGICAL|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
214235835|NCT01688206|BIOLOGICAL|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
214235836|NCT05427617|DRUG|Control group|Physician chosen treatment
214235837|NCT05427617|DRUG|Case group|Druggable ctDNA alterations-guided therapy
214235838|NCT01648556|OTHER|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
214235839|NCT01889745|DRUG|HX-1171|Anti-oxidatant, Anti-inflamation
214235840|NCT04809103|DRUG|cis-diamminedichloroplatinum|Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
214235841|NCT01073501|DRUG|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
214235842|NCT01073501|DRUG|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
214235843|NCT02836743|DRUG|Circadin|Slow-release melatonin
214235844|NCT02836743|DRUG|Placebo|
214235845|NCT02739672|DRUG|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
214235846|NCT02739672|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
214235847|NCT02739672|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
214235848|NCT04096482|DEVICE|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
214235849|NCT04096482|DEVICE|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
214235850|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
214235851|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
214235852|NCT00576420|PROCEDURE|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
214235853|NCT04836325|PROCEDURE|transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of tSMS in the primary motor cortex.
214235854|NCT04836325|PROCEDURE|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment
214235855|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and magnesium|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate
214235856|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and normal saline|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
214235857|NCT00006103|DRUG|fluorouracil|
214235858|NCT00006103|DRUG|irinotecan hydrochloride|
214235859|NCT00006103|DRUG|leucovorin calcium|
214235860|NCT02402959|OTHER|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
214235861|NCT02000154|DRUG|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
214235862|NCT00000527|DRUG|aspirin|
214235863|NCT00000527|DRUG|dipyridamole|
214235864|NCT01502332|OTHER|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
214235865|NCT01502332|OTHER|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
214235866|NCT00831649|DRUG|natalizumab|
214235867|NCT00979797|OTHER|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
214235868|NCT03004573|OTHER|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
214235869|NCT04865874|OTHER|PPV-GDT|fluid-therapy based on PPV monitoring
214235870|NCT04865874|OTHER|Zero-balance|fluid-therapy based on urinary output balance
214235871|NCT04884451|BEHAVIORAL|Lifestyle modification|Diet and physical activity modification and behavioral approach
214235872|NCT04133064|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
214235873|NCT01771809|DRUG|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
214235874|NCT01771809|DRUG|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
214235875|NCT01459029|DRUG|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
214235876|NCT00008450|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
214235877|NCT00008450|DRUG|Cyclosporine|Given PO or IV
214235878|NCT00008450|OTHER|Laboratory Biomarker Analysis|Correlative studies
214235879|NCT00008450|DRUG|Mycophenolate Mofetil|Given PO or IV
214235880|NCT00008450|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
214235881|NCT00008450|RADIATION|Total-Body Irradiation|Undergo TBI
214235882|NCT03167567|BEHAVIORAL|Presence of a medical clown during labor|Presence of a medical clown during labor
214235883|NCT03802214|DRUG|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
214235884|NCT00970775|DRUG|AZD2423|oral solution, single dose
214235885|NCT00970775|DRUG|Placebo|oral solution,single dose
214235886|NCT06147375|DRUG|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
214235887|NCT02770209|BIOLOGICAL|biomimetic cartilage matrix + autologous chondrocytes|
214235888|NCT02770209|PROCEDURE|arthroscopic debridement|
214235889|NCT02770209|PROCEDURE|microfracture surgery|
214235890|NCT03924557|DIAGNOSTIC_TEST|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
214235891|NCT04989452|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
214235892|NCT02656680|BEHAVIORAL|Continuous Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
214235893|NCT02656680|BEHAVIORAL|Closed Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
214235894|NCT03306797|OTHER|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward"
214235895|NCT03306797|DEVICE|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
214235896|NCT00130312|DRUG|Sulodexide|100 mg gelcap in the morning and evening
214235897|NCT00130312|DRUG|Placebo|1 placebo gelcap in the morning and evening
214235898|NCT06449365|DEVICE|midazolam by nasal atomizer|midazolam
214235899|NCT06449365|DRUG|intravenous midazolam|midazolam
214235900|NCT05470257|OTHER|Cast|Application of fiberglass long arm cast.
214235901|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
214235902|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
214235903|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
214235904|NCT00911443|BIOLOGICAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
214235905|NCT00911443|DRUG|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
214235906|NCT06518850|DRUG|Rifaximin|Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
214235907|NCT00912444|DRUG|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
214235908|NCT00912444|DRUG|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
214235909|NCT02127268|DRUG|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
214235910|NCT03821662|BEHAVIORAL|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
214235911|NCT02496572|DRUG|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
214235912|NCT00627146|DRUG|ChAgly CD3|6 days treatment 8mg/d intravenous
214235913|NCT00627146|DRUG|Placebo|6 days
214235914|NCT00297024|PROCEDURE|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
214235915|NCT01908400|BIOLOGICAL|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
214235916|NCT03386877|PROCEDURE|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
214235917|NCT01142089|DRUG|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
214235918|NCT01142089|DRUG|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
214235919|NCT00697580|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
214651977|NCT01245673|BIOLOGICAL|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
214651978|NCT05853471|DRUG|[18F]MC225|All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
214651979|NCT05653375|OTHER|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
214651980|NCT05653375|OTHER|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
214235920|NCT00697580|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
214235921|NCT00697580|BEHAVIORAL|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
214235922|NCT02592187|BEHAVIORAL|ReMemory-MCI training|
214235923|NCT02592187|BEHAVIORAL|Control intervention|
214235924|NCT05449470|DEVICE|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
214235925|NCT05449470|DEVICE|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
214235926|NCT00789074|DRUG|Varenicline|Varenicline 1mg twice daily
214235927|NCT00789074|DRUG|Placebo|Placebo 1mg BD
214235928|NCT01490398|DRUG|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
214235929|NCT00531687|DRUG|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
214235930|NCT00531687|DRUG|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
214235931|NCT00531687|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
214235932|NCT04170478|DEVICE|Echolaser X4 system|Transperineal laser ablation
214235933|NCT01840644|OTHER|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
214235934|NCT02208401|PROCEDURE|conventional cold snare polypectomy|conventional cold snare polypectomy
214235935|NCT02208401|PROCEDURE|Cold snare polypectomy with suction|Cold snare polypectomy with suction
214235936|NCT02907892|PROCEDURE|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
214235937|NCT04199702|OTHER|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
214235938|NCT02910128|BEHAVIORAL|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
214235939|NCT06522984|DRUG|Tranexamic acid injection|"to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma."
214235940|NCT01974765|DRUG|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
214235941|NCT05324865|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
214235942|NCT00864019|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
214235943|NCT00864019|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
214235944|NCT02915328|DEVICE|Filterwire EZ™|
214235945|NCT02915328|DEVICE|MO.MA Ultra|
214235946|NCT02915328|DEVICE|Stent Roadsaver®|
214235947|NCT02915328|DEVICE|Carotid Wallstent|
214235948|NCT04043390|DIAGNOSTIC_TEST|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
214235949|NCT04043390|DIAGNOSTIC_TEST|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
214235950|NCT04043390|DIAGNOSTIC_TEST|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
214235951|NCT04043390|DIAGNOSTIC_TEST|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
214235952|NCT06665308|OTHER|No intervention|No intervention will be administered to study participants. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.
214235953|NCT02673047|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
214235954|NCT06112964|PROCEDURE|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
214235955|NCT06112964|BEHAVIORAL|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
214235956|NCT06112964|BEHAVIORAL|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
214235957|NCT00649545|BIOLOGICAL|adalimumab|40 mg every other week
214235958|NCT00528970|DRUG|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
214235959|NCT00528970|DRUG|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
214235960|NCT00146159|DRUG|Mitoxantrone|dosage
214235961|NCT03860935|DRUG|acoramidis|TTR stabilizer administered orally twice daily (BID)
214235962|NCT03860935|DRUG|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
214235963|NCT05675683|DRUG|Capmatinib|Patients receiving Capmatinib
214235964|NCT05753397|DRUG|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
214235965|NCT04671953|DRUG|BMS-986165|Specified dose on specified days
214235966|NCT04671953|DRUG|Metformin|Specified dose on specified days
214235967|NCT01426932|OTHER|Video recording of Head Impulse Test|Video recording of Head Impulse Test
214235968|NCT01430754|DRUG|tasimelteon|20 mg tasimelteon capsules, daily
214235969|NCT01430754|DRUG|Placebo|Placebo capsules, daily
214235970|NCT00202527|DEVICE|Nasal continuos positive airway pressure|
214235971|NCT04306185|PROCEDURE|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
214235972|NCT04576377|BIOLOGICAL|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
214235973|NCT04576377|OTHER|Placebo|0.5mL saline placebo.
214235974|NCT01685645|DEVICE|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
214235975|NCT05150444|OTHER|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
214235976|NCT01931176|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
214235977|NCT01931176|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
214235978|NCT01020006|DRUG|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated."
214235979|NCT01020006|DRUG|Gemcitabine|
214235980|NCT01271582|DRUG|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
214235981|NCT01698138|DRUG|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
214651981|NCT03404648|DRUG|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
214235982|NCT01698138|DRUG|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
214235983|NCT04096183|OTHER|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
214235984|NCT05266573|OTHER|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
214235985|NCT04841473|OTHER|TRAIN Concussion Education|Participants will receive the TRAIN concussion education module.
214235986|NCT04841473|OTHER|Standard Concussion Education|Participants will receive a standard concussion education module.
214235987|NCT04416360|OTHER|Interview by psychologists|"Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement"
214651982|NCT03404648|DRUG|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
214235988|NCT00701662|BIOLOGICAL|Vivaglobin|
214235989|NCT00635024|BIOLOGICAL|anti-thymocyte globulin|2.5 mg/kg
214235990|NCT00635024|DRUG|melphalan|16 mg/m\^2
214235991|NCT03371888|BIOLOGICAL|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
214235992|NCT03371888|BIOLOGICAL|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
214235993|NCT05402371|DRUG|Rencofilstat|Rencofilstat soft gel capsule
214235994|NCT05402371|DRUG|Placebo|placebo soft gel capsule
214235995|NCT05339776|BEHAVIORAL|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
214235996|NCT04551313|BEHAVIORAL|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
214235997|NCT04717206|OTHER|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
214651983|NCT03404648|DEVICE|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
214235998|NCT04717206|OTHER|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
214235999|NCT01105065|DRUG|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
214236000|NCT02935426|DEVICE|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
214236001|NCT02935426|DEVICE|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
214651984|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
214651985|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
214236002|NCT05714319|OTHER|Data collection|"Variables collected will include:~* demographics (sex, age)~* comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~* echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~* angiographic data (presence of non-obstructive CAD (any coronary lesion \<50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~* laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~* medical therapy at admission~* response to intracoronary provocative test with ACh."
214236003|NCT05714319|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
214236004|NCT00303589|DRUG|Standard care|As prescribed
214236005|NCT00303589|DRUG|beta-lactam|750mg iv q8h
214236006|NCT00303589|DRUG|beta-lactam|1500mg iv q8h
214236007|NCT05423860|OTHER|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
214236008|NCT04113590|PROCEDURE|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
214236009|NCT05443139|BEHAVIORAL|Well-being online|Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
214236010|NCT00228215|BEHAVIORAL|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
214236011|NCT02636140|OTHER|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
214236012|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
214236013|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
214236014|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
214236015|NCT05608928|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
214236016|NCT05608928|DEVICE|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
214236017|NCT05608928|COMBINATION_PRODUCT|Placebo|microcrystalline cellulose
214236018|NCT05191056|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day for 8 weeks
214236019|NCT05191056|DIETARY_SUPPLEMENT|MelaGene drink|consume 1 bottle per day for 8 weeks
214236020|NCT02025153|OTHER|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
214236021|NCT02843997|GENETIC|Endophenotype and sequencing|Draw an endophenotype and genetic study
214236022|NCT01414920|DRUG|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
214236023|NCT01414920|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
214236024|NCT01414920|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
214236025|NCT01414920|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
214236026|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
214236027|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
214236028|NCT05581901|DRUG|Methadone (Dose1)|Dose: 0.10mg/kg
214236029|NCT05581901|DRUG|Methadone (Dose 2)|Dose: 0.15mg/kg
214236030|NCT05581901|DRUG|Methadone (Dose 3)|Dose 0.20mg/kg
214236031|NCT03276169|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
214236032|NCT03276169|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
214236033|NCT03276169|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
214236034|NCT00880464|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
214236035|NCT01791959|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
214236036|NCT01791959|OTHER|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
214236037|NCT03876301|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
214236038|NCT02162407|DRUG|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
214236039|NCT02162407|DRUG|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
214236040|NCT02470637|DRUG|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
214236041|NCT02470637|DRUG|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214236042|NCT02310009|DRUG|Anakinra (AN)|
214236043|NCT02310009|BEHAVIORAL|Exercise (EX)|
214236044|NCT02310009|BEHAVIORAL|Control (CON)|
214651986|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
214651987|NCT04531384|DEVICE|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
214651988|NCT04531384|OTHER|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
214651989|NCT01796002|DRUG|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
214651990|NCT01796002|DRUG|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
214651991|NCT04420130|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
214651992|NCT04420130|DRUG|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
214651993|NCT04420130|PROCEDURE|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
214651994|NCT04942392|DEVICE|Digital dance for PD|The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
214651995|NCT03541473|DIETARY_SUPPLEMENT|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
214651996|NCT03541473|DIETARY_SUPPLEMENT|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
214651997|NCT04608214|DRUG|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
214651998|NCT04608214|OTHER|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
214651999|NCT00024232|BIOLOGICAL|monoclonal antibody huJ591|
214652000|NCT04492566|DEVICE|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
214652001|NCT01457183|DEVICE|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
214652002|NCT01474655|PROCEDURE|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
214652003|NCT03162679|BEHAVIORAL|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
214652004|NCT00630331|BIOLOGICAL|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
214652005|NCT00630331|BIOLOGICAL|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
214652006|NCT00630331|BIOLOGICAL|Placebo|One dose (0.5 mL) of phosphate buffered solution.
214652007|NCT04640766|DEVICE|PRISM|"The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes."
214652008|NCT00814242|PROCEDURE|surgical resection|radical resection performed in patinets with HCC.
214652009|NCT00814242|PROCEDURE|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
214652010|NCT00974987|RADIATION|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
214652011|NCT00974987|RADIATION|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
214236045|NCT00606047|RADIATION|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
214236046|NCT03203343|PROCEDURE|Operation - PIRS|Operation by its known design for PIRS group
214652012|NCT00974987|DRUG|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
214652013|NCT00317460|OTHER|Physician Management|Standard physician care
214652014|NCT00317460|BEHAVIORAL|Counseling|Physician Management and Counseling
214652015|NCT02846103|OTHER|Biological samples|blood and tumor tissue samples
214652016|NCT01565980|BEHAVIORAL|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
214652017|NCT01565980|BEHAVIORAL|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
214652018|NCT02944019|DRUG|Edoxaban|Prescribed according to approved label
214236047|NCT03203343|PROCEDURE|Operation - MARCY|Operation by its known design for MARCY group
214236048|NCT03207373|DIAGNOSTIC_TEST|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
214236049|NCT01704612|DRUG|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
214236050|NCT00506532|DRUG|Surfactant (calfactant)|
214236051|NCT03098888|PROCEDURE|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
214236052|NCT04837677|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
214236053|NCT01038869|DRUG|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
214236054|NCT03779243|DIETARY_SUPPLEMENT|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
214236055|NCT03779243|OTHER|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
214236056|NCT03521895|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
214236057|NCT04609163|OTHER|data collection|retrospective data collection
214236058|NCT04575597|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
214236059|NCT04575597|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
214236060|NCT03138993|BEHAVIORAL|Patient decision aid|Web-based patient decision aid plus a paper workbook.
214236061|NCT03138993|BEHAVIORAL|General sleep education|Web-based information about sleep plus a paper workbook
214236062|NCT05610189|DRUG|Tavapadon|Oral tablets
214236063|NCT00689442|DRUG|JTT-705 600 mg and atorvastatin 20 mg|"* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
214236064|NCT00689442|DRUG|Placebo and atorvastatin 20 mg|"* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
214236065|NCT04970953|PROCEDURE|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
214236066|NCT04038203|DEVICE|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
214236067|NCT03207438|DRUG|Quetiapine 50 MG Extended Release Oral Tablet|OD
214236068|NCT03207438|DRUG|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
214236069|NCT03207438|DRUG|Placebos|Placebo
214236070|NCT02128685|DRUG|Dydrogesterone|
214236071|NCT02128685|DRUG|Placebo|
214236072|NCT01014923|BEHAVIORAL|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
214236073|NCT03153384|PROCEDURE|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
214236074|NCT05101200|OTHER|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
214236075|NCT05101200|OTHER|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
214236076|NCT02567058|DEVICE|Ultrasound exam|"Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III"
214236077|NCT02567058|BEHAVIORAL|IPAQ questionnaire|IPAQ questionnaire
214236078|NCT00892840|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
214236079|NCT00892840|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
214236080|NCT03316911|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
214236081|NCT01119937|DRUG|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
214236082|NCT01119937|DRUG|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
214236083|NCT05916911|DIETARY_SUPPLEMENT|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
214652019|NCT05660304|DEVICE|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
214236084|NCT05916911|OTHER|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
214236085|NCT00329056|DRUG|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
214236086|NCT03343353|OTHER|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
214236087|NCT01455909|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
214236088|NCT01455909|DRUG|sitagliptin|sitagliptin oral 100 mg/day
214236089|NCT00220922|PROCEDURE|Alcohol Wipes vs. No Alcohol Wipes|
214236090|NCT01512667|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
214236091|NCT04235413|BEHAVIORAL|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
214236092|NCT02846298|BIOLOGICAL|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
214236093|NCT03257917|OTHER|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
214236094|NCT00473122|PROCEDURE|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
214236095|NCT00233831|DEVICE|Generator of electromagnetic millimeter waves|
214236096|NCT01495312|DEVICE|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
214236097|NCT00195208|DRUG|Pantoprazole for approximately 9 weeks|
214236098|NCT04023838|PROCEDURE|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
214236099|NCT04132804|BEHAVIORAL|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
214236100|NCT01820624|DRUG|tretinoin|Given PO
214236101|NCT01820624|DRUG|lithium carbonate|Given PO
214236102|NCT01820624|OTHER|laboratory biomarker analysis|Correlative studies
214236103|NCT06393959|PROCEDURE|Caudal epidural pulsed radiofrequency|The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.
214236104|NCT06393959|PROCEDURE|Caudal epidural steroid enjection|The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
214236105|NCT00389402|DRUG|saquinavir/ritonavir|
214236106|NCT00389402|DRUG|atazanavir/ritonavir|
214236107|NCT00853996|DRUG|acolbifene hydrochloride|Given orally
214236108|NCT00002543|DRUG|gallium nitrate|
214236109|NCT03907618|DIAGNOSTIC_TEST|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
214236110|NCT02536404|DRUG|Etrasimod|
214236111|NCT02536404|DRUG|Placebo|
214236112|NCT00770146|DRUG|Mipomersen sodium|200 mg/mL
214236113|NCT00770146|DRUG|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
214236114|NCT02439333|DEVICE|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
214236115|NCT02439333|DEVICE|nasal catheter or Venturi mask|Conventional oxygen therapy
214652020|NCT05660304|DEVICE|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
214236116|NCT02003274|OTHER|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
214236117|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
214236118|NCT02268929|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
214236119|NCT02268929|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
214236120|NCT01836874|DRUG|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
214236121|NCT00040456|DRUG|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
214236122|NCT00040456|DRUG|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
214236123|NCT00081510|DRUG|Lonafarnib|
214236124|NCT00081510|DRUG|Placebo|
214236125|NCT00081510|DRUG|anastrozole|
214236126|NCT01569243|OTHER|Text messages|"* Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages."
214236127|NCT01569243|OTHER|Usual care|"* Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
214236128|NCT01649843|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
214236129|NCT01463137|BEHAVIORAL|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
214236130|NCT03940976|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
214236131|NCT01967784|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
214236132|NCT00816023|DRUG|ecallantide|infusion administered IV over the duration of the surgical procedure
214236133|NCT00816023|DRUG|placebo|solution for IV infusion over the duration of the surgical\>\> procedure
214236134|NCT04739371|DRUG|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
214236135|NCT04739371|DRUG|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
214236136|NCT04746742|PROCEDURE|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
214236137|NCT04746742|PROCEDURE|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
214236138|NCT02737033|DRUG|Rhodiola|Rhodiola rosea 800mg
214236139|NCT02737033|DRUG|Placebo|innocuous pill manufactured to mimic Rhodiola
214236140|NCT04607278|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
214652021|NCT04707755|OTHER|Motor imagery technique|"The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs."
214652022|NCT04707755|OTHER|Conventional Physical Therapy|It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
214236141|NCT04607278|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
214236142|NCT04607278|DIETARY_SUPPLEMENT|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
214236143|NCT05027971|DEVICE|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
214236144|NCT04506762|PROCEDURE|Regional analgesia|Insertion of bilateral ESP catheters
214236145|NCT06361992|OTHER|Blue Cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
214236146|NCT00968032|DEVICE|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
214236147|NCT02962375|DIETARY_SUPPLEMENT|Active|100% orange juice with orange pomace fiber
214236148|NCT02962375|DIETARY_SUPPLEMENT|Control|100% orange juice
214236149|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
214236150|NCT02829541|DRUG|BIIB068|Administered as specified in the treatment arm.
214236151|NCT02829541|DRUG|Placebo|Administered as specified in the treatment arm
214236152|NCT01661985|DRUG|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
214236153|NCT01661985|DRUG|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
214236154|NCT01661985|DRUG|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
214236155|NCT00005646|DRUG|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
214236156|NCT03325023|DIETARY_SUPPLEMENT|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
214236157|NCT03325023|OTHER|Placebo|Placebo
214236158|NCT04061928|DRUG|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
214236159|NCT00401024|DRUG|imatinib mesylate|
214236160|NCT00401024|OTHER|pharmacological study|
214236161|NCT00401024|PROCEDURE|conventional surgery|
214236162|NCT05272995|DIAGNOSTIC_TEST|IIEF-5|The participants will be asked to complete a validated IIEF-5 questionnaire, an abridged version of the IIEF. The IIEF is a validated, brief and reliable self-administered questionnaire for assessing erectile function. Moreover, this tool is easily administered in clinical setting and demonstrates adequate sensitivity and specificity for detecting treatment-related changes in erectile function in patients with erectile dysfunction (ED).According to Rosen et al the abridged five-item version of the 15-item IIEF possesses favorable properties for detecting the presence and severity of ED for the preceding 6 months. The IIEF-5 consists of five questions, each of which is scored on a five-point ordinal scale and ED may be classified into five categories based on the calculated scores.
214236163|NCT06073223|OTHER|Usual Care|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
214236164|NCT06073223|OTHER|CQUPLE|"Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making."
214236165|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
214236166|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
214236167|NCT02619539|PROCEDURE|plasma fibrinogen measurement|plasma fibrinogen measurement
214236168|NCT04136119|OTHER|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
214236169|NCT02181517|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
214236170|NCT02181517|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
214236171|NCT02181517|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
214236172|NCT01204723|DRUG|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
214236173|NCT01204723|DRUG|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
214236174|NCT00936689|PROCEDURE|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
214236175|NCT00936689|PROCEDURE|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
214236176|NCT04061993|PROCEDURE|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
214652023|NCT05536323|DRUG|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years
214236177|NCT04061993|PROCEDURE|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
214236178|NCT01238588|DRUG|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
214236179|NCT01544088|BEHAVIORAL|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
214236180|NCT01544088|BEHAVIORAL|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
214236181|NCT05468528|PROCEDURE|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
214236182|NCT05468528|PROCEDURE|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
214236183|NCT01127828|OTHER|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
214236184|NCT01127828|OTHER|Probiotic yoghurt (Cultura)|200 ml per day
214236185|NCT04096768|DRUG|Dexmedetomidine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
214236186|NCT04096768|DRUG|Ketamine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
214236187|NCT02055638|DRUG|SRX246|capsules
214236188|NCT02055638|DRUG|Placebo|
214236189|NCT00346424|DRUG|Alfimeprase|
214236190|NCT03535246|BIOLOGICAL|Engineered Immune Cells|Engineered immune effector cells (EIE)
214236191|NCT05006742|PROCEDURE|CB study arm|Included patients are randomized to receive cryobiopsy
214236192|NCT05006742|PROCEDURE|FB-CB study arm|Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session
214236193|NCT01519193|BEHAVIORAL|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
214236194|NCT01423188|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
214236195|NCT01423188|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
214236196|NCT02136888|DRUG|Ponesimod Placebo|
214236197|NCT02136888|DRUG|Moxifloxacin Placebo|
214236198|NCT02136888|DRUG|Ponesimod 10 mg|
214236199|NCT02136888|DRUG|Ponesimod 20 mg|
214236200|NCT02136888|DRUG|Ponesimod 40 mg|
214236201|NCT02136888|DRUG|Ponesimod 60 mg|
214236202|NCT02136888|DRUG|Ponesimod 80 mg|
214236203|NCT02136888|DRUG|Ponesimod 100 mg|
214236204|NCT02136888|DRUG|Moxifloxacin 400 mg|
214236205|NCT01654913|DEVICE|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
214236206|NCT06427395|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
214236207|NCT03453788|DEVICE|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
214236208|NCT04687514|DRUG|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
214236209|NCT04687514|DRUG|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
214236210|NCT04334083|BEHAVIORAL|Comparison of biomarkers of stress|Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
214236211|NCT01096628|OTHER|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
214236212|NCT01096628|OTHER|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
214236213|NCT03900689|OTHER|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
214236214|NCT03900689|OTHER|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
214236215|NCT02587182|DEVICE|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
214236216|NCT02835040|OTHER|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
214236217|NCT02835040|OTHER|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
214236218|NCT02319629|DRUG|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
214236219|NCT02319629|DRUG|Placebo|
214236220|NCT03543072|DRUG|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
214236221|NCT03124667|BEHAVIORAL|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
214236222|NCT03124667|BEHAVIORAL|Videos|The video training will emphasize health and educational information.
214236223|NCT02914002|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
214236224|NCT05300204|OTHER|Self-help strategies for depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding self-help strategies for depression."
214236225|NCT05300204|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
214236226|NCT01903252|DRUG|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
214236227|NCT01903252|DRUG|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
214236228|NCT02437110|DRUG|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
214236229|NCT02437110|DRUG|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
214236230|NCT02437110|DRUG|Dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
214236231|NCT02437110|DRUG|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
214652024|NCT05536323|DRUG|Remimazolam continuous|Remimazolam 12 mg/kg/hr
214652025|NCT05533892|DRUG|Nocardia rubra cell wall skeleton|Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
214236232|NCT03598517|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation."
214236233|NCT01458093|OTHER|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
214236234|NCT00749047|DRUG|Pioglitazone|15-45 mg/day
214236235|NCT04270279|DRUG|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
214236236|NCT04270279|DRUG|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
214236237|NCT04270279|DRUG|Nitroglycerin tablets|Be used when angina attack
214236238|NCT03467685|DEVICE|Vibratory Anesthetic Device (VAD)|This is a handheld \~10cm long tool, battery operated, which provides vibration at a rate of \~150 Hz
214236239|NCT03279393|DRUG|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
214236240|NCT04887376|DEVICE|Mirror frame|Combined Mirror and NMES therapy
214236241|NCT04887376|DEVICE|Control|Only NMES therapy
214652026|NCT05533892|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
214652027|NCT05533892|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
214652028|NCT05533892|DRUG|Tislelizumab|200mg intravenously every 3 weeks
214652029|NCT06120530|DRUG|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
214652030|NCT06120530|OTHER|Saline|Placebo
214652031|NCT01629615|DRUG|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
214652032|NCT01929135|DRUG|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
214652033|NCT01929135|DRUG|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
214652034|NCT02425098|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
214236242|NCT00027872|DRUG|tipifarnib|Given orally
214236243|NCT00027872|OTHER|laboratory biomarker analysis|Correlative studies
214236244|NCT01701050|OTHER|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
214236245|NCT01683097|OTHER|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
214236246|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
214236247|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
214236248|NCT00323817|DRUG|Z-338|
214236249|NCT05834387|PROCEDURE|EICU Transfer Routine Care|EICU Transfer Routine Care
214236250|NCT05834387|PROCEDURE|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
214236251|NCT02856360|OTHER|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
214236252|NCT02856360|OTHER|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
214236253|NCT00131924|BIOLOGICAL|esterified estrogens|
214236254|NCT03497598|DRUG|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
214236255|NCT03497598|DRUG|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
214236256|NCT03986372|BIOLOGICAL|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
214236257|NCT04303728|DIAGNOSTIC_TEST|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
214236258|NCT03836001|DRUG|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
214236259|NCT03836001|DRUG|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
214236260|NCT03946722|DRUG|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
214236261|NCT03946722|OTHER|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
214236262|NCT06276738|DIAGNOSTIC_TEST|LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
214236263|NCT04184388|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
214236264|NCT04184388|DIETARY_SUPPLEMENT|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
214236265|NCT00289029|DRUG|Iopamidol 370 mgI/mL|
214236266|NCT01961583|DRUG|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
214236267|NCT00798278|DRUG|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
214236268|NCT00798278|PROCEDURE|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
214236269|NCT01381562|DRUG|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
214236270|NCT01381562|DRUG|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
214236271|NCT01381562|OTHER|Placebo|saline placebo
214236272|NCT06341790|OTHER|jowar based products|jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
214236273|NCT02971033|DRUG|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
214236274|NCT02971033|DRUG|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
214236275|NCT02971033|DRUG|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
214236276|NCT01642732|OTHER|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
214236277|NCT04816968|DRUG|Cefepime|Cefepime from 3 to 6 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
214652035|NCT02425098|BIOLOGICAL|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
214236278|NCT04816968|DRUG|Piperacillin/tazobactam|Piperacillin/Tazobactam 18 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
214236279|NCT04816968|DRUG|Meropenem|Meropenem 3 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
214236280|NCT04816968|DRUG|Vancomycin|Vancomycin 30 mg/kg, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
214236281|NCT04753424|PROCEDURE|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
214236282|NCT02659774|BEHAVIORAL|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
214236283|NCT02659774|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
214236284|NCT02659774|BEHAVIORAL|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
214236285|NCT02659774|BEHAVIORAL|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
214236286|NCT02659774|BEHAVIORAL|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
214236287|NCT02659774|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
214236288|NCT02478567|OTHER|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
214236289|NCT02478567|OTHER|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
214236290|NCT01630278|DRUG|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
214236291|NCT01630278|DRUG|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
214236292|NCT02060916|DRUG|PAZ320|Single-center pilot study, open label dose escalation design
214236293|NCT03012126|BEHAVIORAL|Healthy Weight Clinic|
214236294|NCT03012126|BEHAVIORAL|Healthy Weight and Your Child|
214236295|NCT02438475|DEVICE|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
214236296|NCT02438475|OTHER|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
214236297|NCT02403466|BEHAVIORAL|Resident Handoff Bundle|1\) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
214236298|NCT00899353|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
214236299|NCT04475198|DRUG|ST-2427|Investigational drug
214236300|NCT04475198|DRUG|Placebo|5% Dextrose Injection
214236301|NCT03027791|BEHAVIORAL|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
214236302|NCT03027791|BEHAVIORAL|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
214236303|NCT04583059|OTHER|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
214236304|NCT00184951|DRUG|Rosuvastatin|
214236305|NCT02730793|DRUG|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
214236306|NCT02730793|DRUG|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
214236307|NCT02730793|DRUG|Nasal Placebo|Placebo (nasal saline twice per day)
214236308|NCT01375855|PROCEDURE|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
214236309|NCT01284491|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
214236310|NCT01284491|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
214236311|NCT01397734|DRUG|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
214236312|NCT03005184|DRUG|Valsartan 80 mg bid|oral medication during run-in and washout period
214236313|NCT03005184|DRUG|Enalapril 10 mg bid|oral medication
214236314|NCT03005184|DRUG|Sacubitril-Valsartan 200 mg bid|oral medication
214236315|NCT03005184|DRUG|Icatibant|intravenous medication
214236316|NCT03005184|DRUG|Placebo|intravenous medication
214236317|NCT02802917|DRUG|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
214236318|NCT02802917|DRUG|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
214236319|NCT02802917|DRUG|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
214236320|NCT02802917|DRUG|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
214236321|NCT02802917|OTHER|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
214236322|NCT03618589|DRUG|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
214236323|NCT03618589|DRUG|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
214236324|NCT04486300|PROCEDURE|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
214236325|NCT01033149|DRUG|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
214236326|NCT01123993|DEVICE|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
214236327|NCT00333944|DRUG|Pralidoxime(drug)|
214236328|NCT04503733|DRUG|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
214236329|NCT04503733|DRUG|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
214236330|NCT04503733|DRUG|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
214236331|NCT04503733|DRUG|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
214236332|NCT04503733|OTHER|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
214236333|NCT06294210|DEVICE|Mobile app and wrist-worn monitor|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
214236334|NCT04668261|OTHER|Advanced imaging investigation|MRI imaging
214236335|NCT05117918|OTHER|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
214652036|NCT00895830|DRUG|APD405|IV
214652037|NCT00895830|DRUG|Placebo|IV
214236336|NCT05117918|OTHER|Telemedicine|Delivery of care via telemedicine
214236337|NCT00709579|DRUG|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
214236338|NCT00709579|DRUG|Placebo|placebo
214236339|NCT06058208|BEHAVIORAL|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
214236340|NCT06058208|BEHAVIORAL|Visual stimulation|Mothers will be shown video images of their babies.
214236341|NCT05761795|DRUG|IVMED 85|Eye drop
214236342|NCT05761795|DRUG|Placebo|Placebo eye drop
214236343|NCT02384642|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
214236344|NCT02384642|BEHAVIORAL|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
214236345|NCT03900325|DRUG|Nimacimab|2.5 mg/kg
214236346|NCT03900325|DRUG|Placebo|0.9% sodium chloride
214236347|NCT00252941|DEVICE|Memokath 028SW Urethral Stent|
214236348|NCT02489422|OTHER|Laboratory Biomarker Analysis|Correlative studies
214236349|NCT02489422|OTHER|Questionnaire Administration|Ancillary studies
214236350|NCT02489422|OTHER|Daily Survey Administration|Ancillary studies
214236351|NCT02489422|BEHAVIORAL|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
214236352|NCT02489422|BEHAVIORAL|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
214236353|NCT02489422|OTHER|Actigraphy Assessment|Ancillary studies
214236354|NCT04527393|DRUG|Individualized oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose."
214652038|NCT02887443|DRUG|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
214652039|NCT02887443|DRUG|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
214652040|NCT05074108|BEHAVIORAL|Pilot study|Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
214652041|NCT04421690|BEHAVIORAL|Cognitive Training|Participants (n=15) will complete computerized cognitive training games and activities online 3 times/week for 8 weeks.
214652042|NCT04421690|BEHAVIORAL|Trivia Training|Participants (n=15) will receive computerized trivia questions to answer and submit 3 times/week for 8 weeks.
214652043|NCT02078219|DRUG|RDEA3170|Oral Treatment
214652044|NCT02078219|DRUG|Allopurinol|Oral Treatment
214652045|NCT02078219|DRUG|Placebo|Oral Treatment
214652046|NCT00376467|DRUG|Imatinib|
214652047|NCT03962985|OTHER|Guided tour at the Montreal Museum of Fine Arts|"* The duration of the participation -3 months~* The duration of the guided tour-45 minutes, each week~* All participants will be asked to fill out some specific online questionnaires during their participations in the study"
214236355|NCT04527393|DRUG|Conventional oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose."
214236356|NCT02941172|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET scan
214236357|NCT02941172|OTHER|[18F]FMPEP-d2|PET radiotracer used in imaging
214236358|NCT02941172|OTHER|[18F]FDG|PET radiotracer used in imaging
214236359|NCT06022471|PROCEDURE|Stapes surgery|Stapedectomy operation
214236360|NCT01376518|PROCEDURE|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
214236361|NCT06289205|DRUG|Methotrexate|Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
214236362|NCT04865523|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
214236363|NCT04922047|DRUG|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
214236364|NCT06174168|OTHER|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
214236365|NCT01311284|DEVICE|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
214236366|NCT01311284|DEVICE|Macintosh laryngoscope|intubate with the macintosh laryngoscope
214236367|NCT01311284|DEVICE|McGrath|Intubate with McGrath device
214236368|NCT01311284|DEVICE|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
214652048|NCT03036527|PROCEDURE|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
214236369|NCT04052178|DEVICE|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
214236370|NCT04052178|DEVICE|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
214236371|NCT04052178|DIETARY_SUPPLEMENT|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
214236372|NCT00832832|OTHER|Eyelid closure|Eyelid will be closed after eye drop instillation
214236373|NCT00832832|OTHER|No intervention will be assigned|No intervention will be assigned to this arm
214236374|NCT06113380|DEVICE|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
214652049|NCT03036527|PROCEDURE|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
214652050|NCT03036527|PROCEDURE|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
214652051|NCT03036527|PROCEDURE|Activity-based training + spinal epidural stimulation|combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
214652052|NCT05352542|BIOLOGICAL|GPC3 Targeting CART Cells|before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen
214652053|NCT02469571|DIETARY_SUPPLEMENT|Winclove 607|multispecies probiotic
214652054|NCT02469571|DIETARY_SUPPLEMENT|Placebo|Placebo
214652055|NCT01130987|OTHER|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
214652056|NCT01130987|BEHAVIORAL|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
214652057|NCT03135405|BEHAVIORAL|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
214652058|NCT03135405|BEHAVIORAL|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
214652059|NCT03135405|BEHAVIORAL|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
214652060|NCT06333873|OTHER|patient-reported outcome|Performance of real-life tests and tasks
214652061|NCT06617754|BIOLOGICAL|Biologic drugs|Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies
214652062|NCT02761967|BEHAVIORAL|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
214236375|NCT06113380|OTHER|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
214236376|NCT02603263|OTHER|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
214236377|NCT04422340|OTHER|Group1|"* Comorbidities (CIRS-G scale),~* Functional status of the patient with~  * Clinical frailty scale (1 month before infection)~ * ADL score (1 month before infection)~* Biological data~  * Blood group~ * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~ * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~* Resuscitation outcomes~  * LDH rate at the start of intensive care~ * PaO2 / FiO2 ratio at the start of intensive care~ * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~ * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~ * Delay between the appearance of the first signs of infection and admission to intensive care"
214236378|NCT00067938|DRUG|lamotrigine|Lamotrigine
214236379|NCT05170867|DIETARY_SUPPLEMENT|Hafnia alvei HA4597™|One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
214236380|NCT05170867|OTHER|Placebo|One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
214236381|NCT05870982|BEHAVIORAL|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
214236382|NCT05870982|BEHAVIORAL|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
214236383|NCT05870982|BEHAVIORAL|DCR|Participants will be instructed to reduce caloric intake by 25%.
214236384|NCT02412514|BIOLOGICAL|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
214236385|NCT02412514|BIOLOGICAL|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
214236386|NCT02412514|BIOLOGICAL|IPV|IPV administered at 6 weeks of age
214236387|NCT02694757|DEVICE|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
214236388|NCT01671527|PROCEDURE|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
214236389|NCT05048550|DEVICE|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
214236390|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
214236391|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
214236392|NCT01640574|DRUG|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
214236393|NCT01640574|DRUG|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
214236394|NCT03693560|DRUG|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
214236395|NCT03693560|DRUG|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
214236396|NCT03693560|DRUG|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
214236397|NCT00667173|DRUG|IDP-115|Topical application for 12 weeks
214236398|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
214236399|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
214236400|NCT01607827|PROCEDURE|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
214236401|NCT01607827|PROCEDURE|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
214236402|NCT02650921|DEVICE|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
214236403|NCT04645121|DEVICE|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
214236404|NCT04645121|DEVICE|Bioimpedance|Measures total volume, intra and extracellular volume.
214236405|NCT04645121|RADIATION|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
214236406|NCT02032043|DRUG|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
214236407|NCT04577157|BEHAVIORAL|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
214236408|NCT04883723|DEVICE|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
214236409|NCT04883723|OTHER|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
214236410|NCT01812447|DEVICE|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
214236411|NCT01812447|OTHER|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
214236412|NCT04276727|DRUG|MINT study IMP|Application of gel for 6 weeks.
214236413|NCT02972385|PROCEDURE|Mouthwash sample|A one time mouthwash sample will be performed.
214236414|NCT02972385|PROCEDURE|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
214236415|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
214236416|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
214236417|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
214236418|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
214236419|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
214236420|NCT04597242|DRUG|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
214236421|NCT00952380|DRUG|dalteparin|dalteparin subcutaneous injection
214236422|NCT03400956|DRUG|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
214236423|NCT03400956|DRUG|Placebo|Orally, coated tablet, once daily
214236424|NCT01409343|DRUG|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
214236425|NCT03505398|PROCEDURE|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
214236426|NCT03505398|PROCEDURE|visual acuity|using ETDRS scales
214236427|NCT03505398|PROCEDURE|automated visual field|recording visual attention based on central or peripheral visual information
214236428|NCT03505398|PROCEDURE|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
214236429|NCT04605614|RADIATION|Copper Cu 64-DOTA-pembrolizumab|Given IV
214236430|NCT04605614|BIOLOGICAL|Pembrolizumab|Given IV
214236431|NCT04605614|PROCEDURE|Positron Emission Tomography|Undergo PET
214236432|NCT00001012|DRUG|AL 721|
214236433|NCT06071728|DIETARY_SUPPLEMENT|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
214236434|NCT02917018|DRUG|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
214236435|NCT04810780|DEVICE|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
214236436|NCT06055335|OTHER|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
214236437|NCT06055335|OTHER|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
214236438|NCT00160667|DRUG|Placebo|Daily oral dose of two equal intakes.
214236439|NCT00160667|DRUG|Brivaracetam|Daily oral dose of two equal intakes.
214236440|NCT02251964|DRUG|Rituximab|2 times 1000mg dose at 14 days interval treatment
214236441|NCT02251964|RADIATION|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
214236442|NCT04605367|DEVICE|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
214236443|NCT05337397|PROCEDURE|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
214236444|NCT00383474|DRUG|Bortezomib|Given IV
214236445|NCT00383474|OTHER|Laboratory Biomarker Analysis|Correlative studies
214236446|NCT00383474|DRUG|Tipifarnib|Given orally
214236447|NCT05139511|DEVICE|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
214236448|NCT05139511|OTHER|Control group|Same procedure but without energy
214236449|NCT00927940|DEVICE|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
214236450|NCT00270842|BEHAVIORAL|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
214236451|NCT00270842|BEHAVIORAL|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
214236452|NCT00270842|BEHAVIORAL|Education Control group|This control group participated in 10 weeks of general health education classes.
214236453|NCT05196711|DRUG|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
214236454|NCT05196711|DRUG|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
214236455|NCT03430076|PROCEDURE|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
214236456|NCT03430076|DEVICE|Propaten®|Propaten®
214236457|NCT03430076|DEVICE|Crude PTFE|Crude PTFE
214236458|NCT03581461|BEHAVIORAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
214236459|NCT01690676|DIETARY_SUPPLEMENT|Epicatechin|
214236460|NCT01690676|DIETARY_SUPPLEMENT|Microcrystalline cellulose|
214236461|NCT02181270|OTHER|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
214236462|NCT02181270|OTHER|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
214236463|NCT05507359|OTHER|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
214236464|NCT05507359|OTHER|Benzocaine gel|20% Benzocaine gel (Opahl gel)
214236465|NCT03044574|DEVICE|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
214652063|NCT06214260|DIAGNOSTIC_TEST|Peripheral blood sample|Peripheral blood will be collected with a 10 ml Ethylenediaminetetra acetic acid (EDTA) tube before surgery during menstrual phase. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
214652064|NCT06214260|DIAGNOSTIC_TEST|Menstrual Blood sample|5ml menstrual blood will be collected before surgery by the women herself. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
214236466|NCT03044574|DEVICE|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
214236467|NCT03044574|DRUG|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
214236468|NCT02805270|OTHER|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
214236469|NCT02557074|DRUG|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
214236470|NCT02557074|DRUG|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
214236471|NCT02834845|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
214236472|NCT02834845|DRUG|Desflurane|Desflurane %6-8 for general anesthesia maintenance
214236473|NCT00890045|DEVICE|HeRO Vascular Access Device|HeRO Vascular Access Device
214236474|NCT00890045|DEVICE|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
214236475|NCT01402427|DRUG|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
214236476|NCT01402427|DRUG|Placebo|Intraarterial administration of 10 mL saline.
214236477|NCT01136187|PROCEDURE|Access site in primary PCI|
214236478|NCT02073383|PROCEDURE|Axillary brachial plexus block|
214236479|NCT04355728|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
214236480|NCT04355728|OTHER|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
214236481|NCT00385164|PROCEDURE|PET/CT scan for RT planning|
214236482|NCT05024292|PROCEDURE|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
214236483|NCT00483756|DRUG|Cyclosporine|Standard of care
214236484|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
214236485|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
214236486|NCT00254579|DRUG|CP-675,206|15 mg/kg Q12W dosing regimen
214236487|NCT04825197|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
214236488|NCT06082973|DEVICE|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
214236489|NCT06082973|DEVICE|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
214236490|NCT05167552|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
214236491|NCT05167552|OTHER|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
214236492|NCT05167552|OTHER|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
214236493|NCT04109339|DRUG|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
214236494|NCT01599143|BEHAVIORAL|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
214236495|NCT01501084|DRUG|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
214236496|NCT01501084|DRUG|Normal saline .2cc subcutaneous injection|sterile saline injection
214236497|NCT02150408|OTHER|PET-CT|
214236498|NCT03413176|DRUG|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
214236499|NCT00146783|DRUG|Sulphadoxine-pyrimethamine|
214236500|NCT00146783|DRUG|Sulphadoxine-pyrimethamine, amodiaquine|
214652065|NCT04095767|DEVICE|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters \[DACs\]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
214652066|NCT02108925|DRUG|Oxygen|supplementary oxygen during exercise
214652067|NCT00004160|DRUG|cisplatin|
214652068|NCT00004160|DRUG|gemcitabine hydrochloride|
214236501|NCT04759183|OTHER|Survey Administration|Ancillary studies
214236502|NCT04759183|PROCEDURE|Virtual Reality Game|"Participate in VR Game Angry Birds"
214236503|NCT04759183|PROCEDURE|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
214652069|NCT00004160|DRUG|paclitaxel|
214652070|NCT00004160|RADIATION|radiation therapy|
214652071|NCT03283085|DRUG|25 mg Ontamalimab|Ontamalimab SC solution for injection
214652072|NCT03283085|DRUG|75 mg Ontamalimab|Ontamalimab SC solution for injection
214236504|NCT00906971|OTHER|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
214236505|NCT04757454|DIAGNOSTIC_TEST|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
214236506|NCT02339220|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
214236507|NCT02339220|BEHAVIORAL|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
214236508|NCT02339220|BEHAVIORAL|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
214236509|NCT02339220|BEHAVIORAL|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
214652073|NCT03136107|OTHER|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
214652074|NCT03136107|OTHER|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
214236510|NCT04054947|BEHAVIORAL|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
214236511|NCT05154370|DRUG|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
214236512|NCT06095622|DIETARY_SUPPLEMENT|Fenugreek Seeds and Indian Rennet|Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.
214236513|NCT02456480|DRUG|CLS001|topical gel
214236514|NCT02456480|DRUG|Vehicle|topical gel
214236515|NCT05958173|DIETARY_SUPPLEMENT|Capsaicin|Oral stimulation with natural TRPV1 agonist
214236516|NCT05958173|DIETARY_SUPPLEMENT|Piperine|Oral stimulation with natural TRPA1/V1 agonist
214236517|NCT05958173|DIETARY_SUPPLEMENT|Placebo|Oral stimulation with placebo solution
214652075|NCT03291561|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
214652076|NCT03291561|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
214652077|NCT04201080|DRUG|Part A: TRV250-20mg/ml|TRV250 SC Injections
214652078|NCT04201080|DRUG|Placebo|Placebo SC injections
214652079|NCT04201080|DRUG|Part B: TRV250 Dose 1|Dose 1of3 TRV250
214652080|NCT04201080|DRUG|Part B: TRV250 Dose 2|Dose 2of3 TRV250 SC injections
214652081|NCT04201080|DRUG|Part B: TRV250 Dose 3|Dose 3of3 TRV250 SC injections
214652082|NCT04201080|DRUG|Placebo|Placebo SC injections
214652083|NCT02038348|DEVICE|PET with 18F-FDOPA|
214652084|NCT00403221|GENETIC|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp~One dose only followed by a radical prostatectomy 4 weeks later."
214236518|NCT03582228|BEHAVIORAL|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
214236519|NCT01606878|DRUG|Crizotinib|Given PO
214652085|NCT01891071|PROCEDURE|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
214652086|NCT02676830|DRUG|K-312 100 mg|Single oral dose
214236520|NCT01606878|DRUG|Cyclophosphamide|Given IV
214236521|NCT01606878|DRUG|Dexrazoxane Hydrochloride|Given IV
214236522|NCT01606878|DRUG|Doxorubicin Hydrochloride|Given IV
214236523|NCT01606878|OTHER|Laboratory Biomarker Analysis|Correlative studies
214236524|NCT01606878|OTHER|Pharmacological Study|Correlative studies
214236525|NCT01606878|OTHER|Questionnaire Administration|Ancillary studies
214236526|NCT01606878|DRUG|Topotecan Hydrochloride|Given IV
214236527|NCT01606878|DRUG|Vincristine Sulfate|Given IV
214236528|NCT06208930|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
214236529|NCT00733447|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
214236530|NCT04183517|DRUG|PXS-5382A|Orally once daily or twice daily
214236531|NCT05862662|OTHER|MOVE Program|Mobility Opportunities Via Education functional therapy program.
214236532|NCT02449343|DRUG|Anlotinib|Anlotinib p.o. qd
214236533|NCT02449343|DRUG|Placebo|Placebo p.o. qd
214236534|NCT05331404|RADIATION|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
214236535|NCT05331404|OTHER|Quality of life assessment|"quality of life assessment by :~* Speech, Spatial and Qualities of Hearing~* Hearing Handicap Inventory For The Elderly Screening~* Short Form Health Survey"
214236536|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
214236537|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
214236538|NCT04672382|DRUG|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
214236539|NCT05771883|DRUG|IMM0306|IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.
214236540|NCT05771883|DRUG|Lenalidomide capsule|Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
214236541|NCT01887093|BEHAVIORAL|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
214236542|NCT04806867|OTHER|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
214236543|NCT02879487|DEVICE|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
214236544|NCT03217253|OTHER|Laboratory Biomarker Analysis|Correlative studies
214236545|NCT03217253|OTHER|Pharmacological Study|Correlative studies
214236546|NCT03217253|DRUG|Tazemetostat|Given PO
214236547|NCT00773045|OTHER|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
214236548|NCT01765010|DRUG|Calcitriol|
214236549|NCT01765010|DRUG|Alfacalcidol|
214236550|NCT01765010|DRUG|Cholecalciferol|
214236551|NCT01765010|DRUG|Placebo|
214236552|NCT06505772|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
214236553|NCT06505772|DRUG|Normal saline|"Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study."
214236554|NCT05437302|DEVICE|prism spectacle|a prism is dispensed in prescription glasses
214652087|NCT02676830|DRUG|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
214652088|NCT01178645|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
214652089|NCT02091609|OTHER|dental interproximal brush|use of this to maintain oral hygiene
214652090|NCT02091609|OTHER|dental floss|use of this to maintain oral hygiene
214236555|NCT03570463|BEHAVIORAL|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
214236556|NCT02669485|DRUG|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
214236557|NCT02669485|DEVICE|Fluorescence imaging|
214236558|NCT00512057|DRUG|allopurinol|allopurinol 300mg twice a day
214236559|NCT00512057|DRUG|placebo|placebo
214236560|NCT00000485|DRUG|diuretics|
214236561|NCT00000485|DRUG|antihypertensive agents|
214236562|NCT03050411|DRUG|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
214236563|NCT03050411|DRUG|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
214236564|NCT03473548|DEVICE|Portable sleep monitor|Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
214236565|NCT03473548|OTHER|In-laboratory Polysomnography|Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
214236566|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
214236567|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
214236568|NCT02101164|BIOLOGICAL|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
214236569|NCT02101164|DRUG|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
214236570|NCT04564300|PROCEDURE|Training|Both groups will perform a standardized training protocol
214236571|NCT05146102|OTHER|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
214236572|NCT03086187|DEVICE|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
214236573|NCT05070780|DEVICE|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
214236574|NCT05631002|DIAGNOSTIC_TEST|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
214236575|NCT04930380|OTHER|phone interview|Cases and controls will receive a phone interview
214236576|NCT01496937|DRUG|GLPG0974|
214236577|NCT01496937|DRUG|GLPG0974|
214236578|NCT00129311|DRUG|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
214236579|NCT00129311|DRUG|Placebo|
214236580|NCT05205473|PROCEDURE|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
214236581|NCT05205473|PROCEDURE|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
214652091|NCT00565331|DRUG|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
214652092|NCT00565331|DRUG|Placebo|saline solution
214236582|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
214652093|NCT00477789|DRUG|allopurinol|
214652094|NCT02808104|DRUG|mazindol|
214652095|NCT00544921|DRUG|GLY-230|
214652096|NCT00544921|OTHER|Placebo|No drug administered
214236583|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
214236584|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
214236585|NCT06009185|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
214236586|NCT01659879|BEHAVIORAL|Multimedia information|
214236587|NCT01659879|BEHAVIORAL|verbal information|
214236588|NCT00455832|PROCEDURE|peginterferon alpha and ribavirin|sperm collection
214236589|NCT03250364|DEVICE|Multilayer bandage|See arm/group descriptions
214236590|NCT03250364|DEVICE|Double compression bandage|See arm/group descriptions
214236591|NCT03250364|DEVICE|Cohesive bandage|See arm/group descriptions
214236592|NCT03250364|DEVICE|Adhesive compression bandage|See arm/group descriptions
214236593|NCT03250364|DEVICE|Kinesiotaping bandage|See arm/group descriptions
214236594|NCT03250364|OTHER|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
214236595|NCT03250364|OTHER|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
214236596|NCT03250364|BEHAVIORAL|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
214236597|NCT05606003|BEHAVIORAL|Multi-Level Multi-Component Intervention (MLI)|The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
214236598|NCT05606003|BEHAVIORAL|Community Just-In-Time Adaptive Intervention (Community JITAI)|This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
214236599|NCT05288907|DRUG|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
214236600|NCT00306111|DRUG|pegfilgrastim|Single dose (6mg) one day after chemotherapy
214236601|NCT01804829|BIOLOGICAL|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
214236602|NCT05207800|OTHER|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
214236603|NCT00158132|DRUG|Propranolol|Propranolol 100mg/day in 3 divided doses
214236604|NCT00158132|DRUG|Amantadine|Amantadine 100mg three times daily
214236605|NCT00158132|DRUG|Placebo|Placebo pills
214236606|NCT02405338|BIOLOGICAL|WT1/PRAME vaccination|
214236607|NCT01543581|DRUG|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
214236608|NCT01543581|DRUG|Placebo|
214236609|NCT02212600|OTHER|Observational|observational cohort of proximal humerus fractures
214236610|NCT01723644|OTHER|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
214236611|NCT01723644|OTHER|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
214236612|NCT04203277|OTHER|IVY|a combination of practice education and quality improvement interventions
214236613|NCT02191215|DRUG|Nevirapine (Viramune®)|
214236614|NCT01467687|DRUG|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
214236615|NCT04985344|DRUG|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
214236616|NCT04985344|DRUG|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
214236617|NCT04985344|OTHER|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
214236618|NCT00074698|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
214236619|NCT03310307|DRUG|Vit D|50,000 IU
214236620|NCT03310307|OTHER|Placebo|
214236621|NCT04592484|BIOLOGICAL|CDK-002|CDK-002 administered intratumorally
214236622|NCT04803123|DRUG|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
214236623|NCT02104388|DRUG|SJP-0035 Ophthalmic Solution|
214236624|NCT02104388|DRUG|Vehicle of SJP-0035 Ophthalmic Solution|
214236625|NCT04357301|DEVICE|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
214236626|NCT00564538|DRUG|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
214236627|NCT00564538|DRUG|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
214236628|NCT03870958|PROCEDURE|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
214236629|NCT03870958|PROCEDURE|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
214236630|NCT06105671|DRUG|Symbicort|Participants are administered 54 μg Formoterol and 1920 μg Budesonide
214236631|NCT06105671|DRUG|Formoterol|Participants are administered 54 μg Formoterol from an inhaler device
214236632|NCT06105671|DRUG|Formoterol|Participants are administered 120 μg Formoterol in a capsule, which is taken orally
214236633|NCT06105671|DRUG|Placebo|Participants are administered placebo
214236634|NCT06105671|DRUG|Mannitol|Participants are administered 600 mg Bronchitol
214236635|NCT05287360|DRUG|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
214236636|NCT00721253|DEVICE|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
214236637|NCT00721253|DEVICE|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
214236638|NCT00721253|DEVICE|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
214236639|NCT03570164|DRUG|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
214236640|NCT03570164|DRUG|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
214236641|NCT05329571|BEHAVIORAL|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
214236642|NCT05329571|BEHAVIORAL|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
214236643|NCT05329571|BEHAVIORAL|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
214236644|NCT00627276|DIETARY_SUPPLEMENT|omega-3 fatty acid|Oral, 3 times daily
214236645|NCT00627276|OTHER|placebo|Oral, 3 times daily
214236646|NCT01301898|DRUG|GC1111_0.5mg/kg|
214236647|NCT01301898|DRUG|GC1111_1.0mg/kg|
214236648|NCT01301898|DRUG|Elaprase_0.5mg/kg|
214236649|NCT01362010|DRUG|Topical Minocycline Foam FXFM244|Topically applied once a day.
214236650|NCT01265264|DRUG|ulodesine|Oral dose administered daily for 84 days.
214236651|NCT01265264|DRUG|Placebo|Oral dose administered daily for 84 days.
214236652|NCT06831084|DEVICE|Silver plated technology (SPT) dressing|Silver-plated technology (SPT) dressing technology is a wound dressing that has a permanently plated metallic surface, which provides the antimicrobial benefits of silver in the dressing without staining the skin and without increasing bioburden, reducing the development of acute radiation dermatitis (ARD).
214236653|NCT04663919|PROCEDURE|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
214236654|NCT04663919|BEHAVIORAL|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
214236655|NCT00664508|PROCEDURE|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
214236656|NCT01340872|DRUG|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
214236657|NCT01340872|DRUG|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
214236658|NCT05463094|DRUG|Test Glucophage® XR|Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
214236659|NCT05463094|DRUG|Reference Glucophage® XR|Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
214236660|NCT03310060|DRUG|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
214236661|NCT03310060|DRUG|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
214236662|NCT04600817|DRUG|TJ107|QW8
214236663|NCT04600817|DRUG|TJ107 placebo|QW8
214236664|NCT03988881|PROCEDURE|Revascularization|PCI or CABG
214236665|NCT03700541|DRUG|Morphine|Morphine intravenous
214236666|NCT03700541|DRUG|Piritramid|Piritramid intravenous
214236667|NCT01732094|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
214236668|NCT01732094|DRUG|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
214236669|NCT01732094|DRUG|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
214236670|NCT02868814|DRUG|Pregabalin Release Tablets|
214236671|NCT02868814|DRUG|Pregabalin Release Tablets|
214236672|NCT02868814|DRUG|Placebo|
214236673|NCT03056599|DRUG|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
214236674|NCT03056599|DEVICE|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
214236675|NCT03603509|DRUG|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
214236676|NCT03603509|DRUG|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
214236677|NCT06516835|OTHER|Enteral fluid|GNAK will be administered to the gastrointestinal tract with EN in the same volume.
214236678|NCT06516835|OTHER|Intravenous fluid|Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
214236679|NCT01407653|PROCEDURE|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
214236680|NCT01407653|PROCEDURE|Usual care|Classical care
214236681|NCT02574572|BIOLOGICAL|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
214236682|NCT00639652|PROCEDURE|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
214236683|NCT00639652|PROCEDURE|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
214236684|NCT02248558|BEHAVIORAL|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
214236685|NCT02248558|BEHAVIORAL|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
214236686|NCT01258998|DRUG|Akt inhibitor MK2206|Given PO
214236687|NCT01258998|OTHER|laboratory biomarker analysis|Correlative studies
214236688|NCT02968862|OTHER|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
214236689|NCT01215929|DRUG|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
214236690|NCT01215929|DRUG|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
214236691|NCT01143389|DRUG|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
214236692|NCT01143389|DEVICE|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
214236693|NCT03970356|OTHER|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
214236694|NCT00093444|DRUG|lyso-thermosensitive liposomal doxorubicin|
214236695|NCT00093444|PROCEDURE|radiofrequency ablation|
214236696|NCT01238627|DRUG|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
214236697|NCT01238627|DRUG|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
214236698|NCT05832554|DEVICE|nasal airway|nasopharyngeal airway
214236699|NCT05832554|DEVICE|oral airway|oropharyngeal airway
214236700|NCT01362868|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
214236701|NCT01165762|DRUG|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
214236702|NCT04966910|BEHAVIORAL|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
214236703|NCT04966910|BEHAVIORAL|Treatment as usual|Regular check-ins, resource/referral provision
214236704|NCT02384057|OTHER|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
214236705|NCT02384057|OTHER|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
214236706|NCT02876250|DRUG|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
214236707|NCT02876250|DRUG|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
214236708|NCT02930980|DEVICE|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
214236709|NCT03387384|OTHER|Non-interventional study|Non-interventional study
214236710|NCT04637009|DRUG|TAS1553|Form: tablet; Route of Administration: oral
214236711|NCT04810728|DRUG|Extract Psidii guava|2 Capsule Extract Psidii guava, three times daily
214236712|NCT04810728|COMBINATION_PRODUCT|Standard therapy for Covid-19 patient|(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
214236713|NCT04892056|OTHER|Friction Mechanics|anterior segment retraction using elastomeric power chains
214236714|NCT04892056|OTHER|Frictionless Mechanics|anterior segment retraction using closing loops
214236715|NCT02038374|PROCEDURE|biopsies|
214236716|NCT02562469|OTHER|ACTIVATE|A home-based computerized brain training intervention for youth.
214236717|NCT03470532|DRUG|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
214236718|NCT03470532|DRUG|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
214236719|NCT00204945|DRUG|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
214236720|NCT01162798|OTHER|infant formula|test infant formula fed to infants until 6 months corrected gestational age
214236721|NCT01162798|OTHER|control infant formula|commercially available infant formula
214236722|NCT02276027|DRUG|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
214236723|NCT02276027|DRUG|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
214236724|NCT02276027|DRUG|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
214236725|NCT02276027|DRUG|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
214236726|NCT00316550|DRUG|AV608|
214236727|NCT04300959|DRUG|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
214236728|NCT04300959|DRUG|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
214236729|NCT04450810|OTHER|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
214236730|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|150,000 IU orally given once
214236731|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU given orally daily for 28 days
214236732|NCT03475953|DRUG|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
214236733|NCT03475953|DRUG|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
214236734|NCT03475953|DRUG|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
214236735|NCT03475953|DRUG|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
214236736|NCT03475953|DRUG|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
214236737|NCT03923803|DIAGNOSTIC_TEST|C- reactive protein|the measurement will be done by chemileumeniscence
214236738|NCT03923803|DIAGNOSTIC_TEST|Pro calcitonin|the measurement will be done by chemileumeniscence
214236739|NCT03272789|OTHER|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
214236740|NCT01577810|DEVICE|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
214236741|NCT03224598|DRUG|A-101 Topical Solution 40%|A-101 Topical Solution 40%
214236742|NCT03233269|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
214236743|NCT01266720|BIOLOGICAL|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
214236744|NCT01266720|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
214236745|NCT02259075|DRUG|Botulinum Toxin Type A|
214236746|NCT02361476|DRUG|Clonidine|Injection - during surgery
214236747|NCT02361476|DRUG|Placebo|Injection - during surgery
214236748|NCT02183103|DRUG|meloxicam rapid release tablet, 12mg, UH AC62MU|
214236749|NCT05252260|PROCEDURE|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
214236750|NCT05252260|PROCEDURE|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
214236751|NCT05252260|OTHER|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
214236752|NCT04281238|OTHER|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
214236753|NCT04281238|OTHER|Control group|Home exercises 5 days a week for 8 weeks
214236754|NCT04617873|PROCEDURE|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
214236755|NCT03402048|DRUG|Carboplatin|
214236756|NCT03402048|DRUG|Gemcitabine|
214652097|NCT05070338|BEHAVIORAL|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]"
214236757|NCT03402048|DRUG|Pemetrexed|
214236758|NCT03402048|DRUG|Docetaxel|
214236759|NCT03402048|DRUG|Vinorelbine|
214236760|NCT00335231|DRUG|gatifloxacin ophthalmic (ZYMAR)|
214236761|NCT00005031|DRUG|irofulven|
214236762|NCT06171308|DEVICE|Traditional Chinese moxibustion apparatus|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
214236763|NCT04562753|PROCEDURE|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
214236764|NCT04562753|PROCEDURE|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
214236765|NCT02767544|PROCEDURE|Vaginal wound local analgesia after laparoscopic hysterectomy|
214236766|NCT00953459|DRUG|sunitinib malate|
214236767|NCT00953459|OTHER|laboratory biomarker analysis|
214236768|NCT00953459|RADIATION|fludeoxyglucose F 18|
214236769|NCT01000038|OTHER|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
214236770|NCT01000038|OTHER|Walking|Half hour daily, five days a week for 8 weeks
214236771|NCT01653379|DRUG|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
214236772|NCT04652596|OTHER|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
214236773|NCT04652596|OTHER|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
214236774|NCT00007007|PROCEDURE|management of therapy complications|
214236775|NCT00007007|PROCEDURE|quality-of-life assessment|
214236776|NCT03733431|DEVICE|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
214236777|NCT03733431|DEVICE|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
214236778|NCT04254042|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
214236779|NCT04254042|DRUG|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
214236780|NCT00729222|DRUG|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
214236781|NCT00729222|DRUG|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
214236782|NCT03355443|PROCEDURE|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
214236783|NCT03355443|PROCEDURE|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
214236784|NCT04002570|OTHER|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
214236785|NCT00562900|PROCEDURE|robotic assisted cholecystectomy|robotic assisted cholecystectomy
214236786|NCT00562900|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214236787|NCT06200142|DIAGNOSTIC_TEST|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
214236788|NCT06200142|GENETIC|WES and WGS|WES reanalysis and WGS analysis
214236789|NCT04689412|DRUG|Resveratrol|Nasal administration of resveratrol
214236790|NCT04048785|OTHER|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
214236791|NCT00103727|DRUG|Talnetant|talnetant
214236792|NCT00103727|OTHER|placebo|Placebo Comparator
214236793|NCT00103727|OTHER|risperidone|Active Comparator
214236794|NCT06246942|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).
214236795|NCT06246942|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).
214236796|NCT06246942|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
214236797|NCT00830791|DRUG|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
214236798|NCT00830791|DRUG|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
214236799|NCT03206996|BEHAVIORAL|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
214236800|NCT03206996|BEHAVIORAL|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
214236801|NCT03206996|BEHAVIORAL|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
214236802|NCT01527357|BIOLOGICAL|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
214236803|NCT01527357|BIOLOGICAL|Gelatin sponge|Absorbable gelatin sponge for topical administration.
214236804|NCT04958512|DRUG|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
214236805|NCT04958512|DRUG|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
214236806|NCT04958512|OTHER|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
214236807|NCT04139746|PROCEDURE|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
214236808|NCT04139746|PROCEDURE|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
214236809|NCT02630199|DRUG|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
214236810|NCT02630199|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
214236811|NCT04897139|DRUG|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
214236812|NCT05098275|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
214236813|NCT05098275|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
214236814|NCT06129357|BEHAVIORAL|180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).|Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
214236815|NCT02850081|DRUG|Statin|"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"
214236816|NCT02850081|DRUG|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
214236817|NCT02850081|OTHER|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
214236818|NCT03679442|DRUG|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
214236819|NCT06408155|OTHER|Isometric Task|The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
214236820|NCT02427178|BIOLOGICAL|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
214236821|NCT06061614|GENETIC|NGGT002|NGGT002
214236822|NCT02446171|DRUG|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
214236823|NCT02446171|DRUG|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
214236824|NCT02446171|DRUG|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
214236825|NCT02446171|DRUG|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
214236826|NCT03363022|DRUG|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
214236827|NCT03363022|OTHER|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
214236828|NCT03363022|OTHER|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
214236829|NCT03021174|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
214236830|NCT03021174|BEHAVIORAL|Nutrition Education Control|12 weeks of implementing eating tips
214236831|NCT05934188|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
214236832|NCT05934188|BEHAVIORAL|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
214236833|NCT05934188|BEHAVIORAL|Eating habits|Information on eating habits will be derived from food questionnaires.
214236834|NCT05934188|DIAGNOSTIC_TEST|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
214236835|NCT05934188|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
214236836|NCT05934188|DIAGNOSTIC_TEST|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
214236837|NCT02875574|DRUG|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
214652098|NCT05070338|BEHAVIORAL|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
214236838|NCT02875574|OTHER|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
214236839|NCT04779749|OTHER|Data extraction from medical files|Data extraction from medical files
214236840|NCT03409042|BEHAVIORAL|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
214236841|NCT05011448|OTHER|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
214236842|NCT05642962|DRUG|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
214236843|NCT03175848|RADIATION|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
214236844|NCT04531462|DRUG|Empagliflozin|Empagliflozin
214236845|NCT04531462|DRUG|Placebo|Placebo
214236846|NCT00504582|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
214236847|NCT04197687|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
214236848|NCT04197687|BIOLOGICAL|Pertuzumab|permitted at physician's discretion
214236849|NCT04197687|OTHER|Placebo Administration|Given ID
214236850|NCT04197687|BIOLOGICAL|Sargramostim|Given ID
214236851|NCT04197687|BIOLOGICAL|Trastuzumab|therapy are at the discretion of the treating physicians
214236852|NCT04197687|BIOLOGICAL|Trastuzumab Emtansine|at the discretion of the treating physicians.
214236853|NCT00005001|BIOLOGICAL|HIV-1 Immunogen|
214236854|NCT04666077|BEHAVIORAL|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
214236855|NCT04666077|BEHAVIORAL|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
214236856|NCT04666077|OTHER|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
214236857|NCT04175509|DRUG|Rectal acetaminophen|Rectal 1300mg
214236858|NCT04175509|DRUG|Intravenous acetaminophen|Intravenous 1000mg
214236859|NCT02292784|DRUG|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
214236860|NCT02292784|DRUG|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
214236861|NCT02292784|DRUG|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
214236862|NCT00348933|DRUG|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
214236863|NCT00348933|DRUG|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
214236864|NCT00348933|DRUG|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
214236865|NCT00348933|DRUG|Vitamin B12|1 mg by mouth per day for all weights and ages
214236866|NCT01264081|DRUG|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
214236867|NCT01489111|DRUG|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
214652099|NCT04440462|OTHER|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
214652100|NCT04440462|OTHER|Sterile water|2 ml of sterile water
214236868|NCT04988633|BEHAVIORAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
214236869|NCT04988633|BEHAVIORAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
214236870|NCT05972603|PROCEDURE|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
214236871|NCT05972603|PROCEDURE|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
214236872|NCT00134784|DRUG|[123I]B-CIT SPECT imaging|To assess \[123I\]B-CIT SPECT imaging
214236873|NCT02065271|DIETARY_SUPPLEMENT|herbal supplement|
214236874|NCT02065271|OTHER|placebo supplement|
214236875|NCT01889095|DRUG|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
214236876|NCT01889095|DRUG|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
214236877|NCT02732197|DRUG|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
214236878|NCT02732197|DRUG|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
214236879|NCT01133327|DEVICE|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
214236880|NCT03223636|DEVICE|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
214236881|NCT03223636|DEVICE|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
214236882|NCT04914039|COMBINATION_PRODUCT|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
214236883|NCT04914039|OTHER|NO CTA examination|NO CTA examination
214236884|NCT05363943|PROCEDURE|double plating|open reduction and internal fixation by using lateral and medial plates.
214236885|NCT05363943|PROCEDURE|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
214236886|NCT04444427|DRUG|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
214236887|NCT01546402|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
214236888|NCT01546402|PROCEDURE|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
214236889|NCT05166239|PROCEDURE|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
214236890|NCT05166239|DRUG|Lenvatinib 1|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
214236891|NCT05166239|DRUG|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
214236892|NCT05166239|DRUG|Lenvatinib 2|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
214236893|NCT05166239|DRUG|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
214236894|NCT00919841|OTHER|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
214236895|NCT04767308|BIOLOGICAL|CT125A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.
214236896|NCT04767308|DRUG|Cyclophosphamide, fludarabine|Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
214236897|NCT04698850|DRUG|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
214236898|NCT04698850|DRUG|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
214236899|NCT04698850|DRUG|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
214652101|NCT02232256|DRUG|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
214236900|NCT00621400|DRUG|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
214236901|NCT00621400|DRUG|Melphalan|0,18mg/Kg/day from day 1- 4
214236902|NCT00621400|DRUG|Dexamethasone|40mg/day from day 1- 4.
214236903|NCT05143190|DRUG|PTR-01|Intravenous recombinant collagen 7
214236904|NCT01991639|OTHER|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
214236905|NCT00333203|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
214236906|NCT00333203|OTHER|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
214236907|NCT04084678|DRUG|Ralinepag|Oral ralinepag
214236908|NCT04084678|DRUG|Placebo|Matching oral tablets
214236909|NCT02641483|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
214236910|NCT05089201|BEHAVIORAL|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
214236911|NCT05089201|BEHAVIORAL|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
214236912|NCT04322201|DEVICE|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
214236913|NCT04322201|PROCEDURE|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
214236914|NCT03705624|OTHER|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
214236915|NCT03705624|OTHER|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
214236916|NCT00332371|DEVICE|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
214236917|NCT02316873|BEHAVIORAL|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
214236918|NCT02316873|BEHAVIORAL|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
214236919|NCT00730028|DRUG|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
214236920|NCT00730028|OTHER|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
214236921|NCT00730028|DRUG|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
214236922|NCT05238571|PROCEDURE|Re-surgery|Re-surgery with meshectomy and selective neurectomy
214236923|NCT03117088|OTHER|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
214236924|NCT03117088|OTHER|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
214236925|NCT04653532|BEHAVIORAL|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
214236926|NCT04653532|DEVICE|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
214236927|NCT05101551|DRUG|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
214236928|NCT05101551|DRUG|Topotecan|"Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
214652102|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
214652103|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
214652104|NCT05873712|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214652105|NCT05873712|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
214236929|NCT05101551|DRUG|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
214236930|NCT01669330|PROCEDURE|Nissen fundoplication|Laparoscopic Nissen fundoplication
214236931|NCT01669330|PROCEDURE|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
214236932|NCT04941625|DIAGNOSTIC_TEST|serum cystatin C|blood sampling
214236933|NCT04941625|DIAGNOSTIC_TEST|serum beta-microglubulin|blood sampling
214236934|NCT04941625|DIAGNOSTIC_TEST|urine|neutrophil gelatinase-associated lipocalin
214236935|NCT04892368|OTHER|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
214236936|NCT05639244|BEHAVIORAL|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
214236937|NCT05639244|BEHAVIORAL|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
214236938|NCT05407740|OTHER|no intervention study|no intervention study
214236939|NCT03811093|DEVICE|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
214236940|NCT03811093|DEVICE|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
214236941|NCT00476567|OTHER|standard|standard antenatal care
214236942|NCT00476567|BEHAVIORAL|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
214236943|NCT00464490|DRUG|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
214236944|NCT00164697|BEHAVIORAL|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
214236945|NCT06406153|BIOLOGICAL|Laronidase|Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
214236946|NCT06406153|DRUG|Antihistamine|An antihistamine is administered one hour before the infusion.
214236947|NCT06406153|DRUG|Antipyretic|An antipyretic is administered one hour before the infusion.
214236948|NCT05344755|OTHER|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
214236949|NCT05344755|OTHER|Control Group|Routine physiotherapy management of the Hallux valgus
214236950|NCT06339476|DIAGNOSTIC_TEST|Serum ADMA, MDA and M30 levels mesurment|Blood samples collected from patienst, only 7 mL
214236951|NCT06078150|BEHAVIORAL|Active video games intervention（1-6weeks）|"Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game."
214236952|NCT06078150|BEHAVIORAL|Active video games intervention（7-12weeks）|"Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time."
214236953|NCT03188042|DEVICE|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
214236954|NCT03188042|DEVICE|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
214236955|NCT00925938|DRUG|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
214236956|NCT00925938|DRUG|placebo|placebo
214236957|NCT00521300|DRUG|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
214236958|NCT00521300|PROCEDURE|Direct surgery for acromegaly|Direct transsphenoidal surgery
214236959|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
214236960|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
214236961|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean starch|Starch treatment
214236962|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean flour|Flour treatment
214236963|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with no faba bean fraction|Control treatment
214236964|NCT05228847|DIETARY_SUPPLEMENT|Human milk-derived HMF|Fortification with human milk-derived product
214236965|NCT05228847|DIETARY_SUPPLEMENT|bovine milk-derived HMF|bovine milk-derived HMF
214236966|NCT03068832|BIOLOGICAL|Personalized peptide vaccine|-It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
214236967|NCT03068832|DRUG|Poly ICLC|-Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
214236968|NCT03068832|PROCEDURE|Peripheral blood draw|"* After trial enrollment and up to 7 days after the 1st vaccine dose~* 2 weeks after last dose~* Time of progression or discontinuation"
214236969|NCT00427180|DEVICE|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
214236970|NCT06506695|DEVICE|Craniofacial implant placement|"* Resection of oncologic process or remnants after trauma if necessary~* Placement of craniofacial implants in the nasal floor and/or the temporal bone.~* Placement of split thickness skin graft around the implants~* Placement of nose and/or ear prosthesis within 3 weeks"
214236971|NCT05761535|RADIATION|Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses|"Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."
214236972|NCT00488709|DRUG|Topotecan|
214236973|NCT00488709|DRUG|Fludarabine|
214236974|NCT00488709|DRUG|Cytarabine|
214236975|NCT00948584|OTHER|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
214236976|NCT05707741|DRUG|dexmetomedine infusion|50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
214236977|NCT05707741|DRUG|Dexmetomedine infusion|50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
214236978|NCT03603067|PROCEDURE|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
214236979|NCT05814354|DRUG|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
214652106|NCT05873712|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214652107|NCT05873712|DRUG|Cyclophosphamide|Given IV
214652108|NCT05873712|DRUG|Fludarabine|Given IV
214236980|NCT05814354|DRUG|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
214236981|NCT03565367|OTHER|Gadolinium|gadolinium enhanced MRI
214236982|NCT03565367|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214236983|NCT03565367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214236984|NCT03565367|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214236985|NCT02410915|DEVICE|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
214236986|NCT02410915|OTHER|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
214236987|NCT04991818|OTHER|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
214236988|NCT02489929|OTHER|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
214236989|NCT02489929|DRUG|azacytidine|
214236990|NCT01003314|BIOLOGICAL|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later
214236991|NCT01003314|BIOLOGICAL|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
214652109|NCT05873712|PROCEDURE|Leukapheresis|Given IV
214652110|NCT05873712|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214652111|NCT05873712|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
214652112|NCT05873712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214652113|NCT05873712|DRUG|Zanubrutinib|Given PO
214652114|NCT00863577|DRUG|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
214652115|NCT01631305|DRUG|Levothyroxine|3 mcg/kg/day
214652116|NCT01631305|OTHER|Calcium magnesia|Placebo.
214652117|NCT00715975|DRUG|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
214652118|NCT00715975|DRUG|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
214652119|NCT00003788|DRUG|carmustine|
214652120|NCT00003788|DRUG|lomustine|
214236992|NCT03466515|PROCEDURE|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
214236993|NCT01955798|PROCEDURE|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
214236994|NCT01955798|PROCEDURE|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
214236995|NCT01955798|DEVICE|Trocar|
214236996|NCT01955798|DEVICE|Veress needle|
214236997|NCT06370078|DRUG|Albumin Human|To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
214236998|NCT05284032|DRUG|isatuximab 10 mg/kg|Given by intravenous infusion
214236999|NCT04507880|DEVICE|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
214237000|NCT04507880|DEVICE|Hemiarthroplasty|The shoulder hemiarthroplasty
214237001|NCT00045474|PROCEDURE|adjuvant therapy|
214237002|NCT00045474|RADIATION|iodine I 125|
214237003|NCT06149468|OTHER|inclusion in the register|socio-demographic data collection and proposed therapy
214237004|NCT03087799|BEHAVIORAL|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
214237005|NCT01760642|DRUG|Midazolam|Midazolam 3 mg IV
214237006|NCT01760642|DRUG|Ketoconazole|ketoconazole 400 mg PO
214237007|NCT01760642|DRUG|Rifampicin|Rifampicin 600 mg PO
214237008|NCT05795049|OTHER|Stool and saliva sample collection|Stool and saliva samples collection
214237009|NCT05795049|OTHER|Questionnaire completion|"Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®"
214237010|NCT00527891|PROCEDURE|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
214237011|NCT03706924|DRUG|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
214237012|NCT03706924|DRUG|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
214237013|NCT03706924|DRUG|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
214237014|NCT05905744|DIAGNOSTIC_TEST|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
214237015|NCT03841084|DRUG|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
214237016|NCT03396952|DRUG|Aspirin|Given PO
214237017|NCT03396952|BIOLOGICAL|Ipilimumab|Given IV
214237018|NCT03396952|OTHER|Laboratory Biomarker Analysis|Correlative studies
214237019|NCT03396952|BIOLOGICAL|Pembrolizumab|Given IV
214237020|NCT00566202|DRUG|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
214237021|NCT00566202|DRUG|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
214237022|NCT00566202|DRUG|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
214237023|NCT03906916|DIAGNOSTIC_TEST|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
214237024|NCT03906916|DRUG|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
214237025|NCT01598142|PROCEDURE|Team 1|experienced endoscopist with a experienced assistant
214237026|NCT01598142|PROCEDURE|Team 2|same experienced endoscopist with a new trained assistant
214237027|NCT04036123|OTHER|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
214237028|NCT02061527|PROCEDURE|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
214237029|NCT02061527|PROCEDURE|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
214237030|NCT02061527|PROCEDURE|Reconstruction with implant|Immediate breast reconstruction with implant
214237031|NCT02061527|PROCEDURE|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
214237032|NCT02061527|PROCEDURE|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
214652121|NCT00003788|DRUG|porfimer sodium|
214652122|NCT00003788|DRUG|procarbazine hydrochloride|
214652123|NCT00003788|PROCEDURE|neoadjuvant therapy|
214237033|NCT00400803|DRUG|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
214237034|NCT01948856|DRUG|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
214237035|NCT01948856|DRUG|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
214237036|NCT01227824|DRUG|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
214237037|NCT01227824|DRUG|raltegravir|raltegravir 400mg taken twice daily
214237038|NCT01227824|OTHER|GSK1349572 Placebo|GSK1349572 placebo taken once daily
214237039|NCT01227824|OTHER|ABC/3TC|Abacavir/Lamivudine background therapy once daily
214237040|NCT01227824|OTHER|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
214237041|NCT01227824|OTHER|raltegravir Placebo|raltegravir placebo taken twice daily
214237042|NCT04526821|DRUG|Bovine Lactoferrin|Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
214237043|NCT04526821|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
214237044|NCT03265223|DRUG|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
214237045|NCT02123914|OTHER|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
214237046|NCT02123914|OTHER|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
214237047|NCT02123914|OTHER|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
214237048|NCT00878761|BIOLOGICAL|STX-100|SC, single dose followed by multiple dose
214237049|NCT04541277|DRUG|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
214237050|NCT05384951|DIETARY_SUPPLEMENT|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
214237051|NCT04678687|PROCEDURE|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
214237052|NCT00709709|PROCEDURE|multislice coronary scan|multislice coronary scan
214237053|NCT03935113|OTHER|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
214237054|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
214237055|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
214237056|NCT01855373|DIETARY_SUPPLEMENT|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
214237057|NCT01855373|OTHER|Placebo|Placebo: 2 capsules twice daily on an empty stomach
214237058|NCT02805504|DRUG|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
214237059|NCT02805504|DRUG|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
214237060|NCT02630043|DRUG|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
214237061|NCT02630043|DRUG|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
214237062|NCT02395302|DEVICE|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
214237063|NCT02672020|BIOLOGICAL|omics identity card|
214237064|NCT04838808|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
214237065|NCT04838808|DRUG|Placebo|Placebo tablet twice daily for 90-days
214237066|NCT02767362|DRUG|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
214237067|NCT02369601|OTHER|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
214237068|NCT02081066|OTHER|cardiovascular risk factors|
214237069|NCT01306929|DRUG|pridopidine|45mg bid
214652124|NCT00003788|PROCEDURE|surgical procedure|
214652125|NCT00003788|RADIATION|radiation therapy|
214652126|NCT00067652|BEHAVIORAL|Education and awareness about body image issues.|
214237070|NCT02823444|OTHER|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
214237071|NCT02589600|DRUG|Zoledronic acid|Annual intravenous 5.0 mg
214237072|NCT02589600|DIETARY_SUPPLEMENT|vitamin D|800 IU daily
214237073|NCT02589600|DIETARY_SUPPLEMENT|calcium|approximately 1200 mg (dietary and supplement)
214237074|NCT02589600|OTHER|Saline|Annual intravenous saline placebo
214237075|NCT06457672|DIAGNOSTIC_TEST|Group I|Complete Crown technique of superimposition
214237076|NCT06457672|DIAGNOSTIC_TEST|Group II|Gold standard technique of superimposition
214237077|NCT02303418|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
214237078|NCT02303418|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
214237079|NCT03090048|DRUG|Vitamin A|Vitamin A 2-3 % concentration
214237080|NCT03090048|DRUG|Azithromycin|azithromycin monohydrate
214237081|NCT00928590|DRUG|Travoprost/Timolol Maleate Fixed Combination solution|
214237082|NCT03815578|OTHER|Clinical examination|"* Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)"
214237083|NCT03815578|OTHER|Pain assessment|"* Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)"
214237084|NCT03815578|OTHER|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
214237085|NCT03815578|OTHER|Patient Reported Outcomes|"* Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire."
214237086|NCT01220544|BIOLOGICAL|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
214237087|NCT06055738|DRUG|Zimberelimab|240mg,d1,iv,Q21D
214237088|NCT06055738|DRUG|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
214237089|NCT06055738|DRUG|Cisplatin|75mg/m2,d1,iv,Q21D
214237090|NCT00403169|DRUG|lenalidomide|drug
214237091|NCT02166177|DRUG|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
214237092|NCT05806827|DIAGNOSTIC_TEST|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
214237093|NCT00243607|OTHER|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
214237094|NCT01090895|DRUG|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
214237095|NCT01090895|DRUG|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
214652127|NCT06929182|OTHER|"non-high risk thrombotic APS patients treated with DOAC"|There is no specific intervention in this study. Routine care data will be collected from patients with a 'non-high-risk' APS profile who are currently being treated with DOACs or have been in the past.
214237096|NCT02807415|DRUG|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
214237097|NCT06363188|DEVICE|Radial Extracorporeal shockwave|a device used by physiotherapist to treat various musculoskeletal problems and it was here firstly used to accelerate the bone healing process after bone fracture
214237098|NCT03330392|DIETARY_SUPPLEMENT|AGP|take two tablets per day (500 mg/day) for 8 weeks
214237099|NCT03330392|DIETARY_SUPPLEMENT|Placebo|take two tablets per day (500 mg/day) for 8 weeks
214237100|NCT04641689|DEVICE|Desk Only|Provision of height-adjustable desk
214237101|NCT04641689|BEHAVIORAL|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
214237102|NCT05133960|OTHER|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
214237103|NCT05861622|OTHER|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
214652128|NCT06930833|DEVICE|Corsano CardioWatch 287-2|Eligible patients are asked to wear the Corsano CardioWatch 287-2 for 6 days, of which 3 days approximately 2 weeks before the procedure and 3 days approximately 2 months after the procedure.
214652129|NCT06911996|BEHAVIORAL|Virtual Reality|"After obtaining written consent, participants will be asked to complete a brief demographic survey and pre-intervention surveys (content knowledge, and wellbeing surveys). They will then be equipped with a VR headset, Quest 3 (Meta, Inc., Menlo Park, CA) displaying the educational field trip. After the VR field trip, participants will participate in a complementary hands-on science experiment. At the conclusion of the experiment, patients will be asked to complete the post intervention surveys (i.e awe, content knowledge, and wellbeing surveys).~Additionally, for the first 20 participants, 15 participants will be randomly selected and asked to participate in a 5 open-ended question qualitative interview regarding engagement of the lesson. Audio will be recorded via zoom."
214652130|NCT06917131|DIETARY_SUPPLEMENT|Royal Jelly|Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
214237104|NCT05694377|BEHAVIORAL|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
214237105|NCT00835029|DRUG|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
214237106|NCT00835029|DRUG|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
214237107|NCT06070220|BEHAVIORAL|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
214237108|NCT06070220|BEHAVIORAL|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
214237109|NCT03971877|DIAGNOSTIC_TEST|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
214237110|NCT00917293|DRUG|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
214237111|NCT00917293|DRUG|Placebo|Placebo 2 pills, po bid.
214237112|NCT04240080|DEVICE|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
214237113|NCT06261281|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
214237114|NCT06261281|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
214237115|NCT06261281|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
214237116|NCT01908946|BEHAVIORAL|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
214237117|NCT04762901|DRUG|Niraparib|Oral tablet
214652131|NCT06917131|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
214652132|NCT06915116|PROCEDURE|Acupuncture|Acupuncture will be delivered by licensed experienced acupuncturists at MSK. The intervention includes 12 treatments of acupuncture over 12 weeks (i.e. one treatment a week) with a +/- 14-day window. When patients experience menses recovery during the treatment period, they have the option to discontinue treatment or continue receiving up to 12 acupuncture sessions for symptom management over 12 weeks.
214652133|NCT06915116|OTHER|No Acupuncture|Will have the option to receive the same acupuncture treatment as the acupuncture group after a 16-week waiting period
214237118|NCT04762901|DRUG|Doxorubicin|IV
214237119|NCT04762901|DRUG|Cyclophosphamide|IV
214237120|NCT04762901|DRUG|Paclitaxel|IV
214237121|NCT04762901|DRUG|Pegfilgrastim|Injection
214237122|NCT04762901|DRUG|Carboplatin|IV
214237123|NCT06433856|OTHER|Cold Water Immersion|Cold water immersion consists in 12 min standing in 10 °C water
214237124|NCT06433856|DEVICE|Percussive Massage Therapy|Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
214237125|NCT04403269|DRUG|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
214237126|NCT00710762|DRUG|BIBF1120|
214237127|NCT00710762|DRUG|Placebo|
214237128|NCT02700633|DEVICE|Pacemaker|
214237129|NCT04397770|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214237130|NCT04397770|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
214237131|NCT04397770|DRUG|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
214237132|NCT01887054|DEVICE|Tower of Hanoi|
214237133|NCT01887054|OTHER|Placebo group - non use of Tower of Hanoi|
214237134|NCT00910507|BEHAVIORAL|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
214237135|NCT00910507|BEHAVIORAL|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
214237136|NCT02610101|OTHER|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
214237137|NCT02610101|OTHER|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
214237138|NCT02610101|OTHER|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
214237139|NCT03838809|DEVICE|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
214237140|NCT02346890|DRUG|AZD1722|
214237141|NCT02346890|DRUG|Renvela|
214237142|NCT05736575|GENETIC|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
214237143|NCT02979860|BEHAVIORAL|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
214237144|NCT02979860|BEHAVIORAL|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
214237145|NCT02979860|BEHAVIORAL|Sleep timing|Sleep timing: bed time kept consistent
214237146|NCT00495040|RADIATION|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
214237147|NCT03337919|DRUG|Nivolumab|Up to 8 cycles of nivolumab
214237148|NCT05268627|DRUG|Liraglutide|endoscopy
214237149|NCT04096378|BEHAVIORAL|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
214237150|NCT04096378|BEHAVIORAL|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
214237151|NCT01761032|DEVICE|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
214237152|NCT05383001|DRUG|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
214237153|NCT05383001|DRUG|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
214237154|NCT00272714|DRUG|Afimoxifene (0.057%) in hydroalcoholic gel|
214237155|NCT02719561|BEHAVIORAL|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
214237156|NCT03660137|DEVICE|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
214237157|NCT02867553|DRUG|rituximab|
214237158|NCT02867553|RADIATION|Multi-fields radiotherapy|
214237159|NCT04069364|BEHAVIORAL|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
214237160|NCT01816451|OTHER|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
214237161|NCT01892384|DRUG|Placebo|matching placebo
214237162|NCT01892384|DRUG|BI 409306|BI 409306
214237163|NCT00002501|BIOLOGICAL|filgrastim|
214237164|NCT00002501|DRUG|cyclophosphamide|
214237165|NCT00592774|DRUG|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
214237166|NCT00592774|DRUG|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
214237167|NCT01700439|DEVICE|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
214237168|NCT02275884|DIETARY_SUPPLEMENT|Dark chocolate (85% cocoa)|
214237169|NCT02275884|DIETARY_SUPPLEMENT|White chocolate (0% cocoa)|
214237170|NCT03279289|DRUG|Aflibercept|4 mg/kg administered intravenous infusion on day 1
214237171|NCT03279289|DRUG|Irinotecan|180 mg/m2 intravenous infusion
214237172|NCT03279289|DRUG|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
214237173|NCT03279289|DRUG|5Fluorouracil|400 mg/m2 intravenous bolus
214237174|NCT03279289|DRUG|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
214237175|NCT02226744|BEHAVIORAL|Focused Breathing|
214237176|NCT05849961|DEVICE|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
214237177|NCT06087419|DRUG|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
214237178|NCT06087419|DRUG|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
214237179|NCT06087419|DRUG|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
214237180|NCT05982951|PROCEDURE|Shoulder PENG block|Ultrasound guided insertion of a needle between subscapularis tendon and deltoid with injection of 10 mi 0.25% bupivacaine after confirming right plane of injection
214237181|NCT01872325|BEHAVIORAL|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
214237182|NCT01390064|BIOLOGICAL|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
214237183|NCT00621621|DEVICE|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
214237184|NCT03896347|OTHER|ViBone®|Viable bone allograft
214237185|NCT03896347|OTHER|Demineralized Bone Matrix|Demineralized Bone Matrix
214237186|NCT03896347|OTHER|Bone Morphogenetic Protein|Bone Morphogenetic Protein
214237187|NCT01529801|DEVICE|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
214237188|NCT01529801|DEVICE|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
214237189|NCT01529801|DEVICE|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
214237190|NCT04722055|DIAGNOSTIC_TEST|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
214237191|NCT05883670|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
214237192|NCT01613976|DRUG|Panobinostat|
214237193|NCT06164821|DRUG|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
214237194|NCT03865888|DRUG|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
214237195|NCT03865888|DRUG|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
214237196|NCT05796830|OTHER|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
214237197|NCT00481507|OTHER|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
214237198|NCT00481507|OTHER|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
214237199|NCT05721807|OTHER|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
214237200|NCT05721807|OTHER|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
214237201|NCT02229656|RADIATION|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
214237202|NCT02229656|DRUG|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
214237203|NCT02802046|RADIATION|Computed tomographic angiography of coronary artery|
214237204|NCT04850781|BEHAVIORAL|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
214237205|NCT04850781|BEHAVIORAL|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
214237206|NCT02452931|DRUG|Leuprolide Acetate 45 mg|Subcutaneous injection
214237207|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
214237208|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
214237209|NCT02577393|DRUG|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
214237210|NCT00608569|DRUG|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
214237211|NCT00608569|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
214237212|NCT00608569|DRUG|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
214237213|NCT00608569|DRUG|Zidovudine|300-mg tablet taken orally twice daily
214237214|NCT00608569|DRUG|Emtricitabine|200-mg tablet taken orally once daily
214237215|NCT02591329|BEHAVIORAL|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
214237216|NCT02591329|BEHAVIORAL|Standard Care|
214237217|NCT05371873|PROCEDURE|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
214237218|NCT05622162|DRUG|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
214237219|NCT05622162|DRUG|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
214237220|NCT00562315|DRUG|FACBC|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
214237221|NCT00562315|OTHER|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
214237222|NCT00385476|BEHAVIORAL|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
214237223|NCT04976270|DRUG|GLPG3667|GLPG3667 capsules
214237224|NCT04976270|DRUG|Placebo|Matching placebo capsules
214237225|NCT02671916|BEHAVIORAL|questionnaire|Investigation on all study patients, no Intervention, no groups
214237226|NCT04161768|DRUG|Norfloxacin|Norfloxacin 400 mg daily
214237227|NCT04161768|DRUG|Itopride|Itopride 50 mg three times daily
214237228|NCT03190733|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
214237229|NCT03741478|DRUG|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1"
214237230|NCT03741478|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
214237231|NCT03741478|DRUG|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
214237232|NCT03741478|OTHER|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
214237233|NCT05535205|OTHER|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
214237234|NCT05535205|OTHER|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
214237235|NCT01059929|DRUG|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
214237236|NCT01059929|DRUG|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
214237237|NCT01059929|DRUG|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
214237238|NCT01059929|DRUG|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
214237239|NCT01059929|BEHAVIORAL|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
214237240|NCT00515424|DRUG|RKI983|
214237241|NCT03120455|BEHAVIORAL|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
214237242|NCT03120455|BEHAVIORAL|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
214237243|NCT03120455|BEHAVIORAL|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
214237244|NCT03712709|DIAGNOSTIC_TEST|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
214237245|NCT03445156|BEHAVIORAL|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
214237246|NCT03445156|BEHAVIORAL|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
214237247|NCT00189410|DRUG|Pegylated Liposomal Doxorubicin and Carboplatin|
214237248|NCT01210417|OTHER|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
214237249|NCT00164970|DIETARY_SUPPLEMENT|Vitamin B12|
214237250|NCT00164970|DIETARY_SUPPLEMENT|folate|
214237251|NCT04140123|DRUG|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
214237252|NCT04140123|DRUG|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
214237253|NCT02292901|DEVICE|Macintosh laryngoscope|
214237254|NCT02292901|DEVICE|McGrath Mac videolaryngoscope|
214237255|NCT05208918|PROCEDURE|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
214237256|NCT05208918|PROCEDURE|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
214237257|NCT00668356|DRUG|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
214237258|NCT00668356|DRUG|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
214237259|NCT00053898|DRUG|anastrozole|1 mg/day and placebo for 5 years
214237260|NCT00053898|DRUG|tamoxifen citrate|20 mg/day and placebo for 5 years
214237261|NCT00053898|RADIATION|Radiation Therapy|Adjuvant radiation therapy
214237262|NCT05873660|OTHER|No treatment given|No treatment given
214237263|NCT02178839|DIETARY_SUPPLEMENT|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
214237264|NCT02178839|DIETARY_SUPPLEMENT|Maltodextrin|8.5 g/d Maltodextrin
214237265|NCT04531631|DRUG|Dorzagliatin|tablet
214237266|NCT04531631|DRUG|placebo|placebo
214237267|NCT02066987|BEHAVIORAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth! If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth!"
214237268|NCT02066987|BEHAVIORAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY).~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY)."
214237269|NCT02066987|BEHAVIORAL|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
214237270|NCT03780023|OTHER|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
214237271|NCT00427401|DRUG|PF-00915275|
214237272|NCT03149367|PROCEDURE|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
214237273|NCT03149367|PROCEDURE|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
214237274|NCT02619773|PROCEDURE|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
214237275|NCT05391191|DEVICE|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
214237276|NCT00837733|PROCEDURE|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
214237277|NCT00837733|PROCEDURE|Endometrial Biopsy|Biopsy catheter
214237278|NCT04011371|PROCEDURE|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
214237279|NCT05570331|DIAGNOSTIC_TEST|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
214237280|NCT04801940|DRUG|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
214237281|NCT04801940|DRUG|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
214237282|NCT06226532|DRUG|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
214237283|NCT06226532|DRUG|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
214237284|NCT05596097|DRUG|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
214237285|NCT04192227|BEHAVIORAL|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
214237286|NCT00497042|DEVICE|Self Adjusting File|
214237287|NCT00366093|DRUG|Eszopiclone|eszopiclone 3 mg
214237288|NCT00366093|DRUG|Placebo|placebo tablet
214237289|NCT01491594|DRUG|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
214237290|NCT01577290|BEHAVIORAL|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
214237291|NCT01577290|BEHAVIORAL|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
214237292|NCT04486898|OTHER|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
214237293|NCT00889616|DRUG|BSAM2/Alhydrogel + CPG 7909|
214237294|NCT01254942|OTHER|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
214237295|NCT01254942|OTHER|Usual Care|
214237296|NCT01847807|DRUG|low dose Astragalus|
214237297|NCT01847807|DRUG|high dose astagalus|
214237298|NCT05088473|OTHER|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
214237299|NCT05370703|BEHAVIORAL|My A:care|Mobile application with Motivational messages
214237300|NCT05370703|BEHAVIORAL|Smart Coach|Mobile application with Motivational messages
214237301|NCT04564131|OTHER|Reflexology|"* Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed."
214237302|NCT04564131|OTHER|Control|No intervention was performed to reduce pain in the control group
214237303|NCT01908881|BEHAVIORAL|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
214237304|NCT01908881|BEHAVIORAL|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
214237305|NCT05355493|BEHAVIORAL|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
214237306|NCT05355493|BEHAVIORAL|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
214237307|NCT05022511|BEHAVIORAL|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
214237308|NCT00545129|DRUG|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
214237309|NCT00545129|DRUG|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
214237310|NCT03504943|OTHER|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
214237311|NCT03504943|OTHER|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
214237312|NCT00633542|DRUG|thalidomide|100 mg/day orally until progression or severe toxicity
214237313|NCT00633542|DRUG|interferon alpha|3 MU 3 times a week until progression or severe toxicity
214237314|NCT04744376|OTHER|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
214237315|NCT04744376|OTHER|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
214237316|NCT04744376|OTHER|Clavien - Dindo classification|It is a classification for postoperative complications.
214237317|NCT00172159|PROCEDURE|Hepatic resection|
214237318|NCT02253927|DRUG|BILR 355 - D1|
214237319|NCT02253927|DRUG|BILR 355 - D2|
214237320|NCT02253927|DRUG|BILR 355 - D3|
214237321|NCT02253927|DRUG|BILR 355 - D4|
214237322|NCT02253927|DRUG|Ritonavir|
214237323|NCT02253927|OTHER|high fat breakfast|
214237324|NCT01728233|DRUG|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
214237325|NCT01081548|DRUG|atorvastatin|20 mg
214237326|NCT01081548|DRUG|atorvastatin|20 mg
214237327|NCT01077752|DRUG|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
214237328|NCT01077752|DRUG|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
214237329|NCT01077752|DRUG|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
214237330|NCT01077752|DRUG|NaCl|NaCl
214237331|NCT04044443|DEVICE|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
214237332|NCT04104269|DIAGNOSTIC_TEST|Heart rupture|Free wall rupture and Ventricular septal rupture
214237333|NCT04411381|OTHER|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
214237334|NCT04474548|OTHER|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
214237335|NCT01894568|DRUG|Insulin Peglispro|Administered SC using a prefilled pen.
214237336|NCT01894568|DRUG|Insulin Glargine|Administered SC using a prefilled pen
214237337|NCT01894568|DRUG|Oral Antihyperglycemic Medications (OAMs)|Administered orally
214237338|NCT00925743|DRUG|cabazitaxel (XRP6258)|"* administered by IV infusion~* in addition to cisplatin treatment"
214237339|NCT02772198|BIOLOGICAL|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
214237340|NCT04545944|DRUG|Vonoprazan|20 mg tablets administered orally
214237341|NCT04545944|DRUG|Midazolam|2 mg syrup administered orally
214237342|NCT06254196|PROCEDURE|Telenursing interventions for monitoring Supportive Care Needs|"Use of the Intelligence2health platform, data collection forms on Google Forms, and dedicated telephone line for telenursing remote nursing monitoring interventions.~Based on the data, nurses will be able to implement patient education interventions aimed at preventing and monitoring healthcare support needs related to treatment."
214237343|NCT02841878|GENETIC|Analysis on colorectal biopsy|
214237344|NCT06209385|DRUG|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
214237345|NCT05851001|OTHER|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
214237346|NCT05851001|OTHER|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
214237347|NCT00912379|BIOLOGICAL|hemoglobin determination|laboratory and non invasive hemoglobin determinations
214237348|NCT01514370|DRUG|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
214237349|NCT01514370|DRUG|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
214237350|NCT01514370|DRUG|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
214237351|NCT05002920|PROCEDURE|alveolar bone grafting|the surgery of alveolar bone graft for alveolar defect in cleft patients
214237352|NCT01551420|DEVICE|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
214237353|NCT01551420|DEVICE|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
214237354|NCT03504137|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
214237355|NCT05604053|BEHAVIORAL|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
214237356|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Full dose|350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
214237357|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Half dose|175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
214237358|NCT03034668|DIETARY_SUPPLEMENT|Placebo|Maltodextrin: 350 mg
214237359|NCT04434378|DRUG|Tamsulosin|0.4 mg tamsulosin will be given to a randomized group of patients
214237360|NCT04434378|DRUG|Placebo|placebo will be given to a randomized group of patients
214237361|NCT00986284|DRUG|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
214237362|NCT04781777|DRUG|insulin|sonar guided insulin combined with dexamethasone and local anesthetics
214237363|NCT00048841|DRUG|alendronate|
214237364|NCT05320497|DEVICE|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
214237365|NCT02241096|DRUG|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
214237366|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
214237367|NCT04199598|DRUG|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
214237368|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
214237369|NCT04199598|DRUG|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
214237370|NCT03744000|PROCEDURE|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
214237371|NCT03744000|PROCEDURE|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
214237372|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
214237373|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
214237374|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
214237375|NCT00624702|DRUG|Placebo|
214237376|NCT05767801|PROCEDURE|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
214237377|NCT02699788|DEVICE|Multifunction Cardiogram|
214237378|NCT06206070|BEHAVIORAL|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
214237379|NCT01070147|OTHER|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
214237380|NCT04711746|BIOLOGICAL|blood sample|Blood sample withdrawal in order to perform DNA sequencing
214237381|NCT01850927|PROCEDURE|Remote ischaemic preconditioning|
214237382|NCT01850927|PROCEDURE|Control|
214237383|NCT00214604|DRUG|Rosuvastatin|10mg
214237384|NCT00214604|DRUG|rosuvastatin|20mg
214237385|NCT00214604|DRUG|pravastatin|40mg
214237386|NCT00720018|DRUG|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
214237387|NCT05268211|DIAGNOSTIC_TEST|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
214237388|NCT04387643|DIETARY_SUPPLEMENT|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
214237389|NCT01739855|DRUG|Calciferol, calcium carbonate|
214237390|NCT00381576|BEHAVIORAL|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
214237391|NCT04592952|DRUG|Calcitonin Gene-Related Peptide|Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
214237392|NCT04592952|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
214237393|NCT04900740|DEVICE|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
214237394|NCT04900740|DEVICE|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
214237395|NCT01337102|PROCEDURE|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
214237396|NCT01337102|PROCEDURE|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
214237397|NCT03068091|DEVICE|Chest CT|Inspiration and expiration chest CT
214237398|NCT03068091|DIAGNOSTIC_TEST|Pulmonary Function Testing|Measure lung function
214237399|NCT03234140|GENETIC|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
214237400|NCT03234140|GENETIC|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
214237401|NCT05990595|DIETARY_SUPPLEMENT|Adlay with white rice|We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.
214237402|NCT05990595|DIETARY_SUPPLEMENT|white rice|white rice
214237403|NCT05232409|BIOLOGICAL|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
214237404|NCT05232409|COMBINATION_PRODUCT|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
214237405|NCT05195060|DRUG|casirivimab with imdevimab|Monoclonal antibody
214237406|NCT05195060|DRUG|sotrovimab|Monoclonal antibody
214237407|NCT05195060|DRUG|molnupiravir|antiviral agent
214237408|NCT04125251|BEHAVIORAL|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
214237409|NCT03353740|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
214237410|NCT02970240|PROCEDURE|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
214237411|NCT02133300|OTHER|electrical stimulation|
214237412|NCT05673174|DIAGNOSTIC_TEST|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
214237413|NCT02232880|DRUG|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
214237414|NCT02232880|DRUG|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
214237415|NCT01666847|PROCEDURE|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
214237416|NCT04070976|RADIATION|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
214237417|NCT04070976|RADIATION|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
214237418|NCT02545543|BIOLOGICAL|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
214237419|NCT02545543|BIOLOGICAL|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
214237420|NCT03320525|DIETARY_SUPPLEMENT|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
214237421|NCT06966128|DEVICE|transcranial Direct Current Stimulation|Stimulation intensity: Variable (between 1 mA and 2 mA), Electrode placement: Dorsolateral prefrontal cortex, Duration: 10 minutes
214237422|NCT05397704|DEVICE|brain pulse oximeter|brain oxygen monitoring during hypoxia
214237423|NCT03826784|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
214237424|NCT03297411|PROCEDURE|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
214237425|NCT03297411|PROCEDURE|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
214237426|NCT03297411|PROCEDURE|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
214237427|NCT03297411|PROCEDURE|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
214237428|NCT02105753|DEVICE|1210nm Diode Laser treatments|
214237429|NCT00711568|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
214237430|NCT00711568|PROCEDURE|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
214237431|NCT00711568|DEVICE|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
214237432|NCT06153979|BIOLOGICAL|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
214237433|NCT03389048|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
214237434|NCT03389048|DIAGNOSTIC_TEST|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
214237435|NCT03133962|OTHER|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
214237436|NCT05420753|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
214237437|NCT06385067|DEVICE|Biolimus Coated Coronary Artery Balloon Dilation Catheter|Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
214237438|NCT00911001|BEHAVIORAL|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
214237439|NCT03195400|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
214237440|NCT03195400|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
214237441|NCT03195400|DIAGNOSTIC_TEST|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
214237442|NCT03195400|DIAGNOSTIC_TEST|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
214237443|NCT00171470|DRUG|Tegaserod|
214237444|NCT01071018|DRUG|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
214237445|NCT01071018|DRUG|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
214237446|NCT03350269|OTHER|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
214237447|NCT06994351|DEVICE|Electroacupuncture|"The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 10-minute maintenance in prone and supine position respectively.~The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA).~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
214237448|NCT06994351|DEVICE|Sham electroacupuncture|"The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral Anmian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 30 seconds, the electric current will be turned down.~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
214237449|NCT06995794|OTHER|kinesio tape|Kinesio tape a therapeutic tape that's applied strategically to the body to provide lessen pain, reduce swelling, improve performance.
214237450|NCT06995794|OTHER|knee strap|knee strap is used to support the tibial tuberosity which lessen the pain and enhance performance of the knee
214237453|NCT06994273|DRUG|Fentanyl|Patients received fentanyl as a 1 μg/kg bolus over 10 min, followed by a 1-5 μg/kg/hr intravenous infusion after 10-15 minutes.
214237454|NCT06994273|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a 1 μg/kg bolus over 10 min, followed by a 0.2-0.7 μg/kg/hr intravenous infusion after 10-15 minutes.
214237455|NCT06994689|DIAGNOSTIC_TEST|Perimetry and ShearWave measurement of the quadriceps muscle before and after a pulmonary rehabilitation (PR) programme|"Patients will undergo a pulmonary rehabilitation (PR) programme.~On day 1, perimetry and ShearWave measurements of the quadriceps muscle will be provided. Supplementary assessments of quadriceps thickness, quadriceps strength with a handheld dynamometry, lean body mass (bioelectrical impedance), constant work-rate endurance test and HAD questionnaire will also be provided on day 1.~The same measurements and questionnaire will be provided on the last day of the patient in the PR programme."
214237456|NCT04267224|DRUG|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
214237457|NCT03802058|DRUG|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
214237458|NCT03802058|DRUG|Carboplatin|Carboplatin AUC=2 for Injection weekly
214237459|NCT03802058|RADIATION|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
214237460|NCT03418103|DEVICE|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
214237461|NCT05406193|OTHER|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
214237462|NCT00205907|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
214237463|NCT01395784|DRUG|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
214237464|NCT00877097|DRUG|Klodronate and Kliogest|
214237465|NCT00877097|PROCEDURE|Placebo+ Kliogest|
214237466|NCT00877097|DRUG|Bonefos|
214237467|NCT04268823|DRUG|QBW251|Capsule 300mg
214237468|NCT04268823|DRUG|Placebo|Capsule 300mg
214237469|NCT02815826|OTHER|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
214237470|NCT02815826|OTHER|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
214237471|NCT02326935|BIOLOGICAL|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
214237472|NCT03538964|PROCEDURE|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
214237473|NCT03538964|PROCEDURE|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
214237474|NCT00000158|PROCEDURE|Argon Blue-Green Laser Photocoagulation|
214237475|NCT02455505|BEHAVIORAL|background questionnaire|
214237476|NCT02455505|BEHAVIORAL|bereavement risk screening tool|
214237477|NCT02055365|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
214237478|NCT02029729|DRUG|omaveloxolone|
214237479|NCT04296643|DEVICE|Medical Mask|Medical Mask (known also as Surgical Mask)
214237480|NCT04296643|DEVICE|N95 respirator|N95 respirator
214237481|NCT00400478|DRUG|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
214237482|NCT00148551|DRUG|Triamcinolone Acetonide|
214237483|NCT03932006|DRUG|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
214237484|NCT03932006|DRUG|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
214237485|NCT03932006|DRUG|Imrecoxib|Imrecoxib 0.1g twice a day,orally
214237486|NCT02882152|PROCEDURE|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
214237487|NCT02882152|PROCEDURE|morphine|Intrathecal morphine injection
214237488|NCT03444532|BEHAVIORAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
214237489|NCT05974423|DRUG|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
214237490|NCT05974423|DRUG|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
214237491|NCT03190044|DIETARY_SUPPLEMENT|PACR|Daily assumption of PACR for a 3-month period
214237492|NCT03190044|DIETARY_SUPPLEMENT|Placebo|Daily assumption of placebo
214237493|NCT02217774|DEVICE|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
214237494|NCT05720754|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
214237495|NCT05720754|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
214237496|NCT00338897|DRUG|SR123781A|
214237497|NCT05413577|BEHAVIORAL|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
214237498|NCT01035450|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
214237499|NCT01035450|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
214237500|NCT06114901|OTHER|SleepFix|SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
214237501|NCT06114901|OTHER|Sleep health Education modules|Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
214237502|NCT02225613|OTHER|Usual protocol|
214237503|NCT02225613|OTHER|Spa protocol|
214237504|NCT00734760|BEHAVIORAL|education|face-to-face education and counseling intervention
214237505|NCT01411553|OTHER|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
214237506|NCT02706223|OTHER|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
214237507|NCT02706223|OTHER|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
214237508|NCT05602896|OTHER|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
214237509|NCT05634447|DRUG|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
214237510|NCT01029301|DEVICE|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
214237511|NCT03049293|DRUG|Midazolam|The impact of Midazolam levels in follicular fluid.
214237512|NCT02755532|DRUG|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
214818071|NCT03552692|DRUG|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
214818072|NCT00965874|DRUG|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
214818073|NCT00965874|DRUG|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
214818074|NCT00965874|DRUG|Placebos|serum salin
214818075|NCT01125059|DRUG|Methadone|0.2 mg/kg methadone IV bolus
214818076|NCT01125059|DRUG|Saline|3 mL saline IV bolus
214818077|NCT02235662|DRUG|TFV IVR|
214818078|NCT02235662|DRUG|TFV/LNG IVR|
214818079|NCT02235662|OTHER|Placebo IVR|
214237513|NCT02755532|DRUG|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
214237514|NCT02648828|OTHER|Clinical deterioration|Patients at risk of clinical deterioration
214237515|NCT06050603|DEVICE|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
214237516|NCT06107179|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
214237517|NCT02835352|OTHER|Essential oils massages|
214237518|NCT02835352|OTHER|Oil massages|
214237519|NCT06374251|PROCEDURE|Discussion|Participate in narrative medicine sessions
214237520|NCT06374251|OTHER|Interview|Ancillary studies
214237521|NCT06374251|OTHER|Survey Administration|Ancillary studies
214237522|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
214237523|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
214237524|NCT00000187|DRUG|Ritanserin|
214237525|NCT03848156|OTHER|biopsy|Biopsy of nasal polyp for RNA sequencing
214237526|NCT04215003|DRUG|A|"Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles."
214237527|NCT04215003|DRUG|B|Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.
214237528|NCT04215003|DRUG|CL4|SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
214237529|NCT02764021|DIETARY_SUPPLEMENT|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
214237530|NCT02764021|DIETARY_SUPPLEMENT|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
214237531|NCT03893344|DIAGNOSTIC_TEST|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
214237532|NCT04665882|PROCEDURE|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
214237533|NCT02029690|DRUG|ADI-PEG 20|
214237534|NCT02739737|OTHER|Blinded manuscript|Blinded version of sham manuscript
214237535|NCT02739737|OTHER|Unblinded manuscript|Unblinded version of sham manuscript
214237536|NCT06074770|OTHER|no intervention|Natural exposure of iodine
214237537|NCT03768557|DRUG|Minocycline|Minocycline (200mg)
214237538|NCT03768557|OTHER|placebo|Lactose (400mg)
214237539|NCT01018446|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
214237540|NCT02531971|DRUG|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
214237541|NCT02531971|DRUG|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
214237542|NCT02531971|DRUG|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
214237543|NCT01721785|DRUG|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
214237544|NCT00612729|PROCEDURE|Polylens Y30 intraocular lens|cataract surgery
214237545|NCT00612729|PROCEDURE|Orange Series Model PC 440 Y intraocular lens|cataract surgery
214237546|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
214237547|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
214237548|NCT04572438|PROCEDURE|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
214237549|NCT00016900|DRUG|liposomal paclitaxel|
214237550|NCT01378182|GENETIC|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
214237551|NCT04733391|OTHER|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
214237552|NCT01343823|DRUG|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
214237553|NCT01343823|DRUG|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
214237554|NCT01343823|DRUG|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
214237555|NCT01343823|DRUG|placebo|Administered as two SC 3 mL injections
214237556|NCT01343823|DRUG|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
214237557|NCT01343823|DRUG|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
214237558|NCT00352716|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
214237559|NCT05392933|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
214237560|NCT02794610|DRUG|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
214237561|NCT03505827|DIAGNOSTIC_TEST|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
214237562|NCT00923364|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
214237563|NCT00923364|DRUG|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
214237564|NCT00923364|PROCEDURE|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
214237565|NCT00923364|PROCEDURE|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
214237566|NCT00923364|DRUG|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
214237567|NCT01752036|RADIATION|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
214237568|NCT00827671|DRUG|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
214237569|NCT00827671|RADIATION|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
214237570|NCT04121351|OTHER|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
214237571|NCT04352127|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
214237572|NCT01385332|PROCEDURE|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
214237573|NCT01385332|PROCEDURE|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
214237574|NCT00413088|DRUG|bemiparin|
214237575|NCT02177487|DRUG|Telmisartan/hydrochlorothiazide|
214237576|NCT00671359|DRUG|TR-701 600mg|TR-701 600mg
214237577|NCT04934631|OTHER|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
214237578|NCT04934631|OTHER|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
214237579|NCT04834765|OTHER|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
214237580|NCT04834765|OTHER|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
214237581|NCT04834765|OTHER|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
214237582|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
214237583|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
214237584|NCT01437995|DRUG|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
214237585|NCT05883371|OTHER|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
214237586|NCT02856126|PROCEDURE|Hepatic arterial infusion chemotherapy|
214237587|NCT02856126|PROCEDURE|Transarterial chemoembolization|
214237588|NCT02856126|DRUG|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
214237589|NCT02856126|DRUG|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
214237590|NCT02856126|DRUG|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
214237591|NCT05737602|BEHAVIORAL|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
214237592|NCT00710437|DRUG|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
214237593|NCT03682575|OTHER|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
214237594|NCT02906228|RADIATION|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
214237595|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
214237596|NCT01924702|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
214237597|NCT01924702|DEVICE|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
214237598|NCT04251676|OTHER|Observational study|Observational study
214237599|NCT04456673|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214237600|NCT04456673|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214237601|NCT04456673|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214237602|NCT04456673|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214237603|NCT04456673|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214237604|NCT04391049|DRUG|Carboplatin|Intravenously (IV)
214237605|NCT04391049|DRUG|Paclitaxel|Intravenously (IV)
214237606|NCT04391049|RADIATION|Radiation Therapy|Daily fractions
214237607|NCT04391049|BIOLOGICAL|Telomerase-specific Type 5 Adenovirus OBP-301|Intra-tumoral injection
214237608|NCT03579017|DIAGNOSTIC_TEST|ECAS-N|All participants included will be tested with the ECAS-N
214237609|NCT03579017|DIAGNOSTIC_TEST|MoCA|All included patients With ALS will be tested With the MoCA
214237610|NCT06307418|OTHER|Carer eSupport|Internet-based support
214237611|NCT05804188|OTHER|tracheal intubation|children between 0-16 requiring tracheal intubation
214237612|NCT02739633|DRUG|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
214237613|NCT02739633|DRUG|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
214237614|NCT03253562|DRUG|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
214237615|NCT03253562|DRUG|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
214237616|NCT05189106|DRUG|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
214237617|NCT05770674|DRUG|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI"
214237618|NCT03874429|DEVICE|T2259|Sodium Hyaluronate and Trehalose
214237619|NCT03874429|DEVICE|Vismed multi|HA
214237620|NCT03721445|DEVICE|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
214237621|NCT02160002|PROCEDURE|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
214237622|NCT02160002|PROCEDURE|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
214237623|NCT04661098|PROCEDURE|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
214237624|NCT00246571|DRUG|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
214237625|NCT00246571|DRUG|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
214237626|NCT04008043|DRUG|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
214237627|NCT04008043|DRUG|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
214237628|NCT05747547|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
214237629|NCT05747547|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
214237630|NCT05747547|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
214237631|NCT05747547|DIAGNOSTIC_TEST|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
214237632|NCT05747547|DIAGNOSTIC_TEST|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
214237633|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
214237634|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
214237635|NCT05518838|DRUG|OKN-007|OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
214237636|NCT01953263|OTHER|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
214237637|NCT05308719|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
214237638|NCT04896229|OTHER|Talk STEM Familia Treatment Condition|This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
214237639|NCT05924295|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will be given 360mg/kg
214237640|NCT05924295|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
214237641|NCT05924295|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
214237642|NCT05924295|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
214237643|NCT05055401|PROCEDURE|Direct Laryngoscopy|The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
214237644|NCT05055401|PROCEDURE|Laryngeal Mask Airways|The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
214237645|NCT05055401|PROCEDURE|Video Laryngoscopy|The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
214237646|NCT05303701|DRUG|GV1001 Placebo|0.9% normal saline
214237647|NCT05303701|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
214237648|NCT05356728|DRUG|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
214237649|NCT05562934|BIOLOGICAL|XXB750 drug|SC injection
214237650|NCT05562934|OTHER|Placebo|SC injection
214237651|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
214237652|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intravenously)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
214237653|NCT04908579|DRUG|bupivacaine(intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
214237654|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214237655|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214237656|NCT05583227|OTHER|Placebo|Placebo subcutaneous injection
214237657|NCT05219799|DRUG|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
214237658|NCT05219799|DRUG|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
214237659|NCT05219799|DRUG|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
214237660|NCT05219799|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
214237661|NCT05638789|PROCEDURE|endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)|EST alone vs EST plus EPLBD in removing common bile duct stone
214237662|NCT05795998|OTHER|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
214237663|NCT02679963|DRUG|Olaparib|
214237664|NCT02679963|DRUG|Placebo|
214237665|NCT05688384|DRUG|Propofol + Alfentanil|In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
214237666|NCT01203644|DRUG|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
214237667|NCT01203644|DRUG|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
214237668|NCT00983008|BEHAVIORAL|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
214237669|NCT03838094|BIOLOGICAL|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
214237670|NCT03838094|BIOLOGICAL|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
214237671|NCT00159822|DRUG|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
214237672|NCT02935751|OTHER|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
214237673|NCT01643785|DRUG|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
214237674|NCT03541915|DRUG|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
214237675|NCT03541915|DRUG|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
214237676|NCT03183154|OTHER|no intervention|no intervention
214237677|NCT05926375|DIETARY_SUPPLEMENT|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
214237678|NCT04618627|OTHER|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
214237679|NCT04825353|PROCEDURE|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
214237680|NCT04825353|PROCEDURE|Standard PCNL|patient undergo SPCNL
214237681|NCT00645255|DRUG|placebo|placebo one capsule daily
214237682|NCT00645255|DRUG|sibutramine or placebo|one capsule daily
214237683|NCT00713310|DRUG|Asacol 400 mg|"High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
214237684|NCT00713310|DRUG|Asacol 400 mg|"Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
214237685|NCT05453734|PROCEDURE|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
214237686|NCT01149954|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
214237687|NCT00875134|OTHER|Verbal prompt|Patient hears a voice recording
214237688|NCT00875134|OTHER|Skin Stimulus|Patient receives either a skin stimulus
214237689|NCT02307253|DEVICE|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
214237690|NCT05566483|BEHAVIORAL|Exercise|exercise protocol
214237691|NCT02225054|DRUG|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
214237692|NCT02225054|DRUG|Ropivacaine|15 ml 0.5%
214237693|NCT02225054|DRUG|Normal Saline|1 mL 0.9%
214237694|NCT05145738|BEHAVIORAL|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
214237695|NCT05145738|BEHAVIORAL|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
214237696|NCT01100476|DEVICE|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
214237697|NCT00628043|DRUG|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
214237698|NCT00628043|DRUG|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
214237699|NCT00275821|DRUG|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
214237700|NCT00275821|DRUG|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
214237701|NCT00275821|DRUG|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
214237702|NCT00590928|DRUG|esomeprazole|40mg once daily
214237703|NCT00590928|DRUG|ranitidine|50mg every h hours
214237704|NCT00329901|BIOLOGICAL|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
214237705|NCT00329901|BIOLOGICAL|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
214237706|NCT00329901|BIOLOGICAL|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
214237707|NCT04169971|OTHER|Music|Played through headphones during the operation under spinal anaesthesia
214237708|NCT00884767|DRUG|FOLFOX regimen|
214237709|NCT00884767|DRUG|fluorouracil|
214237710|NCT00884767|DRUG|leucovorin calcium|
214237711|NCT00884767|DRUG|oxaliplatin|
214237712|NCT00884767|GENETIC|gene expression analysis|
214237713|NCT00884767|GENETIC|protein expression analysis|
214237714|NCT00884767|GENETIC|proteomic profiling|
214237715|NCT00884767|OTHER|laboratory biomarker analysis|
214237716|NCT00884767|OTHER|pharmacogenomic studies|
214237717|NCT00228982|DRUG|Ceftobiprole medocaril|
214237718|NCT00228982|DRUG|Vancomycin|
214237719|NCT00992589|DRUG|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
214237720|NCT00992589|DRUG|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
214237721|NCT00992589|DRUG|Placebo|Matching placebo capsules once daily in the morning.
214237722|NCT02890108|DIETARY_SUPPLEMENT|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
214237723|NCT02890108|DIETARY_SUPPLEMENT|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
214237724|NCT00585598|OTHER|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
214237725|NCT01561196|PROCEDURE|arterial catheterisation|arterial catheterisation in Arterial Radialis
214237726|NCT01215916|DRUG|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\]."
214237727|NCT01215916|DRUG|Pemetrexed|"375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
214237728|NCT01886027|BEHAVIORAL|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
214237729|NCT01886027|BEHAVIORAL|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
214237730|NCT03772002|DIAGNOSTIC_TEST|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
214237731|NCT02142387|OTHER|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
214237732|NCT00643084|PROCEDURE|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
214237733|NCT00643084|PROCEDURE|standard bowel preparation|standard bowel preparation
214237734|NCT05028361|BIOLOGICAL|mRNA COVID-19|ACIP-CDC recommended vaccine
214237735|NCT05028361|BIOLOGICAL|IIV4|ACIP recommended vaccine
214237736|NCT05028361|OTHER|Placebo (saline)|Saline Control
214237737|NCT01848782|BEHAVIORAL|interpretation of the abstract of the systematic review|
214237738|NCT03640780|OTHER|observation|The surgical ages and other information between two groups were compared.
214237739|NCT05814276|BEHAVIORAL|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
214237740|NCT06493292|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
214237741|NCT00465309|PROCEDURE|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat \< 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH \> 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
214237742|NCT05855876|PROCEDURE|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
214237743|NCT06449404|OTHER|7T-MRI scaning|7T-MRI scaning
214237744|NCT00299468|BEHAVIORAL|Patient Activation Measure Intervention Package|
214237745|NCT00618098|BIOLOGICAL|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
214237746|NCT00618098|BIOLOGICAL|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
214237747|NCT02513147|DRUG|Dolutegravir|
214237748|NCT02513147|DRUG|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
214237749|NCT02513147|DRUG|2 NRTI|
214237750|NCT02513147|DRUG|2 NRTI|
214237751|NCT05934669|DRUG|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
214237752|NCT05934669|DRUG|Intranasal Dexmedetomidine|See above
214237753|NCT05934669|DRUG|Intranasal Ketamine|See above
214237754|NCT04727021|DRUG|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
214237755|NCT04727021|DRUG|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
214237756|NCT03452449|PROCEDURE|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
214237757|NCT05095012|OTHER|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
214237758|NCT03691740|DEVICE|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
214237759|NCT00912561|BEHAVIORAL|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
214237760|NCT03893253|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
214237761|NCT03893253|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
214237762|NCT06299488|OTHER|Sip2Sleep: Montmorency Cherry and Apocynum Venetum|See arm description
214237763|NCT04951167|DRUG|Norepinephrine|in the form of infusion
214818080|NCT03222063|OTHER|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
214818081|NCT02146118|DRUG|Erlotinib|Erlotinib 150 mg/day q 4 weeks
214237764|NCT04951167|DRUG|Norepinephrine|in the form of bolus
214818082|NCT02146118|DIETARY_SUPPLEMENT|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
214818083|NCT04694586|DRUG|rifampicin|rifampicin 35 mg/kg
214818084|NCT04694586|DRUG|pyrazinamide|pyrazinamide 40 mg/kg
214237765|NCT05477433|BEHAVIORAL|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
214237766|NCT00779259|DRUG|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
214237767|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
214237768|NCT00779259|DRUG|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
214237769|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
214237770|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237771|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
214237772|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237773|NCT04552678|BEHAVIORAL|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
214237774|NCT04552678|BEHAVIORAL|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237775|NCT04552678|BEHAVIORAL|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
214237776|NCT04552678|BEHAVIORAL|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237777|NCT04552678|BEHAVIORAL|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
214818085|NCT04694586|DRUG|HRZE|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets
214818086|NCT04694586|DRUG|HR|isoniazid 75 mg + rifampicin 150 mg combination tablets
214818087|NCT04480762|DRUG|SHR-1703|SHR-1703
214818088|NCT04480762|DRUG|Placebo|Placebo of the SHR-1703
214818089|NCT01816490|DRUG|Intravenous Silibinin (iSIL)|
214818090|NCT00993122|DRUG|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
214237778|NCT04552678|BEHAVIORAL|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237779|NCT04552678|BEHAVIORAL|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
214237780|NCT04552678|BEHAVIORAL|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237781|NCT04552678|BEHAVIORAL|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
214237782|NCT04552678|BEHAVIORAL|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237783|NCT04552678|BEHAVIORAL|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
214237784|NCT04552678|BEHAVIORAL|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
214237785|NCT04552678|BEHAVIORAL|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
214237786|NCT02280122|OTHER|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
214237787|NCT04772742|DRUG|Placebo|Placebo - solution for infusion
214237788|NCT04772742|DRUG|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
214237789|NCT05824143|DRUG|Darigabat|Oral tablet
214237790|NCT05824143|DRUG|Carbamazepine|Oral tablets
214237791|NCT05421884|BEHAVIORAL|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
214237792|NCT00879008|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
214237793|NCT00854412|OTHER|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
214237794|NCT02047318|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
214237795|NCT04622228|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
214237796|NCT04622228|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214237797|NCT04622228|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214237798|NCT04622228|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214237799|NCT04622228|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
214237800|NCT06482242|BEHAVIORAL|My Best Alaska Life|MBAL's combination of digital innovation, inclusive content, and youth-driven design positions it as a leading-edge intervention in the field of sexual health, with the potential to significantly impact the lives of Y/YA in AK and beyond. The open-access digital website enhances the reach and engagement of MBAL, particularly among adolescents who may prefer to seek information and support online in a private, self-paced setting. By allowing youth to fill out this tool at their own pace and return to their home page as they want to reflect/change answers, they can update it as their lives change. Additionally, MBAL incorporates interactive elements (question types of open response, ranking, scales, drag/drop; journaling prompts \& space) and personalized features (ex. avatars of common AK animals designed by Y/YA), allowing users to tailor their life planning experience according to their individual needs and preferences and return to their answers.
214237801|NCT01830023|DEVICE|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
214237802|NCT06099145|DEVICE|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
214237803|NCT02296138|DRUG|olodaterol|fixed dose combination
214237804|NCT02296138|DRUG|tiotropium|fixed dose combination
214237805|NCT02296138|DRUG|tiotropium|
214237806|NCT02762851|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
214237807|NCT02762851|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
214237808|NCT00711516|DRUG|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
214237809|NCT00711516|DRUG|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
214237810|NCT03709732|OTHER|no intervention|observational study
214237811|NCT00224653|PROCEDURE|Mechanical Ventilation|
214237812|NCT05946434|OTHER|Kinesio Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
214237813|NCT05946434|OTHER|Rigid Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
214237814|NCT01322776|DRUG|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
214237815|NCT00177710|DRUG|Amphotericin B|
214237816|NCT00184769|DRUG|somatropin|
214237817|NCT02921061|DRUG|Cladribine|Given IV
214237818|NCT02921061|DRUG|Cytarabine|Given IV
214237819|NCT02921061|DRUG|Decitabine|Given IV
214237820|NCT02921061|BIOLOGICAL|Filgrastim|Given SC
214237821|NCT02921061|OTHER|Laboratory Biomarker Analysis|Correlative studies
214237822|NCT02921061|DRUG|Mitoxantrone Hydrochloride|Given IV
214237823|NCT01455129|DRUG|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
214237824|NCT01455129|DRUG|placebo|placebo, once daily, inhaled by HandiHaler
214237825|NCT02254239|DRUG|Brentuximab Vedotin|Given IV
214237826|NCT02254239|DRUG|Everolimus|Given PO
214237827|NCT02254239|OTHER|Laboratory Biomarker Analysis|Correlative studies
214237828|NCT02254239|OTHER|Pharmacological Study|Correlative studies
214237829|NCT01967368|DRUG|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
214237830|NCT01967368|DRUG|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
214237831|NCT01431209|OTHER|Laboratory Biomarker Analysis|Correlative studies
214237832|NCT01431209|DRUG|Ruxolitinib Phosphate|Given PO
214237833|NCT03758885|DRUG|Nolasiban|Nolasiban single oral administration
214237834|NCT03758885|DRUG|Placebo|Placebo single oral administration
214237835|NCT03315052|DRUG|Budesonide|Oral steroid with high first-pass metabolism in liver
214237836|NCT03315052|DRUG|Tacrolimus（FK506）|Calcineurin immunosuppressant
214237837|NCT03315052|DRUG|Mycophenolate Mofetil|Immunosupressant
214237838|NCT03315052|DRUG|Prednisone|Immunosuppresant
214237839|NCT01711385|BEHAVIORAL|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
214237840|NCT04482985|DRUG|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
214237841|NCT03631108|DIAGNOSTIC_TEST|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
214237842|NCT01029405|DRUG|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
214237843|NCT01029405|DRUG|Placebo|Ointment B Vehicle applied once or twice daily
214237844|NCT05592873|DRUG|Neoadjuvant chemoradiotherapy (CRT)|Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
214237845|NCT00409175|DRUG|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
214237846|NCT00409175|DRUG|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
214237847|NCT06112873|OTHER|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
214237848|NCT04809077|OTHER|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
214237849|NCT04918056|DIAGNOSTIC_TEST|Hematological Analysis and Genetical Analysis|"Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay."
214237850|NCT00703703|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
214237851|NCT00703703|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
214237852|NCT00703703|DRUG|Placebo|Placebo tablet once daily
214237853|NCT01307605|BIOLOGICAL|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
214237854|NCT01307605|DRUG|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
214237855|NCT00004382|DRUG|tin mesoporphyrin|
214237856|NCT00004382|PROCEDURE|Phototherapy|
214237857|NCT05058495|OTHER|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
214237858|NCT05058495|OTHER|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
214237859|NCT05858840|OTHER|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
214237860|NCT02596750|DEVICE|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
214237861|NCT02596750|DEVICE|Sham microneedle Roller|Flat roller without microneedles
214237862|NCT02108262|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
214237863|NCT02108262|BIOLOGICAL|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
214237864|NCT05030961|BEHAVIORAL|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
214237865|NCT05030961|BEHAVIORAL|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
214237866|NCT03375073|OTHER|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
214237867|NCT02643056|DRUG|Panitumumab|IV administration every 2 weeks
214237868|NCT05053542|PROCEDURE|Enema|Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
214237869|NCT04644367|OTHER|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
214237870|NCT04644367|OTHER|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
214237871|NCT00761150|DRUG|ABT-712|ABT-712 extended-release tablet
214237872|NCT00761150|DRUG|Placebo|Placebo tablet
214237873|NCT00479921|BIOLOGICAL|Trivalent influenza subunit vaccine|
214237874|NCT02424214|OTHER|Artificial Oocyte activation|
214237875|NCT02424214|DRUG|Ca Ionophore|
214237876|NCT02424214|DRUG|Strontium Chloride|
214237877|NCT02184351|DRUG|Roxanes's clotrimazole troches|
214237878|NCT02184351|DRUG|Mycelex® troches|
214237879|NCT02166372|OTHER|Observation of natural course of Diabetes Mellitus Type 2|
214237880|NCT01192243|DRUG|Gefitinib|250mg qd po d3-16
214237881|NCT01192243|DRUG|Pemetrexed|500mg/m2 venous infusion,D1,q3w
214237882|NCT01192243|DRUG|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
214237883|NCT04822584|DRUG|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
214237884|NCT04822584|DRUG|Placebo|Placebo once a day orally for 36 weeks
214237885|NCT00068133|GENETIC|Plasmid based Gene Transfer product-VLTS-589|
214237886|NCT05463198|DEVICE|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
214237887|NCT05457894|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
214237888|NCT05457894|BIOLOGICAL|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
214237889|NCT06150144|DRUG|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
214237890|NCT06150144|OTHER|SURGERY|Total excision of the lesion
214237891|NCT02385227|OTHER|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
214237892|NCT02385227|OTHER|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
214237893|NCT02385227|OTHER|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
214237894|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
214237895|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
214237896|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
214237897|NCT02385227|OTHER|Nicotine product cessation C|Nicotine cessation
214237898|NCT03304496|DRUG|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
214237899|NCT03304496|DRUG|Saline Solution|Previously described.
214237900|NCT03500185|OTHER|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
214237901|NCT03500185|OTHER|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
214237902|NCT05993975|DRUG|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
214237903|NCT05993975|DRUG|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
214237904|NCT04957433|DIAGNOSTIC_TEST|Blood Specimen|Blood and Sputum Specimen Samples
214237905|NCT01856764|DRUG|0.5% Roflumilast Cream|Roflumilast 0.5% cream
214237906|NCT01856764|DRUG|Vehicle Cream|Roflumilast formulation vehicle
214237907|NCT01254955|BIOLOGICAL|H1N1 vaccine Pandemrix|
214237908|NCT02724670|RADIATION|IGRT|MR-based IGRT
214237909|NCT03516903|DRUG|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
214237910|NCT03516903|DRUG|Placebo|Placebo-LDE (Lipid nanoemulsion)
214237911|NCT03516903|DRUG|Folic Acid|Folic acid pill
214237912|NCT00466687|BIOLOGICAL|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
214237913|NCT00466687|DRUG|erlotinib hydrochloride|150mg PO qd
214237914|NCT00466687|GENETIC|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
214237915|NCT00466687|GENETIC|gene expression analysis|gene expression analysis
214237916|NCT00466687|OTHER|immunologic technique|immunologic technique
214237917|NCT00466687|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214237918|NCT00466687|PROCEDURE|biopsy|biopsy
214237919|NCT01331018|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow harvest
214237920|NCT01331018|BIOLOGICAL|Filgrastim|Given SC
214237921|NCT01331018|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
214237922|NCT01331018|OTHER|Laboratory Biomarker Analysis|Correlative studies
214237923|NCT01331018|PROCEDURE|Leukapheresis|Undergo leukapheresis
214237924|NCT01331018|DRUG|Methylprednisolone|Given IV
214237925|NCT01331018|DRUG|Plerixafor|Given SC
214237926|NCT01331018|DRUG|Prednisone|Given PO
214237927|NCT02383225|BEHAVIORAL|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
214237928|NCT02383225|BEHAVIORAL|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
214237929|NCT02383225|BEHAVIORAL|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
214237930|NCT01594151|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
214237931|NCT01925989|BIOLOGICAL|LY2605541|Administered SQ
214237932|NCT01925989|BIOLOGICAL|Insulin Glargine|Administered SQ
214237933|NCT04025476|DRUG|Steroids|IV and oral steroids
214237934|NCT01992978|PROCEDURE|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
214237935|NCT01992978|PROCEDURE|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
214237936|NCT01680237|BEHAVIORAL|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
214237937|NCT01680237|BEHAVIORAL|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
214237938|NCT02842905|OTHER|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
214237939|NCT02842905|OTHER|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
214237940|NCT00238602|PROCEDURE|Stereotactic radiosurgery|
214237941|NCT03152006|OTHER|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
214237942|NCT01724619|DRUG|[F-18] fluorinated dihydrotestosterone (FDHT)|
214237943|NCT05719727|DIAGNOSTIC_TEST|colonoscopy|lower colonoscopy
214237944|NCT01489241|PROCEDURE|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
214237945|NCT00103350|DRUG|TG100-115|
214237946|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
214237947|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
214237948|NCT05719987|OTHER|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
214237949|NCT05719987|OTHER|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
214237950|NCT01535976|DRUG|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
214237951|NCT01535976|DRUG|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
214237952|NCT01235871|DRUG|SB1578|JAK2 Inhibitor
214237953|NCT01235871|DRUG|Placebo|Control arm
214237954|NCT01268371|DEVICE|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
214237955|NCT01268371|DEVICE|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
214237956|NCT01271790|DRUG|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
214237957|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
214237958|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
214237959|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
214237960|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg QD
214237961|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
214237962|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
214237963|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
214237964|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
214237965|NCT01271790|DRUG|GS-9451 placebo|placebo matching GS-9451 tablet QD
214237966|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
214237967|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
214237968|NCT03967691|DRUG|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
214237969|NCT03967691|DRUG|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
214237970|NCT06032897|OTHER|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
214237971|NCT00456664|GENETIC|IE gene|
214237972|NCT02034344|PROCEDURE|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
214237973|NCT02034344|PROCEDURE|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
214237974|NCT02034344|PROCEDURE|Urine collection|Urine will be collected from all participants.
214237975|NCT04964193|DRUG|Elzsa film-coated tablet|Administered with 240 mL of water
214237976|NCT04964193|DRUG|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
214237977|NCT00868517|OTHER|True group auricular acupuncture|Received true group auricular acupuncture
214237978|NCT00868517|OTHER|Sham group auricular acupuncture|Received sham auricular acupuncture.
214237979|NCT00868517|OTHER|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
214237980|NCT05331079|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
214237981|NCT05473585|OTHER|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
214237982|NCT05473585|OTHER|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
214237983|NCT05473585|OTHER|Study e-cigarette|E-cigarette provided by study
214237984|NCT05289401|OTHER|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
214237985|NCT04431089|DRUG|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
214818091|NCT01728181|DRUG|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
214818092|NCT01728181|DRUG|Erlotinib|150 mg/day for 28 day cycle. No rest period.
214237986|NCT03513081|BEHAVIORAL|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
214237987|NCT06228911|DRUG|steroid (triamcinolone)|triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
214237988|NCT04909476|PROCEDURE|Endotracheal intubation|Airways management in COVID 19 patients pneumonia
214237989|NCT01982968|PROCEDURE|Surgery|Full fundoplication surgery for the treatment of abnormal GER
214237990|NCT05834595|DRUG|CKD-828, D064, D701|QD, PO
214237991|NCT00259129|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
214237992|NCT01997385|PROCEDURE|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
214237993|NCT01997385|PROCEDURE|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
214237994|NCT03281993|OTHER|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
214237995|NCT04461041|DRUG|Empagliflozin|Single oral tablet
214237996|NCT04461041|DRUG|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
214237997|NCT04935645|BEHAVIORAL|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
214237998|NCT00828100|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
214237999|NCT00828100|DEVICE|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A \& B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
214238000|NCT05480345|DIAGNOSTIC_TEST|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
214238001|NCT05988502|OTHER|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
214238002|NCT04133922|DRUG|GLP-1|glucagon-like peptide 1
214238003|NCT04133922|DRUG|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
214238004|NCT04133922|DRUG|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
214238005|NCT00812643|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
214238006|NCT04924439|OTHER|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
214238007|NCT00100334|DRUG|PPI-1019 (APAN)|
214238008|NCT04725357|DRUG|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
214238009|NCT04725357|PROCEDURE|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
214238010|NCT04725357|PROCEDURE|arthroscopic labral repair|participant will have their standard surgical procedure done
214238011|NCT00219895|DRUG|Ibuprofen|
214238012|NCT01104532|DRUG|ASP1941|oral tablet
214238013|NCT01104532|DRUG|sitagliptin|oral tablet
214238014|NCT01447667|PROCEDURE|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
214238015|NCT00420641|DRUG|GSK372475|GSK372475 1.0-1.5 mg/day
214238016|NCT00420641|DRUG|Paroxetine|Paroxetine 20-30 mg/day
214238017|NCT00420641|OTHER|Placebo|Placebo to Match
214818093|NCT01728181|OTHER|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
214818094|NCT03878654|DRUG|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
214818095|NCT06872034|DRUG|Venostasin (horse chestnut seed extract tablets)|Venostasin (horse chestnut seed extract tablets) ，twice daily, 400 mg per dose, for 14 days
214818096|NCT06872034|OTHER|standard treatment|standard treatment
214818097|NCT02350647|DEVICE|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
214238018|NCT01117909|OTHER|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
214238019|NCT01117909|OTHER|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
214238020|NCT02219802|PROCEDURE|Treatment according arm|
214238021|NCT00004071|DRUG|leflunomide|
214238022|NCT00004071|DRUG|mitoxantrone hydrochloride|
214238023|NCT00004071|DRUG|prednisone|
214238024|NCT03920540|COMBINATION_PRODUCT|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
214238025|NCT03920540|COMBINATION_PRODUCT|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
214238026|NCT04249609|OTHER|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
214238027|NCT04249609|OTHER|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
214238028|NCT05787600|DRUG|Perhyal rinse|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
214238029|NCT05787600|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
214238030|NCT05787600|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
214238031|NCT05424432|DRUG|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
214238032|NCT05424432|DRUG|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
214238033|NCT05424432|RADIATION|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
214238034|NCT03723603|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
214238035|NCT03459690|BEHAVIORAL|Meditation|Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
214238036|NCT03459690|DEVICE|Enobio 32- EEG machine|This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
214238037|NCT05165498|PROCEDURE|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
214238038|NCT06044766|PROCEDURE|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
214238039|NCT02358317|BEHAVIORAL|Video Game Motor Training|
214238040|NCT02358317|BEHAVIORAL|Sedentary Video Game Training|
214238041|NCT00088036|DRUG|Olanzapine|
214238042|NCT05185206|DEVICE|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
214818098|NCT02350647|DEVICE|Suture anchor Twinfix Ultra HA|
214818099|NCT04739384|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
214818100|NCT04739384|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
214818101|NCT01504763|PROCEDURE|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
214818102|NCT04456881|OTHER|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
214238043|NCT05185206|DEVICE|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
214238044|NCT01147133|DRUG|Plavix|1x75 mg
214238045|NCT01147133|DRUG|Kardogrel|1x75 mg
214238046|NCT04106024|DRUG|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
214238047|NCT00046800|DRUG|OSI-211 (Liposomal Lurtotecan)|
214238048|NCT05449015|DRUG|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
214238049|NCT06328478|DEVICE|Observational prospective study.|Observational prospective study
214238050|NCT02586506|DRUG|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
214238051|NCT02586506|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
214238052|NCT04391985|DRUG|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
214238053|NCT01604356|PROCEDURE|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
214238054|NCT06092229|DIAGNOSTIC_TEST|Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
214238055|NCT06092229|DIAGNOSTIC_TEST|Ultrasonography with TACA approach|identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
214238056|NCT02284425|DRUG|REGN1193|
214238057|NCT02284425|DRUG|Placebo|
214238058|NCT02247648|DRUG|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
214238059|NCT02247648|DRUG|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
214238060|NCT03796845|OTHER|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
214238061|NCT03956719|DRUG|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
214238062|NCT03956719|PROCEDURE|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
214238063|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
214238064|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
214238065|NCT00684047|PROCEDURE|Manual Compression|Manual Compression. Primary Part (II)
214238066|NCT00316108|DEVICE|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
214238067|NCT05244980|DRUG|TDM-105795|TDM-105795 topical solution
214238068|NCT05244980|DRUG|Placebo|Placebo for TDM-105795 topical solution
214652134|NCT06915935|RADIATION|dualenergy X-ray absorptiometry|Dual-energy X-ray Absorptiometry (DXA) is an accurate, safe, and rapid bone mineral density measurement method that is widely used in the diagnosis of osteoporosis and the assessment of fracture risk. The principle is based on the difference in absorption of different energy X-rays in bone and soft tissue, and bone mineral content (BMC) and bone mineral density (BMD) are obtained through mathematical calculations. DXA is commonly used to measure bone mineral density in the lumbar spine, femoral neck, and forearm, and to assess the degree of osteoporosis using a T score, where T ≤ -2.5 is defined as osteoporosis. Due to the advantages of high precision, low radiation dose and convenient operation, DXA is considered as the gold standard for clinical bone mineral density detection.
214238069|NCT06492499|PROCEDURE|Zero-Fluoroscopy Radiofrequency Catheter Ablation|Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
214238070|NCT04734678|DRUG|Tocilizumab|400 mg IV only once
214238071|NCT04734678|DRUG|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
214238072|NCT04865926|OTHER|Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises|The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
214652135|NCT06917118|DRUG|Oxycodone 5mg taken first|10 pills of 5mg oxycodone Q4hrs as needed
214238073|NCT04865926|OTHER|McKenzie and Kendall exercises|Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
214238074|NCT05484687|DRUG|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
214238075|NCT04571983|OTHER|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
214238076|NCT01367080|DRUG|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
214238077|NCT01367080|DRUG|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
214238078|NCT02815280|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
214238079|NCT02815280|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
214238080|NCT04315584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT Scans
214238081|NCT04315584|PROCEDURE|Computed Tomography|Undergo PET/CT Scans
214238082|NCT04315584|PROCEDURE|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
214238083|NCT04315584|RADIATION|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
214238084|NCT04315584|RADIATION|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
214238085|NCT04495699|OTHER|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
214238086|NCT02009605|DRUG|Icotinib|125mg, oral administration, three times per day.
214238087|NCT00448396|DRUG|Patupilone|
214238088|NCT02257762|DIETARY_SUPPLEMENT|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
214238089|NCT02257762|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
214238090|NCT02257762|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet.
214238091|NCT03127982|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
214238092|NCT05466487|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
214238093|NCT05466487|BEHAVIORAL|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
214238094|NCT03965273|BEHAVIORAL|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
214238095|NCT03965273|BEHAVIORAL|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
214238096|NCT00603642|DRUG|Placebo|Subcutaneously administered, once a week, for 12 weeks
214238097|NCT00603642|DRUG|AMG 531|Subcutaneously administered, once a week, for 12 weeks
214238098|NCT02571738|BIOLOGICAL|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
214238099|NCT02571738|OTHER|Control|Standard of Care
214238100|NCT01514162|DEVICE|Trifecta valve|surgical replacement of aortic valve
214238101|NCT02394197|DRUG|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
214238102|NCT02394197|DRUG|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
214238103|NCT00040846|BIOLOGICAL|alemtuzumab|Given IV
214238104|NCT00040846|DRUG|fludarabine phosphate|Given IV
214238105|NCT00040846|RADIATION|total-body irradiation|Undergo TBI
214238106|NCT00040846|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
214238107|NCT00040846|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214238108|NCT00040846|DRUG|mycophenolate mofetil|Given PO
214238109|NCT00040846|DRUG|cyclosporine|Given IV or PO
214238110|NCT02483871|DRUG|Rosuvastatin|
214238111|NCT05036473|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
214238112|NCT05036473|DRUG|Placebo|placebo tablets-matching the active groups.
214238113|NCT00680719|BEHAVIORAL|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
214238114|NCT00680719|BEHAVIORAL|IBFT|Integrated Behavioral and Family Therapy (IBFT).
214238115|NCT02836509|DRUG|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
214238116|NCT02836509|DRUG|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
214238117|NCT05459090|OTHER|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
214238118|NCT05361902|RADIATION|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
214238119|NCT00654147|DRUG|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
214238120|NCT00654147|DRUG|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
214238121|NCT03513445|DRUG|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
214238122|NCT03513445|DRUG|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
214238123|NCT03513445|DRUG|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
214238124|NCT01230177|DRUG|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
214238125|NCT02538783|BEHAVIORAL|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
214238126|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
214238127|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
214238128|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
214238129|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
214238130|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
214238131|NCT05440773|OTHER|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
214238132|NCT05440773|OTHER|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
214238133|NCT05440773|OTHER|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
214238134|NCT02194257|DRUG|[14C]-cyclohexane ambroxol oral solution|
214238135|NCT02194257|DRUG|[14C]-benzyl ambroxol oral solution|
214238136|NCT02194257|DRUG|Ambroxol lozenge|
214238137|NCT02647450|OTHER|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
214238138|NCT04272879|OTHER|Observational Group|Those requiring NIV following an acute exacerbation of COPD
214238139|NCT01534182|DRUG|Fingolimod|0.5 mg orally once a day
214238140|NCT01534182|DRUG|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
214238141|NCT01534182|DRUG|Glatiramer acetate (GA)|20 mg subcutaneously once a day
214238142|NCT05981976|BIOLOGICAL|Abatacept|Specified dose on specified days
214238143|NCT04293627|BEHAVIORAL|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
214238144|NCT05873127|BEHAVIORAL|web-based guided self-help Enhanced Cognitive Behavioral therapy|The subjects would learn and practice CBT-E course through the online learning platform for 12 times, and were required to complete the course once a week.
214238145|NCT05873127|BEHAVIORAL|online Enhanced Cognitive Behavioral therapy|A closed structured group would be established by online video conference for group CBT-E therapy. Each group would receive 12 group sessions, once a week for 120 minutes each time. Each group would be led by two CBT therapists, all of whom are nationally registered psychotherapists with systematic professional training.
214238146|NCT05959980|PROCEDURE|Posterior cervical fixation surgery|These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
214238147|NCT03460743|BIOLOGICAL|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
214652136|NCT06917118|DRUG|Acetaminophen|30 pills of 500mg acetaminophen Q4hrs
214652137|NCT06917118|DRUG|Naproxen Tablets, 500 mg|30 pills of 500mg naproxen Q4hrs
214652138|NCT06917118|DRUG|OxyCODONE 5 mg Oral Tablet|Only used for breakthrough pain
214238148|NCT03460743|BIOLOGICAL|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
214238149|NCT02489916|DRUG|CM4307|CM4307 300mg bid, each 4 week cycle
214238150|NCT01592656|RADIATION|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
214238151|NCT01592656|OTHER|Lung compliance measurement|At baseline
214238152|NCT01592656|DEVICE|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
214238153|NCT01944839|DRUG|E10030|
214238154|NCT01944839|DRUG|ranibizumab|
214238155|NCT01944839|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
214238156|NCT03425422|DEVICE|VITARIA System|Chronic stimulation of the right cervical vagus nerve
214238157|NCT05810818|DIAGNOSTIC_TEST|Dry Needling|Dry needling treatment will be consisting of two treatments per week
214238158|NCT05810818|DIAGNOSTIC_TEST|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
214238159|NCT04637828|DRUG|GNS561|study drug
214238160|NCT01178827|DRUG|trospium chloride|trospium chloride (60mg) once daily for 10 days
214238161|NCT01178827|DRUG|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
214238162|NCT01178827|DRUG|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
214238163|NCT05384704|BEHAVIORAL|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
214238164|NCT00251160|PROCEDURE|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
214238165|NCT00251160|PROCEDURE|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
214238166|NCT05093790|DRUG|Ticagrelor|Specified dose on specified days
214238167|NCT05093790|DRUG|BMS-986141|Specified dose on specified days
214238168|NCT05093790|DRUG|Aspirin|Specified dose on specified days
214238169|NCT02427269|OTHER|Specimen Collection|"* 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~* Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~* Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~* Two biopsies from normal squamous epithelium, and~* One biopsy from each area of esophageal nodularity seen during the procedure~* Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~* Up to 4 cytology brushes during the procedure."
214238170|NCT03889301|BEHAVIORAL|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
214238171|NCT03889301|BEHAVIORAL|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
214238172|NCT02250833|DRUG|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
214238173|NCT02250833|DRUG|Telmisartan|\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
214238174|NCT02250833|DRUG|S-amlodipine|\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
214238175|NCT01687647|OTHER|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
214238176|NCT00924170|DRUG|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
214238177|NCT00924170|DRUG|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day"
214238178|NCT00924170|DRUG|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day"
214238179|NCT00579436|DRUG|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
214652139|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
214652140|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
214652141|NCT06916273|DRUG|PA9159 Inhalation aerosol, 60 μg one day treatment|single dose of PA9159 (60 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 2 puffs.
214238180|NCT00579436|DRUG|placebo|4 inert capsules daily by mouth for 12 weeks.
214238181|NCT04449029|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
214238182|NCT04449029|DRUG|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
214238183|NCT04449029|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
214238184|NCT02312882|DRUG|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
214238185|NCT04529187|DRUG|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
214238186|NCT04529187|DRUG|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
214238187|NCT02550977|DRUG|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
214238188|NCT03934697|BEHAVIORAL|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
214238189|NCT02025556|DRUG|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
214238190|NCT02025556|DRUG|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
214238191|NCT02025556|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
214652142|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg one day treatment|single dose of PA9159 (120 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 4 puffs.
214238192|NCT03585127|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
214238193|NCT03585127|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
214238194|NCT00396448|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
214238195|NCT00396448|DRUG|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
214238196|NCT00396448|DRUG|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
214238197|NCT03681288|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion Intervention
214238198|NCT02985424|OTHER|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
214652143|NCT06916273|DRUG|PA9159 Inhalation aerosol, 240 μg one day treatment|single dose of PA9159 (240 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 8 puffs.
214818103|NCT04482465|DIAGNOSTIC_TEST|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
214238199|NCT02040636|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
214238200|NCT02040636|BIOLOGICAL|Hepatitis B vaccine|0.5 ml, Intramuscular
214238201|NCT00627445|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
214238202|NCT00627445|DRUG|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
214238203|NCT00627445|DRUG|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
214238204|NCT06472167|BEHAVIORAL|Breathing exercises|Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
214238205|NCT04098224|DEVICE|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
214238206|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
214238207|NCT05881239|DEVICE|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
214238208|NCT06326476|DRUG|Siplizumab|40 mg doses
214238209|NCT02217527|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
214238210|NCT02217527|DRUG|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
214652144|NCT06916273|DRUG|PA9159 Inhalation aerosol, 300 μg one day treatment|single dose of PA9159 (300 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 10 puffs.
214652145|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg 7-day treatment|Repeated doses of PA9159 (120 μg/inhaler spray) i is administered by inhalation through an inhaler via the mouth, with 4 puffs, twice a day.
214652146|NCT06916273|DRUG|Placebo, the same Inhalation aerosol solution without PA9159 active ingredient|Placebo is delivered via the mouth through an inhaler with the same volume as the corresponding PA9159 dose group
214818104|NCT00000541|BEHAVIORAL|dietary supplements|
214818105|NCT00000541|DRUG|vitamin C|
214818106|NCT00000541|DRUG|vitamin E|
214818107|NCT00000541|DRUG|beta-carotene|
214818108|NCT00000541|DRUG|folic acid/Vitamin B6/Vitamin B12|
214238211|NCT05478629|OTHER|Survey|Questioning through google forms
214238212|NCT01203852|DRUG|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
214238213|NCT01203852|DRUG|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
214238214|NCT02756988|DRUG|Coppertone (BAY987704)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
214238215|NCT02811276|OTHER|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
214238216|NCT01251640|DRUG|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
214238217|NCT02536183|DEVICE|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
214238218|NCT02536183|DRUG|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
214238219|NCT03567317|DEVICE|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
214238220|NCT01433276|DRUG|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
214238221|NCT01433276|DRUG|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
214238222|NCT06349005|OTHER|Tracheal intubation using Storz VL|Video-assisted intubation technique using Storz VL
214238223|NCT06349005|OTHER|Tracheal intubation using Macintosh laryngoscopy|Traditional intubation technique using Macintosh laryngoscopy
214238224|NCT06349005|OTHER|Tracheal intubation using MacGrath VL|Video-assisted intubation technique using MacGrath VL
214238225|NCT06349005|OTHER|Tracheal intubation using EzVision VL|Video-assisted intubation technique using EzVision VL
214238226|NCT02982603|DRUG|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
214238227|NCT02982603|DRUG|Ginkgo Biloba Extract 761|Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
214238228|NCT02982603|DRUG|Placebos|Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
214238229|NCT03133065|DRUG|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
214238230|NCT00081861|DRUG|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
214238231|NCT00081861|DRUG|Rituximab|375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
214238232|NCT00247611|BEHAVIORAL|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
214238233|NCT00247611|OTHER|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
214238234|NCT06577220|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
214818109|NCT00731783|DRUG|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
214238235|NCT06577220|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
214238236|NCT06577220|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
214818110|NCT00731783|DRUG|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
214818111|NCT00731783|BEHAVIORAL|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
214238237|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
214238238|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
214238239|NCT03182543|DIETARY_SUPPLEMENT|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
214238240|NCT05051930|DRUG|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
214238241|NCT05051930|DRUG|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
214238242|NCT04308889|DRUG|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
214238243|NCT04308889|OTHER|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
214238244|NCT04308889|OTHER|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
214238245|NCT04161638|BEHAVIORAL|Stigma Video Exposure|The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
214238246|NCT04161638|BEHAVIORAL|Neutral video exposure|The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
214238247|NCT05182112|RADIATION|Whole liver irradiation (WLI)|Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
214238248|NCT05182112|DRUG|Gemcitabine and Cisplatin|Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
214238249|NCT01964196|DRUG|ASP1517|Oral administration
214238250|NCT01964196|DRUG|Placebo|Oral
214238251|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
214238252|NCT05161780|DRUG|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
214238253|NCT05161780|DRUG|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
214238254|NCT00127465|PROCEDURE|Issue of information booklet|
214238255|NCT01587898|DRUG|GSK1278863|Tablet
214238256|NCT01587898|OTHER|Placebo|Tablet
214238257|NCT00502203|DRUG|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
214818112|NCT06248827|OTHER|Data Collection|Patient data : gender, age, height, weight, daily life (type of job) Diagnostic data : Description of first symptoms/medical history (pain), previous medical history, MRI exams
214238258|NCT00502203|DRUG|Paclitaxel|175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
214238259|NCT05570461|OTHER|Modified Constraint-Induced Movement Therapy|Experimental group will receive Modified Constraint-Induced Movement Therapyand traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the mCIMT group will be constrained by wearing a mitten during the treatment session and for 3 hours/day outside the therapy hours, 6(six) days/week for two weeks by an experienced Physical therapist.The time duration for Group A will be 40 minutes.
214238260|NCT02578368|DRUG|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
214818113|NCT01591603|PROCEDURE|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
214238261|NCT02578368|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
214238262|NCT02578368|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
214238263|NCT02578368|DRUG|Docetaxel|50mg/m², d1, i.v., every 2 weeks
214238264|NCT02578368|DRUG|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
214238265|NCT02578368|DRUG|sodium folinate|can be used to replace leucovorin (calcium folinate)
214238266|NCT02578368|PROCEDURE|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
214238267|NCT02871037|DRUG|PF-05221304|Single or repeated, escalating dose of PF-05221304
214238268|NCT02871037|OTHER|Placebo|single or repeated dose of placebo
214238269|NCT00489125|OTHER|physiologic testing|physical testing of range of motion, grip strength etc.
214238270|NCT03364829|DRUG|Indacaterol/Glycopyrronium|
214238271|NCT03157570|BEHAVIORAL|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
214238272|NCT05212857|DRUG|Leuprolide acetate|Given subcutaneously or as an injection
214238273|NCT05212857|DRUG|Goserelin acetate|Given subcutaneously or as an injection
214238274|NCT05212857|DRUG|Triptorelin acetate|Given subcutaneously or as an injection
214238275|NCT05212857|DRUG|Degarelix acetate|Given subcutaneously or as an injection
214238276|NCT05212857|DRUG|Abiraterone acetate|Given orally
214238277|NCT05212857|DRUG|Apalutamide|Given orally
214238278|NCT05212857|DRUG|Enzalutamide|Given orally
214238279|NCT05212857|PROCEDURE|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
214238280|NCT05212857|RADIATION|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
214238281|NCT05212857|RADIATION|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
214238282|NCT05908643|DRUG|pTTL|pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
214238283|NCT05365945|OTHER|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
214238284|NCT05365945|OTHER|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
214238285|NCT02796417|BEHAVIORAL|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
214238286|NCT02796417|BEHAVIORAL|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
214818114|NCT01591603|PROCEDURE|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
214818115|NCT01633645|DRUG|Bortezomib|Velcade
214818116|NCT01633645|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
214238287|NCT03608150|DEVICE|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
214238288|NCT03608150|DEVICE|Refractive Correction|Standard of care refractive correction (ex. spectacles)
214238289|NCT01190735|DRUG|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
214238290|NCT02595632|OTHER|No intervention|
214238291|NCT01829243|DRUG|Milnacipran|
214238292|NCT01829243|DRUG|Placebo|
214238293|NCT01439815|DRUG|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
214238294|NCT01439815|DRUG|Saline Nasal Spray|two sprays in each nostril once daily
214238295|NCT03160313|BEHAVIORAL|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
214238296|NCT03160313|BEHAVIORAL|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
214238297|NCT02846220|BEHAVIORAL|Overcoming Immunity to Change health coaching|
214238298|NCT05616481|PROCEDURE|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
214238299|NCT05616481|PROCEDURE|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
214238300|NCT00553722|DRUG|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
214238301|NCT00553722|DRUG|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
214238302|NCT03460509|DRUG|Sugammadex|Dose-response
214238303|NCT03753581|DEVICE|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
214238304|NCT03753581|DEVICE|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
214238305|NCT00075192|DRUG|CP-675,206 and leuprolide acetate and bicalutamide|
214238306|NCT00075192|DRUG|leuprolide acetate and bicalutamide|
214238307|NCT04363190|DIAGNOSTIC_TEST|Cytogenetic analysis|"1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
214238308|NCT01484288|DEVICE|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
214238309|NCT03610529|DEVICE|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
214238310|NCT03610529|DEVICE|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
214238311|NCT02337231|DIETARY_SUPPLEMENT|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
214238312|NCT06449274|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
214238313|NCT06449274|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
214238314|NCT04564638|DRUG|Corticosteroid|
214238315|NCT06133712|DRUG|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
214238316|NCT06133712|DRUG|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/ml) plus to 1 ml lidocaine (1%) using a 25 G needle.
214238317|NCT06133712|DRUG|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
214238318|NCT04377347|OTHER|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
214238319|NCT01331421|DRUG|exemestane|25 mg tablet
214238320|NCT05401396|OTHER|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
214238321|NCT05787990|DIAGNOSTIC_TEST|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
214238322|NCT02829944|DRUG|Ropivacaine|
214238323|NCT02829944|DRUG|Ketorolac|
214238324|NCT02829944|DRUG|Placebo|
214818117|NCT01633645|DRUG|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
214238325|NCT05053451|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.
214238326|NCT06613893|DRUG|TIVA|Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
214238327|NCT06613893|DRUG|Inhalational anesthesia|Anesthesia will be maintained with inhaled isoflurane, Iso-MAC from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
214238328|NCT00417456|OTHER|Evisit|Asynchronous,remote care delivery via a secure web platform
214238329|NCT00417456|OTHER|Office visit|Conventional office-based care
214238330|NCT03816670|DRUG|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
214238331|NCT00806871|DRUG|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
214238332|NCT00806871|DRUG|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
214238333|NCT00806871|DRUG|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
214238334|NCT03828773|DRUG|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
214238335|NCT03828773|DRUG|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
214238336|NCT05844709|OTHER|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
214238337|NCT05841901|DRUG|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
214238338|NCT05841901|DRUG|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
214238339|NCT00336583|DRUG|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
214238340|NCT05553067|GENETIC|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
214238341|NCT05588557|DRUG|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
214238342|NCT05588557|DRUG|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
214238343|NCT06504693|DIAGNOSTIC_TEST|CBC|diagnostic tests for iron status
214238344|NCT00129012|PROCEDURE|Tomotherapy|
214238345|NCT00399672|DRUG|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
214238346|NCT00399672|DRUG|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
214238347|NCT02439528|GENETIC|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
214238348|NCT03039621|DRUG|Ergoferon|For oral use.
214238349|NCT03039621|DRUG|Placebo|For oral use.
214238350|NCT02099669|OTHER|Red Blood Cell Transfusions|
214238351|NCT03106766|DRUG|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
214238352|NCT03106766|DRUG|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
214238353|NCT02048982|BEHAVIORAL|Guideline|Physicians will receive information on the Choosing Wisely Guideline
214238354|NCT02048982|BEHAVIORAL|Cost|Physicians will receive cost information.
214238355|NCT02048982|BEHAVIORAL|Victim|Physicians will receive information on an identifiable victim.
214238356|NCT02368301|DRUG|Elotuzumab in combination with Lenalidomide and Dexamethasone|Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
214238357|NCT06273371|OTHER|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
214238358|NCT00400608|DRUG|ADVAIR HFA|
214238359|NCT00400608|DRUG|ADVAIR DISKUS|
214238360|NCT03726567|PROCEDURE|Bariatric surgery|Roux-en-Y surgery
214238361|NCT00636701|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
214238362|NCT04867031|DIETARY_SUPPLEMENT|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.
214238363|NCT04867031|DIETARY_SUPPLEMENT|Fish|One portion of cod (approx. 130g), providing \~140µg of iodine.
214238364|NCT04867031|DIETARY_SUPPLEMENT|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
214238365|NCT00814333|DRUG|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
214238366|NCT00814333|DRUG|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
214238367|NCT03127800|DRUG|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
214238368|NCT05148520|BEHAVIORAL|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~\- arrange for follow-up."
214818118|NCT05293145|OTHER|Building Futures Program Primary Services|Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
214238369|NCT04048811|DRUG|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
214238370|NCT04048811|DRUG|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
214238371|NCT04048811|DRUG|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
214238372|NCT00894374|DRUG|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
214238373|NCT00894374|DRUG|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
214238374|NCT02927067|DRUG|Maribavir|Participants will receive 400 mg of maribavir BID orally.
214238375|NCT02927067|DRUG|Valganciclovir|Participants will receive valganciclovir tablets orally.
214238376|NCT02927067|OTHER|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
214238377|NCT04581447|DRUG|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
214238378|NCT04581447|OTHER|Standard Care|Standard Care
214238379|NCT04581447|DIETARY_SUPPLEMENT|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
214238380|NCT03540498|DIETARY_SUPPLEMENT|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
214238381|NCT03540498|DIETARY_SUPPLEMENT|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
214238382|NCT02716896|RADIATION|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
214238383|NCT02716896|PROCEDURE|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
214238384|NCT01727700|DRUG|Aripiprazole|Once-daily, tablet
214238385|NCT01727700|DRUG|Placebo|
214238386|NCT00320723|DRUG|bupropion, transdermal nicotine patch|
214238387|NCT01780532|PROCEDURE|Photoacoustic Imaging (PAI)|Standard of Care
214238388|NCT04551391|OTHER|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
214238389|NCT00212940|BEHAVIORAL|Supportive Therapy for Adherence to ART (behavior)|
214238390|NCT02086279|DRUG|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
214238391|NCT01284049|DRUG|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
214238392|NCT01284049|DRUG|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
214238393|NCT02561910|DEVICE|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
214238394|NCT02403687|DRUG|baclofen 2%|compound topical cream
214238395|NCT02403687|DRUG|Bupivacaine hydrochloride 1%|compound topical cream
214238396|NCT02403687|DRUG|Cyclobenzaprine hydrochloride 2%|compound topical cream
214238397|NCT02403687|DRUG|Diclofenac Sodium 3%|compound topical cream
214238398|NCT02403687|DRUG|Flurbiprofen 10%|compound topical cream
214238399|NCT02403687|DRUG|Gabapentin 6%|compound topical cream
214238400|NCT02403687|DRUG|Ketamine 10%|compound topical cream
214238401|NCT02403687|DRUG|Lidocaine 2%|compound topical cream
214238402|NCT02403687|DRUG|Prilocaine 2.5%|compound topical cream
214238403|NCT02403687|DRUG|Meloxicam 0.09%|compound topical cream
214238404|NCT02403687|DRUG|Sumatriptan 5%|compound topical cream
214238405|NCT02403687|DRUG|Tizanidine 0.1%|compound topical cream
214238406|NCT02403687|DRUG|Topiramate 2.5%|compound topical cream
214238407|NCT02403687|DRUG|Capsaicin, USP 0.0375%|compound topical cream
214238408|NCT02403687|DRUG|Menthol, NF 5.00 %|compound topical cream
214238409|NCT00925171|BEHAVIORAL|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
214238410|NCT04178083|DIAGNOSTIC_TEST|medical examination|medical examination
214238411|NCT01066442|DRUG|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
214238412|NCT00583479|OTHER|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
214238413|NCT00583479|OTHER|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
214238414|NCT05135312|DRUG|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
214238415|NCT05135312|DEVICE|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
214238416|NCT05869084|DIAGNOSTIC_TEST|pulmonary function tests|pulmonary function tests
214238417|NCT04216914|DEVICE|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
214238418|NCT02599675|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
214238419|NCT02599675|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
214238420|NCT03762538|DRUG|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
214238421|NCT04344288|DRUG|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
214238422|NCT04344288|OTHER|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
214238423|NCT05588804|DRUG|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
214238424|NCT05588804|DRUG|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
214238425|NCT05771168|DEVICE|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
214238426|NCT05771168|DEVICE|Male sling|Retrourethral implantation of male sling
214238427|NCT05198778|DRUG|URC102|tablet
214238428|NCT05198778|DRUG|URC102|tablet
214238429|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
214238430|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
214238431|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
214238432|NCT04890743|OTHER|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
214238433|NCT02651181|DEVICE|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
214238434|NCT02355873|DEVICE|AN69ST hemofilter|
214238435|NCT02355873|DEVICE|AN69 hemofilter|
214238436|NCT03639532|PROCEDURE|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
214238437|NCT03639532|PROCEDURE|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
214238438|NCT06482918|BEHAVIORAL|Cognitive Remediation|Computer-assisted top-down or bottom-up cognitive remediation using tablets
214238439|NCT01680510|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|
214238440|NCT01680510|OTHER|Placebo (starch)|
214238441|NCT02234856|PROCEDURE|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
214238442|NCT01887301|DRUG|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
214238443|NCT01369654|BEHAVIORAL|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
214238444|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
214238445|NCT01678937|PROCEDURE|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
214238446|NCT01678937|PROCEDURE|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
214238447|NCT01678937|PROCEDURE|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
214238448|NCT01678937|PROCEDURE|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
214652147|NCT06917729|OTHER|CardioBreath|Twice a day for ten minutes,5 days during the week CardioBreath app will be based on Prescription section , using breathing technique Ujjayi Pranayama, based on spontaneous respiratory rate of users, gamified to induce the user to improve performance of the exercises reducing the exercises respiratory exercises
214652148|NCT06916234|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
214652149|NCT06916234|DRUG|Naproxen Sodium + Codeine Phosphate|Naproxen Sodium + Codeine Phosphate (550mg + 30mg) is a NSAID. It was given to the patients twice a day.
214652150|NCT06911359|DRUG|Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given a placebo when they receive their dextrose prolotherapy (DPT) injection
214652151|NCT06911359|DRUG|Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given Ibuprofen when they receive their dextrose prolotherapy (DPT) injection
214238449|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
214238450|NCT02935374|DRUG|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
214238451|NCT02935374|DRUG|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
214238452|NCT02935374|DRUG|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
214238453|NCT00479895|DRUG|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
214238454|NCT06280846|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The patients will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
214238455|NCT06280846|DEVICE|low-intensity laser acupuncture and Exercise therapy program|"The patients will receive low-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
214238456|NCT06280846|DEVICE|Sham laser acupuncture|Sham laser acupuncture and exercise therapy program. The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of: - strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises
214238457|NCT03293511|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
214238458|NCT03293511|DRUG|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
214238459|NCT00398489|BIOLOGICAL|trastuzumab|
214238460|NCT00398489|DRUG|anastrozole|
214238461|NCT00398489|DRUG|cyclophosphamide|
214238462|NCT00398489|DRUG|docetaxel|
214238463|NCT00398489|DRUG|epirubicin hydrochloride|
214238464|NCT00398489|DRUG|goserelin acetate|
214238465|NCT00398489|DRUG|tamoxifen citrate|
214238466|NCT00398489|PROCEDURE|adjuvant therapy|
214238467|NCT00398489|PROCEDURE|conventional surgery|
214238468|NCT00398489|PROCEDURE|neoadjuvant therapy|
214238469|NCT00398489|RADIATION|radiation therapy|
214238470|NCT03998813|DRUG|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
214238471|NCT03998813|DRUG|Ropivacaine|Tissue infiltration
214238472|NCT02824172|OTHER|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
214652152|NCT06916949|DIAGNOSTIC_TEST|Electrocardiogram|two leads ECG
214652153|NCT06916949|DIAGNOSTIC_TEST|Pupillometry|During the simulation, automatic pupillometry will be performed on all team members at the following time points: Baseline (T0) During the simulation (T1) End of the simulation (T2) End of the debriefing (T3)
214652154|NCT06916949|DIAGNOSTIC_TEST|Electroencephalogram|EEG monitoring throughout the entire simulation. The EEG recordings will be sampled at: Baseline (T0) During the simulation (T1) End of the debriefing (T2)
214652155|NCT06917443|OTHER|Abdominally targeted exercises|The interventional exercise regimen will include specific abdominally targeted exercises postulated to increase blood flow to the intestine and decrease inflammation.
214652156|NCT06917443|OTHER|General exercises|Generally recommended exercises, without particular attention to the abdomen
214652157|NCT06916351|OTHER|Acupressure|Acupressure will be applied to a total of three points: the 4th point of the Large Intestine Meridian (LI4-Hegu point) and the 6th point of the pericardial meridian (PC6- Nei Guan point), located three fingers above the wrist.
214652158|NCT06916351|OTHER|Sham acupressure|Sham acupressure will be applied to three points parallel to HT7, LI4 and PC6, approximately 1-1.5 cm away from the meridians.
214818119|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
214238473|NCT02824172|OTHER|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
214238474|NCT06786325|DRUG|Psilocybin|PEX010 is the Psilocybin produced by Filament
214238475|NCT06415513|OTHER|ASMR|We used 7 ASMR videos published on the most watched ASMR channel on the YouTube platform, in which applications such as hair combing, brushing, massaging the head are applied sequentially and repeatedly, and there is no speech.
214238476|NCT00246415|DRUG|Memantine|
214238477|NCT03109314|DRUG|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
214238478|NCT03109314|BEHAVIORAL|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
214238479|NCT03109314|BEHAVIORAL|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
214238480|NCT06210126|OTHER|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
214238481|NCT06210126|OTHER|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
214238482|NCT04663841|OTHER|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
214238483|NCT02122601|DRUG|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
214238484|NCT02519855|BIOLOGICAL|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
214238485|NCT02519855|BIOLOGICAL|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
214238486|NCT02519855|BIOLOGICAL|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
214238487|NCT03034291|DIETARY_SUPPLEMENT|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
214238488|NCT03034291|DIETARY_SUPPLEMENT|White chocolate|
214238489|NCT00008255|DRUG|INS316|
214238490|NCT00008255|OTHER|sputum cytology|
214238491|NCT05718999|DIAGNOSTIC_TEST|Not intervention|Not having intervention is an observational study
214652159|NCT06916663|BEHAVIORAL|Upper Body Exercise Protocol (UBE)|"Participants randomized to the Upper Body Exercise Group will perform a structured, supervised exercise regimen focused exclusively on the upper extremities and core muscles, while rigorously maintaining foot offloading prescribed for diabetic foot ulcers (DFU). This intervention is delivered face-to-face in hospital-based outpatient rehabilitation centers. Sessions are held three times per week for 12 consecutive weeks (total 36 sessions), with each session lasting 45-60 minutes.~Each UBE session comprises a 10-minute warm-up on an arm ergometer at 40-50% of the participant's heart rate reserve (HRR), followed by a circuit of eight upper body and core exercises."
214652160|NCT06916663|BEHAVIORAL|Combined Non-Weight Bearing Exercise Protocol (CE)|"Participants in the Combined Exercise Group will engage in a structured exercise regimen that integrates upper body, core, and modified lower extremity exercises-all performed in a non-weight bearing or seated position to ensure complete offloading of the affected foot. Sessions are conducted face-to-face in hospital-based rehabilitation centers. Participants attend three sessions per week for 12 weeks (36 sessions total), each lasting 45-60 minutes.~Each session begins with a 10-minute warm-up on an arm ergometer at 40-50% HRR."
214818120|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
214818121|NCT05090215|BEHAVIORAL|Aerobic and resistance training 12 week exercise programme|See arm/group description
214818122|NCT05090215|DIAGNOSTIC_TEST|Venous blood sampling|full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
214818123|NCT05090215|DIAGNOSTIC_TEST|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
214238492|NCT06114459|DRUG|Sodium Chloride|Post surgery disinfection
214238493|NCT06458335|BEHAVIORAL|Cognitive-Behavioral Therapy for Perceived Social Isolation|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use
214238494|NCT06458335|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a health lifestyle
214238495|NCT04378452|BEHAVIORAL|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
214238496|NCT05577455|DRUG|Medical prescription before ovulation|Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
214238497|NCT05577455|DRUG|Medical prescription after ovulation|Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
214238498|NCT03140696|DIETARY_SUPPLEMENT|Egg Alone|A chicken egg will be offered for 2 days
214238499|NCT03140696|DIETARY_SUPPLEMENT|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
214238500|NCT03140696|DIETARY_SUPPLEMENT|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
214238501|NCT02027805|BIOLOGICAL|T-Guard|
214238502|NCT03061747|DEVICE|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
214238503|NCT03930563|DIETARY_SUPPLEMENT|Pre-beetroot juice supplementation|Before administering beetroot juice to subjects.
214238504|NCT03930563|DIETARY_SUPPLEMENT|Post-beetroot juice supplementation|After administering beetroot juice to subjects.
214238505|NCT02480036|RADIATION|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
214238506|NCT02480036|DEVICE|Intrabeam®|
214238507|NCT01732003|DIETARY_SUPPLEMENT|Omega-3 Complete|
214238508|NCT01732003|DIETARY_SUPPLEMENT|Placebo Pill|
214238509|NCT04611672|DIAGNOSTIC_TEST|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
214238510|NCT04611672|DIAGNOSTIC_TEST|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
214238511|NCT03873857|DRUG|Venetoclax|tablet;oral
214238512|NCT02415842|OTHER|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
214238513|NCT05206877|DRUG|Insulin, 4 units|Topical insulin 100 U/ml, 1 drop per day
214238514|NCT05206877|DRUG|Insulin, 20 units|Topical insulin 500 U/ml, 1 drop per day
214238515|NCT05206877|DRUG|insulin, 4 units twice daily|1 drop of low dose insulin twice daily.
214238516|NCT05206877|DRUG|insulin, 20 units twice daily|1 drop of high dose insulin twice daily
214238517|NCT05206877|DRUG|insulin, 4 units three times daily|1 drop of low dose insulin three times daily.
214238518|NCT05206877|DRUG|insulin, 20 units three times daily|1 drop of high dose insulin three times daily.
214238519|NCT06451731|BEHAVIORAL|PHOLEXSEM|Phonological, Lexical, and Semantic training
214238520|NCT06451731|BEHAVIORAL|PACE|See arm description
214238521|NCT06064994|BEHAVIORAL|Mindfulness meditation|"The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~1. Being mindful of breathing (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of thought (5 minutes).~4. Being mindful of sounds (5 minutes).~5. Being mindful of taste (5 minutes)~6. Full meditation"
214238522|NCT00003830|PROCEDURE|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
214238523|NCT00003830|PROCEDURE|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
214652161|NCT06916663|BEHAVIORAL|Standard Diabetic Foot Ulcer Wound Care (SC)|Participants assigned to the Standard Care Control Group will receive comprehensive DFU wound management in accordance with International Working Group on the Diabetic Foot (IWGDF) guidelines. This includes standard offloading strategies (using Total Contact Cast or removable cast walker), regular weekly wound assessments, and debridement if necessary. Diabetes management education is provided along with routine adjustments and monitoring of the offloading device to ensure proper healing support. No structured exercise intervention is added; however, all aspects of care such as continuous glucose monitoring and vascular assessments will be uniformly applied to allow comparison with the exercise groups.
214652162|NCT03642184|DRUG|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
214652163|NCT03642184|DRUG|Linagliptin|Dosage adjustment based on glucose targets. Once daily
214652164|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
214238524|NCT01840059|DEVICE|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
214238525|NCT02316275|OTHER|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
214238526|NCT02316275|OTHER|Standard post-operative activity restriction|
214238527|NCT06319612|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
214238528|NCT06319612|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214238529|NCT06319612|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.
214238530|NCT06319612|PROCEDURE|Placebo injection|Normal saline is used. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214238531|NCT06514196|DEVICE|Hintermann Series H3 Total Ankle Replacement System|The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
214238532|NCT04179409|DRUG|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
214238533|NCT04179409|DRUG|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
214238534|NCT04179409|DRUG|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
214238535|NCT03329183|DRUG|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
214238536|NCT05595759|OTHER|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
214238537|NCT05595759|OTHER|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
214238538|NCT05593549|DRUG|Trehalose|Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
214238539|NCT05593549|DRUG|Placebo|Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
214652165|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
214652166|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
214652167|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
214238540|NCT03416062|DRUG|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
214238541|NCT03416062|DRUG|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
214238542|NCT03331510|OTHER|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
214238543|NCT05537987|DRUG|ICP-723|3+3 dose escalation
214238544|NCT00280111|BIOLOGICAL|116E AGMK|Single dose of 116E 10\^5 FFu
214238545|NCT00280111|DRUG|I321|Single dose of I321 10\^5 FFu
214238546|NCT00280111|DRUG|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
214238547|NCT05423223|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
214238548|NCT05423223|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
214238549|NCT06171932|DRUG|Methylprednisolone,|No intervention required
214238550|NCT00821444|DRUG|ziprasidone|40 mg capsule, single dose x 3
214238551|NCT00821444|DRUG|B16 Fasted|40 mg tablet, single dose X 3
214238552|NCT00821444|DRUG|B16 Fed|40 mg tablet, single dose X 3
214238553|NCT04385329|OTHER|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
214238554|NCT04385329|OTHER|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
214238555|NCT01467635|DEVICE|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
214238556|NCT02407145|OTHER|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
214238557|NCT02819778|PROCEDURE|usual care|
214238558|NCT02819778|PROCEDURE|S100B|
214238559|NCT00603590|DRUG|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
214238560|NCT00603590|DRUG|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
214238561|NCT05765773|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
214238562|NCT04519606|PROCEDURE|Optimal lung compliance during OLV|Stepwise increase of tidal volume from 4 ml/kg PBW to 7 ml/kg PBW during OLV to determine the optimal tidal volume at the level the the pressure-volume loop reaches upper refection point where the peak airway pressure at or just below 30 cmH2O
214238563|NCT03815045|PROCEDURE|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
214238564|NCT03815045|PROCEDURE|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
214238565|NCT03254303|OTHER|Difficulty of catheterization in group 60 s|
214238566|NCT03254303|OTHER|Difficulty of catheterization in group 90 s|
214238567|NCT03254303|OTHER|Difficulty of catheterization in group 120 s|
214238568|NCT00782431|BIOLOGICAL|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
214238569|NCT00782431|BIOLOGICAL|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
214238570|NCT05061680|DEVICE|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
214238571|NCT05479669|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
214238572|NCT05479669|DIAGNOSTIC_TEST|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
214238573|NCT05479669|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
214238574|NCT05479669|DIAGNOSTIC_TEST|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
214238575|NCT05479669|DIAGNOSTIC_TEST|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
214238576|NCT05985564|OTHER|imaging diagnosis|no intervention
214238577|NCT01634256|DIETARY_SUPPLEMENT|Placebo|Placebo(3.0g/day)
214238578|NCT01634256|DIETARY_SUPPLEMENT|Fermented turmeric|Fermented turmeric(3.0g/day)
214238579|NCT02057042|BEHAVIORAL|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
214238580|NCT02057042|BEHAVIORAL|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
214652168|NCT06553833|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
214652169|NCT06553833|OTHER|Patient Blood Management|PBM is a strategy to manage the participants own blood. Its focus is on anemia, bleeding and coagulation management (using predominantly pharmaceutical and technological means).
214652170|NCT05304962|DRUG|RGT-419B|oral capsules
214652171|NCT05304962|DRUG|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
214818124|NCT05090215|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
214818125|NCT05090215|BEHAVIORAL|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
214818126|NCT05073419|OTHER|Standard of Care|Routine monitoring of post AMI patient with clinic visits
214238581|NCT00874614|RADIATION|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
214238582|NCT04729400|DEVICE|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
214238583|NCT04729400|OTHER|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
214238584|NCT04729400|PROCEDURE|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
214238585|NCT04729400|PROCEDURE|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
214238586|NCT03699475|BIOLOGICAL|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
214238587|NCT03699475|DRUG|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
214238588|NCT03699475|DRUG|Cyclophosphamide|GVHD prophylaxis
214238589|NCT03699475|PROCEDURE|haplo-HSCT|treatment for disease
214238590|NCT02523469|BIOLOGICAL|ALT-803|
214238591|NCT02523469|BIOLOGICAL|Nivolumab|
214238592|NCT06213675|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
214238593|NCT06213675|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
214238594|NCT00137839|DRUG|Erlotinib|
214238595|NCT05198375|DIAGNOSTIC_TEST|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
214238596|NCT02788877|DRUG|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
214238597|NCT06506370|OTHER|nonsurgical periodontal treatment|The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
214238598|NCT03725254|PROCEDURE|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
214238599|NCT03725254|RADIATION|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
214238600|NCT06505967|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
214238601|NCT06505967|OTHER|Placebo|Rice flour
214238602|NCT01440543|PROCEDURE|Water immersion insertion AND CO2 insufflation|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
214238603|NCT01440543|PROCEDURE|Water immersion insertion|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection"
214238604|NCT01440543|PROCEDURE|CO2 insufflation|\- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
214238605|NCT00762593|DEVICE|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
214238606|NCT00762593|DEVICE|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
214238607|NCT04405232|OTHER|Non-interventional|Observational study
214238608|NCT02133170|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
214238609|NCT02133170|BEHAVIORAL|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
214238610|NCT02133170|BEHAVIORAL|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
214818127|NCT05073419|DEVICE|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
214818128|NCT00732563|DRUG|chemotherapy|Given IV and Orally
214818129|NCT00732563|PROCEDURE|lymphadenectomy|Removal of lymph nodes
214238611|NCT00410709|DRUG|NatrOVA Creme Rinse (1%)|
214238612|NCT00237510|DRUG|terazosin|
214238613|NCT00158821|DRUG|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
214238614|NCT00158821|DRUG|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
214238615|NCT00158821|DRUG|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
214238616|NCT00158821|DRUG|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
214238617|NCT03874312|DIAGNOSTIC_TEST|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
214238618|NCT04781920|OTHER|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
214238619|NCT04693143|OTHER|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
214238620|NCT01917877|DRUG|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
214238621|NCT01917877|DRUG|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
214238622|NCT00942071|BIOLOGICAL|MVA-NP+M1|1\. Intradermal injection at 5 x 10\^7 pfu at day 0
214238623|NCT00942071|BIOLOGICAL|MVA-NP+M1|2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
214238624|NCT00942071|BIOLOGICAL|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
214238625|NCT04615169|BEHAVIORAL|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
214238626|NCT04490330|OTHER|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
214238627|NCT01111929|DRUG|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
214238628|NCT05983783|DRUG|Docetaxel|This is Triple drug regimen for mHSPC
214238629|NCT05983783|DRUG|Rezvilutamide|This is doubling drug regimen for mHSPC
214238630|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
214238631|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
214238632|NCT01047098|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
214238633|NCT03213314|DIAGNOSTIC_TEST|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
214238634|NCT01514786|BEHAVIORAL|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
214238635|NCT05547971|RADIATION|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
214238636|NCT04713527|DIAGNOSTIC_TEST|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
214238637|NCT04713527|DRUG|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
214238638|NCT00694538|DEVICE|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
214238639|NCT00613067|DRUG|escitalopram|"* Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs"
214238640|NCT03739242|DIETARY_SUPPLEMENT|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
214238641|NCT03739242|OTHER|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
214238642|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
214238643|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
214238644|NCT01143233|OTHER|control formula|infants are fed a commercial hydrolyzed formula
214238645|NCT01143233|OTHER|intervention formula 1|formula has hydrolysed protein and a different protein content
214818130|NCT00732563|PROCEDURE|neoadjuvant therapy|Tumor reduction
214238646|NCT01143233|OTHER|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
214238647|NCT01143233|OTHER|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
214238648|NCT06280586|OTHER|Multidisciplinary intervention|"* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró."
214238649|NCT02446743|BIOLOGICAL|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
214238650|NCT03721679|BIOLOGICAL|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
214238651|NCT04935671|DIETARY_SUPPLEMENT|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
214238652|NCT00966784|OTHER|Dietary Fibers|
214238653|NCT04139200|BEHAVIORAL|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
214238654|NCT04139200|BEHAVIORAL|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
214238655|NCT01876433|DRUG|Mirabegron|
214238656|NCT01876433|DRUG|Placebo|
214238657|NCT03718299|DRUG|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
214238658|NCT04363229|OTHER|maslach burnout inventory questionnair|The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout
214238659|NCT03036475|DEVICE|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
214238660|NCT00559832|OTHER|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
214238661|NCT01556347|DRUG|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
214238662|NCT02013141|DRUG|Telavancin|
214238663|NCT01153464|BEHAVIORAL|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
214238664|NCT04172129|DEVICE|Total Hip Arthroplasty|
214818131|NCT00732563|PROCEDURE|quality-of-life assessment|Correlative Study
214238665|NCT00786851|DRUG|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
214238666|NCT01475071|DRUG|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
214238667|NCT01475071|DRUG|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
214238668|NCT06455618|PROCEDURE|not Indwelling the ureteral stent|"Before the end of surgery, the urologist does not Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
214238669|NCT06455618|PROCEDURE|Indwelling the ureteral stent|"Before the end of surgery, the urologist Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
214238670|NCT03045510|DRUG|decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
214238671|NCT00146588|DRUG|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
214818132|NCT00732563|PROCEDURE|therapeutic conventional surgery|Treatment for cancer
214818133|NCT00732563|PROCEDURE|thoracic surgical procedure|removal of tissue
214818134|NCT00732563|RADIATION|fludeoxyglucose F 18|given IV
214818135|NCT00732563|RADIATION|radiation therapy|undergoing radiotherapy
214818136|NCT05757414|DEVICE|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
214818137|NCT05757414|DEVICE|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
214818138|NCT02219620|BEHAVIORAL|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
214238672|NCT00146588|DRUG|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
214238673|NCT00146588|DRUG|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
214238674|NCT01011478|DRUG|rosuvastatin|
214238675|NCT01011478|OTHER|placebo|
214238676|NCT03790007|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
214238677|NCT04820127|BEHAVIORAL|personalized care preceded by a standardized assessment|"* personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
214238678|NCT02403388|OTHER|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
214238679|NCT04163731|OTHER|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
214238680|NCT04508764|OTHER|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
214238681|NCT01354054|PROCEDURE|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
214238682|NCT01354054|PROCEDURE|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
214238683|NCT01354054|PROCEDURE|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
214238684|NCT02924415|BEHAVIORAL|Tele-care support|Psychoeducation treatment based on telemedicine
214238685|NCT02924415|OTHER|Control group|Standard care
214238686|NCT01505504|DRUG|mirtazapine|30 mg at bedtime
214238687|NCT04563676|BIOLOGICAL|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
214238688|NCT04306679|OTHER|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
214238689|NCT04306679|OTHER|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
214238690|NCT02925533|DRUG|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
214238691|NCT02925533|DRUG|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
214818139|NCT02219620|BEHAVIORAL|Social Control|social conversational group facilitated by care counselor
214818140|NCT00467896|DRUG|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
214238692|NCT00794027|BEHAVIORAL|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
214238693|NCT00794027|BEHAVIORAL|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
214238694|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
214238695|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
214238696|NCT00564720|DRUG|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
214238697|NCT00564720|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
214238698|NCT01403272|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
214818141|NCT00467896|DRUG|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
214238699|NCT01877733|OTHER|Maximal strength training|
214238700|NCT02642744|OTHER|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
214238701|NCT02515812|DRUG|I-123-MIBG|
214238702|NCT02515812|DEVICE|CZT Camera (D-SPECT)|
214238703|NCT02515812|DEVICE|Anger Camera|
214238704|NCT01549769|DRUG|Bardoxolone Methyl|Oral, once daily
214238705|NCT04741464|DRUG|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
214238706|NCT03738748|OTHER|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
214238707|NCT03738748|OTHER|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
214238708|NCT06628765|DEVICE|8.6 Fr single-use fURS (XFGC-FU-660RC)|Comparative device
214238709|NCT06628765|DEVICE|6.3 Fr single-use fURS (Hugemed, HU30S)|Device being tested
214238710|NCT05601492|DRUG|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
214238711|NCT05601492|BEHAVIORAL|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
214238712|NCT05601492|BEHAVIORAL|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
214238713|NCT06304636|DRUG|Descartes-15|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
214238714|NCT06191549|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|"Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training"
214238715|NCT02855554|OTHER|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
214238716|NCT02610959|OTHER|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
214238717|NCT02610959|OTHER|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
214238718|NCT01435551|OTHER|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
214238719|NCT01312623|OTHER|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
214238720|NCT06554483|OTHER|Exercise|supportive reliable exercise programs
214238721|NCT02787239|DRUG|HLX01|
214238722|NCT02787239|DRUG|Rituximab|
214238723|NCT02787239|DRUG|CHOP|
214238724|NCT04501029|DRUG|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
214238725|NCT02691598|DRUG|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
214238726|NCT05072470|DEVICE|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
214238727|NCT05072470|DEVICE|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
214238728|NCT03990350|OTHER|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
214238729|NCT03990350|OTHER|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
214238730|NCT03990350|OTHER|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
214238731|NCT03990350|OTHER|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
214238732|NCT02433431|BEHAVIORAL|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
214238733|NCT02433431|BEHAVIORAL|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
214238734|NCT02433431|BEHAVIORAL|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
214238735|NCT01005121|DRUG|colchicine|2mg, per-os, once daily for six months
214238736|NCT04951297|OTHER|None, just observation|None ,just observation test
214238737|NCT03856268|PROCEDURE|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
214238738|NCT03856268|DRUG|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
214238739|NCT05520242|OTHER|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
214238740|NCT02158364|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
214238741|NCT02514473|DRUG|VX-809|
214238742|NCT02514473|DRUG|Placebo|
214238743|NCT02514473|DRUG|VX-770|
214238744|NCT01607203|DRUG|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
214238745|NCT01607203|DRUG|pregnyl|5000 IU SC
214238746|NCT00117533|DRUG|pegylated IFN alfa-2b plus ribavirin|
214238747|NCT01718977|OTHER|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
214238748|NCT01718977|OTHER|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
214238749|NCT03463876|DRUG|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
214238750|NCT03332511|DRUG|Nilotinib|Nilotinib 300mg twice-daily
214238751|NCT02373501|PROCEDURE|Intra-abdominal repair|Intra abdominal repair of uterine incision
214238752|NCT02373501|PROCEDURE|Extra-abdominal repair|Extra abdominal repair of uterine incision
214238753|NCT00674154|DRUG|Cholecalciferol|2800 IE daily in 52 weeks
214238754|NCT03097354|OTHER|no intervention/observational survey study design|no intervention/observational survey study design
214238755|NCT06253221|DRUG|Mavacamten|Specified dose on specified days
214238756|NCT06253221|DRUG|Placebo|Specified dose on specified days
214238757|NCT03976869|DRUG|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
214238758|NCT00928122|DEVICE|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
214238759|NCT00928122|DEVICE|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
214238760|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
214238761|NCT00928122|DEVICE|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
214238762|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
214238763|NCT00575835|DIETARY_SUPPLEMENT|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
214238764|NCT00575835|DIETARY_SUPPLEMENT|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
214238765|NCT00782587|DRUG|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
214238766|NCT01716871|DEVICE|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
214238767|NCT01716871|DEVICE|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
214238768|NCT01107379|DEVICE|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
214238769|NCT01733797|DEVICE|Wooden spatula|Lollipop sticks placed between incisors
214238770|NCT01733797|DEVICE|Therabite|Hand held device placed in mouth that exercises the jaw
214238771|NCT04559529|DRUG|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
214238772|NCT04559529|DRUG|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
214238773|NCT00609362|DRUG|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
214238774|NCT00609362|DRUG|Placebo pill|One encapsulated placebo pill a day for 14 weeks
214238775|NCT02967380|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
214238776|NCT02967380|DRUG|Gadobenate Dimeglumine|Given IV
214238777|NCT02967380|DRUG|Gadobutrol|Given IV
214238778|NCT02967380|RADIATION|Gadopentetate Dimeglumine|Given IV
214238779|NCT03553030|DEVICE|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
214238780|NCT01278654|BEHAVIORAL|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
214238781|NCT01009281|DRUG|AIN457|
214238782|NCT05861180|DEVICE|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
214238783|NCT01981369|DRUG|Dexmedetomidine|Intravenous sedation with dexmedetomidine
214238784|NCT01981369|DRUG|Propofol|Intravenous sedation with propofol
214238785|NCT01981369|PROCEDURE|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
214238786|NCT05472701|BEHAVIORAL|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
214238787|NCT05472701|BEHAVIORAL|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
214238788|NCT05472701|BEHAVIORAL|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
214238789|NCT05472701|BEHAVIORAL|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
214238790|NCT05472701|BEHAVIORAL|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
214238791|NCT05472701|BEHAVIORAL|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
214238792|NCT02128360|DRUG|Letrozole, Gonadotropins|
214238793|NCT02128360|DRUG|Gonadotropins|
214238794|NCT01153776|PROCEDURE|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
214238795|NCT01920035|DEVICE|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
214238796|NCT00548405|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
214238797|NCT00548405|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
214238798|NCT00548405|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
214238799|NCT03473080|BEHAVIORAL|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
214238800|NCT06094985|GENETIC|DNA exome sequencing of tumor and blood|A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
214238801|NCT05207137|BEHAVIORAL|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
214652172|NCT05632237|BEHAVIORAL|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
214652173|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
214238802|NCT04985396|DRUG|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
214238803|NCT06017466|DIAGNOSTIC_TEST|Visual Vertigo Analogue Scale (VVAS)|The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
214238804|NCT06216470|DRUG|VIR-3434|VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
214238805|NCT00065559|DRUG|celecoxib|
214238806|NCT06284174|DRUG|Povidone-iodine solution; chlorhexidine gluconate|Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
214238807|NCT03264079|DRUG|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
214238808|NCT03264079|DRUG|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
214238809|NCT01946906|DRUG|Rifaximin|
214238810|NCT06364930|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab QD for 60 months.
214238811|NCT06364930|DRUG|Placebo 10mg Tab|Placebo 10mg Tab QD for 60 months.
214238812|NCT02582684|DRUG|Dolutegravir|Participants were prescribed 50 mg of DTG orally daily
214238813|NCT02582684|DRUG|Lamivudine|Participants were prescribed 300 mg of 3TC orally daily.
214238814|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
214652174|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
214238815|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt|daily intake of low fat yogurt for 8 weeks
214238816|NCT04783623|PROCEDURE|Surgical endometrioma excision|We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
214238817|NCT00327808|DRUG|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
214238818|NCT00327808|DRUG|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
214238819|NCT04486209|DEVICE|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
214238820|NCT02548728|DRUG|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
214238821|NCT02548728|DRUG|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
214238822|NCT06468748|DRUG|Semaglutide|During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
214238823|NCT01431300|DRUG|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
214238824|NCT00031967|DRUG|therapeutic melatonin|
214238825|NCT00031967|RADIATION|radiation therapy|
214238826|NCT05976828|DRUG|IBRX-042|"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
214238827|NCT05775367|DEVICE|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
214238828|NCT00755703|BIOLOGICAL|Pandemic Influenza Vaccine|Undetermined
214238829|NCT00755703|BIOLOGICAL|Placebo|
214238830|NCT02912637|OTHER|Hyperpolarized Xenon MRI|MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
214238831|NCT05464888|BEHAVIORAL|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
214238832|NCT05464888|BEHAVIORAL|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
214652175|NCT04665557|BEHAVIORAL|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
214652176|NCT04396977|PROCEDURE|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
214238833|NCT05464888|BEHAVIORAL|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
214238834|NCT06054269|BIOLOGICAL|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
214652177|NCT04396977|PROCEDURE|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
214238835|NCT06054269|BIOLOGICAL|FluQuadri|0.5 mL intramuscular dose of FluQuadri
214238836|NCT05788016|BEHAVIORAL|opioid taper|The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
214238837|NCT02498171|DRUG|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
214238838|NCT02498171|DRUG|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
214238839|NCT00745355|BEHAVIORAL|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
214238840|NCT05582928|DEVICE|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
214238841|NCT00670943|OTHER|Platelet function testing|
214238842|NCT01911910|BEHAVIORAL|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
214238843|NCT04914013|OTHER|no intervention|no intervention
214238844|NCT02653118|BIOLOGICAL|V503|
214238845|NCT02653118|BIOLOGICAL|GARDASIL|
214652178|NCT00522392|DRUG|bortezomib|Given IV
214652179|NCT00522392|DRUG|lenalidomide|Given PO
214652180|NCT00522392|DRUG|dexamethasone|Given PO
214238846|NCT04898647|OTHER|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
214238847|NCT04898647|BIOLOGICAL|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
214238848|NCT04898647|PROCEDURE|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
214238849|NCT02720172|BEHAVIORAL|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
214238850|NCT02720172|OTHER|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
214238851|NCT06140537|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg orally daily
214238852|NCT06140537|DRUG|Placebo|Placebo one tablet orally daily
214238853|NCT04660838|OTHER|ACB intervention|Stopping and/or switching ACB medication to an alternative
214238854|NCT03034239|DIETARY_SUPPLEMENT|Protein supplementation|\+ insect protein
214238855|NCT03034239|OTHER|Resistance training|Resistance exercise
214238856|NCT02328378|PROCEDURE|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
214238857|NCT00899392|OTHER|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
214238858|NCT02200198|OTHER|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
214238859|NCT02200198|OTHER|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
214238860|NCT02200198|OTHER|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
214238861|NCT02067975|DRUG|Tryptophan|
214238862|NCT02067975|DRUG|Placebo|
214238863|NCT03877640|DEVICE|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
214238864|NCT01718340|DRUG|Metformin|metformin tablet 500mg three time per day
214238865|NCT06172985|OTHER|No intervention|Due to observational study
214238866|NCT05938049|DEVICE|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
214238867|NCT00678756|DRUG|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
214238868|NCT00678756|RADIATION|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
214238869|NCT00866229|DRUG|Rosuvastatin|10 mg per day for 12 weeks
214238870|NCT00866229|DRUG|Simvastatin|20 mg per day
214238871|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
214238872|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
214238873|NCT02258776|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1/day for 12 weeks.
214238874|NCT02621840|BEHAVIORAL|Mandatory On-Site Pre-Admission Testing|
214238875|NCT04850508|DEVICE|Mapping and ablation with the Advisor HD Grid catheter|"After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.~If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed."
214238876|NCT01261780|DEVICE|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
214238877|NCT01261780|DRUG|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
214238878|NCT03896893|OTHER|Skin antisepsis|1% aqueous chlorhexidine gluconate
214238879|NCT03896893|OTHER|Emollient|Aquaphor skin cream
214238880|NCT01870323|BEHAVIORAL|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
214238881|NCT01870323|BEHAVIORAL|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
214238882|NCT01534858|DEVICE|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
214238883|NCT01239732|DRUG|Paclitaxel|175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
214238884|NCT01239732|DRUG|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
214238885|NCT01239732|DRUG|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
214238886|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
214238887|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
214238888|NCT02241889|DEVICE|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
214238889|NCT02241889|DEVICE|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
214238890|NCT05320809|BIOLOGICAL|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
214238891|NCT05596383|DIETARY_SUPPLEMENT|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
214238892|NCT05596383|DIETARY_SUPPLEMENT|Placebo|Placebo
214238893|NCT04478344|OTHER|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
214238894|NCT03127332|OTHER|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
214238895|NCT04284462|OTHER|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
214238896|NCT00646932|DRUG|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
214238897|NCT00646932|DRUG|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
214238898|NCT00646932|DRUG|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
214238899|NCT00646932|DRUG|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
214238900|NCT00933413|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
214238901|NCT00274092|DRUG|tiotropium inhalation capsules (18 mcg once daily)|
214238902|NCT00274092|DRUG|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
214652181|NCT06337201|DEVICE|Test of the application Min Memoria|Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
214652182|NCT02479789|DRUG|Lidocaine|
214652183|NCT02479789|DRUG|Placebo|
214652184|NCT04755829|DEVICE|BreathX test for breath VOCs|Breath samples are collected into an ultra-clean bag and breath VOCs are analyzed with GC-SAW.
214238903|NCT04052802|OTHER|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
214238904|NCT00705744|DRUG|Lactic acid (Dermacyd Femina)|
214238905|NCT00663247|DEVICE|Mesalazine|3 grams daily for 3 months
214238906|NCT00663247|DRUG|Placebo|3 grams daily for 3 months
214238907|NCT00002167|DRUG|Tin ethyl etiopurpurin|
214238908|NCT02920788|BEHAVIORAL|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
214238909|NCT02920788|OTHER|Brain Health Education (BHE)|BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.
214238910|NCT02920788|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the Brain
214652185|NCT01910792|DEVICE|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
214652186|NCT00006449|DRUG|naltrexone (Revia)|
214652187|NCT00006449|BEHAVIORAL|broad spectrum treatment|
214238911|NCT02051075|BIOLOGICAL|PXN sperm treatment|immotile sperm activation with PXN
214652188|NCT00006449|BEHAVIORAL|motivational enhancement therapy|
214652189|NCT00140803|DRUG|Visudyne|
214652190|NCT00140803|DRUG|Kenalog|
214652191|NCT04891237|BIOLOGICAL|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
214238912|NCT02051075|BIOLOGICAL|Sperm activation with PXN and oocyte activation|
214238913|NCT04821505|BEHAVIORAL|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
214238914|NCT04821505|BEHAVIORAL|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
214238915|NCT04597151|DIETARY_SUPPLEMENT|Dietary Intervention|Attend diet education sessions
214238916|NCT05315011|OTHER|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
214238917|NCT05315011|OTHER|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
214238918|NCT05830110|DEVICE|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
214238919|NCT05830110|DEVICE|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
214238920|NCT02004288|DIETARY_SUPPLEMENT|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
214238921|NCT06397521|PROCEDURE|Crown lengthening|Investigation of the three techniques for aesthetic crown lengthening
214238922|NCT00082472|DRUG|Doxorubicin HCl Inhalation Solution|
214238923|NCT00082472|DRUG|Docetaxel|
214238924|NCT00082472|DRUG|Cisplatin|
214238925|NCT05655806|DRUG|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
214238926|NCT05655806|DRUG|aminophylline bolus|after discontinuation of isoflurane
214652192|NCT04891237|BIOLOGICAL|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
214652193|NCT04891237|OTHER|Placebo|The same solution and presentation as the active treatment, but without active ingredients
214652194|NCT02154594|DRUG|Acacia catechu|
214652195|NCT02154594|DRUG|Chlorhexidine gluconate|
214652196|NCT02154594|OTHER|Distilled water|
214652197|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
214652198|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
214652199|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
214652200|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
214652201|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
214238927|NCT05655806|DRUG|normal saline|given as placebo
214238928|NCT01685333|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
214238929|NCT03455790|DIAGNOSTIC_TEST|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
214238930|NCT04695613|DRUG|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
214238931|NCT04695613|DRUG|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
214238932|NCT03970408|PROCEDURE|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
214238933|NCT04908943|BEHAVIORAL|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
214238934|NCT06297252|DIAGNOSTIC_TEST|standardized clinical psychiatric evaluations|"The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire"
214652202|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
214652203|NCT06959940|OTHER|experimental group (gum group)|"After the pregnant woman in the experimental group was admitted to the delivery room, the data collection tools Personal Information Form and Pregnant Follow-up Form were applied. Pregnant women who agreed to participate in the study were given information about chewing gum. Pain, anxiety, fatigue and thirst scales were administered to the pregnant woman before she started chewing gum. The pregnant woman was allowed to chew gum for 15 minutes. At the end of 15 minutes, the measurements were repeated. Applications were repeated as stated above every two hours until the pregnant woman's dilation reached 5 cm. Routine medical treatment of pregnant women continued."
214238935|NCT06297252|DIAGNOSTIC_TEST|self-administered psychiatric questionnaire assessments|"* EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)"
214238936|NCT06297252|OTHER|blood sampling|"A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA"
214238937|NCT00212017|DRUG|voglibose|
214238938|NCT00212017|BEHAVIORAL|diet and exercise therapy|
214238939|NCT02642588|DIETARY_SUPPLEMENT|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
214238940|NCT02905396|DEVICE|Spinal cord stimulation|implantation of spinal cord stimulator
214238941|NCT04064008|DEVICE|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
214238942|NCT00388427|DRUG|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
214238943|NCT00388427|DRUG|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
214238944|NCT04465201|DEVICE|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
214238945|NCT04610697|BEHAVIORAL|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
214238946|NCT04610697|BEHAVIORAL|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
214238947|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
214238948|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
214238949|NCT05003271|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
214238950|NCT03894176|OTHER|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
214238951|NCT05262348|DEVICE|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
214238952|NCT05262348|DEVICE|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
214238953|NCT06080724|DRUG|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
214238954|NCT00401388|DRUG|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
214652204|NCT06960369|COMBINATION_PRODUCT|rTMS combined with Live Probiotic tablet|rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week.
214238955|NCT00401388|OTHER|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
214238956|NCT00401388|OTHER|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
214238957|NCT00401388|OTHER|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
214238958|NCT05444998|DRUG|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
214238959|NCT04857229|DEVICE|Histolog Scanner|Confocal Microscope
214238960|NCT03936452|DRUG|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
214238961|NCT05451927|DIETARY_SUPPLEMENT|Phaseolus Vulgaris|Weight loss
214238962|NCT05451927|DIETARY_SUPPLEMENT|Placebo|Placebo
214238963|NCT00266877|DRUG|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
214238964|NCT02487342|OTHER|milk|small serving (217 mL) of british semi-skimmed milk
214238965|NCT02487342|OTHER|orange fruit-juice|small serving (217 mL) of orange juice
214652205|NCT06960369|DEVICE|rTMS combined placebo|rTMS group received 1 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
214652206|NCT06960369|DRUG|shamrTMS combined with Live Probiotic tablet|Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week.
214652207|NCT06960369|OTHER|shamrTMS combined placebo group|shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
214652208|NCT06961019|OTHER|Sugar support effervescent Tablets|"Dissolve one effervescent tablet in a full glass of water (approximately 200 mL). Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation.~Frequency: Twice a day before the meal Route of Administration: Oral"
214652209|NCT06960850|DRUG|Propranolol|A set of 154 numbers will receive oxytocin and propranolol once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
214238966|NCT02508298|PROCEDURE|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
214238967|NCT02508298|DRUG|Indocyanine Green Retention test|As decribed in arm descriptions
214238968|NCT02508298|DEVICE|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
214238969|NCT02508298|DEVICE|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
214238970|NCT05945862|BEHAVIORAL|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
214238971|NCT02387476|DEVICE|FRESCA mask first night|FRESCA nasal mask first night
214238972|NCT02387476|DEVICE|CPAP Mask first night|CPAP Nasal Mask first night
214238973|NCT03705273|DRUG|Dexamethasone IV for PO|Common pediatric emergency department practice
214238974|NCT03705273|DRUG|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
214238975|NCT02630901|DRUG|PRX003|
214238976|NCT02630901|OTHER|Placebo|
214238977|NCT05258370|OTHER|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
214238978|NCT05258370|OTHER|Cardiac echography|12 months after patient enrollment
214238979|NCT01551940|DRUG|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
214238980|NCT01551940|DRUG|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
214238981|NCT00830076|DRUG|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
214238982|NCT00830076|DRUG|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
214238983|NCT00830076|DRUG|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
214238984|NCT00830076|DRUG|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
214238985|NCT05054660|OTHER|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
214238986|NCT03441672|BEHAVIORAL|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
214238987|NCT01138878|OTHER|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
214238988|NCT01138878|OTHER|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
214652210|NCT06960850|OTHER|Placebo|A set of 154 numbers will receive oxytocin and placebo once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
214238989|NCT01138878|OTHER|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
214238990|NCT01138878|OTHER|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
214238991|NCT01311635|DRUG|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
214238992|NCT01311635|DRUG|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
214238993|NCT01311635|DRUG|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
214238994|NCT00732004|DEVICE|Silicone Hydrogel Contact Lenses|
214238995|NCT00732004|DEVICE|1x PMBH preserved MPS|
214238996|NCT00732004|DEVICE|1x Polyquad/Aldox MPS|
214238997|NCT02644681|PROCEDURE|Aortic Aneurysm, Thoracic surgery|
214238998|NCT03320551|BEHAVIORAL|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
214238999|NCT02045953|DEVICE|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
214239000|NCT02045953|DEVICE|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
214239001|NCT01077375|DRUG|Placebo|"* Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
214239002|NCT01077375|DRUG|Milnacipran|"* Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
214239003|NCT03273569|PROCEDURE|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
214239004|NCT03088085|PROCEDURE|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
214239005|NCT03088085|PROCEDURE|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
214239006|NCT05908058|OTHER|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
214239007|NCT03862508|OTHER|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
214239008|NCT06091072|OTHER|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
214239009|NCT04339842|OTHER|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
214239010|NCT03720392|DRUG|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
214239011|NCT03720392|DRUG|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
214239012|NCT03441217|DRUG|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
214239013|NCT03441217|DRUG|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
214239014|NCT04561999|DEVICE|Elastography|Performance of Ultrasound, Elastography
214239015|NCT05999760|DEVICE|evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge|Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
214239016|NCT05999760|DEVICE|chewing efficiency by electromyograph(E.M.G)|Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
214239017|NCT05999760|OTHER|masticatory performance(questionnaire)|Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
214239018|NCT02097017|DRUG|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
214239019|NCT02097017|OTHER|placebo comparator|
214239020|NCT01910077|DRUG|Tacrobell capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
214239021|NCT01910077|DRUG|Prograf capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
214239022|NCT02977182|OTHER|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
214239023|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg single dose|Subcutaneous injection of CPX101 or placebo
214239024|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg single dose|Subcutaneous injection of CPX101 or placebo
214239025|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg single dose|Subcutaneous injection of CPX101 or placebo
214239026|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg Q2W|Subcutaneous injection of CPX101 or placebo
214239027|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
214239028|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
214239029|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg Q2W|Subcutaneous injection of CPX101 or placebo
214239030|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg single dose|CPX101 or placebo 200mg single dose
214239031|NCT00002975|DRUG|aminolevulinic acid|
214239032|NCT01453387|DRUG|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
214239033|NCT01453387|DRUG|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
214239034|NCT01802918|DRUG|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
214239035|NCT01802918|DRUG|Placebo|Visually matching GSK2838232
214239036|NCT01802918|DRUG|Ritonavir|100mg tablets once daily for 12 days
214239037|NCT02202330|OTHER|Video Arm|"1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
214239038|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
214239039|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
214239040|NCT01677390|DRUG|SGN-75|1-2 mg/kg IV every 21 days
214239041|NCT01677390|DRUG|everolimus|10 mg PO daily
214239042|NCT03985878|DRUG|Eteplirsen|Eteplirsen IV infusion once weekly.
214239043|NCT01821573|DRUG|botulinum toxin type A|"Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)"
214239044|NCT01821573|DRUG|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points"
214239045|NCT02176720|DRUG|FDOPA PET|\[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
214239046|NCT05843227|OTHER|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
214239047|NCT01181401|DRUG|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
214239048|NCT01181401|DRUG|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
214239049|NCT01181401|RADIATION|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
214239050|NCT05301712|DRUG|Naloxone hydrochloride 5.0mg/5ml|"* Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg"
214239051|NCT05301712|DRUG|Sodium Chloride 45mg/5ml|"* Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml"
214239052|NCT03403842|DEVICE|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
214239053|NCT03403842|DEVICE|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
214239054|NCT03403842|DRUG|PCA Morphine|Administration of endovenous morphine with a PCA
214239055|NCT03603327|DRUG|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
214239056|NCT05911282|DRUG|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
214239057|NCT05911282|OTHER|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
214239058|NCT00729846|DRUG|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
214239059|NCT00729846|DEVICE|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
214239060|NCT00729846|DEVICE|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
214239061|NCT03817450|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
214239062|NCT05436340|DEVICE|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
214239063|NCT05436340|DEVICE|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
214239064|NCT01165736|DRUG|PF-05186462|single intravenous infusion of 100 microgram
214239065|NCT01165736|DRUG|PF-05186462|single oral administration of 100 microgram
214239066|NCT01165736|DRUG|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
214239067|NCT01165736|DRUG|PF-05089771|single oral administration of 100 microgram PF-05089771
214239068|NCT01165736|DRUG|PF-05150122|single intravenous administration of 100 microgram PF-05150122
214239069|NCT01165736|DRUG|PF-05150122|single oral administration of 100 microgram PF-05150122
214239070|NCT01165736|DRUG|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
214239071|NCT01165736|DRUG|PF-05241328|single oral administration 100 microgram PF-05241328
214239072|NCT04503915|PROCEDURE|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
214239073|NCT05683431|BEHAVIORAL|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
214239074|NCT02994888|DRUG|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
214239075|NCT00599131|DRUG|Cisplatin|1\. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
214239076|NCT00599131|DRUG|Cetuximab|1\. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
214239077|NCT00599131|DRUG|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
214239078|NCT00599131|DRUG|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
214239079|NCT02700087|DRUG|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
214239080|NCT02700087|DRUG|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
214239081|NCT00655135|DRUG|LDP-02|Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
214239082|NCT00655135|DRUG|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
214239083|NCT00593580|DRUG|placebo|placebo
214239084|NCT00593580|DRUG|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
214239085|NCT05353803|OTHER|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
214239086|NCT04667143|DRUG|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
214239087|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
214652211|NCT06960408|OTHER|sleep hygiene education and progressive relaxation exercise|The study will be conducted with diabetic individuals who come to the endocrine clinic. The study will be conducted for 6 months. Intervention group Individuals who accept the study will be given face-to-face Progressive Relaxation Exercise training by the researcher in the first week of the first month of the study and will be applied. The Progressive Relaxation Exercise application will also be sent to the patient via WhatsApp and will be applied with the researcher via online interviews in the 2nd, 3rd and 4th weeks for 30 minutes 3 days a week (Monday-Wednesday-Friday). From the 2nd month of the study to the end of the 6th month, the patient will be asked to do the Progressive Relaxation Exercise on their own for 30 minutes 3 days a week (Monday, Wednesday, Friday). No intervention will be made to the control group.
214818142|NCT03772522|BEHAVIORAL|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
214239088|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
214239089|NCT03472443|OTHER|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
214239090|NCT04828473|DEVICE|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~* It is not an implant~* It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
214239091|NCT03621345|PROCEDURE|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
214239092|NCT03621345|OTHER|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
214239093|NCT00260611|DRUG|Oxaliplatin|
214239094|NCT00260611|DRUG|Taxotere|
214239095|NCT04484168|PROCEDURE|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
214239096|NCT04484168|PROCEDURE|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
214239097|NCT03501771|OTHER|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
214239098|NCT00191087|DRUG|Duloxetine|
214239099|NCT04932187|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
214239100|NCT05261776|OTHER|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
214239101|NCT05261776|OTHER|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
214239102|NCT00204243|DRUG|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
214239103|NCT00204243|DRUG|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
214239104|NCT00278915|DRUG|Fulvestrant|Participants will receive intramuscular injection of fulvestrant as stated in arm description.
214239105|NCT01273285|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
214239106|NCT02026570|BEHAVIORAL|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
214239107|NCT02026570|BEHAVIORAL|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
214239108|NCT06236191|DEVICE|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
214239109|NCT06236191|DRUG|Melatonin|Melatonin
214239110|NCT03478488|DRUG|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
214239111|NCT03478488|DRUG|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
214239112|NCT02520089|PROCEDURE|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
214239113|NCT02520089|PROCEDURE|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
214652212|NCT06959732|DRUG|zanubrutinib, obinutuzumab,combined with CVP|Zanubrutinib (160 mg, twice daily \[bid\]), obinutuzumab (1000 mg on cycle 1 \[C1\], days 1, 8, and 15; on cycle 2 - 6 \[C 2-6\], day 1), cyclophosphamide (750 mg/㎡ on day 1), vincristine (1.4 mg/㎡, maximum dose 2 mg on day 1), and prednisone tablets (40 mg/㎡ once daily \[qd\] orally on days 1-5) were used every 21 days as a treatment cycle. Six cycles of treatment were completed, and the efficacy was reviewed every two cycles. Patients with PD were excluded from the group. MRD was detected after six cycles. If MRD was negative, routine maintenance therapy was performed (obinutuzumab 1000 mg once every 8 weeks, a total of 12 times). If MRD was positive, Zanubrutinib (160 mg, continuous bid) was added to the conventional maintenance therapy for 12 months.
214652213|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214239114|NCT02499445|DRUG|Remifentanil|administering remifentanil for anesthesia maintenance
214239115|NCT02499445|DRUG|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
214239116|NCT02499445|DRUG|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
214239117|NCT02499445|DRUG|propofol|administering propofol for anesthesia maintenance
214239118|NCT02499445|DRUG|sufentanil|administering sufentanil for anesthesia maintenance
214239119|NCT04242667|BEHAVIORAL|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
214239120|NCT04242667|BEHAVIORAL|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
214239121|NCT03931135|DRUG|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
214239122|NCT02081248|OTHER|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
214239123|NCT02081248|OTHER|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
214239124|NCT04939506|BEHAVIORAL|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
214239125|NCT04270903|DEVICE|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
214239126|NCT02894008|DRUG|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
214239127|NCT00102492|DRUG|GW679769|
214239128|NCT04249726|PROCEDURE|Direct composite resin restoration|A direct composite resin restoration will be provided intracoronally without cuspal coverage.
214239129|NCT04249726|PROCEDURE|Direct composite resin restoration followed by full coverage metal ceramic crown|A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
214239130|NCT02888418|BIOLOGICAL|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
214239131|NCT02888418|BIOLOGICAL|placebo|
214239132|NCT04883411|DEVICE|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
214239133|NCT01091727|DRUG|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
214239134|NCT05939011|BEHAVIORAL|Well-formulated Ketogenic Diet|1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
214239135|NCT02374047|DRUG|CAT-2054|
214239136|NCT02374047|DRUG|Placebo|
214239137|NCT02374047|DRUG|CAT-2054-C|
214239138|NCT02374047|DRUG|Atorvastatin|
214239139|NCT06326307|BEHAVIORAL|Tell Show and Do Guidance|In this technique, the dentist tells explains the procedure using the Tell show and do method.
214239140|NCT06326307|BEHAVIORAL|Puppet Guidance|In this technique, the dentist using the puppet to explains the procedure.
214239141|NCT00053781|DRUG|perifosine|
214239142|NCT02342093|DRUG|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
214239143|NCT02342093|DRUG|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
214239144|NCT05722886|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214239145|NCT05722886|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214239146|NCT05722886|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214239147|NCT05722886|DRUG|Trastuzumab in combination with pertuzumab|"The initial loading dose of trastuzumab is 8 mg/kg body weight followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days.~The initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight.~Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214239148|NCT05722886|DRUG|Vemurafenib in combination with cobimetinib|"Patients will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214239149|NCT05722886|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
214239150|NCT04615455|DRUG|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
214239151|NCT04615455|DRUG|Cryostor CS10|CryoStor® CS10 freeze medium
214239152|NCT01911338|DEVICE|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
214239153|NCT01911338|DEVICE|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
214239154|NCT03467009|BEHAVIORAL|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
214239155|NCT03467009|OTHER|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
214239156|NCT03467009|BEHAVIORAL|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
214239157|NCT06354556|DRUG|HRS-1893 tablet|HRS-1893 tablet single dose
214239158|NCT06354556|DRUG|Verapamil tablet|Verapamil tablet 80 mg tid
214239159|NCT00002931|BIOLOGICAL|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
214239160|NCT00002931|DRUG|carboplatin|AUC=7, daily X 3
214239161|NCT00002931|DRUG|etoposide|20 mg/kg by 2 hours infusion daily X 3
214239162|NCT00002931|DRUG|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
214239163|NCT00002931|DRUG|paclitaxel|425 mg/m2 as 24 hour continuous infusion
214239164|NCT00002931|PROCEDURE|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
214239165|NCT00002931|PROCEDURE|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
214239166|NCT04864860|DIETARY_SUPPLEMENT|brown seaweed (ecklonia cava)|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
214239167|NCT04438070|DIAGNOSTIC_TEST|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
214239168|NCT01535300|PROCEDURE|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
214239169|NCT00215670|DRUG|pegaptanib sodium (Macugen)|
214239170|NCT05886985|DRUG|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
214239171|NCT02197455|DRUG|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
214239172|NCT05761184|DIAGNOSTIC_TEST|Serum collection for proteomic analysis|Serum collection for proteomic analysis
214239173|NCT01698281|DRUG|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
214239174|NCT01698281|DRUG|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
214239175|NCT01698281|DRUG|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
214239176|NCT00936429|BIOLOGICAL|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
214652214|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214652215|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214239177|NCT00936429|BIOLOGICAL|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
214239178|NCT05843383|DRUG|Ciprofol|Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
214239179|NCT05843383|DRUG|Propofol|Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil
214239180|NCT01283243|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
214239181|NCT01954147|DRUG|GLP-1|GLP-1 therapy
214239182|NCT01954147|BIOLOGICAL|SC|Stem cell infusion
214239183|NCT01954147|OTHER|Standard Medical Treatment|Standard Medical Treatment
214239184|NCT00910247|DRUG|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
214239185|NCT05435040|DEVICE|proprioceptive knee brace|the patient will perform the tests with the knee brace
214239186|NCT05435040|DEVICE|No knee brace|the patient will perform the tests without the knee brace
214239187|NCT06295978|DIAGNOSTIC_TEST|Biochemical marker assays|DOSAGE BIOMARKERS
214239188|NCT04351061|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
214239189|NCT01407003|DRUG|LIK066|Participants will receive a single or multiple doses of LIK066
214239190|NCT01407003|DRUG|Placebo|Participants will receive a single or multiple doses of a matching placebo
214239191|NCT01047969|DRUG|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
214239192|NCT01047969|PROCEDURE|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
214239193|NCT01283854|BEHAVIORAL|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
214239194|NCT06179433|PROCEDURE|Root canal treatment|Two-visit root canal treatment will be performed.
214239195|NCT06179433|PROCEDURE|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
214239196|NCT06400771|DRUG|DNP007|DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
214239197|NCT01879579|OTHER|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
214239198|NCT00726141|BEHAVIORAL|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
214239199|NCT06520540|DRUG|HDM1002 100 mg QD 12weeks|Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
214239200|NCT06520540|DRUG|HDM1002 200 mg QD 12weeks|Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
214239201|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 2W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
214239202|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 3W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
214239203|NCT06520540|DEVICE|Placebo|Placebo
214239204|NCT01695668|DRUG|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
214239205|NCT01695668|DRUG|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
214239206|NCT04552262|DRUG|BAY2327949|Single dose of 90 mg BAY2327949
214239207|NCT04552262|DRUG|Placebo|Single dose of placebo to BAY 2327949
214239208|NCT05154968|DRUG|Sodium chloride|Administered SC infusion.
214652216|NCT06960499|OTHER|Surveys|No intervention will be carried out in this study; the recruited patients will only complete the questionnaires provided below
214239209|NCT05154968|DRUG|Citrate buffer|Administered SC infusion.
214239210|NCT05154968|DRUG|Mannitol|Administered SC infusion.
214239211|NCT05154968|DEVICE|Prefilled Autoinjector|Used to administer the drug through SC infusion.
214239212|NCT02853630|DRUG|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
214239213|NCT02853630|DRUG|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
214239214|NCT05834855|DRUG|Rituximab|Treatment with rituximab
214239215|NCT02677727|OTHER|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
214239216|NCT03643614|PROCEDURE|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
214239217|NCT04146298|DRUG|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
214239218|NCT04146298|DRUG|Fludarabine|Fludarabine will be administered prior to cell infusion.
214239219|NCT04146298|BIOLOGICAL|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
214239220|NCT04146298|DRUG|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
214239221|NCT01593462|PROCEDURE|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
214239222|NCT01593462|PROCEDURE|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
214239223|NCT01593462|BEHAVIORAL|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
214239224|NCT01921088|OTHER|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
214239225|NCT01921088|BEHAVIORAL|Ambulatory Training|Subjects are provided with an ambulatory training.
214239226|NCT02404532|DEVICE|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
214239227|NCT01757691|DRUG|Fingolimod 0.5mg/daily|
214239228|NCT01757691|DRUG|Placebo|
214239229|NCT01706679|DRUG|ATX-101 (10 mg/ml)|
214239230|NCT01706679|DRUG|ATX-101 (20 mg/ml)|
214239231|NCT01706679|DRUG|Moxifloxacin (400 mg)|
214239232|NCT01706679|DRUG|Placebo vehicle (PBS)|
214239233|NCT03603366|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
214239234|NCT02484859|DRUG|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
214239235|NCT02484859|DRUG|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
214239236|NCT02484859|DRUG|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
214239237|NCT04144218|DRUG|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
214239238|NCT04144218|DRUG|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
214239239|NCT03583203|DEVICE|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
214239240|NCT02806193|PROCEDURE|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
214239241|NCT05598827|OTHER|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
214239242|NCT02933580|DRUG|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
214239243|NCT02933580|OTHER|Placebo|Participants will receive matching placebo tablets on Day 1.
214239244|NCT05906238|BEHAVIORAL|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
214239245|NCT05906238|BEHAVIORAL|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
214239246|NCT00731432|DRUG|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
214239247|NCT00731432|DRUG|Placebo Patch|Identical in shape and texture to treatment patch
214239248|NCT05930704|DRUG|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
214239249|NCT05930704|DRUG|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
214239250|NCT03431103|BEHAVIORAL|Exercise|12 week home exercise program
214239251|NCT05908318|BEHAVIORAL|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
214239252|NCT00349427|DRUG|Rosiglitazone 4 mg|
214818143|NCT03428386|PROCEDURE|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
214239253|NCT06309615|OTHER|Standard of Care|To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,
214239254|NCT03609151|PROCEDURE|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
214239255|NCT03609151|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
214239256|NCT04211571|DEVICE|Theranova 400 dialyzer|Hemodialysis using Theranova 400 dialyzer
214239257|NCT04211571|DEVICE|High-flux dialyzer|Hemodialysis using high-flux dialyzer
214239258|NCT00993161|DEVICE|Motriplate|Number of contact couples
214239259|NCT00993161|DEVICE|Motriplate|Number of contact couples
214239260|NCT00851760|PROCEDURE|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
214239261|NCT00851760|PROCEDURE|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
214239262|NCT03386253|DEVICE|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
214239263|NCT03386253|DEVICE|sham tDCS|sham tDCS session given for same length of time as active
214239264|NCT00008554|DRUG|Abacavir sulfate|
214239265|NCT00008554|DRUG|Nelfinavir mesylate|
214239266|NCT00008554|DRUG|Lamivudine|
214239267|NCT00008554|DRUG|GW433908|
214239268|NCT02783846|OTHER|normal saline|receive equal volume of normal saline
214239269|NCT02783846|DRUG|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
214239270|NCT02783846|DRUG|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
214239271|NCT00970866|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
214239272|NCT00970866|DIETARY_SUPPLEMENT|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
214239273|NCT00970866|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
214239274|NCT06353230|PROCEDURE|injection 5% phenol in almond oil|Group A were given 5% phenol in almond oil
214239275|NCT06353230|PROCEDURE|injection 15% hypertonic saline|Group B were given hypertonic saline
214239276|NCT06353230|PROCEDURE|injection 50% dextrose water|group C were given 50% dextrose water
214239277|NCT00637871|DRUG|Casodex|150mg once daily
214239278|NCT00637871|DRUG|Tamoxifen|
214239279|NCT04247685|DEVICE|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
214239280|NCT04247685|DEVICE|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
214239281|NCT01949337|DRUG|enzalutamide|Enzalutamide 160 mg daily, orally
214239282|NCT01949337|DRUG|abiraterone|abiraterone 1000 mg daily, orally
214239283|NCT01949337|DRUG|prednisone|prednisone 5 mg twice daily, orally
214239284|NCT02037581|BEHAVIORAL|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
214239285|NCT02037581|BEHAVIORAL|Standard Care|Standard care as being offered by private psychiatrists
214239286|NCT04115930|DEVICE|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
214818144|NCT00834795|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
214239287|NCT04555473|PROCEDURE|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~1. Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~2. Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
214239288|NCT04360135|DRUG|Acetaminophen|Preemptive acetaminophen the day before surgery
214239289|NCT04360135|DRUG|Placebo|Preemptive placebo the day before surgery
214239290|NCT01094912|DRUG|opioids|
214239291|NCT05465473|OTHER|Distalization|Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
214239292|NCT02367222|OTHER|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
214239293|NCT02367222|OTHER|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
214239294|NCT00012519|DRUG|indinavir sulfate|
214239295|NCT00012519|DRUG|ritonavir|
214239296|NCT02919969|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
214239297|NCT02397499|DRUG|LIPO-202|
214239298|NCT02397499|DRUG|Placebo|
214818145|NCT00834795|DRUG|COREG® 25 mg tablets|1 x 25 mg
214818146|NCT02005497|OTHER|HealthLinks|
214239299|NCT00238940|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214239300|NCT06492850|GENETIC|FT-002|Intraocular injection of a single dose
214239301|NCT01655966|DRUG|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
214239302|NCT01655966|DRUG|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
214239303|NCT01481441|DRUG|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
214239304|NCT01842633|DRUG|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
214239305|NCT01842633|DRUG|Ibuprofen|Caplets containing 200 mg of ibuprofen
214239306|NCT01842633|OTHER|Placebo|Matching placebo caplets
214239307|NCT05420350|DRUG|Lamotrigine and Bupropion|Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
214239308|NCT05420350|DRUG|Placebo|Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
214239309|NCT00197158|BIOLOGICAL|Hepatitis B vaccine|
214239310|NCT02138799|DRUG|enzalutamide|oral
214239311|NCT02138799|DRUG|rifampin|oral
214239312|NCT02621684|OTHER|Community Health Activities Model Program for Seniors (CHAMPS)|"* Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took"
214239313|NCT02621684|OTHER|Lifetime Total Physical Activity Questionnaire|"* Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
214239314|NCT02621684|OTHER|Expanded Prostate Cancer Index Composite (EPIC)|"* Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function"
214239315|NCT02621684|OTHER|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
214239316|NCT02621684|OTHER|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
214239317|NCT02621684|OTHER|Questionnaire regarding behavior/lifestyle changes since diagnosis|
214239318|NCT02621684|OTHER|12 week Walking Program|
214239319|NCT02621684|OTHER|12 week Resistance Training Program|
214239320|NCT05173545|DRUG|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
214239321|NCT00972933|DRUG|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
214239322|NCT03196700|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
214239323|NCT01864226|DRUG|RO5545965|Multiple ascending doses
214239324|NCT01864226|DRUG|placebo|Multiple ascending doses
214239325|NCT00559494|DRUG|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
214239326|NCT00559494|DRUG|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
214239327|NCT00559494|PROCEDURE|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
214239328|NCT00559494|PROCEDURE|SCPP control|maintenance of Mean arterial pressure of \>65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
214239329|NCT03860558|OTHER|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
214239330|NCT03860558|OTHER|No Intervention|Participants will not undergo an intervention.
214239331|NCT05347147|DRUG|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
214239332|NCT05347147|DRUG|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
214239333|NCT03550859|DRUG|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
214239334|NCT03550859|DRUG|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
214239335|NCT03346356|BEHAVIORAL|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
214239336|NCT02858297|DRUG|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
214239337|NCT02858297|DRUG|triamcinolone acetonide|Topical corticosteroid
214239338|NCT00539760|DRUG|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
214239339|NCT00539760|DRUG|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
214239340|NCT03920904|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
214239341|NCT01787344|DRUG|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
214239342|NCT01787344|DRUG|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
214239343|NCT05818111|DRUG|steroid|triamcinolone 40mg 4cc
214239344|NCT05818111|DRUG|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
214239345|NCT05818111|DRUG|Normal saline 2cc|normal saline 2cc
214239346|NCT05818111|DRUG|normal saline 12cc|normal saline 12cc
214239347|NCT03027479|OTHER|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
214239348|NCT01444677|DRUG|MB12066|MB12066 300mg
214239349|NCT01444677|DRUG|MB12066|MB12066 400mg
214239350|NCT01444677|DRUG|MB12066|MB12066 100mg
214239351|NCT01444677|DRUG|MB12066|MB12066 200mg
214239352|NCT01444677|DRUG|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
214239353|NCT05796336|DEVICE|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
214239354|NCT03767803|OTHER|Non-interventional study|This is an observational, non-interventional study.
214239355|NCT04131218|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
214239356|NCT01264627|BEHAVIORAL|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
214239357|NCT01264627|BEHAVIORAL|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
214239358|NCT04537221|BIOLOGICAL|Blood transfusion|Transfusion of red blood cells peri-operatively
214239359|NCT02050971|BIOLOGICAL|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
214239360|NCT02050971|BIOLOGICAL|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
214239361|NCT04729478|DEVICE|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
214239362|NCT04729478|DEVICE|Natural sleep endoscopy|Endoscopy during natural sleep.
214239363|NCT04686487|PROCEDURE|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
214239364|NCT05607836|DEVICE|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
214239365|NCT05607836|DEVICE|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
214239366|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
214239367|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
214239368|NCT02809261|DRUG|Normal Saline|Normal saline is safe for perineural injection.
214239369|NCT02809261|DRUG|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
214239370|NCT01555957|DRUG|intravenous lipid|intravenous given daily for 6 weeks
214239371|NCT00718081|DRUG|Oral sufentanil|Oral dosage of sufentanil
214239372|NCT00718081|DRUG|Placebo|Oral dosage of placebo
214239373|NCT01422967|BEHAVIORAL|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
214239374|NCT03833947|DRUG|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
214239375|NCT03833947|DRUG|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
214239376|NCT01397825|DRUG|Alisertib (MLN8237)|Alisertib (MLN8237) enteric coated tablet (ECT).
214239377|NCT01397825|DRUG|Rituximab|Rituximab IV infusion.
214239378|NCT01397825|DRUG|Vincristine|Vincristine IV Infusion.
214239379|NCT04589715|OTHER|electroacupuncture|the same as described in experimental arm.
214239380|NCT04589715|OTHER|sham electroacupuncture|the same as described in sham comparator.
214239381|NCT00357032|DRUG|belinostat|Given IV
214239382|NCT00357032|OTHER|laboratory biomarker analysis|Correlative studies
214239383|NCT01931670|OTHER|placebo|
214239384|NCT01931670|DRUG|Elagolix|
214239385|NCT01323842|PROCEDURE|EDTU|bedside ultrasound imaging by the treating emergency physician
214239386|NCT03686644|PROCEDURE|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
214239387|NCT03686644|PROCEDURE|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
214239388|NCT00244842|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
214239389|NCT00244842|DRUG|Placebo|Placebo
214239390|NCT03671473|DEVICE|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
214239391|NCT00704665|DRUG|Relaxin|10 ug/kg/day or 25 ug/kg/day
214239392|NCT00704665|DRUG|Relaxin|Placebo
214239393|NCT02597816|RADIATION|Three dimensional ultrasound|
214239394|NCT02696187|BEHAVIORAL|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
214239395|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
214239396|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
214239397|NCT01919840|PROCEDURE|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
214239398|NCT01919840|OTHER|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
214239399|NCT05692973|BEHAVIORAL|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
214239400|NCT05692973|BEHAVIORAL|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
214239401|NCT02810678|OTHER|Latent Tuberculosis Infection program evaluation & diagnosis|
214239402|NCT03671278|OTHER|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
214239403|NCT05249166|OTHER|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
214239404|NCT05249166|OTHER|Control|control group
214239405|NCT01857557|OTHER|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
214239406|NCT02895997|OTHER|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
214239407|NCT03517488|BIOLOGICAL|XmAb20717|Monoclonal bispecific antibody
214239408|NCT03044639|DRUG|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
214239409|NCT02274701|OTHER|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
214239410|NCT05299788|OTHER|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
214239411|NCT05299788|OTHER|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
214239412|NCT00570479|DRUG|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
214239413|NCT00054171|DRUG|aminolevulinic acid hydrochloride|
214239414|NCT06000176|DEVICE|Optical coherence tomography angiography|diagnostic test OCTA macula and ONH
214239415|NCT04805320|PROCEDURE|Dental Extraction|Extraction
214239416|NCT01124630|DRUG|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
214239417|NCT01124630|DRUG|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
214239418|NCT05112276|OTHER|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
214239419|NCT00976508|DRUG|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
214239420|NCT00976508|DRUG|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
214239421|NCT04862195|DEVICE|Attune™|Software as a medical device
214239422|NCT04862195|DEVICE|Cerena™|Software as a medical device
214239423|NCT00376818|BEHAVIORAL|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
214239424|NCT00376818|OTHER|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
214239425|NCT00376818|OTHER|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
214239426|NCT00376818|OTHER|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
214239427|NCT00376818|BEHAVIORAL|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
214239428|NCT00376818|PROCEDURE|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
214239429|NCT01661088|DRUG|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
214239430|NCT01661088|RADIATION|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
214239431|NCT01661088|PROCEDURE|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
214239432|NCT04149392|DEVICE|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
214239433|NCT04817527|DRUG|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
214239434|NCT05809739|DEVICE|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
214239435|NCT05438108|COMBINATION_PRODUCT|SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab|SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
214239436|NCT00082927|DRUG|ibandronate sodium|
214239437|NCT05170568|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
214239438|NCT01205581|BIOLOGICAL|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
214239439|NCT01205581|BIOLOGICAL|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
214239440|NCT03645018|DIAGNOSTIC_TEST|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
214239441|NCT03007108|OTHER|blood withdrawal|
214239442|NCT02840084|DEVICE|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
214239443|NCT01879527|DRUG|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
214239444|NCT01879527|DRUG|Sugar pill|containing placebo
214239445|NCT02669277|DRUG|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
214239446|NCT02669277|DRUG|standard IVIG product|to compare efficacy and safety with the minipool IVIG
214239447|NCT02233764|OTHER|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
214239448|NCT02233764|OTHER|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
214239449|NCT02187874|PROCEDURE|delayed umbilical cord occlusion|
214239450|NCT02187874|PROCEDURE|early umbilical cord occlusion|
214239451|NCT02187874|DRUG|Oxytocin|
214239452|NCT00664027|DRUG|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
214239453|NCT01191879|OTHER|Blood test|Blood test
214239454|NCT00611910|DEVICE|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
214239455|NCT00611910|DEVICE|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
214239456|NCT00611910|DEVICE|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
214239457|NCT00611910|DEVICE|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
214239458|NCT01188174|DRUG|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
214239459|NCT02142010|DRUG|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
214239460|NCT01063712|DEVICE|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
214239461|NCT00677703|OTHER|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
214239462|NCT04687618|DEVICE|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
214239463|NCT04687618|DEVICE|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
214239464|NCT01186497|DRUG|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
214239465|NCT01186497|DRUG|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
214239466|NCT01186497|DRUG|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
214239467|NCT01186497|DRUG|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
214239468|NCT01186497|DRUG|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
214239469|NCT01759134|OTHER|Post discharge formula|Babies will be given either materna sensitive or similac neosure
214239470|NCT04814901|PROCEDURE|Curing small and medium sized oronasal fistula|"* Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures."
214239471|NCT01208831|DRUG|LDE225|
214239472|NCT00978432|DRUG|RAD001|10 mg/day for Part 1 of the trial
214239473|NCT00978432|DRUG|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
214239474|NCT00978432|DRUG|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
214239475|NCT03850288|OTHER|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
214239476|NCT03850288|OTHER|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
214239477|NCT01596543|OTHER|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
214239478|NCT05202132|DIAGNOSTIC_TEST|Questionnaire|A 3 item validated questionnaire assessing masticatory function
214239479|NCT05202132|DIAGNOSTIC_TEST|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
214239480|NCT00470665|DRUG|Rapamune|
214239481|NCT06526975|OTHER|Gamification exercise through a videogame|Different exercises will be performed through a videogame.
214239482|NCT05946265|DEVICE|Photobiomodulation|120 patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) The dosimetric parameters for the treatment included a wavelength of 660 nm applied in continuous mode with a radiant power of 100 mW (0.1 W). The irradiance ranged from 35.385 mW/cm² to 35 W/cm², with a beam area of 0.002826 cm². Each point received an exposure time of 30 seconds, resulting in a radiant exposure of 1.061 J/cm² and a total radiant energy of 3 J. The procedure involved six irradiated points per tooth, distributed across the vestibular surface (apical, middle, and cervical regions) and the palatal surface. The application technique was performed in contact, maintaining a 90-degree angle to the surface. The treatment consisted of a single session.
214239483|NCT05946265|DEVICE|simulation of Photobiomodulation|Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
214239484|NCT04974775|DIAGNOSTIC_TEST|Blood collection|Sampling on admission to ICU (all patients)
214239485|NCT04974775|DIAGNOSTIC_TEST|Blood collection, serial sampling|"Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months."
214239486|NCT00571584|DRUG|activated recombinant human factor VII|
214239487|NCT04587180|PROCEDURE|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
214239488|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
214818147|NCT06045598|OTHER|Semmes Weinstein Monofilament Test|The 10 g Semmes-Weinstein monofilament assessment (SWME) is used to assess sensory loss and screen for diabetic neuropathy. In our study, the evaluation will be made on the plantar surfaces of the 1st fingers, the plantar surfaces of the 1st, 3rd, and 5th metatarsal heads, and the plantar surfaces of the heel in the right and left feet. The first force value felt will be taken as the evaluation data.
214239489|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
214239490|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
214239491|NCT04418661|DRUG|Vociprotafib|Pharmaceutical form: Varies Route of administration: Varies
214239492|NCT04418661|DRUG|Pembrolizumab|Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
214239493|NCT04418661|DRUG|Adagrasib|Pharmaceutical form:Sterile Tablet Route of administration: Oral
214239494|NCT05660421|DRUG|Itacitinib|Given by mouth
214239495|NCT05660421|DRUG|Corticosteroid|Given by mouth or by vein
214239496|NCT05660421|PROCEDURE|Endoscopic Procedure|Undergo endoscopic procedure
214239497|NCT05660421|PROCEDURE|Skin biopsy|Undergo skin biopsy
214239498|NCT05660421|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
214239499|NCT01563562|DRUG|Bardoxolone Methyl|Oral, Single dose
214239500|NCT02192333|PROCEDURE|Management of Therapy Complications|Receive survivorship care
214239501|NCT02192333|OTHER|Quality-of-Life Assessment|Ancillary studies
214239502|NCT02192333|OTHER|Questionnaire Administration|Ancillary studies
214239503|NCT02192333|BEHAVIORAL|Telephone-Based Intervention|Receive phone-based booster intervention
214239504|NCT04248621|DRUG|Leuprorelin|LHRH agonist
214239505|NCT04248621|DRUG|Goserelin|LHRH agonist
214239506|NCT04248621|DRUG|Triptorelin|LHRH agonist
214239507|NCT04248621|DRUG|Degarelix|LHRH antagonist
214239508|NCT04248621|DRUG|Bicalutamide|Antiandrogen
214239509|NCT04248621|DRUG|Flutamide|Antiandrogen
214239510|NCT04248621|DRUG|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
214239511|NCT00002671|DRUG|aminocamptothecin|
214239512|NCT04211220|OTHER|A decision support software|Insulin pump Continuous glucose monitoring
214239513|NCT05411575|DRUG|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
214239514|NCT05411575|OTHER|Placebo|Placebo continuous intravenous infusion for 7 days
214239515|NCT03702244|DIAGNOSTIC_TEST|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
214239516|NCT00045942|DRUG|Itraconazole|Itraconazole was commercially available.
214239517|NCT00045942|DRUG|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
214239518|NCT04779736|BEHAVIORAL|A set of implementation strategies to reduce sexual stigma|The set of implementation strategies was finalized based on formative interviews and consultation with an advisory board. This included an in-person workshop for skills development, environmental restructuring through a website of information resources for healthcare consumers and HCWs, and supportive coaching components (i.e., coaching calls, an optional email listserve) and quality improvement meetings with two clinics to encourage and respond to the implementation of recommended practices.
214239519|NCT04164693|DRUG|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
214239520|NCT04164693|OTHER|non anticoagulant therapy group|no anticoagulant was used after operation.
214239521|NCT03526380|BEHAVIORAL|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
214239522|NCT01542424|DRUG|biphasic insulin aspart 30|Prescribed at the discretion of the physician
214239523|NCT01542424|DRUG|insulin detemir|Prescribed at the discretion of the physician
214239524|NCT03857347|OTHER|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
214239525|NCT01376440|OTHER|household water treatment|household water treatment with 1.25% sodium hypochlorite
214239526|NCT02823639|PROCEDURE|Transcranial direct current stimulation|
214239527|NCT01446614|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
214239528|NCT01488474|PROCEDURE|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
214239529|NCT00159497|DEVICE|porous coated Trilogy®|THA
214239530|NCT00159497|DEVICE|Trilogy Calcicoat®|THA
214239531|NCT05088239|DRUG|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
214239532|NCT06504745|OTHER|Peer education|experimental group
214239533|NCT06504745|OTHER|control group|instruction training
214239534|NCT04847089|DEVICE|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
214239535|NCT02095132|DRUG|Adavosertib|Given PO
214239536|NCT02095132|DRUG|Irinotecan Hydrochloride|Given PO
214239537|NCT06521879|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v probiotic support|Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
214239538|NCT06217185|DRUG|Pyrotinib|Pyrotinib 400mg qd po continuously
214239539|NCT06217185|DRUG|Trastuzumab|For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
214239540|NCT06217185|DRUG|Taxanes|Taxanes: Usual clinical dose is administered, in a 21-day cycle.
214239541|NCT06217185|DRUG|Capecitabine|Capecitabine: 650mg/m2 each time, given twice daily
214239542|NCT04041791|DRUG|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
214239543|NCT04041791|DRUG|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
214239544|NCT04041791|DRUG|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
214239545|NCT04041791|DRUG|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
214239546|NCT04041791|OTHER|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
214239547|NCT04041791|OTHER|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
214239548|NCT04041791|DRUG|Ampicillin|Ampicillin is a penicillin-type antibiotic.
214239549|NCT03492840|DRUG|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
214239550|NCT02518503|DRUG|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239551|NCT02518503|DRUG|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239552|NCT02518503|DRUG|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239553|NCT02518503|DRUG|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239554|NCT02518503|DRUG|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239555|NCT02518503|DRUG|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239556|NCT02518503|DRUG|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239557|NCT02518503|DRUG|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239558|NCT02518503|DRUG|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
214239559|NCT01895361|DRUG|SelG1|
214239560|NCT01895361|DRUG|Placebo|
214239561|NCT00203281|DRUG|tacrolimus|
214239562|NCT00203281|DRUG|mycophenolate mofetil|
214239563|NCT00203281|DRUG|daclizumab|
214239564|NCT00203281|DRUG|intravenous immune globulin|
214239565|NCT00203281|PROCEDURE|plasmapheresis|
214239566|NCT06311552|OTHER|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
214239567|NCT04485065|DRUG|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
214239568|NCT00873470|PROCEDURE|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
214239569|NCT01887743|DRUG|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
214239570|NCT00539201|DRUG|GSK706769|
214239571|NCT02760043|DRUG|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
214239572|NCT02760043|OTHER|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
214239573|NCT02760043|DRUG|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
214239574|NCT05271279|BIOLOGICAL|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
214239575|NCT02447783|DIETARY_SUPPLEMENT|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
214239576|NCT02447783|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
214239577|NCT00761748|DEVICE|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
214239578|NCT00761748|DEVICE|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
214239579|NCT05898269|DIAGNOSTIC_TEST|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
214239580|NCT05898269|DIAGNOSTIC_TEST|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
214239581|NCT05898269|DIAGNOSTIC_TEST|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
214239582|NCT05898269|DIAGNOSTIC_TEST|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
214239583|NCT05898269|DIAGNOSTIC_TEST|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index \> 15% will be identified as being fluid responders, and the others as non-responders."
214239584|NCT01498094|PROCEDURE|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
214239585|NCT01498094|OTHER|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
214239586|NCT01209832|DRUG|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
214239587|NCT01209832|DRUG|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
214239588|NCT01268579|DRUG|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
214239589|NCT00197067|BIOLOGICAL|RTS,S/AS02D and RTS,S/AS02A|
214239590|NCT05704985|BIOLOGICAL|DK210 (EGFR)|Solution for SC administration
214239591|NCT05704985|RADIATION|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
214239592|NCT05704985|BIOLOGICAL|Immune checkpoint blockers|IV administration of approved PD1 blocker
214239593|NCT05704985|DRUG|Chemotherapy|Single agent or combination of not more than two
214239594|NCT02753244|OTHER|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
214239595|NCT02753244|OTHER|iPad Apps|Commercially available iPad game applications
214239596|NCT01267695|DRUG|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
214239597|NCT01267695|PROCEDURE|conventional surgery|All the patients should receive elective surgery with R0 resection.
214239598|NCT03843710|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
214239599|NCT03722290|DRUG|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
214239600|NCT03744143|PROCEDURE|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
214239601|NCT03744143|PROCEDURE|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
214239602|NCT03744143|PROCEDURE|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
214239603|NCT02692651|DRUG|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
214239604|NCT02692651|DRUG|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
214239605|NCT01245361|DRUG|Infliximab|Infliximab 3 mg/kg wk 0,2,6
214239606|NCT01245361|DRUG|sodium chloride|Group II : Placebo wk 0,2,6
214239607|NCT01381146|BEHAVIORAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
214239608|NCT01381146|BEHAVIORAL|TAU|have access to other jail programs and services
214239609|NCT03002376|DRUG|REGN2810|REGN2810 treatment
214239610|NCT05036811|OTHER|data collection|data collection
214239611|NCT01548144|DRUG|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
214239612|NCT01548144|DRUG|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
214239613|NCT01548144|DRUG|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
214239614|NCT00907660|BEHAVIORAL|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
214239615|NCT00907660|DIETARY_SUPPLEMENT|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
214239616|NCT02480712|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
214239617|NCT00733889|DRUG|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
214239618|NCT06450951|DIAGNOSTIC_TEST|Urinary EDC metabolite testing|Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.
214239619|NCT06450951|BEHAVIORAL|Educational curriculum|A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.
214239620|NCT01695278|BEHAVIORAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
214239621|NCT06485115|DEVICE|Digital Telerehabilitation (Euleria Home)|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
214239622|NCT06485115|OTHER|Conventional therapy|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
214239623|NCT00885001|PROCEDURE|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
214239624|NCT02402842|DRUG|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
214239625|NCT00353028|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
214239626|NCT00353028|DRUG|Placebo|Placebo
214239627|NCT05018936|DRUG|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
214239628|NCT03566836|DEVICE|Garmin Smart Watch|Garmin Smart Watch
214239629|NCT03566836|DEVICE|Garmin Chest Band|Garmin Chest Band
214239630|NCT06322290|DIAGNOSTIC_TEST|assessment of pathogens in blood specimens|Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
214239631|NCT02239120|DRUG|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
214239632|NCT02239120|DRUG|placebo to ASA|placebo to comparator drug
214239633|NCT02239120|DRUG|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
214239634|NCT02239120|DRUG|placebo to dabigatran etexilate|placebo
214239635|NCT02239120|DRUG|ASA 100 mg|active comparator drug
214239636|NCT02239120|DRUG|dabigatran etexilate|active drug
214239637|NCT05967897|DIETARY_SUPPLEMENT|Blueberries|22 g freeze-dried blueberry powder mixed with water
214239638|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
214239639|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
214239640|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
214239641|NCT04089215|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
214239642|NCT01376531|PROCEDURE|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
214239643|NCT01136200|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
214239644|NCT03673735|DRUG|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
214239645|NCT03673735|RADIATION|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
214239646|NCT03673735|DRUG|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
214239647|NCT03673735|DRUG|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
214239648|NCT05292144|DEVICE|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
214239649|NCT05438901|BIOLOGICAL|leech therapy|effects of medicinal leeches
214239650|NCT02963961|BEHAVIORAL|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
214239651|NCT00184574|DRUG|biphasic insulin aspart|
214239652|NCT00184574|DRUG|metformin|
214239653|NCT05841121|DRUG|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
214239654|NCT03831685|OTHER|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
214239655|NCT00167466|DEVICE|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
214239656|NCT00167466|DEVICE|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
214239657|NCT04009083|DEVICE|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
214239658|NCT04009083|OTHER|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
214239659|NCT05715671|DRUG|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
214239660|NCT03507114|BEHAVIORAL|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
214239661|NCT05297435|DIAGNOSTIC_TEST|Questionnaires|Questionnaire study
214239662|NCT03639571|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
214239663|NCT03639571|OTHER|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
214239664|NCT03333668|DRUG|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
214239665|NCT03333668|DRUG|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
214239666|NCT03333668|DRUG|Placebo|Vitamin C (10mg) tablet
214239667|NCT00741429|DRUG|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
214239668|NCT00741429|DRUG|Comparator|Subjects previously treated with other anti-diabetic medications
214239669|NCT01698710|DRUG|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
214239670|NCT00998777|PROCEDURE|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
214239671|NCT02830438|DEVICE|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
214239672|NCT00105053|BIOLOGICAL|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
214239673|NCT01710410|DEVICE|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
214239674|NCT01710410|DEVICE|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
214239675|NCT04745273|DRUG|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
214239676|NCT04745273|OTHER|Salin solution|Salin solution 2ml (iv) will administer to participants
214239677|NCT00785616|OTHER|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
214239678|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
214239679|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
214239680|NCT02660008|DRUG|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
214239681|NCT02660008|DRUG|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
214239682|NCT03346707|DEVICE|10.5 Tesla|10.5Tesla MR scan
214239683|NCT01280045|PROCEDURE|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
214239684|NCT01986777|DRUG|lisdexamfetamine|
214239685|NCT01986777|DRUG|Placebo|The placebo capsules will be filled with lactose.
214239686|NCT02837484|OTHER|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
214239687|NCT02272387|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|
214239688|NCT02272387|OTHER|Placebo|
214239689|NCT05049720|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
214239690|NCT03102190|DRUG|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
214239691|NCT05304091|OTHER|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
214239692|NCT00195845|DRUG|Galantamine|
214239693|NCT00195845|DRUG|Placebos|
214239694|NCT05200741|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
214239695|NCT05200741|BIOLOGICAL|Matching placebo|Solution for Intranasal Spray
214239696|NCT05664854|DEVICE|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
214239697|NCT02985931|OTHER|Diagnostic imaging scans of SPECT and MRI|
214239698|NCT00421447|DRUG|Anastrozole|Group of women with breast cancer
214239699|NCT04332809|PROCEDURE|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
214239700|NCT04332809|PROCEDURE|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
214239701|NCT06335147|DRUG|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
214239702|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
214239703|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
214239704|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
214239705|NCT02702245|OTHER|Placebo Comparator: Control|75 g pure glucose.
214239706|NCT04024384|DRUG|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
214239707|NCT00300079|DRUG|brinzolamide 1.0%|
214239708|NCT05421403|PROCEDURE|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
214239709|NCT05421403|BEHAVIORAL|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
214239710|NCT05258669|BIOLOGICAL|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
214239711|NCT00625703|DRUG|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
214239712|NCT06271174|DRUG|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
214239713|NCT06271174|DRUG|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~\- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
214239714|NCT01710371|DRUG|18F-AV-133|296 MBq (8 mCi)
214239715|NCT01710371|DRUG|10% Arginine Hydrochloride-R-Gene 10|
214239716|NCT06798675|DRUG|nC-001|solid dosage form single dose
214239717|NCT06798675|DRUG|Placebo|Placebo
214239718|NCT00119093|PROCEDURE|Laboratory and clinical monitoring regimens|
214239719|NCT01456767|DIETARY_SUPPLEMENT|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
214239720|NCT06454188|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day.
214239721|NCT06454188|DRUG|Placebo|15mg tablet once per day.
214239722|NCT04664738|BIOLOGICAL|10% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
214239723|NCT04664738|DRUG|TISSEEL|Fibrin sealant made from pooled human plasma
214239724|NCT04664738|BIOLOGICAL|20% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
214239725|NCT05116254|COMBINATION_PRODUCT|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
214239726|NCT05116254|COMBINATION_PRODUCT|AZD1390 + durvlaumab + radiotherapy|AZD1390 combined with durvalumab and preoperative radiotherapy
214239727|NCT06267313|BEHAVIORAL|Attention Bias Modification|Training attention away from threat
214239728|NCT06267313|BEHAVIORAL|Attention Control Training|Training attention control
214239729|NCT06267313|BEHAVIORAL|Neutral training|Attention training with Neutral stimuli
214239730|NCT03304314|DIAGNOSTIC_TEST|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
214239731|NCT00266058|DRUG|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
214239732|NCT04185597|OTHER|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
214239733|NCT04185597|OTHER|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
214239734|NCT04185597|OTHER|Control|Current Standard of Practice
214239735|NCT03248349|DRUG|Pharmacokinetics|"* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
214239736|NCT06238102|OTHER|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
214239737|NCT01640431|OTHER|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
214239738|NCT04332588|DRUG|[18F]FMISO PET/MRI imaging|\[18F\]FMISO PET/MRI imaging
214239739|NCT03977740|OTHER|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
214239740|NCT03977740|OTHER|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
214239741|NCT06393556|OTHER|Virtual reality experience|An immersive VR experience, delivered using a VR head-mounted display, of the real-world environment at the hospital, featuring the pre-operative admission suite, pre-anesthetic bay, operating theatre, postoperative recovery room, and medical staff.
214239742|NCT01318005|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
214239743|NCT01318005|DRUG|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
214239744|NCT01318005|DRUG|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
214239745|NCT03021161|DRUG|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
214239746|NCT03021161|OTHER|Placebo Oral Capsule|Capsule containing no probiotic
214239747|NCT00307008|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection
214239748|NCT00319072|BEHAVIORAL|TalkToYourDoc(sm) hormone therapy module|
214239749|NCT05631678|DRUG|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
214239750|NCT05631678|DRUG|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
214239751|NCT05207345|OTHER|Interventional programme|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
214239752|NCT05207345|OTHER|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
214239753|NCT02249247|DRUG|Low dose of BIIL 284 BS tablets|
214239754|NCT02249247|DRUG|Medium dose of BIIL 284 BS tablets|
214239755|NCT02249247|DRUG|High dose of BIIL 284 BS tablets|
214239756|NCT02249247|DRUG|Placebo|
214239757|NCT05235503|DRUG|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
214239758|NCT05235503|DRUG|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
214239759|NCT04690439|DEVICE|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
214239760|NCT04690439|PROCEDURE|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
214239761|NCT04045509|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
214239762|NCT04045509|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
214239763|NCT04045509|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
214239764|NCT02048241|BEHAVIORAL|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
214239765|NCT02048241|OTHER|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
214239766|NCT02048241|DRUG|Intuniv|Weekly administration of medication in doses as per protocol
214239767|NCT00402233|DRUG|Pramipexole|
214239768|NCT00402233|DRUG|Placebo|
214239769|NCT02483767|DRUG|goserelin|Gonadotropin-Releasing Hormone Agonist
214239770|NCT02483767|DRUG|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
214239771|NCT03105466|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
214239772|NCT03105466|DEVICE|Acellular Porcine Cornea|
214239773|NCT03105466|DRUG|Tacrolimus eye drops|
214239774|NCT03105466|DRUG|Tobradex eyedrops|
214239775|NCT04440423|DRUG|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
214239776|NCT04440423|DRUG|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
214239777|NCT00456144|DRUG|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
214239778|NCT03220698|DEVICE|Tracheal ultrasonography|Tracheal ultrasonography
214239779|NCT02819908|DRUG|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
214239780|NCT02819908|DRUG|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
214239781|NCT04882969|DEVICE|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
214239782|NCT01863589|DRUG|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
214239783|NCT03493932|DRUG|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
214239784|NCT03493932|DRUG|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
214239785|NCT04658940|DEVICE|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
214239786|NCT01143740|DRUG|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
214239787|NCT05270447|OTHER|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
214239788|NCT05270447|BEHAVIORAL|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
214239789|NCT02591771|DRUG|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
214239790|NCT03579602|DRUG|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
214239791|NCT03579602|DEVICE|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
215031409|NCT05497687|OTHER|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
214239792|NCT03839043|BEHAVIORAL|Brief behavioral intervention|"Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
214239793|NCT03839043|OTHER|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
214239794|NCT03317301|DRUG|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
214239795|NCT03317301|DRUG|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
214239796|NCT04851093|DRUG|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
214239797|NCT04851093|DRUG|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
214239798|NCT00252044|DRUG|Pergolide|
214239799|NCT03415776|PROCEDURE|Hemodialysis|Renal replacement therapy
214239800|NCT03508791|OTHER|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
214239801|NCT03508791|OTHER|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
214239802|NCT03508791|OTHER|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
214239803|NCT01922401|OTHER|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
214239804|NCT01873469|RADIATION|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
214239805|NCT02518464|DRUG|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
214239806|NCT04738305|OTHER|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
214239807|NCT01128764|BEHAVIORAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
214239808|NCT01128764|BEHAVIORAL|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
214239809|NCT00045981|DRUG|ALT-711|
214239810|NCT01789931|DEVICE|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
214239811|NCT05425316|BEHAVIORAL|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
215031410|NCT03246880|DRUG|Tamsulosin 0.2mg|per oral for 12weeks after 2\~4weeks run-in period
215031411|NCT03246880|DRUG|Tadalafil 5mg|per oral for 12weeks after 2\~4weeks run-in period
215031412|NCT02766855|DRUG|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
215031413|NCT04429763|BIOLOGICAL|Umbilical cord derived mesenchymal stem cells|One dosis of 1\*10\^6 cells/Kg
215031414|NCT04429763|BIOLOGICAL|Placebo|Placebo
215031415|NCT01890031|OTHER|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
214239812|NCT05425316|BEHAVIORAL|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
214239813|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
214239814|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
214239815|NCT05425316|BEHAVIORAL|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
214239816|NCT05532696|DRUG|ABT-101|Patients will receive ABT-101 by oral administration on a 28-day cycle
214239817|NCT02472509|DRUG|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
214239818|NCT04814238|PROCEDURE|Aortic Root Surgery|First time, isolated, minimally invasive (mini-sternotomy, RALT) aortic root or aorta surgery
214239819|NCT04456153|DRUG|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
214239820|NCT04456153|DRUG|Placebo Group|Continued standard of care therapy together with matching placebo
214239821|NCT05613712|OTHER|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
214239822|NCT05613712|OTHER|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
214239823|NCT01120067|BEHAVIORAL|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
214239824|NCT01120067|BEHAVIORAL|Treatment as Usual|Treatment as Usual.
214239825|NCT02370576|OTHER|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
214239826|NCT06129513|BEHAVIORAL|Bilateral resistance exercise|A bout of bilateral resistance exercise consisting of barbell back squat, leg leg press and leg extension
214239827|NCT06129513|DIETARY_SUPPLEMENT|Whey protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
215031416|NCT01890031|OTHER|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
215031417|NCT03109457|OTHER|oral squamous cell carcinoma|Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
215031418|NCT05851547|RADIATION|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
214239828|NCT06129513|DIETARY_SUPPLEMENT|Plant-blend protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from plant-blend protein isolate
214239829|NCT00819793|DEVICE|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
214239830|NCT04232709|OTHER|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
214239831|NCT01711060|DRUG|oxytocin|
214239832|NCT01711060|PROCEDURE|balloon catheter|
214239833|NCT03848871|DRUG|Enstilar|Enstilar foam applied to affected area once daily
214239834|NCT06103331|OTHER|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
214239835|NCT00591110|BEHAVIORAL|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
214239836|NCT00591110|BEHAVIORAL|Social-contact control|Participants receive an engaging informational session on a non-health related topic
214239837|NCT02299973|PROCEDURE|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
214239838|NCT02299973|PROCEDURE|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
214239839|NCT00480948|BEHAVIORAL|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
214239840|NCT00480948|DIETARY_SUPPLEMENT|Control|Standard vegetable oil based infant formula
214239841|NCT00184171|DRUG|Budesonide|Budesonide 9 mg
214239842|NCT00184171|DRUG|Bismuth|Bismuth mixture
214239843|NCT00184171|DRUG|Fiber|Fiber for control
215031419|NCT05851547|DRUG|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
215031420|NCT01940419|DRUG|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
214239844|NCT01603524|OTHER|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
214239845|NCT01603524|BEHAVIORAL|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
214239846|NCT04334538|DIETARY_SUPPLEMENT|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
214239847|NCT04334538|DIETARY_SUPPLEMENT|oat RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
214239848|NCT05292300|DIETARY_SUPPLEMENT|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
214239849|NCT05292300|BEHAVIORAL|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
214239850|NCT05703633|OTHER|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
214239851|NCT00572221|BEHAVIORAL|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
214239852|NCT00572221|BEHAVIORAL|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
214239853|NCT01574742|DRUG|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
214239854|NCT04334018|DEVICE|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
214239855|NCT04334018|DEVICE|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
214239856|NCT02940002|DRUG|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
214239857|NCT02940002|DRUG|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
214239858|NCT02940002|DRUG|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
214239859|NCT04058171|DIAGNOSTIC_TEST|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
214239860|NCT04022161|DRUG|Nitrogen Gas for Inhalation|See arm description
214239861|NCT04022161|OTHER|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
214239862|NCT04022161|DRUG|Nitric Oxide|See arm description
214239863|NCT06398405|OTHER|Epigallocatechin-3-gallate|Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
214239864|NCT02162576|DEVICE|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
214239865|NCT02593045|BIOLOGICAL|IPH4102|
214239866|NCT03403387|DIETARY_SUPPLEMENT|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
214239867|NCT03403387|OTHER|Placebo|Avicel (cellulose) and bentonite powder
214239868|NCT04510636|DRUG|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214239869|NCT04510636|DRUG|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
214239870|NCT05054842|DRUG|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
214239871|NCT05054842|DRUG|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
214239872|NCT01574001|BEHAVIORAL|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
215031421|NCT01940419|DRUG|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
214239873|NCT01574001|BEHAVIORAL|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
214239874|NCT01574001|BEHAVIORAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
214239875|NCT04686045|OTHER|observational study|observational study
214239876|NCT02417948|OTHER|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
214239877|NCT02417948|OTHER|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
214239878|NCT02069340|DRUG|zoledronic acid|Given IV
214239879|NCT02069340|OTHER|pharmacological study|Correlative studies
214239880|NCT04093063|OTHER|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
214239881|NCT04721067|DEVICE|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
214239882|NCT04721067|BEHAVIORAL|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
214239883|NCT05575921|DIAGNOSTIC_TEST|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
214239884|NCT04612608|PROCEDURE|upright bed|moving the bed into an upright position
214239885|NCT04434170|DRUG|Sacubitril-Valsartan|outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
214239886|NCT02233478|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice alone
214239887|NCT02233478|DIETARY_SUPPLEMENT|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
214239888|NCT02233478|DIETARY_SUPPLEMENT|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
214239889|NCT03972891|OTHER|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques"
214239890|NCT01346995|OTHER|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
214239891|NCT01346995|OTHER|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
214239892|NCT02622997|OTHER|Cervico-vaginal self-sample taken with first flocked swab|Cervico-vaginal self-sample taken with first flocked swab
214239893|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a second flocked swab|Cervico-vaginal self-sample taken with a second flocked swab
214239894|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a HerSwab device|Cervico-vaginal self-sample taken with a HerSwab device
214239895|NCT00423787|BIOLOGICAL|Ragweed MATA MPL|"4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml"
214239896|NCT01947907|DRUG|ACP-001|Once weekly subcutaneous injection
215031422|NCT06010979|PROCEDURE|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
215031423|NCT06010979|PROCEDURE|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
214239897|NCT01947907|DRUG|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
214239898|NCT00604214|DRUG|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
214239899|NCT00604214|DRUG|Placebo|0.9% sodium chloride, intravenous, 96 hours
214239900|NCT03409887|PROCEDURE|Intraorifice barrier of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
214239901|NCT03409887|PROCEDURE|Base of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
215031424|NCT06010979|PROCEDURE|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
215031425|NCT06010979|PROCEDURE|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
214239902|NCT03409887|PROCEDURE|Direct composite restoration|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
214239903|NCT00288743|DRUG|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
214239904|NCT04355611|OTHER|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
214239905|NCT01643980|DRUG|Vaginal micronized progesterone|200 mg vaginal route per day
214239906|NCT01643980|DEVICE|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
214239907|NCT00686998|DRUG|AZD2624|Oral Suspension
214239908|NCT00686998|DRUG|Olanzapine|PO BID
214239909|NCT00686998|DRUG|Placebo|
214239910|NCT02653261|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
214239911|NCT02653261|DRUG|Placebo|An equal volume of saline
214239912|NCT01066676|DRUG|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
214239913|NCT01066676|DRUG|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
214239914|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
214239915|NCT06480760|DRUG|Carnosine|Food ingredient (supplement)
214239916|NCT06013215|OTHER|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
214239917|NCT06823479|DRUG|Nivolumab|3 mg/kg
214239918|NCT06823479|DRUG|Ipilumimab|1 mg/kg
214239919|NCT05780151|OTHER|Methodological intervention|All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
214239920|NCT05780151|DRUG|Toujeo|All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
214239921|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
214239922|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
214239923|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
214239924|NCT03189056|DIAGNOSTIC_TEST|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
214239925|NCT03189056|BIOLOGICAL|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
214239926|NCT03189056|PROCEDURE|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
214239927|NCT06982495|DEVICE|NCKU-NG system|Nasogastric tube insertion with a novel nasogastric tube assisted placement system (NCKU-NG system)
214239928|NCT06982495|OTHER|Conventional blind insertion|Conventional blind insertion following standard external measurement methods (eg. Nose-Earlobe-Xiphoid + 10 cm)
214239929|NCT05625503|DRUG|Verapamil|All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.
214239930|NCT05625503|DRUG|Nicardipine|Calcium channel blocker
214239931|NCT01985854|DRUG|Propofol|
214239932|NCT01985854|DRUG|Desflurane|
214239933|NCT00130442|DRUG|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
214239934|NCT00130442|DRUG|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
214239935|NCT00627614|OTHER|breast imaging study|"1\. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
214239936|NCT02233946|BEHAVIORAL|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
214239937|NCT04412993|OTHER|withdraw blood samples|withdraw blood sample from gorup O donors
214239938|NCT03325660|OTHER|whole body vibration|pelvic floor exercises
214239939|NCT00002779|DRUG|fludarabine phosphate|
214239940|NCT00002779|DRUG|octreotide acetate|
215031426|NCT02362763|PROCEDURE|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
214239941|NCT02531243|BEHAVIORAL|CALMS|Family Therapy; Multi-user Biofeedback Videogames
214239942|NCT02054481|DRUG|BI 655066|Medium dose
214239943|NCT02054481|DRUG|BI 655066|High dose
214239944|NCT02054481|DRUG|Ustekinumab|
214239945|NCT02054481|DRUG|BI 655066|Low dose
214239946|NCT01273376|DRUG|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
214239947|NCT05323565|DRUG|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
214239948|NCT04356365|OTHER|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
214239949|NCT04213573|DRUG|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
214239950|NCT04213573|DRUG|MI Varnish|topical fluoride varnish with calcium and phosphate
214239951|NCT00882973|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
214239952|NCT03351985|DEVICE|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
214239953|NCT01612728|OTHER|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
214239954|NCT01612728|DRUG|Women with Arthralgia|
214239955|NCT03911310|DIAGNOSTIC_TEST|[18F]PSMA-11|\[18F\]PSMA-11 PET/CT
214239956|NCT03911310|DIAGNOSTIC_TEST|[68Ga]PSMA-11|\[68Ga\]PSMA-11 PET/CT
214239957|NCT05583669|DRUG|DS-2325a|Subcutaneous injection (starting dose 300 mg)
214239958|NCT05583669|DRUG|Placebo|Subcutaneous injection
214239959|NCT02320903|DEVICE|VillageWhere App|
214239960|NCT05806879|OTHER|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
214239961|NCT02140632|PROCEDURE|Local methylprednisolone acetate and lidnocaine injection|
214239962|NCT02140632|DEVICE|wrist splinting|
214239963|NCT00844168|DRUG|sorafenib tosylate|Given orally
214239964|NCT00844168|OTHER|laboratory biomarker analysis|Correlative studies
214239965|NCT03074942|DRUG|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
214239966|NCT06087003|DRUG|Basiliximab Injection|As an induction treatment for kidney transplantation
214239967|NCT06087003|DRUG|rabbit ATG|As an induction treatment for kidney transplantation
214239968|NCT00773383|DRUG|RG1507|iv 9mg/kg weekly
214239969|NCT00773383|DRUG|erlotinib [Tarceva]|150mg oral daily
214239970|NCT03548090|OTHER|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
214239971|NCT03548090|OTHER|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
214239972|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
214239973|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
214239974|NCT03548090|OTHER|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
214239975|NCT03548090|OTHER|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
214239976|NCT03548090|OTHER|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
214239977|NCT03548090|OTHER|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
214239978|NCT03384693|DRUG|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
214239979|NCT05024318|DRUG|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
214239980|NCT05024318|RADIATION|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
214239981|NCT05024318|PROCEDURE|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
214239982|NCT05828771|PROCEDURE|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
215031427|NCT05061836|DRUG|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
214239983|NCT05973396|OTHER|Physical Fatiguing Task only|Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
214239984|NCT05973396|OTHER|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
214239985|NCT05436366|DEVICE|Soleus loading response in able-bodied participants|Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
214239986|NCT05436366|DEVICE|Soleus loading response in participants with hemiparesis|Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
214239987|NCT04236388|DIETARY_SUPPLEMENT|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
214239988|NCT04236388|DIETARY_SUPPLEMENT|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
214239989|NCT02605044|DRUG|Masitinib (AB1010)|
214239990|NCT02605044|DRUG|FOLFIRI|
214239991|NCT04208581|DRUG|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
214239992|NCT04208581|DRUG|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
214239993|NCT05906511|DRUG|Dronabinol 5 MG|Dronabinol 5 mg
214239994|NCT05906511|DRUG|Dronabinol 10 MG|Dronabinol 10mg
214239995|NCT05906511|DRUG|2mg Purified THC in an ethanolic solution|2mg Purified THC in an ethanolic solution
214239996|NCT05906511|DRUG|4mg Purified THC in an ethanolic solution|4mg Purified THC in an ethanolic solution
214239997|NCT05906511|DRUG|Placebo|Oral placebo and/or vaporized saline
214239998|NCT06961669|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）.
214239999|NCT00991068|DRUG|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
214240000|NCT00036374|DRUG|Infliximab|
214240001|NCT00023192|DRUG|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
214652217|NCT06960109|BEHAVIORAL|A Mindfulness-Based Stress Reduction Program for Pregnant Women with Gestational Diabetes|The Gestational diabetes mellitus(GDM) pregnant women in the intervention group who agreed to participate in the study and completed the pre-test were invited to the WhatsApp group created by the researcher. 3 separate groups were created with a maximum of 11 participants in each group. The days (for example; Group 1: Tuesday, Saturday) on which the program, which will continue for 4 weeks, will be implemented were determined, considering the participants in each group and the times they were available. For each group, the conscious awareness-based stress reduction program for pregnant women with GDM; For 4 weeks, there were 8 sessions, 2 sessions per week, with each session varying in duration, for an average of 45-60 minutes. The program was carried out using the Google Meet application created online by the researcher, and the connection details were shared with the participants via WhatsApp groups. In the implementation of the mindfulness-based stress reduction program for pregnant
214652218|NCT06961188|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension + Standard Therapy Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 12 weeks (maximum treatment duration: 12 weeks), whichever occurred first.
214652219|NCT06961188|OTHER|Standard Therapy|Standard Therapy
215031428|NCT05061836|DRUG|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
214240002|NCT00790257|DEVICE|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
214240003|NCT03673410|PROCEDURE|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
214240004|NCT03673410|PROCEDURE|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
214240005|NCT02113839|PROCEDURE|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
214240006|NCT02113839|PROCEDURE|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
214240007|NCT02113839|PROCEDURE|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
214240008|NCT02113839|PROCEDURE|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
214240009|NCT04350346|DRUG|Motilitone|"1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
214240010|NCT04350346|DRUG|Gasmotin|"1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
214240011|NCT03841838|OTHER|Energy drink|Two 12 oz bottles of commercially available energy drink
214240012|NCT03841838|OTHER|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
214240013|NCT00780390|OTHER|Autonomic Function Assessment|
214240014|NCT05736484|BEHAVIORAL|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
214240015|NCT01071226|DEVICE|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
214240016|NCT01071226|DEVICE|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
214240017|NCT01071226|OTHER|HSCT|Peripheral Blood Stem Cell Transplant
215031429|NCT05061836|DRUG|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
214240018|NCT05527327|DEVICE|traxi® Panniculus Retractor|This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
214240019|NCT03838315|OTHER|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
214240020|NCT03838315|OTHER|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
214240021|NCT03493815|PROCEDURE|Transabdominal Ultrasound Guided IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
214240022|NCT03493815|PROCEDURE|Traditional Blind IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
214240023|NCT05521880|DRUG|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
214240024|NCT01109160|DRUG|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
214240025|NCT04599153|OTHER|Ventriculoperitoneal shunt opening pressure setting|The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.
214240026|NCT05344703|DEVICE|Y Balance Plus Visual Perturbations|Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.
214240027|NCT05344703|DIAGNOSTIC_TEST|Y balance|Subjects will perform Y-balance without any interventional strategies.
214240028|NCT01713764|BEHAVIORAL|Low Carbohydrate Diet|
214240029|NCT01713764|BEHAVIORAL|American Diabetes Association Diet|
214240030|NCT01713764|BEHAVIORAL|Mindfulness and Positive Affect Skills|
214240031|NCT03621475|DEVICE|Novel restraint|Use of a novel arm restraint
215031430|NCT05061836|DRUG|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
215031431|NCT05050669|OTHER|No Intervention for this observational study|No Intervention for this observational study
215031432|NCT05021848|OTHER|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
214240032|NCT03684239|BEHAVIORAL|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
214240033|NCT03684239|OTHER|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
214240034|NCT00354003|BEHAVIORAL|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
214240035|NCT00852332|DIETARY_SUPPLEMENT|Curcumin|
214240036|NCT00852332|DRUG|Taxotere|
214240037|NCT04877925|DEVICE|standard chest tubes|2 standard postoperative chest tube used
214240038|NCT04877925|DEVICE|coaxial chest tube|1 postoperative smart drain coaxial tube
214240039|NCT00923988|OTHER|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
214240040|NCT03914846|PROCEDURE|Ultrasound|Undergo ultrasound with elastography
214240041|NCT00178503|DRUG|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
214240042|NCT00178503|DRUG|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
214240043|NCT00178503|OTHER|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
214240044|NCT02185742|BEHAVIORAL|Strength Based Case Management|
214240045|NCT03584529|DRUG|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
214240046|NCT01095094|DRUG|ritonavir|Given orally
214240047|NCT01095094|DRUG|lopinavir|Given orally
214240048|NCT04569071|DEVICE|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
215031433|NCT02884479|DRUG|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
215031434|NCT02884479|DRUG|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
214240049|NCT05124301|BEHAVIORAL|Perceptual learning|Reaching task with visual feedback offset from target finger position.
214240050|NCT05124301|BEHAVIORAL|Control|Reaching task with unmanipulated feedback.
214240051|NCT03129256|DRUG|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
214240052|NCT02093351|DRUG|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
214240053|NCT02093351|DRUG|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
214240054|NCT02093351|DRUG|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
214240055|NCT02093351|DRUG|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
214240056|NCT02093351|PROCEDURE|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
214240057|NCT04628533|BEHAVIORAL|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
214652220|NCT06961383|BIOLOGICAL|NG01 - Autologous bone marrow derived human stromal cells|NG01 is a cellular therapy product of autologous stromal cells derived from the bone marrow of multiple sclerosis (MS) patients. NG01 is provided as a cell suspension for intrathecal injection.
214652221|NCT06961383|OTHER|Sodium Chloride 0.9%|The placebo for use in the NG01 clinical trial is 0.9% Sodium Chloride Solution for Injection
214652222|NCT06960824|DRUG|Life-Cycle Pharma Tacrolimus|Patients receiving LCPT Envarsus® \[Life-Cycle Pharma Tacrolimus\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics (SmPC).
215031435|NCT00003670|DRUG|arzoxifene hydrochloride|
215031436|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
214240058|NCT04628533|BEHAVIORAL|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
214240059|NCT04942457|BEHAVIORAL|Fasting|Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
214240060|NCT03146598|OTHER|No intervention as it is a observational study|No intervention as it is a observational study
214240061|NCT04360655|PROCEDURE|bronchoscopic microwave intervention|bronchoscopic microwave intervention
214240062|NCT04360655|DRUG|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
214240063|NCT06530186|DEVICE|LiviWell Postcoital Vaginal Insert|subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
214240064|NCT05326724|DEVICE|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
214240065|NCT04748588|DRUG|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
214240066|NCT04161339|DRUG|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
214240067|NCT04161339|DRUG|Placebo oral tablet|Amido pills/daily for 8 weeks
214240068|NCT06229314|DEVICE|Inspiratory muscle training|In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
214240069|NCT01510288|DRUG|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
214240070|NCT05398081|DRUG|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
214240071|NCT05398081|DRUG|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
214240072|NCT02585570|DRUG|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
214652223|NCT06960824|PROCEDURE|Kidney transplantation|Kidney transplant patients using the iBox prognostic system (risk prediction system for kidney transplants)
214652224|NCT06961201|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication.
214652225|NCT06961201|DRUG|standard treatment|standard treatment
214652226|NCT06961396|DEVICE|Relaxation Technique|utilizing virtual reality and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
214652227|NCT06961396|DEVICE|Pain treatment|utilizing cold laser and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
214240073|NCT04493515|DRUG|Oral Oxytocin|Administration of oxytocin orally (24 IU)
214240074|NCT04493515|DRUG|Oral Placebo|Administration of placebo orally (24 IU)
214240075|NCT01193296|DRUG|Vildagliptin|
214240076|NCT01193296|DRUG|Sitagliptin|
214240077|NCT03970889|DEVICE|Klue|Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
214240078|NCT04872270|PROCEDURE|Total Shoulder Arthroplasty|Participant will have total shoulder replacement
214240079|NCT04872270|DRUG|Caffeine Pill|2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
214240080|NCT04872270|DRUG|Percocet 10Mg-325Mg Tablet|given postoperatively as standard post-op pain management
214240081|NCT04872270|DRUG|Zofran 4Mg Tablet|given postoperatively as standard post-op management
214652228|NCT06961240|DIAGNOSTIC_TEST|AI-Based Difficult Airway Prediction Model|"The AI-Based Difficult Airway Prediction Model is an artificial intelligence system designed to predict difficult intubation in patients undergoing general anesthesia. It combines clinical data (age, BMI, Mallampati score, mouth opening, thyromental distance, sternomental distance, neck circumference) and anatomical image data. Machine learning (Random Forests, SVM, Gradient Boosting) and deep learning (ANN, CNN) algorithms are used to classify airway difficulty. The model's predictions are compared with clinical assessments by anesthesiologists using Cormack-Lehane grading. The goal is to improve prediction accuracy, enhance airway management, and support clinical decision-making."
214652229|NCT01388400|OTHER|conventional occupational therapy|upper limb exercises
214240082|NCT01099709|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
214240083|NCT01099709|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
214240084|NCT04333043|DIAGNOSTIC_TEST|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
214240085|NCT06284629|DEVICE|Neptune|Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.
214240086|NCT06284629|OTHER|Standard clinical care|Treatment and management according to standard clinical care
214240087|NCT00002455|BIOLOGICAL|Corynebacterium granulosum P40|
214240088|NCT00002455|PROCEDURE|adjuvant therapy|
214240089|NCT05925387|OTHER|CANAP Education|The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
214240090|NCT04614051|BIOLOGICAL|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
214240091|NCT05915039|OTHER|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
214240092|NCT03636698|OTHER|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
214240093|NCT02996643|DEVICE|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
214240094|NCT02095496|DEVICE|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
214240095|NCT02095496|DEVICE|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
214240096|NCT06678633|DEVICE|T-Control® (experimental)|Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.
214240097|NCT06678633|DEVICE|Folysil® (control)|Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
214240098|NCT00266851|DRUG|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
214240099|NCT00266851|DRUG|Placebo|Matching placebo
214240100|NCT03521804|DEVICE|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
214240101|NCT05762770|PROCEDURE|PICSI|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
214240102|NCT02060448|BEHAVIORAL|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
214240103|NCT02060448|BEHAVIORAL|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
214240104|NCT02428127|DIETARY_SUPPLEMENT|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
214240105|NCT02428127|DIETARY_SUPPLEMENT|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
214240106|NCT02428127|OTHER|Water|lukewarm water
214240107|NCT02346578|DRUG|Enzalutamide|
214240108|NCT02346578|DRUG|Flutamide|
214240109|NCT03956069|BIOLOGICAL|blood sample|for patient and its parents
214240110|NCT03956069|GENETIC|genome sequencing|whole genome sequencing
214240111|NCT05377073|OTHER|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
214240112|NCT05377073|OTHER|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
214240113|NCT05849285|OTHER|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
214240114|NCT03616223|DRUG|FX-322|Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
214240115|NCT03616223|DRUG|Placebo|Intratympanic injection
214240116|NCT06307860|DEVICE|pulsed field ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
214652230|NCT01388400|DEVICE|video capture virtual reality|virtual reality delivered uppe limb exercises
214240117|NCT06307860|PROCEDURE|radiofrequency ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
214240118|NCT02218476|DRUG|CoQ10|
214240119|NCT02218476|DRUG|Placebo|
214240120|NCT01122394|BEHAVIORAL|TI|Tailored intervention based on the transtheoretical model
214240121|NCT01122394|BEHAVIORAL|AP|Attention placebo
214240122|NCT02970370|OTHER|no intervention|
214240123|NCT03787979|OTHER|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
214240124|NCT03787979|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
214240125|NCT00039871|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
214240126|NCT00039871|DRUG|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
214240127|NCT04638504|OTHER|ultrasonography|vascular and adipose tissue measurement by ultrasonography
214240128|NCT03751774|BEHAVIORAL|MAMAACT|Post graduate training and health education materials
214240129|NCT00006487|DRUG|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
214240130|NCT00006487|DRUG|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
214240131|NCT00006487|DRUG|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
214240132|NCT00006487|RADIATION|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
214240133|NCT01251627|DRUG|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
214240134|NCT00008827|BEHAVIORAL|Behavioral weight loss|
214240135|NCT02153476|DRUG|2.0mg of ALG-1001|
214240136|NCT02153476|DRUG|Balanced Salt Solution|
214240137|NCT03198039|BEHAVIORAL|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
214240138|NCT02708082|DEVICE|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
214240139|NCT02399436|BEHAVIORAL|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:~* Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~* The installation of new filtered water fountains outfitted with water-filling stations;~* The distribution of re-usable water bottles to students at participating schools; and~* A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
214240140|NCT02399436|BEHAVIORAL|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
214240141|NCT06324916|RADIATION|Xray|X rays for ankle to see distal fibular remenant
214240142|NCT04308798|PROCEDURE|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
214240143|NCT05791370|DIETARY_SUPPLEMENT|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
214240144|NCT04577339|PROCEDURE|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
214240145|NCT02394145|DRUG|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
214240146|NCT02394145|DRUG|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
214652231|NCT06959979|DRUG|CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)|Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).
214240147|NCT06127537|BEHAVIORAL|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual."
214240148|NCT00278239|PROCEDURE|cognitive assessment|
214240149|NCT00278239|PROCEDURE|psychosocial assessment and care|
214240150|NCT00278239|PROCEDURE|quality-of-life assessment|
214240151|NCT00815516|DRUG|micafungin|Administered by intravenous infusion
214240152|NCT00815516|DRUG|amphotericin B deoxycholate|Administered by intravenous infusion
214240153|NCT01541345|DEVICE|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
214240154|NCT01541345|DRUG|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
214240155|NCT01541345|PROCEDURE|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
214240156|NCT04863209|OTHER|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
214240157|NCT04863209|OTHER|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
214240158|NCT01736657|DEVICE|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
214240159|NCT00607932|BEHAVIORAL|behavioral dietary intervention|
214240160|NCT00607932|DIETARY_SUPPLEMENT|Brassica vegetable|
214240161|NCT00607932|DRUG|indole-3-carbinol|follow up at 2,4,6 months post baseline.
214240162|NCT00607932|OTHER|counseling intervention|2, 4, 6 months post baseline
214240163|NCT00607932|OTHER|medical chart review|2,4,6 months post baseline
214240164|NCT00607932|OTHER|questionnaire administration|
214240165|NCT00607932|PROCEDURE|adjuvant therapy|
214240166|NCT02415855|DRUG|Dabigatran|
214240167|NCT04309747|PROCEDURE|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
214240168|NCT04524338|DEVICE|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
214240169|NCT01049477|OTHER|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
214240170|NCT01049477|OTHER|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
214240171|NCT00099645|DRUG|Mifepristone|
214240172|NCT02326311|DRUG|imatinib|Tyrosin kinase inhibitor
214240173|NCT02326311|DRUG|nilotinib|Tyrosin kinase inhibitor
214240174|NCT02326311|DRUG|dasatinib|Tyrosin kinase inhibitor
214240175|NCT00947050|OTHER|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
214240176|NCT06198140|OTHER|myofascial release and quick icing|In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
214240177|NCT06198140|OTHER|myofascial release|In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
214240178|NCT06024733|DRUG|Sevoflurane|patient recieve propofol for induction and sevoflurane for maintenance
214240179|NCT06024733|DRUG|Target Controlled Infusion|target controlled infusion of propofol
214240180|NCT06024733|DRUG|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
214240181|NCT01111409|DEVICE|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
214240182|NCT06321627|RADIATION|Radiation therapy as curative treatment|Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
214240183|NCT04198818|DRUG|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
214240184|NCT01463332|DRUG|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
214240185|NCT01463332|DRUG|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
214240186|NCT01463332|DRUG|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
214240187|NCT00518245|DRUG|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
214240188|NCT00766441|DRUG|Sitagliptin|tablet, 100mg, once daily, 4 weeks
214240189|NCT00766441|DRUG|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
214240190|NCT02551627|DIETARY_SUPPLEMENT|Test Product|MMN fortified beverage powder.
214240191|NCT02551627|DIETARY_SUPPLEMENT|Control|Isocaloric beverage powder without micronutrient fortification.
214240192|NCT01285687|DEVICE|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
214240193|NCT06432868|DIETARY_SUPPLEMENT|Solarplast (R)|Daily supplementation for 28 days prior to heavy resistance exercise.
214240194|NCT06432868|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 28 days prior to heavy resistance exercise.
214240195|NCT01285947|DEVICE|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
214240196|NCT01285947|OTHER|Needle Application|30-gauge needle insertion into skin
214240197|NCT01285947|DEVICE|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
214240198|NCT01285947|DEVICE|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
214240199|NCT03989726|PROCEDURE|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
214240200|NCT03142061|PROCEDURE|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
214240201|NCT05983887|OTHER|Therapeutic Climbing|The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
214240202|NCT05222243|DRUG|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
214240203|NCT05222243|DRUG|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
214240204|NCT05222243|DRUG|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
214240205|NCT05037188|BIOLOGICAL|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
214240206|NCT05037188|BIOLOGICAL|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
214240207|NCT05037188|BIOLOGICAL|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
214240208|NCT05037188|OTHER|Placebo injection|Placebo injection
214240209|NCT02329366|OTHER|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
214240210|NCT05346432|DIETARY_SUPPLEMENT|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
214240211|NCT04920227|PROCEDURE|phacoemulsification;|Group A: class combined with phacoemulsification
214240212|NCT00003101|BIOLOGICAL|filgrastim|
214240213|NCT00003101|DRUG|busulfan|
214240214|NCT00003101|DRUG|lomustine|
214240215|NCT00003101|DRUG|procarbazine hydrochloride|
214240216|NCT00003101|DRUG|thiotepa|
214240217|NCT00003101|DRUG|vincristine sulfate|
214240218|NCT00003101|PROCEDURE|autologous bone marrow transplantation|
214240219|NCT00003101|PROCEDURE|peripheral blood stem cell transplantation|
214240220|NCT03555838|OTHER|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
214240221|NCT03555838|OTHER|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
214240222|NCT00943553|DRUG|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)
214240223|NCT00943553|DRUG|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
214240224|NCT04810572|DIETARY_SUPPLEMENT|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
214240225|NCT04810572|DIETARY_SUPPLEMENT|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
214240226|NCT02653885|OTHER|Red red cell distribution width|Results from hemogram
214240227|NCT05354804|DIAGNOSTIC_TEST|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
214240228|NCT05354804|DIAGNOSTIC_TEST|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
214240229|NCT02723578|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
214240230|NCT02723578|DRUG|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
214240231|NCT02388282|DEVICE|diaphragm ecography|recording of diaphragm ecography
214240232|NCT03574324|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
214240233|NCT03574324|DRUG|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
214240234|NCT02573038|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
214240235|NCT06020729|OTHER|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
214240236|NCT06020729|OTHER|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
214240237|NCT05386628|OTHER|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises"
214240238|NCT05386628|OTHER|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
214240239|NCT05386628|OTHER|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
214240240|NCT01649479|BIOLOGICAL|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
214240241|NCT01649479|BIOLOGICAL|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII"
214240242|NCT01649479|OTHER|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
214240243|NCT03687905|DRUG|Chloroquine|group1 received chloroquine .
214652232|NCT03713190|COMBINATION_PRODUCT|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
214652233|NCT03713190|DRUG|Placebo|A substance without specific pharmacology principles
214652234|NCT06108102|OTHER|Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)|Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
214652235|NCT05434884|PROCEDURE|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
214652236|NCT05434884|PROCEDURE|endocrown restorations|endocrown restorations
215031437|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
214240244|NCT03687905|DRUG|Hydroxychloroquine|Group 2 received hydroxychloroquine
214240245|NCT04173364|DRUG|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
214240246|NCT04173364|DRUG|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
215031438|NCT02233569|DEVICE|Ventralight ST implant|
215031439|NCT02233569|DEVICE|ETHICON PHYSIOMESH®|
214240247|NCT05157919|BEHAVIORAL|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
214240248|NCT00354185|DRUG|tanespimycin|Given IV
214240249|NCT00354185|DRUG|belinostat|Given IV
214240250|NCT00354185|OTHER|laboratory biomarker analysis|Correlative studies
214240251|NCT00354185|OTHER|pharmacological study|Correlative studies
214240252|NCT01992159|DRUG|Romosozumab|Administered by subcutaneous injection
214240253|NCT01992159|DRUG|Placebo|Administered by subcutaneous injection
214240254|NCT06260527|DRUG|ARTS-011|Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
214240255|NCT06260527|DRUG|Placebo|Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
214240256|NCT03377088|OTHER|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
214240257|NCT03377088|OTHER|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
214240258|NCT01198158|BIOLOGICAL|Bevacizumab|Given IV
214240259|NCT01198158|DRUG|Everolimus|Given PO
214240260|NCT01198158|OTHER|Laboratory Biomarker Analysis|Correlative studies
214240261|NCT01198158|OTHER|Pharmacological Study|Correlative studies
214240262|NCT03023046|DRUG|Cyclophosphamide|Given IV
214240263|NCT03023046|DRUG|Dasatinib|Given PO
214240264|NCT03023046|DRUG|Doxorubicin|Given IV
214240265|NCT03023046|DRUG|Etoposide|Given IV
214240266|NCT03023046|DRUG|Imatinib Mesylate|Given PO
214240267|NCT03023046|OTHER|Laboratory Biomarker Analysis|Correlative studies
214240268|NCT03023046|DRUG|Prednisone|Given PO
214240269|NCT03023046|BIOLOGICAL|Rituximab|Given IV
214240270|NCT03023046|DRUG|Vincristine Sulfate|Given IV
214240271|NCT03473028|PROCEDURE|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer
214240272|NCT03473028|PROCEDURE|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
214240273|NCT05300373|DIAGNOSTIC_TEST|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
214240274|NCT01479218|DEVICE|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
214240275|NCT01600742|DRUG|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
214240276|NCT01600742|DRUG|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
214240277|NCT06181279|PROCEDURE|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
214240278|NCT06181279|PROCEDURE|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
214240279|NCT00929812|DRUG|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
214240280|NCT00929812|DRUG|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
214240281|NCT00531674|DIETARY_SUPPLEMENT|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
214240282|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
214240283|NCT00531674|DIETARY_SUPPLEMENT|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
214240284|NCT00531674|DIETARY_SUPPLEMENT|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
214240285|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
214240286|NCT00531674|DIETARY_SUPPLEMENT|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
214240287|NCT06489379|DEVICE|high flow nasal cannula|humidified and heated oxygen
214240288|NCT06489379|OTHER|standard oxygen|oxygen delivery through Venturi mask
214240289|NCT05857423|OTHER|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
214240290|NCT02278471|DRUG|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
214652237|NCT03268356|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
214240291|NCT03628261|DEVICE|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
214240292|NCT03628261|OTHER|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
214240293|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
214240294|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
214240295|NCT01741012|DRUG|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
214240296|NCT03789617|BIOLOGICAL|EBViNT Cell|"1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL~2. Administration: Inject intravenously over 30 minutes~3. Dosing schedule: Single dose"
214240297|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
214240298|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
214652238|NCT02005822|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
214652239|NCT02472457|OTHER|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
214240299|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
214240300|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
214240301|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
214240302|NCT03468543|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
214240303|NCT00119873|BIOLOGICAL|VRC-HIVADV014-00-VP|
214240304|NCT03578770|DEVICE|Hot Axios stent|Hot Axios stent
214240305|NCT04243109|DRUG|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
214240306|NCT00586729|DEVICE|Vashe|Antimicrobial irrigant
214240307|NCT00586729|DRUG|Mafenide acetate|Antimicrobial solution
214240308|NCT02643758|DEVICE|Bifocal soft contact lenses|
214240309|NCT04618770|DEVICE|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
214652240|NCT02472457|OTHER|Free Diet|This diet contains no restrictions.
214652241|NCT00956826|DEVICE|Agit Vacuum|With an electrode and a regular vacuum device
214240310|NCT02732717|OTHER|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
214240311|NCT05933070|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
214240312|NCT03458793|BEHAVIORAL|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
214240313|NCT05472454|OTHER|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
214652242|NCT00631878|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
214652243|NCT03051633|BEHAVIORAL|Be Under Your Own Influence|School based anti-drug use communications campaign
214652244|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
214652245|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
214652246|NCT02507804|OTHER|Patient diary PROMs|
214652247|NCT02507804|OTHER|Counselling|
214652248|NCT05211336|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
214652249|NCT05211336|DRUG|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
214240314|NCT01171508|DEVICE|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
214240315|NCT01171508|DEVICE|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
214240316|NCT01171508|DEVICE|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
214240317|NCT01171508|PROCEDURE|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
214240318|NCT01171508|OTHER|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
214240319|NCT01171508|OTHER|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
214240320|NCT01171508|OTHER|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
214240321|NCT04393298|DRUG|ginisortamab|Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
214240322|NCT04393298|DRUG|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
214240323|NCT04393298|DRUG|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
214240324|NCT05033002|BEHAVIORAL|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
214240325|NCT03937544|BIOLOGICAL|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
214240326|NCT03937544|DRUG|Cyclophosphamide|Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
214240327|NCT03937544|DRUG|Fludarabine|Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
214240328|NCT06017102|DEVICE|wired magnetic assisted capsule endoscopy|once
214240329|NCT06017102|DEVICE|esophagogastroduodenoscopy|once
214240330|NCT03272269|DRUG|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
214240331|NCT03272269|OTHER|Placebo|Solvent: alum hydroxide
214240332|NCT05285748|BEHAVIORAL|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
214240333|NCT05285748|BEHAVIORAL|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
214240334|NCT06001385|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
214240335|NCT06001385|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
214240336|NCT06001385|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
214240337|NCT06001385|DRUG|Post-Transplant Cyclophosphamide|"Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant."
214652250|NCT05211336|DRUG|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
214240338|NCT06001385|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
214240339|NCT06001385|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
214240340|NCT06001385|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
214240341|NCT06001385|OTHER|Patient Reported Outcomes|Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
214652251|NCT05211336|DRUG|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
214240342|NCT06001385|DRUG|Melphalan|Given IV pre transplant as part of conditioning regimen
214240343|NCT06001385|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
214240344|NCT06001385|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
214240345|NCT06160284|DRUG|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
214652252|NCT05211336|DRUG|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
214652253|NCT05211336|DRUG|Acetaminophen|650 mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
214652254|NCT05211336|DRUG|Diphenhydramine|50mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
214652255|NCT05211336|OTHER|Peg-filgrastim|6 mg subcutaneous once on day 8 only.
214240346|NCT06831942|BEHAVIORAL|ASSIP-OA|"ASSIP-OA + TAU~* First session. Narrative interview focusing on the background of the suicidal crisis. The patient receives a psychoeducational text to read and comment on as homework.~* Second session. Video playback. The patient and therapist watch the video recording from session 1 together, periodically pausing the video to comment and add information.~* Third session. Compilation of a written case conceptualization of the individual's vulnerability and triggering events that preceded the suicidal crisis.~* Fourth session. An optional extra session to further train safety strategies.~* Fifth session (optional). Includes one or two close relatives or other support person(s), chosen by the participant. The session focus on how safety measures learned in in ASSIP-OA can be translated into everyday life.~* Standardized letters. therapists will send standardized letters every third month during the first year and biannually during the second year."
214240347|NCT06831942|OTHER|Treatment as Usual (TAU)|Antidepressant medication, alone or in combination with other types of psychoactive drugs (sedatives/antipsychotics/hypnotics/mood stabilizers) constitute the cornerstone of treatment for suicidal older adults. Persons with serious depression or treatment-resistant depression may be offered electroconvulsive therapy (ECT). Some persons may receive supportive/therapeutic contacts with mental health professionals (nurses/social workers/psychologists) but no psychosocial interventions designed specifically for suicidal older adults are offered as part of ordinary treatment at the participating clinics.
214240348|NCT02311582|BIOLOGICAL|MK-3475|Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
214240349|NCT02311582|DEVICE|MRI-guided laser ablation|MLA is a minimally invasive laser surgery, which employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of the tumor mass where it delivers hyperthermic ablation from the core to the rim.
214240350|NCT05822531|BEHAVIORAL|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
214240351|NCT06631937|OTHER|Human Milk Oligosaccharides|Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
214240352|NCT06631937|OTHER|Placebo|An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
214240353|NCT06369064|OTHER|CVVHD Dialysis parameters|Patients will receive a CVVHD dialysis with a dose of 25ml/kg/h dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate
214240354|NCT06369064|OTHER|CVVHDF Dialysis parameters|Patients will receive a CVVHDF dialysis with a dose of 25ml/kg/h dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine
214240355|NCT03703570|DRUG|KW-6356|Oral administration
214240356|NCT03703570|DRUG|Placebo|Oral administration
214240357|NCT04691284|OTHER|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
214240358|NCT06101628|OTHER|Gel nail application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
214652256|NCT05211336|DIAGNOSTIC_TEST|CT Scan (chest, abdomen, and pelvis)|To assess sites of disease.
214652257|NCT05211336|DIAGNOSTIC_TEST|MRI|If clinically indicated.
214652258|NCT05211336|DIAGNOSTIC_TEST|18f-FDG-PET|If clinically indicated.
214652259|NCT05211336|DIAGNOSTIC_TEST|PET|If clinically indicated.
214652260|NCT05211336|DIAGNOSTIC_TEST|Lumbar puncture/Ommaya tap|If clinically indicated.
214652261|NCT05211336|DIAGNOSTIC_TEST|Bone marrow aspiration/biopsy|If clinically indicated.
214240359|NCT05265052|DRUG|3D1002 (50 mg)(Phase IIa)|1 tablet of 3D1002 per oral dose
214240360|NCT05265052|DRUG|3D1002 (100 mg)(Phase IIa)|2 tablets of 3D1002 per oral dose
214240361|NCT05265052|DRUG|3D1002 (150 mg)(Phase IIa)|3 tablets of 3D1002 per oral dose
214240362|NCT05265052|DRUG|3D1002 monotherapy (Phase IIb)|3D1002 is administered at recommended dose with mimic OxyContin tablets.
214240363|NCT05265052|DRUG|OxyContin monotherapy (Phase IIb)|OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
214240364|NCT05265052|DRUG|3D1002 + OxyContin (Phase IIb)|3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
214652262|NCT05211336|COMBINATION_PRODUCT|EKG|To determine eligibility.
214652263|NCT06303622|PROCEDURE|MRI-USG fusion approach|MRI-USG fusion approach prostate biopsy
214652264|NCT06303622|PROCEDURE|Cognitive-guided approach|Cognitive-guided approach prostate biopsy
214652265|NCT01834235|DRUG|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
214652266|NCT01834235|DRUG|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
214652267|NCT01834235|DRUG|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
214652268|NCT05191043|OTHER|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
215031440|NCT03292029|DIAGNOSTIC_TEST|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
215031441|NCT00538447|OTHER|Database|data base for CML
214240365|NCT04972630|BEHAVIORAL|Pal-Care|"Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies."
214240366|NCT04972630|BEHAVIORAL|Control-Usual Care|"The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
214240367|NCT01053936|DRUG|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
214240368|NCT02446652|DRUG|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
214240369|NCT02446652|DRUG|Placebo|Placebo (orally) starting 1 week before the first day of the QT
214240370|NCT02446652|DRUG|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
214240371|NCT02446652|DRUG|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
214240372|NCT06131762|OTHER|Active release technique|This include active release technique for 4 weeks
214240373|NCT06131762|OTHER|Positional release technique|This include positional release technique for 4 weeks
214240374|NCT03452475|DRUG|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
214240375|NCT03452475|DRUG|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
214240376|NCT03452475|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
214240377|NCT02814331|DEVICE|multimodal high-resolution EEG-NIRS|
214240378|NCT06394687|DIETARY_SUPPLEMENT|Milk Protein Concentrate|Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.
214240379|NCT06394687|DIETARY_SUPPLEMENT|Micellar Casein Isolate|Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.
214240380|NCT01070797|BIOLOGICAL|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
214240381|NCT05115994|DEVICE|Continous positive airway pressure|
214240382|NCT05868148|DEVICE|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
214240383|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240384|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240385|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240386|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240387|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240388|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240389|NCT01905215|DRUG|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
214240390|NCT03518749|OTHER|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
214240391|NCT03518749|OTHER|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
214240392|NCT03518749|BEHAVIORAL|Cognitive control training|cognitive control training with the PASAT
214240393|NCT03461679|PROCEDURE|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
214240394|NCT03461679|PROCEDURE|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
214240395|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
215031442|NCT04942847|DEVICE|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
215031443|NCT04942847|DEVICE|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
214240396|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
214240397|NCT02666963|DRUG|RTA 901 Capsules, 10 or 40 mg|
214240398|NCT02666963|DRUG|Placebo|
214240399|NCT04653246|DRUG|Isatuximab|Via IV at predetermined dosage and predetermined days during each cycle
214240400|NCT04653246|DRUG|Lenalidomide|Oral, predetermined dosage and predetermined days during each cycle
214240401|NCT04653246|DRUG|Bortezomib Injection|SQ Oral, predetermined dosage and predetermined days during each cycle
214240402|NCT04653246|DRUG|Dexamethasone|IV or Oral predetermined dosage and predetermined days during each cycle
214240403|NCT06450041|DRUG|Universal Donor (UD) TGFβi NK Cells|Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
214240404|NCT06450041|DRUG|Temozolomide|Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
214240405|NCT06450041|DRUG|Irinotecan|50mg/m2/dose IV daily on days 1-5 of each cycle
214240406|NCT06450041|DRUG|Dinutuximab|17.5mg/m2/dose IV daily on days 2-5 of each cycle
214240407|NCT06450041|DRUG|GM-CSF|250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
214240408|NCT02392871|RADIATION|Palliative radiotherapy|
214240409|NCT02392871|DRUG|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
214240410|NCT05564195|DIAGNOSTIC_TEST|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
214240411|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
214240412|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
214240413|NCT04221204|DRUG|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
214240414|NCT06101641|OTHER|Shellac nail polish application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
214240415|NCT02339376|DEVICE|Low-frequency repetitive transcranial magnetic stimulation|
214652269|NCT05191043|OTHER|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
214240416|NCT02339376|DEVICE|High-frequency repetitive transcranial magnetic stimulation|
214240417|NCT02339376|DEVICE|Sham repetitive transcranial magnetic stimulation|
214240418|NCT00811889|OTHER|Placebo|Placebo
214240419|NCT00811889|DRUG|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
214240420|NCT04827667|DIAGNOSTIC_TEST|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
214240421|NCT03390842|DRUG|TRC101|Oral suspension
214240422|NCT03390842|DRUG|Placebo|Oral suspension
214240423|NCT03947476|DEVICE|thoracic band|Thoracic band fixation
214240424|NCT01351675|DRUG|Placebo|Oral, once daily
214240425|NCT01351675|DRUG|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
214240426|NCT01860729|DRUG|Anacetrapib|
214240427|NCT01860729|DRUG|Placebo|
214240428|NCT03481179|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
214240429|NCT03481179|OTHER|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
214240430|NCT01129024|DRUG|Lusutrombopag|tablet
214240431|NCT04039100|OTHER|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
214652270|NCT04271761|OTHER|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
214240432|NCT02631993|RADIATION|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
214240433|NCT05754840|DRUG|MPL-001|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
214240434|NCT05754840|DRUG|MPL-005|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
214240435|NCT05754840|DRUG|MPL-009|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
214240436|NCT05418309|DRUG|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
214240437|NCT01871480|DRUG|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
214240438|NCT01871480|DRUG|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
214240439|NCT04042246|BEHAVIORAL|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
214240440|NCT01239719|DRUG|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
214240441|NCT01239719|DRUG|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
214240442|NCT03348436|PROCEDURE|radiofrequency ablation|
214240443|NCT01394640|BIOLOGICAL|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
214240444|NCT03997292|DRUG|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
214240445|NCT03997292|DRUG|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
214240446|NCT00382642|DRUG|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
214240447|NCT00382642|DRUG|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
214240448|NCT01115192|PROCEDURE|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
214240449|NCT01115192|PROCEDURE|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
214240450|NCT03442868|DEVICE|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
214240451|NCT05228379|PROCEDURE|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
214240452|NCT06449937|PROCEDURE|Radical local Surgery|Radical local resection of liver metastases ( hepatectomy, ablation )
214240453|NCT06449937|DRUG|Systemic therapy|Chemotherapy, targeted drug therapy, immunotherapy treatment.
214240454|NCT06449937|OTHER|Interventional therapy|Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
214240455|NCT06414785|OTHER|analysis of samples of periprosthetic capsules taken during breast implant change procedure|characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment
214240456|NCT01261468|DEVICE|Active SCS|SCS IPG activated
214652271|NCT05408689|DEVICE|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
214652272|NCT05408689|DEVICE|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
214240457|NCT01261468|DEVICE|Deactivated|SCS IPG deactivated
214240458|NCT02228616|DRUG|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
214240459|NCT02228616|DRUG|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
214240460|NCT02228616|DRUG|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
214240461|NCT05864456|DEVICE|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
214240462|NCT04173598|BEHAVIORAL|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
214240463|NCT04173598|BEHAVIORAL|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
214240464|NCT03254615|BEHAVIORAL|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
214240465|NCT05973149|DRUG|QLH12016|according to the scheme description
214240466|NCT02266953|BEHAVIORAL|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
214240467|NCT02266953|BEHAVIORAL|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
214240468|NCT04656899|BEHAVIORAL|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
214240469|NCT00231556|DRUG|topiramate|
214240470|NCT04372056|BEHAVIORAL|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
214240471|NCT01072565|OTHER|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
214240472|NCT01072565|OTHER|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
214240473|NCT00000477|DRUG|lovastatin|
214240474|NCT02011139|BEHAVIORAL|Cognitive-behavioral group therapy|
214240475|NCT04145843|PROCEDURE|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
214240476|NCT00838864|DRUG|ceftrioxone|500 mg iv q12h for 3 days
214240477|NCT00838864|DRUG|ceftrioxone|500 mg q12h for 7 days
214240478|NCT02828215|DEVICE|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
214240479|NCT03513848|DEVICE|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
214240480|NCT03513848|DEVICE|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
214240481|NCT06024512|DEVICE|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
214240482|NCT01453582|DRUG|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
214240483|NCT01453582|DRUG|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
214240484|NCT04095585|GENETIC|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
214240485|NCT00686634|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth once daily
214240486|NCT00672113|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
214652273|NCT05408689|DEVICE|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
214652274|NCT01784887|DRUG|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
214652275|NCT04697966|BEHAVIORAL|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
214240487|NCT00672113|DRUG|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
214240488|NCT05179551|PROCEDURE|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
214240489|NCT00335270|DRUG|fos-amprenavir calcium, ritonavir|
214240490|NCT00335270|DRUG|abacavir/lamivudine as Epzicom|
214240491|NCT00799773|DRUG|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
214240492|NCT00799773|PROCEDURE|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
214240493|NCT00799773|DRUG|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
214240494|NCT06003179|DRUG|Cyclophosphamide|Conditioning chemo at different doses
214240495|NCT06003179|RADIATION|TLI|radiation given with conditioning chemo
214240496|NCT06003179|DRUG|Fludarabine|Fludarabine given as part of standard treatment
214240497|NCT03303027|DEVICE|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
214240498|NCT03303027|DEVICE|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
214240499|NCT01439698|DEVICE|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
214240500|NCT00924781|DRUG|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
214240501|NCT00924781|DRUG|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
214240502|NCT00924781|DRUG|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
214240503|NCT03819907|COMBINATION_PRODUCT|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
214240504|NCT03819907|COMBINATION_PRODUCT|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
214652276|NCT04697966|BEHAVIORAL|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
214240505|NCT02042820|OTHER|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
214240506|NCT01385228|DRUG|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
214240507|NCT01385228|DRUG|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
214240508|NCT01385228|DRUG|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
214240509|NCT01385228|DRUG|Prednisone|5mg Prednisone given twice daily days 1-21.
214240510|NCT01385228|DRUG|Pegfilgrastim|
214240511|NCT00069888|DRUG|Docetaxel|
214240512|NCT00937885|BEHAVIORAL|Implementation of reminiscence|
214240513|NCT01294527|DEVICE|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
214240514|NCT06032481|PROCEDURE|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
214240515|NCT01653132|DRUG|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
214240516|NCT01653132|DRUG|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
214240517|NCT03865797|OTHER|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
214240518|NCT03865797|OTHER|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
214240519|NCT03828370|BEHAVIORAL|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
214240520|NCT03828370|BEHAVIORAL|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
214240521|NCT04690062|DRUG|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
214240522|NCT01663077|DRUG|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
214240523|NCT03016676|OTHER|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
214240524|NCT03016676|OTHER|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
214240525|NCT03231020|OTHER|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
214240526|NCT03986073|DRUG|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
214240527|NCT03986073|DRUG|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
214240528|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
214240529|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
214240530|NCT03986073|DRUG|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
214240531|NCT03986073|DRUG|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
214240532|NCT01830400|DRUG|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
214240533|NCT03518476|BEHAVIORAL|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
214240534|NCT03518476|OTHER|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
214240535|NCT02677324|DRUG|ABT199|Oral BCL-2 antagonist
214652277|NCT06848361|DEVICE|MPowerHub|The MPowerHub app allows participants to visualize combined trends from a continuous glucose monitor (CGM) and activity monitor as well as daily self-reports in a display that the participant can customize to overlay the behavioral data they would like to compare to intraday and daily glucose data. Summary data will be displayed over time to allow users to identify potential associations between activity, sleep, stress, diet, and medication adherence and time-in-range and blood glucose variability. Participants receive daily prompts to complete five brief questions about daily health behaviors and two weekly goals/action plans and reflections based on motivational interviewing principles.
214240536|NCT00461331|DRUG|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
214240537|NCT00461331|DRUG|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
214240538|NCT05860010|DRUG|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
214240539|NCT05860010|DRUG|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
214240540|NCT05860010|DRUG|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
214240541|NCT03312751|DRUG|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
214240542|NCT00241501|DRUG|Esomeprazole (Nexium)|
214240543|NCT03748043|DRUG|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
214240544|NCT03748043|DRUG|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
214240545|NCT05578027|PROCEDURE|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
214240546|NCT00475423|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214240547|NCT04700033|DEVICE|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
214240548|NCT04700033|DEVICE|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
214240549|NCT04700033|DEVICE|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
214240550|NCT00287170|DRUG|Delayed Release 6MP or Calcitriol vs. Purinethol|
214240551|NCT05111275|OTHER|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
214240552|NCT01348009|DRUG|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
214240553|NCT00088998|BIOLOGICAL|bevacizumab|
214240554|NCT00088998|DRUG|capecitabine|
214240555|NCT00088998|DRUG|docetaxel|
214240556|NCT01492543|DRUG|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
214240557|NCT03473418|DRUG|Ketoconazole|Ketoconazole as a topical vaginal gel
214240558|NCT03473418|DRUG|Terconazole|Terconazole 80 mg as a topical vaginal cream
214240559|NCT04309123|DEVICE|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
214240560|NCT04224545|DRUG|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
214240561|NCT04224545|DRUG|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
214240562|NCT02127060|DRUG|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
214240563|NCT02127060|DRUG|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
214240564|NCT05956184|DEVICE|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
214240565|NCT01954420|BEHAVIORAL|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
214240566|NCT01954420|OTHER|Attention Control|Standard care + Cancer education
214240567|NCT02633852|DRUG|Aflibercept|
214240568|NCT00879931|DRUG|Methylprednisolone|Methylprednisolone
214240569|NCT00879931|DRUG|Placebo|Placebo (NaCl 0.9%)
214240570|NCT00719797|BIOLOGICAL|bevacizumab|Given IV
214240571|NCT00719797|DRUG|fluorouracil|Given IV
214240572|NCT00719797|DRUG|irinotecan hydrochloride|Given IV
214240573|NCT00719797|DRUG|leucovorin calcium|Given IV
214240574|NCT00719797|DRUG|oxaliplatin|Given IV
214240575|NCT00046891|DRUG|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
214240576|NCT00046891|OTHER|Placebo|Patients will take 1 tablet BID
214240577|NCT06143605|PROCEDURE|salvage treatment|salvage radical surgery or endoscopic resection
214240578|NCT04349293|PROCEDURE|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
214240579|NCT04349293|PROCEDURE|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
214240580|NCT03252600|DRUG|Cyclophosphamide|Given IV
214240581|NCT03252600|DRUG|Dexamethasone|Given IV
214240582|NCT03252600|BIOLOGICAL|Elotuzumab|Given IV
214240583|NCT03252600|OTHER|Laboratory Biomarker Analysis|Correlative studies
214240584|NCT03252600|DRUG|Lenalidomide|Given PO
214240585|NCT03252600|OTHER|Pharmacological Study|Correlative studies
214240586|NCT01589627|DEVICE|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
214240587|NCT04378985|DEVICE|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
214240588|NCT01198379|DRUG|aspirin|aspirin 100 mg qd for 3 years
214240589|NCT01198379|DRUG|Placebo|
214240590|NCT02496676|DIETARY_SUPPLEMENT|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
214240591|NCT02496676|OTHER|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
214240592|NCT02496676|DRUG|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
214240593|NCT02265601|OTHER|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
214240594|NCT02265601|OTHER|standard care|paper/pencil living will form
214240595|NCT05444140|BEHAVIORAL|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
214240596|NCT00006157|DRUG|Desipramine|
214240597|NCT00006157|BEHAVIORAL|Cognitive Behavioral Treatment|
214240598|NCT00756925|DRUG|Acthrel|1 ug/kg, i.v., 1 minute
214240599|NCT06195761|PROCEDURE|computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide
214240600|NCT06195761|PROCEDURE|free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
214240601|NCT02666703|DEVICE|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
214240602|NCT02666703|DRUG|Methylprednisolone|
214240603|NCT06329089|PROCEDURE|Reoperative Sentinel Lymph Node Biopsy|Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
214240604|NCT04048161|DRUG|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
214240605|NCT04048161|DRUG|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
214240606|NCT02203084|OTHER|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
214240607|NCT00235001|DRUG|trandolapril/verapamil|180/2 mg QD
214240608|NCT05636488|OTHER|No intervention|There is no intervention group in this study
214240609|NCT00644644|OTHER|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
214240610|NCT04417426|OTHER|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
214240611|NCT01693302|OTHER|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
214240612|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
214240613|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
214240614|NCT01795820|DRUG|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
214240615|NCT01795820|DRUG|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
214240616|NCT04698330|DRUG|Berberine|0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
214240617|NCT04698330|DRUG|Inulin|0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
214240618|NCT04698330|DRUG|Berberine placebo tablets|0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
214240619|NCT04698330|DRUG|Inulin placebo tablets|0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
214240620|NCT06570824|DEVICE|active TMS|Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
214240621|NCT06570824|DEVICE|sham TMS|Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
214240622|NCT05518877|DRUG|Ketamine|Administration of Ketamine
214240623|NCT01079702|DRUG|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
214240624|NCT01079702|DRUG|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
214240625|NCT03734705|BEHAVIORAL|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
214240626|NCT03734705|OTHER|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
214240627|NCT06158581|BEHAVIORAL|The Emotion Awareness and Skills Enhancement Program|"EASE is a cutting-edge program created by researchers at the University of Alabama and the University of Pittsburgh in collaboration with autistic individuals, caregivers of autistic youth, and therapists. The overarching goal of the program is to support autistic clients who want to work on emotion regulation. EASE is unique because it targets emotional distress in autistic youth and adults, instead of targeting the core symptoms of autism (i.e., it is not a social skills intervention).~The program is a 16-session, mindfulness-based intervention. Each session is 1:1 for 45 minutes to one hour. While the program is designed for individual intervention, caregivers are also invited to play an active role on the care team."
214240628|NCT06158581|BEHAVIORAL|The Unified Protocol|"UP is a thoroughly-studied, manualized intervention created by researchers at the University of Miami in conjunction with researchers at Boston University. The program was designed to be customizable to meet the needs of people with a variety of diagnoses, allowing more individuals to access emotion regulation resources. The protocol also has different modules to accommodate different developmental levels (UP-Children, UP-Adolescent, UP-Adult). The overall goal of UP is to help clients identify emotions and build new strategies to cope with stressful life situations and distressing emotions.~The protocol is flexible, with each session is about 45 to 60 minutes and the number of sessions varying between 12 - 21 sessions. For the current study, the treatment will take place over 16 sessions. The intervention is cognitive behavioral therapy (CBT) based but also includes hints of mindfulness-based intervention strategies."
214240629|NCT04489901|OTHER|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
214240630|NCT03849391|DIETARY_SUPPLEMENT|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
214240631|NCT03849391|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
214240632|NCT01967498|DRUG|Montelukast|
214240633|NCT01789918|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
214240634|NCT04221243|DEVICE|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
214240635|NCT04221243|DEVICE|Conventional Band and Loop|metal space maintainer
214240636|NCT00098982|DRUG|bortezomib|
214240637|NCT00098982|DRUG|fluorouracil|
214240638|NCT00098982|DRUG|leucovorin calcium|
214240639|NCT00098982|DRUG|oxaliplatin|
214240640|NCT02484625|OTHER|Potato chips|Commercially available potato chips, 180 kcal
214240641|NCT02484625|OTHER|Greek yogurt|Commercially available Greek yogurt, 180 kcal
214240642|NCT02484625|OTHER|Cookies|Commercially available cookies, 180 kcal
214240643|NCT02484625|OTHER|Cheese|Commercially available cheese, 180 kcal
214240644|NCT02484625|OTHER|Milk|Commercially available milk, 180 kcal
214240645|NCT00659477|DRUG|insulin glargine|once daily
214240646|NCT05331027|DRUG|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
214240647|NCT05331027|DRUG|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
214240648|NCT00319319|DRUG|Mecamylamine hydrochloride (Inversine)|
214240649|NCT01334827|OTHER|high volume gel|4 mL HEC
214240650|NCT01334827|OTHER|low volume gel|2 mL HEC
214240651|NCT01334827|OTHER|vaginal film|"1 x 2 intravaginal quick-dissolving film"
214240652|NCT04315974|DRUG|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
214240653|NCT04315974|PROCEDURE|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
214240654|NCT02078973|DRUG|15 mg tolvaptan|15 mg pr day for 1 day
214240655|NCT02078973|DRUG|30 mg tolvaptan|30 mg pr day for 1 day
214240656|NCT02078973|DRUG|45 mg tolvaptan|45 mg pr day for 1 day
214240657|NCT02078973|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
214240658|NCT05638672|DRUG|Huashi Baidu Granule|Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
214240659|NCT05638672|DRUG|Monapiravir|Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
214240660|NCT06189781|DRUG|Ropivacaine injection|The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.
214240661|NCT06189781|DRUG|Bupivacaine, lidocaine, ropivacaine|The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
214240662|NCT04672252|DRUG|CBD Oral Disintegrating Tablet (ODT)|Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
214240663|NCT04672252|OTHER|Placebo ODT|"Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine."
214240664|NCT02927912|RADIATION|Electron Beam Therapy|Undergo IOERT boost
214240665|NCT02927912|PROCEDURE|Lumpectomy|Undergo lumpectomy
214240666|NCT02927912|OTHER|Quality-of-Life Assessment|Ancillary studies
214240667|NCT02927912|OTHER|Questionnaire Administration|Ancillary studies
214240668|NCT02927912|RADIATION|Radiation Therapy|Undergo whole breast radiation therapy
214240669|NCT02927912|PROCEDURE|Reconstructive Surgery|Undergo oncoplastic reconstruction
214240670|NCT02391805|DRUG|Entecavir|Entecavir will be administered as per local labeling.
214240671|NCT02391805|DRUG|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
214240672|NCT02391805|DRUG|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
214240673|NCT02391805|DRUG|Tenofovir|Tenofovir will be administered as per local labeling.
214240674|NCT03751735|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
214240675|NCT04391569|DRUG|Ganaxolone|Ganaxolone will be administered.
214240676|NCT04391569|DRUG|Placebo|Placebo will be administered.
214240677|NCT05911243|PROCEDURE|Acupressure Therapy|Undergo auricular acupressure
214240678|NCT05911243|OTHER|Best Practice|Receive usual care
214240679|NCT05911243|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214240680|NCT05911243|OTHER|Questionnaire Administration|Ancillary studies
214240681|NCT04463797|OTHER|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
214240682|NCT04463797|OTHER|Stretching and strengthening|whole-body stretching and upper extremity strengthening
214240683|NCT01952808|BEHAVIORAL|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
214240684|NCT01952808|BEHAVIORAL|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
214240685|NCT00935155|PROCEDURE|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
214240686|NCT00935155|PROCEDURE|exercises|Coordination, mobilizing, endurance, strength
214240687|NCT03647189|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser
214240688|NCT00305929|DRUG|Treatment with Tookad VTP|
214240689|NCT00305929|DRUG|Treatment with Tookad VTP|Tookad 2 mg/kg
214240690|NCT00305929|DRUG|Treatment with Tookad VTP|2 mg/kg
214240691|NCT03037645|DRUG|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
214240692|NCT01431638|DRUG|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
214240693|NCT00536393|DRUG|Doxorubicin|
214240694|NCT00536393|DRUG|Doxorubicin pegylated|
214240695|NCT04253054|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
214240696|NCT04253054|OTHER|Aging related health problems|Aging related health problems
214240697|NCT03603171|DIAGNOSTIC_TEST|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
214240698|NCT03603171|DIAGNOSTIC_TEST|R-PAct|A Rasch-built Pompe-specific activity scale.
214240699|NCT03603171|DIAGNOSTIC_TEST|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
214240700|NCT03603171|DIAGNOSTIC_TEST|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
214240701|NCT03603171|DIAGNOSTIC_TEST|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
214240702|NCT03603171|DIAGNOSTIC_TEST|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
214240703|NCT03603171|DIAGNOSTIC_TEST|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
214240704|NCT03603171|DIAGNOSTIC_TEST|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
214240705|NCT03603171|DIAGNOSTIC_TEST|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
214240706|NCT03603171|DIAGNOSTIC_TEST|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
214240707|NCT03603171|DIAGNOSTIC_TEST|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference \> 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
214240708|NCT03603171|DIAGNOSTIC_TEST|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
214240709|NCT03603171|DIAGNOSTIC_TEST|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
214240710|NCT03603171|DIAGNOSTIC_TEST|Quick motor function test|Assessment of proximal motor function.
214240711|NCT03603171|DIAGNOSTIC_TEST|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
214240712|NCT03603171|DIAGNOSTIC_TEST|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
214240713|NCT03603171|DIAGNOSTIC_TEST|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
214240714|NCT03603171|DIAGNOSTIC_TEST|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
214240715|NCT03603171|DIAGNOSTIC_TEST|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
214240716|NCT00108108|DRUG|HCD122|
214240717|NCT00168792|DRUG|Tenecteplase|
214240718|NCT00168792|PROCEDURE|PCI|
214240719|NCT03543488|DIAGNOSTIC_TEST|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
214240720|NCT02227940|DRUG|Ceritinib|Given PO
214240721|NCT02227940|DRUG|Cisplatin|Given IV
214240722|NCT02227940|DRUG|Gemcitabine Hydrochloride|Given IV
214240723|NCT02227940|OTHER|Laboratory Biomarker Analysis|Correlative studies
214240724|NCT02227940|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214240725|NCT02227940|OTHER|Pharmacological Study|Correlative studies
214240726|NCT04967040|PROCEDURE|medial plantar artery flap|Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
214240727|NCT04967040|PROCEDURE|Distally based sural artery flap|Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
214240728|NCT05824507|DIAGNOSTIC_TEST|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
214240729|NCT03338413|BEHAVIORAL|Goal Management Training|9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
214240730|NCT03338413|BEHAVIORAL|Computerized Cognitive Training|9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
214240731|NCT03706651|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
214652278|NCT06848361|DEVICE|Continuous Glucose Monitor (CGM)|A CGM is a wearable device that collects frequent data on glucose levels. It includes an integrated sensor that is inserted under the skin and is connected to a small transmitter that automatically sends information to a smart device, allowing the user to track changes in glucose levels.
214652279|NCT06848361|DEVICE|Activity Monitor|A wearable activity monitor will be used to track activity (e.g., steps) and sleep levels. Data can be viewed on the activity monitor or a smart device.
214652280|NCT00720928|DRUG|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
214652281|NCT06203054|DEVICE|Penditure™ Left Atrial Appendage (LAA) Exclusion System|Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
214240732|NCT00773838|DRUG|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
214240733|NCT00773838|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
214240734|NCT00773838|DRUG|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
214240735|NCT02139059|PROCEDURE|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
214240736|NCT02139059|PROCEDURE|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
214240737|NCT03627390|DRUG|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
214240738|NCT03627390|DRUG|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
214240739|NCT03351101|DEVICE|Senofilcon C|Senofilcon C Contact Lens
214240740|NCT03351101|DEVICE|Samfilcon A|Samfilcon A Contact Lens
214240741|NCT06134531|DRUG|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
214240742|NCT06984107|DEVICE|MRONJ resection plus PN+HA|Surgical management will be performed by reflecting a full-thick flap to expose the entire affected area, followed by removal of necrotic bone until a vital, unaffected bony margin will be obtained. After bone resection, the PN+HA (Regenfast®) will be applied on the residual bone surface. Wound management will be done via primary closure.
214240743|NCT04445792|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
214240744|NCT04445792|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
214240745|NCT06987864|BIOLOGICAL|eculizumab|Intravenous infusion of BCD-148 every 2 weeks
214240746|NCT05671809|OTHER|NCRT with surgery, or NCT with surgery, or surgery|The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
214240747|NCT06995027|PROCEDURE|BBAP and RAA pacing|Bachmann's bundle area pacing and conventional pacing in the right atrial appendage during regular pacemaker implantation procedures are applied for acute electrocardiogram and echocardiogram testings.
214240748|NCT06993727|OTHER|Blood sampling|For the analysis of the autoimmune endocrine disease related antibodies (Ab) before the start of the immunotherapy, a blood sample will be collected aligned with the first visit with the treating gastro-enterologist/oncologist/pneumologist for analysis of: anti-thyroglobulin Ab (aTg), anti-thyroperoxidase Ab (aTPO), TSH receptor antibodies (TRAb), pituitary Ab, adrenal Ab, and anti-glutamic acid decarboxylase (GAD) Ab.
214240749|NCT06993701|BEHAVIORAL|Vimala Massage Training for Fathers|Fathers will receive Vimala massage training and apply it regularly to their babies at home.
214240750|NCT06993701|OTHER|Control Intervention|babies in the control group will not receive any intervention
214240751|NCT06993701|BEHAVIORAL|Vimala Massage Training for Mothers|Mothers will receive Vimala massage training and apply it regularly to their babies at home.
214240752|NCT06995664|PROCEDURE|radiotherapy|External Beam Radiotherapy - hypofractionated, short radiotherapy regime of 30Gy in 5 fractions (6Gy per fraction) delivered on alternate days over 2 weeks
214652282|NCT02651090|DRUG|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
214652283|NCT02733029|DRUG|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
214652284|NCT02733029|DEVICE|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
214652285|NCT00332709|DRUG|Letrozole|2.5 mg/day for 3 years
214652286|NCT00332709|DRUG|Zoledronic acid|4 mg every 6 months
214652287|NCT03575104|DRUG|Daridorexant|Daridorexant will be administered as tablets, orally, once daily in the evening.
214652288|NCT03575104|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
214652289|NCT04988698|OTHER|none intervention|none intervention
214240753|NCT06995768|OTHER|Sweat patch|Wear sweat patch during regular team sports practice session
214240754|NCT06995222|DIAGNOSTIC_TEST|renal resistive index with Doppler ultrasound|"Renal resistive index uses doppler ultrasonography which assesses blood flow velocity in the renal arteries. The Renal Resistive Index (RI) is calculated by substracting diastolic velocity from systolic velocity then dividing result by systolic velocity~Where:~Systolic velocity is the peak velocity of the blood flow during the systolic phase of the cardiac cycle.~Diastolic velocity is the velocity of blood flow during the diastolic phase."
214652290|NCT05944536|OTHER|Balance Exercises (BE)|Each exercise was performed with 10 repetitions for both lower limbs.
214652291|NCT05944536|OTHER|BE + Dual Task|Cognitive and motor secondary tasks were given
214652292|NCT05726357|PROCEDURE|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
214652293|NCT02145962|DEVICE|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
214240755|NCT06993532|OTHER|Validity and Reliability|The TASD questionnaire, the Thumb Disability Examination (TDX) questionnaire, the Visual Analogue Scale (VAS) for pain, as well as hand grip and pinch strength measurements using the Jamar® Hydraulic Hand Dynamometer and Jamar Hydraulic Pinch Gauge Dynamometer were employed to assess thumb function and muscle strength. The questionnaires were administered twice, with a 7-day interval, during which no medical or rehabilitation intervention was made that could alter the clinical condition of the patients.
214240756|NCT06995443|OTHER|Photobiomodulation|12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)
214240757|NCT06995599|PROCEDURE|Thoracic Duct Ligation (TDL)|Following the minimally invasive right-sided lung cancer resection, during mediastinal lymph node dissection, the posterior aspect of the azygos vein is identified. The mediastinal pleura is then longitudinally incised along the medial border of the azygos vein and posterior to the esophagus. Between the azygos vein and aorta, the thoracic duct is meticulously localized as a milky-white translucent structure measuring 2-3 mm in diameter. A 5-mm segment of the duct is carefully mobilized and double-clamped with vascular clips under direct thoracoscopic visualization. The surgical field is thoroughly inspected to confirm the absence of chylous leakage, and the procedure is concluded after standard closure and confirmation of hemostasis.
214240758|NCT06988592|DRUG|GemCis plus PD-1/PD-L1 inhibitor|"Gemcitabine: 1000 mg/m², intravenous infusion, on Day 1 and Day 8 Cisplatin: 25 mg/m², intravenous infusion, on Day 1 and Day 8 PD-1/PD-L1 inhibitor: An approved agent (e.g., Pembrolizumab, Nivolumab, Atezolizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.~Each treatment cycle lasts 21 days, continuing until disease progression, unacceptable toxicity, or patient/physician decision to discontinue."
214240759|NCT06995040|DIAGNOSTIC_TEST|Cerebral MRI without contrast agent injection|Cerebral MRI at inclusion or after
214240760|NCT06995040|GENETIC|saliva sample|Saliva sample for DNA analysis at inclusion or send to their home.
214240761|NCT06995040|OTHER|Questionnaires|Quality of life and cognitive questionnaires at inclusion
214240762|NCT06995560|DEVICE|Active Transcranial Electrical Stimulation|Active tES delivered using the Soterix Medical MXN-33 HD-tES stimulator. Stimulation is applied via high definition electrodes targeting either the left DLPFC or L-aINS at intensities up to 1.9 mA. Stimulation is performed for up to 45 minutes during task execution. Participants perform the ROBoT-r task during stimulation.
214240763|NCT06995560|DEVICE|Sham Transcranial Electrical Stimulation|Sham tES using the same Soterix Medical MXN-33 HD-tES stimulator and electrode placements. Stimulation ramps up and down over 20 seconds to mimic sensation but provides no continuous current. Participants perform the ROBoT-R task under sham conditions.
214240764|NCT06995157|BIOLOGICAL|Offering HPV vaccine|During regular cervical cancer prevention visit with the gynecologist, HPV vaccine will be offered to participants 35 years or younger.
214240765|NCT06994039|PROCEDURE|EUS-lePPG|EUS-PPG measured in left lateral decubitus position
214240766|NCT06995287|DRUG|Xeomin|One injection will be performed via hysteroscopy under local anesthesia.
214240767|NCT06995287|DRUG|Placebo|One injection will be performed via hysteroscopy under local anesthesia.
214240768|NCT01074905|DRUG|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
214240769|NCT01074905|DRUG|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
214240770|NCT01074905|DRUG|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
214240771|NCT01848197|DRUG|paclitaxel|
214240772|NCT03529812|BEHAVIORAL|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
214240773|NCT04085367|DRUG|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
214240774|NCT04085367|DRUG|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
214240775|NCT05060523|DRUG|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
214240776|NCT05060523|DRUG|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
214240777|NCT05060523|OTHER|Placebo|Placebo of Midodrine
214240778|NCT03455959|PROCEDURE|Bronchoscopy/BAL|Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
214240779|NCT03455959|PROCEDURE|Airway Brushing|After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
214240780|NCT00733850|DRUG|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
214240781|NCT00733850|DRUG|Gemcitabine|Intravenous repeating dose
214240782|NCT03697174|OTHER|200 ppb ozone group|The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
214240783|NCT03697174|OTHER|0 ppb ozone group|The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
214240784|NCT01245517|OTHER|Education|Dietary Phosphorus Education Program
214240785|NCT05502536|OTHER|Traditional rehabilitation programs with Individualized fairytales class|In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
214240786|NCT02383030|DRUG|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
214240787|NCT06332638|DRUG|Tegoprazan 12.5mg|Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
214240788|NCT06332638|DRUG|Tegoprazan 25mg|Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
214240789|NCT06332638|DRUG|Famotidine 20mg|Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
214240790|NCT06287606|DRUG|CTP0302-A|Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
214240791|NCT06287606|DRUG|CTP0302-B|Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
214240792|NCT06287606|DRUG|Conventional OST|Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
214240793|NCT04949919|OTHER|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
214240794|NCT05634356|BEHAVIORAL|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
214240795|NCT05719142|OTHER|Picture exposure|Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
214240796|NCT01528423|PROCEDURE|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
214240797|NCT02821143|OTHER|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
214240798|NCT02821143|OTHER|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
214240799|NCT02981576|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
214240800|NCT05175118|DEVICE|Minimal invasive surgical fixation of distal radius Fractures|Fixation of distal radius Fractures by minimal invasive technique
214240801|NCT03789409|DIETARY_SUPPLEMENT|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
214240802|NCT06433362|DRUG|CMOEP|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
214240803|NCT03874481|OTHER|Observation|follow up regularly for MACE
214240804|NCT02262312|OTHER|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
214240805|NCT00879944|OTHER|Blood pressure|Blood pressure will be measured once while patient is seated
214240806|NCT00879944|OTHER|Height|Height will be measured in centimeters at the time of enrollment
214240807|NCT00879944|OTHER|Weight|Weight will be measured in kilograms at enrollment
214240808|NCT00879944|OTHER|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
214240809|NCT00879944|OTHER|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
214240810|NCT03274999|DEVICE|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
214240811|NCT03076229|BEHAVIORAL|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
214240812|NCT01097876|DRUG|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
214240813|NCT01097876|DRUG|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
214240814|NCT03624530|DRUG|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
214240815|NCT02749123|DRUG|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
214240816|NCT02749123|DRUG|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
214240817|NCT02749123|DRUG|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
214240818|NCT06468384|PROCEDURE|thoracic erector spinae plane (ESP) block|The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
214240819|NCT04258137|GENETIC|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
214240820|NCT02898571|DIETARY_SUPPLEMENT|Placebo|Placebo comparitor
214240821|NCT02898571|DIETARY_SUPPLEMENT|Vitamin C|Active treatment
214240822|NCT02898571|DIETARY_SUPPLEMENT|epicatechin|Active treatment
214240823|NCT04438564|OTHER|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
214240824|NCT02097927|BEHAVIORAL|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
214240825|NCT01752712|DRUG|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
214240826|NCT01752712|DRUG|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
214240827|NCT05200494|PROCEDURE|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
214240828|NCT00375869|DRUG|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
214240829|NCT00375869|DRUG|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
214240830|NCT02440412|OTHER|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
214240831|NCT02440412|OTHER|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
214240832|NCT03495544|DIAGNOSTIC_TEST|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
214240833|NCT00003854|OTHER|immunohistochemistry staining method|
214240834|NCT00003854|PROCEDURE|lymphangiography|
214240835|NCT00003854|PROCEDURE|sentinel lymph node biopsy|
214240836|NCT00003854|PROCEDURE|therapeutic conventional surgery|
214240837|NCT00003854|RADIATION|whole breast irradiation|
214240838|NCT04475809|PROCEDURE|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
214240839|NCT04475809|PROCEDURE|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
214240840|NCT04475809|PROCEDURE|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
214240841|NCT04475809|PROCEDURE|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
214240842|NCT01631656|DRUG|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
214240843|NCT01631656|DEVICE|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
214240844|NCT03923478|DRUG|ABI-M201|Active Treatment
214240845|NCT03923478|DRUG|Placebo|Control Treatment
214240846|NCT05954104|DRUG|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
214240847|NCT06164210|BEHAVIORAL|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
214240848|NCT06079528|DEVICE|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
214240849|NCT06079528|OTHER|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
214240850|NCT06079528|OTHER|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
214240851|NCT06079528|OTHER|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
214240852|NCT03484260|DRUG|Testosterone Product|Men used testosterone product following prescription
214240853|NCT04518202|DRUG|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
214240854|NCT04518202|DRUG|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
214240855|NCT04325984|DRUG|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
214240856|NCT06381271|PROCEDURE|Transcatheter aortic valve replacement|A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
214652294|NCT02145962|DEVICE|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
214652295|NCT04226469|PROCEDURE|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
214240857|NCT00507468|PROCEDURE|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
214240858|NCT04776044|DRUG|ATR-002|150mg tablets for oral intake
214240859|NCT04776044|DRUG|Placebo|matching tablets for oral intake
214240860|NCT00849888|BIOLOGICAL|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
214652296|NCT06300515|BEHAVIORAL|Control Group (Active Comparator)|During the intervention phase (hospitalization for HSCT and subsequent 8-week outpatient phase following discharge), the control group will participate in a Health Counseling Program (1 time/week) on aspects related to a healthy lifestyle such as reducing sedentary lifestyle, acquiring healthy nutritional habits, the importance sleep, screen use, and how to address barriers related to clinical status. We will adapt the program to the needs and timing of the patient's treatment, providing the content in one session/week orally (e.g. using presentations) and in writing (e.g. through brochures).
215031444|NCT04379830|DIETARY_SUPPLEMENT|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
215031445|NCT01522872|DRUG|TH-302|
214240861|NCT00849888|OTHER|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
214240862|NCT01843478|OTHER|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
214240863|NCT01843478|OTHER|Usual Care|
214240864|NCT02744001|OTHER|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
214240865|NCT04250311|DRUG|MMH-407|MMH-407: For oral use.
214240866|NCT04250311|DRUG|Placebo|Placebo: For oral use.
214240867|NCT05764070|DEVICE|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
214240868|NCT05764070|DEVICE|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
214240869|NCT06287567|DRUG|Lusutrombopag Oral Tablet|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
214240870|NCT01176942|DIETARY_SUPPLEMENT|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
214240871|NCT01656174|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
214240872|NCT02920853|BEHAVIORAL|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
214240873|NCT02920853|BEHAVIORAL|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
214240874|NCT05171725|DIAGNOSTIC_TEST|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
214240875|NCT05171725|DIAGNOSTIC_TEST|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
214240876|NCT05171725|DIAGNOSTIC_TEST|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
214240877|NCT05171725|DIAGNOSTIC_TEST|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
214240878|NCT05171725|DIAGNOSTIC_TEST|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
214240879|NCT03818984|BEHAVIORAL|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
214240880|NCT00000203|DRUG|Buprenorphine|
214240881|NCT03778775|DIAGNOSTIC_TEST|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
214240882|NCT03088462|OTHER|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
214240883|NCT03088462|BEHAVIORAL|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
214240884|NCT03088462|BEHAVIORAL|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
214240885|NCT03067831|BIOLOGICAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
215031446|NCT01522872|DRUG|TH-302 and Dexamethasone|
214240886|NCT03299179|DEVICE|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
214240887|NCT03299179|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
214240888|NCT03299179|BIOLOGICAL|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
214240889|NCT03299179|DEVICE|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
214240890|NCT03299179|DEVICE|Body temperature|Measuring body temperature before and after MRI-scan
214240891|NCT03299179|OTHER|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
214240892|NCT03299179|DIAGNOSTIC_TEST|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
215031447|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
215031448|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
215031449|NCT04785638|COMBINATION_PRODUCT|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
215031450|NCT04021745|BEHAVIORAL|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
214240893|NCT04440371|COMBINATION_PRODUCT|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
214240894|NCT04440371|COMBINATION_PRODUCT|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
214240895|NCT01849081|DEVICE|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
214240896|NCT01849081|BEHAVIORAL|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
214240897|NCT00434395|DRUG|MOA-728|
214240898|NCT03641885|BEHAVIORAL|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
214240899|NCT03641885|BEHAVIORAL|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
214240900|NCT03641885|BEHAVIORAL|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
214240901|NCT03103815|DRUG|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
214240902|NCT04341753|OTHER|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~\- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
214240903|NCT02684318|DRUG|PM01183 + olaparib|
214240904|NCT02425072|DEVICE|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
214240905|NCT06515509|PROCEDURE|immediate implant placement with or without loading|immediate implant placement with or without loading
214240906|NCT04921098|PROCEDURE|Diode Laser Cyclophotocoagulation|A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
214240907|NCT01713387|DRUG|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
214240908|NCT05592522|OTHER|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
214240909|NCT05592522|OTHER|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
214240910|NCT05592522|OTHER|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
214240911|NCT05105022|DRUG|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
214240912|NCT04961970|DRUG|oxaliplatin , fluorouracil, and leucovorin|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214240913|NCT04961970|DRUG|gemcitabine and cisplatin|administration of gemcitabine and cisplatin via vein
214240914|NCT03663738|BEHAVIORAL|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
214652297|NCT06300515|BEHAVIORAL|Intervention Group|"Same as Control Group + exercise program as described below:~Same as Control Group + exercise program as described below:~Hospital ward (during HSCT); and Hospital Gym or online (patients' home) during the outpatient phase. Frequency: 3-5 days/week. Session duration: 30 to 55-60 minutes Aerobic training (5-25 minutes): bicycling, crank-ergometry, circuit-style exercises, and games. Muscle strength training (10-20 minutes): large muscle group exercises (upper/lower limb + trunk exercises) performed as a circuit using body weight or against resistance (against gravity and with body weight, elastic bands, dumbbells, weighted vests, machines), with a wide range of joint mobility and at submaximal/maximum voluntary speed. Inspiratory muscle training will also be performed (5 min daily, using a specific device that creates resistance against inspiration)."
214240915|NCT02812303|OTHER|Centralized support for population health management activities|
214240916|NCT01545843|BEHAVIORAL|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
214240917|NCT01545843|DRUG|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
214240918|NCT04455984|OTHER|Date collection|Retrospective data analysis
214240919|NCT04243421|DEVICE|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
214240920|NCT03607643|DRUG|Cannabidiol|"* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
214240921|NCT03607643|DRUG|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
214240922|NCT03607643|DRUG|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
214240923|NCT03607643|DRUG|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
214240924|NCT03607643|DRUG|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
214240925|NCT03607643|DRUG|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
214240926|NCT03607643|DRUG|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
214240927|NCT03607643|DRUG|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
214240928|NCT03607643|DRUG|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
214240929|NCT06341803|DEVICE|Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100|MagproX 100 and Axilium Cobot with Localite camera
214240930|NCT05420363|OTHER|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
214240931|NCT05420363|OTHER|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
214240932|NCT01575288|DRUG|Placebo|100g maltose 1/day
214240933|NCT01575288|DRUG|High-dose trehalose|100g 1/day
214240934|NCT03571282|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
214240935|NCT00083096|DRUG|lonafarnib|
214240936|NCT00083096|DRUG|temozolomide|
214240937|NCT00306332|PROCEDURE|T-cell and B-cell depletion|
214240938|NCT04968054|DRUG|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
214240939|NCT04968054|DRUG|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
214240940|NCT02749526|DRUG|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
214240941|NCT02749526|DRUG|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
214240942|NCT02749526|DRUG|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
214240943|NCT02749526|DRUG|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
214240944|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc combined|Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
214652298|NCT03584763|DIAGNOSTIC_TEST|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
214652299|NCT02312570|DEVICE|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
214240945|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc on separate days|Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
214240946|NCT00470158|DIETARY_SUPPLEMENT|iron|Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
214240947|NCT00470158|DIETARY_SUPPLEMENT|Zinc|Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
214240948|NCT00470158|DIETARY_SUPPLEMENT|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
214240949|NCT00841373|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
214240950|NCT00841373|PROCEDURE|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
214652300|NCT02312570|OTHER|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
214240951|NCT01249118|DRUG|GDC-0973 IV Infusion|IV infusion.
214240952|NCT01249118|DRUG|GDC-0973 Oral Capsules|Oral dose.
214652301|NCT00689247|DRUG|AZD1305|oral solution, single dose
214240953|NCT05565885|OTHER|Sampling|4 blood sampling per patient and an additional one in case of relapse
214240954|NCT00541463|DRUG|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
214240955|NCT00541463|DRUG|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
214240956|NCT00880685|DRUG|Memantine|10-30mg, daily for 8 weeks
214240957|NCT05819684|DRUG|SHR-4602 for injection|be administered via intravenous (IV) infusion
214240958|NCT04211805|DRUG|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
214240959|NCT04211805|DRUG|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
214240960|NCT05776797|PROCEDURE|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
214240961|NCT05776797|DRUG|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
214240962|NCT04564118|DRUG|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
214240963|NCT02902796|DEVICE|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
214240964|NCT05380999|DIAGNOSTIC_TEST|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
214240965|NCT05631288|GENETIC|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
214240966|NCT03566069|DRUG|Intranasal Oxytocin|32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
214240967|NCT03566069|OTHER|Intranasal Placebo|32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol.
214240968|NCT03361579|OTHER|Education|c.p. intervention description
214240969|NCT03915522|PROCEDURE|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
214240970|NCT03915522|PROCEDURE|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
214240971|NCT00891111|BEHAVIORAL|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
214240972|NCT00891111|BEHAVIORAL|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
215031451|NCT04412239|BEHAVIORAL|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
214240973|NCT00997438|DIETARY_SUPPLEMENT|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
214240974|NCT05513131|DRUG|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7 Homoharringtonine 2mg/d d1\~d7
214240975|NCT00133393|DRUG|Pentoxifylline|
214240976|NCT03319290|GENETIC|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
214240977|NCT00526877|DRUG|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
214240978|NCT01236118|DRUG|LY2439821|Administered subcutaneously
214240979|NCT02520128|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
214240980|NCT02133521|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
214240981|NCT02133521|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
214240982|NCT00095238|DRUG|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
214240983|NCT00095238|DRUG|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
214240984|NCT01094639|PROCEDURE|Scaling root planing|Deep gum cleaning with local anesthesia
214240985|NCT01094639|PROCEDURE|Supragingival Prophylaxis|Plaque removal
214240986|NCT00421291|BEHAVIORAL|Education|
214240987|NCT00221312|DRUG|Fosamax|
214240988|NCT03505671|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
214240989|NCT03505671|OTHER|Best Practice|Receive usual care
214240990|NCT03505671|OTHER|Quality-of-Life Assessment|Ancillary studies
215031452|NCT02231580|DRUG|BN82451B|BN82451B capsule
215031453|NCT02231580|DRUG|Placebo|Placebo capsule
214240991|NCT03505671|OTHER|Questionnaire Administration|Ancillary studies
214240992|NCT04476823|OTHER|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
214240993|NCT01408329|DEVICE|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
214240994|NCT01453192|DRUG|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
214240995|NCT01407731|GENETIC|protein expression analysis|
214240996|NCT01407731|GENETIC|western blotting|
214240997|NCT01407731|OTHER|laboratory biomarker analysis|
214240998|NCT02632903|DRUG|Zoledronic acid|
214240999|NCT04535167|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
214241000|NCT04535167|DRUG|Placebo|Placebo will be formulated for intravenous delivery
214241001|NCT02038829|DRUG|Placebo|Placebo
214241002|NCT02038829|DRUG|SUN101 3 mcg|SUN-101 3 mcg bid
214241003|NCT02038829|DRUG|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
214241004|NCT02038829|DRUG|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
214241005|NCT02038829|DRUG|SUN-101 50 mcg|SUN-101 50 mcg bid
214241006|NCT02038829|DRUG|Aclidinium|Aclidinium 400 mcg bid
214241007|NCT04733443|DEVICE|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
214241008|NCT04733443|DEVICE|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
214241009|NCT03329781|DIETARY_SUPPLEMENT|BCM-95|Consuming 1 capsule of BCM-95 per day.
214241010|NCT03329781|DIETARY_SUPPLEMENT|Placebo|Consuming 1 placebo capsule per day
214241011|NCT02827565|OTHER|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
214241012|NCT00638807|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
214241013|NCT00638807|OTHER|Placebo|Matched oral placebo for 6 weeks
214241014|NCT04670224|OTHER|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
214241015|NCT04670224|OTHER|Intravenous anesthesia without QLB|only intravenous anesthesia
214241016|NCT04601831|RADIATION|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
214241017|NCT00075270|DRUG|Paclitaxel|Active Comparator
214241018|NCT00075270|DRUG|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
215031454|NCT05787015|BEHAVIORAL|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
214241019|NCT01646294|DRUG|YM178 modified release (OCAS)|oral
214241020|NCT01646294|DRUG|YM178 immediate release (IR)|oral
214241021|NCT04841200|DRUG|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
214241022|NCT04841200|DRUG|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
214241023|NCT03469570|DEVICE|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
214241024|NCT03667170|BIOLOGICAL|KN035|subcutaneous injection
214241025|NCT06449313|DRUG|Cemiplimab-Rwlc|350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
214241026|NCT06831058|DRUG|efgartigimod|intravenous efgartigimod weekly with monitoring of ADAMTS13 activity for 8 weeks, followed by an observational period of 8 weeks or until treatment failure.
214241027|NCT04656275|DRUG|BI 1323495|BI 1323495
214241028|NCT04656275|DRUG|Placebo|Placebo
214241029|NCT00300742|DRUG|Topiramate|Topiramate up to 300 mg per day.
214241030|NCT05600621|BEHAVIORAL|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
214652302|NCT00689247|DRUG|AZD1305|iv infusion, single dose
214652303|NCT01035190|DRUG|Budesonide|Inhalation, 200 µg/puff
214652304|NCT01409928|DEVICE|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
214241031|NCT05600621|BEHAVIORAL|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
214241032|NCT05600621|BEHAVIORAL|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
214241033|NCT05600621|BEHAVIORAL|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
214241034|NCT05600621|OTHER|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
214241035|NCT01699347|DRUG|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
214241036|NCT04515862|OTHER|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
214241037|NCT02361580|OTHER|Diary|Subject keeps diary of recovery
214241038|NCT02323360|RADIATION|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
214241039|NCT02323360|PROCEDURE|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
214241040|NCT04016740|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
214241041|NCT04016740|DRUG|Ketamine|Intraoperative infusion
214241042|NCT04016740|DRUG|Remifentanil|Intraoperative infusion
214241043|NCT04016740|DRUG|Dexmedetomidine|Intraoperative infusion
214241044|NCT04016740|DRUG|Rocuronium|Intraoperative intermittent bolus
214241045|NCT04016740|DRUG|Propofol|Intraoperative infusion
214241046|NCT04016740|DRUG|Sevoflurane|Intraoperative inhaled as needed
214241047|NCT04016740|DRUG|Dexmedetomidine|Post-operative infusion
214241048|NCT04016740|DRUG|Propofol|Post-operative infusion
214241049|NCT04016740|DEVICE|EEG monitoring|Perioperative monitoring
214241050|NCT03490981|OTHER|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
214241051|NCT03490981|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
214652305|NCT05195788|BEHAVIORAL|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
214652306|NCT06413004|OTHER|Elimination and re-introduction of CLE or COLAP positive food item(s)|Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
214652307|NCT04918563|DRUG|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
214241052|NCT03108781|DRUG|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
214241053|NCT03108781|DRUG|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
214241054|NCT02324543|DRUG|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
214241055|NCT02324543|DRUG|Taxotere|IV on days 4 and 11 of a 21 day cycle
214241056|NCT02324543|DRUG|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
214241057|NCT02324543|DRUG|Cisplatin|IV on days 4 and 11 of a 21 day cycle
214652308|NCT04918563|DRUG|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
214241058|NCT02324543|DRUG|Irinotecan|IV on days 4 and 11 of a 21 day cycle
214241059|NCT00882401|DRUG|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
214241060|NCT00882401|DRUG|Placebo|Matching placebo at same dose schedule as ergocalciferol
214241061|NCT00916214|OTHER|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
214241062|NCT01230775|DRUG|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
214241063|NCT01230775|DRUG|Placebo|"Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
214241064|NCT01995045|DRUG|Triamcinolone|Retrobulbar anesthesia
214241065|NCT01995045|DRUG|Bupivicaine Hydrochloride|Retrobulbar anesthesia
214241066|NCT00590837|DRUG|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
214241067|NCT05419427|DRUG|Denosumab|Denosumab 60 MG/ML
214241068|NCT05419427|DRUG|Denosumab-Ref|Denosumab 60 MG/ML
214241069|NCT01179035|OTHER|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
214241070|NCT01179035|OTHER|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
214241071|NCT01802970|DRUG|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
214241072|NCT06142227|OTHER|Reading a Pictorial Storybook|The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
214241073|NCT01888887|OTHER|Cetaphil Daily Facial Cleanser|
214241074|NCT03539796|PROCEDURE|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
214241075|NCT03539796|PROCEDURE|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
214241076|NCT03539796|PROCEDURE|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
214241077|NCT02217540|OTHER|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
214652309|NCT04349137|DEVICE|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
214652310|NCT04349137|DEVICE|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
215031455|NCT05787015|BEHAVIORAL|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
214241078|NCT02217540|OTHER|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
214241079|NCT00470912|DRUG|sunscreen RV 2547C|
214241080|NCT00002988|DRUG|carmustine|
214241081|NCT00002988|DRUG|irinotecan hydrochloride|
214241082|NCT00723203|DRUG|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
214241083|NCT00723203|GENETIC|gene expression analysis|Day 1 and day 28 samples
214241084|NCT00723203|GENETIC|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
214241085|NCT00723203|OTHER|laboratory biomarker analysis|Day 1 and day 28 samples
214241086|NCT06147973|BEHAVIORAL|Acceptance-based Treatment (ABT)|Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
214241087|NCT06147973|BEHAVIORAL|Health Education (HE) Comparison|Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
214241088|NCT01687556|OTHER|topical EGCG application on acne|two times application of topical EGCG on acne lesion
214241089|NCT03253419|OTHER|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
214241090|NCT00740051|DRUG|Linagliptin|5mg once daily
214241091|NCT00740051|DRUG|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
214241092|NCT00740051|DRUG|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
214241093|NCT00274924|BIOLOGICAL|filgrastim|Given subcutaneously or intravenous bolus.
214241094|NCT00274924|BIOLOGICAL|rituximab|Given IV
214241095|NCT00274924|DRUG|carboplatin|Given IV
214241096|NCT00274924|DRUG|cyclophosphamide|Given IV
214241097|NCT00274924|DRUG|doxorubicin hydrochloride|Given IV
214241098|NCT00274924|DRUG|etoposide|Given IV
214652311|NCT03122626|BEHAVIORAL|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
214241099|NCT00274924|DRUG|ifosfamide|Given IV
214241100|NCT00274924|DRUG|prednisone|Taken orally
214241101|NCT00274924|DRUG|vincristine|Given IV
214241102|NCT04739865|DRUG|Psilocybin|Open label
214652312|NCT05051956|DRUG|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
214241103|NCT00981942|DRUG|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
214241104|NCT01903525|DRUG|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
214241105|NCT01903525|DRUG|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
214241106|NCT00048087|DRUG|ZD1839|250 mg by mouth daily each day for 4 weeks.
214241107|NCT00048087|DRUG|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
214241108|NCT01076127|BEHAVIORAL|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
214241109|NCT01076127|BEHAVIORAL|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
214652313|NCT02582996|DRUG|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
214652314|NCT02582996|DRUG|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
214241110|NCT05334810|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
214241111|NCT04381988|DRUG|Hydroxychloroquine|400mg daily
214241112|NCT04381988|OTHER|Placebo|400mg daily
214241113|NCT04381988|RADIATION|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
214241114|NCT04074239|OTHER|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
214241115|NCT00231374|PROCEDURE|Myelogram|
214241116|NCT04608942|DEVICE|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
214241117|NCT04608942|PROCEDURE|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
214241118|NCT03025035|DRUG|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
214241119|NCT03025035|DRUG|Olaparib|Olaparib administered orally twice a day
214241120|NCT02091505|DRUG|Ranibizumab|
214241121|NCT05780268|BIOLOGICAL|LY3819253|LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
214241122|NCT05780268|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
214241123|NCT05780268|BIOLOGICAL|Remdesivir|Antiviral agent
214241124|NCT01116856|OTHER|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
214241125|NCT05153889|OTHER|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
214241126|NCT05153889|OTHER|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
214241127|NCT02812888|DRUG|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
214241128|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
214241129|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
214241130|NCT01135563|DRUG|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
214241131|NCT00124839|DRUG|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
214241132|NCT00494767|DRUG|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
214241133|NCT00494767|DRUG|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
214241134|NCT00494767|DRUG|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
214241135|NCT00494767|DRUG|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
214241136|NCT02502006|DRUG|Celecoxib|
214241137|NCT02502006|DRUG|Naproxen|
214241138|NCT02502006|DRUG|Placebo|
214241139|NCT01456975|PROCEDURE|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
214241140|NCT00023127|PROCEDURE|Integrated Pest Management|
214241141|NCT00134420|DRUG|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
214241142|NCT00134420|PROCEDURE|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
214241143|NCT00134420|PROCEDURE|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
214241144|NCT00134420|PROCEDURE|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
214241145|NCT00573287|DRUG|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
214241146|NCT00573287|DRUG|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
214241147|NCT01311869|DIETARY_SUPPLEMENT|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
214241148|NCT01311869|DIETARY_SUPPLEMENT|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
214241149|NCT01890720|DEVICE|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
214241150|NCT01890720|OTHER|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
214241151|NCT03320694|DRUG|Metformin|metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
214241152|NCT03320694|DRUG|Insulin|The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
214241153|NCT04097782|BEHAVIORAL|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
214652315|NCT03908944|DRUG|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
214241154|NCT06454266|DRUG|ORM regimen|"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"
214241155|NCT03562767|BEHAVIORAL|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
214241156|NCT03562767|BEHAVIORAL|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
214241157|NCT03562767|BEHAVIORAL|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
214241158|NCT04330105|DEVICE|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
214241159|NCT00691119|BEHAVIORAL|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
214241160|NCT00691119|OTHER|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
214241161|NCT02218177|DRUG|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
214241162|NCT02218177|DRUG|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
214241163|NCT02218177|PROCEDURE|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
214241164|NCT00226629|PROCEDURE|Endovascular vs Open Repair|
214241165|NCT04371302|DIAGNOSTIC_TEST|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
214241166|NCT01230125|DRUG|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
214241167|NCT01230125|DRUG|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
214241168|NCT01589770|OTHER|cardiac Magnetic Resonance imaging|
214241169|NCT00936091|DRUG|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
214241170|NCT00936091|DRUG|Placebo|125 children received placebo capsules
214652316|NCT03908944|DRUG|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
214652317|NCT00972465|DRUG|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
214652318|NCT00893516|BIOLOGICAL|CHOP + CD4|
214241171|NCT03511898|DRUG|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
214241172|NCT03511898|DRUG|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
214241173|NCT03511898|DRUG|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
214241174|NCT00736047|BIOLOGICAL|NIC002|
214241175|NCT00736047|BIOLOGICAL|Placebo|
214241176|NCT04080271|DEVICE|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
214241177|NCT00294281|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
214241178|NCT02956902|OTHER|Clinician supported smartphone application intervention|
214241179|NCT00725842|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
214241180|NCT00725842|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
214241181|NCT00129909|DRUG|fixed dose combination therapy|
214241182|NCT04661254|OTHER|Lymphapheresis|\- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
214241183|NCT05389852|DRUG|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
214241184|NCT01044329|DRUG|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
214241185|NCT01044329|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
214652319|NCT00893516|DRUG|CHOP|
214241186|NCT02535780|PROCEDURE|Transcranial magnetic stimulation|TMS
214241187|NCT02535780|PROCEDURE|Transcranial direct current stimulation|tDCS
214241188|NCT00201162|DIETARY_SUPPLEMENT|Soy|Dietary supplement of isolated soy protein containing isoflavones
214241189|NCT00201162|DIETARY_SUPPLEMENT|Placebo|dietary supplement casein placebo
214241190|NCT00997113|DRUG|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
214241191|NCT00997113|DRUG|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
214241192|NCT01853618|DRUG|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
214652320|NCT04484350|DRUG|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
214652321|NCT04484350|DRUG|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
214652322|NCT04484350|DRUG|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
214652323|NCT00432237|DRUG|MK0974 50 mg|
214652324|NCT00432237|DRUG|MK0974 150 mg|
214652325|NCT00432237|DRUG|MK0974 300 mg|
214241193|NCT01853618|PROCEDURE|RFA|Performed on Day 36
214241194|NCT01853618|PROCEDURE|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
214241195|NCT01853618|PROCEDURE|Cryoablation|Performed on Day 36
214241196|NCT02556164|PROCEDURE|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
214241197|NCT02556164|OTHER|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
214241198|NCT02948218|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
214241199|NCT02593136|DIETARY_SUPPLEMENT|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
214241200|NCT02593136|OTHER|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
214241201|NCT00045721|DRUG|O6-benzylguanine|
214241202|NCT00045721|DRUG|polifeprosan 20 with carmustine implant|
214241203|NCT00045721|PROCEDURE|adjuvant therapy|
214241204|NCT00045721|PROCEDURE|conventional surgery|
214241205|NCT00045721|PROCEDURE|neoadjuvant therapy|
214241206|NCT01658813|DRUG|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
214652326|NCT00432237|DRUG|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
214652327|NCT01356381|DRUG|Vildagliptin|Dosage 50mg b.i.d.
214652328|NCT01356381|DRUG|Placebo|50mg bid
214652329|NCT03426176|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
214652330|NCT03426176|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
214241208|NCT00938886|DRUG|Naltrexone|Daily 50 mg naltrexone
214241209|NCT00938886|DRUG|Placebo|Matched naltrexone placebo
214241210|NCT00482352|OTHER|laboratory biomarker analysis|Correlative studies
214241211|NCT02907190|OTHER|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
214241212|NCT02907190|OTHER|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
214652331|NCT03426176|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
214241213|NCT03415386|DRUG|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
214241214|NCT05324488|OTHER|No intervention|In this registry no intervention is carried out
214241215|NCT04365101|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
214241216|NCT00353860|DEVICE|SOLEX 300i Stem Cell Selection|
214241217|NCT02461472|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
214241218|NCT01315821|DRUG|Saccharomyces boulardii|5 million units/day for 3 months
214241219|NCT01315821|DRUG|Placebo|Placebo for 3 months
214241220|NCT03269162|DRUG|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
214241221|NCT03269162|DRUG|Docetaxel|75mg/m2,ivgtt 30mins, d1
214241222|NCT03269162|DRUG|Pemetrexed|500mg/m2, ivgtt 30mins, d1
214241223|NCT03269162|DRUG|Cisplatin|75mg/m2, ivgtt \>2h, d1
214241224|NCT04774458|PROCEDURE|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
214241225|NCT00537901|RADIATION|First-Line Bevacizumab and Chemotherapy|Chemotherapy
214241226|NCT00537901|DRUG|Bevacizumab|Chemotherapy
214241227|NCT03015480|BEHAVIORAL|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
214652332|NCT03426176|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
214652333|NCT04668508|DRUG|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
214241228|NCT02094768|DIETARY_SUPPLEMENT|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
214241229|NCT02094768|DIETARY_SUPPLEMENT|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
214241230|NCT03786627|OTHER|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
214241231|NCT03786627|OTHER|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
214241232|NCT03377140|DIETARY_SUPPLEMENT|Hesperidin|2 capsuls
214241233|NCT03377140|OTHER|control|2 capsuls
214241234|NCT02901756|DIETARY_SUPPLEMENT|Antemig|Participants were instructed to take one tablet every morning for three months.
214241235|NCT02674854|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
214241236|NCT02674854|DRUG|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
214241237|NCT02674854|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
214241238|NCT04309799|DEVICE|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
214241239|NCT04919447|PROCEDURE|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
214241240|NCT00430131|PROCEDURE|Cognitive Orientation to Occupational Performance|
214241241|NCT00430131|PROCEDURE|Contemporary Treatment Approach|
214241242|NCT01114230|DRUG|AGS-16M8F|IV
214241243|NCT04121624|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
214241244|NCT01030601|DRUG|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
214241245|NCT00913692|DRUG|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
214241246|NCT00913692|DRUG|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
214241247|NCT02102503|BEHAVIORAL|Standard Treatment|
214241248|NCT02102503|BEHAVIORAL|MI and Medication review|
214241249|NCT01552733|DEVICE|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
214241250|NCT01552733|OTHER|Standard of care|Rehabilitation Therapy
214241251|NCT00233909|DRUG|Zosuquidar|
214241252|NCT00233909|DRUG|gemtuzumab ozogamicin|
214241253|NCT04738318|DRUG|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
214241254|NCT04738318|DRUG|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
214241255|NCT00899080|GENETIC|gene expression analysis|
214241256|NCT00899080|GENETIC|reverse transcriptase-polymerase chain reaction|
214241257|NCT00899080|OTHER|immunoenzyme technique|
214241258|NCT00899080|OTHER|laboratory biomarker analysis|
214241259|NCT00899080|OTHER|platelet aggregation test|
214241260|NCT00573729|OTHER|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
214241261|NCT00573729|OTHER|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
214241262|NCT04903821|DRUG|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
214652334|NCT05699148|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
214652335|NCT00603239|DRUG|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
214652336|NCT00603239|DRUG|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
214241263|NCT04456231|DRUG|Plenvu|Patients will receive Plenvu for preparation of endoscopy
214241264|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
214241265|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
214241266|NCT01226121|BIOLOGICAL|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
214241267|NCT01718912|DRUG|metronidazole-nystatin oral rinse|
214241268|NCT05255185|PROCEDURE|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
214652337|NCT01354132|DRUG|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
214241269|NCT04781660|DEVICE|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
214241270|NCT04231981|DRUG|Retifanlimab|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
214241271|NCT01701518|DRUG|Ozurdex|biodegradable 0.7mg dexamethasone implant
214241272|NCT06200025|OTHER|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
214241273|NCT06200025|OTHER|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
214241274|NCT03177629|DRUG|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
214241275|NCT02973633|DEVICE|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
214241276|NCT02973633|DRUG|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
214241277|NCT01043042|OTHER|No interventions will be used in this study|No interventions will be used in this study
214241278|NCT05399576|DRUG|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
214241279|NCT05399576|DRUG|Saline|intracoronary of 4ml saline
214241280|NCT03095547|DRUG|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
214241281|NCT03095547|DRUG|Posaconazole|Pharmacokinetic assessment AUC 0-tau
214241282|NCT03095547|DRUG|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
214241283|NCT03095547|DRUG|F901318|Pharmacokinetic assessment AUC 0-tau
214241284|NCT03095547|DRUG|Tacrolimus|Pharmacokinetic assessment AUC 0-t
214241285|NCT00476801|DEVICE|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
214241286|NCT05979545|DIAGNOSTIC_TEST|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
214241287|NCT04241679|DEVICE|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
214241288|NCT05765981|DRUG|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
214241289|NCT06396182|OTHER|group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).|"group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
214241290|NCT02112955|BEHAVIORAL|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
214241291|NCT02112955|BEHAVIORAL|Usual care|Usual care such as hospital-based or community-based health education or services.
214241292|NCT03872414|BEHAVIORAL|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
214241293|NCT03872414|BEHAVIORAL|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
214241294|NCT02889562|DRUG|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
214241295|NCT02889562|DRUG|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
214241296|NCT00358072|BEHAVIORAL|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
214241297|NCT01943474|DEVICE|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
214241298|NCT01943474|DEVICE|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
214241299|NCT05117957|DRUG|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
214241300|NCT02685475|DRUG|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
214241301|NCT02246712|DRUG|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
214241302|NCT02246712|OTHER|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
214241303|NCT02246712|OTHER|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
214241304|NCT02246712|GENETIC|CYP2B6 genotype|The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
214241305|NCT04128787|DRUG|AG881 Formulation 1|AG881 uncoated tablets
214652338|NCT01354132|DRUG|Placebo|Placebo tablets are placed in water or juice in the AM and PM
214652339|NCT05858190|PROCEDURE|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
214652340|NCT05444712|PROCEDURE|Chemotherapy + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
214652341|NCT05444712|PROCEDURE|Chemotherapy + ASCT + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
214652342|NCT00701493|DRUG|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
214652343|NCT03601871|DRUG|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
214652344|NCT03601871|DRUG|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
214652345|NCT03601871|DRUG|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
214652346|NCT00929955|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
214652347|NCT00929955|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
214241306|NCT04128787|DRUG|AG881 Formulation 2|AG881 film-coated tablets
214241307|NCT04128787|DRUG|Omeprazole|Omeprazole capsules
214241308|NCT00865488|BIOLOGICAL|ADHEXIL|Adhesions prevention
214241309|NCT05409378|DEVICE|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
214241310|NCT01470989|DRUG|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
214241311|NCT01470989|DRUG|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
214241312|NCT04998201|DRUG|ARO-APOC3|ARO-APOC3 Injection
214241313|NCT04998201|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
214241314|NCT03346798|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
214241315|NCT03346798|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
214241316|NCT03346798|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
214652348|NCT00929955|DRUG|Placebo|Placebo added to TAU
214652349|NCT05650034|RADIATION|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
214241317|NCT00969280|DEVICE|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
214241318|NCT00969280|DEVICE|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
214241319|NCT04288544|DIETARY_SUPPLEMENT|Microalgae|Open, monocentric intervention study in crossover design
214241320|NCT04288544|DIETARY_SUPPLEMENT|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
214241321|NCT04288544|DIETARY_SUPPLEMENT|sea fish|Open, monocentric intervention study in crossover design
214241322|NCT01705782|BIOLOGICAL|E. coli endotoxin, US standard|
214241323|NCT04935450|DIAGNOSTIC_TEST|Bronchoalveolar lavage|Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis
214241324|NCT03033147|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
214241325|NCT03033147|DRUG|Oral placebo|placebo 30 minutes before root canal treatment
214241326|NCT00314483|DRUG|Mesenchymal Stem Cell Infusion|
214241327|NCT05871515|DEVICE|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
214241328|NCT04441762|DRUG|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
214241329|NCT04441762|DRUG|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
214241330|NCT04144491|DIETARY_SUPPLEMENT|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
214241331|NCT04144491|DIETARY_SUPPLEMENT|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
214241332|NCT06364293|OTHER|Observational design does not include interventional behavior.|Observational design does not include interventional behavior.
214241333|NCT04469491|DRUG|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
214241334|NCT04469491|DRUG|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
214241335|NCT01809977|PROCEDURE|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
214241336|NCT01809977|PROCEDURE|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
214241337|NCT05346445|DRUG|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
214241338|NCT05346445|DRUG|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
214241339|NCT02119676|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
214241340|NCT02119676|DRUG|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
214241341|NCT02119676|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
214241342|NCT01230203|PROCEDURE|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
214241343|NCT04357691|BEHAVIORAL|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
214241344|NCT04357691|BEHAVIORAL|AI-led training|Participants will perform an AI-led training for 4 weeks
214241345|NCT04764266|DIAGNOSTIC_TEST|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
214241346|NCT01251471|DRUG|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
214241347|NCT00719433|DEVICE|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
214241348|NCT00719433|OTHER|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
214241349|NCT03046914|GENETIC|HLA-B*5801 test|Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
214241350|NCT04153214|BEHAVIORAL|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
214241351|NCT03491189|DEVICE|Lag screw fixation|surgical fixation
214241352|NCT03491189|DEVICE|Helical blade fixation|surgical fixation
214241353|NCT06325930|DRUG|[14C]-HU6|\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
214241354|NCT04396054|DEVICE|Lag Screws|Method of internal fixation
214241355|NCT04396054|DEVICE|double Y-shaped plates|Method of internal fixation
214241356|NCT05807061|BEHAVIORAL|EmBARK|The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
214241357|NCT05807061|BEHAVIORAL|Popular guidance|The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
214241358|NCT05807061|BEHAVIORAL|Practice first|Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
214241359|NCT02433158|DRUG|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
214241360|NCT00570232|DRUG|Erlotinib|150 mg per day by mouth for 12 months
214241361|NCT06520969|OTHER|Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
214241362|NCT04872530|DIETARY_SUPPLEMENT|Pea-protein concentrate|Pea-protein concentrate
214241363|NCT04872530|DIETARY_SUPPLEMENT|Fava-bean protein concentrate|Fava-bean protein concentrate
214241364|NCT04872530|DIETARY_SUPPLEMENT|Chickpea protein concentrate|Chickpea protein concentrate
214241365|NCT04872530|DIETARY_SUPPLEMENT|Red lentil protein concentrate|Red lentil protein concentrate
214241366|NCT04872530|DIETARY_SUPPLEMENT|Non-essential amino acid blend|Non-essential amino acid blend
214241367|NCT04872530|DIETARY_SUPPLEMENT|Whey protein concentrate|Whey protein concentrate
214241368|NCT06402253|BEHAVIORAL|Music composition / edition|"Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch."
214241369|NCT06402253|BEHAVIORAL|Photography composition / edition|"Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch."
214241370|NCT05393258|RADIATION|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
215031456|NCT02979990|OTHER|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
214241371|NCT03579901|DEVICE|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
214241372|NCT04817852|OTHER|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
214241373|NCT05302661|BEHAVIORAL|re-education|Contact patients by phone or wechat and guide them
214241374|NCT04592263|OTHER|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
214241375|NCT04148872|OTHER|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
214241376|NCT04148872|DRUG|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
214241377|NCT04148872|OTHER|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
214241378|NCT03969966|OTHER|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
214241379|NCT03849755|DEVICE|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
214241380|NCT03460600|OTHER|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
214241381|NCT04705844|DRUG|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
214241382|NCT04705844|DRUG|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
214241383|NCT03947554|DIETARY_SUPPLEMENT|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
215031457|NCT02979990|OTHER|Control Video|The control group will have access to a video about the IVF process
215031458|NCT04573985|BEHAVIORAL|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
214241384|NCT03947554|DIETARY_SUPPLEMENT|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
214241385|NCT03947554|DIETARY_SUPPLEMENT|Placebo|800 mg excipient
214241386|NCT03115281|DEVICE|PCI|PCI
214241387|NCT01037088|DRUG|Mild dose cannabis|3.53% THC by weight
214241388|NCT01037088|DRUG|Low dose cannabis|1.29% THC by weight
214241389|NCT01037088|DRUG|Cannabis|0.00% THC by weight
214241390|NCT05838989|DEVICE|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
214241391|NCT05838989|OTHER|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
214241392|NCT05838989|OTHER|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
214241393|NCT05959642|DEVICE|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
214241394|NCT05959642|DEVICE|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
214241395|NCT02708303|OTHER|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
214241396|NCT00340574|DRUG|AMA1-C1/Alhydrogel + CpG 7909|
214241397|NCT01447212|DRUG|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
214241398|NCT01447212|DRUG|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
214241399|NCT01447212|DRUG|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
214241400|NCT01447212|DRUG|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
214241401|NCT02216812|DRUG|500 mg vitamin c, 1 pill per day for 6 weeks|
214241402|NCT02216812|DRUG|1 placebo pill for 6 weeks|
214241403|NCT01585584|DRUG|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
214241404|NCT00527488|DRUG|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
214241405|NCT00527488|DRUG|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
214241406|NCT00527488|DRUG|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
214241407|NCT00527488|DRUG|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
214241408|NCT01958827|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
214241409|NCT06273800|PROCEDURE|Blood sample|Collection of serum sample at the day of start of neo adjuvant treatment
214241410|NCT02848443|DRUG|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
214241411|NCT02848443|DRUG|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
214241412|NCT02848443|DRUG|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
214241413|NCT02848443|DRUG|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
214241414|NCT03874260|DRUG|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
214241415|NCT05059899|BEHAVIORAL|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
214241416|NCT00266864|DRUG|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
214241417|NCT01832168|PROCEDURE|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
214241418|NCT01832168|OTHER|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
214241419|NCT01832168|OTHER|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
214241420|NCT00004393|DRUG|risperidone|
214241421|NCT03492008|OTHER|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
214241422|NCT03492008|OTHER|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
214241423|NCT03492008|OTHER|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
214241424|NCT05202470|OTHER|TE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
214241425|NCT05202470|OTHER|CE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
214241426|NCT02372214|PROCEDURE|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
214241427|NCT00280670|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
214241428|NCT03036800|DRUG|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
214241429|NCT03036800|OTHER|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
214241430|NCT06553859|OTHER|No intervention conducts.|The type and method of breast reconstruction with sillicon implants and ADM implanting is now the standard treatment of breast cancer in korea. no any specific intervention has occurred during the surgery.
214241431|NCT02050126|DEVICE|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
214241432|NCT03303482|BEHAVIORAL|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
214241433|NCT03313908|PROCEDURE|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
214241434|NCT01077154|DRUG|Placebo|Administered subcutaneously for up to 5 years
214241435|NCT01077154|DRUG|Denosumab|Administered subcutaneously for up to 5 years
214241436|NCT05167110|DIETARY_SUPPLEMENT|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
214241437|NCT05167110|DIETARY_SUPPLEMENT|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
214241438|NCT04067583|OTHER|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
214241439|NCT00035867|DRUG|TLK199 HCl Liposomes for Injection|
214241440|NCT02511964|BEHAVIORAL|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
214241441|NCT02511964|BEHAVIORAL|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
214241442|NCT01580748|DRUG|Roflumilast|500 microgram once daily for 16 weeks
214241443|NCT00070733|DRUG|testosterone enanthate|
214241444|NCT00070733|DRUG|duastride|
214241445|NCT05996991|OTHER|Positive expectation speech regarding spinal manipulative therapy|Patients will watch a short video with positive expectations regarding spinal manipulative therapy.
214241446|NCT05996991|OTHER|Neutral expectation speech regarding spinal manipulative therapy|Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.
214241447|NCT05996991|OTHER|Negative expectation speech regarding spinal manipulative therapy|Patients will watch a short video with negative expectations regarding spinal manipulative therapy.
214241448|NCT05996991|PROCEDURE|Spinal Manipulative Therapy|One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
214241449|NCT05985980|DIAGNOSTIC_TEST|Exercise Treadmill Test (ETT)|The study population consists of premenopausal women who applied to the outpatient clinic with chest pain. ETT is ordered as a routine diagnostic workup. Two ETTs are performed on each participant. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
214241450|NCT05144334|DRUG|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
214241451|NCT06292299|DEVICE|Pneumowave|Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring data
214241452|NCT05758441|BEHAVIORAL|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
214241453|NCT05758441|BEHAVIORAL|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
214241454|NCT05024214|DRUG|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
214241455|NCT05024214|DRUG|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
214241456|NCT06242197|OTHER|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
214241457|NCT00933777|DRUG|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
214241458|NCT04944056|OTHER|conventional physiotherapy|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
214241459|NCT04944056|OTHER|compression mobilization|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
214241460|NCT02207946|DRUG|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214241461|NCT02207946|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214241462|NCT02174588|DRUG|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
214241463|NCT02174588|DRUG|propofol|propofol are used for sedation drug
214241464|NCT00811642|DRUG|Posaconazole|400mg BID oral suspension for 12 weeks
214241465|NCT06297785|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
214241466|NCT03037723|OTHER|CT simulation|
214241467|NCT02642549|BEHAVIORAL|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
214241468|NCT05117671|OTHER|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
214241469|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
214241470|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
214241471|NCT05667415|DRUG|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
214241472|NCT05667415|DRUG|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
214241473|NCT00176189|DEVICE|All ceramic FPDs|
214241474|NCT01216371|DRUG|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
214241475|NCT01216371|DRUG|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
214241476|NCT03460015|DRUG|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
214241477|NCT03460015|DRUG|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
214241478|NCT01419444|BEHAVIORAL|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
214241479|NCT05340127|DEVICE|CEREBO®|Usability Study
214241480|NCT01633593|DRUG|Donepezil|5 mg PO a day, during 2 weeks
214241481|NCT03447977|OTHER|cervical|cervical spine manual therapy
214241482|NCT03447977|OTHER|thoracic|thoracic spine manual therapy
214241483|NCT03447977|OTHER|exercises|exercises for pain
214241484|NCT04382677|BEHAVIORAL|Promoting First Relationships ®|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
214241485|NCT04382677|OTHER|Resource & Referral|This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
214241486|NCT05419999|DEVICE|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
214241487|NCT05419999|OTHER|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
214241488|NCT05419999|BEHAVIORAL|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
214241489|NCT05005793|DRUG|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
214241490|NCT05005793|DRUG|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
214241491|NCT05744258|DEVICE|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
214241492|NCT06967064|DRUG|lidocaine cream|Group U receives 1 mL of lidocaine cream extracted using a syringe and evenly applied across the entire posterior surface of the LMA cuff by carefully spreading the cream to ensure uniform coverage, while Group N receives 1 mL of lidocaine cream also extracted using a syringe but applied without ensuring even distribution, resulting in a patchy or non-uniform application.
214241493|NCT06967064|OTHER|Placebo|No lidocaine cream will be applied to the LMA
214241494|NCT05387915|RADIATION|Radiation Therapy|Undergo reduced dose radiation therapy
214241495|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
214241496|NCT01702636|DRUG|Tranexamic Acid|
214241497|NCT01702636|DRUG|Placebo|
214241498|NCT01848041|DRUG|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
214241499|NCT01848041|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
214241500|NCT00540618|DRUG|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
214241501|NCT00540618|OTHER|Placebo|
214241502|NCT00540618|DRUG|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
214241503|NCT00540618|DRUG|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
214241504|NCT06436664|OTHER|Tooth brushing|Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
214241505|NCT01464905|BIOLOGICAL|NU100|0.25 mg SQ, every other day for 12 months
214241506|NCT01464905|BIOLOGICAL|Placebo|1 mL SQ, every other day for 4 months
214241507|NCT01464905|BIOLOGICAL|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
214241508|NCT00871507|DRUG|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
214241509|NCT00871507|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
214241510|NCT00871507|DRUG|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
214241511|NCT00871507|DRUG|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
214241512|NCT00893620|DEVICE|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
214241513|NCT04879979|BEHAVIORAL|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
214241514|NCT02417493|BEHAVIORAL|Simulation of epinephrine self-injection|
214241515|NCT06969521|BEHAVIORAL|Visual acoustic biofeedback: ORDER|In visual-acoustic biofeedback treatment, elements of traditional articulation treatment are used, including auditory models, verbal descriptions of correct articulator placement, cues for repetitive motor practice via images and diagrams of the vocal tract as visual aids. These strategies are supplemented with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum (Sona-Match module of PENTAX Sona- Speech software). Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak on the visual display.
214241516|NCT06969521|BEHAVIORAL|Perception Training: ORDER|Description: Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program (Gorilla). Stimuli are organized into three separate tasks. In tasks 1 and 3, which train category goodness judgment, participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels. In task 2, participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline, but they will recei
214241517|NCT01689116|DRUG|Bardoxolone Methyl 20mg|Oral
214241518|NCT01689116|DRUG|Bardoxolone Methyl 80mg|Oral
214241519|NCT01689116|DRUG|Bardoxolone Methyl Placebo|Oral
214241520|NCT01689116|DRUG|Moxifloxacin 400mg|Oral
214241521|NCT01689116|DRUG|Moxifloxacin Placebo|Oral
214241522|NCT05671133|DIAGNOSTIC_TEST|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
214241523|NCT03090321|BEHAVIORAL|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
214241524|NCT03090321|BEHAVIORAL|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
214241525|NCT03090321|BEHAVIORAL|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
214241526|NCT03090321|BEHAVIORAL|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
214241527|NCT03579654|BIOLOGICAL|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
214241528|NCT04782531|OTHER|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
214241529|NCT04782531|OTHER|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
214241530|NCT06256159|OTHER|12 MSWS questionnaire|The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
214241531|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
214241532|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
214241533|NCT06486077|DIETARY_SUPPLEMENT|Power Line Program|Power Line program consisting of 4 nutritional supplements: a meal replacement shake, a vegetable based green drink, a vascular health product, and a pre-meal fiber supplement
214241534|NCT05737225|DEVICE|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
214241535|NCT00027222|PROCEDURE|retinal ablation|
214241536|NCT05821517|DEVICE|Helmet virtual reality.|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
214241537|NCT05821517|DRUG|Administration of METHOXYFLURANE|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
214241538|NCT05821517|DRUG|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
214241539|NCT00505492|DRUG|Carboplatin|AUC 5 by vein once every 28 Days
214241540|NCT00505492|DRUG|Cisplatin|40 mg/m\^2 by vein (IV) Weekly Over 4 Hours
214241541|NCT00505492|DRUG|Paclitaxel|135 mg/m\^2 by vein (IV) Once Every 28 Days
214241542|NCT06432088|DEVICE|Extended Magnetic Grasper Device|The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.
214241543|NCT00533793|PROCEDURE|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
214241544|NCT01006603|DRUG|Saxagliptin|5 mg, oral tablet, once daily
214241545|NCT01006603|DRUG|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
214241546|NCT06995365|OTHER|Risk Prediction Model|This study analyzes retrospective electronic health record (EHR) data from older adults to refine and validate a predictive model for other conditions in future studies.
214241547|NCT06994429|DIAGNOSTIC_TEST|MRI Techniques for Graft Function Assessment|"\### Intervention Description~The intervention in this study is the use of advanced MRI techniques for assessing liver transplant graft function. It includes:~* \*\*Diffusion Weighted Imaging (DWI):\*\* To evaluate tissue integrity and detect early graft dysfunction.~* \*\*Dynamic Contrast-Enhanced MRI (DCE-MRI):\*\* To assess vascular complications and blood flow in the graft.~* \*\*Blood Oxygenation Level-Dependent (BOLD) MRI:\*\* To monitor oxygenation levels, indicative of graft health.~These MRI methods provide a non-invasive, comprehensive assessment of liver graft function, distinguishing this intervention from traditional invasive methods like biopsy."
214241548|NCT06994546|DEVICE|ArtiBest ® Intra articular Injection|single intra articular injection of 3 ml (one syringe) per knee joint. Each syringe contains 20 mg/mL sodium hyaluronate.
214241549|NCT06993818|OTHER|Gingival Crevicular Fluid|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
214241550|NCT06993818|DIAGNOSTIC_TEST|Serum Asprosin|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
214241551|NCT06994728|DEVICE|Left STN-DBS on, right STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
214241552|NCT06994728|DEVICE|Right STN-DBS on, left STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
214241553|NCT06471140|OTHER|magnetic resonance imaging (MRI)|MRI performed three times during pregnancy and 6 months postpartum
214241554|NCT06518512|DEVICE|Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system|"AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit"
214241555|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
214241556|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
214241557|NCT06876506|DIAGNOSTIC_TEST|Venepuncture|Whole blood flow cytometry analysis of T-/B-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4
214241558|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
214241559|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
214241560|NCT06897163|DEVICE|Specialized Absorbent Intestinal Tampon|The specialized absorbent intestinal tampon is designed to be self-inserted by participants with ileostomies. It aims to collect ileostomy output and improve the quality of life by reducing complications associated with traditional stoma bags. The study will test different tampon designs and coatings to find the most suitable one for insertion and retention. Participants will be observed and interviewed during the insertion process, and their feedback on discomfort or pain will be collected using a numerical rating scale (NRS). Stool samples will be collected before and after tampon use for microbiota analysis.
214241561|NCT06899074|DIETARY_SUPPLEMENT|Omega 3 Polyunsaturated Fats|Omega-3 PUFA dietary supplement daily for 12 weeks. The intervention is 1 teaspoon of liquid omega-3 containing oil profile 40% EPA / 60% DHA.
214241562|NCT06899074|OTHER|Matching Placebo|The placebo is a matched 1 teaspoon liquid of coconut oil, consisting mainly of saturated fatty acids and lacking omega-3 fatty acids.
214241563|NCT01067547|DRUG|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
214241564|NCT01067547|DRUG|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
214241565|NCT04514302|DRUG|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
214241566|NCT04514302|DRUG|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
214241567|NCT06326489|DEVICE|Switching to the Medtronic 780G insulin pump|Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
214241568|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
214241569|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
214241570|NCT01908920|OTHER|Osteopathic manipulative treatment|
214241571|NCT01908920|OTHER|SHAM|
214241572|NCT01908920|OTHER|CONTROL|
214241573|NCT05376943|DRUG|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
214241574|NCT03564730|PROCEDURE|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
214241575|NCT03564730|PROCEDURE|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
214241576|NCT01322308|DRUG|pioglitazone|30 mg tablet QD (taken once daily)
214241577|NCT01322308|DRUG|placebo|tablet taken once a day
214241578|NCT01481129|DRUG|Akt Inhibitor MK2206|Given PO
214241579|NCT01481129|OTHER|Laboratory Biomarker Analysis|Correlative studies
214241580|NCT01481129|OTHER|Pharmacological Study|Correlative studies
214241581|NCT03983148|BEHAVIORAL|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
214241582|NCT03983148|BEHAVIORAL|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
214241583|NCT06202092|DEVICE|Phonophoresis|Ultrasound using honey as a media over the knee joint
214241584|NCT06202092|DEVICE|Ultrasound|ultrasound using gel as a media over the knee joint
214241585|NCT06202092|PROCEDURE|conventional physiotherapy|TENS, Strengthening, and stretching exercises
214241586|NCT02764424|DEVICE|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
214241587|NCT03050775|DEVICE|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
214241588|NCT03050775|DEVICE|Standard Ventilator Circuit|no active heat and humidification during anesthesia
214241589|NCT02016547|PROCEDURE|abciximab IV and thrombectomy|
214241590|NCT02016547|DRUG|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
214241591|NCT05882643|OTHER|moderate to deep neuromuscular blockade|"* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)~* Rocuronium (intravenous, 1.0 mg/kg at induction period)"
214241592|NCT05882643|OTHER|shallow to minimal neuromuscular blockade|"* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg at induction period)"
214241593|NCT05298878|OTHER|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
214241594|NCT01425216|DRUG|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
214241595|NCT03084627|BEHAVIORAL|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
214241596|NCT06465212|DEVICE|TopCon Maestro 2 OCT|Ophthalmic Coherence Tomography
214241597|NCT05945680|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
214241598|NCT05945680|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
214241599|NCT02309619|PROCEDURE|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
214241600|NCT03387644|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
214241601|NCT03387644|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
214241602|NCT01667510|DIETARY_SUPPLEMENT|Cardio Mato|Soft gel capsule for oral use
214241603|NCT01667510|DIETARY_SUPPLEMENT|Placebo|Soft gel capsule without test material
214241604|NCT01211431|DRUG|Reference|Intrathécale morphine is used for post-cesarean pain control
214241605|NCT01211431|DRUG|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
214241606|NCT00149448|BEHAVIORAL|TB Contact Priority Model|
214241607|NCT01206387|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
214241608|NCT01206387|DRUG|placebo comparator|Placebo administered to affected area twice a day for 28 days
214241609|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
214241610|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
214241611|NCT00235170|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
214241612|NCT00706849|DRUG|mipomersen sodium|200 mg /mL
214241613|NCT00706849|DRUG|placebo|1 mL matching placebo
214241614|NCT01611454|DEVICE|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
214241615|NCT01611454|DEVICE|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
214241616|NCT02873585|DEVICE|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
214241617|NCT02873585|DEVICE|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
214241618|NCT00821067|DIETARY_SUPPLEMENT|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
214241619|NCT00821067|DIETARY_SUPPLEMENT|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
214241620|NCT03249688|OTHER|Regular health advice|Routine healthy lifestyle counseling
214241621|NCT03249688|BEHAVIORAL|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
214241622|NCT03249688|DIETARY_SUPPLEMENT|Medical food|Medical food product (Fortasyn Connect)
214241623|NCT01343225|DRUG|atripla|once a day
214241624|NCT01343225|DRUG|darunavir ritonavir raltegravir|as directed
214241625|NCT03269552|DRUG|Carfilzomib|Given IV
214241626|NCT03269552|OTHER|Laboratory Biomarker Analysis|Correlative studies
214241627|NCT03269552|BIOLOGICAL|Rituximab|Given IV
214241628|NCT03590431|DIETARY_SUPPLEMENT|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
214241629|NCT03590431|DIETARY_SUPPLEMENT|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
214241630|NCT03590431|DIETARY_SUPPLEMENT|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
214241631|NCT00208546|DRUG|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
214241632|NCT00208546|DRUG|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
214241633|NCT01405066|BEHAVIORAL|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
214241634|NCT01405066|BEHAVIORAL|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
214241635|NCT00981773|DRUG|Maraviroc|Maraviroc 150 mg bid
214241636|NCT00981773|DRUG|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
214241637|NCT00920907|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
214241638|NCT00356837|PROCEDURE|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
214241639|NCT02616601|DRUG|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
214241640|NCT02616601|DRUG|Carac® (Fluorouracil) Cream|Topical cream, brand product.
214241641|NCT02616601|DRUG|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
214241642|NCT04445974|BEHAVIORAL|Expand your horizons: More than my skin|'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
214241643|NCT04445974|BEHAVIORAL|Creative writing activities|In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
214241644|NCT04512339|DRUG|Dupilumab|Dupilumab injections (blinded labels)
214241645|NCT04512339|DRUG|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
214241646|NCT01490723|DRUG|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
214241647|NCT01490723|DRUG|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
214241648|NCT01490723|PROCEDURE|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
214241649|NCT01490723|DRUG|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
214241650|NCT01490723|DRUG|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
214241651|NCT01490723|DRUG|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
214241652|NCT01490723|DRUG|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
214241653|NCT01490723|DRUG|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
214241654|NCT01490723|DRUG|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
214241655|NCT01490723|DRUG|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
214241656|NCT01490723|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
214241657|NCT01490723|PROCEDURE|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
214241658|NCT02496507|OTHER|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
214241659|NCT05949944|DRUG|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
214652350|NCT01774214|PROCEDURE|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
214652351|NCT01774214|PROCEDURE|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
214652352|NCT03695029|DRUG|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
214241660|NCT04389970|BEHAVIORAL|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
214241661|NCT06265480|OTHER|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
214241662|NCT00736177|PROCEDURE|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
214241663|NCT00736177|PROCEDURE|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
214241664|NCT03102840|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
214241665|NCT03102840|DIAGNOSTIC_TEST|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
214241666|NCT06074601|DIAGNOSTIC_TEST|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
214241667|NCT02599948|OTHER|no intervention|
214241668|NCT05057910|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
214241669|NCT03289364|DEVICE|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
214241670|NCT03047681|DIAGNOSTIC_TEST|venous blood withdrawl|patients will be asked for a venous blood sample
214241671|NCT03247803|DEVICE|air-Q® SP|air-Q SP placement for airway maintenance,
214241672|NCT03247803|DEVICE|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
214241673|NCT01455467|DEVICE|One iStent|Implantation of one iStent in conjunction with cataract surgery
214241674|NCT01455467|DEVICE|Two iStent|Implantation of two iStent in conjunction with cataract surgery
214241675|NCT03772860|OTHER|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
214241676|NCT03772860|OTHER|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
214241677|NCT03772860|OTHER|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
214241678|NCT03772860|OTHER|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
214241679|NCT01665612|DEVICE|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
214241680|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
214652353|NCT04233489|BEHAVIORAL|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
214241681|NCT04179890|DRUG|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
214241682|NCT04179890|DRUG|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
214241683|NCT04179890|DRUG|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
214241684|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|As first line therapy.
214241685|NCT04179890|DRUG|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
214241686|NCT00001115|DRUG|Acyclovir|
214241687|NCT06063707|OTHER|Taking peripheral blood|Taking peripheral blood of no more than 3ml
214241688|NCT00075673|DRUG|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
214241689|NCT00075673|DRUG|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
214241690|NCT00674167|DRUG|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
214241691|NCT00674167|DRUG|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
214241692|NCT00674167|DRUG|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
214241693|NCT05563480|DRUG|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
214241694|NCT05563480|DRUG|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
214241695|NCT05563480|DRUG|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
214241696|NCT02125474|RADIATION|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
214241697|NCT05004454|DIETARY_SUPPLEMENT|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
214241698|NCT05004454|DIETARY_SUPPLEMENT|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
214241699|NCT04916782|OTHER|Quality of life Questionnaire|Quality of life questionnaire
214241700|NCT06415734|DEVICE|rTMS|LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
214241701|NCT02579928|DRUG|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
214241702|NCT02579928|DRUG|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
214241703|NCT02172066|BEHAVIORAL|Narrative Exposure Therapy (NET)|
214241704|NCT05076591|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
214241705|NCT00882219|DEVICE|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
214241706|NCT06097013|OTHER|Routine clinical rehabilitation|Routine clinical rehabilitation
214241707|NCT02352922|DRUG|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
214241708|NCT02352922|DRUG|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
214241709|NCT04833829|BEHAVIORAL|CHIMES Intervention|"There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings."
214241710|NCT04833829|BEHAVIORAL|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
214241711|NCT03754972|DIAGNOSTIC_TEST|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
214241712|NCT04811196|DRUG|Selinexor|Selinexor
214241713|NCT05161754|PROCEDURE|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
214241714|NCT05966337|PROCEDURE|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
214241715|NCT05966337|PROCEDURE|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
214652354|NCT03669978|PROCEDURE|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
214241716|NCT05966337|PROCEDURE|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
214241717|NCT02785289|DEVICE|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
214241718|NCT03800303|BEHAVIORAL|Family-based treatment|2-week family-based treatment
214241719|NCT06251479|BEHAVIORAL|behavioral 1|verbal and non verbal tasks
214241720|NCT06251479|BEHAVIORAL|behavioral 2|verbal and non verbal tasks with other partecipants
214241721|NCT06251479|DEVICE|neuromodulation 1|registration with neurophysiological tecniques during verbal and non verbal tasks
214241722|NCT06251479|DEVICE|neuromodulation 2|registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
214241723|NCT00437970|DRUG|Pioglitazone|15mg of Pioglitazone taken orally twice a day
214241724|NCT00437970|DRUG|Metformin|500 mg of Metformin taken orally twice a day
214241725|NCT00475475|BEHAVIORAL|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
214241726|NCT00475475|BEHAVIORAL|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
214241727|NCT00475475|BEHAVIORAL|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
214652355|NCT04000646|OTHER|standard care|standard care non-pharmacologic interventions during anesthesia induction
214652356|NCT04000646|OTHER|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
214241728|NCT02916238|DRUG|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
214241729|NCT02916238|BEHAVIORAL|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
214652357|NCT02852525|DEVICE|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
214652358|NCT00191854|DRUG|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
214652359|NCT00191854|DRUG|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
214241730|NCT03422627|DRUG|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
214241731|NCT01393028|OTHER|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
214241732|NCT01393028|OTHER|Standard care|Standard care according to international guidelines
214241733|NCT05946980|OTHER|Multi-component hand hygiene intervention in primary health care facilities|"Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination."
214241734|NCT04895189|OTHER|No intervention|There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.
214241735|NCT05480696|DIETARY_SUPPLEMENT|Fructo-oligosaccharide enriched inulin supplement|Experiment
214241736|NCT05480696|OTHER|Maltodextrin|Placebo.
214241737|NCT06638879|DRUG|Tacrolimus|Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
214241738|NCT04896645|DEVICE|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
214241739|NCT03691324|OTHER|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
214241740|NCT06526468|DEVICE|Artificial Intelligence|AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
214241741|NCT01676597|DRUG|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
214241742|NCT01676597|DRUG|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
214241743|NCT06536608|OTHER|Massage|"The Oketani Method is based upon practical breastfeeding theory, but is original in its practice. Oketani breast massage improves breastmilk secretion, can prevent and treat problems such as mastitis. In addition, the massage is painless, allowing your body to relax and breathe, something very much appreciated by mothers.~The Oketani breast massage consists of massaging and milking the base of the breasts. These delicate glands are massaged as well as protected."
214241744|NCT05373940|DEVICE|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
214241745|NCT05373940|DEVICE|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
214652360|NCT00191854|DRUG|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
214652361|NCT00191854|DRUG|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
214652362|NCT00928811|DRUG|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
214652363|NCT00928811|DRUG|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
214652364|NCT04355013|DEVICE|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
214652365|NCT05173129|DIAGNOSTIC_TEST|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
214652366|NCT06183008|DRUG|Intravenous immunoglobulin|Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
214652367|NCT06183008|DRUG|Placebo|Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
214652368|NCT00003956|DRUG|fluorouracil|
214652369|NCT00003956|DRUG|leucovorin calcium|
214652370|NCT00003956|DRUG|lonafarnib|
214652371|NCT03011229|DEVICE|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
214652372|NCT03011229|DEVICE|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
214652373|NCT05973370|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214652374|NCT05973370|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
214652375|NCT00566787|DEVICE|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
214241746|NCT06265584|DRUG|ATG dosing platform when combined with standard tacrolimus and mini methotrexate|On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
214241747|NCT03919188|PROCEDURE|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
214241748|NCT03919188|PROCEDURE|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
214241749|NCT00528554|PROCEDURE|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
214241750|NCT00528554|PROCEDURE|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
214241751|NCT02819232|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
214241752|NCT00000496|DRUG|aspirin|
214241753|NCT00000496|DRUG|dipyridamole|
214241754|NCT03526588|BIOLOGICAL|Autologous umbilical cord blood|6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
214241755|NCT01797406|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
214241756|NCT01797406|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
214241757|NCT00946140|PROCEDURE|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
214241758|NCT01012648|DRUG|Fluid resuscitation|Volume resuscitation
214241759|NCT01012648|DRUG|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
214241760|NCT05293392|BEHAVIORAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
214241761|NCT05293392|BEHAVIORAL|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
214241762|NCT03284918|DIETARY_SUPPLEMENT|Plant stanol ester|
214241763|NCT03284918|DIETARY_SUPPLEMENT|Placebo|
214241764|NCT04933643|OTHER||
214241765|NCT00735189|OTHER|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
214241766|NCT00735189|OTHER|usual care|patient receives usual anticoagulation care from their regular primary care physician
214241767|NCT01868919|BEHAVIORAL|Positive Parenting Program|Level 3 or 4 of Triple P
214241768|NCT05806489|OTHER|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
214241769|NCT05806489|OTHER|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
214241770|NCT01843647|DRUG|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
214241771|NCT01843647|DRUG|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
214241772|NCT05195138|BEHAVIORAL|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
214241773|NCT05195138|BEHAVIORAL|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
214241774|NCT04896450|PROCEDURE|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
214241775|NCT04896450|DEVICE|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
214241776|NCT02475824|DRUG|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
214241777|NCT02475824|DRUG|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
214652376|NCT02941367|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214652377|NCT02941367|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
214241778|NCT02475824|DRUG|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
214241779|NCT02475824|DRUG|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
214241780|NCT00934648|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214241781|NCT00934648|DRUG|methotrexate|10-25mg weekly
214241782|NCT02689102|DEVICE|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
214241783|NCT01482390|DRUG|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
214241784|NCT01482390|DRUG|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
214241785|NCT01482390|DRUG|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
214241786|NCT01482390|DRUG|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
214241787|NCT01482390|DRUG|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
214241788|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
214241789|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
214241790|NCT03131401|DIAGNOSTIC_TEST|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
214241791|NCT05885308|BEHAVIORAL|Otago|Group training is compared with training performed at participants' homes, using an online film
214241792|NCT04399746|DRUG|Ivermectin|6mg once daily in day 0,1,7 and 8
214241793|NCT04399746|DRUG|Azithromycin|500mg once daily for 4 days
214241794|NCT04399746|DRUG|Cholecalciferol|400 IU twice daily for 30 days
214241795|NCT03748615|DEVICE|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
214241796|NCT03454009|BEHAVIORAL|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
214241797|NCT05448820|DRUG|YH001|Anti-CTLA4 antibody
214241798|NCT05448820|DRUG|Envafolimab|Anti-PD-L1 antibody
214241799|NCT05448820|DRUG|Doxorubicin|Anthracycline
214241800|NCT00000481|BEHAVIORAL|diet, fat-restricted|
214241801|NCT04954248|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
214241802|NCT04239430|DIAGNOSTIC_TEST|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
214241803|NCT01915329|DEVICE|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
214241804|NCT01915329|DEVICE|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
214241805|NCT05265780|PROCEDURE|kinesiotape|an elastic adhesive tape
214241806|NCT05265780|PROCEDURE|sham taping|a sham taping without the tension
214652378|NCT02941367|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214241807|NCT01993836|DRUG|Total intravenous anesthesia with propofol|
214241808|NCT01993836|DRUG|General anesthesia with isoflurane|
214241809|NCT04707547|BIOLOGICAL|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
214241810|NCT04707547|PROCEDURE|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
214241811|NCT02612831|PROCEDURE|Early bariatric surgery|
214241812|NCT02612831|PROCEDURE|Delayed bariatric surgery|
214652379|NCT02941367|DRUG|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214652380|NCT00004255|BIOLOGICAL|anti-thymocyte globulin|
214652381|NCT00004255|BIOLOGICAL|filgrastim|
214652382|NCT00004255|DRUG|cyclophosphamide|
214652383|NCT00004255|DRUG|fludarabine phosphate|
214652384|NCT00004255|DRUG|methylprednisolone|
214652385|NCT00004255|DRUG|tacrolimus|
214652386|NCT00004255|PROCEDURE|allogeneic bone marrow transplantation|
214241813|NCT02195687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
214241814|NCT02195687|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
214241815|NCT01753778|DEVICE|Cryo-Touch III Device|Treatment with Cryo-Touch III
214241816|NCT02263170|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
214241817|NCT02263170|OTHER|US (ultra sound)|Assessment of the sphincter morphology
214241818|NCT02263170|OTHER|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
214241819|NCT02263170|OTHER|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
214241820|NCT02155803|DRUG|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
214241821|NCT00479583|DRUG|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
214241822|NCT00479583|DRUG|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
214241823|NCT01197001|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan low dose
214241824|NCT01197001|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
214241825|NCT02755792|BEHAVIORAL|Calligraphy Training|
214241826|NCT02755792|BEHAVIORAL|iPad Training|
214241827|NCT03539809|DIETARY_SUPPLEMENT|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
214241828|NCT05279404|OTHER|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
214241829|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
214241830|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
214241831|NCT03372889|BEHAVIORAL|Patient educaiton materials - Print based|Print (paper) based materials
214241832|NCT03372889|BEHAVIORAL|Patient educaiton materials - Media based|Media (electronic) based materials
214241833|NCT02217072|BEHAVIORAL|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
214241834|NCT02217072|BEHAVIORAL|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
214241835|NCT04156516|BEHAVIORAL|HEART|sexual health intervention
214241836|NCT04156516|BEHAVIORAL|HealthyMinds|Growth mindsets of personality and mental health
214241837|NCT03224780|DIAGNOSTIC_TEST|maternal serum creatine kinase|Biochemical marker
214241838|NCT03224780|DIAGNOSTIC_TEST|3D Doppler ultrasound|Doppler for placental vessels
214241839|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
214241840|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
214241841|NCT00002967|DRUG|cyclophosphamide|
214241842|NCT00002967|DRUG|doxorubicin hydrochloride|
214241843|NCT00002967|DRUG|octreotide pamoate|
214241844|NCT00002967|DRUG|tamoxifen citrate|
214241845|NCT04369924|BEHAVIORAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
214241846|NCT04369924|BEHAVIORAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
214241847|NCT05818605|BEHAVIORAL|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
214241848|NCT05254054|OTHER|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
214241849|NCT05254054|OTHER|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
214241850|NCT01642810|BEHAVIORAL|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
214241851|NCT01642810|OTHER|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
214241852|NCT00558129|DEVICE|X-STOP®|Surgical implantation of X-STOP IPD device
214241853|NCT00558129|PROCEDURE|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
214241854|NCT00708201|DRUG|Alvimopan|
214241855|NCT00708201|DRUG|Placebo|
214241856|NCT01125787|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
214241857|NCT01398878|BEHAVIORAL|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
214241858|NCT02359175|DRUG|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
214241859|NCT02359175|DRUG|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
214241860|NCT02359175|DRUG|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
214241861|NCT02359175|DRUG|Oral Paracetamol|Paracetamol to be given orally
214241862|NCT02359175|DRUG|Oral NSAID|NSAID to be given orally
214241863|NCT02359175|DRUG|Oral opioids|Opioids to be given orally
214241864|NCT02359175|DRUG|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
214241865|NCT02101814|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery)|
214241866|NCT01076894|PROCEDURE|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
214241867|NCT01076894|PROCEDURE|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
214241868|NCT03633760|DRUG|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
214241869|NCT03633760|DRUG|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
214241870|NCT04127812|BEHAVIORAL|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
214241871|NCT04335201|DRUG|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
214652387|NCT00004255|PROCEDURE|in vitro-treated bone marrow transplantation|
214652388|NCT00004255|RADIATION|radiation therapy|
214652389|NCT05215184|DEVICE|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
214652390|NCT05163886|DRUG|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
214652391|NCT05163886|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
214652392|NCT06130085|DIETARY_SUPPLEMENT|Partially hydrolyzed formula|Partially hydrolyzed formula given as the milk supplement for cow milk allergy patients after 6 months of strict elimination diet
214652393|NCT01451801|BIOLOGICAL|Twinrix|"A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin."
214652394|NCT04508387|PROCEDURE|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
214241872|NCT00041587|DRUG|IL13-PE38QQR|
214241873|NCT00041587|PROCEDURE|targeted fusion protein therapy|
214241874|NCT00041587|PROCEDURE|surgery|
214241875|NCT05214846|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
214241876|NCT00503945|DEVICE|Nasal continuous positive airway pressure (nCPAP)|
214241877|NCT03032770|DEVICE|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
214241878|NCT04240353|OTHER|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
214241879|NCT03800472|DRUG|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
214241880|NCT03800472|DRUG|Placebo|Placebo tablets
214241881|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
214241882|NCT03800472|DRUG|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
214241883|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
214241884|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
214241885|NCT03800472|DRUG|Placebo|Placebo optimized tablets
214241886|NCT06092060|DIETARY_SUPPLEMENT|the group GS (probiotic)|The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24
214241887|NCT06092060|DIETARY_SUPPLEMENT|the group GP (placebo)|The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.
214241888|NCT03253471|DRUG|AL-611|AL-611 tablets
214241889|NCT03253471|DRUG|Placebo|Placebo to Match AL-611
214241890|NCT02712814|DRUG|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
214241891|NCT02712814|PROCEDURE|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
214241892|NCT02712814|PROCEDURE|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
214241893|NCT05543434|DRUG|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
214652395|NCT00862251|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
214652396|NCT00862251|DRUG|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
214652397|NCT00862251|DRUG|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
214652398|NCT00862251|DRUG|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
214652399|NCT02958943|BEHAVIORAL|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
214652400|NCT00166790|DRUG|chemotherapy agents|
214652401|NCT00166790|PROCEDURE|suction curettage|
214241894|NCT03255070|DRUG|ARX788|An antibody drug conjugate
214241895|NCT01221844|DIETARY_SUPPLEMENT|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
214241896|NCT01221844|DRUG|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
214241897|NCT04929665|PROCEDURE|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
214241898|NCT04678206|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
214241899|NCT04678206|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
214241900|NCT02582762|DRUG|Nail gel|apply nail gel on affected nails twice daily for 2 months
214241901|NCT00282464|DRUG|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
214241902|NCT00282464|DRUG|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
214241903|NCT02273609|DRUG|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
214241904|NCT00003184|BIOLOGICAL|BCG vaccine|
214241905|NCT00003184|BIOLOGICAL|CD80 breast cancer vaccine|
214241906|NCT00003184|BIOLOGICAL|sargramostim|
214241907|NCT00375947|OTHER|Hand Exercise|
214241908|NCT00375947|OTHER|sham hand cream|placebo intervention
214241909|NCT02258984|DEVICE|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
214241910|NCT06179368|DIAGNOSTIC_TEST|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
214241911|NCT06179368|DIAGNOSTIC_TEST|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
214241912|NCT00812487|DRUG|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
214241913|NCT00812487|DRUG|Subcutaneous insulin|4 injections of insulin/day
214241914|NCT01680133|OTHER|Hyperinsulinemic euglycemic clamp|
214241915|NCT04695587|DIAGNOSTIC_TEST|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
214241916|NCT04695587|DIAGNOSTIC_TEST|MSNA|MSNA in subacute phase and 12 months after the acute episode
214241917|NCT04695587|DIAGNOSTIC_TEST|ABPM|ABPM in subacute phase and 12 months after the acute episode
214241918|NCT04695587|DIAGNOSTIC_TEST|ECHO|ECHO in subacute phase and 12 months after the acute episode
214241919|NCT04695587|DIAGNOSTIC_TEST|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
214241920|NCT04695587|DIAGNOSTIC_TEST|CMR|CMR in 12 months after the acute episode
214241921|NCT01364675|DRUG|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
214241922|NCT01364675|DRUG|Placebo tablet|Identical Placebo Tablet
214241923|NCT02207660|DRUG|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
214241924|NCT00121407|DRUG|Visudyne for injection|
214241925|NCT02360605|BEHAVIORAL|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
214241926|NCT02360605|BEHAVIORAL|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
214241927|NCT02360605|BEHAVIORAL|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
214241928|NCT05039827|OTHER|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
214241929|NCT05039827|OTHER|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
214241930|NCT03291301|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
214241931|NCT03291301|OTHER|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
214241932|NCT03209453|OTHER|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
214241933|NCT03630276|DIAGNOSTIC_TEST|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
214241934|NCT02222025|OTHER|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
214241935|NCT04791527|BEHAVIORAL|Mind-body therapy|Online yoga, meditation, behavior change tips, and nutrition tips
214241936|NCT04171427|OTHER|Lithium liposome|Cosmetic product
214241937|NCT04171427|OTHER|Placebo|Cosmetic product vehicle
214241938|NCT06326970|DIAGNOSTIC_TEST|99mTc-FAPI SPECT imaging|99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
214241939|NCT03742648|OTHER|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
214241940|NCT00290407|DRUG|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
214241941|NCT00290407|DIETARY_SUPPLEMENT|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
214241942|NCT00121797|PROCEDURE|urine culture|
214241943|NCT00121797|DRUG|antibiotics according to culture|
214241944|NCT00597844|OTHER|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
214241945|NCT00597844|OTHER|undergo voice evaluation and fMRI prior|in approximately one month and six months
214241946|NCT00020332|DRUG|alvocidib|
214241947|NCT00020332|DRUG|docetaxel|
214241948|NCT01499862|DEVICE|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
214241949|NCT05095493|DIETARY_SUPPLEMENT|Zinc Acetate|50 mg tablet
214241950|NCT05095493|DIETARY_SUPPLEMENT|Placebo|Zinc Acetate matched placebo tablet
214241951|NCT04447872|PROCEDURE|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
214241952|NCT02710643|DRUG|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
214241953|NCT04441866|DIAGNOSTIC_TEST|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
214241954|NCT04441866|DIAGNOSTIC_TEST|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
214241955|NCT00050687|DRUG|Gallium maltolate|
214241956|NCT02391896|DEVICE|Dual energy and tomosynthesis xray|
214241957|NCT01117792|DEVICE|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
214241958|NCT02964403|DRUG|Cox-2|
214241959|NCT02964403|DRUG|Indomethacin|
214241960|NCT04425044|OTHER|Other|No Intervention
214241961|NCT06135194|DRUG|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
214241962|NCT00401141|PROCEDURE|Blood samples|
214241963|NCT01856283|DRUG|Nilotinib 300mg BID|Nilotinib
214241964|NCT06171490|OTHER|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
214241965|NCT06171490|OTHER|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
214241966|NCT06171490|OTHER|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
214241967|NCT06171490|OTHER|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
214241968|NCT00005665|DRUG|interferon alpha|
214241969|NCT04656483|OTHER|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
214241970|NCT04656483|OTHER|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
214241971|NCT00002083|DRUG|Peptide T|
214241972|NCT02125643|DRUG|Caffeine|
214241973|NCT02125643|OTHER|Flour|Flour will be administered as the placebo.
214241974|NCT05888571|PROCEDURE|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
214241975|NCT05888571|PROCEDURE|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
214241976|NCT02049671|DRUG|Growth Hormone Therapy|
214241977|NCT04099771|DRUG|Ketamine|Ketamine infusion
214241978|NCT01894815|DRUG|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
214241979|NCT01894815|DEVICE|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
214241980|NCT01894815|OTHER|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
214241981|NCT01721577|DRUG|AXL1717|IGF-1 receptor inhibitor
214241982|NCT05503121|DIAGNOSTIC_TEST|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
214241983|NCT01640093|DRUG|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
214241984|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
214241985|NCT01640093|DRUG|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
214241986|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
214241987|NCT05086068|DEVICE|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
214241988|NCT00277641|DRUG|Lamotrigine|25 mg or 100 mg
214241989|NCT00277641|DRUG|placebo|identical tablets to study drug
214241990|NCT01277081|DRUG|Paracetamol hot drink|Hot drink containing paracetamol
214241991|NCT01277081|DRUG|Paracetamol tablets|Paracetamol tablets
214241992|NCT01772511|BEHAVIORAL|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
214241993|NCT02330328|OTHER|No Telemetry Monitoring|
214241994|NCT02330328|DEVICE|Telemetry Monitoring|
214241995|NCT01178996|BIOLOGICAL|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
214241996|NCT01178996|DRUG|Ribavirin|Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
214241997|NCT01178996|BIOLOGICAL|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
214241998|NCT01178996|DRUG|Placebo|Placebo
214241999|NCT04259892|BIOLOGICAL|2019-nCoV PCR|Nasopharyngeal swabs
214652402|NCT01727089|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
214652403|NCT01727089|BIOLOGICAL|Bevacizumab|Given IV
214242000|NCT03579030|DRUG|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
214242001|NCT03579030|DRUG|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
214242002|NCT05811533|OTHER|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
214242003|NCT05811533|OTHER|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
214242004|NCT01653028|DRUG|Alisertib|Given PO
214242005|NCT01653028|OTHER|Laboratory Biomarker Analysis|Correlative studies
214242006|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 6 g/day|dark chocolate 6 g/day
214242007|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 25 g/day|dark chocolate 25 g/day
214242008|NCT00164229|BEHAVIORAL|math|
214242009|NCT00164229|BEHAVIORAL|behavior regulation|
214242010|NCT04995796|OTHER|Surveys for Research Purposes|"VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
214242011|NCT06166030|DIETARY_SUPPLEMENT|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
214242012|NCT00522964|BEHAVIORAL|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
214242013|NCT04936464|DEVICE|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
214242014|NCT04936464|DEVICE|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
214242015|NCT05242861|RADIATION|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
214242016|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
214242017|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
214242018|NCT05805358|DRUG|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
214652404|NCT01727089|OTHER|Laboratory Biomarker Analysis|Correlative studies
214652405|NCT01727089|OTHER|Pharmacological Study|Correlative studies
214652406|NCT02033356|PROCEDURE|Adductor canal block with lidocaine 1%|US-guided adductor canal block
214652407|NCT02033356|DRUG|Lidocaine|
214652408|NCT02844127|PROCEDURE|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
214652409|NCT01453881|DEVICE|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
214652410|NCT01453881|DEVICE|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
214242019|NCT05152316|OTHER|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
214242020|NCT04526990|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
214242021|NCT04526990|BIOLOGICAL|Placebo|Intramuscular administration
214242022|NCT02590302|OTHER|Implementation Phase|"Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
214242023|NCT03487679|OTHER|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
214242024|NCT01108289|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
214242025|NCT06152471|DRUG|SPC-flakes|Aktive drug
214242026|NCT06152471|DRUG|Salovum|Active drug
214242027|NCT06152471|DRUG|Placebo|Placebo drugs
214242028|NCT02602678|PROCEDURE|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
214242029|NCT02602678|PROCEDURE|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
214242030|NCT04087928|DEVICE|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
214242031|NCT04087928|DEVICE|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
214242032|NCT02524977|BEHAVIORAL|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
214242033|NCT02524977|BEHAVIORAL|Educational Intervention Only|Educational conference series
214652411|NCT05373550|BEHAVIORAL|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
214242034|NCT03550651|OTHER|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
214242035|NCT03550651|OTHER|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
214242036|NCT03550651|OTHER|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
214242037|NCT03550651|OTHER|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
214242038|NCT03550651|OTHER|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
214242039|NCT04062500|OTHER|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
214242040|NCT00304369|DRUG|Metronidazole|
214242041|NCT00107926|DRUG|Licarbazepine|
214242042|NCT00107926|DRUG|Placebo|
214242043|NCT00117065|DRUG|Aranesp®|
214652412|NCT03388593|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
214652413|NCT03388593|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
214242044|NCT03736707|DEVICE|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
214242045|NCT03736707|DEVICE|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
214242046|NCT04698265|BIOLOGICAL|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
214242047|NCT00181623|DRUG|Recombinant Human Prolactin|
214242048|NCT00633620|DEVICE|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
214242049|NCT05965297|DEVICE|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
214242050|NCT05965297|DEVICE|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
214242051|NCT02856893|DRUG|Osimertinib|Osimertinib 60 or 40 mg daily until progression
214242052|NCT02856893|DRUG|Gefitinib|Gefitinib 250mg daily until progression
214242053|NCT00963677|PROCEDURE|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
214242054|NCT00955227|DIETARY_SUPPLEMENT|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
214242055|NCT00955227|DRUG|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
214242056|NCT01568307|DRUG|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
214242057|NCT03446144|DRUG|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
214242058|NCT03446144|DRUG|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
214242059|NCT01717144|BEHAVIORAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
214242060|NCT01116479|OTHER|Blood transfusion|Blood transfusion with packed erythrocytes
214242061|NCT02782078|BIOLOGICAL|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
214242062|NCT01361854|DEVICE|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
214242063|NCT05561010|DRUG|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
214242064|NCT05561010|DRUG|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
214242065|NCT04323605|OTHER|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
214242066|NCT00400114|DRUG|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
214242067|NCT00400114|DRUG|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
214242068|NCT00400114|PROCEDURE|Radiation|Radiation 50 Gy (weeks 4-9)
214242069|NCT00400114|PROCEDURE|Surgery|Esophagectomy
214242070|NCT00400114|DRUG|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
214242071|NCT01673282|DRUG|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
214242072|NCT02531100|DEVICE|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
214242073|NCT02531100|OTHER|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
214242074|NCT03158792|DRUG|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
214242075|NCT03158792|DRUG|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
214242076|NCT02393586|DRUG|Faropenem|Single oral dose
214242077|NCT02393586|DRUG|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
214242078|NCT02393586|DRUG|Rifampicin|Single oral dose
214242079|NCT03446261|DRUG|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
214242080|NCT03446261|DRUG|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
214242081|NCT02735889|OTHER|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
214242082|NCT02735889|OTHER|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
214242083|NCT02735889|OTHER|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
214242084|NCT03935399|DRUG|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
214242085|NCT03935399|DRUG|Saline|1.5 ml preservative free saline for intramuscular injection
214242086|NCT01358279|PROCEDURE|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
214242087|NCT04824716|PROCEDURE|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
214242088|NCT04824716|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
214242089|NCT05778643|BEHAVIORAL|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
214242090|NCT01373307|BEHAVIORAL|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
214242091|NCT01813045|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
214242092|NCT01813045|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
214242093|NCT01813045|RADIATION|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
214242094|NCT01112683|DRUG|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
214242095|NCT01112683|DRUG|Placebo|These are identically-looking pills to those in the Memantine Arm.
214242096|NCT01931709|RADIATION|fludeoxyglucose F 18|Undergo FDG PET
214242097|NCT01931709|DEVICE|positron emission tomography|Undergo FDG PET
214242098|NCT01931709|DEVICE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214242099|NCT01931709|OTHER|laboratory biomarker analysis|Correlative studies
214242100|NCT01007682|OTHER|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
214242101|NCT03232125|DRUG|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
214242102|NCT03232125|DRUG|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
214242103|NCT03363425|DRUG|Lidocaine Iv|Lidocaine Iv
214242104|NCT03363425|DRUG|Dexmedetomidine|dexmedetomidine iv
214242105|NCT03363425|DRUG|Normal saline|placebo
214242106|NCT03003299|DEVICE|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
214242107|NCT02879396|BEHAVIORAL|PA4LE Program|"1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
214242108|NCT01732653|OTHER|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
214242109|NCT01732653|OTHER|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
214242110|NCT06345196|BEHAVIORAL|motivational interview|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
214242111|NCT02311101|DRUG|Mitomycin C|Given intravesically
214242112|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
214242113|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
214242114|NCT02106923|DRUG|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
214242115|NCT02106923|DRUG|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
214242116|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
214242117|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
214242118|NCT04304547|DRUG|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet"
214242119|NCT04304547|DRUG|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once"
214242120|NCT04304547|DRUG|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet"
214242121|NCT03485495|DRUG|Divaza|Oral administration.
214242122|NCT03485495|DRUG|Placebo|Oral administration.
214242123|NCT06506305|DRUG|FB1001|Intravitreal (IVT) injection
214242124|NCT05824520|OTHER|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
214242125|NCT05824520|OTHER|OMT|Optimal medical therapy alone
214242126|NCT05977361|PROCEDURE|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
214242127|NCT05977361|PROCEDURE|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
214242128|NCT01323920|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 IV
214242129|NCT01323920|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
214242130|NCT01323920|DRUG|Methotrexate|Methotrexate 15 mg/m\^2 IV
214242131|NCT02088242|DRUG|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
214242132|NCT02088242|DRUG|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
214242133|NCT01028690|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
214242134|NCT01028690|DIETARY_SUPPLEMENT|Placebo|placebo
214242135|NCT01629199|DRUG|rhEGF(recombinant human Epidermal Growth Factor)|
214242136|NCT01629199|DRUG|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
214242137|NCT01864356|DRUG|NT100|
214242138|NCT01864356|DRUG|Placebo|
214242139|NCT00736515|DRUG|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
214242140|NCT00736515|DRUG|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
214242141|NCT04264052|DIAGNOSTIC_TEST|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
214242142|NCT04875247|DEVICE|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
214242143|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
214242144|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
214242145|NCT00001965|DRUG|Cyclosporine A|
214242146|NCT02915874|BEHAVIORAL|Acceptance and Commitment Therapy|
214242147|NCT03479645|BEHAVIORAL|Serial text messages and mailed FIT kit|"1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message"
214242148|NCT03103061|DRUG|Lexiscan|Coronary vasodilator
214242149|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242150|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242151|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
214242152|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242153|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
214242154|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242155|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
214242156|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242157|NCT00677053|DRUG|Placebo|Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
214242158|NCT04730414|DRUG|Full-spectrum hemp (0.018% THC)|Topical Application
214242159|NCT04999254|OTHER|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
214242160|NCT04999254|OTHER|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
214242161|NCT00216866|DRUG|Dalteparin|
214242162|NCT00216866|DRUG|Warfarin|
214242163|NCT03549351|OTHER|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
214242164|NCT00268580|BEHAVIORAL|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
214242165|NCT03988413|DRUG|25mg|SYHA1402 25mg or Placebo 25mg
214242166|NCT03988413|DRUG|50mg|SYHA1402 50mg or Placebo 50mg
214242167|NCT03988413|DRUG|100mg|SYHA1402 100mg or Placebo 100mg
214242168|NCT03988413|DRUG|200mg|SYHA1402 200mg or Placebo 200mg
214242169|NCT03988413|DRUG|400mg|SYHA1402 400mg or Placebo 400mg
214242170|NCT03988413|DRUG|800mg|SYHA1402 800mg or Placebo 800mg
214242171|NCT04743518|OTHER|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
214242172|NCT04743518|OTHER|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
214242173|NCT01056380|DRUG|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
214242174|NCT01056380|DRUG|Placebo|Tablet, twice daily with food for 5 days
214242175|NCT03439527|OTHER|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
214242176|NCT01655108|DRUG|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
214242177|NCT01655108|DRUG|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
214242178|NCT03901456|BEHAVIORAL|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
214242179|NCT03901456|BEHAVIORAL|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
214242180|NCT03724747|DRUG|BAY2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
214242181|NCT03724747|DRUG|Darolutamide(BAY1841788)|600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
214242182|NCT05043285|BIOLOGICAL|SCTV01C|intramuscular injection
214242183|NCT05043285|OTHER|Placebo|Intramuscular injection
214242184|NCT03119207|BEHAVIORAL|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
214242185|NCT05912426|BEHAVIORAL|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
214242186|NCT01071811|BEHAVIORAL|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
214242187|NCT00600145|DRUG|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
214242188|NCT00600145|OTHER|Placebo|Placebo
214242189|NCT01213667|DRUG|Ranibizumab|upload (three monthly injections), re-treatment as needed
214652414|NCT02310620|BEHAVIORAL|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
214242190|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
214242191|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
214242192|NCT02937220|PROCEDURE|monolithic zirconia crown|New crown material used as final restoration for dental implants
214242193|NCT02937220|PROCEDURE|metal ceramic crown|Conventional crown material used as final restoration for dental implants
214242194|NCT03752411|OTHER|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
214242195|NCT03752411|OTHER|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
214242196|NCT01136278|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
214242197|NCT01136278|DRUG|Clonidine|150 μg per os
214242198|NCT01136278|DRUG|placebo|capsules identical to MDMA or clonidine
214242199|NCT03964337|DRUG|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
214242200|NCT03964337|PROCEDURE|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
214242201|NCT01988285|OTHER|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
214652415|NCT05679414|DIAGNOSTIC_TEST|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
214652416|NCT02673229|DRUG|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
214242202|NCT01988285|OTHER|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
214242203|NCT03608761|DRUG|Rebamipide|rebamipide 2%
214242204|NCT03608761|BIOLOGICAL|autologous serum|AS for 3 months
214242205|NCT03608761|OTHER|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
214242206|NCT00814216|DRUG|QAV680|
214242207|NCT00814216|DRUG|Matching placebo for QAV680|
214242208|NCT00814216|DRUG|Fluticasone Propionate|
214242209|NCT02937974|DRUG|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
214242210|NCT02937974|DRUG|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
214242211|NCT06119958|DRUG|DWC202313|Experimental Drug 1
214242212|NCT06119958|DRUG|DWC202314|Experimental Drug 2
214242213|NCT00471614|DRUG|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
214242214|NCT00947505|DEVICE|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
214242215|NCT00947505|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
214242216|NCT03858439|OTHER|Dietary|Low sodium, low protein dietary recommendation
214242217|NCT01517971|OTHER|laboratory biomarker analysis|Correlative studies
214242218|NCT02492737|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
214242219|NCT02325843|OTHER|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
214242220|NCT04457388|OTHER|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
214242221|NCT06046352|PROCEDURE|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
214242222|NCT01247805|DRUG|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
214242223|NCT01247805|DRUG|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
214242224|NCT01247805|DRUG|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
214242225|NCT03487601|OTHER|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
214242226|NCT03487601|OTHER|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
214242227|NCT02858700|BIOLOGICAL|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
214242228|NCT01715129|DRUG|Triptorelin Pamoate 11.25mg|
214242229|NCT00712556|RADIATION|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
214242230|NCT06156124|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
214242231|NCT02044328|DRUG|Icotinib|Icotinib is administered 125 mg three times per day.
214242232|NCT02299518|DRUG|mitoxantrone hydrochloride|Given IV
214242233|NCT02299518|DRUG|etoposide|Given IV and PO
214242234|NCT02299518|DRUG|cytarabine|Given IV
214242235|NCT02299518|DRUG|selinexor|Given PO
214242236|NCT02299518|OTHER|laboratory biomarker analysis|Correlative studies
214242237|NCT02299518|OTHER|pharmacological study|Correlative studies
214242238|NCT04668612|DEVICE|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
214242239|NCT04668612|DEVICE|Standard bolus|Standard boluses for all meals
214242240|NCT00133978|OTHER|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
214242241|NCT00133978|OTHER|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
214242242|NCT00133978|OTHER|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
214242243|NCT00133978|OTHER|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
214242244|NCT00298753|PROCEDURE|fluid restriction for 14 days (15ml fluid per kg weight)|
214242245|NCT06492343|OTHER|fMRI based neurofeedback|participants will receive neurofeedback from their brain in order to modify their own brain function
214242246|NCT02972476|DRUG|Budesonide & formoterol fumarate and Aclidinium bromide|
214242247|NCT02972476|DRUG|Fluticasone 500 & salmeterol and Aclidinium bromide|
214242248|NCT02972476|DRUG|Fluticasone 250 & salmeterol and Aclidinium bromide|
214242249|NCT02972476|DRUG|Aclidinium bromide & formoterol fumarate|
214242250|NCT05245448|DRUG|Tetrandrine|Administered orally
214242251|NCT05245448|DRUG|Placebo|Administered orally
214242252|NCT04223492|DIAGNOSTIC_TEST|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
214242253|NCT04223492|DIAGNOSTIC_TEST|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
214242254|NCT05125185|OTHER|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
214242255|NCT04504058|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
214242256|NCT03625908|DEVICE|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
214242257|NCT03625908|DEVICE|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
214242258|NCT05926076|OTHER|Treatment plan|Patients with different diagnoses will get different treatment options
214242259|NCT00061282|DRUG|Clotrimazole|One retention enema, administered nightly
214242260|NCT05694143|OTHER|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education."
214242261|NCT05694143|OTHER|No Intervention|They will have their regular curriculums and normal physical activity routine
214242262|NCT03320876|DRUG|filgotinib|one filgotinib oral tablet once daily.
214242263|NCT00555308|OTHER|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
214242264|NCT03557996|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush
214242265|NCT03557996|DRUG|Sodium Fluoride Varnish|NaF will be applied with a brush
214242266|NCT01962168|DEVICE|Evolution® Biliary Stent - Uncovered|Commercially available device
214242267|NCT02715297|RADIATION|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
214242268|NCT02068768|DEVICE|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
214242269|NCT06409832|DRUG|Rimegepant 75 mg|Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
214242270|NCT04180449|OTHER|Screening for dysphagia along clinical routine|Screening for dysphagia using the water swallow test in intermediate care unit patients
214242271|NCT02463552|DRUG|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
214242272|NCT03947411|DRUG|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
214242273|NCT03947411|DRUG|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
214242274|NCT00002952|BIOLOGICAL|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
214242275|NCT00002952|BIOLOGICAL|recombinant MAGE-3.1 antigen|
214242276|NCT00002952|BIOLOGICAL|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
214242277|NCT03647787|OTHER|observational study|This study is a longitudinal observational study
214242278|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
214242279|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
214242280|NCT00344942|DRUG|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
214242281|NCT00344942|DRUG|placebo|a double spray into each nostril once daily
214242282|NCT04879602|BEHAVIORAL|suction with bronchoscopy|suction with bronchoscopy
214242283|NCT00294710|DRUG|Aliskiren|
214242284|NCT03048136|DRUG|Nivolumab|Specified dose on specified days
214242285|NCT03048136|DRUG|Ipilimumab|Specified dose on specified days
214242286|NCT04783688|OTHER|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
214242287|NCT01622283|DRUG|Levocetirizine|Levocetirizine
214242288|NCT01622283|DRUG|Cetirizine|Cetirizine
214242289|NCT05946304|BEHAVIORAL|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
214242290|NCT05946304|BEHAVIORAL|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
214242291|NCT00211744|DRUG|topiramate|
214242292|NCT01874678|DRUG|TS-1/Cisplatin|
214242293|NCT03357939|DRUG|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
214242294|NCT03357939|DRUG|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
214242295|NCT01067924|BEHAVIORAL|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
214242296|NCT02735499|DRUG|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
214242297|NCT03513107|OTHER|ospeoporosis score|"* Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass \& Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein \& Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~* Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
214242298|NCT02128100|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
214242299|NCT02128100|RADIATION|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
214242300|NCT04065165|DRUG|Telotristat Ethyl|250 mg TID orally
214242301|NCT04065165|DRUG|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
214242302|NCT03448874|DEVICE|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
214242303|NCT01932879|OTHER|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
214242304|NCT01932879|OTHER|Jello|
214242305|NCT00021372|DRUG|estramustine phosphate sodium|
214242306|NCT00021372|DRUG|paclitaxel|
214242307|NCT05354674|DRUG|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
214242308|NCT02989987|BEHAVIORAL|Narrative Exposure Therapy|
214242309|NCT02989987|BEHAVIORAL|Social Support|A local counselors provides social support on demand.
214242310|NCT02398994|DRUG|Intravenous Methylprednisolone|
214242311|NCT02398994|DRUG|Intravenous Immunoglobulin|
214242312|NCT00167869|BEHAVIORAL|dairy peptides|
214242313|NCT02995369|DEVICE|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
214242314|NCT02995369|OTHER|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
214242315|NCT03109912|BEHAVIORAL|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
214242316|NCT03109912|BEHAVIORAL|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
214242317|NCT03109912|BEHAVIORAL|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
214242318|NCT03109912|BEHAVIORAL|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
214242319|NCT05301374|BEHAVIORAL|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
214242320|NCT04013399|DEVICE|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
214242321|NCT03769376|DEVICE|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
214242322|NCT03769376|DEVICE|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
214242323|NCT00162955|DRUG|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
214242324|NCT00800462|DRUG|Oxybutynin Cl|15 mg qd for 3 months
214242325|NCT00800462|DRUG|Trospium Cl|20mg bid for 3 months
214242326|NCT00800462|DRUG|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
214242327|NCT02005198|OTHER|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
214242328|NCT02901665|OTHER|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
214242329|NCT02763592|DRUG|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
214242330|NCT02763592|OTHER|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
214242331|NCT00400153|DRUG|Atrovent Respimat (20 mcg)|
214242332|NCT00400153|DRUG|COMBIVENT MDI (36/206 mcg)|
214242333|NCT00400153|DRUG|Combivent Respimat (20 mcg/100 mcg)|
214242334|NCT00400153|DRUG|Placebo via corresponding inhaler for blinding purposes|
214242335|NCT05364801|OTHER|Survey|Online anonymous survey
214242336|NCT02763969|DRUG|BMS-986202|
214242337|NCT02763969|DRUG|Placebo|
214242338|NCT02763969|DRUG|Interferon alpha-2a recombinant|
214242339|NCT02763969|DRUG|Famotidine|
214242340|NCT02763969|DRUG|Ustekinumab|
214242341|NCT00533091|BIOLOGICAL|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
214242342|NCT00533091|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
214242343|NCT04537780|OTHER|Placebo|Placebo tabled every day
214242344|NCT04537780|DRUG|Montelukast|Montelukast 10 mg daily at bed time.
214242345|NCT01380938|DRUG|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
214242346|NCT05604183|PROCEDURE|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
214242347|NCT05604183|PROCEDURE|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
214242348|NCT05604183|DIAGNOSTIC_TEST|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
214242349|NCT01423604|DRUG|Capecitabine|Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
214242350|NCT01423604|DRUG|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
214242351|NCT01423604|DRUG|Placebo|Placebo matching ruxolitinib
214242352|NCT05343468|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
214242353|NCT00000931|BEHAVIORAL|Behavioral intervention|
214242354|NCT00000931|BEHAVIORAL|Risk-reduction counseling|
214242355|NCT00424255|DRUG|Lapatinib|Dual ErbB1/2 inhibitor
214242356|NCT00424255|RADIATION|Chemoradiation|Radiation plus platinum based chemotherapy
214242357|NCT00424255|OTHER|Placebo|Placebo
214242358|NCT03737071|BEHAVIORAL|Low Carbohydrate Diet|Ketogenic dietary intervention
214242359|NCT03737071|BEHAVIORAL|Simple Calorie Restriction Diet|Simple calorie restriction dietary intervention
214242360|NCT03766282|DEVICE|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
214242361|NCT00357929|PROCEDURE|Permissive hypercarbia|
214242362|NCT00002805|BIOLOGICAL|filgrastim|
214242363|NCT00002805|DRUG|cladribine|
214242364|NCT00002805|DRUG|cytarabine|
214242365|NCT00002805|DRUG|etoposide|
214242366|NCT00002805|DRUG|methotrexate|
214242367|NCT00002805|DRUG|mitoxantrone hydrochloride|
214242368|NCT00002805|DRUG|therapeutic hydrocortisone|
214242369|NCT00002805|PROCEDURE|allogeneic bone marrow transplantation|
214242370|NCT00002805|PROCEDURE|autologous bone marrow transplantation|
214242371|NCT00002805|PROCEDURE|peripheral blood stem cell transplantation|
214242372|NCT00002805|RADIATION|low-LET cobalt-60 gamma ray therapy|
214242373|NCT00002805|RADIATION|low-LET electron therapy|
214242374|NCT00002805|RADIATION|low-LET photon therapy|
214652417|NCT02673229|DRUG|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
214652418|NCT01371461|DRUG|Paroxetine|
214242375|NCT00374205|DRUG|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
214242376|NCT00374205|DRUG|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
214242377|NCT06993961|DEVICE|Ultrasound|Ultrasound (US) measurement of optic nerve sheath diameter (ONSD) was performed.
214242378|NCT03609398|BIOLOGICAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
214242379|NCT06491667|DIAGNOSTIC_TEST|CBC|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
214242380|NCT06491667|DIAGNOSTIC_TEST|C-reactive protein|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
214242381|NCT02186301|DRUG|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
214242382|NCT02186301|DRUG|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
214242383|NCT00371761|BIOLOGICAL|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
214242384|NCT00371761|DRUG|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
214242385|NCT05506137|DRUG|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
214242386|NCT05506137|OTHER|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
214242387|NCT05341388|DIAGNOSTIC_TEST|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
214242388|NCT05341388|DIAGNOSTIC_TEST|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
214242389|NCT05341388|OTHER|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
214242390|NCT05341388|DIAGNOSTIC_TEST|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
214242391|NCT03560739|COMBINATION_PRODUCT|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
214242392|NCT03560739|COMBINATION_PRODUCT|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
214242393|NCT03361176|DRUG|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
214242394|NCT03361176|COMBINATION_PRODUCT|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
214242395|NCT05347004|DRUG|BI 425809|BI 425809
214242396|NCT00179244|DRUG|Rispridone (drug) and Bupropion ER (drug)|
214242397|NCT03123185|DRUG|Placebo|Tablet and solution formulation
214242398|NCT03123185|DRUG|BI 705564 (Test)|Fed state
214242399|NCT03123185|DRUG|BI 705564 (Reference)|Fasting state
214242400|NCT02129218|OTHER|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
214242401|NCT02129218|OTHER|laboratory biomarker analysis|Correlative studies
214242402|NCT02129218|BEHAVIORAL|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
214242403|NCT02129218|BEHAVIORAL|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
214242404|NCT02129218|BEHAVIORAL|Low glycemic load|
214242405|NCT02129218|BEHAVIORAL|Medium Glycemic Load|
214242406|NCT03396393|DRUG|Dihydroartemisinin tablet|DHA tablet
214242407|NCT03396393|DRUG|Placebo tablet|Placebo tablet
214242408|NCT06423729|DRUG|Nicorandil 10 MG|Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
214242409|NCT06318962|BEHAVIORAL|Aviva|Digital phone app for BCBT
214242410|NCT03950037|DRUG|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
214242411|NCT04489160|DRUG|C1 Inhibitor, Human|6000 IU C1-INH
214242412|NCT04489160|DRUG|Placebo|0.9% saline
214242413|NCT00005863|BIOLOGICAL|filgrastim|
214242414|NCT00005863|DRUG|cytarabine|
214242415|NCT00005863|DRUG|daunorubicin hydrochloride|
214242416|NCT00005863|DRUG|etoposide|
214242417|NCT00005863|DRUG|fludarabine phosphate|
214242418|NCT00005863|DRUG|tretinoin|
214242419|NCT00127595|DRUG|gemcitabine, oxaliplatin|
214242420|NCT01788176|DRUG|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
214242421|NCT01788176|DRUG|Placebo|one single intravenous infusion of 100ml of saline.
214652419|NCT02649101|DRUG|Thalidomide|Thalidomide tablet 100mg qn po.
214652420|NCT02649101|DRUG|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
214242422|NCT01142518|DRUG|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
214242423|NCT02705027|DEVICE|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
214242424|NCT03659786|OTHER|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
214242425|NCT03654027|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
214242426|NCT03654027|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
214242427|NCT00209508|DRUG|GPI 1485|
214242428|NCT03298776|DEVICE|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
214242429|NCT03298776|DIAGNOSTIC_TEST|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
214242430|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
214242431|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
214242432|NCT04808284|DEVICE|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
214242433|NCT03722199|DIETARY_SUPPLEMENT|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
214242434|NCT03722199|OTHER|Placebo|single intake of capsules with a placebo
214242435|NCT00000434|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
214242436|NCT02328911|DEVICE|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
214242437|NCT02328911|DEVICE|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
214242438|NCT02752971|DRUG|Bupivacaine|
214242439|NCT02752971|DRUG|Sodium diclofenac|
214242440|NCT03718182|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D3 daily oral supplement
214242441|NCT05386823|DRUG|HF1K16|HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
214242442|NCT05386823|DRUG|Placebo|Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
214242443|NCT02869061|PROCEDURE|Liposuction|
214242444|NCT02869061|PROCEDURE|Transurethral bladder neck resection.|
214242445|NCT02869061|BIOLOGICAL|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
214242446|NCT02869061|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
214242447|NCT04561427|OTHER|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
214242448|NCT04585152|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
214242449|NCT05109052|DRUG|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
214242450|NCT05468385|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
214242451|NCT05468385|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
214242452|NCT05660980|DRUG|Once daily CAB tablet + RPV tablet|Tablet
214242453|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
214242454|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
214242455|NCT05002153|OTHER|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
214242456|NCT05002153|OTHER|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
214242457|NCT00599781|GENETIC|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
214242458|NCT03621618|DIAGNOSTIC_TEST|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
214242459|NCT03621618|DIAGNOSTIC_TEST|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
214242460|NCT02519387|DRUG|Buprenorphine Transdermal Patch|
214242461|NCT05851326|DEVICE|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
214242462|NCT05851326|DEVICE|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
214242463|NCT05638919|DRUG|Oral Antiviral|Nirmatrelvir plus ritonavir or molnupiravir
214242464|NCT02288377|DRUG|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
214242465|NCT02288377|DRUG|Placebo|
214242466|NCT00976118|DRUG|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
214242467|NCT00976118|DRUG|placebo|matching placebo to masitinib
214242468|NCT02844686|OTHER|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
214242469|NCT02554279|DRUG|menotropin|
214242470|NCT02554279|DRUG|recombinant FSH|
214242471|NCT02146144|PROCEDURE|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made"
214242472|NCT05606653|OTHER|Measurement of critical airway closing pressure|Measurement of critical airway closing pressure
214242473|NCT05606653|OTHER|Respiratory function tests|CO2 response test
214242474|NCT05606653|OTHER|pharyngometry|measure of the pharyngometry
214242475|NCT05752266|DIETARY_SUPPLEMENT|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
214242476|NCT05752266|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
214242477|NCT06305871|PROCEDURE|Ablation therapy|Ablative treatment of hyperthyroidism
214242478|NCT01933789|BEHAVIORAL|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
214242479|NCT00145678|BEHAVIORAL|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
214652421|NCT04212000|DRUG|Levoketoconazole|Levoketoconazole tablet
214242480|NCT00145678|BEHAVIORAL|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
214242481|NCT01911637|DRUG|VBY-036|Study drug VBY-036
214242482|NCT01911637|DRUG|Placebo|Placebo
214242483|NCT01966432|BEHAVIORAL|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
214242484|NCT01966432|BEHAVIORAL|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
214242485|NCT05884632|RADIATION|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
214242486|NCT05305417|PROCEDURE|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
214242487|NCT05305417|PROCEDURE|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
214652422|NCT04212000|DRUG|Ketoconazole|Ketoconazole tablet
214652423|NCT05057364|OTHER|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
214652424|NCT05239845|DIETARY_SUPPLEMENT|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
214652425|NCT05239845|OTHER|Control|Maltodextrin
214652426|NCT00499109|DRUG|Docetaxel|"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
214652427|NCT00499109|DRUG|Vinorelbine|DV Group: 35 mg/m\^2 on days 1 and 15
214242488|NCT01295931|DRUG|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
214242489|NCT01295931|PROCEDURE|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
214242490|NCT05319093|DRUG|Ozanimod|Three-months, longitudinal observational period
214242491|NCT00930982|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
214242492|NCT00930982|DRUG|Placebo|Inhalation of matching placebo twice a day
214242493|NCT02676128|BEHAVIORAL|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
214242494|NCT02676128|BEHAVIORAL|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
214242495|NCT04230564|DRUG|azacitidine|Patients taking azacitidine
214242496|NCT04230564|DRUG|venetoclax|patients taking venetoclax
214242497|NCT04230564|DRUG|glasdegib|patients taking glasdegib
214242498|NCT04678479|DRUG|Ganaxolone|ganaxolone
214242499|NCT02270437|DRUG|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
214242500|NCT04422795|DEVICE|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
214242501|NCT04422795|DEVICE|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
214242502|NCT04422795|DRUG|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
214242503|NCT04650061|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
214242504|NCT04650061|DEVICE|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
214242505|NCT01609478|DRUG|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
214242506|NCT01609478|DRUG|placebo|placebo delivered via Concept 1 inhaler
214242507|NCT01609478|DRUG|mometasone furoate|via Twisthaler inhaler
214242508|NCT04019587|DIAGNOSTIC_TEST|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
214242509|NCT00150644|DRUG|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
214242510|NCT00150644|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
214242511|NCT00150644|DRUG|Placebo|Placebo Tablet, oral Daily for 12 weeks
214242512|NCT02309866|GENETIC|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
214242513|NCT00458874|BEHAVIORAL|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
214242514|NCT05465720|BEHAVIORAL|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
214242515|NCT04080687|DEVICE|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
214242516|NCT02004639|RADIATION|Masticators sparing techniques|
214242517|NCT02004639|OTHER|electro-acupunture treatment|electro-acupunture treatment and sham-EA
214242518|NCT01082822|BIOLOGICAL|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
214242519|NCT01302015|BIOLOGICAL|RNL-Vascostem®|
214242520|NCT04635670|DIETARY_SUPPLEMENT|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
214242521|NCT04635670|DIETARY_SUPPLEMENT|Placebo|Soluble powder for oral use twice daily.
214242522|NCT01884727|DIETARY_SUPPLEMENT|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
214242523|NCT01884727|DIETARY_SUPPLEMENT|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
214242524|NCT06097780|GENETIC|NestaCell®|Human Dental Pulp Stem Cells (hDPSCs).
214242525|NCT03042273|DIETARY_SUPPLEMENT|High Strength Cranberry|Softgel capsule
214242526|NCT03042273|DIETARY_SUPPLEMENT|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
214242527|NCT03383731|PROCEDURE|Group 1|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
214242528|NCT03383731|PROCEDURE|Group 2|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
214242529|NCT05687604|BEHAVIORAL|multiple behavior change therapy|goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
214242530|NCT03768297|PROCEDURE|dual zone concept|immediate implant with bone fill till soft tissue level
214242531|NCT00000495|BEHAVIORAL|diet, reducing|
214242532|NCT00000495|BEHAVIORAL|diet, sodium-restricted|
214242533|NCT00000495|BEHAVIORAL|alcohol restriction|
214242534|NCT00000495|BEHAVIORAL|exercise|
214242535|NCT06630819|OTHER|1.8 ml of 4% Articaine|Buccal infiltration of 1.8 ml of 4% Articaine
214242536|NCT06630819|OTHER|3.6 ml of 4% Articaine|Buccal infiltration of 3.6 ml of 4% Articaine.
214242537|NCT04966741|DRUG|Setmelanotide|SC injection once daily.
214242538|NCT06595030|DEVICE|Active Lighting Intervention|The TLI will allow researchers to use a light source that will control how the circadian system is stimulated and provide the participants with options as to how the light treatment will be delivered.
214242539|NCT06595030|DEVICE|Control Lighting Intervention|The TLI will allow researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
214242540|NCT05161039|DEVICE|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
214242541|NCT05161039|DEVICE|POBA|Plain balloon angioplasty device
214242542|NCT03487978|DIAGNOSTIC_TEST|resting-state functional MRI|"1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not."
214242543|NCT00234910|DRUG|Tenofovir DF|TDF 300mg QD for 72 wks
214242544|NCT00234910|DRUG|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
214242545|NCT00202176|DRUG|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
214242546|NCT03668418|DRUG|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242547|NCT03668418|DRUG|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242548|NCT03668418|DRUG|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242549|NCT03668418|DRUG|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242550|NCT03668418|DRUG|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242551|NCT03668418|DRUG|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242552|NCT03668418|DRUG|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242553|NCT03668418|DRUG|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242554|NCT03668418|DRUG|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
214242555|NCT05577468|DRUG|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
214242556|NCT06576739|PROCEDURE|Spinal Manipulation|Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
214242557|NCT03486145|DIETARY_SUPPLEMENT|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
214242558|NCT03486145|DIETARY_SUPPLEMENT|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
214242559|NCT04942197|OTHER|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
214242560|NCT04732897|PROCEDURE|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
214242561|NCT02783469|GENETIC|Identification of genetic causes of diabetic neuropathic pain|
214242562|NCT04517955|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
214242563|NCT02048280|PROCEDURE|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
214242564|NCT02048280|OTHER|NAVA level|Increase NAVA level every 3 minutes
214242565|NCT00247221|BEHAVIORAL|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
214242566|NCT00247221|BEHAVIORAL|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
214242567|NCT02171559|DRUG|Enoxaparin prefilled syringes|
214242568|NCT02171559|DRUG|Dabigatran etexilate capsules|
214242569|NCT01965886|PROCEDURE|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
214242570|NCT01965886|PROCEDURE|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
214242571|NCT06035770|OTHER|Mental Health First Aid (educational training program)|"The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors."
214242572|NCT04894214|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
214242573|NCT04894214|OTHER|Recording of hemodynamic monitoring|Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
214242574|NCT04894214|OTHER|Recording of respiratory monitoring|Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
214242575|NCT01552707|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
214242576|NCT01552707|PROCEDURE|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
214242577|NCT00008866|BIOLOGICAL|Tetanus Toxoid Vaccine|
214242578|NCT00008866|DRUG|Hydroxyurea|
214242579|NCT00008866|DRUG|Didanosine|
214242580|NCT03207919|BEHAVIORAL|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
214242581|NCT00284492|PROCEDURE|Traditional chinese medicine type acupuncture|10 acupuncture sessions
214242582|NCT00284492|BEHAVIORAL|Self Care|Lifestyle advice on diet, physical activity
214242583|NCT02410785|DEVICE|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
214242584|NCT02410785|OTHER|Placebo|Placebo tablet
214242585|NCT05121493|OTHER|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
214242586|NCT05121493|OTHER|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
214242587|NCT00957593|DRUG|Oxytocin|Continuation of oxytocin once in active labor
214242588|NCT00957593|DRUG|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
214242589|NCT05669313|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
214242590|NCT00263939|BEHAVIORAL|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
214242591|NCT06139692|DRUG|Dexmedetomidine|Patients receive perioperative sedation with dexmedetomidine
214242592|NCT06139692|DRUG|Midazolam|Patients receive perioperative sedation with midazolam
214242593|NCT02328469|DRUG|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
214242594|NCT02328469|DRUG|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
214242595|NCT02328469|OTHER|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
214242596|NCT02328469|DRUG|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
214242597|NCT03875170|OTHER|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
214242598|NCT03875170|OTHER|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
214242599|NCT01546129|DEVICE|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
214242600|NCT01551446|DRUG|Bardoxolone Methyl|Oral, once daily
214242601|NCT06126731|DRUG|Enzalutamide 40mg|Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
214242602|NCT06126731|DRUG|Amoxicillin 500mg|"Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder"
214242603|NCT06126731|DRUG|Metronidazole 400mg|"Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other"
214242604|NCT06126731|DRUG|Vancomycin 125mg|"Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass"
214242605|NCT06126731|DRUG|Ciprofloxacin 500g|"White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side"
214242606|NCT04249830|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
214242607|NCT04249830|DEVICE|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
214242608|NCT03160859|OTHER|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
214242609|NCT03160859|DEVICE|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
214242610|NCT02915120|PROCEDURE|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
214242611|NCT02915120|PROCEDURE|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
214242612|NCT05294120|DEVICE|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
214242613|NCT05294120|RADIATION|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
214242614|NCT05959603|DRUG|Vancomycin|Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
214242615|NCT02953509|DRUG|Magrolimab|Administered intravenously
214242616|NCT02953509|DRUG|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
214242617|NCT02953509|DRUG|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
214242618|NCT02953509|DRUG|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
214242619|NCT02953509|DRUG|Allopurinol|Administered orally during Cycle 1
214242620|NCT06361797|OTHER|Rotator cuff repair augmented with whole bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.
214242621|NCT06361797|OTHER|Rotator cuff repair augmented with concentrated bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. This volume will be concentrated and, at the end of the procedure, the concentrate will be injected back into the joint space.
214242622|NCT05617209|OTHER|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
214242623|NCT05658575|DRUG|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
214242624|NCT05658575|OTHER|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
214242625|NCT03952299|DRUG|Oxybutynin Transdermal Patch|Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
214242626|NCT03952299|DRUG|Oral Oxybutynin|Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
214242627|NCT06312670|DRUG|EPI-7386|600 mg orally administered twice daily
214242628|NCT06312670|DRUG|Enzalutamide|160 mg administered orally once daily, with or without food
214242629|NCT06312670|DRUG|Androgen Deprivation Therapy (ADT)|LHRH agonist/antagonist or orchiectomy
214242630|NCT06033976|PROCEDURE|Endoscopic submucosal dissection (ESD)|Endoscopic injection of fluid into the gastrointestinal submucosal space followed by endoscopic knife dissection around and under the lesion so as to remove the lesion specimen in one piece with lesion free resection margins.
214242631|NCT05944328|OTHER|systematic and structured review of patient pharmacotherapeutic treatment plans|"The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient."
214242632|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
214242633|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
214242634|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
214242635|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
214242636|NCT00000843|DRUG|Adefovir dipivoxil|
214242637|NCT00484185|DRUG|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
214242638|NCT06299371|DRUG|Adebrelimab|Adebrelimab IV
214242639|NCT06299371|DRUG|paclitaxel for injection (albumin bound)|paclitaxel for injection (albumin bound) IV
214242640|NCT06299371|DRUG|Cisplatin or Carboplatin|Cisplatin or Carboplatin IV
214242641|NCT03952390|OTHER|control|
214242642|NCT03952390|OTHER|sepsis|
214242643|NCT04607798|DEVICE|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
214242644|NCT00933218|DIETARY_SUPPLEMENT|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
214242645|NCT00933218|DIETARY_SUPPLEMENT|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
214242646|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
214242647|NCT04769999|BEHAVIORAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
214652428|NCT00499109|DRUG|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
214652429|NCT00499109|DRUG|Gemcitabine|"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
214242648|NCT00459056|DRUG|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
214242649|NCT00459056|DRUG|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
214242650|NCT00170924|DRUG|Valsartan|
214242651|NCT00812760|DRUG|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
214242652|NCT03216928|DIAGNOSTIC_TEST|Blood test|
214242653|NCT05530629|DEVICE|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
214242654|NCT05530629|DEVICE|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
214242655|NCT03430453|PROCEDURE|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
214242656|NCT02522871|DEVICE|OCS™ Liver System|
214242657|NCT02522871|OTHER|Control|
214242658|NCT02562690|OTHER|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
214242659|NCT04138979|DRUG|cyclophosphamide|First use of chemotherapy after breast cancer
214242660|NCT05179174|GENETIC|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
214242661|NCT04944862|BIOLOGICAL|CDX-0159|administered intravenously
214242662|NCT04944862|DRUG|Normal saline|administered intravenously
214242663|NCT02206178|DRUG|N-acetylcysteine combination with acetaminophen|
214242664|NCT02206178|DRUG|Placebo|
214242665|NCT00377130|OTHER|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
214242666|NCT03195296|OTHER|No intervention|No intervention related to the study is foreseen
214242667|NCT02620371|PROCEDURE|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
214242668|NCT05062395|PROCEDURE|Computed Tomography|Undergo FDG PET CT
214242669|NCT05062395|OTHER|Fludeoxyglucose F-18|Undergo FDG PET CT
214242670|NCT05062395|OTHER|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
214242671|NCT05062395|PROCEDURE|Positron Emission Tomography|Undergo FDG PET CT
214242672|NCT00509262|DRUG|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
214242673|NCT00509262|DRUG|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
214242674|NCT00509262|DRUG|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
214242675|NCT00509262|DRUG|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
214242676|NCT05034666|BEHAVIORAL|Before the education program|Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
214242677|NCT05034666|BEHAVIORAL|After the education program|After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
214242678|NCT02569827|DRUG|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
214242679|NCT02569827|DRUG|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
214242680|NCT02569827|DRUG|Placebo|Placebo Q6H for 5 days
214242681|NCT02569827|DRUG|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
214242682|NCT04388371|DRUG|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
214242683|NCT04951739|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
214242684|NCT00801671|PROCEDURE|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
214242685|NCT00065364|BEHAVIORAL|Newborn Individualized Developmental Care Assessment Program|
214242686|NCT00558571|DRUG|BI 10773 low dose|
214242687|NCT00558571|DRUG|placebo to BI 10773|
214242688|NCT00558571|DRUG|BI 10773 medium dose|
214242689|NCT00558571|DRUG|BI 10773 high dose|
214242690|NCT03380936|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
214242691|NCT03380936|OTHER|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
214242692|NCT03029637|DEVICE|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
214242693|NCT03029637|DEVICE|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
214242694|NCT04860908|OTHER|no intervention, observation only|no intervention, observation only
214242695|NCT02588001|DRUG|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
214242696|NCT04613401|OTHER|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
214242697|NCT06116240|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
214242698|NCT06116240|DRUG|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
214242699|NCT06116240|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
214242700|NCT06116240|DRUG|Cisplatin injection|Cisplatin is a chemotherapy drug.
214242701|NCT02793622|DRUG|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
214242702|NCT02793622|DRUG|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
214242703|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
214242704|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
214242705|NCT02821663|BEHAVIORAL|vocal intervention|10 x 60 min. sessions of vocal intervention
214242706|NCT03556488|DIAGNOSTIC_TEST|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
214242707|NCT04138966|DEVICE|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
214242708|NCT04138966|DEVICE|Skin Conductance|Measures skin conductance as a surrogate to nociception
214242709|NCT04705740|OTHER|ERCP|ERCPs performed annually by an endoscopist
214242710|NCT01146860|DRUG|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
214242711|NCT01146860|DRUG|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
214242712|NCT04260932|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
214242713|NCT01650129|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
214242714|NCT01650129|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
214242715|NCT00728143|DIETARY_SUPPLEMENT|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
214242716|NCT00151203|DRUG|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
214242717|NCT02916121|DIETARY_SUPPLEMENT|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
214242718|NCT02916121|OTHER|Placebo|placebo
214242719|NCT02721186|DRUG|MDA with DHAp and SLD Primaquine|
214242720|NCT02306031|DRUG|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
214242721|NCT02306031|DRUG|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
214242722|NCT01555385|DIETARY_SUPPLEMENT|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
214242723|NCT04572516|DRUG|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
214242724|NCT04572516|DRUG|BTX A Injection|In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
214242725|NCT01092832|DRUG|voriconazole|"Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
214242726|NCT01341392|DRUG|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
214242727|NCT01341392|DRUG|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
214242728|NCT01341392|DRUG|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
214242729|NCT03139942|DEVICE|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
214242730|NCT02257671|DRUG|Oral contraceptive|Neovletta
214242731|NCT00225927|PROCEDURE|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
214652430|NCT02221544|DEVICE|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
214242732|NCT03681223|DEVICE|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
214242733|NCT03681223|DEVICE|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
214242734|NCT03681223|PROCEDURE|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
214242735|NCT03681223|PROCEDURE|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
214242736|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
214242737|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene free form|One capsule with Pterostilbene free form
214242738|NCT06437704|OTHER|Brain training game Lumosity|. Group A, the experimental group will be trained using five selected games i.e. Speed Match, Memory Matrix, Tidal treasure, Ebb and Flow and Lost in Migration from Lumosity for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
214242739|NCT06437704|OTHER|Simulation game simcity buildit|Group B, the active control will be trained for the same number of sessions using a simulation game, SimCity Build it, for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
214242740|NCT05098977|PROCEDURE|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
214652431|NCT02221544|DEVICE|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
214242741|NCT05098977|PROCEDURE|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
214242742|NCT02721771|PROCEDURE|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
214242743|NCT05428189|DIAGNOSTIC_TEST|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
214242744|NCT05428189|DEVICE|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
214242745|NCT02014870|OTHER|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
214242746|NCT02014870|OTHER|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
214242747|NCT02014870|OTHER|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
214242748|NCT01190787|DRUG|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
214242749|NCT01190787|DRUG|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
214242750|NCT01190787|DRUG|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
214242751|NCT04598256|PROCEDURE|Endoscopic procedure|Esophagogastroscopy and colonoscopy
214242752|NCT03240744|BIOLOGICAL|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
214242753|NCT02582177|DRUG|Candicort®|Apply on the affected area and around it twice a day
214242754|NCT02582177|DRUG|Nizoral®|Apply on the affected area and around it twice a day
214242755|NCT02582177|DRUG|Baycuten N®|Apply on the affected area and around it twice a day
214242756|NCT02582177|DRUG|Canesten®|Apply on the affected area and around it twice a day
214242757|NCT05677672|BIOLOGICAL|Human TH-SC01 Cell Injection|Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg
214242758|NCT05677672|OTHER|Saline solution|saline solution will be given at the same quantity and following the same schedule
214242759|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
214242760|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
214242761|NCT02442401|DEVICE|The negative pressure wound therapy|
214242762|NCT05843773|PROCEDURE|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
214242763|NCT06000267|PROCEDURE|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
214242764|NCT04032574|COMBINATION_PRODUCT|Herbal Medicinal Product|
214242765|NCT04032574|OTHER|Placebo|
214242766|NCT03383705|DEVICE|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
214242767|NCT04294745|PROCEDURE|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
214242768|NCT04294745|PROCEDURE|Inferior alveolar nerve block|Standard technique of mandibular nerve block
214242769|NCT03761771|DEVICE|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
214242770|NCT02514954|DRUG|Biochaperone® Combo|Subcutaneous injection of an individualized dose
214242771|NCT02514954|DRUG|Humalog® Mix25|Subcutaneous injection of an individualized dose
214242772|NCT02919384|OTHER|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
214242773|NCT04692727|OTHER|Exercise program|"* Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises"
214242774|NCT04692727|OTHER|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
214242775|NCT04692727|OTHER|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
214242776|NCT03653871|BEHAVIORAL|Performing Arts Instruction|Professionally delivered performing arts curriculum
214242777|NCT02793648|DRUG|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
214242778|NCT02793648|DRUG|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
214242779|NCT02793648|DRUG|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
214242780|NCT01171664|DRUG|Placebo|Tablet, one BID
214242781|NCT01171664|DRUG|STAHIST|STAHIST in tablet form dosed one BID
214242782|NCT03230305|OTHER|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
214242783|NCT04381338|OTHER|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
214242784|NCT00495079|DRUG|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
214242785|NCT00862108|DRUG|Methylphenidate|mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
214242786|NCT02400411|OTHER|Wheat bread|
214652432|NCT02221544|DEVICE|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
214242787|NCT02400411|OTHER|margarine|
214242788|NCT02400411|OTHER|ham|
214242789|NCT02400411|OTHER|soup|
214242790|NCT02400411|OTHER|rye bread|
214242791|NCT00159562|BEHAVIORAL|individual education|individual sessions of psycho-education
214242792|NCT00159562|BEHAVIORAL|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
214242793|NCT02040727|BEHAVIORAL|Resistance Training|Supervised strength training 3 days per week for 24 weeks
214242794|NCT02040727|BEHAVIORAL|No Resistance Training|No supervised strength training throughout the study
214242795|NCT00393042|DRUG|Dexmethylphenidate|10, 20, 25-30 mg.
214242796|NCT00393042|DRUG|Mixed Amphetamine Salts, ER|10, 20, 25-30
214242797|NCT00393042|DRUG|placebo|randomized placebo week during each 4 week period
214242798|NCT05280483|DRUG|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
214242799|NCT05280483|DRUG|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
214242800|NCT00330161|DRUG|vorinostat|Given orally
214242801|NCT00330161|OTHER|laboratory biomarker analysis|Correlative studies
214242802|NCT03777631|PROCEDURE|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
214652433|NCT02221544|DEVICE|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
214652434|NCT01756274|DEVICE|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
214652435|NCT01756274|DEVICE|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
214652436|NCT01756274|DEVICE|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
214652437|NCT05255003|BIOLOGICAL|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
214242803|NCT03008564|OTHER|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~* Age~* Gender~* Weight~* Height~* BMI~* Distance of ASIS to base of patella~* Distance of Point A to base of patella~* Distance of Point B to base of patella~* Distance of apex of femoral triangle to base of patella"
214242804|NCT02655770|DRUG|Liraglutide|
214242805|NCT02655770|DRUG|Placebo|
214242806|NCT05666115|DIETARY_SUPPLEMENT|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
214242807|NCT05666115|OTHER|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
214242808|NCT02927405|DRUG|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
214242809|NCT02927405|PROCEDURE|TAP Block|a procedure done anesthetize the anterior abdominal wall
214242810|NCT04632914|OTHER|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
214242811|NCT04632914|OTHER|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
214242812|NCT00769327|DRUG|imatinib mesylate|
214242813|NCT00769327|DRUG|nilotinib|
214242814|NCT00769327|GENETIC|cytogenetic analysis|
214242815|NCT00769327|GENETIC|fluorescence in situ hybridization|
214242816|NCT00769327|GENETIC|microarray analysis|
214242817|NCT00769327|GENETIC|mutation analysis|
214242818|NCT00769327|GENETIC|polymerase chain reaction|
214242819|NCT00769327|GENETIC|polymorphism analysis|
214242820|NCT00769327|OTHER|laboratory biomarker analysis|
214242821|NCT03024580|DRUG|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
214242822|NCT03024580|DRUG|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
214242823|NCT03024580|DRUG|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
214242824|NCT03024580|DRUG|Exemestane 25 MG|Exemestane 25 mg PO daily
214242825|NCT03024580|DRUG|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
214242826|NCT03024580|DRUG|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
214242827|NCT03301974|PROCEDURE|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
214242828|NCT03301974|PROCEDURE|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
214242829|NCT03301974|PROCEDURE|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
214242830|NCT00965328|PROCEDURE|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
214242831|NCT00965328|PROCEDURE|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
214242832|NCT03705936|DEVICE|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
214242833|NCT01150474|DRUG|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
214242834|NCT01150474|DRUG|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
214242835|NCT04597060|DEVICE|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
214242836|NCT04597060|OTHER|corticosteroid injection|corticosteroid injection using TA 10mg/ml
214242837|NCT02290431|DRUG|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
214242838|NCT02290431|DRUG|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).
214242839|NCT02290431|DRUG|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)
214242840|NCT00432601|BEHAVIORAL|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
214242841|NCT02556476|PROCEDURE|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
214242842|NCT02556476|PROCEDURE|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
214242843|NCT02556476|PROCEDURE|renal replacement therapy|the procedures used to treat acute kidney injury
214242844|NCT02556476|PROCEDURE|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
214242845|NCT03528395|OTHER|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
214242846|NCT03528395|OTHER|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
214242847|NCT00821327|DRUG|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2\. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3\. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
214242848|NCT03986762|DRUG|Clavulanic Acid|\~10 days of Clavulanic Acid
214242849|NCT03122301|DRUG|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
214242850|NCT03122301|DRUG|Saline|sham injection with saline
214242851|NCT03960021|RADIATION|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
214242852|NCT02555280|DEVICE|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
214242853|NCT02555280|PROCEDURE|Decompression|Decompression alone
214652438|NCT05255003|BIOLOGICAL|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"
214652439|NCT05255003|BIOLOGICAL|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
214652440|NCT01147926|DRUG|Placebo|Placebo matched to Prucalopride tablet orally once daily.
214242858|NCT03924271|DIAGNOSTIC_TEST|Iron deficiency testing|Blood sample for complete iron status
214652441|NCT01147926|DRUG|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
214242859|NCT01281527|DRUG|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
214242860|NCT04983953|DEVICE|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
214242861|NCT01171833|DRUG|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
214242862|NCT01171833|DRUG|Desflurane|6.0 vol% prefilled in a corrugated circuit.
214242863|NCT01171833|DRUG|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
214242864|NCT03559426|DRUG|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
214242865|NCT03559426|DRUG|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
214242866|NCT04983303|OTHER|TICK-B group|These interventions will distract the child during venipuncture
214242867|NCT00459979|DRUG|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
214242868|NCT00459979|PROCEDURE|conventional surgery|nephrectomy
214242869|NCT02820701|PROCEDURE|OMT|Osteopathic Manipulative Treatment to low back region
214242870|NCT04456010|OTHER|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
214242871|NCT00453388|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
214242872|NCT00453388|DRUG|Cyclophosphamide|Given IV
214242873|NCT00453388|DRUG|Cyclosporine|Given IV or PO
214242874|NCT00453388|DRUG|Fludarabine Phosphate|Given IV
214242875|NCT00453388|OTHER|Laboratory Biomarker Analysis|Correlative studies
214242876|NCT00453388|DRUG|Mycophenolate Mofetil|Given PO
214242877|NCT00453388|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
214242878|NCT00453388|RADIATION|Total-Body Irradiation|Undergo TBI
214242879|NCT03920072|DRUG|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
214242880|NCT00056498|DRUG|Placebo|Placebo capsule daily for 16 weeks
214242881|NCT00056498|DRUG|Risperdal|Risperdal 4 mg per day for 16 weeks
214242882|NCT05760118|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214242883|NCT05371171|PROCEDURE|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
214242884|NCT05371171|PROCEDURE|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
214242885|NCT00423748|DRUG|ambrisentan|
214242886|NCT03787563|DRUG|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
214242887|NCT03787563|DRUG|Placebo Tea|Similar looking inert placebo tea.
214242888|NCT01007253|DRUG|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
214242889|NCT01007253|DRUG|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
214242890|NCT01007253|DRUG|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
214242891|NCT01007253|DRUG|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
214242892|NCT00576212|BEHAVIORAL|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
214242893|NCT01575886|OTHER|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
214242894|NCT00814801|DRUG|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
214242895|NCT00814801|DRUG|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
214242896|NCT00814801|DRUG|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
214242897|NCT05646472|DIAGNOSTIC_TEST|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
214242898|NCT04856865|BIOLOGICAL|Low dose ADP101|Active powder formulation
214242899|NCT04856865|BIOLOGICAL|High dose ADP101|Active powder formulation.
214242900|NCT04856865|BIOLOGICAL|Pooled Placebo|Placebo powder
214242901|NCT02982785|BEHAVIORAL|Standard post-operative rehabilitation|
214242902|NCT01163032|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
214242903|NCT01163032|DRUG|Placebo|Placebo capsules, PO daily for 6 months
214242904|NCT00728767|OTHER|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
214242905|NCT00728767|OTHER|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
214242906|NCT04119154|DIAGNOSTIC_TEST|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
214242907|NCT00766961|PROCEDURE|Trans-catheter arterial embolization|Trans-catheter arterial embolization
214242908|NCT00766961|PROCEDURE|Surgery|Surgery
214242909|NCT02751931|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight \>=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became \>=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
214242910|NCT02677311|PROCEDURE|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
214242911|NCT02677311|PROCEDURE|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
214242912|NCT01700868|OTHER|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
214242913|NCT01700868|OTHER|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
214242914|NCT00355277|DRUG|Amitriptyline|
214242915|NCT00000750|DRUG|Zidovudine|
214242916|NCT02380690|BEHAVIORAL|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
214242917|NCT04673279|DIAGNOSTIC_TEST|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
214242918|NCT03343418|DRUG|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
214242919|NCT03343418|DRUG|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
214242920|NCT02002585|PROCEDURE|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
214242921|NCT02843737|OTHER|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
214242922|NCT04045418|DEVICE|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
214242923|NCT02311218|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
214242924|NCT02311218|DIETARY_SUPPLEMENT|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
214242925|NCT03473457|BIOLOGICAL|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
214242926|NCT04183751|OTHER|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
214242927|NCT04647890|DRUG|FT011|Two x 100mg capsules once daily for 12 weeks
214242928|NCT04647890|DRUG|FT011|Two x 200mg capsules once daily for 12 weeks
214242929|NCT04647890|DRUG|Placebo|Two placebo capsules once daily for 12 weeks
214242930|NCT05582954|BEHAVIORAL|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
214242931|NCT05582954|BEHAVIORAL|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
214242932|NCT06579391|DIETARY_SUPPLEMENT|Essential amino acids|Twice daily consumption for two weeks before and one week after surgery.
214242933|NCT06579391|DIETARY_SUPPLEMENT|Alanine|Twice daily consumption for two weeks before and one week after surgery.
214242934|NCT06246279|BEHAVIORAL|Adaptation to Adolescence and Type 1 Diabetes Management Training Program|The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
214242935|NCT00534261|DRUG|Interferon beta-1a|IM injection
214242936|NCT02414503|DRUG|8IU intranasal oxytocin|
214242937|NCT02414503|DRUG|24IU intranasal oxytocin|
214242938|NCT02414503|DRUG|Placebo|
214242939|NCT02414503|DEVICE|OptiNose Breath Powered Bi|
214242940|NCT00025805|DRUG|G-CSF|
214242941|NCT00958490|OTHER|Walking program|4 week physical activity walking program
214242942|NCT01731184|DRUG|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
214242943|NCT05557318|DEVICE|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
214242944|NCT05557318|DEVICE|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
214242945|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
214242946|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
214242947|NCT02866851|OTHER|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
214242948|NCT05337033|DRUG|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
214242949|NCT02785237|DEVICE|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
214242950|NCT02785237|DEVICE|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
214242951|NCT03787043|DRUG|FDC(MP-513 10mg/Metformin XR 750mg)|
214242952|NCT00004190|DRUG|gemcitabine hydrochloride|
214242953|NCT00004190|DRUG|oxaliplatin|
214242954|NCT05048069|DRUG|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
214242955|NCT01967381|DRUG|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
214242956|NCT02019901|OTHER|Nurse-led clinic|
214242957|NCT04278274|PROCEDURE|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
214242958|NCT04278274|PROCEDURE|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
214242959|NCT03907839|OTHER|clinical trials|examined two type of training on cognitive parameters for COPD patients
214242960|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
214652442|NCT02241473|OTHER|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
214652443|NCT05936762|DEVICE|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
214242961|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 2|High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
214242962|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 1|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
214242963|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 2|Addition of a 3rd dose, TBD depending on outcome of Part A
214242964|NCT04220853|DIAGNOSTIC_TEST|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
214242965|NCT04220853|DIAGNOSTIC_TEST|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
214242966|NCT05599776|OTHER|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
214242967|NCT02555241|BEHAVIORAL|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
214242968|NCT02555241|BEHAVIORAL|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
214652444|NCT01290627|DEVICE|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
214652445|NCT01290627|DEVICE|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
214652446|NCT03417440|OTHER|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
214242969|NCT02555241|BEHAVIORAL|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
214242970|NCT01015001|PROCEDURE|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
214242971|NCT01015001|PROCEDURE|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
214242972|NCT01015001|PROCEDURE|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
214242973|NCT05024643|PROCEDURE|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
214242974|NCT00817479|DRUG|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
214242975|NCT00817479|DRUG|Placebo|Placebo saline
214242976|NCT04319679|DEVICE|Extracorporeal shockwave therapy|6 times during 2 weeks
214242977|NCT04319679|DEVICE|Sham therapy|6 times during 2 weeks
214242978|NCT02276573|BIOLOGICAL|buccal cavity sample|
214242979|NCT03767595|DEVICE|ProACT Adjustable Continence Therapy for Men|The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
214242980|NCT02005289|BIOLOGICAL|MOR00208|Given by IV infusion
214242981|NCT02005289|DRUG|lenalidomide|Given PO
214242982|NCT02005289|OTHER|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
214242983|NCT05652348|OTHER|Establishment of organoid cultures and in vitro sensitivity testing|Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.
214242984|NCT05539703|OTHER|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
214242985|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
214242986|NCT04808999|DRUG|Pembrolizumab Injection|200 mg IV infusion
214242987|NCT04030026|DRUG|NAL ER|Participants received NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID.
214242988|NCT04030026|DRUG|Placebo|Participants received Placebo tablet (matching NAL ER ).
214242989|NCT06031389|DRUG|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
214242990|NCT06031389|DRUG|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
214242991|NCT03507530|OTHER|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
214242992|NCT02776202|DRUG|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
214242993|NCT03175055|DEVICE|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
214242994|NCT00523367|PROCEDURE|24 hour pH testing|24 hour pH testing will be used to screen patients
214242995|NCT01278927|BEHAVIORAL|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
214242996|NCT01278927|BEHAVIORAL|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
214242997|NCT01278927|BEHAVIORAL|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
214242998|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
214242999|NCT03635411|DIETARY_SUPPLEMENT|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
214243000|NCT03635411|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Basis supplement.
214243001|NCT05394493|DRUG|avelumab|as provided in real world setting
214243002|NCT05394493|DRUG|axitinib|as provided in real world settings
214243003|NCT06086015|DEVICE|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
214243004|NCT01302132|DRUG|ASP1941|Oral solution
214243005|NCT00383773|PROCEDURE|Retinal endo vascular surgery|
214243006|NCT02830984|PROCEDURE|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
214243007|NCT02830984|PROCEDURE|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
214243008|NCT02954042|DEVICE|Pelvital probe|Pelvital probe
214243009|NCT02954042|DEVICE|Placebo Probe|Placebo Probe
214243010|NCT04252521|DRUG|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
214243011|NCT04252521|DRUG|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
214243012|NCT04252521|DRUG|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
214243013|NCT06400875|DEVICE|InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)|weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and compression therapy
214243014|NCT03754725|DRUG|Deferiprone pill|1000 mg of deferiprone (oral) BID (15 mg/Kg)
214243015|NCT03754725|DRUG|placebo|patients will receive placebo orally
214243016|NCT03754725|BEHAVIORAL|Montreal Cognitive Assessment|Neurocognitive assessment, lower score indicates lower cognitive level
214243017|NCT05201456|DEVICE|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
214243018|NCT03961477|OTHER|Interferential therapy|Exercise therapy
214243019|NCT02242591|DRUG|Ropivacaine 7,5 mg/ml|
214243020|NCT02242591|DRUG|Saline|
214243021|NCT02179138|DRUG|TFV 1% gel|
214243022|NCT05175053|OTHER|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
214243023|NCT05175053|OTHER|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
214243024|NCT03773003|DIETARY_SUPPLEMENT|Probiotics|"The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus"
214243025|NCT03773003|DIETARY_SUPPLEMENT|Placebo|Identically looking to verum, containing corn starch.
214243026|NCT04824027|PROCEDURE|Harmonic motion imaging|Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
214243027|NCT00282347|DRUG|Rituximab|Rituximab was provided as a sterile solution for injection.
214243028|NCT00282347|DRUG|Placebo|Placebo was provided as a sterile solution for injection.
214243029|NCT00282347|DRUG|Mycophenolate mofetil|
214243030|NCT00282347|DRUG|Methylprednisolone|
214243031|NCT00282347|DRUG|Diphenhydramine|
214243032|NCT00282347|DRUG|Acetaminophen|
214243033|NCT00282347|DRUG|Prednisone|
214243034|NCT04813627|PROCEDURE|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every 3 months for 21 months
214243035|NCT00007059|DRUG|mycophenolate mofetil|
214243036|NCT06391190|DRUG|Albumin-Bound Paclitaxel, cisplatin, Sintilimab|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
214243037|NCT00333346|DRUG|Administration of tramadol intravenously|
214243038|NCT04176042|BEHAVIORAL|Track 1|Intervention + Follow-up
214243039|NCT04176042|BEHAVIORAL|Track 2|Wait list + Intervention
214243040|NCT02996032|OTHER|Vascular and Pulmonary Ultrasound|
214243041|NCT03643471|DEVICE|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
214243042|NCT03347578|DIAGNOSTIC_TEST|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
214243043|NCT04244812|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
214243044|NCT04244812|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
214243045|NCT00675207|DRUG|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
214243046|NCT00675207|DRUG|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
214243047|NCT00675207|DRUG|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
214243048|NCT06712875|DRUG|Trametinib and Nivolumab|Trametinib combined with nivolumab (Cohort A)
214243049|NCT06712875|DRUG|Dabrafenib, trametinib, nivolumab|Dabrafenib + trametinib combined with nivolumab (Cohort B)
214243050|NCT05164666|BIOLOGICAL|TAK-103|TAK-103 intravenous infusion
214243051|NCT03944187|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
214243052|NCT03916315|BEHAVIORAL|Transdiagnostic Treatment|"The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each."
214243053|NCT01693588|OTHER|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
214243054|NCT01881490|DEVICE|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
214243055|NCT03403335|BEHAVIORAL|Mindfulness Based Practices for Health Care Professionals in Training|Eight weekly sessions including didactic lecture, discussion, homework, gentle yoga, and meditation and mindfulness exercises
214243056|NCT03464370|OTHER|Measure of emotional stressors|"For the Epileptic Group~* Rapid interrogation, completing the clinical data~* A scale of impact of the precipitating factors of crises~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A measure of the perception of emotions using film clips~* A scale of measurement of perceived stress~* The transfer of psychiatric scales~For the healthy volunteers group :~* A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A scale of measurement of perceived stress~* A measure of the perception of emotions using film clips~* A rapid neuropsychological assessment"
214243057|NCT02206581|DEVICE|Hydration Monitor|
214243058|NCT05555940|DEVICE|Transcranial magnetic stimulation|The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
214243059|NCT06051045|DRUG|Bulevirtide|Hepcludex, 2 mg daily subcutaneous injection
214243060|NCT04476589|DIAGNOSTIC_TEST|Functional MRI|measurement of functional brain networks
214243061|NCT02965287|OTHER|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
214243062|NCT02361346|DRUG|MT-3724 Phase 1|Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
214243063|NCT02361346|DRUG|MT-3724 Phase 2|Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
214243064|NCT03488758|OTHER|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
214243065|NCT03488758|OTHER|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
214243066|NCT06072209|BEHAVIORAL|Behavioral Activation|\- instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
214243067|NCT06072209|BEHAVIORAL|Mindfulness and Gratitude|\- instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
214243068|NCT06072209|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
214243069|NCT05483998|DRUG|TLC-2716|TLC-2716
214243070|NCT05483998|OTHER|Placebo|Placebo to match
214243071|NCT01766661|PROCEDURE|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
214243072|NCT01766661|PROCEDURE|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
214243073|NCT01766661|PROCEDURE|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
214652447|NCT03417440|OTHER|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
214243074|NCT00782795|DRUG|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
214243075|NCT00782795|DRUG|Placebo|
214243076|NCT01931072|BEHAVIORAL|High-intensity interval training|Interval training 3 times a week for 8 weeks
214243077|NCT01931072|BEHAVIORAL|Moderate training|Moderate training 3 times a week for 8 weeks
214243078|NCT01161030|DIETARY_SUPPLEMENT|Almonds|
214243079|NCT05771064|BEHAVIORAL|Gentle Moves|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
214243080|NCT03593460|DRUG|Synthetic PreImplantation Factor|peptide
214243081|NCT04480424|BIOLOGICAL|GAMUNEX-C|Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
214243082|NCT04480424|DRUG|Standard Medical Treatment|SMT per local policies or guidelines.
214243083|NCT00004407|DRUG|immune globulin|
214243084|NCT06573866|BEHAVIORAL|Preventive Participatory workplace intervention|The Participatory Workplace Intervention (PPWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles or changes and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. In a subsequent meeting, the implementation of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
214243085|NCT05763485|PROCEDURE|Anti reflux mucosal ablation (ARMA)|"In patients fulfilling the inclusion criteria and being randomized for ARMA, the procedure using argon plasma coagulation involves two semicircular ablations of the mucosa of the EGJ in a butterfly shape of a width of 2 cm. The approximate duration of the procedure is 30min.~Follow includes objective evaluation of reflux disease by reflux questionnaires, esophagogastroduodenoscopy, esophageal manometry, pH metry."
214243086|NCT05763485|PROCEDURE|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, the procedure involves esophagogastroduodenoscopy with the same set of movements and duration as the ARMA procedure without the actual ablation.
214243087|NCT01729585|PROCEDURE|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
214243088|NCT03646240|DRUG|ABI-009|For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
214243089|NCT02782923|DEVICE|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
214243090|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
214243091|NCT03333538|OTHER|Placebo|Placebo vaccination
214243092|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
214243093|NCT03333538|BIOLOGICAL|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
214243094|NCT02828501|PROCEDURE|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
214243095|NCT06731296|OTHER|Presence of a risk factor|Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
214243096|NCT03765879|OTHER|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of an avatar receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
214243097|NCT03765879|OTHER|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of an avatar receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
214243098|NCT00538343|DRUG|berubicin hydrochloride (RTA 744)|
214243099|NCT04683042|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
214243100|NCT04683042|OTHER|PT only|Routine PT therapy only
214243101|NCT05455619|DRUG|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
214243102|NCT06080737|OTHER|quality of life questionnaire|telephone interview to assess mortality and quality of life in the population included in a trial
214243103|NCT06574464|OTHER|BIG SCORE|"The trauma BIG score is used to predict posttraumatic injury severity and mortality. It was originally designed for the pediatric population. The score is calculated using the Base Deficit (BD), International Normalized Ratio (INR), and Glasgow Coma Scale (GCS) score on admission using the following formula:~BIG score = (admission BD) + (2.5 × INR) + (15 - GCS)."
214243104|NCT06574464|OTHER|Glasgow coma scale|The Glasgow Coma Scale is a neurological assessment tool used to evaluate the level of consciousness of a patient. It assesses three items: eye-opening (spontaneous, 4 points; to verbal stimuli, 3 points; to pain stimuli, 2 points; no response, 1 point); verbal responses (oriented, 5 points; confused but coherent speech, 4 points; inappropriate words, 3 points; incomprehensible speech, 2 points; no response, 1 point); and motor responses (obeys commands, 6 points; localizes pain, 5 points; withdraws from pain, 4 points; flexes in response to pain, 3 points; extends in response to pain, 2 points; no response, 1 point). The total GCS score is obtained by summing the scores for the three items, and it ranges from 3 to 15.
214243105|NCT06574464|OTHER|Revised Trauma Score|The Revised Trauma Score (RTS) is a physiological scoring system used to assess the severity of a traumatic injury. It considers three key parameters, Glasgow Coma Scale (GCS), Systolic Blood Pressure (SBP), and Respiratory Rate (RR), with a total score of 12 points. The study team retrospectively computed the RTS on admission by retrieving the GCS score, SBP, and RR per minute from the hospital's automated systems and archives.
214243106|NCT06574464|OTHER|Injury Severity Score|The Injury Severity Score (ISS) is an anatomical scoring system used to assess the severity of injuries sustained by trauma patients. It provides a numerical value based on the anatomical regions of the body affected by trauma and the severity of those injuries. The ISS is calculated by dividing the body into six regions: the head/neck, face, chest, abdomen/pelvis, extremities, and external. Each region is assigned a score ranging from 1 to 6, with 1 indicating minor injury and 6 indicating severe injury. The highest score from each region is squared and then the scores are summed to calculate the overall ISS.
214243107|NCT06571760|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
214243108|NCT00140465|DRUG|Clopidogrel|after PCI
214243109|NCT00140465|DRUG|Clopidogrel|after PCI
214243110|NCT03368118|DRUG|ABX464|All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
214243111|NCT03970746|BIOLOGICAL|PDC*lung01|PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
214243112|NCT03970746|DRUG|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
214243113|NCT03970746|DRUG|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
214243114|NCT05985824|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
214243115|NCT05505227|BEHAVIORAL|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
214243116|NCT05505227|BEHAVIORAL|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
214243117|NCT03818633|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
214243118|NCT00000375|DRUG|Nortriptyline-lithium (NOR-Li)|
214243119|NCT00000375|PROCEDURE|Bilateral electroconvulsive therapy (ECT)|
214243120|NCT00000375|DRUG|Continuation therapy|
214243121|NCT00000375|BEHAVIORAL|Continuation ECT|
214243122|NCT03991546|BEHAVIORAL|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
214243123|NCT06422754|DEVICE|Becure GmbH|Becure Balance System
214243124|NCT00993044|DRUG|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
214243125|NCT00993044|DRUG|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
214243126|NCT00993044|DRUG|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
214652448|NCT03417440|OTHER|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
214243127|NCT00993044|DRUG|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
214243128|NCT04768998|OTHER|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
214243129|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
214243130|NCT04725006|DEVICE|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
214243131|NCT00734747|DEVICE|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
214243132|NCT05560646|DRUG|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
214243133|NCT05560646|DRUG|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
214243134|NCT01465685|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
214243135|NCT01465685|DRUG|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
214243136|NCT01465685|DRUG|Placebo|capsules identical to MDMA or methylphenidate
214243137|NCT06983015|PROCEDURE|sticky bone|extraction socket will be augmented using a sticky bone.
214243138|NCT06983015|PROCEDURE|xenograft mixed with cross-linked hyaluronic acid|Socket will be augmented with a mixture of xenograft and cross linked hyaluronic acid.
214243139|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
214243140|NCT06984900|OTHER|Group Aerobic Exercise Session|"The Aerobic Exercise Program is designed to improve mood and reduce stress among university students through structured, moderate-intensity aerobic activities.~Session Structure: Participants engage in moderate-intensity aerobic exercises such as treadmill walking or running, tailored to individual fitness levels, ensuring accessibility and inclusivity. Each session consists of a 10-minute warm-up, 30 minutes of aerobic exercise, and a 5-minute cool-down.~This intervention incorporates a dual assessment approach using the Profile of Mood States (POMS) and the Perceived Stress Scale (PSS) to evaluate mood and stress levels both before and after exercise. Participants complete these assessments multiple times, allowing for a nuanced understanding of how aerobic exercise influences mood and stress over time."
214243141|NCT06986278|DEVICE|tDCS|Stimulation will be applied at an intensity of 2 mA for 20 minutes, with an average ramp-up and ramp-down rate of 0.1 mA/s, using rectangular electrodes of 35 cm² (resulting in a current density of 0.06 mA/cm²) covered with sponges moistened with 0.9% saline solution. A Sooma tDCS™ direct current stimulator (Sooma Oy Ltd, Helsinki, Finland), certified for clinical use, will be used. The anode will be placed over the Cz stimulation site, and the cathode will be placed on the right shoulder. The electrode will be secured to the participant's head using a neoprene cap (Neuroelectrics, Barcelona, Spain) and to the shoulder with a crepe bandage.
214243142|NCT06986278|DEVICE|shamtDCS|The sham tDCS group will use the same device and electrode placement as the active stimulation group. The protocol will consist of a 10-second ramp-up to 1 mA, followed by a 7-second ramp-down to 0.3 mA, which will be maintained for 19 minutes and 40 seconds, and a final 3-second ramp-down to 0 mA. This sham stimulation method is integrated into the Sooma stimulator.
214243143|NCT06985992|PROCEDURE|Group morphine|Group Morphine: Spinal anesthesia will be applied to patients who will undergo caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml saline
214243144|NCT06985992|PROCEDURE|Group morfin+dexamethasone|Group morfin+dexamethasone: Spinal anesthesia will be applied to patients who will undergo a caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml (2 mg) dexamethasone
214243145|NCT06986096|BEHAVIORAL|Aerobic-strength training and nutritional counseling|The intervention consists of a structured program that includes aerobic-strength training (1h training, 3 times per week) conducted by professional trainers combined with nutritional counseling.
214243146|NCT06986096|BEHAVIORAL|Cognitive training and stretching.|The intervention consists of a structured program that includes cognitive training combined with stretching training (90mins training, 2x per week).
214243147|NCT06984939|DEVICE|Grasp|Participants assigned to the intervention group will be instructed to squeeze the Grasp ball at regular intervals of approximately every 1-2 seconds. This action will activate a melody played through a speaker connected to the iPad, accompanied by a dynamic wavy line displayed on the screen. Participants will begin squeezing the Grasp ball at least 10 seconds prior to the start of the procedure and will continue until the procedure is completed.
214243148|NCT06979687|PROCEDURE|knotless barbed suture closure of the hysterotomy at caesarean section|Use of Medtronic V-loc 180 suture (VL) for a 2 layer closure of the caesarean hysterotomy rather than the standard 2 layer closure using the 910 polyglactin suture (SS).
214243149|NCT06979687|PROCEDURE|Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)|Standard 2 layer closure using the 910 polyglactin suture (SS)
214243150|NCT06820307|DRUG|Suzetrigine|Tablets for Oral Administration.
214243151|NCT06820307|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
214243152|NCT06820307|DRUG|NGM/EE|Combination Tablets for Oral Administration.
214243153|NCT05533125|DRUG|Rituximab|Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
214243154|NCT05533125|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously with usual premedication
214243155|NCT06986291|DIAGNOSTIC_TEST|Imaging and biomarkers|MR imaging of the heart, ECG and TTE measurements, blood sample
214243156|NCT06585930|BIOLOGICAL|Blood sample|Additional 8.1 ml blood sample
214243157|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid composite block|This refers to restorations fabricated from nano-ceramic hybrid composite blocks via chairside CAD/CAM workflow and cemented to permanent molars affected by MIH (molar-incisor hypomineralization).
214243158|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid ceramic block|This refers to restorations fabricated from polymer-infiltrated hybrid ceramic blocks using a digital workflow, then cemented to MIH-affected permanent molars.
214243159|NCT06990425|PROCEDURE|Groin closure with PDS suture|Closure of the groin will be performed with PDS suture
214243160|NCT06990425|PROCEDURE|Groin closure suture material|Closure of the groin will be performed with Vicryl suture
214243161|NCT06989567|DRUG|L-citrulline|This intervention uses intravenous L-citrulline as an acute treatment for vaso-occlusive crisis (VOC) in sickle cell disease, administered as a 50 mg/kg IV bolus followed by a 9 mg/kg/hr continuous infusion. Unlike other studies that evaluate oral citrulline or chronic VOC prevention, this study focuses on real-time symptom resolution in the emergency department setting by targeting impaired nitric oxide production and vasoconstriction. The selected dosing regimen was optimized in prior studies to achieve a therapeutic plasma concentration associated with improved pain scores and reduced opioid use, distinguishing it mechanistically and clinically from other interventions.
214243162|NCT06989567|OTHER|Placebo|Placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline
214243163|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
214243164|NCT06598527|RADIATION|Stereotactic body radiotherapy (SBRT)|"Radiation source: 6MV photon linear gas pedal is used. Position immobilization: supine position, hands up, vacuum bag or styrofoam immobilization.~Radiotherapy plan design: 4DCT positioning, radiotherapy plan design at 20% respiratory time-phase CT, isocentric irradiation, IMRT or VMAT design.~Definition of target area:~Gross tumor volume (GTV) includes the primary tumor in the lung, excluding lymph nodes. Internal target volume (ITV); Internal target volume (ITV) is formed by the fusion of 10 respiratory phases of GTV; Planning target volume (PTV) is formed by expanding the ITV by 0.5 cm in all directions."
214243165|NCT06598527|DRUG|Tislelizumab|PD-L1 inhibitor
214243166|NCT06598527|DRUG|Chemotherapy|platinum-based double-agent chemotherapy
214243167|NCT06862648|DEVICE|Acoustic Stimulation Therapy Device|The SUI-100 Device is a non-invasive device designed for the treatment of stress urinary incontinence (SUI) in females.
214243168|NCT06862648|DEVICE|Sham Acoustic Stimulation Therapy Device|The sham intervention uses the same device setup with sham procedures.
214243169|NCT06993558|PROCEDURE|Poly-L-Lactic Acid (Sculptra) injection|1 to 2 sessions at intervals of 4 to 6 weeks are planned with PLLA (Sculptra®, Galderma Laboratories). PLLA will be injected into the face or neck region using a blunt cannula. For reconstitution, 7 ml of saline solution and 1 ml of 1 % lidocaine will be used. 5 minutes of massaging for 5 times a day are recommended.
214243170|NCT06993558|PROCEDURE|Calcium Hydroxyapatite|For CaHA treatment (Radiesse®, Merz Pharma; HarmonyCa®, Allergan), 1 session is planned. The face (cheeks, jawline) or neck will be augmented using a blunt cannula, either diluted (Radiesse® 1:0.2 - 1:2) or undiluted (HarmonyCA®) depending on the product and the region being treated.
214243171|NCT06993558|PROCEDURE|Radiofrequency Microneedling|For RFMN treatment (Genius®, Lutronic Medical Systems), 1 to 3 sessions at intervals of 6 to 8 weeks are planned. Prior to treatment, subjects were given topical anesthesia (23% lidocaine, 3.5% tetracaine) under occlusion for at least 1.5 hours. The face will be treated with an RFMN system, using parameters adjusted for each anatomical location. Each region received three passes with 50 - 70 % overlap, starting with the longest needle setting. A minimum total energy of 1000 J will be aimed. Treatment will be performed using forced cooled air (Cryo6, Zimmer Aesthe cDivision).
214243172|NCT06995586|DIETARY_SUPPLEMENT|Vitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose|This is a randomized and controlled trial with an intervention group that will be administered orally daily in addition to the Optimal Medical Therapy (OMT), namely 1000 mg Vitamin C, 840 mg EPO/DHA, 2130 mg Lignin \& 720 mg Lactulose and a control group that will receive only the OMT.
214652449|NCT03417440|OTHER|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
214652450|NCT06020794|BEHAVIORAL|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
214652451|NCT06020794|BIOLOGICAL|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
214652452|NCT04004949|OTHER|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
214652453|NCT00923429|PROCEDURE|Stay-active care|No other treatment than the stay-active care
214652454|NCT00923429|PROCEDURE|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
214652455|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
214243173|NCT06994247|BEHAVIORAL|Motivational Telephone Call|This intervention consists of a single, personalized motivational telephone call delivered by a medical doctor, one month after initiation of CPAP treatment, uniquely timed to address early barriers and enhance self-efficacy. Unlike standard care or automated follow-ups, it offers tailored support based on patient experience, making it a low-cost yet targeted behavioral strategy to improve adherence. Content of the telephone call includes inquiry about patient's experience with CPAP therapy, identification of barriers to regular use, education on the health benefits of consistent CPAP usage, and personalized motivational messages aimed at increasing compliance.
214243174|NCT04657107|DRUG|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
214243175|NCT04657107|OTHER|normal saline|Saline group: pregnant women received saline, intravenous drip
214243176|NCT04657107|DRUG|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
214243177|NCT02586883|OTHER|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
214243178|NCT06629558|DRUG|Silver Nitrate|bronchoscopic lung volume reduction in management of localized emphysema
214243179|NCT06629558|DRUG|Nano-silver nitrate|bronchoscopic lung volume reduction in management of localized emphysema
214243180|NCT06629558|DEVICE|Bronchoscopic lung volume reduction|bronchoscopic lung volume reduction in management of localized emphysema
214243181|NCT05542745|DEVICE|palatal and buccal retraction|comparison
214243182|NCT02048293|DRUG|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
214243183|NCT02048293|DRUG|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
214243184|NCT02048293|DRUG|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
214243185|NCT05829200|DEVICE|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
214243186|NCT04376177|DIAGNOSTIC_TEST|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
214243187|NCT04376177|DIAGNOSTIC_TEST|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
214243188|NCT04376177|DIAGNOSTIC_TEST|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
214243189|NCT04376177|DIAGNOSTIC_TEST|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
214243190|NCT04376177|DIAGNOSTIC_TEST|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
214243191|NCT04376177|DIAGNOSTIC_TEST|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
214243192|NCT04376177|DIAGNOSTIC_TEST|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
214243193|NCT05591742|DIETARY_SUPPLEMENT|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
214243194|NCT05591742|OTHER|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
214243195|NCT04095832|PROCEDURE|Epidural anesthesia|Epidural anesthesia using standardized technique
214243196|NCT02269748|PROCEDURE|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
214243197|NCT02269748|PROCEDURE|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
214243198|NCT02269748|DRUG|Analgesic Therapy|Ibuprofen 600 mg TID
214243199|NCT03845374|DEVICE|Hyper-CL™ lens|Use of the Hyper-CL™
214243200|NCT04399031|DRUG|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
214243201|NCT00234403|DRUG|gefitinib and fulvestrant|
214243202|NCT01275339|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
214243203|NCT01275339|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
214243204|NCT02469038|DEVICE|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
214243205|NCT02469038|DEVICE|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
214243206|NCT02206243|DRUG|Embozene Microspheres|Intraarterial application
214243207|NCT03663153|OTHER|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
214652456|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
214652457|NCT02952976|DEVICE|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
214243208|NCT03663153|OTHER|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
214243209|NCT02825407|DIETARY_SUPPLEMENT|Oral physiology|
214243210|NCT01234818|DEVICE|Mirena (LNG-IUS)|* General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
214243211|NCT04730167|OTHER|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
214243212|NCT04965909|OTHER|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
214243213|NCT01216995|BIOLOGICAL|Dose A|ADRC Dose A
214243214|NCT01216995|BIOLOGICAL|Placebo|Placebo Comparator
214243215|NCT02568982|OTHER|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
214243216|NCT04997590|BIOLOGICAL|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
214243217|NCT04997590|DRUG|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
214243218|NCT01402895|OTHER|Exercise|Transversus abdominus exercise
214243219|NCT01402895|OTHER|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
214243220|NCT01507454|DRUG|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
214243221|NCT03028350|DRUG|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
214243222|NCT03028350|DRUG|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
214243223|NCT02405936|PROCEDURE|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
214243224|NCT02777749|DRUG|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
214243225|NCT03110939|OTHER|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
214243226|NCT05198700|DIETARY_SUPPLEMENT|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
214243227|NCT05198700|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
214243228|NCT06052098|DEVICE|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
214243229|NCT06052098|DEVICE|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
214243230|NCT01850602|DRUG|PA21|
214243231|NCT01850602|DRUG|Sevelamer hydrochloride|
214243232|NCT05911425|DRUG|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
214243233|NCT01108978|DRUG|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
214243234|NCT01108978|DRUG|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
214652458|NCT02952976|DEVICE|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
214243235|NCT00612898|DRUG|apricitabine|800mg BID apricitabine orally for 48 weeks
214243236|NCT00612898|DRUG|lamivudine|150mg BID lamivudine orally for 48 weeks
214243237|NCT06438627|DRUG|TPC combined with Apatinib and Camrelizumab|Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
214243238|NCT06438627|DRUG|GP Combined With Camrelizumab|Gemcitabine, Cisplatin regimen Combined With Camrelizumab
214243239|NCT03771547|DIAGNOSTIC_TEST|ERCP|
214243240|NCT01857310|DIETARY_SUPPLEMENT|5 mg folic acid and 30 mg elemental zinc|
214243241|NCT01857310|DRUG|Placebo Comparator: Placebo|
214243242|NCT03573102|DRUG|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
214243243|NCT03573102|DRUG|ACE inhibitor|ACE inhibitor once daily
214243244|NCT01041378|DRUG|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
214243245|NCT02873520|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
214243246|NCT02873520|BIOLOGICAL|Precision Cell Immunotherapy|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
214243247|NCT04118582|OTHER|Body composition and resting metabolic rate analisys|
214243248|NCT03926546|BEHAVIORAL|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
214243249|NCT03508427|OTHER|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
214243250|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
214243251|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
214243252|NCT01337271|PROCEDURE|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
214243253|NCT01337271|PROCEDURE|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
214243254|NCT05025540|DIAGNOSTIC_TEST|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
214243255|NCT04757428|PROCEDURE|Endocrown|Endocrown
214243256|NCT02220127|RADIATION|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
214243257|NCT02220127|RADIATION|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
214243258|NCT02497976|BIOLOGICAL|Certolizumab pegol|400 mg
214243259|NCT02497976|DRUG|Placebo|Normal saline
214243260|NCT00170963|DRUG|valsartan/amlodipine|
214243261|NCT05871983|DEVICE|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
214243262|NCT00584740|DRUG|AIN457|10 mg/kg
214243263|NCT00584740|DRUG|Placebo|Matching placebo to AIN457
214243264|NCT02973607|PROCEDURE|Nephrectomy|This is observational in design.
214243265|NCT04688879|PROCEDURE|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
214243266|NCT02272543|DIETARY_SUPPLEMENT|Fish surimi peptide|
214243267|NCT04637906|DIETARY_SUPPLEMENT|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
214243268|NCT05155462|OTHER|One or two phone call|Phone call to collect patient data
214243269|NCT01231854|DRUG|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
214243270|NCT01231854|DRUG|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
214243271|NCT03625271|DEVICE|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
214243272|NCT03217981|OTHER|Sepsis protocol|Adherence to the sepsis protocol
214243273|NCT04195737|PROCEDURE|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
214243274|NCT04195737|PROCEDURE|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
214243275|NCT00121173|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
214243276|NCT01121731|DRUG|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
214243277|NCT01121731|DRUG|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
214652459|NCT05799014|PROCEDURE|CT-guided percutaneous lung biopsy|The participants would undergo CT-guided percutaneous lung biopsy.
214652460|NCT05799014|PROCEDURE|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology|The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.
214243278|NCT01121731|DRUG|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
214243279|NCT01792570|DRUG|RPV + DRV/r|Switch to dual HAART
214243280|NCT01792570|DRUG|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
214243281|NCT03860883|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
214243282|NCT03860883|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
214243283|NCT05628688|DIAGNOSTIC_TEST|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
214243284|NCT00860977|DRUG|valacyclovir|oral valacyclovir 500mg twice daily
214243285|NCT00860977|DRUG|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
214243286|NCT03915860|DRUG|Trifarotene|Topical Cream
214243287|NCT02195011|DEVICE|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
214243288|NCT02195011|DRUG|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
214243289|NCT00993876|DRUG|citalopram|20 to 30 mg per day for 4 weeks
214243290|NCT00993876|DRUG|reboxetine|4 to 8 mg per day for 4 weeks
214243291|NCT00993876|BEHAVIORAL|interpersonal psychotherapy|
214243292|NCT03256890|BEHAVIORAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
214243293|NCT03256890|OTHER|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
214243294|NCT05224011|DEVICE|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
214243295|NCT00065130|DRUG|human insulin|
214243296|NCT00065130|DRUG|insulin NPH|
214243297|NCT00065130|DRUG|insulin aspart|
214652461|NCT01217502|BEHAVIORAL|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
214243298|NCT00293488|DRUG|polyamine analogue PG11047|
214243299|NCT02194608|DEVICE|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
214652462|NCT01217502|BEHAVIORAL|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
214243300|NCT04676971|DRUG|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
214243301|NCT04676971|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
214243302|NCT02551250|DEVICE|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
214243303|NCT02551250|DEVICE|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
214243304|NCT03865576|DIAGNOSTIC_TEST|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
214243305|NCT00617643|DRUG|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
214243306|NCT00617643|DRUG|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
214243307|NCT06239623|DRUG|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
214243308|NCT01975987|DEVICE|Bonfils fiberscope|
214243309|NCT00924625|OTHER|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
214652463|NCT03304522|DRUG|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
214652464|NCT03304522|DRUG|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
214652465|NCT02415790|DRUG|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
214243310|NCT00924625|OTHER|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
214243311|NCT01915628|DEVICE|BioMatrix Flex|Percutaneous coronary intervention
214243312|NCT00141570|DRUG|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
214243313|NCT01325792|DEVICE|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
214243314|NCT01067443|DRUG|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
214243315|NCT01067443|DRUG|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
214243316|NCT01067443|DRUG|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
214243317|NCT02832583|DEVICE|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
214243318|NCT03448055|DIETARY_SUPPLEMENT|Immunocal|cysteine-rich whey protein isolate
214243319|NCT02598570|DRUG|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
214243320|NCT04584697|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
214243321|NCT04584697|DRUG|Placebo|Diluent solution
214243322|NCT03520244|BEHAVIORAL|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
214243323|NCT02607566|BEHAVIORAL|Yoga|
214243324|NCT02607566|BEHAVIORAL|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
214243325|NCT01673750|OTHER|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
214243326|NCT04584307|DRUG|Elotuzumab|Elotuzumab 10-20mg/kg
214243327|NCT04584307|DRUG|Pomalidomide|Pomalidomide 2mg
214243328|NCT06108986|OTHER|tabata training|this include tabata training thrice a week for six weeks
214243329|NCT06108986|OTHER|plyometric training|this include plyometric training thrice a week for six weeks
214243330|NCT05796778|PROCEDURE|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
214243331|NCT05796778|PROCEDURE|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
214243332|NCT05222490|DEVICE|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
214243333|NCT05222490|DEVICE|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
214243334|NCT06041776|DRUG|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
214243335|NCT06041776|DRUG|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
214243336|NCT02029599|DRUG|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
214243337|NCT02029599|DRUG|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
214243338|NCT02029599|DRUG|Methotrexate|7.5-15mg per week，All patients should be used
214243339|NCT02029599|DRUG|Acetaminophen tablets|Oral,0.5g, 1\~2 times a day, when vas=10
214243340|NCT03063671|DRUG|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
214243341|NCT00768469|DRUG|Neratinib|Administered orally, continuous, once daily.
214243342|NCT00768469|DRUG|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
214243343|NCT02474225|DRUG|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
214243344|NCT02953158|OTHER|Haas Avocado|Hypocaloric weight loss diet
214243345|NCT02953158|BEHAVIORAL|Dietary Counseling|Dietary Counseling
214243346|NCT02236481|DRUG|Anakinra|
214243347|NCT02236481|DRUG|TNF alpha inhibitors|
214243348|NCT02102360|DEVICE|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
214243349|NCT02102360|DEVICE|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
214243350|NCT01450111|DRUG|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
214243351|NCT01450111|DRUG|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
214243352|NCT01450111|DRUG|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
214243353|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
214243354|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
214243355|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
214243356|NCT02487823|DRUG|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
214243357|NCT03859206|OTHER|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
214243358|NCT06008834|PROCEDURE|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
214243359|NCT04431427|DEVICE|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
214243360|NCT04431427|DEVICE|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
214243361|NCT00883844|DRUG|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
214243362|NCT00883844|DRUG|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
214243363|NCT03706898|DRUG|Elpida®|Elpida® capsules, 20mg
214243364|NCT03706898|DRUG|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
214243365|NCT03706898|DRUG|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
214243366|NCT03706898|DRUG|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
214243367|NCT03911219|OTHER|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
214243368|NCT01725412|DIETARY_SUPPLEMENT|Thiamine 300mg PO once daily|
214243369|NCT01725412|DIETARY_SUPPLEMENT|placebo|
214243370|NCT05526209|PROCEDURE|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
214243371|NCT00272727|BEHAVIORAL|Dialog tool for caregivers|
214243372|NCT00741962|DIETARY_SUPPLEMENT|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
214243373|NCT00741962|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
214243374|NCT01419067|PROCEDURE|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
214243375|NCT01419067|DEVICE|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
214652466|NCT02415790|DRUG|E2027 matching placebo|E2027 matching placebo capsule will be administered.
214243376|NCT01419067|DRUG|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
214243377|NCT01419067|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
214243378|NCT05632289|OTHER|osteopathic manipulative therapy|osteopathic manipulative therapy : manuel therapy
214243379|NCT05632289|OTHER|sham osteopathic manipulative therapy|placebo of osteopathic treatment
214652467|NCT03038347|BEHAVIORAL|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
214652468|NCT03038347|BEHAVIORAL|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
214652469|NCT01305512|DRUG|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
214652470|NCT01958957|DRUG|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
214652471|NCT00486603|DRUG|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
214243380|NCT04395508|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
214243381|NCT00715416|DEVICE|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
214243382|NCT00715416|PROCEDURE|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
214243383|NCT05425576|DRUG|OT-101|OT-101 in combination of pembrolizumab
214243384|NCT01766193|PROCEDURE|vaginal delivery|
214243385|NCT01766193|PROCEDURE|forceps extraction|vaginal delivery by forceps extraction
214243386|NCT01766193|PROCEDURE|vacuum extraction|vaginal delivery by vacuum extraction
214243387|NCT01766193|PROCEDURE|cesarean section|
214243388|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
214243389|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
214243390|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
214243391|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
214243392|NCT01139424|DEVICE|endoscopic suturing|endoscopic suturing of the anastomotic leak
214243393|NCT04693026|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
214243394|NCT04693026|DRUG|Baricitinib|Baricitinib oral tablet form
214243395|NCT04693026|DRUG|Tocilizumab|Tocilizumab IV Infusion
214243396|NCT02219113|PROCEDURE|Arthroscopic surgery|
214243397|NCT02219113|PROCEDURE|Liposuction|
214243398|NCT02219113|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
214243399|NCT02219113|OTHER|Intraarticular administration of autologous ADRC|
214652472|NCT00486603|DRUG|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
214652473|NCT00486603|OTHER|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
214243400|NCT02065115|OTHER|Cryotherapy (ice pack)|
214243401|NCT03923322|DRUG|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
214243402|NCT03923322|OTHER|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
214243403|NCT06636266|OTHER|Survey using a questionnaire.|This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
214243404|NCT04726397|RADIATION|Reduced margin adaptive radiotherapy|Reduced (5 mm) clinical target volume margin with weekly contrast-enhanced adaptive radiation on the MR-Linac treatment machine
214243405|NCT05340907|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
214243406|NCT01784393|RADIATION|chemoradiation|
214243407|NCT00276913|DRUG|STA-5312|
214652474|NCT00486603|RADIATION|Radiation|Radiation during the first six weeks of treatment Monday-Friday
214652475|NCT03939234|COMBINATION_PRODUCT|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
214652476|NCT04401657|DIAGNOSTIC_TEST|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
214652477|NCT00367211|DRUG|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
214652478|NCT00367211|DRUG|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
214243408|NCT03835728|DRUG|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
214243409|NCT03835728|DRUG|Saline|This will be the matching placebo used in the study.
214243410|NCT05662462|DEVICE|DEXCOM G7 PRO Continuous Glucose Monitor|Participants in the intervention arm will be provided with DEXCOM® G7 PRO CGM sensors and transmitters. The Dexcom G7 CGM system is accurate and safe in pregnant individuals with diabetes. Participants will be taught how to place and remove CGM sensors by a trained research nurse, and will be given sensors to change themselves at home every 10 days. Of note, the DEXCOM® G7 PRO can be applied as a patch on the abdomen, arm, or upper buttocks, is well-tolerated in pregnancy, and does not require calibration. Our mHealth app will allow for wireless synchronization with the CGM sensor so that data are seamlessly reported back to the healthcare team.
214243411|NCT05662462|DEVICE|Patient mHealth app linked to a provider dashboard|The mHealth app is based on our team's prototype intervention developed at our study site. The mHealth app provides diverse functions, including education, reminders, care goals, care pathway recommendations, CGM data and PROs reporting and monitoring, messaging and video conferencing, and a calendar function. Content is based on clinical guidelines for diabetes in pregnancy. Participants will be directed to appropriate resources and online learning to help them navigate the app and its resources. PROs in the mHealth app will be embedded to address health and social needs, and rule-based algorithms will provide tailored care goals, show care pathways, and establish the frequency of elicited PROs.
214243412|NCT05662462|BEHAVIORAL|Care team coaching for medical and social needs (HUB)|"Participants will be screened at enrollment and throughout the intervention for social needs using a survey adapted from validated instruments, such as the Accountable Health Communities Health-Related Social Needs Screening Tool. The care team will refer participants with affirmative responses to the HUB through the provider dashboard to address social needs (e.g., food insecurity, housing, employment). HUB community health workers will perform comprehensive social needs assessments and connect participants to community resources through care pathways, a defined action plan addressing patient needs which is recorded and tracked."
214243413|NCT05662462|DEVICE|Provider dashboard|The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
214243414|NCT06159101|DRUG|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
214243415|NCT06159101|DRUG|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
214243416|NCT06159101|DRUG|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
214243417|NCT06159101|DRUG|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
214243418|NCT02577432|DRUG|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
214243419|NCT02577432|DRUG|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
214243420|NCT02577432|DRUG|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
214243421|NCT02577432|DRUG|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
214243422|NCT04331197|DRUG|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
214243423|NCT04331197|DRUG|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
214243424|NCT04918901|COMBINATION_PRODUCT|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
214243425|NCT03490279|DIETARY_SUPPLEMENT|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
214243426|NCT03490279|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
214243427|NCT01166243|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
214243428|NCT01166243|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
214243429|NCT04079569|BEHAVIORAL|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
214243430|NCT04079569|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
214243431|NCT04581135|OTHER|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
214243432|NCT00056056|DRUG|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
214243433|NCT00056056|DRUG|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
214243434|NCT00056056|PROCEDURE|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
214243435|NCT04808700|OTHER|Follow-up of Episealer implant|Follow-up and radiographic evaluation in patients who received an Episealer implant
214243436|NCT04500756|DRUG|Metformin|Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
214243437|NCT04500756|OTHER|Placebo|One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
214243438|NCT04276363|BEHAVIORAL|Thrive Professional Learning plus ParentCorps|led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
214243439|NCT04276363|BEHAVIORAL|Thrive Professional Learning only|Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
214243440|NCT04276363|BEHAVIORAL|Inspire Professional Learning|Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
214652479|NCT05075668|DEVICE|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
214652480|NCT05075668|DEVICE|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
214243441|NCT01964456|OTHER|Joint perception task|
214243442|NCT01964456|BEHAVIORAL|Body Shape Questionnaire|
214243443|NCT01964456|OTHER|Measure of the heart rate|
214243444|NCT05939778|BIOLOGICAL|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1\. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2\. 7 subjects were included in the second step."
214243445|NCT04803682|BEHAVIORAL|Preventive Intervention|Participate in ASPIRE and mentorship program
214243446|NCT04803682|BEHAVIORAL|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
214243447|NCT00941577|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
214652481|NCT00747487|DRUG|Idebenone|Idebenone 900 mg/day
214652482|NCT00747487|DRUG|Placebo|Placebo
214243448|NCT00941577|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
214243449|NCT06271473|PROCEDURE|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
214243450|NCT03596632|DRUG|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
214243451|NCT02100709|DEVICE|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
214243452|NCT00000128|DEVICE|Bifocal Spectacle Lenses|
214243453|NCT05357729|DEVICE|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
214243454|NCT05349253|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
214243455|NCT05349253|DIETARY_SUPPLEMENT|Placebo|One intake in total
214652483|NCT05069584|PROCEDURE|Biopsy|patient must have a biopsy for his prostate cancer
214652484|NCT05340972|DIAGNOSTIC_TEST|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
214652485|NCT00331305|BEHAVIORAL|Supervised Exercise|
214652486|NCT00331305|BEHAVIORAL|Home-Based Exercise|
214243456|NCT00722371|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
214243457|NCT00722371|DRUG|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
214243458|NCT00722371|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
214652487|NCT00331305|DRUG|Sertraline (Zoloft)|
214652488|NCT00331305|DRUG|Placebo Pill|
214652489|NCT00037648|DRUG|Anakinra|anakinra
214652490|NCT00037648|DRUG|Placebo|placebo
214652491|NCT01670994|BIOLOGICAL|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
214652492|NCT03696329|DRUG|Tetrabenazine Tablets 25 mg|
214652493|NCT02013544|DRUG|Placebo|
214652494|NCT02013544|DRUG|Prasterone (DHEA)|
214652495|NCT04741373|DIETARY_SUPPLEMENT|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
214652496|NCT04741373|BEHAVIORAL|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
214243459|NCT00722371|DRUG|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
214243460|NCT00722371|DRUG|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
214243461|NCT04493840|DRUG|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
214243462|NCT04493840|DRUG|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
214243463|NCT01488344|DRUG|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
214243464|NCT03667300|DRUG|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
214243465|NCT03667300|DRUG|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
214243466|NCT03433729|OTHER|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
214243467|NCT01456377|DRUG|predinose oral|1 mg for kg for 3 wekees
214243468|NCT01456377|DRUG|placebo group|use a oral placebo
214243469|NCT00712062|DRUG|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
214243470|NCT02036554|DRUG|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
214652497|NCT04741373|OTHER|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
214652498|NCT02785809|OTHER|Pausing oral contraceptive|
214652499|NCT05503355|DRUG|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
214652500|NCT05503355|DRUG|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
214652501|NCT00837187|DRUG|Intravenous dexmedetomidine|100 ug
214652502|NCT00837187|DRUG|Intranasal dexmedetomidine|100 ug
214652503|NCT02557087|DRUG|Hyoscine|
214652504|NCT02557087|DRUG|Pethidine|
214652505|NCT03110588|DRUG|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
214652506|NCT03110588|DRUG|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
214652507|NCT06487013|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
214652508|NCT06487013|OTHER|Sham MRgHIFU treatment|Sham MRgHIFU treatment
214652509|NCT01295125|DEVICE|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
214652510|NCT01295125|PROCEDURE|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
214652511|NCT00003558|DRUG|carboplatin|
214243471|NCT02036554|DRUG|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
214243472|NCT02036554|DRUG|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
214243473|NCT04479462|PROCEDURE|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
214243474|NCT00510965|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
214243475|NCT04079673|PROCEDURE|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
214243476|NCT04079673|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
214243477|NCT05959005|OTHER|No intervention|There is no intervention.
214243478|NCT01753050|DEVICE|Stroke volume monitoring|Pulse contour stroke volume monitoring
214243479|NCT02635646|OTHER|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
214243480|NCT02635646|OTHER|individual approach|"individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
214243481|NCT05404984|OTHER|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
214243482|NCT05404984|OTHER|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
214243483|NCT03295565|DRUG|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
214652512|NCT00003558|DRUG|etoposide|
214652513|NCT00003558|DRUG|fluorouracil|
214652514|NCT00003558|DRUG|leucovorin calcium|
214652515|NCT00003558|DRUG|paclitaxel|
214243484|NCT03295565|DRUG|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
214243485|NCT03295565|DRUG|Enzalutamide|Enzalutamide 160mg oral taken daily
214243486|NCT01567228|OTHER|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
214243487|NCT05955976|OTHER|BIOPSY|biopsy
214243488|NCT02447705|DRUG|telbivudine|telbivudine replace Lamivudine
214243489|NCT04303923|PROCEDURE|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
214243490|NCT01504061|OTHER|Mederma N&I|Topical gel applied three times a day for eight weeks.
214243491|NCT01504061|OTHER|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
214243492|NCT03410264|BEHAVIORAL|CR-EXP|See arm/group descriptions
214652516|NCT05729841|OTHER|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
214652517|NCT03182439|DEVICE|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
214652518|NCT03182439|DEVICE|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
214652519|NCT03182439|DEVICE|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
214652520|NCT03182439|DEVICE|Apple Watch|Apple Watch Heart Rate Monitoring Device
214243493|NCT03410264|BEHAVIORAL|EXP-CR|See arm/group descriptions
214243494|NCT03410264|BEHAVIORAL|Stress Management|See arm/group descriptions
214243495|NCT03189381|RADIATION|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
214243496|NCT03189381|RADIATION|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
214243497|NCT03761797|DRUG|TRADIANCE® Combination Tablets AP|Fixed dose combination
214243498|NCT03761797|DRUG|TRADIANCE® Combination Tablets BP|Fixed dose combination
214652521|NCT05229939|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
214652522|NCT00474916|DRUG|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
214652523|NCT00474916|DRUG|Placebo|Normal Saline given as dose escalation for placebo
214243499|NCT00251004|DRUG|Everolimus|oral, bis in diem/twice a day (bid)
214243500|NCT00251004|DRUG|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
214243501|NCT00251004|DRUG|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
214243502|NCT00251004|DRUG|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
214243503|NCT00251004|DRUG|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
214243504|NCT05742386|BEHAVIORAL|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
214243505|NCT05742386|BEHAVIORAL|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
214243506|NCT04873271|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
214243507|NCT03239691|DRUG|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
214243508|NCT03239691|DRUG|Placebo|Matching placebo available as matching capsules for oral administration
214243509|NCT02566408|OTHER|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
214243510|NCT02566408|OTHER|Survey Questions|Complete survey
214243511|NCT00746200|PROCEDURE|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
214243512|NCT00746200|PROCEDURE|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
214243513|NCT06053710|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
214652524|NCT02036320|DEVICE|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
214652525|NCT01247857|DRUG|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
214243514|NCT05260281|DEVICE|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
214243515|NCT00545285|PROCEDURE|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
214243516|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
214243517|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
214243518|NCT04770077|OTHER|Intubation on manikin|Training of medical student to focus on manikin vocal cord before intubation
214243519|NCT01799382|OTHER|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
214243520|NCT01799382|DEVICE|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
214243521|NCT00239525|DEVICE|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
214243522|NCT00239525|DRUG|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
214243523|NCT05860101|OTHER|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
214243524|NCT04284150|DRUG|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
214243525|NCT06300593|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
214243526|NCT06300593|DIAGNOSTIC_TEST|Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
214243527|NCT05278637|DRUG|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
214243528|NCT05278637|DRUG|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
214243529|NCT01791556|OTHER|HIV-1 viral load testing|
214243530|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
214243531|NCT00645788|DRUG|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
214243532|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
214243533|NCT00645788|DRUG|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
214243534|NCT01205178|DRUG|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
214243535|NCT01205178|DRUG|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
214243536|NCT01205178|DRUG|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
214243537|NCT03149848|DRUG|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
214243538|NCT03149848|DRUG|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
214243539|NCT01244490|DRUG|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
214243540|NCT01244490|DRUG|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
214243541|NCT01244490|DRUG|Placebo Comparator|Placebo
214243542|NCT00133731|DRUG|Otamixaban (XRP0673)|
214243543|NCT00133731|DRUG|Unfractionated Heparin|
214243544|NCT00133731|PROCEDURE|Percutaneous Coronary Intervention|
214243545|NCT01486810|DRUG|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
214243546|NCT01486810|BEHAVIORAL|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
214243547|NCT04786509|DIAGNOSTIC_TEST|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
214243548|NCT00474682|DRUG|Micronized dispersible ferric pyrophosphate|
214243549|NCT02165176|DRUG|Oral cannabis|
214243550|NCT00983697|PROCEDURE|therapeutic conventional surgery|
214243551|NCT00983697|RADIATION|fludeoxyglucose F 18|
214243552|NCT00971620|BIOLOGICAL|Botulinum toxin type A|Given as an intralesional injection.
214243553|NCT00971620|OTHER|Placebo|Given as an intralesional injection
214243554|NCT04564885|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
214243555|NCT04564885|DEVICE|Mobi-C Cervical Disc|surgery
214243556|NCT04715334|DEVICE|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
214243557|NCT00824070|DRUG|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
214243558|NCT00824070|DRUG|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
214243559|NCT00824070|DRUG|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
214243560|NCT01951859|OTHER|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
214243561|NCT01216605|DRUG|Syntocinon 24 IU|
214243562|NCT01216605|DRUG|Placebo|
214243563|NCT02071927|DRUG|CB-839|Single-agent CB-839
214243564|NCT02071927|DRUG|CB-Aza|CB-839 in combination with standard dose azacitidine
214243565|NCT03128151|BEHAVIORAL|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
214243566|NCT02312427|DRUG|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
214243567|NCT02312427|DRUG|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
214243568|NCT02312427|DRUG|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
214243569|NCT02573701|DRUG|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
214243570|NCT02573701|BEHAVIORAL|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
214243571|NCT02573701|DRUG|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
214243572|NCT02188043|BEHAVIORAL|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
214243573|NCT04080076|DRUG|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
214243574|NCT04080076|DRUG|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
214243575|NCT03804073|RADIATION|standard treatment|3000 cGy in 10 daily fractions
214243576|NCT03804073|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
214243577|NCT00914303|DRUG|AZD3241|Oral Tablet, Repeated Administration
214243578|NCT00914303|DRUG|Placebo Tablet|Oral Tablet. Repeated Administration
214243579|NCT04880330|DEVICE|Cryo-Auriculotherapy|1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
214243580|NCT04880330|DEVICE|Sham comparator|1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
214243581|NCT04549974|OTHER|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
214243582|NCT01797172|PROCEDURE|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
214243583|NCT01797172|PROCEDURE|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
214243584|NCT00954252|DRUG|CHF 5074|1x, oral capsule, single dose
214243585|NCT00954252|DRUG|placebo|placebo, oral capsule, single dose
214243586|NCT00954252|DRUG|CHF 5074|2x, oral capsule, single dose
214243587|NCT00954252|DRUG|CHF 5074|4x, oral capsule, single dose
214243588|NCT00954252|DRUG|CHF 5074|8x, oral capsule, single dose
214243589|NCT00954252|DRUG|CHF 5074|16x, oral capsule, single dose
214243590|NCT00954252|DRUG|CHF 5074|24x, oral capsule, single dose
214243591|NCT02345746|DRUG|Oxaliplatin|infusion over 12 hours via HAI
214243592|NCT02345746|DRUG|Folinic Acid|as a 2-hour infusion via HAI on day 2
214243593|NCT02345746|DRUG|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
214243594|NCT03020446|DEVICE|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
214243595|NCT01173887|DRUG|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
214243596|NCT01173887|BIOLOGICAL|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
214243597|NCT01874990|DIETARY_SUPPLEMENT|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
214243598|NCT01874990|DIETARY_SUPPLEMENT|low-salt diet|
214243599|NCT00256282|DRUG|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
214243600|NCT00256282|DRUG|Docetaxel|40mg/m2 IV over 1 hour every 14 days
214243601|NCT00256282|DRUG|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
214243602|NCT03489954|OTHER|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
214243603|NCT00812695|DEVICE|CPAP|Gold standard treatment for Obstructive sleep apnea
214243604|NCT03206905|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
214243605|NCT03206905|BEHAVIORAL|Diet and Exercise|nutritional/exercise counseling
214243606|NCT06165627|DEVICE|Lehfilcon A toric contact lenses|Commercially available soft contact lenses worn as indicated
214243607|NCT06165627|DEVICE|Comfilcon A toric contact lenses|Commercially available soft contact lenses) worn as indicated
214243608|NCT06165627|DEVICE|CLEAR CARE|Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
214243609|NCT06146998|OTHER|3D health education model|explanation combined with 3D health education model
214243610|NCT06146998|OTHER|Verbal explanation|Regular explanation
214243611|NCT02095314|BIOLOGICAL|Pentavalen|Batch 5010613
214243612|NCT06052215|BEHAVIORAL|Online Information Cards Education|Providing family planning education to women through online information cards
214652526|NCT01247857|DRUG|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
214652527|NCT01247857|DRUG|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
214243613|NCT03304444|DRUG|Bupivacaine|bupivacaine hydrochloride used in TAP block
214243614|NCT03304444|DRUG|liposomal bupivacaine|liposomal bupivacaine used in TAP block
214243615|NCT00327470|DRUG|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
214243616|NCT00328978|DRUG|Quetiapine|
214243617|NCT02362568|PROCEDURE|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
214243618|NCT01536275|OTHER|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
214243619|NCT05860374|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214243620|NCT04110600|OTHER|Coffee effect on early gastric motility|this group 100ml coffee after two hours
214243621|NCT04110600|OTHER|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
214243622|NCT00004644|DRUG|acyclovir|
214243623|NCT06421818|DRUG|Baitouweng Tang|Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
214243624|NCT06421818|OTHER|Placebo|The same volume and color as Baitouweng Decoction.
214243625|NCT01723696|DIETARY_SUPPLEMENT|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
214243626|NCT01723696|DIETARY_SUPPLEMENT|Placebo tablet+prenatal vitamin|
214243627|NCT03291418|DRUG|ATB-346 OR Placebo|Comparison of gastrointestinal effects
214243628|NCT03291418|DRUG|Naproxen sodium|Comparison of gastrointestinal effects
214243629|NCT00579085|DRUG|Ketamine|IV Ketamine .35mg/kg times ten days.
214243630|NCT00579085|OTHER|IV NSS|Placebo inactive ingredients
214243631|NCT00579085|OTHER|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
214243632|NCT04219462|DEVICE|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
214243633|NCT04219462|DEVICE|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
214243634|NCT01141777|DIETARY_SUPPLEMENT|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
214243635|NCT01141777|DIETARY_SUPPLEMENT|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
214243636|NCT03462290|DRUG|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
214243637|NCT03462290|DRUG|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
214243638|NCT02581943|DRUG|Carboplatin|Given IV
214243639|NCT02581943|OTHER|Laboratory Biomarker Analysis|Correlative studies
214243640|NCT02581943|DRUG|Paclitaxel|Given IV
214243641|NCT02581943|BIOLOGICAL|Pembrolizumab|Given IV
214243642|NCT02581943|OTHER|Quality-of-Life Assessment|Ancillary studies
214243643|NCT02115126|BIOLOGICAL|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
214243644|NCT02115126|BIOLOGICAL|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
214243645|NCT02758405|DRUG|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
214243646|NCT02758405|DRUG|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
214243647|NCT02758405|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
214243648|NCT03888638|PROCEDURE|Hepatectomy|Removal of a part of the liver because of tumor
214243649|NCT01830777|DRUG|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
214243650|NCT01830777|DRUG|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
214243651|NCT01830777|DRUG|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
214243652|NCT01830777|DRUG|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
214243653|NCT04513821|DRUG|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
214243654|NCT06067659|OTHER|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
214243655|NCT06067659|OTHER|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
214243656|NCT06067659|OTHER|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
214243657|NCT00311480|BIOLOGICAL|Influenza vaccine surface antigen adjuvanted with MF59|
214243658|NCT03271294|DEVICE|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
214243659|NCT01415089|BEHAVIORAL|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
214243660|NCT03274375|DRUG|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
214243661|NCT03274375|DRUG|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"
214243662|NCT03021564|OTHER|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
214243663|NCT01987947|DRUG|Placebo|Two administrations by subcutaneous injection
214243664|NCT01987947|DRUG|Quilizumab|Two administrations by subcutaneous injection
214243665|NCT03374618|OTHER|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
214243666|NCT03920384|BEHAVIORAL|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
214243667|NCT03920384|BEHAVIORAL|Active control arm|Standard psychological therapy for psychosis without new therapy components
214243668|NCT04136756|DRUG|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
214243669|NCT04136756|DRUG|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
214243670|NCT04136756|DRUG|Rituximab|Rituximab administered intravenously at specified dose on specified days
214243671|NCT04136756|DRUG|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
214243672|NCT00739271|OTHER|Early feeding|
214243673|NCT00739271|OTHER|late feeding after bowel sounds return|Traditional method
214243674|NCT03503890|DRUG|rovalpituzumab tesirine|intravenous
214652528|NCT00701987|DRUG|ALS-357|Topical application of ALS-357
214243675|NCT04112589|DRUG|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
214243676|NCT04112589|DRUG|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
214243677|NCT04112589|DRUG|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
214243678|NCT04112589|DRUG|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
214243679|NCT04112589|DRUG|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
214243680|NCT03444077|DIAGNOSTIC_TEST|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.
214243681|NCT03444077|DIAGNOSTIC_TEST|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
214243682|NCT03444077|OTHER|STTTOPPP the bleeding|"* Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
214243683|NCT03444077|OTHER|Regular Care|Regular local pre-hospital care.
214243684|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
214243685|NCT01167985|DEVICE|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
214243686|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
214243687|NCT04308811|BIOLOGICAL|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
214243688|NCT04308811|COMBINATION_PRODUCT|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
214243689|NCT04308811|DEVICE|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
214243690|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
214243691|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
214243692|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
214243693|NCT00219544|DRUG|Placebo|Placebo
214243694|NCT05599919|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
214243695|NCT00505882|DRUG|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
214243696|NCT00505882|DRUG|Glargine|
214243697|NCT00505882|DRUG|Lispro|
214243698|NCT00505882|DRUG|Aspart|
214243699|NCT00745615|DRUG|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
214243700|NCT00745615|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
214243701|NCT00625573|DRUG|Abraxane|100mg/m2 every week X's 3
214243702|NCT02655393|DIETARY_SUPPLEMENT|Mitopure|
214243703|NCT03385083|BEHAVIORAL|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
214243704|NCT03385083|BEHAVIORAL|Step count monitoring without consultation|Subject counseled on step counts at initial visit
214243705|NCT03385083|DEVICE|Fitbit tracker|Fitbit tracker given to participant
214243706|NCT05130944|BEHAVIORAL|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
214652529|NCT00456703|OTHER|intraoperative fluid management|fluid restriction
214652530|NCT00456703|OTHER|fluid restriction|restriction of fluids
214243707|NCT05130944|BEHAVIORAL|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
214243708|NCT00907062|DIETARY_SUPPLEMENT|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
214243709|NCT03405636|DEVICE|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
214243710|NCT05765656|BEHAVIORAL|GP - pharmacist collaboration and pharmacist motivational interviewing|"1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
214243711|NCT04932070|DIETARY_SUPPLEMENT|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
214243712|NCT06302738|DIAGNOSTIC_TEST|polysomnography|patients will undergo a home sleep study to evaluate the presence of sleep disorders
214243713|NCT02554851|DRUG|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
214243714|NCT02554851|OTHER|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
214243715|NCT02481427|PROCEDURE|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
214243716|NCT02481427|PROCEDURE|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
214243717|NCT02909803|OTHER|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
214243718|NCT02909803|OTHER|White Bread|Participants will consume white bread on at least two different test days
214243719|NCT02689687|BEHAVIORAL|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
214243720|NCT02689687|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
214243721|NCT02689687|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
214243722|NCT02689687|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
214243723|NCT03932968|PROCEDURE|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
214243724|NCT00084461|DRUG|romidepsin|Given IV
214243725|NCT00084461|OTHER|laboratory biomarker analysis|Correlative studies
214243726|NCT03492775|DRUG|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
214243727|NCT03492775|DRUG|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
214243728|NCT00586664|DRUG|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
214243729|NCT00586664|DRUG|placebo comparator|sterile ophthalmic solution
214652531|NCT01008345|DRUG|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
214652532|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
214652533|NCT03013465|OTHER|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
214243730|NCT00586664|DRUG|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
214243731|NCT01464723|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
214243732|NCT03127787|DIAGNOSTIC_TEST|CMV Assay|Molecular diagnostic test to detect CMV
214243733|NCT02306499|PROCEDURE|ICSI|Intracytoplasmic Sperm Injection
214243734|NCT06288373|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
214243735|NCT06288373|DRUG|Cisplatin|Cisplatin：75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
214243736|NCT06288373|DRUG|Nab paclitaxel|Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
214243737|NCT06288373|PROCEDURE|Radical surgery|Radical surgery
214243738|NCT06288373|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
214243739|NCT06288373|DRUG|Cisplatin|Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
214243740|NCT03248700|OTHER|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
214243741|NCT01042782|DRUG|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
214243742|NCT02553668|DRUG|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
214243743|NCT02553668|DEVICE|Facemask|
214243744|NCT03734484|DIAGNOSTIC_TEST|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
214243745|NCT04413227|DRUG|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
214243746|NCT00727532|DRUG|Sorafenib|400mg by mouth twice daily for 28 consecutive days
214243747|NCT00829933|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
214243748|NCT00829933|DRUG|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
214243749|NCT02338336|DRUG|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
214243750|NCT02338336|DRUG|Placebo|Matching placebo liquid for topic administration.
214243751|NCT05055245|OTHER|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
214243752|NCT01990144|DRUG|Bendamustine+Rituximab|"Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
214243753|NCT01986933|DRUG|nemolizumab (CIM331)|
214243754|NCT01986933|OTHER|Placebo|
214243755|NCT03119701|DRUG|Interferon Beta-1A|Lyophilisate for solution for injection.
214243756|NCT03119701|DRUG|Placebo|Lyophilisate for solution for injection as placebo.
214243757|NCT01198171|OTHER|Laboratory Biomarker Analysis|Correlative studies
214243758|NCT01198171|OTHER|Study of Socioeconomic and Demographic Variables|
214243759|NCT04215133|OTHER|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
214243760|NCT00663442|DRUG|OROS methylphenidate|18, 36, 54 mg
214243761|NCT00596362|DRUG|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
214243762|NCT02043379|DRUG|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
214243763|NCT02043379|OTHER|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
214243764|NCT03504930|OTHER|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
214243765|NCT04153071|DEVICE|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
214243766|NCT02457585|DRUG|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
214243767|NCT05530876|OTHER|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
214243768|NCT03798899|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
214243769|NCT03798899|DRUG|Normal Saline|Placebo
214243770|NCT02874768|DRUG|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
214243771|NCT02874768|DRUG|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
214243772|NCT06221527|PROCEDURE|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
214243773|NCT03999151|BEHAVIORAL|Exercise and Diet|Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
214243774|NCT05388123|DRUG|Low dose vemurafenib plus rituximab|Vemurafenib 240 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
214243775|NCT06194851|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each bCBCT session.
214243776|NCT06194851|DRUG|Saline nasal spray|Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.
214243777|NCT06194851|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized bCBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
214243778|NCT04029480|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
214243779|NCT04029480|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
214243780|NCT04029480|DRUG|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
214243781|NCT04029480|DRUG|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
214243782|NCT04029480|BIOLOGICAL|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
214243783|NCT04029480|DRUG|Metformin|Participants will receive stable dose of background metformin.
214243784|NCT05112991|DRUG|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
214243785|NCT05112991|DRUG|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
214243786|NCT05957211|DRUG|0.09% cyclosporine A ophthalmic solution|Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
214243787|NCT00697944|DRUG|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
214243788|NCT02528539|OTHER|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
214243789|NCT04386824|OTHER|Erectil dysfunction|A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
214243790|NCT00356122|DRUG|Docetaxel|70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
214243791|NCT00356122|DRUG|Oxaliplatin|100 mg/m\^2 administered IV on Day 1 for Cycles 1-6
214243792|NCT00356122|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
214243793|NCT00491556|PROCEDURE|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
214243794|NCT00491556|PROCEDURE|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
214243795|NCT00990457|BEHAVIORAL|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.~The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
214243796|NCT05800730|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214243797|NCT05800730|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
214243798|NCT05800730|OTHER|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
214243799|NCT05800730|OTHER|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
214243800|NCT05907538|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
214243801|NCT05907538|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
214243802|NCT05907538|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
214243803|NCT03975140|PROCEDURE|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
214243804|NCT03975140|PROCEDURE|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
214243805|NCT04701164|DRUG|ANX005|Solution for intravenous infusion
214243806|NCT04701164|DRUG|Placebo|Solution for intravenous infusion
214243807|NCT02684201|DEVICE|Boston Scientific Stimulator Lead|A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
214243808|NCT05016180|DRUG|Ropivacaine|Before the induction of anesthesia, ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
214243809|NCT02418156|DEVICE|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
214243810|NCT02405104|DRUG|chlorzoxazone|ATC-code: M03BB03
214243811|NCT02405104|DRUG|Placebo|Placebo
214243812|NCT02405104|PROCEDURE|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
214243813|NCT02405104|PROCEDURE|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
214243814|NCT01445626|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
214243815|NCT03171428|PROCEDURE|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
214243816|NCT04609475|PROCEDURE|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
214243817|NCT04609475|PROCEDURE|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
214243818|NCT04134351|OTHER|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
214652534|NCT00723684|OTHER|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
214652535|NCT00723684|OTHER|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
214652536|NCT00885365|DRUG|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
214243819|NCT05408065|DRUG|Triamcinolone Hexacetonide and hyaluronic acid|infiltration under fluoroscopy
214243820|NCT05408065|DRUG|Triamcinolone Hexacetonide|infiltration under fluoroscopy
214243821|NCT04008381|BIOLOGICAL|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
214243822|NCT00161421|DRUG|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
214243823|NCT00161421|DRUG|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
214243824|NCT00161421|DRUG|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
214243825|NCT01576887|DRUG|Bardoxolone Methyl 20 mg|Oral, once daily
214243826|NCT01576887|DRUG|Placebo|Oral, once daily
214243827|NCT06979232|DEVICE|Enhanced White Light Imaging|Use of E-WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
214243828|NCT06979232|DEVICE|White Light lmaging|Use of WLl for colon inspection during both insertion and withdrawal phase of colonoscopy
214243829|NCT06111547|DRUG|TAK-279|TAK-279 oral tablet.
214243830|NCT06111547|DRUG|Placebo|TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
214243831|NCT06985186|DRUG|Ultra-Long GnRH Agonists + Letrozole|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. Upon initiation of the GnRH agonist, patients will also receive 2.5mg of Letrozole every 12h for 60 days. The start of therapy will be during the menstrual phase of the cycle.
214652537|NCT00885365|DRUG|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
214652538|NCT03030963|OTHER|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
214652539|NCT03030963|OTHER|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
214652540|NCT00417872|DRUG|Nitazoxanide|
214652541|NCT00417872|DRUG|Metronidazole|
214652542|NCT03807531|DEVICE|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
214652543|NCT01824979|DEVICE|CPAP mask ( Pilairo)|
214243832|NCT06985186|DRUG|Ultra-Long GnRH Agonists|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. The first injection of GnRH agonist will be administered during the menstrual phase of the cycle.
214243833|NCT06184737|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
214243834|NCT06184737|BEHAVIORAL|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
214243835|NCT04070911|OTHER|WATER|ORAL WATER
214243836|NCT04070911|OTHER|ICE APPLICATION|ICE APPLICATION
214243837|NCT06985459|DEVICE|PIP extension deficit treated with an exercise RMF orthosis|The RM orthoses will be worn between 6-12 hours per day during functional use.
214243838|NCT06985459|DEVICE|PIP extension deficit treated with a placebo RMF orthosis|"The placebo orthosis has the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
214243839|NCT06985459|DEVICE|PIP flexion deficits treated with a placebo RMF orthosis|"The placebo orthosis have the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
214243840|NCT06985459|DEVICE|PIP flexion deficits treated with an exercise RME orthosis|The dedicated orthosis wearing time is 6-12 hours per day during functional use.
214243841|NCT06984848|COMBINATION_PRODUCT|Oral7® mouth spray contains Natural Enzymes (Lactoperoxidase, Glucose Oxidase, Lactoferrin, Lysozyme), Calcium, Xylitol, Aloe Vera, Natural peppermint.|This study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia
214243842|NCT06987344|OTHER|Field-based closed kinetic chain exercise with progressively increased time under tension|This intervention is uniquely characterized by the integration of field-based closed kinetic chain (CKC) exercises with a systematically increased eccentric time under tension (TUT), specifically tailored for university-level soccer players. Unlike conventional strength training protocols, which are often gym-based and rely on traditional resistance machines or free weights, this program emphasizes functional, sport-specific movement patterns performed on the field, enhancing ecological validity and transfer to soccer performance.
214243843|NCT06987344|OTHER|Regular soccer training routines|Trained three times a week: two days were dedicated to functional and tactical on-field training, while the third day was reserved for a two-hour gym session focused on flexibility, muscular strength, and endurance development.
214243844|NCT06242743|OTHER|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
214243845|NCT06242743|OTHER|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
214243846|NCT03344523|DRUG|Iron protein succinylate oral solution|Iron protein succinylate oral solution
214243847|NCT03344523|OTHER|standard treatment|standard treatment
214243848|NCT01397097|DRUG|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
214243849|NCT01397097|DRUG|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
214243850|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
214243851|NCT06990152|OTHER|MCTs and fiber|Water-soluble powder containing medium-chain triglycerides, soluble and unsoluble fiber.
214652544|NCT01824979|PROCEDURE|Other CPAP mask|
214652545|NCT01625806|DRUG|RO4602522|Single oral dose
214652546|NCT01625806|DRUG|ketoconazole|Multiple oral doses
214652547|NCT01982825|BEHAVIORAL|Online intervention arm|See online intervention arm
214652548|NCT01982825|BEHAVIORAL|Online control arm|See online control arm
214652549|NCT02133417|DEVICE|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
214652550|NCT03102229|OTHER|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
214652551|NCT03102229|OTHER|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
214652552|NCT01592994|BEHAVIORAL|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
214243852|NCT06990152|OTHER|Placebo powder|Water-soluble powder containing no medium-chain triglycerides and no fiber.
214243853|NCT06993376|PROCEDURE|PENG block|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
214243854|NCT06993376|PROCEDURE|ESPB|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
214243855|NCT03757390|DRUG|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
214243856|NCT03757390|DRUG|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
214243857|NCT06994312|DRUG|Nafamostat Mesylate|Anticoagulation with Nafamostat Mesylate for SIC Patients Undergoing Hemofiltration
214243858|NCT06994312|DRUG|sodium citrate|Anticoagulation with Sodium Citrate for SIC Patients Undergoing Hemofiltration
214243859|NCT06994169|DRUG|Glofitamab|Glofitamab received for DLBCL in Early Phase Access
214243860|NCT06994910|OTHER|Maitland mobilization techniques|Participants with temporomandibular joint dysfunction received Maitland mobilization techniques applied to the TMJ over a defined treatment period. Outcomes were assessed at baseline (pre-intervention) and after completion of the intervention (post-intervention)
214243861|NCT06994481|DIAGNOSTIC_TEST|optic nerve sheet diameter measurement|Both groups will undergo bilateral optic nerve sheath diameter measurement with ultrasonography after induction, after airway manipulations, and before awakening.
214243862|NCT06995534|OTHER|splint|static wrist-hand splint + education on activity modification and positioning in daily life
214243863|NCT06995534|OTHER|Exercise Therapy|Home-based Exercise Therapy + Education on activity modification and positioning in daily life
214243864|NCT06993519|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
214243865|NCT06993649|BEHAVIORAL|Experimental High Reality Simulator|The process steps including normal labour skills will be shown on d1= High Reality simulator (full-size, computer-based, time-setting, expressions of pain from the mother, performed with a female robotic simulator, Noelle S575 Mother and Newborn simulator), d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) and d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the labour scenario) will be done to each student in the group respectively.
214243866|NCT06993649|BEHAVIORAL|Experimental Medium Reality Simulator|The process steps including normal labour skills will be shown on d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) will be done to each student in the group respectively.
214243867|NCT06993649|BEHAVIORAL|Experimental Simulated Woman|Then, the process steps including normal labour skills will be shown d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the scenario of labour by the midwifery student) will be done to each student in the group respectively.
214243868|NCT06994624|OTHER|Nutritional intervention|A plant-based diet
214243869|NCT06994403|DIETARY_SUPPLEMENT|Durum wheat pasta enriched with carob flour|Participants will consume 68 g of durum wheat pasta enriched with carob flour (231 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
214243870|NCT06994403|DIETARY_SUPPLEMENT|Standard durum wheat pasta|Participants will consume 63 g of standard durum wheat pasta (221 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
214243871|NCT06994403|DIETARY_SUPPLEMENT|White bread reference meal|Participants will consume 84 g of white bread (225 kcal), providing 50 g of available carbohydrates. The bread will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
214243872|NCT06995248|BEHAVIORAL|Laughter Yoga|Laughter yoga sessions are a behavioral intervention regularly conducted to help participants reduce stress, build social connections, and enhance overall well-being.
214243873|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 IM on Days 1, 8, 15, and 22."
214652553|NCT05196893|BEHAVIORAL|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
214243874|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 IM on Days 1, 8, 15, and 22."
214243875|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive high dose of KSHN001034 IM on Days 1, 8, 15, and 22."
214243876|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 SC on Days 1, 8, 15, and 22."
214243877|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 SC on Days 1, 8, 15, and 22."
214243878|NCT06995482|DRUG|Fulvestrant|"Reference Product: Faslodex® (Fulvestrant), 5 mL pre-filled syringe containing 250 mg/5 mL of fulvestrant, administered as two 5 mL injections (total 500 mg) via intramuscular (IM) injection. Marketed by AstraZeneca.~• 2 subjects will receive 500 mg Fulvestrant IM on Days 1 and 15."
214243879|NCT06994234|BEHAVIORAL|In-Place Slow Jogging|ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes.
214243880|NCT06995417|OTHER|Smoking counseling|"The investigator, upon enrollment, will initiate a standardized strategy from clinical practice: the investigator will conduct brief counseling (minimal advice) using the administration of of a questionnaire that will include, in addition to questions about current and past, the administration of the Fagerstrom test to measure physical dependence on nicotine and questions to investigate intention to quit smoking (Mondor test)"
214243881|NCT06994741|OTHER|Quantitative movement analysis|During their reeducation, patient can go through an quantitative movement analysis. Inside a movement laboratory, we observe their gait with 5 passageways.
214243882|NCT06993987|OTHER|Descriptive analysis|The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.
214243883|NCT06993883|DRUG|Venetoclax|observational study for the result of venetoclax use combined with chemotherapy in AML patients in Sohag governorate
214243884|NCT06994585|DRUG|Drinklear|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
214243885|NCT06994585|DRUG|Niflec|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
214243886|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (with strategy)|Participants will learn to play a complex online game using specific guidance or strategy.
214243887|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (without strategy)|Participants will learn to play a complex online game without specific guidance or strategy.
214243888|NCT06995404|PROCEDURE|TAP Block Group|Patients in the TAP group will receive a bilateral Transversus Abdominis Plane (TAP) block under ultrasound guidance prior to surgery after general anaesthesia, with the local anesthetic administered between the internal oblique and transversus abdominis muscles. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
214243889|NCT06995404|PROCEDURE|M-TAPA Block group|Patients in the M-TAPA group will receive a bilateral Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA) under ultrasound guidance prior to surgery after general anaesthesia. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
214243890|NCT06995092|OTHER|Music therapy|Patient will receive a 15-minute RAS session immediately before patient standard physiotherapy session. The RAS session will consist of metronome beats matched to your walking cadence. After completing the RAS sessions, patient will continue with the standard rehabilitation program as usual.
214243891|NCT06995092|OTHER|Standard physiotherapy program|Patient will receive the standard physiotherapy program without the RAS pre-gait training. Therapy will include sessions aimed at improving balance and gait, conducted for 15 minutes during each session. Assessments will be conducted at baseline, after completing the therapy, and during two follow-up evaluations.
214243892|NCT06994702|DEVICE|MRI without mask|MRI in position of cerebral radiotherapy treatment without mask
214243893|NCT06994702|DEVICE|MRI with mask 1|MRI in position of cerebral radiotherapy treatment with mask 1
214243894|NCT06994702|DEVICE|MRI with mask 2|MRI in position of cerebral radiotherapy treatment with mask 2
214243895|NCT06995079|PROCEDURE|Postoperative pain assessment of patients who underwent block|Postoperative pain assessment of patients who underwent block
214243896|NCT06993779|OTHER|Deep learning system for prognostication prediction in upper tract urothelial carcinoma|develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.
214243897|NCT06995105|PROCEDURE|TACE|The first day of TACE treatment is the first day (D1). TACE is started on D1. Subsequent TACE is arranged by the investigator based on a comprehensive assessment of the patient's physical condition, disease progression, adverse reactions, etc. The total number of TACEs shall not exceed 4 times, with at least 4 weeks between each two times.
214243898|NCT06995105|DRUG|Sintilimab combined with Bevacizumab|Sintilimab (200 mg) combined with bevacizumab (Dayoutong injection, 15 mg/kg), intravenous infusion, once every 3 weeks, until the patient is intolerant or the tumor progresses
214243899|NCT06995105|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
214243900|NCT06994221|DIAGNOSTIC_TEST|18F FAPI-42 PET/CT scan|During the hospital stay, participants will receive an 18F FAPI-42 PET/CT scan. 18F FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for fibrosis imaging. PET/CT will be performed using the ultra-high-resolution digital PET/CT uEXPLORER (United Imaging, Shanghai, China)
214243901|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|doxycycline gel exhibits bacteriostatic activity against prevalent periodontal pathogens
214243902|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|the formulation of doxycycline and incorprating it with PLGA nano-particles will increase the absorption rate in gingival sulcus
214243903|NCT06994455|PROCEDURE|scaling and root planing|control group in the study
214243904|NCT06994637|OTHER|Liquid Hourglass|The liquid hourglass to be used in the study is made of high-quality plastic material, approximately 14 cm long. It contains colored liquid gel. When the hourglass is turned, the colored liquid gel inside flows downwards in the form of bubbles, drop by drop. It is suitable for use by all age groups of children. The visual and moving nature of the liquid hourglass may distract the child during the blood collection process.
214652554|NCT04281797|DIAGNOSTIC_TEST|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
214243905|NCT06994637|OTHER|Spiky Ball|The spiky ball to be used in the study is a ball made of sturdy environmentally friendly plastic, approximately 6 cm in size. This ball has a hard body with thorns on it and provides tactile stimulation by pricking the child's fingers. The pressure applied by the thorns on the balls to the hand can reduce pain, muscle tension and stress by stimulating the nerve endings more quickly. It is suitable for use by children over the age of two. The tactile stimulation on the spiky ball can distract the child during the blood collection process.
214243906|NCT06994780|PROCEDURE|dynamic compliance guided PEEP titration|In order to find the individualized optimal PEEP value, PEEP will be increased at 2-minute intervals with a maximum peak pressure of 45 cmH2O and a driving pressure of 15 cmH2O. Recruitment will be performed. When the target is reached, the PEEP value will be adjusted to the value at which the highest dynamic compliance is achieved by decreasing it.
214243907|NCT06994650|DRUG|HRS9531|HRS9531 will be administered by Subcutaneous injection
214243908|NCT06994650|DRUG|Placebo|Matching Placebo will be administered by Subcutaneous injection
214243909|NCT06995547|DEVICE|implant overdenture|Each patient will be receive two dental implants for overdenture fixation
214243910|NCT06994845|DRUG|iptacopan|Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd
214243911|NCT06995274|BIOLOGICAL|Umbilical Cord Blood Infusion (Autologous and Allogeneic)|"The intervention consists of three intravenous infusions of umbilical cord blood (UCB) in a pediatric patient diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder (ASD). The first infusion uses autologous UCB stored at a certified cord blood bank. The second and third infusions use allogeneic UCB units selected from a hospital-based donor cord blood bank. Donor units are matched at a minimum of 3 out of 6 HLA loci (HLA-A, B, DRB1) and contain ≥ 3×10⁷ total nucleated cells per kilogram of body weight.~Each infusion is administered intravenously via peripheral vein at the Cell Therapy Center of CHA Bundang Medical Center. Prior to each infusion, the participant receives premedication with intravenous chlorpheniramine maleate (0.6 mL/10 kg) to reduce the risk of allergic reactions. For allogeneic infusions, oral cyclosporine (0.07 mL/kg twice daily) is administered for 7 days (3 days before, day of, and 3 days after infusion) to minimize immune-mediated reactions"
214243912|NCT04461509|DRUG|18F-PSMA|"Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer"
214243913|NCT06688331|BIOLOGICAL|ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)|regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)
214243914|NCT06688331|BIOLOGICAL|Anti-CD20 (rituximab)|rituximab
214243915|NCT06688331|OTHER|Placebo|intrevenous 0,9% NaCl
214243916|NCT06688331|OTHER|Treg sham|intrevenous 0,9% NaCl
214243917|NCT06689696|DEVICE|miLens system|The miLens system consists of the miLens contact lens made of soft, biocompatible materials, the miLens imaging system, and miLens analysis software.
214243918|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB).|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
214243919|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB)|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
214243920|NCT03640520|OTHER|FACETS: Pediatric Resuscitation|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
214243921|NCT03640520|OTHER|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
214243922|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
214243923|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214243924|NCT06049355|OTHER|Educational Intervention|Receive educational materials
214652555|NCT06190587|DIETARY_SUPPLEMENT|Goji Berry|As a functional food goji berry contains 19 amino acids, 21 minerals, a wide range of carotenoids (β-Carotene, Neoxanthin, Cryptoxanthin, Zeaxanthin), polysaccharides, flavonoids, phytosterols, vitamin A, C and E.
214652556|NCT06196502|OTHER|Gentle Human Touch (GHT)|Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.
214243925|NCT06218264|DIETARY_SUPPLEMENT|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
214243926|NCT06878235|OTHER|Assessment of the functional status|assessment of their functional status using the French version of the PLSFRS scale during a routine multidisciplinary assessment every 3-6 months for all patients with motor neurone disease, as recommended by the FILSLAN network
214243927|NCT01406405|PROCEDURE|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
214243928|NCT06710717|BIOLOGICAL|CD19 CAR-T cells|Study participant will be given single infusion of autologous CD19 CAR-T cells following lymphodepletion chemotherapy
214243929|NCT04932798|DIAGNOSTIC_TEST|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
214243930|NCT04932798|DIAGNOSTIC_TEST|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
214243931|NCT04932798|DIAGNOSTIC_TEST|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
214243932|NCT06715280|DRUG|Riociguat (Adempas)|Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period
214243934|NCT01094561|DRUG|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
214243935|NCT01094561|PROCEDURE|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
214243936|NCT01094561|PROCEDURE|Secretin-Enhanced Endoscopic Ultrasound|
214243937|NCT05953090|DEVICE|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
214243938|NCT06711952|DIAGNOSTIC_TEST|Subjective Cognitive Decline-Questionnaire (SCD-Q)|The SCD-Q is an established instrument to quantify self-perceived cognitive decline. In addition to the self-perceived cognitive complaints, a 24 items questionnaire of informants is part of SCD-Q. The self-reported SCD-Q will be included in the standard health questionnaire that all patients of the memory clinic of the LMU Department of Psychiatry and Psychotherapy are required to complete before the examination date. The health questionnaire will be sent per mail. All routine clinical procedures will remain unchanged.
214243939|NCT06711952|DIAGNOSTIC_TEST|Cognitive Failure Questionnaire (CFQ)|The Cognitive Failure Questionnaire (CFQ) is a questionnaire for measuring self-reported subjective failures in cognition, memory and motor functions in everyday life. The German CFQ consists of 32 items related to everyday possibilities of error, whose frequency in the last six months is to be estimated by means of a five-point rating scale.
214243940|NCT06711952|DIAGNOSTIC_TEST|biomarkers|"Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer.~Only available clinical and biomarker data will be used (Routine cerebrospinal fluid biomarkers, routine imaging biomarkers)."
214243941|NCT06711952|DIAGNOSTIC_TEST|Cognitive Tests|"The investigators plan to examine the patients´ visuospatial performance on site with a digital clock-drawing test, which has been validated in large community-based studies.~The Functional Activities Questionnaire (FAQ) shall be filled out by an informant. FAQ is a reliable and valid measure of activities of daily living. The results of the routine neuropsychological tests (Consortium to Establish a Registry for AD, Mini-Mental-State Examination) will be used in the analysis."
214243942|NCT02104739|DRUG|Exenatide|Single subcutaneous injection (10 mcg)
214243943|NCT02104739|DRUG|Saxagliptin|Single dose orally (5 mg)
214243944|NCT02104739|DRUG|Exenatide extended-release (ER)|Subcutaneous injection (2mg) weekly for 6 weeks
214243945|NCT02104739|OTHER|Placebo|Placebo tablets and Placebo (normal saline) injections
214243946|NCT05218954|DIAGNOSTIC_TEST|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
214243947|NCT00139867|DRUG|PARCOPA|
214243948|NCT06556654|DEVICE|TRBR Device|The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
214243949|NCT06747130|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
214243950|NCT06747130|DRUG|Montelukast Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
214243951|NCT06880367|BEHAVIORAL|The intervention is an audio-proprio-phonatory training|The audio-proprio-phonatory training involves engaging in group workshops and performing exercise sessions independently, following the guidance provided by the specialist, over a duration of five weeks
214243952|NCT06880367|DIAGNOSTIC_TEST|high-density electroencephalogram (HD-EEG)|HD-EEG examination with 256 channels distributed throughout the skull that record resting brain connectivity(10 min).
214243953|NCT06900426|OTHER|10 PEEP|Using 10cmH2O PEEP during anesthetic induction monitored by EIT.
214243954|NCT06900426|OTHER|ZEEP|No PEEP
214243955|NCT06900426|OTHER|5PEEP|Using 5cmH2O PEEP
214243956|NCT06309355|DRUG|YR001 ointment|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
214243957|NCT06309355|OTHER|Placebo|The intervention is Placebo on a range of body surface area for multiple topical administration
214243958|NCT05519644|OTHER|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
214243959|NCT05519644|OTHER|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
214243960|NCT05519644|OTHER|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
214243961|NCT05519644|OTHER|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
214243962|NCT05519644|OTHER|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
214243963|NCT05519644|BEHAVIORAL|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
214243964|NCT05519644|OTHER|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
214243965|NCT05519644|OTHER|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
214243966|NCT05519644|OTHER|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
214243967|NCT05519644|OTHER|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
214243968|NCT05519644|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
214243969|NCT05519644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
214243970|NCT05519644|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
214243971|NCT06781333|BIOLOGICAL|hMSC|Participants will come in person to receive one intravenous infusion of approximately 25 million cells up to 20 minutes.
214243972|NCT04537377|GENETIC|VTX-801|"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."
214243973|NCT04227301|OTHER|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
214243974|NCT05772702|DEVICE|Closed-loop tACS|Individual alpha tACS
214243975|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
214243976|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
214243977|NCT01909453|DRUG|LGX818|LGX818- Orally 100 mg and 50 mg capsules
214243978|NCT01909453|DRUG|MEK162|MEK162- Orally 15 mg tablets
214243979|NCT01909453|DRUG|vemurafenib|Tablets in bottles or blisters 240 mg
214243980|NCT06926114|DEVICE|Microlearning intervention|thirteen students will be included into the microlearning group will receive sequential daily learning units over ten days, . Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
214243981|NCT06926114|DEVICE|Traditional block-format module group|eleven students will be inclued into the self block module group will engage in a comprehensive two-day self-learning module. Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
214243982|NCT06820450|OTHER|Blood test|A blood test (2 x 5 ml dry tubes) will be taken to analyze steroid profiles
214243983|NCT06820450|OTHER|urine sample|a 20 ml urine sample will be taken to analyze steroid profiles
214243984|NCT06820450|OTHER|vaginal sample|to characterize the microbiota.
214243985|NCT06801847|BEHAVIORAL|Socialization|Socialization lasting from 30-60 minutes each session
214243986|NCT06801847|BEHAVIORAL|Walking|Twice weekly walking (30 minutes)
214243987|NCT06801847|BEHAVIORAL|Moderate Exercise|Twice weekly moderate exercise (30 minutes)
214243988|NCT06909019|BEHAVIORAL|Control (QR) Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
214243989|NCT06909019|BEHAVIORAL|Low Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Low Climate Impact labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
214243990|NCT06909019|BEHAVIORAL|High Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
214243991|NCT06909019|BEHAVIORAL|Traffic Light Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
214243992|NCT06909019|BEHAVIORAL|Climate Grade Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
214243993|NCT06524453|BEHAVIORAL|Wheelchair accessible exercise program|"1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes"
214243994|NCT06908174|DIAGNOSTIC_TEST|ADOS-2|The subjects in case group will receive the ADOS-2 assessment to confirm their diagnosis.
214243995|NCT06520787|COMBINATION_PRODUCT|ACDP® and pharmacological treatment for obesity|40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).
214243996|NCT04268498|DRUG|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
214243997|NCT04268498|DRUG|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
214243998|NCT04268498|DRUG|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
214243999|NCT04268498|DRUG|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
214244000|NCT04268498|DRUG|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
214244001|NCT04268498|DRUG|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
214244002|NCT04268498|DRUG|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
214244003|NCT04268498|DRUG|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
214244004|NCT04268498|BIOLOGICAL|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
214244005|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
214244006|NCT05941832|DEVICE|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
214244007|NCT06919068|DIAGNOSTIC_TEST|Colon capsule endoscopy|PillCam Colon 2
214244008|NCT01382147|DRUG|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
214244009|NCT04166227|PROCEDURE|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
214244010|NCT04166227|PROCEDURE|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
214244011|NCT02151136|DRUG|24% sucrose|
214244012|NCT02151136|DRUG|Sterile water|
214244013|NCT02151136|OTHER|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
214244014|NCT04081896|OTHER|Exercise|"Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do \>20 repetitions. If they are able to reach \>10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy."
214244015|NCT04798495|OTHER|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
214244016|NCT00596856|BEHAVIORAL|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
214244017|NCT01998815|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass surgery|
214244018|NCT00884377|DRUG|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
214244019|NCT00884377|DEVICE|ThermoMed|ThermoMed heat treatment device, one treatment
214244020|NCT01070758|DRUG|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
214244021|NCT01887340|DRUG|Carboplatin|"\- carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)"
214244022|NCT01887340|DRUG|Etoposide|100 mg/m2 D1 to D5
214244023|NCT01887340|DRUG|Cisplatin|20 mg/m2 de D1 to D5
214244024|NCT02003365|DRUG|FX006 10 mg|Extended-release formulation
214244025|NCT02003365|DRUG|FX006 40 mg|Extended-release formulation
214244026|NCT02003365|DRUG|TCA IR 40 mg|Immediate-release formulation
214244027|NCT05787288|BIOLOGICAL|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
214244028|NCT01834118|PROCEDURE|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
214244029|NCT04064788|OTHER|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
214244030|NCT04064788|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
214244031|NCT04064788|OTHER|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
214244032|NCT01533129|DRUG|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
214244033|NCT01533129|DRUG|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
214244034|NCT00572143|OTHER|ca coli follow-up by GP|patients randomized to follow up by GP
214244035|NCT06281301|OTHER|education tool|Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.
214244036|NCT06281301|OTHER|no additional information|Survey will be administered without reviewing the single sided card
214244037|NCT05275660|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
214244038|NCT05275660|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
214244039|NCT00566644|DEVICE|levonorgestrel-releasing intrauterine system|
214244040|NCT00566644|OTHER|questionnaire administration|
214244041|NCT00566644|PROCEDURE|observation|
214244042|NCT03735173|PROCEDURE|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
214244043|NCT03735173|PROCEDURE|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
214244044|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
214244045|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
214244046|NCT04985188|DIAGNOSTIC_TEST|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
214244047|NCT00321724|DRUG|cediranib maleate|Given orally
214244048|NCT00321724|OTHER|laboratory biomarker analysis|Correlative studies
214244049|NCT05969327|DRUG|Vitamin D|oral supplementation of two different doses
214244050|NCT05091203|DRUG|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
214244051|NCT03213353|DRUG|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
214244052|NCT03213353|DRUG|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
214244053|NCT01915264|DRUG|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
214244054|NCT01258270|PROCEDURE|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
214652557|NCT06196502|OTHER|Kangaroo Care|"Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total."
214244055|NCT01258270|PROCEDURE|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
214244056|NCT03406923|OTHER|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
214652558|NCT06196502|OTHER|Lactation|Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
214244057|NCT01030627|DEVICE|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
214244058|NCT00902161|DRUG|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
214244059|NCT00902161|DRUG|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
214244060|NCT00902161|DRUG|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
214244061|NCT00195871|DRUG|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
214244062|NCT00195871|PROCEDURE|hematopoietic stem cell allograft|conventional procedures
214244063|NCT02670343|DRUG|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
214244064|NCT01837771|DEVICE|Diaphragmatic stimulation|
214244065|NCT02514317|PROCEDURE|percutaneous treatment|
214244066|NCT02514317|DEVICE|Ultrasound|
214244067|NCT03858478|DRUG|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
214244068|NCT01565837|DRUG|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
214244069|NCT01565837|RADIATION|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
214244070|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
214244071|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
214244072|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
214244073|NCT02097537|DRUG|Methacholine Chloride (SK-1211)|
214244074|NCT02779712|PROCEDURE|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
214244075|NCT02779712|PROCEDURE|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
214244076|NCT04019418|DIETARY_SUPPLEMENT|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
214244077|NCT04019418|OTHER|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
214244078|NCT04019418|OTHER|Rest|30 minutes laying on a bed
214244079|NCT04019418|OTHER|Water|A drink containing 300ml of water
214244080|NCT03887403|BEHAVIORAL|Multimodal Intervention|
214244081|NCT03887403|OTHER|Usual care|
214244082|NCT00344240|BEHAVIORAL|Functional circuit training with lifestyle behavior|
214244083|NCT03593434|DRUG|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
214244084|NCT06325904|PROCEDURE|Uniportal VATS|"* single port video-assisted thoracoscopic surgery in the 5th intercostal space~* performed under general anesthesia.~* pleural fluid/pus was drained~* pleural adhesions was removed"
214244085|NCT06325904|PROCEDURE|Tube thoracostomy|"* Chest tube is inserted in 5th mid-axillary line~* performed under local anaesthesia"
214244086|NCT01452009|DRUG|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
214244087|NCT01452009|DRUG|TRAVATAN®|TRAVATAN® administered one drop once daily
214244088|NCT04620395|DIAGNOSTIC_TEST|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
214244089|NCT06243224|OTHER|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
214244090|NCT06243224|OTHER|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
214244091|NCT03387150|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
214244092|NCT03387150|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
214244093|NCT01158508|PROCEDURE|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
214244094|NCT02667327|DRUG|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
214244095|NCT02667327|OTHER|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
214244096|NCT02680899|BEHAVIORAL|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
214244097|NCT01889940|BEHAVIORAL|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
214244098|NCT04522531|OTHER|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
214244099|NCT06143553|DRUG|Paclitaxel Polymeric Micelles for Injection|Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
214244100|NCT06143553|DRUG|Eribulin Mesilate injection|Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
214244101|NCT06143553|DRUG|Capecitabine Tablets|Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
214244102|NCT06143553|DRUG|Gemcitabine Hydrochloride for Injection|Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
214244103|NCT06143553|DRUG|Vinorelbine Tartrate Injection|Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
214244104|NCT06143553|DRUG|Paclitaxel (albumin-bound)|Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
214244105|NCT06094127|DEVICE|Endovascular aortic treatment|Use of ZTA to treat diseases in the descending thoracic aorta, such as thoracic aortic aneurysm and penetrating aortic ulcer.
214244106|NCT02937272|DRUG|LY3200882|Administered orally
214244107|NCT02937272|DRUG|LY3300054|Administered intravenously
214244108|NCT02937272|DRUG|Gemcitabine|Administered intravenously
214244109|NCT02937272|DRUG|nab-Paclitaxel|Administered intravenously
214244110|NCT02937272|DRUG|Cisplatin|Administered intravenously
214244111|NCT02937272|RADIATION|Intensity Modulated Radiotherapy|
214244112|NCT02718001|DEVICE|Edwards EVOQUE Eos Mitral Valve Replacement System|Replacement of the mitral valve through a transcatheter approach
214244113|NCT05039853|BEHAVIORAL|Brief cognitive task-based intervention|Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation +/- Boosters
214244114|NCT05039853|BEHAVIORAL|Placebo activity|Listening to a pod-cast on a smart-device for approximately 15 minutes.
214244115|NCT06590324|DRUG|Apabetalone|100-mg capsule, twice daily oral administration with meals
214244116|NCT06055985|OTHER|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
214244117|NCT06055985|DRUG|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
214244118|NCT06210282|DIAGNOSTIC_TEST|Focused lung ultrasound (FLUS)|We will use a 14-zone scanning approach. Each hemithorax is divided into anterior, lateral, and posterior surfaces. The anterior and lateral surfaces on each hemithorax are divided into an upper and lower quadrant. The posterior surfaces on each hemithorax are divided into an upper, middle, and lower quadrant. Each quadrant represents a scanning zone. Each scanning zone should be assessed using FLUS. The participating general practitioners use point-of-care ultrasound on a weekly basis before trial commencement and will use the ultrasonography device already available to them.
214244119|NCT06210282|OTHER|Usual Care|Participants assigned to the control group will receive the GP's usual care of adults (≥ 18 years) presenting with symptoms of an acute LRTI where the GP suspects CAP. Usual care will be used as a pragmatic comparator to reflect the current standard examinations and care of these patients in general practices in Denmark. Usual care is recommended to follow applicable guidelines from the Danish Society of General Practitioners (DSAM) and Lægehåndbogen \[The Doctor's Handbook\].
214244120|NCT05300152|PROCEDURE|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days \& subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
214244121|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Fibronectin Antibody|"1. Deparaffinization/Rehydration~   * Slides heated in an oven at 65C for 1 hour.~  * De-paraffinization~2. Antigen Retrieval~   * Immersion of slides into staining dish containing Antigen Retrieval Solution.~  * Placing the staining dish into rice cooker.~  * When turned to warm, unplug cooker~  * Allow to cool down for 20 min~3. Staining~   * Wash slides with TBST for 5 min on a shaker.~  * Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~  * Block slides with blocking solution for 1 hour.~  * Dilute primary antibody in blocking buffer~  * Apply primary antibody to each section and incubate overnight in humidified chamber~  * Wash slides three times with TBST"
214244122|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
214244123|NCT05929079|DRUG|Retatrutide|Administered SC
214244124|NCT05929079|DRUG|Placebo|Administered SC
214244125|NCT04617795|DEVICE|Omnipod 5 Automated Insulin Delivery System|"The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers."
214244126|NCT03442764|DRUG|mavacamten|MYK-461
214244127|NCT03442764|DRUG|Placebo|Placebo
214244128|NCT02746367|OTHER|Diagnostic test (LDT)|Proteomic assay
214244129|NCT04850313|DEVICE|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
214652559|NCT05503290|BEHAVIORAL|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
214652560|NCT01634932|OTHER|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
214244130|NCT06710964|OTHER|The Ten Item Personality Inventory|"The Ten Item Personality Inventory (TIPI) is a brief self-report measure of the Big Five personality dimensions, which will provide the mock basis for the self-dehumanization induction. Participants will indicate responses on 7-point Likert scale ranging from 1 (disagree strongly) to 7 (agree strongly).~Building off previously validated tasks participants will be told that the TIPI measure provided certain information about their personalities (and therefore expectations for their future). To establish credibility, participants will receive accurate feedback surrounding their reported levels of extraversion (high, medium, low). Participants will be randomly assigned to receive one of the following pre-written, feedback scripts as additional implications about their extraversion scores in relationship to future social expectations."
214244131|NCT06710964|OTHER|Mechanistic Self-Dehumanization Condition|"Future Mechanistic Self-Dehumanization Script: Based on your responses, you're the type who will feel at times that you're just a number in the system. The day-to-day pattern of going to work and fulfilling responsibilities will seem repetitive, like you are a mechanical device just going through the motions. You might find that relationships feel distant or lack the warmth you seek, making it challenging to form deeper connections. Over time, each day will blend into the next, which will likely lead to you operating on autopilot, existing among humans."
214244132|NCT06710964|OTHER|Debrief|Debrief: Those in the self-dehumanized condition will receive a brief rehumanization intervention to undo the effects of the self-dehumanized condition. This intervention will involve a reminder that the condition was fabricated and will involve reading quotes involving general themes of humanness. The participants will then share with the experimenter how they connect to their humanness. The experimenter will document responses and encourage engagement in humanizing activities following the study visit. Findings from these qualitative responses will inform a rehumanization intervention in another study.
214244133|NCT06710964|OTHER|Control Condition|"Future Control Script: Based on your responses, you're the type who will have a very normal life. You will wake up, go to your job during the weekdays, and complete all necessary tasks. On the weekends you will spend time doing fulfilling activities. Relationships will have natural ups and down, but overall, you will feel satisfied by your connectedness to others. Though some days may feel monotonous, you will feel relaxed knowing you belong."
214244134|NCT06710964|DIAGNOSTIC_TEST|Clinical Interview|Clinical Interview. Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
214244135|NCT06710964|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
214244136|NCT06710964|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled Ethylenediaminetetraacetic Acid (EDTA) tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
214244137|NCT06324708|DIAGNOSTIC_TEST|DXA|Patients will undergo a femoral and lumbar DXA
214244138|NCT02395016|DRUG|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
214244139|NCT02395016|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
214244140|NCT02395016|OTHER|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
214244141|NCT03418623|DRUG|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
214244142|NCT03418623|OTHER|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
214244143|NCT05541068|DEVICE|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
214244144|NCT04551729|BEHAVIORAL|Lifestyle advice for liberal fluid intake|Lifestyle advice for liberal fluid intake for 3 months
214244145|NCT01547780|DRUG|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
214244146|NCT03038685|BEHAVIORAL|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
214652561|NCT01634932|OTHER|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
214652562|NCT01634932|OTHER|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
214244147|NCT02195414|DEVICE|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
214244148|NCT00738192|DRUG|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
214244149|NCT00738192|DRUG|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
214244150|NCT00738192|DRUG|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
214244151|NCT01418560|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
214244152|NCT06142526|DEVICE|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
214244153|NCT06177574|DRUG|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
214244154|NCT03137576|PROCEDURE|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
214244155|NCT03137576|PROCEDURE|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
214244156|NCT01288976|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
214244157|NCT01288976|DRUG|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
214244158|NCT01288976|PROCEDURE|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
214244159|NCT02800954|BIOLOGICAL|blood samples|
214244160|NCT02800954|BIOLOGICAL|Bone marow samples|
214244161|NCT01852357|OTHER|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
214244162|NCT01852357|OTHER|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
214244163|NCT01867073|OTHER|Biomarker|
214244164|NCT05249777|DRUG|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
214244165|NCT05249777|DRUG|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
214244166|NCT01276197|OTHER|Story-Telling DVD|DVD will contain both informational and story-telling components.
214244167|NCT01276197|OTHER|Non-Storytelling DVD|DVD will contain only informational component.
214244168|NCT01554631|DRUG|Acarbose (Glucobay ODT, BAYG5421)|
214244169|NCT01554631|DRUG|Acarbose (Glucobay, BAYG5421)|
214244170|NCT06506071|DIAGNOSTIC_TEST|Spectral CT|Myocardial tissue characterization with Spectral CT
214244171|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
214244172|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
214244173|NCT02176824|BEHAVIORAL|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
214244174|NCT02176824|BEHAVIORAL|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
214244175|NCT02176824|OTHER|Treatment as usual|
214244176|NCT00558376|DRUG|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
214244177|NCT00558376|DRUG|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
214244178|NCT01966692|DRUG|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
214244179|NCT01966692|DRUG|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
214244180|NCT01966692|DRUG|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
214244181|NCT01966692|DRUG|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation."
214244182|NCT00171678|DRUG|Diclofenac Topical Sodium Gel 1%|
214244183|NCT01742676|DRUG|ADVAGRAF|oral
214244184|NCT01742676|DRUG|PROGRAF|oral
214244185|NCT00649311|DRUG|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
214244186|NCT00649311|DRUG|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
214244187|NCT01823510|DRUG|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
214244188|NCT01823510|DRUG|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
214244189|NCT03503851|DEVICE|MitraClip implantation|Device to approximate the mitral valve leaflets
214244190|NCT00112398|PROCEDURE|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
214244191|NCT02392533|OTHER|Education|Education
214244192|NCT02607644|DEVICE|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
214244193|NCT02607644|DEVICE|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
214244194|NCT02478398|BIOLOGICAL|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
214244195|NCT02478398|BIOLOGICAL|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
214244196|NCT02478398|DRUG|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
214244197|NCT02478398|DRUG|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
214244198|NCT02478398|DRUG|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
214244199|NCT02478398|DRUG|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
214244200|NCT02478398|DRUG|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
214244201|NCT03544788|DEVICE|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
214244202|NCT02379845|DEVICE|NBTXR3|One intratumor implantation by injection
214244203|NCT02379845|DEVICE|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
214244204|NCT03230201|PROCEDURE|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
214244205|NCT06331845|DRUG|Gemcitabine|1000 mg/m2 on Days 1 and 8
214652563|NCT04490889|DIAGNOSTIC_TEST|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
214652564|NCT06318884|DRUG|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
214652565|NCT01221857|DRUG|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
214244206|NCT06331845|DRUG|Cisplatin|a total of 80-100 mg/m2 for d1-3
214244207|NCT06331845|DRUG|Paclitaxel protein-bound|260 mg/m2 on Day 1
214244208|NCT06331845|DRUG|Capecitabine|a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
214244209|NCT06331845|DRUG|Tislelizumab|200 mg on Day 1
214244210|NCT03054090|OTHER|Quality Improvement Support|Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
214244211|NCT00611871|DRUG|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
214244212|NCT00611871|DRUG|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
214244213|NCT00435500|DRUG|Fluoride varnish|
214244214|NCT03901703|OTHER|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
214244215|NCT01511666|DEVICE|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
214244216|NCT01511666|OTHER|Standard care|Standard care as per recent guidelines will be provided.
214244217|NCT01257360|DRUG|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
214244218|NCT01257360|RADIATION|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
214244219|NCT00321061|DRUG|VRC-HIVDNA016-00, VRC-HIVADV014-00|
214244220|NCT00334074|DRUG|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
214244221|NCT01348971|DIETARY_SUPPLEMENT|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
214244222|NCT01348971|OTHER|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
214244223|NCT01362595|DRUG|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
214244224|NCT01455376|DRUG|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
214244225|NCT00067912|DRUG|Duloxetine Hydrochloride|
214244226|NCT00067912|DRUG|Venlafaxine Extended Release|
214244227|NCT00959374|DEVICE|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
214244228|NCT00959374|DEVICE|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
214244229|NCT03620825|OTHER|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
214244230|NCT03620825|DRUG|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
214244231|NCT03254368|DRUG|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
214244232|NCT03254368|DRUG|Placebo|Placebo has the same excipients and appearance as ZGN-1061
214244233|NCT01357200|OTHER|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
214244234|NCT02448680|BIOLOGICAL|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
214244235|NCT06214494|OTHER|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
214244236|NCT06214494|OTHER|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
214244237|NCT05427955|PROCEDURE|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
214244238|NCT05427955|PROCEDURE|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
214244239|NCT05715879|DIAGNOSTIC_TEST|covid infection|patients with covid infection which was proved with positive test
214244240|NCT05715879|BIOLOGICAL|admission to hispital|patients with sever covid disease, who was admitted in hospital
214244241|NCT01816841|PROCEDURE|fluorescence imaging|Undergo DVFE
214244242|NCT01816841|PROCEDURE|biopsy|Undergo scalpel biopsy
214244243|NCT01816841|PROCEDURE|examination|Undergo COE
214244244|NCT01816841|PROCEDURE|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
214244245|NCT01840839|DEVICE|brain stimulation|
214244246|NCT01840839|DEVICE|Sham Stimulation|
214244247|NCT05891964|DRUG|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
214244248|NCT00355901|DRUG|Visilizumab (Nuvion®; HuM291)|
214244249|NCT00636987|DEVICE|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
214244250|NCT01251146|DRUG|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
214244251|NCT01251146|DRUG|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
214244252|NCT01196039|DRUG|MEMP1972A|Intravenous repeating dose
214244253|NCT01196039|DRUG|placebo|Intravenous repeating dose
214244254|NCT03524079|DRUG|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
214244255|NCT00859261|PROCEDURE|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
214244256|NCT00859261|PROCEDURE|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
214244257|NCT01689909|DRUG|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
214244258|NCT01689909|DRUG|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
214244259|NCT00414427|PROCEDURE|Intraarticular steroids|
214244260|NCT06519110|DRUG|Neratinib tablets|In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
214244261|NCT02876640|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214244262|NCT02876640|DRUG|Retinoid 9cUAB30|Given PO
214244263|NCT02876640|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection surgery
214244264|NCT03722043|BEHAVIORAL|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
214244265|NCT01146210|OTHER|laboratory biomarker analysis|Correlative studies
214244266|NCT01810965|PROCEDURE|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
214244267|NCT01563146|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
214244268|NCT01630785|DEVICE|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
214244269|NCT02179775|DRUG|propranolol|
214244270|NCT02179775|DRUG|Quince's oxymel|
214244271|NCT02179775|DRUG|placebo|
214244272|NCT01643603|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
214244273|NCT01643603|OTHER|laboratory biomarker analysis|Correlative studies
214244274|NCT03238846|OTHER|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
214244275|NCT03238846|OTHER|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
214244276|NCT05196399|DRUG|Aprocitentan (Formulation A)|A single oral dose of 25 mg.
214244277|NCT05196399|DRUG|Aprocitentan (Formulation B)|A single oral dose of 25 mg.
214244278|NCT04969003|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
214244279|NCT05992571|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
214244280|NCT05992571|DIETARY_SUPPLEMENT|β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
214244281|NCT02990156|DEVICE|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
214244282|NCT02990156|DEVICE|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
214244283|NCT02609698|DEVICE|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
214244284|NCT02609698|DRUG|3 months DAPT|
214244285|NCT02609698|DRUG|6 months DAPT|
214244286|NCT00132561|DRUG|Sulfadoxine/pyrimethamine and artesunate|
214244287|NCT04132882|DRUG|Sodium Thiosulfate (STS)|
214244288|NCT03486717|DEVICE|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
214244289|NCT04534465|DRUG|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
214244290|NCT04534465|DRUG|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
214244291|NCT03589014|DRUG|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
214244292|NCT05368272|OTHER|Processed electroencephalography|Acquisition of raw EEG data from processed EEG monitor. Analysis of data acquired for prespecified bandwidth properties
214244293|NCT05368272|OTHER|Postoperative delirium assessment|Twice daily assessment for the incidence of postoperative delirium using validated tool (questionnaire)
214244294|NCT04387760|DRUG|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
214244295|NCT04387760|DRUG|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
214244296|NCT04387760|OTHER|Routine care for COVID-19 patients|Supportive care according to local guidelines
214244297|NCT02457273|DRUG|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
214244298|NCT00737464|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
214244299|NCT04520893|PROCEDURE|ventilator setting vcv with pause|ventilator setting vcv with pause
214244300|NCT04520893|PROCEDURE|ventilator setting vcv|ventilator setting vcv without pause
214244301|NCT04520893|PROCEDURE|ventilator setting pcv-vg|ventilator setting with pcv-vg
214244302|NCT01487473|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
214244303|NCT03022227|OTHER|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
214244304|NCT04054063|DRUG|HSK3486+ etomidate|
214244305|NCT03261180|OTHER|Best Practice|Receive regular diet
214244306|NCT03261180|OTHER|Laboratory Biomarker Analysis|Correlative studies
214244307|NCT03261180|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive Nestle Impact AR
214244308|NCT02090868|OTHER|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
214244309|NCT02834377|OTHER|Treatment algorithm targeting individual cardiac output|
214244310|NCT04505397|DRUG|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
214652566|NCT04430907|BIOLOGICAL|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
214244311|NCT04505397|DRUG|Placebo|Sugar pill manufactured to mimic SKL24741
214244312|NCT00872027|DRUG|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
214244313|NCT00872027|DRUG|Placebo|Placebo pills for 8 weeks
214244314|NCT00244166|DRUG|prednisolone|
214652567|NCT01577862|DRUG|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
214244315|NCT06259201|DEVICE|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
214244316|NCT04733378|PROCEDURE|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
214244317|NCT03079180|OTHER|Strength training at 80% 1RM|Detailed in Arms section's
214244318|NCT03079180|OTHER|Strength training at 55% 1RM|Detailed in Arms section's
214244319|NCT06275490|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
214244320|NCT06275490|BIOLOGICAL|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
214244321|NCT01695200|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
214244322|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
214652568|NCT01577862|DRUG|Rifampicin|600 mg every 12 hours intravenously
214244323|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
214244324|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
214244325|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
214244326|NCT03220438|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
214244327|NCT01554696|DRUG|peficitinib|oral
214244328|NCT01554696|DRUG|Placebo|oral
214244329|NCT01554696|DRUG|methotrexate|oral
214244330|NCT05372536|OTHER|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
214244331|NCT06481176|BEHAVIORAL|12-Week RLS Exercise Program|"Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week"
214244332|NCT05676593|DEVICE|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
214244333|NCT05676593|OTHER|Therapeutic education|Therapeutic education
214244334|NCT04618887|PROCEDURE|pallidotomy|deep brain nuclei lesion of GPi
214244335|NCT04618887|PROCEDURE|deep brain stimulation|deep brain stimulation of GPi
214244336|NCT00634270|DRUG|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
214244337|NCT05476484|DRUG|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
214244338|NCT04999774|DIAGNOSTIC_TEST|Different diagnostic tests|Each SAC will be tested with all tests
214244339|NCT05338398|DEVICE|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
214244340|NCT05338398|DRUG|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
214244341|NCT00416897|DRUG|chemotherapy|
214244342|NCT00416897|DRUG|dexamethasone|
214244343|NCT00416897|PROCEDURE|plasmapheresis|
214244344|NCT04676555|DRUG|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214244345|NCT04676555|DRUG|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214244346|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
214244347|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
214244348|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
214244349|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
214244350|NCT01566760|DRUG|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
214244351|NCT00095927|DRUG|Amifostine|Given subcutaneously
214244352|NCT00095927|DRUG|Carboplatin|Given IV
214244353|NCT00095927|DRUG|Paclitaxel|Given IV
214652569|NCT05011487|DRUG|Osimertinib|80mg/qd oral for 60 days
214244354|NCT00095927|RADIATION|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
214244355|NCT06356701|DIETARY_SUPPLEMENT|Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)|"Medication for Research :~* Spirulina Bifidobacterium Capsules~* Fish Oil Grape Seed Blueberry Soft Capsules;~* Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin)~  * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin)~ * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion"
214244356|NCT06119022|PROCEDURE|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
214244357|NCT06119022|OTHER|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
214244358|NCT02103543|OTHER|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
214244359|NCT02103543|PROCEDURE|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
214244360|NCT02103543|DRUG|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
214244361|NCT03583242|DRUG|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
214244362|NCT03583242|DRUG|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
214652570|NCT05011487|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
214244363|NCT01633437|DRUG|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
214244364|NCT01633437|OTHER|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
214244365|NCT03477929|DRUG|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
214244366|NCT03477929|DRUG|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
214244367|NCT02022774|DRUG|Fimasartan|Fimasartan 60 \~ 120 mg/po take one tablet once a day
214244368|NCT01360775|BEHAVIORAL|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
214244369|NCT00458497|DEVICE|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
214244370|NCT00458497|DEVICE|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
214244371|NCT05204875|RADIATION|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
214244372|NCT03588247|PROCEDURE|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
214244373|NCT00521911|BEHAVIORAL|Cognitive Behavioural Therapy|
214244374|NCT00407290|DRUG|neostigmine|
214244375|NCT01275547|DRUG|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
214652571|NCT05011487|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
214652572|NCT02563301|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
214652573|NCT00006430|BIOLOGICAL|Autologous dendritic cells transfected with amplified tumor RNA|
214652574|NCT05266404|DRUG|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
214652575|NCT05266404|DRUG|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
214652576|NCT05266404|DRUG|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
214652577|NCT02507349|BEHAVIORAL|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
214652578|NCT02507349|BEHAVIORAL|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
214652579|NCT06016816|PROCEDURE|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
214652580|NCT06016816|PROCEDURE|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
214652581|NCT00135057|DRUG|insulin glulisine|
214652582|NCT00135057|DRUG|insulin glargine|
214652583|NCT00357773|DRUG|Azithromycin (T1225)|
214244376|NCT01275547|DRUG|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
214244377|NCT06136988|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
214244378|NCT06136988|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
214244379|NCT06136988|DRUG|Cisplatin for injection|Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
214244380|NCT06136988|DRUG|Paclitaxel|Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
214244381|NCT06136988|RADIATION|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
214244382|NCT01634178|DRUG|Apremilast|Tablet for oral administration
214244383|NCT01759888|DRUG|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
214244384|NCT01358071|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
214652584|NCT00888238|DRUG|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
214652585|NCT00888238|DRUG|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
214652586|NCT05673538|DRUG|TT-00973-MS tablets treatment|The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
214652587|NCT03184844|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
214244385|NCT01358071|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
214244386|NCT01358071|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
214244387|NCT04016584|BEHAVIORAL|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
214244388|NCT02757950|BIOLOGICAL|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
214244389|NCT03398278|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
214244390|NCT03398278|DRUG|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
214244391|NCT02625883|OTHER|Interview|Interview by validated Quality-of-life-questionnaire
214244392|NCT06325475|PROCEDURE|labor with neuraxial labor analgesia|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
214244393|NCT06325475|PROCEDURE|labour without noroaxial labor analgesia|"Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen."
214244394|NCT01527266|DIETARY_SUPPLEMENT|Carbohydrate drink|sucrose beverage
214244395|NCT01527266|DIETARY_SUPPLEMENT|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
214244396|NCT00494845|BEHAVIORAL|Mindfulness|8-week mindfulness program will be compared to an education control group.
214244397|NCT00494845|BEHAVIORAL|Control: Health Education Class|8-week education program
214244398|NCT03191578|DRUG|RUTI®|Administration of RUTI®
214244399|NCT03191578|DRUG|Placebo|Administration of placebo
214244400|NCT00307879|DRUG|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
214244401|NCT00307879|PROCEDURE|collection of mobilized peripheral blood stem cells|
214244402|NCT00307879|PROCEDURE|Intracoronary infusion of mobilized cells|
214244403|NCT00124397|DRUG|Atorvastatin|
214244404|NCT05894122|DIAGNOSTIC_TEST|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
214652588|NCT04972877|OTHER|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
214244405|NCT04052724|BEHAVIORAL|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
214244406|NCT03053765|OTHER|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
214244407|NCT05629104|OTHER|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
214244408|NCT03318718|DRUG|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
214244409|NCT03318718|DIAGNOSTIC_TEST|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
214244410|NCT03318718|DIAGNOSTIC_TEST|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
214244411|NCT01778179|DRUG|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~\- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
214244412|NCT01778179|PROCEDURE|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
214244413|NCT04801316|BEHAVIORAL|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
214244414|NCT04801316|BEHAVIORAL|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
214244415|NCT05143359|DIAGNOSTIC_TEST|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
214244416|NCT05143359|DIAGNOSTIC_TEST|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
214244417|NCT00745225|DRUG|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
214244418|NCT00745225|DRUG|placebo comparator|1 capsule daily, 96 weeks.
214244419|NCT03013127|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
214244420|NCT05610085|DRUG|Levetiracetam Injection|Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
214244421|NCT05610085|DRUG|Phenobarbital Sodium Injection|Standard of care for neonatal seizures
214244422|NCT04049227|DRUG|Abemaciclib|Given PO
214244423|NCT04049227|DRUG|Letrozole|Given PO
214244424|NCT04049227|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
214244425|NCT06231836|DEVICE|High flow nasal cannula (HFNO)|O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
214244426|NCT06231836|DEVICE|nasal cannula|O2 is administered by nasal cannula at 6L/min
214244427|NCT06424665|DRUG|FZ-AD005|Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
214244428|NCT03657303|DEVICE|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
214244429|NCT02299778|DIETARY_SUPPLEMENT|13C6-p-aminobenzoic acid|
214244430|NCT00991952|DRUG|alvocidib|Given IV
214244431|NCT00991952|DRUG|irinotecan hydrochloride|Given IV
214244432|NCT00991952|OTHER|laboratory biomarker analysis|Correlative studies
214244433|NCT00034749|DRUG|Risperidone|
214244434|NCT01993251|DRUG|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
214244435|NCT01993251|DRUG|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
214244436|NCT01993251|DRUG|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
214244437|NCT01993251|DRUG|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
214244438|NCT06290973|PROCEDURE|surgery of varicose veins|including ablation with radiofrequency, phlebectomy and saphenectomy.
214244439|NCT01704898|DRUG|Efavirenz 600 Test-Stocrin 600 Reference|
214244440|NCT01704898|DRUG|Stocrin 600 Reference-Efavirenz 600 Test|
214244441|NCT06331676|PROCEDURE|Tissue collection|Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
214244442|NCT06331676|OTHER|Data collection|Questionnaire on menstrual health and history of hormone treatments for the research purpose
214652589|NCT04972877|OTHER|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
214244443|NCT05502640|OTHER|Education model|Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
214244444|NCT05502640|OTHER|Routine Education model|In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
214244445|NCT00021671|DRUG|Erythromycin|
214244446|NCT00021671|DRUG|Nevirapine|
214244447|NCT00021671|DRUG|Ampicillin sodium|
214244448|NCT00021671|DRUG|Metronidazole|
214244449|NCT02240147|BEHAVIORAL|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
214244450|NCT05920902|OTHER|routine therapy of acute ischemia stroke|Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
214244451|NCT01740843|DEVICE|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
214244452|NCT02288143|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm."
214244453|NCT02616471|DIETARY_SUPPLEMENT|High-fat cheese|
214244454|NCT02616471|DIETARY_SUPPLEMENT|Low-fat cheese|
214244455|NCT02616471|DIETARY_SUPPLEMENT|No-cheese/carbohydrate|
214244456|NCT05245396|DRUG|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
214244457|NCT05245396|DRUG|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
214244458|NCT05245396|DRUG|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
214244459|NCT05245396|DRUG|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
214244460|NCT05245396|DRUG|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
214244461|NCT05245396|DRUG|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
214244462|NCT05245396|DRUG|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
214244463|NCT05245396|DRUG|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
214244464|NCT05245396|DRUG|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
214244465|NCT05245396|DRUG|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
214244466|NCT02224118|DRUG|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
214244467|NCT02224118|DRUG|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
214244468|NCT02224118|DRUG|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
214244469|NCT02224118|DRUG|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
214244470|NCT02224118|DRUG|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
214244471|NCT00964080|DRUG|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
214244472|NCT03742440|BIOLOGICAL|GrafixPL PRIME|GrafixPL PRIME
214244473|NCT02483533|DRUG|LIPO-202|
214244474|NCT02483533|DRUG|Placebo|
214244475|NCT00597337|BEHAVIORAL|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
214244476|NCT01168960|BEHAVIORAL|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
214244477|NCT05479773|DEVICE|Standard NIV mask|The hospital standered NIV mask
214244478|NCT05479773|DEVICE|Lumena NIV mask|aerosol-reducing mask
214244479|NCT02416310|DEVICE|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
214652590|NCT03023904|BIOLOGICAL|Nivolumab|Given IV
214244480|NCT03111069|PROCEDURE|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
214244481|NCT03111069|DRUG|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
214244482|NCT03111069|RADIATION|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
214244483|NCT03452527|BIOLOGICAL|ICON-1|ICON-1 0.6 mg by intravitreal injection
214244484|NCT03452527|BIOLOGICAL|aflibercept|aflibercept 2 mg by intravitreal injection
214244485|NCT00582816|DEVICE|Clinimacs Cell Separation System|Depletion of T-cells
214244486|NCT00582816|DRUG|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
214244487|NCT00582816|OTHER|DLI|NK Cell selected DLI
214244488|NCT00350454|DEVICE|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
214244489|NCT00350454|DEVICE|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
214244490|NCT00350454|DEVICE|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
214244491|NCT02684487|DRUG|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
214244492|NCT02684487|DRUG|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
214244493|NCT04756180|DRUG|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
214244494|NCT05084729|DEVICE|Imagio OA/US|Imagio optoacoustic
214244495|NCT03255330|DRUG|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
214244496|NCT03255330|DRUG|Metamizol|Standardized treatment
214244497|NCT03255330|DRUG|Tramadol|Standardized treatment
214244498|NCT00055224|DEVICE|Threat of shock|During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
214244499|NCT01782001|DIETARY_SUPPLEMENT|vitamin A|vitamin A with placebo
214244500|NCT01782001|DIETARY_SUPPLEMENT|vitamin A and zinc|combination of vitamin A and zinc supplements
214244501|NCT04281953|DIAGNOSTIC_TEST|High frequency audiometry|Simple hearing test
214244502|NCT04281953|OTHER|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
214244503|NCT04281953|OTHER|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
214244504|NCT04281953|OTHER|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
214244505|NCT00002681|BIOLOGICAL|aldesleukin|
214244506|NCT00002681|BIOLOGICAL|daclizumab|
214652591|NCT03023904|OTHER|Laboratory Biomarker Analysis|Correlative studies
214244507|NCT04200040|BIOLOGICAL|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
214244508|NCT04200040|DRUG|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
214244509|NCT03282331|PROCEDURE|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
214244510|NCT03282331|PROCEDURE|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
214244511|NCT03282331|PROCEDURE|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
214244512|NCT05023824|DRUG|alpha-blocker or 5-ARI withdrawal|Withdrawal of either alpha-blocker or 5-ARI
214244513|NCT05023824|DRUG|Maintenance of alpha-blocker and 5-ARI|Maintenance of alpha-blocker and 5-ARI
214244514|NCT01686802|DRUG|oral morphine|
214244515|NCT01686802|DRUG|Ibuprofen|
214244516|NCT01537107|DRUG|vismodegib|Given PO
214244517|NCT01537107|DRUG|sirolimus|Given PO
214244518|NCT01537107|PROCEDURE|positron emission tomography|Correlative studies
214244519|NCT01537107|PROCEDURE|computed tomography|Correlative studies
214244520|NCT01537107|OTHER|pharmacological study|Correlative studies
214244521|NCT01537107|OTHER|laboratory biomarker analysis|Correlative studies
214244522|NCT01537107|RADIATION|fludeoxyglucose F 18|Correlative studies
214244523|NCT02067052|PROCEDURE|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
214244524|NCT02067052|PROCEDURE|Surgery|Vulvectomy \& lymphadenectomy
214244525|NCT02853227|OTHER|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
214244526|NCT02585128|OTHER|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
214244527|NCT02585128|OTHER|MMSE (Mini Mental State Examination)|
214244528|NCT02585128|OTHER|Barthel index|
214244529|NCT02585128|OTHER|HADS (Hospital Anxiety and Depression Scale)|
214244530|NCT02585128|OTHER|MNA-SF (Mini Nutritional Assessment - Short Form)|
214244531|NCT02585128|DEVICE|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
214244532|NCT02585128|OTHER|CIRS (Cumulative Illness Rating Scale)|
214244533|NCT01677312|PROCEDURE|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
214244534|NCT01677312|PROCEDURE|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
214244535|NCT05678049|DIAGNOSTIC_TEST|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
214244536|NCT04746872|DIAGNOSTIC_TEST|Alinity m HR HPV|A qualitative in vitro test that amplifies and detects HR HPV DNA in cervical tissue samples.
214244537|NCT02873403|DEVICE|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
214244538|NCT02873403|DEVICE|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
214244539|NCT02301611|DRUG|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
214244540|NCT02301611|DRUG|Placebo|
214244541|NCT03923985|DIETARY_SUPPLEMENT|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
214244542|NCT05373771|OTHER|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
214244543|NCT04291001|DEVICE|ENG implant|This is an FDA-approved contraceptive device
214244544|NCT04291001|DRUG|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
214244545|NCT06497036|DRUG|GP404141|subcutaneous injection
214244546|NCT06497036|DRUG|Nplate|subcutaneous injection
214244547|NCT00876798|DRUG|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
214244548|NCT00876798|DRUG|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
214244549|NCT00174291|DRUG|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
214244550|NCT02970201|OTHER|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
214244551|NCT02313454|DEVICE|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
214652592|NCT00733525|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
214652593|NCT00733525|DRUG|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
214652594|NCT00733525|BEHAVIORAL|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
214652595|NCT00061256|DRUG|Alendronate|
214244552|NCT04044027|BEHAVIORAL|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
214244553|NCT01417182|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
214244554|NCT00412490|BEHAVIORAL|Questionnaire|Written survey at 1 Month \& 6 Months post surgery.
214244555|NCT00412490|BEHAVIORAL|Interview|One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
214244556|NCT02744937|DRUG|Aspirin|aspirin is continued by its regular dosing
214244557|NCT00260078|DRUG|Atazanavir|200 mg to 400 mg orally daily
214244558|NCT00260078|DRUG|Darunavir|300 mg or 600 mg orally twice daily
214244559|NCT00260078|DRUG|Efavirenz|Dosage dependent on participant
214244560|NCT00260078|DRUG|Nevirapine|Dosage dependent on participant
214244561|NCT00260078|DRUG|Ritonavir|50 mg or 100 mg orally twice daily
214244562|NCT00260078|DRUG|Tenofovir disoproxil fumarate|300 mg orally daily
214244563|NCT00260078|PROCEDURE|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
214244564|NCT03116347|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
214244565|NCT03116347|BIOLOGICAL|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
214244566|NCT03116347|BIOLOGICAL|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
214244567|NCT04738929|OTHER|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
214244568|NCT06222359|DEVICE|COMPASS|Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
214244569|NCT04679545|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
214244570|NCT04679545|DRUG|Placebo|An inactive compound.
214244571|NCT03170232|DRUG|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
214244572|NCT03170232|DRUG|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
214244573|NCT03170232|DEVICE|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
214244574|NCT03170232|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
214244575|NCT02355600|OTHER|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
214244576|NCT02931266|DEVICE|PASS MIS®|Posterior mini-invasive osteosynthesis
214244577|NCT02730897|PROCEDURE|Central/Peripheral|Central versus peripheral location of the primary tumor
214244578|NCT06028100|PROCEDURE|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
214244579|NCT03498001|DRUG|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
214244580|NCT03498001|PROCEDURE|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
214244581|NCT03498001|OTHER|Follow up by phone|at 2 and 4 mois
214244582|NCT00586326|DEVICE|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
214244583|NCT02656212|DRUG|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
214244584|NCT02656212|DRUG|Placebo|Placebo pill, taken orally, one pill/day in the morning
214244585|NCT03889171|BEHAVIORAL|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
214244586|NCT02968589|BEHAVIORAL|Training|
214244587|NCT01546064|DEVICE|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
214244588|NCT01546064|DEVICE|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
214244589|NCT06111391|DEVICE|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
214244590|NCT01439347|DRUG|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
214244591|NCT01439347|DRUG|Vincristine Sulfate Injection (VSI)|1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
214244592|NCT02054871|PROCEDURE|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
214244593|NCT00284076|DRUG|L-arginine|
214244594|NCT04161300|OTHER|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
214244595|NCT04161300|OTHER|Control Group (CG)|The CG did not receive any intervention.
214244596|NCT04161300|OTHER|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
214244597|NCT02972762|DRUG|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
214244598|NCT00739492|BEHAVIORAL|financial incentives|financial incentives based on attaining weight loss goals
214244599|NCT01525121|OTHER|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
214244600|NCT00882700|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
214244601|NCT00882700|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
214244602|NCT03494777|BEHAVIORAL|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.
214244603|NCT03494777|BEHAVIORAL|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
214244604|NCT03494777|BEHAVIORAL|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.
214244605|NCT03494777|BEHAVIORAL|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
214244606|NCT03494777|BEHAVIORAL|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
214244607|NCT05337930|DEVICE|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
214244608|NCT05854927|DIAGNOSTIC_TEST|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
214244609|NCT02879240|OTHER|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
214244610|NCT02879240|OTHER|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
214244611|NCT03931668|DRUG|TPN-672|single dose of TPN-672 maleate tablet
214244612|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
214244613|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
214244614|NCT06556966|DRUG|LY03020|LY03020 for one single dose
214244615|NCT06556966|DRUG|Placebo|Placebo for one single dose
214244616|NCT04885439|BEHAVIORAL|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
214244617|NCT01016899|RADIATION|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
214244618|NCT01108276|DEVICE|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
214244619|NCT00902395|DRUG|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
214244620|NCT00902395|BEHAVIORAL|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
214244621|NCT00902395|DRUG|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
214244622|NCT03265392|OTHER|Bread|Serving of wheat bread providing 50 g of carbohydrates
214244623|NCT03265392|OTHER|Water|250 mL of water
214244624|NCT03265392|OTHER|Lemon juice|250 mL of lemon juice
214244625|NCT03265392|OTHER|Tea|250 mL of tea
214244626|NCT03265392|OTHER|Peas|20 peas
214244627|NCT01563822|BIOLOGICAL|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
214244628|NCT03929718|DRUG|Spironolactone|receive spironolactone treatment after CTI ablation
214244629|NCT03929718|DRUG|No Spironolactone|no spironolactone treatment
214244630|NCT04605263|DEVICE|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
214244631|NCT04605263|PROCEDURE|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
214244632|NCT03425227|OTHER|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
214244633|NCT05361031|BIOLOGICAL|Engensis (VM202)|Intramuscular injections
214244634|NCT04068896|BIOLOGICAL|NGM120 30mg|NGM120 30mg Subcutaneous Injection
214244635|NCT04068896|BIOLOGICAL|NGM120 100mg|NGM120 100mg Subcutaneous Injection
214244636|NCT04068896|BIOLOGICAL|NGM120 30mg with Gemcitabine and Abraxane|NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
214244637|NCT04068896|BIOLOGICAL|NGM120 100mg with Gemcitabine and Abraxane|NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
214244638|NCT04068896|BIOLOGICAL|NGM120 100mg Q3W|NGM120 100mg Subcutaneous Injection every 3 weeks
214244639|NCT04068896|OTHER|Placebo|Placebo
214244640|NCT06371508|BEHAVIORAL|Education based on breast cancer and breast examination|Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
214244641|NCT01461161|DRUG|bardoxolone methyl|oral, single dose
214244642|NCT01655186|DRUG|Bardoxolone Methyl|
214244643|NCT01655186|DRUG|Placebo|
214244644|NCT04034953|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
214244645|NCT04034953|DIAGNOSTIC_TEST|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
214244646|NCT04034953|DIAGNOSTIC_TEST|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
214244647|NCT05504772|GENETIC|Whole Genome Sequencing|Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
214244648|NCT05504772|GENETIC|RNA seq|Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
214244649|NCT05504772|GENETIC|DNA Methylation|Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
214244650|NCT05504772|GENETIC|Targeted Panel Sequencing|"Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type"
214244651|NCT05504772|GENETIC|High Throughput Sequencing (in vitro)|High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
214244652|NCT05504772|GENETIC|Patient Derived Xenograft (PDX)(in vivo)|In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
214244653|NCT05504772|OTHER|Liquid Biopsy|Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
214244654|NCT01101191|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
214244655|NCT01101191|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
214244656|NCT04926454|DRUG|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
214244657|NCT01891045|BEHAVIORAL|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
214244658|NCT01891045|BEHAVIORAL|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
214244659|NCT02009384|DRUG|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
214244660|NCT02530047|GENETIC|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."
214244661|NCT02530047|BEHAVIORAL|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
214244662|NCT03442400|DEVICE|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
214244663|NCT00718237|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
214244664|NCT00718237|BIOLOGICAL|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
214244665|NCT06165770|PROCEDURE|laparoscopy|Conservative or surgery treatment for cornual pregnancies
214244666|NCT03538574|BEHAVIORAL|CBT-I|CBT-I is a behavioral treatment for insomnia
214244667|NCT03538574|BEHAVIORAL|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
214652596|NCT00061256|DRUG|Calcium carbonate|
214652597|NCT00061256|DRUG|Vitamin D|
214244668|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
214244669|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
214244670|NCT05942209|DIAGNOSTIC_TEST|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
214244671|NCT05384977|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
214244672|NCT02694718|DRUG|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
214244673|NCT02694718|DRUG|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
214244674|NCT02925793|DRUG|DS107|
214244675|NCT02925793|OTHER|Vehicle cream|
214244676|NCT00879879|DRUG|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
214244677|NCT02581839|DRUG|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
214244678|NCT02581839|DEVICE|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
214244679|NCT02581839|DRUG|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
214244680|NCT02581839|DRUG|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
214244681|NCT00868179|DRUG|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
214244682|NCT03824509|OTHER|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
214244683|NCT00667446|DRUG|Leuprolide Acetate 3 Month Depot|
214244684|NCT03889483|DEVICE|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
214244685|NCT05428982|PROCEDURE|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
214244686|NCT02655146|DRUG|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
214244687|NCT02655146|DRUG|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
214244688|NCT02655146|DRUG|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
214244689|NCT02655146|DRUG|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
214244690|NCT04647487|DRUG|LY3484356|Administered orally.
214244691|NCT00746408|OTHER|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
214244692|NCT03505931|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
214244693|NCT03277833|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
214244694|NCT03277833|DIETARY_SUPPLEMENT|Placebo|Placebo, parallel design
214244695|NCT02951676|PROCEDURE|Extraction|Extraction of impacted third molar teeth
214244696|NCT00101829|DRUG|Rituximab|1000 mg intravenous infusion
214244697|NCT04365062|DEVICE|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
214244698|NCT04365062|DEVICE|Excimer laser and plain balloon|Excimer laser and plain balloon
214244699|NCT04365062|DEVICE|plain balloon and drug coated balloon|plain balloon and drug coated balloon
214652598|NCT05784207|OTHER|Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern|The aim is to evaluate the performance of AI with the performance of doctors
214652599|NCT00850252|DEVICE|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
214652600|NCT01748799|DRUG|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
214652601|NCT01748799|DRUG|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
214244700|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
214244701|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
214244702|NCT01343901|DRUG|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
214244703|NCT06194019|DEVICE|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
214244704|NCT05523687|DRUG|[14C]-PC14586|Single, oral dose of \[14C\]-PC14586
214244705|NCT04604847|DIAGNOSTIC_TEST|blood test|blood test to explore BDNF level
214244706|NCT01412918|DEVICE|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
214244707|NCT05249335|DRUG|OST|The subject will receive Orafang for colonoscopy
214244708|NCT05249335|DRUG|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
214244709|NCT02837081|OTHER|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
214244710|NCT02837081|OTHER|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
214244711|NCT02251522|DEVICE|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
214244712|NCT02251522|DEVICE|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
214244713|NCT05982067|OTHER|mindfulness-based phsycial exercise intervention|The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.
214244714|NCT05982067|OTHER|health education|The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
214244715|NCT01897376|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
214244716|NCT01897376|PROCEDURE|vertical skin incision|vertical skin incision at time of cesarean section
214244717|NCT02551952|DEVICE|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
214652602|NCT03482869|DIAGNOSTIC_TEST|walking ability|Included patients will perform a 6 min walk test
214652603|NCT05066685|OTHER|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
214244718|NCT03219463|DIETARY_SUPPLEMENT|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
214244719|NCT03839927|OTHER|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
214244720|NCT05089071|DEVICE|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
214244721|NCT05776602|DIAGNOSTIC_TEST|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
214244722|NCT03924466|DRUG|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
214652604|NCT00516919|DRUG|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
214652605|NCT00516919|BEHAVIORAL|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
214652606|NCT03371355|DRUG|Placebo|Placebo (Matched with ISIS 703802)
214652607|NCT03371355|DRUG|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
214652608|NCT03371355|DRUG|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
214652609|NCT03371355|DRUG|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
214652610|NCT01997151|BEHAVIORAL|Healthy Pregnancy: Step by Step|
214652611|NCT05086679|DEVICE|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
214244723|NCT05106790|BEHAVIORAL|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
214244724|NCT05106790|BEHAVIORAL|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
214244725|NCT05106790|BEHAVIORAL|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
214244726|NCT06400927|OTHER|HF-guided VA|VA guided recommendation
214244727|NCT06400927|OTHER|Standard-of-care|Standard-of-care
214244728|NCT06387433|BEHAVIORAL|mobile app use|The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
214244729|NCT03763227|DRUG|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
214244730|NCT03763227|DRUG|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
214244731|NCT01203176|PROCEDURE|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
214244732|NCT00706069|DRUG|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
214244733|NCT00706069|DRUG|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
214244734|NCT05475782|PROCEDURE|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
214244735|NCT05475782|PROCEDURE|ESWL|ESWL+ERCP
214244736|NCT02793843|DRUG|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
214244737|NCT02793843|DRUG|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
214244738|NCT02793843|OTHER|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
214244739|NCT02547883|DRUG|Cessation of statin|The intervention evaluated is the cessation of statin
214244740|NCT01030367|DRUG|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
214244741|NCT02070471|DRUG|Placebo|Placebo
214244742|NCT02070471|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
214244743|NCT02070471|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
214244744|NCT02070471|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
214244745|NCT00769483|DRUG|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
214244746|NCT00769483|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
214244747|NCT00769483|DRUG|Erlotinib|100 mg by mouth daily.
214244748|NCT03455764|DRUG|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
214244749|NCT03455764|DRUG|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
214244750|NCT03455764|DRUG|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
214244751|NCT01212133|DRUG|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
214244752|NCT03699384|DRUG|Azacitidine|AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
214244753|NCT03699384|DRUG|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
214244754|NCT02528266|DEVICE|Nerve Capping Device|
214244755|NCT05649202|OTHER|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
214244756|NCT05649202|OTHER|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
214244757|NCT04204785|BEHAVIORAL|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
214244758|NCT00209651|DRUG|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
214244759|NCT00209651|DRUG|TS-1|80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
214244760|NCT03302520|DEVICE|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
214244761|NCT03302520|DEVICE|PEEK cage|PEEK cage
214244762|NCT02707159|DRUG|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
214244763|NCT05265377|DEVICE|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
214244764|NCT04798807|DIAGNOSTIC_TEST|Nutritional screening|
214244765|NCT05997472|DIAGNOSTIC_TEST|evaluation af mobility and balance|evaluation af mobility and balance Timed Up and Go Test Berg Balance Scale
214244766|NCT00000523|BEHAVIORAL|exercise|
214244767|NCT04426903|OTHER|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
214244768|NCT04426903|OTHER|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
214244769|NCT02602977|OTHER|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
214244770|NCT02602977|OTHER|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
214244771|NCT02602977|BIOLOGICAL|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
214244772|NCT05080660|DRUG|LY3526318|Administered orally.
214244773|NCT05080660|DRUG|Placebo|Administered orally.
214244774|NCT00002065|DRUG|Disulfiram|
214244775|NCT02148146|DRUG|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
214244776|NCT06003569|BEHAVIORAL|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
214244777|NCT06003569|BEHAVIORAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
214244778|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
214244779|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
214244780|NCT04533685|BEHAVIORAL|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
214244781|NCT04533685|BEHAVIORAL|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
214244782|NCT01608854|OTHER|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
214244783|NCT04221230|DRUG|NMRA-335140|Active Drug
214244784|NCT04221230|DRUG|Placebo|Placebo
214244785|NCT06243627|OTHER|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
214244786|NCT06243627|OTHER|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
214244787|NCT06243627|OTHER|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
214652612|NCT05086679|DEVICE|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
214652613|NCT05086679|BEHAVIORAL|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
214652614|NCT02633540|RADIATION|IMRT Radiation|Radiation to Larynx
214244788|NCT06243627|OTHER|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
214244789|NCT00371007|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
214244790|NCT00371007|DRUG|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
214244791|NCT02774733|DEVICE|spirometer;Intraocular pressure;Color doppler imaging|
214244792|NCT03615508|DRUG|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
214244793|NCT04841226|DEVICE|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
214244794|NCT02750215|DRUG|Capmatinib (INC280)|treatment with Capmatinib (INC280)
214244795|NCT04599179|DEVICE|self-expandable metal stent|self-expandable metal stent endoscopic positioning
214244796|NCT02022176|OTHER|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
214244797|NCT02022176|OTHER|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
214244798|NCT02022176|OTHER|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
214244799|NCT02192840|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
214244800|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
214244801|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
214244802|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
214244803|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
214244804|NCT01307020|DRUG|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
214244805|NCT01307020|DRUG|Placebo|Placebo, oral film-coated table, once
214244806|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
214244807|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
214244808|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
214244809|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
214244810|NCT01871064|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
214244811|NCT02021656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
214244812|NCT04898621|DIETARY_SUPPLEMENT|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
214244813|NCT04898621|DIETARY_SUPPLEMENT|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
214244814|NCT05772988|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine
214244815|NCT05772988|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
214244816|NCT04325555|DRUG|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
214244817|NCT05026190|DIAGNOSTIC_TEST|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
214244818|NCT05669248|DIAGNOSTIC_TEST|mid covid-19 patients|Collect the patient's whole blood for testing
214244819|NCT01574833|DEVICE|pulsed electromagnetic field|PEMF treatment
214244820|NCT01574833|DEVICE|sham|sham treatment
214244821|NCT00019110|BIOLOGICAL|human papillomavirus 16 E7 peptide|
214244822|NCT00019110|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
214244823|NCT02421003|PROCEDURE|heart surgery|
214244824|NCT02300727|DRUG|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
214244825|NCT02300727|DRUG|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
214244826|NCT02300727|DRUG|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
214244827|NCT01952470|DRUG|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
214244828|NCT01952470|DRUG|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
214244829|NCT02392832|BIOLOGICAL|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
214244830|NCT05740995|DRUG|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
214244831|NCT00207571|BEHAVIORAL|Computer|
214244832|NCT03562871|BIOLOGICAL|IO102|test immunotherapy
214244833|NCT03562871|BIOLOGICAL|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
214244834|NCT03562871|DRUG|Carboplatin (Carboplatin Kabi)|chemotherapy
214244835|NCT03562871|DRUG|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
214244836|NCT04604691|DRUG|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
214244837|NCT06536231|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
214244838|NCT02266043|DEVICE|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
214244839|NCT00259675|DRUG|carboplatin/gemcitabine, carboplatin/taxol|
214244840|NCT00744458|OTHER|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
214244841|NCT00744458|OTHER|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
214244842|NCT00744458|OTHER|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
214244843|NCT02037152|BEHAVIORAL|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
214244844|NCT04600011|OTHER|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
214244845|NCT04600011|OTHER|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
214244846|NCT03228199|OTHER|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
214244847|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
214244848|NCT06709716|DRUG|Quadratus Lumborum Block (QLB)|Pre-operative quadratus lumborum block with liposomal bupivacaine
214244849|NCT06709716|DRUG|Quadratus lumborum block|Pre-operative quadratus lumborum block with saline
214244850|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of 0.25% bupivacaine at each incision site
214244851|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of saline at each incision site.
214244852|NCT06842316|OTHER|1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)|Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.
214244853|NCT04211233|DEVICE|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
214244854|NCT04211233|OTHER|Control arm|Standard Treatment based on Brain Trauma Foundation
214244855|NCT06786494|OTHER|Tart Cherry Juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of tart cherry juice at approximately 1 hour before bedtime for 4 weeks.
214244856|NCT06786494|OTHER|Placebo juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of placebo juice at approximately 1 hour before bedtime for 4 weeks.
214244857|NCT05903469|OTHER|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
214244858|NCT05680727|PROCEDURE|transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
214244859|NCT06268730|OTHER|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
214818148|NCT06045598|OTHER|Proprioception measurement|"Ankle proprioception will be measured with the participant's knees lying on their back in a semi-flexed position. The test will be performed for 10 degrees of dorsiflexion and 20 degrees of plantar flexion, respectively. Measurements will be made with an electrogoniometer device. The difference between the required degree and the degree in the position brought by the participant will be taken as evaluation data.~Lumbal region proprioception measurement will be made with lumbar flexion and extension movements. The participant will be asked to perform active lumbar flexion. Then, lumbar flexion movement will be performed up to 50% of the measured active flexion angle and it will be requested to stay in this position for 10 seconds. After the participant returns to the upright position, he will be asked to come back to the learned angle and the difference in angle will be taken as evaluation data. The same procedure will be done for the lumbar extension movement."
214244860|NCT04174040|BEHAVIORAL|Gross's Process of Emotion Regulation Model Interventions|"Interventions were based on Gross's Process Model which include the basis concepts of cognitive-behavioral therapy and carried on with five semi-structured sessions. Cognitive-behavioral theories accept the existence of a thought process (attention-perception-interpretation) that appears in the mind about the event just before the anger emerges. Therefore, anger studies with cognitive-behavioral approach generally proceed with the steps of gaining awareness about this concealed thought, identifying behavioral response and avoidance attitudes and thus regulating emotion. It consists of five 90-minute group sessions structured in this context. While being an accredited cognitive behavioral therapist, investigator have qualified to manage these approach.~The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
214244861|NCT04174040|BEHAVIORAL|Musical Rhythm Interventions|"This musical group rhythm intervention was continued with 90 minute long five sessions. The students participated in the practice together with a music expert and lead researcher. The lead researcher took on the role of observer in these sessions. Each session was continued with warming, improvisation and targeted semi-structured rhythm practices aiming anger regulation. The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
214244862|NCT04174040|BEHAVIORAL|Musical Rhythm Integrated Gross's Emotion Regulation Process Interventions|"The students participated in the practice together with a music expert and lead researcher. The lead researcher ensured the integration of rhythm applications into the Process Model through cognitive-behavioral semi-structured interventions. Five semi-structured 90-minute group sessions were performed. The effectiveness of the experiment was evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
214244863|NCT03856775|DEVICE|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
214244864|NCT06939894|BEHAVIORAL|Drama activities|iintervention group will paticipate drrama activities aabout pain assessment of a patient.
214464750|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
214464751|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
214464752|NCT05919979|BEHAVIORAL|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
214464753|NCT05919979|BEHAVIORAL|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
214464754|NCT05254574|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
214464755|NCT05254574|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
214464756|NCT04986995|DRUG|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
214464757|NCT06346678|OTHER|Accuhaler tester|Patients will perform testing with Accuhaler tester, Ellipta tester and Turbutester.
214464758|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
214464759|NCT00248287|DRUG|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
214464760|NCT00248287|DRUG|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
214464761|NCT05825755|OTHER|vitalera telemonitoring platform|Patients will be followed-up with measurements from medical devices and health questionnaires delivered through the app
214464762|NCT05131581|OTHER|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
214464763|NCT05131581|BEHAVIORAL|Extra time allotted|Extra time allotted for each visit for CST
214464764|NCT05131581|BEHAVIORAL|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
214244865|NCT05587348|BEHAVIORAL|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
214244866|NCT05587348|BEHAVIORAL|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
214244867|NCT05463367|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
214244868|NCT05463367|DRUG|Naproxen 500 Mg|Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
214244869|NCT05463367|DRUG|Opioids|Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
214244870|NCT05008211|OTHER|Information-Motivation-Behavioral skills (IMB) model-based intervention|A six-week programme
214244871|NCT05008211|OTHER|Control - usual care|he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
214244872|NCT05288777|DRUG|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
214244873|NCT05288777|DRUG|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
214244874|NCT05288777|RADIATION|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
214244875|NCT05288777|RADIATION|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
214244876|NCT02071147|OTHER|No Clinical Follow up|
214244877|NCT02071147|OTHER|Quality of Life questionnaire|
214244878|NCT02071147|OTHER|Patient satisfaction Questionnaire|Conducted at Research clinic.
214244879|NCT04199936|DEVICE|Electrical Muscle stimulation|Electrical muscle stimulation
214244880|NCT05384275|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
214244881|NCT02092272|BEHAVIORAL|instructional exercise video source|instructional exercise video source
214244882|NCT01702831|DRUG|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
214244883|NCT01702831|DRUG|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
214244884|NCT01702831|DRUG|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
214652615|NCT05527002|OTHER|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
214244885|NCT01460589|PROCEDURE|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
214244886|NCT03768973|PROCEDURE|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
214244887|NCT03613480|OTHER|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
214244888|NCT01135823|PROCEDURE|Patient survey|
214244889|NCT03939156|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
214244890|NCT05199740|OTHER|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
214244891|NCT04908657|DRUG|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
214244892|NCT03293797|BEHAVIORAL|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
214244893|NCT05859256|OTHER|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
214244894|NCT05859256|OTHER|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
214652616|NCT01392833|DRUG|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
214652617|NCT01392833|DRUG|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
214652618|NCT01392833|DRUG|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
214652619|NCT01508455|DRUG|Dexmedetomidine|
214244895|NCT03152032|BEHAVIORAL|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
214244896|NCT02622334|DRUG|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
214244897|NCT02622334|DRUG|Placebo|Matching placebo formulation will be administered in Part A.
214244898|NCT02622334|DRUG|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
214244899|NCT03490162|DRUG|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
214244900|NCT03490162|OTHER|Placebo|Placebo
214244901|NCT00494065|OTHER|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
214244902|NCT00494065|OTHER|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
214244903|NCT00002567|BIOLOGICAL|filgrastim|
214244904|NCT00002567|DRUG|etoposide|
214244905|NCT00002567|PROCEDURE|peripheral blood stem cell transplantation|
214244906|NCT00002567|RADIATION|low-LET electron therapy|
214244907|NCT00002567|RADIATION|low-LET photon therapy|
214244908|NCT05637658|OTHER|Exercise|aerobic exercise
214244909|NCT04040868|DEVICE|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
214244910|NCT04040868|DEVICE|Freehand|conventional fluoroscopy-assisted
214244911|NCT06115031|DRUG|Remimazolam|General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
214244912|NCT06115031|DRUG|Propofol|General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
214244913|NCT03150485|DEVICE|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
214244914|NCT02763761|DRUG|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
214244915|NCT02763761|DRUG|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
214244916|NCT01128751|PROCEDURE|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
214244917|NCT01128751|PROCEDURE|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
214244918|NCT01128751|PROCEDURE|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
214244919|NCT04138888|DRUG|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
214244920|NCT04138888|DRUG|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
214244921|NCT00957385|DRUG|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
214244922|NCT02857361|DRUG|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
214244923|NCT01394718|DRUG|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
214244924|NCT01394718|OTHER|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
214652620|NCT01508455|DRUG|Midazolam|
214652621|NCT01508455|DRUG|Fentanyl|
214244925|NCT04386915|DRUG|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
214244926|NCT04386915|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
214244927|NCT00814879|DRUG|Raltegravir|400 mg BID
214244928|NCT00814879|DRUG|Atazanavir|300 mg BID
214244929|NCT00814879|OTHER|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
214244930|NCT02140476|DEVICE|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
214244931|NCT02140476|PROCEDURE|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
214652622|NCT01508455|DRUG|Morphine|
214244932|NCT00174239|DRUG|cabergoline|
214244933|NCT00174239|DRUG|controlled-release levodopa / carbidopa|
214244934|NCT05930587|OTHER|Cold water immersion|Cold water immersion (15 degree celsius, 20 minutes)
214244935|NCT00463073|DRUG|Cetuximab|
214244936|NCT00463073|DRUG|Bevacizumab|
214244937|NCT00463073|DRUG|Irinotecan|
214244938|NCT03988959|PROCEDURE|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
214244939|NCT01382511|DRUG|Simvastatine|80 mg
214244940|NCT04541251|DRUG|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
214244941|NCT05340647|PROCEDURE|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
214244942|NCT05340647|PROCEDURE|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
214244943|NCT05340647|PROCEDURE|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
214244944|NCT04856670|PROCEDURE|Cataract surgery|Cataract surgery- Manual or femtosecond laser assisted
214244945|NCT01461057|DRUG|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
214244946|NCT01461057|DRUG|Cisplatin|80 mg/m2 on Day 1 of each cycle
214244947|NCT01461057|DRUG|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
214244948|NCT01461057|DRUG|Pertuzumab|840 mg once every three weeks
214244949|NCT01461057|DRUG|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
214244950|NCT05733403|DRUG|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
214244951|NCT05733403|DRUG|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
214244952|NCT01908738|DRUG|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
214244953|NCT01908738|DRUG|10%lidocaine spray|
214244954|NCT03072771|DRUG|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
214244955|NCT03072771|PROCEDURE|Autologous stem cell transplant|-Standard of care
214244956|NCT03072771|DRUG|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
214244957|NCT03072771|DRUG|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
214244958|NCT03072771|DRUG|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
214244959|NCT03072771|DRUG|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
214244960|NCT03072771|PROCEDURE|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
214244961|NCT01445054|DRUG|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
214244962|NCT02637128|DRUG|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
214244963|NCT02637128|DRUG|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
214244964|NCT06156475|PROCEDURE|Proprioception exercises|Patients trained for proprioception exercises.
214244965|NCT06156475|PROCEDURE|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
214244966|NCT06156475|PROCEDURE|Wand Exercise|Patients were educated with wand exercises.
214244967|NCT01739400|DRUG|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
214244968|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
214244969|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
214244970|NCT03350984|DRUG|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
214244971|NCT03350984|DRUG|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
214244972|NCT01203254|DRUG|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
214244973|NCT01203254|DRUG|Placebo|Placebo tablet: 3 times daily 2 tablets
214244974|NCT00015938|BIOLOGICAL|filgrastim|
214244975|NCT00015938|DRUG|docetaxel|
214244976|NCT00015938|DRUG|vinorelbine|
214244977|NCT00642473|DRUG|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
214244978|NCT00642473|DRUG|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
214244979|NCT00642473|OTHER|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
214244980|NCT04195126|DEVICE|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
214244981|NCT04459767|DRUG|Vupanorsen|80 mg subcutaneous injection
214244982|NCT04459767|DRUG|Placebo|Subcutaneous injection
214244983|NCT03849027|DRUG|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
214244984|NCT03849027|DRUG|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
214244985|NCT02262052|OTHER|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
214244986|NCT06514443|OTHER|survey|survey exploring barriers and faciltiators for physical activity
214244987|NCT05458726|DRUG|Osimertinib|Osimertinib or chemotherapy
214244988|NCT00048711|DRUG|N-acetylgalactosamine 4-sulfatase|
214244989|NCT01483586|DRUG|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
214244990|NCT01483586|DRUG|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
214244991|NCT01221103|DRUG|Combination of dexamethasone, ofatumumab and bendamustine|"* Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
214244992|NCT04682873|DRUG|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
214244993|NCT04682873|DRUG|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
214244994|NCT01680549|DRUG|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
214244995|NCT00242983|PROCEDURE|quality-of-life assessment|
214244996|NCT03256188|BEHAVIORAL|Active classroom|30 minutes of moderate-to-vigorous physical activity
214244997|NCT05868720|DRUG|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
214244998|NCT02906969|OTHER|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
214244999|NCT02906969|OTHER|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
214245000|NCT00827580|DRUG|Eniluracil|
214245001|NCT04289350|DIAGNOSTIC_TEST|fetal heart rate variability|An observational study. No intervention
214245002|NCT03092804|PROCEDURE|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
214245003|NCT04280146|BEHAVIORAL|daily energy intake|Investigate daily energy intake according to eating rate and food processing
214245004|NCT02301585|PROCEDURE|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
214245005|NCT02301585|PROCEDURE|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
214245006|NCT00478881|DRUG|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
214245007|NCT00478881|DRUG|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
214245008|NCT04432337|PROCEDURE|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
214245009|NCT01046370|BEHAVIORAL|Amygdala Retraining Program|Mind-body intervention.
214245010|NCT00193388|DRUG|Topotecan|
214245011|NCT02156531|BEHAVIORAL|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
214245012|NCT02156531|BEHAVIORAL|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
214245013|NCT00225303|DRUG|TMC125|
214245014|NCT05260970|PROCEDURE|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
214245015|NCT02188342|BEHAVIORAL|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
214245016|NCT05113342|DRUG|Descartes-25|allogeneic Mesenchymal Stem Cell product.
214245017|NCT06226467|BEHAVIORAL|Neurobehavioral Affective Control Training|"The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control."
214245018|NCT04110262|OTHER|High dietary sodium intake|Fourteen day feeding period of high dietary sodium (3400 mg/day)
214245019|NCT04110262|OTHER|Low dietary sodium intake|Fourteen day feeding period of low dietary sodium (2300 mg/day)
214245020|NCT05837819|DEVICE|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
214245021|NCT05837819|DEVICE|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
214245022|NCT03410823|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
214245023|NCT03410823|DIETARY_SUPPLEMENT|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
214245024|NCT03410823|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
214245025|NCT05249192|DEVICE|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
214245026|NCT05249192|DEVICE|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
214245027|NCT03988543|BEHAVIORAL|Patient Self-management|Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
214245028|NCT05725096|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies according to CCTA results
214245029|NCT05725096|OTHER|Traditional cardiovascular risk stratification|Intervention strategies according to traditional cardiovascular risk stratification based on Chinese guidelines for lipid management (2023)
214245030|NCT06449963|BEHAVIORAL|Health Belief Model Education|"Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress."
214245031|NCT04911426|BEHAVIORAL|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
214245032|NCT05198609|PROCEDURE|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
214245033|NCT05198609|DRUG|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
214245034|NCT05198609|DRUG|Apatinib|Apatinib was administered orally 250mg once per day
214245035|NCT05128929|DRUG|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
214245036|NCT05128929|DRUG|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
214245037|NCT02480907|BEHAVIORAL|Workshop Group|Workshop support group
214245038|NCT02480907|BEHAVIORAL|Internet-based support group|Internet based support group with E-mail coaching
214245039|NCT02742246|BEHAVIORAL|Individual clinician-provided CBT|Individual clinician-provided CBT
214245040|NCT02742246|BEHAVIORAL|CBT4CBT|CBT computer program assisted therapy
214245041|NCT00809029|OTHER|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
214245042|NCT04173208|OTHER|Fecal microbial transplant|Fecal microbial transplant
214245043|NCT04173208|OTHER|Placebo|Placebo
214245044|NCT05675605|DRUG|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
214245045|NCT06207578|PROCEDURE|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
214245046|NCT06207578|PROCEDURE|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
214245047|NCT00464243|DRUG|volinanserin|oral administration
214245048|NCT00464243|DRUG|placebo|oral administration
214245049|NCT06387537|PROCEDURE|Conventional physical therapy|Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.
214245050|NCT06387537|PROCEDURE|Scapular mobilization.|Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
214245051|NCT04338984|DRUG|General anesthetic|Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
214245052|NCT04338984|DRUG|Ropivacaine 0.5% Injectable Solution|"Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%."
214245053|NCT03081221|DIAGNOSTIC_TEST|USG|
214245054|NCT06532799|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
214245055|NCT06532799|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
214245056|NCT06532799|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
214245057|NCT06532799|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
214245058|NCT06532799|DRUG|Pembrolizumab|Intravenous (IV) infusion
214245059|NCT05997680|BEHAVIORAL|Parent-child yoga|The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
214245060|NCT05959746|OTHER|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
214245061|NCT04377490|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
214245062|NCT04377490|BIOLOGICAL|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
214818149|NCT06045598|OTHER|Postural control assessment|"Postural control evaluation will be done with the Gyko-Microgate software. Bluetooth data transmission enables real-time measurements to be transferred directly to the computer. After the device was placed on the body of the person thanks to the wearable vest, a connection was established with the software on the computer.~To evaluate postural control, with eyes open, eyes closed and eyes open on a hard surface, accompanied by a cognitive dual task; On soft ground, with eyes open, eyes closed and eyes open, the person is asked to remain in a stable balance for 30 seconds, accompanied by a cognitive dual task. For the cognitive dual task, two countdowns and K-A-S verbal fluency exercises will be performed in each assessment. As a result of each evaluation, data on ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained."
214245063|NCT05968508|DRUG|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
214245064|NCT05113394|DRUG|HDM sublingual Immunotherapy|HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
214245065|NCT05113394|DRUG|Placebo|Placebo sublingual therapy
214245066|NCT05737771|DRUG|DWC202213|DWC202213
214245067|NCT05737771|DRUG|DWJ1563|DWJ1563
214245068|NCT05737771|DRUG|DWP16001|DWP16001
214245069|NCT06479395|OTHER|Pediatric Endurance and Limb Strengthening (PEDALS) program|Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
214245070|NCT06479395|OTHER|Task-Oriented Training (TOT)|The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
214245071|NCT02017600|DRUG|ND-420|ND-420 50 mg/m2 on day1
214245072|NCT02017600|PROCEDURE|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
214245073|NCT02017600|DRUG|Cisplatin|cisplatin 70 mg/m2 on day1
214245074|NCT02017600|DRUG|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
214245075|NCT01687621|PROCEDURE|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
214245076|NCT00000832|BIOLOGICAL|MF59|
214245077|NCT00000832|BIOLOGICAL|rgp120/HIV-1 SF-2|
214245078|NCT03976245|DRUG|Etanercept|injection
214245079|NCT03976245|DRUG|tofacitinib|tablet
214245080|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
214245081|NCT05843396|BEHAVIORAL|Neonatal Massage|caregivers providing therapeutic touch techniques on their neonate
214245082|NCT02397564|DEVICE|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
214245083|NCT00075439|DRUG|gefitinib|Given orally
214245084|NCT00075439|OTHER|laboratory biomarker analysis|Correlative studies
214245085|NCT03584373|DRUG|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
214245086|NCT03584373|DRUG|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
214245087|NCT03584373|DRUG|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
214245088|NCT01487577|DRUG|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
214245089|NCT06289621|BEHAVIORAL|False Safety Behavioral Elimination Treatment (FSET)|5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
214245090|NCT06289621|BEHAVIORAL|Enhanced Standard Care|Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
214245091|NCT01415193|PROCEDURE|Selective Tibial Nerve block|Use of selective pain block.
214245092|NCT01415193|PROCEDURE|Sciatic Nerve Block|Use of Sciatic Nerve Block
214245093|NCT00805376|DRUG|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
214245094|NCT00805376|PROCEDURE|Tumor Removal|Surgical Tumor Resection
214245095|NCT00673270|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
214245096|NCT00673270|DRUG|Hydrocortisone|50 mg of intravenous hydrocortisone
214245097|NCT00673270|DRUG|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
214245098|NCT00673270|DRUG|Placebo of Hydrocortisone|2 ml of isotonic saline solution
214245099|NCT04903379|OTHER|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
214245100|NCT05765227|DEVICE|Lehfilcon A multifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
214245101|NCT05765227|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
214245102|NCT05765227|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
214245103|NCT00662532|DRUG|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
214245104|NCT02280083|DRUG|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
214245105|NCT02280083|DRUG|placebo|placebo
214245106|NCT01595945|PROCEDURE|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
214245107|NCT01595945|BEHAVIORAL|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
214245108|NCT00367770|DRUG|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
214245109|NCT05314985|OTHER|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
214245110|NCT02771587|DIETARY_SUPPLEMENT|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
214245111|NCT02771587|DIETARY_SUPPLEMENT|Alcohol|Multiple oral dose of alcohol
214245112|NCT02771587|DIETARY_SUPPLEMENT|Energy drink|Multiple oral dose of energy drink
214245113|NCT02771587|DIETARY_SUPPLEMENT|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
214245114|NCT01155479|DRUG|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
214245115|NCT01155479|DRUG|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
214245116|NCT01155479|DRUG|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
214245117|NCT01155479|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
214245118|NCT01155479|DRUG|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
214245119|NCT01155479|DRUG|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
214245120|NCT03018665|DRUG|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
214245121|NCT03018665|DRUG|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
214245122|NCT03018665|DRUG|Metformin|oral，0.85g，twice a day in three months
214245123|NCT01197443|BEHAVIORAL|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
214245124|NCT01197443|BEHAVIORAL|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
214652623|NCT05249049|DEVICE|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
214245125|NCT02779387|DRUG|Goserelin Acetate|
214245126|NCT02910375|OTHER|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
214245127|NCT02910375|OTHER|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
214245128|NCT00955383|DRUG|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
214245129|NCT00955383|DRUG|Placebo|Matching placebo
214652624|NCT00452712|PROCEDURE|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
214652625|NCT02291211|DRUG|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
214652626|NCT01574534|DEVICE|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
214245130|NCT05673564|PROCEDURE|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
214245131|NCT01216267|DRUG|Lansoprazole|lansoprazole 30 mg HS x 7 days
214245132|NCT01216267|DRUG|lansoprazole|lanzoprazole 30 mg HS for 7 days
214245133|NCT00998764|DRUG|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
214245134|NCT04761627|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
214245135|NCT04761627|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
214245136|NCT00005566|BEHAVIORAL|Desperation Scale|
214245137|NCT03689933|DEVICE|Root analog implant|a custom made root analogue implant made from milled titanium
214245138|NCT01214174|DRUG|IBI-10090|
214245139|NCT04626466|OTHER|Biological investigations|(complete blood count, platelet count, renal function evaluation)
214245140|NCT03551080|BIOLOGICAL|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
214245141|NCT03551080|BIOLOGICAL|Placebo|Saline administered intravenously
214245142|NCT03342300|DRUG|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
214245143|NCT03342300|DRUG|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
214245144|NCT02929784|DEVICE|Intervention|Device: neuroConn\_CE\_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
214245145|NCT02929784|DEVICE|Sham|no meaningful stimulation will be given.
214245146|NCT00689091|DEVICE|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
214245147|NCT00689091|DEVICE|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
214652627|NCT01574534|DEVICE|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
214652628|NCT03499730|DRUG|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
214652629|NCT03305640|PROCEDURE|acetabular fracture surgery|acetabular fracture surgery
214652630|NCT00540891|DRUG|ALFUZOSIN|
214245148|NCT01252303|BEHAVIORAL|Nutrisystem|Nutrisystem meal replacements for 12 weeks
214245149|NCT04628832|BEHAVIORAL|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
214245150|NCT04628832|BEHAVIORAL|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
214245151|NCT04628832|BEHAVIORAL|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
214245152|NCT00290979|DRUG|insulin glulisine|
214245153|NCT02259790|DRUG|Telmisartan/amlodipine fixed-dose combination tablet|
214245154|NCT02259790|DRUG|Telmisartan|
214245155|NCT02259790|DRUG|Amlodipine|
214245156|NCT00336180|BEHAVIORAL|HealthWise South Africa curriculum|18 classroom lessons
214245157|NCT05271708|DRUG|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
214245158|NCT05271708|DRUG|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
214245159|NCT03823378|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
214245160|NCT03823378|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
214245161|NCT03823378|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
214245162|NCT03823378|DRUG|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
214245163|NCT04385927|BEHAVIORAL|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
214245164|NCT02382250|BEHAVIORAL|Survey|Survey will be given to all participants
214245165|NCT02093026|DRUG|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
214245166|NCT02093026|DRUG|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
214245167|NCT02093026|DRUG|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
214652631|NCT02797119|DRUG|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
214652632|NCT02797119|DRUG|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
214652633|NCT02797119|DRUG|Saline Solution (TA0)|
214652634|NCT00977470|DRUG|Erlotinib|150 mg taken orally once daily
214652635|NCT00977470|DRUG|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
214652636|NCT01488006|DEVICE|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
214652637|NCT01199666|OTHER|Text message|text message appointment and immunization reminders
214652638|NCT00032084|BEHAVIORAL|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
214652639|NCT00032084|DRUG|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
214245168|NCT02093026|DRUG|Folic Acid|Participants will receive folic acid \>= 5 mg/week or equivalent.
214245169|NCT00501579|DRUG|Difluprednate|
214245170|NCT00501579|DRUG|Prednisolone Acetate|
214245171|NCT04325399|OTHER|Volitional help sheet|
214245172|NCT02376829|DEVICE|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
214245173|NCT00006367|BIOLOGICAL|filgrastim|
214245174|NCT00006367|DRUG|busulfan|
214245175|NCT00006367|DRUG|cytarabine|
214245176|NCT00006367|DRUG|idarubicin|
214245177|NCT00006367|PROCEDURE|peripheral blood stem cell transplantation|
214245178|NCT05846477|DEVICE|MySpine|patient specific guide for screw positioning
214245179|NCT03614767|DIAGNOSTIC_TEST|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
214245180|NCT05110547|BIOLOGICAL|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
214245181|NCT05644847|OTHER|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
214245182|NCT05644847|PROCEDURE|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
214245183|NCT01255787|DRUG|Vortioxetine|Vortioxetine tablets
214245184|NCT01255787|DRUG|Placebo|Vortioxetine placebo-matching tablets
214245185|NCT04443751|DRUG|SHR-1702|SHR-1702 monotherapy, administered IV
214245186|NCT01261832|DRUG|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
214245187|NCT03085277|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
214245188|NCT03085277|DIETARY_SUPPLEMENT|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
214245189|NCT00476047|COMBINATION_PRODUCT|Tositumomab and Iodine I 131 Tositumomab|Give IV
214245190|NCT03249493|OTHER|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL"
214245191|NCT03381157|OTHER|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
214245192|NCT05695664|DRUG|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
214245193|NCT05695664|DRUG|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
214245194|NCT03642093|COMBINATION_PRODUCT|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
214245195|NCT03642093|BEHAVIORAL|Physical Activity Intervention|Walking and Inspiratory Muscle Training
214245196|NCT03549403|BEHAVIORAL|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
214652640|NCT00032084|DRUG|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
214245197|NCT02122731|DRUG|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
214245198|NCT05041530|DEVICE|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
214245199|NCT02775201|PROCEDURE|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
214245200|NCT02775201|PROCEDURE|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
214245201|NCT02499458|OTHER|None- observational study|
214245202|NCT04447612|DRUG|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
214652641|NCT00032084|PROCEDURE|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
214245203|NCT04447612|DRUG|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
214245204|NCT04447612|DRUG|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
214245205|NCT02200783|DEVICE|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
214245206|NCT02200783|DEVICE|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
214245207|NCT02200783|DEVICE|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
214245208|NCT02793193|DIETARY_SUPPLEMENT|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
214245209|NCT02793193|DIETARY_SUPPLEMENT|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
214245210|NCT02793193|DRUG|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
214245211|NCT02793193|DIETARY_SUPPLEMENT|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
214245212|NCT00272753|DRUG|budesonide/formoterol Turbuhaler|
214245213|NCT00272753|DRUG|formoterol Turbuhaler|
214245214|NCT00272753|DRUG|salbutamol|
214245215|NCT03500471|PROCEDURE|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214245216|NCT03500471|PROCEDURE|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214245217|NCT05153473|DEVICE|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
214245218|NCT00176722|OTHER|table tilt|One group randomized to table tilt. One group will be flat.
214245219|NCT04330196|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participant ingests 75g of glucose
214245220|NCT04330196|DIAGNOSTIC_TEST|Ingestion of placebo|Participant ingests 700mg of aspartame
214245221|NCT01796496|OTHER|Manipulative Therapy Techniques|"* Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
214245222|NCT01796496|OTHER|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
214245223|NCT02552615|OTHER|body awareness therapy|
214245224|NCT02552615|OTHER|core stabilization exercises|
214245225|NCT02552615|OTHER|traditional exercises|
214245226|NCT01859585|DRUG|Parecoxib|Parecoxib 40 mg intravenous
214245227|NCT01859585|DRUG|Ketorolac|Ketorolac 30 mg intravenous
214245228|NCT05407610|PROCEDURE|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
214245229|NCT05407610|PROCEDURE|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
214245230|NCT05407610|PROCEDURE|Sham procedure|Sham procedure with placing of needles subcutaneously.
214245231|NCT00014027|DRUG|Docosahexaenoic acid (DHA)|
214245232|NCT00014027|DRUG|Eicosapentaenoic acid|
214245233|NCT01902251|DRUG|Enzalutamide tablet|Oral
214245234|NCT01902251|DRUG|Enzalutamide capsule|Oral
214245235|NCT06386731|OTHER|Intermittent Phototherapy|2-hour phototherapy application in the intervention group
214245236|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
214245237|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
214245238|NCT02992561|BEHAVIORAL|FORNET (adapted version)|
214245239|NCT03925168|BEHAVIORAL|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
214245240|NCT02519673|DEVICE|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
214245241|NCT03474315|DIAGNOSTIC_TEST|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
214245242|NCT01215864|DRUG|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2"
214245243|NCT01227148|OTHER|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
214245244|NCT01227148|OTHER|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
214245245|NCT03333733|BEHAVIORAL|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
214245246|NCT03763565|BIOLOGICAL|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
214245247|NCT03763565|OTHER|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
214245248|NCT02854475|PROCEDURE|Venous blood collection|weekly within two weeks
214245249|NCT02854475|PROCEDURE|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
214245250|NCT02063971|OTHER|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
214245251|NCT04152980|DRUG|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
214245252|NCT02283177|DRUG|crenolanib|
214245253|NCT02283177|DRUG|cytarabine|
214245254|NCT02283177|DRUG|daunorubicin|
214245255|NCT02283177|DRUG|idarubicin|
214245256|NCT00990275|OTHER|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
214245257|NCT00910468|PROCEDURE|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
214245258|NCT01362751|OTHER|No intervention|This study is an observational cohort study \> no interventions
214245259|NCT02398227|BEHAVIORAL|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
214245260|NCT02398227|BEHAVIORAL|PCT|Present Centered Therapy for PTSD
214245261|NCT00407680|DRUG|Intensive therapy Valsartan,Fluvastatin|
214245262|NCT04739176|OTHER|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
214245263|NCT05664698|BEHAVIORAL|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri \& Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
214245264|NCT01185834|DEVICE|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
214245265|NCT00804037|PROCEDURE|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
214245266|NCT01450904|PROCEDURE|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
214245267|NCT01450904|PROCEDURE|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
214245268|NCT01450904|PROCEDURE|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
214245269|NCT03812627|OTHER|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
214245270|NCT03812627|OTHER|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
214245271|NCT02678598|DRUG|Micafungin|Intravenous
214245272|NCT02315443|DRUG|Nerinetide (NA-1)|
214245273|NCT02315443|DRUG|Placebo|
214245274|NCT01975831|DRUG|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
214245275|NCT01975831|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
214245276|NCT01216007|DRUG|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
214245277|NCT01216007|DRUG|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
214245278|NCT02702596|OTHER|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
214245279|NCT02702596|BEHAVIORAL|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
214245280|NCT02702596|BEHAVIORAL|Standard Education|The the use of a pamphlet to educate people about depression.
214245281|NCT01456910|BEHAVIORAL|Resistance Training Program|Frequency, volume, repetitions, load, interval
214245282|NCT00887744|DEVICE|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
214245283|NCT05658523|BIOLOGICAL|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
214245284|NCT05658523|BIOLOGICAL|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
214245285|NCT02510755|OTHER|MRI|
214245286|NCT04351776|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
214245287|NCT04351776|OTHER|VR-Distraction|Participants will be instructed to use one of three applications
214245288|NCT04351776|OTHER|360 Video|Participants will be instructed which video to view
214245289|NCT03905447|DRUG|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
214245290|NCT03905447|DRUG|Standard of Care|Standard of Care antifungal medication
214245291|NCT05447221|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
214245292|NCT02392715|DEVICE|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
214245293|NCT02392715|DEVICE|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
214245294|NCT04551339|DIETARY_SUPPLEMENT|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
214245295|NCT04551339|DIETARY_SUPPLEMENT|Multivitamin with 11mg of zinc|One tab taken daily for three months
214652642|NCT04103866|DEVICE|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
214245296|NCT00003395|DRUG|arsenic trioxide|
214245297|NCT04652739|DRUG|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
214245298|NCT04652739|DRUG|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
214245299|NCT03486275|DEVICE|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
214245300|NCT03486275|DEVICE|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
214245301|NCT02982278|BEHAVIORAL|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
214245302|NCT01432210|OTHER|Post-prandial Feeding Study|
214245303|NCT00264862|PROCEDURE|DynaCT|
214245304|NCT01063777|OTHER|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
214245305|NCT01063777|OTHER|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
214245306|NCT03229460|OTHER|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
214245307|NCT03229460|DEVICE|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
214245308|NCT03229460|DEVICE|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
214245309|NCT03680469|BEHAVIORAL|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
214245310|NCT03680469|BEHAVIORAL|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
214245311|NCT03895762|DRUG|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
214245312|NCT01500343|DRUG|Saccharomyces boulardii|1 gram per day, during 3 months
214245313|NCT03954327|DRUG|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
214245314|NCT03954327|DRUG|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
214245315|NCT03954327|DRUG|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
214245316|NCT04112498|DRUG|relatlimab|Specified dose on Specified days
214245317|NCT04112498|DRUG|nivolumab|Specified dose on Specified days
214245318|NCT04112498|DRUG|rHuPH20|Specified dose on Specified days
214245319|NCT00829985|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
214245320|NCT00829985|BIOLOGICAL|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
214245321|NCT03631797|PROCEDURE|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
214245322|NCT06416995|DIAGNOSTIC_TEST|first trimester serum diagnostic test|First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
214245323|NCT00997542|DRUG|Allopurinol|
214245324|NCT00997542|DRUG|Placebo|
214245325|NCT06254222|OTHER|No intervention|No intervention
214245326|NCT01115582|DRUG|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
214245327|NCT00810927|PROCEDURE|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
214245328|NCT00810927|PROCEDURE|Laser Doppler flowmetry|Measurement of choroidal blood flow
214245329|NCT00810927|PROCEDURE|Measurement of intraocular pressure|
214245330|NCT03324581|DRUG|OPC-64005|OPC-64005 film coated tablets
214245331|NCT03324581|DRUG|Atomoxetine|Atomoxetine gelatin capsules
214245332|NCT03324581|DRUG|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
214245333|NCT04426760|PROCEDURE|Transcervical resection of fibroids|Transcervical resection of fibroids
214245334|NCT04426760|PROCEDURE|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
214245335|NCT00442884|BEHAVIORAL|Trier Social Stress Test (TSST)|
214245336|NCT03575481|DIAGNOSTIC_TEST|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
214245337|NCT03498664|DEVICE|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
214245338|NCT03498664|DEVICE|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
214245339|NCT04340427|DRUG|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
214245340|NCT02274038|DRUG|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
214245341|NCT02274038|DRUG|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
214245342|NCT02274038|DRUG|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
214245343|NCT01727778|BIOLOGICAL|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
214245344|NCT03783702|DRUG|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
214245345|NCT03783702|DRUG|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
214245346|NCT03783702|DRUG|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
214245347|NCT03239028|BEHAVIORAL|Observational|
214245348|NCT04411862|DIETARY_SUPPLEMENT|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
214245349|NCT04411862|BEHAVIORAL|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
214245350|NCT04473482|BEHAVIORAL|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
214245351|NCT03007069|OTHER|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
214245352|NCT03007069|OTHER|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
214245353|NCT06516367|OTHER|Ain Shams University Screening Tool for Malnutrition, Sarcopenia, and Cachexia (ASUST-MSC)|25 items dichotomous questionnaire
214245354|NCT05573412|OTHER|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
214245355|NCT03704701|DIAGNOSTIC_TEST|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
214245356|NCT00469261|DRUG|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
214245357|NCT00469261|DRUG|Current medical therapy for AMI|Current medical therapy for AMI
214245358|NCT01662414|DIETARY_SUPPLEMENT|Whey protein|1 sachect (10 g) 2times/ day
214245359|NCT01662414|DIETARY_SUPPLEMENT|Soy protein|1 sachect (10g) 2times/day
214245360|NCT03099070|BEHAVIORAL|Stress|Trier Social Stress Test
214245361|NCT03099070|OTHER|Fasting|12-hour fasting prior to study visit
214245362|NCT01120834|DRUG|azacytidine|"* Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
214245363|NCT01120834|DRUG|vorinostat|"* Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
214245364|NCT02596282|PROCEDURE|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
214245365|NCT00321893|DRUG|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
214245366|NCT00321893|OTHER|Placebo|Inhaled placebo twice daily for one year.
214245367|NCT05352776|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
214245368|NCT04231591|DIAGNOSTIC_TEST|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
214245369|NCT00001282|DRUG|Zidovudine (AZT) & Interleukin-2 (IL2)|
214245370|NCT05346367|RADIATION|SRT|SRT
214245371|NCT05346367|RADIATION|fSRT|fSRT
214245372|NCT00003171|DRUG|bryostatin 1|
214245373|NCT01113476|DRUG|Nab-paclitaxel|Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
214245374|NCT01113476|DRUG|Bevacizumab|Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
214245375|NCT01113476|DRUG|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
214245376|NCT05946655|DRUG|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
214245377|NCT01306877|DEVICE|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
214245378|NCT01306877|DEVICE|Endosurgery Proximate PPH03 Stapling Set|Surgical device
214245379|NCT05697978|DEVICE|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
214245380|NCT00116792|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
214245381|NCT01437800|DRUG|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
214245382|NCT01211587|DRUG|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
214245383|NCT01211587|DRUG|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
214245384|NCT04631991|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
214245385|NCT01179997|DEVICE|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
214245386|NCT01179997|DEVICE|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
214245387|NCT02948101|BIOLOGICAL|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
214245388|NCT02948101|DRUG|Cyclophosphamide|Given PO
214245389|NCT02948101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214245390|NCT01859104|BEHAVIORAL|Use of smartphone app|
214245391|NCT00004727|DRUG|aspirin|
214245392|NCT00004727|DRUG|ticlopidine|
214245393|NCT03754192|RADIATION|perfusion Computed Tomography|Will be carried before liver surgery
214245394|NCT06642246|BEHAVIORAL|Intervention|During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
214245395|NCT03702296|OTHER|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
214245396|NCT04954170|DIAGNOSTIC_TEST|IRRTM|IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
214245397|NCT04954170|DIAGNOSTIC_TEST|the lift-off test|The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
214245398|NCT04954170|DIAGNOSTIC_TEST|the belly-press test|The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
214245399|NCT04954170|DIAGNOSTIC_TEST|the IRLS test|IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
214245400|NCT04954170|DIAGNOSTIC_TEST|the bear-hug test|The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
214245401|NCT04954170|DIAGNOSTIC_TEST|IRRT 0°|IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
214245402|NCT04954170|DIAGNOSTIC_TEST|Diagnostic arthroscopy|At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
214245403|NCT00474656|DEVICE|High-frequency oscillation|
214245404|NCT00474656|DEVICE|Conventional lung-open mechanical ventilation|
214245405|NCT06066801|PROCEDURE|Bedside blind bone biopsy procedure|It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
214245406|NCT03227341|OTHER|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
214245407|NCT00806507|PROCEDURE|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
214245408|NCT00806507|PROCEDURE|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
214245409|NCT06283927|PROCEDURE|Re-resection|Resection of the recurrent tumor
214245410|NCT06283927|DRUG|Temozolomide|Re-challenge Temozolomide chemotherapy
214245411|NCT06283927|DRUG|Lomustine|Second line chemotherapy with Lomustine
214245412|NCT06283927|RADIATION|Re-irradiation|Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
214245413|NCT06283927|PROCEDURE|Experimental therapy|Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
214245414|NCT06283927|OTHER|Best supportive care|Best supportive care, focused on alleviating symptoms
214245415|NCT00539097|DIETARY_SUPPLEMENT|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
214245416|NCT03684252|BEHAVIORAL|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
214245417|NCT03684252|OTHER|Treatment as Usual|Participants' will receive treatment as usual.
214245418|NCT05968365|DEVICE|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
214245419|NCT05635188|PROCEDURE|Intestinal ostomy confection|Surgical procedure for fecal diverting
214245420|NCT00422318|DRUG|Benzbromarone (drug)|
214245421|NCT04330820|DRUG|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
214245422|NCT04853303|DEVICE|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
214245423|NCT01958112|DRUG|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
214245424|NCT01958112|DRUG|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
214245425|NCT02943252|DRUG|Apatinib|apatinib 500 mg in tablet once daily
214245426|NCT02943252|DRUG|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
214245427|NCT00600860|OTHER|No interventions|Only registration of clinical practice
214245428|NCT01781169|DIETARY_SUPPLEMENT|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
214245429|NCT00939952|DRUG|ertapenem|500 mg IV once
214245430|NCT03052933|DRUG|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
214245431|NCT03052933|DRUG|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
214245432|NCT02732743|DIETARY_SUPPLEMENT|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
214245433|NCT02138526|DRUG|pazopanib|pazopanib 800mg OD without food
214245434|NCT02138526|OTHER|continental breakfast|pazopanib 600mg OD with food
214245435|NCT00999921|DRUG|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
214245436|NCT00999921|DRUG|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
214652643|NCT05548478|PROCEDURE|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
214652644|NCT05548478|PROCEDURE|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
214652645|NCT00257634|DRUG|dexamethasone to injury site|
214652646|NCT03065829|BEHAVIORAL|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
214245437|NCT05635058|OTHER|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
214245438|NCT01326559|DRUG|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
214245439|NCT04315935|DRUG|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
214245440|NCT04315935|DRUG|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
214245441|NCT00060398|BIOLOGICAL|epoetin alfa|
214245442|NCT00060398|DRUG|dexamethasone|
214245443|NCT03494348|DEVICE|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
214245444|NCT02376283|DRUG|Prasugrel|
214245445|NCT02376283|DRUG|Clopidogrel|
214245446|NCT02376283|DRUG|ticagrelor|
214245447|NCT03608423|DEVICE|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
214245448|NCT00989573|DRUG|Placebo|oral administration of placebo once-daily for 8 weeks
214245449|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
214245450|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
214245451|NCT00450775|DRUG|Dermatix Q|Dermatix Q applied twice daily
214245452|NCT00610584|PROCEDURE|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
214245453|NCT00610584|PROCEDURE|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
214245454|NCT00610584|DRUG|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
214245455|NCT03800082|BEHAVIORAL|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
214245456|NCT05074173|BEHAVIORAL|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
214245457|NCT03548571|BIOLOGICAL|Dendritic cell immunization|Intradermal injection
214245458|NCT03548571|DRUG|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
214245459|NCT01712321|DRUG|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
214245460|NCT01712321|DRUG|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
214245461|NCT01933815|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
214245462|NCT01933815|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
214245463|NCT00046111|DRUG|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
214245464|NCT01247181|OTHER|Mobile phone text message|Weekly message with motivational content
214245465|NCT01247181|OTHER|Usual care|Usual care provided at clinic
214245466|NCT03193125|DIETARY_SUPPLEMENT|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
214245467|NCT03193125|DIETARY_SUPPLEMENT|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
214245468|NCT05068895|OTHER|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
214245469|NCT05409820|PROCEDURE|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
214245470|NCT05287542|OTHER|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
214245471|NCT05287542|OTHER|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
214245472|NCT02116478|PROCEDURE|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
214245473|NCT01076075|DRUG|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
214245474|NCT01076075|DRUG|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
214245475|NCT01076075|DRUG|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
214245476|NCT01076075|DRUG|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
214245477|NCT01076075|DRUG|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
214245478|NCT01076075|DRUG|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
214245479|NCT01076075|DRUG|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
214245480|NCT03769103|DRUG|Osimertinib|Daily oral osimertinib
214245481|NCT03769103|RADIATION|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
214245482|NCT02106039|PROCEDURE|intensive monitoring|
214245483|NCT00553865|DRUG|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
214245484|NCT01860573|DRUG|Amino acids|
214245485|NCT03680430|RADIATION|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
214245486|NCT04617535|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
214245487|NCT05628961|DRUG|HOPO 14-1|HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
214245488|NCT00995865|BIOLOGICAL|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL
214245489|NCT00995865|BIOLOGICAL|Placebo|NaCl Injectable 0.9%
214245490|NCT01456273|PROCEDURE|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
214245491|NCT01456273|PROCEDURE|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
214245492|NCT04926727|OTHER|Survey|Observational study
214245493|NCT00439465|BIOLOGICAL|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
214245494|NCT04689438|DIAGNOSTIC_TEST|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
214245495|NCT03687970|OTHER|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
214245496|NCT03687970|OTHER|Hospital Anxiety and Depression Scale|"* 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
214245497|NCT03687970|OTHER|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
214245498|NCT03687970|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
214245499|NCT03687970|PROCEDURE|Quantitative sensory testing|"* Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
214245500|NCT03687970|PROCEDURE|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
214245501|NCT03687970|OTHER|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
214245502|NCT01377285|DRUG|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
214245503|NCT01377285|DRUG|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
214245504|NCT01377285|DRUG|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
214245505|NCT01604109|DRUG|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
214245506|NCT01604109|DRUG|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
214245507|NCT02104973|BEHAVIORAL|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
214245508|NCT05650528|DRUG|QG101-23-0 capsules|Single and Multiple Dose for oral
214245509|NCT05650528|DRUG|Placebo|Single and Multiple Dose for oral
214245510|NCT03624829|OTHER|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
214245511|NCT00320359|DRUG|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
214245512|NCT00320359|DRUG|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
214245513|NCT01652300|BEHAVIORAL|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
214245514|NCT01652300|BEHAVIORAL|no education|women in the control group received no education
214245515|NCT00677430|BEHAVIORAL|Questionnaire|A brief questionnaire packet will be completed.
214245516|NCT00677430|PROCEDURE|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
214245517|NCT02850133|OTHER|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
214245518|NCT04483687|DRUG|Filgotinib|Tablets administered orally once daily
214245519|NCT04483687|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
214245520|NCT05963893|BEHAVIORAL|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
214245521|NCT04533477|PROCEDURE|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
214245522|NCT04533477|PROCEDURE|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
214245523|NCT02359851|BIOLOGICAL|Pembrolizumab|Given IV
214245524|NCT02359851|OTHER|Laboratory Biomarker Analysis|Correlative studies
214245525|NCT01888003|DRUG|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
214245526|NCT01888003|DRUG|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
214245527|NCT01888003|OTHER|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
214245528|NCT04075370|OTHER|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
214245529|NCT04993222|DRUG|Amphotericin B liposome for injection|IV infusion
214245530|NCT04993222|DRUG|AmBisome®|IV infusion
214245531|NCT00785967|BIOLOGICAL|Various vaccines|VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
214245532|NCT04029532|DEVICE|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
214245533|NCT04029532|DEVICE|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
214245534|NCT04029532|DEVICE|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
214245535|NCT04029532|BEHAVIORAL|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
214245536|NCT04029532|BEHAVIORAL|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
214245537|NCT04029532|BEHAVIORAL|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
214245538|NCT04029532|BEHAVIORAL|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
214245539|NCT00215579|DRUG|Depot Risperidone Microsphere (Consta)|
214245540|NCT06424418|DEVICE|Robotic Scope Cleaner|The device is used to clean the scope when it visualization becomes obstructed during a surgical procedure.
214245541|NCT06518889|PROCEDURE|Selective Dorsal Rhizotomy|Selective Dorsal Rhizotomy (SDR) is an irreversible neurosurgical procedure where 50-70% of the sensory nerve roots are cut at the spinal level. The procedure is used to reduce lower limb spasticity permanently and is augmented by intensive rehabilitation for at least two years after surgery to optimise outcomes.
214245542|NCT00055471|DRUG|ZD4054 10 mg|1 x 10 mg oral tablets once daily
214245543|NCT00055471|DRUG|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
214245544|NCT00055471|DRUG|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
214245545|NCT03385161|PROCEDURE|Botulinum toxin A|
214245546|NCT03385161|PROCEDURE|Ethanol|
214245547|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
214245548|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
214245549|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
214652647|NCT03065829|BEHAVIORAL|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
214652648|NCT04957563|BEHAVIORAL|olfactory rehabilitation|treatment for improve olfactory function
214652649|NCT06217250|PROCEDURE|Traditional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
214245550|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
214245551|NCT03190356|DEVICE|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
214245552|NCT01854944|DRUG|Brexpiprazole 1mg to 4mg|
214245553|NCT01935310|DRUG|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
214245554|NCT02285556|BEHAVIORAL|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
214245555|NCT02285556|BEHAVIORAL|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
214245556|NCT02285556|RADIATION|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
214245557|NCT02285556|RADIATION|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
214245558|NCT03742089|DEVICE|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
214245559|NCT06546930|BEHAVIORAL|DREAM intervention|"Virtual Peer Groups (VPGs)~Participants will have multiple opportunities to attend a VPG on a specific topic during their 12-month participation period. The VPG topics will include the following:~* Diabetes technology - basics or advanced use (audience-dependent)~* Family relationships and diabetes~* Diabetes in real life - school, work, social gatherings, travel~* Wellbeing and support when living with diabetes~* Working with your diabetes care team - who to call for what~* Eating and activity - what's different with T1D?~In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies."
214245560|NCT03983278|OTHER|School Model|Free delivery of glasses at the school within two weeks after screening
214245561|NCT03983278|OTHER|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
214245562|NCT03983278|OTHER|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
214245563|NCT04110067|OTHER|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
214245564|NCT01449643|DEVICE|Threshold|
214245565|NCT01449643|DEVICE|Sham Threshold|
214245566|NCT02101112|DRUG|Apixaban|
214245567|NCT05505994|DRUG|DWP16001|DWP16001 A mg tablet
214245568|NCT05505994|DRUG|Dapagliflozin|Dapagliflozin tablet
214245569|NCT05505994|DRUG|DWP16001 Placebo|DWP16001 Placebo tablet
214245570|NCT05505994|DRUG|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
214245571|NCT00004904|BIOLOGICAL|anti-thymocyte globulin|
214245572|NCT00004904|BIOLOGICAL|filgrastim|
214245573|NCT00004904|DRUG|cladribine|
214245574|NCT00004904|DRUG|cyclophosphamide|
214245575|NCT00004904|DRUG|etoposide|
214245576|NCT00004904|DRUG|methylprednisolone|
214245577|NCT00004904|DRUG|tacrolimus|
214245578|NCT00004904|PROCEDURE|allogeneic bone marrow transplantation|
214245579|NCT00004904|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214245580|NCT01150331|DRUG|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
214245581|NCT01150331|DRUG|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
214245582|NCT01683773|BIOLOGICAL|AERAS-402|Intramuscular needle injection 1x10\^11 vp
214245583|NCT01683773|BIOLOGICAL|MVA85A|Intradermal needle injection 1x10\^8 pfu
214245584|NCT04124718|GENETIC|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
214245585|NCT01724320|DRUG|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
214245586|NCT05088655|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
214245587|NCT04864210|DRUG|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
214245588|NCT04864210|DRUG|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
214245589|NCT04340063|DEVICE|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
214245590|NCT04340063|DEVICE|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
214245591|NCT06975982|OTHER|No intervention|No intervention
214245592|NCT06574412|DRUG|cardonilizumab combined with renvastinib|Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \&lt;60kg, 8mg, once a day, orally, for 4 cycles Weight \&gt;60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \&lt;60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \&gt; 60kg, 12mg, once a day, orally, a total of 8 cycles.
214245593|NCT06575933|DRUG|MK-1084|Oral administration
214245594|NCT06575933|DRUG|Midazolam|Oral administration
214245595|NCT06575933|DRUG|Digoxin|Oral administration
214245596|NCT04577027|DRUG|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
214245597|NCT04577027|DEVICE|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
214245598|NCT04577027|DEVICE|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
214245599|NCT04577027|OTHER|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
214245600|NCT04577027|OTHER|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
214245601|NCT04577027|OTHER|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
214245602|NCT01598571|DRUG|Fostamatinib|Fostamatinib 50 mg tablet
214245603|NCT01598571|DRUG|Fostamatinib|Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
214245604|NCT04438733|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
214245605|NCT04438733|DRUG|reference-anastrozole tablet (Arimidex)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
214245606|NCT03413267|OTHER|Custard|Food matrix: custard (liquid emulsion)
214245607|NCT03413267|OTHER|Flan|Food matrix: flan (soft gel)
214245608|NCT03413267|OTHER|Sponge cake|Food matrix: sponge cake (porous and spongy)
214245609|NCT03413267|OTHER|Biscuit|Food matrix: biscuit (thick and crunchy)
214245610|NCT04488211|OTHER|Survey|The IVM survey will be structured as a series of open questions and multiple-choice questions.
214245611|NCT02789722|OTHER|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
214245612|NCT02789722|OTHER|Placebo|Take 3 capsules, 3 times daily for 28 days.
214245613|NCT05481450|DIETARY_SUPPLEMENT|Nutritears®|Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
214245614|NCT05481450|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule (Total capsule weight ≈670 mg)
214245615|NCT05923619|PROCEDURE|Total pulpotomy|Total pulpotomy procedures explained in arm descriptions.
214245616|NCT05923619|PROCEDURE|Root canal treatment|Root canal treatment procedures explained in arm descriptions.
214245617|NCT01718795|DEVICE|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
214245618|NCT06102746|DRUG|Sintilimab，Surufatinib|Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
214245619|NCT01857583|DRUG|15mg DU-176b|
214245620|NCT01857583|DRUG|30mg DU-176b|
214245621|NCT01857583|DRUG|Fondaparinux|
214245622|NCT06640335|OTHER|Co-ingestion|Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.
214245623|NCT06640335|OTHER|0 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.
214245624|NCT06640335|OTHER|5 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.
214245625|NCT06640335|OTHER|10 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
214245626|NCT06640335|OTHER|15 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
214245627|NCT06640335|OTHER|20 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 20 minutes, then consume 300 g of mashed potatoes.
214245628|NCT06640335|OTHER|Spinach only / 10 min preload|Subjects consume 200 g baby round spinach WITHOUT canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
214245629|NCT06640335|OTHER|Canola oil only / 10 min preload|Subjects consume 20 g of canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
214245630|NCT03971513|PROCEDURE|Trans abdominal plane|"Trans abdominal plane block is performed with ultra sound guidance.~1. \- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~2. \- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
214245631|NCT01510457|DRUG|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
214245632|NCT01510457|DRUG|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
214245633|NCT02824861|BEHAVIORAL|Bemobile|
214245634|NCT00134537|DEVICE|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
214245635|NCT00134537|DEVICE|Conservative Care|Medication, exercise and spinal injections
214245636|NCT01187719|DRUG|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
214245637|NCT04163679|PROCEDURE|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
214245638|NCT04235465|OTHER|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
214245639|NCT00458536|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
214245640|NCT00458536|DRUG|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
214245641|NCT01676363|DRUG|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
214245642|NCT06003998|DRUG|Irinotecan|2 weekly IP irinotecan (max 12 cycles), dose 75 mg flat dose
214245643|NCT06003998|DRUG|FOLFOX regimen|FOLFOX-4 regimens consist of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1 followed by 1600 mg/m2 5-FU as a 46-h infusion
214245644|NCT06003998|DRUG|Bevacizumab|Bevacizumab according to standard of care
214245645|NCT02811354|DRUG|AZD9291|oral administration as a single daily dose of 80 mg
214245646|NCT00538525|DRUG|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
214245647|NCT05117632|DRUG|ALTO-100 PO tablet|one tablet twice daily
214245648|NCT06333756|OTHER|Cross education|Cross education training of the biceps brachii (12 rep./set, 3sets, 60%MVIC,180°/s, eccentric contraction)
214245649|NCT04894916|OTHER|My Diabetes Care Mobile (MDC-m)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
214245650|NCT05821634|BEHAVIORAL|Personalized intervention condition: Cognitive behavioral therapy skills|An 11-session cognitive behavioral therapy (CBT) skills based intervention will be delivered to participants randomized to the personalized intervention. Influential constructs will be identified using the person specific digital phenotyping model, targeted using CBT skills, and tracked across sessions.
214245651|NCT05821634|BEHAVIORAL|Therapeutic control condition: Cognitive behavioral therapy skills|Participants randomized to this condition will receive an 11-session CBT skills based treatment targeting a non-personalized construct selected from the person-specific digital phenotyping model.
214245652|NCT05821634|BEHAVIORAL|Tracking control condition: Supportive counseling|Participants randomized to this condition will receive 11 supportive counseling sessions that are non-directive in nature (providing support and validation for non-acute weekly stressors). Participants will continue digital phenotyping, controlling for the effect of counseling and digital phenotyping.
214245653|NCT02776267|DEVICE|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
214245654|NCT06566521|PROCEDURE|thoracic paravertebral block|After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
214245655|NCT04397887|PROCEDURE|micro-surgical varicocelectomy|Sub-inguinal micro-surgical varicocelectomy
214245656|NCT06987773|DRUG|RLF-OD032 100 mg/mL oral suspension|Sapropterin dihydrochloride
214245657|NCT06987773|DRUG|Kuvan 100 MG Powder for Oral Solution|Sapropterin dihydrochloride
214245658|NCT06986460|DEVICE|MagPro X100/R30 stimulator, Cool-B70 coil|1Hz rTMS delivered to the right DLPFC
214245659|NCT06816836|PROCEDURE|Bed Side ultrasound guided muscle mass estimation of lower extremity|Bed Side ultrasound guided muscle mass estimation of psoas major, rectus femoris, vastus intermedius and tibialis anterior.
214245660|NCT06589778|DRUG|SHR-A2102|SHR-A2102: injection, 80mg/ bottle, intravenous drip
214245661|NCT06589778|DRUG|Adebelimab (SHR-1316)|Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
214245662|NCT06589778|DRUG|SHR-8068|SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
214245663|NCT06666504|OTHER|Combined Retrospective and Prospective Data Analysis|Collection of both retrospective and prospective data all ready available for participant
214245664|NCT06993857|OTHER|Neuromuscular taping applied with no tension|Neuromuscular taping applied with no tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
214245665|NCT06993857|OTHER|Neuromuscular taping applied with distal-to-proximal tension|Neuromuscular taping applied with distal-to-proximal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
214245666|NCT06993857|OTHER|Neuromuscular taping applied with proximal-to-distal tension|Neuromuscular taping applied with proximal-to-distal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
214245667|NCT06994533|PROCEDURE|methods on bone reconstrucion after chest wall tumor resection|Selecting appropriate implants for chest wall bone reconstruction
214245668|NCT06993571|DEVICE|Active-tACS|30 seconds of closed-loop tACS at 2-4 mA, with 6 alternating phase alignments and 1-3 repetitions. Phase alignment is adjusted to the patient's tremor frequency and rhythm in real time. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
214245669|NCT06993571|DEVICE|Sham-tACS|30 seconds of tACS at 0 mA and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The sham protocol begins with a 3-second ramp-up and ends with a 3-second ramp-down.
214245670|NCT06993571|DEVICE|Unlocked-tACS|30 seconds of open-loop tACS at 2-4 mA, with no phase alignments and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
214245671|NCT06994390|DEVICE|tDCS|This group will receive single-phase direct current with an intensity of 2 mA up. Electrodes with a size of 35cm² (5 x 7 centimeters) will be used. Electrodes will be placed on the scalp, fixed with elastic bands, and immersed in 10 to 12 mL of saline solution.
214245672|NCT06994390|DEVICE|sham intervention|The device displays will be identical across active and sham groups, and to ensure blinding, an active current will be applied for 30 seconds at the beginning and end of the sham stimulation to mimic the sensation of the current ramp experienced in active stimulation. Stimulations of less than 3 minutes of tDCS do not induce cortical excitability effects, according to Nitsche and Paulus (2000), being safely inactive for the expected results.
214245673|NCT06994572|DRUG|CT-01|Investigational small-molecule degrader targeting transcription factors in HCC. Used as monotherapy or with everolimus in dose-escalation/expansion settings. Specific to protocol CT-01-CD-1.
214245674|NCT06994572|DRUG|EVEROLIMUS|Approved mTOR inhibitor used in combination with CT-01 for HCC in this study. Evaluated for safety, tolerability, and PK/PD in CT-01-CD-1 protocol.
214245675|NCT06994520|OTHER|Cannabidiol (CBD)|5%CBD cream
214245676|NCT06994520|DRUG|Triamcinolone (TAC) 0.1% cream|comparator
214245677|NCT06993948|DEVICE|Transthoracic echocardiography|Transthoracic echocardiography (TTE) was carried out. The assessment of left ventricular ejection fraction (LVEF) relied primarily on two-dimensional echocardiography using visual estimation.
214245678|NCT01591850|DRUG|RO5093151|Single oral dose
214245679|NCT01591850|DRUG|atazanavir|Multiple oral doses
214245680|NCT01591850|DRUG|ketoconazole|Multiple oral doses
214245681|NCT01591850|DRUG|rifampicin|Multiple oral doses
214245682|NCT01591850|DRUG|ritonavir|Multiple oral doses
214245683|NCT02516267|DEVICE|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG
214245684|NCT06056765|DEVICE|"Minilith, Storz, Swiss"|shock waves
214245685|NCT02386670|OTHER|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
214245686|NCT02386670|OTHER|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
214245687|NCT04354961|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214245688|NCT03829774|DEVICE|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
214245689|NCT03829774|DRUG|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
214245690|NCT03249389|BIOLOGICAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
214245691|NCT06458426|DEVICE|shock-absorbing prosthesis|the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
214245692|NCT04232306|DRUG|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
214245693|NCT04232306|DRUG|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
214245694|NCT03729687|COMBINATION_PRODUCT|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
214245695|NCT01918722|DRUG|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
214245696|NCT01918722|DRUG|placebo|placebo herbal medicine, one dose,bid, for 10 days
214245697|NCT01918722|DRUG|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
214245698|NCT03794960|BIOLOGICAL|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
214245699|NCT03794960|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
214245700|NCT00119600|DRUG|AMG 114|
214245701|NCT05611177|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
214245702|NCT05500066|DEVICE|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
214652650|NCT06217250|PROCEDURE|"the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms"|"The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR."
214245703|NCT03249220|DEVICE|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
214245704|NCT03688425|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
214245705|NCT03688425|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
214245706|NCT05523518|DEVICE|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
214245707|NCT05523518|DEVICE|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
214245708|NCT04644445|DIETARY_SUPPLEMENT|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
214245709|NCT04759027|OTHER|subacromial distance measurement|distance between acromion and humerus
214245710|NCT06240507|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
214245711|NCT06240507|PROCEDURE|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
214245712|NCT02430506|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
214245713|NCT02430506|BIOLOGICAL|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
214245714|NCT02048189|DRUG|LEVEMIR|
214245715|NCT02048189|DRUG|APIDRA|
214245716|NCT00562627|DRUG|ropivacaine|intraoperative and 1. postoperative day
214245717|NCT00562627|DRUG|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
214245718|NCT00562627|DRUG|ketorolac|intraoperative and 1. postoperative day
214245719|NCT00562627|DRUG|morphine|intraoperative
214245720|NCT00562627|DRUG|fentanyl|continuous postoperatively
214245721|NCT00562627|DRUG|bupivacaine|continuous postoperatively
214245722|NCT01139840|DIETARY_SUPPLEMENT|vitamin D2|Study Supplement
214245723|NCT01139840|DIETARY_SUPPLEMENT|vitamin D3|Study Supplement
214652651|NCT04187027|DEVICE|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
214245724|NCT01994499|DEVICE|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
214652652|NCT03656913|DIAGNOSTIC_TEST|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
214245725|NCT01994499|DRUG|Medical drainage|Medical pleural drainage
214245726|NCT00625742|BEHAVIORAL|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
214245727|NCT00625742|BEHAVIORAL|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
214245728|NCT00625742|DRUG|Melatonin|20 mg by mouth (PO) Daily
214245729|NCT00625742|DIETARY_SUPPLEMENT|Juven|90 calories of Juven, twice a day.
214245730|NCT00625742|DRUG|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
214245731|NCT00625742|DRUG|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
214245732|NCT00333892|PROCEDURE|leukapheresis|pack of cells as per protocol
214245733|NCT01709578|DRUG|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
214245734|NCT01709578|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
214245735|NCT01709578|DRUG|hydroxychloroquine|Dispensed according to the local practice.
214245736|NCT01709578|DRUG|methotrexate|Dispensed according to the local practice.
214245737|NCT01709578|DRUG|sulfasalazine|Dispensed according to the local practice.
214245738|NCT01709578|DRUG|leflunomide|Dispensed according to the local practice.
214245739|NCT04050371|DRUG|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
214245740|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (\~140 mg tablet)
214245741|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (\~275 mg tablet)
214245742|NCT03206957|DIAGNOSTIC_TEST|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
214245743|NCT03206957|DIAGNOSTIC_TEST|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
214245744|NCT03206957|DIAGNOSTIC_TEST|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
214245745|NCT03206957|DIAGNOSTIC_TEST|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
214245746|NCT03206957|DIAGNOSTIC_TEST|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
214245747|NCT05503316|OTHER|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
214245748|NCT05503316|OTHER|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
214245749|NCT03758326|OTHER|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
214245750|NCT02935543|BIOLOGICAL|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
214245751|NCT03718325|DEVICE|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
214245752|NCT03718325|DEVICE|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
214245753|NCT02931591|DRUG|Metformin|Metformin is administered as an oral solution
214245754|NCT02931591|DRUG|Growth Hormone|Growth Hormone- no specific band
214245755|NCT02931591|DRUG|Placebo|
214245756|NCT04545359|BEHAVIORAL|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
214245757|NCT04545359|BEHAVIORAL|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
214245758|NCT03454321|OTHER|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
214245759|NCT04877223|OTHER|No intervention|No intervention
214245760|NCT00623116|DRUG|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
214245761|NCT01314911|DRUG|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
214245762|NCT01314911|DRUG|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
214245763|NCT04540939|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
214245764|NCT04540939|BEHAVIORAL|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
214245765|NCT03905473|BEHAVIORAL|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
214245766|NCT03269461|DEVICE|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
214245767|NCT01541202|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
214245768|NCT01541202|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
214245769|NCT00255801|DRUG|Targretin® (bexarotene)|
214245770|NCT00255801|DRUG|pegylated liposomal doxorubicin hydrochloride|
214245771|NCT00130273|BEHAVIORAL|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
214245772|NCT00130273|BEHAVIORAL|Standard care|Participants will receive standard of care for 12 months.
214245773|NCT05625620|DEVICE|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
214245774|NCT05625620|DEVICE|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
214245775|NCT03937700|DEVICE|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
214245776|NCT01764035|BEHAVIORAL|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
214245777|NCT01764035|BEHAVIORAL|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
214245778|NCT05277961|RADIATION|Ultraviolet radiation|UV6 tubes
214245779|NCT03688009|BEHAVIORAL|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
214245780|NCT03688009|BEHAVIORAL|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
214245781|NCT04174014|PROCEDURE|Recruitment manoeuvre|PEEP increment and decrement
214245782|NCT00647218|DRUG|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
214652653|NCT03282032|OTHER|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
214652654|NCT05462184|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
214652655|NCT05462184|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|
214245783|NCT00647218|DRUG|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
214245784|NCT00647218|PROCEDURE|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
214652656|NCT01870635|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
214652657|NCT01870635|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
214652658|NCT02298101|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
214245785|NCT00647218|RADIATION|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
214652659|NCT02298101|DEVICE|Aeroneb Solo Adapter|Nebulizer
214652660|NCT02298101|DEVICE|Opti-Mist Plus Nebulizer|Standard jet nebulizer
214652661|NCT02298101|OTHER|Planar scintigraphy|Imaging technique to investigate whole lung deposition
214652662|NCT02298101|OTHER|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
214245786|NCT00647218|DRUG|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
214245787|NCT00588952|DRUG|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
214245788|NCT01277042|BIOLOGICAL|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
214245789|NCT01277042|BIOLOGICAL|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
214245790|NCT00360152|PROCEDURE|Fine needle aspiration biopsy (FNAB)|
214245791|NCT00360152|PROCEDURE|Sentinel Lymph Node Biopsy|
214245792|NCT03914508|BEHAVIORAL|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
214245793|NCT02366598|OTHER|Hemp shake|Hemp protein shake
214245794|NCT02366598|OTHER|Soybean shake|Soybean protein shake
214245795|NCT02366598|OTHER|Control|Non-protein shake
214245796|NCT02318576|OTHER|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
214245797|NCT01178255|DRUG|homeopathic q-potencies|individualised homeopathic medicines
214245798|NCT01178255|DRUG|Placebo|placebo
214245799|NCT01178255|OTHER|homeopathic case history taking type I|one special homeopathic technique for case history taking
214245800|NCT01178255|OTHER|homeopathic case history type II|another type of homeopathic case history taking
214245801|NCT02172170|DRUG|BI 10773 single rising dose|
214245802|NCT02172170|DRUG|Placebo|
214245803|NCT04451642|PROCEDURE|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
214245804|NCT06274905|DRUG|EMLA|EMLA cream
214245805|NCT06274905|DRUG|Ethyl chloride|Ethyl chloride
214245806|NCT06274905|DRUG|Aqueous cream BP|Aqueous cream
214245807|NCT05817279|DIAGNOSTIC_TEST|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
214245808|NCT03700879|RADIATION|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
214245809|NCT05682248|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
214245810|NCT05682248|DEVICE|Sham Transcranial magnetic stimulation|Sham Transcranial magnetic stimulation
214245811|NCT01175837|OTHER|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
214245812|NCT01175837|OTHER|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
214245813|NCT01175837|OTHER|laboratory biomarker analysis|Correlative studies
214245814|NCT02284178|OTHER|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
214652663|NCT02298101|OTHER|Spirometry|FEV1, FVC assessment
214652664|NCT00125034|BIOLOGICAL|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
214652665|NCT00125034|DRUG|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
214245815|NCT02284178|OTHER|Usual Care|Oral suction with suction swab every 4 hours
214245816|NCT04946461|DRUG|Dexamfetamine Sulfate 5 Mg Oral Tablet|The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
214245817|NCT04946461|DRUG|Lisdexamfetamine Dimesylate|The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
214245818|NCT04946461|BIOLOGICAL|blood samples|The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
214245819|NCT00569829|BEHAVIORAL|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
214245820|NCT00582283|DRUG|I124-NM404|I-124-NM404
214245821|NCT02547714|DRUG|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
214245822|NCT00381251|DRUG|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
214245823|NCT04396496|DRUG|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
214245824|NCT02162641|PROCEDURE|Sentinel lymph node biopsy|
214245825|NCT04466345|BIOLOGICAL|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
214245826|NCT04466345|BIOLOGICAL|Placebo|Semaglutide placebo capsules
214245827|NCT01483690|DRUG|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
214245828|NCT01483690|DRUG|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
214245829|NCT01483690|DRUG|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
214245830|NCT01483690|DRUG|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
214245831|NCT01483690|DRUG|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
214245832|NCT01483690|DRUG|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
214245833|NCT01483690|DRUG|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
214245834|NCT05262725|BEHAVIORAL|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
214245835|NCT02524093|BEHAVIORAL|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
214245836|NCT02524093|OTHER|treatment as usual|
214245837|NCT04633460|DIETARY_SUPPLEMENT|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
214245838|NCT04633460|DIETARY_SUPPLEMENT|placebo drink|KE free placebo drink
214245839|NCT05410392|BEHAVIORAL|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
214245840|NCT05410392|BEHAVIORAL|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
214245841|NCT05410392|BEHAVIORAL|Health education|Provision of general information about a variety of topics
214245842|NCT05086939|DRUG|Autologous MSCs|Intra-articular injection 40 million/4 ml.
214245843|NCT05086939|DRUG|Allogenic MSCs|Intra-articular injection 40 million/4 ml.
214245844|NCT05086939|DRUG|Hyaluronic Acid|Intra-articular injection 60mg / 3 ml .
214245845|NCT03569293|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
214245846|NCT03569293|DRUG|Upadacitinib|Tablets taken orally once a day
214245847|NCT05803603|BEHAVIORAL|Stipend and Social Work Supports|Same as arm description
214245848|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
214245849|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
214245850|NCT03553836|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
214245851|NCT03553836|OTHER|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
214245852|NCT06642935|DEVICE|Totally implantable cochlear Implant|Totally implantable cochlear Implant
214245853|NCT04062123|DRUG|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
214245854|NCT04062123|DRUG|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
214245855|NCT04062123|DRUG|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
214245856|NCT04062123|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
214245857|NCT04062123|DRUG|Placebo|Crystalloid IV solution will be infused, with no active drug.
214245858|NCT05475340|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
214245859|NCT05944224|DRUG|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
214245860|NCT05944224|DRUG|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
214245861|NCT04482478|DIETARY_SUPPLEMENT|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
214245862|NCT04482478|OTHER|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
214245863|NCT01706692|BIOLOGICAL|Adalimumab|all dosages, frequencies and durations prescribed
214245864|NCT01706692|BIOLOGICAL|Etanercept|all dosages, frequencies and durations prescribed
214245865|NCT01706692|BIOLOGICAL|Infliximab|all dosages, frequencies and durations prescribed
214245866|NCT01706692|BIOLOGICAL|Ustekinumab|all dosages, frequencies and durations prescribed
214245867|NCT01706692|DRUG|Cyclosporine A|all dosages, frequencies and durations prescribed
214245868|NCT01706692|DRUG|Fumaric acids|all dosages, frequencies and durations prescribed
214245869|NCT01706692|DRUG|Methotrexate|all dosages, frequencies and durations prescribed
214245870|NCT01706692|DRUG|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
214245871|NCT05806775|BEHAVIORAL|Low-load resistance training with blood flow restriction|A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
214245872|NCT06546969|DRUG|Gemcitabine|1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
214245873|NCT06546969|DRUG|Cisplatin|25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
214245874|NCT06546969|DRUG|Durvalumab|1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
214245875|NCT06546969|RADIATION|Spatially Fractionated RT|Administered to 1 measurable lesion on cycle 2-day 1
214245876|NCT06546969|DEVICE|Deep Hyperthermia|Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1
214245877|NCT06109285|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
214245878|NCT01041495|DRUG|cyclobenzaprine ER (AMRIX)|active drug
214245879|NCT01041495|DRUG|placebo|matching placebo for cyclobenzaprine ER (AMRIX)
214652666|NCT05490420|OTHER|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
214652667|NCT04455711|DRUG|Lidocaine Iv|Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
214245880|NCT02882074|DRUG|Human albumin|human albumin 5% during surgery
214245881|NCT02882074|DRUG|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
214245882|NCT03066973|BEHAVIORAL|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
214245883|NCT05651568|OTHER|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
214245884|NCT05651568|OTHER|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
214245885|NCT01840995|PROCEDURE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
214245886|NCT02331160|BEHAVIORAL|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
214245887|NCT03905109|DRUG|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
214245888|NCT03905109|DRUG|Placebo|In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
214245889|NCT06298604|DEVICE|EUS-guided standard fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.
214245890|NCT06298604|DEVICE|EUS-guided motorized fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
214245891|NCT01993095|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
214245892|NCT01993095|BEHAVIORAL|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
214245893|NCT02398279|DIETARY_SUPPLEMENT|L-Arginine|Experimental supplement
214245894|NCT02398279|OTHER|Placebo|Placebo capsules in the same color and shape with the experimental supplement
214245895|NCT00084591|DRUG|capecitabine|
214245896|NCT00084591|PROCEDURE|conventional surgery|
214245897|NCT00084591|PROCEDURE|neoadjuvant therapy|
214245898|NCT00084591|RADIATION|radiation therapy|
214245899|NCT01633580|DRUG|corifollitropin alfa|long acting FSH
214245900|NCT04809636|OTHER|This is not an interventional study|While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes
214245901|NCT05440149|RADIATION|No PMRT for mastectomy / No regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
214245902|NCT05440149|RADIATION|PMRT for mastectomy / WBI + Regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
214245903|NCT05048082|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
214245904|NCT05048082|PROCEDURE|Tumor resection surgery|Standard of care surgical removal of cancerous lung lesion
214245905|NCT03780400|BEHAVIORAL|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
214245906|NCT01479985|OTHER|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
214245907|NCT03571477|DEVICE|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
214245908|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
214245909|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
214245910|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
214245911|NCT01653782|BEHAVIORAL|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
214652668|NCT04455711|DRUG|Remifentanil|Continuous infusion of remifentanil 1.5 ng/ml until extubation
214245912|NCT01653782|BEHAVIORAL|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
214245913|NCT01653782|BEHAVIORAL|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
214245914|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
214245915|NCT02538861|DIAGNOSTIC_TEST|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
214245916|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
214245917|NCT05124418|DIAGNOSTIC_TEST|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
214245918|NCT01142128|DRUG|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
214245919|NCT01142128|DRUG|Placebo to Nexium|one capsule per day for one month
214245920|NCT01142128|DRUG|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
214245921|NCT01142128|DRUG|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
214245922|NCT00611039|DRUG|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
214245923|NCT00611039|DRUG|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
214245924|NCT00155870|BEHAVIORAL|questionnaires|
214245925|NCT03838783|DRUG|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
214245926|NCT01562067|DEVICE|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
214245927|NCT03174899|RADIATION|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
214245928|NCT02598336|DEVICE|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
214245929|NCT02598336|DEVICE|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
214245930|NCT06268145|DRUG|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
214245931|NCT05171829|OTHER|Track U|Track U diary
214245932|NCT05478954|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
214245933|NCT05478954|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
214245934|NCT03000127|DRUG|AndroGel 1 % Topical Gel|testosterone gel
214245935|NCT03000127|DRUG|Placebos|Placebo gel
214245936|NCT05977725|DIAGNOSTIC_TEST|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
214245937|NCT03665857|BEHAVIORAL|a multicomponent intervention|"1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
214245938|NCT00950261|RADIATION|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
214245939|NCT04643171|DEVICE|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
214245940|NCT04643171|DEVICE|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
214245941|NCT01618812|PROCEDURE|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
214245942|NCT00393640|PROCEDURE|Early and regular breast milk expression|Breast pump given to be used on regular intervals
214245943|NCT02296879|GENETIC|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
214245944|NCT04782960|DRUG|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
214245945|NCT04782960|DRUG|Placebo|0.9 saline
214245946|NCT00442468|OTHER|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
214245947|NCT00579007|BEHAVIORAL|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
214245948|NCT00931346|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
214245949|NCT00931346|DRUG|Placebo|Placebo
214245950|NCT04728672|OTHER|Kinesio Tape|Kinesio Tape
214245951|NCT04728672|OTHER|Micropore Tape|Micropore Tape
214245952|NCT03199339|DRUG|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
214245953|NCT03199339|DRUG|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
214245954|NCT05836779|DRUG|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
214245955|NCT02718950|DRUG|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
214245956|NCT05606146|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
214245957|NCT00208182|DRUG|Risperidone|
214245958|NCT03551353|OTHER|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
214245959|NCT03551353|OTHER|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
214245960|NCT05448976|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
214245961|NCT04300374|OTHER|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
214245962|NCT02571400|OTHER|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics \>90 days post-surgery
214245963|NCT00926588|DRUG|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
214245964|NCT02644200|DEVICE|Gelatin tannate|
214245965|NCT04710277|OTHER|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
214245966|NCT04710277|OTHER|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
214245967|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
214245968|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
214245969|NCT02866487|PROCEDURE|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
214245970|NCT00000253|DRUG|10% N2O|
214245971|NCT00000253|DRUG|20% N2O|
214245972|NCT00000253|DRUG|30% N2O|
214245973|NCT00000253|DRUG|40% N2O|
214245974|NCT02803515|BIOLOGICAL|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
214245975|NCT02326545|BEHAVIORAL|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
214245976|NCT02326545|BEHAVIORAL|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
214245977|NCT02157207|DIETARY_SUPPLEMENT|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
214245978|NCT02157207|OTHER|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
214245979|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
214245980|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
214245981|NCT04375475|DIETARY_SUPPLEMENT|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
214245982|NCT03809793|OTHER|Exercise Program|12-week walking based intervention (3 sessions per week)
214245983|NCT03809793|DIAGNOSTIC_TEST|DXA|Participants will undergo an assessment of body composition (DXA)
214245984|NCT03809793|DIAGNOSTIC_TEST|MRI|used to measure fat stored in the liver
214245985|NCT03809793|DIAGNOSTIC_TEST|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
214245986|NCT03809793|DIAGNOSTIC_TEST|VO2 Max|Assessment of maximum aerobic capacity.
214245987|NCT03809793|DIAGNOSTIC_TEST|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
214245988|NCT03809793|PROCEDURE|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
214245989|NCT03809793|DRUG|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
214245990|NCT05867342|DRUG|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
214245991|NCT05867342|DRUG|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
214245992|NCT05867342|DRUG|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
214245993|NCT05791903|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
214245994|NCT02385188|DRUG|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
214245995|NCT02385188|DRUG|paracetamol|
214245996|NCT02385188|DRUG|lidocaine in Vaseline ointment|
214245997|NCT03600688|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair
214245998|NCT00470184|DRUG|capecitabine|Oral
214245999|NCT00470184|DRUG|oxaliplatin|IV
214246000|NCT00470184|GENETIC|gene expression analysis|Correlative Study
214246001|NCT00470184|GENETIC|microarray analysis|Correlative Study
214246002|NCT00470184|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative Study
214246003|NCT00470184|PROCEDURE|adjuvant therapy|Metastatic growth control
214246004|NCT00470184|PROCEDURE|biopsy|Examination of tissue type
214246005|NCT00470184|PROCEDURE|conventional surgery|Tissue removal
214246006|NCT00470184|PROCEDURE|neoadjuvant therapy|Tumor shrinkage
214246007|NCT00470184|PROCEDURE|quality-of-life assessment|Correlative Study
214246008|NCT00470184|RADIATION|radiation therapy|Undergoing radiation therapy
214246009|NCT05953714|OTHER|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
214246010|NCT05998928|DRUG|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"
214246011|NCT05442775|DRUG|Reldesemtiv|Oral tablet
214246012|NCT01020539|DRUG|Fludarabine|Conditioning Regimen
214246013|NCT01020539|DRUG|Busulfan|Conditioning Regimen
214246014|NCT01020539|DRUG|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
214652669|NCT03470181|DIETARY_SUPPLEMENT|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
214246015|NCT01020539|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
214246016|NCT01020539|DRUG|Anti-Thymocyte Globulin|Unrelated Donors only
214246017|NCT01020539|DRUG|Isotretinoin|JMML patients only
214246018|NCT01410552|DEVICE|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
214246019|NCT02001025|DEVICE|Absorb scaffold|
214246020|NCT02001025|DEVICE|Xience stent|
214246021|NCT00058539|DRUG|rhuMAb 2C4 (pertuzumab)|
214246022|NCT04849325|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
214246023|NCT04849325|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
214246024|NCT04387825|DRUG|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
214246025|NCT05976438|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
214246026|NCT05976438|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
214246027|NCT04455360|OTHER|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
214246028|NCT03190369|DEVICE|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
214246029|NCT03190369|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
214246030|NCT05386485|OTHER|None intervation|Observational Study
214246031|NCT04991428|OTHER|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
214246032|NCT02963831|BIOLOGICAL|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
214246033|NCT02963831|DRUG|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
214246034|NCT02963831|DRUG|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
214246035|NCT05036720|BEHAVIORAL|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
214246036|NCT05036720|BEHAVIORAL|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
214246037|NCT04224883|PROCEDURE|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
214246038|NCT04224883|PROCEDURE|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
214246039|NCT04224883|PROCEDURE|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
214246040|NCT04766372|OTHER|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
214246041|NCT04543409|BIOLOGICAL|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
214246042|NCT04543409|BIOLOGICAL|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
214246043|NCT01923168|DRUG|alpelisib|BYL719 + Letrozole
214246044|NCT01923168|DRUG|buparlisib|BKM120 + Letrozole
214246045|NCT01923168|DRUG|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
214246046|NCT03418571|BIOLOGICAL|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
214246047|NCT03418571|OTHER|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
214246048|NCT06418464|DEVICE|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
214246049|NCT00847639|DRUG|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
214246050|NCT03348787|BEHAVIORAL|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
214246051|NCT02908867|OTHER|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
214246052|NCT03742908|DRUG|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
214652670|NCT00650858|DRUG|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
214246053|NCT01733927|DEVICE|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
214246054|NCT03582644|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
214246055|NCT05837143|BIOLOGICAL|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
214246056|NCT00965510|BEHAVIORAL|care coordination|patients receive care coordination to improve their type II diabetes
214246057|NCT03882008|DRUG|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
214246058|NCT00857402|DIETARY_SUPPLEMENT|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
214246059|NCT00857402|DIETARY_SUPPLEMENT|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
214246060|NCT05658536|BEHAVIORAL|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
214246061|NCT03156361|DRUG|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
214246062|NCT03156361|DRUG|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
214246063|NCT00655460|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
214246064|NCT02506569|DEVICE|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
214246065|NCT02506569|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
214246066|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
214246067|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
214246068|NCT01411930|DRUG|Intramuscular olanzapine, aripiprazole|"1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
214246069|NCT01411930|DRUG|Intramuscular aripiprazole, olanzapine|"1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
214246070|NCT02875925|OTHER|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
214246071|NCT06256627|DRUG|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
214246072|NCT04341662|BEHAVIORAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
214246073|NCT04341662|BEHAVIORAL|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
214246074|NCT06533137|OTHER|Neutral ginger-flavored drink described as energizing, hypoglycemic, caffeine-based drink|"It is a neutral ginger-flavored drink with no energizing properties, although it was presented as particularly energizing, hypoglycemic, caffeine-based, and designed to reduce fatigue and improve performance."
214246075|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger flavoured drink described as an energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance.
214246076|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger-flavored beverage bescribed as a mineral salt-based drink
214246077|NCT04722835|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage (BAL)|"1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~5. Blood draw~6. Medical Health and Symptom Questionnaires~7. Physical Exam by study doctor to determine suitability and safety for participation."
214246078|NCT03101267|DRUG|ASP4070|Intradermal vaccination at 2-week intervals
214246079|NCT03101267|DRUG|Placebo|Intradermal vaccination at 2-week intervals
214246080|NCT05674552|DRUG|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
214246081|NCT02470715|GENETIC|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
214246082|NCT04444830|DRUG|Sprix|Intranasal Ketorolac - used as directed for an appropriate, previously established indication
214246083|NCT05027360|DRUG|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
214246084|NCT04178369|OTHER|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
214246085|NCT04178369|OTHER|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
214246086|NCT06020638|DEVICE|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
214246087|NCT06020638|DEVICE|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
214246088|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
214246089|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
214246090|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
214246091|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
214246092|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
214246093|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
214246094|NCT01222403|BIOLOGICAL|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
214246095|NCT01222403|BIOLOGICAL|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
214246096|NCT02064075|DRUG|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
214246097|NCT02064075|DRUG|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
214246098|NCT03709641|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
214246099|NCT00618839|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
214246100|NCT00618839|PROCEDURE|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
214246101|NCT05165589|DEVICE|ActiveInsights accelerometer device|Accelerometer device
214246102|NCT04673123|OTHER|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
214464765|NCT05202964|OTHER|Tolerance and adherence to oral antibiotics in patients managed for BJI|"Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire).~Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3.~Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse."
214464766|NCT05354544|BIOLOGICAL|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
214246103|NCT04673123|OTHER|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
214246104|NCT02642939|DRUG|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
214246105|NCT05623865|OTHER|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
214246106|NCT05623865|OTHER|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
214246107|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
214246108|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
214246109|NCT00701623|DRUG|folder water|patients will receive the application of folder water directly on the injured area
214246110|NCT01086839|DRUG|sodium chloride 6%|"* one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days"
214246111|NCT01086839|DRUG|sodium chloride 0,9%|"* one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days"
214246112|NCT01262352|DRUG|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
214246113|NCT01262352|DRUG|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
214246114|NCT02792621|DIETARY_SUPPLEMENT|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
214246115|NCT02792621|DIETARY_SUPPLEMENT|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
214246116|NCT02153879|DRUG|Fenofibrate|fenofibrate 145/day for 12 weeks
214246117|NCT02153879|DRUG|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
214246118|NCT02235727|DRUG|GBR 900|
214246119|NCT02235727|DRUG|Placebo|
214246120|NCT02420782|DRUG|ASP6282|oral
214246121|NCT02420782|DRUG|Itraconazole|oral
214246122|NCT02420782|DRUG|Pilocarpine|oral
214246123|NCT02420782|DRUG|Placebo|oral
214246124|NCT02420782|DRUG|Midazolam|oral
214246125|NCT04615585|OTHER|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
214246126|NCT04615585|PROCEDURE|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
214246127|NCT01325220|DRUG|arbaclofen|5 mg bid
214246128|NCT01325220|DRUG|arbaclofen|10 mg bid
214246129|NCT01325220|DRUG|arbaclofen|10 mg tid
214246130|NCT01325220|DRUG|Placebo|tid
214246131|NCT03754231|OTHER|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
214246132|NCT03754231|OTHER|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
214246133|NCT00130351|DEVICE|formoterol|
214246134|NCT03091972|PROCEDURE|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
214246135|NCT03091972|PROCEDURE|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
214246136|NCT03091972|PROCEDURE|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
214246137|NCT00344890|PROCEDURE|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
214246138|NCT00600054|BIOLOGICAL|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
214246139|NCT00042029|DRUG|MK0869, aprepitant|
214246140|NCT00042029|DRUG|Comparator: placebo|
214246141|NCT02454231|BIOLOGICAL|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
214246142|NCT02454231|BIOLOGICAL|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
214246143|NCT00035347|DRUG|IV azithromycin|500 mg once daily
214246144|NCT00035347|DRUG|ceftriaxone|1 gram once daily for 2 to 5 days
214246145|NCT00035347|DRUG|oral azithromycin|2 x 250 mg once daily
214246146|NCT00035347|DRUG|IV levofloxacin|500 mg once daily
214246147|NCT00035347|DRUG|oral levofloxacin|500 mg once daily
214246148|NCT00897338|OTHER|flow cytometry|laboratory analysis
214246149|NCT00897338|OTHER|fluorescence activated cell sorting|laboratory analysis
214246150|NCT00897338|OTHER|immunohistochemistry staining method|laboratory analysis
214246151|NCT00897338|OTHER|immunologic technique|laboratory analysis
214246152|NCT00897338|OTHER|biomarker analysis|laboratory analysis
214246153|NCT03286127|OTHER|specialized palliative care|specialized palliative care provided in different settings
214246154|NCT05043376|DRUG|Standard of care|Standard COVID-19 care as per the hospital guidelines
214246155|NCT05043376|DIETARY_SUPPLEMENT|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
214246156|NCT03016143|BIOLOGICAL|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
214246157|NCT03016143|BIOLOGICAL|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
214246158|NCT00466492|PROCEDURE|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
214246159|NCT03551925|BEHAVIORAL|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
214246160|NCT03551925|BEHAVIORAL|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
214246161|NCT04066764|DRUG|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
214246162|NCT04066764|DRUG|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
214246163|NCT04066764|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
214246164|NCT00296608|DRUG|fluorouracil|
214246165|NCT00296608|DRUG|leucovorin calcium|
214246166|NCT00296608|PROCEDURE|conventional surgery|
214246167|NCT00296608|RADIATION|radiation therapy|
214246168|NCT05956210|DEVICE|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
214246169|NCT00227071|BEHAVIORAL|exercise|
214246170|NCT02962843|BEHAVIORAL|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
214246171|NCT00629278|BIOLOGICAL|trastuzumab|
214246172|NCT00629278|DRUG|aromatase inhibition therapy|
214246173|NCT00629278|DRUG|cyclophosphamide|
214246174|NCT00629278|DRUG|docetaxel|
214246175|NCT00629278|DRUG|doxorubicin hydrochloride|
214246176|NCT00629278|DRUG|epirubicin hydrochloride|
214246177|NCT00629278|DRUG|fluorouracil|
214246178|NCT00629278|DRUG|paclitaxel|
214246179|NCT00629278|DRUG|releasing hormone agonist therapy|
214246180|NCT00629278|DRUG|tamoxifen citrate|
214246181|NCT00629278|PROCEDURE|adjuvant therapy|
214246182|NCT00629278|RADIATION|radiation therapy|
214246183|NCT02539615|DEVICE|ForeCYTE Breast Aspirator|
214246184|NCT04028661|DEVICE|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
214246185|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 30 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
214246186|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 100 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
214246187|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 300 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
214246188|NCT05471076|OTHER|Placebo|Administered via injection as a split dose into the deltoid muscle (both left and right).
214246189|NCT05471076|BIOLOGICAL|BG505|A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
214246190|NCT03539224|DRUG|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
214246191|NCT03539224|DRUG|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
214246192|NCT01989260|DEVICE|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
214246193|NCT02045303|DEVICE|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
214246194|NCT02045303|DEVICE|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
214246195|NCT01642407|DRUG|Sildenafil|Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
214246196|NCT00026611|BIOLOGICAL|Dryvax vaccine|
214246197|NCT02318108|OTHER|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
214246198|NCT02318108|OTHER|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
214246199|NCT03448081|DRUG|SNA-120|SNA-120 (0.5%) active ointment
214246200|NCT03448081|DRUG|Placebo|Vehicle Ointment
214246201|NCT03448081|DRUG|Calcipotriene|Calcipotriene ointment (0.005%)
214246202|NCT04946227|DRUG|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
214246203|NCT03533686|DEVICE|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
214246204|NCT03533686|DEVICE|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
214246205|NCT02523612|PROCEDURE|Biopsy|
214246206|NCT02523612|PROCEDURE|Blood sample|
214246207|NCT00755911|BIOLOGICAL|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
214246208|NCT00755911|DEVICE|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
214246209|NCT04132375|DRUG|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
214246210|NCT04132375|DRUG|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
214246211|NCT00245583|DRUG|Topiramate|minimum does of 50mg/day
214246212|NCT00245583|DRUG|Placebo|matching tablet
214246213|NCT00205400|PROCEDURE|medical care delivery model|
214246214|NCT00796354|DRUG|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
214246215|NCT00796354|DRUG|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
214246216|NCT00829283|BEHAVIORAL|Behavioral Weight Loss|weekly individual sessions for 6 months
214246217|NCT00829283|BEHAVIORAL|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
214246218|NCT00829283|DRUG|Placebo|One pill daily
214246219|NCT00829283|DRUG|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
214246220|NCT01411072|DRUG|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
214246221|NCT01411072|DRUG|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
214246222|NCT03316183|OTHER|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
214246223|NCT02923544|PROCEDURE|YUMI manipulator|
214246224|NCT06057740|BEHAVIORAL|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig \& Levin, 2017).
214246225|NCT06057740|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
214246226|NCT04387383|DEVICE|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
214246227|NCT04387383|DEVICE|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
214246228|NCT04167956|DEVICE|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
214246229|NCT00001860|DRUG|Sandostatin LAR Depot versus transsphenoidal surgery|
214246230|NCT03004248|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular Injection
214246231|NCT01879540|BIOLOGICAL|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
214246232|NCT06312969|BEHAVIORAL|Video game based training|"Type of intervention: Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games~Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
214246233|NCT01644370|DRUG|HAART|as per Thai HIV Treatment guidelines
214246234|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
214246235|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
214246236|NCT00591578|DRUG|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
214246237|NCT05047627|BEHAVIORAL|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
214246238|NCT00791232|DRUG|extended-release (ER) OROS paliperidone|
214246239|NCT03712254|DRUG|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
214246240|NCT02352584|BIOLOGICAL|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
214246241|NCT02352584|BIOLOGICAL|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
214246242|NCT02352584|BIOLOGICAL|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
214246243|NCT06133738|OTHER|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
214246244|NCT06133738|OTHER|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
214246245|NCT06133738|OTHER|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
214246246|NCT03143491|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
214246247|NCT01165567|DRUG|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
214246248|NCT04652180|PROCEDURE|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
214246249|NCT05930366|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
214246250|NCT05930366|PROCEDURE|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
214246251|NCT03468569|OTHER|Functional Movement Screen|
214246252|NCT02261025|DRUG|acetylsalicylic acid|75-100mg,per day
214246253|NCT04077476|BEHAVIORAL|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
214246254|NCT04077476|BEHAVIORAL|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
214246255|NCT03945175|DRUG|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
214246256|NCT03945175|DRUG|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
214246257|NCT03230669|OTHER|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
214246258|NCT00951782|DEVICE|High frequency TMS|deep TMS HADD coil
214246259|NCT00951782|DEVICE|Sham TMS|sham deep TMS HADD coil
214246260|NCT00951782|DEVICE|Low frequency TMS|Deep TMS - HADD coil
214246261|NCT00870233|BEHAVIORAL|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
214246262|NCT00349271|PROCEDURE|Stem cell|Stem cell
214246263|NCT00349271|DRUG|Filgrastime (G-CSF)|Filgrastime (G-CSF)
214246264|NCT00349271|DRUG|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
214246265|NCT01768247|DRUG|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
214246266|NCT02686190|OTHER|Luxtherapy|
214246267|NCT00378079|OTHER|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
214246268|NCT00378079|DRUG|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
214246269|NCT00378079|DRUG|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
214246270|NCT02778360|DEVICE|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
214246271|NCT02778360|DRUG|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
214246272|NCT02902679|DRUG|BMS-986177|
214246273|NCT04123028|OTHER|observatory|observation for 1 year period
214246274|NCT05840029|PROCEDURE|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
214246275|NCT05694000|DEVICE|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
214246276|NCT05694000|DEVICE|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
214246277|NCT00006389|DRUG|bryostatin 1|Given IV
214246278|NCT00006389|DRUG|cisplatin|Given IV
214246279|NCT00006389|OTHER|laboratory biomarker analysis|Correlative studies
214246280|NCT03977428|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
214246281|NCT01210287|DRUG|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
214246282|NCT03037268|DEVICE|Lytro Plenoptic Camera and 28D lens|"* visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader"
214246283|NCT05451342|DIAGNOSTIC_TEST|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
214652671|NCT03688217|BEHAVIORAL|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
214652672|NCT03688217|BEHAVIORAL|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
214246284|NCT03891160|OTHER|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
214246285|NCT03114059|DIAGNOSTIC_TEST|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
214246286|NCT04694456|OTHER|cytokines dosage|Mesure of cytokines concentration in serum
214246287|NCT04694456|PROCEDURE|test of walk|patient must walk during 6 minutes on a flat surface
214246288|NCT04694456|PROCEDURE|Manual muscular test|test performed to evaluate the patient muscular weakness
214246289|NCT04694456|PROCEDURE|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
214246290|NCT00169884|BEHAVIORAL|cognitive-behavioural therapy|
214246291|NCT04466228|DEVICE|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
214246292|NCT04862858|OTHER|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
214246293|NCT02728778|DRUG|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
214246294|NCT02728778|PROCEDURE|Acupuncture|Application of acupuncture into the forehead
214246295|NCT06104371|DEVICE|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
214246296|NCT05038904|DRUG|Acalabrutinib|100 mg oral capsule
214246297|NCT04177238|DIETARY_SUPPLEMENT|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
214246298|NCT04545203|OTHER|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
214246299|NCT02845518|PROCEDURE|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
214246300|NCT01771575|OTHER|Placebo device|Placebo device
214246301|NCT01771575|DEVICE|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
214246302|NCT00224627|PROCEDURE|Capsule GIVEN IMAGING LTD|
214246303|NCT03949491|PROCEDURE|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
214246304|NCT02770469|BEHAVIORAL|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
214246305|NCT02770469|BEHAVIORAL|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
214246306|NCT01253330|OTHER|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
214246307|NCT03069118|BEHAVIORAL|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
214246308|NCT03069118|BEHAVIORAL|Control - Resource List|Tailored list of resources.
214246309|NCT04590079|DEVICE|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
214246310|NCT02959164|DRUG|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
214246311|NCT02959164|DRUG|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
214246312|NCT00004017|PROCEDURE|conventional surgery|
214246313|NCT00004017|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
214246314|NCT03015883|RADIATION|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214246315|NCT02524964|DRUG|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
214246316|NCT02524964|OTHER|control|equivalent volume of sodium chloride solution
214246317|NCT04538196|OTHER|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
214246318|NCT03360786|OTHER|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
214246319|NCT03360786|OTHER|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
214246320|NCT01771185|PROCEDURE|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
214652673|NCT03529409|BEHAVIORAL|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
214652674|NCT05438381|PROCEDURE|Atraumatic Restorative Technique (ART)|Glass ionomer capsule (GC, USA)
214652675|NCT05438381|PROCEDURE|SMART Technique|silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
214652676|NCT04751942|DEVICE|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
214246321|NCT01771185|DRUG|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
214246322|NCT01522586|DRUG|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
214246323|NCT01522586|DRUG|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
214246324|NCT03096015|BEHAVIORAL|Intensive Comprehensive Aphasia Program|
214246325|NCT00002585|DRUG|pyrazoloacridine|
214246326|NCT01440062|DRUG|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
214246327|NCT01440062|DRUG|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
214246328|NCT04867434|DRUG|RZL-012|small synthetic molecule for submental fat reduction
214246329|NCT04867434|DRUG|Placebo|Placebo
214246330|NCT01445886|DRUG|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
214246331|NCT01445886|DRUG|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
214246332|NCT03858465|DRUG|Ephedrine|intravenous 25 mg of ephedrine
214246333|NCT03858465|DRUG|Phenylephrine|intravenous 0,3 mg of phenylephrine
214246334|NCT01872234|DEVICE|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
214246335|NCT04956770|PROCEDURE|Implantation surgery|"The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
214246336|NCT02385136|DRUG|Temozolomide|
214246337|NCT05029973|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
214246338|NCT05029973|DRUG|Sintilimab|200mg IV d1,Q3W
214246339|NCT05029973|DRUG|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
214246340|NCT00079131|BIOLOGICAL|oblimersen sodium|Given IV
214246341|NCT00079131|OTHER|pharmacological study|Correlative studies
214246342|NCT00079131|OTHER|laboratory biomarker analysis|Correlative studies
214246343|NCT06077708|DIETARY_SUPPLEMENT|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
214246344|NCT06077708|OTHER|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
214246345|NCT02704910|BEHAVIORAL|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
214246346|NCT05366673|OTHER|massage|Perform a 10-minute back massage every day for a week
214246347|NCT05295797|BEHAVIORAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
214246348|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
214246349|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
214246350|NCT04671173|DEVICE|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
214246351|NCT03500679|BIOLOGICAL|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
214246352|NCT03500679|BIOLOGICAL|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
214246353|NCT03473938|DEVICE|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
214246354|NCT00404703|DRUG|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
214246355|NCT00404703|DRUG|Platinum-based chemotherapy|As prescribed
214246356|NCT03300518|DRUG|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
214246357|NCT03300518|DRUG|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
214246358|NCT03300518|DRUG|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
214246359|NCT03300518|DRUG|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
214246360|NCT01962922|DRUG|LCP-Tacro|once-daily extended release tablet
214246361|NCT01962922|DRUG|Tacrolimus -IR|twice daily capsules
214246362|NCT04073329|OTHER|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with \> 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
214246363|NCT04128332|RADIATION|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
214246364|NCT03368573|DEVICE|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
214246365|NCT04319822|OTHER|blood sample and muscular biopsy|blood sample and muscular biopsy
214246366|NCT00391261|DRUG|Metformin|open-label, flexible dosing
214246367|NCT01759485|DRUG|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
214246368|NCT01759485|DRUG|placebo|
214246369|NCT04658173|DRUG|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
214246370|NCT04658173|DRUG|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
214246371|NCT04923165|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
214246372|NCT04923165|DIAGNOSTIC_TEST|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
214246373|NCT04923165|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
214246374|NCT04923165|DIAGNOSTIC_TEST|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
214246375|NCT01418027|OTHER|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
214246376|NCT01418027|OTHER|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
214246377|NCT02882373|DIETARY_SUPPLEMENT|Arginine|Given PO
214246378|NCT02882373|DRUG|Placebo|Given PO
214246379|NCT03913325|OTHER|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
214246380|NCT03913325|OTHER|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
214246381|NCT00013195|BEHAVIORAL|Telephone Care|
214246382|NCT03098771|PROCEDURE|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
214246383|NCT03098771|DRUG|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
214246384|NCT06473987|OTHER|Personalized cognitive-sensorimotor VR/AR training|Thinking task integrated walking and balance training program
214246385|NCT06473987|OTHER|Traditional dual-task training|Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training
214246386|NCT06473987|OTHER|Standard of Care|Standard walking and balance training
214246387|NCT01616134|OTHER|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
214246388|NCT01616134|OTHER|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
214246389|NCT00254774|DRUG|quetiapine fumarate or valproate|
214246390|NCT05641675|DIAGNOSTIC_TEST|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
214246391|NCT02319356|DIETARY_SUPPLEMENT|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
214246392|NCT02319356|DIETARY_SUPPLEMENT|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
214246393|NCT05730816|DRUG|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
214246394|NCT05730816|DRUG|Normal Saline|Intravenous infusion of normal saline.
214246395|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
214246396|NCT00989690|DRUG|docetaxel|
214246397|NCT00989690|DRUG|erlotinib hydrochloride|
214246398|NCT00989690|DRUG|pemetrexed disodium|
214246399|NCT00989690|GENETIC|fluorescence in situ hybridization|
214246400|NCT00989690|GENETIC|mutation analysis|
214246401|NCT00989690|GENETIC|proteomic profiling|
214246402|NCT00989690|OTHER|immunohistochemistry staining method|
214246403|NCT00989690|OTHER|laboratory biomarker analysis|
214246404|NCT00989690|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
214246405|NCT00989690|PROCEDURE|breath test|
214246406|NCT02891616|DRUG|fludeoxyglucose F 18|
214246407|NCT02891616|DEVICE|Positron emission tomography-computed tomography|
214246408|NCT02891616|DRUG|18F-fluorothymidine|
214246409|NCT02891616|DEVICE|Positron emission tomography-magnetic resonance imaging|
214246410|NCT00451139|DRUG|artemether/lumefantrine|
214246411|NCT00451139|DRUG|quinine|
214246412|NCT00451139|DRUG|atovaquone/proguanil|
214246413|NCT03224546|BEHAVIORAL|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
214246414|NCT01041729|DRUG|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
214246415|NCT01041729|DRUG|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
214246416|NCT00644748|DRUG|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
214246417|NCT03088215|DEVICE|shock-waves|Application of shock-waves (radial and focused)
214246418|NCT02780323|DRUG|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
214246419|NCT02780323|DRUG|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
214246420|NCT02780323|DRUG|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
214246421|NCT02780323|DRUG|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
214246422|NCT04673084|DEVICE|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
214246423|NCT03268473|OTHER|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
214246424|NCT03268473|OTHER|Control|Control: Non-surgical periodontal therapy in Periodontitis
214246425|NCT05806671|DRUG|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
214246426|NCT05806671|DRUG|Pyrotinib|Pyrotinib 320mg/day orally continuously
214246427|NCT05806671|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
214246428|NCT04594954|DIETARY_SUPPLEMENT|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
214246429|NCT04594954|OTHER|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure."
214246430|NCT04594954|OTHER|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
214246431|NCT00775385|DRUG|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
214246432|NCT00775385|DRUG|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
214246433|NCT00238537|DRUG|Alteplase t-PA|
214246434|NCT04432220|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
214246435|NCT04140136|DIETARY_SUPPLEMENT|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
214246436|NCT04140136|DIETARY_SUPPLEMENT|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
214246437|NCT02730208|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
214246438|NCT02730208|DRUG|Ivacaftor|IVA 150 mg tablet.
214246439|NCT02730208|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
214246440|NCT02730208|DRUG|Placebo|Placebo matched to IVA tablet.
214246441|NCT01206673|OTHER|Blood sampling|One blood sampling is required for the research
214246442|NCT02890290|DIETARY_SUPPLEMENT|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
214246443|NCT02890290|DIETARY_SUPPLEMENT|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
214246444|NCT02978131|OTHER|Histopathological study|
214246445|NCT02978131|OTHER|Molecular study (Polymerase chain reaction)|
214652677|NCT04751942|DEVICE|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
214246446|NCT00245219|BEHAVIORAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
214246447|NCT00245219|BEHAVIORAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
214246448|NCT04641520|OTHER|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
214246449|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
214246450|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
214246451|NCT01687374|DRUG|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
214246452|NCT01687374|DRUG|Placebo|Saline injection daily for 8 weeks.
214246453|NCT00510952|DRUG|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
214246454|NCT00510952|DRUG|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
214246455|NCT03918668|BEHAVIORAL|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
214246456|NCT03551262|DEVICE|OTSC|Positioning of OTSC in bleeding peptic ulcer
214246457|NCT03551262|DEVICE|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
214246458|NCT03457233|DRUG|Gonadotropins|1\) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
214246459|NCT03457233|DRUG|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
214246460|NCT03457233|DRUG|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
214246461|NCT03457233|DRUG|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
214246462|NCT00048893|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10\^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
214246463|NCT00048893|BIOLOGICAL|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10\^8 pfu x 1 dose subcutaneously.
214246464|NCT00048893|BIOLOGICAL|filgrastim|5 mcg/kg/day subcutaneously
214246465|NCT00048893|BIOLOGICAL|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
214246466|NCT00048893|DRUG|cyclophosphamide|"First induction chemotherapy: 2700 mg/m\^2 per cycle (900 mg/m\^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m\^2 per cycle (600 mg/m\^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m\^2 per cycle (600 mg/m\^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4)."
214246467|NCT00048893|DRUG|doxorubicin hydrochloride|60 mg/m\^2 per cycle (60 mg/m\^2 slow intravenous push day 1).
214246468|NCT00048893|DRUG|fludarabine phosphate|120 mg/m\^2 (30 mg/m\^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
214246469|NCT00048893|DRUG|paclitaxel|160 mg/m\^2 per cycle (53.3 mg/m\^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
214246470|NCT00048893|DRUG|Mesna|"Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.~3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)"
214246471|NCT02717845|DEVICE|Ellipse|diagnostic CT scan imaging
214246472|NCT02717845|DEVICE|Tomofix|diagnostic CT scan imaging
214246473|NCT02691962|DEVICE|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
214246474|NCT06330688|PROCEDURE|percutaneous cholecystostomy|PC is a minimally invasive, nonsurgical, image-guided intervention that aims to drain and decompress the gallbladder by placing a pigtail catheter through the abdominal wall into the gallbladder lumen.
214246475|NCT05806684|OTHER|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
214246476|NCT02325856|DEVICE|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
214246477|NCT02325856|BEHAVIORAL|Clinical judgement|
214246478|NCT00138411|DRUG|Ciprofloxacin 500 mg|
214246479|NCT00138411|DRUG|ETI-204 (Anthim)|
214246480|NCT06336161|DRUG|Fentanyl|to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
214246481|NCT00867477|PROCEDURE|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
214246482|NCT00867477|BEHAVIORAL|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
214246483|NCT00867477|PROCEDURE|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
214246484|NCT02793128|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
214246485|NCT03469674|RADIATION|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
214246486|NCT03469674|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
214246487|NCT03469674|OTHER|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
214246488|NCT02355977|DRUG|minocycline|Periocline dental ointment
214246489|NCT02355977|PROCEDURE|surface and root planning|surface and root planning
214246490|NCT02340273|DEVICE|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
214246491|NCT02340273|DEVICE|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
214246492|NCT00127621|PROCEDURE|early tracheotomy|
214246493|NCT00127621|PROCEDURE|prolonged endotracheal intubation|
214246494|NCT06278415|OTHER|Physiological based cord clamping|see Arm Description
214246495|NCT06278415|OTHER|Differed cord clamping|see Arm Description
214246496|NCT06993506|DRUG|SKB264 Monotherapy or Combination Therapy|The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.
214246497|NCT03757013|DRUG|Apremilast|Apremilast
214246498|NCT06685588|DRUG|5-FU (fluorouracil)|Topical 5-FU (fluorouracil) pretreatment prior to dovonex
214246499|NCT06685588|DRUG|Calcipotriol|Calcipotriol pre-treatment prior to PDT
214246500|NCT06682247|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
214246501|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).
214246502|NCT06683703|DRUG|Utidelone|Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
214246503|NCT06683703|DRUG|Utidelone combined with Bevacizumab|In the combination group, the dose of Utidelone was determined according to the safety run-in period, 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3W.
214246504|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The dose of Utidelone was 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3w.
214246505|NCT06684873|DRUG|AK112 Injection|AK112 injection plus chemotherapy was administered to all eligible patients
214246506|NCT06684522|DRUG|Upadacitinib 15 MG|Upadacitinib 15mg daily
214246507|NCT05952271|OTHER|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
214246508|NCT06708377|OTHER|dry needling of masseter|"Experimental group included Dry needling of masseter muscle for 30 second to 2 minutes into the trigger point.~Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day."
214246509|NCT06708377|OTHER|myofascial massage therapy on masseter muscle|Control group included Myofascial massage - sliding and kneading, for 30 minutes per session/3x per week. Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day
214246510|NCT06878495|OTHER|Discontinuation of 5-ASA|Discontinuation of 5-ASA from the time of study enrollment.
214246511|NCT06717334|DIAGNOSTIC_TEST|Low Dose CT imaging|at baseline and at Year 1.
214246512|NCT06717334|OTHER|blood draws|at baseline and at Year 1.
214246513|NCT06717334|OTHER|screening questionnaire|at baseline and at 1 year after registration.
214246514|NCT03287635|DRUG|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
214246515|NCT03670836|DEVICE|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
214246516|NCT03670836|DRUG|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
214246517|NCT00396032|DRUG|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
214246518|NCT00396032|DRUG|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
214246519|NCT06921356|BEHAVIORAL|Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention|Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.
214246520|NCT06921356|BEHAVIORAL|Self-Shopping DASH diet advice|Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.
214246521|NCT06894992|DRUG|Tegoprazan|Tegoprazan 50 mg tab PO OD in 2 weeks
214246522|NCT06894992|DRUG|Lansoprazole|Lansoprazole 30 mg tab PO OD in 2 weeks
214246523|NCT06730750|DRUG|BMS-986490|Specified dose on specified days.
214246524|NCT06730750|DRUG|Bevacizumab|Specified dose on specified days.
214246525|NCT01598363|DRUG|Digoxin|Oral, Day 1 and Day 10
214246526|NCT01598363|DRUG|Rosuvastatin|Oral, Day 1 and Day 10
214246527|NCT06770517|BEHAVIORAL|Exposure therapy|The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.
214246528|NCT06770517|BEHAVIORAL|Usual Care|The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.
214246529|NCT04981834|OTHER|Quality-of-Life Assessment|Ancillary studies
214246530|NCT04981834|OTHER|Questionnaire Administration|Ancillary studies
214246531|NCT04981834|PROCEDURE|Radical Prostatectomy|Undergo RARP
214246532|NCT04981834|PROCEDURE|Vesicopexy|Undergo vesicopexy
214246533|NCT06871124|DEVICE|transcranial electrical stimulation|Anodal transcranial electrical stimulation (A-tES) is a widely used and well tolerated non-invasive electrical stimulation paradigm that promotes adaptive neuroplasticity and may prevent or reduce pathological sequela following brain injury. It has been used in a wide variety of neurologic and psychiatric disorders for cognitive and motor rehabilitation.
214246534|NCT06871124|DEVICE|Sham Comparator|Sham comparator consist of A-tES in the beginning and end of stimulation block but no stimulation during the actual stimulation period.
214246535|NCT05423912|BEHAVIORAL|Keeping on Course Program|MCI dyads engaging in the testing aim of the Keeping on Course Program take part in group meetings lasting 90 to 120 minutes over the course of 6 virtual meetings. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be invited to take part in a virtual, semi-structured 30-60 minute qualitative interview focused on their experiences in and perceptions of the intervention.
214246536|NCT04914416|DIETARY_SUPPLEMENT|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
214246537|NCT04914416|DIETARY_SUPPLEMENT|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
214246538|NCT04914416|DIETARY_SUPPLEMENT|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
214246539|NCT04914416|DIETARY_SUPPLEMENT|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
214246540|NCT04914416|DIETARY_SUPPLEMENT|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
214246541|NCT04914416|DIETARY_SUPPLEMENT|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
214246542|NCT04914416|DIETARY_SUPPLEMENT|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
214246543|NCT04914416|DIETARY_SUPPLEMENT|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
214246544|NCT04914416|DIETARY_SUPPLEMENT|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
214246545|NCT04914416|DIETARY_SUPPLEMENT|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
214246546|NCT04914416|DIETARY_SUPPLEMENT|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
214246547|NCT04914416|DIETARY_SUPPLEMENT|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
214246548|NCT04914416|DIETARY_SUPPLEMENT|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
214246549|NCT04914416|DIETARY_SUPPLEMENT|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
214246550|NCT04914416|DIETARY_SUPPLEMENT|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
214246551|NCT04914416|DIETARY_SUPPLEMENT|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
214246552|NCT04914416|DIETARY_SUPPLEMENT|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
214246553|NCT05629637|BEHAVIORAL|Mindfulness-Based Resilience Training (MBRT)|MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
214246554|NCT06938945|BEHAVIORAL|Digitized patient-reported outcomes|Patients fill out the PRO scale regularly online through a specific cell phone program or website, which intelligently analyzes the patient's physical condition, gives symptom management recommendations (which are based on clinical guidelines and expert consensus, and are updated monthly by oncology clinical experts during the study period), and sends alerts to clinical caregivers when the scale scores are abnormal.
214246555|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
214246556|NCT01964131|DRUG|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
214246557|NCT01964131|DRUG|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
214246558|NCT03166878|BIOLOGICAL|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
214246559|NCT03070444|DEVICE|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
214246560|NCT03070444|DEVICE|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
214246561|NCT03070444|DEVICE|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
214246562|NCT03070444|PROCEDURE|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
214246563|NCT03070444|OTHER|Questionnaire|A questionnaire is completed at the follow-up visits.
214246564|NCT05012761|DRUG|SR419 capsules|Ascending single and multiple doses of SR419 orally
214246565|NCT05012761|DRUG|Placebo|Ascending single and multiple doses of placebo orally
214246566|NCT06557525|BEHAVIORAL|Neurofeedback|Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
214246567|NCT01373489|BEHAVIORAL|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
214246568|NCT00174330|DRUG|atorvastatin|
214246569|NCT00174330|DRUG|amlodipine|
214246570|NCT02112006|PROCEDURE|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
214246571|NCT02112006|PROCEDURE|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
214246572|NCT04444349|DRUG|Coenzyme Q10|Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
214246573|NCT04444349|DIETARY_SUPPLEMENT|Standard Medical Therapy|Patients only received standard medical therapy without CoQ10.
214246574|NCT05647096|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber
214246575|NCT06433570|GENETIC|multiplex PCR|Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
214246576|NCT04088656|OTHER|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
214246577|NCT05191979|OTHER|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
214246578|NCT05780606|OTHER|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
214246579|NCT04591860|DEVICE|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
214246580|NCT02586285|DRUG|S-Adenosyl Methionine|500mg-1000mg,iv,qd
214246581|NCT06004908|DEVICE|MRI|a type of scan that uses strong magnetic field sand radio waves to produce detailed images of the inside of the body
214246582|NCT01425775|DRUG|vitamin D 25(OH)D|2000IU/day for 12 months
214246583|NCT01425775|OTHER|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
214464767|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
214464768|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
214464769|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
214246584|NCT05272085|PROCEDURE|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
214246585|NCT05272085|PROCEDURE|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
214246586|NCT00188331|BEHAVIORAL|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
214246587|NCT03838965|DEVICE|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
214246588|NCT01850433|BEHAVIORAL|Internet based CBT for body dysmorphic disorder|
214246589|NCT06233760|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
214246590|NCT06233760|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
214246591|NCT06233760|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
214246592|NCT06233760|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
214246593|NCT06233760|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
214246594|NCT06233760|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
214246595|NCT06233760|OTHER|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
214246596|NCT06233760|OTHER|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
214246597|NCT05405127|OTHER|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
214246598|NCT05405127|OTHER|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
214246599|NCT02306733|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
214246600|NCT02306733|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
214246601|NCT05404360|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
214246602|NCT05404360|DEVICE|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
214246603|NCT05125887|OTHER|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
214246604|NCT04285580|DRUG|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
214246605|NCT04285580|DRUG|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
214246606|NCT01383668|DRUG|sirolimus|Given PO
214246607|NCT01383668|DRUG|gold sodium thiomalate|Given IM
214246608|NCT01383668|OTHER|pharmacological study|Correlative studies
214246609|NCT01383668|GENETIC|RNA analysis|Correlative studies
214246610|NCT01383668|GENETIC|polymerase chain reaction|Correlative studies
214246611|NCT02582255|BIOLOGICAL|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
214246612|NCT01459848|BEHAVIORAL|block play|30 minutes of block play
214246613|NCT01459848|BEHAVIORAL|baby dvd|30 minutes of dvd viewing
214246614|NCT01744912|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
214246615|NCT01744912|DRUG|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
214246616|NCT06523192|OTHER|Questionnaires|No intervention
214246617|NCT00057122|DRUG|Isoniazid|300mg
214246618|NCT00057122|DRUG|Rifapentine|Rifapentine 900 mg
214246619|NCT00057122|DRUG|Rifampin|Rifampin 600 mg
214464770|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
214246620|NCT04854642|DRUG|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
214246621|NCT03268148|DEVICE|LaserPen|low level laser is used before heel-lancing for newborn screening
214246622|NCT00375375|DRUG|Lactulose|
214246623|NCT01409759|PROCEDURE|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
214246624|NCT01372982|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
214246625|NCT04285099|DEVICE|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
214246626|NCT04285099|DEVICE|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
214246627|NCT00847171|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
214246628|NCT00847171|BIOLOGICAL|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
214246629|NCT00847171|DRUG|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
214246630|NCT00847171|OTHER|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
214246631|NCT00847171|OTHER|immunoenzyme technique|
214246632|NCT00847171|OTHER|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
214246633|NCT00847171|OTHER|laboratory biomarker analysis|
214246634|NCT00847171|OTHER|pharmacological study|
214246635|NCT00847171|PROCEDURE|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
214246636|NCT05320627|DRUG|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
214246637|NCT05578157|DIAGNOSTIC_TEST|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
214246638|NCT01596673|DRUG|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
214246639|NCT01596673|DRUG|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
214246640|NCT05352490|DIAGNOSTIC_TEST|calculate LUS score|calculate LUS score
214246641|NCT02895633|OTHER|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
214246642|NCT02895633|OTHER|CT scan|With injection of Iomeron 400
214246643|NCT02895633|OTHER|MRI|With injection of gadolinium (Multihance)
214246644|NCT03264170|DIAGNOSTIC_TEST|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
214246645|NCT01107418|DRUG|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
214246646|NCT01107418|DRUG|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
214246647|NCT01107418|DRUG|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
214246648|NCT01107418|DRUG|RO5185426|960 mg orally twice daily, from day 22 onward
214246649|NCT01107418|DRUG|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
214246650|NCT00597701|DRUG|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
214246651|NCT00597701|DRUG|Placebo|Placebo
214246652|NCT00597701|DRUG|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
214246653|NCT04369170|DEVICE|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
214246654|NCT04369170|DEVICE|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
214246655|NCT00436930|BIOLOGICAL|autologous tumor cell vaccine|Given subcutaneously
214246656|NCT00436930|BIOLOGICAL|sargramostim|Given subcutaneously
214246657|NCT00436930|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously
214246658|NCT01736384|PROCEDURE|Gastric bypass or cholecystectomy|
214246659|NCT01314612|BEHAVIORAL|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
214246660|NCT02269826|DEVICE|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
214246661|NCT02269826|DEVICE|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
214246662|NCT02029339|DEVICE|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
214246663|NCT02029339|DEVICE|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
214246664|NCT02749669|OTHER|Qualitative research|Semi-structured Interviews
214246665|NCT02417844|DRUG|tamsulosin (Astellas)|
214246666|NCT02417844|DRUG|Tamsulosin HCL|
214246667|NCT00076024|DRUG|Placebo|5 mg twice daily \[bid\] continuous dosing
214246668|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
214246669|NCT00076024|DRUG|AG-013736 (axitinib)|5mg twice daily \[bid\] continuous dosing
214246670|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
214246671|NCT06040879|PROCEDURE|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
214246672|NCT00728078|DRUG|thalidomide|thalidomide 50mg tid for 6 months
214246673|NCT00937781|GENETIC|RNA analysis|
214246674|NCT00937781|GENETIC|gene expression analysis|
214246675|NCT00937781|GENETIC|microarray analysis|
214246676|NCT00937781|GENETIC|polymerase chain reaction|
214246677|NCT00937781|OTHER|immunohistochemistry staining method|
214246678|NCT00937781|OTHER|laboratory biomarker analysis|
214246679|NCT00988325|DRUG|Tamiflu|oral repeating dose
214246680|NCT01155219|DRUG|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
214246681|NCT01155219|DRUG|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
214246682|NCT01785095|DRUG|FSH (Follicle Stimulating Hormone)|
214246683|NCT00301821|BIOLOGICAL|epratuzumab|
214246684|NCT00301821|BIOLOGICAL|rituximab|
214246685|NCT00301821|DRUG|cyclophosphamide|
214246686|NCT00301821|DRUG|doxorubicin hydrochloride|
214246687|NCT00301821|DRUG|prednisone|
214246688|NCT00301821|DRUG|vincristine sulfate|
214246689|NCT03124238|OTHER|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
214246690|NCT04333771|DRUG|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
214246691|NCT04333771|DRUG|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
214246692|NCT00892918|DRUG|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
214246693|NCT00848575|DEVICE|Flexible Endoscope|
214246694|NCT03912896|BEHAVIORAL|Taekwondo|Children will participate in a 7-week taekwondo program.
214246695|NCT03012516|BEHAVIORAL|PAP-treatment by physiotherapist|
214246696|NCT03012516|BEHAVIORAL|Ordinary PAP-treatment at the health care center|
214246697|NCT01179893|BIOLOGICAL|IVIG|Intravenous immunoglobulin
214246698|NCT01179893|PROCEDURE|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
214246699|NCT04473625|OTHER|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
214246700|NCT00141583|DRUG|Enalapril 20 mg bd|
214246701|NCT00141583|DRUG|Candesartan 8 mg bd|
214246702|NCT02369562|PROCEDURE|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
214246703|NCT01843595|BEHAVIORAL|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
214246704|NCT01173861|BEHAVIORAL|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
214246705|NCT00460369|DRUG|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
214246706|NCT00460369|DRUG|artemether-lumefantrine|"tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight"
214246707|NCT00460369|DRUG|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
214246708|NCT00000762|BIOLOGICAL|rgp120/HIV-1MN|
214246709|NCT00000762|BIOLOGICAL|rgp120/HIV-1 SF-2|
214246710|NCT00000762|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214246711|NCT01981759|DRUG|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
214246712|NCT01981759|OTHER|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
214246713|NCT01981759|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
214246714|NCT03810144|GENETIC|Vectra MBDA Test|Vectra Guided versus Usual Care
214246715|NCT06157060|DIAGNOSTIC_TEST|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
214246716|NCT01836224|DRUG|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
214246717|NCT01836224|DRUG|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
214246718|NCT05838235|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
214246719|NCT02642874|DRUG|Methocarbamol|Methocarbamol twice daily
214246720|NCT02642874|DRUG|Calcium Carbonate|Calcium carbonate twice daily
214246721|NCT05868018|BEHAVIORAL|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
214246722|NCT06145607|DRUG|ABBV-CLS-7262|ABBV-CLS-7262
214246723|NCT02922595|DEVICE|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
214246724|NCT02922595|DEVICE|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
214246725|NCT00048451|DRUG|paricalcitol|
214246726|NCT05921318|COMBINATION_PRODUCT|Beijing protocol|"For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
214246727|NCT04357366|DRUG|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
214246728|NCT00403403|DRUG|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
214246729|NCT00403403|DRUG|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
214246730|NCT00403403|DRUG|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
214246731|NCT05612022|PROCEDURE|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
214246732|NCT05612022|PROCEDURE|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
214246733|NCT05748080|OTHER|Eating apples|the eating of 2 apples a day for a period of 6 weeks
214246734|NCT04078178|DIETARY_SUPPLEMENT|Niagen|Nicotinamide Riboside
214246735|NCT04078178|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo
214246736|NCT04004130|OTHER|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
214246737|NCT06382805|OTHER|Physiotherapy program|The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
214246738|NCT06382805|OTHER|Kinesio Tape|The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
214246739|NCT06382805|OTHER|High Intensity Laser therapy|High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
214246740|NCT04006119|BIOLOGICAL|Ad-RTS-hIL-12|"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"
214246741|NCT04006119|DRUG|Veledimex|20mg/day 15 oral daily doses of veledimex
214246742|NCT04006119|DRUG|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
214246743|NCT05957055|BEHAVIORAL|parental training in behavior management|Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.
214246744|NCT05957055|DRUG|Lisdexamfetamine|Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
214246745|NCT05957055|DRUG|Methylphenidate|Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
214246746|NCT00472459|PROCEDURE|Photodynamic therapy with Metvix 160 mg/g cream|
214246747|NCT03271229|BIOLOGICAL|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
214246748|NCT03271229|BIOLOGICAL|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
214246749|NCT05753033|DRUG|SR750 tablet|Ascending single and multiple doses of SR750 orally
214246750|NCT05753033|DRUG|Placebo|Ascending single and multiple doses of placebo orally
214246751|NCT00730444|DRUG|Iobenguane I 123 Injection|1-10 mCi administered intravenously
214246752|NCT04916002|DRUG|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
214246753|NCT04916002|DRUG|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
214246754|NCT05375747|DRUG|Remimazolam|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
214246755|NCT05375747|DRUG|Propofol|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
214246756|NCT03989167|OTHER|Clinical decision support|Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
214246757|NCT04094051|DRUG|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
214246758|NCT01695148|DIETARY_SUPPLEMENT|β-Carotene Biofortified Maize Flour|
214246759|NCT01695148|DIETARY_SUPPLEMENT|White Maize Flour|
214246760|NCT02528175|DEVICE|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
214246761|NCT02528175|RADIATION|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
214246762|NCT02528175|DRUG|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
214246763|NCT06168695|DEVICE|removable anterior expansion screw|"For the upper and lower arches, precise and profound alginate impressions were obtained and plaster study models were created. The removable appliance was constructed using acrylic resin with bilateral occlusal coverage for posterior teeth. The removable appliance was inserted in the patient's mouth and the patient was recalled after 24 hours to check the appliance fit.~Patient was recalled every four weeks until the dental cross-bite was corrected."
214246764|NCT06168695|DIAGNOSTIC_TEST|Speech and language evaluation|"speech evaluation was done by a Phoniatrician and all children were subjected to the Protocol of speech evaluation before expansion screw appliance insertion and after complete correction of anterior crossbite using an articulation test, intelligibility test, and spectrographic analysis.~* Articulation test: Five speech sounds were chosen to be studied /s/, /s /, /z/, /z/, /∫ /. The consonants were tested in the initial, medial, and final word positions.~* Speech intelligibility test : The general intelligibility score was calculated using Speech intelligibility in context: 5 -point scale:~* Spectrographic analysis: Using the computerized speech lab, the child was seated in an upright position \& allowed to talk freely \& repeated syllables were said to him/her."
214246765|NCT06168695|OTHER|Oral Health Related Quality of Life (OHRQoL) Assessment|The Child Perceptions Questionnaire (CPQ 8-10) in Brazilian version was used to gauge how the anterior cross bite affected the children's OHRQoL. It has twenty-five items total, broken down into four health domains (subscales): five questions each about oral symptoms (OS), five questions about functional limitations (FL), five questions about emotional wellbeing (EW), and ten questions about social well-being (SW). The responses never (0), once/twice (1), occasionally (2), often (3), and every day/almost every day (4) are provided for each question on an ordinal scale. The sum of the scores for all questions is used to calculate the scores for each subscale. The CPQ 8-10 was used to assess the OHRQoL before appliance insertion and after complete correction of anterior crossbite.
214246766|NCT04469426|OTHER|Interactive online informational and peer support app|The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
214246767|NCT02024282|DEVICE|Use of C-reactive protein (CRP) point of care test|
214246768|NCT02024282|OTHER|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
214246769|NCT02024282|DEVICE|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
214246770|NCT05550649|PROCEDURE|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
214246771|NCT03306706|DIETARY_SUPPLEMENT|Whole pea muffins|2 muffins containing whole peas
214246772|NCT03306706|DIETARY_SUPPLEMENT|Split pea muffins|2 muffins containing split peas
214246773|NCT03306706|DIETARY_SUPPLEMENT|Wheat muffins|2 muffins containing wheat
214246774|NCT03203278|BEHAVIORAL|Web-based exercise programme|Aerobic, resistance and balance exercises
214246775|NCT05589090|BEHAVIORAL|Super Skills for Life program|Children in the experimental group received eight sessions of the Super Skills for Life protocol. The intervention was implemented using a structured manual for the therapist and a workbook for the children \[Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández\]. The intervention was administered via an online virtual platform for eight weeks, with each session lasting approximately one hour.
214246776|NCT06138054|BEHAVIORAL|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
214246777|NCT06138054|BEHAVIORAL|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
214246778|NCT01520831|DRUG|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
214246779|NCT01520831|DRUG|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
214246780|NCT01520831|DRUG|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
214246781|NCT01520831|DRUG|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
214246782|NCT00454831|DEVICE|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
214246783|NCT04944628|DIETARY_SUPPLEMENT|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
214246784|NCT05755165|BEHAVIORAL|Depression|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
214246785|NCT05755165|BEHAVIORAL|Depression, adjusted|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
214246786|NCT05755165|BEHAVIORAL|Control|\~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
214246787|NCT01516528|PROCEDURE|Spirometry|Assessment of lung function by spirometry
214246788|NCT04815746|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
214246789|NCT04815746|BEHAVIORAL|Standard Education|Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
214246790|NCT06505629|BEHAVIORAL|the online Paired Emotion Reading Intervention (PERI)|In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
214246791|NCT06505629|BEHAVIORAL|the online Paired General Reading Intervention (PGRI)|Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
214246792|NCT04920318|COMBINATION_PRODUCT|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
214246793|NCT04920318|COMBINATION_PRODUCT|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
214246794|NCT03269110|DIAGNOSTIC_TEST|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
214246795|NCT05782465|PROCEDURE|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
214246796|NCT05782465|PROCEDURE|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
214246797|NCT05782465|DIAGNOSTIC_TEST|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
214246798|NCT05558267|DIETARY_SUPPLEMENT|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
214246799|NCT05558267|DIETARY_SUPPLEMENT|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
214246800|NCT05152862|PROCEDURE|Laser|Retinal laser photocoagulation
214246801|NCT05152862|PROCEDURE|Anti VEGF|Anti-VEGF intravitreous injection
214246802|NCT06157398|OTHER|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
214246803|NCT06846385|BIOLOGICAL|Placebo|A single dose was administered
214246804|NCT06846385|BIOLOGICAL|MG-K10 Humanized Monoclonal Antibody Injection|MG-K10 Humanized Monoclonal Antibody Injection
214246805|NCT04370899|OTHER|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
214246806|NCT05283928|DEVICE|OsseoDensification (OD) protocol|Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
214246807|NCT05283928|DEVICE|standard drilling (SD) protocol (NobelReplace® Conical)|osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
214246808|NCT03544775|PROCEDURE|Isolated General Anesthesia|No nerve block identified through physician billing codes
214246809|NCT03544775|PROCEDURE|Peripheral Nerve Block|Nerve block identified through physician billing codes
214246810|NCT06272669|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
214246811|NCT06272669|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
214246812|NCT00743782|DRUG|Synthetic Human Parathyroid Hormone 1-34|
214246813|NCT03981822|COMBINATION_PRODUCT|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
214246814|NCT03981822|COMBINATION_PRODUCT|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
214246815|NCT06460493|DRUG|Ensifentrine 3 mg twice daily|All subjects will receive ensifentrine.
214246816|NCT05595369|DRUG|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
214246817|NCT05595369|DRUG|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
214246818|NCT05595369|DRUG|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
214246819|NCT06475118|OTHER|Dynamometry measurement, myokine dosing, sarcopenia calculation|Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index
214246820|NCT01852370|BIOLOGICAL|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
214246821|NCT05355402|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214246822|NCT05355402|DRUG|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
214464771|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
214464772|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
214464773|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1|Components of LMN-201
214246823|NCT06273540|DRUG|STP7 (mavoglurant) or Placebo|"STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline."
214246824|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
214246825|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
214246826|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
214246827|NCT05627661|DEVICE|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
214246828|NCT04166149|DIAGNOSTIC_TEST|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
214246829|NCT03987373|OTHER|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
214246830|NCT06321029|BEHAVIORAL|Diabetes Tune-Up Group|The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
214246831|NCT00309660|DRUG|Rosiglitazone|
214246832|NCT03558412|COMBINATION_PRODUCT|CODOX-M/IVAC|Given ivgtt
214246833|NCT03558412|DRUG|Decitabine|Given ivgtt
214246834|NCT04307745|OTHER|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
214246835|NCT02651714|DRUG|Tradipitant|
214246836|NCT02651714|DRUG|Placebo|
214246837|NCT05853627|BEHAVIORAL|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
214246838|NCT05853627|DRUG|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
214246839|NCT05791981|BEHAVIORAL|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
214246840|NCT05791981|BEHAVIORAL|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
214246841|NCT05791981|DEVICE|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
214246842|NCT05559333|PROCEDURE|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
214246843|NCT01976078|DRUG|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
214246844|NCT01622127|DEVICE|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
214246845|NCT03489551|DRUG|Haldol|
214246846|NCT01515540|DRUG|lidocaine|5% lidoderm patch
214246847|NCT01515540|DRUG|placebo|placebo
214246848|NCT03251677|PROCEDURE|Surgical procedure, Hysterectomy|Surgical removal of the uterus
214246849|NCT05988697|DRUG|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
214246850|NCT06253689|DEVICE|Defecation Posture Modification Device|Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
214246851|NCT05272215|PROCEDURE|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
214246852|NCT05272215|PROCEDURE|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
214246853|NCT05929066|DRUG|Retatrutide|Administered SC
214246854|NCT05929066|DRUG|Placebo|Administered SC
214246855|NCT00143117|DRUG|UK-390,957|
214464774|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-2|Components of LMN-201
214464775|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-3|Components of LMN-201
214464776|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3|Components of LMN-201
214246856|NCT01920009|BEHAVIORAL|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
214246857|NCT05793515|DIAGNOSTIC_TEST|whole genome sequencing|Whole genome sequencing will be performed in patients whose test was negative for the targeted resequencing and/or clinical exome sequencing.
214246858|NCT02779465|DRUG|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
214246859|NCT01389518|DRUG|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
214246860|NCT01389518|DRUG|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
214246861|NCT01850264|DEVICE|Application of quadripolar / bipolar LV electrodes|
214246862|NCT00978107|BIOLOGICAL|MVA-FCU1, flucytosine|"1. TG4023: single IT injection; possibility to re-administer once,~   * Percutaneous IT injections, under radiological or ultrasound imaging guidance~  * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~  * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~   * Dose and dosing schedule:~     * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~    * Duration: 2 weeks.~  * Possible routes of administration:~     * PO: 500 mg tablets, qid~    * IV: 1% 250 mL vials, 45-minute infusions."
214246863|NCT02987660|PROCEDURE|Topography Guided LASIK|Corneal surgery for refractive error correction
214246864|NCT02987660|PROCEDURE|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
214246865|NCT02987660|DEVICE|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
214246866|NCT02987660|DEVICE|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
214652678|NCT04964011|OTHER|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
214246867|NCT01465061|BEHAVIORAL|Online support group|Joining online support group
214246868|NCT06267430|BEHAVIORAL|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
214246869|NCT03624400|BEHAVIORAL|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
214246870|NCT03624400|BEHAVIORAL|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
214246871|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
214246872|NCT01933711|DRUG|rituximab|
214246873|NCT03310710|DEVICE|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
214246874|NCT05341934|OTHER|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine …; The CS referring to soft drinks will be the words Coca-Cola, Fanta… and Filling CS referring to vegetables and fruits will be: Apple, Banana…In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
214246875|NCT04168697|BEHAVIORAL|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
214246876|NCT01087242|DRUG|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
214246877|NCT00715000|PROCEDURE|Oral rehydration therapy|oral rehydration solution
214652679|NCT02102750|DRUG|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
214246878|NCT00715000|PROCEDURE|classical hydration via intravenous infusion|intravenous infusion
214246879|NCT02789878|DRUG|Goserelin|Androgen Deprivation Therapy
214246880|NCT02789878|DRUG|Prednisone|Corticosteroid
214246881|NCT02789878|DRUG|Abiraterone|CYP17 inhibitor
214246882|NCT02789878|DRUG|Apalutamide|Androgen-receptor antagonist
214652680|NCT02367950|BEHAVIORAL|Exercise|10 exercise sessions with a personal trainer
214652681|NCT05307458|DRUG|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
214652682|NCT01569581|BIOLOGICAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
214652683|NCT01569581|BIOLOGICAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
214246883|NCT06069648|BEHAVIORAL|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
214246884|NCT06069648|BEHAVIORAL|a leaftlet|a leaflet containing information about healthy lifestyles
214246885|NCT06069648|BEHAVIORAL|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
214246886|NCT04634838|DEVICE|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
214246887|NCT00054717|DRUG|Tipranavir|
214246888|NCT00054717|DRUG|Ritonavir(r)|
214246889|NCT00054717|DRUG|Comparator Protease Inhibitor (CPI)|
214246890|NCT02448186|BEHAVIORAL|ESTEEM|10-session cognitive behavioral treatment
214246891|NCT06255834|DRUG|IPG11406|"IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets"
214246892|NCT03284437|BEHAVIORAL|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
214246893|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
214246894|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
214246895|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
214246896|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
214246897|NCT06256120|DIAGNOSTIC_TEST|Restrictive|3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
214246898|NCT06256120|DIAGNOSTIC_TEST|Liberal|7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
214246899|NCT06535919|BEHAVIORAL|Treatment as Usual|Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
214246900|NCT03707184|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214246901|NCT03707184|DRUG|Fluciclovine F18|Given IV
214246902|NCT03707184|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214246903|NCT05602649|DRUG|Cannabis|Cannabis will be orally ingested
214246904|NCT05602649|DRUG|Placebo|Placebo will be orally ingested
214246905|NCT06206213|BEHAVIORAL|Assessment of two different locomotion types.|Exposure to virtual environment by the HMD in two different locomotion styles.
214246906|NCT05267665|BEHAVIORAL|Brief Family Intervention (BFI)|A 2-session psychoeducational and skills-based family intervention.
214246907|NCT04704154|DRUG|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
214246908|NCT04704154|DRUG|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
214246909|NCT03370614|OTHER|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
214246910|NCT03370614|OTHER|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
214246911|NCT04251156|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
214246912|NCT04251156|DRUG|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
214246913|NCT06631209|DEVICE|Transcranial Magnetic Stimulation (TMS)|Specifically, Continual Theta Burst Stimulation
214246914|NCT06631209|OTHER|Sham|Sham TMS
214246915|NCT04350866|BEHAVIORAL|Expert Recommendations for Implementing Change bundle of strategies|"* Develop a formal implementation blueprint/checklist~* Conduct educational meetings~* Develop and distribute educational materials~* Organize implementation meetings~* Facilitation~* Increase demand with marketing to patients~* Promote adaptability"
214246916|NCT04350866|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|"An adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) that is focused on behavioral components stimulus control and sleep restriction (the four rules):~1. Reduce time awake in bed.~2. Don't go to bed unless ready for sleep.~3. Don't stay in bed unless asleep.~4. Get up and out of bed at the same time everyday.~Delivered weekly to bi-weekly over 4-6 sessions, with each session typically 30 minutes or less, consistent with other interventions delivered in PCMHI."
214246917|NCT03419221|PROCEDURE|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
214246918|NCT03419221|OTHER|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
214464777|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
214464778|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
214464779|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
214464780|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
214246919|NCT01453660|OTHER|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
214246920|NCT01453660|OTHER|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
214246921|NCT04300920|DRUG|N-acetyl cysteine|600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
214246922|NCT04300920|DRUG|Placebo|Matching oral placebo tablet three times daily for 24 months.
214246923|NCT06172465|OTHER|EOIP|Ultrasound guided External oblique intercostal block will be performed bilaterally.
214246924|NCT06172465|OTHER|OSTAP|Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
214246925|NCT01303887|DRUG|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
214246926|NCT01303887|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
214246927|NCT01303887|DRUG|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
214246928|NCT01303887|DRUG|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
214246929|NCT01303887|DRUG|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
214246930|NCT05114538|BEHAVIORAL|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
214246931|NCT05327959|DEVICE|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
214246932|NCT01949454|DRUG|Fluorometholone 0.1% ophthalmic solution|
214246933|NCT01949454|OTHER|Artificial tears (Placebo)|Artificial tears (Placebo)
214246934|NCT03306810|OTHER|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
214246935|NCT02068456|DRUG|Roflumilast|
214246936|NCT04845373|OTHER|Mediterranean diet|Diet intervention:Mediterranean diet
214246937|NCT04845373|OTHER|Control diet: Low fat diet|Low fat diet
214246938|NCT01057771|BEHAVIORAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
214246939|NCT01057771|BEHAVIORAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
214246940|NCT04251715|DRUG|Dexamethasone|Given intraarterially via HAI pump
214246941|NCT04251715|DRUG|Floxuridine|Given intraarterially via HAI pump
214246942|NCT04251715|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
214246943|NCT04251715|DRUG|Irinotecan|Given IV
214246944|NCT04251715|DRUG|Leucovorin|Given IV
214246945|NCT04251715|DRUG|Oxaliplatin|Given IV
214246946|NCT04251715|OTHER|Quality-of-Life Assessment|Ancillary studies
214246947|NCT05088863|OTHER|flaxseed|40g of flaxseed per day
214246948|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
214246949|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
214652684|NCT01569581|BIOLOGICAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
214652685|NCT01569581|BIOLOGICAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
214246950|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
214246951|NCT03586518|DIAGNOSTIC_TEST|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
214246952|NCT03586518|DIAGNOSTIC_TEST|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
214246953|NCT03586518|PROCEDURE|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
214246954|NCT03586518|DIAGNOSTIC_TEST|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
214246955|NCT03586518|DIAGNOSTIC_TEST|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
214246956|NCT01583920|RADIATION|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
214246957|NCT02978560|DIAGNOSTIC_TEST|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
214246958|NCT04423939|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
214246959|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
214246960|NCT05394129|DIAGNOSTIC_TEST|SurePath™|In the liquid-based cytology, a fine-needle aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
214246961|NCT05882071|DRUG|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
214246962|NCT06207617|PROCEDURE|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
214246963|NCT06207617|PROCEDURE|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
214246964|NCT03844477|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
214246965|NCT03844477|PROCEDURE|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
214246966|NCT02285283|DRUG|Itraconazole|
214246967|NCT02285283|DRUG|Placebo|
214246968|NCT06080048|DRUG|SOR102|SOR102 capsules
214246969|NCT06080048|DRUG|Placebo|Matching placebo capsules
214246970|NCT05349682|DIAGNOSTIC_TEST|dynamic contrast enhanced MRI|An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
214246971|NCT05349682|PROCEDURE|geniculate artery embolization|The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
214246972|NCT03223753|OTHER|Educational Intervention|Receive educational handouts about to physical activity
214246973|NCT03223753|OTHER|Internet-Based Intervention|Access limited version of device app/website
214246974|NCT03223753|OTHER|Internet-Based Intervention|Access full version of interactive reward-based device app/website
214246975|NCT03223753|OTHER|Laboratory Biomarker Analysis|Correlative studies
214246976|NCT03223753|DEVICE|Medical Device Usage and Evaluation|Wear physical activity tracking device
214246977|NCT03223753|OTHER|Quality-of-Life Assessment|Ancillary studies
214246978|NCT03223753|OTHER|Questionnaire Administration|Ancillary studies
214246979|NCT05749432|DRUG|Hemay181|Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
214246980|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - emotion regulation skills training|"Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions."
214464781|NCT04930874|OTHER|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
214464782|NCT05565417|DRUG|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
214246981|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - interpersonal effectiveness skills training|Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
214246982|NCT04626310|BEHAVIORAL|Interpersonal psychotherapy|Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
214246983|NCT06311877|DIETARY_SUPPLEMENT|mBerry|mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.
214246984|NCT06311877|OTHER|No intervention|The control group will not received intervention.
214246985|NCT02278341|DRUG|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
214246986|NCT02278341|DRUG|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
214246987|NCT02278341|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
214246988|NCT02278341|DRUG|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
214246989|NCT05851105|BIOLOGICAL|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
214246990|NCT02604017|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
214246991|NCT00740246|DRUG|VIT-45|15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously
214246992|NCT00740246|DRUG|Placebo|for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously
214246993|NCT02906384|RADIATION|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
214246994|NCT04578080|DEVICE|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
214246995|NCT06521450|PROCEDURE|anti incontinence surgery|anti incontinence surgery with prolapse surgery will be performed simultaneously
214246996|NCT04297657|OTHER|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
214246997|NCT03682809|DRUG|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
214246998|NCT02628665|DRUG|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
214246999|NCT02628665|DEVICE|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
214247000|NCT01606254|DRUG|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
214247001|NCT05461807|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
214247002|NCT05461807|DRUG|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
214247003|NCT02011893|DEVICE|Tonic Stimulation|Prodigy Neurostimulation System with associated components
214247004|NCT02011893|DEVICE|Burst Stimulation|Prodigy Neurostimulation System with associated components
214247005|NCT04488107|DRUG|FCN-437c|\- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
214247006|NCT04488107|DRUG|Letrozole 2.5mg|"* Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
214247007|NCT03977454|PROCEDURE|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
214247008|NCT03977454|PROCEDURE|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1\. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
214247009|NCT03977454|DRUG|Ropivacaine|60 ml 0.2% ropivacaine
214247010|NCT03977454|DRUG|Dex|10 mg DEX/ 80 mg MPA
214247011|NCT00229918|DRUG|triamcinolone acetonide|
214247012|NCT03541876|OTHER|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
214247013|NCT01875003|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
214247014|NCT01875003|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
214247015|NCT01875003|DRUG|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
214247016|NCT05584371|DIETARY_SUPPLEMENT|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
214247017|NCT01289782|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
214247018|NCT01289782|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
214247019|NCT01289782|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
214247020|NCT01289782|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
214247021|NCT04433143|DRUG|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
214247022|NCT01241240|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
214247023|NCT01241240|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
214247024|NCT01410539|DEVICE|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
214247025|NCT01410539|DRUG|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
214247026|NCT02563132|PROCEDURE|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
214247027|NCT04499599|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
214247028|NCT04499599|OTHER|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
214247029|NCT04499599|OTHER|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
214247030|NCT03493659|BEHAVIORAL|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
214247031|NCT03493659|BEHAVIORAL|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
214247032|NCT03493659|BEHAVIORAL|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
214247033|NCT04365257|DRUG|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
214247034|NCT04365257|OTHER|Standard of care|Participants in this arm will receive standard of care.
214247035|NCT06143111|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
214652686|NCT04011202|BEHAVIORAL|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
214652687|NCT05685940|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
214247036|NCT06143111|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
214247037|NCT06488547|OTHER|Diaphragmatic breathing (DF)|Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
214247038|NCT06488547|OTHER|Progressive Muscle Relaxation (PMR)|"Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation."
214247039|NCT05078918|OTHER|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
214247040|NCT05078918|OTHER|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
214247041|NCT04076527|DRUG|UDCA|Routine data is collected for UDCA therapy.
214247042|NCT04076527|DRUG|Ocaliva|Routine data is collected for OCA therapy.
214247043|NCT00715169|DRUG|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
214247044|NCT00715169|OTHER|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
214247045|NCT00518973|DRUG|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
214247046|NCT00518973|DRUG|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
214247047|NCT02597634|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
214247048|NCT02597634|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
214247049|NCT01218282|BEHAVIORAL|Home exercise training|20-30 min/day for at least 4 days/week
214247050|NCT01218282|BEHAVIORAL|NO Exercise Training|No intervention
214247051|NCT06115668|OTHER|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
214247052|NCT06115668|OTHER|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
214247053|NCT01262209|DEVICE|portable CCTV|This is a small handheld mini screen intended to improve reading.
214247054|NCT01262209|DEVICE|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
214247055|NCT01262209|DEVICE|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
214247056|NCT03812432|DEVICE|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
214247057|NCT04744038|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
214247058|NCT06329843|DEVICE|Picterus Jaundice Pro (JP)|"Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw)."
214247059|NCT03239665|BEHAVIORAL|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
214247060|NCT03239665|BEHAVIORAL|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
214247061|NCT02218983|DEVICE|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
214247062|NCT02218983|OTHER|Usual care|
214247063|NCT05953376|DRUG|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
214247064|NCT00772083|BEHAVIORAL|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
214247065|NCT00772083|BEHAVIORAL|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
214247066|NCT01001299|DRUG|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
214247067|NCT01001299|DRUG|RO5185426|960 mg orally twice daily
214652688|NCT05685940|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
214247068|NCT01754909|DRUG|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
214652689|NCT02040142|PROCEDURE|HIPEC|
214247069|NCT01754909|DRUG|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
214247070|NCT04081233|PROCEDURE|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
214247071|NCT04081233|PROCEDURE|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
214247072|NCT00822809|DRUG|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
214247073|NCT00822809|DRUG|Prednisolone|25 mg premedication
214247074|NCT01784627|BEHAVIORAL|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
214247075|NCT01565499|DRUG|Nab-paclitaxel|
214247076|NCT02895009|DEVICE|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
214247077|NCT02895009|DEVICE|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
214247078|NCT05682573|DIAGNOSTIC_TEST|hospitalized patient|Collect the patient's whole blood for testing
214247079|NCT06169228|DEVICE|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
214247080|NCT04033523|BEHAVIORAL|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
214247081|NCT02004392|DRUG|EVP-6124|
214247082|NCT05370456|DEVICE|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
214247083|NCT05370456|PROCEDURE|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
214247084|NCT03251664|DIETARY_SUPPLEMENT|Food groups consumed|
214247085|NCT00781508|DRUG|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
214247086|NCT00781508|OTHER|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
214247087|NCT01866553|DRUG|Nilotinib|300 mg capsule BID oral use
214652690|NCT02040142|DRUG|Mitomycin C|
214247088|NCT01866553|DRUG|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
214247089|NCT03221075|OTHER|Registry|There is no intervention.
214247090|NCT00848003|DRUG|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
214247091|NCT00848003|DRUG|Placebo|Strawberry flavored yogurt
214247092|NCT05293509|DRUG|Fludarabine|40 mg/m2/day i.v.- by vein
214247093|NCT05293509|DRUG|Dexamethasone|25 mg/m2/day i.v.-by vein
214247094|NCT05293509|DRUG|Cyclophosphamide|100 mg/m2 IV-by vein
214247095|NCT05293509|DRUG|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
214247096|NCT05293509|DRUG|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
214247097|NCT05293509|DRUG|Busulfan|110 mg/m2 i.v-by vein
214247098|NCT05293509|DRUG|Cyclophosphamide (Cy)|by vein
214247099|NCT05293509|DRUG|Tacrolimus (or cyclosporine)|by vein
214247100|NCT05293509|DRUG|Mycophenolate mofetil (MMF)|given by PO
214247101|NCT05293509|DRUG|Rabbit ATG|by vein
214247102|NCT03519386|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
214247103|NCT03519386|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
214247104|NCT05225337|OTHER|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
214247105|NCT05225337|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
214247106|NCT03299114|OTHER|Whirlpool|
214247107|NCT05659966|BEHAVIORAL|Plant-based diet|Participants will receive a behavioral intervention on a plant-based diet in partnership with a local restaurant.
214247108|NCT05659966|OTHER|Voucher only|Participants will receive vouchers to a local restaurant. Participants will not attend nutrition classes but will receive a class at the end of the 12-week study.
214247109|NCT01582854|DRUG|Actovegin|Actovegin solution for infusion and Actovegin tablets
214247110|NCT01582854|DRUG|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
214247111|NCT00704080|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
214247112|NCT00704080|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
214247113|NCT00485147|PROCEDURE|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
214247114|NCT06247683|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
214247115|NCT06779136|DRUG|Placebo|Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
214247116|NCT04214249|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214652691|NCT04190446|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214247117|NCT04214249|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214247118|NCT04214249|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214247119|NCT04214249|PROCEDURE|Computed Tomography|Undergo CT
214247120|NCT04214249|DRUG|Cytarabine|Given via continuous IV infusion
214247121|NCT04214249|DRUG|Daunorubicin Hydrochloride|Given IV
214247122|NCT04214249|PROCEDURE|Echocardiography Test|Undergo ECHO
214247123|NCT04214249|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
214247124|NCT04214249|DRUG|Idarubicin Hydrochloride|Given IV
214247125|NCT04214249|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214247126|NCT04214249|BIOLOGICAL|Pembrolizumab|Given IV
214247127|NCT04214249|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
214247128|NCT04414514|DRUG|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
214247129|NCT06455995|BEHAVIORAL|DEPTH|All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.
214247130|NCT06455995|BEHAVIORAL|DEPTH-Morning|Morning will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
214247131|NCT06455995|BEHAVIORAL|DEPTH-Evening|Evening will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
214247132|NCT02935400|DRUG|Hemin|Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
214247133|NCT06138145|OTHER|Video|Different videos were shown for the generic and appeal groups. No videos were shown to the control or ink-pen incentive groups
214247134|NCT06138145|BEHAVIORAL|Survey|Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
214247135|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
214247136|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
214247137|NCT05488756|OTHER|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
214247138|NCT05488756|OTHER|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
214247139|NCT05488756|OTHER|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
214247140|NCT02652767|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
214247141|NCT02652767|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
214247142|NCT03464565|DEVICE|Penumbra System|Penumbra System
214247143|NCT06082271|DEVICE|Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)|Anti-inflammatory and regenerative effect, 5 mg/ml
214247144|NCT06082271|DRUG|Cortisone|DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
214247145|NCT01125501|DIETARY_SUPPLEMENT|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
214247146|NCT02262182|OTHER|KP group|
214247147|NCT02262182|OTHER|KM group|
214247148|NCT04779931|BEHAVIORAL|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
214247149|NCT05917769|OTHER|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
214247150|NCT05917769|OTHER|Postural correction exercises|"* Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
214247151|NCT04598789|OTHER|no intervention|no intervention, observational study
214247152|NCT02747654|GENETIC|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
214247153|NCT00663949|DRUG|Captopril|25 mg captopril tablet q8h
214247154|NCT00663949|DRUG|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
214247155|NCT01028378|DEVICE|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
214247156|NCT04783675|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
214247157|NCT05158647|OTHER|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
214247158|NCT05158647|DRUG|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
214247159|NCT06258473|COMBINATION_PRODUCT|Multicomponent decentralized care|"1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
214247160|NCT06258473|COMBINATION_PRODUCT|mHealth|Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
214247161|NCT05587465|DEVICE|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
214247162|NCT00645710|DRUG|gemcitabine hydrochloride|Given IV
214247163|NCT00645710|DRUG|floxuridine|Given via hepatic arterial infusion
214247164|NCT00645710|GENETIC|proteomic profiling|Correlative studies
214247165|NCT00645710|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
214247166|NCT00645710|OTHER|liquid chromatography|Correlative studies
214247167|NCT00645710|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
214247168|NCT00645710|OTHER|laboratory biomarker analysis|Correlative studies
214247169|NCT00645710|OTHER|mass spectrometry|Correlative studies
214247170|NCT00645710|OTHER|pharmacological study|Correlative studies
214247171|NCT01063933|DRUG|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
214247172|NCT03989739|DEVICE|Da Vinci|
214247173|NCT04572360|OTHER|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
214247174|NCT04572360|OTHER|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
214247175|NCT00373061|DRUG|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
214247176|NCT02618356|DRUG|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
214247177|NCT01092065|DRUG|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
214247178|NCT01092065|DRUG|Placebo|hard gelatin capsule to be taken bid for six weeks
214247179|NCT04459429|DEVICE|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
214247180|NCT00540371|OTHER|Port wine stain Birthmark|Port wine stain Birthmark
214247181|NCT00107952|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
214247182|NCT00107952|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
214247183|NCT05546853|DRUG|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
214247184|NCT05546853|DRUG|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
214247185|NCT05546853|DRUG|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
214247186|NCT05546853|DRUG|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
214247187|NCT05546853|DRUG|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
214247188|NCT04074876|DEVICE|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension"
214247189|NCT01401959|DRUG|Eribulin|1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
214247190|NCT01401959|DRUG|Trastuzumab|6 mg/kg IV Day 1 every 21 days
214247191|NCT05811650|BEHAVIORAL|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
214247192|NCT02039440|OTHER|Blood draw|One-time blood draw
214247193|NCT03872011|DRUG|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
214247194|NCT03872011|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
214247195|NCT02879149|DEVICE|AUGMENT® Bone Graft|AUGMENT® Bone Graft
214247196|NCT02879149|PROCEDURE|Standard of Care|Autologous Bone Graft
214247197|NCT05896579|BEHAVIORAL|Exercise training|Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
214247198|NCT05888012|DEVICE|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
214247199|NCT05888012|DEVICE|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
214247200|NCT02051816|DEVICE|Video Laryngoscopy|
214247201|NCT02051816|DEVICE|Apneic Oxygenation|
214247202|NCT02051816|DEVICE|Direct Laryngoscopy|
214247203|NCT02051816|DEVICE|No Apneic Oxygenation|
214247204|NCT01097798|DRUG|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
214247205|NCT01097798|DRUG|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
214247206|NCT03120988|BIOLOGICAL|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
214247207|NCT05245279|DIAGNOSTIC_TEST|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
214247208|NCT05245279|DIAGNOSTIC_TEST|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
214247209|NCT01509690|OTHER|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
214247210|NCT05260346|DIETARY_SUPPLEMENT|Cranberry juice|composition: Water, cranberry juice concentrate
214247211|NCT05260346|DIETARY_SUPPLEMENT|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
214247212|NCT03794882|COMBINATION_PRODUCT|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
214247213|NCT03794882|PROCEDURE|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
214247214|NCT03400982|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone densitometry and measurement of body composition
214247215|NCT04439565|GENETIC|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
214247216|NCT03614975|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
214247217|NCT03614975|BIOLOGICAL|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
214247218|NCT00450385|DRUG|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
214247219|NCT00450385|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
214247220|NCT00450385|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
214247221|NCT00450385|DRUG|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
214247222|NCT00450385|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
214464783|NCT05565417|COMBINATION_PRODUCT|Fruquintinib|Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
214247223|NCT06047184|DRUG|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
214247224|NCT06047184|DRUG|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
214247225|NCT06047184|DRUG|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
214247226|NCT04042935|DRUG|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
214247227|NCT01569464|DRUG|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
214247228|NCT01569464|OTHER|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
214247229|NCT03687164|OTHER|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
214247230|NCT04600310|DEVICE|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
214247231|NCT04600310|DEVICE|No Intervention|Conventional skin preparation technique
214247232|NCT04144465|DRUG|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
214247233|NCT04144465|DRUG|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
214247234|NCT01286831|DRUG|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
214247235|NCT03739788|DRUG|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
214247236|NCT04839575|DRUG|Latiglutenase|Administered orally (daily)
214247237|NCT04839575|DRUG|Placebo|Administered orally (daily)
214247238|NCT04948931|OTHER|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
214247239|NCT04948931|OTHER|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
214247240|NCT04948931|OTHER|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
214247241|NCT04445116|DEVICE|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
214247242|NCT04726098|DRUG|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
214247243|NCT04726098|DRUG|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
214247244|NCT03458598|PROCEDURE|Rectus sheath block|Rectus sheath block under ultrasound
214247245|NCT03458598|PROCEDURE|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
214247246|NCT03458598|DRUG|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
214247247|NCT03458598|PROCEDURE|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
214247248|NCT02831907|PROCEDURE|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
214247249|NCT02178683|DRUG|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
214247250|NCT03877081|BIOLOGICAL|Probiotics|Administration of oral probiotics with 2 doses a day
214247251|NCT03877081|OTHER|Placebo|Administration of oral placebo with 2 doses a day
214247252|NCT03407339|OTHER|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
214247253|NCT02565927|DEVICE|Traditional airway stent|process airway stenting
214247254|NCT02565927|DRUG|Iodine-125 seeds|process intraluminal brachytherapy
214247255|NCT04473573|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
214247256|NCT03932097|BEHAVIORAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
214247257|NCT03932097|OTHER|Active Control Materials|NIAAA materials on underage drinking for parents
214247258|NCT02631356|DRUG|Ringer's lactate solution|
214247259|NCT02631356|DRUG|Succinylated gelatin|
214247260|NCT01721980|DRUG|GLPG0974|
214247261|NCT01721980|DRUG|Placebo|
214247262|NCT01376557|DRUG|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
214247263|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
214247264|NCT01376557|DRUG|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
214247265|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
214247266|NCT01376557|DRUG|Placebo|Subjects will receive placebo once daily.
214247267|NCT02940106|DEVICE|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
214247268|NCT02940106|DEVICE|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
214247269|NCT02576769|OTHER|No intervention|
214247270|NCT01390220|DRUG|USL261|
214247271|NCT01390220|DRUG|Placebo|
214247272|NCT04651101|DIAGNOSTIC_TEST|coronary angiography|extent of coronary artery disease in invasive coronary angiography
214247273|NCT01466543|DRUG|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
214247274|NCT01466543|DRUG|Placebo|Placebo
214247275|NCT04268849|DRUG|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
214247276|NCT04268849|DRUG|Saline|Placebo for Ferumoxytol
214247277|NCT04268849|DRUG|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
214247278|NCT04268849|DRUG|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
214247279|NCT06299423|DEVICE|Howdy Senior® device|Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
214247280|NCT05019976|RADIATION|Radiation - Dose Level 0|"Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14"
214247281|NCT05019976|RADIATION|Radiation - Dose Level 1|"Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10"
214247282|NCT05019976|RADIATION|Radiation - Dose Level 2|"Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7"
214247283|NCT05019976|RADIATION|Radiation - Dose Level 3|"Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5"
214247284|NCT05019976|RADIATION|Radiation - Dose Level 4|"Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3"
214247285|NCT02723318|BEHAVIORAL|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
214247286|NCT02723318|BEHAVIORAL|Access to Referrals to Social Services|
214247287|NCT03063203|DRUG|Decitabine|"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
214247288|NCT03063203|PROCEDURE|Bone marrow biopsy/aspirate|"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
214247289|NCT03063203|PROCEDURE|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
214247290|NCT03063203|PROCEDURE|Skin biopsy|"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
214247291|NCT03063203|PROCEDURE|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
214247292|NCT00555139|DRUG|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
214247293|NCT00555139|DRUG|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
214247294|NCT00555139|DRUG|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
214247295|NCT00555139|DRUG|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
214247296|NCT00721903|PROCEDURE|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
214247297|NCT00721903|PROCEDURE|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
214247298|NCT05517460|OTHER|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
214247299|NCT05517460|OTHER|health education|health education for self-care and medication adherence
214247300|NCT00017485|DRUG|HPPH|
214247301|NCT03657966|BIOLOGICAL|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
214247302|NCT03657966|DRUG|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
214247303|NCT02587247|DRUG|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
214247304|NCT05958693|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
214247305|NCT05958693|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
214247306|NCT00453960|DIETARY_SUPPLEMENT|Genivis|54 mg/day daily for 6 months
214247307|NCT00453960|DRUG|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
214247308|NCT00453960|OTHER|placebo|tablets daily for 6 months
214247309|NCT00676221|DRUG|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
214247310|NCT01039012|OTHER|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
214247311|NCT01039012|OTHER|Standard Care|Participant follow the standard care recommended by their physician.
214247312|NCT05965648|BEHAVIORAL|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
214247313|NCT01046760|BEHAVIORAL|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
214247314|NCT04718103|BIOLOGICAL|GSK3511294|GSK3511294 was administered using a pre-filled syringe.
214247315|NCT04718103|BIOLOGICAL|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
214247316|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
214247317|NCT00136604|BIOLOGICAL|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
214247318|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
214247319|NCT00136604|BIOLOGICAL|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
214247320|NCT06477809|DEVICE|ARIA Glasses ( Augmented Reality in Audio )|ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
214247321|NCT03631355|DRUG|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
214247322|NCT03716570|DRUG|BIIB054|Administered as specified in the treatment arm.
214247323|NCT03716570|DRUG|Placebo|Administered as specified in the treatment arm.
214247324|NCT03917433|BEHAVIORAL|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
214247325|NCT03917433|BEHAVIORAL|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
214247326|NCT03917433|BEHAVIORAL|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
214247327|NCT03654430|OTHER|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
214247328|NCT01449695|BEHAVIORAL|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
214247329|NCT01449695|BEHAVIORAL|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
214247330|NCT01449695|BEHAVIORAL|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
214652692|NCT04190446|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214652693|NCT04190446|OTHER|Quality-of-Life Assessment|Ancillary studies
214247331|NCT05038176|BEHAVIORAL|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
214247332|NCT02526329|BIOLOGICAL|donor regulatory T lymphocytes|Given IV
214247333|NCT02526329|OTHER|laboratory biomarker analysis|Correlative studies
214247334|NCT04186091|PROCEDURE|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
214247335|NCT00633867|DEVICE|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
214247336|NCT00633867|DEVICE|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
214247337|NCT04452929|DRUG|Erenumab|Subcutaneous injection of 140 mg erenumab.
214247338|NCT04452929|DRUG|Placebo|Subcutaneous injection of saline placebo.
214247339|NCT04452929|DRUG|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
214247340|NCT04452929|DRUG|Cilostazol|Oral intake of 200 mg cilostazol.
214247341|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation
214247342|NCT04610164|DRUG|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
214247343|NCT02599805|DEVICE|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
214247344|NCT04586361|COMBINATION_PRODUCT|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
214247345|NCT04586361|COMBINATION_PRODUCT|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
214247346|NCT04586361|OTHER|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
214247347|NCT02982512|DRUG|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
214247348|NCT04496310|PROCEDURE|Telemedicine|Telemedicine versus usual care (face to face visit)
214247349|NCT02054468|DRUG|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
214247350|NCT02054468|DRUG|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
214247351|NCT02054468|DRUG|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
214247352|NCT02054468|DRUG|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
214247353|NCT02054468|DRUG|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
214247354|NCT02054468|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
214247355|NCT02054468|DRUG|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
214247356|NCT02054468|DRUG|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
214247357|NCT02054468|DRUG|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
214247358|NCT01603238|DRUG|[14C]-LC15-0444|A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
214247359|NCT03640559|DRUG|Seroguard|
214247360|NCT03640559|DRUG|Placebos|
214247361|NCT03638843|PROCEDURE|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
214247362|NCT04157556|OTHER|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705."
214247363|NCT03052543|DEVICE|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
214247364|NCT05270161|PROCEDURE|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
214247365|NCT05270161|PROCEDURE|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
214464784|NCT03728790|DEVICE|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
214247366|NCT05270161|PROCEDURE|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
214247367|NCT05270161|PROCEDURE|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
214247368|NCT01825954|DEVICE|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
214247369|NCT03843242|DEVICE|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
214247370|NCT03843242|DEVICE|Pacemaker with VpS® algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
214247371|NCT03843242|DEVICE|Pacemaker with IRSplus algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
214247372|NCT02788162|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
214247373|NCT04401527|DRUG|Sodium Nitrite|Continuous intravenous infusion of Sodium Nitrite Injection
214247374|NCT04401527|DRUG|Normal Saline|Continuous intravenous infusion of Normal Saline
214247375|NCT02125604|DRUG|dimethyl fumarate|capsules administered according to the prevailing product label
214247376|NCT04756674|OTHER|No intervetion will be used|No intervention will be used
214247377|NCT05049733|DRUG|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
214247378|NCT05049733|DRUG|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
214247379|NCT05049733|DRUG|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
214247380|NCT05049733|DRUG|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
214247381|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
214247382|NCT05176093|OTHER|Placebo|Injectable Liquid
214247383|NCT01876810|DRUG|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
214247384|NCT01876810|DRUG|Placebo|One lactose pill twice a day for two weeks.
214247385|NCT00548587|DRUG|E5555|
214247386|NCT00548587|DRUG|Placebo|
214247387|NCT04768907|DRUG|MaaT013|
214247388|NCT05733065|OTHER|saliva sample|Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.
214247389|NCT05733065|OTHER|questionnaire|Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
214247390|NCT02277613|BIOLOGICAL|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
214247391|NCT02277613|OTHER|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
214247392|NCT03816501|OTHER|music|The preference of the patients will be listened to preoperatively through the headphones
214247393|NCT03816501|OTHER|no music|the patients will not be listened
214247394|NCT04412161|PROCEDURE|Liver transplantation|Living donor liver transplantation
214247395|NCT02096874|DRUG|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
214247396|NCT02621710|OTHER|Questionnaire 3 months post-operatively|
214247397|NCT06006533|OTHER|taping|Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
214247398|NCT06006533|OTHER|massage|Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
214247399|NCT00248066|DRUG|RESTEN-MP|
214247400|NCT05025228|DRUG|Paracetamol|Paracetamol given orally or intravenously
214247401|NCT05402410|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
214247402|NCT01030783|DRUG|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
214247403|NCT01030783|DRUG|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
214247404|NCT02966886|PROCEDURE|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version."
214247405|NCT02966886|PROCEDURE|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
214247406|NCT02966886|PROCEDURE|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
214247407|NCT04631484|DRUG|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
214247408|NCT04631484|DRUG|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
214247409|NCT06420466|BEHAVIORAL|Time-restricted Feeding|Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
214247410|NCT02789579|DRUG|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
214247411|NCT02789579|DRUG|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
214247412|NCT02789579|DRUG|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
214247413|NCT06666049|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric Ultrasound
214247414|NCT06995313|BEHAVIORAL|Biofeedback training|This is an audio-luminous stimulation on the micro perimeter that teaches the brain to use a different fixation locus on the retinal other than the fovea and develops visual attention to the surrounding retinal areas. 20 minutes exercises for stimulation are performed on the micro perimeter, once a week, for 5 weeks.
214247415|NCT06995209|DIETARY_SUPPLEMENT|Placebo|20 g, \~74 Kcal, 97% flavored maltodextrin, similar in color, flavor, taste, and energy as PWS
214247416|NCT06995209|DIETARY_SUPPLEMENT|Pre-workout Supplement|20 g, \~73 Kcal, 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate, and 5 g branched chained amino acid (BCAA)
214247417|NCT05824741|BEHAVIORAL|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
214247418|NCT06277791|DRUG|Adebrelimab|Adebrelimab：20mg/kg, ivdrip, D1，Q3W
214247419|NCT06622070|DRUG|SPY002-072|Experimental
214247420|NCT06622070|OTHER|Placebo|Placebo
214247421|NCT04996498|DRUG|Oxytocin|intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
214247422|NCT04996498|OTHER|sterile bacteriostatic water ampule|a placebo drug similar in shape to oxytocin ampules
214247423|NCT00719264|DRUG|RAD001(everolimus)|10 mg qd
214247424|NCT00719264|DRUG|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
214247425|NCT00719264|DRUG|bevacizumab|10 mg/kg every 2 weeks
214247426|NCT01568801|BEHAVIORAL|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
214247427|NCT03375229|OTHER|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
214247428|NCT03375229|DEVICE|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
214247429|NCT00531986|DRUG|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
214247430|NCT00531986|DRUG|HAART|Patients will continued their current HAART
214247431|NCT00003409|DRUG|motexafin gadolinium|
214247432|NCT00003409|RADIATION|radiation therapy|
214247433|NCT03034200|DRUG|ONC201|625mg ONC201 will be given on two consecutive days each week
214247434|NCT06518694|DRUG|Βeta-Blockers discontinued (with tapering)|"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."
214247435|NCT01084447|DEVICE|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
214247436|NCT01084447|DEVICE|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
214247437|NCT01561027|DRUG|CNV1014802|Administered as specified in treatment arm.
214247438|NCT01561027|DRUG|Placebo|Administered as specified in treatment arm
214247439|NCT05523323|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
214247440|NCT05523323|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
214247441|NCT05523323|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
214247442|NCT00494598|DRUG|Sufentanil|200 mcg intra-arterial one time bolus
214247443|NCT03435640|DRUG|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
214247444|NCT03435640|DRUG|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
214247445|NCT03435640|DRUG|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
214247446|NCT04648501|OTHER|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
214247447|NCT03882775|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
214247448|NCT03882775|DRUG|Heparin|heparin with or without gpi during emergency PCI.
214652694|NCT04190446|OTHER|Questionnaire Administration|Ancillary studies
214247449|NCT03676985|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
214247450|NCT03676985|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
214247451|NCT03676985|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
214247452|NCT06319352|DEVICE|Active UroShield|Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.
214247453|NCT06319352|DEVICE|Sham UroShield|Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.
214247454|NCT05012787|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
214247455|NCT05012787|BIOLOGICAL|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
214247456|NCT05012787|OTHER|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
214247457|NCT03354975|BEHAVIORAL|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
214247458|NCT03354975|BEHAVIORAL|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
214247459|NCT01927302|BEHAVIORAL|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
214652695|NCT04190446|PROCEDURE|Computed Tomography|Undergo CT scan
214652696|NCT04190446|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214652697|NCT04190446|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214652698|NCT05998395|DRUG|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
214652699|NCT04912960|DEVICE|Mechanical ventilation|Optimum PEEP
214652700|NCT06365619|DRUG|Ipilimumab|Two cycles of neoadjuvant ipilimumab prior to surgical resection.
214652701|NCT06365619|DRUG|Nivolumab|two cycles of neoadjuvant nivolumab prior to surgical resection.
214247460|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
214247461|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
214247462|NCT01927302|BEHAVIORAL|No Treatment|No treatment will be administered.
214247463|NCT02857595|BEHAVIORAL|Online Behavioral Weight Loss program|
214247464|NCT02857595|BEHAVIORAL|Weight Loss Nomogram|
214247465|NCT02857595|BEHAVIORAL|Bite Counter|
214247466|NCT00792077|DRUG|Lenalidomide|5 mg daily for 56 days.
214247467|NCT03593941|OTHER|Standard Diet|Participants will consume the standard diet provided in care home
214247468|NCT05437835|DRUG|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
214247469|NCT04835467|DEVICE|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
214247470|NCT02075970|DRUG|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
214247471|NCT02075970|DRUG|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
214247472|NCT04927000|DRUG|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
214247473|NCT02016339|BEHAVIORAL|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
214247474|NCT02016339|BEHAVIORAL|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
214247475|NCT03083860|DEVICE|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
214247476|NCT01225536|DRUG|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
214247477|NCT04389814|DIAGNOSTIC_TEST|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
214247478|NCT01948310|DRUG|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
214247479|NCT01948310|BEHAVIORAL|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
214247480|NCT01948310|DRUG|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
214247481|NCT03442387|OTHER|Frame of numerical information|Each group received only one frame of information.
214247482|NCT03226873|BEHAVIORAL|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
214247483|NCT06084728|DIAGNOSTIC_TEST|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
214247484|NCT05912452|OTHER|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
214652702|NCT05535764|DRUG|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
214247485|NCT05912452|OTHER|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
214247486|NCT05912452|OTHER|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
214247487|NCT03277521|OTHER|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
214247488|NCT03929484|DEVICE|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
214247489|NCT00775944|BEHAVIORAL|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
214247490|NCT00775944|BEHAVIORAL|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
214247491|NCT00775944|DRUG|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
214652703|NCT03651947|DRUG|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
214247492|NCT00674778|PROCEDURE|Any percutaneous cardiovascular procedure|
214247493|NCT00920829|DRUG|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
214247494|NCT00920829|DRUG|Placebo|placebo
214247495|NCT03375827|OTHER|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
214247496|NCT04533880|DEVICE|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
214247497|NCT04533880|DEVICE|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
214247498|NCT04533880|OTHER|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
214247499|NCT05793437|BEHAVIORAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
214247500|NCT05793437|BEHAVIORAL|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
214247501|NCT05684731|BIOLOGICAL|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
214247502|NCT05684731|DRUG|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
214247503|NCT03665415|BEHAVIORAL|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
214247504|NCT02394678|DEVICE|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
214247505|NCT04082832|DRUG|Cu(II)ATSM|oral suspension
214247506|NCT04082832|DRUG|Placebos|oral suspension
214247507|NCT04974918|PROCEDURE|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.|A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
214247508|NCT05654441|BIOLOGICAL|Influenza vaccine|0.5 mL single-dose injection
214247509|NCT05654441|BIOLOGICAL|Placebo|0.5 mL single-dose injection with no therapeutic effect
214247510|NCT05592834|BEHAVIORAL|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
214247511|NCT05592834|BEHAVIORAL|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
214247512|NCT05592834|OTHER|Control|This group will receive neither the PD nor the PFT interventions but care as usual
214247513|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
214247514|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
214247515|NCT00443612|DRUG|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
214247516|NCT00443612|DRUG|Irbesartan|Administration of irbesartan 150 mg/day
214247517|NCT03824028|DEVICE|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
214247518|NCT02005328|DEVICE|Tested product : DC161-DP0291|Application of product in the mouth twice daily
214247519|NCT02005328|DEVICE|Tested product : DC161-DP0292|Application of product in the mouth twice daily
214247520|NCT02005328|DEVICE|Tested product : DC161-DP0293|Application of product in the mouth twice daily
214247521|NCT02005328|DEVICE|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
214464785|NCT06503471|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
214464786|NCT06503471|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
214652704|NCT03651947|DRUG|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
214652705|NCT00888511|DRUG|Tarceva|Tarceva 150 mg/day
214247522|NCT01607268|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
214247523|NCT02849665|OTHER|Kangaroo Position|
214247524|NCT06385990|DRUG|UTD1|UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
214247525|NCT04830644|DRUG|Iguratimod|Iguratimod orally twice a day
214247526|NCT04830644|DRUG|Placebo|Placebo orally twice a day
214247527|NCT00660556|DEVICE|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
214247528|NCT04867239|OTHER|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
214247529|NCT04768985|DRUG|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
214247530|NCT04768985|DRUG|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
214247531|NCT06168760|DIAGNOSTIC_TEST|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
214247532|NCT01955980|DRUG|Budesonide|Inhalation
214247533|NCT01955980|DRUG|Budesonide|Nasal Spray
214247534|NCT04259554|DEVICE|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
214247535|NCT02530567|PROCEDURE|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
214247536|NCT04177927|DEVICE|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
214247537|NCT04177927|DEVICE|Rutine monitoring|peripheric Oxygen saturation is monitored.
214247538|NCT02477267|DRUG|SL spray|
214247539|NCT02477267|DRUG|SL film|
214247540|NCT00474838|DRUG|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
214247541|NCT00474838|DRUG|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
214247542|NCT03311620|PROCEDURE|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
214247543|NCT01037322|DRUG|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
214247544|NCT01037322|DRUG|placebo in drops|olive oil containing no drug given in drops twice daily
214247545|NCT02793011|DRUG|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
214247546|NCT02793011|DRUG|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
214247547|NCT03512015|OTHER|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
214247548|NCT03512015|OTHER|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
214247549|NCT04535765|OTHER|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
214247550|NCT04535765|OTHER|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
214247551|NCT01711879|DRUG|Aflibercept|Details covered in arm description
214247552|NCT05692167|DRUG|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
214247553|NCT05692167|DRUG|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
214247554|NCT04426201|DRUG|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
214247555|NCT04426201|DRUG|Placebo|Same number, volume and frequency of IM administration of saline
214247556|NCT04160481|DIETARY_SUPPLEMENT|FruitFlow|300mg tomato extract
214247557|NCT04160481|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214247558|NCT00503438|DEVICE|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
214247559|NCT04542538|OTHER|No intervention, observational study|
214247560|NCT05768971|OTHER|Mild diet|
214247561|NCT05768971|OTHER|Provocative diet|
214247562|NCT00752024|DEVICE|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
214247563|NCT00752024|DRUG|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
214247564|NCT03892473|OTHER|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
214247565|NCT03892473|OTHER|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
214247566|NCT03071198|PROCEDURE|TME|"1. Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~2. At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
214247567|NCT03071198|RADIATION|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
214247568|NCT03071198|DRUG|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
214247569|NCT03071198|DRUG|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
214247570|NCT03658707|OTHER|questionnaire|Shoulder questionnaire
214247571|NCT01231308|PROCEDURE|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
214247572|NCT01231308|BEHAVIORAL|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
214247573|NCT02783677|PROCEDURE|Percutaneous balloon angioplasty|
214247574|NCT05035641|DRUG|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
214247575|NCT05035641|DRUG|Placebo|Orally, 3 times per week
214247576|NCT02343133|BIOLOGICAL|HemaMax|
214247577|NCT02343133|DRUG|Placebo|
214247578|NCT02464917|DEVICE|Device: simple facemask to administer supplemental oxygen|
214247579|NCT00234390|DRUG|Pulmicort (budesonide) pMDI|
214247580|NCT02147028|RADIATION|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
214247581|NCT02147028|RADIATION|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
214247582|NCT05910177|DRUG|Karelizumab combined with etoposide and cisplatin|Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
214247583|NCT02239224|BIOLOGICAL|Placebo|Concentrate for solution for infusion
214247584|NCT02239224|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
214247585|NCT05730634|DRUG|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
214247586|NCT02395510|DRUG|Vortioxetine|Vortioxetine 5-20mg
214247587|NCT03718871|BEHAVIORAL|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
214247588|NCT05291026|OTHER|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
214247589|NCT03183778|DRUG|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
214247590|NCT03183778|DIETARY_SUPPLEMENT|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
214247591|NCT03031236|BEHAVIORAL|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
214247592|NCT00101712|DRUG|vildagliptin|
214247593|NCT00101712|DRUG|Vildagliptin Placebo|
214247594|NCT01512056|DRUG|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
214247595|NCT05337436|BIOLOGICAL|Lymphatic drainage|Biological determination in plasma:
214247596|NCT05337436|BIOLOGICAL|Total and ionized magnesium|Total and ionized magnesium
214247597|NCT05337436|BIOLOGICAL|Total and ionized calcium|Total and ionized calcium
214247598|NCT00073073|DRUG|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
214247599|NCT00073073|DIETARY_SUPPLEMENT|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
214247600|NCT00073073|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 400 international units PO every day x 2 years
214247601|NCT01466179|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
214247602|NCT02248415|OTHER|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
214247603|NCT02248415|OTHER|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
214652706|NCT00888511|RADIATION|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
214652707|NCT00338507|DRUG|Erdosteine|
214247604|NCT02248415|OTHER|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
214247605|NCT02248415|OTHER|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
214247606|NCT02248415|OTHER|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
214247607|NCT02248415|OTHER|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
214247608|NCT01640626|OTHER|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
214247609|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
214247610|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
214247611|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
214247612|NCT00749580|DRUG|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
214247613|NCT04732169|DRUG|Active study drug ( oral CBD)|CBD in single dose syringes
214247614|NCT04732169|DRUG|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
214247615|NCT02921360|DRUG|acetylsalicylic acid|
214247616|NCT04758910|DEVICE|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
214247617|NCT04758910|DEVICE|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
214247618|NCT05417243|OTHER|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
214247619|NCT00000656|DRUG|Zidovudine|
214247620|NCT00000656|DRUG|Didanosine|
214247621|NCT02725853|DEVICE|tDCS|Application of 1.5 mA tDCS for 30 minutes
214247622|NCT02725853|DEVICE|sham tDCS|Application of sham tDCS for 30 minutes
214247623|NCT02725853|BEHAVIORAL|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
214247624|NCT02725853|BEHAVIORAL|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
214247625|NCT05830903|BEHAVIORAL|VR-assisted occupational training|VR-assisted occupational training
214247626|NCT02929173|OTHER|Allceram|Pressed E-max coping veneered with E-max veneering system
214247627|NCT02929173|OTHER|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
214247628|NCT00272428|BEHAVIORAL|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
214247629|NCT05281952|PROCEDURE|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
214247630|NCT05281952|PROCEDURE|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
214247631|NCT04119310|OTHER|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
214247632|NCT04119310|OTHER|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
214247633|NCT04038931|OTHER|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
214247634|NCT05465746|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
214247635|NCT05465746|DIAGNOSTIC_TEST|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
214247636|NCT05574166|DRUG|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
214247637|NCT05574166|DRUG|Placebo|Placebo for SP-8356 powder
214247638|NCT03670927|OTHER|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
214247639|NCT02266914|DEVICE|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
214247640|NCT04689815|DRUG|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
214247641|NCT04204122|DRUG|Vigamox|-FDA approved medication
214247642|NCT04204122|DRUG|Placebo|-The placebo is artificial tear drops
214247643|NCT04958772|BIOLOGICAL|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
214247644|NCT04958772|BIOLOGICAL|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
214247645|NCT02090075|DRUG|apixaban|5 po or 2.5 po bid.
214247646|NCT02090075|DRUG|warfarin|
214247647|NCT00144131|DRUG|Aranesp®|
214247648|NCT02600065|OTHER|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
214247649|NCT02218255|DEVICE|Eeva™ results|
214247650|NCT05857943|DEVICE|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
214247651|NCT02547324|RADIATION|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
214247652|NCT02547324|RADIATION|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
214247653|NCT06278662|OTHER|video directly observed therapy (vDOT)|The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.
214247654|NCT04837092|DRUG|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
214247655|NCT03868124|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
214247656|NCT03868124|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
214247657|NCT04106908|BIOLOGICAL|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
214247658|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.
214247659|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.
214247660|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.
214247661|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
214247662|NCT03958383|BIOLOGICAL|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
214247663|NCT03958383|RADIATION|Radiation Therapy|Palliative radiation therapy
214247664|NCT03958383|BIOLOGICAL|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
214247665|NCT03958383|BIOLOGICAL|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
214247666|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 1|self-amplifying mRNA vaccine
214247667|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 2|self-amplifying mRNA vaccine
214247668|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 3|self-amplifying mRNA vaccine
214247669|NCT06028347|BIOLOGICAL|Placebo|Saline for injection
214247670|NCT05228184|DRUG|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
214247671|NCT05228184|DRUG|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
214247672|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
214247673|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
214247674|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
214247675|NCT06581796|OTHER|pepsinogen-1|association between pepsinogen 1 serum level with hyperemesis gravidarum
214247676|NCT04953052|DRUG|Imatinib Mesylate|An isotonic sterile solution of imatinib.
214247677|NCT04953052|DRUG|Placebo|An isotonic sterile solution
214247678|NCT06427759|PROCEDURE|arm aesthetic surgery|liposuction of arms brachioplasty of arms
214247679|NCT02974309|BEHAVIORAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
214247680|NCT02974309|BEHAVIORAL|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
214247681|NCT06544057|BEHAVIORAL|CBT-MI|CBT-MI combines elements from Cognitive Behavioural Therapy and Motivational Interviewing in treating nicotine addiction, delivered remotely via Zoom by trained 'layperson coaches'
214247682|NCT06559540|RADIATION|Hypofractionated radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
214247683|NCT06559540|RADIATION|Ultra-hypofractionated breast/chest wall and regional nodal radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
214247684|NCT04057989|DRUG|ketamine|
214247685|NCT05211687|OTHER|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~1. Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~2. Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~3. Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
214247686|NCT02698995|DRUG|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
214247687|NCT02698995|DRUG|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
214247688|NCT02698995|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
214247689|NCT02698995|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
214247690|NCT02698995|DRUG|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
214247691|NCT01117051|DRUG|placebo|placebo
214247692|NCT01117051|DRUG|prucalopride|1 or 2 mg prucalopride once daily before breakfast
214247693|NCT05596123|BEHAVIORAL|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
214247694|NCT05596123|BEHAVIORAL|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
214247695|NCT04758000|DRUG|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
214247696|NCT02755688|PROCEDURE|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
214247697|NCT02755688|PROCEDURE|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
214247698|NCT02911207|BEHAVIORAL|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
214247699|NCT03535571|DIETARY_SUPPLEMENT|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
214652708|NCT04217564|BEHAVIORAL|Nutritional counselling|Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
214652709|NCT01132105|DEVICE|Vestibular myogenic evoked potential analyzer|
214652710|NCT00141947|DRUG|bexarotene (Targretin)|
214652711|NCT05448677|DRUG|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
214652712|NCT05448677|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
214247700|NCT03447197|PROCEDURE|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
214247701|NCT04643470|DRUG|Zanubrutinib|Administered as specified in the treatment arm
214247702|NCT04643470|DRUG|Placebo|Placebo to match zanubrutinib
214247703|NCT05244642|DRUG|Penpulimab|A humanized monoclonal immunoglobulin.
214652713|NCT05448677|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214652714|NCT04172285|BEHAVIORAL|Physical activity|Home-based physical activity program
214652715|NCT04172285|DIETARY_SUPPLEMENT|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
214652716|NCT04172285|OTHER|Control|No intervention
214652717|NCT03889587|PROCEDURE|Innervation|There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.
214652718|NCT03889587|PROCEDURE|Non-innervation|This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
214247704|NCT05244642|DRUG|Investigator's choice of Chemotherapy|Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
214247705|NCT05847712|OTHER|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
214247706|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
214247707|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil monotherapy
214247708|NCT05163873|PROCEDURE|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
214247709|NCT01087866|DRUG|Metformin|
214247710|NCT01087866|DRUG|Insulin|
214247711|NCT00005934|DRUG|5-Azacytidine|
214247712|NCT01894412|BIOLOGICAL|Etanercept (Enbrel)|
214247713|NCT01894412|BIOLOGICAL|HD203|
214247714|NCT05956379|OTHER|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
214247715|NCT00550056|BEHAVIORAL|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
214247716|NCT00550056|BEHAVIORAL|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
214247717|NCT02661711|DRUG|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
214247718|NCT02808572|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
214247719|NCT02808572|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
214247720|NCT02808572|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
214247721|NCT01060345|DRUG|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
214247722|NCT02545231|DRUG|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214247723|NCT02545231|DRUG|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214247724|NCT02545231|DRUG|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214247725|NCT05602311|DRUG|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
214247726|NCT00366340|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
214247727|NCT00366340|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
214247728|NCT04699253|DEVICE|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
214247729|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
214652719|NCT05733585|DEVICE|Purabond|hemostatic efficacy of PuraBond
214247730|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
214247731|NCT01464983|DRUG|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
214247732|NCT01464983|DRUG|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
214247733|NCT01464983|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
214247734|NCT03355664|DRUG|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
214652720|NCT00743808|OTHER|quality improvement|3-phase quality improvement intervention
214652721|NCT00707798|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
214247735|NCT03355664|DRUG|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
214247736|NCT06338605|OTHER|no intervention, observational study of AKI under CDK4/6 inhibitor treatment|no intervention
214247737|NCT01242397|DEVICE|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
214247738|NCT00354900|DRUG|Aprotinin|
214247739|NCT06057155|DIAGNOSTIC_TEST|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
214247740|NCT03280927|DRUG|Jublia®|Jublia® topical solution
214247741|NCT01110070|DEVICE|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
214247742|NCT01110070|DEVICE|ChonDux|single use device
214247743|NCT03597217|DRUG|PF-05221304|3, 10, 50 mg
214247744|NCT03597217|DRUG|PF-05221304|50 mg multiple dose
214247745|NCT03597217|DRUG|Placebo|Placebo
214247746|NCT03152422|DIAGNOSTIC_TEST|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
214247747|NCT00132106|DRUG|phentolamine|
214247748|NCT03745430|DRUG|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
214247749|NCT00489190|DRUG|Insulin Glulisine|
214247750|NCT04763876|DRUG|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
214247751|NCT04763876|DRUG|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
214247752|NCT03671590|DRUG|TG-1701|Oral daily dose
214652722|NCT00707798|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
214652723|NCT01979497|PROCEDURE|Suture with Adhesive Stripping|
214652724|NCT01979497|PROCEDURE|Suture without Adhesive Stripping|
214652725|NCT05635890|OTHER|Cawthorne Cooksey exercise protocol|Cawthorne Cooksey exercise protocol
214652726|NCT05635890|OTHER|conventional vestibular rehabilitation|conventional vestibular rehabilitation
214652727|NCT04360967|OTHER|Standard Formula|Standard Formula
214652728|NCT04360967|OTHER|Nutrient-enriched Formula|Nutrient-enriched Formula
214247753|NCT03671590|DRUG|Umbralisib|Oral Daily Dose
214247754|NCT03671590|BIOLOGICAL|Ublituximab|IV infusion
214247755|NCT03662243|BEHAVIORAL|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
214247756|NCT03792984|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
214247757|NCT03792984|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
214247758|NCT03792984|DRUG|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
214247759|NCT03792984|DRUG|Placebo|PO for 8 weeks.
214247760|NCT02034136|DIETARY_SUPPLEMENT|Ginsenoside|3.0 g/ d for 28 days
214247761|NCT02034136|DIETARY_SUPPLEMENT|Dietary fiber fill|3g/day, 28days
214247762|NCT01232218|OTHER|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
214247763|NCT01232218|OTHER|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
214247764|NCT06497231|OTHER|Beautifil II LS|Beautifil II LS is a low shrinkage bioactive giomer resin composite.
214247765|NCT06497231|OTHER|Nanohybrid resin composite material|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
214247766|NCT00276042|DRUG|Faropenem Medoxomil|
214247767|NCT00084773|BIOLOGICAL|cetuximab|
214247768|NCT00084773|DRUG|fluorouracil|
214247769|NCT00084773|PROCEDURE|neoadjuvant therapy|
214247770|NCT00084773|RADIATION|radiation therapy|
214247771|NCT05276648|DIAGNOSTIC_TEST|CAM ICU test|CAM ICU for delirium
214247772|NCT05276648|DIAGNOSTIC_TEST|MOCA test|MOCA for cognitif disfonction
214247773|NCT05276648|DIAGNOSTIC_TEST|brief pain test|BRİEF PAİN for chronic pain
214247774|NCT05276648|DIAGNOSTIC_TEST|VAS scale|VAS scale for acute pain
214247775|NCT05413278|BEHAVIORAL|Behavioral|Patient education, information and empowerment
214247776|NCT02392845|DRUG|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
214247777|NCT00218101|DRUG|Buprenorphine|
214247778|NCT01337687|DRUG|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
214652729|NCT05150548|OTHER|No Intervention|Not applicable, non-interventional study
214652730|NCT02316834|OTHER|Laboratory Biomarker Analysis|Correlative studies
214247779|NCT01337687|DRUG|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
214247780|NCT02577276|DEVICE|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
214247781|NCT04784104|DRUG|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
214247782|NCT04784104|DRUG|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
214247783|NCT04784104|DRUG|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
214247784|NCT04784104|PROCEDURE|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
214247785|NCT04784104|PROCEDURE|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
214247786|NCT02389075|PROCEDURE|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
214247787|NCT02389075|PROCEDURE|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
214247788|NCT00057681|DRUG|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
214247789|NCT00057681|DRUG|Valproate|Titrated until blood level is 111 to 125 ug/mL
214652731|NCT02316834|DRUG|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
214247790|NCT00057681|DRUG|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
214247791|NCT01158664|DEVICE|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
214247792|NCT01158664|DEVICE|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
214247793|NCT05345041|BEHAVIORAL|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
214247794|NCT05345041|BEHAVIORAL|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
214247795|NCT01315236|DRUG|Liposomal amikacin for inhalation (LAI)|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
214247796|NCT01315236|DRUG|placebo|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
214247797|NCT05216601|BIOLOGICAL|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
214247798|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
214247799|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
214247800|NCT00377975|DRUG|Ephedrine|
214247801|NCT00377975|DRUG|Pioglitazone|
214247802|NCT00377975|DRUG|Caffeine|
214247803|NCT00696475|DRUG|Diazoxide choline|
214247804|NCT00696475|DRUG|Diazoxide choline|
214247805|NCT00696475|DRUG|Diazoxide choline|
214247806|NCT00696475|DRUG|Placebo|
214247807|NCT01751802|DRUG|Ecopipam|Antagonist of the dopamine D1 receptor
214247808|NCT01751802|DRUG|Placebo|Placebo for Ecopipam
214247809|NCT05999539|DEVICE|Transtibial prosthesis|A transtibial prosthesis to be used for at least one year.
214247810|NCT00240474|DRUG|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
214247811|NCT00240474|DRUG|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
214247812|NCT02483052|DEVICE|RejuvenAir|RejuvenAir
214247813|NCT03186885|BEHAVIORAL|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
214247814|NCT03186885|BEHAVIORAL|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
214247815|NCT03186885|BEHAVIORAL|Control|Participants receive standard of care
214247816|NCT00613197|DRUG|Epanova|4g/day in divided doses
214247817|NCT05065775|DEVICE|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
214247818|NCT04568343|DEVICE|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
214247819|NCT03115580|DEVICE|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
214247820|NCT03115580|DEVICE|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
214247821|NCT02069418|RADIATION|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
214247822|NCT02069418|RADIATION|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
214247823|NCT04873128|GENETIC|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
214247824|NCT00814125|DRUG|Anastrozole (Arimidex)|1mg, orally, once daily
214247825|NCT00814125|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
214247826|NCT00814125|DRUG|Nolvadex placebo|
214247827|NCT00814125|DRUG|Arimidex placebo|
214247828|NCT05829187|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
214247829|NCT05829187|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
214247830|NCT05829187|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
214247831|NCT05829187|DRUG|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
214247832|NCT00589784|DRUG|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
214247833|NCT02669238|DEVICE|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
214247834|NCT02669238|DRUG|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
214247835|NCT06477328|PROCEDURE|Telemedicine|Video calls were made with the telemedicine group.
214247836|NCT04494022|DIAGNOSTIC_TEST|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
214247837|NCT04639037|DEVICE|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
214247838|NCT04639037|DEVICE|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
214247839|NCT00521001|DRUG|everolimus|
214247840|NCT00521001|DRUG|temozolomide|
214247841|NCT01960387|DRUG|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
214247842|NCT01960387|DRUG|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
214247843|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
214247844|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
214247845|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
214247846|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
214247847|NCT02821910|DRUG|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
214247848|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
214247849|NCT02822547|DRUG|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
214247850|NCT00287079|DRUG|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
214247851|NCT00287079|OTHER|No Treatment|No treatment for 96 weeks
214247852|NCT02758977|PROCEDURE|ALPPS|For detailed information please refer to description of experimental arm
214247853|NCT02758977|PROCEDURE|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
214247854|NCT02380820|DEVICE|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
214247855|NCT02380820|DEVICE|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
214247856|NCT04218123|DRUG|Venlafaxine|Daily oral intake 37.5 mg
214247857|NCT04218123|DRUG|Placebo oral tablet|Daily oral intake
214247858|NCT05832021|PROCEDURE|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
214247859|NCT05832021|PROCEDURE|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
214247860|NCT00571376|OTHER|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
214247861|NCT00286611|PROCEDURE|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
214247862|NCT03590197|DRUG|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
214247863|NCT03590197|OTHER|Placebo|Placebo with Valproate
214247864|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
214247865|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
214247866|NCT01071473|OTHER|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
214247867|NCT03901118|DRUG|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
214247868|NCT03901118|DRUG|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
214247869|NCT03901118|DRUG|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
214247870|NCT05637671|DRUG|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
214247871|NCT05637671|DRUG|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
214247872|NCT04942353|BEHAVIORAL|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
214247873|NCT04942353|BEHAVIORAL|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
214247874|NCT03613597|DRUG|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
214247875|NCT03613597|DRUG|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
214247876|NCT00508768|DRUG|Oral SCIO-469 capsule|
214247877|NCT01082640|DRUG|Febuxostat|Febuxostat capsules
214247878|NCT01082640|DRUG|Placebo|Febuxostat placebo-matching capsules
214247879|NCT04148677|DIETARY_SUPPLEMENT|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
214247881|NCT03636711|OTHER|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
214247882|NCT02671162|DRUG|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
214247883|NCT02671162|DRUG|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
214247884|NCT00413478|DRUG|5-Azacytidine|Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
214247885|NCT00776685|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
214247886|NCT00162721|DRUG|doxorubicin, ifosfamide, cisplatin|
214247887|NCT00156572|PROCEDURE|Sodium supplementation|
214247888|NCT00156572|PROCEDURE|Fluid restriction|
214247889|NCT03598634|PROCEDURE|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
214247890|NCT03598634|PROCEDURE|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
214247891|NCT00315354|OTHER|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
214247892|NCT00315354|OTHER|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
214247893|NCT00315354|OTHER|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
214247894|NCT03577171|DRUG|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
214247895|NCT03577171|DRUG|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
214247896|NCT03577171|DRUG|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
214247897|NCT01830075|BEHAVIORAL|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
214247898|NCT04577352|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
214247899|NCT04577352|DRUG|Placebo|Placebo will be administered per schedule specified in the arm.
214247900|NCT01278303|DEVICE|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
214247901|NCT05443360|DIETARY_SUPPLEMENT|DENSITY™ (Amorphous calcium carbonate, ACC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
214247902|NCT05443360|DIETARY_SUPPLEMENT|Crystalized calcium carbonate (CCC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
214247903|NCT02337348|OTHER|Optical coherence tomography|Preintervention imaging
214247904|NCT02337348|RADIATION|Coronary angiography|Conventional coronary intervention
214247905|NCT00669760|OTHER|non-interventional study|does not apply
214247906|NCT03701321|DRUG|Bortezomib|Given SC
214247907|NCT03701321|BIOLOGICAL|Daratumumab|Given IV
214247908|NCT03701321|DRUG|Dexamethasone|Given PO
214247909|NCT03701321|DRUG|Venetoclax|Given PO
214247910|NCT04335422|DEVICE|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
214247911|NCT04335422|BEHAVIORAL|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
214247912|NCT04163822|OTHER|no intervention|no intervention, only observation
214247913|NCT05493618|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
214247914|NCT05493618|DRUG|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
214247915|NCT05493618|DRUG|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
214247916|NCT00198796|BIOLOGICAL|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
214247917|NCT02537795|DEVICE|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
214247918|NCT02537795|PROCEDURE|anterior capsulotomy|
214247919|NCT01623986|DEVICE|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
214247920|NCT01623986|DEVICE|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
214247921|NCT04349085|DEVICE|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
214247922|NCT04349085|DEVICE|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
214247923|NCT05895799|OTHER|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
214247924|NCT05333783|BEHAVIORAL|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
214247925|NCT03431311|BIOLOGICAL|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
214247926|NCT05369260|OTHER|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
214247927|NCT05369260|OTHER|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
214247928|NCT01943708|DEVICE|SPAP|Novel Auto-algorithm for Auto-CPAP device
214247929|NCT01943708|DEVICE|CPAP|Standard CPAP therapy
214247930|NCT02783885|DRUG|immunotherapy|
214247931|NCT04870736|PROCEDURE|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
214247932|NCT04870736|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
214247933|NCT00400790|DRUG|propofol|Propofol used as the primary anaesthetic agent
214247934|NCT00400790|DRUG|desflurane|Desflurane used as the primary anaesthetic
214652732|NCT02500693|BIOLOGICAL|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
214652733|NCT05302635|OTHER|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
214652734|NCT04653493|BIOLOGICAL|CD19 CAR engineered autologous T-cells|"Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities."
214652735|NCT04653493|DRUG|Cyclophosphamide|Given IV
214247935|NCT00847119|BIOLOGICAL|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
214247936|NCT00847119|DRUG|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
214247937|NCT00847119|RADIATION|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
214247938|NCT04900168|DEVICE|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
214247939|NCT03315091|DRUG|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
214247940|NCT03315091|DRUG|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
214247941|NCT01082380|DRUG|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
214247942|NCT05990998|DRUG|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
214247943|NCT06256757|PROCEDURE|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
214247944|NCT03409068|PROCEDURE|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
214247945|NCT03409068|PROCEDURE|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
214247946|NCT01496768|DIETARY_SUPPLEMENT|Leucine|7,2 g/day during 3 months
214247947|NCT01496768|DIETARY_SUPPLEMENT|Alanine|7,2 g/day during 3 months
214247948|NCT02147912|OTHER|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
214247949|NCT06130007|DRUG|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
214247950|NCT04733612|OTHER|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
214247951|NCT03211962|OTHER|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
214247952|NCT05368532|OTHER|Temperature|The temperature will be reduced for approximately one hour.
214247953|NCT02040285|DRUG|Bisacodyl & PEG-CS|"the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
214247954|NCT02040285|DRUG|Iopamidol|"the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet"
214247955|NCT02129777|DRUG|Namilumab|Namilumab subcutaneous injection
214247956|NCT02129777|DRUG|Placebo|Placebo subcutaneous injection
214247957|NCT03436810|PROCEDURE|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
214247958|NCT03436810|PROCEDURE|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
214247959|NCT03436810|PROCEDURE|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
214247960|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
214247961|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
214247962|NCT00797342|DRUG|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
214247963|NCT00977808|DEVICE|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
214247964|NCT00977808|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
214247965|NCT05509946|DRUG|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
214247966|NCT05509946|DRUG|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
214247967|NCT05509946|DRUG|Placebo|Placebo
214247968|NCT00542451|DRUG|Paclitaxel|Every week for 12 weeks
214247969|NCT00542451|DRUG|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
214247970|NCT03046173|OTHER|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
214247971|NCT03046173|OTHER|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
214247972|NCT05082610|DRUG|HMBD-002|IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
214247973|NCT05082610|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
214247974|NCT06177808|DEVICE|Wolverine cutting balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
214247975|NCT06177808|DEVICE|Non-compliant balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
214247976|NCT05992324|DEVICE|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
214247977|NCT05423249|DRUG|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
214247978|NCT05423249|DRUG|Prenatal|Oral prenatal vitamin once daily for both groups
214247979|NCT05423249|DRUG|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
214247980|NCT05423249|DRUG|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
214247981|NCT05423249|DRUG|Placebo|Oral placebo pill once daily
214247982|NCT06047548|DRUG|Tirzepatide|Administered SC
214247983|NCT06047548|DRUG|Placebo|Administered SC
214652736|NCT04653493|DRUG|Fludarabine|Given IV
214247984|NCT01871103|PROCEDURE|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
214247985|NCT03906188|OTHER|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
214247986|NCT02889276|OTHER|Functional Resistance Training|Supervised group-based Functional Resistance Training
214247987|NCT02889276|BEHAVIORAL|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
214247988|NCT02399007|DEVICE|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
214247989|NCT02399007|DEVICE|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
214247990|NCT06002685|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
214247991|NCT06002685|OTHER|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
214247992|NCT00527670|PROCEDURE|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
214247993|NCT00527670|PROCEDURE|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
214247994|NCT00419809|DRUG|SB-681323 oral tablets|
214247995|NCT04148729|DRUG|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally. 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.
214247996|NCT04148729|DRUG|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
214247997|NCT03148119|DRUG|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
214247998|NCT03148119|DEVICE|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
214247999|NCT03367247|BEHAVIORAL|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
214248000|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
214248001|NCT04059367|DRUG|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
214248002|NCT04059367|DRUG|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
214248003|NCT00752596|DRUG|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
214248004|NCT00064298|DIETARY_SUPPLEMENT|fruit and vegetable extracts|Given orally
214248005|NCT00064298|DIETARY_SUPPLEMENT|placebo|Given orally
214248006|NCT02468011|OTHER|vibration|vibration will be applied at 35 Hz
214248007|NCT04983212|OTHER|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
214248008|NCT00419679|PROCEDURE|x-ray diffraction of human hair|
214248009|NCT01025765|DRUG|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
214248010|NCT01025765|DRUG|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
214248011|NCT01025765|DRUG|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
214248012|NCT06136442|DRUG|Atogepant|atogepant in real life in Italy
214248013|NCT06154681|OTHER|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
214248014|NCT02881333|GENETIC|Blood samples|
214248015|NCT04877873|BEHAVIORAL|Gait analysis pre- and post- surgery|None (observational)
214248016|NCT01585012|DEVICE|Cervical cap (Focus Touch™ Conception System)|Cervical cap
214248017|NCT01856023|DRUG|High Dose Interleukin-2|
214248018|NCT01856023|DRUG|Ipilimumab|
214248019|NCT04082039|OTHER|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
214248020|NCT04082039|OTHER|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
214248021|NCT03419975|DRUG|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
214248022|NCT03419975|DRUG|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
214248023|NCT03190642|DRUG|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
214248024|NCT05186428|OTHER|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
214248025|NCT05186428|OTHER|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
214248026|NCT01652911|DEVICE|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
214248027|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
214248028|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
214248029|NCT02609997|DRUG|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
214248030|NCT02609997|DEVICE|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
214248031|NCT02609997|DRUG|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
214248032|NCT00536861|DRUG|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
214248033|NCT04573647|DRUG|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
214248034|NCT05982431|OTHER|Traditional physical therapy program|60-minutes exercise program, three times a week on alternate days for 12 successive weeks
214248035|NCT05982431|OTHER|Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
214248036|NCT05982431|OTHER|placebo Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
214248037|NCT00005093|DRUG|gemcitabine hydrochloride|
214248038|NCT00005093|DRUG|tacedinaline|
214248039|NCT00825851|DRUG|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
214248040|NCT00825851|DRUG|Placebo patch|
214248041|NCT00825851|BEHAVIORAL|Smoking cessation|
214248042|NCT00825851|BEHAVIORAL|Continuous smoking|subjects smoke 20 cigarettes per day
214248043|NCT02545595|DRUG|Sugammadex 1 mg/kg|
214652737|NCT04653493|DRUG|Mesna|Given IV
214248044|NCT02545595|DRUG|Sugammadex 2 mg/kg|
214248045|NCT02545595|DRUG|Sugammadex 4 mg/kg|
214248046|NCT02756065|OTHER|no intervention|no intervention is used
214248047|NCT01016704|BEHAVIORAL|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
214248048|NCT06352333|PROCEDURE|supraclavicular ultrasound guided brachial plexus block|two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
214248049|NCT02829983|DRUG|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
214248050|NCT02829983|DRUG|Placebo|Use of placebo tablets twice a day for 3 days.
214248051|NCT02829983|OTHER|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
214248052|NCT00322153|DRUG|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
214248053|NCT00322153|DRUG|Placebo|Matching placebo oral administration once daily.
214248054|NCT02798614|DEVICE|10-day cast|Removal of plaster cast fixation 10 days after reduction
214248055|NCT01309893|DEVICE|Investigational Lens|Lenses worn on a daily wear basis for one week
214248056|NCT01309893|DEVICE|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
214248057|NCT01087697|DEVICE|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
214248058|NCT02414139|DRUG|Capmatinib|"Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food."
214248059|NCT05325710|BEHAVIORAL|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
214248060|NCT02632838|DEVICE|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
214248061|NCT02859818|OTHER|therapeutic education program|
214248062|NCT02810340|BIOLOGICAL|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
214248063|NCT02810340|BIOLOGICAL|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
214248064|NCT02810340|BIOLOGICAL|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
214248065|NCT05879510|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
214248066|NCT04063527|DRUG|adjuvant chemotherapy|combination of paclitaxel and carboplatin
214248067|NCT03900962|OTHER|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
214248068|NCT03900962|OTHER|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
214248069|NCT05880823|DEVICE|Synergy cervical disc system|motion preservation disc
214248070|NCT03291171|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
214248071|NCT04252833|DRUG|CT-044|CT-044 HCl is a reactive species decomposition accelerant
214248072|NCT01983150|BEHAVIORAL|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
214248073|NCT01983150|BEHAVIORAL|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
214248074|NCT00688207|DRUG|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
214248075|NCT04036643|RADIATION|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
214248076|NCT00122733|DRUG|loxapine|
214248077|NCT02088515|DRUG|Nedaplatin|
214248078|NCT02088515|DRUG|Cisplatin|
214248079|NCT02088515|DRUG|Docetaxel|
214248080|NCT00457964|DRUG|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
214248081|NCT02797054|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
214248082|NCT02797054|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
214248083|NCT02797054|BEHAVIORAL|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
214248084|NCT02717377|BEHAVIORAL|physical activity|
214248085|NCT04644783|DIAGNOSTIC_TEST|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
214248086|NCT00602745|DRUG|S-1|oral administration
214248087|NCT00602745|DRUG|5-Fluorouracil|intravenous bolus
214248088|NCT05546801|OTHER|questionnaire|questionnaire on postnatal development
214248089|NCT00825773|DEVICE|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
214248090|NCT05999942|DRUG|Liposomal Amikacin for Inhalation|Administered via the Pari LC STAR™ nebulizer.
214248091|NCT03221764|DRUG|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
214248092|NCT03221764|DEVICE|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
214248093|NCT01363414|DRUG|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
214248094|NCT01363414|DRUG|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
214248095|NCT05832476|OTHER|No intervention|No intervention
214248096|NCT04955860|OTHER|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
214248097|NCT01747018|BIOLOGICAL|Platelet-rich Plasma|
214248098|NCT02699216|DEVICE|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
214248099|NCT00943943|DRUG|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
214248100|NCT00943943|DRUG|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
214248101|NCT00943943|DRUG|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
214248102|NCT01795066|DEVICE|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
214248103|NCT01847911|OTHER|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
214248104|NCT01847911|OTHER|instructor training|a pre-validated OSCE neonatal resuscitation program
214248105|NCT04178356|OTHER|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
214248106|NCT04178356|OTHER|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
214248107|NCT01609101|DEVICE|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
214248108|NCT01609101|DEVICE|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
214248109|NCT01609101|DEVICE|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
214248110|NCT01609101|DEVICE|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
214248111|NCT01609101|DEVICE|King Vision® videolaryngoscope|King Vision® videolaryngoscope
214248112|NCT01609101|DEVICE|Venner® videolaryngoscope|Venner® videolaryngoscope
214248113|NCT01609101|DEVICE|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
214248114|NCT00097851|DRUG|docetaxel|
214248115|NCT00097851|DRUG|PI-88|
214248116|NCT03109847|DRUG|Metformin Hydrochloride|Given Orally
214248117|NCT03109847|OTHER|Radioactive Iodine|Undergo radioactive iodine treatment
214248118|NCT03109847|OTHER|Placebo|Given orally
214248119|NCT01233687|DRUG|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
214248120|NCT01296243|DRUG|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
214248121|NCT00846170|DRUG|co-biotic|give probiotic 2 t/day
214248122|NCT00846170|DRUG|placebo 2T/day|cross over of patients from study arm to placebo arm
214248123|NCT00876603|PROCEDURE|ACDF|Anterior cervical decompression and fusion
214248124|NCT00876603|PROCEDURE|Cervical laminoplasty|Cervical laminoplasty
214248125|NCT02918981|BEHAVIORAL|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
214248126|NCT02918981|DIETARY_SUPPLEMENT|14 g Whey protein|
214248127|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine|
214248128|NCT02918981|DIETARY_SUPPLEMENT|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
214248129|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
214248130|NCT02918981|OTHER|Water control|
214248131|NCT01484938|DEVICE|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
214248132|NCT01326325|DRUG|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
214248133|NCT01326325|DRUG|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
214248134|NCT03869827|OTHER|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
214248135|NCT04783142|OTHER|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
214248136|NCT04783142|OTHER|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
214248137|NCT00003950|DRUG|cyclosporine|
214248138|NCT00003950|DRUG|CPT-11|
214248139|NCT00805233|DRUG|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
214248140|NCT00805233|DRUG|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
214248141|NCT02747979|OTHER|hemodialysis only|hemodialysis treatment only
214248142|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
214248143|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
214248144|NCT05745194|BEHAVIORAL|Promotion of adherence to the MedDiet|"Participants will be followed in six individual nutrition consultations with a duration of 30 to 60 minutes. The consultations will be focused on promoting the adherence to the MedDiet.~The nutritional intervention will be personalized to each individual ad libitum, without calories or macronutrients restriction and without the goal to promote weight change. The intervention will begin with an initial assessment of the dietary patterns of the participants in which the nutritionist will identify potential behavioural changes to promote adjustments in dietary habits and therefore adherence to the MedDiet.~The intervention will promote positive recommendations (behaviours recommended to follow) and negative recommendations (behaviours recommended to reduce or eliminate) (26), using the strategy and MedDiet definition proposed by Estruch et al. in the Primary Prevention of Cardiovascular Disease with a Mediterranean Diet study (3).~The participants will also maintain MDD TAU."
214248145|NCT06491329|OTHER|high-intensity interval training|high-intensity interval training ： 40-50 minutes, patients engage in power cycling with intervals of high-intensity exercise at 75%-100% of VO2peak for 30s-1min, followed by 30s-1min of passive recovery, totaling 15-25 cycles.
214248146|NCT06491329|OTHER|moderate-intensity interval training|40-50 minutes, involves power cycling with 8 minutes of moderate-intensity exercise at 40%-60% of VO2peak followed by 2 minutes of passive recovery, totaling 4 cycles.
214248147|NCT00033852|PROCEDURE|Massage Therapy|
214248148|NCT01697098|DRUG|Dexamethasone 24 hours|
214248149|NCT01697098|DRUG|Dexamethasone 12|
214248150|NCT02211638|DRUG|Candesartan Cilexetil|Candesartan Cilexetil tablet
214248151|NCT03237195|OTHER|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
214248152|NCT04029155|DEVICE|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
214248153|NCT01260961|DIETARY_SUPPLEMENT|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
214248154|NCT01260961|DIETARY_SUPPLEMENT|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
214248155|NCT03173534|DEVICE|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
214248156|NCT03173534|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
214248157|NCT04571515|DRUG|MR-107A-01|Oral tablet
214248158|NCT04571515|DRUG|Placebo|Oral tablet
214248159|NCT05140382|DRUG|AZD4573|AZD4573 will be given intravenously
214248160|NCT06612424|DRUG|ANTERİOR QUADRATUS LUMBORUM BLOCK|In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 20 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
214248161|NCT06612424|DRUG|İNTRATECHAL MORPHİNE GROUP|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
214248162|NCT06684444|BEHAVIORAL|firefighter Sleep Health Coaching Intervention (ffSHC)|This multi-component intervention is based on principles of cognitive behavioral therapy for insomnia. It includes telephone-based sleep health coaching to individuals, targeted training and sleep health education to fire service leaders, agency-level sleep health promotion, and facilitation strategies to internal facilitators.
214248163|NCT06684444|BEHAVIORAL|Control (Minimally Enhanced Usual Care)|The control arm is minimally enhanced usual care. Usual care interventions for sleep disturbance include any health or wellness interventions administered by the agency on the topic of sleep, including occupational health intervention, employee assistance programs, education, signage, and webinars. The type and dose of care will be assessed at each timepoint. Minimal enhancement is a referral to the agency's Employee Assistance Program and will address the ethical problem in the control condition of identifying but not treating a sleep disturbance.
214248164|NCT06682325|OTHER|Multi-drug interaction|The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.
214248165|NCT06682052|OTHER|anti-stress ball|The women will be given a round, silicone, medium-sized and medium-hard anti-stress ball, and they will be told how to use the stress ball, and they will be asked to squeeze the anti-stress ball throughout the examination, allowing the patients to rest occasionally as they wish. The women will be told to count to 3 as they squeeze the anti-stress ball, then to relax the stress ball and repeat this process.
214248166|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
214248167|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
214248168|NCT06689800|BEHAVIORAL|Let's Get REAL|Family health communication tool
214248169|NCT04067440|DIAGNOSTIC_TEST|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
214248170|NCT06684717|BEHAVIORAL|Educational video intervention|A 3-minute educational video mainly about the benefits of Continuous positive airway pressure therapy in OSA patients. The video starts with basic knowledge about OSA and how it affects human health. What is a CPAP machine and how does it works? It was developed from consensus among expert opinions of Neurobehavioral specialists and sleep physicians.
214248171|NCT06696183|DRUG|Gilteritinib (GILT)|80 mg
214248172|NCT06696183|DRUG|Venetoclax (VEN)|400 mg
214248173|NCT06696183|DRUG|Azacitidine (AZA)|75 mg/m²
214248174|NCT06994117|DRUG|Mezigdomide|Mezigdomide
214248175|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
214248176|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
214248177|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
214248178|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
214248179|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
214248180|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
214248181|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
214248182|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
214652738|NCT05359393|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
214652739|NCT03052647|DEVICE|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
214248183|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
214248184|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
214248185|NCT04526899|BIOLOGICAL|BNT111|IV injection
214248186|NCT04526899|BIOLOGICAL|Cemiplimab|IV infusion
214248187|NCT06683950|DRUG|Aflibercept 8mg|"Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing."
214248188|NCT06878391|PROCEDURE|Preemptive ultrasound-guided interscalene brachial plexus block and suprascapular nerve block and axillary nerve block|Preemptive ultrasound-guided interscalene brachial plexus block using ropivacaine, and suprascapular nerve block and axillary nerve block using ropivacaine or saline. Low fixed dose patient controlled analgesia (PCA) were done in the two group.
214248189|NCT06708039|OTHER|Mobile Instant Messaging Application based Self-management and Exercise Programme (SMEP)for Older Adults with Chronic Knee Pain.|The Mobile Instant Messaging Application based self-management and exercise programme (SMEP) consists of 10 short videos of self-management on chronic knee pain in older adults (5-10 minutes/video), 10 short videos of exercise interventions (5-10 minutes/video) and group discussions (10-20 minutes/session) with each video/session focusing on different content. A WhatsApp group that includes all participants in the intervention group will be created to deliver the three components of the program twice a week for five weeks. At the end of each session, they will be given the power point slides from the self-management video in Pdf format and an e-pamphlet of the exercise video. A total of 30-40 minutes will be allocated for each session to allow for socialization between the participants and researcher and also for a question and answer session.
214248190|NCT06707051|DRUG|Tranexamic Acid|Group A received Trannexamic Acid 500mg three times a day for 5 days
214652740|NCT03052647|DEVICE|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
214248191|NCT06707051|DRUG|Calcium dobesilate (Doxium)|Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
214248192|NCT05501366|DIETARY_SUPPLEMENT|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) \& 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
214248193|NCT05501366|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
214248194|NCT05501366|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
214248195|NCT05501366|OTHER|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
214248196|NCT05501366|OTHER|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
214248197|NCT05501366|OTHER|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day
214248198|NCT05501366|RADIATION|DXA|Lean Body Mass will be assessed once via DXA
214248199|NCT05501366|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
214248200|NCT06704646|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
214248201|NCT06656195|OTHER|glueus maximus strengthening|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
214248202|NCT06656195|OTHER|hamstring stretching group|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
214248203|NCT06715696|DEVICE|"HANBIO Gauze (Sterilized, 1% Collagen)"|"After tissue resection in a standard procedure for gynecological surgery, direct application of HANBIO Gauze to cover the bleeding site/area which identified during dissection."
214248204|NCT05401019|DRUG|Pramipexole|Oral medication, once a day during 16 weeks
214248205|NCT05401019|DRUG|Risperidone|Oral medication, once a day during 16 weeks
214248206|NCT01711372|DEVICE|Groundskeeper game for controls|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
214248207|NCT01711372|DEVICE|Groundskeeper game for ADHD|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
214248208|NCT06725901|DEVICE|Web-Based Application|The intervention involves the DIAGEN-IA platform, a diagnostic support tool designed to identify pediatric neurological diseases with a genetic basis. Using a Bayesian network model and integrating ontologies such as ORDO, HPO, and HOOM, DIAGEN-IA links phenotypic data entered by physicians to suggested diagnoses and tests. Pediatric neurologists will be trained to use the platform during a 12-month intervention. DIAGEN-IA allows clinicians to input clinical and diagnostic data, generating differential diagnoses and recommended tests, with results exportable in PDF for integration into medical records. Platform usage will be tracked, including login frequency, time spent, and evaluations performed.
214248209|NCT03893916|PROCEDURE|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
214248210|NCT06738173|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
214652741|NCT04897321|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
214248211|NCT00385190|DRUG|HCV-796|
214248212|NCT06893185|OTHER|Dry cupping therapy|Dry cupping therapy will perform on the skin areas containing the EX-B2, A-shi, and GB21 acupuncture points every 3 days for 2 weeks.
214652742|NCT04897321|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
214652743|NCT04897321|DRUG|MESNA|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
214248213|NCT06893185|OTHER|Electroacupuncture|Electroacupuncture therapy will be performed five times a week for 2 weeks. The acupoints are the Huatuojiaji (EX-B2), A-shi, and Jianjing (GB21).
214248214|NCT06118892|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
214248215|NCT06742710|DRUG|Liraglutide and metformin|Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
214248216|NCT06742710|DRUG|Metformin|Metformin 1500 mg/day until pregnancy
214248217|NCT05329584|DEVICE|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
214248218|NCT06748170|OTHER|ChatGPT|OpenAI's ChatGPT language model with chat interface.
214248219|NCT06754917|BEHAVIORAL|Face-Forward-Web|This is a self-administered web-based mind-body intervention that consists of 5 30-minute video sessions disseminating tailored relaxation, mindfulness, and cognitive-behavioral skills for COP. Ultimately, the Face-Forward-Web program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive coping behaviors.
214248220|NCT06809894|PROCEDURE|Application of an action protocol for the management of delirium through the use of non-pharmacological interventions|The interventions carried out stand out for being non-pharmacological, this avoiding the use of drugs and polypharmacy in elderly patients, avoiding the appearance of clinical complications derived from the side effects that the use of these substances can lead to in the patient. In addition, it also encourages the education of health professionals and nurses' families or caregivers in the management of delirium.
214248221|NCT06809894|OTHER|Tradicional management of delirium|The use of the pharmacological treatment and the mechanical patients restrain were de base of the traditional treatment in deliriums patient in the University hospital of Igualada, because of the less knowledge of the professionals and non-existence protocol of non-pharmacological interventions to management the delirium.
214248222|NCT00323869|DRUG|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
214248223|NCT00323869|DRUG|Gemcitabine|Nucleoside analog
214248224|NCT00323869|DRUG|Carboplatin|Alkylating agent
214248225|NCT00000506|DRUG|fenfluramine|
214248226|NCT00000506|DRUG|phentermine|
214248227|NCT04840030|BEHAVIORAL|Multimodal intervention (MM-int)|"1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
214248228|NCT00921245|DRUG|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
214248229|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
214248230|NCT04152031|OTHER|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
214248231|NCT02587039|PROCEDURE|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
214248232|NCT02587039|BEHAVIORAL|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
214248233|NCT01941043|DRUG|CERC-301|
214248234|NCT01941043|OTHER|Placebo|
214248235|NCT05041946|DRUG|Methylphenidate|Given PO
214248236|NCT05041946|OTHER|Placebo (Sugar Pill)|Given PO
214248237|NCT02588937|DRUG|EntecaBell ODT. 0.5mg|
214248238|NCT02588937|DRUG|Baraclude Tab. 0.5mg|
214248239|NCT05201742|OTHER|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
214248240|NCT05201742|OTHER|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
214248241|NCT04014023|DRUG|DWP16001|DWP16001 tablets
214248242|NCT04014023|DRUG|Placebo|DWP16001 placebo-matching tablets
214248243|NCT00905827|BEHAVIORAL|CAMS|Collaborative assessment management in suicidality
214248244|NCT02556827|OTHER|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
214248245|NCT02556827|DEVICE|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
214248246|NCT02556827|DEVICE|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
214248247|NCT02556827|DEVICE|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
214248248|NCT04467931|DRUG|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
214464787|NCT03878589|DRUG|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
214248249|NCT04467931|DRUG|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
214248250|NCT04467931|DRUG|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
214248251|NCT04467931|DRUG|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
214248252|NCT06086691|OTHER|Strength Training with Caffeine|"The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
214248253|NCT06086691|OTHER|Endurance Training with Caffeine|"The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
214248254|NCT02857179|PROCEDURE|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
214248255|NCT00509392|DEVICE|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
214248256|NCT00509392|DEVICE|Endovenous Laser|laser catheter
214248257|NCT03619343|PROCEDURE|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
214248258|NCT00372203|PROCEDURE|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
214248259|NCT02210273|DEVICE|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
214248260|NCT02210273|DEVICE|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
214248261|NCT03004222|DRUG|Bupivacaine|20 ml of 0.5% Bupivacaine
214248262|NCT03004222|DRUG|Placebos|
214248263|NCT02330484|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
214248264|NCT02330484|BEHAVIORAL|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
214248265|NCT04951440|DRUG|Nitrate ketone oxazine|Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
214248266|NCT00428662|DEVICE|drug eluting nonpolymeric nanoporous stent|
214248267|NCT05241483|DIAGNOSTIC_TEST|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
214248268|NCT03024879|DRUG|Erythromycin|
214248269|NCT03024879|DRUG|Saline|
214652744|NCT04897321|DRUG|B7-H3 CAR T cells|The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
214652745|NCT02330419|DRUG|Placebo|Placebo capsules will contain microcrystalline cellulose (Medisca). Placebo and active medication will be provided in capsules that are an exact match in color, so as to make the placebo and active medication indistinguishable from each other.
214248270|NCT05324722|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
214248271|NCT05324722|OTHER|cross body stretch|crossbody stretch performed by an individual
214248272|NCT05802173|DRUG|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
214248273|NCT05802173|DRUG|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
214248274|NCT05802173|DRUG|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
214652746|NCT02330419|DRUG|Naltrexone|REVIA is a white, crystalline compound. The hydrochloride salt is soluble in water to the extent of about 100 mg/mL. REVIA is available in scored film-coated tablets containing 50 mg of naltrexone hydrochloride.
214652747|NCT02330419|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist
214248275|NCT04602689|DRUG|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
214248276|NCT01165333|DRUG|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800"
214248277|NCT01165333|DRUG|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
214248278|NCT01165333|RADIATION|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
214248279|NCT01165333|BIOLOGICAL|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
214248280|NCT01165333|BIOLOGICAL|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
214248281|NCT01165333|BIOLOGICAL|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
214248282|NCT05099393|DIETARY_SUPPLEMENT|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
214248283|NCT01632917|DRUG|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
214248284|NCT01632917|DRUG|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
214248285|NCT04120285|BEHAVIORAL|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
214248286|NCT03861923|OTHER|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
214248287|NCT03861923|OTHER|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
214248288|NCT03861923|OTHER|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
214248289|NCT04795427|DRUG|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
214248290|NCT04795427|OTHER|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
214248291|NCT05192122|OTHER|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
214248292|NCT03920618|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
214248293|NCT03920618|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
214248294|NCT03920618|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
214248295|NCT06139796|DRUG|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
214248296|NCT05534087|DRUG|mFOLFIRINOX-FOLFIRI intensified chemotherapy|"(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2"
214248297|NCT05534087|DRUG|FOLFOX or CAPOX adjuvant chemotherapy|"1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14"
214248298|NCT00488280|BEHAVIORAL|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
214652748|NCT02330419|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers:|Urine samples will be collected weekly and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours).
214248299|NCT06053463|DEVICE|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
214248300|NCT03703050|DRUG|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
214248301|NCT03703050|DRUG|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
214248302|NCT06262464|BEHAVIORAL|Prevention|A cognitive-behavioural prevention programme.
214652749|NCT02330419|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measure that will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection
214652750|NCT02330419|DIAGNOSTIC_TEST|Dried Blood Spot (DSB) Testing for Phosphatidylethanol|Phosphatidylethanol (PEth)-a phospholipid formed only in the presence of alcohol-is a novel, direct biochemical marker of alcohol that has shown high (\>95%) sensitivity and specificity to detect heavy drinking over a period of 2-3 weeks in several studies of dependent patients and abstainers. DSB samples will be collected at enrollment, weeks 3, 6, 9, 12, and post-treatment visits at month 1, 3, and 6.
214248303|NCT05343000|BEHAVIORAL|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
214248304|NCT04931212|PROCEDURE|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
214248305|NCT05945745|DRUG|Chemotherapy|different treatments based on the molecular analysis
214248306|NCT05008185|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
214248307|NCT05008185|PROCEDURE|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
214248308|NCT06313008|DRUG|Empagliflozin 10 MG|eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
214248309|NCT06313008|DRUG|Vildagliptin 50 MG|eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
214248310|NCT06537609|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol)."
214248311|NCT06537609|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole."
214248312|NCT06537609|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed."
214248313|NCT06537609|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses"
214248314|NCT06537609|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
214248315|NCT01135108|DRUG|Placebo|Placebo IV Infusion
214248316|NCT01135108|DRUG|KAI-1678|KAI-1678 IV Infusion
214248317|NCT06533527|DRUG|Semaglutide|GLP1 medication
214248318|NCT06533527|DRUG|Tirzepatide|GLP1/GIP medication
214248319|NCT06533527|DRUG|Liraglutide|GLP1 medication
214248320|NCT06533527|DRUG|Dulaglutide|GLP1 Medication
214248321|NCT03073967|DRUG|Pritelivir|100 mg oral tablets
214248322|NCT03073967|DRUG|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
214652751|NCT02330419|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments are SMS texts to collect data on alcohol consumption, number of drinks on drinking days, and targeted medication administration prior to anticipated drinking sessions. Messages will use short-hand notations to maintain participant confidentiality
214652752|NCT06494579|DRUG|Lamivudine|Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy
214652753|NCT06494579|DRUG|PD-L1 Blocker|PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
214652754|NCT04535193|DRUG|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
214652755|NCT00183690|PROCEDURE|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
214652756|NCT00183690|PROCEDURE|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
214248323|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
214248324|NCT05499650|BEHAVIORAL|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
214248325|NCT06048718|DRUG|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
214248326|NCT04902326|BEHAVIORAL|Automated educational text messages|"During the first two weeks, participants receive a series of educational messages delivered via text message. These messages welcome participants to the study, set expectations for the next 12 months, and establish a general level of knowledge among all participants on prediabetes, the Diabetes Prevention Program (DPP), and metformin.~For the next 11.5 months, participants receive three automated text messages per week that provide evidence-based educational content about prediabetes and tips on prevention. Additionally, participants receive monthly messages reminding them about their health insurance plan's coverage of the DPP at no cost and coverage of metformin as a low co-pay medication, and monthly messages providing feedback on their participation in the DPP and use of metformin in the previous calendar month. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months."
214248327|NCT04902326|BEHAVIORAL|Autonomy-supportive automated educational text messages|Participants receive the same text messages as in the automated educational text message intervention, but the thrice weekly messages have been modified, where applicable, to support the participant's autonomy, in accordance with principles of Self-Determination Theory. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months.
214248328|NCT04902326|BEHAVIORAL|Financial incentives|Participants in this arm have the opportunity to earn a financial incentive ranging from $50 to $250 per month for taking an evidence-based action to prevent T2DM (i.e., engagement in a DPP or fill of a metformin prescription) in the previous month.
214248329|NCT04902326|BEHAVIORAL|Tailored text messages|Participants receive twice-weekly tailored text messages that link evidence-based actions to prevent T2DM to the participant's self-identified top values, roles, and strengths. Text messages are also tailored, when possible, to participants' self-reported importance of taking action to try to prevent T2DM (i.e., participating in the DPP or taking metformin), confidence in being able to take such preventive action, and past preventive actions taken.
214248330|NCT02810353|DEVICE|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
214248331|NCT02810353|DEVICE|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
214248332|NCT05835973|OTHER|Sleep activity|"Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
214248333|NCT05835973|OTHER|Questionnaires|"The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit."
214248334|NCT03335917|OTHER|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
214248335|NCT03335917|OTHER|Exercise|Graded cycling exercise to volitional fatigue
214248336|NCT00427960|BEHAVIORAL|Dietary advice|
214248337|NCT00427960|DRUG|rosuvastatin|rosuvastatin 5 mg
214248338|NCT00427960|DRUG|atorvastatin|atorvastatin 10 mg
214248339|NCT01617148|DRUG|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
214248340|NCT06278233|DEVICE|Transcranial direct current stimulation|TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
214248341|NCT04111952|DEVICE|CO2 laser|A single session of CO2 vaginal laser treatment
214248342|NCT04111952|DEVICE|Sham laser|A single session of sham laser treatment.
214248343|NCT04804020|PROCEDURE|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
214248344|NCT04804020|PROCEDURE|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
214464788|NCT03878589|DRUG|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
214248345|NCT04804020|PROCEDURE|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
214248346|NCT03935620|BEHAVIORAL|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
214248347|NCT05115890|OTHER|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
214248348|NCT00405327|BIOLOGICAL|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
214248349|NCT00405327|OTHER|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
214248350|NCT02901639|OTHER|counseling|
214248351|NCT03127956|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
214248352|NCT01564771|OTHER|Non Intervention|This Is A Non Interventional Study
214248353|NCT05447962|BEHAVIORAL|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
214248354|NCT05447962|BEHAVIORAL|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
214248355|NCT04245462|OTHER|No intervention|Cross-sectional
214248356|NCT00423670|DRUG|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
214248357|NCT00423670|DRUG|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
214248358|NCT00423670|DRUG|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
214248359|NCT00423670|DRUG|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
214248360|NCT01011023|OTHER|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
214248361|NCT01861171|DIETARY_SUPPLEMENT|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
214248362|NCT05832827|DRUG|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
214248363|NCT05832827|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
214248364|NCT05832827|DRUG|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
214248365|NCT05832827|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
214248366|NCT05196178|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
214248367|NCT03734744|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
214248368|NCT01631019|BEHAVIORAL|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
214248369|NCT01631019|BEHAVIORAL|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
214248370|NCT04403490|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
214248371|NCT04403490|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
214248372|NCT04163718|DRUG|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
214464789|NCT01476839|BIOLOGICAL|basiliximab|Given IV
214464790|NCT01476839|DRUG|carmustine|Given IV
214464791|NCT01476839|DRUG|etoposide|Given IV
214464792|NCT01476839|DRUG|cytarabine|Given IV
214464793|NCT01476839|DRUG|melphalan|Given IV
214464794|NCT01476839|OTHER|pharmacological study|Correlative studies
214464795|NCT01476839|OTHER|laboratory biomarker analysis|Correlative studies
214248373|NCT04026581|BEHAVIORAL|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
214248374|NCT04026581|BEHAVIORAL|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
214248375|NCT02983396|DEVICE|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
214248376|NCT04565184|DRUG|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
214248377|NCT04565184|DRUG|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
214248378|NCT05151601|DIETARY_SUPPLEMENT|Experimental|2 x sachets per day
214248379|NCT05151601|OTHER|Placebo|2 x sachets per day
214248380|NCT00002576|DRUG|cyclophosphamide|
214248381|NCT00002576|DRUG|doxorubicin hydrochloride|
214248382|NCT00002576|DRUG|mitoxantrone hydrochloride|
214248383|NCT00002576|DRUG|prednisolone|
214248384|NCT00002576|DRUG|vincristine sulfate|
214248385|NCT03157960|OTHER|Blueberry drink|Participant receive blueberry drink
214248386|NCT03157960|OTHER|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
214248387|NCT03157960|OTHER|Soft beverage|Participant receive a soft beverage drink
214248388|NCT03157960|OTHER|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
214248389|NCT03157960|OTHER|Fructose|Participant receive a drink containing fructose
214248390|NCT03157960|OTHER|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
214248391|NCT01019811|PROCEDURE|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
214248392|NCT01905111|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
214248393|NCT00477581|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
214248394|NCT00477581|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
214248395|NCT02886156|DEVICE|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
214248396|NCT02886156|DIETARY_SUPPLEMENT|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
214248397|NCT01386905|DEVICE|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
214248398|NCT00270829|DRUG|nesiritide|Drug given intrarenally or placebo
214248399|NCT02594540|DEVICE|Mechanical Peripheral Stimulation (GONDOLA)|
214248400|NCT04884776|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
214248401|NCT04884776|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
214248402|NCT02913040|OTHER|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
214248403|NCT02913040|OTHER|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
214248404|NCT05049369|DEVICE|Polysomnography|Polysomnography is performed one time overnight
214248405|NCT01025154|DRUG|Clofarabine|Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
214248406|NCT01025154|DRUG|Idarubicin|Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
214248407|NCT01025154|DRUG|Cytarabine|Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
214248408|NCT00415454|GENETIC|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
214248409|NCT01406925|DRUG|Placebo control|Placebo cream
214248410|NCT01406925|DRUG|NRL001 cream|Cream for single-dose intra-anal application
214248411|NCT00071266|DRUG|Niacin Extended Release and Lovastatin Tablets|
214248412|NCT05868889|DRUG|Trabectedin and PLD|The main treatment observed in this study is trabectedin in combination with PLD in elderly patients with platinum-sensitive relapsed ovarian cancer, according to the SmPC.
214248413|NCT04950114|DRUG|GFB-887|GFB-887 is a potent, small molecule inhibitor of TRPC5.
214248414|NCT04043780|DEVICE|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
214248415|NCT04043780|DEVICE|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
214248416|NCT01358773|OTHER|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
214248417|NCT01657929|BIOLOGICAL|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
214248418|NCT01657929|BIOLOGICAL|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
214248419|NCT01657929|BIOLOGICAL|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
214248420|NCT01657929|BIOLOGICAL|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
214248421|NCT05638477|BEHAVIORAL|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
214248422|NCT03857152|DIAGNOSTIC_TEST|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
214248423|NCT03696927|DEVICE|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
214248424|NCT01580371|DRUG|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
214248425|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
214248426|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
214248427|NCT02942576|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
214248428|NCT02942576|DRUG|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
214248429|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
214248430|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
214248431|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
214248432|NCT01631955|DRUG|Ciprobay|Ciprobay (250mg, bid, oral)
214248433|NCT01403233|DIETARY_SUPPLEMENT|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
214248434|NCT01403233|DIETARY_SUPPLEMENT|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
214248435|NCT01403233|DIETARY_SUPPLEMENT|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
214248436|NCT03373799|OTHER|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
214248437|NCT03373799|OTHER|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
214248438|NCT06301243|OTHER|Inactivity|Low physical activity level prior to the exercise intervention.
214248439|NCT00192686|PROCEDURE|culture a.m. Kamme-Lindberg|
214248440|NCT04188171|PROCEDURE|Polidocanol foam sclerotherapy|"* Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
214248441|NCT04503291|PROCEDURE|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
214248442|NCT00938964|DRUG|Lidocaine|Lidocaine versus placebo infusion for 48 hours
214248443|NCT00938964|DRUG|Placebo|Lidocaine versus placebo infusion for 48 hours
214248444|NCT01858636|DEVICE|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
214248445|NCT02139800|PROCEDURE|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
214248446|NCT02139800|PROCEDURE|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
214248447|NCT01765803|DRUG|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
214248448|NCT00746447|DRUG|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
214248449|NCT00746447|DRUG|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
214248450|NCT00746447|DRUG|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
214248451|NCT05656989|OTHER|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
214248452|NCT05480774|DRUG|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
214248453|NCT05480774|DRUG|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
214248454|NCT02646202|PROCEDURE|Sclerotherapy|Injection of varices
214248455|NCT02646202|PROCEDURE|Band ligation|endoscopic banding of varices
214248456|NCT02646202|PROCEDURE|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
214248457|NCT05751616|OTHER|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
214248458|NCT05751616|OTHER|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
214248459|NCT00842452|DRUG|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214248460|NCT00842452|OTHER|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
214248461|NCT02986880|DRUG|Botulinum toxin A|
214248462|NCT02986880|PROCEDURE|Placebo|Injection of sodium chloride (NaCl) 9/1000
214248463|NCT05977478|DEVICE|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
214248464|NCT03523000|OTHER|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
214248465|NCT03523000|DRUG|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
214248466|NCT03523000|DRUG|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
214248467|NCT03523000|DRUG|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
214248468|NCT03523000|DEVICE|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
214248469|NCT04230720|DRUG|Systane Complete|1 drop 4 times a day for 14 days
214248470|NCT05578001|DRUG|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
214248471|NCT03000270|DEVICE|Impella unloading prior to PPCI|Impella unloading prior to PPCI
214248472|NCT02958384|BIOLOGICAL|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214248473|NCT04246736|BEHAVIORAL|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
214248474|NCT03420027|OTHER|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
214248475|NCT03709329|DEVICE|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
214464796|NCT01476839|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
214464797|NCT01476839|BIOLOGICAL|yttrium Y 90-labeled basiliximab|Given IV
214464798|NCT03623464|OTHER|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
214464799|NCT03623464|OTHER|Standard of care|Post-operative standard of care information
214464800|NCT05010421|DRUG|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
214464801|NCT05010421|DEVICE|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
214464802|NCT03550950|DRUG|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
214464803|NCT03550950|DRUG|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
214464804|NCT03550950|DRUG|Placebo|Matching placebo will be administered as IV infusion or SC injection.
214464805|NCT05895175|OTHER|Questionnaires|Questionnaires
214464806|NCT05228158|DRUG|Tazemetostat|Tazemetostat oral tablets.
214248476|NCT03709329|DEVICE|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
214248477|NCT02586402|DRUG|pegol-Sihematide|
214248478|NCT02586402|DRUG|Epoetin Alfa|
214248479|NCT01085500|BEHAVIORAL|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
214248480|NCT01085500|PROCEDURE|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
214248481|NCT03784287|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
214248482|NCT00480974|OTHER|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
214248483|NCT01513369|DRUG|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
214248484|NCT01513369|DRUG|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
214248485|NCT06516601|OTHER|no intervention|observational study, the patients received corticosteroids according to the physician on duty
214248486|NCT01227564|BIOLOGICAL|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
214248487|NCT01227564|BIOLOGICAL|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
214248488|NCT01227564|OTHER|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
214248489|NCT04616742|DRUG|[14C]SHR6390|Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
214248490|NCT04697381|BIOLOGICAL|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
214248491|NCT04697381|BIOLOGICAL|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
214248492|NCT04697381|BIOLOGICAL|somatropin - adult cohort|somatropin 0.084 mg/kg/week
214248493|NCT02687659|DEVICE|TEMIS system|Wearing TEMIS system over the day during one week
214248494|NCT04812080|DEVICE|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
214248495|NCT06309407|DEVICE|Hand Dosimeters|Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
214248496|NCT06309407|DEVICE|Standard Practice|Participants only wore standard chest dosimeters
214248497|NCT01057901|DRUG|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
214248498|NCT01057901|DRUG|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
214248499|NCT00230477|DRUG|Hepsera|
214248500|NCT00230477|DRUG|Hepsera and lamivudine|
214248501|NCT00890188|DRUG|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
214248502|NCT02799979|DEVICE|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
214248503|NCT03825471|PROCEDURE|electrotherapy|Cranial electrotherapy stimulation
214248504|NCT03825471|DRUG|Opioid Anesthetics|consumption of opioids during general anesthesia
214248505|NCT03825471|PROCEDURE|colon cancer surgery|laparoscopic colon cancer surgery
214248506|NCT02096575|OTHER|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
214248507|NCT05463627|DRUG|Metformin|All participants among the three groups were treated with metformin
214248508|NCT02862600|DRUG|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
214248509|NCT02862600|DEVICE|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
214248510|NCT05193357|DEVICE|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
214248511|NCT05990621|BIOLOGICAL|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
214248512|NCT05501262|DEVICE|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
214248513|NCT05501262|PROCEDURE|Nerve block|Ultrasound and fluoroscopic guided nerve block.
214248514|NCT04859114|BEHAVIORAL|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
214464807|NCT03481530|DEVICE|Continuing Glucose Monitor System|glucose monitoring
214464808|NCT06416800|DRUG|Digoxin|Oral; Tablet
214464809|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
214464810|NCT06416800|DRUG|Metformin|Oral; Tablet
214464811|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
214464812|NCT06416800|DRUG|Probenecid|Oral; Tablet
214248515|NCT04859114|BEHAVIORAL|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
214248516|NCT02503345|DRUG|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
214248517|NCT02503345|DRUG|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
214248518|NCT02503345|DRUG|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
214248519|NCT02503345|DRUG|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
214248520|NCT02906462|OTHER|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
214248521|NCT02906462|OTHER|Usual practices|the centres applies their usual practices
214248522|NCT03809923|DRUG|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
214248523|NCT03809923|DRUG|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
214248524|NCT03809923|DRUG|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
214248525|NCT03809923|DRUG|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
214248526|NCT04223648|DRUG|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
214248527|NCT03826576|BEHAVIORAL|Multicomponent intervention|"The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants"
214248528|NCT03245229|DRUG|Aprocitentan|Capsule for oral administration
214248529|NCT03245229|DRUG|Rosuvastatin|Tablet for oral administration
214248530|NCT02378025|BEHAVIORAL|Yoga Group|A 10-week yoga course designed to treat pain.
214248531|NCT02378025|BEHAVIORAL|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
214248532|NCT04291378|RADIATION|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
214248533|NCT03750422|DEVICE|Picoway|1064/532nm picosecond laser
214248534|NCT03750422|OTHER|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
214652757|NCT06286462|OTHER|Cancer Tracking System (CATSystem)|The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
214248535|NCT03750422|OTHER|Aquasonic|clear ultrasound gel
214248536|NCT05151627|PROCEDURE|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
214248537|NCT05151627|DEVICE|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
214248538|NCT02495103|DRUG|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
214248539|NCT02495103|DRUG|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
214248540|NCT02495103|DRUG|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
214248541|NCT01807832|OTHER|capsaicin challenge|
214248542|NCT02187770|DEVICE|IMED-4|Non invasive recording electrode used to assess lung fluid
214248543|NCT01654796|DEVICE|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
214248544|NCT01654796|DEVICE|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
214248545|NCT04971330|DIAGNOSTIC_TEST|Access HCV|"All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
214248546|NCT01497145|DRUG|KRN321|
214248547|NCT00649415|DRUG|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
214248548|NCT00649415|DRUG|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
214248549|NCT03486704|BEHAVIORAL|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
214248550|NCT03486704|BEHAVIORAL|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
214248551|NCT03486704|BEHAVIORAL|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
214248552|NCT03486704|BEHAVIORAL|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
214248553|NCT03486704|BEHAVIORAL|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
214248554|NCT00745576|DRUG|SAM-531|
214248555|NCT04276454|DEVICE|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
214248556|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
214248557|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
214248558|NCT05590221|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
214248559|NCT05590221|DRUG|Fludarabine|Administered according to package insert
214248560|NCT05590221|DRUG|Cyclophosphamide|Administered according to package insert
214248561|NCT02663583|BEHAVIORAL|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
214248562|NCT02663583|BEHAVIORAL|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
214248563|NCT02663583|BEHAVIORAL|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
214248564|NCT04735718|DEVICE|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
214248565|NCT03785743|PROCEDURE|TLPD Surgery|TLPD
214248566|NCT03785743|PROCEDURE|OPD Surgery|OPD
214248567|NCT04327479|DIAGNOSTIC_TEST|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
214248568|NCT01692873|PROCEDURE|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
214248569|NCT03714737|BIOLOGICAL|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
214248570|NCT03714737|BIOLOGICAL|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
214248571|NCT03714737|BIOLOGICAL|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
214248572|NCT01309308|PROCEDURE|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
214248573|NCT01309308|OTHER|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
214248574|NCT02172053|OTHER|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
214248575|NCT02172053|OTHER|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
214248576|NCT01949285|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
214248577|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
214248578|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
214248579|NCT01017575|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
214248580|NCT01017575|DRUG|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
214248581|NCT01017575|DRUG|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
214248582|NCT06438146|DRUG|Liraglutide|"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"
214248583|NCT04401644|DIAGNOSTIC_TEST|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
214248584|NCT05445934|DRUG|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
214248585|NCT05445934|DRUG|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
214248586|NCT02854410|DIETARY_SUPPLEMENT|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
214248587|NCT02854410|DIETARY_SUPPLEMENT|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
214248588|NCT05344638|DRUG|AGS (Experimental)|tid
214248589|NCT05344638|DRUG|AGU (Active Comparator)|tid
214248590|NCT06265779|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214248591|NCT06265779|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214248592|NCT06265779|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
214248593|NCT05320302|DRUG|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
214464813|NCT05907564|DEVICE|Thrombectomy|Use of Aventus Thrombectomy System to treat pulmonary embolism
214464814|NCT00223171|DRUG|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
214464815|NCT06288503|OTHER|Hydrolysed Rice Protein Formula|Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
214464816|NCT06288503|OTHER|Cow's Milk Based Extensively Hydrolysed Formula|Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
214248594|NCT03810404|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
214248595|NCT03810404|DIETARY_SUPPLEMENT|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
214248596|NCT04485429|DRUG|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
214248597|NCT04485429|DRUG|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
214248598|NCT06278220|DEVICE|placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam )|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo pentacam and topolyzer examination to asses corneal high order aberrations before LASIK procedure.~Patients will be assigned to undergo LASIK. Follow up pentacam and topolyzer examination will be done 3 months after LASIK."
214248599|NCT02399618|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
214248600|NCT01476644|OTHER|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
214248601|NCT01476644|OTHER|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
214248602|NCT01476644|OTHER|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
214248603|NCT02922491|DIETARY_SUPPLEMENT|vitamin E|daily intake of vitamin E
214248604|NCT02922491|DIETARY_SUPPLEMENT|starch|daily intake of starch (control)
214248605|NCT04410770|BEHAVIORAL|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
214248606|NCT04661969|PROCEDURE|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
214248607|NCT00468039|DRUG|vildagliptin + metformin|
214248608|NCT00238511|DRUG|SPM 927|
214248609|NCT01486485|DRUG|heparinized saline priming group|
214248610|NCT01486485|DRUG|nafamostat infusion after heparinized saline priming|
214248611|NCT05550610|BEHAVIORAL|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
214248612|NCT00095628|DRUG|ispinesib|Given IV
214248613|NCT00095628|OTHER|laboratory biomarker analysis|Correlative studies
214248614|NCT00095628|OTHER|pharmacological study|Correlative studies
214248615|NCT03777735|PROCEDURE|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
214248616|NCT02851186|DEVICE|Acupuncture|
214248617|NCT02851186|DEVICE|Sham acupuncture|
214248618|NCT04373668|BEHAVIORAL|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
214248619|NCT04373668|BEHAVIORAL|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
214248620|NCT04373668|BEHAVIORAL|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
214248621|NCT02201511|DRUG|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
214248622|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
214248623|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
214248624|NCT02201511|DRUG|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
214248625|NCT03555773|PROCEDURE|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
214248626|NCT04271280|OTHER|Non-interventional|This is a non-interventional study.
214248627|NCT00423696|BIOLOGICAL|bevacizumab|
214248628|NCT00423696|DRUG|capecitabine|
214248629|NCT00423696|DRUG|fluorouracil|
214248630|NCT00423696|DRUG|irinotecan hydrochloride|
214248631|NCT00423696|DRUG|leucovorin calcium|
214248632|NCT03231982|DRUG|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
214248633|NCT03231982|DRUG|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
214248634|NCT01480128|PROCEDURE|Single-port|Single-port laparoscopic colon resection
214248635|NCT01480128|PROCEDURE|Multi-port|Multi-port laparoscopic colon resection
214248636|NCT05242523|OTHER|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
214248637|NCT05242523|OTHER|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
214248638|NCT06275581|DEVICE|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
214248639|NCT06275581|DEVICE|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
214248640|NCT00939757|DRUG|mirabegron|oral tablet
214248641|NCT04235803|OTHER|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
214248642|NCT02962154|RADIATION|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
214248643|NCT02962154|OTHER|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
214248644|NCT02962154|OTHER|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
214248645|NCT02962154|OTHER|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
214652758|NCT04418856|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
214652759|NCT04418856|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
214248646|NCT02962154|OTHER|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
214248647|NCT02962154|OTHER|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
214248648|NCT02962154|OTHER|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
214652760|NCT05764967|OTHER|Low Dye Taping|The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.
214652761|NCT05764967|OTHER|Temporary Felt Insoles|A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
214652762|NCT03198689|DRUG|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
214248649|NCT00190515|DRUG|5FU+l-leucovorin|5FU+l-leucovorin
214248650|NCT00190515|DRUG|UFT+Leucovorin|UFT+Leucovorin
214248651|NCT05927324|BEHAVIORAL|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
214248652|NCT03276819|PROCEDURE|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
214248653|NCT03276819|BEHAVIORAL|Psychological and Sociological evaluation|Cohort B ....
214248654|NCT03276819|BEHAVIORAL|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
214248655|NCT03276819|BEHAVIORAL|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
214248656|NCT02765776|OTHER|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
214248657|NCT06404424|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
214248658|NCT06404424|DEVICE|Efferon CT|"Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
214248659|NCT05000333|OTHER|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
214248660|NCT01846520|OTHER|educational intervention|Receive FCPCI home education sessions
214248661|NCT01846520|BEHAVIORAL|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
214248662|NCT01846520|PROCEDURE|quality-of-life assessment|Ancillary studies
214248663|NCT01846520|OTHER|questionnaire administration|Ancillary studies
214248664|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
214248665|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
214248666|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 10 mg IV every 8 weeks
214248667|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 5mg IV every 8 weeks
214652763|NCT05761964|BEHAVIORAL|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
214652764|NCT05761964|BEHAVIORAL|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
214248668|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
214248669|NCT00744471|BIOLOGICAL|Placebo|Placebo to match tanezumab IV every 8 weeks
214248670|NCT01775462|DRUG|EDI200|3 or 10 mg/kg of EDI200
214248671|NCT02786524|BEHAVIORAL|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
214652765|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
214652766|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
214652767|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
214248672|NCT03978715|OTHER|No intervention-retrospective study|This is a retrospective study. No intervention
214248673|NCT02034422|DIETARY_SUPPLEMENT|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
214248674|NCT02034422|OTHER|Exercise rehabilitation|8 weeks of exercise rehabilitation
214248675|NCT05596396|BEHAVIORAL|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
214248676|NCT05596396|BEHAVIORAL|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
214248677|NCT01511185|DRUG|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
214248678|NCT01511185|DRUG|placebo|A single dose administered subcutaneously in random order
214248679|NCT03461510|PROCEDURE|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
214248680|NCT03461510|PROCEDURE|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
214248681|NCT04552730|DRUG|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
214248682|NCT02577783|DRUG|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
214248683|NCT02577783|DRUG|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
214248684|NCT01525173|DRUG|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
214248685|NCT01525173|DRUG|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
214248686|NCT01525173|DRUG|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
214248687|NCT01525173|DRUG|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
214248688|NCT04706416|DIETARY_SUPPLEMENT|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
214248689|NCT04706416|OTHER|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
214652768|NCT03710447|OTHER|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
214652769|NCT03710447|OTHER|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
214248690|NCT03706222|DRUG|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
214248691|NCT01733849|OTHER|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
214248692|NCT01733849|OTHER|Data collection|Log books
214248693|NCT05294536|DRUG|Liraglutide injection,RD12014|single dose, s.c. injection
214248694|NCT05294536|DRUG|Liraglutide injection,Victoza|single dose, s.c. injection
214248695|NCT04478331|BEHAVIORAL|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
214248696|NCT05091502|DIAGNOSTIC_TEST|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
214248697|NCT03455049|OTHER|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
214248698|NCT00425633|DRUG|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
214248699|NCT04385407|DRUG|Sofosbuvir + Simeprevir + Ribavirin|
214248700|NCT00249158|DRUG|Risperidone|
214248701|NCT01432509|OTHER|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~* Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and \< 1,26 g/l) or fasting blood glucose ≥ 1 g/l and \< 1,10 g/l with HbA1c ≥ 6,5%.~* First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~* Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~* End of study phone call"
214248702|NCT03014492|DEVICE|Q Collar|Collar designed to mitigate slosh in the brain
214248703|NCT06207565|PROCEDURE|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
214248704|NCT06207565|PROCEDURE|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
214248705|NCT05261451|OTHER|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
214248706|NCT01736332|DRUG|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
214248707|NCT01736332|OTHER|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
214248708|NCT06403631|OTHER|observational|Data will be gathered longitudinally from participants newly diagnosed with multiple sclerosis. Participants will fill in online questionnaires measuring flow, mindfulness, positive mental health, anxiety and depression. The questionnaires, including both scaled and open-ended questions, will be proposed at the project start (T1) and 6 months later (T2).
214248709|NCT04891731|DRUG|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
214248710|NCT01539317|DRUG|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
214248711|NCT01539317|DRUG|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
214248712|NCT02903212|BIOLOGICAL|Autologous apoptotic cells injection|cells injection
214248713|NCT04705363|BEHAVIORAL|High Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used high dialectal variation that will guide participants through the interaction.
214248714|NCT04705363|BEHAVIORAL|Low Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used low dialectal variation that will guide participants through the interaction.
214248715|NCT04705363|BEHAVIORAL|Non-Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used no dialectal variation that will guide participants through the interaction.
214248716|NCT04705363|BEHAVIORAL|Text-only|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide participants through the interaction. No voice will accompany the photos or text.
214248717|NCT01423149|DRUG|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
214248718|NCT00938223|BIOLOGICAL|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
214248719|NCT04350398|OTHER|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
214464817|NCT06132581|DEVICE|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
214464818|NCT06132581|DEVICE|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
214464819|NCT06132581|DEVICE|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
214464820|NCT05252520|DRUG|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
214464821|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
214464822|NCT05219396|DEVICE|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
214464823|NCT04835103|BEHAVIORAL|CM|Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation
214464824|NCT04835103|BEHAVIORAL|P/T|Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
214248720|NCT04350398|OTHER|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
214248721|NCT01776385|OTHER|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
214248722|NCT01776385|OTHER|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
214248723|NCT01616082|BEHAVIORAL|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
214248724|NCT01616082|DRUG|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
214248725|NCT06138288|BEHAVIORAL|acupressure|The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
214248726|NCT02847468|OTHER|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
214248727|NCT02847468|OTHER|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
214248728|NCT03551483|DEVICE|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
214248729|NCT03551483|DEVICE|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
214248730|NCT00976573|BIOLOGICAL|bevacizumab|Given IV
214248731|NCT00976573|DRUG|carboplatin|Given IV
214248732|NCT00976573|DRUG|everolimus|Given orally
214248733|NCT00976573|DRUG|paclitaxel|Given IV
214248734|NCT02370771|PROCEDURE|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
214248735|NCT02370771|DEVICE|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
214248736|NCT00411931|DRUG|Multihance|0.5M administered as a single injection
214248737|NCT04322214|DRUG|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
214248738|NCT04322214|DRUG|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
214248739|NCT04322214|DRUG|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
214248740|NCT00002398|DRUG|Levocarnitine|
214248741|NCT00002398|DRUG|Adefovir dipivoxil|
214248742|NCT02531334|DIETARY_SUPPLEMENT|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
214248743|NCT02285660|PROCEDURE|4D PET-CT Scan|
214248744|NCT02285660|OTHER|No intervention|
214248745|NCT02117427|BIOLOGICAL|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
214248746|NCT05357547|DRUG|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
214248747|NCT05357547|DRUG|Placebo comparator|Lactose-sucrose tablets in opaque capsule
214248748|NCT00296803|DRUG|clopidogrel|
214248749|NCT02818491|DRUG|Placebo|Normal saline 0.9% in 2 mls
214248750|NCT02818491|DRUG|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
214248751|NCT02818491|DRUG|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
214248752|NCT02818491|DRUG|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
214248753|NCT02818491|DRUG|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
214248754|NCT02818491|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
214248755|NCT02761291|DRUG|Gemcitabine|Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
214248756|NCT02761291|DRUG|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
214248757|NCT02761291|DRUG|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
214248758|NCT06025929|OTHER|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
214248759|NCT06025929|OTHER|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
214248760|NCT06025929|OTHER|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
214248761|NCT01604759|DEVICE|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
214248762|NCT02732080|DEVICE|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
214248763|NCT02732080|DEVICE|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
214248764|NCT06110520|DEVICE|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
214248765|NCT06110520|DEVICE|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
214248766|NCT04639115|DRUG|Ozanimod|Ozanimod
214248767|NCT04720261|DRUG|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
214248768|NCT02942589|OTHER|Meal portion size|
214248769|NCT04616027|DRUG|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
214248770|NCT03020290|DEVICE|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
214248771|NCT06134609|BEHAVIORAL|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
214248772|NCT00468767|DRUG|Vernakalant Injection 20 mg/mL|
214248773|NCT01195077|OTHER|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
214248774|NCT04290390|DRUG|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
214248775|NCT04290390|DRUG|Rifampin|CYP3A inducer
214248776|NCT04290390|DRUG|Itraconazole|CYP3A inhibitor
214248777|NCT00318227|PROCEDURE|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
214248778|NCT04490031|DRUG|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
214248779|NCT01400685|DRUG|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
214248780|NCT01400685|DRUG|Bendamustine|90 mg/m\^2 IV days 1-2 of each cycle for 6 cycles
214248781|NCT01400685|DRUG|Rituximab|375 mg/m\^2 IV day 1 (cycle 1), 500 mg/m\^2 day 1 (cycles 2-6)
214248782|NCT01987531|OTHER|left ventricular epicardial pacing lead|
214248783|NCT05658666|BEHAVIORAL|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
214248784|NCT03737851|DRUG|elezanumab|solution for infusion
214248785|NCT03737851|DRUG|placebo|solution for infusion
214248786|NCT04173793|DRUG|AK102|Administered by subcutaneous injection
214248787|NCT04173793|DRUG|Placebo|Administered by subcutaneous injection
214248788|NCT04173793|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
214248789|NCT05675982|OTHER|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
214248790|NCT04113031|BEHAVIORAL|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
214248791|NCT02125773|BEHAVIORAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
214248792|NCT03930160|OTHER|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
214248793|NCT04534803|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
214248794|NCT04534803|OTHER|Placebo|.1 nL of diluent (saline) given intradermally at baseline
214248795|NCT06256198|OTHER|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
214248796|NCT04426578|DRUG|Perhexiline|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
214248797|NCT04426578|OTHER|Placebo|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
214248798|NCT00184873|BEHAVIORAL|Health Counseling|
214248799|NCT00937391|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
214248800|NCT02884843|DEVICE|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
214248801|NCT02884843|DEVICE|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
214248802|NCT03613610|RADIATION|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
214248803|NCT02547285|OTHER|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
214248804|NCT06002243|DIAGNOSTIC_TEST|SPLASH echocardiography screening|Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
214248805|NCT04623385|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
214248806|NCT04623385|DRUG|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
214248807|NCT02958189|BEHAVIORAL|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
214248808|NCT02958189|BEHAVIORAL|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
214248809|NCT01253707|DRUG|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
214248810|NCT01854931|BEHAVIORAL|Tai Ji Quan|single aim intervention
214248811|NCT01753739|DRUG|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
214248812|NCT01753739|DRUG|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
214248813|NCT03759288|DRUG|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
214248814|NCT03759288|DRUG|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
214248815|NCT03759288|DRUG|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
214248816|NCT03759288|DRUG|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
214248817|NCT00371501|DRUG|Rosuvastatin|10mg/day
214248818|NCT00371501|DRUG|placebo|one tablet/day
214248819|NCT00371501|DRUG|aspirin|80mg/day
214248820|NCT00371501|DRUG|placebo|placebo
214248821|NCT04572555|OTHER|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
214248822|NCT01232205|DIETARY_SUPPLEMENT|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
214248823|NCT01232205|DIETARY_SUPPLEMENT|Control|supplementation with milk
214248824|NCT02945787|BEHAVIORAL|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
214248825|NCT02945787|BEHAVIORAL|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
214248826|NCT03062410|OTHER|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
214248827|NCT04245371|DRUG|Lidocaine 1.8%|Topical Patch
214248828|NCT04245371|DRUG|Placebo|Matching Placebo Patch
214248829|NCT01397812|DEVICE|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
214248830|NCT01397812|DEVICE|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
214248831|NCT04071587|DEVICE|Brain Computer Interface training|Training with RecoveriX system.
214248832|NCT04071587|BEHAVIORAL|Control|Standard physiotherapy and occupational therapy according to clinical routines.
214248833|NCT06187675|BEHAVIORAL|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
214248834|NCT03391531|PROCEDURE|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
214248835|NCT04192370|DRUG|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
214248836|NCT01436162|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
214248837|NCT01436162|DRUG|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
214248838|NCT00946400|OTHER|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
214248839|NCT00946400|OTHER|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
214248840|NCT04184258|BIOLOGICAL|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
214248841|NCT04184258|OTHER|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
214248842|NCT05032859|DRUG|tapinarof cream, 1%|applied topically once daily
214248843|NCT05032859|DRUG|vehicle cream|applied topically once daily
214248844|NCT05694052|BEHAVIORAL|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
214248845|NCT05364021|DRUG|LP352|LP352 administered three times daily, orally or through G-tube
214248846|NCT05364021|DRUG|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
214248847|NCT01931085|DRUG|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
214248848|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in enhanced standard care
214248849|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in psychological intervention
214248850|NCT02787070|DRUG|PQ supervised|
214248851|NCT02787070|DRUG|PQ unsupervised|
214248852|NCT01535664|OTHER|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"
214248853|NCT06080139|BEHAVIORAL|Refugee parenting education in a participatory community|"Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas."
214248854|NCT02283151|DIETARY_SUPPLEMENT|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
214248855|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
214248856|NCT01586273|DEVICE|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
214248857|NCT00657826|DEVICE|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
214248858|NCT03456609|DRUG|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
214248859|NCT03456609|DRUG|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
214248860|NCT01742247|OTHER|Physiogel|Application of moisturizer on laser-treated area
214248861|NCT01742247|OTHER|Moisturizer|Application of moisturizer on laser-treated area
214248862|NCT00700076|DRUG|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
214248863|NCT00700076|DRUG|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
214248864|NCT00247533|PROCEDURE|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
214248865|NCT01931202|DRUG|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
214248866|NCT01931202|DRUG|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
214248867|NCT03272984|PROCEDURE|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
214248868|NCT03272984|PROCEDURE|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
214248869|NCT02153710|BEHAVIORAL|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
214248870|NCT02153710|BEHAVIORAL|Phonomotor Therapy|Experimental therapy.
214248871|NCT00983398|DRUG|Carboplatin|Given IA
214248872|NCT00983398|DRUG|Mannitol|Given IA
214248873|NCT00983398|DRUG|Melphalan|Given IA
214248874|NCT00983398|OTHER|Quality-of-Life Assessment|Ancillary studies
214248875|NCT00983398|OTHER|Questionnaire Administration|Ancillary studies
214248876|NCT00983398|DRUG|Sodium Thiosulfate|Given IV
214248877|NCT05748665|DRUG|Remimazolam besylate|Using remimazolam for induction of general anesthesia
214248878|NCT05748665|DRUG|etomidate|Using etomidate for induction of general anesthesia
214248879|NCT05022875|DEVICE|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
214248880|NCT05022875|DEVICE|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
214248881|NCT05333081|OTHER|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
214248882|NCT00193193|DRUG|Paclitaxel|
214248883|NCT00193193|DRUG|Estramustine|
214248884|NCT00193193|DRUG|Carboplatin|
214248885|NCT05538819|DRUG|Glimepiride|Glimepiride 1-4 mg/day
214248886|NCT03954652|GENETIC|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
214248887|NCT04597918|DRUG|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
214248888|NCT00395538|DRUG|PTH 1-34|Given twice daily by subcutaneous
214248889|NCT02240173|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
214248890|NCT02240173|DRUG|Haloperidol|Conventional drug normally used for psychotic problems
214248891|NCT02752555|OTHER|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
214248892|NCT05572554|OTHER|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
214248893|NCT04299893|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
214248894|NCT04299893|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
214248895|NCT06322329|OTHER|Dynamic MRI|Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
214248896|NCT01074047|DRUG|Azacitidine|75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
214248897|NCT01074047|DRUG|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end"
214248898|NCT04094103|DIETARY_SUPPLEMENT|Active strawberry powder|Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
214248899|NCT04094103|DIETARY_SUPPLEMENT|Placebo strawberry powder|Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
214248900|NCT04094103|DIETARY_SUPPLEMENT|Mixed strawberry powder|Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
214248901|NCT03160196|OTHER|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
214248902|NCT03160196|OTHER|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
214248903|NCT02186132|DRUG|Atropine 0.6 mg|Atropine 0.6 mg intravenous
214248904|NCT02186132|DRUG|Atropine 1.2 mg|Atropine 1.2 mg intravenous
214248905|NCT04468932|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
214248906|NCT03041012|DRUG|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
214248907|NCT03041012|DRUG|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
214248908|NCT03041012|DRUG|Antiretrovirals|Combination antiretroviral therapy
214248909|NCT01770587|BEHAVIORAL|Behavioral Insomnia Treatment|
214248910|NCT06575946|DIAGNOSTIC_TEST|Vestibular Hypofunction Group|Demographic information form, vestibular tests, balance tests will be used in the evaluation. The demographic information form includes demographic information (name, surname, gender, smoking, alcohol use, etc.) and clinical conditions (past illnesses and/or surgeries, medications used, whether there is a history of falls, if any, frequency, whether they are afraid of heights and uncomfortable in the dark, etc.). The patients will be diagnosed with videonystagmography (VNG) after the decision of the ENT physician, and their hypofunction levels will be recorded. Vestibular and balance tests will be applied to the patients in the clinical setting. At the end of the study, it will be examined whether there is a relationship between the degree of vestibular hypofunction and the vestibular tests applied in the clinic.
214248911|NCT04059705|BEHAVIORAL|Dual-Task Training|The ThinkFIT intervention will involve two days per week participation in simultaneous cognitive and motor training activities, facilitated by the SMARTFit Multisensory FItness System.
214248912|NCT05545163|DEVICE|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
214248913|NCT05606874|OTHER|Pre-heating of flowable resin composite used as a pit and fissure sealant.|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
214248914|NCT05606874|OTHER|Conventional resin fissure sealant|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
214248915|NCT00025675|DRUG|gefitinib|
214248916|NCT00655941|BEHAVIORAL|Dietary instruction|Weekly instruction by dieticians
214248917|NCT00655941|OTHER|Exercise|Supervised exercise in groups
214248918|NCT01419262|DRUG|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
214248919|NCT01419262|DRUG|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
214248920|NCT01069185|PROCEDURE|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
214248921|NCT01069185|PROCEDURE|Routine endotracheal suctioning|Endotracheal suctioning every two hours
214248922|NCT00474981|BEHAVIORAL|IMNCI|Implementation of IMNCI in the intervention sites
214248923|NCT06247527|BEHAVIORAL|Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy|This is a brief transdiagnostic psychological intervention based on the trauma-focused cognitive behavioral therapy (TF-CBT) designed for delivery by non-specialist providers to adolescents and youth with psychological distress
214248924|NCT06247527|BEHAVIORAL|Standard of care|Any intervention, including counseling, provided as a routine intervention at the HIV clinic selected as a control clinic
214248925|NCT01564446|OTHER|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
214248926|NCT06207981|DRUG|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)"
214248927|NCT06207981|DRUG|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
214248928|NCT06207981|RADIATION|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
214248929|NCT00859027|DRUG|risedronate|35 mg/week by mouth
214248930|NCT00859027|DRUG|Placebo risedronate oral tablet|One tablet by mouth every week as directed
214464825|NCT03896867|DEVICE|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
214652770|NCT03710447|OTHER|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
214652771|NCT03710447|OTHER|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
214248931|NCT04041700|DEVICE|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
214248932|NCT02775903|DRUG|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
214248933|NCT02775903|BIOLOGICAL|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
214464826|NCT03896867|DEVICE|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
214652772|NCT05187377|DRUG|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
214652773|NCT05187377|DRUG|Saline|Placebo (saline) will be administered subcutaneously once daily.
214248934|NCT05611125|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
214248935|NCT06404346|DIAGNOSTIC_TEST|High Velocity Thrust|Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
214248936|NCT06404346|OTHER|Bowen therapy|participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
214248937|NCT00188799|PROCEDURE|daily Xray volume imaging for planning radiotherapy|
214248938|NCT01284673|OTHER|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
214248939|NCT04881656|OTHER|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
214248940|NCT04588532|DRUG|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
214248941|NCT04588532|DRUG|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
214248942|NCT04588532|DRUG|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
214248943|NCT04588532|DRUG|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
214248944|NCT03868982|DEVICE|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
214248945|NCT02861378|DRUG|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
214248946|NCT02861378|DRUG|Water|Injection of 1ml of physiologic saline water at injection site
214248947|NCT04104542|BEHAVIORAL|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
214248948|NCT04104542|BEHAVIORAL|Healthy Lifestyle|Diet and Exercise
214248949|NCT03255447|DEVICE|Immunoadsorption|Fresenius Globaffin
214652774|NCT03183362|DEVICE|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
214652775|NCT03183362|DEVICE|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
214652776|NCT06542146|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet is consisting of fruits, vegetables , legumes, whole grains, nuts, and olive oil as the main source ofdietary fat
214652777|NCT06542146|DIETARY_SUPPLEMENT|Usual diet|Usual diet including routine diet we already eat
214652778|NCT04735003|DEVICE|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
214652779|NCT03644160|BEHAVIORAL|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
214652780|NCT01438008|DRUG|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
214652781|NCT01438008|DRUG|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
214652782|NCT03804385|PROCEDURE|intercostal tube|surgical operation
214248950|NCT01913587|DEVICE|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
214248951|NCT01913587|PROCEDURE|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
214248952|NCT06575036|DRUG|Sugammadex|The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
214248953|NCT03620656|DIAGNOSTIC_TEST|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
214248954|NCT01815203|DRUG|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
214248955|NCT01815203|DRUG|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
214248956|NCT06994078|DRUG|68Ga-NOTA-Nectin-4 antibody fragment|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed urothelial carcinoma, breast cancer, lung carcinoma and other malignant tumors with high Nectin-4 expression and healthy volunteers, using specific positron imaging agents targeting Nectin-4 (taking \[68Ga\]Ga-NOTA-Nectin-4 antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
214248957|NCT06676631|BIOLOGICAL|NK 010 or NK042|NK010 is an allogeneic non-genetically modified NK cell infusion. NKX010 will be administered at a dose of 2.5 × 109 NK cells, 5.0 × 109 NK cells and 7.5 × 109 NK cells by a dose-escalation design and administered IV. N042 is an allogeneic genetic modification of NK cell. NKX042 will be administered at a dose of 6 × 108 NKR positive NK cells, 1.2 × 109 NKR positive NK cells and 2.4 × 109 NKR positive NK cells by a dose-escalation design and administered IV.
214248958|NCT06676631|DRUG|Rituximab|RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
214248959|NCT07010770|OTHER|Web-Based Training (WBT)|A self-paced online training course that includes video demonstrations, self-guided modules, and clinical materials/resources.
214248960|NCT07010770|OTHER|Work Sample Review (WR)|Four months of weekly hour-long consultation that will include trainer-led reviews of work samples, focusing on the Impact Statement and Stuck Point Log.
214248961|NCT07010770|OTHER|Step down to fidelity self-monitoring|"After four months, and for participants who are classified as meeting early fidelity, for the next two months, therapists in self-monitored fidelity will no longer attend group consultation. Instead, they will assess their own fidelity through self-report surveys."
214248962|NCT07010770|OTHER|Step up to session audio review|"After four months, and for participants who are classified as meeting fidelity in progress, for the next two months, therapists will have their session audio recordings reviewed and rated for fidelity."
214248963|NCT07010770|OTHER|Standard Consultation (SC)|Four months of weekly hour-long group consultation
214248964|NCT07010770|OTHER|Standard Training (ST)|2-day instructor-led CPT workshop.
214248965|NCT07010770|OTHER|Continue in Standard Consultation|After four months, therapists will continue to attend weekly hour-long group consultation for another two months.
214248966|NCT00911742|DRUG|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
214248967|NCT00911742|DRUG|Zytram|1 Zytram 200 mg tablet as a single dose
214248968|NCT06683755|DRUG|Nivolumab|Given by IV
214248969|NCT06683755|DRUG|Relatlimab|Given by IV
214248970|NCT06683755|DRUG|Ipilimumab|Given by IV
214248971|NCT07024797|DRUG|ABBV-932|Oral Capsule
214248972|NCT07024797|DRUG|Placebo for ABBV-932|Oral Capsule
214248973|NCT06577870|PROCEDURE|Hospitalization in intensive care or continuing care unit|Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
214464827|NCT04208984|DEVICE|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
214464828|NCT04208984|OTHER|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
214464829|NCT04524442|DRUG|arginine/lysine|1000 milliliters (mL) administered at a constant rate of 250 mL per hour
214464830|NCT06241872|OTHER|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
214464831|NCT04469569|BEHAVIORAL|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
214248974|NCT04430205|PROCEDURE|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
214248975|NCT05331248|BEHAVIORAL|Leaders in Action: Household Treatment|The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.
214248976|NCT05331248|BEHAVIORAL|Leaders in Action: Group Treatment|The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.
214248977|NCT07052344|OTHER|Preload condition|Participants will consume a fixed compulsory preload meal of Campbell's Tomato soup (\~300 grams) 30 minutes after the baseline assessments. Fifteen minutes after consuming the preload meal, participants will receive the ad libitum test meal, consisting of a pre-weighed serving of Stouffer's Macaroni and Cheese (\~700 g).The pre-load condition will be completed at only one of two visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. Duration for the pre-load condition visit will be up to 6 hours
214248978|NCT07052344|OTHER|Ad-libitum control condition|Participants will only consume the ad libitum test meal, which consists of a pre-weighted serving of Stouffer's Macaroni and Cheese (\~700 g). The ad-libitum meal will be consumed at both visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. The ad-libitum control condition visit will take up to 2 hours.
214248979|NCT07136870|DEVICE|Medical tape|The purpose of this exploratory study is to assess the adhesion to skin properties of test material samples over 24 hours to establish the peel-off measurement method at the new Essity study site. As the performance and safety of the tapes, WAFs and post-OPs in its intended use are not tested in the current study it is not considered a medical device study according to EU medical device regulation (MDR) 2017/745
214248981|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
214248982|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
214248983|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
214248984|NCT06179160|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
214248985|NCT06179160|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
214248986|NCT06034002|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
214248987|NCT06034002|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
214248988|NCT06916286|DEVICE|K-Lock|Surgical drain securement with a novel sutureless K-LOCK device
214248989|NCT06916286|OTHER|Suture|Surgical drain securement with traditional suture-based methods
214248990|NCT06912685|OTHER|Technology Enhanced Implementation Package|The Technology Enhanced Implementation Package for SafeCare delivery consists of protocol adaptations, evidence-informed guidelines, and digital health resources to improve SafeCare outcomes related to reach, quality, and equity.
214248991|NCT06912685|OTHER|SafeCare|SafeCare is an evidence-based home visiting parenting program with three modules focused on child health, home safety, and parent-child relationships. SafeCare sessions typically occur weekly over 18 weeks.
214248992|NCT02502162|DRUG|LDN|
214248993|NCT02502162|DRUG|Placebo|Sugar pill
214248994|NCT07117708|OTHER|Early Surgical Consent|Surgical consent for possible cesarean delivery will be completed upon arrival to labor and delivery before induction of labor begins
214248995|NCT07117708|OTHER|Surgical Consent if Clinically Indicated|Surgical consent for possible cesarean delivery will be completed if it appears clinically indicated during a participant's induction of labor.
214248996|NCT06362226|DRUG|Steroid/Antibiotic (Maxitrol)|Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
214248997|NCT06362226|DRUG|5-FU/Kenalog|Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
214248998|NCT07126912|DEVICE|Alcarisa (hyaluronic acid filler)|A single injection of Alcarisa filler with a maximum dose of 2 to 4 cc , was administered in the zygomaticomalar area, and if deemed appropriate by the physician, also in the anteromedial cheek and submalar areas on each side of the face.
214248999|NCT06934161|PROCEDURE|dynamic computer-guided Corticotomy|corticotomy cuts were made guided by a dynamic navigation system, ensuring accuracy and reducing the risk of injuries
214249000|NCT06934161|PROCEDURE|static computer-guided Corticotomy|corticotomy cuts were made guided by a static system (using reticulated surgical template), ensuring accuracy and reducing the risk of injuries
214249001|NCT06934161|DIAGNOSTIC_TEST|smartphone-based thermography|a Mini2 Infrared Smartphone Camera (Hangzhou HIKMICRO Sensing Technology Co., China) was initially calibrated with the surrounding ambient temperature. The calibration phase was essential as it enabled the device's algorithm to have a reference point based on the surrounding conditions and eliminate any bias caused by varying environmental temperatures. Then, pre-operative temperatures of attached gingiva and alveolar mucosa surfaces were recorded. The measurements were registered by distinguishing, for both arches, the temperature corresponding to soft tissues from incisor region (from central incisor to homolateral canine), premolar region (first and second premolars), and molar region (first and second molars).
214249002|NCT06934577|OTHER|Standard optometric examination|Participants will see the optometrist at the Federally Qualified Health Center. The guidelines define usual care as: an in-person comprehensive eye examination with assessment of patient history, visual acuity, pupil examination, ocular motility and alignment, intraocular pressure, and biomicroscopy with additional tests, as appropriate. A glasses prescription will be given to the participant if needed. Participants will complete surveys at baseline before their eye exam and 6 weeks after the eye exam.
214249003|NCT06934577|OTHER|Technology enhanced eye disease detection protocol|Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (no disease detected) or an in-depth appointment with the optometrist (disease detected). During the first visit, participants receive care navigation support to purchase low-cost glasses from an on-line retailer. When participants return for the optometrist exam, glasses will be fit. Participants will receive care navigation support to attend any recommended specialty follow-up appointments.
214249004|NCT04161456|DRUG|Apremilast|Apremilast twice daily 30 mg
214249005|NCT06941012|OTHER|Blood draw for the laboratory assessment|Participants' clinical histories will be reviewed at T0 (baseline) and T1 (24 months). They will also undergo a clinical assessment at T0 and T1. The assessments will be tailored based on whether the participant belongs to the PD or non-PD group, as outlined below: • MDS-UPDRS + H\&Y: Used to evaluate the neurological domain, applied to the PD group. • BERG: Used to assess balance and performance, applied to both PD and non-PD groups. • CIRS-G: Used to evaluate comorbidities, applied to both PD and non-PD groups. • PD-CRS: Used to assess cognitive function, applied to the PD group. • MMSE (temporal and spatial orientation only): Used to assess cognitive function, applied to both PD and non-PD groups. • PDQ-8: Used to evaluate quality of life, applied to the PD group. • PD-CFRS: Used for functional assessment, applied to the PD group. • GDS: Used to assess depression, applied to both PD and non-PD groups. Blood samples will be collected at T0 and T1, with 20 mL drawn per participant.
214249006|NCT05551052|DIAGNOSTIC_TEST|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
214249007|NCT00511212|DRUG|intravenous immunoglobulin|
214249008|NCT06949098|PROCEDURE|Local Tumor Resection|All enrolled patients will first undergo local tumor resection.
214249009|NCT06949098|RADIATION|Radiotherapy|"Pelvic field irradiation 45Gy in 25 fractions plus Local tumor bed boost 5.4Gy in 3 fractions.~For patients with positive surgical margins after local resection, a radiotherapy boost (pelvic field 45Gy/25 fractions + tumor bed local boost 14.4Gy/8 fractions) can be given."
214249010|NCT06949098|DRUG|Chemotherapy|Concurrent oral capecitabine 825 mg/m² twice daily with radiotherapy
214249011|NCT05498116|DRUG|Montelukast|10mg daily
214249012|NCT05498116|OTHER|Placebo|1 capsule daily
214249013|NCT07150572|PROCEDURE|surgery assisted rapid maxillary expansion|Under general anesthesia, the patients underwent a maxillary expansion procedure, during which the maxillary resistance sites were surgically released
214249014|NCT07149662|DRUG|monoclonal CD-20 antibodies|Treatment with monoclonal CD-20 antibodies 6 months before or during pregnancy
214249015|NCT07149662|DRUG|No Drug|No medication
214249016|NCT07149662|DRUG|Other treatment|Any other immune modulating treatment
214249017|NCT07149337|OTHER|Oral phosphate load|Participants ingest an oral phosphate load containing 558 mg of phosphorus once.
214249018|NCT07150234|DEVICE|Acupuncture|The needles will be inserted in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
214249019|NCT07150234|DEVICE|sham acupuncture|The needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
214249020|NCT07150767|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 5.0×10\^10 viral particle (VP) ,2.0×10\^11 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
214249021|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced)"|"Enhanced Standard of Care (Enhanced) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, and SA Starter Packs."
214249022|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced-Plus)"|"Enhanced Standard of Care (Enhanced-Plus) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, SA Starter Packs, and three additional intensive external facilitation components."
214249023|NCT07150559|PROCEDURE|Arch-Clamping Technique under Mild Hypothermia|This procedure is performed under mild hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allows bilateral antegrade cerebral perfusion (bACP) through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
214464832|NCT06461923|DEVICE|Insole wearing|The insole-wearing group is instructed to wear the insole gait analysis device as frequently and for as long as possible during outdoor activities. Participants receive feedback during 3rd to 4th week via telephone. Following a period of 6 weeks, an evaluation of the usability and satisfaction of the insole gait analysis device will be conducted.
214249024|NCT07150559|PROCEDURE|Arch-Clamping Technique under Moderate Hypothermia|This procedure is performed under moderate hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allow bACP through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
214249025|NCT07150559|PROCEDURE|Total Arch Replacement combined Frozen Elephant Trunk Implantation using Bilateral Antegrade Cerebral Perfusion under Moderate Hypothermic Circulatory Arrest|This procedure is performed using bACP under MHCA, which involves FET deployment in the descending aorta followed by total arch replacement with a four-branched vascular graft. Deployment of the FET and suture of distal anastomosis are completed during bACP. MHCA is terminated and distal reperfusion is initiated once the distal anastomosis is completed, and the left carotid artery is reconstructed first (after which bACP is stopped, rewarming is started and the brain is perfused bilaterally). The root or valve procedures and some concomitant operations, if indicated, are performed during the cooling phase.
214249026|NCT07149792|DIAGNOSTIC_TEST|Prescreen platform|Different biomarkers on PsO, PsA and paradoxical PsA
214249027|NCT07149792|BIOLOGICAL|biologics treatment|All psoriasis patients are receiving biologics treatment
214249028|NCT07150299|DRUG|Mavacamten in clinical routine use|Clinical observation of mavacamten use
214249029|NCT01683019|DEVICE|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
214249030|NCT01683019|DEVICE|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
214249031|NCT01343927|BEHAVIORAL|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
214249032|NCT01343927|BEHAVIORAL|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
214249033|NCT01343927|BEHAVIORAL|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
214249034|NCT04604158|BEHAVIORAL|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
214249035|NCT06275607|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
214249036|NCT06275607|BEHAVIORAL|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
214249037|NCT01570920|BEHAVIORAL|physical training|walking many times a week
214249038|NCT05732220|BEHAVIORAL|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
214249039|NCT05732220|BEHAVIORAL|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
214249040|NCT05732220|BEHAVIORAL|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
214249041|NCT01645904|BEHAVIORAL|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
214249042|NCT01645904|BEHAVIORAL|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
214249043|NCT01645904|BEHAVIORAL|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
214652783|NCT02667145|OTHER|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
214249044|NCT01645904|BEHAVIORAL|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
214249045|NCT01015053|PROCEDURE|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
214249046|NCT01015053|PROCEDURE|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
214249047|NCT02373878|BEHAVIORAL|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
214249048|NCT02373878|BEHAVIORAL|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
214249049|NCT05640804|DRUG|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
214652784|NCT00033865|BEHAVIORAL|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
214652785|NCT02293122|OTHER|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F\&A Specular Microscope.
214249050|NCT05640804|DRUG|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
214249051|NCT03457688|DIETARY_SUPPLEMENT|prebiotic inulin-type fructans|
214249052|NCT03457688|DIETARY_SUPPLEMENT|placebo maltodextrin|
214249053|NCT05533723|PROCEDURE|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
214249054|NCT05533723|PROCEDURE|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
214249055|NCT00950287|DEVICE|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
214249056|NCT04629885|DRUG|Oxytocin 400 IU vaginal gel|
214249057|NCT04629885|DRUG|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
214249058|NCT05415683|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
214249059|NCT00032097|DRUG|motexafin gadolinium|
214249060|NCT00032097|RADIATION|radiation therapy|
214249061|NCT05023798|DEVICE|ATD (device test)|Medical device test (no intervention)
214249062|NCT04832087|DRUG|Teduglutide|Standard of care Teduglutide dosing
214249063|NCT00543855|DRUG|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
214249064|NCT00543855|DRUG|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
214249065|NCT00543855|DRUG|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
214249066|NCT00543855|DRUG|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
214249067|NCT02732522|DRUG|Sublingual misoprostol|
214249068|NCT02732522|DRUG|Vaginal misoprostol|
214249069|NCT01459939|DIETARY_SUPPLEMENT|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
214249070|NCT01459939|DIETARY_SUPPLEMENT|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
214652786|NCT06250140|DEVICE|Tie up device|The recurrence rate of internal hemorrhoids in different treatment methods
214652787|NCT01813890|DRUG|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
214652788|NCT01813890|DRUG|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
214652789|NCT01813890|DRUG|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
214652790|NCT02071433|PROCEDURE|Saphenous nerve blockade|
214249071|NCT00967928|DRUG|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
214249072|NCT00967928|DRUG|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
214249073|NCT00967928|RADIATION|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
214652791|NCT02071433|PROCEDURE|Femoral nerve blockade|
214652792|NCT05294367|DRUG|Magnesium Chloride-based Lotion|Given topically
214652793|NCT05294367|OTHER|Quality-of-Life Assessment|Ancillary studies
214652794|NCT05294367|BEHAVIORAL|Special Diet Therapy|Consume magnesium rich foods
214652795|NCT01556984|OTHER|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
214652796|NCT02229201|DRUG|Propofol|4-6 mg/kg/h during anaesthesia
214652797|NCT02229201|DRUG|Sevoflurane|0.8 MAC
214652798|NCT03939013|DIAGNOSTIC_TEST|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
214652799|NCT02230176|DRUG|Sunitinib|
214249074|NCT04727281|OTHER|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
214249075|NCT00386971|DIETARY_SUPPLEMENT|L-carnitine|3 grams daily in liquid form by mouth
214249076|NCT00386971|OTHER|placebo|1 oz sweet tasting liquid daily by mouth
214249077|NCT04969796|OTHER|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
214249078|NCT02974101|OTHER|registration of AdaptiveStim|
214249079|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
214249080|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
214249081|NCT02723253|RADIATION|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
214249082|NCT02723253|DRUG|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
214249083|NCT04491097|DEVICE|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
214249084|NCT04491097|DEVICE|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
214249085|NCT02102971|PROCEDURE|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
214249086|NCT05054244|OTHER|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
214249087|NCT05054244|PROCEDURE|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
214249088|NCT02284971|BIOLOGICAL|CDX1127|
214249089|NCT02284971|RADIATION|SBRT|
214249090|NCT03565471|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography.
214249091|NCT03565471|DIAGNOSTIC_TEST|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
214249092|NCT03565471|DIAGNOSTIC_TEST|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
214249093|NCT03565471|DIAGNOSTIC_TEST|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
214652800|NCT02230176|DRUG|177Lu-DOTA0-Tyr3-Octreotate|
214652801|NCT05042830|PROCEDURE|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
214652802|NCT05042830|PROCEDURE|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
214652803|NCT05042830|BIOLOGICAL|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
214249094|NCT04509739|BEHAVIORAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
214249095|NCT05537090|DRUG|BV100|Rifabutin for Infusion
214249096|NCT05537090|DRUG|Midazolam|Syrup for oral administration
214249097|NCT01607840|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
214249098|NCT06432634|OTHER|Standard care|The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.
214249099|NCT06432634|OTHER|Comprehensive pulmonary rehabilitation programs|"1. Warm-up and cool-down exercises: stretching various muscle groups for a duration of 15 to 20 minutes and a slow 3-minute walk~2. Aerobic training: using a lower-limb cycle ergometer for a duration of 30 to 40 minutes. Initiated warm-up at 0 wattages for 5 minutes. Incrementally increased wattages within 5-10 minutes until reaching the 40-80% heart rate reserve or 4 to 6 of modified Borg scale for at least 20 minutes. Concludes with a 5-minute cool-down period at 10 wattages.~3. The resistance training involves both upper and lower limbs:~（1） Upper Limb Resistance Training: Shoulder lift, abduction, and horizontal abduction exercises are performed. Each exercise is repeated for three sessions comprising 10 repetitions each. A 0.5-2 kg dumbbell is utilized for resistance.~（2） Lower Limb Resistance Training: Sit-to-stand exercises are performed. Each session consists of three sets of 10 repetitions."
214249100|NCT05887375|DRUG|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
214249101|NCT05887375|DRUG|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
214249102|NCT05887375|DRUG|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
214249103|NCT05887375|DRUG|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
214249104|NCT06358131|DEVICE|Endoscopy|upper and lower endoscopy
214249105|NCT04444895|DRUG|Lanadelumab|Lanadelumab SC injection
214652804|NCT05042830|PROCEDURE|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
214652805|NCT05042830|PROCEDURE|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
214249106|NCT05085288|DEVICE|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
214249107|NCT05085288|OTHER|Turning population every two hours|The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
214249108|NCT01670318|DEVICE|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
214249109|NCT02119169|DEVICE|Pigtail catheter|pigtail catheter for pleural drainage
214249110|NCT00182871|DRUG|testosterone|
214249111|NCT05959200|DEVICE|Serafilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
214249112|NCT05959200|DEVICE|Senofilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
214249113|NCT05959200|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
214249114|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
214249115|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
214249116|NCT04342273|DRUG|Placebo|Placebo will be administered once daily at Day 1 through Day 7
214249117|NCT04342273|DRUG|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
214249118|NCT02906904|OTHER|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
214249119|NCT02906904|OTHER|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
214249120|NCT03954041|DRUG|BIIB093|Administered as specified in the treatment arm.
214249121|NCT03954041|DRUG|Placebo|Administered as specified in the treatment arm.
214249122|NCT06110572|DRUG|Carboplatin|Given by IV
214249123|NCT06110572|BIOLOGICAL|Atezolizumab|Given by IV
214249124|NCT06110572|DRUG|Etoposide|Given by IV
214249125|NCT06110572|RADIATION|Total Body Irradiation|Undergo Total Body Irradiation
214249126|NCT06110572|RADIATION|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
214249127|NCT06110572|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
214249128|NCT04210778|BEHAVIORAL|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
214249129|NCT04210778|BEHAVIORAL|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
214249130|NCT05446636|DEVICE|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
214249131|NCT06343389|DIAGNOSTIC_TEST|serum creatinine|to detect patients with Acute kidney injury
214249132|NCT03054454|PROCEDURE|Podiatry|Podiatry treatments and care from the multidisciplinary team.
214249133|NCT05926414|DRUG|Enavogliflozin|treated with Envlo tab. 0.3mg
214249134|NCT05926414|DRUG|Enavogliflozin|Envlomet SR Tablet 0.3/1,000mg
214249135|NCT02837068|DEVICE|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
214249136|NCT02837068|DEVICE|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
214249137|NCT03622528|RADIATION|Chest CT scan|Standard dose chest CT scan
214249138|NCT05620108|PROCEDURE|Endotracheal Intubation at TOFC=1|Intubation using a video laryngoscopy will be performed after train-of-four (TOFC) stimulation indicates neuromuscular blockade
214249139|NCT05620108|PROCEDURE|Endotracheal Intubation 2 minutes after rocuronium administration|Intubation using a video laryngoscopy will be performed 2 minutes after administration of rocuronium at 0.6 mg/kg (usual current clinical routine)
214249140|NCT04177355|BIOLOGICAL|BG505 SOSIP.664 gp140|Administered by IM injection
214249141|NCT04177355|BIOLOGICAL|Placebo|Administered by IM injection
214249142|NCT04177355|BIOLOGICAL|3M-052-AF|Administered by IM injection
214249143|NCT04177355|BIOLOGICAL|CpG 1018|Administered by IM injection
214249144|NCT04177355|BIOLOGICAL|GLA-LSQ|Administered by IM injection
214249145|NCT04177355|BIOLOGICAL|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
214249146|NCT04177355|BIOLOGICAL|Trimer 4571|Administered by IM injection
214249147|NCT05922046|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
214249148|NCT05152875|OTHER|biological|fungal colonization by weekly cultures
214249149|NCT04986579|DEVICE|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
214249150|NCT04986579|DRUG|Eribulin|Intravenous Infusion
214249151|NCT04986579|DRUG|Sacituzumab govitecan|Intravenous Infusion
214249152|NCT04986579|DRUG|Trastuzumab deruxtecan|Intravenous Infusion
214249153|NCT05834296|BIOLOGICAL|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
214249154|NCT05834296|DRUG|Placebo|Saline
214249155|NCT06259084|DEVICE|Seedchrony|The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
214249156|NCT06395688|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one|AEF0117 soft capsules of 1mg
214249157|NCT06395688|DRUG|Placebo|Placebo soft capsules (identical to active compound)
214249158|NCT00397943|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
214249159|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
214249160|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
214249161|NCT00397943|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
214249162|NCT00205829|DEVICE|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
214249163|NCT03718975|DEVICE|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
214249164|NCT03718975|DEVICE|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
214249165|NCT06574165|BEHAVIORAL|Moderate Intensity Continuous Training|6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
214249166|NCT00216554|DRUG|risperidone|
214249167|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
214249168|NCT06218069|DRUG|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
214249169|NCT06218069|RADIATION|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
214249170|NCT06218069|DRUG|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
214249171|NCT05255653|DRUG|Olaparib|300 mg twice daily for one year
214249172|NCT05255653|RADIATION|Pelvic external beam radiotherapy|45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
214249173|NCT05255653|DRUG|Chemotherapy|Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
214249174|NCT05255653|DRUG|Durvalumab|1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
214652806|NCT05042830|PROCEDURE|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
214652807|NCT05042830|PROCEDURE|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
214249175|NCT05255653|DRUG|Medroxyprogesterone Acetate|Oral medroxyprogesterone acetate for two years
214249176|NCT05255653|DRUG|Megestrol Acetate|Oral medroxyprogesterone acetate for two years
214249177|NCT05255653|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
214249178|NCT05255653|OTHER|Observation|No adjuvant therapy
214249179|NCT06293924|DIAGNOSTIC_TEST|Pericardiocentesis|"Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
214249180|NCT06293924|DIAGNOSTIC_TEST|Pericardiotomy|"During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
214249181|NCT06293924|DIAGNOSTIC_TEST|Cytofluorometry and Gene expression analysis|"A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules."
214652808|NCT05042830|BIOLOGICAL|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
214249182|NCT04874038|DRUG|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
214249183|NCT04874038|DRUG|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
214249184|NCT02232191|BIOLOGICAL|Pneumovax-23|
214249185|NCT05607797|OTHER|Epidemiological study|Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
214249186|NCT04090723|BEHAVIORAL|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
214249187|NCT05432297|BEHAVIORAL|Preventive physical exercise|Daily physical activity depending on daily condition
214249188|NCT05481437|DRUG|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
214249189|NCT05346250|BEHAVIORAL|Non-exercise control|12 month lifestyle education
214249190|NCT05346250|BEHAVIORAL|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
214249191|NCT05346250|BEHAVIORAL|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
214249192|NCT04912011|DRUG|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
214249193|NCT04912011|DRUG|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
214249194|NCT05007717|BEHAVIORAL|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
214249195|NCT03436563|BIOLOGICAL|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
214249196|NCT06583239|OTHER|Engagement Navigator Service (ENS)|ENS will be a centralized service, staffed by dedicated professional to (1) receive and organize referrals, (2) complete ongoing specialized training in engagement science and evidence-based strategies, (3) provide unbiased support when participants' and/or families' relationships with a CSC program are poor, (4) re-engage participants in CSC or actively connect them with other services if preferred, and (5) continue contact with those who refuse treatment in case they reconsider.
214249197|NCT02806973|DRUG|Nasal Glucagon|Administered intranasally.
214249198|NCT02629484|OTHER|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
214249199|NCT04540575|BEHAVIORAL|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
214249200|NCT04540575|BEHAVIORAL|Mother Provides MOM|Mother receives standard Rush NICU lactation care
214249201|NCT02840240|DRUG|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
214249202|NCT02840240|DRUG|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
214249203|NCT04223583|DRUG|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
214249204|NCT03900442|DRUG|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
214249205|NCT06287918|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
214249206|NCT02477423|DRUG|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
214249207|NCT02477423|DRUG|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
214249208|NCT02477423|DRUG|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
214249209|NCT03465423|PROCEDURE|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
214249210|NCT00625482|BIOLOGICAL|OPV|
214249211|NCT00625482|BIOLOGICAL|OPV plus BCG|
214249212|NCT00625482|BIOLOGICAL|OPV|
214249213|NCT00625482|BIOLOGICAL|OPV plus BCG|
214249214|NCT06197425|DRUG|"FOLFIRI cures"|(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
214249215|NCT06197425|DRUG|Trifluridine cures|Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
214249216|NCT06197425|BIOLOGICAL|BIOLOGICAL ASSESSMENT|blood sample ACE markers
214249217|NCT06197425|OTHER|Questionnaires|Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
214249218|NCT06197425|OTHER|Thoracic-abdomino-pelvic scan or MRI|Thoracic-abdomino-pelvic scan or MRI
214249219|NCT03155360|OTHER|Non interventional study|Non interventional study
214249220|NCT02962947|DRUG|Propranolol|80 mgR propranolol once daily
214249221|NCT02962947|DRUG|Placebo|placebo once daily
214249222|NCT01466140|OTHER|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
214249223|NCT00797368|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
214249224|NCT00797368|OTHER|Home exercises|Home exercises
214249225|NCT05173480|OTHER|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
214249226|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
214249227|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
214249228|NCT05648656|DRUG|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
214249229|NCT05648656|OTHER|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
214249230|NCT00842764|PROCEDURE|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
214249231|NCT00660283|DRUG|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7\. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
214249232|NCT03282565|OTHER|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
214249233|NCT03282565|OTHER|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
214249234|NCT03282565|OTHER|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
214249245|NCT02917473|BEHAVIORAL|In-person counseling|"In-person counseling~Sun protection"
214249246|NCT02917473|BEHAVIORAL|Written advice|Written advice
214249247|NCT02917473|BEHAVIORAL|Medical skin screening|Medical skin screening
214249248|NCT05547152|OTHER|massages|The experimental rehabilitation protocol includes massages
214249249|NCT05547152|OTHER|motor stimulation and stretching|motor stimulation and stretching
214249250|NCT05547152|OTHER|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
214249251|NCT02131532|BEHAVIORAL|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
214249252|NCT06229782|DIAGNOSTIC_TEST|Orbital Doppler ultrasonography|During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
214249253|NCT06229782|DIAGNOSTIC_TEST|Transcranial Doppler ultrasonography|"During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used."
214249254|NCT06229782|DIAGNOSTIC_TEST|Computed Tomography Angiography|Cranial Computed Tomography Angiography
214249255|NCT02583243|BEHAVIORAL|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
214249256|NCT02583243|DRUG|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
214249257|NCT04622982|OTHER|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
214249258|NCT00146107|BEHAVIORAL|Diet|10 percent weight loss through diet and behavioral modification
214249259|NCT00146107|OTHER|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
214249260|NCT00146107|OTHER|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
214249261|NCT02900001|PROCEDURE|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
214249262|NCT02900001|PROCEDURE|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
214249263|NCT01169597|DRUG|prednisone|prednisone 12.5 mg daily po
214249264|NCT01466595|DRUG|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
214249265|NCT01685346|BEHAVIORAL|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
214249266|NCT00450112|DEVICE|Gel-200|Single Intra-articular Injection
214249267|NCT01672229|DRUG|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
214249268|NCT00562744|OTHER|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
214249269|NCT02410733|BIOLOGICAL|Lipo-MERIT|vaccination
214249270|NCT01244698|DRUG|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
214249271|NCT01244698|DRUG|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
214249272|NCT01957527|DEVICE|Peripheral arterial tonometry (EndoPAT)|
214249273|NCT01264016|DEVICE|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
214249274|NCT05160610|BEHAVIORAL|Multilevel intervention|Multilevel intervention based on AACTT theory
214249275|NCT02117414|DEVICE|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
214249276|NCT02117414|OTHER|Waiting Period Visit|Waiting period time will equate to 1 hour
214249277|NCT03504579|OTHER|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
214249278|NCT01451268|DRUG|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
214249279|NCT01451268|DRUG|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
214249280|NCT03444987|GENETIC|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method"
214249281|NCT04665193|DIAGNOSTIC_TEST|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
214249282|NCT04394182|RADIATION|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
214249283|NCT04394182|DEVICE|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
214249284|NCT04394182|DRUG|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
214249285|NCT04394182|DRUG|Hydroxychloroquine|200 mg/12h
214249286|NCT04394182|DRUG|Azithromycin|500 mg/24h, 3 days
214249287|NCT04394182|DRUG|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
214249288|NCT04394182|DRUG|Low molecular weight heparin|prophylactic doses
214249289|NCT04394182|DRUG|Corticosteroid injection|250mg x 3 boluses
214249290|NCT04394182|DRUG|Tocilizumab|600mg single dose
214249291|NCT02182648|DRUG|etomidate|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction"
214249292|NCT02182648|DRUG|propofol|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction"
214249293|NCT02182648|DRUG|sevoflurane|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance"
214249294|NCT00911378|PROCEDURE|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
214249295|NCT00911378|PROCEDURE|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
214249296|NCT03128645|DEVICE|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
214249297|NCT00276081|DRUG|Gabapentin, Estrogen and placebo administration|
214249298|NCT02801344|DIETARY_SUPPLEMENT|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
214249299|NCT02801344|DIETARY_SUPPLEMENT|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
214249300|NCT02801344|DIETARY_SUPPLEMENT|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
214249301|NCT02801344|OTHER|Controlled-diet|the diet containing 0.8 g protein /kg/day
214249302|NCT03924531|BEHAVIORAL|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
214249303|NCT03924531|BEHAVIORAL|Health Promotion Program|Health Promotion Program
214249304|NCT00079534|BEHAVIORAL|Non-local/distant healing or prayer|
214249305|NCT00417482|DRUG|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
214249306|NCT04551144|DRUG|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
214249307|NCT04551144|DRUG|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
214249308|NCT05402020|DRUG|Tiotropium (Tio)|Tiotropium (Tio)
214249309|NCT05402020|DRUG|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
214249310|NCT05402020|DRUG|Olodaterol (Olo)|Olodaterol (Olo)
214249311|NCT05402020|DRUG|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
214249312|NCT06400979|DEVICE|Elequil aromatab|Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
214249313|NCT03433027|DRUG|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
214249314|NCT05199727|DEVICE|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
214249315|NCT05199727|DRUG|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
214652809|NCT00386906|PROCEDURE|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
214652810|NCT04591392|DEVICE|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
214249316|NCT03403270|OTHER|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
214249317|NCT04399174|DEVICE|US|
214249318|NCT01384643|DRUG|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
214249319|NCT05901792|OTHER|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
214249320|NCT05901792|OTHER|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
214249321|NCT05468138|DRUG|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
214249322|NCT05468138|DRUG|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
214249323|NCT05468138|OTHER|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
214249324|NCT05468138|DRUG|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
214249325|NCT02545140|OTHER|No intervention|
214249326|NCT04706117|DEVICE|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
214249327|NCT04536831|DRUG|Vitamin D|Vitamin D will be given to group A selected by Lottery method
214249328|NCT04536831|DRUG|Normal saline|Vitamin D will be given to group B slected by Lottery method
214249329|NCT01526122|DRUG|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
214249330|NCT01526122|DRUG|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
214249331|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
214249332|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
214249333|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
214249334|NCT01545453|DRUG|placebo|subcutaneous dose every 4 weeks
214249335|NCT03739840|DRUG|Padsevonil|Padsevonil in different dosages.
214652811|NCT05281757|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
214652812|NCT03952559|DRUG|Baricitinib|Administered orally
214652813|NCT03952559|DRUG|Placebo|Administered orally
214652814|NCT03952559|DRUG|Topical corticosteroid|Administered as standard-of-care
214249336|NCT03739840|DRUG|Placebo|Placebo will be provided matching padsevonil.
214249337|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
214249338|NCT05519449|DRUG|Darolutamide|Darolutamide is dosed via oral tablets
214249339|NCT00688727|BEHAVIORAL|CBT|CBT, up to 12 sessions.
214249340|NCT00688727|BEHAVIORAL|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
214249341|NCT03411915|BIOLOGICAL|XmAb18087|monoclonal bispecific antibody
214249342|NCT02433327|OTHER|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
214249343|NCT02433327|OTHER|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
214249344|NCT00573196|RADIATION|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
214249345|NCT04428775|DRUG|ALZT-OP1a (cromolyn)|"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"
214249346|NCT06314620|DRUG|Heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
214249347|NCT06314620|OTHER|Without heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
214249348|NCT05041517|BEHAVIORAL|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
214249349|NCT04729946|DEVICE|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
214249350|NCT00147420|DRUG|Zhi Byed 11|
214249351|NCT03531034|OTHER|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
214249352|NCT01646060|DEVICE|CM-1500|Blood Volume Monitor
214249353|NCT01828515|DRUG|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
214249354|NCT01828515|DRUG|Placebo|
214249355|NCT01828515|DRUG|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
214249356|NCT01095471|BIOLOGICAL|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
214249357|NCT02593201|DRUG|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
214249358|NCT02593201|DRUG|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
214249359|NCT04246255|DRUG|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
214249360|NCT04246255|DRUG|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
214249361|NCT05993182|DRUG|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
214249362|NCT05993182|DRUG|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
214249363|NCT05993182|DRUG|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
214249364|NCT02992080|OTHER|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
214249365|NCT04309071|OTHER|Dietary intervention|Salivary insulin responses to a standardized mixed meal
214249366|NCT03970213|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
214249367|NCT03970213|DRUG|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
214249368|NCT00961766|DRUG|BG00010 (Neublastin)|Single dose, weight-based IV administration
214249369|NCT00961766|DRUG|Placebo|Single dose IV matched placebo
214249370|NCT01511393|OTHER|No treatment given|None. Non-interventional study.
214249371|NCT01058265|OTHER|Integrative|Integrative Medicine medical evaluation.
214249372|NCT01058265|OTHER|Standard|Standard general medical evaluation.
214249373|NCT04601922|OTHER|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
214249374|NCT02594332|DRUG|Mepolizumab|100 mg SC every 4 weeks for 13 injections
214249375|NCT02594332|DRUG|Placebo|
214249376|NCT05802875|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
214249377|NCT05802875|BEHAVIORAL|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
214249378|NCT02897765|BIOLOGICAL|NEO-PV-01|Personal cancer vaccine
214249379|NCT02897765|BIOLOGICAL|Nivolumab|monoclonal antibody against PD1
214249380|NCT02897765|OTHER|Adjuvant|immune adjuvant
214249381|NCT05633004|DEVICE|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
214249382|NCT05344885|BEHAVIORAL|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.
214249383|NCT05344885|BEHAVIORAL|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
214249384|NCT05220800|DRUG|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
214249385|NCT05220800|DRUG|Placebo|Isoton saline infusion
214249386|NCT02343081|DRUG|Temozolomide|
214249387|NCT02343081|DRUG|Temozolomide|
214249388|NCT06207435|BEHAVIORAL|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
214249389|NCT00750880|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
214249390|NCT00729287|DIETARY_SUPPLEMENT|selenium|Given orally
214249391|NCT00729287|OTHER|placebo|Given orally
214249392|NCT05428293|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
214249393|NCT05428293|DRUG|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
214652815|NCT06199076|DRUG|Oxytocin nasal spray|The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
214652816|NCT02867306|DRUG|ASP1707|Oral
214652817|NCT02867306|DRUG|methotrexate (MTX)|Oral
214652818|NCT05327322|BEHAVIORAL|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
214249394|NCT05428293|DRUG|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
214249395|NCT00952627|DIETARY_SUPPLEMENT|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
214249396|NCT00952627|DIETARY_SUPPLEMENT|Placebo|
214652819|NCT05327322|BEHAVIORAL|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
214652820|NCT05327322|BEHAVIORAL|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
214249397|NCT02613949|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
214818150|NCT06045598|OTHER|Dynamic balance assessment|Dynamic balance evaluation will be done with the Gyko device. To evaluate dynamic balance, walking with eyes open on hard ground, walking with cognitive dual task on hard ground; walking with eyes open on soft ground, and cognitive dual task on soft ground will be evaluated. The walking distance is determined as 6 meters. The first 1 meter and the last 1 meter will not be taken into consideration. The measurement will start at the 1st meter and end at the 5th meter. The measurement will be carried out at a distance of 4 meters. As a cognitive task, the participants will be given the task of counting down by two and K-A-S verbal fluency. As a result of each evaluation, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained.
214652821|NCT04555941|DEVICE|intermittent theta burst stimulation|active or Sham iTBS will be given to the AD/MCI patient
214249400|NCT02738632|DRUG|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
214249401|NCT02738632|DRUG|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
214249402|NCT02738632|DRUG|Placebo for Hydrochlorothiazide|
214249403|NCT00984568|BIOLOGICAL|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
214249404|NCT00984568|DRUG|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
214249405|NCT00984568|DRUG|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
214249406|NCT00984568|DRUG|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
214249407|NCT05456919|OTHER|SFQ28 Questionnaire|SFQ28 Questionnaire
214249408|NCT02415257|DRUG|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
214249409|NCT01316354|OTHER|Bread types|Bread with 50 g available carbohydrate
214249410|NCT01284582|BIOLOGICAL|ATH03|4 vaccinations
214249411|NCT03647332|PROCEDURE|Cooled RFA treatment|cooled radiofrequency ablation
214249412|NCT03647332|DRUG|Steroid Drug|steroid injection
214249413|NCT05950958|OTHER|Multimodal therapy for prevention of delirium|Multimodal therapy for prevention of delirium
214249414|NCT03360825|DEVICE|TetraGraph|The TetraGraph is a dedicated neuromuscular stimulator / recorder intended to evoke, record, and analyze muscle action potentials during surgical procedures
214249415|NCT03800810|DRUG|Hyaluronic Acid|
214249416|NCT03800810|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
214249417|NCT03800810|BIOLOGICAL|Recombinant Human Somatropin|
214249418|NCT03802695|BIOLOGICAL|OrcaGraft (Orca-Q)|engineered donor allograft
214249419|NCT04883957|DRUG|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
214249420|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
214249421|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, IM
214249422|NCT02687178|DRUG|Canrenone 50 vs canrenone 100 mg|
214249423|NCT00455910|DRUG|Thalidomide|
214249424|NCT04638192|DEVICE|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
214249425|NCT03964844|OTHER|No intervention|No intervention
214249426|NCT06013982|BEHAVIORAL|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video"
214249427|NCT02964507|DRUG|GSK525762|GSK525762 will be administered.
214249428|NCT02964507|DRUG|Placebo|Placebo will be administered.
214249429|NCT02964507|DRUG|Fulvestrant|Fulvestrant will be administered.
214249430|NCT03874494|DRUG|Brexpiprazole|Brexpiprazole 2-4 mg/day
214249431|NCT03874494|DRUG|Aripiprazole|Aripiprazole 10-20 mg/day
214249432|NCT05351294|OTHER|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
214249433|NCT05351294|COMBINATION_PRODUCT|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
214249434|NCT05585320|DRUG|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
214249435|NCT05585320|DRUG|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2"
214249436|NCT05585320|DRUG|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2"
214249437|NCT05585320|DRUG|IMM-1-104 + dabrafenib (Treatment Group D)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with twice daily oral dose of dabrafenib until treatment discontinuation criteria are met. Dabrafenib will be administered at a dose of 150mg daily (75mg twice daily).
214249438|NCT05585320|DRUG|IMM-1-104 + pembrolizumab (Treatment Group E)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of pembrolizumab in sequence or concurrently depending on the enrolled cohort (two sub cohorts) until treatment discontinuation criteria are met. Pembrolizumab will be administered at a dose of 400mg.
214249439|NCT05014490|DRUG|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
214249440|NCT05014490|DRUG|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
214249441|NCT06647420|BEHAVIORAL|Sedative Music|The participants will come twice in person and listen to 9 minutes of sedative music.
214249442|NCT06647420|BEHAVIORAL|Stimulative Music|The participants will come twice in person and listen to 9 minutes of stimulative music.
214249443|NCT04781530|DEVICE|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
214249444|NCT05587673|DRUG|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
214249445|NCT05078138|DRUG|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
214249446|NCT05915182|COMBINATION_PRODUCT|Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler|Participants with moderate to severe Chronic Obstructive Pulmonary Disease
214249447|NCT03880461|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention
214249448|NCT04847622|DRUG|Remdesivir|treated with Remdesivir
214249449|NCT06416670|OTHER|Skilled nursing facility care at home|Skilled nursing facility care at home delivers a range of advanced rehabilitation services in patients' homes, enabling care at home despite requiring intensive rehabilitative care. Our approach blends personalized, high-level professional care with innovative technology applications to ensure adequate rehabilitation.
214249450|NCT03828318|OTHER|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
214249451|NCT03325751|DIAGNOSTIC_TEST|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
214249452|NCT00210860|DRUG|topiramate|
214249453|NCT02848053|OTHER|no intervention|
214249454|NCT01503112|OTHER|No intervention, observational study|
214249455|NCT04134403|DRUG|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
214249456|NCT03862040|DRUG|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
214249457|NCT03862040|DRUG|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
214249458|NCT04118933|DRUG|JS001|JS001 240mg, Q3W
214249459|NCT04094077|DRUG|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
214249460|NCT06324669|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
214249461|NCT06324669|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
214249462|NCT06322264|DIAGNOSTIC_TEST|Measurement of variation in heart rate|The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
214249463|NCT01407042|PROCEDURE|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
214249464|NCT03764488|DRUG|Tofersen|Administered as specified in the treatment arm.
214249465|NCT03764488|DRUG|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
214249466|NCT04025710|DEVICE|BIOMONITOR III and BIOMONITOR IIIm|"* Insertion of BIOMONITOR III or BIOMONITOR IIIm~* three scheduled in-office follow-ups~* 48-hour Holter ECG"
214249467|NCT03695874|OTHER|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
214249468|NCT03695874|OTHER|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
214249469|NCT02431247|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
214249470|NCT02431247|DRUG|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
214249471|NCT02431247|DRUG|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
214249472|NCT02431247|DRUG|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
214249473|NCT02431247|DRUG|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
214652822|NCT05406323|BEHAVIORAL|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
214652823|NCT05937412|OTHER|Alcohol sterilization|Sterilizing skin using alcohol
214652824|NCT05937412|OTHER|Honey sterilization|Sterilizing skin using honey
214249474|NCT02431247|DRUG|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
214249475|NCT02091674|DEVICE|Hyaluronic acid|Injected gel
214249476|NCT03174249|BEHAVIORAL|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
214249477|NCT01765660|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
214249478|NCT01765660|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
214249479|NCT04448054|OTHER|MRI|"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* \+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
214249480|NCT00769665|OTHER|Systane Ultra|Re-wetting ocular eye drop
214249481|NCT00769665|OTHER|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
214249482|NCT06276985|DEVICE|low intensity pulsed ultrasound and iPRF|iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
214249483|NCT03029130|DEVICE|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
214249490|NCT05942859|DIAGNOSTIC_TEST|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
214249491|NCT01690338|DRUG|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
214249492|NCT01690338|DRUG|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
214249493|NCT01690338|DRUG|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
214652825|NCT05943704|DIETARY_SUPPLEMENT|beef broth|It indicates if the child has allergy of Beef or not.
214249494|NCT03711227|DIAGNOSTIC_TEST|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
214249495|NCT01113047|DRUG|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
214249496|NCT06423989|COMBINATION_PRODUCT|IVIG|treatment of subfertility
214249497|NCT02855515|PROCEDURE|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
214249498|NCT01562873|DRUG|Ruxolitinib|
214249499|NCT00291733|DRUG|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
214652826|NCT06936059|DEVICE|Mixed Reality based analgesic therapy|"The intervention is a single 15 min MR therapy. The MR therapy is consisted of MR device and software. The model of MR device used is Pico Neo 3 Pro. The software run on the MR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.~And the placebo-group used the same non-mixed reality(Non-MR) scenario to treat patients, although the scenario is completely identical, it is not presented in a mixed reality scenario. It only presents the scene in normal display mode."
214652827|NCT04172883|OTHER|Treatment arm|All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
214249500|NCT00291733|DRUG|Placebo|Placebo tabl
214249501|NCT01369485|DEVICE|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
214249502|NCT01369485|DEVICE|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
214249503|NCT00416728|DRUG|Aliskiren|
214249504|NCT00416728|DRUG|Valsartan|
214249505|NCT02048579|BEHAVIORAL|Behavior Therapy + Motivational Interviewing|
214249506|NCT03280043|PROCEDURE|Hematoma|Hematoma requiring return to operating room.
214249507|NCT05312047|PROCEDURE|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
214249508|NCT05501912|DRUG|ABM-1310|"Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level."
214249509|NCT04047927|DEVICE|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
214249510|NCT01415739|OTHER|laboratory biomarker analysis|Correlative studies
214652828|NCT00002120|DRUG|Trimetrexate glucuronate|
214652829|NCT00002120|DRUG|Trimethoprim|
214652830|NCT00002120|DRUG|Sulfamethoxazole|
214652831|NCT00002120|DRUG|Dapsone|
214652832|NCT00002120|DRUG|Leucovorin calcium|
214652833|NCT01997463|DRUG|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
214249511|NCT05034445|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
214249512|NCT05351398|DRUG|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
214249513|NCT05351398|DRUG|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
214249514|NCT05991921|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
214249515|NCT05991921|OTHER|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
214249516|NCT04344743|DEVICE|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
214249517|NCT02695212|DRUG|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
214249518|NCT06523517|DRUG|Eliglustat Tartrate Capsules|The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
214249519|NCT04562272|PROCEDURE|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
214249520|NCT02914145|DRUG|Dihydroartemisinin-piperaquine|Mass drug administration
214249521|NCT01171170|DRUG|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
214249522|NCT01171170|DRUG|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
214249523|NCT02633618|BIOLOGICAL|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
214249524|NCT02633618|BIOLOGICAL|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
214249525|NCT02041442|PROCEDURE|Electrical mapping of the urinary bladder|
214249526|NCT02898584|OTHER|BP Track|
214249527|NCT06070571|DRUG|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
214249528|NCT05396703|PROCEDURE|TOETVA|Completed procedure.
214249529|NCT02985970|OTHER|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
214249530|NCT04149275|DRUG|Cabozantinib|Treatment with oral Cabozantinib once daily
214249531|NCT04149275|DRUG|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
214249532|NCT04149275|DRUG|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
214249533|NCT03039972|DIAGNOSTIC_TEST|No intervention|No intervention
214249534|NCT01613196|OTHER|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days."
214249535|NCT04589312|BIOLOGICAL|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
214249536|NCT04589312|BIOLOGICAL|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
214249537|NCT01064245|DRUG|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
214249538|NCT01064245|OTHER|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
214249539|NCT02436655|PROCEDURE|surgical aortic valve replacement|open heart aortic valve replacement
214249540|NCT04397627|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
214249541|NCT01865071|PROCEDURE|loop ileostomi|
214249542|NCT00812344|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
214249543|NCT00812344|DRUG|Ketoconazole|tablets, orally, once daily for 3 days
214249544|NCT00812344|DRUG|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
214249545|NCT01043900|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
214249546|NCT04109898|DEVICE|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
214652834|NCT03892161|DRUG|Darunavir/ritonavir 800/100 mg tablet|Standard dose DRV/r administered
214249547|NCT03141645|OTHER|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
214249548|NCT03141645|DRUG|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
214249549|NCT03195842|OTHER|Recordable card|
214249550|NCT04421807|OTHER|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
214249551|NCT04421807|OTHER|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
214249552|NCT04143529|BEHAVIORAL|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
214249553|NCT04143529|BEHAVIORAL|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
214249554|NCT06415851|DRUG|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
214249555|NCT00730262|DRUG|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
214249556|NCT04811573|DRUG|EU-sourced Otezla®|Test product
214249557|NCT04811573|DRUG|US-sourced Otezla®|Reference product 1
214249558|NCT04811573|DRUG|Japan-sourced Otezla®|Reference product 2
214249559|NCT05120843|BEHAVIORAL|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
214249560|NCT02869984|DRUG|Ramosetron|
214249561|NCT03358537|DIETARY_SUPPLEMENT|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
214249562|NCT03358537|DIETARY_SUPPLEMENT|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
214249563|NCT01177332|OTHER|exercise|2 hours cycling exercise at 50 % of maximal power output
214249564|NCT00194675|DRUG|Dutasteride|Dutasteride 0.5 mg orally daily
214249565|NCT00194675|DRUG|Testosterone gel|Testosterone gel 7.5 g daily topical
214249566|NCT00194675|DRUG|Placebo dutasteride|placebo dutasteride orally daily
214249567|NCT05072327|PROCEDURE|Mohs surgery|Mohs surgery of eyelid
214249568|NCT05072327|PROCEDURE|cryotherapy|cryotherapy of eyelid
214249569|NCT01285960|DEVICE|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
214249570|NCT00433264|PROCEDURE|peritoneal dialysis|individualised
214249571|NCT02515032|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
214249572|NCT02515032|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
214249573|NCT02516735|DEVICE|I-scan with magnification|
214249574|NCT02516735|DEVICE|Standard endoscopy|
214249575|NCT04664244|COMBINATION_PRODUCT|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
214249576|NCT00586196|DRUG|donepezil|5 mg each day for 30 days
214249577|NCT00586196|DRUG|Placebo|Encapsulated cornstarch One capsule daily for 30 days
214652835|NCT03892161|DRUG|Rifampicin 600mg QD tablet and DTG 50mg BD|Rifampicin and DTG added
214249578|NCT04910373|OTHER|Experimental Extensively Hydrolyzed Formula|experimental powder formula
214249579|NCT04910373|OTHER|Placebo Extensively Hydrolyzed Formula|placebo powder formula
214249580|NCT04914507|DEVICE|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
214249581|NCT05969418|DIAGNOSTIC_TEST|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
214249582|NCT04368273|DRUG|PD-1 antibody|a new treatment drug combined radical radiotherapy concurrent chemotharpy
214249583|NCT03804034|DEVICE|Block of resin|
214249584|NCT03804034|DEVICE|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
214249585|NCT03690323|PROCEDURE|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
214249586|NCT03690323|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
214249587|NCT03690323|DRUG|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
214249588|NCT03690323|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
214249589|NCT05497635|DRUG|STSA-1002 Injection|Intravenous injection
214249590|NCT05497635|DRUG|Placebo|Intravenous injection
214249591|NCT02280473|DRUG|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
214249592|NCT02280473|DRUG|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
214249593|NCT01469104|OTHER|3 day fast|Subjects will fast for 72 hours
214249594|NCT01469104|OTHER|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
214249595|NCT05453266|PROCEDURE|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
214249596|NCT05453266|PROCEDURE|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
214249597|NCT05529940|DRUG|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
214249598|NCT00972855|DRUG|Bicalutamide|50 mg Tablet
214249599|NCT00972855|DRUG|Casodex®|50 mg Tablet
214249600|NCT01484054|DEVICE|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
214249601|NCT01484054|DEVICE|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
214249602|NCT02163122|PROCEDURE|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
214249603|NCT02163122|OTHER|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
214249604|NCT02163122|BIOLOGICAL|Cat allergen (FelD1)|
214249605|NCT01610271|DEVICE|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
214249606|NCT04968379|DRUG|Ferric carboxymaltose|Intravenous
214249607|NCT00364130|DEVICE|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
214249608|NCT00364130|DEVICE|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
214249609|NCT05777018|PROCEDURE|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
214249610|NCT05777018|PROCEDURE|ultrasound-guided recruitment maneuvers|"* Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
214249611|NCT03207334|DRUG|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
214249612|NCT03207334|DRUG|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
214249613|NCT03310320|DRUG|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
214249614|NCT03310320|DRUG|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
214249615|NCT05129891|DRUG|Semaglutide D|Tablet given orally
214249616|NCT05129891|DRUG|Semaglutide G|Tablet given orally
214249617|NCT05129891|DRUG|Semaglutide H|Tablet given orally
214249618|NCT05129891|DRUG|Semaglutide I|Tablet given orally
214249619|NCT05129891|DRUG|NNC0385-0434 B|Tablet given orally
214249620|NCT05129891|DRUG|NNC0385-0434 C|Tablet given orally
214249621|NCT05129891|DRUG|NNC0385-0434 D|Tablet given orally
214249622|NCT05129891|DRUG|NNC0385-0434 E|Tablet given orally
214249623|NCT04526327|OTHER|exercise|the combination of aerobic and resistive exercise, three time a week
214249624|NCT02789332|DRUG|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
214249625|NCT02789332|DRUG|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
214249626|NCT02789332|DRUG|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
214249627|NCT02789332|PROCEDURE|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
214249628|NCT02789332|OTHER|Stratification|Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
214249629|NCT03810820|DEVICE|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
214249630|NCT00519298|DRUG|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
214249631|NCT00519298|OTHER|placebo|placebo
214249632|NCT00519298|DRUG|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
214249633|NCT01571024|DRUG|BKM120|BKM120 40 mg, orally, once daily.
214249634|NCT01571024|DRUG|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
214249635|NCT01328171|DRUG|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214249636|NCT01328171|DRUG|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214249637|NCT02701920|DEVICE|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
214249638|NCT02701920|DEVICE|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
214249639|NCT02701920|DEVICE|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
214249640|NCT02701920|DEVICE|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
214249641|NCT02701920|OTHER|parental feedback|Questionnaire
214249642|NCT02701920|OTHER|healthcare provider feedback|Questionnaire
214249643|NCT01110655|OTHER|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
214249644|NCT01110655|OTHER|Oral hypertonic saline|Oral 100mL bolus of 3% saline
214249645|NCT04884932|DEVICE|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
214249646|NCT04884932|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
214249647|NCT00808431|BEHAVIORAL|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
214249648|NCT05027893|DRUG|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
214249649|NCT05027893|DRUG|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
214249650|NCT05027893|OTHER|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
214249651|NCT00410202|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
214249652|NCT00410202|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily
214249653|NCT00410202|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
214249654|NCT00410202|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
214249655|NCT05695534|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
214249656|NCT04840576|OTHER|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
214249657|NCT04840576|OTHER|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
214249658|NCT00773916|DRUG|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
214249659|NCT02653027|DRUG|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
214249660|NCT02653027|OTHER|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
214249661|NCT05314088|BEHAVIORAL|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
214249662|NCT05314088|BEHAVIORAL|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
214249663|NCT01482351|BEHAVIORAL|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
214249664|NCT01482351|BEHAVIORAL|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
214249665|NCT00144027|BEHAVIORAL|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
214249666|NCT00107367|PROCEDURE|conventional surgery|
214249667|NCT00107367|RADIATION|intraoperative radiation therapy|
214249668|NCT06197399|PROCEDURE|Detethering Surgery|Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
214249669|NCT06197399|PROCEDURE|Spinal Column Shortening Surgery|"Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols."
214249670|NCT04624438|OTHER|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
214249671|NCT04624438|OTHER|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
214249672|NCT04624438|OTHER|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
214249673|NCT02521571|BEHAVIORAL|Resiliance Alliance|"The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
214249674|NCT02521571|BEHAVIORAL|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
214249675|NCT01810211|OTHER|Horizontal Adduction Stretch and Pendulums|
214249676|NCT01810211|OTHER|Modified Sleeper Stretch and Pendulum|
214249677|NCT02474888|OTHER|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
214249678|NCT04425824|DRUG|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
214249679|NCT01668927|DRUG|Proton Pump Inhibitor|
214249680|NCT01668927|DRUG|Bismuth|
214249681|NCT01668927|DRUG|Metronidazole|
214249682|NCT01668927|DRUG|Tetracycline|
214249683|NCT01668927|DRUG|Furazolidone|
214249684|NCT01668927|DRUG|Amoxicillin|
214249685|NCT03824067|DIAGNOSTIC_TEST|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
214249686|NCT03824067|DIAGNOSTIC_TEST|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
214249687|NCT00295971|BIOLOGICAL|anti-thymocyte globulin|
214249688|NCT00295971|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214249689|NCT00295971|DRUG|fludarabine phosphate|
214249690|NCT00295971|DRUG|thiotepa|
214249691|NCT00295971|PROCEDURE|allogeneic bone marrow transplantation|
214249692|NCT00295971|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214249693|NCT00295971|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214249694|NCT00295971|RADIATION|total-body irradiation|
214249695|NCT05834413|DRUG|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
214249696|NCT05834413|DRUG|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
214249697|NCT03702686|DEVICE|FEEDBACK System|Smart Nipple Shield and Monitor Unit
214249698|NCT02169193|RADIATION|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
214249699|NCT06115837|PROCEDURE|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
214249700|NCT02323932|BEHAVIORAL|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
214249701|NCT03317132|BEHAVIORAL|IPS|One year of IPS Support
214249702|NCT05223335|DRUG|Clopidogrel|75 mg/day
214249703|NCT05223335|DRUG|Prasugrel|60 mg bolus then 10 mg daily
214249704|NCT05223335|DRUG|Tricagrelor|180 mg bolus then 90 mg twice daily
214249705|NCT05621915|DRUG|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
214249706|NCT04853381|OTHER|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
214249707|NCT04853381|OTHER|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
214249708|NCT04853381|OTHER|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
214249709|NCT04853381|OTHER|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
214249710|NCT03779360|DRUG|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
214249711|NCT03779360|DRUG|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
214249712|NCT03779360|DRUG|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
214249713|NCT03779360|DRUG|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
214249714|NCT03779360|OTHER|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
214249715|NCT03552458|DRUG|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
214249716|NCT03552458|DRUG|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
214249717|NCT02312921|OTHER|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
214249718|NCT01520454|DRUG|Saline|IV saline at 0.83 mL/kg/hr for six hours
214249719|NCT01520454|DRUG|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
214249720|NCT01520454|DIETARY_SUPPLEMENT|Water|Water by mouth
214249721|NCT01520454|DIETARY_SUPPLEMENT|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
214249722|NCT01520454|DRUG|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
214249723|NCT01351246|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
214249724|NCT04292392|OTHER|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
214249725|NCT04292392|OTHER|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
214249726|NCT04292392|OTHER|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
214249727|NCT01851915|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
214249728|NCT01851915|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
214249729|NCT05554523|DEVICE|Photoacoustic imaging|Photoacoustic imaging
214249730|NCT00392821|DRUG|Sorafenib|Sorafenib
214249731|NCT00392821|DRUG|RAD001|RAD001
214249732|NCT04411524|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
214249733|NCT04411524|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
214249734|NCT04411524|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
214249735|NCT04411524|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
214249736|NCT01338142|OTHER|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
214249737|NCT01338142|OTHER|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
214249738|NCT02812355|DRUG|Heparin|
214249739|NCT02449720|DRUG|Ropivacaine|Intraperitoneal instillation and infusion
214249740|NCT02449720|DRUG|0.9% Saline|Intraperitoneal instillation and infusion
214249741|NCT03304639|BIOLOGICAL|Pembrolizumab|Given IV
214652836|NCT06089447|BEHAVIORAL|A story based intervention called 'The Shadow of Tallystick Valley'|'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
214652837|NCT03426098|DEVICE|Secret RF|A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
214249742|NCT03304639|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214249743|NCT00003173|BIOLOGICAL|filgrastim|
214249744|NCT00003173|DRUG|thiotepa|
214249745|NCT00003173|PROCEDURE|autologous bone marrow transplantation|
214249746|NCT00003173|PROCEDURE|peripheral blood stem cell transplantation|
214249747|NCT00881478|OTHER|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
214249748|NCT00881478|OTHER|Nutrition counseling|Nutrition counseling with registered dietician
214249749|NCT01157156|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
214249750|NCT02653404|OTHER|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
214249751|NCT05462041|OTHER|DBD Donor Heart Transplantation|A technique of donor heart procurement.
214249752|NCT05462041|DEVICE|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
214249753|NCT02772679|BIOLOGICAL|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
214249754|NCT03411837|BIOLOGICAL|Dupilumab|Biologic (monoclonal antibody)
214249755|NCT03811275|BEHAVIORAL|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
214249756|NCT03811275|BEHAVIORAL|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
214249757|NCT04898205|OTHER|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
214249758|NCT04898205|OTHER|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
214249759|NCT04898205|OTHER|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
214249760|NCT06324227|OTHER|multimodal music therapy|music therapy
214249761|NCT06324227|OTHER|no intervention|no intervention
214249762|NCT03266198|OTHER|No intervention|No intervention
214249763|NCT03194490|OTHER|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
214249764|NCT03194490|OTHER|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
214249765|NCT00477074|PROCEDURE|bronchoalveolar lavage, blood analysis|
214249766|NCT01214148|DEVICE|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
214249767|NCT02975583|DRUG|Vorapaxar|2.08 mg oral tablet daily
214249768|NCT02975583|DRUG|Placebos|Placebo oral tablet daily
214249769|NCT05165745|BEHAVIORAL|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
214249770|NCT03833518|OTHER|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
214249771|NCT03833518|OTHER|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
214249772|NCT03833518|OTHER|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
214249773|NCT04101201|DIETARY_SUPPLEMENT|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
214249774|NCT04101201|OTHER|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
214249775|NCT03793868|DRUG|Perampanel|Oral tablet
214249776|NCT03793868|OTHER|Placebo|Placebo (not drug)
214249777|NCT04279288|DEVICE|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
214249778|NCT05547022|PROCEDURE|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
214249779|NCT03934814|DRUG|TJ011133|TJ011133 will be administered weekly.
214249780|NCT03934814|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
214249781|NCT03934814|DRUG|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
214249782|NCT03348384|RADIATION|[C-11]|Radiolabel
214249783|NCT03348384|DRUG|NOP-1A|Tracer
214249784|NCT03303703|OTHER|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
214249785|NCT04964284|BIOLOGICAL|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
214249786|NCT04964284|RADIATION|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
214249787|NCT02648321|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
214249788|NCT02648321|BEHAVIORAL|Health Education|General education about healthy lifestyle and diet.
214249789|NCT03347708|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
214249790|NCT03347708|DRUG|Saline Solution|Sodium Chloride Solution
214249791|NCT03347708|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
214249792|NCT03125291|BEHAVIORAL|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
214249793|NCT03094039|PROCEDURE|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
214249794|NCT03094039|PROCEDURE|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
214249795|NCT02707809|DRUG|Dexmedetomidine|Dexmedetomidine infusion
214249796|NCT01818960|PROCEDURE|IRA-PCI|IRA only PCI at the time of Primary PCI
214249797|NCT01818960|PROCEDURE|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
214249798|NCT01574079|OTHER|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
214249799|NCT01574079|OTHER|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
214249800|NCT02865343|DEVICE|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
214249801|NCT02865343|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
214249802|NCT00924417|BEHAVIORAL|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
214249803|NCT00924417|BEHAVIORAL|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
214249804|NCT06324929|BEHAVIORAL|CARRII Native Rapid Pilot Testing|The candidates that will be tested are: 1) Telephone-administered 30 day timeline follow-back of drinking, sex, and contraception, administered by phone at enrollment and monthly, which should increase awareness of AEP risk and motivation for alcohol and contraception behavior change, 2) Mailed pregnancy tests sent monthly to raise consciousness of pregnancy risk and to detect a new pregnancy early, which should increase motivation for contraception behavior change, 3) Automated, personalized digital safer sex and drink counting/reduction skills training, to improve drinking self-management skills and self-efficacy for drinking reduction and contraception use, 4) Fully automated text messages prompting usage of safer sex and drink reduction skills, which should increase self-efficacy for behavior change, and 5) access to an anonymized Community Message Board of Native women to discuss challenges in behavior change, which should increase perceived social support.
214249805|NCT00028275|DRUG|Gamma Interferon 1b|
214249806|NCT03724175|DRUG|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
214249807|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
214249808|NCT05919264|DRUG|mFOLFOX-6|mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
214249809|NCT05919264|DRUG|Nivolumab|Nivolumab will be administered per the prescribing information in combination with FOG-001
214249810|NCT05919264|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
214249811|NCT05919264|DRUG|Bevacizumab|Bevacizumab will be administered per the prescribing information in combination with FOG-001
214464833|NCT02675777|OTHER|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
214249812|NCT05128500|PROCEDURE|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
214249813|NCT02828527|OTHER|Observational|
214249814|NCT01834859|BEHAVIORAL|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
214249815|NCT01834859|BEHAVIORAL|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
214249816|NCT01467245|PROCEDURE|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
214249817|NCT01467245|PROCEDURE|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
214249818|NCT06307431|BIOLOGICAL|Intismeran autogene|IM injection
214249819|NCT06307431|BIOLOGICAL|Pembrolizumab|IV infusion
214249820|NCT06307431|BIOLOGICAL|Placebo|IM injection
214249821|NCT02600754|BEHAVIORAL|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
214249822|NCT02600754|BEHAVIORAL|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
214249823|NCT05362578|DEVICE|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
214249824|NCT05362578|DEVICE|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
214249825|NCT06267001|DRUG|Atezolizumab|Atezolizumab will be administered IV.
214249826|NCT06267001|DRUG|Tiragolumab|Tiragolumab will be administered IV.
214249827|NCT06267001|DRUG|Placebo|Placebo will be administered IV.
214249828|NCT02145702|OTHER|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
214249829|NCT02145702|PROCEDURE|Standard Care Dialysis|12 weeks of standard of care.
214249830|NCT04604509|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
214249831|NCT04604509|DRUG|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
214249832|NCT04604509|OTHER|Questionnaire Administration|Ancillary studies
214249833|NCT04604509|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
214249834|NCT04604509|DRUG|Varenicline|Given PO
214818151|NCT06045598|OTHER|Timed Up and Go Test|"The Timed Get Up and Walk Test is used to assess balance and fall risk. The participant stands up from the chair, walks 3 meters, turns back, and sits back on the chair. The time elapsed during these phases was recorded.~In our study, the patient will be asked to start the test after the Gyko device is fixed with a wearable vest. During the test, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be taken."
214249837|NCT03894592|OTHER|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
214249838|NCT06429761|DRUG|Trastuzumab deruxtecan|IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.
214249839|NCT05262231|BEHAVIORAL|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
214249840|NCT06259799|BEHAVIORAL|Smart Water Bottle|Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
214249841|NCT00285207|DRUG|placebo|5 days of 28 day cycle for 2 cycles
214249842|NCT00285207|DRUG|A007|5 days of 28 day cycle
214249843|NCT05175885|DEVICE|Ex vivo normothermic perfusion|Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
214249844|NCT05175885|DEVICE|Cold preservation|Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
214249845|NCT06809621|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
214249846|NCT06809621|DRUG|Insulin aspart|Insulin aspart will be administered subcutaneously.
214249847|NCT06809881|OTHER|olfactory testing, MRI acquisition, clinical assessment|
214464834|NCT06114082|PROCEDURE|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
214249848|NCT07129798|PROCEDURE|ILM flap with no endotamponade technique|Standard 3-port pars plana vitrectomy will be performed under either local anesthesia or general anesthesia. After core vitrectomy, posterior vitreous detachment induction will be done using vitrectomy cutter suction with the staining of intravitreal triamcinolone if necessary. This is followed by staining of the ILM with ILM blue dye. A half-moon shaped temporal ILM flap will be created, bridging the MH, using an end-gripping intraocular forceps. The posterior pole would be filled with perfluorocarbon (PFC) liquid and cohesive viscoelastic will be injected under the PFC to stabilize the ILM flap over the MH. Removal of PFC and search for peripheral retinal breaks will be done before removal of vitrectomy trocars and closure of sclerotomies wounds. Surgery will be combined with cataract removal (phacoemulsification) with intraocular lens implantation if patients have visually significant cataract. No specific post-operative posture will be required.
214249849|NCT07118592|DIETARY_SUPPLEMENT|Low Salt Diet|8 days of diet with low salt content will be given to the study participants
214249850|NCT07118592|DIETARY_SUPPLEMENT|High Salt Diet|8 days of diet with high salt content will be given to the study participants
214249851|NCT07118592|DIETARY_SUPPLEMENT|Saline Infusion|2 Liters of normal saline infusion (0.25 ml/kg/min over 2 hours) will be given to the study participants at the end of each study period
214249852|NCT06666569|DEVICE|Use of the test for treatment optimization|Intervention cohort, where the clinician will have information on the test results to support decision making on treatment optimization. The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up.
214249853|NCT06683547|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester.
214249854|NCT06683547|DIETARY_SUPPLEMENT|Flavour matched placebo drink (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
214249855|NCT06683547|OTHER|Resistance Exercise|\- 5 sets of 10 repetitions of leg press and 3 sets of 12 repetitions of leg extension/leg curl 'supersets' (1 set of each back to back with no rest in between sets) at 95% of their 10-RM. Between-set rest intervals for the leg exercises will be 60 seconds.
214249856|NCT06746441|DRUG|Psilocybin|"Psilocybin is a naturally occurring serotonergic psychedelic compound found in Psilocybe mushrooms. It is metabolized in the body into its active form, psilocin, which has a high affinity for serotonin 5-HT2A receptors. This enables psilocin to bypass the default serotonin pathway, producing antidepressant effects.~For this study:~Psilocybin will be administered orally in a dose of 5-6 grams per session. Each participant in the Psilocybin and Psilocybin-assisted CBT arms will receive two sessions spaced six weeks apart.~The therapy will be conducted in a controlled hospital setting with medical monitoring during the session to ensure safety until the hallucination phase subsides.~Psilocybin will be added to routine antidepressant medication."
214249857|NCT06746441|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Cognitive Behavioral Therapy (CBT) is a structured, time-limited psychotherapy aimed at alleviating symptoms of depression. It involves addressing negative thoughts and behavioral patterns through the following steps:~Identifying troubling life situations. Recognizing thoughts, emotions, and beliefs about those situations. Identifying negative or inaccurate thinking patterns. Restructuring those thoughts into positive and realistic perspectives.~In this study:~CBT will consist of 8-10 structured sessions, each lasting approximately 90 minutes.~Participants will attend therapy sessions twice weekly over a six-week period. The intervention will be delivered by trained psychotherapists in a controlled hospital setting.~Routine antidepressant medications will be continued alongside CBT."
214249858|NCT06928298|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
214249859|NCT07140718|BEHAVIORAL|Fundamental Adaptive Skills Training|The FAST intervention will be approximately 60 minutes in duration. The video component of FAST, animated using the Vyond software, will be presented via computer or projector. Pause points and brief interactive exercises will be added throughout the presentation to promote engagement and ensure comprehension of FAST material. The treatment will be sectioned into thirds: a physical health section focused on sleep hygiene and physical activity, an anxiety sensitivity section dispelling common AS myths, and a social health section. Each section will contain brief psychoeducation focused on dispelling common myths or promoting adaptive skills use.
214464835|NCT06114082|PROCEDURE|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
214464836|NCT05932836|OTHER|No interventions.|No interventions to be administered.
214464837|NCT05994625|DEVICE|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
214464838|NCT05994625|DEVICE|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
214249860|NCT07140718|BEHAVIORAL|Relaxation and Mindfulness Training|The RMT intervention will be primarily psychoeducational and focused on explaining relaxation methods used in various psychological treatments such as progressive muscle relaxation, guided imagery, and mindfulness-focused breathing exercises. Interactive relaxation and mindfulness exercises and brief discussions following each relaxation component will be included to control for time spent on interactive exercises in the FAST condition. The intervention will take approximately 60 minutes. Tailored to control for the effects of general education, practice exercises, and time spent on the FAST intervention, RMT will be a stronger control in comparison to a waitlist or repeated contact condition. Like the FAST intervention, this program will also be digitalized to allow for ease-of-administration.
214249861|NCT07149870|OTHER|Pain Management Team + Whole Health Coach (PMT-WHC)|"Whole Health Coaching (WHC) begins by completing a Personalized Health Inventory (PHI), where progress is evaluated within 8 dimensions of health and wellness. The PHI culminates in defining personal values and overall goals for health and wellness (i.e., What do you want your health for?). This is used to create goals for a Personal Health Plan. The Plan emphasizes self-management strategies to manage pain. After the Plan is developed, ongoing support is provided from the Coach through 8 coaching sessions over approximately 5 months."
214249862|NCT07149870|OTHER|Pain Management Team-Usual Care (PMT-UC)|Pain Management Team-Usual Care (PMT-UC) involves working with VA PMTs that includes working with PMTs comply with legislation requiring each medical center to have PMTs with expertise in pain, addiction, behavioral approaches, and rehabilitation approaches. PMTs will conduct multidisciplinary intakes (at least two provider types) with biopsychosocial assessments for all new patients. Follow-up care will be determined by the PMTs based on what is clinically indicated (with recommended minimum medication management follow ups at 1- 3- and 6-months for patients making medication changes).
214249863|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Negative Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
214249864|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education (Control Group)|Control group
214249865|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Positive Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
214249866|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) alone.
214249867|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training (PFMT) with medical treatment|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) with medical treatment.
214249868|NCT07150936|BEHAVIORAL|stress ball application|Participants' demographic information will be collected interview using the Patient Information Form. Approximately 30 minutes before surgery, patients' systolic and diastolic blood pressure, heart rate, respiratory rate, and oxygen saturation will be measured and recorded. Pain severity will also be assessed using the VAS, and anxiety levels will be assessed using the VAS-A and Spielberger Trait Anxiety Scale. Intraoperative Period: All patients will be placed in the supine position on the operating room table. Patients in the intervention group will continue to use the stress ball for 15 minutes during the surgery, as per randomization. All patients will undergo a repeat 15-minute postoperative assessment of vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, oxygen saturation), pain with a VAS, and anxiety levels with a VAS-A. After the patients are taken to the clinic after the surgery, the same physiological measurements will repeated 10 mnt later
214249869|NCT04724395|OTHER|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
214249870|NCT04221412|DRUG|JNJ-53718678|JNJ-53718678 will be administered as directed by treating physician.
214249871|NCT06517810|DEVICE|QUELIMMUNE (SCD-PED)|QUELIMMUNE device used as part of clinical practice.
214249872|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
214249873|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
214249874|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
214652838|NCT06253039|OTHER|Repeated sprint|"* The group will endure four weeks (8 sessions) of the assigned training program in addition to the regular swimming training.~* Data collection sessions: All groups will be evaluated before and after the supervised training period in three testing sessions in normoxia separated by at least 24 hours within 7 days.~* Training sessions: will be performed in the ski ergometer and consist of 4 sets of 5x6s all-out sprints with 24s and 5 min of passive rest between the sprints and sets, respectively."
214652839|NCT05624463|BEHAVIORAL|Modified intubation protocol|1\. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
214249875|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
214249876|NCT00071578|BEHAVIORAL|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
214249877|NCT00071578|BEHAVIORAL|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
214249878|NCT02158260|BEHAVIORAL|Position changing|
214249879|NCT01250288|OTHER|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
214249880|NCT02294773|PROCEDURE|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
214249881|NCT02294773|DRUG|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
214249882|NCT02294773|DRUG|Letrozole|Patient is to take letrozole during cycle days 3-7.
214249883|NCT05932784|DEVICE|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
214249884|NCT03052764|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
214249885|NCT03052764|DRUG|Placebo (saline)|Placebo (saline) injection into the bladder.
214249886|NCT05828095|BIOLOGICAL|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
214249887|NCT05828095|BIOLOGICAL|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
214249888|NCT02199860|DRUG|SD I|
214249889|NCT02199860|DRUG|SD II|
214249890|NCT02199860|DRUG|Placebo|
214249891|NCT03206073|DRUG|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
214249892|NCT03206073|DRUG|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
214249893|NCT03206073|BIOLOGICAL|Pexa-Vec|3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
214249894|NCT03206073|BIOLOGICAL|Pexa-Vec|1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
214249895|NCT03332771|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214652840|NCT05624463|BEHAVIORAL|Conventional intubation protocol|1\. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.
214249896|NCT03332771|DRUG|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
214249897|NCT03332771|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214249898|NCT03332771|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214249899|NCT03332771|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
214249900|NCT00096954|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
214249901|NCT00096954|DRUG|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
214249902|NCT02414659|PROCEDURE|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
214249903|NCT02460445|PROCEDURE|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
214249904|NCT02460445|DRUG|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
214249905|NCT02460445|DRUG|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
214249906|NCT02855073|BIOLOGICAL|ReJoinTM|adipose derived mesenchymal progeinitor cells
214249907|NCT02855073|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Injection
214249908|NCT00654121|DRUG|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
214249909|NCT04176497|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
214249910|NCT06084689|DRUG|Ezabenlimab + BI907828|A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.
214249911|NCT04347096|BEHAVIORAL|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
214249912|NCT04347096|BEHAVIORAL|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
214249913|NCT05621460|OTHER|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
214249914|NCT05621460|OTHER|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
214249915|NCT05621460|OTHER|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
214249916|NCT02435329|OTHER|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
214652841|NCT05624463|BEHAVIORAL|Early resumption of oral intake|Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
214652842|NCT05624463|BEHAVIORAL|Delayed resumption of oral intake|Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
214652843|NCT04257760|BEHAVIORAL|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
214249917|NCT04478123|DRUG|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
214249918|NCT00463203|DRUG|Bevacizumab|10 mg/kg every 2 weeks
214249919|NCT00463203|DRUG|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
214249920|NCT06706596|OTHER|Screening for TB symptoms|Individuals will be screened for cough, blood in sputum, fever, weight loss, night sweats and chills lasting for \>2 weeks
214249921|NCT06706596|DIAGNOSTIC_TEST|Chest X-ray|Chest X-ray will be performed to diagnose or exclude TB
214249922|NCT02026960|DEVICE|RNA extraction and amplification from biopsy specimens|
214249923|NCT02496962|DRUG|Atorvastatin|atorvastatin were taken daily for 5 days
214249924|NCT02496962|DRUG|placebo|placebo were taken daily for 5 days
214249925|NCT02643329|DRUG|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
214249926|NCT02643329|DRUG|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
214249927|NCT06166602|DRUG|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
214249928|NCT04314154|OTHER|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
214249929|NCT04822649|DIAGNOSTIC_TEST|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
214249930|NCT04999982|OTHER|Screening|Parent-report screening for remediable, unmet social needs.
214249931|NCT04999982|OTHER|Resource Packet|"Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted."
214249932|NCT04999982|OTHER|Resource Navigation|Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.
214249933|NCT04999982|OTHER|Care as usual|Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
214652844|NCT00851071|BEHAVIORAL|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
214652845|NCT01870739|DRUG|sacubitril/valsartan (LCZ696)|200 mg tablets
214249934|NCT03581786|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
214249935|NCT03581786|DRUG|Placebos|placebo combine with chemotherapy
214249936|NCT01083927|PROCEDURE|Rotational Narrow Strip Conjunctival Graft|Surgical technique
214249937|NCT01083927|PROCEDURE|Full Conjunctival Graft|Surgical technique
214249938|NCT05718050|DIAGNOSTIC_TEST|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
214249939|NCT06517108|PROCEDURE|Chuna therapy|"The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
214249940|NCT06517108|PROCEDURE|Physical therapy|"The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
214249941|NCT00572897|DRUG|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
214652846|NCT01870739|DRUG|olmesartan|
214652847|NCT01870739|OTHER|placebo to sacubitril/valsartan (LCZ696)|placebo
214249942|NCT01347307|RADIATION|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
214249943|NCT01347307|RADIATION|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
214249944|NCT06707870|OTHER|Cervical retraction exercise|"Neck retraction exercises are performed on patients either in sitting or standing in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range (3 seconds hold)of 10 repetitions in each session at sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
214249945|NCT06707870|OTHER|Facet oscillatory mobilization|"Facet joint oscillatory mobilization on the cervical spine C2-C7(6 to 10 repetitions in each session) in the sitting position.~Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
214249946|NCT06790290|BIOLOGICAL|Formulation B|IVT PCV-25
214249947|NCT06790290|BIOLOGICAL|Formulation C|IVT PCV-25
214249948|NCT06790290|BIOLOGICAL|Formulation D|IVT PCV-25
214249949|NCT06790290|BIOLOGICAL|Prevnar20|20 valent pneumococcal conjugate vaccine
214249950|NCT01339026|DRUG|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
214249951|NCT01339026|DRUG|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
214249952|NCT00446589|DRUG|ibandronate|iv 1mg ibandronate monthly for one year
214249953|NCT00446589|DRUG|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
214249954|NCT02069288|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
214652848|NCT01870739|OTHER|placebo to olmesartan|placebo
214652849|NCT01870739|DRUG|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
214652850|NCT03033771|DEVICE|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
214652851|NCT01384214|BIOLOGICAL|botulinum toxin Type A|750 U at Visit 1
214249955|NCT02069288|DRUG|Placebo|1 tablet of placebo per os
214249956|NCT03252184|DEVICE|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
214249957|NCT03252184|DEVICE|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
214249958|NCT03252184|DEVICE|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
214249959|NCT03470974|BEHAVIORAL|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
214249960|NCT04823416|PROCEDURE|Resection|Left hemicolectomy
214249961|NCT04823416|PROCEDURE|Stoma|Colostomy
214249962|NCT01530347|DEVICE|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
214249963|NCT00606944|BEHAVIORAL|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
214249964|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
214249965|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
214249966|NCT02808091|RADIATION|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
214652852|NCT00327522|BIOLOGICAL|pneumococcal vaccine|
214652853|NCT05664984|BEHAVIORAL|1-face-to-face|The cognitive rehabilitation intervention consists of 45-minute sessions, 2 days a week for 12 weeks. The same rehabilitation intervention program was applied to both groups by face-to-face or tele-rehabilitation method. The main purpose of the study is to see the effectiveness of cognitive rehabilitation intervention in the elderly with amnestic mild cognitive impairment and to compare the two methods.
214652854|NCT05664984|BEHAVIORAL|2-tele rehabilitation|2-tele rehabilitation
214652855|NCT01986062|DRUG|AR11|
214652856|NCT01986062|DRUG|Placebo|
214652857|NCT03538743|DRUG|Placebo|Tablet, 0 mg, twice daily, 28 days
214249967|NCT05561179|PROCEDURE|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
214249968|NCT05561179|PROCEDURE|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
214249969|NCT01557894|OTHER|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
214249970|NCT05266274|DRUG|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
214249971|NCT01386112|DRUG|EUR-1100|Active oral medication
214249972|NCT01386112|DRUG|placebo|matching placebo
214249973|NCT04827121|PROCEDURE|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
214249974|NCT04827121|PROCEDURE|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
214249975|NCT00964132|DRUG|NRX194204|Once Daily, Oral
214249976|NCT06083935|DRUG|Daflon|Daflon; two film coated tablets 500 mg daily
214249977|NCT06083935|DRUG|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
214249978|NCT06083935|DRUG|Metformin|Glucophage ® 500 tablets twice daily
214249979|NCT04123665|DRUG|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
214249980|NCT04123665|DRUG|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
214249981|NCT02237911|OTHER|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
214249982|NCT02237911|OTHER|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
214249983|NCT03015545|DEVICE|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
214249984|NCT03015545|DEVICE|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
214249985|NCT03015545|DEVICE|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
214652858|NCT03538743|DRUG|PF-06882961|Tablet, 15 mg twice daily, 28 days
214652859|NCT03538743|DRUG|PF-06882961|Tablet, 50 mg twice daily, 28 days
214652860|NCT03538743|DRUG|PF-06882961|Tablet, 150 mg twice daily, 28 days
214652861|NCT03538743|DRUG|PF-06882961|Tablet, 300 mg twice daily, 28 days
214249986|NCT03015545|DEVICE|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
214249987|NCT02809326|BEHAVIORAL|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
214249988|NCT02809326|BEHAVIORAL|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
214249989|NCT02809326|BEHAVIORAL|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
214652862|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 5, 28 days
214652863|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 6, 28 days
214652864|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 7, 28 days
214652865|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 8, 28 days
214249990|NCT04960410|COMBINATION_PRODUCT|Types and exposure of different air pollutants|Types and exposure of different air pollutants in COPD patients' living and working environment
214249991|NCT00053365|DRUG|irofulven|Given IV
214249992|NCT01938872|PROCEDURE|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
214249993|NCT01546012|DEVICE|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
214249994|NCT01546012|DEVICE|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
214249995|NCT05755737|DRUG|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
214249996|NCT05755737|DRUG|Placebo|Matching placebo identical in appearance.
214249997|NCT03708185|DIETARY_SUPPLEMENT|Beta-alanine|N/A: see arm description
214249998|NCT03708185|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
214249999|NCT01583543|DRUG|Olaparib|400mg PO BID Continuous
214250000|NCT02493582|BIOLOGICAL|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
214250001|NCT02493582|DRUG|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
214250002|NCT02260531|DRUG|Cabozantinib|
214250003|NCT02260531|DRUG|Trastuzumab|
214250004|NCT03234777|BEHAVIORAL|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
214250005|NCT03234777|BEHAVIORAL|Regular video|Developed by CDC
214250006|NCT05241431|DRUG|SGLT2 inhibitor|10 mg orally once daily in addition to standard medical treatment.
214250007|NCT05241431|DRUG|Placebo|Placebo tablets similar to active treatment.
214250008|NCT00543491|DRUG|MK0767|
214250009|NCT02584699|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
214250010|NCT04680676|DRUG|BI 730357|BI 730357
214250011|NCT04680676|DRUG|Placebo|Placebo
214250012|NCT04233463|DIETARY_SUPPLEMENT|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
214250013|NCT04233463|DRUG|Budesonide|Standard treatment for mild Crohn Disease patients
214250014|NCT04741698|DRUG|Propranolol|Propranolol 2mg IV
214250015|NCT01242059|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
214250016|NCT01242059|OTHER|yellow pea fiber|Served in a tomato soup
214250017|NCT01242059|DIETARY_SUPPLEMENT|Control|Served in a tomato soup
214250018|NCT00295828|OTHER|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
214250019|NCT00295828|PROCEDURE|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
214250020|NCT05515172|OTHER|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
214250021|NCT00958789|DEVICE|Triathlon TS Knee System|Total knee replacement for revision cases
214250022|NCT05509790|DRUG|LY3484356|Administered orally.
214250023|NCT00253500|BIOLOGICAL|pegfilgrastim|6 mg in a syringe
214250024|NCT00253500|DRUG|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
214250025|NCT00253500|PROCEDURE|conventional surgery|to remove small piece of cancer
214250026|NCT00356733|DRUG|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
214250027|NCT01409395|DRUG|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
214250028|NCT01409395|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
214250029|NCT04108442|BEHAVIORAL|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
214250030|NCT04108442|BEHAVIORAL|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
214250031|NCT04376879|OTHER|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
214250032|NCT00721123|DRUG|Tocilizumab|Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
214250033|NCT01885871|DEVICE|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
214250034|NCT00246896|BEHAVIORAL|care management|
214250035|NCT05753527|BEHAVIORAL|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
214250036|NCT04398251|DRUG|Febuxostat 40mg Tab|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
214250037|NCT04398251|BEHAVIORAL|Non-drug control group|All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
214250038|NCT00877201|DRUG|CDR2|
214250039|NCT04215588|DEVICE|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
214250040|NCT04215588|DEVICE|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
214250041|NCT06016192|BEHAVIORAL|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
214250042|NCT06667765|DRUG|RPT1G|Dose formulation- Oral capsule
214250043|NCT06667765|DRUG|Placebo|Dose formulation- Oral capsule
214250044|NCT03213600|DEVICE|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
214250045|NCT00168402|DRUG|Botulinum Toxin Type A|
214250046|NCT00415376|DRUG|levetiracetam|
214250047|NCT00415376|PROCEDURE|quality-of-life assessment|
214652866|NCT02828800|OTHER|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith \& Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
214652867|NCT02608918|DRUG|BMS-955176|
214652868|NCT04207047|DEVICE|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
214652869|NCT04207047|DEVICE|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
214652870|NCT04207047|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
214652871|NCT04207047|DEVICE|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
214652872|NCT04207047|DEVICE|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
214652873|NCT06357650|OTHER|No intervention. This is an observational study|This is an observational study. Hence there is no intervention
214652874|NCT02786823|DIETARY_SUPPLEMENT|Folic acid|tab. Folic acid 5 mg
214652875|NCT02786823|DIETARY_SUPPLEMENT|Vitamin B12|tab. Vitamin B12 500 mcg
214652876|NCT02786823|DRUG|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea"
214652877|NCT03664128|OTHER|Coping with Anxiety through Living Mindfully (CALM) Pregnancy|Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
214652878|NCT00171860|DRUG|imatinib mesylate|
214652879|NCT02488122|OTHER|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
214652880|NCT02488122|OTHER|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
214652881|NCT02369081|DRUG|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
214652882|NCT02369081|DRUG|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
214652883|NCT02369081|DRUG|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
214652884|NCT02369081|DRUG|Placebo|Placebo treatment for 12 weeks.
214652885|NCT00667615|DRUG|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
214652886|NCT05402826|DIETARY_SUPPLEMENT|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
214652887|NCT05402826|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
214250048|NCT00791310|DRUG|Flucis|FDG injected i.v
214250049|NCT01279473|DRUG|Nilotinib|
214250050|NCT03007407|DRUG|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
214250051|NCT03007407|DRUG|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
214250052|NCT03960931|OTHER|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
214250053|NCT03960931|OTHER|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
214250054|NCT03960931|OTHER|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
214250055|NCT00364754|DRUG|Tesmilifene (YMB 1002)|
214250056|NCT00850161|DRUG|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
214250057|NCT00850161|DRUG|Nasulin™|100 IU(2 puffs in each nostril)
214250058|NCT00090051|DRUG|Rituximab|Intravenous repeating dose
214250059|NCT00090051|DRUG|Fludarabine Phosphate|Intravenous repeating dose
214250060|NCT00090051|DRUG|Cyclophosphamide|Intravenous repeating dose
214250061|NCT05805488|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
214250062|NCT05805488|DIETARY_SUPPLEMENT|TCI904 sachet|consume 1 sachet per day
214250063|NCT00198926|BEHAVIORAL|covert v overt nutrition labeling|
214250064|NCT00198926|BEHAVIORAL|varying meal nutrition manipulation|
214250065|NCT02186431|DEVICE|senofilcon A|
214250066|NCT03696173|OTHER|Non-Interventional|Non-Interventional
214250067|NCT03696173|OTHER|Non-Interventional|Non-Interventional
214250068|NCT04450888|OTHER|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
214250069|NCT03754673|DEVICE|MRI|MRI pulmonary with no contrast administration
214250070|NCT05419986|GENETIC|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
214250071|NCT02961673|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
214250072|NCT02961673|BIOLOGICAL|Botox Inj|Clostridium botulinum type A
214250073|NCT05356078|DRUG|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
214250074|NCT01055522|DRUG|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
214250075|NCT01055522|DRUG|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
214250076|NCT01055522|DRUG|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
214250077|NCT06033053|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
214250078|NCT04343820|PROCEDURE|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
214250079|NCT02330965|PROCEDURE|Blood Draw|Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
214250080|NCT02330965|PROCEDURE|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
214250081|NCT06557070|OTHER|The Emotional Freedom Technique|Emotional freedom technique (EFT) is a method to help manage emotions and troubling thoughts and lower stress and anxiety. EFT is applying by tapping. To do EFT, you tap your fingertips on certain points on your hand, head, and torso which are used in acupuncture.
214250082|NCT06457919|DRUG|Tinengotinib|Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
214250083|NCT06457919|DRUG|abiraterone acetate with prednisone|Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
214250084|NCT06457919|DRUG|Enzalutamide|Enzalutamide 160 mg PO QD
214652888|NCT01827384|DRUG|Adavosertib|Given by mouth (PO)
214652889|NCT01827384|DRUG|Carboplatin|Given intravenous (IV)
214250085|NCT06796998|BIOLOGICAL|Epcoritamab|"Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 0.16 mg~* Cycle 1, Day 8: 0.8 mg~* Cycle 1, Day 15: 3 mg~* Cycle 1, Day 22: 48 mg~* Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg~* Cycles 4 to 9, Days 1 and 15: 48 mg~* Cycles 10 to 12; Day 1: 48 mg"
214250086|NCT03003117|BEHAVIORAL|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
214250087|NCT03003117|BEHAVIORAL|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
214250088|NCT06736847|PROCEDURE|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer
214250089|NCT05933395|DRUG|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
214250090|NCT05933395|DRUG|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
214250091|NCT05933395|DRUG|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
214250092|NCT05933395|DRUG|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
214250093|NCT05933395|DRUG|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
214250094|NCT05815524|OTHER|Physical activity training|training on treadmill
214250095|NCT01896479|DRUG|Cabozantinib (XL184) 140 mg|
214250096|NCT01896479|DRUG|Cabozantinib (XL184) 60 mg|
214250097|NCT01896479|DRUG|Placebo tablet|
214250098|NCT01896479|DRUG|Placebo capsule|
214250099|NCT00433511|BIOLOGICAL|Bevacizumab|Given IV
214250100|NCT00433511|DRUG|Cyclophosphamide|Given IV
214250101|NCT00433511|DRUG|Doxorubicin Hydrochloride|Given IV
214250102|NCT00433511|OTHER|Laboratory Biomarker Analysis|Correlative studies
214250103|NCT00433511|DRUG|Paclitaxel|Given IV
214250104|NCT00433511|OTHER|Placebo Administration|Given IV
214250105|NCT00433511|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
214250106|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
214250107|NCT06183502|BEHAVIORAL|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer not to take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
214250108|NCT06183502|PROCEDURE|HIV and STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
214250109|NCT06183502|BEHAVIORAL|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
214250110|NCT03240731|BIOLOGICAL|bone marrow transplant|haploidentical bone marrow transplant
214250111|NCT04474132|DEVICE|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
214250112|NCT03139604|DRUG|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
214250113|NCT03139604|DRUG|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
214652890|NCT01827384|DRUG|Everolimus|Given by mouth (PO)
214652891|NCT01827384|DRUG|Temozolomide|Given by mouth (PO)
214652892|NCT01827384|DRUG|Trametinib|Given by mouth (PO)
214652893|NCT01827384|DRUG|Veliparib|Given by mouth (PO)
214250114|NCT03139604|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
214250115|NCT03139604|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
214250116|NCT05669482|DRUG|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
214250117|NCT06635395|OTHER|Scale validity and reliability|The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
214250118|NCT05977439|DEVICE|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
214250119|NCT05977439|DEVICE|fNIRS-EEG-TMS|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
214250120|NCT05977439|DEVICE|fNIRS-EEG-rTMS Interleaved with CBT|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
214250121|NCT03322891|OTHER|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
214250122|NCT03322891|OTHER|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
214250123|NCT06003712|BEHAVIORAL|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
214250124|NCT05912413|OTHER|there is no intervention|there is no intervention
214250125|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
214250126|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
214250127|NCT05693805|BEHAVIORAL|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
214250128|NCT05693805|BEHAVIORAL|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
214250129|NCT06121466|DRUG|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
214250130|NCT06495424|DRUG|Capsaicin 8%|Repeat applications every 12 weeks in patients with PDPN of the feet.
214250131|NCT06387030|BIOLOGICAL|Blood sampling|3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
214250132|NCT06387030|BIOLOGICAL|Esophageal biopsies|4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
214250133|NCT06387030|BIOLOGICAL|Unstimulated saliva sampling|A esophageal brushing will be done during digestive endoscopy.
214652894|NCT02368327|BIOLOGICAL|Fluad|
214652895|NCT02368327|BIOLOGICAL|Fendrix|
214652896|NCT02368327|BIOLOGICAL|Placebo|
214652897|NCT00584961|OTHER|non-interventional|non-interventional
214652898|NCT05010460|DRUG|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
214652899|NCT05010460|DRUG|Placebo|orally 100mg every other day for 5-8 days prior to CABG
214652900|NCT01110252|DRUG|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
214652901|NCT01110252|PROCEDURE|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
214652902|NCT01110252|GENETIC|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
214652903|NCT01902979|BEHAVIORAL|Lifestyle intervention|
214652904|NCT00804115|DRUG|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
214250134|NCT06387030|BIOLOGICAL|Urine sampling|A urine sample will be collected during hospitalization for digestive endoscopy.
214250135|NCT06387030|BIOLOGICAL|Stool sampling|A stool sample will be collected during hospitalization for digestive endoscopy.
214250136|NCT05488483|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
214250137|NCT06070441|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
214250138|NCT06070441|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
214250139|NCT06070441|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
214250140|NCT06042257|DRUG|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
214250141|NCT06042257|DRUG|Placebo|Matching placebo capsule
214250142|NCT04902053|DIAGNOSTIC_TEST|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
214250143|NCT04449991|PROCEDURE|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI \> 3
214250144|NCT05785429|DRUG|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
214250145|NCT05785429|DRUG|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
214250146|NCT03844607|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
214250147|NCT03844607|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
214250148|NCT03606044|DEVICE|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
214250149|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
214250150|NCT05940311|PROCEDURE|Blood sampling in addition to the blood normally required for their clinical management|Patients will undergo blood sampling in addition to the blood normally required for their clinical management. The study aims to collect 50 blood samples (one to 4) from 20 patients undergoing treatment in the adjuvant or advanced (metastatic) setting, as per standard of care. The first blood sample (T1) will be carried out immediately before the treatment, the subsequent blood samples (T2-T4) will coincide with the periodic radiographic re-evaluations, typically at months 3 and 6 (M3 and M6, T2 and T3), and at progression/recurrence, if and when recorded.
214250151|NCT05940311|PROCEDURE|Blood plasma and circulating tumor DNA (ctDNA)|Blood drawing by venepuncture (elbow) in K2EDTA vacutainers to obtain blood plasma.The patients will otherwise receive the most appropriate treatment for their condition. The following data will be collected and pseudo-anonymised: demographic data (age and gender), histopathology including primary and metastatic sites, BRAF status, medical imaging, previous therapies assigned if any
214250152|NCT04349514|OTHER|Natural history|Longitudinal observation of neuroimaging, clinical, and blood markers.
214250153|NCT00585559|DRUG|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
214250154|NCT00585559|DRUG|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
214250155|NCT00585559|DRUG|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
214250156|NCT00585559|DRUG|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
214250157|NCT00585559|DRUG|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
214250158|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
214250159|NCT06191380|BEHAVIORAL|PACE-MS|A single bout of cycling.
214250160|NCT01953640|OTHER|Laboratory Biomarker Analysis|Correlative studies
214250161|NCT01953640|OTHER|Quality-of-Life Assessment|Ancillary studies
214250162|NCT04418440|DIETARY_SUPPLEMENT|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
214250163|NCT04803877|DRUG|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
214250164|NCT04803877|DRUG|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
214652905|NCT06043440|DRUG|Oxygen|Active nocturnal oxygen concentrator
214250165|NCT04803877|DRUG|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
214250166|NCT06079190|DRUG|GSK4527226|GSK4527226 will be administered.
214250167|NCT06079190|OTHER|Placebo|Placebo will be administered.
214250168|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
214250169|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
214250170|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
214250171|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
214250172|NCT06833359|OTHER|Observation|The Cervical Disability Index will be taught individually online through the Google questionnaire.
214250173|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
214250174|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
214250175|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
214250176|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
214250177|NCT05417737|OTHER|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
214250178|NCT06328361|PROCEDURE|Nonoperative surveillance|Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
214250179|NCT06486441|DRUG|Sacituzumab govitecan-hziy|Administered intravenously
214250180|NCT06486441|DRUG|Doxorubicin|Administered intravenously
214250181|NCT06486441|DRUG|Paclitaxel|Administered intravenously
214250182|NCT02379338|DRUG|[18F]Fluortriopride|All subjects will receive a \[18F\]Fluortriopride PET/CT scan
214250183|NCT05507008|DIETARY_SUPPLEMENT|Kenetik Ketone Drink|BHB supplementation
214250184|NCT06347159|DRUG|EDG-7500|Liquid suspension formulation of EDG-7500
214250185|NCT06347159|DRUG|EDG-7500|Solid oral formulation of EDG-7500
214250186|NCT06403514|OTHER|Psychological Skills Training (PST)|PST will include self-talk, imagery, goal-setting and arousal regulation (Biofeedback)
214250187|NCT06462547|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
214250188|NCT06848088|DRUG|Fianlimab+cemiplimab|No study drug administered in this observational study.
214250189|NCT04632953|OTHER|No Intervention|No Intervention
214250190|NCT01165632|PROCEDURE|biopsy|Correlative studies
214250191|NCT01165632|PROCEDURE|computed tomography|Undergo computed tomography
214250192|NCT01165632|PROCEDURE|therapeutic conventional surgery|Undergo stereotactic craniotomy
214250193|NCT01165632|RADIATION|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
214250194|NCT01165632|RADIATION|radiation therapy|Undergo radiation therapy
214250195|NCT01165632|PROCEDURE|magnetic resonance imaging|Undergo magnetic resonance imaging
214250196|NCT01165632|PROCEDURE|positron emission tomography|Undergo positron emission tomography
214250197|NCT01165632|DRUG|fluorine F 18 fluorodopa|Given IV
214250198|NCT06427083|DRUG|Envlo Tablet|Enavogliflozin 0.3mg
214250199|NCT06427083|DRUG|Envolomet SR Tablet|Enavogliflozin 0.3mg/Metformin1,000mg
214250200|NCT06347107|DEVICE|Robotic subretinal tPA injection|-The insertion of a 41G subretinal needle adjacent to a subretinal hemorrhage using the stabilizing (tremor-reducing) properties of a robotic instrument in order to slowly inject tPA and evaluate whether the needle can be held in place for up tot 3 minutes.
214250201|NCT06101784|DRUG|Avenanthramide|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
214250202|NCT06101784|DRUG|Placebo|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
214250203|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
214250204|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
214250205|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
214250206|NCT04851184|DEVICE|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
214250207|NCT04851184|BEHAVIORAL|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
214250208|NCT05336045|PROCEDURE|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
214250209|NCT04924179|DRUG|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
214250210|NCT04205097|DRUG|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
214250211|NCT04205097|DRUG|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
214250212|NCT03355118|OTHER|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
214250213|NCT03899688|PROCEDURE|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
214250214|NCT04374968|DEVICE|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
214250215|NCT02902978|DRUG|E6130|
214250216|NCT02902978|DRUG|Placebo|E6130 matched placebo
214250217|NCT04816201|OTHER|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
214250218|NCT05016284|OTHER|JW-100|Cosmetic CBD cream (JW-100)
214250219|NCT05016284|DRUG|Eucrisa|Topical EUCRISA®, Pfizer
214250220|NCT03986632|BEHAVIORAL|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
214250221|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
214250222|NCT02145507|DRUG|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
214250223|NCT02145507|DRUG|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
214250224|NCT01182779|RADIATION|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
214250225|NCT01182779|RADIATION|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
214250226|NCT01490970|OTHER|Database|Database
214250227|NCT01807702|DRUG|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
214250228|NCT03277079|DRUG|statin + ezetimibe|Combination of two drugs
214250229|NCT03277079|DRUG|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
214250230|NCT02811601|PROCEDURE|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
214250231|NCT04499547|BEHAVIORAL|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
214250232|NCT06274528|DRUG|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
214652906|NCT03170752|BEHAVIORAL|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
214250233|NCT06274528|DRUG|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
214250234|NCT06274528|DRUG|Placebo|0 mg; capsule; QD; 6 month duration
214250235|NCT00608543|DRUG|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
214250236|NCT00869427|DRUG|vitamin C|vitamin C 1g bid for 1 year
214250237|NCT01654861|DRUG|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
214250238|NCT03137030|DRUG|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
214250239|NCT03137030|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
214250240|NCT00095680|DRUG|SCIO-469|two 30-mg capsules three times daily
214250241|NCT00095680|DRUG|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
214250242|NCT05859555|OTHER|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
214250243|NCT01076816|DRUG|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
214250244|NCT01076816|PROCEDURE|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
214250245|NCT01076816|PROCEDURE|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
214250246|NCT05984368|DRUG|BG136|Subjects injected with BG136 in Part 1 and Part 2
214250247|NCT05984368|DRUG|Placebo|Subjects injected with Placebo in Part 1 and Part 2
214250248|NCT00366015|PROCEDURE|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
214250249|NCT00366015|PROCEDURE|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
214250250|NCT02722096|DRUG|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
214250251|NCT02722096|DRUG|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
214250252|NCT03026088|DRUG|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
214250253|NCT05390190|DEVICE|Non ablative radiofrequency|Device
214250254|NCT03565965|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
214250255|NCT03565965|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
214250256|NCT04949971|BEHAVIORAL|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
214250257|NCT05162040|DEVICE|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
214250258|NCT01536288|DRUG|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
214250259|NCT01536288|DRUG|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
214250260|NCT04174950|OTHER|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
214652907|NCT03720171|DEVICE|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
214652908|NCT01404663|BIOLOGICAL|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
214250261|NCT04174950|OTHER|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
214250262|NCT01522885|DEVICE|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
214250263|NCT01522885|PROCEDURE|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
214250264|NCT03574480|BEHAVIORAL|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
214250265|NCT03574480|BEHAVIORAL|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
214250266|NCT00300118|DRUG|budesonide|9 mg
214250267|NCT00300118|DRUG|mesalazine|4.5 g
214250268|NCT00003930|DRUG|cisplatin|
214250269|NCT00003930|DRUG|gemcitabine hydrochloride|
214250270|NCT00003930|DRUG|paclitaxel|
214250271|NCT00003930|PROCEDURE|conventional surgery|
214250272|NCT00003930|RADIATION|radiation therapy|
214250273|NCT02769676|OTHER|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
214250274|NCT02769676|OTHER|usual care|Participants in the usual care arm will receive no additional interventions.
214250275|NCT05455762|OTHER|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
214250276|NCT00033072|DRUG|Selegiline|
214250277|NCT01825603|DRUG|ADH-1|Given IV
214250278|NCT01825603|DRUG|Cisplatin|Given IV
214250279|NCT01825603|DRUG|Gemcitabine Hydrochloride|Given IV
214250280|NCT01825603|OTHER|Laboratory Biomarker Analysis|Correlative studies
214250281|NCT02517970|BEHAVIORAL|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
214250282|NCT06313879|OTHER|online education|Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.
214250283|NCT03004196|DRUG|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
214250284|NCT03004196|DRUG|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
214250285|NCT03004196|OTHER|Control Group|No Probiotic toothpaste \& Chlorhexidine Mouthwash
214250286|NCT03981302|OTHER|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
214250287|NCT04406285|OTHER|Standard protocol Leukemia|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
214250288|NCT04406285|OTHER|Periodic Resistance Training Program Leukemia|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
214250289|NCT04406285|OTHER|Standard protocol Lymphoma|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
214250290|NCT04406285|OTHER|Periodic Resistance Training Program Lymphoma|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
214250291|NCT05821673|PROCEDURE|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
214250292|NCT05821673|PROCEDURE|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
214250293|NCT04383899|OTHER|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
214250294|NCT04768673|DRUG|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
214250295|NCT04768673|DRUG|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
214250296|NCT04768673|DRUG|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
214250297|NCT05350735|BEHAVIORAL|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
214250298|NCT01869725|DRUG|gallium Ga 68-edotreotide|Given IV
214250299|NCT01869725|PROCEDURE|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
214250300|NCT01869725|RADIATION|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
214250301|NCT01869725|PROCEDURE|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
214250302|NCT01869725|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
214250303|NCT01143207|DRUG|Medroxyprogesterone acetate|Injectable hormonal contraceptive
214250304|NCT02235259|DRUG|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
214250305|NCT02235259|DRUG|Placebo|
214250306|NCT03490968|BEHAVIORAL|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
214250307|NCT03490968|BEHAVIORAL|Vascular Assessment|"Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
214250308|NCT00123968|BIOLOGICAL|VRC-HIVDNA016-00-VP|1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
214250309|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
214250310|NCT00123968|BIOLOGICAL|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
214250311|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
214250312|NCT01669564|OTHER|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
214250313|NCT01669564|OTHER|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
214250314|NCT00281073|DEVICE|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
214818152|NCT06045598|OTHER|Montreal Cognitive Assessment|MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.
214250315|NCT00281073|DEVICE|Intracardiac Echo|Intracardiac Echo Viewmate
214250316|NCT00281073|DEVICE|ICE|ICE or TEE
214250317|NCT04457973|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
214250318|NCT04457973|DEVICE|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
214250319|NCT01056328|DEVICE|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
214250320|NCT01056328|DEVICE|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
214250321|NCT00187759|DRUG|cephalexin|
214250322|NCT02960997|DRUG|Sirolimus, 2%|
214250323|NCT02960997|DRUG|Vehicle|
214250324|NCT05920928|RADIATION|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
214250325|NCT05920928|RADIATION|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
214250326|NCT01639586|BEHAVIORAL|respite platform|Impact of the respite platform patient care on health profit
214250327|NCT01639586|BEHAVIORAL|Day care|Impact of the day care on health profit of patient
214250328|NCT01639586|BEHAVIORAL|No access to a respite structure|Control group without access to a respite structure
214250329|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
214250330|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
214250331|NCT01553032|DRUG|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
214250332|NCT01553032|RADIATION|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
214250333|NCT00218725|BEHAVIORAL|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
214250334|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
214250335|NCT00003301|DRUG|irinotecan hydrochloride|
214250336|NCT00902733|OTHER|medical chart review|
214250337|NCT00902733|OTHER|questionnaire administration|
214250338|NCT00902733|PROCEDURE|fatigue assessment and management|
214250339|NCT00902733|PROCEDURE|psychosocial assessment and care|
214250340|NCT00902733|PROCEDURE|quality-of-life assessment|
214250341|NCT01218633|DRUG|saline infusion|saline infused at 30ml/hour
214250342|NCT01218633|DRUG|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
214250343|NCT01218633|DRUG|Exendin-9,39 at low dose|infused at 30pmol/kg/min
214250344|NCT01218633|DRUG|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
214250345|NCT04824365|DRUG|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
214250346|NCT04824365|OTHER|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
214250347|NCT03395054|OTHER|cervical stabilization exercises|cervical stabilization exercises
214250348|NCT03395054|OTHER|conventional exercises|conventional exercises
214250349|NCT03792425|PROCEDURE|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
214250350|NCT01577654|DRUG|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
214250351|NCT01577654|DRUG|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
214250352|NCT01577654|DRUG|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
214250353|NCT01577654|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
214250354|NCT02193698|DRUG|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
214250355|NCT05931588|OTHER|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
214250356|NCT05931588|OTHER|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
214250357|NCT01770652|DRUG|Deferiprone|Oral iron chelator
214250358|NCT05542134|DIAGNOSTIC_TEST|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
214250359|NCT00185653|PROCEDURE|Autologous followed by non-myeloablative allogeneic transplantation|
214250360|NCT00010127|BIOLOGICAL|therapeutic autologous dendritic cells|
214250361|NCT03416374|DRUG|Ixazomib|Ixazomib capsules
214250362|NCT03416374|DRUG|Bortezomib|Bortezomib injections
214250363|NCT03416374|DRUG|Carfilzomib|Carfilzomib intravenous infusions
214250364|NCT03416374|DRUG|Lenalidomide|Lenalidomide capsules
214250365|NCT03416374|DRUG|Dexamethasone|Dexamethasone tablets
214250366|NCT04282512|OTHER|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
214250367|NCT00928798|DRUG|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
214250368|NCT00928798|DRUG|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
214250369|NCT01165190|OTHER|pioglitazone|
214250370|NCT05156476|PROCEDURE|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
214250371|NCT05156476|PROCEDURE|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
214250372|NCT05156476|PROCEDURE|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
214250373|NCT04327310|DRUG|Meplazumab for Injection|humanized mAb against CD147
214250374|NCT04327310|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
214250375|NCT01266941|DRUG|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
214250376|NCT02147002|DIETARY_SUPPLEMENT|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
214250377|NCT01052844|DRUG|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
214250378|NCT01052844|DRUG|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
214250379|NCT03599401|OTHER|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
214250380|NCT03671993|PROCEDURE|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
214250381|NCT03671993|PROCEDURE|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
214250382|NCT02647840|BEHAVIORAL|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
214250383|NCT06252298|BIOLOGICAL|SCTC21C|SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
214250384|NCT01159977|BEHAVIORAL|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
214250385|NCT01159977|BEHAVIORAL|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
214250386|NCT01159977|BEHAVIORAL|Usual practice|No protected time provided.
214250387|NCT03472066|OTHER|Previous conization|a group of women who have been conized,
214250388|NCT03472066|OTHER|no previous conization|group with asymptomatic patients on routine second trimester echography
214250389|NCT03463031|DRUG|GSP 301 NS|1 spray in each nostril twice daily for 14 days
214250390|NCT03463031|DRUG|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
214250391|NCT02171702|DRUG|BIBW 2992|
214250392|NCT00290212|DRUG|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
214250393|NCT00290212|DRUG|Placebo capsules|
214250394|NCT03508271|OTHER|Non-Interventional|Non-Interventional
214250395|NCT02744469|OTHER|No intervention (observational study)|
214250396|NCT04348890|DRUG|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
214250397|NCT06081400|PROCEDURE|Cryoablation|Percutaneous imaging-guided cryoablation
214652909|NCT03327233|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
214652910|NCT04144439|DRUG|GABA|Gamma amino butyric acid
214652911|NCT03952260|OTHER|Fasting time for clear fluid prior to anaesthesia|"This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery."
214652912|NCT01233206|DRUG|Metformin|Metformin pre-treatment and co-administration
214250398|NCT06081400|DRUG|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
214250399|NCT04709939|OTHER|OPAT|Observation of patients who are discharged from the hospital on OPAT.
214250400|NCT04709939|OTHER|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
214250401|NCT05572190|DRUG|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
214250402|NCT01133561|DRUG|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
214250403|NCT01133561|DRUG|actozone B|one tablet of vehicle without active ingredient pioglitazone
214250404|NCT02160353|DRUG|Abiraterone acetate, Prednisolone|
214250405|NCT02803762|DRUG|Pacritinib|400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
214250406|NCT03512990|PROCEDURE|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
214250407|NCT00920231|DEVICE|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
214250408|NCT00920231|DEVICE|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
214250409|NCT06552247|DIAGNOSTIC_TEST|Fundus Picture AI testing|G-Risk AI algorithm will assess the optic disc centered fundus picture and determine whether or not there is a need for referrable based on a pre-determined threshold (\>=0.73)
214250410|NCT01013298|DEVICE|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
214250411|NCT04792515|DRUG|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
214250412|NCT02891811|DRUG|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
214250413|NCT02891811|DRUG|Thalidomide|100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
214250414|NCT02891811|DRUG|Lenalidomide|25mg p.o. on days 1-21 of each cycle
214250415|NCT02891811|DRUG|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
214250416|NCT00154726|DRUG|Paclitaxel-HDFL|
214250417|NCT01137318|BEHAVIORAL|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
214250418|NCT03110731|BEHAVIORAL|Physical training|Physical training (2x / week) was performed for 12 weeks
214250419|NCT01822704|DEVICE|Low intensity whole body vibration|
214250420|NCT01822704|DEVICE|High intensity whole body vibration|
214250421|NCT01822704|BEHAVIORAL|Leg exercises|
214250422|NCT00454701|DRUG|Alefacept exposure|Observational
214250423|NCT01684020|BIOLOGICAL|ARTISS human fibrin sealant|
214250424|NCT00240695|DRUG|galantamine hydrobromide|
214652913|NCT01233206|DRUG|Placebo administration|Placebo pre-treatment and co-administration
214652914|NCT04946266|PROCEDURE|Surgical intervention|Surgical intervention with collection of tissue material
214652915|NCT06271525|OTHER|cupping therapy|"All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~1. -Primary sucking~2. -Scarification 3- Bloodletting 4-Removal~5 -Dressing"
214652916|NCT01370967|OTHER|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
214250425|NCT01727843|DRUG|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
214250426|NCT01727843|OTHER|placebo|applied topically to surgical site in OR.
214250427|NCT01429038|BIOLOGICAL|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
214250428|NCT06007859|OTHER|section orientation|The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
214250429|NCT04448782|DIAGNOSTIC_TEST|Asynchronies detection|Asycnhronies detection
214250430|NCT02537574|DRUG|NTX/BUP|Daily doses
214250431|NCT02537574|DRUG|NTX/PBO-B|Daily doses
214250432|NCT02537574|DRUG|PBO-N/PBO-B|Daily doses
214250433|NCT02891005|DEVICE|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
214250434|NCT02891005|DEVICE|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
214250435|NCT00190944|DRUG|Teriparatide|
214250436|NCT00190944|DRUG|placebo|
214250437|NCT00246688|DRUG|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
214250438|NCT02359162|DRUG|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
214250439|NCT02359162|DRUG|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
214250440|NCT02359162|DRUG|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
214250441|NCT02359162|DRUG|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
214250442|NCT02359162|DRUG|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
214250443|NCT02359162|DRUG|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
214652917|NCT01370967|OTHER|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
214250444|NCT02359162|DRUG|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
214250445|NCT02359162|DRUG|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
214652918|NCT01370967|OTHER|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
214652919|NCT04141176|DEVICE|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
214652920|NCT00288574|DRUG|Fluoxetine|
214652921|NCT00288574|DRUG|Placebo|
214652922|NCT03623867|DRUG|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
214652923|NCT03623867|DRUG|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
214250446|NCT02359162|RADIATION|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
214250447|NCT00926068|DRUG|HO/03/03 10µg|
214250448|NCT00926068|DRUG|Placebo|
214250449|NCT05440071|DEVICE|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
214250450|NCT05812079|DIAGNOSTIC_TEST|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
214250451|NCT02428985|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
214250452|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|2.5mg po daily
214250453|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
214250454|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
214250455|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|150mg po monthly
214250456|NCT00048061|DIETARY_SUPPLEMENT|Calcium|500 mg/day
214250457|NCT00048061|DIETARY_SUPPLEMENT|Vitamin D|400 IU/day
214250458|NCT02245204|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
214250459|NCT03560830|OTHER|2 submaximal exercise stress tests|
214250460|NCT05315856|BIOLOGICAL|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
214250461|NCT05450978|DRUG|Lamotrigine|Anti-seizure concentrations
214250462|NCT05450978|DRUG|Levetiracetam|Anti-seizure concentrations
214250463|NCT05450978|DRUG|Oxcarbazepine|Anti-seizure concentrations
214250464|NCT05979779|DRUG|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
214250465|NCT05979779|OTHER|Placebo|Placebo
214250466|NCT06051448|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|This program teaches the four pillars of resilience (stress management, goal setting, cognitive restructuring, and benefit-finding) in a one-on-one training program consisting of four 20-30 minute sessions occurring once weekly.
214250467|NCT06051448|BEHAVIORAL|Clinical-focused narrative (CFN)|This program consists of questions posed to adults with primary mitochondrial disease at regular mitochondrial medicine center visits. Specific topics will be discussed at each session. This consists four 20-30 minute sessions occurring once weekly.
214250468|NCT06524895|OTHER|Medical Reiki|Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
214250469|NCT06524895|OTHER|Sham Reiki|Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
214250470|NCT02675231|DRUG|Abemaciclib|Administered Orally
214250471|NCT02675231|DRUG|Trastuzumab|Administered IV
214250472|NCT02675231|DRUG|Fulvestrant|Administered IM
214250473|NCT02675231|DRUG|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
214250474|NCT06370325|PROCEDURE|VPOD Wireless Tens Unit|The VPOD unit will deliver NMES to participants in the Intervention Group.
214250475|NCT06370325|PROCEDURE|Physical Therapy|Physical therapy as per standard of care.
214250476|NCT06370325|DEVICE|Biodex|Used to assess strength, endurance, power, and range of motion.
214250477|NCT05468476|OTHER|No intervention|No intervention
214250478|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
214250479|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
214250480|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
214250481|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
214250482|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
214250483|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
214250484|NCT05133492|DEVICE|Endovascular Aneurysm Stabilization Treatment (EAST)|Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.
214250485|NCT02610569|DEVICE|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
214250486|NCT02610569|DEVICE|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
214250487|NCT05279079|DIAGNOSTIC_TEST|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
214250488|NCT06490445|DRUG|Medical Cannabis|Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
214250489|NCT06490445|DRUG|Placebo|Placebo administered using Fixed-dose Syqe Inhaler.
214250490|NCT06144840|DRUG|Dersimelagon|MT-7117
214250491|NCT06144840|DRUG|Placebo|Placebo
214250492|NCT05734430|GENETIC|Genetic profiling|Whole exome sequencing
214250493|NCT05734430|OTHER|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
214250494|NCT03392324|DEVICE|PRIMA|Implantation of PRIMA device
214250495|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
214250496|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
214250497|NCT04677413|RADIATION|Ultrafractionated radiotherapy for rectal cancer|To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
214250498|NCT05788796|BEHAVIORAL|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
214250499|NCT02495233|DRUG|Gilteritinib|oral
214250500|NCT02495233|DRUG|Erlotinib|oral
214250501|NCT04232553|DRUG|Mirikizumab|Administered IV
214250502|NCT04232553|DRUG|Mirikizumab|Administered SC
214250503|NCT01875224|DRUG|Belatacept|
214250504|NCT01875224|DRUG|Tacrolimus|Standard administration of tacrolimus
214250505|NCT05304832|OTHER|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
214250506|NCT05304832|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
214250507|NCT01873703|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi)
214250508|NCT01873703|DRUG|Placebo|Placebo
214250509|NCT01873703|DRUG|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
214250510|NCT00672204|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
214250511|NCT00672204|DRUG|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
214250512|NCT00672204|DRUG|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
214250513|NCT00672204|DRUG|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
214250514|NCT01295268|OTHER|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
214250515|NCT01295268|OTHER|Inert oil|A specified amount of inert oil will be applied daily to area.
214250516|NCT01973530|PROCEDURE|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
214250517|NCT01973530|PROCEDURE|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
214250518|NCT04722653|DRUG|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
214250519|NCT04722653|DRUG|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
214250520|NCT06391801|BEHAVIORAL|Neuroathletic training|Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
214250521|NCT06391801|BEHAVIORAL|Traditional movement therapy in outpatient rehabilitation|Traditional movement therapy in outpatient rehabilitation
214250522|NCT05684939|BEHAVIORAL|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
214250523|NCT06190353|BEHAVIORAL|An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.|An eight module self help program
214250524|NCT00004076|DRUG|mureletecan|
214818153|NCT00579345|BIOLOGICAL|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
214250525|NCT00246779|PROCEDURE|Modified ultrafiltration|
214250526|NCT03703596|DRUG|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
214250527|NCT03703596|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
214250528|NCT03415854|DRUG|Paricalcitol (Zemplar)|combination therapy
214250529|NCT03143881|BEHAVIORAL|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
214250530|NCT05064839|PROCEDURE|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
214250531|NCT00000188|DRUG|Selegiline|
214250532|NCT05494320|DRUG|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
214250533|NCT02264873|DRUG|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
214250534|NCT00506610|DRUG|T-62|
214250535|NCT05495087|DEVICE|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
214250536|NCT05495087|OTHER|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
214250537|NCT03038451|DRUG|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
214250538|NCT02981355|PROCEDURE|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
214250539|NCT02981355|DEVICE|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
214250540|NCT04972747|OTHER|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
214250541|NCT06260761|PROCEDURE|MIPO|minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
214250542|NCT06260761|PROCEDURE|Conventional|standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
214250543|NCT04609111|DRUG|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
214250544|NCT04609111|DRUG|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
214250545|NCT00546221|BEHAVIORAL|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
214250546|NCT00546221|BEHAVIORAL|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
214250547|NCT01642121|OTHER|laboratory biomarker analysis|Correlative studies
214250548|NCT00833079|DRUG|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
214250549|NCT00833079|DRUG|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
214250550|NCT00833079|DRUG|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
214250551|NCT02914821|BEHAVIORAL|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
214250552|NCT00600509|DRUG|Levetiracetam|
214250553|NCT04585139|DEVICE|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
214250554|NCT00248885|PROCEDURE|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
214250555|NCT06286371|PROCEDURE|Laparoscopic Endometriosis Surgery|Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
214250556|NCT03231150|PROCEDURE|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
214250557|NCT03231150|PROCEDURE|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
214250558|NCT03231150|PROCEDURE|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
214250559|NCT02503995|BEHAVIORAL|Physical Exercise Participation|
214250560|NCT02220998|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
214250561|NCT02220998|DRUG|SOF|SOF 400 mg tablet administered orally once daily
214250562|NCT02220998|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214250563|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
214250564|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
214250565|NCT02314143|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
214250566|NCT02314143|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
214250567|NCT02354482|BEHAVIORAL|Patient Communication and Care Management|"Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers"
214250568|NCT02354482|BEHAVIORAL|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment"
214250569|NCT02354482|BEHAVIORAL|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers"
214250570|NCT02354482|BEHAVIORAL|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment"
214250571|NCT02354482|BEHAVIORAL|Assessment and Teach Back|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills"
214250572|NCT02354482|OTHER|Standard of Care (Reference)|No specific Transitional Care Strategy
214250573|NCT00873860|OTHER|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
214250574|NCT00873860|BIOLOGICAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
214250575|NCT00873860|BIOLOGICAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
214250576|NCT00873860|BIOLOGICAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
214250577|NCT02818647|PROCEDURE|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
214250578|NCT02448342|DEVICE|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
214250579|NCT01022827|OTHER|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes \[about 6 minutes for each muscle and order was random\] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
214250580|NCT04507854|OTHER|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
214250581|NCT02734420|DRUG|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
214250582|NCT02734420|DRUG|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
214250583|NCT02734420|DEVICE|Laser|
214250584|NCT02436642|DEVICE|AVERT Plus System|
214652924|NCT04888663|DRUG|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
214652925|NCT00382031|DRUG|Zalutumumab|Individual dose titration weekly i.v doses
214652926|NCT00382031|OTHER|Control|Best Supportive Care
214652927|NCT03639948|DRUG|Carboplatin|Intravenous solution
214652928|NCT03639948|DRUG|Docetaxel|Intravenous solution
214652929|NCT03639948|DRUG|Pembrolizumab|Intravenous solution
214652930|NCT03639948|DRUG|Pegfilgrastim|Injectable product
214250585|NCT02252276|PROCEDURE|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
214250586|NCT02252276|PROCEDURE|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
214250587|NCT01936402|BEHAVIORAL|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
214250588|NCT00708071|BIOLOGICAL|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
214250589|NCT01164384|DRUG|Baminercept|
214250590|NCT02140775|BEHAVIORAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
214250591|NCT01304784|DRUG|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
214250592|NCT01304784|DRUG|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
214250593|NCT01304784|DRUG|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
214250594|NCT01304784|DRUG|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
214250595|NCT01304784|DRUG|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
214250596|NCT02710500|DRUG|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
214250597|NCT00329940|DRUG|Letrozole|
214250598|NCT00079014|DRUG|triapine|Given IV
214250599|NCT00079014|DRUG|doxorubicin hydrochloride|Given IV
214250600|NCT00079014|OTHER|laboratory biomarker analysis|Correlative studies
214250601|NCT00079014|OTHER|pharmacological study|Correlative studies
214652931|NCT01260103|DRUG|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
214250602|NCT00081965|PROCEDURE|acupuncture therapy|
214250603|NCT00081965|PROCEDURE|hot flashes attenuation|
214250604|NCT00081965|PROCEDURE|management of therapy complications|
214250605|NCT05540080|DEVICE|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
214250606|NCT01766700|BEHAVIORAL|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
214250607|NCT01766700|BEHAVIORAL|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
214250608|NCT04800666|PROCEDURE|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
214250609|NCT04800666|PROCEDURE|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
214250610|NCT04800666|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
214250611|NCT06515028|PROCEDURE|Group GA|Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.
214652932|NCT01260103|DRUG|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
214652933|NCT03883737|OTHER|PNM|an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
214652934|NCT04880928|DRUG|Eye injection (Mydrane)|"Mydrane 0.2 mg/ml + 3.1 mg/ml~\+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride"
214652935|NCT04880928|DRUG|eye drops (Phenylephrin)|Phenylephrine 10%
214652936|NCT04880928|DRUG|eye drops (Tropicamid)|Tropicamid 0,5%
214652937|NCT03849339|DRUG|CKD-387|Test drug
214652938|NCT03849339|DRUG|D635|Reference drug
214652939|NCT05136963|DRUG|Iohexol|5 milliliter of iohexol will be administrated.
214652940|NCT05136963|BIOLOGICAL|pharmacokinetics|10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
214250612|NCT06515028|PROCEDURE|Group IB|infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
214250613|NCT01795378|BIOLOGICAL|donor natural killer cell infusion|"* Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~* The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~* For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~* The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
214250614|NCT02669654|OTHER|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
214250615|NCT06178705|BEHAVIORAL|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
214250616|NCT00945854|OTHER|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
214250617|NCT00945854|OTHER|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
214250618|NCT06278610|DIAGNOSTIC_TEST|PELVIC EXENTERATION|PELVIC EXENTERATION
214250619|NCT03927599|OTHER|Data Collection|Colleciton of data from medical records only
214250620|NCT04650646|OTHER|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
214250621|NCT04650646|OTHER|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
214250622|NCT06477224|OTHER|Scooter Board Activities|Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.
214250623|NCT06477224|OTHER|Routine Physical Therapy|Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
214250624|NCT04650854|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
214250625|NCT04631302|BEHAVIORAL|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
214250626|NCT04631302|BEHAVIORAL|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
214250627|NCT00704808|PROCEDURE|Primary surgical treatment|Primary surgery for tumor resection.
214250628|NCT00704808|RADIATION|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
214250629|NCT00704808|DRUG|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
214652941|NCT00054587|BIOLOGICAL|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
214652942|NCT00054587|DRUG|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
214250630|NCT02025062|OTHER|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
214250631|NCT01091337|DRUG|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~\+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
214250632|NCT01091337|DRUG|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
214250633|NCT06409403|DEVICE|clinical application of robotic technique|effect of various surgical technique on clinical efficacy of TME
214250634|NCT06071936|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214250635|NCT06071936|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214250636|NCT03862716|DRUG|IDegLira|Dose is titrated to achieve fasting normoglycemia
214250637|NCT03862716|DRUG|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
214250638|NCT03862716|DRUG|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
214250639|NCT03862716|BEHAVIORAL|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
214250640|NCT01462786|DRUG|ATX-101|2 mg/cm2 ATX-101
214250641|NCT05321160|DRUG|Esketamine|0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
214250642|NCT05321160|DRUG|Sevoflurane|4% sevoflurane for induction and 2-4% sevoflurane for maintain
214250643|NCT01388920|DRUG|Tesamorelin|
214250644|NCT01388920|DRUG|Placebo|
214250645|NCT01858311|DIETARY_SUPPLEMENT|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
214250646|NCT01858311|OTHER|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
214250647|NCT03583515|BEHAVIORAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
214250648|NCT03583515|BEHAVIORAL|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
214250649|NCT04598464|OTHER|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
214250650|NCT00727831|DRUG|glucarpidase|
214250651|NCT00727831|DRUG|leucovorin calcium|
214250652|NCT00727831|DRUG|methotrexate|
214250653|NCT00727831|OTHER|laboratory biomarker analysis|
214250654|NCT00727831|PROCEDURE|quality-of-life assessment|
214250655|NCT00727831|RADIATION|radiation therapy|
214250656|NCT01280955|DRUG|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
214250657|NCT00749554|DEVICE|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
214250658|NCT00749554|DEVICE|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
214250659|NCT05246904|OTHER|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
214250660|NCT06380829|OTHER|Questionnaire|Self-Care Assessment Scale for Children with CP aged 3-6 years - Parent Form (SPÇÖS-EF): A draft scale named SPÇÖS-EF was prepared by the researchers, using the literature, to determine the self-care status of children with cerebral palsy aged 3-6.
214250661|NCT01497327|DRUG|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
214250662|NCT01497327|DRUG|PSI-7977|PSI-7977 400mg QD for seven days
214250663|NCT00904306|DIETARY_SUPPLEMENT|Sugar Pill|placebo oral tablet taken once per day
214250664|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|1000 ug/day chromium picolinate for 6 months
214250665|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|600 ug/day chromium picolinate
214250666|NCT04295655|OTHER|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
214250667|NCT04295655|OTHER|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
214250668|NCT04295655|OTHER|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
214250669|NCT04461249|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
214250670|NCT04461249|DRUG|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
214250671|NCT04461249|DRUG|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
214250672|NCT01314157|OTHER|Isostretching|12 interventions (two times per week) for 45 minutes
214250673|NCT05360368|DRUG|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
214250674|NCT04749511|BEHAVIORAL|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
214250675|NCT02632643|BEHAVIORAL|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
214250676|NCT04223232|DRUG|[14C]-MD1003|single oral dose of 100mg \[14C\]-MD1003
214250677|NCT03860142|BEHAVIORAL|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
214250678|NCT03660631|BEHAVIORAL|CVRS Intervention|"1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider"
214250679|NCT06132399|DEVICE|META QUEST 3 virtual reality glasses|The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
214250680|NCT06132399|DEVICE|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)|This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
214250681|NCT06132399|OTHER|Usual care|The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
214250682|NCT04878887|PROCEDURE|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
214250683|NCT05751096|DEVICE|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
214250684|NCT05751096|DEVICE|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
214250685|NCT04448873|DRUG|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
214250686|NCT05281601|DRUG|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
214250687|NCT01145612|DRUG|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
214250688|NCT01145612|DRUG|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
214250689|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
214250690|NCT03172910|DRUG|Placebo|Saline for injection
214250691|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
214250692|NCT06069726|DRUG|Atezolizumab|One dose of atezolizumab will be given prior to resection.
214250693|NCT04945330|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
214250694|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
214250695|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
214250696|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
214250697|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
214250698|NCT05307705|DRUG|LOXO-783|Oral
214250699|NCT05307705|DRUG|Fulvestrant|Intramuscular
214652943|NCT00054587|DRUG|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
214652944|NCT00054587|DRUG|Epirubicin|100 mg/m², D1 and every 3 weeks
214250700|NCT05307705|DRUG|Imlunestrant|Oral
214250701|NCT05307705|DRUG|Abemaciclib|Oral
214250702|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
214250703|NCT05307705|DRUG|Paclitaxel|Intravenous
214250704|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
214250705|NCT01659658|DRUG|IXAZOMIB|IXAZOMIB capsules
214250706|NCT01659658|DRUG|Dexamethasone|Dexamethasone tablets
214250707|NCT01659658|DRUG|Melphalan|Melphalan tablets
214250708|NCT01659658|DRUG|Cyclophosphamide|Cyclophosphamide tablets
214250709|NCT01659658|DRUG|Thalidomide|Thalidomide capsules
214250710|NCT01659658|DRUG|Lenalidomide|Lenalidomide capsules
214250711|NCT05183815|OTHER|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
214250712|NCT02380144|OTHER|Fresh orange fruit and pasteurized fruit juice|
214250713|NCT00283231|BEHAVIORAL|Paced Respiration|
214250714|NCT02421029|DRUG|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
214250715|NCT05996627|DRUG|Belumosudil|Given PO
214250716|NCT05996627|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214250717|NCT05996627|OTHER|Electronic Health Record Review|Ancillary studies
214250718|NCT05996627|DRUG|Placebo Administration|Given PO
214250719|NCT01054326|OTHER|Exercises|
214250720|NCT04648280|DRUG|Fostemsavir|fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
214652945|NCT00054587|DRUG|Fluorouracil|500 mg/m², D1 and every 3 weeks
214652946|NCT05617287|DIETARY_SUPPLEMENT|Semaine Menopause Supplement|Synergistic Dietary Supplement
214652947|NCT03633357|DRUG|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
214652948|NCT03633357|DRUG|Placebo|Participants will take two placebo tablets daily, for seven days.
214250721|NCT05335278|DRUG|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
214250722|NCT03539848|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
214250723|NCT04356326|DRUG|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
214250724|NCT04356326|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
214250725|NCT06472245|DRUG|OSE2101|OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
214250726|NCT06472245|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
214250727|NCT06472245|DEVICE|NGS HLAA2 assay|Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
214250728|NCT06039410|DEVICE|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
214250729|NCT05271162|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg q.d; p.o
214250730|NCT05271162|OTHER|Placebo|Placebo 1 tabl q.d; p.o
214250731|NCT04603053|BEHAVIORAL|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
214652949|NCT02800187|DEVICE|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
214652950|NCT04336904|DRUG|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
214652951|NCT04336904|OTHER|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
214652952|NCT02487875|OTHER|rehabilitation|
214652953|NCT03551587|DEVICE|Vibringe|The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
214652954|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
214652955|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
214250732|NCT00462631|DEVICE|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
214250733|NCT00462631|DEVICE|paclitaxel eluting stent|paclitaxel eluting stent
214250734|NCT00462631|DEVICE|bare metal stent|bare metal stent
214250735|NCT02739165|DRUG|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
214250736|NCT02739165|DRUG|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
214250737|NCT05368077|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy is a standard surgical procedure for pediatric OSA treatment, which involves removal of hypertrophied tonsils and adenoids.
214250738|NCT02759978|OTHER|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
214250739|NCT03668366|DRUG|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
214250740|NCT04878627|DRUG|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
214250741|NCT04878627|DRUG|Placebo|patients receive placebo for 3 weeks
214250742|NCT00347841|DRUG|Bimatoprost 0.03%, Latanoprost|
214250743|NCT04237012|DRUG|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
214250744|NCT04237012|OTHER|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
214250745|NCT01225770|DIETARY_SUPPLEMENT|green tea|Gargling three times daily for 90 days
214250746|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
214250747|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
214250748|NCT04755244|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
214250749|NCT04755244|DRUG|venetoclax|BCL-2 inhibitor
214250750|NCT04755244|DRUG|azacitidine|Hypomethylating agent (HMA)
214250751|NCT03320603|OTHER|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
214250752|NCT03320603|OTHER|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
214250753|NCT02013869|DEVICE|Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas|Desflurane Dialed setting 18 % on the machine gas vaporized
214250754|NCT02013869|DEVICE|Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated|Desflurane dialed 18% on the machine gas vaporized
214250755|NCT01872260|DRUG|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
214250756|NCT01872260|DRUG|Letrozole|Letrozole 2.5 mg/day
214250757|NCT01872260|DRUG|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
214250758|NCT01728948|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
214250759|NCT00471016|BEHAVIORAL|Guided intervention|
214250760|NCT03878186|OTHER|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
214250761|NCT03878186|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
214250762|NCT03402659|DRUG|neflamapimod|40 mg neflamapimod capsule
214250763|NCT03402659|OTHER|placebo|matching placebo capsule
214250764|NCT04414332|OTHER|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
214250765|NCT05419531|OTHER|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
214250766|NCT02878824|OTHER|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
214250767|NCT02878824|OTHER|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
214652956|NCT03636906|BIOLOGICAL|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
214652957|NCT03636906|BIOLOGICAL|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
214250768|NCT01442038|DRUG|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
214250769|NCT01442038|DRUG|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
214250770|NCT00089284|DRUG|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
214250771|NCT00089284|DRUG|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
214652958|NCT03636906|BIOLOGICAL|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
214652959|NCT03636906|BIOLOGICAL|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
214652960|NCT03636906|DRUG|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
214250772|NCT00089284|DRUG|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
214250773|NCT01658618|BIOLOGICAL|HP802-247|
214250774|NCT02428608|BIOLOGICAL|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
214250775|NCT06305624|DEVICE|Connections App|mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
214250776|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
214250777|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
214250778|NCT06377696|OTHER|Best Practice|Receive SOC
214250779|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
214250780|NCT06377696|DRUG|Metformin|Given PO
214250781|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
214250782|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
214250783|NCT06959108|DRUG|Pucotenlimab|200mg every 3 weeks (21-day cycles) for a total of 3 cycles.
214250784|NCT06959108|DRUG|MRG003|2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.
214250785|NCT05716451|DEVICE|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
214250786|NCT06797401|DRUG|RBD5044|RBD5044, active drug.
214250787|NCT06797401|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
214250788|NCT06789913|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
214250789|NCT06789913|DRUG|Placebo|RLY-2608 matched-placebo
214250790|NCT05773742|DEVICE|Low-volume irrigation|Qufora IrriSedo MiniGo
214250791|NCT05892653|DRUG|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
214250792|NCT06431984|DIAGNOSTIC_TEST|prick test|self-sampling of capillary blood using the finger prick test method
214250793|NCT02549157|PROCEDURE|Pelvic Floor Muscle Training|
214250794|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
214250795|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
214250796|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
214250797|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
214250798|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
214250799|NCT06358651|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
214652961|NCT01301989|BEHAVIORAL|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
214250800|NCT06358651|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
214250801|NCT03646643|PROCEDURE|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
214250802|NCT03646643|PROCEDURE|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
214250803|NCT04481009|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
214250804|NCT04481009|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
214250805|NCT04481009|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
214250806|NCT04481009|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
214250807|NCT06430814|OTHER|No intervention|No intervention
214250808|NCT04521777|BEHAVIORAL|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
214250809|NCT04521777|OTHER|Physical Performance Testing|Complete a physical function test
214250810|NCT04521777|OTHER|Questionnaire Administration|Ancillary studies
214250811|NCT02314208|DRUG|Xenbilox|
214250812|NCT02314208|DIETARY_SUPPLEMENT|Resveratrol|
214250813|NCT02314208|DRUG|Tahor|
214250814|NCT06092580|BIOLOGICAL|AWT020|Participants receiving AWT020 once every two weeks or longer at designated dose levels
214250815|NCT05498220|DRUG|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
214250816|NCT05498220|DRUG|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
214250817|NCT05498220|DRUG|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
214250818|NCT05498220|DRUG|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
214250819|NCT05498220|DRUG|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
214250820|NCT05498220|DRUG|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
214250821|NCT05498220|DRUG|GCSF|granulocyte-colony stimulating factor (GCSF )
214250822|NCT06377501|OTHER|Whole-food, plant-based diet|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
214250823|NCT05700539|BEHAVIORAL|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
214250824|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
214250825|NCT06219941|DRUG|AZD0901|Antibody-drug conjugate/Biologic
214250826|NCT06219941|DRUG|5-Fluorouracil|Chemotherapy agents
214250827|NCT06219941|DRUG|Leucovorin|Chemotherapy agents
214250828|NCT06219941|DRUG|l-leucovorin|Chemotherapy agents
214250829|NCT06219941|DRUG|Irinotecan|Chemotherapy agents
214250830|NCT06219941|DRUG|Nanoliposomal Irinotecan|Chemotherapy agents
214250831|NCT06219941|DRUG|Gemcitabine|Chemotherapy agents
214250832|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
214250833|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary motor cortex|It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
214250834|NCT06262425|DEVICE|sham repetitive Transcranial Magnetic Stimulation|It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
214250835|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
214652962|NCT01301989|OTHER|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
214250836|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
214250837|NCT01135576|DIETARY_SUPPLEMENT|non-fortified fruit juices consumed as part of the usual diet|
214250838|NCT01135576|DIETARY_SUPPLEMENT|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
214250839|NCT05005520|DRUG|DTRI-031|Investigational drug
214250840|NCT05005520|DRUG|Placebo|Matching placebo to DTRI-031
214250841|NCT03557827|DRUG|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
214250842|NCT03557827|PROCEDURE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
214250843|NCT05274685|PROCEDURE|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
214250844|NCT03375710|DEVICE|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
214250845|NCT00396747|DRUG|Infliximab, methylprednisolone, methotrexate|
214250846|NCT00396747|DRUG|Methotrexate|
214250847|NCT00396747|DRUG|Methotrexate + Methylprednisolone|
214250848|NCT00396747|DRUG|Methotrexate + Infliximab|
214250849|NCT05310188|DIAGNOSTIC_TEST|pseudocholinesterease|blood samples
214250850|NCT03503071|PROCEDURE|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
214250851|NCT00900601|PROCEDURE|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
214250852|NCT03141073|DRUG|HMS5552|BID oral administration
214250853|NCT03141073|DRUG|Placebo|BID oral administration
214250854|NCT04095273|DRUG|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
214250855|NCT04095273|DRUG|Pembrolizumab (Keytruda®)|Study drugs will be administered as scheduled
214250856|NCT01637987|PROCEDURE|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
214250857|NCT01637987|PROCEDURE|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
214250858|NCT01637987|PROCEDURE|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
214250859|NCT02233062|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition Therapy|
214250860|NCT02836353|DRUG|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
214250861|NCT02836353|DRUG|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
214250862|NCT03300531|BIOLOGICAL|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
214250863|NCT03300531|BIOLOGICAL|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
214250864|NCT03300531|DRUG|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
214250865|NCT04008823|OTHER|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
214250866|NCT05521724|PROCEDURE|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
214250867|NCT00931736|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
214250868|NCT00931736|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
214250869|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed High Dose|26 gram flaxseed intervention
214250870|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed Low Dose|13 grams flaxseed
214250871|NCT00089856|BIOLOGICAL|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
214250872|NCT00089856|DRUG|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
214250873|NCT02568137|BEHAVIORAL|Smart-phone based technology|
214250874|NCT04704973|BEHAVIORAL|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
214250875|NCT02316912|DRUG|ATX2417|Randomised double blind parallel group ascending dose assessment
214250876|NCT02316912|DRUG|Placebo|Randomised double blind parallel group ascending dose assessment
214250877|NCT01669096|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
214250878|NCT06386289|DEVICE|Cereglide 92|Aspiration of cerebral large vessels occlusions
214250879|NCT00004834|DRUG|imipramine|
214250880|NCT00004834|BEHAVIORAL|cognitive-behavioral therapy|
214250881|NCT01542073|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
214250882|NCT02636842|DRUG|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
214250883|NCT03507062|OTHER|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
214250884|NCT03507062|OTHER|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
214250885|NCT03507062|OTHER|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
214250886|NCT02822391|OTHER|observation|
214250887|NCT05722457|OTHER|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
214250888|NCT05722457|OTHER|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
214250889|NCT00721266|DRUG|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
214250890|NCT03246620|DRUG|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
214250891|NCT03246620|DRUG|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
214250892|NCT03246620|DRUG|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
214250893|NCT05655052|DEVICE|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
214250894|NCT05655052|DEVICE|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
214250895|NCT04659239|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
214250896|NCT04659239|BIOLOGICAL|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
214250897|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
214250898|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
214250899|NCT05695300|DIETARY_SUPPLEMENT|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
214250900|NCT04661020|DRUG|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
214250901|NCT00076973|DRUG|montelukast sodium|Duration of Treatment: 6 months
214250902|NCT00076973|DRUG|Comparator: placebo|Duration of Treatment: 6 months
214250903|NCT03600298|OTHER|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
214250904|NCT01994928|DEVICE|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
214250905|NCT01994928|DEVICE|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
214250906|NCT01994928|PROCEDURE|Intubation|Intubation
214250907|NCT01356979|PROCEDURE|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
214250908|NCT00415350|DRUG|Azithromycin|Azithromycin Tablet 250 mg daily
214250909|NCT00415350|OTHER|Placebo|Placebo tablet 1 daily
214250910|NCT03413943|OTHER|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
214250911|NCT00214500|DRUG|migalastat HCl|
214250912|NCT04935437|OTHER|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
214250913|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals \[kPa\] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity \[(m/sec)/kHz\] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
214250914|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
214250915|NCT00147251|DRUG|FDA approved drugs to treat blood pressure and cholesterol|
214250916|NCT04795986|PROCEDURE|HEARO Procedure|robotic access to the middle and inner ear in cochlear implantation
214250917|NCT05324176|RADIATION|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
214250918|NCT01629706|DEVICE|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
214250919|NCT01629706|DEVICE|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
214250920|NCT01629706|DEVICE|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
214250921|NCT01629706|DEVICE|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
214250922|NCT01629706|DEVICE|Habitual lens care|Lens care per habitual use
214250923|NCT03376048|PROCEDURE|Wound infiltration plus TAP|"1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
214250924|NCT03376048|PROCEDURE|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
214250925|NCT03376906|PROCEDURE|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
214250926|NCT03376906|PROCEDURE|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
214250927|NCT03376906|PROCEDURE|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
214250928|NCT00701376|OTHER|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
214250929|NCT02663687|DRUG|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
214250930|NCT02663687|DRUG|Placebo|Subjects will receive matching placebo
214250931|NCT02663687|DRUG|SHP623|SHP623
214250932|NCT02663687|DRUG|Placebo|Placebo
214250933|NCT05774977|OTHER|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
214250934|NCT05774977|OTHER|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
214250935|NCT05774977|OTHER|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
214652963|NCT04815837|BEHAVIORAL|Intervention|"1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8."
214250936|NCT05774977|OTHER|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
214250937|NCT05774977|OTHER|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
214250938|NCT05774977|OTHER|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
214250939|NCT02492581|DRUG|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
214250940|NCT01424202|DEVICE|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
214250941|NCT03595774|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice
214250942|NCT00112697|DRUG|cisplatin|
214250943|NCT00112697|DRUG|docetaxel|
214250944|NCT00112697|DRUG|fluorouracil|
214250945|NCT00112697|RADIATION|radiation therapy|
214250946|NCT01997710|DEVICE|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
214250947|NCT01997710|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
214250948|NCT04158791|PROCEDURE|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
214250949|NCT01151098|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
214652964|NCT04817501|OTHER|Taking 5 ml of venous blood at different time intervals|
214250950|NCT04988828|DEVICE|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
214250951|NCT03771053|DRUG|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
214250952|NCT03771053|DRUG|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
214250953|NCT06329115|OTHER|Exercise training|Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
214250954|NCT04384588|BIOLOGICAL|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
214250955|NCT04686123|OTHER|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
214250956|NCT04686123|OTHER|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
214250957|NCT06515522|OTHER|differential diagnosis|this is a retrospective observational study. no intervention has been or will be performed
214250958|NCT00160589|DRUG|Levocetirizine|
214250959|NCT01880047|DRUG|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
214250960|NCT01880047|DRUG|Placebo|
214250963|NCT03533582|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214250964|NCT03533582|DRUG|Carboplatin|Given IV
214250965|NCT03533582|DRUG|Cisplatin|Given IV
214250966|NCT03533582|DRUG|Doxorubicin|Given IV
214250967|NCT03533582|DRUG|Etoposide|Given IV
214250968|NCT03533582|DRUG|Fluorouracil|Given IV
214250969|NCT03533582|DRUG|Gemcitabine|Given IV
214250970|NCT03533582|DRUG|Irinotecan|Given IV
214250971|NCT03533582|DRUG|Oxaliplatin|Given IV
214250972|NCT03533582|OTHER|Patient Observation|Undergo watchful waiting
214652965|NCT04817501|OTHER|Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any|
214652966|NCT04633590|BEHAVIORAL|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
214250973|NCT03533582|PROCEDURE|Resection|Undergo surgical resection
214250974|NCT03533582|DRUG|Sorafenib|Given PO
214250975|NCT03533582|DRUG|Vincristine Sulfate|Given IV
214652967|NCT05876559|OTHER|Joyuus Self-care Mobile App|Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.
214250976|NCT03210987|PROCEDURE|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
214250977|NCT03210987|PROCEDURE|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
214250978|NCT01015144|DRUG|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
214250979|NCT04186936|DRUG|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
214250980|NCT04186936|DRUG|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
214250981|NCT04186936|DRUG|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
214250982|NCT05909527|BIOLOGICAL|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
214250983|NCT01593722|DRUG|Diethylcarbamazine|single dose
214250984|NCT01593722|DRUG|Ivermectin|single dose
214250985|NCT01489371|OTHER|Laboratory Biomarker Analysis|Correlative studies
214250986|NCT01489371|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
214250987|NCT01489371|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214250988|NCT00434343|OTHER|Global Therapeutic Massage (GTM)|
214250989|NCT00434343|OTHER|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
214250990|NCT05141825|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
214250991|NCT01148797|DRUG|Canakinumab|
214250992|NCT01554228|OTHER|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
214250993|NCT00346944|PROCEDURE|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
214250994|NCT00116168|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
214250995|NCT00116168|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
214250996|NCT00116168|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
214250997|NCT00116168|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
214250998|NCT03110744|DRUG|Palbociclib|application on 21 consecutive days of a 28 days cycle
214250999|NCT06364306|PROCEDURE|Robotically-assisted ventral hernia repair (RVHR)|"3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes."
214251000|NCT06364306|PROCEDURE|Open ventral hernia repair (OVHR)|Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
214251001|NCT01763671|DRUG|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
214251002|NCT01763671|DRUG|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
214251003|NCT01763671|DRUG|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
214251004|NCT02788474|DRUG|nintedanib|
214251005|NCT02788474|DRUG|placebo|
214251006|NCT04340297|DRUG|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
214251007|NCT04340297|DRUG|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
214251008|NCT04340297|DRUG|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
214251009|NCT02317146|DRUG|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
214251010|NCT01272284|DEVICE|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
214251011|NCT02351986|PROCEDURE|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
214251012|NCT02351986|OTHER|ice pack|
214251013|NCT00117286|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
214251014|NCT04152707|DEVICE|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
214251015|NCT05102695|DIAGNOSTIC_TEST|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
214251016|NCT03555435|OTHER|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
214251017|NCT03555435|BEHAVIORAL|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
214251018|NCT03555435|BEHAVIORAL|Wait|Participants in this group will wait 6 weeks.
214652968|NCT05876559|OTHER|Standard Care|Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
214652969|NCT02348515|PROCEDURE|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
214652970|NCT02348515|PROCEDURE|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
214652971|NCT02348515|PROCEDURE|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
214652972|NCT02348515|PROCEDURE|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
214652973|NCT02348515|PROCEDURE|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
214251019|NCT03961373|PROCEDURE|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
214251020|NCT03961373|PROCEDURE|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
214251021|NCT00348244|DRUG|Ketorolac, Prednisolone Acetate|
214251022|NCT00063193|DRUG|minocycline|
214251023|NCT00063193|DRUG|creatine|
214251024|NCT02758756|OTHER|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
214251025|NCT02758756|OTHER|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
214251026|NCT01206868|PROCEDURE|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
214251027|NCT01206868|PROCEDURE|Control|Standard kidney transplantation
214251028|NCT03300310|OTHER|nursing visit|nursing visit at patient home
214251029|NCT03300310|OTHER|no nursing visit|the patient take his treatment without nursing visit
214251030|NCT00992927|PROCEDURE|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
214251031|NCT00992927|PROCEDURE|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
214251032|NCT03543618|DEVICE|Sloped|Placement of implant with sloped design
214251033|NCT03543618|DEVICE|Control|Placement of implant with conventional design
214652974|NCT03493360|OTHER|Visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.
214652975|NCT03493360|OTHER|No visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
214652976|NCT01629147|DIETARY_SUPPLEMENT|Biogaia|5 drops containing Lactobacillus reuteri Protectis
214251034|NCT03871335|DIAGNOSTIC_TEST|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
214251035|NCT04005170|DRUG|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
214251036|NCT04005170|DRUG|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
214251037|NCT04005170|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
214652977|NCT01629147|OTHER|Placebo|5 drops
214251038|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
214251039|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
214251040|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
214251041|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
214251042|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
214251043|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
214251044|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
214251045|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
214652978|NCT00508573|BEHAVIORAL|Questionnaire|Follow-up questionnaire done once a year for five years.
214652979|NCT06813404|BEHAVIORAL|Heavy resistance training|The heavy resistance training intervention will consist of twice weekly exercise sessions of 60 minutes each.
214652980|NCT06813404|BEHAVIORAL|Yoga|Twice weekly yoga sessions of 60 minutes each
214652981|NCT03564873|DRUG|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
214652982|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
214251046|NCT03585348|OTHER|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
214251047|NCT02670174|OTHER|Traditional training|
214251048|NCT02670174|OTHER|Separate kinetic chain training|
214251049|NCT02670174|OTHER|Integrated kinetic chain training|
214251050|NCT03947203|BEHAVIORAL|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
214251051|NCT05005754|DIETARY_SUPPLEMENT|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
214251052|NCT05005754|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
214251053|NCT05288699|BEHAVIORAL|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
214251054|NCT04354727|DRUG|APG-1252|infusion once weekly
214251055|NCT04354727|DRUG|Ruxolitinib|taken orally twice a day
214251056|NCT01926665|DRUG|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
214251057|NCT01926665|DRUG|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
214251058|NCT02549053|PROCEDURE|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
214251059|NCT02549053|PROCEDURE|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
214251060|NCT04489732|BIOLOGICAL|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland"
214251061|NCT04094623|OTHER|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
214251062|NCT04094623|OTHER|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
214251063|NCT03704987|DIAGNOSTIC_TEST|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
214652983|NCT03564873|DRUG|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
214652984|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
214251064|NCT01415895|DRUG|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
214251065|NCT01415895|DRUG|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
214251066|NCT01272661|BEHAVIORAL|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
214251067|NCT01272661|BEHAVIORAL|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
214251068|NCT01272661|BEHAVIORAL|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
214251069|NCT05784961|DEVICE|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
214251070|NCT01543373|DEVICE|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
214251071|NCT01543373|DEVICE|Bare Metal Stent|Bare metal coronary stent
214251072|NCT04710420|DEVICE|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
214251073|NCT03773211|DRUG|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
214251074|NCT03773211|DRUG|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
214251075|NCT04314310|DRUG|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
214251076|NCT04314310|DRUG|Placebo|equal volume of normal saline
214652985|NCT02631707|OTHER|High protein diet|The intervention diet is higher in protein than the control diet.
214818154|NCT00579345|BIOLOGICAL|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV\_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
214818155|NCT00579345|BIOLOGICAL|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV\_a administered.
214251077|NCT02145988|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
214251078|NCT02145988|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
214251079|NCT05229978|OTHER|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
214251080|NCT04290780|OTHER|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
214251081|NCT03877731|PROCEDURE|isolated septal myectomy|
214251082|NCT03877731|PROCEDURE|septal myectomy + edge-to-edge mitral valve repair|
214251083|NCT03877731|PROCEDURE|septal myectomy + posterior leaflet sliding plasty|
214251084|NCT03877731|PROCEDURE|septal myectomy + secondary chordae transection|
214251085|NCT02869438|DRUG|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
214251086|NCT02869438|OTHER|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
214251087|NCT03400644|DEVICE|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
214251088|NCT00856648|DEVICE|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
214251089|NCT03408002|BEHAVIORAL|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
214251090|NCT00005110|DRUG|Salmeterol|
214251091|NCT00005110|DRUG|Albuterol|
214251092|NCT01840618|DEVICE|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
214251093|NCT00658580|DRUG|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
214251094|NCT00658580|DRUG|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
214251095|NCT04115644|DRUG|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
214251096|NCT04115644|DRUG|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
214251097|NCT04115644|DRUG|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
214652986|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
214251098|NCT01033721|DRUG|Palomid 529|comparison of different dosages of drug
214251099|NCT05023876|OTHER|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
214251100|NCT05023876|OTHER|Respiratory Exercise|Respiratory Exercise
214251101|NCT01601431|DEVICE|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
214251102|NCT01601431|DEVICE|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
214251103|NCT03526731|OTHER|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
214251104|NCT05958667|BEHAVIORAL|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
214251105|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
214251106|NCT06637839|BEHAVIORAL|Moderate-Intensity Locomotor Training Program|The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
214251107|NCT06637839|BEHAVIORAL|High-Intensity Locomotor Training Program|The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
214251108|NCT06637839|BEHAVIORAL|High-Step Count Locomotor Training Program|The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
214251109|NCT02660398|PROCEDURE|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
214251110|NCT05305027|BEHAVIORAL|Prompt diagnois pregnancy outcome|
214251111|NCT05613803|DRUG|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
214251112|NCT05613803|OTHER|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
214251113|NCT04092569|BEHAVIORAL|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
214251114|NCT04173234|OTHER|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
214652987|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
214652988|NCT06820242|BEHAVIORAL|HIPS|HIPS is a 6-session (one 30-minute session per week) mind-body intervention delivered in person by a trained physical therapist (PT). Across these six 30-minute sessions, the HIPS intervention aims to teach relaxation and coping skills (e.g., SMART goal-setting, coping thoughts, deep breathing, and progressive muscle relaxation) and provides pain education.
214251115|NCT04173234|OTHER|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
214251116|NCT06392971|DRUG|Deep-sea fish oil|Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
214251117|NCT06392971|OTHER|Placebo|Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
214251118|NCT02169284|DRUG|Erlotinib Hydrochloride|Given PO
214251119|NCT02169284|OTHER|Laboratory Biomarker Analysis|Correlative studies
214251120|NCT02169284|OTHER|Pharmacological Study|Correlative studies
214652989|NCT02719340|PROCEDURE|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
214652990|NCT01291017|DRUG|PD0332991|PD0332991 125 mg PO days 1 - 21
214251121|NCT02169284|OTHER|Placebo|Given PO
214251122|NCT02169284|OTHER|Quality-of-Life Assessment|Ancillary studies
214251123|NCT02169284|PROCEDURE|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
214251124|NCT06568783|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
214251125|NCT03048916|OTHER|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
214251126|NCT03048916|OTHER|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
214251127|NCT06195683|DRUG|Serplulimab|Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
214251128|NCT04482712|DRUG|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
214251129|NCT04482712|DRUG|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
214251130|NCT01843088|DRUG|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
214251131|NCT01843088|DRUG|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
214251132|NCT04857970|OTHER|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
214251133|NCT04857970|OTHER|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
214251134|NCT05059587|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
214818156|NCT00579345|BIOLOGICAL|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
214818157|NCT03699696|DRUG|Propofol|Induction of anesthesia prior to surgery with propofol
214251135|NCT05059587|DRUG|BOTOX|Botox will be injected into the Glabellar line.
214251136|NCT05893355|BEHAVIORAL|Acupressure group|"Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
214251137|NCT06324760|DIETARY_SUPPLEMENT|Alpha-lipoic acid combined with B vitamins|The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system
214251138|NCT00185068|DRUG|Olmesartan medoxomil|
214251139|NCT00185068|DRUG|Olmesartan medoxomil/hydrochlorothiazide|
214251140|NCT00185068|DRUG|Hydrochlorothiazide|
214251141|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
214251142|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
214251143|NCT00072631|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
214251144|NCT05439642|OTHER|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
214251145|NCT02932683|DEVICE|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
214251146|NCT03439059|BEHAVIORAL|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
214251147|NCT05318482|BEHAVIORAL|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
214251148|NCT05318482|OTHER|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
214251149|NCT03886662|DRUG|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
214251150|NCT05544370|BEHAVIORAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
214251151|NCT05544370|BEHAVIORAL|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
214251152|NCT04843059|OTHER|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
214251153|NCT03281460|DEVICE|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
214251154|NCT03281460|PROCEDURE|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
214251155|NCT05185115|DRUG|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
214251156|NCT05185115|OTHER|no oxygen therapy|No oxygen therapy during hospitalization
214251157|NCT04505540|OTHER|Bridge Clinic|Specialized addiction bridge clinic
214251158|NCT06293300|DRUG|BoNT A|Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
214251159|NCT04920799|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
214251160|NCT04920799|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
214251161|NCT03583073|BEHAVIORAL|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
214251162|NCT03583073|BEHAVIORAL|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
214251163|NCT03690453|DRUG|Ivermectin|single dose of Ivermectin
214251164|NCT04555226|PROCEDURE|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
214251165|NCT04555226|RADIATION|Standard chemoradiation±pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
214251166|NCT04555226|RADIATION|Chemoradiation± pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
214251167|NCT04941781|DRUG|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
214251168|NCT01367119|DRUG|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
214251169|NCT01367119|DRUG|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
214251170|NCT04570722|OTHER|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
214251171|NCT05515666|DIAGNOSTIC_TEST|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
214251172|NCT00645684|PROCEDURE|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
214251173|NCT06030310|OTHER|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
214251174|NCT05860335|DRUG|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
214251175|NCT00206310|DRUG|CRESTOR|
214652991|NCT06861582|DIAGNOSTIC_TEST|Point-of-care ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using point-of-care (POC) technology, the Atellica® VTLi Patient-side Immunoassay Analyzer (Siemens Healthineers) will be used. This high-sensitivity troponin I (hs-cTnI) test utilizes Magnotech® Technology with paramagnetic particles and external magnetic fields, providing rapid results (\~8 minutes) using whole capillary blood collected via fingertip puncture, and/or with direct withdrawal from the test tube. Additionally, venous blood samples will be collected for laboratory comparison. The assay measures hs-cTnI within a range of 0-1250 pg/mL, with values \<LoD and \>1250 pg/mL recorded accordingly. Samples will be collected at 0 and 1 hour. Reference values (99th percentile, pg/mL): Women: 18.5, Men: 27.1. This intervention enables bedside testing, reducing turnaround time compared to standard laboratory assays, facilitating early myocardial infarction diagnosis.
214251176|NCT02238171|DRUG|Atrovent® inhalets|
214251177|NCT05082532|OTHER|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
214251178|NCT06043284|DEVICE|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
214251179|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
214251180|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
214251181|NCT04088604|DRUG|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
214251182|NCT01578564|DRUG|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
214251183|NCT04455243|DRUG|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
214251184|NCT04455243|DRUG|Placebo|Matching placebo administered in the same schedule and volume as NAC
214251185|NCT03315182|BIOLOGICAL|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
214251186|NCT00560378|DRUG|Tacrolimus ointment 0.1%|Topical
214251187|NCT05342532|DRUG|Amoxicillin|1 g
214251188|NCT05342532|DRUG|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
214251189|NCT05342532|DRUG|Clarithromycin|500 mg twice daily
214251190|NCT02480985|OTHER|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)"
214251191|NCT04360863|OTHER|Telephone survey|Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
214251192|NCT01257802|DRUG|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
214251193|NCT01257802|DRUG|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
214251194|NCT02794740|DRUG|X0002|External Spray
214251195|NCT02794740|DRUG|Placebo|External Spray
214251196|NCT00330798|DRUG|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
214251197|NCT00330798|OTHER|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
214251198|NCT05464173|DRUG|Chidamide|10-30mg biw
214251199|NCT05464173|DRUG|Abemaciclib|150mg or 100mg bid
214251200|NCT05464173|DRUG|endocrinotherapy（doctor's choice）|According to the drug insert
214251201|NCT00884533|DRUG|Rosi XR|Rosi XR
214251202|NCT00884533|OTHER|Placebo|Placebo
214251203|NCT00884533|DRUG|Moxifloxacin|400mg single dose
214251204|NCT02057393|DRUG|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
214251205|NCT02057393|DRUG|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
214251206|NCT02057393|DRUG|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
214251207|NCT05164718|BEHAVIORAL|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
214251208|NCT05164718|OTHER|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
214251209|NCT03180684|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
214251210|NCT03180684|DRUG|Imiquimod 5% Cream|Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
214251211|NCT03180684|DEVICE|CELLECTRA™ 2000|IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
214251212|NCT05809622|BEHAVIORAL|Elbow focused rehabilitation|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
214251213|NCT05809622|BEHAVIORAL|Scapular and rotator cuff muscles strengthening|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~* Scapular stabilizer muscle + rotator cuff (RM) strengthening"
214251214|NCT06059209|DIETARY_SUPPLEMENT|Enfamil NeuroPro|FDA Infant formula
214251215|NCT06059209|DIETARY_SUPPLEMENT|Enfamil Infant|FDA Infant formula
214251216|NCT05155709|DRUG|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
214251217|NCT05155709|DRUG|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
214251218|NCT05155709|DRUG|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
214251219|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
214251220|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
214251221|NCT05366205|DIETARY_SUPPLEMENT|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
214251222|NCT05366205|BEHAVIORAL|Nutrition consultation|Nutritional treatment advice will be given
214251223|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
214251224|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
214251225|NCT05893797|DRUG|Insulin Lispro|As prescribed.
214251226|NCT05893797|DEVICE|Tempo Smart Button|Attached to the Tempo Pen
214251227|NCT05893797|DEVICE|Dexcom G6 CGM|Continuous glucose monitor
214251228|NCT05893797|DEVICE|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
214251229|NCT01115803|DRUG|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
214251230|NCT01115803|DRUG|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
214251231|NCT01115803|DRUG|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
214251232|NCT02885168|DRUG|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
214251233|NCT02885168|DEVICE|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
214251234|NCT02885168|DRUG|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
214251235|NCT02885168|BIOLOGICAL|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
214251236|NCT04489238|OTHER|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
214251237|NCT03475875|DEVICE|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
214251238|NCT03475875|DEVICE|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
214251239|NCT05942105|PROCEDURE|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
214251240|NCT02524210|DRUG|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
214251241|NCT02524210|DRUG|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
214251242|NCT02524210|DRUG|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
214251243|NCT03686826|PROCEDURE|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
214251244|NCT03536897|RADIATION|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
214251245|NCT01396330|BEHAVIORAL|stress|3 professional safe drive training courses each lasting 30 minutes
214251246|NCT01291433|DRUG|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
214251247|NCT01291433|DRUG|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
214251248|NCT01291433|DRUG|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
214251249|NCT01291433|DRUG|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
214251250|NCT01291433|DRUG|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
214251251|NCT01291433|DRUG|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
214251252|NCT01104220|OTHER|Weight loss|Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
214251253|NCT04737057|PROCEDURE|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
214251254|NCT04737057|PROCEDURE|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
214251255|NCT01155505|DRUG|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
214251256|NCT02533791|BIOLOGICAL|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10\^10vp/1ml per dose
214251257|NCT02533791|BIOLOGICAL|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
214251258|NCT02533791|BIOLOGICAL|placebo|
214251259|NCT05208307|BIOLOGICAL|Belantamab Mafodotin|Given IV
214251260|NCT05208307|DRUG|Dexamethasone|Given PO
214251261|NCT05208307|DRUG|Pomalidomide|Given PO
214251262|NCT03260439|DRUG|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
214251263|NCT03260439|DRUG|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
214251264|NCT05967143|DEVICE|SIRT|Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
214251265|NCT02017171|DRUG|Allopurinol|
214251266|NCT02017171|DRUG|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
214251267|NCT05185336|DIAGNOSTIC_TEST|ultrasound assessment|gastric volume assessment by ultrasound
214251268|NCT06004687|DRUG|acetaminophen mannitol|Intravenous acetaminophen was administered 30 minutes before anesthesia
214251269|NCT06004687|DRUG|Normal saline|Intravenous acetaminophen was administered 30 minutes before anesthesia
214251270|NCT04450459|DIAGNOSTIC_TEST|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
214251271|NCT02721979|DRUG|Apalutamide|Given PO
214251272|NCT02721979|OTHER|Laboratory Biomarker Analysis|Correlative studies
214251273|NCT02721979|OTHER|Quality-of-Life Assessment|Ancillary studies
214251274|NCT02721979|OTHER|Questionnaire Administration|Ancillary studies
214251275|NCT00622076|PROCEDURE|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
214251276|NCT02347696|BEHAVIORAL|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
214251277|NCT02347696|BEHAVIORAL|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
214251278|NCT02347696|BEHAVIORAL|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1."
214251279|NCT02347696|BEHAVIORAL|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session"
214251280|NCT02347696|BEHAVIORAL|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
214251281|NCT02347696|BEHAVIORAL|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
214251282|NCT03169751|DEVICE|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
214251283|NCT03091777|DRUG|GDC-229|GDC-229 is a vaginal gel.
214251284|NCT03091777|DRUG|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
214251285|NCT03091777|DRUG|Placebo|Inactive arm of the study
214251286|NCT03371771|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
214251287|NCT03371771|BEHAVIORAL|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
214251288|NCT02536833|DRUG|SM04690|
214251289|NCT02536833|DRUG|Placebo|
214251290|NCT00003567|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
214251291|NCT00003567|BIOLOGICAL|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
214251292|NCT00003567|BIOLOGICAL|therapeutic autologous lymphocytes|
214251293|NCT00003567|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
214251294|NCT00003567|DRUG|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
214251295|NCT00003567|DRUG|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
214251296|NCT00003567|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
214251297|NCT00922701|DRUG|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
214251298|NCT05381337|PROCEDURE|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
214251299|NCT05381337|PROCEDURE|coronal scalp incision|Coronal scalp incisions were used as control group.
214251300|NCT00621803|DRUG|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
214251301|NCT00899509|OTHER|laboratory biomarker analysis|correlative studies
214251302|NCT00652691|BIOLOGICAL|filgrastim|
214251303|NCT00652691|DRUG|carboplatin|
214251304|NCT00652691|DRUG|cyclophosphamide|
214251305|NCT00652691|DRUG|topotecan hydrochloride|
214251306|NCT00652691|PROCEDURE|autologous hematopoietic stem cell transplantation|
214251307|NCT00652691|PROCEDURE|peripheral blood stem cell transplantation|
214251308|NCT00004229|BIOLOGICAL|recombinant human endostatin|
214251309|NCT02764190|BEHAVIORAL|I-ACT with Check Yourself|
214251310|NCT00569751|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
214251311|NCT02142114|DEVICE|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
214251312|NCT04467996|DEVICE|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
214251313|NCT04356170|DRUG|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
214251314|NCT04356170|DRUG|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
214251315|NCT04356170|DRUG|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
214251316|NCT03580304|BEHAVIORAL|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
214251317|NCT03580304|BEHAVIORAL|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
214251318|NCT03580304|BEHAVIORAL|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
214251319|NCT04228575|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
214251320|NCT01244360|DIETARY_SUPPLEMENT|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
214251321|NCT01244360|OTHER|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
214251322|NCT01172275|DRUG|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
214251323|NCT01172275|OTHER|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
214251324|NCT04470921|PROCEDURE|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
214251325|NCT02168426|PROCEDURE|Guardix|Applying 6g of guardix during abdominal surgery
214251326|NCT02168426|PROCEDURE|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
214251327|NCT01661816|BEHAVIORAL|interview|psychological, emotional, family and social parameters
214251328|NCT03243266|DIAGNOSTIC_TEST|CBC/Diff Reference Interval|Results will not be used to manage patients
214251329|NCT02325310|BIOLOGICAL|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
214251330|NCT05269251|DEVICE|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
214251331|NCT02438527|BEHAVIORAL|Chart for CPR guidance|
214251332|NCT05218265|DIAGNOSTIC_TEST|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
214251333|NCT01810588|DEVICE|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
214251334|NCT01810588|DRUG|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
214251335|NCT01810588|DRUG|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
214251336|NCT01810588|DRUG|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
214251337|NCT01810588|DRUG|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
214251338|NCT01810588|RADIATION|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
214251339|NCT01810588|DRUG|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
214251340|NCT01810588|DRUG|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
214251341|NCT03986515|DRUG|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
214251342|NCT05308290|OTHER|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
214251343|NCT05308290|OTHER|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
214251344|NCT04437368|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
214251345|NCT02068339|DRUG|Oltipraz 1 (90mg)|
214251346|NCT02068339|DRUG|Placebo|
214251347|NCT02068339|DRUG|Oltipraz 2 (120mg)|
214251348|NCT03178695|OTHER|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
214251349|NCT03362307|DEVICE|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
214251350|NCT03362307|DEVICE|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
214652992|NCT06861582|DIAGNOSTIC_TEST|Laboratory-based ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using the local laboratory, the Alinity™ i STAT High Sensitive Troponin-I assay (Abbott) will be used. Samples will be taken at 0 and 1 hour after admission by venipuncture and collected in 5 mL serum tubes with a separator. This chemiluminescence microparticle immunoassay (CMIA) quantifies cardiac troponin I (cTnI) in serum and plasma using the Alinity™ i analyzer, with a measurement range of 10-50,000 pg/mL. Analysis will follow the manufacturer's instructions. Reference values (99th percentile, pg/mL): Women (21-75 years): 15.6, Men (21-73 years): 34.2.
214652993|NCT04596891|BEHAVIORAL|Psychotherapy|Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
214652994|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 180 mg/day
214251351|NCT01982331|BIOLOGICAL|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
214251352|NCT01982331|OTHER|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
214251353|NCT06468969|OTHER|Enhanced Follow-up|"Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)"
214652995|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 300 mg/day
214652996|NCT03690869|DRUG|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
214251354|NCT00266773|BEHAVIORAL|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
214251355|NCT00121888|BEHAVIORAL|Prolonged Exposure Therapy|
214251356|NCT00121888|DRUG|Paroxetine-CR|
214652997|NCT03690869|DRUG|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
214251357|NCT04646772|PROCEDURE|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
214251358|NCT03937869|DRUG|Secnidazole|One dose
214251359|NCT03551340|DIAGNOSTIC_TEST|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
214251360|NCT04498494|DEVICE|ECG|12-lead ECG
214251361|NCT01469117|OTHER|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
214251362|NCT03679585|OTHER|Internet-Based Intervention|Undergo Talking Pictures social media intervention
214251363|NCT03679585|OTHER|Quality-of-Life Assessment|Ancillary studies
214251364|NCT03679585|OTHER|Questionnaire Administration|Ancillary studies
214251365|NCT06288789|OTHER|Social Frailty Index|Social Frailty Index will be applied twice, one week apart.
214251366|NCT02914847|BEHAVIORAL|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
214251367|NCT04145479|BEHAVIORAL|physical activity|exercise
214251368|NCT03181373|OTHER|Cognitive rehabilitation program|Rehabilitation
214251369|NCT01490788|DRUG|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
214251370|NCT01490788|DRUG|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
214251371|NCT01490788|DRUG|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
214251372|NCT03832075|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
214251373|NCT03832075|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
214251374|NCT03832075|DIAGNOSTIC_TEST|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
214251375|NCT00062322|DRUG|cisplatin|
214251376|NCT00062322|DRUG|irinotecan hydrochloride|
214251377|NCT00062322|PROCEDURE|conventional surgery|
214251378|NCT00062322|PROCEDURE|neoadjuvant therapy|
214251379|NCT00062322|RADIATION|radiation therapy|
214251380|NCT04186481|DEVICE|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
214251381|NCT01247038|DEVICE|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
214251382|NCT01247038|DEVICE|Metal-on-Metal|Metal on Metal articulation
214251383|NCT01477203|DRUG|Escitalopram|2-4 weeks, 5-10mg, max 20mg
214652998|NCT03690869|RADIATION|Conventional or hypofractionated|Combined with cemiplimab IV administration
214652999|NCT03690869|RADIATION|Re-irradiation|Combined with cemiplimab IV administration
214653000|NCT02722681|PROCEDURE|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
214653001|NCT02722681|PROCEDURE|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
214653002|NCT06682442|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
214653003|NCT06682442|PROCEDURE|Radiographic Imaging|Undergo imaging procedure
214653004|NCT06682442|PROCEDURE|Biospecimen Collection|Blood samples will be collected
214653005|NCT06689410|OTHER|blood or saliva sample|Collection of blood or saliva
214251384|NCT01054807|DEVICE|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
214251385|NCT01054807|DEVICE|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
214251386|NCT01054807|DEVICE|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
214251387|NCT04980573|OTHER|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
214251388|NCT04980573|OTHER|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
214251389|NCT01231230|DRUG|fluticasone|220- mcg once
214251390|NCT01231230|DRUG|placebo inhalation|placebo inhalation once
214251391|NCT01231230|DRUG|Salmeterol|50 mcg salmeterol once
214251392|NCT01231230|DRUG|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
214251393|NCT04723758|DEVICE|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
214251394|NCT04723758|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
214251395|NCT04529473|DIETARY_SUPPLEMENT|Eubacterium hallii|Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
214251396|NCT04529473|OTHER|Placebo|Placebo capsules are identical to the active treatment
214251397|NCT06267976|DEVICE|ProSomnus RPMO2|The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
214251398|NCT05580510|DRUG|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
214251399|NCT05580510|DRUG|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
214251400|NCT00590629|DRUG|Niaspan|1500 mg Niaspan for 16 weeks
214251401|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
214251402|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
214251403|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
214251404|NCT02467335|DRUG|BMS-663068|BMS-663068
214251405|NCT05031598|OTHER|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
214251406|NCT04105543|DRUG|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
214251407|NCT02809521|OTHER|Activity Liking|
214251408|NCT02393690|RADIATION|Iodine I-131|Given PO
214251409|NCT02393690|OTHER|Placebo Administration|Given PO
214251410|NCT02393690|DRUG|Selumetinib|Given PO
214251411|NCT00686179|DRUG|AZD3480|Capsule, oral, single dose, 6 days
214251412|NCT00686179|DRUG|Moxifloxacin|Capsule(encapsulated), oral, single dose
214251413|NCT00686179|DRUG|PLACEBO|Capsule, oral, single dose
214251414|NCT01954732|DRUG|metformin hydrochloride|Given PO
214251415|NCT01954732|OTHER|pharmacological study|Correlative studies
214251416|NCT00586846|DRUG|Cisplatin|Cisplatin 120 mg/m\^2
214653006|NCT02229422|DRUG|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
214251417|NCT00586846|DRUG|Doxorubicin|75mg/m\^2
214251418|NCT00586846|DRUG|Methotrexate|Methotrexate 12g/m\^2
214251419|NCT00626054|DRUG|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
214251420|NCT00626054|DRUG|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
214251421|NCT00069966|BIOLOGICAL|filgrastim|
214251422|NCT00069966|BIOLOGICAL|rituximab|
214251423|NCT00069966|DRUG|cisplatin|
214251424|NCT00069966|DRUG|cytarabine|
214251425|NCT00069966|DRUG|methylprednisolone|
214251426|NCT00069966|DRUG|pixantrone dimaleate|
214251427|NCT00069966|PROCEDURE|autologous bone marrow transplantation|
214251428|NCT00069966|PROCEDURE|peripheral blood stem cell transplantation|
214251429|NCT00715923|OTHER|Modified consent form|modified consent form used
214251430|NCT00715923|OTHER|Standard consent form|standard consent form used
214251431|NCT06011031|DEVICE|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
214251432|NCT06011031|DEVICE|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
214251433|NCT06288113|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214251434|NCT06288113|PROCEDURE|Computed Tomography|Undergo PET/CT and SPECT/CT
214251435|NCT06288113|OTHER|Gallium Ga 68 Gozetotide|Given IV
214251436|NCT06288113|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214251437|NCT06288113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214251438|NCT06288113|OTHER|Questionnaire Administration|Ancillary studies
214251439|NCT06288113|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214251440|NCT04408131|BIOLOGICAL|Blood sample|virological test
214251441|NCT04408131|BIOLOGICAL|Blood sample|serological test
214251442|NCT04075110|DRUG|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
214251443|NCT04075110|DRUG|Placebo|Placebo tablet once daily
214251444|NCT00001431|DRUG|gemcitabine|
214251445|NCT00801918|DRUG|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
214251446|NCT00801918|DRUG|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
214251447|NCT01778777|DEVICE|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
214251448|NCT04984603|PROCEDURE|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
214251449|NCT04526301|DEVICE|Tablo Hemodialysis System|Home hemodialysis treatments \~4 times a week.
214251450|NCT04907461|PROCEDURE|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
214251451|NCT01674634|BIOLOGICAL|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
214251452|NCT05731531|DEVICE|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
214251453|NCT04471597|DRUG|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
214251454|NCT04471597|DRUG|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
214251455|NCT04151342|DRUG|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
214251456|NCT04151342|OTHER|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
214251457|NCT00935298|DRUG|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
214251458|NCT05684523|DRUG|Valerian-Hop Extract|herbal drug
214251459|NCT05684523|DRUG|Placebo|Placebo
214251460|NCT01003444|PROCEDURE|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
214251461|NCT04302818|BEHAVIORAL|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
214251462|NCT04302818|BEHAVIORAL|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
214251463|NCT03813771|DRUG|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
214251464|NCT03813771|DRUG|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
214251465|NCT03813771|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
214251466|NCT03813771|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
214251467|NCT02761928|OTHER|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
214251468|NCT00636883|DRUG|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
214251469|NCT02059005|BEHAVIORAL|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
214251470|NCT02059005|BEHAVIORAL|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
214251471|NCT05037968|DEVICE|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
214251472|NCT05037968|DEVICE|Trinity Elite|Procedure: Instrumented Posterolateral Lumbar Fusion
214251473|NCT06799026|DRUG|Elranatamab|Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.
214251474|NCT06799026|BIOLOGICAL|GM-CSF|Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.
214251475|NCT06799026|BIOLOGICAL|DC/MM Fusion Vaccine|Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.
214251476|NCT02650427|DRUG|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
214251477|NCT05511701|BEHAVIORAL|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is \> 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
214251478|NCT05511701|BEHAVIORAL|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is \> 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
214251479|NCT06186479|DRUG|Aconite pain oil|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
214251480|NCT06186479|DRUG|Placebo|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
214251481|NCT06553326|DEVICE|EndoStyle|The EndoStyle system is able to transform the style of the different video-processor images.
214251482|NCT04042298|OTHER|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
214251483|NCT04042298|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
214251484|NCT04042298|OTHER|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
214251485|NCT04042298|OTHER|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
214251486|NCT05725499|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
214251487|NCT05725499|DIAGNOSTIC_TEST|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
214251488|NCT04619225|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
214251489|NCT05749770|OTHER|blood testing|blood testing for basal hormones and markers of inflammation
214251490|NCT02142803|BIOLOGICAL|Bevacizumab|Given IV
214251491|NCT02142803|OTHER|Laboratory Biomarker Analysis|Correlative studies
214251492|NCT02142803|OTHER|Pharmacological Study|Correlative studies
214251493|NCT02142803|DRUG|Sapanisertib|Given PO
214251494|NCT01298544|PROCEDURE|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
214251495|NCT02900560|DRUG|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
214251496|NCT02900560|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
214251497|NCT05950503|RADIATION|Hepatic MRI|The patients will undergo hepatic MRI in pre-established timepoints
214251498|NCT04929379|DRUG|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
214251499|NCT04929379|OTHER|Placebo|Inactive tablets identical to fenofibrate
214251500|NCT06224673|DRUG|ARX788|Given IV
214251501|NCT06224673|PROCEDURE|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
214251502|NCT06224673|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214251503|NCT06224673|DRUG|Amiloride|Ophthalmologic drops given topically to participants for an eye toxicity substudy
214251504|NCT04050917|DEVICE|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
214251505|NCT04050917|DEVICE|no stimulation|The smartwatch generates no stimulation.
214251506|NCT02196571|OTHER|Structured Exercise|
214251507|NCT00657904|DRUG|Bicalutamide|150mg daily
214251508|NCT00657904|DRUG|Placebo|once daily
214251509|NCT04321096|DRUG|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
214251510|NCT04321096|DRUG|Placebo oral tablet|Placebo
214251511|NCT07119840|DRUG|Listerine Mouthwash Product|Participants in this group will receive Listerine mouthwash containing essential oils (menthol, thymol, eucalyptol, and methyl salicylate). They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
214251512|NCT07119840|DRUG|Chlorhexidine mouthwash|Participants in this group will receive Chlorhexidine mouthwash at a concentration of 0.12%. They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
214251513|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
214251514|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
214251515|NCT06059547|DRUG|Placebo|Placebo (NaCl) for Visugromab (CTL-002)
214251516|NCT02718300|DRUG|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
214251517|NCT02718300|DRUG|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
214251518|NCT02718300|DRUG|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
214251519|NCT02718300|DRUG|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
214251520|NCT02718300|DRUG|Parsaclisib|"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
214251521|NCT06276530|OTHER|EOS imaging for musculoskeletal disorder|The patients will have a low radiation 2D/3D biplane imaging of the rib cage, and spine before and after surgery.
214251522|NCT06276530|OTHER|Movement analysis by an optoelectronic camera.|Movement analysis by an optoelectronic camera before and after surgery.
214251523|NCT06276530|OTHER|Stabilometric measurement by strength platform|Stabilometric measurement by strength platform before and after surgery.
214251524|NCT06813690|DEVICE|Cold Therapy with Axanova Cold Hot Pearls Maxi Pack|This intervention involves the application of the Axanova Cold Hot Pearls Maxi Pack, a cooling device designed to provide targeted cold therapy. The device will be used to cool both thighs for 20-minute sessions, three times per day, following a muscle soreness protocol. The cold therapy aims to reduce inflammation, swelling, and muscle pain associated with Delayed Onset Muscle Soreness (DOMS). The intervention begins immediately after completing the muscle soreness protocol in Group A, and 24 hours later in Group B. Participants will receive cooling treatment for a total of 72 hours, with temperature and duration carefully monitored to ensure effective cooling.
214251525|NCT03836976|OTHER|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
214251529|NCT05132439|DRUG|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
214251530|NCT05132439|DRUG|placebo|Matched to active study drug
214251531|NCT01996046|OTHER|FDG PET/CT scan|\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
214251532|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
214251533|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
214653007|NCT06742411|DRUG|XELOX+Sintilimab+HBOT|"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."
214251534|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
214251535|NCT03120624|OTHER|Pharmacological Study|Correlative studies
214251536|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
214251537|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
214251538|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
214251539|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
214251540|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
214251541|NCT06216015|OTHER|Exercise training|"Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each."
214251542|NCT06216015|OTHER|Continue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
214653008|NCT06621394|OTHER|nutritional intervention|nutritional intervention to mediterranean diet
214653009|NCT06621394|BEHAVIORAL|Mindful Eating|intervention regarding mindful eating, e.g. attention while eating, apprechiation of food
214251543|NCT06216015|OTHER|Discontinue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
214251544|NCT06147037|DRUG|FPI-2053|FPI-2053 is a bispecific antibody that targets EGFR and cMET
214251545|NCT06147037|DRUG|[111In]-FPI-2107|"\[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
214251546|NCT06147037|DRUG|[225Ac]-FPI-2068|"\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
214251547|NCT03315910|BEHAVIORAL|Motivational Interviewing (MI)|two counseling sessions
214251548|NCT03315910|DRUG|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
214251549|NCT03315910|DRUG|Nicotine Lozenge|6 packs of NRT 2mg lozenge
214251550|NCT03315910|BEHAVIORAL|Message Framing|health communication literature and quitting messages
214251551|NCT03315910|OTHER|saliva sample|saliva samples from those reporting abstinence and analyze samples
214251552|NCT07130552|DEVICE|femoral triangle block and popliteal plexus block|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for PPB
214251553|NCT07130552|DEVICE|Femoral triangle block and distal iPACK|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for distal iPACK
214251554|NCT05642039|BEHAVIORAL|Mindfulness Course|Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.
214251555|NCT05642039|BEHAVIORAL|HS Educational Course|Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.
214251556|NCT06619366|OTHER|coach-guided personalized depression risk communication|see information in arm description.
214653010|NCT06621394|OTHER|Attention Control|Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games
214653011|NCT05026905|DRUG|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
214653012|NCT05026905|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
214653013|NCT05026905|DRUG|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day"
214653014|NCT05026905|DRUG|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
214653015|NCT05026905|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
214653016|NCT00289679|DEVICE|Hip prosthesis revision|
214653017|NCT06782269|PROCEDURE|ankle fusion|fusion of ankle joint
214653018|NCT01052649|OTHER|Blood sampling|
214251557|NCT06619366|OTHER|depression risk information|see information in arm description.
214251558|NCT06076005|OTHER|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
214251559|NCT03098628|BIOLOGICAL|PCV Vaccine|PCV vaccination
214251560|NCT06694285|DIAGNOSTIC_TEST|Ultrasound evaluation|The subjects will constitute a cohort whose medical history, clinical, ultrasound and treatment data reported in the appropriate data collection form will be prospectively collected. Enrolled patients will undergo clinical and ultrasonographic evaluation in a manner not unlike routine clinical practice.
214251561|NCT06630039|OTHER|Scale validity and reliability|The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
214251562|NCT06691724|OTHER|LLM-based transcription and reporting tool|"The LLM-based transcription and reporting tool works in three steps:~1. The conversation between patient and GP is transcribed to text with a speech-to-text LLM~2. The text is summarized according to the Subjective, Objective, Assessment, Plan (SOAP) rules~3. The SOAP summary is imported in the electronic health record of the GP"
214251563|NCT05063318|DRUG|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
214251564|NCT05063318|DRUG|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
214251565|NCT07017387|BEHAVIORAL|Motivational interviewing based health education|Participants will receive three sessions of face-to-face health education using motivational interviewing techniques through home visits, along with an informational brochure.
214251566|NCT07017387|BEHAVIORAL|Health education|Participants will receive one face-to-face health education session and a brochure, followed by two reminder sessions via phone.
214653019|NCT06481137|DIAGNOSTIC_TEST|Electrophysiological study (EP study)|Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
214653020|NCT06481137|DIAGNOSTIC_TEST|ePatch (extended Holter Monitoring)|Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
214653021|NCT06916572|OTHER|Scapular stabilization exercises|"Individuals in the Scapular Stabilization group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included scapular stabilization exercises in addition to conventional treatment. Scapular stabilization exercises were planned to be applied only on the days of the session. Each of the exercises was applied as 10 repetitions and 2 sets.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
214251567|NCT07024706|DRUG|Acalabrutinib|Acalabrutinib is an orally available cBTKi that inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
214251568|NCT07024706|DRUG|Venetoclax|Venetoclax is an orally bioavailable inhibitor of the anti-apoptotic protein BCL-2
214251569|NCT07026279|DRUG|narmafotinib ascending doses|once daily capsules
214251570|NCT07026279|DRUG|narmafotinib dose comparison|once daily capsules
214251571|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
214251572|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
214251573|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
214251574|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
214251575|NCT06699732|BEHAVIORAL|Mindful Self Compassion Therapy|"Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.~Week 8: Integration - Consolidate skills to maintain self-compassion in daily life."
214251576|NCT06878261|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214251577|NCT06878261|OTHER|Placebo|Placebo subcutaneous injection
214251578|NCT07136103|DRUG|ABBV-277|• Intravenous (IV) infusion
214251579|NCT07136103|DRUG|Placebo|• Intravenous (IV) infusion
214251580|NCT07149519|DIETARY_SUPPLEMENT|probiotics - Lactobacillus spp|Group 1: Specific dietary guidance (low-FODMAP diet ) combined with placebo Group 2: Specific dietary guidance (low-FODMAP diet ) combined with probiotic Group 3: Control - Exclusive habitual diet After the 12-week period, we will evaluate the clinical improvement response of pelvic pain
214251581|NCT05887648|BEHAVIORAL|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
214251582|NCT00538564|DRUG|tadalafil|10mg oral tablets taken 3 times a week for 2 months
214251583|NCT00538564|DRUG|placebo|Placebo tablets taken orally 3 times a week for 2 months
214251584|NCT04885946|OTHER|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
214251585|NCT04885946|OTHER|Placebo|Food coloring, water, glycerol
214251586|NCT02999399|OTHER|Brussel Sprouts|Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
214251587|NCT02999399|DRUG|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
214251588|NCT00729924|DRUG|Raltegravir|400mg orally every 12 hours for 7 days
214251589|NCT06199037|DRUG|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
214251590|NCT06199037|DRUG|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
214251591|NCT04070144|DEVICE|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
214251592|NCT01638767|DRUG|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
214251593|NCT01638767|DRUG|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
214251594|NCT00400231|DRUG|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
214251595|NCT00400231|DRUG|Study Drug: Metformin|2000mg/day
214251596|NCT00400231|DRUG|Study Drug: fenofibrate|145mg/day of fenofibrate
214251597|NCT00400231|DRUG|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
214251598|NCT02862899|DEVICE|Thermowire|
214251599|NCT02250859|DRUG|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
214251600|NCT00311662|DRUG|Tonabersat|Tablet 40mg daily for 12 weeks
214251601|NCT00311662|DRUG|Placebo|Tablet once daily for 12 weeks
214251602|NCT01847001|DRUG|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
214251603|NCT01847001|OTHER|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
214251604|NCT01847001|DRUG|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
214251605|NCT01847001|DRUG|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
214251606|NCT01847001|DRUG|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
214251607|NCT01847001|DRUG|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
214251608|NCT01847001|DRUG|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
214251609|NCT01847001|DRUG|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
214251610|NCT01847001|PROCEDURE|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
214251611|NCT01847001|DRUG|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
214251612|NCT01847001|DRUG|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
214251613|NCT01847001|DRUG|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
214251614|NCT05131360|BEHAVIORAL|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
214251615|NCT05131360|BEHAVIORAL|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
214251616|NCT05131360|BEHAVIORAL|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
214251617|NCT05131360|BEHAVIORAL|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
214251618|NCT05131360|BEHAVIORAL|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
214251619|NCT05131360|BEHAVIORAL|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
214251620|NCT05131360|BEHAVIORAL|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
214251621|NCT05131360|BEHAVIORAL|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
214251622|NCT06403670|DRUG|Dexmedetomidine|Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
214251623|NCT06403670|DRUG|Remifentanil|Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
214251624|NCT04652232|OTHER|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
214251625|NCT04652232|OTHER|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
214251626|NCT06220279|DRUG|Diclofenac|Each were monitored for pain within 24 hours
214251627|NCT01927341|DRUG|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
214251628|NCT01927341|DRUG|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
214251629|NCT02235519|DRUG|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
214251630|NCT02235519|DRUG|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
214251631|NCT03250169|DRUG|Alemtuzumab|Licensed dose
214251632|NCT02022631|OTHER|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
214251633|NCT02022631|OTHER|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
214251634|NCT00411112|PROCEDURE|blue and isotopic detection of sentinel lymph nodes|
214251635|NCT06166082|DEVICE|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
214251636|NCT06166082|DEVICE|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214251637|NCT04918576|DRUG|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
214251638|NCT04918576|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
214251639|NCT00248131|DRUG|Octreotide acetate in microspheres|
214251640|NCT04209062|DEVICE|Medical device validation|The medical devices will both record electrical signals for comparison
214251641|NCT05064904|DRUG|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
214251642|NCT00849537|DRUG|Triamcinolone|Injection of intravitreal Triamcinolone
214251643|NCT00000612|DRUG|estrogens, conjugated|
214251644|NCT00000612|BEHAVIORAL|diet, soy proteins|
214251645|NCT00000612|BEHAVIORAL|dietary supplements|
214251646|NCT01464892|BEHAVIORAL|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
214251647|NCT01464892|BEHAVIORAL|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
214251648|NCT00171743|DRUG|Cyclosporine microemulsion|
214251649|NCT01135602|DRUG|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
214251650|NCT02858011|OTHER|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
214251651|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
214251652|NCT02858011|DIETARY_SUPPLEMENT|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
214251653|NCT02858011|OTHER|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
214251654|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
214251655|NCT02026284|OTHER|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
214251656|NCT04233034|DEVICE|HCL|Hybrid Closed Loop therapy
214251657|NCT04233034|DRUG|verapamil 120mg tablet|verapamil tablet
214653022|NCT06916572|OTHER|Scapular PNF|"Physiotherapy and rehabilitation program was applied to the individuals in the PNF group for 6 weeks, 3 days a week, as in the Scapular Stabilization group. In addition to conventional treatment, scapular PNF approaches were added to the treatment of individuals in this group.~The scapular PNF patterns of anterior elevation - posterior depression and anterior depression - posterior elevation were applied with rhythmic initiation, repeated contractions (stretches) and rhythmic stabilization techniques with 10 repetitions of each technique.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
214251658|NCT04233034|DEVICE|non-HCL|Usual diabetes care
214251659|NCT04233034|DRUG|placebo|placebo pill manufactured to mimic verapamil 120mg tablet
214251660|NCT06201416|BIOLOGICAL|SBT777101|Experimental treatment
214251661|NCT02791399|BEHAVIORAL|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
214251662|NCT01991106|BEHAVIORAL|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
214251663|NCT01991106|BEHAVIORAL|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
214251664|NCT01991106|DIETARY_SUPPLEMENT|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
214251665|NCT06283524|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214251666|NCT00451451|DRUG|BG00012|
214251667|NCT00451451|DRUG|Placebo|
214251668|NCT00451451|DRUG|Glatiramer Acetate|
214251670|NCT02804529|DEVICE|Veress needle|
214251671|NCT05447039|DRUG|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
214251672|NCT00084838|BIOLOGICAL|filgrastim|
214251673|NCT00084838|DRUG|cisplatin|
214251674|NCT00084838|DRUG|cyclophosphamide|
214251675|NCT00084838|DRUG|cytarabine|
214251676|NCT00084838|DRUG|dexrazoxane hydrochloride|
214251677|NCT00084838|DRUG|doxorubicin hydrochloride|
214251678|NCT00084838|DRUG|etoposide|
214251679|NCT00084838|DRUG|leucovorin calcium|
214251680|NCT00084838|DRUG|methotrexate|
214251681|NCT00084838|DRUG|temozolomide|
214251682|NCT00084838|DRUG|therapeutic hydrocortisone|
214251683|NCT00084838|DRUG|vincristine sulfate|
214251684|NCT00084838|RADIATION|radiation therapy|
214251685|NCT00084838|DRUG|Dactinomycin|
214251686|NCT01764425|DRUG|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
214251687|NCT01654627|DEVICE|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
214251688|NCT01654627|DEVICE|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
214251689|NCT00017238|DRUG|KRN5500|Given IV
214251690|NCT00017238|OTHER|pharmacological study|Correlative studies
214251691|NCT05785104|OTHER|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
214251692|NCT05785104|OTHER|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
214251693|NCT00122278|DRUG|Dexamethasone|Dexamethasone 10mg IV
214251694|NCT00122278|OTHER|Placebo|Placebo Dexamethasone 10mg IV
214251695|NCT06045169|PROCEDURE|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
214251696|NCT00558727|DRUG|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
214251697|NCT06431373|DRUG|Brepocitinib PO QD|Brepocitinib PO QD
214251698|NCT06431373|DRUG|Placebo PO QD|Placebo PO QD
214251699|NCT01871857|DRUG|Hypertonic saline and epinephrine|
214251700|NCT01871857|DRUG|Normal saline and epinephrine|
214251701|NCT02898155|OTHER|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
214251702|NCT03480035|PROCEDURE|lightwand intubation|intubation using lightwand
214251703|NCT01865084|DRUG|Tadalafil|Administered orally
214251704|NCT01865084|DRUG|Placebo|
214251705|NCT01598675|OTHER|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
214251706|NCT01598675|OTHER|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
214251707|NCT02469376|DRUG|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
214251708|NCT02289001|BEHAVIORAL|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
214251709|NCT02653534|BEHAVIORAL|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
214251710|NCT04351997|PROCEDURE|Cord clamping|Umbilical cord clamping after delivery.
214251711|NCT00503516|DRUG|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
214251712|NCT00503516|DRUG|Placebo|1 sachet of 160 mg of placebo b.i.d.
214251713|NCT05132868|OTHER|Educational video and pamphlet|The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
214251714|NCT05132868|OTHER|Traditional genetic counseling|Patients will receive traditional genetic counseling
214251715|NCT06957080|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
214251716|NCT06957080|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
214251717|NCT03732690|OTHER|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
214251718|NCT03732690|OTHER|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
214251719|NCT03294473|BEHAVIORAL|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
214251720|NCT03294473|BEHAVIORAL|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
214251721|NCT03294473|BEHAVIORAL|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
214251722|NCT01994590|DRUG|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
214251723|NCT01994590|DRUG|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
214251724|NCT01994590|DRUG|Prednisone|5 mg by mouth twice daily.
214251725|NCT05023707|BIOLOGICAL|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
214251726|NCT03607422|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
214251727|NCT03607422|DRUG|Upadacitinib|Tablets taken orally once a day
214251728|NCT00261183|DRUG|Melatonin|
214251729|NCT05899062|OTHER|"Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp"|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
214251730|NCT05899062|OTHER|Training and exercise practices with the telerehabilitation method.|The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 4 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
214251731|NCT03964805|OTHER|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
214251732|NCT03964805|OTHER|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
214251733|NCT03964805|OTHER|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
214251734|NCT06710951|PROCEDURE|Change of normal concentration of povidone-iodine 5% to 1%|Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.
214251735|NCT03693170|DRUG|encorafenib|300 mg administered orally once daily (QD)
214653023|NCT06915350|OTHER|maspin ( mammary serine protease inhibitor)|Maspin is an immunohistochemical marker to detect the prognosis of colorectal carcinoma
214653024|NCT06916611|OTHER|Cardiac Magnetic Resonance Imaging|This study included patients who were diagnosed with HFpEF and had completed CMR.
214653025|NCT06916104|OTHER|search for respiratory allergies|analyses in terms of biotherapy and respiratory allergy
214653026|NCT06915701|DIETARY_SUPPLEMENT|Will take vitamin E 800mg/day|Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.
214653027|NCT06915701|DRUG|Will take 200mg/day magnesium oxide placebo.|Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.
214251736|NCT03693170|DRUG|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
214251737|NCT03693170|DRUG|Cetuximab|"Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
214653028|NCT06917040|DEVICE|Spatial repellant emanator|Spatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).
214251738|NCT06319638|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
214251739|NCT06319638|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214251740|NCT06319638|PROCEDURE|Placebo block|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214251741|NCT06319638|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
214251742|NCT06802172|BEHAVIORAL|Time-restricted eating|Participate in time-restricted eating plan
214251743|NCT06802172|OTHER|Questionnaire Administration|Complete questionnaire
214251744|NCT06802172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
214251745|NCT06802172|BEHAVIORAL|Health coaching|Receive nutrition counseling
214251746|NCT03875118|BEHAVIORAL|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
214251747|NCT03875118|BEHAVIORAL|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
214251748|NCT06515977|PROCEDURE|TXI (Group A)|Patients in Group A will undergo colonoscopy with TXI.
214251749|NCT06515977|PROCEDURE|TXI followed by WLI (Group B)|Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
214251750|NCT06515977|PROCEDURE|WLI (Group C)|Patients in Group C will undergo colonoscopy with WLI.
214251751|NCT06515977|PROCEDURE|WLI followed by TXI (Group D)|Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
214251752|NCT01043146|DRUG|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
214251753|NCT01043146|DRUG|placebo|intravenous 0.9 % NaCl
214251754|NCT00215202|DRUG|Iressa (ZD1839)|
214251755|NCT03092024|OTHER|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
214251756|NCT04360590|DEVICE|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
214251757|NCT04765215|BIOLOGICAL|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
214251758|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
214251759|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
214251760|NCT01423019|OTHER|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
214251761|NCT01416844|BIOLOGICAL|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
214251762|NCT05391542|OTHER|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
214251763|NCT01499069|DRUG|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
214251764|NCT02919371|DRUG|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
214251765|NCT02919371|DRUG|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
214251766|NCT01545258|OTHER|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
214251767|NCT00420667|DRUG|Enoxaparin|
214251768|NCT02128828|DRUG|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
214251769|NCT02310932|BEHAVIORAL|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
214251770|NCT03228420|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
214251771|NCT03228420|OTHER|CMM|Conventional Medical Management
214251772|NCT03090841|BIOLOGICAL|Bio-specimen collected|
214251773|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
214251774|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
214251775|NCT01298531|DRUG|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
214251776|NCT04343300|OTHER|Pilates|Intervention of12 weeks of Pilates
214251777|NCT04343300|OTHER|exercise without Pilates|exercise without Pilates
214251778|NCT03897504|PROCEDURE|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
214251779|NCT04833673|BEHAVIORAL|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
214251780|NCT04833673|BEHAVIORAL|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
214251781|NCT05650060|DRUG|Secukinumab|all patients with psoriasis who received secukinumab
214251782|NCT04703387|DIAGNOSTIC_TEST|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
214251783|NCT01841736|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214251784|NCT01841736|PROCEDURE|Computed Tomography|Undergo CT
214251785|NCT01841736|PROCEDURE|Echocardiography Test|Undergo ECHO
214251786|NCT01841736|OTHER|Laboratory Biomarker Analysis|Correlative studies
214251787|NCT01841736|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214251788|NCT01841736|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214251789|NCT01841736|DRUG|Pazopanib Hydrochloride|Given PO
214251790|NCT01841736|OTHER|Placebo Administration|Given PO
214251791|NCT01841736|OTHER|Quality-of-Life Assessment|Ancillary studies
214251792|NCT01841736|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
214251793|NCT01933217|DRUG|Methylphenidate|
214251794|NCT01933217|DRUG|Placebo|
214251795|NCT04779996|DIAGNOSTIC_TEST|Laboratory Samples|"1. After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~2. Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~3. Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
214251796|NCT03111173|DEVICE|Holter Device|MyECG E3.80 Holter Recorder
214251797|NCT04757740|BIOLOGICAL|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
214251798|NCT04757740|DRUG|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
214251799|NCT02706054|OTHER|saline|The patients received an IM injection of saline near the nerve root (periradicular)
214251800|NCT02706054|DRUG|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
214251801|NCT04378907|OTHER|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214251802|NCT03115073|DRUG|Candiplus|Administration of Candiplus
214251803|NCT03115073|DRUG|Clotrimazole|Administration of Clotrimazole
214251804|NCT01377571|BIOLOGICAL|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
214251805|NCT02861131|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
214251806|NCT02861131|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
214251807|NCT00027937|BIOLOGICAL|aldesleukin|
214251808|NCT00027937|BIOLOGICAL|filgrastim|
214251809|NCT00027937|BIOLOGICAL|sargramostim|
214251810|NCT00027937|DRUG|busulfan|
214251811|NCT00027937|DRUG|cyclophosphamide|
214251812|NCT00027937|DRUG|melphalan|
214251813|NCT00027937|DRUG|paclitaxel|
214251814|NCT00027937|DRUG|thiotepa|
214251815|NCT00027937|PROCEDURE|bone marrow ablation with stem cell support|
214251816|NCT00027937|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214251817|NCT03923738|DRUG|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
214251818|NCT03189771|PROCEDURE|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
214251819|NCT04953299|BEHAVIORAL|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
214251820|NCT04953299|BEHAVIORAL|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
214251821|NCT05234658|BIOLOGICAL|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
214251822|NCT05234658|BIOLOGICAL|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
214251823|NCT05234658|BIOLOGICAL|Skin Autograft|Skin Autograft
214251824|NCT02937428|BEHAVIORAL|Look away from the needle|Participant looks away from the needle during vaccination
214251825|NCT02937428|BEHAVIORAL|Look at the needle|Participant looks at the needle during vaccination
214251826|NCT05922956|OTHER|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
214251827|NCT00209768|DEVICE|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
214251828|NCT03303014|DEVICE|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
214251829|NCT03583164|DRUG|Olorofim|30mg oral tablets
214251830|NCT00620789|DRUG|Escitalopram + CBT-I|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase."
214251831|NCT00620789|BEHAVIORAL|CBT-I plus placebo antidepressant medication|"* CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months)."
214251832|NCT00620789|DRUG|Escitalopram|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase"
214251833|NCT02291744|PROCEDURE|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
214251834|NCT02291744|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
214251835|NCT01413412|PROCEDURE|Ventral hernia repair using full thickness skin graft|25 patients
214251836|NCT01413412|PROCEDURE|Ventral hernia repair using mesh|25 patients
214251837|NCT02164149|OTHER|Patients with primary colon cancer|CT scan two days after surgery
214251838|NCT05369676|DRUG|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
214251839|NCT05369676|DRUG|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
214251840|NCT06087913|DRUG|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
214251841|NCT06087913|DRUG|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
214251842|NCT03320226|DIETARY_SUPPLEMENT|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
214251843|NCT00486551|BEHAVIORAL|Anger control training|
214251844|NCT00735254|DEVICE|pulsed dye laser|patient will have scar treated with pulsed dye laser
214251845|NCT00735254|DEVICE|Affirm Laser|patient will have scar treated with Affirm laser
214251846|NCT00735254|DEVICE|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
214251847|NCT00735254|OTHER|Placebo|patient will receive no treatment
214251848|NCT04882046|OTHER|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
214251849|NCT04882046|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
214251850|NCT03603054|OTHER|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
214251851|NCT03603054|OTHER|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
214251852|NCT02835131|DRUG|Pasireotide|
214251853|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
214251854|NCT04147572|DRUG|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
214251855|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
214251856|NCT04147572|DEVICE|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
214251857|NCT04147572|DEVICE|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
214251858|NCT02494362|OTHER|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
214251859|NCT02976298|OTHER|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
214251860|NCT04176887|DRUG|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
214251861|NCT04176887|DRUG|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
214251862|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
214251863|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
214251864|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
214251865|NCT02144129|OTHER|active Whole Body Electromyostimulation|
214251866|NCT02144129|OTHER|Passive WB-EMS|
214251867|NCT02144129|DEVICE|WB-EMS application|
214251868|NCT02764125|DRUG|Stalevo|levodopa/carbidopa/entacapone
214251869|NCT02764125|DRUG|levodopa MR|levodopa MR/carbidopa/ODM-104
214251870|NCT04327960|DIAGNOSTIC_TEST|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
214251871|NCT02729675|OTHER|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F\&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F\&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F\&V fresh.
214251872|NCT02729675|BEHAVIORAL|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F\&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F\&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
214251873|NCT02729675|BEHAVIORAL|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
214251874|NCT02606695|DEVICE|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
214251875|NCT02606695|DEVICE|NuvaMap|Clinical imaging software used to assess spinal alignment
214251876|NCT05807633|DEVICE|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
214251877|NCT04034082|DEVICE|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
214251878|NCT04034082|OTHER|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
214251879|NCT03537612|DRUG|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
214251880|NCT03537612|OTHER|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
214251881|NCT05161195|DRUG|Ribociclib|Participants continue ribociclib as was administered in their parent study
214251882|NCT05161195|DRUG|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
214653029|NCT06915649|PROCEDURE|Amygdalo-Hippocampectomy|"This technique is characterized by specific hallmarks that distinguish it from other approaches, including the Yasargil technique and newer minimally invasive methods. It integrates precise anatomical targeting with optimized surgical pathways to enhance outcomes in patients with those pathologies. The approach of the choroidal fissure will be explained in the article.~By addressing limitations observed in traditional techniques, it aims to minimize neurological deficits while achieving better seizure control."
214653030|NCT06916793|DRUG|CKD-843 dose#1|IM injection every 3 months for 12 months
214653031|NCT06916793|DRUG|CKD-843 dose#2|IM injection every 3 months for 12 months
214653032|NCT06916793|DRUG|Placebo of CKD-843 dose|IM injection every 3 months for 12 months
214653033|NCT06916793|DRUG|Dutasteride Capsules|oral, once daily, 12 months
214653034|NCT06916793|DRUG|Placebo of Dutasteride Capsule|oral, once daily, 12 months
214653035|NCT05648474|DIAGNOSTIC_TEST|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
214251883|NCT05161195|DRUG|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
214251884|NCT05161195|DRUG|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
214251885|NCT05161195|DRUG|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
214251886|NCT05161195|DRUG|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
214251887|NCT03819426|BEHAVIORAL|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
214251888|NCT03819426|BEHAVIORAL|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
214251889|NCT04454164|BIOLOGICAL|PRP|platelet rich plasma
214251890|NCT04454164|DRUG|Saline|serum physiologic
214251891|NCT02797015|DRUG|RPC1063|Oral capsule daily
214251892|NCT04213521|OTHER|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
214251893|NCT04213521|OTHER|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
214251894|NCT05258643|OTHER|Blood analysis|Venipuncture and collection of serum and whole blood
214251895|NCT00132639|DRUG|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
214251896|NCT00132639|DRUG|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
214251897|NCT02330809|OTHER|Daily extra water intake|Amount of extra daily water intake to consume
214251898|NCT02330809|OTHER|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
214251899|NCT01404975|OTHER|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
214251900|NCT00316771|DRUG|P38 Inhibitor (4) 150mg|150mg po qd
214251901|NCT00316771|DRUG|P38 Inhibitor (4) 25mg|25mg po bid
214251902|NCT00316771|DRUG|P38 Inhibitor (4) 300mg|300mg po qd
214251903|NCT00316771|DRUG|P38 Inhibitor (4) 50mg|50mg po qd
214251904|NCT00316771|DRUG|P38 Inhibitor (4) 75mg|75mg po bid
214251905|NCT00316771|DRUG|Placebo|po bid
214653036|NCT03684655|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
214251906|NCT00057954|PROCEDURE|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
214251907|NCT00057954|DRUG|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
214251908|NCT00057954|RADIATION|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
214251909|NCT00057954|PROCEDURE|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
214251910|NCT00057954|DRUG|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
214251911|NCT00057954|DRUG|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
214251912|NCT00057954|DRUG|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
214251913|NCT00559754|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
214251914|NCT00559754|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
214251915|NCT00559754|DRUG|Standard chemotherapy|As prescribed
214251916|NCT06219694|DEVICE|Laser Acupuncture|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
214251917|NCT06219694|DEVICE|Sham|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After \> 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
214251918|NCT01251744|PROCEDURE|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
214251919|NCT01251744|PROCEDURE|Cord blood sample|Cord blood sample taken at the time of delivery.
214251920|NCT01251744|PROCEDURE|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
214653037|NCT06533592|PROCEDURE|Continous suture technique|Duct-to-duct anastomosis will be performed using continuous suture technique for study group
214653038|NCT06533592|PROCEDURE|Interrupted suture technique|Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
214251921|NCT01251744|PROCEDURE|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
214251922|NCT01251744|PROCEDURE|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
214251923|NCT05839483|DIAGNOSTIC_TEST|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
214251924|NCT00315146|DRUG|Pioglitazone|
214251925|NCT00315146|BEHAVIORAL|Resistance exercise training to maximize muscle power|
214251926|NCT00315146|BEHAVIORAL|Hypocaloric diet|
214251927|NCT00315146|DRUG|Placebo|
214251928|NCT02830061|OTHER|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
214251929|NCT04863547|OTHER|Data collection|Data collection
214251930|NCT02334631|DRUG|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
214251931|NCT02334631|DRUG|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
214251932|NCT05179850|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
214251933|NCT01299701|DRUG|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
214251934|NCT03325699|DEVICE|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
214251935|NCT00920101|DRUG|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
214251936|NCT00920101|BEHAVIORAL|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
214251937|NCT05104554|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
214251938|NCT05104554|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
214251939|NCT05067673|OTHER|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
214251940|NCT05067673|OTHER|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
214251941|NCT00009061|DRUG|Ritonavir|
214251942|NCT00009061|DRUG|Abacavir sulfate|
214251943|NCT00009061|DRUG|Nelfinavir mesylate|
214251944|NCT00009061|DRUG|Lamivudine|
214251945|NCT00009061|DRUG|GW433908|
214653039|NCT05799261|PROCEDURE|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
214251946|NCT01068652|DRUG|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
214251947|NCT01068652|DRUG|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
214251948|NCT01068652|DRUG|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
214251949|NCT01068652|DRUG|metformin|1000-2000 mg/day in combination with insulin treatment
214251950|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
214251951|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
214251952|NCT06224543|DEVICE|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
214251953|NCT06224543|DRUG|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
214251954|NCT03601000|DRUG|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
214251955|NCT03601000|DRUG|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
214251956|NCT06556758|OTHER|stripping massage + conventional therapy|Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks. Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks
214251957|NCT06556758|OTHER|Conventional therapy|conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
214251958|NCT03149393|DRUG|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
214251959|NCT03149393|DRUG|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
214251960|NCT04804501|DEVICE|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
214251961|NCT04804501|OTHER|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
214251962|NCT04437953|DRUG|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, … 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
214251963|NCT05732987|OTHER|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
214251964|NCT05732987|OTHER|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
214251965|NCT05732987|OTHER|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
214251966|NCT05732987|OTHER|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
214251967|NCT03368248|OTHER|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
214251968|NCT05536505|GENETIC|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
214251969|NCT03003156|PROCEDURE|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214251970|NCT03003156|PROCEDURE|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214251971|NCT04807478|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
214251972|NCT06556264|DRUG|Dupilumab|Dupilumab 300mg every 2 weeks for 24 weeks
214251973|NCT06556264|OTHER|Placebo|Placebo 300mg every 2 weeks for 24 weeks
214251974|NCT02297282|BEHAVIORAL|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
214251975|NCT05648071|DRUG|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
214251976|NCT03220529|DEVICE|Brillouin Ocular Scanner|
214251977|NCT02770261|DRUG|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
214251978|NCT02770261|DRUG|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
214251979|NCT02770261|DRUG|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
214251980|NCT02770261|DRUG|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
214251981|NCT02770261|DRUG|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
214251982|NCT02770261|DRUG|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
214251983|NCT00751621|BIOLOGICAL|IgPro20|
214251984|NCT01270854|OTHER|Plasmalyte A|Intravenous fluid
214251985|NCT01270854|OTHER|Normal Saline|Intravenous fluid
214251986|NCT03059433|OTHER|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
214251987|NCT04490824|DEVICE|KELEA Excellerated Water|Water with increased kinetic activity as assessed by published methods of the PI
214251988|NCT04490824|DEVICE|Water Without an Elevated Level of KELEA|Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
214251989|NCT03343067|DRUG|elagolix|Tablets
214251990|NCT03343067|DRUG|estradiol/norethindrone acetate (E2/NETA)|Capsules
214251991|NCT01285453|DRUG|vadimezan|
214251992|NCT04804007|DRUG|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
214251993|NCT03751228|DRUG|BMS-986165|Swish and expectorate after tasting
214251994|NCT03751228|DRUG|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
214251995|NCT04205994|DRUG|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
214251996|NCT04205994|OTHER|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
214251997|NCT01323946|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
214251998|NCT02860455|DEVICE|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
214251999|NCT02860455|DEVICE|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
214252000|NCT02824965|DRUG|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
214252001|NCT02824965|BIOLOGICAL|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
214252002|NCT03282851|DRUG|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
214252003|NCT03282851|DRUG|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
214252004|NCT03282851|DRUG|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
214252005|NCT00773929|DRUG|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
214252006|NCT04226534|OTHER|Maximal effort test|Performing a maximal effort test on the treadmill
214252007|NCT05174845|DRUG|1L PEG + ASCORBIC ACID|"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
214252008|NCT04033198|PROCEDURE|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
214252009|NCT02193451|PROCEDURE|Urodynamics|Diagnostic test for urinary storage and voiding function
214252010|NCT02193451|PROCEDURE|Usual care|
214252011|NCT03057379|OTHER|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
214252012|NCT01243671|BIOLOGICAL|Adalimumab|
214252013|NCT00312637|PROCEDURE|Magnetic Resonance Spectroscopy|
214252014|NCT06145906|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
214252015|NCT06145906|PROCEDURE|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
214252016|NCT03470948|OTHER|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
214252017|NCT04806958|OTHER|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
214252018|NCT02175784|DRUG|ipragliflozin|oral
214252019|NCT02175784|DRUG|placebo|oral
214252020|NCT00573248|DRUG|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
214252021|NCT00573248|OTHER|Placebo|Placebo Patch
214252022|NCT02737046|DRUG|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
214252023|NCT02737046|DRUG|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
214252024|NCT02737046|DRUG|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
214252025|NCT02737046|DRUG|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
214252026|NCT05059795|DRUG|Albumin + electrolyte solution|Type of resuscitation fluid, dose and use of inotrope
214252027|NCT05059795|DIAGNOSTIC_TEST|POCUS guided fluid resuscitation|Conventional goal directed therapy
214252028|NCT02602392|BEHAVIORAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
214252029|NCT02602392|BEHAVIORAL|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
214252030|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
214252031|NCT05790174|BEHAVIORAL|"ROS chubby and healthy - a multidisciplinary family-based weight-loss treatment program"|"The weight-loss treatment program ROS is family-based and delivered by a multidisciplinary team of physicians, nurses, dieticians, and psychologists. The treatment is based on an individualized tailored plan made together with the family. The plan consists of dietary changes, more physical activity, regular weight checks, and motivational conversations. The program includes options of cooking classes, group session with a psychologist and participation in structured physical activity called ROS sports twice a week. Follow up visits are scheduled every 2-3 months at the different health care professionals."
214252032|NCT05790174|BEHAVIORAL|Overweight Clinic for Children and Adolescents|The 'Overweight Clinic for Children and Adolescents' program at the municipal Health Center is based on the family-centered, multidisciplinary protocol developed by the Children's Obesity Clinic (TCOCT) at Holbæk Hospital. The intervention is individualized, informed by medical history and a structured questionnaire-based interview to identify behavioral and lifestyle changes needed to reduce the child's degree of overweight or obesity. The program consists of individual consultations every 6-8 weeks over approximately 12-18 months, with additional follow-up appointments as needed.
214252033|NCT05790174|BEHAVIORAL|Family Nutrition Guidance|"This treatment program is based on the Danish Health Authority's recommendations for lifestyle interventions. It follows a family-centered approach tailored to the family's everyday life and habits, focusing on sustainable changes in diet and physical activity. The program provides guidance on healthy eating, physical activity, and strategies for integrating these behaviors into daily routines.~The program included the entire family and began with school-based consultations delivered by health nurses during the first three months, followed by additional sessions at the municipal Health Center when needed. Families were offered 4-6 consultations within the first six months and follow-up sessions twice a year."
214252034|NCT05619523|BEHAVIORAL|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
214252035|NCT04965493|DRUG|Pirtobrutinib|Oral
214252036|NCT04965493|DRUG|Venetoclax|Oral
214252037|NCT04965493|DRUG|Rituximab|Intravenous (IV)
214252038|NCT06063772|DRUG|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
214252039|NCT06063772|DRUG|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
214252040|NCT01013649|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
214252041|NCT01013649|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214252042|NCT01013649|DRUG|Capecitabine|Given PO
214252043|NCT01013649|DRUG|Chemotherapy|Given combination chemotherapy
214252044|NCT01013649|PROCEDURE|Computed Tomography|Undergo CT
214252045|NCT01013649|DRUG|Erlotinib Hydrochloride|Given PO
214252046|NCT01013649|DRUG|Fluorouracil|Given IV
214252047|NCT01013649|DRUG|Gemcitabine Hydrochloride|Given IV
214252048|NCT01013649|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
214252049|NCT01013649|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214252050|NCT01013649|OTHER|Quality-of-Life Assessment|Ancillary studies
214252051|NCT01013649|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214252052|NCT06399198|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
214252053|NCT04967612|OTHER|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
214252054|NCT02808871|DRUG|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
214252055|NCT02808871|DRUG|Placebo|Placebo three times daily for 52 weeks
214252056|NCT06340854|DRUG|Insulin icodec|Insulin Icodec will be administered subcutaneously.
214252057|NCT06340854|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
214252058|NCT05748470|OTHER|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
214252059|NCT05748470|OTHER|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
214252060|NCT04776239|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
214252061|NCT04776239|OTHER|Placebo|Placebo delivered via peripheral intravenous infusion
214252062|NCT04337450|DRUG|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
214252063|NCT04337450|DRUG|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
214252064|NCT05826782|BIOLOGICAL|Proxeed Plus 2*1 A arm|Proxeed plus 2 x daily sachets (2\*1) three mounths
214653040|NCT05799261|PROCEDURE|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
214252065|NCT05826782|BIOLOGICAL|Placebo|Placebo 2 x daily sachets (2\*1) three mounths
214252066|NCT03978481|COMBINATION_PRODUCT|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
214252067|NCT06043323|DRUG|Axicabtagene Ciloleucel|Given by IV (vein)
214252068|NCT06043323|DRUG|Cyclophosphamide|Given by IV (vein)
214252069|NCT06043323|DRUG|Fludarabine phosphate|Given by IV (vein)
214252070|NCT06043323|DRUG|Prednisone|Given by IV (vein)
214252071|NCT06043323|DRUG|Diphenhydramine|Given by IV (vein)
214252072|NCT06043323|DRUG|Acetaminophen|Given by IV (vein)
214653041|NCT04558593|PROCEDURE|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
214252073|NCT06434038|DRUG|Low Dose Regular insulin|Administered intranasally at 40 IU
214252074|NCT06434038|DRUG|High Dose Regular insulin|Administered Intranasally at 80 IU
214252075|NCT06434038|OTHER|0.9% Saline|Placebo control
214252076|NCT02284711|DEVICE|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
214252077|NCT02284711|DEVICE|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
214252078|NCT04685226|DRUG|ICP-723|ICP-723 is a white, round, uncoated table
214252079|NCT06513312|DRUG|Lenacapavir Injection|Administered subcutaneously
214252080|NCT06513312|DRUG|Lenacapavir Tablet|Administered orally
214252081|NCT06513312|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
214252082|NCT05227547|OTHER|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
214252083|NCT05323656|DRUG|Setanaxib|Oral tablets, 400 mg per tablet
214252084|NCT05323656|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
214252085|NCT05323656|DRUG|Placebo|Oral tablets
214252086|NCT05942469|BEHAVIORAL|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
214252087|NCT02398409|BEHAVIORAL|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
214252088|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
214252089|NCT03799172|DRUG|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
214252090|NCT03799172|DRUG|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
214252091|NCT03792243|PROCEDURE|Complication|Readmission, reoperation
214252092|NCT03370289|BIOLOGICAL|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
214252093|NCT05814601|DRUG|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
214252094|NCT03309046|OTHER|REACH Individual Session|Individual telephone session with parent
214252095|NCT03309046|OTHER|Education Webinar|Videos with information on caregiving
214252096|NCT00401895|DEVICE|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
214252097|NCT04934280|DIAGNOSTIC_TEST|sonohysterography|saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
214252098|NCT01584570|DRUG|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
214252099|NCT04758845|DIETARY_SUPPLEMENT|Cocktail|Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.
214252100|NCT04758845|DIETARY_SUPPLEMENT|CGI314|Subjects will consume 1B CFU of CGI314 once daily for 45 days.
214252101|NCT04758845|DIETARY_SUPPLEMENT|CSI08|Subjects will consume 1B CFU of CSI08 once daily for 45 days.
214252102|NCT04758845|DIETARY_SUPPLEMENT|MIT411|Subjects will consume 1B CFU of MIT411 once daily for 45 days.
214252103|NCT05549427|OTHER|Ventilation|Ventilation in ICU
214252104|NCT00236951|DRUG|iron sucrose injection USP|
214252105|NCT00236951|DRUG|stable erythropoietin therapy|
214252106|NCT03963401|DRUG|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
214252107|NCT03963401|OTHER|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
214252108|NCT00652639|DRUG|Clonazepam|Tablets, 1 mg, single-dose
214252109|NCT00652639|DRUG|Klonopin|tablets, 1 mg, single-dose
214252110|NCT03095768|OTHER|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
214252111|NCT03279471|DRUG|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
214252112|NCT03279471|BEHAVIORAL|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
214252113|NCT03279471|DRUG|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
214252114|NCT01050478|DRUG|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
214252115|NCT01050478|DRUG|Benzodiazepine|Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
214252116|NCT06271499|OTHER|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
214252117|NCT06271499|OTHER|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
214252118|NCT01834482|DIETARY_SUPPLEMENT|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
214252119|NCT01834482|DIETARY_SUPPLEMENT|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
214252120|NCT03096145|BEHAVIORAL|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
214252121|NCT03096145|BEHAVIORAL|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
214252122|NCT03096145|BEHAVIORAL|Health incentive|Smokers receive a $25 gift card if they call the quitline
214252123|NCT05025748|BEHAVIORAL|Behavioral Intervention|Complete questionnaires
214252124|NCT02123628|DRUG|duration of the antibiotic therapy|
214252125|NCT00273507|DRUG|Carboplatin and Paclitaxel|
214252126|NCT00225043|DRUG|Epinephrine/phenylephrine|
214252127|NCT03488823|DIETARY_SUPPLEMENT|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
214252128|NCT03488823|DIETARY_SUPPLEMENT|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
214252129|NCT02305043|OTHER|non-interventional|non-interventional
214252130|NCT05075057|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
214252131|NCT00003046|BIOLOGICAL|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
214252132|NCT04895800|DIETARY_SUPPLEMENT|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
214252133|NCT04895800|DIETARY_SUPPLEMENT|Placebo|Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)
214252134|NCT04895800|DIETARY_SUPPLEMENT|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
214252135|NCT06822972|DRUG|Selinexor 40 mg|Patients will receive 40mg of oral SEL, weekly, beginning after they have completed step-up dosing and are 5 (± 2) days out from administration of the first full treatment dose of bispecific antibody therapy for 12 months or until disease progression.
214252136|NCT05160987|DRUG|Remimazolam|Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
214252137|NCT05160987|DRUG|Midazolam|Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
214252138|NCT04732156|BIOLOGICAL|Blood sample|Measurement of PHI Index
214252139|NCT04732156|OTHER|Follow up questionnaire|3 years after inclusion
214252140|NCT04732156|DIAGNOSTIC_TEST|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
214252141|NCT02057627|BEHAVIORAL|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
214252142|NCT02057627|BEHAVIORAL|Placebo Comparator|Standard care plus depression monitoring by phone
214252143|NCT00410228|DRUG|AHT956|
214252144|NCT00979069|BEHAVIORAL|Aerobic group|12 weeks of aerobic exercise 3 times a week
214252145|NCT02981810|DEVICE|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
214252146|NCT02981810|PROCEDURE|tonsillectomy|
214252147|NCT04951232|DRUG|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
214252148|NCT04951232|OTHER|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
214252149|NCT04880005|BEHAVIORAL|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
214252150|NCT04880005|BEHAVIORAL|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
214252151|NCT04880005|BEHAVIORAL|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
214252152|NCT02935101|DRUG|Prednisolone|formulated for oral administration. encapsulated.
214252153|NCT02935101|DRUG|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
214252154|NCT00006169|BEHAVIORAL|Behavioral Treatment|
214252155|NCT04842422|DRUG|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
214252156|NCT05266027|DRUG|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
214252157|NCT05266027|DRUG|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
214653042|NCT04558593|PROCEDURE|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
214252158|NCT01721070|DRUG|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
214252159|NCT01721070|DRUG|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
214653043|NCT06550362|DRUG|iron sulfate|Oral iron administration
214653044|NCT04531722|PROCEDURE|Intraoperative brain microdialysis|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
214252160|NCT02025517|OTHER|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
214252161|NCT02250027|DRUG|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
214252162|NCT02250027|DRUG|Placebo|2 capsules at once, 3 times a day, for 7 days
214252163|NCT00934258|DRUG|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
214252164|NCT00934258|GENETIC|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
214252165|NCT00687232|DRUG|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
214252166|NCT00687232|DRUG|Placebo|
214252167|NCT00596297|DRUG|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
214252168|NCT00596297|PROCEDURE|pars plana vitrectomy|4 weeks after baseline
214252169|NCT04152044|OTHER|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
214252170|NCT00355654|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
214252171|NCT00355654|BIOLOGICAL|DT3aP-HBs-IPV|0.5 mL, IM
214252172|NCT00666874|BEHAVIORAL|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
214252173|NCT00666874|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
214252174|NCT00284596|PROCEDURE|High tibial osteotomy|HTO
214252175|NCT02204007|DEVICE|3D imaging & surrogate bone model|3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
214252176|NCT03052907|BEHAVIORAL|BSPAN|"1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
214252177|NCT00092690|DRUG|MK0653A, ezetimibe (+) simvastatin|
214252178|NCT00092690|DRUG|Comparator: atorvastatin|
214252179|NCT02341105|PROCEDURE|Catheter ablation|Pulmonary vein isolation by catheter ablation
214252180|NCT02341105|DRUG|Amiodarone|antiarrhythmic therapy using Amiodarone
214252181|NCT02477137|DEVICE|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
214252182|NCT01514500|DRUG|somapacitan|Administered s.c. (subcutaneously, under the skin)
214252183|NCT01514500|DRUG|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
214252184|NCT05345054|OTHER|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
214252185|NCT00910988|DRUG|Olanzapine|olanzapine/Zyprexa
214252186|NCT00910988|DRUG|Ziprasidone|ziprasidone/Geodon
214252187|NCT04722549|DIETARY_SUPPLEMENT|Placebo|Cellulose
214252188|NCT04722549|DIETARY_SUPPLEMENT|Butyrate|Sodium butyrate
214252189|NCT02578771|DRUG|ZuraPrep with 70% IPA|Apply topically
214252190|NCT02578771|DRUG|ZuraPrep without 70% IPA|Apply topically. 0% IPA
214252191|NCT02578771|DRUG|ChloraPrep CHG/IPA Teal Tint|Apply topically
214252192|NCT02578771|OTHER|Normal Saline|Apply topically
214252193|NCT00766883|BEHAVIORAL|Problem Solving Education|
214252194|NCT05616806|BEHAVIORAL|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
214252195|NCT00494273|BEHAVIORAL|Cognitive Behavioral and Standard Care with Healthy Living|
214252196|NCT02671773|DRUG|Inhaled corticosteroid dose/type|
214252197|NCT05034133|DRUG|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
214252198|NCT05350176|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
214252199|NCT05350176|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
214252200|NCT00526604|BEHAVIORAL|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
214252201|NCT02701842|DEVICE|ImPACT Online/Paper Pencil Tests|
214252202|NCT02701842|DEVICE|ImPACT Online|
214252203|NCT00400530|DRUG|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
214252204|NCT00400530|DRUG|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
214252205|NCT06045650|OTHER|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
214252206|NCT06045650|OTHER|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
214252207|NCT06045650|OTHER|Neuro-economical game|A game played to assess the trust-index of participants
214252208|NCT06045650|OTHER|Childhood Trauma Questionnaire|to assess childhood trauma score
214252209|NCT06045650|OTHER|Relationships Questionnaire|to assess attachment type
214252210|NCT06045650|OTHER|demographic questionnaire|To obtain basic data on demographics
214252211|NCT01624051|OTHER|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
214252212|NCT01624051|OTHER|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
214252213|NCT05425589|PROCEDURE|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
214252214|NCT05618431|OTHER|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
214252215|NCT03004443|DRUG|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
214252216|NCT03004443|DRUG|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
214252217|NCT00003800|OTHER|immunohistochemistry staining method|
214653045|NCT05639569|DEVICE|Ankura™ TAA Stent Graft System|All patients will be implanted with Ankura™ TAA Stent Graft System in accordance with the instructions for use (IFU).
214252218|NCT00003800|OTHER|laboratory biomarker analysis|
214252219|NCT00003800|PROCEDURE|radionuclide imaging|
214252220|NCT04176575|OTHER|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
214252221|NCT00828854|DRUG|Entinostat|Entinostat 5 mg PO every week
214252222|NCT00828854|DRUG|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
214252223|NCT05774275|DRUG|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
214252224|NCT05774275|DRUG|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
214252225|NCT05774275|DRUG|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
214252226|NCT05774275|RADIATION|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
214252227|NCT03476668|OTHER|MIRT|4-week multidisciplinary intensive rehabilitation treatment
214252228|NCT06087146|OTHER|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
214252229|NCT05605431|DIAGNOSTIC_TEST|Polysomnography|over nightSleep study
214252230|NCT00543738|DRUG|MK0767|
214252231|NCT00137865|GENETIC|EGEN-001 (phIL-12-005/PPC)|
214653046|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
214653047|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
214653048|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214252232|NCT04253912|DRUG|VBP-245|2% Povidone-Iodine Gel
214252233|NCT04253912|DRUG|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
214252234|NCT05183893|DIETARY_SUPPLEMENT|L-citrulline|5 g of L-citruline + 5 g of additives
214252235|NCT05183893|DIETARY_SUPPLEMENT|Citrulline-malate|8g of citrulline-malate + 2 g of additives
214252236|NCT05183893|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrine
214252237|NCT04630639|DEVICE|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
214252238|NCT01522729|DRUG|Fentanyl|Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
214252239|NCT01522729|DRUG|Placebo comparator|placebo \[NaCl\]
214252240|NCT00685555|BEHAVIORAL|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
214653049|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
214653050|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214653051|NCT06320405|DRUG|Paclitaxel|Given IV
214653052|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214653053|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
214653054|NCT05646056|DEVICE|Software|Observation only
214653055|NCT05920798|PROCEDURE|Biopsy|Undergo biopsy
214653056|NCT05920798|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214653057|NCT05920798|PROCEDURE|Computed Tomography|Undergo CT
214252241|NCT00685555|BEHAVIORAL|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
214252242|NCT03188627|BIOLOGICAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
214252243|NCT04430829|DIAGNOSTIC_TEST|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
214252244|NCT04430829|DIAGNOSTIC_TEST|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
214252245|NCT04095390|DRUG|Pyrotinib|400 mg
214252246|NCT04095390|DRUG|SHR6390|125mg
214252247|NCT04095390|DRUG|Letrozole|2.5mg
214252248|NCT04095390|DRUG|Capecitabine|500mg
214252249|NCT05938179|DRUG|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
214252250|NCT05938179|DRUG|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
214252251|NCT05938179|DRUG|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
214252252|NCT05938179|DRUG|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
214252253|NCT02826850|PROCEDURE|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
214252254|NCT02826850|PROCEDURE|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
214252255|NCT04948567|OTHER|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
214252256|NCT04948567|OTHER|split-dose of PEG|purgative for bowel preparation
214252257|NCT06851195|DEVICE|lower limb neuromuscular electrical stimulation|The study adopts a quasi-experimental design with convenience sampling. Data collection will be done through structured questionnaires. Patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. The experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. The control group will only participate in pulmonary rehabilitation exercises. Based on Hill et al. (2018), neuromuscular electrical stimulation should continue for 4 to 8 weeks. Questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, Modified Medical Research Council Dyspnea Scale, Manchester COPD Fatigue Scale,
214252258|NCT06851195|BEHAVIORAL|pulmonary rehabilitation exercises|The control group will only participate in pulmonary rehabilitation exercises
214252259|NCT03118973|PROCEDURE|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
214252260|NCT03911843|DRUG|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
214252261|NCT03911843|DRUG|Vitamin D supplementation|Cholecalciferol 1000 IU/die
214252262|NCT02142985|DRUG|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
214252263|NCT06515249|OTHER|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
214252264|NCT01907100|DRUG|Nintedanib|triple kinase inhibitor; 200mg starting dose
214252265|NCT01907100|DRUG|Pemetrexed|backbone chemo
214252266|NCT01907100|DRUG|Cisplatin|backbone chemo
214252267|NCT01907100|DRUG|Cisplatin|backbone chemo
214252268|NCT01907100|DRUG|Pemetrexed|backbone chemo
214252269|NCT01907100|DRUG|Placebo|Nintedanib matching placebo
214252270|NCT01048489|BEHAVIORAL|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
214252271|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks \& 9 months
214252272|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks \& 9 months
214252273|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6\&14 weeks \& 9 months
214252274|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks \& 9 months
214252275|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks \& 9 months
214252276|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6\&14 weeks \& 9 months
214252277|NCT03192878|DRUG|Infliximab|infliximab biosimilar
214252278|NCT02257853|OTHER|Stress reduction intervention|Gentle chair yoga and breath work
214252279|NCT05904990|DEVICE|traditional exercise therapy only|50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises
214252280|NCT05904990|DEVICE|HILT alongside traditional exercise therapy|YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2. It operates with short pulse durations between 120 and 150 μs, at low frequencies of 10 to 40 Hz, and has a duty cycle of about 0.1%.
214252281|NCT00817284|DRUG|bevacizumab and Irinotecan and radiotherapy|"* Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
214252282|NCT00817284|DRUG|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
214252283|NCT03381573|DRUG|Roflumilast|Roflumilast
214252284|NCT06148389|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
214252285|NCT06148389|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
214252289|NCT05698810|OTHER|CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability|tests
214252290|NCT05698810|OTHER|CE marked Medical Device Magnetic Resonance Imaging (MRI) usability|tests
214252291|NCT05698810|OTHER|CE marked Medical Device ElectroEncephaloGraphy (EEG) usability|tests
214252292|NCT05698810|OTHER|CE marked Medical Device ElectroCardioGraphy (ECG) usability|tests
214252293|NCT06403163|PROCEDURE|Transfusion|Transfusion of an hemostatic product
214252294|NCT04799054|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT injection
214252295|NCT04799054|DRUG|Pembrolizumab|Pembrolizumab will be administered IV
214252296|NCT05993767|DRUG|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
214252297|NCT05993767|DRUG|Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)|Single arm
214252299|NCT04295486|DRUG|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
214252300|NCT04025671|DEVICE|Nasal Spray Naloxone|Nasal spray naloxone device.
214252301|NCT04025671|DEVICE|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
214252302|NCT04025671|DEVICE|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
214252303|NCT03635788|DRUG|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
214252304|NCT03635788|DRUG|Oral RPV|RPV 25 mg tablets
214252305|NCT03635788|DRUG|Oral CAB|CAB 30 mg tablets
214252306|NCT03635788|DRUG|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
214252307|NCT03635788|DRUG|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
214252308|NCT03635788|DRUG|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
214252309|NCT03635788|DRUG|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
214252310|NCT06976450|OTHER|ChemoNurs Mobile Application Group|Participants in the mobile app group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. U
214252311|NCT06976450|DEVICE|Personal Smartphone|Used by participants to access and interact with the CHEMONURS mobile application during the study period.
214252312|NCT06805032|OTHER|Observation of EMG and AMG readings|Simultaneous readings from electromyograph and acceleromyograph
214252313|NCT01213784|OTHER|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
214252314|NCT02354157|OTHER|no intervention|no intervention
214252315|NCT04382755|DRUG|Zilucoplan®|14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
214252316|NCT04382755|DRUG|Placebo|standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
214252317|NCT03004144|OTHER|FLOAT|
214252318|NCT02624414|DEVICE|PillCam® COLON 2 Capsule Endoscopy|
214252319|NCT05114668|DRUG|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
214252320|NCT04777357|DRUG|Cariprazine|Oral Capsule
214252321|NCT04777357|DRUG|Placebo|Oral Capsule
214252322|NCT03107533|OTHER|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
214252323|NCT05000138|DIAGNOSTIC_TEST|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
214252324|NCT04548154|OTHER|Proximal Resistance Training|Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
214252325|NCT05674708|OTHER|Fat intake|Four different sources of dietary fat
214252326|NCT03811002|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214252327|NCT03811002|DRUG|Atezolizumab|Given IV
214252328|NCT03811002|PROCEDURE|Biospecimen Collection|Correlative studies
214252329|NCT03811002|DRUG|Carboplatin|Given IV
214252330|NCT03811002|DRUG|Cisplatin|Given IV
214252331|NCT03811002|DRUG|Etoposide|Given IV
214252332|NCT03811002|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214252333|NCT03811002|OTHER|Quality-of-Life Assessment|Ancillary studies
214252334|NCT03811002|OTHER|Questionnaire Administration|Ancillary studies
214252335|NCT04701684|DEVICE|Direct to Angio Suite (DTAS) Philips' CBCT triage|Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
214252336|NCT04701684|PROCEDURE|Conventional CT/MR triage|First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
214653058|NCT05920798|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214252337|NCT06407427|DEVICE|App for in-bed conditioning exercises|Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients
214252338|NCT06407427|OTHER|Usual care|All participants will receive usual care in the post-operative setting.
214252339|NCT04191187|DRUG|Fludarabine|Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2
214252340|NCT04191187|DRUG|Melphalan|Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
214252341|NCT04191187|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
214252342|NCT06197685|BEHAVIORAL|The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
214252343|NCT06197685|BEHAVIORAL|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.
214252344|NCT06197685|BEHAVIORAL|Stretching and Toning (S/T)|The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
214252345|NCT00305825|BIOLOGICAL|bevacizumab|
214252346|NCT00305825|DRUG|letrozole|
214653059|NCT05920798|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
214653060|NCT05920798|BIOLOGICAL|Pembrolizumab|Given IV
214653061|NCT05920798|PROCEDURE|Pheresis|Undergo apheresis
214653062|NCT02750670|DRUG|Obinutuzumab|Type II anti-CD20 monoclonal antibody
214653063|NCT02750670|DRUG|Gemcitabine|Antineoplastic agent
214252347|NCT04893837|DEVICE|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
214252348|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
214252349|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
214252350|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
214252351|NCT06225596|DRUG|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
214252352|NCT06225596|DRUG|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
214252353|NCT06225596|DRUG|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
214252354|NCT05643560|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
214653064|NCT02750670|DRUG|Dexamethasone|Corticosteroid
214653065|NCT02750670|DRUG|Cisplatin|Antineoplastic Agent
214653066|NCT00881660|DEVICE|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
214653067|NCT03099733|OTHER|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
214653068|NCT04714372|DRUG|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
214653069|NCT04714372|DRUG|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
214653070|NCT04714372|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
214653071|NCT04714372|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
214653072|NCT01938157|PROCEDURE|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
214653073|NCT03219164|DRUG|AZLI|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
214653074|NCT03219164|DRUG|Placebo|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
214653075|NCT01116050|DRUG|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
214653076|NCT01116050|DRUG|Placebo|5 tablets in opque introducer
214653077|NCT04265066|DIAGNOSTIC_TEST|microcirculation|measurement of microcirculation
214653078|NCT01334398|BEHAVIORAL|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
214653079|NCT00313274|DRUG|Clevudine|
214653080|NCT02126059|BEHAVIORAL|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
214653081|NCT02126059|BEHAVIORAL|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
214653082|NCT02126059|BEHAVIORAL|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
214653083|NCT02029976|BEHAVIORAL|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
214653084|NCT02029976|BEHAVIORAL|Mailed monthly newsletters|Newsletters
214653085|NCT04617808|OTHER|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~* Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~* Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~* If possible, patient information on the collection of their data for research and possibility of opposing~* Filling of a medical questionnaire by the regulating doctor~* Weekly collection of medical questionnaires by investigating doctors"
214252355|NCT07006324|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta. 3-4 home visits with appropriate interventions through a referral and support process.
214252356|NCT05079516|OTHER|Theta burst transcranial magnetic stimulation|Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
214653086|NCT01142414|BIOLOGICAL|panitumumab|
214653087|NCT01142414|DRUG|cisplatin|
214653088|NCT01142414|DRUG|fluorouracil|
214653089|NCT01142414|OTHER|laboratory biomarker analysis|
214653090|NCT01142414|PROCEDURE|adjuvant therapy|
214653091|NCT01142414|PROCEDURE|quality-of-life assessment|
214653092|NCT01142414|RADIATION|3-dimensional conformal radiation therapy|
214653093|NCT01142414|RADIATION|intensity-modulated radiation therapy|
214653094|NCT03733912|OTHER|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
214653095|NCT00295945|DRUG|fentanyl citrate|
214653096|NCT00295945|DRUG|hydromorphone hydrochloride|
214653097|NCT00295945|DRUG|ropivacaine hydrochloride|
214653098|NCT04643184|OTHER|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
214653099|NCT02303054|PROCEDURE|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
214653100|NCT04025632|DRUG|zilucoplan|Daily subcutaneous (SC) inection
214653101|NCT04025632|OTHER|Placebo|Daily subcutaneous (SC) inection
214252357|NCT06114732|BEHAVIORAL|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
214252358|NCT06625801|DEVICE|IVUS|Intravascular Ultrasound
214252359|NCT05564091|DEVICE|Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device|360 degree microcatheterization and viscodilation of Schlemm's canal
214252360|NCT05564091|PROCEDURE|Cataract surgery|Cataract surgery alone
214252361|NCT06685172|OTHER|f-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
214252362|NCT06685172|OTHER|r-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
214818158|NCT04487158|BEHAVIORAL|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
214252365|NCT06622889|OTHER|Multidomain Intervention Program|The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.
214252366|NCT04799535|PROCEDURE|Ultrasound|Undergo breast ultrasound
214252367|NCT06470711|OTHER|Non-Interventional Study|Non-interventional study
214252368|NCT05530850|BEHAVIORAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
214252369|NCT05530850|OTHER|Thoracic exercise program|Thoracic region focused exercise program
214252370|NCT06693960|DIETARY_SUPPLEMENT|Oregano|Oil of oregano administered as a softgel (180 mg).
214252371|NCT06693960|DRUG|Drug cocktail|Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
214252372|NCT06630026|OTHER|The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.|• The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
214252373|NCT05541250|BIOLOGICAL|Autologous Human Schwann Cell|A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
214252374|NCT06698120|PROCEDURE|Awake prone positioning (APP)|"* APP are realized following the diagnosis of ACS~* Prone positioning or supine positioning are performed under supervision of a physician or a nurse~* Maximum session duration: 16 hours per day~* Sessions of prone positioning can be shortened, if necessary (30 minutes minimum), for better tolerance~* Tolerance of prone positioning is assessed by the physician in charge and sessions and may be stopped in case of poor tolerance"
214252375|NCT07025421|OTHER|Intervention Upright Bed positioning|Patient in receipt of the upright bed positioning will receive daily upright bed positioning time each day of mechanical ventilation following the time required by institutional protocol for ARDS - associated prone positioning
214252376|NCT06683118|DEVICE|Rapamycin neurovascular Balloon Catheter|Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
214653102|NCT03592459|DEVICE|Macy Catheter|Undergo placement of Macy catheter
214653103|NCT03592459|PROCEDURE|Pain Therapy|Receive opioids via Macy catheter
214252377|NCT06683118|DEVICE|Conventional Balloon|Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis
214252378|NCT06884657|DRUG|mannitol|2.5 mg/kg Mannitol will be given intravenously
214252379|NCT06884657|OTHER|Saline|2.5 ml/kg saline will be given as plasebo
214252380|NCT06727773|DRUG|Memantine|memantine capsule
214252381|NCT06727773|DRUG|Placebo medication|placebo capsule
214252382|NCT06727773|OTHER|Exercise Intervention|Exercise Intervention participants will concurrently engage in remotely delivered Get Real \& Heel, 3d/week. Intensity for aerobic and strength-training components will progress as tolerated under the direction of a trained exercise physiologist.
214252383|NCT06727773|OTHER|Exercise Control|Exercise control will have access to a library of pre-recorded Get Real \& Heel sessions.
214653104|NCT03592459|OTHER|Questionnaire Administration|Ancillary studies
214653105|NCT03592459|OTHER|Survey Administration|Ancillary studies
214653106|NCT00127127|DRUG|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
214252384|NCT06885697|DEVICE|mesothelin expression testing|Assay done at screening to determine mesothelin expression levels
214252385|NCT06885697|BIOLOGICAL|TNhYP217 CAR T Cells|Variable doses, administered intravenously on Day 0
214252386|NCT06885697|DRUG|fludarabine|30 mg/m\^2 IV infusion administered followed by cyclophosphamide on days both are given. Daily x 4 doses on Day -7, -6, -5 and -4
214252387|NCT06885697|DRUG|cyclophosphamide|600 mg/m\^2 IV infusion. Daily x 3 doses on Day -6, -5, -4
214252388|NCT07050368|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
214252389|NCT07050368|DRUG|Placebo|Capsule with no active ingredients
214252390|NCT06093360|PROCEDURE|flapless surgery|Implant-supported restorations were unscrewed and modified if necessary (biofilm control). All the restorations were relocated at the end of each intervention session. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement. Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was simultaneously performed to remove the granulation tissue. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Oral hygiene instructions were given. Systemic antibiotics, when prescribed, were metronidazole or azithromycin
214252391|NCT06731504|DRUG|Abatacept|Abatacept is a monoclonal antibody that suppresses T-cell activation through costimulatory blockade. In 2021, abatacept was FDA approved to prevent acute GVHD following allogeneic HCT.
214252392|NCT06736171|DEVICE|Robotic Exoskeleton|EksoNR, Ekso Bionics, San Rafael, CA, USA Atalante X, Wandercraft, Paris, France ReStore™, Lifeward Inc, Marlborough, MA
214252393|NCT06736171|OTHER|SOC|Standard of Care
214252394|NCT06743477|OTHER|Supergraft|This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.
214252395|NCT07053969|DEVICE|Enamel Matrix Derivative|EMD is an FDA approved medical device used in periodontal procedures since 1996. It has been shown to enhance soft and hard tissue healing, increased root coverage and aid in periodontal regeneration. It's use as an adjunct during implant uncovering may increase peri-implant mucosal thickness.
214252396|NCT07056634|BEHAVIORAL|Active Nature Engagement|Participants in this group will walk at a comfortable pace for 30 minutes in an urban park, three times per week for four weeks. They will be guided to focus on their surroundings using a grounding exercise (e.g., noticing sights, sounds, and smells) and instructed not to use mobile phones or listen to music during the walk.
214252397|NCT07056634|BEHAVIORAL|Passive Nature Engagement|Participants in this group will sit quietly for 30 minutes in a designated spot within an urban park, three times per week for four weeks. They will engage in grounding exercises and draw aspects of the natural environment. Participants will be instructed not to use mobile phones or listen to music during the walk.
214252398|NCT07056634|BEHAVIORAL|Indoor Exercise|Participants will be asked to walk on a treadmill in an indoor room without windows for 30 minutes. The treadmill will be set to the speed that match the average pace in nature walk group (approximately 3 km/hr). The speed could be adjusted by the participant if needed, but kept within the range of 2.6 km/hr to 4.6 km/hr. Participants will be asked to not use their phones or listen to music.
214252399|NCT07069374|BEHAVIORAL|Wellness, Intervention Strategies and HIV Care (WISH)|A structured behavioral group program consisting of five weekly sessions, each approximately 60-90 minutes in length. The intervention is designed for individuals living with HIV who use substances and focuses on: managing stress, addressing barriers to care, and enhancing engagement with HIV-related health services. Sessions are delivered in a small-group format and facilitated by trained staff using a manualized curriculum.
214252400|NCT07069374|BEHAVIORAL|Movie Night Club - Attention and Time Matched Control|Weekly 90-minute group sessions over 5 weeks in which participants watch non-therapeutic, neutral-content movies in a group setting. Sessions are facilitated to control for social interaction and time spent in a structured group environment but do not include any therapeutic content.
214252401|NCT07098130|OTHER|US-guided PNM 100 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 5 cycles of 5 seconds stimulation (100 Hz and 350 µs pulse width), followed by 55 seconds rest.
214252402|NCT07098130|OTHER|US-guided PNM 10 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 10 cycles of 10 seconds stimulation (10 Hz and 250 µs pulse width), followed by 10 seconds rest.
214252403|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist/delegated staff as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
214252404|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
214252405|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
214818159|NCT04487158|BEHAVIORAL|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
214252406|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
214252407|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
214252408|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
214252409|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks~177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion. One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
214252410|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~Synonyms are:~177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE LUTATHERA, lutetium (177Lu) oxodotreotide 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
214252411|NCT06878664|DRUG|Amino acid solution|Renal protection starting 30 minutes before RLT and lasting 4 hours (iv) amino acid solution of 14.4-20 g of lysine and 14.9-20.7 g of arginine in 1 to 2 liters of solution)
214252412|NCT06878664|DRUG|Lanreotide (Autogel formulation) or Octreotide LAR|Long-acting standard doses of SSA (Lanreotide autogel 120 mg subcutaneous (sc) or Octreotide LAR 30 mg im, starting 24h after RLT and every 4 weeks during RLT (q16w interval SSA administration should be adjusted to RLT administrations so that SSA is always given 24h after each RLT dose and at least 4 weeks prior to next RLT administration cycle) and q4w following last RLT administration until disease progression.
214252413|NCT07135843|BEHAVIORAL|Digital exercise program|KOKU is a digital adaptation of the evidence based Otago Exercise Program and Falls Management Exercise program, both designed to improve strength, balance, and reduce fall risk in older adults. KOKU includes 26 balance and strength exercises of varying difficulty. Each exercise is accompanied by written and audio instructions for safe performance and is demonstrated by a virtual trainer. Training sessions consist of three exercises suggested by the KOKU app, which participants are encouraged to perform for as many repetitions as possible until fatigue. Progression is guided by the participant's subjective assessment of effort and difficulty. Participants may choose to perform any exercise at any time, regardless of the app-suggested sequence. The KOKU app also provides reminders to exercise if no activity is detected for two days.
214252414|NCT07135843|BEHAVIORAL|Personal coaching for physical activity promotion|Personal coaching consists of three video calls conducted via the study tablet by staff trained in BCTs and motivational communication skills. Participants receive a low cost, wrist worn activity tracker during the initial home visit to support self-monitoring and provide feedback on PA behavior. The first virtual coaching session (week 2) focuses on goal setting and action planning, the second session (week 3) addresses identification and management of barriers, and the third session (week 12) serves as a booster to review and adjust activity goals for the post intervention period.
214252415|NCT07142603|OTHER|Metabolic response to protein source|Participants will be given a 350-400 kcal meal challenge containing 30% energy from animal protein. They will be given 10 minutes to consume the meal and meal response will be measured 240 minutes following the meal.
214252416|NCT07141836|PROCEDURE|Elastomeric chain|Elastic chain used to apply force that is capable of canine retraction. The chains were attached between canine bracket and molar band on the side that selected Randomly.
214252417|NCT07141836|PROCEDURE|Elastics|Elastics were used to bring a continuous force for maxillary canine retraction in orthodontic patients. Elastics were stretched between the canine bracket and the molar band to retract the canine distally
214252418|NCT07140796|BEHAVIORAL|Blood Flow Restriction Training|Participants perform squats with 15% of their body weight under blood flow restriction using a thigh cuff. Hip internal rotation is set at 15 degrees. The training is conducted twice a week for 4 weeks. Cuff pressure is estimated using a predictive formula based on thigh circumference and systolic blood pressure.
214252419|NCT07140796|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial extracorporeal shockwave therapy (rESWT) is applied to the gluteus medius region prior to each exercise session. The protocol includes 2000 pulses per session, applied twice per week for 4 weeks, using a radial shockwave device.
214252420|NCT04679844|DEVICE|MagnetOs Easypack Putty|MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.
214252421|NCT04679844|DEVICE|Demineralized Bone Matrix or Fibers mixed with local autograft bone|Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
214818160|NCT05746104|DRUG|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
214818161|NCT03651804|PROCEDURE|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
214252422|NCT06933563|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
214252423|NCT06931951|PROCEDURE|Knee Pharmacoacupuncture|Physician choose the adequate type and dose of pharmacoacupuncture and needle type
214252424|NCT06931951|PROCEDURE|Oriental medicine integrated treatment|Physician choose the integrated oriental medicine treatment other than herbal acupuncture.
214252425|NCT06937944|BIOLOGICAL|Rcombinant botulinum toxin type A for injection（Eveotox)|Rcombinant botulinum toxin type A for injection（Eveotox)
214252426|NCT06937944|BIOLOGICAL|OnabotulinumtoxinA (Botox)|OnabotulinumtoxinA (Botox)
214252427|NCT06937944|BIOLOGICAL|Placebo|Placebo
214252428|NCT06941519|BEHAVIORAL|Telephonic Outreach|Higher Intensity (active telephonic outreach from a health navigator with follow-up contacts for up to 3 months)
214252429|NCT06941519|BEHAVIORAL|Virtual Outreach|Lower Intensity (outreach via text, email, and/or letter with materials that contain information about available local, state, and federal governmental benefits and services)
214252430|NCT06954623|RADIATION|Radiation Therapy|proton beam radiation
214252431|NCT07150754|DRUG|Heart failure pharmacological treatments|Identify a positive signal for fall with one or more of the recommended pharmacological treatments for heart failure
214252432|NCT07149545|DRUG|Arm A (Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after surgical site disinfection; during ablation, fentanyl 2 mL and midazolam 0.5 mg were administered intravenously. Additional fentanyl or midazolam was given if needed.
214252433|NCT07149545|DRUG|Arm B (Flurbiprofen axetil + Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; flurbiprofen axetil (100 mg) administered intravenously after transseptal puncture; fentanyl 2 mL and midazolam 0.5 mg administered during ablation. Additional fentanyl was given if needed.
214252434|NCT07149545|DRUG|Arm C (Fentanyl + Dexmedetomidine)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; dexmedetomidine continuous infusion (0.4 μg/kg/h) was administered throughout.
214818162|NCT03651804|DRUG|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
214818163|NCT03651804|DRUG|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
214252437|NCT07150364|OTHER|Square Stepping Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
214252438|NCT07150364|OTHER|Wobble Board Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
214252439|NCT07149779|OTHER|Exercise|A total of 20 kickboxers between the ages of 20-26, healthy, and actively involved in this branch for at least 4 years participated in the study. The volunteers participating in the study were randomly divided into two groups as the study and control groups. The study group applied calisthenic strength exercises in addition to routine kickboxing technical training for 8 weeks and 3 days a week, while the control group continued only their weekly routine kickboxing training without applying any strength training. Static strength performance (grip-leg-back), dynamic strength performance (1RM bench press and 1RM barbel squat), 30-second push-ups and 30-second sit-ups tests were applied to the athletes participating in the study before and after the 8-week training.
214252440|NCT07149961|DIETARY_SUPPLEMENT|Curcumin plus Piperine|A loading dose of 2 capsules (each containing 390 mg curcumin + 20 mg piperine) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized curcumin extract (390 mg) combined with piperine (20 mg), given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI). The curcumin-piperine formulation is used to enhance bioavailability and anti-inflammatory effects, aiming to improve post-MI recovery and reduce oxidative stress.
214252441|NCT07149961|OTHER|Placebo capsules|A loading dose of 2 capsules (each containing saccarum lactic) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized placebo capsule, given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
214818164|NCT03651804|DRUG|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
214252442|NCT07149441|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
214252443|NCT07149441|DRUG|infliximab|Intravenous infusion of infliximab once every 8 weeks.
214252444|NCT07150221|DEVICE|Vivacit-E Elevated Liners|Primary total hip arthroplasty
214252445|NCT07150507|OTHER|Session 1: Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
214252446|NCT07150507|OTHER|Session 2: Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
214252447|NCT07150507|OTHER|Session 3: Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
214252448|NCT07150507|OTHER|Session 4: What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
214252449|NCT07150507|OTHER|Session 5: Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
214252450|NCT07150507|OTHER|Session 6: What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
214252451|NCT07150507|OTHER|Session 7: Relaxation|Practicing the relaxation CD with patients
214252452|NCT07150507|OTHER|Session 8: Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
214818165|NCT03651804|BEHAVIORAL|Physical therapy|Physical Therapy.
214818166|NCT03651804|DRUG|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
214818167|NCT03399214|DRUG|IOP Injection|T1 and T2
214252453|NCT07149480|PROCEDURE|Underlay Tympanoplasty|Tympanoplasty performed using the underlay graft technique, where the graft is positioned beneath all three layers of the tympanic membrane remnant.
214252454|NCT07149480|PROCEDURE|Interlay Tympanoplasty|Tympanoplasty performed using the interlay graft technique, where the graft is positioned between the mucosal and fibrous layers of the tympanic membrane.
214252455|NCT07149701|DEVICE|Intervention|Treatment with intervention of catheter ablation or Implantable cardioverter defibrillator.
214252456|NCT07150741|BEHAVIORAL|Exercise-Assisted Ergonomic Training|The program includes structured ergonomic and exercise activities designed to improve posture, reduce musculoskeletal pain, enhance sleep quality, and decrease anxiety levels among nursing students. Theoretical lectures cover ergonomics principles, postural assessment, body mechanics, and ergonomic risks in nursing. Practical sessions are delivered via video twice a week for 4 weeks, each lasting 30-40 minutes, including warm-up, stretching, strengthening, balance, and posture exercises. The intervention is supervised by an exercise specialist to ensure safety and proper technique.
214252457|NCT07149935|OTHER|Rehabilitation Training|The rehabilitation training has two parts: the exercise training at home（5 times per week, as well as the Inspiratory muscle training(once per day) including Respiratory trainer exercise and abdominal breathing training.
214252458|NCT07150468|OTHER|sampling blood|"Sampling~1. patient~   1. Peripheral blood samples in a volume of 25 cc will be collected before HCT and 2 weeks after HCT, and peripheral blood samples in a volume of 20 cc will be collected 4 weeks, 3 months, 6 months, and 12 months after HCT.~  2. If GVHD occurs, additional blood sample (20 cc) will be collected.~  3. In case of organ-specific GVHD including skin, gut, liver, muscle, etc., tissue samples from biopsy will be obtained for further analysis.~2. donor a. Peripheral blood samples in a volume of 20 cc will be collected before HCT"
214252459|NCT07150104|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214252460|NCT07150104|DRUG|Nirogacestat|Nirogacestat will be administered.
214252461|NCT07150104|DRUG|Pomalidomide|Pomalidomide will be administered.
214252462|NCT07150104|DRUG|Dexamethasone|Dexamethasone will be administered.
214252463|NCT07149922|OTHER|Blood pressure was regulated within the normal target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<120 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 120-160 mmHg (\<160 mmHg and \>120 mmHg). For SBP \>160 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 120-160 mmHg, standard supportive care was provided.
214252464|NCT07149922|OTHER|Blood pressure was regulated within the elevated target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<160 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 160-180 mmHg ( ≥160 mmHg and ≤120 mmHg). For SBP \>180 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 160-180 mmHg, standard supportive care was provided.
214252465|NCT07149688|DEVICE|Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)|"Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)~Enhanced monitoring with 7-day ECG"
214252466|NCT07149467|DRUG|Ustekinumab (approximately 6 mg/kg)|"At Week 0:~≤55 kg: 260 mg administered by intravenous (IV) infusion.~\>55 kg and ≤85 kg: 390 mg administered by intravenous (IV) infusion.~\>85 kg: 520 mg administered by intravenous (IV) infusion.~From Week 8 onward (i.e., at Week 8 and then every 8 weeks up to Week 52 or the end of the follow-up period):~90 mg administered by subcutaneous (SC) injection."
214252467|NCT07149467|DRUG|Upadacitinib|"From Week 0 to Week 12: 45 mg once daily, administered orally.~From Week 13 through Week 52 or the end of the follow-up period: 30 mg once daily, administered orally."
214653107|NCT03898648|OTHER|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
214653108|NCT03041727|OTHER|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
214653109|NCT03041727|OTHER|Standard exercises protocol|Stretching and strengthening exercises
214252468|NCT07150949|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
214252469|NCT07150949|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214252470|NCT07150949|DRUG|Capecitabine|Xeloda
214252471|NCT07150949|DRUG|Celecoxib|celecoxib 200 mg orally twice a day
214252472|NCT07150949|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
214252473|NCT07150949|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
214653110|NCT04387292|PROCEDURE|Ophthalmologic exam|"* Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)"
214252474|NCT07149831|DRUG|Flotufolastat F-18 Injection|Single dose intravenous injection of Flotufolastat F-18 Injection . Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
214252475|NCT07150819|BEHAVIORAL|Standard Nursing Care Protocol|The control group received standard perioperative nursing care in accordance with the Chinese Consensus and Clinical Guidelines for Enhanced Recovery After Surgery (2021 edition) and the Expert Consensus on Perioperative Nursing of Anorectal Diseases (2022 edition). Preoperative fasting included a 6-hour restriction on solid food and a 2-hour restriction on clear liquids. At 8:00 p.m. on the night before surgery, patients were instructed to orally ingest 500 mL of 10% glucose solution to supplement energy reserves. Fifteen minutes of structured health education was delivered preoperatively by the assigned nurse using 3D animations to explain the surgical process. Intraoperatively, an inflatable warming blanket was used to maintain the core temperature at 38°C, and all infusion fluids were pre-warmed to 37°C. For infection prophylaxis, 30 minutes before incision, patients received intravenous cefazolin (1 g for body mass index \[BMI\] \< 25 kg/m²; 2 g for BMI ≥ 25 kg/m²).
214252476|NCT07150819|BEHAVIORAL|MDC-based Pain Management|In accordance with the IASP Guidelines for Multidisciplinary Postoperative Pain Management (2023) and the Expert Consensus on Multidisciplinary Collaboration for Pain Management in China, a three-tier MDC framework was established;Surgeons were responsible for optimizing surgical procedures (e.g., using the tissue selecting technique for stapled hemorrhoidectomy) and administering a local injection of 5 mL 0.25% ropivacaine around the wound margin at the end of surgery. Anesthesiologists performed preoperative ASA physical status classification, monitored intraoperative vital signs, and configured postoperative patient-controlled analgesia (PCA) with sufentanil at 0.02 μg/kg/h.Compound Methylene Blue Nerve Block: A solution was prepared by mixing 2 mL of 1% methylene blue, 10 mL of 0.75% ropivacaine, and 8 mL of normal saline, yielding final concentrations of 0.02% methylene blue and 0.25% ropivacaine.
214252477|NCT01350154|DRUG|Sildenafil|20 mg in gelatine capsules, oral, three times daily
214252478|NCT01350154|DRUG|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
214252479|NCT00032032|DRUG|carboplatin|
214252480|NCT00032032|DRUG|paclitaxel|
214252481|NCT00032032|RADIATION|radiation therapy|
214252482|NCT02546115|DEVICE|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
214252483|NCT02546115|OTHER|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
214252484|NCT01199107|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
214252485|NCT01199107|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
214252486|NCT01199107|BEHAVIORAL|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
214252487|NCT06227455|PROCEDURE|Maxillary alveolar ridge augmentation|The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.
214252488|NCT01330706|DRUG|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
214252489|NCT05030324|DRUG|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
214252490|NCT05030324|DRUG|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
214653111|NCT00482963|DRUG|levonorgestrel, efavirenz|
214653112|NCT05896345|DEVICE|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
214653113|NCT05896345|COMBINATION_PRODUCT|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
214252491|NCT05030324|DRUG|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
214252492|NCT01397201|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
214252493|NCT01397201|DRUG|BI 54903|BI 54903
214252494|NCT01397201|DRUG|Fluticasone propionate|Fluticasone propionate
214252495|NCT04691401|DEVICE|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
214653114|NCT02355301|PROCEDURE|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
214653115|NCT00129025|PROCEDURE|Hypofractionated radiotherapy|
214653116|NCT01000103|DEVICE|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
214653117|NCT01000103|DEVICE|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
214653118|NCT00565630|DEVICE|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
214653119|NCT06123156|DRUG|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
214653120|NCT06123156|OTHER|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
214653121|NCT05168618|BIOLOGICAL|Atezolizumab|Given IV
214653122|NCT05168618|DRUG|Cabozantinib S-malate|Given PO
214653123|NCT03265587|OTHER|No intervention|No intervention
214252496|NCT05272839|DIETARY_SUPPLEMENT|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
214252497|NCT05272839|DIETARY_SUPPLEMENT|Control group|The control group will receive only lifestyle and dietary recommendations.
214252498|NCT01245920|BIOLOGICAL|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
214252499|NCT01245920|OTHER|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
214252500|NCT04960800|OTHER|Specific exercises|Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
214252501|NCT01319357|DRUG|Saxagliptin|orally 5 mg/d for 6 weeks
214252502|NCT01319357|DRUG|Placebo|orally for 6 weeks
214252503|NCT00215683|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
214252504|NCT01083485|DRUG|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
214252505|NCT01083485|DRUG|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
214252506|NCT04493333|DRUG|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
214252507|NCT04493333|COMBINATION_PRODUCT|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
214252508|NCT04855929|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
214252509|NCT04855929|DRUG|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
214252510|NCT02135159|DRUG|TDM1|administration of the TDM1 by IV perfusion
214252511|NCT02135159|RADIATION|Brain Sequential RT|local RT
214252512|NCT06156540|OTHER|virtual reality glasses|Using virtual reality glasses, caregivers in the experimental group were shown 360-degree VR relaxing videos.
214252513|NCT04407260|DEVICE|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
214252514|NCT02002611|DRUG|Lobeglitazone|
214252515|NCT02002611|DRUG|Warfarin|
214252516|NCT02619669|DRUG|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
214252517|NCT02619669|DRUG|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
214252518|NCT03319667|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
214252519|NCT03319667|DRUG|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous"
214252520|NCT03319667|DRUG|Lenalidomide|"Pharmaceutical form: Capsules~Route of administration: Oral"
214252521|NCT03319667|DRUG|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
214252522|NCT05067907|PROCEDURE|Early physiotherapy|"Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration."
214252523|NCT02969564|OTHER|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
214252524|NCT02969564|OTHER|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
214252525|NCT00634400|DRUG|Candesartan|
214252526|NCT00634400|DRUG|Placebo|
214252527|NCT02247531|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
214252528|NCT02247531|OTHER|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
214252529|NCT03432520|GENETIC|SPK-8011|Observational long-term safety follow-up study of participants previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study
214252530|NCT03432520|GENETIC|SPK-8016|Observational long-term safety follow-up study of participants previously treated with SPK-8016 in any Spark-sponsored SPK-8016 study
214818168|NCT02175095|DRUG|Regorafenib|Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
214252531|NCT02493387|OTHER|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
214252532|NCT02493387|OTHER|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
214252533|NCT02503007|DIETARY_SUPPLEMENT|Placebo|
214252534|NCT02503007|DIETARY_SUPPLEMENT|HMB-FA|
214252535|NCT04615897|PROCEDURE|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
214252536|NCT04523948|BEHAVIORAL|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
214252537|NCT02777736|DRUG|Methotrexate|i.v. or intrathecal CNS prophylaxis
214252538|NCT05346497|PROCEDURE|Bentall|Bentall procedure: include replacement of both aortic valve and root
214252539|NCT05346497|PROCEDURE|David|David procedure: include replacement of aortic root and aortic valvuloplasty
214252540|NCT05346497|PROCEDURE|ARR|Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
214252541|NCT06247800|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
214252542|NCT06247800|OTHER|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
214252543|NCT05859685|OTHER|Experimental|"Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
214252544|NCT05859685|OTHER|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
214252545|NCT03835104|DEVICE|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
214252546|NCT03094988|BEHAVIORAL|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
214252547|NCT03094988|OTHER|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
214653124|NCT05890703|DRUG|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
214252548|NCT03468985|DRUG|Cabozantinib|Given PO
214252549|NCT03468985|BIOLOGICAL|Ipilimumab|Given IV
214252550|NCT03468985|BIOLOGICAL|Nivolumab|Given IV
214252551|NCT05933447|DRUG|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
214252552|NCT05933447|DRUG|Moxifloxacin|Oral, Tablet, 400 mg QD
214252553|NCT05933447|DRUG|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
214252554|NCT05933447|DRUG|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
214252555|NCT03095833|OTHER|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
214252556|NCT03095833|OTHER|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
214252557|NCT03095833|OTHER|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
214252558|NCT03095833|OTHER|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
214252559|NCT03095833|OTHER|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
214252560|NCT03095833|OTHER|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
214252561|NCT03095833|OTHER|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
214252562|NCT03095833|OTHER|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
214252563|NCT03095833|OTHER|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
214252564|NCT03095833|OTHER|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
214252565|NCT03095833|OTHER|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
214252566|NCT00535457|OTHER|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
214252567|NCT04393285|DRUG|Abemaciclib|Abemaciclib 150mg orally twice a day
214252568|NCT04393285|DRUG|Letrozole|Letrozole 2.5mg orally once a day
214252569|NCT00080275|DRUG|Niacin Extended-Release and simvastatin Tablets|
214252570|NCT04367233|OTHER|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
214252571|NCT04367233|OTHER|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
214252572|NCT04367233|OTHER|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
214252573|NCT02718560|BEHAVIORAL|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
214252574|NCT02661451|DEVICE|SAPIEN 3 THV|
214252575|NCT02661451|BIOLOGICAL|Optimal Heart Failure Therapy|
214252576|NCT06443944|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
214252577|NCT06443944|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
214252578|NCT05318417|DEVICE|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
214252579|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 8 days of total exposure to furosemide over the 16-day N-of-1 trial.
214252580|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
214252581|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulation. Frequency of 10 Hz|The US-guided PNM intervention will be performed with the patient in the prone position, the shoulder to be treated flexed at 90 degrees, the humerus partially supported on the table, the elbow flexed at 90 degrees, and the musculature relaxed. Needles will be inserted near the perineurium of the axillary and suprascapular nerves. Prior to needle insertion, the skin will be cleaned with isopropyl alcohol and chlorhexidine. The PNM intervention will consist of applying a compensated asymmetric biphasic current, with a rectangular positive phase and a triangular negative phase, at a frequency of 10 Hz, pulse width of 240 μs, and the maximum tolerated intensity that elicits a painless maximal muscle contraction, following this protocol: 10 stimulations of 10 seconds each, with a 10-second rest between stimulations.
214252582|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulación. Frequency of 1 Hz|Same intervention as previously described, with the only difference being that the frequency will be 1 Hz instead of 10 Hz.
214653125|NCT05890703|DRUG|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
214653126|NCT04693871|DEVICE|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
214252583|NCT04974047|DRUG|Tislelizumab|Administered intravenously as specified in the treatment arm.
214252584|NCT06005142|DIETARY_SUPPLEMENT|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
214252585|NCT06005142|DIETARY_SUPPLEMENT|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
214252586|NCT06005142|DIETARY_SUPPLEMENT|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
214252587|NCT04069572|DEVICE|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
214252588|NCT04069572|DEVICE|Sham Stimulation|Low-frequency sham of VCR stimulation
214252589|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
214252590|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
214252591|NCT03554616|OTHER|Chlorfenapyr LLIN|Dual active ingredient Long Lasting Insecticidal Net
214252592|NCT03554616|OTHER|pyriproxyfen LLIN|Dual active ingredient Long Lasting Insecticidal Net
214252593|NCT03554616|OTHER|Piperonyl butoxide LLIN|Combination insecticide and synergist Long Lasting Insecticidal Net
214252594|NCT03554616|OTHER|Standard LLIN|Standard Long Lasting Insecticidal Net with one insecticide
214252595|NCT03560310|DRUG|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
214653127|NCT01136551|DRUG|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
214653128|NCT02332252|DEVICE|Scalpel|Skin incision performed with a scalpel during cesarean section.
214653129|NCT02332252|DEVICE|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
214252596|NCT03560310|DRUG|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
214252597|NCT06005974|DRUG|REC-4881|REC-4881 4mg capsules
214252598|NCT06142019|DEVICE|Controlled desaturation (hypoxemia)|Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures
214252599|NCT04131556|DRUG|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
214252600|NCT06126744|BIOLOGICAL|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
214252601|NCT06470867|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
214252602|NCT06470867|BEHAVIORAL|Control training|"An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention."
214252603|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
214252604|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
214252605|NCT05985161|DRUG|Selinexor|This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
214252606|NCT04882501|OTHER|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
214252607|NCT04882501|OTHER|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
214653130|NCT02332252|PROCEDURE|Skin incision|
214653131|NCT01401569|BEHAVIORAL|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
214252608|NCT06580080|BEHAVIORAL|Are You Ready? (AYR)|"AYR is a group-based entertainment education (EE) intervention designed for sexually active youth who are at risk for or involved in the juvenile justice and/or child welfare systems. AYR is delivered in one, 2.5-hour (150-minute) session with a group of between 2 to 20 youth. The session includes screening a 40-minute video, Happy Birthday, Leonard and group-based discussions led by one to two facilitators. Discussions are guided by a participant workbook with journal prompts and handouts.~The session includes two modules; each module involves screening approximately 20 minutes of Happy Birthday, Leonard followed by a 40-minute group discussion. Module 1 includes topics related to contraception, condom use (with a condom demonstration), healthy communication, and stress management. Module 2 includes topics related to condom negotiation, communication styles, and intergenerational cycles."
214252609|NCT06580080|BEHAVIORAL|Social Media Awareness Shorts (SMAS)|SMAS is a virtually delivered, individual-based health program focused on social media use awareness. Participants are directed to a learning management platform that contains a pre-recorded, facilitated program. The program involves watching several short films and independently completing several activities related to social media use. The program does not include information related to the primary outcomes for this study.
214252610|NCT06788249|DRUG|Ketamine only|The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
214252611|NCT02207465|RADIATION|Radiotherapy|
214252612|NCT02207465|DRUG|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
214252613|NCT04060862|DRUG|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
214252614|NCT04060862|DRUG|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
214252615|NCT04060862|DRUG|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
214252616|NCT04060862|DRUG|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
214252617|NCT02051413|DRUG|Venlafaxine extended release|antidepressant drug
214252618|NCT06504381|GENETIC|DB107-RRV|Given intracranially (IC) during resection and intravenously (IV) immediately following
214252619|NCT06504381|DRUG|DB107-FC|Given orally (PO)
214252620|NCT06504381|RADIATION|Radiation Therapy (RT)|Undergo RT
214252621|NCT06504381|DRUG|Temozolomide|Given PO
214252622|NCT06504381|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo standard of care MRI
214252623|NCT06504381|PROCEDURE|Surgical resection|Undergo non-investigational tumor resection
214252624|NCT05407844|OTHER|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
214252625|NCT04629508|DRUG|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
214252626|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
214252627|NCT03288454|DRUG|Placebo|Saline for injection
214252628|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
214252629|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
214252630|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
214653132|NCT05651646|OTHER|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
214252631|NCT02397668|DEVICE|CorMatrix Cor TRICUSPID ECM Valve|CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
214252632|NCT01678027|DRUG|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
214653133|NCT05217914|DRUG|Copanlisib (BAY80-6946)|Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
214818169|NCT02175095|DIAGNOSTIC_TEST|[18F]FLT-PET|\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
214818170|NCT02175095|DIAGNOSTIC_TEST|[18F]FDG-PET|\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
214818171|NCT02408367|BEHAVIORAL|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
214818172|NCT02408367|BEHAVIORAL|Relaxation|30
214818173|NCT04699084|OTHER|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
214252633|NCT01678027|DRUG|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
214252634|NCT05701488|DRUG|Durvalumab|Intravenous infusion
214252635|NCT05701488|DRUG|Tremelimumab|Intravenous infusion
214252636|NCT05701488|DEVICE|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
214252637|NCT03051646|DRUG|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
214252638|NCT03051646|DRUG|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
214252639|NCT01973543|BIOLOGICAL|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
214252640|NCT00504985|BEHAVIORAL|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
214252641|NCT05558917|PROCEDURE|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
214252642|NCT05558917|PROCEDURE|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
214252643|NCT00788398|PROCEDURE|Saline Solution|Irrigation with Saline
214252644|NCT00788398|PROCEDURE|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
214252645|NCT00788398|PROCEDURE|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
214252646|NCT00788398|PROCEDURE|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
214252647|NCT00788398|PROCEDURE|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
214252648|NCT06409351|BEHAVIORAL|Intervention group|Please refer to arm descriptions
214252649|NCT00048763|DRUG|Pletal|
214252650|NCT00378586|PROCEDURE|Rectal biopsy|Rectal biopsy.
214252651|NCT00378586|PROCEDURE|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
214252652|NCT00378586|PROCEDURE|Measurement of rectal lactic acid|Equilibrium dialysis.
214252653|NCT01732731|OTHER|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
214252654|NCT04643821|DRUG|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
214252655|NCT00176527|BIOLOGICAL|recombinant interferon alfa-2b|
214252656|NCT00176527|DRUG|docetaxel|
214252657|NCT00176527|DRUG|estramustine phosphate sodium|
214252658|NCT00176527|DRUG|isotretinoin|
214252659|NCT00176527|GENETIC|polyacrylamide gel electrophoresis|
214252660|NCT00176527|GENETIC|protein expression analysis|
214252661|NCT00176527|OTHER|immunohistochemistry staining method|
214252662|NCT05380310|DEVICE|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
214252663|NCT05380310|DEVICE|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
214252664|NCT05310656|BEHAVIORAL|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
214252665|NCT01222858|BEHAVIORAL|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
214252666|NCT01222858|BEHAVIORAL|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
214252667|NCT05087849|BIOLOGICAL|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
214252668|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
214252669|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
214252670|NCT00760214|DRUG|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
214252671|NCT04134702|OTHER|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
214252672|NCT02005432|DRUG|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
214252673|NCT02005432|DRUG|panfotocoagulation (PASCAL)|
214252674|NCT02005432|DRUG|panfotocoagulation (PRP) single shoot (ETDRS)|
214252675|NCT00493376|PROCEDURE|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
214252676|NCT00493376|PROCEDURE|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
214252677|NCT00493376|PROCEDURE|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
214252678|NCT00493376|PROCEDURE|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
214252679|NCT03126370|DRUG|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
214252680|NCT03126370|DRUG|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
214252681|NCT03126370|DRUG|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
214252682|NCT02854176|PROCEDURE|Somatosensory electrical stimulation|
214252683|NCT02854176|PROCEDURE|Control|
214252684|NCT04157621|DEVICE|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
214252685|NCT04157621|DEVICE|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
214252686|NCT04391413|DEVICE|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
214252687|NCT03960554|DRUG|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
214252688|NCT03960554|OTHER|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
214252689|NCT00430430|PROCEDURE|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
214252690|NCT00430430|PROCEDURE|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
214252691|NCT03865134|DIAGNOSTIC_TEST|Snellen Test|Visual acuity measurement
214252692|NCT03865134|DIAGNOSTIC_TEST|Autorefractometer|Refraction measurement
214252693|NCT03865134|DIAGNOSTIC_TEST|Titmus Stereo Fly Test|Stereopsis measurement
214252694|NCT03865134|DIAGNOSTIC_TEST|Optical Kohlerans Tomography|Retinal development measurement
214252695|NCT03865134|BEHAVIORAL|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
214252696|NCT03865134|BEHAVIORAL|Peabody Developmental Motor Scales - II|Evaluation of motor development
214252697|NCT03865134|BEHAVIORAL|World Health Organization Quality of Life - BREF|Assesment of quality of life
214252698|NCT03865134|BEHAVIORAL|State - Trait Anxiety Inventory|Assesment of anxiety
214252699|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
214252700|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
214252701|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
214252702|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
214252703|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
214252704|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
214252705|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
214252706|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
214252707|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
214252708|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
214252709|NCT01454115|DRUG|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
214252710|NCT01454115|DRUG|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
214252711|NCT00150540|DRUG|Lanthanum carbonate|
214252712|NCT02922400|BEHAVIORAL|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
214252713|NCT02180269|DRUG|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
214252714|NCT02180269|DRUG|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
214252715|NCT02180269|DRUG|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
214252716|NCT02180269|DRUG|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
214252717|NCT03432312|DRUG|Nicotine lozenge|Nicotine mint lozenge, 4 mg
214252718|NCT03432312|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
214252719|NCT05272462|DRUG|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
214252720|NCT02097043|DRUG|DA-7218|
214252721|NCT02097043|DRUG|Placebo|
214252722|NCT02545075|DRUG|Ipilimumab|
214252723|NCT02545075|DRUG|Dacarbazine|
214252724|NCT01279031|DEVICE|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
214252725|NCT01279031|DEVICE|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
214252726|NCT01737450|DRUG|BKM120|
214252727|NCT00530101|DRUG|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
214252728|NCT05232981|PROCEDURE|Ligation of the bilateral internal iliac arteries|"opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures ."
214252729|NCT05232981|PROCEDURE|Shehat's technique|"The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours"
214252730|NCT00533923|DRUG|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
214252731|NCT04538573|DEVICE|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
214252732|NCT04538573|DRUG|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
214252733|NCT00261300|DRUG|Pantoprazole|Long term Pantoprozole trial
214252734|NCT00138177|DRUG|oxaliplatin|Given IV
214252735|NCT00138177|DRUG|leucovorin calcium|Given IV
214252736|NCT00138177|DRUG|vorinostat|Given orally
214252737|NCT00138177|DRUG|fluorouracil|Given IV
214252738|NCT01810432|DRUG|Evacetrapib|Administered orally
214252739|NCT01810432|OTHER|High-fat Meal|Administered orally, at breakfast.
214252740|NCT00736879|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
214252741|NCT00736879|DRUG|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
214252742|NCT03090412|DRUG|HPPH|Given IV
214252743|NCT03090412|OTHER|Laboratory Biomarker Analysis|Correlative studies
214252744|NCT03090412|DRUG|Photodynamic Therapy|Undergo PDT
214252745|NCT03090412|OTHER|Quality-of-Life Assessment|Ancillary studies
214252746|NCT03090412|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214252747|NCT04476550|DRUG|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
214252748|NCT02360111|DRUG|Cyclophosphamide|
214252749|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
214252750|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
214252751|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
214252752|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
214252753|NCT03120442|DRUG|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
214252754|NCT03120442|DRUG|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
214252755|NCT03120442|DRUG|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
214252756|NCT05032248|DRUG|Tacrolimus ointment|oral gel
214252757|NCT00718302|DEVICE|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
214252758|NCT00718302|DEVICE|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
214252759|NCT00589901|DRUG|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
214252760|NCT00286507|PROCEDURE|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
214252761|NCT00657449|DRUG|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
214252762|NCT00657449|DRUG|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
214252763|NCT04944095|OTHER|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
214252764|NCT04104334|DRUG|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
214252765|NCT04104334|DRUG|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
214252766|NCT01940562|DRUG|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
214252767|NCT00876876|DRUG|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
214252768|NCT05053711|DEVICE|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214252769|NCT05053711|DEVICE|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214252770|NCT05053711|DEVICE|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
214252771|NCT05053711|DEVICE|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214252772|NCT05053711|DEVICE|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
214252773|NCT05053711|DEVICE|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
214252774|NCT01670604|DRUG|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
214252775|NCT01670604|DRUG|Tetraspan, B. Braun, Melsungen, Germany|
214252776|NCT00953381|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214252777|NCT00953381|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214252778|NCT00953381|DRUG|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214252779|NCT00953381|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
214252780|NCT04274387|BEHAVIORAL|Mindfulness-based Stress Reduction(MBSR)|A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
214252781|NCT04268589|OTHER|virtual reality game|routine
214252782|NCT01567735|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
214252783|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy)|"The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~For study GROUP 1:~Study drugs are:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 1 will receive one of the following for each treatment period: monotherapy with Indapamide, bitherapy with Indapamide plus Perindopril, or bitherapy with Perindopril plus Amlodipine."
214252784|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy)|"Study drugs:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 2 will receive one of the following monotherapies: Perindopril , Indapamide, or Amlodipine."
214252785|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment|"For study GROUP 3:~Subjects will be prescribed an individualized new antihypertensive treatment at their consultation with the Investigator at Visit 1."
214252786|NCT05314075|PROCEDURE|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
214252787|NCT05314075|PROCEDURE|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
214252788|NCT02978924|DEVICE|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
214252789|NCT05519241|DRUG|PLZ4-coated paclitaxel-loaded micelles (PPM)|PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
214252790|NCT06213545|DIAGNOSTIC_TEST|In-clinic interpretation|Reading patch test result at clinic
214252791|NCT06213545|DIAGNOSTIC_TEST|Photo interpretation|Reading patch test result by sending photo to clinic
214252792|NCT06273592|OTHER|Animal-based meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
214252793|NCT06273592|OTHER|Plant-based meat meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
214252794|NCT01764152|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
214252795|NCT05669365|BEHAVIORAL|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
214252796|NCT05135403|DEVICE|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
214252797|NCT06562777|OTHER|Non-Interventional Study|Non-Interventional Study
214252798|NCT05781789|OTHER|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
214252800|NCT04723654|DEVICE|Wireless Wearable Vital Sign Monitor|Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours
214252801|NCT06223958|DRUG|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
214252802|NCT06223958|DRUG|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
214252803|NCT04991103|DRUG|DaraVRD|"All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22)."
214252804|NCT04189835|DIAGNOSTIC_TEST|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
214252805|NCT05323006|OTHER|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
214252806|NCT03165292|RADIATION|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
214252807|NCT03165292|DRUG|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
214252808|NCT03165292|DRUG|Thiotepa|Day 1-3 Thiotepa
214252809|NCT03165292|PROCEDURE|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
214252810|NCT05754996|DRUG|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
214252811|NCT05754996|DRUG|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
214252812|NCT05754996|DRUG|Rifaximin 550Mg Tab|Rifaximin 550 MG twice daily
214653134|NCT01413269|RADIATION|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
214653135|NCT04575948|DRUG|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
214252813|NCT06494631|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
214252814|NCT04665180|DIAGNOSTIC_TEST|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
214252815|NCT02310321|DRUG|Gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
214252816|NCT02310321|DRUG|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
214252817|NCT02310321|DRUG|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
214252818|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
214252819|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
214252820|NCT02839278|BIOLOGICAL|Blood sample|
214252821|NCT06511895|DRUG|AZD4205|AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
214252822|NCT06168058|DIAGNOSTIC_TEST|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
214252823|NCT06168058|PROCEDURE|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
214252824|NCT06584240|DRUG|Sequence 1|Single treatment, intramuscularly injected. The total injection 100-150U.
214252825|NCT06584240|DRUG|Sequence 2|Single treatment, intramuscularly injected. The total injection 200-250U.
214252826|NCT06584240|DRUG|Sequence 3|Single treatment, intramuscularly injected. The total injection 350-400U.
214252827|NCT06584240|DRUG|Sequence 4|Single treatment, intramuscularly injected. The total injection ≤400U.
214252828|NCT06584240|DRUG|Sequence 5|Single treatment, intramuscularly injected.
214252829|NCT02656407|DEVICE|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
214252830|NCT03275181|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
214252831|NCT03275181|DIAGNOSTIC_TEST|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
214252832|NCT03275181|DIAGNOSTIC_TEST|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
214252833|NCT01698905|DRUG|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
214252834|NCT05731986|DIAGNOSTIC_TEST|Orthostatic challenge|"Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation."
214252835|NCT05731986|DEVICE|Biostim-5 transcutaneous spinal stimulation - Mapping|Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
214252836|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Optimal testing"|Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
214252837|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Sham testing"|Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
214252838|NCT02445443|DEVICE|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
214464839|NCT05819346|BEHAVIORAL|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
214653136|NCT04575948|DRUG|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
214653137|NCT04575948|DRUG|Base formula|Base formula is a negative control
214653138|NCT00585234|OTHER|Digital Photography|Digital Photography
214252839|NCT04298723|DEVICE|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (Watchman or Watchman FLX) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
214252840|NCT03207555|DRUG|Ibrutinib|420 mg by mouth once daily.
214252841|NCT03568890|DRUG|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
214252842|NCT03568890|DRUG|Clopidogrel -75 mg/day|Duration of treatment: 60 days
214252843|NCT03568890|DRUG|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
214252844|NCT05900206|DRUG|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
214252845|NCT05900206|DRUG|Docetaxel|Active comparator. IV infusion.
214252846|NCT05900206|DRUG|Paclitaxel|Active comparator. IV infusion.
214252847|NCT05900206|DRUG|Carboplatin|Active comparator. IV infusion.
214252848|NCT05900206|DRUG|Trastuzumab|Active comparator. IV infusion.
214252849|NCT05900206|DRUG|Pertuzumab|Active comparator. IV infusion.
214252850|NCT05900206|DRUG|Ribociclib|Experimental drug. Tablets.
214252851|NCT05900206|DRUG|Letrozole|Experimental drug. Tablets.
214252852|NCT05900206|DRUG|Epirubicin|Active comparator. IV infusion.
214252853|NCT05900206|DRUG|Cyclophosphamide|Active comparator. IV infusion.
214252854|NCT04107727|DRUG|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
214252855|NCT04107727|DRUG|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
214252856|NCT04107727|DRUG|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
214252857|NCT04107727|DRUG|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
214252858|NCT01106716|DRUG|Placebo|Placebo IV Infusion
214252859|NCT01106716|DRUG|KAI-1678|KAI-1678 IV Infusion
214252860|NCT01106716|DRUG|Lidocaine|Lidocaine
214252861|NCT02481453|DRUG|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
214252862|NCT02481453|DRUG|Placebo|Comparator: placebo
214252863|NCT06327542|OTHER|Group Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
214252864|NCT06327542|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
214252865|NCT00381953|DRUG|Peginterferon alfa-2a|
214252866|NCT00381953|DRUG|Interferon alfa-2a|
214252867|NCT00381953|DRUG|Ribavirin|
214252868|NCT00282542|PROCEDURE|Hepatocyte Infusion|
214252869|NCT01729247|DEVICE|NIOX MINO® Instrument (09-1100)|
214252870|NCT04673981|DIAGNOSTIC_TEST|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
214252871|NCT02779751|DRUG|Abemaciclib|Administered orally
214252872|NCT02779751|DRUG|Pembrolizumab|Administered IV
214252873|NCT02779751|DRUG|Anastrozole|Administered orally
214252874|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with inner side of the graft|Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
214252875|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with outer side of the graft|The tunnel technique for root coverage with CTG with outer side of the graft
214252876|NCT01669707|DRUG|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
214252877|NCT01669707|DRUG|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
214252878|NCT00500305|PROCEDURE|Withhold standard INDO dose if BNP < 100 pg/ml|
214252879|NCT01393015|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
214464840|NCT05024760|DRUG|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
214252880|NCT01393015|DEVICE|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
214252881|NCT05555758|DRUG|Adamgammadex Sodium|Aom0319 will be administered intravenously with water for injection.
214252882|NCT05555758|DRUG|0.9% Sodium Chloride Injection|0.9% Sodium Chloride will be administered intravenously.
214252883|NCT02325791|DRUG|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
214252884|NCT02325791|DRUG|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
214252885|NCT02325791|DRUG|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
214252886|NCT02325791|DRUG|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
214252887|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
214252888|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
214252889|NCT03953183|OTHER|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
214252890|NCT03953183|OTHER|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
214252891|NCT00006324|DRUG|Ethinyl estradiol/levonorgestrel|
214252892|NCT00006324|DRUG|Medroxyprogesterone acetate|
214252893|NCT06185127|DRUG|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
214252894|NCT06185127|DRUG|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
214252895|NCT06185127|DRUG|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
214252896|NCT06185127|DRUG|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
214252897|NCT00679744|DRUG|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
214252898|NCT02658058|OTHER|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
214252899|NCT02658058|OTHER|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
214252900|NCT02658058|OTHER|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
214252901|NCT01100736|DRUG|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
214252902|NCT01100736|DRUG|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
214252903|NCT01100736|DRUG|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
214252904|NCT01100736|BIOLOGICAL|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
214252905|NCT05436223|DRUG|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
214252906|NCT04568824|OTHER|GraphoLearn reading intervention|This is an Edtech reading intervention
214252907|NCT04568824|OTHER|Vektor math control intervention|This is an Edtech math/cognition intervention
214252908|NCT00068783|DRUG|imatinib mesylate|Given orally
214252909|NCT00068783|OTHER|laboratory biomarker analysis|Correlative studies
214252910|NCT05345171|GENETIC|DTX301|non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
214252911|NCT05345171|OTHER|Placebo|normal saline infusion
214252912|NCT05345171|DRUG|Oral Corticosteroids|Participants who receive DTX301 solution will receive oral corticosteroids.
214252913|NCT05345171|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
214252914|NCT05345171|DRUG|Sodium Acetate|A tracer for the Ureagenesis Rate Test (URT)
214252915|NCT05397132|GENETIC|Blood draw|Patients will provide a blood draw for research and repository
214653139|NCT04363333|DIAGNOSTIC_TEST|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
214252916|NCT05661357|DRUG|Disitamab Vedotin Combined With Fruquintinib|Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
214252917|NCT03070366|DRUG|Chemotherapy|"* cisplatin~* 5FU~* carboplatin~* cetuximab"
214252918|NCT03070366|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy
214252919|NCT01465191|DRUG|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
214252920|NCT00000977|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214252921|NCT02607839|BIOLOGICAL|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
214252922|NCT03445182|PROCEDURE|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
214252923|NCT03445182|DEVICE|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
214252924|NCT03064581|BEHAVIORAL|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
214252925|NCT02925325|BEHAVIORAL|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
214252926|NCT02925325|OTHER|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
214252927|NCT01558193|DIETARY_SUPPLEMENT|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
214252928|NCT01558193|DIETARY_SUPPLEMENT|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
214252929|NCT01558193|DIETARY_SUPPLEMENT|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
214252930|NCT01558193|DIETARY_SUPPLEMENT|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
214252931|NCT01663168|DRUG|Rifabutin|
214252932|NCT02273739|DRUG|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
214252933|NCT04795622|DEVICE|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
214252934|NCT04795622|DEVICE|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
214252935|NCT02195284|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
214252936|NCT02195284|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
214252937|NCT02195284|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
214252938|NCT02195284|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
214252939|NCT03295526|PROCEDURE|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
214464841|NCT05024760|DRUG|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
214464842|NCT03355274|DIAGNOSTIC_TEST|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up)."
214464843|NCT03355274|DIAGNOSTIC_TEST|Photopletysmography|Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
214464844|NCT03355274|OTHER|Questionnaires of Quality of Life (QoL)|Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
214464845|NCT05304364|COMBINATION_PRODUCT|Combination Product: Naltrexone|Naltrexone Implant
214464846|NCT05664633|DRUG|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
214464847|NCT06335095|OTHER|Kinematic sensors|Comparative analysis of kinematic data acquired in supervised and unsupervised environment
214252940|NCT05779735|DIAGNOSTIC_TEST|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
214252941|NCT00996723|DRUG|vandetanib and dasatinib|Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
214252942|NCT00882492|BIOLOGICAL|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
214252943|NCT00882492|BIOLOGICAL|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
214252944|NCT00089674|DRUG|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
214252945|NCT00089674|DRUG|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
214252946|NCT00188708|PROCEDURE|hypoxia measurement|transrectal oxygen measurement
214252947|NCT06666400|BEHAVIORAL|LHMoms Intervention|The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 12-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
214252948|NCT06666400|OTHER|No intervention|Standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
214252949|NCT01435317|DEVICE|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
214252950|NCT04005989|BIOLOGICAL|Stromal Cells Injection|Adipose stromal cell
214252951|NCT03893331|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
214252952|NCT00983788|DRUG|Bezafibrate|3 x 200 mg/ day
214252953|NCT00983788|OTHER|Placebo|Placebo
214252954|NCT03492411|OTHER|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
214252955|NCT05671328|OTHER|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
214252956|NCT00782327|DRUG|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
214252957|NCT00782327|DRUG|Placebo|Daily placebo capsule
214252958|NCT05982210|OTHER|Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol|The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
214252959|NCT00002898|BIOLOGICAL|dactinomycin|
214252960|NCT00002898|DRUG|carboplatin|
214252961|NCT00002898|DRUG|cyclophosphamide|
214252962|NCT00002898|DRUG|epirubicin hydrochloride|
214252963|NCT00002898|DRUG|etoposide|
214252964|NCT00002898|DRUG|ifosfamide|
214252965|NCT00002898|DRUG|vincristine sulfate|
214252966|NCT00002898|PROCEDURE|adjuvant therapy|
214252967|NCT00002898|PROCEDURE|conventional surgery|
214252968|NCT00002898|PROCEDURE|neoadjuvant therapy|
214252969|NCT00002898|RADIATION|brachytherapy|
214252970|NCT00002898|RADIATION|radiation therapy|
214252971|NCT03967678|DIETARY_SUPPLEMENT|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
214252972|NCT03144024|DEVICE|band implantation|
214252973|NCT03144024|DEVICE|rigid ring implantation|
214252974|NCT04493879|OTHER|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
214252975|NCT02961218|DRUG|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
214252976|NCT02961218|DRUG|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
214252977|NCT01210573|DEVICE|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
214252978|NCT06135480|OTHER|subcision ,PRP or saline and microneedling|minimally invasive procedures
214252979|NCT02639156|DIETARY_SUPPLEMENT|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
214252980|NCT02606890|OTHER|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
214252981|NCT05398926|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
214252982|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
214252983|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
214252984|NCT00591266|DRUG|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
214252985|NCT05050552|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
214252986|NCT03902106|DRUG|salbutamol|subjects ingest salbutamol
214252987|NCT03902106|OTHER|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
214252988|NCT03488927|BEHAVIORAL|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
214252989|NCT01135212|DRUG|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
214252990|NCT01135212|DRUG|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
214252991|NCT01135212|DRUG|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
214252992|NCT01889524|OTHER|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
214252993|NCT01889524|OTHER|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
214252994|NCT01889524|OTHER|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
214252995|NCT00901927|DRUG|Bendamustine|Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
214252996|NCT00901927|DRUG|Mitoxantrone|10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
214252997|NCT00901927|DRUG|Rituximab|375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
214252998|NCT05773703|DRUG|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
214252999|NCT05773703|DRUG|PTI-122|Cytoprotective agent
214253000|NCT00814151|OTHER|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
214253001|NCT04121416|DRUG|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
214253002|NCT04121416|DRUG|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
214253003|NCT00018070|PROCEDURE|Angiography|
214253004|NCT00018070|PROCEDURE|Laser Treatment|
214253005|NCT04623398|DRUG|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
214253006|NCT04623398|DRUG|Placebo|Placebo
214253007|NCT03913403|PROCEDURE|ECHO|Echocardiogram at baseline and 24 hours later
214253008|NCT03913403|PROCEDURE|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
214253009|NCT02239627|DRUG|Epidural steroid|
214253010|NCT02239627|DRUG|Clonidine|
214253011|NCT03412071|DRUG|Oral Tinidazole|Please see description under arms
214253012|NCT03412071|DRUG|Topical metronidazole|Please see description under arms
214253013|NCT03412071|DRUG|Topical Clindamycin|Please see description under arms
214253014|NCT03412071|DRUG|Topical Hydrogen Peroxide|Please see description under arms
214253015|NCT02572193|PROCEDURE|POEM|To determine the feasibility of same-day discharge following a POEM procedure
214253016|NCT06370273|DRUG|Rivaroxaban|10mg once daily via oral ingestion
214253017|NCT06370273|DRUG|Apixaban|2.5mg twice daily via oral ingestion
214253018|NCT06370273|DRUG|Enoxaparin Injectable Solution|40mg once daily via subcutaneous injection
214253019|NCT06370273|DRUG|Tinzaparin Injectable Solution|4500 IU once daily via subcutaneous injection
214253020|NCT06370273|DRUG|Dalteparin Injectable Solution|5000 IU once daily via subcutaneous injection
214253021|NCT06370273|DRUG|Fondaparinux Injectable Product|2.5 mg once daily via subcutaneous injection
214253022|NCT01131767|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
214253023|NCT04407481|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214253024|NCT04407481|DRUG|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
214253025|NCT04407481|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
214253026|NCT03005938|PROCEDURE|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
214253027|NCT03005938|PROCEDURE|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
214253028|NCT01626638|PROCEDURE|Confocal Micro Endoscopy|
214253029|NCT05733377|DIAGNOSTIC_TEST|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
214253030|NCT05733377|DIAGNOSTIC_TEST|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
214253031|NCT00397410|DEVICE|Hip protectors|
214253032|NCT04581759|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
214253033|NCT04581759|DRUG|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
214253034|NCT02676466|DIETARY_SUPPLEMENT|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
214253035|NCT02676466|DRUG|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
214253036|NCT02676466|OTHER|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
214253037|NCT02676466|OTHER|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
214253038|NCT00120354|PROCEDURE|Blood Testing|
214253039|NCT00120354|PROCEDURE|Percutaneous Liver Biopsy|
214253040|NCT00120354|PROCEDURE|Lamivudine Therapy|
214253041|NCT01016561|RADIATION|intracavitary balloon brachytherapy|
214253042|NCT01016561|RADIATION|external beam radiation therapy|
214653140|NCT06472856|PROCEDURE|Acupuncture|Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
214253043|NCT01016561|RADIATION|intensity-modulated radiation therapy|
214253044|NCT01016561|RADIATION|radiation therapy treatment planning/simulation|
214253045|NCT01016561|RADIATION|3-dimensional conformal radiation therapy|
214253046|NCT01016561|DRUG|Cisplatin|
214253047|NCT01119560|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214253048|NCT01119560|OTHER|Laboratory Biomarker Analysis|Correlative studies
214253049|NCT01119560|OTHER|Questionnaire Administration|Ancillary studies
214253050|NCT01178073|DRUG|ambrisentan|ambrisentan (target dose: 10mg)
214253051|NCT01178073|DRUG|tadalafil|tadalafil (target dose: 40mg)
214253052|NCT01352468|OTHER|Multifaceted cognitive training|Four computerized training tasks
214253053|NCT00438438|BEHAVIORAL|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
214253054|NCT01473056|DRUG|JTK-853|Tablets, twice a day for 3 days
214253055|NCT01473056|DRUG|Dose 2 JTK-853|Tablets, twice a day for 3 days
214253056|NCT01473056|DRUG|Dose 3 JTK-853|Tablets, three times a day for 3 days
214253057|NCT01473056|DRUG|Dose 4 JTK-853|Tablets, twice a day for 3 days
214253058|NCT01473056|DRUG|Placebo|Tablets, twice a day or three times a day for 3 days
214253059|NCT01936077|DRUG|Recombinant LH (Luveris)|150 IU recombinant LH daily.
214253060|NCT03497676|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
214253061|NCT03497676|DRUG|Oral Rilpivirine (RPV)|25 mg tablets administered orally
214253062|NCT03497676|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
214253063|NCT03497676|DRUG|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
214253064|NCT03497676|DRUG|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
214253065|NCT00589485|DEVICE|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
214253066|NCT00589485|DEVICE|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
214253067|NCT03927807|DRUG|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
214253068|NCT03496571|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
214253069|NCT03496571|OTHER|Placebo|Placebo
214253070|NCT00484718|DRUG|celecoxib|oral, 100 mg bid
214253071|NCT00484718|DRUG|Oxycodone|oral, 20 mg bid
214253072|NCT00484718|DRUG|placebo|oral bid
214253073|NCT06533397|PROCEDURE|Sinus floor elevation (SFE)|Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
214253074|NCT06533397|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
214253075|NCT06533397|DIAGNOSTIC_TEST|postoperative CBCT|A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
214253076|NCT06533397|DIAGNOSTIC_TEST|bone core biopsy|At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
214253077|NCT06533397|PROCEDURE|dental implant placement|Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
214253078|NCT06533397|PROCEDURE|fixed dental prosthesis (FDP) fabrication|3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
214253079|NCT06533397|DEVICE|bone grafting|A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.
214253080|NCT04684290|PROCEDURE|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
214253081|NCT04684290|PROCEDURE|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
214253082|NCT02636374|BEHAVIORAL|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
214253083|NCT01226043|DRUG|Insulin Glargine|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous"
214253084|NCT01110304|OTHER|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
214253085|NCT01110304|DEVICE|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
214253086|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
214253087|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
214253088|NCT01841307|DRUG|Cromolyn Sodium|
214253089|NCT02644031|PROCEDURE|mtwo rotary system|post-treatment pain after using mtwo rotary system
214253090|NCT02644031|PROCEDURE|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
214253091|NCT02644031|PROCEDURE|hand files|post-treatment pain after using hand files
214253092|NCT02103049|DRUG|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
214253093|NCT02015702|OTHER|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
214253094|NCT02015702|OTHER|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
214253095|NCT01600508|OTHER|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
214253096|NCT03425019|DEVICE|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
214253097|NCT05116358|DEVICE|Phototherapy device|The active phototherapy device will emit light
214253098|NCT00294476|DRUG|IVIG|
214253099|NCT00294476|PROCEDURE|Biological Therapy|
214253100|NCT05861310|DRUG|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
214253101|NCT05861310|DRUG|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
214253102|NCT05736510|OTHER|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
214253103|NCT05736510|OTHER|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
214253104|NCT02770833|OTHER|Fish and carbohydrats with low or high GI|
214253105|NCT02770833|OTHER|Veal and carbohydrats with low or high GI|
214253106|NCT00140634|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
214253107|NCT01974154|OTHER|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
214253108|NCT01974154|OTHER|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
214253109|NCT03508531|PROCEDURE|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
214253110|NCT03508531|PROCEDURE|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
214253111|NCT03508531|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214253112|NCT01720212|DRUG|YM178|oral
214253113|NCT03602729|OTHER|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
214653141|NCT06518629|OTHER|Photobiomodulation with low power laser|All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
214653142|NCT03442803|DEVICE|Target-Controlled Infusion|Propofol Target-Controlled Infusion
214653143|NCT03914352|DRUG|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
214253114|NCT00191646|DRUG|Gemcitabine|"1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
214253115|NCT00191646|DRUG|Paclitaxel|"175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
214253116|NCT00191646|DRUG|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
214253117|NCT00453518|DEVICE|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
214253118|NCT01932073|DEVICE|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
214253119|NCT01501396|DRUG|Megestrol Acetate|
214253120|NCT01501396|DRUG|Mirtazapine|
214253121|NCT00322101|RADIATION|total-body irradiation|Radiation
214253122|NCT00322101|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
214253123|NCT00322101|DRUG|cyclophosphamide|Given IV
214253124|NCT00322101|DRUG|mycophenolate mofetil|Given orally
214253125|NCT00322101|DRUG|busulfan|Given IV or orally
214253126|NCT00322101|DRUG|cyclosporine|Given IV or orally
214253127|NCT00322101|DRUG|fludarabine phosphate|Given IV
214253128|NCT00322101|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
214253129|NCT00322101|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
214253130|NCT00322101|OTHER|laboratory biomarker analysis|Correlative studies
214253131|NCT00322101|GENETIC|cytogenetic analysis|Correlative studies
214253132|NCT00322101|OTHER|flow cytometry|Correlative studies
214253133|NCT00322101|GENETIC|fluorescence in situ hybridization|Correlative studies
214253134|NCT00322101|OTHER|pharmacological study|Correlative studies
214253135|NCT00322101|GENETIC|polymorphism analysis|Correlative studies
214253136|NCT00322101|DRUG|tacrolimus|Given IV or orally
214253137|NCT00322101|DRUG|methotrexate|Given IV
214253138|NCT02666534|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
214253139|NCT02666534|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
214253140|NCT02666534|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
214253141|NCT02666534|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
214253142|NCT03579576|DRUG|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
214253143|NCT04142593|OTHER||
214253144|NCT00003099|DRUG|Fenretinide|Daily for 14-28 days.
214253145|NCT00003099|DRUG|Tamoxifen Citrate|Daily for 14-28 days.
214253146|NCT00003099|OTHER|Placebo|Daily for 14-28 days
214253147|NCT00723931|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
214253148|NCT04350606|BIOLOGICAL|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
214253149|NCT00328549|DRUG|Pegylated Interferon and Ribavirin|
214253150|NCT04483323|PROCEDURE|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
214253151|NCT04483323|PROCEDURE|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
214253152|NCT03139097|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214464848|NCT06380868|PROCEDURE|Intravascular imaging-guided PCI|Intravascular imaging including intravascular ultrasound or optical coherence tomography.
214253153|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B|Intervention group will receive a nutritional formula A and, after 1-week washout period, will receive a nutritional formula B
214253154|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A|Intervention group will receive a nutritional formula B and, after 1-week washout period, will receive a nutritional formula A
214253155|NCT02996734|PROCEDURE|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
214253156|NCT05211284|DRUG|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of treatment (24 weeks).
214253157|NCT05211284|DRUG|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of treatment (24 weeks).
214253158|NCT04992624|DRUG|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
214253159|NCT04992624|DRUG|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
214253160|NCT04992624|DRUG|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
214253161|NCT03593161|BEHAVIORAL|Humor therapy|Clown visits
214253162|NCT04898114|DRUG|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
214253163|NCT04898114|DRUG|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
214253164|NCT04898114|OTHER|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
214253165|NCT06310044|OTHER|Root canal irrigant Commiphora Myrrh 50%|Root canal irrigant
214253166|NCT05597670|OTHER|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
214253167|NCT05597670|OTHER|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
214253168|NCT05388396|OTHER|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
214253169|NCT04449471|DRUG|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
214253170|NCT05456945|OTHER|acupressure application|Acupressure will be applied to the UB32 point
214253171|NCT05456945|DEVICE|Shotblocher|Shotblocher will be administered during injection
214253172|NCT03464695|DEVICE|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
214253173|NCT02859506|OTHER|Respiratory quotient|
214253174|NCT02859506|OTHER|Olfactory liking|
214253175|NCT02914587|DEVICE|ARTAS System|
214253176|NCT02914587|OTHER|Manual Implantation|
214253177|NCT01863810|DRUG|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
214253178|NCT01863810|DRUG|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
214253179|NCT01863810|DRUG|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
214253180|NCT01863810|DRUG|Placebo of KW21052|Oral,once a day, for 8 weeks
214253181|NCT01863810|DRUG|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
214253182|NCT01466777|PROCEDURE|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
214253183|NCT01466777|PROCEDURE|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
214253184|NCT04738409|OTHER|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
214253185|NCT04738409|OTHER|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
214253186|NCT05876260|BEHAVIORAL|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
214253187|NCT05876260|BEHAVIORAL|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
214253188|NCT05876260|BEHAVIORAL|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
214253189|NCT02820714|DRUG|BLI801 Laxative|BLI801 Laxative
214253190|NCT06168227|DRUG|Disitamb Vedotin|RC48-ADC based therapy
214253191|NCT03901898|BEHAVIORAL|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
214253192|NCT03901898|BEHAVIORAL|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
214253193|NCT04990336|COMBINATION_PRODUCT|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
214253194|NCT04990336|DRUG|Rhubarb single medicine|Rhubarb single medicine
214253195|NCT04990336|COMBINATION_PRODUCT|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
214253196|NCT01138839|DRUG|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
214253197|NCT01138839|DRUG|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
214253198|NCT06255210|DRUG|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
214253199|NCT00739596|DRUG|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
214253200|NCT00739596|DRUG|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
214253201|NCT02103218|BEHAVIORAL|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
214253202|NCT02103218|BEHAVIORAL|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
214253203|NCT05334511|OTHER|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
214253204|NCT00908011|DRUG|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
214253205|NCT00908011|DRUG|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
214253206|NCT00815724|BEHAVIORAL|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
214253207|NCT06476964|PROCEDURE|skin biopsies|Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
214253208|NCT05597436|DRUG|Trehalose|Once weekly 0.75g/kg administration
214253209|NCT04054570|OTHER|No intervention|No Intervention
214253210|NCT06060821|OTHER|No intervention|No intervention
214253211|NCT00491426|DRUG|Ampicillin|Drug prescribed per routine medical care.
214253212|NCT00491426|DRUG|Metronidazole|Drug prescribed per routine medical care.
214253213|NCT00491426|DRUG|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
214253214|NCT00491426|DRUG|Acyclovir|Drug prescribed per routine medical care.
214253215|NCT00491426|DRUG|Amphotericin B|Drug prescribed per routine medical care.
214253216|NCT00491426|DRUG|Ambisome|Drug prescribed per routine medical care.
214253217|NCT00491426|DRUG|Anidulafungin|Drug prescribed per routine medical care.
214253218|NCT00491426|DRUG|Caspofungin|Drug prescribed per routine medical care.
214253219|NCT02567552|DRUG|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
214253220|NCT02567552|DRUG|Intramuscular progesterone|intramuscular progesterone 50 mg/day
214253221|NCT06965621|DRUG|18F-metaFluorobenzylguanidine|PET Radiopharmaceutical to assess myocardial sympathetic innervation
214253222|NCT06965621|DRUG|Rubidium-82|PET Radiopharmaceutical to assess myocardial perfusion
214253223|NCT05368844|DEVICE|rTMS treatment using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of rTMS treatment
214253224|NCT05368844|DEVICE|sham TMS using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of sham iTBS treatment
214253225|NCT06458595|DRUG|KH658|KH658 Ophthalmic Injection
214253226|NCT03534518|OTHER|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
214253227|NCT03534518|OTHER|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
214253228|NCT03911128|OTHER|Observational|Observational study - no intervention
214464849|NCT06380868|PROCEDURE|Angiography-guided PCI group|Deployment of a drug-eluting stent under angiography.
214464850|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
214464851|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
214253229|NCT06965946|PROCEDURE|Intermittent Hypoxia-Hyperoxia Therapy (IHHT)|Participants receive 4 cycles per session of 5 minutes of hypoxia (13-15% O₂) followed by 2 minutes of hyperoxia (40% O₂) using a hypoxia generator (Olive OLV 10H). Sessions are delivered before each conventional physical therapy session, 3 times per week for 4 weeks (total 12 sessions). Participants are monitored for heart rate, blood pressure, and oxygen saturation throughout the intervention.
214253230|NCT06965946|PROCEDURE|Conventional Physical Therapy|Participants receive individualized conventional physical therapy for knee osteoarthritis based on current clinical practices in tertiary hospitals of Peshawar. Therapy is delivered 3 times per week for 4 weeks (total 12 sessions) and includes strength training, mobility exercises, and patient education.
214253231|NCT06965946|PROCEDURE|Normoxic Air Placebo|Participants in the control group inhale normoxic air (19.8% O₂) using the same Olive OLV 10H hypoxia generator to maintain blinding. Each session consists of 4 cycles of 5 minutes of normoxia followed by 2 minutes of normoxia, simulating the timing of hypoxia-hyperoxia therapy. Sessions are administered prior to conventional physical therapy, 3 times per week for 4 weeks (total 12 sessions). Patients are monitored for vital signs throughout.
214253232|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
214253233|NCT05706779|DRUG|Encorafenib Oral Capsule + Cetuximab|Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
214253234|NCT01055873|BIOLOGICAL|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
214253235|NCT02904447|OTHER|x-ray and pedobar foot pressure mapping|
214253236|NCT06971263|BEHAVIORAL|Consultation on both nutrition, and palliative care|The intervention on the nutrition and palliative care components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian and one palliative care physician to discuss patient needs and required to improve their health consequences.
214253237|NCT06971263|BEHAVIORAL|Counselling on nutrition and healthy diet|The intervention on the nutrition and healthy diet components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian to discuss patient dietary needs for improving their health consequences.
214253238|NCT05548010|OTHER|No intervention as this is an observational study|No intervention
214253239|NCT06522997|DRUG|BAY3283142|Tablet, intake orally once daily
214253240|NCT06522997|DRUG|Placebo|Matching with BAY3283142
214253241|NCT06297616|DRUG|LY3841136|Administered SC
214253242|NCT06297616|DRUG|LY3841136-Placebo|Administered SC
214253243|NCT06297616|DRUG|Tirzepatide|Administered SC
214253244|NCT06297616|DRUG|Tirzepatide-Placebo|Administered SC
214253245|NCT03763318|BIOLOGICAL|EQ001|Itolizumab \[Bmab 600\])
214253246|NCT03763318|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
214253247|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
214653144|NCT03914352|PROCEDURE|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
214253248|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
214253249|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
214253250|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
214253251|NCT01548586|DEVICE|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
214253252|NCT00056589|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
214253253|NCT04267757|PROCEDURE|rectovaginal fistula repair with Martius flap|rectovaginal fistula repair with Martius flap
214253254|NCT06016348|PROCEDURE|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
214818174|NCT05283629|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
214253256|NCT07134257|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
214653145|NCT01827891|PROCEDURE|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
214818175|NCT05283629|BEHAVIORAL|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
214818176|NCT01344291|DRUG|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
214253257|NCT07134257|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 4 weeks, 8 weeks, and optionally at 12 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
214253258|NCT07134257|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
214253259|NCT07134257|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program includes isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent joint stiffness, reduce swelling, and improve circulation. All exercises are performed within a pain-free range (not exceeding 4/10 on the VAS scale) with gradual progression according to the rehabilitation plan.
214253260|NCT01716325|OTHER|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
214253261|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
214253262|NCT04107259|DIAGNOSTIC_TEST|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
214253263|NCT04068584|OTHER|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
214253264|NCT02452697|BIOLOGICAL|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
214253265|NCT02452697|BIOLOGICAL|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
214253266|NCT02658097|DRUG|Pembrolizumab|200mg Pembrolizumab by IV infusion
214253267|NCT02658097|RADIATION|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
214253268|NCT06324357|DRUG|Zongertinib|Zongertinib
214253269|NCT06324357|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan
214253270|NCT06324357|DRUG|Trastuzumab emtansine|Trastuzumab emtansine
214253271|NCT06324357|DRUG|Trastuzumab|Herceptin®
214253272|NCT06324357|DRUG|Capecitabine|Xeloda®
214253273|NCT06587750|BEHAVIORAL|Cognitive Multisensory Rehabilitation|CMR targets somatosensory and multisensory and cognitive functions through sensory discrimination exercises.
214253274|NCT06604624|DRUG|HD1916|HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
214253275|NCT06604624|DRUG|semaglutide|semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
214253276|NCT04582916|DRUG|11C-MCI|Injected IV followed by PET scanning
214253277|NCT04582916|DRUG|11CPS13|Injected IV followed by PET scanning
214253278|NCT03552965|OTHER|Robust Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue
214253279|NCT03552965|OTHER|Margin-Based Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
214253280|NCT05897398|OTHER|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
214253281|NCT05897398|OTHER|Blood sampling|Blood sampling for routine care (max 15mL)
214464852|NCT05456880|BIOLOGICAL|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
214464853|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
214464854|NCT03883945|DRUG|AIV001|intradermal injection
214464855|NCT03883945|DRUG|Vehicle|intradermal injection
214464856|NCT03171129|DEVICE|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
214464857|NCT03171129|DEVICE|High flow Nasal Canula|Oxygen will be administered via nasal canula
214464858|NCT05228457|DEVICE|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
214464859|NCT06130345|BIOLOGICAL|SPIKEVAX|Intramuscular injection
214464860|NCT04774445|BEHAVIORAL|MyCancerGene|Interactive Health Communication Application
214653146|NCT05798052|BEHAVIORAL|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
214253282|NCT05897398|OTHER|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
214253283|NCT06592378|DEVICE|Addinex|Medication dispensing system to control and monitor opioid use
214253284|NCT06592378|DEVICE|Standard Pill Bottle|Access and use of opioids in a standard pill bottle.
214253285|NCT06589154|DIAGNOSTIC_TEST|Multi-modal artificial intelligence model (BEAM)|Data from mpMRI and cfDNA analysis will be integrated and processed by deep learning. The model's output will be compared against the final pathological diagnosis from the prostate biopsy to evaluate its performance.
214253286|NCT02394002|DRUG|Propofol|
214253287|NCT06817213|BEHAVIORAL|General education control|Participants will complete an online survey before reviewing education material for eosinophilic esophagitis, prior to patient's clinical physician's appointment (this appointment is a standard of care visit). Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
214253288|NCT06817213|BEHAVIORAL|Decision support tool|Participants will complete an online survey before reviewing tailored educational materials for eosinophilic esophagitis prior to patient's clinical physician's appointment (this appointment is a standard of care visit). The intervention is a tailored, electronic decision support intervention with a patient-facing decision aid (DA) with three components-EoE knowledge/education, values clarifications, and communication. Tailored feedback from the patient will be given to the patient's provider prior to the visit to facilitate shared decision-making in the visit. Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
214253289|NCT04875429|DEVICE|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2|Endovascular aneurysm repair
214253290|NCT05824364|OTHER|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
214253291|NCT05824364|OTHER|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
214253292|NCT06665932|PROCEDURE|Stereotactic radiotherapy|Stereotactic surgery is a minimally invasive form of surgical intervention that makes use of a three-dimensional coordinate system to locate small targets inside the body and to perform on them some action such as ablation, biopsy, lesion, injection, stimulation, implantation, radiosurgery, etc.
214253293|NCT06336928|OTHER|Non-Interventional Study|Non-interventional study
214253294|NCT06588049|DIETARY_SUPPLEMENT|Beet Root|Beet Root powder used as a mouth rinse in suspension with water
214253295|NCT06588049|OTHER|Water|Water used as a mouth rinse
214253296|NCT06068647|DIAGNOSTIC_TEST|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
214253297|NCT05407753|DIETARY_SUPPLEMENT|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
214253298|NCT05407753|DIETARY_SUPPLEMENT|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
214253299|NCT03316534|DRUG|Aspirin|Aspirin (100 mg once a day)
214653147|NCT06548321|DIAGNOSTIC_TEST|Extracorporeal Shockwave Therapy|" The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.~Once treatment is completed, patients should do their best to physical activity… higher levels of energy Shockwaves into deeper tissue locations… ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke."
214253300|NCT02908893|BEHAVIORAL|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
214653148|NCT02780076|OTHER|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
214653149|NCT05486403|BEHAVIORAL|Appetite Toolbox Programme|Preschool educators are trained to deliver a bio-behavioural classroom-based programme focusing on building skills in i) appetite awareness, ii) attention/attention control and iii) sensing body cues. The programme is delivered using a combination of interactive story books, classroom props and activities, and mealtime transitions/routines.
214653150|NCT04239846|DRUG|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
214653151|NCT04239846|OTHER|Placebo Gel|Placebo Gel, BID
214253301|NCT06981507|DEVICE|MARPE (Miniscrew-Assisted Rapid Palatal Expansion)|MARPE (Miniscrew-Assisted Rapid Palatal Expansion) is an orthodontic expansion technique that uses a palatal expander anchored with miniscrews inserted into the palatal bone. The device applies lateral force to widen the maxilla skeletally in patients with transverse maxillary deficiency. In this study, all participants will receive MARPE treatment as part of their orthodontic management, and its potential effects on speech will be evaluated over time.
214253302|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
214253303|NCT06991972|PROCEDURE|Needling + NBUVB|Participants in this arm will undergo needling using a sterile 30G (4mm) needle to manually puncture and implant melanocytes from perilesional pigmented skin into depigmented lesions. The procedure will be performed once every four weeks for a total of six sessions.
214253304|NCT06991972|PROCEDURE|Microneedling + NBUVB|Participants in this arm will undergo microneedling using a Dermapen device with 1.5 mm needles to create controlled micro-injuries in depigmented skin to enhance melanocyte migration and repigmentation. This procedure will be performed once every four weeks for six sessions.
214253305|NCT06615609|BEHAVIORAL|Smart family doctor|"Based on health managers, participants were additionally provided Smart family doctor, which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'."
214253306|NCT06615609|BEHAVIORAL|Health manager|Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
214253307|NCT06671054|DRUG|AP1189, 40 mg|AP1189 tablets for oral use
214253308|NCT06671054|DRUG|AP1189, 70 mg|AP1189 tablets for oral use
214253309|NCT06671054|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
214253310|NCT06671054|DRUG|AP1189 matching placebo|AP1189 tablets for oral use
214253311|NCT06666582|DRUG|Paclitaxel and ramucirumab|Second-line treatment with paclitaxel/ramucirumab vs other regimens
214253312|NCT06666738|BEHAVIORAL|Structured antimicrobial review|The appropriateness of the documented indication, route of administration, expected duration and stop date of all antimicrobials will be reviewed within 48 hours of their prescription.
214253313|NCT06514651|DRUG|MAQ-001|MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
214253314|NCT06514651|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
214253315|NCT06667622|DRUG|sodium glycididazole|Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
214253316|NCT04169347|DRUG|Oxaliplatin|2 week cycles
214253317|NCT06208852|OTHER|Virtual Navigator Program|For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
214253318|NCT02943083|BEHAVIORAL|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
214253319|NCT02160483|OTHER|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
214253320|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
214253321|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
214253322|NCT02477696|DRUG|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
214253323|NCT02477696|DRUG|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
214253324|NCT06617832|DRUG|Active drug for acute migraine treatment|Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
214653152|NCT02274688|BEHAVIORAL|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
214653153|NCT00219115|DRUG|aliskiren|
214653154|NCT03009604|DRUG|Simethicone|Simethicone 40mg oral tablets
214653155|NCT03009604|DRUG|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
214653156|NCT03656965|DRUG|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
214653157|NCT03656965|COMBINATION_PRODUCT|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
214253325|NCT06617832|DRUG|Placebo Oral Tablet|Inactive placebo pill (100 mg) looking like the active drug
214253326|NCT03971266|OTHER|Activity Monitor|Wear a Fitbit
214253327|NCT03971266|OTHER|Media Intervention|Complete smartphone based PRO diary
214253328|NCT06679842|DIAGNOSTIC_TEST|ascitis paracentesis|ascitis paracentesis
214253329|NCT04658472|DRUG|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
214253330|NCT04658472|DRUG|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
214253331|NCT06120777|DEVICE|INVSENSOR00069|Noninvasive pulse oximeter
214253332|NCT06608212|DRUG|Finerenone (Kerendia, BAY948862)|Follow clinical practice/administration.
214253333|NCT06608212|DRUG|Others except finerenone|Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
214253334|NCT05419908|DRUG|Fezolinetant|Oral Capsule
214253335|NCT05419908|DRUG|Placebo|Oral Capsule
214253336|NCT06683664|OTHER|Integrated health service delivery for very young adolescents|The proposed HPV-PASSREV intervention will aim to increase adolescent-centered access to HPV vaccination and other very young adolescent health services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health facility and community levels.
214253337|NCT06698575|DRUG|ABI-1179|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
214253338|NCT06698575|DRUG|ABI-1179 Placebo|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
214253339|NCT07150091|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214253340|NCT07150091|DRUG|Nirogacestat|Nirogacestat will be administered.
214253341|NCT07150091|DRUG|Lenalidomide|Lenalidomide will be administered.
214253342|NCT07150091|DRUG|Dexamethasone|Dexamethasone will be administered.
214253343|NCT07150169|DEVICE|Active TMS disruption|Active TMS disruption delivered to the personalized target
214253344|NCT07150169|DEVICE|Sham TMS disruption|Sham TMS disruption delivered to the personalized target
214253345|NCT07150637|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
214253346|NCT07149909|OTHER|Other (Conventional Therapy)|Participants received standard therapy including culture-guided antibiotics, tracheal lavage, and aspiration. Sputum samples were collected from the lower trachea for culture and sensitivity testing to guide antibiotic selection.
214253347|NCT07149909|PROCEDURE|Fiberoptic Bronchoscopy|Participants underwent fiberoptic bronchoscopy through the endotracheal tube for secretion clearance, sample collection, and alveolar lavage once daily for one week. Sterile sodium chloride solution with ambroxol hydrochloride was instilled, and antibiotics were administered immediately after lavage. Samples were cultured to guide antibiotic therapy.
214253348|NCT07150312|BEHAVIORAL|HIIT|"A 12-week home-based HIIT exercise plan (running). Duration: Each session consists of 10 x 1-minute high-intensity bouts interspersed with 10 x 1-minute recovery periods. Adding the 3-minute warmup and 3-minute cool-down, each session totals approximately 26 minutes. This protocol is followed for 12 weeks.~Intensity: High-intensity bouts are performed at 80-90% of HRmax (RPE 15-18). Recovery periods are at 40-50% of HRmax (RPE 11-13). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
214253349|NCT07150312|BEHAVIORAL|MICT|"A 12-week home-based MICT exercise plan (running). Duration: Each session consists of 20 minutes of continuous exercise. Including the 3-minute warm-up and 3-minute cool-down, each session totals 26 minutes. This protocol is followed for 12 weeks.~Intensity: Exercise is performed at 64-76% of HRmax (RPE 12-14). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
214253350|NCT07150052|OTHER|Artifical intelligence in whatsapp|AI-based tool Tia Bete, designed to assist patients with T1DM in carbohydrate counting and insulin dose adjustment. The tool provides real-time recommendations based on personalized insulin-to-carbohydrate ratios, insulin sensitivity factors, and individualized glycemic goals.
214253351|NCT07150325|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
214253352|NCT07150325|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is commonly applied in Mirror therapy.
214253353|NCT07150325|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
214253354|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of dexamethasone and lidocaine 2%
214253355|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of alcohol 30%, dexamethasone and lidocaine 2%
214253356|NCT07149493|DEVICE|Placebo nanofiber floss|Identical floss without probiotic coating, used under the same conditions.
214253357|NCT07149493|DEVICE|Probiotic nanofiber floss|Nanofiber floss infused with Ligilactobacillus salivarius (strain BCRC 14759), used twice daily for 14 days.
214253358|NCT07150481|DRUG|IV Lidocaine infusion|2 mg/kg/h (the total dose of lidocaine per hour will be calculated and add to normal saline 0.9% to total volume 50 ml and infused by a rate 50 ml/h till the end of the procedure
214253359|NCT07150481|DRUG|IV normal saline|IV normal saline 0.9% , rate 50 ml/h
214253360|NCT07150026|DRUG|Vorinostat (SAHA)|oral suspension
214253361|NCT07150026|DRUG|Placebo|placebo
214653158|NCT04047888|OTHER|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
214653159|NCT04047888|OTHER|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
214253362|NCT07150416|DRUG|Recombinant Human Ad-p53 Injection|A replication-deficient recombinant human type 5 adenovirus vector encoding the human wild-type p53 tumor suppressor gene. For this study, it will be administered via nebulized inhalation.
214253363|NCT07150065|DRUG|Levofloxacin|Oral 200 mg levofloxacin tablet
214253364|NCT07150065|DRUG|ciprofloxacin|Oral 900-1,000 mg ciprofloxacin tablet
214253365|NCT07150533|DIETARY_SUPPLEMENT|Placebo Arm|Participants receive a placebo consisting of maltodextrin in capsule form, matched in appearance and taste to the active supplements.
214253366|NCT07150533|DIETARY_SUPPLEMENT|Green Tea Extract|Participants receive 500 mg of standardized green tea extract in capsule form.
214253367|NCT07150533|DIETARY_SUPPLEMENT|Ginger|Participants receive 1 g of ginger supplement in capsule form.
214253368|NCT07150533|DIETARY_SUPPLEMENT|Combined Supplement (Green Tea + Ginger)|Participants receive a combination of 500 mg green tea extract and 1 g ginger, both administered in capsule form.
214253370|NCT07150039|OTHER|Manual therapy intervention (Chaitow's myofascial diaphragm release)|Participants were given a myofascial release technique from a seated position, as described by Chaitow. With this technique, the athlete slightly bends his/her torso in order to relax the abdominal wall and breathes calmly and deeply (Figure 2). The therapist is behind the athlete holding his/her lower ribs, and during exhalation the therapist directs his hands caudally. This steady but gentle 'traction' is maintained throughout the breathing cycles for 4-5 minutes.
214253371|NCT07150039|OTHER|Sham Comparison|With this sham comparator technique, the therapist stood behind the athlete (who was sitting) touching the outside of the person's lower ribs without folding his or her fingers or applying any pressure. The athlete is verbally instructed, after fully exhaling the air in their lungs to take deep breaths opening his/her ribs as much as he/she can whistle the therapist's hands follow the movement (without applying any manual pressure or traction). The procedure here also lasted for 4-5 minutes
214253372|NCT07151040|DRUG|TH9619|"Phase 1a - DOSE ESCALATION~Description:~Single arm dose escalation of TH9619 as monotherapy.~Phase 1b - DOSE EXPANSION~Description:~Single arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available."
214253373|NCT07150013|DRUG|Vorinostat (SAHA)|oral suspension
214253374|NCT07150013|DRUG|Placebo|placebo
214253375|NCT07150962|DRUG|HRS-9531 Tablet|HRS-9531 tablet.
214253376|NCT07150988|DRUG|HSK44459 dose level 1|HSK44459 dose level 1 oral administration
214253377|NCT07150988|DRUG|HSK44459 dose level 2|HSK44459 dose level 2 orally administration
214253378|NCT07150988|DRUG|placebo|placebo oral adminisitration
214253379|NCT07150897|OTHER|exercise for lower abdominal muscle wall|the exercise session will start with light walking for 5 minutes followed by, posture correction exercises from crock lying, supine, and sitting and standing positions (each exercise will be maintained for 5 seconds and then the woman relaxed for 10 seconds and repeated each exercise 10 times) to overcome the effect of poor pregnancy posture. Then, participants will perform first step of prone plank exercises which is a stable prone plank with attention to maintain a neutral position in the hip joints, pelvis and lumbar spine. The feet will be placed to match the width of the hip and forearm and acted as support points. The elbows place under the glenohumeral joints, and the arms support the body vertically to the surface. Second step of prone plank exercises will involve performing the unilateral stable prone plank which is the same as the stable prone plank but with the dominant leg in a fully extended position. Third step includes, prone bridge on a Swiss Ball with a diameter of 65
214253380|NCT07150676|OTHER|Long term follow-up|Long term follow-up as part of standard of care
214253381|NCT07150715|DRUG|Actinium Ac 225 Vipivotide Tetraxetan|Given IV
214253382|NCT07150715|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214253383|NCT07150715|OTHER|Gallium Ga 68 Gozetotide|Given IV
214253384|NCT07150715|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214253385|NCT07150715|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT scan
214253386|NCT07150715|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214253387|NCT07150858|OTHER|Erythropoietin and albumin PRF gel + implant placement|This group will be treated by transcrestal sinus lifting with erythropoietin and albumin PRF gel with simultaneous implant placement.
214253388|NCT07150858|OTHER|Albumin PRF gel +implant placement|This group (the Control group) will be treated with transcrestal sinus lifting using albumin PRF gel, with simultaneous implant placement.
214253389|NCT07150780|PROCEDURE|Pre-operative instructions to eat and drink at liberty|Subjects will be instructed to eat and drink at liberty prior to their schedule elective cardiac catheterization.
214253390|NCT07149363|DRUG|Durvalumab 50 MG/ML|Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).
214253391|NCT07151001|DEVICE|No intervention|No intervention. Evaluate the automated DR screening software.
214253392|NCT07150286|DRUG|Levofloxacin-Based H. pylori Eradication Therapy|"This intervention consists of a 14-day levofloxacin-based triple therapy regimen for Helicobacter pylori eradication in ITP patients. The regimen follows current ACG guidelines and typically includes:~Levofloxacin - antibiotic targeting H. pylori~Amoxicillin - antibiotic used in combination for enhanced efficacy~Proton Pump Inhibitor (PPI) - to reduce stomach acid and improve antibiotic effectiveness~Patients will receive the full 14-day course, and platelet counts will be measured at baseline and four weeks post-therapy to assess hematological response. This intervention is unique to H. pylori-positive ITP patients in this study and is not administered to H. pylori-negative patients."
214253393|NCT07150130|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
214464861|NCT06217393|DRUG|Itopride Hydrochloride 150 mg extended release tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
214253394|NCT07149896|DEVICE|Collagen Scaffold (Colla-Plug)|The collagen cartilage scaffold(COLTRIX® CartiRegen) used in this study consist of an injection needle, a syringe, and a collagen gel prefilled in a syringe. The collagen gel contains phosphate buffer and type Ⅰ collagen which the telopeptides are removed.. After the product is implanted in the body, it forms a degradable three-dimensional scaffold to provide an environment for cells to adhere, proliferate, migrate, differentiate and secrete, thereby promoting cartilage repair. At present, it has been commercially applied to clinical repair of knee cartilage defect.
214253395|NCT07149896|PROCEDURE|microfracture|Microfracture to repair cartilage defect is a minimally invasive procedure that is usually done arthroscopically. The doctor first cleans the damaged cartilage area, and then uses a special microfracture cone to drill vertically in the subchondral bone plate, forming multiple tiny holes, allowing mesenchymal stem cells and growth factors in the bone marrow to overflow, forming a blood clot rich in repair components, and finally stimulating fibrocartilage regeneration to fill the defect area.
214253396|NCT07149649|DRUG|Magnesiocard|2.5 mmol film-coated tablets in addition to standard first line therapy
214253397|NCT07149649|DRUG|Magnesium Diasporal|4 mmol IV formulation in addition to standard first line therapy
214253398|NCT07149649|OTHER|Microcrystalline cellulose|Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy
214253399|NCT07149649|OTHER|Isotonic saline solution 0.9%|Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy
214253400|NCT07150871|OTHER|Patients diagnosed with syphilis|Collection of clinical data from patients aged ≥18 years with a microbiological and/or clinical diagnosis of syphilis, treated by the Infectious Diseases Department of the University Hospital of Alessandria from 2017 to 2025.
214253401|NCT01173939|DRUG|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
214253402|NCT01173939|DRUG|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
214253403|NCT05237297|DRUG|Ilaprazole|Ilaprazole 10mg
214253404|NCT05237297|DRUG|Naproxen|Naproxen 500mg
214253405|NCT05237297|DRUG|Aceclofenac|Aceclofenac 100mg
214253406|NCT05237297|DRUG|Celecoxib|Celecoxib 200mg
214253407|NCT05548309|DEVICE|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
214253408|NCT05548309|DEVICE|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
214253409|NCT03939026|GENETIC|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
214253410|NCT03939026|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214253411|NCT03939026|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214253412|NCT03939026|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214253413|NCT01536743|DRUG|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
214253414|NCT05096052|DRUG|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
214253415|NCT05096052|DRUG|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
214253416|NCT02076633|DRUG|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
214253417|NCT00091416|BIOLOGICAL|VRC-HIVADV014-00-VP|
214253418|NCT04096742|DRUG|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
214253419|NCT04096742|OTHER|Vehicle|Lotion not containing active ingredient (tretinoin)
214253420|NCT06269107|DRUG|IcoSema|IcoSema will be administered subcutaneously.
214253421|NCT06269107|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
214253422|NCT03272230|BEHAVIORAL|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
214253423|NCT03272230|BEHAVIORAL|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
214253424|NCT03272230|DIAGNOSTIC_TEST|Neuropsychological assessment|STARKSTEIN APATHY SCALE (SAS) / DAS / MMSE / MADRS / EBI / MINI-SEA / FAB / HAD / MATTIS / HAYLING / STROOP / Verbal Span / Lexical verbal fluency / TMT / CDRS
214253425|NCT03272230|BEHAVIORAL|ICM_APATHY_TASKS|Apathy experimental task
214253426|NCT03272230|OTHER|MRI|T1 / T2 / rs-fMRI / MS-DWI
214253427|NCT03272230|BIOLOGICAL|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
214253428|NCT03082482|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials
214253429|NCT03082482|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
214253430|NCT03082482|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
214253431|NCT03082482|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
214253432|NCT03947996|OTHER|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
214253433|NCT03947996|OTHER|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
214253434|NCT05312372|DRUG|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
214253435|NCT00085709|DRUG|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
214253436|NCT00085709|OTHER|observation|No treatment given
214253437|NCT00085709|DRUG|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
214253438|NCT00085709|DRUG|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
214253439|NCT03269604|PROCEDURE|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
214253440|NCT03269604|PROCEDURE|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
214253441|NCT03269604|PROCEDURE|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
214253442|NCT00293215|DRUG|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
214253443|NCT00293215|DRUG|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
214253444|NCT05967000|OTHER|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching."
214253445|NCT05271461|RADIATION|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
214253446|NCT05271461|OTHER|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
214253447|NCT06056557|DEVICE|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
214253448|NCT05777330|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
214253449|NCT05777330|DIAGNOSTIC_TEST|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
214253450|NCT05777330|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
214253451|NCT00841971|DRUG|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
214253452|NCT00841971|DRUG|Fluconazole|400 mg IV for 21 days
214253453|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
214253454|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
214253455|NCT06570395|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic)."
214253456|NCT05324137|DRUG|CM326|CM326 injection
214253457|NCT05324137|OTHER|Placebo|Placebo
214253458|NCT05860933|DRUG|LY3537982|Administered orally.
214253459|NCT05860933|DRUG|Itraconazole|Administered orally.
214253460|NCT05860933|DRUG|Carbamazepine|Administered orally.
214253461|NCT04622735|COMBINATION_PRODUCT|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
214253462|NCT04622735|DRUG|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
214253463|NCT04622735|DRUG|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
214253464|NCT05314478|DEVICE|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored."
214253465|NCT00277797|DEVICE|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
214253466|NCT00277797|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
214253467|NCT06104527|COMBINATION_PRODUCT|Standard protein enteral nutrition with enteral tracer|Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
214253468|NCT06104527|COMBINATION_PRODUCT|High protein enteral nutrition with enteral tracer|Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
214253469|NCT03207893|BEHAVIORAL|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
214253470|NCT03207893|OTHER|Routine Care|Subject's current t2d treatment
214253471|NCT03497078|OTHER|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
214253472|NCT06221917|OTHER|Face-to-face|FTF group are participants who will learn simple sutures physically present with the instructor in the same room.
214253473|NCT06221917|OTHER|Live-streaming|One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
214253474|NCT05991388|DRUG|Odronextamab|CD20xCD3 bispecific antibody
214253475|NCT05991388|DRUG|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
214253476|NCT05991388|DRUG|Rituximab|Modified R-ICE chemotherapy
214253477|NCT05991388|DRUG|Ifosfamide|Modified R-ICE chemotherapy
214253478|NCT05991388|DRUG|Carboplatin|Modified R-ICE chemotherapy
214253479|NCT05991388|DRUG|Etoposide|Modified R-ICE chemotherapy
214253480|NCT05991388|DRUG|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
214253481|NCT05991388|DRUG|Dexamethasone|Modified R-ICE chemotherapy
214253482|NCT05991388|BIOLOGICAL|CAR T-cells (TBC)|Modified R-ICE chemotherapy
214253483|NCT05775354|DIAGNOSTIC_TEST|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
214253484|NCT06245629|DRUG|Bortezomib-bendamustine-melphalan|The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
214253485|NCT05054036|DRUG|MoviPrep|Split-dose MoviPrep bowel preparation
214253486|NCT05054036|DRUG|Golytely|Split-dose GoLYTELY bowel preparation
214653160|NCT02684071|DRUG|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
214253487|NCT03241069|OTHER|Reference position|patient is put in a 30 degree supine position during 5 minutes
214253488|NCT03241069|OTHER|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
214253489|NCT03241069|OTHER|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
214253490|NCT03241069|OTHER|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
214464862|NCT06217393|DRUG|Itopride Hydrochloride 50 mg film coated tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
214653161|NCT02684071|DRUG|topotecan|To be administered in conjunction with methotrexate
214653162|NCT02684071|DRUG|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
214653163|NCT01524991|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
214653164|NCT01524991|DRUG|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
214653165|NCT01524991|DRUG|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
214653166|NCT02221089|DRUG|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
214253491|NCT04282798|OTHER|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
214253492|NCT02923427|DEVICE|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
214253493|NCT02923427|DEVICE|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
214253494|NCT01325623|DEVICE|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
214253495|NCT01229397|BIOLOGICAL|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
214253496|NCT01229397|BIOLOGICAL|Inflexal V|Inflexal V 0.5 mL administrated once only
214253497|NCT00426998|DRUG|Verteporfin|
214253498|NCT00426998|DRUG|Bevacizumab|
214253499|NCT04019431|DIETARY_SUPPLEMENT|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
214253500|NCT02694523|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
214253501|NCT02694523|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
214253502|NCT02694523|DRUG|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
214253503|NCT02694523|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
214253504|NCT05289531|PROCEDURE|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
214253505|NCT00428129|DRUG|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
214253506|NCT01248481|DRUG|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
214253507|NCT03204461|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
214253508|NCT03204461|OTHER|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
214253509|NCT03736694|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
214653167|NCT02221089|DIETARY_SUPPLEMENT|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
214653168|NCT02221089|OTHER|Placebo|Placebo capsules identical in appearance to Retaron capsules
214653169|NCT01185847|DRUG|RO5083945|intravenously, until disease progression
214253510|NCT03736694|BEHAVIORAL|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
214253511|NCT04453228|OTHER|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
214253512|NCT00956956|DRUG|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
214253513|NCT00956956|DRUG|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
214253514|NCT05688007|DIAGNOSTIC_TEST|parathyroid hormone level|Serum level of parathyroid hormone
214253515|NCT05688007|DIAGNOSTIC_TEST|serum electrolytes|Serum levels of: magnesium, phosphorus, calcium, and albumin
214253516|NCT05952492|BEHAVIORAL|Stress Management Skills Training|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include stress management skills training and health education content.
214253517|NCT05295550|OTHER|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
214253518|NCT06158620|DRUG|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
214653170|NCT01185847|DRUG|cisplatin|standard treatment, up to 6 cycles
214653171|NCT01185847|DRUG|gemcitabine|standard treatment, up to 6 cycles
214653172|NCT01185847|DRUG|pemetrexed|standard treatment, up to 6 cycles
214253519|NCT06158620|DRUG|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
214253520|NCT05539716|DEVICE|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
214253521|NCT05539716|BEHAVIORAL|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
214253522|NCT05449366|DRUG|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
214253523|NCT06631170|DRUG|Roflumilast Cream 0.15%|Roflumilast cream 0.15% is applied once daily for 4 weeks
214253524|NCT06631170|DRUG|Vehicle cream|Vehicle cream is applied once daily for 4 weeks
214253525|NCT02188225|PROCEDURE|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
214253526|NCT02188225|DRUG|fluoxetine|10 mg/ daily
214253527|NCT00085228|BIOLOGICAL|oblimersen sodium|
214253528|NCT00085228|DRUG|docetaxel|
214253529|NCT04095156|DIAGNOSTIC_TEST|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
214253530|NCT01867112|BEHAVIORAL|Physical Activity|Physical activity either by individualized program or general guidelines
214253531|NCT02091219|DRUG|Vitamin D|2400 IU/day by mouth for 16 weeks
214253532|NCT02091219|DRUG|25(OH)D3|20 micrograms/day by mouth for 16 weeks
214253533|NCT05789381|PROCEDURE|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
214253534|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
214253535|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
214253536|NCT03780777|BEHAVIORAL|Home Hazard Removal|Removal of home barriers or hazards
214253537|NCT06010251|OTHER|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
214253538|NCT04066959|BEHAVIORAL|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
214253539|NCT04066959|BEHAVIORAL|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
214253540|NCT04066959|BEHAVIORAL|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
214253541|NCT05720702|DIETARY_SUPPLEMENT|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
214253542|NCT03707431|BEHAVIORAL|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
214253543|NCT03707431|BEHAVIORAL|Pain Education|The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
214253544|NCT04922723|DRUG|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
214253545|NCT05650242|DRUG|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
214253546|NCT05896748|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
214253547|NCT05896748|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
214253548|NCT05715333|BIOLOGICAL|CM326|CM326 Injection
214253549|NCT05715333|OTHER|Placebo|Subcutaneous injection
214253550|NCT04150406|DIETARY_SUPPLEMENT|Flexofytol|Curcuma extract
214253551|NCT04150406|OTHER|Placebo|placebo
214253552|NCT03353389|OTHER|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
214253553|NCT03353389|OTHER|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
214253554|NCT03353389|OTHER|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
214253555|NCT03784365|DRUG|One dose of Cefo-perazone Sulbactum|Antibiotic
214253556|NCT01180166|DRUG|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
214253557|NCT02425527|BEHAVIORAL|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
214253558|NCT02425527|BEHAVIORAL|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
214253559|NCT00063375|BEHAVIORAL|Computer Based Cognitive Behavioral Therapy|
214253560|NCT02594241|DRUG|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
214253561|NCT02594241|DRUG|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
214253562|NCT05497700|DRUG|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
214253563|NCT05497700|DRUG|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
214253564|NCT01755273|PROCEDURE|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
214253565|NCT00752115|DRUG|sildenafil|50mg, day1,8 and 15 in each cycle
214253566|NCT00752115|DRUG|placebo|1 tab, day 1,8 and 15 in each cycle.
214253567|NCT00752115|DRUG|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
214253568|NCT00752115|DRUG|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
214253569|NCT00877474|DRUG|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
214253570|NCT03895021|BEHAVIORAL|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\])."
214253571|NCT00880373|DRUG|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
214253572|NCT00880373|DRUG|Placebo|Matching placebo three times daily for 4 days
214253573|NCT00880373|DRUG|Diamorphine or Morphine|Diamorphine or Morphine by PCA
214253574|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
214253575|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
214253576|NCT01905410|DRUG|VVZ-149 Injection|VVZ-149 in water for injection
214253577|NCT01905410|DRUG|placebo|water for injection
214253578|NCT06548165|DEVICE|Wearable|Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
214253579|NCT01913132|DEVICE|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
214253580|NCT01763242|OTHER|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
214253581|NCT01298193|DRUG|Aprepitant|Efficacy phase (second cycle)
214253582|NCT02815488|DRUG|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
214253583|NCT02815488|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
214253584|NCT02815488|DRUG|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
214253585|NCT02815488|DRUG|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
214253586|NCT02815488|DRUG|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
214253587|NCT02815488|DRUG|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
214253588|NCT02815488|DRUG|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
214253589|NCT02815488|DRUG|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
214253590|NCT03624296|DEVICE|MRI 7T|MRI 7T
214253591|NCT03624296|OTHER|TEST EDSS|EDSS - Expanded Disability Status Scale
214253592|NCT03624296|OTHER|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
214253593|NCT04010539|DRUG|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
214253594|NCT04010539|DRUG|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
214253595|NCT04010539|DRUG|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
214253596|NCT03987776|BEHAVIORAL|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
214253597|NCT03987776|BEHAVIORAL|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
214253598|NCT00249288|DRUG|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
214253599|NCT00249288|DRUG|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
214253600|NCT03059446|DRUG|Cenicriviroc|Cenicriviroc immediate release tablets
214253601|NCT02089854|DRUG|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
214253602|NCT00398333|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
214253603|NCT01440790|DIETARY_SUPPLEMENT|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
214253604|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
214253605|NCT01440790|DIETARY_SUPPLEMENT|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
214253606|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
214253607|NCT05808283|OTHER|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
214253608|NCT05570201|OTHER|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
214253609|NCT00548106|DIETARY_SUPPLEMENT|partially hydrolyzed whey|Total infant feeding by study formula.
214253610|NCT00548106|DIETARY_SUPPLEMENT|Nan HA|Total infant diet by study formula.
214253611|NCT04921215|BEHAVIORAL|Morning bright light|All participants will receive phase advancing morning bright light.
214253612|NCT05629000|PROCEDURE|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
214253613|NCT05629000|DIAGNOSTIC_TEST|MRI-PWI|Multi-modal MRI before and after surgery.
214253614|NCT05629000|DIAGNOSTIC_TEST|CTA|CTA before and after surgery.
214253615|NCT05629000|DIAGNOSTIC_TEST|PET/MRI|PET/MRI before surgery.
214253616|NCT05629000|DIAGNOSTIC_TEST|Ultrasound|Ultrasound before and after surgery.
214253617|NCT02225392|PROCEDURE|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
214253618|NCT02225392|DEVICE|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
214253619|NCT06551103|BEHAVIORAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
214253620|NCT03973801|OTHER|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
214253621|NCT04596553|DIETARY_SUPPLEMENT|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
214253622|NCT04596553|DIETARY_SUPPLEMENT|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
214253623|NCT04596553|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
214253624|NCT05270421|DRUG|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
214253625|NCT05270421|OTHER|Conventional Treatment|Standard ESWL
214253626|NCT05716503|DEVICE|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
214253627|NCT05716503|OTHER|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
214253628|NCT04838197|OTHER|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
214253629|NCT01005043|RADIATION|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
214253630|NCT04561674|OTHER|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
214253631|NCT03723200|OTHER|Fibrinogen and blood products|Fibrinogen and blood products
214253632|NCT06346808|DRUG|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
214253633|NCT05060887|BIOLOGICAL|OVX836-003|One single administration intramuscularly at Day 1.
214253634|NCT05060887|BIOLOGICAL|Saline solution|One single administration intramuscularly at Day 1.
214253635|NCT00002178|DRUG|Ritonavir|
214253636|NCT00002178|DRUG|Nelfinavir mesylate|
214253637|NCT00002178|DRUG|Saquinavir|
214253638|NCT00002178|DRUG|Delavirdine mesylate|
214253639|NCT04132245|BEHAVIORAL|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
214253640|NCT04132245|BEHAVIORAL|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
214253641|NCT04231318|DRUG|Cingal|Single intra-articular injection of Cingal into the knee.
214253642|NCT04231318|DRUG|Triamcinolone Hexacetonide (TH)|Single intra-articular injection of TH into the knee.
214253643|NCT04231318|DRUG|Placebo|Single intra-articular injection Placebo (0.9% Saline) into the knee.
214253644|NCT01036061|DRUG|GSK618334 Low Dose|GSK618334 low dose
214253645|NCT01036061|DRUG|GSK618334 PET subjects|PET subjects
214253646|NCT01036061|DRUG|GSK618334 Medium Dose|Medium Dose
214653173|NCT00951821|BEHAVIORAL|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
214253647|NCT01036061|DRUG|GSK618334 High Dose|GSK618334 High Dose
214253648|NCT05240287|DIAGNOSTIC_TEST|Navicular Drop Test|The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
214653174|NCT00951821|BEHAVIORAL|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
214653175|NCT05637255|DRUG|SYL1801|1 drop in the eligible eye
214653176|NCT01417676|RADIATION|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
214653177|NCT06146894|PROCEDURE|Single obturation technique (Bioceramic Sealer)|Root canal will be obturated using single cone technique using Bioceramic Sealer
214253649|NCT05240287|DIAGNOSTIC_TEST|Foot Posture Index|The index consists of six items in which the foot is evaluated observationally. In the evaluation, the individual is asked to stand in a comfortable and relaxed position. The researcher observes the medial longitudinal arch structure, the structure of the talonavicular joint region, the degree of abduction/adduction in the forefoot relative to the hindfoot in the front part of the foot. In the back foot, inversion/eversion of the calcaneus, talus head position, and curvatures above and below the lateral malleolus are evaluated. The total score is reached by scoring each criterion between -2 and +2 values. 0; neutral position, (+) values; pronation (pes planus), (-) values indicate supination (pes cavus). Individuals with +6 to +12 points from this index will be included in our study.
214253650|NCT05240287|DIAGNOSTIC_TEST|Balance|Static and dynamic balance and stability limit values of individuals will be evaluated with the HUR Smart Balance (SME Inc, USA) balance measurement device. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals will be asked to place their feet on the marked places on the platform. The researchers will evaluate the balance in four different situations, 30 seconds each. In the first test, individuals keep the balance on firm ground with their eyes open. The second test performed on the firm ground with eyes closed, in the third test, on the soft ground with eyes open, and in the fourth test, on the soft ground with eyes closed. For dynamic balance, individuals will be asked to extend their body weight to the front, back, and sides with their feet in 4 different directions for 8 seconds.
214253651|NCT05240287|DIAGNOSTIC_TEST|Plantar Pressure Analysis|Plantar pressure analysis of individuals will be evaluated by measuring with the DIERS Pedoscan DICAM 3 v3.10.8 (2019) device. DIERS Pedoscan is a system integrated into the treadmill that measures the pressure distribution on the sole during stance. As a result of this evaluation, right-left and anterior-posterior weight transfer, left-right foot rotation, lateral mobility, the center of gravity movement, and swing area data will be recorded.
214253652|NCT05240287|DIAGNOSTIC_TEST|Gait Analysis|Gait analysis of individuals will be evaluated with the DIERS Leg Axis DICAM 3 v3.10.8 (2019) system. The system consists of a treadmill, computer, and cameras. Before the measurement, colored markers will be placed on the knee and ankle joints of the individual. For gait assessment, individuals will walk at their preferred comfortable walking speed. In the evaluation, joint angles, walking speed, step lengths are recorded. Evaluation time is approximately 5 minutes.
214253653|NCT02622750|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
214253654|NCT02622750|PROCEDURE|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
214253655|NCT02852772|BEHAVIORAL|Cognitive function tests|
214253656|NCT03201627|DRUG|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
214253657|NCT03310827|BEHAVIORAL|Personalized Nutrition|Diet plan based on nutrition-related gene test results
214253658|NCT04491253|BEHAVIORAL|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
214253659|NCT00312403|PROCEDURE|Blood Sample|A single venous blood sample will be taken (10 ml).
214253660|NCT02985203|DRUG|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
214253661|NCT01129570|DRUG|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
214253662|NCT03729973|DRUG|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
214253663|NCT03729973|DRUG|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
214253664|NCT03729973|DRUG|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
214253665|NCT03729973|DRUG|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
214253666|NCT04405427|PROCEDURE|head acupoints acupuncture|The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
214253667|NCT04405427|PROCEDURE|body acupoints acupuncture|The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
214253668|NCT02793466|DRUG|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
214653178|NCT06146894|PROCEDURE|lateral condensation technique (Bioceramic Sealer)|Root canal will be obturated using lateral condensation technique using Bioceramic Sealer
214653179|NCT06146894|PROCEDURE|Warm Vertical condensation technique (Bioceramic Sealer)|Root canal will be obturated using vertical condensation technique using Bioceramic Sealer
214653180|NCT06146894|PROCEDURE|lateral condensation technique (AH Plus Sealer)|Root canal will be obturated using lateral condensation technique using AH plus Sealer
214653181|NCT06146894|PROCEDURE|Warm Vertical condensation technique (AH plus Sealer)|Root canal will be obturated using vertical condensation technique using AH plus Sealer
214653182|NCT04764435|OTHER|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
214253669|NCT02800759|DIETARY_SUPPLEMENT|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
214253670|NCT02800759|DIETARY_SUPPLEMENT|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
214253671|NCT02800759|DIETARY_SUPPLEMENT|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
214653183|NCT04764435|OTHER|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
214253672|NCT02800759|DIETARY_SUPPLEMENT|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
214253673|NCT02876744|OTHER|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
214253674|NCT06550271|DRUG|Rapamycin|Rapamycin in 2 different dosage forms (compounded and generic)
214253675|NCT01234207|DEVICE|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
214253676|NCT01234207|DEVICE|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
214253677|NCT06304038|DRUG|Flu Vaccine|Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
214253678|NCT00062673|DRUG|Duloxetine|
214253679|NCT00062673|DRUG|Placebo|
214253680|NCT05237271|OTHER|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
214253681|NCT05237271|OTHER|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
214253682|NCT02049320|DRUG|Remifentanil|
214253683|NCT05771792|OTHER|ECCENTRIC EXERCISE|Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
214253684|NCT05771792|OTHER|CONVENTIONAL EXERCISES PROGRAM|The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
214253685|NCT02942420|DRUG|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
214253686|NCT04490239|DRUG|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
214253687|NCT05298306|DRUG|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A"
214253688|NCT05298306|DRUG|Placebo|Matching placebo'given as a single intravenous infusion at all dose levels
214253689|NCT03857906|DEVICE|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
214253690|NCT00291538|DRUG|bortezomib|
214253691|NCT03625206|BEHAVIORAL|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
214253692|NCT03625206|BEHAVIORAL|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
214253693|NCT04483167|DRUG|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
214653184|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
214653185|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
214653186|NCT05507957|DIAGNOSTIC_TEST|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
214253694|NCT03139695|DIAGNOSTIC_TEST|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
214253695|NCT03469050|DRUG|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
214253696|NCT03469050|OTHER|Placebo|Placebo BID + Placebo BID
214253697|NCT00413166|DRUG|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
214253698|NCT00413166|DRUG|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
214253699|NCT00413166|DRUG|Idarubicin|"1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
214253700|NCT00413166|DRUG|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
214253701|NCT01061983|DEVICE|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
214253702|NCT04490811|OTHER|no intervention. observational cohort study|blood sampling is part of care
214253703|NCT03965208|DRUG|Bivalirudin|titrated continuous infusion
214253704|NCT03965208|DRUG|Unfractionated heparin|titrated continuous infusion
214253705|NCT04702854|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
214253706|NCT06169631|DEVICE|Gen0b|The ultrasound will be administered to the brain region of interest.
214253707|NCT05078502|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
214253708|NCT03538431|DRUG|Buspirone|Buspirone is an atypical anxiolytic medication.
214253709|NCT01061632|PROCEDURE|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
214253710|NCT01061632|PROCEDURE|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
214253711|NCT00620464|DRUG|Radiopaque Implanon|Radiopaque rod for 3 years
214253712|NCT00620464|DRUG|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
214653187|NCT05679206|DIAGNOSTIC_TEST|Echocardiography images|"Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient"
214653188|NCT05679206|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring|Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
214653189|NCT00004479|DRUG|midodrine|
214653190|NCT00391599|PROCEDURE|enema|
214253713|NCT03210181|OTHER|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
214253714|NCT03210181|OTHER|Placebo|Patients will receive an equivalent volume of normal saline
214253715|NCT03548233|BIOLOGICAL|bcg vaccine|live attenuated vaccine
214253716|NCT01753804|OTHER|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
214253717|NCT03324672|PROCEDURE|TRIGGER|only TRIGGER point will be included for the manual therapy
214253718|NCT03324672|PROCEDURE|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
214253719|NCT01267656|DEVICE|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
214253720|NCT01267656|DEVICE|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
214253721|NCT03359239|DRUG|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
214253722|NCT03359239|BIOLOGICAL|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
214253723|NCT03359239|DRUG|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
214253724|NCT03359239|DRUG|Normal saline|0.19 mL
214253725|NCT00227773|DRUG|octreotide acetate|
214253726|NCT00227773|DRUG|vatalanib|
214253727|NCT00227773|PROCEDURE|anti-cytokine therapy|
214253728|NCT00227773|PROCEDURE|antiangiogenesis therapy|
214253729|NCT00227773|PROCEDURE|biological therapy|
214253730|NCT00227773|PROCEDURE|endocrine therapy|
214253731|NCT00227773|PROCEDURE|enzyme inhibitor therapy|
214253732|NCT00227773|PROCEDURE|growth factor antagonist therapy|
214253733|NCT00227773|PROCEDURE|hormone therapy|
214253734|NCT00227773|PROCEDURE|protein tyrosine kinase inhibitor therapy|
214253735|NCT00227773|PROCEDURE|somatostatin analogue therapy|
214253736|NCT03327454|BIOLOGICAL|Benepali|Administered as specified in the treatment arm.
214253737|NCT00642720|DRUG|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
214253738|NCT02861989|OTHER|qualitative study|
214253739|NCT00287651|PROCEDURE|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
214253740|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
214253741|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
214253742|NCT03235843|DEVICE|AAIR pacing|Rate adaptive pacing using a MV sensor.
214253743|NCT03235843|DEVICE|DDI-pacing|Rate adaptive pacing OFF
214653191|NCT04954482|OTHER|No Intervention|This is an observation study, with no intervention
214653192|NCT03455673|DIAGNOSTIC_TEST|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1"
214653193|NCT03856957|DEVICE|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
214653194|NCT03856957|DEVICE|control|colonoscopy without endocuff
214653195|NCT04006184|OTHER|Chart review|Retrospective review of medical records at a single site with six physicians
214253744|NCT05659056|DRUG|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
214253745|NCT02173184|BIOLOGICAL|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
214253746|NCT02173184|BIOLOGICAL|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
214253747|NCT05182099|DIAGNOSTIC_TEST|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
214253748|NCT02325661|OTHER|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
214253749|NCT03258138|BEHAVIORAL|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
214253750|NCT03258138|BEHAVIORAL|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
214253751|NCT03258138|BEHAVIORAL|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
214253752|NCT03258138|BEHAVIORAL|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
214253753|NCT03258138|BEHAVIORAL|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
214253754|NCT04398992|OTHER|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
214253755|NCT02968511|BIOLOGICAL|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
214253756|NCT01982058|OTHER|communication intervention|
214253757|NCT01982058|OTHER|counseling intervention|
214253758|NCT01982058|OTHER|nutrition intervention|
214253759|NCT01982058|OTHER|questionnaire administration|
214253760|NCT05794971|DRUG|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
214253761|NCT05794971|DRUG|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
214253762|NCT04190173|DRUG|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
214253763|NCT04190173|DRUG|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
214253764|NCT01213550|DRUG|Chlorhexidine gluconate|
214253765|NCT01213550|DRUG|Placebo mouthrinse|
214253766|NCT01293500|PROCEDURE|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
214253767|NCT03815617|DIETARY_SUPPLEMENT|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
214253768|NCT03815617|DIETARY_SUPPLEMENT|Placebo|Given as comparable packets. Same duration.
214253769|NCT05236153|DIAGNOSTIC_TEST|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
214253770|NCT03470571|DIAGNOSTIC_TEST|CMR|Outcome analysis of CMR features in suspected myocarditis patients
214653196|NCT04159090|DIAGNOSTIC_TEST|F18-PSMA|Patients with moderate or high risk of prostate cancer
214253771|NCT03547986|DIAGNOSTIC_TEST|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
214253772|NCT03547986|DIAGNOSTIC_TEST|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
214253773|NCT03642743|OTHER|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
214253774|NCT01712646|DRUG|Intranasal Oxytocin|
214253775|NCT05560035|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
214253776|NCT05560035|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
214253777|NCT06102915|DRUG|Rocuronium Bromide 10 MG/ML|Comparative
214253778|NCT06102915|DRUG|Nimbex 10 MG in 5 ML Injection|Comparative
214253779|NCT02570841|DRUG|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
214253780|NCT02570841|DRUG|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
214253781|NCT00986479|DRUG|AZD6765|Single IV infusion of 150 mg AZD6765.
214253782|NCT00986479|DRUG|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
214253783|NCT04672330|DRUG|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
214253784|NCT02730520|OTHER|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
214253785|NCT03657862|DEVICE|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
214253786|NCT03657862|OTHER|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
214253787|NCT06644612|PROCEDURE|Light Weight Mesh|Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
214253788|NCT06644612|PROCEDURE|Heavy Weight Mesh|Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
214653197|NCT04963478|OTHER|exercise|exercise testing
214653198|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
214653199|NCT00582556|DRUG|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
214653200|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
214653201|NCT03294993|DEVICE|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
214253789|NCT02730338|BEHAVIORAL|High intensity aerobic and resistance training|
214253790|NCT02730338|BEHAVIORAL|Psychosocial support|
214253791|NCT06644118|BIOLOGICAL|OL-101 infusion|OL-101 infusion will be administered to patients via IV infusion at the assigned dose.
214253792|NCT00458068|DRUG|Oral administration of ferrous sulphate|
214253793|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
214253794|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
214253795|NCT02073110|DEVICE|Percutaneous Optical Biopsy (OCT and DRS)|
214253796|NCT01782833|OTHER|This is Non-interventional study|
214253797|NCT00362037|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
214253798|NCT02715479|DRUG|Dolutegravir|Dolutegravir
214253799|NCT02715479|DRUG|BMS955176|BMS955176
214253800|NCT00187031|DRUG|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
214253801|NCT01580358|DRUG|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
214253802|NCT01580358|DRUG|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
214253803|NCT05835531|DEVICE|Catheters comparation|Assessment of incidence of complications associated with midline catheters
214653202|NCT01341457|DRUG|LY2603618|Administered intravenously
214253804|NCT06202456|DRUG|Huazhi Rougan granule|Huazhi Rougan granule
214253805|NCT02998216|PROCEDURE|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
214253806|NCT05116007|DRUG|AK112|IV infusion
214253807|NCT05116007|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214253808|NCT05116007|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
214253809|NCT04149873|PROCEDURE|MIE|MIE
214253810|NCT03995836|DEVICE|CPAP|Decision of CPAP treatment is according to clinical guidelines
214253811|NCT03995836|PROCEDURE|Bariatric Surgery|All patients.
214253812|NCT04890431|DRUG|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
214653203|NCT01341457|DRUG|Gemcitabine|Administered intravenously
214653204|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
214253813|NCT04890431|DRUG|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
214253814|NCT06061731|DRUG|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
214253815|NCT05685654|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
214253816|NCT06202690|PROCEDURE|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
214253817|NCT06202690|PROCEDURE|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
214253818|NCT01842815|DEVICE|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
214253819|NCT03221907|DRUG|GLA5PR GLARS-NF1|Pregabalin tablet
214253820|NCT03221907|DRUG|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
214253821|NCT03221907|DRUG|Pregabalin|Pregabalin capsule
214253822|NCT03221907|DRUG|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
214253823|NCT04461288|BEHAVIORAL|Social media-based education, counseling, and support|This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
214253824|NCT04461288|OTHER|Nicotine replacement therapies (NRT)|"Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette."
214253825|NCT04461288|OTHER|Gamification|Gaming elements designed to encourage participation in the program and behavior change.
214253826|NCT04560790|DRUG|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
214253827|NCT00046748|DRUG|Omalizumab|
214253828|NCT05716399|DEVICE|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
214253829|NCT05716399|DEVICE|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
214253830|NCT05716399|DEVICE|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
214253831|NCT00771316|DRUG|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
214253832|NCT00771316|DRUG|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
214253833|NCT05266716|BEHAVIORAL|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
214253834|NCT02526901|OTHER|No intervention|
214253835|NCT03163810|DEVICE|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
214253836|NCT03163810|DEVICE|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
214253837|NCT02055807|OTHER|PEEP and recruitment maneuvers|
214253838|NCT02055807|OTHER|ZEEP (no PEEP nor recruitment maneuver)|
214253839|NCT05511519|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
214253840|NCT05511519|DRUG|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
214253841|NCT02027376|DRUG|LDE225|
214253842|NCT02027376|DRUG|Docetaxel|
214253843|NCT05400915|DRUG|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
214253844|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
214253845|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
214653205|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
214253846|NCT04069169|DRUG|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
214253847|NCT04069169|DRUG|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
214253848|NCT04148820|DRUG|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
214253849|NCT01761864|BEHAVIORAL|academic detailing intervention|
214253850|NCT03610451|BEHAVIORAL|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
214253851|NCT03610451|BEHAVIORAL|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
214253852|NCT01782911|DIETARY_SUPPLEMENT|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
214253853|NCT01782911|DIETARY_SUPPLEMENT|Placebo pills|The patients will take placebo for 40 days.
214253854|NCT00562250|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
214253855|NCT00562250|DRUG|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
214253856|NCT00562250|DRUG|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
214253857|NCT00723216|DRUG|enoxaparin|20 mg twice a day
214253858|NCT00723216|OTHER|Physical prophylaxis|
214253859|NCT05413031|DEVICE|relative motion splint|splint with ability to move the fingers
214253860|NCT05413031|DEVICE|static splint|splint with immobility of wrist, and fingers
214253861|NCT02095067|DEVICE|Video consultation|
214253862|NCT05475613|PROCEDURE|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
214253863|NCT05475613|PROCEDURE|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
214253864|NCT02526173|PROCEDURE|RALP using full nerve sparing technique|RALP using full nerve sparing technique
214253865|NCT02526173|OTHER|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
214253866|NCT05466448|DRUG|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
214253867|NCT05836090|BEHAVIORAL|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
214253868|NCT05836090|BEHAVIORAL|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
214253869|NCT00252629|OTHER|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
214253870|NCT01952782|DRUG|Kisspeptin 112-121|Subjects will receive up to 10 IV doses of kisspeptin 112-121
214253871|NCT01952782|DRUG|Naloxone|Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.
214253872|NCT01952782|DRUG|GnRH|Subjects will receive up to 10 doses of IV GnRH
214253873|NCT04112888|COMBINATION_PRODUCT|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
214253874|NCT04112888|PROCEDURE|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
214253875|NCT02966041|DRUG|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
214253876|NCT02966041|DRUG|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
214253877|NCT00575250|BEHAVIORAL|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
214253878|NCT00575250|BEHAVIORAL|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
214253879|NCT03171051|DEVICE|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
214253880|NCT03171051|DEVICE|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
214253881|NCT03164577|BEHAVIORAL|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
214253882|NCT03164577|OTHER|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
214253883|NCT02245178|PROCEDURE|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
214253884|NCT02245178|OTHER|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
214253885|NCT00972088|DEVICE|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
214253886|NCT00745173|DRUG|Premarin|
214253887|NCT03925064|OTHER|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
214253888|NCT02595996|DRUG|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
214253889|NCT01858584|DRUG|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
214253890|NCT01858584|DIETARY_SUPPLEMENT|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
214253891|NCT00895856|OTHER|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
214253892|NCT02872571|DRUG|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
214253893|NCT05833334|BEHAVIORAL|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
214253894|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
214253895|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
214253896|NCT05833334|BEHAVIORAL|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
214253897|NCT00880165|DEVICE|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
214253898|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
214253899|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
214253900|NCT06252714|DEVICE|Defecation Posture Modification Device|Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
214253901|NCT03010761|DRUG|escitalopram|antidepressant use for the betel-quid abstinence
214253902|NCT03010761|DRUG|Moclobemide|antidepressant use for the betel-quid abstinence
214253903|NCT03010761|DRUG|Placebo - Cap|Placebo - Cap
214253904|NCT05250752|DRUG|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
214253905|NCT02459652|DRUG|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
214253906|NCT02459652|RADIATION|Radiation Therapy|Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
214253907|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
214253908|NCT00667602|BIOLOGICAL|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
214253909|NCT00667602|BIOLOGICAL|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
214253910|NCT00667602|BIOLOGICAL|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
214253911|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
214253912|NCT05899010|DRUG|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
214253913|NCT05899010|DRUG|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
214253914|NCT01184131|OTHER|Mentor Training|Four 2 hour sessions of Mentor Training
214253915|NCT05961644|DRUG|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
214253916|NCT05961644|DRUG|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
214253917|NCT06484673|DRUG|Bosentan Dispersible Tablets|1 tablet of 32 mg Bosentan
214253918|NCT06484673|DRUG|Tracleer Tablet for Oral Suspension|1 tablet of 32 mg Bosentan
214253919|NCT01594385|BIOLOGICAL|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
214653206|NCT00333216|OTHER|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
214253920|NCT05221827|DIAGNOSTIC_TEST|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
214253921|NCT00285467|DRUG|doxercalciferol|form of vitamin D that is already in active form.
214253922|NCT00285467|DRUG|Cholecalciferol|from of vitamin D that requires cells in the body to make active
214253923|NCT06336759|DEVICE|Restylane Defyne|Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.
214253924|NCT06336759|DEVICE|Restylane Lyft|Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.
214253925|NCT02698059|DEVICE|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
214253926|NCT00052780|DRUG|O6-benzylguanine|Given IV
214253927|NCT00052780|DRUG|temozolomide|Given PO
214253928|NCT00052780|BIOLOGICAL|filgrastim|Given SC or IV
214253929|NCT00052780|OTHER|pharmacological study|Correlative studies
214253930|NCT00052780|OTHER|laboratory biomarker analysis|Correlative studies
214653207|NCT05317767|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
214653208|NCT05317767|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
214253931|NCT06229639|DEVICE|Passy Muir Valve|
214253932|NCT06229639|DEVICE|Tracheostomy Plug|
214253933|NCT03827837|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214253934|NCT03827837|DRUG|Famitinib|a small-molecule multikinase inhibitor
214253935|NCT05578703|PROCEDURE|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
214253936|NCT05578703|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
214253937|NCT05578703|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
214253938|NCT00503295|BIOLOGICAL|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
214253939|NCT04620655|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
214253940|NCT06131320|DIAGNOSTIC_TEST|PVSE Test|Completion of the PVSE test
214253941|NCT06131320|OTHER|Cerebral MRI|Cerebral MRI scan
214653209|NCT04222283|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
214253942|NCT00089323|PROCEDURE|Bone Marrow Aspiration|
214253943|NCT06561126|BEHAVIORAL|Participatory, Learning and Action Based Intervention|The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
214253944|NCT05293964|DRUG|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
214253945|NCT05293964|DRUG|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
214253946|NCT05293964|DRUG|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
214253947|NCT06201195|PROCEDURE|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
214253948|NCT06201195|PROCEDURE|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
214253949|NCT04572802|PROCEDURE|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
214253950|NCT05076071|GENETIC|NGS|Next Generation Sequencing
214253951|NCT05992480|BIOLOGICAL|rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)|It is an Ebola virus vaccine
214253952|NCT06481631|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
214253953|NCT04989387|DRUG|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
214253954|NCT04989387|DRUG|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
214253955|NCT04989387|DRUG|INCB106385|INCB106385 will be administered orally once or twice a day.
214253956|NCT00644228|DRUG|Bortezomib|Given IV
214253957|NCT00644228|DRUG|Dexamethasone|Given PO
214253958|NCT00644228|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214253959|NCT00644228|DRUG|Lenalidomide|Given PO
214253960|NCT03475693|DRUG|Magnesium Oxide|400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
214253961|NCT03475693|DRUG|Acetaminophen|500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
214253962|NCT03475693|DRUG|Zofran ODT 4 MG Disintegrating Oral Tablet|Given once in the Emergency department
214253963|NCT00760084|DRUG|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
214253964|NCT06554821|DRUG|Rosuvastatin|Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
214253965|NCT06554821|DRUG|Ticagrelor|Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
214253966|NCT00973349|BIOLOGICAL|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
214253967|NCT00920205|DRUG|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
214253968|NCT00765024|DRUG|Ivermectin|single dose of 200 mcg/kg
214253969|NCT00765024|DRUG|ivermectin|two single dose of 200mcg/kg in 2 weeks
214253970|NCT00765024|DRUG|Albendazole|Albendazole 7 days
214253971|NCT03187756|DRUG|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
214253972|NCT02301988|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
214253973|NCT02301988|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
214253974|NCT02301988|DRUG|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
214253975|NCT01721707|DRUG|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
214253976|NCT01721707|DRUG|Latanoprost|1 drop in each eye, 1x/day, at 9PM
214253977|NCT04178473|PROCEDURE|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
214253978|NCT04178473|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
214253979|NCT06033716|OTHER|Measurement correlation variable|resilience and anxiety and depression
214253980|NCT04167371|BEHAVIORAL|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
214253981|NCT04167371|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
214464863|NCT03531073|DRUG|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
214253982|NCT04620707|DEVICE|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
214253983|NCT04620707|BEHAVIORAL|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
214253984|NCT05262959|DRUG|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
214253985|NCT05262959|PROCEDURE|TACE|TACE will be performed by the investigator based on the patient's tumor status.
214253986|NCT04755283|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
214253987|NCT04755283|DRUG|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
214253988|NCT00177476|BEHAVIORAL|behavioral weight loss|
214253989|NCT02750943|DRUG|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
214253990|NCT02750943|DRUG|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
214253991|NCT00768937|DRUG|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
214253992|NCT00768937|PROCEDURE|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
214253993|NCT01012076|BEHAVIORAL|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
214253994|NCT00171054|DRUG|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
214653210|NCT02590029|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
214653211|NCT02590029|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
214653212|NCT02590029|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
214653213|NCT03422484|OTHER|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
214253995|NCT00171054|DRUG|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
214253996|NCT00171054|DRUG|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
214253997|NCT03176875|OTHER|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
214253998|NCT03176875|OTHER|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
214253999|NCT05629013|BEHAVIORAL|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
214254000|NCT02004574|DRUG|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
214254001|NCT05450575|DRUG|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
214254002|NCT06378125|DRUG|controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
214653214|NCT05555810|PROCEDURE|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
214653215|NCT00412256|DRUG|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
214254003|NCT06378125|DRUG|immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
214254004|NCT06378125|DRUG|Placebo controlled-ileal-release nicotinic acid (SAD/MAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
214254005|NCT06378125|DRUG|Placebo immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
214254006|NCT01040078|BIOLOGICAL|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
214254007|NCT01040078|BIOLOGICAL|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
214254008|NCT01040078|BIOLOGICAL|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
214254009|NCT06417073|BEHAVIORAL|Face-To-Face Task-orianted Training|In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
214254010|NCT06417073|BEHAVIORAL|Tele-Rehabilitation Task-orianted Training|This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
214254011|NCT06417073|BEHAVIORAL|Home-based Task-orianted Training|"Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention."
214254012|NCT01327911|BIOLOGICAL|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
214254013|NCT01352351|BEHAVIORAL|Breastfeeding promotion intervention|"* Breastfeeding counseling during monthly microcredit meetings~* Weekly cell phone messages about breastfeeding"
214254014|NCT02597153|DRUG|Mitoxantrone HCL Liposome Injection|
214254015|NCT06649721|DRUG|bedaquiline|400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)
214254016|NCT06649721|DRUG|delamanid|"* for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w"
214254017|NCT06649721|DRUG|linezolid|"* for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
214254018|NCT06649721|DRUG|Levofloxacin|"Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
214254019|NCT06649721|DRUG|Clofazimine|"Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
214254020|NCT06488924|DRUG|JR-446|IV infusion
214254021|NCT05677100|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
214254022|NCT03609216|DRUG|Gemcitabine Hydrochloride|Given IV
214254023|NCT03609216|DRUG|Cisplatin|Given IV
214254024|NCT03609216|BIOLOGICAL|Pegfilgrastim|Given SC
214254025|NCT03609216|PROCEDURE|Conventional Surgery|Undergo bladder sparing
214254026|NCT03609216|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
214254027|NCT03609216|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
214254028|NCT05696860|DEVICE|Capnography Monitoring|Capnography monitoring
214254029|NCT06977152|DEVICE|Memory foam pillow|Patients in the memory foam pillow intervention group will have a memory foam pillow placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
214254030|NCT06977152|DEVICE|Fluidized Positioner|Patients in the fluidized positioner intervention group will have a fluidized positioner placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
214254031|NCT06087640|BIOLOGICAL|aQIV or aTIV|Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
214653216|NCT01918254|DRUG|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
214653217|NCT01918254|DRUG|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
214653218|NCT01918254|DRUG|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
214254032|NCT06087640|BIOLOGICAL|QIV or TIV|Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
214254033|NCT06810999|OTHER|From Fear to Purpose (Acceptance and Commitment Therapy)|The From Fear to Purpose ACT Protocol is based on Acceptance and Commitment Therapy (ACT) strategies, build around identifying and committing to personal values. The intervention will be group-based (90 minutes session).
214254034|NCT06810999|OTHER|Placebo|The placebo condition consists of a group-based attentional control intervention.
214254035|NCT06605027|OTHER|Therapeutic Ketogenic Diet|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
214254036|NCT04523779|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
214254037|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
214254038|NCT06673212|OTHER|Control Wheat Bread|Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
214254039|NCT06673212|OTHER|Berneray Bere barley bread|Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
214254040|NCT06673212|OTHER|Black Barley bread|Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
214254041|NCT06994949|DEVICE|fCTOT cap|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the subarachnoid space (SAS), draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the neonatal intensive care unit (NICU) for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
214254042|NCT06994949|DEVICE|NIRF planar imaging|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
214254043|NCT06994949|DRUG|ICG|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
214254044|NCT07001930|DRUG|Epidiolex|Oral cannabidiol
214254045|NCT06679075|PROCEDURE|Full pulpotomy using propolis and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material
214254046|NCT06679075|PROCEDURE|Full pulpotomy using Propolis and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
214254047|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material
214254048|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
214254049|NCT06680245|DRUG|Mitomycin c|Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
214653219|NCT02609581|DRUG|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
214254050|NCT04504812|DRUG|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
214254051|NCT04504812|COMBINATION_PRODUCT|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
214254052|NCT04504812|PROCEDURE|Nerve Procedure with long acting blocks|People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
214254053|NCT04504812|PROCEDURE|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
214254054|NCT04504812|BEHAVIORAL|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
214254055|NCT04504812|OTHER|Best Practices|Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
214254056|NCT03727607|DRUG|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
214254057|NCT06682156|DRUG|Carfilzomib|carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。
214254058|NCT06878066|DRUG|thrombolysis therapy|All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.
214254059|NCT06708221|DEVICE|Real-Time Image Guided Radio Therapy (IGRT)|Real-time image guided radiation therapy (IGRT) methods image the cancerous tumour in real-time, enabling the treatment beam to focus its destructive energy on the patient's cancer, not their healthy tissue.
214254060|NCT06709274|DRUG|Osimertinib|80mg daily, for EGFR-positive patients
214254061|NCT06709274|DRUG|Alectinib|600mg BID, for ALK-rearranged patients
214254062|NCT06709274|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
214254063|NCT06707831|OTHER|Teleassessment|Children underwent assessments on two occasions: one in face-to-face within a clinical setting, and the other through teleassessment using video conferencing. This video conference session was recorded to be later reviewed and scored by two separate raters.
214254064|NCT06710639|BEHAVIORAL|Health Education Program|Instructions and recommendations will be provided in an informational leaflet to encourage an active and healthy lifestyle, promoting self-care and good health practices. This leaflet will include the new WHO guidelines recommending specific measures to reduce the risk of cognitive impairment.
214254065|NCT06710639|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study.
214254066|NCT06709924|OTHER|EXERCISE TRAINING WITHOUT MEDICATION|After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.
214254067|NCT06708767|DRUG|Contrast Media|IV contrast media administration
214254068|NCT06708767|DRUG|Placebo|Saline
214254069|NCT06709352|OTHER|non|non
214254070|NCT07131332|BEHAVIORAL|Mindful eating group|Behavioral group intervention involving 8, 2-hour long sessions
214254071|NCT06714396|DRUG|QRL-101|Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
214254072|NCT06714396|OTHER|Placebo|Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
214254073|NCT06702423|BEHAVIORAL|AI-based chatbot|A tailored Japanese HPV vaccination chatbot.
214254074|NCT06702423|BEHAVIORAL|Leaflet|A publicly accessible HPV vaccination leaflet prepared by the Ministry of Health, Labour, and Welfare.
214254075|NCT07039292|BEHAVIORAL|Harm Reduction (E-cigarette switching)|Participants will be assigned to receive an e-cigarette and try to switch completely from smoking to using the e-cigarette
214254076|NCT07039292|BEHAVIORAL|Standard of Care|Participants will be assigned to receive tobacco treatment referrals and the opportunity to re-enroll in the Tobacco Treatment Program
214254077|NCT07041853|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha|Root extract ashwagandha, KSM-66
214254078|NCT07041853|DIETARY_SUPPLEMENT|Placebo|Organic chickpea flour
214254081|NCT07043088|PROCEDURE|Membrane sweeping|Serial membrane sweeping from gestational age 39+5-40+2 with 2-3 days interval and a maximum og three times.
214254082|NCT06030622|DRUG|Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)|Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)
214254083|NCT06030622|DRUG|C3 (Metformin, Simvastatin, and Digoxin) only|C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
214254084|NCT06884410|DEVICE|MRI|Multiparametric renal MRI on 1.5T scanners
214254085|NCT04868045|DRUG|Thyrotropin Releasing Hormone (TRH)|TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
214254086|NCT04868045|DRUG|levothyroxine|"Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning."
214254087|NCT04868045|OTHER|Hypothyroidism QOL questionnaire|Administer standardized Hypothyroidism QOL questionnaire.
214254088|NCT05108636|OTHER|Therapeutic Touch|Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).
214254089|NCT05108636|OTHER|Music Rest|The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor \& Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
214254090|NCT04539899|OTHER|VR+|Use of a virtual reality helmet during IUD insertion
214254091|NCT06728891|OTHER|In addition to routine diagnosis and treatment, no additional intervention measures were taken.|This study does not impose any intervention on the patients
214254092|NCT04711187|DRUG|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
214254093|NCT04711187|OTHER|Placebo Comparator|Placebo Comparator
214254094|NCT04711187|DRUG|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
214254095|NCT03944746|OTHER|Education Curriculum|Different educational curriculums were applied to each cohort
214254096|NCT06633692|OTHER|Head down tilt (HDT)|In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
214254097|NCT06878560|BIOLOGICAL|10 GE Xenokidney|Porcine-derived kidney containing intentional genomic alterations for xenotransplantation
214254098|NCT02981940|DRUG|Abemaciclib|Abemaciclib capsule
214254099|NCT02981940|PROCEDURE|Surgery|Surgery
214254100|NCT04938349|BEHAVIORAL|Dual task perturbation training|Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
214254101|NCT04967664|DRUG|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
214254102|NCT04967664|DRUG|capsaicin 0.04% topical system|Low-dose capsaicin control
214254103|NCT07057414|DRUG|GMDTC for injection|GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (e.g., The initial dose group: 2 g reconstituted in 500 mL, with each 1 g reconstituted in 250 mL, resulting in a 4 mg/mL concentration.). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
214254104|NCT07057414|OTHER|0.9% Sodium Chloride Injection(0.9% NaCl)|0.9% Sodium Chloride Injection with a specification of 250mL/bag, and administered by intravenous infusion. The infusion should be strictly adhering to the assigned dosage. All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
214254105|NCT06759701|DRUG|Tirzepatide|Participants will perform weekly self-injection of tirzepatide as standard of care, following manufacturer instructions
214254106|NCT06875960|DRUG|BMS-986165|Specified dose on specified days
214254107|NCT06883526|BIOLOGICAL|ZG005 for Injection|intravenous infusion
214254108|NCT06883526|DRUG|Gecacitinib Hydrochloride Tablets|Oral
214254109|NCT06749197|DEVICE|Rehacom|Home-based cognitive training program
214254110|NCT06897566|DIAGNOSTIC_TEST|Fasting lipid profile|Recruited patients will be requested to provide data from their most recent fasting lipid profile
214254111|NCT06776211|BEHAVIORAL|Virtual Reality Simulation|"Virtual reality simulation application:~The video content to be used in the virtual reality-based application was created by researchers from the Ministry of Health of the Republic of Turkey, General Directorate of Public Health, Neonatal Resuscitation Programme (NRP) Practitioner Certified Training Programme. The duration of the video was planned not to exceed 10 minutes in order not to reduce the interest and attention span."
214254112|NCT06776211|BEHAVIORAL|Low-Reality Simulation|Low reality simulation application: The low reality simulation application to be used will use a neonatal model as a teaching aid, with human anatomy and functional features designed to simulate neonatal resuscitation applications.
214464864|NCT04646096|DEVICE|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
214464865|NCT05109351|BEHAVIORAL|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
214254113|NCT06765941|DEVICE|Probe-based near-infrared parathyroid autofluorescence detection system|The surgeon will use the PTeye as an intraoperative tool to identify whether a suspect tissue is parathyroid or not during the surgery. The surgeon will first take five baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent), to establish a reference point for subsequent measurements, using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements. The subsequent step involves touching the target tissue in the neck with the fiber optic probe, after which the PTeye will indicate to the surgeon whether the tissue is parathyroid or not. Parameters displayed on the PTeye console - Baseline values, Detection Intensity, Parathyroid Detection Ratio - will be recorded for each patient in the study arm. PTeye indicates that a tissue is parathyroid if the 'Parathyroid Detection Ratio' is greater than 1.2. The rest of the surgical procedure will follow the standard protocol.
214254114|NCT06765941|PROCEDURE|Surgeons naked eyes for parathyroid glands identification|The surgeons will not use the probe-based near-infrared parathyroid autofluorescence detection system and will proceed with the procedure as usual, relying on their surgical experience to identify parathyroid glands. At the end of the procedure, the thyroid specimen will be evaluated visually to search for inadvertently resected parathyroid glands. If this is the case, these parathyroid glands will be reimplanted in the sternocleidomastoid muscle, following standard protocol.
214254115|NCT06782139|DRUG|Enavogliflozin|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
214254116|NCT06782139|DRUG|Placebo|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
214254117|NCT07069660|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of solutions for each problem, implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
214254118|NCT07069660|BEHAVIORAL|Education Program|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
214254119|NCT07070427|OTHER|Exercise|Cognitive-based balance exercises.
214254120|NCT04268615|OTHER|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
214254121|NCT04268615|OTHER|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
214254122|NCT04268615|OTHER|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
214254123|NCT07068438|DEVICE|Pulse electric field ablation system|Bronchial rheoplasty (BR) is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
214254124|NCT07068438|DEVICE|Sham Procedure|Staged sham procedure: the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient).
214254125|NCT04876729|BEHAVIORAL|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
214464866|NCT04826588|DRUG|Methylprednisolone sodium succinate 10 mg/kg intravenously|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
214464867|NCT04826588|BIOLOGICAL|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
214464868|NCT00167674|DRUG|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
214464869|NCT00167674|DRUG|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
214653220|NCT02979756|PROCEDURE|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
214653221|NCT03124459|DRUG|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
214254126|NCT06900712|BEHAVIORAL|PATH-SS|"This single-session intervention includes the following components:~* Providing the PATH-SS rationale.~* A review of life events (PATH of life: negative and positive).~* A verbal narrative of the sexual assault (revisiting and processing as is done in imaginal exposure)~* Reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. In positive reminiscence, clients vividly remember the positive event providing details and focus on positive emotions. The therapist will encourage savoring of the experience and encourage facial expression of the positive emotions, so that clients do not dampen, avoid, or minimize the experience. This is particularly relevant with depression.~* Summary of content, integration and consolidation of learning, application of new learning and resilience in real life as next steps."
214254127|NCT07075185|DRUG|KLN-1010|Given at specified dose one time
214254128|NCT06927856|BEHAVIORAL|Test-to-PrEP|Participants, called Egos, will come once to the clinic throughout the duration of the study, for up to 1 hour. During the visit, participants will receive up to 4 Test-to-PrEP Packs, which include an HIV self-test kit and HIV prevention education materials and a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Test-to-PrEP Packs to Social Network Contacts (peers), called Alters.
214254129|NCT06927856|BEHAVIORAL|Access by Referral|Participants, called Egos, will receive up to 4 Access by Referral Cards once. Participants will receive a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Access by Referral Cards to Social Network Contacts (peers), also called Alters. The Referral Card can be used to order a Test-to-PrEP Pack, including the HIV self-test and HIV prevention education material, that will be mailed to an address of the Alter's choice.
214254130|NCT07138066|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
214254131|NCT07138066|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and 15 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
214254132|NCT07138066|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan.
214254133|NCT07138066|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program consists of a structured set of isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility. Exercises are performed in a supine, prone, or seated position, as appropriate, with 2 sets of 5-12 repetitions or sustained holds of 20-30 seconds, progressing gradually according to the rehabilitation plan. All movements are conducted within a pain-free range (not exceeding 4/10 on the VAS scale), with additional hourly ankle mobility work prescribed to reduce swelling and prevent thrombosis.
214254134|NCT07138066|DEVICE|Orthopedic shoes for use during rehabilitation period|Patients are provided with orthopedic shoes to be worn during the rehabilitation period (up to 6-10 weeks).
214254135|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
214254136|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
214254137|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
214254138|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
214254139|NCT06886152|PROCEDURE|Transcutaneous Spinal Cord Stimulation|A portable transcutaneous spine stimulator (Digitimer ®, USA) will supply biphasic stimulation superficial to the thoracolumbar spine.
214254140|NCT06886152|OTHER|Sham|A portable transcutaneous spine stimulator (Digitimer ®, USA) will be applied superficially with no electrical current.
214254141|NCT07081815|DEVICE|JOCOAT(TM) APN-3003|10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery
214254143|NCT06665373|BEHAVIORAL|Modified Atkins Diet|The Atkins diet is a low-carb eating plan that focuses on balancing protein, fat, and carbohydrates.
214254144|NCT06665373|BEHAVIORAL|Fitness Program|12 weeks of two weekly supervised exercise sessions combined with an individualized home exercise program based on physical capabilities and available equipment.
214254145|NCT07076004|BEHAVIORAL|Medically Tailored Grocery Plus Nutrition Counseling Group|Weekly delivery of medically tailored groceries plus 8 remote nutritional counselling sessions.
214254146|NCT07076004|BEHAVIORAL|Experimental: Medically Tailored Grocery Group|Weekly delivery of medically tailored groceries.
214254147|NCT07076004|BEHAVIORAL|Standard of Care Group with Delayed Medically Tailored Grocery Delivery|Option to pick up fresh produce weekly from participating clinics. Medically tailored grocery delivery will be available for 6 months beginning at the end of the study.
214254148|NCT07087197|DRUG|SKB107 for injection|177Lu-DOTA-IBA is a Radionuclide conjugated drugs (RDC) targeting bone.
214254151|NCT06928766|DRUG|Eszopiclone 3 mg|Both eszopiclone and lemborexant taken together at bedtime for one night
214653222|NCT03124459|DRUG|Placebo|Recombinant fusion protein or buffer solution
214653223|NCT01116193|DRUG|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
214254152|NCT06928766|DRUG|Placebo|Placebo sugar pills that looks like the eszopiclone and lemborexant capsules taken at bedtime for one night.
214254153|NCT06928766|DRUG|Lemborexant 10mg|Both eszopiclone and lemborexant taken together at bedtime for one night
214254154|NCT07078435|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
214254155|NCT07078435|BIOLOGICAL|Blood test|Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
214254156|NCT07078435|BIOLOGICAL|Stool samples|Before the surgery, the patient will take a stool sample.
214254157|NCT07078435|BIOLOGICAL|Stool samples|After 1 year's follow-up, the patient will take a stool sample.
214254158|NCT06234930|DEVICE|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
214254159|NCT05176418|DRUG|low dose Nicotine|IV nicotine infused over different delivery rates
214254160|NCT05176418|DRUG|high dose Nicotine|IV Nicotine infused over different delivery rates
214254161|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
214254162|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
214254163|NCT06223750|OTHER|population-based screening for chronic kidney disease|Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
214254164|NCT06073132|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
214254165|NCT06073132|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
214254166|NCT02179658|DRUG|OPT-80|oral
214254167|NCT02179658|DRUG|vancomycin|oral
214254168|NCT07090395|DEVICE|EVO Sleep and Snore Device|ProSomnus EVO Sleep and Snore Device mandibular advancement device
214254169|NCT07084129|OTHER|personalized dosing adjustment of vancomycin|A personalized vancomycin PK model that incorporates kidney injury biomarkers will be used for vancomycin dose adjustments to achieve goal AUC levels.
214653224|NCT00496366|DRUG|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
214653225|NCT00496366|DRUG|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
214653226|NCT00576771|PROCEDURE|PSV|Pressure Support Ventilation
214653227|NCT00576771|PROCEDURE|NAVA|Neurally Adjusted Ventilatory Assist
214653228|NCT00576771|PROCEDURE|patient-controlled|assisted controlled MV through a button
214254174|NCT07091539|OTHER|Fruit/vegetable vouchers|The intervention is $80 of fruit/vegetable vouchers (EatSF Veggies4Vouchers) per month x 6 months
214254175|NCT05500248|BEHAVIORAL|Leave In Situ|"Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials."
214254176|NCT05500248|BEHAVIORAL|Standard|All identified polyps will be removed and sent to pathology.
214653229|NCT04647110|DRUG|crizotinib|as provided in real world practice
214653230|NCT04647110|DRUG|alectinib|as provided in real world practice
214653231|NCT04647110|DRUG|brigatinib|as provided in real world practice
214254177|NCT07132541|DRUG|Pancreatic parenchymal injection of N-butyl-2-cyanoacrylate(Histoacryl®)|"This procedure is integrated into the standard pancreaticoduodenectomy.~Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma circumferentially (3, 6, 9, and 12 o'clock positions) around the main pancreatic duct (MPD) orifice, extending 5-8 mm deep and 5-10 mm laterally from the future anastomotic line, avoiding the main pancreatic duct and vessels. Total volume injected typically ranges from 0.2 ml to 0.6 ml.~Follow with standard duct-to-mucosa pancreaticojejunostomy:~* Tying down the posterior duct-to-mucosa sutures.~* Placing and tying the anterior duct-to-mucosa sutures.~* Tying down the posterior outer layer sutures.~* Placing the anterior outer layer sutures. Meticulously avoid glue contact with sutures/mucosa~Reconstruction: Complete the hepaticojejunostomy and duodenojejunostomy (or gastrojejunostomy)."
214254178|NCT07089238|DIETARY_SUPPLEMENT|Citicoline|Oral
214254179|NCT07089238|DIETARY_SUPPLEMENT|Placebo|Oral
214254180|NCT07105722|BIOLOGICAL|Pn-MAPS30plus|The Pn-MAPS30plus vaccine will be administered intramuscularly.
214254181|NCT07105722|COMBINATION_PRODUCT|PCV20|The PCV20 vaccine will be administered intramuscularly.
214254182|NCT07103993|OTHER|Low meal condition|Participants will consume a standardized meal (500 grams) with a low nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours
214254183|NCT07103993|OTHER|Moderate meal condition|Participants will consume a standardized meal (500 grams) with a moderate nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
214254184|NCT07103993|OTHER|High meal condition|Participants will consume a standardized meal (500 grams) with a high nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
214254185|NCT07103993|OTHER|Ad-libitum control condition|The ad-libitum meal consists of 600-700 g of a standardized control meal one time at all visits. Participants will attend one visit per week for 3 weeks. Each visit is separated by one week and each visit will take approximately 6 hours.
214254186|NCT06437834|OTHER|Information Sheet|Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.
214254187|NCT06437834|OTHER|High-touch connect|Engagement with a patient navigator.
214254188|NCT06811493|PROCEDURE|bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients|using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process)
214254189|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
214254190|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
214254191|NCT07112521|DEVICE|active tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
214254192|NCT07112521|DEVICE|sham tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.
214254193|NCT05797246|DRUG|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
214254194|NCT07109726|DRUG|TER-2013|Oral Capsules
214254195|NCT07109726|DRUG|Fulvestrant injection|Fulvestrant 500 mg Intramuscular Injection
214254196|NCT07115966|BEHAVIORAL|Computerized decision support by best practice alert (BPA)|"The antimicrobial stewardship intervention encourages prescribers by a simple alert to follow guidelines for reviewing antimicrobial prescriptions after a set timeframe for potential de-escalation to targeted therapy or discontinuation of the antibiotics, as recommended by national and international guidelines.~An automated simple BPA will trigger after an antibiotic prescription with therapeutic indication (72 hours) or surgical prophylaxis (24 hours, reminding prescribers to reassess treatment for possible de-escalation, adaption to targeted therapy, or cessation.~If ignored, the prescription remains unchanged, but the alert will continue until addressed. Prescribers must select reasons for not changing the prescription, such as pending microbiology results. The control group corresponds to the inpatient wards not yet receiving the BPA, where antibiotics are managed according to standard-of-care."
214254197|NCT07118904|OTHER|Rapid weight loss through dehydration|Dehydration will be induced by exposing athletes to sauna heat with an average temperature of 70-80°C. The participants will undergo consecutive 15 minute sessions in sauna with 5 minute breaks until 3% weight loss is achieved. No liquids or food will be consumed between sessions.
214254198|NCT07116759|DEVICE|Real-time head stabilization with robotic platform|A robotic platform will use data from motion-detection cameras to position a person's head in real time. This procedure is non-invasive.
214254199|NCT07103772|DIETARY_SUPPLEMENT|Ananá|"The supplement consists of a box containing 14 sachets of the product for 14 days of treatment. Patients should preferably consume the supplement in the morning.~The Ananá's Nutraceutical Group will receive the real supplement for consumption over 14 days, while the Ananá's Placebo Group will receive a placebo supplement for comparison at the end of the trial."
214254200|NCT00182702|DRUG|ixabepilone|Given IV
214653232|NCT04647110|DRUG|ceritinib|as provided in real world practice
214653233|NCT04647110|DRUG|lorlatinib|as provided in real world practice
214254201|NCT00182702|OTHER|laboratory biomarker analysis|Correlative studies
214653234|NCT05135364|DRUG|Camrelizumab|Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
214653235|NCT05135364|DRUG|HAIC|A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
214653236|NCT05135364|DRUG|TKI|Lenvatinib or Regorafenib
214254202|NCT06933771|OTHER|LAVENDER ESSENCE GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Afterwards, the researcher explained to the children in the intervention group and their parents how to apply the lavender essence and what kind of a plant lavender is, and showed the bottle of essential oil to be used during the procedure. A 5x5 cm sponge with 2 drops of almond oil that contains 1% lavender essence was located on the shoulder of the children to smell for 5 minutes.
214254203|NCT06933771|OTHER|CONTROL GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Routine nursıng care provıed.
214254204|NCT06934941|DRUG|NM-101|NM-101 IV versus placebo
214254205|NCT06934941|DRUG|Placebo|Placebo
214254206|NCT06933914|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d
214254207|NCT06934005|DEVICE|Baseplate type A|Type A: Acrylate tested for 35 days behind one ear
214254208|NCT06934005|DEVICE|Baseplate type C|Type C: Hydrocolloid tested for 35 days behind the other ear
214254210|NCT07139457|DEVICE|Wearable seizure prediction and alert glasses|A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.
214254211|NCT06933992|DEVICE|Chocolate PTA Balloon Catheter|The Chocolate PTA balloon catheter is a nitinol-constrained percutaneous transluminal angioplasty balloon designed to minimize vessel trauma during treatment of peripheral arterial lesions. The device is used according to its standard indications and instructions for use in patients with symptomatic peripheral artery disease.
214254212|NCT06933654|PROCEDURE|IOL implantation surgery for aphkic eye|Aphakic eyes underwent secondary intraocular lens (IOL) implantation using one of two techniques. In Group A, an iris-claw IOL (Artisan aphakia IOL, Ophtec BV, The Netherlands) was implanted and fixated to the mid-peripheral iris via enclavation. In Group B, a posterior chamber foldable PMMA IOL was fixated to the iris using transscleral sutures passed through eyelets in the haptics. All procedures were performed under peribulbar anesthesia using standard aseptic technique, and postoperative management included topical antibiotics and corticosteroids.
214254213|NCT01828320|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
214254214|NCT01828320|BEHAVIORAL|Psychoeducation|
214254215|NCT07143591|OTHER|Not found|No intervention
214254216|NCT06937892|BEHAVIORAL|Transdiagnostic metacognitive therapy|A single, generic treatment protocol focusing on metacognitions.
214254217|NCT06937892|BEHAVIORAL|Disorder-specific cognitive-behavioral therapy|Disorder-specific treatment protocols focusing on cognitions and/or behaviors.
214254218|NCT07140653|OTHER|Femto arcs|Femtosecond laser-assisted arcuate corneal relaxing incisions (AK) will be performed to correct astigmatism.
214254219|NCT07140653|DEVICE|Light Adjustable Lens (LAL)|The LAL is intended to replace the natural lens at time of lens removal.
214254220|NCT06946576|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure|FETO procedure involves insertion of a balloon into the fetal trachea under IV sedation with local anesthesia or combined spinal-epidural anesthesia. Balloon removal will take place up to 7 weeks after insertion.
214254221|NCT06933758|DIAGNOSTIC_TEST|Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio|Demonstrate utility of LDCT in COPD characterization Determine exacerbation risk and symptom burden in this patient population Determine the severity of COPD identified through this process Describe phenotypic characteristics including imaging analysis of THCI population Determine the suitability and acceptance of patients to participate in COPD clinical trials Determine the incidence of comorbid lung (ILA, bronchiectasis, pulmonary artery enlargement) and non-lung problems (cardiac and aortic calcifications, osteopenia/osteoporosis and for gut abnormalities) identified by LDCT in a patient population at risk for lung cancer and/or COPD Determine the correlation between clinical measurements and imaging biomarkers
214254222|NCT07141849|BEHAVIORAL|Power Resistance Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
214254223|NCT07141849|BEHAVIORAL|Periodized Resistance Training|Participants will receive three weeks of hypertrophy training to increase muscle size followed by six weeks of strength training, and then three weeks of power training twice per week for a total of twenty-four 45-minutes in-person training sessions. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
214254224|NCT07125677|DEVICE|I-gel first|After general anesthesia, I-gel is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel plus is inserted, and the same procedure is repeated.
214254225|NCT07125677|DEVICE|I-gel plus first|After general anesthesia, I-gel plus is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel is inserted, and the same procedure is repeated.
214254226|NCT02576431|DRUG|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
214254227|NCT07150000|DIAGNOSTIC_TEST|Ex Vivo Assay|Ex vivo assay with patient's PBMCs. Cytokine quantification (e.g. TNFα, IL-1β). HCI with single-cell analysis (\>100 features/cell). Data preprocessing and normalization to transfer for machine learning.
214254228|NCT07150624|DRUG|Experimental Group|Receiving 930mg of polyene phosphatidylcholine injection one day before the operation,twice a day. And 930mg of polyene phosphatidylcholine injection,twice a day, combined with 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
214254229|NCT07150624|DRUG|control group|Receiving 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
214254230|NCT07150182|OTHER|The Integrated Shared Decision-making Program|The Integrated Shared Decision-making Program
214254231|NCT07150208|DRUG|Bevacizumab (Bev)|Bevacizumab is a drug that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis, thereby inhibiting tumor growth and spread. In the treatment of breast cancer, Bevacizumab can be used in combination with chemotherapy to improve treatment outcomes and extend patients' progression-free survival and overall survival.
214254232|NCT07150208|DRUG|Trastuzumab Deruxtecan (T-DXd)|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients."
214254233|NCT07149623|PROCEDURE|Experimental|sectioning and submitting fresh surgical specimens from the ileum mesentery
214254234|NCT07150832|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by individuals who are not mental health professionals. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy.
214254235|NCT07150546|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214254236|NCT07150546|DRUG|Lutetium Lu 177 Dotatate|Given IV
214254237|NCT07150546|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214254238|NCT07150546|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214254239|NCT07150546|RADIATION|Gallium Ga 68-DOTATATE|Undergo gallium Ga 68-DOTATATE PET/CT
214254240|NCT07150546|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214254241|NCT07150546|OTHER|Questionnaire Administration|Ancillary studies
214254242|NCT07151014|OTHER|blood sample collection|blood sample collection in old patients in order to study the trombophilic risk
214254243|NCT07149987|PROCEDURE|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area. The implants used in this study were C-Tech® implants (C-Tech Implant, Italy) with the following dimensions: Diameter: 3.8 mm Length: 11 mm . Cone-Beam Computed Tomography (CBCT): To assess bone quality, quantity, and anatomical structures . Digital Intraoral Scans Heron Scanner (USA) to obtain detailed gingival contours, occlusion, and existing teeth. The scan data was exported as an STL file for digital planning. Easy Check Implant Stability Measuring System is used for implant stability measurement, the tapping rod was gently placed in slight contact with the healing abutment, avoiding any axial or lateral pressure, and aligned within 0°-30° relative to the abutment's occlusal surface. If the angle exceeded 30°, the device issued an alert and prevented measurement, ensuring consistent alignment
214254244|NCT07150650|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
214254245|NCT07149805|PROCEDURE|open surgery or interventional treatment|open surgery or interventional treatment
214254246|NCT07149883|OTHER|Complete blood count|Complete blood count
214254247|NCT07149883|DEVICE|ECHO|device that used to evaluate the cardiac function
214254248|NCT07149454|DRUG|Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection|intramuscular injection
214254249|NCT07149454|DRUG|Human Tetanus Immunoglobulin|intramuscular injection
214254250|NCT07149454|DRUG|Placebo|intramuscular injection
214254251|NCT07150377|DRUG|First-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
214254252|NCT07150377|DRUG|Second-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
214254253|NCT07149740|DEVICE|OCT|A10900 is an optical coherence tomography device
214254254|NCT05548738|DRUG|medthylprednisolone|a type of steroids injected in epidural space
214254255|NCT05548738|DRUG|prolotherapy|a type of hypertonic glucose
214254256|NCT02160782|DRUG|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
214254257|NCT02160782|DRUG|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
214254258|NCT00309738|DRUG|pitavastatin|
214254259|NCT00309738|DRUG|simvastatin|
214254260|NCT03175757|DIETARY_SUPPLEMENT|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
214254261|NCT03175757|DIETARY_SUPPLEMENT|Placebo|Placebo
214254262|NCT00993902|PROCEDURE|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
214254263|NCT00993902|PROCEDURE|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
214254264|NCT02454725|BEHAVIORAL|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
214653237|NCT01475890|DIETARY_SUPPLEMENT|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
214653238|NCT01475890|DIETARY_SUPPLEMENT|Placebo|Once a day for 12 months.
214254265|NCT02454725|BEHAVIORAL|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
214254266|NCT01956435|DEVICE|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
214254267|NCT01483300|DRUG|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
214254268|NCT01483300|DRUG|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
214254269|NCT00401531|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
214254270|NCT00401531|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
214254271|NCT01801072|DRUG|Levetiracetam|Details covered in Arm Descriptions.
214254272|NCT01573351|DRUG|Asunaprevir|
214254273|NCT01573351|DRUG|Daclatasvir|
214254274|NCT01573351|DRUG|Peg-interferon Alfa-2a|
214254275|NCT01573351|DRUG|Ribavirin|
214254276|NCT05760105|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214254277|NCT00632073|DRUG|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
214254278|NCT05342610|OTHER|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
214254279|NCT00053573|BIOLOGICAL|Myozyme|20 mg/kg to 40 mg/kg qow
214254280|NCT05931640|DEVICE|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
214254281|NCT05931640|DEVICE|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
214254282|NCT03920748|OTHER|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
214254283|NCT03920748|OTHER|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
214254284|NCT05281016|BEHAVIORAL|Usual Care|"Participants will be offered standard care which consists of the following:~* Clinic consultation with physician and dietician,~* pamphlets on weight management principles."
214254285|NCT05281016|BEHAVIORAL|Online community LITE programme|"Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support."
214254286|NCT05374668|BEHAVIORAL|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
214254287|NCT03215979|PROCEDURE|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
214254288|NCT03215979|PROCEDURE|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
214653239|NCT01740336|DRUG|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
214254289|NCT04363177|BEHAVIORAL|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
214254290|NCT06058559|DIETARY_SUPPLEMENT|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
214254291|NCT06058559|DIETARY_SUPPLEMENT|Olive oil|Extra virgin olive oil
214254292|NCT02872168|OTHER|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
214254293|NCT02340507|OTHER|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
214254294|NCT02340507|OTHER|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
214254295|NCT02486354|DRUG|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
214653240|NCT01740336|DRUG|Placebo|Placebo matching to GDC-0941
214653241|NCT01740336|DRUG|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
214653242|NCT02368470|DRUG|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
214254296|NCT03906461|DEVICE|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
214254297|NCT05251311|BEHAVIORAL|Social Risk Screening Tool|"Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need."
214254298|NCT05251311|OTHER|Electronic Resource Map|All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
214254299|NCT05251311|BEHAVIORAL|Resource Menu|Participants randomized to this experimental arm will receive a social resource menu tool, which assess desire for social resources.
214254300|NCT05579691|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
214254301|NCT05579691|OTHER|Placebo|Placebo Comparator
214254302|NCT06064266|OTHER|plant-based mild ketogenic controlled diet|Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
214254303|NCT06064266|OTHER|high-fat shake|The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
214254304|NCT02560181|RADIATION|HDR brachytherapy|Whole gland salvage
214254305|NCT02886689|DRUG|TNF-alpha antagonist and other biotherapy|
214254306|NCT00660621|DRUG|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
214254307|NCT03813797|DEVICE|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
214254308|NCT03813797|DEVICE|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
214254309|NCT03126877|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
214254310|NCT03126877|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
214254311|NCT01050127|DRUG|ABT-436|See Arm Description for details.
214254312|NCT01050127|DRUG|Placebo|See Arm Description for details.
214254313|NCT00510874|BIOLOGICAL|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
214254314|NCT00510874|BIOLOGICAL|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
214254315|NCT06035055|DRUG|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
214254316|NCT00869843|PROCEDURE|RF Ablation|
214254317|NCT03415100|BIOLOGICAL|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
214254318|NCT03447184|DRUG|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
214254319|NCT00941382|DRUG|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
214254320|NCT00941382|DRUG|Sibutramine|15 mg per day for 180 days
214254321|NCT00941382|DRUG|Metformin|Metformin 850 mg per day for 180 days
214254322|NCT02772484|DEVICE|HS-1000|
214254323|NCT02525315|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
214254324|NCT06309537|DIAGNOSTIC_TEST|chemoreflex evaluation|the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
214254325|NCT02922933|DRUG|entinostat|HDAC (histone deacetylase inhibitor)
214254326|NCT02922933|DIETARY_SUPPLEMENT|Omeprazole|Proton pump inhibitor
214653243|NCT02368470|DRUG|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
214254327|NCT02922933|DIETARY_SUPPLEMENT|Famotidine|Histamine-2 blocker
214254328|NCT06332248|DIETARY_SUPPLEMENT|Magnesium|The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
214254329|NCT06332248|DIETARY_SUPPLEMENT|Placebo|Placebo tablet, oral intake once a day for up to three months.
214254330|NCT01436916|DRUG|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
214254331|NCT01436916|DRUG|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
214254332|NCT00085124|BIOLOGICAL|oblimersen sodium|Given IV
214254333|NCT00085124|DRUG|cytarabine|Given IV
214254334|NCT00085124|DRUG|daunorubicin hydrochloride|Given IV
214254335|NCT00085124|OTHER|laboratory biomarker analysis|Correlative studies
214254336|NCT03037801|DEVICE|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
214254337|NCT04007211|DEVICE|ABT13107|Dose: 3mL, maximum 10mL
214254338|NCT04007211|DEVICE|Hyalobarrier|Dose: 10mL
214254339|NCT03208595|DIAGNOSTIC_TEST|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
214254340|NCT03689673|OTHER|Data collection|
214254341|NCT05290545|OTHER|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.
214254342|NCT05290545|OTHER|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
214254343|NCT05290545|OTHER|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
214254344|NCT03973073|COMBINATION_PRODUCT|CapulinTM|camouflage
214254345|NCT03973073|OTHER|topical applications and NB-UVB|combination therapy of vitiligo
214254346|NCT00695578|DRUG|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
214254347|NCT00695578|DRUG|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
214254348|NCT00214643|DRUG|Fosmidomycin|30 mg/kg
214254349|NCT00214643|DRUG|clindamycin|10 mg/kg
214254350|NCT00408538|DRUG|UC-781 microbicide gel (0.1% and 0.25%)|
214254351|NCT00408538|DRUG|placebo|
214254352|NCT04308603|DIAGNOSTIC_TEST|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
214254353|NCT00003742|DRUG|cisplatin|
214254354|NCT00003742|DRUG|irinotecan hydrochloride|
214254355|NCT00003742|DRUG|paclitaxel|
214254356|NCT02423109|DEVICE|fanfilcon A|contact lens
214254357|NCT02423109|DEVICE|enfilcon A|contact lens
214254358|NCT03956056|BIOLOGICAL|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
214254359|NCT03956056|DRUG|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
214254360|NCT03956056|PROCEDURE|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
214254361|NCT06154538|DRUG|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
214254362|NCT06154538|DRUG|FOLFOX regimen|FOLFOX chemotherapy
214254363|NCT01892215|PROCEDURE|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
214254364|NCT01892215|PROCEDURE|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
214254365|NCT04138069|OTHER|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
214254366|NCT04138069|OTHER|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
214254367|NCT04375969|OTHER|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
214254368|NCT04375969|OTHER|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
214254369|NCT04375969|OTHER|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
214254370|NCT04375969|OTHER|HIIT training group|This group will do the training program without cold exposure
214254371|NCT06255184|BEHAVIORAL|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
214254372|NCT00894023|DRUG|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
214254373|NCT00894023|DRUG|IV abciximab|IV abciximab + infusion
214254374|NCT06403215|OTHER|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
214254375|NCT06403215|OTHER|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
214254376|NCT06403215|OTHER|Chewing gum+Fennel tea group|Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
214254377|NCT06403215|OTHER|Control group|No intervention
214254378|NCT06391346|DIAGNOSTIC_TEST|MSOT|Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
214254379|NCT03403374|DRUG|evolocumab|Administered by SC injection via autoinjector (AI)/pen
214254380|NCT02563977|DEVICE|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
214254381|NCT04875962|DRUG|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
214254382|NCT04875962|DRUG|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
214254383|NCT03455127|OTHER|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
214254384|NCT00265551|DRUG|SCA-136 (200 mg)|
214254385|NCT00265551|DRUG|SCA-136 (400 mg)|
214254386|NCT00265551|DRUG|olanzapine (15 mg)|
214254387|NCT00265551|DRUG|placebo|
214254388|NCT05105230|DIAGNOSTIC_TEST|soluble programmed death 1biomarker|soluble programmed death 1biomarker
214254389|NCT06244017|DEVICE|EEG spectrogram|In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
214254390|NCT06244017|DEVICE|Bispectral index|In the control group, the general anesthesia is guided by using the bispectral index
214254391|NCT01904539|DRUG|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
214254392|NCT06097338|PROCEDURE|bariatric surgery (BS)|bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
214254393|NCT05936125|OTHER|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
214254394|NCT02242188|DRUG|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
214254395|NCT02242188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (packed in identical sachets as active products)
214254396|NCT00886184|PROCEDURE|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
214254397|NCT00886184|PROCEDURE|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
214254398|NCT02439983|DIETARY_SUPPLEMENT|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
214254399|NCT02439983|DIETARY_SUPPLEMENT|Placebo|2 capsules taken by mouth with morning and evening meals.
214254400|NCT05159284|DRUG|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
214254401|NCT05159284|DEVICE|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
214254402|NCT05159284|DEVICE|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
214254403|NCT05159284|DEVICE|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
214254404|NCT05894226|PROCEDURE|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
214254405|NCT04541160|DIAGNOSTIC_TEST|CR|Lung imaging evaluation performed with CR
214254406|NCT04541160|DIAGNOSTIC_TEST|ULDCT|Lung imaging evaluation performed with ULDCT
214254407|NCT01384071|DEVICE|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
214254408|NCT01384071|DEVICE|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
214254409|NCT05622370|DRUG|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
214254410|NCT05622370|DRUG|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
214464870|NCT05017545|BIOLOGICAL|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
214254411|NCT05622370|DRUG|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
214254412|NCT02675101|OTHER|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
214254413|NCT02675101|OTHER|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
214254414|NCT02675101|OTHER|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
214254415|NCT03183011|OTHER|MRI|Cardiac MRI
214254416|NCT00905216|DRUG|heparin sodium - Bergamo|5.000 UI/mL
214254417|NCT00905216|DRUG|heparin sodium - APP|5.000 USP
214254418|NCT04499976|DRUG|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
214254419|NCT04499976|DRUG|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
214254420|NCT04499976|DRUG|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
214254421|NCT02682407|BIOLOGICAL|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
214254422|NCT03880604|PROCEDURE|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
214254423|NCT03880604|DRUG|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
214254424|NCT03880604|OTHER|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
214254425|NCT04870034|DRUG|Binimetinib|Given PO
214254426|NCT04870034|DRUG|Palbociclib|Given PO
214254427|NCT04870034|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214254428|NCT00003548|DRUG|aminocamptothecin colloidal dispersion|
214254429|NCT03395925|DEVICE|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
214254430|NCT02796742|OTHER|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
214254431|NCT02474680|GENETIC|Pharmacogenetic testing|Psychotropic genotyping panel
214254432|NCT03570879|DEVICE|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
214254433|NCT03570879|PROCEDURE|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
214254434|NCT03136731|DIAGNOSTIC_TEST|Celiac disease antibody screening|Observational parameters
214254435|NCT00950911|DRUG|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
214254436|NCT03012568|DEVICE|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
214254437|NCT02030054|DRUG|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
214254438|NCT02030054|DRUG|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
214254439|NCT00708565|DRUG|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
214254440|NCT01742936|DEVICE|CoaguChek|Hand held coagulation monitor.
214254441|NCT01742936|OTHER|Hospital Laboratory|Coagulation testing done by hospital laboratory.
214254442|NCT03530566|OTHER|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
214254443|NCT03530566|OTHER|standard diet|standard low calorie diet for weight loss
214254444|NCT06345846|DEVICE|IFIOL|Implanted IFIOL
214254445|NCT06345846|DEVICE|SFIOL|Implanted SFIOL
214254446|NCT02476422|DRUG|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
214254447|NCT02476422|DRUG|Ibuprofen|Single dose of ibuprofen 400 mg tablet
214254448|NCT02476422|DRUG|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
214254449|NCT02476422|DRUG|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
214254450|NCT03205137|DRUG|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
214254451|NCT03205137|DRUG|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
214254452|NCT03205137|DRUG|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
214254453|NCT03205137|DRUG|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
214254454|NCT06175975|OTHER|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
214254455|NCT01589328|OTHER|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
214254456|NCT01683227|BEHAVIORAL|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
214254457|NCT01683227|BEHAVIORAL|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
214254458|NCT01310881|DRUG|NSI-189 Phosphate|Once daily oral administration
214254459|NCT04185870|DIAGNOSTIC_TEST|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
214254460|NCT04185870|DIAGNOSTIC_TEST|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
214254461|NCT03793218|DEVICE|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
214254462|NCT03793218|PROCEDURE|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
214254463|NCT04121988|DIAGNOSTIC_TEST|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging"
214254464|NCT03383471|BIOLOGICAL|Invossa K Inj.|Invossa K Inj.
214254465|NCT03383471|DRUG|Placebo|Placebo control
214254466|NCT03805607|DRUG|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
214254467|NCT03805607|DRUG|Placebos|Normal Saline
214254468|NCT03300960|DRUG|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
214254469|NCT03300960|DRUG|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
214254470|NCT02602899|PROCEDURE|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
214254471|NCT02380027|DEVICE|MRI|This will be a multi-parametric MRI of the prostate
214254472|NCT02380027|PROCEDURE|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
214254473|NCT02380027|PROCEDURE|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
214254474|NCT06377306|BEHAVIORAL|Effect of training loads and sport performance level on health and sport performance|Effect of training loads and sport performance level on health and sport performance
214254475|NCT01288027|BIOLOGICAL|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
214254476|NCT01240876|DRUG|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
214254477|NCT01240876|DRUG|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
214254478|NCT04367129|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram
214254479|NCT00455767|DRUG|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
214254480|NCT00455767|DRUG|Placebo|Placebo
214254481|NCT05324618|DRUG|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
214254482|NCT05324618|DRUG|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
214254483|NCT02225509|PROCEDURE|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
214254484|NCT00994318|DRUG|FCM (Ferric carboxymaltose) high ferritin target|
214254485|NCT00994318|DRUG|FCM (Ferric carboxymaltose) low ferritin target|
214254486|NCT00994318|DRUG|Oral Iron (Ferrous sulphate)|
214254487|NCT05855070|DRUG|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
214254488|NCT05855070|DRUG|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
214254489|NCT01134315|DRUG|Paricalcitol|
214254490|NCT01134315|DRUG|Calcitriol|
214254491|NCT03024814|DRUG|Acetaminophen|"The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
214254492|NCT03024814|DRUG|Dextrose 5|"The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
214254493|NCT02896244|OTHER|no intervention|
214254494|NCT02818231|OTHER|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
214254495|NCT04575454|OTHER|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
214254496|NCT04014309|OTHER|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
214254497|NCT04014309|OTHER|Usual care|Usual care
214254498|NCT05323110|DRUG|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
214254499|NCT05323110|DRUG|Placebo|CBS001 matched placebo
214254500|NCT01722773|DEVICE|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
214254501|NCT01943773|PROCEDURE|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
214254502|NCT01943773|PROCEDURE|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
214254503|NCT00739999|DRUG|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
214254504|NCT00739999|DRUG|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
214254505|NCT02180165|DRUG|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
214254506|NCT02180165|DRUG|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
214254507|NCT01884623|DRUG|Cetuximab|
214254508|NCT01884623|DRUG|Methotrexate|
214254509|NCT00982124|DRUG|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
214254510|NCT01385631|DRUG|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
214254511|NCT01385631|DRUG|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
214254512|NCT03875768|BEHAVIORAL|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
214254513|NCT03895242|BEHAVIORAL|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
214653244|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
214653245|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
214653246|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
214653247|NCT04372095|PROCEDURE|oral smears|oral smears
214254514|NCT03895242|BEHAVIORAL|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
214254515|NCT02690883|DRUG|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
214254516|NCT02690883|DRUG|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
214254517|NCT01902238|PROCEDURE|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
214254518|NCT01374711|DRUG|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
214254519|NCT01374711|DRUG|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
214254520|NCT01374711|OTHER|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
214254521|NCT04774120|DRUG|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
214254522|NCT00737438|DRUG|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
214254523|NCT04594148|BEHAVIORAL|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
214254524|NCT05391451|PROCEDURE|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
214254525|NCT05391451|PROCEDURE|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
214254526|NCT00734123|DRUG|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
214254527|NCT00734123|DRUG|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
214254528|NCT00734123|DRUG|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
214254529|NCT00734123|DRUG|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
214254530|NCT02027038|DEVICE|Pelvic belt application|
214254531|NCT01572259|DRUG|Growth Hormone|
214254532|NCT01572259|OTHER|interruption of the traitment with growth hormone|
214254533|NCT00917111|DRUG|Nasal CO2|Four times a day for 14 days
214653248|NCT04561349|OTHER|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
214653249|NCT04561349|OTHER|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
214254534|NCT00917111|DRUG|Inactive Placebo Gas|Placebo
214254535|NCT03861650|OTHER|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
214254536|NCT03861650|OTHER|Saline|Physiological saline is added in control group to act as placebo
214254537|NCT00431678|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
214254538|NCT00431678|DRUG|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
214254539|NCT05357638|BEHAVIORAL|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
214254540|NCT05357638|BEHAVIORAL|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
214254541|NCT05357638|BEHAVIORAL|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
214254542|NCT01982565|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
214254543|NCT01982565|OTHER|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
214254544|NCT00011557|DEVICE|Assistance in Voiding|
214254545|NCT02791594|DRUG|Pembrolizumab|Patients were treated with pembrolizumab according to standard of care.
214254546|NCT04855864|OTHER|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
214254547|NCT04855864|OTHER|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
214254548|NCT04855864|OTHER|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
214254549|NCT03036605|DRUG|Bupivacaine|%0.5 bupivacaine
214254550|NCT03036605|DRUG|Dexamethasone|8 mg Dexamethasone
214254551|NCT01298973|DRUG|Viscoat|One group will receive Viscoat for incision closure
214254552|NCT01298973|DRUG|Saline|One group will receive Saline to irrigate the wound
214254553|NCT00117195|DEVICE|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
214254554|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
214254555|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
214254556|NCT05736783|OTHER|plyometric exercises|"1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
214254557|NCT05736783|OTHER|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
214254558|NCT04008238|DRUG|Trabectedin|\- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
214254559|NCT04926077|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
214254560|NCT06146881|DRUG|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
214254561|NCT06146881|DRUG|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
214254562|NCT02234986|DRUG|ENMD-2076|250 mg oral dose, once daily (QD) for 28 day cycles
214254563|NCT04872218|DRUG|Abatacept|24 week treatment of IV abatacept following recommended dosages from the monograph
214653250|NCT01717638|BIOLOGICAL|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
214653251|NCT01717638|BIOLOGICAL|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
214653252|NCT02570451|OTHER|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
214653253|NCT02570451|OTHER|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
214653254|NCT02570451|OTHER|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
214653255|NCT02570451|OTHER|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
214653256|NCT02570451|OTHER|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
214254564|NCT04872218|DRUG|Placebo|24 week treatment of IV placebo following recommended dosages from the abatacept monograph
214254565|NCT04872218|OTHER|Peanut oral immunotherapy|Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
214254566|NCT05276180|OTHER|Arm A) Multifactorial intervention strategy|"Implementation of the multifactorial intervention strategy will be supported by the following components:~1\) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3\) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4\) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection."
214254567|NCT05276180|OTHER|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
214254568|NCT06155643|DEVICE|Eko Sensora|The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
214254569|NCT05712369|OTHER|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
214254570|NCT03888924|DRUG|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
214254571|NCT03888924|DRUG|Placebo|isotonic solution of sodium chloride (2mL vials).
214254572|NCT04950166|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
214254573|NCT05745532|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
214254574|NCT06197347|BEHAVIORAL|Web-based nursing intervention : Ch@ngeons Ensemble|"The web-based nursing intervention, named Ch@ngeons Ensemble, was designed to increase physical activity and quality of life among older adults living with CHD. The intervention will be multicomponent, including educational content, videos, forums, goal planning, an electronic physical activity journal, and virtual written interactions with a nurse. An initial in-person meeting with the nurse will be provided to foster the older adult's commitment to the intervention and help build a relationship of trust. Throughout the intervention, the nurse will asynchronously provide counseling, feedback, and encouragement, and attempt to promote quality of life, knowledge, motivation, and self-efficacy among the older adults."
214254575|NCT04234386|RADIATION|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
214254576|NCT00546468|PROCEDURE|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
214254577|NCT00546468|PROCEDURE|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
214254578|NCT05920915|OTHER|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
214254579|NCT03599635|DRUG|liposomal bupivacaine|Experimental
214254580|NCT03599635|DRUG|Bupivacaine|Active Comparator
214254581|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
214464871|NCT05017545|BIOLOGICAL|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
214653257|NCT02570451|OTHER|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
214254582|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
214254583|NCT00857415|DRUG|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
214254584|NCT02129829|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
214254585|NCT03785288|RADIATION|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
214254586|NCT03660488|DRUG|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
214254587|NCT03660488|DRUG|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
214254588|NCT03824171|DRUG|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
214254589|NCT03824171|DRUG|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
214254590|NCT04508140|PROCEDURE|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
214254591|NCT04508140|DRUG|BO-112 with pembrolizumab|BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
214254592|NCT06019429|BEHAVIORAL|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 \& 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 \& 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
214254593|NCT06019429|BEHAVIORAL|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
214254594|NCT06019429|BEHAVIORAL|School as usual|Any amount of classes offered to promote social-emotional development
214254595|NCT01130103|DRUG|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
214254596|NCT01130103|BEHAVIORAL|Prolonged Exposure Therapy|Weekly for 10 weeks
214254597|NCT02232334|OTHER|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
214254598|NCT04766073|PROCEDURE|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
214254599|NCT00289367|DRUG|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
214254600|NCT00289367|DRUG|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
214254601|NCT00570414|DEVICE|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
214254602|NCT00570414|DEVICE|Endotracheal tube|Airway management by the use of endotracheal tube
214254603|NCT01199731|DRUG|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
214254604|NCT01199731|DRUG|GSK2248761 200 mg once daily|2 100mg capsules OAD
214254605|NCT01199731|DRUG|Etravirine|2 100mg tablets twice daily
214254606|NCT00554112|BEHAVIORAL|Exercise|Exercise
214254607|NCT01284530|DRUG|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
214254608|NCT01727908|OTHER|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
214653258|NCT02570451|OTHER|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
214653259|NCT02570451|OTHER|Grip Strength|Measured using the JAMAR dynamometer
214653260|NCT02012010|PROCEDURE|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
214653261|NCT02012010|PROCEDURE|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
214653262|NCT06478862|DRUG|Promitil|The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
214653263|NCT03732547|DRUG|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
214653264|NCT03732547|DRUG|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
214653265|NCT05704114|DRUG|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
214653266|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation A|
214653267|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation B|
214254609|NCT04466176|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
214254610|NCT04466176|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
214254611|NCT04648254|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
214254612|NCT03964766|DEVICE|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
214254613|NCT03964766|DEVICE|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
214254614|NCT03985384|DRUG|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
214254615|NCT03985384|DRUG|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
214254616|NCT05146154|DRUG|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
214254617|NCT00985816|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
214254618|NCT00985816|DIETARY_SUPPLEMENT|Placebo|Placebo
214254619|NCT03332550|PROCEDURE|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
214254620|NCT03332550|PROCEDURE|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
214254621|NCT02992132|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
214254622|NCT02992132|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
214254623|NCT02992132|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth
214254624|NCT01385007|BEHAVIORAL|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
214254625|NCT05749211|DRUG|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
214254626|NCT02687373|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
214254627|NCT02687373|OTHER|Normal Saline|0.9% Sodium chloride
214653268|NCT00687453|DRUG|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
214653269|NCT00687453|DRUG|NPH twice-daily|Addition of morning NPH to bedtime NPH
214653270|NCT06959927|OTHER|Standard Care Group|"Patients in this group received conventional hemodialysis care, including:~Continuous monitoring of vital signs (blood pressure, respiratory rate, pulse, heart rhythm); Supplemental oxygen therapy as needed; Instruction on effective coughing techniques; Strict fluid and electrolyte management; Metabolic support therapies; Positional adjustments (upright posture with lower limb dependency); Environmental regulation (temperature: 22-24°C; humidity: 50-60%); Individualized dietary counseling."
214254628|NCT02914015|PROCEDURE|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
214254629|NCT02914015|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
214254630|NCT02914015|DRUG|Ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
214254631|NCT02914015|DRUG|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
214254632|NCT04148833|DRUG|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
214254633|NCT04148833|DRUG|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
214254634|NCT05423054|OTHER|Abdominal massage|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
214254635|NCT05486741|OTHER|Optical cehernce tomography|OCT macula and disc
214254636|NCT03773445|DIAGNOSTIC_TEST|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
214254637|NCT03773445|DIAGNOSTIC_TEST|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
214254638|NCT03773445|DIAGNOSTIC_TEST|Histology|Histology of colonic biopsies using the Geboes Index
214254639|NCT03773445|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
214254640|NCT05205967|OTHER|MCED|Multi-cancer early detection (MCED) test
214254641|NCT05205967|OTHER|SOC|Standard of care cancer screening
214254642|NCT02231047|DIETARY_SUPPLEMENT|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
214254643|NCT02231047|OTHER|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
214254644|NCT01289457|DRUG|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
214254645|NCT01289457|DRUG|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
214254646|NCT01289457|DRUG|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
214254647|NCT01289457|DRUG|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
214254648|NCT05961878|DIETARY_SUPPLEMENT|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
214254649|NCT05789108|DIAGNOSTIC_TEST|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
214254650|NCT03786614|OTHER|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
214254651|NCT03786614|OTHER|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
214254652|NCT06084598|DRUG|BMS-986446|Specified dose on specified days
214254653|NCT06084598|OTHER|Placebo|Specified dose on specified days
214254654|NCT00595777|BEHAVIORAL|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
215031459|NCT01533415|DEVICE|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
214254655|NCT02267642|BIOLOGICAL|AbGn-168H|monoclonal antibody
214254656|NCT00596180|DRUG|HBOT|total body exposure to greater than atmospheric pressure oxygen
214254657|NCT00005851|DRUG|fludarabine phosphate|Given IV
214254658|NCT00005851|RADIATION|total-body irradiation|Undergo TBI
214254659|NCT00005851|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
214254660|NCT00005851|DRUG|cyclosporine|Given PO or IV
214254661|NCT00005851|DRUG|mycophenolate mofetil|Given PO or IV
214254662|NCT00005851|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
214254663|NCT00005851|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
214254664|NCT00005851|OTHER|laboratory biomarker analysis|Correlative studies
214254665|NCT04172662|BEHAVIORAL|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
214254666|NCT05715801|PROCEDURE|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
214254667|NCT05715801|PROCEDURE|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
214254668|NCT02592811|PROCEDURE|ERCP|Common bile duct cannulation with a cannulation catheter
214254669|NCT02592811|PROCEDURE|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
214254670|NCT02592811|DEVICE|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
214254671|NCT02592811|PROCEDURE|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
214254672|NCT03568084|OTHER|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
214254673|NCT03568084|OTHER|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
214254674|NCT03206255|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
214254675|NCT03206255|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
214254676|NCT06387160|DRUG|as per institutional protocol|This is an observational study. Treatment will be given to the patients as per institutional protocol
214254677|NCT01627171|DRUG|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
214254678|NCT01627171|DRUG|Polyethelene Glycol|280g reconstituted in 4 liters of water
214254679|NCT01627171|DRUG|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
214254680|NCT00129818|DRUG|Famciclovir|
214254681|NCT04707352|DRUG|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
214254682|NCT03194503|DEVICE|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
214254683|NCT03497793|OTHER|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
214254684|NCT01180530|DEVICE|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
214254685|NCT03491943|PROCEDURE|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
214254686|NCT03491943|PROCEDURE|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
214254687|NCT03216031|BEHAVIORAL|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
214254688|NCT04957355|DEVICE|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
214653271|NCT06959927|OTHER|Risk-Stratified Management Group|"Patients in this group received standard care plus targeted risk management interventions:~System Enhancement:~Standardized nursing protocols and accountability frameworks Competency-based staff training (emergency response, fluid management) Individualized care plans (e.g., intensified glycemic control for diabetics, optimized BP monitoring for hypertensives)~Risk Stratification:~Admission assessments and follow-up evaluations to identify high-risk patients Hemodynamic monitoring with alert thresholds for early deterioration detection Strict pharmacological supervision and fluid balance protocols~Environmental Modification:~Optimized dialysis unit conditions (temperature: 22-24°C; humidity: 50-60%) Dedicated cardiac care zones for HF patients~Quality Control:~Quarterly audits of critical care domains (patient education, vital signs documentation, protocol compliance, satisfaction metrics) Corrective actions for identified deficiencies"
214254689|NCT04692740|DRUG|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
214254690|NCT02003339|OTHER|Additional RMIs|
214254691|NCT04255797|BEHAVIORAL|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
214254692|NCT02841527|PROCEDURE|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
214254693|NCT02841527|PROCEDURE|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
214254694|NCT02841527|PROCEDURE|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
214254695|NCT00381381|DRUG|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
214254696|NCT03364907|OTHER|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
214254697|NCT03364907|OTHER|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
214254698|NCT00711074|DRUG|AZD5672|single dose 200mg aqueous solution
214254699|NCT02997267|PROCEDURE|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
214254700|NCT05062278|DRUG|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
214254701|NCT05062278|DRUG|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
214254702|NCT04516044|BEHAVIORAL|Video games|See arm description
214254703|NCT04256889|DEVICE|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
214254704|NCT00160966|DRUG|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
214254705|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
214254706|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
214254707|NCT00337350|DRUG|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
214254708|NCT00337350|DRUG|placebo|matched placebo for rosiglitazone 4mg/day
214254709|NCT00846287|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
214254710|NCT00846287|DRUG|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
214254711|NCT00846287|DRUG|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
214254712|NCT05569811|DRUG|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
214254713|NCT05569811|DRUG|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
214254714|NCT05569811|DRUG|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
214254715|NCT02909179|OTHER|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
214254716|NCT02240290|DRUG|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
214254717|NCT02240290|DRUG|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
214254718|NCT03640767|BEHAVIORAL|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
214254719|NCT00557401|DRUG|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
214254720|NCT00557401|DRUG|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
214254721|NCT00557401|DRUG|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
214254722|NCT00557401|DRUG|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
214254723|NCT00557401|DRUG|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
214254724|NCT05274139|DRUG|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
214254725|NCT05274139|DRUG|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
214254726|NCT01437878|DRUG|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
214254727|NCT01437878|DRUG|Placebo|matching placebo
214254728|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
214254729|NCT04838392|DEVICE|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
214254730|NCT01070043|DRUG|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
214254731|NCT01070043|DRUG|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
214254732|NCT01194427|DRUG|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
214254733|NCT01164540|DRUG|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
214254734|NCT01164540|DRUG|Placebo|Oral dose (od)
214254735|NCT05012436|DRUG|YHD1119 75mg|A single oral dose
214254736|NCT01323738|BEHAVIORAL|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
214254737|NCT04965558|OTHER|No intervention|No intervention
214254738|NCT00473746|DRUG|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
214254739|NCT00473746|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
214254740|NCT00473746|DRUG|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
214254741|NCT00832390|DRUG|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
214653272|NCT05591781|DEVICE|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
214653273|NCT05591781|DEVICE|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
214653274|NCT00419796|DRUG|Lumiracoxib|
214254742|NCT00667420|DRUG|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
214254743|NCT03832244|DIAGNOSTIC_TEST|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
214254744|NCT01554969|DRUG|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
214653275|NCT00434967|DRUG|Candesartan cilexetil|32 mg oral tablet
214254745|NCT05994560|OTHER|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
214254746|NCT01528215|DEVICE|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
214254747|NCT01528215|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
214254748|NCT01043510|DRUG|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
214254749|NCT01043510|DRUG|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
214254750|NCT06264310|DRUG|Placebo|Matching placebo SC injection
214254751|NCT06264310|DRUG|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
214254752|NCT05245253|RADIATION|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
214254753|NCT04793061|OTHER|blood sample collection|Blood is samples from peripheral vein during routine care
214254754|NCT03722771|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
214254755|NCT03722771|OTHER|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
214254756|NCT03722771|OTHER|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
214254757|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
214254758|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
214254759|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
214254760|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
214464872|NCT05017545|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
214464873|NCT05300048|DRUG|Serabelisib|serabelisib administered orally
214464874|NCT05300048|OTHER|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
214464875|NCT05300048|DRUG|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
214464876|NCT01420783|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214653276|NCT00434967|DRUG|Hydrochlorothiazide|25 mg oral tablet
214653277|NCT00434967|DRUG|Candesartan/HCT 32/25 mg|
214254761|NCT00042367|DRUG|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
214254762|NCT00042367|DRUG|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
214254763|NCT00042367|DRUG|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
214254764|NCT00042367|DRUG|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
214254765|NCT00042367|DRUG|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
214254766|NCT00042367|DRUG|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1\."
214254767|NCT00042367|DRUG|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir."
214254768|NCT00042367|DRUG|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
214254769|NCT00042367|DRUG|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
214254770|NCT00042367|RADIATION|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
214254771|NCT03858231|DRUG|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
214254772|NCT03858231|DRUG|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
214254773|NCT03858231|DRUG|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
214254774|NCT01331941|DRUG|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
214254775|NCT01331941|DRUG|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
214254776|NCT01715714|DRUG|Statin Recapture Therapy|Given 12h and 2h before CABG
214254777|NCT01715714|DRUG|Placebo|Given 12h and 2h before CABG.
214653278|NCT05749835|OTHER|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
214254778|NCT02130726|PROCEDURE|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
214254779|NCT02130726|PROCEDURE|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
214254780|NCT05553951|BEHAVIORAL|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
214254781|NCT05553951|BEHAVIORAL|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
214254782|NCT00573365|DEVICE|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
214254783|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
214254784|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
214254785|NCT01462227|DRUG|Naltrexone High Dose|Naltrexone 100mg for two administrations.
214254786|NCT01462227|DRUG|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
214254787|NCT01158703|DRUG|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
214254788|NCT01158703|DRUG|sugar pill|sugar pill by mouth daily for 12 months
214254789|NCT01158703|DRUG|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
214254790|NCT04165811|OTHER|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
214254791|NCT04165811|OTHER|Counselling|Only physical activity counseling will be given to the subjects in this group.
214254792|NCT05045833|DRUG|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
214254793|NCT00606827|DRUG|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
214254794|NCT00606827|DRUG|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
214254795|NCT06065423|OTHER|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
214653279|NCT05749835|OTHER|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
214653280|NCT04444245|PROCEDURE|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
214254796|NCT02776371|DRUG|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
214653281|NCT04444245|PROCEDURE|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
214653282|NCT04444245|PROCEDURE|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
214254797|NCT02776371|DRUG|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
214254798|NCT03346044|DEVICE|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
214254799|NCT03346044|DEVICE|Medtronic Mosaic bioprostheses|
214254800|NCT03200665|DIAGNOSTIC_TEST|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
214254801|NCT00440778|DRUG|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
214254802|NCT01500512|OTHER|Clinical Observation|Undergo observation
214254803|NCT05403333|DRUG|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
214254804|NCT05753631|PROCEDURE|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
214653283|NCT04444245|DEVICE|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000
214653284|NCT04444245|DRUG|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
214653285|NCT04444245|DEVICE|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
214254805|NCT02271373|BEHAVIORAL|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
214254806|NCT01387373|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
214254807|NCT00586066|DRUG|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
214254808|NCT00586066|DRUG|Placebo|Inactive comparator. Placebo-matching memantine tablet.
214254809|NCT02320318|DRUG|Ibodutant 10 mg|Oral tablet, once daily.
214254810|NCT02320318|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
214254811|NCT03191240|DRUG|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
214254812|NCT03191240|DRUG|Normal saline|Placebo
214254813|NCT04644536|DEVICE|Bone graft substitute|Orthopaedic or Spine bony defects
214254814|NCT00013234|PROCEDURE|Teledermatology|
214254815|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks from baseline
214254816|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
214254817|NCT00124488|DEVICE|Tomotherapy Treatment Planning|
214254818|NCT03219918|DEVICE|EndoRings II Distal Attachment|Colonoscopy cap
214254819|NCT01498835|DRUG|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
214254820|NCT00151853|DRUG|PPSB-SD|
214254821|NCT04082559|OTHER|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
214254822|NCT04082559|OTHER|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
214254823|NCT04082559|OTHER|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
214254824|NCT04082559|OTHER|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
214254825|NCT04082559|OTHER|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
214254826|NCT04082559|OTHER|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
214254827|NCT04082559|OTHER|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
214254828|NCT06182280|BEHAVIORAL|PrEP4T|PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
214254829|NCT06182280|BEHAVIORAL|LS4TM|LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
214254830|NCT02207985|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
214254831|NCT01812590|BEHAVIORAL|Exercise|
214254832|NCT01743456|OTHER|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
214254833|NCT01216124|DRUG|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6"
214254834|NCT00467610|DRUG|Panhematin|
214254835|NCT02557659|DEVICE|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
214254836|NCT01369615|DRUG|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
214254837|NCT03557554|OTHER|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
214254838|NCT04263454|DRUG|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
214254839|NCT04263454|PROCEDURE|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
214254840|NCT03518931|DIAGNOSTIC_TEST|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
214254841|NCT00417573|DRUG|IV Gamunex 10%|
214254842|NCT05093348|DEVICE|Click2Print artificial eye|Digitally designed and manufactured ocular prosthesis
214254843|NCT05093348|DEVICE|Hand-made artificial eye|Hand-made artificial eye
214254844|NCT00130676|DRUG|Mifepristone|daily for 7 days
214254845|NCT00130676|DRUG|matching placebo|daily for 7 days
214254846|NCT03911154|DEVICE|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
214254847|NCT03911154|DEVICE|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
214254848|NCT03911154|DEVICE|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
214254849|NCT01785407|DIETARY_SUPPLEMENT|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
214254850|NCT05752981|DEVICE|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
214254851|NCT01600118|DEVICE|Extracorporeal shockwave therapy|1000 impulses
214254852|NCT01600118|DEVICE|No extracorporeal shockwave|0 impulses, acoustic effect
214254853|NCT05591846|BEHAVIORAL|Face-to-face training|Face-to-face training
214254854|NCT05591846|BEHAVIORAL|web-based training|web-based training
214254855|NCT00752037|DRUG|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
214254856|NCT05527405|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
214254857|NCT04353414|PROCEDURE|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
214254858|NCT04353414|PROCEDURE|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
214254859|NCT04353414|DRUG|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
214254860|NCT04542044|OTHER|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
214254861|NCT00023244|DRUG|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
214254862|NCT00023244|DRUG|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
214254863|NCT00023244|DRUG|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
214254864|NCT00023244|DRUG|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
214254865|NCT00023244|DRUG|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
214254866|NCT00023244|DRUG|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
214254867|NCT00023244|DRUG|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
214254868|NCT02314390|BEHAVIORAL|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
214254869|NCT02314390|BEHAVIORAL|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
214254870|NCT02534818|DRUG|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
214254871|NCT02534818|DRUG|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
214254872|NCT04332380|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
214254873|NCT01225107|DIETARY_SUPPLEMENT|Cranberry Extract|500mg TID
214254874|NCT01225107|DRUG|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
214254875|NCT02947412|OTHER|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
214254876|NCT02675712|OTHER|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
214254877|NCT02761434|OTHER|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
214254878|NCT02761434|OTHER|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
214254879|NCT00815243|PROCEDURE|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
214254880|NCT00815243|PROCEDURE|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
214254881|NCT05588271|OTHER|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
214254882|NCT02035475|DEVICE|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
214254883|NCT02159612|OTHER|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
214254884|NCT00178750|DEVICE|18G Tuohy epidural needle|
214254885|NCT00178750|DEVICE|CompuFlo® computerized syringe pump|
214254886|NCT03828409|PROCEDURE|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
214254887|NCT03828409|PROCEDURE|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
214254888|NCT05864170|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
214254889|NCT01776047|DRUG|Exforge®|
214254890|NCT01776047|DRUG|G-0081|
214653286|NCT04200612|BEHAVIORAL|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
214254891|NCT01231347|DRUG|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
214254892|NCT01231347|DRUG|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
214254893|NCT01231347|DRUG|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
214254894|NCT01231347|DRUG|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
214254895|NCT01461278|DEVICE|iStent supra|Cataract surgery and implantation of one iStent supra
214254896|NCT01461278|PROCEDURE|Cataract surgery|Cataract surgery alone
214254897|NCT02085915|OTHER|strip Peri Screen|
214254898|NCT06333821|BIOLOGICAL|Nimotuzumab|Nimotuzumab 400mg
214254899|NCT06333821|DRUG|Cisplatin|Cisplatin 40mg/m\^2
214254900|NCT06333821|RADIATION|External Beam Radiotherapy (EBRT)|External Beam Radiotherapy (EBRT)
214254901|NCT06333821|RADIATION|Brachytherapy|Brachytherapy
214254902|NCT06333821|DRUG|placebo for Nimotuzumab|placebo for Nimotuzumab 400mg
214254903|NCT00326794|PROCEDURE|mobilisation (rehabilitation)|
214254904|NCT02322021|DRUG|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
214254905|NCT02322021|DRUG|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
214254906|NCT06327659|DEVICE|30 mL syringe manual thrombectomy catheter|30 mL syringe manual thrombectomy catheter
214254907|NCT06327659|DEVICE|50 mL syringe manual thrombectomy catheter|50 mL syringe manual thrombectomy catheter
214254908|NCT00232167|DRUG|Indiplon|
214254909|NCT00232167|DRUG|Sertraline|
214254910|NCT03356054|COMBINATION_PRODUCT|R-DHAP|3 cycles q 3 weeks
214254911|NCT03356054|DRUG|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
214254912|NCT00135733|DRUG|Amevive (Alefacept)|
214254913|NCT00135733|DRUG|Placebo|
214254914|NCT00992329|DRUG|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
214254915|NCT00406094|DRUG|montelukast|10mg
214254916|NCT00406094|DRUG|placebo|placebo
214254917|NCT05355610|DRUG|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
214254918|NCT05355610|DRUG|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
214254919|NCT02185846|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
214254920|NCT02185846|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
214254921|NCT04180774|BIOLOGICAL|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
214254922|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
214254923|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
214254924|NCT00861536|DRUG|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
214254925|NCT00861536|DRUG|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
214254926|NCT04386031|DIAGNOSTIC_TEST|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
214254927|NCT02516254|DIETARY_SUPPLEMENT|fortified bread|50 g of fortified bread + placebo daily
214254928|NCT02516254|DIETARY_SUPPLEMENT|supplement|vitamin D supplement+ plain bread
214254929|NCT02516254|DIETARY_SUPPLEMENT|placebo|plain bread+placebo
214254930|NCT02047227|DRUG|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
214254931|NCT02047227|DRUG|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
214254932|NCT02047227|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
214254933|NCT05665179|BEHAVIORAL|Removing Barriers to Recovery|Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
214254934|NCT02466373|DRUG|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
214254935|NCT00551044|DRUG|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
214254936|NCT01428362|DRUG|VI-1121|
214254937|NCT01428362|DRUG|Placebo|
214254938|NCT03368703|DEVICE|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
214254939|NCT03368703|DEVICE|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
214254940|NCT05032430|BEHAVIORAL|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
214254941|NCT05032430|BEHAVIORAL|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
214254942|NCT00225446|DEVICE|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
214254943|NCT05300633|BEHAVIORAL|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
214254944|NCT03031158|BEHAVIORAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
214254945|NCT03031158|BEHAVIORAL|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
214254946|NCT03267732|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
214254947|NCT05276947|OTHER|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
214254948|NCT00136331|BIOLOGICAL|Pandemic influenza vaccine|
214254949|NCT01209923|DEVICE|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
214254950|NCT00719095|DRUG|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
214254951|NCT00719095|BEHAVIORAL|Behavioral therapy|
214254952|NCT04017247|DRUG|Oxytocin|Intermittent oxytocin Infusion
214254953|NCT04017247|DRUG|Oxytocin|Continous oxytocin Infusion for 16 hours
214653287|NCT04200612|BEHAVIORAL|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
214653288|NCT04200612|OTHER|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
214254954|NCT02279238|PROCEDURE|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest \[Washout time\] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of \[HR, SPO2, PSG RPE scale, Distance walked, BP\] the participants are collected before, during and after the completion of each lap \[according to American Thoracic Society \[ATS\] protocol\]."
214254955|NCT03652376|DRUG|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
214254956|NCT03882931|OTHER|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
214254957|NCT03882931|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
214254958|NCT03882931|OTHER|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
214254959|NCT01483807|BEHAVIORAL|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
214254960|NCT01483807|BEHAVIORAL|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
214254961|NCT01900639|BEHAVIORAL|change time of intake of aspirin|
214254962|NCT06392802|DEVICE|Rehabilitation treatment using Muvity|The users have the support of the telerehabilitation system Muvity
214254963|NCT01634763|DRUG|LDK378|
214254964|NCT02123043|BEHAVIORAL|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
214254965|NCT02123043|BEHAVIORAL|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
214254966|NCT01571297|DRUG|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
214254967|NCT01571297|DRUG|Placebo|Placebo given subcutaneously for 35 days
214254968|NCT02370446|OTHER|personalized medication log|
214254969|NCT02370446|OTHER|standard of care|
214254970|NCT02370446|BEHAVIORAL|questionnaires|
214254971|NCT02370446|BEHAVIORAL|Cognitive Interview|
214254972|NCT06517784|OTHER|No treatment given|No treatment given
214254973|NCT03422601|DIAGNOSTIC_TEST|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
214254974|NCT03577613|PROCEDURE|Open radical hysterectomy|
214254975|NCT03577613|PROCEDURE|laparoscopic radical hysterectomy|
214254976|NCT03577613|PROCEDURE|Robotically assisted radical hysterectomy|
214254977|NCT01187680|DEVICE|Spraygel|
214254978|NCT01187680|DEVICE|Control|Good surgical technique, no adhesion barrier
214254979|NCT03980951|PROCEDURE|Dural Puncture Epidural Technique|three labor analgesia techniques
214254980|NCT03980951|PROCEDURE|Combined Spinal Epidural without intrathecal opioids|three labor analgesia techniques
214254981|NCT03980951|PROCEDURE|epidural|three labor analgesia techniques
214254982|NCT05411614|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip|Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation
214254983|NCT05411614|DEVICE|Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
214254984|NCT05495633|OTHER|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
214254985|NCT05495633|OTHER|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
214254986|NCT03671018|DRUG|Mosunetuzumab (IV)|Participants will receive intravenous (IV) mosunetuzumab.
214254987|NCT03671018|DRUG|Mosunetuzumab (SC)|Participants will receive subcutaneous (SC) mosunetuzumab.
214254988|NCT03671018|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin.
214254989|NCT03671018|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed.
214254990|NCT03671018|DRUG|Rituximab|Participants will receive IV rituximab.
214254991|NCT05532475|DIAGNOSTIC_TEST|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
214254992|NCT04468321|DEVICE|Apple Watch|Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
214254993|NCT04468321|DEVICE|Withings Move|Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
214254994|NCT04737135|OTHER|Non intervention|Patients without intervention
214254995|NCT00550251|DEVICE|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
214254996|NCT00550251|DEVICE|Placebo wristbands|Elasticated wrist bands without active bead.
214254997|NCT05644496|DRUG|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
214254998|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
214254999|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
214255000|NCT06145659|BEHAVIORAL|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
214255001|NCT00982696|BIOLOGICAL|Opioid Growth Factor|250ug per kilogram weekly IV infusions
214255002|NCT06676709|BIOLOGICAL|IMMUNEPOTENT-CRP (I-CRP)|IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.
214255003|NCT06676709|BIOLOGICAL|Placebo Comparator|The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
214255004|NCT06671002|DRUG|NSAID|"Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)"
214255005|NCT06671002|DRUG|Opioid|"Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses"
214255006|NCT06671002|DRUG|Acetaminophen|Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
214255007|NCT06671002|DRUG|Ibuprofen|Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
215031460|NCT01533415|DEVICE|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
214255008|NCT03306862|DIETARY_SUPPLEMENT|Whole yellow pea soup|Soup containing whole yellow peas
214255009|NCT03306862|DIETARY_SUPPLEMENT|Split yellow pea soup|Soup containing split yellow peas
214255010|NCT03306862|DIETARY_SUPPLEMENT|Potato soup|Soup containing potatoes
214255011|NCT04021563|DRUG|SR419|Ascending single and multiple doses of SR419 orally
214255012|NCT04021563|DRUG|Placebo|Ascending single and multiple doses of placebo orally
214255013|NCT06686238|DEVICE|MITOVIT® Hypoxic Training System|The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
214255014|NCT06686238|DEVICE|Sham MITOVIT® Hypoxic Training System|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
214255015|NCT06690814|OTHER|Ficus septica exudate (antiseptic plant exudates)|F. septica sap contains the antibacterial alkaloid ficuseptine which exhibits activivity agaisnt S. pyogenes and H. ducreyi, two pàthogens associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
214255016|NCT06690814|OTHER|Pterocarpus indicus exudate|P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
214255017|NCT06690814|OTHER|Curcuma longa aqueous extract|C. longa is a culinary herb that contains the antibatieral compound curcumin. Curcumin exhibits antibacterial activity agasint S. pyogenes and has profound effects on bacterial biofilms. This intervention uses a mulch of the rhizome that has been sqeeezed to produce a curcumin containing aqueous fluid.
214255018|NCT06690814|DRUG|Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)|Common over the counter antiseptic cream
214255019|NCT06686316|DEVICE|Device: Hypoxic Gas Mixture|The EG (Experimental Group) will undergo a 6-week intervention protocol of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
214255020|NCT06686316|OTHER|Sham Hypoxic-Hyperoxic exposure|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
214255021|NCT06696586|DRUG|Fentanyl infusion|will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.
214255022|NCT06696586|DRUG|Fentanyl Injection|will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
214255023|NCT03307057|BEHAVIORAL|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
214255024|NCT03307057|BEHAVIORAL|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
214255025|NCT03307057|BEHAVIORAL|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
214255026|NCT03307057|BEHAVIORAL|Usual Care|Care as recommended and provided by the child's pediatrician or other health care providers in the community.
214255027|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
214255028|NCT07030543|BEHAVIORAL|Individualized Dietary Plan (IDP) for Type 2 Diabetes|This study evaluates the feasibility of an Individualized Dietary Plan (IDP), a structured, patient-tailored nutrition intervention designed to improve glycemic control and lipid profiles in adults with Type 2 Diabetes Mellitus (T2DM).
214255029|NCT07030543|BEHAVIORAL|Usual care|Standard dietary advice as per the current clinical practice.
214255030|NCT06708715|DEVICE|PEACE Patch|A topical patch that incorporates a sensory pattern of vibrotactile haptic technology.
214255031|NCT06708715|DEVICE|Topical Sham Patch|Sham Patch that does not include vibrotactile haptic technology
214255032|NCT06708065|DEVICE|Armeo Power robot restores upper limb motor function.|"ArmeoPower is a robotic rehabilitation device developed by Hocoma, designed to assist patients with impaired upper limb motor functions following conditions such as stroke or neurological injuries. The device features an exoskeleton that supports and tracks movements of the arm and hand, utilizing motor-assisted motion based on the principle of adaptive support, which adjusts assistance levels according to the patient's capabilities. ArmeoPower integrates interactive exercises, often in the form of engaging games, to enhance patient motivation and maintain focus during therapy sessions. It also collects and tracks performance data, enabling clinicians to evaluate progress over time. This device is widely used in rehabilitation centers and hospitals to improve muscle control, strength, and range of motion in patients recovering from severe motor impairments."
214653289|NCT03448744|DRUG|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
214653290|NCT03448744|DRUG|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
214653291|NCT02972827|DEVICE|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
214653292|NCT02972827|OTHER|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
214255033|NCT06708065|BEHAVIORAL|A Home Exercise Program|A Home Exercise Program (HEP) is a personalized set of exercises designed to support recovery and enhance functional abilities outside of clinical therapy sessions. For patients with hemiplegia due to cerebral infarction, the program typically includes range of motion (ROM) exercises to maintain joint flexibility and prevent stiffness, as well as strengthening exercises using resistance bands or light weights to improve muscle function. Balance and postural control exercises, such as weight shifting or standing on one leg, help enhance stability and reduce fall risks. Functional training focuses on practicing daily movements like reaching, grasping, or transferring between positions, while fine motor skill tasks aim to restore hand functionality. The program may also incorporate low-impact aerobic exercises, such as walking or seated cycling, to boost cardiovascular health, along with relaxation and breathing techniques to reduce stress and improve overall well-being. These exercises a
214255034|NCT06708065|BEHAVIORAL|Occupational therapy activities|Occupational therapy activities are designed to help individuals regain independence in daily life by addressing functional abilities, motor skills, and cognitive functions. For patients with hemiplegia due to cerebral infarction, these activities often include practicing Activities of Daily Living (ADLs) such as dressing, grooming, bathing, and feeding, as well as more complex tasks like cooking and managing finances. Fine motor skills development is emphasized through exercises involving tasks like buttoning, tying shoelaces, or handling small objects, sometimes using adaptive tools. Additionally, functional mobility training focuses on teaching safe movement strategies, such as transferring between surfaces or navigating stairs, and may include wheelchair mobility or energy conservation techniques. These activities are tailored to the patient's needs to enhance their ability to perform meaningful and necessary daily tasks independently.
214255035|NCT06708494|BEHAVIORAL|video decision aids|The video includes an introduction to geriatric frailty (3 minutes) and ACP (5 minutes). ACP includes three levels of medical care: life-prolonging care, limited care, and comfort care.
214255036|NCT04721847|OTHER|Pain Neuroscience Education|In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
214255037|NCT04721847|OTHER|Conventional Physical therapy|Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
214255038|NCT06707363|PROCEDURE|orthopedic surgery|Surgeries involving major interventions on the musculoskeletal system, such as joint replacement surgeries or fracture repairs.
214255039|NCT06707064|BEHAVIORAL|SFEE Diet Management Intervention|"A structured diet management program designed to improve glycemic control, dietary adherence, and maternal outcomes. It includes:~Self-empowerment: Goal-setting, dietary planning, and evaluation. Family empowerment: Emotional support and supervision. Environmental empowerment: Peer group interaction and education via WeChat groups and in-person meetings."
214255040|NCT06707064|BEHAVIORAL|Standard Dietary Advice|Routine nursing care, including dietary education, exercise planning, and self-monitoring for gestational diabetes management.
214255041|NCT06707350|DEVICE|Remote ischemic preconditioning (RIPC)|8 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower limbs with a blood pressure cuff
214255042|NCT06707350|DEVICE|sham condition (control group)|8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation.
214255043|NCT06708871|PROCEDURE|Thermal ablation|Thermal ablation is a minimally invasive procedure used to treat primary hyperparathyroidism, a condition where one or more of the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). The treatment involves using heat to destroy the overactive parathyroid tissue. This can be done through various methods such as radiofrequency ablation (RFA) and microwave ablation(MWA).
214255044|NCT06708871|PROCEDURE|Parathyroidectomy|Parathyroidectomy is a surgical procedure to remove one or more of the parathyroid glands in cases of hyperparathyroidism.
214255045|NCT06706921|DRUG|18F-Fluciclovine PET/CT Scan|In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
214255046|NCT06733636|OTHER|Sudoku Puzzles|Sudoku puzzles of consistent and regular difficulty
214255047|NCT06733636|OTHER|ScentCare (Olfactory Training Device)|ScentCare is a smell training device with eight encapsulated scents housed in separate compartments and is contained using a charcoal filter, which will be dispersed in the base of our device to prevent smell contamination in the user's environment. The outer casing contains an opening that can be manually rotated to line up with the casing on each scent. This is facilitated by a rod in the center of the device, which serves as the axis of rotation. By pressing the capsule, the desired scent is released through a hole in the casing, similar to the mechanism of a pen. The user presses the compartment back downwards into the casing when done. The ScentCare mobile application offers clear instructions for at-home smell training and testing, with features like scent randomization to prevent users from getting accustomed to a specific order. It provides detailed guidance on device use and allows users to schedule sessions and receive daily reminders, ensuring a structured training regimen.
214255048|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback|Participants will receive accurate feedback about their sleep data.
214255049|NCT06602960|BEHAVIORAL|Inflated Sleep Data Feedback|Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).
214255050|NCT06602960|BEHAVIORAL|Deflated Sleep Data Feedback|Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).
214255051|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback + Sleep-related Educational Information|Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
214653293|NCT02760251|DRUG|romiplostim|
215031461|NCT02843633|DEVICE|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
214255052|NCT07149766|OTHER|Breast crawling|"The newborn will be placed on the mother's abdomen for no more than 60 minutes, during which breast crawling and suckling behaviors will be observed. Throughout this period, the researcher will maintain active communication with the mother, providing information on the importance of breastfeeding.~The mother will be gently guided to support the baby when necessary, without interfering with the baby's natural instincts. The newborn's heart rate, respiratory rate, and body temperature will be recorded at birth and at the 60th minute."
214255053|NCT07150975|DRUG|GZR18|Administered SC
214255054|NCT07150975|DRUG|Semaglutide(Wegovy® )|Administered SC
214255055|NCT04180085|DRUG|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
214255056|NCT07149818|DRUG|Parsaclisib|parsaclisib 40mg qd
214255057|NCT07150728|BEHAVIORAL|dignity therapy|"Dignity therapists use the Dignity Psychotherapy Question Protocol to guide patients through life's most important issues, providing them with the opportunity to participate in and discuss the things they would like their families to remember them for. During the process, dignity therapists use audio recording to fully record, transcribe, and edit the interview material, creating a valuable record that the patient wishes to preserve. The edited document is then returned to the patient, who then gives it to their family members."
214255058|NCT07150728|BEHAVIORAL|Hospice palliative care|Participants regularly receive hospice care
214255059|NCT07150689|PROCEDURE|Rigid bronchoscopy|Participants will undergo rigid bronchoscopy under general anesthesia using an age-appropriate rigid bronchoscope. The airway will be systematically inspected. Any identified foreign body will be removed using appropriate retrieval devices (optical forceps, retrieval basket, suction). Post-removal, the airway will be re-examined to confirm clearance and detect trauma.
214255060|NCT07150689|PROCEDURE|Flexible scope|Participants will undergo flexible fiberoptic bronchoscopy under sedation or general anesthesia. The bronchoscope will be inserted transorally or transnasally. The airway will be inspected, and foreign body retrieval attempted using retrieval baskets, forceps, or cryoprobe
214255061|NCT07150689|PROCEDURE|Combined Flexible-Rigid Bronchoscopy|Initial flexible bronchoscopy will be performed to locate the foreign body and inspect distal airways, followed by rigid bronchoscopy for definitive removal.
214255062|NCT07150689|PROCEDURE|Imaging-Guided Bronchoscopy|Participants will undergo pre-procedure high-resolution CT or virtual bronchoscopy. Based on imaging, either rigid or flexible bronchoscopy will be performed, targeting the suspected location to reduce procedure time.
214255063|NCT02286557|DRUG|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
214255064|NCT02286557|DRUG|Placebo|
214255065|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
214255066|NCT00492050|DRUG|Bortezomib|1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
214255067|NCT00492050|DRUG|Rituximab|375 mg/m\^2 IV on Day 8 and 22.
214255068|NCT00492050|DRUG|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
214255069|NCT05218239|BEHAVIORAL|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
214255070|NCT05218239|BEHAVIORAL|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
214255071|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
214255072|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
214255073|NCT05979285|DEVICE|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
214255074|NCT04645888|PROCEDURE|Impacted tooth surgery|Surgical extraction of İmpacted tooth
214255075|NCT00482027|BIOLOGICAL|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
214255076|NCT01104701|DRUG|exenatide once weekly|subcutaneous injection, 2 mg, once a week
214255077|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
214255078|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
214255079|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
214255080|NCT04926623|DEVICE|FreeStyle Libre 24 weeks|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
214255081|NCT04926623|OTHER|SMBG (22 weeks) and blind CGM (2 weeks)|Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
214255082|NCT02883192|DRUG|Ondansetron|Zofran 4 mg.
214255083|NCT02883192|DRUG|Placebo|Placebo
214255084|NCT00437892|DRUG|atorvastatin|tablets, 40 mg day, 3 months
214255085|NCT00437892|DRUG|atorvastatin|tablets, 40 mg once daily
214255086|NCT00437892|BEHAVIORAL|diet|daily
214255087|NCT00437892|BEHAVIORAL|diet|daily diet
214255088|NCT05312073|OTHER|Biological samples|Blood samples Superficial skin Biopsy Collection of fallen squames Tapes - stripping
214255089|NCT05312073|OTHER|Skin biopsy|healthy skin from surgery interventions
214255090|NCT01329484|BEHAVIORAL|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
214255091|NCT01329484|BEHAVIORAL|Cognitive training|Cognitive training using a computerized system
214255092|NCT01329484|OTHER|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
215031462|NCT02843633|DRUG|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
214255093|NCT03436836|DRUG|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
214255094|NCT03436836|DRUG|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
214255095|NCT03436836|DRUG|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
214255096|NCT02413021|DRUG|Cytarabine|20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
214255097|NCT02413021|DRUG|Deferasirox|20 mg/kg ,oral, per day
214255098|NCT04592107|DIAGNOSTIC_TEST|eGFR|estimated glomerular filtration rate
214255099|NCT03437512|DEVICE|Anodal tDCS|20 minutes of 2mA anodal stimulation.
214255100|NCT03437512|BEHAVIORAL|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
214255101|NCT03437512|DEVICE|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
214255102|NCT02583373|DRUG|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
214255103|NCT02583373|DRUG|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
214255104|NCT02583373|DRUG|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
214255105|NCT01413061|PROCEDURE|Subtalar Arthrodesis|
214255106|NCT06558539|DEVICE|Transcutaneous Tibial Nerve Stimulation(TTNS)|Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.
214255107|NCT06558539|COMBINATION_PRODUCT|Combination Therapy|Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device
214255108|NCT06558539|DRUG|Standard Medication Therapy|Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
214255109|NCT06331026|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
214255110|NCT06331026|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
214255111|NCT02414672|BEHAVIORAL|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
214255112|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
214255113|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
214255114|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
214255115|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
214255116|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
214255117|NCT00263276|DRUG|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
214255118|NCT00263276|DRUG|metformin|Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
214255119|NCT02919098|BEHAVIORAL|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
214255120|NCT02919098|BEHAVIORAL|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
214255121|NCT00674973|DRUG|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
214255122|NCT00674973|DRUG|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
214255123|NCT00763048|DRUG|Fluoride|Brush twice daily for 6 weeks
214255124|NCT00763048|DRUG|Fluoride, triclosan|Brush twice daily
214255125|NCT04824183|OTHER|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
214255126|NCT02602847|BIOLOGICAL|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
214255127|NCT04766827|DRUG|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
214255128|NCT02640040|DEVICE|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
214255129|NCT02640040|DEVICE|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
214255130|NCT02640040|PROCEDURE|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
214255131|NCT02136108|OTHER|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
214255132|NCT02136108|OTHER|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
214255133|NCT01002482|DEVICE|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
214255134|NCT01002482|DEVICE|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
214255135|NCT06337422|DRUG|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule
214255136|NCT05318339|DRUG|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
214255137|NCT05073640|DRUG|Oxopurin|Subjects will receive two capsules per day.
214255138|NCT04378946|BEHAVIORAL|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
214255139|NCT04378946|DEVICE|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
214255140|NCT04378946|DEVICE|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
214255141|NCT04378946|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
214255142|NCT04378946|DIAGNOSTIC_TEST|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
214255143|NCT00315159|PROCEDURE|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
214255144|NCT04105829|OTHER|Bond-a braid|Stainless steel lingual retainer application
214255145|NCT04105829|OTHER|EverStick-Ortho|Fiber reinforced lingual retainer
214255146|NCT04105829|OTHER|Ribbond|Fiber reinforced lingual retainer
214255147|NCT05272449|DEVICE|Sleep apnea diagnosis|Split-night
214255148|NCT03861611|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
214255149|NCT03861611|DRUG|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
214255150|NCT03861611|DRUG|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
214255151|NCT03861611|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
214255152|NCT02946320|DEVICE|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
214255153|NCT02946320|DEVICE|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
214255154|NCT02946320|DEVICE|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
214255155|NCT05108922|DRUG|Donanemab|Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
214255156|NCT05108922|DRUG|Aducanumab|Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
214255157|NCT00796185|DRUG|Paliperidone ER|
215031463|NCT05006755|COMBINATION_PRODUCT|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
215031464|NCT05006755|COMBINATION_PRODUCT|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
214255158|NCT00954304|DRUG|HM30181AK 1mg|HM30181AK 1mg tablet
214255159|NCT00954304|DRUG|HM30181AK 5mg|HM30181AK 5mg tablet
214255160|NCT00954304|DRUG|HM30181AK 15mg|HM30181AK 15mg tablet
214255161|NCT00954304|DRUG|HM30181AK 60mg|HM30181AK 60mg tablet
214255162|NCT00954304|DRUG|Loperamide 2mg|Loperamide 2mg capsule
214255163|NCT05536479|PROCEDURE|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
214255164|NCT05536479|PROCEDURE|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
214255165|NCT05036369|DEVICE|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
214255166|NCT05036369|DEVICE|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
214255167|NCT00604305|DEVICE|Acrysof|Monofocal IOL
214255168|NCT00604305|DEVICE|Acuity's AIOL|Accommodating IOL
214255169|NCT00051389|DRUG|Fosinopril|
214255170|NCT01039974|DRUG|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
214255171|NCT01039974|DRUG|Ketoconazole|400 mg
214255172|NCT04766710|OTHER|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
214255173|NCT04766710|OTHER|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
214255174|NCT03637023|BEHAVIORAL|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
214255175|NCT03637023|BEHAVIORAL|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
214255176|NCT03084731|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
214255177|NCT00000842|DRUG|Nerve Growth Factor, Recombinant Human|
214255178|NCT02599896|BIOLOGICAL|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
214255179|NCT02599896|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
214255180|NCT06418893|DRUG|Target control infusion propofol|target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
214255181|NCT06418893|DRUG|Inhalational isoflurane|Inhalational Isoflurane at concentration 1-2%
214255182|NCT05522387|DRUG|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
214255183|NCT00664469|DRUG|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
214255184|NCT00664469|DRUG|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
214255185|NCT00664469|DRUG|Comparator: Atorvastatin|Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
214255186|NCT00664469|DRUG|Comparator: Rosuvastatin|Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
214255187|NCT01032902|DEVICE|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
214255188|NCT04925271|DEVICE|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
214255189|NCT04925271|DEVICE|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
214255190|NCT00426231|BEHAVIORAL|Navigation by a health worker|Help provided by health worker to navigate medication access programs
214255191|NCT00426231|BEHAVIORAL|Information control|Information about medication access programs provided to the participant and their healthcare provider
214255192|NCT00000862|DRUG|Zidovudine|
214255193|NCT00446342|DRUG|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
214255194|NCT00185991|DRUG|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
214255195|NCT01795638|DRUG|Sodium chloride|
214255196|NCT01795638|DRUG|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
214255197|NCT04012918|DRUG|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
214255198|NCT04012918|DRUG|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
214255199|NCT01799031|OTHER|internet-based intervention|Receive access to the WISE web-based educational intervention
214255200|NCT01799031|PROCEDURE|management of therapy complications|Receive standard of care
214255201|NCT01799031|OTHER|educational intervention|Receive access to the WISE web-based educational intervention
214255202|NCT01799031|OTHER|questionnaire administration|Ancillary studies
214255203|NCT01799031|PROCEDURE|quality-of-life assessment|Ancillary studies
214255204|NCT05970718|DRUG|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
214255205|NCT05970718|DRUG|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
214255206|NCT06008158|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI
214255207|NCT01655680|DRUG|ABT-126|ABT-126 Middle Dose
214255208|NCT01655680|DRUG|ABT-126|ABT-126 Low Dose
214255209|NCT01655680|DRUG|ABT-126|ABT-126 High Dose
214255210|NCT01655680|DRUG|Placebo|Placebo
214255211|NCT02778971|DRUG|[18F]Flutemetamol|amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
214255212|NCT04776031|DEVICE|R:GEN Laser System|Laser Treatment
214255213|NCT00542568|BIOLOGICAL|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
214255214|NCT06085794|PROCEDURE|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
214255215|NCT06085794|PROCEDURE|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
214255216|NCT00006363|DRUG|cytarabine|Given IV
214255217|NCT00006363|DRUG|daunorubicin hydrochloride|Given IV
214255218|NCT00006363|DRUG|etoposide|Given IV
214255219|NCT00006363|DRUG|valspodar|Given IV
214255220|NCT00006363|BIOLOGICAL|filgrastim|Given SC
214255221|NCT00006363|DRUG|busulfan|Given orally
214255222|NCT00006363|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
214255223|NCT00006363|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous PBSCT
214255224|NCT00006363|BIOLOGICAL|aldesleukin|Given SC
214255225|NCT00006363|OTHER|clinical observation|Undergo clinical observation
214255226|NCT00006363|OTHER|pharmacological study|Correlative studies
214255227|NCT02047149|DRUG|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
214255228|NCT02047149|DRUG|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
214255229|NCT02047149|DRUG|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
214255230|NCT02047149|DRUG|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
214255231|NCT03061097|BIOLOGICAL|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
214255232|NCT03061097|OTHER|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
214255233|NCT01297998|DRUG|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
214255234|NCT02469207|OTHER|Removal of tissue post-mortem|
214255235|NCT05410015|OTHER|Normal clinical treatment without intervention|Normal clinical treatment without intervention
214255236|NCT05454904|BEHAVIORAL|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) \<3 teaspoons/day of olive or Canola oil and \<3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
214255237|NCT05454904|BEHAVIORAL|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (\>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or \>3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) \>2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (\<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) \<1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and \<4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
214255238|NCT05454904|BEHAVIORAL|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
214255239|NCT03250429|PROCEDURE|Sinus surgery|Standard Clinical Sinus Surgery
214255240|NCT00032942|DRUG|Lofexidine|
214255241|NCT05803629|DIAGNOSTIC_TEST|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
214255242|NCT05803629|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
214255243|NCT00610623|DRUG|azithromycin|300 mg/day, IV from day 1 to 20
214255244|NCT00610623|DRUG|placebo|once per day, IV from day 1 to 20
214255245|NCT05712876|DRUG|CK-0045|Interleukin-22 agonist
214255246|NCT05712876|DRUG|Placebo|Matching placebo
214255247|NCT00004920|DRUG|cisplatin|
214255248|NCT00004920|DRUG|raltitrexed|
214255249|NCT04877743|OTHER|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
214255250|NCT02746068|DRUG|AXS-02|
214255251|NCT02746068|DRUG|Placebo|
214255252|NCT02436252|DRUG|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
214255253|NCT06174064|DEVICE|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
214255254|NCT06174064|DEVICE|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
214255255|NCT03911713|DRUG|VX-561|VX-561 tablets for oral administration.
214255256|NCT03911713|DRUG|IVA|150-mg film-coated tablet for oral administration.
214255257|NCT03911713|DRUG|Placebo|Placebo matched to IVA.
214255258|NCT03911713|DRUG|Placebo|Placebos matched to VX-561.
214255259|NCT02616419|DEVICE|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
214255260|NCT02616419|DRUG|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
214255261|NCT03180697|DIAGNOSTIC_TEST|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
214255262|NCT01690026|BEHAVIORAL|Motivation interviewing based brief intervention|
214255263|NCT01690026|BEHAVIORAL|Standard Intervention|
214255264|NCT02889692|DRUG|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
214255265|NCT02889692|DRUG|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
214255266|NCT02889692|DRUG|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
214255267|NCT02889692|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
214255268|NCT02889692|DRUG|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
214255269|NCT02889692|DRUG|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
214255270|NCT02889692|DRUG|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
214255271|NCT02437513|DEVICE|NewBreez|Intralaryngeal prosthesis to protect the airways
214255272|NCT03054753|BEHAVIORAL|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
214255273|NCT05432141|BIOLOGICAL|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
214255274|NCT05432141|BIOLOGICAL|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
214255275|NCT03956134|DRUG|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
214255276|NCT03956134|DRUG|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
214255277|NCT03956134|DRUG|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
214255278|NCT06496464|BEHAVIORAL|Intervention|"Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices."
214255279|NCT03802812|DEVICE|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
214255280|NCT00697359|DEVICE|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
214255281|NCT00011973|DRUG|fenretinide|
214255282|NCT00422097|DRUG|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255283|NCT00422097|DRUG|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255284|NCT00422097|DRUG|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255285|NCT00422097|DRUG|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255286|NCT00422097|DRUG|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255287|NCT00422097|DRUG|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
214255288|NCT00422097|DRUG|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
214255289|NCT00422097|DRUG|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
214255290|NCT03931824|OTHER|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
214255291|NCT03931824|OTHER|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
214255292|NCT05504473|DEVICE|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
214255293|NCT02360995|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
214255294|NCT02360995|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
214255295|NCT02360995|DRUG|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
214255296|NCT02360995|DRUG|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
214255297|NCT02360995|DRUG|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
214255298|NCT03974360|DRUG|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
214255299|NCT02680509|PROCEDURE|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
214255300|NCT04171154|BEHAVIORAL|Expectation|writing task
214255301|NCT04171154|BEHAVIORAL|Acceptance|listening
214255302|NCT02970916|DRUG|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
214255303|NCT00820352|DRUG|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
214255304|NCT00820352|DRUG|placebo|placebo twice a day for 12 weeks
214255305|NCT06557109|OTHER|Popular Music|A funky D mix version of a popular Turkish song
214255306|NCT06427824|OTHER|Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)|An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
214255307|NCT06427824|OTHER|Geriatric Service/ Discharge Planning|A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.
214255308|NCT06427824|OTHER|Questionnaires|These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
214255309|NCT04764487|DEVICE|KidneyPRO|Web-application for symptoms assessment
214255310|NCT04764487|OTHER|standard follow-up|usual follow-up
214255311|NCT06199778|BEHAVIORAL|Rehabilitation therapy|"1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers."
214255312|NCT06199778|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
214255313|NCT06199778|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
214255314|NCT06199778|DRUG|Reserpine|Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
214255315|NCT06199778|DRUG|Levofloxacin|The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
214255316|NCT02536651|PROCEDURE|Ankle surgery|Plastic or orthopedic surgery of the ankle
214255317|NCT00887406|DRUG|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
214255318|NCT00887406|DRUG|GSK961081 3mcg SD|single dose delivered via nebulsier
214255319|NCT00887406|DRUG|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
214255320|NCT00887406|DRUG|Placebo SD|single dose via nebuliser
214255321|NCT00887406|DRUG|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
214255322|NCT00887406|DRUG|GSK961081 200mcg SD|single dose via nebuliser
214255323|NCT00887406|DRUG|GSK961081 300mcg SD|single dose via nebuliser
215031465|NCT05295472|BEHAVIORAL|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
215031466|NCT05295472|BEHAVIORAL|Vector|A computer game focusing on children's development of mathematic skills
214255324|NCT00887406|DRUG|GSK961081 100mcg RD|repeat dose via nebuliser
214255325|NCT00887406|DRUG|GSK961081 300mcg RD|repeat dose vai nebuliser
214255326|NCT00887406|DRUG|Placebo RD|repeat dose via nebuliser
214255327|NCT03728530|OTHER|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
214255328|NCT01554020|DIETARY_SUPPLEMENT|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
214255329|NCT01554020|DIETARY_SUPPLEMENT|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
214255330|NCT02020187|OTHER|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
215031467|NCT05295472|BEHAVIORAL|Usual schooling|No GL or Math computer games, only the usual schooling
214255331|NCT01851460|DEVICE|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
214255332|NCT02395666|DRUG|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
214255333|NCT02611960|BIOLOGICAL|Pembrolizumab|IV infusion
214255334|NCT02611960|DRUG|Capecitabine|oral tablet
214255335|NCT02611960|DRUG|Gemcitabine|IV infusion
214255336|NCT02611960|DRUG|Docetaxel|IV infusion
214255337|NCT00805454|DRUG|OPC-34712|Single oral dose, 0.5 to 25 mg
214255338|NCT00994929|BIOLOGICAL|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
214255339|NCT03468829|BIOLOGICAL|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
214255340|NCT03468829|BIOLOGICAL|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
214255341|NCT03468829|BIOLOGICAL|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
214255342|NCT01238185|DRUG|acetylsalicylic acid|
214255343|NCT01238185|GENETIC|gene expression analysis|
214255344|NCT01238185|GENETIC|protein expression analysis|
214255345|NCT01238185|OTHER|laboratory biomarker analysis|
214255346|NCT01238185|OTHER|questionnaire administration|
214255347|NCT01238185|PROCEDURE|biopsy|
214255348|NCT04839146|BIOLOGICAL|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
214255349|NCT03570944|PROCEDURE|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
214255350|NCT05136352|PROCEDURE|adductor canal block|loco-regional anesthesia using adductor canal block
214255351|NCT05136352|PROCEDURE|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
214255352|NCT03872323|PROCEDURE|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
214255353|NCT03872323|PROCEDURE|Open surgery|The arteries injuries are repaired by open surgical operation.
214255354|NCT03798847|DEVICE|Journey II XR TKA|Journey II XR Total Knee System
214255355|NCT05270122|DEVICE|Mechanical thrombectomy with ThrombX Retriever|Revascularization
214255356|NCT02469740|DRUG|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
214255357|NCT02469740|DRUG|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
214255358|NCT06192784|PROCEDURE|DEB-TACE|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
214255359|NCT06192784|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
214255360|NCT01340547|DRUG|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
214255361|NCT01340547|DRUG|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
214255362|NCT05351502|DRUG|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
214255363|NCT05351502|DRUG|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
214255364|NCT05351502|DRUG|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
214255365|NCT05351502|DRUG|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
214255366|NCT05593133|OTHER|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
214255367|NCT05593133|OTHER|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
214255368|NCT00016159|BIOLOGICAL|filgrastim|
214255369|NCT00016159|BIOLOGICAL|lintuzumab|
214255370|NCT00016159|DRUG|arsenic trioxide|
214255371|NCT00016159|DRUG|idarubicin|
214255372|NCT00016159|DRUG|tretinoin|
214255373|NCT03030807|DIAGNOSTIC_TEST|Right heart catheterization (in case of suspected PH)|
214255374|NCT03470961|DRUG|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
214255375|NCT03470961|DRUG|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
214255376|NCT04429048|DEVICE|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
214255377|NCT04429048|DEVICE|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
214255378|NCT04123275|OTHER|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
214255379|NCT01409434|DRUG|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
214255380|NCT01727401|DRUG|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
214255381|NCT05267288|DRUG|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
214255382|NCT03189485|DRUG|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
214255383|NCT05264415|BEHAVIORAL|Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)|Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
214255384|NCT05264415|OTHER|Parenting Education Website|A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
214255385|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
214255386|NCT05672121|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
214255387|NCT00002895|DRUG|chemotherapy|
214255388|NCT00173888|DRUG|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
214255389|NCT00173888|DRUG|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
214255390|NCT03225742|DIAGNOSTIC_TEST|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
214255391|NCT05061966|BEHAVIORAL|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
214255392|NCT05061966|BEHAVIORAL|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
214255393|NCT02213042|DRUG|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
214255394|NCT02213042|BIOLOGICAL|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
214255395|NCT02213042|DRUG|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
214255396|NCT01562158|PROCEDURE|standard therapy|Standard treatment of bleeding
214255397|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
214255398|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
214255399|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
214255400|NCT01562158|DRUG|placebo|Placebo
214255401|NCT02685514|DEVICE|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
214255402|NCT01554085|DRUG|ALS-002158|ALS-002158
214255403|NCT01554085|DRUG|Placebo|placebo
214255404|NCT01442454|OTHER|chronic pancreatitis|No intervention, subjects followed through surgery
214255405|NCT04402918|DIAGNOSTIC_TEST|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
214255406|NCT05630755|DRUG|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
214255407|NCT05630755|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
214255408|NCT05630755|DRUG|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
214255409|NCT05630755|DRUG|Placebo to DOR/ISL|0 mg oral tablets once daily
214255410|NCT05718726|OTHER|Questionnaire, interview or observation study|Questionnaire administered by telephone
214255411|NCT04644003|DRUG|STP1|STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
214255412|NCT04644003|DRUG|Placebo|Placebo medication (capsule and tablet) identical in appearance to active medication
214255413|NCT06437353|DRUG|Paclitaxel|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
214255414|NCT01265251|DEVICE|Computerized neuropsychological test|Computerized neuropsychological test battery.
214255415|NCT01265251|OTHER|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
214255416|NCT04763928|DRUG|Venetoclax+Decitabine|"Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes."
214255417|NCT01969643|DRUG|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
214255418|NCT01969643|DRUG|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
214255419|NCT05080127|COMBINATION_PRODUCT|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
214255420|NCT05385185|DRUG|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
214255421|NCT01146275|RADIATION|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
214255422|NCT03761667|OTHER|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
214255423|NCT05555771|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
214255424|NCT05555771|BEHAVIORAL|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
214255425|NCT00436774|PROCEDURE|assessment of therapy complications|
214255426|NCT00436774|PROCEDURE|quality-of-life assessment|
214255427|NCT06556784|BEHAVIORAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
214255428|NCT02224092|DIETARY_SUPPLEMENT|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
214255429|NCT00002665|DRUG|asparaginase|10,000 units/d IV or IM 15 - 24
214255430|NCT00002665|DRUG|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
214255431|NCT00002665|DRUG|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
214255432|NCT00002665|DRUG|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
214255433|NCT00002665|DRUG|dexamethasone|main: 10 mg/m2/day PO 1 - 28
214255434|NCT00002665|DRUG|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
214255435|NCT00002665|DRUG|etoposide|60 mg/kg based on ideal body weight day -3
214255436|NCT00002665|DRUG|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
214255437|NCT00002665|DRUG|mercaptopurine|con: 60 mg/m2 PO 1 - 28
214255438|NCT00002665|DRUG|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
214255439|NCT00002665|DRUG|prednisone|"ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
214653294|NCT04274439|OTHER|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
214255440|NCT00002665|DRUG|thioguanine|main: 60 mg/m2/day PO 1 - 14
214255441|NCT00002665|DRUG|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
214255442|NCT00002665|PROCEDURE|allogeneic bone marrow transplantation|day 0
214255443|NCT00002665|RADIATION|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
214255444|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the power arm will be used for canine retraction.
214255445|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the canine bracket will be used for canine retraction.
214255446|NCT05532787|OTHER|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
214255447|NCT04396665|BEHAVIORAL|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
214255448|NCT00121264|DRUG|sorafenib tosylate|Given orally
214255449|NCT00121264|DRUG|tanespimycin|Given IV
214255450|NCT00121264|OTHER|laboratory biomarker analysis|Correlative studies
214255451|NCT00121264|OTHER|pharmacological study|Correlative studies
214255452|NCT00121264|PROCEDURE|magnetic resonance imaging|Correlative studies
214255453|NCT01395862|DRUG|Salmeterol and Fluticasone|
214255454|NCT02015585|PROCEDURE|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
214255455|NCT02015585|PROCEDURE|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
214255456|NCT02015585|PROCEDURE|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
214255457|NCT03714802|PROCEDURE|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
214255458|NCT03714802|PROCEDURE|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
214255459|NCT02126371|DRUG|LEO32731|
214255460|NCT01543971|DRUG|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
214255461|NCT01543971|DRUG|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
214255462|NCT03918889|DRUG|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
214255463|NCT03918889|DRUG|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
214255464|NCT00777205|BEHAVIORAL|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
214255465|NCT00777205|BEHAVIORAL|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
214255466|NCT04298372|DRUG|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
214255467|NCT04835519|BIOLOGICAL|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
214255468|NCT00630474|DRUG|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
214255469|NCT04674579|DEVICE|MRI|magnetic resonance imaging
214255470|NCT04240470|PROCEDURE|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
214255471|NCT02116218|PROCEDURE|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
214255472|NCT02116218|PROCEDURE|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
214255473|NCT02737280|DEVICE|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
214255474|NCT02737280|DEVICE|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
214255475|NCT03388515|BIOLOGICAL|SSS11|IV infusion for 60 min.
214255476|NCT03388515|OTHER|placebo|IV infusion for 60 min.
214255477|NCT00145171|DRUG|apomorphine HCl injection|
214255478|NCT02080910|BEHAVIORAL|Psychoeducation|
214255479|NCT01287078|DRUG|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
214255480|NCT01354067|BEHAVIORAL|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
214255481|NCT01354067|BEHAVIORAL|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
214255482|NCT02907580|BEHAVIORAL|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
214255483|NCT02907580|BEHAVIORAL|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
214255484|NCT04537260|BEHAVIORAL|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
214255485|NCT02138422|BIOLOGICAL|Xilonix|
214255486|NCT02138422|BIOLOGICAL|Placebo|
214255487|NCT01236014|DRUG|Eltrombopag|Eltrombopag \& standard of care
214255488|NCT01236014|DRUG|Romiplostim|Romiplostim \& standard of care
214255489|NCT01236014|DRUG|Placebo|Placebo \& standard of care
214255490|NCT04923815|DEVICE|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
214255491|NCT03053271|DRUG|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
214255492|NCT03053271|DRUG|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
214255493|NCT03342014|DEVICE|Ultrasound|3DPD and UAD acquisitions (10 min)
214255494|NCT03342014|BIOLOGICAL|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
214255495|NCT06150755|PROCEDURE|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
214255496|NCT06150755|PROCEDURE|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
214255497|NCT00557427|DRUG|hypericum|250mg tablets twice daily for 8 weeks
214255498|NCT00557427|DRUG|fluoxetine|20mg - 40mg daily for 8 weeks
214255499|NCT04064385|DEVICE|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
214255500|NCT04647071|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
214255501|NCT04647071|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
214255502|NCT03830385|DRUG|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
214255503|NCT02155569|PROCEDURE|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
214255504|NCT02155569|PROCEDURE|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
214255505|NCT00600444|PROCEDURE|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
214255506|NCT00600444|PROCEDURE|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
214255507|NCT02045173|OTHER|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
214255508|NCT02045173|DEVICE|Polysomnography/polygraphy|1 night polysomnography/polygraphy
214255509|NCT04648709|DIAGNOSTIC_TEST|ELISPOT|measure of immune response by ELISPOT
214255510|NCT04648709|DIAGNOSTIC_TEST|QUANTIFERON|measure of immune response by QUANTIFERON
214255511|NCT06058403|DIETARY_SUPPLEMENT|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
214255512|NCT06058403|DIETARY_SUPPLEMENT|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
214255513|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
214255514|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
214255515|NCT00559936|DRUG|Topical Avastin 1%|Avastin (bevacizumab) 1%
214255516|NCT02331875|DRUG|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
214255517|NCT02331875|PROCEDURE|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
214255518|NCT02331875|RADIATION|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
214255519|NCT04137224|BIOLOGICAL|IgPro20|Human normal immunoglobulin for subcutaneous administration
214255520|NCT04137224|BIOLOGICAL|IgPro10|Human normal immunoglobulin for intravenous administration
214255521|NCT00414921|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
214255522|NCT00414921|DRUG|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
214255523|NCT00414921|OTHER|placebo|inactive substance
214255524|NCT01225887|DRUG|Nintedanib|Given PO
214255525|NCT01017471|PROCEDURE|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
214255526|NCT01669928|DRUG|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
214653295|NCT04274439|OTHER|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
214255527|NCT06136247|DIAGNOSTIC_TEST|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
214255528|NCT06136247|DIAGNOSTIC_TEST|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
214255529|NCT02439879|DRUG|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
214255530|NCT05342402|OTHER|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
214255531|NCT05342402|OTHER|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
214255532|NCT00004637|DRUG|Vitamin E|
214255533|NCT03843112|DRUG|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
214255534|NCT03843112|DRUG|Placebo - Cap|Vaginal supplements
214255535|NCT02098824|DRUG|Galantamine|Single administration of capsule containing 16 mg of Galantamine
214255536|NCT02098824|DRUG|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
214255537|NCT02098824|DRUG|Placebo|Single administration of capsule containing placebo
214255538|NCT03425513|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
214255539|NCT03425513|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
214255540|NCT01417936|DRUG|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
214255541|NCT00925990|DRUG|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
214255542|NCT00925990|DRUG|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
214255543|NCT00925990|DRUG|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
214255544|NCT00679055|DRUG|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
214255545|NCT00679055|DRUG|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
214255546|NCT06637215|PROCEDURE|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
214255547|NCT06637215|PROCEDURE|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
214255548|NCT00835159|DRUG|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
214255549|NCT00835159|OTHER|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
214255550|NCT01270542|DRUG|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
214255551|NCT01270542|OTHER|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
214255552|NCT05266534|DRUG|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
214255553|NCT05266534|DRUG|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
214255554|NCT05266534|DRUG|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
214255555|NCT04102670|DEVICE|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
214255556|NCT04102670|DEVICE|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
214255557|NCT04102670|DEVICE|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
214255558|NCT04102670|DEVICE|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
214255559|NCT04102670|OTHER|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
214255560|NCT00810524|DRUG|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
214255561|NCT00810524|DRUG|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
214255562|NCT00810524|DRUG|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
214255563|NCT00810524|DRUG|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
214255564|NCT05880654|PROCEDURE|Scaling & root planning|Non Surgical periodontal therapy
214255565|NCT04348110|DIETARY_SUPPLEMENT|Placebo tablets|consume 2 tablets per day for 8 weeks
214255566|NCT04348110|DIETARY_SUPPLEMENT|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
214255567|NCT02080858|DRUG|Ticagrelor + Apixaban + ASA|
214255568|NCT02080858|DRUG|Ticagrelor + Apixaban|
214255569|NCT00935051|OTHER|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
214255570|NCT05392517|OTHER|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
214255571|NCT05392517|OTHER|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
214255572|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
214255573|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
214255574|NCT02595138|DRUG|Zoledronic acid|
214255575|NCT02124486|PROCEDURE|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
214255576|NCT02124486|BEHAVIORAL|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
214255577|NCT03767101|BEHAVIORAL|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
214255578|NCT05914922|OTHER|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
214255579|NCT03751644|OTHER|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
214255580|NCT06438939|OTHER|Biopsy for diagnostical purposes|Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
214255581|NCT00661973|DRUG|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
214255582|NCT04623307|DIAGNOSTIC_TEST|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
214255583|NCT03839082|OTHER|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
214255584|NCT03839082|OTHER|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
214255585|NCT06005597|COMBINATION_PRODUCT|Combination Therapy|tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
214255586|NCT06005597|DRUG|Monotherapy obicetrapib|tablet; 10mg obicetrapib
214255587|NCT06005597|DRUG|Monotherapy ezetimibe|capsule; 10mg ezetimibe
214255588|NCT06005597|OTHER|Combination Therapy placebo|tablet; no active ingredient
214255589|NCT06005597|OTHER|Obicetrapib Placebo|tablet; no active ingredient
214255590|NCT06005597|OTHER|Ezetimibe Placebo|capsule; no active ingredient
214255591|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
214255592|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
214255593|NCT01822678|DRUG|Placebo|Placebo
214255594|NCT01200862|DRUG|Investigational new drug company code: BGS649|
214255595|NCT01200862|DRUG|Placebo|
214255596|NCT04150380|BIOLOGICAL|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
214255597|NCT04150380|OTHER|Placebo|See arm descriptions
214255598|NCT00943124|DRUG|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
214255599|NCT00943124|DRUG|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
214255600|NCT00943124|DRUG|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
214255601|NCT02034071|DRUG|DCCR|
214255602|NCT02034071|DRUG|Placebo|
214255603|NCT01509508|DRUG|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
214653296|NCT03204630|DIETARY_SUPPLEMENT|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
214653297|NCT03204630|DIETARY_SUPPLEMENT|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
214653298|NCT03204630|OTHER|Control|Standard infant formula
214255604|NCT01509508|OTHER|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
214255605|NCT04895540|DIAGNOSTIC_TEST|ECG|All study subjects will undergo ECG recording.
214255606|NCT04895540|DIAGNOSTIC_TEST|Echocardiography|All study subjects will undergo transthoracic echocardiography
214255607|NCT04895540|DIAGNOSTIC_TEST|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
214255608|NCT04895540|DIAGNOSTIC_TEST|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
214255609|NCT04895540|DIAGNOSTIC_TEST|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
214255610|NCT04895540|GENETIC|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
214255611|NCT05090462|DEVICE|PICO dressing|Negative Pressure Wound Therapy device
214255612|NCT02255578|DEVICE|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
214255613|NCT02255578|DRUG|clomiphene citrate treatment|
214255614|NCT01726660|DEVICE|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
214255615|NCT03071146|DEVICE|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
214255616|NCT01355029|BEHAVIORAL|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
214255617|NCT03783247|PROCEDURE|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
214255618|NCT03783247|PROCEDURE|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
214255619|NCT02686281|DRUG|GMC-252-L-Lysine|
214255620|NCT02686281|OTHER|Placebo|
214255621|NCT03150667|DRUG|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
214255622|NCT03150667|DRUG|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
214255623|NCT00179127|DRUG|glargine|0.3u/kg of glargine, subcutaneously, once
214255624|NCT00179127|DRUG|saline|0.3u/kg of saline, subcutaneously, once
214255625|NCT03961074|OTHER|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
214255626|NCT00462371|DEVICE|Insulin pump (CSII)|
214255627|NCT03522753|DEVICE|Metal skin staples|Routine closure methods/material for surgical wounds
214255628|NCT03522753|DEVICE|Nylon sutures|Routine closure methods/material for surgical wounds
214255629|NCT02746003|OTHER|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
214255630|NCT01916967|DRUG|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
214255631|NCT01916967|DRUG|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
214255632|NCT03486431|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
214255633|NCT01912963|DRUG|Pertuzumab|
214255634|NCT01912963|DRUG|Trastuzumab|
214255635|NCT01912963|DRUG|eribulin|
214255636|NCT00817583|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
214255637|NCT00817583|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
214255638|NCT04167722|PROCEDURE|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
214255639|NCT03005171|DRUG|Bupivacaine|Thoracic epidural bupivacaine infusion
214255640|NCT03005171|DRUG|Lidocaine|Intravenous lidocaine infusion
214255641|NCT03616171|BEHAVIORAL|SLEEP-Extend intervention|"1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
214255642|NCT03616171|OTHER|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
214255643|NCT01702571|DRUG|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
214255644|NCT05030246|DRUG|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
214255645|NCT01295229|PROCEDURE|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
214255646|NCT01295229|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
214255647|NCT02269046|OTHER|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
214255648|NCT02269046|DRUG|Simvastatin|10mg/d,p.o,12 weeks.
214255649|NCT02269046|OTHER|Therapeutic Lifestyle Change|"* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity"
214255650|NCT04160728|OTHER|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
214255651|NCT04160728|OTHER|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
214255652|NCT04160728|OTHER|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
214255653|NCT04160728|OTHER|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
214255654|NCT04160728|OTHER|Business as usual scenario|No interference with the usual work day of the participants
214255655|NCT04160728|OTHER|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
214255656|NCT01721473|OTHER|positron emission tomography scan|2-FA positron emission tomography scan
214255657|NCT01241773|DRUG|raltegravir|One 400 mg tablet twice daily for 7 days
214255658|NCT01241773|DRUG|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
214255659|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 7 days
214255660|NCT01241773|DRUG|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
214255661|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 14 days
214255662|NCT01241773|DRUG|efavirenz|One 600 mg tablet once daily for 14 days
214255663|NCT01977937|DRUG|Gabapentin 250mg/5mL NDC:59762-5025-01|
214255664|NCT01977937|DRUG|Simple Syrup|
214255665|NCT01094756|DIETARY_SUPPLEMENT|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
214255666|NCT03144531|BEHAVIORAL|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
214255667|NCT00390598|DRUG|PEG (solution given 4 L)|
214255668|NCT00390598|DRUG|senna glycoside 36 mg and PEG (solution given 2 L)|
214255669|NCT00915356|DRUG|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
214255670|NCT00915356|DRUG|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
214255671|NCT01302379|DRUG|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
214255672|NCT01302379|DRUG|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
214255673|NCT01302379|BEHAVIORAL|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
214255674|NCT01302379|BEHAVIORAL|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
214255675|NCT03875820|DRUG|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
214255676|NCT03875820|DRUG|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
214255677|NCT01699932|DRUG|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
214255678|NCT01438073|DRUG|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
214255679|NCT01438073|DRUG|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
214255680|NCT01370668|BEHAVIORAL|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
214255681|NCT01370668|BEHAVIORAL|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
214255682|NCT01370668|BEHAVIORAL|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
214255683|NCT02595359|DRUG|Moxifloxacin|Moxifloxacin intracameral
214255684|NCT02101203|DRUG|Placebo|
214255685|NCT02101203|DRUG|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
214255686|NCT05691907|DEVICE|THE therapy|"THE therapy consisting of:~* Heating Pad~* Interferential Therapy"
214255687|NCT05691907|PROCEDURE|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
214255688|NCT05691907|PROCEDURE|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
214255689|NCT02386969|DEVICE|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
214255690|NCT02386969|DEVICE|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
214255691|NCT00725504|DRUG|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
214255692|NCT02001181|DRUG|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
214255693|NCT02001181|DRUG|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
214255694|NCT00292318|BEHAVIORAL|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
214255695|NCT00292318|BEHAVIORAL|control group|Medical counseling and ano-sphinctal exercises.
214255696|NCT05226273|OTHER|no intervention|no intervention
214255697|NCT00756015|OTHER|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
214255698|NCT00756015|OTHER|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
214255699|NCT05255029|DEVICE|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
214255700|NCT00013468|PROCEDURE|Tinnitus|
214653299|NCT03224286|DEVICE|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
214653300|NCT02372617|PROCEDURE|periacetabular osteotomy|
214653301|NCT05305716|OTHER|Online Pilates Training|The group that received telerehabilitation and telerehabilitation-based pilates training.
214653302|NCT05305716|OTHER|Control group|The group who received breathing and relaxation exercises with a home program.
214255701|NCT06359431|DEVICE|Novel Smart Speculum|"The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
214255702|NCT06359431|DEVICE|Standard speculum|"he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
214255703|NCT05080907|OTHER|Observational|Subjects for observational study Various conditions \& healthy subjects
214255704|NCT05616715|DEVICE|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
214255705|NCT05616715|OTHER|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
214255706|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
214255707|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
214255708|NCT01278160|DRUG|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
214255709|NCT00497276|PROCEDURE|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
214255710|NCT00806338|DRUG|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
214255711|NCT00806338|DRUG|Placebo|
214255712|NCT04866329|OTHER|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
214255713|NCT04866329|OTHER|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
214255714|NCT04866329|OTHER|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
214255715|NCT03084510|DEVICE|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
214255716|NCT01502280|DRUG|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
214255717|NCT01502280|DRUG|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
214255718|NCT00201331|DRUG|leucovorin+5-FU|
214255719|NCT02819518|BIOLOGICAL|Pembrolizumab|IV infusion
214255720|NCT02819518|DRUG|Nab-paclitaxel|IV infusion
214255721|NCT02819518|DRUG|Paclitaxel|IV infusion
214255722|NCT02819518|DRUG|Gemcitabine|IV infusion
214255723|NCT02819518|DRUG|Carboplatin|IV infusion
214255724|NCT02819518|DRUG|Normale Saline Solution|IV infusion
214255725|NCT06191835|BEHAVIORAL|myCare Start|The service consists of 2 times 10-minutes semi-structured pharmaceutical interventions between community pharmacist and patient, tailored to the patient's needs, positioned as partner, during the first 6 weeks after treatment initiation.
214255726|NCT00603421|OTHER|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
214255727|NCT00603421|OTHER|treatment as usual|Treatment as usual
214255728|NCT00540098|DRUG|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
214255729|NCT00540098|DRUG|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
214255730|NCT00540098|DRUG|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
214255731|NCT00540098|DRUG|Placebo + relaxation|placebo pill once daily + regular relaxation training
214255732|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
214255733|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
214255734|NCT03442283|DIETARY_SUPPLEMENT|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
214255735|NCT03504670|PROCEDURE|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
214653303|NCT04701125|DEVICE|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
214653304|NCT04408456|DRUG|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
214653305|NCT04408456|OTHER|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
214255736|NCT03504670|PROCEDURE|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
214255737|NCT04539145|DEVICE|Chocolate PTA Balloon|Chocolate PTA Balloon
214255738|NCT04539145|DEVICE|conventional balloon angioplasty|conventional bal-loon angioplasty
214255739|NCT03540043|DRUG|Administration of Placebo|Botanical Drug Phase 2 clinical study
214255740|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
214255741|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
214255742|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
214255743|NCT03112590|BIOLOGICAL|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
214255744|NCT03112590|DRUG|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
214255745|NCT03112590|DRUG|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
214255746|NCT03112590|OTHER|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
214255747|NCT03112590|PROCEDURE|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
214255748|NCT02815774|DRUG|SP2086|all subjects were given SP2086 50mg only one time.
214255749|NCT05449522|DIETARY_SUPPLEMENT|Vitamin D|High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
214255750|NCT05449522|DIETARY_SUPPLEMENT|Placebo|Medium-chain triglyceride (MCT)
214255751|NCT04169100|DRUG|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
214255752|NCT02186366|OTHER|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
214255753|NCT02186366|DRUG|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
214255754|NCT03606395|DRUG|NV-5138|single ascending dose
214255755|NCT03606395|DRUG|Placebos|Placebo liquid solution to mimic NV-5138
214255756|NCT03979430|OTHER|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
214255757|NCT03280095|DRUG|co-codamol 15mg/500mg capsule|
214255758|NCT03280095|DRUG|co-codamol 30mg/500mg tablet|
214255759|NCT04568993|PROCEDURE|Proximal phalangeal level|Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
214255760|NCT04568993|DRUG|Volar to the MCP-joint|Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
214255761|NCT05589272|OTHER|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
214255762|NCT05589272|OTHER|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
214255763|NCT00843726|RADIATION|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
214255764|NCT00843726|RADIATION|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
214255765|NCT01863238|OTHER|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
214255766|NCT01863238|DRUG|Ivacaftor Exposed|
214255767|NCT01498328|DRUG|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
214255768|NCT01498328|DRUG|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
214255769|NCT01498328|DRUG|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
214255770|NCT04595604|PROCEDURE|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
214255771|NCT04595604|PROCEDURE|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
214653306|NCT01346930|DRUG|Macitentan|10 mg, tablet, once daily
214255772|NCT05603663|GENETIC|Informing study subjects about their high CVD polygenic risk score|During a visit, the family physician will announce the value of the subject's polygenic risk for CVD (either at the start or end of the trial, depending on the group) and discuss what it means, calculate the subject's overall risk for CVD using the Kardiokompass tool, advise the subject on weight loss and physical activity, and, if necessary, commence preventive treatment. Between visits, a mobile application will be utilized to collect data about the subjects' level of physical activity and body weight as well as to send reminders to the subjects every two weeks regarding exercise and healthy lifestyle choices.
214255773|NCT02134197|DRUG|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
214255774|NCT03161132|DRUG|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
214255775|NCT03161132|DRUG|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
214255776|NCT01880216|DRUG|Bemiparin sodium|subcutaneous application daily for 7±2 days
214255777|NCT01880216|DRUG|Enoxaparin sodium|subcutaneous for 7±2 days
214255778|NCT00406718|BEHAVIORAL|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
214255779|NCT00406718|BEHAVIORAL|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
214255780|NCT00406718|BEHAVIORAL|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
214255781|NCT06322979|PROCEDURE|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
214255782|NCT06322979|PROCEDURE|Premixed Bioceramic Putty|Apexification treatment was done with Premixed Bioceramic Putty (Well-Root™ PT)
214255783|NCT02765685|DEVICE|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
214255784|NCT02765685|OTHER|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
214255785|NCT05530031|PROCEDURE|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
214255786|NCT01837732|OTHER|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
214255787|NCT01837732|OTHER|Relational:|Relational: 10 mn verbal patient's centered exchanges
214255788|NCT05965726|DRUG|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
214255789|NCT05965726|DRUG|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
214255790|NCT05965726|DRUG|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
214255791|NCT06352060|OTHER|No intervention or administration will be performed due to the observational nature of the study|Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
214255792|NCT05433584|DRUG|Tirzepatide|Administered SC
214255793|NCT05433584|DRUG|Antihyperglycemic medication|As prescribed
214255794|NCT04187677|PROCEDURE|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
214255795|NCT04187677|OTHER|classical hand therapy|classical hand therapy
214255796|NCT05569473|PROCEDURE|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
214255797|NCT03602820|BIOLOGICAL|AAV2-hRPE65v2|
214255798|NCT01389271|DRUG|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
214255799|NCT02176343|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214255800|NCT04061473|DRUG|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
214255801|NCT04061473|DRUG|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
214255802|NCT04061473|OTHER|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
214255803|NCT00504036|DEVICE|inflatable intra-gastric balloon|inflatable intra-gastric balloon
214255804|NCT03007901|BEHAVIORAL|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
214255805|NCT06134271|DRUG|Rezvilutamide|Rezvilutamide 240mg qd
214255806|NCT06134271|DRUG|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
214255807|NCT06134271|DRUG|Continue previous treatment|Continue using the previous treatment regimen for treatment.
214255808|NCT02780609|DRUG|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
214255809|NCT02780609|DRUG|Melphalan|Melphalan 100 mg/m\^2 IV over 30-45 minutes.
214255810|NCT02780609|DRUG|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
214255811|NCT02780609|PROCEDURE|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
214255812|NCT02780609|DRUG|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
214255813|NCT02898116|DRUG|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
214255814|NCT02898116|DRUG|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
214255815|NCT01138943|DRUG|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
214255816|NCT01138943|DRUG|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
214255817|NCT05120661|OTHER|food product|a food product containing 50 gram carbohydrates
214255818|NCT02745210|DIAGNOSTIC_TEST|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
214255819|NCT03381105|DIAGNOSTIC_TEST|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
214255820|NCT02312271|OTHER|enteral formula|standard tube feeding formulas
214255821|NCT04179851|DIAGNOSTIC_TEST|Thermal imaging of neck veins|Thermal imaging of neck veins
214255822|NCT03636737|OTHER|pathology associated|list of pathology associated to Pyoderma gangrenosum
214255823|NCT04352231|DIETARY_SUPPLEMENT|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
214255824|NCT04352231|DIETARY_SUPPLEMENT|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
214255825|NCT04457219|DEVICE|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
214255826|NCT04457219|DEVICE|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
214255827|NCT04457219|DEVICE|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
214255828|NCT04457219|DEVICE|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
214255829|NCT00415571|DRUG|Fispemifene (once daily for 8 weeks)|
214255830|NCT04150029|DRUG|MBG453|Solution for intravenous infusion
214255831|NCT04150029|DRUG|Venetoclax|Tablet for oral administration
214255832|NCT04150029|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
214255833|NCT05353647|BIOLOGICAL|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
214255834|NCT04095195|RADIATION|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
214255835|NCT04095195|PROCEDURE|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
214255836|NCT05776316|BEHAVIORAL|Integrated Harm Reduction Intervention (IHRI)|8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.
214255837|NCT06211335|DRUG|Losartan|Given PO
214255838|NCT06211335|BIOLOGICAL|Pembrolizumab|Given IV
214255839|NCT06211335|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214255840|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
214255841|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
214255842|NCT05169567|DRUG|Abemaciclib|Administered orally.
214255843|NCT05169567|DRUG|Fulvestrant|Administered IM.
214255844|NCT05169567|DRUG|Placebo|Administered orally.
214255845|NCT01015131|RADIATION|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
214255846|NCT05430022|BEHAVIORAL|Autism-adapted Group Cognitive Behavioral Therapy|The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
214255847|NCT04140097|OTHER|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
214255848|NCT05725668|BEHAVIORAL|dual-task tai ji quan|dual-task tai ji quan training
214255849|NCT05725668|BEHAVIORAL|standard tai ji quan|standard tai ji quan training
214255850|NCT05725668|BEHAVIORAL|stretching|stretching exercise
214255851|NCT03029702|DRUG|Insulin|Insulin will be used for GDM treatment
214255852|NCT03029702|DRUG|Glyburide|Glyburide will be used for GDM treatment
214255853|NCT03029702|DRUG|Metformin|Metformin will be used for GDM treatment
214255854|NCT00777218|DRUG|propranolol|standard pediatric doses, based on body weight
214255855|NCT00777218|DRUG|zonisamide|standard pediatric dosages, based on body weight
214255856|NCT00777218|DRUG|topiramate|standard pediatric dosages, based on body weight
214255857|NCT02741388|DRUG|selinexor|
214255858|NCT02741388|DRUG|Rituximab|
214255859|NCT02741388|DRUG|Dexamethasone|
214255860|NCT02741388|DRUG|Oxaliplatin|
214255861|NCT02741388|DRUG|Cisplatin|
214255862|NCT02741388|DRUG|Cytarabine|
214255863|NCT02741388|DRUG|Gemcitabine|
214255864|NCT04208568|PROCEDURE|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
214255865|NCT02819661|DEVICE|SOMNOTOUCH RESP|Ventilatory effort recorder
214255866|NCT02819661|PROCEDURE|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
214255867|NCT02819661|DRUG|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
214255868|NCT06091787|DRUG|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
214255869|NCT06091787|OTHER|Standard Medical Treatment|Standard Medical Treatment
214255870|NCT00040261|DRUG|Memantine HCL|
214255871|NCT04081038|DIAGNOSTIC_TEST|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
214255872|NCT06404775|DRUG|mastalgia-oil, tamoxifen placebo|external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
214255873|NCT06404775|DRUG|mastalgia-oil placebo, tamoxifen|oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
214255874|NCT06666946|DEVICE|Electroacupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm), and SDZ-V EA apparatuses will be used. Participants in the EA group will receive acupuncture at bilateral ST36 and GB34. After sterilisation, sterile adhesive pads will be placed on bilateral ST36 and GB34, and acupuncture needles will be inserted through the adhesive pads approximately 20 to 30 mm into the skin. Following needle insertion, manual manipulation of needles will be performed on all needles to reach de qi (a composite of sensations including soreness, numbness, distention, heaviness, and other sensations). Then, paired electrodes from the EA apparatus will be attached transversely to the needle handles at bilateral ST36 and GB34. EA stimulation lasted for 30 minutes with a continuous wave of 10 Hz and a current intensity of 0.5 to 1 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 6 treatment sessions once daily for 6 consecutive days.
214255875|NCT06666946|DEVICE|Sham electroacupuncture|Non-insertive placebo needles (size 0.30 × 30 mm), and SDZ-V EA apparatuses will be used. Participants in the sham EA group will receive sham EA with a non-insertive placebo needle on sham acupoints. The sham ST36 point is located at 1 cun (≈20 mm) lateral to ST36, and the sham GB34 point is located at 1 cun (≈20mm) lateral to GB 34. Procedures, electrode placements, and other treatment settings will be the same as in the EA group but with no skin penetration, electricity output, or de qi.
214255876|NCT06512545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)"
214255877|NCT06306144|BEHAVIORAL|Psychoeducation|Arm 1 : Psychoeducation aims to inform patients about post-stroke cognitive impairment, teach them coping strategies to compensate for these difficulties, provide information on symptom recognition and management, and offer emotional and psychological support to help them meet the challenges associated with these potential cognitive impairments.
214255878|NCT06306144|BEHAVIORAL|Computerised Cognitive Stimulation|Arm 2 :Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician
214255879|NCT06306144|BEHAVIORAL|Usual Care|Arm 3 : No specific care.
214255880|NCT04956250|OTHER|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
214255881|NCT04956250|OTHER|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
214255882|NCT03237871|BEHAVIORAL|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
214255883|NCT05072886|DRUG|AT193|Topical applied to affected areas daily
214255884|NCT01334242|DRUG|Schedule A|Dosing 1 hour before breakfast
214255885|NCT01334242|DRUG|Schedule B|Dosing 0.5 hour before breakfast
214255886|NCT01334242|DRUG|Schedule C|Dosing immediately before breakfast
214255887|NCT01334242|DRUG|Schedule D|Dosing immediately before lunch
214255888|NCT01334242|DRUG|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
214255889|NCT03959228|DRUG|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
214255890|NCT05595382|BEHAVIORAL|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
214255891|NCT05595382|BEHAVIORAL|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
214255892|NCT06656312|DEVICE|Use ASUS EndoAim as an assistant software to perform colonoscopy|Use ASUS EndoAim as an assistant software to perform colonoscopy
214255893|NCT00043121|DRUG|oxaliplatin|Given IV
214255894|NCT00043121|DRUG|leucovorin calcium|Given IV
214255895|NCT00043121|DRUG|fluorouracil|Given IV
214255896|NCT00043121|DRUG|capecitabine|Given orally
214255897|NCT00043121|OTHER|pharmacological study|Correlative studies
214255898|NCT06825494|DRUG|LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
214255899|NCT06825494|DRUG|Tislelizumab+Oxaliplatin+Capecitabine|"Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1).~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
214255900|NCT06825494|DRUG|LM-108 injection 10mg/kg +penpulimab|"LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
214255901|NCT06825494|DRUG|LM-108 injection 600mg + penpulimab|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
214255902|NCT02422940|DRUG|dalfampridine-ER 7.5 mg|
214255903|NCT02422940|DRUG|dalfampridine-ER 10 mg|
214255904|NCT06486558|DRUG|HU6 450 mg Tablet|new 450 mg tablet test formulation
214255905|NCT06486558|DRUG|HU6 150 mg Capsules x 3 (Total dose = 450 mg)|150 mg capsule reference formulation (3 x 150 mg).
214255906|NCT06585982|DIETARY_SUPPLEMENT|Treatment|RILLUS is a synbiotic produced by Kalbe Farma
214255907|NCT06585982|DIETARY_SUPPLEMENT|Control|Placebo produced by Kalbe Farma
214255908|NCT06591286|DEVICE|RT-CGM|This group of patients will wear RT-CGM for blood glucose monitoring for three months.
214255909|NCT06591286|DEVICE|SMBG|This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.
214255910|NCT02942329|DRUG|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
214255911|NCT02942329|DRUG|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
214255912|NCT02216825|DIETARY_SUPPLEMENT|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
214255913|NCT02216825|DIETARY_SUPPLEMENT|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
214255914|NCT02445391|DRUG|Capecitabine|Given PO
214255915|NCT02445391|DRUG|Carboplatin|Given IV
214255916|NCT02445391|DRUG|Cisplatin|Given IV
214255917|NCT06608368|DRUG|Test Dentifrice (Sensodyne Repair and Protect Original Mint)|Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
214255918|NCT06608368|DRUG|Positive Control Dentifrice (Sensodyne Fresh Mint)|Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
214255919|NCT06608368|DRUG|Reference Dentifrice (Crest Cavity Protection Regular)|Dentifrice containing 1100 ppm fluoride as sodium fluoride.
214255920|NCT06587308|OTHER|Dorsal-Double-Layered 10% Circumferential Reduction (DD-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the DD-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
214653307|NCT06960473|DEVICE|Intravascular Ultrasound|In the IVUS group, the diameter of the reference vessel (the normal segment of the artery distal to the occlusion) is measured using Intravascular Ultrasound (IVUS). Based on the IVUS measurements, an appropriate balloon is selected to dilate the occluded segment.
214255921|NCT06587308|OTHER|Single-Layered 10% Circumferential Reduction (S-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
214255922|NCT06587308|OTHER|Single-Layered No Circumferential Reduction (S-0) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-0 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
214255923|NCT03722173|DRUG|Itraconazole|Oral solution
214255924|NCT03722173|DRUG|BI 894416|Tablet
214255925|NCT05928871|DRUG|Misoprostol 200mcg Tab|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
214255926|NCT05928871|DRUG|Misoprostol Pill|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
214255927|NCT01176344|DRUG|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
214255928|NCT01176344|DRUG|Placebo|Inert placebo capsules once monthly for 2 years.
214255929|NCT05024045|DRUG|LOXO-338|Oral
214255930|NCT05024045|DRUG|Pirtobrutinib|Oral
214255931|NCT06678698|DEVICE|Panel Effective Photobiomodulation Therapy|"Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs"
214255932|NCT06678698|DEVICE|Sham Panel Photobiomodulation Therapy|Use of common red lamp to perform the sham photobiomodulation for the panel group
214255933|NCT06678698|DEVICE|Modified ILIB Sham Photobiomodulation Therapy|ILIB Therapy device turned off for the sham ILIB therapy
214255934|NCT06678698|DEVICE|Modified ILIB Photobiomodulation Therapy|Common laser used in ILIB mode for modified ILIB therapy
214255935|NCT06677866|BEHAVIORAL|Cognitive behavioral therapy|"Cooperative Group Therapy (CGT) is a cognitive-behavioral group therapy based on the theoretical and practical principles of the Cooperative Parent-Mediated Therapy model \[Valeri et al., 2020\].~The goal of CGT is to promote the following core skills: Pragmatics, Executive Functions, and Cooperative Interactions. The CGT program consists of 15 sessions over a total duration of 6 months: 12 group therapy sessions with adolescents and 3 sessions with their parents. Each session focuses on a specific topic and lasts between 90 and 120 minutes.~The CGT therapist is a psychotherapist with a cognitive-behavioral orientation who utilizes evidence.-based strategies to enhance pragmatic, socio-conversational skills, cognitive flexibility, emotional regulation, and cooperative interactions. The CGT intervention is conducted by two cognitive-behavioral psychotherapists specialized respectively in the treatment of FXS and ASD."
214255936|NCT06677866|OTHER|Waiting List|The Waiting List (WL) is a control group in which participants who do not receive the experimental treatment are placed on a waiting list to receive the intervention after the active treatment group has completed it. In the case of the WL, the CGT intervention is carried out after at least 6 months to allow the patients in the first group to complete the treatment cycle. This approach enables a comparison between a group of treated patients and a group of patients who have not yet been treated, while still allowing the latter to access the treatment at a later stage.
214255937|NCT06675812|OTHER|Information intervention|The participant will receive information on what treatment that is offered in their municipal, how the help-seeking process goes (where they can be anonymous etc), and tailored information regarding the barriers that the participant has stated preventing him or her for seeking help today.
214255938|NCT06871046|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over 7 days
214255939|NCT06624449|BEHAVIORAL|Cold debriefing|Manipulation (experimental): The researcher assigned a cold debriefing (after one-day post-simulation) for undergraduate nursing students in the intervention group.
214255940|NCT06624449|BEHAVIORAL|Hot Debriefing|The control group received a hot debriefing (immediately after the simulation).
214255941|NCT06688851|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|A CBCT scan is performed before the surgical intervention.
214255942|NCT06688851|PROCEDURE|Cystostomy|Under local anesthesia, a full-thickness flap is prepared and cystostomy is performed.
214255943|NCT06688851|DIAGNOSTIC_TEST|Histology to confirm the initial diagnosis|A sample of the cyst lining is sent for histologic diagnosis.
214255944|NCT06688851|DEVICE|Patient Specific Implant|The PSI is fixed on the surface of the bone using osteosynthesis screws.
214255945|NCT06688851|PROCEDURE|Cyst decompression|The PSI enables the discharge of the cystic liquid into the oral cavity. The resulting decrease in cystic pressure induces bone healing. Patients are recalled monthly for controls and panoramic X-rays are performed to monitor the decompression.
214255946|NCT06688851|DIAGNOSTIC_TEST|CBCT|Post-operative CBCT is performed six months after cystostomy to assess whether the cyst volume has been sufficiently reduced for enucleation, minimizing the risk of damage to anatomical landmarks.
214255947|NCT06688851|PROCEDURE|Enucleation|Under local anesthesia a full-thickness flap is raised and the PSI is removed by unscrewing the osteosynthesis screws. The wall of the cyst is completely enucleated and the flap is sutured.
214255948|NCT06688851|DIAGNOSTIC_TEST|Histology performed on the entire lining of the cyst|The residual cyst wall is sent for histopathologic examination.
214255949|NCT06934707|BEHAVIORAL|Three meals a day|This group will follow a dietary prescription consisting of three meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 30% for breakfast, 40% for lunch, and 30% for dinner, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 15-20% of the total carbohydrate intake, 7-10% of the total protein intake, and 10% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
214255950|NCT06934707|BEHAVIORAL|Six meals a day|This group will follow a dietary prescription consisting of six meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 20% for breakfast, 10% morning snack, 30% for lunch, 10% afternoon snack, 25% for dinner and 5% bedtime snack, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 5-10% of the total carbohydrate intake, 2-7% of the total protein intake, and 2-8% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
214255951|NCT03367013|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
214255952|NCT03367013|OTHER|No Bovine Lactoferrin added|Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
214255953|NCT06722183|DRUG|Futibatinib orally administered|Futibatinib will be administered 20mg orally, once daily, continously
214255954|NCT06722183|DRUG|Tislelizumab (i.v. 200mg)|Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle
214255955|NCT06886256|DEVICE|Polar H10 Heart Rate Monitor|Wearable sensors to capture movement-based data during physical therapy session. The Polar H10 Heart Rate Monitor measures heart rate and will transfer the data to the mHealth app.
214255956|NCT06886256|DEVICE|Empatica EmbracePlus|Wearable sensors to capture movement-based data during physical therapy session. The Empatica EmbracePlus measures physiological parameters and will transfer the data to the mHealth app.
214255957|NCT06886256|DEVICE|Apple Watch Ultra 2|Wearable sensors to capture movement-based data during physical therapy session. The Apple Watch Ultra 2 measures heart rate, will transfer the data to the mHealth app, and will provide an alert when the heart rate is too high or too low.
214255958|NCT06708975|OTHER|Insulin therapy phonophoresis|Insulin therapy phonophoresis is the use of ultrasound to deliver drugs through patients skin, Insulin therapy will be used to determine its effect on wound healing in patients with chronic diabetes mellites because in addition to its systemic impact, numerous reports suggest that applying insulin topically causes localized effects. Many trials and case reports have been released reporting positive effects of topical insulin for many diseases such as dermatological compromises, ophthalmological diseases and others
214255959|NCT06708975|OTHER|Hyperpolarized light therapy and Standard wound cleaning and dressing.|Hyperpolarized light therapy safely accelerates wound healing by stimulating blood circulation, reducing inflammation and relieving muscle spasms.
214255960|NCT06708923|PROCEDURE|Intervention Name: Acupuncture Therapy Before and After Embryo Transfer Description: The intervention involves acupuncture therapy performed at two key time points during the IVF cycle: 25 minutes be|"Acupuncture Therapy Before and After Embryo Transfer~This intervention consists of acupuncture sessions designed to support implantation and improve pregnancy outcomes during frozen embryo transfer (FET) cycles.~Procedure:~Acupuncture is performed using sterile, single-use needles by certified practitioners trained in reproductive health.~Sessions occur at two critical time points:~Before Embryo Transfer: A 25-minute session targeting acupoints such as Baihui (DU20), Guanyuan (CV4), and Sanyinjiao (SP6) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second 25-minute session targeting acupoints such as Zusanli (ST36) and Taichong (LR3) to promote implantation and relaxation.~Purpose:~Improve uterine blood flow and receptivity. Regulate hormonal balance to optimize the implantation environment. Reduce psychological stress associated with IVF procedures. This intervention is compared retrospectively to standard IVF protocols without acupuncture to asses"
214255961|NCT06709794|BEHAVIORAL|Informational flyer|In addition to a standard eligibility notice informing participants of their eligibility for marketplace coverage, they receive an informational flyer describing what Covered California is, the availability of financial assistance, and information on benefit design and private insurance terminology, such as deductibles and copays
214255962|NCT06709794|BEHAVIORAL|Modified eligibility notice with plan information|a modified eligibility notice that includes information on the pre-selected lowest-cost silver health insurance plan with a personalized quote for their net premium amount in addition to the informational flyer and instead of a standard eligibility notice
214255963|NCT06708013|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It\&#39;s primarily used to treat depression, especially in patients who haven\&#39;t responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
214255964|NCT06708273|OTHER|Constraint induced movement therapy|Constraint the sound side and encourage movement of the burned side
214255965|NCT06708273|OTHER|Positioning - stretching|Position hand in functional hand position - stretching against deformity position
214255966|NCT06708273|OTHER|constraint induced movement therapy|constraining sound hand to enforce patient to use affected burned dominant hand
214255967|NCT06902805|DRUG|OnabotulinumtoxinA|intra-articular injection
214255968|NCT06902805|DRUG|Normal saline (placebo)|intra-articular injection
214255969|NCT06903091|PROCEDURE|SMS|Usual follow-up
214255970|NCT06933680|PROCEDURE|Sphenopalatine Ganglion Block|"To perform an SPG block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of 0.5% bupivacaine is injected.~The procedure is performed on both sides"
214255971|NCT06933680|PROCEDURE|Sham Block|"To perform a Sham block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of %0,9 NaCl is injected.~The procedure is performed on both sides."
214255972|NCT06934460|DEVICE|Composite resin|Direct composite resin restoration after application of an adhesive system
214255973|NCT06934460|DEVICE|lithium disilicate endocrown|Lithium disilicate endocrown in conjunction with Immediate Dentin Sealing
214255974|NCT06933407|DIAGNOSTIC_TEST|Strain Elastography|Strain elastography (SE) is a parametric imaging modality that assesses tissue deformation in response to externally applied pressure, providing qualitative and semi-quantitative information on tissue elasticity and mechanical properties. Unlike conventional 2D ultrasound, SE enables the objective evaluation of paraurethral tissue stiffness, which may play a role in the pathophysiology of stress urinary incontinence (SUI). SE will be performed on three predefined paraurethral regions to assess pelvic floor elasticity and biomechanical characteristics. A standardized protocol will be implemented to ensure high reproducibility, with controlled probe compression and precisely defined regions of interest. SE may improve the diagnostic accuracy and therapeutic decision-making for SUI by identifying differences in tissue compliance among affected women.
214255975|NCT06934811|DRUG|Ciprofol|Continuous intravenous infusion (0.05-0.3 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
214255976|NCT06934811|DRUG|Midazolam|Continuous intravenous infusion (0.02-0.1 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
214255977|NCT06933615|OTHER|Training prepared with mobile application|The m-BAFY program will be loaded onto the mobile phones of patients in the mobile application group. Each patient will be informed on how to use the mobile program. In addition, a short training will be given on how to use the application. With this application, the symptoms and vital signs recorded by the patients will be monitored and individual feedback will be provided. Information on the management of the disease prepared in line with the guidelines is included.
214255978|NCT06934551|DEVICE|obturator|conventionally constructed and polished obturator
214255979|NCT06933966|OTHER|observation alone|Patient will not received post-operative chemotherapy. There will be only surveillance until progression.
214255980|NCT05766501|DRUG|DOR/ISL|FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
214255981|NCT00775216|BEHAVIORAL|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
214255982|NCT00239902|DRUG|FTY720|
214255983|NCT00195572|DRUG|Isovorin|
214255984|NCT00195572|DRUG|TS-1|
214255985|NCT02037958|DEVICE|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
214255986|NCT02037958|DEVICE|Endotracheal Tube|Patients who receive endotracheal intubation
214255987|NCT00960739|DRUG|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
214255988|NCT00960739|PROCEDURE|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
214255989|NCT00960739|RADIATION|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
214255990|NCT00960739|RADIATION|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
214255991|NCT04954287|BIOLOGICAL|CVXGA1 low dose|see arm/group description
214255992|NCT04954287|BIOLOGICAL|CVXGA1 high dose|see arm/group description
214255993|NCT02947555|OTHER|Non interventional|
214255994|NCT05693116|PROCEDURE|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
214255995|NCT05594654|OTHER|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
214255996|NCT00413400|DRUG|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
214255997|NCT00413400|DRUG|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
214255998|NCT02932215|DRUG|lorcaserin|Open label
214255999|NCT02932215|OTHER|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
214256000|NCT05289427|PROCEDURE|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
214256001|NCT05289427|PROCEDURE|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
214256002|NCT04625816|DEVICE|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
214256003|NCT04231890|OTHER|IPI monitoring|Patients in this arm will have IPI monitoring
214256004|NCT04046198|OTHER|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
214256005|NCT02828969|OTHER|Phone call or physical consultation|
214256006|NCT05191563|DRUG|HCP1904-1|Take it once per period.
214256007|NCT05191563|DRUG|RLD2006|Take it once per period.
214256008|NCT05191563|DRUG|RLD2001-2|Take it once per period.
214256009|NCT02400177|BEHAVIORAL|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
214256010|NCT05830773|OTHER|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
214256011|NCT03400995|DRUG|AK0529|A solution containing 300 mg radiolabelled AK0529.
214256012|NCT01297556|BEHAVIORAL|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
214256013|NCT02505178|OTHER|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
214256014|NCT02387177|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
214256015|NCT02387177|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
214256016|NCT02504996|DRUG|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
214256017|NCT02504996|DRUG|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
214256018|NCT02504996|DRUG|Placebo|Intravenous 100 ml normal saline
214256019|NCT01149837|DEVICE|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
214256020|NCT04710134|BIOLOGICAL|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
214256021|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
214256022|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
214256023|NCT00891462|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
214256024|NCT04172896|PROCEDURE|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
214256025|NCT04172896|PROCEDURE|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
214256026|NCT00970073|BIOLOGICAL|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
214256027|NCT00970073|BIOLOGICAL|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
214256028|NCT00970073|DRUG|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
214256029|NCT00970073|DRUG|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
214256030|NCT00970073|DRUG|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
214256031|NCT04359667|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
214256032|NCT01786655|DRUG|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
214256033|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
214256034|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
214256035|NCT01786655|OTHER|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
214256036|NCT01757262|DRUG|90 mg Ticagrelor|Morning and Evening dose for 5 days
214256037|NCT01757262|DRUG|75mg Clopidogrel|Morning dose for 5 days
214256038|NCT01817244|OTHER|care management|6-month care management
214256039|NCT03063242|DRUG|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
214256040|NCT03063242|BIOLOGICAL|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
214256041|NCT05938842|BEHAVIORAL|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
214256042|NCT05938842|BEHAVIORAL|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz \& Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz \& Oz, 2020; Dowd et al., 2015).
214256043|NCT03102333|DEVICE|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
214256044|NCT03102333|DEVICE|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
214256045|NCT03029442|DRUG|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
214256046|NCT03029442|OTHER|Placebo (normal saline)|Identical Denosumab volume of normal saline
214256047|NCT00423722|DRUG|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
214256048|NCT00423722|DRUG|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
214256049|NCT05922111|DEVICE|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
214256050|NCT05922111|DEVICE|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
214256051|NCT06354062|BEHAVIORAL|Talent management intervention program|Talent management intervention program
214256052|NCT00293527|DRUG|Interferon Alpha-2b|
214256053|NCT04205708|DIAGNOSTIC_TEST|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
214256054|NCT04205708|DIAGNOSTIC_TEST|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
214256055|NCT04205708|DIAGNOSTIC_TEST|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
214256056|NCT03124446|BEHAVIORAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
214256057|NCT03124446|BEHAVIORAL|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
214256058|NCT03531125|PROCEDURE|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
214256059|NCT03531125|PROCEDURE|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
214256060|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
214256061|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
214256062|NCT06204978|OTHER|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
214256063|NCT05390931|BEHAVIORAL|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
214256064|NCT05390931|OTHER|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
214256065|NCT05390931|OTHER|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
214256066|NCT05390931|OTHER|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
214256067|NCT05578079|OTHER|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
214256068|NCT05578079|OTHER|Music|Intervention-2 group will listen to lullaby.
214256069|NCT05578248|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
214256070|NCT05578248|PROCEDURE|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
214256071|NCT01722123|OTHER|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
214256072|NCT00414271|DRUG|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
214256073|NCT00414271|DRUG|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
214256074|NCT02604056|BEHAVIORAL|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
214256075|NCT02604056|BEHAVIORAL|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
214256076|NCT03507231|BEHAVIORAL|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
214256077|NCT03507231|BEHAVIORAL|Incentive for Vaccination|$5 gift card offered for vaccination
214256078|NCT03507231|BEHAVIORAL|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
214256079|NCT02746172|DEVICE|Cochlear implant with in-situ audiometry|
214256080|NCT05414877|DRUG|Ephedrine|vasopressor
214256081|NCT05414877|DRUG|Phenylephrine|vasopressor
214256082|NCT05414877|DRUG|Norepinephrine|vasopressor
214256083|NCT05509270|BEHAVIORAL|Letter|Mailed letter about flu vaccination
214256084|NCT05509270|BEHAVIORAL|Patient portal|Patient portal message about flu vaccination
214256085|NCT05509270|BEHAVIORAL|SMS|SMS about flu vaccination
214256086|NCT00518687|BIOLOGICAL|V710|0.5-mL single injection of V710 (60 µg)
214256087|NCT00518687|BIOLOGICAL|Placebo|0.5-mL single injection of matching placebo
214256088|NCT00881101|DRUG|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
214256089|NCT04027543|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
214256090|NCT04027543|PROCEDURE|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
214256091|NCT04027543|DRUG|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
214256092|NCT02223312|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
214256093|NCT04970784|OTHER|Activities of Daily Living (ADL) questionnaire (The Katz index )|"For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30."
214256094|NCT01842022|DIETARY_SUPPLEMENT|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
214256095|NCT01842022|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
214256096|NCT01842022|DIETARY_SUPPLEMENT|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
214256097|NCT01846104|BIOLOGICAL|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
214256098|NCT03691155|OTHER|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
214256099|NCT02883959|OTHER|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
214256100|NCT03854201|BEHAVIORAL|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
214256101|NCT01937754|DIETARY_SUPPLEMENT|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
214256102|NCT01937754|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
214256103|NCT02095223|DEVICE|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
214256104|NCT02095223|BEHAVIORAL|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
214256105|NCT05138211|DEVICE|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. \- Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. \- Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. \- Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
214256106|NCT05565131|DEVICE|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
214256107|NCT01397162|DRUG|Fluticasone propionate|Fluticasone propionate
214256108|NCT01397162|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
214256109|NCT01397162|DRUG|BI 54903|BI 54903
214256110|NCT02339285|DEVICE|tACS (alpha)|
214256111|NCT02339285|DEVICE|tACS (gamma)|
214256112|NCT00931879|DRUG|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
214256113|NCT00931879|DRUG|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
214256114|NCT06556498|PROCEDURE|Proflor group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Proflor mesh.
214256115|NCT06556498|PROCEDURE|Progrip group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Progrip mesh.
214256116|NCT00342940|BIOLOGICAL|influenza surface antigen inactivated vaccine|
214256117|NCT03714971|BEHAVIORAL|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
214653308|NCT06960473|DEVICE|Digital Subtraction Angiography|The DSA group patients will have the appropriate balloon dilation selected for the occluded segment based on the DSA measurement results.
214256118|NCT01907997|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
214256119|NCT01907997|DRUG|normal saline infusion|In group C, the patients receive same volume of normal saline
214653309|NCT06555627|BEHAVIORAL|High Protein Breakfast|For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
214256120|NCT03024619|OTHER|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
214256121|NCT00282412|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
214256122|NCT00282412|DRUG|Fludarabine|inhibits DNA synthesis or repair
214256123|NCT00282412|DRUG|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
214256124|NCT00282412|DRUG|Campath 1H|humanized monoclonal antibody against CD52 antigen
214256125|NCT00282412|DRUG|GCSF|Hematopoietic growth factor
214256126|NCT00282412|DRUG|Cyclosporins|immune suppressive drug
214256127|NCT00282412|DRUG|Mycophenolate Mofetil|immune suppressive drug
214256128|NCT00287482|DRUG|Essiac|
214256129|NCT03502083|DRUG|GLP-1 (7-36)Amide|IV infusion
214256130|NCT00045968|DRUG|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
214256131|NCT06046885|DEVICE|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
214256132|NCT05993039|DRUG|Isoflurane Inhalant Product|1.5-2%
214256133|NCT05993039|DRUG|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
214256134|NCT05993039|DRUG|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
214256135|NCT05993039|DRUG|Remifentanil Injection|0.05-2ug/kg/min adults and children
214256136|NCT03095443|OTHER|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
214256137|NCT03095443|OTHER|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
214256138|NCT03095443|OTHER|Attention Control|Participant receives an audio-book.
214256139|NCT03211338|BIOLOGICAL|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
214256140|NCT03211338|BIOLOGICAL|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
214256141|NCT03211338|BIOLOGICAL|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
214256142|NCT03454685|OTHER|without intervention type|Without intervention,this study is just an observational study.
214256143|NCT03851471|DRUG|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
214256144|NCT00585390|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams"
214256145|NCT00585390|OTHER|Olive oil placebo|Olive oil capsules, 8 capsules per day
214256146|NCT00585390|DIETARY_SUPPLEMENT|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
214653310|NCT06555627|BEHAVIORAL|Morning Exercise|Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.
214256147|NCT00585390|DRUG|Placebo|Olive oil capsule
214256148|NCT01501331|DEVICE|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
214256149|NCT05005910|DRUG|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
214256150|NCT05005910|DRUG|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
214256151|NCT03804008|DRUG|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
214256152|NCT03804008|OTHER|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
214256153|NCT03804008|OTHER|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
214256154|NCT02572362|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
214256155|NCT02538328|DEVICE|Harmonic scapel|different surgical devices used in the obesity surgery
214256156|NCT02538328|DEVICE|Ligasure|Bipolar vessel sealing system used in obesity surgery
214256157|NCT03734575|DEVICE|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
214256158|NCT03376100|PROCEDURE|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
214256159|NCT03376100|PROCEDURE|Hematoma Block|Conventional local anesthetic method using hematoma block
214256160|NCT04858256|DRUG|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
214256161|NCT04437849|DEVICE|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
214256162|NCT05997771|OTHER|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
214256163|NCT00697073|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
214256164|NCT03438318|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
214256165|NCT03438318|DRUG|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
214256166|NCT03438318|RADIATION|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
214256167|NCT00526045|DRUG|AUY922 2 mg/m2|
214256168|NCT00004347|BEHAVIORAL|diet|
214256169|NCT06708052|BEHAVIORAL|voodoo flossing|"The voodoo flossing intervention used the standard voodoo flossing, wrapping a voodoo flossing (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
214256170|NCT06708052|BEHAVIORAL|Control group|The control group did not use voodoo flossing.
214256171|NCT06434818|COMBINATION_PRODUCT|EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)|EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.
214256172|NCT06434818|COMBINATION_PRODUCT|CBOT with olfactory stimulants & OFC tasks|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
214256173|NCT06434818|COMBINATION_PRODUCT|CBOT Sham|CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
214256174|NCT03538678|OTHER|Kwit smartphone app|Kwit smarphone app
214256175|NCT03791827|DRUG|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
214256176|NCT03791827|DRUG|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
214256177|NCT03791827|DRUG|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
214256178|NCT03791827|DRUG|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
214256179|NCT03791827|DRUG|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
214256180|NCT03791827|DRUG|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
214256181|NCT03791827|DRUG|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
214256182|NCT03791827|DRUG|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
214256183|NCT05250089|OTHER|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
214256184|NCT03068598|DEVICE|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
214256185|NCT05305339|OTHER|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
214256186|NCT04625790|DEVICE|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
214256187|NCT04625790|OTHER|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
214256188|NCT00145704|DRUG|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
214256189|NCT00145704|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
214256190|NCT00145704|DIETARY_SUPPLEMENT|Calcium|calcium supplement given to patients with growth hormone deficiency
214256191|NCT02580903|RADIATION|Radiology|Only a small subsample will require CT and right heart catherisation
214256192|NCT04738851|OTHER|Therapy Mirror task|"The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
214256193|NCT02525276|BEHAVIORAL|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
214256194|NCT02525276|DRUG|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
214256195|NCT00612183|DRUG|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
214256196|NCT01030068|BEHAVIORAL|Yoga|Yoga twice weekly
214256197|NCT01030068|BEHAVIORAL|Wellness|Health and wellness classes twice weekly
214256198|NCT01030068|OTHER|Smoking cessation therapy|Smoking cessation therapy
214256199|NCT00729755|DIETARY_SUPPLEMENT|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
214256200|NCT00729755|DIETARY_SUPPLEMENT|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
214256201|NCT04687384|PROCEDURE|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
214256202|NCT04687384|PROCEDURE|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
214256203|NCT05472324|DRUG|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
214256204|NCT05472324|DRUG|Placebo|The drug is a placebo Comparator.
214256205|NCT01896336|DRUG|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
214256206|NCT04163497|DEVICE|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
214256207|NCT04269590|BEHAVIORAL|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
214256208|NCT04269590|BEHAVIORAL|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
214653311|NCT06555627|BEHAVIORAL|High Carb Breakfast|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
214256209|NCT02457481|DEVICE|Embryo Culture medium|Two step sequential embryo culture medium system
214256210|NCT02562833|DEVICE|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
214653312|NCT06419205|DRUG|ADX-097|Open Label
214653313|NCT06081075|OTHER|Genetic testing|Rapid whole genome sequencing
214653314|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
214256211|NCT02562833|DEVICE|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
214256212|NCT01303328|DRUG|C1|Local application of the experimental gel or placebo gel.
214256213|NCT04754243|DRUG|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
214256214|NCT04754243|DRUG|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
214256215|NCT01874743|DRUG|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
214256216|NCT03836703|DRUG|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
214256217|NCT03836703|DRUG|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
214256218|NCT03368612|OTHER|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
214256219|NCT03368612|OTHER|Electronic evaluation system|AirGo recording
214256220|NCT04937855|OTHER|no intervention|no intervention
214256221|NCT02537782|DEVICE|Cardiac resynchronisation therapy|
214256222|NCT02537782|OTHER|Echocardiography|
214256223|NCT02537782|OTHER|Magnetic Resonance Imaging|
214256224|NCT02537782|OTHER|Positron Emission Tomography|
214256225|NCT01593189|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
214256226|NCT04996381|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
214256227|NCT01854203|DRUG|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
214256228|NCT01854203|DRUG|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
214256229|NCT05129670|DEVICE|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
214256230|NCT05129670|DEVICE|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
214256231|NCT01677546|DEVICE|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
214256232|NCT01677546|DEVICE|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
214256233|NCT02187705|DRUG|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
214256234|NCT00418639|DRUG|Nitazoxanide|
214256235|NCT05688449|DRUG|Bupivacaine-fentanyl|A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
214256236|NCT05688449|DRUG|Saline|A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
214256237|NCT00736957|DRUG|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
214256238|NCT02138773|DRUG|Tamsulosin formulation-A|oral
214256239|NCT02138773|DRUG|Tamsulosin formulation-B|oral
214256240|NCT00462540|DRUG|Formoterol Fumurate inhalation solution 20 mcg|
214256241|NCT00462540|DRUG|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
214256242|NCT02841189|DEVICE|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
214256243|NCT02547948|BIOLOGICAL|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
214256244|NCT05877768|DIAGNOSTIC_TEST|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
214256245|NCT05626582|PROCEDURE|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
214256246|NCT05626582|PROCEDURE|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
214256247|NCT01526772|PROCEDURE|Endoscopy|Transoral endoscopy versus transoral endoscopy
214256248|NCT02231918|DRUG|MIRAPEX® - low|
214256249|NCT02231918|DRUG|MIRAPEX® - medium|
214256250|NCT02231918|DRUG|MIRAPEX® - high|
214256251|NCT06270329|OTHER|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
214653315|NCT05567562|DRUG|Placebo|Placebo
214256252|NCT06270329|OTHER|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
214256253|NCT04045548|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
214256254|NCT04045548|DRUG|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
214256255|NCT06170892|OTHER|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
214256256|NCT02479269|OTHER|Aerobic exercise|Aerobic exercise for 8 weeks
214256257|NCT03234673|DRUG|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
214256258|NCT03234673|DRUG|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
214256259|NCT03234673|DRUG|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
214256260|NCT04425356|BEHAVIORAL|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
214256261|NCT06203379|OTHER|Neuromuscular Exercise Training|Neuromuscular Exercise Training
214256262|NCT06203379|OTHER|control exercise|Exercise Training
214256263|NCT00331864|DRUG|Ranibizumab|
214256264|NCT03996759|DIAGNOSTIC_TEST|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
214256265|NCT00555685|DRUG|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
214256266|NCT00555685|DRUG|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
214256267|NCT03898843|OTHER|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
214256268|NCT03898843|BIOLOGICAL|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
214256269|NCT03898843|BEHAVIORAL|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
214256270|NCT03898843|PROCEDURE|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
214653316|NCT05966272|DRUG|HRS9531 injection|single dose
214653317|NCT05966272|DRUG|HRS9531 injection Placebo|single dose
214653318|NCT01430351|DRUG|Mefloquine|Given PO
214653319|NCT01430351|DRUG|Memantine Hydrochloride|Given PO
214653320|NCT01430351|DRUG|Metformin Hydrochloride|Given PO
214256271|NCT03898843|OTHER|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
214256272|NCT03898843|BEHAVIORAL|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
214256273|NCT03898843|BEHAVIORAL|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
214256274|NCT03898843|BIOLOGICAL|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
214256275|NCT04202471|DEVICE|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
214653321|NCT01430351|DRUG|Temozolomide|Given PO
214653322|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
214653323|NCT04809766|DRUG|Cyclophosphamide|Given IV
214653324|NCT04809766|DRUG|Fludarabine|Given IV
214653325|NCT04809766|DRUG|Bendamustine|Given IV
214653326|NCT01018355|DEVICE|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
214653327|NCT04098315|OTHER|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
214653328|NCT01848145|DRUG|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of \>= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE \>= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
214653329|NCT01091636|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
214653330|NCT01799876|PROCEDURE|Autologous Cell|
214653331|NCT01799876|PROCEDURE|Standard microfracture arthroscopic surgery|
214653332|NCT00773487|OTHER|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
214653333|NCT03903510|DEVICE|Virtual Reality (VR)|Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
214653334|NCT01276184|BEHAVIORAL|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
214256276|NCT01092507|BIOLOGICAL|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
214256277|NCT01092507|BIOLOGICAL|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
214256278|NCT03179527|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
214256279|NCT03179527|DRUG|Lipid Regulating Drugs|Mainly including statins
214256280|NCT03179527|DRUG|Coronary Vasodilator|Mainly including nitrates
214256281|NCT03179527|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
214256282|NCT06402630|DRUG|STS01|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
214256283|NCT06402630|DRUG|Placebo|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
214256284|NCT04487522|PROCEDURE|Open retromuscular ventral hernia repair|With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
214256285|NCT04487522|PROCEDURE|Laparoscopic retromuscular ventral hernia repair|With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
214256286|NCT04487522|DEVICE|Robotic-assisted retromuscular ventral hernia repair|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
214256287|NCT04799327|DRUG|SHR20004|SHR20004：low dose
214256288|NCT04799327|DRUG|SHR20004|SHR20004: medium dose
214256289|NCT04799327|DRUG|SHR20004|SHR20004: high dose
214256290|NCT04799327|DRUG|placebo|Placebo
214256291|NCT04148690|OTHER|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
214256292|NCT04148690|OTHER|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
214256293|NCT04920981|OTHER|atezolizumab|observational
214256294|NCT05500599|DRUG|Fentanyl Citrate|Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
214653335|NCT02886702|DRUG|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
214653336|NCT02886702|DRUG|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
214653337|NCT02886702|DRUG|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
214653338|NCT00203684|DRUG|Flunisolide-HFA|
214653339|NCT01438645|DEVICE|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
214256295|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
214256296|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
214256297|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
214256298|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
214256299|NCT04910256|DRUG|Huatuo Zaizao Pills|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
214256300|NCT04910256|OTHER|Basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
214256301|NCT04735536|DRUG|CT1812|Active Treatment- CT1812 at a dose of 300mg
214256302|NCT04735536|OTHER|Placebo|Placebo Comparator
214256303|NCT04073368|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
214256304|NCT04073368|DIETARY_SUPPLEMENT|AXA1125|Amino acids, food study
214256305|NCT04073368|DIETARY_SUPPLEMENT|Placebo|Amino acids, food study
214256306|NCT02646254|OTHER|blood cardioplegia|
214256307|NCT02646254|OTHER|del nido cardioplegia|
214256308|NCT01910571|DRUG|P7435|
214256309|NCT01910571|OTHER|Placebo|
214256310|NCT01681797|DEVICE|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
214256311|NCT00728052|DRUG|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
214256312|NCT00728052|DRUG|Placebo|Placebo capsules will be administered orally with water.
214256313|NCT00145600|DRUG|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
214256314|NCT00145600|DRUG|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
214256315|NCT00145600|DRUG|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
214256316|NCT00145600|DRUG|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
214256317|NCT03257176|BEHAVIORAL|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
214256318|NCT06025643|OTHER|TENS - Cervical stimulation group|TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.
214256319|NCT06025643|OTHER|TENS - Plus cervical stimulation group|TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.
214256320|NCT06025643|OTHER|TENS - Renal stimulation group|TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
214256321|NCT01427322|DRUG|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
214256322|NCT01427322|RADIATION|Radiation therapy|Standard radiation therapy
214256323|NCT01420653|DRUG|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
214256324|NCT01420653|DRUG|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
214256325|NCT01420653|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
214256326|NCT01420653|DRUG|Placebo|placebo, three tablets four times a day, with food for 48 hours
214256327|NCT05377203|DRUG|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
214256328|NCT05377203|DRUG|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
214256329|NCT04465162|OTHER|Radiation Therapy|Undergo radiation therapy
214256330|NCT01539642|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
214256331|NCT01539642|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
214256332|NCT03098355|BIOLOGICAL|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
214256333|NCT03098355|DRUG|Interleukin-2|Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
214256334|NCT02518412|OTHER|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
214256335|NCT02518412|OTHER|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
214256336|NCT00898378|GENETIC|gene expression analysis|gene expression analysis
214256337|NCT00898378|GENETIC|polymerase chain reaction|polymerase chain reaction
214256338|NCT00898378|GENETIC|polymorphism analysis|polymorphism analysis
214256339|NCT00898378|GENETIC|protein expression analysis|protein expression analysis
214256340|NCT00898378|GENETIC|proteomic profiling|proteomic profiling
214256341|NCT00898378|OTHER|gas chromatography|gas chromatography
214256342|NCT00898378|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214256343|NCT00898378|OTHER|liquid chromatography|liquid chromatography
214256344|NCT00898378|OTHER|mass spectrometry|mass spectrometry
214256345|NCT00898378|OTHER|questionnaire administration|questionnaire administration
214256346|NCT03031535|DRUG|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
214256347|NCT03031535|DRUG|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
214256348|NCT03031535|DIAGNOSTIC_TEST|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
214256349|NCT03031535|DIAGNOSTIC_TEST|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
214256350|NCT04758078|OTHER|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
214256351|NCT04758078|OTHER|Placebo|Nebulized 0.9% saline will be given four times per day
214256352|NCT03644680|DIAGNOSTIC_TEST|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
214256353|NCT03644680|OTHER|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
214256354|NCT00167557|DRUG|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
214256355|NCT00167557|DRUG|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
214256356|NCT00167557|PROCEDURE|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
214256357|NCT05648760|BEHAVIORAL|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
214256358|NCT00635791|DRUG|Sorafenib|Given by mouth
214256359|NCT00635791|DRUG|Vorinostat|Given by mouth
214256360|NCT01729260|DRUG|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
214256361|NCT05152563|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
214256362|NCT05152563|OTHER|Placebo|Placebo
214256363|NCT04860427|DEVICE|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
214256364|NCT04860427|DEVICE|two miniplates|two miniplates open reduction and fixation
214256365|NCT02753218|DRUG|Midazolam|
214256366|NCT02753218|DRUG|LEO 32731|
214256367|NCT00761579|DRUG|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
214256368|NCT03253458|DEVICE|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
214256369|NCT04840173|BEHAVIORAL|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
214256370|NCT03611010|DRUG|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
214256371|NCT03517124|OTHER|Ceramic tooth restoration|Dental restorations
214256372|NCT00111878|DRUG|MEDI-534|
214256373|NCT00877110|DRUG|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
214256374|NCT00359918|DRUG|fibrinolysis|Primary PCI
214256375|NCT00359918|PROCEDURE|Primary PCI|Primary PCI
214256376|NCT00598702|DRUG|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
214256377|NCT01749774|BEHAVIORAL|Physical activity counseling|
214256378|NCT04416308|DIAGNOSTIC_TEST|NG test|rapid diagnosis Covid 19
214256379|NCT04416308|DIAGNOSTIC_TEST|Blood test|sample
214256380|NCT04416308|BEHAVIORAL|Self-questionnary|behavioral survey
214256381|NCT02600351|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214256382|NCT02600351|DRUG|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214256383|NCT02607007|OTHER|2% M.F. Milk|
214256384|NCT02607007|OTHER|White Bread|
214256385|NCT02607007|OTHER|Strawberry Jam|
214256386|NCT02607007|OTHER|31% M.F. Cheddar Cheese|
214256387|NCT02607007|OTHER|2% M.F. Plain Greek yogurt|
214256388|NCT02607007|OTHER|Soy Beverage|
214256389|NCT02607007|OTHER|Water|
214256390|NCT01813110|DRUG|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
214256391|NCT01813110|DRUG|Placebo|olive oil
214256392|NCT01621503|DEVICE|NT-530P|intraocular pressure and central corneal thickness measurement
214256393|NCT00003678|DRUG|tamoxifen citrate|
214256394|NCT00003678|PROCEDURE|adjuvant therapy|
214256395|NCT00289484|DRUG|Omega-3 Polyunsaturated Fatty Acids|
214256396|NCT04087213|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
214256397|NCT01859143|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
214256398|NCT01859143|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
214256399|NCT04708600|BEHAVIORAL|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
214256400|NCT04708600|BEHAVIORAL|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise"
214256401|NCT04708600|BEHAVIORAL|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns"
214256402|NCT02712255|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
214256403|NCT02712255|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
214256404|NCT02712255|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
214256405|NCT02712255|BEHAVIORAL|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
214256406|NCT02126358|DRUG|Gemigliptin and/or Rosuvastatin|
214256407|NCT00438451|DRUG|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
214256408|NCT00438451|DRUG|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
214256409|NCT00438451|DRUG|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
214256410|NCT05702866|DIAGNOSTIC_TEST|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
214256411|NCT04672720|DRUG|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
214256412|NCT00540319|BEHAVIORAL|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
214256413|NCT04433533|DRUG|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
214256414|NCT04433533|DRUG|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
214256415|NCT00689598|DRUG|Spironolactone|25 mg po qd 25 mg po bid
214256416|NCT00689598|DRUG|Placebo|Spironolactone 25 mg po qd
214256417|NCT01739114|PROCEDURE|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
214256418|NCT01739114|PROCEDURE|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
214256419|NCT06038981|DRUG|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
214256420|NCT02413372|DRUG|BMS-986036|
214256421|NCT02413372|DRUG|BMS-986036|
214256422|NCT02413372|DRUG|Placebo|
214256423|NCT01550471|DRUG|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
214256424|NCT01550471|DRUG|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
214256425|NCT01550471|DRUG|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
214256426|NCT01550471|DRUG|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
214256427|NCT01550471|DRUG|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
214256428|NCT01550471|DRUG|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
214256429|NCT00795925|DRUG|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
214256430|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
214256431|NCT02556203|DRUG|Acetylsalicylic Acid (ASA)|75-100mg OD
214256432|NCT02556203|DRUG|Clopidogrel|75mg OD
214256433|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
214256434|NCT02556203|DRUG|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
214256435|NCT05631665|OTHER|Survey results before and after laser treatment|Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
214256436|NCT02404467|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
214256437|NCT05092854|OTHER|PR Lotion - AMP Human Performance|"Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03"
214256438|NCT05092854|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
214256439|NCT05092854|OTHER|AminoVital - Rapid Recovery|AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
214256440|NCT05092854|OTHER|Placebo Supplement|Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
214256441|NCT00452855|PROCEDURE|Sevoflurane-remifentanil anaesthesia|
214256442|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
214256443|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
214256444|NCT04587271|DIETARY_SUPPLEMENT|Placebo|Mothers and children will receive porridge with placebo.
214256445|NCT06407271|DEVICE|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
214256446|NCT06407271|DEVICE|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
214256447|NCT02586051|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
214256448|NCT02586051|DRUG|Intravenous Immunoglobulin|High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
214256449|NCT01310504|PROCEDURE|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
214256450|NCT01310504|PROCEDURE|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
214256451|NCT05546918|OTHER|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups"
214256452|NCT02563990|PROCEDURE|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
214256453|NCT02563990|PROCEDURE|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
214256454|NCT00093782|DRUG|temsirolimus|Given IV
214256455|NCT00093782|OTHER|laboratory biomarker analysis|Correlative studies
214256456|NCT02010827|BIOLOGICAL|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
214256457|NCT02010827|BIOLOGICAL|Oral glucose tolerance test, day A|
214256458|NCT02010827|BIOLOGICAL|intravenous iv glucose infusion, day B|
214256459|NCT01490554|PROCEDURE|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
214256460|NCT01995630|DEVICE|AMO Tecnis ZA9003|
214256461|NCT01995630|DEVICE|AMO Sensar AR40e|
214256462|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
214256463|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
214256464|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
214256465|NCT00395772|DRUG|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
214256466|NCT00826761|DIETARY_SUPPLEMENT|probiotic|One capsule per meal test (high dose or low dose)
214256467|NCT00826761|DIETARY_SUPPLEMENT|placebo|1 capsuel every morning
214256468|NCT06392607|DEVICE|Euclid orthokeratology (standard coating)|Lens with the current coating
214256469|NCT06392607|DEVICE|Euclid orthokeratology (enhanced coating)|Lens with the enhanced coating
214256470|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
214256471|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
214256472|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
214653340|NCT03625531|OTHER|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
214653341|NCT03625531|DRUG|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
214256473|NCT01008397|DRUG|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
214256474|NCT03036306|DRUG|SCX-001|Nefopam cream formulation
214256475|NCT03036306|OTHER|Placebo|Cream formulation without Nefopam
214256476|NCT05780697|PROCEDURE|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
214256477|NCT03677908|OTHER|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
214256478|NCT02775604|BEHAVIORAL|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
214256479|NCT02775604|BEHAVIORAL|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
214256480|NCT01303354|PROCEDURE|Lumbar Transforaminal Epidural Steroid Injection|
214256481|NCT00051454|BIOLOGICAL|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
214256482|NCT05790083|OTHER|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
214256483|NCT03222011|PROCEDURE|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
214256484|NCT03222011|PROCEDURE|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
214256485|NCT02943460|DRUG|Cilofexor|Tablet(s) administered orally once daily with food
214256486|NCT02943460|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
214256487|NCT05631600|BIOLOGICAL|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
214256488|NCT01176331|PROCEDURE|20 and 23 gauge pars plana vitrectomy|
214256489|NCT05400863|BEHAVIORAL|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
214256490|NCT05400863|BEHAVIORAL|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
214256491|NCT02161029|DEVICE|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
214256492|NCT02161029|DEVICE|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
214256493|NCT03057509|DRUG|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
214256494|NCT03057509|DEVICE|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
214256495|NCT03057509|OTHER|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
214256496|NCT03057509|DRUG|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
214256497|NCT01925274|DRUG|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
214256498|NCT01925274|DRUG|irinotecan|90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
214256499|NCT01925274|DRUG|Cetuximab|120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
214256500|NCT01925274|DRUG|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
214256501|NCT01967433|DRUG|Diphenhydramine|
214256502|NCT01967433|DRUG|Placebo|
214256503|NCT01031381|DRUG|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
214256504|NCT01031381|DRUG|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
214256505|NCT00537992|PROCEDURE|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
214256506|NCT00723398|DIETARY_SUPPLEMENT|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
214256507|NCT00723398|DRUG|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
214256508|NCT00723398|DRUG|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
214256509|NCT00723398|DRUG|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
214256510|NCT05482542|OTHER|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214256511|NCT05482542|DRUG|Cyclophosphamide/ATG|Cyclophosphamide/ATG
214256512|NCT05482542|DRUG|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
214256513|NCT06301217|OTHER|There is no intervention|There is no intervention
214256514|NCT05927701|OTHER|Group comparaison|Questionnaires
214256515|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
214256516|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
214256517|NCT05044091|DRUG|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
214256518|NCT03533101|DRUG|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
214653342|NCT03625531|DRUG|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
214256519|NCT03283111|BIOLOGICAL|autologous stem cell transplantation|autologous stem cell transplantation
214256520|NCT01031602|BEHAVIORAL|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
214256521|NCT02626767|OTHER|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
214256522|NCT05464550|BEHAVIORAL|Eye tracker|Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
214256523|NCT00000631|BIOLOGICAL|HIVAC-1e|
214256524|NCT00000631|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214256525|NCT06210464|OTHER||Trial have no Intervention measures.
214256526|NCT06202417|DRUG|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
214256527|NCT02297243|DEVICE|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
214256528|NCT00544999|DRUG|cytarabine|
214256529|NCT00544999|DRUG|daunorubicin hydrochloride|
214256530|NCT00544999|DRUG|everolimus|
214256531|NCT00544999|OTHER|laboratory biomarker analysis|
214256532|NCT00544999|OTHER|pharmacological study|
214256533|NCT03248843|DRUG|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
214653343|NCT02429856|DEVICE|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
214653344|NCT00978302|DRUG|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214653345|NCT00978302|DRUG|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214653346|NCT00978302|DRUG|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214256534|NCT06199050|OTHER|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
214256535|NCT06199050|OTHER|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
214256536|NCT06199050|OTHER|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
214256537|NCT06199050|OTHER|General questions|"* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline"
214256538|NCT06199050|OTHER|Clinical data collected|"Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
214256539|NCT03668769|OTHER|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
214256540|NCT03668769|OTHER|Interview|Ancillary studies
214256541|NCT03668769|OTHER|Questionnaire Administration|Ancillary studies
214256542|NCT03668769|BEHAVIORAL|Smoking Cessation Intervention|Participate in individual smoking cessation program
214256543|NCT03707054|DIAGNOSTIC_TEST|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
214256544|NCT04865640|DIAGNOSTIC_TEST|Noninterventional and noninvasive|The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
214256545|NCT00580970|DRUG|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
214256546|NCT03781544|DRUG|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
214256547|NCT03781544|DRUG|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
214256548|NCT03781544|DRUG|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
214256549|NCT02018068|OTHER|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
214256550|NCT02018068|OTHER|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
214256551|NCT03105804|OTHER|FT21039|An electronic cigarette
214256552|NCT03105804|OTHER|FT21041|An electronic cigarette
214653347|NCT00978302|DRUG|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214256553|NCT03105804|OTHER|FT21044|An electronic cigarette
214256554|NCT03105804|OTHER|FT21042|An electronic cigarette
214256555|NCT01292785|DRUG|Hormones|"FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
214256556|NCT02672228|DEVICE|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
214256557|NCT04376892|OTHER|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
214256558|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
214256559|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
214653348|NCT00978302|DRUG|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214653349|NCT00978302|DRUG|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
214256560|NCT05633225|OTHER|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
214256561|NCT01632137|DRUG|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
214256562|NCT01632137|DRUG|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
214256563|NCT03161821|OTHER|Observational|
214256564|NCT05473884|DEVICE|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
214256565|NCT05473884|DEVICE|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
214256566|NCT03712631|PROCEDURE|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
214256567|NCT01008150|DRUG|Paclitaxel|
214256568|NCT01008150|DRUG|Trastuzumab|
214256569|NCT01008150|DRUG|Neratinib|
214256570|NCT01008150|DRUG|Doxorubicin|
214256571|NCT01008150|DRUG|Cyclophosphamide|
214256572|NCT01038193|OTHER|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
214256573|NCT05550844|RADIATION|Chest HRCT|A chest HRCT to identify emphysema
214256574|NCT05550844|GENETIC|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
214256575|NCT05550844|OTHER|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
214256576|NCT01400815|DRUG|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
214256577|NCT01400815|DRUG|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
214256578|NCT00037960|PROCEDURE|Constrained Induced Therapy|
214256579|NCT04247776|COMBINATION_PRODUCT|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
214256580|NCT04247776|OTHER|ERAS|Enhanced Recovery After Surgery guidelines are applied.
214256581|NCT04247776|BEHAVIORAL|Fitbit|Fitbit is worn to monitor step counts.
214256582|NCT04856202|BEHAVIORAL|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
214256583|NCT02193581|DEVICE|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
214256584|NCT00805948|DEVICE|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
214256585|NCT03805906|PROCEDURE|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
214256586|NCT05135247|OTHER|Exercise|3 different types of training or control
214256587|NCT04627662|BEHAVIORAL|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
214256588|NCT03509610|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
214256589|NCT04429243|DEVICE|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
214256590|NCT03739671|DIETARY_SUPPLEMENT|Vitamin D|Group will receive 5000 units of vitamin D daily
214256591|NCT03739671|DIETARY_SUPPLEMENT|No Vitamin D|No vitamin D supplementation
214256592|NCT06514976|DRUG|Cytoflavin|Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
214256593|NCT02883647|DRUG|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
214256594|NCT04783597|DIAGNOSTIC_TEST|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
214256595|NCT04007198|DRUG|EQ001|Itolizumab \[Bmab 600\]
214256596|NCT04007198|DRUG|EQ001 Placebo|EQ001 Placebo
214256597|NCT06414096|DRUG|Follicle Stimulating Hormone|Pulsatile FSH administration via a portable pump.
214256598|NCT00815269|DRUG|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
214256599|NCT00815269|DRUG|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
214256600|NCT00815269|DRUG|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
214256601|NCT00815269|DRUG|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
214256602|NCT00815269|DRUG|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
214256603|NCT05783986|OTHER|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
214256604|NCT04255927|DRUG|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
214256605|NCT04255927|DRUG|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
214256606|NCT02649114|BEHAVIORAL|Cognitive-Behavioural Therapy|
214256607|NCT02649114|BEHAVIORAL|Compassion-Focused Therapy|
214256608|NCT04805944|DRUG|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
214256609|NCT04805944|DRUG|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
214256610|NCT04805944|DRUG|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
214256611|NCT04805944|DRUG|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
214256612|NCT04805944|DRUG|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
214256613|NCT04165642|OTHER|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
214256614|NCT05693844|BIOLOGICAL|Pan-T booster co-expressing MSLN CAR T cell|Starting Dose: 1×10\^6 cells/kg
214256615|NCT05693844|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
214256616|NCT05693844|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
214256617|NCT05693844|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
214256618|NCT03467607|PROCEDURE|tidal volume ventilation|low tidal volume ventilation
214256619|NCT00662688|DRUG|daltéparine|
214256620|NCT00662688|DRUG|Chemotherapy at the investigator's discretion|
214256621|NCT03024697|PROCEDURE|Pectoral Plane Block|
214256622|NCT03024697|PROCEDURE|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
214256623|NCT05693766|DRUG|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
214256624|NCT05693766|OTHER|Endocrine-therapy|Endocrine therapy administered
214256625|NCT05693766|OTHER|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
214256626|NCT05542186|PROCEDURE|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
214653350|NCT00978302|DRUG|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
214256627|NCT00233428|PROCEDURE|Blood Draw|
214256628|NCT02185755|OTHER|Internet-Based Glucose Monitoring System|
214256629|NCT02185755|DRUG|Normal Medication Positive Control|
214256630|NCT00823342|DRUG|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
214256631|NCT00823342|DRUG|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
214256632|NCT00823342|DRUG|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
214256633|NCT00116662|DRUG|Resiquimod|
214256634|NCT03439943|DRUG|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
214256635|NCT03439943|DRUG|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
214256636|NCT00397566|DRUG|HIV Integrase Inhibitor (BMS-707035)|
214256637|NCT02273518|DRUG|Asasantin ER, new formulation I|
214256638|NCT02273518|DRUG|Asasantin ER, new formulation II|
214256639|NCT02273518|DRUG|Asasantin ER, present commercial formulation|
214256640|NCT00678340|DEVICE|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
214256641|NCT00678340|DEVICE|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
214256642|NCT00014404|DRUG|celecoxib|
214256643|NCT01967758|BIOLOGICAL|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
214256644|NCT01967758|BIOLOGICAL|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
214256645|NCT01967758|BIOLOGICAL|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
214256646|NCT01967758|DRUG|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
214256647|NCT02759354|OTHER|Blood Sample|Blood sample at approx. 4 years of age
214256648|NCT01590992|BEHAVIORAL|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
214256649|NCT01590992|BEHAVIORAL|Relaxation therapy|Progressive muscle relaxation (Jacobson)
214256650|NCT03701737|OTHER|questionnaires|"* VAS on the feeling of hunger~* Evaluation of food wanting by the Finlayson test~* PREFQUEST Questionnaire~* 24-hour food recall~* Stunkard Questionnaire~* Measurement of daytime sleepiness by Epworth score"
214256651|NCT03701737|DEVICE|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
214653351|NCT00035451|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
214653352|NCT00035451|DRUG|Placebo|tablets, twice daily for 6 months
214256652|NCT03701737|BIOLOGICAL|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
214256653|NCT02198872|OTHER|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
214256654|NCT02198872|OTHER|Land Group|Patients of this group perform physical training on bicycle.
214256655|NCT02135939|BEHAVIORAL|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
214256656|NCT04234139|PROCEDURE|liver transplant|solid organ transplant
214256657|NCT00284622|PROCEDURE|Arthroscopy|HTO with pre-scope
214256658|NCT02313324|DEVICE|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
214256659|NCT02313324|DEVICE|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
214256660|NCT03458663|DEVICE|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
214256661|NCT00976170|DRUG|GC33(RO5137382)|IV administration at 6 escalating dose levels.
214256662|NCT00976170|DRUG|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
214256663|NCT04243785|DRUG|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
214256664|NCT04243785|DRUG|Azacitidine|Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
214256665|NCT05348135|OTHER|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
214256666|NCT05348135|OTHER|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
214256667|NCT05348135|OTHER|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
214256668|NCT00568685|DRUG|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
214256669|NCT00568685|DRUG|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
214256670|NCT00568685|DRUG|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
214256671|NCT00792831|DRUG|ITF2357|Histone-Deacetylase Inhibitor
214256672|NCT05697744|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
214256673|NCT00845780|DRUG|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
214256674|NCT01384279|DRUG|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
214256675|NCT01147172|DEVICE|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
214256676|NCT02406950|DRUG|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
214256677|NCT01181648|BEHAVIORAL|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
214256678|NCT02171572|DRUG|Dabigatran etexilate low|
214256679|NCT02171572|DRUG|Dabigatran etexilate high|
214653353|NCT00035451|DRUG|Sotalol|160 mg sot twice daily for 6 months
214653354|NCT05588427|DIETARY_SUPPLEMENT|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
214653355|NCT05588427|DIETARY_SUPPLEMENT|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
214256680|NCT05025254|OTHER|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
214256681|NCT02787551|DRUG|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256682|NCT02787551|DRUG|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256683|NCT02787551|DRUG|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256684|NCT02787551|DRUG|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256685|NCT02787551|DRUG|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256686|NCT02787551|DRUG|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214256687|NCT02787551|DRUG|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
214256688|NCT00753779|DRUG|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
214256689|NCT00753779|DRUG|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
214256690|NCT04810663|RADIATION|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
214256691|NCT02957565|BEHAVIORAL|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
214256692|NCT02957565|OTHER|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
214256693|NCT02957565|BEHAVIORAL|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
214256694|NCT05530785|COMBINATION_PRODUCT|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
214256695|NCT05663268|BIOLOGICAL|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
214256696|NCT02715973|DIETARY_SUPPLEMENT|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
214256697|NCT02715973|DIETARY_SUPPLEMENT|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
214256698|NCT05462470|PROCEDURE|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
214256699|NCT05462470|PROCEDURE|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
214256700|NCT02554188|BIOLOGICAL|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
214256701|NCT02554188|OTHER|Diet|A 5-day low calorie fasting-mimicking diet
214256702|NCT05587218|BEHAVIORAL|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
214256703|NCT01638819|BIOLOGICAL|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
214256704|NCT01638819|BIOLOGICAL|Placebo|Saline
214256705|NCT06025851|DRUG|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
214256706|NCT06025851|DRUG|Placebo|Placebo Comparator
214256707|NCT00590798|BEHAVIORAL|Walking|Patient will walk within 30 minutes of vascular closure system procedure
214256708|NCT00813033|OTHER|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
214256709|NCT03111966|OTHER|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
214256710|NCT02526836|PROCEDURE|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
214256711|NCT02526836|PROCEDURE|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
214256712|NCT02795793|DRUG|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
214256713|NCT02795793|PROCEDURE|Appendectomy group (Operative management, OM)|
214256714|NCT01008631|DRUG|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
214256715|NCT00537784|BIOLOGICAL|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
214256716|NCT00537784|BIOLOGICAL|no injection|
214256717|NCT00074438|DRUG|methotrexate|Oral or parenteral repeating dose
214256718|NCT00074438|DRUG|rituximab|Intravenous repeating dose
214256719|NCT00074438|DRUG|corticosteroids|Intravenous repeating dose
214256720|NCT00074438|DRUG|placebo|Intravenous repeating dose
214256721|NCT01942473|DEVICE|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
214256722|NCT06023524|DEVICE|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
214256723|NCT06023524|DEVICE|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
214256724|NCT03625934|BIOLOGICAL|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
214256725|NCT03625934|BIOLOGICAL|Placebo|5 s.c. injections of matching Placebo four weeks apart
214256726|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% gel pump|
214256727|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% tube|
214256728|NCT06518902|DRUG|mesenchymal stem cells (umbilical cord) injection|Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
214256729|NCT00135070|DRUG|Detemir|
214256730|NCT04025281|OTHER|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
214256731|NCT04025281|OTHER|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
214256732|NCT05708027|PROCEDURE|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
214256733|NCT05895864|DRUG|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
214256734|NCT03857035|OTHER|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
214256735|NCT00402272|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214256736|NCT00070655|DRUG|SR34006 (idraparinux sodium) Injection|
214256737|NCT00070655|DRUG|vitamin K antagonist (warfarin or acenocoumarol) tablets|
214256738|NCT04406610|BIOLOGICAL|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
214256739|NCT00237185|DRUG|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
214256740|NCT04920682|DRUG|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
214256741|NCT04920682|DRUG|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
214256742|NCT04920682|DRUG|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
214256743|NCT04920682|DRUG|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
214256744|NCT06356090|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE)|SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
214256745|NCT00959712|BEHAVIORAL|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
214256746|NCT06334276|OTHER|Drowning|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
214256747|NCT06620042|DRUG|Ketamine|Open-label Ketamine
214256748|NCT06620042|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) of the brain
214256749|NCT06698601|DIETARY_SUPPLEMENT|blueberry-rich diet|"The study participants follow a diet rich in blueberries for 12 weeks based on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will drink approximately 35g of a powder made from wild, freeze-dried blueberries containing 780mg of anthocyanines stirred in a glas of water every morning for a period of 12 weeks."
214256750|NCT06698601|OTHER|Control diet|"The study participants will focus on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will receive no additional blueberry treatment."
214256751|NCT06699888|OTHER|cervicothoracic manipulation group|"The participant lay prone with the head firmly into the head piece Palpation of the upper cervico-thoracic segment observed the side of the restriction.~The participants head was rotated to the contralateral side of the restriction. The practitioner's hand contacted the forehead and the other hand's thumb contacted the spinous process of the restricted side.~A low amplitude, high velocity thrust towards the axilla was applied, on the spinous process in PA direction.~Experimental group also received following exercises Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks"
214256752|NCT06699888|OTHER|forward head correction exercises traditional group|Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks.
214256753|NCT06709560|OTHER|Moderate Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer at moderate intensity (50% HRR)
214256754|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer, at a vigorous intensity (80% HRR).
214256755|NCT06709560|OTHER|Moderate Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at moderate intensity (50% HRR).
214256756|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a different cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at vigorous intensity (80% HRR).
214256757|NCT06706765|BEHAVIORAL|Behavioral Treatment|Behavioral cough suppression therapy delivered in a group setting via telehealth.
214256758|NCT06710431|DRUG|AFA-281|AFA-281
214256759|NCT06709326|DIAGNOSTIC_TEST|Apheresis|Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.
214256760|NCT06709326|OTHER|Androgen deprivation therapy|Apheresis will be performed before initiation of systemic therapy (androgen deprivation therapy) and 4 weeks after. Androgen deprivation therapy is treatment as per clinical routine and not part of the protocol.
214256761|NCT06709326|DIAGNOSTIC_TEST|Anti androgen therapy|Apheresis will be performed before initiation of systemic therapy (anti androgen therapy). Anti androgen therapy is treatment as per clinical routine and not part of the protocol.
214256762|NCT06709313|DRUG|Chromium|Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
214256763|NCT06707285|DEVICE|MRI|1.5T siemens
214256764|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg
214256765|NCT06710600|RADIATION|UVA and UVB radiation|The skin of the inner arm will be exposed to five fixed incremental doses of UVA and UVB. Each dose will be applied to a circular area on the inner forearm of 1 cm diameter for both UVA and UVB.
214256766|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|"acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg"
214256767|NCT06708585|OTHER|progressive relaxation exercises and training|Considering the high incidence of cesarean section and the prevalence of anxiety and fear as psychological symptoms, providing comfort and pain support to women is of great importance. Therefore, the effect of progressive relaxation exercise and education before cesarean section surgery on care outcomes will be determined.
214256768|NCT06709638|OTHER|Placebo Comparator|Placebo Comparator
214256769|NCT06709638|DRUG|Zhilong Huoxue Tongyu capsule|Zhilong Huoxue Tongyu capsule
214256770|NCT06706947|PROCEDURE|Lymphaticovenous Anastomosis|"Lymphaticovenous Anastomosis (LVA) is an emerging super-microsurgical procedure pioneered by Professor Xie Qingping and his team, a group of Chinese microsurgery experts. This technique has been published in the official journal of the American Society of Plastic Surgeons (ASPS), confirming its effectiveness in improving the drainage function of the brain and reducing lymphatic pressure in deep brain tissues. By establishing an anastomosis between lymphatic vessels and veins in the neck, the surgery enhances the drainage of cerebrospinal fluid, alleviating the accumulation of toxins and waste within the brain, thereby easing the symptoms of Alzheimer's disease. Due to its significant contribution to the field of microsurgery, this innovative surgery has been selected as one of the Top Seven Advances in Microsurgery for 2022."
214256771|NCT06708650|RADIATION|Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF|Patients received intravenous PD-1 inhibitor 200mg(Camrelizumab, Tislelizumab, or Sintilimab) plus oral Apatinib 250 mg or Lenvatinib 12mg (for bodyweight ≥60 kg) or 8 mg/kg (for bodyweight \<60 kg) daily, and additional SFRT for primary liver tumor. PD-1 inhibitor is administered for 2 years or until disease progression or intolerance. Anti-VEGFR is continued until disease progression or intolerance. SFRT implementation plan is as follows: The GTV consists of 2-5 sub-target volumes, which are cylindrical shapes with a diameter of 1.6cm, a height of 2cm, and an interval of 3-5cm. The total volume of the GTV is about 8-20cc, and the distance between the GTV and the OARs is greater than 2cm. The prescribed dosage for each course of radiotherapy is 24 Gy in 3 daily fractions (8Gy x 3F), with a 3-week interval between courses (Q3W). The total courses of radiotherapy shall not be less than 2 (depending on the efficacy and cumulative dose of OARs).
214256772|NCT06708858|DRUG|Surufatinib|200mg，qd，po
214256773|NCT06708858|DRUG|Gemcitabine|1000mg/ m2, IV，d1，8，q3w
214256774|NCT06708858|DRUG|Cisplatin|25mg/m2，IV，d1，8，q3w
214256775|NCT06708858|DRUG|Durvalumab|1500mg，IV，d1，q3w
214256776|NCT06708858|DRUG|Pembrolizumab|200mg，IV，d1，q3w
214256777|NCT06709508|OTHER|Examination group|This study differs from other clinical studies because the participants of this study consisted of patients undergoing single-member implant-supported restoration treatment at the Department of Prosthodontics, Afyonkarahisar Health Sciences University.
214256778|NCT06707779|OTHER|PNF with electrical stimulation|"Group A receive PNF including combination of isotonic and rhythmic stabilization on trunk with electrical stimulation Participants perform three sets10 repetitions at maximal resistance The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes. 'BURST' TENS (acupuncture-like TENS), characterized by discontinuous stimulation at low frequencies (1-4 Hz), with wave durations of 100-400 ms and high intensities, inducing weak muscle twitches for 10 minutes."
214256779|NCT06707779|OTHER|PNF without electrical stimulation|"Group B receive PNF including combination of isotonic and rhythmic stabilization on trunk without electrical stimulation. Participants perform three sets of 10 repetitions at maximal resistance will be provided by the same physiotherapist.~The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes."
214256780|NCT06710743|OTHER|Glucose solution Day 1, Day 8, and Day 15|Glucodin powder diluted with water
214256781|NCT06710743|OTHER|Food (cereal). Ten different cereals served once each|Variety of cooked or flake cereal
214256782|NCT06705062|DRUG|reduced-dose PTCy|Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.
214256783|NCT06705062|DRUG|Standard dose PTCY|Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
214256784|NCT06707467|OTHER|occlusal splint|nineteen patients diagnosed with internal temporomandibular derangement will receive occlusal splint therapy, a treatment method with proven effectiveness.
214256785|NCT06707467|OTHER|occlusal splints combined with rocabado exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with Rocabado exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether Rocabado exercises have a positive effect on the treatment process.
214256786|NCT06707467|OTHER|occlusal splint combined with posture exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with posture exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether posture exercises have a positive effect on the treatment process.
214256787|NCT06709365|PROCEDURE|Tibiotalar calcaneal fusion by hindfoot|Hindfoot nail for ankle fusion
214256788|NCT06709729|DEVICE|Insulin pump with closed-loop system|Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS
214256789|NCT04275635|DEVICE|Orthokeratology lenses|Orthokeratology lenses
214256790|NCT05001542|OTHER|Educational moral injury video|Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
214256791|NCT06879249|DEVICE|critical ultrasonography|In the CUGP group, attending physicians utilized a designed fluid management strategy guided by ultrasonographic evaluation of the inner diameter of IVC, ejection fraction (EF) value and passive leg raising-induced changes in VTI (ΔVTI). This ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. Additionally, patients did not preclude the concurrent use of conventional hemodynamic monitoring methods. At each of these time points, attending physicians would make comprehensive decisions on fluid management based on the results of ultrasonographic evaluation, along with other monitoring methods. The researcher recorded the basis of decisions, disposal strategy and outcomes.
214256792|NCT05889416|OTHER|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
214256793|NCT05889416|OTHER|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
214256794|NCT06776315|DEVICE|Resistive threshold inspiratory muscle training device|"In the other arm of the study, respiratory muscle training is performed in addition to the standard pulmonary rehabilitation program. Respiratory muscle strengthening training is performed with a resistive thereshold inspiratory muscle strengthening device. The exercise is performed at an intensity of 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The exercise is performed in 7 sets, with 2 minutes of work and 1 minute break for a total of 21 minutes."
214256795|NCT06776315|PROCEDURE|Standard pulmonary rehabilitation programme|Patients are asked to perform thoracic, diaphragmatic breathing, and lower basal breathing exercises with 10 repetitions. Then, strengthening exercises are performed on the major muscle groups of the upper and lower extremities. In accordance with the resistance training program in the ATS/ERS guidelines for pulmonary rehabilitation, two to four sets of 6-12 repetitions are performed with intensities ranging from 50% to 85% of one maximum repetition, two to three times a week. During the exercises, the patient is questioned about their fatigue and dyspnea levels using the Borg scale, and breaks are given when necessary. The aerobic exercise program is performed as a 12-week, 3-day-a-week self-walking exercise. The walking program is performed in the form of walking on flat ground at 60% workload, based on the data obtained from the 6-minute walking test result (land-based walking).
214256796|NCT06776315|GENETIC|No intervention|Peripheral blood samples will be taken once from the participants in the control group and no other intervention will be performed.
214256797|NCT06775769|PROCEDURE|Sclerotherapy|Laparoscopic ethanol sclerotherapy of endometrioma
214256798|NCT06775769|PROCEDURE|Routine Care|Routine surgical management of endometrioma
214256799|NCT06900127|BEHAVIORAL|Safe Swaddling|newborns will be wrapped with the safe wrapping method.
214256800|NCT05069259|OTHER|Stool sample collection|collection for measuring calprotectin levels
214256801|NCT03894137|DIETARY_SUPPLEMENT|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
214256802|NCT03148275|OTHER|Questionnaire Administration|Ancillary studies
214256803|NCT03148275|DRUG|Trametinib|Given PO
214256804|NCT06933212|OTHER|Mediterranean Diet with Extra Virgin Olive Oil|participants in this group will follow a Mediterranean Diet enriched with extra virgin olive oil
214256805|NCT06933212|OTHER|Mediterranean Diet with Walnuts|participants in this group will follow a Mediterranean Diet enriched with walnuts
214256806|NCT06933212|OTHER|Low-Fat Control Diet|participants in this group will follow a low-fat control diet as a comparison to the Mediterranean Diet groups
214256807|NCT06933836|DEVICE|DSLT enables newly diagnosed patients to remain well controlled and off medications|DSLT enables newly diagnosed patients to remain well controlled and off medications
214653356|NCT00363831|DRUG|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
214653357|NCT01797718|DRUG|Testosterone|1mg/kg every 4 weeks for 6 months
214653358|NCT01797718|DRUG|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
214653359|NCT02763956|DEVICE|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
214256808|NCT06933303|DEVICE|Distraction with kaleidoscope|During the intervention measurement, the pediatric patient will be distracted by the use of a kaleidoscope during the procedure. Distraction by use of the kaleidoscope will be initiated at the start of the procedure (dressing change) and the kaleidoscope will be offered until at least a minute after the procedure is completed. Removal of the dressing will be started when the child seems distracted as indicated by response with a smile or laughter, or a verbal response
214256809|NCT06934096|DEVICE|Ultrasound Pulsed Doppler Imaging System|Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.
214256810|NCT03424473|DRUG|Tucatinib|
214256811|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
214256812|NCT06275620|BIOLOGICAL|AGTC-501 (low dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
214256813|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and modified corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
214256814|NCT05165225|DRUG|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
214256815|NCT03803683|DEVICE|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
214256816|NCT03803683|BEHAVIORAL|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
214256817|NCT03803683|DEVICE|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
214256818|NCT04125277|OTHER|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
214256819|NCT02207023|BEHAVIORAL|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
214256820|NCT04567823|DIETARY_SUPPLEMENT|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
214256821|NCT05948787|BEHAVIORAL|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
214256822|NCT02652832|DEVICE|non invasive brain stimulation|non invasive brain stimulation
214256823|NCT01897714|DRUG|Melflufen|
214256824|NCT01897714|DRUG|Dexamethasone|
214256825|NCT04864301|PROCEDURE|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
214256826|NCT03431766|DEVICE|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
214256827|NCT03431766|DEVICE|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
214256828|NCT03905408|DRUG|50 mL of 50% Glucose|1st dose
214256829|NCT03905408|DRUG|100 mL of 50% Glucose|2nd dose
214256830|NCT03905408|DRUG|150 mL of 50% Glucose|3rd dose
214256831|NCT03905408|DRUG|200 mL of 50% Glucose|4th dose
214256832|NCT06129162|DEVICE|Conventional Syringe|Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
214256833|NCT06129162|DEVICE|STA Single Tooth Anesthesia® System.|Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
214256834|NCT06129162|DEVICE|Star Pen anesthesia device.|Dental local anesthesia injection is given by Star Pen anesthesia device by two injection methods inferior alveolar nerve block and buccal infiltration.
214256835|NCT05040048|OTHER|Clinical, biological and imaging assessment|
214256836|NCT00121381|DRUG|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
214256837|NCT00121381|DRUG|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
214256838|NCT03545100|OTHER|motor control therapy|scapular muscle progressive resistive exercise(PRE)
214256839|NCT03545100|OTHER|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
214256840|NCT06556836|DEVICE|Doppler color and M-Mode ultrasound|A diagnostic test intervention using color Doppler and M-Mode ultrasound will be conducted to localize the catheter within the epidural space and compared with epidurography.
214256841|NCT06556836|DEVICE|Epidurography|An epidurography is an imaging procedure used to visualize the epidural space of the spine. The process involves inserting an epidural catheter, through which a contrast dye is injected. Fluoroscopy or X-rays are then used to capture real-time images of the contrast flow, helping to ensure the catheter's correct placement and to detect any localization anomalies. In this study, the epidurography will be performed in the radiology department by a radiologist and a pain management interventionist.
214256842|NCT01595672|DEVICE|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
214256843|NCT01595672|OTHER|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
214653360|NCT02763956|OTHER|Placebo|Intradiscal saline injection
214256844|NCT04601402|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
214256845|NCT04601402|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
214256846|NCT04672343|OTHER|Data collection|from D0 to hospital discharge
214256847|NCT04672343|OTHER|Querying the INSEE database|Vital status at 3 months and 12 months
214256848|NCT04901546|OTHER|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
214256849|NCT00683085|BIOLOGICAL|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
214256850|NCT00704912|DRUG|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
214256851|NCT00704912|DRUG|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
214256852|NCT00704912|DRUG|Combination of treatments|Medications will be administered as described for the other 2 arms.
214256853|NCT02876627|BEHAVIORAL|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
214256854|NCT04394611|OTHER|Obstetric ultrasound- doppler examination|Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
214256855|NCT03094403|DRUG|Azelaic Acid 15% topical gel|Gel
214256856|NCT03094403|DRUG|Finacea® (azelaic acid) Gel, 15%|Gel
214256857|NCT03094403|DRUG|Placebo|Gel
214256858|NCT01262131|DEVICE|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
214256859|NCT01262131|DEVICE|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
214653361|NCT00327938|DEVICE|Measuring of skin conductance|
214653362|NCT00327938|PROCEDURE|Tetanic stimuli|
214256860|NCT01262131|DEVICE|placebo therapy|Application of inactive magnetic fields using the Resonator device
214256861|NCT05265416|PROCEDURE|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
214256862|NCT05265416|OTHER|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.
214256863|NCT05265416|DEVICE|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
214256864|NCT02983565|DEVICE|Intelligent oxygen therapy system (iO2Ts)|
214256865|NCT02930330|BEHAVIORAL|INT|"* 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
214256866|NCT02930330|BEHAVIORAL|CONT|"* 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
214256867|NCT05210673|OTHER|ERAS|Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
214256868|NCT05210673|OTHER|Non ERAS pathway|standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
214653363|NCT02734173|DRUG|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
214256869|NCT00001624|DRUG|Insulin|
214256870|NCT00851630|DRUG|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
214653364|NCT02494570|DRUG|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
214653365|NCT01840046|DRUG|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
214653366|NCT03339804|OTHER|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
214653367|NCT04267640|BIOLOGICAL|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
214653368|NCT04267640|BIOLOGICAL|Placebo|Matching placebo
214653369|NCT01560351|DEVICE|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
214653370|NCT03514914|BEHAVIORAL|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
214256871|NCT03940287|OTHER|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
214256872|NCT03940287|OTHER|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
214256873|NCT03940287|OTHER|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
214256874|NCT03464578|PROCEDURE|Therapy of proximal humeral fractures (irrespective conservative or operative)|
214256875|NCT06378931|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life.
214256876|NCT02349061|DRUG|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
214256877|NCT02349061|DRUG|Placebo Infusion|Placebo intravenously at Week 0.
214256878|NCT02349061|DRUG|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
214256879|NCT02349061|DRUG|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
214256880|NCT02349061|OTHER|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
214256881|NCT05500157|PROCEDURE|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
214256882|NCT00398411|DRUG|moxifloxacin|400 mg p.o. per day
214256883|NCT00398411|DRUG|placebo|one tablet per day p.o.
214256884|NCT02772107|DRUG|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
214256885|NCT02772107|DRUG|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
214256886|NCT02772107|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
214256887|NCT02772107|RADIATION|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
214256888|NCT05457426|PROCEDURE|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
214256889|NCT00750997|DRUG|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
214256890|NCT04423783|BEHAVIORAL|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
214256891|NCT04423783|BEHAVIORAL|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
214256892|NCT06706856|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.
214256893|NCT06706856|DIAGNOSTIC_TEST|US exam|Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.
214256894|NCT06706856|OTHER|Blood draw|Participants will undergo a blood draw of approximately 25 mL volume.
214256895|NCT06706856|OTHER|Physical measurements|Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.
214653371|NCT03707457|DRUG|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214256896|NCT06706856|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).
214256897|NCT06077448|DEVICE|MRI|imaging modality
214256898|NCT03621774|BEHAVIORAL|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
214256899|NCT03621774|BEHAVIORAL|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
214256900|NCT00694915|BIOLOGICAL|Mycobacterium w|Immunomodulator
214256901|NCT00694915|BIOLOGICAL|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
214256902|NCT03763864|OTHER|Skin Biopsy|Skin Biopsy
214256903|NCT00537238|DRUG|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
214256904|NCT00537238|DRUG|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
214256905|NCT01315912|DRUG|Letrozole|2.5 mg /day for 5 days
214256906|NCT01334892|DRUG|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
214256907|NCT02084212|OTHER|Microperimetry|
214256908|NCT03531983|PROCEDURE|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
214256909|NCT02831374|DRUG|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
214256910|NCT02831374|PROCEDURE|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
214256911|NCT02831374|BIOLOGICAL|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
214256912|NCT02831374|PROCEDURE|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
214256913|NCT02831374|PROCEDURE|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
214256914|NCT02831374|DRUG|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
214256915|NCT00335920|DRUG|Dexamethasone-dihydrogenphosphate (4mg/ml)|
214256916|NCT00473473|DRUG|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
214256917|NCT00473473|DRUG|Placebo homeopathic remedy|identical to treatment without active component
214653372|NCT03707457|DRUG|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214653373|NCT03707457|DRUG|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214653374|NCT03707457|DRUG|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
214653375|NCT03432728|PROCEDURE|Dental rehabilitation under general anesthesia|Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
214256918|NCT03926871|OTHER|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
214256919|NCT00729599|DRUG|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
214256920|NCT06076954|BEHAVIORAL|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
214256921|NCT04036734|DIAGNOSTIC_TEST|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
214256922|NCT04036734|DIAGNOSTIC_TEST|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
214256923|NCT02708901|DIETARY_SUPPLEMENT|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
214256924|NCT02708901|DIETARY_SUPPLEMENT|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
214256925|NCT03347188|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
214256926|NCT03347188|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
214256927|NCT00110903|DRUG|Etanercept Liquid|
214256928|NCT01193660|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
214256929|NCT01193660|DRUG|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
214256930|NCT01193660|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
214256931|NCT01193660|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
214256932|NCT01193660|OTHER|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
214256933|NCT05285800|DRUG|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
214256934|NCT01519232|RADIATION|Liver Irradiation|Patients already scheduled to undergo radiation treatment
214256935|NCT04953429|BEHAVIORAL|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
214256936|NCT01114152|DRUG|AZD9742|IV Formulation
214256937|NCT01114152|DRUG|Placebo|IV Formulation
214256938|NCT03852004|OTHER|ostheopathy|standardized osteopathic treatment
214256939|NCT03852004|OTHER|simulated osteopathic treatment|standardized simulated osteopathic treatment
214256940|NCT00290277|BIOLOGICAL|HPV-16/18 L1/AS04|
214256941|NCT02725034|DEVICE|Standard endoscopy|
214256942|NCT02725034|DEVICE|High definition endoscopy with Optic Enhancement|
214256943|NCT06357312|DEVICE|hip trochanteric nail|hip trochanteric nail with and without distal interlocking screw
214256944|NCT05596942|DIETARY_SUPPLEMENT|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
214256945|NCT02572388|BIOLOGICAL|R21|
214256946|NCT02572388|BIOLOGICAL|Matrix-M1|
214256947|NCT05816720|DRUG|Lutetium-177 DOTATATE|Intravenous administration
214256948|NCT00161473|DRUG|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
214256949|NCT00161473|DRUG|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
214256950|NCT00810108|DRUG|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
214256951|NCT01368978|DEVICE|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
214256952|NCT01051466|DRUG|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
214256953|NCT01232231|DRUG|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
214256954|NCT01232231|BEHAVIORAL|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
214256955|NCT03820180|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
214256956|NCT03820180|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
214256957|NCT04045275|BEHAVIORAL|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
214256958|NCT01446107|OTHER|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
214256959|NCT01446107|OTHER|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
214256960|NCT01446107|OTHER|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
214256961|NCT01446107|OTHER|placebo control|application of water onto tooth surface every year
214256962|NCT03559673|DRUG|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
214256963|NCT01291953|PROCEDURE|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
214256964|NCT01291953|PROCEDURE|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
214256965|NCT03326726|DRUG|2% CHG|Chlorhexidine Gluconate
214256966|NCT01286727|DRUG|BB3|intravenous drug
214256967|NCT04355507|DIAGNOSTIC_TEST|Chest computed tomography (CT)|Chest computed tomography (CT) examination
214256968|NCT04355507|DIAGNOSTIC_TEST|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
214256969|NCT00794781|DRUG|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
214256970|NCT01568515|PROCEDURE|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
214256971|NCT00234273|PROCEDURE|Rehabilitation programme in Adapted Physical Activity (APA)|
214256972|NCT00234273|BEHAVIORAL|Therapeutic education primarily focused on dietary|
214256973|NCT00484627|PROCEDURE|Use of creatine monohydrate (a dietary supplement)|
214256974|NCT00484627|BEHAVIORAL|Progressive resistance exercise training|
214256975|NCT00579592|DRUG|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
214256976|NCT05143450|OTHER|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
214256977|NCT05391529|BEHAVIORAL|Interview|Semi structured patient interview via telephone
214256978|NCT00772473|OTHER|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
214256979|NCT03419520|BEHAVIORAL|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
214653376|NCT01488253|DRUG|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
214653377|NCT01488253|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
214653378|NCT02850419|DRUG|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
214256980|NCT05014217|BEHAVIORAL|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
214256981|NCT05014217|BEHAVIORAL|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
214256982|NCT03562910|OTHER|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
214256983|NCT00072657|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
214256984|NCT00072657|BEHAVIORAL|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
214653379|NCT02850419|RADIATION|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
214256985|NCT00072657|BEHAVIORAL|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
214256986|NCT03498066|DRUG|Beta-blockers withdrawal|withdrawal of all type of betablockers
214256987|NCT03498066|DRUG|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
214256988|NCT00547196|BIOLOGICAL|filgrastim|
214256989|NCT00547196|DRUG|Busulfan|
214256990|NCT00547196|DRUG|Cyclophosphamide|
214256991|NCT00547196|DRUG|Cyclosporine|
214256992|NCT00547196|DRUG|Fludarabine phosphate|
214256993|NCT00547196|DRUG|Melphalan|
214256994|NCT00547196|DRUG|Mycophenolate Mofetil|
214256995|NCT00547196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214256996|NCT00547196|PROCEDURE|umbilical cord blood transplantation|
214256997|NCT00547196|RADIATION|total-body irradiation|
214256998|NCT00547196|RADIATION|Fractionated total body irradiation|
214256999|NCT01381484|DRUG|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
214257000|NCT05123911|OTHER|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
214257001|NCT05123911|OTHER|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
214257002|NCT05123911|OTHER|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
214257003|NCT05906979|OTHER|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
214257004|NCT05906979|OTHER|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
214257005|NCT04088643|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
214257006|NCT04088643|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
214257007|NCT05734300|PROCEDURE|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
214257008|NCT05734300|PROCEDURE|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
214257009|NCT01676727|DEVICE|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
214257010|NCT01578330|DRUG|Fingolimod|Fingolimod 0.5mg orally once a day without food.
214257011|NCT01086423|BIOLOGICAL|Infanrix-IPV/Hib™|Intramuscular, three doses
214257012|NCT01086423|BIOLOGICAL|Infanrix Hib™|Intramuscular, three doses
214257013|NCT01086423|BIOLOGICAL|Poliorix™|Intramuscular, three doses
214257014|NCT04585373|OTHER|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
214257015|NCT04585373|OTHER|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
214653380|NCT02850419|DEVICE|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
214653381|NCT01855256|DRUG|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
214653382|NCT01855256|DRUG|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
214653383|NCT01841632|DRUG|MultiStem|
214653384|NCT02183714|DRUG|Songha Night ®|
214653385|NCT02183714|DRUG|Placebo|
214653386|NCT02575430|OTHER|No treatment: retrospective chart review|
214257016|NCT04585373|OTHER|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
214257017|NCT03114488|DEVICE|tDCS|Transcranial electrical stimulator
214257018|NCT03075046|DEVICE|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
214257019|NCT03075046|OTHER|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
214257020|NCT02276404|BEHAVIORAL|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
214257021|NCT02276404|OTHER|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
214257022|NCT02892032|BEHAVIORAL|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
214257023|NCT02892032|BEHAVIORAL|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
214257024|NCT04693455|DRUG|ZD03|ZD03 capsule
214257025|NCT04693455|OTHER|Placebo|placebo capsule
214257026|NCT04965051|DRUG|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
214257027|NCT04965051|DRUG|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
214257028|NCT06638268|PROCEDURE|Acute TAVI|TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
214257029|NCT06638268|OTHER|Stabilization and subacute TAVI|Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
214257030|NCT02009007|DRUG|dopamine|continuous infusion during operation
214257031|NCT02009007|DRUG|phenylephrine|continuous infusion of phenylephrine during operation
214257032|NCT00566501|DRUG|Donepezil|Donepezil SR 23 mg once daily orally.
214257033|NCT02977130|BEHAVIORAL|Map group|diabetes shared care plus conversation map intervention
214257034|NCT02977130|BEHAVIORAL|Control group|diabetes shared care
214257035|NCT04558281|DRUG|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
214257036|NCT04558281|DRUG|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
214257037|NCT05111808|DEVICE|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
214257038|NCT03583723|RADIATION|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
214257039|NCT03711201|BEHAVIORAL|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
214257040|NCT04418284|OTHER|survey|online survey
214257041|NCT03580148|DRUG|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
214257042|NCT03580148|BIOLOGICAL|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
214257043|NCT00749515|DRUG|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
214257044|NCT00749515|DRUG|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
214257045|NCT00749515|RADIATION|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
214257046|NCT05955053|OTHER|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
214257047|NCT01368432|DRUG|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
214257048|NCT01368432|DRUG|Placebo|Sugar pill placebo
214257049|NCT04058418|OTHER|Survey Administration|Completion of a short survey.
214257050|NCT03432156|BIOLOGICAL|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
214257051|NCT02409810|DRUG|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
214257052|NCT04462510|PROCEDURE|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
214257053|NCT00251355|DRUG|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
214257054|NCT00251355|DRUG|5-Fluorouracil|5-FU via continuous IV infusion.
214257055|NCT00251355|PROCEDURE|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
214257056|NCT00003307|DRUG|amifostine trihydrate|
214257057|NCT00003307|RADIATION|radiation therapy|
214257058|NCT03564028|OTHER|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
214257059|NCT03564028|OTHER|control session|Patients will realize one session of stair climbing at their own pace
214257060|NCT00480883|DRUG|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
214257061|NCT00480883|DRUG|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
214257062|NCT00480883|DRUG|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
214257063|NCT05484908|OTHER|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
214257064|NCT05484908|OTHER|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
214257065|NCT05484908|OTHER|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
214257066|NCT02016430|BEHAVIORAL|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
214257067|NCT02016430|BEHAVIORAL|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling.
214257068|NCT02016430|BEHAVIORAL|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
214257069|NCT04798456|BEHAVIORAL|Coma scales|CRS-R and GOSE
214257070|NCT04798456|DIAGNOSTIC_TEST|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
214257071|NCT04798456|BEHAVIORAL|Questionnaires|several questionnaires and an interview with the caregiver
214257072|NCT00437320|DRUG|Metvix Cream 160 mg/g|Participants were treated with topical administration of Metvix cream.
214257073|NCT00437320|DRUG|Metvix Vehicle Group|Participants were treated with topical administration of Metvix Vehicle cream.
214257074|NCT00969904|DRUG|N-acetylcysteine|600 mg TID for 12 weeks
214257075|NCT00969904|DRUG|placebo|placebo tablet TID for 12 weeks
214257076|NCT01741090|BIOLOGICAL|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
214257077|NCT01938573|DRUG|Cisplatin|Given IV
214257078|NCT01938573|DRUG|Gemcitabine Hydrochloride|Given IV
214257079|NCT01938573|DRUG|Sirolimus|Given PO
214257080|NCT01938573|PROCEDURE|Cystectomy|Undergo cystectomy when appropriate
214257081|NCT01995643|DIETARY_SUPPLEMENT|Active Capsule|GSE Capsule
214257082|NCT01995643|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo Capsule
214257083|NCT05705414|DRUG|Valine|A medical food intended for use under medical supervision
214257084|NCT05705414|DRUG|EEA|A medical food intended for use under medical supervision
214257085|NCT01649609|DRUG|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
214257086|NCT01649609|DRUG|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
214257087|NCT01649609|DRUG|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
214257088|NCT04721951|PROCEDURE|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
214257089|NCT00139061|DRUG|Torcetrapib/Atorvastatin|
214257090|NCT00139061|DRUG|Fenofibrate|
214257091|NCT06218212|DIETARY_SUPPLEMENT|Renastart formula|"* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium."
214257092|NCT06218212|DRUG|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
214257093|NCT03036904|DRUG|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
214653387|NCT05207150|DEVICE|LINQII/Apple Watch Series 6|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
214653388|NCT05207150|DEVICE|LINQII/SkyLabs CART-I ring|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
214653389|NCT05289960|OTHER|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
214653390|NCT04080011|DEVICE|NP-PWD|Application of NP-PWD device.
214257094|NCT03036904|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
214257095|NCT03036904|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214257096|NCT03036904|DRUG|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214257097|NCT03036904|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214257098|NCT03036904|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
214257099|NCT03036904|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214257100|NCT02617888|RADIATION|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
214257101|NCT01460316|BIOLOGICAL|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
214257102|NCT01225796|DRUG|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
214257103|NCT04814862|BEHAVIORAL|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
214257104|NCT00762216|DEVICE|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
214257105|NCT01408797|PROCEDURE|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
214257106|NCT01408797|DRUG|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
214257107|NCT01408797|PROCEDURE|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
214257108|NCT00484809|DRUG|Enbrel (Etanercept)|
214257109|NCT00277446|DRUG|Soy isoflavones|
214257110|NCT05668975|DEVICE|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
214257111|NCT04986644|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
214257112|NCT02302534|DEVICE|MRI|MRI
214257113|NCT03845543|DEVICE|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
214257114|NCT06495866|RADIATION|ultrasound|Ultrasound finding of entheseal sites of upper \& lower limbs of all groups and scoring according to enthesitis scoring system
214257115|NCT01799577|PROCEDURE|Laparoscopic surgery|Two methods will be compare
214257116|NCT00398827|DRUG|Dexmedetomidine|
214257117|NCT00398827|DRUG|Placebo|
214257118|NCT01327456|BEHAVIORAL|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
214257119|NCT01682668|PROCEDURE|Bilateral subthalamic stimulation|
214257120|NCT00482261|DRUG|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
214257121|NCT00482261|DRUG|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
214257122|NCT00482261|DRUG|aspirin|100mg/day
214257123|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
214257124|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
214257125|NCT05113095|BIOLOGICAL|Darvadstrocel|Darvadstrocel injection
214257126|NCT04045301|BIOLOGICAL|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
214653391|NCT00869297|OTHER|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
214653392|NCT00869297|OTHER|Control|Fluids titrated at discretion of anesthesiologist.
214653393|NCT02325544|BEHAVIORAL|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
214653394|NCT02325544|BEHAVIORAL|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
214653395|NCT04514263|OTHER|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
214653396|NCT04514263|OTHER|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
214653397|NCT04337957|OTHER|geriatric nephrology|Collection of the geriatrician's opinion
214653398|NCT00041314|DRUG|carboplatin|
214257127|NCT04045301|BIOLOGICAL|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
214257128|NCT04045301|BIOLOGICAL|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
214257129|NCT04045301|OTHER|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
214257130|NCT04640181|DRUG|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
214257131|NCT04640181|DRUG|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
214257132|NCT06523283|OTHER|Natural Landscape Pictures Accompanied by Music|after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
214257133|NCT04072562|DRUG|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
214257134|NCT02456103|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
214257135|NCT03750370|DEVICE|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity \[PSV\] and end diastolic velocity \[EDV\]) and the resistance indices against this flow (resistive index \[RI\] and pulsatility index \[PI\]) in the testis can be measured with this technique.
214257136|NCT00558779|PROCEDURE|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
214257137|NCT00558779|PROCEDURE|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
214257138|NCT03292211|BEHAVIORAL|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
214257139|NCT03292211|BEHAVIORAL|early standard intervention|Conventional early in-bed activities within three days after stroke
214257140|NCT06123663|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
214257141|NCT06123663|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
214257142|NCT03480867|DRUG|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
214653399|NCT00041314|DRUG|exisulind|
214653400|NCT00041314|DRUG|gemcitabine hydrochloride|
214257143|NCT03480867|RADIATION|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
214257144|NCT05438641|DRUG|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
214257145|NCT05438641|DRUG|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
214257146|NCT00005928|DRUG|Ramipril|
214257147|NCT02923258|DRUG|Docetaxel|20mg/m2/w
214257148|NCT02923258|DRUG|Cisplatin|100mg/m2/q3w
214257149|NCT02923258|RADIATION|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
214257150|NCT03649867|OTHER|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
214257151|NCT00602173|DRUG|Cilostazol|
214257152|NCT03242538|BEHAVIORAL|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
214257153|NCT03706131|OTHER|cervical mobilisation|manual therapy
214257154|NCT02724150|DRUG|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
214257155|NCT02724150|DRUG|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
214257156|NCT02640469|OTHER|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
214257157|NCT02640469|OTHER|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
214257158|NCT02640469|OTHER|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
214257159|NCT03071159|DEVICE|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
214257160|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
214257161|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
214653401|NCT03373019|DRUG|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
214653402|NCT00292084|DRUG|Celgosivir|
214653403|NCT04899648|BEHAVIORAL|Behavioral Intervention Group|Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
214653404|NCT05939297|OTHER|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
214653405|NCT05939297|OTHER|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
214653406|NCT05939297|OTHER|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
214653407|NCT02506530|PROCEDURE|intensive decongestive treatment|intensive decongestive treatment
214257162|NCT02448810|BIOLOGICAL|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
214257163|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
214257164|NCT02448810|BIOLOGICAL|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
214257165|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
214257166|NCT02448810|DRUG|Standard of Care|"* Investigator's choice~* Dose according to drug label"
214257167|NCT02448810|BIOLOGICAL|Standard of Care|"* Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only"
214257168|NCT01360281|OTHER|Neuromuscular Electrical Stimulation|
214257169|NCT01360281|OTHER|ECR|Resisted exercises
214257170|NCT02801305|DRUG|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
214257171|NCT02801305|DRUG|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
214257172|NCT02801305|DRUG|Vaseline|This is used as the topical placebo agent.
214257173|NCT06045104|DIETARY_SUPPLEMENT|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
214257174|NCT06045104|DIETARY_SUPPLEMENT|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
214257175|NCT00730197|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
214257176|NCT00730197|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
214653408|NCT02506530|DEVICE|Cellu M6|Use of Cellu M6
214653409|NCT01355289|DRUG|Avatrombopag|
214653410|NCT01355289|DRUG|Placebo|
214257177|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
214257178|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in PA, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
214257179|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
214257180|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
214257181|NCT04190667|DIAGNOSTIC_TEST|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
214257182|NCT05708586|BEHAVIORAL|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
214257183|NCT05708586|DEVICE|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
214257184|NCT06352983|PROCEDURE|Fixed dental prosthesis|Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
214257185|NCT02907268|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
214257186|NCT02907268|DRUG|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
214257187|NCT00470847|DRUG|Lapatinib|Orally twice daily
214257188|NCT00470847|PROCEDURE|Whole Brain Radiation|15 treatments over a period of 3 weeks
214257189|NCT00470847|DRUG|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
214257190|NCT05504395|DRUG|CSTI-500|Single 10 mg capsule
214257191|NCT03459482|OTHER|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
214257192|NCT02225769|OTHER|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
214257193|NCT02225769|OTHER|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
214257194|NCT05584332|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
214257195|NCT05584332|BIOLOGICAL|Placebo|0.5 ml injection in 3 dosing regimen
214257196|NCT00590460|BIOLOGICAL|CAMPATH-1H|Given intravenous on days -8, -7, and -6
214257197|NCT00590460|BIOLOGICAL|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
214257198|NCT00590460|DRUG|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
214257199|NCT00590460|PROCEDURE|Stem cell infusion|Stem cells are infused on day 0
214257200|NCT00125684|DRUG|morphine|
214257201|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
214257202|NCT01070862|DRUG|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
214257203|NCT01070862|DRUG|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
214257204|NCT01070862|DRUG|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
214257205|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
214257206|NCT04304157|DRUG|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
214257207|NCT04856475|DRUG|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
214257208|NCT05533476|BEHAVIORAL|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
214257209|NCT05533476|BEHAVIORAL|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
214257210|NCT01719978|DRUG|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
214257211|NCT01719978|PROCEDURE|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
214257212|NCT01719978|DRUG|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
214257213|NCT01719978|DRUG|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
214257214|NCT03258177|OTHER|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
214257215|NCT05653726|OTHER|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
214257216|NCT01687036|DEVICE|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
214257217|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
214257218|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
214257219|NCT06420128|OTHER|Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
214257220|NCT00457366|DRUG|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
214257221|NCT00457366|DRUG|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
214257222|NCT00457366|DRUG|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
214257223|NCT00457366|DRUG|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
214257224|NCT06198764|DRUG|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
214257225|NCT06198764|DRUG|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
214257226|NCT06198764|DRUG|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
214653411|NCT01355289|DRUG|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
214257227|NCT01082731|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
214257228|NCT01082731|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
214257229|NCT02905656|BEHAVIORAL|Brief Advice|Psychoeducation
214257230|NCT02905656|BEHAVIORAL|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
214257231|NCT02905656|BEHAVIORAL|Rate Reduction|Reducing the number of cigarettes consumed.
214257232|NCT02905656|DRUG|Pharmacological|Nicotine Replacement Therapy in the form of gum.
214257233|NCT02905656|BEHAVIORAL|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
214257234|NCT00066144|DRUG|Cimicifuga racemosa|
214257235|NCT00066144|DRUG|Trifolium pratense|
214257236|NCT00066144|DRUG|Black cohosh|
214257237|NCT00066144|DRUG|Red clover|
214257238|NCT00844818|BEHAVIORAL|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
214257239|NCT06143774|DRUG|TRX-920 Oral Gel (10 mg and 30 mg)|"TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified."
214257240|NCT02119091|DRUG|Moxifloxacin|
214257241|NCT03456440|DIAGNOSTIC_TEST|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
214257242|NCT05323578|OTHER|Survey|Prevalence of safe caffeine consumption among anesthetists
214257243|NCT04654884|OTHER|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
214653412|NCT01355289|DRUG|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
214257244|NCT04805827|DRUG|Gabapentin|1 tablet contains 600 mg Gabapentin
214257245|NCT04805827|DRUG|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
214257246|NCT01551537|OTHER|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
214257247|NCT01551537|OTHER|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
214257248|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
214257249|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
214257250|NCT02462174|DRUG|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
214257251|NCT02462174|DRUG|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
214257252|NCT03462069|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214257253|NCT03462069|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214257254|NCT03462069|DRUG|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
214653413|NCT01355289|DRUG|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
214653414|NCT02814773|OTHER|questionnaires|
214653415|NCT01795651|PROCEDURE|identification of take-home message of lecture|
214653416|NCT05877131|DRUG|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
214257255|NCT03462069|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
214257256|NCT00478374|DRUG|Sorafenib|Sorafenib 400mg bid
214257257|NCT00478374|PROCEDURE|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
214257258|NCT04856891|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
214257259|NCT04856891|OTHER|Placebo|Placebo
214257260|NCT05144204|BEHAVIORAL|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
214257261|NCT00390234|DRUG|ziv-aflibercept|Given IV
214257262|NCT00229151|BEHAVIORAL|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
214257263|NCT00229151|OTHER|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
214257264|NCT00069433|PROCEDURE|Social skills and symptom management training|
214257265|NCT00441454|DEVICE|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
214257266|NCT00441454|DEVICE|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
214257267|NCT02210468|DEVICE|APIC-CF, 4 cc|
214257268|NCT02210468|DEVICE|APIC-CF, 2 cc|
214257269|NCT02210468|OTHER|Placebo Comparator: Saline|Placebo Comparator: Saline
214257270|NCT05693727|DIAGNOSTIC_TEST|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
214257271|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
214257272|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
214257273|NCT00859183|DRUG|Placebo|Placebo oral
214257274|NCT02121990|DRUG|Paclitaxel,|
214257275|NCT02121990|DRUG|Bevacizumab|
214257276|NCT02121990|DRUG|Cisplatin|
214257277|NCT02121990|DRUG|Olaparib|
214257278|NCT00837928|DRUG|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
214257279|NCT00837928|OTHER|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
214257280|NCT00837928|PROCEDURE|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
214257281|NCT00837928|RADIATION|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
214257282|NCT03139279|DRUG|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
214257283|NCT03139279|OTHER|Saline placebo|Intravenous saline/placebo
214257284|NCT03139279|DRUG|Propofol|Propofol titrated intravenous boluses
214257285|NCT04084327|OTHER|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
214257286|NCT06090591|OTHER|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
214257287|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
214257288|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
214257289|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
214257290|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
214257291|NCT03866187|BIOLOGICAL|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
214257292|NCT03866187|BIOLOGICAL|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
214257293|NCT03866187|DRUG|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
214257294|NCT02890667|OTHER|Incident cancer|The number of incident cancer cases
214653417|NCT05877131|DRUG|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
214257295|NCT04307914|RADIATION|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
214257296|NCT04307914|PROCEDURE|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
214257297|NCT04964843|DRUG|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
214257298|NCT04964843|DRUG|Placebo|Placebo
214257299|NCT02637336|DEVICE|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
214257300|NCT02637336|DEVICE|Aerobic exercise|aerobic exercise of moderate intensity
214257301|NCT02637336|DEVICE|Aromatherapy|inhalation of eucalyptus essential oil
214257302|NCT04940208|OTHER|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
214257303|NCT04940208|DIAGNOSTIC_TEST|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
214257304|NCT05389046|DRUG|Escitalopram|Escitalopram
214257305|NCT05389046|DRUG|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
214257306|NCT05389046|DRUG|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
214257307|NCT05389046|DRUG|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
214257308|NCT02864719|OTHER|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
214257309|NCT04336410|DRUG|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
214257310|NCT04336410|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
214257311|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
214257312|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
214257313|NCT02290327|DRUG|Pantoprazole|Proton pump inhibitor
214257314|NCT02290327|DRUG|Placebo|50 ml of 0.9% normal saline
214257315|NCT05268107|DRUG|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
214257316|NCT02434367|BEHAVIORAL|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
214257317|NCT01369160|BEHAVIORAL|Quality of Life measures|measuring QOL with different therapies
214257318|NCT05199493|DRUG|Angiotensin II|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
214257319|NCT05199493|DRUG|Control|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
214257320|NCT01841177|DRUG|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
214257321|NCT03986151|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
214257322|NCT01739673|OTHER|Ultraviolet-A and riboflavin|
214257323|NCT00017017|DRUG|paclitaxel poliglumex|
214257324|NCT00126607|BIOLOGICAL|trastuzumab|Given IV
214257325|NCT00126607|OTHER|laboratory biomarker analysis|Correlative studies
214257326|NCT01798680|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
214257327|NCT01798680|OTHER|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
214257328|NCT04206007|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
214257329|NCT00703196|DIETARY_SUPPLEMENT|folic acid|Given orally once daily
214257330|NCT00703196|OTHER|placebo|Given orally once daily
214257331|NCT00957112|PROCEDURE|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
214257332|NCT00957112|PROCEDURE|standard follow-up care|Patients receive standard care
214257333|NCT05043558|DRUG|beprostaglandin sodium|beprostaglandin sodium
214257334|NCT00614328|DRUG|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
214257335|NCT06207838|DEVICE|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
214257336|NCT06008028|DRUG|BR1015|One tablet administered alone
214257337|NCT06008028|DRUG|BR1015-1|One tablet administered alone
214257338|NCT06008028|DRUG|BR1015-2|One tablet administered alone
214257339|NCT03405610|BEHAVIORAL|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
214257340|NCT01962831|DRUG|Dinoprostone|
214257341|NCT01962831|DEVICE|Single balloon foley catheter|
214257342|NCT02499978|DRUG|Darunavir/Cobicistat|Fixed dose combination medication
214257343|NCT02499978|DRUG|Dolutegravir|single tablet medication
214257344|NCT06147453|DEVICE|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
214257345|NCT05635071|DRUG|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
214257346|NCT05635071|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
214257347|NCT00160173|DRUG|Estrogel|
214257348|NCT00160173|OTHER|Placebo|
214257349|NCT04595240|DIAGNOSTIC_TEST|semen analysis|semen analysis
214257350|NCT02069132|DRUG|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
214257351|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
214257352|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
214257353|NCT01464944|DRUG|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
214257354|NCT01464944|DRUG|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
214257355|NCT01464944|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
214257356|NCT02091973|DRUG|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
214257357|NCT02091973|DRUG|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
214257358|NCT01090973|DRUG|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
214257359|NCT03648827|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
214257360|NCT05239260|DIAGNOSTIC_TEST|CMR|CMR
214257361|NCT03401736|DEVICE|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
214257362|NCT03401736|DRUG|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
214257363|NCT03401736|DRUG|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
214257364|NCT03132012|BEHAVIORAL|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
214257365|NCT03132012|BEHAVIORAL|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
214257366|NCT02854150|GENETIC|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
214257367|NCT02054377|OTHER|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
214257368|NCT04317976|OTHER|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
214257369|NCT04317976|OTHER|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
214257370|NCT03109054|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
214257371|NCT00706810|DRUG|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
214257372|NCT00706810|DRUG|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
214257373|NCT03848104|OTHER|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
214257374|NCT01626495|BIOLOGICAL|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
214257375|NCT01149811|DRUG|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
214257376|NCT01149811|DRUG|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
214257377|NCT04324931|OTHER|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
214257378|NCT04324931|OTHER|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
214257379|NCT03949985|OTHER|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
214257380|NCT01451580|DRUG|Lipo-Dox|
214257381|NCT04290312|OTHER|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
214257382|NCT02808377|OTHER|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
214257383|NCT00650234|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
214257384|NCT00650234|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
214257385|NCT02368704|OTHER|No intervention|
214257386|NCT05625893|RADIATION|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
214257387|NCT02193477|DEVICE|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
214257388|NCT02193477|DEVICE|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
214257389|NCT02196207|DRUG|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
214257390|NCT02196207|DRUG|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
214257391|NCT02196207|DRUG|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
214257392|NCT02196207|DRUG|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
214257393|NCT01934972|OTHER|CR + DCS (D-cycloserine)|CR + DCS
214257394|NCT01934972|OTHER|CR + placebo|CR + placebo
214257395|NCT06286358|DIAGNOSTIC_TEST|Kinocardiography|Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
214257396|NCT03131453|DRUG|CNP520 50mg|50 mg capsule
214257397|NCT03131453|DRUG|CNP520 15mg|15 mg capsule
214257398|NCT03131453|OTHER|Matching placebo|Matching placebo for 15 and 50 mg capsules
214257399|NCT03864770|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
214257400|NCT03864770|PROCEDURE|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
214257401|NCT03975062|DRUG|dabigatran etexilate|150 mg twice daily (BID)
214257402|NCT00950495|DEVICE|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
214257403|NCT00950495|DEVICE|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
214653418|NCT06450665|BEHAVIORAL|VR Social Avoidance Intervention|The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
214257404|NCT00950495|DEVICE|placebo|as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
214257405|NCT00006223|BIOLOGICAL|recombinant flt3 ligand|
214257406|NCT01945112|DEVICE|Paper Tape|Applied to blister prone areas of the foot
214257407|NCT04205253|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
214257408|NCT04840732|BEHAVIORAL|VR training program|Use VR software to make a training education program.
214257409|NCT04840732|BEHAVIORAL|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
214653419|NCT03492593|OTHER|lycopene|A tomato oleoresin containing lycopene
214653420|NCT03492593|OTHER|beta-carotene|13C beta-carotene
214257410|NCT04768725|BEHAVIORAL|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
214257411|NCT04768725|BEHAVIORAL|Dietary intervention|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
214257412|NCT04768725|BEHAVIORAL|Physical-cognitive intervention|Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
214257413|NCT02988154|OTHER|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
214257414|NCT02988154|OTHER|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
214257415|NCT04020328|DRUG|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
214257416|NCT01483768|PROCEDURE|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
214257417|NCT02378623|DRUG|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
214257418|NCT02378623|DRUG|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
214257419|NCT00087165|BIOLOGICAL|GTI-2040|
214257420|NCT00087165|DRUG|docetaxel|
214257421|NCT00087165|DRUG|prednisone|
214257422|NCT06047925|PROCEDURE|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
214257423|NCT06047925|PROCEDURE|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
214257424|NCT05227378|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
214257425|NCT04867057|DRUG|Trichomylin for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
214257426|NCT04867057|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
214257427|NCT04867057|DRUG|Trichomylin for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
214257428|NCT04867057|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
214257429|NCT04956926|DRUG|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
214257430|NCT01960673|DEVICE|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
214257431|NCT01960673|DEVICE|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
214257432|NCT01960673|DEVICE|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
214257433|NCT01960673|DEVICE|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
214257434|NCT05280210|OTHER|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
214653421|NCT03492593|OTHER|control|emulsified liquid meal alone
214257435|NCT02660931|OTHER|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
214257436|NCT04876144|DEVICE|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
214257437|NCT01819376|OTHER|Facebook Status Update|
214257438|NCT01407744|OTHER|laboratory biomarker analysis|Correlative studies
214257439|NCT05060484|BIOLOGICAL|SCT1000|HPV vaccine
214257440|NCT05060484|BIOLOGICAL|Gardasil®9|HPV vaccine
214257441|NCT05060484|BIOLOGICAL|Gardasil®|HPV vaccine
214257442|NCT05060484|OTHER|placebo|adjuvent
214257443|NCT04086875|BEHAVIORAL|Focus Group|Participate in focus group
214257444|NCT04086875|OTHER|Text Message|Receive text messages
214257445|NCT04086875|OTHER|Best Practice|Receive usual care
214257446|NCT04086875|OTHER|Questionnaire Administration|Ancillary studies
214257447|NCT03438383|DEVICE|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
214257448|NCT03438383|DEVICE|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
214257449|NCT02766465|DRUG|Busulfan|"A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics."
214257450|NCT02766465|DRUG|Fludarabine|"A:~Fludarabine dose will be 35 mg/m\^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m\^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4"
214257451|NCT02766465|DRUG|r-ATG|"A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg)."
214257452|NCT02766465|PROCEDURE|Hematopoietic Cell Transplant|"A,B,C:~Day 0 is the day of transplantation."
214257453|NCT02766465|DRUG|Tacrolimus|"A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines"
214257454|NCT02766465|DRUG|Methotrexate|"A:~Methotrexate will be administered intravenously on day+1 at 15mg/m\^2, day+3 at 10mg/m\^2, day+6 at 10mg/m\^2, and day+11 at 10mg/m\^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant"
214257455|NCT02766465|PROCEDURE|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
214257456|NCT02766465|DRUG|Alemtuzumab|"B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days."
214257457|NCT02766465|DRUG|Total Body Irradiation (TBI)|Total Body Irradiation 300 cGY on Day -2
214653422|NCT05612919|OTHER|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development."
214257458|NCT02766465|DRUG|Sirolimus|Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ \>50%
214257459|NCT02766465|DRUG|Melphalan|"C:~Melphalan 140 mg/m2 IV dose will be given on Day -3"
214257460|NCT02766465|DRUG|G-CSF|G-CSF 5 μg/kg/day continue until neutrophil engraftment.
214257461|NCT03513523|DIETARY_SUPPLEMENT|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
214257462|NCT03513523|DIETARY_SUPPLEMENT|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
214257463|NCT03513523|OTHER|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
214257464|NCT00914680|PROCEDURE|magnetic seizure therapy|antidepressant treatment with MST
214257465|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
214257466|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
214257467|NCT00715455|DRUG|Unfractionated Heparin|Heparin will be administered per standard of care at sites
214257468|NCT03516825|OTHER|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
214257469|NCT02435069|DRUG|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
214257470|NCT02435069|DRUG|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
214257471|NCT04143893|DEVICE|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
214257472|NCT04143893|DRUG|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
214257473|NCT02682771|DEVICE|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
214257474|NCT02682771|DEVICE|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
214257475|NCT02682771|PROCEDURE|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
214257476|NCT01528033|DEVICE|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
214257477|NCT01528033|OTHER|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
214257478|NCT01242683|BEHAVIORAL|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
214257479|NCT03588871|OTHER|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
214257480|NCT03588871|OTHER|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
214257481|NCT03588871|OTHER|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
214257482|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
214257483|NCT03588871|OTHER|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
214257484|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
214257485|NCT00808561|OTHER|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
214257486|NCT00808561|OTHER|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
214257487|NCT04407052|DRUG|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
214257488|NCT04407052|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
214257489|NCT05350306|DEVICE|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
214257490|NCT05350306|OTHER|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
214257491|NCT02571036|DRUG|DCC-2618|50 mg formulated tablets
214257492|NCT02571036|DRUG|DCC-2618|10 mg and 50 mg formulated tablets
214257493|NCT00046514|DRUG|ABI-007|
214257494|NCT01936727|PROCEDURE|cataract surgery|
214257495|NCT00000663|DRUG|CD4-IgG|
214257496|NCT03813823|BEHAVIORAL|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
214257497|NCT05517993|DRUG|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
214257498|NCT02520661|BEHAVIORAL|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
214257499|NCT02165371|BEHAVIORAL|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
214257500|NCT05770583|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
214257501|NCT05770583|PROCEDURE|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
214257502|NCT05420792|BEHAVIORAL|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
214257503|NCT00121095|DRUG|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
214257504|NCT05508997|DEVICE|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
214257505|NCT00384527|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
214257506|NCT00384527|DRUG|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
214257507|NCT06072248|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
214257508|NCT06072248|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
214257509|NCT06072248|DEVICE|ventilator|ventilator
214257510|NCT05250128|PROCEDURE|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
214257511|NCT03170856|OTHER|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
214257512|NCT05354154|PROCEDURE|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
214257513|NCT03512899|PROCEDURE|Right internal jugular access.|Implantation using percutaneous puncture.
214257514|NCT03512899|PROCEDURE|Left internal jugular access.|Implantation using percutaneous puncture.
214257515|NCT03512899|PROCEDURE|Right axillary vein access.|Implantation using percutaneous puncture.
214257516|NCT03512899|PROCEDURE|Left axillary vein access.|Implantation using percutaneous puncture.
214257517|NCT01444131|DRUG|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
214257518|NCT01444131|DRUG|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
214653423|NCT05612919|OTHER|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
214653424|NCT05782829|DIETARY_SUPPLEMENT|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
214257519|NCT00163111|DRUG|VFENDÂ® I.V., Oral|
214257520|NCT00163111|DRUG|Conventional amphotericin B|
214257521|NCT00163111|DRUG|Diflucan IV, oral|
214257522|NCT03788629|OTHER|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
214257523|NCT03788629|OTHER|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
214257524|NCT03167905|DEVICE|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214257525|NCT03167905|DRUG|Entonox|Entonox will be given upon request in non-epidural group.
214257526|NCT03167905|DRUG|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
214257527|NCT03167905|DRUG|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
214257528|NCT03167905|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214257529|NCT03167905|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214257530|NCT01042574|DRUG|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
214257531|NCT00625066|OTHER|biologic sample preservation procedure|
214257532|NCT00625066|OTHER|cytology specimen collection procedure|
214257533|NCT00625066|OTHER|medical chart review|
214257534|NCT00625066|OTHER|questionnaire administration|
214257535|NCT00625066|OTHER|survey administration|
214257536|NCT00625066|PROCEDURE|biopsy|
214257537|NCT00625066|PROCEDURE|evaluation of cancer risk factors|
214257538|NCT00625066|PROCEDURE|screening colonoscopy|
214257539|NCT06296212|DRUG|TAD® 600 mg/4 mL powder and solvent for solution for injection|TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
214257540|NCT06296212|DRUG|Saline solution 0.9% of sodium chloride|Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
214257541|NCT05035511|DEVICE|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
214257542|NCT05156073|OTHER|Educational Materials|"1. Patient care partner cohort:~   a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~2. Primary care physician cohort:~   1. education on deprescribing through a 15-45-minute presentation~  2. one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations."
214257543|NCT01532973|DRUG|Elbasvir|Elbasvir was administered orally by tablet(s)
214257544|NCT01532973|DRUG|Placebo|Dose-matched placebo tablets were administered orally.
214257545|NCT02891161|DRUG|durvalumab|1500 mg Q4 weekly
214257546|NCT02891161|RADIATION|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
214257547|NCT06557187|RADIATION|ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
214257548|NCT03309150|DRUG|Berzosertib|Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.
214257549|NCT06223737|DIAGNOSTIC_TEST|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
214257550|NCT06223737|DIAGNOSTIC_TEST|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
214257551|NCT05446181|BEHAVIORAL|Perioperative delirium|Perioperative delirium
214257552|NCT05446181|PROCEDURE|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
214257553|NCT05281211|DIETARY_SUPPLEMENT|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
214257554|NCT05281211|BEHAVIORAL|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
214257555|NCT04401605|OTHER|Fermented Food-supplemented Diet|Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
214257556|NCT04401605|OTHER|Regular Diet|No change in diet.
214257557|NCT04266769|DEVICE|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
214257558|NCT05916560|DRUG|LY3437943|Administered SC.
214257559|NCT05266898|BIOLOGICAL|Human papillomavirus 9-valent vaccine, recombinant|Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
214257560|NCT05266898|BIOLOGICAL|human papillomavirus vaccine, recombinant|Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus. Administered as part of participant's clinical care prior to study enrollment (intervention not delivered as part of study design).
214257561|NCT06785428|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d.
214257562|NCT01512290|OTHER|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
214257563|NCT02734433|DRUG|Pexidartinib|
214257564|NCT02628769|DRUG|Solithromycin|
214257565|NCT02628769|DRUG|Placebo|
214257566|NCT02374086|BEHAVIORAL|Exercise training|
214257567|NCT00883584|DRUG|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
214257568|NCT00883584|DRUG|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
214257569|NCT00990938|DRUG|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
214257570|NCT00990938|DRUG|Saline|Subcutaneous injection once per week for four weeks
214257571|NCT05568407|DRUG|Avelumab|As used in real world practice
214257572|NCT05726734|DRUG|Vonoprazan|potassium-competitive acid blocker
214257573|NCT05726734|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
214257574|NCT05726734|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214257575|NCT05726734|DRUG|Esomeprazole|Proton pump inhibitor
214257576|NCT05860803|DEVICE|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
214257577|NCT05860803|BEHAVIORAL|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
214257578|NCT04911257|DEVICE|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
214257579|NCT04407611|BEHAVIORAL|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
214257580|NCT04407611|BEHAVIORAL|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
214257581|NCT06575309|BIOLOGICAL|Blood test|The procedures added as part of this research are 6 blood samples, the volumes of which do not exceed the volume authorized in the order of February 17, 2021, i.e. 27mL.
214257582|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
214257583|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
214257584|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
214257585|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.
214257586|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
214257587|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
214257588|NCT05588778|BEHAVIORAL|BAILAMOS™ @home/en casa|The BAILAMOS™ dance program and dance manual. BAILAMOS™ originally encompassed four dance styles: Merengue, Cha Cha Cha, Bachata, and Salsa. These four styles of Latin dance are generally considered the most popular in terms of recognition and preference. We have added two styles to appeal to the largely Mexican-origin Latinos in Chicago (i.e., Cumbia and Samba). The dances were jointly choreographed by the PI and Mr. Mendez, a professional dance instructor and owner of The Dance Academy of Salsa and http://www.salsachicago.com/. The PI and dance instructor co-developed the extensive manual is used by program instructors and includes background information on the authors, an introduction describing the goals of the program, and descriptions of the various styles of dance. The manual also has photos and descriptions of each dance broken down into its component parts.
214257589|NCT05588778|BEHAVIORAL|¡En Forma y Fuerte! @home/en casa|The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
214257590|NCT04552925|OTHER|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
214653425|NCT05782829|DIETARY_SUPPLEMENT|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
214653426|NCT04336163|DEVICE|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
214653427|NCT03983551|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
214653428|NCT03983551|DRUG|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
214653429|NCT01880307|DRUG|Azathioprine|
214653430|NCT01880307|DRUG|Infliximab|
214653431|NCT01880307|DRUG|Prednisolon|
214257591|NCT05521906|BEHAVIORAL|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
214257592|NCT02458456|OTHER|Isometric resistance training|Isometric exercise using a hand dynamometer.
214257593|NCT06656208|OTHER|Pubic symphysis manipulation|Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.
214257594|NCT06656208|OTHER|Traditional sacroiliac treatment|Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
214257595|NCT06857006|PROCEDURE|brain metastases radiosurgery|Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
214257596|NCT00560885|DEVICE|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
214257597|NCT01993784|DRUG|nimotuzumab|
214257598|NCT03955380|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
214257599|NCT06207604|PROCEDURE|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
214257600|NCT06207604|PROCEDURE|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
214257601|NCT04272853|OTHER|Interview|Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
214257602|NCT01542671|BEHAVIORAL|Intervention|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals"
214257603|NCT01542671|BEHAVIORAL|Control|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period"
214257604|NCT06863571|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
214257605|NCT06665802|BEHAVIORAL|Questionnaire|Questionnaire completion
214257606|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
214257607|NCT02367989|DIETARY_SUPPLEMENT|2g barley β-glucan|Food containing low amounts of barley β-glucan
214257608|NCT02367989|DIETARY_SUPPLEMENT|4g barley β-glucan|Food containing medium amounts of barley β-glucan
214257609|NCT02367989|DIETARY_SUPPLEMENT|6g barley β-glucan|Food containing high amounts of barley β-glucan
214257610|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
214257611|NCT06679933|OTHER|Hand grip strength measurament|That intervention includes making the patient sit down and rest for 5 minutes on a comfortable chair. Then make them handle a hand dynamometer with their dominant hand and ask them to squeeze it with all of their effort. Repeat that squeeze three times with 2-minute intervals. The highest number recorded on the dynamometer is the hand grip strength of the patient.
214257612|NCT06681415|DRUG|Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution|"Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion."
214257613|NCT06623721|DEVICE|Movement-evoked transcutaneous auricular Vagus nerve stimulation|"Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur."
214257614|NCT02887859|BIOLOGICAL|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
214257615|NCT06680115|DRUG|Sintilimab|Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
214257616|NCT06682169|DRUG|Rovadicitinib|Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
214257617|NCT06682169|DRUG|Imatinib|Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.
214257618|NCT06682169|DRUG|Methotrexate|Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
214257619|NCT06682169|DRUG|Mycophenolate mofetil|Metoprolol ester is an organic compound mainly used as an immunosuppressant
214257620|NCT06682169|DRUG|Rituximab|Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
214257621|NCT06682065|OTHER|Telemedicine for contraceptive counseling (TECC)|WhatsApp algorithmic chatbot that screens preferences and medical eligibility to recommend two methods, informs about all methods, allows choice out of all methods, produce summary to substitute for clinical record
214257622|NCT06682065|OTHER|Standard Care|In-personcontraceptive counseling with a nurese according to clinical standard of care
214257623|NCT06877923|DIETARY_SUPPLEMENT|Elemental 028 Extra|Elemental 028 Extra formulations. Both powder and liquid versions will be used
214257624|NCT06906120|BEHAVIORAL|Virtual Reality-Based Operating Room Education|"For the Intervention Group:~Written informed consent will be obtained one day before surgery when patients visit the anesthesia clinic.~Subsequently, the Patient Introduction Form, State-Trait Anxiety Inventory (STAI-I, STAI-II), and Surgical Fear Scale will be completed, and electrodermal activity data and physiological parameters will be recorded for 5 minutes.~Participants will watch a 3D training video created by the researcher using Meta Quest 3 virtual reality headsets. This video will provide an introduction to the operating room environment and related procedures.~After the video, physiological parameters will be recorded again, and STAI-I and the Surgical Fear Scale will be completed.~On the day of the surgery, after the patients are admitted and necessary preparations are made, STAI-I and the Surgical Fear Scale will be completed again, and physiological parameters will be recorded.~Electrodermal activity data will be recorded 15-20 minutes before anesthesia is administ"
214257625|NCT06923345|COMBINATION_PRODUCT|Reduced CTV|"Long-course radiotherapy with selective CTV reduction (lower to S2/S3 level) + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
214257626|NCT06923345|COMBINATION_PRODUCT|Conventional CTV|"Long-course radiotherapy with conventional CTV irradiation + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
214257627|NCT06933394|DRUG|Arsenic trioxide|Patients will receive 9 cycles of chemotherapy. ATO dosing: Arsenic trioxide（ATO） is administered 0.18mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10.
214257628|NCT06933394|DRUG|MAPK inhibitors|"The dosage of MAPK inhibitors is adjusted based on the specific drug. For example, Trametinib is used as follows: Trametinib will be administered daily from Cycle 5 until the end of induction chemotherapy. Patients start at Dose Level I; if no hematologic toxicity or severe drug-related complications occur after 1 cycle, the dose is escalated to the next level, otherwise, it is maintained. Dose Level I: 0.016 mg/kg/day (\<6 years) or 0.012 mg/kg/day (\>6 years), po. qd. Dose Level II: 0.024 mg/kg/day (\<6 years) or 0.018 mg/kg/day (\>6 years), po. qd. Dose Level III: 0.032 mg/kg/day (\<6 years) or 0.025 mg/kg/day (\>6 years), po. qd.~The dosages of other MAPK inhibitors should be modified according to their respective recommended therapeutic guidelines."
214257629|NCT06933394|DRUG|Chemotherapy|"The conventional chemotherapy regimens are as follows:~Cycles 1, 2, 4, and 6 follow the CAV regimen (cyclophosphamide(1.2g/m2.d, d3-d4), pirarubicin(25mg/m2.d,d3-d5), vincristine(0.022mg/kg.d or 0.67mg/m2.d，d3-d5)).~Cycles 3, 5, and 7 follow the PVP regimen (cisplatin(50mg/m2.d, d3-d6), etoposide(200mg/ m2.d, d3-d5)).~Cycles 8 and 9 follow the CT regimen (cyclophosphamide(1.2g/m2.d, d3-d4), topotecan(2mg/m2.d, d3-d5))."
214257630|NCT06933576|DEVICE|DSOC EyeMAX 11Fr|digital single-operator cholangioscopy using the new EyeMAX™ 11Fr (Micro-Tech Endoscopy, Nanjing, China)
214257631|NCT06934304|OTHER|new preoperative handout|A new preoperative handout for robotic sacrocolpopexy was designed at a lower reading level and providing more perioperative details
214257632|NCT06934304|OTHER|old preoperative handout|The old or standard preoperative handout for robotic sacrocolpopexy
214257633|NCT06934824|PROCEDURE|Sixty patients with early gastric cancer in stage T1bN0-1M0 were divided into Group A-N0 and Group B-N + according to the presence or absence of lymph node metastasis. When the enrolled patients und|"Patients in group A-No lymph node metastasis, who underwent simple Double-Endoscopic Combined with local full-thickness resection.~Patients in group B-imaging examination showed lymph node metastasis. patients were randomly divided into Group N + a and Group N + b.~Group N + a: Local full-thickness gastric wall and lymph nodes dissection on D1 or D1 + were performed with Double-Endoscopic Group N + b: Traditional standard surgical gastrectomy and D1 or D1 + lymph nodes dissection was performed ."
214257634|NCT06930898|BEHAVIORAL|Gamified Mammoverse Platform|A gamified, metaverse-based platform delivering breast health education through story-based tasks, interactive challenges, points, rewards, badges, and virtual incentives.
214257635|NCT06930898|BEHAVIORAL|Standard Mammoverse Platform|A non-gamified version of the Mammoverse platform that provides the same breast health educational content.
214653432|NCT03906266|DIAGNOSTIC_TEST|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
214257636|NCT06934031|OTHER|translation software|ChatGPT, Google Translate, and UD talk
214653433|NCT01085682|BEHAVIORAL|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
214653434|NCT01085682|BEHAVIORAL|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
214257637|NCT06934525|BEHAVIORAL|Team-delivered, exposure-based CBT|Patient sees licensed provider 1x/month and non-licensed provider 3x/month for exposure-based cognitive behavioral therapy
214257638|NCT06934486|DEVICE|TissuePatch Sealant Film|Sealant film
214257639|NCT06933849|BEHAVIORAL|Structured case management|When a Bluestone Accountable Care Organization registers in an emergency department, a Bluestone chronic care manager contacts emergency department clinicians by phone and fax to provide up-to-date clinical and discharge support information.
214257640|NCT06933264|DIETARY_SUPPLEMENT|Exclusion diet|Experimental Group: Patients will receive modifications to their pharmacological and will be assigned to an intervention consisting of an exclusion diet in conjunc-tion with supplemental enteral nutrition. This nutritional strategy will involve a progressive increase in the caloric intake derived from the diet, coupled with a corresponding reduction in supplemental enteral nutrition.
214257641|NCT06933147|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|This intervention involved constraining the unaffected upper limb for 6 hours per day and performing 3-hour intermittent daily sessions of functional task practice with the affected limb for 12 weeks, 5 days per week. Exercises included stretching, grasping, dexterity tasks, and functional activities like self-feeding and button pressing. The program used shaping techniques to increase task difficulty and improve motor recovery. A home exercise program was also prescribed for daily practice.
214257642|NCT06933147|BEHAVIORAL|Resistance Training (RT)|This intervention consisted of structured progressive resistance exercises targeting the affected upper limb muscles (shoulder, elbow, wrist) using weight cuffs (½-1 kg). Sessions were 60 minutes/day, 5 days/week, for 12 weeks. Intensity progressed from 50% to 70% of 1-repetition maximum (1RM) based on individual capacity. Exercises were performed in 3 sets of 8 repetitions for each muscle group, with 2-minute rest intervals. A home program included additional wrist and hand strengthening tasks.
214257644|NCT05765396|DEVICE|imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope|The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
214257645|NCT03816488|DRUG|Metformin|Metformin (usual dose) administered 2 h before surgery
214257646|NCT03816488|DRUG|Salsalate|Salsalate 1.5 g administered 2 h before surgery
214257647|NCT02007993|OTHER|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
214257648|NCT02007993|OTHER|Tongue Scraper|The pacient will scrap the tongue 10 times.
214257649|NCT05663567|BEHAVIORAL|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
214257650|NCT02260440|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
214257651|NCT02260440|DRUG|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
214257652|NCT00252395|DEVICE|PDA-based Electronic Prescribing Software|
214257653|NCT01814384|DEVICE|prosthesis GMK ® without the ancillary MyKnee ® LBS|
214257654|NCT01814384|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
214257655|NCT03484377|DEVICE|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
214257656|NCT03484377|DEVICE|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
214257657|NCT00115752|DRUG|Valdecoxib|
214257658|NCT00115752|DRUG|COX Inhibitor|
214257659|NCT05282329|DEVICE|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
214257660|NCT05282329|DEVICE|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
214257661|NCT05343442|PROCEDURE|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
214257662|NCT02715180|RADIATION|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
214257663|NCT05561569|PROCEDURE|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
214653435|NCT01451645|DRUG|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
214653436|NCT01451645|DRUG|placebo|daily placebo dosing for 16 weeks
214653437|NCT01451645|DRUG|allopurinol|background therapy
214257664|NCT02793921|BEHAVIORAL|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
214257665|NCT03228264|DEVICE|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
214257666|NCT03228264|DEVICE|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
214257667|NCT01632046|DRUG|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
214257668|NCT00282074|PROCEDURE|laparoscopic bilateral hernia repair|
214257669|NCT06291974|DIAGNOSTIC_TEST|electromyography|"Surface Electromyography (SEMG) is a measurement of the electrical activity in muscles as a byproduct of contraction.~It is the summation of action potentials from the muscle fibers under the electrodes placed on the skin"
214257670|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
214257671|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
214257672|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
214257673|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
214257674|NCT01920555|DRUG|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
214257675|NCT03238742|DRUG|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
214257676|NCT03238742|DRUG|normal saline|200ml normal saline every 12 hours for 5 days
214257677|NCT05788900|BIOLOGICAL|Heparin|intravenous Heparin
214257678|NCT01088737|DRUG|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
214257679|NCT03265665|BEHAVIORAL|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
214257680|NCT03265665|OTHER|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
214257681|NCT06374771|DRUG|Melatonin 10 MG|10 mg of Melatonin will be given orally pre and post-operative
214257682|NCT06374771|DRUG|Vitamin C|1 gm of Vitamin C will be given orally pre and post-operative
214257683|NCT01614600|DEVICE|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
214257684|NCT03484637|OTHER|Lifestyle-medicine intervention|
214257685|NCT03855956|OTHER|KB174|KB174 is a novel mixture of oligosaccharides.
214257686|NCT03855956|OTHER|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
214257687|NCT01230723|DEVICE|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
214257688|NCT01230723|DEVICE|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
214257689|NCT00141388|DRUG|Pregabalin|
214257690|NCT05320185|DEVICE|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
214257691|NCT00199069|DRUG|Asparaginase|
214257692|NCT00199069|DRUG|Vincristine|
214257693|NCT00199069|DRUG|Daunorubicin, Adriamycin|
214257694|NCT00199069|DRUG|Cyclophosphamide|
214653438|NCT03089307|DEVICE|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
214257695|NCT00199069|DRUG|Ifosfamide|
214257696|NCT00199069|DRUG|Cytarabine|
214257697|NCT00199069|DRUG|Mitoxantrone|
214257698|NCT00199069|DRUG|Methotrexate|
214257699|NCT00199069|DRUG|6-Mercaptopurine|
214257700|NCT00199069|DRUG|6-Thioguanine|
214257701|NCT00199069|DRUG|VM26|
214257702|NCT00199069|DRUG|Dexamethasone / Prednisolone|
214257703|NCT00199069|PROCEDURE|CNS Irradiation|
214257704|NCT00199069|PROCEDURE|Mediastinal Irradiation|
214257705|NCT00199069|PROCEDURE|Stem Cell Transplantation|
214257706|NCT06516484|DRUG|Romiplostim|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
214257707|NCT04507100|BEHAVIORAL|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
214257708|NCT01475409|BIOLOGICAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
214257709|NCT05231044|DRUG|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
214257710|NCT05231044|DRUG|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
214257711|NCT04156477|DIETARY_SUPPLEMENT|Ketone ester|Intake of weight adjusted drink of a ketone ester
214257712|NCT04156477|DIETARY_SUPPLEMENT|Glucose|Isocaloric and - volumetric taste adjusted drink
214257713|NCT04156477|DIETARY_SUPPLEMENT|Tap water|Isovolumetric taste adjusted tap water (placebo)
214257714|NCT03998878|BEHAVIORAL|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
214257715|NCT03998878|BEHAVIORAL|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
214257716|NCT03998878|BEHAVIORAL|Hunger Training|Participants will be instructed to follow Hunger Training.
214257717|NCT06115785|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
214257718|NCT06393543|OTHER|No intervention, only registration|No intervention, only registration
214257719|NCT02954627|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
214257720|NCT05413070|BEHAVIORAL|Multimodal approach to QI for Low-Value Care|Up to 4 brief educational components in existing quality meetings Informational email/newsletter Individualized performance feedback reports Educational resources for patients
214257721|NCT02219347|DRUG|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
214257722|NCT01681017|BEHAVIORAL|HBB/ENC Training and Equipment|See the detailed description section
214257723|NCT01681017|OTHER|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
214257724|NCT01680965|DRUG|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
214257725|NCT05883423|OTHER|FPCMP-Old Age|"1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
214257726|NCT00195273|DRUG|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
214257727|NCT00195273|DRUG|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
214653439|NCT06140771|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214653440|NCT06140771|DRUG|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214653441|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214257728|NCT00195273|DRUG|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
214257729|NCT00195273|DRUG|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
214257730|NCT00195273|DRUG|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
214257731|NCT02186873|DRUG|Placebo|Participants will receive matching placebo.
214257732|NCT02186873|DRUG|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
214257733|NCT00595465|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
214257734|NCT00244062|BEHAVIORAL|counseling|
214257735|NCT00004868|DRUG|semaxanib|
214257736|NCT02343107|BEHAVIORAL|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
214257737|NCT03878238|DIETARY_SUPPLEMENT|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
214257738|NCT03878238|OTHER|Placebo|Placebo with maltodextrin base.
214257739|NCT01613365|DRUG|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
214257740|NCT01613365|DRUG|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
214257741|NCT00241085|DRUG|valsartan|
214257742|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
214257743|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
214257744|NCT02537028|DRUG|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
214257745|NCT02595970|DRUG|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
214257746|NCT06130917|OTHER|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
214257747|NCT06130917|OTHER|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
214257748|NCT06435728|DIAGNOSTIC_TEST|AccuIMR and AccuFFR|AccuFFR and AccuIMR were obtained by reviewing coronary angiography at the time of primary PCI
214653442|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214653443|NCT05065112|PROCEDURE|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
214653444|NCT05065112|PROCEDURE|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
214653445|NCT02318056|OTHER|Aquacel® Ag Burn Glove|burn dressing
214653446|NCT02318056|OTHER|Mepilex® Transfer Ag|burn dressing
214653447|NCT02318056|DRUG|antibiotic|antibiotic burn dressing
214257749|NCT04750603|DRUG|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
214257750|NCT04750603|DRUG|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
214257751|NCT00107783|DRUG|Nitisinone (NTBC)|Treatment
214257752|NCT05663229|DEVICE|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
214257753|NCT01886716|BEHAVIORAL|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
214257754|NCT01886716|BEHAVIORAL|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
214257755|NCT01886716|BEHAVIORAL|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
214257756|NCT00315536|DRUG|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
214257757|NCT02910362|DEVICE|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
214257758|NCT02910362|DEVICE|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
214257759|NCT04879225|BEHAVIORAL|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
214257760|NCT04879225|BEHAVIORAL|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
214257761|NCT04879225|BEHAVIORAL|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
214257762|NCT04879225|BEHAVIORAL|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
214257763|NCT05059171|DEVICE|OneSahpe single file|The rotary motion of OneShape single file
214653448|NCT03920969|BEHAVIORAL|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
214257764|NCT05059171|DEVICE|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
214257765|NCT03388385|DRUG|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
214257766|NCT03388385|DRUG|Ferinject|Ferric carboxymaltose will be infused in day 2.
214257767|NCT02116231|DRUG|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
214257768|NCT02116231|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
214257769|NCT04200560|OTHER|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
214257770|NCT04200560|OTHER|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
214257771|NCT03257696|DIAGNOSTIC_TEST|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
214257772|NCT00806975|DEVICE|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
214257773|NCT01413477|DRUG|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
214257774|NCT03657446|DRUG|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
214257775|NCT03657446|DRUG|Placebo|Matching placebo infusion
214257776|NCT03657446|DRUG|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
214257777|NCT03587948|DIAGNOSTIC_TEST|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
214257778|NCT03894046|DRUG|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
214257779|NCT03894046|DRUG|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
214257780|NCT03894046|DRUG|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
214257781|NCT03894046|DRUG|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
214257782|NCT03654859|OTHER|cardiopulmonary resuscitation|no pre-specified
214257783|NCT06009029|RADIATION|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
214257784|NCT06009029|DRUG|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
214257785|NCT05449769|BEHAVIORAL|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
214257786|NCT00251212|BEHAVIORAL|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
214257787|NCT05657925|DRUG|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
214257788|NCT05657925|DRUG|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
214653449|NCT03156036|DRUG|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
214257789|NCT02367131|DRUG|JARDIANCE®|JARDIANCE®
214257790|NCT01973569|DRUG|denosumab|denosumab administered subcutaneously
214257791|NCT01973569|DRUG|placebo|placebo administered subcutaneously to match denosumab
214257792|NCT05089162|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
214257793|NCT05089162|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
214257794|NCT05089162|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
214257795|NCT05089162|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
214257796|NCT05089162|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214257797|NCT06432231|OTHER|Low glycemic index diet treatment|This study was a non-randomized, single centre, pre/post-intervention study. A low glycemic index diet was prescribed by a dietician for 3 months. LGID treatment consisted of 10% (40-60 g) low glycaemic index (glycaemic index \<50) carbohydrate, 20-30% protein and 60-70% lipid
214257798|NCT00632840|DRUG|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
214257799|NCT03714620|DRUG|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
214257800|NCT00949273|PROCEDURE|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
214257801|NCT00508222|DRUG|Kaletra Tablets|Kaletra 800/200 OD
214257802|NCT06119035|OTHER|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
214257803|NCT04781504|BEHAVIORAL|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
214257804|NCT05038670|DEVICE|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
214257805|NCT02431338|PROCEDURE|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
214257806|NCT03115047|DRUG|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
214257807|NCT03115047|DRUG|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
214257808|NCT05341687|OTHER|No applicable|No applicable
214257809|NCT02484183|DEVICE|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
214257810|NCT05686954|OTHER|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
214257811|NCT05686954|OTHER|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
214257812|NCT05686954|OTHER|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
214257813|NCT05686954|OTHER|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
214257814|NCT04140838|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
214257815|NCT04140838|BEHAVIORAL|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
214257816|NCT04140838|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
214257817|NCT02284542|PROCEDURE|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
214257818|NCT02284542|PROCEDURE|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
214257819|NCT06556693|DEVICE|Dual Channel Stimulation|implant of dual channel stimulation device
214257820|NCT00137631|BEHAVIORAL|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
214257821|NCT00351000|DRUG|Ziprasidone|
214257822|NCT03813667|BEHAVIORAL|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
214653450|NCT03262376|DIETARY_SUPPLEMENT|Minerals + Vitamins|A mineral and vitamin tablet
214653451|NCT03262376|DIETARY_SUPPLEMENT|Botanical A|Botanical extract administered in capsule form
214653452|NCT03262376|DIETARY_SUPPLEMENT|Botanical B|Botanical extract administered in capsule form
214653453|NCT03262376|OTHER|Placebo|Cellulose crystalline tablet
214257823|NCT02601599|BEHAVIORAL|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
214257824|NCT02829255|OTHER|altitude exposure|altitude exposure
214257825|NCT01228864|PROCEDURE|quality of life|survey
214257826|NCT01228864|PROCEDURE|Quality of life|
214257827|NCT05149599|DRUG|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
214257828|NCT05511194|OTHER|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
214257829|NCT05511194|OTHER|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
214257830|NCT00100061|DRUG|Cranberry juice|liquid juice taken daily
214257831|NCT00100061|DIETARY_SUPPLEMENT|Cranberry Juice|Taken orally
214257832|NCT00100061|DIETARY_SUPPLEMENT|Placebo cranberry juice|Placebo comparitor
214257833|NCT02299882|DRUG|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
214257834|NCT06558084|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor in first and second lines
214257835|NCT01565720|DRUG|Isavuconazole|oral
214257836|NCT01565720|DRUG|Placebo|oral
214257837|NCT01565720|DRUG|Moxifloxacin|oral
214257838|NCT02486302|DRUG|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
214257839|NCT01542333|GENETIC|gene expression analysis|
214257840|NCT01542333|GENETIC|proteomic profiling|
214257841|NCT01542333|GENETIC|reverse transcriptase-polymerase chain reaction|
214257842|NCT01542333|GENETIC|western blotting|
214257843|NCT01542333|OTHER|immunohistochemistry staining method|
214257844|NCT01542333|OTHER|laboratory biomarker analysis|
214257845|NCT01542333|PROCEDURE|spectroscopy|
214257846|NCT01871142|DRUG|Placebo|100 mL
214257847|NCT01871142|DRUG|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
214257848|NCT01871142|DRUG|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
214653454|NCT04201743|DRUG|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
214653455|NCT03749395|PROCEDURE|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
214653456|NCT05410990|DIAGNOSTIC_TEST|eosinophil and other hematological parameters|
214653457|NCT04948008|BIOLOGICAL|IBI306|IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
214257849|NCT02754557|OTHER|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
214257850|NCT02754557|DEVICE|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
214257851|NCT00997061|DRUG|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
214257852|NCT04384783|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
214257853|NCT06569251|DRUG|Dexamethasone 12 mg QD|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
214257854|NCT06569251|DRUG|Dexamethasone 6 mg BID|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
214257855|NCT01237821|DRUG|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
214257856|NCT01237821|DRUG|Effaclar|Topical, Bid, 12 weeks
214257857|NCT03534934|DIAGNOSTIC_TEST|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
214257858|NCT03534934|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
214257859|NCT03534934|OTHER|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
214257860|NCT03534934|DIAGNOSTIC_TEST|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
214257861|NCT03534934|DIAGNOSTIC_TEST|Duel-energy X-ray absorptiometry scan|Bone density measurement
214257862|NCT03534934|DIAGNOSTIC_TEST|Multi-detector computed tomography|Hip and ankle CT scan
214257863|NCT03534934|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
214257864|NCT06529965|BEHAVIORAL|covivio|Participants will receive access to the digital health intervention covivio in addition to TAU.
214257865|NCT06187662|BEHAVIORAL|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
214257866|NCT06187662|BEHAVIORAL|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
214257867|NCT03304821|DRUG|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
214257868|NCT03304821|DRUG|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
214257869|NCT01815983|OTHER|Videolaryngoscopy review.|Review of video recordings.
214257870|NCT05015530|DEVICE|Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract|Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
214257871|NCT05436275|BIOLOGICAL|CM310|300 mg every two weeks
214257872|NCT05436275|BIOLOGICAL|Placebo|once every two weeks
214257873|NCT04968847|DEVICE|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
214257874|NCT00560469|OTHER|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
214257875|NCT02722486|DEVICE|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
214653458|NCT03623919|OTHER|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
214653459|NCT03756090|DRUG|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
214257876|NCT02722486|OTHER|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
214257877|NCT05804474|OTHER|Observational study|Observational study
214257878|NCT01556737|DIETARY_SUPPLEMENT|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
214257879|NCT01556737|DIETARY_SUPPLEMENT|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
214257880|NCT04920422|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
214257881|NCT01387399|PROCEDURE|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
214257882|NCT03287583|BEHAVIORAL|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
214257883|NCT03287583|OTHER|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
214257884|NCT05919004|DIAGNOSTIC_TEST|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
214257885|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
214257886|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
214257887|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
214257888|NCT01444352|BIOLOGICAL|Placebo|0.5 mL, Intramuscular
214653460|NCT03756090|DRUG|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
214257889|NCT00354471|PROCEDURE|Uterine Artery Embolization|
214257890|NCT02063880|OTHER|Urgent ART|Children will be started on HAART \<48 hours after enrollment.
214257891|NCT02063880|OTHER|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
214257892|NCT00567593|DRUG|Rosiglitazone|8mg tablet once a day for 14 days
214653461|NCT03756090|DRUG|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
214653462|NCT03756090|DRUG|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
214653463|NCT03756090|DRUG|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
214653464|NCT01365156|PROCEDURE|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
214257893|NCT02106910|DEVICE|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
214257894|NCT02521766|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
214257895|NCT02521766|DEVICE|Commercially Available Intraocular Lens|IOL per investigator's standard of care
214257896|NCT02521766|PROCEDURE|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
214257897|NCT06412575|PROCEDURE|JNT Guided OGT-overlap Oesophagojejunostomy|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
214257898|NCT06412575|PROCEDURE|TNT Guided OGT-overlap Oesophagojejunostomy|In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
214257899|NCT00696683|OTHER|None, this is an observational study|
214257900|NCT01675427|OTHER|Interleukin 28B testing|Blood sampling for ILB28 genotyping
214257901|NCT05997758|OTHER|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
214257902|NCT05997758|BEHAVIORAL|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
214257903|NCT04343729|DRUG|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
214257904|NCT04343729|DRUG|Placebo solution|injectable saline solution
214257905|NCT05068024|DRUG|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
214257906|NCT01291654|DRUG|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
214257907|NCT01291654|DRUG|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
214257908|NCT01291654|DRUG|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
214257909|NCT00002121|DRUG|Diethylhomospermine|
214257910|NCT01524757|DRUG|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
214257911|NCT04322981|BEHAVIORAL|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
214653465|NCT01365156|RADIATION|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
214653466|NCT02198833|BIOLOGICAL|Urine Culture|Obtain urine culture every third day
214653467|NCT02198833|DEVICE|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
214653468|NCT02198833|DEVICE|Scanning Electron Microscopy|Houston Site Only
214257912|NCT04322981|BEHAVIORAL|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
214257913|NCT00700570|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
214257914|NCT00700570|DRUG|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
214653469|NCT02198833|PROCEDURE|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
214653470|NCT02198833|PROCEDURE|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
214257915|NCT00700570|DRUG|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
214257916|NCT04379544|OTHER|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
214257917|NCT04040270|BEHAVIORAL|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
214653471|NCT05210595|DRUG|Clopidogrel 75 mg|75 mg/day as maintenance dose.
214653472|NCT05210595|DRUG|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
214653473|NCT05210595|DRUG|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
214653474|NCT00004396|DRUG|heme arginate|
214653475|NCT00004396|DRUG|tin mesoporphyrin|
214257918|NCT04040270|BEHAVIORAL|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
214257919|NCT05895071|DRUG|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
214257920|NCT05895071|DRUG|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
214257921|NCT01796756|OTHER|Handover program|
214257922|NCT05734573|BEHAVIORAL|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
214257923|NCT01316471|BEHAVIORAL|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
214257924|NCT01316471|OTHER|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
214257925|NCT04708379|BEHAVIORAL|Lifestyle intervention|Nutrition and physical activity education.
214257926|NCT00611533|DRUG|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
214257927|NCT00611533|DRUG|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
214257928|NCT02727413|PROCEDURE|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
214257929|NCT02727413|OTHER|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
214257930|NCT01431131|PROCEDURE|Intrasocket graft|Intrasocket mineralized cancellous allograft
214257931|NCT01431131|PROCEDURE|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
214257932|NCT00968318|PROCEDURE|Excision of strip of deep fascia|operative technique to excise deep fascia.
214257933|NCT05246397|DRUG|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
214257934|NCT04899427|DRUG|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
214257935|NCT04899427|DRUG|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
214257936|NCT04899427|DRUG|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
214653476|NCT03931655|DIAGNOSTIC_TEST|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
214653477|NCT01911858|DEVICE|Askina Calgitrol Paste|
214653478|NCT05619458|BEHAVIORAL|Mindfulness Intervention|6-week mindfulness intervention
214653479|NCT01186393|BEHAVIORAL|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
214653480|NCT01186393|BEHAVIORAL|Low Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
214653481|NCT01186393|BEHAVIORAL|High Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
214653482|NCT00289822|DRUG|intracoronary infusion of progenitor cells|
214653483|NCT06257212|DRUG|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
214653484|NCT06257212|DRUG|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
214653485|NCT06257212|DRUG|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
214653486|NCT03311672|DRUG|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
214257937|NCT01924988|DEVICE|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
214257938|NCT04666675|DRUG|Upadacitinib|Oral; Tablet
214257939|NCT04666675|DRUG|Placebo for Upadacitinib|Oral; Tablet
214257940|NCT01297075|BEHAVIORAL|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
214257941|NCT00921128|DRUG|Muscimol|
214257942|NCT01787422|OTHER|Traditional versus Telemedicine office visit|
214257943|NCT00152360|DRUG|Orlistat|See Detailed Description.
214257944|NCT01978418|DRUG|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
214257945|NCT01978418|DRUG|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
214257946|NCT01006460|DRUG|Rhodiola rosea, L|3 Capsules twice a day
214257947|NCT01006460|DRUG|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
214257948|NCT01006460|DRUG|Panax ginseng|3 capsules twice a day
214257949|NCT01006460|DRUG|Placebo - dark brown sugar|3 capsules twice a day
214257950|NCT00400738|DRUG|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
214257951|NCT01359007|DRUG|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
214257952|NCT02860377|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
214257953|NCT02860377|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
214257954|NCT01892267|DEVICE|PEG-J placement|PEG-J placement
214257955|NCT03702517|DEVICE|lateral stair walking exercise|15 minutes of lateral stair walking exercise
214257956|NCT03702517|DEVICE|traditional physiotherapy|strengthening exercise, balance training and gait training
214257957|NCT06534749|DEVICE|ultrasound|Ultrasound screening: by (SonoScape A6, Yizhe Building, Yuquan, Road Shenzhen, 518051, China). General-purpose diagnostic abdominal ultrasound equipment was used, with a 7.5-MHz linear-type probe. Screenings will be performed by radiologist with appropriate practice. The ultrasound examination will take 10 min for each patient. The recordings will consist of two bilateral renal images will be obtained and one transverse and longitudinal images. The urinary bladder will be observed with the patient in a supine position, and images will be recorded when abnormalities will be identified. The following will be investigated by ultrasound: number, size (including differences between sides), and location of the kidneys; pelvic dilatation; echogenicity, and other findings indicating cysts or tumours. Shape and wall thickening of the urinary bladder, as well as ureter dilatation, will be also examined
214257958|NCT05296733|DRUG|BI 456906|BI 456906
214257959|NCT05551208|DRUG|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
214257960|NCT06173934|DRUG|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
214257961|NCT06173934|DRUG|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
214257962|NCT04138004|DRUG|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
214257963|NCT04138004|DRUG|polyethylene glycol alone|4-litre polyethylene glycol split-dose
214653487|NCT03311672|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
214257964|NCT00190970|DRUG|Ruboxistaurin|
214257965|NCT00135564|BIOLOGICAL|MenC-TT|
214257966|NCT00135564|BIOLOGICAL|Hib-MenC-TT|
214653488|NCT03311672|RADIATION|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
214257967|NCT01825525|DEVICE|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
214257968|NCT03563287|DRUG|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
214257969|NCT00922233|DRUG|levonorgestrel|oral contraceptive pills
214257970|NCT04256226|PROCEDURE|Tumor excision|Excision of GIST
214257971|NCT02540616|DEVICE|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
214257972|NCT00630643|BIOLOGICAL|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
214257973|NCT00630643|DRUG|Placebo|Placebo
214257974|NCT00001966|DRUG|Mind-body therapy|
214257975|NCT01461980|BIOLOGICAL|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
214257976|NCT01461980|BIOLOGICAL|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
214257977|NCT01461980|BIOLOGICAL|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
214257978|NCT00179543|BEHAVIORAL|Relaxation response|
214257979|NCT02785315|BEHAVIORAL|rehabilitation & remediation approach|The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
214257980|NCT02785315|BEHAVIORAL|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
214257981|NCT06029738|BEHAVIORAL|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
214257982|NCT00808678|DRUG|ABT-143|once, see arm description for more information
214257983|NCT00808678|DRUG|ABT-335|once, see arm description for more information
214257984|NCT00808678|DRUG|rosuvastatin|once, see arm description for more detail
214257985|NCT06556524|BEHAVIORAL|observation|Behavioral observation and trauma measurement in live mannequin application
214257986|NCT02364921|DEVICE|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
214257987|NCT02364921|DEVICE|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
214257988|NCT06228274|DEVICE|ARTHRUM 2.5%|ARTHRUM 2.5%
214257989|NCT05958732|OTHER|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
214257990|NCT05958732|OTHER|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
214257991|NCT03731845|GENETIC|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
214257992|NCT03731845|BIOLOGICAL|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
214257993|NCT03731845|OTHER|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
214257994|NCT03491306|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
214257995|NCT03491306|OTHER|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
214257996|NCT01933958|DRUG|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
214257997|NCT04903665|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
214257998|NCT04102943|DRUG|tacrolimus tablet|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
214257999|NCT04102943|DRUG|tacrolimus capsules|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
214258000|NCT00011661|BEHAVIORAL|Education on behaviors to reduce lead exposure|
214258001|NCT05117333|OTHER|Reminder (information letter)|Reminders
214258002|NCT05769309|PROCEDURE|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
214258003|NCT05769309|DRUG|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
214258004|NCT02655978|OTHER|Magnetic Resonance Imaging|
214258005|NCT00122109|BEHAVIORAL|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
214258006|NCT01341197|OTHER|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
214258007|NCT03584100|DEVICE|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
214258008|NCT03153956|DEVICE|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
214258009|NCT03153956|DEVICE|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
214258010|NCT00109200|DRUG|Xolair (omalizumab)|
214258011|NCT00480285|PROCEDURE|Laparoscopic Nissen Fundoplication|
214258012|NCT00480285|PROCEDURE|Laparoscopic anterior partial fundoplication|
214258013|NCT02540226|DRUG|Intravenous tranexamic acid|
214258014|NCT02540226|DRUG|Topical tranexamic acid|
214258015|NCT02540226|DRUG|Intravenous saline|
214258016|NCT02540226|DRUG|Topical saline|
214258017|NCT00809354|DRUG|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
214258018|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
214258019|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
214258020|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
214258021|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
214258022|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
214258023|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
214258024|NCT03416907|BEHAVIORAL|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
214258025|NCT03416907|BEHAVIORAL|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
214653489|NCT05621356|OTHER|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
214653490|NCT04919915|DEVICE|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
214258026|NCT03416907|BEHAVIORAL|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
214258027|NCT03416907|BEHAVIORAL|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
214258028|NCT03416907|BEHAVIORAL|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
214258029|NCT03177057|BEHAVIORAL|Compliance Monitoring|Record behavior
214258030|NCT03177057|OTHER|Health Telemonitoring|Receive health monitoring text messages
214653491|NCT05785195|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
214653492|NCT03268629|BEHAVIORAL|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
214653493|NCT03268629|BEHAVIORAL|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
214653494|NCT01886118|PROCEDURE|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
214653495|NCT01886118|OTHER|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
214258031|NCT03177057|OTHER|Questionnaire Administration|Ancillary studies
214258032|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
214258033|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
214258034|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
214258035|NCT00267189|DRUG|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
214258036|NCT00267189|DRUG|Calcineurin inhibitors (CNI)|
214258037|NCT00267189|DRUG|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
214258038|NCT00267189|DRUG|Steroids|
214258039|NCT05559398|DRUG|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
214258040|NCT05559398|DRUG|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
214653496|NCT01886118|OTHER|Conventional media culture|embryos are cultured in conventional media
214258041|NCT03970642|OTHER|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
214258042|NCT05978778|DEVICE|wii sports game|wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
214258043|NCT05978778|OTHER|pre-hand writing skills|pre-hand writing skills
214258044|NCT02736994|DRUG|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
214258045|NCT02736994|DRUG|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
214258046|NCT02736994|OTHER|Water|Water
214258047|NCT01489397|DEVICE|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
214258048|NCT01556880|BEHAVIORAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
214258049|NCT02544178|RADIATION|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
214258050|NCT03458975|RADIATION|MRI|Magnetic Resonance Imaging
214258051|NCT03458975|RADIATION|Perfusion CT scan|Perfusion Computerized tomography scan
214258052|NCT03458975|OTHER|Contrast enhanced ultrasound|Contrast enhanced ultrasound
214258053|NCT03458975|DRUG|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
214258054|NCT00100178|DRUG|Mycophenolate mofeteil (MMF)|
214258055|NCT00100178|DRUG|Daclizumab (DZB)|
214258056|NCT00100178|DRUG|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
214258057|NCT00100178|DRUG|Placebo control for Daclizumab (DZB)|saline intravenous infusions
214258058|NCT03458962|GENETIC|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
214258059|NCT05712434|OTHER|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
214258060|NCT05712434|OTHER|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
214258061|NCT05712434|OTHER|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
214258062|NCT00783965|DRUG|tazarotene|Applied to the skin
214258063|NCT00783965|OTHER|placebo|Applied to the skin
214258064|NCT03427112|DEVICE|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
214258065|NCT06317376|OTHER|MICT with Aerobic exercise on treadmill|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
214258066|NCT06317376|OTHER|standard hospital protocol|standard hospital protocol
214258067|NCT02477839|DRUG|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
214258068|NCT02477839|OTHER|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
214258069|NCT02781779|DEVICE|Silverlon®|Silverlon wound dressings
214258070|NCT02781779|DEVICE|AQUACEL® AG|AQUACEL® AG wound dressings
214258071|NCT04137029|DRUG|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
214258072|NCT04137029|DRUG|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
214258073|NCT04137029|DIAGNOSTIC_TEST|metacholine test|The participants will receive inhalation of metacholine once
214258074|NCT00745940|BEHAVIORAL|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
214258075|NCT03617354|PROCEDURE|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
214258076|NCT06025305|DIAGNOSTIC_TEST|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
214258077|NCT03610282|DRUG|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
214258078|NCT03610282|DRUG|Propofol|Subjects will received propofol for up to 100 minutes.
214258079|NCT04743076|PROCEDURE|Endovascular treatment|Endovascular treatment
214258080|NCT04743076|OTHER|Standard medical treatment|Standard medical treatment
214258081|NCT02268955|DRUG|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
214258082|NCT02268955|DRUG|Saline|Saline will be administered to the placebo group
214258083|NCT05720260|DRUG|Goserelin|Hormone therapy
214258084|NCT05720260|DRUG|Fulvestrant|Hormone therapy
214258085|NCT05720260|DRUG|Capivasertib|AKT inhibitor
214258086|NCT05720260|DRUG|Durvalumab|immunotherapy
214258087|NCT01439568|DRUG|LY2510924|Administered subcutaneous injection
214258088|NCT01439568|DRUG|Carboplatin|Administered intravenously
214258089|NCT01439568|DRUG|Etoposide|Administered intravenously
214258090|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS at sham point
214258091|NCT01492569|OTHER|questionnaire administration|Ancillary studies
214258092|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS
214258093|NCT05107427|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
214258094|NCT05107427|BIOLOGICAL|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
214258095|NCT05401968|BEHAVIORAL|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
214258096|NCT04937361|OTHER|rectal swab|collection of rectal swabs
214258097|NCT00275964|DRUG|TMN-1|
214258098|NCT06134908|BEHAVIORAL|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
214258099|NCT04726670|OTHER|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
214258100|NCT01784848|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
214258101|NCT01784848|OTHER|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
214258102|NCT00691067|DRUG|mifepristone|200 mg po per day x 6 weeks
214258103|NCT00691067|DRUG|Placebos|placebo
214258104|NCT04373174|DEVICE|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
214258105|NCT04373174|PROCEDURE|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
214258106|NCT02607930|DRUG|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
214258107|NCT02607930|DRUG|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
214258108|NCT02607930|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
214258109|NCT02607930|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
214258110|NCT03198078|DRUG|Brexpiprazole (OPC-34712)|Once-daily, tablets
214258111|NCT03198078|DRUG|Aripiprazole|Once-daily, tablets
214258112|NCT03198078|DRUG|Placebo|Once-daily, tablets
214258113|NCT01400165|DRUG|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
214258114|NCT01400165|DRUG|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
214258115|NCT01400165|DRUG|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
214258116|NCT01400165|PROCEDURE|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
214258117|NCT06428682|DRUG|Tranexamic acid|Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
214258118|NCT06428682|DRUG|Placebo|Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
214258119|NCT06421116|PROCEDURE|Synovial ultrasound-guided biopsy Intestinal biopsy|Patients will undergo biopsies if needed for standard-of-care follow-up and after clinical indication.
214258120|NCT00630370|DRUG|Placebo|2 Placebo tablets, TID, orally, 58 days
214258121|NCT00630370|DRUG|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
214258122|NCT00630370|DRUG|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
214258123|NCT00630370|DRUG|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
214258124|NCT02777619|DRUG|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
214258125|NCT02777619|DRUG|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
214258126|NCT02777619|DRUG|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
214258127|NCT02777619|DRUG|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
214258128|NCT02777619|DRUG|Propofol|
214653497|NCT01885780|DEVICE|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
214653498|NCT01923025|DRUG|RO5545965|Single dose
214258129|NCT03913546|PROCEDURE|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
214258130|NCT03913546|OTHER|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
214258131|NCT03272516|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
214258132|NCT03272516|OTHER|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
214258133|NCT04329442|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
214258134|NCT03180593|DRUG|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
214258135|NCT05870293|BEHAVIORAL|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
214258136|NCT03711266|BEHAVIORAL|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
214258137|NCT02423837|DRUG|Rituximab, bendamustine|
214258138|NCT01826721|OTHER|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
214258139|NCT03366779|DEVICE|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
214258140|NCT03935412|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
214258141|NCT01646073|BIOLOGICAL|Adalimumab|adalimumab eow
214258142|NCT01646073|BIOLOGICAL|placebo|placebo
214258143|NCT00057876|DRUG|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
214258144|NCT00057876|RADIATION|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
214258145|NCT00259454|BEHAVIORAL|In-home intervention|occupational therapy techniques to reduce caregiver stress
214258146|NCT00535366|DRUG|Tiotropium|Oral inhalation by HandiHaler® device
214258147|NCT00535366|DRUG|Salmeterol|Oral inhalation from Diskus®
214258148|NCT00535366|DRUG|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
214258149|NCT00535366|DRUG|Ciclesonide low|Oral inhalation from MDI
214258150|NCT00535366|DRUG|Ciclesonide high|Oral inhalation from MDI
214258151|NCT00535366|DRUG|Placebo|Oral inhalation from MDI
214258152|NCT05841836|DEVICE|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
214258153|NCT05841836|DEVICE|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
214258154|NCT04633356|DEVICE|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
214258155|NCT04040244|OTHER|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
214258156|NCT04040244|OTHER|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
214258157|NCT00520832|DEVICE|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
214258158|NCT00520832|DEVICE|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
214258159|NCT04723901|BIOLOGICAL|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
214258160|NCT00975637|DRUG|70 mg SC|70 mg SC
214258161|NCT00975637|DRUG|210 mg SC|210 mg SC
214258162|NCT00975637|DRUG|140 mg SC|140 mg SC
214258163|NCT00975637|DRUG|280 mg SC|280 mg SC
214258164|NCT00975637|DRUG|Placebo|Placebo SC
214258165|NCT03176758|DRUG|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
214653499|NCT00457496|BEHAVIORAL|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
214258166|NCT03176758|DRUG|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
214258167|NCT03176758|DEVICE|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
214258168|NCT00000671|DRUG|Zidovudine|
214258169|NCT00000671|DRUG|Didanosine|
214258170|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214258171|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
214258172|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214258173|NCT01199900|DRUG|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
214258174|NCT01199900|DRUG|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
214258175|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214258176|NCT01199900|DRUG|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
214258177|NCT03850665|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
214258178|NCT03850665|PROCEDURE|Anterolateral approach|Anterolateral approach surgery to replace the hip.
214258179|NCT05581875|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
214258180|NCT05581875|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
214258181|NCT05581875|DRUG|Pomalidomide|Pomalidomide will be administered per os.
214258182|NCT05581875|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
214258183|NCT05319769|PROCEDURE|Atrial fibrillation ablation|Pulmonary vein isolation
214258184|NCT02374515|DEVICE|EndoCuff-assisted colonoscopy|Adenoma detection rate
214258185|NCT02374515|DEVICE|Standard Colonoscopy|
214258186|NCT02276365|DRUG|BI 10773|
214258187|NCT02276365|DRUG|Pioglitazone|
214258188|NCT04807140|DRUG|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
214258189|NCT04807140|DRUG|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
214258190|NCT04807140|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
214258191|NCT03799211|BEHAVIORAL|Motivational Interviewing|Phone call using motivational interviewing technique
214258192|NCT03799211|BEHAVIORAL|Treatment as Usual|will receive a regular study phone call after three months
214258193|NCT00892658|DRUG|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
214258194|NCT03182062|PROCEDURE|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
214258195|NCT03182062|PROCEDURE|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
214258196|NCT03182062|PROCEDURE|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
214258197|NCT05432362|OTHER|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
214258198|NCT05432362|OTHER|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
214258199|NCT03509831|DRUG|INT-2150|"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
214258200|NCT03509831|DRUG|Irsogladine maleate 2 mg+Nizatidine 150 mg|"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"
214258201|NCT04265469|OTHER|Diabetic foot education|Give Diabetic foot education via mobile phone
214258202|NCT00041821|PROCEDURE|Nasal irritation thresholds and irritant provocation|
214258203|NCT00764491|DEVICE|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
214258204|NCT00764491|DEVICE|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
214258205|NCT04777838|DRUG|Citalopram 10 MG|10 mg of citalopram every day
214258206|NCT04777838|DRUG|Amitriptyline|25mg of Amitriptyline every
214258207|NCT04777838|DEVICE|Bite Splint|Night use of occlusal splint
214258208|NCT00002664|BIOLOGICAL|edrecolomab|
214258209|NCT00002664|BIOLOGICAL|sargramostim|
214258210|NCT00542971|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily (days 1-3)
214258211|NCT00542971|DRUG|Sorafenib|Starting dose 400 mg by mouth for 7 days
214258212|NCT00542971|DRUG|Ara-C|1.5 g/m\^2 IV over 24 hours daily (days 1-4)
214258213|NCT05561374|DRUG|Low-dose OKN-007, BID|Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
214258214|NCT05561374|DRUG|Low-dose OKN-007, TID|Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
214258215|NCT05561374|DRUG|Mid-dose OKN-007, TID|Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
214258216|NCT05561374|DRUG|High-dose OKN-007, TID|Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
214258217|NCT00447317|BEHAVIORAL|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
214258218|NCT00447317|BEHAVIORAL|Attention control|Standard peritoneal dialysis dietary education
214258219|NCT02484287|DEVICE|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
214258220|NCT02484287|DEVICE|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
214258221|NCT02484287|DEVICE|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
214258222|NCT05869565|DRUG|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
214258223|NCT02344615|PROCEDURE|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
214258224|NCT02344615|PROCEDURE|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
214258225|NCT02396251|DEVICE|HA experimental|
214258226|NCT02396251|DEVICE|HA comparator|
214258227|NCT04868058|DRUG|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
214258228|NCT01367431|DIETARY_SUPPLEMENT|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
214258229|NCT00896636|PROCEDURE|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
214258230|NCT00896636|OTHER|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
214258231|NCT01598168|DRUG|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
214258232|NCT02927262|DRUG|Gilteritinib|Oral tablet
214258233|NCT02927262|DRUG|Placebo|Oral tablet
214258234|NCT00923936|DRUG|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
214258235|NCT00923936|DRUG|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
214258236|NCT01697358|DEVICE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
214258237|NCT01697358|DRUG|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
214258238|NCT02874287|DRUG|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
214258239|NCT02874287|DRUG|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
214258240|NCT02066220|RADIATION|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
214258241|NCT02066220|DRUG|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
214258242|NCT02066220|RADIATION|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
214258243|NCT02066220|DRUG|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
214258244|NCT02066220|RADIATION|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
214258245|NCT02066220|RADIATION|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
214258246|NCT02066220|DRUG|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
214258247|NCT02066220|RADIATION|SHH-TP53 M0|"* with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
214258248|NCT02066220|RADIATION|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
214258249|NCT02066220|RADIATION|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
214258250|NCT02066220|DRUG|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
214258251|NCT00831350|DRUG|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
214258252|NCT02038452|DRUG|Depo-Medrone|Steroid Injection
214258253|NCT02038452|DEVICE|Wrist Splint|Simple wrist splint
214258254|NCT02617784|DRUG|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
214258255|NCT00208299|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
214258256|NCT00208299|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
214258257|NCT00486174|DRUG|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
214258258|NCT01223638|OTHER|Audiometry|Audiometry
214258259|NCT00253760|DRUG|dietary amino acids; cysteine and methionine|
214258260|NCT01641510|DRUG|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
214258261|NCT01641510|DRUG|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
214258262|NCT02366858|PROCEDURE|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
214258263|NCT02366858|PROCEDURE|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
214258264|NCT00402142|BIOLOGICAL|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
214258265|NCT00402142|BIOLOGICAL|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
214258266|NCT00402142|BIOLOGICAL|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
214258267|NCT00402142|BIOLOGICAL|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
214258268|NCT00402142|BIOLOGICAL|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
214258269|NCT05689944|BEHAVIORAL|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
214258270|NCT05689944|BEHAVIORAL|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
214258271|NCT05689944|BEHAVIORAL|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
214258272|NCT02354183|BEHAVIORAL|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
214258273|NCT02207673|PROCEDURE|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
214258274|NCT05063890|PROCEDURE|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
214258275|NCT05063890|PROCEDURE|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
214258276|NCT05063890|PROCEDURE|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
214258277|NCT05063890|PROCEDURE|Heating and TENS|Heating and TENS for 10 minutes
214258278|NCT05777343|OTHER|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
214258279|NCT05777343|OTHER|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
214258280|NCT05777343|OTHER|Cognitive training|Online sessions of cognitive training.
214258281|NCT01460368|DRUG|LY2409021|Administered orally
214258282|NCT01460368|DRUG|Placebo|Administered orally
214258283|NCT01460368|DRUG|Moxifloxacin|Administered orally
214258284|NCT02866994|BEHAVIORAL|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
214258285|NCT02866994|BEHAVIORAL|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
214258286|NCT04529915|DIAGNOSTIC_TEST|Exosome sampling|"* Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis"
214258287|NCT00629174|BEHAVIORAL|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
214258288|NCT00629174|BEHAVIORAL|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
214258289|NCT01516229|DRUG|somatropin|Prescription of somatropin at the discretion of the physician
214258290|NCT05235139|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
214258291|NCT05235139|DEVICE|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
214258292|NCT05019794|DRUG|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
214258293|NCT00147758|DRUG|Colesevelam hydrochloride|
214258294|NCT05126498|OTHER|no intervention|no intervention was applied
214258295|NCT00273910|DRUG|gp100:209-217 (210M)|
214258296|NCT00273910|DRUG|Montanide ISA-51|
214258297|NCT00273910|DRUG|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
214258298|NCT05177133|DRUG|Capecitabine|PO Capecitabine
214258299|NCT05177133|DRUG|Oxaliplatin|IV Oxaliplatin
214258300|NCT05177133|DRUG|Retifanlimab|IV retifanlimab
214258301|NCT03300323|DIAGNOSTIC_TEST|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
214258302|NCT04753476|BIOLOGICAL|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
214258303|NCT04753476|DRUG|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
214258304|NCT05579925|BIOLOGICAL|CM310|CM310 600 mg + 300 mg, subcutaneous injection
214258305|NCT05058352|DRUG|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
214258306|NCT04025983|DIETARY_SUPPLEMENT|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
214258307|NCT04025983|OTHER|Placebo|The placebo contains neither IgY nor L. johnsonii.
214258308|NCT04559360|DEVICE|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
214258309|NCT06207968|DEVICE|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
214258310|NCT02620007|DRUG|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
214258311|NCT02620007|DRUG|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
214258312|NCT02620007|DRUG|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
214258313|NCT02620007|DRUG|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
214258314|NCT05075382|PROCEDURE|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
214258315|NCT03130491|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
214258316|NCT03130491|DEVICE|EMBLOK filter|Embolic Filter Protection System During TAVR
214258317|NCT01244945|DIETARY_SUPPLEMENT|L. reuteri DSM 17938|L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
214258318|NCT01244945|OTHER|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
214258319|NCT04733144|DRUG|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
214258320|NCT04733144|DRUG|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
214258321|NCT05055453|DEVICE|MyPhonak Junior App|The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
214258322|NCT05055453|DEVICE|Phonak Sky hearing aid|A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
214258323|NCT04669327|OTHER|gait analysis|Vicon nexus with MTI force plate form
214258324|NCT03796832|DEVICE|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
214258325|NCT03796832|DEVICE|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
214258326|NCT03796832|OTHER|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
214258327|NCT04326959|BIOLOGICAL|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
214258328|NCT04326959|BIOLOGICAL|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
214258329|NCT04326959|BIOLOGICAL|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
214258330|NCT05276154|OTHER|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
214258331|NCT04515927|DRUG|JS002|Biological: JS002 Administered by subcutaneous injection
214258332|NCT03169309|DEVICE|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
214258333|NCT02031211|DRUG|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
214258334|NCT02031211|DRUG|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
214258335|NCT01224665|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
214258336|NCT01224665|PROCEDURE|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
214258337|NCT01224665|PROCEDURE|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
214258338|NCT03589781|DIETARY_SUPPLEMENT|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
214258339|NCT03589781|DIETARY_SUPPLEMENT|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
214258340|NCT05428098|OTHER|education|Oral and written education according to the life model
214258341|NCT05884710|OTHER|Foot core exercises|2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
214258342|NCT05884710|OTHER|Conventional Physiotherapy|Electrotherapeutic modalities and range of motion exercises
214258343|NCT00218127|DRUG|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
214258344|NCT00218127|DRUG|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
214258345|NCT00218127|DRUG|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
214258346|NCT00740077|OTHER|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
214258347|NCT00299182|DRUG|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
214258348|NCT00299182|DRUG|Rituximab|375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
214258349|NCT00299182|DRUG|Cyclophosphamide|300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
214258350|NCT00299182|DRUG|Vincristine|1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
214258351|NCT00299182|DRUG|Doxorubicin|50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
214258352|NCT00299182|DRUG|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
214258353|NCT00299182|DRUG|Methotrexate|200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
214258354|NCT00299182|DRUG|Cytarabine|3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
214258355|NCT00299182|DRUG|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
214258356|NCT06021665|OTHER|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
214258357|NCT06021665|OTHER|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
214258358|NCT02296944|OTHER|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
214258359|NCT03325049|BEHAVIORAL|The health-promoting conversations|The health-promoting conversations
214258360|NCT03325049|OTHER|Usual Care|Usual Care
214258361|NCT04609969|DIAGNOSTIC_TEST|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
214258362|NCT04609969|DIAGNOSTIC_TEST|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
214258363|NCT04685031|DRUG|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
214258364|NCT04685031|DRUG|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
214258365|NCT05726916|DRUG|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
214258366|NCT05726916|DRUG|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
214258367|NCT06170203|OTHER|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
214258368|NCT06298890|DEVICE|Artificial tears (sodium hyaluronate 0.2%)|Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
214258369|NCT03325088|PROCEDURE|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
214258370|NCT03325088|PROCEDURE|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
214258371|NCT03325088|PROCEDURE|Bronchial alveolar enema|For participants who had signed ancillary research consent
214258372|NCT00154492|DRUG|activated recombinant human factor VII|
214258373|NCT05306431|DRUG|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
214258374|NCT05306431|DRUG|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
214258375|NCT03267251|OTHER|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
214258376|NCT03267251|OTHER|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
214258377|NCT06557174|DRUG|IMC-002|intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
214258378|NCT06557174|DRUG|mycophenolate mofetil， MMF|daily oral 0.2g
214258379|NCT04627025|DRUG|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
214258380|NCT01703273|BEHAVIORAL|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
214258381|NCT01703273|BEHAVIORAL|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
214653500|NCT03628157|OTHER|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
214258382|NCT01580514|DRUG|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
214258383|NCT01580514|DRUG|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
214258384|NCT00156702|BEHAVIORAL|Feedback and Motivational Interviewing|
214258385|NCT00156702|BEHAVIORAL|Smoking Prevention Video|
214258386|NCT00213408|PROCEDURE|Radiofrequency catheter ablation of typical atrial flutter|
214258387|NCT03658057|DRUG|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
214258388|NCT04266223|DEVICE|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
214258389|NCT05678582|DIAGNOSTIC_TEST|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
214258390|NCT01631812|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
214258391|NCT03469388|DIAGNOSTIC_TEST|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
214258392|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TEA LIQUID PACKETS|JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
214258393|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TANG HENG POWDER DRINK|JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
214258394|NCT00224848|BEHAVIORAL|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
214258395|NCT05890742|DRUG|Sintilimab|In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
214258396|NCT05890742|DRUG|IBI310&Sintilimab|In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
214258397|NCT05890742|PROCEDURE|Radical surgery|In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
214258398|NCT05781373|PROCEDURE|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
214258399|NCT04170842|OTHER|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
214258400|NCT02800902|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
214258401|NCT02800902|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
214258402|NCT02800902|DRUG|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
214258403|NCT04459624|PROCEDURE|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
214258404|NCT04459624|PROCEDURE|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
214258405|NCT00590889|DEVICE|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
214258406|NCT02561624|BEHAVIORAL|Behaviour change communication via text message|
214258407|NCT03344354|DEVICE|Biogel|Sterile surgical gloves used during surgical procedures.
214258408|NCT03344354|DEVICE|Ansell|Sterile surgical gloves used during surgical procedures.
214258409|NCT03344354|DEVICE|Cardinal|Sterile surgical gloves used during surgical procedures.
214258410|NCT03344354|DEVICE|Medline|Sterile surgical gloves used during surgical procedures.
214258411|NCT00072176|DRUG|temsirolimus|Given IV
214258412|NCT00072176|OTHER|laboratory biomarker analysis|Correlative studies
214653501|NCT05733455|DRUG|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
214653502|NCT05733455|DRUG|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
214258413|NCT00200096|PROCEDURE|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
214258414|NCT00200096|PROCEDURE|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
214258415|NCT00065208|BEHAVIORAL|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
214258416|NCT00065208|BEHAVIORAL|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
214258417|NCT00065208|BEHAVIORAL|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
214258418|NCT05097612|DEVICE|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
214258419|NCT05097612|DEVICE|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
214258420|NCT05097612|DEVICE|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
214258421|NCT05097612|DEVICE|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
214258422|NCT05500547|OTHER|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
214258423|NCT03318900|BIOLOGICAL|Aldesleukin|Given IV
214258424|NCT03318900|DRUG|CD8-Positive T-Lymphocyte|Given IV
214258425|NCT03318900|DRUG|Cyclophosphamide|Given IV
214258426|NCT03318900|PROCEDURE|Leukapheresis|Undergo leukapheresis
214258427|NCT03318900|BIOLOGICAL|Utomilumab|Given IV
214258428|NCT06450158|DEVICE|Robot (Amadeo)-assisted Training|"Amadeo® is an FDA Class I Exempt hand/finger robot that has the capacity to precisely measure hand/finger functions.~To use Amadeo, a participant will be seated in a chair. The height of the robot arm support will be adjusted to achieve a comfortable position for the participant. One of the participant's arms will be will be placed on the robot arm support. Magnetic finger tips will then be attached to fingers and thumb. After this, fingers and thumb will be connected to the robot finger sliders. To use Amadeo, the movement range and maximal force of each finger will be configured according to the finger's capability. The following four types of function assessments will be performed with Amadeo: Force, range of motion, tone, and spasticity. Each session will last approximately one hour."
214258429|NCT04831606|PROCEDURE|debridement|Cleaning of the wound area
214258430|NCT04831606|DEVICE|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
214258431|NCT04831606|DEVICE|Advanced dressing|Protect the wound with Advanced dressing
214258432|NCT04831606|DEVICE|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
214258433|NCT04985370|OTHER|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
214258434|NCT04985370|OTHER|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
214258435|NCT02024555|DRUG|Levofloxacin|
214258436|NCT02024555|DRUG|Ethambutol|
214258437|NCT02024555|DRUG|Azithromycin|
214258438|NCT02024555|DRUG|Rifampin|
214258439|NCT02024555|DRUG|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
214258440|NCT02292342|DIETARY_SUPPLEMENT|Water|Control
214258441|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
214258442|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.5 mg/kg|EC 0.5
214258443|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 1.0 mg/kg|EC 1.0
214258444|NCT05879835|DEVICE|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
214258445|NCT05879835|DEVICE|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
214258446|NCT03861702|DRUG|FOLFOX regimen|FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)
214258447|NCT03861702|DRUG|Liposomal Irinotecan|Liposomal Irinotecan
214258448|NCT00267618|BEHAVIORAL|FHP Pain|Evidence-based psychological and behavioural Intervention
214258449|NCT05897099|BEHAVIORAL|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
214258450|NCT05897099|BEHAVIORAL|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
214258451|NCT03805646|OTHER|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
214258452|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
214258453|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
214258454|NCT06236243|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
214258455|NCT06184867|BEHAVIORAL|Relational Agent (RA)|Consists of a clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among cancer survivors.
214258456|NCT06184867|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of a clinical letter and recommendation for genetic testing for hereditary cancer risk among cancer survivors.
214258457|NCT03806491|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
214258458|NCT03806491|BEHAVIORAL|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
214258459|NCT03806491|BEHAVIORAL|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
214258460|NCT03193190|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
214258461|NCT03193190|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
214258462|NCT03193190|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
214258463|NCT03193190|DRUG|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
214258464|NCT03193190|DRUG|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
214258465|NCT03193190|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
214258466|NCT03193190|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
214258467|NCT03193190|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
214258468|NCT03193190|DRUG|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
214258469|NCT03193190|DRUG|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
214258470|NCT03193190|DRUG|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
214258471|NCT03193190|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
214258472|NCT03193190|DRUG|AB928|AB928 will be administered as per the schedule specified in the respective arm.
214258473|NCT03193190|DRUG|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
214258474|NCT03193190|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
214258475|NCT03493516|DIAGNOSTIC_TEST|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195
214258476|NCT05979727|DRUG|RE02|Low, medium or high dose of RE02
214258477|NCT05979727|DRUG|Manitol|Placebo Comparator
214258478|NCT06386146|DRUG|JAB-30355|Oral administration
214258479|NCT06386146|DRUG|JAB-30355|Oral administration
214258480|NCT05868044|DEVICE|PRIMUS|PRIMUS system
214258481|NCT00430651|DRUG|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
214258482|NCT00430651|DRUG|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
214258483|NCT03350620|DRUG|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
214258484|NCT03350620|DRUG|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
214258485|NCT03350620|DRUG|Placebo|Vehicle (placebo) will be administered, once daily (QD)
214258486|NCT03051854|BEHAVIORAL|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
214258487|NCT00757107|DEVICE|Taperloc Microplasty|primary total hip arthroplasty
214258488|NCT00757107|DEVICE|Taperloc standard|primary total hip arthroplasty
214258489|NCT02948283|OTHER|Laboratory Biomarker Analysis|Correlative studies
214258490|NCT02948283|DRUG|Metformin Hydrochloride|Given PO
214258491|NCT02948283|OTHER|Pharmacological Study|Correlative studies
214258492|NCT02948283|DRUG|Ritonavir|Given PO
214258493|NCT02948283|OTHER|Quality-of-Life|Ancillary studies
214258494|NCT02948283|OTHER|Questionnaire|Ancillary studies
214258495|NCT06842004|OTHER|Participatory action|The reality of audiovisual fiction in Spain and professionals' perceptions of how motherhood is portrayed will be explored. Through participatory action, participants will share their experiences and knowledge to identify areas for improvement in the representation of reproductive processes. The result will be a manual of good practices for fiction production, aimed at promoting more inclusive, realistic and stereotype-free representations, in order to improve both public perception and professional training in the audiovisual field.
214258496|NCT02208700|OTHER|Oxepa|Therapeutic nutrition with EPA, GLA\< and antioxidants
214258497|NCT02208700|OTHER|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
214258498|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
214258499|NCT06683235|DIETARY_SUPPLEMENT|flaxseed|Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.
214258500|NCT06683222|DIAGNOSTIC_TEST|Blood sample|36 ml of blood in 3 x 7 ml dry tubes, 1 x 5 ml EDTA tube, 1 x 5 ml heparinized tube, 1 x 5 ml anti-protease tube)
214258501|NCT06683222|DIAGNOSTIC_TEST|Saliva sample|5 ml of saliva will be taken.
214258502|NCT06683222|DIAGNOSTIC_TEST|Grip test|The grip strength of the dominant arm will be measured with the participant in a standing position, with the arm close to the body and the elbow at 90◦ flexion, while the non-dominant arm will be positioned alongside the body. Three measurements will be taken for the dominant hand, and the mean value will be calculated and used for analysis. One minute is allowed between each repetition, to avoid muscle fatigue. Dynamometer quality control is ensured by regularly checking known resistance values.
214258503|NCT06683222|OTHER|MicroFET2® maximum isometric force test|The microFET2 device is used to test isometric force. The microFET2 dynamometer is battery-powered and ergonomically designed to fit in the palm of the hand. The system is microprocessor-controlled to provide accurate, repeatable muscle force readings. The microFET Clinical software automatically performs calculations and validity tests, and allows graphs to be generated from the data, enabling reports of different patient tests to be compared
214258504|NCT06683222|OTHER|Maximum isometric knee extension bench test.|The maximal isometric knee extension strength test on a specially-adapted strength bench consists in performing 3 maximal contractions with 1 minute's rest between each test.
214258505|NCT06683222|OTHER|The SPPB (Short Physical Performance Battery)|Battery of tests comprising a balance test, a walking speed test and a chair-lift test
214258506|NCT06683222|OTHER|The 6-minute walking test.|Muscular function will be determined by the 6-minute walk test to assess aerobic endurance. Participants will be asked to walk for 6 min as fast as possible on a shuttle track. The distance (m) covered in 6 min will be measured. Walking speed (m/s) will be calculated as the distance (m) covered in 6 min. A walking speed \<0.8 m/s has been defined as a low value.
214258507|NCT06683222|OTHER|Segmental impedancemetry examination.|Segmental impedancemetry involves measuring body composition using the body's resistance to the passage of a low-intensity electric current. This test is harmless to the body.
214258508|NCT06683222|OTHER|Indirect calorimetry test.|An Indirect calorimetry is the standard method for measuring energy expenditure at rest. It is based on the principle that the human body burns nutrients using O2 and producing CO2.
214258509|NCT06683222|OTHER|Fardellone's questionnaire|Completion of a questionnaires on calcium intake (Fardellone)
214258510|NCT06683222|OTHER|ONAPS questionnaire|The ONAPS questionnaire contains questions on physical activity and sedentariness
214258511|NCT06683222|OTHER|Dietary intake.questionnaire|The dietary intake questionnaire contains questions regarding the person's eating habits - how many meals a day, where they eat, whether they eat alone, what foods they eat/drink and whether they are following a particular diet and, if so, the reasons why.
214258512|NCT06905132|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
214258513|NCT06240741|DRUG|[68Ga]Ga-DOTA-TATE|Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
214258514|NCT06240741|DRUG|68Ge/68Ga Generator|Radionuclide generator
214258515|NCT00814788|DRUG|Bicalutamide|50 mg oral tablet daily
214258516|NCT00814788|DRUG|Everolimus|10 mg oral capsule daily
214258517|NCT06518642|DEVICE|Sooma tDCS portable device - active stimulation|Treatment followed common tDCS protocol upon considering safety and tolerability, comprising five consecutive sessions in five days of 30-minute 2 mA tDCS. We utilized the Soterix Medical tDCS device (Soterix Medical, New York, NY, USA, Model 1x1 tDCS-CT) in the research lab and the Sooma Oy device (Sooma Depression Therapy Comfort, Helsinki, Finland) for patient self-administration.Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device.Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or. Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or the Soterix device based on availability during their initial session. A current of 2 mA was applied with the anode positioned left DLPFC, corresponding to area F3 in the international 10-20 system. The cathode (reference electrode) was applied at the right dPLFC, F4.
214258518|NCT06518642|DEVICE|Sooma tDCS portable device - sham stimulation|Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device for effective blinding, distinguishable only by serial number and managed by an external data manager following the randomization sequence.To ensure blinding to the participant and their caregiver, at the beginning of the stimulation sessions, participants receiving both the active and sham stimulation would experience a ramp-up in current from 0 to 2 mA, and then the current would ramp down to 0 mA for participants receiving sham stimulation. Participants were told that they may experience sensations such as tingling, headache, or mild burning during the first 30-60 seconds of the stimulation session but that they may subside afterwards as they got used to it. In other words, participants would not be able to tell if diminishing of side effects were due to habituation (active tDCS) or ramping down of current (sham tDCS).
214258519|NCT06933420|DEVICE|Cern Device|The Cern Device is an Intravaginal device utilizing low level microbicidal visible light at a 450nm low level microbicidal light, in visible spectrum for treatment of vaginitis, including both bacterial vaginosis and fungal vaginitis.
214258520|NCT06935071|OTHER|Data Collection and Analysis|Patient data will be analyzed to ensure that all data fields are available and that suitable sample size is available to answer the research objectives. The rate of ambulation at discharge, ambulation at 3 month follow up (if available), time to death, and pain score between the historic cohort with a current cohort of patients will be compared.
214258521|NCT06935045|DRUG|Placebo Beverage|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow placebo beverage consumption (180 minutes total).
214258522|NCT06935045|DRUG|Alcohol (Ethanol)|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow alcoholic beverage consumption (180 minutes total).
214258523|NCT06934330|BEHAVIORAL|Mindfulness practice with Tao Art (Calligraphy and Song Greatest Love)|During mindfulness practice with Tao Art (Calligraphy and Song Greatest Love), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for six weeks.
214258524|NCT06934330|OTHER|Drinking Energized water|Participants will drink energized water from a bottle that received subtle energy transmission. They will replenish water daily and activate the transmission in the bottle to energize the water. Participants will drink about 1 litre of energized water a day for six weeks.
214258525|NCT06933641|PROCEDURE|Regional Analgesia|20 cc of local anesthetic solution, comprising 10 cc of 0.5% bupivacaine and 10 cc of 0.9% NaCl bilaterally, was injected into each side once
214258526|NCT06933290|OTHER|Beverage|15 milliliter aliquot interspersed with tastants with a 3 minute break between tastants
214258527|NCT06934746|OTHER|DSM-5 criteria.|The DSM-5 defines three levels of ADHD severity based on symptom count and frequency: 1. Mild ADHD • Symptom Count: Just meets the diagnostic criteria (6 symptoms in children for either inattention or hyperactivity/impulsivity). • Frequency: Symptoms occur but are not excessively frequent. 2. Moderate ADHD • Symptom Count: More than the minimum required for diagnosis. • Frequency: Symptoms occur frequently (e.g., several times a week). 3. Severe ADHD • Symptom Count: Many symptoms well beyond the diagnostic threshold. • Frequency: Symptoms occur daily or multiple times per day.(National Center for Biotechnology Information, n.d.)
214258528|NCT06934733|OTHER|Oral cryotherapy|Patients randomly assigned to the experimental group underwent TROP2-ADC treatment. They continuously held ice cubes and ice water from 15 minutes before the infusion, throughout the infusion process, and for 15 minutes after the infusion. Ice cubes were promptly replaced with fresh ones as they melted. Patients were instructed not to consume any food or liquids orally for 1 hour following the completion of the ice therapy.
214258529|NCT06934733|OTHER|Routine oral care|Patients in the control group did not receive oral cryotherapy during the TROP2-ADC infusion but only received routine oral care.
214653503|NCT05733455|DEVICE|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
214653504|NCT05733455|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
214653505|NCT05733455|DIETARY_SUPPLEMENT|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
214653506|NCT03244358|DRUG|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
214653507|NCT04097548|BEHAVIORAL|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
214258530|NCT06934655|DRUG|Semaglutide 2.4 mg|The dosing regimen will follow standard titration protocols, starting with a dose of 0.25 mg weekly for the first month, with gradual increases in dosage each month to a target dose of 2.4 mg weekly by the fifth month. To minimize the potential for side effects impacting daily activities, youth in the semaglutide group will be instructed to administer the medication weekly on Fridays.
214653508|NCT02034487|OTHER|retrospective data collection|
214653509|NCT03614572|BEHAVIORAL|Group MI|refer to the arm description
214653510|NCT04513691|DIAGNOSTIC_TEST|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
214653511|NCT01379625|DRUG|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
214653512|NCT02324166|DRUG|Cefazolin|cephalosporin antibiotic
214653513|NCT02324166|DRUG|Lidocaine|local anesthetic
214653514|NCT01447394|BIOLOGICAL|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
214653515|NCT01447394|BIOLOGICAL|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
214653516|NCT01447394|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
214258531|NCT06934850|OTHER|Hand grip strength|Collection Tools a) Hand Grip Force Measurement: Hand grip strength will be measured using a digital dynamometer. The measurement will be performed three times in the dominant and nondominant hand of the participant and the average value will be taken (1). b) Trunk Control Assessment: Trunk control will be assessed with the McGill core endurance test. This scale is a valid and reliable tool to objectively measure trunk stability and dynamic control levels (2). c) Motor skill assessment: Timed Up and Go Test: The Timed Up and Go Test was used to assess functional mobility and dynamic balance (3). The patient was told to get up from the chair, walk 3 meters, return and sit back in the chair. The time was recorded. Timed Stair Climbing Test: It consists of the individual climbing the stairs and returning to the starting point. The elapsed time was recorded
214258532|NCT06935032|DEVICE|Twin block appliance|An appliance that facilitates forward positioning of the mandible and soft tissues
214258533|NCT06935032|OTHER|Fixed orthodontic treatment|Patients undergoing orthodontic treatment with fixed appliances
214258534|NCT06934902|BEHAVIORAL|"Old vs new objects encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks.~The following week, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase."
214258535|NCT06934902|BEHAVIORAL|" incongruent vs. congruent contexts  encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. This time, the objects will be chosen according to the participant's location.~The following week, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent/incongruent contexts."
214258536|NCT06933953|OTHER|Questionnaires|"Patients will complete various questionnaires at J0: FHSQ-Fr, EQ-5D-5L, Foot Function Index, Visual analog pain scale, SF-12.~Patients who needs to come back for a visit at Day 7 (+ 3 days) will complete the FHSQ-Fr questionnaire for a second time"
214258537|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session, once daily for five consecutive days, with EEG monitoring conducted before and after electrical stimulation.
214258538|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
214258539|NCT00427271|DRUG|aspirin|
214258540|NCT01080742|DRUG|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
214258541|NCT01254097|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule, 2 capsules twice daily
214258542|NCT04672395|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
214258543|NCT04672395|BIOLOGICAL|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
214258544|NCT04672395|BIOLOGICAL|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
214258545|NCT04672395|BIOLOGICAL|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
214258546|NCT02474381|BIOLOGICAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
214258547|NCT02474381|DEVICE|Single PTA|Angioplasty of arteries below tibial plateau level only
214258548|NCT04382391|DEVICE|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
214258549|NCT04382391|OTHER|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
214258550|NCT00257608|DRUG|bevacizumab|Intravenous repeating dose
214258551|NCT00257608|DRUG|placebo|Oral repeating dose
214258552|NCT00257608|DRUG|erlotinib HCl|Oral repeating dose
214258553|NCT05207254|DIAGNOSTIC_TEST|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
214258554|NCT01197664|DRUG|paricalcitol|Given PO
214258555|NCT01197664|RADIATION|radiation therapy|Undergo radiotherapy
214258556|NCT01197664|OTHER|laboratory biomarker analysis|Correlative studies
214258557|NCT01197664|DRUG|fluorouracil|Given PO
214258558|NCT03748693|PROCEDURE|Hysterectomy|Surgery performed on women with a variety of gynecological indications
214258559|NCT03748693|PROCEDURE|Colporrhaphy|Surgery performed on women with POP
214258560|NCT02171065|DEVICE|sham|
214258561|NCT02171065|DEVICE|ABSORB BVS|
214258562|NCT00000337|DRUG|Selegiline|
214258563|NCT05015439|DRUG|Cannabidiol|The study intervention will be supplied as a softgel capsule containing cannabidiol.
214258564|NCT05015439|DRUG|Placebo|The study intervention will be supplied as a softgel capsule containing inert filler.
214258565|NCT00562029|PROCEDURE|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
214258566|NCT06558513|DRUG|XNW5004 tablets|XNW5004 an EZH2 inhibitor, BID, administered in continuous
214258567|NCT03245684|DIAGNOSTIC_TEST|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
214258568|NCT03134404|OTHER|No Intervention|No Intervention is required for this study
214258569|NCT06169046|DRUG|Clenbuterol|tablets
214258570|NCT06169046|DRUG|Placebo|tablets
214258571|NCT01435278|DEVICE|Glucosanol|2 tablets taken 3 times a day.
214258572|NCT03968770|DIETARY_SUPPLEMENT|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
214258573|NCT03968770|DIETARY_SUPPLEMENT|Control group|Placebo of Probiotic once daily taken by 6 weeks.
214258574|NCT03968770|OTHER|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
214258575|NCT00066638|DRUG|Romidepsin|Given IV
214258576|NCT00066638|OTHER|Laboratory Biomarker Analysis|Correlative studies
214258577|NCT06063278|BEHAVIORAL|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
214258578|NCT01121653|DRUG|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
214258579|NCT03332290|BEHAVIORAL|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
214258580|NCT05863338|BEHAVIORAL|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
214258581|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
214258582|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
214258583|NCT01705990|BIOLOGICAL|Ad35-GRIN (0.5mL)|(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
214258584|NCT04663373|OTHER|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
214258585|NCT04258514|PROCEDURE|Virtual Reality during vasectomy|Virtual Reality
214258586|NCT04258514|PROCEDURE|Standard Vasectomy|No Virtual Reality
214258587|NCT01139931|GENETIC|DNA methylation analysis|
214258588|NCT01139931|GENETIC|gene expression analysis|
214258589|NCT01139931|GENETIC|microarray analysis|
214258590|NCT01139931|GENETIC|polymorphism analysis|
214258591|NCT01139931|OTHER|laboratory biomarker analysis|
214258592|NCT04512417|DRUG|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
214258593|NCT04512417|DRUG|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
214653517|NCT01461681|PROCEDURE|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
214258594|NCT05557435|OTHER|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
214258595|NCT05557435|OTHER|Placebo|Placebo
214258596|NCT00000519|BEHAVIORAL|diet, reducing|
214258597|NCT00000519|BEHAVIORAL|exercise|
214258598|NCT00000519|BEHAVIORAL|diet, fat-restricted|
214653518|NCT00697957|BEHAVIORAL|Exercise|Progressive impact exercise
214258599|NCT05444621|RADIATION|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
214258600|NCT03137342|BEHAVIORAL|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
214258601|NCT04680091|DRUG|Pyrotinib Maleate|single oral dose, 400 mg, fed.
214258602|NCT04680091|DRUG|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
214258603|NCT06311825|OTHER|Horticultural Therapy|"One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up."
214258604|NCT04099407|DRUG|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
214258605|NCT04099407|OTHER|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
214258606|NCT05608759|BEHAVIORAL|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
214258607|NCT05932966|DEVICE|Insulin closed-loop delivery system|Insulin closed-loop delivery system
214258608|NCT03555032|DRUG|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
214258609|NCT00090168|DRUG|MK0653A , ezetimibe (+) simvastatin|
214258610|NCT00090168|DRUG|Comparator: atorvastatin|
214258611|NCT00090168|DRUG|Duration of Treatment: 6 weeks|
214258612|NCT00232973|DRUG|ICXP007|
214258613|NCT04796545|DEVICE|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
214258614|NCT04813640|DEVICE|Spectacles|Novel spectacles for myopia control
214258615|NCT00250055|PROCEDURE|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
214258616|NCT03449875|DEVICE|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
214258617|NCT03803995|PROCEDURE|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
214258618|NCT03803995|PROCEDURE|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
214258619|NCT02874157|BIOLOGICAL|blood draw|
214258620|NCT06285708|BEHAVIORAL|Prolonged exposure|PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
214258621|NCT03616275|OTHER|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
214258622|NCT00004075|DRUG|tanespimycin|
214258623|NCT02829632|BEHAVIORAL|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
214258624|NCT02829632|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
214258625|NCT02829632|BEHAVIORAL|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
214653519|NCT06363162|DIAGNOSTIC_TEST|Immunohistochemistry or genetic test|Perform two diagnostic methods on the same sample
214258626|NCT03832777|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
214258627|NCT05900271|DEVICE|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
214258628|NCT05900271|DEVICE|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
214258629|NCT02053051|DEVICE|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
214258630|NCT02053051|DEVICE|Standard bolus calculator|
214653520|NCT00813995|DRUG|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
214258631|NCT04571814|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
214258632|NCT02467400|DRUG|Atenolol|beta blocker
214258633|NCT02467400|DRUG|Nebivolol|beta blocker
214258634|NCT02467400|DRUG|Propranolol|beta blocker
214258635|NCT02467400|DRUG|placebo|placebo
214258636|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
214258637|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
214258638|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
214258639|NCT04847856|BEHAVIORAL|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
214258640|NCT00292214|DRUG|Paracetamol (acetaminophen)|
214258641|NCT01628705|OTHER|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
214258642|NCT01628705|DIETARY_SUPPLEMENT|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
214258643|NCT01570556|OTHER|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
214258644|NCT02609009|OTHER|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
214258645|NCT02609009|OTHER|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
214258646|NCT01854658|DRUG|GFF MDI (PT003)|GFF MDI administered as two puffs BID
214258647|NCT01854658|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
214653521|NCT00813995|DRUG|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
214653522|NCT05497726|PROCEDURE|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
214653523|NCT03124225|DRUG|DMARD|
214653524|NCT03476044|DRUG|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
214653525|NCT03476044|DRUG|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
214653526|NCT01614964|DRUG|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
214653527|NCT01614964|DRUG|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
214653528|NCT03424161|DEVICE|Secret RF|Subjects will receive treatment with the Secret RF device
214258648|NCT01854658|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
214258649|NCT01854658|DRUG|Placebo|
214258650|NCT05776368|OTHER|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
214258651|NCT05776368|OTHER|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
214258652|NCT05776368|OTHER|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~* Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~* Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~* Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~* Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
214258653|NCT05776368|OTHER|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
214258654|NCT05776368|OTHER|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
214258655|NCT05776368|OTHER|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
214258656|NCT05776368|OTHER|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
214258657|NCT05776368|OTHER|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
214258658|NCT01858376|DIETARY_SUPPLEMENT|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
214258659|NCT01391754|BEHAVIORAL|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
214258660|NCT01391754|OTHER|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
214258661|NCT01391754|BEHAVIORAL|Services As Usual|Home based services not using the SafeCare model
214258662|NCT01391754|OTHER|Uncoached|No in vivo coached quality control or fidelity monitoring
214258663|NCT03150160|DRUG|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
214258664|NCT03150160|DRUG|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
214258665|NCT03150160|DRUG|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
214258666|NCT03725215|BEHAVIORAL|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
214258667|NCT05700318|DEVICE|neurostimulator|The ShiraTronics Migraine Therapy System
214258668|NCT03025841|DRUG|Ceftaroline|
214258669|NCT03383458|BIOLOGICAL|Nivolumab|Specified dose on specified days
214258670|NCT03383458|OTHER|Placebo|specified dose on specified days
214258671|NCT05412875|OTHER|Best Practice|Given usual care
214258672|NCT05412875|DRUG|Nicotine Replacement|Given JUUL
214258673|NCT05412875|OTHER|Quality-of-Life Assessment|Ancillary studies
214258674|NCT05412875|OTHER|Questionnaire Administration|Ancillary studies
214258675|NCT04041297|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
214653529|NCT06117514|DRUG|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
214653530|NCT06117514|DRUG|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
214653531|NCT06117514|DRUG|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
214653532|NCT06117514|DRUG|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
214653533|NCT06117514|DRUG|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
214653534|NCT06117514|OTHER|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
214653535|NCT06117514|OTHER|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
214653536|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
214653537|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
214653538|NCT03618030|DRUG|PRC-063 oral capsules|Daily dose
214258676|NCT03071471|DEVICE|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~* Only two screws are used~* Incision size is much smaller~* Simpler operation with shorter operative time~* Less complication thanks to the three points above.~* Minimal spinal mobility loss"
214258677|NCT03140228|DEVICE|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
214258678|NCT03140228|DEVICE|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
214258679|NCT01411618|OTHER|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214258680|NCT03798197|DRUG|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
214258681|NCT04234802|OTHER|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
214258682|NCT04449887|DRUG|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
214258683|NCT01317381|PROCEDURE|Observational|Blood draw
214258684|NCT04537455|DIAGNOSTIC_TEST|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
214258685|NCT04484948|OTHER|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
214653539|NCT03618030|DRUG|Placebo oral capsules|Daily dose
214258686|NCT05770869|DEVICE|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
214258687|NCT05420675|OTHER|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
214258688|NCT02834728|BEHAVIORAL|telephone interview|
214258689|NCT01593410|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
214258690|NCT01593410|DRUG|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
214258691|NCT04048187|DEVICE|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
214653540|NCT02082197|DRUG|ABT-SLV176|ABT-SLV176 administered daily
214258692|NCT00940030|OTHER|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
214258693|NCT00940030|OTHER|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
214258694|NCT00014118|DRUG|carboplatin|
214258695|NCT00014118|DRUG|paclitaxel|
214653541|NCT01583348|PROCEDURE|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
214653542|NCT01053312|DRUG|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
214258696|NCT00014118|PROCEDURE|conventional surgery|
214258697|NCT00014118|RADIATION|radiation therapy|
214258698|NCT06340061|OTHER|Observational study|The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
214258699|NCT03835871|DRUG|Placebo|Intervention: Drug: placebo
214258700|NCT03835871|DRUG|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
214258701|NCT03835871|DRUG|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
214258702|NCT03835871|DRUG|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
214258703|NCT01012167|DRUG|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
214258704|NCT01012167|DRUG|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
214258705|NCT01012167|OTHER|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
214258706|NCT01012167|OTHER|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
214258707|NCT00486473|DRUG|Multihance|0.5 Molar at a single dose injection
214258708|NCT00486473|DRUG|Magnevist|0.5M at a single dose injection
214653543|NCT02684305|DRUG|Administration of Propess|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
214653544|NCT02684305|DEVICE|balloon|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
214653545|NCT02684305|DRUG|Intravenous oxytocin infusion|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
214653546|NCT02909868|DEVICE|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
214653547|NCT01851538|OTHER|Observational study; no intervention.|
214653548|NCT00541983|DRUG|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
214653549|NCT00541983|DRUG|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
214653550|NCT06448793|DRUG|Approved Non-small Cell Lung Cancer (NSCLC) therapies|As prescribed by treating physician
214653551|NCT01105637|BEHAVIORAL|Augmented Exercise Program|12 week (3 x per week) exercise prescription
214653552|NCT02700984|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
214653553|NCT02700984|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
214653554|NCT02759042|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214258709|NCT06306053|COMBINATION_PRODUCT|tDCS+EuleriaLab|Home based: Non invasive Neuromodulation treatment + Motor Training
214258710|NCT06306053|DEVICE|tDCS|Non invasive brain stimulation
214258711|NCT06306053|OTHER|EuleriaLab|Home Motor Training
214258712|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
214258713|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
214258714|NCT00641303|PROCEDURE|acupuncture therapy|Given weekly for 8 sessions
214258715|NCT00641303|PROCEDURE|sham intervention|Given weekly for 8 sessions
214258716|NCT01823354|OTHER|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
214258717|NCT01823354|OTHER|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
214258718|NCT01823354|OTHER|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
214258719|NCT01823354|OTHER|Medical consultation|open questions
214258720|NCT04260711|DRUG|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
214258721|NCT01768052|DEVICE|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
214258722|NCT02545257|OTHER|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
214258723|NCT01006369|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
214258724|NCT02796703|DIETARY_SUPPLEMENT|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
214258725|NCT02796703|DIETARY_SUPPLEMENT|Placebo|2 cc of milk will be given to control group
214258726|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|
214258727|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|
214258728|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|
214258729|NCT02439294|DEVICE|CPAP|
214258730|NCT05843760|OTHER|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
214258731|NCT05843760|OTHER|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
214258732|NCT05843760|OTHER|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
214258733|NCT06467942|DRUG|Chinese medicine and Lactobacillus|combined drug group
214258734|NCT06467942|DRUG|Chinese medicine|Single Chinese medicine group
214258735|NCT06467942|DRUG|Lactobacillus|Single Lactobacillus group
214258736|NCT03364569|PROCEDURE|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
214258737|NCT03461263|OTHER|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
214258738|NCT02821637|OTHER|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
214258739|NCT02821637|BEHAVIORAL|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
214653555|NCT00331435|PROCEDURE|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
214653556|NCT00619008|OTHER|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
214653557|NCT00619008|OTHER|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
214653558|NCT00619008|OTHER|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
214653559|NCT01543347|DRUG|Temocillin|Antibiotic treatment
214653560|NCT04600167|DRUG|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
214653561|NCT04600167|DRUG|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
214653562|NCT02557061|PROCEDURE|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
214653563|NCT02557061|BIOLOGICAL|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
214653564|NCT03254173|DRUG|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
214258740|NCT02821637|OTHER|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
214258741|NCT03186495|DRUG|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
214258742|NCT03475680|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
214258743|NCT03475680|DRUG|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
214258744|NCT03475680|DRUG|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
214258745|NCT03475680|DRUG|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
214258746|NCT03475680|DRUG|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
214258747|NCT03192956|OTHER|No active intervention|No active intervention is performed
214258748|NCT03830242|DIAGNOSTIC_TEST|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
214258749|NCT03830242|DIAGNOSTIC_TEST|B-ultrasonography|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
214258750|NCT00026962|PROCEDURE|measuring estradiol and progesterone levels in saliva|
214258751|NCT00326066|DEVICE|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
214258752|NCT00326066|PROCEDURE|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
214258753|NCT01722396|DIETARY_SUPPLEMENT|Vitamin D|
214258754|NCT05143385|OTHER|Virtual reality|"* Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
214258755|NCT02875912|BEHAVIORAL|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
214258759|NCT05115669|DEVICE|Wortie freeze plus|treatment of common and plantar warts
214258760|NCT05194865|DEVICE|cardiac MRI|assessment of the viability using CMR
214258761|NCT05194865|PROCEDURE|Percutaneous coronary intervention|direct revascularization using PCI
214258762|NCT02129114|DEVICE|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
214258763|NCT02129114|DEVICE|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
214258764|NCT02021578|BEHAVIORAL|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
214258765|NCT02021578|BEHAVIORAL|Written information|Reading materials about depression
214258766|NCT04960631|DIAGNOSTIC_TEST|Double site CT guided needle biopsy|Double site CT guided needle biopsy
214258767|NCT00192361|BIOLOGICAL|CAIV-T|
214258768|NCT03302195|DRUG|Heparin|Based on patient body weight (UI/kg)
214258769|NCT03302195|PROCEDURE|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
214258770|NCT05007093|DRUG|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
214258771|NCT02436304|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
214258772|NCT02436304|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
214258773|NCT03061383|OTHER|8% Arginine based toothpaste|toothpaste
214258774|NCT03061383|OTHER|8% strontium acetate based toothpaste|toothpaste
214258775|NCT03061383|OTHER|placebo|toothpaste
214258776|NCT02818361|DRUG|Topical tripterygium gel|
214258777|NCT02818361|DRUG|Placebo gel|
214258778|NCT06276231|DRUG|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
214258779|NCT06276231|OTHER|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
214258780|NCT06276231|DRUG|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
214258781|NCT06061354|DRUG|Teriparatide|mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
214258782|NCT06061354|PROCEDURE|Maxillary Sinus Augmentation|Local anesthesia will be performed, mucoperiosteal flap will be raised to access the anterior wall of the maxillary sinus. Access to the maxillary sinus will be done through osteotomy, using a piezosurgery under irrigation with saline solution. Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material (Bio-Oss® mixed with saline solution or Bio-Oss® mixed with Forteo®) will be delivered for placement on the sinus floor maxilla below Schneider's membrane.Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed.
214653565|NCT03254173|DRUG|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
214653566|NCT03705481|DEVICE|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
214258783|NCT06061354|PROCEDURE|Dental Implant Installation|Local anesthesia will be performed a mucoperiosteal flap will be raised in the area for implant placement and a bone core 10 mm high and 2 mm in diameter will be removed with a 2 mm trephine bur. The bone biopsied through this nucleus is part of the region where the implant will be installed, and the height of the sample depends on the surgical planning carried out previously (3-month radiographic control). The sequence of drills to place the implant will continue, installation of the implant itself and, finally, verification of the insertion torque and measurement of the resonance frequency in the already installed implant. The mucoperiosteal flap must be repositioned and sutured.
214258784|NCT06061354|COMBINATION_PRODUCT|Bone graft|One arm:mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® In other arm: 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
214258785|NCT00920933|BIOLOGICAL|AIN457|
214258786|NCT00920933|OTHER|Placebo|
214258787|NCT00920933|DRUG|prednisolone|
214258788|NCT00185562|DRUG|Adalimumab|
214258789|NCT04295551|DRUG|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
214258790|NCT04295551|DRUG|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
214258791|NCT00302185|PROCEDURE|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
214258792|NCT00302185|BEHAVIORAL|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
214258793|NCT02515643|OTHER|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method"
214258794|NCT01585870|DRUG|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
214258795|NCT01585870|DRUG|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
214258796|NCT03793556|DEVICE|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
214258797|NCT03793556|DRUG|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
214258798|NCT00398788|DRUG|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
214258799|NCT04828239|DEVICE|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
214258800|NCT04828239|OTHER|acupuncture|Needle type: C\&G, gauge and size: 0.25x40mm
214258801|NCT04828239|DEVICE|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
214258802|NCT01805804|DRUG|placebo/valsartan|
214258803|NCT06111521|DRUG|LY3537982|Administered orally
214258804|NCT06111521|DRUG|Digoxin|Administered orally
214258805|NCT06111521|DRUG|Rosuvastatin|Administered orally
214258806|NCT06111521|DRUG|Midazolam|Administered orally
214258807|NCT06111521|DRUG|Midazolam|Administered IV
214258808|NCT05727462|OTHER|Manual Therapy with TECAR|"The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference."
214258809|NCT05727462|OTHER|Manual Therapy without TECAR|Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
214258810|NCT05509751|BEHAVIORAL|GAM, exercise, health education|geriatric assessment, exercise and health education
214258811|NCT05509751|BEHAVIORAL|online chair-based exercise combined with health education|online chair-based exercise and health education for 12 weeks
214258812|NCT04416633|DRUG|Durvalumab|500-mg/120-mg IV
214258813|NCT06288009|PROCEDURE|Running locking suture|In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
214258814|NCT06288009|PROCEDURE|Standard running suture|In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
214258815|NCT04612790|BIOLOGICAL|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
214258816|NCT04612790|BIOLOGICAL|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
214258817|NCT00785928|BIOLOGICAL|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
214258818|NCT00785928|DRUG|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
214258819|NCT03881410|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
214258820|NCT00975520|OTHER|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
214258821|NCT00975520|RADIATION|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
214258822|NCT03699683|OTHER|Combined aerobic and resistance training program|
214258823|NCT03424668|BEHAVIORAL|diet|lifestyle factors
214258824|NCT00261079|DRUG|Fexofenadine|
214258825|NCT05644769|OTHER|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
214258826|NCT05644769|DRUG|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
214258827|NCT05554588|PROCEDURE|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
214258828|NCT05554588|PROCEDURE|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
214258829|NCT03764007|DRUG|18F-Fluorocholine|Given intravenously
214258830|NCT03764007|PROCEDURE|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
214653567|NCT05233358|PROCEDURE|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
214258831|NCT05962749|OTHER|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
214258832|NCT03572244|DEVICE|Laser-Lok|A microgrooved abutment will be placed
214258833|NCT03572244|DEVICE|Machined|A machined transmucosal healing abutment will be placed
214258834|NCT06441669|DRUG|Letermovir|Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
214258835|NCT00111982|BIOLOGICAL|Liatermin|Liatermin
214258836|NCT00037622|DRUG|ACH-126, 443 (beta-L-Fd4C)|
214258837|NCT04558580|DRUG|Rufinamide|Rufinamide
214258838|NCT00365144|BIOLOGICAL|bevacizumab|
214258839|NCT00365144|DRUG|erlotinib hydrochloride|
214258840|NCT00365144|OTHER|laboratory biomarker analysis|
214258841|NCT02678273|OTHER|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
214258842|NCT01588639|DRUG|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
214258843|NCT01588639|DRUG|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
214258844|NCT01588639|DRUG|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
214653568|NCT05233358|PROCEDURE|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
214258845|NCT04256096|DEVICE|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
214258846|NCT00111488|DEVICE|Flex 4 and Generator|
214258847|NCT01924507|DEVICE|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
214258848|NCT02169973|DRUG|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
214258849|NCT02169973|DRUG|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
214258850|NCT00860444|BEHAVIORAL|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
214258851|NCT00860444|BEHAVIORAL|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
214258852|NCT04452032|PROCEDURE|Dental avulsion|Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.
214258853|NCT04452032|RADIATION|Radiotherapy|"Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT)."
214258854|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
214258855|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
214258856|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
214258857|NCT06198283|OTHER|Low Level LASER Therapy with Pressure Garment|This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
214258858|NCT06198283|OTHER|Low Level LASER Therapy without Pressure Garment|This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
214258859|NCT00476359|DRUG|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
214258860|NCT05486754|BEHAVIORAL|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
214258861|NCT05486754|BEHAVIORAL|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
214258862|NCT04130984|DEVICE|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
214258863|NCT05661123|OTHER|Complete decongestive therapy|"1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
214258864|NCT06364475|BEHAVIORAL|16:8 Time-Restricted Intermittent Fasting Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.
214258865|NCT06364475|BEHAVIORAL|Energy-Restricted Six-Meal Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
214258866|NCT04056351|DIAGNOSTIC_TEST|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
214258867|NCT04056351|OTHER|Questionnaires on patient activity and comorbidities|"* Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score"
214258868|NCT04056351|OTHER|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
214258869|NCT04056351|OTHER|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
214258870|NCT00366977|BEHAVIORAL|Multi-session telephone counseling|
214258871|NCT00366977|DRUG|NRT patches|
214258872|NCT01782547|BEHAVIORAL|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
214258873|NCT01782547|OTHER|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
214258874|NCT04004546|BEHAVIORAL|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
214258875|NCT00003254|DRUG|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
214258876|NCT00003254|DRUG|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
214258877|NCT01504568|OTHER|Treatment|Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
214258878|NCT03459261|DIAGNOSTIC_TEST|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
214258879|NCT01146990|DRUG|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
214258880|NCT01595711|DEVICE|Pain Monitor|Measurement of cutaneous conductance
214258881|NCT03525093|BEHAVIORAL|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
214258882|NCT03525093|BEHAVIORAL|Health education|Participants receive a health education booklet on improving coping with stress.
214258883|NCT02325986|DRUG|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
214258884|NCT02325986|DRUG|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
214258885|NCT02325986|RADIATION|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
214258886|NCT04749875|OTHER|blood sample|sampling of blood for research during routine care
214258887|NCT04478981|OTHER|No intervention|This concerns a natural history study; no interventions will be used
214258888|NCT00643773|DIETARY_SUPPLEMENT|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
214258889|NCT00643773|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour
214258890|NCT05129423|DRUG|MTPS9579A|MTPS9579A will be administered.
214258891|NCT05129423|DRUG|Placebo|Placebo matched with MTPS9579A will be administered.
214258892|NCT00570765|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
214258893|NCT00570765|DRUG|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
214258894|NCT02414451|DRUG|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
214258895|NCT02414451|DRUG|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
214258896|NCT03463174|PROCEDURE|Mandibular overdenture|Placement of an implant in the mandibular midline.
214258897|NCT03463174|OTHER|Mandibular complete denture|No intervention.
214258898|NCT04234607|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214258899|NCT04234607|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
214258900|NCT04234607|DRUG|Etoposide|Etoposide is a cell cycle-specific antitumor drug
214258901|NCT04234607|DRUG|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
214258902|NCT04234607|DRUG|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
214258903|NCT04234607|DRUG|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
214258904|NCT01129674|DRUG|LY2140023|Administered orally, twice daily for 104 weeks
214258905|NCT01129674|DRUG|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
214258906|NCT01129674|DRUG|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
214258907|NCT01129674|DRUG|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
214258908|NCT01129674|DRUG|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
214258909|NCT04784039|DIAGNOSTIC_TEST|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
214258910|NCT04784039|DIAGNOSTIC_TEST|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
214258911|NCT00215748|DRUG|Dexamethasone|
214258912|NCT04238416|DRUG|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
214258913|NCT04238416|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
214258914|NCT01298310|DRUG|Xylocaine|1 mg/mL solution for injection
214258915|NCT01298310|DRUG|Xylocaine|10 mg/mL solution for injection
214258916|NCT01298310|DRUG|Placebo|solution for injection
214258917|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
214258918|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
214258919|NCT05883683|OTHER|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
214258920|NCT02002390|DRUG|Fingolimod|A sphingosine-1-phosphate receptor regulator
214258921|NCT00234234|DRUG|Adalimumab|
214258922|NCT05371678|OTHER|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
214258923|NCT05371678|OTHER|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
214258924|NCT03387683|DRUG|dapagliflozin|dapagliflozin 10mg
214258925|NCT03387683|DRUG|placebo|placebo to match dapagliflozin
214258926|NCT00744276|DRUG|danazol|danazol applied topically once per day for 4 treatment cycles
214258927|NCT00744276|DRUG|Placebo|placebo topically applied once daily for 4 treatment cycles
214258928|NCT04210583|DEVICE|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
214653569|NCT05233358|DRUG|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
214258929|NCT02148107|DRUG|BI 691751|BI 691751 Dose 1
214258930|NCT02148107|DRUG|BI 691751|BI 691751 Dose 2
214258931|NCT02148107|DRUG|BI 691751|BI 691751 Dose 3
214653570|NCT05233358|DRUG|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
214258932|NCT02148107|DRUG|BI 691751|BI 691751 Dose 4
214258933|NCT02148107|DRUG|BI 691751|BI 691751 Dose 5
214258934|NCT02148107|DRUG|BI 691751|BI 691751 Dose 6
214258935|NCT02148107|DRUG|Placebo|Placebo
214258936|NCT01028885|PROCEDURE|radiation therapy treatment planning/simulation|
214258937|NCT01028885|PROCEDURE|intensity-modulated radiation therapy|
214258938|NCT01028885|PROCEDURE|image-guided radiation therapy|
214258939|NCT01028885|PROCEDURE|magnetic resonance imaging|
214258940|NCT01028885|PROCEDURE|computed tomography|
214258941|NCT00079768|DRUG|Alemtuzumab (Campath)|
214258942|NCT02697487|OTHER|No treatment|This is an observational study with no intervention.
214258943|NCT03500575|DEVICE|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
214653571|NCT00473876|DRUG|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
214653572|NCT00473876|DRUG|Matched Placebo (Capsules)|Similar dosing regime as active comparator
214653573|NCT03911622|DEVICE|MRI|medical device that is used as an imaging tool for soft tissues
214258944|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
214258945|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
214258946|NCT00875979|DRUG|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
214258947|NCT00366132|DEVICE|Extracorporeal Shockwaves|
214258948|NCT05720208|DEVICE|SCiP|Noninvasive Spinal Cord Neuromodulator
214258949|NCT06319131|PROCEDURE|TIPS|Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
214258950|NCT06319131|DRUG|Nadroparin|Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
214258951|NCT04926142|DEVICE|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
214258952|NCT04926142|PROCEDURE|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
214258953|NCT03130608|OTHER|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
214258954|NCT01554436|BEHAVIORAL|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
214258955|NCT01649804|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
214258956|NCT03938467|DRUG|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
214258957|NCT04391491|DIAGNOSTIC_TEST|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
214258958|NCT03266523|OTHER|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
214258959|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
214258960|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
214258961|NCT04214873|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
214258962|NCT05816031|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
214258963|NCT03686514|BIOLOGICAL|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
214258964|NCT05010408|OTHER|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
214258965|NCT01948037|OTHER|hydrotherapy|30-minutes/per day,for 4weeks
214258966|NCT01948037|OTHER|hydrotherapy|30-minutes/per day;4weeks
214258967|NCT01192373|OTHER|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
214258968|NCT01192373|OTHER|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
214258969|NCT05012657|DEVICE|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
214258970|NCT04242173|DRUG|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
214258971|NCT00739050|DRUG|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
214258972|NCT00739050|DRUG|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
214258973|NCT03420859|DIAGNOSTIC_TEST|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
214258974|NCT01123850|DEVICE|Copios|Bone Void Filler
214258975|NCT00775476|DRUG|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
214258976|NCT00775476|DRUG|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
214258977|NCT05780931|BEHAVIORAL|Study-specific rehabilitation (SSR) procedures|Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
214258978|NCT05704010|DEVICE|Video capsule endoscopy|Video capsule endoscopy every 2 years
214258979|NCT04708119|PROCEDURE|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
214653574|NCT00348140|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
214653575|NCT00348140|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
214653576|NCT00348140|OTHER|Placebo|Placebo
214258980|NCT03578757|BEHAVIORAL|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
214258981|NCT02841436|DEVICE|Irreversible Electroporation (IRE) System|
214258982|NCT01461083|DRUG|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
214258983|NCT02083081|BEHAVIORAL|Community level intervention|Community intervention plus individual counseling
214258984|NCT01975961|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
214258985|NCT03495037|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
214258986|NCT03495037|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
214258987|NCT03295461|PROCEDURE|SRP+ 10% Emblica officinalis irrigation|
214258988|NCT03295461|PROCEDURE|SRP + 0.2% Chlorhexidine irrigation)|
214258989|NCT03295461|PROCEDURE|SRP + 0.9% Saline irrigation|
214653577|NCT01032629|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily
214653578|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
214653579|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
214653580|NCT06064760|BEHAVIORAL|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself."
214258990|NCT03295461|PROCEDURE|SRP +10% E. officinalis gel application.|
214258991|NCT03295461|PROCEDURE|SRP+ placebo gel application.|
214258992|NCT01456390|DEVICE|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
214258993|NCT03003611|PROCEDURE|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
214258994|NCT03003611|PROCEDURE|general anesthesia|Patient will be anesthetized with a classical general anesthesia
214258995|NCT03149510|BEHAVIORAL|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
214258996|NCT01336296|DRUG|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
214258997|NCT02575131|OTHER|whole wheat bread yeast basis|
214258998|NCT02575131|OTHER|Oatmeal|
214258999|NCT02575131|OTHER|Cheerios|
214653581|NCT04795479|DRUG|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
214653582|NCT04795479|DRUG|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
214653583|NCT04795479|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
214653584|NCT02489370|DEVICE|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
214653585|NCT02216565|OTHER|Hospitalization in specialized neuro-vascular unit|
214653586|NCT02216565|DRUG|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
214653587|NCT02216565|OTHER|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
214653588|NCT02216565|PROCEDURE|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
214259000|NCT02575131|OTHER|whole wheat sourdough bread|
214259001|NCT02575131|OTHER|standard breakfast|
214259002|NCT04108676|DRUG|Fluzoparib|PARP inhibitor
214259003|NCT04108676|DRUG|Omeprazole|proton pump inhibitor
214259004|NCT04504773|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
214259005|NCT04228393|DRUG|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
214259006|NCT04228393|PROCEDURE|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
214259007|NCT04228393|PROCEDURE|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
214259008|NCT04462185|DIAGNOSTIC_TEST|A genomic and transcriptomic landscape analysis|A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
214259009|NCT04493580|BEHAVIORAL|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
214259010|NCT04493580|BEHAVIORAL|In-Person DBT|In-person DBT
214259011|NCT02028871|DRUG|Intranasal Insulin|
214259012|NCT02028871|DRUG|Placebo|
214259013|NCT03661710|OTHER|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
214259014|NCT01691898|DRUG|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
214259015|NCT01691898|DRUG|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
214259016|NCT01691898|DRUG|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
214259017|NCT01691898|DRUG|Rituximab|RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
214259018|NCT04911413|DRUG|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
214259019|NCT06418750|OTHER|dermo-cosmetic product|For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
214259020|NCT01913223|DEVICE|Nestis® jet injector system with a bi-functional catheter|
214259021|NCT05353309|PROCEDURE|Standard Angioplasty|Angioplasty Iliac done following standard practice
214259022|NCT05353309|PROCEDURE|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
214259023|NCT00920634|DRUG|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
214259024|NCT02938845|BEHAVIORAL|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
214259025|NCT02938845|PROCEDURE|total laparoscopic hysterectomy(TLH)|
214259026|NCT02938845|PROCEDURE|total abdominal hysterectomy(TAH)|
214259027|NCT02291536|DRUG|tetrahydrocannabinol|
214259028|NCT02291536|DRUG|cannabidiol|
214259029|NCT02291536|OTHER|placebo|
214259030|NCT02276326|DIETARY_SUPPLEMENT|VSL#3 sachets|4 sachets a day for 4 months
214259031|NCT00001443|DRUG|indinavir (MK-0639)|
214259032|NCT05664607|OTHER|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
214259033|NCT00000328|DRUG|Opioid-Related Disorders|
214259034|NCT02378675|OTHER|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
214259035|NCT04375618|DRUG|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
214259036|NCT04375618|DRUG|Plain Collagen|A collagen membrane without FGF-2 will be used.
214259037|NCT05560204|DEVICE|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
214259038|NCT00331253|PROCEDURE|Indocyanine Green-Mediated Photothrombosis|
214259039|NCT03775291|DIAGNOSTIC_TEST|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
214259040|NCT01104155|DRUG|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
214259041|NCT01104155|DRUG|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
214259042|NCT01484132|PROCEDURE|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
214259043|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
214259044|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
214259045|NCT03139318|RADIATION|GRID radiotherapy|Patients will be treated with GRID radiotherapy
214259046|NCT02808650|OTHER|Laboratory Biomarker Analysis|Correlative studies
214259047|NCT02808650|OTHER|Pharmacokinetic (PK) study|Correlative studies
214259048|NCT02808650|DRUG|Prexasertib|Given IV
214259049|NCT03630367|DRUG|Dexamethasone|Intramuscular injection 8 mg
214259050|NCT03630367|DRUG|L-Carnitine 1G/5mL Injection|slow intravenous injection
214259051|NCT02350673|DRUG|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
214259052|NCT02350673|DRUG|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
214259053|NCT04743349|PROCEDURE|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
214259054|NCT02826135|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
214259055|NCT01922674|PROCEDURE|Standard open tension-free inguinal hernia repair with mesh|
214259056|NCT02693392|DRUG|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents"
214259057|NCT02693392|DIETARY_SUPPLEMENT|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
214259058|NCT00424801|DRUG|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
214259059|NCT00424801|DRUG|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
214259060|NCT00424801|DRUG|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
214259061|NCT00424801|DRUG|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
214259062|NCT00424801|DRUG|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
214259063|NCT00424801|DRUG|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
214259064|NCT00424801|DRUG|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
214259065|NCT06621316|DRUG|HRS-7535 Tablet|at multiple dose levels
214259066|NCT06621316|DRUG|Placebo|at multiple dose levels (matching active arm HRS-7535 Tablet)
214259067|NCT06216834|OTHER|No intervention|No intervention
214259068|NCT02979717|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|
214259069|NCT02979717|OTHER|Low protein, low fiber comparator|
214259070|NCT02939079|DRUG|Fingolimod|Produced by Osveh ® Pharm Company in Iran
214259071|NCT02939079|DIETARY_SUPPLEMENT|Fish Oil|produced by Zahravi ® Pharm Company in Iran
214259072|NCT02939079|DRUG|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
214259073|NCT03654443|DIAGNOSTIC_TEST|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
214259074|NCT00537875|DIETARY_SUPPLEMENT|Ginger|Capsule, 1000 mg, BID, 3 days
214259075|NCT00537875|DIETARY_SUPPLEMENT|Placebo|Capsule, 1000 mg, BID, 3 days
214259076|NCT01248845|OTHER|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
214259077|NCT04524169|DRUG|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
214259078|NCT02355496|OTHER|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
214259079|NCT04093414|DEVICE|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
214259080|NCT02666716|DRUG|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
214259081|NCT04209348|BEHAVIORAL|Physical Activity Intervention|Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
214259082|NCT04209348|OTHER|Wellness Education|The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
214259083|NCT03236831|OTHER|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)"
214259084|NCT05185323|OTHER|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
214259085|NCT05185323|OTHER|Breastfeeding usual known aids|Breastfeeding usual known aids
214259086|NCT03539354|DEVICE|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
214259087|NCT03539354|PROCEDURE|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
214259088|NCT03539354|DRUG|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
214259089|NCT06344182|OTHER|Step Up and Down Test|Step Up and Down Test In the StUD test, the patient completes maximum number of step-up-down repetitions in 15 seconds. Starting from a standing position, the participant took a full step up, leading with the test leg, then the non-testing leg, until both knees were fully extended and both hips were at least in neutral extension. In order to stress the testing limb concentrically and eccentrically, the participant stepped off the step first with the non-testing limb, then the testing limb. The patient was asked to repeat for 15 seconds as quickly as possible. The physical therapist stood to the side of the step for safety and so that he/she could observe the technique and ensure that the participant came to a full step up and down during the test.
214259090|NCT00240227|DRUG|Prazosin|FDA approved medication for hypertension
214259091|NCT00240227|DRUG|placebo|
214259092|NCT03694912|PROCEDURE|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
214259093|NCT01296438|DRUG|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
214259094|NCT01296438|DRUG|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
214259095|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
214259096|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
214259097|NCT04037046|BEHAVIORAL|Screening HCV at primary care center|DBS for HCV screening at primary care center
214259098|NCT04348461|DRUG|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
214259099|NCT03182803|BIOLOGICAL|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
214259100|NCT02720237|BEHAVIORAL|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
214259101|NCT02720237|BEHAVIORAL|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
214259102|NCT02720237|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
214259103|NCT04595344|OTHER|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
214259104|NCT04595344|OTHER|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
214259105|NCT04595344|OTHER|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
214259106|NCT05689697|DIETARY_SUPPLEMENT|PanTrek|administration of exogenouse keton body
214259107|NCT04102956|DRUG|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
214259108|NCT04185376|OTHER|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
214259109|NCT04398316|DRUG|Lidocaine Iv|2 mg/kg over 5 minutes
214259110|NCT04398316|DRUG|HYDROmorphone Injection|1 mg over 5 minutes
214259111|NCT02463968|PROCEDURE|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
214259112|NCT02463968|PROCEDURE|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
214259113|NCT05215990|DRUG|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
214259114|NCT05215990|DRUG|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
214259115|NCT05210231|OTHER|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
214259116|NCT03624231|DRUG|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
214259117|NCT03624231|DRUG|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
214259118|NCT03624231|RADIATION|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
214259119|NCT02969551|DEVICE|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
214259120|NCT00857428|DRUG|oxymorphone|Tablets
214259121|NCT00857428|DRUG|Oxymorphone|40 mg tablets
214259122|NCT02080637|DRUG|Ambrisentan|Once daily oral dosing
214259123|NCT02080637|OTHER|Placebo|
214259124|NCT04252365|DRUG|Sintilimab|Given i.v.
214259125|NCT04252365|DRUG|Pembrolizumab|Given i.v.
214259126|NCT03835910|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
214259127|NCT03835910|PROCEDURE|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
214259128|NCT03835910|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
214259129|NCT03835910|PROCEDURE|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
214259130|NCT03298373|DRUG|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
214259131|NCT03298373|DRUG|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
214259132|NCT04171284|DRUG|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
214259133|NCT04171284|DRUG|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
214259134|NCT04171284|DRUG|Placebo|200 mg, Q3W, maximum treatment up to six cycles
214259135|NCT02770170|DRUG|BI 655064 dose 1|
214259136|NCT02770170|DRUG|BI 655064 dose 2|
214259137|NCT02770170|DRUG|BI 655064 dose 3|
214259138|NCT02770170|DRUG|Placebo|
214259139|NCT06534034|PROCEDURE|Dental implant placement|Dental implant placement on edentulous jaw.
214259140|NCT00445978|DRUG|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
214259141|NCT02497300|DRUG|Spironolactone|
214259142|NCT02497300|DRUG|Amiloride|
214259143|NCT05913648|OTHER|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
214259144|NCT02670434|DRUG|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
214259145|NCT02670434|DRUG|Placebo|Placebo daily for 12 weeks
214259146|NCT02670434|DRUG|Livalo|Livalo® IR daily from week 12 to week 52
214259147|NCT05078242|DEVICE|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
214259148|NCT01822496|RADIATION|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
214259149|NCT01822496|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
214259150|NCT01822496|DRUG|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
214259151|NCT01822496|DRUG|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
214259152|NCT01822496|DRUG|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
214259153|NCT01822496|DRUG|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
214259154|NCT01822496|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
214259155|NCT05843955|OTHER|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
214259156|NCT03946488|DEVICE|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
214259157|NCT02902068|DEVICE|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
214259158|NCT00304239|COMBINATION_PRODUCT|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
214259159|NCT00304239|COMBINATION_PRODUCT|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
214259160|NCT00244517|DRUG|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
214259161|NCT00244517|DRUG|Sevoflurane, Isoflurane, Desflurane|1 MAC
214259162|NCT02979197|DRUG|OE 10 mg amlodipine besylate tablet|
214259163|NCT02979197|DRUG|OE 200 mg celecoxib capsule|
214259164|NCT02979197|DRUG|Matched placebo for OE amlodipine besylate tablet|
214259165|NCT02979197|DRUG|Matched placebo for OE celecoxib capsule|
214259166|NCT00384254|BEHAVIORAL|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
214259167|NCT00384254|BEHAVIORAL|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
214259168|NCT05969431|DIAGNOSTIC_TEST|measurement of cortisol level|We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.
214259169|NCT03572751|DIAGNOSTIC_TEST|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
214259170|NCT03126903|DEVICE|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
214259171|NCT03643159|COMBINATION_PRODUCT|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
214259172|NCT03643159|DRUG|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
214259173|NCT01828879|DRUG|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
214259174|NCT01056731|DRUG|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
214259175|NCT00177996|DRUG|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
214259176|NCT00449410|DRUG|Atorvastatin|
214259177|NCT00449410|DRUG|ezetimibe|
214259178|NCT03847870|DIAGNOSTIC_TEST|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
214259179|NCT03467048|DEVICE|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
214259180|NCT03467048|DEVICE|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
214259181|NCT01488500|OTHER|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
214259182|NCT02284360|DRUG|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
214259183|NCT01898208|DEVICE|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
214259184|NCT01898208|BEHAVIORAL|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
214259185|NCT01898208|OTHER|Bacterial culture|This test identifies the pathogen responsible for an infection.
214259186|NCT01898208|OTHER|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
214259187|NCT05986760|BEHAVIORAL|SPARK|Functional Motor training
214259188|NCT02496065|DRUG|BLZ-100|
214259189|NCT02994134|BEHAVIORAL|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
214259190|NCT02994134|BEHAVIORAL|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
214259191|NCT06151431|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
214259192|NCT06151431|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
214259193|NCT00194909|DRUG|sildenafil (Viagra)|
214259194|NCT01854996|DRUG|PF-05089771|450mg
214259195|NCT01854996|DRUG|PF-05089771|450mg
214259196|NCT01854996|DRUG|PF-05089771|450mg
214259197|NCT05303077|DIETARY_SUPPLEMENT|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
214259198|NCT05303077|DIETARY_SUPPLEMENT|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
214259199|NCT05303077|DIETARY_SUPPLEMENT|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
214259200|NCT06520670|DIAGNOSTIC_TEST|Urinary galectin-3 binding protein|Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
214259201|NCT02643173|OTHER|Volatile anesthetics|
214259202|NCT02643173|OTHER|Intravenous anesthetics|
214259203|NCT04021420|DEVICE|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
214259204|NCT04021420|DRUG|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
214259205|NCT02436681|DEVICE|MIROMESH|
214259206|NCT01498601|OTHER|Enhanced oral care protocol|"* Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care"
214259207|NCT02030938|DEVICE|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
214259208|NCT01879514|DRUG|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
214259209|NCT01879514|DRUG|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
214259210|NCT00819299|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
214259211|NCT00752544|DRUG|TMC435350|
214259212|NCT00805701|DRUG|avodart|0.5 avodart once daily for 13 weeks
214259213|NCT00805701|DRUG|Placebo|placebo
214259214|NCT01599832|DRUG|pazopanib hydrochloride|Given PO
214259215|NCT01599832|OTHER|laboratory biomarker analysis|Correlative studies
214259216|NCT01599832|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
214259217|NCT01599832|OTHER|pharmacogenomic studies|Correlative studies
214259218|NCT05293015|OTHER|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
214259219|NCT03169686|BEHAVIORAL|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
214259220|NCT05882188|PROCEDURE|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
214259221|NCT05882188|PROCEDURE|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
214259222|NCT00399620|PROCEDURE|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
214259223|NCT00000432|BEHAVIORAL|Education about disease prevention|
214259224|NCT05186285|DRUG|CM338|CM338 : a humanized monoclonal antibody.
214259225|NCT05186285|DRUG|Placebo|Placebo.
214259226|NCT02359344|DRUG|CNV1014802|
214259227|NCT02359344|DRUG|Placebo|
214259228|NCT01480648|DRUG|BI 144807 Placebo|Placebo that represents BI drug
214259229|NCT01480648|DRUG|BI 144807|single dose (low to high dose)
214259230|NCT04017000|DIAGNOSTIC_TEST|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
214259231|NCT04017000|OTHER|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
214259232|NCT00334607|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
214259233|NCT03954132|DRUG|Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
214259234|NCT03954132|DRUG|Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
214259235|NCT02883166|DRUG|abiraterone|integested with a continental breakfast
214259236|NCT00834678|DRUG|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
214259237|NCT00834678|DRUG|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
214259238|NCT00834678|DRUG|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
214259239|NCT01739361|DRUG|Acetaminophen|
214259240|NCT01739361|DRUG|placebo|
214259241|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
214259242|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
214259243|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
214259244|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
214259245|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
214259246|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
214259247|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
214259248|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
214259249|NCT04107779|OTHER|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
214259250|NCT04107779|OTHER|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
214259251|NCT04107779|OTHER|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
214259252|NCT02370277|OTHER|Cytology Specimen Collection Procedure|Undergo collection of stool samples
214259253|NCT02370277|OTHER|Laboratory Biomarker Analysis|Correlative studies
214259254|NCT02370277|OTHER|Questionnaire Administration|Ancillary studies
214259255|NCT00067574|BEHAVIORAL|Structured treatment interruption|
214259256|NCT01904565|RADIATION|Hyperthermia and Proton Beam|"1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
214259257|NCT05738629|DRUG|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
214259258|NCT04660253|BEHAVIORAL|LTP Plus Dads|
214259259|NCT00302198|BEHAVIORAL|ALS Registry|
214259260|NCT02443519|BEHAVIORAL|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
214259261|NCT04155489|PROCEDURE|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
214259262|NCT04022434|DIETARY_SUPPLEMENT|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
214259263|NCT04022434|DIETARY_SUPPLEMENT|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
214259264|NCT00932737|DRUG|Placebo|1-5 tablets per episode
214259265|NCT00932737|DRUG|HBB 20 mg|Active drug, one to five tablets per episode
214259266|NCT01812772|DEVICE|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
214259267|NCT01812772|DEVICE|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
214259268|NCT04126551|OTHER|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
214259269|NCT01689636|DRUG|Tc 99m EC20|
214259270|NCT05325060|DEVICE|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
214259271|NCT05325060|DEVICE|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
214259272|NCT06281288|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive behavioral therapy
214259273|NCT06281288|OTHER|Exercise Training|Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
214259274|NCT03451942|DRUG|FLOT regimen chemotherapy|FLOT regimen chemotherapy
214259275|NCT03451942|PROCEDURE|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
214259276|NCT04879277|BIOLOGICAL|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
214259277|NCT04399837|DRUG|Spesolimab|Solution for injection
214259278|NCT04399837|DRUG|Placebo|Solution for injection
214259279|NCT05269732|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
214259280|NCT05361785|BIOLOGICAL|FMT|FMT from healthy donor or placebo
214259281|NCT03239158|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
214259282|NCT03239158|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214259283|NCT01638364|DRUG|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
214259284|NCT01638364|DRUG|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
214259285|NCT01122433|DEVICE|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
214259286|NCT00646789|DRUG|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
214259287|NCT06441955|DRUG|Ritonavir-Boosted Nirmatrelvir (Paxlovid)|"Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment."
214259288|NCT06441955|DIAGNOSTIC_TEST|Physiological Evaluation|Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.
214818177|NCT06121219|DEVICE|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
214259289|NCT06441955|BIOLOGICAL|Moderna COVID-19 Vaccine|Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
214259290|NCT06441955|BEHAVIORAL|Biopsychological|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
214259291|NCT06441955|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
214259292|NCT06441955|GENETIC|Genetic (including gene transfer, stem cell and recombinant DNA)|Full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time to address the intersection of genomics and health disparities, recognizing that genetic variations can contribute to health disparities in several ways. Understanding these genetic contributions to health disparities is crucial for developing targeted interventions and personalized healthcare strategies that can help address these disparities. genetics, epidemiology, public health, and social sciences, the study aims to shed light on the complex interplay between genomics and health equity. To evaluate cellular errors and the effects of myocardial DNA, you may need to consider tests such as DNA sequence.
214259293|NCT06441955|COMBINATION_PRODUCT|Multidisciplinary approach|The aim of utilizes psychology-applied science and science in nursing frameworks to address health disparities and promote health and wellness across the health span to improve patient population outcomes, evaluate cost-effectiveness, and patient health literacy competencies. The experimental framework of a compilation of the bio-psychosocial model, Eric Erickson developmental stages, AI/AML, and cognitive learning theories address system decision making factors, for sound decision making and behavioral change cognitive behavioral therapies protocol segmentation demographic and urban areas affected by social-economic access to healthcare and related ethical stance of United States healthcare policy developmental outlines. Biology plays a role in the content of development stages, and the great debate of nurture vs. nature sets the foundation for addressing the psychosocial approach to healthcare integration as an applied science model for strengthening primary services and improving
214259294|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
214259295|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
214259296|NCT01049399|DRUG|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
214259297|NCT01049399|DRUG|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
214259298|NCT01049399|DRUG|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
214259299|NCT05606718|DRUG|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
214259300|NCT05606718|OTHER|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
214653589|NCT05411302|OTHER|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
214818178|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
214818179|NCT04756245|BEHAVIORAL|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
214259301|NCT04048200|DRUG|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
214259302|NCT04048200|DRUG|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
214259303|NCT04938479|BIOLOGICAL|blood sample|D-dimer measurement in blood sample
214259304|NCT02906371|DRUG|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
214259305|NCT02906371|DRUG|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
214259306|NCT02906371|BIOLOGICAL|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
214259307|NCT04417543|DRUG|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
214259308|NCT04417543|DRUG|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
214259309|NCT00894127|DEVICE|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
214259310|NCT02386306|DRUG|GC021109|
214259311|NCT02386306|OTHER|Placebo|
214259312|NCT06402643|PROCEDURE|Pterygium Excision|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
214259313|NCT01945827|DEVICE|DeltaMaxx Microcoil System|
214259314|NCT00990873|GENETIC|gene expression analysis|
214259315|NCT00990873|GENETIC|microarray analysis|
214259316|NCT00990873|GENETIC|reverse transcriptase-polymerase chain reaction|
214259317|NCT00990873|OTHER|laboratory biomarker analysis|
214259318|NCT04949685|PROCEDURE|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
214259319|NCT04266249|DRUG|Docetaxel|Given IV
214259320|NCT04266249|PROCEDURE|Lumpectomy|Undergo lumpectomy
214259321|NCT04266249|PROCEDURE|Mastectomy|Undergo mastectomy
214259322|NCT04266249|DRUG|Nab-paclitaxel|Given IV
214259323|NCT04266249|DRUG|Paclitaxel|Given IV
214259324|NCT04266249|BIOLOGICAL|Pertuzumab|Given IV
214259325|NCT04266249|RADIATION|Radiation Therapy|Undergo radiation therapy
214259326|NCT04266249|BIOLOGICAL|Trastuzumab|Given IV
214259327|NCT04266249|BIOLOGICAL|Trastuzumab Emtansine|Given IV
214259328|NCT05469685|DRUG|Vonoprazan|Potassium-competitive acid blocker
214259329|NCT05469685|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214259330|NCT06434298|BEHAVIORAL|Choose to Move|As described under study arm description
214259331|NCT06612853|OTHER|Sleep Quality Scale (SQS)|"For the pilot testing, each patient will complete the pre-final version of the SQS.~The patients involved in the field study will have to fill in the SQS twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale."
214259332|NCT06612853|OTHER|Pittsburgh Sleep Quality Index (PSQI)|The patients involved in the field test will have to fill in the PSQI twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.
214259333|NCT04330183|DRUG|Ketamine|0.3mg/kg of ketamine
214259334|NCT04330183|DRUG|Normal Saline|3cc of normal saline
214259335|NCT05184478|DRUG|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached."
214259336|NCT05184478|DRUG|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
214259337|NCT06482307|DIAGNOSTIC_TEST|[18F]-olaparib PET scan|The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
214259338|NCT06709937|OTHER|Prospective multicenter registry of patients with cutaneous metastases from breast carcinoma treated with electrochemotherapy.|electrochemotherapy.
214259339|NCT06545825|OTHER|Standard enteral nutrition|Enteral nutrition will be given with standard isocaloric mixtures. Mixture volume calculation will be performed after indirect calorimetry, adjusted for daily nitrogen loss.
214259340|NCT06681675|PROCEDURE|The group that applied the Intrapartum Care Model|"In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied."
214259341|NCT05249790|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
214259342|NCT05249790|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
214259343|NCT01298635|PROCEDURE|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
214259344|NCT01298635|PROCEDURE|trabeculectomy|
214259345|NCT06614829|DEVICE|Stratafix Suture|Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
214259346|NCT06614829|DEVICE|DERMABOND PRINEO|"DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure."
214259347|NCT06685250|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214259348|NCT01554397|RADIATION|PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing
214259349|NCT01554397|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
214259350|NCT01554397|RADIATION|IMRT|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
214259351|NCT06703242|OTHER|Health promotion for mothers of children with ADHD in the ultra-orthodox community|The intervention will consist of 3 modules with six sessions. Mothers will gain knowledge in topics related to understanding the ADHD health condition and its biological origins, optimal and recommended treatment options, school management techniques, and the importance of taking care of their own health.
214259352|NCT06708533|BEHAVIORAL|Physical Activity|"This intervention involves a structured 12-week walking program designed to increase routine physical activity among participants diagnosed with IBS. The intervention focuses on moderate-intensity walking, performed regularly, in line with World Health Organisation (WHO) guidelines with the aim of relieving IBS symptoms.~Key elements include:~Participants will be guided to adhere to an individualised walking protocol, ensuring consistency in activity levels.~Physical activity levels will be monitored using self-reported diaries and wearable activity trackers to ensure compliance.~Participants will also attend three scheduled visits to the university (baseline, week 6, and week 12) for biological sample collection, sub-maximal fitness assessments, and the completion of validated questionnaires on IBS symptoms, quality of life (QoL), anxiety, and depression."
214259353|NCT06712446|BEHAVIORAL|EFT|Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.
214259354|NCT06712446|DEVICE|high frequency rTMS|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling . For dlPFC, we will measure position F3. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. Intermittent theta burst stimulation (iTBS) (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the resting motor threshold (RMT) and will last \~3 minutes. Participants will receive 2 sessions of iTBS to the dlPFC brain region with a 15-20-minute interval between sessions
214259355|NCT06712446|DEVICE|sham frequency rTMS|Participants will receive sham TMS to the dlPFC. They may feel the TMS from the A/P coil electrodes, but there will not be any real stimulation of the brain.
214259356|NCT06707129|OTHER|life-style|The patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.
214259357|NCT06706726|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy during the management of breast cancer
214259358|NCT06706726|PROCEDURE|Single-port robotic-assisted axillary lymph node dissection|Single-port robotic-assisted（Endoscopic Instrument Control System SP1000) axillary lymph node dissection during the management of breast cancer
214259359|NCT06710652|DEVICE|rTMS|Stimulation coil Cool-B65 A CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
214259360|NCT06710652|DEVICE|Sham Comparator|Stimulation coil Cool-B65 P CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
214653590|NCT03545282|BEHAVIORAL|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
214653591|NCT00755079|DRUG|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
214653592|NCT00755079|DRUG|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
214653593|NCT04629560|DRUG|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
214653594|NCT00854646|DRUG|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
214259361|NCT06706895|DRUG|Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules|"Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles. If the patient has AE of grade 3 or above, the dose of fruquintinib capsules is reduced to 3 mg / day(dose discontinuation to dose reduction).~Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle. Do not need special infusion device.~Paclitaxel Polymeric Micelles for Injection and Fruquintinib Capsules are used for 6 cycles. Subsequently, dual-drug or single-drug maintenance therapy was selected according to the tolerance of the patients. Subsequently, Paclitaxel Polymeric Micelles for Injection ( 120mg / m2, if the patient is intolerable, the dose can be reduced to 100mg / m2 ), until occur the disease progress, the intolerant toxicity or the patient withdrawal."
214259362|NCT06707948|PROCEDURE|Arthroscopic meniscus surgery|Comparison of the incidence of osteoarthritis with conservative treatment as well as arthroscopic partial resection as well as arthroscopic repair surgery for a condition known as posterior meniscus root injury.
214259363|NCT06710236|DEVICE|Hearing instrument|Conventional, daily wear hearing instruments will be used in this study.
214259364|NCT06709027|DEVICE|Intervention Group (Mobile Health Management Intervention)|Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring,et al， with the aim of improving the mental health status of elderly patients with depression.
214259365|NCT06934083|BEHAVIORAL|E-health education briefs|Participants will be asked to complete self-administered questionnaire regarding the six healthy lifestyles delivered via text message to their cell phone. Then, during the six-month intervention, participants will receive text messages at intervals set by their preference but at least 2 times per week to ensure adequate space for education delivery and assessment through Likert scale text message surveys relating to Lifestyle Health Education topics including Nutrition, Physical Activity, Tobacco Avoidance, Sleep, Stress Management, and Social Connection. As to the clinical outcomes, self-reported blood pressure, blood glucose, total cholesterol, waist circumference, and body mass index (BMI) will be collected from the participants at enrollment and at the live or virtual community celebration at the close of the study.
214259366|NCT06933667|BEHAVIORAL|Physical Activity|Participants can chose (with input from a kinesiologist as required) from courses of varying intensity in our gym, warm water pool, or classrooms.
214259367|NCT06933667|BEHAVIORAL|Brain-healthy Eating|Participants take five foundational courses: Brain-healthy eating, Healthy protein choices, Colour your diet: Maximize the benefits of fruits and vegetables; Interpreting nutrition facts labels; and Salt and sugar: How much is too much? They are also encouraged to take additional nutrition programs.
214259368|NCT06933667|BEHAVIORAL|Cognitive Engagement|Participants can sign up for any lecture, discussion group, book club, creative arts program, etc. linked to the Cognitive Engagement risk factor.
214259369|NCT06933667|BEHAVIORAL|Social Connections|Social Connections are baked into all other programming. Our instructors are trained in how to foster connections among participants, through peer coaching, ice-breakers, etc., and are asked to leave some time at the beginning and end of programs for participants to chat. We also hold special social events such as game nights.
214259370|NCT06933667|BEHAVIORAL|Mental Wellbeing|Participants are encouraged to enroll in one a week of relevant programming (e.g., meditation, relaxation).
214259371|NCT06933446|OTHER|Myofascial Release|A myofascial release protocol, applied to the thigh muscles in post-effort recovery in water polo athletes.
214259372|NCT06933446|OTHER|Classic Massage|Massagem clássica, com pressão superficial, utilizada para atingir apenas tecidos subcutâneos, sem que haja ação sobre músculos e fáscias
214259373|NCT06350474|OTHER|Discontinuation of dornase alfa (Dnase)|Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
214259374|NCT06350474|OTHER|Continuation of dornase alfa (Dnase)|Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
214259375|NCT06181578|PROCEDURE|ganglionated plexus ablation|This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
214259376|NCT06556641|DRUG|GZR33 Injection|Administered as once daily subcutaneous dose
214259377|NCT06556641|DRUG|GZR101 Injection|Administered as once daily subcutaneous dose
214259378|NCT06556641|DRUG|Placebo|Administered as once daily subcutaneous dose
214259379|NCT06556641|DRUG|Insulin Degludec|Administered as once daily subcutaneous dose
214259380|NCT01966601|DRUG|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
214653595|NCT04095455|PROCEDURE|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
214259381|NCT01966601|DRUG|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
214259382|NCT01966601|DRUG|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
214259383|NCT01966601|DRUG|Placebo|Placebo continuous intravenous infusion
214259384|NCT05169996|OTHER|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
214259385|NCT05169996|OTHER|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
214259386|NCT05169996|OTHER|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
214259387|NCT05169996|OTHER|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
214259388|NCT05169996|OTHER|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
214259389|NCT05405933|DIAGNOSTIC_TEST|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
214259390|NCT05405933|DIAGNOSTIC_TEST|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
214259391|NCT04242550|BEHAVIORAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
214259392|NCT04242550|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
214259393|NCT04673968|OTHER|prehabilitation|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
214259394|NCT02219438|DRUG|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
214259395|NCT02219438|DRUG|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
214259396|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
214259397|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
214259398|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
214259399|NCT00809848|DRUG|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
214259400|NCT00809848|DRUG|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
214259401|NCT03378661|DRUG|Benznidazole|Benznidazole tablet
214259402|NCT03378661|DRUG|E1224|E1224 capsules
214259403|NCT03378661|DRUG|E1224 Placebo|E1224 matched placebo capsules
214259404|NCT03378661|DRUG|Benznidazole Placebo|Benznidazole matched placebo tablets
214259405|NCT03039452|BEHAVIORAL|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
214259406|NCT03633136|BEHAVIORAL|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
214653596|NCT04095455|DRUG|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
214259407|NCT05314738|COMBINATION_PRODUCT|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
214259408|NCT05314738|COMBINATION_PRODUCT|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
214259409|NCT05314738|COMBINATION_PRODUCT|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
214259410|NCT05314738|COMBINATION_PRODUCT|Sham Treatment|Sham Drops and No exposure to NXL system
214653597|NCT04095455|DRUG|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
214259411|NCT01664065|DRUG|200 mg Ceftaroline fosamil|1 h infusion
214259412|NCT01664065|DRUG|600 mg Ceftaroline fosamil|1 h infusion
214259413|NCT02160990|DRUG|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
214259414|NCT02160990|DRUG|Placebo|placebo subcutaneously twice daily for 30 days
214259415|NCT01914731|DRUG|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
214259416|NCT02938039|DEVICE|Ambu LMA|Ambu Laryngeal Mask Airways
214259417|NCT02938039|DEVICE|I-Gel LMA|I-Gel Laryngeal Mask Airways
214259418|NCT00807131|BEHAVIORAL|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
214653598|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
214259419|NCT00807131|BEHAVIORAL|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
214259420|NCT00807131|BEHAVIORAL|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
214259421|NCT00807131|BEHAVIORAL|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
214259422|NCT02402101|DEVICE|Procedure: active tDCS|Intensity 2 mA during 20 minutes
214259423|NCT02402101|DEVICE|Procedure: sham tDCS|sham condition as delivered by the stimulator
214259424|NCT05804097|DRUG|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
214259425|NCT01649050|DRUG|BGG492|
214259426|NCT01649050|DRUG|Placebo|
214259427|NCT00320931|DEVICE|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
214259428|NCT05441761|DRUG|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
214259429|NCT01252381|OTHER|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
214259430|NCT04872153|BEHAVIORAL|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
214259431|NCT03378765|BEHAVIORAL|Diet and physical activity monitoring|Lifestyle monitoring
214259432|NCT04137432|DRUG|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
214259433|NCT04137432|DRUG|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
214259434|NCT00369122|BIOLOGICAL|Bevacizumab|Given IV
214259435|NCT00369122|DRUG|Cisplatin|Given IV
214259436|NCT00369122|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214259437|NCT00369122|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
214653599|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
214653600|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
214259438|NCT00176787|DRUG|Capecitabine|
214259439|NCT00176787|PROCEDURE|Radiation|
214259440|NCT00176787|PROCEDURE|Surgery|
214259441|NCT00004635|DRUG|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
214259442|NCT00004635|DRUG|leuprolide acetate|Injections of leuprolide once a month for six months.
214259443|NCT00004635|DRUG|goserelin|Injections of Goserelin once a month for six months.
214259444|NCT00004635|OTHER|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
214259445|NCT01999153|DRUG|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
214259446|NCT01999153|DRUG|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
214259447|NCT05514418|PROCEDURE|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
214259448|NCT04464057|DIETARY_SUPPLEMENT|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
214259449|NCT00235469|DRUG|SPM 927|
214259450|NCT00408629|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
214259451|NCT00408629|BIOLOGICAL|placebo|Matching Placebo for prefilled syringe, 40 mg,
214259452|NCT03349931|DIAGNOSTIC_TEST|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
214259453|NCT01660204|OTHER|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
214653601|NCT00799526|PROCEDURE|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
214653602|NCT00799526|PROCEDURE|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
214653603|NCT01968941|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
214653604|NCT01968941|RADIATION|Conventional Radiotherapy (CRT)|
214653605|NCT03254056|PROCEDURE|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
214259454|NCT06169293|BEHAVIORAL|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
214259455|NCT01800396|DIETARY_SUPPLEMENT|Milk protein|
214259456|NCT01800396|DIETARY_SUPPLEMENT|Milk protein rich in phospholipids|
214259457|NCT00191906|DRUG|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
214259458|NCT00191906|DRUG|placebo|Placebo, every day (QD), by mouth (PO)
214259459|NCT06533917|DEVICE|Main Group|Thoracolumbar spine AP, Thoracolumbar spine LAT
214259460|NCT05247593|DRUG|Dayingpian|The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
214259461|NCT05247593|DRUG|conventional mood stabilizers|Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
214259462|NCT02301130|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
214259463|NCT02301130|BIOLOGICAL|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
214259464|NCT02301130|BIOLOGICAL|tremelimumab|Tremelimumab will be administered intravenously (IV).
214259465|NCT05938530|DEVICE|Sirolimus drug-coated balloon|The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.
214259466|NCT05938530|DEVICE|Stent graft|Stent graft has been shown to be superior than plain balloon angioplasty in the treatment of AVG dysfunction.
214259467|NCT04948515|DIAGNOSTIC_TEST|laboratory test|genotyping of IL 17 and IL23
214259468|NCT04948515|DIAGNOSTIC_TEST|laboratory test|estimation of serum level of IL 17
214259469|NCT02112344|RADIATION|IMRT|
214259470|NCT00333801|BEHAVIORAL|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
214259471|NCT00333801|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
214259472|NCT06333301|OTHER|Surveys|Group will complete several surveys
214259473|NCT04051281|BEHAVIORAL|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
214259474|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
214653606|NCT03254056|PROCEDURE|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
214653607|NCT01231412|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
214653608|NCT01231412|DRUG|Cyclosporine|Given PO or IV
214653609|NCT01231412|DRUG|Fludarabine Phosphate|Given IV
214653610|NCT01231412|DRUG|Mycophenolate Mofetil|Given PO
214653611|NCT01231412|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214653612|NCT01231412|DRUG|Sirolimus|Given PO
214259475|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
214259476|NCT05642078|BIOLOGICAL|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
214259477|NCT03683160|OTHER|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
214653613|NCT01231412|RADIATION|Total-Body Irradiation|Undergo TBI
214653614|NCT04416802|COMBINATION_PRODUCT|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
214653615|NCT04680117|OTHER|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
214653616|NCT04680117|OTHER|Saliva sample|Saliva sample by subject at J0
214259478|NCT03761693|OTHER|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast."
214259479|NCT02387138|DRUG|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
214259480|NCT02387138|DRUG|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
214259481|NCT02387138|DRUG|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
214259482|NCT02387138|OTHER|G-csf|G-csf : d8 to d13 systematically
214259483|NCT03633617|DRUG|Dupilumab|Solution for injection administered subcutaneously
214259484|NCT03633617|DRUG|Placebo|Matching placebo
214259485|NCT01890746|DRUG|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
214259486|NCT01890746|DRUG|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
214259487|NCT01890746|DRUG|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
214259488|NCT01890746|DRUG|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
214259489|NCT06556550|RADIATION|stereotactic ablative radiation therapy|stereotactic ablative radiation therapy in effective doses to each metastatic site
214259490|NCT06556550|RADIATION|palliative radiation therapy|palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
214259491|NCT06556550|DRUG|Chemotherapy|prescribed drug line
214259492|NCT02642029|DEVICE|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
214259493|NCT02642029|DEVICE|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
214259494|NCT02642029|DEVICE|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
214259495|NCT05493332|PROCEDURE|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
214259496|NCT05493332|DRUG|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
214259497|NCT05493332|DRUG|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
214259498|NCT05493332|DRUG|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
214259499|NCT05493332|DRUG|Toripalimab|240mg IVdrip，D3, Q3W
214259500|NCT05493332|DRUG|Donafenib|0.1g. P.O, BID, continuously
214259501|NCT03676998|DEVICE|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
214259502|NCT02059902|DRUG|Lidocaine|Lidocaine infusion runs for a total of 24 hours
214259503|NCT02059902|OTHER|Placebo|Normal saline runs for a total of 24 hours
214259504|NCT03028103|DRUG|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
214259505|NCT03028103|DRUG|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
214259506|NCT03028103|DRUG|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
214259507|NCT03028103|DRUG|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
214259508|NCT04537039|DIAGNOSTIC_TEST|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
214653617|NCT04680117|OTHER|Nasal|Nasal brushing by subject at J0
214259509|NCT01701921|DRUG|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
214259510|NCT01701921|DRUG|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
214259511|NCT01701921|DRUG|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
214259512|NCT04612582|DRUG|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
214259513|NCT04612582|DRUG|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
214259514|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
214259515|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
214259516|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
214259517|NCT01385761|DEVICE|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
214259518|NCT01385761|DEVICE|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
214259519|NCT00436241|DRUG|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
214259520|NCT00436241|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
214259521|NCT05543889|OTHER|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
214259522|NCT00951548|DIETARY_SUPPLEMENT|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
214259523|NCT00951548|DIETARY_SUPPLEMENT|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
214259524|NCT04894695|DIAGNOSTIC_TEST|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
214259525|NCT02787382|DEVICE|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
214259526|NCT03434574|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
214259527|NCT03434574|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
214259528|NCT05801133|DRUG|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
214259529|NCT05273333|DEVICE|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
214259530|NCT06343233|OTHER|usual care|The aim is to set up a collection of clinical and instrumental data of usual care from patients hospitalized for acute heart failure aged ≥ 65; at the time of admission and after 6-12 and 18 months from the event (admission).
214818180|NCT04756245|BEHAVIORAL|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
214259531|NCT01971242|DRUG|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
214259532|NCT01971242|OTHER|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
214259533|NCT01622803|PROCEDURE|parallel stent|bilateral parallel stent insertion (right and left side)
214259534|NCT01622803|DEVICE|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
214259535|NCT05761041|DRUG|Sodium Fluoride Varnish (5%)|Applied at baseline
214818181|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
214259536|NCT05761041|BEHAVIORAL|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
214259537|NCT05761041|DRUG|SDF|Applied bianually
214259538|NCT03200184|DRUG|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
214259539|NCT06114160|OTHER|Data collection|Data collection
214259540|NCT04091009|DRUG|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
214259541|NCT04091009|DRUG|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
214259542|NCT01050543|DRUG|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
214259543|NCT01050543|DRUG|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
214259544|NCT05432375|DRUG|Tinostamustine|infusion given over 60 minutes
214259545|NCT03710005|PROCEDURE|Ascent|Dehydrated Cell and Protein Concentrate injection
214259546|NCT03710005|PROCEDURE|Standard|Standard corticosteroid injection
214259547|NCT04521816|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
214259548|NCT00469378|DRUG|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
214259549|NCT05773443|DEVICE|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
214259550|NCT04076878|DEVICE|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
214259551|NCT05975879|DIETARY_SUPPLEMENT|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
214259552|NCT05975879|DIETARY_SUPPLEMENT|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
214259553|NCT00165659|DRUG|DONEPEZIL HYDROCHLORIDE|
214259554|NCT03985111|DEVICE|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
214259555|NCT03810339|DRUG|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
214259556|NCT00676338|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
214259557|NCT00676338|DRUG|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
214259558|NCT00676338|DRUG|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
214259559|NCT00676338|DRUG|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
214259560|NCT00149734|DRUG|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
214259561|NCT00149734|DRUG|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
214259562|NCT01100346|DRUG|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
214259563|NCT02703233|DRUG|Nitrous Oxide|
214259564|NCT02703233|OTHER|Oxygen|
214259565|NCT00017199|DRUG|bortezomib|
214259566|NCT01278836|PROCEDURE|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
214259567|NCT01497717|DRUG|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
214259568|NCT02411760|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
214259569|NCT00154622|BEHAVIORAL|work hardening program|
214259570|NCT00412542|DRUG|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
214259571|NCT00412542|DRUG|CPT-11|125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
214259572|NCT00412542|PROCEDURE|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
214259573|NCT00412542|PROCEDURE|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
214259574|NCT04055961|DEVICE|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
214259575|NCT02670720|DRUG|avoralstat|
214259576|NCT02654314|DRUG|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
214259577|NCT02654314|OTHER|Placebo|Blue capsule matching the melatonin arm
214259578|NCT04532502|DRUG|Anesthetics, Inhalation|Work environmental exposure
214259579|NCT03565978|DEVICE|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
214259580|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
214259581|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
214259582|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
214259583|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
214259584|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
214259585|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
214259586|NCT05499715|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
214259587|NCT03949530|DRUG|IDL-2965 Oral Capsule|Investigational drug
214259588|NCT03949530|DRUG|Placebos|Placebo
214259589|NCT04014946|DEVICE|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
214259590|NCT06534684|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
214259591|NCT03173027|DRUG|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
214259592|NCT04226560|DEVICE|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
214653618|NCT02149225|DRUG|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
214653619|NCT02149225|DRUG|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
214653620|NCT02086019|DRUG|Conservative Arm|crossover to angiogram only if predefined criteria met
214653621|NCT02086019|PROCEDURE|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
214653622|NCT03377634|BEHAVIORAL|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
214818182|NCT05911165|OTHER|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
214818183|NCT05911165|OTHER|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
214259593|NCT04226560|DEVICE|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
214259594|NCT04226560|OTHER|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
214259595|NCT04226560|OTHER|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
214259596|NCT02517866|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
214259597|NCT04477889|OTHER|Treatment for COVID-19|Patients treated for COVID-19
214259598|NCT02986971|DEVICE|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
214259599|NCT00778544|DRUG|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
214259600|NCT02322346|OTHER|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
214259601|NCT02322346|DRUG|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
214259602|NCT02322346|DRUG|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
214259603|NCT01690637|DRUG|Oseltamivir phosphate suspension|
214259604|NCT01690637|DRUG|Placebo|
214259605|NCT01147640|DRUG|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
214259606|NCT01147640|DRUG|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
214259607|NCT01957774|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
214259608|NCT01957774|DRUG|Placebo|
214259609|NCT01364077|DRUG|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
214259610|NCT01364077|DRUG|Placebo|Matched placebo
214259611|NCT02650635|DRUG|Cyclophosphamide|Given IV
214259612|NCT02650635|OTHER|Laboratory Biomarker Analysis|Correlative studies
214259613|NCT02650635|BIOLOGICAL|Pegfilgrastim|Given SC
214259614|NCT02650635|OTHER|Pharmacological Study|Correlative studies
214259615|NCT02650635|DRUG|TLR8 Agonist VTX-2337|Given SC
214259616|NCT01797731|DEVICE|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
214259617|NCT01797731|DEVICE|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
214259618|NCT05993819|OTHER|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
214259619|NCT05993819|OTHER|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
214259620|NCT01199328|DRUG|Aspirin|81mg Tablet oral, once daily
214259621|NCT01199328|DRUG|Esomeprazole|20 mg Tablet oral, once daily
214259622|NCT02163980|DRUG|Caudal ropivacaine + normal saline|
214259623|NCT02163980|DRUG|Caudal ropivacaine + dexmedetomidine|
214259624|NCT06643026|OTHER|Food preference|Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
214259625|NCT05735353|BEHAVIORAL|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
214259626|NCT05735353|BEHAVIORAL|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
214259627|NCT06556290|OTHER|Gluten free and casein free diet|Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
214259628|NCT00690222|PROCEDURE|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
214259629|NCT05034718|OTHER|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
214259630|NCT05034718|OTHER|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
214259631|NCT04547790|DIETARY_SUPPLEMENT|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
214259632|NCT04547790|DIETARY_SUPPLEMENT|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
214259633|NCT01631110|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
214259634|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
214259635|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
214818184|NCT05574777|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
214259636|NCT02175628|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
214259637|NCT04840069|DRUG|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV\_5400. The GTV\_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV\_5400 will include the GTV\_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV\_5400 must also include the entirety of the GTV\_6000. There is no CTV\_6000. PTV\_5400 is the CTV\_5400 plus a geometric 3 mm expansion in all dimensions; PTV\_6000 is GTV\_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV\_5400 must contain the PTV\_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV\_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV\_6000. PTV\_6000 will be defined as GTV\_6000 plus a geometric 3 mm expansion in all dimensions.
214259638|NCT03263585|DEVICE|Spinal orthosis Spinomed|
214259639|NCT03263585|OTHER|Equipment training|
214259640|NCT05111704|OTHER|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
214259641|NCT05191654|DIAGNOSTIC_TEST|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
214259642|NCT03634644|DRUG|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
214259643|NCT03634644|DRUG|Placebo oral capsule|mainly composed of corn oil
214259644|NCT05406141|DIETARY_SUPPLEMENT|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
214259645|NCT00629772|DRUG|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
214259646|NCT00629772|DRUG|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
214259647|NCT02215031|DRUG|BI 44370|
214259648|NCT02215031|DRUG|Placebo|
214259649|NCT03207204|PROCEDURE|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
214259650|NCT03207204|PROCEDURE|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
214259651|NCT03207204|PROCEDURE|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
214259652|NCT03207204|PROCEDURE|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
214259653|NCT03207204|PROCEDURE|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
214259654|NCT03207204|PROCEDURE|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
214259655|NCT03207204|PROCEDURE|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
214259656|NCT03207204|PROCEDURE|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
214259657|NCT05052658|PROCEDURE|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
214259658|NCT05782712|BIOLOGICAL|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
214259659|NCT04108702|DEVICE|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
214259660|NCT04108702|DEVICE|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
214259661|NCT04108702|OTHER|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
214259662|NCT01804023|OTHER|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
214259663|NCT03135626|DRUG|Biodentine|
214259664|NCT03135626|DRUG|ProRoot (Aggregate)|
214259665|NCT03135626|DRUG|MTA Plus|
214259666|NCT03135626|DRUG|Ferric Sulfate 20 % Dental Gel|
214259667|NCT06378580|DRUG|Surufatinib combine immune checkpoint inhibitor|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"
214259668|NCT06378580|DRUG|AG/FOLFIRINOX|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."
214259669|NCT04558944|DEVICE|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
214259670|NCT01497275|DRUG|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
214259671|NCT06426719|PROCEDURE|Alveolar ridge wideninig via applying osseodensification protocol using densah burs|alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion
214259672|NCT06426719|PROCEDURE|Alveolar ridge widening via hand osteotomes|Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
214259673|NCT01108120|DRUG|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
214259674|NCT01108120|DRUG|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
214259675|NCT04400942|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
214259676|NCT04400942|BEHAVIORAL|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
214259677|NCT04400942|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
214259678|NCT01950169|DRUG|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
214653623|NCT04028037|PROCEDURE|FTPGT treated patients|"The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
214653624|NCT04028037|PROCEDURE|CAF+SCTG treated patients|According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
214259679|NCT01950169|OTHER|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
214259680|NCT01950169|DIETARY_SUPPLEMENT|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
214259681|NCT00503529|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
214259682|NCT03948607|OTHER|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
214259683|NCT03292575|DRUG|Anticoagulants|
214259684|NCT04531839|BEHAVIORAL|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
214259685|NCT02899845|OTHER|postural task|
214259686|NCT02899845|OTHER|walk task|
214259687|NCT06206642|DIAGNOSTIC_TEST|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
214259688|NCT03420625|DEVICE|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
214259689|NCT03420625|DEVICE|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
214259690|NCT03420625|DEVICE|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
214259691|NCT03420625|DEVICE|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
214259692|NCT01424709|DRUG|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
214259693|NCT01424709|DRUG|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
214259694|NCT03671980|OTHER|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
214259695|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
214259696|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
214259697|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
214259698|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
214259699|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
214259700|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
214259701|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
214259702|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
214259703|NCT04962048|DEVICE|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
214259704|NCT04962048|OTHER|Control - no intervention|The other leg serves as non-treated control
214259705|NCT01724879|DRUG|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
214259706|NCT02103712|OTHER|Qualitative|
214653625|NCT00764725|DRUG|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
214653626|NCT00764725|BIOLOGICAL|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
214259707|NCT01680887|DRUG|Varenicline|
214259708|NCT01680887|DRUG|Placebo|
214259709|NCT03326739|PROCEDURE|Arterial Line Placement|arterial line placement
214259710|NCT03949842|DRUG|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
214259711|NCT03949842|DRUG|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
214653627|NCT01957956|OTHER|Laboratory Biomarker Analysis|Correlative studies
214653628|NCT01957956|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
214653629|NCT01957956|DRUG|Temozolomide|Given PO
214653630|NCT01961427|DIETARY_SUPPLEMENT|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
214653631|NCT01961427|DIETARY_SUPPLEMENT|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
214259712|NCT01747226|OTHER|Fluoride rinse|rinse with 15 ml for 1 minute
214259713|NCT01747226|OTHER|Halita|rinsing with 15 ml for 1 minute
214259714|NCT01747226|OTHER|Meridol Halitosis|rinsing with 15 ml for 1 minute
214259715|NCT01747226|OTHER|Water|rinsing with 15ml for 1 minute
214259716|NCT03617510|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
214259717|NCT03617510|DRUG|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
214259718|NCT00702104|OTHER|survey administration|
214259719|NCT05189080|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
214259720|NCT05189080|OTHER|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
214259721|NCT05189080|OTHER|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
214259722|NCT03673579|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
214259723|NCT03064230|OTHER|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
214259724|NCT03106350|OTHER|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
214259725|NCT04470271|OTHER|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
214259726|NCT02055417|BEHAVIORAL|Personal Approaches to Treatment Choices for HIV|
214259727|NCT02055417|BEHAVIORAL|Stress Reduction Skills Program|
214259728|NCT01606644|PROCEDURE|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
214259729|NCT01770496|BEHAVIORAL|Childhood vaccination reminder / recall notification|
214259730|NCT04525352|BIOLOGICAL|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
214259731|NCT05191342|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
214259732|NCT06144892|DEVICE|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
214259733|NCT01955564|DRUG|NW-3509a|single dose
214259734|NCT06254378|PROCEDURE|Sinus lifting with allograft|Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
214259735|NCT06254378|OTHER|Sinus lifting without graft|Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
214259736|NCT03378375|OTHER|nutritional assessement|
214259737|NCT00619138|BEHAVIORAL|individual cognitive-behavioural therapy|1 session per week for 12 weeks
214259738|NCT00619138|BEHAVIORAL|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
214259739|NCT03275792|DRUG|D5-0.9%NS|Admission for intravascular volume expansion
214259740|NCT03275792|DRUG|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
214259741|NCT02943031|OTHER|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
214259742|NCT00900107|PROCEDURE|Exercise|
214259743|NCT06334458|DIAGNOSTIC_TEST|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
214259744|NCT00285818|DRUG|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
214259745|NCT00285818|DRUG|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
214259746|NCT02344862|DRUG|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
214259747|NCT02344862|DRUG|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
214259748|NCT02344862|DRUG|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
214259749|NCT02344862|DRUG|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
214259750|NCT03868761|BEHAVIORAL|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
214259751|NCT00061347|PROCEDURE|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
214259752|NCT04374071|DRUG|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
214259753|NCT01986946|OTHER|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
214259754|NCT01986946|DRUG|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
214259755|NCT01232595|DRUG|LFF571|
214259756|NCT01232595|DRUG|Vancomycin (POC)|
214259757|NCT02263131|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
214259758|NCT02263131|BIOLOGICAL|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
214259759|NCT03843827|DEVICE|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
214259760|NCT03843827|DEVICE|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
214259761|NCT01230710|DRUG|Erlotinib|Erlotinib was supplied as tablets.
214259762|NCT00750386|DRUG|Paclitaxel|175 mg/m2, I.V, every 2 weeks
214259763|NCT00750386|DRUG|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
214259764|NCT02209831|DEVICE|BIBR 796 BS|single dose
214259765|NCT02209831|DRUG|Pantoprazole|5 days
214259766|NCT01066403|DRUG|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
214259767|NCT03775031|DEVICE|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
214259768|NCT05140850|BIOLOGICAL|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
214259769|NCT00496223|DRUG|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
214259770|NCT00496223|DRUG|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
214259771|NCT05005078|DRUG|WST-057|WST-057 topical solution
214259772|NCT05005078|DRUG|Placebo|WST-057 Matching placebo
214259773|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
214259774|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
214259775|NCT01225627|OTHER|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
214259776|NCT01225627|OTHER|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
214259777|NCT05440188|DIAGNOSTIC_TEST|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
214259778|NCT06215612|OTHER|Blood draw, MRI|Blood draw, MRI
214259779|NCT04996641|PROCEDURE|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
214259780|NCT04485910|OTHER|Single step media|Usage of single step media in embryo culture
214259781|NCT04485910|OTHER|Sequential media|Usage of sequential media in embryo culture
214259782|NCT01237964|DRUG|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
214259783|NCT05394350|DRUG|MK-1088|Oral Tablet
214259784|NCT05394350|BIOLOGICAL|Pembrolizumab|IV Infusion
214259785|NCT01336569|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
214259786|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
214259787|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
214259788|NCT03530800|DRUG|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
214259789|NCT03530800|DRUG|Placebo|Placebo for 10 weeks
214259790|NCT02963935|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
214259791|NCT02963935|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
214259792|NCT02963935|BEHAVIORAL|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
214259793|NCT02993718|DRUG|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
214259794|NCT02993718|DRUG|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
214259795|NCT03929627|OTHER|Cortisol awakening response|Cortisol awakening response
214259796|NCT02192073|PROCEDURE|Suprapectoral Biceps tenodesis|
214259797|NCT02192073|PROCEDURE|Subpectoral biceps tenodesis|
214259798|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
214259799|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
214259800|NCT01924624|DRUG|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
214259801|NCT05661214|OTHER|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
214259802|NCT02273531|DRUG|Asasantin ER, new formulation|
214259803|NCT02273531|DRUG|Asasantin ER, present commercial formulation|
214259804|NCT00464269|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
214259805|NCT00464269|DRUG|Brivaracetam 2.5 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
214259806|NCT00464269|DRUG|Brivaracetam 10 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
214259807|NCT00464269|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
214259808|NCT05806723|DRUG|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
214259809|NCT02337738|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
214259810|NCT02337738|DRUG|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
214259811|NCT02337738|DRUG|Placebo|Placebo Tablets
214259812|NCT04945031|OTHER|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
214259813|NCT05612698|BEHAVIORAL|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
214259814|NCT05612698|BEHAVIORAL|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
214259815|NCT05612698|BEHAVIORAL|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
214259816|NCT00406354|DRUG|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
214259817|NCT00406354|DRUG|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
214259818|NCT00186329|DRUG|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
214259819|NCT01304160|RADIATION|stereotactic body radiotherapy|30Gray in 5 fractions
214259820|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
214259821|NCT05427591|PROCEDURE|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
214259822|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
214259823|NCT05427591|PROCEDURE|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
214259824|NCT03392077|PROCEDURE|Caesarean section|Caesarean section will be done to deliver the baby
214259825|NCT03392077|OTHER|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
214259826|NCT03392077|OTHER|No cervical dilatation|after delivery of the baby cervix will be remain closed
214259827|NCT01517685|DIETARY_SUPPLEMENT|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
214259828|NCT01517685|DIETARY_SUPPLEMENT|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
214259829|NCT00747461|DEVICE|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
214259830|NCT04870281|DEVICE|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
214259831|NCT01212107|DRUG|FGF Receptor|LY2874455 administered orally.
214259832|NCT01212107|DRUG|Phosphate Binders|
214259833|NCT00973271|DRUG|290 mg DCCR|290 mg diazoxide choline
214259834|NCT00973271|DRUG|435 mg DCCR|435 mg diazoxide choline
214259835|NCT00973271|DRUG|135 mg fenofibric acid|135 mg fenofibric acid
214259836|NCT00973271|DRUG|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
214259837|NCT00973271|DRUG|atorvastatin|20 mg atorvastatin
214259838|NCT00753428|OTHER|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
214259839|NCT04968795|OTHER|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
214259840|NCT03276988|DRUG|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
214259841|NCT03276988|DRUG|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
214259842|NCT00546650|DRUG|Sumatriptan succinate|NP101 iontophoretic transdermal system
214259843|NCT00546650|DRUG|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
214259844|NCT04181320|DEVICE|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
214259845|NCT02413177|BEHAVIORAL|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
214259846|NCT02413177|BEHAVIORAL|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
214259847|NCT05956873|DEVICE|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
214259848|NCT02427828|DEVICE|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
214259849|NCT00810381|DRUG|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
214259850|NCT00810381|DRUG|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
214259851|NCT00810381|DRUG|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
214259852|NCT00810381|DRUG|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
214259853|NCT01565642|BEHAVIORAL|Goals of care decision support|Decision aid and care plan meeting
214259854|NCT02608203|DRUG|[68Ga]-DOTANOC PET/CT|
214259855|NCT03784417|DEVICE|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
214259856|NCT00619593|OTHER|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"* Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication"
214259857|NCT00619593|OTHER|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
214259858|NCT01604187|DRUG|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
214259859|NCT01604187|DRUG|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
214259860|NCT03885440|OTHER|Age|Age\<40 years old is chosen as the cutoff value.
214259861|NCT03885440|OTHER|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
214259862|NCT05910814|BEHAVIORAL|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
214259863|NCT05910814|BEHAVIORAL|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
214259864|NCT05910814|BEHAVIORAL|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
214259865|NCT05910814|BEHAVIORAL|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
214259866|NCT05910814|BEHAVIORAL|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
214259867|NCT05910814|BEHAVIORAL|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
214259868|NCT02281565|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
214259869|NCT01033461|DIETARY_SUPPLEMENT|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
214259870|NCT01033461|DIETARY_SUPPLEMENT|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
214259871|NCT01033461|OTHER|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
214259872|NCT00237887|DRUG|adalimumab|
214259873|NCT02482207|DRUG|Rosuvastatin|
214259874|NCT02482207|BEHAVIORAL|Life style modification|
214259875|NCT04834232|DEVICE|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
214259876|NCT04834232|PROCEDURE|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
214259877|NCT04248803|OTHER|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
214259878|NCT02213354|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
214259879|NCT02213354|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
214259880|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
214259881|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
214259882|NCT02952729|DRUG|XMT-1522|one intravenous dose administered in-clinic every 21 days
214259883|NCT03577288|BEHAVIORAL|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
214259884|NCT03577288|BEHAVIORAL|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
214259885|NCT03577288|BEHAVIORAL|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
214653632|NCT01306760|DRUG|Ketamine|Ketamine used as the anaesthetic during ECT.
214653633|NCT01306760|DRUG|Propofol|The standard anaesthetic used for ECT.
214653634|NCT02284165|OTHER|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
214653635|NCT00620061|DRUG|Lubiprostone 24|24 mcg capsules for oral administration
214653636|NCT00944827|DIETARY_SUPPLEMENT|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
214259886|NCT03577288|BEHAVIORAL|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
214259887|NCT00561769|DRUG|Norditropin pen|12 IU per day
214259888|NCT01498978|BIOLOGICAL|ipilimumab|Given IV
214259889|NCT01498978|OTHER|laboratory biomarker analysis|Correlative studies
214259890|NCT05002283|OTHER|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
214259891|NCT01716390|DIETARY_SUPPLEMENT|Drink that contains plant stanols|
214259892|NCT01716390|DIETARY_SUPPLEMENT|Placebo drink|
214259893|NCT05361421|DRUG|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
214259894|NCT05361421|DRUG|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
214259895|NCT04834674|COMBINATION_PRODUCT|DEB-TACE combined with apatinib and PD-1 antibody|combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
214259896|NCT03230253|BEHAVIORAL|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
214259897|NCT03230253|BEHAVIORAL|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
214259898|NCT03230253|BEHAVIORAL|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
214259899|NCT05912660|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
214259900|NCT01165580|DRUG|valganciclovir [Valcyte]|oral dose, Days 1 and 2
214259901|NCT00961649|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
214259902|NCT00961649|DRUG|Brinzolamide ophthalmic suspension, 1%|
214259903|NCT00961649|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
214259904|NCT00961649|OTHER|Vehicle|Inactive ingredients used as placebo
214259905|NCT06558175|RADIATION|stereotactic body radiation therapy (SBRT)|Patients will be assigned to treatment doses using the TITE-CRM model.
214259906|NCT02711345|DRUG|LTT462|ERK Inhibitor
214259907|NCT01315184|BEHAVIORAL|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
214259908|NCT02297048|DIETARY_SUPPLEMENT|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
214259909|NCT04143087|DRUG|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
214259910|NCT04043728|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
214259911|NCT05923528|DEVICE|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
214259912|NCT05923528|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
214259913|NCT05923528|DEVICE|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
214259914|NCT05923528|DEVICE|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
214259915|NCT05160090|DRUG|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
214259916|NCT01033851|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course
214259917|NCT01033851|BEHAVIORAL|Stress Management Education|8 week course
214259918|NCT00785018|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
214259919|NCT00785018|DRUG|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
214653637|NCT00944827|DIETARY_SUPPLEMENT|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
214653638|NCT05396209|PROCEDURE|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
214818185|NCT05409625|DEVICE|Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)|Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
214259920|NCT01570166|PROCEDURE|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
214259921|NCT01570166|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
214259922|NCT02349542|DRUG|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
214259923|NCT01093638|BIOLOGICAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
214259924|NCT01093638|BIOLOGICAL|Placebo|Oral formulation of placebo fed concomitantly with infant formula
214259925|NCT04197752|OTHER|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
214259926|NCT04979520|DRUG|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
214259927|NCT02402829|PROCEDURE|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
214259928|NCT00800748|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
214259929|NCT00800748|DRUG|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
214259930|NCT00560768|DEVICE|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
214259931|NCT00114387|DRUG|DL-alpha-tocopherol|
214259932|NCT06340516|DIAGNOSTIC_TEST|Plasma NT-proBNP|Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
214259933|NCT00005673|DRUG|Capravirine|
214259934|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
214259935|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
214259936|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
214259937|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
214259938|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
214259939|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
214259940|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
214259941|NCT01303783|DRUG|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
214259942|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
214259943|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
214259944|NCT04080960|BEHAVIORAL|Lifestyle modification education|Lifestyle modification education and goal setting
214259945|NCT04708106|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
214653639|NCT05396209|PROCEDURE|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
214653640|NCT05396209|PROCEDURE|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
214653641|NCT01717534|DIETARY_SUPPLEMENT|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
214259946|NCT04708106|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
214259947|NCT04708106|OTHER|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
214653642|NCT00737529|DRUG|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
214653643|NCT01133964|DIETARY_SUPPLEMENT|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
214653644|NCT01339455|PROCEDURE|AHSCT|"AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF"
214653645|NCT01724892|DRUG|Dexamethasone|
214653646|NCT01724892|DRUG|Loteprednol etabonate|
214653647|NCT00783627|PROCEDURE|Angiography|Angiography done at the J1 visit
214259948|NCT01502007|OTHER|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
214259949|NCT01502007|OTHER|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
214259950|NCT04612439|DEVICE|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
214259951|NCT04612439|DEVICE|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
214259952|NCT05933824|DRUG|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
214259953|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
214259954|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
214259955|NCT00302263|DRUG|Metobes-compound|
214259956|NCT04383158|OTHER|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
214259957|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
214259958|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
214259959|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
214259960|NCT03676335|DRUG|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
214259961|NCT03676335|DRUG|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
214259962|NCT03676335|DRUG|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
214259963|NCT00600535|DRUG|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
214259964|NCT00600535|DRUG|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
214259965|NCT00600535|DRUG|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
214259966|NCT00600535|DRUG|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
214259967|NCT00600535|DRUG|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
214259968|NCT00600535|DRUG|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
214653648|NCT00134914|DRUG|Buprenorphine|single doses given by sublingual and parenteral routes
214259969|NCT00600535|DRUG|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
214259970|NCT06556355|OTHER|neoadjuvant chemoradiation and McKeown esophagectomy|"Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen)."
214259971|NCT01617525|OTHER|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
214259972|NCT01163266|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
214259973|NCT01163266|DRUG|Placebo|Vortioxetine placebo-matching capsules
214259974|NCT03521219|DRUG|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
214259975|NCT05024604|DRUG|Progesterone Only Product in Oral Dose Form|mini pills as a contraceptive method
214259976|NCT05024604|OTHER|office hysterscopy|office hysteroscoy
214653649|NCT00572884|OTHER|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
214653650|NCT02910427|OTHER|Regular salt|Participants eat a regular salt diet.
214653651|NCT02910427|OTHER|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
214653652|NCT02910427|OTHER|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
214653653|NCT03757039|DEVICE|Multifocal soft contact lenses|Commercially available contact lenses
214653654|NCT03757039|OTHER|Progressive addition lens spectacles|Per subject's habitual prescription
214653655|NCT02976415|OTHER|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
214259977|NCT02586064|BEHAVIORAL|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
214259978|NCT02586064|BEHAVIORAL|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
214259979|NCT04863235|BEHAVIORAL|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
214259980|NCT04863235|BEHAVIORAL|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
214259981|NCT03686761|PROCEDURE|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
214259982|NCT01046162|DRUG|Alprazolam|Single tablet
214259983|NCT01046162|DRUG|Alprazolam|Single tablet
214259984|NCT02919696|DRUG|Abemaciclib|Administered orally
214259985|NCT06119724|PROCEDURE|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
214259986|NCT06119724|PROCEDURE|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
214259987|NCT03882190|DRUG|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
214259988|NCT01588249|DIETARY_SUPPLEMENT|Pasteurized maple syrup|
214259989|NCT01588249|DIETARY_SUPPLEMENT|Placebo|
214259990|NCT04308304|DRUG|MK-1942|MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
214259991|NCT04308304|DRUG|Donepezil|Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
214653656|NCT03501056|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214653657|NCT03501056|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214653658|NCT00188084|PROCEDURE|DNA Index|
214653659|NCT00188084|PROCEDURE|S-Phase%|
214653660|NCT00188084|PROCEDURE|CD45 expression|
214653661|NCT00188084|PROCEDURE|P16 metabolic way|
214653662|NCT01126346|BEHAVIORAL|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
214653663|NCT01126346|BEHAVIORAL|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
214259992|NCT04308304|DRUG|Placebo|Placebo capsule matched to MK-1942 taken BID by mouth.
214259993|NCT02035501|DRUG|L-Tyrosine|
214259994|NCT02035501|DRUG|Placebo|
214259995|NCT01270061|BEHAVIORAL|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
214259996|NCT01270061|BEHAVIORAL|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
214259997|NCT00945555|DRUG|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
214259998|NCT00662220|DRUG|ribavirin|25-29 mg/kg/day
214259999|NCT00662220|DRUG|ribavirin|12-15 mg/kg/day
214260000|NCT01033188|PROCEDURE|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
214653664|NCT01126346|OTHER|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
214653665|NCT00096161|DRUG|Cyclosporine|Given PO
214653666|NCT00096161|DRUG|Mycophenolate Mofetil|Given PO
214653667|NCT00096161|DRUG|Pentostatin|Given IV
214653668|NCT00096161|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
214653669|NCT03056443|DEVICE|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
214653670|NCT04609748|DRUG|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
214653671|NCT04609748|DRUG|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
214653672|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
214260001|NCT01033188|PROCEDURE|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
214260002|NCT06560619|BEHAVIORAL|MENTOR|Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
214260003|NCT03374631|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
214260004|NCT03374631|DEVICE|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
214260005|NCT00514566|DEVICE|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
214260006|NCT03107663|DRUG|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
214260007|NCT02869997|DEVICE|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
214260008|NCT01902433|PROCEDURE|Astym|
214260009|NCT01527175|OTHER|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
214260010|NCT03980431|DIAGNOSTIC_TEST|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
214260011|NCT03877549|DRUG|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
214260012|NCT04489459|DRUG|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
214260013|NCT04489459|DRUG|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
214260014|NCT04489459|DRUG|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
214260015|NCT02812173|DEVICE|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
214260016|NCT02812173|DEVICE|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
214260017|NCT02812173|DEVICE|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
214260018|NCT01706822|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
214260019|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
214260020|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
214260021|NCT03838146|BEHAVIORAL|Types of Exercise|moderate intensity exercise
214653673|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
214653674|NCT04696497|DIAGNOSTIC_TEST|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment"
214260022|NCT02876094|DRUG|celecoxib|dose-response
214260023|NCT05396807|DEVICE|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
214653675|NCT04696497|DIAGNOSTIC_TEST|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
214260024|NCT03237078|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
214260025|NCT05660681|DRUG|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
214260026|NCT05660681|DRUG|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
214260027|NCT04128774|DRUG|Dexamethasone|The case group receives dexamethasone based on the clinical indication.
214260028|NCT02815410|DRUG|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
214260029|NCT04502979|BEHAVIORAL|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
214260030|NCT03049527|BEHAVIORAL|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
214260031|NCT04794088|DRUG|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
214260032|NCT04794088|DRUG|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
214260033|NCT03158987|OTHER|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
214260034|NCT02856698|DRUG|Midazolam|Dose use according to the product technical sheet
214260035|NCT02856698|DRUG|Morphine|Dose use according to the product technical sheet
214260036|NCT00002078|DRUG|Interferon alfa-n3|
214260037|NCT02422173|DEVICE|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
214260038|NCT02422173|DEVICE|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
214260039|NCT02422173|DEVICE|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
214260040|NCT02422173|DEVICE|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
214260041|NCT01658852|DRUG|metronidazole|
214260042|NCT01658852|DRUG|Placebo|
214260043|NCT06309186|OTHER|Evaluation of midwifes' burnout|Burnout evaluated by questionnaires
214260044|NCT04864418|DRUG|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
214260045|NCT00775073|DRUG|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
214260046|NCT04736342|OTHER|PALI questionaire|Survey comprised of a series of multiple choice questions
214260047|NCT02216760|DEVICE|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
214260048|NCT02216760|DEVICE|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
214260049|NCT01398553|DEVICE|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
214260050|NCT01398553|OTHER|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
214260051|NCT02681601|DIETARY_SUPPLEMENT|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
214260052|NCT02681601|OTHER|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
214260053|NCT02681601|DIETARY_SUPPLEMENT|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
214260054|NCT00772304|DRUG|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
214260055|NCT01628172|DEVICE|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
214260056|NCT04110587|BIOLOGICAL|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
214653676|NCT04696497|DIAGNOSTIC_TEST|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
214260057|NCT04110587|PROCEDURE|Temporomandibular Joint Arthroscopy|Lysis and Lavage
214260058|NCT04110587|DRUG|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
214260059|NCT04110587|DRUG|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
214260060|NCT04110587|DRUG|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
214260061|NCT04110587|DRUG|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
214260062|NCT04110587|OTHER|Exercise program|Home exercise program
214260063|NCT04112459|OTHER|prolonged mechanical ventilation|No intervention will be applied in this study
214260064|NCT01522508|PROCEDURE|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
214260065|NCT00305214|PROCEDURE|T Wave Alternans Test|
214260066|NCT01892865|OTHER|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
214260067|NCT01892865|OTHER|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
214260068|NCT04967378|BEHAVIORAL|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
214260069|NCT05345873|BIOLOGICAL|SCTV01E|one dose of SCTV01E on D0, intramuscular
214260070|NCT05345873|BIOLOGICAL|mRNA-1273|one dose of mRNA-1273 on D0, intramuscular
214260071|NCT05212519|OTHER||For observational research
214260072|NCT03645564|OTHER|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
214260073|NCT01823978|BIOLOGICAL|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
214260074|NCT06966583|DIETARY_SUPPLEMENT|NAD supplement|NAD supplement NMN：NMN12000 GeneHarbor
214260075|NCT06966583|RADIATION|Radiotherapy|Low Dose Radiotherapy or Stereotactic Ablative Radiotherapy or Conventional Radiotherapy
214260076|NCT06966583|DRUG|Immunotherapy|PD-1 inhibitor
214260077|NCT05951257|BEHAVIORAL|Personalized multimodal intervention involving hypnosis and/or music|"The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself."
214260078|NCT06543043|DRUG|Phenytoin|Administered orally.
214260079|NCT06543043|DRUG|Itraconazole|Administered orally.
214260080|NCT06543043|DRUG|sonrotoclax|Administered orally.
214260081|NCT01558739|DRUG|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
214260082|NCT05201924|BEHAVIORAL|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
214260083|NCT05201924|BEHAVIORAL|Control|a healthy control checklist
214260084|NCT06424834|DRUG|Amlodipine|Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
214260085|NCT06424834|DRUG|Nebivolol|Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
214260086|NCT06424834|DRUG|Placebo|Placebo taken once orally daily.
214260087|NCT05652283|DRUG|Pamiparib|Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
214260088|NCT05652283|DRUG|Surufatinib|Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
214260089|NCT05630092|DIAGNOSTIC_TEST|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
214260090|NCT05630092|DIAGNOSTIC_TEST|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
214260091|NCT06087458|BIOLOGICAL|VOY-101|VOY-101
214260092|NCT06101563|PROCEDURE|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
214260093|NCT06101563|PROCEDURE|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
214260094|NCT06648798|DEVICE|Limber Limb|Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
214260095|NCT05473897|DEVICE|Catalyst Cryohelmet|The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
214260096|NCT01397669|PROCEDURE|Colon biopsy, lymph node biopsy, lumbar puncture, Leukapheresis, Brain MRI/MRS/DTI|"Eligible subjects will undergo a flexible sigmoidoscopy/biopsy and Brain MRI/MRS/DTI at Chulalongkorn University Hospital.~Lumbar puncture, lymph node biopsy, and leukapheresis will be done at TRCARC or IHRI."
214260097|NCT03950791|BEHAVIORAL|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
214260098|NCT03950791|BEHAVIORAL|Health Education|Education about improving lifestyle factors to improve participants' overall health.
214260099|NCT06458855|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
214260100|NCT05076565|DEVICE|Airbag Belt Fall Protection System|Both versions of Airbags features different number of IMU sensors. Participant's will be randomly assigned one of the two versions. The algorithms developed in this project will help the researcher to identify the optimal performance (sensitivity and specificity values for detecting falls). Based on this information the research team will be able to choose a version for home/community deployment portion of the study. Based on the performance of the airbags in detecting true positives (falls) and true negatives (non-falls) accurately one of the airbags will be used in community deployment phase of the study.
214260101|NCT03408314|OTHER|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
214260102|NCT03408314|OTHER|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
214260103|NCT04294277|DRUG|Pemigatinib|At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
214260104|NCT02719327|DRUG|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
214260105|NCT02719327|OTHER|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
214260106|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
214260107|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
214260108|NCT06509334|DRUG|Omalizumab|Participants will receive Omalizumab every 4 weeks for 12 weeks
214260109|NCT01645722|PROCEDURE|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
214260110|NCT00586131|DRUG|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
214260111|NCT00586131|DRUG|Sodium citrate/citratic acid|dictated by pH
214260112|NCT03733340|DRUG|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
214653677|NCT05009758|PROCEDURE|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
214653678|NCT05009758|PROCEDURE|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
214653679|NCT05009758|PROCEDURE|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
214260113|NCT04012125|DEVICE|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
214260114|NCT04000230|BEHAVIORAL|TCIT|"TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
214653680|NCT05009758|PROCEDURE|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
214260115|NCT04000230|BEHAVIORAL|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
214260116|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
214260117|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
214260118|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
214260119|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
214260120|NCT01470859|DRUG|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
214260121|NCT01470859|DRUG|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
214260122|NCT05816096|COMBINATION_PRODUCT|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
214260123|NCT05816096|COMBINATION_PRODUCT|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
214260124|NCT01066000|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
214260125|NCT00566111|DRUG|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
214260126|NCT00566111|DRUG|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
214260127|NCT06654791|DRUG|[14C] SIM0270 Oral Preparation|Use according to the prescribed protocol
214260128|NCT05209178|DIAGNOSTIC_TEST|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
214260129|NCT03262402|PROCEDURE|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
214260130|NCT01793831|PROCEDURE|FMT|Standard FMT
214260131|NCT05891561|DRUG|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
214260132|NCT06709768|BEHAVIORAL|Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)|This is a pilot test of the MAPSS-MS intervention in a virtual delivery format.
214260133|NCT06710808|OTHER|Virtual walking and transcranial direct current stimulation|"Participants will receive VW-therapy combined with tDCS. The intervention is adapted from Soler et al. 2010 and consists of 10 sessions over 2 weeks, each session lasting around 20 minutes.~For the virtual walking the participant sits on a modified wheelchair, which is positioned at a distance of two meters from the screen. The setting provides an illusion of a third person perspective and the participant can see himself/herself walk through a forest ambience.~The tDCS session is according the same protocol from Soler et al., 2010. Hereby, the device from Starstim, Neuroelectrics will be used, which is equipped with a neoprene cap containing electrodes. The anodes will be placed over C3 or C4 (EEG 10/20 system) to target the motor cortex (M1) contralateral to the painful side and the cathodes will be placed over the contralateral supraorbital area. Symmetric pain participants receive stimulation on the dominant hemisphere. The tDCS applies a constant current of 2 mA over 20 minutes."
214260134|NCT06709092|DRUG|lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)|For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
214260135|NCT02137421|DIETARY_SUPPLEMENT|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
214260136|NCT06774196|BEHAVIORAL|Behavioral Therapy Group|Includes Cognitive Behavioral Therapy (CBT), relaxation techniques, and biofeedback.
214260137|NCT06774196|PROCEDURE|Standard Care Group|Includes pharmacological treatment (e.g., NSAIDs, muscle relaxants) and physical therapy interventions
214260138|NCT06929442|BEHAVIORAL|Resilience Training (RT)|RT is a 4-week program of weekly 90-minute sessions in which participants are taught the following skills: mindfulness, self-compassion and mentalization.
214260139|NCT06929442|BEHAVIORAL|Life Skills Training (LST)|LST is a 4-week program of weekly 90-minute sessions, in which participants are provided information about helpful life skills, including financial literacy, health, physical and internet safety.
214260140|NCT06908382|DRUG|Iparomlimab and Tuvonralimab Injection|QL1706 (5 mg/kg, q3w) +Paclitaxel for injection (albumin bound) (260mg/m2 D1, q3w)+cisplatin (75mg/m2 D1, q3w)/carboplatin (AUC 5 D1) ， 3 cycles
214260141|NCT05540782|BEHAVIORAL|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
214653681|NCT05009758|PROCEDURE|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
214653682|NCT05009758|PROCEDURE|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
214818186|NCT05409625|DEVICE|Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)|Intraoral camera used for caries detection in the occlusal and proximal surfaces.
214260142|NCT06924073|OTHER|ATP-Youth Enhanced Strategy (ATP-YES)|ATP-YES is a multi-component youth led implementation strategy that incorporates data audits and feedback, cyclical small tests of change and learning collaboratives
214260143|NCT06934629|DEVICE|TECAR therapy|TECAR application will be 20 mins per session (10 mins capacitive and 10 mins resistive) during ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
214260144|NCT06934629|OTHER|therapeutic exercises|the conventional therapy which is ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
214260145|NCT06934967|DRUG|LNP023|Cohort 1-administered orally a dosing scheme of 200 mg twice-daily (two 100 mg capsules). Cohort 2- administered orally a dosing scheme based on weight at the Day 1, Week 12, 26 and 38.
214260146|NCT06934317|DIAGNOSTIC_TEST|measurement of maximum bite force using bite fork|using bite fork the bite force will be recorded for all teeth preoperative and post operative
214260147|NCT06934317|PROCEDURE|conventional root canal treatment|General principles of conventional endodontic treatment will be applied in all cases, such as the administration of an appropriate local anaesthetic and rubber dam isolation. access and cleaning and shaping using rotary files and obturation. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
214260148|NCT06934317|PROCEDURE|pulp revascularization by induced bleeding|Regeneration procedures will be conducted in two appointments, adhering to the 'Clinical Considerations for a Regenerative Procedure' proposed by the American Association of Endodontists (AAE) in 2021. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
214260149|NCT06934317|PROCEDURE|MTA apexification|MTA apical plug will be randomly applied to teeth with open apex
214260150|NCT06934408|DRUG|HRS-5817 Injection|HRS-5817 injection administered subcutaneously (SC).
214260151|NCT06934408|DRUG|HRS-5817 Injection Placebo|HRS-5817 injection placebo administered subcutaneously (SC).
214260152|NCT06934759|OTHER|No Intervention: Observational Cohort|There is no intervention
214260153|NCT06934928|DEVICE|GentleMax Pro (with skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration.~The laser system includes a dynamic cryogen spray cooling device (DCD) for epidermal protection. A spurt of cryogen cools the epidermis just before arrival of the treatment laser pulse."
214260154|NCT06934928|DEVICE|GentleMax Pro (without skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration."
214260155|NCT06933186|BEHAVIORAL|Neuropsychological rehabilitation|Neuropsychological rehabilitation includes an integrated approach, consisting of three components: cognitive training; psychoeducation; and social skills/emotional management training. Cognitive training uses a combination of different tasks (always covering attention, memory and executive functions exercises), with a 30-minute session on the online cognitive training platform and 1 hour of pencil and paper exercises in a group, in a total of 36 sessions . Psychoeducation addresses specific topics related to Alcohol Use Disorder and its cognitive impact. Social skills/emotional management training includes problem-solving exercises, assertiveness training, emotion identification and management, among others. These sessions will be held once a week, for a total of 12 sessions.
214653683|NCT05009758|PROCEDURE|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
214653684|NCT05009758|DIAGNOSTIC_TEST|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
214653685|NCT05009758|OTHER|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
214653686|NCT05009758|DIAGNOSTIC_TEST|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
214653687|NCT05009758|PROCEDURE|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
214260156|NCT06933186|BEHAVIORAL|Weekly therapeutic groups|The control group will attend weekly therapeutic groups, which consist of open groups, aimed to promote abstinence and relapse prevention, supporting the management of difficulties in the person's daily life related to consumption, promoting psychoeducation about the disease and coping strategies to deal with craving
214260157|NCT06933719|OTHER|Study on existing health data|Study on existing health data
214260158|NCT01634009|DIETARY_SUPPLEMENT|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
214260159|NCT04281303|PROCEDURE|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
214260160|NCT04929574|DIAGNOSTIC_TEST|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
214260161|NCT00646919|PROCEDURE|Nose swab|
214260162|NCT00378339|DEVICE|gold berlocks|
214260163|NCT05928260|DEVICE|Medtronic Guardian Connect Sensor 3|This is a real-time CGMS which transmits all the blood glucose readings into the application downloaded in a device continuously and also gives alarms and alerts to the person.
214260164|NCT05928260|DEVICE|Abott Freestyle Libre Sensor|This system is an is-CGMS in which the participant gets his blood glucose only when the device is scanned.
214260165|NCT05928260|OTHER|Self blood Glucose monitoring by a glucometer|In this all patients will check their blood glucose using a needle prick and glucometer at pre-specified intervals.
214260166|NCT00685542|DRUG|diacerein|Diacerein 50mg bid
214260167|NCT00685542|DRUG|placebo|placebo
214260168|NCT06323187|DIAGNOSTIC_TEST|Cervical Sampling|Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
214260169|NCT06250777|DRUG|Trastuzumab deruxtecan|"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~\- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"
214260170|NCT06130527|PROCEDURE|Nicardipine|Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.
214260171|NCT06130527|PROCEDURE|Remifentanil|Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
214260172|NCT03350165|DRUG|K-877|0.2mg tablet
214653688|NCT05009758|PROCEDURE|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
214653689|NCT05009758|PROCEDURE|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
214653690|NCT05095025|DRUG|Bupivacaine Hydrochloride 20ml injectate|Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
214653691|NCT01507376|DRUG|recombinant hCG|recombinant hCG(250 µg Ovitrell)
214653692|NCT01507376|DRUG|recombinant hCG|recombinant hCG(500 µg Ovitrell)
214653693|NCT01507376|DRUG|urinary hCG|10,000 IU urinary hCG
214653694|NCT03502850|DRUG|ASK120067|patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
214653695|NCT01818297|DEVICE|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
214653696|NCT04468217|DIAGNOSTIC_TEST|Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples|Each patient will undergo a sample collection where two nasopharyngeal samples will be obtained, one of them with lysis buffer as the transport medium and the other with the AAA-Safe solution as the transport medium. Oropharyngeal, buccal, nasal, and salivary samples will also be obtained using AAA-Safe as the transport medium
214653697|NCT01798576|DRUG|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
214653698|NCT01798576|DRUG|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
214260173|NCT03350165|DRUG|Placebo|K-877 matching placebo tablet
214260174|NCT00935948|DRUG|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
214260175|NCT00935948|DRUG|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
214260176|NCT04255030|BEHAVIORAL|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
214260177|NCT04255030|BEHAVIORAL|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
214260178|NCT04255030|BEHAVIORAL|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
214260179|NCT03460938|PROCEDURE|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
214260180|NCT05233293|PROCEDURE|Spyglass + RFA|SpyGlass direct Vision guided RFA
214260181|NCT05233293|PROCEDURE|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
214260182|NCT02671409|OTHER|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
214260183|NCT05221307|OTHER|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
214260184|NCT02405754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
214260185|NCT00098098|BIOLOGICAL|rBV A/B|
214260186|NCT03412708|OTHER|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
214260187|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~\- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
214260188|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
214260189|NCT02373722|PROCEDURE|Mohs Surgery|Undergo Mohs surgery
214260190|NCT02373722|OTHER|Internet-Based Intervention|Watch website application based educational video
214653699|NCT04582838|DIAGNOSTIC_TEST|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
214653700|NCT04582838|DIAGNOSTIC_TEST|ECG|ECG signal is used to monitor respiratory rate (RR).
214260191|NCT02373722|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
214260192|NCT02373722|OTHER|Educational Intervention|Watch website application based educational video
214260193|NCT02373722|BEHAVIORAL|Exercise Intervention|Use Fitbit
214260194|NCT02373722|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
214260195|NCT02373722|OTHER|Questionnaire Administration|Ancillary studies
214260196|NCT02373722|OTHER|Survey Administration|Ancillary studies
214260197|NCT02497612|DRUG|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
214260198|NCT02497612|DRUG|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
214260199|NCT02497612|OTHER|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
214260200|NCT04539873|DRUG|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
214260201|NCT04539873|COMBINATION_PRODUCT|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
214260202|NCT00221260|PROCEDURE|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
214260203|NCT00063323|DRUG|Bupropion|
214260204|NCT01455831|DRUG|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
214260205|NCT01455831|DRUG|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
214260206|NCT02817074|BEHAVIORAL|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
214260207|NCT02817074|BEHAVIORAL|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
214260208|NCT05203289|DRUG|BI 695501 - higher concentration|BI 695501 - higher concentration
214260209|NCT05203289|DRUG|BI 695501 - lower concentration|BI 695501 - lower concentration
214818187|NCT05409625|DEVICE|X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)|X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
214260210|NCT06101550|PROCEDURE|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
214260211|NCT06101550|PROCEDURE|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
214260212|NCT06306989|DRUG|Letermovir|Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
214260213|NCT04533633|PROCEDURE|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
214260214|NCT02231697|OTHER|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
214260215|NCT05677022|OTHER|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
214260216|NCT04603612|PROCEDURE|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
214260217|NCT00001438|DRUG|all-trans-retinoic acid with IFN-alpha2a|
214260218|NCT02286583|DEVICE|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
214260219|NCT00093548|BIOLOGICAL|alpha fetoprotein adenoviral vector vaccine|
214260220|NCT00093548|BIOLOGICAL|alpha fetoprotein plasmid DNA vaccine|
214260221|NCT00093548|BIOLOGICAL|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
214260222|NCT00760500|OTHER|Nasopharyngeal Swab|Nasopharyngeal Swab
214260223|NCT04734951|OTHER|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
214260224|NCT04734951|DIETARY_SUPPLEMENT|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
214260225|NCT01781533|PROCEDURE|algorithm|
214260226|NCT03731039|OTHER|Observational study|Pain assessment, Anxiety assessment, Depression assessment
214260227|NCT03502096|BEHAVIORAL|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
214260228|NCT03502096|OTHER|Control|Subjects were not provided a to-go container with the meal
214260229|NCT05731323|DRUG|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
214260230|NCT05731323|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
214818188|NCT05409625|PROCEDURE|Oral cleaning|Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
214818189|NCT03697109|DRUG|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
214818190|NCT03697109|OTHER|Placebo|Placebo matched to study drug
214260231|NCT02167425|OTHER|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
214260232|NCT05828134|OTHER|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
214260233|NCT01669499|DRUG|Dexamethasone acetate|
214260234|NCT01669499|DRUG|Placebo|
214260235|NCT05021081|DEVICE|TRP-200|JJVC Investigational Contact Lens
214260236|NCT05021081|DEVICE|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
214260237|NCT03055182|OTHER|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
214260238|NCT04935281|OTHER|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
214260239|NCT04935281|OTHER|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
214260240|NCT05438784|PROCEDURE|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
214260241|NCT05438784|PROCEDURE|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
214260242|NCT01157923|DEVICE|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
214260243|NCT02651467|OTHER|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
214260244|NCT02651467|OTHER|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
214260245|NCT02651467|OTHER|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
214260246|NCT00334685|DRUG|[S,S]-Reboxetine + Pregabalin|\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
214260247|NCT00334685|DRUG|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
214260248|NCT01072669|DRUG|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
214260249|NCT00252824|DRUG|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
214260250|NCT02024529|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
214260251|NCT02024529|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
214260252|NCT06557486|BEHAVIORAL|Mindfulness-Based Stress reduction|Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
214260253|NCT01315964|DIETARY_SUPPLEMENT|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
214260254|NCT06167564|DIAGNOSTIC_TEST|Routine allergy tests|Prick test, specific IgE detection
214260255|NCT06167564|DIAGNOSTIC_TEST|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
214260256|NCT00573937|DRUG|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
214260257|NCT00573937|DRUG|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
214653701|NCT04758494|OTHER|Questionnaire|"In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population."
214260258|NCT00689780|DRUG|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
214260259|NCT00689780|DRUG|Midazolam|Oral solution given orally once daily on day -1 and day 14
214260260|NCT04171765|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
214260261|NCT04171765|DRUG|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
214260262|NCT00082589|DRUG|Eplerenone|
214260263|NCT04348643|BIOLOGICAL|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
214260264|NCT04275570|BEHAVIORAL|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
214260265|NCT00693849|DRUG|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
214260266|NCT00693849|DRUG|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
214260267|NCT00693849|DRUG|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
214260268|NCT00232089|DRUG|Tegaserod|
214260269|NCT04543825|DEVICE|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
214260270|NCT00448838|BIOLOGICAL|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
214260271|NCT00448838|DRUG|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
214260272|NCT00448838|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
214260273|NCT00002451|DRUG|Indinavir sulfate|
214260274|NCT00002451|DRUG|Ritonavir|
214260275|NCT00002451|DRUG|Lamivudine|
214260276|NCT00002451|DRUG|Stavudine|
214260277|NCT02904889|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
214260278|NCT02904889|OTHER|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
214260279|NCT00978978|DRUG|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
214260280|NCT01480089|DRUG|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
214260281|NCT01480089|DRUG|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
214653702|NCT06199245|OTHER|emotional freedom technique experimental group|Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
214653703|NCT06366243|DRUG|Emraclidine|Oral tablet
214653704|NCT06366243|DRUG|Esomeprazole|Oral delayed-release capsule
214653705|NCT04502303|DIAGNOSTIC_TEST|18F-FDG and 68Ga-FAPI PET/CT|Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.
214653706|NCT02519881|PROCEDURE|Microfracture|simple microfracture of ankle
214653707|NCT02519881|DEVICE|CartiFill|add collagen when doing microfracture
214653708|NCT01857921|DRUG|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
214653709|NCT01857921|DRUG|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
214260282|NCT04589455|DIETARY_SUPPLEMENT|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
214260283|NCT00631696|DRUG|Pregabalin|pregabalin 600 mg given twice a day
214260284|NCT00631696|DRUG|Placebo|Placebo
214260285|NCT03532061|BEHAVIORAL|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
214260286|NCT03532061|OTHER|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
214260287|NCT04046055|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214260288|NCT04046055|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214260289|NCT04046055|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
214260290|NCT05704231|BEHAVIORAL|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
214260291|NCT03041857|RADIATION|Observational use of fluoroscopy|
214260292|NCT01173757|DRUG|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
214260293|NCT05476406|OTHER|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
214260294|NCT05476406|OTHER|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
214260295|NCT01426438|DRUG|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
214260296|NCT01426438|DRUG|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
214260297|NCT01426438|DRUG|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
214260298|NCT01984788|DRUG|BCX4161|
214260299|NCT01984788|DRUG|Placebo|
214260300|NCT02422472|DEVICE|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
214260301|NCT01134731|DRUG|paliperidone|1-5 mg daily (QD)
214260302|NCT01134731|DRUG|lithium|300-1500mg QD
214260303|NCT01134731|DRUG|Placebo|1-5 placebo capsules
214260304|NCT02122458|DEVICE|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
214260305|NCT01549470|BIOLOGICAL|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
214260306|NCT01549470|BIOLOGICAL|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
214260307|NCT01976195|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
214260308|NCT01976195|DRUG|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
214260309|NCT00394823|BEHAVIORAL|Set of supportive tools/measures vs. standard care|
214260310|NCT03161093|DRUG|Fasinumab|Solution for injection in pre-filled syringe
214260311|NCT03161093|DRUG|Naproxen|Pharmaceutical form: Capsule
214260312|NCT03161093|DRUG|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
214260313|NCT03161093|DRUG|Naproxen-matching placebo|Capsule
214260314|NCT01200849|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
214260315|NCT00709657|DRUG|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
214260316|NCT03878953|DRUG|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
214260317|NCT03231657|DIAGNOSTIC_TEST|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
214260318|NCT04803539|DRUG|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
214260319|NCT04803539|DRUG|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
214260320|NCT00091442|DRUG|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
214260321|NCT00091442|DRUG|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
214260322|NCT00351988|BEHAVIORAL|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
214260323|NCT00351988|BEHAVIORAL|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
214260324|NCT03076619|OTHER|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
214260325|NCT02140112|BIOLOGICAL|Trichuris suis ova|
214260326|NCT02140112|OTHER|Placebo|
214260327|NCT01473043|DRUG|Axitinib|5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
214260328|NCT00002240|DRUG|Atazanavir|
214260329|NCT00002240|DRUG|Nelfinavir mesylate|
214260330|NCT00002240|DRUG|Stavudine|
214260331|NCT00002240|DRUG|Didanosine|
214260332|NCT02836275|OTHER|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
214260333|NCT02869503|OTHER|Data collection|
214260334|NCT00763711|DEVICE|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
214260335|NCT05914012|OTHER|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
214260336|NCT02518204|OTHER|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
214260337|NCT02518204|OTHER|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV"
214260338|NCT06277557|OTHER|Virtual Reality|Virtual reality learning platform as intervention in this study
214260339|NCT01922557|DEVICE|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
214260340|NCT05194657|DEVICE|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
214260341|NCT05194657|DEVICE|monofocal IOL|Acrysof IQ, monofocal IOL
214260342|NCT01332331|DRUG|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
214260343|NCT01332331|DRUG|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
214260344|NCT00004198|BIOLOGICAL|keyhole limpet hemocyanin|
214260345|NCT00004198|BIOLOGICAL|sargramostim|
214260346|NCT00004198|BIOLOGICAL|tumor cell-based vaccine therapy|
214260347|NCT04554173|PROCEDURE|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
214260348|NCT01076231|RADIATION|proton beam radiation therapy|
214260349|NCT01076231|DRUG|cisplatin|Given IV
214260350|NCT01076231|DRUG|etoposide|Given IV
214260351|NCT01076231|PROCEDURE|therapeutic conventional surgery|
214260352|NCT04810481|DEVICE|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
214260353|NCT00142610|DIETARY_SUPPLEMENT|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
214260354|NCT04956952|DEVICE|EECP|1 hour of treatment with EECP
214260355|NCT02664610|BEHAVIORAL|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
214260356|NCT03577873|OTHER|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
214260357|NCT03577873|PROCEDURE|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
214260358|NCT02208531|BEHAVIORAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
214260359|NCT06448078|DEVICE|External chest wall fixator|External chest wall fixator is applied in the form of external bonding to the rib fracture area
214260360|NCT02605785|DRUG|F-18 AV 1451|Tau PET scan
214260361|NCT05941559|OTHER|EMDR|Eye Movement Desensitization and Reprocessing
214260362|NCT02585583|RADIATION|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
214260363|NCT00597974|PROCEDURE|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
214260364|NCT00597974|DEVICE|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
214260365|NCT00597974|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
214260366|NCT00597974|PROCEDURE|Angiography|(non-experimental) Coronary angiography
214260367|NCT01474369|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
214260368|NCT01474369|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
214260369|NCT01474369|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
214260370|NCT05739630|DRUG|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
214260371|NCT05739630|DRUG|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
214260372|NCT04319731|BIOLOGICAL|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
214260373|NCT05120609|DEVICE|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
214260374|NCT05120609|DEVICE|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
214260375|NCT04753307|DIAGNOSTIC_TEST|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
214260376|NCT03645590|BEHAVIORAL|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
214260377|NCT05843162|DRUG|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
214260378|NCT05843162|DRUG|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
214260379|NCT00096083|DRUG|isolated perfusion|
214260380|NCT00096083|DRUG|melphalan|
214260381|NCT05982548|OTHER|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
214260382|NCT05982548|OTHER|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
214260383|NCT01570296|DRUG|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
214260384|NCT05601037|PROCEDURE|Axilla dissection + Lymphovenous anastomosis|surgical bypass between lymphatic vessel and vein
214260385|NCT00967629|DRUG|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
214260386|NCT00967629|DRUG|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
214260387|NCT03400566|BEHAVIORAL|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
214260388|NCT03400566|BEHAVIORAL|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
214260389|NCT04537429|DRUG|Eptinezumab|up to four iv infusions of eptinezumab
214260390|NCT04429360|PROCEDURE|pelvic reconstructive surgery|Pelvic reconstructive surgery
214260391|NCT03825523|OTHER|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
214260392|NCT03825523|OTHER|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
214260393|NCT04377243|BIOLOGICAL|V8|one pill per day either V8 or placebo
214260394|NCT02378727|DEVICE|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
214260395|NCT02378727|DEVICE|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
214260396|NCT04981392|BEHAVIORAL|Primary care text message outreach to unvaccinated patients and resources to support PCPs|"Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase)."
214260397|NCT05899088|OTHER|Mindful Movement|Mindful Movement Program with Researcher Follow-up
214260398|NCT03219541|BEHAVIORAL|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
214260399|NCT03219541|BEHAVIORAL|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
214260400|NCT01866722|BEHAVIORAL|Usual care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
214260401|NCT01866722|BEHAVIORAL|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
214260402|NCT01866722|BEHAVIORAL|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
214260403|NCT06203574|RADIATION|[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4|The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
214260404|NCT02490410|DIETARY_SUPPLEMENT|protein supplement|
214260405|NCT01600807|DRUG|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
214260406|NCT01600807|DRUG|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
214260407|NCT01833546|DRUG|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
214260408|NCT01833546|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
214260409|NCT01624337|DRUG|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
214260410|NCT01624337|DRUG|placebo|
214653710|NCT03047525|BIOLOGICAL|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
214653711|NCT00242294|DRUG|Roflumilast|
214260411|NCT06228885|BEHAVIORAL|handwriting experiment and motor ability test|Participants will be instructed to participate in a handwriting experiment, which involves utilizing a Force Acquisition Pen (FAP) system and Near Infrared Spectroscopy (NIRS) to collect force data and cortical activation, respectively, during handwriting tasks. Children will be tasked with completing various assignments, such as tracing lines, writing numbers, and characters, among others. Additionally, assessments of motor ability and handwriting proficiency will be conducted using the Movement Assessment Battery for Children (MABC) and the Chinese Handwriting Evaluation Form (CHEF). The Pinch Holding Up Activity (PHUA) Test will also be administered to assess their sensorimotor ability.
214260412|NCT02044835|DRUG|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
214260413|NCT04894292|OTHER|Non intervention|During the study there is no extra intervention planned for the participants.
214260414|NCT04441671|DRUG|Disodium Pyrophosphate|Absorption trial
214260415|NCT05792787|DIAGNOSTIC_TEST|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
214260416|NCT05055128|DRUG|X842|Patients will receive X842 tablets.
214260417|NCT05055128|DRUG|X842 Dummy|Patients will receive matching placebo tablets for X842.
214260418|NCT05055128|DRUG|Lansoprazole|Patients will receive Lansoprazole capsule.
214260419|NCT05055128|DRUG|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
214260420|NCT04161027|DRUG|Pregabalin 75mg|Pregabalin 75 mg capsule
214260421|NCT04161027|DRUG|Placebos|Placebo capsule
214260422|NCT04579029|PROCEDURE|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
214260423|NCT03521427|OTHER|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
214260424|NCT03521427|OTHER|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
214260425|NCT04650776|OTHER|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
214260426|NCT02356315|OTHER|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
214260427|NCT01385371|BIOLOGICAL|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
214260428|NCT01385371|BIOLOGICAL|Placebo for SCH 697243|One dissolving tablet sublingually once daily
214260429|NCT01469624|DRUG|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
214260430|NCT02164773|DRUG|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
214260431|NCT02164773|DRUG|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
214260432|NCT03029273|DRUG|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
214260433|NCT03029273|BIOLOGICAL|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
214260434|NCT02315573|PROCEDURE|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
214260435|NCT05840718|DRUG|Thiamin|Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
214260436|NCT00732797|BEHAVIORAL|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
214260437|NCT00732797|BEHAVIORAL|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
214260438|NCT05862597|DIAGNOSTIC_TEST|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
214260439|NCT05537896|DRUG|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"
214260440|NCT00936611|DRUG|LBH589|
214260441|NCT00239395|DRUG|Meloxicam ampoule|
214260442|NCT00239395|DRUG|Meloxicam tablet|
214260443|NCT00449527|DRUG|Budesonide/formoterol pMDI|
214260444|NCT00449527|DRUG|Budesonide HFA pMDI|
214260445|NCT04276337|DIAGNOSTIC_TEST|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
214260446|NCT01346969|DRUG|EXC 001|Single-dose administered by injection four different times
214260447|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
214260448|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
214260449|NCT01346969|DRUG|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
214260450|NCT05535231|DIETARY_SUPPLEMENT|Turmeric test product|2 capsules of 490 mg Turmeric are taken with water once
214260451|NCT05535231|DIETARY_SUPPLEMENT|Turmeric comparator|2 capsules of 200 mg Turmeric are taken with water once
214260452|NCT04113720|DRUG|Levobupivacaine hydrochloride|levobupivacaine 0.25%
214260453|NCT04113720|DRUG|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
214260454|NCT00563420|PROCEDURE|Bronchoscopy|
214260455|NCT00211484|DRUG|Anecortave Acetate|
214260456|NCT02024438|DRUG|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
214653712|NCT04273074|RADIATION|sonographic assessment|preoperative sonographic assessment to airway
214653713|NCT02368548|OTHER|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
214653714|NCT02368548|OTHER|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
214653715|NCT01412229|DRUG|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
214653716|NCT01412229|DRUG|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
214653717|NCT01412229|DRUG|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
214653718|NCT02139956|DEVICE|ultrasonography|open
214653719|NCT05388747|DRUG|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
214653720|NCT03883074|DEVICE|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
214260457|NCT02024438|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
214260458|NCT05426798|DRUG|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
214653721|NCT03883074|DEVICE|Placebo|tablets with the same aspect of the active device
214260459|NCT05600738|DEVICE|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
214260460|NCT00943696|DIETARY_SUPPLEMENT|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
214260461|NCT04293731|DIETARY_SUPPLEMENT|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
214260462|NCT04293731|DIETARY_SUPPLEMENT|Placebo|Placebo
214260463|NCT05077878|BIOLOGICAL|DSPP level in GCF|quantification of DSPP
214260464|NCT02662634|BIOLOGICAL|AGS-003-LNG|autologous dendritic cell immunotherapy
214260465|NCT02662634|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
214653722|NCT01889602|DRUG|Lorazepam|Lorazepam: 2mg, po, 1x
214260466|NCT02662634|DRUG|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
214260467|NCT02662634|DRUG|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
214260468|NCT02662634|DRUG|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
214260469|NCT02662634|DRUG|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
214260470|NCT02662634|RADIATION|Radiation Therapy|Causes DNA strand breaks.
214260471|NCT02728622|DRUG|Tamoxifen|endocrine treatment
214260472|NCT02728622|DRUG|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
214260473|NCT05610514|OTHER|E-Cigarette|Altering the availability of e-cigarettes
214260474|NCT05610514|BEHAVIORAL|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
214260475|NCT02549729|BEHAVIORAL|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
214653723|NCT01889602|OTHER|Placebo|Non-active placebo, po, 1x
214653724|NCT01889602|DRUG|Topiramate 100mg|Topiramate: 100 mg, po, 1x
214653725|NCT01889602|DRUG|Topiramate 150mg|Topiramate: 150 mg, po, 1x
214653726|NCT01889602|DRUG|Topiramate 200mg|Topiramate: 200 mg, po, 1x
214653727|NCT00404092|DRUG|caspofungin|i.v.
214653728|NCT01783067|OTHER|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
214653729|NCT01783067|OTHER|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
214260476|NCT06573931|OTHER|Lumbar Erector Spinae Plane Block|Patients will receive lumbar erector spinae plane block at the end of surgery.
214260477|NCT06573931|OTHER|Fascia Iliaca Block|Patients will receive fascia iliaca block at the end of surgery.
214260478|NCT06573931|OTHER|Lumbar Plexus Block|Patients will receive lumbar plexus block at the end of surgery.
214260479|NCT03312998|RADIATION|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
214260480|NCT04498312|OTHER|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
214260481|NCT01736462|DRUG|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
214260482|NCT02958501|DRUG|Colecalciferol|Drug
214260483|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
214260484|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
214260485|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
214260486|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
214260487|NCT01044251|DRUG|Frovatriptan|2.5 mg po bid for 10 days
214260488|NCT01044251|DRUG|Placebo|1 tab po bid for 10 days
214260489|NCT00734370|BEHAVIORAL|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention"
214260490|NCT00734370|BEHAVIORAL|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)"
214260491|NCT02328417|OTHER|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
214260492|NCT05995119|DRUG|Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)|The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
214260493|NCT01516073|DRUG|Fluticasone Propionate|FP BID for 12 weeks
214260494|NCT03297814|BIOLOGICAL|Platelet lysate|Intramuscular injection of platelet lysate
214260495|NCT03297814|BIOLOGICAL|Placebo|intramuscular injection of normal saline
214260496|NCT03664180|DRUG|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
214260497|NCT03664180|DRUG|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
214260498|NCT03664180|DRUG|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
214260499|NCT03664180|DRUG|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
214260500|NCT03664180|DRUG|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
214260501|NCT03664180|DRUG|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
214260502|NCT05013034|DRUG|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
214260503|NCT05013034|DRUG|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
214653730|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
214260504|NCT06393036|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
214260505|NCT03883399|OTHER|Survey|Survey among colorectal surgeons
214260506|NCT03715101|DRUG|Rosuvastatin|Open-label, one-sequence, multiple administration
214260507|NCT05667194|DRUG|KH617|KH617 is s freeze-dried powder injection
214260508|NCT05758571|DRUG|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
214260509|NCT00004397|DRUG|heme arginate|
214260510|NCT00004397|DRUG|tin mesoporphyrin|
214260511|NCT05888454|OTHER|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
214260512|NCT05888454|OTHER|Conventional treatment for T2DM|Conventional medical treatment for T2DM
214260513|NCT04118504|DEVICE|Mobile application|Lifestyle intervention on through mobile application
214260514|NCT01881373|OTHER|CHL program|Multiple component environmentally focused program designed with community engagement.
214260515|NCT01881373|OTHER|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
214260516|NCT01658631|DEVICE|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
214260517|NCT05991167|DEVICE|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
214260518|NCT02831140|BEHAVIORAL|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
214260519|NCT02831140|BEHAVIORAL|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
214260520|NCT02831140|BEHAVIORAL|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
214653731|NCT03303989|DRUG|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
214653732|NCT03303989|DRUG|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
214653733|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
214653734|NCT04453735|DRUG|Atorvastatin mylan 40 Mg Oral Tablet|Oral tablet on regular prescription
214653735|NCT01278290|DIAGNOSTIC_TEST|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
214260521|NCT02831140|BEHAVIORAL|commun interventions|"* In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
214260522|NCT02752204|DRUG|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
214260523|NCT02752204|DRUG|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
214260524|NCT04941963|DIAGNOSTIC_TEST|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
214260525|NCT02140242|DRUG|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
214260526|NCT02140242|PROCEDURE|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
214260527|NCT06431204|OTHER|Obstetric comorbidity index|Obstetric comorbidity index score
214260528|NCT02906332|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
214260529|NCT02906332|DRUG|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
214260530|NCT02906332|DRUG|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
214260531|NCT02384161|OTHER|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
214260532|NCT02949700|DRUG|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
214260533|NCT06273631|OTHER|diverse carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 45\~50% of carbohydrate supply sources are refined grains, 45\~50% of carbohydrate supply sources are whole grains or beans.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
214260534|NCT06273631|OTHER|middle carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 90\~95% of carbohydrate supply sources are refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
214260535|NCT01403311|DRUG|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
214260536|NCT03945266|BEHAVIORAL|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
214260537|NCT03945266|BEHAVIORAL|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
214260538|NCT03483025|OTHER|Skin Testing of Hair cleansing products|6 different commercially available shampoos
214260539|NCT04820517|OTHER|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management"
214260540|NCT04399226|DRUG|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
214260541|NCT06441448|BEHAVIORAL|case focus groups|The study is in a monocentric, exploratory, participatory study conceptualization phase. Within the study, a mixed-methods assessment involves various interview and group exercise formats among scientists, medical personnel, affected individuals, and their caregivers to develop components for a future psychotherapeutic program for ALS patients and their caregivers. Therapists provide an overview of therapy forms by presenting components based on format, content, and applied techniques. Case studies and focus groups are used for practical experience for the participants. Participants qualitatively assess the significance of therapeutic approaches and make a quantitative prioritization to establish a ranking of therapy components.
214260542|NCT03629210|DRUG|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
214260543|NCT03629210|BIOLOGICAL|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
214260544|NCT02929914|PROCEDURE|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
214260545|NCT02929914|PROCEDURE|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
214260546|NCT02929914|PROCEDURE|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
214260547|NCT02929914|PROCEDURE|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
214260548|NCT02929914|PROCEDURE|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
214260549|NCT01686828|DRUG|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
214260550|NCT01686828|DRUG|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
214260551|NCT01686828|DRUG|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
214260552|NCT01686828|DRUG|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
214260553|NCT01686828|DRUG|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
214260554|NCT02966769|OTHER|Overall survival|Compare overall survival between both groups.
214260555|NCT04637113|OTHER|This is a non-interventional study|This is a non-interventional study.
214260556|NCT01635335|BEHAVIORAL|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
214260557|NCT03191279|PROCEDURE|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
214260558|NCT04934475|DRUG|Isatuximab|Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
214260559|NCT04934475|PROCEDURE|ASCT|ASCT for ams B, C and D during consolidation
214260560|NCT00393354|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
214260561|NCT00393354|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
214260562|NCT06272201|DEVICE|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
214260563|NCT01062204|DEVICE|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
214260564|NCT01062204|DEVICE|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
214260565|NCT01915966|DIETARY_SUPPLEMENT|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
214260566|NCT01915966|DIETARY_SUPPLEMENT|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
214260567|NCT04331236|BEHAVIORAL|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
214260568|NCT04331236|OTHER|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
214260569|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
214260570|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
214260571|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
214260572|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
214260573|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
214260574|NCT05086952|DRUG|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
214260575|NCT01751893|DRUG|Henna|natural henna in the form of paste
214260576|NCT01751893|DRUG|Placebo|placebo
214260577|NCT01791010|OTHER|Inspiratory muscle training|
214260578|NCT01791010|OTHER|Training sham|Conducting fake training with the aim of blind the control group
214260579|NCT04746716|OTHER|Phone call|Phone call to the patient to complete quality of life scales
214260580|NCT01642654|OTHER|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
214260581|NCT01642654|OTHER|Educational lectures|Educational lectures
214260582|NCT00359697|DRUG|Hypertonic Saline, Mannitol|
214260583|NCT02908243|OTHER|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
214260584|NCT00136071|DEVICE|Transobturator tape-ARIS|
214260585|NCT00136071|DEVICE|TVT-O|
214260586|NCT04264689|PROCEDURE|serratus anterior block|ultrasound guided block
214260587|NCT04264689|PROCEDURE|thoracic epidural|thoracic epidural
214260588|NCT04264689|PROCEDURE|erector spinae block|ultrasound guided block
214653736|NCT01278290|DIAGNOSTIC_TEST|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
214260589|NCT03708848|DRUG|Esomeprazole|Proton pump inhibitor
214260590|NCT03708848|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214260591|NCT03708848|DRUG|Clarithromycin|antibiotic for H. pylori eradication
214260592|NCT03708848|DRUG|Metronidazole|antibiotic for H. pylori eradication
214260593|NCT03708848|DRUG|Levofloxacin|antibiotic for H. pylori eradication
214260594|NCT03708848|DRUG|Tetracycline|antibiotic for H. pylori eradication
214260595|NCT05885854|DRUG|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
214653737|NCT02896530|OTHER|No intervention. Description study|
214653738|NCT02674945|DEVICE|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
214260596|NCT05769998|BEHAVIORAL|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
214260597|NCT05769998|OTHER|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
214260598|NCT04676698|BEHAVIORAL|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
214260599|NCT04676698|BEHAVIORAL|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
214260600|NCT05772208|DRUG|Camrelizumab|camrelizumab 200mg q3w
214260601|NCT05772208|DRUG|Nimotuzumab|nimotuzumab 200mg qw
214260602|NCT05772208|DRUG|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
214260603|NCT01237938|BEHAVIORAL|Low Glycemic Diet|Changing to low glycemic diet
214260604|NCT01161784|DIETARY_SUPPLEMENT|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
214260605|NCT01161784|DIETARY_SUPPLEMENT|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
214260606|NCT03750461|DEVICE|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
214260607|NCT02202525|DRUG|Micardis®|
214260608|NCT02202525|DRUG|Other hypertensives|
214260609|NCT05171543|PROCEDURE|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
214260610|NCT05886504|OTHER|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
214260611|NCT01688518|DRUG|Heated Lidocaine/Tetracaine Patch|
214260612|NCT01688518|DRUG|5% Lidocaine Patch|
214260613|NCT06966570|OTHER|Study Product A: Mixed-macronutrient beverage|Participants will consume a beverage that contains mixed macronutrients.
214260614|NCT06966570|OTHER|Study Product B: Single-macronutrient beverage|Participants will consume a beverage that contains a single macronutrient.
214260615|NCT03098459|OTHER|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
214260616|NCT04176705|DRUG|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
214260617|NCT04176705|DRUG|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
214260618|NCT04176705|DEVICE|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
214260619|NCT04560543|PROCEDURE|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
214260620|NCT04560543|PROCEDURE|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
214260621|NCT02423772|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
214260622|NCT04815278|BEHAVIORAL|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
214260623|NCT04815278|BEHAVIORAL|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
214260624|NCT04815278|BEHAVIORAL|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
214260625|NCT01350518|DIETARY_SUPPLEMENT|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
214260626|NCT01350518|DIETARY_SUPPLEMENT|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
214260627|NCT04570267|BIOLOGICAL|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
214260628|NCT04570267|DRUG|Placebo|Sterile solution of CSL324 formulation buffer for injection
214260629|NCT04041739|DIAGNOSTIC_TEST|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
214260630|NCT04562493|PROCEDURE|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
214260631|NCT02149615|OTHER|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
214260632|NCT02972853|BEHAVIORAL|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
214260633|NCT01806727|BEHAVIORAL|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
214260634|NCT01806727|BEHAVIORAL|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
214260635|NCT01607671|DRUG|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
214260636|NCT02138435|OTHER|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
214260637|NCT02138435|OTHER|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
214260638|NCT03882788|DRUG|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
214260639|NCT03882788|DRUG|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
214260640|NCT03882788|DRUG|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
214260641|NCT03830112|BEHAVIORAL|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
214260642|NCT03830112|BEHAVIORAL|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
214260643|NCT03727425|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
214260644|NCT04637490|DEVICE|patellar component|patellar resurfacing
214260645|NCT02788929|DEVICE|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
214260646|NCT06260098|BEHAVIORAL|Yoga with High Breath work & meditation; Low movement/postures|Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
214260647|NCT06260098|BEHAVIORAL|Yoga with Low Breath work & meditation; High movement/postures|Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
214260648|NCT02484690|DRUG|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
214260649|NCT02484690|DRUG|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
214260650|NCT02484690|DRUG|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
214260651|NCT03360747|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
214260652|NCT02643030|BEHAVIORAL|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
214260653|NCT02643030|BEHAVIORAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
214260654|NCT03764085|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
214260655|NCT03764085|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
214260656|NCT04432272|BIOLOGICAL|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
214260657|NCT02827916|DEVICE|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
214260658|NCT02827916|DEVICE|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
214260659|NCT02827916|DEVICE|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
214260660|NCT03377114|PROCEDURE|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
214260661|NCT03377114|PROCEDURE|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
214260662|NCT02517216|OTHER|parabolic flight|
214260663|NCT02517216|DEVICE|MRI|
214260664|NCT04603716|OTHER|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
214260665|NCT04603716|OTHER|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
214260666|NCT01759511|DRUG|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
214260667|NCT01860781|DRUG|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
214260668|NCT02127723|DEVICE|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
214260669|NCT02933112|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
214260670|NCT05927584|PROCEDURE|Transanal local excision|Transanal full thickness local excision
214260671|NCT02389985|DRUG|CRLX101|
214260672|NCT02389985|DRUG|Paclitaxel|
214260673|NCT00343590|DEVICE|Whole Body Vibration machine|
214260674|NCT05750160|OTHER|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
214260675|NCT02772055|OTHER|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
214260676|NCT02772055|OTHER|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
214260677|NCT00802087|DRUG|hydrocodone|Extended Release tablet
214260678|NCT00802087|DRUG|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
214260679|NCT01161108|DRUG|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
214260680|NCT01161108|DRUG|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
214260681|NCT01161108|DRUG|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
214260682|NCT01161108|DRUG|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
214260683|NCT01887223|PROCEDURE|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
214260684|NCT01887223|DRUG|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
214260685|NCT00398294|DRUG|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
214260686|NCT03318666|BEHAVIORAL|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
214260687|NCT03318666|OTHER|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
214260688|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with applesauce
214260689|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with yogurt
214260690|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of intact bosutinib capsules
214260691|NCT03878342|RADIATION|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
214260692|NCT03878342|OTHER|No Radiotherapy|No Irradiation- Active surveillance
214260693|NCT03772678|DRUG|LSALT peptide|novel 16 amino acid peptide
214260694|NCT03772678|OTHER|0.9% Saline|saline
214260695|NCT06312722|DEVICE|Optilume® BPH Catheter System|The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
214260696|NCT04183062|DRUG|Chemotherapy (gemcitabine & docetaxel) plus BIO-11006|"BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8."
214260697|NCT03306927|DIETARY_SUPPLEMENT|Whole yellow pea chili|Chili containing whole yellow peas
214260698|NCT03306927|DIETARY_SUPPLEMENT|Split yellow pea chili|Chili containing split yellow peas
214260699|NCT03306927|DIETARY_SUPPLEMENT|Rice chili|Chili containing long grain white rice
214260700|NCT05483270|BIOLOGICAL|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
214260701|NCT05417217|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
214260702|NCT05417217|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
214260703|NCT04093349|GENETIC|SPK-3006|adeno-associated viral (AAV) vector
214260704|NCT03783091|DRUG|Hydroxocobalamin|Single IV administration of Vitamin B12
214260705|NCT03783091|DRUG|Placebo|Single IV administration of saline
214260706|NCT05732623|BEHAVIORAL|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions"
214260707|NCT05636826|DRUG|atherolive-drug|The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
214260708|NCT05636826|DRUG|Placebo Atherolive|The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
214260709|NCT06122116|OTHER|Physical Therapy|The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
214260710|NCT06122116|BIOLOGICAL|Platelet-Rich Plasma Injection|PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
214260711|NCT06122116|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm\^2 and applied in a circular pattern to the knee area.
214260712|NCT05736198|DRUG|Dexmedetomidine|dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
214260713|NCT04490161|OTHER|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
214260714|NCT03036319|DEVICE|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
214260715|NCT03036319|DEVICE|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
214260716|NCT03036319|BEHAVIORAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
214260717|NCT03036319|DEVICE|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
214260718|NCT03036319|DEVICE|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
214260719|NCT03036319|DEVICE|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
214260720|NCT03036319|DEVICE|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
214260721|NCT03561753|DRUG|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
214260722|NCT03561753|DRUG|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
214260723|NCT05633693|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
214260724|NCT05633693|BEHAVIORAL|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
214260725|NCT01818661|DRUG|AV-1451|This is used to assess Tau burden in the brain.
214260726|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
214260727|NCT02799485|OTHER|Pharmacological Study|Correlative studies
214260728|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
214260729|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214260730|NCT05942261|OTHER|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
214260731|NCT05635851|DRUG|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
214260732|NCT05635851|OTHER|Placebo sublingual spray|A placebo sublingual spray will be administered.
214260733|NCT04829448|DIETARY_SUPPLEMENT|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
214260734|NCT03755388|DEVICE|Episealer|Placing Episealer device
214260735|NCT06388382|OTHER|Alert tone demonstration|Patients are demonstrated the alert tone of their ICD
214260736|NCT06051591|BEHAVIORAL|Food FARMacia Program|Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.
214260737|NCT06051591|BEHAVIORAL|Self-directed meal preparation support|Nutrition education and anticipatory guidance to support healthy meal preparation
214260738|NCT04430192|DRUG|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
214260739|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, partial LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.
214260740|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
214260741|NCT06008613|DEVICE|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
214260742|NCT06405139|DRUG|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
214260743|NCT06578559|DRUG|Cetuximab|500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
214260744|NCT06578559|DRUG|Encorafenib|300 mg once daily (four 75 mg oral capsules).
214260745|NCT04481113|DRUG|Abemaciclib|Given PO
214260746|NCT04481113|DRUG|Niraparib Tosylate Monohydrate|Given PO
214260747|NCT06572241|DRUG|Intrathecal morphine|morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
214260748|NCT06572241|OTHER|Saline solution (placebo)|normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).
214260749|NCT04526509|DRUG|GSK3901961|GSK3901961 as an IV infusion.
214260750|NCT04526509|DRUG|GSK3845097|GSK3845097 as an IV infusion.
214653739|NCT05666557|OTHER|manual erector spinae myofascial realease|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
214260751|NCT04526509|DRUG|GSK4427296|GSK4427296 as an IV infusion.
214260752|NCT04526509|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
214260753|NCT04526509|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
214260754|NCT05029700|OTHER|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
214260755|NCT05029700|OTHER|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
214260756|NCT05491538|BEHAVIORAL|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
214260757|NCT05935514|BEHAVIORAL|WW Intervention|The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.
214653740|NCT05666557|OTHER|self-myofascial release technique|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
214260758|NCT05935514|BEHAVIORAL|Usual Care|The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
214260759|NCT04309812|DEVICE|transcranial direct current stimulation (tDCS)|Electrical stimulation of scalp over a seizure focus
214260760|NCT05925075|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
214260761|NCT03143322|RADIATION|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
214260762|NCT06235983|DRUG|LY3537982|Administered orally.
214260763|NCT05885542|DRUG|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
214260764|NCT05885542|DRUG|Placebo|Double-blind placebo oral solution administered once
214260765|NCT06277037|OTHER|Non-interventional|This is a rollover study
214260766|NCT03448653|OTHER|Colonoscopy with NBI|Colonoscopy with NBI
214260767|NCT02385214|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
214260768|NCT02385214|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
214260769|NCT05230459|GENETIC|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
214260770|NCT05230459|GENETIC|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
214653741|NCT06088927|DEVICE|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
214260771|NCT05230459|OTHER|Placebo|Single intravenous infusion of Placebo
214260772|NCT05309590|DRUG|Dose|The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
214260773|NCT04340193|DRUG|nivolumab|Specified dose on specified days
214260774|NCT04340193|DRUG|ipilimumab|Specified dose on specified days
214260775|NCT04340193|PROCEDURE|TACE|TACE (Trans-arterial ChemoEmbolization)
214260776|NCT00818675|DRUG|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
214260777|NCT00818675|DRUG|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
214260778|NCT00818675|DRUG|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
214260779|NCT05274659|DRUG|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
214260780|NCT05274659|DRUG|Placebo|Placebo
214260781|NCT02912988|DRUG|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
214260782|NCT05455385|OTHER|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
214260783|NCT05455385|OTHER|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
214260784|NCT05455385|OTHER|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
214260785|NCT01515007|DRUG|Ciprofloxacin dispersion for inhalation|
214260786|NCT01515007|DRUG|Placebo|
214653742|NCT00255073|DRUG|baclofen|
214653743|NCT00073840|DRUG|levalbuterol|"* Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID"
214260787|NCT04282278|DRUG|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
214260788|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
214260789|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
214260790|NCT01999101|DRUG|Px-104|28 days treatment
214260791|NCT04428437|DRUG|Lenvatinib|Prescribed by physician.
214260792|NCT03753269|DRUG|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
214260793|NCT03753269|DRUG|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
214260794|NCT03200158|OTHER|Endoscopy biopsy and blood|Medical operation
214260795|NCT01814618|DRUG|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
214260796|NCT02788760|DEVICE|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
214260797|NCT03659955|OTHER|Autologous blood applied to dry eye|See previous description for the study arm.
214260798|NCT04747639|OTHER|500 ml glucose-depleted apple juice|
214260799|NCT04747639|OTHER|500 ml conventional apple juice|
214260800|NCT04747639|OTHER|250 ml glucose-depleted apple juice|
214260801|NCT04747639|OTHER|250 ml conventional apple juice|
214260802|NCT06019585|DEVICE|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
214260803|NCT06019585|DEVICE|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
214260804|NCT04676854|DEVICE|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
214260805|NCT06345092|DRUG|Vitamin C|addition of vitamin C to IPRF
214260806|NCT06345092|OTHER|Injectable platelet rich fibrin|injection of IPRF alone
214260807|NCT06225037|DEVICE|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
214260808|NCT06225037|DEVICE|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
214260809|NCT05907122|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
214653744|NCT04152382|DRUG|LY3462817 - IV|Administered IV
214653745|NCT04152382|DRUG|LY3462817 - SC|Administered SC
214653746|NCT04152382|DRUG|Placebo - IV|Administered IV
214653747|NCT04152382|DRUG|Placebo - SC|Administered SC
214653748|NCT04152382|DRUG|LY3509754|Administered orally.
214653749|NCT04152382|DRUG|Placebo|Administered orally.
214653750|NCT00591734|DRUG|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
214653751|NCT00591734|DRUG|Everolimus|10 mg by mouth daily
214653752|NCT04790227|DEVICE|MRI|MRI
214260810|NCT05907122|DRUG|FDA-licensed Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
214260811|NCT05907122|DRUG|EU-authorized Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
214260812|NCT06529042|OTHER|Non-Interventional|Non-Interventional
214260813|NCT00589290|DRUG|Belinostat (PDX101)|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
214260814|NCT01067976|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
214260815|NCT02706678|DRUG|Tacrolimus sustained-release capsule|Oral
214260816|NCT06019507|BIOLOGICAL|TCD601|Investigational Product
214260817|NCT06019507|BIOLOGICAL|Cyclophosphamide|Conditioning Regimen
214260818|NCT06019507|DRUG|TAC|Immunosuppression Therapy
214260819|NCT06019507|DRUG|MMF|Immunosuppression Therapy
214260820|NCT06019507|DRUG|Corticosteroids|Immunosuppression Therapy
214260821|NCT04926376|DEVICE|Eye90 Microspheres|Y90 glass microspheres
214260822|NCT03979131|COMBINATION_PRODUCT|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
214260823|NCT04449861|DRUG|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
214260824|NCT06541314|DRUG|Fluzoparib|Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.
214260825|NCT05084651|DRUG|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
214260826|NCT05084651|COMBINATION_PRODUCT|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
214260827|NCT05084651|DRUG|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
214260828|NCT05303272|DRUG|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
214260829|NCT05303272|DRUG|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
214260830|NCT02812407|DEVICE|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm"
214260831|NCT03397173|DRUG|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
214260832|NCT03397173|DRUG|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
214260833|NCT06016907|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
214260834|NCT06016907|BEHAVIORAL|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
214260835|NCT04981067|OTHER|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
214260836|NCT04981067|OTHER|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
214260837|NCT04981067|OTHER|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
214260838|NCT06708247|PROCEDURE|Standard Peri-implant Reconstructive Surgery|This intervention involves standard peri-implant reconstructive surgery without the additional step of electrolytic cleaning. The procedure includes mechanical debridement of the implant surface to remove biofilm, followed by bone grafting using autogenous bone harvested from the tuberosity and coverage with a resorbable collagen membrane for bone regeneration and stabilization of the implant.
214260839|NCT06708247|PROCEDURE|Electrolytic Cleaning with Peri-implant Reconstructive Surgery|This intervention involves peri-implant reconstructive surgery with an added step of electrolytic cleaning for enhanced implant surface decontamination. The procedure starts with mechanical debridement of the implant surface, followed by the use of an electrolytic cleaning device to remove biofilm and contaminants without damaging the implant surface. This is then followed by bone grafting using autogenous tuberosity bone and coverage with a resorbable collagen membrane to promote bone regeneration and implant stability.
214653753|NCT02407626|DRUG|Propofol|Total intravenous anesthesia is a clinical standard procedure
214653754|NCT02407626|DRUG|Sevoflurane|Volatile anesthesia is a clinical standard procedure
214260840|NCT01689961|BEHAVIORAL|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
214260841|NCT05268055|OTHER|"Sign Here training intervention"|Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.
214260842|NCT05268055|OTHER|Intervention as usual|"Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
214260843|NCT06588218|OTHER|Watermelon|2.5 cups of whole fresh watermelon (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks
214260844|NCT06588218|OTHER|Belvita Breakfast Sandwich + 12 oz Water|Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
214260845|NCT04175054|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
214260846|NCT03507400|BEHAVIORAL|Introvision: mental and emotional self-regulation|Participants learn Introvision
214260847|NCT06589661|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
214260848|NCT05881460|DEVICE|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
214260849|NCT05881460|DEVICE|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
214260850|NCT01336192|DRUG|Gemcitabine|Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
214260851|NCT01336192|DRUG|Best supportive care|Best supportive care
214260852|NCT02755298|DRUG|Acetazolamide|
214260853|NCT02755298|DRUG|Placebo|
214260854|NCT03260920|DRUG|Syntocinon|Intranasal Oxytocin
214260855|NCT01555983|DRUG|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
214260856|NCT03239964|DRUG|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
214260857|NCT03239964|OTHER|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
214260858|NCT06660550|PROCEDURE|laparoscopic inguinal hernia repair|traditional laparoscopic repair
214260859|NCT06660550|PROCEDURE|Needlescopic inguinal hernia repair|Needlescopic inguinal hernia repair
214260860|NCT04834752|OTHER|No intervention (Retrospective Cohort Observational)|History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
214260861|NCT06598033|DRUG|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
214260862|NCT02353754|DRUG|Intrathecal morphine injection|0.2 mg
214260863|NCT02353754|DRUG|EXPAREL|266 mg
214260864|NCT06468215|DRUG|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.|Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
214260865|NCT00630695|DRUG|Lanreotide LP 90|Lanreotide LP 90
214260866|NCT00630695|DRUG|Placebo lanreotide|Placebo
214260867|NCT03335111|OTHER|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
214260868|NCT03335111|PROCEDURE|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
214260869|NCT02475031|DEVICE|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
214653755|NCT05888350|DRUG|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
214260870|NCT02475031|DRUG|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
214260871|NCT00289718|BIOLOGICAL|Twinrix™ adult|Intramuscular administration
214653756|NCT05888350|DRUG|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
214653757|NCT03306654|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
214653758|NCT00130338|DRUG|Rivastigmine|
214260872|NCT05184075|PROCEDURE|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
214260873|NCT05184075|PROCEDURE|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
214260874|NCT02577497|DRUG|beclomethasone|
214260875|NCT02577497|DRUG|fluticasone|
214260876|NCT06517823|DRUG|Etoricoxib + Cyanocobalamin fixed dose|One tablet of 90 mg / 0.50 mg a day
214260877|NCT06517823|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
214260878|NCT06593106|PROCEDURE|Cryosurgery|Undergo cryodevitalization
214260879|NCT06593106|PROCEDURE|Robotic Bronchoscopy|Undergo standard of care robotic bronchoscopy with biopsy
214260880|NCT06593106|PROCEDURE|Bronchoscopy with Biopsy|Undergo standard of care robotic bronchoscopy with biopsy
214260881|NCT06593106|PROCEDURE|Resection|Undergo standard of care surgical resection
214260882|NCT06593106|PROCEDURE|Chest Radiography|Undergo chest x-ray
214260883|NCT06593106|PROCEDURE|Computed Tomography|Undergo Computed Tomography
214260884|NCT06593106|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
214260885|NCT06593106|OTHER|Electronic Health Record Review|Ancillary studies
214260886|NCT04128579|DRUG|Itolizumab [Bmab 600]|EQ001
214260887|NCT06602102|DEVICE|Mixed reality Glasses|Mixed reality glasses are devices that combine elements of augmented reality and virtual reality. They allow users to overlay digital images onto the real world, enabling interaction with virtual objects in a physical environment. These glasses typically use sensors, cameras, and tracking technology to map the surroundings and provide an immersive experience. They are used in various applications, such as gaming, education, design, and professional training.
214260888|NCT06680154|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current was delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) were used throughout the stimulation. Before placing the electrodes on the head, the subject's hair was moved to the side
214260889|NCT06680154|DEVICE|Theta burst stimulation|the intermittent theta burst stimulation (iTBS) which is regarded as safe for high-frequency neuromodulation. Compared to classical rTMS, where pulses are applied repeatedly at a fixed frequency, iTBS consists of bursts of pulse triplets. In the classical protocol, the bursts are applied for two seconds in 5Hz intervals followed by an eight-second break, before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol.
214260890|NCT06680154|DEVICE|Sham (No Treatment)|In the case of sham TMS, two different sham coils (double 70mm pCool-SHAM coil, Mag\&More GmbH, Munich, Germany) will produce audible clicks at the decibel intensity corresponding to an active coil without the induction of an electromagnetic pulse. Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
214260891|NCT06686264|OTHER|core stability group A|Abdominal hollowing in supine (10 reps \& 2 sets) Single leg bridge (10 reps \& 2 sets), 3 session per week for 6 weeks Prone Single leg raise(10 reps \& 2 sets) Double leg bridge (10 reps \& 2 sets) Abdominal hallowing in 4 point kneeling(10 reps \& 2 sets), Complete Back stretch Pelvic rotations Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
214260892|NCT06686264|OTHER|traditional exercises group B|Complete Back stretch Pelvic rotations, 3 sessions per week for 6 week Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
214260893|NCT05807763|PROCEDURE|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
214260894|NCT06695312|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise
214260895|NCT06695312|DEVICE|High Tone Power Therapy|High Tone Power Therapy delivered in cervical region 3 times per week for four weeks
214260896|NCT06706479|DEVICE|high-definition transcranial direct current stimulation|High-definition transcranial direct current stimulation is a novel non-invasive brain stimulation technique based on the principle that when weak intensity electric currents are targeted on specific areas of the scalp, they cause underlying cortical stimulation. The anode increases cortical excitability, while cathode decreases cortical excitability.
214260897|NCT06709742|OTHER|Gross Motor Function Measure-88 Based Therapy|Children will be assessed initially by using GMFM-88 and selecting specific items for individuals according to his/her needs with the help of experts and family. At least 3 items will be selected for each subject in which they score less such that 0, 1 or 2. Training based on those specific items will be given to the children. This is goal-oriented training in which, according to the needs of children training will be provided.
214260898|NCT06707597|OTHER|Patient Interaction Group|No interventions or procedures will be applied to the patients. To evaluate whether the pain, anxiety, and comfort of patients undergoing the same surgical procedure are influenced by each other, the average scale scores of patients in double and single rooms will be compared.
214653759|NCT04334382|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.
214653760|NCT04334382|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
214260899|NCT06709105|OTHER|Kinesiotape|The application was performed using 5 cm x 5 m kinesio tape material. After preparing the standing patient in terms of clothing and skin readiness, the patient was asked to lean forward. To adhere the tape to the right paravertebral region, the lower end of the tape was first adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. Then, while the patient was leaning forward, a slight rotation to the left was requested, and in this position, the tape was adhered upwards along the paravertebral muscles without any tension. When applying the tape to the left paravertebral region, the same procedure was mirrored as on the right, with the tape again applied without any tension. The third tape was applied while the patient was standing upright and leaning slightly forward, placed over the sacroiliac joints and parallel to the floor, stretching the tape by 25%.
214260900|NCT06709105|OTHER|Sham (no implant)|Sham Kinesio taping was applied to the patients in the control group. In this sham protocol, Kinesio bands were attached between the 12th rib on both sides and the corresponding sacroiliac joint, passing over the paravertebral muscles without employing any specific banding technique. The third tape was adhered between both sacroiliac joints, also without any adhesive technique. Patients were inquired about any discomfort and informed that the tapes would remain in place until the second session.
214260901|NCT06706843|BEHAVIORAL|Transtheoretical Model Based Motivational Interviewing|Transtheoretical Model Based Motivational Interviewing was applied to haemodialysis patients in 6 sessions.
214260902|NCT06706843|OTHER|routine clinical care|routine clinical care
214260903|NCT04538053|DRUG|Oral cefalexin only|High-dose oral cefalexin
214260904|NCT04538053|DRUG|IV cefazolin or IV flucloxacillin followed by oral cefalexin|Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
214260905|NCT02875132|DRUG|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
214260906|NCT06460922|PROCEDURE|Radial osteotomy|3D printing models and personalized guides in surgical planning in distal radius osteotomies for Kienböck´s disease. Osteosynthesis with a plate in distal radius.
214260907|NCT06929390|PROCEDURE|BTVA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the BTVA group will undergo BTVA treatment.
214260908|NCT06929390|PROCEDURE|MWA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the MWA group will undergo MWA treatment.
214260909|NCT05283382|DRUG|Cannabidiol Oral Product|Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
214260910|NCT05283382|OTHER|Placebo|Participants will receive a one-time dose of placebo capsules in the form of six capsules.
214260911|NCT03524352|OTHER|fecal microbiota|fecal microbiota in suspension
214260912|NCT03524352|OTHER|Placebo|sterile saline
214260913|NCT06913569|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
214260914|NCT06913569|PROCEDURE|EBUS-TTFB|Participants with lymphadenopathy would receive EBUS-TTFB attempts to conduct diagnoses.
214260915|NCT06921655|PROCEDURE|Variation of Pressure Support Levels|Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).
214260916|NCT06933823|BEHAVIORAL|Dietary modification intervention involving family support|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The participants will be asked to invite one of their family members to attend the sessions together. Family members will be engaged in discussions to help enhance the participant's adherence to the recommended diet regimen. The aims of the sessions are to raise awareness among participants and their families about sarcopenia obesity and the recommended dietary modifications, emphasizing the critical role of family in supporting adherence to these changes. It also focuses on boosting participants' motivation, reducing barriers to dietary adjustments, and enhancing family-driven social support to help sustain long-term adherence to the prescribed regimen.
214260917|NCT06933823|BEHAVIORAL|Dietary modification intervention|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The sessions will only focus on educating the participants on following the dietary regimen and addressing the barriers they may encounter during dietary modification without family involving in the intervention.
214260918|NCT00219167|DRUG|aliskiren|
214260919|NCT03246984|DEVICE|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
214260920|NCT04387721|OTHER|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
214260921|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
214260922|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
214260923|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
214260924|NCT06401707|DRUG|Perampanel|Perampanel is a non-competitive AMPA glutamate receptor antagonist.
214260925|NCT06401707|DRUG|Placebo|Placebo
214260926|NCT06489925|DRUG|Cerebrolysin|The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
214260927|NCT02515448|DRUG|gentamicin|
214260928|NCT02598960|DRUG|BMS-986156|
214260929|NCT02598960|DRUG|Nivolumab|
214260930|NCT04716088|DIAGNOSTIC_TEST|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
214653761|NCT01247311|DIETARY_SUPPLEMENT|Dietary supplement|Placebo given orally 3xweek for six months
214260931|NCT03220984|BIOLOGICAL|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
214260932|NCT02597868|DRUG|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
214260933|NCT02597868|PROCEDURE|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
214260934|NCT02641132|DRUG|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
214260935|NCT02641132|PROCEDURE|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
214260936|NCT02165709|PROCEDURE|Salpingectomy|
214260937|NCT02165709|PROCEDURE|Traditional sterilization|
214260938|NCT05617443|DEVICE|stackable guide|different types of stackable guide
214260939|NCT03243942|DRUG|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
214260940|NCT00108433|DRUG|Cefazolin IV|
214260941|NCT00108433|DRUG|Linezolid IV|
214260942|NCT00108433|DRUG|Vancomycin (IV)|
214260943|NCT02319512|OTHER|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
214260944|NCT02319512|OTHER|Glucose|12ml glucose solution (13,6g) per day
214260945|NCT03473951|DIAGNOSTIC_TEST|Hyperuricemia|Hyperuricemia vs. normouricemia
214260946|NCT05399654|DRUG|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
214260947|NCT02322073|PROCEDURE|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
214260952|NCT06556628|DEVICE|Increased Body Temperatures|Collecting data on patients whose body temperatures increase due to fighting an illness.
214260953|NCT02753933|OTHER|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
214260954|NCT02753933|OTHER|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
214260955|NCT06558058|DRUG|Rivaroxaban 10 mg film-coated tablet|One tablet of the test drug was given orally after an overnight fast.
214260956|NCT06558058|DRUG|Xarelto 10 mg film-coated tablet|One tablet of the reference drug was given orally after an overnight fast.
214260957|NCT03047876|PROCEDURE|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
214260958|NCT05377879|DEVICE|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
214260959|NCT04195906|DRUG|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
214260960|NCT04195906|DRUG|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
214653762|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
214260961|NCT04195906|DRUG|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
214260962|NCT04418674|DRUG|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
214260963|NCT04418674|DRUG|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
214260964|NCT03127046|DRUG|Aceclofenac|Oral single dose administration of aceclofenac 200mg
214260965|NCT03127046|DRUG|Esomeprazole|Oral single dose administration of aceclofenac 200mg
214260966|NCT03127046|DRUG|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
214260967|NCT04725422|DRUG|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260968|NCT04725422|DRUG|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260969|NCT04725422|DRUG|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214653763|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
214653764|NCT05219422|BEHAVIORAL|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
214653765|NCT05219422|BEHAVIORAL|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
214653766|NCT05690659|OTHER|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
214260970|NCT04725422|DRUG|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260971|NCT04725422|DRUG|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260972|NCT04725422|DRUG|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260973|NCT04725422|DRUG|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260974|NCT04725422|DRUG|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260975|NCT04725422|DRUG|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260976|NCT04725422|DRUG|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
214260977|NCT04725422|DRUG|NSAID|first-line treatment
214260978|NCT02006888|DRUG|IBI-10090|
214260979|NCT02006888|DRUG|Placebo|Placebo
214260980|NCT05204251|BEHAVIORAL|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
214260981|NCT02554695|DRUG|placebo|subcutaneous saline injection
214260982|NCT02554695|DRUG|denosumab|single subcutaneous injection of denosumab 60 mg
214260983|NCT03485391|BEHAVIORAL|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
214260984|NCT02649270|BIOLOGICAL|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
214260985|NCT00371826|DRUG|Everolimus (RAD001)|
214260986|NCT00371826|DRUG|Cyclosporine (Calcineurin Inhibitor (CNI))|
214260987|NCT00371826|DRUG|Methylprednisone/prednisone|
214260988|NCT00371826|DRUG|Mycophenolate sodium (MPA)|
214260989|NCT05682365|BEHAVIORAL|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
214260990|NCT01137396|DRUG|Modafinil|Modafinil 400mg PO QDaily following up-titration for \~8weeks
214260991|NCT01137396|BEHAVIORAL|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
214260992|NCT00734474|DRUG|LY2189265|
214260993|NCT00734474|DRUG|Sitagliptin|
214260994|NCT00734474|DRUG|Placebo solution|
214260995|NCT00734474|DRUG|Placebo tablet|
214260996|NCT00734474|DRUG|Metformin|
214260997|NCT02488161|OTHER|No intervention|
214260998|NCT01601860|OTHER|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);"
214260999|NCT01601860|OTHER|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
214653767|NCT03114449|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
214653768|NCT03114449|DEVICE|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
214653769|NCT01576211|GENETIC|DNA methylation analysis|
214653770|NCT01576211|GENETIC|RNA analysis|
214261000|NCT05652881|PROCEDURE|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
214261001|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
214261002|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
214261003|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
214261004|NCT00942448|OTHER|Placebo s.c.|1 single injection at day of dental surgical extraction
214261005|NCT04497935|DRUG|PLENVU|Bowel preparation for a colonoscopy
214261006|NCT04497935|DRUG|MoviPrep|Bowel preparation for a colonoscopy
214261007|NCT03089320|BEHAVIORAL|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
214261008|NCT03089320|BEHAVIORAL|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
214261009|NCT03089320|BEHAVIORAL|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
214653771|NCT01576211|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
214653772|NCT01576211|GENETIC|gene expression analysis|
214261010|NCT04775069|BIOLOGICAL|BNT162b2|Intramuscular injection
214261011|NCT04775069|BIOLOGICAL|CoronaVac|Intramuscular injection
214261012|NCT04775069|BIOLOGICAL|AZD1222|Intramuscular injection
214261013|NCT00385762|DRUG|paroxetine|paroxetine 10-40mg daily x 5 weeks
214261014|NCT03100097|DEVICE|Aspen Horizon 627 LSO|
214261015|NCT06222190|RADIATION|online-adaptive radiotherapy|A conebeam CT is taken to determine the current tumour extent and the deformations occurring in comparison to the dose distribution to be applied. Normal tissues heart, lung and tracheal tree are automatically contoured by the Ethos therapy system in that cone-beam CT. A specialist physician and a physicist are present during this process. These organ contours are used to determine the extent of the current target volume and the adaptive radiotherapy plan is adjusted to the new target volume. If the current tumour extent is not sufficiently covered by the initial radiotherapy plan planned for the series with its planned tolerances, or if the surrounding normal tissue is exposed to too much radiation, then the online adaptive radiotherapy plan for the current treatment is selected by the specialist. Otherwise, the initial radiotherapy plan is used for IGRT.
214261016|NCT04047329|OTHER|general anesthesia or neuraxial anesthesia|
214261017|NCT05508711|DEVICE|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
214261018|NCT06463834|DRUG|Sintilimab|"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"
214261019|NCT05218135|OTHER|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
214261020|NCT01164800|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
214261021|NCT01164800|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
214261022|NCT03402646|BEHAVIORAL|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
214261023|NCT03402646|BEHAVIORAL|Photovoice|Same as described under arm/group descriptions
214261024|NCT00573183|BEHAVIORAL|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
214261025|NCT00573183|BEHAVIORAL|Treatment as Usual|
214261026|NCT01126801|DRUG|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
214261027|NCT01126801|OTHER|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
214261028|NCT00004488|DRUG|alendronate sodium|
214261029|NCT00004488|DRUG|calcium carbonate|
214261030|NCT00004488|DRUG|cholecalciferol|
214261031|NCT03994107|DRUG|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
214261032|NCT03994107|DRUG|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
214261033|NCT03994107|DRUG|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
214261034|NCT01805375|DRUG|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
214261035|NCT04467606|BEHAVIORAL|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
214261036|NCT00428792|DRUG|Methylphenidate 20 mg long-acting capsules|
214261037|NCT04816266|DEVICE|Iol master|Iol master measures the distance between anterior pole of the cornea and the anterior surface of the lens to calculate the anterior chamber depth
214261038|NCT04816266|DEVICE|Pentacam|The Pentacam HR calculates Anterior chamber depth from the corneal endothelial layer along a line from the apex of the cornea to the anterior surface of the lens
214261039|NCT06389500|DRUG|Adebrelimab|Adebrelimab, IV
214261040|NCT06389500|DRUG|Lenvatinib|Lenvatinib, PO
214261041|NCT06389500|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|GC regimen±5-FU
214261042|NCT02570074|DRUG|Fosfomycin|Broad spectrum antibiotic
214261043|NCT01251939|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
214261044|NCT02531204|DRUG|ASP1585|oral
214261045|NCT04676178|DRUG|PRA023|PRA023
214261046|NCT04676178|OTHER|Placebo|Placebo
214261047|NCT05259514|DEVICE|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
214261048|NCT00804284|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
214261049|NCT00804284|BIOLOGICAL|Other DTap Vaccines|0.5 mL, Intramuscular
214261050|NCT05170464|BEHAVIORAL|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
214261051|NCT05170464|DRUG|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
214653773|NCT01576211|GENETIC|nucleic acid sequencing|
214653774|NCT01576211|GENETIC|polymorphism analysis|
214653775|NCT01576211|OTHER|laboratory biomarker analysis|
214261052|NCT05027464|BEHAVIORAL|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
214261053|NCT06516822|PROCEDURE|CPVI-MLA|The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.
214261054|NCT06516822|PROCEDURE|CPVI only|After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
214261055|NCT05361161|DRUG|Transarterial Chemoembolization|Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
214261056|NCT03154593|OTHER|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
214261057|NCT00244283|DRUG|Sevoflurane|
214261058|NCT00244283|PROCEDURE|High thoracic epidural analgesia|
214261059|NCT02646514|DEVICE|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
214261060|NCT02646514|DEVICE|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
214261061|NCT06406790|DEVICE|CraniSeal|CraniSeal is a PEG Dural Sealant
214261062|NCT06406790|DEVICE|DuraSeal|DuraSeal is a PEG Dural Sealant
214261063|NCT05901311|DRUG|LY3537982|Administered orally.
214261064|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered orally.
214261065|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered IV.
214261066|NCT05476536|BEHAVIORAL|self-management skills and healthy technology APP|self-management skills and healthy technology APP
214261067|NCT03652883|OTHER|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
214261068|NCT03652883|OTHER|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
214261069|NCT02298985|DRUG|Curcumin|3 g/day (3 capsules/day) for 6 months
214261070|NCT02298985|DRUG|placebo|3 g/day (3 capsules/day) for 6 months
214261071|NCT01459237|DRUG|Acthrel|Ovine Corticorelin
214261072|NCT01953861|DRUG|EC905|Oral
214261073|NCT00168701|DRUG|BG00012|
214261074|NCT04749667|OTHER|MSCs|Autologous bone-marrow derived mesenchymal stem cells
214261075|NCT04749667|DRUG|Saline|Isotonic saline
214261076|NCT01275456|PROCEDURE|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
214261077|NCT00268866|BEHAVIORAL|Education|
214261078|NCT03299270|OTHER|Questionnaires|Quality of Life and Functional recovery questionnaires
214261079|NCT05746962|DEVICE|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
214261080|NCT05746962|DEVICE|Navigation screen|ScopeGuide's 3D visualisation screen
214261081|NCT04512170|DRUG|HEC585|single or Mulltiple doses up to 10 days
214261082|NCT04512170|DRUG|placebo|single or Mulltiple doses up to 10 days
214261083|NCT04446572|BIOLOGICAL|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
214261084|NCT03824418|PROCEDURE|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
214653776|NCT04752384|DRUG|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
214261085|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
214261086|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
214261087|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
214261088|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
214261089|NCT00529984|BIOLOGICAL|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
214261090|NCT05254223|OTHER|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
214261091|NCT05254223|OTHER|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
214261092|NCT05594810|BEHAVIORAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
214261093|NCT05594810|BEHAVIORAL|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
214261094|NCT01331733|DRUG|hMG-HP|
214261095|NCT01331733|DRUG|hMG + GnRH antagonist|
214261096|NCT04553354|PROCEDURE|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
214261097|NCT00882466|DRUG|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
214261098|NCT00269594|DRUG|Lamictal (lamotrigine)|
214261099|NCT02288598|DEVICE|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
214261100|NCT02288598|BEHAVIORAL|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
214261101|NCT00608972|DRUG|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
214261102|NCT00608972|DRUG|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
214261103|NCT00608972|DRUG|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
214261104|NCT04812730|OTHER|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
214261105|NCT04812730|OTHER|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
214261106|NCT04812730|OTHER|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
214261107|NCT04812730|OTHER|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
214261108|NCT01039844|DRUG|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
214261109|NCT00251173|BEHAVIORAL|Strengths Based Case Management (SBCM)|
214261110|NCT00251173|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
214261111|NCT00251173|BEHAVIORAL|Brief Informational Feedback (BIF) session|
214261112|NCT00336154|DRUG|tetracyclin|
214261113|NCT04027829|DRUG|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
214261114|NCT03048474|DRUG|nivolumab and ipilimumab|
214653777|NCT04752384|DRUG|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
214261115|NCT05133908|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
214261116|NCT05133908|BEHAVIORAL|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
214261117|NCT03270644|DRUG|Lasmiditan|Administered orally
214261118|NCT03270644|DRUG|Propranolol|Administered orally
214261119|NCT04066647|DRUG|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
214261120|NCT00354614|DEVICE|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
214261121|NCT02624960|DEVICE|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
214261122|NCT04613050|OTHER|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
214261123|NCT04613050|OTHER|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
214261124|NCT02915796|BIOLOGICAL|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
214261125|NCT02915796|BIOLOGICAL|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
214261126|NCT02915796|PROCEDURE|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
214261127|NCT02915796|BIOLOGICAL|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
214261128|NCT01500031|DEVICE|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
214261129|NCT02657538|OTHER|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
214261130|NCT02657538|OTHER|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
214261131|NCT02657538|DEVICE|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
214261132|NCT02657538|OTHER|Visual examination and bitewing (BW) radiography|established diagnostic methods
214261133|NCT04894448|BIOLOGICAL|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
214261134|NCT01903174|DEVICE|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
214261135|NCT01907581|OTHER|Quality of life questionnaires|
214261136|NCT03169543|BEHAVIORAL|Sleep deprivation|36-hours total sleep deprivation
214261137|NCT02100800|OTHER|MR and CT measurements of emphysema quantification|
214261138|NCT00815607|DRUG|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
214261139|NCT00815607|BIOLOGICAL|INXN-3001|Intratumoral injection
214261140|NCT01856907|DRUG|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
214261141|NCT01856907|DRUG|Metformin|Biguanide- insulin sensitizer
214653778|NCT04752384|DEVICE|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
214261142|NCT01856907|DRUG|Placebo pill|Will evaluate effect of lifestyle and diet only
214261143|NCT02927327|DEVICE|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
214261144|NCT02927327|DEVICE|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
214261145|NCT00844584|PROCEDURE|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
214261146|NCT00569465|DRUG|Arginine|1200 mg, once a day
214261147|NCT00569465|DRUG|Acetylcysteine|600 mg twice a day
214261148|NCT00569465|DRUG|Placebo|3 vials a day
214261149|NCT04624854|DRUG|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
214261150|NCT04624854|DRUG|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
214261151|NCT04489797|DRUG|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
214261152|NCT04489797|DRUG|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
214261153|NCT01604408|BIOLOGICAL|LY2495655|Administered SC
214261154|NCT01604408|DRUG|Placebo|Administered SC
214261155|NCT03711318|DRUG|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
214261156|NCT00804622|DRUG|telbivudine|daily oral administration,600mg,over 12 weeks
214261157|NCT00804622|DRUG|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
214261158|NCT00804622|DRUG|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
214261159|NCT00917501|DRUG|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
214261160|NCT00917501|DRUG|Placebo|Placebo given twice a day which will be compared to Omega 3
214261161|NCT00581243|DRUG|SLV-313 SR|sustained relase tablets taken once daily for 14 days
214261162|NCT00903318|BEHAVIORAL|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
214261163|NCT02008175|RADIATION|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
214261164|NCT06557694|OTHER|Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
214261165|NCT05288478|COMBINATION_PRODUCT|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
214261166|NCT02148159|DEVICE|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
214261167|NCT02148159|DEVICE|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
214261168|NCT00394160|DRUG|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
214261169|NCT06465095|GENETIC|Baseline|Measurements and sampling
214261170|NCT03722069|OTHER|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
214261171|NCT03722069|OTHER|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
214261172|NCT01387620|DRUG|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
214261173|NCT00000471|BEHAVIORAL|diet, vegetarianism|
214261174|NCT00000471|BEHAVIORAL|diet, fat-restricted|
214261175|NCT00000471|BEHAVIORAL|exercise|
214261176|NCT00000471|BEHAVIORAL|smoking cessation|
214261177|NCT05920694|DEVICE|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
214261178|NCT05920694|OTHER|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
214261179|NCT00236444|DRUG|risperidone|
214261180|NCT00227929|PROCEDURE|Care Management|
214261181|NCT03785938|DIETARY_SUPPLEMENT|Probiotic|Liquid probiotic supplied by the company Symprove
214261182|NCT03785938|OTHER|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
214261183|NCT01781364|BEHAVIORAL|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
214261184|NCT05095454|DEVICE|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
214261185|NCT05095454|DEVICE|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
214261186|NCT03464877|OTHER|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
214261187|NCT05840640|DRUG|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
214261188|NCT05840640|DRUG|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
214261189|NCT05840640|DRUG|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
214261190|NCT04943718|BIOLOGICAL|personalized vaccine|Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
214261191|NCT03227185|DEVICE|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
214261192|NCT03227185|DEVICE|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
214261193|NCT04974983|OTHER|Observation of neurological deficits|Observation of neurological deficits
214261194|NCT00425347|DRUG|HuLuc63|Not applicable for HuLuc63.
214261195|NCT06302478|BEHAVIORAL|5E program|"Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission"
214261196|NCT02470416|DEVICE|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
214261197|NCT05175027|DRUG|hypochlorous acid|Randomize
214261198|NCT01365247|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
214261199|NCT01365247|BEHAVIORAL|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
214261200|NCT01365247|BEHAVIORAL|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
214261201|NCT02153333|PROCEDURE|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
214261202|NCT03254290|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
214261203|NCT03254290|BIOLOGICAL|Formocresol|Control group
214261204|NCT02566447|DEVICE|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
214261205|NCT02407418|OTHER|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
214261206|NCT02407418|OTHER|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
214261207|NCT03857399|DRUG|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
214261208|NCT02548416|PROCEDURE|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214261209|NCT02548416|PROCEDURE|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214261210|NCT03218709|COMBINATION_PRODUCT|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
214261211|NCT03218709|COMBINATION_PRODUCT|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
214261212|NCT03218709|COMBINATION_PRODUCT|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
214261213|NCT03218709|COMBINATION_PRODUCT|Placebo|The placebo tablets contained maltodextrin and tartrazine.
214261214|NCT00833820|PROCEDURE|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
214261215|NCT00833820|PROCEDURE|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
214261216|NCT03221699|OTHER|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
214261217|NCT03221699|OTHER|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
214261218|NCT01999114|DRUG|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
214261219|NCT01999114|DRUG|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
214261220|NCT01999114|DRUG|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
214261221|NCT01999114|DRUG|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
214261222|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
214261223|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
214261224|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
214261225|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
214261226|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
214261227|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
214261228|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
214261229|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
214261230|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
214261231|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
214261232|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
214261233|NCT04659720|DEVICE|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
214261234|NCT04659720|BEHAVIORAL|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
214261235|NCT06341101|DRUG|Perindopril|In case of side effects Perindopril will be replaced by Valsartan
214261236|NCT02437383|DRUG|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
214261237|NCT02437383|DRUG|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
214261238|NCT02722369|DRUG|Gemcitabine|Chemotherapy
214261239|NCT02722369|DRUG|Carboplatin|Chemotherapy
214261240|NCT02722369|DRUG|Etoposide|Chemotherapy
214261241|NCT02722369|DRUG|Hydroxychloroquine|Maintenance Agent
214261242|NCT03032133|PROCEDURE|Regional pain control|Regional pain catheter
214261243|NCT03032133|PROCEDURE|Local pain control|Local intraarticular pain catheter
214261244|NCT04336358|OTHER|Telemedicine|Telemedicine consultation online
214261245|NCT00794703|DRUG|micafungin (Mycamine)|Intravenous
214261246|NCT00794703|DRUG|itraconazole|oral
214261247|NCT00722423|BEHAVIORAL|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
214261248|NCT00722423|BEHAVIORAL|Usual Care Model|
214261249|NCT00643396|RADIATION|thoracic radiotherapy|
214261250|NCT01501370|DRUG|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
214261251|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
214261252|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
214261253|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
214261254|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
214261255|NCT04423510|PROCEDURE|Crystallized phenol treatment|
214653779|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
214261256|NCT00497315|DRUG|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
214261257|NCT00497315|RADIATION|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
214261258|NCT05133232|DEVICE|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
214261259|NCT00736814|DRUG|carboplatin|Given intravenously
214261260|NCT00736814|DRUG|docetaxel|Given intravenously
214261261|NCT00736814|DRUG|gemcitabine hydrochloride|Given intravenously
214261262|NCT00736814|DRUG|vinorelbine tartrate|Given intravenously
214261263|NCT03216642|DIAGNOSTIC_TEST|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
214261264|NCT06058026|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
214261265|NCT01274650|PROCEDURE|Indirect Calorimetry|Indirect Calorimetry
214261266|NCT05489757|DEVICE|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
214261267|NCT00239304|DRUG|Gefitinib|
214261268|NCT00239304|DRUG|Cisplatin|
214261269|NCT00239304|PROCEDURE|Radiotherapy|
214261270|NCT01923831|DRUG|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
214261271|NCT01923831|DRUG|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
214261272|NCT01954160|DEVICE|Symplicity Renal Denervation|Renal denervation
214261273|NCT04746196|OTHER|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
214261274|NCT03584061|PROCEDURE|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
214261275|NCT05085730|DEVICE|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
214261276|NCT04010032|DEVICE|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
214261277|NCT04010032|DEVICE|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
214261278|NCT01549600|DIETARY_SUPPLEMENT|psyllium|1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
214261279|NCT01549600|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
214261280|NCT01976676|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate|
214261281|NCT01976676|DIETARY_SUPPLEMENT|folic Acid|
214261282|NCT03507803|OTHER|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
214261283|NCT01419522|OTHER|Gait Training Method|Treadmill training at constant velocity
214261284|NCT03969732|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
214261285|NCT05469581|OTHER|A set of preventive interventions to improve adherence in vulnerable elderly people|"* reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
214261286|NCT05578911|OTHER|"medical students group"|medical student in general practice or in specialty medicine
214261287|NCT01453725|BIOLOGICAL|Golimumab|Golimumab 50 mg SC injection every 4 weeks
214261288|NCT01453725|BIOLOGICAL|Placebo|Placebo SC injection every 4 weeks
214261289|NCT03920787|DIETARY_SUPPLEMENT|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
214261290|NCT03920787|OTHER|Placebo|2 capsules every day for 1 month
214261291|NCT02309593|DEVICE|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
214261292|NCT04915898|OTHER|Oral Hygiene - teeth brushing|Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
214653780|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
214261293|NCT05842733|DRUG|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
214261294|NCT05842733|DRUG|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
214261295|NCT05842733|DRUG|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
214261296|NCT03239184|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
214261297|NCT03239184|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214261298|NCT01717911|DRUG|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
214261299|NCT01717911|DRUG|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
214261300|NCT01717911|DRUG|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
214261301|NCT01512212|PROCEDURE|biopsy|fnab
214261302|NCT02501226|OTHER|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
214261303|NCT02501226|BEHAVIORAL|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
214261304|NCT03841812|DRUG|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
214261305|NCT03841812|DRUG|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
214261306|NCT03841812|DRUG|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
214261307|NCT02903641|BEHAVIORAL|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
214261308|NCT02903641|BEHAVIORAL|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
214261309|NCT05600660|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
214261310|NCT05600660|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
214261311|NCT05600660|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
214261312|NCT01685892|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
214261313|NCT01685892|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
214261314|NCT01340612|DEVICE|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
214261315|NCT01340612|DEVICE|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
214261316|NCT02736760|DRUG|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
214261317|NCT02736760|PROCEDURE|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
214261318|NCT04164355|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
214261319|NCT01248208|BIOLOGICAL|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
214261320|NCT01248208|BIOLOGICAL|"Intramuscular influenza injection (flu shot)"|"Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
214261321|NCT03656770|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
214261322|NCT06246175|DRUG|HRS9531|Receive a single dose of HRS9531 injection
214261323|NCT05962437|DEVICE|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
214261324|NCT05962437|DEVICE|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
214261325|NCT05962437|BEHAVIORAL|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
214261326|NCT05929053|OTHER|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
214261327|NCT02910869|GENETIC|Pathway Genomics FIT test|
214261328|NCT04683562|OTHER|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
214261329|NCT04683562|OTHER|at delivery|women delivered at term
214261330|NCT06247423|DEVICE|Active group 10kHz|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group."
214261331|NCT06247423|DEVICE|Sham intervention|"Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
214261332|NCT03606629|DEVICE|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
214261333|NCT03361254|BIOLOGICAL|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
214261334|NCT03605212|DRUG|Febuxostat|Intervention is orally administered to patients in this arm.
214261335|NCT06449898|OTHER|hemodialysis group|Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.
214261336|NCT03369470|BEHAVIORAL|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
214261337|NCT03369470|BEHAVIORAL|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
214261338|NCT01756053|DRUG|ABT-089|Selective neuronal nicotinic receptor agonist.
214261339|NCT01756053|DRUG|Placebo|Matched placebo capsules supplied by study drug supplier.
214261340|NCT03997604|DEVICE|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
214261341|NCT04090073|PROCEDURE|Electroacupuncture|As above
214261342|NCT04090073|OTHER|Fast-track Perioperative program|As above
214261343|NCT05118243|OTHER|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
214261344|NCT05118243|OTHER|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
214261345|NCT01986140|DEVICE|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
214261346|NCT01986140|OTHER|Control No treatment|No treatment to prevent hair loss
214261347|NCT04802070|DRUG|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
214261348|NCT04573998|PROCEDURE|LSG|bariatric surgery
214261349|NCT04447378|DRUG|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
214261350|NCT03453411|OTHER|Non interventional study|Non interventional study
214261351|NCT03853343|DIETARY_SUPPLEMENT|Seaweed extract|1 capsule 3 times per day
214261352|NCT03853343|DIETARY_SUPPLEMENT|Placebo|1 capsule 3 times per day
214261353|NCT00452478|DRUG|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
214261354|NCT04288271|BEHAVIORAL|Adherence Intervention|"Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
214261355|NCT04288271|OTHER|Healthy living education intervention|"Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
214261356|NCT01527318|DRUG|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
214261357|NCT03576222|DEVICE|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
214261358|NCT03576222|DEVICE|MEPORE dressing|MEPORE dressing
214261359|NCT05420727|DRUG|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
214261360|NCT05420727|DRUG|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
214261361|NCT03903601|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
214261362|NCT03903601|DIAGNOSTIC_TEST|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
214261363|NCT03903601|DIAGNOSTIC_TEST|Neuropsychological tests|Cognitive functions assessment
214261364|NCT04048122|BEHAVIORAL|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
214261365|NCT04048122|BEHAVIORAL|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
214261366|NCT00351546|DRUG|Vildagliptin|
214261367|NCT00135044|PROCEDURE|intravenous taurine in nutritional supplement|
214261368|NCT04426708|DRUG|HMS5552|single dose of HMS5552 25mg
214261369|NCT00411437|DRUG|Tolterodine ER|
214261370|NCT00411437|DRUG|Oxybutynin ER|
214261371|NCT05812274|OTHER|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
214261372|NCT05577871|DRUG|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
214261373|NCT05577871|DRUG|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
214261374|NCT04771884|DRUG|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
214261375|NCT01069627|DRUG|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
214261376|NCT01069627|DRUG|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
214261377|NCT02863276|PROCEDURE|Intensified insulin therapy|
214261378|NCT02061618|BEHAVIORAL|Bollywood Dance Exercise|
214261379|NCT00471146|DRUG|AG-013736|oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
214261380|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
214261381|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
214261382|NCT00471146|DRUG|placebo|placebo
214261383|NCT00412568|PROCEDURE|Photorefractive Keratectomy (PRK)|vision correction with PRK
214261384|NCT05213000|BEHAVIORAL|Exercise|90 minute exercise session
214261385|NCT04196751|OTHER|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
214261386|NCT01333579|OTHER|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
214261387|NCT00005602|DRUG|carboplatin|
214261388|NCT00005602|DRUG|cereport|
214261389|NCT00005602|RADIATION|radiation therapy|
214261390|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day screener|See descriptions
214261391|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day information sheet|See descriptions
214261392|NCT02942875|OTHER|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
214261393|NCT02942875|OTHER|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
214261394|NCT00085904|DRUG|SB-485232|
214261395|NCT06345131|OTHER|Non invasive blood pressure monitoring|Non invasive blood pressure monitoring
214261396|NCT05073978|OTHER|No intervention|This is an observational study without any intervention
214261397|NCT05027672|DRUG|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
214261398|NCT05657431|OTHER|essential oils (Ylang ylang oil)|inhaler aromatherapy
214261399|NCT05657431|OTHER|placebo (saline solutions)|placebo saline solutions
214261400|NCT05657431|OTHER|essential oils (lemon oil)|inhaler aromatherapy
214261401|NCT02149875|DRUG|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
214261402|NCT02149875|DRUG|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
214261403|NCT02149875|DRUG|Placebo|100 ml saline intravenous infusion once daily for 10 days.
214261404|NCT02478372|DRUG|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
214261405|NCT02478372|DRUG|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
214261406|NCT03503136|DRUG|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
214261407|NCT03503136|DRUG|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
214261408|NCT03503136|DRUG|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
214261409|NCT03503136|DRUG|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
214261410|NCT03503136|DRUG|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
214261411|NCT03503136|DRUG|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
214261412|NCT02643290|DEVICE|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
214261413|NCT01529684|DRUG|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
214261414|NCT01529684|DRUG|OSI-906|Part B: oral tablets OSI-906
214261415|NCT04234451|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
214261416|NCT04234451|PROCEDURE|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
214261417|NCT05399303|PROCEDURE|obturation|obturation using different types of sealers
214261418|NCT00698984|DIETARY_SUPPLEMENT|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
214261419|NCT00698984|DIETARY_SUPPLEMENT|Placebo|2 capsules per day over a period of 6 months
214261420|NCT04483973|DRUG|Ebselen|Glutathione peroxidase mimetic
214261421|NCT04483973|DRUG|Placebo|Matching placebo containing excipients
214261422|NCT02810977|DEVICE|Ultrasound|Ultrasound assessment of gastric content and volume
214261423|NCT03339687|BEHAVIORAL|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
214261424|NCT06243484|DIETARY_SUPPLEMENT|TOTUM-070|12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
214261425|NCT06243484|DIETARY_SUPPLEMENT|PLACEBO|8 capsules per day to consume orally in two intakes
214261426|NCT04644991|OTHER|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
214261427|NCT04644991|OTHER|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
214261428|NCT04644991|OTHER|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
214261429|NCT00005878|DRUG|celecoxib|
214261430|NCT02002273|PROCEDURE|Switching level of suction|
214261431|NCT05192473|DEVICE|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
214261432|NCT05421871|BEHAVIORAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
214261433|NCT05421871|BEHAVIORAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
214261434|NCT03821207|BEHAVIORAL|The exercise group|The students will make exercise during the first three days of the menstrual period
214261435|NCT03821207|BEHAVIORAL|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
214261436|NCT03821207|BEHAVIORAL|Control Group|The students will nor massage or exercise
214261437|NCT04836312|BEHAVIORAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
214261438|NCT05634915|DRUG|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
214261439|NCT05634915|DRUG|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
214261440|NCT00004364|DRUG|desmopressin|
214261441|NCT00812851|DRUG|Dronabinol|
214261442|NCT01768767|DRUG|Placebo|
214261443|NCT01768767|DRUG|Ketamine|
214261444|NCT01768767|DRUG|Ketamine/Lithium|
214261445|NCT02819869|DRUG|Statin and Metformin use|
214261446|NCT03860597|DRUG|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
214261447|NCT03860597|DRUG|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
214261448|NCT02940080|OTHER|Dietary|
214261449|NCT01931332|PROCEDURE|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
214261450|NCT01931332|PROCEDURE|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
214261451|NCT03800173|DRUG|galidesivir|galidesivir IV infusion
214261452|NCT03800173|DRUG|placebo|placebo IV infusion
214261453|NCT04737928|DRUG|Latanoprost|latanoprost 0.05%(one drop, once daily)
214261454|NCT04737928|DRUG|tafluprost|tafluprost 0.015% (one drop, once daily)
214261455|NCT02507973|OTHER|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
214261456|NCT02507973|OTHER|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
214261457|NCT00376376|DRUG|levofloxacin at 250, 500, 750, and 1000 mg doses|
214261458|NCT00140946|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
214261459|NCT00140946|DRUG|Comparator: placebo / Duration of Treatment: 16 weeks|
214261460|NCT04515446|DIAGNOSTIC_TEST|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
214261461|NCT04515446|DIAGNOSTIC_TEST|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
214261462|NCT03714308|DRUG|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
214261463|NCT02519465|OTHER|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min
214261464|NCT02519465|OTHER|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
214261465|NCT02519465|OTHER|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
214261466|NCT01074372|DRUG|REGN727|4 cohorts (dose 1, 2, 3, 4)
214261467|NCT01074372|DRUG|Placebo|4 cohorts (dose 1, 2, 3, 4)
214261468|NCT05820061|DIAGNOSTIC_TEST|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
214261469|NCT02372240|DRUG|VLX1570 and dexamethasone|
214261470|NCT03773380|COMBINATION_PRODUCT|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
214261471|NCT05567315|DRUG|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
214261472|NCT05567315|DEVICE|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
214653781|NCT02527356|BEHAVIORAL|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
214653782|NCT02796105|DRUG|Progevera|
214653783|NCT02796105|DRUG|Orgalutran|
214653784|NCT02921386|DRUG|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
214261473|NCT00002746|BIOLOGICAL|aldesleukin|
214261474|NCT02730689|DRUG|DP-R207|
214261475|NCT02730689|DRUG|Rosuvastatin|
214261476|NCT02730689|DRUG|Ezetimibe|
214261477|NCT06134960|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
214261478|NCT01162928|DRUG|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
214261479|NCT01162928|DRUG|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
214261480|NCT06279520|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
214261481|NCT06279520|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
214261482|NCT06279520|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
214261483|NCT06279520|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
214261484|NCT00412997|DRUG|LBH589|
214261485|NCT01443273|OTHER|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
214261486|NCT00003976|DRUG|indisulam|
214261487|NCT01674283|DRUG|Glucagon|
214261488|NCT01674283|DRUG|placebo|
214261489|NCT05285657|DIAGNOSTIC_TEST|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~* PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~* PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~* PfHRP2(-)/pLDH(-): negative results~* PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~* If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~* If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
214261490|NCT03090438|PROCEDURE|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
214261491|NCT04997278|DEVICE|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006)."
214261492|NCT02228434|BEHAVIORAL|Monitoring and Tailored prescription|
214261493|NCT02228434|BEHAVIORAL|Happy 10 program|
214261494|NCT02228434|BEHAVIORAL|Specified nutrition education|
214261495|NCT02228434|BEHAVIORAL|General Health Education|
214261496|NCT02263209|DEVICE|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
214261497|NCT02263209|DEVICE|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
214261498|NCT03203070|DRUG|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
214261499|NCT03203070|PROCEDURE|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
214261500|NCT02759874|DEVICE|specialized breathalyzer w face recognition technology|
214261501|NCT00913575|OTHER|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
214261502|NCT00913575|BEHAVIORAL|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
214261503|NCT04993560|BIOLOGICAL|BBIBP-CorV|Inactivated virus COVID-19 vaccine
214261504|NCT04993560|BIOLOGICAL|BNT162b2|mRNA-based COVID-19 vaccine
214261505|NCT04958668|OTHER|Post-operative intensive care using volatile sedation|Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
214261506|NCT04160962|PROCEDURE|lappg|Laparoscopic gastrectomy for pylorus preservation
214261507|NCT01090284|DEVICE|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
214261508|NCT00910273|DRUG|etanercept|etanercept 50 mg/week
214261509|NCT00754988|DRUG|Metformin|As prescribed
214261510|NCT00754988|DRUG|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
214261511|NCT00754988|DRUG|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
214261512|NCT00754988|DRUG|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
214261513|NCT00754988|DRUG|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
214261514|NCT01596387|DRUG|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
214261515|NCT05965778|DEVICE|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
214261516|NCT05965778|DEVICE|Vismed® Multi|Hyaluronic acid
214261517|NCT06098274|BEHAVIORAL|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
214261518|NCT01923987|RADIATION|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
214261519|NCT01923987|DRUG|Chemotherapy|"* Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
214261520|NCT01923987|PROCEDURE|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
214261521|NCT05592951|DIETARY_SUPPLEMENT|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
214261522|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
214261523|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
214261524|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
214261525|NCT03091933|BIOLOGICAL|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
214261526|NCT04953351|PROCEDURE|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
214261527|NCT04953351|PROCEDURE|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
214261528|NCT03989765|OTHER|Programme to reduce involuntary treatment episodes|See description of trial arms
214261529|NCT00195546|DRUG|DVS-233|
214261530|NCT03841448|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
214261531|NCT03841448|DRUG|Cemdisiran|Cemdisiran was administered by SC injection.
214261532|NCT00992277|PROCEDURE|Ablation and skin resurfacing|
214261533|NCT02152800|DRUG|valacyclovir hydrocholoride|
214261534|NCT00543543|BIOLOGICAL|Comparator: GARDASIL|GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
214261535|NCT00543543|BIOLOGICAL|Experimental: V503|V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
214653785|NCT01955707|DRUG|natalizumab|Administered as described in the treatment arm
214261536|NCT05148065|DEVICE|BIS|Bispectral index monitoring
214261537|NCT05148065|DEVICE|PSi|Patient state index monitoring
214261538|NCT04298515|DIAGNOSTIC_TEST|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
214261539|NCT04135742|DEVICE|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
214653786|NCT01955707|DRUG|Placebo|Matched placebo
214261540|NCT04135742|BEHAVIORAL|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
214261541|NCT04924205|DEVICE|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
214261542|NCT05666622|OTHER|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
214261543|NCT02121782|BIOLOGICAL|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
214261544|NCT02121782|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
214261545|NCT03904732|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
214261546|NCT00115648|DRUG|Nevirapine|Oral NVP daily dosage
214261547|NCT00115648|DRUG|AZT|Oral AZT daily
214261548|NCT00115648|DRUG|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
214261549|NCT00115648|DRUG|NVP|Oral NVP daily to age 14 weeks
214261550|NCT00115648|DRUG|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
214261551|NCT01805128|OTHER|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
214261552|NCT01805128|OTHER|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
214653787|NCT01714466|DRUG|NER1006|
214653788|NCT01714466|DRUG|MOVIPREP|
214653789|NCT01905956|DIETARY_SUPPLEMENT|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
214653790|NCT01905956|DIETARY_SUPPLEMENT|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
214653791|NCT01817790|DRUG|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
214653792|NCT01817790|DRUG|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
214653793|NCT03033329|DRUG|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
214261553|NCT01805128|OTHER|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
214261554|NCT02122432|OTHER|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
214261555|NCT01836965|BEHAVIORAL|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
214261556|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
214261557|NCT01361568|DRUG|Placebo|Single i.v. dose administered preoperatively
214261558|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
214261559|NCT01361568|DRUG|Placebo|Single i.v. dose administered postoperatively for pain
214261560|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
214261561|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
214261562|NCT01206075|DRUG|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
214261563|NCT06151132|PROCEDURE|Direct current cardioversion|Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
214261564|NCT01846390|DRUG|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
214261565|NCT01846390|DRUG|Dexamethasone|40 mg D1 - D4
214261566|NCT01846390|DRUG|Cisplatin|75 mg/m2 D1
214261567|NCT01846390|DRUG|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
214261568|NCT04905888|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
214261569|NCT04668573|OTHER|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
214261570|NCT02674776|DRUG|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
214653794|NCT03033329|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
214261571|NCT02674776|DRUG|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
214261572|NCT06180746|BEHAVIORAL|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
214261573|NCT02959983|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
214261574|NCT02959983|DRUG|Placebo|Placebo matching eluxadoline oral tablets BID with food.
214261575|NCT03951714|BEHAVIORAL|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
214261576|NCT00424450|PROCEDURE|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
214261577|NCT00424450|PROCEDURE|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
214261578|NCT01020149|OTHER|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
214261579|NCT04040946|DIAGNOSTIC_TEST|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
214261580|NCT04040946|DIAGNOSTIC_TEST|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
214261581|NCT02738034|OTHER|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
214261582|NCT04098848|OTHER|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
214261583|NCT00484094|DRUG|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
214261584|NCT02605070|DRUG|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
214261585|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 1|The product under investigation is a unique probiotic.
214261586|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 2|The product under investigation is a unique probiotic.
214261587|NCT03482765|OTHER|Placebo|Microcrystalline Cellulose
214261588|NCT00586625|DRUG|Bepreve|One drop, both eyes, twice a day
214261589|NCT00586625|DRUG|Placebo|One drop, both eyes, twice a day
214261590|NCT01047670|DRUG|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
214261591|NCT04128085|DRUG|TQB3804|A kind of tyrosine kinase inhibitor.
214261592|NCT05444101|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214261593|NCT05444101|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214261594|NCT05444101|BEHAVIORAL|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
214261595|NCT02635763|PROCEDURE|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
214261596|NCT02635763|PROCEDURE|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
214261597|NCT05352100|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
214261598|NCT05051995|DRUG|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
214261599|NCT05051995|OTHER|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
214261600|NCT06535425|OTHER|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
214261601|NCT06535425|OTHER|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
214261602|NCT06535425|OTHER|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
214261603|NCT06535425|OTHER|Control|Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
214653795|NCT03033329|DRUG|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
214653796|NCT03033329|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
214653797|NCT03033329|DRUG|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
214653798|NCT03137979|BIOLOGICAL|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
214653799|NCT03137979|BIOLOGICAL|Collagen scaffolds|Patients in this group were given collagen scaffolds.
214261604|NCT03316365|OTHER|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
214261605|NCT02465645|DRUG|Carvedilol|
214261606|NCT02465645|DRUG|Carvedilol + Simvastatin|
214261607|NCT02008578|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
214261608|NCT02008578|BIOLOGICAL|Placebo|
214261609|NCT04337385|BEHAVIORAL|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
214261610|NCT04337385|BEHAVIORAL|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
214261611|NCT00000574|DRUG|ibuprofen|
214261612|NCT01375426|DRUG|Oral amoxicillin|
214261613|NCT06365541|DRUG|Dapagliflozin|oral Dapagliflozin tablets 10mg/day for 6 months
214261614|NCT04680156|DRUG|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
214261615|NCT00603785|DRUG|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
214261616|NCT00603785|DRUG|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
214261617|NCT05991349|DRUG|IBI129|Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
214261618|NCT01736124|OTHER|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
214261619|NCT01736124|OTHER|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
214261620|NCT03206437|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
214261621|NCT03206437|BEHAVIORAL|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
214261622|NCT03553927|DIETARY_SUPPLEMENT|Low Energy Diet|Caloric restriction to achieve weight loss
214261623|NCT03553927|OTHER|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
214261624|NCT00531401|DRUG|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
214261625|NCT04346082|BEHAVIORAL|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
214261626|NCT04902131|DRUG|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
214261627|NCT04902131|DRUG|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
214261628|NCT00659750|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
214261629|NCT00659750|DRUG|Placebo|placebo
214261630|NCT05083468|DRUG|SR750 tablet|The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
214261631|NCT05083468|DRUG|matching placebo|The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
214261632|NCT05984472|PROCEDURE|Edelweiss prefabricated veneers|Individual Randomized Clinical Trial
214261633|NCT05984472|PROCEDURE|Ceram-X Duo SphereTec with U-Veneer|Ceram-X Duo SphereTec with U-Veneer
214261634|NCT06242600|DEVICE|Drainage of the bladder by indwelling Foley catheter|Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
214261635|NCT03242824|DRUG|Fluorine F 18 Fluorodopa|Contrast used in PET
214261636|NCT03242824|RADIATION|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
214261637|NCT03242824|PROCEDURE|Positron Emission Tomography|imaging test
214261638|NCT02887573|DRUG|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
214261639|NCT02887573|DRUG|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
214261640|NCT02887573|PROCEDURE|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
214261641|NCT02887573|DRUG|2L PEG|2L PEG are laxatives for experiment group.
214261642|NCT02887573|DRUG|4L PEG|4L PEG are laxatives in the control group.
214261643|NCT02887573|DRUG|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
214261644|NCT02887573|DRUG|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
214261645|NCT03342521|DIAGNOSTIC_TEST|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
214653800|NCT03137979|PROCEDURE|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
214261646|NCT04621565|DRUG|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
214261647|NCT04621565|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
214261648|NCT03903653|DRUG|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
214261649|NCT03903653|DEVICE|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
214261650|NCT03779958|OTHER|Mobile App|a mobile app that demonstrates hand therapy exercises
214261651|NCT02634749|OTHER|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
214261652|NCT02634749|OTHER|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
214261653|NCT02634749|OTHER|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
214261654|NCT04460456|DRUG|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
214261655|NCT04460456|DRUG|pembrolizumab|400 mg IV
214261656|NCT04460456|DRUG|Cemiplimab|350 mg IV
214261657|NCT04117139|DIAGNOSTIC_TEST|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
214261658|NCT01193842|DRUG|Cyclophosphamide|Given IV
214261659|NCT01193842|DRUG|Doxorubicin Hydrochloride|Given IV
214261660|NCT01193842|DRUG|Etoposide|Given IV
214261661|NCT01193842|OTHER|Laboratory Biomarker Analysis|Correlative studies
214261662|NCT01193842|OTHER|Pharmacological Study|Correlative studies
214261663|NCT01193842|DRUG|Prednisone|Given PO
214261664|NCT01193842|BIOLOGICAL|Rituximab|Given IV
214261665|NCT01193842|DRUG|Vincristine Sulfate|Given IV
214261666|NCT01193842|DRUG|Vorinostat|Given PO
214261667|NCT03698331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214261668|NCT03698331|DRUG|Placebo oral capsule|non-active dosage form
214261669|NCT01468103|PROCEDURE|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
214261670|NCT01468103|PROCEDURE|Laser Iridotomy|alternative choice to surgical iridectomy
214261671|NCT02362178|PROCEDURE|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
214261672|NCT02362178|PROCEDURE|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
214261673|NCT03862859|DRUG|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
214261674|NCT00185770|BEHAVIORAL|Reducing television and other screen time (SMART curriculum)|
214261675|NCT04966052|OTHER|No intervention|No intervention
214261676|NCT06033521|DRUG|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
214261677|NCT03423134|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive
214261678|NCT02715401|DRUG|HCP1303|
214261679|NCT02715401|DRUG|HGP1201|
214261680|NCT02715401|DRUG|HIP1402|
214261681|NCT02130024|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
214261682|NCT02130024|DRUG|Aflibercept 2.0 mg|Administered as an intravitreal injection
214261683|NCT01467583|DRUG|Fondaparinux|2.5 mg every 48 hours
214261684|NCT03848338|PROCEDURE|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
214261685|NCT02717273|DRUG|standard|peri-operative antibiotic regimen only
214261686|NCT02717273|DRUG|extended|extended three-day course of antibiotics
214261687|NCT02717273|OTHER|liver transplant|orthotopic liver transplantation
214261688|NCT02760576|DRUG|BAY 987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214261689|NCT05274165|DEVICE|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
214261690|NCT05274165|DEVICE|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
214261691|NCT01690429|DEVICE|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
214261692|NCT06934369|OTHER|Strategies to improve HIV care engagement|Based on the barriers to HIV care experienced by the pre-intervention cohort, we will design a system intervention to be implemented at the Radiotherapy Centre at Parirenyatwa Hospital. This intervention will include 2-3 components, each intended to improve engagement in HIV care or address specific barriers to HIV care. It may include strategies like improving documentation of HIV-related information in oncology patient records, improving processes for referrals and access to HIV-related prescriptions, and supporting better communication between oncology and HIV clinical care teams.
214261693|NCT06501690|BEHAVIORAL|Late bedtime|Participants will go to bed 1 hour later than their habitual bedtime
214261694|NCT06501690|BEHAVIORAL|Variable bedtime|Participants will go to bed at a prescribed time that varies each day within +/-1 hour of habitual bedtime
214261695|NCT00094029|DRUG|Sutent|Sutent, 25, 37.5, or 50 mg daily
214261696|NCT01982578|DIETARY_SUPPLEMENT|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
214261697|NCT01982578|OTHER|Placebo|360 days of double blind treatment of placebo.
214261698|NCT02562768|DRUG|LY3154207|Administered orally
214261699|NCT02562768|DRUG|Placebo|Administered orally
214261700|NCT01386008|DEVICE|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
214261701|NCT01386008|DEVICE|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
214261702|NCT03001882|BIOLOGICAL|Nivolumab|Specified dose on specified days
214261703|NCT03001882|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214261704|NCT06654258|BEHAVIORAL|Spiritual Self-Care Smartphone App|"Participants will be asked to engage with a commercially available spiritual self-care smartphone app on a daily basis for 6 weeks. The content spans several domains, including meditation, prayer, affirmations, movement (i.e., stretching and yoga), and music. The user experience is highly personalized, allowing the user to select content that matches their current: mood or needs (e.g., anxiety, loneliness, stress, self-esteem, and sleep), time of day (e.g., recommendations for morning and evening practices), and/or availability (e.g., very brief micro-interventions lasting no more than 90 seconds or longer activities up to 30 minutes in duration). The content is delivered via a combination of audio and visual modalities on a personal smartphone that can be toggled on and off to adjust to surroundings."
214261705|NCT00976677|DRUG|erlotinib hydrochloride|Given PO
214261706|NCT00976677|DRUG|paclitaxel|Given IV
214261707|NCT00976677|DRUG|carboplatin|Given IV
214261708|NCT00976677|BIOLOGICAL|bevacizumab|Given IV
214261709|NCT00485433|DRUG|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
214261710|NCT00485433|DRUG|SKY0402|SKY0402 given during hernia repair
214261711|NCT05633797|DEVICE|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
214261712|NCT06597760|DRUG|Enlicitide|Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
214261713|NCT06597760|DRUG|Digoxin|Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
214261714|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
214261715|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
214261716|NCT06002490|DRUG|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
214261717|NCT06002490|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
214261718|NCT06002490|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
214261719|NCT05961059|BIOLOGICAL|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
214261720|NCT05961059|BIOLOGICAL|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
214653801|NCT01671345|BEHAVIORAL|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
214261721|NCT05961059|BIOLOGICAL|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
214261722|NCT05961059|BIOLOGICAL|Placebo|Placebo vaccination with commercially available saline solution.
214261723|NCT01672762|DRUG|ipragliflozin|oral
214261724|NCT06597916|BIOLOGICAL|Arexvy powder and suspension for injection|Arexvy powder and suspension for injection (RSV vaccine)
214261725|NCT06592300|DRUG|Tenofovir Alafenamide Film coated Tablet|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
214261726|NCT06592300|DRUG|Vemlidy® film-coated tablets|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
214653802|NCT01671345|BEHAVIORAL|Control|Attention control
214653803|NCT05323422|PROCEDURE|intravenous Ketamine induction|preoperatively ketamine wll administer in group 1-3
214653804|NCT04007315|DEVICE|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
214653805|NCT04007315|BEHAVIORAL|Usual care|6-weeks of usual NHS care
214261729|NCT06668155|PROCEDURE|Autograft Group|If assigned the autograft group, the surgeon will choose either bone patella tendon bone (BPTB) or all soft tissue quadriceps tendon for the graft. The graft choice will be based upon surgeon preference.
214261730|NCT06668155|PROCEDURE|Allograft with LET Group|The allograft used will be a non-irradiated quadriceps tendon with bone plug allograft with a donor age less than 45 years.
214261731|NCT03553771|DEVICE|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
214261732|NCT06557031|DIAGNOSTIC_TEST|ABTest Card®REF and ABTest Card®NEW|Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device).
214261733|NCT04029506|OTHER||this is an obsevational study which needs no interventions
214261734|NCT03252860|OTHER|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
214261735|NCT03866031|OTHER|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
214261736|NCT05409495|PROCEDURE|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
214261737|NCT05409495|PROCEDURE|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
214261738|NCT05544812|DRUG|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
214261739|NCT01182610|DRUG|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
214261740|NCT01182610|DRUG|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
214261741|NCT01182610|DRUG|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
214261742|NCT01182610|DRUG|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
214261743|NCT01694264|DRUG|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
214261744|NCT01694264|DRUG|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
214261745|NCT03267836|DRUG|Avelumab|-10mg/kg IV
214261746|NCT03267836|RADIATION|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
214261747|NCT03267836|PROCEDURE|Surgery|-Standard of care
214261748|NCT02031796|OTHER|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
214261749|NCT03746171|DIAGNOSTIC_TEST|Colonic polyp characterization by BLI|"All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
214261750|NCT00546104|DRUG|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
214261751|NCT02050243|DRUG|5ALA|20mg/kg of oral suspension of 5ALA
214261752|NCT05225649|BEHAVIORAL|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
214261753|NCT04424810|OTHER|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
214261754|NCT04424810|OTHER|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
214261755|NCT02021032|DEVICE|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
214261756|NCT02114801|DEVICE|manual brushing|Tooth brushing
214261757|NCT02114801|DEVICE|electric toothbrush linked|Tooth brushing
214261758|NCT02114801|DEVICE|off electric toothbrush|Tooth brushing
214261759|NCT04068935|PROCEDURE|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
214261760|NCT06159790|DRUG|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
214261761|NCT06159790|DRUG|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
214261762|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
214261763|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
214261764|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
214261765|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
214261766|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
214261767|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
214261768|NCT00376064|DRUG|Octreotide acetate and cabergoline/Octrotide and Somavert|
214261769|NCT03356756|DIAGNOSTIC_TEST|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
214261770|NCT05550285|DEVICE|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
214261771|NCT01826773|DRUG|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
214261772|NCT05818098|DEVICE|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
214261773|NCT03660345|PROCEDURE|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
214261774|NCT03660345|DRUG|Intravitreal injection|Intravitreal ziv-Aflibercept
214261775|NCT06556303|OTHER|Acupressure|Acupressure
214261776|NCT01393301|BEHAVIORAL|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
214261777|NCT01393301|BEHAVIORAL|Control|Enhanced standard smoking cessation treatment and NRT.
214261778|NCT02758171|DRUG|Empagliflozin|
214261779|NCT02758171|DRUG|Linagliptin|
214261780|NCT00853073|DRUG|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
214261781|NCT00853073|OTHER|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
214261782|NCT05330572|OTHER|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
214261783|NCT02047383|OTHER|Respiratory infection|An assessment of the patients included in the study will be conducted
214261784|NCT02917850|PROCEDURE|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
214261785|NCT02917850|PROCEDURE|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
214261786|NCT05235477|PROCEDURE|Tube technique|"An excavator (smaller than the width of the defect; evaluated pre-surgically on a study model) is used to carefully reflect the papilla away from the alveolar bone and root surfaces on the buccal aspect to access the interproximal region to prepare the bed for the graft. The excavator is used to do the same on the palatal aspect. The amount of reflection should yield a very relaxed papilla flap that permits placement of the papilla at the new coronal position without tension. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect."
214261787|NCT02351375|OTHER|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
214261788|NCT02351375|DEVICE|IntelliCap® system|
214261789|NCT01842100|DRUG|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
214261790|NCT01842100|OTHER|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
214261791|NCT00053937|DRUG|pirfenidone|
214261792|NCT04297059|OTHER|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
214261793|NCT04882384|PROCEDURE|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
214261794|NCT03643575|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
214261795|NCT03643575|DRUG|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
214261796|NCT03643575|DRUG|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
214261797|NCT01309165|BEHAVIORAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
214261798|NCT01309165|BEHAVIORAL|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
214261799|NCT02103907|OTHER|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
214261800|NCT04709471|DRUG|Nicotine|Participants will reduce their nicotine intake
214261801|NCT04709471|DEVICE|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
214261802|NCT04709471|BEHAVIORAL|Reduction|Participants will reduce the number of Juul pods that they use
214261803|NCT02508857|DRUG|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
214261804|NCT02508857|DRUG|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
214261805|NCT02508857|DRUG|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
214653806|NCT05333094|OTHER|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
214261806|NCT03380715|DEVICE|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
214261807|NCT03380715|DEVICE|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
214261808|NCT05143541|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
214653807|NCT02065544|BEHAVIORAL|behavioral weight loss and exercise|Weight loss and exercise counseling
214653808|NCT04093596|GENETIC|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
214261809|NCT04336540|OTHER|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
214261810|NCT04336540|OTHER|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
214653809|NCT04093596|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214653810|NCT04093596|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214653811|NCT04093596|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214653812|NCT04093596|DRUG|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
214653813|NCT06170645|OTHER|APA program|An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
214653814|NCT06170645|OTHER|Active transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
214653815|NCT06170645|OTHER|Sham transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
214653816|NCT06654713|OTHER|Commercial AID system|AID system that is commercially available and FDA approved for use
214653817|NCT06654713|OTHER|Open source AID system|AID system that uses unregulated open-source software to customize an insulin delivery algorithm to connect an insulin pump to a continuous glucose monitor
214261811|NCT03081468|DEVICE|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
214261812|NCT03081468|DEVICE|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
214261813|NCT04099095|BEHAVIORAL|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
214261814|NCT04099095|BEHAVIORAL|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
214261815|NCT05877573|DRUG|Toripalimab|Toripalimab 240mg,d1,q3w
214261816|NCT05877573|RADIATION|short-term radiotherapy|25Gy/5Fx
214261817|NCT05877573|DRUG|Oxaliplatin|135mg/m2 d1 q3w
214261818|NCT05877573|DRUG|Capecitabine|1200mg/m2 d1-14 q3w
214261819|NCT01056029|DRUG|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
214261820|NCT02758314|OTHER|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
214261821|NCT03505554|DRUG|Lorlatinib|100 mg QD
214261822|NCT02410551|DRUG|Pacritinib|200 mg by mouth twice a day for 60 days.
214261823|NCT02410551|DRUG|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
214261824|NCT02410551|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
214261825|NCT02410551|BEHAVIORAL|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
214261826|NCT02410551|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
214261827|NCT02410551|DRUG|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
214261828|NCT00854542|BEHAVIORAL|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
214261829|NCT02315989|RADIATION|proton therapy|proton therapy
214261830|NCT05553314|DRUG|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
214261831|NCT05553314|DRUG|Placebo|patients randomized to placebo group will receive placebo.
214261832|NCT01792271|OTHER|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
214261833|NCT01739309|DRUG|Abemaciclib|Administered orally
214261834|NCT02337270|BIOLOGICAL|Ad5Ag85A|Aerosol administration of Ad5Ag85A
214261835|NCT04610385|PROCEDURE|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
214261836|NCT04786392|DIETARY_SUPPLEMENT|Lutein supplement|5 mg lutein supplement.
214261837|NCT04786392|OTHER|Food, blended|5 mg lutein from baby spinach, blended.
214261838|NCT04786392|OTHER|Food, unprocessed|5 mg lutein from baby spinach, in whole food form.
214261839|NCT04137627|DRUG|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
214261840|NCT04137627|DRUG|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
214261841|NCT03248336|PROCEDURE|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
214261842|NCT04112420|DIAGNOSTIC_TEST|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
214261843|NCT04945512|PROCEDURE|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
214261844|NCT05426772|OTHER|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
214261845|NCT06362070|DEVICE|DaVinci® Surgical System|Assisted-robotic radical Gastrectomy
214261846|NCT06362070|DEVICE|Hugo™ RAS System|Assisted-robotic radical Gastrectomy
214261847|NCT06362070|DEVICE|Versius® Robotic Surgery System|Assisted-robotic radical Gastrectomy
214261848|NCT03436004|DEVICE|Colonoscopy|Patients undergoing screening colonoscopy
214261849|NCT03436004|DEVICE|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
214261850|NCT02702804|OTHER|High Intensity Interval Training|High Intensity Interval Training
214261851|NCT00986830|DEVICE|FinESS Sinus Treatment|
214261852|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
214261853|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
214261854|NCT01457820|DRUG|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
214261855|NCT00929123|PROCEDURE|neural mobilization|manual therapy technique known to directly stress the median nerve
214261856|NCT00929123|PROCEDURE|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
214261857|NCT00929123|OTHER|healthy controls|People without carpal tunnel syndrome for comparison
214261858|NCT00881673|DRUG|AL38583 Ophthalmic Solution|Topical ophthalmic
214261859|NCT00881673|DRUG|Maxidex|Topical ophthalmic
214261860|NCT00881673|DRUG|Vehicle|AL38583 Vehicle
214261861|NCT04354142|DEVICE|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
214261862|NCT01784757|DRUG|ODM-201 Tablet A|Tablet A formulation of ODM-201
214261863|NCT01784757|DRUG|ODM-201 Tablet B|Tablet B formulation of ODM-201
214261864|NCT01784757|DRUG|ODM-201 capsule formulation|Capsule formulation of ODM-201
214261865|NCT04317404|DRUG|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
214261866|NCT01495975|OTHER|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
214261867|NCT00332878|BEHAVIORAL|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
214261868|NCT00332878|BEHAVIORAL|stepping Stones short|3 hour intervention on HIV and safer sex
214261869|NCT01592682|BEHAVIORAL|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
214261870|NCT06506682|BEHAVIORAL|Constraint Induced Movement Therapy|CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
214261871|NCT06506682|BEHAVIORAL|CIMT + VR|Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
214261872|NCT00946361|OTHER|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
214261873|NCT02053870|OTHER|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
214261874|NCT02053870|DRUG|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
214261875|NCT05627297|OTHER|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
214261876|NCT05447897|OTHER|Qualitative Group Interviews|One time interview, 60-90 minutes
214261877|NCT05447897|OTHER|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
214261878|NCT04712383|COMBINATION_PRODUCT|Fitbit Care intervention arm|Entire suite of Fitbit Care.
214261879|NCT05487352|OTHER|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
214261880|NCT03849248|OTHER|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
214261881|NCT06248060|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
214261882|NCT06248060|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
214261883|NCT01691131|OTHER|Exercise training|Comparison of high intensity exercise training on land versus water.
214261884|NCT00963222|DRUG|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
214261885|NCT00963222|DRUG|placebo|1 cap placebo/day for 3 month
214261886|NCT02583282|OTHER|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
214261887|NCT02583282|OTHER|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
214261888|NCT01039870|PROCEDURE|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
214261889|NCT01039870|PROCEDURE|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
214261890|NCT06557096|DRUG|Osimertinib 80 MG|Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.
214261891|NCT06557096|DRUG|Bevacizumab|Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
214261892|NCT04553679|BEHAVIORAL|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
214261893|NCT00699764|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
214261894|NCT00699764|BIOLOGICAL|Placebo injection|Intramuscular injection, 3 doses
214261895|NCT00333840|DRUG|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
214261896|NCT00333840|DRUG|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
214261897|NCT00333840|DRUG|cytarabine (ARA-C)|cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
214261898|NCT04928443|OTHER|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
214261899|NCT04928443|OTHER|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
214261900|NCT04664192|OTHER|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
214261901|NCT03870100|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
214261902|NCT03870100|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
214261903|NCT00014482|PROCEDURE|pain therapy|
214261904|NCT00014482|PROCEDURE|psychosocial assessment and care|
214261905|NCT02211625|DRUG|Open-label TRV734 125 mg|125 mg
214261906|NCT02211625|DRUG|TRV734 blinded|blinded, multiple ascending dose
214261907|NCT02211625|DRUG|Oxycodone IR 10 mg|
214261908|NCT02211625|DRUG|Placebo|TRV734-matched and oxycodone placebo
214261909|NCT01975714|DRUG|Preservative-free latanoprost|
214261910|NCT01975714|DRUG|Preservative-free bimatoprost|
214261911|NCT02759484|BEHAVIORAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
214261912|NCT02759484|BEHAVIORAL|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
214261913|NCT00722332|BIOLOGICAL|HepaGam B|Hepatitis B Immunoglobulin
214261914|NCT04435587|DRUG|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
214261915|NCT04435587|DRUG|Combined ART/hydroxychloroquine|"1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
214261916|NCT00111501|BEHAVIORAL|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
214261917|NCT00111501|BEHAVIORAL|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
214261918|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
214261919|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
214261920|NCT00871325|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
214261921|NCT02847975|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium nitrate will be ingested orally
214261922|NCT02573168|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
214261923|NCT02573168|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
214261924|NCT02573168|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
214261925|NCT00392860|DEVICE|Natural-Fit|Ergonomic handrim for wheelchairs
214261926|NCT00392860|DEVICE|PalmRim|Ergonomic handrim for wheelchair
214261927|NCT00392860|DEVICE|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
214261928|NCT00388830|PROCEDURE|Ultrasound|
214261929|NCT05285072|RADIATION|PET-CT scan|PET-CT scan using 68Ga-DFO
214261930|NCT05332730|DRUG|BAT2506 injection|50 mg, subcutaneous administration
214261931|NCT05332730|DRUG|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
214261932|NCT05332730|DRUG|Simponi® (US commercially available product)|50 mg, subcutaneous administration
214261933|NCT03109730|DRUG|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
214261934|NCT03109730|DRUG|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
214261935|NCT03109730|DRUG|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
214261936|NCT03109730|DRUG|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
214261937|NCT03109730|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
214261938|NCT02328183|DRUG|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
214261939|NCT03307642|OTHER|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
214261940|NCT06051370|PROCEDURE|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
214261941|NCT06051370|PROCEDURE|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
214261942|NCT04382300|DRUG|pyrotinib combined with thalidomide|Single Group Assignment
214261943|NCT04871971|DIETARY_SUPPLEMENT|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
214261944|NCT04871971|DIETARY_SUPPLEMENT|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
214261945|NCT04871971|DIETARY_SUPPLEMENT|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
214261946|NCT04871971|DIETARY_SUPPLEMENT|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
214261947|NCT04871971|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
214261948|NCT04769661|DIAGNOSTIC_TEST|Cytokines|Doing cord blood cytokines level in preterm infants
214261949|NCT02835742|DRUG|Sargramostim|
214261950|NCT02835742|DRUG|Placebo|
214261951|NCT04002739|DIAGNOSTIC_TEST|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
214261952|NCT00074984|BIOLOGICAL|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
214261953|NCT00074984|BIOLOGICAL|Placebo|1 mg/kg placebo intravenously every 2 weeks
214261954|NCT02470832|DRUG|RG1662|
214261955|NCT02470832|DRUG|itraconazole|
214261956|NCT02023593|DRUG|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
214261957|NCT01148888|DRUG|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
214261958|NCT00994071|DRUG|Temozolomide|
214261959|NCT00994071|DRUG|ABT-888|
214261960|NCT02960152|OTHER|diagnostic|full-mouth periodontal examination
214261961|NCT02700113|OTHER|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
214261962|NCT05384964|OTHER|Questionnaire|Questionnaire completed by ICU nurses
214261963|NCT01956383|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
214261964|NCT01170143|DRUG|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
214261965|NCT01720056|DRUG|Verapamil|
214261966|NCT01720056|DRUG|Kenalog 10|
214261967|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
214261968|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
214261969|NCT05806086|OTHER|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
214261970|NCT03437096|OTHER|venipuncture pain|postoperative sleeve gastrectomy patients pain
214261971|NCT03459170|BIOLOGICAL|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
214261972|NCT03459170|DRUG|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
214261973|NCT02031068|BEHAVIORAL|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation."
214261974|NCT02031068|BEHAVIORAL|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
214261975|NCT06311786|DRUG|[14C]-BIIB091|Administered as specified in the treatment arm.
214261976|NCT02283619|OTHER|None - no intervention, observational study|No intervention, observational study
214261977|NCT00965809|DRUG|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
214261978|NCT00965809|OTHER|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
214261979|NCT01360593|DRUG|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
214261980|NCT01360593|DRUG|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
214261981|NCT01360593|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
214261982|NCT03719586|DRUG|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
214261983|NCT03719586|DRUG|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
214261984|NCT03719586|DRUG|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
214261985|NCT03719586|DRUG|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
214261986|NCT05395689|BIOLOGICAL|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
214261987|NCT05395689|BIOLOGICAL|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
214261988|NCT04471142|DEVICE|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
214261989|NCT05820945|OTHER|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
214261990|NCT03566784|PROCEDURE|Inguinal hernia repair|Standard procedure for inguinal hernia repair
214261991|NCT00189995|DRUG|clozapine|
214261992|NCT00189995|DRUG|haloperidol|
214261993|NCT03441269|DRUG|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
214261994|NCT03359772|OTHER|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
214261995|NCT06192277|OTHER|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
214261996|NCT06192277|DRUG|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
214261997|NCT06192277|DRUG|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
214261998|NCT06192277|OTHER|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
214653818|NCT02617238|OTHER|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
214261999|NCT01457469|OTHER|questionnaire administration|Ancillary studies
214262000|NCT01457469|PROCEDURE|quality-of-life assessment|Ancillary studies
214262001|NCT01457469|OTHER|counseling intervention|Undergo counseling session
214262002|NCT01457469|OTHER|internet-based intervention|Receive enhanced quitline intervention
214262003|NCT01457469|BEHAVIORAL|telephone-based intervention|Receive enhanced quitline intervention
214262004|NCT01457469|OTHER|educational intervention|Receive usual care plus
214262005|NCT01457469|DRUG|nicotine replacement therapy|Receive nicotine replacement patches
214262006|NCT01457469|OTHER|educational intervention|Receive enhanced quitline intervention
214262007|NCT02464371|OTHER|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
214262008|NCT01342276|BEHAVIORAL|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
214262009|NCT00924079|DRUG|nalbuphine|oral dosage form, 66 mg, single dose
214262010|NCT05962671|DRUG|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
214262011|NCT05962671|DRUG|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
214262012|NCT04805177|PROCEDURE|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
214262013|NCT00369707|DRUG|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
214262014|NCT00369707|DRUG|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
214262015|NCT06525597|BIOLOGICAL|Stapokibart Injection|IL-4Rα monoclonal antibody
214262016|NCT06525597|DRUG|Placebo|Placebo
214262017|NCT06051214|BIOLOGICAL|thrombogram|blood sampling every month for 12 months
214262018|NCT03436654|DRUG|Apalutamide|240mg daily orally
214262019|NCT03436654|DRUG|Abiraterone Acetate|1000mg daily orally
214262020|NCT03436654|DRUG|Prednisone|5mg BID orally
214262021|NCT03436654|PROCEDURE|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
214262022|NCT03436654|PROCEDURE|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
214262023|NCT03436654|DRUG|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
214653819|NCT02795455|BEHAVIORAL|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
214653820|NCT02795455|BEHAVIORAL|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
214653821|NCT02795455|DIETARY_SUPPLEMENT|meal replacement shake|
214653822|NCT06597032|BEHAVIORAL|Resilience Challenge|We previously have tested this online program in people facing health- and work-related stressors (e.g., dementia caregivers, healthcare workers), and in 2020 we enrolled adults in a test of the online program to support coping with the stress of the COVID pandemic. This intervention has been tailored for a widespread, public audience (e.g., we have added a few other safety measures including limits on public forum posting and have clarified wording on some of the intervention content to make it clearer and easier to understand).
214653823|NCT00462787|BIOLOGICAL|filgrastim|
214262024|NCT03436654|RADIATION|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
214262025|NCT02046733|DRUG|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
214262026|NCT02046733|DRUG|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
214653824|NCT00462787|DRUG|clofarabine|
214653825|NCT00462787|DRUG|dexamethasone|
214653826|NCT00462787|DRUG|thiotepa|
214653827|NCT00462787|DRUG|topotecan hydrochloride|
214653828|NCT00462787|DRUG|vinorelbine tartrate|
214262027|NCT06533735|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
214262028|NCT01563744|PROCEDURE|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
214262029|NCT01563744|PROCEDURE|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
214262030|NCT01296360|BIOLOGICAL|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
214262031|NCT01296360|BIOLOGICAL|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
214262032|NCT00002311|DRUG|Wobenzym|
214262033|NCT02835560|DRUG|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
214262034|NCT02835560|DRUG|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
214262035|NCT02394548|RADIATION|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
214262036|NCT03849807|OTHER|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
214262037|NCT03849807|OTHER|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
214262038|NCT04562792|DRUG|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
214262039|NCT05416151|OTHER|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
214262040|NCT05416151|OTHER|Maltodextrin|2 sticks of 3g consumed daily for 28 days
214262041|NCT02848170|DRUG|CS-3150|CS-3150 2.5mg, oral
214262042|NCT02848170|DRUG|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
214262043|NCT01254292|DRUG|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
214262044|NCT01254292|DRUG|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
214262045|NCT04687995|PROCEDURE|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
214262046|NCT04728022|BEHAVIORAL|Education program|Mentored high school summer research program
214262047|NCT01951222|DRUG|V0162|
214262048|NCT01951222|OTHER|Placebo|
214262049|NCT05898685|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
214262050|NCT05898685|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
214262051|NCT02798146|OTHER|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
214262052|NCT05836181|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
214262053|NCT04041375|BEHAVIORAL|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
214262054|NCT04041375|OTHER|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
214262055|NCT01971840|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
214262056|NCT00515177|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
214262057|NCT00515177|DRUG|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
214262058|NCT01967342|BEHAVIORAL|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
214262059|NCT01967342|BEHAVIORAL|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
214262060|NCT01967342|OTHER|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
214262061|NCT03823508|DEVICE|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
214262062|NCT03823508|DEVICE|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
214262063|NCT04674644|BEHAVIORAL|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
214262064|NCT00199875|DRUG|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
214653829|NCT03204149|DEVICE|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
214653830|NCT03204149|DEVICE|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
214653831|NCT06671626|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
214653832|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
214653833|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
214653834|NCT04881565|OTHER|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
214653835|NCT01750892|BEHAVIORAL|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
214653836|NCT01750892|BEHAVIORAL|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
214653837|NCT01750892|OTHER|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
214653838|NCT03454854|DEVICE|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
214653839|NCT04101149|OTHER|No intervention|No intervention.
214262065|NCT06535165|DIETARY_SUPPLEMENT|Red Beetroot Juice|200ml/d for 14 days
214262066|NCT06535165|OTHER|Placebo|200ml/d for 14 days
214262067|NCT03789214|DRUG|Placebo oral capsule|Placebo Sleep Medication
214262068|NCT03789214|DRUG|Low Dose Suvorexant|Low Dose Suvorexant
214262069|NCT03789214|DRUG|High Dose Suvorexant|High Dose Suvorexant
214262070|NCT02178085|OTHER|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
214262071|NCT00107393|BIOLOGICAL|trastuzumab|
214262072|NCT00107393|DRUG|capecitabine|
214262073|NCT05962931|BIOLOGICAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
214262074|NCT05962931|PROCEDURE|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
214262075|NCT00007683|DRUG|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
214262076|NCT00007683|DRUG|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
214262077|NCT00007683|DRUG|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
214262078|NCT04229784|PROCEDURE|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
214262079|NCT04200859|OTHER|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
214262080|NCT05435209|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
214262081|NCT02884531|OTHER|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
214262082|NCT02884531|BEHAVIORAL|Patient Education|Patient education (1/2 day)
214262083|NCT00627549|PROCEDURE|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
214262084|NCT00627549|PROCEDURE|Conventional surgery (anterior repair)|Anterior repair surgery
214262085|NCT06010706|OTHER|Supervised physical therapy manual exercise program.|"1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
214262086|NCT06010706|OTHER|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
214262087|NCT03277690|DRUG|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
214262088|NCT03277690|DRUG|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
214262089|NCT04562467|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
214262090|NCT00747812|DEVICE|Precision|Implantable Neurostimulator
214262091|NCT04852497|PROCEDURE|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
214262092|NCT03812120|PROCEDURE|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
214262093|NCT03812120|PROCEDURE|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
214262094|NCT05088720|DRUG|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
214262095|NCT05088720|DRUG|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
214262096|NCT00169754|OTHER|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
214262097|NCT04666480|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
214262098|NCT03540212|DRUG|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
214262099|NCT05168449|OTHER|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
214262100|NCT01708161|DRUG|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
214262101|NCT01708161|DRUG|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
214262102|NCT02831452|OTHER|pelvic floor muscle strength evaluation|
214262103|NCT03599388|BEHAVIORAL|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
214262104|NCT02019277|DRUG|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
214262105|NCT02019277|DRUG|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
214262106|NCT02019277|DRUG|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
214262107|NCT02019277|DRUG|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
214262108|NCT02019277|DRUG|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
214262109|NCT02883842|BEHAVIORAL|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
214262110|NCT01780571|PROCEDURE|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
214262111|NCT05077527|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
214262112|NCT05077527|DRUG|Cyclophosphamide|Given IV
214262113|NCT05077527|DRUG|Fludarabine|Given IV
214262114|NCT01349231|DRUG|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
214262115|NCT04213482|RADIATION|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
214262116|NCT01944033|DRUG|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
214262117|NCT01944033|DRUG|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
214262118|NCT01988220|OTHER|sensory retraining|
214262119|NCT01988220|OTHER|repeated sensory input|sensory stimulation without attentive learning focus
214262120|NCT06041490|DRUG|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
214262121|NCT00341055|DRUG|Epoetin alfa|
214262122|NCT02633501|DRUG|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
214262123|NCT02633501|DRUG|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
214262124|NCT02633501|DEVICE|MRI|
214262125|NCT04110678|DRUG|NeuroEPO|NeuroEPO \[CIMAB S.A, Havana, Cuba\]
214262126|NCT02703831|PROCEDURE|Dual attending|Two attending spine surgeons perform surgery
214262127|NCT02703831|PROCEDURE|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
214262128|NCT00140933|DRUG|MK0966; rofecoxib|
214262129|NCT00140933|DRUG|Comparator: diclofenac, placebo|
214262130|NCT02326675|OTHER|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
214262131|NCT02326675|OTHER|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
214262132|NCT01488305|DIETARY_SUPPLEMENT|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
214262133|NCT01488305|OTHER|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
214262134|NCT00585962|RADIATION|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
214262135|NCT00395733|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
214262136|NCT00395733|DRUG|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
214262137|NCT03295500|RADIATION|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
214262138|NCT05835323|DEVICE|Robotic-assisted mini-PCNL|Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
214262139|NCT04633577|DRUG|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
214262140|NCT04633577|DRUG|0.9% normal saline|0.9% normal saline
214262141|NCT02826278|OTHER|External genitalia measurements in female newborns|
214262142|NCT06143800|BEHAVIORAL|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
214262143|NCT06143800|BEHAVIORAL|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
214262144|NCT02894632|DEVICE|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
214262145|NCT05371730|DRUG|NCR300|Intravenous infusion of NK cells（NCR300）
214262146|NCT03352479|OTHER|Opioid Return|Calculate the percentage of prescribed to returned opioids
214262147|NCT05854199|BEHAVIORAL|Telehealth solution|Telehealth nutrition education platform
214262148|NCT04059198|DRUG|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
214262149|NCT04059198|DRUG|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
214262150|NCT06463574|OTHER|self-adhesive resin restoration|Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
214262151|NCT00137683|BEHAVIORAL|one-on-one education, group education, small media|
214262152|NCT04676217|PROCEDURE|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
214262153|NCT03819673|BEHAVIORAL|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
214262154|NCT02422316|OTHER|Non-contrast Cardiac CT scan|
214262155|NCT02072239|DEVICE|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
214262156|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
214262157|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
214262158|NCT00517803|DIETARY_SUPPLEMENT|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
214262159|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
214262160|NCT05607771|DEVICE|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
214262161|NCT05607771|DEVICE|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
214262162|NCT00242073|PROCEDURE|MRI Prostate|
214262163|NCT05082831|BIOLOGICAL|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
214262164|NCT04497207|OTHER|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
214262165|NCT01672736|DRUG|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
214262166|NCT06551636|OTHER|respiratory physiotherapy (AAD)|The AAD technique involves placing the physiotherapist's hands on the chest where the secretions are identified and applying pressure to the chest. The maneuver will last according to the patient's tolerance, in an average of approximately 10 min.
214262167|NCT01773772|DRUG|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
214262168|NCT01773772|DRUG|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
214262169|NCT01736020|DRUG|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
214262170|NCT01736020|DRUG|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
214262171|NCT01736020|DRUG|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
214262172|NCT01736020|DRUG|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
214262173|NCT01736020|DRUG|Placebo|Placebo
214262174|NCT04211168|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
214262175|NCT02366988|DEVICE|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
214262176|NCT02366988|PROCEDURE|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
214262177|NCT00521612|DRUG|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
214262178|NCT00521612|DRUG|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
214262179|NCT02542982|DEVICE|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
214262180|NCT06341764|DRUG|Durvalumab 1120 mg|Durvalumab 1120 mg day 1 i.v
214262181|NCT06341764|DRUG|Durvalumab 1500 mg|Durvalumab i.v. at 1500 mg once every 4 weeks
214262182|NCT06341764|DRUG|Tremelimumab i.v. at 300 mg|Single dose
214262183|NCT06341764|COMBINATION_PRODUCT|Cisplatin (CDDP) 25 mg/mq i.v|Four cycles
214262184|NCT06341764|COMBINATION_PRODUCT|Gemcitabine (GEM) 1000 mg/mq i.v.|Days 1 and 8 every 21 days
214262185|NCT02495012|DRUG|placebo|Freeze-dried powder without snake venom will be dissovled in saline
214262186|NCT02495012|DRUG|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
214262187|NCT02590926|PROCEDURE|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
214262188|NCT05554575|BIOLOGICAL|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
214262189|NCT00361582|DRUG|CG5503 IR; tapentadol|
214262190|NCT06203236|DRUG|Furosemide 20 MG|"1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
214262191|NCT06203236|OTHER|diuretic therapy|diuretic therapy
214262192|NCT05290207|DIAGNOSTIC_TEST|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
214262193|NCT01044706|DRUG|Bicalutamide|50 mg Oral Tablet
214262194|NCT01485393|DRUG|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
214262195|NCT01485393|DRUG|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
214262196|NCT02853344|BIOLOGICAL|Pembrolizumab|IV infusion
214262197|NCT03868306|OTHER|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
214262198|NCT00799110|DRUG|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
214262199|NCT00799110|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
214262200|NCT00799110|DRUG|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
214262201|NCT02913612|DRUG|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
214262202|NCT02913612|DRUG|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
214262203|NCT02589379|PROCEDURE|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
214262204|NCT06410404|PROCEDURE|transversus thoracis plane block|with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
214262205|NCT06410404|DRUG|Dexmedetomidine|the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
214262206|NCT06410404|DRUG|Levobupivacaine|A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
214262207|NCT01434407|OTHER|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
214262208|NCT00885053|DIETARY_SUPPLEMENT|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
214262209|NCT00885053|DIETARY_SUPPLEMENT|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
214262210|NCT00389727|DRUG|Radiotherapy|Radiotherapy
214262211|NCT02120612|OTHER|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
214262212|NCT05074043|COMBINATION_PRODUCT|antiviral, surgical|surgical debridment
214262213|NCT04756869|OTHER|COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology|Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
214262214|NCT06333093|PROCEDURE|Cold snare|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
214262215|NCT00549380|DEVICE|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
214262216|NCT02447562|DEVICE|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
214262217|NCT02447562|OTHER|Phone-based care group|
214262218|NCT02447562|OTHER|Usual care group|
214262219|NCT02838446|PROCEDURE|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
214262220|NCT05352373|DIETARY_SUPPLEMENT|calcium|calcium carbonate
214262221|NCT05352373|DIETARY_SUPPLEMENT|placebo|sodium bicarbonate
214262222|NCT00140478|DRUG|Mifepristone|200mg orally once daily
214262223|NCT03134833|BEHAVIORAL|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
214262224|NCT03134833|BEHAVIORAL|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
214262225|NCT03134833|BEHAVIORAL|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
214262226|NCT00743899|PROCEDURE|The aggressive group|Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.
214262227|NCT00743899|PROCEDURE|The conservative group|Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
214262228|NCT03452228|DRUG|evinacumab|Administered by Intravenous (IV)
214262229|NCT03452228|DRUG|Placebo|Administered by Intravenous (IV)
214262230|NCT05742958|DRUG|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
214262231|NCT05742958|DRUG|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
214262232|NCT02699359|DEVICE|HS-1000 recording|
214262233|NCT04627337|DRUG|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
214262234|NCT04627337|BEHAVIORAL|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
214262235|NCT04281641|DIAGNOSTIC_TEST|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
214262236|NCT04352946|DRUG|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
214262237|NCT04352946|DRUG|Placebo oral tablet|Placebo tablets 400mg daily
214262238|NCT06076707|DRUG|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
214262239|NCT01262573|PROCEDURE|Closure of vaginal cuff|Closure of the vaginal cuff
214262240|NCT06476327|BEHAVIORAL|experimental 1 group|"A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
214262241|NCT06476327|BEHAVIORAL|experimental 2 group|"Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
214262242|NCT04970641|BEHAVIORAL|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
214262243|NCT00166465|DRUG|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
214262244|NCT04686604|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
214262245|NCT04120948|DEVICE|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
214262246|NCT04120948|DEVICE|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
214262247|NCT00036296|DRUG|talampanel|75mg per day divided into 3 doses for 22 days
214262248|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
214262249|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
214262250|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214262251|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
214262252|NCT01783054|PROCEDURE|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
214653840|NCT06872190|OTHER|ED-Based Clinical Decision Support for Opioid Use Disorder|"The original clinical decision support (CDS) tool, EMergency department initiated BuprenorphinE for opioid use Disorder or EMBED, was designed by researchers at Yale to support emergency department (ED) clinicians with varying levels of experience prescribing buprenorphine for patients with opioid use disorder (OUD). The tool alerts ED providers of a patient who is potentially eligible for MOUD using Epic's storyboard. The provider must then click on the notification to open the OUD evaluation tool, which has multiple components: OUD assessment, OUD diagnosis, withdrawal assessment, and readiness for treatment. These components are then paired with an orderset, ED Opioid Use Disorder Treatment that includes nursing orders, prescriptions for buprenorphine and ancillary medications, and substance use disorder discharge resources."
214653841|NCT06872190|OTHER|Social Care-Enhanced Clinical Decision Support for Opioid Use Disorder|The investigators will use human-centered design to adapt the basic CDS tool to incorporate patient social needs, involving patients, staff, and end-user ED clinicians in the iterative design process. This tool is being actively developed.
214262253|NCT01783054|GENETIC|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
214262254|NCT01783054|DRUG|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
214262255|NCT02577562|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
214262256|NCT01825070|DIETARY_SUPPLEMENT|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
214653842|NCT06625086|OTHER|Convensional exercises|Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.
214653843|NCT06625086|OTHER|Supervised exercises|Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.
214653844|NCT06625086|OTHER|Web based exercises|The exercises will be administered to participants through a web-based application.
214262257|NCT05660226|OTHER|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
214262258|NCT05660226|OTHER|Standard care|Standard outpatient blood pressure management
214262259|NCT04064177|DEVICE|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
214262260|NCT05665023|DRUG|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
214262261|NCT03102112|OTHER|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
214262262|NCT04597164|OTHER|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
214262263|NCT04357340|OTHER|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
214262264|NCT00622973|OTHER|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
214262265|NCT00622973|OTHER|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
214262266|NCT05040399|OTHER|Locking Compression Plates|Plates and screws for sternal fixation
214262267|NCT05040399|OTHER|Sternal Wires|sternal wires used for fixation of sternum
214262268|NCT04245072|PROCEDURE|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
214262269|NCT04245072|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
214262270|NCT04245072|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
214262271|NCT04245072|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
214262272|NCT04245072|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
214262273|NCT04245072|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
214262274|NCT04245072|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
214262275|NCT02081183|DRUG|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
214262276|NCT02081183|DRUG|Cyclophosphamide, Maintenance Phase|0.5-1 g/m\^2 IV pulse once every 3 months
214262277|NCT02081183|DRUG|Cyclophosphamide, Induction Phase|0.5 - 1 g/m\^2 IV pulse once per month
214262278|NCT02081183|DRUG|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
214262279|NCT00003927|BIOLOGICAL|filgrastim|
214262280|NCT00003927|DRUG|amifostine trihydrate|
214262281|NCT00003927|DRUG|cyclophosphamide|
214262282|NCT00003927|DRUG|doxorubicin hydrochloride|
214262283|NCT00003927|DRUG|paclitaxel|
214262284|NCT00003927|PROCEDURE|peripheral blood stem cell transplantation|
214262285|NCT01021306|DEVICE|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
214262286|NCT01021306|DEVICE|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
214262287|NCT01021306|OTHER|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
214262288|NCT01021306|OTHER|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
214262289|NCT03012724|DEVICE|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
214262290|NCT03012724|DEVICE|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
214262291|NCT05248620|DRUG|Amoxicillin Clavulanic 500/125mg or placebo|Prophylactic antibiotic treatment
214262292|NCT05189379|OTHER|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
214262293|NCT05189379|OTHER|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
214262294|NCT05189379|OTHER|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
214262295|NCT05189379|OTHER|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
214262296|NCT01882348|BEHAVIORAL|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
214262297|NCT04473846|DRUG|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
214262298|NCT04473846|DRUG|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
214262299|NCT01858571|DRUG|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
214262300|NCT00865670|DRUG|Azithromycin Monohydrate 600 mg Tablets|
214262301|NCT00865670|DRUG|Zithromax (azithromycin dihydrate) 600 mg Tablets|
214262302|NCT05936268|DRUG|Genakumab for injection|150 mg/1ml/bottle
214262303|NCT05936268|DRUG|Colchicine|0.5mg/table
214262304|NCT00309478|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
214262305|NCT00309478|DRUG|Methotrexate|Methotrexate 40mg/m2
214262306|NCT00309478|DRUG|Fluorouracil implant|Fluorouracil 600mg/m2
214262307|NCT00309478|DRUG|Goserelin|Zoladex 3.6mg/28 days for 3 years
214262308|NCT00309478|DRUG|Tamoxifen|Nolvadex 20mg/day for 5 years
214262309|NCT02440971|DEVICE|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
214262310|NCT04128371|BIOLOGICAL|mepolizumab|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
214262311|NCT05540444|DEVICE|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
214262312|NCT01747148|DRUG|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
214262313|NCT03250871|OTHER|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
214262314|NCT03250871|OTHER|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
214262315|NCT02297191|PROCEDURE|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
214262316|NCT02297191|DRUG|Ropivicaine|
214262317|NCT04488939|DEVICE|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
214262318|NCT05405413|OTHER|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
214262319|NCT00968864|DEVICE|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
214262320|NCT02407795|RADIATION|conventional radiotherapy|1x8Gy
214262321|NCT02407795|RADIATION|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
214262322|NCT00118690|DRUG|Fluticasone propionate/salmeterol|
214262323|NCT04925726|OTHER|Land based exercise|The patients who had land based exercise
214262324|NCT04925726|OTHER|Water based exercise|The patients who had water based exercise
214262325|NCT00479323|BIOLOGICAL|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
214262326|NCT02308189|BEHAVIORAL|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
214262327|NCT02308189|BEHAVIORAL|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
214262328|NCT00291889|BIOLOGICAL|Mtb72F/AS02.|
214262329|NCT02718066|DRUG|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
214262330|NCT03022435|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
214262331|NCT03022435|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
214262332|NCT03022435|BIOLOGICAL|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
214262333|NCT00644189|DRUG|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
214262334|NCT00524381|DRUG|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
214262335|NCT00524381|DRUG|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
214262336|NCT03355781|DEVICE|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
214262337|NCT03355781|PROCEDURE|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
214262338|NCT03355781|OTHER|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
214262339|NCT00397215|BIOLOGICAL|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
214262340|NCT00397215|BIOLOGICAL|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
214262341|NCT02291354|DRUG|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
214262342|NCT02291354|OTHER|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
214262343|NCT02291354|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
214262344|NCT02128932|DRUG|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
214262345|NCT02128932|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
214262346|NCT06117358|OTHER||Descriptive cross section study
214262347|NCT01433731|DRUG|placebo for SHAPE (SHP-141)|topical gelled solution
214262348|NCT01433731|DRUG|SHAPE (SHP-141) 0.1% BID|topical gelled solution
214262349|NCT01433731|DRUG|SHAPE (SHP-141) 0.5% BID|topical gelled solution
214818191|NCT06849700|OTHER|Active gamification|"The experimental group participated in a physical exercise program for primary school children, with 45-minute sessions three times a week, including warm-up, main activities, and awards. Designed to enhance engagement through game mechanics, the program progressed in three phases: Explorers in Action (Weeks 1-4) focused on coordination, agility, and teamwork with games like Conquering Territories; Movement Heroes (Weeks 5-8) emphasized endurance, collaboration, and strategy through activities like Quest for the Gems; and Health Guardians (Weeks 9-12) incorporated strength, planning, and teamwork challenges, culminating in a final integrated skills circuit. The program promoted continuous improvement in physical and cooperative abilities."
214262350|NCT01433731|DRUG|SHAPE (SHP-141) 1.0% BID|topical gelled solution
214262351|NCT02225197|RADIATION|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
214262352|NCT00044720|DRUG|Rapamune|
214262353|NCT04079010|PROCEDURE|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
214262354|NCT04079010|DIETARY_SUPPLEMENT|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
214262355|NCT04079010|DIETARY_SUPPLEMENT|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
214818192|NCT04935177|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
214818193|NCT04935177|PROCEDURE|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
214262356|NCT04759144|DEVICE|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
214262357|NCT04759144|DEVICE|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
214262358|NCT04304274|PROCEDURE|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
214262359|NCT04304274|PROCEDURE|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
214262360|NCT04304274|DRUG|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
214262361|NCT00657358|DRUG|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
214262362|NCT05791175|DEVICE|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
214262363|NCT03860610|DIAGNOSTIC_TEST|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
214262364|NCT03860610|DIAGNOSTIC_TEST|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
214262365|NCT03860610|DIAGNOSTIC_TEST|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
214262366|NCT03860610|DIAGNOSTIC_TEST|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
214262367|NCT03860610|DIAGNOSTIC_TEST|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
214262368|NCT03860610|DIAGNOSTIC_TEST|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
214262369|NCT03860610|DIAGNOSTIC_TEST|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
214262370|NCT00912860|DRUG|Interferon beta-1a|serum free Avonex given IM once a week
214262371|NCT00002449|DRUG|Aldesleukin|
214262372|NCT03314142|OTHER|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214262373|NCT03314142|OTHER|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214262374|NCT03314142|OTHER|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214262375|NCT03314142|OTHER|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214262376|NCT03314142|OTHER|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214653845|NCT06629610|BEHAVIORAL|DAiLY|The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
214653846|NCT02507583|DRUG|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
214262377|NCT04432025|PROCEDURE|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
214262378|NCT04432025|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
214262379|NCT01052571|PROCEDURE|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
214262380|NCT01020383|DRUG|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
214262381|NCT01020383|DRUG|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
214262382|NCT02728596|OTHER|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
214262383|NCT02728596|OTHER|Quality-of-Life Assessment|Ancillary studies
214262384|NCT02728596|OTHER|Questionnaire Administration|Ancillary studies
214262385|NCT03892070|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
214262386|NCT03892070|DIETARY_SUPPLEMENT|Mannitol|1.5 g twice daily for 12 weeks
214262387|NCT04232774|DEVICE|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
214262388|NCT03221270|DEVICE|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
214262389|NCT03221270|DEVICE|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
214262390|NCT03221270|DEVICE|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
214262391|NCT03221270|DEVICE|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
214262392|NCT01578421|DEVICE|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
214262393|NCT03114774|DEVICE|The bispectral index (BIS) monitoring|
214262394|NCT03114774|BEHAVIORAL|Ramsay Sedation Scale (RSS) Score monitoring|
214262395|NCT01408264|DEVICE|Conventional 0.035 guidewire|0.035 guidewire
214653847|NCT04838873|PROCEDURE|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
214262396|NCT01408264|DEVICE|Olympus Visiglide 0.025 guidewire|0.025 guidewire
214262397|NCT03991858|OTHER|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
214262398|NCT03991858|OTHER|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
214262399|NCT00955318|DRUG|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
214262400|NCT05788653|PROCEDURE|Thiele Massage|Transvaginal Massage
214262401|NCT05788653|PROCEDURE|Transverse Friction Massage|Transvaginal Massage
214262402|NCT06184386|OTHER|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
214262403|NCT06184386|BEHAVIORAL|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
214262404|NCT04286399|DRUG|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
214262405|NCT04286399|DRUG|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
214262406|NCT04286399|DRUG|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
214262407|NCT04306029|OTHER|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
214262408|NCT03985306|PROCEDURE|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
214262409|NCT00365222|DRUG|Temozolomide|temozolomide 75 mg/m2 /d
214262410|NCT03353246|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
214653848|NCT04838873|PROCEDURE|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
214653849|NCT06695221|DIETARY_SUPPLEMENT|Traditional Kefir|350 mL/day of traditional fermented/prepared kefir
214653850|NCT06695221|DIETARY_SUPPLEMENT|Milk (placebo)|350 mL/day of commercial 2% fat milk
214653851|NCT00191373|DRUG|Gemcitabine|
214262411|NCT03101787|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes."
214653852|NCT00191373|DRUG|Trastuzumab|
214653853|NCT06734767|BEHAVIORAL|Mindfulness Based Stress Reduction 8-week course|The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
214653854|NCT06889766|BIOLOGICAL|NY-ESO-1 TCR redirected autologous T cell product|Ex vivo expanded autologous CD4+/CD8+ cells expressing the transgenic TCR I53F recognizing NY-ESO-1 peptides presented on tumor cells in the context of HLA-A\*02. The LauT-1-ACT infusion contains a minimum of 3x10\^8 transduced cells (i.e. CD3+vβ13.1+) and a maximum of 1x10\^10 total cells.
214653855|NCT06889766|RADIATION|Low-dose irradiation|1Gy will be administered using tomotherapy (Accuray) to all irradiable lesions.
214653856|NCT06889766|DRUG|Non-myeloablative lymphodepleting chemotherapy|Fludarabine (30 mg/m2 x 4 days, from D-6 to D-3) and cyclophosphamide (2400 mg/ m2 x 2 days, on days -6 and -5) are administered as an IV infusion. The cyclophosphamide dose may be reduced to 1800mg/m2 on days -6 and -5, if the patient has previously been exposed to significant cumulative doses of chemotherapy)
214653857|NCT03370393|BEHAVIORAL|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
214653858|NCT06759792|OTHER|eye hand coordination exercises|exercises to improve eye hand coordination post strabismus surgery
214653859|NCT06771895|BEHAVIORAL|Combined exercise and nutritional intervention|The intervention consists of a combined exercise and nutritional intervention. All subjects will perform 20 weeks of supervised resistance and endurance type exercise training 2 to 3 days per week. The dietary intervention aims to attain a diet that comprises sufficient protein and is otherwise in line with the Dutch Healthy Diet guidelines. In support, subjects will consume a daily high protein multi-nutrient supplement which will be ingested pre-sleep. There will be an additional supplement intake moment following each training session.
214653860|NCT06900452|DIETARY_SUPPLEMENT|0.5 serving of pistachios|"The equivalent of 0.5 servings (15g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 15g pistachio, 35g muesli base, 150g full fat natural yoghurt, 15g unsalted butter (melted), 10g unflavoured whey powder"
214653861|NCT06900452|DIETARY_SUPPLEMENT|1 serving of pistachios|"The equivalent of 1 serving (30g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 30g pistachio, 35g muesli base, 150g full fat natural yoghurt, 10g unsalted butter (melted), 5g unflavoured whey powder"
214653862|NCT06900452|DIETARY_SUPPLEMENT|2 servings of pistachios|"The equivalent of 2 servings (60g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 60g pistachios, 25g muesli base, 150g low fat natural yoghurt"
214653863|NCT06900452|DIETARY_SUPPLEMENT|Placebo|Macronutrient-matched placebo breakfast meal. Ingredients: 40g muesli base, 150g full fat natural yoghurt, 25g unsalted butter (melted), 15g unflavoured whey powder
214653864|NCT06755879|BEHAVIORAL|digital game-based learning activity|learning interventions to prevent surgical site infections with a digital game-based learning activity
214653865|NCT06755879|BEHAVIORAL|traditional method|Evaluation of the effectiveness of students' learning of interventions to prevent surgical site infections in the theoretical course taught by traditional method
214653866|NCT06855082|BEHAVIORAL|stoma self-care apps|This study uses a stoma self-care app, accessed through LINE official account, a communication software commonly used by Chinese people, as an intervention measure to integrate technology acceptance and task technology adaptation models to explore the correlation of each aspect and its impact on self-care ability and quality of life. Whether the factors and task technology adaptability will affect the willingness and usage behavior of enterostomy patients, the research subjects can effectively improve their self-care ability, quality of life, usage willingness, and usage behavior after intervention.
214653867|NCT06855082|BEHAVIORAL|Traditional Education Receive colostomy health education manual with oral instruction|conventional
214653868|NCT06901284|DIAGNOSTIC_TEST|Graded Exercise Test|"Participants will perform a graded exercise test on either a cycle ergometer or treadmill. The testing protocol will begin with a 5- 10 min warm-up of either cycling or running/walking at the participants preferred pace.~If the graded exercise test is on a bike, exercise will begin at wattage that elicits \~50% of their heart rate max, HRmax = 208 - 0.7 × age and increase by either 10W, 15W, or 20W every two minutes in a stepwise fashion until symptom limitation. The step of the wattage increase will be at the discretion of the investigators.~If the graded exercise test is on a treadmill, the test will begin at a speed that elicits \~50% of predicted HRmax. Following, the speed of the treadmill will increase 0.5 mph (0.8 km/hr) every two minutes in a stepwise fashion until symptom limitation. If the participant maxes out the speed of the treadmill, we will increase the grade 2% every 2-minutes until symptom limitation."
214818194|NCT04935177|DRUG|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
214818195|NCT04935177|DRUG|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
214818196|NCT04935177|DRUG|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
214262412|NCT03646825|DIETARY_SUPPLEMENT|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
214262413|NCT03147677|DRUG|Alfacalcidol|
214262414|NCT03147677|DRUG|Irbesartan|
214262415|NCT00880984|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
214262416|NCT03565601|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
214262417|NCT01172236|DRUG|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
214262418|NCT01172236|DRUG|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
214262419|NCT02967432|DRUG|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
214262420|NCT02967432|DRUG|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
214262421|NCT05244304|DRUG|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
214262422|NCT05244304|DRUG|Placebo|Not active drug
214262423|NCT05570383|DRUG|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
214262424|NCT03745807|BIOLOGICAL|NKTR-214|Specified dose on specified days
214262425|NCT03745807|BIOLOGICAL|Nivolumab|Specified dose on specified days
214262426|NCT01414608|RADIATION|Brachytherapy|Undergo brachytherapy
214262427|NCT01414608|DRUG|Carboplatin|Given IV
214262428|NCT01414608|DRUG|Cisplatin|Given IV
214262429|NCT01414608|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214818197|NCT04935177|OTHER|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
214262430|NCT01414608|DRUG|Paclitaxel|Given IV
214262431|NCT01414608|OTHER|Quality-of-Life Assessment|Ancillary studies
214262432|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
214262433|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
214262434|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
214262435|NCT00876525|DEVICE|Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis|The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.
214262436|NCT00993681|BIOLOGICAL|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
214262437|NCT00993681|BIOLOGICAL|TD Vaccine System|placebo
214262438|NCT00907868|RADIATION|partial breast irradiation|Patients undergo radiation tumor bed boost
214262439|NCT00907868|RADIATION|whole breast irradiation|Patients undergo whole breast irradiation
214262440|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
214262441|NCT04976062|DIAGNOSTIC_TEST|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
214262442|NCT02197793|BEHAVIORAL|Community Mobilization Program|
214262443|NCT03672643|DRUG|Crizotinib|receive crizotinib orally
214262444|NCT06554730|OTHER|Belzutifan|There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.
214262445|NCT05736224|DRUG|Sunscreen|The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
214262446|NCT05736224|OTHER|UV Light|UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
214262447|NCT04932512|DRUG|ION224|ION224 will be administered by SC injection.
214262448|NCT04932512|OTHER|Placebo|ION224-matching placebo solution will be administered by SC injection.
214262449|NCT06091579|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
214262450|NCT06091579|DRUG|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
214818198|NCT05116176|DEVICE|Implantable cardioverter-defibrillators|500 patients age \>65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
214818199|NCT06268418|OTHER|Artificial intelligence|Segmentation
214818200|NCT01056666|DEVICE|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
214262451|NCT04195282|OTHER|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
214262452|NCT04195282|OTHER|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
214262453|NCT04593849|OTHER|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
214262454|NCT00914173|DEVICE|Scanlaf Circulator and water bath|Cold Pressor Test
214262455|NCT00914173|DEVICE|Medoc TSA 2000|Thermal stimuli pain
214262456|NCT04060849|DRUG|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
214262457|NCT04060849|OTHER|Best Practice|Receive standard of care
214262458|NCT06517836|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
214262459|NCT06665672|DEVICE|Wrist worn vibro-acoustic device|The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.
214262460|NCT05348473|DEVICE|Alpha type|Tips of the seton will be tied as alpha-shaped.
214262461|NCT05348473|DEVICE|Beta type|Tips of the seton in this group will be overlapped and tied
214262462|NCT05348473|DEVICE|Comfort type|Knotless seton will be applied
214262463|NCT06710678|BEHAVIORAL|Physical Activity Study Break|A 10-minute walking/upper extremity light movement indoor break from study session
214262464|NCT06710678|BEHAVIORAL|Social Media Study Break|Participants will engage in social media use/engagement during a 10-minute study session break
214262465|NCT06058078|DRUG|RY_SW01 cell injection|Injected RY\_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
214262466|NCT06058078|DRUG|Basic treatment|Drugs for LN treatment
214262467|NCT04375228|DRUG|Rituximab|375mg/m\^2 IV weekly for 4 doses
214262468|NCT04375228|DRUG|Tocilizumab|4mg/kg IV once a month for up to 2 doses
214262469|NCT03227328|DRUG|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
214262470|NCT03227328|DRUG|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
214262471|NCT05426096|OTHER|Best Practice Advisory|The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
214262472|NCT04622462|PROCEDURE|Standard of Care Histopathology|Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
214262473|NCT04622462|PROCEDURE|STRATICYTE Assessment|Assessment for risk of progression to oral cancer
214262474|NCT06679998|DRUG|Single dose, AAPB by injection, intravenous drip.|Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
214262475|NCT06679998|OTHER|Single dose, placebo, intravenous drip.|Subjects received a single intravenous infusion of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time.
214262476|NCT06679998|DRUG|Multiple dosing, AAPB for injection, intravenous drip|Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
214262477|NCT06679998|OTHER|Multiple dosing, placebo, IV drip|Subjects received multiple intravenous doses of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time for 7 consecutive days.
214262478|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
214262479|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
214262480|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 3|One dose of Reinovax PCV24 formulation 1（0.5mL）
214262481|NCT06678620|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
214262482|NCT03615573|OTHER|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
214818201|NCT01056666|DEVICE|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
214818202|NCT02517684|DRUG|Infliximab|
214818203|NCT02517684|DRUG|Prednisolone|
214818204|NCT02517684|OTHER|Exclusive enteral nutrition|
214262483|NCT06680726|OTHER|Matching with RWD|A set of clinical and genetic data are matched to generate a RWD cohort for comparison.
214262484|NCT06680726|OTHER|Imaging Mass Cytometry|Protein expression patterns in tumor tissue and tumor microenvironment are analyzed by Imaging Mass Cytometry.
214818205|NCT02517684|DRUG|Azathioprine|
214818206|NCT03610113|DEVICE|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
214818207|NCT00283361|DRUG|ZP120|
214818208|NCT00283361|PROCEDURE|I.v. catherization|
214262485|NCT06680895|OTHER|FeNO Observation|FeNO was observed and measured among patients with advanced respiratory support
214262486|NCT06681532|PROCEDURE|Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars|The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.
214262487|NCT06681532|PROCEDURE|Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars|the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
214262488|NCT05574998|DRUG|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
214262489|NCT06709118|DEVICE|fiberoptic|Tracheal intubation was performed with different outer diameters of fiberoptic.
214262490|NCT06707454|DEVICE|Digital Electroencephalography (DEEG)|The enrolled patients will undergo Digital Electroencephalography (DEEG) monitoring for at least two hours. A senior epileptologist will make a DEEG interpretation to detect DEEG abnormality. DEEG patterns will be categorized according to the American Clinical Neurophysiology Society's standardized critical care DEEG terminology(normal, slowing and asymmetry, sharp and wave, periodic discharges, ictal patterns burst suppression, and electrocerebral silence)
214262491|NCT06710691|OTHER|Physical activity intervention using traditional strength training protocols|Strength training participants performed the 6 reps of the first exercise at the prescribed RPE and then rested for 1 minute. Participants then completed another set of their first exercise with the required rest until the prescribed sets were completed. Participants performed the second and third exercises in the same fashion. Once the first block was completed, participants rested 5 min, then completed the second block. Six exercises were completed.
214262492|NCT06710691|OTHER|Physical activity intervention using high-resistance circuit training.|An adapted version of Alcaraz's high-resistance circuit training (HRC) was utilized in the intervention. Exercises and intensities used by strength training was the same for HRC except HRC participants performed the first three exercises as a circuit with 35 seconds rest between exercises, then completed the second block of exercises in the same fashion.
214262493|NCT06707168|DIAGNOSTIC_TEST|Digital palpation|Digital palpation for IOP measurement
214262494|NCT06707168|DIAGNOSTIC_TEST|Cotton-tipped applicator (CTA)|Cotton-tipped applicator (CTA) for IOP measurement
214262495|NCT06710912|BEHAVIORAL|Group acceptance and commitment therapy (ACT)|The ACT intervention module utilized in this study was adapted from Hayes foundational work on ACT and Harris. A summary of the general contents and exercises in each week was in accordance with the 6 core processes of Acceptance and Commitment Therapy based on Hayes. It was conducted in the Malay language. The same workbook with guided exercise and homework were used by all the therapists to assure standardization of the intervention to ensure that each group received similar contents in each session.
214262496|NCT06710912|OTHER|Treatment as usual|Standard care and follow-up for major depressive disorder
214262497|NCT06707857|OTHER|tendon neuroplastic training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
214262498|NCT06707857|OTHER|conventional training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
214262499|NCT06708741|DRUG|Vitamin D|High dose oral vitamin D supplementation (50,000 IU/once per month)
214262500|NCT06710470|DRUG|Deucravacitinib|As per product label
214262501|NCT06710470|DRUG|Systemic psoriasis medications|As per product label
214262502|NCT06710470|OTHER|No systemic medications|Participants not exposed to any systemic medications
214262503|NCT06708624|DRUG|FYB201 0.5 mg (0.05 mL of 10 mg/mL)|IVT administration of FYB201 in a PFS
214262504|NCT06710496|OTHER|analysis of medical records|analysis of medical records of the patients
214262505|NCT01484041|DRUG|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
214262506|NCT01484041|DRUG|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
214262507|NCT00427947|DRUG|ropivacaine/placebo|Continuous sciatic nerve bloc
214262508|NCT06921915|OTHER|eLearning|Participants in the intervention arms view a website developed by urinary bladder experts that presents information about how to prevent inconvenient urinary urges.
214262509|NCT06924840|OTHER|Utixira Lotion tablet as regimen|"Mode of Usage: To be applied over the affected areas twice a day as a thin film and rubbed in gently and completely. Take 1 capsule twice a day for better results.~Marketed By: SAVA Healthcare Ltd Frequency: Twice a Day"
214653869|NCT06901284|DIAGNOSTIC_TEST|Graded Hypoxia Exercise Test|"Participants will perform a single constant work rate exercise tests during graded hypoxia. They will be outfitted with either a facemask or mouthpiece connected to a uni-directional breathing valve. During inspiration, subjects will breathe from a closed-system Douglas bag balloon reservoir (\~200 L) connected to the value on the inspired side via air-tight clean-bor tubing.~The participant will complete the same mode of exercise as they did during visit 1, either bike or treadmill. The resistance on the bike or incline of the treadmill will be set to elicit an intensity equivalent to \~50% of their V̇O2max determined during visit 1. Participants will complete 5-minute stages over a range of FiO2 values. The exercise test will begin in an FiO2=0.21 (i.e. room air). Following this first 5-min stage the FiO2 will increase to 0.25, afterwards, participants will complete another stage at FiO2=0.21 and then decrease in a stepwise fashion every 5-minutes."
214653870|NCT04981223|DEVICE|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
214653871|NCT04280081|DRUG|Selpercatinib|Administered orally
214262510|NCT04147533|DRUG|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
214262511|NCT04147533|DRUG|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
214262512|NCT04147533|DRUG|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
214262513|NCT06933082|BEHAVIORAL|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers t|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers to implementing the occupational health and safety program despite the existence of this program in the company.this intervention program based on health belief model in improventing workers' adherence related to occupatioan hazards prevention by wearing PPE. Validity and pre-test are applied prior to the implementation of the intervention program. The program is comprised of five main lecture each lecture is designed and scheduled for at least (45) minutes which deals with changing of workers' health beliefs about occupatioan hazards prevention.All lectures are presented at conference hall in the company.The implementation of health intervention program is initiated during the period of June 20th, 2024 to June 25th, 2024. Each lecture is designed and scheduled for approximately (45)
214262514|NCT06935006|PROCEDURE|Sonographic guided Erector spinae plane block|Ultrasound guided plane block using 20 ml of 0.25% bupivacaine at the level of transverse process of T8
214262515|NCT06935006|DRUG|Intravenous opioid|0.1 mg/kg morphine intravenous pre operative
214262516|NCT06933238|DRUG|Fuzheng Tongfu Jiedu prescription (FZTFJD)|"Fuzheng Tongfu Jiedu prescription (FZTFJD), a kind of Traditional Chinese medicine (TCM).Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
214262517|NCT06933238|DRUG|Placebo|"Fuzheng Tongfu Jiedu prescription plaebo. Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
214262518|NCT04033510|OTHER|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
214262519|NCT00522015|DRUG|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
214262520|NCT01805440|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
214262521|NCT01805440|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
214262522|NCT01645137|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
214262523|NCT01645137|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
214262524|NCT04222231|OTHER|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
214262525|NCT04222231|OTHER|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
214262526|NCT01999751|DEVICE|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
214262527|NCT03216187|DRUG|Pregabalin|pregabalin 150 mg capsules
214262528|NCT03216187|DRUG|Placebos|capsules identical to pregabalin but without active drug
214262529|NCT04806503|DRUG|UNR844|Ophthalmic solution for topical ocular administration
214262530|NCT04806503|DRUG|Placebo|Placebo
214653872|NCT06927778|OTHER|Exercise|Individualised corrective exercise protocols based on Functional Movement Screening
214653873|NCT06916130|DRUG|AD-120A|Administered before the breakfast during 7 days, Oral, Tablet
214262531|NCT03589469|DRUG|Loncastuximab tesirine|intravenous infusion
214262532|NCT04549857|BEHAVIORAL|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment."
214653874|NCT06916130|DRUG|AD-120|Administered before the breakfast during 7 days, Oral, Tablet
214653875|NCT06915168|OTHER|Informational Intervention|Given CIPN DecisionAid
214653876|NCT06915168|OTHER|Survey Administration|Ancillary studies
214818209|NCT00283361|PROCEDURE|6-minutes walk performance|
214818210|NCT00283361|BEHAVIORAL|Dyspnea severity assessment|
214818211|NCT00283361|PROCEDURE|Blood sampling for laboratory tests|
214818212|NCT00283361|PROCEDURE|ECG|
214262533|NCT01259765|DRUG|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
214262534|NCT01259765|DRUG|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
214262535|NCT03069443|OTHER|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
214262536|NCT00257465|BIOLOGICAL|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
214262537|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
214262538|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|2.5 million cells
214262539|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0.5 million cells
214262540|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0 cells
214262541|NCT02538081|DRUG|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
214262542|NCT02538081|DRUG|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
214262543|NCT03760055|DEVICE|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
214262544|NCT03299465|BEHAVIORAL|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
214262545|NCT05591807|OTHER|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
214262546|NCT02938429|OTHER|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
214262547|NCT03836599|DRUG|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
214262548|NCT03836599|DRUG|Allopurinol|Participants will receive allopurinol 300 mg once daily.
214262549|NCT03836599|DRUG|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
214262550|NCT03116360|DIAGNOSTIC_TEST|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
214262551|NCT02010710|DEVICE|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
214262552|NCT00889408|BIOLOGICAL|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
214262553|NCT01115361|BEHAVIORAL|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
214262554|NCT05177705|BEHAVIORAL|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
214262555|NCT00812669|BIOLOGICAL|pegfilgrastim|
214262556|NCT00812669|BIOLOGICAL|rituximab|
214262557|NCT00812669|DRUG|cyclophosphamide|
214262558|NCT00812669|DRUG|fludarabine phosphate|
214262559|NCT00812669|GENETIC|cytogenetic analysis|
214262560|NCT00812669|GENETIC|fluorescence in situ hybridization|
214262561|NCT00812669|GENETIC|gene expression analysis|
214818213|NCT00283361|PROCEDURE|Physical examination|
214262562|NCT00812669|GENETIC|mutation analysis|
214262563|NCT00812669|GENETIC|protein expression analysis|
214262564|NCT00812669|OTHER|flow cytometry|
214262565|NCT00812669|OTHER|laboratory biomarker analysis|
214262566|NCT02672280|DEVICE|Medical Collagen Membrane with MSC|
214262567|NCT02672280|DEVICE|Medical Collagen Membrane|
214262568|NCT02685046|DRUG|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
214262569|NCT05058716|DIAGNOSTIC_TEST|blood sample|weekly blood sample - coenzym q10 levels
214262570|NCT02081131|PROCEDURE|Open surgery|pancreatic head resection by open method
214262571|NCT02081131|PROCEDURE|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
214262572|NCT06181591|DRUG|Mirabegron 50 MG|Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
214262573|NCT06181591|DRUG|Oxybutynin Chloride 5 MG|Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
214262574|NCT06198127|OTHER|combination of core stability exercises and kinesio-taping|the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
214262575|NCT06198127|OTHER|Core stability exercises|After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
214262576|NCT05722093|DRUG|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
214262577|NCT03274232|DEVICE|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
214262578|NCT04568421|DRUG|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
214262579|NCT01877018|BEHAVIORAL|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
214262580|NCT03334110|PROCEDURE|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
214262581|NCT03334110|PROCEDURE|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
214262582|NCT05707936|DRUG|Normal Saline Flush 20 ml|Normal Saline Flush 20 ml
214262583|NCT05707936|DRUG|Normal Saline Flush 10 ml|Normal Saline Flush 10 ml
214262584|NCT05707936|DRUG|Heparin Flush (1000 USP, 10ml)|Heparin Flush (1000 USP, 10ml)
214262585|NCT00617851|BIOLOGICAL|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
214262586|NCT00617851|BIOLOGICAL|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
214262587|NCT00617851|BIOLOGICAL|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
214262588|NCT00617851|BIOLOGICAL|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
214262589|NCT00617851|BIOLOGICAL|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
214262590|NCT02248831|DEVICE|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
214262591|NCT02556658|DEVICE|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
214262592|NCT02556658|DEVICE|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
214262593|NCT05879601|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
214262594|NCT05879601|OTHER|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
214262595|NCT02239354|COMBINATION_PRODUCT|VC-01™ Combination Product|Biologic and Device
214262596|NCT02056639|DEVICE|Bioteque cup pessary|
214262597|NCT03395665|OTHER|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
214262598|NCT03395665|OTHER|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
214262599|NCT03395665|OTHER|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
214653877|NCT06916650|DEVICE|High-Intensity Laser Therapy (HILT)|Nd:YAG laser (1064 nm) applied to anterior, lateral, posterior glenohumeral joint aspects. Three-phase protocol per session: (1) 10 J/cm² @ 10 Hz; (2) 12 J/cm² @ 2000 Hz; (3) 10 J/cm² @ 15 Hz. Total energy \~1200 J/session. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by trained PTs.
214262600|NCT04761510|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
214262601|NCT03285672|DRUG|FP-101|Dose 1
214262602|NCT03285672|DRUG|Placebo Comparator|Dose 1
214262603|NCT03965767|DRUG|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
214262604|NCT02664259|PROCEDURE|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
214262605|NCT02664259|PROCEDURE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
214262606|NCT02664259|PROCEDURE|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
214262607|NCT01482273|PROCEDURE|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
214262608|NCT01482273|PROCEDURE|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
214262609|NCT03959254|PROCEDURE|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
214262610|NCT00224705|DEVICE|Molecular Adsorbent Recirculating System (MARS®)|
214262611|NCT02280070|OTHER|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
214262612|NCT02280070|OTHER|Medical history and physical examination|medical history and physical examination
214262613|NCT02280070|OTHER|BW and height|Body weight (kg) and height (cm)
214262614|NCT02280070|OTHER|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
214262615|NCT02280070|OTHER|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
214262616|NCT02280070|OTHER|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
214262617|NCT02280070|RADIATION|Contrasting CT|Computed tomography
214262618|NCT02280070|OTHER|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
214262619|NCT02280070|OTHER|HBs antigen and HCV antibody|check for exclusion criteria
214262620|NCT02280070|OTHER|Endoscopy|Endoscopy for lower digestive tract
214262621|NCT02280070|OTHER|HBs antibody and HBc antibody|Check according to hepatitis B guideline
214262622|NCT02280070|DRUG|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
214262623|NCT02280070|DRUG|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
214262624|NCT02280070|DRUG|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
214262625|NCT02280070|DRUG|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
214262626|NCT02280070|DRUG|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
214262627|NCT04768075|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
214262628|NCT04768075|DRUG|Placebo|IV infusion Simulator of Camrelizumab
214262629|NCT04768075|DRUG|Cisplatin|IV infusion
214262630|NCT04768075|DRUG|Carboplatin|IV infusion
214262631|NCT04768075|DRUG|Pemetrexed|IV infusion
214262632|NCT04768075|DRUG|Paclitaxel|IV infusion
214262633|NCT04768075|DRUG|Albumin paclitaxel|IV infusion
214262634|NCT02285647|DRUG|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
214262635|NCT02285647|DRUG|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
214262636|NCT02875054|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
214262637|NCT02875054|BEHAVIORAL|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
214262638|NCT05737849|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
214262639|NCT04172623|BEHAVIORAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
214262640|NCT04172623|BEHAVIORAL|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
214262641|NCT01250431|BEHAVIORAL|EFT (Emotional Freedom Techniques)|10 EFT sessions
214262642|NCT03368534|DEVICE|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
214262643|NCT01136031|DRUG|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week"
214262644|NCT00902668|DRUG|lovastatin|
214262645|NCT00902668|OTHER|questionnaire administration|
214262646|NCT00902668|PROCEDURE|adjuvant therapy|
214262647|NCT00902668|RADIATION|accelerated partial breast irradiation|
214262648|NCT00902668|RADIATION|external beam radiation therapy|
214262649|NCT04962620|DRUG|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
214262650|NCT01209507|OTHER|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
214262651|NCT01914757|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
214262652|NCT01914757|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
214262653|NCT00050271|DRUG|Acetyl-L-carnitine|
214262654|NCT03328767|BEHAVIORAL|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
214262655|NCT04224038|OTHER|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
214262656|NCT02973490|DEVICE|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
214262657|NCT01069016|PROCEDURE|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
214262658|NCT01069016|PROCEDURE|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
214262659|NCT05130918|DEVICE|Phenolmicin P3 and Bosexil suppository|The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
214262660|NCT05139082|DRUG|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
214262661|NCT03509883|DRUG|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
214262662|NCT03509883|DRUG|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
214262663|NCT01499758|DRUG|Atorvastatin|80 Mg tablets
214262664|NCT00333177|BEHAVIORAL|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
214262665|NCT00333177|BEHAVIORAL|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
214262666|NCT00333177|DRUG|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
214262667|NCT00333177|DRUG|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
214262668|NCT03564431|DEVICE|Magnetic resonance|magnetic resonance spectrum of brain
214262669|NCT03959631|BEHAVIORAL|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
214262670|NCT04799574|OTHER|music therapy activities|"Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities."
214262671|NCT03278756|BEHAVIORAL|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
214262672|NCT03278756|BEHAVIORAL|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
214262673|NCT02884882|OTHER|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
214262674|NCT00004195|DRUG|eniluracil|Will be given to either subject pre-operative and metastatic disease
214262675|NCT00004195|PROCEDURE|conventional colon surgery|Only if the subject is amenable to surgical resections
214262676|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|UNSUP will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
214262677|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|UNSUP+ will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
214262678|NCT05619250|BEHAVIORAL|Supervised center-based exercise group without motivational intervention (SUP)|SUP will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
214262679|NCT05619250|BEHAVIORAL|Supervised center-based exercise group with motivational intervention (SUP+)|SUP+ will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
214262680|NCT00386386|OTHER|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
214262681|NCT03265301|PROCEDURE|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
214262682|NCT03265301|PROCEDURE|Office hysteroscopy|will be done in out patient clinic without anesthesia
214262683|NCT03265301|PROCEDURE|Conventional hysteroscopy|will be done in operative room under general anesthesia
214262684|NCT02833350|DRUG|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
214262685|NCT02833350|DRUG|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
214262686|NCT02833350|DRUG|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
214262687|NCT02833350|DRUG|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
214262688|NCT02833350|DRUG|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
214262689|NCT06166485|OTHER|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
214262690|NCT02210546|OTHER|Magnetic Resonance Imaging (MRI)|
214262691|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|
214262692|NCT05280171|OTHER|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
214262693|NCT05280171|OTHER|Standard of care|Standard of care
214262694|NCT04284852|DRUG|Niraparib|PARP inhibitor
214262695|NCT02420522|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
214653878|NCT06916650|DRUG|Ultrasound-Guided Intra-articular Corticosteroid Injection|Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered at baseline by an experienced orthopedic physician.
214262696|NCT02420522|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
214262697|NCT01414660|PROCEDURE|transplantation|transplantation of islet, kidney or liver
214262698|NCT02802943|BIOLOGICAL|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
214262699|NCT02802943|DRUG|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
214262700|NCT04337268|DRUG|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
214262701|NCT04337268|DRUG|saline 0.9%|Intravenous infusion for 60 min.
214262702|NCT03624985|DRUG|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
214262703|NCT03624985|DRUG|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
214262704|NCT03342963|DRUG|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
214262705|NCT03342963|DRUG|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
214262706|NCT01553383|DEVICE|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
214262707|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
214262708|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
214262709|NCT00879099|DRUG|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
214262710|NCT00879099|DRUG|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
214262711|NCT00879099|DRUG|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
214262712|NCT00879099|DRUG|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
214262713|NCT01963273|PROCEDURE|Video Assisted Ablation of Pilonidal Sinus|
214262714|NCT01388595|DRUG|FLUTICASONE PROPRIONATE|1\. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
214262715|NCT01388595|DRUG|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
214262716|NCT01388595|DRUG|PLACEBO|4\. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
214262717|NCT01667484|DRUG|Adderall XR 5mg|
214262718|NCT01667484|DRUG|Adderall XR 10 mg|
214262719|NCT01667484|DRUG|Placebo|
214653879|NCT06916650|BEHAVIORAL|Manual Therapy|Skilled hands-on techniques including glenohumeral joint mobilizations (Maitland grades III-IV), posterior capsule stretching, scapular mobilization, and soft tissue techniques targeting restricted tissues. Session duration: \~30 minutes. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by PTs specialized in manual therapy.
214262720|NCT01374828|DRUG|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
214262721|NCT00839722|PROCEDURE|embolization|fertility after embolization
214262722|NCT04517500|BEHAVIORAL|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
214262723|NCT04517500|BEHAVIORAL|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
214262724|NCT04517500|BEHAVIORAL|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
214262725|NCT02284269|DRUG|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
214262726|NCT04747080|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
214262727|NCT04747080|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
214262728|NCT06050005|DIAGNOSTIC_TEST|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
214262729|NCT04242329|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
214262730|NCT04242329|DRUG|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
214653880|NCT06916650|BEHAVIORAL|Standard Exercise Program|Standardized program including pendulum exercises, active-assisted range of motion exercises (e.g., wand, wall climbs), stretching (e.g., cross-body, sleeper stretch), and progressive resistive exercises using resistance bands. Includes supervised instruction/progression and a daily home exercise program component. Supervised instruction frequency: 2 sessions/week for first 6 weeks, then 1 session/week for next 6 weeks (total 18 supervised sessions over 12 weeks). Delivered by trained PTs.
214262731|NCT05276518|PROCEDURE|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
214262732|NCT02973061|OTHER|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
214262733|NCT03009500|DRUG|Bupivacaine|
214262734|NCT03009500|DRUG|Depo-Medrol Injectable Product|
214262735|NCT03009500|OTHER|Saline (Sodium Chloride) solution|
214262736|NCT03009500|DRUG|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
214262737|NCT06464796|OTHER|Motor Imagery Techniques|"* Play a video of person doing a toe-raise exercise where carrying a big barbell on his shoulders.~* The individual in the video proceeded from a neutral upright position to a tiptoe standing while loud a heavy barbell; the plantar-flexors are used in this workout.~* The members were said to imagine engaging their ankle flexor muscles in an effort to generate ankle flexion. Both limbs were used during the 10-second imaginary contraction, which was tailed by a 10-second rest. Subsequently five repetitions of the contraction, there was a 30 second pause. Two-minutes of rest were interspersed between five-sets of five-contractions. Fifty imaginary contractions in total."
214262738|NCT06464796|OTHER|Conventional Exercise Therapy|"1. ROM drills for pronation, flexion and extension.~2. Ankle strengthening trainings include stand-up on tiptoe, walking on toe-tip, hopping on single foot, and resistance exercise with a latex elastic band.~3. Proprioceptive exercise include the following exercises: (a) sit on a proprioception board and move the injured limb in a round motion; (b) stand-up with both legs on the board while performing both eyes open and closed; (c) standing with single leg on the board while performing both eyes open; and (d) exercises on a mini-tramp (stand-up on double legs, single leg stances, hops on both left and right legs and on single leg).~4. Strengthening of the muscles of ankle completed with flexible bands at moderate Intensities.~5. Training on a stationary bicycle.~6. lunges forward into a wall.~7. Steps up and down on the transverse or sagittal plane."
214262739|NCT04269707|DRUG|Ferric carboxymaltose|IV iron
214262740|NCT00816296|OTHER|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
214262741|NCT00816296|OTHER|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
214262742|NCT00816296|OTHER|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
214262743|NCT00816296|OTHER|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
214262744|NCT03270371|DEVICE|Medium cut off dialysis|Hemodialysis
214262745|NCT03270371|DEVICE|Standard High Flux Dialyzer|Hemodialysis
214262746|NCT03138304|BEHAVIORAL|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
214262747|NCT03138304|BEHAVIORAL|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
214262748|NCT02824575|DRUG|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
214262749|NCT02824575|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
214262750|NCT02824575|DRUG|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
214262751|NCT05622695|DEVICE|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
214653881|NCT01468311|PROCEDURE|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
214653882|NCT01468311|DRUG|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
214262752|NCT01000402|DRUG|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
214262753|NCT02183896|BIOLOGICAL|Platelet-rich plasma (PRP)|
214262754|NCT02183896|DRUG|Saline|
214262755|NCT04069962|BEHAVIORAL|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
214262756|NCT03594526|BEHAVIORAL|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
214262757|NCT03594526|BEHAVIORAL|Control Group: usual care|"This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding."
214262758|NCT02987842|DEVICE|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
214262759|NCT06255964|DRUG|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
214262760|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
214262761|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
214262762|NCT05393011|DRUG|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
214262763|NCT03922126|OTHER|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
214262764|NCT03922126|DIAGNOSTIC_TEST|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
214262765|NCT01880281|OTHER|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
214262766|NCT00250120|DRUG|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
214262767|NCT01189604|DRUG|Placebo|Infusion of placebo, same infusion rates as for arm 2
214262768|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
214262769|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
214262770|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
214262771|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
214262772|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
214262773|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
214262774|NCT04555343|DRUG|Tranexamic acid|1gm instilled instravesically
214262775|NCT03555734|OTHER|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
214262776|NCT03626168|DIETARY_SUPPLEMENT|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
214262777|NCT03626168|OTHER|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
214262778|NCT03477123|DEVICE|Walking therapy with Exo-H2 exoskeleton|
214262779|NCT00878670|DRUG|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
214262780|NCT02248701|DRUG|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
214262781|NCT02248701|DRUG|Finasteride|Subjects receive finasteride (5 mg/day) orally
214262782|NCT02248701|DRUG|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
214262783|NCT02248701|DRUG|Placebo pill|Subjects receive placebo pill (daily) orally
214262784|NCT04304742|PROCEDURE|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
214262785|NCT00185835|DRUG|ZD-1839|
214262786|NCT00185835|DRUG|Cisplatin|
214653883|NCT01468311|RADIATION|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
214653884|NCT01468311|RADIATION|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
214262787|NCT02025166|DRUG|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
214262788|NCT02025166|DRUG|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
214262789|NCT02760797|DRUG|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
214262790|NCT02760797|DRUG|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
214262791|NCT05303363|DEVICE|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
214262792|NCT02074930|DEVICE|Microporation by P.L.E.A.S.E. Professional / Prick needle|
214262793|NCT03585842|OTHER|No intervention|No intervention
214262794|NCT05515315|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
214262795|NCT05515315|DRUG|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
214262796|NCT05515315|DRUG|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
214262797|NCT05515315|RADIATION|radiotherapy|50-60Gy/25-30f
214653885|NCT06498986|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214653886|NCT06498986|DRUG|Osimertinib Mesylate Tablets|Oral administration, 80mg daily for a cycle of 3 weeks.
214262798|NCT05291325|DRUG|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
214262799|NCT05291325|DRUG|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
214262800|NCT05291325|DRUG|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
214262801|NCT00808483|OTHER|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
214262802|NCT01941693|BEHAVIORAL|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
214262803|NCT01941693|BEHAVIORAL|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
214262804|NCT02038881|BIOLOGICAL|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
214262805|NCT01171040|OTHER|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
214262806|NCT05604677|PROCEDURE|Breast Surgery|Breast-conserving Surgery or modified radical mastectomy
214262807|NCT02357979|DEVICE|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
214262808|NCT02357979|OTHER|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
214262809|NCT01232777|DRUG|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
214262810|NCT03151343|DRUG|Empagliflozin|Empagliflozin tablet
214262811|NCT03151343|DRUG|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
214262812|NCT03945214|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
214262813|NCT03945214|BEHAVIORAL|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
214262814|NCT03945214|BEHAVIORAL|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
214262815|NCT03108274|DRUG|Danicopan|Oral tablet.
214262816|NCT03108274|DRUG|Midazolam|Oral syrup.
214262817|NCT03108274|DRUG|Fexofenadine|Oral tablet.
214262818|NCT03108274|DRUG|Mycophenolate Mofetil|Oral tablet.
214653887|NCT06935708|DRUG|Intrathecal Morphine|In Spinal group, 25 G or 27 G pencil point needle, depending on the preference of the anesthesiologist, will be inserted at L2-L3 or L3-L4 intervertebral space and 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
214262819|NCT05979506|PROCEDURE|Cutaneous wraps|"The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel"
214262820|NCT06365112|PROCEDURE|Endoscopy assisted|Endoscopy
214262821|NCT02435446|DEVICE|Cone-beam computed tomography|Cone-beam computed tomography
214262822|NCT01733784|OTHER|Induced central apneas|
214262823|NCT02418429|OTHER|waxy maize starch|pancake test meal with waxy maize starch only
214262824|NCT02418429|OTHER|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
214262825|NCT02418429|OTHER|Resistant Starch|pancake test meal with resistant starch only
214262826|NCT02418429|OTHER|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
214262827|NCT03300284|BEHAVIORAL|Questionnaires|Quality of Life Questionnaires
214262828|NCT01077570|DRUG|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
214262829|NCT03474861|BIOLOGICAL|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
214262830|NCT00880542|DRUG|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
214262831|NCT00880542|DRUG|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
214262832|NCT01529242|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
214262833|NCT01529242|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
214262834|NCT00850070|DRUG|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
214262835|NCT00850070|DRUG|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
214262836|NCT06442280|DRUG|Dapagliflozin tablet|Dapagliflozin 10 mg 1 tablet once daily
214262837|NCT06442280|DRUG|Hypertonic Saline Solution, 1 Ml|Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
214262838|NCT06442280|DRUG|Furosemide Injection|Furosemide 20 mg
214262839|NCT05047770|BIOLOGICAL|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
214262840|NCT05047770|COMBINATION_PRODUCT|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
214262841|NCT05047770|BIOLOGICAL|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
214262842|NCT02391701|BEHAVIORAL|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
214262843|NCT03845777|DIAGNOSTIC_TEST|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
214653888|NCT06935708|PROCEDURE|Epidural Analgesia|Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery. Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery.
214262844|NCT02371148|DRUG|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
214262845|NCT01724931|DRUG|LD-aminopterin|
214262846|NCT01724931|DRUG|placebo|
214653889|NCT06934278|DRUG|Pooled human plasma|Infusion of pooled human plasma (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
214653890|NCT06934278|DRUG|Placebo|Infusion of cryst (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
214262847|NCT01181908|DRUG|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
214262848|NCT00589992|DRUG|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
214262849|NCT03214315|PROCEDURE|Visceral adipose tissue specimen|specimen
214262850|NCT05490303|OTHER|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
214262851|NCT06189690|DEVICE|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
214262852|NCT03719820|DRUG|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
214262853|NCT03047655|BEHAVIORAL|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
214262854|NCT03047655|DIETARY_SUPPLEMENT|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
214262855|NCT01830231|DRUG|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
214262856|NCT01830231|DRUG|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
214262857|NCT05819281|DIETARY_SUPPLEMENT|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
214262858|NCT05819281|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin
214262859|NCT02322476|OTHER|No intervention will be performed|No intervention will be performed
214262860|NCT03468803|DIAGNOSTIC_TEST|Beta D Glucan test|Measurement of BDG before, during and after surgery
214262861|NCT03566862|DIAGNOSTIC_TEST|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
214262862|NCT04289623|BEHAVIORAL|Email|Email
214262863|NCT04289623|BEHAVIORAL|Loss frame|Email
214262864|NCT04289623|BEHAVIORAL|Testimonial (medical expert)|Email
214262865|NCT04289623|BEHAVIORAL|Testimonial (rank-and-file)|Email
214262866|NCT04289623|BEHAVIORAL|Social norms (percentage)|Email
214262867|NCT04289623|BEHAVIORAL|Social norms (number)|Email
214262868|NCT02646657|DRUG|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
214262869|NCT05614232|RADIATION|Chest X-ray|Chest radiographs
214262870|NCT04185948|BEHAVIORAL|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
214262871|NCT04185948|BEHAVIORAL|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
214262872|NCT03758443|DRUG|TD-1473 Dose A|See Arm description
214262873|NCT03758443|DRUG|TD-1473 Dose B|See Arm description
214262874|NCT03758443|DRUG|TD-1473 Dose C|See Arm description
214262875|NCT03758443|DRUG|Placebo|See Arm description
214262876|NCT05234996|DEVICE|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
214262877|NCT00899769|GENETIC|protein expression analysis|
214262878|NCT00899769|GENETIC|proteomic profiling|
214262879|NCT00899769|OTHER|immunoenzyme technique|
214262880|NCT00899769|OTHER|laboratory biomarker analysis|
214262881|NCT00899769|OTHER|liquid chromatography|
214262882|NCT00899769|OTHER|mass spectrometry|
214262883|NCT05541042|OTHER|Observational only|This is an observational study
214262884|NCT01484223|BEHAVIORAL|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
214262885|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
214262886|NCT01436396|BIOLOGICAL|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
214262887|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
214262888|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
214262889|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
214262890|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
214262891|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
214262892|NCT01436396|BIOLOGICAL|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
214262893|NCT01436396|BIOLOGICAL|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
214262894|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
214262895|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
214262896|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
214262897|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
214262898|NCT01064596|OTHER|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
214262899|NCT01102270|DRUG|Eszopiclone|3mg tablet once prior to sleep
214262900|NCT01102270|DRUG|Placebo|1 placebo capsule prior to sleep
214262901|NCT05021263|DRUG|IV Medications|IV magnesium sulfate, used to replete magnesium stores
214262902|NCT05021263|OTHER|placebo|placebo
214262903|NCT00618683|PROCEDURE|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
214262904|NCT00812682|DRUG|Symbicort|
214262905|NCT00827528|PROCEDURE|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
214262906|NCT00827528|PROCEDURE|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
214262907|NCT03133130|DRUG|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
214262908|NCT03133130|DRUG|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
214262909|NCT00013962|DRUG|Vitamin D|
214262910|NCT00843531|DRUG|RAD001|5 mg/day PO (oral)
214262911|NCT00843531|DRUG|erlotinib|100 mg/day (oral)
214262912|NCT01845142|DRUG|single administration of 100.000 I.U. vitamin D|
214262913|NCT01845142|DRUG|Placebo|
214262914|NCT02182739|DRUG|Meloxicam|tablets or injectable solution
214262915|NCT01633073|DEVICE|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
214262916|NCT01633073|DEVICE|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
214262917|NCT02632331|DRUG|ASP8825|Oral
214262918|NCT00143182|DRUG|Asenapine|Asenapine , 9 weeks
214262919|NCT00143182|DRUG|Olanzapine|Olanzapine, 9 weeks
214262920|NCT02707107|DRUG|Intravenous infusions of WCK 5222|
214262921|NCT02707107|DRUG|Placebo|
214262922|NCT02182102|DRUG|BIBF 1120|
214262923|NCT02182102|DRUG|Pemetrexed|
214262924|NCT03855865|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
214262925|NCT03855865|DRUG|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
214262926|NCT03855865|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
214262927|NCT01772160|OTHER|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
214653891|NCT03463772|PROCEDURE|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
214653892|NCT03463772|DRUG|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
214653893|NCT00168350|DRUG|memantine|
214262928|NCT05815641|DIETARY_SUPPLEMENT|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
214262929|NCT02016001|OTHER|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
214262930|NCT02016001|OTHER|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
214262931|NCT00901407|DRUG|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
214262932|NCT00901407|DRUG|placebo|placebo: 1-2 tablets bid; 10 weeks
214262933|NCT00901407|DRUG|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
214262934|NCT03722823|DRUG|Tucatinib|300mg oral single dose
214262935|NCT05681663|OTHER|Electroshock Wave therapy|Randomized- Controlled trial
214262936|NCT03562533|DRUG|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
214262937|NCT03562533|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
214262938|NCT01813188|PROCEDURE|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
214262939|NCT01813188|PROCEDURE|autologous bone graft|autologous bone graft
214262940|NCT03004742|DIETARY_SUPPLEMENT|Flavonoid|Flavonoid rich supplement
214262941|NCT03004742|DIETARY_SUPPLEMENT|Placebo|Placebo
214262942|NCT06227260|OTHER|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
214262943|NCT04306848|DEVICE|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
214262944|NCT01865097|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
214262945|NCT01865097|BEHAVIORAL|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
214262946|NCT02488850|PROCEDURE|Surgery|
214262947|NCT02488850|RADIATION|SABR|
214262948|NCT00667160|DRUG|tacrolimus ointment|topical
214262949|NCT00667160|DRUG|pimecrolimus cream|topical
214262950|NCT00576784|DRUG|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
214262951|NCT06034847|DEVICE|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
214653894|NCT02366000|OTHER|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
214262952|NCT06034847|DEVICE|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
214262953|NCT02005731|DEVICE|Low intensity linear focused shockwave device ('Renova')|
214262954|NCT04312750|DRUG|Lidocaine topical system 1.8%|
214262955|NCT02272426|BEHAVIORAL|CARET|Combined Aerobic and Resistance Exercise Training
214262956|NCT02272426|BEHAVIORAL|CTI|Cognitive Training Intervention
214262957|NCT02272426|BEHAVIORAL|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
214262958|NCT02272426|BEHAVIORAL|Sham CTI|Sham Cognitive Training Intervention
214262959|NCT01522248|BIOLOGICAL|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
214262960|NCT03713892|DRUG|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
214262961|NCT03713892|DRUG|Placebo|orally administered
214262962|NCT03391089|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
214653895|NCT06198686|DRUG|Nalmefene|Opioid antagonist
214653896|NCT04958785|DRUG|Magrolimab|Administered intravenously
214653897|NCT04958785|DRUG|Nab-Paclitaxel|Administered intravenously
214653898|NCT04958785|DRUG|Paclitaxel|Administered intravenously
214262963|NCT03159117|DRUG|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
214262964|NCT00303901|PROCEDURE|cryosurgery|
214262965|NCT00303901|PROCEDURE|positron emission tomography|
214262966|NCT02298608|DEVICE|Nano Knife|Percutaneous, CT guided, ablation of renal mass
214262967|NCT03855969|PROCEDURE|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
214262968|NCT00178633|PROCEDURE|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
214262969|NCT00257374|DRUG|Gatorade, Pedialyte and New Solution|
214262970|NCT02940535|DRUG|Diphereline (Triptorelin embonate)|
214262971|NCT02940535|DRUG|Decapeptyl (Triptorelin)|
214262972|NCT02940535|DRUG|human menopausal gonadotropin|
214262973|NCT02940535|DRUG|human chorionic gonadotropin|
214262974|NCT00144196|DRUG|tiotropium (Spiriva)|
214262975|NCT04680130|DRUG|C-11 PiB|Completing PET scan looking for amyloid protein
214262976|NCT04680130|DRUG|AV1451 Tau|Completing PET scan looking for tau protein
214262977|NCT04680130|DRUG|C-11 ER176|Completing PET scan looking for neuroinflammation
214262978|NCT04299074|OTHER|addiction|questionnaire
214262979|NCT04482881|DRUG|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
214262980|NCT04482881|DRUG|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
214262981|NCT04482881|DRUG|Misoprostol|Giving women misoprostol
214262982|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
214262983|NCT00538291|BIOLOGICAL|cetuximab|
214262984|NCT00538291|DRUG|capecitabine|
214262985|NCT00538291|GENETIC|gene expression analysis|
214262986|NCT00538291|GENETIC|microarray analysis|
214262987|NCT00538291|GENETIC|polymorphism analysis|
214262988|NCT00538291|GENETIC|reverse transcriptase-polymerase chain reaction|
214262989|NCT00538291|OTHER|immunohistochemistry staining method|
214653899|NCT04958785|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214653900|NCT03919240|BIOLOGICAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
214653901|NCT04533711|BEHAVIORAL|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
214262990|NCT00591344|BEHAVIORAL|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
214262991|NCT00591344|BEHAVIORAL|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
214262992|NCT00571610|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
214262993|NCT04671524|OTHER|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
214262994|NCT05119673|OTHER|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
214262995|NCT00694707|DRUG|Placebo|Placebo was supplied in capsules.
214262996|NCT00694707|DRUG|Cariprazine|Cariprazine was supplied in capsules
214262997|NCT00694707|DRUG|Risperidone|Risperidone was supplied in capsules
214262998|NCT02460107|BIOLOGICAL|Botulinum toxin type A|
214262999|NCT02460107|OTHER|Normal saline|Placebo
214263000|NCT03308032|BEHAVIORAL|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
214263001|NCT03308032|BEHAVIORAL|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
214263002|NCT05908110|BEHAVIORAL|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
214263003|NCT04568889|BEHAVIORAL|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
214263004|NCT04568889|BEHAVIORAL|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
214263005|NCT04568889|BEHAVIORAL|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
214263006|NCT04568889|BEHAVIORAL|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
214263007|NCT04568889|BEHAVIORAL|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
214263008|NCT04568889|BEHAVIORAL|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
214263009|NCT04568889|BEHAVIORAL|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
214263010|NCT04568889|BEHAVIORAL|No Messaging|Individuals will see no messaging in the baseline survey.
214263011|NCT02640716|BEHAVIORAL|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
214263012|NCT02640716|BEHAVIORAL|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
214263013|NCT03420417|DEVICE|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
214818214|NCT05246462|OTHER|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
214263014|NCT00514423|OTHER|Psychoeducation by professonals|
214263015|NCT00514423|OTHER|Psychoeducation by peer-moderators|
214263016|NCT00514423|OTHER|Video-education|
214263017|NCT00514423|OTHER|Noneducational video group (control group)|
214263018|NCT04081324|DRUG|Lasmiditan|Administered orally
214263019|NCT04081324|DRUG|Placebo|Administered orally
214263020|NCT03181815|DRUG|Cladribine|5mg/㎡ d1-5
214263021|NCT03181815|DRUG|G-CSF|300ug d0-9
214263022|NCT03181815|DRUG|Aclarubicin|10mg d3-6
214263023|NCT03181815|DRUG|Cytarabine|10mg/㎡ q12h SC d3-9
214263024|NCT01641874|PROCEDURE|Exercise|Directional specific exercise
214263025|NCT01641874|PROCEDURE|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
214263026|NCT01464996|PROCEDURE|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
214263027|NCT01464996|PROCEDURE|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
214263028|NCT03959072|DEVICE|Robotic CTO PCI|Randomized to robotic CTO PCI.
214263029|NCT03959072|PROCEDURE|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
214263030|NCT04436211|PROCEDURE|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
214263031|NCT01904058|DRUG|LUM001|
214653902|NCT04533711|BEHAVIORAL|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
214263032|NCT01904058|DRUG|Placebo|
214263033|NCT01904058|DRUG|Ursodeoxycholic Acid|
214263034|NCT05038046|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
214263035|NCT05485454|DEVICE|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
214263036|NCT05485454|DEVICE|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
214263037|NCT01118871|DRUG|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
214263038|NCT01118871|DRUG|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
214263039|NCT01934244|DEVICE|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
214263040|NCT03096483|DEVICE|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
214263041|NCT03428607|DRUG|AZD6738|AZD6738 160mg QD
214653903|NCT01750918|DRUG|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
214653904|NCT01750918|DRUG|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
214818215|NCT03232619|BIOLOGICAL|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.
214263042|NCT03428607|DRUG|Olaparib|Olaparib 300mg BID
214263043|NCT00097318|DRUG|Interferon beta-1a|
214263044|NCT00751218|DRUG|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
214263045|NCT00751218|DRUG|placebo|placebo, once daily for 28 days
214263046|NCT00751218|DRUG|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
214263047|NCT02575742|DEVICE|3D-Transit system|
214263048|NCT01435070|PROCEDURE|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
214263049|NCT01435070|PROCEDURE|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
214263050|NCT03678883|DRUG|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
214263051|NCT03678883|DRUG|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
214263052|NCT03678883|DRUG|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
214263053|NCT03678883|DRUG|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
214263054|NCT03678883|DRUG|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
214263055|NCT03678883|DRUG|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
214263056|NCT03678883|DRUG|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
214263057|NCT03678883|DRUG|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
214263058|NCT03678883|DRUG|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
214263059|NCT00857883|DRUG|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
214263060|NCT01318642|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
214263061|NCT01318642|DRUG|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
214263062|NCT01318642|DRUG|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
214263063|NCT06059573|PROCEDURE|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
214263064|NCT06059573|PROCEDURE|Freehand surgery|Implant will be placed under freehand surgery.
214263065|NCT03749473|BEHAVIORAL|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
214263066|NCT03749473|BEHAVIORAL|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
214263067|NCT03749473|BEHAVIORAL|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
214263068|NCT03749473|BEHAVIORAL|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
214263069|NCT03749473|BEHAVIORAL|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
214263070|NCT03749473|BEHAVIORAL|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
214263071|NCT05007210|OTHER|Prenatal massage therapy|Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
214263072|NCT05887414|OTHER|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
214263073|NCT05887414|OTHER|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
214263074|NCT02320617|PROCEDURE|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
214263075|NCT04719637|DEVICE|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
214263076|NCT05000697|DRUG|Oxaliplatin|Patients will receive 5FU + Oxaliplatin during the consolidation chemotherapy after long course chemoradiation
214263077|NCT05000697|DRUG|5FU|Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
214263078|NCT05735197|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
214263079|NCT05735197|DRUG|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
214263080|NCT06416033|PROCEDURE|Serum Irisin|Measurement of plasma irisin level in leprosy patients.
214653905|NCT01750918|DRUG|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
214263081|NCT02556736|DRUG|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
214263082|NCT04434066|PROCEDURE|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
214263083|NCT04335838|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
214263084|NCT05421923|DRUG|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
214263085|NCT05421923|OTHER|Placebo|Ascending single and multiple doses of Placebo orally
214263086|NCT06161610|DEVICE|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
214263087|NCT06161610|OTHER|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
214263088|NCT03594435|DRUG|Ibudilast|targets neurotrophin signaling and neuroimmune function
214263089|NCT03594435|DRUG|Placebo oral capsule|matched to active drug, ibudilast
214263090|NCT05659992|DRUG|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
214263091|NCT06469515|OTHER|Elective or urgent cardiac surgery|This is a longitudinal observational study to explore postoperative cognitive recovery among older persons (aged 65 or older) undergoing elective or urgent cardiac surgery via sternotomy.
214263092|NCT01354327|DIETARY_SUPPLEMENT|Limicol|3 tablets / day during 4 months
214263093|NCT01354327|DIETARY_SUPPLEMENT|Placebo|3 tablets / day during 4 months
214263094|NCT02857985|DEVICE|3D RA|3D RA is realised just after angioplasty.
214263095|NCT02857985|DEVICE|MRI|MRI is realised between 24h and 96h post angioplasty.
214263096|NCT05122871|OTHER|Scape Room|Practical training through scape-room with simulator
214263097|NCT05122871|OTHER|Simulation|Practical training through simulator
214263098|NCT03616132|DEVICE|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
214263099|NCT00570167|PROCEDURE|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
214263100|NCT00570167|PROCEDURE|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
214263101|NCT00886912|OTHER|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
214263102|NCT00886912|OTHER|normoxia|training under normoxic conditions
214263103|NCT03499548|OTHER|INSPiRe Programme|Intensive CBT for suicide
214263104|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
214263105|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
214263106|NCT03971123|DRUG|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
214263107|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
214263108|NCT02329821|OTHER|hartmann solution|hartmann solution infusion in patients for hepatic resection
214263109|NCT04888078|PROCEDURE|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
214263110|NCT02787265|DEVICE|spinal cord stimulation|
214263111|NCT05099081|PROCEDURE|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
214653906|NCT01750918|DEVICE|5-fluorouracil|5-fluorouracil-based chemotherapy
214263112|NCT05099081|PROCEDURE|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
214653907|NCT03805880|DIAGNOSTIC_TEST|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
214653908|NCT01509027|BEHAVIORAL|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
214653909|NCT01509027|BEHAVIORAL|Standard care|standard care
214653910|NCT01509027|BEHAVIORAL|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
214653911|NCT05426811|DRUG|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
214653912|NCT05426811|DRUG|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
214263113|NCT03334591|DRUG|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
214263114|NCT02651831|OTHER|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
214263115|NCT02651831|OTHER|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
214653913|NCT03027167|DRUG|Aspirin|
214653914|NCT03027167|DEVICE|(Post- discharge) Mechanical Compression Device|
214653915|NCT03226093|PROCEDURE|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
214653916|NCT00460993|DRUG|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
214653917|NCT02610309|BEHAVIORAL|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
214263116|NCT04225962|OTHER|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
214263117|NCT03506932|DIETARY_SUPPLEMENT|Untreated|Bread made with 20% yellow pea flour that was untreated.
214263118|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
214263119|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
214263120|NCT03506932|DIETARY_SUPPLEMENT|Wheat|Bread made with 100% wheat
214263121|NCT01024231|DRUG|BMS-936558 (MDX1106-04)|
214263122|NCT01024231|DRUG|Ipilimumab|
214263123|NCT02514603|DRUG|Prexasertib|Administered IV
214263124|NCT03815539|DEVICE|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
214263125|NCT04932759|BEHAVIORAL|music listening|music listening during dental treatment
214263126|NCT00416546|DRUG|AEB071|
214263127|NCT02869607|OTHER|Data collection|
214263128|NCT04951804|PROCEDURE|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
214263129|NCT04951804|PROCEDURE|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
214263130|NCT03472651|DRUG|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
214263131|NCT03472651|DRUG|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
214263132|NCT00887874|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
214263133|NCT06417125|DRUG|Dexmedetomidine Hydrochloride|Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.
214263134|NCT06417125|DRUG|Midazolam|Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
214263135|NCT06417125|DRUG|normal Saline|Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
214263136|NCT06417125|DRUG|Glucose solution|Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
214263137|NCT04135365|BEHAVIORAL|neurocognitive assessment|Observational study therefore there are no interventions
214263138|NCT04135365|BEHAVIORAL|neuroimaging assessment|Observational study therefore there are no interventions
214263139|NCT00156520|DRUG|aprotonin; epsilon aminocaproic acid|
214263140|NCT01931930|DIETARY_SUPPLEMENT|Perilla extract|
214263141|NCT01931930|DIETARY_SUPPLEMENT|Maltodextrin|
214263142|NCT04677790|BEHAVIORAL|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
214263143|NCT00352443|DRUG|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
214263144|NCT00352443|DRUG|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
214263145|NCT02544646|OTHER|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
214263146|NCT04728867|OTHER|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
214263147|NCT02702063|OTHER|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
214263148|NCT02702063|PROCEDURE|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
214263149|NCT02702063|OTHER|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
214263150|NCT06210581|OTHER|Supervised Exercise Program Group|The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
214263151|NCT06210581|OTHER|Internet Based Exercise Program Group|"Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system."
214263152|NCT04886739|DRUG|CGB-400|Topical gel
214263153|NCT04886739|DRUG|Vehicle Gel|Topical gel
214263154|NCT03225274|OTHER|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
214263155|NCT06402084|DIAGNOSTIC_TEST|abdominal ultrasound|abdominal ultrasound and lipid profile will be done
214653918|NCT02561897|DRUG|Edoxaban|
214653919|NCT02561897|DRUG|Warfarin|
214653920|NCT03135392|PROCEDURE|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
214653921|NCT03135392|PROCEDURE|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
214653922|NCT03135392|PROCEDURE|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
214653923|NCT01967043|DRUG|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
214653924|NCT00170976|DRUG|valsartan + amlodipine|
214263156|NCT05337293|BEHAVIORAL|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
214263157|NCT05337293|OTHER|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
214263158|NCT05252065|OTHER|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
214263159|NCT03637179|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214263160|NCT03637179|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214263161|NCT06391385|PROCEDURE|protective ileostomy|Preparation of the bowel was performed before surgery with the administration of intravenous perioperative antibiotic prophylaxis. The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn.
214263162|NCT01419639|DRUG|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
214263163|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
214263164|NCT05751642|BIOLOGICAL|Placebo|Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
214263165|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by SC infusion.
214263166|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
214263167|NCT01024218|DEVICE|NovoFine® needle 8 mm|
214263168|NCT01024218|DEVICE|autocover needle|
214263169|NCT02634281|DRUG|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
214263170|NCT02634281|DRUG|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
214263171|NCT01724411|OTHER|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
214263172|NCT03361267|DIAGNOSTIC_TEST|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
214263173|NCT03361267|DIAGNOSTIC_TEST|CLO test|CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
214263174|NCT05785351|PROCEDURE|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
214263175|NCT03384888|DEVICE|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
214263176|NCT03384888|DEVICE|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
214263177|NCT00493532|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
214263178|NCT00767949|BIOLOGICAL|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
214263179|NCT00660751|DRUG|Duloxetine|SNRIs
214263180|NCT04112524|DEVICE|App|"* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
214263181|NCT04977921|OTHER|lab session|assign students to clinical modules for study the clinical lab scope of practice
214263182|NCT01035580|DRUG|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
214263183|NCT01035580|DRUG|curcumin|all patients received the drug
214263184|NCT04510376|DEVICE|Test Article|Omeza Collagen Matrix
214263185|NCT04510376|OTHER|Positive Control|1.0 mg/mL Histamine Base
214263186|NCT04510376|OTHER|Negative Control|Aqueous Negative Control
214263187|NCT01164683|BEHAVIORAL|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
214263188|NCT01164683|OTHER|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
214263189|NCT04124653|DRUG|PF-06842874|Single dose administration of PF-06842874
214263190|NCT04124653|DRUG|Placebo|Single dose administration of placebo
214263191|NCT04124653|DRUG|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
214263192|NCT02612038|DEVICE|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
214263193|NCT02612038|DEVICE|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
214653925|NCT04177836|BEHAVIORAL|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
214653926|NCT00371267|BEHAVIORAL|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
214263194|NCT04757246|OTHER|MouthLab Device|Use of MouthLab system
214263195|NCT02450188|DRUG|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
214263196|NCT02450188|BEHAVIORAL|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
214263197|NCT06330454|DEVICE|I-ONE|Pulsed Electromagnetic fields joint therapy
214263198|NCT05088395|OTHER|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
214263199|NCT05088395|OTHER|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
214263200|NCT05820373|BEHAVIORAL|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
214263201|NCT05820373|BEHAVIORAL|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
214263202|NCT05820373|BEHAVIORAL|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
214263203|NCT02767505|OTHER|gastric bypass|Type of surgery: gastric bypass
214263204|NCT02767505|OTHER|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
214263205|NCT02787460|BEHAVIORAL|Behavioral Text Messages|
214263206|NCT02471976|OTHER|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
214263207|NCT01561378|DRUG|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
214263208|NCT01561378|DRUG|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
214263209|NCT01561378|DEVICE|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
214263210|NCT06174259|OTHER|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
214653927|NCT00371267|OTHER|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
214653928|NCT03429218|DRUG|TP-0184|Oral dose once weekly for 4 weeks
214818216|NCT06441097|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
214818217|NCT06441097|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
214263211|NCT00973674|DRUG|Premarin IV|One time dose of Premarin IV
214263212|NCT00973674|DRUG|Placebo|One time dose of Placebo
214263213|NCT02645721|BEHAVIORAL|Extended self-help program with guidance|See arm description for Experimental
214263214|NCT02645721|BEHAVIORAL|Briefer Self-help program, no guidance|See arm description for Active Comparator
214263215|NCT02645721|BEHAVIORAL|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
214263216|NCT02666885|RADIATION|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
214263217|NCT03274271|BEHAVIORAL|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
214263218|NCT03274271|BEHAVIORAL|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
214263219|NCT03274271|BEHAVIORAL|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
214263220|NCT03274271|BEHAVIORAL|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
214263221|NCT00014261|BIOLOGICAL|PEG-interferon alfa-2b|
214263222|NCT00014261|DRUG|temozolomide|
214263223|NCT04087174|DRUG|Capivasertib|Patients will receive multiple oral dose of capivasertib.
214263224|NCT04087174|DRUG|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
214263225|NCT04087174|DRUG|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
214263226|NCT00978471|DRUG|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
214263227|NCT02321631|DIETARY_SUPPLEMENT|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
214263228|NCT02321631|DIETARY_SUPPLEMENT|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
214263229|NCT04504279|BIOLOGICAL|FB-401|Topical application
214263230|NCT04504279|BIOLOGICAL|Placebo|Vehicle
214263231|NCT04300439|DEVICE|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
214263232|NCT02563951|DRUG|GNS Spray 0.5mg|
214263233|NCT02563951|DRUG|GNS Spray 1.0mg|
214263234|NCT02563951|DRUG|GNS Spray 2.0mg|
214263235|NCT02563951|DRUG|Kytril 1mg (IV injection)|
214263236|NCT02563951|DRUG|Kytril 1mg (Tablet)|
214263237|NCT06191523|OTHER|Control Group|The control group will receive standard therapy and placebo.
214263238|NCT06191523|DRUG|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
214263239|NCT04215250|OTHER|andropulous method|Counts the CVC depth using specific equation
214263240|NCT04215250|DEVICE|ECG|Using ECG to monitor the insertion of the CVC
214263241|NCT00487682|DRUG|ASP2151|oral
214263242|NCT00487682|DRUG|Valacyclovir hydrochloride|oral
214263243|NCT04549246|RADIATION|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
214263244|NCT02713204|DRUG|REGN910-3|
214263245|NCT02713204|DRUG|Intravitreal Aflibercept Injection (IAI)|
214263246|NCT05548673|BEHAVIORAL|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
214263247|NCT00004756|PROCEDURE|Tailored educational program|
214263248|NCT00004756|PROCEDURE|Educational materials|
214263249|NCT05685836|DRUG|Bevacizumab Zirconium Zr-89|See Arm description.
214263250|NCT02534220|DEVICE|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
214263251|NCT02534220|DEVICE|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
214263252|NCT03352310|BIOLOGICAL|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
214263253|NCT03352310|PROCEDURE|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
214263254|NCT02350569|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
214263255|NCT05031273|BEHAVIORAL|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
214263256|NCT05400824|DIAGNOSTIC_TEST|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
214263257|NCT01372228|BIOLOGICAL|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
214263258|NCT04605042|PROCEDURE|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
214263259|NCT04605042|PROCEDURE|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
214263260|NCT02229331|OTHER|Gait analysis|
214263261|NCT02891109|BIOLOGICAL|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
214263262|NCT01710046|DRUG|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
214263263|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
214263264|NCT01710046|DRUG|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
214263265|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
214263266|NCT00001122|DRUG|Nelfinavir mesylate|
214263267|NCT00001122|DRUG|Efavirenz|
214263268|NCT00001122|DRUG|Stavudine|
214263269|NCT00001122|DRUG|Didanosine|
214263270|NCT00851344|DRUG|GSK835726 (10mg)|GSK835726 (10mg) tablet
214263271|NCT00851344|DRUG|GSK835726 (50mg)|GSK835726 (50mg) tablet
214263272|NCT00851344|DRUG|GSK835726 (100mg)|GSK835726 (100mg) tablet
214263273|NCT00851344|DRUG|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
214263274|NCT00851344|OTHER|Placebo|Placebo to match active
214263275|NCT05321108|OTHER|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
214263276|NCT05321108|OTHER|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
214263277|NCT05888077|OTHER|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
214263278|NCT05613881|OTHER|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
214263279|NCT01180101|BEHAVIORAL|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
214263280|NCT01180101|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery
214263281|NCT00498524|DEVICE|ICD|Received an ICD
214263282|NCT00498524|DEVICE|ICD|Have not received an ICD
214263283|NCT06285331|DEVICE|Automatic Bed|The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
214263284|NCT06285331|DEVICE|Manual|The clinicians will perform passive leg raising on patients by touching their legs physically.
214263285|NCT01776411|DRUG|forodesine hydrochloride|
214263286|NCT03896165|OTHER|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
214263287|NCT01904227|BEHAVIORAL|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
214263288|NCT01904227|BEHAVIORAL|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
214263289|NCT00199485|DRUG|Angelica Sinensis|Angelica Sinensis / placebo
214263290|NCT00645723|DRUG|Colistin|intravenous colistin and nebulized colistin
214263291|NCT00645723|DRUG|Colistin and saline solution|intravenous colistin and nebulized saline solution
214263292|NCT05405465|DRUG|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
214263293|NCT03078400|DRUG|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
214263294|NCT03844932|DRUG|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
214263295|NCT00002008|DRUG|Sargramostim|
214263296|NCT01193270|DRUG|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
214263297|NCT01193270|DRUG|Placebo|Sterile water in volume equal to that of the comparator drug
214263298|NCT03784703|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
214818218|NCT06441097|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214818219|NCT06441097|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214263299|NCT03784703|DRUG|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
214263300|NCT03181893|DRUG|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
214263301|NCT03181893|DRUG|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
214263302|NCT03181893|DRUG|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
214818220|NCT06441097|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
214263303|NCT02532530|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
214263304|NCT03000569|DRUG|SAGE-217|
214263305|NCT03000569|DRUG|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
214263306|NCT03000569|DRUG|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
214263307|NCT02524405|OTHER|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
214263308|NCT05968131|OTHER|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
214263309|NCT05968131|OTHER|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
214263310|NCT02353520|OTHER|motricity index strength assessment|
214263311|NCT04815031|BIOLOGICAL|BNT162b2|Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.
214263312|NCT00232648|DRUG|Pulmicort (budesonide) Respules|
214263313|NCT05995808|PROCEDURE|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
214263314|NCT05995808|DIAGNOSTIC_TEST|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
214263315|NCT04004962|DEVICE|Infrared spectroscopy|Infrared spectroscopy
214263316|NCT00507091|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
214263317|NCT00507091|DRUG|Irinotecan|intravenous infusion
214263318|NCT00507091|DRUG|5-Fluorouracil|intravenous infusion
214263319|NCT00507091|DRUG|Leucovorin|intravenous infusion
214263320|NCT00507091|DRUG|ZD6474 (vandetanib) 300mg|once daily oral tablet
214263321|NCT04122534|BEHAVIORAL|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
214263322|NCT06452589|DEVICE|FieldForce Ablation System|The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
214263323|NCT00579878|DRUG|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
214263324|NCT00579878|DRUG|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
214263325|NCT00579878|DRUG|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
214263326|NCT06057077|DRUG|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
214263327|NCT01872221|PROCEDURE|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
214263328|NCT02824237|DEVICE|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
214263329|NCT05188196|PROCEDURE|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
214263330|NCT03515252|BIOLOGICAL|Immune Killer Cells (IKC)|
214263331|NCT00885287|DRUG|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
214263332|NCT00318058|BIOLOGICAL|influenza vaccine Fluarix, Adjuvanted Fluarix|
214263333|NCT04932460|PROCEDURE|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
214263334|NCT04932460|PROCEDURE|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
214263335|NCT01254630|BIOLOGICAL|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
214263336|NCT01254630|BIOLOGICAL|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
214263337|NCT05328674|PROCEDURE|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
214263338|NCT05328674|PROCEDURE|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
214263339|NCT06112548|PROCEDURE|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
214263340|NCT06112548|DRUG|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
214263341|NCT06112548|DRUG|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
214263342|NCT06112548|DRUG|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
214263343|NCT06112548|DRUG|Paracetamol|IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
214263344|NCT06112548|DRUG|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
214263345|NCT06112548|DRUG|Tramadol|IV Tramadol \[Ultram\] introduced when needed after surgery
214263346|NCT05072782|DRUG|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
214263347|NCT05072782|DRUG|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
214263348|NCT02020577|DRUG|Cetuximab( erbitux®)|once per week
214653929|NCT05780866|OTHER|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
214818221|NCT06441097|DRUG|Acalabrutinib|Acalabrutinib PO will be administered as per the schedule specified in the respective arm.
214263349|NCT02020577|DRUG|Afatinib|once per day
214263350|NCT01910961|PROCEDURE|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
214263351|NCT01225692|BEHAVIORAL|Head Injury Guideline|
214263352|NCT06436261|PROCEDURE|Hybrid Fractional Laser|A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
214263353|NCT06436261|OTHER|Facial Cleanser|Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
214263354|NCT06436261|OTHER|Facial Moisturizer|"Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon)."
214263355|NCT06436261|OTHER|Sunscreen|During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
214263356|NCT04444388|DIETARY_SUPPLEMENT|cocoa|Sachets of 5 grams of cocoa daily supplementation
214263357|NCT04444388|DIETARY_SUPPLEMENT|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
214263358|NCT05164250|DRUG|REGN5458|
214263359|NCT00761631|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
214263360|NCT06966531|PROCEDURE|Coronary angiography|distinguish between true MI with significant lesion and MINOCA with insignificant lesions (less than 50%)
214263361|NCT03472872|DRUG|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
214263362|NCT03472872|DRUG|Acetaminophen|1,000mg acetaminophen IVPB
214263363|NCT05137990|BEHAVIORAL|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
214263364|NCT05137990|BEHAVIORAL|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
214263365|NCT06652529|DRUG|AROG4-01|AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
214263366|NCT06652529|DRUG|AROG4-01|"AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2)."
214263367|NCT06702878|COMBINATION_PRODUCT|nasal antimicrobial photodisinfection therapy|Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
214263368|NCT00292396|DRUG|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
214263369|NCT00292396|DRUG|placebo|12 doses
214263370|NCT01748266|OTHER|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
214263371|NCT03319173|BEHAVIORAL|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
214263372|NCT05928793|BEHAVIORAL|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
214263373|NCT02848404|DEVICE|Categorical Language Fluency Smartphone Application|4 weeks' training
214263374|NCT04652440|DRUG|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
214263375|NCT04652440|PROCEDURE|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
214263376|NCT02555774|BEHAVIORAL|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
214263377|NCT02555774|BEHAVIORAL|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
214263378|NCT03673046|DEVICE|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
214263379|NCT03817879|PROCEDURE|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
214263380|NCT03817879|PROCEDURE|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
214263381|NCT00227838|BEHAVIORAL|Behavior Therapy|
214263382|NCT02681783|DRUG|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
214263383|NCT04360941|DRUG|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
214263384|NCT04360941|DRUG|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
214263385|NCT06129565|DEVICE|Q-collar|Q-collar is placed for all patients that are admitted with low-pressure hydrocephalus
214653930|NCT06378827|DRUG|Dexmedetomidine|Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
214653931|NCT04224363|PROCEDURE|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
214263386|NCT05037292|OTHER|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
214263387|NCT05117515|DEVICE|Vascular reconstruction|Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
214653932|NCT04224363|PROCEDURE|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
214653933|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
214263388|NCT05900609|DIETARY_SUPPLEMENT|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (\~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes + 2 snacks per day. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
214263389|NCT05900609|DIETARY_SUPPLEMENT|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
214263390|NCT05900609|DIETARY_SUPPLEMENT|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
214263391|NCT00825578|DEVICE|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
214263392|NCT06215807|PROCEDURE|Femtosecond laser arcuate keratotomy|The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
214263393|NCT06215807|PROCEDURE|Toric intraocular lens implantation|The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
214263394|NCT03428932|DEVICE|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
214263395|NCT03428932|OTHER|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
214263396|NCT05449119|BIOLOGICAL|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
214263397|NCT05449119|OTHER|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
214263398|NCT05449119|OTHER|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
214263399|NCT05449119|OTHER|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
214263400|NCT05449119|OTHER|Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)|at T0, T3 months, T6 months, T9 months and T12 months
214263401|NCT05449119|OTHER|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
214263402|NCT05449119|OTHER|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
214263403|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to 24 months post index surgery
214263404|NCT06257628|DEVICE|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
214263405|NCT01896050|DRUG|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
214263406|NCT01896050|DRUG|Tamoxifen|Patients were treated with tamoxifen for up to one year
214263407|NCT00392015|BIOLOGICAL|NMRC-M3V-Ad-PfCA|Malaria Vaccine
214263408|NCT00392015|BIOLOGICAL|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
214263409|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
214263410|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
214263412|NCT05159388|DRUG|PRS-344/S095012|PRS-344/S095012 Monotherapy
214263413|NCT06956781|BEHAVIORAL|Emotion Regulation|Participants learn to reduce acute subjective distress, stabilize negative mood, promote positive mood, and alter physiological responses to trauma
214263414|NCT06956781|BEHAVIORAL|Exposure|Participants engage in written exercises to reduce avoidance of trauma reminders and reinforce approach behaviors consistent with personal goals
214263415|NCT06956781|BEHAVIORAL|Cognitive Processing|Participants learn ways to identify, challenge, and overcome the influence of cognitive distortions resulting from trauma exposure
214263416|NCT06956781|BEHAVIORAL|Bi-lateral Stimulation|Participants engage in horizontal eye movements while recalling a traumatic memory and describing their affective and physiological state
214263417|NCT06956781|BEHAVIORAL|Psychological Placebo|Participants receive non-directive support therapy, where they will guide the treatment session but not be required to discuss prior trauma exposure
214653934|NCT01991561|BIOLOGICAL|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
214263418|NCT03591835|OTHER|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
214263419|NCT03591835|OTHER|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
214263420|NCT03693300|DRUG|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
214263421|NCT01891110|PROCEDURE|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
214263422|NCT01891110|PROCEDURE|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
214263423|NCT01891110|PROCEDURE|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
214263424|NCT01628315|DEVICE|MRI|Annual MRIs as part of participation in the ASA study.
214263425|NCT02582502|OTHER|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
214263426|NCT03940040|OTHER|Usual care|Usual Care
214263427|NCT03940040|OTHER|High flow nasal oxygen|High flow nasal oxygen
214263428|NCT06233981|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
214263429|NCT06233981|DRUG|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
214263430|NCT02598804|OTHER|5 educational workshop|
214263431|NCT02598804|OTHER|written information booklet|
214263432|NCT02206048|DRUG|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
214263433|NCT02206048|PROCEDURE|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
214263434|NCT01685866|DEVICE|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
214263435|NCT04325646|OTHER|Human Biological samples|Blood samples for serological tests
214263436|NCT04325646|OTHER|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
214263437|NCT01057095|GENETIC|RNA analysis|
214263438|NCT01057095|GENETIC|gene expression analysis|
214263439|NCT01057095|GENETIC|reverse transcriptase-polymerase chain reaction|
214263440|NCT01057095|OTHER|laboratory biomarker analysis|
214263441|NCT03652168|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
214263442|NCT00686283|BEHAVIORAL|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
214263443|NCT00089414|DRUG|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
214263444|NCT00089414|DRUG|Placebo|
214263445|NCT00089414|DRUG|CDB 2914|
214263446|NCT01754870|DRUG|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
214263447|NCT02925923|DRUG|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
214263448|NCT02925923|DRUG|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
214653935|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
214653936|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
214653937|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
214653938|NCT01991561|BIOLOGICAL|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
214653939|NCT02338843|DRUG|LJPC-501|Treatment arm
214263449|NCT02925923|DRUG|Clopidogrel|
214263450|NCT02692222|OTHER|Calculation of PPV and CO with two methods|
214263451|NCT02221830|DRUG|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
214263452|NCT02221830|DRUG|Placebo|This intervention utilizes a Placebo Camparator
214263453|NCT01970657|BIOLOGICAL|No treatment specified|No intervention
214263454|NCT01970657|BIOLOGICAL|No treatment|None specified
214263455|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
214263456|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
214263457|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
214263458|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
214653940|NCT02338843|DRUG|Placebo|PBO
214263459|NCT03848429|PROCEDURE|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
214263460|NCT03643354|DIAGNOSTIC_TEST|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
214263461|NCT05367427|DIETARY_SUPPLEMENT|Heat treated postbiotic Bifidobacterium Longum consumption|Regular consumption in breakfast of heat treated postbiotic B. longum
214263462|NCT05367427|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214263463|NCT02883686|BEHAVIORAL|Alma|Alma peer-mentoring
214263464|NCT00382304|DRUG|tolevamer potassium-sodium (GT267-004)|
214263465|NCT01577368|DRUG|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
214263466|NCT01577368|DRUG|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
214263467|NCT05662007|OTHER||no intervention
214263468|NCT00866788|DRUG|omalizumab|Administered by subcutaneous injection
214263469|NCT00866788|DRUG|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
214263470|NCT00866788|DRUG|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
214263471|NCT00866788|DRUG|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
214263472|NCT04853550|DEVICE|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
214263473|NCT05464693|DIAGNOSTIC_TEST|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~1. Its macroscopic appearance will be analyzed: yellow, black, or purulent.~2. Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
214263474|NCT02837289|OTHER|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
214263475|NCT02837289|OTHER|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
214263476|NCT06275347|OTHER|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
214263477|NCT06275347|OTHER|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
214263478|NCT01509092|PROCEDURE|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
214263479|NCT06556316|BEHAVIORAL|Cognitive Intervention with the Categorization Program|Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
214263480|NCT06556316|BEHAVIORAL|Social Cognitive Communication Program|An 11 week group intervention targeting social and cognitive-communication abilities
214263481|NCT06556316|DEVICE|Non-Invasive Brain Stimulation with tDCS|20 minute tDCS intervention as a non-invasive neuromodulation treatment
214263482|NCT04751565|OTHER|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
214263483|NCT01403181|DRUG|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
214263484|NCT04450446|DRUG|Low molecular weight heparin|Anticoagulation therapy
214263485|NCT00082979|GENETIC|cytogenetic analysis|
214263486|NCT00082979|GENETIC|proteomic profiling|
214263487|NCT00082979|OTHER|cytology specimen collection procedure|
214263488|NCT00082979|OTHER|immunohistochemistry staining method|
214263489|NCT00082979|OTHER|laboratory biomarker analysis|
214263490|NCT00082979|PROCEDURE|breast duct lavage|
214653941|NCT00023322|DRUG|Peginterferon Alpha-2a|Treatment
214653942|NCT02828267|BEHAVIORAL|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
214653943|NCT02828267|BEHAVIORAL|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
214263491|NCT04244682|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
214263492|NCT04307303|DEVICE|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
214263493|NCT03022136|OTHER|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
214263494|NCT03642119|DEVICE|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
214263495|NCT02742441|DRUG|122-0551 Foam|Topical Foam containing active drug
214263496|NCT02742441|DRUG|Vehicle Foam|Topical Foam containing no active drug
214263497|NCT05993377|OTHER|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
214263498|NCT06556446|DRUG|Tenecteplase and Alteplase|The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
214263499|NCT01564914|DRUG|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
214263500|NCT01564914|DRUG|Bevacizumab|IV
214263501|NCT01517074|DRUG|Sirolimus|Subconjunctival injection
214263502|NCT04279405|DRUG|YY-20394|YY-20394 80mg tablet administered orally once daily
214263503|NCT03616626|RADIATION|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
214263504|NCT03616626|RADIATION|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
214263505|NCT03616626|RADIATION|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
214263506|NCT00252915|BIOLOGICAL|GM-CSF (verum)|sagramostim
214653944|NCT02828267|BEHAVIORAL|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
214653945|NCT03335501|DEVICE|Insulin pump|The participant's insulin pump will be used to infuse insulin
214653946|NCT03335501|DEVICE|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
214818222|NCT06441097|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
214263507|NCT06101758|DIAGNOSTIC_TEST|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
214263508|NCT06101758|DIAGNOSTIC_TEST|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
214263509|NCT06101758|DIAGNOSTIC_TEST|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
214263510|NCT00795496|PROCEDURE|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
214263511|NCT00795496|PROCEDURE|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
214263512|NCT00795496|PROCEDURE|Serum IgE blood testing|One blood test to measure total serum IgE
214263513|NCT00795496|PROCEDURE|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
214263514|NCT00690105|DRUG|tacrolimus 0.1%|ointment
214263515|NCT00690105|DRUG|fluticasone 0.005 %|ointment
214263516|NCT03052491|DIETARY_SUPPLEMENT|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
214263517|NCT06324812|DRUG|Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)|subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
214263518|NCT06271213|OTHER|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
214263519|NCT04793217|BEHAVIORAL|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
214263520|NCT04793217|BEHAVIORAL|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
214818223|NCT06441097|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
214263521|NCT03268837|DEVICE|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
214263522|NCT03268837|DEVICE|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
214263523|NCT00509041|DRUG|dasatinib|50 mg PO bid
214263524|NCT03848442|OTHER|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
214263525|NCT00978770|DRUG|systemic chemotherapy|
214263526|NCT00978770|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214263527|NCT00978770|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214263528|NCT00978770|PROCEDURE|magnetic resonance spectroscopic imaging|
214263529|NCT00978770|PROCEDURE|neoadjuvant therapy|
214263530|NCT01854242|OTHER|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
214263531|NCT02221024|PROCEDURE|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
214263532|NCT02221024|DRUG|Normal saline|
214263533|NCT02221024|DEVICE|MicroClave ICU Medica|
214263534|NCT03424200|BEHAVIORAL|Routine care|Participants will receive routine care
214263535|NCT03424200|OTHER|Coaching plus routine care|Participants will receive coaching plus routine care
214263536|NCT03252119|DEVICE|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
214263537|NCT00814866|DRUG|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
214263538|NCT06039488|BEHAVIORAL|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
214263539|NCT02098252|PROCEDURE|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
214263540|NCT02098252|RADIATION|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
214263541|NCT02098252|PROCEDURE|Embolization|Curative embolization, when the lesion is considered curable by embolization.
214263542|NCT03002363|BEHAVIORAL|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
214263543|NCT03002363|BEHAVIORAL|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
214263544|NCT05890144|OTHER|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
214263545|NCT05890144|OTHER|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
214263546|NCT05890144|OTHER|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
214818224|NCT01816997|DRUG|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
214263547|NCT02372370|PROCEDURE|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
214263548|NCT02372370|PROCEDURE|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
214263549|NCT02372370|PROCEDURE|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
214818225|NCT01816997|DRUG|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
214818226|NCT01816997|DRUG|Control|placebo
214263550|NCT02372370|PROCEDURE|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
214263551|NCT02372370|PROCEDURE|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
214263552|NCT02372370|DRUG|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
214263553|NCT02372370|OTHER|Untreated Control|Untreated control. No interventions.
214263554|NCT03487523|BEHAVIORAL|Text Message|As already stated
214263555|NCT04771312|BEHAVIORAL|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
214263556|NCT04771312|BEHAVIORAL|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
214263557|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
214263558|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
214263559|NCT04948788|DRUG|Gemcitabine-Oxaliplatin|Gemcitabine-Oxaliplatin
214263560|NCT02486666|DRUG|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
214263561|NCT05920278|DEVICE|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
214263562|NCT00068328|PROCEDURE|psychosocial assessment and care|
214263563|NCT00068328|PROCEDURE|quality-of-life assessment|
214263564|NCT00971880|OTHER|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
214263565|NCT00082342|DEVICE|Phoressor II (IOMED)|sham stimulation
214263566|NCT00082342|DEVICE|Phoressor II (IOMED)|real tDCS stimulation
214263567|NCT02266498|DRUG|BIBB 515 BS|
214263568|NCT02266498|OTHER|Standard breakfast (40 g fat)|
214263569|NCT01081288|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
214263570|NCT04406974|PROCEDURE|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
214263571|NCT04406974|PROCEDURE|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
214263572|NCT06384898|OTHER|Remote Tai Chi|Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
214263573|NCT04877483|PROCEDURE|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
214263574|NCT04877483|DIAGNOSTIC_TEST|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
214263575|NCT04877483|DIAGNOSTIC_TEST|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
214263576|NCT04877483|DIAGNOSTIC_TEST|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
214263577|NCT04877483|DIAGNOSTIC_TEST|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
214263578|NCT04877483|DIAGNOSTIC_TEST|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
214263579|NCT04877483|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
214263580|NCT04877483|DIAGNOSTIC_TEST|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
214263581|NCT04877483|DIAGNOSTIC_TEST|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
214263582|NCT04877483|DIAGNOSTIC_TEST|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
214263583|NCT04877483|DIAGNOSTIC_TEST|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
214263584|NCT04877483|DIAGNOSTIC_TEST|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
214263585|NCT04877483|DIAGNOSTIC_TEST|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
214263586|NCT04877483|DIAGNOSTIC_TEST|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
214263587|NCT04877483|DIAGNOSTIC_TEST|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
214263588|NCT03302650|DRUG|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
214263589|NCT03302650|DRUG|Normal saline|Patients will receive normal saline.
214263590|NCT03302650|DRUG|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
214263591|NCT03031132|BEHAVIORAL|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
214263592|NCT03031132|BEHAVIORAL|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
214263593|NCT03031132|BEHAVIORAL|Breakfast Skipping|Participants will skip breakfast each morning.
214263594|NCT02105883|OTHER|Use of identification badge during scenarios|
214263595|NCT01824342|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
214263596|NCT04650022|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
214263597|NCT01629992|OTHER|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
214263598|NCT03950479|DIAGNOSTIC_TEST|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
214263599|NCT00112008|DRUG|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
214263600|NCT02495831|DRUG|Diclofenac sodium|Diclofenac sodium 50 mg single dose
214263601|NCT02495831|DRUG|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
214263602|NCT00619736|DRUG|NSA-789|
214263603|NCT00619736|OTHER|Placebo|
214263604|NCT01404273|BEHAVIORAL|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
214263605|NCT05780190|DEVICE|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
214263606|NCT06012474|OTHER|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
214263607|NCT06012474|OTHER|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
214263608|NCT06012474|OTHER|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~* Loosen any tight clothing, especially around neck.~* Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~* The patient will be instructed to exhale letting all the breath out.~* patient will asked to close the lips around the mouthpiece of the spirometer.~* patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~* patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~* Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~* Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
214263609|NCT03320317|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
214263610|NCT03320317|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
214263611|NCT03320317|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
214263612|NCT03320317|OTHER|Learning session 4|Feedback report, Best practice symposium
214263613|NCT04479930|OTHER|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
214263614|NCT03789396|OTHER|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
214263615|NCT03789396|OTHER|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
214263616|NCT00928395|DEVICE|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
214263617|NCT04540276|DRUG|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
214263618|NCT03460275|DRUG|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
214263619|NCT06166589|DRUG|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
214263620|NCT06166589|DRUG|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
214263621|NCT06166589|DRUG|S-1|S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
214263622|NCT06166589|DRUG|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
214263623|NCT02008318|DRUG|Galunisertib|Administered orally
214263624|NCT02008318|DRUG|Placebo|Administered orally
214263625|NCT00992290|BIOLOGICAL|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
214263626|NCT00992290|BIOLOGICAL|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
214263627|NCT04750512|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
214263628|NCT04750512|PROCEDURE|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
214263629|NCT03768232|OTHER|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
214263630|NCT02095418|DRUG|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
214263631|NCT02095418|DRUG|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
214263632|NCT01551901|DEVICE|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
214653947|NCT03335501|OTHER|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
214653948|NCT03157544|BEHAVIORAL|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
214653949|NCT03918512|OTHER|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~* Demographical and clinical characteristics at baseline~* Consolidated version of the CSS-48 questionnaire~* Lumbar pain numeric rating scale (NRS)~* Radicular pain NRS~* Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~* Oswestry Disability Index (ODI)~* Fukushima LSS Scale 25 (FLS-25)~* 12-Item Short Form Health Survey (SF-12)~* Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
214653950|NCT00476138|DRUG|Epigallocatechin-gallate|
214653951|NCT00419250|DRUG|lenalidomide|
214653952|NCT00419250|DRUG|lenalidomide|
214653953|NCT00419250|DRUG|lenalidomide|
214653954|NCT00419250|DRUG|lenalidomide|
214653955|NCT00419250|DRUG|lenalidomide|
214653956|NCT03522545|BIOLOGICAL|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
214653957|NCT03522545|BIOLOGICAL|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
214653958|NCT05452603|DEVICE|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
214818227|NCT05557747|OTHER|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
214263633|NCT02281773|DRUG|BI 409306 100 mg QD|
214263634|NCT02281773|DRUG|BI 498306 50 mg QD|
214263635|NCT02281773|DRUG|Placebo|
214263636|NCT02281773|DRUG|BI 498306 25 mg QD|
214263637|NCT02281773|DRUG|BI 409306 10 mg QD|
214263638|NCT02778087|BEHAVIORAL|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
214263639|NCT02778087|BEHAVIORAL|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
214653959|NCT05132166|OTHER|Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.|Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
214653960|NCT05132166|BIOLOGICAL|Decidual Stromal Cells|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
214653961|NCT03884686|OTHER|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
214653962|NCT02863341|OTHER|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
214653963|NCT01793792|DEVICE|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
214653964|NCT02185521|OTHER|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
214653965|NCT00459030|OTHER|educational intervention via internet|additional cancer screening information via password protected internet site
214653966|NCT00459030|OTHER|educational intervention mailed|
214653967|NCT00459030|OTHER|No additional educational intervention|
214653968|NCT00185861|DRUG|Arsenic Trioxide|
214653969|NCT00185861|PROCEDURE|Stereotactic radiosurgery|
214653970|NCT04379752|DEVICE|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
214653971|NCT05641350|BEHAVIORAL|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
214653972|NCT05766722|DEVICE|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
214653973|NCT01676831|DRUG|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
214653974|NCT01676831|DRUG|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
214653975|NCT00999830|DRUG|IPH2101|One infusion of IPH2101 every 4 weeks
214653976|NCT00003200|DRUG|Taxotere|
214653977|NCT00003200|RADIATION|Radiation therapy|
214263640|NCT04576325|DRUG|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
214263641|NCT04576325|DRUG|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
214263642|NCT06110078|DRUG|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
214263643|NCT00481143|DRUG|ICL670/Deferasirox|
214653978|NCT02850848|DRUG|Entigin Film Coated Tablet 0.5mg|
214653979|NCT02850848|DRUG|(Baraclude 0.5mg Tablets|
214653980|NCT04475341|BIOLOGICAL|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
214653981|NCT04475341|PROCEDURE|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
214653982|NCT00004386|GENETIC|recombinant adenovirus containing the ornithine transcarbamylase gene|
214653983|NCT05774821|PROCEDURE|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
214653984|NCT05987761|BEHAVIORAL|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
214653985|NCT04640727|PROCEDURE|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
214653986|NCT04640727|PROCEDURE|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
214653987|NCT03751293|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
214653988|NCT02285829|DRUG|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
214653989|NCT02072629|OTHER|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
214653990|NCT00146692|BEHAVIORAL|Free medical treatment|
214653991|NCT05723887|BEHAVIORAL|Attachment-Based Intervention Program|Attachment-Based Intervention Program
214653992|NCT04305392|DRUG|SHR4640|orally SHR4640
214653993|NCT03220412|BEHAVIORAL|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
214653994|NCT03290014|DIAGNOSTIC_TEST|polysomnography|Monitoring of brain activity and respiratory variables during sleep
214653995|NCT03290014|DIAGNOSTIC_TEST|Actigraphy|monitoring daily physical activity for 7 days
214653996|NCT03290014|DIAGNOSTIC_TEST|Osler test|Evaluation of subjects´ ability to remain awake
214653997|NCT03071718|OTHER|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
214653998|NCT03071718|OTHER|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
214653999|NCT00135421|DRUG|Pexacerfont|Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
214654000|NCT00135421|DRUG|Escitalopram|Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
214654001|NCT00135421|DRUG|Placebo|Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
214263644|NCT05944211|DRUG|Hetrombopag Olamine|"The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator."
214654002|NCT03815890|DRUG|Nivolumab|2 courses 240 mg flat dose
214654003|NCT03815890|DRUG|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
214654004|NCT03815890|DRUG|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
214654005|NCT02633449|BEHAVIORAL|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
214654006|NCT02633449|DEVICE|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
214654007|NCT02633449|DEVICE|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
214654008|NCT03638492|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
214654009|NCT03638492|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
214654010|NCT05521165|OTHER|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
214654011|NCT03804671|DRUG|BI 730357|Oral dose
214654012|NCT03804671|DRUG|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
214654013|NCT04268134|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
214654014|NCT05961748|OTHER|Multi-disciplinary assessment|Multi-disciplinary assessment
214654015|NCT03303001|PROCEDURE|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
214654016|NCT03303001|PROCEDURE|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
214654017|NCT05641883|COMBINATION_PRODUCT|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
214654018|NCT03902080|DRUG|Vibegron|oral administration
214654019|NCT03902080|DRUG|Placebo|oral administration
214654020|NCT05571683|OTHER|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
214654021|NCT02812199|DEVICE|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
214654022|NCT02812199|DRUG|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
214654023|NCT02812199|PROCEDURE|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
214654024|NCT04013126|DIAGNOSTIC_TEST|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
214263645|NCT01041326|RADIATION|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
214263646|NCT01041326|PROCEDURE|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
214263647|NCT01130675|OTHER|caffeinated coffee|8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
214263648|NCT03056404|OTHER|additional blood sample|
214263649|NCT03056404|OTHER|respiratory functional exploration|
214263650|NCT06157359|PROCEDURE|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
214263651|NCT02104752|DRUG|Curcumin|360 mg/day (divided into twice daily oral doses)
214654025|NCT03226990|OTHER|impression technique|impression technique with and without wax spacer
214654026|NCT00751413|DRUG|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
214263652|NCT02104752|DRUG|Placebo|"Inactive, matched placebo (Sugar Pill)"
214263653|NCT05439941|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
214263654|NCT00231842|DRUG|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
214263655|NCT00231842|DEVICE|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
214263656|NCT00231842|DRUG|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
214263657|NCT05981339|OTHER|breathing exercises|For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
214654027|NCT04321161|DRUG|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
214654028|NCT01634373|DRUG|Torrent's Quetiapine Fumarate Tablets|
214654029|NCT00457405|DRUG|dipyridamole|dipyridamole 200mg twice daily
214654030|NCT01479348|DRUG|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
214654031|NCT01479348|DRUG|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m\^2, IV
214654032|NCT01479348|DRUG|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
214654033|NCT01479348|DIAGNOSTIC_TEST|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
214654034|NCT01838057|DEVICE|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
214654035|NCT01838057|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
214654036|NCT03766425|DRUG|Aflibercept|subconjunctival injection
214654037|NCT03766425|DRUG|Mitomycin|subconjunctival injection
214654038|NCT00507325|PROCEDURE|Blood Sample|Blood samples will be collected.
214654039|NCT00507325|PROCEDURE|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
214654040|NCT02220387|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
214263658|NCT05981339|OTHER|osteopathic manual therapy techniques|"* Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006)."
214263659|NCT03538548|BEHAVIORAL|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
214263660|NCT02422303|DRUG|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
214263661|NCT04958135|DRUG|Acoramidis|Film-coated immediate release oral tablet.
214263662|NCT00541684|DRUG|MK0954, /Duration of Treatment : 16 Weeks|
214263663|NCT00541684|DRUG|Comparator : atenolol /Duration of Treatment : 16 Weeks|
214263664|NCT03481907|DEVICE|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
214263665|NCT02899299|BIOLOGICAL|Nivolumab|
214263666|NCT02899299|BIOLOGICAL|Ipilimumab|
214263667|NCT02899299|DRUG|Pemetrexed|
214263668|NCT02899299|DRUG|Cisplatin|
214263669|NCT02899299|DRUG|Carboplatin|
214263670|NCT01577420|OTHER|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
214263671|NCT01577420|OTHER|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
214263672|NCT00761904|BEHAVIORAL|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
214263673|NCT01931592|DRUG|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
214263674|NCT01931592|DRUG|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
214263675|NCT03534414|DIETARY_SUPPLEMENT|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)"
214263676|NCT03534414|DIETARY_SUPPLEMENT|NCEP Based Diet|A low saturated fat, low cholesterol diet.
214263677|NCT00055250|DRUG|Gemcitabine|
214263678|NCT00055250|DRUG|LY293111|
214263679|NCT00055250|DRUG|placebo|
214263680|NCT02966431|BEHAVIORAL|Counseling|
214263681|NCT02966431|BEHAVIORAL|No Counseling|
214263682|NCT00440583|DRUG|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
214263683|NCT02433561|PROCEDURE|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
214263684|NCT02433561|PROCEDURE|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
214263685|NCT03470870|OTHER|Comparative analysis of the characteristics|"* Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program"
214263686|NCT00313300|DRUG|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
214263687|NCT00313300|DRUG|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
214263688|NCT00313300|DRUG|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
214263689|NCT00313300|DRUG|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
214263690|NCT02321410|OTHER|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
214263691|NCT02321410|OTHER|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
214263692|NCT02327065|DEVICE|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
214263693|NCT02327065|DEVICE|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
214263694|NCT01334346|OTHER|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
214263695|NCT01334346|OTHER|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
214263696|NCT01334346|OTHER|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
214263697|NCT03145233|OTHER|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
214263698|NCT03145233|OTHER|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
214654041|NCT02220387|OTHER|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
214654042|NCT02752828|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214263699|NCT02543710|PROCEDURE|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
214263700|NCT02543710|DRUG|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
214263701|NCT03954197|OTHER|No hormone|No hormonal injection before oocytes retrieval
214263702|NCT03954197|OTHER|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
214263703|NCT03954197|OTHER|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
214263704|NCT02336373|DRUG|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
214263705|NCT04840004|DRUG|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
214263706|NCT05344911|DRUG|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
214263707|NCT05344911|DRUG|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
214263708|NCT04803461|DIAGNOSTIC_TEST|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
214263709|NCT03703115|BEHAVIORAL|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
214263710|NCT04716465|OTHER|Dysautonomia|Indicators of dysautonomia
214263711|NCT00726375|DRUG|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
214263712|NCT00850343|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
214263713|NCT00228683|PROCEDURE|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
214263714|NCT03552731|BEHAVIORAL|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
214263715|NCT00745329|OTHER|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
214263716|NCT00699569|DIETARY_SUPPLEMENT|hyperimmune colostrum|hyperimmune colostrum
214263717|NCT00699569|DIETARY_SUPPLEMENT|Placebo|
214263718|NCT04923438|OTHER|Telerehabilitation|The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
214263719|NCT04923438|OTHER|Control|The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.
214263720|NCT03120000|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
214263721|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
214263722|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
214263723|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
214263724|NCT01926015|BIOLOGICAL|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
214263725|NCT01926015|BIOLOGICAL|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
214263726|NCT00639678|DRUG|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
214263727|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
214263728|NCT00639678|DRUG|placebo|40 mg/kg placebo, single dose (day 0), Group 4
214263729|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
214263730|NCT00897208|OTHER|high performance liquid chromatography|
214263731|NCT00897208|OTHER|laboratory biomarker analysis|
214263732|NCT00897208|OTHER|mass spectrometry|
214263733|NCT00897208|OTHER|medical chart review|
214263734|NCT00897208|PROCEDURE|evaluation of cancer risk factors|
214263735|NCT05938517|DRUG|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
214263736|NCT05938517|DRUG|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
214263737|NCT04883229|DEVICE|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
214263738|NCT00536679|DRUG|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
214263739|NCT00536679|DRUG|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
214263740|NCT00536679|DRUG|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
214263741|NCT06398236|DIETARY_SUPPLEMENT|SE5-OH tablets|SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
214263742|NCT01364649|DRUG|Vortioxetine|Vortioxetine tablets
214263743|NCT01364649|DRUG|Escitalopram|Escitalopram tablets
214263744|NCT01364649|DRUG|Placebo|Vortioxetine Placebo-matching capsules
214263745|NCT04245852|OTHER|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
214263746|NCT04245852|OTHER|standard PT care|standard PT care
214263747|NCT04863040|BEHAVIORAL|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
214263748|NCT01566734|OTHER|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
214263749|NCT01566734|OTHER|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
214263750|NCT00760123|OTHER|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
214263751|NCT02114671|DRUG|Faldaprevir high dose|capsules, oral
214263752|NCT02114671|DRUG|Placebo|capsule, oral
214263753|NCT02114671|DRUG|Ciprofloxacin|tablets, oral
214263754|NCT02114671|DRUG|Faldaprevir low dose|capsules, oral
214263755|NCT00976040|OTHER|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
214263756|NCT03673449|DEVICE|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
214263757|NCT01011777|DRUG|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
214263758|NCT03041077|DIETARY_SUPPLEMENT|Instaflex Advanced|Joint function
214263759|NCT03041077|DIETARY_SUPPLEMENT|Placebo|Placebo
214654043|NCT02752828|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214654044|NCT02752828|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
214263760|NCT01134276|PROCEDURE|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
214263761|NCT04198298|DRUG|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
214263762|NCT04198298|DRUG|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
214263763|NCT04198298|DRUG|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
214263764|NCT02341365|OTHER|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
214263765|NCT05756491|OTHER|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
214263766|NCT05756491|OTHER|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
214263767|NCT05756491|OTHER|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
214263768|NCT05756491|OTHER|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
214263769|NCT02468232|DRUG|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
214263770|NCT02468232|DRUG|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
214263771|NCT02468232|DRUG|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
214263772|NCT02468232|DRUG|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
214263773|NCT00497718|PROCEDURE|Chiropractic Manipulation|
214263774|NCT00002914|DRUG|piritrexim|
214263775|NCT02677532|DRUG|Paracetamol|1 g every 8 hours
214263776|NCT02677532|DRUG|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
214263777|NCT02677532|DRUG|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
214263778|NCT02677532|DRUG|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
214263779|NCT02677532|DRUG|Morphine|Intravenous slow bolus of 10 mg morphine
214263780|NCT02677532|DEVICE|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
214263781|NCT02677532|DEVICE|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
214263782|NCT02677532|DRUG|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
214263783|NCT02677532|DRUG|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
214263784|NCT02080234|DRUG|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
214263785|NCT02080234|RADIATION|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
214263786|NCT03499704|DRUG|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
214263787|NCT03499704|DRUG|Alogliptin|Alogliptin tablets.
214263788|NCT03499704|DRUG|Metformin|Metformin tablets.
214263789|NCT03499704|DRUG|Dapagliflozin|Dapagliflozin tablets.
214263790|NCT01924000|DRUG|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
214263791|NCT01924000|DRUG|Placebo|
214263792|NCT05723302|DIAGNOSTIC_TEST|MIP/MEP|MIP/MEP
214263793|NCT00246753|DRUG|lapatinib ditosylate|1500 mg, daily until disease progression
214263794|NCT04654676|DRUG|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
214263795|NCT01994447|OTHER|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
214263796|NCT06266572|BEHAVIORAL|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
214263797|NCT06391840|OTHER|Airway ultrasound|Pre-operative airway ultrasound
214263798|NCT02296281|DRUG|Pirfenidone|
214263799|NCT02254941|DRUG|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
214263800|NCT02254941|BIOLOGICAL|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
214263801|NCT04166500|PROCEDURE|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
214263802|NCT05968456|OTHER|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
214263803|NCT04715425|PROCEDURE|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
214263804|NCT04715425|PROCEDURE|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
214263805|NCT04443699|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
214263806|NCT00972582|DIETARY_SUPPLEMENT|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
214263807|NCT06103539|DEVICE|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
214654045|NCT04929639|OTHER|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
214654046|NCT00412529|DRUG|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
214654047|NCT00412529|DRUG|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
214654048|NCT02529527|BEHAVIORAL|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
214654049|NCT01769911|DRUG|carmustine|Given IV
214654050|NCT01769911|DRUG|cytarabine|Given IV
214654051|NCT01769911|DRUG|melphalan|Given IV
214654052|NCT01769911|DRUG|etoposide|Given IV
214654053|NCT01769911|DRUG|O6-benzylguanine|Given IV
214654054|NCT01769911|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
214654055|NCT01769911|PROCEDURE|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
214654056|NCT01769911|OTHER|laboratory biomarker analysis|Correlative studies
214654057|NCT05654402|DIAGNOSTIC_TEST|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"* Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~* Measurement of the distance between the carotid and femoral points with a tape measure (m).~* Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~* Before induction (awake without premedication)~* During general anesthesia or loco-regional anesthesia~* Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
214654058|NCT03542838|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
214263808|NCT00545766|DRUG|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
214263809|NCT05915078|COMBINATION_PRODUCT|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
214263810|NCT03423641|DRUG|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
214263811|NCT03643796|DRUG|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
214263812|NCT03643796|DRUG|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
214263813|NCT03643796|DRUG|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
214263814|NCT01529047|BEHAVIORAL|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
214654059|NCT03542838|DRUG|Saline|Saline is a normal physiological solution
214263815|NCT03460860|DIETARY_SUPPLEMENT|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
214263816|NCT03460860|DIETARY_SUPPLEMENT|Placebo|The intervention is to be taken once daily, for 12 weeks.
214654060|NCT02160067|DRUG|Second generation BTDS patch|
214654061|NCT02160067|DRUG|First generation BuTrans patch|
214654062|NCT06269523|OTHER|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
214654063|NCT06269523|OTHER|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
214654064|NCT02309463|DRUG|Endothelin receptor antagonist therapy|
214654065|NCT06959953|OTHER|Low-cost model|The primary structure of a low-cost training model fashioned from an old portable 3-drawer organizer unit repurposed to serve as the foundation for the training apparatus. This training apparatus will act as the experimental arm to compare it to the Airway Part-Task Trainer in FBTI.
214654066|NCT06959953|OTHER|Airway Part-task Trainer|Training using Airway Part-Task Trainer
214654067|NCT06959966|COMBINATION_PRODUCT|Placebo|Starch capsule, 4 grams, two capsules per day for six months.
214654068|NCT06959966|COMBINATION_PRODUCT|Oligo Fucoidan|Oligo fucoidan capsule, 4 grams, two capsules per day for six months.
214654069|NCT06959745|DRUG|Magnesium-L-Threonate|Magnesium L-threonate, 1740 mg, taken orally, twice a day, for 8 weeks.
214654070|NCT06959745|DRUG|Placebo|Placebo, 1740 mg, taken orally, twice a day, for 8 weeks.
214654071|NCT06961955|RADIATION|Radiation Therapy|Undergo hypofractionated radiation therapy
214654072|NCT01586988|BEHAVIORAL|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
214654073|NCT05008328|OTHER|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
214654074|NCT05008328|PROCEDURE|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
214654075|NCT02204904|GENETIC|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
214654076|NCT04122287|DRUG|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
214654077|NCT04122287|DRUG|tinidazole|tinidazole-tetracycline-containing quadruple regimens
214654078|NCT06289569|OTHER|Home telerehabilitation therapy|Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
214654079|NCT05935306|DRUG|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
214654080|NCT05935306|OTHER|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
214654081|NCT05935306|DEVICE|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
214654082|NCT05935306|OTHER|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
214654083|NCT04138394|DRUG|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
214654084|NCT04138394|DRUG|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
214654085|NCT00408005|DRUG|Asparaginase|Given IM or IV
214654086|NCT00408005|DRUG|Cyclophosphamide|Given IV
214654087|NCT00408005|DRUG|Cytarabine|Given IT, IV, or SC
214654088|NCT00408005|DRUG|Daunorubicin Hydrochloride|Given IV
214654089|NCT00408005|DRUG|Dexamethasone|Given IV or PO
214654090|NCT00408005|DRUG|Doxorubicin Hydrochloride|Given IV
214654091|NCT00408005|OTHER|Laboratory Biomarker Analysis|Correlative studies
214654092|NCT00408005|DRUG|Leucovorin Calcium|Given PO
214654093|NCT00408005|DRUG|Mercaptopurine|Given PO
214654094|NCT00408005|DRUG|Methotrexate|Given IT or PO
214654095|NCT00408005|DRUG|Nelarabine|Given IV
214654096|NCT00408005|DRUG|Pegaspargase|Given IM or IV
214654097|NCT00408005|DRUG|Prednisone|Given IV or PO
214654098|NCT00408005|RADIATION|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
214654099|NCT00408005|DRUG|Thioguanine|Given PO
214654100|NCT00408005|DRUG|Vincristine Sulfate|Given IV
214654101|NCT00962845|DRUG|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
214654102|NCT06475300|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214654103|NCT06475300|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
214654104|NCT04130646|DEVICE|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
214654105|NCT04130646|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
214654106|NCT06232512|DEVICE|Haptic Device|Provides sensory substitution by mapping pressure from the insole sensor onto a corresponding vibrating and heating patch to be worn where more sensation is present.
214654107|NCT06462417|DRUG|Arbidol|Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
214654108|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
214654109|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
214654110|NCT03155997|DRUG|Abemaciclib|Administered orally.
214654111|NCT03155997|DRUG|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
214654112|NCT02145494|RADIATION|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
214818228|NCT05557747|OTHER|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
214818229|NCT05557747|OTHER|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
214818230|NCT02209571|OTHER|Venous blood markers|Routine venous blood sampling
214818231|NCT01181622|DRUG|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
214654113|NCT04317755|BEHAVIORAL|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
214654114|NCT02660125|PROCEDURE|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
214654115|NCT01072292|BEHAVIORAL|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
214654116|NCT01278576|DRUG|BOTOX-A®|200 units, single treatment only
214654117|NCT03093402|DRUG|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
214654118|NCT03093402|DRUG|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
214654119|NCT05573802|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
214654120|NCT05573802|DRUG|Lenalidomide|Lenalidomide will be administered per os.
214654121|NCT05573802|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
214654122|NCT05573802|DRUG|Nirogacestat|Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
214654123|NCT02692625|DIETARY_SUPPLEMENT|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
214654124|NCT02692625|DIETARY_SUPPLEMENT|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
214654125|NCT00002085|DRUG|Azithromycin|
214654126|NCT03216460|DEVICE|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
214654127|NCT05533567|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
214654128|NCT05533567|DRUG|Propofol|The control group was sedated with propofol.
214654129|NCT03803527|PROCEDURE|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
214654130|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract|
214654131|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin|
214654132|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract placebo|
214654133|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin placebo|
214654134|NCT02347631|DEVICE|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
214654135|NCT02347631|DEVICE|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
214654136|NCT03496753|DEVICE|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
214654137|NCT05760716|OTHER|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
214818232|NCT01181622|DRUG|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
214263817|NCT02710396|DRUG|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
214654138|NCT05559307|DRUG|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
214654139|NCT01830530|DRUG|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
214654140|NCT01830530|DRUG|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
214654141|NCT01830530|DRUG|placebo|two tablets daily in the morning
214654142|NCT04756414|BEHAVIORAL|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
214654143|NCT01305447|BEHAVIORAL|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
214263818|NCT02710396|DRUG|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
214654144|NCT01305447|BEHAVIORAL|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
214654145|NCT01305447|BEHAVIORAL|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
214654146|NCT05947240|OTHER|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
214654147|NCT05947240|OTHER|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
214654148|NCT05154474|OTHER|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
214263819|NCT02710396|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
214654149|NCT05024006|DRUG|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
214654150|NCT05024006|DRUG|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
214654151|NCT05024006|DRUG|Lopinavir / Ritonavir|Orally twice daily for 14 days
214654152|NCT05024006|DRUG|Interferon beta-1a|Daily injection for 6 days
214263820|NCT02710396|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
214263821|NCT04732143|OTHER|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
214263822|NCT05969808|OTHER|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
214263823|NCT05969808|OTHER|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
214654153|NCT05024006|DRUG|Acalabrutinib|Orally twice daily for 10 days
214654154|NCT04472728|DRUG|BIO101|BIO101 capsules
214263824|NCT02764333|BIOLOGICAL|TPIV200|
214263825|NCT02764333|BIOLOGICAL|Durvalumab|
214263826|NCT00818597|DEVICE|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
214654155|NCT04472728|DRUG|Placebo|placebo capsules
214654156|NCT04272593|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
214654157|NCT03017209|DIETARY_SUPPLEMENT|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
214818233|NCT05214924|BIOLOGICAL|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
214818234|NCT05214924|BIOLOGICAL|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
214263827|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
214263828|NCT06960213|DRUG|ADX-324|siRNA duplex oligonucleotide
214263829|NCT06960213|DRUG|Placebo|saline
214263830|NCT06832059|OTHER|The precise diet intervention|The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l
214263831|NCT05676970|BEHAVIORAL|Telehealth: Personalized Preventative Medicine Strategies|Individuals in this arm will complete a personalized telehealth interventions that focus on nutrition, work-life balance, medication compliance, herbals, exercise targets hyperlipidemia, diabetes and hypertension around individual risks for development of the disease state. All educations will be completed one-on-one as well as small group.
214263832|NCT05676970|BEHAVIORAL|TeleHealth: Preventative Medicine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension general education. All educations will be completed one-on-one as well as small group.
214263833|NCT04638296|OTHER|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
214263834|NCT00817544|DRUG|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
214263835|NCT01348607|DRUG|methylphenidate hydrochloride|Given orally
214263836|NCT01348607|DRUG|modafinil|Given orally
214263837|NCT01348607|DRUG|placebo|Given orally
214263838|NCT00493623|DRUG|Placebo|Placebo i.v. single dose
214263839|NCT00493623|DRUG|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
214263840|NCT00175695|DRUG|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
214263841|NCT04319991|DIETARY_SUPPLEMENT|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
214263842|NCT00258284|DRUG|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
214263843|NCT00258284|DRUG|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
214263844|NCT03183531|DIAGNOSTIC_TEST|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
214263845|NCT04292769|DRUG|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
214263846|NCT04292769|BIOLOGICAL|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
214263847|NCT00812747|OTHER|observation|
214263848|NCT05698056|OTHER|No intervention.|No intervention.
214263849|NCT05813145|DRUG|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
214263850|NCT05813145|DRUG|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
214263851|NCT00560274|DRUG|Pegasys|As prescribed
214263852|NCT00560274|DRUG|Ribavirin|As prescribed
214263853|NCT00560274|DRUG|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
214263854|NCT01175460|DRUG|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
214263855|NCT00528827|DRUG|Cardene® I.V.|"* 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V."
214263856|NCT05718804|OTHER|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
214263857|NCT00752102|DRUG|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
214263858|NCT00752102|DRUG|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
214263859|NCT00444652|DRUG|Enoxaparin|injection of enoxaparin a few time
214263860|NCT02234570|DRUG|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
214263861|NCT02234570|OTHER|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
214263862|NCT02520830|DIETARY_SUPPLEMENT|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
214263863|NCT02520830|DIETARY_SUPPLEMENT|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
214263864|NCT01303861|DRUG|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
214263865|NCT01303861|DRUG|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
214263866|NCT01303861|DRUG|Nicotine patches|"Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week"
214263867|NCT01303861|DRUG|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
214263868|NCT05064319|DRUG|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
214263869|NCT05064319|DRUG|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
214263870|NCT00659360|DRUG|saracatinib|Given orally
214263871|NCT01061216|DEVICE|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
214263872|NCT01061216|DEVICE|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
214654158|NCT03017209|DIETARY_SUPPLEMENT|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
214654159|NCT03017209|OTHER|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
214654160|NCT03067090|DEVICE|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
214654161|NCT02835170|BIOLOGICAL|Autologous immunoglobulin|Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
214654162|NCT02835170|OTHER|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
214654163|NCT05595278|DIAGNOSTIC_TEST|(CBC) ,(NT-proBNP) ,(cTnT)|complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.
214654164|NCT00278603|BIOLOGICAL|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
214654165|NCT05722184|DIAGNOSTIC_TEST|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
214654166|NCT02271165|DRUG|Immunoglobulin (Hizentra)|
214654167|NCT03471455|DRUG|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
214654168|NCT03471455|DRUG|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
214654169|NCT03471455|DRUG|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
214654170|NCT04456829|DIETARY_SUPPLEMENT|Resveratrol drink|Subjects will consume a bottle of resveratrol drink for two months.
214654171|NCT04456829|DIETARY_SUPPLEMENT|Placebo drink|Subjects will consume a bottle of placebo drink for two months.
214654172|NCT05850078|OTHER|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
214263873|NCT01582568|DRUG|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
214263874|NCT01422460|BIOLOGICAL|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
214263875|NCT03352973|OTHER|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
214263876|NCT03352973|OTHER|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
214263877|NCT04157543|OTHER|electroacupuncture|acupuncture with electricity
214654173|NCT00188578|PROCEDURE|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
214654174|NCT02159144|OTHER|cold stress|
214654175|NCT05243849|DEVICE|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
214654176|NCT05430620|DRUG|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
214654177|NCT04816240|DRUG|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90)
214654178|NCT04816240|BIOLOGICAL|Albumin|80grams/week for 2 weeks followed by 40gram/week
214654179|NCT04816240|OTHER|Standard Medical Treatment|Standard Medical Treatment
214654180|NCT04816240|OTHER|Placebo|Placebo
214654181|NCT03700047|DEVICE|GAL1704|new dermal filler
214654182|NCT03700047|DEVICE|Juvederm Voluma|hyaluronic acid
214654183|NCT03967821|OTHER|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
214654184|NCT00863551|DRUG|Trospium Chloride|Extended release, 60 mg, oral daily
214654185|NCT04939857|DRUG|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
214654186|NCT05146557|OTHER|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
214654187|NCT03014960|OTHER|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
214654188|NCT04471896|DEVICE|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
214654189|NCT03837184|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
214654190|NCT06172556|PROCEDURE|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
214654191|NCT00415220|PROCEDURE|Spinal Manipulation, Microdiscectomy|
214654192|NCT01096147|DEVICE|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
214654193|NCT00758784|DRUG|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
214654194|NCT00000312|DRUG|M-CPP|
214654195|NCT05527951|OTHER|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
214654196|NCT05527951|OTHER|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
214654197|NCT02047006|DRUG|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
214654198|NCT03226626|DRUG|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
214654199|NCT03226626|DEVICE|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
214654200|NCT00004054|DRUG|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
214654201|NCT00004054|DRUG|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
214654202|NCT00004054|DRUG|etoposide|50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
214654203|NCT00004054|DRUG|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
214654204|NCT00004054|DRUG|paclitaxel|135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
214654205|NCT00004054|DRUG|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
214654206|NCT00004054|RADIATION|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
214654207|NCT00004054|DRUG|warfarin|To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
214654208|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
214654209|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
214654210|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
214654211|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
214654212|NCT02639351|BIOLOGICAL|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
214654213|NCT01211808|DRUG|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
214654214|NCT01211808|DRUG|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
214654215|NCT01466842|PROCEDURE|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
214654216|NCT04828044|DEVICE|Microwave Ablation/ Coagulation Arm|An 11-gauge microwave probe from MedWaves, Inc., will be placed in the tumor. An ablation lesion will then be generated at the appropriate power (10-35 watts) to maintain up to 130C degrees at the MW applicator tip thermocouple for 10 minutes duration. Palpation and/or ultrasound may be used to place the MWA needle and monitor the progress of the microwave ablation.
214654217|NCT05340504|DRUG|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
214654218|NCT05340504|DRUG|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
214654219|NCT05807009|OTHER|core exercise|the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
214654220|NCT05807009|OTHER|traditional therapy|the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
214654221|NCT02666326|PROCEDURE|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
214654222|NCT01872455|DIETARY_SUPPLEMENT|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
214654223|NCT01872455|DIETARY_SUPPLEMENT|Usual diet|Usual diet of the patients
214654224|NCT03135366|BEHAVIORAL|Keheala|
214654225|NCT03135366|OTHER|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
214654226|NCT00558935|DIETARY_SUPPLEMENT|Red Wine|20g alcohol daily/red wine for 4 weeks
214654227|NCT05318521|DRUG|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
214654228|NCT05318521|DRUG|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
214654229|NCT02619422|OTHER|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
214654230|NCT02669979|OTHER|Intervention|Professional oral care
214654231|NCT02432547|DRUG|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
214654232|NCT02432547|PROCEDURE|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
214654233|NCT06354933|DIAGNOSTIC_TEST|Neurological Soft Signs|Neurological Soft Signs score according to the Heidelberg Manual
214654234|NCT02704247|DEVICE|CARDIOSPACE System|"* autonomic nervous system test~* tilt test~* ultrasound exploration at rest (heart / vessels)~* laser doppler + iontophoresis test~* sub-maximal exercise test"
214654235|NCT00348166|DRUG|cyclopentolate|
214654236|NCT00619957|DRUG|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
214654237|NCT00619957|DRUG|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
214654238|NCT00751894|DRUG|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
214654239|NCT00815646|DRUG|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
214654240|NCT04222985|BIOLOGICAL|HSV 2 Formulation 1|Route of administration: Intramuscular
214654241|NCT04222985|BIOLOGICAL|HSV 2 Formulation 2|Route of administration: Intramuscular
214654242|NCT04222985|BIOLOGICAL|HSV 2 Formulation 3|Route of administration: Intramuscular
214654243|NCT04222985|BIOLOGICAL|HSV 2 Formulation 4|Route of administration: Intramuscular
214654244|NCT04222985|BIOLOGICAL|HSV 2 Formulation 5|Route of administration: Intramuscular
214654245|NCT04222985|BIOLOGICAL|HSV 2 Formulation 6|Route of administration: Intramuscular
214654246|NCT04222985|BIOLOGICAL|Sodium Chloride 0.9%|Route of administration: Intramuscular
214654247|NCT01956006|DRUG|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
214654248|NCT04636905|OTHER|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
214654249|NCT00056706|PROCEDURE|Transient deafferentation|
214654250|NCT04722718|DRUG|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
214654251|NCT04268030|OTHER|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
214654252|NCT05278390|RADIATION|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
214654253|NCT05753111|DIETARY_SUPPLEMENT|PEA|PEA supplementation
214654254|NCT05753111|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin supplementation
214654255|NCT00190775|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
214654256|NCT00190775|DRUG|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
214654257|NCT02568436|RADIATION|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
214654258|NCT02262403|OTHER|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
214654262|NCT06030011|BEHAVIORAL|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
214654263|NCT06030011|BEHAVIORAL|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
214654264|NCT02916277|BIOLOGICAL|endocan|to look series Endocan level for 5 days in intubated patients
214654265|NCT01526148|DRUG|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
214654266|NCT01526148|DRUG|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
214654267|NCT03308851|PROCEDURE|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
214654268|NCT03308851|PROCEDURE|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
214654269|NCT03567655|DRUG|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
214654270|NCT00219908|DRUG|Mitoxantrone|
214654271|NCT06167161|DEVICE|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
214654272|NCT03943329|PROCEDURE|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
214654273|NCT03943329|PROCEDURE|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
214654274|NCT02107144|DRUG|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
214654275|NCT01173653|OTHER|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
214654276|NCT01173653|OTHER|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
214654277|NCT00454233|DRUG|YM543|Oral
214654278|NCT00454233|DRUG|Metformin|Oral
214654279|NCT00454233|DRUG|Placebo|oral
214654280|NCT02610985|DEVICE|3-D laparoscopy|3-D laparoscopy
214654281|NCT02610985|DEVICE|2-D laparoscopy|2-D laparoscopy
214654282|NCT00227357|DRUG|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
214654283|NCT00227357|DRUG|Off-site - methadone or no agonist|
214654284|NCT02926339|BEHAVIORAL|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
214654285|NCT00206570|DRUG|Estradiol|
214654286|NCT01334073|DRUG|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
214654287|NCT05169671|DRUG|ATH-1020|ATH-1020 in oral capsule form
214654288|NCT05169671|DRUG|Placebo|Placebo in oral capsule form
214654289|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
214654290|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
214654291|NCT01415388|DIETARY_SUPPLEMENT|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
214654292|NCT03547141|DRUG|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
214654293|NCT03547141|DRUG|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
214654294|NCT03890055|DRUG|Anlotinib Hydrochloride|Best supportive care
214654295|NCT00762346|DRUG|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
214654296|NCT04261244|RADIATION|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
214654297|NCT04261244|RADIATION|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
214654298|NCT02062931|BIOLOGICAL|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
214654299|NCT00326092|DRUG|Brinzolamide/Timolol|
214654300|NCT01956981|DRUG|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
214654301|NCT01956981|DRUG|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
214654302|NCT04610255|OTHER|Assigned Interventions|"* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
214654303|NCT04610255|OTHER|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
214654304|NCT03237468|OTHER|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
214654305|NCT04624425|OTHER|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
214654306|NCT04624425|OTHER|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
214654307|NCT04409938|OTHER|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
214654308|NCT04409938|OTHER|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
214654309|NCT05840939|BEHAVIORAL|Pranayama|"Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity."
214654310|NCT05840939|BEHAVIORAL|diaphragm breathing exercise|Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
214654311|NCT00408967|DRUG|Tucotuzumab celmoleukin (EMD 273066)|
214654312|NCT03280979|DRUG|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
214654313|NCT03280979|DRUG|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
214654314|NCT00481065|BIOLOGICAL|MF59-eH5N1|
214654315|NCT00481065|BIOLOGICAL|eTIV_a|
214654316|NCT00481065|BIOLOGICAL|MF59-eH5N1 + eTIV_a|
214654317|NCT00885079|DRUG|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
214654318|NCT00885079|DRUG|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
214654319|NCT00850746|DRUG|YM443|Oral
214654320|NCT00850746|DRUG|Placebo|Oral
214654321|NCT00850746|DRUG|Moxifloxacin|Oral
214654322|NCT02953041|DRUG|Glycopyrronium|long-acting muscarinic antagonist
214654323|NCT02953041|DRUG|Indacaterol|ultra long-acting beta agonist
214654324|NCT01709331|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
214654325|NCT01709331|DRUG|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
214654326|NCT00138086|DRUG|Zevalin plus BEAM|
214654327|NCT03553394|DRUG|Ringer's Acetate|Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
214654328|NCT02630953|BEHAVIORAL|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
214654329|NCT02630953|BEHAVIORAL|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
214654330|NCT02844998|BEHAVIORAL|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
214654331|NCT02844998|DRUG|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
214654332|NCT05791279|OTHER|Heart age|information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
214654333|NCT04415398|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
214654334|NCT01494363|DRUG|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
214654335|NCT01494363|DRUG|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
214654336|NCT01494363|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
214654337|NCT01494363|DRUG|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
214654338|NCT01903941|BEHAVIORAL|Aerobic Exercise|
214654339|NCT01903941|BEHAVIORAL|Only Counseling|
214654340|NCT02914509|DRUG|Travoprost|
214654341|NCT02914509|OTHER|Placebo Vehicle|
214654342|NCT00140764|DRUG|Metronidazole gel versus placebo gel|
214654343|NCT06375304|DRUG|B/F/TAF|"The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements."
214654344|NCT05020561|BEHAVIORAL|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
214654345|NCT05020561|BEHAVIORAL|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
214654346|NCT01651780|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
214654347|NCT01651780|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
214654348|NCT02096094|PROCEDURE|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
214654349|NCT02096094|PROCEDURE|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
214654350|NCT02096094|PROCEDURE|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
214654351|NCT01422993|OTHER|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
214654352|NCT02956811|DRUG|Dapagliflozin|SGLT2 inhibitor
214654353|NCT02956811|DRUG|Placebo|Matching Placebo
214654354|NCT00200265|BEHAVIORAL|diet|diet
214654355|NCT01628926|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
214654356|NCT01628926|DRUG|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
214654357|NCT01628926|DRUG|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
214654358|NCT03029832|DRUG|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
214654359|NCT03029832|DRUG|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
214654360|NCT04880122|DIAGNOSTIC_TEST|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
214654361|NCT00003141|BIOLOGICAL|filgrastim|Given IV
214654362|NCT00003141|DRUG|carboplatin|Given IV
214654363|NCT00003141|DRUG|cisplatin|Given IV
214654364|NCT00003141|DRUG|cyclophosphamide|Given IV
214654365|NCT00003141|DRUG|etoposide|Given IV
214654366|NCT00003141|DRUG|thiotepa|Given IV
214654367|NCT00003141|DRUG|vincristine sulfate|Given IV
214654368|NCT00003141|PROCEDURE|conventional surgery|
214654369|NCT00003141|PROCEDURE|peripheral blood stem cell transplantation|
214654370|NCT05207475|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
214654371|NCT02467998|DEVICE|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
214654372|NCT05398198|DRUG|GSK3923868|GSK3923868 dose and administration as per study intervention.
214654373|NCT05398198|DRUG|Placebo|Placebo matching GSK3923868 will be administered.
214654374|NCT02382094|DRUG|Bicalutamide|
214654375|NCT03359902|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
214654376|NCT03359902|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
214654377|NCT05548036|DEVICE|OPEP|OPEP (Aerobika (tm)
214654378|NCT00323284|DEVICE|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
214654379|NCT00323284|PROCEDURE|Cataract surgery only|Cataract surgery only
214654380|NCT01051089|BEHAVIORAL|Lifestyle modification|Exercise and diet education
214654381|NCT02930174|DEVICE|noninvasive positive pressure ventilation|Application of various levels of positive pressure
214654382|NCT05855161|OTHER|Rebound therapy|Participants will receive exercise-based training on a trampoline
214654383|NCT05855161|OTHER|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
214654384|NCT01907386|OTHER|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
214654385|NCT00151892|DRUG|SPD476|2.4 g/day Once Daily (QD)
214654386|NCT00151892|DRUG|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
214654387|NCT02901431|DRUG|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
214654388|NCT02901431|DRUG|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
214654389|NCT03474055|BIOLOGICAL|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
214654390|NCT06484894|DEVICE|Pentacam and IOL master|Device used for measurement of central corneal thickness
214654391|NCT00435734|BEHAVIORAL|obesity intervention|
214654392|NCT01256216|DEVICE|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
214654393|NCT04799561|BEHAVIORAL|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
214654394|NCT01272583|DRUG|Sitagliptin|100 mg once daily for six weeks
214654395|NCT01272583|DRUG|Placebo|placebo, once daily for six weeks
214654396|NCT02945592|BEHAVIORAL|Cueing|
214654397|NCT05812391|PROCEDURE|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
214654398|NCT05812391|PROCEDURE|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
214654399|NCT03141944|OTHER|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
214654400|NCT04223609|DRUG|Oxycodone|5 mg tablet
214654401|NCT04223609|DRUG|Placebo|Oxycodone-matched placebo tablet
214654402|NCT04223609|DEVICE|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
214654403|NCT04223609|DIAGNOSTIC_TEST|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
214654404|NCT04223609|DEVICE|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
214654405|NCT00433238|BEHAVIORAL|Participants will be screened for depression and cognitive impairment, then receive screening results.|
214654406|NCT03871686|BEHAVIORAL|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
214654407|NCT02154399|DRUG|EF5|Given IV
214263878|NCT04753528|DEVICE|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
214263879|NCT04753528|DEVICE|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
214654408|NCT02154399|OTHER|Laboratory Biomarker Analysis|Correlative studies
214654409|NCT02154399|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
214654410|NCT02154399|OTHER|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
214654411|NCT06277973|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention is based on EMDR therapy for PTSD treatment. Participants will answer demographic questions, choose a primary distress source and watch a therapist-guided video (male or female, based on participant choice) that will instruct them through the 'Butterfly Hug' method (tapping alternately on both sides of the body) while hearing positive statements from the therapists on the chosen distress source. Before and after each video participants will rate their distress level on a scale between 0 and 10 and they can view up to 8 videos per session. The system will monitor distress levels, and if it detects a sustained deterioration, it will end the intervention. At the end of the intervention, participants will be given information about possible reactions to it and how to deal with them, they will be encouraged to use the technique whenever necessary, and they will be informed of relevant support lines that they can contact if needed.
214654412|NCT02222402|BEHAVIORAL|INTRA-DIALYTIC EXERCISE TRAINING|
214654413|NCT02549716|DRUG|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
214654414|NCT02549716|DRUG|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
214654415|NCT02549716|DRUG|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
214654416|NCT02549716|DRUG|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
214654417|NCT04995094|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
214654418|NCT04995094|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
214654419|NCT02713451|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
214263880|NCT04753528|DEVICE|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
214263881|NCT01238354|BEHAVIORAL|With friend|
214263882|NCT01238354|BEHAVIORAL|Without friend|
214654420|NCT01275222|DRUG|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
214654421|NCT01275222|DRUG|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
214654422|NCT01275222|DRUG|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
214654423|NCT02146339|OTHER|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654424|NCT02146339|OTHER|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654425|NCT02146339|OTHER|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654426|NCT02146339|OTHER|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654427|NCT02146339|OTHER|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654428|NCT02146339|OTHER|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
214654429|NCT00125047|BIOLOGICAL|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
214654430|NCT00125047|BIOLOGICAL|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
214654431|NCT04318392|OTHER|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
214654432|NCT04318392|OTHER|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
214654433|NCT04318392|OTHER|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
214654434|NCT04318392|OTHER|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
214654435|NCT04318392|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
214654436|NCT04318392|OTHER|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
214654437|NCT04318392|OTHER|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
214654438|NCT03440944|DEVICE|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
214654439|NCT03440944|DEVICE|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
214654440|NCT01146925|DRUG|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
214654441|NCT01146925|DRUG|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
214654442|NCT06200350|OTHER|Experimental group|Tailored training based on the profile of each participant.
214654443|NCT06200350|OTHER|Control group|They will continue with the traditional training.
214654444|NCT04294485|BEHAVIORAL|Physical therapy|Electrostimulation combined with exercise
214654445|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
214654446|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
214654447|NCT03043144|OTHER|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
214654448|NCT03043144|OTHER|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
214263883|NCT00384657|DRUG|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
214654449|NCT03043144|OTHER|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
214654450|NCT03043144|OTHER|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
214654451|NCT03043144|OTHER|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
214654452|NCT03043144|OTHER|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
214654453|NCT01400256|DRUG|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
214654454|NCT04899583|DEVICE|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
214654455|NCT04899583|DEVICE|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
214654456|NCT00943683|DRUG|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
214654457|NCT00943683|DRUG|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
214654458|NCT02652039|OTHER|Questionnaires|Questionnaires
214654459|NCT04672083|DRUG|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
214654460|NCT04672083|DRUG|Placebo|matching placebo
214654461|NCT02500537|DEVICE|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
214654462|NCT01597102|OTHER|No interventions|No intervention is planned in this study
214654463|NCT03505437|OTHER|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
214654464|NCT03505437|OTHER|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
214654465|NCT01963494|BEHAVIORAL|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
214654466|NCT01963494|BEHAVIORAL|Individual planning intervention|Target persons form action plans on their own.
214654467|NCT01963494|BEHAVIORAL|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
214654468|NCT03266679|OTHER|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
214654469|NCT00987844|DRUG|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
214654470|NCT05359107|BEHAVIORAL|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
214654471|NCT05359107|BEHAVIORAL|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
214654472|NCT04796519|PROCEDURE|Total knee arthroplasty|Surgical procedure
214654473|NCT01646359|DEVICE|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
214654474|NCT01646359|DEVICE|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
214654475|NCT05451420|DRUG|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
214654476|NCT01551745|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
214654477|NCT01551745|DRUG|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
214654478|NCT04492904|OTHER|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
214654479|NCT06287879|DIAGNOSTIC_TEST|Dry eye examination|"1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images"
214654480|NCT04684654|BIOLOGICAL|BMS-986325|Specified dose on specified days
214654481|NCT04684654|OTHER|Placebo for BMS-986325|Specified dose on specified days
214654482|NCT01661790|DRUG|Bevacizumab|Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
214654483|NCT01661790|DRUG|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
214654484|NCT04695509|DRUG|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
214654485|NCT04695509|DRUG|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
214654486|NCT00914693|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
214654487|NCT03152942|DRUG|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
214654488|NCT03152942|DRUG|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
214654489|NCT00631631|DRUG|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
214654490|NCT05360550|DRUG|LSP-5415|pregnancy prevention
214654491|NCT04738357|DRUG|HSK21542|HSK21542：1 µg/kg
214654492|NCT04738357|DRUG|Placebo|Placebo
214654493|NCT02870725|BEHAVIORAL|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
214654494|NCT00382148|DRUG|omalizumab|SC repeating dose
214654495|NCT05485207|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
214654496|NCT01479608|PROCEDURE|Liver transplantation and liver resection|
214654497|NCT02048904|DRUG|Sitagliptin|Sitagliptin 100 mg/day for 3 months
214654498|NCT02048904|DRUG|Placebo|Placebo 1 pill/day for 3 months
214654499|NCT02536248|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
214654500|NCT02536248|DRUG|Placebo|Placebo for 6 weeks
214654501|NCT04042480|DRUG|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
214654502|NCT06071611|OTHER|Experimental: Oxygen-Ozone (O2-O3)|Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
214654503|NCT06071611|OTHER|Active Comparator: Oxygen (O2)|Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
214654504|NCT06071611|OTHER|Placebo Comparator: Placebo (Air)|Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
214654505|NCT05200793|DRUG|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
214263884|NCT02550262|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
214263885|NCT02550262|DRUG|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
214263886|NCT02550262|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
214263887|NCT01788046|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
214263888|NCT01788046|DRUG|Placebo|Administered intravenously (IV) three times per week.
214263889|NCT03343379|OTHER|Core stability tests|A test battery comprised of field tests to evaluate core stability
214263890|NCT00751166|DRUG|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
214263891|NCT00751166|DRUG|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
214263892|NCT00751166|DRUG|placebo|placebo once daily for 28 days
214263893|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, single, 1 day
214263894|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, twice a day, 14 days
214263895|NCT01691274|DRUG|PF-04895162|Tablets, to be decided, twice a day, 14 days
214654506|NCT05200793|DRUG|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
214654507|NCT05200793|DRUG|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
214654508|NCT01449890|BEHAVIORAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
214654509|NCT04156321|DIETARY_SUPPLEMENT|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
214654510|NCT03035760|DRUG|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
214654511|NCT01552343|DRUG|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
214654512|NCT01552343|DRUG|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
214654513|NCT05637268|DRUG|Camrelizumab|Camrelizumab 200mg iv q2w
214654514|NCT05637268|DRUG|Paclitaxel|150mg/m² iv d1 q2w
214654515|NCT05637268|DRUG|Cisplatin|50 mg/m² iv d2 q2w
214654516|NCT02339467|OTHER|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
214654517|NCT02339467|OTHER|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
214654518|NCT02624648|BEHAVIORAL|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
214654519|NCT02624648|BEHAVIORAL|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
214654520|NCT02624648|BEHAVIORAL|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
214654521|NCT02624648|DRUG|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
214654522|NCT02624648|DRUG|Placebo|They will receive a capsule of Placebo twice a day for 120 days
214654523|NCT05792384|PROCEDURE|transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
214654524|NCT05792384|PROCEDURE|transbronchial lung biopsy with biopsy forceps|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps
214654525|NCT01446211|DRUG|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
214654526|NCT01446211|DRUG|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
214654527|NCT00784758|DEVICE|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
214654528|NCT00784758|DEVICE|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
214654529|NCT06057311|OTHER|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
214654530|NCT06057311|OTHER|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
214654531|NCT06057311|OTHER|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
214654532|NCT02844361|OTHER|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
214654533|NCT02844361|OTHER|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
214654534|NCT00130871|DRUG|levosimendan|
214654535|NCT03877406|DRUG|Empagliflozin 10 MG|addition of empagliflozin 10 MG
214654536|NCT03877406|DRUG|Hypoglycemics Oral|dose escalation of hypoglycemics oral
214654537|NCT06852443|BEHAVIORAL|Selfhelp modules|16 web-based structured selfhelp modules, based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
214654538|NCT06852443|BEHAVIORAL|Therapist Chat Service|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
214654539|NCT06386458|DEVICE|AThrough radiofrequency transseptal puncture system|Utilizing AThrough radiofrequency transseptal puncture system for left atrial access
214654540|NCT06386458|DEVICE|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
214654541|NCT04418921|BEHAVIORAL|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
214654542|NCT04418921|BEHAVIORAL|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
214654543|NCT00730743|PROCEDURE|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
214654544|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
214654545|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
214654546|NCT06153862|DIAGNOSTIC_TEST|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
214654547|NCT02954315|OTHER|Almonds|
214654548|NCT03767569|DRUG|Myo-inositol|Myo-inositol and Folic acid daily
214654549|NCT03767569|DRUG|Folic Acid|Folic Acid daily
214654550|NCT02797470|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
214654551|NCT02797470|DRUG|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
214654552|NCT02797470|DRUG|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
214654553|NCT02797470|DRUG|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
214654554|NCT02797470|OTHER|Laboratory Biomarker Analysis|Correlative studies
214654555|NCT02797470|BIOLOGICAL|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
214654556|NCT02797470|DRUG|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
214654557|NCT02797470|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
214263896|NCT01691274|DRUG|Placebo|Tablets, twice a day, 14 days
214263897|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
214654558|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
214654559|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
214654560|NCT05280496|DRUG|Metformin|Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
214654561|NCT05445349|DEVICE|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
214654562|NCT03542058|DRUG|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
214654563|NCT02356809|DRUG|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
214654564|NCT04311658|DRUG|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
214654565|NCT04311658|DRUG|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
214654566|NCT04742335|OTHER|Survey|Survey will be applied to the participants.
214654567|NCT04439123|DRUG|Capivasertib|Given PO
214654568|NCT02875223|DRUG|CC-90011|Specified dose on specified days
214654569|NCT02875223|DRUG|Rifampicin|Specified dose on specified days
214654570|NCT02875223|DRUG|Itraconazole|Specified dose on specified days
214654571|NCT04895306|DRUG|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
214654572|NCT04895306|DRUG|Placebo|Weekly intramuscular administration of Placebo
214654573|NCT01608035|PROCEDURE|Sciatic catheter|presurgical sciatic catheter insertion
214654574|NCT01608035|PROCEDURE|Stump catheter|intraoperative placed stump catheter
214654575|NCT01233479|DRUG|systemic chemotherapy|
214654576|NCT01233479|OTHER|laboratory biomarker analysis|
214654577|NCT01233479|PROCEDURE|therapeutic surgical procedure|
214654578|NCT01233479|RADIATION|radiation therapy|
214654579|NCT01951001|DRUG|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
214654580|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
214654581|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
214654582|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
214654583|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
214654584|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
214654585|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
214654586|NCT00245947|DRUG|ERB-041|
214654587|NCT04526184|PROCEDURE|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
214654588|NCT00000573|PROCEDURE|enteral nutrition|
214654589|NCT05222074|OTHER|Venous congestion|Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg
214654590|NCT05222074|OTHER|Introperation hypotension|Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
214654591|NCT05585255|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
214263898|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
214654592|NCT05998915|OTHER|observe only|observe only
214654593|NCT00503256|BEHAVIORAL|Questionnaire|Questionnaires each taking 60 minutes to complete.
214654594|NCT01572090|BEHAVIORAL|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
214654595|NCT01572090|OTHER|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
214654596|NCT01572090|PROCEDURE|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
214654597|NCT01572090|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
214654598|NCT00330707|DRUG|Bacillus Calmette Guerin and interferon alpha|
214654599|NCT06100575|BEHAVIORAL|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
214654600|NCT00268645|DRUG|Insulin Glargine|
214654601|NCT03275545|OTHER|No intervention|No intervention is being examined in this study
214654602|NCT05238051|OTHER|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
214654603|NCT00793351|PROCEDURE|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~* Enrollment - Pre-RIST treatment - RIST~* 4 cycles of conventional chemotherapy will be given prior to RIST.~* Surgery will be done whenever possible prior to RIST.~* Local radiotherapy will be applied whenever possible prior to RIST.~* topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~* Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
214654604|NCT04126655|DRUG|Arfolitixorin|Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
214654605|NCT01274884|PROCEDURE|Tightrope fixation|Arthroscopic repair
214654606|NCT02313831|OTHER|Interval training|Patients of this group will be submitted to an interval training program
214654607|NCT04870073|PROCEDURE|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
214654608|NCT04870073|DRUG|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
214654609|NCT04870073|PROCEDURE|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
214654610|NCT04774939|PROCEDURE|Endovenous laser ablation|The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment
214654611|NCT00094614|DRUG|Atropine|
214654612|NCT03604666|OTHER|Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
214654613|NCT06645886|DRUG|KQB198|Oral KQB198
214654614|NCT06645886|DRUG|Dasatinib|Oral dasatinib
214654615|NCT04211337|DRUG|Selpercatinib|Administered orally
214654616|NCT04211337|DRUG|Cabozantinib|Administered orally
214654617|NCT04211337|DRUG|Vandetanib|Administered orally
214654618|NCT03148210|DRUG|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
214654619|NCT03148210|BEHAVIORAL|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
214654620|NCT03148210|BEHAVIORAL|Participant Education|Standardized education for asthma or COPD disease
214654621|NCT06807606|DRUG|Drugs Cyclophosphamide|Given as standard of care treatment through IV infusion
214654622|NCT06807606|DRUG|Fludarabine|Given as standard of care treatment through IV infusion
214654623|NCT06807606|DRUG|Thiotepa|Given as standard of care treatment through IV infusion
214654624|NCT06807606|DRUG|Tacrolimus|Given as standard of care treatment through IV infusion
214654625|NCT06807606|DRUG|Mycophenolate mofetil|Given as standard of care treatment through IV infusion
214654626|NCT06814561|DRUG|Marcaine 0.5% Solution for Injection|The study involves the administration of 0.5% Marcaine heavy for spinal anesthesia in patients undergoing vascular surgery. The aim is to assess how this anesthesia affects urine output relative to mean arterial pressure.
214654627|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
214654628|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
214654629|NCT06223698|DRUG|Letrozole|Letrozole 2.5 mg daily
214654630|NCT06223698|DRUG|Anastrozole|Anastrozole 1 mg daily
214654631|NCT06223698|DRUG|Exemestane|Exemestane 25 mg daily
214654632|NCT06223698|DRUG|Tamoxifen|Tamoxifen 20 mg daily
214654633|NCT04977037|DEVICE|Active tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
214654634|NCT04977037|DEVICE|Sham tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
214654635|NCT06819488|DRUG|[14C]HRS-7535|\[14C\]HRS-7535.
214654636|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
214654637|NCT03042000|OTHER|non-NCRT|without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
214654638|NCT03042000|OTHER|NCRT|the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
214654639|NCT03042000|DRUG|capecitabine with oxaliplatin|combined chemotherapy with capecitabine with oxaliplatin
214654640|NCT03042000|DRUG|capecitabine|single-agent chemotherapy with capecitabine
214654641|NCT03042000|PROCEDURE|TEM|transanal endoscopic microsurgery (TEM) excision of the lesion
214654642|NCT03042000|PROCEDURE|radical resection|radical resection of rectal cancer
214654643|NCT02069002|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
214654644|NCT02069002|BEHAVIORAL|Applied relaxation group therapy|
214654645|NCT02069002|BEHAVIORAL|Information session (psychoeducation)|
214654646|NCT02514759|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
214654647|NCT04920032|DRUG|TAS-102|Given PO
214654648|NCT04920032|DRUG|Irinotecan|Given IV
214654649|NCT04920032|COMBINATION_PRODUCT|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
214654650|NCT04920032|DIAGNOSTIC_TEST|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
214654651|NCT06351033|DIETARY_SUPPLEMENT|High ozonide (HOO) ozonated oil|ozonated oil with high ozonides (HOO) administered orally (os) in gastro-resistant capsules
214654652|NCT06856252|GENETIC|Liver resection to isolate cells|Isolation and culture of organoids Isolation of hepatic stellate cells Isolation and culture of sinusoidal stellate cells Generation of assembloids
214654653|NCT05133102|OTHER|Sample collection|Collection of saliva sample
214654654|NCT04855773|OTHER|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
214654655|NCT04855773|DEVICE|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
214654656|NCT02376465|DRUG|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
214654657|NCT02376465|DRUG|PEG based bowel preparation|Oral bowel preparation for colonoscopy
214654658|NCT06666829|OTHER|Multidomain intervention|"treatment plan using combination of more than one technological or robotic devices, choosing from: Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~In this way, the child will be taken care of holistically, considering their needs from a motor, cognitive, and speech therapy perspective. The treatment plan will also include a conventional multi-level rehabilitation program."
214654659|NCT06666829|DEVICE|Single domain intervention|"Treatment plan using only one of these technological or robotic device:~Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~Technological rehabilitation will focus on the main specific need for the child, it'll be chosen individually. The treatment plan will also include a conventional multi-level rehabilitation program."
214654660|NCT06856707|DEVICE|Use of the MIRA Surgical System during surgery|Use of the MIRA Surgical System to perform robotically assisted colorectal surgery.
214654661|NCT03396770|PROCEDURE|Standard clinical routine|Patient management is carried out according to the usual service protocol
214654662|NCT03396770|PROCEDURE|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~* If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~* If the test is negative, patient management is carried out according to the usual protocol.~* A second test is realized 6 hours after the first test whatever the result of it."
214654663|NCT01036399|DRUG|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
214654664|NCT05839535|BEHAVIORAL|BDJ|BDJ is a mind-body intervention
214654665|NCT05839535|DEVICE|tDCS|tDCS is a brain stimulation method.
214654666|NCT05839535|DEVICE|sham tDCS|sham tDCS
214654667|NCT05839535|OTHER|exercise|exercise including stretching and other activities.
214654668|NCT06299280|OTHER|dual task training|students will be given additional cognitive tasks while exercising in physical education class
214654669|NCT06299280|OTHER|single task training|students will exercise in physical education class, without additional cognitive tasks
214654670|NCT06695663|BEHAVIORAL|Referral and communication skills learning|assigned to receive a brief, live, experiential training on the referral process and communication strategies.
214654671|NCT06695663|BEHAVIORAL|Written guide to the referral process|assigned to receive only written information about the referral process
214654672|NCT06695663|BEHAVIORAL|Empowered Generations (eGen): parent training|eGen is a six-session parent training program provided by therapists via video chat online to parents with a child between the ages of 3-8 years.
214654673|NCT06695663|BEHAVIORAL|control|The control condition consists of a single scripted session, in which therapists guide the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) vetted parenting advice websites; (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools; and (d) a list of culturally tailored parenting advice websites.
214654674|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
214654675|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
214654676|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
214654677|NCT06724445|BEHAVIORAL|Thabo cartoon|The animated cartoon features Thabo, a Black South African man living with HIV. Through his narrative, viewers follow his daily experiences managing his condition and confronting societal stigma in a South African context. The story explores his interactions with family, friends, and community members, highlighting both challenges and moments of resilience. The animation concludes with Thabo delivering an anti-stigma message directly to viewers.
214654678|NCT06724445|BEHAVIORAL|Steve cartoon|The animated cartoon follows Steve, a White man living with HIV. His narrative parallels Thabo's, showing his daily experiences managing HIV and facing societal stigma. The story depicts his interactions with family, friends, and community members, presenting the same situations and challenges as in Thabo's story. The animation ends with Steve delivering the same anti-stigma message to viewers.
214654679|NCT06926049|OTHER|The Effect of The Mindfulness-Based Psycho-Educational Program Focused on Emotions|The mindfulness based psychoeducation program focusing on emotions that aims to reduce the difficulties in regulating emotions and depressive symptoms in schizophrenia patients and to increase the level of hope.
214654680|NCT06895525|DIETARY_SUPPLEMENT|HellenCare|2 g, twice daily, to be taken on an empty stomach.
214654681|NCT06895525|DIETARY_SUPPLEMENT|Placebo|2 g, twice daily, to be taken on an empty stomach.
214654682|NCT06771037|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|Transcutaneous Auricular stimulation will be delivered using the Spark Biomedical Sparrow Link pulse generator with Sparrow Ascent earpieces. The Sparrow Link generator is based on FDA-cleared predicate Sparrow Ascent.
214654683|NCT06900556|PROCEDURE|Dry cupping with suction|Dry cupping with suction applied to the biceps
214654684|NCT06900556|PROCEDURE|Dry cupping without suction|Dry cupping without suction applied to the biceps
214654685|NCT03820817|DRUG|Rifaximin|Given PO
214654686|NCT06907511|BIOLOGICAL|Pandemic flu H5 HA mRNA SD2 vaccine|"Pharmaceutical Form:~Suspension in a vial~Route of Administration:~Intramuscular injection"
214654687|NCT06907511|OTHER|Placebo|"Pharmaceutical Form:~Liquid solution in a vial~Route of Administration:~Intramuscular injection"
214654688|NCT04577040|DRUG|Tadalafil 5mg|Drugs
214654689|NCT06915129|DIETARY_SUPPLEMENT|Prebiotic galactooligosaccharides (GOS)|Galactooligosaccharides (GOSs) are a group of nondigestible oligosaccharides consisting of galactose units linked via glycosidic bonds to galactose, terminal glucose, or sucrose. The linkages are not digested by human and animal pancreatic or intestinal enzymes. Some recent papers reported that daily supplementation with prebiotic GOS to lactose-intolerant individuals altered the gut microbiome and decreased lactose intolerance (LI) symptoms.
214654690|NCT06915337|DEVICE|Gastric-Jejunal Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: gastric-jejunal anastomosis creation in subjects undergoing surgical procedures. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into portions of the stomach and the jejunum that are intended to be anastomosed. An OTOLoc device will be deployed into the gastric wall of the stomach to provide access for the deployment of a Flexagon SFM into the stomach. The process is repeated at an intended section of jejunum. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
214654691|NCT06915974|DIAGNOSTIC_TEST|Interleukin 6|Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
214654692|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
214654693|NCT03596073|OTHER|Topical Vaseline|Placebo
214654694|NCT03510325|DRUG|Phase 1: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
214654695|NCT03510325|DRUG|Phase 1: Risperidone|Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks
214654696|NCT03510325|DRUG|Phase 1: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
214654697|NCT03510325|DRUG|Phase 1: Aripiprazole|Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks
214654698|NCT03510325|DRUG|Phase 1: Perphenazine|Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks
214654699|NCT03510325|DRUG|Phase 2: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
214654700|NCT03510325|DRUG|Phase 2: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
214654701|NCT03510325|DRUG|Phase 2: Clozapine|Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks
214654702|NCT03510325|OTHER|Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy|"Clozapine extended treatment:~dosage: 200-600 mg/d; dosage form: po.~Combined clozapine-MECT therapy:~Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month."
214654703|NCT03510325|DRUG|Phase 3B: Clozapine or another SGAs|"Clozapine:~Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks~Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2."
214654704|NCT06935565|OTHER|Trifocal IOL implantation|Patients were implanted bilaterally with Asqelio Trifocal IOL 270±90 days before study visit
214654705|NCT06936735|DRUG|HS-20108 Monotherapy|Intravenous (IV) Infusion
214654706|NCT06935318|OTHER|Exercise|The exercise group performed an 11-week high-functional resistance program in a group training format. They trained 3-4 days a week following nationally assigned workouts
214654707|NCT06935318|OTHER|Control|Did not participate in exercise related activities for the duration of the study period.
214654708|NCT06936865|BEHAVIORAL|VIVIFIL App Program|A digitally supported multicomponent exercise program delivered through the VIVIFIL mobile application. Participants followed a daily home-based routine including strength, balance, flexibility, and aerobic exercises, adapted to their functional reserve. The app provided video instructions, progression tracking, and a chat for remote communication with healthcare professionals.
214654709|NCT06936865|BEHAVIORAL|Hospital-Based Multicomponent Exercise|A supervised multicomponent exercise program delivered at a geriatric day hospital by trained professionals. Sessions lasted 45-60 minutes, 2-4 times per week for 8 weeks. Exercises included strength training, balance, flexibility, and aerobic components, adjusted to the participant's functional status.
214654710|NCT06936332|DEVICE|Omnilux Clear Light Emitting Diode Treatment|Omnilux Clear is a medical-grade, home light emitting diode (LED) treatment for acne-prone skin, using the most clinically effective LED's available, optimized for superior results. The blue light (415nm) targets and kills P. acnes bacteria living on the skin's surface. Red light (633nm) penetrates the dermis, triggering the body's own natural healing response, including the production of new collagen, the downregulation of excess oils, and the reduction of inflammation and redness.
214654711|NCT06935864|DIAGNOSTIC_TEST|KLF factor (4 and 7)|Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.
214654712|NCT06935279|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
214654713|NCT06935552|DRUG|Ketamine infusion|group A will receive ketamine intravenous infusion
214654714|NCT06935552|DRUG|Lidocaine Intravenous Infusion|group B will receive lidocaine intravenous infusion
214654715|NCT06935552|DRUG|Dextrose 5% in water|group C will only receive Dextrose 5% in water
214654716|NCT06936358|OTHER|Control|Control group received bone graft alone after extraction
214654717|NCT06936358|OTHER|A-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 1500 rpm for 14 minutes.
214654718|NCT06936358|OTHER|I-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 700 rpm for 3 minutes
214654719|NCT06935617|PROCEDURE|nissein|nissein surgery
214654720|NCT06936267|OTHER|rehabilitation : eyes closed|proprioceptive exercise with eyes closed
214654721|NCT06936267|OTHER|rehabilitation : eyes open|proprioceptive exercise with eyes open
214654722|NCT06936137|DRUG|lactobacillus LS|Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients
214654723|NCT06936371|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|Participants received a removable open bite activator constructed with the mandible opened beyond the freeway space and combined with vertical intermaxillary elastics applying 150g of force, supported by mini-screws placed between the lateral and canine teeth in both the maxilla and mandible. The appliance was worn 20-22 hours daily for 12 months. This approach aimed to treat skeletal open bite without using extraoral appliances by promoting anterior mandibular rotation and inhibiting posterior vertical dentoalveolar development.
214654724|NCT06936514|PROCEDURE|Bilateral Cervical Deep Lymphatic Trunk Decompression Combined with Mid-Cervical Deep Lymph Node-External Jugular Vein Anastomosis for Alzheimer's Disease|This intervention involves a surgical approach that combines bilateral cervical deep lymphatic trunk decompression with mid-cervical deep lymph node-external jugular vein anastomosis (LVA) to enhance lymphatic drainage in Alzheimer's Disease (AD) patients. The aim is to reduce the accumulation of neurotoxic substances in the brain, potentially improving cognitive function by facilitating waste clearance via the lymphatic system. The procedure is intended to restore normal lymphatic flow, potentially slowing disease progression in AD patients who have moderate to severe cognitive impairment.
214654725|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
214654726|NCT06935682|DRUG|Y-4 tables|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 tablets on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 tablets continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
214654727|NCT06935682|DRUG|Y-4 placebos|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 placebos on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 placebos continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
214654728|NCT06936969|PROCEDURE|Autologous blood patch pleurodesis|The intervention in this study is distinguished by the fact that patients are randomized, the dose of both glucose and ABPP is 120 ml, the patient remains in a supine position for 2 hours after administration, the procedure can be repeated at 48-hour intervals, a maximum of 3 times.
214654729|NCT06936969|PROCEDURE|40% glucose solution pleurodesis|"After obtaining informed consent, the patient will lie supine in their room. 30 minutes before the procedure, the patient's capillary blood glucose level will be measured. The patient does not have to fast before the procedure. The nurse will be asked to collect 120 ml of peripheral venous blood from the patient. Then the doctor, assisted by the nurse, will first administer 20 ml of 1% Lignocaine through the pleural drain, and then after about 5-10 minutes, the patient's previously collected venous blood. At the moment of blood administration, the drainage system will be disconnected. Then, the drain will be injected with 20 ml of air to avoid clogging the drain. The patient will remain supine for two hours post-procedure, maintaining fasting status. After 30 minutes from the administration of the patient's own blood, the capillary blood glucose level will be measured again. After two hours, the patient, with nursing assistance, may resume normal activities."
214654730|NCT06937008|OTHER|Whole body vibration|"All women in group (A) received whole body vibration and balance board training, three times per week for three months.~Parameters: The WBV was performed by using whole body vibration which is a side-alternating vibration device working as a teeterboard with amplitude of 0 to 5.3 mm (medial to distal) and a variable frequency of 5 to 30 Hz. The amplitude was controlled by adjusting the foot position from 1 to 3, with the larger the position, the greater the amplitude. Before the treatment, procedures of using the Galileo 900 were instructed by the research assistant and its safety issues explained.~Patient's position: The patient was asked to stand on WBV device by Hold hand support for those elderly women. the vibrating platform in a 100 to 110° squat position, the oscillating platform operating at 20Hz in bare feet at the second foot position for 15 minutes a day for 3 days a week for 3 months. All unusual or uncomfortable complaints from subjects during the WBV treatment were docu"
214654731|NCT06937008|OTHER|Balance training|Balance training exercises treatment: All women in both group (A, B) received balance training exercises on balance ball, half ball and balance board exercises three times per week for 3 months
214654732|NCT06955728|DRUG|Vaccine|The active ingredients in RSVpreF are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution.
214654733|NCT06955728|OTHER|Placebo|Placebo matched to vaccine but not containing any active ingredients
214654734|NCT04068103|DRUG|Capecitabine|Given PO
214654735|NCT04068103|DRUG|Fluorouracil|Given IV
214654736|NCT04068103|DRUG|Leucovorin|Given IV
214654737|NCT04068103|DRUG|Leucovorin Calcium|Given IV
214654738|NCT04068103|DRUG|Oxaliplatin|Give IV
214654739|NCT04068103|OTHER|Patient Observation|Undergo active surveillance
214654740|NCT06119191|DEVICE|Control Lenses (comfilcon A with current process)|Daily wear lenses for 30±2 days
214654741|NCT06119191|DEVICE|Test Lenses (comfilcon A with novel process)|Daily wear lenses for 30±2 days
214654742|NCT04304820|DRUG|Eltrombopag|Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
214654743|NCT04304820|DRUG|Cyclosporine|Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
214654744|NCT04304820|DRUG|Horse-Anti-thymocyte-Globulin|h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
214654745|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
214654746|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
214654747|NCT05177796|DRUG|Carboplatin|Given IV
214654748|NCT05177796|DRUG|Cyclophosphamide|Given IV
214654749|NCT05177796|DRUG|Doxorubicin|Given IV
214654750|NCT05177796|DRUG|Paclitaxel|Given IV
214654751|NCT05177796|BIOLOGICAL|Panitumumab|Given IV
214654752|NCT05177796|BIOLOGICAL|Pembrolizumab|Given IV
214654753|NCT04815096|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
214654754|NCT04914897|DRUG|THOR-707|Intravenous infusion: solution for infusion
214654755|NCT04914897|DRUG|Pembrolizumab|Intravenous infusion: solution for infusion
214654756|NCT00002285|DRUG|Zidovudine|
214654757|NCT05390216|PROCEDURE|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
214654758|NCT01775748|OTHER|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
214654759|NCT01775748|OTHER|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
214654760|NCT01717248|DRUG|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
214654761|NCT03089788|OTHER|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
214654762|NCT03089788|OTHER|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
214654763|NCT01838135|DEVICE|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
214654764|NCT06541444|DRUG|NK520|The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
214654765|NCT05742321|GENETIC|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
214654766|NCT05742321|DIAGNOSTIC_TEST|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
214654767|NCT05742321|OTHER|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
214654768|NCT03688386|BEHAVIORAL|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
214654769|NCT03688386|BEHAVIORAL|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
214654770|NCT03688386|BEHAVIORAL|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
214654771|NCT03688386|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
214654772|NCT03688386|BEHAVIORAL|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
214654773|NCT03395678|DEVICE|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
214654774|NCT03395678|DEVICE|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
214654775|NCT02732951|DRUG|BI 1026706|
214654776|NCT02732951|DRUG|Placebo|
214654777|NCT05751525|DRUG|Sulfonylurea|Glibenlclamide / glyburide
214654778|NCT02149641|RADIATION|Intensity modulated radiotherapy with chemotherapy|
214654779|NCT01337349|DRUG|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
214654780|NCT01337349|DRUG|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
214654781|NCT04724525|OTHER|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
214654782|NCT03263806|DIAGNOSTIC_TEST|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
214654783|NCT03263806|DIAGNOSTIC_TEST|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
214654784|NCT02249715|DEVICE|Brainsway Multiway deep TMS device (two channels)|
214654785|NCT01412879|BIOLOGICAL|rituximab|Given IV
214654786|NCT01412879|DRUG|bendamustine hydrochloride|Given IV
214654787|NCT01412879|DRUG|cyclophosphamide|Given IV
214654788|NCT01412879|DRUG|cytarabine|Given IV
214654789|NCT01412879|DRUG|dexamethasone|Given PO or IV
214654790|NCT01412879|DRUG|doxorubicin hydrochloride|Given IV
214654791|NCT01412879|DRUG|leucovorin calcium|Given PO or IV
214654792|NCT01412879|DRUG|methotrexate|Given IV
214654793|NCT01412879|DRUG|vincristine sulfate|Given IV
214654794|NCT00622193|DRUG|anamorelin HCl|50 mg tablet
214654795|NCT00622193|DRUG|anamorelin HCl|100 mg tablet
214654796|NCT00622193|DRUG|placebo|placebo tablet
214654797|NCT04840667|DRUG|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
214654798|NCT01676038|PROCEDURE|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
214654799|NCT01676038|PROCEDURE|Conventional Total Knee Arthroplasty|Conventional technique.
214654800|NCT02704962|DRUG|full-dose olanzapine|trifluoperazine 5mg/d
214654801|NCT01445171|DEVICE|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
214654802|NCT04544566|DEVICE|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
214654803|NCT04544566|DEVICE|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
214654804|NCT04544566|DEVICE|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
214654805|NCT00787111|DRUG|Fluoxetine (prozac)|Formulation: ODT
214654806|NCT03195894|DEVICE|TripleA|
214654807|NCT03332069|DEVICE|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
214654808|NCT03332069|RADIATION|External beam radiation|
214654809|NCT03332069|DRUG|Cisplatin|
214654810|NCT03332069|RADIATION|Brachytherapy|High Dose Rate
214654811|NCT06117189|OTHER|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
214654812|NCT05995444|DRUG|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
214654813|NCT05995444|DRUG|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
214654814|NCT05995444|DRUG|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
214654815|NCT05995444|DRUG|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
214654816|NCT00957541|DEVICE|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
214654817|NCT06541847|DRUG|HLX-1502|Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
214654818|NCT05415579|OTHER|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
214654819|NCT00162773|DRUG|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
214654820|NCT00162773|OTHER|Placebo|150-375 milligrams depending on body weight and serum IgE.
214654821|NCT05219565|DEVICE|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
214654822|NCT00654927|DRUG|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
214654823|NCT00503191|BEHAVIORAL|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
214654824|NCT04412304|DRUG|Dose of Tinzaparin or Dalteparin|The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
214654825|NCT01745003|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
214654826|NCT04847128|BEHAVIORAL|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
214654827|NCT06487377|BIOLOGICAL|IX001 TCR-T cells|IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
214654828|NCT05700461|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
214654829|NCT02473796|OTHER|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
214654830|NCT04673994|BEHAVIORAL|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
214654831|NCT06151925|DEVICE|Laminaria|mechanical method for induction of labor
214654832|NCT06151925|DRUG|Vaginal prostaglandin|Vaginal prostaglandin for ripening
214654833|NCT01724281|OTHER|No intervention, only follow up|
214654834|NCT00469937|DRUG|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
214654835|NCT00469937|PROCEDURE|cognitive assessment|cognitive assessment
214654836|NCT00469937|PROCEDURE|quality-of-life assessment|quality-of-life assessment
214654837|NCT00469937|RADIATION|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
214654838|NCT02592005|OTHER|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
214654839|NCT04085432|OTHER|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
214654840|NCT06006975|RADIATION|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
214654841|NCT06006975|DIAGNOSTIC_TEST|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
214654842|NCT03503123|DEVICE|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
214654843|NCT04917783|BEHAVIORAL|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
214654844|NCT04917783|BEHAVIORAL|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
214654845|NCT02773797|DRUG|IN-DEX 1.0 mcg/kg, intranasal saline|
214654846|NCT02773797|DRUG|IN-DEX 1.5 mcg/kg, intranasal saline|
214654847|NCT02773797|DRUG|Placebo - Saline|
214654848|NCT01725139|DRUG|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
214654849|NCT01725139|DRUG|Placebo|Matching placebo will be available
214654850|NCT02226484|DRUG|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
214654851|NCT02490852|OTHER|Investigational infant formula|fed ad libitum
214654852|NCT02490852|OTHER|Active Comparator: Commercially available Infant formula|fed ad libitum
214654853|NCT02490852|OTHER|Active Comparator: Human milk|fed ad libitum
214654854|NCT03645187|DRUG|FOLFERI|FOLFERI regimen
214654855|NCT03645187|DRUG|Folferi and celecoxib|Folferi regimen and celecoxib
214654856|NCT03829761|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
214654857|NCT03829761|DEVICE|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
214654858|NCT03959436|DRUG|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
214654859|NCT01300104|BEHAVIORAL|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
214654860|NCT01300104|BEHAVIORAL|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
214654861|NCT01300104|BEHAVIORAL|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
214654862|NCT06108661|PROCEDURE|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
214654863|NCT06108661|PROCEDURE|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
214654864|NCT06108661|PROCEDURE|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
214654865|NCT03283839|DIAGNOSTIC_TEST|Posturography|Evaluation of postural control and of orientation function
214654866|NCT04163198|DEVICE|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
214654867|NCT04163198|DEVICE|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
214654868|NCT03319628|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
214654869|NCT04934202|OTHER|Teleconsultation|"Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties"
214654870|NCT04934202|OTHER|Outpatient clinic|"During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation"
214654871|NCT03910192|BEHAVIORAL|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
214654872|NCT03910192|BEHAVIORAL|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
214654873|NCT03783195|OTHER|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
214654874|NCT05643144|DEVICE|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
214654875|NCT06252116|DRUG|Pregabalin group|Pregabalin group
214654876|NCT06252116|DRUG|Duloxetine group|Duloxetine group
214654877|NCT02162888|DRUG|Test Product (Bendamustine)|
214654878|NCT03115931|OTHER|no intervention|no intervention
214654879|NCT03871907|BEHAVIORAL|Digital technology|Lifestyle-Focused Text Messaging
214654880|NCT05666089|DRUG|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
214654881|NCT05666089|DRUG|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
214654882|NCT01517880|DRUG|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
214654883|NCT01517880|DRUG|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
214654884|NCT04507009|DEVICE|Ozone|topical gaseous ozone application
214654885|NCT04507009|OTHER|CGF|concentrated growth factor (CGF) application
214654886|NCT04507009|OTHER|Traditional treatment|Alvogyl application
214654887|NCT06322758|OTHER|Tidal volume customization in the acute respiratory distress syndrome|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
214654888|NCT04023084|DRUG|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
214654889|NCT04490629|DEVICE|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
214654890|NCT04490629|DEVICE|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
214654891|NCT04255511|DEVICE|Twin Block|Functional appliance
214654892|NCT04255511|DEVICE|Fixed orthodontic appliance|Braces
214654893|NCT04720703|BEHAVIORAL|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
214654894|NCT04720703|BEHAVIORAL|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
214654895|NCT01903876|BEHAVIORAL|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
214654896|NCT01903876|BEHAVIORAL|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
214654897|NCT03231514|DIETARY_SUPPLEMENT|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
214654898|NCT03231514|OTHER|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
214654899|NCT03231514|OTHER|Exercise|All groups will participate in a standardized exercise intervention.
214654900|NCT00001087|DRUG|Ritonavir|
214654901|NCT00001087|DRUG|Nelfinavir mesylate|
214654902|NCT00001087|DRUG|Efavirenz|
214654903|NCT00001087|DRUG|Levocarnitine|
214654904|NCT00001087|DRUG|Adefovir dipivoxil|
214654905|NCT00001087|DRUG|Saquinavir|
214654906|NCT00001087|DRUG|Lamivudine|
214654907|NCT00001087|DRUG|Stavudine|
214654908|NCT00001087|DRUG|Zidovudine|
214654909|NCT00001087|DRUG|Zalcitabine|
214654910|NCT00001087|DRUG|Didanosine|
214654911|NCT02427165|DRUG|RPL554|A dual PDE3 and PDE4 inhibitor
214654912|NCT02427165|DRUG|Salbutamol|a beta-2 receptor agonist
214654913|NCT02427165|DRUG|Placebo|RPL554 placebo containing no active ingredients
214654914|NCT06246383|DIETARY_SUPPLEMENT|Q Actin|cucumber extract
214654915|NCT04610099|DEVICE|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
214654916|NCT04610099|DEVICE|Standard SG|Standard SG
214654917|NCT05551130|OTHER|Restoration|Restorations completed with these materials.
214654918|NCT03083717|DIAGNOSTIC_TEST|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
214654919|NCT03780998|DRUG|Life7|Life7 will used on the perianal skin with finger tips
214654920|NCT03661684|DRUG|Prednisone|40 mg po q day of Prednisone for 3 days
214654921|NCT02612909|BIOLOGICAL|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
214654922|NCT02612909|BIOLOGICAL|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
214654923|NCT05090956|OTHER|mri|
214654924|NCT04470895|DIAGNOSTIC_TEST|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
214654925|NCT01871883|PROCEDURE|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
214654926|NCT01871883|PROCEDURE|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
214654927|NCT04486560|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
214654928|NCT01947270|OTHER|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
214654929|NCT00450580|DRUG|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
214654930|NCT01587066|DRUG|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
214654931|NCT01587066|DRUG|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
214654932|NCT02418130|DRUG|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
214654933|NCT02418130|DRUG|Placebo|
214654934|NCT02268162|PROCEDURE|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
214654935|NCT03977779|DEVICE|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
214654936|NCT06181955|OTHER|Extracorporeal Shock Wave Therapy|The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).
214654937|NCT06181955|OTHER|conventional physical therapy|Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
214654938|NCT00393718|DRUG|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
214654939|NCT00393718|DRUG|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
214654940|NCT00393718|DRUG|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
214654941|NCT00393718|DRUG|placebo|glibenclamide placebo. Given orally once or twice daily.
214654942|NCT01015508|OTHER|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
214654943|NCT01015508|OTHER|Weight maintenance|10 months
214654944|NCT05946967|OTHER|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
214654945|NCT05946967|OTHER|Biofeedback only|Constipation patients will be given biofeedback treatment only
214654946|NCT03737656|DRUG|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
214654947|NCT00286052|DRUG|Low Dose Naloxone|
214654948|NCT01583426|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
214654949|NCT01583426|DRUG|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
214654950|NCT05861505|DRUG|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
214654951|NCT05861505|OTHER|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
214654952|NCT02902094|DEVICE|Drug eluting balloons|
214654953|NCT02902094|DEVICE|Non drug eluting balloons|
214654954|NCT03850821|BEHAVIORAL|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
214654955|NCT04008017|DIAGNOSTIC_TEST|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
214654956|NCT00674011|DRUG|Bevacizumab|Given as part of standard of care or another research protocol
214654957|NCT06063473|DRUG|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
214654958|NCT06063473|DRUG|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
214654959|NCT06063473|DRUG|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
214654960|NCT05693402|PROCEDURE|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
214654961|NCT05781048|DRUG|HRS-6209|HRS-6209
214654962|NCT04080206|DRUG|188-0551 Spray|Applied topically twice daily for two weeks
214654963|NCT04080206|DRUG|RLD|Applied topically twice daily for two weeks
214654964|NCT04502615|OTHER|Sand|sand surface
214654965|NCT04502615|OTHER|artificial grass|grass surface
214654966|NCT04502615|OTHER|firm ground|firm surface
214654967|NCT03115450|DEVICE|Ultrasound|Type of imaging technology to look at organs and structures inside the body
214654968|NCT03115450|DEVICE|Pupilometer|A device that measures pupil size and how it changes.
214654969|NCT04938648|BEHAVIORAL|Pharmacist-led deprescribing intervention|1\) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
214654970|NCT00662961|PROCEDURE|Periosteum|Periosteum fixation
214654971|NCT00662961|PROCEDURE|Bone|Bone tunnel fixation
214654972|NCT06488118|DRUG|R848|Inhaled R848 dose ranging from 0.1 to 100 μg/mL
214654973|NCT06488118|DRUG|Saline|Inhaled Saline control
214654974|NCT01172379|DRUG|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
214654975|NCT01172379|DRUG|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
214654976|NCT01172379|DRUG|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
214654977|NCT01172379|OTHER|Placebo Comparator|Placebo 1 tablet per day
214654978|NCT02834130|BEHAVIORAL|Evaluation of psychological and psychopathological|
214654979|NCT03293654|DRUG|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
214654980|NCT03293654|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
214654981|NCT03293654|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
214654982|NCT01191814|PROCEDURE|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
214654983|NCT01191814|PROCEDURE|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
214654984|NCT01474577|OTHER|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
214654985|NCT01106261|PROCEDURE|Metastasectomy|Pulmonary Metastasectomy
214654986|NCT01106261|PROCEDURE|Active monitoring|Active monitoring
214654987|NCT06008548|PROCEDURE|TACE|
214654988|NCT03246438|BEHAVIORAL|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
214654989|NCT03246438|BEHAVIORAL|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
214654990|NCT03246438|BEHAVIORAL|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
214654991|NCT00679861|BEHAVIORAL|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
214654992|NCT00679861|BEHAVIORAL|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
214654993|NCT00603005|DEVICE|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
214654994|NCT00688038|PROCEDURE|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
214654995|NCT00688038|PROCEDURE|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
214654996|NCT01761734|BEHAVIORAL|text message|
214654997|NCT05759052|BEHAVIORAL|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
214654998|NCT05548686|OTHER|adapted physical activity|3 sessions of adapted physical activity per week during 12 weeks for each patient
214654999|NCT05374486|DEVICE|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
214655000|NCT01485874|DRUG|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
214655001|NCT01485874|DRUG|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
214655002|NCT01919307|OTHER|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
214655003|NCT05766735|BEHAVIORAL|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
214655004|NCT05766735|OTHER|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
214655005|NCT02327650|PROCEDURE|The examinations for bones in joints of OA and RA patients|
214655006|NCT05413681|DIAGNOSTIC_TEST|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
214655007|NCT05413681|DIAGNOSTIC_TEST|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
214655008|NCT03742427|DIAGNOSTIC_TEST|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
214655009|NCT04507815|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
214655010|NCT04507815|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
214655011|NCT06962696|OTHER|No intervention|no intervention provided
214655012|NCT06961227|OTHER|No investigational intervention|No investigational intervention. Patients will be observed under standard ventilation modes (SIMV and MMV) as part of routine care.
214655013|NCT06961136|DRUG|Fuzheng Yangxin prescription|Fuzheng Yangxin prescription
214655014|NCT06961136|DRUG|placebo|placebo
214655015|NCT04459845|BEHAVIORAL|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
214655016|NCT04459845|BEHAVIORAL|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
214655017|NCT02736747|OTHER|Cryotherapy|
214655018|NCT02736747|OTHER|Placebo|
214655019|NCT06110650|DRUG|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
214655020|NCT00318435|DEVICE|Stent or stent-graft deployment|
214655021|NCT05762198|DEVICE|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
214655022|NCT05762198|DEVICE|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
214655023|NCT01569633|DRUG|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
214655024|NCT01569633|DRUG|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
214655025|NCT01569633|DRUG|placebo|The dose of sugar water is 1 ml per 8 hours.
214655026|NCT00680225|DRUG|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
214655027|NCT00763009|DRUG|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
214655028|NCT01055509|BEHAVIORAL|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
214655029|NCT02906553|DRUG|Glyceryl Trinitrate|
214655030|NCT02906553|DRUG|Placebo|
214655031|NCT05773391|DRUG|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
214655032|NCT03978273|DEVICE|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
214655033|NCT03978273|OTHER|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
214655034|NCT00918944|OTHER|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families"
214655035|NCT00918944|OTHER|Intervention|"Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link"
214655036|NCT04587115|DRUG|Risperidone|Risperidone 1mg to be used in combination with other drugs
214655037|NCT04587115|DRUG|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
214655038|NCT04587115|DRUG|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
214655039|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade the Flexor Hallucis|
214655040|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade adductor of the thumb.|
214655041|NCT00891735|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
214655042|NCT04290182|BIOLOGICAL|MSC-KI-PL-204|Autologous MSC product
214655043|NCT01561664|OTHER|muscle and fat biopsy|muscle and fat biopsy
214655044|NCT01964248|DRUG|Placebo|Placebo cream applied 2 hours before blood sample
214655045|NCT01964248|DRUG|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
214655046|NCT02005055|PROCEDURE|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
214655047|NCT02547623|DRUG|Dexamethasone|depot intracameral
214655048|NCT02547623|DRUG|Prednisolone|Prednisolone eye drops 1%
214655049|NCT02676258|DEVICE|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
214655050|NCT02676258|DEVICE|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
214655051|NCT01480739|DRUG|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
214655052|NCT01480739|DRUG|100 mg Placebo|Twice daily for 7 days
214655053|NCT03573167|BEHAVIORAL|In-Person Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
214655054|NCT03573167|BEHAVIORAL|Mobile Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
214655055|NCT00673595|DRUG|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
214655056|NCT00673595|DRUG|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
214655057|NCT01743430|OTHER|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
214655058|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
214655059|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
214655060|NCT02562547|DEVICE|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
214655061|NCT03663166|RADIATION|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
214655062|NCT03663166|DRUG|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
214655063|NCT03663166|DRUG|ipilimumab|ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
214655064|NCT03663166|DRUG|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
214655065|NCT00004029|BIOLOGICAL|recombinant viral vaccine therapy|
214655066|NCT00004029|BIOLOGICAL|sargramostim|
214655067|NCT01666223|DRUG|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
214655068|NCT01666223|DRUG|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
214655069|NCT01666223|OTHER|saline|100 ml saline
214655070|NCT01666223|DRUG|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
214655071|NCT02148367|DRUG|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
214655072|NCT00924157|DIETARY_SUPPLEMENT|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
214655073|NCT00924157|OTHER|Placebo|Matching placebo capsules
214655074|NCT01516827|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
214655075|NCT02978222|BIOLOGICAL|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
214655076|NCT02978222|DRUG|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
214655077|NCT01686568|DRUG|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
214655078|NCT01686568|DRUG|placebo|
214655079|NCT03972072|OTHER|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
214655080|NCT03972072|DIAGNOSTIC_TEST|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
214655081|NCT01908595|DRUG|M518101|
214655082|NCT02703857|DRUG|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
214655083|NCT05314673|DRUG|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
214655084|NCT05314673|PROCEDURE|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
214655085|NCT03838484|DRUG|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
214655086|NCT03838484|DRUG|Placebo patch|Placebo skin patch will be applied to the skin.
214655087|NCT04675047|OTHER|no intervention for healthy control|observational study - no intervention
214655088|NCT01523080|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
214655089|NCT05294029|OTHER|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
214655090|NCT04727671|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
214655091|NCT04727671|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
214655092|NCT04727671|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
214655093|NCT04727671|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
214655094|NCT01021943|DRUG|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
214655095|NCT01021943|DRUG|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
214655096|NCT06263088|OTHER|EQUITY GI|"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
214655097|NCT01511484|BEHAVIORAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
214655098|NCT01511484|BEHAVIORAL|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
214655099|NCT01511484|BEHAVIORAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
214655100|NCT05105386|DEVICE|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
214655101|NCT04530162|PROCEDURE|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
214655102|NCT04151108|OTHER|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
214655103|NCT04151108|OTHER|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
214655104|NCT04856137|DRUG|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
214655105|NCT00158184|DRUG|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
214655106|NCT00158184|DRUG|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
214655107|NCT00158184|DRUG|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
214655108|NCT01755832|PROCEDURE|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
214655109|NCT06011135|OTHER|No intervention|No intervention - qualitative study only using semi-structured interview
214655110|NCT04833439|OTHER|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
214655111|NCT06301360|BEHAVIORAL|Internet based Emotional Awareness and Expression Therapy (I-EAET)|"In I-EAET with therapist support, the therapist and participants communicate asynchronous using written messages. The therapist gives feedback each week on home-work assignments and is available on demand for support.~In I-EAET without therapist support, the participants works with home-work assignments on their own and only have technical support."
214655112|NCT00014092|BIOLOGICAL|aldesleukin|
214655113|NCT00014092|BIOLOGICAL|recombinant interferon alfa|
214655114|NCT00014092|BIOLOGICAL|sargramostim|
214655115|NCT00014092|DRUG|temozolomide|
214655116|NCT04673058|PROCEDURE|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
214655117|NCT04673058|PROCEDURE|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
214655118|NCT02168595|DRUG|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
214655119|NCT02168595|DRUG|Placebo|
214655120|NCT06151652|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
214655121|NCT06151652|DRUG|Placebo|placebo
214655122|NCT04890873|DRUG|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
214655123|NCT04890873|DRUG|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
214655124|NCT03537040|OTHER|Method of Levels|Talking Therapy
214655125|NCT02059876|DRUG|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
214655126|NCT06213662|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
214655127|NCT03624816|DEVICE|Restylane Defyne|hyaluronic acid dermal filler gel
214655128|NCT05965037|DEVICE|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
214655129|NCT05642377|DRUG|HGR4113|Once-daily oral administration
214655130|NCT05642377|DRUG|Placebo|Once-daily oral administration
214655131|NCT05642377|DRUG|HGR4113|Twice-daily oral administration
214655132|NCT05642377|DRUG|Placebo|Twice-daily oral administration
214655133|NCT06546865|DEVICE|22F Sheath Size|Participants in this group will have the 22F sheath size used in their procedure.
214655134|NCT06546865|DEVICE|26F Sheath Size|Participants in this group will have the 26F sheath size used in their procedure.
214655135|NCT03386084|DEVICE|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
214655136|NCT02511977|OTHER|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
214655137|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
214655138|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
214655139|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
214655140|NCT00844493|BIOLOGICAL|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
214655141|NCT02236689|PROCEDURE|Non operative|no surgical intervention
214655142|NCT02236689|PROCEDURE|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
214655143|NCT02868892|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
214655144|NCT04751721|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
214655145|NCT01106924|OTHER|Probiotic|daily probiotic consumption
214655146|NCT01106924|OTHER|Placebo|daily placebo consumption
214655147|NCT02131844|OTHER|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
214655148|NCT02131844|OTHER|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
214655149|NCT04378777|PROCEDURE|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
214655150|NCT04378777|PROCEDURE|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
214655151|NCT06185855|OTHER|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
214655152|NCT00208637|BEHAVIORAL|moderate carbohydrate, high protein diet (MCHP)|
214655153|NCT00208637|BEHAVIORAL|high carbohydrate-high fibre (HCHF) diet|
214655154|NCT04048512|PROCEDURE|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
214655155|NCT04048512|PROCEDURE|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
214655156|NCT01455974|OTHER|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
214655157|NCT02984462|PROCEDURE|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
214655158|NCT04814979|DEVICE|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
214655159|NCT04814979|OTHER|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
214655160|NCT00661583|DRUG|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
214655161|NCT00661583|DRUG|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
214655162|NCT00661583|DRUG|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
214655163|NCT05116657|DIAGNOSTIC_TEST|Nasal Lavage and Oral Wash|"* Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
214655164|NCT01973855|DRUG|Western Medicine|Physical cooling,Hydrocortisone
214655165|NCT01973855|DRUG|TCM and Western Medicine|Third Infectious diseases soup recipe
214655166|NCT02393209|DRUG|Docetaxel|Docetaxel intravenous infusion
214655167|NCT02393209|DRUG|TAK-117|TAK-117 Tablets
214655168|NCT00899652|GENETIC|Southern blotting|
214655169|NCT00899652|GENETIC|chromosomal translocation analysis|
214655170|NCT00899652|GENETIC|cytogenetic analysis|
214655171|NCT00899652|GENETIC|gene rearrangement analysis|
214655172|NCT00899652|GENETIC|mutation analysis|
214655173|NCT03393026|DRUG|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
214655174|NCT03841552|DEVICE|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
214655175|NCT03841552|OTHER|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
214655176|NCT03545139|BIOLOGICAL|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
214655177|NCT03545139|BIOLOGICAL|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
214655178|NCT00006131|DRUG|Valacyclovir|
214655179|NCT04052841|PROCEDURE|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
214655180|NCT04052841|PROCEDURE|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
214655181|NCT04052841|PROCEDURE|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
214655182|NCT00868790|DRUG|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
214655183|NCT00868790|DRUG|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
214655184|NCT00868790|DRUG|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
214655185|NCT00868790|DRUG|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
214655186|NCT02582671|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
214655187|NCT02582671|DRUG|Dasabuvir|Tablet
214655188|NCT02582671|DRUG|Ribavirin|Tablet
214655189|NCT03578679|DRUG|Ivermectin Oral Product|treatment of pediculosis (head lice)
214655190|NCT05043584|DEVICE|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
214655191|NCT00728429|BEHAVIORAL|exercise intervention|24 week program of exercise
214655192|NCT05495347|OTHER|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
214655193|NCT01293617|OTHER|Blackberries|300 g blackberries daily for 5 days
214655194|NCT01293617|OTHER|Gelatin|300 g gelatin per day for 5 days
214655195|NCT03068715|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
214655196|NCT03068715|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214655197|NCT03068715|DEVICE|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
214655198|NCT02210156|DIETARY_SUPPLEMENT|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
214655199|NCT02210156|OTHER|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
214655200|NCT05671276|DRUG|aspirin and clopidogrel|DAPT (until 6 months) + ASA
214655201|NCT05671276|DRUG|Rivaroxaban|half-dose NOAC
214655202|NCT00078130|DRUG|Buprenorphine/naloxone|
214655203|NCT05174091|OTHER|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
214655204|NCT03462251|COMBINATION_PRODUCT|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
214655205|NCT03462251|COMBINATION_PRODUCT|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
214655206|NCT03787069|DRUG|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
214655207|NCT05015309|DRUG|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
214655208|NCT01276288|DRUG|BI 10773|multiple oral doses
214655209|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
214655210|NCT01276288|DRUG|torasemide|multiple oral doses
214655211|NCT01276288|DRUG|BI 10773|multiple oral doses
214655212|NCT01276288|DRUG|torasemide|multiple oral doses
214655213|NCT01276288|DRUG|BI 10773|multiple oral doses
214655214|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
214655215|NCT03429868|DEVICE|integrated PET/MRI|"The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
214655216|NCT03496701|DEVICE|Test lens|contact lens
214655217|NCT03496701|DEVICE|control lens|contact lens
214655218|NCT01484964|DRUG|ASP015K|oral
214655219|NCT03168867|BEHAVIORAL|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
214655220|NCT04348851|BEHAVIORAL|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
214655221|NCT04348851|BEHAVIORAL|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
214655222|NCT04209231|OTHER|1.25(OH)2D3|
214655223|NCT04209231|OTHER|25(OH)D|
214655224|NCT05658757|OTHER|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
214655225|NCT05658757|OTHER|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
214655226|NCT05658757|OTHER|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
214655227|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
214655228|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
214655229|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
214655230|NCT00971308|DRUG|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
214655231|NCT00971308|DRUG|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
214655232|NCT06488677|BEHAVIORAL|Lifestyle changes (diet and physical activity)|Nurse-led telephone personalized dietary and PA advice
214655233|NCT02235818|DEVICE|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
214655234|NCT02235818|DEVICE|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
214655235|NCT00003176|DRUG|carmustine|
214655236|NCT00003176|DRUG|temozolomide|
214655237|NCT05144425|PROCEDURE|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
214655238|NCT04911387|DEVICE|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
214655239|NCT03401749|DRUG|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
214655240|NCT03401749|OTHER|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
214655241|NCT03026738|PROCEDURE|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
214655242|NCT03026738|PROCEDURE|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
214655243|NCT03026738|DEVICE|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
214655244|NCT05003115|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
214655245|NCT03519048|PROCEDURE|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
214655246|NCT03519048|OTHER|Low Dose Chest CTscan|every year in patients with tobacco consumption history of \> 20 pack-year
214655247|NCT03519048|OTHER|injected CT-scan|the first performed 12 months after inclusion
214655248|NCT03519048|OTHER|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
214655249|NCT03519048|PROCEDURE|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
214655250|NCT03519048|PROCEDURE|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
214655251|NCT00682656|DRUG|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
214655252|NCT00682656|DRUG|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
214655253|NCT05134909|DEVICE|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
214655254|NCT05657262|OTHER|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
214655255|NCT05657262|BEHAVIORAL|experimental group|The experiment group will be applied with the Z technique.
214655256|NCT03040024|DRUG|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
214655257|NCT03040024|DRUG|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
214655258|NCT03040024|DEVICE|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
214655259|NCT05934214|DRUG|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
214655260|NCT02227576|DRUG|Romiplostim|
214655261|NCT01086787|OTHER|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
214655262|NCT06337396|DIAGNOSTIC_TEST|WGS and transcriptome analysis|In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
214655263|NCT06112587|BEHAVIORAL|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
214655264|NCT03248921|PROCEDURE|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
214655265|NCT04970329|DRUG|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
214655266|NCT05182164|DRUG|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
214655267|NCT05192343|DEVICE|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
214655268|NCT05192343|OTHER|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
214655269|NCT03366714|DEVICE|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
214655270|NCT03366714|DEVICE|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
214655271|NCT03295825|DIAGNOSTIC_TEST|Biomarker|Measument of heparin-binding protein in the serum of patients
214655272|NCT03989830|DRUG|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
214655273|NCT03989830|DRUG|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
214655274|NCT01133743|DRUG|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
214655275|NCT05779891|OTHER|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
214655276|NCT05779891|OTHER|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
214655277|NCT03179917|DRUG|Pembrolizumab|pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.
214655278|NCT03179917|RADIATION|Involved Site Radiation Therapy|30 Gy of ISRT
214655279|NCT02792140|DRUG|Naltrexone|one week
214655280|NCT02792140|OTHER|Placebo|one week
214655281|NCT00444015|DRUG|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
214655282|NCT00519077|DRUG|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
214655283|NCT01967225|DRUG|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
214655284|NCT01967225|DRUG|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
214655285|NCT06006078|DEVICE|Endoscopic Patient Facemask|A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
214655286|NCT00012610|PROCEDURE|Telepsychiatry|
214655287|NCT05811065|DEVICE|OPTIVF dosage|Opt-IVF dosage
214655288|NCT05811065|DEVICE|traditional drug treament|Traditional drug treatment
214655289|NCT00889044|DRUG|clopidogrel by chewing|600 mg clopidogrel by chewing
214655290|NCT00889044|DRUG|Placebo|Placebo p.o
214655291|NCT00766805|DRUG|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
214655292|NCT00766805|OTHER|EVL alone|
214655293|NCT05295537|PROCEDURE|PERCUTANEOUS LIVER BIOPSY (PLB)|Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.
214655294|NCT05295537|PROCEDURE|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)|EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
214655295|NCT02058901|DRUG|Sunitinib|
214655296|NCT05023031|DRUG|NVP-2102|Tablet formulation for oral administration, single dose of NVP-2102 at Day 1
214655297|NCT05023031|DRUG|NVP-2102-R|Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
214655298|NCT00372918|PROCEDURE|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
214655299|NCT05868369|DEVICE|iVR Group|"On the day of surgery, the iVR group will receive a 30-minute sessions or dose of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes."
214655300|NCT05868369|DRUG|Standard pain management regimen|In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
214655301|NCT04529967|OTHER|no interventions|it is a observational study, do not have interventions.
214655302|NCT05786950|DRUG|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)|inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
214655303|NCT00157547|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
214655304|NCT00351364|DRUG|Montelukast Sodium|100 mg P.O. One time only
214655305|NCT04325477|DEVICE|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
214655306|NCT00764556|DRUG|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
214655307|NCT00003454|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214655308|NCT05588388|DRUG|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
214818235|NCT05502250|DRUG|gemcitabine, cisplatin and tislelizumab|"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
214655309|NCT06543433|DEVICE|Skincubator 2|"The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator."
214655310|NCT03529747|OTHER|Online self-help|As detailed in experimental arm description.
214655311|NCT01984515|BEHAVIORAL|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
214655312|NCT05957705|PROCEDURE|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
214655313|NCT05957705|PROCEDURE|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
214655314|NCT01846780|PROCEDURE|PTA & stenting|PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
214655315|NCT06330909|RADIATION|Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT|"technique: IMRT/IGRT/SBRT~The HypoFocal-SBRT study combines ultra-hypofractionated RT / stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts."
214655316|NCT06330909|RADIATION|Radiotherapy (RT) Arm B - IMRT/IGRT|"technique: IMRT/IGRT~Moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide."
214655317|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
214655318|NCT05945264|BEHAVIORAL|Music Intervention (MI)|The intervention will involve listening, playing and/or singing melodies or songs, that are meaningful to the participant, with interpretation/reflection on their relevance/capacity to alter stress.
214655319|NCT05945264|OTHER|Sham Control (SC)|The intervention will be to support a woman to talk about anything she wants that is important to her.
214655320|NCT01712347|DRUG|Bevacizumab|Bevacizumab will be administered as per approved label.
214655321|NCT01712347|DRUG|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
214655322|NCT06648590|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
214655323|NCT06648590|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
214263899|NCT06468852|PROCEDURE|Goal-Directed Fluid Therapy|Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
214263900|NCT00133029|DRUG|Timing of prophylactic antibiotic administration|
214263901|NCT00567307|DRUG|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
214263902|NCT00567307|OTHER|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
214263903|NCT03922997|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
214655324|NCT05296304|DRUG|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
214655325|NCT05296304|RADIATION|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
214655326|NCT04696861|BEHAVIORAL|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
214263904|NCT05155150|BEHAVIORAL|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
214263905|NCT01031706|DRUG|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
214263906|NCT01031706|DRUG|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
214655327|NCT04696861|BEHAVIORAL|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
214655328|NCT03809897|DRUG|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
214655329|NCT03809897|DRUG|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
214655330|NCT06385704|PROCEDURE|DMR Procedure|Endoscopic procedure
214655331|NCT04923594|DRUG|mazindol extended release|Dosed orally, once daily for up to 3 weeks
214655332|NCT04923594|DRUG|Placebo|Dosed orally, once daily for up to 4 weeks.
214655333|NCT01393093|PROCEDURE|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
214655334|NCT06295445|PROCEDURE|care cardio-pulmonary ultrasound|Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome
214655335|NCT06295445|OTHER|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
214655336|NCT00448292|DRUG|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
214655337|NCT00448292|DRUG|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
214655338|NCT06134297|DEVICE|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (\> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
214655339|NCT06134297|DEVICE|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
214655340|NCT06134297|DEVICE|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
214655341|NCT03866200|DRUG|resveratrol|125 mg/day or 5 ml once per day for 90 days
214655342|NCT03866200|DRUG|Placebo|5 ml once per day for 90 days
214655343|NCT02254343|DEVICE|proximal robot-assisted therapy|
214655344|NCT02254343|DEVICE|distal robot-assisted therapy|
214655345|NCT02254343|BEHAVIORAL|individualized intensive therapy|
214655346|NCT01500837|DRUG|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
214655347|NCT01500837|DRUG|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
214655348|NCT00434200|PROCEDURE|long-term intensive exercise|
214263907|NCT03879395|PROCEDURE|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
214263908|NCT05138107|OTHER|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
214263909|NCT05138107|OTHER|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
214263910|NCT04396340|BIOLOGICAL|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
214263911|NCT05560776|PROCEDURE|Endobronchial ultrasound|Two or three passes per lymph node
214655349|NCT00216567|DRUG|topamax|
214655350|NCT05335538|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
214655351|NCT00004486|DRUG|fluoxetine|
214655352|NCT02803333|OTHER|No Intervention|No intervention
214655353|NCT02382133|DEVICE|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
214655354|NCT04969055|OTHER|Not|Not
214655355|NCT01348737|DRUG|AZD3839|Single Oral Dose
214655356|NCT01348737|DRUG|AZD3839 Placebo|Single Oral Dose
214655357|NCT00655928|DRUG|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
214655358|NCT00655928|DRUG|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
214655359|NCT02125214|DEVICE|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
214818236|NCT01566617|OTHER|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
214818237|NCT01566617|OTHER|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
214655360|NCT04906707|DEVICE|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
214655361|NCT04906707|BEHAVIORAL|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
214655362|NCT00841451|DRUG|Lovaza (Fish Oils)|Double blinded placebo controlled
214655363|NCT05834738|DRUG|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
214655364|NCT05834738|DRUG|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
214655365|NCT05834738|DRUG|Placebo|Placebo
214655366|NCT01904799|OTHER|Cognitive Assessment test|
214655367|NCT03700099|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
214655368|NCT03700099|DRUG|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
214655369|NCT01707992|DRUG|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
214655370|NCT01707992|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
214655371|NCT06244459|OTHER|VR Assessment Tool|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
214655372|NCT05019937|BEHAVIORAL|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
214655373|NCT05019937|BEHAVIORAL|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
214655374|NCT05019937|BEHAVIORAL|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
214655375|NCT05019937|BEHAVIORAL|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
214655376|NCT05019937|BEHAVIORAL|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
214655377|NCT04409847|DIAGNOSTIC_TEST|ABPM|24 hour ambulatory blood pressure monitoring
214655378|NCT04409847|DIAGNOSTIC_TEST|ECG|Electrocardiogram
214655379|NCT04409847|DIAGNOSTIC_TEST|FMD|Flow mediated dilatation
214655380|NCT04409847|DIAGNOSTIC_TEST|PWV|Pulse wave velocity
214655381|NCT04409847|DIAGNOSTIC_TEST|Rarefaction|nailbed capillaroscopy
214655382|NCT05330026|COMBINATION_PRODUCT|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
214655383|NCT00002310|DRUG|Crofelemer|
214655384|NCT06331091|OTHER|Home exercise|Home exercise are done at home without the supervision of a specialist.
214655385|NCT06331091|OTHER|Manual therapy|Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
214655386|NCT06331091|DEVICE|Neuromuscular electrical stimulation|"Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist."
214655387|NCT06331091|OTHER|Supervised exercise|Supervised exercise is done under the supervision of a physiotherapist.
214655388|NCT01512940|PROCEDURE|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
214655389|NCT01976806|DRUG|Aspirin|
214263912|NCT03809676|OTHER|periodontal examination|clinical measurements were recorded
214655390|NCT01976806|DRUG|Docosahexaenoic acid|
214655391|NCT01976806|DRUG|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
214655392|NCT04188730|DRUG|Lofexidine (granules for reconstitution)|All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
214655393|NCT04188730|DRUG|LUCEMYRA (lofexidine) tablets|All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
214655394|NCT02484469|DEVICE|The Virtual Human Project|Virtual Human educational videos about leprosy
214655395|NCT03006614|DRUG|NVB|
214655396|NCT03006614|DRUG|EPI|
214655397|NCT03006614|DRUG|DDP|
214655398|NCT03006614|DRUG|CAP|
214655399|NCT03006614|DRUG|GEM|
214655400|NCT03006614|DRUG|H|
214655401|NCT03006614|DRUG|CTX|
214655402|NCT03006614|DRUG|T|
214655403|NCT03582358|OTHER|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
214655404|NCT03046420|OTHER|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
214655405|NCT05122130|DRUG|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
214655406|NCT05122130|DRUG|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
214655407|NCT01453504|DRUG|DHAP|Dexamethasone, Cytarabine, Cisplatin
214655408|NCT01453504|DRUG|Everolimus|
214655409|NCT01904981|DRUG|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
214655410|NCT01904981|DRUG|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
214655411|NCT01041248|DRUG|Tocilizumab|8mg/kg every 2 weeks i.v.
214655412|NCT06206889|OTHER|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
214655413|NCT04551014|DEVICE|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
214655414|NCT04551014|DEVICE|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
214655415|NCT02654002|DRUG|Cilofexor|Tablets administered orally
214655416|NCT02654002|DRUG|Placebo|Tablets administered orally
214655417|NCT06398873|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300mg/2 weeks
214655418|NCT00891202|DRUG|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
214655419|NCT00891202|DRUG|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
214655420|NCT06264609|DRUG|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
214655421|NCT06264609|DRUG|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
214655422|NCT06264609|DRUG|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
214655423|NCT02992002|OTHER|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
214655424|NCT06042673|DIETARY_SUPPLEMENT|Pomegranate seed oil|10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
214655425|NCT06042673|DIETARY_SUPPLEMENT|Mixed vegetable oil|50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
214655426|NCT01216774|OTHER|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
214655427|NCT04947644|PROCEDURE|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
214655428|NCT04947644|PROCEDURE|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
214655429|NCT04108429|BEHAVIORAL|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
214655430|NCT03951636|PROCEDURE|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
214655431|NCT03951636|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
214655432|NCT03951636|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
214655433|NCT06253416|OTHER|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
214655434|NCT06253416|OTHER|Control|exercise freely and without supervision with their daily routine
214655435|NCT04348448|DRUG|Canakinumab 150 MG/ML [Ilaris]|COVID-19
214655436|NCT02257424|DRUG|Trametinib 2 mg daily|
214655437|NCT02257424|DRUG|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
214655438|NCT02257424|DRUG|dabrafenib 150 mg orally twice a day|
214655439|NCT02006992|OTHER|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
214655440|NCT02006992|OTHER|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
214655441|NCT00546975|DIETARY_SUPPLEMENT|Resource Support®|
214655442|NCT00546975|DIETARY_SUPPLEMENT|Resource Protein®|
214655443|NCT00546975|DIETARY_SUPPLEMENT|Placebo|
214655444|NCT01668368|OTHER|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
214655445|NCT05863611|OTHER|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
214655446|NCT01213030|DRUG|[F-18] FMISO|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
214655447|NCT01213030|DRUG|[F-18] HX4|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
214655448|NCT02486861|OTHER|optical coherence tomography|
214655449|NCT06381193|DIETARY_SUPPLEMENT|Probiotic|oral, daily
214655450|NCT06381193|DIETARY_SUPPLEMENT|Prebiotic|oral, daily
214655451|NCT06381193|DIETARY_SUPPLEMENT|Probiotic + Prebiotic|oral, daily
214655452|NCT06381193|DIETARY_SUPPLEMENT|Placebo|oral, daily
214655453|NCT02246972|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
214655454|NCT01654679|DEVICE|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
214263913|NCT04940767|DRUG|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
214655455|NCT01654679|OTHER|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
214655456|NCT01587950|DRUG|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
214655457|NCT01587950|DRUG|Placebo|Sterile Water
214655458|NCT06960330|OTHER|Wearable Biofeedback + Virtual Physiotherapy|Participants will use wearable devices designed to monitor physiological parameters and provide real-time feedback during exercises. The intervention includes remote guidance from physiotherapists via virtual consultations.
214655459|NCT06960330|OTHER|Standard Physiotherapy Exercises|Participants will be given printed or video instructions for standard physiotherapy exercises commonly used for arthritis and fibromyalgia management, without any digital monitoring or remote guidance.
214655460|NCT01914952|DIETARY_SUPPLEMENT|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
214655461|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
214655462|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid mixed in water|0.8 g HMB free acid in water
214655463|NCT01914952|DIETARY_SUPPLEMENT|CaHMB in water|1.0 g CaHMB powder mixed in water
214655464|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid|0.8 g HMB free acid
214655465|NCT02059083|BEHAVIORAL|Heart rate variability biofeedback|
214655466|NCT02059083|BEHAVIORAL|CBT|
214655467|NCT03313050|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
214655468|NCT03313050|BIOLOGICAL|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
214655469|NCT03313050|BIOLOGICAL|polysaccharide|23-valent pneumococcal polysaccharide vaccine
214655470|NCT05124223|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
214655471|NCT04188366|BEHAVIORAL|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
214655472|NCT04188366|BEHAVIORAL|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
214655473|NCT02158559|DRUG|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
214655474|NCT02158559|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
214655475|NCT06599736|DEVICE|RhinAer Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810).
214655476|NCT05783700|DIAGNOSTIC_TEST|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
214655477|NCT04630379|OTHER|Palliative Therapy|Visit with palliative care team
214655478|NCT04630379|OTHER|Quality-of-Life Assessment|Ancillary studies
214655479|NCT04630379|OTHER|Supportive Care|Visit with neuro-oncologist
214655480|NCT04630379|OTHER|Survey Administration|Complete survey
214655481|NCT01722513|DRUG|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
214655482|NCT03970343|DEVICE|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~1. Optimizer Smart or Optimizer Smart Mini~2. Vesta Charger or Guardio Charger~3. Two commercially available intravascular leads"
214655483|NCT01189383|BIOLOGICAL|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
214655484|NCT01422005|OTHER|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
214655485|NCT01422005|OTHER|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
214655486|NCT00261235|BEHAVIORAL|Supported Employment|
214655487|NCT00261235|BEHAVIORAL|Using Strengths in Employment System (USES)|
214655488|NCT06587100|DEVICE|Fitbit|Participants will wear Fitbit device
214263914|NCT04940767|DRUG|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
214263915|NCT00303173|BEHAVIORAL|Guided Imagery|
214263916|NCT03764696|DEVICE|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
214655489|NCT06587100|DEVICE|Apple HealthKit-based devices|Participants will wear personal device and share data with study team.
214655490|NCT06767969|DRUG|Acetaminophen|Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
214655491|NCT04394442|DRUG|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
214655492|NCT00875069|OTHER|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
214655493|NCT02093702|BEHAVIORAL|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
214655494|NCT02093702|BEHAVIORAL|Unstructured Physical Activity and Exercise Education|
214655495|NCT02963376|DRUG|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
214655496|NCT02963376|DRUG|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
214655497|NCT02963376|DRUG|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
214655498|NCT02963376|DRUG|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
214655499|NCT02963376|DRUG|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
214655500|NCT02963376|DRUG|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
214655501|NCT05777733|DRUG|n-acetylcystine|Single daily oral administration of N\_acetylcystein on dose 10mg /kg/day
214655502|NCT02848833|DRUG|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
214655503|NCT02848833|DRUG|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
214655504|NCT02847598|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
214655505|NCT02847598|DRUG|Placebo|Administered as specified in the treatment arm.
214655506|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
214655507|NCT05351476|BEHAVIORAL|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
214655508|NCT05351476|BEHAVIORAL|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
214655509|NCT00369031|BIOLOGICAL|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
214655510|NCT00369031|BIOLOGICAL|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
214655511|NCT00369031|BIOLOGICAL|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
214655512|NCT05651516|DRUG|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
214655513|NCT04167345|DRUG|VX-814|Tablet for oral administration.
214655514|NCT04167345|DRUG|Placebo|Placebo matched to VX-814 for oral administration.
214655515|NCT03337256|DIAGNOSTIC_TEST|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~* 75 2.5 Haemoglobin(g/L)~* 10.0 0 \<9.9 2 Systolic blood pressure (mmHg)~* 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0~* 100 1.5 Creatinine (mmol/L) \<200 0~* 200 3.5 Number of blood transfusion 0 0~  1 1.5~* 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
214655516|NCT06842524|DRUG|Dihydroartemisinin|Dihydroartemisinin tablets 40mg tid po for 90 days
214655517|NCT06842524|DRUG|Placebo|Identical placebo tid for 90 days
214655518|NCT06796608|BEHAVIORAL|Behavioral Activation|Behavioral activation is an evidence-based intervention based on the idea that depression leads to withdrawal from rewarding activities, which sustains or exacerbates depression, and breaks this cycle by increasing the frequency with which people engage in rewarding activities regardless of their motivation. Like those with depression, people living with advanced cancer may reduce or stop participation in meaningful life activities resulting in decreased positive emotion and worse quality of life. The goal of this intervention is to adapt and test a fully remote technology-supported behavioral activation intervention aimed at supporting patients with advanced cancer to optimize the quality of their remaining years of life.
214655519|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin 5% cream will be given as a single application
214655520|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin Cream will be given as twice application
214655521|NCT06896929|DRUG|Ivermectin 200 µg/kg|Group C will be given Tab Ivermectin
214655522|NCT06910787|DEVICE|VR-directed BGBT|VR-directed BGBT using the Oculus Meta Quest 3 VR headset will be delivered using the Synergi application. The program includes 4-weeks of daily self-led activities using 5 virtual modules: (1) education (2) two interactive games (3) breathing exercises (4) gut-directed meditation and (5) gastroenterology-specific Cognitive behavioral therapy (CBT). Participants will also receive standard care. On day 1, intervention arm participants will undergo a brief in-person or virtual (i.e., zoom or Microsoft teams) training with study staff to learn how to use the VR headset and access intervention modules. On day 1 participants will be asked to explore each of the program modules to achieve initial familiarity. Participants will be encouraged to use the VR-BGBT program for at least 15 minutes daily, but at minimum 3-4 days each week. Additionally, study assessments will be completed at baseline, 2-weeks, 4-weeks, and 8-weeks, with an interview within 1-2 weeks of completing the program.
214655523|NCT06910787|OTHER|E-TAU|Participants will receive standard of care, as directed by the participant's gastroenterologist. Participants will also receive an educational video and fact sheet on pain in IBD. This will be 4-weeks with study assessments at baseline, 2-weeks, and 4-weeks, 8-weeks.
214655524|NCT05832918|OTHER|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
214655525|NCT03598244|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214655526|NCT03598244|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214655527|NCT03598244|DRUG|Savolitinib|Given PO
214655528|NCT03598244|PROCEDURE|X-Ray Imaging|Undergo X-ray imaging
214655529|NCT06823973|BEHAVIORAL|CBT-based transdiagnostic approach to sexual distress|"It is constituted by 8 modules:~1. Psychoeducation about sexual function~2. Difficulties in emotional regulation~3. Non-judgmental emotional awareness~4. Cognitive flexibility~5. Worry and rumination~6. Perfectionism~7. Communication~8. Summary"
214263917|NCT05981430|BIOLOGICAL|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
214263918|NCT05981430|BIOLOGICAL|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
214655530|NCT06823973|BEHAVIORAL|Waiting list condition|The participants in the waiting list condition will receive the intervention after the participants in the intervention condition.
214655531|NCT03270215|PROCEDURE|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
214655532|NCT06858709|PROCEDURE|True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment|"Participants will receive a total of 8 treatments over 6 weeks, with twice a week treatments for the first and the forth weeks and weekly treatment for the remaining weeks.The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. In the meantime, participants will receive the same standard anti-CIPN treatments."
214655533|NCT06858709|PROCEDURE|Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid de qi sensation. In the meantime, participants will receive the same standard anti-CIPN treatments."
214655534|NCT06935539|DEVICE|Cryoneurolysis|"The iovera° system consists of a reusable, portable Handpiece, along with single-patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study."
214655535|NCT06935539|DEVICE|Radiofrequency ablation|Radiofrequency ablation is a minimally invasive procedure that uses heat at the lumbosacral spine to destroy the target spinal nerves.
214655536|NCT06935773|OTHER|High-Fidelity Simulated Emergency Training|A high-fidelity simulation-based in-service training program focusing on emergency scenarios. The training includes simulated resuscitation cases, teamwork drills, and post-simulation debriefings conducted at Chang Bing Show Chwan Memorial Hospital.
214655537|NCT06935773|OTHER|No intervention (observational study)|Participants in this arm will not receive any training or simulation intervention during the study period.
214655538|NCT06935929|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
214655539|NCT06935292|DRUG|Dexmedetomidine|Nebulized Dexmedetomidine (1μg/kg)
214655540|NCT06935292|DRUG|Melatonin|Oral Melatonin tablet (5mg)
214655541|NCT06937021|OTHER|Art and philosophy intervention (APBI)|8 session intervention delivered during school time. Each session involves an art activity with a corresponding philosophical discussion.
214655542|NCT06937021|OTHER|Art based intervention (ABI)|A 8 session intervention delivered during school time. Each session involve a creative arts activity.
214655543|NCT06936228|DIETARY_SUPPLEMENT|Propolis spray|The product obtained from 30% pure Anatolian propolis was applied once daily.
214655544|NCT06936397|BEHAVIORAL|Cognitive Remediation Therapy|CRT is a structured behavioral intervention consisting of weekly 60-minute sessions for 12 weeks. The therapy includes tasks to enhance cognitive skills such as attention, memory, executive function, and emotional regulation using computer-based training and therapist-guided exercises.
214655545|NCT06936644|DRUG|IBI351+AK112|The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in first-line treatment
214655546|NCT06935955|DIAGNOSTIC_TEST|upper endoscopy|"All subjects will be asked to complete a medical history questionnaire, followed by physical examination (height, body weight, waist circumference and blood pressure), and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, with assessment of chronic and acute gastritis, atrophic gastritis and metaplasia. The endoscopist will obtain five biopsies samples, two from the antrum, two from the corpus and one from incisura.~All biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two sets of tissue sections will be stained: one with hematoxylin and eosin (H\&E) and the other with Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atro"
214655547|NCT02908399|DEVICE|FLIR ONE|
214655548|NCT03690154|DRUG|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
214655549|NCT05995704|DRUG|Apraglutide|Peptide analogue of GLP-2
214655550|NCT05995704|DRUG|Placebo|Matching placebo to apraglutide
214655551|NCT05995704|DRUG|Acetaminophen|Acetaminophen mixed with a liquid meal
214655552|NCT04837014|OTHER|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
214655553|NCT04837014|OTHER|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
214655554|NCT03125603|OTHER|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
214655555|NCT02569515|DRUG|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
214655556|NCT05163665|PROCEDURE|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
214655557|NCT00042809|DRUG|paclitaxel|Given IV
214655558|NCT00042809|BIOLOGICAL|trastuzumab|Given IV
214655559|NCT00042809|DRUG|erlotinib hydrochloride|Given orally
214655560|NCT00042809|OTHER|laboratory biomarker analysis|Correlative studies
214655561|NCT00042809|OTHER|pharmacological study|Correlative studies
214655562|NCT04844138|BEHAVIORAL|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
214655563|NCT03757598|OTHER|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
214655564|NCT01834495|DEVICE|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
214655565|NCT01834495|DEVICE|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
214655566|NCT02693964|OTHER|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
214655567|NCT05109312|DRUG|Bupivacaine Hydrochloride|100 mg
214655568|NCT05109312|DRUG|Bupivacaine Hydrochloride|125 mg
214655569|NCT05109312|DRUG|HTX-011|400 mg
214655570|NCT05109312|DEVICE|Luer lock applicator|Applicator for instillation
214655571|NCT05109312|DRUG|Ibuprofen|400 mg
214655572|NCT05109312|DRUG|Acetaminophen|1 g
214655573|NCT03050125|DEVICE|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
214655574|NCT03050125|DEVICE|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
214655575|NCT03050125|DEVICE|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
214655576|NCT01575912|OTHER|experimental pain tests|
214655577|NCT05377632|PROCEDURE|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
214655578|NCT01715844|DIETARY_SUPPLEMENT|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
214655579|NCT02493179|DRUG|Serodase 5 mg|Serodase 5mg two tablets three times per day
214655580|NCT02493179|DRUG|Placebo|Placebo two tablets three times per day
214655581|NCT06060301|DRUG|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
214655582|NCT06060301|DRUG|corticosteroids|The patients will use topical corticosteroids 4 times per day.
214655583|NCT05856864|DRUG|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
214655584|NCT05856864|DRUG|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
214655585|NCT00896961|DRUG|EF5|
214655586|NCT00896961|OTHER|diagnostic laboratory biomarker analysis|
214655587|NCT00896961|OTHER|pharmacological study|
214655588|NCT05806242|OTHER|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
214655589|NCT03397836|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
214655590|NCT03397836|OTHER|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
214655591|NCT00390832|DRUG|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
214655592|NCT00390832|OTHER|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
214263919|NCT00225069|PROCEDURE|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
214263920|NCT01814631|OTHER|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
214655593|NCT03415230|OTHER|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
214655594|NCT03415230|OTHER|Sham massage|Sham massage involves only light touch massage in a non systematic way
214655595|NCT01737775|PROCEDURE|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
214655596|NCT03463330|BEHAVIORAL|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
214655597|NCT03463330|BEHAVIORAL|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
214655598|NCT04287530|DIETARY_SUPPLEMENT|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
214655599|NCT04287530|BEHAVIORAL|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
214655600|NCT04287530|DIETARY_SUPPLEMENT|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
214655601|NCT00601978|DRUG|carbidopa/levodopa|
214655602|NCT00601978|DRUG|Carbidopa/Levodopa/Entacapone|
214655603|NCT00150189|BEHAVIORAL|Sucrose|
214655604|NCT06121128|PROCEDURE|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
214263921|NCT01814631|OTHER|image quality and resolution|image quality and resolution will be viewed on the EU-me2
214263922|NCT01806558|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
214263923|NCT00890266|PROCEDURE|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
214263924|NCT00443495|DRUG|Chitin microparticles by nasal route|
214263925|NCT03202888|BEHAVIORAL|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
214263926|NCT05668884|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
214655605|NCT06121128|PROCEDURE|Normal Breathing|No IMT performed
214655606|NCT05928741|BEHAVIORAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
214655607|NCT04652362|BEHAVIORAL|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
214655608|NCT04652362|BEHAVIORAL|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
214655609|NCT04691661|DRUG|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
214655610|NCT04691661|DRUG|Placebo|Placebo
214655611|NCT02639377|DRUG|Chlorhexidine gluconate|
214655612|NCT02639377|DRUG|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
214655613|NCT02807077|DRUG|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
214263927|NCT02438020|DRUG|Metformin|One tablet of 500 mg will be ingested before the main meal
214263928|NCT02438020|OTHER|Placebo|A placebo tablet will be ingested daily before main meal.
214263929|NCT01919671|DRUG|Tongxinluo capsule|for 90 days
214263930|NCT01919671|DRUG|placebo capsule|for 90 days
214263931|NCT03840174|BIOLOGICAL|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
214263932|NCT03840174|OTHER|Placebo|Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
214263933|NCT05043909|BEHAVIORAL|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
214818238|NCT01111461|DRUG|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
214655614|NCT00909272|PROCEDURE|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
214655615|NCT00909272|PROCEDURE|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
214655616|NCT02276261|PROCEDURE|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
214655617|NCT02276261|PROCEDURE|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
214655618|NCT03217162|DRUG|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
214655619|NCT03217162|DRUG|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
214655620|NCT01542307|BIOLOGICAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
214655621|NCT01542307|BIOLOGICAL|Room air|Placebo
214655622|NCT02830425|OTHER|No intervention|
214655623|NCT03222271|DEVICE|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
214655624|NCT03572088|DRUG|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
214655625|NCT03572088|DRUG|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
214655626|NCT02790229|OTHER|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
214655627|NCT02790229|OTHER|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
214655628|NCT04578210|BIOLOGICAL|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
214655629|NCT03322800|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
214655630|NCT03322800|OTHER|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
214655631|NCT05917886|OTHER|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
214655632|NCT04029376|DRUG|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
214655633|NCT03616743|BEHAVIORAL|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
214655634|NCT03616743|BEHAVIORAL|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
214655635|NCT00550628|GENETIC|DNA methylation analysis|
214655636|NCT00550628|GENETIC|fluorescence in situ hybridization|
214655637|NCT00550628|GENETIC|gene expression analysis|
214655638|NCT00550628|GENETIC|polymerase chain reaction|
214655639|NCT00550628|GENETIC|protein expression analysis|
214655640|NCT00550628|GENETIC|reverse transcriptase-polymerase chain reaction|
214655641|NCT00550628|OTHER|diagnostic laboratory biomarker analysis|
214655642|NCT00550628|OTHER|immunoenzyme technique|
214655643|NCT00550628|OTHER|immunohistochemistry staining method|
214655644|NCT00550628|PROCEDURE|biopsy|
214655645|NCT00550628|PROCEDURE|therapeutic conventional surgery|
214655646|NCT00550628|RADIATION|fludeoxyglucose F 18|
214655647|NCT03338556|DRUG|PrEP-001|
214655648|NCT03338556|OTHER|Placebo|
214655649|NCT06031753|BEHAVIORAL|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
214655650|NCT00937235|DRUG|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
214655651|NCT00937235|BEHAVIORAL|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
214655652|NCT00937235|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
214655653|NCT00961532|DRUG|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
214655654|NCT02948894|DEVICE|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
214655655|NCT02010203|BIOLOGICAL|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
214655656|NCT02010203|BIOLOGICAL|Placebo|Injection containing sterile solution but no cells
214655657|NCT02010203|BIOLOGICAL|BCG|Vaccine derived from a live bacterium
214655658|NCT01649492|DIETARY_SUPPLEMENT|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
214655659|NCT00337389|DRUG|5- Fluorouracil (5-FU)|
214655660|NCT00337389|DRUG|bevacizumab (Avastin)|
214655661|NCT00337389|DRUG|Leucovorin|
214655662|NCT00337389|DRUG|CoFactor (ANX-510)|
214818239|NCT02023229|DIETARY_SUPPLEMENT|Branched-chain aminoacids|
214655663|NCT05446948|DEVICE|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
214655664|NCT05446948|DEVICE|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
214655665|NCT05047523|DRUG|ALXN1840|Administered as an oral tablet.
214655666|NCT05047523|DRUG|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
214655667|NCT03414879|DRUG|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
214655668|NCT03414879|DRUG|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
214655669|NCT06096519|BEHAVIORAL|Information, motivation, behavioral skills treatment arm|Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of all adolescents.
214655670|NCT06096519|BEHAVIORAL|Information only control arm|This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
214655671|NCT00811629|OTHER|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
214655672|NCT03607344|PROCEDURE|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
214655673|NCT01804855|BEHAVIORAL|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
214655674|NCT01804855|DEVICE|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
214655675|NCT04363216|DRUG|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
214655676|NCT06435507|DRUG|IM-250 (50 mg)|Single dose
214655677|NCT06435507|DRUG|IM-250 (100 mg)|Single dose
214655678|NCT06435507|DRUG|IM-250 (200 mg)|Single dose
214655679|NCT06435507|DRUG|IM-250 (400 mg)|Single dose
214655680|NCT02923271|DEVICE|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
214655681|NCT03047538|DRUG|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
214655682|NCT01434225|DRUG|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
214655683|NCT01014715|OTHER|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
214655684|NCT02528344|BEHAVIORAL|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
214655685|NCT02708823|OTHER|CogCheck application|The application is administered once to all study participants.
214655686|NCT00489762|PROCEDURE|Installation of an energy efficient heater|
214655687|NCT04918121|DRUG|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
214655688|NCT01495819|DRUG|Saline|5cc's of saline give at least once.
214655689|NCT01495819|DRUG|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
214655690|NCT03946176|DIETARY_SUPPLEMENT|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
214655691|NCT03946176|DIETARY_SUPPLEMENT|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
214655692|NCT03946176|DEVICE|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
214655693|NCT06136858|DEVICE|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
214655694|NCT03898570|BEHAVIORAL|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
214655695|NCT04246554|DRUG|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
214655696|NCT04246554|DRUG|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
214655697|NCT06066879|DRUG|Ketamine Hydrochloride|Pre-Operative Ketamine infusion
214655698|NCT06793670|DRUG|Landiolol|Intravenous infusion of landiolol
214655699|NCT06793670|DRUG|Placebo|Intravenous infusion of saline solution of NaCl 0.9%
214655700|NCT06464406|BEHAVIORAL|Virtual Reality condition|Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
214655701|NCT06464406|BEHAVIORAL|Control condition|Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
214818240|NCT02023229|OTHER|High-fiber high protein diet|
214818241|NCT05750394|PROCEDURE|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
214818242|NCT05750394|DEVICE|Suture Type|Barbed or smooth
214655702|NCT06106698|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
214655703|NCT04684030|DEVICE|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
214655704|NCT04684030|DEVICE|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
214655705|NCT03306537|DEVICE|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
214655706|NCT03340350|DRUG|Minocycline|Minocycline capsule
214655707|NCT04886765|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
214655708|NCT05718102|OTHER|Population-health management|Population-health management
214655709|NCT00283829|DRUG|docetaxel|chemotherapy
214655710|NCT00283829|DRUG|IL2|immunotherapy
214655711|NCT00075517|DRUG|docetaxel|
214655712|NCT00075517|DRUG|gemcitabine hydrochloride|
214655713|NCT04323501|OTHER|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
214655714|NCT04323501|OTHER|Control group|Usual care
214655715|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
214655716|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
214655717|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
214655718|NCT03006211|OTHER|Nitrogen protoxide|
214655719|NCT03006211|OTHER|Oxygen|
214655720|NCT02811744|DRUG|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
214655721|NCT01975103|PROCEDURE|Topcon Endpoint Management|
214263934|NCT03656107|BEHAVIORAL|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
214655722|NCT01771783|DRUG|ACEI-ARB-RI|
214655723|NCT01771783|DRUG|ARB-RI-ACEI|
214655724|NCT01771783|DRUG|RI-ACEI-ARB|
214655725|NCT03509506|BEHAVIORAL|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
214263935|NCT05203640|BEHAVIORAL|High repetition (HI)|Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum
214263936|NCT05203640|BEHAVIORAL|Moderate repetition (MOD)|Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
214263937|NCT01757327|DRUG|Erismodegib|
214263938|NCT01757327|DRUG|Placebo|
214263939|NCT02201849|DRUG|Study Drug|
214655726|NCT03389243|DRUG|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
214655727|NCT03389243|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
214655728|NCT03389243|DRUG|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
214655729|NCT05092607|DIAGNOSTIC_TEST|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
214655730|NCT01906749|DRUG|Colchicine|0.5mg once daily orally
214655731|NCT01906749|DRUG|Placebo|
214655732|NCT03323749|COMBINATION_PRODUCT|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
214655733|NCT03323749|COMBINATION_PRODUCT|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
214655734|NCT03323749|COMBINATION_PRODUCT|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
214655735|NCT01895530|DIETARY_SUPPLEMENT|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
214655736|NCT02071940|DRUG|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
214655737|NCT05773456|OTHER|Sushi and wakame salad|One serving of mixed sushi and wakame salad
214655738|NCT06475404|BIOLOGICAL|verenafusp alfa 6 mg/kg|Single intravenous administration of 6 mg/kg of verenafusp alfa
214655739|NCT06475404|BIOLOGICAL|verenafusp alfa 9 mg/kg|Single intravenous administration of 9 mg/kg of verenafusp alfa
214818243|NCT05750394|PROCEDURE|Endometrium|Included or excluded
214818244|NCT06119763|DIAGNOSTIC_TEST|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
214263940|NCT02201849|DRUG|Active Control|
214263941|NCT02201849|DRUG|Placebo|
214263942|NCT00131508|DRUG|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
214263943|NCT00131508|DRUG|Placebo|Placebo
214655740|NCT06475404|BIOLOGICAL|verenafusp alfa 12 mg/kg|Single intravenous administration of 12 mg/kg of verenafusp alfa
214655741|NCT01306981|DRUG|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
214655742|NCT01306981|DRUG|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
214655743|NCT04847271|BEHAVIORAL|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
214655744|NCT01719757|DRUG|Oxycodone/Naloxone|Twice daily
214655745|NCT02626338|DRUG|Crenolanib|
214655746|NCT02626338|DRUG|Mitoxantrone|
214655747|NCT02626338|DRUG|Cytarabine|
214655748|NCT02626338|DRUG|Etoposide|
214655749|NCT02626338|DRUG|Fludarabine|
214655750|NCT02626338|DRUG|G-CSF|
214818245|NCT03890796|BEHAVIORAL|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
214818246|NCT03890796|BEHAVIORAL|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
214263944|NCT04948528|OTHER|Active Comparator: Surgery Pathology or Cystoscopy|Case group will be followed up with surgery pathology or cystoscopy.
214263945|NCT04948528|OTHER|Active Comparator: Clinical Diagnosis|Control group will be diagnosed in clinical.
214263946|NCT00003568|BIOLOGICAL|aldesleukin|
214263947|NCT00003568|BIOLOGICAL|gp100 antigen|
214263948|NCT00003568|BIOLOGICAL|incomplete Freund's adjuvant|
214263949|NCT05211362|BIOLOGICAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
214655751|NCT02626338|DRUG|Idarubicin|
214655752|NCT00876031|DRUG|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
214655753|NCT05617170|OTHER|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
214655754|NCT04101812|DRUG|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
214655755|NCT04101812|DRUG|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
214655756|NCT04710108|OTHER|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
214655757|NCT01901224|DRUG|Metformin 1000 mg|
214655758|NCT01901224|DRUG|Placebo|
214655759|NCT04967690|DRUG|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
214655760|NCT00241267|DEVICE|Dedicated ultrasonographic probe during bronchoscopy|
214655761|NCT01760434|OTHER|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
214655762|NCT00566306|OTHER|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
214655763|NCT02306278|DRUG|gabapentin|gabapentin capsules 0.3g
214818247|NCT01415232|DEVICE|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
214818248|NCT01112254|PROCEDURE|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
214818249|NCT00440518|DRUG|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
214818250|NCT00440518|OTHER|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
214818251|NCT00440518|DRUG|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
214818252|NCT06597370|OTHER|Gene expression mRNA of IgG anti-spike|"b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance."
214818253|NCT04435197|DRUG|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
214818254|NCT05155683|DEVICE|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
214818255|NCT05155683|DEVICE|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, \<8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
214818256|NCT05155683|DEVICE|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
214818257|NCT06185322|OTHER|Physical therapy program with upper cross syndrome specific exercises|Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.
214818258|NCT06185322|OTHER|Physical therapy program with conventional neck strengthening exercises|Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
214818259|NCT01851135|OTHER|Neuropsychological examination and quality of life measures|
214818260|NCT03076593|OTHER|Exposure: Fall|Participants will be asked about prior falls
214818261|NCT00742547|OTHER|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
214818262|NCT01777711|BEHAVIORAL|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
214818263|NCT01777711|BEHAVIORAL|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
214818264|NCT02258347|DEVICE|Echopulse|
214818265|NCT00365365|DRUG|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
214818266|NCT00365365|DRUG|Docetaxel (T) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
214818267|NCT00365365|DRUG|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
214818268|NCT00365365|DRUG|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
214818269|NCT00365365|DRUG|Bevacizumab and trastuzumab maintenance therapy|"* bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
214818270|NCT00365365|DRUG|Bevacizumab maintenance therapy|"\- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
214818271|NCT00781339|DRUG|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
214818272|NCT06570291|DRUG|Mesenchymal Stem Cells|Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
214263950|NCT05211362|BIOLOGICAL|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
214818273|NCT06570291|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
214263951|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
214263952|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
214655764|NCT02306278|DRUG|vitamin capsules|vitamin B
214655765|NCT06372925|DRUG|atorvastatin|20mg atorvastatin PO
214655766|NCT06372925|PROCEDURE|IVUS/OCT|performed the IVUS/OCT at baseline and Day 360
214655767|NCT06372925|DRUG|inclisiran|Inclisiran 284mg SC
214655768|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
214655769|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
214655770|NCT04676477|DRUG|Osimertinib|Oral administration at 40 mg or 80 mg once daily
214655771|NCT04676477|DRUG|Osimertinib|Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
214655772|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg Q3W
214655773|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 4.8 mg/kg Q3W
214655774|NCT04676477|DRUG|Osimertinib|Oral administration at 80 mg once daily
214655775|NCT06640114|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin)."
214655776|NCT03624738|PROCEDURE|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
214655777|NCT03061708|DRUG|AZD2014|mTOR inhibitor
214655778|NCT03485989|OTHER|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
214655779|NCT06256848|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214655780|NCT06256848|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
214655781|NCT01996787|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
214655782|NCT01996787|DEVICE|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
214655783|NCT06053021|DRUG|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
214655784|NCT00627666|BIOLOGICAL|anti-thymocyte globulin|
214655785|NCT00627666|DRUG|busulfan|
214655786|NCT00627666|DRUG|fludarabine phosphate|
214655787|NCT00627666|DRUG|leucovorin calcium|
214655788|NCT00627666|DRUG|methotrexate|
214655789|NCT00627666|PROCEDURE|allogeneic bone marrow transplantation|
214655790|NCT00627666|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214655791|NCT00627666|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214655792|NCT02988856|DEVICE|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
214655793|NCT04125680|BEHAVIORAL|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
214655794|NCT00432692|PROCEDURE|Falls Prevention Program|
214818274|NCT00984022|DEVICE|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
214818275|NCT00984022|DEVICE|Type of dressing - Aquacel|Aquacel dressing
214818276|NCT01810419|DEVICE|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
214818277|NCT01810419|DEVICE|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
214818278|NCT00755313|BIOLOGICAL|trastuzumab|
214818279|NCT00755313|DRUG|aromatase inhibition therapy|
214818280|NCT00755313|DRUG|carboplatin|
214818281|NCT00755313|DRUG|cyclophosphamide|
214818282|NCT00755313|DRUG|docetaxel|
214818283|NCT00755313|DRUG|doxorubicin hydrochloride|
214818284|NCT00755313|OTHER|metabolic assessment|
214818285|NCT00755313|OTHER|questionnaire administration|
214818286|NCT00755313|OTHER|study of socioeconomic and demographic variables|
214818287|NCT00755313|PROCEDURE|cognitive assessment|
214818288|NCT00755313|PROCEDURE|positron emission tomography|
214818289|NCT00755313|RADIATION|fludeoxyglucose F 18|
214818290|NCT03589313|DRUG|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
214818291|NCT01153503|PROCEDURE|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
214818292|NCT03469843|OTHER|Non intervention|patients without intervention
214818293|NCT04654143|DRUG|BVL-GSK098 capsule, placebo|Oral QD
214818294|NCT05474079|OTHER|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
214818295|NCT00905606|DRUG|Topiramate Tablets|
214818296|NCT00905606|DRUG|Topamax® Tablets|
214818297|NCT04596670|DRUG|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
214818298|NCT00459420|DRUG|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
214818299|NCT00459420|DRUG|placebo|placebo
214818300|NCT05080894|DEVICE|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
214818301|NCT00443391|DRUG|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
214818302|NCT01293474|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
214818303|NCT02651272|DRUG|macitentan|10mg macitentan tablets
214818304|NCT04523168|DEVICE|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
214818305|NCT00104481|BEHAVIORAL|cognitive behavior therapy|
214818306|NCT00307996|DRUG|Coenzyme Q10 (drug)|
214818307|NCT03591458|DRUG|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
214818308|NCT03591458|DRUG|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
214818309|NCT00325663|PROCEDURE|Acupuncture|
214818310|NCT06561035|DRUG|Opiate Sparing|Subjects will receive medications in the Opiate Sparing arm for pain control.
214818311|NCT06561035|DRUG|Opiate Based|Subjects will receive medications in the Opiate Based arm for pain control.
214818312|NCT06223191|OTHER|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
214818313|NCT06223191|OTHER|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
214818314|NCT06167694|DRUG|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
214818315|NCT03831139|BEHAVIORAL|TIM&SARA|
214818316|NCT05547737|DRUG|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
214818317|NCT05911152|PROCEDURE|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
214818318|NCT02573441|BEHAVIORAL|Jump Math|Jump Math is a workbook based program aimed at improving math skills
214818319|NCT02573441|BEHAVIORAL|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
214818320|NCT02573441|BEHAVIORAL|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
214818321|NCT05244213|BIOLOGICAL|Sintilimab|200mg Q3W
214818322|NCT05244213|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
214818323|NCT05244213|DRUG|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
214655795|NCT00391976|DRUG|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
214655796|NCT06499636|OTHER|other|other
214655797|NCT02724033|PROCEDURE|regional nerve block|regional nerve block
214655798|NCT02724033|DRUG|Antiemetic|Antiemetic
214655799|NCT06838091|OTHER|Observational|"During anesthesia administration:~T0, T1, T2, T3, T4 represent the following periods:~T0: Double lumen ventilation in the supine position immediately after intubation T1: Double lumen ventilation in the lateral position T2: Single lumen ventilation in the lateral position (with the chest wall closed) T3: Single lumen ventilation in the lateral position (with the chest wall open) T4: Just before extubation~1. Airway pressure (P plateau, Ppeak) values from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (Routinely from pharyngeal temperature probe),~4. Oxygen saturation (Routinely from the patient monitor)~5. End-tidal CO₂,~6. Inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. Inspiratory and expiratory desflurane/sevoflurane concentrations,~9. Tidal volume,~10. MAC, routinely from anesthesia device data~11. Blood Gas Analysis (COHgb, Ph, PO 2 , PCO 2 , SaO 2, HCO 3 , Base deficit, glucose, lactate)"
214655800|NCT00057707|DRUG|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
214655801|NCT00057707|PROCEDURE|Functional MRI|
214655802|NCT00057707|PROCEDURE|Neuropsychological Testing|
214655803|NCT06190483|DRUG|Diazepam 5 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
214655804|NCT06190483|DRUG|Ascorbic Acid 50 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
214655805|NCT00925847|DRUG|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
214655806|NCT05347823|DIAGNOSTIC_TEST|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
214655807|NCT00220376|DRUG|SPM 907|
214655808|NCT01649700|BIOLOGICAL|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
214655809|NCT05784389|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
214655810|NCT06637176|DEVICE|Laser speckle contrast imaging|"LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments"
214655811|NCT06640907|BEHAVIORAL|e-Perinatal personalized mHealth intervention integrated into routine maternal care|The e-Perinatal intervention combines a personalized mobile health (mHealth) app with targeted training for healthcare professionals to support perinatal mental health within routine maternal care. Participants allocated to the intervention arm will use the app for a period of two months. The app offers psychoeducational content, video-guided physical activities, mindfulness exercises, mood-tracking tools, personalized recommendations through a rule-based algorithm, and social-community features. Healthcare professionals assigned to the intervention arm receive specialized training to integrate the app into their daily practice, enhancing their ability to promote and support mental health during the perinatal period.
214655812|NCT06640907|OTHER|Standard routine maternal care with general perinatal health information|Standard maternal care as routinely provided by the Andalusian public healthcare system (Spain). This includes scheduled visits with midwives, nurses, and pediatrician for maternal and infant health monitoring, as well as access to childbirth education programmes. Participants also receive monthly psychoeducational emails (two months) containing general information on perinatal mental health, pregnancy, and infant development. Healthcare professionals in this arm do not receive specialized training in perinatal mental health or in the use of digital interventions, and participants do not have access to the e-Perinatal app.
214655813|NCT05521087|DRUG|JNJ-75276617|JNJ-75276617 will be administered orally.
214655814|NCT05521087|DRUG|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
214655815|NCT05521087|DRUG|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
214655816|NCT05521087|DRUG|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
214655817|NCT05521087|DRUG|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
214655818|NCT05521087|DRUG|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
214655819|NCT05521087|DRUG|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
214655820|NCT06346548|OTHER|oral photography|The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner
214655821|NCT05910827|DRUG|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
214655822|NCT05910827|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
214655823|NCT05910827|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
214655824|NCT05528146|DIETARY_SUPPLEMENT|Psyllium huks|psyllium in 250ml of water
214655825|NCT06140927|DRUG|Ketamine|Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
214655826|NCT06654726|DRUG|aldafermin|aldafermin
214655827|NCT06654726|DRUG|Placebo|placebo
214655828|NCT06335082|DEVICE|Pulsed Field Ablation|Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)
214818324|NCT06561672|DRUG|tramadol plus paracetamol|Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
214818325|NCT06561672|DRUG|Fentanyl|Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
214818326|NCT06561672|DRUG|propofol and muscle relaxant (cisatracurium)|propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
214818327|NCT06561672|DRUG|Propofol|propofol 2mg/kg
214818328|NCT02331823|DRUG|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
214818329|NCT02331823|DRUG|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
214818330|NCT03787641|DRUG|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
214818331|NCT05832658|DEVICE|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
214818332|NCT05832658|BEHAVIORAL|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
214818333|NCT05832658|BEHAVIORAL|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
214818334|NCT06626724|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma.
214818335|NCT02557035|DRUG|Palonosetron|
214818336|NCT02557035|DRUG|Dexamethasone|
214818337|NCT06440343|DIETARY_SUPPLEMENT|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
214818338|NCT06440343|DIETARY_SUPPLEMENT|Placebo|Placebo
214818339|NCT03797703|DRUG|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
214818340|NCT03407287|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
214818341|NCT03407287|PROCEDURE|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
214818342|NCT03407287|PROCEDURE|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
214818343|NCT03280862|DEVICE|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
214818344|NCT03868891|DEVICE|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
214818345|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
214818346|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
214818347|NCT01315990|DRUG|FOLFIRI + Cetuximab|"1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
214818348|NCT00264108|DRUG|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
214818349|NCT00264108|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length.
214818350|NCT05257564|DEVICE|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
214818351|NCT02115165|DRUG|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
214818352|NCT02006212|PROCEDURE|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
214818353|NCT00003766|DRUG|O6-benzylguanine|
214818354|NCT04807426|OTHER|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
214818355|NCT04807426|OTHER|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
214818356|NCT04807426|OTHER|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
214818357|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
214818358|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
214818359|NCT00777023|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
214818360|NCT03835286|DRUG|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
214818361|NCT03835286|DRUG|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
214818362|NCT06628050|DEVICE|ORIGIN® PS Modular devices|Consecutive eligible subjects have been included which have been treated with the ORIGIN® PS Modular devices.
214818363|NCT03123094|DRUG|Spesolimab|single dose
214818364|NCT03123094|DRUG|Placebo|single dose
214818365|NCT04511039|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214818366|NCT04511039|DRUG|Talazoparib Tosylate|Given PO
214818367|NCT01059058|PROCEDURE|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
214818368|NCT01059058|PROCEDURE|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
214818369|NCT01059058|PROCEDURE|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
214818370|NCT02739503|DEVICE|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
214818371|NCT03641079|DRUG|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
214818372|NCT01814904|DRUG|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
214818373|NCT01814904|DRUG|colestilan-M|BSAeq 6 g/day
214818374|NCT01814904|DRUG|colestilan-H|BSAeq 9 g/day
214818375|NCT01814904|DRUG|CBPB|
214818376|NCT03624751|RADIATION|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
214818377|NCT05106296|DRUG|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
214818378|NCT05106296|DRUG|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
214818379|NCT05106296|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
214818380|NCT05106296|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
214818381|NCT05726838|OTHER|Inclisiran|There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
214818382|NCT03261323|PROCEDURE|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
214818383|NCT03261323|PROCEDURE|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
214818384|NCT03261323|OTHER|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
214818385|NCT04827368|OTHER|Breath Test|Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.
214818386|NCT04893109|DRUG|trastuzumab-emtansine|intravenous infusion
214818387|NCT04893109|DRUG|Trastuzumab SC|Muscular injection
214818388|NCT04893109|DRUG|Paclitaxel|intravenous infusion
214818389|NCT04030429|DRUG|Crizotinib 250 MG|bid orally
214818390|NCT01109862|PROCEDURE|Total hip arthroplasty|All cemented THA
214818391|NCT01109862|PROCEDURE|Hemiarthroplasty|Cemented bipolar HAP
214818392|NCT04247282|DRUG|M7824|M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).
214818393|NCT04247282|DRUG|N803|N-803 (15 mcg/kg, subcutaneously) will be given on day 1 to patients enrolled in arm 3.
214818394|NCT04247282|BIOLOGICAL|TriAd vaccine|TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3
214818395|NCT04111965|DRUG|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
214818396|NCT04111965|DRUG|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
214818397|NCT06002230|DRUG|Homeopathic medicines|Globules were administered orally..
214818398|NCT00054873|DRUG|tezacitabine|
214818399|NCT00054873|DRUG|5-fluorouracil|
214818400|NCT02566239|OTHER|Share activity data with care team|Share participant in-home activity data with retirement community care team.
214818401|NCT01645995|DIETARY_SUPPLEMENT|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
214818402|NCT01645995|DIETARY_SUPPLEMENT|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
214818403|NCT00443716|DRUG|estrogen|
214818404|NCT03496623|DRUG|Inhaled treprostinil solution|Treprostinil inhalation solution
214818405|NCT03496623|DRUG|Placebo solution|Placebo solution
214818406|NCT03210480|DRUG|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
214818407|NCT03210480|DRUG|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
214818408|NCT01346007|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
214818409|NCT01590485|OTHER|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
214818410|NCT01590485|OTHER|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
214818411|NCT05126355|BEHAVIORAL|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
214818412|NCT01739101|BEHAVIORAL|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
214818413|NCT01926912|DRUG|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
214818414|NCT02681263|DRUG|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
214818415|NCT00191763|DRUG|Gemcitabine|
214818416|NCT00191763|DRUG|cisplatin|
214818417|NCT01037114|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
214818418|NCT01037114|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
214818419|NCT01037114|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
214818420|NCT01565902|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
214818421|NCT01061021|BEHAVIORAL|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
214818422|NCT01061021|BEHAVIORAL|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
214818423|NCT03645785|DIETARY_SUPPLEMENT|Normal fluid intake without true lemon|16.9oz water with True Lemon
214818424|NCT03645785|DIETARY_SUPPLEMENT|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
214818425|NCT00509561|BIOLOGICAL|cetuximab|
214818426|NCT00509561|DRUG|capecitabine|
214818427|NCT00509561|DRUG|cisplatin|
214818428|NCT00509561|RADIATION|radiation therapy|
214818429|NCT02256293|BEHAVIORAL|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
214818430|NCT05663411|DRUG|SHR6508|SHR6508
214818431|NCT05663411|DRUG|SHR6508|SHR6508
214818432|NCT05663411|DRUG|Cinacalcet|Cinacalcet
214818433|NCT02892253|DEVICE|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
214818434|NCT03472105|DIETARY_SUPPLEMENT|New Nordic Renal Diet|One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
214818435|NCT06225076|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
214818436|NCT06225076|PROCEDURE|Stellate ganglion block|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214818437|NCT06225076|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214818438|NCT02959580|DRUG|Hydrocortisone Butyrate|topical use
214818439|NCT02959580|PROCEDURE|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
214818440|NCT00942318|DRUG|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
214818441|NCT06312488|DIAGNOSTIC_TEST|Clot Pro|This study enrolls patients admitted to the Adult ICU of Milan Policlinico Hospital with a diagnosis of sepsis or septic shock. A ClotPro® TPA test is performed at admission and on day 1, 2, 3, and 7. Specific markers of coagulation (PAI-1, Plasminogen, Protein C and S) and inflammation (Il-1beta, IL-6, IL-8, TNF-alpha, ADM) are tested at enrollment. Routine laboratory tests are performed daily. Hemorrhagic and thrombotic events are searched. The study ends at 28 days or upon ICU discharge.
214818442|NCT02214615|DRUG|Carbamazepine|"Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.~Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days."
214818443|NCT02214615|DRUG|Placebo|
214818444|NCT02212847|OTHER|vestibular stimulation|
214818445|NCT04977739|DIAGNOSTIC_TEST|No intervention|No intervention
214818446|NCT06047977|BIOLOGICAL|Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2|Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
214818447|NCT00043394|DRUG|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
214818448|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
214818449|NCT00043394|DRUG|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
214818450|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
214655829|NCT06099288|BEHAVIORAL|Home-Based Video and Motivational Interviewing Intervention|The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
214655830|NCT06099288|BEHAVIORAL|Read Educate and Develop Youth (READY) Comparison|The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
214655831|NCT02601950|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
214655832|NCT05723055|DRUG|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
214655833|NCT05723055|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
214655834|NCT03878147|BEHAVIORAL|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
214655835|NCT05817045|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
214655836|NCT05817045|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
214655837|NCT06508619|DEVICE|Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring|Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication
214655838|NCT05010148|DRUG|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
214655839|NCT05010148|DRUG|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
214655840|NCT05432999|DEVICE|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
214655841|NCT02896582|DRUG|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
214655842|NCT02896582|DRUG|Dexamethasone|40 mg D1 to D4 in GA-DHAP
214655843|NCT02896582|DRUG|Aracytine|2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
214655844|NCT02896582|DRUG|Cisplatinum|100 mg/m² D1 in GA-DHAP
214655845|NCT02896582|DRUG|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
214655846|NCT02896582|DRUG|Melphalan|140 mg/m² D-2 in GA-BEAM
214655847|NCT02896582|DRUG|Carmustine|300 mg/m² D-7 in GA-BEAM
214655848|NCT05826353|DRUG|Ripasudil|K-321 ophthalmic solution
214655849|NCT05826353|DRUG|Placebo|Placebo ophthalmic solution
214655850|NCT05475002|OTHER|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
214655851|NCT05475002|OTHER|dementia education|dementia education manual and family support group
214655852|NCT06584110|OTHER|Buddy-Up Dyadic Physical Activity (BUDPA) program|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."
214655853|NCT06584110|OTHER|Usual care with waiting list|Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
214655854|NCT04122196|DRUG|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
214655855|NCT04122196|DRUG|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
214655856|NCT05074264|PROCEDURE|Biopsy|Undergo biopsy
214655857|NCT05074264|PROCEDURE|Biospecimen Collection - Anal|Undergo collection of anal swabs
214655858|NCT05074264|PROCEDURE|Biospecimen Collection - Cervical|Undergo collection of cervical swabs
214655859|NCT05074264|PROCEDURE|Colposcopy|Undergo colposcopy
214655860|NCT05074264|PROCEDURE|High Resolution Anoscopy|Undergo high-resolution anoscopy
214655861|NCT05074264|PROCEDURE|Imaging Technique|Undergo cervical imaging
214818451|NCT00043394|DRUG|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
214818452|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
214818453|NCT00043394|DRUG|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
214818454|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
214818455|NCT03181594|DEVICE|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
214818456|NCT01392794|DRUG|YM060|oral, without water
214818457|NCT03945422|DEVICE|AccuTite/FaceTite|Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
214818458|NCT04657965|DRUG|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
214818459|NCT00476281|PROCEDURE|Urinary collect|
214818460|NCT00476281|PROCEDURE|Continuous Glucose Monitoring System (CGMS)|
214818461|NCT02365012|DRUG|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
214818462|NCT04327128|DEVICE|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
214818463|NCT01499628|BEHAVIORAL|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
214818464|NCT01499628|BEHAVIORAL|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
214818465|NCT01499628|BEHAVIORAL|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
214818466|NCT03379467|OTHER|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
214818467|NCT03379467|OTHER|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
214818468|NCT02787876|DRUG|Pegteograstim|
214818469|NCT02017262|BEHAVIORAL|Self-management group|8 weekly sessions of group self-management
214818470|NCT02017262|BEHAVIORAL|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
214818471|NCT05381220|OTHER|early mobilization|Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
214818472|NCT01727180|OTHER|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
214818473|NCT01051765|DRUG|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
214818474|NCT00885144|DIETARY_SUPPLEMENT|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
214818475|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
214818476|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
214818477|NCT00885144|DIETARY_SUPPLEMENT|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
214818478|NCT03247972|DRUG|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
214818479|NCT06563024|DEVICE|18F-FET PET/CT|The enrolled patients receive the 18F-FET PET/CT.
214818480|NCT05840796|DIETARY_SUPPLEMENT|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
214818481|NCT05840796|DIETARY_SUPPLEMENT|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
214818482|NCT00118235|DRUG|cisplatin|Given IV
214818483|NCT00118235|DRUG|irinotecan hydrochloride|Given IV
214818484|NCT00118235|BIOLOGICAL|bevacizumab|Given IV
214818485|NCT00118235|OTHER|laboratory biomarker analysis|Correlative studies
214818486|NCT06126263|DRUG|Linezolid|Adjunctive antitoxin therapy
214818487|NCT06126263|DRUG|Clindamycin|Adjunctive antitoxin therapy
214818488|NCT03682341|GENETIC|endometriosis|patients with or without ovarian endometriosis
214818489|NCT02955641|DRUG|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
214818490|NCT02955641|DRUG|Nepafenac 0.1%|four drops a day for four days after LPI treatment
214818491|NCT02955641|DRUG|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
214818492|NCT00968812|DRUG|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
214818493|NCT00968812|DRUG|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
214818494|NCT00968812|DRUG|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
214818495|NCT01010555|DEVICE|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
214818496|NCT01010555|DEVICE|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
214818497|NCT01010555|DEVICE|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
214818498|NCT01010555|DEVICE|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
214818499|NCT01126203|PROCEDURE|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
214818500|NCT01126203|PROCEDURE|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
214818501|NCT01004341|BEHAVIORAL|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
214818502|NCT02914990|DRUG|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
214818503|NCT06553664|DRUG|Treat with Vibrabot capsules for at least 7 weeks|Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
214818504|NCT00655590|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
214818505|NCT00655590|DRUG|Sildenafil|100 mg daily dosing
214818506|NCT00655590|DRUG|Placebo|Matching placebos
214818507|NCT06406608|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
214818508|NCT03827707|BEHAVIORAL|Noise|Noise applied via headphones during 60 min after meal ingestion
214818509|NCT03827707|BEHAVIORAL|Silence|Headphones without sound applied during 60 min after meal ingestion
214818510|NCT01887652|OTHER|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
214818511|NCT01887652|OTHER|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
214818512|NCT01593852|RADIATION|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
214818513|NCT01593852|RADIATION|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
214818514|NCT04425928|PROCEDURE|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
214818515|NCT04425928|PROCEDURE|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
214818516|NCT01551498|DIETARY_SUPPLEMENT|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
214818517|NCT01551498|DIETARY_SUPPLEMENT|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
214818518|NCT04009486|DEVICE|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
214818519|NCT00123734|DRUG|ThromboView|
214818520|NCT02348463|DRUG|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
214818521|NCT01471886|DRUG|Ketorolac Tromethamine|Every 8 hours for 4 days.
214818522|NCT01471886|DRUG|Naproxen|Every 8 hours for 4 days.
214818523|NCT03506763|DRUG|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
214818524|NCT03506763|DRUG|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
214818525|NCT03506763|DRUG|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
214818526|NCT03266263|DEVICE|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
214818527|NCT03266263|OTHER|instructor-led feedback|feedback for CPR quality by instructors
214818528|NCT06187363|PROCEDURE|Tubularized incised plate procedure|Tubularized incised plate urethroplasty procedure
214818529|NCT06187363|PROCEDURE|Other procedures|Other procedures than tubularized incised plate urethroplasty procedure
214818530|NCT00988663|DRUG|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
214818531|NCT00988663|DRUG|Placebo|will give placebo that looks like memantine
214818532|NCT05287763|PROCEDURE|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
214818533|NCT00113386|BIOLOGICAL|filgrastim|Consolidation chemotherapy
214655862|NCT00808743|DRUG|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
214655863|NCT00808743|DRUG|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
214655864|NCT00808743|DRUG|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
214655865|NCT04298762|OTHER|No peer comparison email|The comparison group received no email communication on their cancer stage documentation activity.
214655866|NCT04298762|OTHER|Peer comparison email|The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
214655867|NCT03135145|DEVICE|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
214655868|NCT03135145|OTHER|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
214655869|NCT03389945|PROCEDURE|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
214655870|NCT03389945|PROCEDURE|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
214655871|NCT05881382|DRUG|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
214655872|NCT05881382|DRUG|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
214655873|NCT00660894|DRUG|folinate calcium|
214655874|NCT00660894|DRUG|tegafur-uracil|
214655875|NCT00660894|DRUG|tegafur-gimeracil-oteracil potassium|
214655876|NCT02296060|PROCEDURE|6 minutes walking test|
214655877|NCT04000477|DEVICE|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
214655878|NCT04000477|DEVICE|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
214655879|NCT03288298|DRUG|luteolin|flavonoid natural extract
214655880|NCT03288298|DRUG|nano-luteolin|nanoparticles of luteolin
214655881|NCT00378326|DRUG|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
214655882|NCT02542176|OTHER|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
214655883|NCT02542176|OTHER|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
214655884|NCT01953952|PROCEDURE|therapeutic conventional surgery|Undergo transoral eHNS
214655885|NCT01953952|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214655886|NCT01953952|DRUG|cisplatin|Given IV
214655887|NCT01953952|PROCEDURE|quality-of-life assessment|Ancillary studies
214655888|NCT01953952|OTHER|laboratory biomarker analysis|Correlative studies
214655889|NCT00000148|PROCEDURE|Argon Laser Trabeculoplasty|
214655890|NCT00000148|PROCEDURE|Trabeculectomy|
214655891|NCT01350089|DRUG|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
214655892|NCT01350089|DRUG|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
214655893|NCT01350089|DRUG|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
214655894|NCT01350089|DRUG|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
214655895|NCT02073487|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
214655896|NCT02073487|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
214655897|NCT02073487|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
214655898|NCT02073487|DRUG|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
214655899|NCT02073487|DRUG|Paclitaxel|chemotherapy - microtubule inhibitor
214655900|NCT02073487|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
214655901|NCT02069691|DEVICE|virtual reality-cycling training system|
214655902|NCT00386841|DRUG|Escitalopram|Escitalopram 10 mg p.o. per day
214655903|NCT00386841|DRUG|Placebo|Placebo
214818534|NCT00113386|BIOLOGICAL|pegfilgrastim|Consolidation chemotherapy
214818535|NCT00113386|DRUG|cisplatin|
214818536|NCT00113386|DRUG|docetaxel|
214818537|NCT00113386|PROCEDURE|adjuvant therapy|
214818538|NCT00113386|PROCEDURE|conventional surgery|
214818539|NCT00113386|PROCEDURE|neoadjuvant therapy|
214818540|NCT00113386|RADIATION|radiation therapy|
214818541|NCT04705714|DRUG|Frankincense Extract|The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
214818542|NCT02288221|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
214818543|NCT02288221|OTHER|Patient's answer without non pharmacological therapeutic|No installation at patient's home
214818544|NCT04645914|BEHAVIORAL|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
214818545|NCT03071666|DIETARY_SUPPLEMENT|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
214818546|NCT03071666|DIETARY_SUPPLEMENT|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
214818547|NCT00275366|DEVICE|Robotic Therapy|
214655904|NCT00333996|DRUG|Dexamethasone|
214655905|NCT02493647|BEHAVIORAL|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
214655906|NCT00550160|DRUG|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
214655907|NCT00054847|PROCEDURE|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
214655908|NCT00054847|PROCEDURE|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
214655909|NCT01147497|DRUG|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
214655910|NCT01147497|DRUG|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
214655911|NCT00972699|BEHAVIORAL|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
214655912|NCT04134650|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214655913|NCT04134650|DRUG|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214655914|NCT02818699|DIETARY_SUPPLEMENT|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
214655915|NCT02818699|DIETARY_SUPPLEMENT|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
214655916|NCT04528485|OTHER|Sea swimming|8 sessions of swimming activities in the sea
214655917|NCT00316823|GENETIC|gene expression analysis|
214655918|NCT00316823|GENETIC|polymerase chain reaction|
214655919|NCT00316823|GENETIC|reverse transcriptase-polymerase chain reaction|
214655920|NCT00316823|OTHER|diagnostic laboratory biomarker analysis|
214655921|NCT00316823|OTHER|immunohistochemistry staining method|
214655922|NCT00316823|PROCEDURE|needle biopsy|
214655923|NCT02991599|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
214655924|NCT02991599|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
214655925|NCT04864587|DIAGNOSTIC_TEST|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
214655926|NCT02731742|BIOLOGICAL|MK-1966|MK-1966 administered as an intravenous (IV) infusion
214655927|NCT02731742|DRUG|SD-101|SD-101 administered as an intratumoral (IT) injection
214655928|NCT01154608|DRUG|Creon|
214655929|NCT01154608|OTHER|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
214655930|NCT04073550|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
214655931|NCT04073550|DRUG|Placebos|Anlotinib blank analog capsule.
214655932|NCT04073550|DRUG|Topotecan|A topoisomerase I inhibitor.
214655933|NCT00055640|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
214655934|NCT00055640|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
214655935|NCT00055640|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
214655936|NCT00055640|DRUG|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
214655937|NCT00055640|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
214655938|NCT00055640|GENETIC|microarray analysis|genetic testing
214818548|NCT03100084|OTHER|Blood sampling|Maternal blood sampling
214818549|NCT00178802|OTHER|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
214818550|NCT01149590|PROCEDURE|Computer Tomography Angiography|Computed Tomography Angiography
214818551|NCT05108779|DRUG|QLF32004|In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
214818552|NCT02732821|PROCEDURE|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
214818553|NCT02679703|DEVICE|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
214818554|NCT02679703|DEVICE|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
214818555|NCT02679703|OTHER|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
214655939|NCT03846245|OTHER|No intervention|No intervention
214655940|NCT04436302|DEVICE|Exergame device|motor-cognitive training
214655941|NCT00046722|DRUG|Smoked Marijuana|
214655942|NCT03792048|PROCEDURE|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
214655943|NCT00559091|DRUG|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
214655944|NCT01576640|DRUG|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
214655945|NCT01576640|DRUG|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
214655946|NCT01576640|OTHER|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
214655947|NCT00649454|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
214655948|NCT00649454|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
214655949|NCT02505256|OTHER|No intervention|
214655950|NCT02303925|DEVICE|NESTER COILS|
214655951|NCT01340183|DRUG|AZD5099|IV Dose
214655952|NCT01340183|DRUG|Placebo|IV Dose
214655953|NCT04480151|OTHER|standard of care|retrospective study: standard of care
214655954|NCT03044392|OTHER|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
214655955|NCT02899169|DRUG|Realgar-Indigo naturalis formula|
214655956|NCT02899169|DRUG|all-trans retinoic acid|
214655957|NCT02899169|DRUG|Arsenic trioxide|
214655958|NCT02899169|DRUG|Hydroxyurea|
214655959|NCT04738955|DRUG|Micafungin Sodium|micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
214655960|NCT04515355|BEHAVIORAL|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
214655961|NCT02786069|DRUG|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
214655962|NCT01969266|DRUG|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
214655963|NCT01969266|DRUG|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
214655964|NCT01350869|DEVICE|Xience|Patients with Xience
214655965|NCT00000769|DRUG|Interleukin-4|
214655966|NCT02999087|DRUG|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
214655967|NCT02999087|DRUG|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
214655968|NCT02999087|DRUG|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
214655969|NCT02999087|RADIATION|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
214655970|NCT00468234|DRUG|nicotine polacrilex|
214655971|NCT00468234|DRUG|nicotine transdermal system|
214655972|NCT00468234|DRUG|nicotine inhaler|
214655973|NCT05896007|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
214655974|NCT05896007|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
214655975|NCT05896007|DRUG|Methotrexate|3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
214655976|NCT05896007|DRUG|Temozolomide|150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
214655977|NCT06033729|DRUG|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
214655978|NCT06033729|DRUG|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
214655979|NCT06033729|DRUG|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
214655980|NCT06033729|DRUG|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
214655981|NCT02906800|DRUG|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
214818556|NCT05970484|BEHAVIORAL|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
214818557|NCT05970484|BEHAVIORAL|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
214818558|NCT02580279|DRUG|EGCG|
214818559|NCT02580279|DRUG|placebo|
214818560|NCT05907733|DIAGNOSTIC_TEST|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
214818561|NCT04527107|DRUG|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
214818562|NCT04527107|DRUG|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
214818563|NCT04527107|DRUG|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
214818564|NCT04527107|DRUG|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
214818565|NCT04527107|DRUG|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
214818566|NCT04527107|DRUG|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
214818567|NCT04527107|DRUG|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
214818568|NCT02774785|DEVICE|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
214818569|NCT02107456|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
214818570|NCT02900209|OTHER|Influenza Vaccination|
214818571|NCT00640562|DRUG|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
214818572|NCT00640562|DRUG|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
214818573|NCT02937870|DEVICE|Test Product 1|Test adhesive 1 with a thin nozzle
214818574|NCT02937870|DEVICE|Test Product 2|Test adhesive 2 with a thin nozzle
214818575|NCT02937870|DEVICE|Reference Product|Adhesive Cream
214818576|NCT02937870|OTHER|Negative Control|No adhesive
214818577|NCT04626167|PROCEDURE|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
214818578|NCT00235352|DRUG|CX516 (Ampakine)|
214818579|NCT00835432|DEVICE|Ossix|Test group
214818580|NCT00835432|DEVICE|Biogide|controls
214818581|NCT04390256|OTHER|Clove water extract|natural product
214818582|NCT04390256|OTHER|Carbopol|Bioadhesive polymer
214818583|NCT04390256|OTHER|Carboxymethyle cellulose|Bioadhesive polymer
214818584|NCT03749252|DRUG|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
214818585|NCT00633451|OTHER|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
214818586|NCT00633451|OTHER|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
214818587|NCT00219154|DRUG|aliskiren|
214818588|NCT00609674|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
214818589|NCT00609674|DRUG|Placebo|Placebo
214818590|NCT03098394|DEVICE|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
214818591|NCT03098394|DEVICE|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
214818592|NCT00176020|DRUG|nicotinic acid|
214818593|NCT00204373|DRUG|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
214818594|NCT03340376|DRUG|Atezolizumab|atezolizumab
214818595|NCT03340376|DRUG|Doxorubicin|Doxorubicin
214818596|NCT04255420|PROCEDURE|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
214818597|NCT04255420|DRUG|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
214818598|NCT05657860|DRUG|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
214818599|NCT05657860|OTHER|Placebo|Placebo will be administered concurrently with GXR during trials.
214818600|NCT01250080|DIETARY_SUPPLEMENT|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
214818601|NCT01250080|OTHER|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
214818602|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
214818603|NCT01915186|DIETARY_SUPPLEMENT|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
214818604|NCT00571064|DRUG|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
214818605|NCT06027710|PROCEDURE|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
214818606|NCT01038817|DRUG|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
214818607|NCT00283608|GENETIC|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
214818608|NCT00283608|OTHER|high performance liquid chromatography|analysis of plasma concentrations of drugs
214818609|NCT00283608|OTHER|measurements by DXA|determine bone mineral density (BMD)
214818610|NCT00283608|OTHER|questionnaire administration|determine attitude changes
214818611|NCT00573417|DRUG|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
214818612|NCT00573417|DRUG|Placebo|
214818613|NCT00244764|DRUG|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
214818614|NCT00244764|DRUG|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
214818615|NCT05408884|OTHER|Social Support|"Social support phone buddy program."
214818616|NCT05408884|OTHER|Basic income|$750 per month for 12 months
214818617|NCT06560775|COMBINATION_PRODUCT|Standard Treatment for SLE|Standard Treatment for SLE
214818618|NCT06558370|OTHER|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
214818619|NCT06558370|OTHER|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
214818620|NCT06043037|PROCEDURE|Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG
214818621|NCT06043037|PROCEDURE|Immediate Implant Placement Using Socket Shield Technique alone|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
214818622|NCT00793832|BEHAVIORAL|supervised exercise|supervised exercise
214818623|NCT00793832|BEHAVIORAL|Diet advice|Diet Advice
214818624|NCT01426633|DRUG|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
214818625|NCT05967715|BEHAVIORAL|exercise training|high intensity interval training
214818626|NCT05967715|OTHER|Probiotics|VSL#3# Probiotic
214818627|NCT05967715|OTHER|Placebo|Probiotic Placebo
214818628|NCT01746615|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter \& oxygen saturation
214818629|NCT01746615|OTHER|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
214818630|NCT02701556|DEVICE|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
214818631|NCT02701556|DEVICE|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
214818632|NCT00572637|DRUG|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
214818633|NCT06466707|OTHER|Collection of microbiome samples|Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
214818634|NCT04023461|DEVICE|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
214818635|NCT06027528|PROCEDURE|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
214818636|NCT06027528|PROCEDURE|dentin graft|extracted tooth will be grafted in the socket
214818637|NCT05890261|DEVICE|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
214818638|NCT00670761|DRUG|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
214818639|NCT00670761|PROCEDURE|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
214818640|NCT00723047|PROCEDURE|Fibrin glue injection in fistula|
214818641|NCT01928147|DRUG|PPI-383|
214818642|NCT01928147|DRUG|Placebo|
214818643|NCT00858754|DRUG|methylnaltrexone|
214818644|NCT00858754|DRUG|placebo|
214818645|NCT03113877|OTHER|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
214818646|NCT00937898|DIETARY_SUPPLEMENT|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
214818647|NCT00937898|DIETARY_SUPPLEMENT|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
214818648|NCT01555645|BEHAVIORAL|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
214818649|NCT04147845|OTHER|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
214818650|NCT04147845|OTHER|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
214818651|NCT04147845|OTHER|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
214263953|NCT05403788|DEVICE|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
214263954|NCT02277730|DEVICE|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
214263955|NCT02277730|DRUG|phenylephrine|
214263956|NCT02277730|DRUG|ephedrine|
214263957|NCT02277730|DEVICE|manual vasopressor delivery|
214818652|NCT04147845|OTHER|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
214263958|NCT04746222|BIOLOGICAL|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
214263959|NCT04746222|OTHER|Placebo|Single dose of 30 oral placebo capsules
214818653|NCT04727398|DEVICE|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
214818654|NCT00240747|DRUG|Synercid|
214818655|NCT01666262|BIOLOGICAL|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
214818656|NCT01666262|OTHER|Placebo:Stabilizer|5% sucrose
214818657|NCT01837654|BEHAVIORAL|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
214818658|NCT01837654|BEHAVIORAL|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
214818659|NCT04038801|PROCEDURE|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
214818660|NCT04038801|PROCEDURE|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
214818661|NCT04038801|PROCEDURE|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
214818662|NCT00906594|DRUG|latanoprost|
214818663|NCT01674166|DRUG|prucalopride|single dose 0.03 mg/kg prucalopride open label
214818664|NCT03410862|DRUG|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
214818665|NCT03410862|DRUG|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
214818666|NCT02600403|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
214818667|NCT02600403|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
214818668|NCT02600403|DIAGNOSTIC_TEST|Humphrey Visual Field (HVF)|Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
214818669|NCT00909662|PROCEDURE|assessment of therapy complications|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
214818670|NCT00909662|PROCEDURE|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
214818671|NCT00909662|PROCEDURE|fatigue assessment and management|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
214818672|NCT01625715|DRUG|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
214818673|NCT02926677|BEHAVIORAL|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
214818674|NCT02926677|BEHAVIORAL|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
214818675|NCT02926677|BEHAVIORAL|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
214818676|NCT02926677|DEVICE|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
214818677|NCT01805505|PROCEDURE|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
214818678|NCT01805505|PROCEDURE|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
214818679|NCT03538327|DRUG|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
214818680|NCT05838391|RADIATION|Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery|Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
214818681|NCT05838391|DRUG|Mitomycin-C|As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
214818682|NCT05838391|DRUG|5-Fluorouracil|As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
214818683|NCT05838391|DRUG|Capecitabine|As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
214818684|NCT01090791|DEVICE|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
214818685|NCT01090791|DEVICE|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
214818686|NCT00840073|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
214263960|NCT05739565|BEHAVIORAL|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
214263961|NCT00731016|DRUG|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
214263962|NCT01479127|DRUG|ABT-SLV187|
214818687|NCT00840073|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
214263963|NCT01479127|DRUG|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
214818688|NCT05901272|OTHER|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
214818689|NCT05901272|OTHER|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
214818690|NCT05901272|OTHER|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
214818691|NCT01352091|DRUG|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
214818692|NCT01352091|DRUG|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
214818693|NCT02486900|DEVICE|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
214818694|NCT04045197|BEHAVIORAL|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
214818695|NCT00007605|DRUG|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
214818696|NCT00007605|DRUG|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
214818697|NCT02775812|DRUG|Cisplatin|Given IV
214818698|NCT02775812|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214818699|NCT02775812|OTHER|Laboratory Biomarker Analysis|Correlative studies
214818700|NCT02775812|BIOLOGICAL|Pembrolizumab|Given IV
214818701|NCT00311441|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
214818702|NCT03285594|DRUG|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
214818703|NCT03285594|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214818704|NCT03285594|DRUG|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
214818705|NCT03285594|DRUG|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
214818706|NCT04267276|DRUG|Part 1: BI 1265162 - intravenous|Intravenous solution
214263964|NCT01479127|DEVICE|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
214818707|NCT04267276|DRUG|Part 2: BI 1265162 - oral|Oral solution
214818708|NCT00958334|DRUG|Proellex®|25 mg daily (two 12.5 mg capsules)
214818709|NCT03702608|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug"
214818710|NCT05058508|OTHER|"Just Move Exercise"|"Subjects complete Just Move Exercises Five Times Per Week"
214818711|NCT05058508|OTHER|Standard of Care Exercise|Subjects exercise/move as tolerated
214818712|NCT04558450|DIAGNOSTIC_TEST|carotid-femoral pulse-wave velocity|early vascular aging tests
214818713|NCT05943613|DRUG|Clonidine|compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
214818714|NCT04255147|BIOLOGICAL|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
214818715|NCT05363020|DRUG|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
214818716|NCT05363020|DRUG|Placebo|400 mg identically appearing placebo
214818717|NCT01615198|DRUG|Olmesartan|10 mg, 20 mg, 40 mg capsules
214818718|NCT01615198|DRUG|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
214818719|NCT01615198|DRUG|LCZ696|100 mg, 200 mg tablets
214818720|NCT01910688|DEVICE|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
214818721|NCT02375685|BIOLOGICAL|Gevokizumab|
214818722|NCT02132494|BEHAVIORAL|Physical activity|
214818723|NCT05396963|DIETARY_SUPPLEMENT|Egg white|Intake of egg white
214818724|NCT05396963|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
214818725|NCT05396963|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
214818726|NCT03443986|OTHER|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
214818727|NCT03443986|OTHER|Resistance training associated with vibration sham|"he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown."
214818728|NCT05572723|DRUG|Remifentanil 2 MG|Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
214818729|NCT05572723|DRUG|dexmedetomidine|"Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability."
214818730|NCT01197248|PROCEDURE|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
214818731|NCT01197248|PROCEDURE|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
214818732|NCT01676194|OTHER|Intra-arterial administration of DC BeadsR|
214818733|NCT05332535|BEHAVIORAL|serious game based web application education|serious game based web application education for nursing students
214263965|NCT01479127|DEVICE|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
214818734|NCT06062498|DRUG|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
214818735|NCT03840291|DRUG|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
214818736|NCT06558916|DRUG|Dexketoprofen Trometamol|
214818737|NCT06558916|DRUG|Meperidine Injectable Solution|
214818738|NCT06558916|DRUG|Paracetamol|
214818739|NCT06558916|DRUG|Fentanyl|Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
214818740|NCT06234722|DRUG|Very Low Nicotine Cigarette|Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g
214818741|NCT06234722|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.
214818742|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
214818743|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
214818744|NCT04608188|BEHAVIORAL|Summer Camp|The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
214263966|NCT01479127|DEVICE|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
214263967|NCT01224964|DRUG|Montelukast|Montelukast, 10 mg
214263968|NCT01224964|DRUG|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
214263969|NCT04079946|PROCEDURE|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
214263970|NCT04079946|PROCEDURE|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
214263971|NCT00531973|DRUG|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
214263972|NCT00531973|DRUG|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
214263973|NCT00769210|DRUG|Simvastatin|Simvastatin 40 mg tablet
214818745|NCT06555913|OTHER|Maitland Mobilization|"MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain"
214818746|NCT06555913|OTHER|Scapular Stabilization|"Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears"
214818747|NCT06555913|OTHER|Traditional Physical Therapy|ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
214818748|NCT06562049|RADIATION|musculoskeletal ultrasound|musculoskeletal ultrasound on both hands
214818749|NCT05606744|DEVICE|Eccentric exercise / Eccentric exercise with blood flow restriction|Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
214818750|NCT00220415|DRUG|SPM 927|
214818751|NCT03118557|OTHER|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
214818752|NCT04984473|DEVICE|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
214818753|NCT05086783|OTHER|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
214818754|NCT05086783|OTHER|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
214818755|NCT05177588|DRUG|Metformin Hydrochloride|Metformin 2000 mg/day
214818756|NCT03317548|DIAGNOSTIC_TEST|progesterone|according progesterone level to decide fresh or frozen embryo transfer
214818757|NCT03317548|DIAGNOSTIC_TEST|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
214818758|NCT04813718|DIETARY_SUPPLEMENT|Omni-Biotic Pro Vi 5|Pre- and probiotic
214818759|NCT04813718|DIETARY_SUPPLEMENT|Placebo|Placebo
214818760|NCT01303549|DRUG|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
214818761|NCT01303549|DRUG|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
214818762|NCT03550781|DRUG|Prednisone, cyclophosphamide|Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
214818763|NCT03122457|DRUG|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
214818764|NCT01469026|RADIATION|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
214818765|NCT02480322|PROCEDURE|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
214818766|NCT02704286|BEHAVIORAL|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
214818767|NCT02704286|BEHAVIORAL|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
214818768|NCT00180986|PROCEDURE|Platelet concentrates|
214818769|NCT00752635|DRUG|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
214818770|NCT03674489|OTHER|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
214818771|NCT03674489|OTHER|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
214818772|NCT03674489|OTHER|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
214263974|NCT02527993|DRUG|Glucobay (acarbose)|Se arm description
214263975|NCT02527993|DRUG|Januvia (sitagliptin)|Se arm description
214263976|NCT02527993|DRUG|Verapamil HEXAL (verapamil)|Se arm description
214263977|NCT02527993|DRUG|Victoza (liraglutide)|Se arm description
214818773|NCT03944447|DRUG|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
214818774|NCT03944447|DEVICE|RYAH-Medtech Inhaler|Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
214818775|NCT05523986|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
214818776|NCT05523986|OTHER|Placebo|Placebo
214818777|NCT04477005|DEVICE|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
214818778|NCT05247463|OTHER|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
214818779|NCT05247463|OTHER|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
214818780|NCT05247463|DIAGNOSTIC_TEST|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
214818781|NCT01141374|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
214818782|NCT01141374|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
214818783|NCT01778205|OTHER|Observational|
214818784|NCT01196000|PROCEDURE|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
214818785|NCT01196000|PROCEDURE|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
214818786|NCT01196000|PROCEDURE|quality-of-life assessment|Ancillary studies
214818787|NCT01196000|OTHER|questionnaire administration|Ancillary studies
214818788|NCT03982030|DRUG|Dalbavancin|Dalbavancin 1.5g IV at day 0, day 8-10
214818789|NCT04877210|DRUG|Topical Insulin|Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
214818790|NCT03776058|DRUG|Cinacalcet|Tablets for oral administration
214818791|NCT03776058|DRUG|Placebo|Tablets for oral administration
214263978|NCT02527993|DRUG|Signifor (pasireotide)|Se arm description
214263979|NCT02527993|DEVICE|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
214263980|NCT02527993|DIETARY_SUPPLEMENT|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
214263981|NCT00242437|DEVICE|Hemostatic matrix|
214818792|NCT04532684|DRUG|Duloxetine|
214818793|NCT04532684|DRUG|Pregabalin|
214818794|NCT06321835|PROCEDURE|Endotracheal tube cuff pressure measurement|This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
214818795|NCT00910221|DRUG|Atorvastatin|Atorvastatin tablet
214818796|NCT00910221|DRUG|Placebo|Placebo tablet
214818797|NCT03740295|DIETARY_SUPPLEMENT|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
214818798|NCT03740295|OTHER|Placebo|Lactose
214263982|NCT00242437|DEVICE|bovine thrombin|
214263983|NCT05274737|DEVICE|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
214263984|NCT05274737|DEVICE|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
214263985|NCT05340075|PROCEDURE|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
214818799|NCT05582915|DIAGNOSTIC_TEST|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
214818800|NCT03273153|DRUG|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
214818801|NCT03273153|DRUG|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
214818802|NCT03273153|DRUG|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
214818803|NCT03916393|DRUG|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
214818804|NCT03916393|OTHER|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
214818805|NCT02962752|DIETARY_SUPPLEMENT|Blackadder Juice|
214818806|NCT02962752|OTHER|Placebo|
214818807|NCT02740647|DRUG|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
214818808|NCT02740647|DRUG|Placebo|50 ml of 0.9% sodium chloride three times a day
214818809|NCT02846285|OTHER|No intervention|
214818810|NCT01908205|DRUG|Intranasal Oxytocin|
214818811|NCT01908205|DRUG|Placebo|
214818812|NCT05528588|COMBINATION_PRODUCT|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
214818813|NCT05528588|DRUG|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
214818814|NCT04940312|BEHAVIORAL|App-based physical activity coaching|Individualized app-based coaching via a smartphone
214818815|NCT04940312|BEHAVIORAL|No Intervention: Observational Cohort|no Intervention
214818816|NCT04940312|BEHAVIORAL|Intervention Group 1|pedometer-based tracking of physical activity
214818817|NCT03134222|DRUG|Lanraplenib|30 mg tablets administered orally once daily with or without food
214818818|NCT03134222|DRUG|Filgotinib|200 mg tablets administered orally once daily with or without food
214263986|NCT01205204|DRUG|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
214263987|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
214263988|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
214818819|NCT03134222|DRUG|Lanraplenib placebo|Tablets administered orally once daily with or without food
214818820|NCT03134222|DRUG|Filgotinib placebo|Tablets administered orally once daily with or without food
214818821|NCT00906165|DEVICE|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
214818822|NCT05279482|OTHER|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
214818823|NCT01221129|OTHER|Acclimation|11 mg Zn/day as a controlled intake level
214818824|NCT01221129|OTHER|Dietary zinc depletion|\< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
214263989|NCT01205204|DRUG|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
214263990|NCT00967603|DRUG|sunitinib|oral sunitinib 37.5 mg daily
214263991|NCT05864755|DRUG|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
214263992|NCT03569033|DRUG|Gefapixant|Gefapixant 45 mg will be administered orally.
214818825|NCT01221129|OTHER|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
214818826|NCT05946460|DRUG|Aumolertinib|Aumolertinib treatment (110mg, p.o., QD) for 8 weeks
214818827|NCT05667272|OTHER|No intervention|No intervention
214818828|NCT06347562|GENETIC|Optical Genome Mapping|to evaluate the capability of OGM, its usefulness in clinical diagnosis, and its impact on genetic counseling.
214818829|NCT03391284|DRUG|acetominophen|INTRAVENOUS
214818830|NCT03391284|DRUG|Acetaminophen|ORAL
214818831|NCT04843995|PROCEDURE|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
214818832|NCT01684657|DRUG|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
214818833|NCT04542356|DRUG|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
214818834|NCT04542356|DRUG|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
214818835|NCT04184518|DRUG|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
214818836|NCT04184518|DRUG|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
214818837|NCT04074603|DEVICE|The needle-free jet injector|Continuous insulin therapy for 2 weeks
214818838|NCT04074603|DEVICE|Conventional insulin pen|Continuous insulin therapy for 2 weeks
214818839|NCT04406753|OTHER|Manual therapy techniques in C0-1 and C2-3 with cervical exercise|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
214818840|NCT04406753|OTHER|Cervical Exercise|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
214818841|NCT06559254|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
214818842|NCT01115647|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
214818843|NCT01115647|DIETARY_SUPPLEMENT|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
214818844|NCT01115647|BEHAVIORAL|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
214818845|NCT03681470|DRUG|Aczone Gel|Aczone Gel 7.5%
214818846|NCT01686477|OTHER|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
214818847|NCT01686477|OTHER|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
214818848|NCT01686477|OTHER|Preterm Formula used when there is a shortfall in mother's own milk|
214818849|NCT01863030|DEVICE|Phasix mesh implant|
214818850|NCT03919058|OTHER|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
214818851|NCT03919058|OTHER|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
214818852|NCT03919058|OTHER|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
214818853|NCT03919058|OTHER|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
214818854|NCT06997523|BEHAVIORAL|Breath Therapy and Benson Relaxation Technique|Relaxing breathing therapy (4-7-8) and Benson relaxation technique will be applied to the intervention group for 6 weeks. No intervention will be made to the control group.
214818855|NCT00827047|PROCEDURE|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
214263993|NCT03569033|DRUG|Placebo|Placebo tablet matching gefapixant will be administered orally.
214818856|NCT00827047|PROCEDURE|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
214818857|NCT00827047|PROCEDURE|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
214818858|NCT07007494|OTHER|Nutritional and Inflammatory Marker Evaluation|This is a prospective observational cohort study evaluating whether preoperative immune-nutritional markers-including Prognostic Nutritional Index (PNI), HALP score, Neutrophil-to-Lymphocyte Ratio (NLR), and C-Reactive Protein (CRP)-can predict early postoperative clinical outcomes (complication development, time to oral intake, mobilization, and length of hospital stay) in patients undergoing elective laparoscopic sleeve gastrectomy. No intervention or treatment is administered as part of this study. All data are collected from routine preoperative laboratory tests and standard postoperative clinical follow-up.
214818859|NCT03290781|DRUG|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
214818860|NCT03290781|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
214818861|NCT01788800|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
214818862|NCT04725708|PROCEDURE|procedure: cerebral oxygenation intervention|During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
214818863|NCT01030848|DEVICE|Total Knee Replacement (LCS rotating platform)|
214818864|NCT01684241|BIOLOGICAL|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
214818865|NCT04328597|PROCEDURE|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
214818866|NCT05098886|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
214818867|NCT05098886|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
214818868|NCT00239863|DRUG|FTY720|
214818869|NCT05755763|OTHER|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
214818870|NCT05081466|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)
214818871|NCT05081466|OTHER|Fruit and vegetable intake|Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire
214818872|NCT05081466|OTHER|Meat intake|Red meat, poultry, processed meat from food frequency questionnaire
214818873|NCT05081466|OTHER|Fish intake|Intake of fish from food frequency questionnaire
214818874|NCT05081466|OTHER|Egg intake|Intake of eggs from food frequency questionnaire
214818875|NCT05081466|OTHER|Dairy intake|Intake of dairy products from food frequency questionnaire
214818876|NCT05081466|OTHER|Tea intake|Intake of tea (drink) from food frequency questionnaire
214263994|NCT03561363|BEHAVIORAL|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
214263995|NCT01268150|DRUG|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
214263996|NCT00553943|DRUG|Rituximab|375 mg/m2 D1
214263997|NCT00553943|DRUG|Cytarabine|50 mg D3
214263998|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of uphill exercise|40 minutes of uphill exercise
214818877|NCT05081466|OTHER|Coffee intake|Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire
214818878|NCT05081466|OTHER|Tea and coffee intake|Combined intake of tea and coffee from food frequency questionnaire
214818879|NCT05081466|OTHER|Protein intake|Estimated intake of protein, derived from food frequency questionnaire
214818880|NCT05081466|OTHER|Calcium intake|Estimated intake of calcium, derived from food frequency questionnaire
214818881|NCT05081466|OTHER|Vitamin D intake|Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
214818882|NCT01136174|DRUG|Placebo|Placebo BID for cohort 1,2,3
214818883|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
214818884|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
214818885|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
214263999|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
214264000|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of uphill exercise|40 minutes of uphill exercise
214264001|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
214264002|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of downhill exercise|40 minutes of downhill exercise
214818886|NCT03919630|OTHER|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
214818887|NCT03919630|OTHER|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
214818888|NCT02939092|DRUG|Pomegranates peel extract|Pomegranate is antimicrobial
214818889|NCT02939092|DRUG|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
214818890|NCT00065312|DRUG|naveglitazar|
214818891|NCT03185039|PROCEDURE|Blood and tumor samples|Blood and tumor samples
214818892|NCT02851992|DEVICE|GTS cementless stem|Total Hip Arthroplasty
214818893|NCT01074541|RADIATION|UVB|0.375 SED x 4 in a week
214818894|NCT01074541|RADIATION|UVB|0.75 SED x 4 in a week
214818895|NCT01074541|RADIATION|UVB|1.5 SED x 4 in a week
214818896|NCT01074541|RADIATION|UVB|3.0 SED x 4 in a week
214818897|NCT03158675|PROCEDURE|fractional carbon dioxide(CO2) laser|-Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
214818898|NCT03158675|DRUG|Topical corticosteroid|Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
214818899|NCT03158675|RADIATION|Ultraviolet B narrow band|Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
214818900|NCT02609256|PROCEDURE|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
214818901|NCT02609256|OTHER|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
214818902|NCT00000661|DRUG|Oxazepam|
214818903|NCT00000661|DRUG|Zidovudine|
214818904|NCT02233985|DRUG|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
214818905|NCT02233985|DRUG|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
214818906|NCT06016894|PROCEDURE|coronally advanced flap|coronally advanced flap operation
214818907|NCT06016894|OTHER|Nanocrystalline hydroxyapatite loaded in PRF|Nanocrystalline hydroxyapatite loaded in PRF
214818908|NCT06016894|OTHER|Nanocrystalline tricalcium phosphate loaded in PRF|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
214818909|NCT00808418|DRUG|Elesclomol Sodium|Chemotherapy agent
214818910|NCT00808418|DRUG|Docetaxel|Chemotherapy agent
214818911|NCT06033456|PROCEDURE|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
214818912|NCT06033456|PROCEDURE|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
214818913|NCT06033456|PROCEDURE|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
214818914|NCT04931563|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
214818915|NCT04931563|DRUG|placebo|Intravenous infusion (IV)
214264003|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
214264004|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
214818916|NCT07016425|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of essential tremor patients.
214818917|NCT01096433|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
214264005|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
214264006|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
214818918|NCT00053287|DRUG|carboplatin|Carboplatin IV over 24 hours on days 1-5
214818919|NCT00053287|DRUG|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
214818920|NCT00053287|DRUG|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
214818921|NCT00053287|DRUG|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
214264007|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
214264008|NCT01191918|DRUG|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
214264009|NCT01191918|DRUG|Placebo plus Lithium|
214818922|NCT05703438|OTHER|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
214818923|NCT02304211|DRUG|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
214818924|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
214818925|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
214818926|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
214818927|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
214818928|NCT02344381|DIETARY_SUPPLEMENT|Sucrose|
214818929|NCT02344381|DIETARY_SUPPLEMENT|Glucose|
214818930|NCT03886935|DIAGNOSTIC_TEST|Metabolomics|
214818931|NCT01140581|DRUG|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
214818932|NCT01300676|DRUG|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
214818933|NCT06295211|OTHER|observational|observational
214818934|NCT02538523|DEVICE|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
214818935|NCT02538523|DEVICE|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
214818936|NCT01763177|OTHER|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
214818937|NCT02874677|OTHER|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
214818938|NCT02209428|DRUG|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
214818939|NCT04975035|DRUG|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
214818940|NCT02769494|DRUG|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
214818941|NCT02769494|DRUG|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
214818942|NCT02587871|DRUG|Cytarabine|Given IV
214818943|NCT02587871|OTHER|Laboratory Biomarker Analysis|Correlative studies
214818944|NCT02587871|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
214818945|NCT02587871|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
214818946|NCT02587871|BIOLOGICAL|G-CSF mobilized peripheral blood cells|microtransplantation
214818947|NCT02820350|DEVICE|SCD-F40|CRRT with SCD
214818948|NCT01367054|DRUG|Metformin|500 mg tablet
214818949|NCT01367054|DRUG|Glifage|500 mg tablet
214818950|NCT00002939|DRUG|irinotecan hydrochloride|
214818951|NCT00002939|DRUG|paclitaxel|
214818952|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
214818953|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
214818954|NCT01055795|DRUG|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
214818955|NCT02818790|BEHAVIORAL|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
214818956|NCT02818790|BEHAVIORAL|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
214818957|NCT03642808|OTHER|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
214818958|NCT06627478|DRUG|NKF-INS(G)|Single subcutaneous dose of 0.5 IU/kg administered over three periods
214818959|NCT06627478|DRUG|US-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
214818960|NCT06627478|DRUG|EU-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
214818961|NCT01597245|DRUG|80 mg ixekizumab Dosing Regimen|Administered SC
214818962|NCT01597245|DRUG|50 mg etanercept|Administered SC
214818963|NCT01597245|DRUG|Placebo|Administered SC
214264010|NCT03210623|DEVICE|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
214264011|NCT03210623|DEVICE|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
214818964|NCT05853328|PROCEDURE|Epley Maneuver|"The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward."
214818965|NCT05853328|PROCEDURE|SemontPLUS maneuver|The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
214818966|NCT00952406|OTHER|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
214818967|NCT03841188|OTHER|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
214818968|NCT03190005|DRUG|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
214818969|NCT03190005|DRUG|Placebos|no medication, healthy subjects.
214818970|NCT01692717|DRUG|Atorvastatin|10 mg
214818971|NCT01692717|DRUG|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
214818972|NCT01692717|DRUG|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
214818973|NCT03429712|DEVICE|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
214818974|NCT04709926|OTHER|Survey|Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
214818975|NCT04709926|OTHER|Interview (optional)|Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
214818976|NCT04986878|PROCEDURE|single-shot adductor canal block|An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.
214818977|NCT01763385|DRUG|Erlotinib|
214818978|NCT01763385|RADIATION|concurrent brain radiotherapy|
214818979|NCT01763385|RADIATION|secondary brain radiotherapy|
214818980|NCT01889498|DRUG|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~* 250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~* One tablet to take two hours before surgery~* 500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
214818981|NCT02572713|PROCEDURE|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
214818982|NCT02572713|PROCEDURE|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
214818983|NCT02572713|DRUG|DaTSCAN™|
214818984|NCT00352989|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
214818985|NCT05411913|DRUG|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
214818986|NCT05411913|DRUG|Icy Hot|a FDA OTC registered topical analgesic.
214818987|NCT05411913|DRUG|Tiger Balm|a FDA OTC registered topical analgesic
214818988|NCT05411913|DRUG|Bengay|a FDA OTC registered topical analgesic.
214818989|NCT05411913|DRUG|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
214818990|NCT05411913|DRUG|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
214818991|NCT05411913|DRUG|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
214818992|NCT05411913|DRUG|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
214818993|NCT06513052|OTHER|Commercial cocoa|daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk
214818994|NCT06513052|OTHER|High flavonols Cocoa|Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
214818995|NCT02816177|OTHER|Telemedicine|
214818996|NCT02816177|OTHER|Usual Care|
214818997|NCT06230588|DRUG|TQH3906 capsule|TQH3906 is a kinase inhibitor.
214818998|NCT06230588|DRUG|TQH3906 placebo|Placebo Comparator
214818999|NCT05282199|OTHER|INSPIRATORY MUSCLE TRAINING|In the group of post-COVID-19 patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
214819000|NCT06217939|DRUG|Early hydrocortisone|"For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
214819001|NCT06217939|DRUG|Normal saline placebo|"For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
214819002|NCT06217939|DRUG|Open-label hydrocortisone|An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
214819003|NCT06962865|DRUG|RC108|RC108 in Combination With Furmonertinib
214819004|NCT06962865|DRUG|Furmonertinib Mesilate Tablets Monotherapy|Furmonertinib
214819005|NCT05013372|DRUG|CD147- CAR T cells|CAR T cells targeting CD147
214819006|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
214819007|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
214819008|NCT02184026|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
214819009|NCT02922777|DRUG|BGB324|75 mg/m2 every 21 days
214819010|NCT02922777|DRUG|Docetaxel|75 mg/m2 given IV every 21 days
214819011|NCT00541788|OTHER|Administration of Common Sage|Administration of Common Sage
214819012|NCT03161158|DEVICE|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
214819013|NCT03161158|OTHER|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
214819014|NCT03083574|DEVICE|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
214819015|NCT05135104|DRUG|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~* in combination with an aromatase inhibitor;~* in combination with fulvestrant in women who have received prior endocrine therapy."
214819016|NCT05238168|OTHER|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
214819017|NCT00101647|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
214819018|NCT02361905|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
214819019|NCT02361905|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
214819020|NCT04766697|BEHAVIORAL|Risk-Reduction Sessions|The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
214819021|NCT00583453|DRUG|Celecoxib|"Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
214819022|NCT00583453|DRUG|Placebo|"Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
214819023|NCT03394547|DEVICE|Allay|pulsed shortwave therapy treatment for painful periods
214819024|NCT03394547|DEVICE|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
214819025|NCT04938635|DRUG|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
214819026|NCT04938635|DRUG|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
214819027|NCT04938635|DRUG|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
214819028|NCT04938635|DRUG|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
214819029|NCT01837810|DRUG|Ibuprofen|800mg every 8 hours as needed for pain
214819030|NCT00681798|DRUG|Vandetanib|100mg/300mg
214819031|NCT06508905|OTHER|Sleep buddy|The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
214819032|NCT03747276|OTHER|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
214819033|NCT04793971|PROCEDURE|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
214819034|NCT01334333|DRUG|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
214819035|NCT01334333|DRUG|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
214819036|NCT03326271|PROCEDURE|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
214819037|NCT03326271|PROCEDURE|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
214819038|NCT04711980|DRUG|Mudan granule|"Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
214819039|NCT04711980|DRUG|Placebo|"Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
214819040|NCT05342740|OTHER|collect whole blood, urine and stool samples|collect whole blood, urine and stool samples
214819041|NCT03537872|BEHAVIORAL|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
214819042|NCT03537872|BEHAVIORAL|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
214819043|NCT00794963|DRUG|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
214819044|NCT00794963|OTHER|As selected by community physician|As selected by community physician
214819045|NCT02420834|OTHER|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
214819046|NCT02420834|OTHER|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
214819047|NCT02420834|OTHER|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
214819048|NCT02420834|OTHER|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
214819049|NCT01932086|DIETARY_SUPPLEMENT|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
214264012|NCT01931618|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
214264013|NCT01931618|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
214655982|NCT05932719|OTHER|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM"
214655983|NCT00619229|DRUG|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
214655984|NCT00619229|OTHER|Placebo|Placebo/d i.v. for 15 days
214655985|NCT06399783|DRUG|Simvastatin|Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
214655986|NCT06399783|DRUG|Mometasone Furoate|Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
214655987|NCT06399783|PROCEDURE|Fractional CO2 laser|Fractional CO2 laser will be used for assisted drug delivery for both topical simvastatin and mometasone Furoate.
214655988|NCT04845217|DRUG|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
214655989|NCT04845217|DRUG|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
214655990|NCT02548065|OTHER|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
214655991|NCT02548065|OTHER|Placebo|Bath with Thermal tap water
214655992|NCT01284881|DEVICE|MRA|daily wear overnight
214655993|NCT00061386|BEHAVIORAL|Nutrition and physical activity program|
214655994|NCT03182764|OTHER|No intervention|No intervention
214655995|NCT01734343|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
214655996|NCT01734343|DEVICE|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
214655997|NCT04626713|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
214655998|NCT02476487|PROCEDURE|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2\. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
214655999|NCT02086227|DRUG|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
214656000|NCT02086227|DRUG|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
214656001|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
214656002|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
214819050|NCT01932086|DIETARY_SUPPLEMENT|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
214819051|NCT01932086|DIETARY_SUPPLEMENT|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
214819052|NCT01932086|DIETARY_SUPPLEMENT|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
214819053|NCT01932086|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
214819054|NCT01461421|BEHAVIORAL|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
214819055|NCT01461421|BEHAVIORAL|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
214819056|NCT01461421|BEHAVIORAL|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
214819057|NCT01461421|BEHAVIORAL|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
214819058|NCT02118532|DEVICE|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
214819059|NCT05261737|PROCEDURE|Corticosteroid Injection|Steroid injection effectiveness will be determined by relief of pain scored by patient using Visual Analogue Scale (VAS). Data will be collected during clinic visit and contacting patients in a determined protocol for the following 6 weeks after steroid injection.After approval of the study, data will collected from participants over a period of 6 weeks follow up; the whole study will be conducted over a total of 2 years.Since the study will not conduct any further test to participants and follow up regimen will only state pain related to the specific condition (De Quervain tenosynovitis) and quick-DASH score, it will not result in any anticipated/unanticipated incidental findings, therefore participants will not be recontacted.
214819060|NCT00905931|DRUG|Lycopene|30 mg oral, daily, for 21 days
214819061|NCT00905931|DRUG|placebo|starch
214819062|NCT01450189|BEHAVIORAL|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
214819063|NCT01450189|BEHAVIORAL|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
214819064|NCT01450189|DRUG|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
214819065|NCT01450189|DRUG|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
214819066|NCT01956786|DRUG|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
214819067|NCT01956786|DRUG|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
214819068|NCT01956786|DRUG|Amlodipine|5mg amlodipine,once daily
214819069|NCT06118918|BEHAVIORAL|Phase II comprehensive cardiac rehabilitation program|the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation …etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
214656003|NCT02786901|DRUG|Vehicle Gel|Gel
214656004|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
214656005|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
214656006|NCT01843010|DRUG|Parecoxib|Parecoxib 40mg will be intravenously infused.
214656007|NCT01843010|DRUG|Placebo|Normal saline 5ml will be intravenously infused.
214656008|NCT03367871|DRUG|Pembrolizumab|IV
214656009|NCT03367871|DRUG|Paclitaxel|Administered intravenously (IV) on day 1
214656010|NCT03367871|DRUG|Cisplatin|Administered intravenously (IV) on day 1
214656011|NCT03367871|DRUG|Carboplatin|Administered intravenously (IV) on day 1
214656012|NCT03367871|DRUG|Bevacizumab|Administered intravenously (IV) on day 1
214656013|NCT04761796|OTHER|Sleeping condition self-questionnaire|Professional flight members will answer a self questionnaire related to their sleeping conditions
214656014|NCT03573713|OTHER|Care Groups|The Care Groups model has strong evidence of improvement of maternal and child health and maternal hygiene/nutrition behaviors.Through Care Groups, women will learn about proper water, sanitation, and hygiene behaviors; Infant and Young Child Feeding practices; management of childhood illnesses; home management, referral and care seeking for sick children; family planning; and use of preventive services available at health facilities (e.g., growth monitoring, deworming, vitamin A supplementation). All children under five years of age will also be screened for acute malnutrition by the Care Group Volunteers, and receive deworming medication and vitamin A supplementation twice a year through the Ministry of Health and Community Health Workers as part of national campaigns.
214819070|NCT01151930|DRUG|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
214819071|NCT02079194|DRUG|P2Y12 antagonist monotherapy|
214819072|NCT02079194|DRUG|aspirin plus P2Y12 antagonist|
214819073|NCT03552744|OTHER|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~1. 2-page structured evidence summary on CRC screening and information about Colonoscopy \& FIT (Decision box)~2. patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~3. video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4. 4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~5. individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~6. 2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~7. sample FIT for PCPs who may not be familiar with its contents and use"
214819074|NCT02704585|DEVICE|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
214819075|NCT02704585|DEVICE|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
214819076|NCT03276247|OTHER|observation|observation
214819077|NCT00567320|DRUG|Varenicline|Varenicline up to 2 mg a day
214819078|NCT00567320|DRUG|Sugar pill or Placebo|Placebo
214819079|NCT03282162|DRUG|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
214819080|NCT03282162|DRUG|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
214819081|NCT03426722|DRUG|L-carnitine|"* L-carnitine VS Placebo is randomized (1:1)~* L-carnitine 500mg TID(PO),~* First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given."
214819082|NCT03426722|DRUG|Placebo|Placebo 500mg TID(PO)
214819083|NCT02334644|DIETARY_SUPPLEMENT|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
214819084|NCT02334644|DIETARY_SUPPLEMENT|Placebo|2 sachets/day x 12 weeks
214819085|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
214819086|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
214819087|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
214819088|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
214819089|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
214819090|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
214819091|NCT01997372|DRUG|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \>1×109/L.
214819092|NCT03610035|DRUG|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
214819093|NCT03610035|DRUG|Placebo|Placebo
214819094|NCT01027923|DRUG|Plerixafor|
214819095|NCT01027923|DRUG|Mitoxantrone|
214819096|NCT01027923|DRUG|Etoposide|
214819097|NCT01027923|DRUG|Cytarabine|
214819098|NCT03837249|DEVICE|Personal Sleep Monitoring|Wearable Sleep Self-Monitoring Device (Actigraphy)
214819099|NCT05901090|OTHER|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
214819100|NCT05901090|OTHER|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
214819101|NCT01527006|DRUG|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
214819102|NCT01409278|PROCEDURE|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
214819103|NCT01409278|PROCEDURE|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
214819104|NCT01409278|PROCEDURE|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
214819105|NCT00367861|DRUG|interruption of Glivec®|interruption of Glivec®
214819106|NCT01394497|DRUG|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
214819107|NCT03755947|DRUG|Ibrutinib|Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
214819108|NCT03755947|DRUG|Obinutuzumab|Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
214819109|NCT03755947|DRUG|Venetoclax|Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
214819110|NCT06082154|DEVICE|ultrasound|Patient will undergo multiorgan ultrasonography
214819111|NCT02995005|DRUG|Tenofovir Disoproxil Fumarate|300 mg daily
214264014|NCT01931618|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
214264015|NCT03557853|DRUG|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
214264016|NCT03738033|OTHER|educational platform|The platform would be opened before they entered the study.
214264017|NCT02700022|DRUG|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
214264018|NCT04738734|DEVICE|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
214264019|NCT04738734|DEVICE|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
214264020|NCT01827956|OTHER|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
214264021|NCT03072732|DEVICE|u-Cor System|Monitoring System
214264022|NCT03072732|DEVICE|ZOE Fluid Status Monitor|Monitoring System
214264023|NCT03048461|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
214264024|NCT03048461|DRUG|Placebo|intradermal injections to an area of alopecia
214264025|NCT02435147|DRUG|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
214264026|NCT05115578|DRUG|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
214264027|NCT05115578|DRUG|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
214264028|NCT05115578|DRUG|Saline solution|Group III Control
214264029|NCT05115578|DEVICE|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
214264030|NCT01753102|DRUG|Estradiol|one tablet will be inserted daily for 14 days
214264031|NCT00891007|BIOLOGICAL|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
214264032|NCT00891007|BIOLOGICAL|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
214264033|NCT00891007|BIOLOGICAL|Rouvax|Standard measles vaccine, approved in South Africa
214264034|NCT00001095|DRUG|Indinavir sulfate|
214264035|NCT00001095|DRUG|Amprenavir|
214264036|NCT00001095|DRUG|Nevirapine|
214264037|NCT00001095|DRUG|Lamivudine|
214264038|NCT00001095|DRUG|Stavudine|
214264039|NCT00001095|DRUG|Zidovudine|
214264040|NCT02385370|DRUG|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
214264041|NCT02385370|DRUG|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
214264042|NCT01050491|DRUG|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
214819112|NCT00447577|DRUG|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
214819113|NCT00447577|DRUG|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
214819114|NCT00296062|BIOLOGICAL|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
214819115|NCT00296062|DRUG|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
214264043|NCT01050491|DRUG|placebo|placebo, one per day, during one year. Bronchial fibroscopy
214264044|NCT05377008|BEHAVIORAL|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
214264045|NCT01725607|DRUG|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
214264046|NCT01725607|PROCEDURE|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
214264047|NCT02395783|DRUG|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
214264048|NCT02395783|DRUG|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
214264049|NCT02395783|OTHER|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
214264050|NCT04248751|DEVICE|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
214264051|NCT04248751|PROCEDURE|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
214264052|NCT04701788|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
214264053|NCT00300105|DRUG|Tesaglitazar|
214264054|NCT05202028|OTHER|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
214264055|NCT05202028|OTHER|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
214264056|NCT05202028|OTHER|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
214264057|NCT00276146|DRUG|oral dipyridamole, oral magnesium, or a combination of both|
214264058|NCT04587544|BEHAVIORAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
214264059|NCT05263596|DIAGNOSTIC_TEST|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA"
214264060|NCT03397615|BEHAVIORAL|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
214264061|NCT02714907|DEVICE|Cortrium C3 device|Data is read from Cortrium C3 monitor
214264062|NCT02714907|DEVICE|Holter device|Date is read from Holter device
214264063|NCT04402060|DRUG|APL-9|Complement (C3) Inhibitor
214819116|NCT00296062|DRUG|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
214819117|NCT00296062|DRUG|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
214819118|NCT04451837|DRUG|Semaglutide|Ozempic s.c. once weekly for 6 months
214819119|NCT04451837|DRUG|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
214264064|NCT04402060|OTHER|Vehicle Control|Normal saline of equal volume to active arm
214264065|NCT05382533|DIETARY_SUPPLEMENT|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
214264066|NCT03145363|BEHAVIORAL|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
214264067|NCT03145363|BEHAVIORAL|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
214819120|NCT01845376|PROCEDURE|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
214819121|NCT01845376|PROCEDURE|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
214819122|NCT01845376|PROCEDURE|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
214819123|NCT00732082|DRUG|Gemcitabine|
214819124|NCT00732082|BIOLOGICAL|LAG-3|
214264068|NCT02256072|OTHER|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
214819125|NCT02009462|DRUG|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
214264069|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
214264070|NCT02648269|DRUG|SEL-110|
214819126|NCT05646381|DRUG|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80mg
214264071|NCT02648269|BIOLOGICAL|SEL-212|
214264072|NCT02648269|BIOLOGICAL|SEL-037|
214819127|NCT05646381|DRUG|Matching placebo|Matching placebo
214819128|NCT03059186|BEHAVIORAL|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
214819129|NCT00593463|DRUG|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
214819130|NCT00593463|DRUG|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
214819131|NCT00593463|DRUG|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
214819132|NCT00593463|DRUG|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
214819133|NCT00593463|DRUG|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
214819134|NCT00593463|DRUG|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
214819135|NCT00593463|DRUG|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
214819136|NCT00593463|DEVICE|Saline|Saline: I.M. injection may possibly be given
214819137|NCT00593463|DRUG|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
214819138|NCT03072433|BEHAVIORAL|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
214819139|NCT03072433|BEHAVIORAL|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
214819140|NCT03368287|DEVICE|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
214264073|NCT00539669|DRUG|Docetaxel|
214264074|NCT04139473|PROCEDURE|Hepaticojejunostomy / Duct-to-duct anastomosis|
214264075|NCT03998566|DEVICE|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
214264076|NCT06512597|BEHAVIORAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
214264077|NCT06512597|BEHAVIORAL|Time and Attention Control - IBD Support Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
214819141|NCT06486298|DEVICE|Vacuum Drain and Passive Drain insertion at abdominoplasty surgery|Compare the subcutaneous collection with Vacuum Drain and Passive Drain insertion at abdominoplasty surgery
214819142|NCT02115347|DRUG|Ertugliflozin 15 mg|Tablet
214819143|NCT01423994|PROCEDURE|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
214819144|NCT01423994|PROCEDURE|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate \<50 bpm, High Heart Rate \>165 bpm, and Pause \> 3 seconds.
214819145|NCT05982691|RADIATION|Radiation Therapy|Radiation Therapy(General guideline) Patients will receive radiotherapy after induction chemotherapy or right after diagnosis without diagnosis. The dose and fields of radiation will be according to the histology, presence of dissemination, and response to the induction chemotherapy or radiotherapy. Radiation therapy can be administered using either of photons or protons. When induction chemotherapy is administered, radiotherapy is recommended to be started within 6 weeks from the last chemotherapy.
214819146|NCT03600467|DRUG|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
214819147|NCT01776190|DEVICE|UVA1 radiation treatment|
214819148|NCT03731234|DRUG|Ibrutinib|Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
214819149|NCT01612091|DEVICE|Monitoring Messenger|Monitoring Messenger prototype device
214819150|NCT01612091|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
214264078|NCT04325178|OTHER|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
214264079|NCT02406183|RADIATION|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
214264080|NCT02406183|DRUG|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
214264081|NCT03049722|DEVICE|Pacemaker|
214264082|NCT05670847|DRUG|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
214264083|NCT06680505|DRUG|YZJ-1139 10mg|YZJ-1139 10mg tablets
214264084|NCT06680505|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets
214819151|NCT04630327|OTHER|Beck Depression Inventory-21 (diagnostic survey)|Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
214264085|NCT06680505|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets
214264086|NCT06680505|DRUG|YZJ-1139 60mg|YZJ-1139 60mg tablets
214264087|NCT06680505|DRUG|Placebo|Match placebo tablets
214264088|NCT06681597|DIETARY_SUPPLEMENT|Raspberry ketone|Human consumed 500mg of raspberry ketone
214264089|NCT06680557|BEHAVIORAL|Aerobic and resistance exercises|"* Aerobic exercise session: A 30-minutes of brisk walking exercise on an indoor track without speed walking or running .~* Resistant exercise session: A 30-minutes of resistance exercise using rubber bands including warm-up and cool-down periods. Rubber band exercises are composed of seven exercises: squat, leg extension, pull apart, seated row, standing biceps curl, overhead press and lateral raise. Each exercise consists of three sets of 10 repetitions with 1 minute rest between each exercise set."
214819152|NCT04630327|OTHER|Beck Anxiety Inventory|Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
214819153|NCT04630327|OTHER|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
214819154|NCT05651191|DRUG|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
214264090|NCT06681844|OTHER|Tooth Shape assessed using an intraoral scanner one after avulsion|"* Tooth Shape assessed using an intraoral scanner one after avulsion and stored as StereoLithography (STL) file~* Age, gender, reason of avulsion, type of tooth taken from the database and stored in a google sheet"
214264091|NCT06680167|DRUG|Spinal anesthesia (heavy bupivacaine 0.5%)|12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
214264092|NCT06680167|DRUG|spinal anesthesia (hyperbaric Prilocaine 2%)|60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
214264093|NCT06238362|OTHER|TPAP|Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP
214264094|NCT06238362|DEVICE|CPAP|Gold standard for treating sleep apnea.
214264095|NCT05136690|DRUG|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
214264096|NCT05136690|DRUG|MK-4334|MK-4334 250 mg capsule taken by mouth.
214264097|NCT05136690|DRUG|Placebo patch|Placebo patch.
214819155|NCT06354894|DEVICE|Proximal humeral fracture fixation|percutaneous pinning VS plate and screws
214819156|NCT02564965|DEVICE|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
214819157|NCT02564965|DEVICE|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
214819158|NCT03474757|OTHER|Data Collection|Data will be extracted from July 2009 to the last available database extraction
214819159|NCT05510830|PROCEDURE|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT \& HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
214264098|NCT05136690|DRUG|Placebo capsule|Placebo capsule taken by mouth.
214264099|NCT06595121|DRUG|budesonide|Budesonide 1 mg/2mL nebuliser suspension
214264100|NCT06595121|DRUG|budesonide|Pulmicort(r) 1 mg/2mL nebuliser suspension
214264101|NCT06595121|OTHER|Activated Charcoal|suspension of 10g activated charcoal slurried in 70mL of water
214264102|NCT06681506|DEVICE|Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.|Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)
214264103|NCT06681506|DEVICE|bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation|Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)
214264104|NCT06680388|DRUG|Drug：CD19 CAR-T|A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
214264105|NCT06681688|DRUG|Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}|Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
214264106|NCT06681688|DRUG|Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}|"On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)"
214264107|NCT06680999|OTHER|Data collection|Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
214264108|NCT06680856|COMBINATION_PRODUCT|PRP+HA|treatment of diabetic foot ulcers with allogeneic PRP+HA
214264109|NCT06680856|COMBINATION_PRODUCT|HA|treatment of diabetic foot ulcers with HA
214264110|NCT02637622|OTHER|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
214264111|NCT02637622|OTHER|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
214264112|NCT04638400|DRUG|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
214264113|NCT04638400|DRUG|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
214264114|NCT06680843|PROCEDURE|Whole blood collection|30 mL at Day 0 with optional visits for up to 2 additional whole blood collections at least 30 days apart
214264115|NCT06681792|BEHAVIORAL|Climate Change Workshops Based on Protection Motivation Theory|"The experimental group will take part in seven weekly workshops. One workshop will last 40 minutes.The workshop to be applied to the experimental group will take place every week and will last 40 minutes. The workshops, which are based on the Protection Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring environmentally friendly behaviour, recycling and the Green School Programme for sustainable environmental education.~The workshops include interactive applications such as students expressing their thoughts on the weekly themes, games, brainstorming, word cloud, planting trees, painting cloth bags, watching videos, making presentations on the themes. Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring enviro"
214264116|NCT06703697|OTHER|eDrugSafe|The eDrugSafe mobile web platform enables management of medication history and provides electronic access to medicinal product information (ePI). QR codes are separately provided for prescription records to facilitate direct access to ePI.
214264117|NCT06703385|OTHER|Instrument Assisted soft tissue mobilization|The blade is a surgical instrument for soft tissue mobilization, made of 100% surgical stainless steel with 8 treatment planes and 2 treatment edges. It is used to locate muscle limitations and apply gentle strokes along the affected muscle, detecting changes in soft tissue consistency. The procedure is repeated three times a week for four weeks.
214264118|NCT06703385|OTHER|Suboccipital release|The patient will lie in a relaxed supine position, with a therapist sitting on a chair. The therapist will apply pressure to the C2 area, holding it until a melting sensation is felt. The intervention time is 4 minutes. The patient will close both eyes during the Suboccipital release procedure to prevent eye movements affecting muscle tone. Interventions will be three times a week for four weeks.
214264119|NCT06703385|OTHER|conventional physical therapy program|The patient is placed in a sitting position and a hot pack is applied to the back of the neck for 15 minutes. The therapist then performs active range of motion exercises for neck flexion, extension, rotation, and lateral flexion without resistance. They also perform stretching exercises for upper Trapezius muscle and suboccipital muscle. Strengthening exercises for neck muscles are performed through isometric exercises, such as side pending to right, side pending to left, extension, and flexion. The interventions are conducted three times, peer-wise, for four weeks. The treatment aims to improve neck flexibility and overall well-being.
214264120|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail A|Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.
214264121|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail B|Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.
214264122|NCT06710392|DIETARY_SUPPLEMENT|Placebo A|Placebo A matching investigational product A given 3 times a day for 4 weeks.
214264123|NCT06710392|DIETARY_SUPPLEMENT|Placebo B|Placebo B matching investigational product B given 3 times a day for 4 weeks.
214264124|NCT06706804|BEHAVIORAL|Wipe Bathing|In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate times, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, women will be provided to perform the procedure on the model appropriate to the gender of their babies for genital area cleaning based on the gender of newborns. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
214264125|NCT06709066|DRUG|mivacurium chloride|mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
214264126|NCT06709066|DRUG|succinylcholine|succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
214264127|NCT06709157|DIAGNOSTIC_TEST|P24 antigens and antibody|estimation of antigens and antibodies to diagnose HIV
214264128|NCT06709157|DIAGNOSTIC_TEST|zeihl - Nelsen stain|staining sputum from patients with HIV to detect tubercle bacilli
214264129|NCT06709157|DIAGNOSTIC_TEST|culture on Lowenstein jensen media|spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies
214819160|NCT04561063|DRUG|Nitazoxanide|Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
214264130|NCT06709157|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|to see the pattern of antibiotic resistance of tubercle bacilli
214264131|NCT06707649|OTHER|Self Management Education|Patients in this group will receive self-management education during the 3 days when they are in the hospital. On the first day of the training, COPD disease, causes of the disease, symptoms, reasons for alleviating complaints, practical information for living comfortably with COPD will be given. On the second day, emergency situations in COPD, what is an exacerbation and prevention suggestions and diaphragmatic breathing-cough exercises will be taught. On the last day, training will be given on pursed lip breathing, medication use, oxygen and nebulizer treatments. The education will be accompanied by a educational booklet prepared by researchers and expert opinion.
214264132|NCT06707649|OTHER|Telephone Follow-up|Patients will receive their first call one week after discharge. The calls will be scheduled weekly during the first month, biweekly in the second month, and monthly starting from the third month. During the calls, it is planned to repeat the educational content and answer the patient's questions.
214264133|NCT06709417|DRUG|Sintilimab|Sintilimab 200mg iv Q3W
214264134|NCT06709417|DRUG|Chemotherapy|Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
214819161|NCT04561063|DRUG|Sofosbuvir/Daclatasvir|Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
214819162|NCT03161717|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
214819163|NCT03161717|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
214819164|NCT01827566|OTHER|gluten|
214819165|NCT01827566|OTHER|gluten free flour|
214819166|NCT02530333|OTHER|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
214819167|NCT03405688|PROCEDURE|Blood sampling|Extra blood samples taken for laboratory analysis
214819168|NCT03597711|DEVICE|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
214819169|NCT06381128|RADIATION|Cardiac CT|Computed tomography angiography
214819170|NCT00247247|DRUG|Comtess®|
214819171|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe assistance|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
214819172|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
214819173|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ|Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
214819174|NCT05074576|OTHER|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
214264135|NCT06709417|RADIATION|radiotherapy|The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).
214264136|NCT06708637|DRUG|FYB203 2 mg (0.05 mL of 40 mg/mL)|IVT administration of FYB203 in a PFS
214264137|NCT06709885|DRUG|Chidamide + Tislelizumab + chemotherapy (CapeOX )|Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox
214264138|NCT06709885|DRUG|CapeOX|4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
214819175|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
214819176|NCT00834340|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
214819177|NCT00834340|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
214819178|NCT01480544|OTHER|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
214819179|NCT01480544|OTHER|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
214819180|NCT05956925|BEHAVIORAL|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
214819181|NCT03399812|DIETARY_SUPPLEMENT|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
214819182|NCT03399812|DIETARY_SUPPLEMENT|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
214264139|NCT06710171|BEHAVIORAL|Counseling|"The intervention consists of using a theory-informed approach to user-centered brief counselling about PrEP uptake, designed specifically to help busy front-line providers in public health, sexual health and primary care settings advance clients along the PrEP cascade (specifically, supporting clients who meet evidence-based criteria for PrEP in accepting provider recommendations to use it) and provide linkage to care for related conditions.~The intervention will be delivered to GBM through participating healthcare providers who would have completed an online training designed by the research team."
214264140|NCT06710171|OTHER|List of resources|This list includes webpages which contain generic information about GBMs sexual health, PrEP, mental health, information about province-wide info lines for the general public about sexual health and/or educational resources for providers.
214264141|NCT06707428|OTHER|compression stockings|compression stockings used during cesarean section
214264142|NCT06708143|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
214264143|NCT06708546|DIETARY_SUPPLEMENT|Dielac Grow Plus|"Dialac Grow Plus is an Oral Nutritional Supplementation made by Vietnam Dairy Products Joint Stock Company - Vinamilk.~Condition: Liquid~Color: White~Date of use: 8 months from the manufactured date.~Preserve: Store in a clean, dry place, and avoid direct sunlight."
214264144|NCT06709950|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
214264145|NCT06709950|BEHAVIORAL|Regular therapy|Standard treatment
214264146|NCT06710769|PROCEDURE|Ovarian tissue removal will be performed laparoscopically|under general anesthesia concomitantly with another scheduled procedure if possible. Following removal, ovarian tissue will be shipped to University of Pittsburg Medical Center, Magee-Womens Research Institute for processing. Freezing and storing techniques will be in accordance with FDA regulations for reproductive tissues, guidelines of the American Association of Tissues Banks and any other applicable federal, state and local regulations. The tissue will be carefully separated dividing the cortex from the medulla. The cortex will then be cryopreserved for long term storage. The medulla will be shipped overnight back to the PCH Department of Pathology for histological evaluation. If pathology finds evidence of cancer in the ovarian tissue provided, they may request that all of the patient's tissue be returned to pathology for a more detailed examination, which may eliminate the tissue available for the patient's future use.
214264147|NCT06707246|DRUG|Secukinumab 300 MG; Tofacitinib 11mg|Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
214264148|NCT06708845|BIOLOGICAL|zamtocabtagene autoleucel|chimeric antigen receptor T-cell (CAR-T) therapy
214264149|NCT06708845|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214819183|NCT04717960|PROCEDURE|nasal submucosal injection of platelet rich plasma|"* The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months"
214819184|NCT04782765|DRUG|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
214819185|NCT03463850|RADIATION|Dual Energy CT (DECT)|Dual Energy CT (DECT)
214819186|NCT03463850|RADIATION|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
214819187|NCT00161850|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
214819188|NCT02849457|DRUG|Early Vigabatrin|Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
214264150|NCT06708845|DRUG|Fludarabine|Lymphodepleting chemotherapy
214819189|NCT02849457|DRUG|Delayed Vigabatrin (Placebo)|Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
214819190|NCT05374876|OTHER|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
214264151|NCT06709586|PROCEDURE|Thermal ablation|Thermal ablation is a treatment for secondary hyperparathyroidism. There are radiofrequency ablation (RFA) and microwave ablation (MWA). For RFA, an electrode needle is inserted into the parathyroid under imaging guidance. High - frequency current heats the tissue to cause necrosis. MWA uses electromagnetic waves to generate heat by friction. Before ablation, imaging and lab tests are done for evaluation. During the process, precise positioning and real - time monitoring are key. After that, patients are observed for bleeding, swelling and other symptoms, and tests are repeated to assess the effect.
214819191|NCT02599558|DEVICE|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
214819192|NCT02257658|DRUG|Doxycycyline|
214819193|NCT02257658|BEHAVIORAL|Incentive|
214819194|NCT00589186|BIOLOGICAL|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
214819195|NCT00589186|DRUG|celecoxib|
214819196|NCT00589186|OTHER|flow cytometry|
214819197|NCT00589186|OTHER|immunoenzyme technique|
214264152|NCT06709586|PROCEDURE|parathyroidectomy|Parathyroidectomy for secondary hyperparathyroidism is a common approach. The surgeon first makes an incision in the neck area under general or local anesthesia. Then, the enlarged parathyroid glands are carefully identified and dissected. Precise surgical skills are required to avoid damaging nearby structures such as the recurrent laryngeal nerve and blood vessels. After the removal of the abnormal parathyroid tissue, the wound is closed.
214264153|NCT06710704|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous PRF at the affected elbow.
214264154|NCT06710704|DRUG|Methylprednisolone and mepacaine|Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
214264155|NCT06707311|OTHER|patients received calcium hydroxide with glass ionomer restorative material|patients received calcium hydroxide with glass ionomer restorative material
214264156|NCT06707311|OTHER|patients received TheraCal LC with glass ionomer restorative material|patients received TheraCal LC with glass ionomer restorative material
214264157|NCT06707311|OTHER|patients received bioactive bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
214264158|NCT06707311|OTHER|patients received universal bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
214264159|NCT03366012|DEVICE|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
214264160|NCT06708884|OTHER|Exercise|exercise programme will be implemented via telerehabilitation
214264161|NCT06708884|OTHER|Exercise|exercise programme will be implemented via face-to-face
214264162|NCT06710821|DRUG|Liposomal irinotecan in combination with vincristine and temozolomide|Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1. Q3W, 4 cycles expected until disease progression or intolerable toxicity occurs
214264163|NCT06709703|PROCEDURE|Kinematic aligned total knee replacement|Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
214264164|NCT06710301|OTHER|Preliminary assessment|Evaluation of the cognitive level through the Raven test and of spatial navigation skills through the Corsi test and the maze sub-test of the WISC-III.
214264165|NCT06710301|OTHER|Navigation task with EEG recording|Administration of the navigation task in an immersive virtual reality environment and EEG signal recording. The participant will wear virtual reality viewers and EEG cap. The task consists in moving and orienting themselves inside a five-way maze in order to reach a treasure. The participant will be asked to carry out 30 trials lasting a maximum of 120s each.
214264166|NCT06710665|DRUG|Chemotherapy|Chemotherapy
214264167|NCT06707181|DRUG|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
214264168|NCT06707714|DIAGNOSTIC_TEST|hypertension|Gastric cancer patients with hypertension
214264169|NCT06707714|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
214264170|NCT06707714|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver
214264171|NCT03009409|DRUG|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
214264172|NCT03009409|OTHER|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
214656015|NCT03573713|BEHAVIORAL|IPT-G|"IPT-G is an effective, low-cost, short-duration community-based method for decreasing depression has been established that was first rigorously tested in Uganda. Several Private Voluntary Organizations in Africa have used this low-cost, short-duration, community-based group psychosocial approach and found it to be a culturally-sensitive, acceptable, and feasible approach to address depression.~IPT-G treatment spans 12 weeks of treatment, consisting of 3 phases (early, middle, and termination). Within this treatment, participants are also assessed for symptoms of depression every week."
214819198|NCT00589186|OTHER|laboratory biomarker analysis|
214819199|NCT05885594|DRUG|[18F]NOS|\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
214819200|NCT02197481|PROCEDURE|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
214819201|NCT02197481|DEVICE|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
214819202|NCT05323916|BEHAVIORAL|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
214264173|NCT06933121|DEVICE|Digital twin for personalized recommendations|"The intervention is the developed eHealth solution, i.e. the healthy lifestyle recommender system. It is based on a previously developed meal recommender system, but will be much extended, resulting in a multilevel portfolio intervention regarding:~1. Suggesting personalized meal recommendations,~2. Proposing physical activities tailored to the individuals' capabilities and preferences,~3. Measuring and considering emotional and psychological parameters,~4. Proposing additional healthy life-style patterns regarding e.g. sleeping patterns, alcohol and tobacco consumption, engaging in social activities etc.~The detailed nature of the interventions will first be developed during co-creation and then targeted to the participating individual. Moreover, particular attention will be given, since this needs to be a eHealth solution easy to be used by children. The intervention will include collecting urine and saliva samples, as well as measuring anthropometrics and collecting data (persona"
214264174|NCT06933862|DIETARY_SUPPLEMENT|Striatin|striation or placebo given for 90 days assigned to striatin
214264175|NCT06933862|DIETARY_SUPPLEMENT|Placebo|placebo
214264176|NCT06934109|OTHER|Narrative Exposure Therapy (NET)|NET is a psychological talking therapy that has been designed for people who have experienced multiple and prolonged traumatic experiences. It is typically 12-sessions, involving first a psychoeducation session, then laying a lifeline where stones are lain to represent traumatic events, and flowers positive life events. The following sessions the person is asked to talk through their life, going into detail on the traumatic memories that they have experienced.
214264177|NCT06934434|OTHER|FMF Study Group|In the study group consisting of children with FMF, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
214264178|NCT06934434|OTHER|control group|In the control group consisting of healthy children, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
214264179|NCT02675114|PROCEDURE|SAVR|SAVR with a commercially available bioprosthetic valve.
214264180|NCT02675114|DEVICE|SAPIEN 3 THV|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
214264181|NCT03777774|PROCEDURE|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
214264182|NCT03777774|PROCEDURE|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
214264183|NCT03777774|PROCEDURE|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
214264184|NCT06120270|DEVICE|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
214264185|NCT05480930|OTHER|paper-based clinical decision support (dCDS) tool|The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
214264186|NCT05480930|OTHER|digital clinical decision support (dCDS) tool|The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
214264187|NCT01863953|DRUG|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
214264188|NCT01863953|DRUG|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
214264189|NCT01863953|DRUG|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
214264190|NCT01863953|DRUG|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
214264191|NCT03716193|OTHER|Oxygen|Patients will be given oxygen via a facemask during the measurement session
214264192|NCT00384410|DRUG|Nabilone|
214264193|NCT03240354|DEVICE|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
214264194|NCT03240354|DEVICE|Control|Cuff of endotracheal tube inflated with air
214264195|NCT05823532|DRUG|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
214264196|NCT05823532|DRUG|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
214264197|NCT03386318|DRUG|Oxycodone|Serum concentration per hour from 1 to 5 h
214264198|NCT02585154|PROCEDURE|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
214264199|NCT02585154|PROCEDURE|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
214264200|NCT02585154|PROCEDURE|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
214264201|NCT02585154|DEVICE|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
214264202|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
214264203|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
214264204|NCT01313858|DRUG|Simponi®|
214264205|NCT01313858|DRUG|Methotrexate|Given concomitantly with Simponi®
214264206|NCT05692128|OTHER|Hematological and chemistry tests|Laboratory tests
214264207|NCT04023435|OTHER|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
214264208|NCT04992598|OTHER|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
214264209|NCT04992598|PROCEDURE|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
214264210|NCT03380403|RADIATION|PDT|clinical treatment of infected diabetic foot
214264211|NCT03380403|OTHER|Ciprofloxacin|antibiotics and or surgical debridment
214264212|NCT03243604|DRUG|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
214264213|NCT04253223|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
214819203|NCT05323916|BEHAVIORAL|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
214819204|NCT05323916|BEHAVIORAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
214819205|NCT05323916|BEHAVIORAL|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
214264214|NCT05325788|OTHER|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
214264215|NCT05325788|OTHER|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
214264216|NCT03824288|DIAGNOSTIC_TEST|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
214264217|NCT03824288|PROCEDURE|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
214264218|NCT00008203|BIOLOGICAL|aldesleukin|
214264219|NCT00008203|BIOLOGICAL|recombinant interferon gamma|
214819206|NCT03673670|DRUG|RPL554 Suspension|A PDE3/4 inhibitor
214819207|NCT03673670|DRUG|Placebo|A placebo solution
214819208|NCT03673670|DRUG|Tiotropium/olodaterol (Respimat)|An anticholinergic/β-agonist combination medication
214819209|NCT00308152|DRUG|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
214819210|NCT04408794|DRUG|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
214819211|NCT01528462|OTHER|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
214819212|NCT00187720|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
214819213|NCT06324825|DRUG|Fuzhegn Nizeng Decoction|Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
214819214|NCT06324825|DRUG|Moluodan granules|Subjects taking prepared Moluodan granules 9g twice daily for 6 month.
214819215|NCT06545890|DRUG|Ketamine|continous infusion during surgery
214264220|NCT00008203|DRUG|carboplatin|
214264221|NCT00008203|DRUG|cyclophosphamide|
214264222|NCT00008203|DRUG|cyclosporine|
214264223|NCT00008203|DRUG|thiotepa|
214264224|NCT00008203|PROCEDURE|autologous bone marrow transplantation|
214264225|NCT00008203|PROCEDURE|peripheral blood stem cell transplantation|
214264226|NCT03894332|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT\_0) and the last (SBT\_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB\_0) and 30 minutes after extubation (SB\_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
214264227|NCT06037070|BIOLOGICAL|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
214264228|NCT00845104|DRUG|fludarabine phosphate|Given IV
214264229|NCT00845104|BIOLOGICAL|rituximab|Given IV
214264230|NCT00845104|BIOLOGICAL|bevacizumab|Given IV
214264231|NCT00845104|OTHER|laboratory biomarker analysis|Correlative studies
214819216|NCT06545890|DRUG|Dexmedetomidine|continous infusion during surgery
214819217|NCT04258917|DEVICE|Study withdrawn|Study withdrawn
214819218|NCT05336643|DEVICE|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
214264232|NCT00845104|OTHER|flow cytometry|Correlative studies
214264233|NCT00845104|GENETIC|polymerase chain reaction|Correlative studies
214264234|NCT00845104|GENETIC|fluorescence in situ hybridization|Correlative studies
214264235|NCT00273832|PROCEDURE|coronary artery computed tomography angiogram|
214264236|NCT00273832|PROCEDURE|single photon emission computed tomography|
214264237|NCT03692468|BEHAVIORAL|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
214264238|NCT00550524|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
214264239|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
214264240|NCT01935791|DRUG|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
214264241|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
214264242|NCT01935791|DRUG|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
214264243|NCT01935791|DRUG|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
214264244|NCT01935791|DRUG|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
214264245|NCT01935791|DRUG|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
214264246|NCT01935791|DRUG|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
214264247|NCT01935791|DRUG|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
214264248|NCT05476198|PROCEDURE|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
214264249|NCT05476198|PROCEDURE|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
214264250|NCT01191333|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
214819219|NCT04987411|DIAGNOSTIC_TEST|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
214819220|NCT04987411|DIAGNOSTIC_TEST|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
214264251|NCT01191333|DEVICE|Sham Device|Placebo Device that simulates active rTMS treatment
214264252|NCT03018769|DRUG|Chinese Herb|
214264253|NCT01626456|DRUG|ALKS 9072, Low|IM injection, given monthly
214264254|NCT01626456|DRUG|ALKS 9072, High|IM injection, given monthly
214264255|NCT00071474|PROCEDURE|shamanic healing|
214264256|NCT05384574|DIETARY_SUPPLEMENT|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
214264257|NCT00506662|DRUG|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
214264258|NCT00506662|DRUG|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
214264259|NCT04015336|BIOLOGICAL|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
214264260|NCT03792191|RADIATION|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
214264261|NCT03792191|RADIATION|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
214264262|NCT03792191|PROCEDURE|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
214264263|NCT03792191|PROCEDURE|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
214264264|NCT03792191|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
214264265|NCT03792191|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
214264266|NCT01306396|BEHAVIORAL|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
214819221|NCT04987411|DIAGNOSTIC_TEST|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
214264267|NCT06792721|GENETIC|Mutation Burden cfMB analysis|Blood samples will be collected (one time only)
214264268|NCT00277836|DRUG|MST-997|
214264270|NCT03695744|DRUG|Daratumumab|Daratumumab
214264271|NCT03695744|DRUG|Bortezomib|Bortezomib
214264272|NCT03695744|DRUG|Dexamethasone|Dexamethasone
214264273|NCT03423082|DRUG|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
214264274|NCT03423082|DEVICE|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
214264275|NCT05340023|BIOLOGICAL|blood sample|to realize proteomic analysis.
214264276|NCT06549790|DRUG|NMS-03597812|Route of Administration: Oral
214264277|NCT04149626|DRUG|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
214264278|NCT04149626|DRUG|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
214264279|NCT04149626|DRUG|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
214264280|NCT01965821|DEVICE|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
214264281|NCT01965821|DEVICE|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
214264282|NCT05626426|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
214264284|NCT03921073|DRUG|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
214264285|NCT01816074|DRUG|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
214264286|NCT01816074|BEHAVIORAL|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
214264287|NCT00270790|DRUG|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
214264288|NCT00270790|DRUG|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
214264289|NCT00270790|DRUG|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
214264290|NCT00270790|DEVICE|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
214264291|NCT01919593|DRUG|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
214264292|NCT01919593|DRUG|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
214264293|NCT01986283|DRUG|Capsule|Taken once
214264294|NCT01986283|DRUG|PF-00345439|40 mg capsule swallowed whole, taken once
214264295|NCT01986283|DRUG|PF-00345439|40 mg capsule chewed, taken once
214264296|NCT01986283|DRUG|oxycodone|40 mg solution, taken once
214264297|NCT02737696|BEHAVIORAL|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
214264298|NCT02737696|BEHAVIORAL|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
214264299|NCT03826589|DRUG|Avelumab|an anti-programmed cell death ligand 1
214264300|NCT03826589|DRUG|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
214264301|NCT02563015|DIETARY_SUPPLEMENT|cholecalciferol|liquid drops
214264302|NCT02563015|DIETARY_SUPPLEMENT|Reference 400|liquid drops
214264303|NCT05812755|DRUG|Vericiguat|Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
214264304|NCT05812755|DRUG|Placebo|Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
214264305|NCT00628056|DRUG|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
214264306|NCT04756843|DEVICE|Quad-helix|Fixed orthodontic appliance
214264307|NCT03659539|DRUG|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
214264308|NCT03659539|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
214264309|NCT00645385|OTHER|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
214264310|NCT05388929|DRUG|Methocarbamol|Methocarbamol after surgery
214264311|NCT05388929|DRUG|Standard Opioid|Standard opioid after surgery or at discharge
214264312|NCT05388929|DRUG|Standard opioid plus methocarbamol|Standard opioid plus methocarbamol after surgery or at discharge
214264313|NCT06285773|DRUG|RIFPB block|For RIFPB, a local anesthetic will be injected into the plane between the costal cartilage and the rectus abdominis muscle at the 6th-7th costal cartilage under US guidance. The in-plane technique will be used. After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).
214264314|NCT06285773|OTHER|Postoperative analgesia management|"Patients will be administered 10mg/kg paracetamol in the postoperative period every eight hours.~If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administered as a rescue analgesic."
214264315|NCT06285773|DRUG|PIFPB block|For PIFPB; the ultrasound probe for PIFB is placed 2-3 cm lateral to the upper third of the sternum, parallel to the sternum. A local anesthetic of 15 ml of 0.25% concentration of marcaine (bupivacaine) will be used between the pectoralis major and external intercostal muscles (bilateral).
214264316|NCT06562725|OTHER|specific ventilator settings|The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
214264317|NCT06507358|BEHAVIORAL|Parent-Child Interaction group|The intervention for the Parent-Child Interaction group consists of a 6-week program involving weekly 40-minute sessions of therapeutic horticulture in a group setting, with 4-6 participants per group. The sessions focus on sensory-motor activities aimed at helping children engage in daily tasks and activities. Various sensory stimuli are provided through different materials used in gardening activities, including visual, auditory, gustatory, tactile, and olfactory stimuli. The program encourages mutual support and sharing among group members, showcases different outcomes, and emphasizes a sense of responsibility for home care. With a family-centered approach, parental involvement serves as a mediator to promote children's overall development and abilities. Participants are required to complete homework assignments and maintain activity records, including documentation of the 6 sessions through photos and written records.
214264318|NCT05194566|DEVICE|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
214264319|NCT05826561|OTHER|Childhood Asthma Passive Digital Marker|"A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care."
214264320|NCT05561205|DEVICE|rTMS|repetitive transcranial magnetic stimulation
214264321|NCT05561205|DRUG|methylphenidate|methylphenidate
214264322|NCT06113016|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214264323|NCT06113016|OTHER|Educational Intervention|Receive handout on physical activity
214264324|NCT06113016|OTHER|Exercise Intervention|Receive individually tailored exercise intervention
214264325|NCT06113016|DRUG|Fisetin|Given PO
214264326|NCT06113016|OTHER|Physical Performance Testing|Ancillary studies
214264327|NCT06113016|DRUG|Placebo Administration|Given PO
214264328|NCT06113016|OTHER|Quality-of-Life Assessment|Ancillary studies
214264329|NCT06113016|OTHER|Questionnaire Administration|Ancillary studies
214264330|NCT03225729|DEVICE|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
214264331|NCT03225729|DEVICE|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
214264332|NCT00261118|DRUG|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
214264333|NCT01612104|BEHAVIORAL|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
214264334|NCT00418249|DRUG|AS101|
214264335|NCT05049681|DRUG|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
214264336|NCT05049681|DRUG|Apatinib|Apatinib 250mg, q.d.po
214264337|NCT02519218|DEVICE|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
214264338|NCT02528604|PROCEDURE|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
214264339|NCT02528604|PROCEDURE|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
214264340|NCT02528604|PROCEDURE|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
214264341|NCT02528604|DEVICE|Implantable loop recorder|
214264342|NCT01572350|OTHER|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
214264343|NCT01572350|DRUG|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
214264344|NCT01572350|DRUG|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
214264345|NCT01865188|DRUG|LCZ696|Experimental monotherapy doses
214264346|NCT01865188|DRUG|Amlodipine|Active comparator monotherapy doses
214264347|NCT01865188|DRUG|LCZ696 and amlodipine combination|Experimental combination doses
214264348|NCT01865188|DRUG|Placebo|Placebo comparator dose
214264349|NCT01557049|OTHER|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
214264350|NCT01557049|OTHER|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
214264351|NCT01200524|DRUG|AZD2423|20 mg tablet
214264352|NCT01200524|DRUG|AZD2423|50 mg tablet
214264353|NCT01200524|DRUG|Placebo|Placebo
214264354|NCT02758132|BIOLOGICAL|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
214264355|NCT02758132|DRUG|Enzalutamide|160 mg enzalutamide by mouth daily
214264356|NCT02758132|DRUG|Abiraterone|1000 mg abiraterone by mouth daily
214264357|NCT02758132|DRUG|Prednisone|5 mg prednisone by mouth twice daily
214264358|NCT03285854|DIAGNOSTIC_TEST|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
214264359|NCT01801826|DEVICE|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
214264360|NCT04500730|DRUG|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
214264361|NCT00357357|DRUG|HF0220|comparison of different dosages of drug
214264362|NCT01636531|DRUG|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
214264363|NCT01636531|DRUG|gantenerumab|Lyophilized formulation (LyoF), single dose sc
214264364|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
214264365|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
214264366|NCT01001013|DRUG|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
214264367|NCT01457222|BEHAVIORAL|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
214264368|NCT01457222|BEHAVIORAL|Music relaxation|Music relaxation 10 minutes daily
214264369|NCT04970355|BIOLOGICAL|Erenumab|Pre-filled syringe; s.c. injection
214264370|NCT04970355|DRUG|Placebo|Pre-filled syring; s.c. injection
214264371|NCT04206059|RADIATION|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
214264372|NCT04206059|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
214264373|NCT04206059|DIAGNOSTIC_TEST|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
214264374|NCT04206059|OTHER|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
214264375|NCT04206059|OTHER|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
214264376|NCT04206059|OTHER|0 db with QST|sham stimulation (0 dB volume)
214264377|NCT04206059|DRUG|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
214264378|NCT04206059|OTHER|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
214264379|NCT02476201|DEVICE|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
214264380|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
214264381|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
214264382|NCT04212871|OTHER|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
214264383|NCT04212871|OTHER|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
214264384|NCT04212871|OTHER|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
214264385|NCT02585843|DRUG|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
214264386|NCT02585843|DRUG|Spironolactone 25mg|25mg/day of spironolactone
214264387|NCT04524806|OTHER|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
214264388|NCT00628485|DEVICE|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
214264389|NCT00628485|DEVICE|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
214264390|NCT00628485|DEVICE|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
214264391|NCT06276673|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
214264392|NCT00398918|DRUG|zonisamide|zonisamide (100 mg)one time
214264393|NCT00398918|DRUG|Placebo|Placebo Comparator
214264394|NCT02552784|BEHAVIORAL|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
214264395|NCT00371072|PROCEDURE|trabeculectomy with mitomycin-C|
214264396|NCT04123652|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
214819222|NCT04987411|DIAGNOSTIC_TEST|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
214264397|NCT05729230|BEHAVIORAL|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
214264398|NCT06068023|DRUG|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
214264399|NCT06068023|DRUG|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
214264400|NCT00723580|DRUG|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
214819223|NCT04238754|DRUG|Epidiolex|Epidiolex 100 mg/mL Oral Solution
214264401|NCT05875571|DRUG|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
214264402|NCT05875571|DRUG|Placebo|Patients will get IV placebo during IUD placement under sedation
214264403|NCT03429660|OTHER|Medical information|"The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)"
214819224|NCT04238754|DRUG|Placebo|Cherry syrup oral solution
214819225|NCT02362997|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
214264404|NCT02037022|BEHAVIORAL|Pivotal Response Treatment Package (PRT-P)|
214264405|NCT02364492|DRUG|MAG-TN3 + AS15|
214264406|NCT03781843|DRUG|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
214819226|NCT01727947|OTHER|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied \> 13% of nuclear area) in each sample will be assessed.
214819227|NCT00828698|OTHER|No intervention|
214819228|NCT05256147|DRUG|Ibuprofen|Patient will receive ibuprofen 400 mg before the phototherapy session.
214819229|NCT00392847|BEHAVIORAL|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
214819230|NCT00392847|BEHAVIORAL|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
214819231|NCT06087861|RADIATION|External Beam Radiotherapy|Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
214264407|NCT03781843|DRUG|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
214264408|NCT03781843|DRUG|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
214264409|NCT01852305|OTHER|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
214264410|NCT01852305|DEVICE|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
214264411|NCT05629078|DEVICE|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
214264412|NCT02505295|DIETARY_SUPPLEMENT|Selenium|4 vials selenase stat and 2 vials daily for 5 days
214264413|NCT02505295|DRUG|normal saline|Normal saline infusion like intervention group
214264414|NCT03745131|OTHER|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
214264415|NCT06043882|PROCEDURE|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
214656016|NCT04531267|DIETARY_SUPPLEMENT|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
214656017|NCT03607721|DEVICE|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
214656018|NCT06548841|OTHER|Nanobiotechnology platforms|"The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal."
214656019|NCT01136395|DRUG|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
214656020|NCT01136395|PROCEDURE|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
214656021|NCT01136395|PROCEDURE|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
214656022|NCT03744455|BIOLOGICAL|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
214656023|NCT01287663|DRUG|Permethrin impregnated|
214656024|NCT01287663|DRUG|no Permethrin impregnated|
214656025|NCT04118803|DEVICE|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
214656026|NCT00618150|BEHAVIORAL|Patient education|An educational program: Three lessons spaced over 2 weeks.
214656027|NCT03649919|OTHER||Patients receive routine diagnostic and treatment medications.
214656028|NCT00928330|DRUG|GDC-0941|Oral repeating dose
214656029|NCT00928330|DRUG|Trastuzumab|Intravenous repeating dose
214656030|NCT00928330|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
214656031|NCT01802359|DRUG|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
214656032|NCT02491385|PROCEDURE|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
214656033|NCT02491385|DRUG|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
214656034|NCT02492945|DRUG|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
214656035|NCT02492945|DRUG|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
214656036|NCT01157117|BIOLOGICAL|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
214264416|NCT03414281|PROCEDURE|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
214264417|NCT03414281|PROCEDURE|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
214264418|NCT03414281|PROCEDURE|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
214819232|NCT05963178|BEHAVIORAL|Pre-operative counselling|"A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions."
214819233|NCT04702971|DRUG|Flunarizine|The flunarizine will be given per clinical routine
214819234|NCT04702971|OTHER|healthy control|no intervention for healthy control
214264419|NCT02916589|DIETARY_SUPPLEMENT|Diet|
214264420|NCT04709107|OTHER|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
214819235|NCT05070572|DEVICE|Accuryn Monitoring System|Utilization of the Accuryn Monitoring System to measure intraabdominal pressure and urine output during laparoscopic inguinal hernia repair surgery.
214819236|NCT01518972|DRUG|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
214819237|NCT01518972|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
214264421|NCT04709107|OTHER|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
214264422|NCT04061265|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
214264423|NCT04061265|DRUG|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
214264424|NCT01848496|PROCEDURE|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
214264425|NCT04216966|DEVICE|Control group|No intervention was given
214264426|NCT04216966|DEVICE|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
214264427|NCT04216966|DEVICE|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
214264428|NCT04216966|DEVICE|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
214264429|NCT03431870|OTHER|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
214264430|NCT03614364|DRUG|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
214264431|NCT03614364|DRUG|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
214264432|NCT05116215|DRUG|Hydrogen|Hydrogen supplement
214819238|NCT00404105|PROCEDURE|PRK|
214819239|NCT00404105|PROCEDURE|LASIK|
214264433|NCT03094429|DRUG|NaBen®|2000 mg/day or 1000 mg/day, twice daily
214264434|NCT03094429|OTHER|Placebo|0 mg total, twice daily
214819240|NCT00803478|PROCEDURE|LASIK|
214819241|NCT00189293|DRUG|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
214819242|NCT00189293|OTHER|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
214264435|NCT02125968|OTHER|interactive video game|short- and medium-term therapeutic effects
214264436|NCT02125968|OTHER|therapeutic exercise|short- and medium-term therapeutic effects
214264437|NCT02505763|PROCEDURE|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
214264438|NCT05862831|BIOLOGICAL|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
214264439|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
214264440|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
214264441|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
214264442|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
214264443|NCT00491764|DRUG|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
214264444|NCT00491764|DRUG|Placebo|Placebo for 24 weeks.
214264445|NCT05455268|OTHER|eHOPE|"e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations."
214264446|NCT05455268|OTHER|Usual care|Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
214264447|NCT01253473|DRUG|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
214264448|NCT01253473|DRUG|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
214264449|NCT01253473|DRUG|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
214264450|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
214819243|NCT02591927|DRUG|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
214819244|NCT02591927|DRUG|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
214264451|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
214819245|NCT04180280|BEHAVIORAL|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
214819246|NCT04180280|BEHAVIORAL|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
214264452|NCT03888586|DEVICE|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
214264453|NCT03888586|OTHER|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
214819247|NCT06552780|DEVICE|TENs , ultrasound therapy|effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
214819248|NCT01203267|DRUG|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
214819249|NCT04293757|PROCEDURE|Rotational angiography|Preprocedural imaging before ablation
214819250|NCT02272556|OTHER|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
214819251|NCT02272556|OTHER|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
214264454|NCT01282632|DRUG|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
214264455|NCT01282632|DRUG|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
214264456|NCT03720353|DRUG|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
214264457|NCT03720353|DRUG|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
214264458|NCT03720353|DRUG|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
214264459|NCT00821106|PROCEDURE|Right radial|diagnostic or interventional procedures performed through right transradial approach
214819252|NCT03575650|OTHER|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
214819253|NCT01638520|DRUG|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
214819254|NCT01638520|DRUG|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
214264460|NCT00821106|PROCEDURE|left radial|diagnostic or interventional procedures performed through left transradial approach
214264461|NCT03144921|BEHAVIORAL|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
214264462|NCT05532917|OTHER|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
214264463|NCT00001963|PROCEDURE|hemoglobin-transported nitric oxide|
214264464|NCT05140785|DIAGNOSTIC_TEST|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
214819255|NCT05138003|DIAGNOSTIC_TEST|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
214819256|NCT05138003|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
214819257|NCT05138003|DIAGNOSTIC_TEST|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
214264465|NCT04312581|DEVICE|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
214264466|NCT04312581|OTHER|Conventional rehabilitation|physical \& occupational therapy
214264467|NCT00419276|PROCEDURE|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
214264468|NCT01142271|PROCEDURE|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
214264469|NCT01142271|PROCEDURE|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
214264470|NCT01479478|DRUG|Placebo|One placebo capsule daily.
214264471|NCT01479478|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
214264472|NCT05527197|DEVICE|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
214264473|NCT03005145|OTHER|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
214264474|NCT03005145|OTHER|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
214264475|NCT00385710|DRUG|valproic acid|Depakine
214264476|NCT00385710|DRUG|Placebo|Placebo
214264477|NCT00689078|DRUG|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
214264478|NCT00689078|DRUG|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
214264479|NCT00689078|DRUG|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
214264480|NCT00689078|DRUG|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
214264481|NCT01188421|DRUG|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
214264482|NCT01188421|DRUG|Clonidine|up to 0.8 mg per day (oral)
214264483|NCT01188421|DRUG|Tramadol ER|up to 600 mg per day
214264484|NCT01506258|PROCEDURE|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
214264485|NCT01506258|PROCEDURE|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
214264486|NCT05536583|PROCEDURE|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
214264487|NCT03401593|DRUG|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
214264488|NCT06292234|DEVICE|PSI|Fabrication of PSI implants using virtual surgical planning
214264489|NCT06292234|DEVICE|Conventional miniplates|Ready made miniplates
214264490|NCT04312204|DRUG|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
214264491|NCT00171483|DRUG|Tegaserod|
214264492|NCT03954691|OTHER|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
214264493|NCT06310915|DRUG|Navelbine oral,Pembrolizumab|Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks
214264494|NCT01460017|PROCEDURE|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
214264495|NCT01460017|PROCEDURE|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
214264496|NCT03389620|DRUG|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
214264497|NCT05582031|COMBINATION_PRODUCT|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
214819258|NCT05138003|DIAGNOSTIC_TEST|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
214819259|NCT01175018|DRUG|Anakinra|Anakinra 100 mg s.c. daily for 14 days
214819260|NCT01175018|DRUG|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
214819261|NCT03818841|DEVICE|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
214819262|NCT03818841|DEVICE|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
214819263|NCT01308164|DEVICE|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
214264498|NCT01790880|BEHAVIORAL|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
214264499|NCT01790880|BEHAVIORAL|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
214264500|NCT03725852|DRUG|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
214264501|NCT03725852|DRUG|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
214264502|NCT05231681|DIETARY_SUPPLEMENT|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
214264503|NCT05358015|PROCEDURE|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
214264504|NCT05192733|OTHER|Survey|This is a cross-sectional practice survey. There is no intervention.
214264505|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
214264506|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
214264507|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
214264508|NCT04796571|BEHAVIORAL|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
214264509|NCT00116428|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
214264510|NCT00116428|DRUG|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
214264511|NCT00365651|PROCEDURE|Youth Soccer|
214264512|NCT01021579|DRUG|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
214264513|NCT01021579|DRUG|Metfomin plus Simvastatin|
214264514|NCT02387931|DIETARY_SUPPLEMENT|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
214264515|NCT02387931|DIETARY_SUPPLEMENT|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
214264516|NCT02387931|OTHER|Placebo|Placebo capsule, 2 taken daily
214264517|NCT00020774|DRUG|gemcitabine hydrochloride|
214264518|NCT00020774|DRUG|lonafarnib|
214264519|NCT00020774|PROCEDURE|conventional surgery|
214264520|NCT00669396|DRUG|Copper T380 IUD|Copper T380 IUD
214264521|NCT00669396|DRUG|levonorgestrel|1.5 mg
214264522|NCT01222624|DRUG|PankoMab-GEX™|
214264523|NCT04642612|DEVICE|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block"
214264524|NCT00358423|DRUG|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
214819264|NCT00575159|DRUG|GSK189075|investigational drug
214819265|NCT00575159|DRUG|placebo|placebo comparator
214264525|NCT00358423|DRUG|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
214264526|NCT02785484|OTHER|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
214264527|NCT02785484|OTHER|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
214264528|NCT05271071|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
214264529|NCT01297920|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
214264530|NCT01297920|DRUG|Brinzolamide ophthalmic suspension, 1%|
214264531|NCT01297920|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
214264532|NCT00132210|DRUG|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
214264533|NCT02754154|DRUG|Warfarin|
214264534|NCT02754154|DRUG|Apixaban|
214264535|NCT02754154|DRUG|Dabigatran|
214264536|NCT02754154|DRUG|Rivaroxaban|
214264537|NCT00263731|OTHER|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
214264538|NCT05406648|OTHER|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
214264539|NCT00474760|DRUG|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
214264540|NCT02572609|DRUG|Ambroxol hydrochloride soft pastille|
214264541|NCT02572609|DRUG|Mucosolvan ® adult syrup|
214264542|NCT02976792|PROCEDURE|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
214264543|NCT04920344|PROCEDURE|Transoral Surgery|Patients will undergo transoral surgery
214264544|NCT04920344|RADIATION|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
214264545|NCT04920344|DRUG|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
214264546|NCT04920344|PROCEDURE|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
214264547|NCT04920344|OTHER|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
214264548|NCT04920344|OTHER|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
214264549|NCT04920344|OTHER|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
214264550|NCT04920344|OTHER|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
214264551|NCT04920344|DIAGNOSTIC_TEST|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
214264552|NCT02145585|DEVICE|Test of pharmacologic anesthesia robot (labVIEW® software)|
214264553|NCT02942927|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
214264554|NCT01848704|BEHAVIORAL|interpretation of the abstract|
214264555|NCT03086278|DRUG|AST-008|AST-008 is a toll-like receptor 9 agonist.
214264556|NCT05840731|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
214264557|NCT05840731|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
214264558|NCT04924959|OTHER|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
214264559|NCT02503410|BEHAVIORAL|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
214264560|NCT02503410|BEHAVIORAL|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
214264561|NCT04206800|DIAGNOSTIC_TEST|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
214656037|NCT01157117|BIOLOGICAL|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
214656038|NCT01157117|DRUG|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
214656039|NCT00002586|DRUG|13-cis retinoic acid|
214656040|NCT00002586|DIETARY_SUPPLEMENT|Tocopherol|
214264562|NCT06556472|DRUG|Terlipressin|1\. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
214264563|NCT06556472|DRUG|Norephrine|1\. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
214264564|NCT02773290|BIOLOGICAL|Romiplostim|Weekly SC administration
214264565|NCT05458934|OTHER|No intervention|no intervention
214264566|NCT02477969|DRUG|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
214264567|NCT02477969|DRUG|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
214819266|NCT02842632|OTHER|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
214819267|NCT02842632|OTHER|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
214264568|NCT02477969|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
214264569|NCT02477969|DRUG|Metformin|0.5mg,oral,tid.
214819268|NCT00006256|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
214264570|NCT03687112|OTHER|non ontervention / observational study|non intervention
214264571|NCT00202059|DRUG|Zoledronic acid|
214264572|NCT00202059|BEHAVIORAL|Physical activity intervention|
214264573|NCT03814473|OTHER|Diet|"Participants provided with a brochure providing a thorough description of the diet, \~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
214819269|NCT00006256|PROCEDURE|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
214819270|NCT00006256|RADIATION|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
214819271|NCT04374487|DRUG|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
214819272|NCT04374487|OTHER|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
214264574|NCT06382831|DRUG|Dexmedetomidine|Opioid free anesthesia
214264575|NCT06382831|DRUG|Fentanyl|Control given Opioid balanced anesthesia
214264576|NCT02155881|DRUG|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
214264577|NCT02155881|DRUG|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
214264578|NCT02188771|DEVICE|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
214264579|NCT02028312|DRUG|Loteprednol etabonate|
214264580|NCT02028312|DRUG|Artificial Tears|
214264581|NCT02028312|DRUG|Restasis|
214264582|NCT03845751|DRUG|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
214264583|NCT02935231|DRUG|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
214264584|NCT02935231|BEHAVIORAL|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
214264585|NCT02935231|OTHER|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
214264586|NCT06157255|DRUG|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
214264587|NCT06157255|DRUG|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
214264588|NCT06157255|DRUG|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
214264589|NCT04548037|OTHER|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
214264590|NCT02969330|DEVICE|Stimulator|
214264591|NCT02969330|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose
214264592|NCT06557824|OTHER|speleotherapeutic intervention|In the study, medical records of 415 Czech children diagnosed with bronchial asthma who took part in speleotherapeutic intervention between January 2022 and October 2023 were analysed.
214264593|NCT05342792|DRUG|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
214264594|NCT05342792|DRUG|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
214264595|NCT05123196|DRUG|MT-8554|Oral Capsule
214264596|NCT05123196|DRUG|Placebo|Oral Capsule
214264597|NCT02526446|BEHAVIORAL|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
214264598|NCT02526446|OTHER|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
214264599|NCT01987635|DEVICE|MEMO 3D ring|The experimental MEMO 3D ring is placed.
214264600|NCT01987635|DEVICE|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
214264601|NCT01987635|PROCEDURE|3D Echocardiography|
214264602|NCT05379777|DRUG|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
214264603|NCT00066729|BIOLOGICAL|NY-ESO-1 peptide vaccine|NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
214264604|NCT05824988|OTHER|Drug exposure|Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
214264605|NCT00446420|DRUG|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
214264606|NCT01435902|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
214264607|NCT01435902|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
214819273|NCT05990907|PROCEDURE|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
214819274|NCT03807037|DIETARY_SUPPLEMENT|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
214819275|NCT03807037|DRUG|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
214819276|NCT02788240|DRUG|Peg GCSF|
214819277|NCT02788240|BIOLOGICAL|20% Albumin|
214819278|NCT02788240|DIETARY_SUPPLEMENT|Nutrition|
214819279|NCT02788240|OTHER|Bowel wash|
214819280|NCT02788240|DRUG|Terlipressin 1- 4mg,if indicated|
214819281|NCT02788240|DRUG|Meropenem or Imepenem, if indicated|
214819282|NCT02788240|DRUG|Placebo|
214819283|NCT04022954|DEVICE|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
214819284|NCT02224742|DEVICE|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
214819285|NCT02224742|OTHER|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~* Formal assessment of ulcer and surrounding skin~* Provision of any necessary off-loading~* Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~* Appropriate dressing products~* Appropriate antibiotic therapy~* Nutrition and self care~* Optimal glycaemic control~* Revascularisation if deemed clinically necessary~* Continued close observation"
214819286|NCT05841628|DEVICE|532 nm laser treatment|The port wine birthmark will be treated with the DermaV 532 nm laser.
214819287|NCT04530994|DRUG|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
214819288|NCT05170607|DIAGNOSTIC_TEST|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
214264608|NCT00000209|DRUG|Buprenorphine|
214264609|NCT04361825|DRUG|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
214264610|NCT03189420|PROCEDURE|Tumor resection|The tumors will be resected in routine therapeutic surgeries
214264611|NCT02298231|OTHER|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
214264612|NCT02298231|OTHER|Mystic Isle Balance Intervention|Balance therapy using virtual reality
214264613|NCT02298231|OTHER|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
214264614|NCT00704678|DRUG|SBR759|1g tid
214264615|NCT00704678|DRUG|Sevelamer HCl|1.6 g tid
214264616|NCT00704678|DRUG|Sevelamer HCl|1.5 g tid
214264617|NCT00704678|DRUG|Sevelamer HCl|0.8 g tid
214264618|NCT06557252|BEHAVIORAL|PDCA training|Improve diagnostic rate
214264619|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 500mg tablet, orally once on Day 1
214264620|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 750mg tablet, orally once on Day 1
214264621|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
214264622|NCT06473948|DRUG|Placebo|Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
214264623|NCT01811225|DRUG|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
214264624|NCT01811225|DRUG|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
214264625|NCT00276497|DRUG|Pioglitazone|
214264626|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
214264627|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
214264628|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
214264629|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
214264630|NCT02789631|OTHER|assessment|
214264631|NCT04216121|RADIATION|Local ablative therapy|Stereotactic body radiotherapy
214264632|NCT04216121|PROCEDURE|Local ablative therapy|Surgery
214264633|NCT04344548|BIOLOGICAL|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
214264634|NCT00137215|DEVICE|Silverlon|dressing for donor site mamagement
214264635|NCT03883360|DRUG|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
214264636|NCT03883360|DRUG|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
214264637|NCT02397031|BEHAVIORAL|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
214264638|NCT02397031|BEHAVIORAL|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
214264639|NCT03813043|DRUG|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
214264640|NCT05581966|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
214264641|NCT04955132|BEHAVIORAL|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
214264642|NCT02554942|DRUG|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
214264643|NCT01816529|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
214264644|NCT01816529|DRUG|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
214264645|NCT01816529|DRUG|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
214264646|NCT01816529|DRUG|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
214264647|NCT04992910|DEVICE|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
214264648|NCT04992910|OTHER|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
214264649|NCT02158975|DRUG|MLN9708|
214264650|NCT06177522|DRUG|Adebrelimab|1200mg，i.v. , q3w
214264651|NCT06177522|DRUG|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
214264652|NCT06177522|DRUG|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
214264653|NCT02000180|BEHAVIORAL|Progressive Group|
214264654|NCT00265629|DEVICE|RF catheter ablation|RF ablation using mesh device
214264655|NCT02550041|OTHER|T specific response for diagnostic of aspergillus bronchitis|
214264656|NCT06119399|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
214264657|NCT06119399|OTHER|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
214656041|NCT02867696|OTHER|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
214656042|NCT02867696|BEHAVIORAL|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
214656043|NCT04203914|DRUG|Empagliflozin Tablets|Add-on 25mg once daily
214656044|NCT03217851|DIAGNOSTIC_TEST|Blood Collection|blood smear and/or rapid diagnostic
214656045|NCT03217851|DIAGNOSTIC_TEST|Dried Blood Spot|Dried Blood Spot on filter paper
214264658|NCT06119399|OTHER|Doming of the diaphragm|"* The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
214264659|NCT06119399|OTHER|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
214819289|NCT00231829|DRUG|Celecoxib|
214819290|NCT01499147|DRUG|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
214264660|NCT04406220|OTHER|Small clog size|Participants will be randomized to run in small clogs
214264661|NCT04406220|OTHER|Large clog size|Participants will be randomized to run in large clogs
214264662|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
214264663|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
214264664|NCT03948243|DIETARY_SUPPLEMENT|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
214264665|NCT03948243|DRUG|Alprazolam 2 MG|probe substrate
214264666|NCT03948243|DRUG|Caffeine 100 MG|probe substrate
214264667|NCT03948243|DRUG|Tolbutamide 250 mg|probe substrate
214264668|NCT03948243|DRUG|Dextromethorphan 30mg|probe substrate
214264669|NCT03005418|BIOLOGICAL|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
214264670|NCT02840721|DRUG|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
214264671|NCT03636165|DRUG|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
214264672|NCT03636165|DRUG|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
214264673|NCT01967173|DRUG|Flovent Diskus® 100 mcg|Flovent is an ICS
214264674|NCT01967173|DRUG|Flovent Diskus® 250 mcg|Flovent is an ICS
214264675|NCT01967173|DRUG|Flovent Diskus® 500 mcg|Flovent is an ICS
214264676|NCT01967173|DRUG|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
214264677|NCT01967173|DRUG|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
214264678|NCT03468101|OTHER|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
214264679|NCT06149026|OTHER|Physical and nutritional therapy|The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
214819291|NCT01499147|DRUG|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl).
214819292|NCT01499147|DRUG|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
214819293|NCT00242398|DEVICE|AN69 ST|
214819294|NCT03872128|DRUG|Pregnenolone300|300mg
214819295|NCT03872128|DRUG|Pregnenolone500|500mg
214819296|NCT03872128|DRUG|Placebo|placebo
214819297|NCT00550758|DRUG|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
214264680|NCT01868464|BIOLOGICAL|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
214264681|NCT05767125|DEVICE|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
214264682|NCT05767125|DEVICE|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
214264683|NCT04127942|PROCEDURE|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
214264684|NCT05363410|DIETARY_SUPPLEMENT|MagnéVie B6®|micronutrient supplement
214264685|NCT05363410|OTHER|Placebo|placebo supplement
214264686|NCT00842582|DRUG|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
214264687|NCT00842582|DRUG|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
214264688|NCT00842582|DRUG|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
214264689|NCT02772887|DIETARY_SUPPLEMENT|L-Citrulline|amino acid supplement
214264690|NCT02772887|OTHER|Placebo|placebo
214264691|NCT02857582|BIOLOGICAL|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
214264692|NCT02857582|DRUG|Vancomycin|Active comparator to treatment with ACHIM
214264693|NCT02857582|DRUG|Metronidazole|Primary treatment for C diff in all treatment arms
214264694|NCT05531331|BEHAVIORAL|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
214819298|NCT00550758|DEVICE|spirometry|spirometry
214264695|NCT00423514|BIOLOGICAL|filgrastim|
214819299|NCT02080663|PROCEDURE|Proximal row carpectomy|
214819300|NCT00492076|BIOLOGICAL|Pangramin Plus D. pteronyssinus 100%|"1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo"
214819301|NCT03557541|DIETARY_SUPPLEMENT|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
214819302|NCT03557541|DIETARY_SUPPLEMENT|Control|They received a common T2D-preventive diet
214819303|NCT06038253|DEVICE|Fibroscan|Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients
214264696|NCT00423514|DRUG|clofarabine|
214264697|NCT00423514|DRUG|melphalan|
214264698|NCT00423514|DRUG|mycophenolate mofetil|
214264699|NCT00423514|DRUG|tacrolimus|
214264700|NCT00423514|DRUG|thiotepa|
214264701|NCT00423514|PROCEDURE|allogeneic bone marrow transplantation|
214264702|NCT00423514|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214264703|NCT00423514|PROCEDURE|peripheral blood stem cell transplantation|
214264704|NCT02623140|DEVICE|Biofreedom|PCI with Biofreedom stent
214264705|NCT02623140|DEVICE|Orsiro|PCI with Orsiro stent
214264706|NCT04111575|BEHAVIORAL|Music Therapy|Music Therapy
214264707|NCT00003591|DRUG|paclitaxel|
214264708|NCT00003591|RADIATION|radiation therapy|
214264709|NCT00310648|BIOLOGICAL|Influenza vaccine|
214264710|NCT06201663|DRUG|Romiplostim|Weekly subcutaneous injections
214264711|NCT01462643|DRUG|LAS41004|once daily, topical ointment, 100 microgram per day
214819304|NCT00882505|DIETARY_SUPPLEMENT|vitamin D|Subject will receive vitamin d supplements
214819305|NCT00882505|OTHER|Placebo|Subject will receive a placebo.
214819306|NCT03442530|BEHAVIORAL|ToPIC|Expanded tobacco cessation counseling for pregnant women.
214819307|NCT03442530|BEHAVIORAL|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
214819308|NCT02199873|DRUG|BIIX 1 XX - single rising dose|
214819309|NCT02199873|DRUG|Placebo|
214819310|NCT06121973|BEHAVIORAL|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
214819311|NCT03986801|OTHER|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
214264712|NCT03569085|DRUG|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
214264713|NCT03569085|DRUG|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
214264714|NCT00607984|DRUG|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
214264715|NCT04330274|OTHER|Bipedal with open eyes|Standing bipedal with open eyes on force platform
214264716|NCT04330274|OTHER|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
214264717|NCT04330274|OTHER|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
214264718|NCT04330274|OTHER|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
214264719|NCT04433663|OTHER|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
214264720|NCT05727436|DIETARY_SUPPLEMENT|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
214264721|NCT05727436|DIETARY_SUPPLEMENT|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
214819312|NCT00556322|DRUG|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
214819313|NCT00556322|DRUG|erlotinib [Tarceva]|150mg po daily
214819314|NCT03733444|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
214819315|NCT03733444|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
214819316|NCT04229225|DRUG|UBX0101|Investigational drug intra-articular (IA) injection
214819317|NCT04229225|OTHER|Placebo|Placebo intra-articular (IA) injection
214264722|NCT02437812|DRUG|Metformin|Metformin with standard chemotherapy
214264723|NCT02437812|DRUG|Paclitaxel|Standard chemotherapy
214264724|NCT02437812|DRUG|Carboplatin|Standard chemotherapy
214264725|NCT01132365|DEVICE|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
214264726|NCT04872400|DRUG|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
214264727|NCT04872400|DRUG|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
214264728|NCT03596008|DIETARY_SUPPLEMENT|Active drink|The freeze-dried strawberry powder (25 g) in active drink
214264729|NCT03596008|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink
214264730|NCT03685123|BEHAVIORAL|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
214264731|NCT03685123|BEHAVIORAL|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
214264732|NCT03685123|BEHAVIORAL|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
214264733|NCT01823302|DIETARY_SUPPLEMENT|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
214264734|NCT01823302|OTHER|nutritional counseling|nutritional counseling
214264735|NCT02416219|PROCEDURE|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
214264736|NCT02416219|DEVICE|Ultrasound|
214264737|NCT03555760|BEHAVIORAL|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
214264738|NCT00400764|DRUG|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
214264739|NCT00400764|DRUG|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
214264740|NCT05351021|DRUG|Metformin|cidophage 850 gm twice daily
214264741|NCT05351021|DRUG|Placebo|placebo twice daily for treatment period
214264742|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
214264743|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
214264744|NCT04042896|BEHAVIORAL|exergame|Exergame is 'exercise + game'.
214264745|NCT04042896|BEHAVIORAL|treadmill exercise|traditional aerobic exercise
214264746|NCT03439917|DIETARY_SUPPLEMENT|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
214264747|NCT03439917|DIETARY_SUPPLEMENT|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
214264748|NCT03439917|DIETARY_SUPPLEMENT|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
214264749|NCT05095038|DIETARY_SUPPLEMENT|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
214264750|NCT05095038|DIETARY_SUPPLEMENT|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
214264751|NCT02195336|DEVICE|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
214264752|NCT02195336|DRUG|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
214264753|NCT02195336|DRUG|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
214264754|NCT03308955|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
214264755|NCT03308955|PROCEDURE|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
214264756|NCT03308955|PROCEDURE|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
214264757|NCT00270335|DRUG|Propofol|
214264758|NCT04234360|DRUG|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
214264759|NCT04234360|DRUG|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
214264760|NCT02628938|OTHER|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
214264761|NCT02628938|OTHER|Miswak stick|Miswak stick twice a day for 7 days
214264762|NCT02628938|OTHER|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
214264763|NCT00529334|RADIATION|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
214264764|NCT02239588|OTHER|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
214264765|NCT03064750|BEHAVIORAL|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
214819318|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
214819319|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
214264766|NCT03064750|OTHER|Waiting list|patients wait as usual until surgery without special treatment.
214264767|NCT03585062|DRUG|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
214264768|NCT03585062|DRUG|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
214264769|NCT02735408|OTHER|Kinesiotape (KT)|
214264770|NCT03113916|BEHAVIORAL|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
214264771|NCT00183989|DRUG|Fludarabine, Mitoxantrone and Rituximab|
214264772|NCT01790854|DRUG|Prasugrel dose 5 mg/day|
214264773|NCT01790854|DRUG|Prasugrel dose 10 mg/day|
214264774|NCT04539353|OTHER|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
214264775|NCT04539353|OTHER|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
214264776|NCT02029170|PROCEDURE|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
214264777|NCT02029170|PROCEDURE|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
214264778|NCT05252455|BEHAVIORAL|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
214264779|NCT00246623|DRUG|Exubera (inhaled insulin)|
214264780|NCT00246623|PROCEDURE|8-point glucose diary (to assess pre- and post prandial glucoses)|
214819320|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
214819321|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
214819322|NCT01756326|DRUG|PREOB® Implantation|
214819323|NCT01756326|PROCEDURE|Bone Autograft|
214819324|NCT05947591|BEHAVIORAL|foot posture index|the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
214819325|NCT01899755|DRUG|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
214819326|NCT01899755|DRUG|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
214819327|NCT01899755|DRUG|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
214264781|NCT00246623|PROCEDURE|Meal Tolerance Test|
214264782|NCT00246623|PROCEDURE|24-hour continuous glucose monitoring (at select sites)|
214264783|NCT00246623|PROCEDURE|Pulmonary Function Testing|
214264784|NCT00246623|PROCEDURE|Hypoglycemic Event Monitoring|
214264785|NCT00246623|PROCEDURE|Laboratory Assessments|
214264786|NCT00246623|BEHAVIORAL|Nutritional Counseling and Diabetes Education|
214264787|NCT00241358|DRUG|AMD3100|
214264788|NCT00241358|PROCEDURE|Stem Cell Transplant|
214264789|NCT04296110|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
214264790|NCT04296110|OTHER|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
214264791|NCT00154557|BEHAVIORAL|elite judo athletes program|
214264792|NCT04036019|BIOLOGICAL|CD20-directed CAR-T cells with CliniMACS Prodigy® system|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
214264793|NCT06021288|OTHER|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
214264794|NCT05807230|BEHAVIORAL|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
214264795|NCT02866708|DEVICE|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
214264796|NCT02000934|DRUG|TAK-659|TAK-659 tablet
214264797|NCT03042325|DRUG|Alogliptin|Alogliptin tablets
214264798|NCT04597775|DRUG|hydroxychloroquine|hydroxychloroquine
214264799|NCT05101642|PROCEDURE|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
214264800|NCT01758523|DRUG|Dutasteride|
214264801|NCT01758523|DRUG|sugar pill|
214264802|NCT00621959|DRUG|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
214264803|NCT00621959|DRUG|placebo|0mg (matching oral tablet)for 14 days
214264804|NCT03465358|OTHER|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
214264805|NCT02985437|DRUG|Surfactants|
214264806|NCT02985437|DRUG|Saline Solution|
214264807|NCT05522452|OTHER|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
214264808|NCT05522452|OTHER|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
214264809|NCT00590135|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
214264810|NCT02398396|BIOLOGICAL|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
214264811|NCT01847742|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|
214264812|NCT06263556|BEHAVIORAL|Pelvic floor exercises|"Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day"
214264813|NCT06263556|DEVICE|Transcutaneous posterior tibial nerve stimulation|Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
214264814|NCT06263556|DEVICE|Sham stimulation|Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
214264815|NCT05100901|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
214264816|NCT02486523|BEHAVIORAL|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
214264817|NCT02486523|DEVICE|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
214264818|NCT02486523|BEHAVIORAL|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
214264819|NCT02486523|BEHAVIORAL|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
214264820|NCT02486523|PROCEDURE|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
214264821|NCT01363648|DRUG|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
214264822|NCT01363648|DRUG|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
214264823|NCT00041288|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214264824|NCT00041288|DRUG|cyclophosphamide|
214264825|NCT00041288|DRUG|cyclosporine|
214264826|NCT00041288|DRUG|fludarabine phosphate|
214264827|NCT00041288|DRUG|methotrexate|
214264828|NCT00041288|DRUG|mycophenolate mofetil|
214264829|NCT00041288|DRUG|tacrolimus|
214264830|NCT00041288|PROCEDURE|peripheral blood stem cell transplantation|
214264831|NCT00041288|RADIATION|radiation therapy|
214264832|NCT03439657|BIOLOGICAL|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
214264833|NCT03439657|BIOLOGICAL|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
214264834|NCT02592525|BEHAVIORAL|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
214264835|NCT03012009|DEVICE|full ablative CO2 laser|ablation to the level of de dermal papilla
214264836|NCT03012009|DEVICE|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
214264837|NCT03012009|DRUG|MAL|
214264838|NCT03012009|DEVICE|LED lamp|peak wavelength 630 nm, 37J/cm2
214264839|NCT03012009|DRUG|lidocaine hydrochloride 2% with epinephrine|
214264840|NCT06045780|OTHER|nothing|disease
214264841|NCT02245984|OTHER|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
214264842|NCT02245984|OTHER|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
214264843|NCT03526575|DRUG|Zolpidem|
214264844|NCT03477136|DIAGNOSTIC_TEST|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
214264845|NCT02401022|DRUG|AZD8529|comparison of different dosages of drug
214264846|NCT00061477|DRUG|Pemetrexed|
214264847|NCT00061477|DRUG|Gemcitabine|
214264848|NCT04214171|DIAGNOSTIC_TEST|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
214264849|NCT00065988|DEVICE|Dispersed phase amalgam restoration /composite restoration|
214264850|NCT04980781|BEHAVIORAL|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
214264851|NCT04980781|PROCEDURE|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
214264852|NCT03417323|OTHER|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
214264853|NCT03805425|RADIATION|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
214656046|NCT00093236|PROCEDURE|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
214656047|NCT00093236|PROCEDURE|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
214656048|NCT01976949|BEHAVIORAL|online social-networking intervention|
214656049|NCT06327230|PROCEDURE|Thoracic Epidural Analgesia|Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
214656050|NCT05179616|PROCEDURE|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
214656051|NCT00135980|BEHAVIORAL|professional audit and feedback|
214656052|NCT00135980|BEHAVIORAL|integrated care programmes|
214656053|NCT03251885|OTHER|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
214656054|NCT05957887|DRUG|Dapagliflozin|Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
214656055|NCT03859284|OTHER|flowable resin composite|gold standard
214656056|NCT03859284|OTHER|self adhering flowable|moist bonding self adhering flowable composite
214656057|NCT03859284|OTHER|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
214656058|NCT06156527|DRUG|Lazertinib|Lazertinib 240mg, QD, daily
214264854|NCT02885207|BIOLOGICAL|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
214264855|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
214264856|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
214264857|NCT04032652|PROCEDURE|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
214264858|NCT04032652|DRUG|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
214264859|NCT04330053|OTHER|Experimental|"* Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
214264860|NCT04330053|OTHER|Control|"* Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
214264861|NCT04250922|DRUG|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
214264862|NCT04250922|DRUG|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
214264863|NCT04250922|RADIATION|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
214264864|NCT00646074|BEHAVIORAL|Self-Care Talk|6 conversational sessions
214264865|NCT01152983|DEVICE|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
214264866|NCT02394483|DRUG|F901318 safety|Safety assessments
214819328|NCT01788423|DEVICE|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
214264867|NCT02394483|DRUG|F901318 tolerability|Tolerability assessments
214264868|NCT02394483|DRUG|F901318 pharmacokinetics|Pharmacokinetic assessments
214264869|NCT02394483|OTHER|Placebo safety|Safety assessments
214264870|NCT02394483|OTHER|Placebo tolerability|Placebo tolerability
214264871|NCT02394483|OTHER|Placebo pharmacokinetics|Plaacebo pharmacokinetics
214264872|NCT03960814|DRUG|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
214264873|NCT01864941|PROCEDURE|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
214819329|NCT03637764|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214819330|NCT03637764|DRUG|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214819331|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine|Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
214819332|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine|Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
214819333|NCT03911037|DRUG|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
214819334|NCT03911037|DRUG|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
214819335|NCT01660945|DRUG|placebo|
214264874|NCT01864941|DEVICE|Catheter venography with balloon venoplasty and balloon|
214264875|NCT02351999|DEVICE|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
214264876|NCT04686214|PROCEDURE|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
214264877|NCT06556901|OTHER|retrospective study about reasons for consultations|retrospective study about reasons for consultations
214264878|NCT00502944|BEHAVIORAL|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
214264879|NCT00502944|BEHAVIORAL|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
214264880|NCT02655133|DRUG|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
214264881|NCT02655133|DRUG|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
214264882|NCT03999177|BEHAVIORAL|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
214264883|NCT05073601|DIAGNOSTIC_TEST|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (\> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
214264884|NCT00417118|DRUG|Saredutant|oral administration (capsules)
214264885|NCT00417118|DRUG|Escitalopram|oral administration (capsules)
214264886|NCT00417118|DRUG|Placebo|oral administration (capsules)
214264887|NCT01590459|DRUG|VX-509|50 mg oral tablet
214264888|NCT01590459|DRUG|VX-509 matching placebo|0 mg oral tablet
214264889|NCT00037804|DRUG|Irinotecan|
214264890|NCT03820271|OTHER|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
214264891|NCT01203631|DRUG|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
214264892|NCT01203631|DRUG|Placebo|A single dose administered subcutaneously (s.c., under the skin)
214264893|NCT00289016|DRUG|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
214264894|NCT05462483|OTHER|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
214264895|NCT01951937|DIETARY_SUPPLEMENT|Fish Meals|Meals containing salmon
214264896|NCT01951937|DIETARY_SUPPLEMENT|Placebo|No fish meals
214656059|NCT06156527|DRUG|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
214656060|NCT01916278|DEVICE|Emervel Lips Lidocaine|
214656061|NCT01916278|DEVICE|Juvéderma Volbella with Lidocaine|
214656062|NCT00064922|BEHAVIORAL|Behavior Therapy|
214656063|NCT01110187|DRUG|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
214656064|NCT01110187|DRUG|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
214656065|NCT05100537|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
214656066|NCT05100537|OTHER|continuing a routine life|No intervention will be made in the control group.
214656067|NCT03954626|BIOLOGICAL|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
214656068|NCT04424563|DEVICE|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
214656069|NCT04424563|DRUG|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
214656070|NCT04424563|DRUG|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
214656071|NCT03862027|DEVICE|Esophageal Balloon catheter|"Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
214264897|NCT04412434|DIAGNOSTIC_TEST|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
214264898|NCT04209192|DRUG|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
214264899|NCT04209192|DRUG|Amikacin|Is the prophylactic drug which will be used in the control group.
214264900|NCT05393674|DRUG|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
214819336|NCT01660945|DRUG|vytorin|
214264901|NCT05393674|DRUG|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
214264902|NCT01214343|DRUG|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
214264903|NCT01214343|DRUG|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
214264904|NCT03097913|DEVICE|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
214264905|NCT00555451|DRUG|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
214264906|NCT03549169|BEHAVIORAL|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
214264907|NCT03549169|BEHAVIORAL|Regular attention|Regular attention focused on education for therapeutic adherence
214264908|NCT03854188|PROCEDURE|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
214264909|NCT01209728|OTHER|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
214264910|NCT02764697|DRUG|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
214264911|NCT02511990|BIOLOGICAL|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
214264912|NCT02511990|BIOLOGICAL|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
214264913|NCT02511990|BIOLOGICAL|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
214264914|NCT04410029|OTHER|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
214264915|NCT04410029|OTHER|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
214264916|NCT03866460|DIAGNOSTIC_TEST|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
214264917|NCT00302107|DRUG|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
214264918|NCT00302107|DRUG|Placebo|Look-a-like placebo tablets under double-blind conditions
214656072|NCT02573116|PROCEDURE|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
214264919|NCT01790932|DRUG|BKM120|
214264920|NCT06404671|PROCEDURE|Delayed interval cytoreductive surgery (DICS)|"patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
214264921|NCT06404671|PROCEDURE|Early interval cytoreductive surgery (EICS)|"patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
214656073|NCT00750984|PROCEDURE|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
214656074|NCT00750984|PROCEDURE|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
214264922|NCT04223973|DEVICE|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM (Continuous Glucose Measurement)
214819337|NCT06302127|OTHER|Team-based care|The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
214819338|NCT06302127|PROCEDURE|Risk-stratified care pathway|Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
214264923|NCT04223973|BIOLOGICAL|Lab A1C|Measure of Lab A1C at baseline and end of study
214264924|NCT06966544|OTHER|Conventional Physiotherapy|"All subjects to be included in our study were evaluated before and after treatment by a physiotherapist acting as a blinded evaluator. In the treatment, conventional physiotherapy approaches are applied twice a week for 8 weeks by the physiotherapist conducting the thesis study. In parallel with the initial evaluation, an individualized conventional physiotherapy program is created according to the functional status of the children and the severity and type of the affected area.~The main topics of this program consist of the following: Normal range of motion exercises for shoulder, elbow, wrist and fingers, strengthening exercises for scapulothoracic, shoulder, elbow, hand-wrist joints in all directions, stretching exercises for shoulder, elbow, wrist, fingers (to be selected depending on the patient's involvement), scapulothoracic mobilization, glenohumeral mobilization and elbow according to possible limitations, hand-wrist joint mobilization techniques (myofascial release, gliding"
214264925|NCT06966544|OTHER|Graded Motor Imagery|"All approaches applied to the conventional physiotherapy group are applied to this group in the same manner and duration (8 weeks-twice a week). However, in addition to conventional physiotherapy, progressive motor imagery (AMI) training program is being applied twice a week for 8 weeks.~In the GMI program, in addition to this program, components of GMI training will be applied to sequentially activate cortical motor networks and improve cortical organization. These are;~* Laterality training with the help of visuals selected in the first stage (0-2 weeks)~* In the second stage, motor imagery activities designed in the form of scenarios to be developed specifically for motor activity deficiencies seen in OBPY (2-5 weeks)~* In the third stage, a mirror therapy program will be prepared (5-8 weeks)."
214264926|NCT05456009|OTHER|No intervention|No intervention
214264927|NCT04908709|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
214264928|NCT04908709|DEVICE|Proton Therapy|Target volume treatment
214264929|NCT02573688|BEHAVIORAL|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
214264930|NCT06045884|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
214264931|NCT06045884|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
214264932|NCT06045884|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
214264933|NCT05768919|DRUG|Treatment Period 1|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
214264934|NCT05768919|DRUG|Treatment Period 2|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
214264935|NCT05768919|DRUG|Treatment Period 3|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
214264936|NCT05768919|DRUG|Treatment Period 4a|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
214264937|NCT04899102|BEHAVIORAL|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
214264938|NCT03630042|DRUG|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
214264939|NCT03630042|DRUG|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
214264940|NCT05598385|PROCEDURE|Open cannulation|A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
214264941|NCT05598385|PROCEDURE|Percutaneous cannulation|Cannulation is performed through a suture-mediated closure system.
214264942|NCT04210323|DEVICE|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
214264943|NCT04210323|DEVICE|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
214264944|NCT01135290|DRUG|Aquaphor|
214264945|NCT01135290|DRUG|HP828-101|
214264946|NCT02748473|OTHER|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
214264947|NCT02748473|OTHER|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
214264948|NCT02748473|OTHER|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
214264949|NCT03025009|DRUG|LY3192767|Administered SC.
214264950|NCT03025009|DRUG|Basal Insulin Peglispro|Administered SC.
214264951|NCT03025009|DRUG|Insulin Glargine|Administered SC.
214264952|NCT03025009|DRUG|Placebo|Administered SC.
214264953|NCT04549961|OTHER|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
214264954|NCT05220917|DRUG|SGLT2 inhibitor|Any SGLT2i dispensing claim
214264955|NCT05220917|DRUG|DPP-4 inhibitor|Any DPP-4 inhibitor claim
214264956|NCT05220917|DRUG|GLP-1RA|Any SGLT2i dispensing claim
214264957|NCT05220917|DRUG|2nd generation SU|Any 2nd generation SU claim
214264958|NCT05338359|BIOLOGICAL|Blood sample|Blood sample of 34 mL
214264959|NCT05338359|OTHER|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
214264960|NCT02325648|DRUG|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
214264961|NCT02890095|PROCEDURE|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~* 1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* 1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
214264962|NCT02890095|PROCEDURE|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~* measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
214264963|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by three human doctors|This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.
214264964|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264965|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214656075|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
214656076|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
214656077|NCT02749214|OTHER|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
214264966|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264967|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264968|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (with search capabilities)|This intervention involves answering patient inquiries by Claude instant with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264969|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (without search capabilities)|This intervention involves answering patient inquiries by Claude instant without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264970|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (with search capabilities)|This intervention involves answering patient inquiries by Claude 2 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264971|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (without search capabilities)|This intervention involves answering patient inquiries by Claude 2 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264972|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (with search capabilities)|This intervention involves answering patient inquiries by Gemini Pro with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214819339|NCT06302127|BEHAVIORAL|Strengthened health education|The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
214819340|NCT06302127|OTHER|Financial incentives for integration of care|Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
214819341|NCT06302127|OTHER|Supporting health information system|A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.
214264973|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (without search capabilities)|This intervention involves answering patient inquiries by Gemini Pro without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
214264974|NCT05847283|PROCEDURE|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
214264975|NCT05847283|PROCEDURE|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
214264976|NCT06562803|DEVICE|double plasma cytokine adsorption system with sequential low-dose plasma exchange|"Both groups received comprehensive medical treatment, including antiviral therapy for hepatitis B, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. Artificial liver therapy was initiated for both groups on the day of enrollment, with treatments administered every other day for a total of two sessions.~The experimental group underwent treatment with the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused."
214264977|NCT06562803|OTHER|plasma exchange|Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.
214264978|NCT05985343|DRUG|Neostigmine / Glycopyrrolate|Patients will receive standard of care for reversal of neuromuscular blockade
214264979|NCT05985343|DRUG|Sugammadex|Patients will receive sugammadex for reversal of neuromuscular blockade
214264980|NCT04426812|OTHER|No intervention; just data collection|No intervention; just data collection
214264981|NCT06271538|COMBINATION_PRODUCT|Skal Pro|One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
214264982|NCT06271538|OTHER|Placebo|One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
214264983|NCT02612129|DRUG|arimoclomol|
214264984|NCT02612129|DRUG|Placebo|
214264985|NCT05705648|DIETARY_SUPPLEMENT|medium chain triglyceride oil|Medium chain triglyceride oil
214264986|NCT05705648|DIETARY_SUPPLEMENT|Safflower oil|Safflower oil
214264987|NCT01422252|DEVICE|Vigi'Fall®|Precocious fall detection device
214264988|NCT06608472|DRUG|N0877|1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®
214264989|NCT06608472|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
214264990|NCT00892242|DRUG|Zoledronic acid|
214264991|NCT06668194|DEVICE|Light Force (150g Niti Coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (150g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
214264992|NCT06668194|DEVICE|Heavy Force (400 g Niti coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (400g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
214264993|NCT05764408|DEVICE|traxi® Panniculus Retractor|traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
214264994|NCT06680336|DIAGNOSTIC_TEST|Mulit-componant neuropsychological assessment|Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.
214264995|NCT06680336|DIAGNOSTIC_TEST|Multimodal MRI|Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
214264996|NCT06680466|DRUG|YZJ-4729|Dose Group 1
214264997|NCT06680466|DRUG|morphine|morphine,
214264998|NCT06680466|DRUG|placebo|placebo
214264999|NCT06680466|DRUG|YZJ-4729|Dose Group 2
214265000|NCT06680466|DRUG|YZJ-4729|Dose Group 3
214265001|NCT06680466|DRUG|YZJ-4729|Dose Group 4
214265002|NCT06681636|BIOLOGICAL|Human papillomavirus 9-valent vaccine, Recombinant|HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
214265003|NCT06681519|PROCEDURE|Experimental Group 1 - Acupoint Pressure Experimental Group 2 - Pressure Ball Control Group - Conventional Treatment|"Interventions Group 1 - Acupoint Pressure Group 2 - Hand-Held Pressure Ball Control Group 3 - Conventional Treatment Other Names: Stress ball holding, acupoint pressure, conventional treatment~Description: Before the intervention, subjects completed a pre-test. Afterward, they assumed a relaxed, comfortable lying position. The examiner applied acupoint pressure at four specific points: Hegu (LI4), Shenmen (HT7), Neiguan (PC6), and Zhongchong (PC9).~The technique involves using the thumb pad to apply circular and vertical pressure on each acupoint, with the other four fingers stabilizing against the skin to ensure even pressure. The pressure is gradually increased from light to moderate until the patient experiences sensations of soreness, numbness, or swelling, commonly described as deqi (Ye Meiling et al., 2020).~Each acupoint is pressed vertically for 3 seconds, then rotated clockwise at a rate of 2-3 rotations per second for another 3 second"
214265004|NCT05730699|BIOLOGICAL|divozilimab|anti-CD20 monoclonal antibody
214265005|NCT03419611|BEHAVIORAL|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
214265006|NCT03419611|OTHER|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
214265007|NCT03419611|BEHAVIORAL|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
214265008|NCT06681038|DRUG|Standard Medical Therapy|"Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses."
214265009|NCT06681038|PROCEDURE|PIPAC|"In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks."
214265010|NCT06680947|DRUG|610|Subcutaneously injection.
214265011|NCT06680947|DRUG|610|Subcutaneously injection.
214265012|NCT06680947|DRUG|Placebo|Subcutaneously injection.
214265013|NCT06708481|DRUG|P11-4, a self-assembling peptide|rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
214265014|NCT06708481|DRUG|P11-4, a self-assembling peptide with flouride|self assembling peptide with 500 ppm sodium fluoride
214265015|NCT06708481|DRUG|resin infilteration|Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion
214819342|NCT00224718|PROCEDURE|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
214819343|NCT00224718|PROCEDURE|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
214819344|NCT05836454|OTHER|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
214265016|NCT06710327|DRUG|Tranexamic Acid (IV)|The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.
214265017|NCT06710327|DRUG|Placebo|Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
214819345|NCT05836454|OTHER|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
214819346|NCT03402906|BEHAVIORAL|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
214819347|NCT00028951|DRUG|fibrin sealant|
214265018|NCT06709625|PROCEDURE|Transversus thoracis plane block|Transversus thoracis plane block will be applied to provide postoperative analgesia.
214265019|NCT06709625|PROCEDURE|Erector spina plane block (ESP)|Erector spina plane block will be applied to provide postoperative analgesia.
214265020|NCT06708078|OTHER|Follow-up according to the Canhope allied health support program|"The Canhope allied health support program consists in:~* providing information tailored to patients' needs, with a dedicated time for patients to ask questions, obtain answers tailored to their needs, and be aware of the resources available to them;~* organizing peer-patient focus groups.~And aims at:~* reducing anxiety and improving patients' quality of life;~* better taking into account the impact of the announcement of intracranial Aneurysm, and to provide them with specific support.~* managing the emotional consequences of the announcement and the uncertainty of living with an intracranial Aneurysm."
214265021|NCT06709755|BEHAVIORAL|Supporting Teen Problem Solving|STePS is a group-based, teen-focused intervention aimed at reducing diabetes-specific emotional distress and building diabetes resilience. STePS is grounded in both cognitive-behavioral and social problem-solving theories, which recognize the interrelationships among difficult situations, beliefs related to the cause and consequences of those situations, and the emotional and behavioral consequences of those beliefs, and which addresses problem solving strategies that influences ones' adaptive functioning in real-life social settings, distinguishing between problem solving and solution implementation. STePS reduces distress by teaching: 1) emotion regulation, helping teens learn to link beliefs, emotions, and behaviors; to challenge negative thinking by evaluating the accuracy of one's beliefs; and learning new coping skills.2) perspective taking, helping teens learn to identify their own thinking style.
214265022|NCT06709755|BEHAVIORAL|Diabetes Education|Arm Description: The Participants will receive diabetes education directed toward adolescents matching time, group experience and homework assignments, delivered virtually
214265023|NCT06709144|PROCEDURE|SMA lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
214265024|NCT06709144|PROCEDURE|SMV lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
214265025|NCT06000111|BEHAVIORAL|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
214265026|NCT06000111|BEHAVIORAL|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
214265027|NCT06933589|OTHER|Test meal with plant protein|The plant protein blend is made up of 5 protein ingredients for which the food grade is guaranteed: a rice protein isolate, a potato protein isolate, a lupin protein isolate, a corn protein isolate.
214819348|NCT00028951|PROCEDURE|surgical wound closure|
214819349|NCT05814900|DEVICE|Two photon microscopy imaging|Excised tissues will be imaged with two photon microscopy
214819350|NCT04754217|DEVICE|VAVGJ|Replacement of the aortic valve and ascending aorta
214819351|NCT04754217|DEVICE|CAVGJ|Replacement of the aortic valve and ascending aorta
214819352|NCT06615752|DRUG|green tea and quercetin + docetaxel|green tea and quercetin supplements in combination with docetaxel infusion
214819353|NCT06615752|DRUG|Placebo + docetaxel|Placebo will be given along with docetaxel chemotherapy
214819354|NCT06343675|OTHER|There is no intervention|There is no intervention
214819355|NCT02760927|DEVICE|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
214819356|NCT03684330|DIETARY_SUPPLEMENT|Vitamin D|a dose once a week
214819357|NCT03684330|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
214265028|NCT06933589|OTHER|Test meal with milk protein|The milk protein product is a food-grade protein isolate.
214265029|NCT06934772|OTHER|M-TAPA|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
214265030|NCT06934772|OTHER|Subcostal TAP|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
214265031|NCT06169852|DEVICE|Unilateral dual-target (STN/GPi) DBS|Participants will be randomly assigned either DBS stimulation in the STN alone, GPi alone, or a combination of stimulation in the STN and GPi.
214265032|NCT06933251|DRUG|Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy|"1. Neoadjuvant Treatment 1.1 Short-Course Radiotherapy (SCRT) Total Dose: 25 Gy in 5 fractions over 5 days. Interval: 1-week rest before the next stage. 1.2 Chemotherapy and Immunotherapy Regimen: Start 1 week after SCRT with 6 cycles of CAPOX chemotherapy combined with PD-1 inhibitor immunotherapy (3 weeks per cycle).~   1.3 PCSK9 Inhibitor Administration: Subcutaneous injection every 4 weeks during neoadjuvant therapy (6 cycles total).~2. Multidisciplinary Team (MDT) Discussion Timing: 2 weeks after completing neoadjuvant therapy.~Approach:~Patients achieving clinical complete response (cCR): Watch-and-wait strategy. Others: Surgery based on MDT evaluation."
214265033|NCT06934954|BEHAVIORAL|EASE|This is the first time EASE is being used in New York to support youth community mental health.
214265034|NCT06933316|OTHER|the intervention group|the intervention group received additional FIC-based care, including individualized health plans, education, daily care guidance, dietary recommendations, micronutrient supplementation, early intervention, growth monitoring, and vaccination support.
214265035|NCT06933316|OTHER|the control group|Infants receive routine healthcare guidance provided by pediatric healthcare professionals. This includes regular check-ups scheduled via phone appointments, general health consultations, vaccinations according to regulations, and tailored feeding and parenting guidance based on examination results.
214265036|NCT06934135|DEVICE|Bilateral Near-Infrared Transcranial Light Therapy (NIR-TLT)|"The NIR-TLT system consists of a laser console coupled via fiber optics to a custom-designed helmet. The console generates 810 nm near-infrared light, formatted by the helmet into a uniform 12 cm² square beam centered over EEG sites F3 and F4, targeting the dorsolateral prefrontal cortex.~The console supports blinded randomization to one of four groups: three active NIR-TLT doses or sham. Active groups receive group-dependent irradiances for \~7 minutes (429 seconds). The sham is indistinguishable from active treatment, with identical helmet placement, session duration, sounds, and visual cues but no therapeutic NIR light.~Participants receive two or three sessions per week for six weeks, followed by a two-week observation period. The intervention evaluates NIR-TLT's impact on depressive symptoms and explores changes in brain metabolism and neural activity."
214265037|NCT00060515|DRUG|RG2133 (2',3',5'-tri-O-acetyluridine)|
214265038|NCT06071845|DEVICE|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
214265039|NCT06071845|DIAGNOSTIC_TEST|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
214265040|NCT06090331|DIAGNOSTIC_TEST|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
214265041|NCT01059084|DRUG|Valacyclovir|1000 mg tid
214265042|NCT00645112|DRUG|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
214265043|NCT00645112|DRUG|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
214265044|NCT00531934|DRUG|Doxycline|100mg po daily
214265045|NCT00531934|DRUG|erlotinib [Tarceva]|150mg po daily
214265046|NCT04049357|DEVICE|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
214265047|NCT00721500|DEVICE|etafilcon A|contact lens
214265048|NCT00721500|DEVICE|narafilcon A|contact lens
214265049|NCT01543698|DRUG|LGX818|
214265050|NCT01543698|DRUG|MEK162|
214265051|NCT01543698|DRUG|LEE011|
214265052|NCT01429415|DRUG|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
214265053|NCT01429415|DRUG|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
214265054|NCT00150709|DRUG|Levetiracetam|"* Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use"
214265055|NCT06558305|OTHER|blood sample|Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
214265056|NCT02809404|DRUG|Everolimus|
214265057|NCT02975336|DRUG|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
214265058|NCT02975336|DRUG|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
214265059|NCT02975336|DRUG|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
214265060|NCT02975336|DRUG|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
214265061|NCT02975336|DRUG|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
214265062|NCT00808860|DIETARY_SUPPLEMENT|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
214265063|NCT00808860|DIETARY_SUPPLEMENT|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
214265064|NCT06540729|DRUG|Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer|Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
214265065|NCT05517551|PROCEDURE|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
214265066|NCT02806531|BIOLOGICAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
214819358|NCT00974558|DEVICE|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
214819359|NCT04480619|DIAGNOSTIC_TEST|Ga-68-IAC|Clinical management and diagnosis of Metastatic Breast Cancer.
214265067|NCT04058873|DRUG|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
214265068|NCT06209931|PROCEDURE|RIRS|RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
214265069|NCT03862560|OTHER|Strength training program|Strength training program in female soccer players
214265070|NCT02661685|BIOLOGICAL|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
214265071|NCT03033485|RADIATION|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
214265072|NCT04731181|BEHAVIORAL|mobile application (little lovely dentist).|mobile application
214265073|NCT00036829|PROCEDURE|pain therapy|
214265074|NCT06570707|OTHER|Brighter Bites|Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
214265075|NCT02418598|GENETIC|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
214265076|NCT02418598|GENETIC|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
214265077|NCT02082275|OTHER|OB Nest|"* Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires."
214265078|NCT06793540|BEHAVIORAL|SELF POSTUROTHERAPIE|a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.
214265079|NCT05265039|BEHAVIORAL|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
214265080|NCT05265039|BEHAVIORAL|Relaxation Training|Guided relaxation
214265081|NCT05955261|DRUG|Venetoclax|Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
214265082|NCT05955261|DRUG|Azacitidine|Given IV over 30 minutes on days 1-5
214265083|NCT05955261|DRUG|Cytarabine|Given IV over 30 minutes q12 hours on days 1-8 (16 doses)
214265084|NCT05955261|DRUG|Gemtuzumab Ozogamicin|Given IV
214265085|NCT05955261|DRUG|Daunorubicin Hydrochloride|IV over 1 hour on days 1, 3, and 5
214265086|NCT05955261|DRUG|Fludarabine Phosphate|Given IV over 30 minutes on days 1-5
214265087|NCT05955261|DRUG|Idarubicin Hydrochloride|Given IV over 15 minutes on days 3-5
214265088|NCT05955261|DRUG|Mitoxantrone Hydrochloride|IV over 1 hour on days 2-4
214265089|NCT05955261|DRUG|Etoposide|Given IV over 1 hour on days 1-5
214265090|NCT05955261|DRUG|Gilteritinib|PO on days 8-28 (21 doses)
214265091|NCT01884532|DEVICE|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
214265092|NCT02993393|OTHER|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
214265093|NCT02993393|OTHER|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
214265094|NCT03824184|PROCEDURE|manipulation of endometrium|Manipulation of endometrium with saline
214265095|NCT02616848|DRUG|Everolimus|
214265096|NCT02616848|DRUG|Eribulin|
214265097|NCT04785248|PROCEDURE|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
214265098|NCT04120441|BEHAVIORAL|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
214265099|NCT00095992|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
214265100|NCT06261918|PROCEDURE|Influence of metabolic syndrome on the achievement of pathological complete response|The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
214265101|NCT02359422|BEHAVIORAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
214265102|NCT02995031|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
214265103|NCT02995031|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214265104|NCT01127035|BIOLOGICAL|sublingual immunotherapy|
214265105|NCT01127035|BIOLOGICAL|placebo|
214819360|NCT04503278|BIOLOGICAL|CLDN6 CAR-T|administered as an intravenous (i.v.) infusion.
214265106|NCT02371304|RADIATION|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
214265107|NCT02371304|PROCEDURE|Additional TME surgery|
214265108|NCT02371304|DRUG|capecitabine|
214819361|NCT04503278|BIOLOGICAL|CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|administered as an i.v. injection at protocol-specified intervals.
214819362|NCT05107089|DEVICE|Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization
214819363|NCT06382636|BEHAVIORAL|Standard Care|This group will utilize standard care with respect to healthcare provider practices.
214265109|NCT03898258|OTHER|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
214265110|NCT03898258|OTHER|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
214265111|NCT00446615|BEHAVIORAL|computer decision support tool|
214265112|NCT00446615|BEHAVIORAL|audit and feedback|
214265113|NCT00446615|BEHAVIORAL|group learning session|
214265114|NCT00325702|BEHAVIORAL|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
214265115|NCT04042181|DIETARY_SUPPLEMENT|Placebo|standard food grade excipients
214819364|NCT06382636|BEHAVIORAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This group will be exposed to the AI enabled healthcare chatbot.
214819365|NCT06516068|DRUG|HRS-1893|HRS-1893
214265116|NCT04042181|DIETARY_SUPPLEMENT|Bifidobacterium longum|Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
214819366|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner|The hospice and palliative care practitioner will be embedded in one medical intensive care unit for the first half of the study timeframe, after which the practitioner will expand to both medical intensive care units. While active in a medical intensive care unit, the practitioner will proactively trigger palliative care consultations based on clinical criteria and estimated mortality risk, in addition to providing immediate availability for standard-of-care hospice or palliative care consultations.
214265117|NCT03650556|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
214819367|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner (Group Effect)|While the hospice and palliative care practitioner is active in one medical intensive care unit with respect to triggering consultations, the other medical intensive care unit can still utilize the practitioner's services for standard-of-care hospice or palliative care consultations.
214819368|NCT06574672|OTHER|None (Historical)|This control arm includes historical patients admitted to the medical intensive care units prior to the study's enrollment timeframe.
214819369|NCT00424619|DRUG|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
214819370|NCT00424619|DRUG|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
214265118|NCT03253575|DIAGNOSTIC_TEST|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
214819371|NCT00424619|DRUG|Placebo|Placebo, 1 time bolus dose
214819372|NCT02418637|OTHER|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
214819373|NCT05538052|DRUG|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
214819374|NCT05538052|DRUG|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
214819375|NCT05769725|DRUG|Serplulimab|Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
214819376|NCT05769725|DRUG|Docetaxel|40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
214819377|NCT05769725|DRUG|S1|Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
214819378|NCT06462066|PROCEDURE|Experimental medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
214265119|NCT00691301|DRUG|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
214265120|NCT00691301|DRUG|pemetrexed disodium|
214265121|NCT01823146|DRUG|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
214265122|NCT01823146|DRUG|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
214265123|NCT03490708|DRUG|Tranilast|Subjects will be treated with tranilast
214265124|NCT02698878|DIETARY_SUPPLEMENT|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
214265125|NCT02698878|OTHER|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
214265126|NCT02698878|DEVICE|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
214265127|NCT02213640|DEVICE|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
214265128|NCT02213640|DEVICE|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
214265129|NCT00463580|DRUG|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
214265130|NCT00463580|DRUG|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
214265131|NCT02624674|DEVICE|Multi-spectral Imaging Device (MSID)|
214265132|NCT03917459|DRUG|LCZ696|sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
214819379|NCT06462066|PROCEDURE|Comparator medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
214265133|NCT03917459|DRUG|Enalapril matching placebo|Placebo to Enalapril 10 mg film-coated tablets
214265134|NCT03917459|DRUG|Enalapril|Enalapril 10 mg film-coated tablets
214265135|NCT03917459|DRUG|LCZ696 matching placebo|Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
214265136|NCT02704260|GENETIC|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
214265137|NCT03515083|DEVICE|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
214265138|NCT00989105|OTHER|immunohistochemistry staining method|
214265139|NCT00989105|OTHER|laboratory biomarker analysis|
214265140|NCT00989105|OTHER|pharmacological study|
214265141|NCT00989105|PROCEDURE|computed tomography|
214265142|NCT00989105|PROCEDURE|magnetic resonance imaging|
214265143|NCT00989105|PROCEDURE|single photon emission computed tomography|
214265144|NCT00989105|RADIATION|technetium Tc 99m demobesin-4|
214819380|NCT05608447|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
214819381|NCT05608447|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
214819382|NCT00612287|DRUG|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
214265145|NCT00075218|DRUG|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
214819383|NCT01451047|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
214819384|NCT00872092|OTHER|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
214819385|NCT01940341|DRUG|TAF|25 mg tablet administered orally once daily
214819386|NCT01940341|DRUG|TDF|300 mg tablet administered orally once daily
214819387|NCT01940341|DRUG|TAF Placebo|Tablet administered orally once daily
214819388|NCT01940341|DRUG|TDF Placebo|Tablet administered orally once daily
214265146|NCT00075218|DRUG|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
214265147|NCT03534362|DEVICE|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
214265148|NCT03534362|DEVICE|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
214265149|NCT01870050|DRUG|Dapsone gel - verum|
214265150|NCT04767620|DRUG|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
214265151|NCT05994365|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
214265152|NCT04391361|DRUG|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
214265153|NCT04391361|DRUG|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
214265154|NCT05896397|PROCEDURE|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
214265155|NCT04820166|OTHER|monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly
214265156|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
214265157|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
214265158|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
214265159|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
214265160|NCT01620554|DRUG|Placebo|1 capsule per week during 2 weeks
214265161|NCT03703622|BEHAVIORAL|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
214265162|NCT03123367|DEVICE|Group 1: Nella VuSleeve|Sleeve
214819389|NCT04673201|PROCEDURE|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
214819390|NCT05277363|OTHER|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
214265163|NCT03123367|DEVICE|Group 2: Nella NuSpec|Speculum
214265164|NCT03123367|DEVICE|Group 3: NellaSpec|Speculum
214265165|NCT03123367|DEVICE|Group 4: Nella Insert|Sleeve
214265166|NCT00002133|DRUG|Itraconazole|
214265167|NCT06383065|OTHER|IMT Group|Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
214265168|NCT00845858|DRUG|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
214265169|NCT00845858|DRUG|Placebo|30 minutes before meals and at bedtime
214265170|NCT03605407|OTHER|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
214265171|NCT02518074|OTHER|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
214265172|NCT05648578|OTHER|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
214265173|NCT02293057|BEHAVIORAL|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
214265174|NCT02293057|BEHAVIORAL|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
214265175|NCT04383483|OTHER|COVICU|COVICU
214265176|NCT01402765|DEVICE|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
214265177|NCT01402765|DEVICE|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
214265178|NCT03979612|GENETIC|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
214265179|NCT01878279|OTHER|Underlying medical illness|
214265180|NCT04184544|OTHER|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
214265181|NCT01363674|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
214265182|NCT00250302|PROCEDURE|autologous mesenchymal stem cells implantation|
214265183|NCT00004006|BIOLOGICAL|filgrastim|
214265184|NCT00004006|DRUG|carboplatin|
214265185|NCT00004006|DRUG|cyclophosphamide|
214265186|NCT00004006|DRUG|doxorubicin hydrochloride|
214265187|NCT00004006|DRUG|etoposide|
214265188|NCT00004006|DRUG|topotecan hydrochloride|
214265189|NCT00004006|PROCEDURE|autologous bone marrow transplantation|
214265190|NCT00004006|RADIATION|radiation therapy|
214265191|NCT05708274|DRUG|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
214265192|NCT05708274|DRUG|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
214819391|NCT02613754|BEHAVIORAL|Contingency Management|See arm description.
214819392|NCT02613754|BEHAVIORAL|Treatment as Usual|See arm description
214819393|NCT04808648|DRUG|SH-1028|tablet, oral, 200 mg once daily for day 1 and day 12
214819394|NCT04808648|DRUG|Itraconazole|capsule, oral, 200 mg twice daily for day 8 to day 14
214265193|NCT05708274|DRUG|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
214265194|NCT05708274|DRUG|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
214819395|NCT04808648|DRUG|Rifampicin|capsule, oral, 600 mg once daily for day 8 to day 16
214265195|NCT05239975|BIOLOGICAL|SCTV01C|intramuscular injection
214265196|NCT05239975|BIOLOGICAL|Comirnaty|intramuscular injection
214265197|NCT03086993|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
214265198|NCT03086993|DRUG|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
214265199|NCT02191137|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
214265200|NCT05744232|BEHAVIORAL|Low calorie total diet replacement|"Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase"
214819396|NCT01218672|DEVICE|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
214265201|NCT05744232|OTHER|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
214265202|NCT02586714|OTHER|No intervention|Observation only
214265203|NCT06070311|COMBINATION_PRODUCT|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
214265204|NCT03901547|BEHAVIORAL|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
214819397|NCT01218672|DEVICE|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
214819398|NCT03703791|BIOLOGICAL|AR101|AR101 powder
214265205|NCT03901547|BEHAVIORAL|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
214819399|NCT03243487|BEHAVIORAL|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
214819400|NCT03243487|BEHAVIORAL|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
214819401|NCT03708458|DRUG|indomethacin suppository|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
214819402|NCT03708458|DRUG|N-acetylcysteine (NAC)|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
214819403|NCT01653951|OTHER|nurse-led care management or peer-led self management|
214265206|NCT03901547|OTHER|Maslach burnout inventory|Maslach burnout inventory
214265207|NCT03901547|OTHER|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
214265208|NCT03901547|OTHER|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
214265209|NCT03901547|BEHAVIORAL|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
214265210|NCT06051422|DEVICE|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
214265211|NCT02956070|DRUG|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
214265212|NCT02956070|DRUG|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
214265213|NCT03172819|BIOLOGICAL|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
214265214|NCT03172819|DRUG|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
214265215|NCT05101785|DRUG|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
214265216|NCT05101785|DRUG|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
214265217|NCT05797259|DRUG|Danosumab|60 mg subcutaneous Danosumab
214265218|NCT05797259|OTHER|Normal Saline|Placebo comparator arm
214265219|NCT05337696|PROCEDURE|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
214265220|NCT05337696|DEVICE|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
214819404|NCT05119946|BEHAVIORAL|Suicide prevention video|The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
214819405|NCT05119946|OTHER|Standard suicide treatment|The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
214265221|NCT01191411|OTHER|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
214265222|NCT01191411|OTHER|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
214819406|NCT06560749|OTHER|Physical Exercise|Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
214819407|NCT00841698|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
214819408|NCT00841698|DRUG|Paxil®|40 mg Film-Coated Tablet
214819409|NCT02785887|OTHER|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
214819410|NCT00185458|DRUG|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
214265223|NCT01191411|OTHER|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
214265224|NCT05612711|DRUG|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
214265225|NCT05176743|BEHAVIORAL|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
214265226|NCT04710394|BEHAVIORAL|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
214265227|NCT02737397|DRUG|JMI-001 (SJP-304 and SJP-223)|
214819411|NCT00251979|DRUG|Esomeprazole|
214265228|NCT02737397|DRUG|SJP-304|
214265229|NCT02737397|DRUG|SJP-223|
214819412|NCT00280553|DRUG|bupivicaine|PCA and bupivicaine infusion for up to five days
214265230|NCT02737397|DRUG|placebo|
214265231|NCT02967731|DRUG|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
214265232|NCT04887844|DRUG|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
214265233|NCT04887844|DRUG|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
214265234|NCT04887844|OTHER|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
214265235|NCT05331651|DRUG|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
214265236|NCT05331651|DRUG|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
214265237|NCT02404220|DRUG|Entospletinib|
214265238|NCT02404220|DRUG|Vincristine|
214265239|NCT02404220|DRUG|Dexamethasone|
214265240|NCT02404220|DRUG|CNS Prophylaxis|
214819413|NCT00280553|OTHER|Saline infusion|PCA and pump with saline infusion for up to five days
214265241|NCT04707508|DRUG|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
214265242|NCT04707508|DRUG|Metformin|Metformin monotherapy
214265243|NCT01259596|BEHAVIORAL|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
214265244|NCT01259596|BEHAVIORAL|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
214819414|NCT00909402|DRUG|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
214819415|NCT00909402|DRUG|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
214819416|NCT00909402|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
214819417|NCT01460147|OTHER|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
214819418|NCT06131853|OTHER|survey evaluation|assessment of physical activity, fatigue, fear of movement, and quality of life
214265245|NCT02627521|PROCEDURE|PRU guided CABG|Coronary Artery Bypass Surgery
214265246|NCT02627521|PROCEDURE|CABG per standard of care|Coronary Artery Bypass Surgery
214265247|NCT02627521|DEVICE|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
214265248|NCT02627521|DRUG|Ticagrelor|Ticagrelor administration prior to randomization
214265249|NCT06201520|PROCEDURE|manual acupuncture|manual acupuncture
214265250|NCT06201520|DEVICE|laser acupuncture|laser acupuncture therapy
214265251|NCT06201520|DEVICE|sham laser acupuncture|sham laser acupuncture
214265252|NCT06201520|DEVICE|wrist splint|wear wrist splint at night
214265253|NCT00242320|DRUG|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
214265254|NCT00242320|DRUG|Placebo|
214265255|NCT03469934|BIOLOGICAL|Etokimab|Administered on Day 1 over 1 hour by IV infusion
214265256|NCT03469934|DRUG|Placebo|Administered on Day 1 over 1 hour by IV infusion
214265257|NCT01005108|DRUG|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
214265258|NCT04405583|DEVICE|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
214265259|NCT03188315|GENETIC|HPV oncogenes|PCR and oncogenes detection
214265260|NCT00658008|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
214265261|NCT00658008|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
214265262|NCT00658008|DRUG|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
214265263|NCT00658008|DRUG|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
214265264|NCT00658008|DRUG|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
214265265|NCT06033612|DRUG|RV299|Oral Suspension
214265266|NCT06033612|DRUG|Placebo|matching placebo
214265267|NCT06033612|DRUG|Midazolam|pre-filled oral syringe
214265268|NCT02329080|DRUG|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
214265269|NCT02329080|DRUG|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
214265270|NCT02329080|DRUG|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
214265271|NCT02329080|DRUG|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
214265272|NCT02329080|DRUG|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
214265273|NCT02329080|DRUG|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
214265274|NCT02329080|DRUG|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
214265275|NCT02329080|DRUG|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
214265276|NCT02329080|RADIATION|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
214265277|NCT03060733|OTHER|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
214265278|NCT00876746|PROCEDURE|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
214265279|NCT04208997|DRUG|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
214265280|NCT00183820|DRUG|paclitaxel, gemcitabine, and oxaliplatin|"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"
214265281|NCT00765557|DRUG|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
214265282|NCT00765557|DRUG|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
214265283|NCT02424448|PROCEDURE|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
214265284|NCT01630642|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
214265285|NCT02922855|BEHAVIORAL|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
214265286|NCT02922855|BEHAVIORAL|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
214265287|NCT02922855|BEHAVIORAL|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
214265288|NCT04305418|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
214265289|NCT02314234|DRUG|sugammadex (Bridion)|single dose of sugammadex at skin incision
214265290|NCT06316115|OTHER|In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement|Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
214265291|NCT00835822|DRUG|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
214265292|NCT00835822|DRUG|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
214265293|NCT03590873|DRUG|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
214265294|NCT03364790|PROCEDURE|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
214265295|NCT03364790|PROCEDURE|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
214265296|NCT05985005|OTHER|online simulation of high alert medication safety training|online simulation of high alert medication safety training
214265297|NCT03810391|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
214265298|NCT03810391|OTHER|physiological saline|intravenous infusion of the same volume of physiological saline
214265299|NCT02715245|PROCEDURE|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
214265300|NCT02387710|DRUG|Tiagabine|GABA reuptake inhibitor
214265301|NCT02387710|DRUG|Placebo|Placebo comparator
214265302|NCT04288180|OTHER|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
214265303|NCT01539798|OTHER|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
214265304|NCT01539798|OTHER|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
214265305|NCT04378127|OTHER|Educational program|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
214265306|NCT02034032|PROCEDURE|Regenexx SD|stem cell treatment
214265307|NCT02034032|BEHAVIORAL|Exercise Therapy|exercise therapy control
214265308|NCT03404427|BEHAVIORAL|Normal sleep night|Usual hours of sleep
214265309|NCT03404427|BEHAVIORAL|Sleepless night|Total sleep deprivation the first night
214265310|NCT01481181|DIETARY_SUPPLEMENT|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
214265311|NCT00058487|DRUG|epirubicin hydrochloride|
214265312|NCT00058487|DRUG|thalidomide|
214265313|NCT02100579|DRUG|Bupivacaine|10 ml of 0.25% bupivacaine
214819419|NCT05800652|BEHAVIORAL|Peer Mentoring Program|Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
214265314|NCT02100579|DRUG|Preservative free normal saline|10 ml of preservative free normal saline
214265315|NCT02151695|PROCEDURE|panretinal photocoagulation|
214265316|NCT02151695|DRUG|Aflibercept intravitreal injections|
214265317|NCT03445520|BEHAVIORAL|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
214265318|NCT05806983|OTHER|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
214265319|NCT00629720|DRUG|alfuzosin (SL770499)|
214265320|NCT06022601|DEVICE|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
214265321|NCT00071396|DRUG|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
214265322|NCT00071396|DRUG|Rituximab|375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
214265323|NCT06282393|DEVICE|FibriCheck recordings|PPG and single-lead ECG measurements
214265324|NCT00040339|PROCEDURE|hypothermia (body temperature lowered to 33°C or 91.4°F)|
214265325|NCT00439023|PROCEDURE|dialysis with glucose in dialysis water|
214265326|NCT03082261|DEVICE|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
214265327|NCT00815399|DRUG|Pioglitazone|15-45 mg/die
214265328|NCT00815399|DRUG|Metformin|500-2000 mg/die
214265329|NCT00549874|DRUG|Rosiglitazone|oral 8 mg/once daily for 6 months
214265330|NCT00549874|DRUG|Glyburide|20 mg/ once daily for 6 months
214265331|NCT01820156|DEVICE|Home Respiratory Polygraphy|
214265332|NCT01820156|DEVICE|Standard Polysomnography|
214265333|NCT01067066|DRUG|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
214265334|NCT01067066|DRUG|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
214265335|NCT02639546|DRUG|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
214265336|NCT00524654|PROCEDURE|HVLA chiropractic manipulation|
214265337|NCT02068027|DRUG|Clonidine Gel 0.1%|
214265338|NCT02068027|DRUG|Placebo|
214265339|NCT05473208|DEVICE|Exoskeleton|Lumbar assistive exoskeleton evaluation
214265340|NCT01032174|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
214265341|NCT01032174|DRUG|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
214265342|NCT02173873|DRUG|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
214265343|NCT02651350|DRUG|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
214265344|NCT02651350|DRUG|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
214265345|NCT01845883|PROCEDURE|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
214265346|NCT03783975|GENETIC|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
214265347|NCT00933829|PROCEDURE|Absorbable Suture Arm|use of irradiated polyglactin 910
214265348|NCT00933829|DEVICE|Non-absorbable suture (Prolene)|suture
214265349|NCT00933829|PROCEDURE|suture|non-absorable sutures and absorable sutures
214265350|NCT06238271|DEVICE|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
214265351|NCT02614651|PROCEDURE|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
214265352|NCT02614651|PROCEDURE|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
214265353|NCT02614651|PROCEDURE|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
214265354|NCT02614651|PROCEDURE|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
214265355|NCT02614651|DEVICE|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
214265356|NCT03143543|DRUG|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
214265357|NCT03143543|DRUG|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
214265358|NCT03143543|OTHER|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
214265359|NCT03143543|OTHER|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
214265360|NCT02623478|DRUG|Insulin Lispro|Administered subcutaneously (SC)
214265361|NCT01147588|DRUG|lansoprazole|60 mg (2x30-mg capsule), once daily
214265362|NCT01147588|DRUG|omeprazole|80 mg (2x40-mg capsule), once daily
214265363|NCT01147588|DRUG|esomeprazole|40 mg (1x40-mg capsule), once daily
214265364|NCT01147588|DRUG|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
214265365|NCT04670055|DRUG|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
214265366|NCT04645420|PROCEDURE|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
214265367|NCT06324331|PROCEDURE|Decidual sparing|Endometrial free uterine closure technique
214265368|NCT06324331|PROCEDURE|Non decidual sparing|Routine uterine closure technique including endometrium
214265369|NCT03508375|BIOLOGICAL|blood samples|blood samples
214265370|NCT00113087|DRUG|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
214265371|NCT00113087|DRUG|Placebo|Participants will receive placebo
214265372|NCT02051842|DRUG|Metadoxine|
214265373|NCT01837407|PROCEDURE|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
214265374|NCT01281137|GENETIC|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
214265375|NCT01281137|OTHER|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
214265376|NCT01281137|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
214265377|NCT04550910|RADIATION|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
214819420|NCT00999050|PROCEDURE|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
214265378|NCT03316339|DRUG|Dexmedetomidine|Opioid-free anesthesia
214265379|NCT03316339|DRUG|Remifentanil|Opioid anesthesia
214265380|NCT03697057|PROCEDURE|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
214265381|NCT02932423|OTHER|Control product E|Plain water
214265382|NCT02932423|OTHER|Test product A|Beverage with no sugar but sweetener
214265383|NCT02932423|OTHER|Test product B|Beverage with 22 g/L sugar and sweetener
214265384|NCT02932423|OTHER|Test product C|Beverage with 33 g/L sugar and sweetener
214819421|NCT01576042|DRUG|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
214819422|NCT01576042|DRUG|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
214819423|NCT01576042|DEVICE|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
214265385|NCT02932423|OTHER|Test product D|Beverage with 47 g/L sugar and sweetener
214265386|NCT02932423|OTHER|Comparative product F|Beverage with 98 g/L sugar
214819424|NCT04287322|BEHAVIORAL|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
214265387|NCT03682887|PROCEDURE|Cryoballoon PV isolation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
214265388|NCT03682887|PROCEDURE|Cryoballoon PV isolation with Additional RA linear ablation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
214265389|NCT03388437|DEVICE|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
214265390|NCT03388437|DEVICE|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
214265391|NCT01581710|DRUG|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
214265392|NCT01581710|DRUG|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
214265393|NCT00386607|DRUG|Aliskiren|Aliskiren 300 mg
214265394|NCT00386607|DRUG|Valsartan|Valsartan 320 mg
214265395|NCT00386607|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
214265396|NCT04997915|OTHER|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
214265397|NCT00853034|DIETARY_SUPPLEMENT|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
214265398|NCT00853034|DIETARY_SUPPLEMENT|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
214265399|NCT00341445|BEHAVIORAL|Effect of Cockroach Allergen|
214265400|NCT00673946|OTHER|True saturation values displayed|Physicians will be presented with real saturations.
214265401|NCT00673946|OTHER|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
214265402|NCT00904319|OTHER|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
214265403|NCT03561116|DIETARY_SUPPLEMENT|XAN|Daily intake of a sachet containing 12 mg of XAN
214265404|NCT03561116|DIETARY_SUPPLEMENT|Placebo|Daily intake of a sachet containing excipient
214265405|NCT01222884|DRUG|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
214265406|NCT01222884|DRUG|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
214265407|NCT00387803|DEVICE|Cardiac Resynchronization Therapy with Defibrillation|
214265408|NCT04251273|OTHER|This is Quitting|Text message-based intervention for quit vaping support.
214265409|NCT04251273|OTHER|Assessment only Control|Assessment only
214265410|NCT01986907|DRUG|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
214265411|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
214265412|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
214265413|NCT00810693|DRUG|Placebo|Matching Placebo tid orally for 12 weeks
214265414|NCT03212690|DRUG|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
214265415|NCT03212690|PROCEDURE|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
214819425|NCT04287322|BEHAVIORAL|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
214819426|NCT01311245|BEHAVIORAL|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
214819427|NCT01311245|BEHAVIORAL|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
214265416|NCT00969254|DRUG|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
214265417|NCT00969254|DRUG|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
214265418|NCT03282370|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
214265419|NCT03282370|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
214265420|NCT05476458|RADIATION|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
214265421|NCT05476458|RADIATION|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
214265422|NCT00625794|DRUG|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
214265423|NCT00625794|BEHAVIORAL|Smoking cessation counseling|8 weeks or counseling
214265424|NCT00312182|DRUG|Nelfinavir|
214265425|NCT02149719|OTHER|Desensitisation using boiled peanut|
214265426|NCT02149719|OTHER|Desensitisation using boiled peanut (deferred start)|
214265427|NCT04193358|DIETARY_SUPPLEMENT|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
214265428|NCT04193358|OTHER|PLACEBO|Sugar pills
214819428|NCT02252133|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
214265429|NCT03675620|DEVICE|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
214265430|NCT03675620|OTHER|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
214265431|NCT03178331|OTHER|Study questionnaires|filled by parents, school nurse and teacher
214265432|NCT00003821|DRUG|aminopterin|
214265433|NCT04052282|DEVICE|Mobile Health App|There is no intervention
214265434|NCT00245661|DRUG|Temazepam|
214265435|NCT03008226|DEVICE|Implementation of 9 mm intrabronchial valves|
214265436|NCT00200642|DEVICE|Stretta® System|
214265437|NCT03146377|DRUG|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
214265438|NCT03146377|DRUG|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
214265439|NCT03146377|DRUG|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
214265440|NCT03724786|DIAGNOSTIC_TEST|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
214265441|NCT01514331|OTHER|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
214265442|NCT01514331|OTHER|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
214265443|NCT03796533|DRUG|Posaconazole|"* PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
214819429|NCT02252133|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
214819430|NCT06562868|OTHER|Bulk-fill Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
214819431|NCT06562868|OTHER|Traditional Posterior Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
214819432|NCT06562868|OTHER|High-filler Flowable Composite|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
214265444|NCT01743417|BEHAVIORAL|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
214265445|NCT06319261|PROCEDURE|guided biofilm therapy|Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
214265446|NCT06319261|PROCEDURE|root surface debridement|Removing plaque and calculus by conventional root surface debridement
214265447|NCT02927782|PROCEDURE|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
214656078|NCT02749214|OTHER|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
214656079|NCT03108716|PROCEDURE|hamate hook removal|The patients were assigned to treat with hamate hook removal.
214265448|NCT02927782|PROCEDURE|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
214265449|NCT01365065|DRUG|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
214265450|NCT05593471|OTHER|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
214265451|NCT05593471|OTHER|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
214265452|NCT00469651|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
214265453|NCT00469651|BIOLOGICAL|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
214265454|NCT00469651|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
214265455|NCT00469651|BIOLOGICAL|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
214265456|NCT00469651|BIOLOGICAL|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
214265457|NCT00193531|DRUG|Paclitaxel|
214265458|NCT00193531|DRUG|Carboplatin|
214265459|NCT00193531|DRUG|Etoposide|
214265460|NCT05690646|DRUG|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
214265461|NCT05690646|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
214265462|NCT05218720|DIAGNOSTIC_TEST|EuroSCORE II|"* Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk \<1, low risk 1-2.99, moderate risk 3-4.99, high risk \>5.~* CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
214265463|NCT04264338|DIAGNOSTIC_TEST|Thyromental height test|Assessment of difficult airway
214265464|NCT02976922|DIETARY_SUPPLEMENT|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
214265465|NCT02851940|PROCEDURE|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
214265466|NCT02851940|PROCEDURE|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
214265467|NCT03358797|BEHAVIORAL|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
214656080|NCT03108716|PROCEDURE|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
214656081|NCT03108716|OTHER|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
214656082|NCT01330901|DRUG|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
214656083|NCT03898635|DRUG|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
214656084|NCT00358813|DRUG|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
214656085|NCT00291720|DRUG|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
214656086|NCT00291720|DRUG|Placebo|matching placebo
214656087|NCT02351362|BEHAVIORAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
214656088|NCT03711383|DIETARY_SUPPLEMENT|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
214656089|NCT03711383|DIETARY_SUPPLEMENT|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
214656090|NCT03711383|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before test day
214656091|NCT01588223|OTHER|Lipid identification|The lipids are identified using Mass Spectrometry
214656092|NCT04579549|DEVICE|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
214656093|NCT02446587|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
214656094|NCT01130506|DRUG|Cytarabine|Given IV
214656095|NCT01130506|DRUG|Decitabine|Given IV
214656096|NCT01130506|OTHER|Laboratory Biomarker Analysis|Correlative studies
214656097|NCT01130506|OTHER|Pharmacological Study|Correlative studies
214656098|NCT01130506|DRUG|Vorinostat|Given PO
214656099|NCT01071070|DRUG|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
214656100|NCT05569135|DEVICE|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
214656101|NCT05859087|BEHAVIORAL|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
214656102|NCT05859087|BEHAVIORAL|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
214656103|NCT04902235|DRUG|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
214656104|NCT04902235|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
214656105|NCT02794337|RADIATION|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
214656106|NCT02794337|PROCEDURE|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
214656107|NCT02794337|DRUG|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
214656108|NCT03214835|DEVICE|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
214656109|NCT03651843|OTHER|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
214819433|NCT01327222|DRUG|Bevacizumab|1.25 mg intravitreal bevacizumab
214819434|NCT00865592|DRUG|dutogliptin|dutogliptin 400 mg, once daily tablet
214819435|NCT04198844|DRUG|warfarin|warfarin user
214819436|NCT04198844|DRUG|apixaban|apixaban user
214265468|NCT03358797|BEHAVIORAL|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
214265469|NCT03358797|BEHAVIORAL|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
214265470|NCT03358797|BEHAVIORAL|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
214265471|NCT00331422|DRUG|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
214265472|NCT00331422|DRUG|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
214265473|NCT00331422|PROCEDURE|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
214265474|NCT04515173|DIAGNOSTIC_TEST|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
214265475|NCT03211871|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
214656110|NCT05627466|DRUG|Magrolimab|Administered intravenously
214656111|NCT02938182|DRUG|clopidogrel|clopidogrel troche 75 mg daily for three months
214265476|NCT03211871|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
214265477|NCT03376269|BIOLOGICAL|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
214265478|NCT03376269|BEHAVIORAL|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
214265479|NCT05824091|DRUG|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
214265480|NCT05824091|OTHER|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
214265481|NCT02345226|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
214265482|NCT02345226|DRUG|EFV/FTC/TDF Placebo|Tablets administered orally once daily
214265483|NCT02345226|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
214265484|NCT02345226|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
214265485|NCT01571310|OTHER|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
214265486|NCT01571310|OTHER|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
214265487|NCT03757338|DRUG|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
214265488|NCT03757338|DRUG|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
214656112|NCT05675137|DEVICE|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
214265489|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
214656113|NCT05675137|OTHER|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
214656114|NCT00745108|DRUG|tibolone|oral 1.25 mg tablet, once daily, for 2 years
214656115|NCT00745108|DRUG|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
214656116|NCT00745108|DRUG|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
214656117|NCT03932526|DRUG|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
214656118|NCT03932526|DRUG|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
214265490|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
214265491|NCT04141046|DEVICE|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
214265492|NCT01844557|OTHER|Swallowing Exercises|Participants perform 3 swallowing exercises.
214265493|NCT01844557|BEHAVIORAL|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
214265494|NCT01844557|BEHAVIORAL|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
214265495|NCT03405896|OTHER|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
214265496|NCT05602350|BEHAVIORAL|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
214819437|NCT02991378|BEHAVIORAL|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
214819438|NCT02727088|PROCEDURE|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
214265497|NCT05602350|BEHAVIORAL|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
214265498|NCT00394446|DRUG|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
214819439|NCT02727088|PROCEDURE|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
214819440|NCT00182429|DRUG|Metronidazole and Rifampin|
214265499|NCT02059252|DEVICE|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
214819441|NCT00280644|DRUG|Leflunomide|
214819442|NCT00925119|DRUG|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
214819443|NCT06065150|PROCEDURE|Standard support|See arm/group descriptions
214819444|NCT06065150|PROCEDURE|Early surgery proposed according to the radiological score|"* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
214819445|NCT03914183|DEVICE|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
214265500|NCT02173938|OTHER|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
214265501|NCT04032548|DRUG|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
214265502|NCT04032548|DRUG|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
214265503|NCT04032548|DRUG|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
214819446|NCT03914183|DEVICE|Control|Use of standard of care insulin pen needle
214819447|NCT06562426|BEHAVIORAL|Descriptive group on vitamin D awareness|300 mothers of under-five children will be recruited in the descriptive study to assess their awareness about vitamin D and observe children for their health status outcome. Three tools will be used which are; sociodemographic characteristics of children and their mothers, Mothers' Awareness of Vitamin D Structured Interview Schedule, and Health Status Outcomes of Under- Five Years Children. Permission to conduct the study will be obtained from the administrative authorities of the settings after an explanation of the aim of the study. Each mother will be interviewed individually to obtain characteristics of mothers and their children, as well as knowledge and performance regarding Vitamin D. Each child will be observed for the manifestation of vitamin D deficiency and to measure their weight and height.
214819448|NCT01904344|DEVICE|Sensor testing and validation|
214265504|NCT02212470|DEVICE|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
214265505|NCT02212470|DEVICE|Nitinol stenting|Nitinol stent deployment
214265506|NCT02127710|DRUG|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
214265507|NCT02744703|DRUG|total-etch adhesive|comparator use of total-etch adhesive
214265508|NCT02744703|DRUG|CAPE-T|experimental group
214265509|NCT02744703|DRUG|self-etch adhesive|comparator use of total-etch adhesive
214265510|NCT02744703|DRUG|CAPE-S|experimental group
214265511|NCT01975051|DRUG|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
214265512|NCT05137704|OTHER|No intervention|This is a non-interventional study.
214265513|NCT04416659|DEVICE|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
214265514|NCT00989157|DRUG|Duloxetine|Single dose of 60 mg of duloxetine
214265515|NCT00586651|DRUG|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
214265516|NCT03386474|DRUG|Brolucizumab 6 mg|Administered as opthalmic solution for an intravitreal injection to the study eye
214265517|NCT03386474|DRUG|Aflibercept 2 mg|Administered as an opthalmic solution for intravitreal injection to the study eye
214265518|NCT05235087|DEVICE|Bovine atelocollagen intradermal injection|Intradermal skin test injection
214265519|NCT06127615|DEVICE|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
214819449|NCT02544386|PROCEDURE|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
214819450|NCT03743961|OTHER|geriatric intervention|Geriatric intervention
214819451|NCT05752734|DRUG|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
214819452|NCT05752734|DRUG|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
214819453|NCT00276926|DRUG|STI571|
214819454|NCT03126747|DRUG|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
214265525|NCT00599950|DRUG|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
214265526|NCT04977674|DRUG|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
214819455|NCT05178927|DEVICE|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
214265527|NCT04977674|DRUG|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
214265528|NCT04977674|DRUG|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
214265529|NCT02623920|DRUG|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214265530|NCT02623920|DRUG|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214265531|NCT02623920|DRUG|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214265532|NCT04651985|OTHER|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
214265533|NCT04473092|DEVICE|TMVR|Patients who undergo TMVR for MR at the PI´s site
214265534|NCT02108782|DRUG|dovitinib lactate|Given PO
214819456|NCT04613258|DIETARY_SUPPLEMENT|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
214819457|NCT04613258|OTHER|Counseling|21 subjects in the control group (C) who only received dietary counseling
214819458|NCT00673647|BEHAVIORAL|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
214265535|NCT02108782|OTHER|pharmacological study|Correlative studies
214265536|NCT02108782|OTHER|laboratory biomarker analysis|Correlative studies
214265537|NCT05369767|DRUG|SAD, SHR-2004|Ascending dose
214265538|NCT05369767|DRUG|SAD, SHR-2004 placebo|Ascending dose
214265539|NCT00052273|DRUG|capecitabine|
214265540|NCT00052273|DRUG|enzastaurin hydrochloride|
214265541|NCT06544122|DEVICE|Transcranial direct current stimulation|Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
214265542|NCT05283278|DRUG|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
214265543|NCT05283278|COMBINATION_PRODUCT|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
214265544|NCT05283278|OTHER|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
214819459|NCT03670017|DEVICE|OptiScanner® 5000 Glucose Monitoring System|The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
214265545|NCT05576675|DRUG|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
214265546|NCT05576675|DRUG|Sufentanil|sufentanil 200 μ g
214265547|NCT05576675|DRUG|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
214265548|NCT04238585|BEHAVIORAL|Mobile messaging|Mobile health messages
214265549|NCT02051231|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
214265550|NCT02282358|DRUG|Mocetinostat|
214265551|NCT03281707|PROCEDURE|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
214265552|NCT03281707|OTHER|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
214265553|NCT04442139|OTHER|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
214265554|NCT01561729|DEVICE|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
214265555|NCT01561729|RADIATION|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
214265556|NCT04203797|DRUG|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
214265557|NCT04203797|DRUG|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
214265558|NCT02637154|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing method
214265559|NCT02637154|BEHAVIORAL|Standard Education|Standard Education material will be used
214265560|NCT00456157|DRUG|Intra-articular Injection of OP-1 to affected knee|
214265561|NCT05868759|RADIATION|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
214265562|NCT05868759|DEVICE|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
214265563|NCT05868759|DIAGNOSTIC_TEST|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
214265564|NCT05868759|DEVICE|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
214265565|NCT05868759|OTHER|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
214265566|NCT05868759|OTHER|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
214265567|NCT05868759|OTHER|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
214265568|NCT04842734|OTHER|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
214265569|NCT04842734|OTHER|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
214265570|NCT04599829|DEVICE|AnkleSTRONG100/500/900|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
214265571|NCT04896879|BEHAVIORAL|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
214265572|NCT03610360|DRUG|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
214265573|NCT05366517|DEVICE|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
214265574|NCT04999488|DRUG|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
214265575|NCT04999488|OTHER|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
214265576|NCT02296073|DRUG|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
214265577|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
214265578|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
214265579|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
214265580|NCT02296073|DRUG|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
214265581|NCT02296073|OTHER|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
214265582|NCT02096237|DEVICE|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
214265583|NCT04977557|DIETARY_SUPPLEMENT|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
214265584|NCT02954250|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
214265585|NCT03980977|OTHER|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
214265586|NCT03980977|OTHER|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
214265587|NCT03980977|OTHER|blood sample|blood sample will be taken for biological collection
214265588|NCT02004600|PROCEDURE|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
214265589|NCT05322733|DRUG|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
214265590|NCT05322733|DRUG|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
214265591|NCT05322733|DRUG|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
214265592|NCT05322733|DRUG|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
214265593|NCT04901676|DRUG|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
214265594|NCT04901676|DRUG|Placebo|Placebo
214265595|NCT04357782|DRUG|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
214265596|NCT01771042|OTHER|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
214265597|NCT01786148|BEHAVIORAL|mobile phone application|
214265598|NCT03388931|RADIATION|Radiation Therapy|Increased radiation therapy dose
214265599|NCT03388931|COMBINATION_PRODUCT|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
214656119|NCT05841472|DRUG|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
214656120|NCT01818544|DRUG|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
214656121|NCT01818544|DRUG|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
214656122|NCT01420133|OTHER|Regimen|regimen normal in salt and sugar
214656123|NCT01420133|OTHER|Standard regimen|with diet low in salt and sugar
214656124|NCT03139292|DEVICE|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
214656125|NCT03139292|DEVICE|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
214656126|NCT00728546|DRUG|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
214656127|NCT05670977|DIETARY_SUPPLEMENT|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
214265600|NCT01356927|DRUG|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
214265601|NCT01356927|DRUG|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
214819460|NCT00678717|PROCEDURE|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
214819461|NCT00835536|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
214265602|NCT04849923|OTHER|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
214265603|NCT00443105|DRUG|Tacrolimus 0.03% ointment (Protopic)|
214819462|NCT00835536|DRUG|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
214265604|NCT00675259|DRUG|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
214265605|NCT00675259|DRUG|carboplatin|AUC 2 IV on days 1, 8, and 15
214265606|NCT00675259|DRUG|nab-paclitaxel|100 mg/M2 IV
214265607|NCT00675259|PROCEDURE|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
214265608|NCT00675259|DRUG|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
214265609|NCT01384942|BEHAVIORAL|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
214265610|NCT01384942|BEHAVIORAL|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
214265611|NCT05043675|DRUG|[18F]APN-1607|Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
214265612|NCT00468468|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
214265613|NCT01089673|OTHER|data collection|retrospective data collection
214265614|NCT01874600|DEVICE|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
214265615|NCT05586646|DIETARY_SUPPLEMENT|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
214265616|NCT05913258|DEVICE|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
214819463|NCT04741620|OTHER|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
214819464|NCT04741620|OTHER|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
214819465|NCT04741620|OTHER|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
214819466|NCT04741620|OTHER|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
214819467|NCT04741620|OTHER|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
214819468|NCT04741620|OTHER|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
214819469|NCT06372457|DRUG|Approved Hypertrophic Cardiomyopathy drug treatments|As per product label
214819470|NCT06372457|DRUG|Mavacamten|As per product label
214819471|NCT00582673|DRUG|AFQ056|
214819472|NCT00582673|DRUG|Placebo|
214819473|NCT00871247|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
214819474|NCT00871247|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
214819475|NCT03173547|DRUG|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
214819476|NCT03173547|DRUG|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
214265617|NCT05913258|DEVICE|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
214265618|NCT03780543|DRUG|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
214265619|NCT04131725|DEVICE|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
214265620|NCT05916820|OTHER|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
214265621|NCT05916820|OTHER|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
214265622|NCT03144973|DIAGNOSTIC_TEST|periosafe|mouth rinsing quick-test
214265623|NCT03349697|DIETARY_SUPPLEMENT|Phyllantus amarus|
214265624|NCT03349697|OTHER|Placebo|
214265625|NCT03505190|DRUG|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
214265626|NCT03505190|DRUG|Placebo|Matching placebo will be administered subcutaneously (SC).
214265627|NCT02001103|DRUG|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
214819477|NCT05945030|OTHER|Clinical Examination|T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
214819478|NCT00657553|DRUG|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
214819479|NCT04820920|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
214819480|NCT04820920|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
214819481|NCT04820920|BEHAVIORAL|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
214819482|NCT00520429|BEHAVIORAL|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
214819483|NCT02691130|BIOLOGICAL|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
214819484|NCT02691130|BIOLOGICAL|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
214819485|NCT02691130|BIOLOGICAL|Saline|0.9% NaCl in double distilled water
214265628|NCT02001103|DRUG|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
214265629|NCT03488355|OTHER|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
214265630|NCT06232694|DRUG|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
214265631|NCT06232694|DRUG|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
214819486|NCT01202734|DRUG|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
214819487|NCT00446563|DRUG|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
214819488|NCT00446563|DRUG|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
214819489|NCT00446563|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
214819490|NCT00446563|DRUG|Losartan|100 mg tablets taken orally once daily in the morning.
214265632|NCT06232694|OTHER|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
214265633|NCT00098956|DRUG|topotecan hydrochloride|Given IV
214265634|NCT00098956|DRUG|7-hydroxystaurosporine|Given IV
214265635|NCT00516074|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214265636|NCT00516074|DRUG|placebo|subcutaneous injection, volume equivalent to active, twice a day
214265637|NCT03867279|OTHER|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
214265638|NCT03867279|OTHER|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
214265639|NCT05254808|DRUG|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
214265640|NCT05254808|DRUG|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
214265641|NCT01331122|DRUG|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
214265642|NCT06426433|OTHER|Proprioceptive Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
214819491|NCT02403947|DRUG|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
214265643|NCT06426433|OTHER|Upper Extremity Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
214265644|NCT02925832|PROCEDURE|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
214265645|NCT02925832|DRUG|Ropivacaine|0.75% ropivacaine soaked sponges
214265646|NCT02925832|DRUG|Bupivacaine|0.5% bupivacaine soaked sponges
214265647|NCT02925832|DRUG|Proparacaine|For anaesthetising conjunctiva
214265648|NCT05668429|DRUG|Ibrexafungerp|carbon-14 (\[14\^C\])-Ibrexafungerp
214265649|NCT02215096|DRUG|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
214265650|NCT02215096|DRUG|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
214265651|NCT01511965|OTHER|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
214265652|NCT04313842|DEVICE|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
214265653|NCT04046484|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
214265654|NCT04046484|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
214265655|NCT00392080|DRUG|CJ-023,423|75 mg BID
214265656|NCT00392080|DRUG|placebo|placebo
214265657|NCT00392080|DRUG|naproxen|naproxen
214265658|NCT03499925|BEHAVIORAL|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
214819492|NCT02403947|DRUG|Suspension media|injection suspension media
214819493|NCT03769025|BEHAVIORAL|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
214265659|NCT03499925|BEHAVIORAL|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
214265660|NCT04674202|OTHER|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
214265661|NCT00287365|DRUG|ozone|2 hour exposure to 0.4 ppm ozone
214265662|NCT05069610|BIOLOGICAL|AD17002|A recombinant protein
214265663|NCT05069610|BIOLOGICAL|Placebo (Formulation buffer)|Formulation buffer
214265664|NCT04597229|DIETARY_SUPPLEMENT|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
214265665|NCT03047707|DIAGNOSTIC_TEST|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
214819494|NCT03769025|OTHER|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
214819495|NCT01169558|DRUG|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
214265666|NCT02642302|BEHAVIORAL|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
214265667|NCT02642302|BEHAVIORAL|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
214265668|NCT02642302|BEHAVIORAL|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
214265669|NCT02552992|BEHAVIORAL|Yoga|
214265670|NCT02552992|BEHAVIORAL|Self-Directed Mind-Body Program|
214265671|NCT01728350|BEHAVIORAL|HOPE - Helping Others through Purpose and Engagement|
214265672|NCT04118842|DRUG|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
214265673|NCT04118842|DRUG|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
214265674|NCT00325273|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
214265675|NCT01997853|DRUG|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
214265676|NCT01997853|DRUG|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
214265677|NCT04280835|BEHAVIORAL|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
214265678|NCT04354103|DRUG|Atomoxetine|Atomoxetine
214265679|NCT05244993|DRUG|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
214265680|NCT05244993|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
214265681|NCT05244993|DRUG|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
214265682|NCT04057508|OTHER|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
214265683|NCT03623555|BEHAVIORAL|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
214819496|NCT01169558|DRUG|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
214819497|NCT06102213|DRUG|B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)|PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
214819498|NCT02184936|OTHER|standard of care|
214819499|NCT04211779|DEVICE|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
214265684|NCT03623555|BIOLOGICAL|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
214265685|NCT03021304|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
214265686|NCT00669656|DRUG|Prostate Health Cocktail|3 capsules daily PO up 12 months
214265687|NCT06161272|DRUG|Fluzoparib|single
214265688|NCT06161272|DRUG|Fluzoparib+Apatinib|combination
214265689|NCT03918161|DEVICE|MRE exam|Magnetic Resonance Elastography
214819500|NCT04211779|DEVICE|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
214265690|NCT04786938|DRUG|Saccharomyces Boulardii-Containing Product in Oral Dose Form|S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
214265691|NCT02418078|PROCEDURE|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
214265692|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
214819501|NCT04211779|OTHER|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
214819502|NCT02702882|DIETARY_SUPPLEMENT|Fenugreek Seeds Extract|Furosap one caps OD
214265693|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
214265694|NCT02663908|DRUG|Degarelix|
214819503|NCT06559358|DEVICE|electrical stimulation|A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
214819504|NCT02749266|OTHER|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
214819505|NCT02749266|OTHER|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
214819506|NCT01310257|OTHER|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
214819507|NCT04215705|PROCEDURE|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
214265695|NCT02663908|DRUG|Leuprolide|
214265696|NCT01910948|DRUG|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
214265697|NCT00963131|DRUG|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
214819508|NCT03251807|DEVICE|Twin-block|Functional treatment will be achieved using the Twinblock appliance
214265698|NCT01354587|DRUG|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
214265699|NCT00193258|DRUG|Bevacizumab|10mg/kg IV infusion every 2 weeks
214265700|NCT00193258|DRUG|Erlotinib|150 mg po daily
214265701|NCT00193258|DRUG|Imatinib|400-600mg daily
214265702|NCT04094129|DIETARY_SUPPLEMENT|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
214819509|NCT03251807|OTHER|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
214819510|NCT03077451|OTHER|Laboratory Biomarker Analysis|Correlative studies
214819511|NCT03077451|DRUG|Nelfinavir Mesylate|Given PO
214819512|NCT04188080|DIETARY_SUPPLEMENT|Jarlsberg Cheese|Oral daily intake of Jarlsberg cheese
214819513|NCT03022786|OTHER|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
214265703|NCT04094129|DIETARY_SUPPLEMENT|Placebo|placebo
214265704|NCT03308786|DRUG|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
214265705|NCT02987556|DEVICE|Continuous Glucose Monitoring|Collection of glucose data
214265706|NCT02987556|DEVICE|External Insulin Pump|insulin delivery
214265707|NCT02987556|OTHER|telemdecine|Remote follow up by care health providers team
214265708|NCT02987556|DEVICE|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
214265709|NCT01630057|DRUG|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
214265710|NCT01630057|DRUG|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
214265711|NCT03374969|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
214819514|NCT03022786|OTHER|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
214819515|NCT03022786|OTHER|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
214265712|NCT03374969|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
214265713|NCT04273373|BIOLOGICAL|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
214265714|NCT04273373|BIOLOGICAL|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
214265715|NCT01932359|OTHER|rapidly absorbable suture (Vicryl Rapide)|
214265716|NCT01932359|OTHER|non-absorbable suture (Ethilon)|
214265717|NCT02056977|OTHER|Titration|Individualized PEEP according to PEEP titration monitored by EIT
214265718|NCT02056977|OTHER|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
214265719|NCT00846235|OTHER|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
214265720|NCT06419738|BEHAVIORAL|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
214265721|NCT06419738|RADIATION|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
214265722|NCT06419738|DEVICE|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
214265723|NCT06097169|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
214265724|NCT06097169|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
214265725|NCT01131611|BEHAVIORAL|CBPT|Cognitive-Behavioral Based Physical Therapy
214265726|NCT01131611|OTHER|Control-Attention|Standard of Care + weekly phone calls
214265727|NCT00219973|DRUG|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
214265728|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
214265729|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
214265730|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
214265731|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
214265732|NCT03698409|DRUG|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
214265733|NCT06318234|DIAGNOSTIC_TEST|18F-FAPI，18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
214265734|NCT05460260|DEVICE|Cascade CGM|21-days of CGM wear
214265735|NCT02067130|PROCEDURE|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
214265736|NCT01393223|DRUG|LP-08 80mg|Intravesical instillation of 80mg LP08
214265737|NCT01393223|DRUG|Normal saline|Intravesical instillation of normal saline
214265738|NCT01393223|DRUG|LP-08 20mg|Intravesical instillation of 20mg LP08
214265739|NCT01372592|PROCEDURE|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
214819516|NCT04709081|DRUG|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
214265740|NCT00370071|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
214265741|NCT04016064|PROCEDURE|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives."
214265742|NCT02272075|DEVICE|Mobile OCT M3 scope|
214265743|NCT00062946|DRUG|(18F)fallypride|
214265744|NCT02864602|DRUG|IV dexamethasone|An infusion of IV dexamethasone
214265745|NCT03919331|DIAGNOSTIC_TEST|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
214265746|NCT04053231|OTHER|liver resection|all type of liver surgical procedures
214265747|NCT03348137|OTHER|Questionnaire Administration|Ancillary studies
214265748|NCT04308096|DRUG|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
214819517|NCT04709081|DRUG|Midazolam|Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
214819518|NCT04709081|DRUG|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
214819519|NCT04709081|DRUG|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
214265749|NCT02701023|DRUG|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
214265750|NCT00354822|DRUG|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts\>150x10\^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10\^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
214265751|NCT00194883|DRUG|Recombinant Human Growth Hormone|
214265752|NCT02399553|OTHER|Soccer boot intervention|
214265753|NCT00239109|DRUG|Ziprasidone|
214819520|NCT04489641|BEHAVIORAL|Psychological treatment|Psychological treatment
214819521|NCT04489641|DRUG|Medication|Pharmacological intervention
214819522|NCT06562517|OTHER|Digital training module|The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
214819523|NCT06556043|OTHER|cM1 transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
214819524|NCT06556043|OTHER|cPPC transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
214265754|NCT00239109|DRUG|Olanzapine|
214265755|NCT00239109|PROCEDURE|Scales|
214265756|NCT00239109|PROCEDURE|measures of the body (Weight...)|
214265757|NCT00239109|PROCEDURE|Serum analysis|
214265758|NCT01242462|PROCEDURE|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
214265759|NCT01242462|OTHER|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
214265760|NCT03360604|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
214265761|NCT03360604|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
214265762|NCT00499499|DRUG|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
214265763|NCT05805930|DRUG|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
214819525|NCT06556043|OTHER|iCBM transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
214819526|NCT06556043|OTHER|sham transcranial direct current stimulation|For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
214819527|NCT00852696|DRUG|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
214265764|NCT05805930|DRUG|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
214819528|NCT00852696|OTHER|Placebo|Take orally once daily for 9 weeks.
214265765|NCT00400283|DRUG|NNC 55-0414|
214265766|NCT03206411|DIAGNOSTIC_TEST|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
214265767|NCT05867303|DRUG|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
214265768|NCT06409923|DEVICE|Stimulation of mandibular growth.|orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
214265769|NCT01441180|DRUG|GS7977|drug intervention
214265770|NCT01441180|DRUG|RBV|drug intervention
214265771|NCT04376463|DIETARY_SUPPLEMENT|Branched Chain Aminoacid|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
214265772|NCT01267045|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
214819529|NCT02512900|DRUG|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
214819530|NCT00031395|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
214819531|NCT00031395|DRUG|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
214819532|NCT00031395|OTHER|placebo|an inactive substance
214819533|NCT02510391|BEHAVIORAL|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
214819534|NCT02409355|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
214819535|NCT02409355|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
214819536|NCT02409355|DRUG|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m\^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
214265773|NCT05984095|OTHER|Telerehabilitation|The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
214265774|NCT02702219|BEHAVIORAL|Mobility of the hamstrings muscles|
214265775|NCT03942666|DRUG|Treatment A|tablet of CHF 6532
214819537|NCT02409355|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 (when coadministered with carboplatin) or 1250 mg/m\^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
214819538|NCT00838539|DRUG|Neratinib|
214819539|NCT00838539|DRUG|Temsirolimus|
214819540|NCT06563271|DRUG|Dexketoprofen Trometamol 50 Mg/mL Solution for Injection|Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
214265776|NCT03942666|DRUG|Treatment B|tablet of CHF 6532
214265777|NCT03942666|DRUG|Treatment C|tablet of CHF 6532
214265778|NCT03942666|DRUG|Treatment D|tablet of CHF 6532
214265779|NCT03942666|DRUG|Treatment E|Placebo tablet of CHF 6532
214265780|NCT03942666|DRUG|Treatment F|tablet of CHF 6532
214265781|NCT01771952|DEVICE|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
214265782|NCT01771952|OTHER|Sham Treatment|A single needle stick without arthrocentesis or injection.
214265783|NCT03204019|DRUG|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
214265784|NCT03204019|DRUG|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
214265785|NCT01610661|OTHER|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
214265786|NCT00507923|DEVICE|Actigraph|Wear actigraph
214265787|NCT00507923|OTHER|Best Practice|Receive usual care
214265788|NCT00507923|OTHER|Quality-of-Life Assessment|Ancillary studies
214265789|NCT00507923|OTHER|Questionnaire Administration|Ancillary studies
214265790|NCT00507923|OTHER|Sleep Diary|Complete sleep diary
214265791|NCT00507923|OTHER|Stretching|Participate in stretching sessions
214265792|NCT00507923|PROCEDURE|Yoga|Participate in Tibetan yoga
214265793|NCT01402011|PROCEDURE|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
214265794|NCT01402011|PROCEDURE|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
214265795|NCT01402011|PROCEDURE|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
214265796|NCT02789995|PROCEDURE|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
214265797|NCT05514483|DRUG|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
214265798|NCT05514483|DRUG|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
214265799|NCT03110094|OTHER|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
214265800|NCT03110094|OTHER|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
214265801|NCT05727904|BIOLOGICAL|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
214265802|NCT05727904|BIOLOGICAL|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
214265803|NCT04028778|DRUG|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
214265804|NCT04028778|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
214265805|NCT04028778|OTHER|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
214265806|NCT04885192|OTHER|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
214265807|NCT06388291|DEVICE|Deep Brain Stimulation|ON/OFF stimulation vs OFF/ON stimulation
214265808|NCT02504684|DEVICE|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
214265809|NCT02504684|DEVICE|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
214265810|NCT04225507|BEHAVIORAL|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
214819541|NCT06563271|DRUG|Ibuprofen 100 MG/ML Solution for Injection|"Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion)."
214265811|NCT04225507|OTHER|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
214819542|NCT06563271|DRUG|Paracetamol 10 Mg/mL Solution for Injection|Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
214819543|NCT06563271|DRUG|isotonic saline|Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
214819544|NCT01255085|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
214819545|NCT01255085|DIETARY_SUPPLEMENT|yellow pea fiber|Served in a tomato soup
214819546|NCT01255085|DIETARY_SUPPLEMENT|Control Tomato Soup|Served in a tomato soup
214265812|NCT02649088|DEVICE|Microscan|It allows to look at sublingual microcirculation
214265813|NCT02649088|DEVICE|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
214265814|NCT04574323|RADIATION|Curative radiotherapy|Standard curative radiotherapy
214265815|NCT04574323|OTHER|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
214265816|NCT05911321|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
214265817|NCT05911321|DRUG|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
214265818|NCT05911321|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
214265819|NCT06601751|OTHER|Neurobic Exercise Program|6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.
214265820|NCT06601751|OTHER|Traditional Brain Exercise|activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
214265821|NCT04332133|PROCEDURE|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
214265822|NCT05514340|DRUG|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
214265823|NCT05514340|DRUG|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
214265824|NCT00169793|OTHER|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
214265825|NCT00169793|OTHER|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
214265826|NCT06664606|BEHAVIORAL|Pain Neuroscience Education Program (PNE)|The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
214265827|NCT00987545|DRUG|QAX576|QAX576 injection
214265828|NCT00987545|DRUG|QAX576 placebo|Placebo to QAX576 injection
214265829|NCT06162429|PROCEDURE|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
214265830|NCT06162429|PROCEDURE|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
214265831|NCT05041426|DRUG|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
214265832|NCT05041426|DRUG|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
214265833|NCT04508335|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
214265834|NCT06708442|BEHAVIORAL|School-based CBT intervention|School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.
214656128|NCT05670977|DIETARY_SUPPLEMENT|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
214656129|NCT05576220|DEVICE|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
214656130|NCT05904444|PROCEDURE|microperimetric biofeedback training|Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
214265835|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) Writing|Guided Narrative Technique (GNT) Writing : GNT writing is an intervention through writing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Writing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
214265836|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) drawing|Guided Narrative Technique (GNT) Drawing: GNT drawing is an intervention through drawing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Drawing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
214265837|NCT06708403|OTHER|Judo-Specific Injury Prevention Exercise Program|The intervention includes a structured program designed specifically for judo athletes to prevent injuries and enhance performance. The program consists of warm-up exercises, strength and conditioning drills, balance improvement exercises, agility training, and sport-specific movements. It is delivered over six weeks, with participants completing three sessions per week. Each session is progressively tailored to improve overall motor skills, prevent overuse injuries, and enhance judo-specific abilities.
214265838|NCT06454435|DRUG|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
214265839|NCT06454435|DRUG|Sintilimab + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
214265840|NCT03969511|PROCEDURE|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
214265841|NCT03969511|PROCEDURE|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
214265842|NCT06218563|OTHER|vibration-induced illusion of movement|Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
214265843|NCT00106197|DRUG|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
214265844|NCT02077244|BEHAVIORAL|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
214265845|NCT05113420|DRUG|Detralex|Diosmin+ Hesperidin
214265846|NCT05113420|DRUG|Troxevasin|Troxerutin
214265847|NCT03948698|OTHER|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
214265848|NCT00418015|PROCEDURE|Blood Draw|Blood for OPRM1 analysis
214265849|NCT00160485|DRUG|Glyburide|dosage required to obtain adequate glucose control
214265850|NCT00160485|DRUG|Insulin|variable dosage to obtain glucose control
214265851|NCT06007885|OTHER|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
214265852|NCT04307784|DIETARY_SUPPLEMENT|VD3|VD3 (50.000 IU/week) for 8 weeks
214265853|NCT04307784|DIETARY_SUPPLEMENT|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
214265854|NCT04307784|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
214265855|NCT04307784|OTHER|Control|No intervention is given
214265856|NCT05747820|OTHER|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
214265857|NCT03868020|PROCEDURE|Computed Tomography|Undergo PET/CT
214265858|NCT03868020|RADIATION|Fluciclovine F18|Given IV
214265859|NCT03868020|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214265860|NCT00825682|OTHER|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
214265861|NCT00079248|BIOLOGICAL|therapeutic progesterone|
214265862|NCT00079248|DRUG|conjugated estrogens|
214265863|NCT04961307|DRUG|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
214656131|NCT02236169|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
214656132|NCT02236169|DRUG|Atrovent CFC inhalation aerosol|
214265864|NCT06000332|DEVICE|InogenOne Rove 6 Portable Oxygen Concentrator|overnight use of Portable Oxygen Concentrator, 6 hours minimum
214265865|NCT05032664|OTHER|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
214265866|NCT05032664|OTHER|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
214265867|NCT03680560|BIOLOGICAL|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
214265868|NCT03680560|DRUG|Trastuzumab|monoclonal antibody targeting HER2
214265869|NCT02557711|DEVICE|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
214265870|NCT01509365|DRUG|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
214265871|NCT01509365|DRUG|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
214265872|NCT01628978|OTHER|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
214265873|NCT01628978|OTHER|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
214265874|NCT04053439|OTHER|Blood test for determination of CHIP|Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
214819547|NCT04418349|PROCEDURE|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
214265875|NCT01952925|PROCEDURE|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
214819548|NCT01704105|BEHAVIORAL|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
214265876|NCT06057844|OTHER|Additional blood sampling|Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
214265877|NCT06202430|PROCEDURE|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
214265878|NCT06202430|PROCEDURE|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
214265879|NCT05715697|PROCEDURE|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
214265880|NCT05715697|PROCEDURE|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
214265881|NCT05768217|BEHAVIORAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
214265882|NCT05768217|BEHAVIORAL|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
214265883|NCT06484738|OTHER|transcriptomic analysis|to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
214265884|NCT02281201|BIOLOGICAL|BE1116 (Prothrombin Complex Concentrate)|
214265885|NCT05501275|BEHAVIORAL|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
214819549|NCT01704105|BEHAVIORAL|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
214265886|NCT04437186|BEHAVIORAL|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
214265887|NCT00316719|DRUG|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
214265888|NCT00316719|DRUG|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
214265889|NCT03493399|BEHAVIORAL|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
214265890|NCT01542320|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
214265891|NCT01542320|OTHER|Placebo|Solution without active Lactobacillus reuteri
214265892|NCT05570292|DRUG|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
214265893|NCT05570292|DRUG|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
214265894|NCT00134459|DRUG|Bifeprunox|
214265895|NCT00134459|DRUG|Placebo|
214265896|NCT04336306|OTHER|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
214265897|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 1
214265898|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 2
214265899|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 3
214265900|NCT02092831|DRUG|GDC-0941|Single dose Phase 2 tablet formulation
214265901|NCT00005073|DRUG|zoledronic acid|
214265902|NCT02086292|PROCEDURE|2 ml 1% Lidocaine|
214265903|NCT02086292|PROCEDURE|1 ml 2% Lidocaine|
214265904|NCT02903355|DRUG|D-methionine|D-methionine, oral liquid suspension
214265905|NCT02903355|DRUG|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
214265906|NCT02738060|DIETARY_SUPPLEMENT|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
214265907|NCT05689476|DEVICE|NAVA GROUP|NAVA ventilation: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
214265908|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
214265909|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|
214265910|NCT01644565|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|
214265911|NCT05984056|BEHAVIORAL|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
214265912|NCT00875875|DRUG|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
214265913|NCT01910857|BEHAVIORAL|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
214265914|NCT06467461|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
214265915|NCT06467461|DIAGNOSTIC_TEST|Speech testing|Speech Testing to quantify evolving signs of 5-HT RBD
214265916|NCT06467461|DIAGNOSTIC_TEST|Ultra high field 7T MRI|7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
214265917|NCT01550289|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
214265918|NCT01550289|BIOLOGICAL|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
214265919|NCT03959943|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
214265920|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
214265921|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
214265922|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
214265923|NCT00025272|DRUG|carboplatin|
214265924|NCT00025272|DRUG|etoposide|
214265925|NCT00025272|DRUG|topotecan hydrochloride|
214265926|NCT00025272|RADIATION|radiation therapy|
214265927|NCT04667481|OTHER|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
214265928|NCT04667481|OTHER|Resistance Exercise Intervention|Participate in resistance exercise intervention
214265929|NCT04667481|OTHER|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
214265930|NCT04667481|OTHER|Questionnaire Administration|Ancillary studies
214265931|NCT04667481|OTHER|Quality-of-Life Assessment|Ancillary studies
214265932|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
214265933|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
214265934|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
214265935|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
214265936|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
214265937|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
214265938|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
214265939|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
214265940|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
214819550|NCT01704105|BEHAVIORAL|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
214819551|NCT01704105|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
214265941|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
214265942|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
214265943|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
214265944|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
214265945|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
214265946|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
214265947|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
214265948|NCT00094172|DRUG|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
214819552|NCT04349475|DIETARY_SUPPLEMENT|Intervention Omega 3 Supplementation|Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
214819553|NCT04349475|DIETARY_SUPPLEMENT|Control Safflower Oil|Participants will consume 2.5g of a Safflower oil supplement daily
214819554|NCT04123080|DEVICE|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
214819555|NCT03182322|DRUG|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
214819556|NCT03182322|OTHER|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
214265949|NCT00094172|DRUG|Placebo|tablet form
214265950|NCT02318875|DIETARY_SUPPLEMENT|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
214265951|NCT02318875|OTHER|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
214265952|NCT00261274|BIOLOGICAL|A-ECO|
214265953|NCT00261274|BIOLOGICAL|Saline|
214265954|NCT02363842|DEVICE|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
214265955|NCT02363842|OTHER|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
214265956|NCT00725374|DRUG|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
214265957|NCT00725374|DRUG|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
214265958|NCT05231304|PROCEDURE|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
214265959|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
214265960|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
214265961|NCT05231304|PROCEDURE|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
214265962|NCT04923061|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
214265963|NCT04923061|OTHER|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
214265964|NCT03476993|BIOLOGICAL|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
214265965|NCT03076320|COMBINATION_PRODUCT|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
214265966|NCT03076320|COMBINATION_PRODUCT|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
214265967|NCT06061536|DRUG|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
214265968|NCT06061536|DRUG|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
214265969|NCT06061536|DRUG|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
214265970|NCT06061536|DRUG|DTG|DTG +3TC + TDF（once daily）.
214265971|NCT02057731|GENETIC|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
214819557|NCT04046783|DEVICE|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
214819558|NCT00760825|BIOLOGICAL|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
214265972|NCT01948297|DRUG|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
214265973|NCT06060743|OTHER|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
214265974|NCT00713323|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
214265975|NCT00437177|DRUG|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
214265976|NCT00437177|DRUG|[(123)I] iodobenzamide|\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
214265977|NCT02398578|DEVICE|Amphora OAB Device|Cystoscopic procedure to treat OAB
214265978|NCT02478632|DRUG|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
214265979|NCT02171377|DEVICE|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
214265980|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
214265981|NCT02171377|DEVICE|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
214265982|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
214265983|NCT02130232|BEHAVIORAL|Lifestyle Intervention|
214265984|NCT02130232|OTHER|Usual Care|
214265985|NCT03698201|OTHER|Non-interventional|Translational, observational study
214265986|NCT05451771|DRUG|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
214265987|NCT05451771|DEVICE|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
214819559|NCT01220362|DRUG|Bupivacain 0.125%|Bupivacain 0.125%
214265988|NCT05451771|DRUG|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
214819560|NCT01220362|DRUG|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
214819561|NCT00627419|DRUG|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
214819562|NCT03482882|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
214819563|NCT01270594|BEHAVIORAL|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
214265989|NCT05451771|DRUG|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
214819564|NCT01270594|BEHAVIORAL|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
214819565|NCT02620891|DEVICE|helium oxygen mixture|
214819566|NCT06249360|OTHER|Veins with reflux|This group included patients who used only recipient veins with reflux
214265990|NCT05451771|DRUG|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
214265991|NCT05451771|DRUG|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
214265992|NCT05451771|DRUG|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
214265993|NCT05451771|DRUG|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
214265994|NCT05451771|DRUG|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
214265995|NCT05451771|DRUG|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
214265996|NCT05299606|DEVICE|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
214819567|NCT06249360|OTHER|Reflux-free recipient veins|This group included patients who utilized only reflux-free recipient veins
214819568|NCT02756663|DRUG|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
214265997|NCT04811378|OTHER|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
214265998|NCT06079658|BEHAVIORAL|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
214265999|NCT04622306|DEVICE|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
214266000|NCT00443027|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
214266001|NCT02043314|DRUG|Isoniazida|
214266002|NCT06078410|PROCEDURE|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
214266003|NCT04668807|DEVICE|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
214819569|NCT02756663|DRUG|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
214266004|NCT04668807|DEVICE|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
214266005|NCT04835480|DRUG|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
214266006|NCT04835480|DRUG|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
214266007|NCT02499276|DEVICE|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
214266008|NCT03897023|BIOLOGICAL|Gut Microbiota|Status of microbiota
214266009|NCT03375008|DIAGNOSTIC_TEST|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
214266010|NCT02777710|DRUG|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
214266011|NCT02777710|DRUG|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
214266012|NCT06000397|OTHER|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
214266013|NCT06000397|OTHER|Standard CANImmunize notifications|"Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date"
214819570|NCT02756663|DRUG|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
214819571|NCT05410002|DIETARY_SUPPLEMENT|Dietary Supplement: N-111|Dietary supplement N-111
214819572|NCT05410002|OTHER|Placebo|Dietary placebo
214819573|NCT04904705|OTHER|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
214819574|NCT04904705|OTHER|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
214266014|NCT04001933|OTHER|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
214266015|NCT02007616|OTHER|Non-action video game training|Based on cognitive training Lumosity
214266016|NCT06450080|OTHER|MRI and MRS acquisitions|All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
214266017|NCT00864721|DRUG|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
214266018|NCT06540027|PROCEDURE|rectal cacer surgery|minimally invasive surgery
214266019|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Colonic-Delivery capsule)|250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
214266020|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Regular Administration capsule)|250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
214819575|NCT02411903|DRUG|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
214819576|NCT02411903|DRUG|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
214819577|NCT01386853|DRUG|Pitavastatin|2 mg QD
214819578|NCT01386853|DRUG|Atorvastatin|10 mg QD
214266021|NCT06097182|OTHER|Placebo|250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
214266022|NCT00489060|PROCEDURE|Cryoablation and External Beam Radiation|
214266023|NCT01868503|DRUG|lapatinib ditosylate|Given PO
214266024|NCT01868503|RADIATION|radiation therapy|Undergo radiation therapy
214819579|NCT03432663|DRUG|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
214266025|NCT01868503|OTHER|laboratory biomarker analysis|Correlative studies
214266026|NCT05825781|DRUG|Pertuzumab|i.v.
214266027|NCT05825781|DRUG|Perjeta®|i.v.
214266028|NCT05515471|DRUG|SHR8058 eye drops|SHR8058 eye drops
214266029|NCT05515471|DRUG|saline eye drops.|saline eye drops.
214266030|NCT03286738|DRUG|FOLFIRI, target agent|"* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
214266031|NCT04521374|BEHAVIORAL|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
214266032|NCT05661110|OTHER|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
214656133|NCT02002143|BEHAVIORAL|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
214819580|NCT03432663|DRUG|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
214266033|NCT00547573|DRUG|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
214266034|NCT00547573|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
214266035|NCT00547573|DRUG|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
214266036|NCT06267248|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
214266037|NCT01050855|DRUG|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
214266038|NCT01050855|DRUG|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
214266039|NCT01050855|DRUG|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
214819581|NCT04641702|DRUG|Atropine challenge|Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
214819582|NCT04641702|PROCEDURE|Esophageal muscle biopsy|Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
214819583|NCT04481451|PROCEDURE|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
214819584|NCT04481451|PROCEDURE|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
214819585|NCT04481451|DRUG|Ropivacaine|ropivacaine 0.2% nerve block injection
214819586|NCT00913627|DRUG|ibuprofen|
214266040|NCT00810914|DRUG|bupivicaine epidural|bupivicaine continuous epidural infusion
214819587|NCT00913627|DRUG|ibuprofen|
214819588|NCT00913627|DRUG|naproxen|
214819589|NCT00913627|DRUG|Placebo|
214819590|NCT06627998|DIAGNOSTIC_TEST|Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice|Biochemical, clinical and radiological data performed for clinical practice will be retrospectively collected. Osteoporosis and vertebral fractures will be diagnosed through DXA scan and vertebral morphometry.
214266041|NCT00810914|DRUG|bupivicaine epidural infusion patient epidural|bupivicaine
214266042|NCT00810914|DRUG|bupivicaine|patient controlled anesthesia only
214266043|NCT01890941|DRUG|KCT-0809 ophthalmic solution|
214266044|NCT01890941|DRUG|Placebo|
214266045|NCT00223015|DRUG|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
214266046|NCT00282100|DRUG|Gefetinib (Iressa)|
214266047|NCT01228643|BIOLOGICAL|Pancreatic enzimes|\- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
214266048|NCT01228643|DEVICE|Creon ®|\- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
214266049|NCT02836392|BEHAVIORAL|Questionnaire|
214266050|NCT03128827|DEVICE|RAM sensor|Acoustic Respiration Monitor
214266051|NCT02154737|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
214266052|NCT02154737|DRUG|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
214266053|NCT05768074|OTHER|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
214266054|NCT04752683|OTHER|MyBuddy Employee Wellbeing App|"The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data)."
214266055|NCT05600803|PROCEDURE|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
214266056|NCT00876057|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy
214266057|NCT00876057|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
214266058|NCT00736944|DRUG|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
214819591|NCT03887676|DRUG|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
214819592|NCT03887676|OTHER|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
214819593|NCT01746238|DRUG|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
214266059|NCT00736944|DRUG|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
214266060|NCT00736944|DRUG|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
214266061|NCT00736944|DRUG|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
214266062|NCT00736944|DRUG|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
214266063|NCT00736944|RADIATION|Radiation (Post induction)|Monday-Friday, weeks 1-7
214266064|NCT00736944|DRUG|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
214266065|NCT00736944|DRUG|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
214266066|NCT03363269|DRUG|ID1201|
214266067|NCT05942560|BEHAVIORAL|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
214266068|NCT05942560|BEHAVIORAL|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
214266069|NCT03266731|DRUG|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
214266070|NCT05956691|DIETARY_SUPPLEMENT|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
214819594|NCT01746238|DRUG|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
214819595|NCT01746238|RADIATION|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
214819596|NCT05847062|PROCEDURE|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
214819597|NCT00609830|BEHAVIORAL|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
214266071|NCT04521660|DEVICE|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
214266072|NCT02675985|OTHER|Physical Therapy|Early Intensive Physical therapy in the ICU
214819598|NCT00609830|BEHAVIORAL|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
214819599|NCT00609830|BEHAVIORAL|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
214819600|NCT00609830|BEHAVIORAL|No Information|Participants received no informational materials.
214819601|NCT01876875|DIETARY_SUPPLEMENT|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
214819602|NCT01876875|DIETARY_SUPPLEMENT|Usual diet|The patients of this group were randomized to continue their usual diet
214819603|NCT01998295|DRUG|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
214819604|NCT05621226|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
214266073|NCT00002854|BIOLOGICAL|filgrastim|
214266074|NCT00002854|DRUG|carboplatin|
214266075|NCT00002854|DRUG|cisplatin|
214266076|NCT00002854|DRUG|cyclophosphamide|
214819605|NCT02110394|OTHER|bendamustine|Routine practice
214266077|NCT00002854|DRUG|etoposide|
214266078|NCT00002854|DRUG|ifosfamide|
214266079|NCT00002854|DRUG|mesna|
214819606|NCT02110394|OTHER|rituximab|Routine practice
214819607|NCT03123471|DRUG|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
214819608|NCT03123471|OTHER|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
214819609|NCT01641380|BEHAVIORAL|Text Messaging Intervention|"1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
214819610|NCT05914454|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
214819611|NCT03500120|DIAGNOSTIC_TEST|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
214819612|NCT05792397|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
214819613|NCT00652977|PROCEDURE|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
214266080|NCT00002854|DRUG|paclitaxel|
214266081|NCT00002854|PROCEDURE|peripheral blood stem cell transplantation|
214819614|NCT00652977|PROCEDURE|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
214819615|NCT00649987|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
214819616|NCT00649987|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
214819617|NCT00836576|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
214819618|NCT00836576|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
214819619|NCT03851939|COMBINATION_PRODUCT|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
214819620|NCT03153540|DEVICE|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
214819621|NCT03153540|DEVICE|Sham iTBS|Sham intervention
214819622|NCT06999655|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
214266082|NCT06303908|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
214266083|NCT06487416|DRUG|Tiotropium Bromide Inhalation Powder|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
214266084|NCT06487416|DRUG|Spiriva®Handihaler®|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
214266085|NCT06314308|BEHAVIORAL|CATCHES|At the baseline visit (T0), informed consent will be obtained, and baseline questionnaires and measurements completed. A physical activity monitor will be provided. After discharge, Task Specific Training guided by Cognitive Behavioral Therapy with Exposure delivered over 7 one-hour sessions including two intake sessions by specialists and five follow up sessions delivered by CHWs individually at home over 3 months. After the final session at 12 weeks (about 3 months), participants will complete a study end visit (T1) which will include follow up questionnaires and measurements.
214266086|NCT05350410|BEHAVIORAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
214266087|NCT06074861|PROCEDURE|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
214266088|NCT04085393|DRUG|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
214266089|NCT01601132|DRUG|theophylline|300mg (80mg/15ml elixir)
214266090|NCT01601132|DRUG|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
214266091|NCT01902823|BEHAVIORAL|Services from a Nurse Navigator|Services from a Nurse Navigator
214266092|NCT05274061|BEHAVIORAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
214266093|NCT02110238|DEVICE|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
214266094|NCT02110238|DEVICE|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
214266095|NCT03532958|DRUG|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
214266096|NCT03532958|DRUG|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
214266097|NCT04824950|OTHER|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
214266098|NCT04333550|DRUG|Deferoxamine|Intravenous infusion of Deferoxamine
214266099|NCT03629431|PROCEDURE|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
214266100|NCT03629431|PROCEDURE|postoperative standard care|Standard care received postoperatively
214266101|NCT00002561|BIOLOGICAL|bleomycin sulfate|10 units/m2
214266102|NCT00002561|DRUG|dacarbazine|375mg/m2
214266103|NCT00002561|DRUG|doxorubicin hydrochloride|25mg/m2
214266104|NCT00002561|DRUG|vinblastine|6mg/m2
214266105|NCT00002561|RADIATION|radiation therapy|35Gy in 20 fractions (daily)
214266106|NCT05687175|OTHER|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
214266107|NCT06088108|DEVICE|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
214266108|NCT05276037|OTHER|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
214266109|NCT02451111|DRUG|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
214266110|NCT02451111|DRUG|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
214266111|NCT02761070|DRUG|Temozolomide|
214266112|NCT02761070|DRUG|Bevacizumab|
214266113|NCT00673504|DRUG|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
214266114|NCT00673504|DRUG|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
214266115|NCT00115635|DRUG|docetaxel|
214266116|NCT00115635|DRUG|gemcitabine|
214266117|NCT05058235|OTHER|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
214266118|NCT05058235|OTHER|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
214266119|NCT06125561|OTHER|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
214266120|NCT03421535|PROCEDURE|Sleeper Stretch|Internal Range of motion of dominant shoulder
214819623|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
214266121|NCT03421535|PROCEDURE|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
214266122|NCT02170194|BEHAVIORAL|Resilience Enhancement Training via Smart Phone|
214266123|NCT02170194|BEHAVIORAL|Daily Text Messages|
214266124|NCT05347277|DIAGNOSTIC_TEST|Kappa Free Light Chain (K-FLC)|A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
214266125|NCT00515489|DRUG|Risperidone|as prescribed
214266126|NCT00435864|PROCEDURE|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
214266127|NCT06295302|DRUG|HWH486|HWH486 capsule was administrated orally
214266128|NCT06295302|DRUG|Placebo|Matching placebo was administrated orally
214266129|NCT03473535|COMBINATION_PRODUCT|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
214266130|NCT03473535|BEHAVIORAL|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
214266131|NCT00697788|DRUG|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
214266132|NCT05374733|DIAGNOSTIC_TEST|Coronary Physiology assessment|"1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
214266133|NCT02432742|DEVICE|Restylane Perlane|Intradermal injection
214266134|NCT02432742|DEVICE|Restylane|Intradermal injection
214266135|NCT06277596|OTHER|Exercise|Clinical Pilates exercises (basic and advanced stabilization exercises)
214266136|NCT05521620|BEHAVIORAL|The father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
214266137|NCT04496700|PROCEDURE|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
214266138|NCT00594048|DEVICE|Resperate|Use of the device 15 minutes a day for 9 weeks
214266139|NCT00594048|DEVICE|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
214266140|NCT06557382|BEHAVIORAL|Cognitive tests and reading-related evaluations|Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
214266141|NCT05295056|DEVICE|AFGen1 Device Wear Test|Participant wears the device for 7 days
214266142|NCT05295056|DEVICE|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
214266143|NCT06315348|PROCEDURE|flapless alveolar decortication with augmentation|piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
214266144|NCT05195190|OTHER|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
214266145|NCT06558097|DRUG|XXB750|Single SC dose of XXB750 (administered by single or multiple injections)
214266146|NCT06558097|OTHER|Placebo|Single SC dose of matching placebo (administered by single or multiple injections)
214266147|NCT03913988|BEHAVIORAL|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
214266148|NCT03913988|BEHAVIORAL|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
214266149|NCT03913988|BEHAVIORAL|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
214266150|NCT03985254|OTHER|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
214266151|NCT03985254|OTHER|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
214266152|NCT04261036|DRUG|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
214266153|NCT04261036|OTHER|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
214819624|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
214819625|NCT02004197|DRUG|Quadruple Allopathic therapy|
214819626|NCT02004197|DRUG|Pylorex plus|
214266154|NCT05081765|DRUG|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
214266155|NCT05081765|DEVICE|Lynparza|correlation between C through and taken drug
214266156|NCT01033760|DRUG|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
214266157|NCT01033760|DRUG|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
214266158|NCT02662829|BEHAVIORAL|Community-based intervention|
214266159|NCT02662829|OTHER|Standard of care|
214266160|NCT05792501|DEVICE|Mechanical ventilation|type of therapy that helps you breathe or breathes for you when you can't breathe on your own
214266161|NCT00324909|DRUG|Hyperbaric Oxygen Therapy|
214266162|NCT02509481|DRUG|Ivermectin|
214266163|NCT02509481|DRUG|Albendazole|
214266164|NCT03226860|DEVICE|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
214819627|NCT02370719|BEHAVIORAL|Mobile application for diabetes self-management|
214819628|NCT04829162|OTHER|Mother with obesity, daughter with obesity|Participants in this group were shown an image of a mother with obesity and a daughter with obesity.
214819629|NCT04829162|OTHER|Mother with obesity, daughter without obesity|Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
214819630|NCT04829162|OTHER|Mother without obesity, daughter with obesity|Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
214819631|NCT04829162|OTHER|Mother without obesity, daughter without obesity|Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
214819632|NCT04829162|OTHER|Mother with obesity, son with obesity|Participants in this group were shown an image of a mother with obesity and a son with obesity.
214819633|NCT04829162|OTHER|Mother with obesity, son without obesity|Participants in this group were shown an image of a mother with obesity and a son without obesity.
214819634|NCT04829162|OTHER|Mother without obesity, son with obesity|Participants in this group were shown an image of a mother without obesity and a son with obesity.
214819635|NCT04829162|OTHER|Mother without obesity, son without obesity|Participants in this group were shown an image of a mother without obesity and a son without obesity.
214819636|NCT04829162|OTHER|Father with obesity, daughter with obesity|Participants in this group were shown an image of a father with obesity and a daughter with obesity.
214819637|NCT04829162|OTHER|Father with obesity, daughter without obesity|Participants in this group were shown an image of a father with obesity and a daughter without obesity.
214819638|NCT04829162|OTHER|Father without obesity, daughter with obesity|Participants in this group were shown an image of a father without obesity and a daughter with obesity.
214819639|NCT04829162|OTHER|Father without obesity, daughter without obesity|Participants in this group were shown an image of a father without obesity and a daughter without obesity.
214819640|NCT04829162|OTHER|Father with obesity, son with obesity|Participants in this group were shown an image of a father with obesity and a son with obesity.
214819641|NCT04829162|OTHER|Father with obesity, son without obesity|Participants in this group were shown an image of a father with obesity and a son without obesity.
214819642|NCT04829162|OTHER|Father without obesity, son with obesity|Participants in this group were shown an image of a father without obesity and a son with obesity.
214819643|NCT04829162|OTHER|Father without obesity, son without obesity|Participants in this group were shown an image of a father without obesity and a son without obesity.
214819644|NCT02957942|DEVICE|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
214819645|NCT06371807|DRUG|Pembrolizumab injection|(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
214266165|NCT03226860|OTHER|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
214266166|NCT01760720|BEHAVIORAL|MMT CARE|
214266167|NCT05587803|DEVICE|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
214266168|NCT03433157|DEVICE|Hall technique|Metal Stainless stain crown placed with Hall technique
214266169|NCT03433157|DEVICE|Traditional technique|Metal Stainless stain crown placed with Traditional technique
214266170|NCT02354495|DIETARY_SUPPLEMENT|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
214266171|NCT04116788|DEVICE|Artefact IRM assessment|IRM
214266172|NCT01419626|DEVICE|Interdental cleaning device with water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
214266173|NCT01419626|DEVICE|Interdental cleaning device with essential-oil mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
214266174|NCT04742959|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
214266175|NCT04742959|COMBINATION_PRODUCT|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
214266176|NCT04153942|BEHAVIORAL|Mobilization|Any movement out of bed
214266177|NCT00180544|DEVICE|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
214266178|NCT04020380|DRUG|Azithromycin 250Mg Capsule|250 mg OD
214819646|NCT05397028|DIETARY_SUPPLEMENT|Meal replacement system|Participants will replace meals with a meal replacement system to assess the efficacy of weight loss leading to remission of diabetes (optimal A1C levels).
214819647|NCT05397028|BEHAVIORAL|Intensive lifestyle Intervention|Participants will sign up with a virtual health program which they will interact with.
214819648|NCT02000362|BIOLOGICAL|Stem cells|
214266179|NCT00562835|DRUG|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
214266180|NCT00562835|OTHER|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
214266181|NCT04609761|DRUG|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
214266182|NCT01365052|DRUG|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
214266183|NCT01365052|DRUG|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
214266184|NCT00275457|DRUG|pramipexole|
214266185|NCT03342677|DIAGNOSTIC_TEST|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
214266186|NCT02462252|DRUG|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
214266187|NCT02462252|DRUG|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
214266188|NCT02462252|DRUG|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
214266189|NCT02462252|DRUG|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
214819649|NCT04383886|OTHER|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
214819650|NCT01242774|DRUG|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
214819651|NCT06275061|PROCEDURE|Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
214819652|NCT03452319|OTHER|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
214819653|NCT03452319|OTHER|Usual care|Preoperative information
214819654|NCT02576730|PROCEDURE|ORIF|surgery for foot and ankle fractures
214819655|NCT00011960|DRUG|cisplatin|
214266190|NCT03369093|DRUG|Amoxicillin|Twice daily doses of injectable amoxicillin
214819656|NCT00011960|DRUG|paclitaxel|
214819657|NCT00011960|PROCEDURE|adjuvant therapy|
214819658|NCT00011960|RADIATION|radiation therapy|
214819659|NCT05401734|DEVICE|Observation and follow up measurement|"The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
214819660|NCT03727620|DRUG|amoxicillin plus metronidazole|patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
214819661|NCT03727620|DRUG|Doxycycline|patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
214819662|NCT04256122|OTHER|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
214819663|NCT00115960|BIOLOGICAL|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
214819664|NCT00115960|BIOLOGICAL|IL-15 DNA adjuvant|Cytokine injection
214819665|NCT00115960|BIOLOGICAL|IL-12 DNA adjuvant|Cytokine injection
214266191|NCT02806245|OTHER|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
214266192|NCT04794309|OTHER|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
214266193|NCT04794309|DIETARY_SUPPLEMENT|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
214266194|NCT00731068|BIOLOGICAL|PRGF|injection of 6cc into injured area of tendon
214266195|NCT00731068|BIOLOGICAL|placebo|injection of 6 cc of saline into injured area
214819666|NCT03557762|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
214266196|NCT01935297|BEHAVIORAL|Exercise|endurance and resistance exercise 3x/week for 8 weeks
214266197|NCT01049568|BEHAVIORAL|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
214266198|NCT03393130|DIAGNOSTIC_TEST|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
214266199|NCT04488796|BEHAVIORAL|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
214266200|NCT04488796|BEHAVIORAL|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
214266201|NCT04488796|BEHAVIORAL|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
214266202|NCT04488796|BEHAVIORAL|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
214266203|NCT04488796|BEHAVIORAL|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
214266204|NCT04488796|BEHAVIORAL|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
214266205|NCT03236025|COMBINATION_PRODUCT|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
214266206|NCT03236025|COMBINATION_PRODUCT|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
214819667|NCT02593357|DEVICE|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
214819668|NCT03238781|DRUG|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
214819669|NCT03238781|DRUG|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
214819670|NCT03331445|DRUG|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
214819671|NCT01188850|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
214819672|NCT00376285|DRUG|CP-742,033|
214266207|NCT03236025|OTHER|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
214266208|NCT03531697|DRUG|Generic Loteprednol Etabonate|Drug
214266209|NCT03531697|DRUG|Reference Listed Drug (RLD)|Drug
214266210|NCT05747287|DEVICE|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
214819673|NCT00376285|DRUG|Fenofibrate|
214819674|NCT03810118|DIAGNOSTIC_TEST|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
214819675|NCT01471041|DEVICE|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
214266211|NCT01524731|DRUG|Saline|Normal Saline
214266212|NCT01524731|DRUG|Dexamethasone|4 mg
214819676|NCT05294783|PROCEDURE|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
214266213|NCT01524731|DRUG|Dexamethasone|8 mg
214266214|NCT05382663|DEVICE|Alio Device|Non-invasive device worn over vasculature.
214266215|NCT00875264|DRUG|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
214266216|NCT01145625|DRUG|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
214266217|NCT01145625|DRUG|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
214266218|NCT04544423|OTHER|Block group|Patients received lumbar erector spinae plane Block before operation
214266219|NCT02680535|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
214266220|NCT05636644|DRUG|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
214266221|NCT06270771|DEVICE|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
214266222|NCT05405868|DRUG|Nicotinomide|Nicotinamide tablets (750mg)
214266223|NCT05405868|DRUG|Matching placebo|Matching placebo
214266224|NCT03080454|DEVICE|sham Doublestim|PathMaker MyoRegulator device
214266225|NCT03080454|DEVICE|anodal Doublestim|PathMaker MyoRegulator device
214266226|NCT02017418|DIETARY_SUPPLEMENT|zeaxanthin|softgel
214266227|NCT02017418|DIETARY_SUPPLEMENT|combinatory supplement|softgel
214266228|NCT01195246|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injection on Day1
214266229|NCT01195246|BIOLOGICAL|Engerix-B|Intramuscular (IM) injection on Day 1
214266230|NCT01195246|BIOLOGICAL|Fendrix|Intramuscular (IM) injection on Day 1
214266231|NCT00053443|DEVICE|Medication Reminder System/Adherence Tracker|
214266232|NCT01068834|GENETIC|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
214266233|NCT03663946|OTHER|Non-Interventional|Non-Interventional
214266234|NCT02430623|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
214266235|NCT02430623|DEVICE|NanoKnife|
214266236|NCT00216476|DRUG|Aripiprazole|10-30 mg oral once daily for 104 weeks
214266237|NCT00216476|DRUG|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
214266238|NCT00216476|DRUG|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
214266239|NCT03385200|DRUG|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
214656134|NCT02002143|BEHAVIORAL|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
214266240|NCT01907243|PROCEDURE|spreader flap|producing of upper lateral cartilage flap as a spreader flap
214266241|NCT02479607|DEVICE|Smartphone or tablet|
214266242|NCT00547235|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214266243|NCT00547235|PROCEDURE|allogeneic bone marrow transplantation|
214266244|NCT00547235|RADIATION|total-body irradiation|
214266245|NCT02241252|DEVICE|iPhone ECG|Please see detailed description for additional information.
214266246|NCT02202980|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214266247|NCT02202980|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214266248|NCT02202980|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214266249|NCT02202980|DRUG|VOX|100 mg tablet administered orally once daily with food
214266250|NCT01573260|OTHER|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
214266251|NCT01573260|OTHER|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
214266252|NCT05200832|OTHER|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
214266253|NCT05200832|OTHER|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
214266254|NCT00705926|DRUG|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
214656135|NCT02349126|DRUG|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
214266255|NCT00705926|OTHER|No treatment|Participants in this group will not receive treatment at this stage of their infection.
214266256|NCT04850820|DIETARY_SUPPLEMENT|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
214266257|NCT04850820|DIETARY_SUPPLEMENT|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
214266258|NCT04850820|DIETARY_SUPPLEMENT|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
214266259|NCT05771012|DRUG|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
214266260|NCT05771012|DEVICE|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
214266261|NCT06437496|DRUG|68Ga-AAZTA-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
214266262|NCT06437496|DRUG|68Ga-PSMA-11//68Ga-PSMA-617|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
214266263|NCT05456269|DRUG|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
214266264|NCT05456269|DRUG|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
214266265|NCT05456269|DRUG|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
214266266|NCT05456269|DRUG|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
214266267|NCT02328300|DRUG|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
214266268|NCT04508348|OTHER|Human Milk|Exclusive Human Milk diet
214656136|NCT00013806|DRUG|131I-MIBG|
214656137|NCT05281263|BIOLOGICAL|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
214656138|NCT02680782|DRUG|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
214656139|NCT05628844|PROCEDURE|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
214656140|NCT04937023|DRUG|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
214656141|NCT02626728|PROCEDURE|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
214656142|NCT01822002|PROCEDURE|Canalith repositioning maneuver|
214656143|NCT06178068|DEVICE|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
214656144|NCT02207907|DRUG|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
214656145|NCT02207907|DRUG|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
214656146|NCT03024216|DRUG|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
214656147|NCT03024216|DRUG|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
214656148|NCT00873002|DRUG|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
214656149|NCT00873002|DRUG|sorafenib tosylate|400 mg PO BID
214656150|NCT00650923|DRUG|ziv-aflibercept|Given IV
214656151|NCT00650923|PROCEDURE|radiation therapy|Undergo RT
214656152|NCT00650923|DRUG|temozolomide|Given PO
214656153|NCT00650923|PROCEDURE|pharmacological study|Correlative studies
214656154|NCT00650923|PROCEDURE|laboratory biomarker analysis|Correlative studies
214656155|NCT00923637|DRUG|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
214266269|NCT04508348|OTHER|Standard of Care|This diet will include mother's milk and/or formula
214266270|NCT01437969|GENETIC|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
214266271|NCT01418170|OTHER|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
214266272|NCT00696800|DRUG|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
214266273|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214266274|NCT00696800|DRUG|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
214266275|NCT00696800|DRUG|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214266276|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
214266277|NCT00696800|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
214266278|NCT00696800|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
214266279|NCT00696800|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
214266280|NCT04715633|DRUG|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
214266281|NCT02672800|BEHAVIORAL|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
214266282|NCT00298584|PROCEDURE|Percutaneous Suprapubic Aspiration|
214266283|NCT00298584|PROCEDURE|Urethral Catheterization|
214266284|NCT02981264|DRUG|Transcricoid Injection|
214266285|NCT02981264|DRUG|Spray as you go|
214266286|NCT05839600|DRUG|BI 1821736|Solution for infusion
214266287|NCT06632002|OTHER|DSF1|220 mL
214266288|NCT06632002|OTHER|DSF2|220 mL
214266289|NCT06632002|OTHER|Standard of Care (SOC)|Standard of care
214266290|NCT01322659|DEVICE|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
214656156|NCT04911621|BIOLOGICAL|Dendritic cell vaccination + temozolomide-based chemoradiation|"1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
214656157|NCT04911621|BIOLOGICAL|Dendritic cell vaccination +- conventional next-line treatment|"1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
214656158|NCT03813030|PROCEDURE|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
214656159|NCT03813030|DRUG|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
214656160|NCT03813030|DRUG|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
214656161|NCT03813030|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
214656162|NCT03813030|DEVICE|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
214656163|NCT03813030|PROCEDURE|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
214819677|NCT06202794|DEVICE|Experimental: Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
214266291|NCT01322659|DEVICE|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
214266292|NCT05788120|OTHER|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
214266293|NCT00766025|DRUG|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
214266294|NCT00562471|OTHER|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
214266295|NCT00562471|OTHER|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
214266296|NCT00822042|OTHER|Samples and procedures|"* Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits"
214266297|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
214266298|NCT05294640|DRUG|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
214266299|NCT05294640|DRUG|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
214266300|NCT05294640|PROCEDURE|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
214266301|NCT03779711|BIOLOGICAL|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
214266302|NCT03779711|PROCEDURE|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
214266303|NCT04711252|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
214266304|NCT04711252|DRUG|Anastrozole|Dosage formulation: Anastrozole tablets will be administered orally.
214266305|NCT04711252|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
214266306|NCT04711252|DRUG|AZD9833 placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
214266307|NCT04711252|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
214266308|NCT04711252|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
214266309|NCT03153280|DRUG|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
214266310|NCT03153280|DRUG|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
214266311|NCT03153280|DRUG|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
214266312|NCT05625594|PROCEDURE|Aspiration|Undergo CSF aspiration
214266313|NCT05625594|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214266314|NCT05625594|PROCEDURE|Catheterization|Undergo catheterization
214266315|NCT05625594|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes|Given ICV
214819678|NCT06202794|DEVICE|Sham Comparator: Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
214266316|NCT05625594|PROCEDURE|Computed Tomography|Undergo CT
214266317|NCT05625594|DRUG|Cyclophosphamide|Given IV
214266318|NCT05625594|DRUG|Fludarabine|Given IV
214266319|NCT05625594|PROCEDURE|Leukapheresis|Undergo leukapheresis
214266320|NCT05625594|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214266321|NCT05625594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214266322|NCT05625594|PROCEDURE|Positron Emission Tomography|Undergo PET
214266323|NCT06297902|RADIATION|Dose painting|Dose painting
214819679|NCT02417298|DRUG|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
214266324|NCT04596514|PROCEDURE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
214266325|NCT04596514|PROCEDURE|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
214266326|NCT03983824|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214266327|NCT03983824|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214266328|NCT03983824|DRUG|Cytarabine|Given IV
214266329|NCT03983824|PROCEDURE|Echocardiogram Recording|Undergo ECHO
214266330|NCT03983824|DRUG|Etoposide Phosphate|Given IV
214266331|NCT03983824|DRUG|Mitoxantrone Hydrochloride|Given IV
214266332|NCT03983824|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214266333|NCT03983824|DRUG|Peposertib|Given PO
214266334|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
214266335|NCT05224141|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
214266336|NCT05224141|DRUG|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
214266337|NCT05224141|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
214266338|NCT05224141|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
214266339|NCT05224141|BIOLOGICAL|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
214266340|NCT05224141|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
214266341|NCT05139004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
214266342|NCT05139004|BIOLOGICAL|Basiliximab|Given IV
214266343|NCT05139004|DRUG|Fludarabine Phosphate|Given IV
214266344|NCT05139004|DRUG|Indium In 111-DOTA-Basiliximab|Given IV
214266345|NCT05139004|DRUG|Melphalan|Given IV
214266346|NCT05139004|BIOLOGICAL|Palifermin|Given IV
214266347|NCT05139004|RADIATION|Total Lymphoid Irradiation|Undergo TMLI
214266348|NCT05139004|RADIATION|Total Marrow Irradiation|Undergo TMLI
214266349|NCT05139004|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
214266350|NCT04460937|DRUG|Adavosertib|Given PO
214266351|NCT04460937|RADIATION|Radiation Therapy|Undergo radiation therapy
214266352|NCT02750202|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
214266353|NCT02750202|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
214266354|NCT00443092|OTHER|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
214266355|NCT00443092|OTHER|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
214266356|NCT05335629|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
214266357|NCT04432259|DRUG|Dexamethasone|4 mg bid for 4 days
214266358|NCT04432259|DRUG|Placebo|oral placebo
214266359|NCT00004431|DRUG|L-baclofen|
214266360|NCT02707939|OTHER|Observation|Patients will be observed before and after they receive anesthesia
214266361|NCT06429111|PROCEDURE|Epidural analgesia|Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
214266362|NCT06429111|PROCEDURE|Immersion water|Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
214266363|NCT05832801|OTHER|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
214266364|NCT05832801|OTHER|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
214266365|NCT06544889|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
214266366|NCT05595941|OTHER|tele-yoga|"Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant."
214266367|NCT03434197|DRUG|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
214266368|NCT03434197|DRUG|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
214266369|NCT00624234|BEHAVIORAL|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
214266370|NCT00624234|BEHAVIORAL|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
214266371|NCT05945628|BEHAVIORAL|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
214266372|NCT05945628|OTHER|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
214266373|NCT00335413|DRUG|Spironolactone|
214266374|NCT05288413|DEVICE|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
214266375|NCT04576624|BEHAVIORAL|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
214266376|NCT04576624|BEHAVIORAL|social activity|24 social gathering events
214656164|NCT03813030|PROCEDURE|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
214656165|NCT05805514|OTHER|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
214656166|NCT05805514|OTHER|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
214656167|NCT05805514|OTHER|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
214656168|NCT06013774|DEVICE|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
214656169|NCT04934826|DIETARY_SUPPLEMENT|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
214656170|NCT04934826|DIETARY_SUPPLEMENT|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
214656171|NCT04568837|DRUG|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
214656172|NCT01617538|DRUG|atorvastatin|40mg per day,duration for 24 weeks
214656173|NCT02620020|DRUG|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
214656174|NCT02620020|DRUG|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
214656175|NCT05750940|DIAGNOSTIC_TEST|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
214656176|NCT04917926|BEHAVIORAL|Financial and social incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
214656177|NCT04917926|BEHAVIORAL|Financial incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
214656178|NCT00313924|DRUG|DETRUSITOL|
214266377|NCT06275568|BEHAVIORAL|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
214266378|NCT06275568|BEHAVIORAL|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
214266379|NCT01609231|DRUG|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
214266380|NCT01609231|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
214266381|NCT01609231|DRUG|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
214266382|NCT04763785|DEVICE|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
214266383|NCT04763785|DEVICE|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
214266384|NCT04763785|DEVICE|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
214266385|NCT04763785|OTHER|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
214266386|NCT02740439|OTHER|Avocado|The intervention meals will contain 1 large avocado.
214266387|NCT02740439|OTHER|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
214656179|NCT03456115|DEVICE|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
214266388|NCT01649388|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
214266389|NCT01715935|DRUG|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
214266390|NCT04335032|DRUG|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
214266391|NCT04335032|DRUG|Placebo|same as in arm/group description
214266392|NCT00000503|DRUG|nitroglycerin|
214266393|NCT00000503|DRUG|streptokinase|
214266394|NCT00000503|PROCEDURE|heart catheterization|
214266395|NCT04569253|DEVICE|TempSure|Non-invasive radiofrequency treatments
214656180|NCT00630045|DRUG|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
214656181|NCT00630045|PROCEDURE|resection of liver metastasis|surgery with the aim of R0 resection
214656182|NCT03494283|BEHAVIORAL|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
214266396|NCT03014557|DEVICE|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
214266397|NCT00833716|DRUG|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
214266398|NCT01927627|DRUG|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
214266399|NCT02701699|BIOLOGICAL|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
214656183|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
214656184|NCT03216993|OTHER|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
214656185|NCT03314285|OTHER|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
214656186|NCT02209506|DRUG|MLN3126|MLN3126 tablets
214656187|NCT02209506|DRUG|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
214656188|NCT00212329|PROCEDURE|T Cell Proliferation and Autoreactivity Assays|
214656189|NCT00212329|PROCEDURE|Cellular Immunoblot Assays|
214656190|NCT00212329|PROCEDURE|Tetramer Studies|
214656191|NCT00212329|PROCEDURE|Cytokine ELISPOT|
214656192|NCT03146286|DIETARY_SUPPLEMENT|Saturated fat|Palm stearin
214656193|NCT03146286|DIETARY_SUPPLEMENT|Placebo|Water
214656194|NCT03146286|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil, Omega 3 PUFA
214656195|NCT01933087|BEHAVIORAL|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
214819680|NCT02417298|DRUG|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
214819681|NCT01280149|BIOLOGICAL|substance P|injections of substance P and low dose allergen or placebo
214819682|NCT01280149|BIOLOGICAL|substance P injections|injections of substance P for 8 weeks
214266400|NCT00467857|PROCEDURE|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
214266401|NCT00467857|OTHER|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
214266402|NCT02162316|DRUG|Motilitone®|
214266403|NCT02162316|DRUG|A-Cilin®, Clari® and Pantoline®|
214266404|NCT02273232|OTHER|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
214266405|NCT02273232|OTHER|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
214266406|NCT02273232|OTHER|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
214266407|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
214266408|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
214266409|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
214266410|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
214266411|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
214266412|NCT04610970|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
214266413|NCT00152620|DRUG|Dexamethasone|
214266414|NCT00152620|DRUG|Methylprednisolone|
214266415|NCT01667692|DRUG|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
214266416|NCT01667692|DRUG|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
214266417|NCT00968890|BIOLOGICAL|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
214266418|NCT00968890|BIOLOGICAL|Fluarix™|Intramuscular injection, 1 dose
214266419|NCT00968890|BIOLOGICAL|Placebo|Intramuscular injection, 1 dose
214266420|NCT04348279|DEVICE|propylene mesh|propylene mesh as a palatal stent for palatal wound
214266421|NCT02272478|DRUG|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
214656196|NCT05014854|DEVICE|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
214656197|NCT04506112|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation|Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
214656198|NCT01755169|DRUG|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
214266422|NCT02272478|DRUG|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
214266423|NCT02272478|DRUG|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
214266424|NCT02272478|DRUG|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
214266425|NCT02272478|DRUG|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
214656199|NCT01755169|DRUG|Placebo|
214656200|NCT01287104|BIOLOGICAL|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
214656201|NCT01287104|BIOLOGICAL|Stem Cell Infusion|Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
214656202|NCT05431244|DRUG|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
214266426|NCT02272478|DRUG|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
214266427|NCT06557317|BEHAVIORAL|Black Girls for Wellness In-Person|Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
214266428|NCT03204201|DRUG|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
214266429|NCT04228874|DEVICE|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as \> 70 % luminar diameter stenos. The following data was obtained:~* Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~* Length, diameter and number of stents.~* TIMI flow after stent deployment."
214266430|NCT00000702|DRUG|Zidovudine|
214266431|NCT03088371|DRUG|Bupivacaine 0.25%|For psoas sciatic block.
214266432|NCT03088371|OTHER|Pajunk Needle|For local anaesthesia application in psoas sciatic block
214266433|NCT03088371|OTHER|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
214266434|NCT03088371|DRUG|Lidocaine 1%|For psoas sciatic block.
214266435|NCT03088371|DRUG|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
214266436|NCT03088371|DRUG|Lidocaine 2 %|For psoas sciatic block in the post-operative period
214266437|NCT03088371|DRUG|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
214266438|NCT04686695|DEVICE|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
214266439|NCT05038943|DEVICE|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
214266440|NCT01126970|DRUG|Velneperit 400 mg|Velneperit 400 mg q.d.
214266441|NCT01126970|DRUG|Orlistat 120 mg|Orlistat 120 mg t.i.d
214266442|NCT01126970|DRUG|Orlistat Placebo|Orlistat Placebo t.i.d.
214266443|NCT01126970|DRUG|Velneperit Placebo|Velneperit Placebo q.d
214819683|NCT02167659|DEVICE|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
214819684|NCT03202459|DRUG|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
214819685|NCT03202459|DRUG|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
214266444|NCT01126970|OTHER|Reduced Calorie Diet|Reduced calorie diet
214266445|NCT02298023|BIOLOGICAL|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
214266446|NCT02298023|BIOLOGICAL|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
214819686|NCT03202459|DRUG|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
214819687|NCT01249651|DRUG|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
214819688|NCT01849003|DRUG|GS-6615|GS-6615 tablet(s) administered orally
214266447|NCT02298023|BIOLOGICAL|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
214266448|NCT04401826|PROCEDURE|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
214266449|NCT04401826|PROCEDURE|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
214266450|NCT01139489|OTHER|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
214266451|NCT00472719|BIOLOGICAL|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
214266452|NCT00472719|BIOLOGICAL|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
214266453|NCT00472719|BIOLOGICAL|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
214266454|NCT01928173|BEHAVIORAL|Abbreviated cognitive behavioral therapy|see arm description
214266455|NCT01928173|BEHAVIORAL|Sleep education/sleep hygiene|see arm description
214266456|NCT05342935|DEVICE|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
214266457|NCT06306820|OTHER|Fixed PEEP|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
214266458|NCT06306820|OTHER|Ultrasound-guided lung recruitment|Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
214266459|NCT06306820|OTHER|Individualized PEEP|Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
214266460|NCT02096679|DRUG|AZD9291|Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
214266461|NCT02502175|DRUG|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
214266462|NCT02502175|DRUG|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
214266463|NCT04015492|BIOLOGICAL|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
214266464|NCT04015492|BIOLOGICAL|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
214266465|NCT02002832|DRUG|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
214266466|NCT02002832|DRUG|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
214266467|NCT03307785|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
214266468|NCT03307785|DRUG|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
214266469|NCT03307785|DRUG|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
214266470|NCT03307785|DRUG|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
214266471|NCT03307785|DRUG|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
214266472|NCT03307785|DRUG|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
214266473|NCT03307785|DRUG|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
214266474|NCT01330784|DRUG|hMG-HP|
214266475|NCT03166059|DEVICE|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
214266476|NCT04108871|PROCEDURE|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
214266477|NCT01811680|DEVICE|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
214266478|NCT03524742|OTHER|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
214266479|NCT03524742|OTHER|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
214266480|NCT05744284|DEVICE|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
214266481|NCT00860288|DRUG|Vildagliptin|
214266482|NCT00860288|DRUG|Metformin|
214266483|NCT00860288|DRUG|Placebo|
214266484|NCT00860288|DRUG|Sitagliptin|
214266485|NCT00001067|DRUG|Lamivudine|
214266486|NCT00001067|DRUG|Stavudine|
214266487|NCT00001067|DRUG|Zidovudine|
214266488|NCT02037360|BEHAVIORAL|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
214266489|NCT02037360|BEHAVIORAL|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
214656203|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
214266490|NCT00492531|DRUG|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
214266491|NCT00492531|DRUG|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
214266492|NCT05143281|DRUG|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
214266493|NCT06213246|BEHAVIORAL|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~* Maintain a consistent wake-up and bedtime schedule during workdays.~* Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~* Keep the bedroom temperature below 22°C.~* Avoid sources of light and noise in the bedroom.~* Use the bed only for sleeping, avoiding other activities before bedtime.~* Avoid daytime naps during workdays.~* Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~* Expose yourself to natural light in the morning and reduce artificial lights in the evening.~* Avoid consuming alcoholic beverages and caffeine in the afternoon.~* Have a moderately sized dinner at least 3 hours before bedtime."
214266494|NCT02293161|DRUG|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
214266495|NCT02293161|DRUG|Placebo|It is Sodium Chloride Intravenous Infusion
214819689|NCT04313855|DIAGNOSTIC_TEST|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
214819690|NCT00781794|DRUG|NSA-789 at 2 different doses|
214819691|NCT00351676|BEHAVIORAL|Integration of a team based clinical pharmacist|
214819692|NCT00351676|DRUG|Optimizing therapeutic treatments|
214819693|NCT00351676|BEHAVIORAL|Optimizing processes of care|
214819694|NCT00128167|DRUG|Liquid CAIV-T|
214819695|NCT05335863|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
214819696|NCT05335863|DIETARY_SUPPLEMENT|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
214819697|NCT00557752|DEVICE|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
214819698|NCT04140877|DEVICE|Visu|An experimental (test) virtual reality display
214819699|NCT04029272|DRUG|Metformin|500 mg tid for 12 weeks
214819700|NCT04029272|DRUG|Exenatide 2 MG|Exenatide injection once weekly for 12 weeks
214819701|NCT04432233|DRUG|Esomeprazole|Proton pump inhibitor
214819702|NCT04432233|DRUG|Metronidazole|antibiotic for H. pylori eradication
214819703|NCT04432233|DRUG|Levofloxacin|antibiotic for H. pylori eradication
214819704|NCT01462279|DRUG|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
214819705|NCT04444050|DRUG|BMS-986331|Specified dose on specified days
214819706|NCT04444050|OTHER|Placebo, Matching BMS-986331|Specified dose on specified days
214266496|NCT02949531|DRUG|oxygen|
214266497|NCT05446441|PROCEDURE|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
214266498|NCT02837146|BIOLOGICAL|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
214266499|NCT02837146|DRUG|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
214266500|NCT05263375|DEVICE|Innovalve TMVR system|Innovalve TMVR system
214266501|NCT04437563|BEHAVIORAL|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
214266502|NCT00843856|DRUG|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
214266503|NCT00843856|DRUG|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
214266504|NCT03529331|DRUG|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
214266505|NCT03529331|DRUG|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
214819707|NCT04044521|OTHER|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 21 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit \& feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will meet with each clinic. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
214819708|NCT06370377|OTHER|the Egyptian code of ethical practice|Nurses' adherence to the Egyptian code of ethical practice
214819709|NCT03475030|OTHER|pre-filled medication trays|
214819710|NCT03475030|OTHER|automated medication reminders|
214266506|NCT03529331|DRUG|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
214266507|NCT02318537|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214819711|NCT03909945|DIETARY_SUPPLEMENT|Annona muricata|Patients with prehypertension or stage 1 hypertension, in dietary measures, will received daily one tablet of 796 mg of aqueous extracts of Annona muricata leaves. During 60 days
214266508|NCT02318537|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol.
214266509|NCT04404205|DIAGNOSTIC_TEST|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
214266510|NCT00092573|DRUG|MK0653, ezetimibe|
214266511|NCT00092573|DRUG|Comparator: fenofibrate monotherapy|
214266512|NCT06323057|DEVICE|Single pulse TMS to the frontal cortex|Single pulse TMS will be delivered to the left frontal cortex, and stimulation intensity will be at 110% of resting motor threshold.
214266513|NCT04534543|RADIATION|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
214266514|NCT04729621|COMBINATION_PRODUCT|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
214266515|NCT04729621|COMBINATION_PRODUCT|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
214266516|NCT04108234|DRUG|HR071603|HR071603 monotherapy ,nasal spray
214266517|NCT04108234|DRUG|placebo|placebo,nasal spray
214266518|NCT02652065|OTHER|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
214266519|NCT02652065|OTHER|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
214266520|NCT02652065|OTHER|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
214266521|NCT02652065|OTHER|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
214266522|NCT00005865|DRUG|vinorelbine tartrate|
214266523|NCT03943160|DEVICE|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
214266524|NCT03148314|DRUG|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
214266525|NCT03148314|DRUG|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
214266526|NCT04882280|BEHAVIORAL|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
214266527|NCT02489760|BIOLOGICAL|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
214266528|NCT02489760|BIOLOGICAL|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
214266529|NCT05221710|BEHAVIORAL|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
214266530|NCT01674114|PROCEDURE|TAP block|
214266531|NCT01674114|PROCEDURE|control|
214266532|NCT06026657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214266533|NCT06026657|PROCEDURE|Computed Tomography|Undergo CT scan
214266534|NCT06026657|DRUG|Gemcitabine|Given IV
214266535|NCT06026657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214266536|NCT06026657|BIOLOGICAL|Naxitamab|Given IV
214266537|NCT06026657|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
214266538|NCT05383521|DRUG|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
214266539|NCT05383521|DRUG|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
214266540|NCT02964975|PROCEDURE|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
214266541|NCT02964975|DRUG|Optimal medical therapy|Medical threatment according to guidelines
214266542|NCT03104543|BEHAVIORAL|Education|30 minute education session; 15 minute booster session at 4 months
214266543|NCT03104543|BEHAVIORAL|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
214266544|NCT04153604|DRUG|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
214266545|NCT03894800|DRUG|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
214266546|NCT03894800|DRUG|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
214266547|NCT03894800|DRUG|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
214266548|NCT03894800|DRUG|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
214266549|NCT00749060|OTHER|conventional treatment|with our without brace
214266550|NCT00749060|PROCEDURE|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
214266551|NCT00749060|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
214266552|NCT04937946|DRUG|Fentanyl|Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
214266553|NCT02925520|DRUG|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
214266554|NCT02741856|DRUG|Carboplatin|For more information please see the arm descriptions section.
214266555|NCT02741856|DRUG|Paclitaxel|For more information please see the arm descriptions section.
214266556|NCT02741856|DRUG|Cisplatin|For more information please see the arm descriptions section.
214266557|NCT02741856|DRUG|Capecitabine|For more information please see the arm descriptions section.
214266558|NCT02741856|RADIATION|Radiotherapy|For more information please see the arm descriptions section.
214266559|NCT01196507|DRUG|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
214266560|NCT01196507|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
214266561|NCT00229073|DRUG|dapoxetine|
214266562|NCT02317588|DIETARY_SUPPLEMENT|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
214266563|NCT02317588|DIETARY_SUPPLEMENT|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
214266564|NCT04336293|DEVICE|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
214266565|NCT04336293|DEVICE|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
214266566|NCT03175978|DRUG|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
214266567|NCT04734938|DIETARY_SUPPLEMENT|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
214266568|NCT02921542|DEVICE|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
214266569|NCT00319501|DRUG|Placebo|Intramuscular autoinjector; administered at onset of an episode
214266570|NCT00319501|DRUG|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
214266571|NCT04789083|OTHER|Propholis extrate|Plassebo
214266572|NCT06068608|DRUG|TNM005|single,intramuscular injection
214266573|NCT06068608|DRUG|Placebo|single,intramuscular injection
214266574|NCT06068608|DRUG|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
214266575|NCT02298530|OTHER|Combination of caffeine and theanine|Beverage containing caffeine and theanine
214266576|NCT02298530|OTHER|Caffeine|Beverage containing caffeine
214266577|NCT02231008|DRUG|tasimelteon|
214266578|NCT02231008|DRUG|placebo|
214266579|NCT05491720|DRUG|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
214266580|NCT05491720|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
214266581|NCT05491720|DRUG|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
214266582|NCT05491720|DEVICE|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
214266583|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
214266584|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
214266585|NCT01696071|DRUG|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
214266586|NCT01696071|DRUG|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
214266587|NCT03709446|DRUG|Leflunomide|Single agent leflunomide
214266588|NCT02242266|DRUG|Tiotropium low dose|inhalation powder, hard PE capsule
214266589|NCT02242266|DRUG|Tiotropium medium dose|inhalation powder, hard PE capsule
214266590|NCT02242266|DRUG|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
214266591|NCT02242266|DRUG|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
214266592|NCT02242266|DRUG|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
214266593|NCT01275820|DIETARY_SUPPLEMENT|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
214266594|NCT03901885|OTHER|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
214266595|NCT02183142|DRUG|Mobic, China, 7.5 mg|
214266596|NCT02183142|DRUG|Mobic, Germany, 7.5 mg|
214266597|NCT03550664|DEVICE|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
214266598|NCT02972671|DEVICE|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
214266599|NCT02972671|DEVICE|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
214266600|NCT01163331|OTHER|Singing Therapy|Singing therapy as a way to improve voice quality
214266601|NCT04665856|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214266602|NCT04665856|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
214266603|NCT04665856|DRUG|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
214266604|NCT04665856|DRUG|Etoposide|Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
214266605|NCT04665856|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
214266606|NCT00670150|DRUG|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
214266607|NCT00670150|DRUG|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
214266608|NCT03572972|DRUG|Apixaban|Treatment for NVAF patients
214266609|NCT03572972|DRUG|Dabigatran|Treatment for NVAF patients
214266610|NCT03572972|DRUG|Rivaroxaban|Treatment for NVAF patients
214266611|NCT03572972|DRUG|warfarin|Treatment for NVAF patients
214266612|NCT03572972|DRUG|Antiplatelets|Treatment for NVAF patients
214266613|NCT01721993|DRUG|T121|
214266614|NCT01721993|DRUG|Zoledronic acid|
214266615|NCT03966144|DEVICE|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
214266616|NCT00078793|DRUG|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
214656204|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
214656205|NCT00643383|DRUG|Combination drug (Acetaminophen + Tramadol)|
214656206|NCT00643383|DRUG|Placebo|
214656207|NCT01849757|OTHER|prime crystalloid|used for priming the CPB circuit
214656208|NCT01849757|OTHER|Human Albumin|Used as a constituent for priming the CPB circuit
214656209|NCT01849757|OTHER|Voluven|Used as a constituent for priming the CPB circuit
214266617|NCT05678569|DIAGNOSTIC_TEST|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
214266618|NCT01801878|BIOLOGICAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
214266619|NCT01801878|BIOLOGICAL|Normal saline|Normal saline inject to the half of irradiated breast
214266620|NCT02138682|DRUG|l-123 Ioflupane|5 millicuries of Ioflupane
214266621|NCT00797771|DEVICE|"Adi Insulin pump"|insulin delivery will be defined by the physician
214266622|NCT01918384|DRUG|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
214266623|NCT01918384|DRUG|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
214266624|NCT05026008|DRUG|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
214266625|NCT05026008|DRUG|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
214266626|NCT01491971|DRUG|Degarelix|
214266627|NCT03739502|DRUG|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
214266628|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
214266629|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
214266630|NCT06385522|BIOLOGICAL|BITR2101|TNFR2 monoclonal antibody
214266631|NCT06826924|BEHAVIORAL|Fasting|7 days of water-only fasting
214266632|NCT06277219|DRUG|LAT010|LAT010 monotherapy
214266633|NCT06277219|DRUG|LAT010 + ICI|LAT010 combination with PD-1 inhibitor
214266634|NCT06215131|BEHAVIORAL|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
214266635|NCT06215131|BEHAVIORAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
214266636|NCT02923596|PROCEDURE|History of prior Surgery|History of prior Surgery will be reviewed
214266637|NCT02923596|RADIATION|History of Radiation Therapy|History of prior radiation therapy will be reviewed
214266638|NCT06857383|OTHER|Fremantle Headache Awareness Questionnaire|"It is a simple Likert-type questionnaire that evaluates individual-specific altered perception (0 = Never/Never feel like this, 1 = Rarely feel like this, 2 = Sometimes or sometimes feel like this, 3 = Often feel like this, 4 = Always or most of the time feel like this). The questionnaire asks individuals 9 questions about how they perceive their heads and headaches in relation to their bodies. The questionnaire was developed by Wand et al. in its first version as The Fremantle Back Awareness Questionnaire. With permission from the author, the questionnaire was created by adapting the questions of the Fremantle Back Awareness Questionnaire to headache."
214266639|NCT01984983|BIOLOGICAL|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
214266640|NCT01984983|OTHER|0.9% saline placebo|
214266641|NCT00904397|DRUG|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
214266642|NCT00904397|DRUG|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
214266643|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
214266644|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
214266645|NCT06668649|DIAGNOSTIC_TEST|Testing with Questionnaires|Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
214266646|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the SARS-pro navigation system|The SARS-pro navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the new navigation system group (patients with suspected lung cancer).
214656210|NCT02598830|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
214656211|NCT02598830|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
214656212|NCT01520246|GENETIC|gene expression analysis|
214656213|NCT01520246|OTHER|laboratory biomarker analysis|
214656214|NCT00116025|DRUG|Human acylated ghrelin|
214656215|NCT03759158|DRUG|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
214656216|NCT03759158|DRUG|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
214266647|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the VBN navigation system|The VBN navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the old navigation system group (patients with suspected lung cancer).
214819712|NCT00813592|DRUG|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
214266648|NCT06681168|DEVICE|transcutaneous auricular vagal nerve stimulation|"Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20)."
214266649|NCT06681168|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
214266650|NCT06681116|DIETARY_SUPPLEMENT|structured nano-water|Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
214266651|NCT06681116|DRUG|Hydrochlorothiazide (HCTZ)|hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
214266652|NCT06681116|OTHER|ordinary bottled drinking water|Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
214266653|NCT03919162|DRUG|PQ912|PQ912 150 mg tablets
214266654|NCT03919162|OTHER|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
214266655|NCT02585622|BIOLOGICAL|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10\^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
214266656|NCT02585622|OTHER|Placebo|Volume total of fluid infused: 40 ml
214266657|NCT07011511|DRUG|MMV055 Dose 1|40mg
214266658|NCT07011511|DRUG|MMV055 Dose 2|100mg
214266659|NCT07011511|DRUG|MMV055 Dose 3|200mg
214266660|NCT07011511|DRUG|MMV055 Dose 4|400mg
214266661|NCT07011511|DRUG|MMV055 Dose 5|800mg
214266662|NCT07011511|DRUG|MMV055 Dose 6|TBCmg
214266663|NCT07011511|DRUG|Matching placebo Part A|Part A
214266664|NCT07011511|DRUG|Matching placebo Part B|Part B
214266665|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 1|Combination 1
214266666|NCT07011511|COMBINATION_PRODUCT|MMV055/MM371 Combo 2|Combination 2
214266667|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 3|Combination 3
214266668|NCT06680973|OTHER|Hospital-Based Resistance Training|"Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks."
214266669|NCT06680973|OTHER|Home-Based Resistance Training|"Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded."
214266670|NCT06680570|DIAGNOSTIC_TEST|Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing|"Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life."
214266671|NCT06190977|OTHER|Otago Exercise Program|Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes
214266672|NCT06190977|OTHER|General TKR pprotocol|Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
214266673|NCT06680739|DRUG|Durvalumab|Durvalumab 1500 mg IV every 4 weeks
214266674|NCT06680739|DRUG|Tremelimumab|Tremelimumab 300 mg IV as a single dose
214266675|NCT06086353|DRUG|Tafamidis|Patients on tafamidis will be observed
214819713|NCT00811655|PROCEDURE|therapeutic conventional surgery|Surgery of a single brain metastasis.
214266676|NCT06251544|GENETIC|HTR2 T Cells|"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"
214266677|NCT06251544|GENETIC|HTR2 T Cells|"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"
214819714|NCT00811655|RADIATION|stereotactic radiosurgery|Pre-operative single fraction SRS
214819715|NCT00494338|DRUG|Docetaxel|
214266678|NCT06681025|DIAGNOSTIC_TEST|NeuMoDx EBV Quant 2.0 Assay|The NeuMoDx™ EBV Quant Assay 2.0 is an automated in vitro nucleic acid amplification test for the quantification of Epstein-Barr virus (EBV) DNA in EDTA plasma from immunocompromised transplant patients. Transplant patients are screened for EBV viral load as part of their standard of care. The remaining samples from these in vitro diagnostic nucleic acid amplification tests (NAAT) will be analyzed using the NeuMoDx EBV Quant Assay 2.0 to quantify EBV DNA in EDTA plasma. That result will be compared to a comparator in vitro diagnostic assay to evaluate the performance of the NeuMoDx EBV Quant 2.0 assay.
214819716|NCT03682653|DRUG|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
214819717|NCT03682653|DRUG|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
214819718|NCT01673685|DEVICE|Portable Oxygen|
214266679|NCT06681337|BIOLOGICAL|BCMA CART + CD19 CART|BCMA CART + CD19 CART
214266680|NCT06702007|BEHAVIORAL|eHaRT-A|Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
214266681|NCT06710587|BEHAVIORAL|Voy Program|Voy Program - coaching and access to the Voy app to support behavioural changes
214266682|NCT06710782|DRUG|Hyaluronic acid|Patients underwent intra-articular hyaluronic acid injection.
214266683|NCT06710782|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
214266684|NCT06708728|OTHER|blood samples|blood samples for CBC parameters , peripheral blood smear, bilirubin levels and kidney function tests
214266685|NCT06708195|DEVICE|Group experimental|Type: Inactive TENS (placebo) Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glan
214266686|NCT07041268|BIOLOGICAL|rituximab|"Rituximab will be administered intravenously in three courses. The 1st course (loading dose) will include six rituximab infusions on days 1, 3, 5, 8, 14, and 21 of the study. On days 1, 3, and 5 rituximab will be infused at doses of 50, 125, and 200 mg per m2 of the participant's body surface area, respectively. On days 8, 14, and 21 rituximab will be infused at doses of 375 mg/m2, but not more than 500 mg total dose.~The 2nd course (maintenance therapy) will include four rituximab infusions on days 63, 70, 77, and 85 at doses of 375 mg/m2, but not more than 500 mg total dose.~The 3rd course (maintenance therapy) will include four rituximab infusions on days 119, 126, 134, and 140 at doses of 375 mg/m2, but not more than 500 mg total dose"
214819719|NCT06064331|DRUG|Lignocaine|IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
214819720|NCT06064331|DRUG|Placebo|IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
214819721|NCT01724372|DRUG|Antidepressant|
214819722|NCT01724372|DRUG|Antipsychotic|
214266687|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with hypertension|Colorectal cancer patients with hypertension
214266688|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with diabetes|Colorectal cancer patients with diabetes
214266689|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with fatty liver|Colorectal cancer patients with fatty liver
214266690|NCT06707415|DIAGNOSTIC_TEST|Auditory evoked potentials|Auditory evoked potentials in parallel systems
214266691|NCT07053124|OTHER|Hand-drawn navigation|Hand-drawn navigation employed for diagnosing patients with PPN in Hand-drawn group.
214266692|NCT07053124|OTHER|Virtual bronchoscopy navigation|Virtual bronchoscopy navigation employed for diagnosing patients with PPN in VBN group.
214266693|NCT07054112|OTHER|Mindfulness-Based Stress Reduction (MBSR) meditation program|"The sessions of the meditation program (Mindfulness on Stress Reduction) will be delivered online, outside of the dialysis sessions. They will receive standard care during their hemodialysis sessions.~The program is composed of 8 sessions of 2h30 + 1 day of mindfulness, during 2 months."
214266694|NCT07054112|OTHER|Control group|Patients in the control group will be in a wait list group. They will receive standard care during their hemodialysis sessions. they will receive the MBSR meditation program between M8 and M10.
214266695|NCT07053072|DRUG|Low Dose PD-1 mRNA LNP Vaccine|Patients will receive PD-1 mRNA LNP vaccine at 50 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
214819723|NCT05434364|OTHER|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
214819724|NCT05434364|OTHER|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
214819725|NCT05434364|OTHER|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
214819726|NCT05044338|DIAGNOSTIC_TEST|imaging|(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.
214819727|NCT00979043|BEHAVIORAL|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
214266696|NCT07053072|DRUG|Medium dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 75 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
214266697|NCT07053072|DRUG|High dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 100 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
214266698|NCT07053267|DIETARY_SUPPLEMENT|Funrional Ice Cream|Single 100 g serving of ice cream enriched with 10 g of Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
214266699|NCT07053267|DIETARY_SUPPLEMENT|Placebo Ice Cream|Single 100 g serving of placebo ice cream identical in flavor, texture, and appearance, but without Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
214266700|NCT07054372|DIAGNOSTIC_TEST|Titres on conventional test tube method with different diluent|Titres on conventional test tube method with different diluent
214819728|NCT00979043|BEHAVIORAL|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
214266701|NCT07054944|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Lymphatic mapping
214266702|NCT07055074|DIAGNOSTIC_TEST|Low Pressure Pneumoperitoneum|Low Pressure Pneumoperitoneum (8-10 mmHg) Details: CO₂ insufflation to 8-10 mmHg IAP, continuous monitoring, measurement at baseline, insufflation, and desufflation.
214266703|NCT07055074|DIAGNOSTIC_TEST|Medium Pressure Pneumoperitoneum|Medium Pressure Pneumoperitoneum (12-14 mmHg) Details: CO₂ insufflation to 12-14 mmHg IAP, parameters measured at key intervals, standard general anesthesia used. High Pressure Pneumoperitoneum (15-20 mmHg) Details: Standard high-pressure technique, monitoring of hemodynamic and respiratory parameters.
214266704|NCT07053514|BEHAVIORAL|SD-ART|SD-ART protocol for PWH with both patients and their HIV clinicians
214266705|NCT01869881|DRUG|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
214266706|NCT01869881|DRUG|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
214266707|NCT06067204|DEVICE|Automatic ventilation|"The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 500-600 ml."
214266708|NCT06067204|DEVICE|Manual ventilation|The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
214266709|NCT05471557|PROCEDURE|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
214266710|NCT01259128|DRUG|SER120 Nasal Spray 500 ng/day|SER120 Level 1
214266711|NCT01259128|DRUG|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
214266712|NCT05236400|DEVICE|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
214266713|NCT05236400|PROCEDURE|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
214266714|NCT02981017|DEVICE|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
214266715|NCT00462566|DEVICE|motor cortex stimulation|
214266716|NCT00917995|DEVICE|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
214266717|NCT01296217|PROCEDURE|lymph nod detection|
214266718|NCT01977794|DRUG|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
214266719|NCT01977794|DRUG|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
214266720|NCT05817643|DRUG|BMS-984923|Oral capsule
214266721|NCT01895062|DEVICE|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
214266722|NCT02649465|DRUG|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
214819729|NCT01937143|BEHAVIORAL|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
214819730|NCT01937143|BEHAVIORAL|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
214819731|NCT01937143|BEHAVIORAL|Control|General information about infant immunizations at birth of a newborn infant
214819732|NCT05369884|DRUG|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
214266723|NCT02649465|DRUG|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
214266724|NCT00622817|DRUG|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
214266725|NCT00622817|DRUG|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
214266726|NCT02680717|DRUG|Clobetasol|ointment, twice daily (alternating weeks)
214266727|NCT02680717|DRUG|Calcipotriene|ointment, twice daily
214266728|NCT02680717|DRUG|Tacrolimus|ointment, 0.1%, twice daily
214266729|NCT04888468|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214819733|NCT05369884|DRUG|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
214819734|NCT01519258|OTHER|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
214266730|NCT00297583|DRUG|Insulin Glulisine|
214266731|NCT02079545|DRUG|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
214266732|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
214819735|NCT01519258|DEVICE|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
214819736|NCT01391273|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
214266733|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
214266734|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
214266735|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
214266736|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
214266737|NCT03853408|PROCEDURE|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
214266738|NCT06498154|RADIATION|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
214266739|NCT00281307|DRUG|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
214266740|NCT03591185|OTHER|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
214266741|NCT03869983|OTHER|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
214266742|NCT03869983|OTHER|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
214266743|NCT04766060|OTHER|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
214819737|NCT01391273|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
214819738|NCT01277835|DRUG|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
214819739|NCT01277835|DRUG|Placebo|Saline Infusion at same rate as experimental arm
214819740|NCT02259972|DRUG|BI 113823 solution|
214819741|NCT02259972|DRUG|BI 113823 tablet|
214819742|NCT02259972|DRUG|Placebo|
214819743|NCT02259972|OTHER|High fat, high calorie breakfast|only for dose group 5
214819744|NCT01554410|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
214819745|NCT01554410|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
214819746|NCT01554410|DRUG|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
214819747|NCT00362596|DRUG|acyclovir|
214266744|NCT06961214|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
214266745|NCT06961214|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered
214266746|NCT00935090|DEVICE|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
214819748|NCT00597454|OTHER|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
214819749|NCT00164684|BEHAVIORAL|Father Friendly Initiative|
214819750|NCT05600699|DEVICE|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
214819751|NCT00048334|DRUG|Depsipeptide, FR901228, FK228|
214266747|NCT04689269|OTHER|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
214266748|NCT04689269|OTHER|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
214266749|NCT04689269|DEVICE|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
214266750|NCT04689269|DEVICE|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
214819752|NCT06406257|DEVICE|3M™ Bair Hugger™ Warming Unit|Utilizing the 3M Temperature Management Unit to ensure intraoperative body temperature of elderly hip surgery patients remains consistent with their preoperative baseline, while patients in Group C receive no intervention.
214266751|NCT04763668|OTHER|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
214819753|NCT00216242|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
214266752|NCT04763668|OTHER|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
214266753|NCT04121923|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
214266754|NCT00003970|DRUG|irinotecan hydrochloride|Given IV
214266755|NCT00446862|DRUG|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
214266756|NCT00826046|DRUG|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
214266757|NCT01139983|GENETIC|DNA analysis|
214266758|NCT01139983|GENETIC|RNA analysis|
214266759|NCT01139983|GENETIC|fluorescence in situ hybridization|
214819754|NCT00216242|BIOLOGICAL|Saline placebo|
214266760|NCT01139983|GENETIC|microarray analysis|
214266761|NCT01139983|GENETIC|polymerase chain reaction|
214266762|NCT01139983|GENETIC|reverse transcriptase-polymerase chain reaction|
214266763|NCT01139983|OTHER|laboratory biomarker analysis|
214266764|NCT05817318|DEVICE|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
214266765|NCT03273543|DEVICE|Restylane® Defyne|hyaluronic acid filler injection
214266766|NCT01024335|DRUG|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
214266767|NCT01024335|DRUG|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
214266768|NCT04996043|DIETARY_SUPPLEMENT|Collagen Peptide Drink|Testing product
214266769|NCT04996043|DIETARY_SUPPLEMENT|Placebo drink|Blank
214266770|NCT03258931|DRUG|Crenolanib|Crenolanib will be administered orally
214266771|NCT03258931|DRUG|Midostaurin|Midostaurin will be administered orally
214266772|NCT03258931|DRUG|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
214266773|NCT03258931|DRUG|Duanorubicin|90 mg/m2 IV
214266774|NCT04185311|BIOLOGICAL|Ipilimumab|Given IV
214266775|NCT04185311|BIOLOGICAL|Nivolumab|Given IV
214266776|NCT04185311|BIOLOGICAL|Talimogene Laherparepvec|Given intratumorally
214266777|NCT03949309|OTHER|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
214266778|NCT01699490|DRUG|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
214266779|NCT01699490|DRUG|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
214266780|NCT01705730|DRUG|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
214266781|NCT00362557|DEVICE|MRI|Magnetic resonance imaging
214266782|NCT01788488|OTHER|Use of procalcitonin as biomarker to guide therapy|
214819755|NCT05444296|OTHER|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
214819756|NCT05444296|OTHER|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
214819757|NCT06626633|DRUG|CRD3874|CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
214266783|NCT02123342|BEHAVIORAL|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
214266784|NCT03228433|DRUG|TAK-418|TAK-418 Capsule.
214266785|NCT03228433|DRUG|TAK-418 Placebo|TAK-418 placebo-matching capsules.
214266786|NCT03268993|DIETARY_SUPPLEMENT|Avmacol|Avmacol is a dietary supplement available over the counter
214266787|NCT03677427|RADIATION|Radiation|Radiation in breast cancer
214266788|NCT06095804|DEVICE|Percutaneous Ultrasound Jejunostomy|Placement of a jejunostomy tube using the PUMA-J System
214266789|NCT02292121|PROCEDURE|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
214266790|NCT02292121|OTHER|a solution of mannitol and lactitol|
214266791|NCT04567498|OTHER|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
214266792|NCT01737320|DRUG|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
214819758|NCT01099007|BEHAVIORAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
214266793|NCT01737320|DRUG|accepted prolonged antibiotic treatment|
214266794|NCT00003805|DRUG|piperacillin sodium|
214266795|NCT00003805|DRUG|piperacillin-tazobactam|
214266796|NCT00003805|DRUG|tazobactam sodium|
214266797|NCT00003805|DRUG|vancomycin|
214266798|NCT06036823|DRUG|Insulin regular|Intravenous insulin
214266799|NCT06036823|DRUG|Dextrose 50|to be given to both arms
214266800|NCT06036823|DRUG|salbutamol|to be given to all patients
214819759|NCT01099007|BEHAVIORAL|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
214819760|NCT06874790|BEHAVIORAL|Catalina|"Catalina transmedia web-based app intervention with 10 story-based videos (including bonus story extender videos) totaling 31 minutes plus the blog of the character, Veronica, which has MH resource links including Veronica's recommendations of at least 3 local Latinx-serving clinics in LA and Orange County ZIP Codes that offer low-cost MH Tx."
214266801|NCT06445296|OTHER|High-fat meal containing beef|High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.
214266802|NCT06445296|OTHER|High-fat meal containing Beyond Meat|High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
214266803|NCT05100459|DIETARY_SUPPLEMENT|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
214266804|NCT05100459|DIETARY_SUPPLEMENT|Conventional whey protein|25 grams of protein delivered 3 times daily
214266805|NCT05100459|DIETARY_SUPPLEMENT|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
214266806|NCT03872154|OTHER|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
214266807|NCT01030536|DRUG|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
214266808|NCT01030536|DRUG|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
214819761|NCT06874790|BEHAVIORAL|Control webpage|Links to informational videos (totaling 31 minutes) on depression and anxiety, listing of the same 3 local Latinx-serving clinics in LA and Orange County ZIP codes that offer low-cost MH Tx, and links to nationally available websites that offer resources (including access to service locators).
214266809|NCT01030536|DRUG|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
214266810|NCT01030536|DRUG|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
214266811|NCT01030536|DRUG|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
214266812|NCT02765269|DEVICE|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
214266813|NCT02121431|BEHAVIORAL|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
214266814|NCT06273462|DRUG|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
214266815|NCT06273462|OTHER|placebo|visually identical placebo capsule
214266816|NCT03218644|OTHER|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
214266817|NCT03218644|OTHER|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
214266818|NCT03242889|DRUG|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
214266819|NCT03289858|DRUG|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
214266820|NCT03289858|DRUG|Sodium Chloride|Saline Injection
214266821|NCT05938062|PROCEDURE|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
214266822|NCT01549678|OTHER|Total contact insole|EVA insole shaped on patient´s foot.
214266823|NCT01549678|OTHER|placebo insole|EVA insole flat
214266824|NCT03154164|DEVICE|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
214266825|NCT01744873|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
214266826|NCT01744873|DRUG|Bisoprolol|10 mg tablet once a day
214266827|NCT03617497|DIAGNOSTIC_TEST|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
214266828|NCT03617497|DIAGNOSTIC_TEST|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
214266829|NCT03918473|OTHER|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
214266830|NCT03918473|OTHER|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
214266831|NCT05397964|DEVICE|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
214266832|NCT01330030|DRUG|Selegiline|6mg/24 hrs for 8 weeks
214266833|NCT01330030|OTHER|matching placebo|placebo/24hrs for 8 weeks
214266834|NCT06294782|RADIATION|STereotactic Arhythmia Radioablation (STAR)|STereotactic Arhythmia Radioablation (STAR)
214266835|NCT04007926|BEHAVIORAL|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
214266836|NCT04007926|BEHAVIORAL|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
214266837|NCT05825339|DIAGNOSTIC_TEST|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
214266838|NCT05562414|BEHAVIORAL|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
214266839|NCT05562414|BEHAVIORAL|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
214266840|NCT01101880|BIOLOGICAL|filgrastim|Given SC
214266841|NCT01101880|DRUG|clofarabine|Given IV
214266842|NCT01101880|DRUG|cytarabine|Given IV
214266843|NCT05789160|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214266844|NCT04424888|OTHER|WB-011|WB-011 medical food product.
214266845|NCT04424888|OTHER|Placebo|Placebo Capsules identical to those containing WB-011.
214266846|NCT04424888|DEVICE|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
214266847|NCT05224986|BEHAVIORAL|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
214266848|NCT05700448|BIOLOGICAL|Sugemalimab|IV infusion
214819762|NCT04093505|DRUG|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
214819763|NCT04093505|DRUG|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
214819764|NCT04093505|DRUG|Glasdegib|Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27
214266849|NCT05700448|DRUG|Placebo|IV infusion
214266850|NCT05700448|DRUG|Pegaspargase|Intramuscular injection
214266851|NCT05700448|DRUG|Gemcitabine|IV infusion
214266852|NCT05700448|DRUG|Oxaliplatin|IV infusion
214266853|NCT04891978|BEHAVIORAL|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
214819765|NCT04093505|DRUG|Placebo Oral Tablet|Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
214266854|NCT04891978|BEHAVIORAL|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
214266855|NCT04891978|BEHAVIORAL|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
214266856|NCT01008592|DRUG|levocetirizine or placebo|oral administration, single tablet, 5 mg.
214266857|NCT06221462|DRUG|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
214266858|NCT06221462|DRUG|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
214266859|NCT05346874|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
214266860|NCT05346874|DRUG|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
214266861|NCT05346874|PROCEDURE|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
214266862|NCT06088875|DRUG|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
214266863|NCT06088875|DRUG|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
214266864|NCT04400994|DRUG|Rituximab|"Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
214266865|NCT04400994|OTHER|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour"
214266866|NCT03447704|DRUG|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
214266867|NCT03447704|OTHER|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
214266868|NCT04448938|OTHER|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
214266869|NCT04448938|OTHER|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
214266870|NCT03317340|OTHER|Background Sounds|Background music or sound of running water
214266871|NCT04390061|DRUG|Tofacitinib|Jak-1/3 inhibitor
214266872|NCT04390061|DRUG|Hydroxychloroquine|Standard Therapy
214266873|NCT01229826|RADIATION|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
214266874|NCT01103336|DRUG|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"* Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
214266883|NCT02390908|BEHAVIORAL|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
214266884|NCT02390908|BEHAVIORAL|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
214266885|NCT02829073|DEVICE|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
214266886|NCT02829073|DEVICE|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
214266887|NCT00003831|PROCEDURE|conventional surgery|
214266888|NCT00117455|DRUG|pegfilgrastim|
214266889|NCT00117455|DRUG|filgrastim|
214266890|NCT02911220|GENETIC|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
214266891|NCT02579837|DEVICE|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
214819766|NCT05087745|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214819767|NCT03861247|DRUG|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
214819768|NCT03861247|DIETARY_SUPPLEMENT|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
214266892|NCT02579837|DEVICE|Zeiss Cirrus|optical coherence tomographer (OCT)
214266893|NCT05454280|PROCEDURE|Intensified post-discharge surveillance|"* TCC Nurse Televisit at post-discharge day 1 and 7~* Televisit with APP/Resident/Fellow between post-discharge day 3-5~* Referral for home health nursing evaluation upon discharge"
214266894|NCT05454280|PROCEDURE|Standard post-discharge surveillance|Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.
214266895|NCT02272660|DRUG|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
214266896|NCT02272660|DRUG|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
214266897|NCT01781975|DRUG|Imatinib Mesylate|
214266898|NCT01781975|DRUG|Placebo (For imatinib mesylate)|
214266899|NCT06445881|DRUG|Modified Si Jun Zi Tang|Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
214266900|NCT03050099|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
214266901|NCT01024075|DRUG|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
214266902|NCT01024075|DRUG|Saline|8cc of Saline mixed with Sinufoam
214266903|NCT00324792|DRUG|intensive insulin therapy|
214266904|NCT01164930|BEHAVIORAL|Acceptance and Commitment Therapy|8-week ACT group
214266905|NCT01940601|DRUG|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
214266906|NCT01940601|DRUG|Filgrastim|Filgrastim 5 μg/kg
214819769|NCT03801707|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
214819770|NCT03801707|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
214819771|NCT03973658|DEVICE|Hearing aids|Fitting of hearing aids (for the first time)
214819772|NCT04003090|DRUG|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
214266907|NCT06558591|DEVICE|Telerehabilitation intervention|"Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study."
214266908|NCT06557200|BEHAVIORAL|Digital Infant- parents support|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
214266909|NCT01622231|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
214819773|NCT05083221|BEHAVIORAL|Hear-Talk-Activity audiological program|The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
214266910|NCT06257797|DIAGNOSTIC_TEST|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
214266911|NCT01984411|PROCEDURE|Radial Technical|Vascular Access for cardiac catheterization
214266912|NCT01984411|PROCEDURE|Femoral Technical|Vascular Access for cardiac catheterization
214266913|NCT01984411|DRUG|Omnipaque|
214266914|NCT00840892|OTHER|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
214819774|NCT00208403|DEVICE|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
214819775|NCT00208403|DEVICE|Palacos R|A high viscosity bone cement for use in total hip replacement
214266917|NCT00046878|DRUG|O6-benzylguanine|
214266918|NCT00046878|DRUG|carmustine|
214266919|NCT06403852|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) with propofol|Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
214819776|NCT06698926|DRUG|ABBV-CLS-616|Oral Tablet
214819777|NCT06698926|DRUG|Placebo|Oral Tablet
214266920|NCT05232071|DRUG|IVA337|800 mg
214266921|NCT05232071|DRUG|Placebo|Placebo to match
214266922|NCT05232071|DRUG|Empagliflozin|10 mg
214266923|NCT06556979|RADIATION|Radiotherapy|Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
214266924|NCT05248581|PROCEDURE|Liver transplantation|living donor liver transplantation
214266925|NCT02264639|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214266926|NCT01655797|BEHAVIORAL|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
214266927|NCT01949831|OTHER|Assessment of functional ability in combination with follow-up at home|
214266928|NCT03062982|DRUG|Fluzoparib|2 doses separated by 7 days.
214266929|NCT00881257|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
214266930|NCT03881670|DEVICE|Lotrafilcon B|commercially available contact lens
214266931|NCT03881670|DEVICE|lotrafilcon B with Hydraluxe|commercially available contact lens
214266932|NCT02368197|DRUG|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
214266933|NCT02368197|DEVICE|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
214266934|NCT05085574|DRUG|Famotidine|80 mg tablet, QID for 14 days
214266935|NCT05085574|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
214266936|NCT05085574|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
214266937|NCT03092271|BEHAVIORAL|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
214266938|NCT03092271|BEHAVIORAL|Zero Suicide Quality Improvement|ZSQI
214266939|NCT04342377|DIAGNOSTIC_TEST|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
214266940|NCT04342377|DIAGNOSTIC_TEST|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
214266941|NCT00914485|BEHAVIORAL|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
214266942|NCT00174811|DRUG|telithromycin (HMR3647)|
214266943|NCT03523234|DRUG|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
214266944|NCT03523234|PROCEDURE|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
214266945|NCT03523234|PROCEDURE|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
214266946|NCT03523234|DRUG|Chemotherapy|etoposide with cisplatin/carboplatin
214266947|NCT04814732|DRUG|Surufatinib|HMP-012
214266948|NCT00348179|PROCEDURE|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
214266949|NCT03391310|OTHER|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
214266950|NCT04889222|DEVICE|INVSENSOR00050|Noninvasive pulse oximeter sensor
214266951|NCT04889222|DEVICE|RD SET SpO2|Noninvasive pulse oximeter sensor
214819778|NCT06698926|DRUG|Itraconazole|Oral Capsule
214819779|NCT03873272|DEVICE|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
214266952|NCT01180647|DRUG|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
214266953|NCT01180647|BEHAVIORAL|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
214819780|NCT03873272|DEVICE|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
214819781|NCT03873272|DEVICE|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
214819782|NCT07033013|DIETARY_SUPPLEMENT|Placebo|Placebo
214266954|NCT05352178|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
214266955|NCT05352178|DRUG|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
214266956|NCT05352178|DRUG|Androgen receptor targeted therapy|Enzalutamide
214266957|NCT02243969|DIETARY_SUPPLEMENT|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
214266958|NCT02243969|DIETARY_SUPPLEMENT|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
214266959|NCT06421207|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
214266960|NCT06293131|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
214266961|NCT02143700|OTHER|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
214266962|NCT00912678|DRUG|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
214266963|NCT00912678|DRUG|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
214819783|NCT07033013|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary supplement containing EstroG-100 and GABA
214266964|NCT00152529|BEHAVIORAL|Screening (Behavior)|
214266965|NCT01704521|DRUG|PegInterferon|
214819784|NCT04206462|OTHER|Questionnaire of eating habits|frequency and type of aliments
214819785|NCT02608177|DRUG|Linagliptin|Receives 4 weeks of study drug linagliptin
214819786|NCT02608177|DRUG|Glipizide|Receives 4 weeks of study drug glipizide
214266966|NCT01704521|DRUG|Ribavirin|
214266967|NCT01704521|DRUG|Telaprevir|
214266968|NCT04558684|DRUG|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
214266969|NCT04558684|DRUG|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
214266970|NCT04558684|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions)
214266971|NCT00702689|DRUG|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
214266972|NCT01833988|DEVICE|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
214266973|NCT01833988|OTHER|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
214266974|NCT02380001|DRUG|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
214266975|NCT02380001|DRUG|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
214266976|NCT02842307|PROCEDURE|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
214266977|NCT02842307|PROCEDURE|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
214266978|NCT02842307|PROCEDURE|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
214266979|NCT02725931|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
214266980|NCT03010670|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
214266981|NCT03010670|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
214266982|NCT05109845|DIAGNOSTIC_TEST|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
214266983|NCT03949439|PROCEDURE|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
214266984|NCT00263770|DEVICE|soft palate implant|
214819787|NCT00787254|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
214266985|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
214266986|NCT01761175|PROCEDURE|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
214266987|NCT01761175|PROCEDURE|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
214266988|NCT00496509|DRUG|ZD6474 (Zactima) 100mg|
214266989|NCT00496509|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
214266990|NCT00496509|PROCEDURE|Biomarker Draws|
214819788|NCT00787254|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
214819789|NCT06719726|PROCEDURE|PECS I Block|The PECS I block is a regional anesthesia technique performed preoperatively under ultrasound guidance. It involves the injection of 10 mL of 0.5% bupivacaine between the pectoralis major and pectoralis minor muscles to block the medial and lateral pectoral nerves. This procedure targets the right breast in the study to reduce postoperative pain and is compared to local anesthetic infiltration.
214819790|NCT06719726|PROCEDURE|Local Anesthetic Infiltration|Local anesthetic infiltration involves the intraoperative administration of 10 mL of 0.5% bupivacaine under direct visualization into the pectoralis major muscle prior to muscle transection. This procedure targets the left breast in the study for pain management and is compared to the PECS I block.
214819791|NCT05573620|BEHAVIORAL|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
214266991|NCT00496509|DRUG|ZD6474 (Zactima) 300mg|
214266992|NCT00784641|DEVICE|Novel Bausch & Lomb daily disposable contact lenses|Lenses to be worn and replaced daily for 2 weeks.
214266993|NCT00784641|DEVICE|Bausch & Lomb SofLens daily disposable contact lenses.|Lenses to be worn and replaced daily for 2 weeks.
214266994|NCT00784641|DEVICE|Johnson and Johnson 1-Day Acuvue Moist contact lenses|Lenses to be worn and replaced daily for 2 weeks.
214266995|NCT02716805|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
214266996|NCT02716805|DRUG|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing \> 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
214266997|NCT02716805|BIOLOGICAL|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
214266998|NCT02716805|DRUG|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
214266999|NCT04356742|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
214267000|NCT04356742|DRUG|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
214267001|NCT04356742|DRUG|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
214267002|NCT04356742|DRUG|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
214267003|NCT04288752|DEVICE|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
214267004|NCT04288752|DEVICE|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
214267005|NCT00764296|OTHER|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
214267006|NCT00764296|OTHER|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
214267007|NCT00005017|DRUG|Ritonavir|
214267008|NCT00005017|DRUG|Abacavir sulfate|
214267009|NCT00005017|DRUG|Amprenavir|
214267010|NCT00005017|DRUG|Efavirenz|
214267011|NCT00005017|DRUG|Lamivudine|
214267012|NCT00005017|DRUG|Stavudine|
214267013|NCT01254071|DRUG|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
214267014|NCT06205823|DRUG|Immunotherapy|Immunotherapy
214267015|NCT04718961|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
214267016|NCT04718961|DRUG|Placebo|Capsules matched to study drug minus active substance.
214267017|NCT04069078|DRUG|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
214267018|NCT04069078|OTHER|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
214267019|NCT02058472|DRUG|G3041|
214267020|NCT02058472|DRUG|SEVIKAR®|
214267021|NCT03120559|DEVICE|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
214267022|NCT03120559|DEVICE|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
214267023|NCT01934881|DEVICE|voltage adjustment only|Only voltage will be adjusted in all programming sections.
214267024|NCT01934881|DEVICE|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
214267025|NCT01154829|DRUG|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
214267026|NCT01154829|DRUG|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
214267027|NCT02121522|DRUG|BI 144807|twice daily
214819792|NCT05573620|BEHAVIORAL|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
214819793|NCT05573620|BEHAVIORAL|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
214267028|NCT03081975|DEVICE|HD white light or NBI|Use of NBI or HD white light
214267029|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
214267030|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
214267031|NCT03993470|BEHAVIORAL|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
214267032|NCT03476278|OTHER|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
214267033|NCT05089955|BEHAVIORAL|Ambient Experience|MRI examination with Ambient Experience
214267034|NCT01141452|DRUG|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
214267035|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
214267036|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
214267037|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
214267038|NCT01141452|DRUG|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
214267039|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
214267040|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
214267041|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
214819794|NCT03255421|OTHER|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
214819795|NCT04647266|PROCEDURE|endoscopic submucosal dissection|endoscopic submucosal dissection
214819796|NCT01305161|OTHER|Blood simple|Single Blood simple at Day 1
214267042|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
214267043|NCT05108714|PROCEDURE|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
214267044|NCT02279446|OTHER|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
214267045|NCT02810522|DEVICE|OneTouch Select® Plus Glucose Test Strips|
214267046|NCT00591994|DRUG|piribedil|50 mg once a day, after lunch 3 month therapy
214267047|NCT05317624|COMBINATION_PRODUCT|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
214267048|NCT05317624|COMBINATION_PRODUCT|Methylprednisolone|1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
214267049|NCT00633750|DRUG|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
214267050|NCT00633750|GENETIC|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
214267051|NCT00633750|GENETIC|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
214267052|NCT00633750|OTHER|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
214267053|NCT00633750|OTHER|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
214267054|NCT00633750|OTHER|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
214267055|NCT00633750|OTHER|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
214267056|NCT00633750|OTHER|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
214267057|NCT00633750|PROCEDURE|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
214267058|NCT05997550|OTHER|Pursed Lip Breathing Exercise|Pursed Lip Breathing Exercise for The COPD
214267059|NCT05997550|OTHER|Laughter Therapy|Laughter Therapy for the COPD
214267060|NCT05997550|OTHER|the control group.|Attention-match training is given to the patients in the control group.
214267061|NCT03311529|BEHAVIORAL|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
214267062|NCT04020588|DRUG|Celecoxib 200mg|Will be administered for 6 weeks
214267063|NCT04020588|DRUG|Placebo oral capsule|Will be administered for 6 weeks
214267064|NCT04020588|DRUG|Minocycline 100mg|Will be administered for 6 weeks
214267065|NCT06201442|OTHER|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
214267066|NCT06201442|OTHER|Blood sampling|blood sample taken and analysis - not standard of care
214267067|NCT06201442|OTHER|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
214267068|NCT06201442|OTHER|Activity monitoring|Actigraph measurement- not standard of care
214267069|NCT06201442|OTHER|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
214267070|NCT06201442|BEHAVIORAL|Questionnaires|Patient reported outcomes (PROMS)
214267071|NCT04043273|BEHAVIORAL|Noninterventional characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
214267072|NCT00122096|DRUG|valdecoxib|
214267073|NCT01515878|DEVICE|Hemocontrol|Blood Volume Tracking system using biofeedback
214267074|NCT01903031|DEVICE|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
214267075|NCT01903031|DRUG|EFV|Participants received EFV 600 mg daily with two or more NRTIs
214267076|NCT01903031|DRUG|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
214267077|NCT01903031|DRUG|TDF|Participants received 300 mg of tenofovir in Arm C
214267078|NCT01903031|DRUG|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
214267079|NCT06069323|DEVICE|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
214267080|NCT02560909|BIOLOGICAL|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
214267081|NCT02560909|BIOLOGICAL|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
214267082|NCT05255211|DRUG|Remimazolam tosilate|IV before procedure
214267083|NCT05255211|DRUG|Propofol|IV before procedure
214267084|NCT05255211|OTHER|saline solution|IV before procedure
214267085|NCT01332084|OTHER|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
214267086|NCT01168141|DRUG|ZD4054|10mg ZD4054 daily in tablet form
214267087|NCT05096728|DRUG|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"
214267088|NCT00033605|DRUG|octreotide acetate|
214267089|NCT00033605|OTHER|placebo|
214267090|NCT00033605|RADIATION|radiation|
214267091|NCT02863744|PROCEDURE|coronally advanced flap with subepithelial connective tissue graft|"* Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
214267092|NCT05702918|DEVICE|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
214267093|NCT05702918|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
214267094|NCT04436159|PROCEDURE|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
214267095|NCT04436159|PROCEDURE|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
214267096|NCT02620722|DEVICE|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
214267097|NCT02620722|DEVICE|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
214267098|NCT01216670|BEHAVIORAL|remote patient's management|scheduled remote CareLink data transmission
214267099|NCT03373292|PROCEDURE|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
214267100|NCT03373292|PROCEDURE|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
214819797|NCT07063485|BEHAVIORAL|Resilience Theory and Satir Model Nursing Skills Training|A structured psychological and nursing intervention program based on resilience theory and the Satir model. It consists of 15 two-hour group sessions during hospitalization, focusing on enhancing resilience, communication, and self-efficacy through themed activities, interactive learning, relaxation techniques, and guided training. The intervention is led by psychologists and psychiatric nurses and includes post-discharge follow-up.
214267101|NCT02489578|OTHER|other|retrospective cohort study
214267102|NCT01126086|DRUG|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
214267103|NCT04544085|BEHAVIORAL|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
214267104|NCT00366574|DEVICE|Amadeus Microkeratome|
214267105|NCT00366574|DEVICE|IntraLase|
214267106|NCT02551861|DRUG|Daclatasvir|
214267107|NCT02551861|DRUG|Sofosbuvir|
214267108|NCT02551861|DRUG|Ribavirin|
214267109|NCT00934479|DRUG|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
214267110|NCT03540030|DRUG|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267111|NCT03540030|DRUG|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267112|NCT03540030|DRUG|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267113|NCT03540030|DRUG|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267114|NCT03540030|DRUG|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267115|NCT03540030|DRUG|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267116|NCT03540030|DRUG|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267117|NCT03540030|DRUG|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267118|NCT03540030|DRUG|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267119|NCT03540030|DRUG|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267120|NCT03540030|DRUG|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
214267121|NCT03329508|DRUG|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
214819798|NCT07063485|BEHAVIORAL|Routine Nursing Intervention|Standard nursing care for patients with depression, including illness monitoring, daily life guidance, psychological support, and health education on disease management, emotion regulation, and medication.
214267122|NCT03329508|DRUG|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
214819799|NCT07063186|OTHER|Group A - Elastomeric power chain on all bracket wings.|Elastomeric power chain is engaged on all bracket wings
214267123|NCT03329508|DRUG|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
214267124|NCT03329508|DRUG|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
214267125|NCT01497457|PROCEDURE|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
214267126|NCT00087503|DRUG|Edotecarin|
214267127|NCT03666624|BEHAVIORAL|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
214267128|NCT03225599|OTHER|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
214267129|NCT00546559|DRUG|statins (simvastatin, pravastatin)|
214267130|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
214267131|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
214267132|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
214819800|NCT07063186|OTHER|Group B - Stainless steel ligatures with elastomeric power chain placed over all bracket wings.|Stainless steel ligatures are used to tie in the archwire on all bracket wings, with an elastomeric power chain placed over the ligatures
214267133|NCT05384678|DRUG|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
214819801|NCT07063186|OTHER|Group C - Elastomeric modules on mesial wings and power chain on distal wings.|Elastomeric modules are placed on the mesial wings of each bracket, while an elastomeric power chain is engaged on the distal wings
214267134|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
214267135|NCT05384678|DRUG|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
214267136|NCT05384678|DRUG|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
214267137|NCT05384678|DRUG|Placebo|A Placebo (saline infusion) will be administered.
214267138|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
214267139|NCT01555450|OTHER|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
214267140|NCT00569270|DRUG|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
214819802|NCT07069062|DRUG|Test product HY0001a for injection|HY0010a for injection should be administered at the recommended dosage
214819803|NCT07068399|PROCEDURE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy (ESWT) delivers acoustic energy transmitted through liquid medium to internal body tissues. The intervention group will receive a total of 9 ESWT treatment sessions and 200 shocks will be applied to each ischaemic zone of myocardium for 3 times a week on the three weeks that the patients receive ESWT.
214819804|NCT07067866|OTHER|Titrated weaning of vasopressin.|The titrated group will follow the vasopressin weaning protocol used in the DOVSS study (reduction of 0.01 U/min per hour).
214819805|NCT07067866|OTHER|Abrupt weaning of vasopressin.|The abrupt group will discontinue the vasopressin infusion at the time of randomization, without dose titration.
214819806|NCT07069257|BEHAVIORAL|Oral Motor Therapy|Structured oral motor exercises will be applied to the lips, tongue, cheeks, and jaw. Facial massage and thermal stimulation (warm and cold) will be performed. Intraoral sensory stimulation will be applied using a brush, lemon juice, and a cold metal probe.
214819807|NCT07069257|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Active NMES will be applied bilaterally to the masseter muscles and to the orbicularis oris muscle in addition to oral motor therapy sessions, using a Chattanooga NMES device. Each application will be performed in cycles of 5 seconds of stimulation and 10 seconds of rest. The stimulation parameters will be set to a frequency of 10-15 Hz and a pulse width of 300 microseconds. The current intensity will be gradually increased to a level just above the motor threshold, sufficient to elicit a noticeable pulling sensation without causing discomfort, and will be adjusted according to each participant's tolerance. NMES will be delivered for a total duration of 15 minutes per session. For the electrical stimulation of the orbicularis oris muscle, a pen-type electrode will be used. In this procedure, four regions of the orbicularis oris muscle (upper, lower, right, and left) will be stimulated in two cycles of 45 pulses each.
214267141|NCT00447005|DRUG|Axitinib (AG-013736)|AG-013736 5mg twice daily \[BID\]
214267142|NCT05646095|BEHAVIORAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
214267143|NCT01595035|BEHAVIORAL|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
214267144|NCT03822182|DRUG|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
214267145|NCT03822182|DRUG|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
214267146|NCT03814083|DEVICE|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
214267147|NCT03814083|DEVICE|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
214819808|NCT07069257|DEVICE|Sham Neuromuscular Electrical Stimulation (Sham NMES)|Simulated neuromuscular electrical stimulation will be applied without delivering active electrical current after oral motor therapy sessions to mimic the treatment experience without producing physiological effects.
214819809|NCT07068126|BIOLOGICAL|Mini-Pool IVIG|Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated, closed-system process. Each participant will receive a loading dose of 1 g/kg infused intravenously over 6-8 hours. Maintenance doses of 0.5 g/kg will be given every 2 to 4 weeks for up to five additional doses, with the dosing schedule adjusted based on platelet count. The preparation contains purified IgG and meets safety standards for sterility and viral inactivation.
214267148|NCT03814083|OTHER|Wait-list|No intervention
214267149|NCT01469234|DRUG|loratadine|loratadine, one 10 mg tablet, orally
214267150|NCT01469234|DRUG|fexofenadine|fexofenadine, one 180 mg tablet, orally
214819810|NCT03117257|DRUG|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
214819811|NCT03117257|DRUG|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
214267151|NCT01469234|DRUG|placebo to loratadine|one tablet, orally
214267152|NCT01469234|DRUG|placebo to fexofenadine|one tablet, orally
214267153|NCT02747290|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
214267154|NCT00810355|BEHAVIORAL|Support Group|General support and problem solving for work activity
214267155|NCT00810355|BEHAVIORAL|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
214267156|NCT00810355|BEHAVIORAL|Cognitive Remediation|Computerized training to enhance cognitive functioning.
214267157|NCT04823182|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
214267158|NCT01942343|DRUG|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
214267159|NCT01346579|OTHER|laboratory biomarker analysis|Correlative sciences
214267160|NCT01479023|DRUG|64Cu-DOTA-U3-1287|
214267161|NCT01479023|DRUG|U3-1287 (unlabeled)|
214267162|NCT00156897|DRUG|ATL-962|
214267163|NCT00156897|DRUG|Orlistat|
214267164|NCT03523130|DIAGNOSTIC_TEST|Imaging|Macrophage-specific inflammation
214267165|NCT01484275|DRUG|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
214267166|NCT01484275|DRUG|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
214267167|NCT03592654|BEHAVIORAL|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
214267168|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
214267169|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
214267170|NCT03729466|OTHER|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
214267171|NCT02587884|PROCEDURE|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
214267172|NCT05929157|DRUG|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
214267173|NCT01008176|BEHAVIORAL|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
214267174|NCT02918201|DRUG|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
214267175|NCT02918201|DRUG|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
214267176|NCT03407625|OTHER|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
214267177|NCT03407625|OTHER|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
214267178|NCT04154930|DEVICE|Restylane-L®|Intradermal injection.
214267179|NCT00951444|BIOLOGICAL|dalotuzumab|Given IV
214819812|NCT03128762|BIOLOGICAL|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
214819813|NCT03567668|PROCEDURE|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
214819814|NCT00316186|DRUG|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
214819815|NCT00316186|DRUG|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
214819816|NCT04499729|DEVICE|IntelliCare|IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
214819817|NCT04499729|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual in the Rush Collaborative Care service
214819818|NCT00305786|DRUG|gemcitabine hydrochloride|
214819819|NCT00305786|DRUG|oxaliplatin|
214819820|NCT00808171|DRUG|Livopan|Inhalation of oxygen and nitrous oxide 50%
214819821|NCT00808171|DRUG|Livopan|equimolar mixture of N2O/O2
214819822|NCT00808171|DRUG|EMLA|Lidocaine-prilocain cream
214819823|NCT03406494|OTHER|Early multicomponent physical therapy program|"1. Positioning (upright bed standing; turning, moving on bed).~2. Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~3. Respiratory muscle training (supine abdominal breathing training).~4. Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~5. Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
214819824|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
214819825|NCT06081348|DRUG|Sertraline|Oral capsule (25mg, 50mg, 100mg, 200mg)
214819826|NCT06081348|OTHER|Placebo|Oral placebo capsule
214819827|NCT00859872|DRUG|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
214819828|NCT00859872|DRUG|haloperidol|haloperidol IM injection (5-20mg/d)
214819829|NCT02895763|OTHER|Form administrations|
214819830|NCT02594358|DRUG|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
214267180|NCT00951444|DRUG|carboplatin|Given IV
214267181|NCT00951444|DRUG|gemcitabine hydrochloride|Given IV
214267182|NCT05654935|RADIATION|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
214267183|NCT05654935|RADIATION|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
214267184|NCT06259123|DRUG|[177Lu]Lu-PSMA I&T|2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
214267185|NCT03404232|DEVICE|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
214267186|NCT04032392|BIOLOGICAL|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
214267187|NCT04634890|BEHAVIORAL|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
214267188|NCT03602430|DRUG|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
214267189|NCT03602430|DRUG|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
214267190|NCT02058173|DRUG|150 mg/daily chloroquine compare to placebo for 12 week|
214267191|NCT02058173|DRUG|Chloroquine|
214267192|NCT02058173|DRUG|placebo|
214267193|NCT04575623|DIAGNOSTIC_TEST|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function."
214267194|NCT04575623|DEVICE|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240."
214267195|NCT02714374|BIOLOGICAL|GL-ONC1|"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
214267196|NCT05303181|DEVICE|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
214267197|NCT00000546|BEHAVIORAL|meditation|
214267198|NCT02130297|DEVICE|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
214267199|NCT00966771|DRUG|Copper T380 IUD|copper T 380 IUD
214267200|NCT00966771|DRUG|Oral levonorgestrel|1.5 mg
214267201|NCT05827731|BEHAVIORAL|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
214819831|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 6 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
214819832|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 9 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
214267202|NCT00921401|BEHAVIORAL|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
214267203|NCT05353179|DRUG|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
214267204|NCT05353179|DRUG|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
214267205|NCT01120535|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
214267206|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
214267207|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
214267208|NCT02904993|OTHER|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
214267209|NCT02904993|OTHER|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
214267210|NCT06253975|BIOLOGICAL|adipose tissue derived extracellular vesicles (AT-EVs)|Extracellular vesicles from patient's adipose tissue together with HA
214267211|NCT06253975|DRUG|Hyaluronic acid|Use HA only as a placebo
214267212|NCT05862142|OTHER|No intervention|No intervention
214819833|NCT04766450|DRUG|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
214819834|NCT03090568|DRUG|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
214819835|NCT06083259|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
214267213|NCT03398044|DRUG|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
214267214|NCT03398044|DRUG|Placebo|Placebo will be administered to patients randomised into the control group arm.
214267215|NCT00347360|DRUG|lisinopril|
214267216|NCT00347360|DRUG|carvedilol controlled release formulation|
214267217|NCT02009306|DRUG|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
214267218|NCT02009306|DRUG|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide"
214819836|NCT06083259|PROCEDURE|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
214267219|NCT02009306|DRUG|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
214267220|NCT05004077|DRUG|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
214267221|NCT03196856|BEHAVIORAL|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
214267222|NCT03196856|DIETARY_SUPPLEMENT|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
214267223|NCT03196856|DIETARY_SUPPLEMENT|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
214267224|NCT00551447|DRUG|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
214267225|NCT00551447|DRUG|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
214267226|NCT00551447|DRUG|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
214819837|NCT01921894|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
214267227|NCT03763175|DRUG|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
214267228|NCT03763175|DRUG|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
214267229|NCT03763175|DRUG|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
214267230|NCT00913380|RADIATION|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
214267231|NCT00913380|RADIATION|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
214267232|NCT00806351|DRUG|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
214267233|NCT00806351|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
214267234|NCT04271527|PROCEDURE|cognitive fusion targeted biopsy|A cognitive fusion targeted biopsy
214267235|NCT02819739|DRUG|medical oxygen|
214267236|NCT02187744|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
214267237|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
214819838|NCT05240989|PROCEDURE|pulmonary rehabilitation|one-year regular lung rehabilitation treatment and control the intensive monitoring of hemodynamic parameters
214819839|NCT00193115|DRUG|Docetaxel|
214819840|NCT00193115|DRUG|Doxorubicin|
214819841|NCT00193115|DRUG|Cyclophosphamide|
214819842|NCT02908776|DIETARY_SUPPLEMENT|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
214267238|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
214267239|NCT02187744|BIOLOGICAL|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
214267240|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
214267241|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
214267242|NCT00134030|DRUG|Cisplatin|Given IV
214267243|NCT00134030|DRUG|Doxorubicin Hydrochloride|Given IV
214267244|NCT00134030|DRUG|Etoposide|Given IV
214267245|NCT00134030|DRUG|Ifosfamide|Given IV
214267246|NCT00134030|DRUG|Methotrexate|Given IV
214267247|NCT00134030|BIOLOGICAL|Peginterferon Alfa-2b|Given subcutaneously
214267248|NCT00134030|OTHER|Quality-of-Life Assessment|Ancillary studies
214267249|NCT00134030|OTHER|Questionnaire Administration|Ancillary studies
214267250|NCT00134030|PROCEDURE|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
214267251|NCT05157438|BEHAVIORAL|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
214267252|NCT05157438|BEHAVIORAL|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
214267253|NCT04941859|BEHAVIORAL|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
214267254|NCT04111198|RADIATION|Cardiac MRI|Cardiac MRI
214267255|NCT00601198|DRUG|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
214267256|NCT01597401|DRUG|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
214267257|NCT01597401|DRUG|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
214267258|NCT01597401|DRUG|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
214267259|NCT01597401|DRUG|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
214267260|NCT01597401|DRUG|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
214267261|NCT05777746|BEHAVIORAL|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
214267262|NCT05777746|BEHAVIORAL|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
214267263|NCT06005480|DRUG|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
214267264|NCT04259320|DEVICE|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
214267265|NCT04259320|BIOLOGICAL|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
214267266|NCT05106517|DRUG|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
214267267|NCT05106517|DRUG|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
214267268|NCT03162588|DRUG|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
214267269|NCT00270439|PROCEDURE|removal of omentum|patients with type 2 diabetes had their omentum removed
214267270|NCT01821196|PROCEDURE|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
214267271|NCT03405584|DRUG|Esomeprazole|Proton pump inhibitor
214267272|NCT03405584|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214267273|NCT03405584|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214267274|NCT06319378|DRUG|psilocybin 25 mg sod|psilocybin 25 mg sod
214267275|NCT06319378|DRUG|psilocybin 1 mg sod|active placebo
214267276|NCT06558045|DRUG|Rivaroxaban 20 mg film-coated tablet|One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
214267277|NCT06558045|DRUG|Xarelto 20 mg film-coated tablet|One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
214819843|NCT02908776|OTHER|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
214267278|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
214267279|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
214267280|NCT02028143|PROCEDURE|Pulmonary vein isolation|
214267281|NCT02028143|PROCEDURE|ICE catheter placed through one of two existing 8F sheaths|
214819844|NCT06558695|DRUG|Sevoflurane|Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
214819845|NCT06558695|DRUG|TIVA|TIVA was managed for maintenance of the general anesthesia during spinal surgeries
214267282|NCT01932307|PROCEDURE|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
214819846|NCT05813847|DRUG|local anaesthetic injection|Local infiltration of study drug
214819847|NCT05643677|DRUG|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
214819848|NCT05643677|DRUG|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
214267283|NCT05749107|DIAGNOSTIC_TEST|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
214267284|NCT05749107|COMBINATION_PRODUCT|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
214267285|NCT00855673|DEVICE|Intermittent Mechanical Compression|FM220 device
214819849|NCT00650377|DRUG|Finasteride Tablets 5 mg|5mg, single dose fed
214819850|NCT00650377|DRUG|Proscar® Tablets 5 mg|5mg, single dose fed
214819851|NCT00828815|DRUG|TMC125|
214267286|NCT00855673|DRUG|Control|Standard medical treatment
214267287|NCT04691271|PROCEDURE|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
214819852|NCT04388722|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
214819853|NCT05761652|OTHER|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
214819854|NCT04356508|DRUG|Nivolumab|Single dose at 0.3mg/kg
214819855|NCT02404753|DRUG|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
214267288|NCT02842359|DRUG|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
214267289|NCT02842359|DRUG|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
214267290|NCT02842359|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
214819856|NCT02404753|PROCEDURE|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
214819857|NCT02404753|PROCEDURE|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
214819858|NCT02404753|DRUG|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
214267291|NCT06194630|DRUG|68Ga-A3|Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
214267292|NCT02643602|OTHER|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
214819859|NCT03255733|DEVICE|Intense Therapeutic Ultrasound Treatment|
214819860|NCT05309850|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
214819861|NCT05284539|DRUG|Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab|Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
214819862|NCT06433258|BEHAVIORAL|Enhanced TSSC curriculum|In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
214819863|NCT06433258|BEHAVIORAL|Original TSSC curriculum|Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
214267293|NCT02643602|OTHER|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
214267294|NCT04690933|OTHER|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
214267295|NCT04775407|PROCEDURE|blood sampling|IgM og IgG analysis
214267296|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
214819864|NCT04299087|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
214819865|NCT04299087|OTHER|Control group|No application of rTMS
214267297|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
214267298|NCT04548583|OTHER|Placebo|Normal saline
214267299|NCT00853775|OTHER|No intervention, observational study|
214267300|NCT00508755|DEVICE|Gait Robot|gait training with the use of a gait robot
214267301|NCT00508755|DEVICE|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
214267302|NCT01765907|DEVICE|HIFU|
214267303|NCT06210607|DRUG|HS-10511 Tablets|HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
214267304|NCT06210607|DRUG|HS-10511 Tablets Placebo|HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
214819866|NCT04629326|OTHER|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
214819867|NCT04309968|DRUG|Drug: SYHA1801|Drug: SYHA1801 administered orally
214267305|NCT03837860|DRUG|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
214267306|NCT03837860|DRUG|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
214267307|NCT03837860|DRUG|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
214819868|NCT00594035|DEVICE|Spinal Sealant System|
214819869|NCT00594035|DEVICE|Standard of care|Standard of care: devices intended to provide a watertight closure
214819870|NCT00795821|DRUG|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
214819871|NCT00795821|DRUG|Placebo|Dose: 3 tablets QD for 10 weeks
214819872|NCT01285713|DRUG|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
214819873|NCT01285713|DRUG|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
214267308|NCT05596344|OTHER|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
214267309|NCT06090396|DIAGNOSTIC_TEST|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
214267310|NCT05072704|DRUG|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
214267311|NCT05072704|DRUG|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
214267312|NCT01406743|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
214267313|NCT05306392|DEVICE|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
214267314|NCT05306392|DEVICE|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
214819874|NCT05312554|DEVICE|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
214819875|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 \*120mg new formulation tablet as test treatment
214819876|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
214819877|NCT00416780|OTHER|counseling intervention|
214267315|NCT03351933|BIOLOGICAL|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
214267316|NCT04623112|DEVICE|Hearing aid feature: Frequency Compression|FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
214267317|NCT03812107|OTHER|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
214819878|NCT00416780|OTHER|educational intervention|
214819879|NCT00416780|PROCEDURE|psychosocial assessment and care|
214819880|NCT04310345|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
214267318|NCT03812107|OTHER|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
214267319|NCT06429488|OTHER|no intervention, questionnaires were used|"The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD)."
214267320|NCT03975036|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules
214267321|NCT03975036|DRUG|pd-1 antibody|Pembrolizumabinjection
214267322|NCT04640857|DEVICE|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
214267323|NCT02421471|DRUG|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
214267324|NCT01435603|BEHAVIORAL|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
214267325|NCT01435603|BEHAVIORAL|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
214267326|NCT05247775|PROCEDURE|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
214267327|NCT04512014|DIAGNOSTIC_TEST|serum lactate|perioperative measurement of lactate levels
214267328|NCT04207021|DIETARY_SUPPLEMENT|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
214267329|NCT04207021|DIETARY_SUPPLEMENT|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
214267330|NCT02846831|OTHER|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
214267331|NCT02846831|OTHER|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
214267332|NCT02846831|DEVICE|Insulin pump|Tandem Diabetes Care
214267333|NCT02846831|DEVICE|Continuous glucose monitoring system|Dexcom G5 Platinum
214267334|NCT02846831|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
214267335|NCT04352569|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
214819881|NCT06627946|PROCEDURE|TAP group|Local anesthesia 0.25% bupivacine was administered in the TAP plane
214819882|NCT00193245|DRUG|Topotecan|
214819883|NCT00193245|DRUG|Docetaxel|
214819884|NCT01079845|BEHAVIORAL|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
214819885|NCT03341013|DRUG|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
214819886|NCT03341013|DRUG|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
214819887|NCT03209115|DRUG|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
214819888|NCT03209115|DRUG|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
214819889|NCT05795140|DRUG|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
214819890|NCT06549998|OTHER|Interprofessional Simulation Experience|"Phase 1 (Pre-Brief): Nursing and physical therapy students will have 10 minutes to gather as a group and prepare for the simulation experience.~The students will work together to review the simulated patient's medical chart, which includes a hand off report, physician orders, patient demographic data, disci-pline-specific progress notes, a physical therapy evaluation, and information from lab results posted on a tri-fold board.~Phase 2 (Simulation): After reviewing the chart and establishing a plan as a group for getting the simulated patient out of bed, the interprofessional team of nursing and physical therapy students will enter the simulated hospital room. The goal for the approximately 20-minute encounter is for the interprofessional group to help the simulated patient to get out of bed while closely monitoring the physiological responses to activity.~Phase 3: The simulation will conclude with a 30-minute faculty guided and structured debriefing session."
214267336|NCT03690531|DEVICE|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
214267337|NCT03690531|DEVICE|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
214267338|NCT01784445|DRUG|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
214267339|NCT06129175|BIOLOGICAL|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
214267340|NCT06129175|OTHER|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
214267341|NCT05879679|BEHAVIORAL|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
214267342|NCT01468675|OTHER|Intervention|risk assessment survey; decision support for providers for prevention based on risk
214267343|NCT00821483|DRUG|Frovatriptan|2.5mg, qd
214267344|NCT05509036|OTHER|No interventions|No interventions
214267345|NCT03734042|BIOLOGICAL|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
214267346|NCT03734042|BIOLOGICAL|Normal saline|Intrauterine infusion of normal saline at day 11
214267347|NCT02004522|DRUG|Duvelisib|PI3K Inhibitor
214819891|NCT04647760|BEHAVIORAL|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
214819892|NCT04471779|OTHER|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
214819893|NCT06239688|BEHAVIORAL|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
214819894|NCT06239688|BEHAVIORAL|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
214819895|NCT06248528|PROCEDURE|Liver resection|Patients in the intervention group received liver resection and postoperative adjuvant therapy
214819896|NCT06248528|PROCEDURE|Locoregional therapy|Patients in the control group received locoregional therapy and systemic therapy
214819897|NCT04026958|DRUG|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
214819898|NCT04026958|DRUG|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
214819899|NCT03511534|BEHAVIORAL|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
214819900|NCT03511534|OTHER|Pharmacotherapy|Pharmacotherapy by a psychiatrist
214819901|NCT05521867|DEVICE|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
214267348|NCT02004522|DRUG|Ofatumumab|monoclonal antibody
214267349|NCT01787331|DRUG|Itraconazole|Given PO
214267350|NCT01787331|OTHER|Laboratory Biomarker Analysis|Correlative studies
214267351|NCT01787331|OTHER|Pharmacological Study|Correlative studies
214267352|NCT04090866|OTHER|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
214267353|NCT01186536|DIETARY_SUPPLEMENT|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
214267354|NCT01186536|DIETARY_SUPPLEMENT|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
214267355|NCT01186536|DIETARY_SUPPLEMENT|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
214267356|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
214267357|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
214267358|NCT05327426|BIOLOGICAL|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
214267359|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
214267360|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
214819902|NCT05521867|DEVICE|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
214819903|NCT05660395|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
214267361|NCT06142708|DRUG|Dual trigger (human chorionic gonadotropin plus GnRH-agonist)|Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
214267362|NCT06142708|DRUG|GnRH-agonist only trigger|GnRH-agonist only will be used for final maturation
214267363|NCT03831789|DEVICE|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
214267364|NCT01999868|BIOLOGICAL|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab."
214819904|NCT06194344|BEHAVIORAL|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
214819905|NCT06194344|BEHAVIORAL|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
214819906|NCT05771558|DEVICE|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
214267365|NCT01999868|BIOLOGICAL|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
214819907|NCT05771558|DEVICE|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
214819908|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
214819909|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
214819910|NCT05706870|DRUG|GN-037|GN-037
214819911|NCT05706870|DRUG|Clobetasol 17-propionate|Clobetasol 17-propionate
214819912|NCT05706870|DRUG|Placebo|Placebo
214267366|NCT01999868|DRUG|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
214267367|NCT01999868|DRUG|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
214267368|NCT00391729|DRUG|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
214267369|NCT00391729|DRUG|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
214267370|NCT02956031|OTHER|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
214267371|NCT02956031|OTHER|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
214267372|NCT02956031|PROCEDURE|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
214267373|NCT00310401|DRUG|Albuterol|5 mg nebulized q4h
214267374|NCT00310401|DRUG|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
214267375|NCT02028819|DRUG|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
214819913|NCT04318886|BEHAVIORAL|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
214819914|NCT05700383|BEHAVIORAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
214819915|NCT05700383|BEHAVIORAL|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
214819916|NCT06837220|BEHAVIORAL|Enhanced Courage to Quit|"Participants will engage in a version of the smoking cessation treatment Courage to Quit that has been optimized for implementation in community behavioral health clinics. The group will run over a period of 3 months, where participants will learn behavioral and cognitive skills for smoking cessation and/or reduction. Special attention will be given to the unique needs of the community, such as technology options or more flexible treatment models. The goal of this intervention is to prove that it is feasible to implement, and can create enhanced engagement and smoking outcomes for adults who smoke (AWS) and have fewer socioeconomic resources."
214819917|NCT02772367|PROCEDURE|skin punch biopsy|
214819918|NCT06054412|DEVICE|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
214819919|NCT02925884|DEVICE|Gunnar OTC Glasses|Gunnar Over-the-Counter Computer Glasses have optical power of 0.5 diopters for reducing accommodation demands at a typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
214819920|NCT01555892|BIOLOGICAL|EBV-specific T cells: A|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
214819921|NCT01555892|BIOLOGICAL|EBV-specific T cells: B|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
214819922|NCT04691973|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
214819923|NCT04691973|OTHER|Usual care|Usual care at ordinary healthcare provider
214819924|NCT06234358|DEVICE|osteosynthesis|calcaneus osteosynthesis is a surgical fixation of a displaced fracture of the calcaneous bone. The surgery is performed under general or regional anesthesia. A scar is made on the lateral side of the ankle below the lateral malleolus. The bone fragments are repositioned as anatomically as possible. They are fixed by a percutaneous nailing fastener.
214819925|NCT04724187|DRUG|Misoprostol|it is prostaglandin E1 .
214819926|NCT04724187|DRUG|Oxytocin|it stimulates uterine contractions
214819927|NCT02301975|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
214819928|NCT02301975|DRUG|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
214819929|NCT02301975|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
214819930|NCT02301975|DRUG|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
214819931|NCT02301975|DRUG|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
214819932|NCT01421264|DRUG|Gabapentin|300mg capsules by mouth
214819933|NCT01038960|BEHAVIORAL|Exercise training|3 months supervised interval training
214819934|NCT02663960|OTHER|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
214819935|NCT02663960|OTHER|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
214267376|NCT02028819|DRUG|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
214267377|NCT01682954|BEHAVIORAL|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
214267378|NCT03925857|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
214267379|NCT03585231|BEHAVIORAL|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
214267380|NCT03585231|BEHAVIORAL|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
214267381|NCT03585231|BEHAVIORAL|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
214819936|NCT04086108|DIETARY_SUPPLEMENT|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
214819937|NCT04086108|DIETARY_SUPPLEMENT|GABA supplement|1 gram of GABA dissolved in water.
214819938|NCT04086108|DIETARY_SUPPLEMENT|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
214819939|NCT05433857|DRUG|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
214819940|NCT06524219|PROCEDURE|unilateral intrafascial resection|Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
214819941|NCT06524219|PROCEDURE|bilateral intrafascial resection|Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
214819942|NCT06524219|PROCEDURE|bilateral extrafascial resection|Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
214819943|NCT06628063|OTHER|ultrasound evaluation|Ultrasound scan of fetus in second and third trimestrers
214819944|NCT00551863|BEHAVIORAL|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
214819945|NCT05003232|DEVICE|Near-infrared spectroscopy (NIRS) and ICM+|The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
214819946|NCT05025085|DRUG|AGEN1777|An immunoglobulin gamma (IgG1) antibody
214819947|NCT05025085|DRUG|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
214819948|NCT05162105|OTHER|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
214819949|NCT05162105|OTHER|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
214819950|NCT02111239|DEVICE|CTA|pelvic/abdominal CTA scan
214819951|NCT02111239|DEVICE|MRA|pelvic/abdominal MRA scan
214819952|NCT04509453|DEVICE|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
214819953|NCT04509453|DEVICE|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
214819954|NCT01882686|OTHER|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
214819955|NCT01440803|DRUG|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
214819956|NCT01440803|DRUG|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
214819957|NCT02949739|BEHAVIORAL|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
214819958|NCT06626581|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
214819959|NCT06626581|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
214819960|NCT00004796|DRUG|lactulose|
214819961|NCT03004703|DRUG|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
214819962|NCT03004703|DRUG|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
214819963|NCT04676503|DIETARY_SUPPLEMENT|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
214819964|NCT02826694|GENETIC|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
214819965|NCT02826694|GENETIC|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
214267382|NCT00354861|BIOLOGICAL|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
214267383|NCT00354861|BIOLOGICAL|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
214267384|NCT00354861|BIOLOGICAL|Engerix B|20 µg hepatitis B antigen absorbed on alum
214267385|NCT00561457|DEVICE|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
214267386|NCT03777488|DRUG|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
214267387|NCT03777488|DRUG|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
214267388|NCT03777488|DRUG|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
214267389|NCT02426944|DRUG|NOAC|Medical arm, patients will be treated by NOAC.
214267390|NCT02426944|DEVICE|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
214267391|NCT05577780|PROCEDURE|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
214267392|NCT00450255|BIOLOGICAL|ziv-aflibercept|Given IV
214267393|NCT00450255|OTHER|pharmacological study|Correlative studies
214819966|NCT03921879|DRUG|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
214819967|NCT03921879|DRUG|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
214819968|NCT04422457|OTHER|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
214819969|NCT04762966|DRUG|Metformin|Level of Metformin blood concentration
214819970|NCT01609257|BIOLOGICAL|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
214819971|NCT01609257|BIOLOGICAL|Saline Comparator|2 doses IM 28 days apart
214819972|NCT03923192|DEVICE|Vistacam|device for early proximal caries detection
214819973|NCT03923192|RADIATION|Bitewing radiograph|radiograph for proximal caries detection
214819974|NCT02125461|DRUG|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
214819975|NCT02125461|OTHER|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
214819976|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
214819977|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
214819978|NCT06332170|DRUG|HS-20093|administered as an IV infusion
214819979|NCT06332170|DRUG|Adebrelimab|administered as an IV infusion
214819980|NCT06332170|DRUG|Cisplatin/ Carboplatin|administered as an IV infusion
214819981|NCT06332170|DRUG|Cetuximab|administered as an IV infusion
214819982|NCT06332170|DRUG|Enzalutamide|160mg once daily (QD) orally
214819983|NCT03884894|DIAGNOSTIC_TEST|molecular assay|performed with blood culture simultaneously
214819984|NCT03884894|DIAGNOSTIC_TEST|Blood culture|performed with molecular assay simultaneously
214819985|NCT04848987|PROCEDURE|Etching|Etching enamel surface using phosphoric acid
214819986|NCT02380976|DRUG|combination drug: DW330SR, DW1030|
214267394|NCT01613534|DRUG|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
214267395|NCT01613534|DRUG|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
214267396|NCT03247751|DEVICE|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
214267397|NCT01264783|DRUG|RNS60|RNS60 for intravenous administration
214267398|NCT01264783|DRUG|Placebo|0.9% normal saline for injection
214267399|NCT02530359|DRUG|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
214267400|NCT02530359|DRUG|Placebo equivalent|Placebo equivalent per mouth
214267401|NCT00003433|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
214267402|NCT06254651|OTHER|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
214267403|NCT06254651|OTHER|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
214819987|NCT02380976|DRUG|DW340|
214819988|NCT01899989|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
214819989|NCT01899989|DRUG|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
214819990|NCT01120340|DRUG|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
214819991|NCT01120340|OTHER|placebo|2 pills/day for ten days/month until 24 months
214819992|NCT03049748|DEVICE|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
214819993|NCT03049748|OTHER|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
214819994|NCT01602939|DRUG|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
214819995|NCT02263703|BIOLOGICAL|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
214819996|NCT06093984|PROCEDURE|duostim vs. two antagonist ovarian stimulations|Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
214819997|NCT05367076|BEHAVIORAL|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time"
214819998|NCT03084263|PROCEDURE|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
214819999|NCT03084263|PROCEDURE|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
214820000|NCT01830335|DRUG|Indomethacin|
214820001|NCT01830335|DRUG|Placebo|
214820002|NCT04855279|OTHER|neutral sodium fluoride|Topically applied
214820003|NCT04855279|OTHER|ACP-CCP gel|Topically applied
214820004|NCT04855279|OTHER|nano-hydroxyapatite solution|Topically applied
214820005|NCT04855279|OTHER|glycerine|Topically applied
214820006|NCT00835484|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
214820007|NCT00835484|DRUG|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
214820008|NCT01602575|BEHAVIORAL|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
214820009|NCT03487081|BEHAVIORAL|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
214820010|NCT03487081|BEHAVIORAL|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
214267404|NCT03685695|OTHER|Laboratory Biomarker Analysis|Correlative studies
214267405|NCT03685695|DEVICE|Monitoring Device|Wear Fitbit Charge 2
214820011|NCT01858493|BEHAVIORAL|Continence promotion group education workshop|Interactive group education workshop promoting continence
214820012|NCT01858493|BEHAVIORAL|Sham health lecture|Interactive group education workshop about general health
214820013|NCT03283358|BEHAVIORAL|Person-centered follow up|
214820014|NCT02243982|OTHER|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
214267406|NCT03685695|OTHER|Physical Activity|Complete aimed walking steps
214267407|NCT03685695|OTHER|Quality-of-Life Assessment|Ancillary studies
214267408|NCT03685695|OTHER|Questionnaire Administration|Ancillary studies
214267409|NCT02587793|OTHER|not interventional study|
214820015|NCT01888276|OTHER|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop"
214820016|NCT05028855|DIAGNOSTIC_TEST|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
214820017|NCT05504902|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
214820018|NCT00348543|PROCEDURE|laser treatment|
214267410|NCT02255903|OTHER|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
214267411|NCT04112407|DEVICE|Blue Light Phototherapy|Phototherapy in the blue light spectrum
214267412|NCT04112407|DRUG|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
214267413|NCT04112407|OTHER|Control|Standard surgical site preparation with no P. acnes pretreatment
214820019|NCT05219864|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214820020|NCT05219864|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214820021|NCT01312064|DRUG|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
214820022|NCT01312064|DRUG|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
214820023|NCT04651036|DRUG|QL0605|a pegfilgrastim biosimilar to US Neulasta.
214820024|NCT04651036|DRUG|US Neulasta|US Neulasta
214820025|NCT04383587|OTHER|Serologic testing|COVID19 IgG antibody testing to be performed
214820026|NCT03675633|DIAGNOSTIC_TEST|FEUrea|FEUrea in decompansated liver cirrhosis
214820027|NCT01916915|DRUG|Tramadol infusion via wound catheter|
214820028|NCT01916915|DRUG|Levobupivacaine|
214820029|NCT03721471|OTHER|Scoring of frailty|"1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer."
214820030|NCT05069688|DRUG|rifampicin|Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
214820031|NCT05144451|DIAGNOSTIC_TEST|Transcranial Doppler|"Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7)."
214820032|NCT04001062|PROCEDURE|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
214820033|NCT04001062|OTHER|Non-Operative Management|"1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
214820034|NCT00736658|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
214820035|NCT00736658|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
214820036|NCT01539096|PROCEDURE|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
214820037|NCT01539096|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
214820038|NCT01539096|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
214820039|NCT01442558|DRUG|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
214820040|NCT04791813|OTHER|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
214820041|NCT03351296|DRUG|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
214820042|NCT03351296|DRUG|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
214820043|NCT03351296|DRUG|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
214820044|NCT03351296|DRUG|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
214820045|NCT03351296|DRUG|Bevacizumab|bevacizumab 5 mg/kg every 14 days
214820046|NCT04994535|DRUG|OnabotulinumtoxinA|Injection
214820047|NCT04994535|DRUG|Placebo|Saline injection
214820048|NCT01488435|DIETARY_SUPPLEMENT|Cow's milk|Powdered whole cow's milk
214820049|NCT01488435|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
214820050|NCT01158118|DRUG|Sargramostim|
214820051|NCT01158118|DRUG|Plerixafor|
214820052|NCT02164435|PROCEDURE|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
214820053|NCT01548053|OTHER|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
214820054|NCT02577653|OTHER|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
214820055|NCT00604162|DEVICE|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
214820056|NCT00604162|PROCEDURE|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
214820057|NCT00611676|DRUG|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
214820058|NCT00470691|PROCEDURE|plaster cast|complete circular plaster cast
214820059|NCT00470691|PROCEDURE|dorsal splint|dorsal plaster splint
214820060|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
214820061|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
214820062|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
214820063|NCT00385320|BIOLOGICAL|HRV vaccine|
214820064|NCT02741687|DRUG|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
214820065|NCT02741687|DRUG|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
214820066|NCT02741687|DRUG|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
214820067|NCT02741687|DRUG|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
214820068|NCT02741687|DRUG|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
214820069|NCT02741687|DRUG|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
214820070|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
214820071|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
214820072|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
214820073|NCT01015287|DRUG|Placebo|Administered once orally
214820074|NCT01015287|DRUG|Prasugrel|Administered orally
214820075|NCT01354886|DRUG|FSH-GEX™|single dose
214820076|NCT01354886|DRUG|Gonal-f|150 IU single dose
214820077|NCT01354886|DRUG|Bravelle|150 IU single dose
214820078|NCT01354886|DRUG|Placebo|single dose
214820079|NCT00440063|DRUG|epoetin beta [NeoRecormon]|
214820080|NCT05653934|BEHAVIORAL|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
214820081|NCT05653934|PROCEDURE|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
214820082|NCT05653934|BEHAVIORAL|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
214820083|NCT03497858|OTHER|Coconut Water|participants will consume coconut water and complete a simulated basketball game
214820084|NCT03497858|OTHER|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
214820085|NCT03497858|OTHER|Sports drink|participants will consume a sports drink and complete a simulated basketball game
214820086|NCT02333123|DRUG|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
214820087|NCT02333123|DRUG|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
214820088|NCT01774058|DRUG|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
214820089|NCT05438433|DEVICE|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
214820090|NCT01228539|BEHAVIORAL|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
214820091|NCT01228539|BEHAVIORAL|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
214820092|NCT00905840|DEVICE|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
214820093|NCT00905840|DEVICE|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
214820094|NCT04375384|DRUG|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
214820095|NCT04375384|OTHER|Questionnaire administration|Ancillary studies
214820096|NCT04375384|OTHER|Quality of life assessment|Ancillary studies
214820097|NCT04552418|DRUG|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
214820098|NCT06099340|OTHER|muscle-strengthening program|a muscle-strengthening program applied to the ankle muscles (triceps surae and dorsal flexors) in physiotherapy, as a complement to conventional rehabilitation
214820099|NCT02504138|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
214820100|NCT02504138|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
214820101|NCT02442063|DRUG|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
214820102|NCT02442063|DRUG|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
214820103|NCT01493635|OTHER|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
214820104|NCT01493635|OTHER|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
214267414|NCT01595633|DRUG|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
214267415|NCT00431288|BEHAVIORAL|diet high in fruits, vegetables, and dairy|
214267416|NCT00431288|OTHER|Routine nutrition care|
214267417|NCT04185064|DEVICE|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
214267418|NCT04185064|OTHER|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
214267419|NCT03233607|PROCEDURE|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
214267420|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
214820105|NCT04665063|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
214820106|NCT04665063|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
214820107|NCT04665063|PROCEDURE|Leukapheresis|Leukapheresis
214820108|NCT03904563|DRUG|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
214820109|NCT03904563|RADIATION|chest radiation|split-course chest radiation
214820110|NCT03904563|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
214820111|NCT03967223|DRUG|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
214820112|NCT03967223|DRUG|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
214820113|NCT03967223|DRUG|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
214820114|NCT01370317|DRUG|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
214267421|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
214267422|NCT03277157|DIETARY_SUPPLEMENT|B. lactis B94|A probiotic dose of 15 billion per capsule.
214820115|NCT01370317|DRUG|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
214820116|NCT01688609|DRUG|lapatinib ditosylate|Given PO
214820117|NCT01688609|DRUG|paclitaxel|Given IV
214820118|NCT01688609|BIOLOGICAL|trastuzumab|Given IV
214820119|NCT01688609|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
214820120|NCT01688609|OTHER|pharmacological study|Correlative studies
214820121|NCT01688609|OTHER|laboratory biomarker analysis|Correlative studies
214820122|NCT03283345|PROCEDURE|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
214820123|NCT04893291|DEVICE|Everolimus Eluting Stent|Patients assigned to this Arm will have an EES implanted after pre-dilatation, the angiography will be conducted as standard of care
214820124|NCT04893291|DEVICE|Sirolimus Coated Balloon|Patients assigned to this Arm will be treated with Magic Touch Drug Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care
214820125|NCT03681080|PROCEDURE|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
214820126|NCT03949426|DRUG|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
214820127|NCT00854711|PROCEDURE|inhaled nitric oxide|80 PPM
214820128|NCT02728674|OTHER|Person in the case is a male.|Person in the case is a male.
214820129|NCT02728674|OTHER|Person in the case is a female.|Person in the case is a female.
214820130|NCT02728674|OTHER|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
214267423|NCT03277157|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
214267424|NCT02210650|PROCEDURE|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
214267425|NCT02210650|PROCEDURE|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
214267426|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
214267427|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
214267428|NCT01580085|OTHER|polysomnography|full night supervised laboratory polysomnography
214267429|NCT04849754|DIAGNOSTIC_TEST|bone scintigraphy|Bone scintigraphy
214820131|NCT02728674|OTHER|Symptom in the case is pain.|Symptom in the case is pain.
214820132|NCT02717260|DEVICE|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
214820133|NCT03133637|DRUG|ceftriaxone|Eligible infants will receive ceftriaxone as standard of care for sepsis
214820134|NCT03341182|PROCEDURE|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
214820135|NCT03341182|PROCEDURE|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
214820136|NCT04599439|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
214820137|NCT04849650|DRUG|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
214820138|NCT04849650|DRUG|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
214820139|NCT01244022|PROCEDURE|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
214820140|NCT06400355|DRUG|Mannitol|in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
214820141|NCT06400355|DRUG|Ringer's Lactate|similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
214820142|NCT00023361|DRUG|Rifabutin|
214820143|NCT02525211|DRUG|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
214820144|NCT02525211|DRUG|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
214820145|NCT01885117|BIOLOGICAL|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
214820146|NCT02083328|DIETARY_SUPPLEMENT|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
214820147|NCT02083328|DIETARY_SUPPLEMENT|Placebo (Mannitol)|Mannitol filled in gelatine capsules
214820148|NCT02505347|OTHER|No splint|Can move arm as tolerated with no restrictions on mobility
214820149|NCT02505347|DEVICE|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
214820150|NCT04582318|BIOLOGICAL|NGM621|NGM621 will be administered via IV infusion
214820151|NCT04582318|BIOLOGICAL|Placebo|Placebo will be administered via IV infusion
214820152|NCT05611593|DRUG|FOL100|FOL100 lotion
214820153|NCT05611593|DRUG|Propecia 1Mg Tablet|Oral Finasteride
214820154|NCT05552482|OTHER|Identification of predictive factors|Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
214820155|NCT05742971|DEVICE|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
214820156|NCT03810950|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
214820157|NCT03810950|BEHAVIORAL|Reading Newspaper|Participants read newspaper
214820158|NCT03810950|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
214820159|NCT04653363|OTHER|assessments|All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
214820160|NCT06196281|OTHER|wooble board proprioceptive training|this includes wooble board proprioceptive training twice a day for four weeks
214820161|NCT06196281|OTHER|multi-station proprioceptive training|this includes multi-station proprioceptive training twice a day for four weeks
214820162|NCT05187923|DIAGNOSTIC_TEST|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
214820163|NCT00057538|BEHAVIORAL|Mantram Repetition|
214820164|NCT04470115|OTHER|General anesthesia|Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
214820165|NCT04470115|OTHER|Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks|The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
214820166|NCT06066047|OTHER|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
214820167|NCT06066047|OTHER|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
214820168|NCT04813354|DEVICE|ELLIPTA|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
214820169|NCT04813354|DEVICE|BREEZHALER|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
214820170|NCT06395792|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
214820171|NCT04521426|OTHER|No other than standard care|No other than standard care.
214820172|NCT02355730|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
214820173|NCT02105272|DRUG|OPC-1085EL ophthalmic solution|
214820174|NCT02105272|DRUG|Latanoprost ophthalmic solution|
214820175|NCT03603990|PROCEDURE|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
214267430|NCT04589325|DRUG|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
214820176|NCT03603990|PROCEDURE|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
214820177|NCT05009212|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (\<5 cm)
214820178|NCT05009212|PROCEDURE|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (\<5 cm)
214820179|NCT04085887|DRUG|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
214820180|NCT04085887|DEVICE|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
214820181|NCT04085887|DEVICE|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
214820182|NCT04085887|DEVICE|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
214820183|NCT03418038|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
214820184|NCT03418038|DRUG|Carboplatin|Given IV or PO
214820185|NCT03418038|DRUG|Cisplatin|Given IV or PO
214820186|NCT03418038|DRUG|Cytarabine|Given IV or PO
214820187|NCT03418038|DRUG|Dexamethasone|Given IV or PO
214820188|NCT03418038|DRUG|Etoposide|Given IV or PO
214820189|NCT03418038|DRUG|Gemcitabine Hydrochloride|Given IV or PO
214820190|NCT03418038|DRUG|Ifosfamide|Given IV or PO
214820191|NCT03418038|OTHER|Laboratory Biomarker Analysis|Correlative studies
214820192|NCT03418038|DRUG|Oxaliplatin|Given IV or PO
214820193|NCT03418038|OTHER|Placebo Administration|Given normal saline IV
214820194|NCT03418038|OTHER|Questionnaire Administration|Ancillary studies
214820195|NCT03418038|BIOLOGICAL|Rituximab|Given IV
214820196|NCT03418038|DRUG|Decitabine|Given IV
214820197|NCT03418038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214820198|NCT03418038|PROCEDURE|Core Biopsy|Undergo core needle biopsy
214820199|NCT03418038|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214820200|NCT03418038|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214820201|NCT03418038|PROCEDURE|Echocardiography|Undergo ECHO
214820202|NCT03418038|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214820203|NCT03418038|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214820204|NCT03418038|PROCEDURE|Central Venous Cannula Insertion|Undergo PICC placement
214820205|NCT03418038|PROCEDURE|Portacath Placement|Undergo portacath placement
214820206|NCT03418038|PROCEDURE|Computed Tomography|Undergo PET/CT
214820207|NCT03450850|DEVICE|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
214267431|NCT04589325|DRUG|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
214267432|NCT02291874|DRUG|Ipragliflozin|oral
214820208|NCT06608537|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
214820209|NCT03190915|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
214820210|NCT03190915|DRUG|Trametinib|Given PO
214820211|NCT06525649|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment.
214820212|NCT02964039|BEHAVIORAL|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
214820213|NCT02964039|BEHAVIORAL|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
214820214|NCT02964039|BEHAVIORAL|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
214820215|NCT05751343|DRUG|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
214820216|NCT04454658|DRUG|ABBV-744|Tablet; Oral
214820217|NCT04454658|DRUG|Navitoclax|Tablet; Oral
214820218|NCT04454658|DRUG|Ruxolitinib|Tablet; Oral
214820219|NCT04850118|BIOLOGICAL|rAAV2tYF-GRK1-hRPGRco|Adeno-associated virus vector expressing a human RPGR gene
214820220|NCT04850118|DRUG|Control|Untreated Control Group 3
214820221|NCT01903161|PROCEDURE|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
214820222|NCT01903161|PROCEDURE|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
214820223|NCT05583721|DRUG|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
214820224|NCT05583721|DRUG|Lexiscan|Given IV prior to PET stress test
214820225|NCT05583721|DIAGNOSTIC_TEST|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
214820226|NCT06457906|COMBINATION_PRODUCT|Experimental group (SRS/SRT/Hypo-RT)|The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.
214820227|NCT06457906|RADIATION|Controled group (HA-WBRT)|The prescription dose of HA-WBRT is 30Gy in 10 fraction.
214820228|NCT06125678|DIAGNOSTIC_TEST|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
214820229|NCT04814381|DRUG|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
214820230|NCT04624321|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
214820231|NCT04624321|OTHER|Usual care|Usual care at ordinary healthcare provider
214820232|NCT04337580|DRUG|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
214820233|NCT04325256|PROCEDURE|Manipal ultrasound scoring system|length of the cervix from the internal to external os, presence or absence of funneling and if present width and length of funneling at internal os were measured. Distance between presenting part to external os will be measured and position of the cervix i.e. whether curved or straight will also noted.
214820234|NCT04325256|PROCEDURE|Levine scoring system|maternal height, parity, body-mass index (BMI) at delivery and the results of modified Bishop's score in calculation of probability of CS
214820235|NCT06057753|BEHAVIORAL|MyStroke|Personalized video-based stroke education platform
214820236|NCT01103713|DRUG|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
214820237|NCT05379972|DRUG|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
214820238|NCT05379972|DRUG|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
214820239|NCT05379972|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
214820240|NCT04601792|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
214820241|NCT04601792|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
214820242|NCT04601792|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
214820243|NCT05524701|BEHAVIORAL|Sleep Restriction and Normal Sleep|The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
214820244|NCT02096783|OTHER|informational intervention|Given scripted intervention
214820245|NCT02096783|OTHER|counseling intervention|Given standard counseling
214820246|NCT02096783|OTHER|questionnaire administration|Ancillary studies
214820247|NCT00153530|DRUG|methotrexate|"1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy"
214820248|NCT00153530|RADIATION|radiotherapy|whole-brain irradiation
214820249|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
214820250|NCT02253420|DRUG|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
214820251|NCT02253420|DRUG|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
214820252|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
214820253|NCT01291121|PROCEDURE|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
214820254|NCT00852020|DIETARY_SUPPLEMENT|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
214820255|NCT02499718|DEVICE|BiPAP mode|Noninvasive ventilator
214820256|NCT02042781|DRUG|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
214820257|NCT02671526|OTHER|Computerized plasticity-based adaptive cognitive training|
214820258|NCT03786822|PROCEDURE|Cryoballoon Pulmonary Vein Isolation - PVI|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
214820259|NCT01884090|BEHAVIORAL|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
214820260|NCT01172145|DRUG|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
214820261|NCT01172145|DRUG|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
214820262|NCT04011917|BEHAVIORAL|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
214820263|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
214820264|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
214820265|NCT02354339|DIETARY_SUPPLEMENT|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
214820266|NCT02354339|OTHER|Placebo|Intervention will be administered 30 minutes before meals
214820267|NCT00505622|DRUG|Perampanel|
214820268|NCT00267592|DRUG|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
214820269|NCT00267592|RADIATION|Radiation Therapy (RT) 5 days a week +|
214820270|NCT00267592|DRUG|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
214820271|NCT00267592|DRUG|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
214820272|NCT03978442|BEHAVIORAL|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
214820273|NCT03978442|DRUG|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
214820274|NCT03978442|BEHAVIORAL|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
214820275|NCT03978442|BEHAVIORAL|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
214820276|NCT03978442|BEHAVIORAL|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
214820277|NCT04991194|DRUG|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
214820278|NCT04239833|DRUG|SH-1028 tablets|"The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
214820279|NCT04239833|DRUG|Placebo SH-1028 tablets|"The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
214820280|NCT04239833|DRUG|Gefitinib|"The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets)."
214820281|NCT04239833|DRUG|Placebo Gefitinib|The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
214267433|NCT04910945|DEVICE|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
214267434|NCT06974097|OTHER|blood sampling|blood sampling
214267435|NCT05048459|OTHER|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
214820282|NCT04138368|BEHAVIORAL|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
214820283|NCT04138368|BEHAVIORAL|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
214820284|NCT00287963|DRUG|topotecan hydrochloride|
214820285|NCT00287963|DRUG|vinorelbine tartrate|
214820286|NCT06331247|BEHAVIORAL|General dietary advice|General dietary advice according to the Chinese Dietary Guidelines 2022.
214820287|NCT06331247|BEHAVIORAL|Localized MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
214820288|NCT06331247|OTHER|Routine medical care|Routine medical care and follow-ups.
214820289|NCT05226923|DRUG|KSP-1007|Single and multiple doses, intravenous administration
214820290|NCT05226923|OTHER|Placebo:0.9% sodium chloride|Single and multiple doses, intravenous administration
214820291|NCT05226923|DRUG|Meropenem|Multiple doses, intravenous administration
214820292|NCT04405765|DEVICE|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
214820293|NCT04405765|DEVICE|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
214820294|NCT00868374|DRUG|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
214820295|NCT00868374|DRUG|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
214820296|NCT05220657|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
214820297|NCT05220657|DIAGNOSTIC_TEST|Submaximal exercise test|A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
214820298|NCT01341730|DRUG|Atorvastatin 20mg|20 mg QD for 3 months
214820299|NCT01341730|DRUG|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
214820300|NCT02491905|DRUG|HL tablet|
214820301|NCT02491905|DRUG|Placebo|
214820302|NCT01848938|BEHAVIORAL|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
214820303|NCT03838276|PROCEDURE|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
214820304|NCT03838276|PROCEDURE|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
214820305|NCT06331910|DRUG|insulin eye drops|Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
214820306|NCT00879918|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
214820307|NCT03244553|DRUG|Prucalopride|5 day treatment
214820308|NCT05352789|OTHER|Non validated Survey|Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.
214820309|NCT01205425|OTHER|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
214820310|NCT01205425|PROCEDURE|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
214820311|NCT03186976|BEHAVIORAL|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2\) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3\) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4\) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5\) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%"
214820312|NCT03186976|OTHER|Standard of Care|Recommendations based on current guidelines
214820313|NCT01665209|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
214820314|NCT06455982|DIETARY_SUPPLEMENT|reduced carbohydrate menu combined with ketogenic supplement|Participants will eat a reduced carb menu for 2 months and they will take 15g of MCT in the morning and the evening for a total of 30g per day.
214820315|NCT01757392|BIOLOGICAL|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
214820316|NCT00053963|DRUG|romidepsin|Given IV
214820317|NCT00857103|BEHAVIORAL|CHOICE|Use of Choice support system as preparation for patient consultations
214820318|NCT05458635|PROCEDURE|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
214820319|NCT06559982|DIETARY_SUPPLEMENT|Brown seaweed and tart cherry blend|Blend of brown seaweed and tart cherry blend taken twice daily
214820320|NCT06559982|OTHER|Placebo|Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
214820321|NCT01552317|OTHER|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
214820322|NCT06176534|DRUG|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
214820323|NCT06176534|DRUG|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
214820324|NCT06498700|DRUG|ketamine|0.5 mg/kg/h ketamine infusion
214820325|NCT06498700|DRUG|dexmedetomidine|0.1 ug/kg/h dexmedetomidine infusion
214820326|NCT06561373|BEHAVIORAL|Calm & Alert yoga and mindfulness|The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
214820327|NCT00545506|DEVICE|conventional bandage|
214820328|NCT00545506|DEVICE|warming bandage|
214820329|NCT01501253|DRUG|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
214820330|NCT01501253|DRUG|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
214820331|NCT01501253|DRUG|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
214820332|NCT00030186|DRUG|CEP-701 60mg|60mg orally 2 times a day for 28 days
214820333|NCT00030186|DRUG|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
214820334|NCT00030186|DRUG|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
214820335|NCT05806957|DEVICE|Fundus Photography|Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT
214820336|NCT01481363|BEHAVIORAL|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
214820337|NCT01481363|BEHAVIORAL|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
214820338|NCT01417663|DRUG|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
214820339|NCT01417663|BEHAVIORAL|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
214820340|NCT02724605|BIOLOGICAL|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
214820341|NCT02724605|BIOLOGICAL|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
214820342|NCT06424457|PROCEDURE|video assisted thoracoscopy (VATS)|the investigators compare the outcomes of intervention by VATS and doing complete decortication or open surgery thoracotomy
214820343|NCT06424457|PROCEDURE|open thoracotomy|the investigators assess the outcomes of intervention by doing complete decortication through open surgery thoracotomy
214820344|NCT05260697|OTHER|sexual counselling with plissit model|sexual counselling
214820345|NCT05119725|DEVICE|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
214820346|NCT05305248|DRUG|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
214820347|NCT05305248|DRUG|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
214820348|NCT04948905|OTHER|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
214820349|NCT00239382|DRUG|Meloxicam ampoule|
214820350|NCT00239382|DRUG|Meloxicam tablet|
214820351|NCT00702377|OTHER|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
214820352|NCT00702377|OTHER|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
214820353|NCT04814160|PROCEDURE|mixture of bioactive glass and autogenous bone graft|bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
214820354|NCT04814160|PROCEDURE|autogenous bone graft|bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
214820355|NCT05855577|DRUG|Terazosin|Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
214820356|NCT02618083|DEVICE|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
214820357|NCT01019421|DRUG|Lu AE58054|Add-on treatment to donepezil
214820358|NCT01019421|DRUG|Placebo|Add-on treatment to donepezil
214820359|NCT03567447|DRUG|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
214820360|NCT03567447|OTHER|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
214820361|NCT06222645|DEVICE|ICG fluorescence imaging technology|Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
214820362|NCT06222645|DEVICE|Imaging photoplethysmography|Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
214820363|NCT03659565|BEHAVIORAL|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
214820364|NCT03659565|BEHAVIORAL|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
214820365|NCT02468258|PROCEDURE|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
214820366|NCT00840606|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
214820367|NCT00840606|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
214820368|NCT03589170|DIAGNOSTIC_TEST|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
214820369|NCT06089382|DRUG|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
214820370|NCT06089382|DRUG|Lenvatinib|8mg orally once a day for 1 year
214820371|NCT06089382|PROCEDURE|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
214820372|NCT00099047|DRUG|celecoxib|Given PO
214820373|NCT00099047|DRUG|placebo|Given PO
214820374|NCT00099047|OTHER|laboratory biomarker analysis|Correlative studies
214820375|NCT02981095|PROCEDURE|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
214820376|NCT02981095|DRUG|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
214820377|NCT02981095|DRUG|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
214820378|NCT06561789|OTHER|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
214820379|NCT06561789|OTHER|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
214820380|NCT06561789|OTHER|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
214820381|NCT00651820|DRUG|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
214820382|NCT00651820|DRUG|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
214820383|NCT00005025|BIOLOGICAL|herpes simplex thymidine kinase|
214820384|NCT00005025|DRUG|ganciclovir|
214820385|NCT04568785|BEHAVIORAL|Brief Intervention for Influenza vaccine|Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.
214820386|NCT04568785|BEHAVIORAL|Normal advice|In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
214820387|NCT01958450|PROCEDURE|Er:YAG laser|acne scar treatment using Er:YAG laser
214820388|NCT01958450|PROCEDURE|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
214820389|NCT04664556|OTHER|observational study|observational study
214820390|NCT02544672|DEVICE|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
214820391|NCT01979861|DEVICE|AEGEA Vapor System(TM)|vapor endometrial ablation
214820392|NCT01878292|DRUG|Placebo|Dose matched placebo tablets, once per day, oral administration.
214820393|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
214820394|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
214820395|NCT05391165|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
214820396|NCT02502474|OTHER|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
214820397|NCT06563206|PROCEDURE|Exergame|Hand Training assisted with Virtual-Reality
214820398|NCT06563206|PROCEDURE|Robotic|Hand Training assisted with Robotic Syrebo
214820399|NCT06563206|PROCEDURE|Conventional|Hand Training with Physical Therapist
214820400|NCT01527890|DRUG|Fentanyl|intravenous patient-controlled analgesia
214820401|NCT04024163|DRUG|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
214820402|NCT01302548|DEVICE|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
214820403|NCT01302548|PROCEDURE|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
214820404|NCT03741777|OTHER|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
214820405|NCT02193724|OTHER|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
214820406|NCT02193724|OTHER|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
214820407|NCT02189811|BIOLOGICAL|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
214820408|NCT02189811|BIOLOGICAL|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
214820409|NCT02189811|BIOLOGICAL|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
214820410|NCT02189811|BIOLOGICAL|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
214820411|NCT02189811|BIOLOGICAL|tOPV|tOPV till 22 weeks of age
214820412|NCT01247103|DRUG|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
214820413|NCT01247103|DRUG|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
214820414|NCT01247103|OTHER|Placebo|Placebo to match AZD4316
214820417|NCT00639028|OTHER|Ankle echography|Ankle echography
214820418|NCT00639028|OTHER|Ankle echography + stress radiography|Ankle echography + stress radiography
214820419|NCT00639028|OTHER|stress radiography|ankle stress radiography
214820420|NCT05396885|BIOLOGICAL|anitocabtagene-autoleucel|Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
214820421|NCT06570109|OTHER|Frailty|defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
214820422|NCT05980156|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
214820423|NCT05980156|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
214820424|NCT05980156|DRUG|Sulfadoxine pyrimethamine|Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
214820425|NCT00001865|DRUG|Daclizumab|
214820426|NCT02942615|OTHER|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
214820427|NCT06413186|DRUG|Uteratonic administration|Administer IV 10 IU oxytocin
214820428|NCT06413186|OTHER|cord clamping|delayed cord clamping
214820429|NCT06413186|OTHER|delivery of the placenta|Applying controlled core traction
214820430|NCT03197207|PROCEDURE|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
214820431|NCT03197207|PROCEDURE|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
214820432|NCT00660426|DRUG|Oxaliplatin|
214820433|NCT00660426|DRUG|Gemcitabine|
214820434|NCT00660426|DRUG|Capecitabine|
214820435|NCT03327545|DEVICE|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
214820436|NCT03327545|DEVICE|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
214820437|NCT03327545|DEVICE|Control group|Did not receive any treatment.
214820438|NCT00950989|DRUG|Brodalumab|3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
214820439|NCT00950989|DRUG|Placebo|3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
214820440|NCT00950989|DRUG|Methotrexate|Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
214820441|NCT00950989|DIETARY_SUPPLEMENT|folic acid|at least 5 mg per week
214820442|NCT05213156|DRUG|Oxatrex|0.3% ofloxacin eye drops in single doses
214820443|NCT01465581|PROCEDURE|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
214820444|NCT06248879|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214820445|NCT06248879|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214820446|NCT06248879|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214820447|NCT03480321|DRUG|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
214820448|NCT03480321|DRUG|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
214820449|NCT03480321|DRUG|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
214820450|NCT01799798|DRUG|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
214820451|NCT05385640|OTHER|NO intervention|NO intervention
214820452|NCT03967938|DRUG|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
214820453|NCT04829981|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
214820454|NCT04829981|BEHAVIORAL|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
214820455|NCT06042205|DEVICE|TISSIUM™ Atraumatic Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
214820456|NCT05133817|DRUG|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
214820457|NCT05133817|DRUG|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
214820458|NCT05133817|DRUG|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
214820459|NCT05133817|DRUG|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
214820460|NCT05133817|DRUG|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
214820461|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
214820462|NCT01955200|DRUG|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
214820463|NCT01955200|DRUG|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
214820464|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
214820465|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
214820466|NCT03527485|DIAGNOSTIC_TEST|11UCB-J PET Scan|11UCB-J PET Scan
214820467|NCT06624267|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
214820468|NCT04930796|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
214820469|NCT05854602|BEHAVIORAL|Component A|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component A focusses on making parents aware of the process of avoidance in children with anxiety, and helps them to identify situations in which they accommodate to the anxiety of their children. Subsequently, a first step that parents can take to reduce accommodation is discussed."
214820470|NCT05854602|BEHAVIORAL|Component B|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component B tries to increase parents empathetic reactions to their anxious child. This is done by teaching parents to label the emotion of their children, empathize with the emotion, and communicate confidence in the abilities of their child to face the situation."
214820471|NCT05854602|BEHAVIORAL|Component C|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component C consists of cognitive restructuring of parental maladaptive cognitions concerning their child's anxiety. Parents are taught to recognize their own cognitions about the anxiety of their child, challenge this thought and come up with an alternative, helpful thought."
214820472|NCT06149130|DRUG|Adebrelimab|adebrelimab:1200mg intravenously, Q3W.
214820473|NCT06149130|DRUG|dalpiciclib|dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
214820474|NCT03923660|OTHER|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
214820475|NCT03923660|OTHER|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
214820476|NCT05048017|DRUG|Regorafenib|Regorafenib, 120 mg, once a day, 3 weeks on/1 week off
214820477|NCT05048017|DRUG|PD-1 inhibitor|"Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks."
214820478|NCT03789019|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
214820479|NCT02892747|BEHAVIORAL|Educational Program|
214820480|NCT02097550|OTHER|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
214820481|NCT00613522|OTHER|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale \> 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
214267436|NCT05048459|OTHER|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
214267437|NCT05048459|OTHER|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
214267438|NCT05627765|BEHAVIORAL|Standard treatment (ST) arm|"participants who are ready to quit smoking: a brief smoking cessation intervention based on the 5A models and STAR method as quitting skills.~participants who are not yet ready to quit smoking: a brief smoking cessation intervention based on the 5R models."
214820482|NCT05814926|DRUG|GP681|GP681, tablet, oral
214820483|NCT01292590|OTHER|High fat meal|40 grams saturated fat
214267439|NCT05627765|BEHAVIORAL|Integrated Intervention (II) arm|"brief advice on alcohol use based on the FRAMES model and the brief smoking cessation intervention based on the 5A and 5R models."
214267440|NCT06271733|DEVICE|TMS|2 sessions of iTBS per day for 5 days
214820484|NCT00730691|DRUG|Placebo|Placebo-matching capsules
214820485|NCT00730691|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
214820486|NCT00730691|DRUG|Duloxetine|Overencapsulated duloxetine capsules
214820487|NCT02649647|PROCEDURE|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
214820488|NCT02649647|PROCEDURE|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
214820489|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
214820490|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
214820491|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
214820492|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
214820493|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
214820494|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
214820495|NCT02965859|DRUG|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
214820496|NCT02965859|DRUG|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
214820497|NCT05314647|DIETARY_SUPPLEMENT|lutein|daily dose of 5 mg lutein
214820498|NCT05314647|DIETARY_SUPPLEMENT|placebo|daily dose of 0 mg lutein
214820499|NCT03427944|DRUG|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
214820500|NCT03427944|DRUG|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
214820501|NCT02554890|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
214820502|NCT02554890|DRUG|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
214820503|NCT02554890|DRUG|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
214820504|NCT02554890|DRUG|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
214820505|NCT01521780|PROCEDURE|MRI|Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
214820506|NCT01521780|PROCEDURE|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
214820507|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
214820508|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
214820509|NCT03336580|DRUG|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
214820510|NCT06059625|PROCEDURE|rotatori cuff repair|rotatori cuff repair
214820511|NCT03073850|DRUG|Antiplatelet|ASA or clopidogrel
214820512|NCT03073850|DRUG|Low dose oral anticoagulant|Edoxaban of 30mg
214820513|NCT03073850|DRUG|Standard dose oral anticoagulant|Edoxaban of 60mg
214820514|NCT05863962|OTHER|walking and Stretching|Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise
214820515|NCT05863962|OTHER|walking and Jacobsons relaxation technique|Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
214820516|NCT06356805|DEVICE|repetitive transcranial magnetic stimulation|Parallel study: Participants are assigned to one of two groups in parallel for 3 months follow up
214820517|NCT03730168|OTHER|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
214820518|NCT02616133|OTHER|chart abstraction|abstraction of breast cancer patients with de-identified data
214820519|NCT02814877|OTHER|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
214820520|NCT03043872|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
214820521|NCT03043872|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
214820522|NCT03043872|DRUG|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
214820523|NCT03043872|DRUG|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
214820524|NCT03043872|DRUG|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
214820525|NCT03411148|BEHAVIORAL|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
214820526|NCT03411148|BEHAVIORAL|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
214820527|NCT05902702|OTHER|Nebulized isotonic saline|The intervention will constitute nebulized isotonic saline.
214820528|NCT05902702|OTHER|Nasal irrigation with isotonic saline|The intervention will constitute isotonic saline administered as nasal drops.
214820529|NCT04862572|OTHER|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
214820530|NCT04572139|DIAGNOSTIC_TEST|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
214820531|NCT05581329|PROCEDURE|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
214820532|NCT04311320|DEVICE|Low-Resource Oxygen Blender|The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
214820533|NCT01161615|DRUG|MRX-7EAT|Application of up to two patches for up to 7 days.
214820534|NCT01161615|DRUG|Placebo|Application of up to two patches for up to 7 days.
214820535|NCT05261945|OTHER|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
214820536|NCT05261945|OTHER|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
214820537|NCT05261945|OTHER|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
214820538|NCT06721455|OTHER|blood sampling|Discarded blood samples will be taken from routine clinical labs drawn during and after heart surgery.
214820539|NCT07035119|OTHER|Transcranial magnetic stimulation|Resting motor threshold will be established by first finding the area of the motor cortex associated with visible twitch of the right abductor pollicis brevis (APB). Parameter Estimation by Sequential Testing (PEST) will be conducted to quantify resting motor threshold using visible APB twitch. The left dorsolateral prefrontal cortex (DLPFC) will be located using the Beam F3 method and marked with a felt-tipped marker on the scalp. TMS will be delivered over left DLPFC at 110% of resting motor threshold at 10Hz (5-seconds-on; 10-seconds-off) for 15 minutes per session (3000 pulses), 3 sessions each day (30-minute rest in-between sessions), for 3 days (within 5 consecutive days; a total of 27,000 pulses).
214820540|NCT03614845|PROCEDURE|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
214820541|NCT03614845|PROCEDURE|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
214820542|NCT03614845|DIAGNOSTIC_TEST|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
214820543|NCT04235595|OTHER|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
214820544|NCT04235595|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
214820545|NCT02906293|OTHER|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
214820546|NCT03649477|DRUG|3.2 mg intranasal carbetocin|three times per day with meals
214820547|NCT03649477|DRUG|9.6 mg intranasal carbetocin|three times per day with meals
214820548|NCT03649477|DRUG|placebo|three times per day with meals
214820549|NCT04142970|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
214820550|NCT05699005|DRUG|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
214820551|NCT05612204|PROCEDURE|Biopsy under MRI|Biopsy under MRI
214820552|NCT04655001|BEHAVIORAL|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
214820553|NCT05519787|DEVICE|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement…). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
214820554|NCT07056894|BEHAVIORAL|Action-Based Cognitive Remediation|ABCR is a 16 session intervention involving computer-based drills, real-life simulations, and therapist-facilitated discussions intended to promote cognitive strategy monitoring and transfer of cognitive strategies to daily life. The sessions cover the follow key topics: Speed \& Attention, Memory, Executive Functioning, and Social Cognition.
214820555|NCT02430480|DRUG|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
214820556|NCT02430480|DRUG|Enzalutamide|160mg orally, daily for 24 weeks
214820557|NCT02430480|DEVICE|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
214820558|NCT02839252|BEHAVIORAL|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
214820559|NCT06139666|DRUG|Exparel Injectable Solution|"Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
214820560|NCT06139666|DRUG|Bupivacaine Injectable Solution|"Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
214820561|NCT06747117|DEVICE|Indigo Aspiration System|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
214820562|NCT07060742|DEVICE|Dividat Senso|Participants in the intervention group will receive cognitive-motor training using the Dividat Senso exergame platform, which records body movements and adapts game difficulty in real time. The training targets cognitive and physical functions through interactive games involving steps and weight shifts. It follows a progressive structure, with difficulty increasing over time, and can be personalized by investigators using the Dividat Manager.
214820563|NCT07060742|OTHER|OTAGO Falls-prevention program|The OTAGO Falls Prevention Program is an evidence-based exercise program designed to reduce falls in older adults. It includes strength and balance training exercises performed at home under the guidance of a physiotherapist. The program aims to improve muscle strength, balance, and mobility, helping to prevent falls and maintain independence.
214820564|NCT07060690|BEHAVIORAL|iCBT with human interaction|The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.
214820565|NCT07060690|BEHAVIORAL|Psychoeducational videos|This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.
214820566|NCT01154231|DRUG|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
214820567|NCT01938339|DEVICE|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
214820568|NCT07059104|PROCEDURE|Breast augmentation|Breast augmentation with an implant
214820569|NCT07059104|PROCEDURE|Breast reconstruction after mastectomy|Breast reconstruction after mastectomy
214820570|NCT07061327|BEHAVIORAL|Online fever management|Online training application will be carried out via Whatsapp
214820571|NCT07060677|PROCEDURE|Inmersive Virtual Reality|Participants will receive a intervention of immersive virtual reality using Meta Quest 3 and the Kinesix XR platform. Sessions will take place twice per week for 8 weeks. The IVR component will focus on balance and mobility through interactive, immersive environments designed to enhance engagement, adherence, and functional outcomes. This multimodal approach aims to reduce fall risk and frailty while improving motivation and quality of life in older adults.
214820572|NCT07060677|PROCEDURE|Conventional occupational therapy sessions|Participants will receive conventional occupational therapy only, with sessions conducted twice per week for 8 weeks. The intervention will focus on cognitive stimulation, manipulative skill training, and psychomotor exercises, all adapted to the functional level of each participant. Activities aim to maintain or improve autonomy, balance, and coordination, following established occupational therapy guidelines for older adults. No immersive virtual reality or digital technology will be included in this group. This control condition allows for comparison with the experimental group to evaluate the added value of immersive virtual reality in fall risk and frailty reduction.
214267441|NCT06271733|DEVICE|Sham|2 sessions per day for 5 days of sham condition
214267442|NCT06464003|OTHER|Questionnaire|Malocclusion impact questionnaire
214267443|NCT01757535|DRUG|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
214267444|NCT01757535|DRUG|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
214820573|NCT07063758|OTHER|Biomarker Analysis|Tumor tissue and serum samples will be collected and analyzed to evaluate the expression of membranous Nectin-4, ADAM10/17, and levels of soluble Nectin-4 (sNectin-4) as predictive biomarkers in patients with advanced urothelial carcinoma receiving standard therapies.
214820574|NCT07063628|DIAGNOSTIC_TEST|TyG-derived index.|"Derived indices included:~* Ty,G×B,M,I = TyG index × body mass index~* TyG×W,C = TyG index × waist circumference~* TyG×WH,tR = TyG index × waist-to-height ratio Quartile-based stratification was applied to each TyG-derived index."
214820575|NCT07063628|DIAGNOSTIC_TEST|Left Ventricular Speckle Tracking|Coronary Angiography and Gensini Scoring: All participants underwent standard diagnostic coronary angiography. CAD was categorized as one-, two-, or three-vessel disease based on the number of vessels with ≥50% stenosis. The severity of CAD was quantified using the Gensini score, which assigns a severity weight to each lesion depending on degree of stenosis and anatomical location. Final scores were calculated by summing weighted values across all coronary segments.
214820576|NCT07067476|OTHER|Instant Anti-Redness Emulsion (FLA#2039188 43)|A topical emulsion not yet marketed, developed to relieve skin redness. It contains panthenol and is applied once to the test side of the face after heat-induced redness.
214820577|NCT07067476|OTHER|Purified Water (Control)|0.3g of water is applied to the control side of the face. Used as placebo comparator to evaluate the redness-relieving efficacy of the test emulsion.
214820578|NCT07068373|DIAGNOSTIC_TEST|Mixed method (Exploratory Sequential)|4-6 Expert SLPs working with Cochlear Implant, A cohort of 100 Urdu speaking children who received cochlear implants
214820579|NCT07068360|COMBINATION_PRODUCT|Strength Training +Postural Correction Exercises + Balance Training +Flexibility Exercises|"Interventions details (Group A) Strength Training Postural Correction Exercises Balance Training Exercises~Flexibility Exercises:"
214820580|NCT07068360|DIAGNOSTIC_TEST|Standard Intervention (Control Group)|"The control group will receive standard physiotherapy for postural hyperkyphosis.~The standard intervention will consist of:~Postural education: Educating participants on proper posture, body mechanics, and ergonomics in daily activities.~Basic stretching exercises targeting the thoracic spine and back muscles. Recommendations for low-impact aerobics activities (e.g., walking or cycling) to promote overall healthThe standard intervention will be delivered over the same 12-week period, with two sessions per week. This group will not receive the integrated multimodal framework with strength training, postural correction, balance training, and flexibility exercises that the experimental group receives. Duration and Frequency"
214820581|NCT07068412|COMBINATION_PRODUCT|3D-printed Orthognathic Surgical Simulation|Two standardized 3D-printed anatomical models were created-one representing skeletal Class II and the other skeletal Class III. Simulated osteotomies, including Le Fort I and Bilateral Sagittal Split Osteotomies, were performed on the models to demonstrate surgical movements. These models are used to help patients visualize the procedures planned for their specific cases.
214820582|NCT07068412|COMBINATION_PRODUCT|2D Visual Representations of Skeletal Movements in Orthognathic Surgery|Two-dimensional images generated from virtual surgical planning-one depicting a Class II skeletal deformity and the other a Class III malocclusion-are used to illustrate the patient's condition and demonstrate the anticipated surgical movements.
214820583|NCT07068269|OTHER|Self-Management Program|"Week 1: Learn about COPD, practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 reps, 2-3x/day), start 5-10 min light walking, conserve energy with frequent rests.~Week 2: Understand benefits of activity and oxygen use, add seated marches/leg raises, walk 10-15 min, pace activities with rest breaks.~Week 3: Begin strength exercises (sit-to-stand, wall push-ups, 2 sets of 10), increase walking to 15-20 min, practice relaxation for anxiety.~Week 4: Focus on nutrition, walk 20-25 min, continue strength work, recognize flare-up signs, create action plan.~Week 5: Seek social support, walk 25-30 min, add stretching (2-3x/week), track activity daily.~Week 6: Set SMART goals, maintain daily walking 30 min, review coping strategies, add new activities if desired."
214820584|NCT07068269|OTHER|Routine Physical Therapy Exercises|"Week 1: Practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 breaths, 2-3x/day), start walking 5-10 min (3-5x/week), add gentle upper body stretches (20-30 sec holds, 2-3 reps).~Week 2: Continue breathing exercises, increase walking slightly each session, maintain stretches 3-5x/week for flexibility.~Week 3: Keep breathing routines, walk or cycle 15-20 min (4-5x/week), start sit-to-stand strength exercises (2-3 sets of 10-15 reps, 2-3x/week), keep stretching routine.~Week 4: Maintain breathing drills, increase walking/cycling intensity if tolerated, continue strength work and flexibility exercises.~Week 5: Keep up breathing exercises, walk/cycle 20-30 min (5x/week), do sit-to-stand exercises (3 sets of 10-15 reps, 3x/week), maintain upper body stretching.~Week 6: Sustain daily breathing practice, aim for 30 min walking/cycling daily, continue strength and stretch exercises, adjust intensity as needed for long-term progress."
214820585|NCT07068321|COMBINATION_PRODUCT|Control Group (transcutaneous electrical nerve stimulation)|Control Group will consist of 20 sessions of 30 min, applied twice per week over a period of 3 months including transcutaneous electrical nerve stimulation, and standardized exercises for LBP through smart phone application.
214820586|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf|Experimental Group will receive 20 sessions of 30 min applied twice per week over a period of 3 months of GDS treatment through smart phone application.
214820587|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf + Cognitive Behavioral Therapy|Experimental Group 2 will receive 20 sessions of 45 min applied twice per week over a period of 3 months of GDS along CBT treatment through smart phone application.
214820588|NCT07068490|DRUG|Routine use of P-CAB on DAPT|This group received P-CAB with DAPT after PCI.
214820589|NCT07068490|DRUG|Guideline Directed Medical Therapy|This group received PPI or not with DAPT after PCI according to GI bleeding risk.
214820590|NCT07068464|PROCEDURE|delayed cytoreduction surgery|Delayed cytoreduction surgery is defined as cytoreduction surgery after six cycles of carboplatin and paclitaxel neoadjuvant chemotherapy.
214820591|NCT07068464|PROCEDURE|interval cytoreduction surgery|Interval cytoreduction surgery is defined as cytoreduction surgery after three cycles of carboplatin-paclitaxel neoadjuvant chemotherapy.
214820592|NCT07067255|BIOLOGICAL|GPC3 CD146 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/GPC3 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~GPC3/CD146 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, GPC3/CD146 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/GPC3 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
214820593|NCT07068100|BEHAVIORAL|Stage-of-change based physical activity counseling|On the first evaluation day, an individual physical activity program will be created for the participants in the group within the scope of physical activity counseling. A 20-30 minute phone call will be made once a week by a psychologist regarding the stage of change they are in, and a 10-15 minute phone call will be made once a week by a physiotherapist for physical activity counseling.
214820594|NCT07068100|BEHAVIORAL|Giving the group a brochure with recommendations for physical activity and the benefits of physical activity for psychological health|The second group will be given a brochure with recommendations for physical activity and the benefits of physical activity for psychological health.
214820595|NCT07069075|GENETIC|MMP-2 Gene Polymorphism (rs243865) Analysis|Participants were genotyped for the MMP-2 rs243865 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, CT, or TT) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
214820596|NCT07069075|GENETIC|TIMP-2 Gene Polymorphism (rs8179090) Analysis|Participants were genotyped for the TIMP-2 rs8179090 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, GC, or GG) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
214820597|NCT07067970|DRUG|serotonin reuptake inhibitor (SSRI)|"Dapoxetine Group~Dosage: 30 mg dapoxetine, taken orally 1-3 hours before anticipated sexual activity, with a maximum of 3 doses per week.~Administration: Provided in blister packs to ensure compliance. Reference: McMahon et al., 2011."
214820598|NCT07067970|DRUG|Placebo|"Dosage: Placebo tablets identical in appearance and taste to dapoxetine, administered on the same schedule (1-3 hours before sexual activity, maximum 3 doses per week).~Administration: Provided in identical blister packs."
214820599|NCT07067970|OTHER|Acupuncture|"Protocol: Two 30-minute acupuncture sessions per week, targeting standardized points (e.g., CV4, SP6, ST36) known to influence sexual function and autonomic nervous system regulation.~Administration: Performed by licensed acupuncturists following a standardized protocol.~Reference: Sunay et al., 2011."
214820600|NCT07067970|OTHER|Sham|"Sham Acupuncture Group:Protocol: Two 30-minute sessions per week using superficial needle insertion at non-active points to minimize therapeutic effects while maintaining the placebo effect.~Administration: Performed by licensed acupuncturists to ensure consistency with the active acupuncture group"
214820601|NCT07067970|BEHAVIORAL|Exercise|"Kegel Exercises Group:Protocol: Participants will perform pelvic floor muscle exercises consisting of three sets of 10-15 contractions daily, each held for 5-10 seconds followed by relaxation.~Training: Participants will receive initial training from a licensed physiotherapist, with weekly follow-up sessions to ensure proper technique and adherence.~Reference: Pastore et al., 2014."
214820602|NCT07068971|BEHAVIORAL|Online cognitive behavioural therapy for insomnia, bright light therapy, activity|Multimodal intervention
214820603|NCT07067411|BEHAVIORAL|Education Program Using Gamification on GDM|"The five games planned to be used in the study are; What is Gestational Diabetes?, Nutrition Education, Complication Precautions, Medical Treatment Applications and Physical Activity. The creation and implementation of these games will be done through the Genially platform. The Genially platform is an easy-to-use and free web tool used to create interactive visual content. The platform includes features such as sharing or downloading via website, social media or e-mail by adding animations, effects, sounds and interactive elements. In addition, the performances of the people who share the created content can be tracked and feedback can be obtained. At the beginning of the games planned to be used in the study, an informative video of not more than five minutes on the subject created by the researcher will be shared. National and international guidelines will be taken into consideration in the creation of these videos. One day after the informative video is"
214267445|NCT04122690|BEHAVIORAL|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
214267446|NCT04122690|BEHAVIORAL|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
214820604|NCT07068828|BEHAVIORAL|Mobilization Encouragement Protocol|This intervention includes a video-based education session delivered before surgery to encourage early mobilization, visual poster reminders in patient rooms on postoperative day 1, and SMS text message reminders sent to patients' phones on postoperative days 1 and 3. Participants will also wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). The goal is to increase physical activity levels, improve recovery quality, and reduce postoperative complications after bariatric surgery.
214820605|NCT07068828|BEHAVIORAL|Smart Watch for Physical Activity Monitoring|Participants in the control group receive standard postoperative care without additional mobilization encouragement. They wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). However, they do not receive video education, posters, or SMS reminders.
214820606|NCT07068061|DEVICE|PDO suture|A biodegradable polymer used in dissolvable sutures and lifting threads, stimulating collagen production as it degrades.
214820607|NCT05141097|OTHER|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
214820608|NCT01548248|DRUG|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
214820609|NCT01548248|DRUG|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
214820610|NCT06826755|DIETARY_SUPPLEMENT|Terry Naturally® melatonin 5mg SR|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
214820611|NCT06826755|DIETARY_SUPPLEMENT|Placebo|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
214820612|NCT02616809|OTHER|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
214820613|NCT02616809|OTHER|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
214820614|NCT02616809|OTHER|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
214820615|NCT02616809|OTHER|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
214820616|NCT03154645|DRUG|Ibuprofen|non-steroidal anti-inflammatory drug
214820617|NCT03154645|DRUG|Acetazolamide|a diuretic
214820618|NCT05402553|DRUG|Ondansetron|patients will receive, in addition to standard therapy, ondansetron IV bolus 8 mg BID for 3 days
214820619|NCT05402553|DRUG|Placebo|patients will receive, in addition to standard therapy, normal saline IV bolus BID for 3 days
214820620|NCT00032396|DRUG|Retisert Implant|
214820621|NCT04037969|DEVICE|Nesofilcon A|Hydrogel contact lens for daily wear
214820622|NCT04037969|DEVICE|Delefilcon A|Silicone hydrogel contact lens for daily wear
214820623|NCT00961168|OTHER|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
214820624|NCT00961168|OTHER|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
214820625|NCT03985865|DRUG|Intragastric quinine hydrochloride|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
214820626|NCT03985865|DRUG|Intragastric denatonium benzoate|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
214820627|NCT03985865|DRUG|Intragastric placebo|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
214820628|NCT03985865|DRUG|Intraduodenal quinine hydrochloride|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
214820629|NCT03985865|DRUG|Intraduodenal denatonium benzoate|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
214820630|NCT03985865|DRUG|Intraduodenal placebo|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
214820631|NCT05040880|DRUG|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
214820632|NCT05040880|DRUG|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
214820633|NCT00059670|PROCEDURE|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
214820634|NCT04870606|DRUG|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
214820635|NCT04870606|DRUG|Placebo|Placebo+Standard of care determined by PI and local regulatory
214820636|NCT04852978|DRUG|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
214820637|NCT04852978|BIOLOGICAL|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
214820638|NCT06323239|RADIATION|SBRT|SBRT for metastatic lesions
214820639|NCT06323239|RADIATION|Low-dose Radiotherapy (LDRT)|LDRT for metastatic lesions
214820640|NCT06323239|DRUG|Toripalimab|6 cycles for combined therapy. Toripalimab maintenance for 1 year.
214820641|NCT06323239|DRUG|Gemcitabine|6 cycles for combined therapy.
214820642|NCT06323239|DRUG|Cisplatin|6 cycles for combined therapy.
214820643|NCT06323239|RADIATION|IMRT|IMRT for primary lesion
214820644|NCT00859430|DRUG|Levetiracetam|1000 mg Tablet
214820645|NCT00859430|DRUG|Keppra®|1000 mg Tablet
214820646|NCT06738160|DRUG|Narlumosbart|Patients who have not received any systemic therapy will receive narlumosbart and bone target lesion SBRT in combination with first-line treatment immunotherapy and chemotherapy after screening eligible subjects. Narlumosbart, 120mg/time, subcutaneous injection, is administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24Gy/3F is used for spinal metastases, and 30Gy/5F or 35Gy/5F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines. The primary endpoint is to assess the objective response rate of NSCLC patients with bone metastases from narlumosbart combined with SBRT and first-line chemotherapy and immunotherapy. The secondary endpoints include progression-free survival, overall survival and safety. Sample size calculation used the Simon Two-Stage method. 27 subjects will be enrolled in this project, considering the dropout rate of 10%.
214820647|NCT06593067|OTHER|Control|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes without a cooling modality.
214820648|NCT06593067|OTHER|Fan|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan as a cooling modality.
214820649|NCT06593067|OTHER|Fan and Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan and water spray as cooling modalities.
214820650|NCT06593067|OTHER|Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with water spray as a cooling modality.
214820651|NCT05844462|DRUG|Tadalafil|Oral Tadalafil
214820652|NCT05844462|DRUG|Placebo|Oral Placebo
214820653|NCT03523156|DRUG|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
214820654|NCT03523156|DRUG|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
214820655|NCT05137834|OTHER|Exercise|Post-surgical exercise
214820656|NCT00001703|BIOLOGICAL|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
214820657|NCT00001703|BIOLOGICAL|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
214267447|NCT06485947|BIOLOGICAL|Dinutuximab beta|Combination of immunotherapy with standard chemotherapy
214267448|NCT06485947|DRUG|chemotherapy treatment called GPOH|chemotherapy treatment called GPOH
214267449|NCT06485947|DRUG|chemotherapy treatment called rapid COJEC|chemotherapy treatment called rapid COJEC
214267450|NCT03439787|DRUG|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
214820658|NCT03242213|BEHAVIORAL|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
214820659|NCT03183986|DEVICE|Phototherapy|Phototherapy for 24 hours.
214820660|NCT04740658|OTHER|No intervention|There is no intervention
214820661|NCT05547711|DIAGNOSTIC_TEST|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
214820662|NCT03119025|BIOLOGICAL|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
214820663|NCT01379222|DEVICE|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
214820664|NCT04438187|OTHER|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
214820665|NCT02186691|OTHER|MRI|
214820666|NCT03091335|OTHER|Music-listening|Patients listen to music on headphones
214820667|NCT06169605|PROCEDURE|removal of primary tumor, neck dissection|removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
214820668|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
214267451|NCT03439787|OTHER|Sodium Chloride 0.9 %|10 ml
214267452|NCT04893226|BEHAVIORAL|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
214267453|NCT06655285|OTHER|This was a retrospective study and no patient intervention was performed.|This was a retrospective study and no patient intervention was performed.
214267454|NCT03105583|DRUG|Medication use during pregnancy|
214267455|NCT03105583|DIETARY_SUPPLEMENT|Supplement use during pregnancy|
214267456|NCT03105583|OTHER|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
214267457|NCT01690585|DRUG|Ferinject 1000 mg|
214820669|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
214820670|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
214820671|NCT03733730|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
214820672|NCT00685607|DRUG|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
214820673|NCT00685607|DRUG|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
214820674|NCT01401803|DRUG|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
214820675|NCT05820360|BEHAVIORAL|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
214820676|NCT01531894|DRUG|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
214820677|NCT02744794|DEVICE|Dermal Cooling System|Treatment with cryotherapy.
214820678|NCT02837991|DRUG|CDX-014|
214820679|NCT01747135|DRUG|VTS-270|
214820680|NCT05674734|BEHAVIORAL|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
214820681|NCT00272519|BEHAVIORAL|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
214820682|NCT02838160|BEHAVIORAL|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
214820683|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
214820684|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
214820685|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
214820686|NCT01948167|BEHAVIORAL|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
214820687|NCT01948167|BEHAVIORAL|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
214820688|NCT04116463|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
214820689|NCT04116463|BEHAVIORAL|Financial Self-Management Program (FSMP)|
214267458|NCT01690585|DRUG|Sodium chlorure 0,9 %|
214267459|NCT06617026|DRUG|Sucralfate|a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
214820690|NCT01138163|DRUG|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
214820691|NCT00320034|DRUG|R-albuterol, S-albuterol|
214820692|NCT04754035|DRUG|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
214820693|NCT04754035|DRUG|Imbruvica Oral Product|Imbruvica 140 mg
214820694|NCT04478435|OTHER|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
214820695|NCT06195579|BEHAVIORAL|Transforming the Intense Child Workbook (Glasser, 2016)|The NHA was delivered in a guided self-help format, using the Transforming the Intense Child workbook (Glasser, 2016) and weekly phone calls.
214820696|NCT01452802|DEVICE|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
214820697|NCT01452802|DRUG|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
214820698|NCT04875117|DEVICE|Hearing aid|One or two behind the ear hearing aids provided by the UK National Health Service.
214820699|NCT02545283|DRUG|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.
214820700|NCT02545283|DRUG|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
214820701|NCT02545283|OTHER|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
214820702|NCT00127153|BIOLOGICAL|V110, pneumococcal vaccine polyvalent|
214820703|NCT03609203|OTHER|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
214820704|NCT03609203|OTHER|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
214820705|NCT05570487|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
214820706|NCT00650871|DRUG|GW679769|
214820707|NCT00650871|DRUG|Placebo|
214820708|NCT03635320|DEVICE|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
214820709|NCT03635320|DEVICE|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
214820710|NCT00088192|DRUG|pegaptanib sodium|
214820711|NCT05905276|OTHER|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
214820712|NCT05905276|OTHER|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
214267460|NCT06617026|DRUG|Azadirachtin|a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
214267461|NCT06617026|PROCEDURE|fissurectomy and lateral sphincterectomy|fissurectomy and lateral sphincterectomy
214267462|NCT06680531|DRUG|YZJ-1139 tablets|YZJ-1139 tablets are administered orally single dose
214820713|NCT04512781|DEVICE|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
214820714|NCT04512781|DEVICE|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
214820715|NCT04364581|DRUG|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
214820716|NCT04364581|DRUG|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
214820717|NCT06549036|BEHAVIORAL|Veteran Peer Decision Coaching Session for PSA Screening|Veterans in the intervention arm will review the content of the mailed DA, including the values clarification exercise, with the Veteran PDC. Veteran PDC Counseling includes: 1) a structured interview with the patient that focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals and values related to his decision making and 2) role playing exercises to improve SDM skills.
214820718|NCT01673672|BIOLOGICAL|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
214820719|NCT01673672|BIOLOGICAL|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
214820720|NCT03448263|PROCEDURE|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
214820721|NCT03448263|PROCEDURE|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
214820722|NCT03448263|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
214820723|NCT00310271|BIOLOGICAL|pPJV7630 with pPJV2012 administered by PMED|
214820724|NCT00202462|DRUG|Testosterone gel|Testosterone gel 7.5 gm qd
214820725|NCT01354626|OTHER|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
214820726|NCT01354626|OTHER|low-protein|The control group will get a diet which is according to healthy eating guidelines.
214820727|NCT00835575|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
214820728|NCT00835575|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
214820729|NCT04842123|DIAGNOSTIC_TEST|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
214820730|NCT03999216|DRUG|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
214820731|NCT02742558|BIOLOGICAL|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
214820732|NCT02742558|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
214820733|NCT01261663|OTHER|oral nutritional energy and protein enriched supplement (NOS)|
214820734|NCT02466451|OTHER|Questionnaires|"For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
214820735|NCT03607253|OTHER|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
214820736|NCT05457920|BEHAVIORAL|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
214820737|NCT05457920|BEHAVIORAL|pulse therapy|pulse therapy
214820738|NCT05472311|OTHER|Thermal Ablation|Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
214820739|NCT00443651|DRUG|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
214820740|NCT00443651|DRUG|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
214267463|NCT06680531|DRUG|Escitalopram oxalate tablets|•oral tablet, QD
214267464|NCT06680531|DRUG|YZJ-1139 simulated tablets|oral tablet, QD
214267465|NCT06680180|DIAGNOSTIC_TEST|Viscoelastometric assessment of fibrinolysis|Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.
214820741|NCT03606174|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
214820742|NCT03606174|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
214820743|NCT03606174|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
214820744|NCT03606174|DRUG|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
214820745|NCT04968821|BEHAVIORAL|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
214820746|NCT04968821|OTHER|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
214820747|NCT02995720|DRUG|Fimasartan/Amlodipine combination drug, Rosuvastatin|
214820748|NCT00247923|PROCEDURE|Hysteroscopic resection of endometrial polyps. (TCRP)|
214267466|NCT06681285|DRUG|Cadonilimab ;Anlotinib|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
214820749|NCT00761813|DEVICE|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
214820750|NCT00761813|DEVICE|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
214820751|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
214820752|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
214820753|NCT02010918|DRUG|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
214820754|NCT02266095|DEVICE|Oval-8 Splint|Splinting with Oval-8
214820755|NCT02266095|DEVICE|Tee Pee Splint|Splinting with Tee Pee
214820756|NCT02266095|DEVICE|Forearm Based Splint|Splinting with Forearm based
214820757|NCT06152458|DRUG|Vitamin C|Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
214820758|NCT02649335|DRUG|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
214820759|NCT02649335|PROCEDURE|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
214820760|NCT05493735|DRUG|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
214820761|NCT05493735|DRUG|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
214820762|NCT03373643|DIAGNOSTIC_TEST|OSA screening|Full night polysomnography
214820763|NCT05651243|DIETARY_SUPPLEMENT|Ketone Ester Supplement|Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
214820764|NCT05651243|OTHER|Placebo|Oral ingestion of cellulose combined with a flavoring agent and diluted in water
214820765|NCT00951457|DRUG|Bendamustine|
214820766|NCT00951457|DRUG|Alemtuzumab|
214820767|NCT00714935|BEHAVIORAL|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
214820768|NCT00714935|BEHAVIORAL|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
214820769|NCT00994058|DEVICE|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
214820770|NCT05393050|DRUG|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
214820771|NCT05393050|DRUG|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
214820772|NCT04721834|DEVICE|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
214820773|NCT04721834|DEVICE|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
214820774|NCT05212350|PROCEDURE|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
214267467|NCT06680609|DRUG|Nefopam 20 MG/ML|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
214267468|NCT06680609|DRUG|Placebo|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
214820775|NCT05212350|PROCEDURE|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
214820776|NCT02645500|BEHAVIORAL|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
214820777|NCT02645500|BEHAVIORAL|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
214820778|NCT04618900|PROCEDURE|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
214820779|NCT01409499|PROCEDURE|hepatic resection|palliative hepatectomy followed by sorafenib
214820780|NCT01409499|PROCEDURE|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
214820781|NCT01409499|DRUG|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
214820782|NCT05911711|OTHER|Prognostic factor|normal person (no sepsis group)
214820783|NCT03911583|BEHAVIORAL|Control Group (CG)|The control group does not receive these notifications (PUSH)
214820784|NCT03911583|BEHAVIORAL|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
214820785|NCT03911583|BEHAVIORAL|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
214820786|NCT00787553|DRUG|cefazolin|2.0 g, IV, 2 hours before surgery
214820787|NCT00787553|DRUG|tinidazole|2.0 g orally, 12 hours before surgery
214820788|NCT00787553|DRUG|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
214820789|NCT06627712|DRUG|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
214820790|NCT06627712|DRUG|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
214820791|NCT03519139|OTHER|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
214820792|NCT03187925|PROCEDURE|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
214820793|NCT00486187|DRUG|rosiglitazone|
214820794|NCT00486187|DRUG|metformin or sulfonylurea|
214820795|NCT02013882|PROCEDURE|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
214820796|NCT04858126|DEVICE|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
214820797|NCT03172286|DEVICE|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
214820798|NCT00004213|DRUG|triapine|
214820799|NCT04635007|DRUG|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
214820800|NCT04635007|DRUG|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
214820801|NCT04410653|DRUG|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
214820802|NCT02045667|DRUG|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
214820803|NCT02045667|DRUG|Placebo|Placebo tablets do not contain any active medicinal component.
214820804|NCT02241551|DRUG|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
214820805|NCT02241551|DRUG|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
214820806|NCT04196062|DEVICE|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
214820807|NCT01963663|DRUG|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
214820808|NCT01963663|DRUG|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
214820809|NCT01920334|DRUG|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
214820810|NCT01920334|DRUG|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
214820811|NCT04197908|DEVICE|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
214820812|NCT05936554|DEVICE|whole body vibration|to improve muscle power and balance.
214820813|NCT05936554|OTHER|Functional strength training|used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
214820814|NCT00469898|DRUG|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"
214820815|NCT00469898|DRUG|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
214820816|NCT05579262|DIETARY_SUPPLEMENT|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
214820817|NCT05230758|DRUG|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
214820818|NCT05230758|DRUG|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
214820819|NCT01205035|DRUG|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
214820820|NCT02739724|PROCEDURE|Adnexal surgery|
214820821|NCT00443274|OTHER|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
214820822|NCT00443274|DEVICE|410 Arm|Anatomically shaped silicone gel-filled breast implants.
214820823|NCT00443274|DEVICE|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
214820824|NCT00109512|DRUG|NBI-56418 (GnRH antagonist)|
214820825|NCT00109512|DRUG|placebo|
214820826|NCT04672538|PROCEDURE|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
214820827|NCT04672538|PROCEDURE|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
214820828|NCT03239314|DRUG|Saline Solution|Injected in the adductor canal
214820829|NCT03239314|DRUG|Dexamethasone|Injected in the adductor canal
214820830|NCT05428943|DRUG|OPT101|15-mer peptide derived from the sequence of mouse CD154.
214820831|NCT04665375|DRUG|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
214820832|NCT05205876|BEHAVIORAL|Eddii mobile application|Participants will use the Eddii mobile application in the intervention arm.
214820833|NCT03931460|DRUG|Medical Abortion|Medical Abortion
214820834|NCT00044135|DRUG|clevudine (drug)|
214820835|NCT03621163|PROCEDURE|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
214820836|NCT03621163|PROCEDURE|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
214820837|NCT01354418|DRUG|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
214820838|NCT01354418|DRUG|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
214820839|NCT01972490|DRUG|avastin|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
214820840|NCT01972490|DRUG|mFOLFOX6|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
214820841|NCT04430985|DRUG|Oxaliplatin|Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
214820842|NCT04430985|DRUG|5-Fluorouracil|Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
214820843|NCT04430985|DRUG|Leucovorin|Day 1 each cycle: 400 mg/m2 i.v.
214820844|NCT04430985|DRUG|Nivolumab|Day 3 in cycle 3 to 8: 3 mg/kg i.v.
214820845|NCT04430985|DEVICE|Ipilimumab|Day 3 in cycle 3 and 6: 1 mg/kg i.v.
214820846|NCT05569629|PROCEDURE|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
214820847|NCT03620591|DRUG|Lidocaine|Intraoperative administration of lidocaine
214820848|NCT03620591|DRUG|Placebo|Intraoperative administration of normal saline
214820849|NCT01844050|DRUG|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
214820850|NCT01844050|DRUG|Placebo|
214820851|NCT03877692|DRUG|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
214820852|NCT03877692|OTHER|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
214820853|NCT05318690|DEVICE|PlayGait|PlayGait is a dynamic energy storing and returning lower-limb exoskeleton.
214820854|NCT05318690|OTHER|Baseline|Baseline condition with no prescribed or intervention lower-limb devices.
214820855|NCT03238183|DRUG|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
214820856|NCT03238183|DEVICE|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
214820857|NCT04588311|DRUG|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
214820858|NCT04588311|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
214820859|NCT02092363|DRUG|OMP-54F28, Paclitaxel and Carboplatin|
214820860|NCT05279742|DRUG|MANP|Single subcutaneous injection 5 µg/Kg
214820861|NCT05279742|DRUG|Sacubitril/Valsartan|Oral single dose 97/103 mg
214820862|NCT05279742|DRUG|Oral Placebo|Oral single dose that contains no active ingredient
214820863|NCT05279742|DRUG|Injection Placebo|Single subcutaneous injection that contains no active ingredient
214820864|NCT01667679|DRUG|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
214820865|NCT01667679|DRUG|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
214820866|NCT02159183|DEVICE|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
214820867|NCT02159183|DEVICE|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
214820868|NCT03570905|OTHER|Sugar Tong Splint|A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
214820869|NCT03570905|OTHER|Clam Shell Splint|A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
214820870|NCT02777580|DRUG|Tenecteplase|Half dose Tenecteplase
214820871|NCT02777580|DRUG|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
214820872|NCT02777580|PROCEDURE|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
214820873|NCT02777580|PROCEDURE|Primary PCI|Primary PCI accoring to local standards
214820874|NCT00029263|DRUG|herbals|
214820875|NCT01294917|DEVICE|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
214820876|NCT01294917|DEVICE|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
214820877|NCT01294917|DEVICE|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
214820878|NCT00611364|OTHER|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
214820879|NCT00611364|OTHER|education meetings|This group only participed of education meeting (every fifteen days)
214820880|NCT01193712|PROCEDURE|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
214820881|NCT06562764|OTHER|Counselling by the Trained Pharmacist|The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
214820882|NCT06562764|OTHER|Pictograms Cards and Counselling by the Trained Pharmacist|The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
214820883|NCT02519348|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
214820884|NCT02519348|BIOLOGICAL|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
214820885|NCT02519348|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
214820886|NCT01444378|DEVICE|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
214820887|NCT00164307|BEHAVIORAL|Parent assisted social skills training|
214820888|NCT04414891|DEVICE|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
214820889|NCT03946891|DRUG|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
214820890|NCT03946891|DRUG|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
214820891|NCT02911792|DRUG|Dapagliflozin|SGLT2 inhibitor
214820892|NCT02911792|DRUG|Metformin|Oral diabetes medicine that helps control blood sugar levels.
214820893|NCT02911792|DRUG|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
214820894|NCT01569269|BEHAVIORAL|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
214820895|NCT01569269|BEHAVIORAL|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
214820896|NCT01569269|BEHAVIORAL|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
214820897|NCT01569269|OTHER|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
214820898|NCT01124305|DEVICE|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
214820899|NCT01124305|DEVICE|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
214820900|NCT01868945|DIETARY_SUPPLEMENT|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
214820901|NCT01868945|DIETARY_SUPPLEMENT|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
214820902|NCT01868945|DIETARY_SUPPLEMENT|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
214820903|NCT01868945|DIETARY_SUPPLEMENT|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
214820904|NCT03315247|BEHAVIORAL|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
214820905|NCT02952456|OTHER|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
214820906|NCT01877317|DEVICE|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
214820907|NCT01244620|DRUG|sitaxentan|sitaxsentan 100 mg QD for 6 days
214820908|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
214820909|NCT01244620|DRUG|sitaxsentan|sitaxsentan 100 mg QD for 6 days
214820910|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
214820911|NCT01244620|DRUG|sitaxsentan|sitaxentan 100 mg QD for 6 days
214820912|NCT01244620|DRUG|sildenafil|sildenafil 20 mg TID for 6 days
214820913|NCT00620711|DEVICE|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
214820914|NCT00897377|RADIATION|Radiation therapy|
214820915|NCT00897377|DRUG|Temozolomide|
214820916|NCT05430776|RADIATION|Photobimodulation|laser therapy application
214820917|NCT02321098|DRUG|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
214820918|NCT02321098|DRUG|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
214820919|NCT02321098|DRUG|Loceryl NL 15 months|Loceryl once/week for additional 15 months
214820920|NCT01610245|DRUG|Nitazoxanide|
214820921|NCT01610245|DRUG|Oseltamivir|
214820922|NCT01610245|DRUG|Placebo Oral Tablet|
214820923|NCT01610245|DRUG|Placebo Oral Capsule|
214820924|NCT02493283|DRUG|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
214820925|NCT02493283|DRUG|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
214820926|NCT02493283|BIOLOGICAL|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
214820927|NCT02493283|BIOLOGICAL|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
214820928|NCT01663233|DRUG|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
214820929|NCT01663233|DRUG|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
214820930|NCT01663233|DRUG|Placebo|Matching placebo to LCZ696
214820931|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose, 1 day
214820932|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
214820933|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
214820934|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
214820935|NCT04825314|DEVICE|Urethral catheter|All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
214820936|NCT03081481|DRUG|PRX302|Single prostate cancer lesion injected with PRX302
214820937|NCT05878964|OTHER|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
214820938|NCT05878964|OTHER|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
214820939|NCT05878964|OTHER|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
214820940|NCT02220647|DRUG|Linagliptin/Metformin FDC|
214820941|NCT02220647|DRUG|Linagliptin|
214820942|NCT02220647|DRUG|Metformin|
214820943|NCT00859105|DRUG|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
214820944|NCT00859105|DRUG|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
214820945|NCT00859105|DRUG|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
214820946|NCT00859105|DRUG|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
214820947|NCT02448862|DEVICE|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
214820948|NCT06364267|DRUG|Tamoxifen 10 MG|Blinded tamoxifen 10 mg every other day
214820949|NCT06364267|DRUG|Exemestane 25 MG|Blinded exemestane 25 mg every other day
214656217|NCT02537678|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
214820950|NCT04881240|BIOLOGICAL|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
214820951|NCT04881240|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
214820952|NCT04881240|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
214820953|NCT04881240|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
214820954|NCT04881240|DEVICE|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
214820955|NCT04881240|PROCEDURE|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
214820956|NCT06132841|DRUG|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
214820957|NCT06132841|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
214820958|NCT02917525|DIETARY_SUPPLEMENT|Vitamin K2|
214820959|NCT02917525|OTHER|Placebo|
214820960|NCT06444178|DRUG|Aspirin|Oral administration
214820961|NCT06444178|DRUG|REGN9933|Administered intravenous (IV)
214820962|NCT06444178|DRUG|REGN7508|Administered IV
214656218|NCT02537678|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
214656219|NCT02229734|RADIATION|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
214656220|NCT02229734|DRUG|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
214820963|NCT06444178|DRUG|Rivaroxaban|Oral administration
214820964|NCT05309876|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
214820965|NCT05628233|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
214820966|NCT06092801|OTHER|No intervention|No intervention
214820967|NCT03302039|DRUG|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
214820968|NCT03302039|DRUG|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
214820969|NCT03302039|DRUG|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
214820970|NCT03302039|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
214820971|NCT05972174|BIOLOGICAL|mRNA-1018 for H5N8|Sterile liquid for injection
214820972|NCT05972174|BIOLOGICAL|mRNA-1018 for H7N9|Sterile liquid for injection
214820973|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only|Sterile liquid for injection
214820974|NCT05972174|BIOLOGICAL|mRNA-1018 for H7 Only|Sterile liquid for injection
214820975|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
214820976|NCT06696118|DEVICE|Electromagnetic Transduction Therapy (EMTT)|Subjects will be treated with Electromagnetic Transduction Therapy (EMTT) using the Curamedix MAGNETOLITH device. Treatments will be administered twice per week, for four weeks. Each treatment will have the following settings: level 8, 8Hz, and 10,000 pulses andwill take about 15 to 20 minutes. Treatments will be spaced 2-3 days apart.
214820977|NCT05630885|DRUG|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
214820978|NCT05630885|DRUG|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
214820979|NCT05630885|OTHER|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
214820980|NCT05630885|OTHER|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
214820981|NCT05922683|DRUG|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
214820982|NCT05922683|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
214820983|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
214820984|NCT06852651|PROCEDURE|Superficial Cervical Block (SCB) Group|"Patients in this group will receive a bilateral superficial cervical block under ultrasound guidance after anesthesia induction but before the surgical procedure begins.~The block will be performed using 0.1 mL/kg of 0.25% bupivacaine per side, targeting the superficial branches of the cervical plexus.~The primary goal is to assess its efficacy in postoperative pain management and its impact on recovery parameters."
214267469|NCT05351905|DRUG|CBD oil ( MPL-001)|MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
214820985|NCT01262001|DRUG|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
214820986|NCT01262001|DRUG|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
214820987|NCT04813081|PROCEDURE|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
214820988|NCT01370733|DEVICE|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
214820989|NCT01370733|DEVICE|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
214820990|NCT02866357|OTHER|No intervention|Just collection of nasopharyngeal aspirate for assessment
214820991|NCT05745363|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
214820992|NCT01909024|PROCEDURE|Coil embolisation|transjugular coil embolisation of pelvic veins
214820993|NCT01909024|PROCEDURE|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
214820994|NCT04050943|OTHER|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
214820995|NCT03510208|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
214820996|NCT03510208|BIOLOGICAL|Panitumumab|Given IV
214820997|NCT03510208|DRUG|Panitumumab-IRDye800|Given IV
214820998|NCT03510208|DEVICE|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
214820999|NCT05242705|DIAGNOSTIC_TEST|Serum Cysteine Rich Protein 61|collection of serum samples for chemical analysis
214821000|NCT06539676|DEVICE|Nighttime Aligners|Nighttime aligners worn 10-12 hours per day or night during 2-8 months
214821001|NCT06539676|DEVICE|Daytime Aligners|Daytime aligners worn 20-22 hours per day or night during 2-8 months
214821002|NCT03202238|OTHER|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
214821003|NCT03202238|DEVICE|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
214821004|NCT03202238|DEVICE|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
214821005|NCT00222625|DRUG|rFVIIa + (vit K in AO patients)|
214821006|NCT00222625|DRUG|FFP or aPCC+ vit K in AO treated patients|
214821007|NCT05201833|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
214821008|NCT05201833|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
214821009|NCT05201833|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
214821010|NCT05201833|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
214821011|NCT02181647|BEHAVIORAL|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
214821012|NCT05615909|RADIATION|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
214821013|NCT05615909|RADIATION|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
214821014|NCT06443151|PROCEDURE|Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)|The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
214821015|NCT06443151|PROCEDURE|venous occlusion plethysmography|Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.
214821016|NCT06443151|DRUG|Acetylcholine|Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
214821017|NCT06443151|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
214821018|NCT06443151|DRUG|Ascorbic acid|Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
214821019|NCT06443151|PROCEDURE|venous phlebotomy|Venous blood samples will be collected to measure baseline cardiometabolic characteristics and isolate endothelial cell microvesicles for characterizations and in vitro experiments.
214821020|NCT04311164|OTHER|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
214821021|NCT04311164|OTHER|No intervention given.|No intervention was given.
214821022|NCT04849390|DRUG|ESO-101|Daily administration in the evening at bedtime for 28 days
214821023|NCT04849390|DRUG|Placebo|Daily administration in the evening at bedtime for 28 days
214821024|NCT03872596|DRUG|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
214821025|NCT03872596|DRUG|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
214821026|NCT03872596|DRUG|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
214821027|NCT03872596|DRUG|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
214821028|NCT03872596|DRUG|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
214821029|NCT04515095|OTHER|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
214821030|NCT03616405|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
214821031|NCT01953185|OTHER|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).
214821032|NCT01953185|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
214821033|NCT01861535|DRUG|Imiquimod|
214821034|NCT01861535|PROCEDURE|Surgery|
214821035|NCT02441621|OTHER|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
214821036|NCT02441621|OTHER|premedication|patients receive premedication with midazolam 7.5 mg p.o.
214821037|NCT02441621|OTHER|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
214821038|NCT02441621|OTHER|central venous catheter|a central venous catheter in the right or left internal jugular vein.
214821039|NCT02441621|OTHER|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
214821040|NCT02441621|OTHER|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
214821041|NCT02441621|OTHER|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
214821042|NCT03122015|OTHER|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
214821043|NCT04345107|DRUG|SY-009|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
214821044|NCT04345107|DRUG|SY-009 matching placebo|SY-009 matching placebo
214821045|NCT02645409|DRUG|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
214821046|NCT02645409|DEVICE|Intraoperative fluorescence imaging system|
214821047|NCT06561607|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
214821048|NCT06561607|DRUG|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle."
214821049|NCT05747807|DEVICE|Percutaneous intradiscal radiofrequency treatment|using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
214821050|NCT00886522|PROCEDURE|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
214267470|NCT05351905|DRUG|CDB+THC oil (MPL-005)|MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
214821051|NCT04407403|BEHAVIORAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
214821052|NCT04407403|BEHAVIORAL|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
214821053|NCT04179058|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
214821054|NCT04440436|DRUG|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
214821055|NCT03419403|DRUG|Steroid eye drops|Solution, eye drop
214821056|NCT03419403|DRUG|Vasoconstrictor eye drops|Solution, eye drop
214821057|NCT03419403|OTHER|Cold compress|Cold compress
214821058|NCT03419403|DRUG|Ophthalmic steroid ointment|Ointment
214821059|NCT03419403|DRUG|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
214821060|NCT03419403|DRUG|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
214821061|NCT03419403|RADIATION|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
214821062|NCT04290858|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
214821063|NCT02525445|PROCEDURE|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
214821064|NCT02525445|PROCEDURE|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle \[20\]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
214821065|NCT02525445|PROCEDURE|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
214821066|NCT02525445|PROCEDURE|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
214821067|NCT04825847|DEVICE|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
214821068|NCT04825847|OTHER|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
214821069|NCT03468764|PROCEDURE|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
214821070|NCT02828449|BEHAVIORAL|therapeutic education program|
214821071|NCT03429725|OTHER|Online prime (statements writing)|Participants to write statements describing themselves or their similarities to their community.
214821072|NCT03429725|OTHER|Online prime (circling)|Participants to circle either pronouns denoting themselves or pronouns denoting others.
214821073|NCT03429725|OTHER|Online prime (Sumarian Warrior)|Participants read a passage which described the factors that led to his success in a war.
214821074|NCT03429725|OTHER|Online prime (all)|Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
214821075|NCT03466866|BEHAVIORAL|PREVENT|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
214821076|NCT03466866|BEHAVIORAL|EUC (Enhanced Usual Care)|In-home diabetes education with no goal setting or telehealth visits
214821077|NCT00060697|BEHAVIORAL|Adolescent sexual activity education for mothers|
214821078|NCT04926480|PROCEDURE|low and high flow Anesthesia|comparison of hemodynamic changes in low and high flow anesthesia groups
214821079|NCT02089685|BIOLOGICAL|Pembrolizumab|IV infusion
214821080|NCT02089685|BIOLOGICAL|PegIFN-2b|Subcutaneous infusion
214821081|NCT02089685|BIOLOGICAL|Ipilimumab|IV infusion
214821082|NCT02068820|DEVICE|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
214821083|NCT02068820|DEVICE|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
214821084|NCT03965377|BEHAVIORAL|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
214821085|NCT00318461|DRUG|liraglutide|0.6 mg for s.c. (under the skin) injection.
214821086|NCT00318461|DRUG|metformin|1.5-2.0 g tablets
214821087|NCT00318461|DRUG|glimepiride|4 mg tablets
214267471|NCT05351905|DRUG|Placebo oil|The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
214267472|NCT06680986|OTHER|Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements)|The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).
214267473|NCT05065528|DIETARY_SUPPLEMENT|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
214821088|NCT00318461|DRUG|placebo|Glimepiride placebo 1 mg and 2 mg tablets
214821089|NCT00318461|DRUG|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
214821090|NCT00318461|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
214821091|NCT00318461|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
214821092|NCT00863083|BEHAVIORAL|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
214821093|NCT03372876|DIETARY_SUPPLEMENT|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
214821094|NCT00171886|DRUG|Octreotide|
214821095|NCT05134220|DIAGNOSTIC_TEST|Serum Calcium|"* Serum calcium level.~* Serum phosphorus level. will be measured to all study population"
214821096|NCT04940494|OTHER|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
214821097|NCT00111098|DRUG|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
214821098|NCT01372345|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
214821099|NCT02338583|DEVICE|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
214821100|NCT04134091|DRUG|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
214821101|NCT04134091|DRUG|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
214821102|NCT04134091|DRUG|Placebo|Oral matching placebo capsule administered as BID
214821103|NCT04256720|BEHAVIORAL|No intervention|No intervention - questionnaire study
214821104|NCT02822326|BIOLOGICAL|CD19-CAR-T2 Cells|
214821105|NCT05669781|DRUG|Metoclopramide 10mg|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
214821106|NCT05669781|COMBINATION_PRODUCT|Gum and metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
214821107|NCT05669781|OTHER|Gum|One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
214821108|NCT05669781|OTHER|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
214821109|NCT00018733|DRUG|paroxetine|
214821110|NCT00018733|DRUG|Desipramine|
214821111|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214821112|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214821113|NCT00796653|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
214821114|NCT00796653|DRUG|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
214821115|NCT01459185|DRUG|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
214821116|NCT03393208|DRUG|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
214821117|NCT03393208|DRUG|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
214821118|NCT06626867|DIETARY_SUPPLEMENT|Dietary Fiber Supplementation|Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
214821119|NCT06626867|OTHER|Placebo|The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
214821120|NCT01498172|BIOLOGICAL|MAGE-A3 ASCI|5 doses every 3 weeks
214821121|NCT01498172|BIOLOGICAL|BCG|1 intravesical dose /week for 6 weeks
214821122|NCT02741895|BEHAVIORAL|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
214821123|NCT01885572|DEVICE|TiLOOP Bra|Titaniferously coated polypropylene mesh
214821124|NCT00066001|DRUG|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
214821125|NCT00539110|DRUG|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
214821126|NCT00539110|DRUG|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
214821127|NCT05357235|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
214821128|NCT06324838|PROCEDURE|Standard laparoscopic ileocecal resection|Participants will undergo standard mesocolic sparing resection.
214821129|NCT06324838|PROCEDURE|Extended laparoscopic ileocecal resection|Extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site.
214821130|NCT06131086|OTHER|stabilization exercises|this include stabilization exercise thrice a week for six weeks
214821131|NCT06131086|OTHER|stabilization exercises along with pectoralis minor stretching|this include stabilization exercise with pectoralis minor thrice a week for six weeks
214821132|NCT03782779|OTHER|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
214821133|NCT03782779|OTHER|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
214821134|NCT00697476|DRUG|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
214821135|NCT02272647|DRUG|IM Saline Placebo (0.25 ml)|
214821136|NCT02272647|DRUG|IM Estradiol valerate (2.5 mg)|
214821137|NCT02272647|DRUG|IM Saline Placebo (0.5 ml)|
214821138|NCT02272647|DRUG|IM Estradiol valerate (5.0 mg)|
214821139|NCT02272647|DRUG|Oral Micronized Progesterone|
214821140|NCT02272647|DRUG|Oral Placebo|
214821141|NCT02272647|DRUG|Ghrelin (0.3 ug/kg)|
214821142|NCT02272647|DRUG|Medroxyprogesterone - Acetate|
214821143|NCT02272647|DRUG|Oral Placebo|(in lieu of Medroxyprogesterone)
214821144|NCT05091645|OTHER|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
214821145|NCT05640531|DRUG|WCK 771 IV Infusion|subjects will receive intravenous infusion of WCK 771
214821146|NCT05640531|OTHER|Placebo IV Infusion|subjects will receive matching placebo intravenous infusion
214821147|NCT02970123|BEHAVIORAL|Sit Less, Interact, Move More (SLIMM)|
214821148|NCT00207090|DRUG|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
214821149|NCT00207090|DRUG|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
214821150|NCT03206008|DRUG|Magnesium Sulfate|
214821151|NCT03206008|DRUG|Normal saline|Placebo
214821152|NCT00191490|DRUG|Gemcitabine|
214821153|NCT00191490|DRUG|docetaxel|
214821154|NCT00191490|DRUG|cisplatin|
214821155|NCT05613686|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
214821156|NCT04498806|OTHER|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
214821157|NCT02571686|DEVICE|Surveyor S4|
214821158|NCT06279039|DRUG|Exosome liquid dressing|This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
214821159|NCT00819754|DRUG|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
214821160|NCT00304187|DRUG|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
214821161|NCT00304187|DRUG|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
214821162|NCT06969287|DRUG|Fluvoxamine|"100mg Fluvoxamine Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
214821163|NCT06969287|DRUG|Placebo|"Placebo Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
214821164|NCT03807180|OTHER|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
214821165|NCT03353896|DEVICE|Wear novoTTF-200A|Wear novoTTF-200A device
214821166|NCT03353896|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214821167|NCT01312415|DRUG|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
214821168|NCT01312415|DRUG|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
214821169|NCT01911676|DRUG|PF-03463275|
214821170|NCT01911676|DRUG|Placebo|
214821171|NCT01695538|OTHER|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
214821172|NCT03187158|DIAGNOSTIC_TEST|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
214821173|NCT00773253|DRUG|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
214821174|NCT04627467|DRUG|Chloroquine|250mg tablet (150mg base chloroquine)
214821175|NCT06330142|OTHER|Participation in 10 horse-assisted therapy sessions|supporting children and teenagers undergoing radiotherapy with a horse-assisted therapy approach
214821176|NCT02834026|OTHER|Cicloergometry training|
214821177|NCT02834026|OTHER|No Cicloergometry training|
214821178|NCT06380816|DRUG|UCB4594|Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
214821179|NCT04519749|BIOLOGICAL|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
214821180|NCT04045925|OTHER|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
214821181|NCT01960374|DRUG|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
214821182|NCT00222118|BEHAVIORAL|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
214821183|NCT00222118|OTHER|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
214821184|NCT00222118|OTHER|usual care|no intervention
214821185|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
214821186|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
214821187|NCT06432595|OTHER|Instability resistance training and Traditional resistance training|The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.
214821188|NCT03378492|DEVICE|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
214821189|NCT03378492|PROCEDURE|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
214821190|NCT01093053|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
214821191|NCT01093053|OTHER|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
214821192|NCT06130436|DEVICE|Sham-Remote Ischemic Conditioning|Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
214821193|NCT06130436|DEVICE|Remote Ischemic Conditioning Once Daily|"Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg."
214821194|NCT06130436|DEVICE|Remote Ischemic Conditioning Twice Daily|Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
214821195|NCT01566721|DRUG|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
214821196|NCT00954590|DRUG|Dimebon (latrepirdine)|20 mg orally three times daily
214821197|NCT00954590|DRUG|Placebo|Placebo orally three times daily
214821198|NCT03286439|OTHER|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
214821199|NCT03374176|DRUG|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
214821200|NCT03374176|DRUG|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
214821201|NCT00398983|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days
214821202|NCT02911701|DRUG|Acetaminophen|
214821203|NCT02911701|DRUG|Ibuprofen|
214821204|NCT06561568|DIAGNOSTIC_TEST|Conventional physical therapy|Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.
214821205|NCT06561568|OTHER|Kinesiotaping|"Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks."
214821206|NCT00699296|DRUG|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
214821207|NCT02102191|DEVICE|e-cigarette|smoking cigarette without tobacco
214821208|NCT02102191|DEVICE|cigarette|smoking cigarette with tobacco
214821209|NCT05024682|DEVICE|conventional pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
214821210|NCT05024682|DEVICE|pulse dosed pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
214821211|NCT06055764|DEVICE|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
214821212|NCT00004786|DRUG|iloprost|
214267474|NCT05065528|DRUG|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
214267475|NCT03913468|DRUG|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
214267476|NCT07016802|DRUG|GenSci134|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
214267477|NCT07016802|DRUG|GenSci134 Placebo|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
214267478|NCT07016802|DRUG|Recombinant Human Growth Hormone Injection (Norditropin®)|A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.
214821213|NCT00031434|DRUG|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
214821214|NCT00031434|DRUG|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
214821215|NCT03537807|DRUG|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
214821216|NCT06287281|OTHER|heel hight shoes|stand upright for 2 hours wearing your own shoes with heels at least 7 cm high
214821217|NCT03596567|DRUG|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
214821218|NCT03596567|DRUG|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
214821219|NCT03596567|DRUG|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
214821220|NCT02116595|OTHER|high or low acid diet|high or low acid diets
214821221|NCT04118335|OTHER|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
214821222|NCT03398486|DIAGNOSTIC_TEST|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
214821223|NCT03398486|DIAGNOSTIC_TEST|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
214821224|NCT03905980|PROCEDURE|vaginal delivery|pregnancy ended by vaginal delivery
214821225|NCT03905980|PROCEDURE|Cesarean section|pregnancy ended by cesarean delivery
214821226|NCT02951858|BEHAVIORAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
214821227|NCT02951858|BEHAVIORAL|Control Group|The participants only receive the materials about the harm of substance use.
214821228|NCT03480880|DEVICE|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
214821229|NCT01237054|DRUG|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
214821230|NCT01237054|OTHER|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
214821231|NCT01237054|DRUG|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
214821232|NCT05367986|DEVICE|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
214821233|NCT06503926|OTHER|SARS-COV-2 vaccination|Vaccination
214821234|NCT06527222|DRUG|Ranolazine|500mg twice daily
214821235|NCT06527222|DRUG|Ranolazine|1000 mg twice daily
214821236|NCT06527222|DRUG|Placebo|Ranolazine placebo twice daily
214821237|NCT04815668|OTHER|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
214821238|NCT04815668|OTHER|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
214821239|NCT04815668|OTHER|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
214821240|NCT03453476|DEVICE|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
214821241|NCT04009434|DEVICE|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
214821242|NCT04009434|DEVICE|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
214821243|NCT00001835|DRUG|Oxaliplatin|
214821244|NCT03820427|DIAGNOSTIC_TEST|impulse oscillometry|impulse oscillometry
214821245|NCT03820427|DIAGNOSTIC_TEST|multiple breath washout test|multiple breath washout test
214821246|NCT03820427|DIAGNOSTIC_TEST|body plethysmography|body plethysmography
214821247|NCT04817904|DRUG|Rosuvastatin 10mg|The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
214821248|NCT01983969|DRUG|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
214821249|NCT01983969|DRUG|Vorinostat|1000 mg by vein on Day -11 through Day -2.
214821250|NCT01983969|DRUG|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
214821251|NCT01983969|DRUG|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
214821252|NCT01983969|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
214821253|NCT01983969|DRUG|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
214821254|NCT01983969|OTHER|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
214821255|NCT01983969|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
214821256|NCT01983969|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
214821257|NCT01983969|DRUG|Rituximab|375 mg/m2 by vein on Days -9.
214821258|NCT05736718|BEHAVIORAL|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
214821259|NCT05736718|BEHAVIORAL|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
214821260|NCT02619682|DRUG|Ixazomib Citrate|Given PO
214821261|NCT02619682|OTHER|Laboratory Biomarker Analysis|Correlative studies
214821262|NCT02619682|DRUG|Lenalidomide|Given PO
214821263|NCT03835689|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
214821264|NCT00002831|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
214821265|NCT00002831|DRUG|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
214821266|NCT00002831|DRUG|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
214821267|NCT00002831|DRUG|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
214821268|NCT00002831|DRUG|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
214821269|NCT00002831|DRUG|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
214821270|NCT00002831|DRUG|Methylprednisolone|Given according to clinical grade of GVHD procedures.
214821271|NCT00002831|DRUG|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
214821272|NCT00002831|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
214821273|NCT00002831|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
214821274|NCT03141840|DEVICE|ABL01|Experimental medical device
214821275|NCT03141840|DEVICE|Placebo|ABL01 lacking active component
214821276|NCT00520234|DRUG|Caspofungin|50 mg IV daily
214821277|NCT00520234|DRUG|Normal Saline|100 cc IV daily
214821278|NCT03700723|BIOLOGICAL|Resusix|spray-dried solvent/detergent treated plasma (blood product)
214821279|NCT03700723|BIOLOGICAL|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
214821280|NCT01143311|GENETIC|Arm A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
214821281|NCT04831307|OTHER|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
214821282|NCT05665205|OTHER|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
214821283|NCT05665205|OTHER|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
214821284|NCT00268203|BIOLOGICAL|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
214821285|NCT06452251|DIAGNOSTIC_TEST|OPG, OC, RANKL, IL-10, IL-1β, Ca, TNF-α and Caspase-1 ELISA|The levels of OPG, OC, RANKL, IL10, IL1β, Ca, TNF-α and Caspase1 in bone and PICF of patients with or without Vitamin D sufficiency were measured by ELISA.
214821286|NCT06452251|DIAGNOSTIC_TEST|Resonance Frequency Analysis|Implant stability was measured by a device (Penguin RFA, Integration Diagnostics, Sweden) based on Resonance Frequency Analysis (RFA) and categorized by Implant Stability Quotient (ISQ) scale.
214821287|NCT06452251|DIAGNOSTIC_TEST|Periodontal clinical examination|Clinical periodontal indices including plaque index (PI) (Silness and Löe 1964), gingival index (GI) (Löe 1967), probing depth (PD), and bleeding on probing (BOP) (Ainamo and Bay 1975) were recorded using a Williams periodontal probe. The BOP percentage (%) was calculated by dividing the number of bleeding sites by the total number of sites examined.
214821288|NCT06452251|PROCEDURE|Dental implant placement and bone sample collection|All patients were received by a single examiner a bone level implant (standard type and Sandblasted, Large-grit, Acid-etched surface) (Implant Swiss, Yverdon, Switzerland).
214821289|NCT06452251|PROCEDURE|Gingival Crevicular Fluid Sampling|One month after the healing caps were inserted, peri-implant crevicular fluid (PISF) samples were collected from 6 different sides of each implant. Before sampling, the area was isolated and dried, and paper strips were gently kept in periimplant sulcus for 30 seconds. Strips with blood or saliva contamination were discarded. PISF volumes of each strip were measured by a device (Periotron 8,010, Oraflow Inc, USA). Strips were then pooled, and inserted into tubes. PISF was recovered from paper strips through agitation in phosphate buffer saline (50 mM Tris-HCl, 5 mM CaCl2, 0.2 M NaCl,pH 7.5). All samples were stored at -80C until the day of analysis.
214821290|NCT01066598|DRUG|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
214821291|NCT00001035|DRUG|Interferon alfa-2b|
214821292|NCT00001035|DRUG|Zidovudine|
214821293|NCT00001035|DRUG|Zalcitabine|
214821294|NCT00001035|DRUG|Didanosine|
214821295|NCT01203215|BEHAVIORAL|2 print based physical activity interventions|physical activity promotion
214821296|NCT01349218|OTHER|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
214821297|NCT01349218|OTHER|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
214821298|NCT05961501|DRUG|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
214821299|NCT05961501|OTHER|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
214821300|NCT06466213|OTHER|single exercise bout about one-leg exercise|cycle exercise includes single leg
214821301|NCT06538181|DRUG|Pacritinib|Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
214821302|NCT03169985|DRUG|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
214821303|NCT03169985|DRUG|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
214821304|NCT06001762|DRUG|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
214821305|NCT06001762|DRUG|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
214821306|NCT06001762|DRUG|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
214821307|NCT06001762|DRUG|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
214821308|NCT06001762|DRUG|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
214821309|NCT06001762|DRUG|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
214821310|NCT02478047|DRUG|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
214821311|NCT02478047|OTHER|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
214821312|NCT02478047|OTHER|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
214821313|NCT02478047|OTHER|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
214821314|NCT04360161|DEVICE|swept-source optical coherence tomography|Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of \<10 μm.
214821315|NCT01083784|DRUG|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
214821316|NCT01083784|DRUG|Control group|Control group
214821317|NCT05860686|OTHER|Monoject syringe|monoject syringe is used to clean the wound
214821318|NCT06415045|DRUG|BI 1015550|BI 1015550
214821319|NCT02208128|DRUG|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
214821320|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
214821321|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
214821322|NCT01055041|DRUG|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
214821323|NCT00322439|DRUG|Etanercept|Observational study - no drug administered
214821324|NCT04266405|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
214821325|NCT04266405|DIETARY_SUPPLEMENT|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
214821326|NCT05423197|DRUG|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
214821327|NCT05423197|DRUG|Panitumumab|Panitumumab 30mg will be given orally
214821328|NCT02280733|OTHER|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
214821329|NCT05929222|RADIATION|Radiotherapy|Involved-Site Radiation Therapy 24Gy
214821330|NCT05929222|OTHER|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
214821331|NCT03769922|PROCEDURE|Extensive mesenteric resection|The mesentery is resected avoiding the root region.
214821332|NCT03769922|PROCEDURE|Limited mesenteric excision|The mesentery is retained.
214821333|NCT04279353|OTHER|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
214821334|NCT03230630|DIAGNOSTIC_TEST|plasma melatonin levels|
214821335|NCT03936556|DRUG|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
214821336|NCT03936556|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
214821337|NCT01039961|DRUG|losmapimod 1 mg|IV infusion
214821338|NCT01039961|DRUG|losmapimod|IV infusion (dose to be determined based on PK from first dose)
214821339|NCT01039961|DRUG|losmapimod 15 mg|oral, two 7.5 mg tablets
214821340|NCT02992366|PROCEDURE|implant placement|implant placement
214821341|NCT01841554|DEVICE|Cardioband|
214821342|NCT03423485|DEVICE|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
214821343|NCT03554577|DEVICE|Hearing Aid without NR|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214821344|NCT03554577|DEVICE|Hearing Aid with NR_A|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214821345|NCT03554577|DEVICE|Hearing Aid with NR_B|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214821346|NCT03554577|DEVICE|Hearing Aid with NR_C|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214821347|NCT05718284|DEVICE|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
214821348|NCT05718284|OTHER|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
214821349|NCT01767103|DRUG|Ferriprox®|
214821350|NCT04486339|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
214821351|NCT00665145|DRUG|SB-509|Active drug
214821352|NCT00665145|DRUG|SB-509|Active drug
214821353|NCT00665145|DRUG|Placebo|Placebo
214821354|NCT00665145|DRUG|SB-509|Active drug
214821355|NCT03600376|DRUG|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
214821356|NCT03600376|OTHER|Standard of Care|Body cooling measures and supportive measures
214821357|NCT03804983|DEVICE|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
214821358|NCT03804983|DEVICE|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
214821359|NCT03644888|OTHER|Cycle ergometer training|Already in arm/group descriptions
214821360|NCT03644888|OTHER|Airway clearance program|Already in arm/group descriptions
214821361|NCT03644888|DEVICE|Vibration therapy|Already in arm/group descriptions
214821362|NCT03644888|DEVICE|Sham vibration therapy|Already in arm/group descriptions
214821363|NCT00139113|BIOLOGICAL|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
214821364|NCT02152163|DRUG|IV Ibuprofen|
214821365|NCT02152163|DRUG|placebo|
214821366|NCT02316015|DIETARY_SUPPLEMENT|Infatrini® or Infatrini Peptisorb®|
214821367|NCT03108911|OTHER|Best Practice|Receive standard diet
214821368|NCT03108911|PROCEDURE|Biospecimen Collection|Provide stool sample
214821369|NCT03108911|OTHER|Dietary Intervention|Receive GFD
214821370|NCT03108911|OTHER|Laboratory Biomarker Analysis|Correlative studies
214821371|NCT05191550|BEHAVIORAL|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
214267479|NCT06689917|DRUG|JY231 Injection|"This study employs two pretreatment regimens:~In the lymphodepletion regimen, upon enrollment, subjects undergo leukapheresis followed by 3-5 days of lymphodepleting therapy with fludarabine and cyclophosphamide, culminating in intravenous infusion of JY231 and autologous patient PBMCs via a double-lumen catheter; in the non-lymphodepletion regimen, subjects receive direct intravenous injection of the JY231 preparation immediately after enrollment."
214267480|NCT00391820|DRUG|TD-5108|
214267481|NCT06708676|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
214267482|NCT06708780|BIOLOGICAL|Ex vivo Expanded Human Autologous Regulatory T Cells|Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
214267483|NCT06708780|OTHER|Routine Care|Routine care is provided to all participants according to clinical guidelines for T1DM.
214821372|NCT03186651|DEVICE|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
214821373|NCT01852487|DIETARY_SUPPLEMENT|400mg /day during 6 months|
214821374|NCT00491192|DRUG|Diclofenac|
214821375|NCT02067611|DRUG|X0002|Parallel Assignment
214821376|NCT02067611|DRUG|Placebo|Parallel Assignment
214821377|NCT00796562|DRUG|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
214821378|NCT00796562|DRUG|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
214821379|NCT00796562|RADIATION|Total body irradiation|Patients will receive TBI once a day for 4 days.
214821380|NCT04571021|OTHER|I-DEPT|Implementation of the novel triage algorithm
214821381|NCT04571021|OTHER|DEPT|Existing triage algorithm
214821382|NCT05710354|DIETARY_SUPPLEMENT|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
214821383|NCT00424047|DRUG|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
214821384|NCT00424047|DRUG|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
214821385|NCT02664961|DRUG|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
214821386|NCT02664961|DRUG|Bevacizumab|Bevacizumab will be dosed every two weeks.
214821387|NCT06322420|BEHAVIORAL|Behavioural Activation (BA)|"Behavioural activation treatment delivered in this single arm study. Individual treatment given to all participants in 12 sessions over 11 weeks. All treatment components have been introduced by session 8 that defines minimum amount of treatment in the trial (i.e. 8 session completed).~Behavioral Activation is a psychological treatment for depression focused on gradually re-engaging people with sources of reinforcement and reward in their environment by re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours."
214821388|NCT05957263|OTHER|Biofeedback training and Osteopathy procedure|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscle. muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, l
214821389|NCT05957263|OTHER|Biofeedback training|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
214821390|NCT05957263|OTHER|Osteopathy procedure|specific techniques included muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. In addition, there was a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, low amplitude manipulation performed three times a week for 15 minutes each session for 10 weeks.
214821391|NCT00394810|DRUG|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
214821392|NCT02067624|OTHER|Thai massage|
214821393|NCT00445445|OTHER|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
214821394|NCT00445445|OTHER|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
214821395|NCT00445445|PROCEDURE|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
214821396|NCT00445445|PROCEDURE|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
214821397|NCT00445445|PROCEDURE|study of high risk factors|"* Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
214821398|NCT06368245|PROCEDURE|long-segment posterior TL instrumented fusion|long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.
214821399|NCT05436860|DEVICE|liver ultrasound|"At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group."
214821400|NCT06656416|DRUG|ALTO-100|ALTO-100 40 mg tablet BID
214821401|NCT06656416|DRUG|Placebo|Placebo tablet BID
214821402|NCT06738966|DRUG|BL0175|"BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue."
214821403|NCT05206344|OTHER|clowns|presence or absence of clowns during the performance of a painful act, on pain
214821404|NCT04891744|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
214821405|NCT04891744|DRUG|Thalidomide|100mg/d, Po. on day1-28
214821406|NCT04891744|DRUG|Dexamethasone|20 mg/d Po. on day 1, 2,8,9,15,16,22,23
214821407|NCT00312897|DRUG|Omega-3 Fatty Acids|10 wk treatment period
214821408|NCT00312897|DRUG|corn oil|placebo comparator
214821409|NCT02485847|PROCEDURE|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
214821410|NCT06275321|OTHER|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
214821411|NCT06275321|OTHER|Exercise recommendation group|General recommendation about physical exercise. No supervised
214821412|NCT04097483|BEHAVIORAL|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
214821413|NCT02414711|OTHER|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)
214821414|NCT02414711|OTHER|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
214821415|NCT01966484|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
214821416|NCT01966484|DRUG|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
214821417|NCT04633564|BIOLOGICAL|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
214821418|NCT04633564|BIOLOGICAL|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
214821419|NCT01010503|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
214821420|NCT02885909|DEVICE|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
214821421|NCT02885909|PROCEDURE|Insulin protocal|Using insulin protocal based on glucose monitor
214821422|NCT04984902|DEVICE|Extracorporal therapy|Extracorporal therapy
214821423|NCT03173872|PROCEDURE|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
214821424|NCT03402503|DRUG|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
214821425|NCT03402503|OTHER|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
214821426|NCT00100776|DRUG|Olanzapine|
214821427|NCT00431912|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
214821428|NCT00131417|DRUG|ready-to-use therapeutic food|
214821429|NCT04187352|DRUG|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
214821430|NCT04187352|DRUG|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
214821431|NCT04755985|DRUG|AD-213-B|1 tablet administered before the breakfast during 5 days
214821432|NCT04755985|DRUG|AD-2132|1 tablet administered before the breakfast during 5 days
214821433|NCT02351024|DRUG|OXP005|
214821434|NCT02351024|DRUG|Naprosyn®|
214821435|NCT06746181|BEHAVIORAL|Fraction of inspiration O2(FiO2)|After the patient was admitted to the room, anesthesia induction was performed after pre-oxygenation for 3 minutes. Tracheal intubation was carried out once the medication had fully taken effect. After the surgery began, the inspired oxygen concentration was adjusted for each group. The first lung recruitment maneuver was performed 10 minutes later, and subsequent lung recruitment maneuvers were conducted when pulmonary compliance returned to baseline levels. This process was repeated, with all patients undergoing one final lung recruitment maneuver immediately at the end of the surgery.
214821436|NCT01165385|DRUG|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
214821437|NCT01165385|DRUG|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
214821438|NCT07061054|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components: Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and Netrod™ Renal Denervation Radiofrequency Generator. The catheter's electrodes deploy into a self adaptive basket structure, optimizing contact with the vessel wall for effective ablation.
214821439|NCT07067879|OTHER|Lip product|Lip product containing Caulerpa lentillifera extract
214821440|NCT07069114|PROCEDURE|Anterior Cervical Discectomy and Fusion with BAK/C Interbody Fusion|The surgical intervention consisted of anterior cervical discectomy and fusion (ACDF). Patients were placed under general anesthesia in a supine position with slight neck extension. A standard right anterior cervical approach was utilized to expose the affected vertebral levels. Following the removal of the degenerated intervertebral disc and osteophytes, the interbody space was prepared. A Bagby and Kuslich (BAK/C) interbody fusion cage, filled with autogenous bone fragments, was implanted to facilitate fusion. In cases of multi-level surgery, an anterior cervical plate was selectively applied for enhanced stability based on intraoperative assessment. Postoperatively, all patients were required to wear a Philadelphia hard neck brace for a period of 2 months.
214821441|NCT07069556|DEVICE|ColoSense|multi-target stool RNA test
214821442|NCT07068451|PROCEDURE|Greater Occipital Nerve Block (GONB)|A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.
214821443|NCT07068451|PROCEDURE|Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)|Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.
214821444|NCT07068698|OTHER|Thumb Manipulation|This intervention consists of chiropractic manipulation techniques applied specifically to the thumb joint. The manipulation will be performed by a trained physiotherapist twice weekly for 4 weeks. The procedure aims to improve thumb joint mobility, hand grip strength, sensory function, and overall hand function. Each session includes standardized manual therapy maneuvers targeting the thumb's range of motion and soft tissue mobility without the use of any devices or medications. The intervention differs from other manual therapies by focusing solely on the thumb region.
214821445|NCT06899022|OTHER|Normal therapeutic DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and current over approximately 20 min.
214821446|NCT06899022|OTHER|Reduced current DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and reduced (50%) current over approximately 20 minutes.
214821447|NCT06899022|OTHER|Reduced frequency DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic current and reduced (4 Hz) frequency over approximately 20 min.
214821448|NCT06899971|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
214821449|NCT04786353|OTHER|LongCOVIDkidsDK|Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
214821450|NCT07068035|BEHAVIORAL|Temporary abstinence and expressive writing|This brief, self-administered intervention combined both temporary gaming abstinence and gaming-focused expressive writing to mitigate gaming problems
214821451|NCT07068035|BEHAVIORAL|Gaming as per usual and control writing|Participants continued with their usual gaming routine and engaged in control writing exercises for 15 minutes every other day for a total of 4 sessions
214821452|NCT06129253|OTHER|Urine Sample Collection|When urine is collected as a sample in either CSS or LS, first flow urine samples will be collected
214821453|NCT06129253|OTHER|Self-collected Vaginal Swab|Self-collected Vaginal Swab will be collected by the participant under the supervision of a trained nurse or other health care worker.
214821454|NCT06129253|OTHER|Blood Samples|If funding permits, a blood sample may be collected from participants in LS once during the follow-up period. If blood sample collection was not feasible during a visit, two additional attempts may be made to collect blood samples from LS participants during the subsequent follow-up visits.
214821455|NCT02566928|DRUG|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
214821456|NCT02566928|OTHER|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
214821457|NCT02566928|BEHAVIORAL|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
214821458|NCT01097577|DRUG|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
214267484|NCT06710041|DEVICE|Kinesiotape|Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression
214267485|NCT06710041|OTHER|Exercise|Tendon and nerve gliding exercise
214267486|NCT06710041|DEVICE|sham taping|In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
214267487|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia after us-assisted technique
214267488|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia using the surface landmark-guided
214267489|NCT06709664|BEHAVIORAL|Questionnaire|Questionnaire study
214821459|NCT01097577|DRUG|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
214821460|NCT03714685|DRUG|Firibastat|Firibastat (QGC001) 500 mg
214821461|NCT01015300|DRUG|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
214821462|NCT06911203|DRUG|BGM0504|Administered SC
214821463|NCT06911203|DRUG|Tirzepatide|Administered SC
214821464|NCT01566396|DEVICE|A3F|A3F fractional RF treatments for facial wrinkles
214821465|NCT02894593|OTHER|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214821466|NCT02894593|OTHER|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214821467|NCT02894593|OTHER|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214821468|NCT02894593|OTHER|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
214821469|NCT06594939|DRUG|Polatuzumab Vedotin|A combination of a monoclonal antibody and a chemotherapy drug.
214821470|NCT06594939|DRUG|Mosunetuzumab|A monoclonal antibody.
214821471|NCT06594939|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent.
214821472|NCT06594939|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic.
214821473|NCT06594939|DRUG|Prednisone|Steroid, anti-inflammatory
214821474|NCT06594939|OTHER|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier.
214821475|NCT03569761|BEHAVIORAL|Colorectal Cancer Screening Decision Aid|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
214821476|NCT03569761|BEHAVIORAL|Control Group|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
214821477|NCT03052309|DEVICE|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
214821478|NCT00748072|DRUG|DDAVP|0.3 mcg/kg subcutaneous
214821479|NCT00748072|DRUG|saline solution|saline solution 1 ml subcutaneous
214821480|NCT04086186|PROCEDURE|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
214821481|NCT04086186|PROCEDURE|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
214821482|NCT06922890|DRUG|STUP-001|in vivo direct cell conversion gene therapy investigational product
214821483|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
214821484|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
214821485|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
214821486|NCT03145493|DEVICE|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
214821487|NCT01963728|DRUG|Insulin, Isophane|daily dosing based on fasting morning glucose levels
214821488|NCT01963728|DRUG|insulin glargine|daily dose based on fasting morning glucose levels
214821489|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
214821490|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
214821491|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
214821492|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
214821493|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
214821494|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
214821495|NCT06944483|PROCEDURE|same-day radioembolization|"On the day of the procedure, angiography is performed, followed by cone-beam CT of the hepatic artery. After injecting 99mTc-MAA into the hepatic artery, the patient is transferred to the nuclear medicine department for a lung shunt scan and lung SPECT/CT. The lung shunt fraction is determined using the planar images.~Using diagnostic CT/MRI and 99mTc-MAA images, the treatment dose is calculated with the multi-compartment MIRD method. The acceptable range for tumor absorbed dose is ≥100 Gy, and the lung dose must be ≤15 Gy. The tumor absorbed dose must be at least 100 Gy and should ideally be within the range of 300 to 600 Gy. There is no upper limit for the tumor absorbed dose."
214821496|NCT06949800|DRUG|EXE-346 Probiotic|Given as a single-dose, powder packet to mix with water
214821497|NCT06949800|DRUG|Placebo|Given as a single-dose, powder packet to mix with water
214821498|NCT06949800|PROCEDURE|Usual Care High Resolution Anoscopy (HRA)|Non-investigational HRA will be performed
214821499|NCT04176029|DEVICE|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
214821500|NCT00286702|DEVICE|hand splint|
214821501|NCT04845802|OTHER|Inspiratory muscle training(high-IMT group)|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
214821502|NCT04845802|OTHER|Inspiratory muscle training(low-IMT group)|Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
214821503|NCT01498939|DRUG|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
214821504|NCT06438224|OTHER|Extracorporeal shock wave therapy (ESWT)|Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
214821505|NCT06438224|OTHER|sham stimulation|the sham group was treated using an adapter that had the same shape but did not emit any energy
214821506|NCT05152576|DRUG|OnabotulinumtoxinA X|Intramuscular Injection
214821507|NCT05152576|DRUG|Placebo|Intramuscular Injection
214821508|NCT04640142|BIOLOGICAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion.
214821509|NCT04115293|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
214821510|NCT04115293|DRUG|Placebo|Daily subcutaneous (SC) injection
214821511|NCT03729271|DRUG|Rifaximin|Rifaximin will be given during weeks 2-4
214821512|NCT03729271|DEVICE|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
214821513|NCT01414153|DRUG|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
214821514|NCT01414153|DRUG|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
214821515|NCT01414153|DRUG|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
214821516|NCT01414153|DRUG|sham injection|administered monthly for 4 months
214821517|NCT01117220|DRUG|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
214821518|NCT01117220|DRUG|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
214821519|NCT04259476|DRUG|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
214821520|NCT06081569|DIAGNOSTIC_TEST|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
214821521|NCT06042738|COMBINATION_PRODUCT|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
214821522|NCT05956561|OTHER|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
214821523|NCT04741893|DEVICE|EndoFLIP|Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
214821524|NCT01874561|DRUG|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
214821525|NCT01874561|DRUG|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
214821526|NCT01874561|DRUG|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
214821527|NCT03196258|BEHAVIORAL|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
214821528|NCT00378963|DEVICE|ProAdjuster|
214821529|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
214821530|NCT02057835|DRUG|BI 691751 high dose|BI 691751 high dose
214821531|NCT02057835|DRUG|BI 691751 middle dose|BI 691751 middle dose
214821532|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
214821533|NCT02057835|DRUG|BI 691751 low dose 1|BI 691751 low dose 1
214821534|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
214821535|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
214821536|NCT02057835|DRUG|BI 691751 low dose 2|BI 691751 low dose 2
214821537|NCT06626698|OTHER|Static stretching|A passive static stretch of the posterior leg muscles will be performed with the subject in a supine position and knees extended, starting with the ankle at 90º and continuing until reaching the maximum tolerated dorsiflexion.
214821538|NCT06626698|DEVICE|Electrical muscle elongation|The intervention will be performed with the subject in a supine position with knees extended. Electrodes will be placed on the gastrocnemius muscles of the leg being assessed. The parameters will be selected. Static stretching will begin until resistance is felt, at which point the intensity of the electrical current will be increased to induce a visible and tolerable contraction. Simultaneously, the subject will be asked to perform an isometric contraction of the antagonist muscles, resisted by the investigator. When the subject feels the stretch again, the intensity of the current will be increased once more until a new movement barrier is reached.
214821539|NCT04500015|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
214821540|NCT04500015|DRUG|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
214821541|NCT04974684|DEVICE|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
214821542|NCT04974684|DRUG|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
214821543|NCT02984098|DRUG|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
214821544|NCT03218813|BEHAVIORAL|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
214821545|NCT03425344|DIAGNOSTIC_TEST|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
214821546|NCT02343926|DRUG|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
214821547|NCT02343926|DRUG|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
214821548|NCT02343926|DRUG|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
214821549|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
214821550|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
214821551|NCT05168787|DRUG|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
214821552|NCT00012818|BEHAVIORAL|relaxation technique|
214821553|NCT00012818|BEHAVIORAL|educational program|
214821554|NCT05368480|OTHER|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
214821555|NCT04307680|DEVICE|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
214821556|NCT03155425|DRUG|SHR-1210|A humanized monoclonal immunoglobulin
214821557|NCT01364493|DRUG|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
214821558|NCT01310647|DRUG|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
214821559|NCT01310647|DRUG|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
214821560|NCT01310647|DRUG|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
214821561|NCT04546334|DRUG|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
214821562|NCT04546334|PROCEDURE|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
214821563|NCT04546334|PROCEDURE|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
214821564|NCT04546334|PROCEDURE|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
214821565|NCT00828295|DRUG|palonosetron|palonosetron IV 1 mcg/kg
214821566|NCT00828295|DRUG|palonosetron|palonosetron 3mcg/kg IV
214821567|NCT05878626|OTHER|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
214821568|NCT01601158|BIOLOGICAL|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
214821569|NCT01601158|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
214821570|NCT02762422|OTHER|Phlebotomy|Removal of 500 cc of blood via forearm vein
214267490|NCT06708806|PROCEDURE|cataract surgery|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (XY1) vs. an toric IOL (XY1A)
214821571|NCT05954598|DIETARY_SUPPLEMENT|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
214821572|NCT02561845|DRUG|rosuvastatin|5mg, 10mg, 20mg
214821573|NCT02267408|OTHER|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
214821574|NCT02267408|OTHER|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
214821575|NCT03757195|PROCEDURE|Augmentation|combination product
214267491|NCT06709170|DEVICE|Novel asymmetrical linear stapler|Novel asymmetrical linear stapler
214267492|NCT06709170|DEVICE|Signia™|Signia™
214267493|NCT06707532|DRUG|Propofol|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~\- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v."
214821576|NCT01402050|DRUG|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
214821577|NCT01402050|DEVICE|FOLEY BALLOON|INDUCTION OF LABOR
214821578|NCT02028221|DRUG|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
214821579|NCT02028221|DRUG|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
214821580|NCT03581097|OTHER|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
214821581|NCT06012006|OTHER|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
214821582|NCT04860349|OTHER|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
214821583|NCT03330990|DRUG|Entrectinib|600 mg oral capsule (fasted and fed)
214821584|NCT03330990|DRUG|Midazolam Hydrochloride|2 mg oral syrup (fasted)
214821585|NCT00721435|PROCEDURE|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
214821586|NCT06374134|BEHAVIORAL|Community Engagement Practice|Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.
214821587|NCT06374134|BEHAVIORAL|Patient-Centric Protocol Element|Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.
214821588|NCT01092455|DRUG|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
214821589|NCT04857138|DRUG|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
214821590|NCT04857138|DRUG|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
214821591|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
214821592|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
214821593|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
214821594|NCT04604262|DEVICE|Waterpik|Waterpik dental water jet
214821595|NCT05735145|DRUG|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
214821596|NCT02375477|OTHER|Educational Intervention|Given educational presentation
214821597|NCT05644184|BIOLOGICAL|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
214821598|NCT05644184|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
214821599|NCT06563115|DRUG|(PEG)-BHD1028 Single Ascending Dose|4, 8, 16, 32, and 64 μg/Kg
214821600|NCT06563115|DRUG|(PEG)-BHD1028 Multiple Ascending Dose|8, 16, and 32 μg/Kg
214821601|NCT06563115|OTHER|Placebo|Diluent
214821602|NCT00744679|DRUG|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
214821603|NCT02977221|PROCEDURE|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
214821604|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
214821605|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
214821606|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
214821607|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
214821608|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
214821609|NCT06625021|PROCEDURE|Chiropractic manipulation|"Chiropractic manipulation: Lower cervical chiropractic manipulation is a technique used to increase mobility and relieve pain in the lower vertebrae of the neck. However, such procedures should only be performed by trained chiropractors; if done incorrectly, they can lead to serious problems. The patient should be placed in a comfortable position. The supine or side-lying position is usually preferred. Contact is established with the transverse processes of the lower cervical vertebrae. High-velocity, Low-amplitude thrust is applied within anatomical limits.~As a graduate of Bahcesehir University Chiropractic Masters Degree, I applied chiropractic twice a week for 3 weeks."
214821610|NCT06625021|PROCEDURE|Exercises to be done for neck pain of mechanical origin|Conservative treatment, which is frequently used in the treatment of mechanical neck pain, was planned. A warm-up period was defined with stretching exercises in all areas of neck movement. Again, isometric exercise should be 10 seconds in all directions. In addition to neck and shoulder mobility exercises, neck region posture exercises were included. It was planned to do these exercises for 4 weeks, 5 days a week, in all 4 groups.
214821611|NCT06625021|PROCEDURE|Classic Hand-Wrist Exercises|The participants of this group will be subjected to wrist range of motion (ROM), stretching and strengthening exercises. Measurements will be made in all axes of motion of the wrist, which are extension, flexion, ulnar and radial deviation. ROM exercises and stretching exercises were applied passively to all axes of motion within anatomical limits. At the last angles of the movement, the individual was forced and stretched without causing discomfort and waited at the last angles for a short time. Stretching exercises were performed five times for each movement. Strengthening exercises for all axes of movement of the wrist will be performed using dumbbells weighing 1 and 2 kilograms and an exercise band suitable for the persons endurance and strength. In exercises performed with dumbbells, all movements of the wrist will be performed against gravity. All applications were applied to the classical hand-wrist exercise group for at least half an hour every day for 4 weeks.
214821612|NCT06625021|PROCEDURE|Proprioceptive exercise group|Similar to the classical wrist exercise group, the participants in this group were applied joint range of motion, stretching and strengthening exercises as well as proprioceptive exercises such as joint approximation, traction and mobilization. In addition to all axes of motion of the wrist, active and passive stretching exercises were applied to the forearm flexor and extensor muscles five times each. The resistance and repetition number were gradually increased according to the wrist strength and endurance of the individuals to at least 10 repetitions. Repetitive contraction and rhythmic stabilization techniques were used from proprioceptive neuromuscular facilitation methods. Joint approximation technique and taping of forearm flexor and extensor muscles were used to increase the level of contraction and stimulation of joint receptors. External stabilization and perturbation exercises were performed with an exercise ball against the wall at different angles of the upper extremity.
214821613|NCT02393014|PROCEDURE|Simple physical exercises|"1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
214821614|NCT00364559|DRUG|Rosuvastatin|20 mg 10 days daily
214821615|NCT05710588|OTHER|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
214821616|NCT05710588|OTHER|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
214821617|NCT01376037|DEVICE|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
214821618|NCT01376037|DEVICE|inactive placebo laser device|non-therapeutic light application
214821619|NCT00004985|DRUG|Capravirine|
214821620|NCT00004985|DRUG|Nelfinavir mesylate|
214821621|NCT02328040|DRUG|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
214821622|NCT02328040|DRUG|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
214821623|NCT03199196|DEVICE|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
214821624|NCT03199196|DEVICE|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
214821625|NCT03199196|BEHAVIORAL|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
214821626|NCT03199196|BEHAVIORAL|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
214821627|NCT03199196|BEHAVIORAL|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
214821628|NCT03199196|BEHAVIORAL|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
214267494|NCT06707532|DRUG|Rocuronium|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~\- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v."
214267495|NCT06707480|DRUG|Taurolidine and Heparin|Catheter Lock Solution
214267496|NCT07045233|DEVICE|Sentinel® Cerebral Protection System|Deploy a Sentinel cerebral protection device during TAVR for patient with aortic stenosis.
214267497|NCT07045233|DIAGNOSTIC_TEST|MRI|Patients receive head MRI before and after the surgery in order to determine the stroke incidence.
214267498|NCT06733038|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at first infusion) day 1
214267499|NCT06733038|DRUG|Bevacizumab|5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
214267500|NCT06733038|DRUG|Irinotecan (CPT-11)|165 mg/sqm iv over 60 minutes day 1
214267501|NCT06733038|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
214267502|NCT06733038|DRUG|Leucovorin|200 mg/sqm iv over 2 hours day 1
214267503|NCT06733038|DRUG|Fluorouracil (5-FU)|3200 mg/sqm 48 h-continuous infusion, starting on day 1
214267504|NCT07041294|DEVICE|7 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (7 vs. 5 mm)
214267505|NCT07041294|DEVICE|5 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (5 vs. 7 mm)
214821629|NCT01278641|BEHAVIORAL|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
214821630|NCT01278641|BEHAVIORAL|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
214821631|NCT06556602|OTHER|MPACT|Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
214821632|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
214821633|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
214821634|NCT03567551|OTHER|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
214821635|NCT03567551|OTHER|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
214821636|NCT03567551|OTHER|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
214821637|NCT02878018|DRUG|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
214821638|NCT02878018|DRUG|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
214821639|NCT03135847|DEVICE|Tactor|The tactor is a small robot providing touch and vibration.
214821640|NCT03996837|OTHER|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
214821641|NCT03495011|DIAGNOSTIC_TEST|Breast MRI|Quantitative, multiparametric breast MRI
214821642|NCT03495011|OTHER|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
214821643|NCT01858168|DRUG|Olaparib|Tablets to be taken on an empty stomach twice a day.
214821644|NCT01858168|DRUG|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
214821645|NCT01858168|DRUG|Irinotecan|Administered via IV
214821646|NCT05679921|DRUG|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
214821647|NCT05642312|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
214821648|NCT05642312|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
214821649|NCT03047746|DEVICE|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
214267506|NCT07050121|DRUG|Ciwujia capsules|Ciwujia capsules for oral use，2-3 capsules per dose, three times daily. 28 days constitute one treatment course; efficacy and safety will be assessed over two courses. Dosage adjustments should follow the physician's instructions.
214267507|NCT07049978|OTHER|Observational follow-up of standard Dupilumab treatment|Patients undergoing Dupilumab treatment for N-ERD will be observed after three to four years of treatment to assess long term changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
214267508|NCT06285461|BEHAVIORAL|Non-palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.
214821650|NCT04726345|DRUG|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
214821651|NCT04726345|DRUG|Placebo|Placebo tablet to be taken orally once a day until stent removal.
214821652|NCT04588922|DRUG|SLS009|Solution for injection
214821653|NCT04588922|DRUG|venetoclax|Tablets
214821654|NCT04588922|DRUG|azacitidine|Solution for injection
214821655|NCT04516434|DEVICE|Neurometer Neurotron CPT|All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
214821656|NCT04516434|PROCEDURE|Cystometry|After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
214821657|NCT04516434|PROCEDURE|Pressure-flow study|A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
214821658|NCT00199758|DRUG|cisplatin|
214821659|NCT00199758|DRUG|Gemcitabine|
214821660|NCT00199758|DRUG|Taxol|
214821661|NCT06326437|OTHER|6-week dyadic intervention|Comprising 6 weekly 60-90min internet-based sessions.
214821662|NCT04120935|OTHER|Observation|Prospective Observation of standard clinical practice.
214821663|NCT05596435|OTHER|No intervention|No intervention
214821664|NCT03100422|DEVICE|ARMin|arm therapy robot
214821665|NCT03100422|OTHER|Occupational Therapy|bilateral arm training
214821666|NCT05519150|DIAGNOSTIC_TEST|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
214821667|NCT05519150|PROCEDURE|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
214821668|NCT05519150|OTHER|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
214821669|NCT05838703|DRUG|tiotropium bromide inhalation powder (Spiriva HandiHaler)|Spiriva HandiHaler is a COPD medication that is available for use.
214821670|NCT05838703|DRUG|tiotropium bromide (Spiriva Respimat)|Spiriva Respimat is a COPD medication that is available for use.
214821671|NCT05838703|DRUG|Hyperpolarized 129XeMRI|Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
214267509|NCT06285461|BEHAVIORAL|Palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
214267510|NCT07054073|OTHER|None - observational study|None - observational study
214267511|NCT07054814|DEVICE|samsung gear VR google|"do some of games based VR exercise Headmaster 3.0 Dream Match Tennis Beat Saber (PSVR) Knockout League Hoops Richie's Plank Experience Pong It VR Egg Time VR Sparc VR plus accelerated functional rehab protocol~General Principles:~Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
214821672|NCT06192303|DIAGNOSTIC_TEST|Bronchoalveolar lavage and pathogen metagenomic sequencing|After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.
214821673|NCT04207203|COMBINATION_PRODUCT|sodium zirconium cyclosilicate and healthy diet|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
214821674|NCT04972864|OTHER|Exercise training group|A regular advanced exercise program was given and followed.
214821675|NCT04972864|OTHER|Control training group|Basic exercises was given at the beginning and did the same exercises
214821676|NCT06560242|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
214821677|NCT01835860|PROCEDURE|Prostate artery embolization|
214821678|NCT01978730|DRUG|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
214821679|NCT01978730|DRUG|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
214821680|NCT01978730|DRUG|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
214821681|NCT04910425|DRUG|Fluorine F 18 DCFPyL|Given IV
214821682|NCT04910425|DRUG|Gadobenate Dimeglumine|Given IV
214821683|NCT04910425|DRUG|Gadobutrol|Given IV
214821684|NCT04910425|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214821685|NCT04910425|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214821686|NCT04910425|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214821687|NCT04910425|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
214821688|NCT02173834|OTHER|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
214821689|NCT02009774|PROCEDURE|NBI Function|
214821690|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after baseline up to 6 months
214821691|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
214821692|NCT03809130|OTHER|Quality-of-Life Assessment|Ancillary studies
214821693|NCT03809130|OTHER|Questionnaire Administration|Ancillary studies
214821694|NCT01959568|PROCEDURE|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
214821695|NCT03079466|OTHER|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
214821696|NCT06135857|DEVICE|Protocol ECOEMS|Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
214821697|NCT01095315|OTHER|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
214821698|NCT05278507|DEVICE|Arrowga+rd Blue Advance Protection PICC Placement|The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
214821699|NCT05278507|DEVICE|Sham Comparator PICC placement|The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
214821700|NCT05349435|DRUG|Fezagepras|Investigational drug
214821701|NCT05349435|DRUG|Sodium phenylbutyrate|Investigational drug
214821702|NCT04278560|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
214821703|NCT04278560|DEVICE|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
214821704|NCT04278560|BEHAVIORAL|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
214821705|NCT00702091|DRUG|Ramipril|10 mg capsule
214821706|NCT02832063|BIOLOGICAL|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
214821707|NCT02832063|BIOLOGICAL|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
214821708|NCT05445739|BEHAVIORAL|The effect of an online exercise course on the increase of elders' regular exercise intention|The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
214821709|NCT00186251|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
214821710|NCT01931722|DIETARY_SUPPLEMENT|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
214821711|NCT01931722|BEHAVIORAL|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
214821712|NCT01521481|OTHER|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
214821713|NCT01521481|OTHER|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
214821714|NCT06560697|RADIATION|SABR VS Intracavitary 3D Brachytherapy|Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
214821715|NCT02303405|DRUG|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
214821716|NCT02303405|DRUG|Pioglitazone|Anti-hyperglycemic agent
214821717|NCT01972386|DEVICE|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
214821718|NCT03789565|OTHER|Biomarker test|Diagnostic biomarker study
214821719|NCT02124135|BEHAVIORAL|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
214821720|NCT01867164|DRUG|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
214821721|NCT01867164|DRUG|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
214821722|NCT01880632|DRUG|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
214821723|NCT02674880|DRUG|HMW-HA|Aerolized administration b.i.d.
214821724|NCT02674880|OTHER|Placebo|Standard therapy
214821725|NCT00522262|BEHAVIORAL|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
214821726|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 \^ 9 CFU/mg
214821727|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 \^ 6 CFU/mg
214821728|NCT04988594|DIETARY_SUPPLEMENT|No culture|No probiotic cultures
214821729|NCT00601120|PROCEDURE|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
214821730|NCT04030091|DRUG|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
214821731|NCT04030091|DRUG|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
214821732|NCT06282874|DRUG|Lorlatinib|Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
214821733|NCT03086460|DRUG|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
214821734|NCT03086460|DRUG|Formoterol Inhalation Solution|Active Control
214821735|NCT03086460|DRUG|Placebo pMDI|Matched Placebo
214821736|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
214821737|NCT05827991|DRUG|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
214821738|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
214821739|NCT01137591|DRUG|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
214821740|NCT01137591|DRUG|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
214821741|NCT01314391|GENETIC|mutation analysis|
214821742|NCT01314391|GENETIC|polymerase chain reaction|
214821743|NCT01314391|OTHER|laboratory biomarker analysis|
214821744|NCT01831362|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|
214821745|NCT01831362|BEHAVIORAL|Focused Attention (FA)|
214821746|NCT01831362|BEHAVIORAL|Open- Monitoring|
214821747|NCT06272266|DEVICE|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
214821748|NCT06272266|DEVICE|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
214821749|NCT06272266|DEVICE|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
214821750|NCT06272266|DEVICE|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
214821751|NCT05315557|DRUG|Terlipressin|1mg/24 hour and titrate according to MAP
214821752|NCT05315557|DRUG|vasopressin|0.03 U/hour and titrate according to MAP
214821753|NCT05294471|DEVICE|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
214821754|NCT03625063|OTHER|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
214821755|NCT03625063|OTHER|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
214821756|NCT00996684|DRUG|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
214821757|NCT00996684|DRUG|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
214821758|NCT04169633|DIAGNOSTIC_TEST|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
214821759|NCT03266393|DRUG|Envarsus XR|Once daily sustained-release tacrolimus
214821760|NCT03266393|DRUG|Tacrolimus|Twice daily immediate-release tacrolimus
214821761|NCT05400694|OTHER|Food|Dairy products with reduced sugar content
214821762|NCT04252001|DEVICE|YESS! game|"The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish."
214267512|NCT07054814|OTHER|Traditional theraapy|"General Principles: accelerated functional rehab protocol Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
214267513|NCT07053202|COMBINATION_PRODUCT|Nivolumab|hepatic artery infusion therapy with nivolumab was performed
214821763|NCT04252001|DEVICE|Snake '97|Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
214821764|NCT04252001|OTHER|Transition-toolkit|The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
214821765|NCT00006468|DRUG|FOLFOX regimen|
214821766|NCT00006468|DRUG|fluorouracil|
214821767|NCT00006468|DRUG|leucovorin calcium|
214821768|NCT00006468|DRUG|oxaliplatin|
214821769|NCT05270135|BEHAVIORAL|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
214821770|NCT04048096|DIETARY_SUPPLEMENT|Krill Oil|Aker Biomarine Superba Krill Oil
214821771|NCT04048096|DIETARY_SUPPLEMENT|Placebo|Mixed vegetable oil
214821772|NCT06448221|BEHAVIORAL|a web-based Relationship Teaching(RT)/communication education programs|receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.
214821773|NCT06448221|BEHAVIORAL|Helper of Emotional Assessment Relationship Teaching (HEART) program|receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
214821774|NCT03600805|DRUG|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214821775|NCT03600805|DRUG|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214821776|NCT03600805|DRUG|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
214821777|NCT03600805|DRUG|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
214821778|NCT00256230|DRUG|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
214821779|NCT04985019|PROCEDURE|Arm I (Prepectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
214821780|NCT04985019|OTHER|Arm II (Subpectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
214821781|NCT04535388|DEVICE|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
214821782|NCT03057730|BIOLOGICAL|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
214821783|NCT01443195|DRUG|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
214821784|NCT04870320|BEHAVIORAL|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
214821785|NCT04870320|BEHAVIORAL|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
214821786|NCT04870320|OTHER|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
214821787|NCT04066088|OTHER|Placebo|Placebo will be administered same times as GXR
214821788|NCT04066088|DRUG|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
214821789|NCT01441297|DRUG|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
214821790|NCT06501222|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214821791|NCT00376493|DRUG|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
214821792|NCT06235723|DEVICE|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
214821793|NCT05646823|DIETARY_SUPPLEMENT|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
214821794|NCT05646823|DIETARY_SUPPLEMENT|Placebo|vehicle only - Maltodextrin gluten free
214821795|NCT05913128|PROCEDURE|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
214821796|NCT02855853|OTHER|serious game et virtual reality|
214821797|NCT02855853|OTHER|Nintendo Wii|
214821798|NCT02663921|OTHER|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure."
214821799|NCT02663921|OTHER|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry"
214821800|NCT06619184|PROCEDURE|NCEHFORSCS transplantation|One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
214821801|NCT06619184|PROCEDURE|MPG procedure|"Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match"
214821802|NCT03168126|DEVICE|Pro-AQT|Use of the device for advanced hemodynamic monitoring
214821803|NCT04367766|PROCEDURE|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
214821804|NCT03631628|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
214821805|NCT03631628|BEHAVIORAL|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
214821806|NCT03631628|BEHAVIORAL|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
214821807|NCT03631628|BEHAVIORAL|Conventional Rehabilitation Program|Standardized upper limb training
214821808|NCT03886129|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
214821809|NCT02247791|PROCEDURE|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
214821810|NCT02247791|PROCEDURE|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
214821811|NCT01619904|PROCEDURE|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
214821812|NCT01619904|PROCEDURE|Standard Therapy|Following standard protocol during peri-operative period
214821813|NCT04581304|DEVICE|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
214821814|NCT04581304|DEVICE|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
214821815|NCT01847495|DRUG|Irinotecan|40mg/m2 x 3-5 days
214821816|NCT01847495|RADIATION|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
214821817|NCT04715295|DRUG|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
214821818|NCT04715295|DRUG|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
214821819|NCT04715295|COMBINATION_PRODUCT|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
214821820|NCT02718963|DEVICE|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214267514|NCT07053202|PROCEDURE|Transarterial Chemoembolization (TACE)|Seldinger technique for femoral artery puncture. Catheterization to celiac trunk/hepatic artery. Infusion of a mixture of idarubicin, raltitrexed, iodized oil, and contrast agent (approx. 8 mL). Embolization with microspheres (300-500 μm and 500-700 μm).
214821821|NCT02188563|OTHER|Comprehensive smoking cessation intervention|
214821822|NCT02188563|BEHAVIORAL|Enhanced usual care|
214821823|NCT03541538|DEVICE|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
214821824|NCT03541538|DEVICE|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
214821825|NCT05305690|OTHER|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
214821826|NCT00258024|DRUG|IPT-sulphadoxinepyrimethamine|
214821827|NCT05150041|DEVICE|Guardian connect|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
214821828|NCT05150041|DEVICE|iPro2|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
214821829|NCT03415308|OTHER|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
214821830|NCT03415308|OTHER|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
214821831|NCT03415308|OTHER|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
214821832|NCT05946486|DRUG|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
214821833|NCT00932841|OTHER|Placebo|One packet PO daily x 8 weeks.
214821834|NCT00932841|DRUG|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
214821835|NCT00932841|DRUG|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
214821836|NCT00447941|DRUG|SCA-136|
214821837|NCT05608642|OTHER|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
214821838|NCT05608642|OTHER|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
214267515|NCT07054203|DEVICE|Water Flosser|Participants in this Arm used a powered oral irrigator delivering a pulsed water stream at 50-90 psi. The intervention consisted of once-daily full-mouth irrigation, added to routine tooth brushing, for a duration of six months.
214821839|NCT05608642|OTHER|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
214821840|NCT04057287|OTHER|No intervention|No intervention
214821841|NCT02601963|DRUG|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
214821842|NCT02601963|DRUG|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
214821843|NCT02601963|DRUG|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
214821844|NCT02342535|BEHAVIORAL|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
214821845|NCT02036788|OTHER|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
214821846|NCT02036788|OTHER|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
214821847|NCT00620893|DRUG|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
214821848|NCT00620893|DRUG|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
214267516|NCT07054203|DEVICE|Interdental Brush|Participants in this Arm used cylindrical, color-coded interdental brushes matched to individual embrasure sizes. The intervention involved once-daily cleaning of all interproximal spaces for six months, in addition to routine twice-daily tooth brushing.
214267517|NCT07054346|DRUG|177 Lutetium Prostate-Specific Membrane Antigen 617|Given intravenously (IV) or intra-arterially (IA)
214267518|NCT07054346|DRUG|Actinium-225 Prostate-Specific Membrane Antigen 617|Given IV or IA
214267519|NCT07054346|PROCEDURE|Non-investigational, Prostatectomy|Undergo non-investigational surgical procedure to remove prostate.
214267520|NCT07054346|PROCEDURE|Prostate Tissue Collection|Whole prostate tissue will be collected for correlative research at time of prostatectomy.
214267521|NCT07054346|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Imaging procedure
214267522|NCT07054346|PROCEDURE|Blood Sample Collection|Blood samples will be obtained for research purposes
214267523|NCT07055243|DRUG|Mitapivat|Mitapivat will be given to adult patients with erythrocyte membranopathies
214821849|NCT01471353|DRUG|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
214821850|NCT00836472|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
214821851|NCT00836472|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
214821852|NCT02804724|OTHER|No intervention|
214821853|NCT04733755|DIETARY_SUPPLEMENT|Beauty Image|1.97g/package; 2 packages one day for 8 weeks
214821854|NCT04733755|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
214821855|NCT01695239|DRUG|Ixekizumab|Administered SC
214821856|NCT01695239|DRUG|Placebo|Administered SC
214821857|NCT01695239|DRUG|Adalimumab|Administered SC
214821858|NCT00538239|DRUG|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
214821859|NCT00538239|DRUG|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
214821860|NCT02007863|PROCEDURE|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
214821861|NCT02007863|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
214821862|NCT02007863|DRUG|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
214821863|NCT02007863|DRUG|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
214821864|NCT03781102|BEHAVIORAL|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
214821865|NCT01843179|DRUG|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
214821866|NCT01843179|DRUG|Sulindac|Taken orally twice per day at home for 12 months
214821867|NCT03881943|DRUG|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
214267524|NCT07053501|DEVICE|Urinary Catheter Carrying Bag Use|A wearable catheter carrying bag was provided to participants. It was designed to conceal the urine bag and increase comfort, privacy, and psychosocial well-being. Participants received training on its use and wore it during all daily activities for 21 days.
214267525|NCT07054567|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214821868|NCT03881943|DRUG|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
214821869|NCT06627543|DIAGNOSTIC_TEST|echo|echocardiographic
214821870|NCT03134664|PROCEDURE|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
214821871|NCT03134664|PROCEDURE|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
214821872|NCT04670107|DRUG|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
214821873|NCT00988715|BIOLOGICAL|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
214821874|NCT00988715|DRUG|Cyclosporine|Given IV
214821875|NCT00988715|DRUG|Mycophenolate Mofetil|Given PO
214267526|NCT07054567|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
214267527|NCT07054567|DRUG|Bevacizumab|Administration for a cycle of 3 weeks.
214821876|NCT00988715|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
214821877|NCT00988715|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
214821878|NCT00988715|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
214821879|NCT00988715|DRUG|Fludarabine Phosphate|Given IV
214821880|NCT00988715|OTHER|Pharmacological Study|Correlative studies
214821881|NCT00988715|OTHER|Laboratory Biomarker Analysis|Correlative studies
214821882|NCT03146156|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
214821883|NCT01834183|DRUG|Tivozanib|
214821884|NCT01834183|DRUG|Gemcitabine|
214821885|NCT01022983|DRUG|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
214821886|NCT01022983|DRUG|Placebo|ml/kg/hours - same infusion rate as active comparator
214821887|NCT03502811|DEVICE|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
214821888|NCT06331715|DRUG|Palbociclib 125mg|Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products
214821889|NCT00694187|DRUG|Zaleplon|
214821890|NCT03333551|DRUG|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
214821891|NCT04353362|DRUG|Ofloxacin|400 mg, 1 time per day for 5 days
214821892|NCT04353362|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
214821893|NCT04353362|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
214821894|NCT01735994|BEHAVIORAL|Healthy Weight|Eating Disorder Prevention Program for Athletes
214821895|NCT01735994|OTHER|Brochure|Brochure on the Female athlete triad
214821896|NCT00767260|DRUG|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
214821897|NCT00767260|DRUG|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
214821898|NCT00767260|DEVICE|HOT|Hyperbaric Oxygen Therapy
214821899|NCT00767260|DRUG|SMT|hypoglycemic drugs or exogenous insulin
214821900|NCT03168763|BEHAVIORAL|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
214821901|NCT03168763|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
214821902|NCT03166267|DEVICE|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
214821903|NCT00735540|OTHER|Observational|Data summary only
214821904|NCT00078039|DRUG|Paliperidone ER|
214821905|NCT02173886|DRUG|Bupropion SR and XL|
214821906|NCT04472039|DEVICE|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
214821907|NCT05239195|OTHER|Video Laryngoscope|Laryngoscope with a camera and a video screen
214821908|NCT05239195|OTHER|Direct Laryngoscope|Laryngoscope without a camera or a video screen
214821909|NCT03850158|DRUG|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
214821910|NCT01934816|OTHER|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
214821911|NCT04425941|OTHER|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
214821912|NCT06626841|DIAGNOSTIC_TEST|Pelvic floor muscles contractile capacity and activation|"An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis)."
214821913|NCT05502835|DEVICE|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
214821914|NCT05502835|OTHER|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
214821915|NCT00069758|DRUG|SDX-105|
214821916|NCT03922763|PROCEDURE|Anatomical cut|Surgeon-derived cut based on patient's anatomy
214821917|NCT03922763|PROCEDURE|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
214821918|NCT03170219|COMBINATION_PRODUCT|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
214821919|NCT03979664|DEVICE|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
214821920|NCT03979664|DEVICE|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
214821921|NCT03979664|DRUG|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
214821922|NCT03552484|BEHAVIORAL|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
214821923|NCT03552484|BEHAVIORAL|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
214821924|NCT01654484|DRUG|DE-117|Ophthalmic Solution, QD, 28 Days
214821925|NCT01654484|DRUG|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
214821926|NCT01654484|DRUG|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
214821927|NCT01654484|DRUG|Placebo|Ophthalmic Solution, QD, 28 days
214821928|NCT05636254|DIAGNOSTIC_TEST|MRI Brain and spine|"* MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)"
214821929|NCT05636254|DIAGNOSTIC_TEST|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
214821930|NCT05146076|OTHER|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
214821931|NCT05146076|OTHER|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
214821932|NCT06430632|DEVICE|Robotic Gait Training|Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
214821933|NCT06430632|OTHER|Usual Care Gait Training|Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
214821934|NCT05959187|DIAGNOSTIC_TEST|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
214821935|NCT02248051|DRUG|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
214821936|NCT03280953|DIAGNOSTIC_TEST|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
214821937|NCT00261391|DRUG|Marimastat|
214821938|NCT03570060|BIOLOGICAL|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
214821939|NCT03570060|PROCEDURE|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
214821940|NCT03570060|PROCEDURE|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
214821941|NCT06443385|BEHAVIORAL|PDMP Legal Mandate E-mail|E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
214821942|NCT06443385|BEHAVIORAL|PDMP Clinical Benefit E-mail|E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
214821943|NCT02726360|BEHAVIORAL|survey|The ILR Scale, a non-English language proficiency self-assessment.
214821944|NCT02726360|BEHAVIORAL|Audio record|Audio record the initial visits between patients and their treating physician
214821945|NCT05891522|PROCEDURE|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
214821946|NCT05891522|PROCEDURE|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
214821947|NCT01411462|DEVICE|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
214821948|NCT03416673|PROCEDURE|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
214821949|NCT03416673|PROCEDURE|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
214821950|NCT04808362|BIOLOGICAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
214821951|NCT00062296|BIOLOGICAL|rituximab|
214821952|NCT00062296|DRUG|epirubicin hydrochloride|
214821953|NCT03256396|PROCEDURE|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
214821954|NCT03264092|PROCEDURE|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
214821955|NCT00253838|PROCEDURE|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
214821956|NCT00253838|PROCEDURE|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
214821957|NCT00429221|BEHAVIORAL|Tailored Medication Messages for Parents|
214821958|NCT04162899|DRUG|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
214821959|NCT01105299|DRUG|CJ anastrozole 1 mg tablet|
214821960|NCT06627023|DEVICE|Implant Placement with Conical or Butt-Joint Connection|Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
214821961|NCT04492696|OTHER|Education|Education
214821962|NCT04982523|BEHAVIORAL|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
214821963|NCT04145635|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
214821964|NCT02663349|BEHAVIORAL|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
214821965|NCT04943549|DRUG|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
214821966|NCT02538549|BEHAVIORAL|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
214821967|NCT00943033|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
214821968|NCT06248294|DIAGNOSTIC_TEST|CT follow-up|Computed tomography angiography assessment of BAV-related aorthopathy
214821969|NCT05391594|DEVICE|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
214821970|NCT04865471|PROCEDURE|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
214821971|NCT05882526|DEVICE|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
214821972|NCT00785135|DEVICE|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
214821973|NCT00785135|DEVICE|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
214821974|NCT05634941|DEVICE|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
214821975|NCT05634941|DEVICE|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
214821976|NCT01452035|OTHER|Exercise|single session of exercise
214821977|NCT02847624|DRUG|tolvaptan|
214821978|NCT04280224|BIOLOGICAL|NK Cells|twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
214821979|NCT04877093|DRUG|Clonidine Pill|The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
214821980|NCT04877093|OTHER|Placebo|Blinded placebo capsules will be provided to participants.
214821981|NCT05173246|DRUG|JS001|JS001 240mg, ivdrip, d1, Q3w
214821982|NCT05173246|DRUG|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
214821983|NCT05173246|DRUG|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
214821984|NCT05173246|DRUG|Carboplatin|Carboplatin AUC 5,d1,Q3w
214821985|NCT06219980|COMBINATION_PRODUCT|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
214821986|NCT06802471|DEVICE|electroacupuncture|"The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device.~The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40.~Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6.~The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm, Φ0.30×50mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
214821987|NCT06802471|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable non-insertive sham control needles (Φ0.3mm×40mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
214821988|NCT05639933|DRUG|HT-001 2% Topical Gel|Topical gel, 2% active
214821989|NCT05639933|DRUG|HT-001 1% Topical Gel|Topical gel, 1% active
214821990|NCT05639933|DRUG|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
214821991|NCT05639933|DRUG|HT-001 Placebo|Topical gel, vehicle gel
214821992|NCT01561807|DRUG|VX-787|
214821993|NCT01561807|DRUG|Placebo|
214821994|NCT06517979|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
214821995|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
214821996|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
214821997|NCT01110473|DRUG|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
214821998|NCT01110473|DRUG|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
214821999|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
214822000|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
214822001|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
214822002|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
214822003|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
214822004|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
214822005|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
214656221|NCT03652922|DRUG|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
214822006|NCT02993380|DIETARY_SUPPLEMENT|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
214822007|NCT02993380|DIETARY_SUPPLEMENT|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
214822008|NCT03382925|PROCEDURE|cervical interlaminar with lidocaine|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.
214822009|NCT03382925|PROCEDURE|cervical interlaminar with normal saline|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
214822010|NCT03382925|DRUG|Lidocaine|2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
214822011|NCT03382925|DRUG|Triamcinolone Acetonide|2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
214822012|NCT03382925|DRUG|Normal saline|2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
214822013|NCT03128723|DEVICE|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
214822014|NCT03158467|OTHER|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
214822015|NCT04069286|DRUG|Oral Aroeira|Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.
214822016|NCT04069286|DRUG|Omeprazole 20Mg Capsule|Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
214822017|NCT00804180|BEHAVIORAL|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
214822018|NCT03059615|DRUG|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
214656222|NCT02633176|DRUG|Cetuximab|400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
214822019|NCT03059615|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
214822020|NCT05836545|DRUG|Remimazolam|The patient with remimazolam
214822021|NCT05836545|DRUG|Midazolam|The patient with midazolam
214822022|NCT05180253|DIAGNOSTIC_TEST|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
214822023|NCT04030286|OTHER|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
214822024|NCT00673660|BEHAVIORAL|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
214822025|NCT03829397|DIAGNOSTIC_TEST|Questionnaire|Questionnaire
214822026|NCT02957994|DRUG|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
214267528|NCT07055100|DIAGNOSTIC_TEST|Needle stick injuries|A descriptive cross-sectional study design will be employed, and data will be collected from all staff working in the trauma center through census sampling. A structured questionnaire will capture demographic data, occupational risk factors, and KAP regarding bloodborne pathogens. Blood samples will be collected to screen for HBV, HCV, and HIV infections.
214822027|NCT01674491|DIETARY_SUPPLEMENT|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
214822028|NCT01269086|BEHAVIORAL|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
214822029|NCT05235386|DEVICE|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
214822030|NCT02924363|DIAGNOSTIC_TEST|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
214822031|NCT02924363|DIAGNOSTIC_TEST|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
214822032|NCT00211263|BEHAVIORAL|Enhanced Clinical Intervention|
214822033|NCT00211263|DRUG|mood stabilizer|
214822034|NCT01383486|DRUG|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
214822035|NCT01383486|DRUG|Advil|Commercially available Advil; oral caplet upon incidence of pain
214822036|NCT06223763|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
214822037|NCT06223763|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
214822038|NCT06223763|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
214822039|NCT01342263|BEHAVIORAL|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
214822040|NCT02437747|DRUG|SRP + Aloe|Scaling and root planing along with aloe vera application was done
214267529|NCT05870189|BEHAVIORAL|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
214267530|NCT05870189|BEHAVIORAL|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
214267531|NCT06403228|OTHER|Mindfulness Based Structured Nursing Interventions|In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
214267532|NCT03989414|DRUG|CC-92480|Specified dose on specified days
214267533|NCT03989414|DRUG|Bortezomib|Specified dose on specified days
214267534|NCT03989414|DRUG|Dexamethasone|Specified dose on specified days
214267535|NCT03989414|DRUG|Daratumumab|Specified dose on specified days
214267536|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
214267537|NCT03989414|DRUG|Elotuzumab|Specified dose on specified days
214267538|NCT03989414|DRUG|Isatuximab|Specified dose on specified days
214267539|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
214267540|NCT00014937|DRUG|lopinavir/ritonavir|
214267541|NCT00014937|DRUG|lamivudine/zidovudine|
214267542|NCT00014937|DRUG|efavirenz|
214267543|NCT00014937|DRUG|lamivudine|
214822041|NCT02437747|PROCEDURE|SRP|Scaling and root planing was done
214822042|NCT03917147|PROCEDURE|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
214822043|NCT02297763|DRUG|quetiapine|"patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
214822044|NCT02297763|DRUG|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
214822045|NCT02471820|DRUG|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
214822046|NCT02471820|DRUG|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
214822047|NCT02471820|DRUG|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
214822048|NCT01986491|DRUG|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
214822049|NCT01986491|DRUG|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
214822050|NCT01986491|DRUG|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
214822051|NCT01986491|DRUG|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
214822052|NCT01986491|DRUG|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
214822053|NCT01526174|DRUG|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
214822054|NCT01857167|DIETARY_SUPPLEMENT|Fish Oil Supplementation|
214822055|NCT01857167|DIETARY_SUPPLEMENT|Flaxseed Oil Supplementation|
214822056|NCT01857167|DIETARY_SUPPLEMENT|placebo|
214822057|NCT04553146|PROCEDURE|Immediate implantation in posterior region with alveolar ridge preservation combined with sealing socket abutment|Twenty BLXⓇ Straumann immediate implants were placed flapless. The gap around the implant was filled with xenogeneic biomaterial. An intra-oral scanner was performed and sent to the dental laboratory to digitally design a customized healing abutment. The abutment was then milled from a block of PEEK and placed a couple of hours later in the clinic. Three months after implantation, the abutment was removed and the final monolithic crown based on the initial IOS was placed. The transmucosal design from the SSA was replicated on the final crown.
214822058|NCT04742686|OTHER|Aerobic exercise training|5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
214822059|NCT01259791|DRUG|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
214822060|NCT01259791|DRUG|Placebo|Placebo
214822061|NCT00084526|PROCEDURE|computed tomography|
214822062|NCT00084526|PROCEDURE|ultrasound imaging|
214822063|NCT02458625|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|
214822064|NCT02458625|DIETARY_SUPPLEMENT|Iron bisglycinate 60 mg|
214822065|NCT00109265|DRUG|Erlotinib HCl (OSI-774)|
214822066|NCT04726163|DEVICE|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
214822067|NCT02778321|DEVICE|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
214822068|NCT04244877|DRUG|Rifaximin|Drug: Rifaximin tablet
214822069|NCT05379647|DRUG|QN-019a|Experimental Interventional Therapy
214822070|NCT05379647|DRUG|Rituximab|Monoclonal Antibody
214822071|NCT05379647|DRUG|Cyclophosphamid|Lympho-conditioning Agent
214822072|NCT05379647|DRUG|Fludarabine|Lympho-conditioning Agent
214822073|NCT05379647|DRUG|VP-16|Lympho-conditioning Agent
214822074|NCT03998605|BEHAVIORAL|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
214822075|NCT03998605|BEHAVIORAL|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
214822076|NCT00952939|GENETIC|fluorescence in situ hybridization|At time of surgery
214822077|NCT00952939|OTHER|laboratory biomarker analysis|At time of surgery
214822078|NCT00952939|PROCEDURE|fine-needle aspiration|At time of surgery
214822079|NCT00952939|PROCEDURE|therapeutic conventional surgery|At time of surgery
214822080|NCT00952939|OTHER|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
214822081|NCT01694212|DRUG|Perioperative Diclofenac eye-drops administration|
214822082|NCT01694212|DRUG|placebo|
214267544|NCT00014937|DRUG|stavudine|
214267545|NCT00014937|DRUG|zidovudine|
214267546|NCT00014937|DRUG|didanosine|
214267547|NCT02280538|DEVICE|Intra-Articular Hyaluronic Acid|
214822083|NCT04936581|PROCEDURE|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
214267548|NCT02280538|DEVICE|Placebo|
214267549|NCT04639700|BEHAVIORAL|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
214267550|NCT06227546|DRUG|MGC018|Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle
214822084|NCT04936581|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
214822085|NCT04936581|PROCEDURE|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
214822086|NCT04936581|PROCEDURE|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
214656223|NCT02633176|DRUG|Cisplatin|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
214656224|NCT02633176|DRUG|Docetaxel|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
214656225|NCT02633176|DRUG|Capecitabine|1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
214656226|NCT02633176|RADIATION|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
214656227|NCT06003062|DRUG|Narcissus Tazetta Bulb Extract and Novel Hemp Extract|Topical nightly application of phytonutraceutical
214656228|NCT02604004|DRUG|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
214656229|NCT02604004|DRUG|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
214656230|NCT02747485|DEVICE|Cardiac MRI|
214656231|NCT02747485|BIOLOGICAL|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
214656232|NCT02747485|PROCEDURE|myocardial biopsy|
214656233|NCT02747485|GENETIC|blood samples|extract DNA to look for genomic mutations associated with the disease.
214656234|NCT00646893|PROCEDURE|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
214656235|NCT00242918|DRUG|docetaxel|
214656236|NCT00242918|DRUG|ZD1839|
214656237|NCT00825604|PROCEDURE|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
214656238|NCT05288712|OTHER|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
214656239|NCT05288712|OTHER|Conventional training protocol|Conventional training protocol
214656240|NCT02965378|DRUG|Docetaxel|Given IV
214656241|NCT02965378|DRUG|FGFR Inhibitor AZD4547|Given PO
214656242|NCT02965378|OTHER|Laboratory Biomarker Analysis|Correlative studies
214656243|NCT05837754|OTHER|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
214656244|NCT05837754|OTHER|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
214656245|NCT02536586|DRUG|LY3023414|LY3023414 administered orally.
214656246|NCT02867631|BEHAVIORAL|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
214656247|NCT04552470|DRUG|Placebo|3 matching placebo tablets taken twice a day (BID)
214656248|NCT04552470|DRUG|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
214656249|NCT05943730|DEVICE|Seismofit|The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
214656250|NCT03931018|OTHER|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
214656251|NCT00902629|PROCEDURE|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
214656252|NCT00058461|DRUG|ifosfamide|Given IV
214656253|NCT00058461|DRUG|etoposide|Given IV
214656254|NCT00058461|BIOLOGICAL|rituximab|Given IV
214656255|NCT00058461|DRUG|carboplatin|Given IV
214656256|NCT00058461|BIOLOGICAL|filgrastim|Given SC
214656257|NCT00058461|DRUG|methotrexate|Given IT
214656258|NCT00058461|DRUG|cytarabine|Given IT
214656259|NCT00058461|OTHER|laboratory biomarker analysis|Correlative studies
214656260|NCT02769598|DEVICE|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
214656261|NCT00073190|BEHAVIORAL|Osteoporosis Education|
214656262|NCT05747989|PROCEDURE|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
214656263|NCT05747989|PROCEDURE|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
214656264|NCT03778489|OTHER|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
214656265|NCT03634982|DRUG|RMC-4630|RMC-4630 for oral administration
214656266|NCT06278623|DEVICE|Focal Muscle Vibratory Energy (EVM) Treatment|"The patients involved in the study will undergo muscle vibratory stimulation in association with conventional rehabilitation treatment three times a week, for three weeks for a total duration of 9 sessions in association with conventional treatment.~The vibration will be applied at a frequency of 100 Hz and an amplitude of 0.2 cm for 30 minutes (three sessions of 10 min each with 1 min break in between) three times a week for three weeks at the level of the quadriceps femoris and triceps surae bilaterally for balance improvement and stimulation of proprioception and in the trapezius and trunk extensor muscles bilaterally for pain relief."
214656267|NCT00024687|DRUG|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
214656268|NCT00629083|DEVICE|Bulkamid|Bulking injection with Bulkamid injection device
214656269|NCT00629083|DEVICE|Contigen|Transurethral bulking injection
214656270|NCT00223340|BEHAVIORAL|Patient Activation and Diabetes Registry|
214822087|NCT02586935|DRUG|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
214822088|NCT02586935|OTHER|Placebo|Administered orally after dispersion in approximately 100 ml of water
214822089|NCT00064038|DRUG|dexamethasone|Given orally
214822090|NCT00064038|DRUG|lenalidomide|Given orally
214822091|NCT00064038|OTHER|placebo|Given orally
214822092|NCT06603532|OTHER|low-load blood flow restriction (BFR) training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
214822093|NCT06603532|OTHER|low-load resistance training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
214822094|NCT02349763|DRUG|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
214822095|NCT02349763|DRUG|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
214822096|NCT03359863|DRUG|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
214822097|NCT01608360|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
214822098|NCT01608360|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
214822099|NCT04661007|DRUG|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
214822100|NCT04661007|DRUG|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
214822101|NCT04661007|DRUG|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
214822102|NCT04661007|DRUG|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
214822103|NCT01747174|DRUG|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
214822104|NCT01747174|DRUG|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
214822105|NCT01747174|PROCEDURE|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
214822106|NCT03986294|DRUG|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
214822107|NCT03986294|DRUG|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
214822108|NCT01875562|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
214822109|NCT02825680|OTHER|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
214822110|NCT02825680|OTHER|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
214822111|NCT04075578|DRUG|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
214822112|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
214822113|NCT06219317|DRUG|Placebo|standard saline solution
214822114|NCT04258735|DIAGNOSTIC_TEST|Genomic analysis|WES, RNASeq, ctDNA, Exosome
214822115|NCT02805166|DRUG|PEG-rhG-CSF|
214822116|NCT00284791|DRUG|Lamotrigine (drug)|
214822117|NCT00284791|DRUG|Fluoxetine (drug)|
214822118|NCT00284791|DRUG|sertraline (drug)|
214822119|NCT06106958|BEHAVIORAL|Home Exercise Program|"Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily."
214822120|NCT06106958|BEHAVIORAL|Minimalist Shoes|"Participants will receive a pair of minimalist shoes. They will wear them for an allotted amount of time per day each week, in order to allow for a slow adjustment into the shoes. The protocol is as follows:~* Week 1: 1 hour per day~* Week 2: 2 hours per day~* Week 3: 4 hours per day~* Week 4: 6 hours per day~* Week 5: 8 hours per day~* Week 6: 8 hours per day~* Week 7: 8 hours per day~* Week 8: 8 hours per day"
214822121|NCT01978925|OTHER|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
214822122|NCT00393276|BIOLOGICAL|Twinrix|Combined hepatitis A and hepatitis B immunization
214822123|NCT00393276|BIOLOGICAL|Decavac|Diphtheria and tetanus toxoid vaccine
214822124|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
214822125|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
214822126|NCT00563264|BEHAVIORAL|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
214822127|NCT04673721|DIETARY_SUPPLEMENT|Fortified eggs|Average 12 eggs consumed per week
214822128|NCT04673721|BEHAVIORAL|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
214822129|NCT04673721|DIETARY_SUPPLEMENT|Non-egg supplemented|2 or less eggs consumed per week
214822130|NCT04673721|BEHAVIORAL|Usual care diet|Consistency with current diet without consideration of intermittent fasting
214822131|NCT06030583|OTHER|Scales and Forms|This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
214822132|NCT06177418|PROCEDURE|Transumbilical laparoscopic appendectomy + Glove finger technique|Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.
214822133|NCT06177418|PROCEDURE|Standard transumbilical laparoscopic appendectomy|Standart transumbilical laparoscopic appendectomy
214822134|NCT06560853|OTHER|Comprehensive School Health Programme|"Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic."
214822135|NCT06560853|OTHER|Deworming and vitamin A supplementation delivery|Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
214822136|NCT01908556|DRUG|Letrozole|
214822137|NCT05790824|OTHER|Spa therapy|"The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~* 54 treatments among the following treatments:~  * Swimming pool, 15 minutes (code 201)~ * Bath with aerobath, 10 minutes (code 205)~ * Bath with immersion shower, 10 minutes (code 206)~ * Cataplasm in multiple local application, 10 minutes (code 408)~* 18 sessions of mobilization pool, 15 minutes (code 601)"
214822138|NCT01924377|PROCEDURE|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
214822139|NCT01924377|PROCEDURE|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
214822140|NCT04137575|BEHAVIORAL|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
214822141|NCT04137575|BEHAVIORAL|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
214822142|NCT01655654|BEHAVIORAL|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
214822143|NCT01655654|BEHAVIORAL|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
214822144|NCT01655654|OTHER|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
214822145|NCT00426621|DRUG|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
214822146|NCT00426621|DRUG|Placebo|4 grams per knee, 4 times per day, for 12 weeks
214822147|NCT06524921|PROCEDURE|dental pulpectomy using metapex|Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
214822148|NCT06524921|PROCEDURE|dental pulpectomy using biodentine|Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
214822149|NCT03612440|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
214822150|NCT03612440|OTHER|normal saline|receive matching placebo (equal volum of normal saline)
214822151|NCT03904329|DRUG|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
214822152|NCT06970028|OTHER|Quantitative Sensory Testing|We will perform QST on the dominant hand and lower back.
214822153|NCT06970028|OTHER|Questionnaires regarding pain and quality of life|Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.
214822154|NCT03435835|DEVICE|Control/Sham Treatment|Water at 33ºC was circulated through water-circulating trousers.
214822155|NCT03435835|DEVICE|Heat Therapy (HT)|Water at 42-43ºC was circulated through the water-circulating trousers.
214822156|NCT00179231|DRUG|olanzapine vs. clozapine|
214822157|NCT04793607|OTHER|Pleural procedures|Any pleural procedure that removes fluid
214822158|NCT02278757|OTHER|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
214822159|NCT02278757|OTHER|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
214822160|NCT05912127|DEVICE|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
214822161|NCT02314403|DRUG|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
214822162|NCT02314403|DRUG|ATG|A T-Cell Depleting Agent
214822163|NCT02314403|DRUG|Rituximab|B-Cell Depleting Agent
214822164|NCT02314403|RADIATION|Total Body Irradiation|
214822165|NCT02314403|RADIATION|Thymic Irradiation|
214822166|NCT02314403|PROCEDURE|Combined Bone Marrow/Kidney Transplantation|
214822167|NCT01929863|DRUG|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]
214822168|NCT01929863|DRUG|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
214822169|NCT01929863|DRUG|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
214822170|NCT00532090|DRUG|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
214822171|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
214822172|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
214822173|NCT05644743|DEVICE|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
214822174|NCT06559514|BEHAVIORAL|Group-based multi-component psychoeducational inventions (GMC-PEIs)|The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
214822175|NCT01734265|DRUG|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
214822176|NCT01734265|DRUG|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
214822177|NCT05545826|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
214656271|NCT04288245|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
214656272|NCT04288245|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
214656273|NCT02909153|DRUG|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
214656274|NCT05465135|DRUG|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
214656275|NCT00534534|BEHAVIORAL|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
214656276|NCT01193686|OTHER|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
214656277|NCT02515513|PROCEDURE|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
214656278|NCT04401059|DRUG|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
214656279|NCT04401059|DRUG|First or third generation EGFR-TKIs|refer to the drug label.
214656280|NCT06294600|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
214656281|NCT06294600|DRUG|Tablets|Oral tablets of similar appearance to active study drug
214656282|NCT01147809|DRUG|Eltrombopag olamine|thrombopoietin receptor agonist
214656283|NCT01147809|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
214656284|NCT01495026|DRUG|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
214656285|NCT01495026|DRUG|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
214656286|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
214656287|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
214656288|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
214656289|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
214656290|NCT01495026|DRUG|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
214656291|NCT01495026|DRUG|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
214656292|NCT01495026|DRUG|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
214656293|NCT01307423|DRUG|Apremilast 20mg|Apremilast 20mg twice daily, orally
214656294|NCT01307423|DRUG|Apremilast 30mg|Apremilast 30mg twice daily, orally
214656295|NCT01307423|DRUG|Placebo|Placebo
214656296|NCT01993472|DRUG|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
214656297|NCT01993472|DRUG|Capecitabine|
214656298|NCT00794287|OTHER|Taking blood samples|No intervention is done. Only blood samples are taken.
214656299|NCT03112811|DEVICE|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
214656300|NCT03112811|DEVICE|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
214656301|NCT01482702|BEHAVIORAL|weight loss intervention|Behavioral weight loss intervention
214656302|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
214656303|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
214656304|NCT03860506|DRUG|PSI-697|
214656305|NCT03860506|DRUG|Placebo|
214656306|NCT04318574|OTHER|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
214656307|NCT03075839|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
214656308|NCT04748029|OTHER|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
214656309|NCT06027801|OTHER|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
214656310|NCT06027801|BIOLOGICAL|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
214656311|NCT06027801|BIOLOGICAL|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
214822178|NCT06451783|OTHER|Traditional Chinese medicine combined with manipulation treatment|"The specific procedure involves administering the Shengyu Decoction, which consists of the following herbs:~* Shu Di Huang 20 grams~* Bai Shao 15 grams~* Dang Gui 15 grams~* Chuan Xiong 8 grams~* Ren Shen 20 grams~* Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks. Add manipulation of massage：~  * Press and grasp the affected limb three times；~    * Five-finger five-acupoint pressing method；~      * Point pressing on Zusanli (ST36) and Sanyinjiao (SP6)；~        * grasp the interior method to treat the calf three times；~          ⑤ Apply rolling technique around the knee joint；~          ⑥ Knead and straighten the standing tendon (the lateral muscle of the calf)；~          ⑦ Six-finger six-acupoint pressing method；~          ⑧ Push and pull the patella to flex and extend the knee joint；~          ⑨ Knee joint reunion and smooth dispersion method."
214822179|NCT06451783|DRUG|Celecoxib capsule|Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
214822180|NCT02692547|DEVICE|Hybrid-logic closed loop system|All patients get to wear the pump
214822181|NCT06290284|PROCEDURE|Long Peripheral Catheter|PowerGlide Pro™ Midline Catheter
214822182|NCT06290284|PROCEDURE|Peripheral Intra-Venous Catheter|Venflon™ Pro Safety Needle Protected IntraVenous Cannula
214822183|NCT00772161|DRUG|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
214822184|NCT00323882|DRUG|MDX-010|selected dose administered IV every 3 weeks
214822185|NCT02120547|DRUG|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
214822186|NCT02120547|DRUG|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
214822187|NCT02882945|OTHER|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
214822188|NCT02882945|OTHER|Group B|200 cases of type 2 DM without complications were enrolled in the study.
214822189|NCT02882945|OTHER|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
214822190|NCT01469351|DRUG|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
214822191|NCT01469351|DRUG|non-active study drug|placebo
214822192|NCT02604420|DRUG|eculizumab|
214822193|NCT02907047|OTHER|tourniquet inflated|
214822194|NCT02907047|OTHER|tourniquet not inflated|
214656312|NCT06027801|OTHER|non-fortified cookies|Study cookies containing no iron
214656313|NCT04101110|OTHER|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
214656314|NCT01499290|DRUG|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
214656315|NCT01499290|DRUG|Metronidazole|500 mg of Metronidazole
214656316|NCT01499290|DRUG|Meropenem|1 gram of Meropenem
214822195|NCT04342559|OTHER|Belamy (vaginal moisturizer)|"The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period"
214822196|NCT05801484|OTHER|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
214822197|NCT00096291|OTHER|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
214822198|NCT00096291|OTHER|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
214822199|NCT02687126|DEVICE|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
214822200|NCT00165685|DRUG|Sibutramine Hydrochloride Monohydrate|
214822201|NCT03820310|BIOLOGICAL|autologous Tcm cellular immunotherapy|autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
214822202|NCT04131842|OTHER|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
214822203|NCT04131842|OTHER|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
214822204|NCT04131842|OTHER|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
214822205|NCT04131842|OTHER|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
214822206|NCT05978726|DRUG|Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel|Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
214822207|NCT03887910|OTHER|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
214822208|NCT03887910|OTHER|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
214822209|NCT06562114|DRUG|TML-6 Granules|Administered orally
214822210|NCT06562114|DRUG|Placebo|Administered orally
214822211|NCT01094457|DRUG|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
214822212|NCT01094457|DRUG|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
214822213|NCT01422291|DRUG|paracetamol|1 gr
214822214|NCT01422291|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
214822215|NCT01422291|DRUG|Dexketoprofen|50 mg
214822216|NCT01422291|DRUG|Paracetamole|1 gr
214822217|NCT06328829|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214822218|NCT06328829|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214822219|NCT06328829|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214822220|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
214822221|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
214822222|NCT03347487|PROCEDURE|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
214822223|NCT04308785|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
214822224|NCT04308785|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
214822225|NCT04308785|OTHER|Placebo|Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
214822226|NCT05852392|OTHER|Adapted PARENT Model|PARENT is a team-based approach to care that utilizes a clinic-based community health worker as part of the WCC team to provide comprehensive and family-centered preventive care services.
214822227|NCT01456221|DIETARY_SUPPLEMENT|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
214822228|NCT01456221|DIETARY_SUPPLEMENT|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
214822229|NCT01499602|DRUG|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
214822230|NCT01499602|DRUG|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
214822231|NCT00436163|DRUG|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
214822232|NCT04416386|OTHER|Vitamin C|Pre and post-operative blood plasma levels of vitamin C will be investigated
214822233|NCT06561191|OTHER|Hemodialysis mode, dialyzer type|Change of hemodialysis mode and dialyzer type
214822234|NCT04518956|PROCEDURE|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
214267551|NCT06495021|PROCEDURE|Lymphatic Pump Osteopathic Manipulative Therapy|OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
214267552|NCT06681311|OTHER|Exercises|During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
214822235|NCT04518956|PROCEDURE|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
214822236|NCT04518956|PROCEDURE|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
214822237|NCT05615324|BEHAVIORAL|Family Talk Preventive Intervention|This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
214822238|NCT00130377|BIOLOGICAL|cell therapy|autologous or allogeneic cells
214822239|NCT02709018|DRUG|losartan|Angiotensin receptor blocker (ARB)
214822240|NCT02709018|DRUG|Placebo|Placebo
214822241|NCT04173273|DRUG|Etrasimod|Dose A taken by mouth, once daily.
214822242|NCT04173273|DRUG|Etrasimod|Dose B taken by mouth, once daily.
214267553|NCT03730012|DRUG|gilteritinib|Oral tablet
214267554|NCT03730012|DRUG|atezolizumab|Intravenous infusion
214267555|NCT05147428|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
214267556|NCT04833465|OTHER|No Intervention|No Intervention
214267557|NCT05123131|DRUG|Isatuximab|Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.
214267558|NCT05123131|DRUG|Bortezomib|Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.
214267559|NCT05123131|DRUG|Lenalidomide|Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 to \<60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.
214267560|NCT05123131|DRUG|Dexamethasone (IV)|Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
214267561|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
214822243|NCT04173273|DRUG|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
214822244|NCT05486338|DEVICE|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
214822245|NCT06647173|BEHAVIORAL|Blued+ Service Platform|During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
214822246|NCT02530905|DRUG|SRP-4045|SRP-4045 solution for IV infusion.
214822247|NCT02530905|DRUG|Placebo|SRP-4045 placebo-matching solution for IV infusion.
214822248|NCT05497804|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214822249|NCT05497804|DRUG|Carfilzomib|Given IV
214822250|NCT05497804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214822251|NCT05497804|BIOLOGICAL|Daratumumab|Given SC
214822252|NCT05497804|DRUG|Dexamethasone|Given IV/PO
214822253|NCT05497804|DRUG|Lenalidomide|Given PO
214822254|NCT05497804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214822255|NCT05497804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214822256|NCT05497804|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214822257|NCT05497804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214822258|NCT05497804|PROCEDURE|Echocardiography|Undergo ECHO
214822259|NCT05497804|PROCEDURE|Chest Radiography|Undergo chest x-ray
214822260|NCT01278953|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
214822261|NCT01473953|DRUG|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
214822262|NCT01473953|DRUG|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
214822263|NCT01019889|DRUG|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
214822264|NCT01019889|DRUG|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
214822265|NCT01019889|DRUG|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
214822266|NCT05778110|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
214822267|NCT00772239|DEVICE|Rotation thromboelastometry (ROTEM)|Coagulation measurement
214822268|NCT00772239|PROCEDURE|Standard coagulation managment procedure|Standard coagulation managment procedure
214822269|NCT01327391|PROCEDURE|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
214822270|NCT01327391|PROCEDURE|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
214822271|NCT03100344|DRUG|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
214822272|NCT03100344|DRUG|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
214822273|NCT01083719|PROCEDURE|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
214822274|NCT06269952|OTHER|No intervention|No intervention. The participants are asked questions from and questionnaire and later also interviewed guide by an interview-guide
214822275|NCT01348438|DEVICE|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
214822276|NCT02358538|DRUG|Ganaxolone|oral suspension or capsules
214822277|NCT00570609|OTHER|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
214822278|NCT00669721|DRUG|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
214822279|NCT00669721|DRUG|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
214822280|NCT05662163|PROCEDURE|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
214822281|NCT05662163|PROCEDURE|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
214822282|NCT05821647|OTHER|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
214822283|NCT02819947|OTHER|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
214822284|NCT06819787|OTHER|Electronic Heath Record Platform to Support Pharmacists in Delivering Contraceptive Services|An electronic health record (EHR) platform specifically designed to support community pharmacists in delivering contraceptive services. The platform streamlines clinical workflows, provides clinical decision support, and promotes adherence to the US Medical Eligibility Criteria (USMEC) guidelines and state regulatory requirements.
214822285|NCT05487547|DEVICE|IPL_RF_MGX|intense pulsed light followed by Radiofrequency followed by meibomian gland expression
214822286|NCT06986421|OTHER|completion of a structured questionnaire|completion of a structured questionnaire
214822287|NCT05033678|DEVICE|Diagnostic algorithms|Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
214822288|NCT01935674|DRUG|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
214822289|NCT01935674|DRUG|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
214822290|NCT06610227|BIOLOGICAL|SapRNA™-MICA/B Tumor Vaccine|patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively
214822291|NCT04684706|DEVICE|intermittent Theta Burst Stimulation|The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
214822292|NCT01472263|DRUG|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
214822293|NCT01472263|DRUG|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
214822294|NCT06611579|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve using a transcatheter approach
214822295|NCT02576522|RADIATION|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
214822296|NCT01494532|DRUG|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
214822297|NCT01494532|DRUG|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
214822298|NCT02684747|OTHER|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
214822299|NCT02684747|OTHER|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
214822300|NCT03633214|OTHER|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
214822301|NCT06861790|BEHAVIORAL|tVNS|Though we will be utilizing a tVNS (Transcutaneous Vegus Nerve Stimulation) device this study is not a device study. The device being used is being done so under its approved usage. The intervention utilizes a non-invasive process to stimulate the Vagus nerve using very small electrical currents. This intervention is completed daily for one month.
214822302|NCT06861790|PROCEDURE|Complete Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
214822303|NCT06861790|PROCEDURE|Anterior Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
214822304|NCT05865769|OTHER|Balance|measuring pulmonary and vestibular functions in all subjects
214822305|NCT06559410|OTHER|Electroencephalogram (EEG), CT Brain, Echocardiogram|analyze the etiology, electroencephalographic (EEG) findings, neuroimaging, and neurological sequalae of newborns with congenital heart disease who were presented with seizures
214822306|NCT05103514|OTHER|Online Survey|There are no interventions planned for this study. This is an observational study only.
214822307|NCT03612232|DRUG|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
214822308|NCT06868056|BEHAVIORAL|Suite of healthy food policies|an online application with a suite of healthy food policies ultra-processed food and beverage taxes, front-of-pack nutrition labeling, and healthy check out regulations that restrict the promotion of ultra-processed products on the checkout page
214822309|NCT02665715|OTHER|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
214822310|NCT02665715|OTHER|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
214822311|NCT06321653|RADIATION|Hypofractionated radiotherapy scheme|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
214822312|NCT01771939|PROCEDURE|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
214822313|NCT01771939|PROCEDURE|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
214822314|NCT05672030|OTHER|Non-Interventional|No intervention.
214822315|NCT04018482|OTHER|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
214822316|NCT04018482|OTHER|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
214822317|NCT01845298|DRUG|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
214822318|NCT01788072|DRUG|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
214822319|NCT01788072|DRUG|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
214822320|NCT07068750|PROCEDURE|patients received dental implants using single drilling system in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will performed and full thickness mucoperiosteal flap will be reflected to access the site. The implant will be prepared using the new specially designed drill. These drills are available with four drilling lengths (7, 9, 11, 13 mm) characterized by different color codes, and three different diameters (4, 4.5, 5 mm). They allow a single drilling procedure before implant placement in bone with all types. Drilling speed of 1500 RPM and profuse normal saline irrigation will be used throughout the drilling procedure. Tapered implants will be inserted in all patients with insertion torque 30-50Ncm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
214822321|NCT07068750|PROCEDURE|patients received dental implants using Densah burs in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using osseodensification burs (Densah, Versah) at 1200 rpm in the following sequence: (I) pilot (clockwise); (II) WT1828 (counterclockwise), and (III) WT2838 (counterclockwise). These burs have a cutting chisel edge, a tapered shank and non- cutting edges with four or more lands with a negative rake angle. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
214822322|NCT07068750|PROCEDURE|patients received dental implants using conventional drills in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using conventional surgical drills at 1200 rpm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
214822323|NCT07067957|OTHER|Arabic Dysfunctional Voiding Symptom Score Questionnaire (DVSS)|A validated Arabic version of the Dysfunctional Voiding Symptom Score Questionnaire (DVSS) questionnaire will be used to screen children for symptoms of lower urinary tract dysfunction. It includes 10 items assessing urinary and bowel habits.
214822324|NCT07067645|PROCEDURE|Horizontal Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive horizontal closure of the vaginal cuff. After removal of the uterus, the vaginal cuff is closed in a transverse (right-to-left) direction using standard absorbable sutures. The technique aims to maintain or optimize the anatomical axis and preserve vaginal length in the horizontal plane. The entire procedure is performed under general or regional anesthesia by an experienced surgical team.
214822325|NCT07067645|PROCEDURE|Vertical Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive vertical closure of the vaginal cuff. After the uterus is removed, the vaginal cuff is closed in a cranio-caudal (top-to-bottom) orientation using absorbable sutures. This technique is hypothesized to better support apical structures and reduce tissue tension. Procedures are performed under general or regional anesthesia with standardized operative technique.
214822326|NCT02761512|DRUG|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
214822327|NCT02761512|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
214822328|NCT02761512|DRUG|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
214822329|NCT02202486|OTHER|Brain MRI|Brain MRI with gadolinium contrast
214822330|NCT05625022|DRUG|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
214822331|NCT02433977|DIETARY_SUPPLEMENT|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
214822332|NCT02433977|DRUG|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
214822333|NCT02433977|DRUG|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
214822334|NCT05900635|DRUG|Lactoferrin|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
214822335|NCT05900635|DRUG|Ferrous Glycine Sulfate|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
214822336|NCT06933173|OTHER|Dynamic neural retraining system|"Description: The DNRS program includes the following components: 1) cognitive-behavioural therapy; 2) mindfulness-based cognitive restructuring; 3) emotional restructuring therapy; 4) neural linguistic programming; 5) incremental training; and 6) behaviour modification therapy. DNRS offered in this study includes a 14-hour online course followed by a 12-week online LIVING DNRS group support program. The 14-hour online course includes a variety of exercises, instructional videos, and a workbook. Upon completion, participants are offered a 12-week LIVING DNRS Group Support program which provides individuals with support in how to best implement DNRS into their daily lives with the help of a trained facilitator as well as peer support."
214822337|NCT06947993|DRUG|GHZ339|GHZ339 administered at dose A, B, C and D
214822338|NCT06947993|DRUG|Placebo|Matching placebo
214822339|NCT06954870|OTHER|Ozone therapy|As detailed in the research arms, major ozone application and local ozone application will be performed.
214822340|NCT01199562|PROCEDURE|infection prophylaxis and management|Undergo infection prophylaxis and management
214822341|NCT01199562|OTHER|laboratory biomarker analysis|Correlative studies
214822342|NCT01199562|OTHER|flow cytometry|Correlative studies
214822343|NCT01199562|GENETIC|DNA analysis|Correlative studies
214822344|NCT01199562|GENETIC|RNA analysis|Correlative studies
214822345|NCT01199562|PROCEDURE|management of therapy complications|undergo infection prophylaxis and management
214822346|NCT01199562|DRUG|ganciclovir|Given IV
214822347|NCT01199562|DRUG|valganciclovir|Given orally
214822348|NCT01199562|DRUG|foscarnet sodium|Given orally
214822349|NCT01199562|PROCEDURE|antiviral therapy|undergo infection prophylaxis and management
214822350|NCT01199562|GENETIC|polymerase chain reaction|Correlative studies
214822351|NCT01199562|GENETIC|protein expression analysis|Correlative studies
214822352|NCT04906070|DEVICE|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214822353|NCT05846022|OTHER|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
214822354|NCT05846022|OTHER|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
214822355|NCT06128967|DRUG|Fluvoxamine Maleate 100 MG|Fluvoxamine Maleate 100 mg each pills
214822356|NCT06128967|DRUG|Placebo|Placebo talc pills of same shape, color, weight if compared with active comparator
214822357|NCT06128967|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended release oral tablets of 750 mg each pill
214822358|NCT03537482|DRUG|APG-2575|APG-2575 will be administered as an oral tablet
214822359|NCT01995227|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine
214822360|NCT01995227|BIOLOGICAL|CRCL|Personalized anti-cancer vaccine
214822361|NCT01995227|BIOLOGICAL|AlloStim|ID injections IV infusion
214822362|NCT02392286|DRUG|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
214822363|NCT06558734|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
214267562|NCT05222308|OTHER|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
214267563|NCT04189770|DEVICE|Accelerometer|Wear accelerometer
214267564|NCT04189770|OTHER|Ecological Momentary Assessment|Complete EMA questionnaire
214267565|NCT04189770|OTHER|Questionnaire Administration|Complete questionnaire
214267566|NCT04189770|OTHER|Survey Administration|Complete survey
214267567|NCT06812793|OTHER|Measurement of Core Muscle Endurance|Endurance of the flexor, extensor and lateral trunk muscles will be assessed using the McGill Trunk Endurance Tests.
214267568|NCT06812793|OTHER|Respiratory Muscle Strength|Inspiratory and expiratory muscle strength will be made with a portable, electronic intra-oral pressure measuring device.
214267569|NCT06812793|OTHER|Respiratory Muscle Endurance|Respiratory muscle endurance testing will be measured using an inspiratory muscle training device at increasing threshold load.
214656317|NCT00550498|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
214656318|NCT03885921|DRUG|Ezetimibe|oral tablet
214656319|NCT03885921|DRUG|Atorvastatin|oral tablet
214656320|NCT03885921|DRUG|Simvastatin|oral tablet
214656321|NCT03561727|PROCEDURE|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
214656322|NCT03561727|PROCEDURE|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
214656323|NCT04052139|DRUG|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
214656324|NCT04052139|DRUG|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
214656325|NCT04052139|DRUG|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
214656326|NCT00743795|DRUG|placebo|oral BID
214656327|NCT00743795|DRUG|GS-9190|40 mg oral BID
214656328|NCT00743795|DRUG|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
214656329|NCT00743795|DRUG|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
214656330|NCT02134600|DIETARY_SUPPLEMENT|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
214656331|NCT04884828|DEVICE|external gas during NIV|The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
214656332|NCT00257036|DRUG|levofloxacin|
214656333|NCT03899701|PROCEDURE|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
214267570|NCT06812793|OTHER|Peripheral Muscle Endurance|Peripheral muscle endurance will be assessed by performing 30 and 60 second sit-to-stand tests.
214656334|NCT03609580|DRUG|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
214656335|NCT03609580|DRUG|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
214656336|NCT05284201|DEVICE|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
214656337|NCT03896295|DRUG|M281|M281 injection administered as intravenous infusion
214656338|NCT00947648|OTHER|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
214656339|NCT00947648|OTHER|Cooked Foods|Diet containing only cooked foods.
214656340|NCT04207476|DEVICE|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
214656341|NCT04207476|DEVICE|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
214656342|NCT03012581|DRUG|Nivolumab|Treatment
214656343|NCT02567448|OTHER|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
214656344|NCT00700804|BEHAVIORAL|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
214656345|NCT00700804|BEHAVIORAL|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
214656346|NCT05451719|DRUG|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
214656347|NCT05451719|DRUG|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
214656348|NCT00312455|DRUG|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
214656349|NCT00312455|DRUG|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
214656350|NCT00312455|DRUG|Placebo|5 capsules/day
214656351|NCT00542711|DRUG|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
214656352|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
214656353|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
214656354|NCT03668756|PROCEDURE|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
214656355|NCT06154629|DIETARY_SUPPLEMENT|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
214656356|NCT06154629|DIETARY_SUPPLEMENT|Control group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
214656357|NCT00373074|OTHER|Epidural Blood Patch|Use 15 cc of blood
214656358|NCT00373074|OTHER|Epidural Blood Patch|Inject 20 cc of blood into epidural space
214656359|NCT00373074|OTHER|Epidural Blood Patch|Inject 30 cc of autologous blood
214656360|NCT00518349|DEVICE|Passive bending function|Colonoscope with a passive bending function
214656361|NCT00518349|DEVICE|No passive bending function|Examination using standard colonoscope without passive bending function
214656362|NCT00005630|BIOLOGICAL|ras peptide cancer vaccine|
214656363|NCT00005630|BIOLOGICAL|sargramostim|
214656364|NCT03633500|OTHER|Sterile water|Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
214656365|NCT03633500|BIOLOGICAL|Breastmilk|Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
214656366|NCT04144621|PROCEDURE|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
214656367|NCT02221492|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
214656368|NCT02221492|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
214656369|NCT06376721|DRUG|Linperlisib|Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
214656370|NCT06376721|DRUG|Camrelizumab|Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
214656371|NCT06376721|DRUG|Pegaspargase|"Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee."
214656372|NCT06376721|DRUG|Dexamethasone|Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
214656373|NCT00998738|DRUG|Calcium Gluconate|Given IV
214656374|NCT00998738|DRUG|Magnesium Sulfate|Given IV
214656375|NCT00998738|OTHER|Placebo|Given IV
214656376|NCT00998738|OTHER|Quality-of-Life Assessment|Ancillary studies
214656377|NCT00998738|OTHER|Questionnaire Administration|Ancillary studies
214656378|NCT00998738|DRUG|Ixabepilone|Given IV
214656379|NCT03445286|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
214656380|NCT03445286|OTHER|Normal Saline|Normal Saline for the control group
214656381|NCT05925205|PROCEDURE|Muscle energy technique combined with the physical therapy program.|A manual therapy technique
214656382|NCT05925205|PROCEDURE|Strain counterstrain technique combined with the physical therapy program|A manual therapy technique
214656383|NCT05925205|PROCEDURE|The physical therapy program|Electrotherapy and exercise.
214656384|NCT00933036|DEVICE|Crosstrees Pod system for PVA|Minimally invasive spine surgery
214656385|NCT04572009|OTHER|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
214656386|NCT04572009|OTHER|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
214656387|NCT06932016|BEHAVIORAL|Grammar Treatment|Behavioral intervention that focuses on improving passive sentence structure knowledge.
214656388|NCT06918509|DEVICE|OdonAssistTM|Innovative medical device for operative vaginal delivery as an alternative to vacuum or forceps
214656389|NCT06936098|PROCEDURE|CRLM surgery|Surgical resection of colorectal cancer liver metastasis (CRLM) involves the removal of metastatic lesions from the liver. This procedure is aimed at improving survival rates and reducing tumor burden in patients diagnosed with CRLM. The resection is performed to treat liver metastasis, and clinical outcomes, such as progression-free survival (PFS) and overall survival (OS), are assessed post-surgery to determine treatment efficacy.
214656390|NCT03946449|DRUG|ARO-AAT|solution for subcutaneous injection
214656391|NCT06416501|OTHER|Mode of detection|Mode of detection
214656392|NCT02536287|PROCEDURE|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
214656393|NCT02536287|PROCEDURE|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1\*1 \*1 mm,and placed into the subcutaneous of the forearm.
214656394|NCT05135286|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
214656395|NCT05135286|DRUG|Carbachol PF|A single drop in each eye at a visit.
214656396|NCT05135286|DRUG|Vehicle|A single drop in each eye at a visit.
214656397|NCT03779178|DRUG|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
214656398|NCT03779178|DRUG|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
214656399|NCT06763536|OTHER|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
214656400|NCT06763536|OTHER|Nicotine Lozenge|Use nicotine lozenge
214656401|NCT06763536|OTHER|Oral Nicotine Pouch|Use oral nicotine pouch
214656402|NCT06763536|OTHER|Nicotine Patch|Use nicotine patch
214656403|NCT06763536|OTHER|Survey Administration|measurements; data gathering
214656404|NCT06763536|OTHER|Check-in Phone Calls|Check-in phone calls to study participants
214656405|NCT04699188|DRUG|JDQ443|KRAS G12C inhibitor
214656406|NCT04699188|DRUG|TNO155|SHP2 inhibitor
214656407|NCT04699188|BIOLOGICAL|tislelizumab|Anti PD1 antibody
214656408|NCT06501443|DRUG|Usual care|Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
214656409|NCT06501443|DRUG|KJX839|Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
214656410|NCT05507216|DRUG|ABX464|Administered once daily in the morning with food
214656411|NCT05507216|DRUG|Placebo|Administered once daily in the morning with food
214656412|NCT04585763|DEVICE|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
214656413|NCT01888094|OTHER|Ultrasound-guided cannulation and examination|
214656414|NCT01609933|DRUG|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
214656415|NCT01609933|DRUG|ABT-267|ABT-267 (tablets)
214656416|NCT01609933|DRUG|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
214656417|NCT01609933|DRUG|Ribavirin (RBV)|Ribavirin (tablets)
214656418|NCT00224016|DRUG|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
214656419|NCT00224016|DRUG|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
214656420|NCT03947294|DEVICE|Q-NRG®|Energy expenditure measurements
214656421|NCT01252966|BEHAVIORAL|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
214656422|NCT01252966|BEHAVIORAL|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
214656423|NCT00197860|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
214822364|NCT06558734|PROCEDURE|Cementation|Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
214822365|NCT01118598|DRUG|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
214822366|NCT01118598|DRUG|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
214822367|NCT00834717|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
214822368|NCT00834717|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
214822369|NCT02222818|DEVICE|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
214822370|NCT02222818|DEVICE|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
214822371|NCT03717805|OTHER|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
214822372|NCT00543205|DRUG|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
214822373|NCT00444353|DEVICE|DL6049 (injectable poly-L-lactic acid)|
214822374|NCT03089515|OTHER|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
214822375|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
214822376|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
214822377|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
214822378|NCT01660243|DRUG|Placebo|Placebo (2capsules) once daily for 8 weeks
214822379|NCT02873845|OTHER|Preliminary validation of the COBQoL questionnaire|
214822380|NCT00262392|DRUG|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
214822381|NCT02108535|DRUG|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
214822382|NCT02108535|DRUG|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
214822383|NCT06491797|BEHAVIORAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
214822384|NCT01743898|DRUG|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
214822385|NCT01743898|OTHER|no anticoagulation|
214822386|NCT05106114|OTHER|Intensive gait training rehabilitation protocole|6 weeks of intensive gait training : 4 weeks at the center and 2 weeks of home-based telerehabilitation
214822387|NCT04405102|DRUG|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
214822388|NCT04405102|OTHER|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
214822389|NCT06563297|DRUG|Alfentanil|We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
214822390|NCT03025087|DRUG|Hydroxychloroquine|Participants will be getting hydroxychloroquine
214822391|NCT04204395|DEVICE|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
214822392|NCT01983501|DRUG|Tucatinib (ONT-380)|Given twice per day, orally
214822393|NCT01983501|DRUG|T-DM1|Given intravenously once every 21 days
214822394|NCT03389113|DEVICE|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
214822395|NCT03389113|OTHER|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
214822396|NCT02940444|DRUG|Heparin|
214656424|NCT05734287|DIAGNOSTIC_TEST|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
214656425|NCT05666154|OTHER|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
214656426|NCT05666154|OTHER|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
214656427|NCT05666154|OTHER|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
214656428|NCT05666154|OTHER|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
214656429|NCT00565955|DRUG|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
214656430|NCT00565955|DRUG|Placebo|The patients will receive placebo tablets.
214656431|NCT01264315|DRUG|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
214656432|NCT03275870|DRUG|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
214656433|NCT03835338|DEVICE|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
214656434|NCT03835338|DEVICE|LAA Isolation|LAA Isolation by RF Ablation
214656435|NCT03835338|DEVICE|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
214656436|NCT04244825|DRUG|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
214656437|NCT04244825|DRUG|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
214656438|NCT04092036|DEVICE|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
214656439|NCT01364415|DRUG|Pasireotide LAR|
214656440|NCT00919022|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
214656441|NCT01133639|DRUG|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
214656442|NCT01133639|DRUG|Placebo|Placebo plus standard of care
214656443|NCT00718133|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
214656444|NCT06527599|OTHER|Opioid Risk Monitoring (ORM)|A brief battery of self-reported screeners for risk factors associated with opioid misuse (e.g., Current Opioid Misuse Measure; Pain, Enjoyment of life, and General activities scale; Pain Catastrophizing Scale). These measures will be administered within seven days of hospital discharge (i.e., baseline), and again at 2-, 4-, 8-, and 12-weeks following discharge to assess for ongoing risk for opioid misuse. Participants will additionally complete the self-reported Opioid Risk Tool within seven days of hospital discharge.
214656445|NCT06527599|BEHAVIORAL|enhanced Trauma Care Coordination (eTCC)|An enhanced care management model with increased patient contact and embedded interventions based on clinical presentation and collaboration with the patient. eTCC is a telehealth-based care coordinating intervention where a care coordinator assesses the participant, creates a plan of care, collaborates with the eTCC team, follows up with a second virtual visit within a week, and communicates with the participant and care team at least bi-weekly for the 3 month intervention period.
214656446|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Brief (PCST-LITE)|PCST-LITE will consist of a single 55-minute videoconference session, in which participants will receive brief psychoeducation grounded in gate control theory, progressive muscle relaxation (PMR), and therapist-guided imagery. Participants will be asked to practice PMR and imagery daily and will receive four weeks of regular (4-5 times per week) text messaging as a reminder.
214656447|NCT06527599|BEHAVIORAL|Standard Trauma Care Coordination (sTCC)|Standard Trauma Care Coordination (sTCC) will functionally serve as a treatment-as-usual arm, as it will involve no study intervention.
214656448|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Plus (PCST+)|PCST+ will include two videoconferencing sessions, in addition to the first videoconferencing session they previously received. In session 1, participants will be taught an activity/rest cycle to schedule activities, so they are productive while avoiding increasing pain severity due to taking insufficient breaks. Session 2 centers around cognitive restructuring, involving brief psychoeducation and skills development surrounding how participants might recognize the influence that cognitions can have on pain intensity and coping. Participants will receive 3 weekly, 15-minute calls to review skills and problem-solve.
214656449|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Maintenance (PCST-M)|PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.
214656450|NCT06183658|DIAGNOSTIC_TEST|Fluids biomarker and neuroimaging of AD diagnosis|Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.
214822397|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
214822398|NCT03368443|BEHAVIORAL|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
214822399|NCT05794685|PROCEDURE|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
214822400|NCT05794685|PROCEDURE|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
214822401|NCT05731687|OTHER|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
214822402|NCT05731687|OTHER|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
214822403|NCT03821675|DEVICE|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
214822404|NCT03821675|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
214822405|NCT01957059|DRUG|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
214822406|NCT01957059|DRUG|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
214822407|NCT01957059|DRUG|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
214822408|NCT01957059|DRUG|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
214822409|NCT01957059|DRUG|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
214822410|NCT03419247|PROCEDURE|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
214822411|NCT03419247|PROCEDURE|Blood draw|Blood will be taken by a needle from a vein.
214822412|NCT03419247|PROCEDURE|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
214822413|NCT00508651|BIOLOGICAL|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
214822414|NCT00508651|BIOLOGICAL|Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
214822415|NCT03841266|DIAGNOSTIC_TEST|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
214822416|NCT04718025|DRUG|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
214822417|NCT04718025|DRUG|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
214267571|NCT06208865|PROCEDURE|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
214822418|NCT04718025|DRUG|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
214267572|NCT04680052|DRUG|tafasitamab|tafasitamab will be administered IV for 12 cycles
214267573|NCT04680052|DRUG|rituximab|Rituximab will be administered IV on cycles 1 - 5
214267574|NCT04680052|DRUG|lenalidomide|Lenalidomide will be administered PO for 12 cycles
214822419|NCT03968172|BEHAVIORAL|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
214822420|NCT03968172|BEHAVIORAL|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
214822421|NCT04949334|DEVICE|Dofin Breathing Strength Builder|"If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O."
214822422|NCT01665690|OTHER|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
214822423|NCT01665690|BEHAVIORAL|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
214822424|NCT05850676|DIAGNOSTIC_TEST|Sleep study|Participants will spend two nights in the Penn Sleep Center
214822425|NCT05777005|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
214822426|NCT05777005|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
214822427|NCT05777005|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
214822428|NCT05777005|BEHAVIORAL|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
214822429|NCT05777005|BEHAVIORAL|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
214822430|NCT04137835|DEVICE|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
214822431|NCT05438550|DRUG|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
214822432|NCT00308906|DRUG|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
214822433|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
214822434|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
214267575|NCT04680052|DRUG|placebo|placebo will be administered IV for 12 cycles
214267576|NCT02780375|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
214267577|NCT00239538|DRUG|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
214267578|NCT00239538|DRUG|valsartan combined with hydrochlorothiazide (160/12.5mg)|
214267579|NCT03971097|BEHAVIORAL|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
214822435|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
214822436|NCT03595436|DIETARY_SUPPLEMENT|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
214822437|NCT03595436|DIETARY_SUPPLEMENT|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
214822438|NCT00816413|DRUG|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
214822439|NCT00816413|DRUG|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
214822440|NCT00816413|DRUG|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
214822441|NCT00816413|GENETIC|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
214822442|NCT00816413|GENETIC|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
214822443|NCT00816413|GENETIC|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
214822444|NCT00816413|OTHER|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
214822445|NCT00816413|OTHER|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
214822446|NCT00816413|OTHER|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
214822447|NCT00816413|OTHER|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
214822448|NCT00816413|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
214822449|NCT00816413|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
214822450|NCT00816413|RADIATION|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
214822451|NCT00506376|BEHAVIORAL|Interview|Interview that will take about 20 minutes to complete.
214822452|NCT03098485|DRUG|Levofloxacin|5 days of levofloxacin administration
214822453|NCT03098485|DRUG|Azithromycin|5 days of azithromycin administration
214822454|NCT03098485|DRUG|Cefpodoxime|5 days of cefpodoxime administration
214822455|NCT04200833|DRUG|Golimumab|subcutaneous injection
214267580|NCT03971097|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
214822456|NCT06054984|DRUG|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
214822457|NCT02508870|DRUG|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
214822458|NCT02508870|DRUG|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
214267581|NCT03395210|DRUG|Rilzabrutinib|BTK inhibitor
214822459|NCT03866265|DIETARY_SUPPLEMENT|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
214822460|NCT03866265|OTHER|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
214822461|NCT00238615|DRUG|Docetaxel|20 mg/m2, 75 mg/m2 infusion
214822462|NCT00238615|DRUG|Carboplatin|AUC of 2 and 6 infusion
214822463|NCT00238615|PROCEDURE|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
214822464|NCT00238615|PROCEDURE|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
214822465|NCT03914105|PROCEDURE|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
214822466|NCT03914105|PROCEDURE|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
214822467|NCT00106223|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
214822468|NCT02881541|PROCEDURE|Enhanced support|
214822469|NCT02881541|PROCEDURE|Usual care|
214822470|NCT04693611|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
214822471|NCT04693611|PROCEDURE|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
214822472|NCT04643691|DRUG|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
214822473|NCT05710718|DEVICE|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC is connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
214822474|NCT05710718|DEVICE|Hollister® Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence. It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
214822475|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
214822476|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
214822478|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 30/30|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
214822479|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 10/10|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
214822480|NCT01098786|BIOLOGICAL|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
214822481|NCT05655494|BEHAVIORAL|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
214822482|NCT05655494|BEHAVIORAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
214822483|NCT04480086|DRUG|Mivebresib|Tablet: Oral
214822484|NCT04480086|DRUG|Navitoclax|Tablet; Oral
214822485|NCT04480086|DRUG|Ruxolitinib|Tablet; Oral
214822486|NCT05951049|DRUG|AT02|Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
214822487|NCT04712045|OTHER|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
214822488|NCT04712045|OTHER|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
214822489|NCT01319383|DRUG|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
214822490|NCT01031394|OTHER|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
214822491|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822492|NCT02404701|DIETARY_SUPPLEMENT|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822493|NCT02404701|DIETARY_SUPPLEMENT|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822494|NCT02404701|DIETARY_SUPPLEMENT|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822495|NCT02404701|DIETARY_SUPPLEMENT|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822496|NCT02404701|DIETARY_SUPPLEMENT|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822497|NCT02404701|DIETARY_SUPPLEMENT|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822498|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
214822499|NCT01987765|DRUG|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
214822500|NCT01499186|OTHER|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
214822501|NCT02310386|DEVICE|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
214822502|NCT00772603|DRUG|Placebo|Non-active tablet identical to study drug tablets
214822503|NCT00772603|DRUG|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
214822504|NCT00772603|DRUG|1200mg SPN-804|two active tablets and two non-active tablets, all identical
214822505|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
214822506|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
214822507|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
214822508|NCT02489461|DRUG|VM-1500|VM-1500 up to 96 weeks
214822509|NCT02489461|DRUG|Efavirenz|Efavirenz up to 48 weeks
214822510|NCT02489461|DRUG|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
214822511|NCT05452785|DRUG|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
214822512|NCT05452785|DRUG|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
214822513|NCT05452785|DRUG|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
214822514|NCT04757298|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
214822515|NCT04757298|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
214822516|NCT04757298|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
214822517|NCT04757298|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
214822518|NCT00938509|DRUG|ibuprofen suppositories|5-10 mg/kg/day-suppositories
214822519|NCT02882776|DIETARY_SUPPLEMENT|Ginger drink|Ginger powder dissolved in water
214822520|NCT00836004|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
214822521|NCT00836004|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
214822522|NCT03548363|DIETARY_SUPPLEMENT|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
214822523|NCT03548363|DIETARY_SUPPLEMENT|Placebo|200 mg/d maltodextrin
214822524|NCT01528696|DEVICE|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
214822525|NCT01528696|DEVICE|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
214267582|NCT05679427|RADIATION|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
214822526|NCT05710783|BIOLOGICAL|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
214822527|NCT05710783|BIOLOGICAL|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
214822528|NCT02143245|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
214267583|NCT05241912|DRUG|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
214267584|NCT05736497|OTHER|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
214822529|NCT02143245|DIAGNOSTIC_TEST|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
214822530|NCT01004562|OTHER|informational intervention|
214822531|NCT01767363|OTHER|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
214822532|NCT01767363|OTHER|Alpha-blockers|Use of alpha-blockers over the study period.
214822533|NCT06313034|BEHAVIORAL|Breastfeeding education based on motivational interviewing technique|"Breastfeeding education based on motivational interviewing technique; Breast milk properties, benefits to mother and baby, breastfeeding positions, the relationship between breastfeeding and attachment, signs of hunger in the newborn, Breastfeeding frequency, duration and termination, Breast milk expressing methods, Expressions showing that the newborn has enough milk, Breast milk storage will cover the topics. These topics will be given based on motivational interviewing technique.~According to the motivational interviewing technique, the mother's intention, importance and confidence-sufficiency regarding breastfeeding will be determined and firstly, an agenda will be created on issues related to breastfeeding with the mother. Each session will be conducted by following the open-ended questioning, verification, reflective listening and summarizing approaches of the motivational interviewing technique."
214822534|NCT01855035|OTHER|prolonged ECG monitoring|10-day Holter ECG measurement
214822535|NCT01855035|OTHER|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
214822536|NCT00378547|DRUG|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
214822537|NCT00378547|DRUG|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
214822538|NCT00378547|DRUG|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
214822539|NCT01056484|BEHAVIORAL|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
214822540|NCT01056484|OTHER|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
214822541|NCT02435160|BIOLOGICAL|Fecal Microbiota Transplantation|
214822542|NCT00033917|DRUG|indomethacin|an anti-inflammatory drug
214822543|NCT00033917|DRUG|placebo|saline
214822544|NCT02185144|BEHAVIORAL|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
214822545|NCT02185144|BEHAVIORAL|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
214822546|NCT04403672|DEVICE|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
214822547|NCT04018404|OTHER|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
214822548|NCT01421901|DRUG|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
214822549|NCT01421901|PROCEDURE|appendectomy|
214822550|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
214822551|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
214267585|NCT03320057|DRUG|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
214267586|NCT03320057|OTHER|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
214822552|NCT01686386|DRUG|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
214822553|NCT01686386|DRUG|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
214822554|NCT01686386|DRUG|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
214822555|NCT00598052|DRUG|Escitalopram|10mg/day
214822556|NCT06366815|OTHER|Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy|clinical and functional data collection of non ambulant patients with Duchenne muscular dystrophy
214822557|NCT00446966|DRUG|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
214822558|NCT03720691|DEVICE|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
214822559|NCT03720691|DEVICE|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
214822560|NCT02975765|PROCEDURE|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
214822561|NCT00100464|DRUG|Paroxetine|
214822562|NCT00100464|DRUG|5HTP|
214822563|NCT01988376|DEVICE|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
214822564|NCT01988376|DEVICE|Conventional Pap smear|Conventional Pap smear
214822565|NCT01564394|BEHAVIORAL|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
214822566|NCT01564394|BEHAVIORAL|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
214822567|NCT00859521|DRUG|Levetiracetam|1000 mg Tablet
214822568|NCT00859521|DRUG|Keppra®|1000 mg Tablet
214822569|NCT02275143|RADIATION|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
214822570|NCT04273971|OTHER|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
214822571|NCT03934281|DEVICE|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
214822572|NCT03934281|DEVICE|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
214822573|NCT02888756|BIOLOGICAL|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
214822574|NCT02888756|BIOLOGICAL|TriMix|Therapeutic vaccination, followed by treatment interruption
214822575|NCT02888756|BIOLOGICAL|Placebo|Therapeutic vaccination, followed by treatment interruption
214822576|NCT06118697|PROCEDURE|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
214822577|NCT00834132|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
214822578|NCT00834132|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
214822579|NCT02305732|BIOLOGICAL|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
214822580|NCT06447948|BEHAVIORAL|Keep Exercising and Stay Steady|"Digital Health, home exercise intervention containing a digital NHS approved falls prevention exercise App (Keep On Keep Up), fitness watches, telephone and/or social media communication, and behavior change techniques.~Currently (date, 13 May 2024) the intervention has not been developed with the community of practice group. Further details of the phase 1 and phase 2 interventions will be provided after the community of practice events."
214822581|NCT01515891|DRUG|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
214822582|NCT02380794|DRUG|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
214822583|NCT02380794|DRUG|Placebo|
214822584|NCT05058430|DEVICE|Electrical salivary stimulator system assigned to subjects with xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
214822585|NCT05058430|DEVICE|No Electrical salivary stimulator system assigned to subjects without xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
214822586|NCT04456972|DIAGNOSTIC_TEST|One arm only|Samples of plasma to analyze ctDNA
214822587|NCT03683667|DRUG|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
214822588|NCT03683667|DRUG|Placebos|Contain inert excipients only
214822589|NCT03683667|DIETARY_SUPPLEMENT|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
214822590|NCT03683667|DIETARY_SUPPLEMENT|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
214822591|NCT03683667|DIETARY_SUPPLEMENT|Egg|Egg provided daily to infants from 6-12 months of age
214822592|NCT03683667|BEHAVIORAL|Nutrition Education|Monthly messaging on infant and young child feeding
214822593|NCT00014768|DRUG|glucose|
214822594|NCT00014768|DRUG|insulin|
214822595|NCT00014768|DRUG|leucine|
214822596|NCT02768701|DRUG|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
214822597|NCT02768701|DRUG|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
214822598|NCT00852163|DRUG|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
214822599|NCT01547286|BIOLOGICAL|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
214822600|NCT01547286|RADIATION|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
214822601|NCT01547286|DRUG|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
214822602|NCT00540995|DRUG|busulfan|Given IV
214822603|NCT00540995|DRUG|etoposide|Given IV
214822604|NCT00540995|RADIATION|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
214822605|NCT00540995|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
214822606|NCT00540995|PROCEDURE|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
214822607|NCT00540995|PROCEDURE|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
214822608|NCT00540995|RADIATION|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
214822609|NCT01464450|DRUG|Rivaroxaban|Single 20 mg-dose
214822610|NCT02376114|DRUG|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
214822611|NCT02376114|DRUG|Placebo to Ginkgo biloba|
214822612|NCT05931458|PROCEDURE|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
214267587|NCT02027883|DEVICE|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
214267588|NCT02027883|DEVICE|Educated T shock setting|Experimental Parameter Set 2 Programming Values
214267589|NCT01367002|DRUG|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
214267590|NCT01367002|DRUG|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
214822613|NCT05931458|DRUG|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
214822614|NCT04176835|DRUG|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
214822615|NCT04176835|DRUG|Placebo|
214822616|NCT03006835|DRUG|Clopidogrel|
214822617|NCT05453422|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
214822618|NCT03257735|DIAGNOSTIC_TEST|next-generation sequencing|"1. Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~2. Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~3. Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
214822619|NCT01804608|OTHER|Strength|
214822620|NCT01804608|OTHER|Sensorimotor|
214822621|NCT03563833|OTHER|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
214822622|NCT03563833|OTHER|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
214822623|NCT05629728|BEHAVIORAL|Tai Chi exercise|Sun-style Tai Chi (21 forms)
214822624|NCT06033417|OTHER|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
214822625|NCT06033417|OTHER|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
214822626|NCT01591564|BEHAVIORAL|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
214822627|NCT03413202|DRUG|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
214822628|NCT03413202|DRUG|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
214822629|NCT01044823|OTHER|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
214822630|NCT04621617|DRUG|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
214822631|NCT04621617|DRUG|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
214822632|NCT04621617|DRUG|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
214822633|NCT03214523|BEHAVIORAL|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
214822634|NCT01465113|DRUG|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
214822635|NCT01465113|DRUG|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
214822636|NCT01465113|DRUG|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
214822637|NCT01465113|PROCEDURE|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
214822638|NCT01465113|DRUG|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
214822639|NCT04322513|DIAGNOSTIC_TEST|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
214822640|NCT05726162|DEVICE|biofeedback-based music program|The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.
214822641|NCT05726162|OTHER|Control|The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
214822642|NCT01690780|DRUG|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
214822643|NCT01690780|DRUG|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
214822644|NCT02695797|OTHER|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
214822645|NCT02695797|DRUG|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
214822646|NCT05823766|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
214822647|NCT05823766|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
214822648|NCT05823766|BEHAVIORAL|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
214822649|NCT05823766|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
214822650|NCT05823766|PROCEDURE|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
214822651|NCT05823766|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
214822652|NCT03784937|DIAGNOSTIC_TEST|Doppler ultrasound|Each patient received Doppler ultrasound for research of DVT, no matter the risk stratification.
214822653|NCT00488774|OTHER|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
214822654|NCT00488774|DRUG|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
214822655|NCT00488774|DRUG|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
214822656|NCT00488774|DRUG|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
214822657|NCT03344055|DEVICE|Endocuff Vision (ECV) second generation|"Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope"
214822658|NCT04244760|BEHAVIORAL|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
214822659|NCT04244760|BEHAVIORAL|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
214822660|NCT04643197|DEVICE|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
214822661|NCT04643197|DEVICE|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
214267591|NCT05575531|OTHER|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
214267592|NCT02655640|OTHER|Questionnaires|Questionnaires will be provided to patients
214267593|NCT03047915|OTHER|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
214267594|NCT00841646|BIOLOGICAL|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
214822662|NCT01560767|DRUG|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
214822663|NCT01560767|DRUG|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
214822664|NCT02682238|DRUG|BBI-4000, 15%|
214822665|NCT02682238|OTHER|Vehicle gel|
214822666|NCT00075478|PROCEDURE|Total-Body Irradiation|Undergo TBI
214822667|NCT00075478|DRUG|Fludarabine Phosphate|Given IV
214822668|NCT00075478|DRUG|Mycophenolate Mofetil|Given PO
214822669|NCT00075478|DRUG|Cyclosporine|Given PO
214822670|NCT00075478|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
214822671|NCT02700776|OTHER|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
214822672|NCT02700776|PROCEDURE|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
214822673|NCT03270462|DRUG|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
214822674|NCT02075463|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
214822675|NCT02075463|DRUG|Placebo|Matching placebo tablet for GSK1278863
214822676|NCT03324594|DEVICE|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"1. WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~2. WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~3. The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
214822677|NCT00061061|BEHAVIORAL|Behavior Therapy|
214822678|NCT00462228|DRUG|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
214822679|NCT00462228|DRUG|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
214822680|NCT00020605|DRUG|naloxone hydrochloride|
214822681|NCT05381688|PROCEDURE|VIM DBS|Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
214822682|NCT00466401|DRUG|Simvastatin|
214822683|NCT00466401|DRUG|Ezetimibe|
214822684|NCT03019367|PROCEDURE|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
214822685|NCT03019367|PROCEDURE|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
214822686|NCT02861560|OTHER|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
214822687|NCT00139594|DRUG|licarbazepine|
214822688|NCT01741948|DRUG|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
214822689|NCT00004801|DRUG|monoclonal factor IX replacement therapy|
214822690|NCT00245063|DRUG|cediranib maleate|Given PO
214822691|NCT00245063|OTHER|laboratory biomarker analysis|Correlative studies
214822692|NCT00245063|OTHER|pharmacogenomic studies|Optional correlative studies
214822693|NCT05174741|OTHER|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
214822694|NCT05174741|OTHER|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
214822695|NCT01370369|DRUG|Testosterone gel (FE 99903)|
214822696|NCT04033276|DRUG|Rituximab|IV rituximab
214822697|NCT04033276|DRUG|intravenous immune globulin|iv intravenous immune globulin
214822698|NCT05099380|DEVICE|senofilcon A C3|TEST Lens
214822699|NCT05099380|DEVICE|senofilcon A|CONTROL Lens
214822700|NCT03789994|BEHAVIORAL|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
214822701|NCT03789994|OTHER|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
214822702|NCT03753230|DEVICE|Electroencephalography|Cerebral measurements from electroencephalography devices while music is presented to the participant
214822703|NCT02295163|PROCEDURE|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
214822704|NCT02295163|PROCEDURE|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
214822705|NCT02405481|BEHAVIORAL|SEPA III|
214822706|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
214822707|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
214822708|NCT04548375|DEVICE|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
214822709|NCT05170594|DRUG|Bevacizumab|Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
214822710|NCT05170594|DRUG|chemotherapy|The non-platinum chemotherapy regimen will be determined by the investigator.
214822711|NCT05170594|DRUG|Fluzoparib|Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
214822712|NCT04446676|DEVICE|stabilization with stem|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
214822713|NCT04446676|DEVICE|stabilization with sleeve|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
214822714|NCT03092466|PROCEDURE|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
214822715|NCT03092466|DRUG|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
214822716|NCT03092466|DRUG|control group|infusion of saline solution (15ml) in femoral catheter
214822717|NCT04518631|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
214822718|NCT00392665|DRUG|Bevacizumab|Given intravenously on day one of each 3 week cycle
214822719|NCT00392665|DRUG|erlotinib|Given orally once a day
214822720|NCT00392665|DRUG|Sulindac|Given orally twice a day
214822721|NCT03730363|DRUG|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
214822722|NCT02846363|OTHER|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
214822723|NCT01350908|OTHER|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
214822724|NCT04677075|PROCEDURE|mastectomy|mastectomy either simple or modified radical
214822725|NCT03902548|DRUG|[18F]P16-129|Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
214822726|NCT00252967|DRUG|Atorvastatin|80 mg of Atorvastatin
214822727|NCT00252967|DRUG|Placebo|
214822728|NCT02294786|DRUG|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
214822729|NCT02294786|DRUG|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
214822730|NCT02294786|DRUG|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
214822731|NCT01717339|OTHER|Sleep Study|
214822732|NCT02283463|DEVICE|Intrauterine device (IUD) insertion|
214822733|NCT02283463|PROCEDURE|Endometrial biopsy|
214822734|NCT01778010|DRUG|Modafinil 0 mg|Modafinil (0 mg/day)
214822735|NCT01778010|DRUG|Modafinil 200 mg|Modafinil (200 mg/day)
214822736|NCT01778010|DRUG|Modafinil 400 mg|Modafinil (400 mg/day)
214822737|NCT01778010|DRUG|Cocaine 0 mg|Cocaine (0 mg/day)
214822738|NCT01778010|DRUG|Cocaine 12 mg|Cocaine (12 mg/day)
214822739|NCT01778010|DRUG|Cocaine 25 mg|Cocaine (25 mg/day)
214822740|NCT01778010|DRUG|Cocaine 50 mg|Cocaine (50 mg/day)
214822741|NCT02157623|DRUG|Levulan|Levulan application followed by Red or Blue light PDT
214822742|NCT02157623|OTHER|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
214822743|NCT02157623|OTHER|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
214822744|NCT05765708|OTHER|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
214822745|NCT05765708|DIAGNOSTIC_TEST|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
214822746|NCT05168150|BEHAVIORAL|Experimental: Experimental Group - Intelligent Continuous Expertise Monitoring System group|During each of the practice task they will receive real-time auditory feedback instructed by the intelligent system. After each attempt, a student takes a 5-minute break. They will be shown the errors they made during the task regarding five performance metrics. After seeing each error, they will be shown video demonstration to learn how to expertly perform at each performance metrics. On their 6th attempt they will perform on the realistic scenario without any feedback given.
214822747|NCT05168150|BEHAVIORAL|Experimental Group In-person expert-mediated instruction group|During each of the practice task, students will receive verbal feedback from the expert instructor present in the room. After each task, experts will summarize their performance and outline the errors the student made. Based on the student's performance, expert will demonstrate how to expertly perform the task in the simulation, and how to improve their performance in the next attempt. Students will perform the 6th attempt on the realistic scenario without any instruction given.
214267595|NCT02614092|BEHAVIORAL|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
214267596|NCT00717093|DRUG|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
214822748|NCT01746056|DEVICE|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
214822749|NCT06196307|COMBINATION_PRODUCT|Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization|"Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)"
214822750|NCT04070547|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
214822751|NCT04070547|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
214822752|NCT04050254|DEVICE|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
214822753|NCT04050254|DEVICE|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
214822754|NCT04050254|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
214822755|NCT00388531|DRUG|Depocyte®|Depocyte® is a cytostatic drug
214822756|NCT05329025|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
214822757|NCT05514392|DEVICE|HP Cosmos Torqoalizer|Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
214822758|NCT00952250|BEHAVIORAL|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
214822759|NCT00952250|BEHAVIORAL|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
214822760|NCT02856386|DIETARY_SUPPLEMENT|polyphenol supplement|8 mL once daily
214822761|NCT05039112|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
214822762|NCT05039112|DEVICE|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
214822763|NCT04306107|DEVICE|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
214822764|NCT00927069|DRUG|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
214822765|NCT00927069|DRUG|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
214822766|NCT02022254|DRUG|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
214822767|NCT02022254|DRUG|placebo|Semaglutide placebo will be administered s.c.
214822768|NCT02022254|DRUG|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
214822769|NCT02022254|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
214822770|NCT02622737|OTHER|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
214822771|NCT02622737|DEVICE|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
214267597|NCT00717093|DRUG|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
214267598|NCT02428270|DRUG|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
214822772|NCT02622737|DEVICE|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
214822773|NCT04459260|BEHAVIORAL|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
214822774|NCT04459260|BEHAVIORAL|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
214822775|NCT02450682|DRUG|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
214822776|NCT02450682|DRUG|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
214822777|NCT04289532|DRUG|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
214822778|NCT00131391|DRUG|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
214822779|NCT00131391|DRUG|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
214822780|NCT05947734|DEVICE|"VTS surgical robotic system"|"TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer."
214822781|NCT02558491|DEVICE|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation."
214822782|NCT02558491|OTHER|Usual Care|During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
214822783|NCT01197391|BIOLOGICAL|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
214822784|NCT00834431|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
214822785|NCT00834431|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
214822786|NCT00746395|DRUG|Lubiprostone|24 mcg oral administration
214822787|NCT00746395|DRUG|Placebo|Oral administration
214822788|NCT06627673|DEVICE|Total Knee Arthroplasty|Primary Total Knee Arthroplasty with a PEEK femoral component
214822789|NCT05384769|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
214822790|NCT05384769|PROCEDURE|Low Dose Computed Tomography of the Chest|Undergo low dose CT
214822791|NCT05384769|OTHER|Survey Administration|Ancillary studies
214822792|NCT05192720|DIETARY_SUPPLEMENT|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
214822793|NCT05192720|DIETARY_SUPPLEMENT|Placebo|drinking water with food colour
214822794|NCT06124638|DIAGNOSTIC_TEST|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
214822795|NCT06429540|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures."
214822796|NCT06429540|BIOLOGICAL|Xenograft|In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
214822797|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray|on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
214822798|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray|on-demand or maintenance
214822799|NCT06293586|PROCEDURE|peribulbar block|"Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes"
214267599|NCT02428270|DRUG|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
214822800|NCT06293586|PROCEDURE|sub-tenon block|Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
214822801|NCT06293586|DRUG|Paracetamol|Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
214822802|NCT01931553|OTHER|Standardized attending morning rounds|
214822803|NCT04979663|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
214822804|NCT04694963|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
214822805|NCT04694963|PROCEDURE|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
214822806|NCT04694963|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
214822807|NCT02514382|DRUG|Bortezomib|Given SC or IV
214822808|NCT02514382|DRUG|Dexamethasone|Given PO, IV, or IM
214822809|NCT02514382|OTHER|Laboratory Biomarker Analysis|Correlative studies
214822810|NCT02514382|OTHER|Pharmacological Study|Correlative studies
214822811|NCT02514382|BIOLOGICAL|Wild-type Reovirus|Given IV
214822812|NCT05248711|BEHAVIORAL|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
214822813|NCT01714895|OTHER|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
214822814|NCT01714895|OTHER|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
214822815|NCT03058003|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext\_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
214822816|NCT03058003|OTHER|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
214822817|NCT02836821|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
214822818|NCT02836821|DRUG|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
214822819|NCT04380181|DRUG|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
214822820|NCT03716466|OTHER|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
214822821|NCT03716466|OTHER|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
214822822|NCT03664063|DRUG|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
214822823|NCT03664063|DRUG|Albendazole|"Single dose of Albendazole weight based dosing~\- 400mg"
214822824|NCT03664063|DRUG|Ivermectin|Ivermectin weight based dosing - max 21mg
214822825|NCT03664063|DRUG|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
214822826|NCT00835263|DRUG|Lamotrigine|200 mg Tablet
214822827|NCT00835263|DRUG|Lamictal®|200 mg Tablet
214822828|NCT06562621|BIOLOGICAL|ON-01|ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
214822829|NCT06562621|DRUG|ONF|ONF is an extended-release formulation of flucytosine.
214267600|NCT04546061|BEHAVIORAL|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
214267601|NCT00804674|DRUG|bupivacain|
214267602|NCT00804674|DRUG|placebo|
214267603|NCT00354536|DRUG|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
214822830|NCT02748707|DRUG|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
214822831|NCT02748707|DRUG|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
214822832|NCT02748707|DRUG|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
214822833|NCT02748707|OTHER|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
214822834|NCT01131637|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
214822835|NCT01131637|DRUG|placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
214822836|NCT01891461|DRUG|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
214822837|NCT03249454|DEVICE|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
214822838|NCT03249454|DEVICE|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
214267604|NCT00354536|BIOLOGICAL|placebo injection|placebo injection
214822839|NCT03249454|DEVICE|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
214822840|NCT05281861|OTHER|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
214822841|NCT05281861|OTHER|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
214822842|NCT01910753|PROCEDURE|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
214822843|NCT03972683|OTHER|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
214822844|NCT03972683|DRUG|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
214822845|NCT03972683|DRUG|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
214822846|NCT03972683|DRUG|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
214822847|NCT03972683|DRUG|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
214822848|NCT03972683|DRUG|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
214822849|NCT04776798|OTHER|Taping|Tape applications will repeat twice per week, for 4 weeks.
214822850|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
214822851|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
214822852|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
214822853|NCT01009229|DIETARY_SUPPLEMENT|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
214822854|NCT05172947|DRUG|Resveratrol|This group received resveratrol with the conventional therapy
214822855|NCT05172947|DRUG|Placebo|This group received placebo with the conventional therapy
214822856|NCT05172947|OTHER|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
214822857|NCT05172947|OTHER|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
214822858|NCT05723393|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound
214822859|NCT00151593|OTHER|Celsior®|Graft preservation solution
214822860|NCT04890353|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
214822861|NCT00489177|DEVICE|A|QuickOpt intra-cardiac electrogram optimization
214822862|NCT00489177|DEVICE|B|Single optimization in initial month post-implant
214822863|NCT02412085|DRUG|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks"
214822864|NCT03036748|DIETARY_SUPPLEMENT|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
214822865|NCT03036748|DRUG|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
214822866|NCT01328652|DRUG|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
214822867|NCT01913405|BIOLOGICAL|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
214822868|NCT06485908|DRUG|administration of axitinib in combination with etoposide|"1. st stage:~   * Axitinib (Inlyta®) PO, in the morning and in the evening every day~  * Level -1 : Dose 1.2 mg/m²~  * Level 1: Dose 1.6 mg/m²~  * Level 2: Dose 2.0 mg/m²~  * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~   * Axitinib (Inlyta®) dosing as selected at the 1st stage~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)"
214822869|NCT00754455|BIOLOGICAL|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
214822870|NCT00754455|BIOLOGICAL|Placebo|Placebo as a single injection of 0.5 mL.
214822871|NCT03856320|BEHAVIORAL|Educational Video|An educational video describing obesity treatment options available in the VA.
214822872|NCT02825160|DRUG|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
214822873|NCT06560060|OTHER|No intervention|There are no interventions. The only medical procedure is a blood draw
214822874|NCT03428880|DRUG|Morphine|spinal morphine is done before cesarean section
214822875|NCT03428880|DRUG|Quadratus lumborum block|a US Block QLB is done after surgery
214822876|NCT03151876|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
214822877|NCT03151876|DRUG|Cladribine|6 mg/m2 intravenously daily for 5 days
214822878|NCT03151876|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
214822879|NCT03151876|DRUG|Busulfan|3.2 mg/kg intravenously daily for 4 days
214822880|NCT03151876|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
214822881|NCT05694676|OTHER|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
214822882|NCT05694676|OTHER|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
214822883|NCT05694676|OTHER|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
214822884|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection|IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
214822885|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo|0.5ml, H. Administer the drug once every 14 days for 64 weeks
214822886|NCT01020474|DRUG|placebo|matching placebo capsules twice daily.
214822887|NCT01020474|DRUG|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
214822888|NCT03987191|DRUG|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
214822889|NCT06562231|OTHER|quality of life scale|This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
214822890|NCT00350389|BEHAVIORAL|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
214822891|NCT01065740|OTHER|Patient education|
214822892|NCT04684186|PROCEDURE|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
214822893|NCT04684186|PROCEDURE|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
214822894|NCT00372086|DRUG|Rosiglitazone|
214822895|NCT01148186|BEHAVIORAL|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
214822896|NCT04964440|DEVICE|Pure-EP|Advanced Signal Acquisition and Processing
214267605|NCT05557708|DRUG|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
214822897|NCT01490567|DRUG|Donepezil|5 mg/day
214822898|NCT01490567|DRUG|placebo|placebo 5mg/d
214822899|NCT03261167|DRUG|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
214822900|NCT03261167|DRUG|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
214822901|NCT05241639|DIAGNOSTIC_TEST|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
214822902|NCT02070458|DRUG|ixazomib|Given PO
214822903|NCT02070458|DRUG|mitoxantrone hydrochloride|Given IV
214822904|NCT02070458|DRUG|etoposide|Given IV
214822905|NCT02070458|DRUG|cytarabine|Given IV
214822906|NCT05464563|DEVICE|Electroencephalogram|An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
214822907|NCT03600363|DRUG|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
214822908|NCT03600363|DRUG|Placebos|oral placebos as a maintenance therapy
214822909|NCT04853563|OTHER|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
214822910|NCT06446479|DRUG|Dronabinol Pill|Dronabinol 20 mg
214822911|NCT06446479|DRUG|Placebo|placebo
214822912|NCT01425086|DEVICE|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
214822913|NCT06319495|BEHAVIORAL|Rehabilitation therapy|"During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
214822914|NCT06319495|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214822915|NCT06319495|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214822916|NCT06319495|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214822917|NCT00835146|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
214822918|NCT00835146|DRUG|COPEGUS™|1 x 200 mg, single-dose fasting
214822919|NCT00663481|DRUG|CoFactor|
214822920|NCT00663481|DRUG|Leucovorin|
214822921|NCT00468455|PROCEDURE|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
214822922|NCT05365308|BEHAVIORAL|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
214822923|NCT03004118|DIETARY_SUPPLEMENT|Nutridrink|Liquid meal of 200ml
214822924|NCT03004118|DEVICE|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
214822925|NCT03004118|DEVICE|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
214822926|NCT03004118|DRUG|Placebo Oral Tablet|4 week oral intake (daily)
214822927|NCT03004118|DRUG|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
214822928|NCT03004118|DEVICE|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
214822929|NCT03004118|PROCEDURE|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
214822930|NCT03004118|PROCEDURE|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
214822931|NCT06627218|DRUG|Prothrombin Complex Concentrate|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
214822932|NCT05086003|COMBINATION_PRODUCT|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
214822933|NCT01198964|PROCEDURE|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
214822934|NCT05502679|OTHER|Weight bearing as tolerated|Bearing weight on lower limb extremity
214822935|NCT05502679|OTHER|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
214822936|NCT04374864|DRUG|Trelagliptin|Anti diabetic
214267606|NCT05557708|DIAGNOSTIC_TEST|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
214267607|NCT02684916|PROCEDURE|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
214822937|NCT04763733|OTHER|laparoscopic splenectomy|surgical
214822938|NCT05637333|DIAGNOSTIC_TEST|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
214822939|NCT03851354|OTHER|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
214822940|NCT06350240|BEHAVIORAL|Exercise|An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
214822941|NCT06350240|BEHAVIORAL|Exercise+texture insoles|In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
214822942|NCT05513677|DEVICE|M4D|Coated catheter
214822943|NCT05513677|DEVICE|Standard of Care|Standard of Care
214822944|NCT03199963|DRUG|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
214822945|NCT03199963|DRUG|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
214822946|NCT00466167|DRUG|Pramipexol Extended Release|
214822947|NCT00466167|DRUG|Pramipexol Immediate Release|
214822948|NCT00466167|DRUG|Placebo|
214822949|NCT06373185|PROCEDURE|Ultrasound-guided sacral erector spinae plane block|Patients were received ultrasound-guided sacral erector spinae plane block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
214822950|NCT06373185|PROCEDURE|Ultrasound-guided caudal block|Patients were received ultrasound-guided caudal block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
214822951|NCT03145623|DRUG|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
214822952|NCT01470976|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%."
214822953|NCT01470976|OTHER|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
214822954|NCT02784262|DRUG|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
214822955|NCT01836380|BEHAVIORAL|Exercise Training|
214822956|NCT00727480|PROCEDURE|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
214822957|NCT01144494|DRUG|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
214822958|NCT01144494|DRUG|Artificial tears|Lubricating drops added three times a day for six weeks
214822959|NCT04435067|GENETIC|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
214822960|NCT04435067|OTHER|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D\_average, Gray Level Co-occurrence Matrix 3D\_combined, Gray Level Run Length 3D\_average, Gray Level Run Length 3D\_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
214822961|NCT02611440|BEHAVIORAL|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
214822962|NCT04354363|OTHER|Platelet rich plasma|Giving women PRP before ICSI
214822963|NCT04452786|PROCEDURE|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
214822964|NCT04452786|PROCEDURE|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
214822965|NCT00684697|DIETARY_SUPPLEMENT|iron|High, intermediate and low iron dosage orally for 2 months
214822966|NCT02125760|OTHER|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
214822967|NCT02125760|OTHER|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
214822968|NCT03686540|PROCEDURE|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
214822969|NCT02463786|OTHER|No intervention|No intervention
214822970|NCT01039363|DRUG|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
214822971|NCT04942496|DRUG|Chlorhexidine Gluconate|Antimicrobial Skin Wash
214822972|NCT04942496|DEVICE|Hibi Universal Bathing System|Cloths used for patient bathing
214822973|NCT04942496|OTHER|0.1% SLS|Positive control
214822974|NCT04942496|OTHER|Distilled Water|Negative Control
214822975|NCT00161785|BIOLOGICAL|FSME-IMMUN 0.5ml|
214822976|NCT02278809|BEHAVIORAL|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
214822977|NCT03559907|BEHAVIORAL|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
214822978|NCT03559907|BEHAVIORAL|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
214822979|NCT06558500|PROCEDURE|Uterocervical angle|"With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form."
214822980|NCT04958915|DIAGNOSTIC_TEST|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
214822981|NCT06412861|DRUG|Ketamine|0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
214822982|NCT06412861|DRUG|Fentanyl|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
214822983|NCT05799677|OTHER|Reflexology|Additive reflexology treatment
214822984|NCT05997797|OTHER|FAAM|The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
214822985|NCT04725747|DRUG|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
214822986|NCT04725747|DRUG|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
214822987|NCT04725747|DRUG|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
214822988|NCT01101620|DRUG|Levosimendan|
214822989|NCT06626165|DRUG|Mirikizumab|Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.
214822990|NCT06626165|DRUG|Vedolizumab|Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
214822991|NCT02189226|DEVICE|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
214822992|NCT00900094|GENETIC|fluorescence in situ hybridization|
214822993|NCT00900094|GENETIC|polymerase chain reaction|
214822994|NCT00900094|GENETIC|protein expression analysis|
214822995|NCT00900094|OTHER|immunohistochemistry staining method|
214822996|NCT00900094|OTHER|laboratory biomarker analysis|
214822997|NCT00900094|OTHER|mass spectrometry|
214822998|NCT06289738|OTHER|ICF|Matching the answers given to the question set consisting of 6 open-ended questions with ICF
214822999|NCT00599820|DRUG|Intravitreal Bevacizumab|
214823000|NCT02465125|BIOLOGICAL|red blood cell transfusion|
214823001|NCT04775004|OTHER|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
214823002|NCT04775004|OTHER|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
214823003|NCT00616863|DRUG|Oxcarbazepine|
214823004|NCT06208358|DEVICE|tACS|We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
214823005|NCT01002963|DRUG|PF-04418948|solution, 30 mg, single
214823006|NCT01002963|DRUG|PF-04418948|solution, 100 mg, single
214823007|NCT01002963|DRUG|PF-04418948|solution, 300 mg, single
214823008|NCT01002963|DRUG|PF-04418948|solution, 1000 mg, single
214823009|NCT01002963|DRUG|PF-04418948|solution, 3000 mg, single
214823010|NCT01002963|DRUG|PF-04418948|solution, 4500 mg, single
214823011|NCT01002963|DRUG|PF-04418948|solution, 6000 mg, single
214823012|NCT03516539|DEVICE|Group ML|Mcgrath videolaryngoscope
214823013|NCT03516539|DEVICE|Group DL|Macintosh laryngoscope
214823014|NCT04987216|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
214823015|NCT00818558|BIOLOGICAL|ISET Methode|Sampling of blood - ISET Methode
214823016|NCT02927639|OTHER|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
214823017|NCT00404963|DRUG|placebo|
214823018|NCT00404963|DRUG|GSK376501|
214823019|NCT04342663|DRUG|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
214823020|NCT04342663|DRUG|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
214823021|NCT01309763|BIOLOGICAL|AFFITOPE AD03|s.c. injection
214823022|NCT01309763|BIOLOGICAL|AFFITOPE AD03 + Alum|s.c. injection
214823023|NCT00346190|DRUG|Alendronate|
214823024|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
214823025|NCT03643250|OTHER|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
214823026|NCT03643250|OTHER|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
214823027|NCT03643250|OTHER|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
214823028|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
214823029|NCT03264521|OTHER|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
214823030|NCT06626984|DRUG|Imatinib|Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
214823031|NCT06626984|DRUG|Compound sodium lactate solution|Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
214823032|NCT05859984|DRUG|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
214823033|NCT05347459|DRUG|Dapagliflozin|usual and customary doses for type 2 diabetes management
214823034|NCT05347459|DRUG|Empagliflozin|usual and customary doses for type 2 diabetes management
214823035|NCT05347459|DRUG|Canagliflozin|usual and customary doses for type 2 diabetes management
214823036|NCT05347459|DRUG|Sitagliptin|usual and customary doses for type 2 diabetes management
214823037|NCT05347459|DRUG|Saxagliptin|usual and customary doses for type 2 diabetes management
214823038|NCT05347459|DRUG|Linagliptin|usual and customary doses for type 2 diabetes management
214823039|NCT05347459|DRUG|Vildagliptin|usual and customary doses for type 2 diabetes management
214823040|NCT02308059|OTHER|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
214823041|NCT02308059|OTHER|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
214823042|NCT06133101|DRUG|Standard Soy Milk|Consumption of commercially available soy milk
214823043|NCT06133101|DRUG|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
214823044|NCT06468839|BEHAVIORAL|digital addiction management model|The experimental group will implement a digital addiction model. No intervention will be made to the control group.
214823045|NCT05069480|DEVICE|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
214823046|NCT05069480|OTHER|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
214823047|NCT04366960|DRUG|Enoxaparin|Subcutaneous enoxaparin
214823048|NCT06042231|BEHAVIORAL|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
214823049|NCT06042231|BEHAVIORAL|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
214823050|NCT03366792|DEVICE|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
214823051|NCT04471922|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
214823052|NCT04471922|DRUG|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
214823053|NCT04471922|DRUG|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
214823054|NCT03545022|PROCEDURE|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
214823055|NCT02450539|DRUG|Abemaciclib|Administered orally
214823056|NCT02450539|DRUG|Docetaxel|Administered IV
214823057|NCT06154096|OTHER|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
214823058|NCT01826838|DRUG|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
214823059|NCT04041713|DRUG|Rett-T|antioxidant cocktail
214823060|NCT04041713|OTHER|Placebo|Placebo
214823061|NCT04525027|DIAGNOSTIC_TEST|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
214823062|NCT04685291|PROCEDURE|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
214823063|NCT04685291|DRUG|Conventional pain management|"* oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
214823064|NCT02532439|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
214823065|NCT02532439|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
214823066|NCT02532439|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
214823067|NCT01640197|DIETARY_SUPPLEMENT|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
214823068|NCT01640197|OTHER|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
214823069|NCT05799313|OTHER|At home removal|Removal of PNE lead at home
214823070|NCT05799313|OTHER|In office removal|Removal of PNE lead in the office
214823071|NCT02256943|DRUG|Amitriptyline|100 mg single dose
214823072|NCT02256943|DRUG|Tolterodine|Placebo 1 mg single dose
214823073|NCT00402103|DRUG|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
214823074|NCT00402103|DRUG|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
214823075|NCT00402103|DRUG|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
214823076|NCT06352138|BIOLOGICAL|Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.|comparison vs the reference product to demonstrate biological similarity
214823077|NCT06352138|BIOLOGICAL|Active comparator: European Union licenced epoetin alfa|comparison vs. the test product to demonstrate biological similarity
214823078|NCT05569512|DRUG|Uproleselan|Administered by intravenous infusion
214823079|NCT05569512|DRUG|Fludarabine|Administered by intravenous infusion
214823080|NCT05569512|DRUG|Clofarabine|Administered by intravenous infusion
214823081|NCT05569512|DRUG|Busulfan|Administered by intravenous infusion
214823082|NCT06559969|DRUG|Intravenous administered opioid|Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
214823083|NCT06559969|DRUG|Epidural administered opioid|Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
214823084|NCT02128308|DRUG|Levofloxacin and Streptomycin added|
214823085|NCT02128308|DRUG|Moxifloxacin and Kanamycin added|
214823086|NCT06560528|DRUG|combination with Disitamab Vedotin and with Tislelizumab and Capecitabine|"Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W."
214823087|NCT01360138|PROCEDURE|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
214823088|NCT06562387|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
214823089|NCT06562387|OTHER|cognitive stimulation|This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
214823090|NCT06562387|DEVICE|sham transcranial direct current stimulation|Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.
214823091|NCT02317263|DRUG|testosterone|
214823092|NCT02317263|DRUG|placebo gel|
214823093|NCT00604474|DEVICE|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
214823094|NCT03823924|PROCEDURE|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
214823095|NCT00000915|BEHAVIORAL|Vaccine preparedness|
214823096|NCT01090687|RADIATION|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
214823097|NCT01090687|DEVICE|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
214823098|NCT04078022|BIOLOGICAL|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
214823099|NCT04078022|OTHER|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
214823100|NCT04078022|BIOLOGICAL|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
214823101|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment A|
214823102|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment B|
214823103|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment C|
214823104|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment D|Placebo
214823105|NCT01895335|DRUG|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
214823106|NCT00418938|DRUG|Panitumumab|6mg/kg IV
214823107|NCT00418938|DRUG|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
214823108|NCT00418938|DRUG|Leucovorin|400mg/m\^2 IV (in the vein)
214823109|NCT00418938|DRUG|Irinotecan|180mg/m\^2 IV (in the vein)
214823110|NCT00418938|DRUG|5-Fluorouracil|400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
214823111|NCT00463684|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
214823112|NCT00463684|BIOLOGICAL|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
214823113|NCT00082147|PROCEDURE|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
214823114|NCT04952857|DRUG|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
214823115|NCT00115063|BEHAVIORAL|group sessions|group sessions lead by a trained primary care clinic employee
214823116|NCT00115063|DRUG|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
214823117|NCT00115063|BEHAVIORAL|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
214823118|NCT00115063|OTHER|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
214823119|NCT00115063|OTHER|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
214823120|NCT05125900|OTHER|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
214823121|NCT05949853|OTHER|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
214823122|NCT00990535|DRUG|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
214823123|NCT04948619|BIOLOGICAL|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
214823124|NCT01857947|OTHER|AECOPD Mr proADM|
214823125|NCT03072030|BIOLOGICAL|GamEvac-Combi (vaccine)|vaccination
214823126|NCT03072030|BIOLOGICAL|Placebo|vaccination
214823127|NCT00789308|DRUG|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
214823128|NCT00789308|DRUG|Heparin|Anticoagulation
214823129|NCT00789308|DRUG|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
214823130|NCT00789308|DRUG|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
214823131|NCT00789308|DRUG|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
214823132|NCT00789308|DRUG|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
214823133|NCT00789308|DRUG|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
214823134|NCT00789308|DRUG|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
214823135|NCT00789308|DRUG|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
214823136|NCT01776138|OTHER|Collect Blood and Survey Instruments|
214823137|NCT01349257|DRUG|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
214823138|NCT00191815|DRUG|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
214823139|NCT00191815|DRUG|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
214823140|NCT02982577|DRUG|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
214823141|NCT02982577|OTHER|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
214823142|NCT06302114|OTHER|Assessment of overhead athletes|Assessment of medicine ball forward throw, Y balance test, Range of motion of the shoulder (internal and external rotation), strength of internal and external rotator muscles.
214823143|NCT04215328|DIETARY_SUPPLEMENT|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
214823144|NCT04215328|DIETARY_SUPPLEMENT|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
214823145|NCT01208935|DRUG|Nicotine Patch|
214823146|NCT01208935|DRUG|Nicotine Gum|
214823147|NCT02552758|BIOLOGICAL|omega-3 fatty acid|omega-3 fatty acid
214823148|NCT02552758|BIOLOGICAL|placebo|placebo
214823149|NCT02552758|DEVICE|positron emission tomography (PET)|
214823150|NCT04454229|OTHER|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
214823151|NCT04454229|OTHER|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
214823152|NCT00926835|DRUG|paroxetine|6 weeks, 20-50mg/day
214823153|NCT00926835|DRUG|Escitalopram|10-20mg/day for 6 weeks
214823154|NCT00926835|DRUG|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
214823155|NCT00926835|DRUG|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
214823156|NCT00926835|DRUG|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
214823157|NCT00926835|DRUG|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
214823158|NCT00926835|DRUG|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
214823159|NCT00926835|DRUG|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
214823160|NCT00926835|DRUG|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
214823161|NCT00831103|DRUG|EPB-348|Treated over seven days
214823162|NCT00831103|DRUG|Valacyclovir|Treated over seven days
214823163|NCT01075282|DRUG|Insulin Glargine|
214823164|NCT01075282|DRUG|LY2189265|
214823165|NCT01075282|DRUG|Metformin|
214823166|NCT01075282|DRUG|Glimepiride|
214823167|NCT05997108|DIAGNOSTIC_TEST|CBC|Platelet and red blood cell volume indices
214823168|NCT05277402|DRUG|ADG116|IV infusion
214823169|NCT00002562|DRUG|paclitaxel|
214823170|NCT03011294|DEVICE|Continuous positive airway pressure (CPAP)|Standard treatment for sleep apnea
214823171|NCT03011294|DEVICE|Nasal strip|Placebo
214823172|NCT02598323|DEVICE|ultrasound|
214823173|NCT03323008|OTHER|Prototype|Usability testing and System Usability Scale
214823174|NCT04521218|OTHER|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
214823175|NCT04521218|OTHER|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
214823176|NCT04415515|BEHAVIORAL|RN case management|A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, \& to develop a case management plan that focuses on improving medication adherence \& reconciliation, condition-based measures \& outcomes, addressing psycho-social needs, \& intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, \& support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment \& coordinate services).
214823177|NCT04415515|BEHAVIORAL|Community Health Worker Case Management|In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).
214823178|NCT04415515|BEHAVIORAL|RN Standard care coordination and disease management|RN Standard care coordination and disease management
214823179|NCT00210587|DRUG|epoetin alfa|
214823180|NCT04371133|DIAGNOSTIC_TEST|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
214823181|NCT05131113|OTHER|Physical exercise|Physical exercise
214823182|NCT05922696|DRUG|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
214823183|NCT00471133|BIOLOGICAL|Xenogeneic Tyrosinase DNA Vaccine|
214823184|NCT00471133|DEVICE|TriGrid Delivery System for Intramuscular Electroporation|
214823185|NCT01468272|DRUG|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
214823186|NCT01468272|DRUG|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
214823187|NCT05229133|DEVICE|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
214823188|NCT02969616|BIOLOGICAL|Trinity Elite|cell based allograft
214823189|NCT03332485|DRUG|ECP Colon Prep Kit|ECP Colon Prep Kit
214823190|NCT03332485|DRUG|MoviPrep®|MoviPrep®
214823191|NCT01794845|DRUG|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
214823192|NCT01794845|DRUG|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
214823193|NCT01794845|RADIATION|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
214823194|NCT02662933|OTHER|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
214823195|NCT03184389|BEHAVIORAL|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
214823196|NCT02139826|DRUG|IX-01|
214823197|NCT00621491|DRUG|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
214823198|NCT02261389|OTHER|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
214823199|NCT00966589|PROCEDURE|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
214823200|NCT00830349|DRUG|Risperidone|1 mg Tablet
214823201|NCT00830349|DRUG|Risperidone|1 mg Tablets
214823202|NCT03507491|DRUG|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
214823203|NCT03507491|DRUG|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
214823204|NCT04802694|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart."
214823205|NCT04802694|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale . Since the hydrocolloid barrier tape can stay on the skin for 7 days and be transparent, the assessment of skin condition will be realized for 7 days and noted down to the chart."
214823206|NCT04802694|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart."
214823207|NCT04584294|BEHAVIORAL|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
214823208|NCT05867862|OTHER|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
214823209|NCT03913065|DIAGNOSTIC_TEST|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
214823210|NCT05235581|OTHER|Intervention A : virtual environment with avatar|30-second right and left unipodal static and dynamic balance test with avatar only
214823211|NCT05235581|OTHER|Intervention B : virtual environment with reinforced visual signal|30-second right and left unipodal static and dynamic balance test with reinforced visual signal only
214823212|NCT05235581|OTHER|Intervention C : virtual environment with avatar and reinforced visual signal|30-second right and left unipodal static and dynamic balance test with avatar and reinforced visual signal
214823213|NCT05235581|OTHER|Intervention D : real environment|30-second right and left unipodal static and dynamic balance test in real environment
214823214|NCT04410263|DIAGNOSTIC_TEST|Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)|"Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy"
214823215|NCT03725969|DIETARY_SUPPLEMENT|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
214823216|NCT03725969|DIETARY_SUPPLEMENT|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
214823217|NCT01747694|BEHAVIORAL|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
214823218|NCT00429416|DRUG|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
214823219|NCT00429416|DRUG|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
214823220|NCT00429416|DRUG|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
214823221|NCT00429416|DRUG|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
214823222|NCT00429416|DRUG|Tacrolimus|Tacrolimus given before and after HSCT infusion
214823223|NCT00429416|DRUG|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
214823224|NCT00429416|BIOLOGICAL|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
214823225|NCT00429416|PROCEDURE|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
214823226|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Tibial Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the tibial nerve on one leg, with electrodes above the malleolus and on the bottom of the foot"
214823227|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Genital Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the genital nerve, with electrodes on either side of the clitoris."
214823228|NCT06999265|BEHAVIORAL|Neutral and Erotic Film Clip Alternation|During the testing period, participants will first view a 5-minute neutral film depicting nature scenes to allow blood flow levels to stabilize. This will be followed by a 10-minute period while the subject watches an erotic film clip for assessment of arousal responses without electrical stimulation. A 10-minute clip of the same neutral film will follow, to allow blood flow levels to return to baseline. Five minutes into this film, electrical stimulation will be resumed at the previously determined amplitude. Finally, the subject will view another 10-minute erotic film clip depicting similar sexually explicit material as the first while electrical stimulation remains on as the last sequence in the testing. Physiological arousal will be assessed with a vaginal photoplethysmography probe, yielding vaginal pulse amplitude (VPA) for analysis. Subjective arousal will be assessed with a subjective arousal questionnaire.
214823229|NCT04564053|DRUG|LNA043|Single intra-articular injection on Day 1
214823230|NCT04564053|DRUG|Placebo|Single intra-articular injection on Day 1
214823231|NCT05526183|BIOLOGICAL|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
214823232|NCT06701240|BEHAVIORAL|ParentChild+|92-session early literacy focused intervention
214823233|NCT06701240|BEHAVIORAL|FamilyNutrition+|92-session active control focused on child nutrition
214823234|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
214823235|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
214823236|NCT05355883|BEHAVIORAL|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
214823237|NCT05355883|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
214823238|NCT05355883|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
214823239|NCT05355883|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
214823240|NCT05355883|BEHAVIORAL|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
214823241|NCT02316548|RADIATION|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
214823242|NCT02571907|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
214823243|NCT02571907|DEVICE|Atrium iCAST™|Implantation of Atrium iCAST
214823244|NCT02571907|DEVICE|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
214823245|NCT01512823|BEHAVIORAL|Education|"Interactive educational intervention:~* 4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~* Emailed notes from second session~* Telephonic/email follow-up (reminders)~Didactic educational intervention:~\- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
214823246|NCT02324660|OTHER|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
214823247|NCT06649110|DRUG|LTP|LTP001
214823248|NCT06649110|DRUG|Placebo|Placebo
214823249|NCT03666026|BEHAVIORAL|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
214823250|NCT03666026|BEHAVIORAL|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
214823251|NCT03666026|BEHAVIORAL|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
214823252|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
214823253|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
214823254|NCT06191094|DRUG|Faricimab Injection|Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.
214823255|NCT06191094|DRUG|sham treatment|Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
214823256|NCT02286739|DEVICE|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA pre-market submission (510K) clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
214823257|NCT02286739|PROCEDURE|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
214823258|NCT02286050|OTHER|CF Nursing Program|
214823259|NCT05572281|DRUG|Tasimelteon Oral Capsule|No additional information
214823260|NCT05572281|DRUG|Tasimelteon Oral Suspension|No additional information
214823261|NCT04071652|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
214823262|NCT01093989|DIETARY_SUPPLEMENT|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
214823263|NCT06035250|DRUG|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
214823264|NCT02566850|DEVICE|Ekso|powered lower extremity exoskeleton
214823265|NCT03913676|BEHAVIORAL|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
214823266|NCT01343004|DRUG|Placebo|Placebo 0 mcg subcutaneous daily
214823267|NCT01343004|DRUG|BA058 80 mcg|BA058 80 mcg subcutaneous daily
214823268|NCT01343004|DRUG|teriparatide|teriparatide 20 mcg subcutaneous daily
214823269|NCT03447353|DRUG|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
214823270|NCT03447353|DRUG|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
214823271|NCT03447353|DRUG|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
214823272|NCT00313794|DRUG|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
214823273|NCT01660789|BEHAVIORAL|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
214823274|NCT03110848|DRUG|Atorvastatin|Atorvastatin 20 mg daily
214823275|NCT03110848|DRUG|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
214823276|NCT05635448|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
214823277|NCT05635448|BEHAVIORAL|No intervention - waitlist control|No intervention - waitlist control
214823278|NCT05217472|DRUG|Ravaglimab|Intravenous Injection
214823279|NCT05217472|DRUG|Ravagalimab|Subcutaneous Injection
214823280|NCT05217472|DRUG|Placebo|Intravenous Injection
214823281|NCT05217472|DRUG|Placebo|Subcutaneous Injection
214823282|NCT02486081|DEVICE|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
214823283|NCT04504617|BEHAVIORAL|Nutrition education intervention to enhance complementary feeding practices|The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
214823284|NCT02399423|BEHAVIORAL|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
214823285|NCT02399423|BEHAVIORAL|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
214823286|NCT03306030|DRUG|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
214823287|NCT03306030|DRUG|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
214823288|NCT03374605|DEVICE|active tDCS|15 minutes of active (2mA) high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
214823289|NCT03374605|DEVICE|sham tDCS|15 minutes of sham high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
214823290|NCT00089011|DRUG|fludarabine phosphate|Given IV
214823291|NCT00089011|RADIATION|total-body irradiation|Undergo radiotherapy
214823292|NCT00089011|DRUG|mycophenolate mofetil|Given IV or PO
214823293|NCT00089011|DRUG|tacrolimus|Given IV or PO
214823294|NCT00089011|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
214823295|NCT00089011|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
214823296|NCT00089011|OTHER|laboratory biomarker analysis|Correlative studies
214823297|NCT06627062|PROCEDURE|moderate and severe subluxated lens extraction|A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
214823298|NCT05343676|DEVICE|ultrasonography|"* For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~* For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~* Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
214823299|NCT05468879|DRUG|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
214823300|NCT05468879|DRUG|Amaryl®|Amaryl®
214823301|NCT00526188|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
214823302|NCT01373593|DRUG|lidocaine|
214823303|NCT01373593|DRUG|Placebo|
214823304|NCT04196907|DEVICE|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
214823305|NCT04102085|OTHER|no intervention|no intervention
214823306|NCT02529709|OTHER|High-Protein Condition|The participants will be fed a high-protein meal
214823307|NCT02529709|OTHER|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
214823308|NCT02570477|PROCEDURE|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
214823309|NCT02570477|DRUG|Vancomycin|125mg Vancomycin four times per day
214823310|NCT02642653|DRUG|Lovastatin|Once per day dosing
214823311|NCT02642653|OTHER|Placebo|Once per day dosing
214823312|NCT03307577|DRUG|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
214823313|NCT03307577|OTHER|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
214823314|NCT00211653|DRUG|N-Acetylcysteine|
214823315|NCT01424761|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
214823316|NCT01424761|OTHER|Placebo|Placebo :starch
214823317|NCT03647254|BEHAVIORAL|Patient education group|Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
214823318|NCT04830462|DRUG|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
214823319|NCT04830462|DRUG|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
214823320|NCT02942563|DRUG|FOLFOXIRI|"Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
214823321|NCT00830258|DRUG|Pravastatin sodium 80 mg tablets|1 x 80 mg
214823322|NCT00830258|DRUG|Pravachol® 80 mg tablets|1 x 80 mg
214823323|NCT00809250|BIOLOGICAL|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
214823324|NCT01344590|OTHER|Normal Saline|Standard saline procedure will be utilized.
214823325|NCT01344590|OTHER|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
214823326|NCT00893685|DEVICE|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
214823327|NCT03909607|DRUG|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
214823328|NCT03909607|DRUG|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
214823329|NCT03909607|DRUG|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
214823330|NCT02267187|PROCEDURE|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
214823331|NCT02267187|DRUG|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
214823332|NCT02267187|DEVICE|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
214823333|NCT02267187|OTHER|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
214823334|NCT00682461|DRUG|Nicotine|Marketed nicotine replacement therapy formulation
214823335|NCT00682461|DRUG|Nicotine|Nicotine prototype
214823336|NCT01497587|DRUG|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
214823337|NCT06060145|OTHER|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
214823338|NCT06060145|OTHER|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
214823339|NCT03579615|DEVICE|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
214823340|NCT03579615|DEVICE|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
214823341|NCT02427763|DEVICE|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
214823342|NCT02427763|OTHER|collect saliva|the patient spit during 30 seconds in a small bottle
214823343|NCT02427763|OTHER|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
214823344|NCT02427763|OTHER|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
214823345|NCT04722198|DIETARY_SUPPLEMENT|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
214823346|NCT00954460|DRUG|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
214823347|NCT01385930|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
214823348|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
214823349|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention without Mutual Gaze|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, social sensory routines, and naturalistic developmental behavioral strategies described in the program manual. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
214823350|NCT04410380|BEHAVIORAL|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
214823351|NCT03665194|DRUG|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
214823352|NCT03665194|DRUG|Placebo|matching placebo
214823353|NCT02697682|BIOLOGICAL|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
214823354|NCT05488158|OTHER|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
214823355|NCT02798458|DEVICE|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
214823356|NCT02798458|PROCEDURE|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
214823357|NCT00864396|DRUG|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
214823358|NCT05936645|PROCEDURE|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
214823359|NCT05936645|PROCEDURE|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
214823360|NCT04035187|DRUG|fast itraconazole tablet|100mg dose
214823361|NCT04035187|DRUG|medium itraconazole tablet|100mg dose
214823362|NCT04035187|DRUG|slow itraconazole tablet|100mg dose
214823363|NCT04035187|DRUG|oral itraconazole solution|100mg dose
214823364|NCT03711253|DRUG|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
214823365|NCT03423654|OTHER|Spatial Training|Spatial Training using a 5x5 grid
214823366|NCT03423654|OTHER|Letter number matching|Letter number matching
214823367|NCT04210557|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
214823368|NCT00217503|BIOLOGICAL|bevacizumab|
214823369|NCT00217503|BIOLOGICAL|filgrastim|
214823370|NCT00217503|BIOLOGICAL|pegfilgrastim|
214823371|NCT00217503|DRUG|bortezomib|
214823372|NCT00217503|DRUG|cyclophosphamide|
214823373|NCT00217503|DRUG|doxorubicin hydrochloride|
214823374|NCT00217503|DRUG|etoposide|
214823375|NCT00217503|DRUG|ganciclovir|
214823376|NCT00217503|DRUG|valganciclovir|
214823377|NCT00217503|DRUG|zidovudine|
214823378|NCT00580541|BEHAVIORAL|variety|variety and nonvariety
214823379|NCT03867071|OTHER|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
214823380|NCT03867071|OTHER|placebo injection|Intravenous injection 0,9% saline solution.
214823381|NCT05826119|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
214823382|NCT05826119|DRUG|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
214823383|NCT02832960|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
214823384|NCT02832960|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
214823385|NCT02589093|DEVICE|Stimulation|
214823386|NCT01669980|DRUG|Ceftaroline fosamil|"* Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
214823387|NCT01669980|DRUG|IV Ceftriaxone and Vancomycin|"* IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
214823388|NCT05693623|OTHER|cold application|cold application
214823389|NCT01429870|DRUG|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
214823390|NCT06402799|BEHAVIORAL|Home-based E-biking|The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised. Heart rate will be monitored as well as power in Watt at each session.
214823391|NCT05276635|BEHAVIORAL|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
214823392|NCT05276635|BEHAVIORAL|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
214823393|NCT01930903|DEVICE|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
214823394|NCT03220958|DRUG|Metoclopramide|Metoclopramide 20mg
214823395|NCT03220958|DRUG|Diphenhydramine|Diphenhydramine 25mg
214823396|NCT03220958|DRUG|Normal saline|100ml normal saline
214823397|NCT05638490|OTHER||no intervention
214823398|NCT01116739|DEVICE|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
214823399|NCT01116739|BEHAVIORAL|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
214823400|NCT01116739|OTHER|Dental services delivered by the Indian Health Service.|
214823401|NCT02255149|DEVICE|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
214823402|NCT01173835|BEHAVIORAL|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
214823403|NCT00973219|DRUG|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
214823404|NCT01361633|DRUG|d-cycloserine|single oral administration of 250 mg d-cycloserine
214823405|NCT01361633|DRUG|Sugar Pill|Single oral administration 250 mg Sugar Pill
214823406|NCT06468514|OTHER|neural tensioning technique on radial nerve|the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
214823407|NCT06468514|OTHER|Sliding technique on radial nerve|The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
214823408|NCT00503919|PROCEDURE|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
214823409|NCT00022555|DRUG|bryostatin 1|Given IV
214823410|NCT00022555|DRUG|vincristine sulfate|Given IV
214823411|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~\+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
214823412|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~\+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
214823413|NCT03121586|DRUG|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
214823414|NCT05840900|BEHAVIORAL|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
214823415|NCT03456063|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
214823416|NCT03456063|DRUG|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
214823417|NCT03456063|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
214823418|NCT03456063|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
214823419|NCT03456063|DRUG|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
214823420|NCT03456063|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
214823421|NCT03456063|DRUG|Gemcitabine|Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
214823422|NCT01639911|DRUG|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
214823423|NCT01639911|DRUG|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
214823424|NCT04548635|DEVICE|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
214823425|NCT04606550|DEVICE|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
214823426|NCT05470153|DEVICE|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
214823427|NCT01350986|BEHAVIORAL|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006)."
214823428|NCT01350986|BEHAVIORAL|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
214823429|NCT03254225|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
214823430|NCT04754984|BEHAVIORAL|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
214823431|NCT02225405|DRUG|Cisplatin|Given IV
214823432|NCT02225405|DRUG|Docetaxel|Given IV
214823433|NCT02225405|OTHER|Laboratory Biomarker Analysis|Correlative studies
214823434|NCT02225405|DRUG|Nintedanib|Given PO
214823435|NCT00907387|DRUG|RT001|Dose A RT001
214823436|NCT00907387|DRUG|RT001|Dose B RT001
214823437|NCT00907387|OTHER|Placebo|Dose C Placebo
214823438|NCT02518360|OTHER|Osteopathic|Body adjustment in three sessions (20 minutes/session).
214823439|NCT02518360|OTHER|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
214823440|NCT04998526|OTHER|Experimental group|The cold gel pack will be applied to the nape.
214823441|NCT04998526|OTHER|Placebo group|The gel pack kept at room temperature will be applied to the nape.
214823442|NCT04865003|OTHER|treatment of infection|
214823443|NCT04631393|DRUG|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
214823444|NCT03548194|DRUG|BNC210|BNC210 300 mg b.i.d
214823445|NCT03548194|DRUG|Placebo|Placebo b.i.d.
214823446|NCT03584308|DIETARY_SUPPLEMENT|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
214823447|NCT03584308|DIETARY_SUPPLEMENT|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
214823448|NCT03584308|DIETARY_SUPPLEMENT|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
214823449|NCT03584308|DIETARY_SUPPLEMENT|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
214823450|NCT01187823|DEVICE|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
214823451|NCT01187823|DEVICE|Nocturnal oxygen|Nocturnal use of oxygen
214823452|NCT02042560|OTHER|Blood samples|
214823453|NCT02042560|OTHER|Spleen samples|
214823454|NCT06024980|PROCEDURE|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
214823455|NCT06024980|PROCEDURE|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd)."
214823456|NCT03125473|BIOLOGICAL|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
214823457|NCT00311974|DRUG|Dihydralazine|
214823458|NCT00974740|DRUG|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
214823459|NCT00974740|DRUG|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
214823460|NCT05230563|DEVICE|Ti-LUNG|"Participating clinicians will perform two image interpretations on all cases. One period the clinicians only will perform lung nodule detection on chest CT images, and the other period will perform lung nodule detection on chest CT images with the aid of Taihao lung CT decision support system. In each interpretation, all lung nodule is marked by each radiologist. This test collects chest computerized tomography cases for computer analysis, and evaluates whether the TaiHao lung CT decision support system helps doctors make more accurate diagnoses."
214823461|NCT04777734|BIOLOGICAL|efgartigimod|an intravenous infusion of efgartigimod
214823462|NCT04941586|OTHER|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
214823463|NCT04941586|OTHER|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
214823464|NCT02909907|DRUG|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
214823465|NCT02909907|OTHER|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
214823466|NCT00002601|BIOLOGICAL|filgrastim|5 ug/kg daily following stem cell reinfusion
214823467|NCT00002601|DRUG|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
214823468|NCT00002601|DRUG|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
214823469|NCT00002601|DRUG|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
214823470|NCT00002601|DRUG|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
214823471|NCT00002601|PROCEDURE|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
214823472|NCT06197009|DRUG|SCT650C|Administered SC
214823473|NCT03726892|DEVICE|PCI|Coronary Intervention
214823474|NCT03498794|PROCEDURE|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
214823475|NCT01281891|DRUG|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
214823476|NCT01281891|DRUG|I/T morphine|Morphine special 0.1 mg injected intrathecally
214823477|NCT04643067|DRUG|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
214823478|NCT04643067|DRUG|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
214823479|NCT04643067|DRUG|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
214823480|NCT04643067|DRUG|Placebo|This is the comparative arm.
214823481|NCT05137821|DEVICE|Er: YSGG laser|Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
214823482|NCT05137821|OTHER|no therapy|new sealed implant without any surface treatment
214823483|NCT01839279|DRUG|Tizanidine|
214823484|NCT01839279|DRUG|Placebo|
214823485|NCT01839279|DRUG|Moxifloxacin|
214823486|NCT05198947|DRUG|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
214823487|NCT05198947|DRUG|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
214823488|NCT00671320|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
214823489|NCT00671320|DRUG|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
214823490|NCT02831920|OTHER|CEUS and targeted biopsies|
214823491|NCT02831920|OTHER|MRI and targeted biopsies|
214823492|NCT06161350|COMBINATION_PRODUCT|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
214823493|NCT04028180|OTHER|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
214823494|NCT04028180|OTHER|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
214823495|NCT01398163|OTHER|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
214823496|NCT01398163|OTHER|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
214823497|NCT03465163|DEVICE|Deep Brain Stimulation|The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
214823498|NCT04034290|BIOLOGICAL|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
214823499|NCT04034290|OTHER|Placebo|Placebo
214823500|NCT03129763|BEHAVIORAL|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
214823501|NCT03129763|BEHAVIORAL|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
214823502|NCT03129763|BEHAVIORAL|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
214823503|NCT03129763|BEHAVIORAL|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
214823504|NCT03129763|BEHAVIORAL|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
214823505|NCT03998150|PROCEDURE|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
214823506|NCT03998150|PROCEDURE|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
214823507|NCT05925010|DIETARY_SUPPLEMENT|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
214823508|NCT05408169|BEHAVIORAL|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible."
214823509|NCT05408169|BEHAVIORAL|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
214823510|NCT00564408|DRUG|Carbachol|3 microgram per kg bodyweight infused intravenously
214823511|NCT00498654|BIOLOGICAL|Ty800 (Salmonella typhi) Oral Vaccine|
214823512|NCT04364126|DEVICE|Home blood pressure apparatus|Target \<125/80 mmHg
214823513|NCT04364126|OTHER|Clinic blood pressure|Target \<130/80 mmHg
214823514|NCT03437265|DRUG|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
214823515|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
214823516|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
214823517|NCT03113708|DRUG|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
214823518|NCT02096185|RADIATION|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
214823519|NCT02096185|RADIATION|2 dimensional digital imaging|
214823520|NCT04435847|BIOLOGICAL|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
214823521|NCT04435847|OTHER|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
214823522|NCT00316277|BEHAVIORAL|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
214823523|NCT00316277|BEHAVIORAL|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
214823524|NCT01400984|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
214823525|NCT05462327|PROCEDURE|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
214823526|NCT05462327|PROCEDURE|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
214823527|NCT04131621|BIOLOGICAL|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
214823528|NCT03517085|GENETIC|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
214823529|NCT03517085|DRUG|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
214823530|NCT00840476|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
214823531|NCT00840476|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
214823532|NCT01220635|BEHAVIORAL|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
214823533|NCT01220635|BEHAVIORAL|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
214823534|NCT03595800|PROCEDURE|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
214823535|NCT02873832|BIOLOGICAL|Blood sample|
214823536|NCT02873832|OTHER|Flow cytometry|
214823537|NCT02873832|OTHER|western blot|
214823538|NCT01798264|DRUG|ITCA 650 (exenatide in DUROS)|
214823539|NCT02045849|DRUG|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
214823540|NCT02045849|DRUG|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
214823541|NCT02045849|DRUG|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
214823542|NCT00121901|DRUG|glyceryl nitrate|
214823543|NCT02471027|PROCEDURE|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
214823544|NCT05887427|OTHER|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
214823545|NCT05887427|OTHER|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
214823546|NCT04145427|BEHAVIORAL|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
214823547|NCT04145427|BEHAVIORAL|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
214823548|NCT01572662|DRUG|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
214823549|NCT01572662|DRUG|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
214823550|NCT01572662|PROCEDURE|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
214823551|NCT01572662|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
214823552|NCT01572662|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
214823553|NCT01572662|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
214823554|NCT03364192|BEHAVIORAL|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
214823555|NCT04624360|DRUG|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
214823556|NCT04624360|OTHER|Placebo|2cc 0.9% Saline
214823557|NCT04266340|DRUG|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
214823558|NCT04266340|DRUG|midazolam|0.5mg/kg oral midazolam
214823559|NCT04266340|DRUG|midazolam|0.05mg/kg intravenous injection midazolam
214823560|NCT04266340|DRUG|Saline|no premedication
214823561|NCT02341846|OTHER|Qualitative interviews|
214823562|NCT01065857|DRUG|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
214823563|NCT01065857|DRUG|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
214823564|NCT02919540|OTHER|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
214823565|NCT01901263|BEHAVIORAL|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
214823566|NCT01789463|OTHER|Self rehabilitation|
214823567|NCT01789463|OTHER|Self rehabilitation plus physiotherapy|
214823568|NCT02528279|DRUG|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
214823569|NCT03251755|BEHAVIORAL|Yoga|Exercise promotion using Chinese Yoga
214823570|NCT04450069|COMBINATION_PRODUCT|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
214823571|NCT05984303|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
214823572|NCT06308484|DEVICE|Transcutaneous vagus nerve stimulation|Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
214823573|NCT06308484|DEVICE|Closed-loop AM-tACS|Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
214823574|NCT02939703|OTHER|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
214823575|NCT03927300|DEVICE|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
214823576|NCT01093833|DEVICE|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
214823577|NCT01093833|DEVICE|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
214823578|NCT01093833|DEVICE|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
214823579|NCT05105607|DRUG|D-4517.2|Subcutaneous (SC) injection
214823580|NCT04972578|DEVICE|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
214823581|NCT06626893|BIOLOGICAL|Functional tests|Functional analyses will be performed on primary sample from each enrolled patient. Isolated blast cells are cultered and incubated with a specific library of drugs (175 drugs) at four different concentrations for 72 hours.
214823582|NCT06626893|GENETIC|Next Generation Sequencing analysis|For each patient, sequencing analyses will be performed on blast cells (for somatic mutations) and on epithelial cells from buccal swab (for germline mutations)
214823583|NCT06626893|BIOLOGICAL|Microvesicles analysis|Analyses on microvesicles isolated from both Bone Marrow samples and Peripheral Blood Samples will be performed to investigate the microenvironment of the disease.
214823584|NCT03069183|DRUG|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
214823585|NCT03069183|DRUG|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
214823586|NCT02183311|DRUG|BI 1356 BS - single rising dose|
214823587|NCT02183311|DRUG|BI 1356 BS - multiple rising dose|
214823588|NCT02183311|DRUG|Placebo|
214823589|NCT05834751|DRUG|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
214823590|NCT05834751|DRUG|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
214823591|NCT03388905|DEVICE|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
214823592|NCT00918645|DRUG|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
214823593|NCT01747668|DIETARY_SUPPLEMENT|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
214823594|NCT01747668|DIETARY_SUPPLEMENT|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
214823595|NCT03110627|DEVICE|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
214823596|NCT03110627|DEVICE|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
214823597|NCT06560827|BIOLOGICAL|CT011 CAR-GPC3 T Cells Injection|The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
214823598|NCT04479527|DRUG|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
214823599|NCT00001991|DRUG|Atovaquone|
214823600|NCT04154592|OTHER|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
214823601|NCT04154592|OTHER|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
214823602|NCT03446768|OTHER|Peer support|Access to educational and informational support by a trained peer coach
214823603|NCT03446768|OTHER|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
214823604|NCT03446768|OTHER|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
214823605|NCT05133180|DRUG|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
214823606|NCT05133180|OTHER|Vehicle|Vehicle will be instilled with the same scheme of the test product
214823607|NCT02821676|PROCEDURE|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
214823608|NCT02821676|PROCEDURE|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
214823609|NCT00636129|BEHAVIORAL|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
214823610|NCT00107991|DRUG|etanercept|etanercept 50 mg/week subcutaneous injection
214823611|NCT00004148|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
214823612|NCT01535222|DRUG|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
214823613|NCT01535222|DRUG|Placebo|Commercially available NaCl
214823614|NCT02036086|DRUG|Vemurafenib|Drug
214823615|NCT02036086|DRUG|Cobimetinib|Drug
214823616|NCT04913974|PROCEDURE|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
214823617|NCT05119504|BEHAVIORAL|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
214823618|NCT05119504|BEHAVIORAL|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
214823619|NCT00370539|DRUG|verteporfin, bevacizumab, triamcinolone acetonide|
214823620|NCT00935012|DRUG|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
214823621|NCT00819312|DRUG|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
214823622|NCT00433719|DRUG|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
214823623|NCT00345696|DRUG|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
214823624|NCT00345696|DRUG|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
214823625|NCT00345696|DRUG|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
214823626|NCT03808519|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
214823627|NCT03808519|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
214823628|NCT01442155|DRUG|Capecitabine|Administered according to the Summary of Product Characteristics.
214823629|NCT01442155|BIOLOGICAL|Oxaliplatin|Administered according to the Summary of Product Characteristics.
214823630|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
214823631|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
214823632|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
214823633|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
214823634|NCT04906538|PROCEDURE|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
214823635|NCT00120887|DRUG|Atorvastatin|
214823636|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
214823637|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
214823638|NCT02226432|PROCEDURE|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified"
214823639|NCT02226432|DEVICE|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
214823640|NCT02226432|OTHER|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
214823641|NCT03669861|DRUG|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
214823642|NCT05628545|BIOLOGICAL|GDKM-100 injection|Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
214823643|NCT05770076|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
214823644|NCT05770076|DIETARY_SUPPLEMENT|Placebo|Placebo
214823645|NCT05049291|BEHAVIORAL|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
214823646|NCT03169062|DEVICE|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
214823647|NCT01804244|DRUG|TMC278|1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
214823648|NCT00429962|DRUG|intravitreal ranibizumab|intraocular injection
214823649|NCT00429962|DRUG|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
214823650|NCT00705666|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
214823651|NCT00705666|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
214823652|NCT00374231|DRUG|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
214823653|NCT00374231|DRUG|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
214823654|NCT00374231|DRUG|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
214823655|NCT03521973|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
214823656|NCT03521973|OTHER|Normal Saline|0.9% Sodium chloride
214823657|NCT03259139|BEHAVIORAL|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
214823658|NCT06541327|DRUG|Chimeric Antigen Receptor|CAR-T
214823659|NCT05187065|OTHER|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
214823660|NCT04570748|PROCEDURE|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
214823661|NCT04570748|PROCEDURE|capsulectomy|capsulectomy without repair
214823662|NCT05180422|DRUG|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
214823663|NCT05180422|DRUG|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
214823664|NCT06262269|OTHER|Home-based adapted physical activity program supervised by an APA teacher via individual video conference.|Participants will follow a 12-week tele-rehabilitation programme involving high-intensity interval training (HIIT) adapted to their AIS. The programme includes three 45-minute individual sessions per week. The exercises are selected from a database designed for AIS patients. The APA teacher will systematically document the patient's presence or absence at each tele-rehabilitation session, thus assessing their adherence to the programme.
214823665|NCT06262269|OTHER|First period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet of specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
214823666|NCT06262269|OTHER|Second period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
214823667|NCT02284867|OTHER|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
214823668|NCT03931616|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
214823669|NCT03931616|PROCEDURE|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
214823670|NCT00553124|DRUG|selenium|
214823671|NCT00553124|DRUG|vitamin E|
214823672|NCT00553124|PROCEDURE|biopsy|
214823673|NCT00553124|PROCEDURE|chemoprevention|
214823674|NCT00553124|PROCEDURE|cryopreservation|
214823675|NCT00553124|PROCEDURE|cytology specimen collection procedure|
214823676|NCT00553124|PROCEDURE|diagnostic procedure|
214823677|NCT00553124|PROCEDURE|gene expression analysis|
214823678|NCT00553124|PROCEDURE|immunohistochemistry staining method|
214823679|NCT00553124|PROCEDURE|laboratory biomarker analysis|
214823680|NCT00553124|PROCEDURE|medical chart review|
214823681|NCT00553124|PROCEDURE|mutation analysis|
214823682|NCT00553124|PROCEDURE|polymerase chain reaction|
214823683|NCT00553124|PROCEDURE|quality-of-life assessment|
214823684|NCT00553124|PROCEDURE|questionnaire administration|
214823685|NCT00553124|PROCEDURE|study of socioeconomic and demographic variables|
214823686|NCT04200586|DRUG|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
214823687|NCT01590563|DEVICE|IUD|Insertion of a spherical IUD, one year follow-up
214823688|NCT02990286|DRUG|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
214823689|NCT02990286|DRUG|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
214823690|NCT02990286|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
214823691|NCT03256695|DRUG|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
214823692|NCT01604941|DRUG|SPD602|50 mg/kg/day orally twice daily for 24 weeks
214823693|NCT06627114|BEHAVIORAL|nutrition education program|"Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress."
214823694|NCT06627114|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
214823695|NCT06627114|OTHER|control group|receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
214823696|NCT05248308|DEVICE|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
214823697|NCT05204979|OTHER|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
214823698|NCT03930732|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214823699|NCT03930732|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214823700|NCT03930732|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214823701|NCT03930732|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
214823702|NCT03930732|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214823703|NCT05025137|OTHER|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
214823704|NCT05025137|OTHER|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
214823705|NCT03406156|DRUG|Obinutuzumab|Administered via intravenous infusion
214823706|NCT03406156|DRUG|Bendamustine|Administered via intravenous infusion
214823707|NCT03406156|DRUG|Venetoclax|The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
214823708|NCT00387933|DRUG|hydroxyurea|
214823709|NCT00387933|DRUG|imatinib mesylate|
214823710|NCT00387933|DRUG|vatalanib|
214823711|NCT01923545|DRUG|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
214823712|NCT01923545|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
214823713|NCT00187928|DRUG|Topiramate|
214823714|NCT06557551|OTHER|Thin catheter surfactant|Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
214823715|NCT04708028|OTHER|Dog Therapy|The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
214823716|NCT00625560|DRUG|Entecavir|entecavir 1.0 mg QD
214823717|NCT00625560|DRUG|Lamivudine|lamivudine 100 mg QD
214823718|NCT01904162|DRUG|400 mg finafloxacin (2 x 200 mg tablets)|
214823719|NCT03342846|DEVICE|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
214823720|NCT05124444|GENETIC|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
214823721|NCT04654182|DRUG|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
214823722|NCT04099758|BEHAVIORAL|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
214823723|NCT04099758|BEHAVIORAL|Audio-recording control|10 minute non-fiction audio-recording delivered online
214823724|NCT01679327|DRUG|Oxaliplatin|
214823725|NCT01679327|DRUG|Xeloda|
214823726|NCT01679327|DRUG|Calcium folinate (CF)|
214823727|NCT01679327|DRUG|5-FU|
214823728|NCT01679327|DRUG|Bevacizumab|
214823729|NCT01530048|DRUG|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
214823730|NCT03013530|PROCEDURE|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
214823731|NCT06438640|BEHAVIORAL|My Anesthesia Choice-HF Model|Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
214823732|NCT02699463|DEVICE|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
214823733|NCT02699463|OTHER|Control Group|Standard sleep hygiene counseling as per published guidelines
214823734|NCT04387786|DRUG|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
214823735|NCT05606458|BEHAVIORAL|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
214823736|NCT06627686|DIAGNOSTIC_TEST|Air way occlusion pressure|Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
214823737|NCT02587663|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
214823738|NCT02587663|PROCEDURE|Mammography|Undergo bilateral mammography
214823739|NCT02587663|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast conserving surgery
214823740|NCT02587663|PROCEDURE|Ultrasonography|Undergo bilateral whole-breast ultrasound
214823741|NCT02587663|PROCEDURE|Ultrasonography|Undergo targeted breast ultrasound
214823742|NCT02587663|OTHER|Gadolinium|Contrast agent used in MRI
214823743|NCT02647463|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|
214823744|NCT04242823|DIAGNOSTIC_TEST|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
214823745|NCT05811793|DRUG|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
214823746|NCT03151577|PROCEDURE|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
214823747|NCT05164354|OTHER|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
214823748|NCT05164354|OTHER|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
214823749|NCT02764853|BEHAVIORAL|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
214823750|NCT02764853|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
214823751|NCT03219853|DIETARY_SUPPLEMENT|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
214823752|NCT03219853|DIETARY_SUPPLEMENT|Conventional parsnips|Parsnips which have been grown in a conventional environment
214823753|NCT01108445|DRUG|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
214823754|NCT01108445|DRUG|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
214823755|NCT01943045|BIOLOGICAL|NGM282|
214823756|NCT01943045|OTHER|Placebo|
214823757|NCT06370104|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention|see arm description
214823758|NCT06370104|BEHAVIORAL|Living under control|see arm description
214823759|NCT00585286|DEVICE|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
214823760|NCT02066038|DRUG|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
214823761|NCT01448096|DRUG|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
214823762|NCT01448096|PROCEDURE|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
214823763|NCT04188392|DRUG|Pimavanserin|pimavanserin tablet
214823764|NCT04593160|DRUG|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
214823765|NCT04593160|DRUG|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
214823766|NCT04593160|DRUG|Placebo|Preoperative single dose of placebo
214823767|NCT01736007|DEVICE|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
214823768|NCT01736007|DEVICE|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
214823769|NCT02541227|DRUG|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
214823770|NCT04185857|DRUG|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
214823771|NCT04185857|DRUG|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
214823772|NCT00625222|PROCEDURE|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
214823773|NCT06455332|OTHER|Optic nerve MRI sequence|Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
214823774|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
214823775|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
214823776|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
214823777|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
214823778|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
214823779|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
214823780|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
214823781|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
214823782|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
214823783|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
214823784|NCT06822374|DRUG|Normosol-R|Standard of care isotonic fluid.
214823785|NCT06822374|DRUG|buffered 2% hypertonic saline|"A solution containing 2% sodium chloride (NaCl) that is buffered by the addition of another salt like sodium acetate."
214823786|NCT00235027|OTHER|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
214823787|NCT01937182|DRUG|Citalopram|Citalopram 10-40 mg per day administered orally
214823788|NCT01937182|DRUG|Placebo|1/2-2 tablets per day with no intrinsic drug activity
214823789|NCT01157130|OTHER|Exercise Regimen|Exercise instruction
214823790|NCT04153877|OTHER|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
214823791|NCT06353139|DEVICE|Modified olfactory training device|Conduct olfactory training in patients with olfactory disorders
214823792|NCT03222557|PROCEDURE|Electroacupuncture|Refer to arm description
214823793|NCT03222557|PROCEDURE|Sham Acupuncture|Refer to arm description
214823794|NCT03222557|DEVICE|Electroacupuncture|Refer to arm description
214823795|NCT03222557|DEVICE|Sham Acupuncture|Refer to arm description
214823796|NCT04953520|PROCEDURE|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
214823797|NCT04953520|PROCEDURE|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
214823798|NCT06571734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214823799|NCT06571734|PROCEDURE|Computed Tomography|Undergo CT
214823800|NCT06571734|PROCEDURE|Echocardiography|Undergo ECHO
214823801|NCT06571734|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214823802|NCT06571734|DRUG|Zanzalintinib|Given PO
214823803|NCT01731457|DRUG|etanercept|adding appropriate dose of etanercept to the perfusion fluid
214823804|NCT01360333|OTHER|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
214823805|NCT05269069|OTHER|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
214823806|NCT04863560|OTHER|Auditory Cueing|Metronome beat to step in time with
214823807|NCT04863560|OTHER|Visual Cueing|Lines on the floor to step over
214823808|NCT04863560|OTHER|tactile Cueing|Vibration to step in time with (metronome like)
214823809|NCT05418374|PROCEDURE|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
214823810|NCT05439707|DEVICE|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
214823811|NCT05439707|DEVICE|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
214823812|NCT01447511|DRUG|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
214823813|NCT01447511|DRUG|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
214823814|NCT01447511|DRUG|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
214823815|NCT04738448|BEHAVIORAL|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
214823816|NCT03893123|OTHER|Observational study, prostate cancer is outcome of interest|Observational study
214823817|NCT01501448|DRUG|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
214823818|NCT01501448|DRUG|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
214823819|NCT06151691|OTHER|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test|"Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test."
214823820|NCT01316055|DRUG|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
214823821|NCT00003470|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214823822|NCT01188863|DRUG|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
214823823|NCT01188863|DRUG|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
214823824|NCT01188863|DRUG|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
214823825|NCT04815759|OTHER|routine dental restorative procedures|pulp and restorative therapy
214823826|NCT05728541|DRUG|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
214823827|NCT05336422|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
214823828|NCT04496349|DRUG|APG-115|QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
214823829|NCT04496349|DRUG|APG-2575|APG-2575 given orally each day in cycle, in repeated 21-day cycles
214823830|NCT01825798|DRUG|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
214823831|NCT01825798|DRUG|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
214823832|NCT06025279|OTHER|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
214823833|NCT05272813|DRUG|MS-553|MS-553
214823834|NCT01633281|PROCEDURE|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
214823835|NCT06575075|DRUG|RR-HNK/Hydroxynorketamine|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.
214823836|NCT06575075|DRUG|Placebo|Sterile Saline
214823837|NCT01125163|DIETARY_SUPPLEMENT|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
214823838|NCT01125163|DIETARY_SUPPLEMENT|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
214823839|NCT06103812|DEVICE|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
214823840|NCT03227276|DIETARY_SUPPLEMENT|Litramine|2 tablets to be taken 3 times a day after meals
214823841|NCT03227276|DIETARY_SUPPLEMENT|Placebo tablet|2 tablets to be taken 3 times a day after meals
214823842|NCT02197741|DRUG|opiate with bolus|
214823843|NCT02183727|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
214823844|NCT02183727|PROCEDURE|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
214823845|NCT03066050|OTHER|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
214823846|NCT03066050|OTHER|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
214823847|NCT03066050|OTHER|CABG|Participants underwent coronary artery bypass grafting
214823848|NCT01616550|OTHER|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
214823849|NCT01616550|OTHER|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
214823850|NCT01616550|OTHER|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
214823851|NCT01616550|OTHER|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
214823852|NCT05271383|DEVICE|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
214823853|NCT03575585|BEHAVIORAL|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
214823854|NCT03575585|BEHAVIORAL|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
214823855|NCT03575585|BEHAVIORAL|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
214823856|NCT03575585|BEHAVIORAL|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
214823857|NCT01923753|DEVICE|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
214823858|NCT01923753|DEVICE|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
214823859|NCT01923753|DEVICE|Sham Aerosure|Deactivated but identical Aerosure HFAO device
214823860|NCT02745054|OTHER|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
214823861|NCT03155672|BEHAVIORAL|Art therapy|Art Therapy
214823862|NCT06986954|DEVICE|Beacon Tip Catheters|Indicated for use in angiographic procedures by physicians trained and experienced in angiographic techniques. Standard techniques for placement of vascular access sheaths, angiographic catheters, and wire guides should be employed. Beacon Tip Sizing Catheters have marker bands that can be used for anatomical measurements.
214823863|NCT03887884|DRUG|CVT-301|Levodopa Inhalation Powder
214823864|NCT03887884|DRUG|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
214823865|NCT01322321|DRUG|ACZ885|
214823866|NCT01322321|DRUG|Placebo|
214823867|NCT06991608|OTHER|Collection of patient data|This non-interventional study and will not influence treatment decisions
214823868|NCT04802655|OTHER|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
214823869|NCT04802655|OTHER|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
214823870|NCT03221543|DEVICE|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
214823871|NCT06615726|BEHAVIORAL|Regular physical exercise|Best medical treatment plus regular physical exercise. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.
214823872|NCT06615726|OTHER|Control group|Best medical treatment
214823873|NCT01261039|RADIATION|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
214823874|NCT04492540|OTHER|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
214823875|NCT04492540|OTHER|MIND diet program|control group will receive diet program for 12 weeks
214823876|NCT04544995|DRUG|Niraparib (Tablet for oral suspension)|Niraparib will be administered as TfOS (Tablet for oral suspension)
214823877|NCT04544995|DRUG|Dostarlimab|Dostarlimab will be administered as IV infusion
214823878|NCT04544995|DRUG|Niraparib (Tablet)|Niraparib will be administered as tablet
214823879|NCT06918002|DRUG|Elranatamab|Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms
214823880|NCT06918002|DRUG|Lenalidomide (Revlimid®)|In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), in monotherapy (Arm C)
214823881|NCT06918002|DRUG|Daratumumab SC (Darzalex)|Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A
214823882|NCT06918002|PROCEDURE|Autologous Stem Cell Transplantation|ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD
214823883|NCT06918002|DRUG|Bortezomib (Velcade®)|Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A
214823884|NCT06918002|DRUG|Dexamethasone|Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A
214823885|NCT01216566|DEVICE|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
214823886|NCT02217293|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
214823887|NCT00609557|DRUG|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
214823888|NCT00848653|DEVICE|CRT device|market approved CRT device
214823889|NCT00641134|OTHER|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
214823890|NCT06623084|OTHER|Platelets characterization|To identify platelet features that correlate with liver disease progression and to study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.
214823891|NCT05350137|PROCEDURE|100% oxygen|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
214823892|NCT05350137|PROCEDURE|Carbon dioxide|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
214823893|NCT00209625|DRUG|irinotecan|
214823894|NCT00209625|DRUG|leucovorin|
214823895|NCT00209625|DRUG|fluorouracil|
214823896|NCT02849093|OTHER|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
214823897|NCT02543632|DEVICE|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
214823898|NCT01367145|DRUG|OMACOR|4 capsules OMACOR 1g per day
214823899|NCT01367145|DRUG|Placebo|4 capsules placebo per day
214823900|NCT00256165|DEVICE|Tissue valve|Aortic valve replacement
214823901|NCT02827266|DRUG|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
214823902|NCT04231422|COMBINATION_PRODUCT|Platelet-rich plasma|12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
214823903|NCT06016361|OTHER|VS-200Cr|Topical cream with moisturizing factors.
214823904|NCT06016361|OTHER|Standard of care|AAD recommended course of care.
214823905|NCT03087747|PROCEDURE|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
214823906|NCT00613145|DRUG|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
214823907|NCT00613145|DRUG|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
214823908|NCT02723721|DRUG|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
214823909|NCT04666116|DIETARY_SUPPLEMENT|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
214823910|NCT02951247|DEVICE|Hearing Aid|Successor of Phonak Virto V90-10 NW O
214823911|NCT00761163|OTHER|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
214823912|NCT00761163|OTHER|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
214823913|NCT00761163|OTHER|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
214823914|NCT02220049|DRUG|Bortezomib|
214823915|NCT01939080|PROCEDURE|Exercise training with supervised sessions|
214823916|NCT04241757|DIAGNOSTIC_TEST|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
214823917|NCT02744287|BIOLOGICAL|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
214823918|NCT02744287|DRUG|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
214823919|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
214823920|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
214823921|NCT07016230|DRUG|Tarlatamab|Patients enrolled in both cohorts will receive treatment with tarlatamab at the dose of 1 mg on D1, 10 mg on D8 and D15 and Q2W thereafter in a 28-day cycle. Tarlatamab will be administrated in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal.
214823922|NCT05652257|DRUG|[14C]-brensocatib|Oral solution.
214823923|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
214823924|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
214823925|NCT01616225|DRUG|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
214823926|NCT03755050|OTHER|general and specific data|General and specific data collected
214823927|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
214823928|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
214823929|NCT03580915|BEHAVIORAL|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
214823930|NCT03580915|BEHAVIORAL|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
214823931|NCT03500094|DRUG|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
214823932|NCT04323683|GENETIC|Microarray|High throughput technique for determining global gene expression of the condition of interest
214823933|NCT03565926|OTHER|Manual Therapy|"1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
214823934|NCT03565926|OTHER|Hypopressive exercises|Protocol 5 Hypopressive exercises
214823935|NCT03605030|DEVICE|Novel Lead Based Armboard|Novel Lead Based Armboard
214823936|NCT03605030|DEVICE|Standard Armboard|Standard Armboard (without lead)
214823937|NCT04342650|DRUG|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
214823938|NCT04342650|DRUG|Placebo oral tablet|150mg placebo tablets
214823939|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Written Emotional Disclosure|A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
214823940|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Healthy Habits Disclosure|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
214823941|NCT05513274|BEHAVIORAL|Health Behavior Control + Written Emotional Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
214823942|NCT05513274|BEHAVIORAL|Health Behavior Control + Healthy Habits Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
214823943|NCT07035925|DEVICE|ECMT-100|Colloidal hydrogel
214823944|NCT06703346|DRUG|Experimental: Letetresgene autoleucel|Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
214823945|NCT04981262|DIETARY_SUPPLEMENT|Stimulance|Intervention with Prebiotic supplement
214823946|NCT05469997|BEHAVIORAL|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
214823947|NCT05469997|DIETARY_SUPPLEMENT|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
214823948|NCT06891313|DEVICE|Piezo Surgery.|Using bone cutting inserts.
214823949|NCT06891313|PROCEDURE|Bone Discs|Selected bone discs diameters mounted on contra angled hand piece and external irrigation hand piece at gear ratio 1:1.
214823950|NCT07057193|DRUG|Dexmedetomidine group (D group)|patients will receive intravenous dexmedetomidine (0.25 μg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
214823951|NCT07057193|DRUG|Ketamine group (K group)|patients will receive intravenous ketamine (0.25mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
214823952|NCT07057193|DRUG|Midazolam group (M group)|patients will receive intravenous midazolam (0.05 mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
214823953|NCT07057193|OTHER|5ml of normal saline|patients will receive 5ml of normal saline intravenous10 min before the end of the surgical procedure as placebo.
214823954|NCT03100019|DIETARY_SUPPLEMENT|Resveratrol|
214823955|NCT03100019|DRUG|Placebo|
214823956|NCT06563141|OTHER|traction and mobilization|The patient undergoes a 15-minute infrared therapy session, followed by flexibility and stretching exercises targeting the trunk and four extremities muscles. Land manipulation techniques are used for cervical, dorsal, and lumbar spine to assess and treat spinal dysfunctions. Deep breathing exercises with rib mobilization are also performed to promote respiratory function and thoracic flexibility. The session aims to improve overall health.
214823957|NCT06563141|OTHER|active exercise therapy|Patients with adolescent idiopathic scoliosis will receive exercise programs from seven major schools under SOSORT, focusing on realigning the spine, rib cage, shoulders, and pelvis to normal anatomical postures.
214823958|NCT07051252|DRUG|HBS-201|On Days 1-7, participants will take HBS-201 17.8 mg per day (one 17.8 mg tablet) and on Days 8-14, participants will take HBS-201 35.6 mg per day (two 17.8 mg tablets).
214823959|NCT07062315|BEHAVIORAL|Chronotype-matched time-restricted eating|A 12 weeks time-restricted eating intervention that match participants' chronotype
214823960|NCT07062315|BEHAVIORAL|Chronotype-unmatched time-restricted eating|A 12 weeks time-restricted eating intervention that not match participants' chronotype
214823961|NCT07067268|DRUG|Adjuvant therapy|Tislelizumab: 200 mg IV on day 1, every 3 weeks Capecitabine: 1000 mg/m² orally twice daily on days 1-14，every 3 weeks Treatment duration: 8 cycles
214823962|NCT07067502|DEVICE|Biphasic cuirass ventilator which is a type of negative pressure ventilator will be applied to patients on the intervention arm|As opposed to patients being placed on Non invasive ventilation (CPAP or BiPAP) the intervention arm patients will be placed on the Biphasic cuirass ventilator which is a form of negative pressure ventilator.
214823963|NCT07067450|DRUG|Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)|The immune checkpoint inhibitors used for adjuvant therapy after surgery were consistent with those used during the neoadjuvant treatment before surgery, including pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab.
214823964|NCT07067450|OTHER|Observation|Postoperative observation is conducted without the use of any anti-tumor treatment.
214823965|NCT07068906|DRUG|CAR-T cells chimenric antigen receptor T cells|CT1194C cells infusion
214823966|NCT07067905|DRUG|68Ga-XT771|68Ga-XT771 is injected intravenously with a dose of 4-8 mCi
214823967|NCT07068945|BEHAVIORAL|Group of 17-year-old patients living in Nice and receiving psychiatric care|Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.
214823968|NCT07069283|BEHAVIORAL|Self-Compassion Program|Program includes four basic practices: breathing meditation, walking meditation, body scan, and mindful movement. Consciously focusing on what is happening allows people to observe and accept what they are experiencing in their bodies, minds, and the world around them at that moment. Mindfulness practices are an 8-week practice consisting of 2-2.5 hour sessions per week by a trained instructor, mindfulness meditation practices, yoga practices, examining the psychological and physiological aspects of stress, and recently including the concept of self-compassion. In addition, daily practices are given to participants, and a suitable day is determined as a retreat day. The aim is to enable individuals to reveal and experience their thoughts, emotions, and bodily sensations and to increase emotional tolerance by revealing avoidance behaviors. Individuals learn to return to and accept intense bodily sensations and emotional discomfort with mindfulness.
214823969|NCT07069205|BEHAVIORAL|Tele-nursing supported respiratory exercises|This intervention consists of a structured tele-nursing supported respiratory exercise program including abdominal breathing, pursed-lip breathing, and effective coughing techniques. The training is delivered through educational booklets and videos over a 12-week period, aiming to improve respiratory function and patient self-management in tuberculosis patients.
214823970|NCT07067528|BEHAVIORAL|A novel PTLD clinical diagnostic algorithm|A clinical diagnostic algorithm designed to help TB clinicians identify patients at risk of post-tuberculosis lung disease (PTLD) at the end of TB treatment. The algorithm is implemented as a visual aid and structured questionnaire integrated into routine care. Clinicians use it to screen TB survivors and refer suspected PTLD cases to a post-TB clinic for confirmatory evaluation and management.
214823971|NCT07068087|PROCEDURE|Preoperative sioldosin to facilitate ureteric access sheath insertion in RIRS|group A (study group) that included 21 patients who received silodosin 'one capsule 8 mg per day for 1 week preoperatively
214823972|NCT07068087|PROCEDURE|ureteric access sheath insertion in RIRS without silodosin (Placebo)|group B (study group) that included 21 patients who received Placebo'one capsule per day for 1 week preoperatively
214823973|NCT07068854|OTHER|HPP mango juice group|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
214823974|NCT07068854|OTHER|control juice|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
214823975|NCT07066046|PROCEDURE|Colonoscopy|"This single-center, randomized, open-label clinical trial will assess the effectiveness of artificial intelligence (AI)-assisted colonoscopy versus standard high-definition colonoscopy in detecting and characterizing colorectal lesions. Conducted over 12 months in São Paulo, Brazil, the study will include 100 adult patients undergoing elective colonoscopy.~Participants will be stratified by age and randomized (1:1) after sedation. All lesions will be resected, recorded, and analyzed histologically. The intervention group will also include AI output data (CAD EYE).~The primary goals are to evaluate adenoma detection rate (ADR) and AI diagnostic accuracy. Given the global burden of colorectal cancer (CRC), particularly in developing countries, this study aims to provide real-world data on the impact of AI in CRC screening."
214823976|NCT07069504|OTHER|AI-based role play|Participants will role play informed consent scenarios with a generative AI-driven patient simulation designed to mimic a realistic consent discussion for an endoscopic procedure.
214823977|NCT07069504|OTHER|Peer role play|Participants will role play informed consent discussions with a peer (i.e., another participant randomized to this group)
214823978|NCT07067840|DEVICE|Treated with the triple branched stent graft system|Participants treated with the triple branched stent graft system
214823979|NCT07069465|DIAGNOSTIC_TEST|flotufolastat F 18|PSMA-PET scan with Posluma agent (x2)
214823980|NCT07069465|DRUG|Relugolix 120 MG|Administration of oral ADT for 3 and 6 weeks
214823981|NCT07069465|DIAGNOSTIC_TEST|Serum PSA and Testosterone|Serum PSA and testosterone at study initiation and again at 3 and 6 weeks after initiation of ADT
214823982|NCT07067372|DEVICE|FireMagic™ Magbot Ablation Catheter|All patients signed informed consent forms, enrolled in the trial, underwent surgical treatment for rapid arrhythmia using XX, and were discharged after follow-up data collection. The total duration for each subject is estimated to be approximately 7 days.
214823983|NCT07067606|DEVICE|ultrasound contrast|All participants will be subjected to full history taking, full clinical examination, laboratory investigations (complete blood count, erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\], blood urea, serum creatinine, serum glutamic-oxaloacetic transaminase \[SGOT\], serum glutamate-pyruvate transaminase \[SGPT\], immunological tests (antinuclear and anti-DNA antibodies and C3 and C4 levels), urine analysis, and 24-h urinary protein). SLE disease activity index (SELDAI) will be also calculated for every patient. (8) Musculoskeletal examination with power Doppler, the ultrasound examination will be performed at the musculoskeletal ultrasonography unit at the rheumatology division of the internal medicine department. Bilateral musculoskeletal US examinations of hands and wrists with power Doppler (PD) evaluation will be done for all patients. US examinations were performed using the standardized scanning technique according to EULAR guidelines for musculoskeletal US in rheumatolog
214823984|NCT07069049|OTHER|electroacupuncture|Sterile acupuncture needles (Huatuo brand, specification: 0.25mm\*40mm) were applied to Hegu (Li4), Neiguan (PC 6), Guanyuan (CV 4) and Sanyinjiao (SP 6) by twidling, rotating, lifting and thrusting for 30 seconds. After getting qi (a feeling of acid, numbness, weight and swelling), the electronic acupuncture instrument (SDZ-II type, Huatuo brand) was connected, and the continuous wave was 50HZ. The current intensity was 1-5mA (preferably as much as the patient could tolerate without pain).
214823985|NCT07069049|OTHER|Sham-electroacupunture|Sham electroacupuncture was applied at the non-meridian and non-acupoint sites 3mm apart from the acupoints in the experimental group. The acupuncture method was shallow acupuncture, only 1-4mm through the skin.
214823986|NCT07068113|OTHER|DANCE GROUP|home exercise program + 50 min/week brisk walking + 100 min/week dance
214823987|NCT07068113|OTHER|EXERCISE GROUP|home exercise program + 150 min/week brisk walking
214823988|NCT07069036|DRUG|SEP-631|Oral, tablet
214823989|NCT07069036|OTHER|Placebo|Oral, tablet
214823990|NCT07068815|DEVICE|Fu's Subcutaneous Needling|Participants were seated while the practitioner identified affected muscles (sternocleidomastoid, scalene, splenius capitis, and upper trapezius) via sliding palpation. After routine disinfection, a disposable FSN needle (Nanjing Paifu Medical Technology Co., Ltd., Jiangsu, China) was inserted parallel to the subcutaneous loose connective tissue surrounding the affected muscle. Once fully inserted, the soft tube stand was secured in the slot. After confirming no pain, the practitioner performed smooth, gentle, fan-shaped swaying movements (120° angle, \~100 times/min) with the index and ring fingers. This was accompanied by reperfusion activities-resistance-based contraction and relaxation of the affected muscles, performed collaboratively by the practitioner and participant. Each set comprised 20 swaying movements and 10 seconds of reperfusion, repeated three times per muscle.
214823991|NCT07068815|DRUG|Flunarizine Hydrochloride|Participants in the drug group were administered 5 mg flunarizine hydrochloride capsules nightly before sleep for 4 weeks.
214823992|NCT07067515|COMBINATION_PRODUCT|non surgical with PUFA injection|The hyperpigmented gingiva in the canine/1st premolar region to the contralateral comparable tooth region in the maxillary aesthetic areas will be the target area for this procedure. A local anesthesia will be used to numb the area. Using an insulin and plastic syringe (needle: 30-gauge, 8 mm length), 1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva at approximately the epithelial connective tissue interface until the tissue blanche, 2-3 mm apart. The insulin syringe, bevel facing upward, will be inserted into the corresponding gingival tissues. For four weeks, this dosage of omega-3 (PUFAs) will be administered once a week. Furthermore, patients will take 2 capsules. Each capsule contains 1 gram of Omega3(PUFAs) as an additional food supplement (up to 3 gram daily for the period of injection except the day of injection. the patients will receive a packet containing required number of capsules have to be taken every week.
214823993|NCT07067515|PROCEDURE|surgical treatment|Patients with gingival hyperpigmentation of oral mucosa. For the scalpel technique, following the administration of a local anesthetic solution, a partial split thickness flap was raised with the help of blade no. 15 with the Bard Parker handle to scrape the epithelium in maxillary anterior area from canine to canine in the other side; will be surgical removal of pigmentation using the scalpel in 45 degrees to remove the superficial layer. Bleeding Will be controlled using a pressure pack with sterile gauze. Care was taken that excessive tissue was not removed thereby avoiding any bone exposure. This will be followed by careful examination of the exposed connective tissue surface, and the wound will be irrigated with saline. Bleeding will be controlled using a pressure pack, and once hemostasis is achieved, the site will be covered by a periodontal dressing for a period of one week. patients will be advised to stop eating hard, acidic, spicy, and colored foods before surgery. All patie
214823994|NCT07067541|DRUG|Control lidocaine cream|lidocaine cream alone
214823995|NCT07067541|DRUG|Experimental lidocaine cream + moisturizer cream|lidocaine cream + moisturizer cream
214823996|NCT07067307|DRUG|melatonin|melatonin 20 mg tablet once daily at bedtime
214823997|NCT07067307|DRUG|Placebo|Placebo once daily at bedtime
214823998|NCT07067437|RADIATION|single-fraction very accelerated partial breast irradiation|Adjuvant accelerated partial breast brachytherapy, with interstitial multicatheter technique, in one fraction.
214823999|NCT07067996|PROCEDURE|erector spinae plane block|erector spinae plane block will be given as intraoperive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
214824000|NCT07067996|DRUG|Nalbuphine|Nalbuphine will be given as intraopertive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
214824001|NCT07069322|BEHAVIORAL|Richards-Campbell Sleep Questionnaire (RCSQ)|\- Score 0 = Very poor sleep, 100 = Very good sleep
214824002|NCT06089239|OTHER|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
214824003|NCT06089239|OTHER|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
214824004|NCT07067489|BEHAVIORAL|Balneotherapy|Participants receive 20-minute balneotherapy sessions involving full-body immersion in thermal-mineral spring water at a therapeutic spa facility. Sessions are conducted five days per week over a three-week period. Water temperature and mineral content are standardized according to institutional protocols. The intervention is designed to provide analgesic, anti-inflammatory, and muscle-relaxant effects through thermally induced vasodilation and neuromuscular modulation.
214824005|NCT07067489|BEHAVIORAL|Whole-Body Vibration Exercise|"Participants perform whole-body vibration (WBV) exercises using the Compex Winplate platform (Uniphy Elektromedizin GmbH \& CoKG), certified under ISO 9001:2000 and DIN EN ISO 13485:2003. The exercise protocol includes static squats, dynamic squats, bridge exercises, dynamic weight shifting, and toe raises. Vibration is applied at a frequency of 30-40 Hz and amplitude of 2-4 mm for 40-60 seconds per set, with two sets per session and a 3-minute rest between sets. WBV is applied following a standardized exercise program, and the full intervention is delivered five days per week for three weeks."
214824006|NCT07067320|BEHAVIORAL|Bibliotherapy combined with games to overcome fear of the dark|Bibliotherapy combined with games, applied by parents at home. Treatment based on cognitive-behavioural techniques. Duration: 4-5 weeks. Experimental group recived this bibliotherapeutic intervention.
214824007|NCT07068620|DEVICE|Home-based cognitive training|"All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD.~Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months."
214824008|NCT07069582|DRUG|Standard dose rifampicin|Single-dose rifampicin at 10 mg/kg body weight
214824009|NCT07069582|DRUG|High dose rifampicin|Single-dose rifampicin at 20 mg/kg body weight
214824010|NCT07069582|DRUG|Standard dose isoniazid|Single-dose isoniazid at 5 mg/kg body weight
214824011|NCT07069582|DRUG|Standard dose levofloxacin|Single-dose levofloxacin at 10-15 mg/kg body weight
214824012|NCT07069582|DRUG|Standard dose rifapentine|Single-dose rifapentine at 10 mg/kg body weight
214824013|NCT07069582|DRUG|Standard dose bedaquiline|Single-dose bedaquiline at 400 mg
214824014|NCT07069231|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
214824015|NCT07067931|OTHER|Exercise stroboscopic|In this study, balance and plyometric exercises will be performed by one group using stroboscopic glasses.
214824016|NCT07067931|OTHER|training|routine training program
214824017|NCT07067931|OTHER|Exercise|balance and plyometric exercises
214824018|NCT07068282|DRUG|Cholecalciferol (vitaminD3)|Vitamin D3 mouthwash was prepared for COVID-19 participants, to compare between the saliva only (control group), and with the use of mouthwash in saliva after the participants swish for 60 seconds (experimental group) and compare the effect of vitamin D over the virus in saliva, from both groups by testing via RAT and R-PCR.
214824019|NCT07069296|DIAGNOSTIC_TEST|blood samples were collected from participants|Blood samples obtained
214824020|NCT07069296|DIAGNOSTIC_TEST|blood samples|Blood sampling
214824021|NCT07067463|DRUG|Orelabrutinib|Orally
214824022|NCT07067463|DRUG|Placebo|Orally
214824023|NCT07068724|COMBINATION_PRODUCT|Gluma Desensitizer and ER:CR;YSGG laser combination|Participants in this group received both treatments: Gluma was applied using the same method as in Gluma, followed by Er,Cr:YSGG laser therapy using the same parameters and technique as in laser.
214824024|NCT07068724|DEVICE|Er,Cr:YSGG laser|Participants received Er,Cr:YSGG laser treatment (Water-Lase iPlusTM; Biolase® Technology Inc., Irvine, CA, USA). Laser parameters were set as follows: 2780 nm wavelength, 0.25 W power, 20 Hz frequency, 140 μs pulse duration, and 30 seconds exposure time. The MZ6 tip (660 μm diameter, 6 mm length, 1 mm spot size) was used in non-contact mode from a 1 mm distance, perpendicular to the dentin surface, with 0% water and 10% air spray. All laser applications followed international safety standards and protocols.
214824025|NCT07067424|OTHER|Lavender Aromatherapy|Participants will inhale lavender essential oil via cotton pads placed near the nose for 20 minutes prior to colonoscopy. The application will take place in a pre-procedure waiting area under nurse supervision.
214824026|NCT07067424|OTHER|Bergamot Aromatherapy|Participants will inhale bergamot essential oil through cotton pads placed near the nose for 20 minutes before the colonoscopy procedure, under the supervision of clinical staff.
214824027|NCT07067424|OTHER|Placebo Inhalation|Participants will inhale an odorless substance (distilled water) using the same method and duration as the intervention groups, to simulate the aromatherapy procedure.
214824028|NCT07067619|BEHAVIORAL|Pain-acceptance intervention|"The intervention start with a conversation and inquiry about the participant's pain while continuously validating his experience and creating a shared understanding of their struggles and difficulties due to the pain.~Next, the experimenter explain the relations between distress, pain and suffering, emphasizing that in many cases trying to control our pain, emotions and thoughts leads us to undesirable results through emotional avoidance, anger and escape. This explanation will be accompanied with commonly used metaphors to enhance participants' understanding. Afterwards, participants are familiarized with the strategy of emotional acceptance of pain. The strategy will be comprehensively explained and participants will practice it with the experimenter twice: Firstly, by practicing with the mental exercise of STOP (i.e. Stop, Take a step back, Observe, Procced Mindfully); Secondly by practicing the pain acceptance strategy while feeling moderate pain, and discuss their experience."
214824029|NCT07067359|DIETARY_SUPPLEMENT|Enteral Nutrition|This study selected patients with esophageal cancer undergoing neoadjuvant therapy as the research subjects. All enrolled patients underwent comprehensive nutritional risk screening and malnutrition assessment prior to enrollment. After the completion of nutritional risk screening and assessment, patients identified with nutritional risk were randomly assigned to two groups: the Standard Nutrition Therapy group (SNT) and the Intensive Nutrition Therapy group (INT). Patients in the SNT group received a conventional nutritional support regimen during hospitalization, which included dietary guidance and necessary nutritional supplements. In addition to the standard regimen, patients in the INT group continued to receive ongoing nutritional counseling and nutritional supplement support after discharge to ensure sustained nutritional support.
214824030|NCT07069270|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab , 240mg, D1, subcutaneous injection, Q4W.
214824031|NCT07069270|DRUG|Adebrelimab|Adebrelimab, 1200 mg, D1, intravenous drip, Q3W
214824032|NCT07069270|DRUG|Chemotherapy|Etoposide, 100mg /m², D1-3, IV, Q3W. Carboplatin, AUC 5, D1, IV, Q3W
214824033|NCT07067281|PROCEDURE|Lichtenstein Tension-Free Mesh Hernioplasty|Open surgical repair of inguinal hernia using a tension-free mesh technique. A standard polypropylene mesh is placed over the posterior wall of the inguinal canal and fixed with non-absorbable sutures under spinal or local anesthesia. This is a conventional method widely used in open hernia surgery.
214824034|NCT07067281|PROCEDURE|Laparoscopic Transabdominal Preperitoneal (TAPP) Repair|Laparoscopic approach to inguinal hernia repair performed under general anesthesia. Three ports are used to access the abdominal cavity, and a peritoneal flap is created to place a large polypropylene mesh in the preperitoneal space. The mesh is fixed with tacks or glue, and the peritoneal flap is closed. This minimally invasive method is designed to reduce postoperative pain and enhance recovery.
214824035|NCT01030133|DEVICE|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
214824036|NCT01030133|DEVICE|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
214824037|NCT01030133|DEVICE|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
214824038|NCT01030133|DEVICE|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
214824039|NCT01030133|DEVICE|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
214824040|NCT07068568|DRUG|Sonidegib|Sonidegib was administered orally at a dose of 200 mg once daily as per approved guidelines. The intervention was applied in a real-world clinical setting to patients with histologically confirmed, locally advanced periocular basal cell carcinoma (laBCC) deemed unsuitable for surgical resection or radiotherapy due to the tumor's extent or proximity to critical ocular structures. A flexible, individualized dose modulation strategy was implemented to manage adverse effects and optimize patient adherence. Modifications included temporary treatment interruptions or reduced dosing frequency, tailored to each patient's clinical status and tolerance. The goal of the intervention was to achieve local tumor control while preserving ocular structures, visual function, and cosmetic appearance. All patients received regular multidisciplinary follow-up, including ophthalmologic and dermatologic assessments.
214824041|NCT07068243|DRUG|1.0% lidocaine with epinephrine (1:100,000)|"The block will be performed by advancing the needle into the posterior rectus sheath compartment, with the local anesthetic deposited posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath.~Drug: 20 mL injection of 1.0% lidocaine with epinephrine (1:100,000) on each side (40mL total/subject)"
214824042|NCT07067853|DEVICE|Lidocaine 2 % Pharmacopuncture|Injection of 0.5mL Lidocaine 2% solution into GB20 acupuncture point, both sides every week for 4 week
214824043|NCT07067853|DRUG|propranolol 20mg|Propranolol 20mg, twice daily for 28 day / 4 week
214824044|NCT07067177|DRUG|Paracetamol (drug)|IV prophylactic paracetamol will be given prior to detection of PDA starting from 6 hours of age. It will be used to measure wethere this intervention reduces the risk of having persistant PDA, HsPDA, or any of their complications.
214824045|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy|Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.
214824046|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy + FAKTR|"Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.~FAKTR Functional and Kinematic Treatment with Rehabilitation) technique:~The FAKTR (Functional and Kinematic Treatment with Rehabilitation) technique applied is a modified IASTM technique in the pain-provocative position (incorporating static positions, motions, functional movements, resistance, and proprioceptive positions)."
214824047|NCT07069023|OTHER|breathing exercise group|Oncology patients with nausea, vomiting and fatigue were given breathing exercises throughout the treatment.
214824048|NCT07069023|OTHER|reiki group|Oncology patients with nausea, vomiting and fatigue received reiki throughout the treatment.
214824049|NCT07067983|DIAGNOSTIC_TEST|Results following systematic screening|The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy
214824050|NCT01944761|BEHAVIORAL|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
214824051|NCT04368624|OTHER|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
214824052|NCT04368624|DIAGNOSTIC_TEST|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
214824053|NCT01654458|BEHAVIORAL|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
214824054|NCT06664931|OTHER|Group (A) Muscle Energy Technique (MET)|"MET will be applied to three key muscles commonly associated with neck pain:~upper trapezius, levator scapulae, and anterior scalenus."
214824055|NCT06664931|OTHER|Group (B) Mulligan Mobilizations Techniques (MMT).|Participants in Group (B) will receive MMT alongside the traditional treatment. MMT utilizes a specific technique called Sustained Natural Apophyseal Glides (SNAGs) to improve joint mobilization.
214824056|NCT03886961|DEVICE|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
214824057|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
214824058|NCT03603808|DEVICE|Electroporation|Undergo electroporation
214824059|NCT03603808|BIOLOGICAL|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
214824060|NCT03603808|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824061|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
214824062|NCT04025229|BEHAVIORAL|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
214824063|NCT05292339|DRUG|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
214824064|NCT05292339|DRUG|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
214824065|NCT05376800|DRUG|BI 907828 (Brigimadlin)|BI 907828 (Brigimadlin)
214824066|NCT06834607|DEVICE|Physician Modified Aortic Endograft repair for complex aortic aneurysm|To assess the use of the Physician-Modified Endovascular Grafts to repair juxtarenal aneurysms in high-risk subjects considered to be unsuitable candidates for open surgical repair, have limited or no other options for treatment, and having appropriate anatomy.
214824067|NCT01718301|DRUG|boceprevir|
214824068|NCT01718301|DRUG|Ribavirin|
214824069|NCT01718301|DRUG|Peginterferon alfa-2a|
214824070|NCT01718301|DRUG|Peginterferon alfa-2b|
214824071|NCT04464200|DRUG|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
214824072|NCT06152302|OTHER|Mobility study in dry conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.
214824073|NCT06152302|OTHER|Mobility study in water conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
214824074|NCT06703840|DRUG|LIB-01|LIB-01 oral suspension
214824075|NCT06703840|DRUG|LIB-01 Placebo|LIB-01 Placebo oral suspension
214824076|NCT06437119|DIETARY_SUPPLEMENT|Compound plant nutrients|The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate.
214824077|NCT06437119|DIETARY_SUPPLEMENT|placebo|A placebo with an indistinguishable appearance and color.
214824078|NCT04727359|OTHER|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
214824079|NCT06385184|OTHER|No Intervention|Observational study with no intervention
214824080|NCT04517604|DEVICE|Magventure MagProx100 with MagOption|The Magventure C-B60 butterfly coil will be used for single-pulse TMS to determine motor threshold. iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B65 Butterfly coils) or active-only Cool-B65 Butterfly (figure 8) coil. Only the active setting will be used.
214824081|NCT01958294|DEVICE|MICHI Neuroprotection System|
214824082|NCT02252250|PROCEDURE|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
214824083|NCT02252250|PROCEDURE|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
214824084|NCT05546138|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
214824085|NCT05546138|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
214824086|NCT05546138|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
214824087|NCT05546138|DIAGNOSTIC_TEST|Corneal confocal Microscopy|Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
214824088|NCT05546138|DIAGNOSTIC_TEST|MRI|Functional and structural MRI pictures of peripheral nerves and CNS
214824089|NCT05546138|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of Sural nerve
214824090|NCT05546138|OTHER|Composite scores and questionnaires|Composite scores and questionnaires
214824091|NCT02508662|OTHER|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
214824092|NCT01753375|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
214824093|NCT01753375|DIETARY_SUPPLEMENT|Placebo|Placebo to be given orally on weekly basis
214824094|NCT06059755|OTHER|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
214824095|NCT06059755|OTHER|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
214824096|NCT04917991|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
214824097|NCT04917991|DIETARY_SUPPLEMENT|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
214824098|NCT04935580|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
214824099|NCT05511935|OTHER|professional development training for CHWs on dental health (GRIN)|multi module online training
214824100|NCT06405243|DRUG|Myoinositol|Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
214824101|NCT06405243|DRUG|Chromium|chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
214824102|NCT06405243|DRUG|l-arginine|new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
214824103|NCT06405243|DRUG|Letrozole 2.5mg|selective aromatase inhibitor
214824104|NCT03966027|OTHER|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
214824105|NCT03966027|OTHER|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
214824106|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED)|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
214824107|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED) Spanish|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day in Spanish.
214824108|NCT02108639|DRUG|DCV 3DAA FDC|
214824109|NCT02108639|DRUG|BMS-791325|
214824110|NCT02677558|OTHER|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
214824111|NCT06006754|OTHER|Observational study|No intervention: observational study
214824112|NCT05874596|BEHAVIORAL|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
214824113|NCT03690349|OTHER|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
214824114|NCT04505826|DRUG|OP-1250|Complete Estrogen Receptor ANtagonist (CERAN)
214824115|NCT06127238|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
214824116|NCT06383988|OTHER|Support for Caregiver - Generic List|Receive a generic resource list
214824117|NCT06383988|OTHER|Support for Caregiver - Personalized List|Receive personalized resource list
214824118|NCT06383988|OTHER|Internet-Based Intervention - CONNECT|Receive access to CONNECT tool
214824119|NCT06383988|BEHAVIORAL|Patient Navigation|Complete calls with caregiver navigator
214824120|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|"Participants randomized to the MTT/antibiotic arm of PART A will be administered oral MTT capsules over the course of 28 days.~Participant enrolled on PART B will be administered oral MTT capsules over the course of 28 days."
214824121|NCT05695261|DRUG|Antibiotic|"Participants randomized to the MTT/antibiotic arm of PART A will receive oral antibiotics for 7 days prior to the MTT administration visit.~Participant enrolled on PART B will receive oral antibiotics for 7 days prior to the MTT administration visit."
214824122|NCT05695261|OTHER|Placebo (in place of MTT)|Participants randomized to the placebo arm of PART A will be administered oral placebo capsules in place of MTT over the course of 28 days.
214824123|NCT05695261|OTHER|Placebo (in place of antibiotics)|Participants randomized to the placebo arm of PART A will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
214824124|NCT05695261|OTHER|Oral Immunotherapy (OIT)|Participant enrolled on PART B will be on maintenance peanut oral immunotherapy (OIT) for their clinical care.
214824125|NCT04966169|DEVICE|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
214824126|NCT05665361|DRUG|Sasanlimab|Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
214824127|NCT05665361|DRUG|Palbocicilib|Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
214824128|NCT06073691|BEHAVIORAL|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
214824129|NCT06073691|OTHER|Placebo|Placebo
214824130|NCT02138539|OTHER|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
214824131|NCT02138539|DRUG|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
214824132|NCT01818024|DRUG|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
214824133|NCT01818024|DRUG|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
214824134|NCT01818024|DRUG|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
214824135|NCT01818024|DRUG|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
214824136|NCT01818024|DRUG|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
214824137|NCT01818024|DRUG|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
214824138|NCT01818024|DRUG|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
214824139|NCT01818024|DRUG|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
214824140|NCT03756441|BEHAVIORAL|Mindfulness meditation|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
214824141|NCT03756441|BEHAVIORAL|Psychotherapy group|Caregivers will learn the technique of group problem solving
214824142|NCT00023881|DRUG|bortezomib|
214824143|NCT03723044|OTHER|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
214824144|NCT03243786|BEHAVIORAL|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
214824145|NCT01510938|DIETARY_SUPPLEMENT|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
214824146|NCT01510938|DIETARY_SUPPLEMENT|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
214824147|NCT02921958|BEHAVIORAL|occupational therapy|Family-centered occupational therapy services
214824148|NCT04084639|DIETARY_SUPPLEMENT|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
214824149|NCT03913377|DEVICE|Spectacles|Subjects' own habitual spectacles
214824150|NCT03913377|DEVICE|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
214824151|NCT02730533|DRUG|Esomeprazole|Proton pump inhibitor
214824152|NCT02730533|DRUG|No PPI treatment|No PPI treatment before ESD procedure
214824153|NCT03499353|DRUG|TALAZOPARIB|Talazoparib 1mg/day
214824154|NCT02179294|DRUG|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
214824155|NCT02179294|DRUG|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
214824156|NCT00868660|DRUG|ZP1848|sc. bolus
214824157|NCT03448094|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
214824158|NCT03448094|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of three months.
214824159|NCT05701384|DRUG|Lazertinib|160mg po qd
214824160|NCT01675115|DRUG|BNG-1|BNG-1 3 grams TID for 4 weeks
214824161|NCT01675115|DRUG|Aspirin|Aspirin 100 mg QD for 4 weeks
214824162|NCT03956420|BEHAVIORAL|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
214824163|NCT03956420|DIETARY_SUPPLEMENT|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
214824164|NCT03956420|DRUG|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
214824165|NCT03956420|OTHER|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
214824166|NCT03956420|OTHER|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
214824167|NCT03956420|DRUG|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
214824168|NCT03956420|DRUG|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
214824169|NCT03956420|DRUG|Intraoperative period|Sevoflurane 1.5 MAC higher in patients \< 60 years old
214824170|NCT03956420|DRUG|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
214824171|NCT03956420|DRUG|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
214824172|NCT00002890|BIOLOGICAL|lintuzumab|
214824173|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824174|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824175|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824176|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824177|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824178|NCT01117623|DRUG|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824179|NCT01117623|DRUG|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824180|NCT01117623|DRUG|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
214824181|NCT05947409|DRUG|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
214824182|NCT05915858|OTHER|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~* The angle of hip flexion should not exceed 60 degree.~* The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
214824183|NCT05915858|OTHER|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~* The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~* The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~* The process is repeated 3-5 times with a 30"
214824184|NCT00862563|DRUG|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
214824185|NCT00862563|DRUG|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
214824186|NCT00862563|DRUG|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
214824187|NCT00862563|DRUG|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
214824188|NCT03822754|BIOLOGICAL|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
214824189|NCT03822754|BIOLOGICAL|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
214824190|NCT04633863|DEVICE|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
214824191|NCT00685464|DRUG|Abciximab|Intravenous.
214824192|NCT00685464|DRUG|Abciximab|Intracoronary
214824193|NCT02285491|DRUG|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
214824194|NCT02285491|DRUG|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
214824195|NCT04337658|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214824196|NCT04337658|DRUG|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214824197|NCT04337658|DRUG|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
214267608|NCT02684916|PROCEDURE|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
214824198|NCT04337658|DRUG|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214824199|NCT00736190|DRUG|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
214824200|NCT04121507|DRUG|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
214824201|NCT04121507|PROCEDURE|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
214824202|NCT04121507|DIAGNOSTIC_TEST|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
214824203|NCT04121507|DIAGNOSTIC_TEST|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
214824204|NCT01556906|DRUG|Lomitapide|Oral administration with escalating doses administered once daily
214824205|NCT01896934|DRUG|Sertraline|50-200mg daily
214824206|NCT05521919|BEHAVIORAL|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
214824207|NCT05521919|BEHAVIORAL|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
214824208|NCT03920449|DRUG|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
214824209|NCT03920449|PROCEDURE|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
214824210|NCT02095522|DRUG|Colchicine|Colchicine 1mg per day for one month
214824211|NCT02095522|DRUG|Placebo|Placebo
214824212|NCT05991362|DRUG|GFH312 100 mg|Participants receive single dose of GFH312 100 mg orally
214824213|NCT05991362|DRUG|GFH312 200 mg|Participants receive single dose of GFH312 200 mg orally
214824214|NCT05991362|DRUG|GFH312 120mg|Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
214824215|NCT05991362|OTHER|Placebo|Participants receive placebo matching with GFH312
214824216|NCT01924286|DRUG|Prednisone|
214824217|NCT01924286|DRUG|Placebo|
214824218|NCT03891095|DRUG|Oxytocin|intranasally administrated
214824219|NCT03891095|DRUG|L-DOPA|orally administered
214824220|NCT03891095|DRUG|Placebos|intranasally administrated and orally administered
214824221|NCT02349022|RADIATION|[89Zr]Df-IAB2M|
214824222|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
214824223|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
214824224|NCT06109779|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous) Q3W
214824225|NCT06109779|DRUG|Placebo|Placebo IV (intravenous) Q3W
214824226|NCT06109779|DRUG|Capecitabine|Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
214824227|NCT06109779|DRUG|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
214824228|NCT06109779|DRUG|S-1 [Tegafur/Oteracil/gimeracil]|S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
214824229|NCT01327781|DRUG|Endoxifen Hydrochloride|Given PO
214824230|NCT01327781|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824231|NCT01327781|OTHER|Pharmacological Study|Correlative studies
214824232|NCT01327781|OTHER|Questionnaire Administration|Ancillary studies
214824233|NCT05990504|DEVICE|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
214824234|NCT05990504|DEVICE|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
214824235|NCT02786160|DIETARY_SUPPLEMENT|HMO|
214824236|NCT02786160|DIETARY_SUPPLEMENT|Dextropur|
214824237|NCT01165060|DRUG|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
214824238|NCT04374799|DRUG|Heparin|two doses of heparin
214824239|NCT04374799|DRUG|Placebos|placebo
214824240|NCT02836574|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC).
214824241|NCT02836574|PROCEDURE|Renal Biopsy|a procedure in which a small sample of kidney tissue is removed
214824242|NCT05451914|OTHER|My Diabetes Care|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
214824243|NCT04343001|DRUG|Aspirin|Aspirin 150mg
214824244|NCT04343001|DRUG|Losartan|Losartan 100mg
214824245|NCT04343001|DRUG|Simvastatin|Simvastatin 80mg
214824246|NCT04852393|PROCEDURE|Block|cervical medial branch block
214267609|NCT01998529|DRUG|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
214824247|NCT05836896|GENETIC|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
214824248|NCT00933686|DRUG|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
214824249|NCT00933686|DRUG|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
214824250|NCT04108572|BEHAVIORAL|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
214824251|NCT06562322|DEVICE|Placebo|Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
214824252|NCT06562322|DEVICE|300 J|Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
214824253|NCT06562322|DEVICE|600 J|Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
214824254|NCT06562322|DEVICE|1260 J|Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
214824255|NCT01042665|DRUG|latanoprost 0.005%|Active comparator
214824256|NCT01042665|DRUG|Placebo|Placebo comparator
214824257|NCT00651131|DRUG|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
214824258|NCT04834440|DRUG|Ropivacaine|all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations
214824259|NCT05994066|OTHER|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
214824260|NCT01384591|DRUG|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
214824261|NCT01384591|DRUG|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
214824262|NCT01384591|DRUG|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
214824263|NCT01384591|DRUG|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
214824264|NCT06560710|OTHER|vitrectimy|Clinical characteristics and surgical outcomes
214824265|NCT00840216|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
214824266|NCT00840216|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
214824267|NCT05527561|BEHAVIORAL|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
214824268|NCT05527561|BEHAVIORAL|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
214824269|NCT06356766|OTHER|Telerehabilitation|Modified Duran Protocol via Telerehabilitation
214824270|NCT06356766|OTHER|Face-to-face rehabilitation|Modified Duran Protocol
214824271|NCT05857774|OTHER|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
214824272|NCT05857774|OTHER|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
214824273|NCT05857774|OTHER|Biological measurements|Skeletal troponin-I
214824274|NCT04924920|DIAGNOSTIC_TEST|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
214824275|NCT04924920|DIAGNOSTIC_TEST|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
214824276|NCT04924920|DIAGNOSTIC_TEST|Fluid challenge|Bolus of fluids of 4 ml/kg given within 10 minutes
214824277|NCT02406560|DRUG|tafamidis|fasted
214824278|NCT02406560|DRUG|tafamidis|high fat meal
214824279|NCT02406560|DRUG|tafamidis|
214824280|NCT04543682|DRUG|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
214824281|NCT04543682|DRUG|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
214267610|NCT01998529|DRUG|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
214267611|NCT06248801|DRUG|Vildagliptin and Metformin-Test product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
214267612|NCT06248801|DRUG|Vildagliptin and Metformin-Reference product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
214267613|NCT00527501|DRUG|Travoprost/brinzolamide|
214267614|NCT03035604|OTHER|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
214824282|NCT04543682|PROCEDURE|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
214824283|NCT04322292|DRUG|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
214824284|NCT01906918|PROCEDURE|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
214824285|NCT04730466|OTHER|Neuropsychological rehabilitation|The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
214824286|NCT01160666|DRUG|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
214824287|NCT04652856|DEVICE|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
214824288|NCT04652856|DEVICE|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
214824289|NCT05041361|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
214824290|NCT05041361|DEVICE|Whole-Body Hyperthermia (WBH)|Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
214824291|NCT01112761|DEVICE|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
214824292|NCT01642277|DRUG|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
214824293|NCT00924547|DIETARY_SUPPLEMENT|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
214824294|NCT00924547|DIETARY_SUPPLEMENT|Placebo|Placebo identical to active treatment.
214824295|NCT03302780|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
214824296|NCT03302780|DEVICE|tDCS active|tDCS will be applied for 20 minutes.
214824297|NCT03302780|DEVICE|tDCS sham|
214824298|NCT01180322|DRUG|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (\>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
214824299|NCT01180322|DRUG|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
214824300|NCT01180322|DRUG|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
214824301|NCT01180322|DRUG|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
214267615|NCT02023567|DRUG|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
214267616|NCT02704715|PROCEDURE|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
214267617|NCT01516437|PROCEDURE|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
214824302|NCT01180322|DRUG|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count \> 0.5 x 109/l."
214824303|NCT03605342|DRUG|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
214824304|NCT03605342|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
214824305|NCT03605342|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
214824306|NCT05234788|PROCEDURE|Transfemoral Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via femoral artery access
214824307|NCT05234788|PROCEDURE|Transradial Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via radial artery access
214824308|NCT00137254|DRUG|Insulin|IV insulin
214824309|NCT00137254|DRUG|Stable Isotopes|IV administration of stable isotopes
214824310|NCT00137254|DRUG|Indocyanine Green|IV administration of ICG
214824311|NCT04254887|PROCEDURE|EPBD|Small incision of the duodenal nipple + EPBD
214824312|NCT04254887|PROCEDURE|EST|Large incision of the duodenal nipple + EPBD
214824313|NCT05734677|BEHAVIORAL|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
214824314|NCT04649593|DIETARY_SUPPLEMENT|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
214824315|NCT06216561|DRUG|CRS-HIPEC + LSTA1|LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
214824316|NCT06216561|PROCEDURE|CRS-HIPEC alone|Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
214824317|NCT04306783|OTHER|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
214824318|NCT05148273|BEHAVIORAL|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
214824319|NCT05580692|PROCEDURE|Biospecimen Collection|Biospecimen Sample Collection
214824320|NCT04514939|OTHER|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
214824321|NCT06210984|DRUG|Low caffeine dose|2 mg/kg dose of caffeine in pill form
214824322|NCT06210984|DRUG|Moderate caffeine dose|5 mg/kg dose of caffeine in pill form
214824323|NCT06210984|DRUG|Placebo|5 mg/kg dose of maltodextrin in pill form
214824324|NCT06366048|DIAGNOSTIC_TEST|the different definitions of PHLF according to 50-50 criteria and ISGLS criteria|Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
214824325|NCT00440167|DRUG|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
214824326|NCT00440167|DRUG|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
214824327|NCT00440167|DRUG|Erlotinib|Erlotinib 150 mg/d oral, daily without break
214824328|NCT02086214|DEVICE|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
214824329|NCT02086214|DEVICE|Control|LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
214824330|NCT05028608|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
214824331|NCT05028608|DRUG|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
214824332|NCT05028608|DRUG|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
214824333|NCT03246763|BEHAVIORAL|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
214824334|NCT03192163|OTHER|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
214824335|NCT00429286|BEHAVIORAL|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
214824336|NCT03508011|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
214824337|NCT00848536|DRUG|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
214824338|NCT00848536|DRUG|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
214824339|NCT05840133|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
214824340|NCT05572437|DEVICE|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
214824341|NCT00796328|DRUG|Phenylephrine infusion|Up-down, biased coin design
214824342|NCT02557347|BEHAVIORAL|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
214824343|NCT04376190|RADIATION|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
214824344|NCT06560593|DRUG|NTQ5082|single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
214824345|NCT06560593|DRUG|Placebo|multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
214824346|NCT04594577|DEVICE|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
214824347|NCT05882630|DRUG|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
214824348|NCT05896995|OTHER|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
214824349|NCT05896995|OTHER|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
214824350|NCT03432182|DIAGNOSTIC_TEST|electroencephalography|Sleep states definition by electroencephalograpy
214824351|NCT03682601|DRUG|5% sinecatechins ointment|Topical 5% sinecatechins ointment will be applied once daily.
214824352|NCT03682601|DRUG|Placebo|Aquaphor/vehicle
214824353|NCT03682601|DRUG|10% sinecatechins ointment|Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
214824354|NCT01293591|OTHER|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
214824355|NCT01293591|OTHER|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
214824356|NCT01366963|BEHAVIORAL|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
214824357|NCT01366963|BEHAVIORAL|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
214824358|NCT01366963|BEHAVIORAL|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
214824359|NCT03037554|DEVICE|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
214824360|NCT03037554|DEVICE|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
214824361|NCT00452920|DRUG|docetaxel|
214824362|NCT00452920|RADIATION|cesium Cs 137|
214824363|NCT00452920|RADIATION|radiation therapy|
214267618|NCT01516437|PROCEDURE|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
214267619|NCT01516437|PROCEDURE|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
214267620|NCT06373627|OTHER|Hypnosis|"A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient."
214824364|NCT03563274|DEVICE|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
214824365|NCT03317444|DRUG|TRC101|Oral suspension
214824366|NCT03317444|DRUG|Placebo|Oral suspension
214824367|NCT02589301|BIOLOGICAL|Pegfilgrastim|
214824368|NCT06429592|OTHER|education|nursing care practice
214824369|NCT02944617|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824370|NCT02944617|DIETARY_SUPPLEMENT|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
214824371|NCT02944617|DRUG|VEGF-TKI|Must be received as standard of care chemotherapy
214824372|NCT02100917|DRUG|DMB-3111|
214824373|NCT02100917|DRUG|trastuzumab|
214824374|NCT06361407|BEHAVIORAL|Illusion task|The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
214824375|NCT05091151|DRUG|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
214824376|NCT05238428|BEHAVIORAL|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
214824377|NCT04602754|DRUG|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
214824378|NCT04602754|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
214824379|NCT04602754|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
214824380|NCT04602754|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
214824381|NCT04602754|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
214824382|NCT04602754|OTHER|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
214824383|NCT04499677|DRUG|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
214824384|NCT04499677|DRUG|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
214824385|NCT04499677|OTHER|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
214824386|NCT04499677|OTHER|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
214824387|NCT02476045|DRUG|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
214824388|NCT02476045|DRUG|panitumumab|Maintenance treatment (ARM B)
214824389|NCT02476045|DRUG|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
214824390|NCT03094598|OTHER|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
214824391|NCT03094598|OTHER|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
214824392|NCT03094598|OTHER|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
214824393|NCT05463848|DRUG|Pembrolizumab|Intravenous infusion
214824394|NCT05463848|DRUG|Olaparib|Pill taken by mouth
214824395|NCT05463848|DRUG|Temozolomide|Pill taken by mouth
214824396|NCT05752552|DRUG|DO-2|Deuterated MET kinase inhibitor
214824397|NCT06491420|OTHER|fixation with arthroscopy|the pipkin fracture is fixed with the help of arthroscopy and percutaneous methods.
214824398|NCT04698473|OTHER|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
214824399|NCT04698473|OTHER|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
214824400|NCT00729976|DRUG|Ibuprofen suppository|5-10mg/Kg of ibuprofen
214824401|NCT00729976|DRUG|Ibuprofen Suspension|5-10mg/Kg
214824402|NCT03090880|DRUG|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
214824403|NCT02742194|DIETARY_SUPPLEMENT|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
214824404|NCT02742194|DIETARY_SUPPLEMENT|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
214824405|NCT04366544|OTHER|Part A1: Survey|Online
214824406|NCT04366544|OTHER|Part A2: Sample collection|Blood and Stool
214824407|NCT04366544|OTHER|Part B:|EEG and fMRI
214824408|NCT00586989|PROCEDURE|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
214824409|NCT05764096|OTHER|No intervention|No intervention
214824410|NCT03745963|BEHAVIORAL|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
214824411|NCT03745963|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
214824412|NCT05635812|OTHER|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
214824413|NCT05635812|OTHER|EEG experimentation|duration: 1 hour
214824414|NCT05635812|OTHER|Oculometry experimentation|duration: 30 minutes
214824415|NCT01637376|DRUG|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
214824416|NCT03115957|OTHER|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
214824417|NCT00506831|DRUG|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
214824418|NCT01770223|DRUG|boceprevir|
214824419|NCT01770223|BIOLOGICAL|PegIFN-2b|
214824420|NCT01770223|DRUG|RBV|
214824421|NCT00582179|PROCEDURE|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
214824422|NCT00582179|DEVICE|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
214824423|NCT04313764|DRUG|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
214824424|NCT04313764|DRUG|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
214824425|NCT03515707|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214824426|NCT03515707|DRUG|Busulfan|Given IV or oral
214824427|NCT03515707|DRUG|Etoposide|Given IV
214824428|NCT03515707|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824429|NCT02942823|OTHER|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
214824430|NCT05464186|BEHAVIORAL|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
214824431|NCT05464186|BEHAVIORAL|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
214824432|NCT04379739|DRUG|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
214824433|NCT04537663|DRUG|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
214824434|NCT04537663|DRUG|Placebo|Intradermal injection of sterile 0.9% NaCl.
214824435|NCT02853643|DRUG|ASN002|Single dose study with food effect
214824436|NCT02937935|BIOLOGICAL|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
214824437|NCT02937935|BIOLOGICAL|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
214824438|NCT02222064|BEHAVIORAL|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
214824439|NCT04710290|DIETARY_SUPPLEMENT|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
214824440|NCT04710290|DIETARY_SUPPLEMENT|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
214824441|NCT04710290|DIETARY_SUPPLEMENT|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
214824442|NCT04710290|DIETARY_SUPPLEMENT|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
214824443|NCT02120677|DRUG|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
214824444|NCT02488239|DEVICE|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
214824445|NCT00932763|DRUG|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
214824446|NCT00932763|DRUG|Norvasc|10 mg dose (Pfizer, USA)
214824447|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
214824448|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
214824449|NCT01028586|DRUG|Placebo|matching placebo tablets
214824450|NCT04854460|DRUG|Revemact|1 tablet contains 6 mg Ivermecin
214824451|NCT04854460|DRUG|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
214824452|NCT04854460|DRUG|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
214824453|NCT01945450|DRUG|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
214267621|NCT06373627|DRUG|Conventional medications used for sedation-analgesia|MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
214824454|NCT01945450|DRUG|Ampicillin|
214824455|NCT01945450|DRUG|Gentamycin|
214824456|NCT01945450|DRUG|Clindamycin|
214824457|NCT04474990|DRUG|Tradipitant|NK-1 Receptor antagonist
214824458|NCT05297227|PROCEDURE|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
214824459|NCT06627127|DEVICE|Target stimulation (HGN, AC, GG, Strap muscles)|Stimulation of the HGN or GG along with AC or strap muscles.
214824460|NCT06140082|GENETIC|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
214824461|NCT05031260|DEVICE|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
214824462|NCT03283982|DEVICE|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
214267622|NCT06373627|DRUG|Medications used in addition to hypnosis|MEOPA + intravenous ketamine (0.3 mg/kg)
214267623|NCT05981898|DEVICE|OPTIVF dosage|Dosage predicted by Opt-IVf
214824463|NCT03283982|DEVICE|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
214824464|NCT03591276|DRUG|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
214824465|NCT04516460|DEVICE|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
214824466|NCT06141486|DRUG|Frexalimab|SAR441344 Solution for IV infusion
214824467|NCT06141486|DRUG|Placebo|Solution for IV infusion
214824468|NCT06141486|DRUG|MRI contrast-enhancing agents|IV, as per respective label
214824469|NCT04325659|DEVICE|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
214824470|NCT04325659|DRUG|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
214824471|NCT04325659|DRUG|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
214824472|NCT04325659|DEVICE|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
214824473|NCT05207878|OTHER|STEGA-MRI|Precision drawing task (movement assessment)
214824474|NCT00064831|DRUG|Black Cohosh Extract (BCE)|
214824475|NCT02145273|BEHAVIORAL|Interpersonal Psychotherapy for Depression -Group|
214824476|NCT03396939|DEVICE|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
214824477|NCT06157905|DRUG|Oral Tofacitinib citrate|oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
214824478|NCT00587730|DEVICE|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
214824479|NCT05877339|DIAGNOSTIC_TEST|Survey|Survey
214824480|NCT03592420|BEHAVIORAL|Interdisciplinary multicomponent interventions|
214267624|NCT05981898|DEVICE|traditional Dosage|Dosage used traditionally by doctors
214267625|NCT00217620|DRUG|sorafenib|800 mg per day, daily until progression
214824481|NCT03592420|BEHAVIORAL|Usual care|standard care
214824482|NCT03614039|DIETARY_SUPPLEMENT|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
214824483|NCT03614039|DIETARY_SUPPLEMENT|Placebo|
214824484|NCT02332967|OTHER|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
214824485|NCT02332967|OTHER|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
214824486|NCT02332967|OTHER|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
214824487|NCT05479058|DRUG|Filgotinib|Administered orally once daily
214824488|NCT05479058|DRUG|Placebo|Administered orally once daily
214824489|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- anodal group|2mA/20mins/session;
214824490|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- sham group|0mA/20mins/session
214824491|NCT06562504|DEVICE|transcranial alternating current stimulation (tACS)-tACS group|1.5 mA/20 min/session; 6HZ, theta
214824492|NCT00113958|DRUG|Cinacalcet|
214824493|NCT05411887|DRUG|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
214824494|NCT03750357|DEVICE|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
214267626|NCT03613844|DRUG|DHA|DHA supplementation
214267627|NCT03613844|DRUG|Placebo|Placebo for DHA
214267628|NCT01650844|OTHER|School-Based Telemedicine Enhanced Asthma Management|
214267629|NCT01650844|OTHER|Enhanced Usual Care|
214824495|NCT05606120|DEVICE|CL TRAUMA femoral stem|Hip arthroplasty according to the instruction for use.
214824496|NCT02022150|BEHAVIORAL|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
214824497|NCT05485064|DRUG|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
214824498|NCT05485064|PROCEDURE|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
214824499|NCT05485064|DRUG|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
214824500|NCT05485064|DRUG|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
214824501|NCT05887934|DEVICE|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
214824502|NCT03279250|DRUG|Abiraterone Acetate|Given PO
214824503|NCT03279250|DRUG|Apalutamide|Given PO
214824504|NCT03279250|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given IM
214824505|NCT03279250|DRUG|Prednisone|Given PO
214824506|NCT03279250|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214824507|NCT03926650|DEVICE|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
214824508|NCT02913924|DRUG|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
214824509|NCT02913924|DRUG|Placebo|
214824510|NCT02890069|BIOLOGICAL|PDR001|anti-PD1 antibody
214824511|NCT02890069|DRUG|LCL161|
214824512|NCT02890069|DRUG|Everolimus|
214824513|NCT02890069|DRUG|Panobinostat|
214824514|NCT02890069|DRUG|QBM076|
214824515|NCT02890069|DRUG|HDM201|
214824516|NCT05173350|OTHER|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
214824517|NCT05173350|OTHER|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
214824518|NCT05301218|PROCEDURE|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
214824519|NCT03006757|OTHER|titanium dioxide denture base|
214824520|NCT03853005|OTHER|HVHDF|Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
214824521|NCT03853005|OTHER|controlled|Patients will receive the usual care
214824522|NCT06397339|OTHER|INTACT Program|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
214824523|NCT03060863|BEHAVIORAL|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
214824524|NCT03060863|BEHAVIORAL|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
214824525|NCT03060863|BEHAVIORAL|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
214824526|NCT03060863|BEHAVIORAL|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
214824527|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
214267630|NCT00784498|DRUG|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
214267631|NCT00784498|DRUG|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
214267632|NCT05190588|OTHER|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
214824528|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
214824529|NCT05457452|DEVICE|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
214824530|NCT03829670|DIAGNOSTIC_TEST|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
214824531|NCT03157193|DRUG|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
214824532|NCT03157193|DRUG|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
214824533|NCT01326494|DRUG|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
214824534|NCT00263588|DRUG|lapatinib|tyrosine kinase inhibitor
214824535|NCT00299871|DRUG|LIXISENATIDE (AVE0010)|
214824536|NCT03668015|OTHER|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
214824537|NCT03668015|OTHER|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
214824538|NCT04690985|BEHAVIORAL|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
214824539|NCT04690985|OTHER|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
214824540|NCT02947945|DRUG|Reslizumab|All subjects will receive Reslizumab
214824541|NCT02889380|DRUG|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
214824542|NCT04012892|COMBINATION_PRODUCT|CD19 CART|CD19 CART
214824543|NCT01277276|DEVICE|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
214824544|NCT05621694|BEHAVIORAL|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
214824545|NCT05721794|OTHER|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
214824546|NCT02074020|DRUG|Blisibimod|Administered via subcutaneous injection once per week
214824547|NCT02074020|DRUG|Placebo|Administered via subcutaneous injection once per week
214824548|NCT04208724|OTHER|Training|Participate in the training program
214824549|NCT04208724|OTHER|Cancer Screening intervention|Receive cancer screening intervention
214824550|NCT04208724|OTHER|Survey Administration|Ancillary studies
214824551|NCT03429361|OTHER|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
214824552|NCT02448160|DEVICE|alfapump|Implantation of alfapump
214824553|NCT02448160|DRUG|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
214824554|NCT02225314|BEHAVIORAL|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
214824555|NCT02225314|BEHAVIORAL|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
214824556|NCT02225314|BEHAVIORAL|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
214824557|NCT02431000|PROCEDURE|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
214824558|NCT04178122|GENETIC|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
214824559|NCT05892081|BIOLOGICAL|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
214824560|NCT05892081|BIOLOGICAL|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
214824561|NCT03447535|OTHER|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
214824562|NCT03447535|OTHER|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
214824563|NCT04421716|DRUG|Ursolic Acid|Ursolic Acid 150mg
214824564|NCT04421716|DRUG|Curcumin|Curcumin 600mg
214824565|NCT02331563|DRUG|Dexmedetomidine|ultrasound guided transvers abdominis plane block
214824566|NCT02331563|DRUG|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
214824567|NCT00044434|DRUG|bupropion (Wellbutrin)|
214824568|NCT06003335|BEHAVIORAL|Regular message delivery|Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.
214824569|NCT06003335|BEHAVIORAL|Chat-type support message delivery|Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
214824570|NCT04819386|OTHER|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
214824571|NCT03313323|BIOLOGICAL|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
214824572|NCT03621995|OTHER|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
214824573|NCT00918684|DRUG|Escitalopram|10mg tab daily
214824574|NCT02462681|DRUG|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
214824575|NCT00887419|BEHAVIORAL|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
214824576|NCT00887419|BEHAVIORAL|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
214824577|NCT04537481|OTHER|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
214824578|NCT06012812|DRUG|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
214824579|NCT01098591|OTHER|cell therapy|
214824580|NCT01701323|BIOLOGICAL|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
214824581|NCT01701323|DRUG|Cytarabine|Given IV
214824582|NCT01701323|DRUG|Filgrastim|Given SC or IV
214824583|NCT01701323|DRUG|Fludarabine Phosphate|Given IV
214824584|NCT05250323|OTHER|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
214824585|NCT05226390|BIOLOGICAL|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
214824586|NCT06559605|PROCEDURE|zirconia barrier|barrier membrane used for guided bone regeneration and augmentation of ridge defect
214824587|NCT06559605|PROCEDURE|titanium mesh|barrier membrane used for guided bone regeneration
214824588|NCT00484679|DRUG|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
214824589|NCT06558708|DRUG|GZR101 Injection|Once daily
214824590|NCT06558708|DRUG|GZR33 Injection|Once daily
214824591|NCT06558708|DRUG|Insulin aspart|Once daily
214824592|NCT06545474|DEVICE|bilateral theta burst stimulation|Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
214824593|NCT06545474|DRUG|SSRI treatment|Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
214824594|NCT00835692|DRUG|Clarithromycin|500 mg Tablet
214824595|NCT00835692|DRUG|Biaxin®|500 mg Tablet
214824596|NCT04451746|DRUG|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
214824597|NCT04828538|DIETARY_SUPPLEMENT|Vitamin D|Daily 4000 IU Vitamin D for 60 days
214824598|NCT04828538|DIETARY_SUPPLEMENT|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
214824599|NCT04828538|DIETARY_SUPPLEMENT|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
214824600|NCT04828538|OTHER|Placebo|Placebo
214824601|NCT05395052|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
214824602|NCT05395052|DRUG|Cyclophosphamide|Lympho-conditioning agent
214267633|NCT06343740|BEHAVIORAL|COMET-Y|Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
214824603|NCT05395052|DRUG|Fludarabine|Lympho-conditioning agent
214824604|NCT05395052|DRUG|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
214824605|NCT05395052|COMBINATION_PRODUCT|Avelumab|Monoclonal antibody
214824606|NCT05395052|COMBINATION_PRODUCT|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
214824607|NCT05395052|COMBINATION_PRODUCT|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
214824608|NCT05395052|COMBINATION_PRODUCT|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
214824609|NCT05395052|COMBINATION_PRODUCT|Trastuzumab|Monoclonal antibody
214824610|NCT05395052|COMBINATION_PRODUCT|Cetuximab|Monoclonal antibody
214824611|NCT05395052|COMBINATION_PRODUCT|Amivantamab|Monoclonal antibody
214824612|NCT05395052|DRUG|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
214824613|NCT06562309|OTHER|take feces and blood samples from patients|this study does not involve any intervention
214824614|NCT03526757|OTHER|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
214824615|NCT03526757|OTHER|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
214824616|NCT01149733|DRUG|Tamsulosin|Test 0.4 mg Capsule
214824617|NCT01149733|DRUG|Tamsulosin|Reference Listed 0.4 Capsule
214824618|NCT05456594|OTHER|Conventional bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).
214824619|NCT05456594|OTHER|Bounceless bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).
214824620|NCT05456594|OTHER|Shefit bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
214824621|NCT04665596|DEVICE|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
214824622|NCT00217763|DRUG|3APS|
214824623|NCT03260153|DRUG|Deproteinised Calf Blood Serum Injection|
214824624|NCT03260153|DRUG|Placebo (Sodium Chloride)|
214824625|NCT02632864|RADIATION|Proton arm|Proton beam therapy
214824626|NCT03910231|DRUG|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
214824627|NCT00360763|DRUG|candesartan cilexetil|
214824628|NCT04345653|DRUG|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
214824629|NCT03964935|DRUG|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
214824630|NCT03964935|DRUG|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
214824631|NCT03964935|OTHER|Distilled water|Used to irrigate periodontal pockets after SRP
214824632|NCT00412503|DRUG|Topotecan, Temozolomide|
214824633|NCT00304538|DRUG|very low dose (VLD) glucagon|
214824634|NCT01798719|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
214824635|NCT01798719|BEHAVIORAL|General Advice|Only general advice about diet
214824636|NCT03808376|DEVICE|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
214824637|NCT01718704|DEVICE|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
214824638|NCT03644550|DRUG|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
214824639|NCT03644550|BIOLOGICAL|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
214824640|NCT03563872|OTHER|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
214824641|NCT03563872|OTHER|Active Comparator|Usual, team-based care
214824642|NCT05521360|BEHAVIORAL|Autonomic Modulation Training|AMT is a six week online behavioral intervention comprised of two components. The first component is an adapted (to online format) version of an established and publicly available HRVBF protocol (Lehrer et al, 2013, Biofeedback).The second is the integration of meta-cognitive coping skills and autonomic modulation breathing techniques into the HRVBF protocol (Arpaia \& Andersen, 2019 Frontiers in Psychiatry; Andersen, Arpaia \& Gustafsberg, 2021 Int J Emerg Ment Health and Human Resilience).
214824643|NCT05633862|DRUG|BI 1015550|BI 1015550
214824644|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
214824645|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
214824646|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
214824647|NCT02630797|DIETARY_SUPPLEMENT|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
214824648|NCT03352362|DRUG|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
214824649|NCT03352362|DRUG|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
214824650|NCT03352362|DRUG|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
214824651|NCT00700739|DEVICE|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
214824652|NCT00700739|DEVICE|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
214824653|NCT06394973|DRUG|T4090 0.2%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
214824654|NCT06394973|DRUG|T4090 0.3%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
214824655|NCT06394973|DRUG|Rhopressa®|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
214824656|NCT01712906|BIOLOGICAL|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
214824657|NCT01712906|BIOLOGICAL|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
214824658|NCT01712906|BIOLOGICAL|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
214267634|NCT04453371|DRUG|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
214267635|NCT04453371|DRUG|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
214267636|NCT01559467|OTHER|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
214824659|NCT01712906|BIOLOGICAL|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
214824660|NCT01712906|BIOLOGICAL|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
214824661|NCT03734861|DEVICE|BreatheSmart System|"* BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence"
214824662|NCT03734861|OTHER|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
214824663|NCT04173858|DRUG|Naloxegol|25 mg oral naloxegol once daily.
214824664|NCT01506622|DRUG|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
214824665|NCT01506622|DRUG|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
214824666|NCT01506622|DRUG|Administration of saline|Saline will be administered to control group at the end of anesthesia.
214824667|NCT04067739|OTHER|non interventional study|non interventional study
214824668|NCT04626154|DIAGNOSTIC_TEST|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
214824669|NCT01067833|DRUG|K201 Tablet|oral tablet, x28 days
214824670|NCT01067833|DRUG|Placebo Tablet|oral tablet, x28 days
214824671|NCT02919462|DRUG|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
214824672|NCT02919462|DRUG|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
214824673|NCT02919462|DRUG|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
214824674|NCT02919462|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
214824675|NCT02919462|DRUG|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
214824676|NCT02919462|DRUG|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
214824677|NCT02915445|BIOLOGICAL|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
214824678|NCT04437199|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
214824679|NCT04437199|DRUG|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
214824680|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
214824681|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
214824682|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
214824683|NCT00111787|DRUG|Lapatinib|Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
214824684|NCT00111787|DRUG|Paclitaxel|Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
214824685|NCT01246687|BEHAVIORAL|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
214824686|NCT00284518|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
214824687|NCT00284518|DRUG|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
214824688|NCT05475964|DEVICE|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
214824689|NCT03488108|OTHER|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
214824690|NCT03488108|DRUG|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
214824691|NCT05412576|DRUG|Lidocaine Hydrochloride 2% Injection Solution|Injectable
214824692|NCT05412576|DRUG|0.9% NaCl|Injectable
214824693|NCT05108467|DIAGNOSTIC_TEST|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
214824694|NCT03810703|DRUG|Placebo oral capsule|Placebo oral capsule
214824695|NCT03810703|DRUG|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
214824696|NCT03810703|DRUG|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
214824697|NCT01218360|DRUG|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
214824698|NCT00748722|DEVICE|CT Angiography|Injection of contrast material (iodine)
214824699|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
214824700|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
214824701|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
214824702|NCT03602339|DRUG|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
214824703|NCT03602339|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
214824704|NCT04807595|OTHER|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
214824705|NCT00161551|DEVICE|Vitatron T70 DR|
214824706|NCT05251155|DIAGNOSTIC_TEST|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
214824707|NCT06182449|DEVICE|Virtual Reality Distraction|In a private NICU room, mothers will wear a head-mounted VR device when they will initiate the expression of their maternal milk. The video within the VR system will provide a calm forest environment with waterfalls, animals, and birdsong (INSPIRE® Program). The baby may or may not be present in the room during the intervention. This will be documented.
214824708|NCT06182449|OTHER|Standard Protocol|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby. Use of any co-interventions for anxiety management (e.g. music) durign this sequence will be documented.
214824709|NCT01348789|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
214824710|NCT06562062|PROCEDURE|Extra-articular Lateral Column Lengthening Procedure|Lateral column lengthening (LCL), originally described by Evans, is an established procedure to correct stage II adult acquired flatfoot deformity (AAFD). However, the relative position between the facets is violated, and other problems may include nonunion, malunion, and calcaneocuboid (CC) joint subluxation. Herein, we report a modified extra-articular technique of LCL with hockey-stick osteotomy, which preserves the subtalar joint as a whole, increases bony apposition to enhance healing ability, and preserves the insertion of the calcaneofibular ligament to stabilize the posterior fragment to promote adduction of the forefoot
214824711|NCT06562478|BEHAVIORAL|Zazen Meditation|The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
214824712|NCT05450653|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
214824713|NCT05168735|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
214824714|NCT05168735|BEHAVIORAL|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
214824715|NCT05168735|BEHAVIORAL|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
214267637|NCT01559467|OTHER|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
214824716|NCT03503318|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
214824717|NCT03503318|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
214824718|NCT01668602|DEVICE|Fast Walking with Fast Functional Electrical Stimulation (FES) Training|Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
214824719|NCT01668602|OTHER|Fast Walking|Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
214824720|NCT02319824|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
214824721|NCT02319824|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824722|NCT02319824|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
214824723|NCT00067535|DRUG|Cocaine-Related Disorders|
214824724|NCT01636661|DEVICE|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
214824725|NCT06099652|DRUG|611 300 mg Q2W|611 subcutaneous (SC) injection
214824726|NCT06099652|DRUG|611 450 mg Q2W|611 subcutaneous (SC) injection
214824727|NCT06099652|DRUG|Matching placebo|placebo subcutaneous (SC) injection
214824728|NCT05802485|OTHER|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
214824729|NCT00200187|PROCEDURE|low venous pressure general anesthesia|
214824730|NCT00200187|PROCEDURE|combined spinal-epidural anesthesia|
214824731|NCT05801315|DEVICE|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
214824732|NCT05801315|DEVICE|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
214824733|NCT02374385|BIOLOGICAL|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
214824734|NCT02374385|OTHER|Placebo|Normal saline
214824735|NCT01445691|DRUG|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
214824736|NCT03311594|DRUG|Low Alcohol|Low Alcohol Consumption
214824737|NCT03311594|DRUG|Moderate Alcohol|Moderate Alcohol Consumption
214824738|NCT03311594|DRUG|Placebo Alcohol|Placebo Alcohol Consumption
214824739|NCT03311594|OTHER|Pain Induction|10% capsaicin solution placed on forearm and heat induction
214824740|NCT03311594|OTHER|No Pain Induction|Water placed on forearm
214824741|NCT05405881|OTHER|Proprioception measurement tool|No intervention, as it is a psychometric properties study
214824742|NCT04350723|PROCEDURE|Awake Proning|The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
214824743|NCT06187441|DRUG|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
214824744|NCT06187441|DRUG|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
214824745|NCT06187441|DRUG|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
214824746|NCT04275479|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
214824747|NCT04275479|OTHER|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
214267638|NCT01212523|DRUG|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
214824748|NCT04275479|OTHER|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
214824749|NCT04275479|DEVICE|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
214824750|NCT04275479|OTHER|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
214824751|NCT04275479|OTHER|Medical History Questionnaires|The participant will be asked to provide detailed medical history
214824752|NCT03867838|DEVICE|compliant support|Participants will be given compliant arm support and their reachable workspace measured
214824753|NCT03874143|OTHER|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
214824754|NCT02982161|DRUG|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
214824755|NCT02982161|DRUG|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
214824756|NCT02982161|DRUG|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
214824757|NCT01441349|DRUG|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days"
214824758|NCT01441349|DRUG|IP chemotherapy plus simvastatin|"* Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1"
214824759|NCT01745679|DRUG|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
214824760|NCT00834873|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
214824761|NCT00834873|DRUG|COREG® 25 mg tablets|1 x 25 mg
214824762|NCT03262051|DIAGNOSTIC_TEST|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
214824763|NCT02354560|DRUG|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
214824764|NCT07004322|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
214824765|NCT07004322|DRUG|Placebo|Placebo matched to NNC0519-0130 will be administered subcutaneously.
214824766|NCT06246786|DRUG|Cyclosporin A|Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
214824767|NCT00794456|DRUG|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
214824768|NCT00794456|DRUG|Valeriana|1 tablet PO twice a day
214824769|NCT06625502|BEHAVIORAL|Culturally-Affirming Racial Equity Framework|The CARE framework is a process-focused, protocol- based, and modular approach to promote mental health equity. It focuses on cultivating the therapeutic alliance across patient-provider differences in the first 3-4 treatment sessions, the critical window for engaging patients in care. Target processes include transparent communication, client-centeredness, client activation, and an affirming and comprehensive approach to assessment and treatment planning. Case conceptualization and treatment planning is collaborative, and guided by the individual clinician based on evidence-based treatments. The therapist receives ongoing biweekly supervision in Alliance-Focused Training and consultation sessions with a group-specific expert.
214824770|NCT05852626|OTHER|Redistribution of diabetes care between nurses and physicians|It will be proposed that nurses and physician share the clinical care of patients with type 2 diabetes, with complementing actions
214824771|NCT05852626|OTHER|Individualized glycemic target|Define the target of individualized glycemic treatment for patients with the support of a tool on the website, which will encourage the intensification and de-intensification of treatment when appropriate
214824772|NCT05852626|OTHER|Minimum care recomendations|It will be proposed to carry out the minimum necessary assessments that, annually, nurses and physicians must do to ensure the adequacy of quality indicators in the care of diabetes in the PHC
214824773|NCT05852626|OTHER|No intervention|Primary care health teams will follow their rotine care of type 2 diabetes
214267639|NCT06349330|DEVICE|Test: 3D intra-oral scanner|"3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush."
214824774|NCT03379883|PROCEDURE|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V"
214824775|NCT03379883|PROCEDURE|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
214824776|NCT04254718|BEHAVIORAL|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
214824777|NCT01658774|DRUG|Albendazole|Single 400mg dose
214824778|NCT01658774|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C
214824779|NCT01885949|DRUG|Tivozanib|Oral
214824780|NCT01885949|DRUG|Enzalutamide|oral
214824781|NCT04827394|DEVICE|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
214267640|NCT06349330|OTHER|Control: Standard oral hygiene|Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
214824782|NCT04827394|DEVICE|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
214824783|NCT03786172|BEHAVIORAL|Smoking cessation Intervention|"* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
214824784|NCT03786172|BEHAVIORAL|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
214824785|NCT05680935|DIAGNOSTIC_TEST|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
214824786|NCT05680935|DIAGNOSTIC_TEST|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
214824787|NCT05680935|DIAGNOSTIC_TEST|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
214824788|NCT05680935|DIAGNOSTIC_TEST|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
214824789|NCT02097160|OTHER|Vitamin D fortified yogurt and cheese products|
214824790|NCT02097160|OTHER|Control Group 1|
214824791|NCT07046949|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Ultrasound-guided anterior QL block performed preoperatively
214824792|NCT07046949|DRUG|Parenteral administration of analgesics|Intravenous opioids or NSAIDs used perioperatively.
214824793|NCT07046949|PROCEDURE|General Anesthesia (GA)|Standard general anesthesia per continious 1% propofol infusion and propofol bolus administration, atracurium and fentanyl administration.
214824794|NCT07061847|DRUG|Lidocaine (drug)|"The study intervention involves the use of 1% cardiac preservative-free lidocaine. Lidocaine is a local anesthetic commonly used in medical procedures to numb a specific area of the body. In this case, the lidocaine is formulated at a concentration of 1% and will be diluted to 50 mL with normal saline.~This treatment is an intra-arterial bilateral lidocaine infusion into the middle meningeal artery (i.e. this is a lidocaine infusion into the brain blood vessels to turn off the pain receptors responsible for causing chronic headaches). Lidocaine is an FDA approved anesthetic (i.e. pain killer) used in common medical practice. Lidocaine, however, has not yet been approved by the FDA for this particular use. For this reason, the use of lidocaine in this study is considered investigational."
214824795|NCT07061847|PROCEDURE|Lidocaine Procedure|All patient who meet eligibility criteria at their baseline visit will be scheduled for the Liocaine procedure.
214824796|NCT06760312|PROCEDURE|Root canal shaping with Continuous Rotation|The root canal shaping is conducted with a continuous rotation kinematic.
214824797|NCT06760312|PROCEDURE|Root canal shaping with Apical Reverse|The root canal shaping is conducted with a apical reverse kinematic.
214824798|NCT06760312|PROCEDURE|Root canal shaping is conducted with Apical slow-down kinematic.|The root canal shaping is conducted with a apical slow-down kinematic.
214824799|NCT06765291|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
214824800|NCT06765291|BEHAVIORAL|This is Quitting (TIQ)|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
214824801|NCT07060924|BEHAVIORAL|Game-Based Learning (GBL)|Participants in this group received practical training in peripheral intravenous cannulation (PIVC) using a game-based learning (GBL) simulation platform called 3D Medsim. The platform offered a scenario-based training environment that included a structured sequence of pre-test, simulated procedural performance, and post-test. Students were required to perform virtual tasks such as preparing the patient, selecting the correct equipment, identifying the puncture site, and performing cannulation. The simulation provided interactive feedback and scoring. The application was accessible via PC, tablet, or smartphone, allowing students to practice flexibly. Training was conducted under the supervision of an anesthesiologist.
214824802|NCT07060924|BEHAVIORAL|Model Arm Practice|Participants in this group practiced PIVC using a high-fidelity model arm simulator designed to replicate human anatomy and venous access. The training model included artificial veins (basilic, cephalic, median cubital, and metacarpal) with realistic skin layers and a circulation system that mimicked blood flow. Students practiced cannulation techniques including vein localization, needle insertion, and catheter placement. The hands-on training provided tactile and visual feedback, and all procedures were supervised by an anesthesiologist. This method aimed to develop psychomotor skills and confidence through realistic simulation.
214824803|NCT07068165|DRUG|5mg lenalidomide|Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
214824804|NCT07068165|DRUG|10mg lenalidomide|Lenalidomide 10mg/ day combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/ day for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
214824805|NCT07068165|DRUG|Prednisone monotherapy|The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).
214824806|NCT07068074|PROCEDURE|Wide local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue.
214824807|NCT07068074|PROCEDURE|Sentinel Lymph Node and Wide Local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well.
214824808|NCT07068984|OTHER|Differences between lower limb balances were assessed by the Y-Balance test|The Y-Balance test was used to evaluate bilateral anterior difference, composite score, lateral and posterior balance, symmetry ratio and bilateral difference
214824809|NCT07067203|DEVICE|Lafayette hand held dynamometer|"Muscle Strength Measurement:~The strength of the quadriceps (knee extensors) and hamstrings (knee flexors) of the amputated limb will be measured using a handheld digital dynamometer (Nicholas MMT, Lafayette Instruments). Measurements will be taken with the prosthesis in place. Quadriceps strength will be assessed in a supine position with the knee at 30° flexion, while hamstring strength will be assessed in a prone position with the knee at 20° flexion. Each participant will perform three maximal effort trials after a practice attempt. The highest value will be scaled to body mass for analysis."
214824810|NCT07067203|DIAGNOSTIC_TEST|Timed up and Go test|"Timed Up and Go (TUG) Test:~Participants will complete a standardized 3-meter TUG assessment to evaluate functional mobility. The test will be broken down into five components: standing, walking, turning, returning, and sitting. After one practice run, two timed trials will be conducted, and the average of both will be used for analysis. All procedures will be conducted by trained physical therapists following a standardized protocol."
214267641|NCT02099578|DIETARY_SUPPLEMENT|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
214824811|NCT07068802|BEHAVIORAL|Message framing|Participants provided electronic informed consent with voluntary withdraw options. Randomization was implemented through a 1:1:1:1 allocation ratio to four conditions: Control group (Group 1, n=154) receiving a standard statement of HPV risks (In mainland China, HPV vaccines are currently approved only for female use. However, in other countries, they are also available for males. HPV can cause cancers throughout the body, from the head to the reproductive system. Thus, HPV vaccination can protect against many cancer types. Annually, over 120,000 Chinese are diagnosed with HPV-related cancers, with about 50,000 dying from them.); Intervention 1 (Group 2, n=152) adding male-specific health risks; Intervention 2 (Group 3, n=153) adding risk to female partners; Intervention 3 (Group 4, n=153) adding both personal risk and risk to female partners. The protocol involved sequential completion of pre-exposure questionnaires, timed 120-second message exposure, and immediate post-exposure asses
214824812|NCT07067099|BIOLOGICAL|Plasma with neutralizing autoantibodies to Type I Interferons|Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies
214824813|NCT07068542|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan: 4mg/kg, IV, Q6W, D1, D15, D22
214824814|NCT07068542|DRUG|Tislelizumab|Tislelizumab: 400mg, IV, Q6W, D1
214824815|NCT07067918|OTHER|Upper Body Plyometric Training|"Upper Body Plyometric Training - Intervention Description:~A 12-week upper-body plyometric training protocol designed to enhance explosive upper-extremity power in elite male kickboxers. Exercises included medicine ball chest passes, overhead throws, plyometric push-ups, clap push-ups, and rotational medicine ball throws. Training was performed three times per week (20-30 minutes per session) in addition to regular kickboxing practice."
214824816|NCT07067918|OTHER|Lower Body Plyometric Training|"Lower Body Plyometric Training - Intervention Description:~A 12-week lower-body plyometric training program targeting explosive leg strength and anaerobic performance in elite male kickboxers. The program included countermovement jumps, squat jumps, lateral hurdle jumps, plyometric bounding, tuck jumps, and depth jumps. Sessions were conducted three times per week (20-30 minutes each), alongside regular kickboxing training."
214824817|NCT07068958|DRUG|0.25% RCI001 Ophthalmic Solution|0.25% RCI001 Ophthalmic Solution
214824818|NCT07068958|DRUG|Placebo Ophthalmic Solution (vehicle)|Placebo Ophthalmic Solution (vehicle)
214824821|NCT07069439|BEHAVIORAL|Turkish Version of the P-DrHy-Q|Participants will complete the Turkish-translated version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), which includes 12 items assessing psychosocial burden in two domains: mental health and social activity. A subgroup of participants (n ≈ 20) will complete the same questionnaire again after 14 days to assess test-retest reliability
214824822|NCT07067216|OTHER|Designed scapular stabilization using pressure biofeedback|Patients will attend 1-hour physical therapy sessions twice weekly for 6 weeks. The program will include posterior capsule mobilization, scapular stabilization using pressure biofeedback (targeting lower trapezius, latissimus dorsi, pectoralis major, deep cervical flexors, and scapular retractors), and strengthening exercises using therabands: external rotation, shoulder diagonals, rows, and extensions. Additional training will involve physioball scapular exercises (up/down \& side/side), prone scapular strengthening (e.g., TYI, superman), and scapular-clock drills to improve mobility, proprioception, and stability.
214824823|NCT07067216|OTHER|Designed physical therapy program|Patients will receive cryotherapy and perform stretching exercises for the pectoralis minor and posterior capsule. Strengthening exercises using theraband will target the rotator cuff (especially external rotators) and scapular depressors/retractors. Scapular stabilization will be trained through prone exercises on a ball (T, Y, W) and on a plinth, including rowing, horizontal abduction, extension, superman, and TYI exercises. Additionally, patients will perform the scapular-clock exercise to enhance mobility, control, and proprioception.
214824824|NCT07067086|OTHER|Test Cream|A facial cream (Formula# 899675 44A, 30 mL) was applied once by participants under supervision. 1g of cream was spread over the entire face and neck, followed by targeted massage on wrinkle-prone areas including forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical and photo-based evaluations were conducted at baseline (T0), 10 hours (T10h), and 24 hours (T24h) after application.
214824825|NCT07067164|OTHER|Bulk fill resin composite restorative material|Both restorative materials were applied in a clinical setting following standard infection control protocols and material-specific preparation techniques. The interventions were performed by the same calibrated operator to ensure consistency, and evaluated using modified USPHS criteria by two blinded, independent assessors at 1 week (baseline), 6 months, and 12 months. The study employed a split-mouth design to allow direct intra-individual comparison between the two materials under similar oral conditions.
214824826|NCT07069335|DRUG|Olaparib 150 MG|Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration
214824827|NCT07068022|OTHER|Organ dysfunction score adjusted to obstetric patients (SOFA-OBS)|The obstetric SOFA (SOFA-OBS) adjusts renal and cardiovascular variables to physiological changes of pregnancy. Moreover, it simplifies respiratory evaluation, in terms of replacing arterial blood gases (ABG) for peripheral oxygen saturation/fraction of inspired oxygen (spO2/FiO2), when ABGs were not available. Variables unchanged during pregnancy (neurologic, hepatic and platelets), won't be modified.
214824828|NCT07067710|OTHER|Motor imagery combined with action observation|To observe and imaging one action with a video resource. Not virtual reality.
214267642|NCT02099578|DIETARY_SUPPLEMENT|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
214824829|NCT07067294|DEVICE|Low-Level Light Therapy|"The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Group, Italy), which delivers low-level polychromatic red and near-infrared light (600-1200 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after cataract surgery.~The treatment is designed to stimulate meibomian gland activity, improve tear film stability, reduce ocular surface inflammation.~This protocol is unique compared to standard treatments for dry eye because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications."
214824830|NCT07067294|DEVICE|Sham (No Treatment)|"Sham-treated controls underwent the same procedural setup as the active treatment group, using the Eye-light® device (Espansione Group, Italy). However, instead of delivering therapeutic levels of light energy, the device operated in demo light mode, emitting less than 30% of the full treatment power. This setting simulated the visual and sensory experience of a low-level light therapy (LLLT) session without delivering biologically effective photobiomodulation.~The sham intervention included two 15-minute sessions: one administered 7 days before cataract surgery and one 7 days after. This approach allowed for masking of participants and investigators to minimize bias, while ensuring that patients in the control group received no active therapeutic exposure."
214824831|NCT07067658|DEVICE|Installation of Heartfelt Device|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
214824832|NCT07067658|OTHER|Enhanced Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation. At the start of the study, they will be reminded (or told) about the importance of self-checks and will be handed a patient booklet (from the British Heart Foundation) to standardise patients' knowledge.
214824833|NCT07067658|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
214824834|NCT07067658|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts on the active comparator arm to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
214824835|NCT07067944|DRUG|Ephedrine|The parturient will receive ephedrine infusion immediately before intrathecal injection till delivery of the baby at a dose of 4mg /min.
214824836|NCT07067944|DRUG|Noradrenaline|The parturient will receive noradrenaline infusion immediately before intrathecal injection till delivery of the baby at a dose of 4 microgram/minute.
214824837|NCT06900933|PROCEDURE|Onlay bone block covered with collagen membrane|Onlay bone block covered with collagen membrane
214824838|NCT06900933|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block covered without collagen membrane
214824839|NCT07068659|OTHER|Circuit Aerobic Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute aerobic portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 3 - 4, participants will complete two circuits of walking for 4 1/2 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 5 - 6, participants will complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 5 minutes, and walking backward and forward for 10 meters for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. The intensity of the aerobic exercises will be maintained at 9 - 15 on the rating of
214824840|NCT07068659|OTHER|Circuit Resistance Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute resistance portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 3 - 4, participants will complete two circuits of hamstring curl with ankle weight on each leg for 4 1/2 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 5 - 6, participants will complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 5 minutes, and modified squats with weights for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. Ch
214824841|NCT07068737|BEHAVIORAL|bathing care package|Participants receive a bathing care package that includes a swaddled immersion bath. Room temperature is maintained at 26-27°C with 40-60% humidity. Bath water temperature is controlled at 37-38°C. The infant is swaddled and immersed in water up to the shoulders while the head remains above water. The bath lasts no longer than 5 minutes. After bathing, the infant is gently dried without rubbing, wrapped in a towel, and placed in a pre-warmed incubator (31-34°C) for 10 minutes.
214824842|NCT07068737|BEHAVIORAL|routine bath|Participants receive routine bathing care according to NICU standards. This includes hand hygiene before the procedure, preparing necessary materials, placing the infant in a mesh sling in the bath, washing the body from clean to dirty areas with soft sponges and hospital-provided cleansing agents. The bath lasts up to 10 minutes. After bathing, the infant is quickly dried without rubbing and then diapered.
214824843|NCT07068256|DRUG|Terbinafine|Terbinafine will be given at a dose of 62.5 mg in patients with a body weight \< 20 kg, 125 mg from 20 to 40 kg, and 250 mg in \> 40 kg for a period of 4 weeks.
214824844|NCT07068256|DRUG|Itraconazole|Itraconazole will be given at a dose of 5 mg/kg/day for 7 days and then 14 days off. Three such pulses will be given to the patients.
214267643|NCT02099578|DIETARY_SUPPLEMENT|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
214267644|NCT01925534|DEVICE|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
214267645|NCT01925534|DEVICE|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
214824845|NCT07069387|BEHAVIORAL|CARE-TB digital adherence package|CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients.
214824846|NCT07069387|BEHAVIORAL|Standard Care|Directly observed therapy at any government healthcare facility (by nurses) or at home (by caretaker)
214824847|NCT07068789|PROCEDURE|balloon angioplasty|endovascular angioplasty of infrapopliteal arteries performed using standard balloon catheters under fluroscopic guidance to restore blood flow to the ischemic area
214824848|NCT06716424|DRUG|iGlarLixi (insulin glargine/lixisenatide)|iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
214824849|NCT07068217|OTHER|Exercise|"Sample size was determined via G\*Power analysis: two groups (n=13 each), total n=26. Participants will be randomized using Random.org into the Rhythmic Exercise Group (REG) or the Exercise Group (EG).~Both groups will receive a supervised home-based exercise program, overseen via telerehabilitation. Exercises will be performed 3 times per week for 45-60 minutes each session, over 4 weeks (12 sessions total). Progression to the next week's program will require an 80% success rate; otherwise, the same week's program will be repeated. Online supervision will monitor weekly performance."
214824850|NCT07069530|BEHAVIORAL|Receptive Music Therapy|Participants received six 30-minute sessions of receptive music therapy delivered by live solo piano performance over two weeks. The same playlist was performed in a fixed order at each session, held one hour before dinner. The intervention was designed to reduce depressive symptoms in dementia patients and alleviate caregiver burden using a structured, low-cost, non-pharmacological approach.
214824851|NCT07068516|DRUG|Tislelizumab|Received tislelizumab combined with investigator's choice of chemotherapy
214824852|NCT07068516|DRUG|SOX or CAPOX regimen|chemotherapy (SOX or CAPOX regimen)
214824853|NCT07069543|PROCEDURE|Adenotonsillectomy|the adenotonsillectomy group children, indicated for immediate adenotonsillectomy
214824854|NCT07069543|PROCEDURE|Rapid maxillary expansion|expansion group children with a narrow palate and posterior crossbite, with indication for rapid maxillary expansion
214824855|NCT07067125|BEHAVIORAL|AR-Supported Scoliosis-Specific Physiotherapy|This intervention consists of scoliosis-specific physiotherapy supported by AR technology. Participants will engage in postural correction exercises delivered by licensed physiotherapists using an AR system that provides real-time avatar feedback, movement guidance, and gamified motivation. The intervention aims to improve body awareness, adherence, and motivation among adolescents diagnosed with AIS. Each participant will complete at least four weeks of structured AR-supported sessions.
214824856|NCT07068048|DRUG|Dexametasone|"Intra-operatively, all participants recruited must have the recurrent laryngeal nerve identify and confirm with Intraoperative Nerve Monitoring (IONM) device.~After removal of thyroid gland, 8mg of dexamethasone will be diluted in 100cc of irrigation water and irrigate the operative field for 1 minute for the intervention group."
214824857|NCT07068048|DRUG|Water for injection|For the placebo group, they will received water irrigation over the operative field only which is the current standard of practice at the moment.
214824858|NCT07068841|DRUG|sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3|"Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.~Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3."
214824859|NCT07068178|DRUG|ICI-HIPET|Patients received the following interventions: On Day 0, intravenous administration of tislelizumab (an anti-PD-1 immune checkpoint inhibitor) was initiated within 3 hours post-HIPEC. Tumor tissue samples were collected before HIPEC, at 30 minutes, 60 minutes, and 90 minutes (end of HIPEC). Serum samples were collected pre- and post-HIPEC. On Day 1, additional serum samples were collected 24 hours after HIPEC-ICI completion. From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy, with serum sampling repeated at 48 hours post-HIPEC-ICI. On Days 21 and 42, the second and third cycles of neoadjuvant chemotherapy (tislelizumab + paclitaxel + carboplatin) were administered intravenously.
214824860|NCT07067333|DEVICE|intramedullary nails for group A|fixation of the shaft femure fracture in this group by intramedullary nails
214824861|NCT07067333|DEVICE|plate for group B|fixation of the shaft femure fracture in the group b by plates
214824862|NCT07067580|OTHER|respiratory exercise|The experimental group will be trained on respiratory exercises by the researcher the day before the surgery. The patients will be asked to perform the post-operative respiratory exercises as 1 set (4 breaths) per hour. The patient's vital signs will be monitored before and after the respiratory exercise. Patients will not have difficulty during the respiratory exercise, they will be asked to do it gradually.
214824863|NCT04284319|PROCEDURE|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
214824864|NCT06891261|DEVICE|Piezo Surgery.|Piezotome woodpecker®: Surgic touch.
214824865|NCT06891261|PROCEDURE|Bone Discs.|bone discs mounted on staight hand piece and contra angled 1:1 gear ratio.
214824866|NCT06930794|DRUG|Vebreltinib combined with platinum-based doublet chemotherapy.|"Vebreltinib: Each cycle is 3 weeks (21 days). It is administered orally twice a day (BID), and the dosage level depends on the cohort assignment.~Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment."
214824867|NCT06930794|DRUG|platinum-based doublet chemotherapy.|Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment.
214824868|NCT02111694|BEHAVIORAL|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
214267646|NCT02095977|PROCEDURE|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
214824869|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
214824870|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
214824871|NCT06911567|DRUG|TEV-56286 Test|Administered orally
214824872|NCT06911567|DRUG|TEV-56286 Reference|Administered orally
214824873|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
214824874|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
214824875|NCT00681161|OTHER|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
214824876|NCT06425302|DRUG|Golcadomide|Specified dose on specified days
214824877|NCT06425302|DRUG|Rituximab|Specified dose on specified days
214824878|NCT06425302|DRUG|Cyclophosphamide|Specified dose on specified days
214824879|NCT06425302|DRUG|Doxorubicin|Specified dose on specified days
214824880|NCT06425302|DRUG|Vincristine|Specified dose on specified days
214824881|NCT06425302|DRUG|Prednisone|Specified dose on specified days
214824882|NCT06425302|DRUG|Bendamustine|Specified dose on specified days
214824883|NCT04594252|DRUG|ALXN1840|Administered orally as tablets.
214824884|NCT03331289|DRUG|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
214824885|NCT03331289|DRUG|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
214824886|NCT03331289|DRUG|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
214824887|NCT03331289|DRUG|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
214824888|NCT04887480|DEVICE|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
214824889|NCT04887480|DRUG|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
214824890|NCT06938295|DIAGNOSTIC_TEST|Comparative Use of High-End and Mid-End Intestinal Ultrasound Devices for IBD Disease activity assessment|This study compares two intestinal ultrasound (IUS) devices-a high-end machine (Samsung RS85) and a mid-end machine (Siemens ACUSON S2000)-for assessing ileocolonic inflammation in IBD patients. The high-end device offers advanced imaging features, including high-resolution, speckle reduction, and extended field of view, allowing for detailed visualization of the bowel wall and vascularity. The mid-end device, while more basic, provides essential IUS functions for examining bowel wall thickness, structure, and inflammation markers. Both devices are used in a single clinical session, with results compared against tandem ileo-colonoscopy as the reference standard. This unique dual approach enables evaluation of the diagnostic performance of each device type. If comparable, the mid-end device may offer a cost-effective solution, increasing access to routine IUS in various healthcare settings, especially where high-end technology is limited.
214824891|NCT06943924|PROCEDURE|Frailty assessment|This study aims to investigate the accuracy and clinical utility of these scoring systems in predicting mortality in individuals aged 65 and older undergoing emergency surgery.
214824892|NCT00477594|DRUG|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
214824893|NCT06945042|OTHER|Arm A|The intervention will consist of systematic financial navigation with consistent screening and intervention on any financial related issues. All patients randomized to the financial navigational group will be contacted by clinical trial staff assigned to the study to screen for financial needs. Based on the results of this assessment, the clinical trials staff will refer to the appropriate services for personalized recommendations and assistance provided by Atrium Health personnel including financial navigators, nurse navigators. All the resources provided to the patient, including counseling, will be free of charge. Assessment will be performed once per month for 6 months.
214824894|NCT06945042|OTHER|Arm B|All patients randomized to the Standard of Care arm will have access to the financial distress resources (Financial Navigation and Nurse Navigation) as per current clinical policy which is per patient or clinician request. Utilization of these resources will be tracked to assess and describe the per-protocol population. All the resources provided to the patient, including counseling, will be free of charge as per institutional policy.
214824895|NCT03011476|DRUG|Donepezil|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
214824896|NCT03011476|DRUG|Placebos|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
214824897|NCT06939803|OTHER|Risk model-driven CDS|"The CDS intervention will use an automated risk model called VTE-AI to add EHR-based prompts in the form of alerts targeting those encounters on which 1) VTE-AI risk is above 5% predicted risk (found to be high risk in prior analyses), 2) no active DVT prophylaxis pharmacologic order is present, 3) no contraindication has been documented in the current admission"
214824898|NCT00712777|DRUG|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
214824899|NCT06948773|DEVICE|Helix Surgical System|A handheld device to viscodilate up to 360 degrees of Schlemm's canal and collector channels that also enables intracanalicular scaffolding procedure to restore the aqueous outflow system of a glaucomatous eye.
214824900|NCT06517056|DEVICE|Emovi Knee Kinesiography|All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
214824901|NCT05261802|OTHER|Descriptive Intervention|A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
214824902|NCT06224803|DIETARY_SUPPLEMENT|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
214824903|NCT06224803|DIETARY_SUPPLEMENT|Indigestible dextrin|Indigestible dextrin as placebo intervention
214824904|NCT03114891|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
214824905|NCT03114891|BEHAVIORAL|Task|Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
214824906|NCT03114891|PROCEDURE|fMRI-guided TMS target|Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
214824907|NCT05117489|DRUG|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
214824908|NCT05117489|DRUG|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
214824909|NCT05117489|DRUG|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
214824910|NCT05117489|DRUG|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
214824911|NCT06495138|DEVICE|StableEyes|"Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit."
214824912|NCT05763589|OTHER|No intervention is involved|No intervention is involved
214824913|NCT05630950|DEVICE|Smoking cessation mobile application|Mobile application for smoking cessation.
214824914|NCT05630950|BEHAVIORAL|Written material for smoking cessation|Written material for smoking cessation
214824915|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
214824916|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
214267647|NCT02095977|PROCEDURE|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
214824917|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
214824918|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
214824919|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
214824920|NCT05714865|DRUG|Surfactant|Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP
214824921|NCT06953505|DIAGNOSTIC_TEST|Ammonia Study Device|Ammonia study device for capillary ammonia measurement
214824922|NCT06834308|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS (100 Hz, 60 ms pulse width) will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to produce strong paresthesia without pain. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
214824923|NCT06834308|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|The participants will be able to see the same parameters as the conventional TENS (100 Hz, 60 ms pulse width) on the screen, but there will be no actual stimulation. Sham TENS will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to 4Hz for all participants in the Sham arm. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
214824924|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
214824925|NCT02068794|OTHER|Laboratory Biomarker Analysis|Correlative studies
214824926|NCT02068794|PROCEDURE|Mesenchymal Stem Cell Transplantation|Given IP
214824927|NCT02068794|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
214824928|NCT02068794|PROCEDURE|Echocardiography|Undergo ECHO
214824929|NCT02068794|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214824930|NCT02068794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214267648|NCT02095977|PROCEDURE|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
214267649|NCT02468674|DRUG|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
214824931|NCT02068794|PROCEDURE|Chest Radiography|Undergo chest X-ray
214824932|NCT02068794|PROCEDURE|Single Photon Tomography and Computed Tomography Scan|Undergo SPECT/CT
214824933|NCT02068794|PROCEDURE|Computed Tomography|Undergo CT
214824934|NCT02068794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214824935|NCT04748796|OTHER|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
214824936|NCT04748796|DRUG|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
214824937|NCT06954233|DIAGNOSTIC_TEST|Uroflowmetry and questionnaires|Uroflowmetry - urine flow assessment Questionnaires: IPSS, ICIQ-MLUTS, IIEF-5, MSHQ-EjD, EQ-5D-5L
214824938|NCT04359407|OTHER|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
214824939|NCT06514014|DIETARY_SUPPLEMENT|Preterm Infant Formula|Transition from donor human milk to preterm infant formula
214824940|NCT06182436|DEVICE|Virtual Reality Distraction|For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.
214824941|NCT06182436|OTHER|Standard Treatment|"Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention.~Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented"
214824942|NCT06788431|DRUG|IMC-001 and Optimal medical treatment|Subjects receive IMC-001 administered by injection once a week for 13 weeks and also receive optimal medical treatment.
214824943|NCT06788431|DRUG|IMC-001 placebo and optimal medical treatment|Subjects receive IMC-001 placebo administered by injection once a week for 13 weeks and also receive optimal medical treatment.
214824944|NCT05607420|BIOLOGICAL|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
214824945|NCT05607420|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
214824946|NCT05679115|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
214824947|NCT05893342|DIAGNOSTIC_TEST|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
214824948|NCT05427708|DEVICE|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
214824949|NCT05427708|BEHAVIORAL|Psycho-Education|See: Arm/group descriptions
214824950|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
214824951|NCT05605522|DRUG|[225]-FPI-2059|"\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation."
214824952|NCT05605522|DRUG|[111In]-FPI-2058|\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
214824953|NCT02256722|DRUG|KUC 7483 CL|
214824954|NCT02256722|DRUG|Bisoprolol|
214824955|NCT02256722|DRUG|Propranolol|
214824956|NCT02256722|DRUG|Acipimox|
214824957|NCT02256722|DRUG|Salmeterol|
214824958|NCT05747950|OTHER|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
214824959|NCT05747950|OTHER|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
214824960|NCT05747950|OTHER|Conventional Therapy|Conventional exercises
214824961|NCT06845202|DRUG|ALN-4324|ALN-4324 will be administered subcutaneously (SC)
214824962|NCT06845202|DRUG|Placebo|Placebo will be administered SC
214824963|NCT04982614|BIOLOGICAL|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
214824964|NCT03707171|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
214824965|NCT03707171|DRUG|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
214824966|NCT03859089|OTHER|Medical Cannabis|N/A - Observational Cohort Study
214824967|NCT02635750|DRUG|BI 409306|
214824968|NCT02635750|DRUG|Donepezil|
214824969|NCT00465621|DRUG|Xalatan|
214824970|NCT00805779|DEVICE|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
214824971|NCT04821349|DEVICE|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
214824972|NCT05383807|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
214824973|NCT02468518|DRUG|Vitamin E capsule|Capsules will be distributed to each participant free of cost
214824974|NCT04053153|DEVICE|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
214824975|NCT00372983|DRUG|NOV-205|
214824976|NCT05305092|DEVICE|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
214824977|NCT05471596|DEVICE|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
214824978|NCT04449315|OTHER|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
214824979|NCT04377087|DRUG|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
214824980|NCT06183788|BEHAVIORAL|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
214824981|NCT06450145|DRUG|interferon α-2b|Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
214824982|NCT02484404|DRUG|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
214824983|NCT02484404|DRUG|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
214824984|NCT02484404|DRUG|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
214824985|NCT02875392|OTHER|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
214824986|NCT02875392|OTHER|placebo pills|taking placebo pills as if patients are under treatment.
214824987|NCT05491187|DRUG|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
214824988|NCT05491187|DRUG|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
214824989|NCT03599193|DRUG|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
214824990|NCT03599193|DRUG|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
214824991|NCT00394303|DRUG|Intraoperative continuous insulin infusion|Nomogram specified in appendix
214824992|NCT00394303|OTHER|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
214824993|NCT05213052|OTHER|Topical cream|Topical cream applied to painful joint or muscle
214824994|NCT02376881|DRUG|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
214824995|NCT02376881|OTHER|placebo|100 ml normal saline in 2 hr for 3 successive days
214824996|NCT06150703|DRUG|Ovulation induction with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
214824997|NCT06150703|DRUG|Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
214824998|NCT03932045|DEVICE|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
214824999|NCT03932045|DEVICE|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
214825000|NCT00571935|DRUG|insulin aspart|
214825001|NCT00571935|DRUG|soluble human insulin|
214825002|NCT00835705|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
214825003|NCT00835705|DRUG|Augmentin®|400 mg-57 mg chewable tablet
214267650|NCT02468674|DRUG|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
214267651|NCT03712956|DRUG|Caelyx®|Caelyx® every two weeks for 8 courses
214825004|NCT01949805|DRUG|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
214825005|NCT01949805|DRUG|Hydroxyurea|Hydroyurea capsules taken daily po
214825006|NCT03407209|OTHER|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
214825007|NCT03417076|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
214825008|NCT03049631|DIETARY_SUPPLEMENT|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
214825009|NCT03049631|DIETARY_SUPPLEMENT|Raspberry|Red raspberries (1 cup equivalent)
214825010|NCT01706094|OTHER|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
214267652|NCT02318147|PROCEDURE|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
214267653|NCT02318147|DRUG|The traditional treatment|the traditional treatments according to associated guidelines
214267654|NCT03478332|DRUG|Yangxinshi pill|0.6g/tablet
214267655|NCT03478332|DRUG|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
214267656|NCT03478332|DRUG|Placebos|Yangxinshi simulant
214825011|NCT05360394|DEVICE|Paclitaxel Coated Balloon|CAS treated with PCB only
214825012|NCT05360394|DEVICE|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
214825013|NCT05539157|DRUG|JCXH-211|JCXH-211 administered once every 28 days
214825014|NCT00582387|GENETIC|specimen samples|blood, urine and tissue
214825015|NCT00582387|BEHAVIORAL|questionnaires|
214825016|NCT03625973|BEHAVIORAL|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
214825017|NCT03625973|BEHAVIORAL|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
214825018|NCT02452619|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
214825019|NCT00889486|DRUG|TZP-102|
214825020|NCT00889486|DRUG|Placebo|
214825021|NCT06556017|DIAGNOSTIC_TEST|Diagnosis of SSI|Comparison of the manual system and ChatGPT for SSI diagnosis in colorectal surgery procedures enrolled in the SSI surveillance programme.
214825022|NCT04584541|BIOLOGICAL|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
214825023|NCT04584541|BIOLOGICAL|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
214825024|NCT04584541|BIOLOGICAL|Stools|SarS-Cov-2 viral load assessment
214825025|NCT01608984|PROCEDURE|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
214825026|NCT01608984|PROCEDURE|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
214825027|NCT01608984|PROCEDURE|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
214825028|NCT06561542|DRUG|LX22001 for Injeciton|single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
214825029|NCT06561542|DRUG|Tegoprazan tablet|50mg,oral,single dose
214825030|NCT06561542|DRUG|Esomeprazole sodium for injection|80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
214825031|NCT03375957|DRUG|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
214825032|NCT03375957|DRUG|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
214825033|NCT05405023|OTHER|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
214825034|NCT05405023|OTHER|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
214825035|NCT02770690|DRUG|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
214825036|NCT02770690|DRUG|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
214825037|NCT02770690|DRUG|placebo|apply normal saline before propofol iv injection
214825038|NCT02864836|PROCEDURE|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
214825039|NCT05488795|BEHAVIORAL|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
214825040|NCT03215641|DEVICE|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
214825041|NCT00063687|DRUG|Oxypurinol|
214825042|NCT02757287|DRUG|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~\- Quality of Life questionnaire the day after the bolus"
214825043|NCT04511156|OTHER|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
214825044|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
214825045|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
214825046|NCT04778878|DEVICE|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
214825047|NCT06182462|DEVICE|Virtual Reality Distraction|"The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded."
214825048|NCT06182462|DEVICE|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
214825049|NCT05676294|DRUG|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
214825050|NCT05676294|DRUG|Placebo|oral matched placebo one hour prior to ambulatory surgery
214825051|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
214825052|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
214825053|NCT06384495|PROCEDURE|REAL-A|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
214825054|NCT06384495|PROCEDURE|REAL-C|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
214825055|NCT06384495|PROCEDURE|SHAM|one session of sham tDCS for 20 minutes to the right ventro-lateral cerebellum.
214825056|NCT06013527|OTHER|Supervised Training|"Two different classes over alternate weeks twice per week :~1. 60-minute step aerobics class (Given week 1,3,5,7)~2. 60 minutes circuit training class (Given week 2,4,6,8)~Each class will include warm-up and cool-down periods both lasting 10-15 min. The exercise period of 30 minutes the maximum target RPE would be set at 14-16 on a 20-point BORG scale, a level of exercise that feels somewhat hard or hard and coincides with about 86-92% of maximal heart rate, 76-85% of maximal VO 2 and 5-7 metabolic equivalents (METs) ideal for improving the related domains of QoL and Cardiovascular endurance (12). During the first 3 weeks, the participants would exercise at a lower level of RPE (approximately 11-13), to adapt to the training and so that newly recruited participants could also join the group without difficulty."
214825057|NCT06013527|OTHER|Individually tailored home program|The type of home training would mainly consist of endurance training such as walking, Nordic walking, or aerobic training, but it would also include jumps and leaps like step aerobics to promote bone health. The Participants will be asked to perform these thrice per week.
214825058|NCT05256160|OTHER|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
214825059|NCT05256160|OTHER|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
214825060|NCT00003003|BIOLOGICAL|sargramostim|
214825061|NCT00003003|DRUG|mitomycin C|
214825062|NCT00003003|DRUG|mitoxantrone hydrochloride|
214825063|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
214825064|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
214825065|NCT04304066|OTHER|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
214825066|NCT02543489|DEVICE|Flex IM rod|
214825067|NCT00271492|DRUG|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
214825068|NCT00271492|DRUG|Atrasentan|1 10mg capsule per day for the 6 month study period.
214825069|NCT00271492|DRUG|atrasentan|One 10 mg capsule per day for 6 month study period
214825070|NCT05869721|OTHER|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
214825071|NCT06635135|DRUG|Aticaprant|Aticaprant will be administered orally.
214825072|NCT06635135|OTHER|Placebo|Placebo will be administered orally.
214825073|NCT02624297|OTHER|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
214267657|NCT01952405|BEHAVIORAL|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
214267658|NCT03323541|DRUG|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
214267659|NCT02036697|DRUG|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
214825074|NCT06081634|BEHAVIORAL|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
214825075|NCT06081634|OTHER|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
214825076|NCT02570958|DRUG|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
214825077|NCT05106803|DRUG|ciprofloxacin|Antibiotics used in vitro n the study
214825078|NCT01260805|DRUG|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
214825079|NCT01260805|DRUG|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
214825080|NCT02670161|DRUG|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
214825081|NCT01791062|DEVICE|HYTOP®|HYTOP® will be implanted once during surgery.
214825082|NCT06562959|BEHAVIORAL|Fluid Restriction Program|In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.
214825083|NCT06562959|OTHER|Intervention Bundle (Fluid Restriction Program and Auricular Acupressure|the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
214825084|NCT02491099|DRUG|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
214825085|NCT01592240|DRUG|PBO|Placebo Q28d
214825086|NCT01592240|DRUG|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
214825087|NCT01592240|DRUG|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
214825088|NCT01592240|DRUG|PBO|Placebo, Q14d
214825089|NCT01592240|DRUG|PF-04950615|PF-04950615 50mg, Q14d
214825090|NCT01592240|DRUG|PF-04950615|PF-04950615 100 mg, Q14d
214825091|NCT01592240|DRUG|PF-04950615|PF-04950615 150mg, Q14d
214825092|NCT03181620|OTHER|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
214267660|NCT02036697|DRUG|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
214825093|NCT00465218|PROCEDURE|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
214825094|NCT02395809|PROCEDURE|lateral internal sphincterotomy|
214825095|NCT02395809|PROCEDURE|TENS|
214825096|NCT04816773|DEVICE|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
214825097|NCT03704103|OTHER|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
214825098|NCT04166162|BEHAVIORAL|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
214825099|NCT04166162|BEHAVIORAL|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
214267661|NCT02036697|DRUG|Morphine|morphine 150 mcg.
214267662|NCT02036697|DRUG|Fentanyl|15 mcg
214267663|NCT02043171|DIETARY_SUPPLEMENT|Placebo|A Placebo comparator
214825100|NCT04166162|BEHAVIORAL|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
214825101|NCT04166162|BEHAVIORAL|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
214825102|NCT01909713|DRUG|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
214825103|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
214825104|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
214825105|NCT01139216|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
214825106|NCT01011413|DRUG|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
214825107|NCT01011413|DRUG|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
214825108|NCT05330533|RADIATION|scrotal duplex|Scrotal colour doppler ultrasonography
214825109|NCT03207152|BIOLOGICAL|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
214825110|NCT05374850|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
214825111|NCT00190541|PROCEDURE|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
214825112|NCT00190541|PROCEDURE|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
214825113|NCT06393530|DRUG|0.9%sodium chloride|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
214825114|NCT06393530|DRUG|0.2% ropivacaine|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
214825115|NCT04835116|DRUG|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
214825116|NCT04835116|DRUG|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
214825117|NCT04763031|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
214825118|NCT04082741|DRUG|BMS-986318|Specified dose on specified days
214825119|NCT04082741|OTHER|Placebo|Placebo Matching BMS-986318
214825120|NCT03246503|DEVICE|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
214825121|NCT05089903|BEHAVIORAL|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
214825122|NCT05089903|BEHAVIORAL|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
214267664|NCT02043171|DRUG|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
214267665|NCT02043171|BEHAVIORAL|Non-Exercise|This group will not participate in 3 times per week strength training
214267666|NCT02043171|BEHAVIORAL|Exercise|This group will participate in a supervised 3 times per week strength training program
214267667|NCT04962178|PROCEDURE|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
214825123|NCT05089903|BEHAVIORAL|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
214825124|NCT05089903|BEHAVIORAL|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
214825125|NCT05089903|BEHAVIORAL|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
214825126|NCT02994836|BIOLOGICAL|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
214825127|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
214825128|NCT02994836|BIOLOGICAL|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
214825129|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
214825130|NCT01216020|DRUG|cetuximab|"* Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
214825131|NCT01216020|DRUG|cisplatin (associated to radiotherapy)|"* CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
214825132|NCT02751424|DRUG|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
214825133|NCT02751424|DRUG|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
214825134|NCT01448434|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
214825135|NCT01448434|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
214825136|NCT03005834|OTHER|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
214825137|NCT01363817|DRUG|BMS-906024|
214825138|NCT01363817|DRUG|Dexamethasone|
214825139|NCT03206749|DRUG|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
214825140|NCT03206749|DRUG|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
214825141|NCT03206749|DRUG|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
214825142|NCT06026267|BIOLOGICAL|20% High Dose Albumin|"A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
214825143|NCT06026267|OTHER|Standard Medical Treatment|Standard Medical Treatment
214825144|NCT06026267|BIOLOGICAL|20% Reduced Dose Albumin|"B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
214825145|NCT03302949|DIETARY_SUPPLEMENT|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
214825146|NCT01298609|DEVICE|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
214825147|NCT05572996|DRUG|Inhaled Treprostinil|
214825148|NCT02870686|PROCEDURE|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
214825149|NCT02870686|PROCEDURE|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
214825150|NCT00716625|DRUG|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
214825151|NCT01492439|BEHAVIORAL|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
214825152|NCT01492439|BEHAVIORAL|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
214825153|NCT03900013|PROCEDURE|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
214825154|NCT03900013|PROCEDURE|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
214825155|NCT00967148|DRUG|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
214825156|NCT00967395|OTHER|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
214825157|NCT00967395|OTHER|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
214267668|NCT04962178|OTHER|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
214825158|NCT04589546|DRUG|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
214825159|NCT04589546|DRUG|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
214825160|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
214825161|NCT03348527|DRUG|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
214825162|NCT02803827|OTHER|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
214825163|NCT02803827|BIOLOGICAL|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
214825164|NCT02803827|OTHER|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
214825165|NCT03332082|PROCEDURE|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
214825166|NCT03531060|DRUG|IRL790|IRL790 capsule 10 mg
214825167|NCT03531060|DRUG|Placebo|Placebo capsule
214825168|NCT04891276|OTHER|Data collection|Data collection on the national PMSI database
214825169|NCT01251068|DEVICE|near infrared spectroscopy: invos 5100|duration:six hours
214825170|NCT01251068|DEVICE|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
214825171|NCT01251068|DEVICE|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
214825172|NCT01846091|OTHER|Laboratory Biomarker Analysis|Correlative studies
214825173|NCT01846091|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
214825174|NCT06498024|OTHER|Kellogg's - rice krispies (control)|One serving size (140g) of whole white rice cereal will be provided. Preparation will be consistently maintained throughout.
214825175|NCT06498024|OTHER|Kellogg's - rice krispies (control) + 125ml milk|One serving size (140g) of whole white rice cereal with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
214825176|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
214825177|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) will be provided. Preparation will be consistently maintained throughout.
214825178|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with a 10% added purple powder (sweet potato) will be provided. Preparation will be consistently maintained throughout.
214825179|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 50% fava bean blend) and 10% purple powder (sweet potato) with 125 ml milk. Preparation will be consistently maintained throughout.
214825180|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
214825181|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
214825182|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
214825183|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
214825184|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
214825185|NCT05690152|DEVICE|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
214825186|NCT04065646|OTHER|Mobile|
214825187|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
214825188|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
214825189|NCT05006690|OTHER|Clinical Pilates-Based Exercise Training|Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
214825190|NCT06238570|DEVICE|Gavi, Merck® (automated vitrification instrument)|"This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.~The oocytes will be stored in closed cassettes in liquid nitrogen"
214267669|NCT02418702|DRUG|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
214267670|NCT02418702|OTHER|placebo|20 patients will randomly be assigned a placebo
214267671|NCT01929096|DRUG|Compound Edaravone Injection|
214267672|NCT01929096|DRUG|Edaravone Injection|
214825191|NCT06238570|DEVICE|Vitrolife system|The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
214825192|NCT04186260|BEHAVIORAL|NAFLD-specific weight loss intervention|This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.
214825193|NCT04186260|OTHER|Wait-list control|Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
214825194|NCT04803162|DIAGNOSTIC_TEST|High-resolution manometry|The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
214825195|NCT04803162|DIAGNOSTIC_TEST|Serum biomarkers|The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
214825196|NCT04803162|DIAGNOSTIC_TEST|Gastrointestinal Quality of Life index|The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
214825197|NCT04803162|DRUG|Omeprazole 20 MG Oral Tablet|The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
214825198|NCT05231824|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
214825199|NCT05231824|BEHAVIORAL|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
214825200|NCT04364087|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
214825201|NCT06244485|DRUG|Valemetostat tosylate|Administered orally once daily
214825202|NCT06244485|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
214825203|NCT06244485|DRUG|Dato-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle.
214825204|NCT05523895|DRUG|Pimavanserin|Pimavanserin
214825205|NCT05523895|DRUG|Placebo|Pimavanserin matching placebo
214825206|NCT03674892|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|TrueTear™ intranasal neurostimulator (ITN)
214825207|NCT05404594|BEHAVIORAL|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
214825208|NCT05610033|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
214825209|NCT04156230|DRUG|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
214825210|NCT02259244|BEHAVIORAL|Weight reduction program|
214825211|NCT06414733|BIOLOGICAL|Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
214825212|NCT05554419|DRUG|Azacitidine|Given IV or SC
214825213|NCT05554419|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214825214|NCT05554419|DRUG|Cytarabine|Given IV
214825215|NCT05554419|PROCEDURE|Echocardiography Test|Undergo ECHO
214825216|NCT05554419|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214825217|NCT05554419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214825218|NCT05554419|DRUG|Venetoclax|Given PO
214825219|NCT00824291|DRUG|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
214825220|NCT00824291|GENETIC|Genotyping|CYP2D6 genotyping at randomization
214267673|NCT05477693|BIOLOGICAL|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
214825221|NCT01330576|PROCEDURE|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
214825222|NCT01330576|PROCEDURE|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
214825223|NCT00848146|PROCEDURE|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
214825224|NCT03656367|DIETARY_SUPPLEMENT|Cheddar cheese|The reference product is a commercial matured cheddar cheese
214825225|NCT03656367|DIETARY_SUPPLEMENT|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
214825226|NCT03656367|DIETARY_SUPPLEMENT|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
214825227|NCT03656367|DIETARY_SUPPLEMENT|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
214825228|NCT05644587|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
214825229|NCT01907607|DRUG|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
214825230|NCT02478983|DEVICE|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
214825231|NCT02478983|DEVICE|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
214825232|NCT02184845|DEVICE|Implant NobelActive 3.0|
214825233|NCT01505933|DRUG|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
214825234|NCT01505933|DRUG|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
214825235|NCT00395694|DRUG|lamictal|anti-epileptic drug
214825236|NCT01648582|DRUG|Dulaglutide|Administered SC
214825237|NCT01648582|DRUG|Insulin glargine|Administered SC per dosing titration schedule
214825238|NCT01648582|DRUG|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
214825239|NCT01648582|DRUG|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
214825240|NCT03142165|DRUG|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
214825241|NCT03142165|OTHER|Placebo|Placebo
214825242|NCT03142165|DRUG|Diphenhydramine|50 mg intravenous administration
214825243|NCT03142165|DRUG|Famotidine|20 mg intravenous administration
214825244|NCT02699866|DEVICE|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
214825245|NCT01959672|PROCEDURE|4-Dimensional Computed Tomography|Correlative studies
214825246|NCT01959672|DRUG|Fluorouracil|Given IV
214825247|NCT01959672|DRUG|Gemcitabine Hydrochloride|Given IV
214825248|NCT01959672|OTHER|Laboratory Biomarker Analysis|Correlative studies
214825249|NCT01959672|DRUG|Leucovorin Calcium|Given IV
214825250|NCT01959672|DRUG|Nelfinavir Mesylate|Given PO
214825251|NCT01959672|BIOLOGICAL|Oregovomab|Given IV
214825252|NCT01959672|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214825253|NCT01959672|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214267674|NCT05477693|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
214267675|NCT02119481|BEHAVIORAL|Mindfulness-based stress reduction|
214267676|NCT02119481|BEHAVIORAL|Expressive writing condition|
214267677|NCT06963463|BEHAVIORAL|TranS-C|This intervention includes participants attending 6-8 sessions with a Sleep Therapist.
214825254|NCT03593512|PROCEDURE|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
214825255|NCT02526121|PROCEDURE|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
214825256|NCT02526121|BEHAVIORAL|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
214267678|NCT06963463|BEHAVIORAL|Sleep Feedback|Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data.
214267679|NCT02092493|DEVICE|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
214267680|NCT06465290|DEVICE|Motor relearning training with wearable ankle robot|Ankle motor control relearning training under real-time feedback
214825257|NCT00682500|DRUG|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
214825258|NCT00682500|DRUG|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
214825259|NCT04530656|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
214825260|NCT04530656|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
214825261|NCT04530656|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
214825262|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Two doses of placebo (0.5ml) at the schedule of day 0, 28
214825263|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（high-dose group）|Two doses of placebo (1.0ml) at the schedule of day 0, 28
214825264|NCT04530656|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）|Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
214825265|NCT01322880|BEHAVIORAL|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
214825266|NCT01322880|BEHAVIORAL|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
214825267|NCT01058668|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214825268|NCT01058668|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
214825269|NCT03695692|BEHAVIORAL|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
214825270|NCT03695692|BEHAVIORAL|pelvic floor exercise|The exercise program is performed every day for 6 weeks
214825271|NCT00817440|OTHER|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
214825272|NCT00817440|OTHER|Fasting|3 days of fasting and then the same as arm 1
214825273|NCT00365430|BEHAVIORAL|safety program|Education, patient involvement, tailored implementation and a computerized registration system
214825274|NCT05955534|DEVICE|TPUG|Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.
214825275|NCT05955534|PROCEDURE|PEG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
214825276|NCT05955534|PROCEDURE|PRG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
214825277|NCT03876639|OTHER|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
214825278|NCT03876639|PROCEDURE|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
214825279|NCT03876639|PROCEDURE|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
214825280|NCT04859517|DRUG|ADG20|Single dose of ADG20
214825281|NCT04859517|DRUG|Placebo|Single dose of placebo
214825282|NCT01068821|OTHER|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
214825283|NCT01068821|OTHER|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
214825284|NCT03772821|OTHER|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
214825285|NCT03772821|OTHER|Incision/scar measurement|Between D0 and D90
214825286|NCT03953287|DRUG|Paracetamol|A randomized, cross over design
214825287|NCT05928156|OTHER|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
214825288|NCT05928156|OTHER|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
214825289|NCT00000261|DRUG|30% Nitrous oxide|
214825290|NCT00000261|OTHER|Placebo|No drug (100% oxygen)
214825291|NCT00000261|DRUG|0.2% sevoflurane|
214825292|NCT00000261|DRUG|0.4% sevoflurane|
214825293|NCT00000261|DRUG|0.6% sevoflurane|
214825294|NCT05675033|DRUG|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
214825295|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using allograft|Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.
214825296|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using xenograft|Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.
214825297|NCT06627829|DEVICE|Usual care|Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
214825298|NCT02906540|PROCEDURE|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
214825299|NCT02906540|PROCEDURE|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
214825300|NCT04178850|BIOLOGICAL|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
214825301|NCT04178850|BIOLOGICAL|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
214825302|NCT02523963|OTHER|family work shop|"1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
214825303|NCT00147563|DRUG|Eplerenone|
214825304|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
214825305|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
214825306|NCT05111223|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
214825307|NCT02091713|OTHER|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
214825308|NCT06356103|DIETARY_SUPPLEMENT|Whey-Based Partially Hydrolyzed Formula|Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
214825309|NCT06356103|DIETARY_SUPPLEMENT|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines|protein and micronutrient requirements according to the recommended dietary allowance (RDA)
214825310|NCT02545803|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
214825311|NCT02281994|DEVICE|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
214825312|NCT00908128|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
214825313|NCT00908128|DRUG|CellCept®|CellCept® Tablets, 500 mg
214825314|NCT02842853|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214825315|NCT02842853|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214825316|NCT04089553|DRUG|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
214825317|NCT04089553|DRUG|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
214825318|NCT04089553|DRUG|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
214825319|NCT01064960|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
214825320|NCT02817867|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
214825321|NCT02817867|DEVICE|TMS|Transcranial magnetic stimulation
214825322|NCT02817867|DEVICE|tDCS + TMS|Association between tDCS and TMS.
214825323|NCT04018768|OTHER|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
214825324|NCT04018768|OTHER|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
214825325|NCT03714594|DRUG|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
214825326|NCT03714594|DRUG|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
214825327|NCT03714594|DRUG|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
214825328|NCT01403194|DEVICE|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
214825329|NCT03153462|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
214825330|NCT03572868|OTHER|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the second or the third trimester of pregnancy.
214825331|NCT05224531|DRUG|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
214825332|NCT06627465|DEVICE|MS Sherpa|The MS Sherpa application is a CE-certified smartphone application (installed on the mobile phone of the patient) that collects digital biomarkers using tests (\~six minutes/test: self-monitoring questionnaires, smartphone 2-MWT, and a smartphone SDMT) once per week in the home environment of the patient.
214825333|NCT06627465|DEVICE|Neurokeys|The NeuroKeys application is a CE-certified application (installed on the mobile phone of the patient) that passively and continuously monitors keystroke dynamics of everyday typing as a digital biomarker.
214825334|NCT04328935|BEHAVIORAL|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
214825335|NCT05181969|DEVICE|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
214825336|NCT05181969|DEVICE|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
214825337|NCT05181969|DEVICE|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
214825338|NCT05181969|DEVICE|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
214825339|NCT06130215|OTHER|Simple meal management|"* Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
214825340|NCT06130215|OTHER|Precise meal management|precise carbohydrate counting for each meal
214825341|NCT02793245|OTHER|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
214825342|NCT02793245|OTHER|Simplified pulmonary function test|
214825343|NCT00015691|DRUG|Metformin hydrochloride|
214825344|NCT00015691|DRUG|Rosiglitazone maleate|
214267681|NCT06465290|DEVICE|Passive stretching with wearable ankle robot|Passive stretching under intelligent robotic control
214267682|NCT06465290|DEVICE|Gamed-based active movement training with wearable ankle robot|Active movement training through movement games with robotic assistance
214825345|NCT03781622|DEVICE|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
214825346|NCT01942122|DRUG|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
214825347|NCT01942122|DRUG|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
214825348|NCT01942122|DRUG|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
214825349|NCT02479763|PROCEDURE|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
214825350|NCT02754089|DRUG|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
214825351|NCT02754089|DRUG|Placebo|500 mg twice daily after meals for 6 weeks
214825352|NCT04626414|DRUG|Ferric maltol capsule|single dose of 30 mg capsule
214825353|NCT04626414|DRUG|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
214825354|NCT02538627|DRUG|MM-151|MM-151
214825355|NCT02538627|DRUG|MM-121|MM-121
214825356|NCT02538627|DRUG|MM-141|MM-141
214825357|NCT02538627|DRUG|trametinib|trametininb
214825358|NCT03933592|PROCEDURE|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
214825359|NCT03933592|PROCEDURE|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
214825360|NCT03958396|DRUG|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
214825361|NCT02451163|DIETARY_SUPPLEMENT|wheat polysaccharides|Consumed once daily for 12 weeks.
214825362|NCT02451163|DIETARY_SUPPLEMENT|maltodextrin|Consumed once daily for 12 weeks.
214825363|NCT03865563|DRUG|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
214825364|NCT01462708|DRUG|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
214825365|NCT00499759|BEHAVIORAL|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
214825366|NCT00499759|BEHAVIORAL|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
214825367|NCT00499759|BEHAVIORAL|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
214825368|NCT00499759|BEHAVIORAL|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
214825369|NCT00499759|BEHAVIORAL|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
214825370|NCT00499759|BEHAVIORAL|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
214825371|NCT03253354|DEVICE|repetitive magnetic stimulation|Neurostimulation
214825372|NCT01094054|PROCEDURE|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
214825373|NCT01094054|BEHAVIORAL|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
214825374|NCT02464657|DRUG|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
214267683|NCT06465290|DEVICE|Passive movement with limited wearable ankle robot|Passive movement in the joint middle range of motion
214267684|NCT06465290|DEVICE|Active movement training with limited wearable ankle robot|Active movement training without robotic assistance
214267685|NCT06465290|DEVICE|Ankle torque and motion measurement with limited wearable ankle robot|Ankle torque and motion measurement with no real-time feedback
214267686|NCT05313555|DEVICE|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
214825375|NCT02464657|DRUG|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
214825376|NCT02464657|DRUG|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
214825377|NCT02464657|DRUG|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
214825378|NCT02464657|DRUG|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
214825379|NCT00287131|PROCEDURE|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
214825380|NCT06499844|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
214825381|NCT05331534|BEHAVIORAL|Eye-tracking assisted attention control training (ACTo)|"ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement."
214825382|NCT05331534|BEHAVIORAL|Attention control training (ACT)|Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
214825383|NCT06230094|OTHER|moderate intensity|Arm Circles, Leg Swings, Lunges, brisk walk
214825384|NCT06230094|OTHER|high intensity|Arm circles, Leg swings, Lunges, skipping rope
214825385|NCT04322344|DRUG|Escin|treatment with escin or escinate sodium
214825386|NCT04322344|DRUG|standard therapy|antiviral drugs
214825387|NCT04786496|BEHAVIORAL|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
214825388|NCT04786496|BEHAVIORAL|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
214825389|NCT04786496|BEHAVIORAL|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
214825390|NCT01429363|PROCEDURE|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
214825391|NCT01808651|DRUG|Fluoxetine|Administered orally
214825392|NCT00644137|DRUG|pregabalin|Help stop smoking
214825393|NCT00644137|OTHER|cigarettes|help stop smoking with study medication
214825394|NCT05235854|DRUG|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
214825395|NCT02485951|PROCEDURE|Central air injection|Air was injected inside the trephination site in the central injection group.
214825396|NCT02485951|PROCEDURE|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
214825397|NCT04398147|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
214825398|NCT04398147|BIOLOGICAL|Placebo|Intramuscular administration
214825399|NCT01165047|DRUG|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
214825400|NCT01934205|DRUG|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
214825401|NCT01934205|DRUG|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
214825402|NCT00747305|DRUG|sunitinib malate|
214825403|NCT00747305|GENETIC|gene expression analysis|
214267687|NCT05313555|DEVICE|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
214267688|NCT03821155|OTHER|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
214825404|NCT00747305|GENETIC|reverse transcriptase-polymerase chain reaction|
214825405|NCT00747305|GENETIC|western blotting|
214825406|NCT00747305|OTHER|immunohistochemistry staining method|
214825407|NCT00747305|OTHER|laboratory biomarker analysis|
214825408|NCT00747305|PROCEDURE|adjuvant therapy|
214825409|NCT00747305|PROCEDURE|neoadjuvant therapy|
214825410|NCT00747305|PROCEDURE|therapeutic conventional surgery|
214825411|NCT06219031|OTHER|no intervention|no intervention
214825412|NCT00967135|DRUG|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
214825413|NCT00967135|DRUG|Placebo|Matching oral placebo twice daily for 5 consecutive days.
214825414|NCT04113109|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
214825415|NCT04113109|DRUG|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
214825416|NCT04113109|DRUG|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
214825417|NCT04113109|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
214825418|NCT04113109|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
214825419|NCT04254198|BEHAVIORAL|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
214825420|NCT04254198|BEHAVIORAL|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
214825421|NCT00292929|DRUG|Intravenous artesunate|
214825422|NCT00000666|DRUG|Pyrimethamine|
214825423|NCT03071562|OTHER|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
214825424|NCT06559657|DEVICE|eKare Insight, imitoMeasure Mobile App, Visitrak|The wound size of the patients was measured with three different methods. Wound depth was measured using manual method and three-dimensional imaging devices.
214825425|NCT06124339|BEHAVIORAL|Physical Activity|There will be three sessions a week over the course of 16 weeks.
214825426|NCT06124339|BEHAVIORAL|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
214825427|NCT06124339|BEHAVIORAL|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
214825428|NCT06426225|OTHER|General Anesthesia|General Anesthesia Applied Group 2 Patients.
214825429|NCT06426225|OTHER|Spinal Aneshtesia|Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
214825430|NCT05169931|BIOLOGICAL|RegenerEyes|Biologic eye drop
214825431|NCT01161420|DEVICE|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
214825432|NCT04435574|DRUG|Lactoferrin|Bovine Lactoferrin 100mg sachets.
214825433|NCT04435574|DRUG|Ferrous Sulfate|6mg/kg of ferrous sulfate.
214825434|NCT05920629|BEHAVIORAL|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 3 months. We will perform a first echocardiography at randomization and a second at 3 months' follow-up.
214825435|NCT06389448|DEVICE|pCLE-gastr|After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
214825436|NCT04228822|OTHER|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
214825437|NCT05846139|COMBINATION_PRODUCT|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
214825438|NCT05846139|COMBINATION_PRODUCT|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
214825439|NCT00608322|DRUG|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
214825440|NCT00608322|OTHER|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
214825441|NCT02761525|OTHER|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
214825442|NCT02761525|OTHER|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
214825443|NCT04491422|COMBINATION_PRODUCT|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
214825444|NCT05817110|OTHER|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
214825445|NCT01321567|DRUG|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
214825446|NCT00834444|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
214825447|NCT00834444|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
214825448|NCT00473772|DEVICE|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
214825449|NCT06559644|BIOLOGICAL|Hema-NeoTIL01|Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
214825450|NCT06321016|OTHER|Physical exercise program|At least two sessions a week for a 6-month supervised and individualized physical exercise program that will have two phases: one that will be carried out in person in the hospital environment taking advantage of medical visits, and a second phase that will allow the patient to carry out the exercise sessions from home with live virtual supervision.
214825451|NCT06321016|OTHER|Type of the physical exercise program|Two types of intervention are proposed depending on the age of the patients: Exercise intervention for adolescents (12 to 18 years): training will be based on strength training (2 - 3 sets of 8 - 12 repetitions) with elastic bands, weights, weights, medicine balls or body weight and aerobic work on a stationary bike, treadmill or other aerobic exercises. Sessions will last about 30-60 minutes (depending on the patient's situation). Exercise intervention for children (4 to 11 years old): The aim will be to work on basic motor skills through play, thus trying to avoid the delay in motor development, and to indirectly work on their physical condition to better cope with the effects of the treatments. Music, games that require movement and materials such as balls, hoops, etc., will be used to motivate the child to move while enjoying themselves. This will be done in sessions of 20 - 40 minutes.
214825452|NCT03855579|DRUG|Levosimendan|Intraoperative infusion of Levosimendan
214825453|NCT03855579|DRUG|Milrinone|Intraoperative infusion of Milrinone
214825454|NCT05105633|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
214825455|NCT05105633|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
214825456|NCT04293653|OTHER|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
214825457|NCT04313751|BEHAVIORAL|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
214825458|NCT04313751|OTHER|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
214825459|NCT04197492|RADIATION|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
214825460|NCT04197492|DRUG|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
214825461|NCT03679091|DRUG|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
214825462|NCT03679091|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
214825463|NCT03135301|DRUG|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
214825464|NCT03135301|DRUG|letrozole|letrozole 5 milligram tablets
214267689|NCT03821155|DRUG|Corticosteroid|Prednisolone
214267690|NCT02173223|DRUG|Rho-Kinase Inhibitor|
214267691|NCT03274596|DRUG|Vitamin E|
214267692|NCT03274596|DRUG|Placebo|
214267693|NCT03663998|BIOLOGICAL|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
214825465|NCT03325881|DRUG|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
214825466|NCT03325881|DRUG|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
214825467|NCT05613972|OTHER|Brief Suicide and Trauma Therapy|12-week trauma therapy
214825468|NCT02933658|DRUG|Telmisartan|
214825469|NCT02933658|DRUG|Amlodipine|
214825470|NCT02933658|DRUG|Rosuvastatin|
214825471|NCT02121067|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
214267694|NCT03663998|BIOLOGICAL|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
214825472|NCT02730650|OTHER|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
214825473|NCT03060486|DEVICE|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
214825474|NCT04935554|OTHER|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
214825475|NCT02216981|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|
214825476|NCT05446519|BEHAVIORAL|Survey|Survey is proposed to all pilots who are members of the National Union of Airline Pilots
214825477|NCT05152745|OTHER|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
214825478|NCT05152745|OTHER|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
214825479|NCT03104231|OTHER|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
214825480|NCT05442034|BIOLOGICAL|growth factors to help in regeneration|regenerative therapy
214825481|NCT00045786|DRUG|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
214825482|NCT03130335|PROCEDURE|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
214825483|NCT03130335|BIOLOGICAL|BMA|Bone marrow will be aspirated from the iliac crest.
214825484|NCT04884841|OTHER|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
214825485|NCT04884841|OTHER|Patients without postoperative complications|Patients without postoperative complications
214825486|NCT01724463|OTHER|Severe Sepsis Management Bundle|"Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels"
214825487|NCT05299463|DIAGNOSTIC_TEST|Exercise Testing|"* Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG)."
214825488|NCT06621784|OTHER|Core stabilization exercises|In most studies, exercises focused on the extremities have been researched. We believe that the positive effects of the core region on walking and postural stability will play a significant role in the treatment of knee osteoarthritis.
214825489|NCT06621784|OTHER|Classical exercise therapy|In the first group of our study, we prescribed exercises that have been proven effective in many studies, are frequently prescribed, and focus on joint range of motion and quadriceps strengthening
214825490|NCT00835614|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
214825491|NCT00835614|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
214825492|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
214825493|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
214825494|NCT00606281|DRUG|Aripiprazole|oral, 24mg/day
214825495|NCT00606281|DRUG|placebo|oral, 0mg(4tablets)/day
214825496|NCT02294981|DEVICE|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
214825497|NCT02875314|DRUG|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
214825498|NCT02875314|DRUG|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
214825499|NCT02875314|DRUG|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
214825500|NCT02927210|DRUG|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
214825501|NCT02927210|DRUG|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
214825502|NCT00525746|BEHAVIORAL|Interview|Interview lasting about 50 minutes.
214825503|NCT06300216|DRUG|Octreotide microspheres|20mg/30mg Q4W
214825504|NCT00617396|DRUG|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
214825505|NCT06013150|DRUG|Epinephrine|Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
214825506|NCT06013150|DRUG|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
214825507|NCT03702218|DRUG|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
214825508|NCT05749887|PROCEDURE|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~1. No parametrial involvement, extrafascial hysterectomy;~2. There is parametrial involvement, extensive hysterectomy(Q-MC);~3. Only bladder invasion, anterior pelvic exenteration;~4. Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~5. Invasion of bladder and rectum, total exenteration.~6. The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
214825509|NCT00003980|DRUG|BIBX 1382|
214825510|NCT02893735|OTHER|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
214825511|NCT02893735|OTHER|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
214825512|NCT03556618|BEHAVIORAL|Whole Person Care (WPC) Reentry Program - Pre & Post Release services|Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
214825513|NCT02589366|DRUG|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
214825514|NCT02213263|BIOLOGICAL|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
214825515|NCT02213263|BIOLOGICAL|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
214825516|NCT06558890|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation
214825517|NCT06559085|PROCEDURE|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
214825518|NCT06559085|PROCEDURE|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
214825519|NCT05752721|BEHAVIORAL|Transition to Online Ordering|The intervention food pantry will transition to online ordering at least once.
214825520|NCT02087553|BIOLOGICAL|Transfusion of red blood cells|(non-experimental) PRBC transfusion
214825521|NCT02087553|BIOLOGICAL|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
214825522|NCT06446869|DIETARY_SUPPLEMENT|Gyntima Menopause|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
214825523|NCT06446869|OTHER|Placebo|Placebo comparator
214825524|NCT01188681|DRUG|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
214825525|NCT01188681|DRUG|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
214267695|NCT05084131|OTHER|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
214267696|NCT01897454|DRUG|Fluorouracil|Given IV
214267697|NCT01897454|DRUG|Gemcitabine Hydrochloride|Given IV
214267698|NCT01897454|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214267699|NCT01897454|DRUG|Irinotecan Hydrochloride|Given IV
214267700|NCT01897454|DRUG|Leucovorin Calcium|Given IV
214267701|NCT01897454|DRUG|Oxaliplatin|Given IV
214267702|NCT03212924|BEHAVIORAL|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
214825526|NCT01188681|DRUG|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
214825527|NCT01188681|DRUG|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
214825528|NCT03492320|OTHER|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
214825529|NCT02937948|OTHER|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
214825530|NCT02937948|RADIATION|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
214825531|NCT05444647|PROCEDURE|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
214825532|NCT04516915|DRUG|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
214825533|NCT04516915|DRUG|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
214825534|NCT03637556|DRUG|DST-0509|Novel iron chelator with improved absorption characteristics
214825535|NCT03637556|DRUG|Jadenu|Commercial iron chelator with standard absorption characteristics
214825536|NCT03637556|DRUG|Exjade|Commercial iron chelator with standard absorption characteristics
214825537|NCT00196963|BIOLOGICAL|Meningococcal (vaccine)|
214825538|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
214825539|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
214825540|NCT05630612|DRUG|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
214825541|NCT05053230|BEHAVIORAL|IM@Home|Participants in the IM@Home group will receive a 12-week virtual, synchronous, mind-body and fitness program. The Classes will be conducted via Zoom video conferencing platform. Patients will choose from a variety of weekly classes, occurring one to four times per week. An Integrative Medicine Service (IMS) clinical therapist (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting will lead each session. Activities range from more movement-based (fitness, yoga, dance therapy, or tai chi) to meditative-based classes (meditation, guided meditation, or music therapy). All clinicians will provide an overview of the session, 25 to 40 minutes of content, and five minutes for feedback and discussion. Each class lasts 30 to 45 minutes with optional audio or video participant participation and group chat.
214825542|NCT05053230|BEHAVIORAL|Enhanced usual care|Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation audio or video recordings for meditation, guided imagery, and relaxation.
214825543|NCT00759317|DRUG|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
214825544|NCT04528784|DEVICE|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
214825545|NCT01183910|DIETARY_SUPPLEMENT|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
214825546|NCT01183910|DIETARY_SUPPLEMENT|Calcium Carbonate|Oral Tablet Taken Twice a Day
214825547|NCT00038363|PROCEDURE|Rehabilitation|
214825548|NCT00038363|PROCEDURE|Subacute care|
214825549|NCT01644253|BIOLOGICAL|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
214825550|NCT01644253|BIOLOGICAL|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
214825551|NCT01644253|BIOLOGICAL|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
214825552|NCT01644253|BIOLOGICAL|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
214825553|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
214825554|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
214825555|NCT02760732|DEVICE|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
214825556|NCT02760732|DEVICE|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
214825557|NCT03236311|DRUG|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
214825558|NCT03236311|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
214825559|NCT03236311|DRUG|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214825560|NCT03236311|DRUG|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214825561|NCT03236311|DRUG|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214825562|NCT03236311|DRUG|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214825563|NCT04554290|DIAGNOSTIC_TEST|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
214825564|NCT03222921|PROCEDURE|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
214825565|NCT00909753|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
214825566|NCT00909753|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
214825567|NCT02351700|DRUG|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
214825568|NCT02351700|DRUG|IV Placebo|IV Placebo intraoperatively and postoperatively
214825569|NCT06469645|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
214825570|NCT02421822|OTHER|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
214825571|NCT01449981|BEHAVIORAL|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
214825572|NCT01449981|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
214825573|NCT03498235|DRUG|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
214825574|NCT03498235|DRUG|Propofol|In Team Propofol ,anesthesia is maintained with propofol
214825575|NCT00845637|DRUG|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
214825576|NCT00845637|DRUG|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
214267703|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
214267704|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
214825577|NCT04682951|PROCEDURE|Decompressive Craniectomy|
214825578|NCT03828708|OTHER|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
214825579|NCT00318188|PROCEDURE|standardized reeducation and readaptation program|
214825580|NCT00174551|DRUG|prazosin|
214825581|NCT00343213|PROCEDURE|colposcopy|
214825582|NCT01539564|DRUG|Minocycline HCl Microspheres|
214825583|NCT04828616|DRUG|DP303c injection|DP303c injection, every 3 weeks (Q3W)
214825584|NCT04423380|DRUG|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
214825585|NCT03552003|OTHER|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
214825586|NCT00532077|DRUG|rhPTH(1-34)|
214825587|NCT00532077|DRUG|SB-751689 100 mg|
214825588|NCT00532077|DRUG|SB-751689 400 mg|
214825589|NCT05990127|DRUG|AK104|AK104 IV, q3w
214825590|NCT05990127|DRUG|Tislelizumab|Tislelizumab IV, q3w
214825591|NCT05990127|DRUG|carboplatin|carboplatin IV, q3w
214825592|NCT05990127|DRUG|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
214825593|NCT05990127|DRUG|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
214825594|NCT01299662|DRUG|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
214825595|NCT01426568|BEHAVIORAL|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
214825596|NCT02336074|DRUG|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
214825597|NCT02336074|DRUG|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
214825598|NCT02336074|DRUG|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
214825599|NCT02336074|BIOLOGICAL|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
214825600|NCT02336074|BIOLOGICAL|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
214825601|NCT05129176|DRUG|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
214825602|NCT05129176|DRUG|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
214825603|NCT04548141|OTHER|Questionnaire|Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
214825604|NCT02679729|DRUG|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
214825605|NCT02679729|DRUG|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
214825606|NCT02679729|OTHER|Placebo|inactive substance
214825607|NCT05213663|OTHER|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
214825608|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
214825609|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
214825610|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
214825611|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
214825612|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
214825613|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
214825614|NCT00836758|DEVICE|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
214825615|NCT00906399|DRUG|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
214825616|NCT00906399|DRUG|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
214825617|NCT04225364|DRUG|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
214825618|NCT04225364|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
214825619|NCT04225364|DRUG|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
214825620|NCT01408654|BEHAVIORAL|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
214825621|NCT05173298|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
214825622|NCT04892420|DRUG|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
214825623|NCT04892420|DRUG|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
214825624|NCT04892420|DRUG|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
214825625|NCT04892420|DRUG|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
214825626|NCT04020796|DIETARY_SUPPLEMENT|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
214825627|NCT01212276|DRUG|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
214825628|NCT06550869|PROCEDURE|Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision|The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.
214825629|NCT06550869|PROCEDURE|Local infiltration anesthesia|The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
214825630|NCT05498662|DEVICE|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
214825631|NCT03265860|DEVICE|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
214825632|NCT03103360|DEVICE|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
214825633|NCT03103360|PROCEDURE|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
214825634|NCT02618460|DEVICE|Non contrast-enhanced magnetic resonance imaging|
214825635|NCT05163691|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
214825636|NCT05163691|DRUG|Placebo|GH001 Placebo administered via inhalation
214825637|NCT00353457|DRUG|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
214825638|NCT00353457|RADIATION|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
214825639|NCT05957146|DEVICE|Routine hemodialysis|"* Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin."
214825640|NCT01124786|DRUG|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
214825641|NCT01124786|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
214825642|NCT00544492|DEVICE|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
214825643|NCT04739735|PROCEDURE|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
214825644|NCT01129986|DEVICE|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
214825645|NCT00750243|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
214825646|NCT00750243|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
214825647|NCT06322485|BEHAVIORAL|Internet-based self-management intervention|An internet-based cognitive-behavioral therapy with six modules.
214825648|NCT03774537|DRUG|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
214825649|NCT03774537|DRUG|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
214825650|NCT06185088|DEVICE|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
214825651|NCT06185088|DEVICE|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
214825652|NCT01450592|OTHER|No drug|Diabetic Population
214825653|NCT01450592|OTHER|No drug|Non-Diabetic Population
214825654|NCT00752466|DRUG|Topiramate; flunarizine|
214825655|NCT02348281|DRUG|Bicalutamide|150mg, po, qd, d1-28
214825656|NCT01619241|OTHER|PET/CT|F-18 FLT PET/CT
214825657|NCT03530852|DEVICE|Relizorb|Tube feeds run across device to digest fats.
214825658|NCT06558942|DEVICE|incisional negative pressure wound technology|Negative pressure device used directly on closed or sutured incisions
214825659|NCT02632968|PROCEDURE|Pinhole surgery with and without buttons|
214825660|NCT00429481|BIOLOGICAL|Rotarix|
214825661|NCT02946424|DRUG|Placebo Oral Capsule|12 month course of daily placebo
214825662|NCT02946424|DRUG|Simvastatin|12 month course of daily simvastatin
214825663|NCT02929472|BEHAVIORAL|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
214825664|NCT02929472|BEHAVIORAL|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
214825665|NCT00006258|BIOLOGICAL|filgrastim|
214825666|NCT00006258|DRUG|cisplatin|
214825667|NCT00006258|DRUG|cyclophosphamide|
214825668|NCT00006258|DRUG|etoposide|
214825669|NCT00006258|DRUG|methotrexate|
214825670|NCT00006258|DRUG|vincristine sulfate|
214825671|NCT00006258|PROCEDURE|adjuvant therapy|
214825672|NCT00006258|RADIATION|radiation therapy|
214825673|NCT04600635|PROCEDURE|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
214825674|NCT04366635|PROCEDURE|Impacted third molar surgery|Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
214825675|NCT04366635|PROCEDURE|Application of mineralised plasmatic matrix|After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
214825676|NCT04366635|PROCEDURE|Application of β-tricalcium phosphate|After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
214825677|NCT05214716|DIAGNOSTIC_TEST|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
214825678|NCT02324452|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
214825679|NCT01901783|PROCEDURE|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
214825680|NCT01901783|PROCEDURE|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
214825681|NCT00395980|DEVICE|surgical table pressure mat|
214825682|NCT02316054|DEVICE|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
214825683|NCT05187208|DRUG|Niraparib|"Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
214825684|NCT01299935|BEHAVIORAL|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
214825685|NCT01299935|BEHAVIORAL|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
214825686|NCT00242554|DRUG|Zoledronic acid|
214825687|NCT04056585|PROCEDURE|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
214825688|NCT04056585|PROCEDURE|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
214825689|NCT00574847|DRUG|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
214825690|NCT00574847|DRUG|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
214825691|NCT05226533|DRUG|DWRX2003|Intramuscular injection of DWRX2003
214825692|NCT05226533|DRUG|Placebo|Intramuscular injection of placebo
214825693|NCT00452218|DRUG|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
214825694|NCT00833300|DRUG|Haloperidol|"* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
214825695|NCT00833300|DRUG|Olanzapine|"* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
214825696|NCT02811003|DEVICE|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
214825697|NCT01732224|DRUG|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
214825698|NCT01732224|DRUG|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
214825699|NCT02055547|DRUG|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
214825700|NCT02055547|DRUG|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
214825701|NCT02055547|DRUG|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
214825702|NCT02055547|DRUG|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
214825703|NCT02055547|DRUG|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
214825704|NCT02055547|DRUG|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
214825705|NCT02055547|DRUG|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
214825706|NCT02055547|DRUG|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
214825707|NCT02055547|DRUG|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
214825708|NCT02055547|DRUG|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
214825709|NCT02055547|DRUG|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
214825710|NCT02055547|DRUG|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
214825711|NCT03858933|DEVICE|eBrainFit Platform|Alpha/Theta regulation with eyes open
214825712|NCT03858933|DEVICE|eBrainFit Platform|Amygdala regulation with eyes open
214825713|NCT04681534|DEVICE|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
214825714|NCT00805402|OTHER|flow cytometry|flow cytometry
214825715|NCT04914351|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
214825716|NCT06982027|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
214825717|NCT06982027|PROCEDURE|Peripheral nerve block|An injection of numbing medicine near a specific nerve or group of nerves to numb the part of the body undergoing surgery.
214825718|NCT05492162|OTHER|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~* Well-being (Workshops)~* Smoking prevention (Conference)~* Balanced diet (Workshop)~* Optimal organization for daily healthy living (Conference)"
214825719|NCT03067987|DEVICE|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
214267705|NCT03212924|BEHAVIORAL|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
214825720|NCT05713058|BEHAVIORAL|eTRC diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
214825721|NCT05713058|BEHAVIORAL|Control diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
214825722|NCT02082808|DRUG|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
214825723|NCT02082808|DRUG|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
214825724|NCT06022146|DRUG|Rifampin and Isoniazid|3HR regimen of isoniazid and rifampicin once daily for three months
214825725|NCT06022146|DRUG|isoniazid and rifapentine|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
214825726|NCT03342339|OTHER|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
214825727|NCT03342339|OTHER|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
214825728|NCT03342339|OTHER|Iowa Gambling Task|Test of Iowa Gambling Task
214825729|NCT07025954|PROCEDURE|Cesarean delivery|"All patients were delivered via cesarean section with standardized perioperative management, including preoperative preparation (e.g., autologous bloodreserve, corticosteroid administration for foetal lungmaturation, etc.), surgical approach, and postoperative care.~Conservative management (intentional placental retention in situ with local resection and pelvic devascularization) was primarily employed, while peripartum hysterectomy was reserved for those with extensive invasion or failed conservative treatment."
214825730|NCT07027306|PROCEDURE|Posterior stabilization (pedicle screws)|"* Any other type of solely vertebral augmentation (stents, etc.), specify~* Posterior stabilization (pedicle screws)~* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with screw augmentation~* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)~* Combined posterior and anterior stabilization"
214825731|NCT05047536|DRUG|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
214825732|NCT00834275|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
214825733|NCT00834275|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
214825734|NCT03568838|DRUG|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
214825735|NCT07038447|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
214825736|NCT07038447|DRUG|Fludarabine|Administered intravenously
214825737|NCT07038447|DRUG|Cyclophosphamide|Administered intravenously
214825738|NCT06544811|OTHER|Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.
214825739|NCT06544811|OTHER|Cultural Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
214825740|NCT07046910|DIAGNOSTIC_TEST|Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy|Hyperpolarized Xenon-129 MRI twice with navigational bronchoscopy twice
214825741|NCT07046910|DRUG|Hyperpolarized Xenon129|Lung transplant recipient with hyperpolarized Xe129 in MRI as an inhalation contrast agent
214825742|NCT06752707|DEVICE|MiGo Tracker|Perform home exercise sessions while wearing MiGo Tracker device that logs exercise data.
214825743|NCT06752707|OTHER|Conventional home exercise program|Exercise following printed sheets or booklet
214825744|NCT07068646|PROCEDURE|CT myocardial thickness map guided PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system. A pre-procedural cardiac CT scan will be used to generate an atrial myocardial thickness map. In this group, atrial segments with wall thickness \>2.5 mm identified on the CT map will receive additional PFA applications (up to 8 per PV) to ensure transmural lesion formation. All other segments will receive the standard minimum of 8 applications per vein. The ablation catheter will remain stationary to allow lesion stacking when needed.
214825745|NCT07068646|PROCEDURE|Empirical PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system according to a standardized empirical protocol. Each pulmonary vein will receive a minimum of 8 PFA applications without adjustment based on anatomical or CT-based parameters. Additional applications may be delivered at the operator's discretion based on procedural findings, but no wall thickness mapping will be used.
214825746|NCT07067814|DRUG|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
214825747|NCT07067814|PROCEDURE|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
214825748|NCT07069413|BEHAVIORAL|tele-ImPACT|Participants will receive 12 weeks of Project ImPACT intervention as delivered via Telehealth
214825749|NCT07069491|DEVICE|Sphygmomanometer|Blood pressure measurement by Sphygmomanometer
214825750|NCT07068009|BEHAVIORAL|Training and Support Programme on Data-driven Quality Development|"The training and support program uses a train-the-trainer strategy.~The research team:~* develop training and support materials~* organize an e-mail helpdesk support~* organize and conduct the scientific examination~The external training providers:~\- train the management representatives and the quality leaders.~The quality leader and the manager:~* elaborate and test a quality development project based on one MQI with PDCA cycle~* animate interprofessional meetings~* organize a collective workshop with residents and relatives~* engage residents and relatives in individual conversations by testing a brochure"
214825751|NCT07067385|BIOLOGICAL|Neoantigen Personalized Cancer Vaccine|Cohort 1: subjects will receive neoantigen tumor vaccine combination with Sintilimab. Cohort 2: subjects will receive neoantigen tumor vaccine combination with Sintilimab and chemotherapy .
214825752|NCT07068685|OTHER|Suicide risk prediction algorithm|Use of a suicide risk prediction algorithm, developed by the Mental Health Research Network (MHRN), will be used to prompt additional mental health monitoring. Mental health monitoring will include asking patients about suicidal thoughts (via the ninth question of the Patient Health Questionnaire-9, PHQ-9), followed by suicide risk assessment (via use of a brief self-administered version of the Columbia Suicide Risk Severity Rating Scale, C-SSRS), followed by Safety Planning with a designated member of the primary care team.
214825753|NCT06882018|OTHER|Repeated practice guided by peers|"This approach involves repeated, peer-guided practice. Each session will involve two participants, who will support each other using the feedback grid from the first section of the Neonatal Mask Ventilation Competency Assessment Tool developed by DiLabio et al. (2018) to provide feedback on practicing technical skills."
214825754|NCT06882018|OTHER|Instructor-guided deliberate practice|In this group, practice is deliberate (PD) and is led by an instructor. Each session will be supervised by an instructor for two to four participants, and the latter will use the same feedback grid as that used in the intervention group to provide feedback.
214825755|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
214825756|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
214825757|NCT06785389|DIAGNOSTIC_TEST|Fear of anesthesia, surgery and hospitals scale|The day before surgery, patients will be interviewed using the scales of Fear of anesthesia, surgery and hospitals.
214825758|NCT06785389|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|The day before surgery, patients will be interviewed using the State-Trait Anxiety Inventory
214825759|NCT06785389|DIAGNOSTIC_TEST|Nummerical Rating Scale for postoperative pain|In the first postoperative day, patients will be monitored using the Nummerical Rating Scale, which will assess postoperative pain.
214267706|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
214267707|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
214267708|NCT01467726|DRUG|Velusetrag|Capsules
214267709|NCT01467726|DRUG|Velusetrag|Capsules
214267710|NCT01467726|DRUG|Placebo|Capsules
214825760|NCT06119477|OTHER|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
214825761|NCT06119477|OTHER|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
214825762|NCT06119477|OTHER|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
214825763|NCT06790394|DRUG|Florbetaben F18|Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
214825764|NCT04205266|DRUG|Ferumoxytol|IV iron infusion
214825765|NCT04205266|DRUG|Ferrous Sulfate|oral iron therapy
214825766|NCT04247945|BIOLOGICAL|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
214825767|NCT01524185|BEHAVIORAL|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
214825768|NCT01524185|BEHAVIORAL|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
214825769|NCT03133260|DIAGNOSTIC_TEST|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
214825770|NCT03133260|DRUG|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
214825771|NCT03133260|DRUG|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
214825772|NCT01975116|DRUG|azurin-derived cell-penetrating peptide p28|Given IV
214825773|NCT06555458|DRUG|Dexmedetomidine|Patient group to be given dexmedetomidine
214825774|NCT06555458|DRUG|Saline|Patient group to be given salin
214825775|NCT06339645|PROCEDURE|PRP|Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection
214825776|NCT04742543|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
214825777|NCT00789386|DRUG|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
214825778|NCT00789386|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
214825779|NCT00018213|DRUG|Naltrexone Hydrochloride|
214825780|NCT00018213|DRUG|Transdermal Nicotine|
214825781|NCT01310998|BEHAVIORAL|High intensity exercise|4x4 intervals
214825782|NCT04790526|OTHER|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
214825783|NCT01896713|OTHER|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
214825784|NCT01750294|DRUG|Chlorthalidone|
214825785|NCT02490072|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
214825786|NCT02490072|DRUG|normal saline(Saline 0.9%)|
214825787|NCT00665925|DRUG|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
214825788|NCT00665925|DRUG|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
214825789|NCT00665925|DRUG|Placebo|Placebo, orally, either once a day, or twice a day
214825790|NCT00687206|DRUG|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
214825791|NCT04423835|PROCEDURE|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
214825792|NCT00615667|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
214825793|NCT00079495|DRUG|NBI-5788|
214825794|NCT00334815|BIOLOGICAL|Bevacizumab|Given IV
214825795|NCT00334815|DRUG|Cisplatin|Given IV
214825796|NCT00334815|DRUG|Docetaxel|Given IV
214825797|NCT00334815|DRUG|Etoposide|Given IV
214825798|NCT00334815|BIOLOGICAL|Filgrastim|Given SC
214825799|NCT00334815|BIOLOGICAL|Pegfilgrastim|Given SC
214267711|NCT05661799|BEHAVIORAL|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
214267712|NCT05661799|BEHAVIORAL|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
214267713|NCT06203860|OTHER|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~* Lipid management~* Blood pressure management~* Antithrombotic therapy~* Glycemic targets~* Prevention of diabetes-related complications~* Treatment of vascular disease affecting the lower extremities~* Evaluation of cardioprotective drugs~* Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~* Guidance on vaccinations"
214825800|NCT00334815|RADIATION|Radiation Therapy|Undergo thoracic radiotherapy
214825801|NCT05231460|DRUG|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
214825802|NCT05231460|DRUG|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
214825803|NCT05231460|DRUG|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
214825804|NCT05231460|DRUG|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
214825805|NCT06960915|DEVICE|immersive virtual reality|The research procedure will be the realization of reminiscence workshops in immersive virtual reality. The residents will be equipped with a virtual reality headset where they will enjoy 360° panoramas that will immerse them in the heart of villages in the Amiens basin and in particular their village based on 3 to 5 images per village: church square, village square, town hall, emblematic places, etc.
214825806|NCT06960915|DEVICE|classic reminiscence workshops|It will be compared to classic reminiscence workshops in which the organizer will propose to discuss memories and past experiences using photographs, objects or music in the control arm.
214825807|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
214825808|NCT06549465|BIOLOGICAL|45 kBq/kg Ac-225 rosopatamab tetraxetan|45 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
214825809|NCT06549465|BIOLOGICAL|55 kBq/kg Ac-225 rosopatamab tetraxetan|55 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
214825810|NCT06549465|BIOLOGICAL|60 kBq/kg Ac-225 rosopatamab tetraxetan|60 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
214825811|NCT00849030|DRUG|Anastozole (Arimidex)|1mg, orally, once daily
214825812|NCT00849030|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
214825813|NCT00849030|DRUG|Anastozole (Arimidex) placebo|1mg, orally, once daily
214825814|NCT00849030|DRUG|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
214825815|NCT04797663|DEVICE|Nd-YAG laser|laser hair removal device
214825816|NCT04797663|DRUG|TCA 20%|chemical peel
214825817|NCT06196047|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
214825818|NCT06196047|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
214825819|NCT06626620|DRUG|Magnesium Sulphate infusion|Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
214825820|NCT06626620|DRUG|Terbutaline Infusion|Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
214825821|NCT00004162|BIOLOGICAL|sargramostim|
214825822|NCT00004162|DRUG|methotrexate|
214825823|NCT00004162|DRUG|pegylated liposomal doxorubicin hydrochloride|
214825824|NCT00004162|DRUG|vincristine sulfate|
214825825|NCT02197416|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
214825826|NCT02451696|DRUG|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
214825827|NCT04345640|OTHER|no intervention|no intervention
214825828|NCT00721162|BIOLOGICAL|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
214825829|NCT05014828|DRUG|lenvatinib|Administered at the dose of 20 mg orally, once daily.
214825830|NCT05014828|DRUG|Tislelizumab|400 mg administered intravenously on Day 1 of each 42-day cycle
214825831|NCT02987985|DRUG|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
214825832|NCT02987985|DRUG|Acetaminophen|acetaminophen 15 mg/kg
214825833|NCT02987985|DRUG|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
214825834|NCT02987985|DRUG|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
214825835|NCT02987985|DRUG|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
214825836|NCT02987985|DRUG|Sevoflurane|Sevoflurane (dose titrated to effect)
214825837|NCT02987985|DRUG|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
214825838|NCT05917925|DIETARY_SUPPLEMENT|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
214825839|NCT05917925|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
214825840|NCT02241863|BEHAVIORAL|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
214825841|NCT02241863|BEHAVIORAL|Routine counseling|
214825842|NCT04017494|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
214825843|NCT04017494|DIAGNOSTIC_TEST|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
214825844|NCT04017494|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
214825845|NCT04017494|DIAGNOSTIC_TEST|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
214825846|NCT04017494|DIAGNOSTIC_TEST|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
214825847|NCT02169063|RADIATION|carbon-11 acetate|Given IV
214825848|NCT02169063|RADIATION|fluorine F 18 sodium fluoride|Given IV
214825849|NCT02169063|PROCEDURE|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
214825850|NCT02169063|OTHER|laboratory biomarker analysis|Correlative studies
214825851|NCT03692663|DRUG|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
214825852|NCT03692663|BIOLOGICAL|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
214825853|NCT03692663|BIOLOGICAL|fludarabine|Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
214825854|NCT00041392|DRUG|Magnesium|100 mg/kg
214825855|NCT00041392|DRUG|0.9% saline|Placebo
214825856|NCT05262985|DRUG|Durvalumab|In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
214825857|NCT04908852|OTHER|Blood Sample Collection - Observational Study|Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.
214825858|NCT04908852|OTHER|Symptom questionnaires - Observational Study|Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
214825859|NCT02574377|DRUG|A: myDC vaccination|
214825860|NCT02574377|DRUG|B: pDC vaccination|
214825861|NCT02574377|DRUG|C: combined myDC/pDC vaccination|
214825862|NCT01369927|BIOLOGICAL|Shigella Sonnei O-SPC/rBRU|
214825863|NCT03266380|DIAGNOSTIC_TEST|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
214825864|NCT00170729|DRUG|Prednisolone acetate|
214825865|NCT01160796|DRUG|placebo|1x14-day course of treatment during 4 cycles
214825866|NCT01160796|DRUG|Lcr35®|1x14-day course of treatment during 4 cycles
214825867|NCT02392195|OTHER|Non-interventional|Observational
214825868|NCT00907907|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
214825869|NCT00907907|DRUG|CellCept® Tablets|CellCept® Tablets, 500 mg
214825870|NCT05898607|OTHER|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
214825871|NCT05898607|OTHER|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
214825872|NCT05351892|DRUG|Elinzanetant (BAY3427080)|Soft gel capsule, oral
214825873|NCT00006376|DRUG|chemotherapy|
214825874|NCT00006376|DRUG|tipifarnib|
214825875|NCT05026294|OTHER|plyometric exercises|Exercises for strength and flexibility
214825876|NCT05026294|OTHER|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
214825877|NCT06164860|OTHER|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
214825878|NCT06164860|OTHER|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
214825879|NCT01561391|DRUG|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
214825880|NCT01561391|DRUG|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
214825881|NCT01561391|OTHER|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
214825882|NCT01561391|DRUG|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
214825883|NCT01783366|DEVICE|TUBE EXCHANGER|
214825884|NCT00545792|DRUG|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
214825885|NCT03265574|DRUG|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
214267714|NCT06298409|DEVICE|CapScan collection capsule|The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
214825886|NCT03991273|OTHER|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
214825887|NCT03991273|OTHER|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
214825888|NCT02891863|DEVICE|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
214825889|NCT01771263|DEVICE|iControl-RP|
214825890|NCT01307124|DRUG|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg"
214267715|NCT01839123|DEVICE|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
214267716|NCT01839123|DEVICE|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
214267717|NCT03642457|DRUG|Bupivacaine|20 cc 0.5%
214825891|NCT00599079|DRUG|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
214825892|NCT03253510|OTHER|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
214825893|NCT03253510|OTHER|Poly-methyl methacrylate|Gold standard denture base material
214825894|NCT03057210|OTHER|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
214825895|NCT03057210|OTHER|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
214825896|NCT00445796|DRUG|Artesunate|
214825897|NCT00445796|DRUG|Amodiaquine|
214825898|NCT02812121|DRUG|umbilical cord blood mesenchymal stem cells|
214825899|NCT01711632|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
214825900|NCT05126485|DEVICE|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
214825901|NCT03325387|DRUG|LY3305677|Administered SC
214825902|NCT03325387|DRUG|Placebo|Administered SC
214825903|NCT05163847|BIOLOGICAL|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
214825904|NCT05163847|BIOLOGICAL|Fluzone HD IIV|Administered intramuscularly on Day 1
214825905|NCT05163847|OTHER|IN Placebo|Administered intranasally on Day 1
214825906|NCT05163847|OTHER|IM Placebo|Administered intramuscularly on Day 1
214825907|NCT03679598|DRUG|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
214825908|NCT03679598|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
214825909|NCT01932177|DRUG|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
214825910|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
214825911|NCT01932177|DRUG|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
214825912|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
214825913|NCT05664087|DRUG|Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
214825914|NCT03136627|DRUG|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
214825915|NCT03136627|DRUG|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
214825916|NCT03077880|PROCEDURE|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
214825917|NCT05373173|BEHAVIORAL|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
214825918|NCT05373173|BEHAVIORAL|Tele-assessment only|Consented families will complete home-based tele-assessment via Zoom that includes the TAP-Preschool. Each participant will have recent data available from comprehensive evaluation tools (ADOS-2, cognitive functioning, adaptive skills). After the session, participating caregivers will provide information about acceptability and challenges.
214825919|NCT04269642|DRUG|PT320 2.0mg Placebo|PT320 2.0mg Placebo
214825920|NCT04269642|DRUG|PT320 2.0 mg|Exenatide slowly released formulation
214825921|NCT04269642|DRUG|PT320 2.5 mg|Exenatide slowly released formulation
214267718|NCT03642457|DRUG|Bupivacaine liposome|133mg liposomal bupivacaine
214267719|NCT03095885|OTHER|Test Meal|
214267720|NCT02609204|DIAGNOSTIC_TEST|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
214825922|NCT04398056|DRUG|Chemotherapy plus radiotherapy and Toripalimab|"1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
214825923|NCT03779334|DRUG|Risdiplam|Risdiplam will be administered orally.
214825924|NCT02649179|DRUG|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
214825925|NCT02649179|DRUG|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
214825926|NCT06101771|DIAGNOSTIC_TEST|echoCARDIOGRAPHY|Assessment of epicardial fat thickness in children with familial dyslipidemia
214825927|NCT06515405|DRUG|Hydrocortisone|"Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023)."
214825928|NCT03388853|DRUG|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
214825929|NCT03388853|OTHER|Placebo|Placebo once daily for four weeks.
214825930|NCT03934476|BEHAVIORAL|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
214825931|NCT03934476|BEHAVIORAL|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
214825932|NCT06465927|OTHER|Clinical data collection|Clinical data of elderly acute appendicitis patients with an appendicolith who underwent emergency appendectomy were collected and analyzed.
214825933|NCT05183191|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
214825934|NCT00797160|DRUG|propofol|2mg/Kg IV in bolus before tracheal intubation
214825935|NCT02275962|DRUG|K-877|
214825936|NCT02275962|DRUG|Rifampin|
214825937|NCT01660594|OTHER|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
214825938|NCT01684774|DRUG|Bupivacaine|
214825939|NCT05735795|OTHER|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
214825940|NCT05512104|PROCEDURE|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
214825941|NCT04836494|DRUG|BBP-671|BBP-671, oral suspension
214825942|NCT04836494|DRUG|Placebo|Placebo matching BBP-671
214825943|NCT04836494|DRUG|BBP-671|BBP-671, tablet
214825944|NCT01175135|DRUG|PF-02545920|5 mg tablet every 12 hours for 28 days
214825945|NCT01175135|DRUG|PF-02545920|15 mg tablet every 12 hours for 28 days
214825946|NCT01175135|DRUG|Placebo|One tablet/capsule every 12 hours for 28 days
214825947|NCT01175135|DRUG|Risperidone|3 mg capsule every 12 hours for 28 days
214825948|NCT00529464|PROCEDURE|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
214825949|NCT00529464|PROCEDURE|Colposcopy|A standard colposcopy will be performed.
214825950|NCT00529464|PROCEDURE|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
214825951|NCT02364258|DRUG|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
214825952|NCT02364258|DRUG|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
214825953|NCT00003725|DRUG|valrubicin|
214825954|NCT00003725|PROCEDURE|conventional surgery|
214825955|NCT06319976|OTHER|open chain exercises for rotator cuff muscles|open chain exercises for rotator cuff muscles, three times per week for six weeks.
214825956|NCT06319976|OTHER|Advices for postural correction|Advices for postural correction like neutral position of head and neck, aliening the shoulder and hip and using a foot stool to rest the feet.
214825957|NCT04194476|DIAGNOSTIC_TEST|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
214825958|NCT01886222|OTHER|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
214825959|NCT01886222|OTHER|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
214825960|NCT04692155|DRUG|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
214825961|NCT04692155|DRUG|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
214825962|NCT01438203|PROCEDURE|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
214825963|NCT01438203|PROCEDURE|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
214825964|NCT02579733|DRUG|Azathioprine|
214825965|NCT02579733|DRUG|Placebo|
214825966|NCT00940563|DRUG|Imatinib|
214825967|NCT04692558|BIOLOGICAL|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
214825968|NCT04692558|PROCEDURE|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
214825969|NCT00934323|DRUG|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
214825970|NCT00934323|DRUG|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
214825971|NCT06225362|DEVICE|Quatera 700|Phacoemulsification device
214825972|NCT06225362|DEVICE|Centurion|Phacoemulsification device
214825973|NCT03206086|DRUG|Eltrombopag|Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
214825974|NCT03957551|DRUG|Cabozantinib|"Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle."
214825975|NCT03957551|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
214825976|NCT05283148|OTHER|Dual-energy X-ray absorptiometry|Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body
214825977|NCT05283148|OTHER|Vertebral fracture analysis|Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA
214825978|NCT05283148|OTHER|Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire|Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
214825979|NCT00095784|DRUG|Decitabine|Given SC
214825980|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
214825981|NCT04131413|DRUG|pNGVL4aCRTE6E7L2|The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
214825982|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
214825983|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
214825984|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
214825985|NCT05947474|DRUG|ORB-011|Drug: ORB-011 is dosed via IV infusion
214825986|NCT04378751|BEHAVIORAL|Decision aid video|Decision aid video
214825987|NCT04378751|BEHAVIORAL|Genetic counseling informational brochure|Genetic counseling informational brochure
214825988|NCT04378309|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
214825989|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
214825990|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
214825991|NCT04149691|DRUG|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
214825992|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (single-shot)|30 mL of 0.25% bupivacaine will be injected as single-shot block 20 mins prior to surgery
214825993|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (catheter)|In addition to administration of 30 mL of 0.25% bupivacaine prior to surgery, a catheter will be placed in the area to administer bolus of 1 mg/kg of 0.25% bupivacaine every 8 hours postoperatively.
214267721|NCT04862819|DRUG|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
214825994|NCT06452030|BEHAVIORAL|Specific sensorimotor control training|Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
214825995|NCT06452030|BEHAVIORAL|Aspecific extension training|Participants allocated to the aspecific group will receive spinal extension exercises.
214825996|NCT06452030|BEHAVIORAL|Fascia training|Participants allocated to the fascia group will receive general movement exercises.
214825997|NCT06847074|BEHAVIORAL|Multimodal Exercise|Each 60-minute class will include a 10-minute warm-up (i.e., stretches for the major muscles and walking on the spot), 40 minutes of training, and a 10-minute cool down (i.e., stretches and relaxation techniques).Instructors will use heart rate monitors to continuously track intensity during and across all sessions.
214825998|NCT06847074|BEHAVIORAL|Cognitve and Social Activities|Each 60-minute class will include 30 minutes of cognitive enrichment activities and 30 minutes of activities that promote social interactions.
214825999|NCT03023449|DRUG|Nitric Oxide|Inhaled Nitric Oxide gas
214826000|NCT06072339|OTHER|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
214826001|NCT06072339|PROCEDURE|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
214826002|NCT06072339|BIOLOGICAL|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
214826003|NCT06072339|OTHER|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
214826004|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
214826005|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
214826006|NCT05331482|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
214826007|NCT05331482|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
214826008|NCT06192368|DEVICE|INSPIRE|Virtual reality application for relaxing.
214826009|NCT06192368|DEVICE|Tablet|Gaming tablet
214826010|NCT06145412|DRUG|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
214826011|NCT06145412|DRUG|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
214826012|NCT06145412|RADIATION|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
214826013|NCT05776420|BEHAVIORAL|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
214826014|NCT06389591|BIOLOGICAL|pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
214826015|NCT06389591|BIOLOGICAL|RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)|personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
214826016|NCT05614765|DRUG|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
214826017|NCT06161506|DEVICE|Elidah Device|The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
214826018|NCT05288972|DEVICE|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
214826019|NCT05288972|DEVICE|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
214826020|NCT02129140|DEVICE|Hernia graft/mesh|observational group
214826021|NCT05866263|OTHER|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
214826022|NCT05498857|DRUG|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
214267722|NCT04862819|PROCEDURE|scaling root planing|In the second group, on one side of the dental arch srp will be performed
214826023|NCT05498857|DRUG|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
214826024|NCT02551640|OTHER|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
214826025|NCT03676634|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
214826026|NCT03705117|BIOLOGICAL|V565|Capsules for oral administration
214826027|NCT04873063|DRUG|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
214826028|NCT03799874|DRUG|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
214826029|NCT03799874|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
214826030|NCT05950919|OTHER|TASKPEN|"The package of integrated HIV/NCD services:~1. Integrated non-communicable/HIV care (one stop shop for services)~2. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~3. Access to cardio-metabolic condition screening \& laboratory monitoring~4. Non-communicable disease-focused electronic medical record module~5. Strengthened NCD medication supply chain"
214826031|NCT03713866|DIAGNOSTIC_TEST|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
214826032|NCT04837469|PROCEDURE|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
214826033|NCT05780463|DRUG|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
214826034|NCT05780463|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
214826035|NCT05780463|BIOLOGICAL|Remdesivir|Antiviral agent
214826036|NCT04367519|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
214826037|NCT05921981|BEHAVIORAL|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
214826038|NCT05921981|BEHAVIORAL|White Noise|White Noise
214826039|NCT01146223|OTHER|laboratory biomarker analysis|Correlative studies
214826040|NCT00540423|DRUG|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
214826041|NCT00540423|DRUG|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
214826042|NCT00540423|DRUG|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
214826043|NCT00540423|DRUG|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
214826044|NCT05968638|OTHER|Regular Diet|Regular Diet
214826045|NCT05968638|OTHER|Ketogenic Diet|Ketogenic Diet
214826046|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
214826047|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
214826048|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
214826049|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
214826050|NCT01969123|DRUG|Drug: EVP-6124|
214826051|NCT01969123|DRUG|Placebo|
214826052|NCT04077645|BEHAVIORAL|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
214826053|NCT04077645|BEHAVIORAL|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
214826054|NCT04077645|BEHAVIORAL|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
214826055|NCT06497972|OTHER|White bread (control, 32 grams, 14.4 grams of carbohydrate)|32 grams of white bread, providing 14.4 grams of carbohydrate, which was incorrectly dosed and matched only half the carbohydrate in the rice cakes.
214826056|NCT06497972|OTHER|Brown rice cake|A 40g rice cake made of 100% brown rice (providing 31 grams of carbohydrate)
214826057|NCT06497972|OTHER|Wild rice (25%) and brown rice (75%) cake|A 40g rice cake made of a blend of 25% wild rice and 75% brown rice (providing 31 grams of carbohydrate)
214826058|NCT06497972|OTHER|White bread (control, 66 grams, 31 grams of carbohydrate)|66 grams of white bread, providing 31 grams of carbohydrate, this arm was added after the mistake in the first control dosing was discovered, so this arm was not randomized and was completed after the first three.
214826059|NCT01214590|DEVICE|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
214826060|NCT02223585|OTHER|Animal-based protein diet|
214826061|NCT02223585|OTHER|Vegan-based protein diet|
214826062|NCT05837832|DIETARY_SUPPLEMENT|Milk-based phospholipids|Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
214826063|NCT00360607|DRUG|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
214826064|NCT00360607|DRUG|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
214826065|NCT00360607|DRUG|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
214826066|NCT00360607|DRUG|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
214826067|NCT01053585|DRUG|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
214826068|NCT01053585|DRUG|Placebo|Placebo single 'dose' 90 minutes prior to study
214826069|NCT05333107|DRUG|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
214826070|NCT05333107|DRUG|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
214826071|NCT05333107|DRUG|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
214826072|NCT06559878|DIAGNOSTIC_TEST|13C-α-Ketoisocaproic Acid Breath Test|13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).
214826073|NCT06559878|DIETARY_SUPPLEMENT|Ethanol|6% ethanol soluted in normal saline is given intravenously during one metabolic visit.
214826074|NCT06559878|DIETARY_SUPPLEMENT|Lipid Emulsion|Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.
214826075|NCT06559878|OTHER|Normal Saline|Normal saline is given intravenously during one metabolic visit.
214826076|NCT02277093|DRUG|Pacritinib|
214826077|NCT01943877|PROCEDURE|scaling root planing|scaling root planing
214826078|NCT01943877|DRUG|Propolis|experimental
214826079|NCT01995162|DEVICE|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
214826080|NCT02903407|DRUG|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
214826081|NCT02903407|DRUG|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
214826082|NCT02903407|DRUG|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
214826083|NCT00525213|DRUG|Rob 803|two capsules per day during 12 weeks
214826084|NCT00525213|DRUG|Placebo|two capsules per day during 12 weeks
214826085|NCT05143047|BEHAVIORAL|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
214826086|NCT04801654|DIAGNOSTIC_TEST|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
214826087|NCT04168398|DRUG|Combination drug|Anticoagulation
214826088|NCT00154739|DRUG|Gemcitabine|
214826089|NCT00154739|DRUG|Cisplatin|
214826090|NCT00154739|DRUG|Epirubicin|
214826091|NCT03848507|DRUG|albumin 20%|Intravenous administration of 20% albumin during cystectomy
214826092|NCT06562465|PROCEDURE|dietary and exercise management|Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
214826093|NCT06562465|PROCEDURE|no dietary and exercise management|NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
214826094|NCT00216736|DRUG|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
214826095|NCT00216736|DRUG|placebo|Single dose oral placebo at ED discharge
214826096|NCT00615823|DRUG|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
214826097|NCT00615823|DRUG|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
214826098|NCT04532879|DEVICE|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
214826099|NCT04960917|BEHAVIORAL|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
214826100|NCT03916861|DEVICE|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
214826101|NCT03916861|PROCEDURE|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
214826102|NCT00193960|PROCEDURE|1) Intraocular pressure 2) visual acuity|
214826103|NCT02273492|DRUG|Asasantin ER|
214826104|NCT02273492|OTHER|Standardized breakfast|
214826105|NCT01406080|DRUG|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
214826106|NCT01406080|DRUG|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
214826107|NCT00857038|DRUG|Doxycycline|Doxycycline tablets, 100mg daily
214826108|NCT00857038|DRUG|Placebo|Placebo tablets 100mg
214826109|NCT04393818|BEHAVIORAL|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
214826110|NCT03774303|OTHER|Mobile application|A mobile application that will be used to prepare families for day surgery
214826111|NCT03774303|OTHER|current practice|the current practice used to prepare families for day surgery
214826112|NCT00035139|DRUG|methylphenidate|
214826113|NCT01961947|BIOLOGICAL|ASP7374|subcutaneous
214826114|NCT01961947|BIOLOGICAL|approved egg-derived TIV|subcutaneous
214826115|NCT06386354|DIAGNOSTIC_TEST|Train-of-four|Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
214826116|NCT04378621|DRUG|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
214826117|NCT04378621|OTHER|Hand training|Physical hand training 10 min twice daily while on stable treatment
214826118|NCT05578443|DRUG|10g Astragalus|Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
214826119|NCT05578443|BEHAVIORAL|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
214826120|NCT05578443|DRUG|20g Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
214826121|NCT02943538|DEVICE|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
214826122|NCT02943538|DEVICE|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
214826123|NCT02943538|OTHER|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
214826124|NCT06559904|OTHER|Mediterranean diet|"The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face."
214826125|NCT06244043|OTHER|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
214826126|NCT06244043|OTHER|Email Support|Email-based support throughout study period
214826127|NCT06244043|OTHER|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
214826128|NCT00480038|OTHER|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
214826129|NCT00418145|DRUG|megadose oral methylprednisolone|1400 mg qd/5 days
214826130|NCT00418145|DRUG|IV methylprednisolone|1000 mg/qd/5 days
214826131|NCT00706277|DRUG|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
214826132|NCT00706277|DRUG|propofol|propofol 2mg
214826133|NCT00706277|DRUG|remifentanil|remifentanil 0,25mcg/kg/hour
214826134|NCT00706277|DRUG|fentanyl|fentanyl 100mcg
214826135|NCT00706277|DRUG|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
214826136|NCT02307994|DRUG|75IU uFSH|
214826137|NCT01714622|PROCEDURE|subtotal gastrectomy with gastroduodenostomy|
214826138|NCT01714622|PROCEDURE|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
214826139|NCT01714622|PROCEDURE|total gastrectomy with Rou-en-Y esophagojejunostomy|
214826140|NCT04494607|DIETARY_SUPPLEMENT|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
214826141|NCT00896688|PROCEDURE|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
214826142|NCT02856308|DEVICE|Hairstetics hair implant device|
214826143|NCT03406598|OTHER|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
214826144|NCT03214588|DRUG|TAK-831|TAK-831 tablets
214826145|NCT03214588|DRUG|TAK-831 Placebo|TAK-831 placebo matching tablets
214826146|NCT01910038|DRUG|corticoids+ tocilizumab 8mg/Kg/4 weeks|
214826147|NCT05806853|DRUG|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
214826148|NCT05806853|DRUG|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
214826149|NCT04124315|OTHER|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
214826150|NCT04124315|OTHER|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
214826151|NCT04026815|OTHER|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
214826152|NCT01798628|DRUG|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
214826153|NCT01798628|DRUG|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
214826154|NCT01798628|DRUG|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
214826155|NCT02206893|BEHAVIORAL|Self-monitoring via Smartphone|
214826156|NCT02206893|BEHAVIORAL|Peer support via Smartphone|
214826157|NCT02206893|BEHAVIORAL|Professional support via Smartphone|
214826158|NCT02206893|BEHAVIORAL|Self-monitoring via Web (Static)|
214826159|NCT06627361|DEVICE|PRO-FLEX PIVOT Foot evaluation|The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
214826160|NCT06627361|DEVICE|Class III ESAR Foot evaluation|The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
214826161|NCT03270254|DEVICE|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
214826162|NCT02211924|DRUG|BI 44847|
214826163|NCT02211924|DRUG|Placebo|
214826164|NCT02061553|BEHAVIORAL|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
214826165|NCT02061553|BEHAVIORAL|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
214826166|NCT02061553|BEHAVIORAL|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
214826167|NCT05592574|OTHER|Blood sample|Blood samples required to performe IL-17 Dosage
214826168|NCT01631552|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
214826169|NCT03480763|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
214826170|NCT03480763|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
214826171|NCT03480763|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
214826172|NCT04481958|BEHAVIORAL|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
214826173|NCT01895764|DRUG|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
214826174|NCT01895764|DRUG|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
214826175|NCT01718873|DRUG|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
214826176|NCT01718873|DRUG|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
214826177|NCT01718873|DRUG|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
214826178|NCT01718873|DRUG|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
214826179|NCT01718873|DRUG|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
214826180|NCT04509167|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
214826181|NCT04034277|OTHER|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
214826182|NCT04034277|OTHER|Conventional Treatment|"speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
214826183|NCT05364177|DRUG|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
214826184|NCT05364177|DRUG|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
214826185|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
214826186|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
214826187|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
214826188|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
214826189|NCT01440179|DRUG|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
214826190|NCT03629054|DRUG|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
214826191|NCT03629054|DRUG|Empagliflozin|single dose
214826192|NCT03629054|DRUG|Linagliptin|single dose
214826193|NCT03629054|DRUG|Metformin HCl|single dose
214826194|NCT01782053|BEHAVIORAL|Picture warning|Warning contains picture proposed for each text statement by FDA
214826195|NCT01782053|BEHAVIORAL|Control|
214826196|NCT05591105|DRUG|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
214826197|NCT05591105|DRUG|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
214826198|NCT06136039|PROCEDURE|Arm I (Sarcopenia)|Same as standard treatment
214826199|NCT06136039|PROCEDURE|Arm II(Normal)|Same as standard treatment
214826200|NCT03703154|DRUG|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
214826201|NCT03703154|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
214826202|NCT01503957|DEVICE|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
214826203|NCT01503957|DEVICE|Saline solution|Nasal spray, 2 sprays in each nostril
214826204|NCT00851305|DEVICE|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
214826205|NCT00851305|DEVICE|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
214826206|NCT00205777|DRUG|Bazedoxifene Acetate|BZA 20mg, daily, oral
214826207|NCT00205777|OTHER|Placebo|Placebo, daily, oral
214826208|NCT01824940|BEHAVIORAL|Standard care|"Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system"
214826209|NCT01824940|OTHER|WASH|"WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
214826210|NCT01824940|DIETARY_SUPPLEMENT|Infant and young child feeding|"IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
214826211|NCT01824940|OTHER|WASH and Nutrition|"WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions"
214826212|NCT02588144|PROCEDURE|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
214826213|NCT02588144|PROCEDURE|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
214826214|NCT02401906|OTHER|MRI|
214826215|NCT04110236|BEHAVIORAL|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
214826216|NCT04110236|BEHAVIORAL|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
214826217|NCT03142152|DEVICE|Carillon Mitral Contour System|The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
214826218|NCT03142152|OTHER|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
214826219|NCT03334058|DRUG|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
214826220|NCT06307639|DIAGNOSTIC_TEST|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
214826221|NCT00194363|BEHAVIORAL|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
214826222|NCT01103843|DRUG|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
214826223|NCT01103843|DRUG|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
214826224|NCT05485662|OTHER|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
214826225|NCT05485662|OTHER|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
214826226|NCT06102148|OTHER|PNF Group|Exercise training and PNF training
214826227|NCT06102148|OTHER|Control Group|Exercise training
214826228|NCT00367133|PROCEDURE|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
214826229|NCT00367133|DRUG|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
214826230|NCT00367133|DRUG|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
214826231|NCT06843252|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
214826232|NCT06843252|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
214826233|NCT01439620|DEVICE|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
214826234|NCT03954431|DIAGNOSTIC_TEST|Dedicated breast CT(BCT)|The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
214826235|NCT01252953|DRUG|Anacetrapib|tablet, 100mg daily
214826236|NCT01252953|DRUG|Placebo anacetrapib|tablet, 1 tablet daily
214826237|NCT03595462|OTHER|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
214826238|NCT03595462|OTHER|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
214826239|NCT06441591|DRUG|Vinpocetine|Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
214826240|NCT06441591|DRUG|Standard Therapy|Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
214826241|NCT06441591|OTHER|Placebo|Starch-filled capsules, matching those of the intervention
214826242|NCT00627796|DRUG|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
214826243|NCT02035163|PROCEDURE|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
214826244|NCT03811145|BIOLOGICAL|Tendoncel|Platelet lysate gel
214826245|NCT03811145|OTHER|Placebo control gel|Placebo control gel
214826246|NCT03340545|OTHER|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
214826247|NCT01446770|DEVICE|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
214826248|NCT06563219|OTHER|Glasgow coma scale|The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
214826249|NCT06563219|OTHER|Hunt-Hess scale|"The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance."
214826250|NCT06563219|OTHER|World Federation of Neurological Surgeons (WFNS) scale|"The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit"
214826251|NCT06563219|OTHER|modified Fisher scale|"The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH."
214826252|NCT06563219|OTHER|VASOGRADE scale|"The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score."
214826253|NCT06563219|OTHER|Ogilvy and Carter scale|"The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size \>10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)"
214826254|NCT04090021|DRUG|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
214826255|NCT04090021|DRUG|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
214826256|NCT04090021|DRUG|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
214826257|NCT04090021|DRUG|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
214826258|NCT04090021|DRUG|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
214826259|NCT04090021|DRUG|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
214826260|NCT00675779|DRUG|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
214826261|NCT00675779|DRUG|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
214826262|NCT01665508|DRUG|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
214826263|NCT03946787|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
214826264|NCT03946787|OTHER|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
214826265|NCT04026243|PROCEDURE|QL block|U/S guided Transmuscular Quadratus Lumborum Block
214826266|NCT04026243|PROCEDURE|TF block|U/S guided Transversalis Fascia Plane Block
214826267|NCT05458687|OTHER|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"* Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
214826268|NCT03272685|DRUG|Very Low Nicotine Content Cigarettes|0.4 mg nicotine/g tobacco; 9 mg tar
214826269|NCT03272685|DRUG|Normal Nicotine Content Cigarettes|15.8 mg nicotine/g tobacco; 9 mg tar
214826270|NCT04272437|DRUG|Concentrated herbal extract granules TRA|Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
214826271|NCT04272437|DRUG|Placebo|Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
214826272|NCT02555137|OTHER|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
214826273|NCT02355847|OTHER|Lectures|Lectures
214826274|NCT04890418|DRUG|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
214826275|NCT04890418|OTHER|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
214826276|NCT06039735|OTHER|Chemotherapy and/or autologous hematopoietic stem cell transplantation|Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
214826277|NCT00151489|DRUG|pregabalin|
214826278|NCT00151489|DRUG|placebo|
214826279|NCT02463981|DEVICE|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
214826280|NCT06056414|OTHER|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
214826281|NCT01278095|DRUG|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
214826282|NCT01278095|DRUG|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
214826283|NCT02355418|PROCEDURE|Mitral valve repair|Standard mitral valve repair surgery
214826284|NCT00883233|DRUG|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
214826285|NCT00883233|DRUG|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
214826286|NCT00883233|DRUG|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
214826287|NCT00883233|DRUG|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
214826288|NCT04468867|DIAGNOSTIC_TEST|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
214826289|NCT04468867|DIAGNOSTIC_TEST|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
214826290|NCT03490058|DRUG|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
214826291|NCT03105947|OTHER|Coconut oil|50g extravirgin coconut oil daily for four weeks
214826292|NCT03105947|OTHER|Butter|50g butter daily for four weeks
214826293|NCT03105947|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
214826294|NCT04583657|OTHER|Eggs|Consumption of two eggs (control or test) per day during three months
214826295|NCT06559631|BEHAVIORAL|Indigenously Adapted CRA|Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
214826296|NCT00858780|DRUG|Etanercept|50 mg etanercept once weekly + methotrexate
214826297|NCT00858780|DRUG|Etanercept|25mg etanercept once weekly + methotrexate
214826298|NCT00858780|DRUG|Placebo|Placebo comparator once weekly + methotrexate
214826299|NCT04172480|OTHER|Blood sampling|Peripheral blood sampling on EDTA
214826300|NCT00863330|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
214826301|NCT04353986|DRUG|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
214826302|NCT03947658|PROCEDURE|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
214826303|NCT01283763|DRUG|Topical Imiquimod|16 weeks
214826304|NCT01283763|PROCEDURE|Conization|Large loop excision of the transformation zone
214826305|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
214826306|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
214826307|NCT02504333|DRUG|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
214826308|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
214826309|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
214826310|NCT02615249|BIOLOGICAL|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
214826311|NCT00741780|DRUG|Placebo|
214826312|NCT00741780|DRUG|plerixafor|
214826313|NCT00741780|DRUG|granulocyte colony-stimulating factor (G-CSF)|
214826314|NCT01192932|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
214826315|NCT00070148|DRUG|Megestrol Acetate|Megace by mouth for 12 weeks
214826316|NCT00070148|DRUG|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
214826317|NCT02254005|DRUG|bivatuzumab mertansine|
214826318|NCT06432751|OTHER|Post Operative Acute Kidney Injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
214826319|NCT05108948|BEHAVIORAL|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
214826320|NCT05108948|PROCEDURE|Radiography|Spinal radiography : full, face, profile
214826321|NCT03937557|DIAGNOSTIC_TEST|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
214826322|NCT04391270|BEHAVIORAL|blended intervention|A blended intervention group combining the web-based components with face-to-face workshops and posters
214826323|NCT04391270|BEHAVIORAL|web-based intervention|A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
214826324|NCT04615741|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
214826325|NCT04615741|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
214826326|NCT05098743|BEHAVIORAL|Medisafe smartphone mobile application|The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.
214826327|NCT05098743|BEHAVIORAL|Printed medication list|Patients will receive a printed out medication list from their electronic medical record.
214826328|NCT04309773|DRUG|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
214826329|NCT04309773|DRUG|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
214826330|NCT01372930|DRUG|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
214826331|NCT01372930|DRUG|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
214826332|NCT00756171|DRUG|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
214826333|NCT00756171|DRUG|placebo|2 times 3 625mg tablets daily
214826334|NCT03257228|GENETIC|comparative semiquantitative immunohistochemistry|
214826335|NCT03493178|DIETARY_SUPPLEMENT|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
214826336|NCT03493178|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
214826337|NCT03493178|DIETARY_SUPPLEMENT|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
214826338|NCT04644068|DRUG|AZD5305|Oral PARP inhibitor
214826339|NCT04644068|DRUG|Paclitaxel|IV Anti-microtubule agent
214826340|NCT04644068|DRUG|Carboplatin|IV Platinum chemotherapeutic
214826341|NCT04644068|DRUG|T- Dxd|IV Antibody-drug conjugate
214826342|NCT04644068|DRUG|Dato-DXd|IV Antibody-drug conjugate
214826343|NCT04644068|DRUG|Camizestrant|Oral SERD Molecule
214826344|NCT06459258|OTHER|Motion-triggered NMES training protocol|Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball
214826345|NCT06459258|OTHER|Non-Motion-triggered NMES training protocol|Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
214826346|NCT00013390|PROCEDURE|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
214826347|NCT00013390|PROCEDURE|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
214826348|NCT03703258|BEHAVIORAL|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
214826349|NCT00351039|DRUG|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
214826350|NCT00351039|DRUG|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
214826351|NCT00351039|DRUG|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
214826352|NCT03033810|DEVICE|Fractional flow reserve and instantaneous wave-free ratio|"1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance."
214826353|NCT01159899|PROCEDURE|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
214826354|NCT03349632|DEVICE|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
214826355|NCT03349632|DEVICE|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
214826356|NCT03349632|DEVICE|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
214826357|NCT03349632|DEVICE|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
214826358|NCT00842309|DRUG|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
214826359|NCT00842309|DRUG|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
214826360|NCT01468688|DRUG|STI571|
214826361|NCT01468688|DRUG|BKM120|BKM120 combination therapy
214826362|NCT03396354|PROCEDURE|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
214826363|NCT03396354|PROCEDURE|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
214826364|NCT03221205|DEVICE|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
214826365|NCT03221205|DEVICE|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
214826366|NCT02997345|OTHER|There is no intervention associated with this study.|There is no intervention associated with this study.
214826367|NCT00893945|DRUG|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
214826368|NCT00893945|DRUG|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
214826369|NCT00893945|DRUG|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
214826370|NCT01444053|DEVICE|No Intervention|No Intervention
214826371|NCT02480660|BEHAVIORAL|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
214826372|NCT00870558|DRUG|ethiodized oil|Given as an intra-arterial infusion
214826373|NCT00870558|RADIATION|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
214826374|NCT02597374|DEVICE|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
214826375|NCT05271890|PROCEDURE|Immediate non-surgical periodontal treatment and oral hygiene instructions|
214826376|NCT06339437|OTHER|ERAS Protocol|Ehanced recovery after surgery protocols were applied
214826377|NCT05326880|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
214826378|NCT05326880|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
214826379|NCT03218787|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
214826380|NCT03218787|DRUG|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
214826381|NCT00246662|DRUG|Vosaroxin|All patients receive vosaroxin Injection
214826382|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
214826383|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
214826384|NCT04276064|DEVICE|Sham stimulation|Sham stimulation
214826385|NCT01129258|DRUG|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
214826386|NCT01129258|DRUG|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
214826387|NCT03719040|DEVICE|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
214826388|NCT02264977|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
214826389|NCT04371224|DRUG|Irinotecan Liposomal Injection [Onivyde]|both arm
214826390|NCT04371224|DRUG|Capecitabine|NaliCap
214826391|NCT04371224|DRUG|5-fluorouracil|NAPOLI
214826392|NCT04371224|DRUG|Leucovorin|NAPOLI
214826393|NCT00207662|DRUG|infliximab or placebo|
214826394|NCT01345539|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
214826395|NCT01345539|DRUG|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
214826396|NCT04979143|PROCEDURE|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
214826397|NCT00227370|DRUG|valganciclovir|valgan 900mg QD x 9 months post lung transplant
214826398|NCT00227370|OTHER|Placebo|
214826399|NCT03476226|OTHER|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
214826400|NCT03856580|BEHAVIORAL|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
214826401|NCT03856580|BEHAVIORAL|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
214826402|NCT06276556|DRUG|ABP-671|"Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study."
214826403|NCT06276556|DRUG|Allopurinol|Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
214826404|NCT03769532|DRUG|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
214826405|NCT03769532|DRUG|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
214826406|NCT03463460|OTHER|Laboratory Biomarker Analysis|Correlative studies
214826407|NCT03463460|BIOLOGICAL|Pembrolizumab|Given IV
214826408|NCT03463460|DRUG|Sunitinib Malate|Given PO
214826409|NCT06973265|DEVICE|TENS|After the surgery, 2 TENS electrodes will be placed on the inner part of the upper arm of the patient's arm on the side where surgery was performed, and the frequency will be 100 Hz, the pulse duration will be 100 µs and the amplitude will be adjusted so as not to cause muscle contraction, and a 20-minute TENS application will be performed.
214826410|NCT02923349|DRUG|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
214826411|NCT06200363|DRUG|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
214826412|NCT06200363|DRUG|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
214826413|NCT00567463|DEVICE|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
214826414|NCT05683561|BIOLOGICAL|CoronaVac|D0; intramuscular injection
214826415|NCT05683561|BIOLOGICAL|SCTV01E|D0; intramuscular injection
214826416|NCT01902719|BEHAVIORAL|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
214826417|NCT01902719|BEHAVIORAL|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
214826418|NCT01902719|BEHAVIORAL|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
214826419|NCT03759704|DRUG|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
214826420|NCT01189747|BIOLOGICAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
214826421|NCT01189747|DRUG|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
214826422|NCT06081972|DIETARY_SUPPLEMENT|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
214826423|NCT06081972|DIETARY_SUPPLEMENT|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
214826424|NCT06081972|DIETARY_SUPPLEMENT|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
214826425|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
214826426|NCT04063878|DEVICE|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
214826427|NCT07130877|DIETARY_SUPPLEMENT|WHO F100|WHO F1OO
214826428|NCT07130877|DIETARY_SUPPLEMENT|WHO RECIPE BASED F100|Recipe-made formula will be given after initial stabilization, starting from 150 kcal per kg per day to a maximum of 220 kcal per kg per day at 4-hourly intervals, and intakes and vitals will be monitored.
214826429|NCT04469959|DRUG|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
214826430|NCT04469959|DRUG|Placebo|Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
214826431|NCT07127094|DRUG|Test Product (Glimcoza)|Tablet formulation
214826432|NCT07127094|DRUG|Reference (R) Twymeeg®|Tablet formulation
214826433|NCT02751827|OTHER|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
214826434|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
214826435|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
214826436|NCT07130656|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
214826437|NCT03047564|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
214826438|NCT03047564|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
214826439|NCT01513434|PROCEDURE|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
214826440|NCT01513434|PROCEDURE|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
214826441|NCT01513434|PROCEDURE|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
214826442|NCT02368639|DEVICE|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
214826443|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
214826444|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
214826445|NCT00147498|DRUG|CP-690,550|30 mg BID for 6 weeks
214826446|NCT00147498|OTHER|Placebo|Placebo tablets
214826447|NCT06209983|PROCEDURE|ERAS|"1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
214826448|NCT06209983|PROCEDURE|Conventional care|"1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
214267723|NCT03689530|BEHAVIORAL|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
214826449|NCT03281135|OTHER|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
214826450|NCT01139970|OTHER|Laboratory Biomarker Analysis|Correlative studies
214826451|NCT01139970|OTHER|Pharmacological Study|Correlative studies
214826452|NCT01139970|DRUG|Temozolomide|Given PO
214826453|NCT01139970|DRUG|Veliparib|Given PO
214826454|NCT00246922|DRUG|Roflumilast|
214826455|NCT03129373|DEVICE|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
214826456|NCT01838681|DRUG|Placebo|Once daily, tablets, orally
214826457|NCT01838681|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
214826458|NCT01838681|DRUG|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
214826459|NCT05816564|BEHAVIORAL|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
214826460|NCT05816564|BEHAVIORAL|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
214826461|NCT03579394|PROCEDURE|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
214826462|NCT03579394|PROCEDURE|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
214826463|NCT05909358|BIOLOGICAL|CAd3|CAd3 candidate vaccine which is one of the investigational products
214826464|NCT05909358|BIOLOGICAL|ChAdox1|ChAdox1 candidate vaccine which is one of the investigational products
214826465|NCT05909358|BIOLOGICAL|rVSV-SUDV|rVSV-SUDV candidate vaccine which is one of the investigational products
214826466|NCT05909358|OTHER|Control|Placebo
214826467|NCT00298415|DRUG|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
214826468|NCT00298415|DRUG|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
214826469|NCT04964973|DEVICE|Control|Post-surgical physiotherapeutic activity.
214826470|NCT04964973|DEVICE|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
214826471|NCT04964973|DEVICE|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
214826472|NCT04573140|BIOLOGICAL|Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)|RNA-LP vaccines will be administered intravenous. Three RNA-LP vaccines will be administered every 2 weeks followed by 12 cycles of adjuvant monthly RNA-LP vaccines for a total of 15 vaccines.
214826473|NCT04945252|DIAGNOSTIC_TEST|Signpost caries|Identify carious lesion according to ICCMS visual criteria
214826474|NCT05826327|DRUG|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
214826475|NCT05826327|DRUG|Sufentanil|Sufentanil for labour analgesia in the control group
214826476|NCT06366386|BEHAVIORAL|Screening and treatment of hypertension among PLHIV in DSD models for HIV|In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
214826477|NCT00104910|RADIATION|Internal Radiation Therapy|
214826478|NCT00104910|RADIATION|3-Dimensional Conformal Radiation Therapy|
214826479|NCT00104910|BIOLOGICAL|Cetuximab|Given IV
214826480|NCT00104910|DRUG|Cisplatin|Given IV
214826481|NCT00815087|DEVICE|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
214826482|NCT00815087|BEHAVIORAL|Exercise home program|Daily exercise training
214826483|NCT01229150|DRUG|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
214826484|NCT01229150|DRUG|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
214826485|NCT01229150|DRUG|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
214826486|NCT01032213|DRUG|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
214826487|NCT01032213|DRUG|normal saline|Group S received the same volume of isotonic saline as same method.
214826488|NCT01954277|DEVICE|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
214267724|NCT03689530|BEHAVIORAL|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
214826489|NCT01954277|DEVICE|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
214267725|NCT06377475|PROCEDURE|Jaw relation|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
214826490|NCT06022588|DRUG|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
214826491|NCT06022588|DRUG|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
214826492|NCT06022588|DIAGNOSTIC_TEST|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
214826493|NCT06022588|DIAGNOSTIC_TEST|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
214826494|NCT02995135|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)"
214826495|NCT02995135|DRUG|SFP Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214826496|NCT05768334|DRUG|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
214826497|NCT02011945|DRUG|Dasatinib|
214826498|NCT02011945|DRUG|Nivolumab|
214826499|NCT03531827|DRUG|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
214826500|NCT03531827|DRUG|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
214826501|NCT04745234|DRUG|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
214826502|NCT01476969|DEVICE|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
214826503|NCT06820970|DEVICE|chronic remote ischemic conditioning|Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is squeezed for 6 minutes per cycle and the rest is 4 minutes, for a total of 4 cycles per cycle.
214826504|NCT06820970|BEHAVIORAL|Mindfulness Therapy|Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.
214826505|NCT06820970|OTHER|sham CRIC|The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as those of the CIRC group.
214826506|NCT06820970|BEHAVIORAL|sham MFT|Sham MFT: Health Education + Relaxation (HER): A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation (music or simple muscle loosening), excluding mindfulness-specific techniques (no present-moment/nonjudgmental awareness training, no breath-focused meditation, no open monitoring).
214826507|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
214826508|NCT06277492|DRUG|Single ascending doses SUL-238|PART 1: SUL-238 single ascending doses
214826509|NCT06277492|DRUG|Single dose Placebo|PART 1: Placebo single dose
214826510|NCT06277492|DRUG|Single dose SUL-238|PART 2: SUL-238 single dose for pharmacokinetics
214826511|NCT06277492|DRUG|Multiple ascending doses SUL-238|PART 3: SUL-238 multiple ascending doses
214826512|NCT06277492|DRUG|Multiple doses Placebo|PART 3: Placebo multiple doses
214267726|NCT06377475|PROCEDURE|Questionnaire|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
214267727|NCT02821169|DRUG|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
214267728|NCT02821169|DRUG|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
214267729|NCT01392443|DRUG|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
214826513|NCT06277492|DRUG|2000 mg SUL-238 single dose for pharmacokinetics (food effect)|PART 2B: 2000 mg single dose of SUL-238
214826514|NCT06277492|DRUG|Single dose placebo (food effect)|PART 2B: Placebo single dose
214826515|NCT06359860|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
214826516|NCT05032742|BEHAVIORAL|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
214826517|NCT06603103|PROCEDURE|SPHERIKA prosthesis|total knee arthroplasty with kinematic alignement with SPHERIKA prosthesis
214826518|NCT06603103|PROCEDURE|ORIGIN prosthesis|total knee arthroplasty with kinematic alignement with ORIGIN prosthesis
214826519|NCT06609278|BEHAVIORAL|harm reduction intervention|Each participant will complete a pre-test at Study Visit 1 prior to the intervention, participate in the intervention, then complete a post-test. After the intervention, participants will participate in a recorded focus group. Participants will be offered FTS, Narcan, first aid supplies at the study visit.
214826520|NCT06987708|OTHER|The Multimodal Lifestyle Intervention|The multimodal lifestyle intervention has six foci: positive cognition, exercise/movement, stress reduction, social connection, emotional well-being, and nutrition
214826521|NCT05649683|BIOLOGICAL|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
214826522|NCT03115697|DRUG|Lactulose|Lactulose 20 mL
214826523|NCT03115697|DRUG|Rifaximin|Rifaximin 550 BD
214826524|NCT03115697|BIOLOGICAL|Plasmapheresis|Plasmapheresis 8 hrly duration
214826525|NCT00849797|DRUG|Oxcarbazepine|600 mg Tablet
214826526|NCT00849797|DRUG|Trileptal®|600 mg Tablet
214826527|NCT02955901|OTHER|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
214826528|NCT02955901|OTHER|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
214826529|NCT06661915|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
214826530|NCT06661915|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214826531|NCT06661915|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214826532|NCT06661915|DRUG|Decitabine and Cedazuridine|Given PO
214826533|NCT06661915|DRUG|Iadademstat|Given PO
214826534|NCT03631056|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)|
214826535|NCT03022643|BEHAVIORAL|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
214826536|NCT03022643|OTHER|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
214826537|NCT00679081|DEVICE|CelTx|Single application; split-mouth design
214826538|NCT00679081|OTHER|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
214826539|NCT01366781|OTHER|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
214826540|NCT02901379|DRUG|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
214826541|NCT02901379|DRUG|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
214826542|NCT06602362|OTHER|Partnered sex involving choking|When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
214826543|NCT06602362|OTHER|Partnered sex not involving choking|When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
214826544|NCT06999798|PROCEDURE|Diagnostic Mammography|Undergo mammography
214826545|NCT06999798|PROCEDURE|Resection|Undergo surgical resection of the lymph node as part of standard care.
214826546|NCT06999798|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging. Ultrasound images will be evaluated for presence and visibility/conspicuity of the twinkling marker.
214826547|NCT06999798|DEVICE|Twinkling Marker Placement|Undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement.
214826548|NCT07001124|DIAGNOSTIC_TEST|duochrome test and +1 blur test|"The participant is seated at a standard testing distance (typically 6 meters or 20 feet). A duochrome chart with black letters on a split red-green background is presented.~After determining the subjective refraction, a +1.00 diopter (DS) lens is added to the final prescription. The participant is asked to read the distance visual acuity (VA) chart. The expectation is that the visual acuity should drop to 4 lines on Snellen chart (6/24) when the +1.00 DS lens is added. If VA reduces to 6/24: Indicates that the refraction is not over-minused or over-plussed (proper end point of refraction). If VA remains better than 6/24: Suggests the patient was still accommodating, possibly leading to over-minus (in myopes) or under-plus (in hyperopes) and the refraction should be re-evaluated."
214267730|NCT05543967|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
214267731|NCT05543967|OTHER|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
214826549|NCT04478370|BIOLOGICAL|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
214826550|NCT06999720|DRUG|HX15001 (SAD)|Part A (Single Ascending Dose), participants will receive a single intravenous dose of HX15001 at escalating dose levels in sequential cohorts (Cohorts 1-7).
214826551|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 1-7 of the study.
214826552|NCT06999720|DRUG|HX15001 (MAD)|In Part B (Multiple Ascending Dose), participants will receive multiple intravenous doses of HX15001 in cohorts 8 and 9 to assess safety, tolerability, and pharmacokinetics.
214826553|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 8-9 of the study.
214826554|NCT03756272|PROCEDURE|Bupivacaine block|stellate ganglion bupivacaine injection
214826555|NCT03756272|PROCEDURE|Placebo ganglion block|stellate ganglion sodium chloride injection
214826556|NCT03517319|DRUG|Normal Saline 0.9% 1.2 ml|
214826557|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
214826558|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
214826559|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
214826560|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
214826561|NCT01369368|DRUG|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
214826562|NCT01318369|DRUG|Namisol|Single dose delta-9-tetrahydrocannabinol
214826563|NCT01318369|DRUG|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
214826564|NCT07131943|DEVICE|Radiofrequency|Radiofrequency (TECAR) therapy is a non-invasive, non-ablative treatment that uses electromagnetic energy to generate endogenous heat, promoting increased blood flow and tissue healing in both superficial and deep tissues. With a long wavelength and low frequency (300 KHz to 1 MHz), it can penetrate deeply into muscles, tendons, and bones, making it suitable even in acute conditions. TECAR operates in two modes: capacitive (targeting soft tissues rich in electrolytes) and resistive (targeting high-resistance tissues like bones and tendons). The therapy stimulates natural repair processes by inducing ion flow and micro-hyperemia, leading to the release of endorphins and cortisone, which help reduce pain, inflammation, and edema, while enhancing immune response and tissue regeneration.
214826565|NCT07131943|DEVICE|Ultrasound|The ultrasound waves accelerate healing, increasing local vascularity and improving several other characteristics, including energy absorption capacity and maximum rupture resistance tension, increased collagen synthesis, fibroblast proliferation, release of growth factors stimulated by mast cell degranulation and improved response of platelets and macrophages anticipating the proliferative and remodeling phase. 1-MHz continuous ultrasound, with a half-value depth of approximately 2.3 cm, is frequently used to treat deep tissues that are approximately 2.3 to 5 cm deep.
214826566|NCT07131943|OTHER|The designed physical therapy program|The designed physical therapy program focuses on improving upper limb mobility and stability through a structured set of exercises targeting the shoulder joint. It includes prolonged stretching performed in a seated position to extend the thumb, fingers, wrist, elbow, and shoulder, along with scapular mobilization in side-lying and stretching of internal rotators in a supine position. The stretching progression begins with external rotation at 45° abduction and advances to 90° abduction and full reach toward the ground if pain-free. Joint stabilization exercises involve resistance band movements in various shoulder and elbow positions, including controlled abduction, flexion, scapular movements, and external rotation, all aimed at enhancing joint control and muscular coordination.
214826567|NCT07128082|DRUG|Tirzepatide|The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
214826568|NCT07128082|DRUG|Placebo|Participants in the control group will receive a placebo instead of active study medication for a 12 month period.
214826569|NCT07135102|DRUG|225Ac-PSMA-XT|Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.
214826570|NCT06867822|DRUG|ProAgio|ProAgio is a pegylated protein with a single pegylated site. The 12,131 Dalton protein is produced in E. coli and is composed of 105 amino acids with no disulfide bonds. The structure of the polyethylene glycol moiety is Methoxy PEG maleimide 30000.
214826571|NCT06867822|DRUG|FOLFIRI|FOLFIRI is a combination of three drugs: (leucovorian, fluorouracil, and irinotecan) used to treat advanced metastatic colorectal cancer. FOLFIRI is commercially available will be administered using standard dosing regimen as per institutional guidelines.
214826572|NCT06867822|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab is commercially available and will be administered using standard dosing regimen as per institutional guidelines.
214826573|NCT02818842|OTHER|Primary Health Insurance Fund data|"Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date"
214826574|NCT02818842|OTHER|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
214826575|NCT02818842|OTHER|Mother and child protection data collection|"Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)"
214826576|NCT02818842|OTHER|Medicalisation Program of Information Systems data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)"
214826577|NCT06036134|BEHAVIORAL|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
214826578|NCT06036134|BEHAVIORAL|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
214826579|NCT06036134|BEHAVIORAL|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
214826580|NCT05096286|DEVICE|Ethos Therapy|FDA-approved treatment planning system
214826581|NCT06620939|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
214826582|NCT06623591|DEVICE|active Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
214826583|NCT06623591|DEVICE|sham Transcutaneous auricular vagus nerve stimulation|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
214826584|NCT06869057|BEHAVIORAL|REDDCAT2 Post-Discharge Navigation|Those in the REDDCAT2 intervention group will be partnered with a patient navigator whose role will be to review the results of the screening survey completed at the beginning of the study. The patient navigator will help coordinate the participant's care before leaving the hospital and for 90 days after. Together, the participant and navigator will form an action plan intended to help address personal, social, or community factors affecting the participant's health. The navigator is expected to contact the participant every 2 weeks, though this can be adjusted based on their preference.
214826585|NCT06869057|OTHER|Treatment as Usual (TAU)|"TAU participants will receive standard care from the UMass Memorial Healthcare (UMMH) hospitalist team as appropriate. Participants will receive a printed list of community resources. No study-related patient navigation support will be provided.~In 2024, Centers for Medicare and Medicaid Services mandated social determinants of health (SDOH) screening for inpatients. UMMH will use a checklist social needs screener. It will be up to the hospitalist teams to act on SDOH screening results. The UMMH hospitalist teams may consult endocrinology and/or inpatient social services to provide support and consultation for all patients regardless of study participation or group assignment. If medically appropriate, the endocrinology service may manage medications and provide referrals for continued treatment post discharge. All services that are normally provided by hospital care teams will remain available."
214826586|NCT06679582|DRUG|Luveltamab tazevibulin|"Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.~Other Names:~* STRO-002~* Luvelta"
214826587|NCT00905528|DRUG|Telmisartan 80 mg/d|
214826588|NCT00905528|DRUG|Ramipril 10 mg/d|
214826589|NCT06223932|DRUG|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
214826590|NCT04774705|OTHER|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
214826591|NCT04774705|OTHER|Placebo group|For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
214826592|NCT03010098|DEVICE|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
214826593|NCT03010098|DEVICE|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
214826594|NCT03651219|DRUG|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
214826595|NCT03651219|DRUG|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
214826596|NCT05811689|DIAGNOSTIC_TEST|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). \[10\] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
214826597|NCT01126463|DRUG|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
214826598|NCT04454307|DRUG|Tramadol|tramadol 100 mg twice daily for 10 days
214826599|NCT04454307|OTHER|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
214826600|NCT02584608|DRUG|ACTIMMUNE|
214826601|NCT04198363|DRUG|Vonoprazan|Vonoprazan Tablets
214826602|NCT04198363|DRUG|Amoxicillin|Amoxicillin Capsules
214826603|NCT04198363|DRUG|Clarithromycin|Clarithromycin Tablets
214826604|NCT04198363|DRUG|Bismuth Potassium citrate|Bismuth Potassium citrate
214826605|NCT04198363|DRUG|Esomeprazole|Esomeprazole Tablets
214826606|NCT04534790|RADIATION|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
214826607|NCT04893408|OTHER|observational study|
214826608|NCT04739358|DRUG|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
214826609|NCT05344118|OTHER|Survey|REDCap survey
214826610|NCT00004398|DRUG|heme arginate|
214267732|NCT05543967|OTHER|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
214267733|NCT04144660|DEVICE|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
214826611|NCT00004398|DRUG|tin mesoporphyrin|
214826612|NCT03442322|OTHER|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
214826613|NCT03442322|OTHER|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
214826614|NCT01439451|PROCEDURE|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
214826615|NCT05238857|OTHER|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
214826616|NCT07064603|PROCEDURE|TCAF|tunnel coronal advanced flap
214826617|NCT07069478|OTHER|Stress Intervention|Experimental Stress: Behavioral induction of acute psychosocial and physiological stress. First, participants will be provided with a speech topic and given 4 minutes to prepare a speech that they subsequently deliver in front of evaluators and a video recorder. Then, participants will complete a mental arithmetic task in front of the evaluators for 8 minutes. Then, participants will complete a cold pressor task in which they submerge their hand in ice water for 90 seconds.
214826618|NCT07069608|DIETARY_SUPPLEMENT|Cheers Restore|Cheers Restore contains a formulation of antioxidants, electrolytes, and plant-based compounds designed to support physiological resilience and sleep recovery after alcohol consumption. This study is structured to evaluate Cheers Restore in a real-world setting without introducing investigational or therapeutic claims.
214826619|NCT01404988|BEHAVIORAL|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
214826620|NCT01404988|BEHAVIORAL|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
214826621|NCT01404988|OTHER|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
214826622|NCT01677754|DRUG|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
214826623|NCT01677754|DRUG|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
214826624|NCT01677754|DRUG|Donepezil|Stable dose as background medication
214826625|NCT01677754|DRUG|Memantine|Stable dose as background medication in combination with AChEIs
214826626|NCT01677754|DRUG|Rivastigmine|Stable dose as background medication
214826627|NCT01677754|DRUG|Galantamine|Stable dose as background medication
214826628|NCT02588339|DRUG|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
214826629|NCT02588339|DRUG|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
214826630|NCT02588339|DRUG|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
214826631|NCT03922490|DEVICE|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
214826632|NCT03922490|PROCEDURE|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
214826633|NCT02794584|DRUG|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
214826634|NCT02794584|PROCEDURE|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
214826635|NCT02794584|PROCEDURE|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
214826636|NCT03597724|OTHER|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
214826637|NCT03578809|BIOLOGICAL|MEDI6012|MEDI6012
214826638|NCT03578809|OTHER|Placebo|Placebo
214826639|NCT05028569|DRUG|BOTOX|Intramuscular Injection
214826640|NCT05028569|DRUG|Placebo|Intramuscular Injection
214826641|NCT05403268|DEVICE|DeltaScan|Twice daily DeltaScan observations
214826642|NCT06253182|BEHAVIORAL|Self-Guided PEPP Intervention Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
214826643|NCT06253182|BEHAVIORAL|Self-Guided PEPP Education Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
214826644|NCT06455969|DRUG|Goserelin 3.6 MG|Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
214826645|NCT06455969|OTHER|Multi-Stressor Training|A 4-week physical training program that mimics military training.
214826646|NCT06455969|DRUG|Testosterone gel (AndroGel 5g)|Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
214826647|NCT06455969|DRUG|Testosterone gel (AndroGel 1.25g)|Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
214826648|NCT06455969|DRUG|Estradiol / Levonorgestrel Transdermal System [Climara Pro]|Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
214826649|NCT06455969|DRUG|Placebo Patch|Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
214826650|NCT06018818|DEVICE|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
214826651|NCT06067919|OTHER|decision tree for the choice of intraoperative antibiotic prophylaxis|Presentation of a decision tree to anaesthetists to guide the choice of intraoperative antibiotic prophylaxis
214826652|NCT05276479|OTHER|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
214826653|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
214826654|NCT06461988|DRUG|Talquetamab|"Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3: 60 mcg/kg C1D5: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13"
214826655|NCT06461988|DRUG|Talquetamab and Lenalidomide|Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)
214826656|NCT06840509|DEVICE|CorSky ICD or CRT-D|Subjects with an indication for an ICD or CRT-D device will be implanted with a CorSky device of the CorSky ICD family according to standard implantation procedures. Device programming will be done according to the medical needs of the subjects.
214826657|NCT06191276|BEHAVIORAL|STEP@Home Intervention|STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.
214826658|NCT06191276|BEHAVIORAL|Usual care|Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
214826659|NCT06257355|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
214826660|NCT06163001|BEHAVIORAL|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
214826661|NCT06163001|DIETARY_SUPPLEMENT|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
214826662|NCT01195038|BIOLOGICAL|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
214826663|NCT02158741|BEHAVIORAL|Home Visits and Lifestyle Education Support|
214826664|NCT06626932|RADIATION|18 FDG (Fludeoxyglucose 18F)|18-f FDG
214826665|NCT00073580|DRUG|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) \>300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
214826666|NCT05561166|OTHER|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
214826667|NCT00592969|DRUG|metformin|
214826668|NCT00592969|DRUG|biphasic insulin aspart|
214826669|NCT04939571|OTHER|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
214826670|NCT01002287|DEVICE|SprayShield Adhesion Barrier System|Adhesion Barrier Device
214826671|NCT01002287|PROCEDURE|Good Surgical Technique Alone|Good Surgical Technique Alone
214826672|NCT00767481|DRUG|Travoprost/Brinzolamide|Eye drop suspension, once daily
214826673|NCT00767481|DRUG|Cosopt|Eye drop solution, one drop BID
214826674|NCT03163160|PROCEDURE|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
214826675|NCT03163160|PROCEDURE|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
214826676|NCT05330780|OTHER|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
214826677|NCT02997176|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
214826678|NCT06335927|DRUG|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
214826679|NCT04273386|OTHER|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
214826680|NCT00265226|BIOLOGICAL|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
214826681|NCT06558968|OTHER|aesthetic functional space maintainers|evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
214826682|NCT01881763|DRUG|Ketamine|Ketamine 1-2 mgr/ kg IV
214826683|NCT01881763|DRUG|Methohexital|Methohexital 0.5-1mg/kg IV
214826684|NCT04595669|BEHAVIORAL|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
214826685|NCT02396888|DRUG|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
214826686|NCT02396888|DRUG|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
214826687|NCT01624233|DRUG|80 mg ixekizumab|Administered SC
214826688|NCT04158128|OTHER|non-intervention|non-interventional, prospective cohort study
214826689|NCT05281354|OTHER|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
214826690|NCT00373256|DRUG|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
214826691|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
214826692|NCT00373256|DRUG|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
214826693|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
214826694|NCT02867358|DRUG|KT07 Capsule|
214826695|NCT02867358|OTHER|Placebo|
214826696|NCT02203539|OTHER|exposure to normal light|exposure for 60 minutes in duration
214826697|NCT02203539|OTHER|exposure to bright light|exposure to bright light for 60 minutes of duration
214826698|NCT02203539|OTHER|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
214826699|NCT01877122|DEVICE|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
214826700|NCT01877122|DEVICE|Marlex® Mesh Implant|
214826701|NCT00327457|BEHAVIORAL|Help with physician office and patient management|
214826702|NCT00327457|BEHAVIORAL|Tailored physician recommendation letter|
214826703|NCT02987634|OTHER|PeriActive|mouthwash
214826704|NCT06122155|DEVICE|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
214826705|NCT06122155|DEVICE|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
214826706|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
214826707|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
214826708|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
214826709|NCT00778453|OTHER|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
214826710|NCT00778453|OTHER|Hospital-based BIT|bilateral symmetric, repetitive arm training
214826711|NCT00778453|OTHER|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
214826712|NCT00778453|OTHER|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
214826713|NCT00778453|OTHER|Home-based BAT|bilateral symmetric, repetitive arm training
214826714|NCT00778453|OTHER|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
214826715|NCT05025033|DRUG|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
214826716|NCT04372238|BEHAVIORAL|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
214826717|NCT04372238|BEHAVIORAL|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
214826718|NCT03278041|PROCEDURE|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
214826719|NCT03278041|DEVICE|maxillary obturator|immediate surgical obturator
214826720|NCT04241458|DRUG|BI 703621|BI 703621
214826721|NCT04241458|DRUG|Placebo|Placebo
214826722|NCT04241458|DRUG|Midazolam|Midazolam
214826723|NCT04837105|OTHER|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
214826724|NCT04837105|OTHER|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
214826725|NCT03656536|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
214826726|NCT03656536|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
214826727|NCT03656536|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
214826728|NCT03862911|RADIATION|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
214826729|NCT03862911|RADIATION|Stereotactic ablative radiotherapy|"Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily"
214826730|NCT06458023|DEVICE|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
214826731|NCT03836040|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
214826732|NCT03836040|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
214826733|NCT03836040|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
214826734|NCT03836040|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
214826735|NCT05625399|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
214826736|NCT05625399|DRUG|rHuPH20|Specified dose on specified days
214826737|NCT05985525|DEVICE|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
214826738|NCT05989412|OTHER|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
214826739|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
214826740|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
214826741|NCT06144424|DRUG|Oral EP262|Once daily
214826742|NCT06144424|DRUG|Placebo|Once Daily
214826743|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
215031468|NCT04586257|PROCEDURE|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
214826744|NCT05539469|DEVICE|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
214826745|NCT05539469|OTHER|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
214826746|NCT06471413|OTHER|The Prevention Toolbox : BOAT®|The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
214826747|NCT05829915|DEVICE|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
214826748|NCT05829915|OTHER|No exercise program|The control group did not received the physical exercise program
214826749|NCT06002126|DIAGNOSTIC_TEST|Xpert HPV|The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV 16, HPV 18/45, HPV 31/33/35/52/58, HPV 51/59, HPV 39/68/56/66 all with a corresponding cycle threshold.
214826750|NCT06002126|DIAGNOSTIC_TEST|QIAsure Methylation Test|The Qiagen QIAsure assay is a multiplex real-time PCR test that amplifies the methylated promoter regions of the tumor suppressor genes, FAM19A4 and has-mir124-2, as well as a methylation-unspecific fragment of the ACTB reference gene. Hypermethylation of the host genes FAM19A4 and has-mir124-2 has been shown to detect high-grade cervical lesions and cancer.
214826751|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
214826752|NCT05526391|DRUG|TAK-341|TAK-341 IV infusion
214826753|NCT05526391|DRUG|Placebo|TAK-341 placebo-matching IV infusion
214826754|NCT06390943|OTHER|Facility-based feeding support package plus (FB-FSP+)|Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
214826755|NCT06390943|OTHER|Transition-to-home feeding support package plus (TTH-FSP+)|Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
214826756|NCT06204991|BIOLOGICAL|ADP-TILIL7|Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement
214826757|NCT06204991|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
214826758|NCT06204991|DRUG|Fludarabine Phosphate|Lymphodepleting Chemotherapy
214826759|NCT06204991|DRUG|Proleukin|IL-2
214826760|NCT06359847|DRUG|ST-1898 tablets|Tablets: 5 mg and 40 mg
214826761|NCT05181982|OTHER|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
214826762|NCT03414450|DRUG|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
214826763|NCT03414450|DRUG|dasatinib|dasatinib tablets at 140 mg will be dosed every day
214826764|NCT05457413|PROCEDURE|Sleeve gastrectomy|Bariatric surgery
214826765|NCT00944294|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
214826766|NCT00944294|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
214826767|NCT01966666|DRUG|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
214826768|NCT01966666|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
214826769|NCT01966666|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
214826770|NCT01966666|DRUG|Placebo|500mL 0.9% sodium chloride.
214826771|NCT05889143|DRUG|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
214826772|NCT04325139|OTHER|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
214826773|NCT04723134|COMBINATION_PRODUCT|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
214826774|NCT06463041|OTHER|Experimental, comparator and control|How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
214826775|NCT01815320|PROCEDURE|Contrast-enhanced ultrasound (CE-US)|
214826776|NCT01815320|DEVICE|SonoVue|
214826777|NCT05322967|OTHER|Time of ordinary antihypertensive medication intake|Time of ordinary antihypertensive medication intake
214826778|NCT03767374|PROCEDURE|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
214826779|NCT03767374|PROCEDURE|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
214826780|NCT03767374|PROCEDURE|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
214826781|NCT03767374|OTHER|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
214826782|NCT05586880|OTHER|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
214826783|NCT05586880|OTHER|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
214826784|NCT06492876|GENETIC|FT-003|Administered via intraocular injection.
214826785|NCT06258421|OTHER|No Intervention|Observatory Study
214826786|NCT03463226|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
214826787|NCT03463226|DIAGNOSTIC_TEST|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
214826788|NCT03463226|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
214826789|NCT03463226|DIAGNOSTIC_TEST|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
214826790|NCT03463226|DIAGNOSTIC_TEST|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
214826791|NCT03463226|DIAGNOSTIC_TEST|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
214826792|NCT05124366|PROCEDURE|dental prophylaxis + oral hygiene instructions|Follow up: 2 weeks and 4 weeks
214826793|NCT01246258|OTHER|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
214826794|NCT01246258|OTHER|Utricular centrifugation test|Standard test of balance function
214826795|NCT04193241|PROCEDURE|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
214826796|NCT05543135|DIAGNOSTIC_TEST|basic audiological evaluation|pure tone audiometry\&immitancemetry
214826797|NCT02645253|DRUG|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
214826798|NCT02645253|DRUG|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
214826799|NCT02645253|DRUG|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
214826800|NCT02645253|DRUG|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
214826801|NCT02645253|DRUG|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
214826802|NCT00000458|DRUG|sertraline (Zoloft)|
214826803|NCT00000458|BEHAVIORAL|cognitive behavior therapy|
214826804|NCT01016782|DRUG|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
214826805|NCT05334875|DIAGNOSTIC_TEST|Electroretinogram (ERG)|Applying electrodes to assess retinal function
214826806|NCT05334875|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
214826807|NCT05490563|DRUG|SLS-005|SLS-005
214826808|NCT05490563|DRUG|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
214826809|NCT03001596|PROCEDURE|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
214826810|NCT03001596|PROCEDURE|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
214826811|NCT03001596|PROCEDURE|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
214826812|NCT05812118|BEHAVIORAL|Physical active learning|The intervention will last for 8-10 weeks. The ALPHYL intervention will be conducted in physical education (PE) and non-PE lessons by teachers. In addition to the PE lessons, at least three physically active activities in subjects other than PE will be conducted every day (5 days per week), with a total duration of approximately 30 minutes of light and moderate-to-vigorous physical activity per day. The weekly dose of physically active learning will thus be 100-150 minutes, so that a volume of 800-1200 minutes is foreseen during the 8-10 weeks. The PE classes will also be conducted in a mix of cooperative learning, non-linear pedagogy and health-based PE.
214826813|NCT05415891|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
214826814|NCT05415891|DEVICE|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
214826815|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID|vaccination
214826816|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
214826817|NCT01897064|BEHAVIORAL|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
214826818|NCT01897064|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
214826819|NCT05592808|DEVICE|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
214826820|NCT05592808|OTHER|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
214826821|NCT05592808|OTHER|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
214826822|NCT02331108|DRUG|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
214826823|NCT04292691|DRUG|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
214826824|NCT04292691|DRUG|40ml of Ringer's Lactate|already outlined in the arm/group description
214826825|NCT04425096|OTHER|Skin to skin contact|Skin to skin contact
214826826|NCT03513224|OTHER|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
214826827|NCT03151824|OTHER|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
214826828|NCT05762458|DRUG|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
214826829|NCT05762458|DRUG|Placebo|placebo to Ammoxetine.
214826830|NCT03681977|DEVICE|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
214826831|NCT03681977|DEVICE|Zimmer Persona Knee-PS|Persona the personalized knee system
214826832|NCT02752074|DRUG|pembrolizumab + epacadostat|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
214826833|NCT02752074|DRUG|pembrolizumab + placebo|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)"
214826834|NCT05101382|OTHER|Observation|Retrospective Observation of standard clinical practice
214826835|NCT06160804|PROCEDURE|Skeletal traction|A pin through the bone with weights attached
214267734|NCT03307681|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
214826836|NCT06160804|PROCEDURE|Femoral shaft splinting|A splint of the broken thigh bone
214826837|NCT04550702|DRUG|Mirabegron 25mg|Mirabegron 25 mg per day
214826838|NCT04244630|COMBINATION_PRODUCT|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
214826839|NCT06395246|BEHAVIORAL|Active Comparator: Continuous calorie restriction|Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
214267735|NCT03307681|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
214267736|NCT03307681|OTHER|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
214267737|NCT03307681|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
214267738|NCT03307681|OTHER|Meal skipping|No food given
214267739|NCT03041883|PROCEDURE|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
214826840|NCT06395246|BEHAVIORAL|eTRE|early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
214826841|NCT05467111|OTHER|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
214826842|NCT04728542|DEVICE|ORIGIN PS System|70 surgeries with the ORIGIN PS System
214826843|NCT04728542|DEVICE|VANGUARD PS System|70 surgeries with the VANGUARD System
214826844|NCT00197353|DRUG|Epidural bupivacaine (dose/concentration/volume ranging)|
214826845|NCT06627868|DIETARY_SUPPLEMENT|NAD+ precursor|NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
214826846|NCT06627868|OTHER|Placebo|Oral placebo daily intake for 6 months
214826847|NCT04580784|RADIATION|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
214826848|NCT05967286|DRUG|Alpelisib|Given PO
214826849|NCT05967286|PROCEDURE|Biopsy|Undergo biopsy
214826850|NCT05967286|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214826851|NCT05967286|PROCEDURE|Bone Scan|Undergo bone scans
214826852|NCT05967286|PROCEDURE|Computed Tomography|Undergo CT
214826853|NCT05967286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214826854|NCT05967286|DRUG|Olaparib|Given PO
214826855|NCT05967286|PROCEDURE|Positron Emission Tomography|Undergo PET
214826856|NCT05039996|BEHAVIORAL|education and relaxation program|randomized controlled trial
214826857|NCT01447017|DRUG|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
214826858|NCT01447017|DRUG|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
214826859|NCT03877939|DIAGNOSTIC_TEST|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
214826860|NCT02365363|OTHER|Control|Non pulse ingredient bagel
214826861|NCT02365363|OTHER|Pea flour|Pulse ingredient bagel
214826862|NCT02365363|OTHER|Pea fibre|Pulse ingredient bagel
214826863|NCT02365363|OTHER|Pea flour and pea fibre|Pulse ingredient bagel
214826864|NCT02365363|OTHER|Pea flour and pea protein|Pulse ingredient bagel
214826865|NCT02365363|OTHER|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
214826866|NCT01701063|DRUG|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
214826867|NCT01701063|DRUG|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
214826868|NCT01701063|DRUG|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
214826869|NCT01773408|DRUG|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
214826870|NCT01773408|DRUG|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
214267740|NCT03041883|PROCEDURE|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
214826871|NCT01773408|DRUG|Idarubicin|Idarubicin will be administered as per standard clinical practice.
214826872|NCT01773408|DRUG|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
214267741|NCT02408627|DEVICE|EEG|
214267742|NCT03539471|DIAGNOSTIC_TEST|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
214826873|NCT01773408|DRUG|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
214826874|NCT06559917|OTHER|life review|"After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed."
214826875|NCT01154712|DEVICE|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
214826876|NCT01154712|DEVICE|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
214826877|NCT05571449|PROCEDURE|Open reduction and internal fixation|Internal fixation of the fracture
214826878|NCT05571449|PROCEDURE|Standard osteosynthesis planning|Plain radiograph and CT images are used
214826879|NCT05571449|PROCEDURE|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
214826880|NCT00171015|DRUG|valsartan plus hydrochlorothiazide|
214826881|NCT04701216|DRUG|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
214826882|NCT03534076|OTHER|Cohort Observational study|Cohort Observational study - there is no intervention
214826883|NCT03957226|DEVICE|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
214826884|NCT05668689|OTHER|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
214826885|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
214826886|NCT01787565|OTHER|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
214826887|NCT01787565|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
214826888|NCT00000330|DRUG|Opioid-Related Disorders|
214826889|NCT00243425|PROCEDURE|Standard Quality Improvement|
214826890|NCT00243425|PROCEDURE|Patient-centered Intervention|
214826891|NCT06396286|PROCEDURE|single rod|surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
214826892|NCT00027664|BIOLOGICAL|recombinant interferon alfa|
214826893|NCT00027664|DRUG|thalidomide|
214826894|NCT02095379|OTHER|oligosecretary|not abvailable
214826895|NCT04467151|DRUG|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
214826896|NCT04467151|OTHER|Placebo|Administration of placebo (albumin 5%)
214826897|NCT02554877|DRUG|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
214826898|NCT02554877|DRUG|Placebo|oral tablet
214826899|NCT01601405|DRUG|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
214826900|NCT01601405|DRUG|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
214826901|NCT04474405|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
214826902|NCT04474405|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
214826903|NCT04474405|PROCEDURE|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
214267743|NCT01100541|DEVICE|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
214267744|NCT05988008|DRUG|CCX168|Administered orally.
214267745|NCT05988008|DRUG|Placebo|Administered orally.
214267746|NCT05108662|PROCEDURE|Surgery method|Patients were subdivided into two groups according to their prostate volume
214826904|NCT04474405|DRUG|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
214826905|NCT04474405|PROCEDURE|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
214826906|NCT00274651|DRUG|belinostat|
214826907|NCT05571462|OTHER|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
214826908|NCT03659994|DIETARY_SUPPLEMENT|Multivitamin|Vitabeard
214826909|NCT03659994|DIETARY_SUPPLEMENT|Placebo|Placebo
214826910|NCT04547192|OTHER|Improving initial care of the injured|Improvement in Care Processes
214826911|NCT02956525|DRUG|Dexibuprofen|Dexibuprofen 200 mg
214826912|NCT03720444|OTHER|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
214826913|NCT01942239|DEVICE|real time continuous glucose monitoring|
214826914|NCT00005040|DRUG|arsenic trioxide|
214826915|NCT05324033|RADIATION|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
214267747|NCT02154776|DRUG|LEE011|3 weeks on and 1 week off
214826916|NCT05324033|PROCEDURE|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
214826917|NCT04150133|OTHER|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
214826918|NCT06433388|DEVICE|MRI|Magnetic Resonance Imaging (MRI) is a non-invasive imaging technology that produces three dimensional detailed anatomical images. Patients will be subjected to MRI scans and imaging of the kidneys and liver
214826919|NCT05866588|BEHAVIORAL|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"1. Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~2. Follow-up: Providing education and counseling for childbirth.~3. Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~4. Follow-up: To provide counseling on the issues needed with the approaching of the birth.~5. Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~6. Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~7. Follow-up: To evaluate the transition to motherhood.~8. Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
214826920|NCT04723693|OTHER|Qualitative Interview|A single one hour semi structured qualitative interview
214826921|NCT03953703|DRUG|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
214826922|NCT03953703|DRUG|Placebo|Placebo 1000 mg twice per day for 6 weeks
214826923|NCT06562647|DRUG|SY001|PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
214826924|NCT01468623|OTHER|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
214826925|NCT01468623|OTHER|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
214826926|NCT00538031|DRUG|cyclophosphamide|Given orally
214826927|NCT00538031|DRUG|celecoxib|Given orally
214826928|NCT02922569|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
214826929|NCT02922569|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
214826930|NCT02922569|OTHER|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
214826931|NCT02922569|OTHER|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
214826932|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
214826933|NCT01410227|BIOLOGICAL|Recombinant von Willebrand factor (rVWF)|Intravenous administration
214826934|NCT01410227|DRUG|Placebo|Syringe supplied with physiologic saline solution for infusion
214826935|NCT01410227|BIOLOGICAL|Recombinant factor VIIII (rFVIII)|Intravenous administration
214826936|NCT04862767|DRUG|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
214826937|NCT04862767|COMBINATION_PRODUCT|Aldesleukin|SC, Bid
214826938|NCT00776763|DRUG|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
214267748|NCT02154776|DRUG|Buparlisib|daily
214267749|NCT02154776|DRUG|Letrozole|2.5 mg daily;
214267750|NCT02160535|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
214826939|NCT01665495|PROCEDURE|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
214826940|NCT03954808|OTHER|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
214826941|NCT03954808|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
214826942|NCT02114788|OTHER|Internet-based|
214826943|NCT04221347|OTHER|blood sampling|blood samples will be taken in specified time points
214826944|NCT05714930|OTHER|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
214826945|NCT05915559|PROCEDURE|Tonsillectomy|Tonsillectomy
214826946|NCT05915559|OTHER|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
214826947|NCT03218150|PROCEDURE|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
214826948|NCT04862039|DEVICE|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
214826949|NCT03497130|OTHER|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
214826950|NCT04002648|PROCEDURE|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
214826951|NCT04002648|PROCEDURE|Sternotomy|Longitudinal resection of the sternum
214826952|NCT04130022|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
214826953|NCT02188628|DEVICE|H-Man|H-man is a portable end-effector planar upper limb robot.
214826954|NCT02188628|OTHER|Additional Conventional Therapy|Repetitive goals based arm therapy
214826955|NCT01484912|DRUG|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
214826956|NCT01484912|DRUG|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
214826957|NCT06258746|DRUG|[14C]HSK31679|A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
214826958|NCT04522258|DIETARY_SUPPLEMENT|Dietary fiber|Fermentable cereal bran
214826959|NCT04522258|DIETARY_SUPPLEMENT|Placebo|Refined cereal flour
214826960|NCT04159285|BEHAVIORAL|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
214826961|NCT04159285|OTHER|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
214826962|NCT05452707|OTHER|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
214826963|NCT00002220|DRUG|Indinavir sulfate|
214826964|NCT00002220|DRUG|Efavirenz|
214826965|NCT00002220|DRUG|Levocarnitine|
214826966|NCT00002220|DRUG|Adefovir dipivoxil|
214826967|NCT02622386|DRUG|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
214826968|NCT02622386|OTHER|Placebo|Matching placebo capsule taken daily for 12 weeks.
214826969|NCT02890992|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
214826970|NCT02890992|DRUG|statins|Pharmaceutical form: tablet Route of administration: oral
214826971|NCT02890992|DRUG|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
214826972|NCT02890992|DRUG|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
214826973|NCT02890992|DRUG|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
214826974|NCT02890992|DRUG|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
214826975|NCT02890992|DRUG|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
214826976|NCT03158727|BIOLOGICAL|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
214826977|NCT03158727|OTHER|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
214826978|NCT06063460|DIAGNOSTIC_TEST|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
214826979|NCT06063460|OTHER|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
214826980|NCT06063460|OTHER|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
214267751|NCT06327035|OTHER|Gait rehabilitation|"Assessment of gait and balance abilities after stroke during neurorehabilitation from the subacute phase of stroke to 6 months after stroke.~The assessments will be carried out on entrance to the neurological center, then at 1 ,3 and 6 months and on hospital discharge."
214267752|NCT03240965|DIAGNOSTIC_TEST|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
214267753|NCT03240965|OTHER|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
214267754|NCT03240965|DIAGNOSTIC_TEST|Taste-/smell-test|Taste-/smell-test
214267755|NCT03240965|DIAGNOSTIC_TEST|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
214826981|NCT06063460|OTHER|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
214826982|NCT06063460|OTHER|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
214826983|NCT06562374|DEVICE|Low Frequency Ultrasound Therapy|The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
214826984|NCT01522820|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
214826985|NCT01522820|OTHER|Laboratory Biomarker Analysis|Correlative studies
214826986|NCT01522820|OTHER|Pharmacological Study|Correlative studies
214826987|NCT01522820|DRUG|Sirolimus|Given PO or PEG
214826988|NCT02287844|OTHER|XOS|5 g of XOS everyday for 4 weeks.
214826989|NCT02287844|OTHER|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
214826990|NCT02287844|OTHER|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
214826991|NCT02680444|BEHAVIORAL|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
214826992|NCT02680444|BEHAVIORAL|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
214826993|NCT02680444|BEHAVIORAL|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
214826994|NCT00669162|DRUG|Docetaxel|20mg/m2 IV weekly for 7 weeks
214826995|NCT00669162|RADIATION|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
214826996|NCT00669162|DRUG|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
214826997|NCT01528163|DRUG|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
214826998|NCT01528163|DRUG|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
214826999|NCT05548465|DRUG|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
214827000|NCT05548465|DRUG|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
214827001|NCT05877274|OTHER|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
214827002|NCT03632031|DEVICE|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
214827003|NCT00911274|DRUG|Mycophenolate Mofetil|250 mg Capsule
214827004|NCT00911274|DRUG|CellCept®|250 mg Capsule
214827005|NCT00807495|DRUG|Alisertib|Alisertib capsules
214827006|NCT00870662|DEVICE|AFS System|AFS System with patient specific flow rate
214827007|NCT03198923|BIOLOGICAL|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
214827008|NCT04376203|PROCEDURE|Thyroidectomy|Typical Thyroidectomy
214827009|NCT05527639|BEHAVIORAL|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
214827010|NCT03822130|DRUG|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
214827011|NCT03822130|DRUG|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
214827012|NCT03822130|DRUG|Systemic Chemotherapy|Systemic Chemotherapy
214827013|NCT03822130|DRUG|Oral Chemotherapy|Oral Chemotherapy
214827014|NCT02412852|DRUG|Sodium nitrite|Sustained release formulation of sodium nitrite
214827015|NCT02412852|DRUG|Placebo|Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
214827016|NCT04737863|PROCEDURE|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
214827017|NCT03142022|OTHER|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
214827018|NCT05198622|PROCEDURE|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
214827019|NCT05198622|PROCEDURE|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
214827020|NCT01237691|BEHAVIORAL|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
214827021|NCT01237691|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
214827022|NCT01555086|PROCEDURE|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
214827023|NCT01555086|PROCEDURE|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
214827024|NCT06354023|DRUG|Recombinant human growth hormone|All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
214827025|NCT03601403|DEVICE|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
214827026|NCT00003223|DRUG|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
214827027|NCT05921864|OTHER|Passive heat exposure|Participants will be exposed to heat in a chamber.
214827028|NCT05921864|OTHER|Active heat exposure|Participants will participate to a 6-hour run.
214827029|NCT05724784|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
214827030|NCT01844843|DEVICE|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
214827031|NCT05600894|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
214827032|NCT05600894|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214827033|NCT05600894|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214827034|NCT05600894|DRUG|Decitabine and Cedazuridine|Given PO
214827035|NCT05600894|DRUG|Venetoclax|Given PO
214827036|NCT06476977|PROCEDURE|Dorsal webspace combined corticosteroid and anesthetic injection|The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
214827037|NCT06476977|PROCEDURE|Palmar combined corticosteroid and anesthetic injection|The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
214827038|NCT05726669|OTHER|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
214827039|NCT01306838|DIETARY_SUPPLEMENT|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
214827040|NCT01306838|OTHER|Routine care|Routine care
214827041|NCT06306404|DRUG|Estrogens and Progestogens|"Menopausal Hormone Therapy, formerly known as Hormone Replacement Therapy (HRT), is a medical treatment that involves the use of hormones to relieve the symptoms of menopause and to reduce the risk of certain long-term health conditions associated with menopause. Menopause is a natural biological process that occurs when a women's ovaries stop producing effects, and her estrogen and progesteron hormone levels subsequently decrease. MHT typically involves administration of a combination of sec steroids.~In this study MHT consists of estradiol transdermal patches (50 mcg (Systen), which provide a stable release of estradiol and lead to more stable blood levels. This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT guidelines."
214827042|NCT06306404|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy|"CBTi is a guided, internet-based cognitive behavioral therapy program for insomnia, containing information and exercises on sleep. It consists of five online sessions:~1. Psycho-education on sleep, disordered sleep and sleep hygiene (i.e. general guidelines about health and environmental factors influencing sleep),~2. Sleep restriction (i.e. restrict time in bed to the average sleep time) and stimulus control training (i.e. reinforce association of bed with sleeping),~3. Rumination and relaxation techniques,~4. Cognitive restructuring (i.e. changing misconceptions about sleep),~5. Relapse prevention."
214827043|NCT00583999|OTHER|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
214827044|NCT00841542|DRUG|Amlodipine Besylate|10 mg Tablet
214827045|NCT00841542|DRUG|Norvasc®|10 mg Tablet
214827046|NCT06563037|OTHER|No intervention|This is an observational study
214827047|NCT01554007|OTHER|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
214827048|NCT03730272|DRUG|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
214827049|NCT01242098|DRUG|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
214827050|NCT01242098|DRUG|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
214827051|NCT04811235|DEVICE|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
214827052|NCT00849823|BEHAVIORAL|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
214827053|NCT00849823|BEHAVIORAL|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
214827054|NCT03564587|BEHAVIORAL|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
214827055|NCT05149209|PROCEDURE|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
214827056|NCT05770388|DEVICE|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
214827057|NCT05770388|BEHAVIORAL|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
214827058|NCT01395628|DRUG|in vitro sensitivity-directed chemotherapy|
214827059|NCT01395628|OTHER|cell proliferation assay|
214827060|NCT01395628|OTHER|fluorescence activated cell sorting|
214827061|NCT01395628|OTHER|laboratory biomarker analysis|
214827062|NCT01395628|OTHER|microscopy|
214827063|NCT03098901|DIAGNOSTIC_TEST|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
214827064|NCT01876667|OTHER|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
214827065|NCT01876667|OTHER|Placebo|Usual Care
214827066|NCT01169753|DRUG|Placebo|Oral tablet every morning for 2 weeks
214827067|NCT01169753|DRUG|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
214827068|NCT06557954|DIAGNOSTIC_TEST|human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)|PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
214827069|NCT05347953|DEVICE|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
214827070|NCT00170677|DRUG|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
214827071|NCT00170677|DRUG|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
214827072|NCT00755677|OTHER|Pulses|subjects consume 1 pulse food daily for eight weeks
214827073|NCT05074745|DIAGNOSTIC_TEST|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
214827074|NCT02729987|BEHAVIORAL|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
214827075|NCT01403363|DRUG|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
214827076|NCT04029545|DEVICE|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
214827077|NCT03928405|OTHER|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
214827078|NCT01756807|DEVICE|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
214827079|NCT06476093|DRUG|Anlotinib hydrochloride|Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
214827080|NCT00779519|DRUG|TTP435|
214827081|NCT00779519|DRUG|Placebo|
214827082|NCT02482922|OTHER|Exercise & Dietary Supplement|
214827083|NCT01749553|OTHER|Sleeper Stretch|Posterior shoulder stretch technique
214827084|NCT00924638|DEVICE|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
214827085|NCT06451653|BEHAVIORAL|Men in Maternity Health (MiM) Intervention|The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
214827086|NCT00051779|DRUG|CAL|
214827087|NCT04237415|PROCEDURE|EMG biofeedback training|
214827088|NCT01463579|OTHER|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
214827089|NCT01463579|OTHER|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
214827090|NCT00064090|DRUG|cytarabine|
214827091|NCT00064090|DRUG|triapine|
214827092|NCT05073380|BEHAVIORAL|Intervention Group - PRO-ECO Intervention|The PRO-ECO intervention will be tailored to individual sites. Through collection of focus group and baseline data, the intervention will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective interventions outlined in the literature have informed the development of the intervention foundation and potential tailoring.
214827093|NCT05073380|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO intervention.
214827094|NCT01007994|DRUG|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"
214827095|NCT00283764|DRUG|Xalatan|
214827096|NCT00408616|BIOLOGICAL|Grazax-R|Grass tablet, 75.000 SQ per day for one year
214827097|NCT00408616|BIOLOGICAL|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
214827098|NCT02491853|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
214827099|NCT03119077|DRUG|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
214827100|NCT03119077|DRUG|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
214827101|NCT03119077|DRUG|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
214827102|NCT03296956|DIETARY_SUPPLEMENT|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
214827103|NCT03296956|OTHER|Placebo|Matching placebo for appearance, taste
214827104|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
214267756|NCT01501175|OTHER|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
214827105|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
214827106|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
214827107|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
214827108|NCT03066544|DRUG|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
214827109|NCT03066544|DRUG|Naratriptan Pill|one pill will be administered twice each day for 5 days
214827110|NCT03066544|DRUG|Dexamethasone|one tablet will be administered twice each day for 3 days
214267757|NCT03109249|DRUG|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
214267758|NCT03109249|DRUG|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
214267759|NCT00989560|PROCEDURE|endoscopy|patients receive best treatment and care with an additional endoscopy
214267760|NCT03019575|DRUG|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
214827111|NCT03066544|DRUG|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
214827112|NCT01728480|DRUG|entolimod|Given SC
214827113|NCT01728480|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214827114|NCT01728480|DRUG|cisplatin|Given IV
214827115|NCT01728480|OTHER|pharmacological study|Correlative studies
214827116|NCT01728480|OTHER|laboratory biomarker analysis|Correlative studies
214827117|NCT04411680|DRUG|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
214827118|NCT04411680|DRUG|Standard of care|Standard of care for COVID-19
214827119|NCT05294276|OTHER|no intervention related|no intervention related
214827120|NCT00748566|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
214827121|NCT04471116|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
214827122|NCT02182596|DRUG|Mylotarg|Dose level study
214827123|NCT05001958|BEHAVIORAL|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
214827124|NCT00137735|DRUG|Gabapentin|300mg tds
214827125|NCT00137735|OTHER|placebo|tds
214827126|NCT00624286|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214827127|NCT00624286|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214827128|NCT05802563|DEVICE|fitness tracker|Study subjects will wear a Fitbit fitness tracker
214827129|NCT01676064|DRUG|ringer lactate solution|
214827130|NCT01676064|OTHER|restrictive fluid regime|
214827131|NCT00841659|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
214827132|NCT00841659|DRUG|Paxil®|40 mg Film-Coated Tablet
214827133|NCT03810937|OTHER|head position|head positioning in sniffing or flat position
214827134|NCT05836311|DEVICE|One Perclose Proglide Suture|One Perclose Proglide Suture
214827135|NCT05836311|DEVICE|Two Perclose Proglide Suture|One Perclose Proglide Suture
214827136|NCT02331511|DRUG|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
214827137|NCT02331511|DRUG|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
214827138|NCT02331511|DRUG|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
214827139|NCT03444883|DRUG|Ilaprazole|10mgx2 tablet once daily for weeks
214827140|NCT04207528|BEHAVIORAL|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
214827141|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
214827142|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
214827143|NCT05492032|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
214827144|NCT05492032|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
214827145|NCT05492032|BEHAVIORAL|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
214827146|NCT04298151|DRUG|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
214827147|NCT04298151|DRUG|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
214827148|NCT05730920|DRUG|Methadone|IV Methadone
214827149|NCT05730920|DRUG|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
214827150|NCT01293097|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
214827151|NCT01293097|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
214827152|NCT03612154|DRUG|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
214827153|NCT03993145|BEHAVIORAL|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
214827154|NCT06562998|DRUG|Pentoxifylline|Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
214827155|NCT04889898|DEVICE|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|\[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
214827156|NCT04889898|RADIATION|Modified Barium Swallow Study (MBSS)|\[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
214827157|NCT04889898|BEHAVIORAL|Speech Intelligibility Test (SIT)|\[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
214827158|NCT04889898|BEHAVIORAL|SIT Scoring|\[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
214827159|NCT01159145|DRUG|D961H|Oral, capsule
214827160|NCT01159145|DRUG|Omeprazole|Oral, tablet
214827161|NCT06102850|BEHAVIORAL|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
214827162|NCT06319625|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
214827163|NCT06319625|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214827164|NCT06319625|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214827165|NCT06319625|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214827166|NCT00205686|DRUG|DHEA|
214827167|NCT00205686|BEHAVIORAL|exercise|
214827168|NCT04296994|BIOLOGICAL|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
214827169|NCT00568672|DRUG|Olanzapine|Olanzapine 5 mg / day for 6 months
214267761|NCT03019575|DRUG|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
214267762|NCT00794378|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
214267763|NCT00794378|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
214267764|NCT05487144|BEHAVIORAL|Learning in a Virtual Environment (LIVE)|Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
214827170|NCT05748535|DEVICE|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
214827171|NCT03227991|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
214827172|NCT03227991|BEHAVIORAL|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
214827173|NCT05633745|DRUG|NEU-723|Oral Doses
214827174|NCT05633745|DRUG|Placebo|Oral Doses
214827175|NCT00495222|PROCEDURE|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
214267765|NCT02208479|OTHER|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
214267766|NCT01325961|RADIATION|Intensity-Modulated Radiation Therapy|
214827176|NCT00495222|DEVICE|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
214827177|NCT00495222|DEVICE|Tissue Plication|Tissue plication for GJ stoma reduction
214827178|NCT00073307|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
214827179|NCT00073307|DRUG|Placebo|Placebo
214827180|NCT01375309|DIETARY_SUPPLEMENT|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
214827181|NCT01375309|DIETARY_SUPPLEMENT|Placebo contains dextrin|0.5 of dextrin
214827182|NCT06187142|BEHAVIORAL|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
214827183|NCT06187142|BEHAVIORAL|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
214827184|NCT06187142|BEHAVIORAL|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
214827185|NCT06187142|BEHAVIORAL|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
214827186|NCT06187142|BEHAVIORAL|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
214827187|NCT06187142|BEHAVIORAL|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
214827188|NCT06187142|BEHAVIORAL|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
214827189|NCT01438060|DRUG|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
214827190|NCT01438060|DRUG|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
214827191|NCT01215760|OTHER|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
214827192|NCT01215760|OTHER|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
214827193|NCT06166862|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
214827194|NCT06166862|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
214827195|NCT03616691|DRUG|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
214827196|NCT03616691|DRUG|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
214827197|NCT05237830|PROCEDURE|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
214827198|NCT04404725|DEVICE|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
214267767|NCT00533897|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
214267768|NCT00533897|DRUG|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
214267769|NCT03479970|OTHER|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
214267770|NCT03479970|OTHER|GNPT|It's a computeritzed program of cognitive telerehabilitation
214827199|NCT04404725|DEVICE|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
214827200|NCT02711644|BEHAVIORAL|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
214827201|NCT02711644|BEHAVIORAL|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
214827202|NCT03456544|DRUG|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
214827203|NCT06202755|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214827204|NCT06202755|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214827205|NCT00264134|DRUG|Docetaxel|
214827206|NCT00264134|DRUG|Irinotecan|
214827207|NCT00264134|DRUG|Carboplatin|
214267771|NCT02040493|RADIATION|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
214827208|NCT00834405|DRUG|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
214827209|NCT00834405|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
214827210|NCT00509990|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214827211|NCT05080387|OTHER|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
214827212|NCT03170622|DIAGNOSTIC_TEST|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
214827213|NCT00794547|DRUG|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
214827214|NCT00794547|DRUG|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
214827215|NCT06559761|PROCEDURE|Hepatectomy|According to guideline recommended procedure of hepatectomy
214827216|NCT04033705|DEVICE|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
214827217|NCT02050685|OTHER|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
214827218|NCT00685477|DRUG|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
214827219|NCT00685477|DRUG|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
214827220|NCT00685477|DRUG|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
214827221|NCT00685477|DRUG|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
214827222|NCT00685477|DRUG|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
214267772|NCT00426790|PROCEDURE|Positive end-expiratory pressure|
214267773|NCT00187577|DRUG|Latanoprost (Xalatan)|
214267774|NCT00187577|DRUG|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
214267775|NCT00187577|DRUG|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
214827223|NCT00685477|DRUG|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
214827224|NCT05313217|DIAGNOSTIC_TEST|Knee extension angle|"Knee Extension Angle (KEA):~* This test will be administered with an ankle-foot orthosis (AFO) maintaining the participants ankle in neutral.~* The participant will lie supine on the examination table with the contralateral lower extremity (LE) stabilized on the support surface using a mobilization strap.~* The hip of the lower being examined will be flexed to 90 degrees.~* The participant will then actively straighten their lower leg while maintaining upper leg in same position~* Once the participant feels they are at maximal knee extension (patient instructed to straighten leg as far as what is comfortable), the angle will be measured with iPhone Inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
214827225|NCT05313217|DIAGNOSTIC_TEST|Straight Leg Raise|"Straight Leg Raise (SLR):~* Position the participant in supine on the plinth with knees extended and L LE strapped to the plinth~* The participant will keep the AFO donned on the R distal ankle to keep the ankle in neutral position.~* A researcher will passively lift the participant's right leg moving at a slow but consistent pace of approximately 15 degrees per second, while keeping it straight until a significant resistance is detected or the participant reports a production of symptoms, whichever occurs first.~* Measurement of the SLR angle will be assessed with iPhone inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
214827226|NCT05313217|DIAGNOSTIC_TEST|Slump Test|"Slump Test Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant will sequentially flex trunk, look down at the floor~* Participant will extend R knee until symptoms are felt. Measure of angle with iPhone inclinometer placed at superior aspect of medial malleolus~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
214267776|NCT00020904|DRUG|ixabepilone|
214827227|NCT05313217|DIAGNOSTIC_TEST|Extended slump test|"Extended Slump Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant is asked to arch their lower back into maximal extension in sitting, stabilized to research bench to maintain hyper-lordosis posture.~* The participant is asked first flex cervical spine, then to extend their knee until it reaches full ROM or symptoms are felt that limit ROM.~* Knee extension ROM is assessed with iPhone inclinometer at superior aspect of medial malleolus.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
214827228|NCT04306952|BEHAVIORAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
214827229|NCT04306952|BEHAVIORAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
214827230|NCT04306952|BEHAVIORAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
214827231|NCT01001403|DRUG|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
214827232|NCT01001403|DRUG|Normal saline|10 ml of normal saline
214827233|NCT06431321|BEHAVIORAL|Tabudira Parenting Intervention for Early Childhood Development|2 session programme delivered weekly over 2 weeks using group-based delivery aimed at reducing child maltreatment, improving parenting behaviours and parent's mental health.
214827234|NCT06431321|OTHER|Nutritional guide for younger children|2 session programme delivered weekly over 2 weeks aimed at providing parents with nutritional education to help provide maximum nutrition to the growing child
214827235|NCT05315063|OTHER|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
214827236|NCT05315063|OTHER|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
214827237|NCT04142918|OTHER|Immunostaining|Immunostaining of oral mucosa/gingiva samples
214827238|NCT02537457|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
214827239|NCT02537457|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
214827240|NCT05351957|PROCEDURE|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
214827241|NCT01190865|BIOLOGICAL|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
214827242|NCT05374057|OTHER|Chiropractic spinal manipulative therapy (CSMT)|See study arm.
214827243|NCT05374057|OTHER|CSMT sham manipulation|See study arm.
214827244|NCT05374057|DRUG|Ibuprofen|See study arm.
214827245|NCT05374057|DRUG|Placebo medication|See study arm.
214827246|NCT00326872|DRUG|Cediranib Maleate|
214827247|NCT06516172|OTHER|Comprehensive disease-specific rehabilitation|"Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes."
214827248|NCT01902394|OTHER|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
214827249|NCT01902394|OTHER|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
214827250|NCT01045681|DRUG|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
214827251|NCT02436200|DEVICE|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
214827252|NCT00957021|DEVICE|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
214827253|NCT00746421|DRUG|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
214827254|NCT00746421|DRUG|Placebo|200mg, 300mg or 400mg
214827255|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
214827256|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
214267777|NCT02299830|PROCEDURE|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
214267778|NCT02299830|PROCEDURE|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
214267779|NCT02299830|PROCEDURE|stent placement|use stent placement to open the airway compressed by out neoplasm
214267780|NCT02299830|PROCEDURE|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
214827257|NCT00108043|PROCEDURE|FES-evoked functional upright gait|
214827258|NCT01822119|DEVICE|Baha Attract System|
214827259|NCT05510141|OTHER|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
214827260|NCT05510141|DRUG|Nitrous oxide|Standard procedure
214827261|NCT02000388|DRUG|Ketorolac Tromethamine|
214827262|NCT02000388|OTHER|Standard of Care|
214827263|NCT02294305|DRUG|Vortioxetine|
214827264|NCT02294305|DRUG|Placebo|
214827265|NCT04386577|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
214827266|NCT04386577|DRUG|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
214827267|NCT02174926|PROCEDURE|Elective laparoscopic sigmoid resection|
214827268|NCT02174926|DIETARY_SUPPLEMENT|Conservative treatment|Written lifestyle guidance and fiber supplements
214827269|NCT04937439|OTHER|Traditional Physical Therapy program|"1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting"
214827270|NCT04937439|OTHER|Segmental trunk training A|Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
214827271|NCT04937439|OTHER|Segmental trunk training B|Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
214827272|NCT04937439|OTHER|Segmental trunk training C|Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
214827273|NCT00205621|DEVICE|Positron Emission Tomography|
214827274|NCT01483820|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
214827275|NCT05204420|PROCEDURE|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
214827276|NCT00867360|DRUG|Mifepristone (RU-486)|
214827277|NCT00867360|DRUG|Placebo|Placebo medication
214827278|NCT04673825|OTHER|Patient initiated care + telemonitoring|See arm/group descriptions.
214827279|NCT04074707|DIETARY_SUPPLEMENT|Labeled iron solution (60mg and 120mg Ferrous Fumarate)|3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
214827280|NCT05604209|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered intramuscularly (IM) at Day 0
214827281|NCT05604209|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered intramuscularly (IM) at Day 0
214827282|NCT05604209|BIOLOGICAL|MVA.tHIVconsv4|Administered intramuscularly (IM) at Day 28
214827283|NCT05604209|BIOLOGICAL|MVA.tHIVconsv3|Administered intramuscularly (IM) at Day 28
214827284|NCT05604209|OTHER|Placebo|Administered at intramuscularly (IM) Day 0 and Day 28
214827285|NCT05812625|OTHER|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
214827286|NCT05812625|OTHER|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
214827287|NCT02986256|BEHAVIORAL|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
214827288|NCT02986256|BEHAVIORAL|Visit at home|Home visit by the referring nurse every 15 days
214827289|NCT04783337|DIAGNOSTIC_TEST|HR-pQCT (high resolution computertomograph)|In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
214827290|NCT04783337|DIAGNOSTIC_TEST|Blood withdrawal|Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
214827291|NCT00112437|DRUG|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
214827292|NCT00112437|DRUG|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
214827293|NCT00112437|DRUG|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
214827294|NCT00112437|DRUG|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
214827295|NCT00112437|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
214827296|NCT00112437|DIETARY_SUPPLEMENT|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
214827297|NCT00112437|DRUG|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
214827298|NCT02011828|DRUG|Ergocalciferol|50,000 IU/week
214827299|NCT02011828|DRUG|Placebo|Placebo tablet
214827300|NCT00531128|BEHAVIORAL|High/Low Sitosterol|
214827301|NCT02440997|OTHER|aromatherapy|
214827302|NCT02440997|OTHER|foot bath|
214827303|NCT04840927|DRUG|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
214827304|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
214827305|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
214827306|NCT03610386|OTHER|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
214827307|NCT03610386|OTHER|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
214827308|NCT02336308|DRUG|Ketamine|
214827309|NCT02336308|DRUG|Placebo, Normal Saline|
214827310|NCT05377164|BEHAVIORAL|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
214827311|NCT03873363|DEVICE|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
214827312|NCT03873363|DEVICE|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
214827313|NCT02363764|PROCEDURE|Nasal swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
214827314|NCT02363764|PROCEDURE|Cough swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
214827315|NCT02363764|PROCEDURE|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~\- Expectorating CF patients"
214827316|NCT02363764|PROCEDURE|Induced sputum|"Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients"
214827317|NCT02363764|PROCEDURE|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~\- Bronchoscopy CF patients"
214827318|NCT02363764|OTHER|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
214827319|NCT02253329|PROCEDURE|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
214827320|NCT02253329|PROCEDURE|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
214827321|NCT00512811|DRUG|furosemide|
214827322|NCT00834353|DRUG|ATT|
214827323|NCT03045536|DEVICE|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
214827324|NCT06464926|DEVICE|Enterra Therapy System|"The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options."
214827325|NCT00427154|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
214827326|NCT00427154|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
214827327|NCT00427154|DRUG|metformin|Tablets, 2000 mg/day.
214827328|NCT00427154|DRUG|glimepiride|Tablets, 8 mg/day.
214827329|NCT00000205|DRUG|Buprenorphine|
214827330|NCT03646409|OTHER|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
214827331|NCT01376596|BEHAVIORAL|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
214827332|NCT01376596|BEHAVIORAL|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
214827333|NCT04752605|BEHAVIORAL|Finnish ENGAGE together|Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
214827334|NCT03285438|DRUG|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
214827335|NCT03285438|DRUG|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
214827336|NCT04054258|DEVICE|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
214827337|NCT01654419|DEVICE|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
214827338|NCT01654419|DEVICE|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
214827339|NCT02878148|DEVICE|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
214827340|NCT04255433|DRUG|Tirzepatide|Administered SC
214827341|NCT04255433|DRUG|Dulaglutide|Administered SC
214827342|NCT01112462|DRUG|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
214827343|NCT01112462|DRUG|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
214827344|NCT01960296|DRUG|Clopidogrel|Continue home dose of clopidogrel into surgery
214827345|NCT01960296|DRUG|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
214827346|NCT02003391|DRUG|Beta-blocker monotherapy|Per participant's current prescribed therapy
214827347|NCT02003391|DRUG|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
214827348|NCT04894630|OTHER|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
214827349|NCT01949324|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
214827350|NCT01949324|PROCEDURE|Sham procedure|Sham surgery for Sham arm
214827351|NCT01949324|DEVICE|NT-501 Implant|NT-501 encapsulated cell implant
214827352|NCT01949324|PROCEDURE|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
214827353|NCT02144844|BEHAVIORAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
214827355|NCT03653299|DEVICE|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
214827356|NCT03076437|COMBINATION_PRODUCT|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
214827357|NCT02272803|DRUG|Lenalidomide|
214827358|NCT02272803|DRUG|Dexamethasone|
214827359|NCT02272803|BIOLOGICAL|Elotuzumab (BMS-901608)|
214827360|NCT06463119|OTHER|Collection of data in a registry|The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
214827361|NCT02577458|DRUG|CM082|CM082 tablets taken orally once a day on 28-day cycles
214827362|NCT02577458|DRUG|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
214827363|NCT05432115|DRUG|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
214827364|NCT03573544|DRUG|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
214827365|NCT03573544|DRUG|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
214827366|NCT03573544|DEVICE|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
214827367|NCT00246792|BEHAVIORAL|Group treatment|
214827368|NCT02736019|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
214827369|NCT02736019|DRUG|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
214827370|NCT02736019|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
214827371|NCT02736019|DRUG|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
214827372|NCT04443998|DEVICE|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
214827373|NCT04584749|DRUG|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
214827374|NCT03846193|BIOLOGICAL|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
214827375|NCT03846193|DEVICE|GT005 / Device: Orbit™ Subretinal Delivery System|"GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).~A single dose of GT005 was administered with subretinal injection via suprachoroidal cannulation approach.~Device: Orbit™ Subretinal Delivery System"
214827376|NCT04693429|DRUG|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
214827377|NCT05114512|OTHER|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
214827378|NCT02389595|OTHER|HIV positive subjects|This group will provide a blood sample.
214827379|NCT02389595|OTHER|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
214827380|NCT01847235|DRUG|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
214827381|NCT06809140|DRUG|Enfortumab vedotin|1.25 mg/kg (maximum dose 125 mg)
214827382|NCT06809140|DRUG|Pembrolizumab|200 mg
214827383|NCT07125664|BIOLOGICAL|alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion)|IV Prolastin administered once at 120 mg per kilogram of body weight
214827384|NCT07125664|DRUG|Placebo|\+ IV administration of 0.9% sodium chloride
214827385|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
214827386|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
214827387|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
214827388|NCT02377778|DRUG|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
214827389|NCT02377778|DRUG|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
214827390|NCT01065610|DRUG|Oxytocin|
214827391|NCT01065610|DRUG|Placebo|
214827392|NCT04778501|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
214827393|NCT01502696|BIOLOGICAL|PEG IFN alfa-2b|3µg/kg weekly injections
214827394|NCT06460272|OTHER|Medically Tailored Meals|Meals culturally tailored to provide essential nutrition
214827395|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through peripheral veins|Umbilical cord-mesenchymal stem cells injected through peripheral veins
214827396|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through hepatic artery|Umbilical cord-mesenchymal stem cells injected through hepatic artery
214827397|NCT06817265|DRUG|TNTL|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
214827398|NCT06817265|DRUG|TNTL simulation preparation|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
214827399|NCT04492553|DRUG|AndroGel|Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
214827400|NCT04917419|OTHER|Luminotherapy and /or Psychoeducation Program|TO complete
214827401|NCT01381653|OTHER|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
214827402|NCT01186835|PROCEDURE|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
214827403|NCT01186835|PROCEDURE|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
214827404|NCT00902538|DRUG|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
214827405|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
214827406|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
214827407|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
214827408|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
214827409|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
214827410|NCT02337322|DRUG|Dolutegravir|
214827411|NCT02337322|DRUG|Darunavir/r|
214827412|NCT06601439|OTHER|Observational Study|Observational Study
214827413|NCT06598956|DRUG|TQ05105|TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
214827414|NCT06979856|BEHAVIORAL|Short animated video|The short animated video (approximately 2 minutes) draws a parallel between cigarette addiction and smartphone addiction.
214827415|NCT06979856|BEHAVIORAL|Informational Control|A short fact sheet presenting written information and statistics about smartphone usage.
214827416|NCT03986463|OTHER|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
214827417|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
214827418|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
214827419|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
214827420|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
214827421|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214827422|NCT06996782|DRUG|Rilvegostomig|Rilvegostomig will be administered as an intravenous (IV) infusion.
214827423|NCT06996782|DRUG|AB248|AB248 will be administered via syringe or an IV bag.
214827424|NCT06996782|DRUG|Cisplatin|Cisplatin will be administered as SoC as an IV infusion.
214827425|NCT06996782|DRUG|Carboplatin|Carboplatin will be administered as SoC as an IV infusion.
214827426|NCT06996782|DRUG|Pemetrexed|Pemetrexed will be administered as SoC as an IV infusion.
214827427|NCT06996782|DRUG|Paclitaxel|Paclitaxel will be administered as SoC as an IV infusion.
214827428|NCT06996782|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as SoC as an IV infusion.
214827429|NCT06996782|DRUG|Ramucirumab|Ramucirumab will be administered as an IV infusion.
214827430|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
214827431|NCT00725322|DRUG|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
214827432|NCT00725322|DRUG|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
214827433|NCT03835767|OTHER|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
214827434|NCT03835767|OTHER|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
214827435|NCT03835767|OTHER|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
214827436|NCT03835767|OTHER|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
214827437|NCT01125072|OTHER|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
214827438|NCT01350557|OTHER|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
214827439|NCT01350557|OTHER|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
214827440|NCT05331508|BEHAVIORAL|gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)|Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
214827441|NCT02612298|DRUG|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
214827442|NCT02612298|DRUG|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
214827443|NCT02252120|DEVICE|Supreme|
214827444|NCT02252120|DEVICE|Laryngeal Tube|
214827445|NCT06683846|DRUG|Ivocizumab|Administered via intravenous (IV) infusion
214827446|NCT07015086|BEHAVIORAL|Guided Imagery and Positive Birth Experience Sharing|The positive experience will be shared by one of the researchers and the pregnant women's questions will be answered after the sharing. The mental imagery techniques prepared by Rossman (2015) to facilitate birth will be used for the mental imagery application. After the training, the mental imagery instructions will be given to the pregnant women as an audio recording in mp3 format. The pregnant women will be asked to do the mental imagery once or twice a day for at least 8 weeks. The mental imagery application takes approximately 20 minutes. The pregnant women will be reminded to do the application every day via the Whatsapp® application. The pregnant women will be asked to mark whether they do the application every day or not on the weekly follow-up chart.
214827447|NCT05288686|PROCEDURE|sentinel lymph node biopsy procedure|Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
214827448|NCT06415903|DRUG|TQB3117 tablets|TQB3117 is a protein inhibitor.
214827449|NCT00880139|PROCEDURE|Blood sampling|Determination of cytokine plasma levels (ELISA)
214827450|NCT00880139|PROCEDURE|Noninvasive measurement of systemic hemodynamics|performed once
214827451|NCT00880139|PROCEDURE|Visual acuity assessment|ETDRS charts
214827452|NCT00880139|DEVICE|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
214827453|NCT00880139|PROCEDURE|Ophthalmic examination and fundus photography|7 + 1 standard fields
214827454|NCT00880139|DEVICE|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
214827455|NCT00880139|DEVICE|High resolution optical coherence tomography (OCT)|performed once
214827456|NCT00440934|DEVICE|Amplitude-modulated electromagnetic fields|
214827457|NCT00926887|DEVICE|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
214827458|NCT00926887|DEVICE|Placebo Laser|Inactive light
214827459|NCT05204368|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
214827460|NCT05204368|DRUG|Meropenem|Meropenem 1g for injection
214827461|NCT03191305|DRUG|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
214827462|NCT03191305|DRUG|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
214827463|NCT01802645|DRUG|Cetuximab|
214827464|NCT01802645|DRUG|Bevacizumab|
214827465|NCT01802645|DRUG|Irinotecan|
214827466|NCT01802645|DRUG|Oxaliplatin|
214827467|NCT01802645|DRUG|5-FU|
214827468|NCT01802645|DRUG|Folinic Acid|
214827469|NCT06503666|BEHAVIORAL|ZAIMARA|"The ZAIMARA curriculum focuses on strengthening communication between adolescent girls and young women (AGYW) and their mother figures (MF) to make healthy sexual decisions, to learn more about HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP). The topics in the curriculum focus on effective communication, mothers talking to daughters on sex, HIV, STIs and PrEP. The intervention consists of participants attending a two day workshops with their MF.~Other names:~ZAIMARA"
214827470|NCT06503666|BEHAVIORAL|Health Promotion|"The health promotion (HP) curriculum focuses on healthy living by encouraging good nutrition, improving knowledge on violence recognition, management and support/resources, exercise, informed consumer behavior, alcohol and substance use.The intervention consists of participants attending a two day workshops with their MF.~Other names:~HP"
214267781|NCT02646137|DRUG|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
214267782|NCT02646137|PROCEDURE|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
214827471|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
214827472|NCT03927495|RADIATION|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
214827473|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
214827474|NCT06408636|OTHER|Cardiac MRI|All selected patients completed a cardiac magnetic resonance examination without other interventions.
214827475|NCT01513044|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
214827476|NCT01513044|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
214827477|NCT04547179|DRUG|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
214827478|NCT04547179|DEVICE|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
214827479|NCT04547179|OTHER|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
214827480|NCT05226741|DEVICE|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
214827481|NCT01361334|DRUG|Pazopanib|800 mg QD p.o.
214827482|NCT02753985|OTHER|Survey|
214827483|NCT02577133|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
214827484|NCT02577133|DIETARY_SUPPLEMENT|Placebo|The placebo consisted of an identical bottle with distilled water
214827485|NCT02867085|OTHER|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
214827486|NCT04746976|DRUG|Diroximel Fumarate|As described in the arm.
214827487|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
214827488|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
214827489|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
214267783|NCT02646137|PROCEDURE|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
214827490|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
214827491|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
214827492|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
214267784|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
214267785|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
214827493|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
214827494|NCT03232541|OTHER|Standard care|A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
214827495|NCT03232541|DEVICE|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
214827496|NCT03232541|DEVICE|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
214827497|NCT06039605|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
214827498|NCT06830993|BEHAVIORAL|"Move More Personalized Exercise Program"|"Move More - a personalized exercise program involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aims to get participants to move more, by any means necessary."
214827499|NCT06830993|BEHAVIORAL|Intradialytic Exercise Program|"Those in the intradialytic exercise group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)."
214827500|NCT05124522|BEHAVIORAL|MSPA eClass|An 8-week MS-HAPA Internet-based intervention
214827501|NCT02658214|DRUG|paclitaxel + carboplatin|IV infusion
214827502|NCT02658214|DRUG|carboplatin + etoposide|IV infusion
214656451|NCT02272192|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
214827503|NCT02658214|DRUG|gemcitabine + carboplatin|IV infusion
214827504|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
214827505|NCT02658214|DRUG|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
214827506|NCT02658214|BIOLOGICAL|durvalumab|IV infusion
214827507|NCT02658214|BIOLOGICAL|tremelimumab|IV infusion
214827508|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
214827509|NCT02658214|DRUG|cisplatin + 5-fluorouracil (5FU)|IV infusion
214827510|NCT06205264|OTHER|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
214827511|NCT04130464|DRUG|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
214827512|NCT04130464|DRUG|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
214827513|NCT04130464|DRUG|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
214827514|NCT02509286|DRUG|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
214827515|NCT02509286|DRUG|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
214827516|NCT02509286|DRUG|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
214827517|NCT02509286|DRUG|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
214827518|NCT02509286|DRUG|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
214827519|NCT02509286|DRUG|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
214827520|NCT02509286|RADIATION|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
214827521|NCT00754507|DRUG|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
214827522|NCT00754507|DRUG|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
214827523|NCT05706415|DIAGNOSTIC_TEST|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
214827524|NCT04132115|DRUG|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827525|NCT04132115|DRUG|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827526|NCT04132115|DRUG|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827527|NCT04132115|DRUG|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827528|NCT04132115|DRUG|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214656452|NCT02272192|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
214827529|NCT04132115|DRUG|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
214827530|NCT04132115|DRUG|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
214827531|NCT04132115|DRUG|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
214827532|NCT04132115|DRUG|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827533|NCT04132115|DRUG|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
214827534|NCT04132115|DRUG|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
214827535|NCT02483195|DRUG|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
214827536|NCT02483195|DRUG|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
214827537|NCT02483195|DRUG|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
214827538|NCT02483195|OTHER|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
214827539|NCT01379313|PROCEDURE|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
214827540|NCT01379313|PROCEDURE|1:1 ratio|I:E ratio of 1:1 is applied.
214827541|NCT01379313|PROCEDURE|2:1 group|Inverse I:E ratio of 2:1 is applied.
214827542|NCT01379313|PROCEDURE|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
214827543|NCT00365053|DRUG|belinostat|Given IV
214827544|NCT00365053|OTHER|laboratory biomarker analysis|Correlative studies
214827545|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
214827546|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
214827547|NCT03318757|DRUG|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
214827548|NCT03318757|DRUG|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
214827549|NCT06312462|BEHAVIORAL|health education|In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
214827550|NCT00564031|DRUG|Femanest|2mg/day
214827551|NCT00564031|DRUG|gestapuran|5mg/day
214827552|NCT00564031|DRUG|placebo|daily
214827553|NCT00564031|DRUG|Femanest plus Gestapuran|combined daily
214827554|NCT04089462|BEHAVIORAL|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
214827555|NCT04089462|BEHAVIORAL|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
214827556|NCT00510393|DEVICE|XIENCE V everolimus eluting coronary stent system|
214827557|NCT00510393|DEVICE|MULTILINK VISION coronary stent system|
214827558|NCT04544800|DEVICE|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
214656453|NCT06657443|OTHER|First Session|Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
214656454|NCT06657443|OTHER|Second Session|Training of peer mentors on communication techniques, interview methods and empathic approach.
214656455|NCT06657443|OTHER|Third session|Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
214656456|NCT06657443|OTHER|Fourth session|Training of peer mentors on social motivation and leader-member interaction
214656457|NCT06657443|OTHER|Fifth Session|Sharing postcasts with peer mentors on social motivation and leader-member interaction.
214656458|NCT06657443|OTHER|Sixth Session|Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
214656459|NCT02315521|PROCEDURE|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
214656460|NCT04677270|BEHAVIORAL|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
214656461|NCT02240134|BEHAVIORAL|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
214656462|NCT02240134|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
214656463|NCT02240134|DEVICE|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
214656464|NCT05951179|BIOLOGICAL|TARA-002|All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
214656465|NCT06351631|DRUG|Bomedemstat|10, 15, 20, and 50 mg oral capsules
214656466|NCT05991973|DRUG|Chidamide|In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
214656467|NCT04546620|DRUG|R-CHOP|Arm A patients will receive R-CHOP alone.
214656468|NCT04546620|DRUG|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
214656469|NCT06364592|DEVICE|Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period)."
214656470|NCT06364592|DEVICE|Sham Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi."
214656471|NCT01382160|BIOLOGICAL|adalimumab|40 mg every two weeks, by subcutaneous way
214656472|NCT01956214|OTHER|FES Exercise|receive FES while exercising
214656473|NCT01956214|OTHER|Mock FES Exercise|participants will receive Mock FES
214656474|NCT01498133|PROCEDURE|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
214656475|NCT04378166|DEVICE|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
214656476|NCT05756192|OTHER|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
214656477|NCT00206726|DRUG|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
214827559|NCT00660660|DRUG|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
214827560|NCT00660660|DRUG|Placebo|once daily
214827561|NCT00566657|BIOLOGICAL|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
214827562|NCT00566657|BIOLOGICAL|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
214827563|NCT04581122|PROCEDURE|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
214827564|NCT00347048|DRUG|tacrolimus|oral
214827565|NCT00347048|DRUG|Placebo|oral
214827566|NCT01025141|DEVICE|Skeletal anchorage (MINISCREW)|Skeletal anchorage
214827567|NCT01025141|DEVICE|dental anchorage|dental anchorage (reference)
214827568|NCT03590119|DRUG|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
214827569|NCT05538858|PROCEDURE|Mechanical Ventilation|Positive pressure mechanical ventilation
214827570|NCT03594617|BEHAVIORAL|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
214827571|NCT04534985|BEHAVIORAL|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
214827572|NCT03414151|OTHER|Observation|No intervention administered.
214827573|NCT02282124|BEHAVIORAL|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
214827574|NCT02282124|BEHAVIORAL|Usual Care, containing one session|Session takes place within the first three months after transplantation
214827575|NCT06520904|DRUG|PCSK9 inhibitor|PCSK9 inhibitors combined with moderate-intensity statin therapy
214827576|NCT06520904|DRUG|Statin|Intensive statin therapy
214827577|NCT01569113|DRUG|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
214827578|NCT01569113|DRUG|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
214827579|NCT06677749|PROCEDURE|Eccentric resistance-exercise|Each participant will complete 300 repetitions of eccentric knee extensions using an isokinetic dynamometer after a baseline skeletal muscle biopsy is taken. Three hours following this, a second muscle biopsy will be taken to evaluate the changes in the dependent variables being measured (myokines).
214827580|NCT02428348|OTHER|Interview about prototype EEG-cap|
214827581|NCT00680940|DRUG|Paclitaxel & Cisplatin|Chemotherapeutic agent
214827582|NCT00680940|BIOLOGICAL|Mycobacterium w.|Immunomodulator
214827583|NCT03420092|DRUG|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
214827584|NCT03420092|DRUG|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
214827585|NCT03420092|DRUG|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
214827586|NCT03420092|DRUG|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
214827587|NCT03420092|DRUG|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
214827588|NCT03420092|DRUG|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
214827589|NCT02132910|OTHER|RESTORE Intervention|
214827590|NCT04857333|DIAGNOSTIC_TEST|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
214827591|NCT04857333|DRUG|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
214827592|NCT04857333|PROCEDURE|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
214827593|NCT04823533|DIETARY_SUPPLEMENT|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
214827594|NCT05385835|OTHER|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
214827595|NCT06137846|DEVICE|Air-Polish|Dental implant will be cleaned with an airpolishing device
214827596|NCT06137846|DEVICE|Ultrasonic|Dental implant will be cleaned with an ultrasonic device with a plastic tip
214827597|NCT01742403|RADIATION|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
214827598|NCT03375749|BEHAVIORAL|Standing desk intervention|Standing desk converter
214827599|NCT03375749|BEHAVIORAL|Waitlist control|Control
214827600|NCT03326167|OTHER|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
214827601|NCT04020016|DRUG|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
214827602|NCT04020016|DRUG|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
214827603|NCT05909241|DRUG|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
214827604|NCT03523650|DRUG|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
214827605|NCT03523650|DRUG|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
214827606|NCT05483608|OTHER|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
214827607|NCT05483608|OTHER|Recumbent cycling|Exercise using a recumbent cycle ergometer
214827608|NCT03256227|BEHAVIORAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
214827609|NCT03256227|BEHAVIORAL|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
214827610|NCT00114322|DEVICE|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
214656478|NCT06441708|OTHER|No intervention|No intervention on patient
214656479|NCT02369783|OTHER|Questionnaire and interview|The aim is to detect social fragility.
214656480|NCT04790942|DRUG|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
214656481|NCT04790942|BEHAVIORAL|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
214656482|NCT05103150|DIAGNOSTIC_TEST|High-definition white light endoscopy (HD-WLE)|"Evaluation of the duodenal mucosa with HD-WLE (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.~There were used the following standard endoscopic findings were: a) scalloping or dented aspect of the duodenal folds; b) submucosal vascular pattern; c) mosaicism or micronodular look of the mucosa; d) grooves and fissurations of the mucosa."
214656483|NCT05103150|DIAGNOSTIC_TEST|HD-WLE plus I-Scan optical enhancement (OE) virtual chromoendoscopy with High-definition optical magnification (HD-OM)|"Evaluation of the duodenal mucosa through upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves using a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode one and mode two without HD-OM to obtain an overview of the duodenal surface and identify any changes in the mucosa, then HD-OM will be implemented.~There were used OE criteria as previously validated by Cammarota et al: brightness, Ave/peak, blue, red, surface, contrast, and tone enhancement."
214656484|NCT01871506|BEHAVIORAL|Standard Care (SC)|"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
214656485|NCT01871506|BEHAVIORAL|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
214656486|NCT01973257|PROCEDURE|imaging diagnostics|
214656487|NCT04239417|OTHER|Graduated abdominal strengthening exercises|"1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing"
214656488|NCT04239417|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
214656489|NCT04239417|COMBINATION_PRODUCT|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
214656490|NCT04627740|DRUG|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
214656491|NCT06147024|OTHER|historical control|Received a conventional preoperative assessment
214827611|NCT05774522|OTHER|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
214827612|NCT05774522|OTHER|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
214827613|NCT05774522|OTHER|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
214827614|NCT00721916|DRUG|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
214827615|NCT00721916|DRUG|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
214827616|NCT04733508|DRUG|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
214827617|NCT04733508|DRUG|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
214827618|NCT05688358|DIAGNOSTIC_TEST|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
214827619|NCT02189603|BIOLOGICAL|Recombinant (E. Coli) Hepatitis E Vaccine|
214827620|NCT02244554|DEVICE|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
214827621|NCT04410705|OTHER|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
214827622|NCT04410705|OTHER|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
214827623|NCT04410705|OTHER|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
214827624|NCT01221649|DEVICE|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
214827625|NCT03815409|OTHER|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
214827626|NCT03815409|OTHER|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
214827627|NCT06043375|DIETARY_SUPPLEMENT|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
214827628|NCT01182519|BEHAVIORAL|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
214827629|NCT03121079|DRUG|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
214827630|NCT06660121|PROCEDURE|Electrochemotherapy with bleomycin|Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
214827631|NCT06819735|DRUG|DT-7012|Intravenous infusion
214827632|NCT06819735|DRUG|Immune checkpoint inhibitor|Intravenous infusion
214827633|NCT06395883|DRUG|Glucocorticoid Effect|Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
214827634|NCT02064673|DRUG|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
214827635|NCT02064673|DRUG|placebo|placebo orally twice a day
214827636|NCT04509596|DRUG|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
214827637|NCT02088931|BIOLOGICAL|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
214827638|NCT00834964|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
214827639|NCT00834964|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
214827640|NCT05095181|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214827641|NCT04101396|DIETARY_SUPPLEMENT|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
214827642|NCT02767804|DRUG|X-396 (ensartinib)|oral ALK inhibitor
214827643|NCT02767804|DRUG|crizotinib|oral ALK inhibitor
214827644|NCT01147939|DRUG|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
214827645|NCT01147939|DRUG|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
214827646|NCT05937841|DRUG|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
214827647|NCT02440607|OTHER|Electronic Cognitive Aid|
214827648|NCT02440607|OTHER|Static Cognitive Aid|
214827649|NCT04404439|DRUG|Nortriptyline + topiramate|Treatment group 1
214827650|NCT04404439|DRUG|Verapamil + paroxetine|Treatment group 2
214827651|NCT04404439|OTHER|Placebo|Placebo comparator
214827652|NCT06618339|BEHAVIORAL|Mindfulness-based intervention|8 Session Mindfulness-based intervention
214827653|NCT02722239|DRUG|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
214827654|NCT02722239|DRUG|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
214827655|NCT02722239|DRUG|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
214827656|NCT06356636|BEHAVIORAL|Financial Inclusion Improves Sanitation and Health|This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
214827657|NCT05411276|DRUG|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
214827658|NCT01899352|PROCEDURE|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
214827659|NCT01664767|OTHER|Sulfur Thermal water|
214827660|NCT01664767|OTHER|Placebo|
214827661|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
214267786|NCT00724022|DRUG|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
214827662|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
214827663|NCT00000653|DRUG|Zalcitabine|
214827664|NCT06371703|RADIATION|automated system in reducing radiation exposure|evaluate the effectiveness of the automated system in reducing radiation exposure for radiographers involved in PET/CT procedures.
214827665|NCT01876992|DRUG|Metformin|
214267787|NCT01394432|PROCEDURE|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
214267788|NCT05081154|OTHER|Product A|P1012915, a nicotine pouch with 8 mg nicotine
214267789|NCT05081154|OTHER|Product B|P1013018, a nicotine pouch with 10 mg nicotine
214267790|NCT05081154|OTHER|Product C|P1013015, a nicotine pouch with 8 mg nicotine
214267791|NCT05081154|OTHER|Product D|P1012815, a nicotine pouch with 8 mg nicotine
214267792|NCT05081154|OTHER|Product E|P1013315, a nicotine pouch with 8 mg nicotine
214827666|NCT04925791|DIAGNOSTIC_TEST|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
214827667|NCT04925791|DIAGNOSTIC_TEST|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
214827668|NCT04911218|DEVICE|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
214827669|NCT04911218|DEVICE|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
214827670|NCT02895802|BEHAVIORAL|Verbal instructions with picture diagram|verbal instructions and picture diagram
214827671|NCT02895802|BEHAVIORAL|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
214827672|NCT02895802|BEHAVIORAL|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
214827673|NCT02895802|BEHAVIORAL|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
214827674|NCT05098223|BEHAVIORAL|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
214267793|NCT05081154|OTHER|Product F|P1013115, a nicotine pouch with 8 mg nicotine
214267794|NCT05081154|OTHER|Product G|P1013215, a nicotine pouch with 8 mg nicotine
214656492|NCT06147024|OTHER|3D printed lesion model|Received 3D printed lesion models for preoperative planning
214656493|NCT00626873|DRUG|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
214656494|NCT00626873|OTHER|medical chart review|
214656495|NCT06368726|DEVICE|tDCS or Transcranial Direct Current Stimulation|We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
214656496|NCT06368726|DRUG|Risperidone|Risperidone Risperidone according to child's weighs
214656497|NCT04339868|DRUG|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
214656498|NCT04339868|DRUG|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
214656499|NCT01028352|DRUG|Duloxetine|"Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
214656500|NCT05738915|DIAGNOSTIC_TEST|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
214656501|NCT02670876|BEHAVIORAL|Anti-bullying intervention|"The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem"
214656502|NCT02718820|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
214656503|NCT02718820|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
214656504|NCT01816503|DRUG|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
214656505|NCT05388851|OTHER|Educational Intervention|Complete educational training module
214656506|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
214656507|NCT01083108|OTHER|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
214656508|NCT01083108|OTHER|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
214656509|NCT00006122|DRUG|cytarabine|
214656510|NCT00006122|DRUG|etoposide|
214656511|NCT00006122|DRUG|gemtuzumab ozogamicin|
214656512|NCT00006122|DRUG|idarubicin|
214656513|NCT00006122|DRUG|mitoxantrone hydrochloride|
214656514|NCT00755820|BEHAVIORAL|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
214656515|NCT00755820|BEHAVIORAL|Exposure Therapy + Placebo|Exposure therapy with placebo medication
214656516|NCT00755820|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy
214656517|NCT00975091|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
214656518|NCT00975091|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
214656519|NCT05741021|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
214656520|NCT05741021|DRUG|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
214656521|NCT05741021|DRUG|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
214656522|NCT05741021|DRUG|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
214656523|NCT03904927|OTHER|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
214656524|NCT03904927|DRUG|Systemic therapy|"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
214656525|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
214656526|NCT01121289|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
214656527|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
214827675|NCT04584138|BEHAVIORAL|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
214827676|NCT03371186|OTHER|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
214827677|NCT03371186|OTHER|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
214827678|NCT03371186|OTHER|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
214827679|NCT03371186|OTHER|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
214656528|NCT01121289|DRUG|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
214656529|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
214656530|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
214656531|NCT02979314|DEVICE|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
214656532|NCT01929252|DRUG|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
214656533|NCT01929252|DRUG|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
214656534|NCT01393587|PROCEDURE|Taking blood samples|
214656535|NCT02091440|DEVICE|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
214656536|NCT06325449|BEHAVIORAL|STREAM program|The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
214656537|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
214656538|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
214656539|NCT02144649|OTHER|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
214656540|NCT02144649|OTHER|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
214656541|NCT06109545|PROCEDURE|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
214656542|NCT05381402|OTHER|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
214656543|NCT02602509|DRUG|Celecoxib|
214656544|NCT02602509|DRUG|Rifampicin|
214656545|NCT02602509|DRUG|Pyrazinamide|
214656546|NCT00768222|DEVICE|silk suture|skin closure
214656547|NCT00768222|DEVICE|VICRYL* Plus suture|skin closure
214656548|NCT04153630|BIOLOGICAL|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
214656549|NCT00779129|DRUG|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
214656550|NCT00779129|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
214827680|NCT03371186|OTHER|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
214827681|NCT02270697|DEVICE|Array|Applications of oligonucleotide array in diagnosis.
214827682|NCT04180969|DRUG|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
214827683|NCT04180969|DEVICE|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
214827684|NCT04180969|DRUG|Placebo oral tablet|placebo stressor
214827685|NCT04180969|DEVICE|sham rTMS|sham mPFC rTMS
214827686|NCT05366582|DEVICE|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
214827687|NCT05366582|DEVICE|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
214827688|NCT06507176|PROCEDURE|flexible ureteroscopic lithotripsy|This group of patients underwent flexible ureteroscopic lithotripsy.
214827689|NCT06507176|PROCEDURE|percutaneous nephrolithotomy|This group of patients underwent percutaneous nephrolithotomy.
214827690|NCT01487720|DRUG|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
214827691|NCT02582190|DRUG|Colchicine group|antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
214827692|NCT00491738|DRUG|bevacizumab|Intravenous repeating dose
214827693|NCT00491738|DRUG|sunitinib|Oral repeating dose
214827694|NCT00491738|DRUG|placebo|Intravenous repeating dose
214827695|NCT00942838|DRUG|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
214827696|NCT00942838|RADIATION|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
214827697|NCT05293106|BIOLOGICAL|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
214827698|NCT05869136|PROCEDURE|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
214827699|NCT05869136|PROCEDURE|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
214827700|NCT03368209|DEVICE|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
214827701|NCT02694536|DRUG|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
214827702|NCT02694536|DRUG|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
214827703|NCT06307288|DRUG|minocycline|The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
214827704|NCT06307288|DRUG|tranilast|The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
214827705|NCT05912335|DRUG|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
214827706|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
214827707|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
214827708|NCT00385736|BIOLOGICAL|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
214827709|NCT00470379|DRUG|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
214827710|NCT04199494|OTHER|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
214827711|NCT00235560|DRUG|rapamycin|sirolimus
214827712|NCT01426360|OTHER|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
214827713|NCT01426360|OTHER|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
214827714|NCT02043392|DEVICE|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
214827715|NCT03695354|DEVICE|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
214827716|NCT03695354|PROCEDURE|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
214827717|NCT00664196|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
214827718|NCT03002935|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
214827719|NCT01662960|BEHAVIORAL|Mirror therapy|A home-based therapy involving mirrored visual feedback
214827720|NCT01662960|BEHAVIORAL|Divider therapy|A home-based therapy involving removed visual feedback.
214827721|NCT06144060|DRUG|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
214827722|NCT06144060|DRUG|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
214827723|NCT04381871|DIETARY_SUPPLEMENT|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
214827724|NCT04381871|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
214827725|NCT05282693|DIETARY_SUPPLEMENT|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
214827726|NCT05282693|DIETARY_SUPPLEMENT|Placebo|Lemon flavored liquid
214827727|NCT00213590|DRUG|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
214827728|NCT00433745|DRUG|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
214827729|NCT02967926|PROCEDURE|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
214827730|NCT01509391|DRUG|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
214827731|NCT02727192|DEVICE|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
214827732|NCT03050866|DRUG|Cabazitaxel|25mg/m2 q3w
214827733|NCT03050866|OTHER|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
214827734|NCT03050866|OTHER|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
214827735|NCT03050866|OTHER|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
214827736|NCT03050866|OTHER|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
214827737|NCT00595140|DRUG|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
214827738|NCT00595140|DRUG|combination with somatostatin analogue octreotide|s.c., 100µg, one time
214827739|NCT00595140|DRUG|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
214827740|NCT00928057|DEVICE|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
214827741|NCT00928057|DEVICE|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
214827742|NCT00928057|DEVICE|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
214827743|NCT03543735|BEHAVIORAL|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
214827744|NCT03543735|OTHER|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
214827745|NCT03461341|OTHER|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
214827746|NCT05278403|OTHER|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
214827747|NCT05278403|OTHER|Neurological physiotherapy|Application of conventional physical therapy techniques.
214827748|NCT06000579|OTHER|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
214827749|NCT04532996|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
214827750|NCT04544618|DEVICE|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
214827751|NCT04448730|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
214827752|NCT00845130|BIOLOGICAL|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
214827753|NCT05497557|DRUG|Omeprazole|Omeprazole will be administered as an oral capsule.
214827754|NCT05497557|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
214827755|NCT05274724|DIAGNOSTIC_TEST|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
214827756|NCT05274724|DIAGNOSTIC_TEST|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
214827757|NCT06316336|DRUG|Alfuzosin Hydrochloride 10 mg|Alfuzosin Hydrochloride 10 mg (test durg)
214827758|NCT06316336|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (reference drug)
214827759|NCT03081897|DRUG|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
214827760|NCT03081897|DRUG|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
214267795|NCT01694472|BIOLOGICAL|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
214267796|NCT04218825|DRUG|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
214267797|NCT00057317|DRUG|Ro 205-2349|
214267798|NCT04194398|DEVICE|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
214267799|NCT02555683|DRUG|QAW039|QAW039 150 mg once daily
214267800|NCT02555683|DRUG|QAW039|QAW039 450 mg once daily
214267801|NCT02555683|DRUG|Placebo|Placebo once daily
214827761|NCT03013036|DEVICE|Ultrasonography|
214827762|NCT03013036|DRUG|Sevoflurane|
214827763|NCT03013036|DRUG|intravenous midazolam|
214827764|NCT03013036|DRUG|Propofol|
214827765|NCT03013036|DRUG|fentanyl and rocuronium|
214827766|NCT04991610|RADIATION|computed tomography|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
214827767|NCT00629122|DRUG|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
214827768|NCT00629122|DRUG|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
214827769|NCT00629122|DRUG|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
214827770|NCT00629122|DRUG|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
214827771|NCT05437848|DRUG|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
214827772|NCT05437848|OTHER|Placebo|Placebo subcutaneous injection
214827773|NCT00002764|BIOLOGICAL|filgrastim|
214827774|NCT00002764|DRUG|doxorubicin hydrochloride|
214827775|NCT00002764|DRUG|ifosfamide|
214827776|NCT00002764|PROCEDURE|conventional surgery|
214827777|NCT06078501|DRUG|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
214827778|NCT06078501|DRUG|Placebo|Placebo buccal administration 2-3 hours prior to procedure
214827779|NCT03155503|DRUG|SUVN-911|Oral Tablet
214827780|NCT03155503|DRUG|Placebo|Oral Tablet
214267808|NCT05074667|DEVICE|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
214267809|NCT05074667|OTHER|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
214827781|NCT01380782|DRUG|BIBF 1120|200 mg BID oral for 28 day cycle
214827782|NCT03676946|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
214827783|NCT03676946|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
214267810|NCT01925677|DEVICE|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
214267811|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
214267812|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
214267813|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
214267814|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
214267815|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
214267816|NCT00631995|DIETARY_SUPPLEMENT|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
214827784|NCT03676946|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
214827785|NCT01839344|DIETARY_SUPPLEMENT|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
214827786|NCT01839344|DRUG|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
214827787|NCT01839344|DRUG|placebo|An oral single dose of a solid, colored empty capsule.
214827788|NCT05747469|DRUG|local anaesthetic injection|Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
214827789|NCT05747469|PROCEDURE|Human Adipose Allograft|Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
214827790|NCT06556849|DEVICE|Defocus Incorporated Multiple Segments (DIMS)|To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
214827791|NCT03125447|OTHER|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
214827792|NCT02369822|DIETARY_SUPPLEMENT|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
214827793|NCT03965286|DRUG|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
214827794|NCT00003035|BIOLOGICAL|filgrastim|
214827795|NCT00003035|DRUG|doxorubicin hydrochloride|
214827796|NCT00003035|DRUG|paclitaxel|
214827797|NCT00003035|DRUG|tamoxifen citrate|
214827798|NCT00003035|PROCEDURE|surgical procedure|
214827799|NCT00003035|RADIATION|radiation therapy|
214827800|NCT05264363|DEVICE|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
214827801|NCT00881634|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
214827802|NCT00881634|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
214827803|NCT05387408|BEHAVIORAL|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
214267817|NCT03098953|DRUG|Loteprednol Etabonate|one drop per eye for each eye
214267818|NCT01826604|DEVICE|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
214267819|NCT01826604|OTHER|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
214656551|NCT02505048|DRUG|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
214656552|NCT03576144|DRUG|BI 1265162|Multiple rising inhaled doses
214656553|NCT03576144|DRUG|Placebo|Multiple rising inhaled doses
214656554|NCT02461017|OTHER|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
214656555|NCT02461017|OTHER|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
214656556|NCT00278629|BIOLOGICAL|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214656557|NCT06390670|DIETARY_SUPPLEMENT|Colostrum Bovinum supplementation|In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.
214656558|NCT06390670|OTHER|Placebo treatment|In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
214656559|NCT01444716|BIOLOGICAL|Ofatumumab|Given IV
214656560|NCT03420976|DIETARY_SUPPLEMENT|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
214656561|NCT04250584|DEVICE|iSlpr™|mandibular advancement device
214656562|NCT04250584|DEVICE|SomnoDent® Classic|mandibular advancement device
214656563|NCT00507715|DRUG|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
214656564|NCT00507715|OTHER|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
214656565|NCT01716819|OTHER|Urine sample|dosages on one spot and 24h collection
214656566|NCT01716819|OTHER|Blood sample|dosages
214656567|NCT01716819|OTHER|Assessment of sleep apnea syndrome|
214656568|NCT01716819|OTHER|Electrocardiogram|
214656569|NCT01716819|OTHER|Glucose tolerance test|
214656570|NCT01716819|OTHER|Echocardiography|
214656571|NCT01716819|OTHER|cardiac and abdominal magnetic resonance imaging|
214656572|NCT01716819|OTHER|Ambulatory blood pressure monitoring|
214656573|NCT01716819|OTHER|Echotracking|
214656574|NCT01716819|OTHER|Pulse wave velocity|
214656575|NCT01716819|OTHER|Composition of body mass by Dual x-ray absorptiometry|
214656576|NCT00312013|DRUG|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
214656577|NCT03263091|DRUG|Roxadustat|Oral tablets
214827804|NCT03657550|DRUG|Levamlodipine, Amlodipine|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
214827805|NCT03657550|DRUG|Amlodipine, Levamlodipine|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
214827806|NCT02695472|DRUG|80 Milligrams NSI-189|Orally Administered
214827807|NCT02695472|DRUG|Placebo|Orally administered
214827808|NCT02695472|DRUG|40 Milligrams NSI-189|Orally Administered
214827809|NCT05963750|OTHER|virtual reality|virtual reality
214827810|NCT01503658|DRUG|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
214827811|NCT03428750|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
214827812|NCT03428750|BIOLOGICAL|Placebo|Placebo
214827813|NCT01078350|PROCEDURE|tumor tissue aspiration|
214827814|NCT01078350|PROCEDURE|phlebotomy|
214827815|NCT01919112|DEVICE|tDCS|Anodal tDCS will be administered with swallowing exercises
214827816|NCT03058614|DRUG|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
214827817|NCT03058614|DIAGNOSTIC_TEST|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
214827818|NCT03058614|DIAGNOSTIC_TEST|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
214827819|NCT04263506|OTHER|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
214827820|NCT00635648|DRUG|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
214827821|NCT06182722|DIAGNOSTIC_TEST|Mental assessments|Patients will receive psychiatric rating scales evaluation every visit.
214267820|NCT05633823|OTHER|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
214267821|NCT06383221|COMBINATION_PRODUCT|"Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care"|Simple and scientific advice
214267822|NCT00491075|DRUG|Pemetrexed|500 mg/m\^2 IV Over 10 Minutes on Day 1.
214267823|NCT00491075|DRUG|Gemcitabine|1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
214267824|NCT05746312|BEHAVIORAL|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
214827822|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
214827823|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
214827824|NCT04194801|DRUG|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
214827825|NCT05213286|DIAGNOSTIC_TEST|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
214827826|NCT04981704|DRUG|Poziotinib|Poziotinib Tablets
214827827|NCT04981704|DRUG|Itraconazole|Itraconazole Oral solution
214827828|NCT04981704|DRUG|Phenytoin|Phenytoin Capsules
214827829|NCT04981704|DRUG|Paroxetine|Paroxetine Tablets
214827830|NCT03969628|DIAGNOSTIC_TEST|ICCMS|Risk caries assessment will consider ICCMS criteria
214827831|NCT00294047|BIOLOGICAL|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214827832|NCT00294047|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214827833|NCT04418297|DRUG|CT-G20|oral tablet
214827834|NCT04418297|DRUG|Placebo|oral tablet
214827835|NCT01689077|OTHER|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
214827836|NCT00080392|DRUG|DNA Plasmid Vector|
214827837|NCT00080392|DRUG|EW-A-401 DNA Plasmid Vector|
214827838|NCT02157974|DRUG|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
214827839|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
214827840|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
214827841|NCT03444792|PROCEDURE|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~\- If failed the surgeon will use artery forceps to dilate cervix"
214827842|NCT01862601|DEVICE|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
214827843|NCT03356691|OTHER|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy."
214827844|NCT03356691|OTHER|Prayer|Individuals will receive prayer during 1 to 2 minutes.
214827845|NCT03356691|OTHER|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
214827846|NCT03356691|OTHER|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
214827847|NCT03356691|OTHER|Fluid therapy.|Individuals will receive fluid therapy.
214827848|NCT03356691|OTHER|No-fluid therapy.|Individuals will receive no-fluid therapy.
214827849|NCT04571294|PROCEDURE|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
214827850|NCT04411576|DIAGNOSTIC_TEST|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
214827851|NCT04411576|DIAGNOSTIC_TEST|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
214827852|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
214827853|NCT00876967|DEVICE|metallic single use blade|metallic single use blade
214827854|NCT00876967|DEVICE|plastic single use blade|plastic single use blade
214827855|NCT00876967|DEVICE|metallic reusable blade|metallic reusable blade
214827856|NCT02393144|DEVICE|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
214827857|NCT02393144|DEVICE|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
214827858|NCT02393144|OTHER|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
214827859|NCT02393144|DRUG|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
214827860|NCT02393144|DRUG|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
214827861|NCT02393144|DRUG|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
214827862|NCT02393144|DRUG|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
214827863|NCT00535912|PROCEDURE|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
214827864|NCT06467513|DRUG|Esketamine hydrochloride injection|The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
214827865|NCT03319108|OTHER|Exercise|Pulmonary Rehabilitation Program for 8 weeks
214827866|NCT05275699|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
214827867|NCT06649006|DRUG|Blinatumomab|IV infusion
214827868|NCT03407963|PROCEDURE|Embolization|Embolization by microparticles (300-500 microns)
214827869|NCT05372744|OTHER|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
214827870|NCT06020430|RADIATION|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
214827871|NCT03694015|RADIATION|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
214827872|NCT03694015|RADIATION|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
214827873|NCT04676529|DRUG|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
214827874|NCT02143258|PROCEDURE|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
214827875|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
214827876|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
214827877|NCT04257838|DRUG|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
214827878|NCT04474587|OTHER|Indirect calorimetry|Measurements of REE by indirect calorimetry
214827879|NCT03431636|OTHER|immersion|cold water immersion
214827880|NCT03431636|OTHER|ice pack|ice packs through the body
214827881|NCT03431636|OTHER|rest|seated rest
214827882|NCT04707963|DIETARY_SUPPLEMENT|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
214827883|NCT04707963|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
214827884|NCT06474936|BEHAVIORAL|Food education|During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
214827885|NCT02319655|PROCEDURE|Air tamponade|Air tamponade
214827886|NCT02319655|PROCEDURE|Balanced salt solution filling|BSS filling
214827887|NCT05758623|DEVICE|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
214827888|NCT01339247|DRUG|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
214827889|NCT01339247|DRUG|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
214267827|NCT01402414|RADIATION|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
214656578|NCT03263091|DRUG|Placebo|Oral tablets
214827890|NCT06267339|DEVICE|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
214827891|NCT06267339|DEVICE|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
214827892|NCT02180321|DRUG|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
214656579|NCT02468193|DRUG|Osilodrostat|Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
214656580|NCT00659672|DIETARY_SUPPLEMENT|Whey Protein|40 grams per day Whey Protein
214656581|NCT00659672|DIETARY_SUPPLEMENT|Soy Protein|40 grams per day soy protein
214656582|NCT00659672|DIETARY_SUPPLEMENT|Control (carbohydrate)|40 grams per day maltodextrin
214656583|NCT06456177|DEVICE|Assessment of nociception in obstetric patients during epidural analgesia|Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index
214656584|NCT04996056|DRUG|TNX-1300|TNX 1300 200 mg Intravenous injection
214656585|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
214656586|NCT04294888|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
214656587|NCT00742781|DIETARY_SUPPLEMENT|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
214656588|NCT06124703|DRUG|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
214656589|NCT06124703|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
214656590|NCT00762151|OTHER|Negative Control (Regular Toothpaste)|Regular Toothpaste
214656591|NCT00762151|OTHER|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
214656592|NCT00762151|DRUG|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
214656593|NCT04674943|OTHER|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
214656594|NCT03714893|DEVICE|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
214656595|NCT00728338|DIETARY_SUPPLEMENT|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
214656596|NCT00728338|DIETARY_SUPPLEMENT|Olive oil|7.5 g olive oil/day
214656597|NCT01979107|BEHAVIORAL|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
214656598|NCT00826748|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
214656599|NCT05951582|OTHER|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone"
214656600|NCT05951582|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills"
214656601|NCT04214080|OTHER|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
214656602|NCT04214080|OTHER|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
214656603|NCT04214080|OTHER|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
214656604|NCT02261623|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
214656605|NCT02261623|DEVICE|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
214656606|NCT02261623|DEVICE|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
214656607|NCT05723146|BEHAVIORAL|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
214656608|NCT03707561|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
214656609|NCT04807361|BEHAVIORAL|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
214656610|NCT04064710|PROCEDURE|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
214656611|NCT04064710|DEVICE|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
214656612|NCT03312218|BEHAVIORAL|Spaced educational intervention|A spaced educational intervention will be provided to participants
214656613|NCT02555800|DRUG|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
214656614|NCT02555800|DRUG|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
214656615|NCT02555800|OTHER|Placebo|Saline solution
214656616|NCT00368173|DRUG|rhIGF-I/rhIGFBP-3|
214656617|NCT00000790|DRUG|Thalidomide|
214656618|NCT02046330|DEVICE|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
214656619|NCT02318004|OTHER|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
214656620|NCT01836861|DRUG|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
214267828|NCT01402414|RADIATION|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
214656621|NCT03802721|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
214656622|NCT03802721|DRUG|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
214656623|NCT03802721|DRUG|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
214656624|NCT00537719|DRUG|GSK716155|albiglutide subcutaneous injection
214656625|NCT00537719|DRUG|Placebo|placebo injection
214656626|NCT05055908|DRUG|Pemetrexed plus Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
214656627|NCT05055908|DRUG|Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
214656628|NCT05055908|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
214656629|NCT02169076|DEVICE|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
214656630|NCT00044447|DRUG|Glimepiride|
214656631|NCT01662089|DRUG|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
214656632|NCT01662089|DRUG|Placebo drug supplement|Placebo drug instead of Zinc supplement
214656633|NCT00714142|DRUG|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
214656634|NCT00714142|DRUG|15O-water|10-20 mCi, IV
214656635|NCT00714142|PROCEDURE|Positron Emission Tomography|PET Scan
214656636|NCT02063529|DRUG|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214656637|NCT02063529|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
214656638|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
214656639|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
214656640|NCT05367531|DEVICE|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
214656641|NCT05367531|DEVICE|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
214656642|NCT05367531|DEVICE|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
214656643|NCT01887912|BIOLOGICAL|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
214656644|NCT01887912|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
214656645|NCT05650229|DRUG|KL1333|Twice daily
214656646|NCT05650229|DRUG|Placebo|Twice daily
214656647|NCT06423885|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214656648|NCT06423885|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
214656649|NCT04611217|OTHER|Dietary fiber: 10-25g|10-25 g/day of fiber
214656650|NCT04611217|OTHER|Dietary fiber: 5g|5 g/day of fiber
214656651|NCT02924896|DIETARY_SUPPLEMENT|Palm olein|60g of palm olein will be given in a milkshake at breakfast
214656652|NCT02924896|DIETARY_SUPPLEMENT|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
214827893|NCT02180321|DRUG|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
214827894|NCT06626607|DRUG|CCB use|Postoperative antihypertensive medication includes CCB
214827895|NCT06626607|DRUG|non-CCB use|Postoperative antihypertensive medication does not include CCB
214827896|NCT02889107|OTHER|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
214827897|NCT06023433|DEVICE|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
214827898|NCT02897375|DRUG|Carboplatin|Given IV
214827899|NCT02897375|DRUG|Cisplatin|Given IV
214267829|NCT01402414|RADIATION|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
214827900|NCT02897375|DRUG|Palbociclib|Given PO
214827901|NCT06097819|OTHER|Mobile app-based game group|Mobile app based game therapy+Occupational therapy+Sensor-based game therapy
214827902|NCT06097819|OTHER|Supervised combined sensor-based game group|Occupational therapy+Sensor-based game therapy
214827903|NCT06097819|OTHER|Individualized occupational therapy group|Occupational therapy
214827904|NCT00193804|RADIATION|IMRT|IMRT in cervical cancers
214827905|NCT01543360|PROCEDURE|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
214827906|NCT01543360|PROCEDURE|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
214827907|NCT03125408|DIAGNOSTIC_TEST|HCV Assay|Molecular diagnostic test to detect Hepatitus C
214827908|NCT06628076|DIAGNOSTIC_TEST|Culture specific antibiotic therapy|Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
214827909|NCT06628076|DIAGNOSTIC_TEST|Antibiotic|Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\&#39;s disc diffusion method on Mueller Hinton Agar.
214827910|NCT06628076|DIAGNOSTIC_TEST|Biofilm assessment|The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
214827911|NCT06628076|DIAGNOSTIC_TEST|nanoparticle zinc oxide|Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
214827912|NCT06628076|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
214827913|NCT00264966|DRUG|ASM8|
214827914|NCT06157268|OTHER|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
214827915|NCT02799992|PROCEDURE|689 nm Laser Treatment of the Macula|
214827916|NCT02799992|PROCEDURE|Half Dose Photodynamic Therapy|
214827917|NCT05779943|DRUG|Furosemide|Given IV
214827918|NCT05779943|OTHER|F18-rhPSMA-7.3|Given IV
214827919|NCT05779943|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214827920|NCT05779943|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214827921|NCT01706757|DEVICE|go-cart|conducts exercises with the help of a go-cart
214827922|NCT02719665|DIETARY_SUPPLEMENT|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
214827923|NCT02719665|DIETARY_SUPPLEMENT|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
214827924|NCT02719665|DIETARY_SUPPLEMENT|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
214827925|NCT02284750|PROCEDURE|Percutaneous coronary intervention|
214827926|NCT00127985|DRUG|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
214827927|NCT00985439|DRUG|Diclofenac Test (lower dose)|18-mg Single dose
214827928|NCT00985439|DRUG|Diclofenac Test (upper dose)|35-mg Single dose
214827929|NCT00985439|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
214827930|NCT00985439|DRUG|Placebo|Capsules 2 Single-dose
214827931|NCT02044731|BEHAVIORAL|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
214827932|NCT02330939|OTHER|Low fat- Low glycemic index meal|
214827933|NCT02330939|OTHER|MUFA- Low glycemic index meal|
214827934|NCT02330939|OTHER|SAFA- Low glycemic index meal|
214827935|NCT02330939|OTHER|Low fat- High glycemic index meal|
214827936|NCT02330939|OTHER|MUFA- High glycemic index meal|
214827937|NCT02330939|OTHER|SAFA- High glycemic index meal|
214827938|NCT00110604|BEHAVIORAL|folic acid (0.8 mg)|
214827939|NCT01174186|DRUG|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
214827940|NCT06241963|DEVICE|Active Comparator: Unilateral real High definition transcranial direct current stimulation|Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
214827941|NCT06241963|DEVICE|Active Comparator: Bilateral real High definition transcranial direct current stimulation|Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
214827942|NCT06241963|DEVICE|Sham Comparator: Sham High definition transcranial direct current stimulation|The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
214827943|NCT05274763|OTHER|Quality-of-Life Assessment|Ancillary studies
214827944|NCT05274763|OTHER|Questionnaire Administration|Ancillary studies
214827945|NCT05274763|PROCEDURE|Spiritual Therapy|Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
214827946|NCT04880616|DRUG|NBI-827104|Capsules for oral administration
214827947|NCT04880616|DRUG|Placebo|Capsules matching NBI-827104 for oral administration
214827948|NCT00250263|DRUG|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
214827949|NCT00250263|DRUG|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
214827950|NCT02960295|DEVICE|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
214827951|NCT02960295|DEVICE|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
214827952|NCT02960295|DEVICE|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
214827953|NCT02960295|DEVICE|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
214827954|NCT02960295|PROCEDURE|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
214827955|NCT03165669|DEVICE|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
214827956|NCT03165669|OTHER|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
214827957|NCT01066858|DRUG|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
214827958|NCT06143202|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor|Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
214827959|NCT01051349|BIOLOGICAL|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
214827960|NCT01051349|BIOLOGICAL|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
214827961|NCT06129084|GENETIC|FGFR Testing|Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
214827962|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
214827963|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
214827964|NCT03262103|BIOLOGICAL|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
214827965|NCT03262103|PROCEDURE|Radical Prostatectomy|as per standard care
214827966|NCT06043388|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
214827967|NCT06043388|BIOLOGICAL|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
214827968|NCT04879537|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
214827969|NCT06512909|OTHER|Virtual Reality Glasses Application|A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
214827970|NCT06512909|OTHER|Stress Ball Application|One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
214827971|NCT01647828|DRUG|OMP-59R5|OMP-59R5 administered intravenously
214827972|NCT01647828|DRUG|Gemcitabine|administered intravenously
214827973|NCT01647828|DRUG|Placebo|administered IV
214827974|NCT01647828|DRUG|Nab-Paclitaxel|administered intravenously
214827975|NCT01111448|DRUG|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
214827976|NCT03608228|OTHER|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
214827977|NCT01043952|DRUG|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
214827978|NCT01043952|DRUG|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
214827979|NCT01043952|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
214827980|NCT01906372|DRUG|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
214827981|NCT03475251|BIOLOGICAL|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
214827982|NCT03475251|BIOLOGICAL|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
214827983|NCT03475251|DRUG|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
214827984|NCT01669460|OTHER|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
214827985|NCT00159458|DRUG|Gemcitabine and oxaliplatin|
214827986|NCT01261949|DEVICE|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
214827987|NCT01261949|DEVICE|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
214827988|NCT02266407|PROCEDURE|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
214827989|NCT02281539|DEVICE|Neuromotus|
214827990|NCT05351567|OTHER|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
214827991|NCT04428307|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
214827992|NCT04428307|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
214827993|NCT05025527|DIAGNOSTIC_TEST|biparametric MRI (bpMRI)|Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
214827994|NCT05025527|DIAGNOSTIC_TEST|Prostate cancer antigen (PSA)|Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
214827995|NCT05291195|DEVICE|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
214827996|NCT05291195|DRUG|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
214827997|NCT05291195|DRUG|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
214827998|NCT02163382|DEVICE|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
214827999|NCT02163382|DEVICE|Neurovent Monitor XIII|RIP jacket installation
214267830|NCT05455697|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214267831|NCT05455697|DRUG|Cyclophosphamide|Given IV
214267832|NCT05455697|DRUG|Doxorubicin|Given IV
214267833|NCT05455697|DRUG|Prednisone|Given PO
214267834|NCT05455697|BIOLOGICAL|Retifanlimab|Given IV
214267835|NCT05455697|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214267836|NCT05455697|BIOLOGICAL|Tafasitamab|Given IV
214267837|NCT05455697|DRUG|Vincristine|Given vincristine
214267838|NCT05455697|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214828000|NCT02163382|DEVICE|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
214828001|NCT02163382|DEVICE|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
214828002|NCT02163382|DEVICE|Neurovent Monitor XIII|Second period with conventional NIV settings
214828003|NCT01891773|BEHAVIORAL|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
214828004|NCT03418753|DIAGNOSTIC_TEST|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
214828005|NCT06345235|DIAGNOSTIC_TEST|blood test|Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
214828006|NCT03899935|PROCEDURE|Laparoscopy|Laparoscopy for endometriosis
214828007|NCT04405479|BEHAVIORAL|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
214828008|NCT02623257|OTHER|mutation detection|
214828009|NCT02623257|OTHER|ARMS|
214828010|NCT02623257|GENETIC|ctDNA analysis|
214828011|NCT03701945|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
214828012|NCT03783663|BEHAVIORAL|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
214828013|NCT03556813|OTHER|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
214828014|NCT04562935|OTHER|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
214828015|NCT04332445|OTHER|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
214828016|NCT03302832|OTHER|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
214828017|NCT03302832|OTHER|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
214828018|NCT04432636|OTHER|Data collection of environmental factors|\- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
214828019|NCT04432636|OTHER|Collection of maternal feces|\- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
214828020|NCT04432636|OTHER|Collection of infant feces|\- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
214828021|NCT04432636|OTHER|food questionnaire|\- A food questionnaire completed by the mother the week after delivery,
214828022|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
214828023|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
214828024|NCT04432636|OTHER|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
214828025|NCT04432636|OTHER|The 'Ages and Stages Questionnaire' ASQ|\- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
214828026|NCT03641001|BEHAVIORAL|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
214828027|NCT05582967|OTHER|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
214828028|NCT00241020|DRUG|Octreotide|
214828029|NCT02458664|GENETIC|Genetic analysis on tumor kept in tumor bank|
214828030|NCT05372250|OTHER|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
214828031|NCT01802112|DIETARY_SUPPLEMENT|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
214828032|NCT01802112|OTHER|placebo|15gr placebo
214828033|NCT02722187|PROCEDURE|subinguinal microscopic varicocelectomy|
214828034|NCT02722187|PROCEDURE|laparoscopic varicocelectomy|
214828035|NCT03482180|DRUG|KI1106 4g, QD|KI1106 4 Capsules
214828036|NCT03482180|DRUG|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
214828037|NCT01715922|DRUG|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
214828038|NCT01715922|DRUG|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
214828039|NCT01715922|PROCEDURE|lumbar punctures|lumbar punctures to control intracranial pressure
214828040|NCT04125407|OTHER|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, …) focusing on the flatfoot deformity.
214828041|NCT00691782|OTHER|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
214828042|NCT03277963|DEVICE|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
214828043|NCT05314257|DRUG|Granisetron Hydrochloride|IV granisetron 1mg
214828044|NCT05314257|OTHER|0.9% normal saline|IV 5ml of 0.9% normal saline
214828045|NCT05248230|BIOLOGICAL|4D-710|4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
214828046|NCT04218435|DRUG|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
214828047|NCT00847535|BIOLOGICAL|autologous muscle cell injection|Injection of autologous muscle cells
214828048|NCT05620862|DRUG|Mitoxantrone Hydrochloride Liposome|In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
214828049|NCT05620862|DRUG|Irinotecan|50mg/ m2，d1-5, 21 days per cycle
214828050|NCT05620862|DRUG|Vincristine|Vincristine 1.5mg/ m2，d1 , 21 days per cycle
214828051|NCT00380679|BIOLOGICAL|Influenza vaccination|
214828052|NCT00380679|BIOLOGICAL|Pneumococcal polysaccharide vaccination|
214828053|NCT05604014|BEHAVIORAL|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
214828054|NCT03922555|DRUG|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
214828055|NCT02182713|DRUG|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
214828056|NCT02182713|DRUG|Salbutamol|Salbutamol 100 mcg per puff
214828057|NCT05159921|OTHER|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
214828058|NCT04056338|OTHER|No intervention|No intervention.
214828059|NCT02943343|OTHER|No intervention|
214828060|NCT04882254|PROCEDURE|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
214828061|NCT02484807|OTHER|no intervention, only observation of different groups|
214828062|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
214828063|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
214828064|NCT02966782|DRUG|venetoclax|Tablet
214828065|NCT02966782|DRUG|azacitidine|Powder for injection, subcutaneously or intravenous
214828066|NCT01889407|DRUG|Idarubicin|8 mg/m2, iv drip on days 1-3
214828067|NCT01325909|BEHAVIORAL|Exercise programme|
214828068|NCT06271005|DIETARY_SUPPLEMENT|NeuroTears|Over-the-counter supplement
214828069|NCT06271005|DIETARY_SUPPLEMENT|Placebo|Oral placebo pill
214828070|NCT06196554|DRUG|Oxaliplatin|"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."
214828071|NCT03393754|BIOLOGICAL|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
214828072|NCT03097445|DRUG|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
214828073|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
214828074|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
214828075|NCT06556329|OTHER|Robot (Intervention)|The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
214828076|NCT03018990|OTHER|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
214828077|NCT02349672|PROCEDURE|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
214828078|NCT06077786|DRUG|Lu AG06474|Oral solution
214267839|NCT05455697|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214267840|NCT05455697|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
214828079|NCT06077786|DRUG|Placebo to Lu AG06474|Oral solution
214828080|NCT06077786|DRUG|Ibuprofen|Capsule
214828081|NCT06077786|DRUG|Pregabalin|Capsule
214828082|NCT06077786|DRUG|Placebo|Capsule
214828083|NCT02054819|OTHER|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
214828084|NCT02054819|OTHER|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
214828085|NCT00075608|BIOLOGICAL|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
214828086|NCT00075608|DRUG|melphalan|140-200 mcg/kg IV over two days
214828087|NCT00075608|PROCEDURE|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
214828088|NCT00075608|PROCEDURE|stem cell infusion|infusion of previously collected stem cells on Day 0
214828089|NCT02177617|DRUG|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
214828090|NCT02177617|BEHAVIORAL|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
214828091|NCT02177617|PROCEDURE|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
214828092|NCT03046550|DRUG|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
214828093|NCT03046550|DRUG|Placebo|placebo
214828094|NCT05845723|DRUG|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
214828095|NCT05845723|DRUG|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
214267841|NCT05455697|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
214267842|NCT05455697|PROCEDURE|Computed Tomography|Undergo FDG-CT
214267843|NCT05455697|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214267844|NCT05455697|DRUG|Polatuzumab Vedotin|Given IV
214828096|NCT05845723|DRUG|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
214828097|NCT03921918|DEVICE|Breast Pump|Hydraulic Breast pump
214828098|NCT01956318|BEHAVIORAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
214828099|NCT03221049|DIAGNOSTIC_TEST|radiomics|
214828100|NCT04800718|OTHER|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
214828101|NCT01988636|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
214828102|NCT01988636|DRUG|Placebo|Placebo
214828103|NCT02054715|BEHAVIORAL|print educational intervention|print educational intervention
214828104|NCT02054715|BEHAVIORAL|multimedia psychoeducational intervention|multimedia psychoeducational intervention
214828105|NCT04138251|DRUG|Empagliflozin|oral administration of Empagliflozin
214828106|NCT05913245|DIETARY_SUPPLEMENT|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
214828107|NCT05913245|OTHER|Water|Preoperative water
214267845|NCT02981121|BEHAVIORAL|Exercise and Diet remedies|
214267846|NCT02981121|DRUG|Metformin|
214267847|NCT06113744|BIOLOGICAL|Placebo|saline
214267848|NCT06113744|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
214267849|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
214267850|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
214828108|NCT04010045|DEVICE|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
214828109|NCT02627235|BEHAVIORAL|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
214828110|NCT02627235|BEHAVIORAL|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
214828111|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|an acute dose of spirulina up to 5 g
214828112|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
214267851|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
214267852|NCT03821649|BEHAVIORAL|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
214267853|NCT03821649|BEHAVIORAL|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
214267854|NCT00144690|DRUG|E2007 (perampanel)|
214267855|NCT00144690|DRUG|Placebo|
214267856|NCT00716703|OTHER|CT Scan using IV contrast alone|CT scan using IV contrast alone
214828113|NCT06560437|OTHER|Chinese Jingjin Manual Therapy|Chinese Jingjin therapy is a form of manual therapy that utilizes the principles of Chinese Jingjin Theory (also known as Chinese Sinew Channel Theory) to alleviate nodular lesions in sinew channels caused by Jingjin injuries and to realign skeletal joints. Chinese Jingjin manual therapy is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
214828114|NCT02725580|GENETIC|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
214828115|NCT00177580|DRUG|Pravastatin|
214828116|NCT05136469|OTHER|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
214828117|NCT05136469|OTHER|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
214828118|NCT05948072|DRUG|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
214828119|NCT05948072|DRUG|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
214828120|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
214828121|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
214828122|NCT01442376|DRUG|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
214828123|NCT01442376|DRUG|Placebo to Ondansetron|
214828124|NCT01442376|DRUG|Placebo to Ondansetron|
214828125|NCT01442376|DRUG|Placebo to Palonosetron|
214828126|NCT04143880|DRUG|Progesterone|intramuscular injection intranasal administration
214828127|NCT04143880|OTHER|saline|intramuscular injection intranasal administration
214828128|NCT06070480|OTHER|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
214828129|NCT06070480|OTHER|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
214828130|NCT06070480|OTHER|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
214828131|NCT01717950|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
214828132|NCT01717950|BIOLOGICAL|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
214828133|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
214828134|NCT03499873|DRUG|Placebos|Placebo
214828135|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
214828136|NCT03646175|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
214828137|NCT03646175|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
214828138|NCT04269122|OTHER|No Intervention|No intervention
214267857|NCT02911857|BIOLOGICAL|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
214828139|NCT06428539|DIAGNOSTIC_TEST|T-reg cells|laboratory test
214828140|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
214828141|NCT05128396|BEHAVIORAL|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
214828142|NCT05128396|BEHAVIORAL|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
214828143|NCT05128396|BEHAVIORAL|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
214828144|NCT05128396|BEHAVIORAL|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
214828145|NCT05871463|BIOLOGICAL|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
214828146|NCT02252016|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
214828147|NCT02252016|DRUG|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
214828148|NCT00840281|DRUG|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
214828149|NCT00840281|DRUG|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
214828150|NCT06346535|DIAGNOSTIC_TEST|Cognitive Testing|Digital Cognitive Testing performed at home.
214828151|NCT06212492|DRUG|NMBAs|Early and systematic use of NMBAs
214828152|NCT06212492|OTHER|Prone positioning|Early and systematic use of prone positioning
214828153|NCT06227858|DIETARY_SUPPLEMENT|Safr'Inside supplement (Activ'Inside, SAS)|Dietary supplementation will be taken in addition to habitual diet of the patients
214267858|NCT03191422|BEHAVIORAL|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
214267859|NCT02061774|DRUG|Acetaminophen|1 gram of intravenous Acetaminophen
214267860|NCT02061774|DRUG|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
214267861|NCT00380822|DRUG|miglitol|
214267862|NCT03670888|BIOLOGICAL|JHL1101|100 mg/10 mL solution in a single-use vial
214267863|NCT03670888|BIOLOGICAL|Rituximab|100 mg/10 mL solution in a single-use vial
214656653|NCT02924896|DIETARY_SUPPLEMENT|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
214656654|NCT04529265|DRUG|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia for 1 h and 1mg/kg MB with 30 min before the end of surgery
214656655|NCT04529265|DRUG|Placebo|Equal volume of normal saline after induction of anesthesia for 1 h and Equal volume of normal saline within 30 min before the end of surgery
214656656|NCT05802810|DRUG|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
214656657|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
214656658|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
214656659|NCT04053387|DRUG|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
214656660|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
214656661|NCT04181424|BEHAVIORAL|Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
214656662|NCT04181424|BEHAVIORAL|Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
214656663|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
214656664|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
214656665|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
214828154|NCT06227858|OTHER|Plcebo|Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
214828155|NCT00944190|BEHAVIORAL|Self-management intervention|Brief counseling technique, self-management,
214828156|NCT00944190|BEHAVIORAL|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
214828157|NCT06627387|OTHER|Balance Training Using Augmented Reality|"The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6)."
214828158|NCT05492279|DIETARY_SUPPLEMENT|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
214828159|NCT05492279|DIETARY_SUPPLEMENT|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
214828160|NCT04941638|PROCEDURE|Distal radial access|Vascular access for primary PCI in patients with STEMI
214828161|NCT04706637|DRUG|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
214828162|NCT04706637|DRUG|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
214828163|NCT02632253|PROCEDURE|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
214828164|NCT02632253|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
214828165|NCT06561984|BEHAVIORAL|antenatal education|Giving educational sessions to the intervention group regarding modes of delivery
214828166|NCT00109954|DRUG|cisplatin|
214828167|NCT00109954|RADIATION|brachytherapy|
214828168|NCT00109954|RADIATION|yttrium Y 90 glass microspheres|
214828169|NCT04762251|OTHER|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
214828170|NCT04762251|OTHER|Current Best Practice|Best practice guidelines to improve diet quality
214828171|NCT02064153|PROCEDURE|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
214828172|NCT02064153|PROCEDURE|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
214828173|NCT04631562|DRUG|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
214828174|NCT04631562|DRUG|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
214828175|NCT04631562|DRUG|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
214828176|NCT04631562|DRUG|Placebo IV|Placebo IV will be administered as an IV infusion.
214828177|NCT01944072|OTHER|Aerobic exercise training intensity|
214828178|NCT06516354|DEVICE|Portable sleep apnea screening|Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
214828179|NCT02651506|PROCEDURE|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
214828180|NCT02651506|PROCEDURE|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
214828181|NCT06627621|PROCEDURE|Alveolar Ridge Reconstruction|scaffold guided alveolar bone regeneration
214828182|NCT04171115|DRUG|G03-52-01|G03-52-01 administered intramuscularly
214828183|NCT04171115|DRUG|Placebo|Placebo administered intramuscularly
214828184|NCT03157115|DEVICE|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
214828185|NCT02471807|DEVICE|Edwards FORMA Tricuspid Transcatheter Repair System|
214828186|NCT00143364|DRUG|varenicline (CP-526,555)|
214828187|NCT05327777|DRUG|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
214828188|NCT05327777|BEHAVIORAL|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
214828189|NCT06596889|PROCEDURE|Successful airway management|"* Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient."
214828190|NCT00961376|BIOLOGICAL|PBMC re-infusion|Autologous PBMC re-infusion
214828191|NCT00961376|BIOLOGICAL|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
214828192|NCT03031795|DRUG|Ketorolac|Oral Tablet
214828193|NCT03031795|DRUG|Placebo|Oral Tablet
214828194|NCT02184715|OTHER|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
214828195|NCT00932477|DRUG|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
214828196|NCT00932477|DRUG|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
214828197|NCT00932477|DRUG|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
214828198|NCT04658225|PROCEDURE|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
214828199|NCT02353936|DRUG|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
214828200|NCT06103097|OTHER|No interventions done (obervational)|Observational study
214828201|NCT00366639|OTHER|Acute Decompensated Heart Failure|Treatment \& outcomes during hospital admission for Acute DHF
214828202|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
214828203|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
214828204|NCT02888964|DRUG|Add-on therapy|Pioglitazone therapy
214828205|NCT02227238|DRUG|DTG|DTG is supplied as 50 mg tablets
214828206|NCT02227238|DRUG|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
214828207|NCT02227238|DRUG|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
214828208|NCT03354338|DRUG|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
214267864|NCT06190990|OTHER|Otago Exercise + Exer gaming|In this group the participant will receive otago exercises and exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 week
214267865|NCT06190990|OTHER|exer gaming based programme|In this group the participant will receive exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 weeks and then after 4 weeks.
214267866|NCT02614586|DRUG|TAK-058|TAK-058 oral solution.
214828209|NCT03354338|OTHER|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
214828210|NCT04025021|DIETARY_SUPPLEMENT|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
214828211|NCT04025021|DEVICE|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
214828212|NCT03306238|PROCEDURE|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
214828213|NCT03306238|PROCEDURE|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
214828214|NCT03966911|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
214828215|NCT05635630|OTHER|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
214828216|NCT05635630|OTHER|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
214828217|NCT01158053|DEVICE|FFR and VH-IVUS|"* Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) \>48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~* No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~* FFR followed by VH-IVUS of study lesion(s)~* Any additional PCI based on routine clinical practice and FFR/IVUS data?~* If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~* If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
214828218|NCT01158053|DEVICE|IVUS and FFR|
214828219|NCT01986647|BEHAVIORAL|On the Move exercise - exercise leader|exercise physiologists
214828220|NCT01986647|BEHAVIORAL|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
214828221|NCT01986647|BEHAVIORAL|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
214828222|NCT01986647|BEHAVIORAL|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
214828223|NCT04212845|DRUG|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
214828224|NCT04212845|DEVICE|Fluoroscopy|Fluoroscopy-guided transforaminal injection
214828225|NCT04212845|DEVICE|Ultrasound|Ultrasound-guided erector spinae plane block
214828226|NCT00868998|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
214828227|NCT06426290|BEHAVIORAL|post-surgery psychological evaluation|"Following questionnaires will be done :~Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor Eating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire (EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)"
214828228|NCT05240417|PROCEDURE|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
214828229|NCT05240417|PROCEDURE|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
214828230|NCT01885819|BIOLOGICAL|Autologous stromal vascular fraction cells|
214828231|NCT06259630|DRUG|Nicotine|Participant receives oral dose of nicotine
214828232|NCT06259630|DRUG|Placebo oral capsule|Participant receives oral dose of placebo
214828233|NCT06034483|OTHER|Pelvic floor exercise training|"* Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
214828234|NCT06034483|OTHER|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
214828235|NCT00595153|DRUG|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
214828236|NCT03459339|DEVICE|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
214828237|NCT06179173|OTHER|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
214828238|NCT06179173|OTHER|Conventional physiotherapy|Conventional physiotherapy
214828239|NCT06204367|DIAGNOSTIC_TEST|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
214828240|NCT03166527|DRUG|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
214828241|NCT03498560|DEVICE|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
214828242|NCT06431776|DRUG|Molgramostim|Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
214828243|NCT02178891|DEVICE|extra short implant|
214828244|NCT04008680|OTHER|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
214828245|NCT05366231|DRUG|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
214828246|NCT05366231|DRUG|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
214828247|NCT04541173|OTHER|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
214828248|NCT04541173|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
214828249|NCT04541173|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
214828250|NCT03587129|DRUG|Apatinib|An anti-tumor Targeted drug
214828251|NCT03985657|DEVICE|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
214828252|NCT00192257|BIOLOGICAL|CAIV-T and TIV|
214828253|NCT04348422|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
214828254|NCT04348422|DIAGNOSTIC_TEST|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
214828255|NCT04348422|OTHER|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
214828256|NCT02763488|DEVICE|DelfiPTS tourniquet system|
214828257|NCT02763488|OTHER|Standard physical therapy|
214828258|NCT00643305|BEHAVIORAL|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
214828259|NCT00643305|BEHAVIORAL|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
214828260|NCT06471725|OTHER|combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound|The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
214828261|NCT01004510|DRUG|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
214828262|NCT01063244|DEVICE|foley balloon only|place foley balloon only in cervix
214828263|NCT01063244|DEVICE|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
214828264|NCT04194333|PROCEDURE|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
214828265|NCT01126606|DRUG|Dermacid Silver (Lactic acid)|Liquid soap, daily use
214828266|NCT01126606|DRUG|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
214828267|NCT03145987|DIETARY_SUPPLEMENT|Vitis vinifera extract|
214828268|NCT03145987|OTHER|Placebo|
214828269|NCT05583409|RADIATION|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
214828270|NCT05583409|DRUG|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
214828271|NCT04175587|DRUG|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
214828272|NCT01790685|DRUG|dexamethasone implant|
214828273|NCT01965093|PROCEDURE|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
214828274|NCT01965093|PROCEDURE|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
214828275|NCT00474188|DRUG|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
214828276|NCT00474188|DRUG|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
214267867|NCT02614586|DRUG|Ondansetron|Ondansetron capsule.
214267868|NCT02614586|DRUG|TAK-058 Placebo|TAK-058 placebo-matching, solution.
214267869|NCT02614586|DRUG|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
214267870|NCT06177938|DIETARY_SUPPLEMENT|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
214267871|NCT05971160|BEHAVIORAL|Financial education videos|Brief videos providing structured information on managing one's money
214828277|NCT04273295|OTHER|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
214828278|NCT03541252|DRUG|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
214828279|NCT00464763|DRUG|Dexmedetomidine|
214828280|NCT00464763|DRUG|Placebo|
214828281|NCT03051945|DRUG|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
214828282|NCT03051945|OTHER|Normal saline|Placebo
214828283|NCT07113821|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion from type II to type IV
214828284|NCT07113821|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion from type II to type IV
214828285|NCT01406353|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
214828286|NCT00357461|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
214828287|NCT00357461|BIOLOGICAL|gp100:280-288(288V) peptide vaccine|
214828288|NCT00357461|BIOLOGICAL|incomplete Freund's adjuvant|
214828289|NCT00357461|BIOLOGICAL|ipilimumab|
214828290|NCT04013841|OTHER|Oral-agents/Enema|"1. Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~2. Enema for mechanical bowel preparation prior to left-side colorectal resection"
214828291|NCT04460716|PROCEDURE|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
214828292|NCT06562088|DRUG|HDM1002 and rifampicin|Administered orally
214828293|NCT06562088|DRUG|HDM1002 and itraconazole|Administered orally
214828294|NCT06687057|BEHAVIORAL|HRV Biofeedback Training|The intervention involves 5 training sessions lasting 45 minutes (specifically, 5-minute baseline and 5 HRV biofeedback trials lasting 5 minutes each) according to the protocol published by Lehrer et al. (2013). Physiological signals (ECG and respiratory rate) will be recorded during all sessions. During the training, participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing. They will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle in order to maximize the difference between the maximum and minimum heart rate within each respiratory cycle \[i.e., respiratory sinus arrhythmia (RSA), an index of vagal modulation on the heart\] (Lehrer et al., 2003; Lehrer et al., 2000).
214828295|NCT06687057|OTHER|Placebo Training|The Placebo procedure requires participants to attend 5 sessions lasting 45 minutes during which they perform a task. Physiological signals (ECG and respiration rate) will be recorded during all sessions. Participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing but these will not directly reflect the subject's cardiorespiratory activity. Participants in the control group will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle, but the feedback on the screen will not reflect that subject's RSA changes.
214828296|NCT07140367|PROCEDURE|Transarterial Microembolization|Identification of the hypervascularization of the knee. Selective and super-selective catheterization of pathological genicular arterial branches, through the use of micro-catheters. - Injection of embolizing material (Nexsphere-F - Kardia) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
214828297|NCT07138729|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT|"For 68Ga-FAPI PET/CT scan，each patient was injected with 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) body weight of 68Ga-FAPI. PET/CT from skull to feet was performed 60±5 min post-injection.~For 99mTc-CTR-FAPI SPECT scan:each patient was injected with 10-20mCi 99mTc-CTR-FAPI . Planar SPECT scan and SPECT/CT were performed 60±5 min post-injection."
214828298|NCT07140302|PROCEDURE|deep brain stimulation|"Stereotactic implantation of DBS electrodes with chronic electrical stimulation of target nuclei for dystonia.~or Stereotactic radiofrequency ablation of dystonia-related target nuclei."
214828299|NCT07139288|BEHAVIORAL|therapeutic exercise program|Each subject completes four dynamic tasks, including ankle resistance exercises, resistance kinematic chain exercises, heel raise exercises, and BOSU ball exercises at 3 times per week for 4 weeks
214828300|NCT07139288|DEVICE|Extra corporeal shock wave therapy|"The extracorporeal shock waves will be delivered with 2,500 shockwave impulses (6 Hz), The intensity of extracorporeal shock waves is adjusted according to the patients' degree of tolerance to the pain. In the experimental group, the extracorporeal shockwave will apply to the anterior talofibular ligament, posterior talofibular ligament, calcaneofibular ligament, and tibialis anterior muscle.~twice per week for 4 weeks"
214267872|NCT05971160|OTHER|Microgrant|$150 stipend
214267873|NCT05971160|BEHAVIORAL|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
214267874|NCT03016806|RADIATION|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
214267875|NCT03016806|RADIATION|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
214267876|NCT03016806|DRUG|Cyclophosphamide|50 mg/kg or 60 mg/kg
214267877|NCT03016806|DRUG|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
214828301|NCT07139288|DEVICE|photobiomodulation Therapy|Photobiomodulation therapy will be performed with a laser an 810 nm wavelength, 0 \~ 500 mW adjustable and continuous power output, and a 0.4 cm beam diameter was used. The subjects in the group C will be treated with the laser at a dose of 239 J/cm2 (power: 100 mW; intensity: 796 mW/cm2; irradiation time: 5 min/point, 20 min in total) at 3 times per week for 4 weeks
214828302|NCT07138859|DEVICE|Robot assisted radical right hemicolectomy (D3 lymph node dissection)|RRH (Robotic Right Hemicolectomy) group: Experimental group: Performing robotic radical right hemicolectomy (D3 lymph node dissection)
214828303|NCT07138859|DEVICE|Laparoscopic assisted radical right hemicolectomy (D3 lymph node dissection)|LRH (Laparoscopic Right Hemicolectomy) group: control group: underwent laparoscopic radical right hemicolectomy (D3 lymph node dissection)
214828304|NCT01952691|DEVICE|kinesiotaping|correction method was used to align hallux.
214828305|NCT02955004|PROCEDURE|Electrical cardioversion|Transthoracic direct current electrical cardioversion
214828306|NCT00199901|BIOLOGICAL|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
214828307|NCT00199901|BIOLOGICAL|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
214828308|NCT06335186|DIAGNOSTIC_TEST|upper endoscopy|to detect esophageal or gastric varices
214828309|NCT01279109|BEHAVIORAL|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
214828310|NCT01279109|BEHAVIORAL|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
214828311|NCT01705483|DRUG|ASP9853|oral
214828312|NCT01705483|DRUG|Docetaxel|intravenous (IV)
214828313|NCT01705483|DRUG|Paclitaxel|Taxol
214828314|NCT05123053|DRUG|Amifampridine|10mg tablet
214828315|NCT05546398|DRUG|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
214828316|NCT05546398|OTHER|No study drug|No study drug was administered during this study.
214828317|NCT06678399|DRUG|KELI-101|KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
214828318|NCT06678399|OTHER|Vehicle (placebo)|Plasmalyte
214828319|NCT02845791|BEHAVIORAL|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
214828320|NCT05776901|DEVICE|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
214828321|NCT00917735|DRUG|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
214828322|NCT00917735|OTHER|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
214828323|NCT05911919|DEVICE|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
214828324|NCT02302716|DRUG|LY2963016|Administered SC
214828325|NCT02302716|DRUG|LANTUS®|Administered SC
214828326|NCT02302716|DRUG|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
214828327|NCT06215196|DIETARY_SUPPLEMENT|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
214828328|NCT06215196|OTHER|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
214828329|NCT04080999|DEVICE|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
214828330|NCT04080999|DEVICE|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
214828331|NCT03681587|OTHER|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
214267878|NCT03016806|PROCEDURE|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
214828332|NCT03681587|OTHER|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
214828333|NCT03581994|DIAGNOSTIC_TEST|DDI Test Report|Test results of simulated patients
214828334|NCT01964872|DRUG|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
214828335|NCT01964872|DRUG|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
214828336|NCT01964872|DRUG|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
214828337|NCT01964872|DRUG|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
214828338|NCT01964872|DRUG|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
214828339|NCT01964872|DRUG|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
214828340|NCT01964872|DRUG|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
214828341|NCT03561558|DRUG|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
214828342|NCT03561558|DRUG|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
214828343|NCT03342235|PROCEDURE|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
214828344|NCT03342235|OTHER|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
214828345|NCT03342235|DEVICE|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
214828346|NCT01215903|DIETARY_SUPPLEMENT|Fish gelatin and omega-3 polyunsaturated fatty acid|
214828347|NCT01215903|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|
214828348|NCT00954603|DRUG|quetiapine|25-100 mg
214828349|NCT00954603|DRUG|haloperidol|0.5-2 mg
214828350|NCT01139606|OTHER|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
214828351|NCT03263793|BEHAVIORAL|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
214828352|NCT03980301|DIAGNOSTIC_TEST|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
214828353|NCT03197818|DRUG|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
214828354|NCT03197818|DRUG|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
214828355|NCT06056115|DRUG|Tislelizumab,Platinum|"1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
214828356|NCT04733456|BEHAVIORAL|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
214828357|NCT04733456|DEVICE|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
214828358|NCT04733456|OTHER|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
214828359|NCT04733456|OTHER|Blood and urine collection|for inflammatory markers and metabolomic \[IMC\] analysis
214828360|NCT00000950|DRUG|Ethambutol hydrochloride|
214828361|NCT00000950|DRUG|Isoniazid|
214828362|NCT00000950|DRUG|Pyrazinamide|
214828363|NCT00000950|DRUG|Pyridoxine hydrochloride|
214828364|NCT00000950|DRUG|Rifampin|
214828365|NCT02604641|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
214828366|NCT02604641|DIETARY_SUPPLEMENT|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
214267879|NCT03016806|DRUG|Busulfan|0.8 mg/kg x 16 doses
214267880|NCT03016806|DRUG|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
214267881|NCT03016806|DRUG|Melphalan|140 mg/m2
214828367|NCT02604641|DIETARY_SUPPLEMENT|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
214828368|NCT01074424|GENETIC|proteomic profiling|
214828369|NCT01074424|OTHER|laboratory biomarker analysis|
214828370|NCT04487184|OTHER|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
214828371|NCT04384224|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
214828373|NCT03187821|PROCEDURE|Laser peripheral iridotomy|location of laser peripheral iridotomy
214828374|NCT00197249|BIOLOGICAL|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
214828375|NCT02305134|DRUG|Tipepidine Hibenzate|
214828376|NCT02305134|DRUG|Placebo|
214828377|NCT04946708|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
214828378|NCT05786118|OTHER|No intervention|There is no intervention in this study
214828379|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
214828380|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
214828381|NCT03995849|DIAGNOSTIC_TEST|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
214828382|NCT04231643|DRUG|Dronabinol|one-time oral administration of 5 mg dronabinol
214828383|NCT04231643|DRUG|Epidiolex|one-time oral administration of 600 mg Epidiolex
214828384|NCT04231643|DRUG|Placebos|one-time oral administration of placebo
214828385|NCT03017729|BIOLOGICAL|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
214828386|NCT01208194|DRUG|MGN1703|solution, 60 mg, twice a week, until progression
214828387|NCT01208194|DRUG|Placebo|solution, 60 mg, twice a week, until progression
214828388|NCT01374646|BEHAVIORAL|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
214828389|NCT01360086|BIOLOGICAL|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
214828390|NCT01360086|DRUG|cisplatin|Cisplatine (50mg/m²)
214828391|NCT01360086|DRUG|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
214828392|NCT01360086|DRUG|leucovorin calcium|
214828393|NCT01360086|PROCEDURE|adjuvant therapy|
214828394|NCT01360086|PROCEDURE|neoadjuvant therapy|
214828395|NCT01360086|PROCEDURE|quality-of-life assessment|
214267882|NCT06446011|PROCEDURE|root canal treatment in Ckd patients|root canal treatment in teeth with apical periodontitis to observe periapical healing , and change in eGFR ,blood urea and creatinine and HSCRP
214267883|NCT06446011|PROCEDURE|root canal treatment in healthy patients|root canal treatment in teeth with apical periodontitis to observe periapical healing and change in HSCRP
214267884|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 6 weeks.|
214267885|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 5 weeks.|
214267886|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
214828396|NCT01360086|PROCEDURE|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
214828397|NCT02488057|DRUG|Liraglutide|Active comparator. See arm descriptions.
214828398|NCT02488057|BEHAVIORAL|Weight loss|Active comparator. See arm descriptions.
214828399|NCT01951209|DRUG|Rifaximin|550mg orally twice daily for 12 weeks
214828400|NCT01951209|DRUG|Placebo|Matched placebo
214828401|NCT06482606|OTHER|Flickering Checkerboard Stimulation|This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
214828402|NCT02941939|OTHER|Hyperbaric chamber|
214828403|NCT02941939|OTHER|Ambient pressure|
214828404|NCT04750681|DIETARY_SUPPLEMENT|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
214828405|NCT04750681|DIETARY_SUPPLEMENT|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
214828406|NCT05270499|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
214828407|NCT01986725|BEHAVIORAL|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
214828408|NCT01986725|BEHAVIORAL|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
214828409|NCT01866124|OTHER|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
214828410|NCT01232049|DRUG|Multiple Oral Dose of|Pitavastatin 4mg
214828411|NCT01232049|DRUG|Multiple Oral Dose of|Valsartan 320mg
214828412|NCT04523480|DRUG|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
214828413|NCT04523480|DRUG|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
214828414|NCT04523480|DRUG|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
214828415|NCT06432140|GENETIC|VGN-R09b injection|Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
214828416|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
214828417|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering \[MSK\]).
214828418|NCT04241341|OTHER|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
214828419|NCT04241341|OTHER|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
214828420|NCT04852133|OTHER|Burn subjects|see eligibility criteria
214828421|NCT03515473|DEVICE|cochlear implant|cochlear implant surgery
214828422|NCT00325182|DRUG|Levetiracetam|
214828423|NCT00325182|OTHER|Historical controls|
214828424|NCT00529191|DRUG|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
214828425|NCT00529191|OTHER|Placebo|One out of three subjects will receive a placebo.
214656666|NCT04709549|BEHAVIORAL|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
214656667|NCT04709549|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
214656668|NCT05067127|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214828426|NCT01911429|DRUG|Lurasidone 40 mg|Lurasidone 40 mg once daily
214656669|NCT05067127|OTHER|Placebo|Sterile solution of equal volume to active arm
214828427|NCT01911429|DRUG|Lurasidone 80 mg|Lurasidone 80 mg once daily
214828428|NCT01911429|DRUG|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
214828429|NCT05285865|OTHER|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
214828430|NCT05285865|OTHER|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
214656670|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
214656671|NCT06306417|DEVICE|acupuncture|acupuncture
214656672|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
214656673|NCT03180450|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
214656674|NCT03180450|DRUG|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
214656675|NCT04462536|DRUG|Placebo|Vehicle only
214656676|NCT04462536|DRUG|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
214656677|NCT06313944|DIAGNOSTIC_TEST|Registry|Clinical data collection of patients scheduled for on-label treatment
214656678|NCT04980898|DEVICE|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
214828431|NCT06563284|OTHER|AURORA Mobile App|"Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety."
214828432|NCT06298123|DRUG|Anti-PD-1 monoclonal antibody|The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
214828433|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 1|
214828434|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 2|
214828435|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 3|
214828436|NCT01252758|OTHER|Placebo|
214828437|NCT01252758|DRUG|Albuterol|
214828438|NCT01252758|DRUG|Albuterol|
214828439|NCT03171194|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
214828440|NCT03864094|DRUG|Ephedrine|0,1 mg/kg
214828441|NCT03864094|DRUG|Phenylephrine|1 microg/kg
214828442|NCT03864094|DRUG|Norepinephrine|0,1 microg/kg
214828443|NCT03864094|DRUG|Sodium chloride|0,1 ml/kg
214828444|NCT03864094|DRUG|Propofol|2 mg/kg
214828445|NCT03864094|DRUG|Remifentanil|1,7 microg/kg
214828446|NCT00327145|DRUG|valsartan|
214828447|NCT00327145|DRUG|hydrochlorothiazide|
214656679|NCT04980898|OTHER|Standard cares|Cleaning and monitoring
214828448|NCT00327145|DRUG|amlodipine|
214828449|NCT05783089|BIOLOGICAL|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
214828450|NCT02207582|DEVICE|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
214828451|NCT02207582|DEVICE|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
214828452|NCT00625157|DRUG|ASF 1096 0.5 % cream|
214656680|NCT06046482|DRUG|Pembrolizumab|Given by IV (vein)
214656681|NCT06046482|DRUG|Magrolimab|Given by IV (vein)
214656682|NCT06046482|DRUG|cetuximab|Given by IV (vein)
214656683|NCT06046482|DRUG|Docetaxel|Given by IV (vein)
214656684|NCT04846309|RADIATION|Radiation|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic. Subjects with tumors identified by imaging as hypoxic will be treated with a higher dose of radiation therapy. Tumors will be defined as being hypoxic if FMISO accumulation occurs as demonstrated by standardized uptake value (SUV) uptake in the tumor.
214656685|NCT04846309|DRUG|FMISO PET CT|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
214656686|NCT02109081|DRUG|Dexamethasone|
214656687|NCT02109081|DRUG|Placebo|
214656688|NCT03312192|DEVICE|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
214828453|NCT00625157|DRUG|ASF 1096 placebo cream|
214828454|NCT03531450|BEHAVIORAL|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
214828455|NCT00422045|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
214828456|NCT02791958|DRUG|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
214828457|NCT02791958|DRUG|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
214828458|NCT02791958|DRUG|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
214828459|NCT01566851|OTHER|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
214828460|NCT02684331|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
214828461|NCT02684331|OTHER|Echocardiography|Standard measurements and strain.
214828462|NCT02684331|OTHER|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
214828463|NCT01557751|GENETIC|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
214828464|NCT04323527|DRUG|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
214828465|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
214828466|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
214828467|NCT02659462|OTHER|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
214828468|NCT01531790|DRUG|Carboplatin|d1, AUC 5, i.v.
214828469|NCT01531790|DRUG|Pemetrexed|d1, 500 mg/m2, i.v.
214828470|NCT01531790|DRUG|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
214828471|NCT01531790|DRUG|Centrum|1 tablet/day
214828472|NCT01949922|PROCEDURE|Injection of autologous muscle fibers into the anal sphincter.|
214828473|NCT01949922|PROCEDURE|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
214828474|NCT01949922|BEHAVIORAL|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
214828475|NCT01949922|DRUG|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
214828476|NCT05461716|DEVICE|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
214828477|NCT02024230|DRUG|Rivaroxaban or Warfarin|a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
214828478|NCT03810586|DEVICE|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
214828479|NCT05795621|BIOLOGICAL|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
214828480|NCT05795621|BIOLOGICAL|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
214828481|NCT03915600|OTHER|Quinoa|Personalized diet added with quinoa
214828482|NCT03915600|OTHER|Flaxseed|personalized diet added with flaxseed
214828483|NCT03915600|OTHER|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
214828484|NCT02043132|DRUG|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
214828485|NCT02043132|DRUG|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
214828486|NCT00012974|BEHAVIORAL|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
214828487|NCT00012974|PROCEDURE|Provider education, computer reminders, nurse case management|
214828488|NCT01923740|DEVICE|XIENCE V EECSS|Subjects receiving XIENCE V
214828489|NCT01923740|DEVICE|Absorb BVS System|Subjects receiving Absorb BVS System
214828490|NCT04037722|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
214828491|NCT04037722|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
214828492|NCT02063139|DRUG|Flutiform 50/5 ug (2 puffs bid) pMDI|
214828493|NCT02063139|DRUG|Fluticasone 50 ug (2puffs bid) pMDI|
214828494|NCT02063139|DRUG|Beclometasone Autohaler 50 ug (2 puffs bid)|
214828495|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
214828496|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
214828497|NCT00158925|DEVICE|EASYTRAK EPI lead|EASYTRAK EPI lead
214828498|NCT01112722|BIOLOGICAL|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
214828499|NCT01112722|BIOLOGICAL|histamine|imitates pain and erythema of honeybee venom
214828500|NCT05515796|DRUG|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
214828501|NCT05515796|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
214828502|NCT05515796|DRUG|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
214828503|NCT05515796|RADIATION|Radiotherapy|25 Gy/5 fractions
214828504|NCT02147379|DRUG|Lurasidone|
214828505|NCT00393250|OTHER|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
214828506|NCT00393250|OTHER|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
214828507|NCT05213624|DRUG|BI 764198|BI 764198
214828508|NCT05213624|DRUG|Placebo|Placebo matching BI 764198
214828509|NCT01883713|DEVICE|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
214828510|NCT05941065|OTHER|Balancing gel cream|Skin balancing gel cream will be applied onto clean skin morning and night
214828511|NCT05389722|DRUG|CC-92480|Specified dose on specified days
214828512|NCT05389722|DRUG|Rifampin|Specified dose on specified days
214828513|NCT05389722|DRUG|Itraconazole|Specified dose on specified days
214828514|NCT05389722|DRUG|Digoxin|Specified dose on specified days
214828515|NCT05389722|DRUG|Rosuvastatin|Specified dose on specified days
214828516|NCT05507801|OTHER|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
214828517|NCT05507801|OTHER|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
214828518|NCT01792726|RADIATION|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
214828519|NCT01837914|PROCEDURE|Maxillary expansion|
214828520|NCT01837914|PROCEDURE|Adenotonsillectomy|
214828521|NCT03195595|DEVICE|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
214828522|NCT03195595|DEVICE|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
214828523|NCT01496495|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
214828524|NCT03811418|DRUG|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
214828525|NCT03811418|DRUG|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
214828526|NCT03811418|DRUG|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
214828527|NCT03811418|DRUG|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
214828528|NCT00223457|BEHAVIORAL|Factors that influence compliance|
214828529|NCT03110874|DRUG|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
214828530|NCT03110874|DRUG|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
214828531|NCT03030664|DIETARY_SUPPLEMENT|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
214828532|NCT03030664|DRUG|Placebo|Same formulation as study product, without probiotics.
214828533|NCT03847688|DEVICE|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
214828534|NCT04461964|DEVICE|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
214828535|NCT02027337|DRUG|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
214828536|NCT02027337|DRUG|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
214828537|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
214828538|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
214828539|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
214828540|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
214828541|NCT00472212|DEVICE|Spectacles|Hyperopic spectacle lenses
214828542|NCT00472212|DEVICE|Control|Plano (no power, control) spectacle lenses
214828543|NCT05059028|OTHER|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
214828544|NCT01534845|DRUG|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
214828545|NCT02945618|DEVICE|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
214828546|NCT02945618|OTHER|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
214828547|NCT05450107|PROCEDURE|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
214828548|NCT05450107|PROCEDURE|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
214828549|NCT05199064|OTHER|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
214828550|NCT02462837|DRUG|Mirabegron|
214828551|NCT02462837|DRUG|Placebo|
214828552|NCT04603703|OTHER|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
214828553|NCT04603703|OTHER|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
214828554|NCT04560231|DRUG|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
214828555|NCT03835468|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
214828556|NCT03835468|DIETARY_SUPPLEMENT|Maltodextrin|sugar based placebo
214828557|NCT01057368|BEHAVIORAL|Day of intensive meditation practice|Long-term meditators practice for \~6 hours of meditation at each time point
214828558|NCT01057368|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
214828559|NCT01057368|BEHAVIORAL|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
214828560|NCT00018460|DRUG|Vitamin B|
214828561|NCT03367260|OTHER|Preference Elicitation|Survey of patient preferences for treatment
214828562|NCT02516189|OTHER|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
214828563|NCT01710748|DEVICE|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
214828564|NCT01710748|DEVICE|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
214828565|NCT06627348|DEVICE|Hilotherm ChemoCare|Hilotherapy
214828566|NCT01519830|DRUG|Iron carboxymaltose (Ferinject)|Intravenous iron
214828567|NCT01519830|DRUG|Placebo|0.9% NaCl solution
214828568|NCT01719770|DRUG|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
214828569|NCT01719770|OTHER|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
214828570|NCT01758601|OTHER|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
214828571|NCT01758601|OTHER|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
214828572|NCT00114504|DRUG|simvastatin|simvastatin 5-10 mg/day
214828573|NCT02705573|DRUG|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
214828574|NCT00966485|DRUG|80 mg ASA dosing|
214828575|NCT00966485|DRUG|500 mg ASA dosing|
214828576|NCT06628141|OTHER|Nutritional support tool|Nutritional support tool
214828577|NCT04444063|PROCEDURE|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
214828578|NCT00958724|DRUG|Neratinib|
214828579|NCT00958724|DRUG|Vinorelbine|
214828580|NCT01026402|DRUG|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
214828581|NCT02010463|OTHER|Exercise|
214828582|NCT01080703|OTHER|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
214828583|NCT05657587|DEVICE|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
214828584|NCT00840203|DRUG|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
214828585|NCT00840203|DRUG|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
214828586|NCT02959879|DRUG|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
214828587|NCT02959879|DRUG|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
214828588|NCT02959879|PROCEDURE|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
214828589|NCT02959879|DRUG|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
214828590|NCT02959879|DRUG|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
214828591|NCT03616379|BEHAVIORAL|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
214828592|NCT03616379|BEHAVIORAL|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
214828593|NCT03616379|BEHAVIORAL|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
214828594|NCT02042859|DEVICE|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
214828595|NCT02121184|DRUG|Routine oxytocin|per regular oxytocin protocols
214267887|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
214828596|NCT02121184|DRUG|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
214828597|NCT04892615|DEVICE|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
214828598|NCT04892615|DEVICE|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
214828599|NCT01438593|PROCEDURE|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
214267888|NCT03494543|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
214267889|NCT05706701|OTHER|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
214267890|NCT05706701|OTHER|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
214828600|NCT06433232|PROCEDURE|ROOT CANAL TREATMENT|ROOT CANAL TREATMENT
214828601|NCT06560671|OTHER|novel type of health education|animation video based health education
214828602|NCT03999645|PROCEDURE|Early laparoscopic cholecystectomy|within 72h from symptom onset
214828603|NCT03999645|PROCEDURE|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
214828604|NCT05562011|DEVICE|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
214828605|NCT04352205|DRUG|Bortezomib|Given SC
214828606|NCT04352205|BIOLOGICAL|Daratumumab|Given IV
214828607|NCT04352205|DRUG|Dexamethasone|Given PO and IV
214828608|NCT04352205|DRUG|Lenalidomide|Given PO
214828609|NCT04352205|DRUG|Thalidomide|Given PO
214828610|NCT03721653|DRUG|Bevacizumab|5 mg/kg iv over 30 minutes day 1
214828611|NCT03721653|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes day 1
214828612|NCT03721653|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
214828613|NCT03721653|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
214828614|NCT03721653|DRUG|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
214828615|NCT03721653|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
214828616|NCT05751447|DIAGNOSTIC_TEST|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
214828617|NCT03349567|BEHAVIORAL|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
214828618|NCT00690027|PROCEDURE|Emergency portacaval shunt|
214828619|NCT00690027|PROCEDURE|Emergency and long-term endoscopic sclerotherapy|
214828620|NCT05661591|DRUG|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
214828621|NCT05661591|DRUG|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
214828622|NCT01659073|PROCEDURE|Caloric Vestibular Stimulation|
214828623|NCT01323491|DRUG|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
214828624|NCT01791751|DRUG|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
214828625|NCT00209690|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214828626|NCT00209690|DRUG|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214828627|NCT00209690|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214828628|NCT03162159|OTHER|Collection of growth and bone maturation data|
214828629|NCT00178178|DEVICE|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
214828630|NCT00178178|DRUG|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
214828631|NCT00178178|DRUG|Placebo|Drug: Placebo
214828632|NCT05032807|DRUG|Standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
214828633|NCT05032807|DRUG|Novel formulation|Cannabidiol 1000mg with lipid matrix, single dose, oral
214828634|NCT05841654|DRUG|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
214828635|NCT04070898|PROCEDURE|Remove urinary catheter after surgery|Remove bladder catheter after surgery
214828636|NCT03118063|DIAGNOSTIC_TEST|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
214828637|NCT01355835|DEVICE|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
214828638|NCT00487435|DRUG|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
214828639|NCT02705716|OTHER|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
214828640|NCT02705716|OTHER|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
214828641|NCT04403035|DIAGNOSTIC_TEST|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
214828642|NCT05624424|DRUG|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
214828643|NCT05624424|DRUG|Propofol|Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
214828644|NCT05624424|DRUG|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
214828645|NCT05624424|DRUG|Sufentanil|Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
214828646|NCT05624424|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
214828647|NCT05624424|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
214828648|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
214828649|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
214828650|NCT03485118|DRUG|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
214828651|NCT02610881|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
214828652|NCT02610881|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
214828653|NCT02610881|BEHAVIORAL|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
214828654|NCT04971512|DRUG|EDP-721|Oral administration (Part 1)
214828655|NCT04971512|DRUG|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
214828656|NCT04971512|DRUG|EDP-721 (Part 2)|Oral administration (Part 2)
214828657|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
214828658|NCT04971512|DRUG|EDP-514|Oral administration
214828659|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-514
214828660|NCT01622764|RADIATION|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
214828661|NCT02454595|BEHAVIORAL|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
214828662|NCT00562718|DRUG|capecitabine|
214828663|NCT00562718|PROCEDURE|adjuvant therapy|
214828664|NCT00562718|RADIATION|radiation therapy|
214828665|NCT01868243|DRUG|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
214828666|NCT01868243|DRUG|Warfarin|Warfarin adjusted-dose
214828667|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
214828668|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
214828669|NCT00452738|BEHAVIORAL|Therapy dog|
214828670|NCT00452738|BEHAVIORAL|Costumed character|
214828671|NCT00452738|BEHAVIORAL|Parents-only|
214828672|NCT02375815|OTHER|Statin Choice Implementation|
214828673|NCT05172687|BEHAVIORAL|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
214828674|NCT05172687|BEHAVIORAL|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
214828675|NCT02751437|DIETARY_SUPPLEMENT|Arginine|
214828676|NCT03601585|DEVICE|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
214828677|NCT02075333|DIETARY_SUPPLEMENT|Ingestion of solution|Participants will ingest the solution
214828678|NCT02075333|DIETARY_SUPPLEMENT|Rinising of solution|Participants rinse the solution in the oral cavity
214828679|NCT06076109|OTHER|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
214828680|NCT06076109|OTHER|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
214828681|NCT03725345|BEHAVIORAL|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
214267891|NCT05706701|OTHER|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
214267892|NCT05706701|OTHER|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
214828682|NCT01608906|DRUG|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
214828683|NCT01608906|DRUG|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
214267893|NCT03019185|DRUG|Placebo Oral Capsule|Capsule containing an inert placebo
214828684|NCT00327847|DRUG|Oral Vitamin D Supplementation|
214828685|NCT02408653|DEVICE|EEG|
214828686|NCT06414200|OTHER|multidisciplinary structured tailored made nutritional advice|The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
214828687|NCT02905435|DEVICE|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
214828688|NCT02086474|DRUG|Hyaluronan|Intra-articular injection
214828689|NCT02086474|DRUG|Bupivacaine|Extra-capsular injection
214828690|NCT01442051|PROCEDURE|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
214828691|NCT02195544|DRUG|Synvisc®|
214828692|NCT01507662|BEHAVIORAL|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
214828693|NCT01627431|DRUG|Acetylsalicylic acid|100 mg once per day
214828694|NCT01627431|DRUG|Clopidogrel|75 mg once per day
214828695|NCT02666482|BEHAVIORAL|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
214828696|NCT05121194|BEHAVIORAL|Cognitive Behaviour Therapy|Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
214828697|NCT05341180|DRUG|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
214828698|NCT05341180|DRUG|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
214828699|NCT05373576|BEHAVIORAL|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
214828700|NCT04805840|DEVICE|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
214828701|NCT05423873|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
214828702|NCT03449225|OTHER|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
214828703|NCT01710722|DRUG|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
214828704|NCT01710722|DRUG|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
214828705|NCT01710722|DRUG|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
214828706|NCT03010657|OTHER|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
214828707|NCT03505996|BIOLOGICAL|CS1001|Monoclonal antibody
214828708|NCT01200186|DRUG|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
214828709|NCT01200186|DRUG|Progestin Only Pills|At the discretion of the attending physician
214828710|NCT05325268|PROCEDURE|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
214267894|NCT03019185|DRUG|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
214267895|NCT05700617|DRUG|1:1 Randomization to receive milrinone|Randomized to receive either inotropic agent: milrinone or no agent
214267896|NCT05196646|DEVICE|Respiratory Acoustic Sensors|Wireless sensor that contains a dual microphone and an inertial measurement unit (IMU) will capture the breathing sound and respiratory effect. Two wireless sensors will be used, with one placed on the suprasternal notch and the other placed on the right upper chest of the infant, in order to determine the sensor placement yielding the best respiratory signal. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller (ISP1807, Insight SIP) and stored on the same device for future analysis.
214828711|NCT02195401|OTHER|Cleanroom|Cleanroom with air the quality of the pre-industrial age
214828712|NCT02000258|PROCEDURE|Double-bundle ACL reconstruction|
214828713|NCT02000258|DEVICE|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
214828714|NCT00220844|DRUG|Desipramine|
214828715|NCT00220844|DRUG|Amitriptyline|
214828716|NCT01395017|DRUG|dasatinib|GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214828717|NCT01395017|DRUG|Placebo|Matching Placebo
214828718|NCT03086434|OTHER|Culturally Tailored Intervention|School-based substance use prevention
214828719|NCT03086434|OTHER|Standard Substance Abuse Education|Class room program
214828720|NCT01808716|DEVICE|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
214828721|NCT04737239|OTHER|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
214828722|NCT06209255|PROCEDURE|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
214267897|NCT05196646|DEVICE|Nasal thermistor|The nasal temperature probe that detects changes in temperature between inhaled and exhaled gases allows for the surrogate measure of airflow. It will be placed in one naris and secured with tape at the upper lip or cheek. The nasal temperature signal will be acquired using the Power Lab analog-digital acquisition system and stored for later analysis.
214656689|NCT03312192|DEVICE|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
214828723|NCT05480423|BEHAVIORAL|Mindfulness-based intervention|1\. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
214828724|NCT03911206|BEHAVIORAL|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
214828725|NCT03911206|BEHAVIORAL|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
214828726|NCT03911206|BEHAVIORAL|IMT and Exercise|Combining IMT training and exercise
214828727|NCT06485518|BEHAVIORAL|The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.|The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
214828728|NCT02285049|OTHER|Urticaria Control Test|"* The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
214828729|NCT01782937|DRUG|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
214828730|NCT04814628|PROCEDURE|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
214656690|NCT01499173|BEHAVIORAL|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
214656691|NCT03198221|DRUG|Golytely|bowel preparation
214656692|NCT03198221|DRUG|Clenpiq|bowel preparation
214656693|NCT02861170|BEHAVIORAL|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
214656694|NCT03234335|OTHER|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
214267898|NCT05196646|DEVICE|Respiratory Inductive Plethysmography|Two respiratory bands will be placed circumferentially around the infant's chest (at the level of nipple line) and around the abdomen (just above the level of the umbilicus) in order to measure chest and abdominal wall movements, respectively. These movements will be recorded using Respiratory Inductive Plethysmography (Respitrace QDC®, Viasys® Healthcare, USA). The Respitrace® signals will be acquired using the Power Lab data acquisition system and stored for later analysis.
214656695|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
214656696|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
214656697|NCT05662644|PROCEDURE|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
214656698|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Group (EBCM-G)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
214656699|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Individual (EBCM-I)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
214656700|NCT05057390|DIETARY_SUPPLEMENT|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
214656701|NCT02119715|DRUG|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
214656702|NCT02119715|DRUG|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
214656703|NCT02119715|DRUG|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
214656704|NCT04670705|OTHER|patients' characteristics|There was no intervention.
214656705|NCT01154101|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
214656706|NCT01154101|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
214656707|NCT02114190|BEHAVIORAL|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
214656708|NCT02114190|BEHAVIORAL|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
214656709|NCT06359184|OTHER|yoga|1 hour yoga practice 2 days a week for 8 weeks
214656710|NCT06359184|OTHER|control|no intervention for 8 weeks
214656711|NCT03158402|OTHER|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
214656712|NCT06211855|DIAGNOSTIC_TEST|doppler assesment|In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
214656713|NCT00460382|DRUG|raltegravir potassium|400 mg twice a day
214656714|NCT00460382|DRUG|darunavir/ritonavir|2 pills of 300 mg twice a day
214656715|NCT00460382|DRUG|etravirine|2 pills of 100 mg twice a day
214656716|NCT00460382|DRUG|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
214828731|NCT04814628|PROCEDURE|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
214828732|NCT04814628|PROCEDURE|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
214828733|NCT04814628|PROCEDURE|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
214828734|NCT05662605|DEVICE|W-PPMA|"W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot."
214828735|NCT06402227|OTHER|gamified instruction|"At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win."
214828736|NCT06402227|OTHER|conventional lesson lecture|The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
214828737|NCT02115776|DRUG|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
214267899|NCT05196646|DEVICE|Pneumotachometer|The pneumotachometer is a pressure-differential based flow sensor that is used to measure respiratory flow. It will be connected to a standard face mask that is gently applied to cover the infant's mouth and nose. The face mask will be similar to the masks used as part of standard of care in the NICU for infants who require continuous positive pressure, with or without ventilation. The flow measurements will be recorded using the Power Lab data acquisition system and stored for later analysis.
214267900|NCT05578326|DRUG|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
214267901|NCT05578326|DRUG|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
214267902|NCT05287126|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
214267903|NCT04949464|PROCEDURE|Computed Tomography|Undergo LDCT
214267904|NCT04949464|BEHAVIORAL|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
214267905|NCT05880862|BEHAVIORAL|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
214267906|NCT05880862|DRUG|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
214267907|NCT05880862|DRUG|Trospium Chloride|A 12-week course of Trospium XL -extended release, 60mg once daily.
214267908|NCT04252066|DRUG|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
214267909|NCT05408117|DEVICE|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
214267910|NCT05408117|DEVICE|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
214267911|NCT05676099|PROCEDURE|Phlebotomy|Participants may elect to submit a blood sample to the Biosample Repository.
214267912|NCT05676099|PROCEDURE|Buccal (cheek) swab|Participants may elect to submit a buccal swab sample to the Biosample Repository.
214656717|NCT04697914|DIAGNOSTIC_TEST|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
214656718|NCT06041243|OTHER|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
214656719|NCT01562028|DRUG|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
214656720|NCT01562028|DRUG|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
214656721|NCT02360098|OTHER|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
214656722|NCT03360929|DRUG|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
214656723|NCT01082276|DRUG|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
214656724|NCT00522860|PROCEDURE|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
214656725|NCT00522860|PROCEDURE|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
214656726|NCT01702116|PROCEDURE|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
214656727|NCT01702116|PROCEDURE|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
214656728|NCT04285918|PROCEDURE|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
214656729|NCT02747784|BEHAVIORAL|Cognitive training program RehaCom®|Cognitive training program RehaCom®
214656730|NCT03849729|DRUG|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
214656731|NCT03849729|OTHER|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
214656732|NCT03193866|DRUG|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
214656733|NCT04439266|DRUG|Crizotinib|Given PO
214656734|NCT03765645|DRUG|Piperacillin + Tazobactam|Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
214656735|NCT02354833|DRUG|Phenylephrine|
214656736|NCT02354833|DRUG|Norepinephrine|
214656737|NCT05485480|DRUG|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
214656738|NCT05485480|DRUG|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
214656739|NCT05196269|DEVICE|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and postoperative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have access to the software installed, and they will have access to all the information about the type of treatment they will receive. All the questions and questionnaires will be filled out online, and they can visualise the expected outcome from excellent to poor.
214656740|NCT01762579|DIETARY_SUPPLEMENT|wheat flour|wheat flour is administered three times per day for 15 days
214656741|NCT01762579|DIETARY_SUPPLEMENT|Xylose|Xylose will be administered three times per day for 15 days
214656742|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
214656743|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
214656744|NCT04609904|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
214656745|NCT04609904|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
214656746|NCT04609904|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
214656747|NCT04609904|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
214656748|NCT04006808|BIOLOGICAL|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
214828738|NCT02115776|DRUG|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
214828739|NCT02115776|DRUG|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
214828740|NCT03294122|RADIATION|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
214828741|NCT03294122|RADIATION|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
214828742|NCT00001864|DRUG|Atropine|
214828743|NCT00001864|DEVICE|Patch|
214828744|NCT04482816|DEVICE|Physiological pacing|Pacing of the his bundle or the left bundle branch
214828745|NCT04482816|DEVICE|Right ventricular pacing|Conventional pacing; right ventricular pacing
214828746|NCT00473616|DRUG|AZD7762|intravenous infusion
214828747|NCT00473616|DRUG|Irinotecan|intravenous injection
214828748|NCT02028416|DRUG|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
214656749|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
214656750|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
214656751|NCT06161012|DEVICE|Senofilcon A contact lenses (TEST)|Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
214656752|NCT06161012|DEVICE|Delefilcon A contact lenses (CONTROL)|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
214656757|NCT04516252|BEHAVIORAL|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
214656758|NCT04516252|BEHAVIORAL|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
214656759|NCT04516252|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
214656760|NCT04516252|BEHAVIORAL|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
214656761|NCT06136546|DRUG|Infliximab|Intravenous infusion of infliximab
214656762|NCT06136546|OTHER|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
214656763|NCT02623972|DRUG|Eribulin|administered IV for 4 cycles
214656764|NCT02623972|DRUG|Adriamycin|administered IV with cyclophosphamide for 4 cycles
214656765|NCT02623972|DRUG|Cyclophosphamide|administered IV with adriamycin for 4 cycles
214656766|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
214656767|NCT03481647|PROCEDURE|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
214656768|NCT06617039|DRUG|Remifentanil and ciprofol|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
214656769|NCT06617039|DRUG|esketamine 0.3mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
214656770|NCT06617039|DRUG|esketamine 0.5mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
214656771|NCT06617039|DRUG|Ciprofol|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
214656772|NCT04774354|DIAGNOSTIC_TEST|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
214656773|NCT01875497|DIETARY_SUPPLEMENT|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
214656774|NCT06405425|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214656775|NCT06405425|DRUG|PD-1|Administration by intravenous infusion for a cycle of 3 weeks.
214828749|NCT04599842|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
214828750|NCT05198505|DRUG|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
214828751|NCT00493727|DRUG|N-acetylcysteine(Mucomyst)|
214828752|NCT02683291|DRUG|sirolimus|
214828753|NCT02683291|DRUG|tacrolimus|
214828754|NCT02683291|DRUG|mycophenolate|
214828755|NCT02683291|DRUG|Prednisone|Prednisone 30mg/day
214828756|NCT02683291|DRUG|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
214828757|NCT02683291|DRUG|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
214828758|NCT00223093|DRUG|TAIZ|
214828759|NCT02125981|DRUG|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
214828760|NCT02125981|DRUG|Placebo|taking placebo drug
214828761|NCT04417439|OTHER|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
214828762|NCT04919616|DRUG|TILs（Tumor Infiltrating Lymphocytes）|10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
214828763|NCT01803594|DIETARY_SUPPLEMENT|Krill Oil|Neptune Krill Oil Gold
214828764|NCT01803594|DIETARY_SUPPLEMENT|Lutein|Jarrow Formulas
214828765|NCT01803594|DIETARY_SUPPLEMENT|Nicotinic acid|Natures Way
214828766|NCT01803594|DIETARY_SUPPLEMENT|Dairy phospholipids|PC700 manufactured by Fonterra
214828767|NCT01803594|OTHER|Control|Control shake without dietary supplements
214828768|NCT05384457|OTHER|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
214828769|NCT05384457|OTHER|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
214828770|NCT00001058|DRUG|Indinavir sulfate|
214828771|NCT00001058|DRUG|Ritonavir|
214828772|NCT00001058|DRUG|Ethambutol hydrochloride|
214828773|NCT00001058|DRUG|Clarithromycin|
214828774|NCT00001058|DRUG|Rifabutin|
214828775|NCT04364191|BEHAVIORAL|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
214828776|NCT04364191|BEHAVIORAL|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
214828777|NCT04495543|BEHAVIORAL|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
214828778|NCT05173792|DRUG|AK119|Subjects will receive AK119 intravenously.
214828779|NCT03961204|OTHER|Data Collection|No study treatment was administered as part of this study
214828780|NCT05787678|BIOLOGICAL|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
214828781|NCT04363554|OTHER|Fluid intake|The participants will intake fluid
214828782|NCT04363554|OTHER|Thirsting|The participants will thirst
214828783|NCT02016274|OTHER|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
214828784|NCT00707330|DRUG|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
214828785|NCT06561490|RADIATION|sonographic assesment of placental thickness and volume|sonographic assesment of placental thickness and volume
214828786|NCT04318808|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
214828787|NCT01670643|BEHAVIORAL|Video camera magnifier|reading with video camera magnifier
214828788|NCT02913287|DIETARY_SUPPLEMENT|Aquamin/Aquamin MG|Marine-based nutraceutical
214828789|NCT02913287|OTHER|Maltodextrin Placebo|Maltodextrin Placebo
214828790|NCT00675142|PROCEDURE|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
214828791|NCT04116957|DEVICE|RTLS current tag|Validate location system performance against manual observation of nursing activity
214828792|NCT04116957|DEVICE|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
214828793|NCT01165450|DRUG|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
214828794|NCT01165450|DRUG|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
214828795|NCT03586219|BEHAVIORAL|Opioid-specific educational patient pamphlets|See prior description
214828796|NCT06144034|DEVICE|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
214828797|NCT06144034|DEVICE|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
214828798|NCT01957280|DRUG|patritumab|
214828799|NCT04934098|DEVICE|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
214828800|NCT04934098|DEVICE|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
214828801|NCT05964049|DEVICE|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
214828802|NCT05964049|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214828803|NCT02865824|DRUG|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
214828804|NCT02865824|DRUG|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
214267913|NCT05676099|GENETIC|Genetic Testing|Biosamples may be processed and analyzed for genetic variants using whole genome sequencing (WGS) or other sequencing methods. Participants whose samples are processed in this manner may be contacted and provided the option to receive TSC1 or TSC2 genetic variant results by opting in using Consent to Return of Genetic Results Form. Participants will be offered a one-time genetic counseling session to review their results, free of charge. CLIA-certified, TSC1 or TSC2 genetic variant results will be returned to participants who opt in to receive such results. Additionally, negative results and results not able to be clinically certified will also be offered to participants with a one-time genetic counseling session to review their results, free of charge using the Return of Genetic Research Results Template Letter. CSS will be responsible for informing clinic participants that their samples have been sequenced and offer to connect participant to the TSC Alliance for further information.
214267914|NCT05676099|OTHER|Tissue donation after routine clinical procedure|Participants may elect to submit a tissue sample to the Biosample Repository following a medical procedure.
214267915|NCT05849129|DRUG|Ascorbic acid|High dose ascorbic acid delivered intravenously
214267916|NCT05849129|OTHER|Normal Saline|0.9% NaCl solution
214267917|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
214267918|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
214267919|NCT06582225|BEHAVIORAL|Internet-delivered exposure and response prevention (I-ERP)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks."
214267920|NCT06582225|BEHAVIORAL|Internet-delivered stress management (I-SM)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks."
214267921|NCT05488171|DRUG|Methylone|Single oral dose of 200 mg of methylone.
214267922|NCT05488171|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
214267923|NCT05488171|DRUG|Placebo|Single oral dose of placebo.
214267924|NCT02202187|DRUG|GSK2140944|Investigational Study Drug
214828805|NCT00664053|DIETARY_SUPPLEMENT|DHEA|50mg daily for 6 months
214828806|NCT00664053|BEHAVIORAL|Yoga|2 sessions per week for 6 months
214828807|NCT00664053|DIETARY_SUPPLEMENT|Placebo|Placebo supplement every day for 6 months
214267925|NCT02202187|OTHER|Placebo|Placebo
214267926|NCT03665454|DRUG|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
214267927|NCT03665454|DRUG|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
214828808|NCT00664053|BEHAVIORAL|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
214828809|NCT00796796|DRUG|Temsirolimus|
214828810|NCT00796796|RADIATION|Radiation therapy|
214828811|NCT00879164|DRUG|bupivacaine hydrochloride|
214267928|NCT06203171|OTHER|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
214267929|NCT04062708|DRUG|Durvalumab|"Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
214267930|NCT04062708|PROCEDURE|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
214267931|NCT04062708|RADIATION|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
214267932|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
214267933|NCT03875365|PROCEDURE|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
214267934|NCT02678975|DRUG|Disulfiram|Disulfiram 400 mg daily
214267935|NCT02678975|DIETARY_SUPPLEMENT|Copper|nutritional supplement with copper, 2 mg daily
214267936|NCT02678975|DRUG|Alkylating Agents|Alkylating antineoplastic agent
214267937|NCT05490784|OTHER|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
214267938|NCT05490784|OTHER|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
214267939|NCT00227448|DRUG|intravenous saline|
214267940|NCT00227448|DRUG|intravenous phenylephrine|
214267941|NCT00227448|DRUG|intravenous levophed|
214267942|NCT00227448|DRUG|oral midodrine|
214267943|NCT05049616|DRUG|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
214267944|NCT05049616|DRUG|NIFEdipine ER|Extended release nifedipine
214267945|NCT05344365|DRUG|Iloperidone|oral tablet
214267946|NCT04746248|OTHER|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
214267947|NCT04746248|OTHER|Inpatient labor induction|The participants are induced following standard inpatient care
214267948|NCT03095339|OTHER|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
214267949|NCT00705289|BIOLOGICAL|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
214267950|NCT02721160|OTHER|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
214267951|NCT03609879|DEVICE|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
214267952|NCT03609879|DEVICE|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
214267953|NCT03609879|DEVICE|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
214267954|NCT03609879|DEVICE|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
214267955|NCT03609879|DEVICE|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
214267956|NCT04167982|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
214267957|NCT04167982|DRUG|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
214828812|NCT00879164|OTHER|questionnaire administration|
214267958|NCT04167982|DRUG|Oral low-dose isotretinoin|low-dose isotretinoin
214828813|NCT06050239|DRUG|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
214828814|NCT00170469|BIOLOGICAL|AVA|
214828815|NCT00170469|BIOLOGICAL|rPA vaccine containing alhydrogel|
214828816|NCT01566435|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214828817|NCT01566435|DRUG|Cisplatin|
214828818|NCT01566435|DRUG|Fluorouracil|
214828819|NCT01566435|RADIATION|Intensity modulated radiation therapy|
214828820|NCT01566435|DRUG|Cetuximab|
214828821|NCT01566435|PROCEDURE|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
214828822|NCT01710696|DRUG|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
214267959|NCT00528177|DRUG|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
214267960|NCT05845736|DRUG|Antihypertensive Agents|number of hypertensive drugs
214267961|NCT02601027|PROCEDURE|Transversus Abdominis Plane (TAP) block|
214267962|NCT02601027|DEVICE|Nimbus Infusion Pump IV Administration|
214267963|NCT02601027|DRUG|Bupivacaine infusion|
214267964|NCT02601027|DRUG|Acetominophen|
214267965|NCT02601027|DRUG|Hydromorphone|
214828823|NCT01710696|DRUG|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
214828824|NCT03999008|DRUG|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
214267966|NCT02601027|DRUG|Oxycodone|
214267967|NCT02601027|DRUG|Ondansetron|
214267968|NCT03532841|DRUG|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
214828825|NCT03999008|DRUG|Placebos|Apple Sauce 5 mL+ 1 mL saline
214267969|NCT03532841|DRUG|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
214267970|NCT01512342|BEHAVIORAL|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
214267971|NCT01512342|BEHAVIORAL|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
214267972|NCT00495365|DRUG|Epoetin alfa|
214267973|NCT01146912|OTHER|Text Message|Text message vaccine reminders
214267974|NCT01146912|OTHER|automated call|Automated call
214267975|NCT06463405|OTHER|Splinted|The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
214267976|NCT02577549|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
214267977|NCT02577549|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
214267978|NCT02548533|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
214267979|NCT02548533|DRUG|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
214267980|NCT02548533|DRUG|EMLA cream|Topical application 2 hours prior to the treatment.
214267981|NCT02609828|DRUG|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
214267982|NCT05205525|OTHER|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
214267983|NCT05205525|OTHER|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
214267984|NCT02980783|DEVICE|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
214267985|NCT00763529|DRUG|Mometasone|Mometasone furoate cream 0.1% applied once daily
214267986|NCT00763529|DRUG|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
214267987|NCT00001688|DRUG|Ritonavir|
214267988|NCT00001688|DRUG|Nevirapine|
214267989|NCT00001688|DRUG|Stavudine|
214267990|NCT03026322|OTHER|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
214267991|NCT03026322|OTHER|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
214267992|NCT01676571|DRUG|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
214267993|NCT04776109|PROCEDURE|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
214267994|NCT05821400|OTHER|observational study|observational study
214828826|NCT06547177|OTHER|fruit juice|During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
214828827|NCT03684928|DEVICE|Comfilcon A (test)|Daily wear contact lenses
214828828|NCT03684928|DEVICE|Senofilcon C (control)|Daily wear contact lenses
214828829|NCT03844334|DEVICE|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
214828830|NCT05804786|DEVICE|Guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
214828831|NCT05278520|PROCEDURE|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
214828832|NCT00135850|GENETIC|VEGF-A165 plasmid|
214828833|NCT04632550|PROCEDURE|Circumferential pulmonary vein isolation(CPVI) group|"1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214828834|NCT04632550|PROCEDURE|Posterior box isolation(POBI) group|"1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214828835|NCT04632550|PROCEDURE|POBI+Anterior linear ablation(AL) group|"1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214828836|NCT05167474|OTHER|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
214828837|NCT02224586|DEVICE|light treatment|clinical routine treatment according to the doctor's advice
214828838|NCT05941390|DEVICE|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
214828839|NCT05941390|DEVICE|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
214828840|NCT00414180|DRUG|Bupropion SR|
214828841|NCT03746795|DEVICE|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
214828842|NCT03746795|DEVICE|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
214828843|NCT00860938|DRUG|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
214828844|NCT04023981|DEVICE|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
214828845|NCT05579548|DRUG|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
214828846|NCT02469363|DEVICE|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
214828847|NCT02469363|DEVICE|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
214828848|NCT02469363|DEVICE|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
214267995|NCT02343679|DRUG|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
214828849|NCT02469363|DEVICE|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
214828850|NCT01600963|DRUG|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
214828851|NCT01600963|DRUG|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
214828852|NCT01600963|DRUG|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
214828853|NCT01600963|DRUG|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
214828854|NCT01023113|PROCEDURE|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
214828855|NCT01023113|PROCEDURE|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
214828856|NCT04221113|PROCEDURE|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
214828857|NCT01222234|DRUG|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
214828858|NCT01222234|DEVICE|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
214267996|NCT01399814|BEHAVIORAL|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation
214267997|NCT01399814|BEHAVIORAL|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
214267998|NCT06125522|DRUG|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
214267999|NCT06125522|DRUG|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
214268000|NCT02570360|BEHAVIORAL|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
214268001|NCT02570360|BEHAVIORAL|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
214268002|NCT03120234|DRUG|Dexmedetomidine|
214268003|NCT03120234|DRUG|Ketamine|
214268004|NCT03120234|DRUG|Fentanyl|
214268005|NCT03120234|DRUG|Placebos|o.9% normal saline will be used instead of ketamine
214268006|NCT01696695|DRUG|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
214268007|NCT01696695|DRUG|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
214268008|NCT02107404|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
214268009|NCT04912193|DRUG|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
214268010|NCT02000583|OTHER|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
214268011|NCT02000583|OTHER|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
214268012|NCT03173313|DEVICE|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
214268013|NCT03863197|BEHAVIORAL|Progressive strength training|Progressive Supervised Home-based Strength Training
214268014|NCT03832036|DIAGNOSTIC_TEST|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
214268015|NCT06015451|OTHER|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
214268016|NCT06174649|DIAGNOSTIC_TEST|Reveal|Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
214268017|NCT05981391|DIAGNOSTIC_TEST|resting-state functional MRI|We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.
214268018|NCT05981391|DIAGNOSTIC_TEST|Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)|The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.
214268019|NCT05981391|DIAGNOSTIC_TEST|Tympanometry|Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.
214268020|NCT05981391|DIAGNOSTIC_TEST|Tinnitus Assessment|Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.
214268021|NCT05981391|DIAGNOSTIC_TEST|Otoscopy|Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear
214268022|NCT05981391|DIAGNOSTIC_TEST|Pure tone air and bone-conduction|Pure tone air- and bone-conduction threshold will be conducted to evaluate audiometry and masking levels in both ears, from 250 Hz. To 16000 Hz.
214268023|NCT05981391|DIAGNOSTIC_TEST|Speech testing|Speech testing will be conducted in both ears, which will include speech reception threshold, speech reception threshold masking level, word recognition presentation level, and word recognition masking level.
214268024|NCT05981391|DIAGNOSTIC_TEST|Loudness Discomfort|Loudness discomfort levels will be tested in both right and left ears, from 500Hz to 4000Hz and speech reception threshold.
214268025|NCT05981391|DIAGNOSTIC_TEST|Quick Speech in Noise Test|Quick Speech in Noise Test (QuickSIN) is a quick method for clinicians to quantify a patient's ability to hear in noise (1 minute).
214268026|NCT05981391|DIAGNOSTIC_TEST|Distortion-Product Otoacoustic Emissions (DPOAE)|Distortion-Product Otoacoustic Emissions (DPOAE) is an automated evaluation of cochlear function. A sensitive microphone is placed in the ear canal via a probe assembly with a disposable ear-tip attached to perform and record the measurements. DPOAEs will be elicited at multiple frequencies in both ears (10 min).
214268027|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from F. Vesiculosus|4 g daily
214268028|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from U. Pinnatifida|4 g daily
214268029|NCT05793138|BEHAVIORAL|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
214828859|NCT01222234|DRUG|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
214268030|NCT05793138|BEHAVIORAL|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
214268031|NCT05803785|DRUG|BBC1501|BBC1501 solution for Intravitreal injection
214268032|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
214268033|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
214268034|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
214268035|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
214268036|NCT05345860|OTHER|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
214268037|NCT05345860|OTHER|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
214268038|NCT05345860|OTHER|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
214268039|NCT05667987|DRUG|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
214268040|NCT00985478|DRUG|SLV342|25 mg once daily - Maximal Tolerated Dose
214268041|NCT00985478|DRUG|placebo|matching placebo
214268042|NCT02498132|OTHER|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
214268043|NCT02498132|OTHER|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
214268044|NCT02498132|OTHER|Treatment as Usual|Individuals will be provided with one on one therapy sessions
214828860|NCT06874764|OTHER|Wireless Lighting Reaction System Training(Agility plus Cognitive)|Agility training and Cognitive trainings(cognitive trainings ready within the device: Eye for detail, Hawk eye, Juggle Factor)
214828861|NCT06626971|DRUG|ARA290|4 mg subcutaneous injections of ARA290 over an 84 day period
214828862|NCT06628232|OTHER|pacifier with breast milk|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk
214828863|NCT06628232|OTHER|heel heating|swaddling in the mother\&#39;s lap together with local dry heat application
214828864|NCT06628232|OTHER|interventions combined|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk and heel heating
214828865|NCT06628232|OTHER|Control|swaddling the baby in the mother\&#39;s lap
214268045|NCT01065597|DEVICE|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
214268046|NCT05170984|DEVICE|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
214828866|NCT02119988|PROCEDURE|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
214828867|NCT02119988|PROCEDURE|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
214828868|NCT07025330|DRUG|Efgartigimod|efgartigimod 1000 mg subcutaneous injection given once weekly
214828869|NCT05124600|DEVICE|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
214828870|NCT07026864|RADIATION|MR-guided Radiation Therapy|MR-guided Radiation Therapy
214828871|NCT07024199|OTHER|The initial pain assessment|The initial pain assessment will be carried out according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
214828872|NCT07024199|DRUG|Drug administration according to protocol (paracetamol + ibuprofen OR paracetamol + metamizol)|"Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi intravenously 10 mg/kg body weight (maximum 400 mg/dose).~Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin intravenously 15 mg/kg body weight (maximum 100 mg/dose)."
214828873|NCT07024199|OTHER|The effectiveness of the treatment|The effectiveness of the treatment will be assessed 60 minutes after the start of the intervention according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
214828874|NCT06691243|DRUG|Semaglutide|The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
214828875|NCT06691243|DRUG|Placebo|Patients randomized to placebo arm will receive placebo injection every week.
214828876|NCT06878989|BEHAVIORAL|Caloric restriction diet|Dietary intervention consisting on a meal plan designed to induce an 8-10% weight loss over a 12-16 week period.
214828877|NCT06878989|BEHAVIORAL|Weight maintenance diet|Dietary intervention consisting on a meal plan designed to maintain a stable body weight for up to 16 weeks.
214828878|NCT06705192|DRUG|VES001|"VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg."
214828879|NCT07138495|DEVICE|AI-personalized virtual reality rehabilitation system for unsupervised home-based stroke therapy|The personalized RGS app rehabilitation is a home-based, virtual reality therapy platform for motor and cognitive stroke recovery. Therapy tasks are gamified, task-specific, and adapt in difficulty based on real-time performance. An AI-driven clinical decision support system personalizes and updates exercise prescriptions after each session, with optional clinician adjustments. Integrated wearable sensors (RGSwear) track real-world activity and adherence. Data are securely uploaded to a cloud-based platform for remote monitoring. This is the first multicenter, international RCT to test AI-personalized VR rehabilitation at home with up to 12-month follow-up, combined with cost-effectiveness and usability evaluation.
214828880|NCT07032389|COMBINATION_PRODUCT|Polypill|The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.
214828881|NCT07138209|DRUG|QLS32015|QLS32015 will be administered subcutaneously.
214828882|NCT07138209|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214828883|NCT07138209|DRUG|Selinexor|Selinexor will be administered orally.
214828884|NCT07138209|DRUG|Dexamethasone|Dexamethasone will be administered orally
214828885|NCT07129837|DIAGNOSTIC_TEST|Clinical evaluation, disease activity and disability scoring, and laboratory testing including RF, anti-CCP, and serum anti-PCOLCE antibody measurement by ELISA.|"For rheumatoid arthritis (RA) patients: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, assessment of disease activity using DAS-28 score, functional disability evaluation by modified Health Assessment Questionnaire (mHAQ), and laboratory investigations including CBC, ESR, CRP, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibodies measured by ELISA.~For healthy controls: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, and laboratory testing limited to serum anti-PCOLCE antibodies measured by ELISA."
214828886|NCT03864380|DIAGNOSTIC_TEST|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
214828887|NCT03864380|DIAGNOSTIC_TEST|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
214828888|NCT03864380|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
214828889|NCT06555640|DRUG|DR10624 Injection|Drug: DR10624 injection
214828890|NCT06555640|DRUG|Placebo|Drug: placebo
214828891|NCT05829460|DRUG|Semaglutide|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
214828892|NCT05829460|DRUG|Placebo|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
214828893|NCT05829460|DRUG|LNG-IUD (Progestin)|Released via the levonorgestrel-releasing IUD.
214828894|NCT05829460|BEHAVIORAL|Telemedicine behavioral weight program|Optional to attend.
214828895|NCT00003885|DRUG|arsenic trioxide|
214828896|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
214268047|NCT01964833|PROCEDURE|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
214268048|NCT01964833|PROCEDURE|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
214268049|NCT00153907|DRUG|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
214828897|NCT02230605|OTHER|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
214828898|NCT02230605|OTHER|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
214828899|NCT02230605|OTHER|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
214828900|NCT02230605|OTHER|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
214828901|NCT02230605|OTHER|Short Form 36 Health Survey|To be completed at the Screening Visit
214828902|NCT02230605|OTHER|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
214828903|NCT02230605|OTHER|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
214828904|NCT02230605|OTHER|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
214828905|NCT00531180|PROCEDURE|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
214828906|NCT00531180|PROCEDURE|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
214828907|NCT01620840|DRUG|Lacosamide 10mg/ml|intravenous administration up to 10 days
214828908|NCT05920447|DEVICE|LMA|Monitor the ventilatory parameter and incidence of complications
214828909|NCT05404789|OTHER|Centrifugation|Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
214828910|NCT06722027|BEHAVIORAL|Compassion Centered Spiritual Health Team Intervention (CCSH-TI)|"Delivered to healthcare teams by spiritual health clinicians proficient in group facilitation. It is composed of 4 sessions delivered every other week and lasting 60 minutes each.~CCSH-TI sessions teach participants to attune to their interpersonal relationships; acknowledge and allow difficult emotions; and access compassion. It also provides psychoeducation about skillful coping strategies. Each session consists of didactic material about team norms and safety, a feeling check-in, facilitated group discussions about social connection and professional team building, and meditations to promote mindfulness, to cultivate a feeling of being nurtured, and to access compassion for self and others. CCSH-TI is delivered to healthcare teams by spiritual health clinicians proficient in group facilitation."
214828911|NCT06722027|BEHAVIORAL|Treatment as Usual|TAU refers to the current buffet of wellness and professional development activities that are available to employees at the Winship Cancer Institute.
214828912|NCT06716580|DEVICE|Circulating Tumor DNA (ctDNA) Assay|Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
214828913|NCT03733145|DRUG|Angiotensin II|Participants in the ACE inhibitors, angiotensin-receptor blockers (ARBs), and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
214828914|NCT06725160|BEHAVIORAL|Parent Coaching|Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
214828915|NCT06725160|BEHAVIORAL|Active Control|General parent support and psychoeducation based on components of standard PCIT.
214268050|NCT00153907|DRUG|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
214828916|NCT00457067|DRUG|Ranibizumab|
214268051|NCT00734175|BIOLOGICAL|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
214268052|NCT03947892|DIAGNOSTIC_TEST|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
214268053|NCT03875404|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
214268054|NCT01631773|GENETIC|microRNA|Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
214268055|NCT01869439|DEVICE|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
214268056|NCT01869439|DEVICE|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
214828917|NCT03512483|BEHAVIORAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
214828918|NCT03317067|DRUG|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
214828919|NCT03317067|OTHER|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
214828920|NCT01263353|DRUG|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
214828921|NCT01263353|DRUG|Everolimus followed by Pasireotide LAR + Everolimus|
214828922|NCT07054554|OTHER|NTRI-MH|NTRI-MH intervention will use evidence-based instructional strategies for adult professional development (i.e., lecture, discussion, case studies, role-playing). NTRI-MH training includes 20 hours of didactic and interactive sessions (5 sessions of 4 hours each) covering the following areas specific to MH needs in young children at-risk: 1) benefits and barriers (professional and family) to early intervention for children with MH concerns, 2) approaches for empowering caregivers, 3) supporting strategies to assist families through early MH access and service engagement , 4) use of the dashboard to track and monitor the course of clinical, functional, and behavioral outcomes, 5) evidence-based working alliances with PCPs and teachers (including a 2 hour session with the child's teacher), and 6) MH resources, treatments and services, and strategies to support parental management of young child behaviors.
214828923|NCT07059403|BIOLOGICAL|SN2001|100 µg, for subcutaneous (SC) injection
214828924|NCT07059403|BIOLOGICAL|SN2001|200 µg, for subcutaneous (SC) injection
214828925|NCT07059403|BIOLOGICAL|SN2001|300 µg, for subcutaneous (SC) injection
214828926|NCT07058662|GENETIC|Single dose intravenous of BBM-D101|BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.The administration is completed by a single intravenous infusion.
214828927|NCT06764680|DRUG|Trifluorouracil tepidopyrimidine|30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w
214828928|NCT06764680|DRUG|Bevacizumab|5mg/kg. ivgtt. d1 and d15. q4w
214828929|NCT06764680|DRUG|Sindilizumab|200mg. ivgtt. d1. q4w
214828930|NCT06764680|RADIATION|IMRT|In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.
214828931|NCT04236596|DEVICE|Participants received a Neurostimulator, which was used to map the pudendal nerve|Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
214828932|NCT07061821|OTHER|accelerated cardiac cine-MRI sequence|Addition of an accelerated cardiac cine-MRI sequence with deep learning-based image reconstruction to the standard cardiac MRI protocol, performed during the same session
214268057|NCT01869439|DEVICE|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
214268058|NCT01869439|DEVICE|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
214268059|NCT05618860|OTHER|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
214268060|NCT00069940|BIOLOGICAL|sargramostim|
214268061|NCT00069940|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
214828933|NCT07065357|DRUG|Empagliflozin (oral)|Participants received Empagliflozin 10 mg orally once daily for six months.
214828934|NCT07065357|OTHER|Matching placebo|Participants received matching placebo orally once daily for six months.
214828935|NCT07075146|DRUG|DOR/3TC/TDF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100/300/300 mg
214828936|NCT07075146|DRUG|BIC/FTC/TAF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
214828937|NCT07128485|OTHER|Fentanyl test strips|Fentanyl test strips (FTS) are small strips of paper that can detect the presence of fentanyl in illicit drugs.
214828938|NCT07128485|BEHAVIORAL|Fentanyl test strip education|Developed in the R61 phase, the educational intervention will provide participants with knowledge about how to correctly use fentanyl strips.
214828939|NCT07128602|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes of anodal tDCS over the primary motor cortex contralateral to the participants surgical limb during a quadriceps torque matching task
214828940|NCT07128602|DEVICE|sham transcranial direct current stimulation (tDCS)|Participants receive sham tDCS in which the device only delivers current during the first and last 30 seconds while participants perform a quadriceps torque matching task
214828941|NCT07075822|OTHER|20g of FiberSMART®|20g of FiberSMART® dissolved in 250g of water
214828942|NCT07075822|OTHER|20g of Dextose|20g of dextrose dissolved in 250g of water
214828943|NCT07075822|OTHER|Water Control|250g of water
214828944|NCT05309135|DRUG|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
214828945|NCT06140355|BEHAVIORAL|Qigong|a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
214828946|NCT06140355|BEHAVIORAL|Daily 2 min pain management survey|Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
214828947|NCT05880082|DRUG|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
214828948|NCT06904378|DRUG|Ontegimod|Per assigned dose level.
214828949|NCT06904378|DRUG|Gemcitabine|The dose of gemcitabine is 1000 mg/m\^2.
214828950|NCT06904378|DRUG|Nab paclitaxel|The dose of nab-paclitaxel is 125 mg/m\^2.
214828951|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
214828952|NCT07089992|DRUG|Pembrolizumab|Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses
214268062|NCT01597960|OTHER|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
214268063|NCT02167087|PROCEDURE|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
214268064|NCT04526431|DRUG|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
214268065|NCT04099147|OTHER|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
214268066|NCT02898883|BEHAVIORAL|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
214268067|NCT01015898|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
214268068|NCT05280782|DRUG|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
214268069|NCT03519620|OTHER|SWWSV|Behaviours to prevent child obesity
214828953|NCT06912295|DRUG|HL-1186|HL-1186 tablet for oral administration.
214268070|NCT02000479|OTHER|training|
214268071|NCT04850521|OTHER|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
214828954|NCT06912295|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
214828955|NCT00025935|DRUG|Lithium|
214828956|NCT06495450|DEVICE|Omnidirectional Virtual Reality and Treadmill Training|Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
214828957|NCT06495450|BEHAVIORAL|Traditional Exercise|A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
214828958|NCT01799538|DRUG|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
214268072|NCT05738954|OTHER|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
214268073|NCT06092385|OTHER|Data collection|"Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)"
214268074|NCT02589405|DRUG|Benzoyl Peroxide|
214268075|NCT02589405|OTHER|Dermotivin® Soft Liquid cleanser|
214828959|NCT01799538|DRUG|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1
214828960|NCT01799538|PROCEDURE|PFT|Breathing Test
214828961|NCT03031821|DRUG|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
214828962|NCT03031821|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
214828963|NCT04981925|BEHAVIORAL|MBSR treatment|"Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up."
214268076|NCT02589405|OTHER|Cetaphil® Dermacontrol Moisturizer SPF30|
214268077|NCT01457573|DRUG|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
214268078|NCT01457573|DRUG|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
214268079|NCT02905149|PROCEDURE|Serrato|Serratus plane block.
214268080|NCT02905149|PROCEDURE|Control|Standard anesthesia
214268081|NCT02332668|BIOLOGICAL|Pembrolizumab|IV infusion
214828964|NCT07112040|BEHAVIORAL|Behavioral - ASSYST-VS Protocol|"The ASSYST-SV protocol consists of three sessions, each lasting approximately 90 minutes, ideally delivered once per week over a three-week period.~The intervention includes:~Session 1: Psychoeducation: Explanation of typical responses to sexual trauma, providing information about the recovery process, and establishing a strong therapeutic alliance between the client and therapist.~Sessions 1-3: Emotional self-regulation using trauma-sensitive yoga exercises adapted for survivors of sexual violence.~Sessions 2-3: Trauma desensitization using EMDR-informed techniques, including bilateral stimulation and self-applied tools such as the Butterfly Hug.~Safety procedures and closure are included in all sessions to ensure emotional containment and promote participant well-being.~The intervention is delivered by trained professionals in specialized support services for victims of gender-based violence."
214268082|NCT05962346|DEVICE|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
214268083|NCT05962346|DEVICE|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
214268084|NCT05962346|DEVICE|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
214268085|NCT03285984|OTHER|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
214268086|NCT03285984|OTHER|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
214268087|NCT03285984|OTHER|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
214268088|NCT03285984|OTHER|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
214268089|NCT05905900|COMBINATION_PRODUCT|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
214268090|NCT04612673|DRUG|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
214268091|NCT03821909|PROCEDURE|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
214268092|NCT00770939|DEVICE|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
214268093|NCT04474158|BEHAVIORAL|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
214268094|NCT04474158|BEHAVIORAL|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
214268095|NCT00203073|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
214268096|NCT00203073|DRUG|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
214268097|NCT00003661|BIOLOGICAL|anti-thymocyte globulin|
214268098|NCT00003661|DRUG|busulfan|
214268099|NCT00003661|DRUG|cyclosporine|
214268100|NCT00003661|DRUG|melphalan|
214268101|NCT00003661|DRUG|methylprednisolone|
214268102|NCT00003661|PROCEDURE|umbilical cord blood transplantation|
214268103|NCT00003661|RADIATION|radiation therapy|
214268104|NCT06180720|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
214268105|NCT06180720|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
214268106|NCT04326075|DEVICE|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
214268107|NCT02892123|DRUG|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
214268108|NCT02892123|DRUG|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
214268109|NCT02892123|DRUG|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
214268110|NCT02892123|DRUG|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
214268111|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
214268112|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
214268113|NCT00990405|DRUG|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
214828965|NCT07110376|OTHER|Nighttime Deep Brain Stimulation with Varying Amplitude Settings|Participants will undergo three different nighttime-only Deep Brain Stimulation (DBS) settings in a randomized crossover design: 0% amplitude (stimulation off), 50% amplitude of their optimal clinical DBS settings, and full clinical DBS settings (100%). Each setting is applied for two weeks during sleep, over a total six-week home monitoring period. The intervention is designed to assess how varying levels of subthalamic nucleus DBS influence sleep quality and neural oscillatory activity. Only nighttime DBS settings are modified; daytime settings remain unchanged.
214828966|NCT00667212|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
214828967|NCT00667212|BEHAVIORAL|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
214828968|NCT06238843|DRUG|Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）|"Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles.~Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)."
214828969|NCT06238843|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .
214828970|NCT06921967|DEVICE|Rose K2|Corneal RGP lens with flexible parameters.
214828971|NCT06921967|DEVICE|Onefit MED|Scleral RGP lens with flexible parameters.
214828972|NCT07110207|BIOLOGICAL|Blood test|Metabolic measurements and measurements of hormones related to food intake
214828973|NCT07110207|OTHER|Interrogation of the subject|Collection of socio-demographic data, medical and family history, medication
214828974|NCT07110207|OTHER|Cognitive assessment|MMSE and MoCA cognitive tests
214828975|NCT07110207|OTHER|Nutritional assessment|Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)
214268114|NCT00620347|DRUG|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
214268115|NCT04727931|BEHAVIORAL|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
214268116|NCT01899664|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
214268117|NCT04709354|DIAGNOSTIC_TEST|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
214268118|NCT02438657|PROCEDURE|median nerve block|
214268119|NCT05868473|DIAGNOSTIC_TEST|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
214268120|NCT05868473|DIAGNOSTIC_TEST|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
214268121|NCT03011619|BEHAVIORAL|Usual Standard of Care|medication management, group therapy, and individual therapy.
214268122|NCT03011619|BEHAVIORAL|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
214268123|NCT01131156|BEHAVIORAL|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
214268124|NCT03530527|PROCEDURE|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
214268125|NCT03530527|PROCEDURE|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
214828976|NCT07110207|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution (prepared beforehand)
214828977|NCT07110207|OTHER|Sucrose taste detection test|Triangular test
214828978|NCT06916221|BEHAVIORAL|Long Term Memory|Tablet computer game designed to stimulate environmental enrichment via an adaptive and immersive experience learning virtual neighborhoods and errands in order to complete assigned errands.
214828979|NCT06916221|BEHAVIORAL|Worder|Tablet computer game designed to stimulate interest in solving word puzzles, much like the Boggle game.
214828980|NCT07116681|DRUG|Inhaled treprostinil|Inhaled treprostinil is an inhaled prostacyclin analog which triggers pulmonary arterial dilation. This is the only intervention in this trial.
214828981|NCT07114796|DIETARY_SUPPLEMENT|Standard Commercial Lactose-Free Formula|"COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration: 7 days"
214268126|NCT04824976|DIETARY_SUPPLEMENT|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
214268127|NCT04824976|DIETARY_SUPPLEMENT|Placebo|matched powder maltodextrin twice daily = 60kcal
214268128|NCT03929510|DRUG|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
214268129|NCT03929510|DRUG|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
214268130|NCT03929510|DRUG|PF-06651600|Oral solution 200mg
214268131|NCT02676115|OTHER|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
214268132|NCT02676115|OTHER|Medipore Tape|"* One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
214828982|NCT07114796|DIETARY_SUPPLEMENT|Rice based recipe method feeding formula|"Rice based recipe method feeding formula Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Rice-Based Lactose-Free Therapeutic Formula~Description: A locally prepared rice-based formula developed as an alternative to F-75, using puffed rice, sugar, oil, and micronutrient mix. It is lactose-free and used for feeding well-nourished children with persistent diarrhea.~Route: Oral/Nasogastric~Dosage: As per WHO feeding schedule - 130 ml/kg/day in 2-hourly feeds.~Duration: 7 days during the stabilization phase~For Arm: COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration:"
214828983|NCT06907017|DEVICE|LVAS|Implantation and use of the CorWave LVAS to evaluate the safety and effectiveness of the CorWave LVAD to treat advanced left ventricular heart failure.
214828984|NCT06920992|BEHAVIORAL|Working memory and set-switching tasks|A behavioral task that requires subjects to switch between stimulus- response contingencies based on a colored contextual cue. In addition, a behavioral task that requires subjects to memorize a set of visual stimuli. Subjects will then be presented with a test set and will be asked to indicate whether any stimulus therein is not part of original memorized set.
214828985|NCT06923033|BEHAVIORAL|Smartphone App|Participants will download a study app that will allow them to track smoking urges and abstinence. Access to augmented reality will become available after 48 hours of self-reported abstinence.
214828987|NCT07121972|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo Magnetic resonance (MR) imaging
214828988|NCT07121972|DEVICE|Artificial Intelligence (AI)|AI applied to MRI images
214828989|NCT07127861|OTHER|Treadmill gait training|Participants will undergo a 15-minute treadmill gait training session using a safety harness and under the continuous supervision of a physiotherapist to ensure patient safety. The study will be carried out for 12 weeks with a frequency of two weekly sessions. During them, the participants will receive treadmill training. All participants will walk at a speed exceeding 2.5 km/h. The speed will be individually adjusted to provide a challenging yet appropriate intensity based on each participant's capabilities.
214828990|NCT07131072|OTHER|daiphragm mobility by ultrsound|fibrosis score, alveolitis score by CT Chest
214828991|NCT07131072|OTHER|spirometry ,DLCo|FEV1, FVC, FEV1/FVC, DLCo
214828992|NCT07139392|BIOLOGICAL|Albumin (5% serum-protein solution containing immunoglobulins)|"* Preoperative Phase:~  * Oral hygiene instruction~ * Phase I periodontal therapy~ * Initial photography and papillary height measurements using digital calipers or customized stents~* Surgical Technique:~  * Local anesthesia~ * Intrasulcular incision around target teeth~ * Papilla preservation flap~ * Harvesting CTG from the palate~ * Injection of liquid Bio-PRF at the papillary base (test group)~ * CTG positioned in the papilla region~ * Suturing with microsurgical technique~* Postoperative Protocol:~  * Analgesics (e.g., ibuprofen 400 mg)~ * Chlorhexidine 0.12% mouth rinse for 2 weeks~ * Suture removal at 10-14 days~ * Follow-up at 1 month, 3 months, and 6 months"
214828993|NCT07139392|BIOLOGICAL|connective tissue graft|Local anesthesia. Intrasulcular incision around target teeth. Papilla preservation flap. Harvesting CTG from the palate
214828994|NCT07139080|BEHAVIORAL|Mobile education|It consists of participants who will download the mobile patient education and breathing exercise reminder program and apply it for 10 weeks.
214828995|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the knee then ankle|"Procedure/Surgery: Procedure/Surgery: Kinesio Taping (KT) applied to the knee or ankle Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
214268133|NCT00839852|DRUG|Cariprazine|Cariprazine was supplied in capsules.
214268134|NCT02761733|BEHAVIORAL|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
214268135|NCT04198597|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
214268136|NCT04198597|BEHAVIORAL|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
214268137|NCT00801320|PROCEDURE|Tumor collection|Tumor collected at the time of planned surgery
214268138|NCT00120523|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214268139|NCT00120523|DRUG|Topical corticosteroids|TCS
214828996|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the ankle then knee|"Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
214828997|NCT07139496|DEVICE|Spinal Cord Stimulator|"After the implantation of the spinal cord stimulator, the study will begin with 3 phases:~For the first phase, SCS over lumbrosacral spinal cord will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the second phase, SCS over lumbrosacral spinal cord will be stopped. SCS over the injury site will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the third phase, SCS over both lumbrosacral spinal cord and injury site of spinal cord will be activated for another 3 months with appropriate stimulation of lower limb muscles for walking~During all the phrases, physiotherapy of individual muscle groups for walking will be arranged. Exoskeleton training will also be arranged for 4 to 5 hours per week."
214828998|NCT07139093|DEVICE|DBS-coupled tACS|tACS will be applied in a phase-coupled manner, so that tACS and DBS are synchronized
214828999|NCT07139678|OTHER|SUMAC|Participant will complete tasks given in SUMAC.
214829000|NCT07138885|PROCEDURE|HAI-FOLFOX + bevacizumab + QL1706|"Arm 1:~HAI-FOLFOX Administration (Day 1 of Each Cycle) Super-selective insertion the arterial catheter into the tumor-feeding artery, then infusion: Oxaliplatin: 85 mg/m², Leucovorin: 400 mg/m², 5-FU: 2500 mg/m²~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via arterial infusion.~Then QL1706 (5 mg/kg, IV infusion, Q3W).~Treatment Schedule: Repeat HAI-FOLFOX + arterial bevacizumab every 3 weeks (max 6 cycles), followed by QL1706 maintenance (Q3W)."
214829001|NCT07138885|PROCEDURE|TACE + bevacizumab + TAS-102 + QL1706|"Arm 2:~On-Demand TACE (Lipiodol: ≤10 mL, mixed with platinum + doxorubicin agent, each ≤50 mg) to form an emulsion. Repeat TACE until TACE resistance develops (typically \~4 sessions).~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via intra-arterial route.~After first TACE, begin TAS-102 (15 mg/m² po BID) once liver function recovers to acceptable levels.~Then QL1706 (5 mg/kg, IV infusion, Q3W)."
214829002|NCT07140107|BEHAVIORAL|AI-generated PLS|Reading AI-generated Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
214829003|NCT07140107|BEHAVIORAL|Original PLS|Reading original Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
214829004|NCT07139639|DRUG|Guanxinning Tablets|"Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* NMPA Approval No. Z20150028~* Administration: 4 tablets orally, three times daily for 6 months"
214829005|NCT07139639|DRUG|Matching Placebo for Guanxinning|"Matching Placebo for Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* Drug Product Certificate of Analysis Approval No.YF-R-C037A-2024104-A~* Administration: 4 tablets orally, three times daily for 6 months"
214829006|NCT07139509|DRUG|allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells|dosage form: UCAR-T cell injection Route of Administration: Single intravenous injection Participants will receive lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) from Day -5 to -3, prior to UCAR-T cell infusion on Day 0.
214829007|NCT07139015|OTHER|CONSTRAINT-INDUCED MOVEMENT THERAPY|Constraint-Induced Movement Therapy (CIMT) involves restricting the unaffected arm to promote use of the affected limb through task-specific exercises. It is delivered 5 days a week for 6 weeks, with sessions lasting 60-90 minutes, focusing on improving strength, dexterity, and function.
214829008|NCT07139015|OTHER|MIRROR THERAPY|"Mirror Therapy (MT) uses a mirror to reflect movements of the unaffected limb, creating the illusion of movement in the affected limb.~Participants will do 60-90 minute sessions, 5 days a week for 6 weeks.~Exercises include hand opening/closing, finger movements, and simple object tasks to improve motor function and coordination through visual feedback."
214829009|NCT07140315|DRUG|[18F]DK222 radiotracer|\[18F\]DK222 is an investigational radiotracer used detect non-small cell lung cancer (NSCLC) or Urothelial Cancer (UC) tissue in the body when used with positron emission tomography/computed tomography. Participants will undergo a PET-CT scan after \[18F\]DK222 is injected into the participant's vein an intravenous line.
214829010|NCT07140198|PROCEDURE|Hyperbaric Oxygen Therapy|HBOT will be administered in five sessions (1 on Day 0, 2 on Day 1, 2 on Day 2), beginning immediately after the lipofilling. Each session consists of 100% oxygen inhalation at 2.5 ATA for 90 minutes. Postoperative MRI will be performed six months after each AFT session to assess the volume of retained graft.
214829011|NCT07140198|OTHER|Control|Patients in the control group will undergo standard follow-up after the lipofilling without HBOT.
214829012|NCT07140536|OTHER|Environmental temperature|The office is day is spent in 19 or 23°C room temperature from 08:30AM to 04:30PM.
214829013|NCT07140536|BEHAVIORAL|Physical activity|From 08:30AM to 04:30PM, the office is day is spent either fully sedentary or interspersed with light walking on a treadmill (60 min at 10:00AM, 15 min at 01:00PM, 15 min at 02:00PM, 15 min at 03:00PM, 15 min at 04:00PM).
214829014|NCT07139977|DRUG|Enfortumab Vedotin|Enfortumab vedotin is an ADC comprised of a fully human IgG1Κ antibody conjugated to the microtubule-disrupting agent MMAE via a protease-cleavable linker. Enfortumab vedotin is thought to induce anti-tumor activity by binding to the nectin-4 protein on the surface of cancer cells, leading to internalization, proteolytic cleavage of the linker, and intracellular release of MMAE that subsequently disrupts tubulin polymerization and leads to mitotic arrest and apoptosis of the tumor cell.
214829015|NCT07138898|DRUG|Methotrexate|Continue throughout perioperative period
214268140|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (T4030)|Eye drop
214268141|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (Ganfort)|Eye drop
214268142|NCT02850354|OTHER|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
214268143|NCT04295772|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
214829016|NCT07138898|DRUG|Sulfasalazine|Continue throughout perioperative period
214829017|NCT07138898|DRUG|Hydroxychloroquine|Continue throughout perioperative period
214829018|NCT07138898|DRUG|Leflunomide|Continue throughout perioperative period
214829019|NCT07138898|DRUG|Azathioprine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
214829020|NCT07138898|DRUG|Mycophenolate|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
214829021|NCT07138898|DRUG|Cyclosporine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
214829022|NCT07138898|DRUG|Tacrolimus|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
214829023|NCT07138898|DRUG|Etanercept|Control group: Schedule surgery 2 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
214829024|NCT07138898|DRUG|Adalimumab|Control group: Schedule surgery 3 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
214829025|NCT07138898|DRUG|Golimumab|"Control group: Schedule surgery 5 weeks after last administered 4-week subcutaneous dose or 9 weeks after last administered 8-week intravenous dose.~Intervention group: Schedule surgery 2 weeks after last administered 4-week subcutaneous dose or 4 weeks after last administered 8-week intravenous dose."
214829026|NCT07138898|DRUG|Certolizumab|Control group: Schedule surgery 5 weeks after last administered dose. Intervention group: Schedule surgery 2 weeks after last administered dose.
214829027|NCT07138898|DRUG|Infliximab|"Control group: Schedule surgery 9 weeks after last administered intravenous dose.~Intervention group: Schedule surgery 4 weeks after last administered dose."
214829028|NCT07138898|BIOLOGICAL|Rituximab|Control: Schedule 7 months after last administered dose. Intervention group: Schedule 3 months after last administered dose.
214829029|NCT07138898|BIOLOGICAL|Belimumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
214829030|NCT07138898|BIOLOGICAL|Tocilizumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
214829031|NCT07138898|BIOLOGICAL|Anakinra|Control group: Schedule surgery 2 days after last administered daily dose. Experimental group: Schedule surgery 1 day after last administered daily dose.
214829032|NCT07138898|BIOLOGICAL|Canakinumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
214829033|NCT07138898|BIOLOGICAL|Abatacept|"Control group: Schedule surgery 2 weeks after last administered weekly subcutaneous dose or 5 weeks after last administered monthly intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly subcutaneous dose or 2 weeks after last administered monthly intravenous dose."
214829034|NCT07138898|BIOLOGICAL|Secukinumab|"Control group: Schedule surgery 5 weeks after last administered subcutaneous dose.~Intervention group: Schedule surgery 2 weeks after last administered subcutaneous dose."
214829035|NCT07138898|BIOLOGICAL|Ixekizumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
214829036|NCT07138898|BIOLOGICAL|Bimekizumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4 weeks after last administered 8-week dose
214829037|NCT07138898|BIOLOGICAL|Ustekinumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6 weeks after last administered 12-week dose.
214829038|NCT07138898|BIOLOGICAL|Guselkumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4.5 weeks after last administered 8-week dose.
214829039|NCT07138898|BIOLOGICAL|Risankizumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6-7 weeks after last administered 12-week dose.
214829040|NCT07138898|DRUG|Tofacitinib|Control group: Schedule surgery 4 days after last administered daily dose. Intervention group: Schedule surgery 2 days after last administered daily dose.
214829041|NCT07138898|DRUG|Upadacitinib|Control group: Withhold 4 days prior to surgery Intervention group: Withhold 2 days prior to surgery
214829042|NCT07138547|DRUG|Eliglustat, CD30 target immunotherapy|"Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week.~CD30 target immunotherapy：Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy."
214829043|NCT05541198|OTHER|Pressure Injury Prevention Care Bundle|"1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
214829044|NCT02293486|DIETARY_SUPPLEMENT|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
214829045|NCT06933602|OTHER|relaxin|"Progressive Muscle Relaxation (PMR) exercises help alleviate symptoms in patients with COPD by reducing the effects of anxiety and stress, distracting attention from pain, and relieving muscle tension and spasms.~These exercises are beneficial in managing:~Tension headaches Back pain Tension and pain in jaw muscles Tension and pain around the eye muscles Muscle spasms Insomnia Stress-related muscle tension The required content of the exercises for relieving stress-related tension will be provided in a booklet. The booklet will be given to the patients following the training session."
214829046|NCT07138924|OTHER|Graston Technique|Firstly, apply a moisturizer or gel to affected part. Then gentle strokes are applied from proximal to distal direction to assess trigger point or taut band. After knowing the exact area, apply strokes gently with minimum force in all directions by keeping tool in 30- 60-degree angle. Total Application time will be between 40-120 seconds. conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
214656776|NCT06123650|DEVICE|Repetitve transcranial magnetic stimulation|"The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days."
214656777|NCT06123650|DEVICE|Sham transcranial magnetic stimulation|Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
214656778|NCT06460350|DEVICE|NEUROCUPLE™ Patch|nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.
214656779|NCT06460350|DEVICE|Placebo Patch|The placebo patch is identical to the active patch but with no active agents.
214656780|NCT04642287|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
214656781|NCT04642287|DRUG|Vaseline|Placebo
214656782|NCT04642287|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
214656783|NCT03754049|DRUG|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
214656784|NCT03754049|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
214656785|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
214656786|NCT03584022|DEVICE|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
214656787|NCT03584022|PROCEDURE|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
214656788|NCT04889209|BIOLOGICAL|Ad26.COV2.S|Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.
214656789|NCT04889209|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
214656790|NCT04889209|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.
214656791|NCT04889209|BIOLOGICAL|mRNA-1273.211|Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
214656792|NCT04889209|BIOLOGICAL|mRNA-1273.222|Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
214656793|NCT04889209|BIOLOGICAL|SARS-CoV-2 rS/M1|SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume \[w/v\]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
214656794|NCT03829579|DRUG|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
214656795|NCT06417515|DRUG|Xiao-Yao-San|Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
214656796|NCT06417515|OTHER|Weight loss class(WLC) group|Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
214656797|NCT04962373|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
214656798|NCT03818269|PROCEDURE|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
214656799|NCT02148029|OTHER|Exercise|Upper and Lower extremity exercise
214656800|NCT02148029|OTHER|Standard Care|anticoagulation, compression, and ad-lib ambulation
214829047|NCT07138924|OTHER|Dynamic Oscillatory Stretch Technique|Passively stretch that is at the first point of stretch sensation. The next component to DOS, 2-sec, passive stretch with slow oscillation. Total 10 reps x 2 sec hold oscillations x 3 sets.conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
214829048|NCT07140627|DRUG|Bupivacain|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants had received 1 mL/kg 0.25% bupivacaine. Post operative pain was assessed.
214829049|NCT07140627|DRUG|Dexmedetomidine & Bupivacaine.|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants were included and administered 1 mL/kg 0.25% bupivacaine and 1 μg/kg dexmedetomidine. Post operative pain was assessed.
214829050|NCT07140393|DRUG|HRS-4508+ Capecitabine|HRS-4508+ Capecitabine
214829051|NCT07140393|DRUG|HRS-4508+ Trastuzumab|HRS-4508+ Trastuzumab
214829052|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Pertuzumab|HRS-4508+ Trastuzumab+ Pertuzumab
214829053|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Capecitabine|HRS-4508+ Trastuzumab+ Capecitabine
214829054|NCT07140393|DRUG|Trastuzumab+ Capecitabine|Trastuzumab+ Capecitabine
214829055|NCT07140393|DRUG|HRS-4508+A1811|HRS-4508+A1811
214829056|NCT07135921|BEHAVIORAL|Sleep Hygiene Education|This intervention consists of a nurse-led sleep hygiene education program delivered through a 30-minute PowerPoint presentation. Participants in the intervention group will also receive twice-daily reminder messages via WhatsApp for four weeks to reinforce healthy sleep habits. The program aims to improve sleep quality and disease management in individuals with cardiovascular disease. After the study, the educational materials will also be shared with the control group.
214829057|NCT07138911|OTHER|Intervention group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Activity plan is calendar on mobile health app. Mobile placed in pocket or bag before starting walk and mark activity on calendar.
214829058|NCT07138911|OTHER|Control group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Manual record of walking and date.
214829059|NCT07139548|DRUG|RAY1225|Administered SC
214829060|NCT07139548|DRUG|Semaglutide|Administered SC
214829061|NCT07139366|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214829062|NCT07139366|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 1 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214829063|NCT07139366|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
214829064|NCT07139366|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
214829065|NCT07139366|DRUG|Saccharomyces Boulardii Oral Powder|Saccharomyces boulardii combined with Bismuth-containing quadruple therapy:given for 14 days at a dose of Saccharomyces boulardii powder 250 mg 2 packets BID#bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214829066|NCT07139249|OTHER|The high intensity interval training|The training program for students in groups 1 and 2 involves high intensity interval training exercises, conducted three times per week for six weeks. The sessions include a 10-minute warm-up at 40% Heart Rate Reserve, four high-intensity work periods at 85-95% Heart Rate Reserve, three low-intensity work periods at 60-70% Heart Rate Reserve, and a 5- 10 minute cool down at 30% Heart Rate Reserve.
214829067|NCT07139249|OTHER|The study moderate continuous training|All students in groups 3\&4 will receive moderate continuous training 3 times per week for 6 weeks. Each session 40 to 50 minutes included a 5 to 10 minute warm-up, fo followed by 30 minutes of moderate aerobic exercise (treadmill walking exercise) with constant intensity at 60% to 70% Heart Rate Reserve and 5 to 10 minutes cool-down
214829068|NCT07140575|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|twice daily rTMS, intermittent theta burst stimulation targeting the left dorsolateral prefrontal cortex with a figure-8 coil
214829069|NCT07140549|OTHER|Survey using a questionnaire.|"A monocentric experimental study conducted as a survey, including patients enrolled in our fertility preservation program between May 2005 and May 2020.~Participants were asked about their current reproductive health status, their experience with the fertility preservation process, and their overall satisfaction with the care they received."
214268144|NCT04693117|OTHER|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
214268145|NCT05887232|PROCEDURE|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
214829070|NCT07138521|DRUG|Linezolid (IV and PO)|No dose change and continued linezolid 600 mg every 12 hours.
214829071|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 300 mg every 12 hours.
214829072|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 600 mg every 24 hours.
214829073|NCT07139470|DRUG|Sacituzumab Tirumotecan + anlotinib|"Phase I part: 3 prespecified doses (sac-TMT 4mg/kg Q2W +anlotinib 8mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib10mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib12 mg Q3W).~Phase II part: sac-TMT patients Q2W +anlotinib RP2D Q3W."
214829074|NCT07139613|OTHER|Control group(PS)Planer occlusal scheme with rounded shoulder finish line|Control group (PS) will have planer occlusal scheme with rounded shoulder finish line.
214829075|NCT07139613|PROCEDURE|First intervention group(FF) flat occlusal scheme with feather edge finish line|First intervention group we will have flat occlusal scheme with feather edge finish line
214268146|NCT05887232|PROCEDURE|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
214268147|NCT02846324|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
214268148|NCT02846324|DRUG|Placebo|Placebo capsules
214656801|NCT05424081|BEHAVIORAL|EMBER|Self-help tool to increase weight management engagement
214656802|NCT05424081|BEHAVIORAL|Control|List of weight management programs
214656803|NCT04676802|DRUG|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
214656804|NCT04676802|DRUG|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
214656805|NCT05862272|DRUG|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
214656806|NCT06517121|DEVICE|Personalized Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
214656807|NCT06517121|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
214656808|NCT06517121|DEVICE|Conventional Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
214656809|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
214656810|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
214656811|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
214656812|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
214656813|NCT05505422|DEVICE|Routine ECMO|Routine ECMO during lung tansplant
214656814|NCT05505422|DEVICE|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field"
214656815|NCT01491087|BIOLOGICAL|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
214656816|NCT06159478|DRUG|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
214656817|NCT01725165|OTHER|Clinical Observation|Undergo clinical observation
214656818|NCT01725165|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214656819|NCT01725165|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214656820|NCT01725165|OTHER|Quality-of-Life Assessment|Ancillary studies
214656821|NCT01725165|PROCEDURE|Standard Follow-Up Care|Undergo standard maintenance therapy
214656822|NCT01725165|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214656823|NCT05039086|DRUG|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
214656824|NCT05039086|DRUG|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
214656825|NCT05113940|DRUG|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
214656826|NCT05113940|DRUG|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
214656827|NCT05113940|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
214656828|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 5mg; (3) If not succeed, the second subject takes 7mg; (4) Until seven sequence reversal inflection points."
214656829|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
214656830|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
214829076|NCT07139613|PROCEDURE|Second intervention group(FS) flat occlusal with rounded shoulder finish line design|Second intervention will have flat occlusal scheme with rounded shoulder finish line design
214829077|NCT07139002|OTHER|Bobath Therapy|The group will repeat 10 exercises (facilitated rolling, sitting balance exercises, weight shifting in standing, functional sit-to-stand, stepping practice, reaching activities, wall slides, therapeutic ball exercises, stair climbing practice, and breathing and relaxation techniques) for 8 weeks.
214829078|NCT07139002|OTHER|Sensory Training|The group will repeat 9 exercises (texture discrimination, shape, size, and discrimination, tactile recognition, proprioception training, temperature differentiation, tactile localization, sensory mapping, sensory training through functional activities, and tabletop sensory exercises) for 8 weeks.
214829079|NCT05885568|BIOLOGICAL|blood sampling|Blood sampling from healthy volunteers
214829080|NCT05885568|OTHER|drone transportation|drone transportation
214829081|NCT05885568|OTHER|car transportation|car transportation
214829082|NCT00469521|DRUG|Refresh Tears, 9582X|
214829083|NCT02347111|DRUG|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
214829084|NCT02347111|DRUG|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
214829085|NCT05984290|DEVICE|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
214829086|NCT07140042|OTHER|Survey|Survey
214829087|NCT07139028|OTHER|Tibialis Anterior resistance training and ladder drills|19 participants will be in experimental group A, they will perform tibialis anterior resistance training exercises with ladder drills (3 times/ week for 6 weeks) along with traditional training
214829088|NCT07139028|OTHER|Traditional training|19 participants will be in control group B,they will perform only traditional training (guided by coach)
214829089|NCT07140510|DRUG|Dinalbuphine Sebacate|Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA
214829090|NCT07140510|DRUG|Normal Saline|Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block
214829091|NCT07138612|BEHAVIORAL|Peer education group|Students will learn urinary catheterization through peer education.
214829092|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
214829093|NCT07139964|DIETARY_SUPPLEMENT|Vitamin D3|Participants receive oral vitamin D3 (cholecalciferol) 10,000 IU daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. Vitamin D3 is provided in identical-appearing capsules. Compliance is monitored using the MMAS-8 adherence scale.
214829094|NCT07139964|OTHER|Placebo|Participants receive an oral placebo capsule daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. The placebo is identical in appearance to the vitamin D3 capsule. Compliance is monitored using the MMAS-8 adherence scale.
214829095|NCT07139730|DRUG|Lignocaine 2% concentration solution|the effect of preoperative nebulized lidocaine on the stress response to intubation, monitored by rise in serum cortisol level post intubation
214829096|NCT07140094|BEHAVIORAL|Structured mindfulness intervention|The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. The mindfulness recordings are between two and twenty minutes long and are accessed online.
214829097|NCT07138742|DRUG|Steroid eye drops|steroid eye drops will be used in control group as usual regimen in treatment of vernal keratoconjunctivitis
214829098|NCT07138742|DRUG|Tacrolimus eye drops|Compound Tacrolimus eye drops in 2 different concentrations will be assessed in treatment of vernal keratoconjunctivitis in terms of efficacy and safety being compared with steroid eye drops
214829099|NCT07138950|OTHER|Mulligan Bent Leg Raise (BLR) Technique|The Mulligan bent leg raise technique involves isometric contraction followed by stretches applied to the hamstring muscle in specific directions. The aim is to increase hamstring flexibility and active knee extension range of motion. The participant lay supine on an elevated bed, while the physiotherapist sat lateral to the leg to be stretched, placing the popliteal fossa of the participant's knee on their shoulder. The hip and knee of the leg to be stretched were flexed to 90°. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with their leg and then relax. At this point of relaxation, the physiotherapist pushed the flexed knee as far forward as possible in the direction of hip flexion within a painless range. This position was held for 5 seconds at the end of the movement. Then, the neutral position was returned, and the procedure was repeated three times
214829100|NCT07138950|OTHER|Static Stretching|Participants lay supine on a stretcher with their backs straight. With the knee fully extended, the physical therapist placed the participant's leg on their shoulder and supported the ankle
214829101|NCT07138846|DRUG|MRG004A plus best supportive care|MRG004A will be administrated as specified in the protocol.
214268149|NCT04151173|PROCEDURE|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
214268150|NCT04151173|PROCEDURE|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
214829102|NCT07138846|DRUG|Placebo plus best supportive care|Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.
214829103|NCT07140003|PROCEDURE|pleural biopsy|To assess whether pleural tissue culture can improve the identification of causative organisms in pleural infections (using the pleural fluid culture), which can aid in selecting appropriate antimicrobial therapy and improve treatment outcomes, thus may provide valuable insights into the utility of pleural tissue culture in managing pleural infection and may guide clinicians in selecting the most appropriate diagnostic approach.
214268151|NCT03993132|DRUG|Empagliflozin|new users (initiators) of Empagliflozin
214268152|NCT03993132|DRUG|Liraglutide|initiators of Liraglutide
214268153|NCT00147212|DRUG|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
214268154|NCT01880619|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
214268155|NCT01880619|DRUG|Solifenacin|Patients in the arm will receive Solifenacin
214268156|NCT01880619|DRUG|Control|Patients in this are will receive placebo
214829104|NCT07139275|OTHER|aerobic exercise|exercise protocol was applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
214829105|NCT07139275|BEHAVIORAL|added sugar elimination|specialized programme of eliminating all kinds of added sugar (all kinds of sugars that are not naturally occurring in natural foods
214829106|NCT07139275|COMBINATION_PRODUCT|aerobic exercise and added sugar elimination|a specialized program of combining added sugar elimination protocols ( elimination of all kinds of added sugars and allowing only sugars naturally occurring in foods) combined with the same aerobic exercise protocol that applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
214829107|NCT07140523|DRUG|SRSD107|SRSD107 is an investigational siRNA product for anticoagulants.
214829108|NCT07140523|DRUG|enoxaparin|Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
214829109|NCT07139600|BIOLOGICAL|CD7 CAR-T cells infusion|Autologous T cells are collected by leukapheresis, activated, and transduced with a retroviral vector encoding a CD7-specific CAR. Following fludarabine/cyclophosphamide lymphodepletion, CD7-CAR-T cells (3 × 10\^6/kg) are infused intravenously. This intervention is distinguished by its CD7 target, aiming to suppress aberrant T-cell-mediated marrow destruction and restore hematopoiesis in aplastic anemia.
214829110|NCT07138755|DRUG|Experimental|Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous） Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma） Radiation:Adaptive radiotherapy with V20\<20%: 1.PGTV60-66Gy/2.0-2.2Gy/30F;PTV54Gy/1.8Gy/30F;2.PGTV54-66Gy/2.0-2.2Gy/30F；3.PGTV50Gy/2.0Gy/25F
214829111|NCT07139769|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' needs and preferences for psychosocial intervention.
214829112|NCT06948747|DRUG|AZD5004|"Participants will receive oral tablets of AZD5004 as single dose on the following days, (i) Day 7, Day 14, Day 21, Day 28, Day 35, Day 42 and Day 55 in Part A. (ii) Day 9 to Day15, Day 16, Day 17 to Day 23, Day 24 to Day 30, Day 31 to Day 37, Day 38 to Day 41 and Day 42 in Part B.~(iii) Day 3 to Day 9, Day 10 to Day 25, Day 26 to Day 33, and Day 34 in Part C."
214829113|NCT06948747|DRUG|Rosuvastatin|Participants will receive single oral tablets of rosuvastatin 10mg on Days 1, 7, 14, 21, 28, and 35.
214829114|NCT06948747|DRUG|Erythromycin|Participants will receive oral doses of erythromycin 500 mg, twice a day from Day 49 to Day 54; and a single dose of 500 mg on Day 55.
214829115|NCT06948747|DRUG|Atorvastatin|Participants will receive single oral doses of 40 mg atorvastatin on Days 4, 8, 16, 38, and 42.
214829116|NCT06948747|DRUG|Simvastatin|Participants will receive single oral doses of 20 mg simvastatin on Days 1 and 31.
214829117|NCT06948747|DRUG|Repaglinide|Participants will receive single oral doses of 0.5 mg repaglinide on Days 1, 10, 26, and 34.
214829118|NCT03366948|OTHER|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
214829119|NCT06894199|OTHER|The Work Shop|Employment intervention consists of 2 days (about 5 hours each) of interactive educational content focused on a variety of topics.
214829120|NCT06949410|DRUG|HER2 Vaccine|MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines
214268157|NCT01034189|DRUG|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
214268158|NCT01034189|DRUG|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
214268159|NCT01034189|DRUG|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
214829121|NCT07138833|DRUG|Dimethyl Fumarate Enteric-coated Capsules|Eligible 50 RMS patients will orally take dimethyl fumarate enteric-coated capsules during treatment, with an initial dose of 120 mg twice daily for 7 days, followed by a maintenance dose of 240 mg twice daily for 48 weeks
214829122|NCT07139145|BEHAVIORAL|Progressive Muscle Relaxation + Standard Physiotherapy|Standard physiotherapy exercises plus PMR sessions. PMR is gradually transitioned from therapist-guided to self-directed practice across the 6 weeks.
214829123|NCT07139145|BEHAVIORAL|Standard Physiotherapy|Participants receive a 6-week standard physiotherapy program delivered twice weekly. Sessions include warm-up, weight-bearing training, balance exercises, gait training, and functional activities. The protocol focuses on improving mobility, weight-bearing capacity, balance, and functional independence. No Progressive Muscle Relaxation or additional behavioral techniques are included.
214829124|NCT07139899|COMBINATION_PRODUCT|Hyperpolarized Xenon 129|Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent
214829125|NCT07139951|PROCEDURE|Biopsy Procedure|Undergo laparoscopy with biopsy
214829126|NCT07139951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214829127|NCT07139951|DRUG|Cisplatin|Given IP
214829128|NCT07139951|PROCEDURE|Computed Tomography|Undergo PET/CT
214829129|NCT07139951|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Given p-HIPEC
214829130|NCT07139951|PROCEDURE|Laparoscopy|Undergo laparoscopy with biopsy
214829131|NCT07139951|PROCEDURE|Lymphadenectomy|Undergo D2 lymphadenectomy
214829132|NCT07139951|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214829133|NCT07139951|DRUG|Paclitaxel|Given IP
214829134|NCT07139951|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
214829135|NCT07139951|PROCEDURE|Surgical Procedure|Undergo gastrectomy and reconstruction
214829136|NCT07139847|DRUG|Magnesium Sulfate Infusion|Magnesium Sulfate (Experimental Group) Intravenous bolus of magnesium sulfate 30 mg/kg administered over 15 minutes immediately after induction of general anesthesia, followed by continuous infusion at 10 mg/kg/h until the end of surgery. Solutions were prepared in identical syringes and infusion bags by an anesthesia technician not involved in patient care. The preparation and administration protocol ensured blinding of participants, anesthesia providers, and outcome assessors.
214829137|NCT07139847|DRUG|0.9% Saline Infusion|ntravenous bolus and continuous infusion of 0.9% sodium chloride solution in the same volume, infusion rate, and duration as the magnesium sulfate group. Solutions were indistinguishable in appearance and prepared under the same blinding procedures.
214829138|NCT07139210|OTHER|perceptual motor training|"Perceptual -motor training program:~1. Balance exercises~2. Awareness training exercises~3. Spatial awareness exercises~4. Training of shape perception exercises~5. Visual perception training exercises~6. Auditory perception training~7. Touch-kinetic perception training~8. Coordination of eye and hand, eye and leg, subtle motor actions"
214829139|NCT07139522|DRUG|Bupivacaine|Patients will receive 20 ml of 0.25% isobaric bupivacaine.
214829140|NCT07139522|DRUG|Dexamethasone|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 4mg of dexamethasone).
214829141|NCT07139522|DRUG|Magnesium sulphate|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 200mg of magnesium sulphate).
214829142|NCT07138664|BEHAVIORAL|Super Skills for Life program|Study-Skills program will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
214829143|NCT07138664|BEHAVIORAL|Study-Skills program|Study-Skills program will be used as a comparator intervention, which will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
214829144|NCT07138638|DEVICE|High-Frequency QRS|All enrolled patients underwent HF-QRS assessment, with subsequent recording of MACE to evaluate the predictive value of HF-QRS parameters for clinical outcomes
214829145|NCT07139704|BEHAVIORAL|Mindfulness-Based Sexual Counseling (MBSR-BA)|A MBSR-based sexual counseling program applied to women after episiotomy, 2 sessions per week for 4 weeks, 8 sessions in total.
214829146|NCT07138703|BEHAVIORAL|Mobile based intervention program|The participants in this group will be using the mobile application
214829147|NCT00023166|DRUG|PEG-paclitaxel|
214268160|NCT01034189|RADIATION|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
214268161|NCT02326662|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
214829148|NCT05738421|DIAGNOSTIC_TEST|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
214829149|NCT06791096|DIAGNOSTIC_TEST|AI-assisted auscultation|The study begins with non-blinded staff collecting medical histories and specialist physicians conducting face-to-face auscultations and assessments. Then, primary care doctors will conduct face-to-face auscultations and first assessments, and use AI-assisted stethoscopes to collect heart sounds following a set protocol. The AI model will analyze the data in real-time and provides an immediate diagnostic result, which is relayed back to the primary care physicians. Based on this, they will make a secondary assessment. All participants will undergo echocardiography.
214829150|NCT06791096|DIAGNOSTIC_TEST|Independent auscultation|It includes medical history collection by non-blinded independent personnel, face-to-face auscultation and evaluations conducted by specialist physicians and primary care doctors separately. All participants will undergo echocardiography.
214829151|NCT02324335|DRUG|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
214829152|NCT02324335|OTHER|Placebo|
214829153|NCT01770002|PROCEDURE|Everted suture technique|
214829154|NCT01770002|PROCEDURE|Non-everted suture technique|
214829155|NCT02780063|OTHER|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
214829156|NCT04735887|OTHER|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
214829157|NCT04336332|COMBINATION_PRODUCT|Hydroxychloroquine Sulfate + Azithromycin|Given PO
214829158|NCT04336332|DRUG|Hydroxychloroquine Sulfate|Given PO
214829159|NCT01619956|DEVICE|SLA dental implants|Dental implant with surface modification.
214829160|NCT01619956|PROCEDURE|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
214268162|NCT03414320|OTHER|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
214268163|NCT05501223|OTHER|Medication review|30-60 minutes extra consultation regarding the patients drugs
214268164|NCT05501223|OTHER|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
214268165|NCT04801173|COMBINATION_PRODUCT|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
214268166|NCT04801173|BEHAVIORAL|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
214268167|NCT02549534|PROCEDURE|Axon Reflexes|"\*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
214268168|NCT02549534|PROCEDURE|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
214268169|NCT02549534|PROCEDURE|Self-Reported Signs & Symptoms of CIPN|Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
214268170|NCT02640573|DRUG|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
214268171|NCT02805972|DRUG|Naloxone|4 mg / 0.1 ml
214268172|NCT02805972|DRUG|Placebo|0.1 ml
214268173|NCT01578070|BIOLOGICAL|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
214268174|NCT01578070|BIOLOGICAL|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
214268175|NCT01578070|BIOLOGICAL|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
214268176|NCT01578070|BIOLOGICAL|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
214268177|NCT01578070|BIOLOGICAL|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
214268178|NCT00407329|PROCEDURE|transurethral resection of the prostate|resection of prostate
214268179|NCT01206166|DRUG|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
214268180|NCT00932126|DRUG|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
214268181|NCT03239600|DRUG|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
214268182|NCT03239600|DRUG|Placebo|Placebo solution will be administered by IV infusion.
214268183|NCT03239600|DRUG|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
214268184|NCT05392257|DRUG|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
214268185|NCT03815474|DRUG|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
214268186|NCT03062007|DRUG|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
214268187|NCT04200573|DRUG|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
214268188|NCT05264688|DIAGNOSTIC_TEST|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
214268189|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
214268190|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
214268191|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
214268192|NCT04495933|OTHER|Placebo|sterile saline
214268193|NCT03939754|BEHAVIORAL|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
214268194|NCT04862377|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
214268195|NCT04862377|DRUG|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
214268196|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
214268197|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
214268198|NCT00299351|DRUG|Depsipeptide|
214268199|NCT05763212|OTHER|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
214268200|NCT05763212|OTHER|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
214268201|NCT02063711|BEHAVIORAL|Yoga intervention|
214268202|NCT03427671|DEVICE|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
214268203|NCT00000488|DRUG|cholestyramine|
214268204|NCT00000488|BEHAVIORAL|diet, fat-restricted|
214268205|NCT02759497|OTHER|serum amyloid A level|serum amyloid A level (SAA)
214268206|NCT01321060|PROCEDURE|Aspiration|
214268207|NCT01321060|PROCEDURE|Catheter drainage|
214268208|NCT01321060|DRUG|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
214268209|NCT02256371|BEHAVIORAL|Hypnosis sessions|1 session per week during 8 weeks
214268210|NCT02256371|BEHAVIORAL|Relaxation group|1 relaxation session per week during 8 weeks
214268211|NCT05960942|DRUG|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
214268212|NCT05960942|DRUG|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
214268213|NCT04203810|DEVICE|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
214268214|NCT04203810|DEVICE|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
214268215|NCT05034562|PROCEDURE|Computed Tomography|Undergo PET/CT
214268216|NCT05034562|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214268217|NCT05034562|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214268218|NCT05034562|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
214268219|NCT02727842|DEVICE|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
214268220|NCT02727842|DEVICE|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
214268221|NCT02605304|DRUG|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
214268222|NCT02605304|DRUG|Ribavirin|"Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
214268223|NCT03542123|DEVICE|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
214268224|NCT00003023|BIOLOGICAL|BCG vaccine|
214268225|NCT00003023|BIOLOGICAL|monoclonal antibody A1G4 anti-idiotype vaccine|
214268226|NCT02547675|DRUG|Rociletinib|Rociletinib will be administered to patients orally
214268227|NCT03576495|OTHER|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
214268228|NCT03576495|OTHER|Standard Residency Curriculum|The standard residency curriculum consists of previously scheduled resident didactic sessions at all academic medical centers that may or may not include topics on cultural competency or cross-cultural care.
214268229|NCT01790425|PROCEDURE|to infuse water into colon to open the lumen for water infusion colonoscopy|
214268230|NCT01790425|PROCEDURE|Air colonoscopy|
214268231|NCT06449417|BEHAVIORAL|Experimental Aurora Training|Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
214268232|NCT03781427|DEVICE|Cardiac resynchronization therapy|Left ventricular pacing
214268233|NCT02908451|BIOLOGICAL|AbGn-107|Antibody Drug Conjugate
214268234|NCT00000304|DRUG|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
214268235|NCT00000304|DRUG|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
214268236|NCT00000304|DRUG|Placebo|Placebo
214268237|NCT02867150|DEVICE|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
214268238|NCT02635776|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
214268239|NCT02635776|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
214268240|NCT00788073|DRUG|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
214268241|NCT00788073|DRUG|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
214268242|NCT05249699|DRUG|Isoniazid|prevent the development of tuberculosis
214268243|NCT05249699|OTHER|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
214268244|NCT03051750|OTHER|Complex Physical Therapy plus Pressotherapy|
214268245|NCT03051750|OTHER|Kinesio Taping|
214268246|NCT05856188|DIETARY_SUPPLEMENT|Glutamine|Biologic
214268247|NCT00375037|BEHAVIORAL|feedback|
214268248|NCT00375037|BEHAVIORAL|Education|
214268249|NCT00375037|OTHER|usual care|
214464877|NCT06101056|BEHAVIORAL|Junior Enlisted Component|"Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7."
214268250|NCT05649566|DEVICE|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
214268251|NCT06557018|DRUG|liposomal bupivacaine|liposomal bupivacaine group
214268252|NCT06557018|DRUG|traditional peri-articular injection|traditional peri-articular injection group
214268253|NCT00446056|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
214268254|NCT00446056|DRUG|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
214268255|NCT00092768|DRUG|MK0663, etoricoxib|
214268256|NCT00092768|DRUG|Comparator: celecoxib|
214268257|NCT01133041|OTHER|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
214268258|NCT01133041|OTHER|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
214268259|NCT01085474|OTHER|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
214268260|NCT01085474|OTHER|2|The best intervention used in the pilot study will be chosen and included in the main study.
214268261|NCT03608254|OTHER|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
214268262|NCT02633813|DRUG|Naftifine hydrochloride 2%|Topical application for two weeks
214268263|NCT02633813|DRUG|Placebo|Topical application for two weeks
214268264|NCT02633813|DRUG|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
214268265|NCT06556459|PROCEDURE|Bariatric Surgery|"The patient performs:~* psychological clinical interview~* psychodiagnostic examination~* internal medical examination~* blood tests~* electrocardiogram~* bariatric surgery~* surgical visit"
214268266|NCT03344133|BEHAVIORAL|Exercise|4-week moderate intensity exercise programme
214268267|NCT03141593|DRUG|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
214268268|NCT03141593|DRUG|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
214268269|NCT03141593|DRUG|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
214268270|NCT03141593|DRUG|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
214268271|NCT06557928|OTHER|measurement|Measurement of multiple physiological indicators and psychological status and multi-omics study
214268272|NCT05890950|DRUG|K-757 and K-833|Both administered orally
214268273|NCT05890950|DRUG|Matching placebo to K-757 and K-833|Both administered orally
214268274|NCT00376883|DRUG|pamidronate|
214268275|NCT03866954|COMBINATION_PRODUCT|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
214268276|NCT00640861|BIOLOGICAL|CpG oligodeoxynucleotide|
214268277|NCT00640861|BIOLOGICAL|HER-2/neu peptide vaccine|
214268278|NCT00640861|BIOLOGICAL|MUC-1 peptide vaccine|
214268279|NCT00640861|BIOLOGICAL|incomplete Freund's adjuvant|
214268280|NCT00640861|BIOLOGICAL|sargramostim|
214268281|NCT00640861|OTHER|immunoenzyme technique|
214268282|NCT00640861|OTHER|immunologic technique|
214268283|NCT04419675|OTHER|Observational Cohort, usual care = physical therapy|usual care = physical therapy
214268284|NCT03873025|COMBINATION_PRODUCT|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
214268285|NCT04177121|OTHER|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
214268286|NCT05711394|DRUG|Atogepant|Oral Tablet
214268287|NCT05711394|DRUG|Placebo-Matching Atogepant|Oral Tablet
214268288|NCT04838782|PROCEDURE|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
214268289|NCT01454960|BEHAVIORAL|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
214268290|NCT01454960|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
214268291|NCT01454960|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
214268292|NCT01216748|OTHER|quiet breathing|Subjects were instructed to breath normally at room air.
214268293|NCT01216748|OTHER|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
214268294|NCT01216748|OTHER|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
214268295|NCT01216748|OTHER|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
214656831|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
214268296|NCT04648228|BEHAVIORAL|ACT+MBRP|Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
214268297|NCT04648228|BEHAVIORAL|Education control|Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
214268298|NCT00092807|DRUG|MK0653, ezetimibe|
214268299|NCT00092807|DRUG|Comparator: placebo|
214268300|NCT00660673|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
214268301|NCT00660673|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
214268302|NCT00660673|DEVICE|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
214268303|NCT03208127|DRUG|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
214268304|NCT03884959|BIOLOGICAL|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
214268305|NCT00776282|DRUG|loratadine 10 mg orally disintegrating|
214268306|NCT06205966|DIETARY_SUPPLEMENT|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
214268307|NCT06205966|OTHER|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
214268308|NCT01817829|DRUG|paracetamol|500 mg oral tablet
214268309|NCT01817829|DRUG|placebo|
214268310|NCT00579098|DRUG|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
214268311|NCT00579098|DRUG|Placebo|Placebo tablet taken by mouth once daily for 90 days
214268312|NCT01713608|DRUG|OZ439|OZ439 x mg once daily for 3 days with milk
214268313|NCT05180617|BEHAVIORAL|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
214268314|NCT05352711|DEVICE|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
214268315|NCT05352711|OTHER|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
214268316|NCT01681940|DRUG|Lamazym|ERT, i.v. infusions weekly
214268317|NCT02552589|OTHER|Amine fluoride|toothpaste
214268318|NCT02552589|OTHER|Placebo|toothpaste
214268319|NCT05578170|DRUG|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
214268320|NCT04652427|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
214268321|NCT04652427|DRUG|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
214268322|NCT02515396|DRUG|MMI-0100|
214268323|NCT02515396|DRUG|Placebo|
214268324|NCT00237172|DRUG|Imatinib Mesylate|once daily
214268325|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|
214268326|NCT01227317|OTHER|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
214268327|NCT00003487|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214268328|NCT02807519|GENETIC|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
214268329|NCT03098121|DRUG|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
214268330|NCT02021227|PROCEDURE|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for \> 1 hour
214268331|NCT02197273|DRUG|Liposomal bupivacaine|
214268332|NCT02197273|DRUG|Standard of care analgesia|
214268333|NCT02776865|DRUG|suprascapular nerve block|4ml 2% xylocaine
214268334|NCT02776865|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
214268335|NCT00499239|DRUG|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
214268336|NCT03412526|DRUG|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
214268337|NCT03412526|RADIATION|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
214268338|NCT03412526|BIOLOGICAL|TIL administration|TIL Administration
214268339|NCT03412526|DRUG|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
214268340|NCT05636059|OTHER|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
214268341|NCT05636059|OTHER|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
214268342|NCT05636059|OTHER|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
214268343|NCT01307982|PROCEDURE|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
214268344|NCT01307982|PROCEDURE|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
214268345|NCT03974243|DRUG|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
214268346|NCT03974243|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
214268347|NCT05427929|DEVICE|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
214268348|NCT03451578|DEVICE|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
214268349|NCT00119431|DRUG|C1 inhibitor concentrate|
214268350|NCT02702453|BEHAVIORAL|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
214268351|NCT05475561|PROCEDURE|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
214268352|NCT05475561|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
214268353|NCT05475561|DRUG|Bupivacain|local anesthetic
214268354|NCT00611507|DRUG|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
214268355|NCT02270008|OTHER|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
214268356|NCT04234074|DEVICE|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
214656832|NCT06021080|PROCEDURE|CVVH|CVVH therapy
214656833|NCT06021080|PROCEDURE|CVVHD|CVVHD therapy
214268357|NCT05209269|OTHER|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
214268358|NCT01888757|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
214268359|NCT01742000|DIETARY_SUPPLEMENT|Karinat|
214268360|NCT01742000|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
214268361|NCT02201641|RADIATION|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
214268362|NCT02201641|RADIATION|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
214268363|NCT02201641|DEVICE|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
214268364|NCT02201641|DEVICE|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
214268365|NCT02109211|DEVICE|Intubation with Magill forceps|
214268366|NCT02109211|DEVICE|Intubation with altered Magill forceps|
214268367|NCT03015857|DRUG|phenylephrine|\- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
214268368|NCT03015857|DRUG|Norepinephrine|\- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
214268369|NCT03015857|DRUG|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
214268370|NCT03015857|DRUG|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
214268371|NCT03015857|DRUG|Placebo (normal saline)|
214268372|NCT03558087|DRUG|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
214268373|NCT03558087|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.
214268374|NCT03558087|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.
214268375|NCT03475823|DIETARY_SUPPLEMENT|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
214268376|NCT03475823|DIETARY_SUPPLEMENT|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
214268377|NCT03475823|DIETARY_SUPPLEMENT|Placebo control|An inert encapsulated powder provided by Finzelberg.
214268378|NCT04584970|DEVICE|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
214268379|NCT04584970|DEVICE|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
214268380|NCT02932202|OTHER|Longitudinal Nutritional Counseling|
214268381|NCT02932202|OTHER|Standard Care|
214268382|NCT04555421|DEVICE|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
214268383|NCT02617043|RADIATION|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
214268384|NCT06260215|OTHER|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
214268385|NCT03855228|DRUG|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
214268386|NCT03855228|DRUG|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
214268387|NCT03855228|DRUG|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
214268388|NCT03855228|DRUG|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
214268389|NCT00737243|DRUG|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
214268390|NCT00737243|DRUG|Carboplatin|AUC 6.0 IV Day 1
214268391|NCT00737243|DRUG|Bevacizumab|15 mg/kg IV infusion Day 1
214268392|NCT00737243|DRUG|Erlotinib|150 mg PO
214268393|NCT00737243|OTHER|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
214268394|NCT04275934|BEHAVIORAL|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
214268395|NCT00635375|DEVICE|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
214268396|NCT00635375|DEVICE|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
214268397|NCT00635375|DEVICE|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
214268398|NCT00635375|DEVICE|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
214268399|NCT05592262|DRUG|SHR2554|On an empty stomach - after meals
214268400|NCT05592262|DRUG|SHR2554|After meals - on an empty stomach
214268401|NCT01893203|DRUG|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
214656834|NCT04193371|OTHER|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
214268402|NCT01893203|DRUG|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
214268403|NCT01828736|BIOLOGICAL|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
214268404|NCT01828736|DRUG|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
214268405|NCT01828736|DRUG|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
214268406|NCT01828736|DRUG|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
214268407|NCT02429843|DRUG|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
214268408|NCT04596800|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
214268409|NCT04596800|OTHER|Enhanced Recovery After Surgery|ERAS
214268410|NCT02564497|BIOLOGICAL|Process E Belatacept|
214268411|NCT02564497|BIOLOGICAL|Process C Belatacept|
214268412|NCT01219673|OTHER|Placebo|1 by mouth twice a day.
214268413|NCT01219673|DRUG|Armodafinil|150 mg by mouth once a day.
214268414|NCT01219673|DRUG|Minocycline|100 mg by mouth twice a day.
214268415|NCT01219673|DRUG|Bupropion|100 mg by mouth twice a day.
214268416|NCT05239442|OTHER|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
214268417|NCT05239442|OTHER|Evaluation of the taste commissions|"At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
214268418|NCT05239442|OTHER|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
214268419|NCT00760422|DEVICE|NIR|Thermometer
214268420|NCT02944032|OTHER|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
214268421|NCT02944032|OTHER|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
214268422|NCT00678080|DRUG|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
214268423|NCT00678080|DRUG|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
214268424|NCT06709183|OTHER|Intervention-Control|Nurses in this group will start the first oral care practice by using the oral care retractor on the model. Before starting the procedure, the nurses will fill in the 'Beck Mouth Assessment Guide' and after the procedure, they will fill in the 'Oral Care Practices Evaluation Form'. A rest period of at least 10 minutes will be provided before the second oral care application. Standard oral care will be applied during the second application. Similarly, nurses will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Assessment Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to collect nurses' experiences and opinions about the oral care procedure. During the interview, audio recordings will be made with the knowledge of the nurses.
214464878|NCT06101056|BEHAVIORAL|Leadership Component|"Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7."
214829161|NCT01619956|PROCEDURE|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
214829162|NCT00792207|OTHER|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
214829163|NCT00792207|OTHER|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
214268425|NCT06709183|OTHER|Control - intervention|In the first oral care procedure, nurses in this group will perform standard oral care on the model without using the oral care retractor. They will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. There will be a rest period of at least 10 minutes before the second oral care procedure. During this procedure, the second group of nurses who initially perform standard oral care will perform oral care using an oral care retractor. Similarly, they will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to obtain nurses' experiences and opinions regarding oral care practices..
214268426|NCT07048158|DIETARY_SUPPLEMENT|Perfect Heartio Drink|Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.
214268427|NCT05305820|BEHAVIORAL|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
214268428|NCT05305820|BEHAVIORAL|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
214268429|NCT04524897|DRUG|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
214268430|NCT00569881|DRUG|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
214268431|NCT02671305|PROCEDURE|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
214268432|NCT02671305|PROCEDURE|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
214268433|NCT03986398|OTHER|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
214268434|NCT04621630|DRUG|PN-235|Active Drug
214268435|NCT04621630|DRUG|Placebo|Matching Placebo
214268436|NCT00222443|DRUG|Irinotecan|
214268437|NCT00329004|DRUG|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
214268438|NCT02671175|DRUG|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
214268439|NCT02671175|DRUG|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
214268440|NCT04694742|OTHER|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
214268441|NCT04893044|BEHAVIORAL|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
214268442|NCT02998944|OTHER||not any intervention for this study
214268443|NCT00793091|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
214268444|NCT00793091|DRUG|Placebo|4 drops applied daily for 120 days
214268445|NCT02515825|DEVICE|CADence|
214268446|NCT06497998|DEVICE|Mechanical characterization|"The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane."
214829164|NCT02179593|OTHER|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
214268447|NCT02994992|DRUG|BAY 987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
214829165|NCT02179593|OTHER|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
214829166|NCT00557245|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
214829167|NCT00557245|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
214268448|NCT02994992|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214268449|NCT04754152|OTHER|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
214268450|NCT04754152|DRUG|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
214268451|NCT02650674|OTHER|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
214268452|NCT02650674|OTHER|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
214268453|NCT02650674|OTHER|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
214268454|NCT02650674|OTHER|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
214268455|NCT02650674|OTHER|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
214268456|NCT02650674|OTHER|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
214268457|NCT05697315|PROCEDURE|Control|No block was performed
214268458|NCT05697315|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
214268459|NCT06259721|DRUG|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
214268460|NCT04234191|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
214268461|NCT04234191|DRUG|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
214268462|NCT01546207|PROCEDURE|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
214268463|NCT04475991|DRUG|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
214268464|NCT04475991|PROCEDURE|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
214268465|NCT04475991|DRUG|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
214268466|NCT04475991|DRUG|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
214268467|NCT06136832|BEHAVIORAL|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
214268468|NCT02949037|OTHER|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
214268469|NCT03660540|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
214268470|NCT01911078|PROCEDURE|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
214268471|NCT01911078|DEVICE|EnligHTN™ Renal Denervation System.|
214268472|NCT04798924|DEVICE|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
214268473|NCT04798924|DEVICE|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
214829168|NCT00557245|DRUG|Placebo|Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
214268474|NCT04798924|DEVICE|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
214268475|NCT02958514|DEVICE|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
214268476|NCT02958514|DRUG|Tobramycin and Dexamethasone Ophthalmic Ointment|
214268477|NCT05589766|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
214268478|NCT05589766|OTHER|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
214268479|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
214268480|NCT03260881|DRUG|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
214268481|NCT03260881|DRUG|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
214268482|NCT03355365|BIOLOGICAL|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
214268483|NCT03355365|OTHER|Intrathecal saline injection|Placebo
214268484|NCT04217330|BEHAVIORAL|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
214268485|NCT04217330|BEHAVIORAL|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
214268486|NCT04988139|OTHER|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
214268487|NCT06395545|DEVICE|Electronic injector|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
214268488|NCT04812899|BEHAVIORAL|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
214268489|NCT03847246|DRUG|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
214268490|NCT03847246|DRUG|Entecavir tablets,1.0 mg|oral,once,under fasting condition
214268491|NCT01358851|PROCEDURE|Cryotherapy|1-2 times during the treatment time
214268492|NCT01358851|DRUG|LAS41005|once daily
214829169|NCT04903340|PROCEDURE|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
214829170|NCT03627598|DEVICE|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
214829171|NCT03627598|DEVICE|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
214829172|NCT00808717|DRUG|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
214829173|NCT01527838|BIOLOGICAL|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
214829174|NCT04569058|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
214829175|NCT04472858|DRUG|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
214829176|NCT04472858|DRUG|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
214829177|NCT00851409|DRUG|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
214829178|NCT03432091|DRUG|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
214829179|NCT02225106|DRUG|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
214268493|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation A
214268494|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
214268495|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
214268496|NCT05490407|DRUG|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
214268497|NCT05898360|COMBINATION_PRODUCT|Time Restricted Eating|time restricted eating
214268498|NCT05898360|OTHER|normal diet|normal diet
214268499|NCT02234232|BEHAVIORAL|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
214268500|NCT03217656|OTHER|No intervention|
214268501|NCT00132652|DRUG|Lamivudine|
214268502|NCT00132652|DRUG|Telbivudine|
214268503|NCT05251766|DRUG|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
214268504|NCT05251766|DRUG|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
214268505|NCT03074955|DEVICE|leg wrapping with tension|"1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages."
214268506|NCT03074955|PROCEDURE|Trendelenburg position|"1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position"
214268507|NCT03074955|DEVICE|leg wrapping without tension|"1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages"
214268508|NCT03074955|PROCEDURE|supine position|1.maintain supine position
214268509|NCT04337801|OTHER|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
214268510|NCT04337801|OTHER|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
214268511|NCT05933616|DEVICE|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
214268512|NCT01034150|DEVICE|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
214268513|NCT01034150|DEVICE|Placebo stimulation|Placebo stimulation
214268514|NCT02040948|DEVICE|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
214268515|NCT02098967|DRUG|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
214268516|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
214268517|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
214268518|NCT01065259|DRUG|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
214268519|NCT01065259|DRUG|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
214268520|NCT03533296|PROCEDURE|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
214268521|NCT03361163|BIOLOGICAL|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
214268522|NCT04966832|DRUG|XW10508|XW10508 capsules or tablets
214268523|NCT04966832|OTHER|Placebo|Placebo capsules or tablets
214268524|NCT00006477|DIETARY_SUPPLEMENT|mistletoe extract|
214268525|NCT00523562|OTHER|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
214268526|NCT01952145|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
214268527|NCT01952145|DRUG|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
214268528|NCT00168870|DRUG|Gemcitabine|
214268529|NCT00168870|DRUG|Treosulfan|
214268530|NCT02025322|BEHAVIORAL|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
214268531|NCT03019783|DRUG|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
214268532|NCT03019783|OTHER|Placebo|The control group will stay on their baseline regimen
214268533|NCT02072083|DRUG|Dexmedetomidine|via intranasal route 1 mcg/kg
214268534|NCT02072083|DRUG|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
214268535|NCT00493025|DRUG|cisplatin|Cisplatin IV
214268536|NCT00493025|DRUG|gefitinib|Gefitinib IV
214268537|NCT00493025|DRUG|paclitaxel|Paclitaxel IV
214268538|NCT00493025|PROCEDURE|adjuvant therapy|Postoperative ZD1839
214268539|NCT00493025|RADIATION|radiation therapy|Radiotherapy
214268540|NCT04149379|DRUG|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
214268541|NCT04033575|DRUG|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
214268542|NCT04033575|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
214268543|NCT00214344|BEHAVIORAL|family preparation for withdrawing life support|
214268544|NCT05338216|BEHAVIORAL|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
214268545|NCT05338216|BEHAVIORAL|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
214268546|NCT06113003|DIETARY_SUPPLEMENT|Prebiotic|Wheat dextrin fiber
214268547|NCT06113003|DIETARY_SUPPLEMENT|Probiotic|Probiotic packet
214268548|NCT01965613|BIOLOGICAL|Xilonix|IV
214268549|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
214268550|NCT04616248|DRUG|Poly ICLC|Given IT
214268551|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
214268552|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
214268553|NCT04616248|DRUG|Pembrolizumab|Given IV
214268554|NCT04616248|DRUG|Tocilizumab|Given SC
214268555|NCT06025825|DRUG|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
214268556|NCT06025825|DRUG|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
214268557|NCT01596478|BEHAVIORAL|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
214268558|NCT01596478|BEHAVIORAL|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
214268559|NCT01596478|BEHAVIORAL|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
214268560|NCT02300246|PROCEDURE|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
214268561|NCT02081287|DRUG|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
214268562|NCT02081287|DRUG|Lamotrigine|Dose up to 200 mg per day over 10 weeks
214268563|NCT03766568|DEVICE|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
214268564|NCT00397345|BIOLOGICAL|Trovax|1ml IM injection 2-8 weeks apart.
214268565|NCT00397345|BIOLOGICAL|Placebo|Placebo
214268566|NCT00397345|BIOLOGICAL|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
214268567|NCT02985372|DRUG|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
214268568|NCT02985372|DRUG|Cytarabine|
214268569|NCT01197261|DRUG|Oxycodone naloxone prolonged release tablets|2 tablets/ day
214268570|NCT01197261|DRUG|Placebo tablets|2 tablets/ day
214268571|NCT05013489|BEHAVIORAL|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
214268572|NCT01319890|PROCEDURE|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
214268573|NCT05133752|DRUG|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
214268574|NCT05901428|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
214268575|NCT05901428|DRUG|Carboplatin|Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
214268576|NCT05901428|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
214268577|NCT05901428|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
214268578|NCT03543150|DRUG|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
214268579|NCT02211040|BEHAVIORAL|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
214268580|NCT01417442|GENETIC|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
214268581|NCT01377883|OTHER|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
214268582|NCT01377883|BEHAVIORAL|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
214268583|NCT02389062|OTHER|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
214268584|NCT00413244|DRUG|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
214268585|NCT00413244|DRUG|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
214268586|NCT00136123|PROCEDURE|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
214268587|NCT03301701|PROCEDURE|Radical prostatectomy|Radical prostatectomy
214268588|NCT03301701|RADIATION|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
214268589|NCT05373277|DRUG|Placebo|one tablet of placebo twice daily for two days
214268590|NCT05373277|DRUG|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
214268591|NCT05373277|DRUG|Rosuvastatin|10 mg tablet, single dose
214268592|NCT00446251|DRUG|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
214268593|NCT00446251|DRUG|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
214268594|NCT04239859|BIOLOGICAL|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
214268595|NCT04239859|DRUG|Methotrexate|Oral tablet up to 15mg per week
214268596|NCT04239859|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
214829180|NCT05608486|DEVICE|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
214829181|NCT00229021|DRUG|doripenum|
214829182|NCT06628115|DEVICE|cerament V or G|Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
214829183|NCT02623647|RADIATION|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
214268597|NCT04239859|DRUG|Acitretin|Oral capsule up to 25mg per day
214268598|NCT04083196|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
214268599|NCT04083196|BIOLOGICAL|Placebo|Placebo
214268600|NCT06402071|DIAGNOSTIC_TEST|Ascitic fluid study|Ascitic fluid study will be obtained from all participants
214268601|NCT05767320|PROCEDURE|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
214268602|NCT05767320|PROCEDURE|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
214268603|NCT01790776|RADIATION|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
214268604|NCT01790776|RADIATION|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
214268605|NCT03865771|BEHAVIORAL|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
214268606|NCT03865771|BEHAVIORAL|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
214268607|NCT03865771|OTHER|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
214268608|NCT06481839|OTHER|Starting dose of NE|Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
214268609|NCT02872207|DRUG|BAY 987516 (Y65-122)|5 µL in one eye
214268610|NCT02872207|DRUG|BAY 987516 (Y65-118)|5 µL in one eye
214268611|NCT02872207|DRUG|Control|5 uL in other eye
214268612|NCT05191173|PROCEDURE|Cardiac Surgery|No intervention, just observation is performed.
214268613|NCT03422042|OTHER|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
214268614|NCT03422042|OTHER|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
214268615|NCT03264313|DEVICE|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
214268616|NCT00294801|DRUG|flex-a-new (food supplement)|
214268617|NCT06462885|BEHAVIORAL|home support, hiving alone|Home support: living alone
214268618|NCT06462885|BEHAVIORAL|home support, living with others|Home support: living with others
214268619|NCT05024201|BEHAVIORAL|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
214268620|NCT01440452|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
214268621|NCT01440452|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
214268622|NCT01440452|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
214268623|NCT01440452|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
214268624|NCT00753766|OTHER|Multifactorial Intervention|
214268625|NCT01689168|BEHAVIORAL|Counseling|Tobacco cessation counseling
214268626|NCT01689168|PROCEDURE|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
214268627|NCT05693883|OTHER|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
214268628|NCT04545554|DRUG|Romosozumab|Participants will receive multiple doses of romosozumab via a SC injection.
214268629|NCT04545554|DIETARY_SUPPLEMENT|Calcium|All participants will receive daily supplements of elemental calcium.
214268630|NCT04545554|DIETARY_SUPPLEMENT|Vitamin D|All participants will receive daily supplementation with vitamin D.
214268631|NCT01518023|OTHER|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
214268632|NCT04087304|BEHAVIORAL|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
214268633|NCT01863420|RADIATION|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
214268634|NCT05623839|DRUG|LY3305677|Administered SC
214268635|NCT05623839|DRUG|Placebo|Administered SC
214268636|NCT00494299|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
214268637|NCT00494299|DRUG|Placebo|Placebo: matching placebo
214268638|NCT03333304|DIAGNOSTIC_TEST|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
214268639|NCT05907590|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
214268640|NCT05907590|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
214268641|NCT05907590|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
214268642|NCT05907590|OTHER|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
214268643|NCT05907590|OTHER|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
214268644|NCT02409212|BEHAVIORAL|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
214268645|NCT02409212|BEHAVIORAL|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
214268646|NCT04299542|PROCEDURE|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
214268647|NCT04299542|PROCEDURE|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
214268648|NCT02890927|OTHER|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
214268649|NCT00907712|OTHER|cardiac echo examination|cardiac echo examination - before and after the surgery
214268650|NCT04685967|DEVICE|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
214268651|NCT04685967|DEVICE|Bulk-fill composite|SonicFill2, Orange, CA, USA
214268652|NCT05424523|DRUG|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
214268653|NCT00066365|BIOLOGICAL|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
214268654|NCT00066365|PROCEDURE|conventional surgery|thoracotomy
214268655|NCT02713373|BIOLOGICAL|Cetuximab|Given IV
214268656|NCT02713373|OTHER|Laboratory Biomarker Analysis|Correlative studies
214268657|NCT02713373|BIOLOGICAL|Pembrolizumab|Given IV
214268658|NCT01807039|PROCEDURE|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
214268659|NCT00787761|BIOLOGICAL|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
214268660|NCT00787761|DRUG|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
214829184|NCT06209749|OTHER|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
214829185|NCT00798603|BIOLOGICAL|bevacizumab|
214829186|NCT00798603|DRUG|carboplatin|
214829187|NCT00798603|DRUG|pemetrexed disodium|
214829188|NCT02435264|OTHER|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
214268661|NCT00787761|DRUG|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
214268662|NCT00787761|DRUG|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
214268663|NCT00787761|DRUG|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
214268664|NCT00787761|DRUG|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
214268665|NCT00787761|PROCEDURE|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
214268666|NCT03527030|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
214268667|NCT03527030|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
214268668|NCT02808793|DRUG|AK002|
214268669|NCT00239590|DRUG|Testosterone undecanoate|Licensed for androgen deficiency
214268670|NCT01268020|DRUG|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
214268671|NCT02083614|PROCEDURE|to clamp or release the catheter for 2 days before removal|
214268672|NCT02033187|OTHER|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
214268673|NCT02033187|OTHER|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
214268674|NCT03638622|COMBINATION_PRODUCT|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
214268675|NCT05890339|PROCEDURE|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
214268676|NCT05890339|PROCEDURE|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
214268677|NCT05901454|DRUG|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
214268678|NCT01589978|DEVICE|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
214268679|NCT01589978|DRUG|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
214268680|NCT01589978|DRUG|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
214268681|NCT00506337|DRUG|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
214268682|NCT02362269|DIETARY_SUPPLEMENT|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
214268683|NCT03867344|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
214268684|NCT03867344|OTHER|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
214268685|NCT05213481|DRUG|Tepotinib|Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
214268686|NCT05213481|DRUG|Carbamazepine|Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
214268687|NCT02256592|DRUG|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
214268688|NCT06220773|DRUG|BR1019A|Subjects take the investigational products once a day for 12 weeks.
214268689|NCT06220773|DRUG|BR1019B|Subjects take the investigational products once a day for 12 weeks.
214268690|NCT06220773|DRUG|BR1019C|Subjects take the investigational products once a day for 12 weeks.
214268691|NCT06220773|DRUG|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
214268692|NCT06220773|DRUG|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
214268693|NCT06220773|DRUG|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
214268694|NCT06284655|BEHAVIORAL|group-based combined with innovative technology education|The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.
214268695|NCT06284655|OTHER|Standard treatment|Treatment as usual.
214268696|NCT00027716|DRUG|bortezomib|
214268697|NCT03115086|DRUG|Cholbam|Cholbam prescribed according to the approved label.
214268698|NCT04189575|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
214268699|NCT01216631|DRUG|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
214268700|NCT01216631|DRUG|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
214268701|NCT01216631|DRUG|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
214268702|NCT00227006|BEHAVIORAL|Behavioral lifestyle/weight-loss intervention|
214268703|NCT02882412|OTHER|observational|
214268704|NCT05114070|OTHER|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
214268705|NCT05433012|DEVICE|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
214268706|NCT03791138|OTHER|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
214268707|NCT00415168|DRUG|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
214268708|NCT00415168|DRUG|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
214268709|NCT00776724|DRUG|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
214268710|NCT00776724|DRUG|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
214268711|NCT03382275|DRUG|Iron Supplement|any oral or intravenous prescription iron supplement
214829189|NCT05387109|DRUG|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
214268712|NCT05837585|DEVICE|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
214268713|NCT02505906|RADIATION|Simultaneous Integrated Boost Technique|
214268714|NCT06132295|OTHER|Nursing care|"1. Consistent Schedule for the Replacement of Positioning Line Pens~2. Tailored Educational Content~3. Hypoallergenic Adhesive Patches~4. Enriched Treatment Care Platform~5. Participants with BMI \> 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI \< 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~6. Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
214268715|NCT06405958|OTHER|gut microbiome|Obtaining new gut microbiome data in organ transplantation
214268716|NCT00332280|DRUG|AMT2003|
214268717|NCT03273270|RADIATION|transcranial magnetic stimulation|transcranial magnetic stimulation
214268718|NCT03528707|DIETARY_SUPPLEMENT|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
214268719|NCT03528707|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
214268720|NCT03623841|OTHER|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
214268721|NCT03623841|OTHER|Treadmill training|Participants in control group will do treadmill training only
214268722|NCT05353361|DRUG|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
214268723|NCT05353361|DRUG|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
214268724|NCT05353361|DRUG|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
214268725|NCT05353361|DRUG|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
214268726|NCT06044389|DEVICE|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
214268727|NCT04765982|DIAGNOSTIC_TEST|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
214268728|NCT05093140|DRUG|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
214268729|NCT05961579|DRUG|Barrier Renew|RoC Skincare (New York, New York, USA) has developed a gentle cleanser and moisturizer that are free of exfoliants, astringents, and other abrasive ingredients. The moisturizer contains emollients, humectants, and silicones to improve the functioning of the skin barrier while antioxidants protect against environmental damage and inflammation
214268730|NCT05744011|OTHER|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
214268731|NCT05744011|OTHER|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
214829190|NCT03501511|BEHAVIORAL|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
214268732|NCT05820607|BIOLOGICAL|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
214268733|NCT02858960|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
214829191|NCT03501511|BEHAVIORAL|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
214829192|NCT05325515|DRUG|Conventional alendronate|Conventional alendronate 70mg weekly
214829193|NCT05325515|DRUG|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
214829194|NCT00966160|DRUG|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
214268734|NCT02858960|DEVICE|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
214268735|NCT05182190|DIETARY_SUPPLEMENT|White bread|Toasted white bread
214268736|NCT05182190|DIETARY_SUPPLEMENT|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
214268737|NCT05182190|DIETARY_SUPPLEMENT|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
214268738|NCT05182190|DIETARY_SUPPLEMENT|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
214268739|NCT05182190|DIETARY_SUPPLEMENT|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
214268740|NCT04239053|DRUG|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
214268741|NCT00334321|RADIATION|IMRT|
214268742|NCT00334321|RADIATION|Intracavitary vaginal brachytherapy|
214268743|NCT00334321|DRUG|Paclitaxel|
214268744|NCT00334321|DRUG|Carboplatin|
214268745|NCT02481583|DRUG|Levosulpiride|different formulations of levosulpiride
214268746|NCT03842514|DIETARY_SUPPLEMENT|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
214268747|NCT00938236|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
214268748|NCT01067937|PROCEDURE|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
214268749|NCT04150055|BEHAVIORAL|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
214268750|NCT00515411|DRUG|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
214268751|NCT00515411|DRUG|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
214268752|NCT00515411|DRUG|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
214268753|NCT01634334|BEHAVIORAL|Real-Time Intervention|Lights and Sound Brief Coaching
214268754|NCT01634334|BEHAVIORAL|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
214268755|NCT01599195|DEVICE|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
214268756|NCT02388919|DRUG|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
214829195|NCT00966160|DRUG|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
214829196|NCT01768260|DEVICE|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
214268757|NCT02388919|DRUG|Placebo|Basic dosage, take once when limosis in the morning.
214268758|NCT02364726|PROCEDURE|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
214268759|NCT02364726|BEHAVIORAL|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
214268760|NCT02364726|BEHAVIORAL|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
214268761|NCT02058693|DRUG|mixed salts amphetamine|adjunctive to ADT
214268762|NCT04741711|PROCEDURE|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
214829197|NCT01768260|DRUG|Aspirin|Standard drug therapy
214829198|NCT01418573|OTHER|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
214268763|NCT04741711|PROCEDURE|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
214268764|NCT04049864|BIOLOGICAL|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
214268765|NCT04049864|BIOLOGICAL|Salmonella oral vaccine|suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
214829199|NCT01418573|OTHER|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
214268766|NCT04049864|DRUG|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
214268767|NCT04721730|BEHAVIORAL|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
214268768|NCT04721730|BEHAVIORAL|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
214268769|NCT02898805|OTHER|Placebo|
214268770|NCT02898805|OTHER|Prescribed Diet|
214268771|NCT02898805|DIETARY_SUPPLEMENT|LopiGLIK®|
214268772|NCT02898805|DIETARY_SUPPLEMENT|Armolipid Plus|
214268773|NCT02056938|DRUG|Anti-Thymocyte Globulins treatment|
214268774|NCT02056938|DRUG|Basiliximab treatment|
214268775|NCT00006111|DRUG|cisplatin|
214268776|NCT00006111|DRUG|fluorouracil|
214268777|NCT00006111|PROCEDURE|conventional surgery|
214268778|NCT00006111|RADIATION|radiation therapy|
214268779|NCT00532558|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
214268780|NCT00532558|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
214268781|NCT04470141|DRUG|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
214268782|NCT03668275|PROCEDURE|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
214268783|NCT00677131|OTHER|Reading the package insert of the drug|package insert of the drug
214268784|NCT00677131|OTHER|Reading the education information provided by the Pharmacy of NTUH|education information
214268785|NCT00677131|OTHER|Oral education provided by the pharmacist|Oral education provided by the pharmacist
214268786|NCT00722800|DRUG|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
214268787|NCT00722800|DRUG|Placebo|1 tablet daily for 24 weeks
214268788|NCT02418650|DRUG|ODM-201 300 mg tablet|
214268789|NCT02418650|DRUG|intravenous14C-ODM-201|
214268790|NCT02418650|DRUG|300 mg 14C-ODM-201 oral solution|
214268791|NCT03808129|DRUG|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
214268792|NCT00316992|DRUG|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
214268793|NCT04798755|DRUG|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
214268794|NCT04798755|DRUG|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
214268795|NCT04798755|DRUG|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
214268796|NCT02827227|BIOLOGICAL|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
214268797|NCT04905966|BEHAVIORAL|Nutrition education and Physical activity intervention|Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
214268798|NCT02850601|DRUG|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
214268799|NCT03864978|DRUG|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
214268800|NCT03864978|DRUG|Placebo|Placebo
214268801|NCT04783818|RADIATION|Adjuvant Radiotherapy|PMRT
214268802|NCT02925117|DRUG|Upadacitinib|Tablet for oral use
214268803|NCT02925117|DRUG|Placebo|Tablet
214268804|NCT03658239|OTHER|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
214268805|NCT05212922|DRUG|YH001 + Toripalimab|YH001 + Toripalimab
214268806|NCT05582473|BEHAVIORAL|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
214268807|NCT03254875|BEHAVIORAL|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
214268808|NCT00956969|BEHAVIORAL|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
214268809|NCT00956969|BEHAVIORAL|Relaxation Training|Teaches patients relaxation training
214268810|NCT04067674|BIOLOGICAL|Blood sampling|Blood sampling for biomarker measurement
214268811|NCT01446315|BEHAVIORAL|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
214268812|NCT01446315|BEHAVIORAL|Asthma APGAR tools|Usual care
214268813|NCT00456248|DRUG|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
214268814|NCT04341077|DRUG|SHR3162|A single oral dose of fluzoparib on Day 1
214268815|NCT02027207|BIOLOGICAL|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
214268816|NCT02027207|BIOLOGICAL|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
214268817|NCT03117920|DRUG|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
214268818|NCT02235805|DIETARY_SUPPLEMENT|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
214268819|NCT02235805|DIETARY_SUPPLEMENT|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
214268820|NCT05719662|OTHER|Weight bearing exercises|Weight bearing exercises
214268821|NCT05719662|OTHER|Jaffrey's core stability exercises|Jaffrey's core stability exercises
214268822|NCT03717246|BEHAVIORAL|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
214268823|NCT03717246|BEHAVIORAL|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
214268824|NCT03504254|DIAGNOSTIC_TEST|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
214268825|NCT01853423|DRUG|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
214268826|NCT05161767|DIAGNOSTIC_TEST|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
214268827|NCT04035109|DRUG|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
214268828|NCT04035109|DRUG|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
214829200|NCT01418573|OTHER|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
214268829|NCT04035109|BIOLOGICAL|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
214268830|NCT04035109|BIOLOGICAL|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
214268831|NCT02043080|OTHER|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
214268832|NCT01533077|DRUG|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
214268833|NCT01533077|DRUG|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
214268834|NCT00651391|DRUG|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
214268835|NCT00651391|DRUG|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
214268836|NCT00651391|DRUG|Placebo|oral placebo once daily in the evening for 12 weeks
214656835|NCT04193371|OTHER|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
214829201|NCT04796480|DIETARY_SUPPLEMENT|YOGURT|Group 1 was given yogurt
214829202|NCT04796480|DIETARY_SUPPLEMENT|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
214268837|NCT04773756|DRUG|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
214656836|NCT04193371|OTHER|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
214268838|NCT04315883|BEHAVIORAL|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
214268839|NCT04315883|RADIATION|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate"
214268840|NCT01810861|OTHER|There is no intervention in this study|This is a non-interventional study.
214268841|NCT01796483|DEVICE|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
214268842|NCT01796483|DEVICE|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
214268843|NCT04209517|OTHER|Filming|Behavioural markers selection from video-recordings of the interview
214268844|NCT00167648|DRUG|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
214268845|NCT00167648|DRUG|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
214268846|NCT00252746|DRUG|ZD6474 (vandetanib) 100mg|once daily oral dose
214268847|NCT00252746|DRUG|ZD6474 (vandetanib) 200mg|once daily oral dose
214268848|NCT00252746|DRUG|ZD6474 (vandetanib) 300mg|once daily oral dose
214268849|NCT02656914|DRUG|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
214268850|NCT02656914|DRUG|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
214268851|NCT00002688|DRUG|cyclosporine|
214268852|NCT00002688|DRUG|etoposide|
214268853|NCT00002688|DRUG|mitoxantrone hydrochloride|
214268854|NCT03259217|DRUG|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
214268855|NCT03989895|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
214268856|NCT01593085|BEHAVIORAL|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~\--------------------------------------------------------------------------------"
214268857|NCT06005350|DIETARY_SUPPLEMENT|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
214268858|NCT06005350|OTHER|Placebo|Placebo Preperation
214268859|NCT01449539|DRUG|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
214268860|NCT01462487|DRUG|Treatment with zanamivir|Subjects treated with zanamivir
214268861|NCT03598543|OTHER|no intervention|no intervention, this is an obervational study.
214268862|NCT02850107|DEVICE|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
214268863|NCT02850107|DEVICE|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
214268864|NCT02850107|DEVICE|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
214268865|NCT02850107|DEVICE|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
214268866|NCT02850107|DEVICE|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
214829203|NCT05496920|DIAGNOSTIC_TEST|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
214268867|NCT01269411|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214268868|NCT01269411|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214268869|NCT01269411|OTHER|pharmacological study|Correlative studies
214268870|NCT01269411|OTHER|laboratory biomarker analysis|Correlative
214268871|NCT02651818|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
214268872|NCT04793087|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
214268873|NCT03506789|DRUG|Dexamethasone|Dexamethasone 24 mg
214268874|NCT03506789|DRUG|Placebos|Isotonic saline
214268875|NCT02259101|BEHAVIORAL|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
214268876|NCT02259101|BEHAVIORAL|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
214268877|NCT01647646|DRUG|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
214268878|NCT04821648|DRUG|RJV001|Subcutaneous injection in the abdomen
214268879|NCT04821648|DRUG|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
214268880|NCT00423904|BEHAVIORAL|Brief intervention|
214268881|NCT01972568|DRUG|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
214268882|NCT01972568|DRUG|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
214268883|NCT01972568|DRUG|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
214268884|NCT05409248|OTHER|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
214268885|NCT05409248|OTHER|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
214268886|NCT05182866|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
214268887|NCT02261454|OTHER|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
214268888|NCT00748735|PROCEDURE|Implantation of a cardiac resynchronization therapy device|
214268889|NCT00748735|PROCEDURE|Echocardiography (myocardial deformation imaging)|
214268890|NCT06502691|OTHER|Best Practice|Receive of standard care
214268891|NCT06502691|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
214268892|NCT06502691|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214268893|NCT06502691|OTHER|Electronic Health Record Review|Ancillary studies
214268894|NCT06502691|OTHER|Fludeoxyglucose F-18|Given FDG
214268895|NCT06502691|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
214268896|NCT06502691|DRUG|Immune Checkpoint Inhibitor|Receive ICI treatment
214268897|NCT06502691|DRUG|Poly (ADP-Ribose) Polymerase Inhibitor|Receive PARP inhibitor treatment
214268898|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET
214268899|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214268900|NCT00306189|DRUG|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
214268901|NCT00306189|DRUG|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
214268902|NCT00306189|DRUG|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
214268903|NCT00306189|DRUG|Placebo|Placebo SC every 6 months
214268904|NCT02572401|BEHAVIORAL|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
214268905|NCT02572401|BEHAVIORAL|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
214268906|NCT01223131|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
214268907|NCT01223131|DRUG|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
214268908|NCT01153074|DEVICE|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
214829204|NCT05496920|DIAGNOSTIC_TEST|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
214268909|NCT01538511|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
214268910|NCT01538511|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
214268911|NCT02059408|OTHER|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
214268912|NCT02059408|OTHER|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
214268913|NCT05158465|BEHAVIORAL|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
214268914|NCT04084431|RADIATION|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
214268915|NCT04084431|OTHER|OSC|optimal supportive Care (OSC) alone
214268916|NCT01088750|DRUG|cyclophosphamide|
214268917|NCT01088750|DRUG|prednisolone|
214268918|NCT01088750|DRUG|vinblastine sulfate|
214268919|NCT01088750|OTHER|watchful waiting|
214268920|NCT01088750|PROCEDURE|therapeutic conventional surgery|
214268921|NCT06171295|DIAGNOSTIC_TEST|Blood draw|The blood draws in specified time points
214829205|NCT02225782|DRUG|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
214268922|NCT04571320|BEHAVIORAL|Summer STRIPES|See arm description.
214268923|NCT04571320|OTHER|Enhanced School Services as Usual|see arm description.
214268924|NCT02586129|DRUG|YH14755|20/1500mg, QD
214268925|NCT02586129|DRUG|Metformin|1500mg, QD
214268926|NCT02586129|DRUG|Rosuvastatin|20mg, QD
214268927|NCT00945893|BIOLOGICAL|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
214268928|NCT00945893|OTHER|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
214268929|NCT02518256|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
214268930|NCT03748784|BIOLOGICAL|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
214268931|NCT02399722|DEVICE|WICVAC|combined wound therapy
214268932|NCT02399722|DEVICE|VAC mono therapy|mono therapy
214268933|NCT03766074|DIETARY_SUPPLEMENT|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
214268934|NCT03766074|DIETARY_SUPPLEMENT|Placebo|placebo
214268935|NCT01752270|DRUG|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
214268936|NCT01752270|DRUG|Diane-35 pretreatment|
214268937|NCT02447939|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
214268938|NCT02447939|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
214268939|NCT01160315|DRUG|Triptorelin|Triptorelin: intramusculAR injection every 3 months
214268940|NCT01160315|DRUG|Norethisterone acetate|5 mg/day per os until during chemotherapy
214268941|NCT00567372|DRUG|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
214268942|NCT02866916|DRUG|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
214268943|NCT05686889|OTHER|Patient self-report|Simulated patient following structured script
214268944|NCT04442113|PROCEDURE|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
214268945|NCT04442113|PROCEDURE|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
214268946|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
214268947|NCT01681472|DRUG|Levoleucovorin 200 mg/m2|i.v. bolus injection
214268948|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
214268949|NCT01681472|DRUG|Levoleucovorin 60 mg/m2|i.v. bolus injection
214268950|NCT00092612|DRUG|MK0653, ezetimibe|
214268951|NCT00092612|DRUG|Comparator: ezetimibe, placebo|
214268952|NCT04311775|DEVICE|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
214268953|NCT04311775|OTHER|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
214829206|NCT05243251|DRUG|Olanzapine 5 MG|, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
214268954|NCT03260101|OTHER|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
214268955|NCT05600452|OTHER|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
214268956|NCT00667875|DRUG|Placebo|placebo
214268957|NCT00667875|DRUG|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
214268958|NCT00667875|DRUG|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
214268959|NCT03799731|DRUG|GM102|GM102 7 mg/kg weekly
214268960|NCT03799731|DRUG|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
214268961|NCT03799731|DRUG|GM102 expansion|GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
214268962|NCT02647242|BEHAVIORAL|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
214268963|NCT03250221|DEVICE|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
214268964|NCT03250221|DEVICE|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
214268965|NCT01972113|DIETARY_SUPPLEMENT|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
214268966|NCT01972113|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
214268967|NCT01972113|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
214268968|NCT01237743|DEVICE|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
214268969|NCT05844410|DRUG|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
214268970|NCT04005911|DEVICE|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
214268971|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
214268972|NCT00795145|DRUG|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
214268973|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
214268974|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
214268975|NCT00795145|DRUG|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
214268976|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
214268977|NCT00795145|DRUG|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
214268978|NCT05797675|PROCEDURE|prf + osseodensification|prf+ osseodensification in close sinus lift
214268979|NCT03651869|DRUG|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
214268980|NCT03651869|DRUG|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
214268981|NCT03651869|DRUG|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
214268982|NCT03651869|DRUG|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
214268983|NCT00119834|DEVICE|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
214268984|NCT05195671|OTHER|Review|Reviewing all protocols
214268985|NCT01470937|DRUG|Acarbose|acarbose 100 mg PO once daily
214268986|NCT01470937|DRUG|Placebo|acarbose placebo
214268987|NCT03473483|OTHER|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~* Sealed and disposable~* Minimum 350 puffs per tank~* Volume of e-liquid per tank \~ 3ml~E-Liquid Characteristics:~* Tobacco flavored~* Nicotine concentration: 15 mg/ml~* Propylene Glycol:\~ 50% (wt / wt)~* Glycerin: \~ 50% (wt / wt)~* Cotinine: \<1 μg/g~* Nornicotine: 5 μg/g~* Myosmine : 3 μg/g~* Anabasine: \<1 μg/g~* Anatabine: \<1 μg/g~* Beta:nicotyrine: \<1 μg/g~* Diacetyl: \<2 μg/g~* 2,3:Pentanedione: \<1 μg/g~* Arsenic: \<0.1 μg/g~* Cadmium: \<0.1 μg/g~* Chromium: \<0.1 μg/g~* Lead: \<0.1 μg/g~* Nickel: \<0.1 μg/g~* Mercury: \<0.05 μg/g"
214268988|NCT06499649|DIETARY_SUPPLEMENT|IBSA Probiotics|Dietary supplement base on probiotic strains.
214268989|NCT06499649|DIETARY_SUPPLEMENT|Placebo|The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
214268990|NCT03318510|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
214268991|NCT00209534|DRUG|fospropofol disodium|
214268992|NCT00159120|OTHER|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
214268993|NCT03314194|OTHER|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
214268994|NCT01187433|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
214268995|NCT01187433|BIOLOGICAL|NaCl 0.9%|0.5 mL, Subcutaneous
214268996|NCT01187433|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
214268997|NCT01187433|BIOLOGICAL|Meningococcal A+C vaccine|0.5 mL, Intramuscular
214268998|NCT01349179|DEVICE|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
214268999|NCT02236442|OTHER|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
214269000|NCT03748108|DRUG|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
214269001|NCT03748108|DRUG|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
214269002|NCT00526942|BEHAVIORAL|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
214269003|NCT00952042|OTHER|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
214269004|NCT00952042|OTHER|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
214269005|NCT01773252|DEVICE|Flow Detection System|
214269006|NCT00547547|DIETARY_SUPPLEMENT|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
214269007|NCT00547547|DRUG|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
214269008|NCT00547547|DRUG|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
214269009|NCT01234831|DEVICE|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
214269010|NCT01234831|OTHER|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
214269011|NCT00074269|BIOLOGICAL|anti-thymocyte globulin|
214269012|NCT00074269|BIOLOGICAL|filgrastim|
214269013|NCT00074269|BIOLOGICAL|graft-versus-tumor induction therapy|
214269014|NCT00074269|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214269015|NCT00074269|DRUG|cyclosporine|
214269016|NCT00074269|DRUG|fludarabine phosphate|
214269017|NCT00074269|DRUG|melphalan|
214269018|NCT00074269|DRUG|methotrexate|
214269019|NCT00074269|PROCEDURE|peripheral blood stem cell transplantation|
214269020|NCT00437983|DIETARY_SUPPLEMENT|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
214269021|NCT00437983|DIETARY_SUPPLEMENT|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
214269022|NCT04495270|DIAGNOSTIC_TEST|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
214269023|NCT00144391|DRUG|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
214269024|NCT04647864|DEVICE|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
214269025|NCT00066352|DRUG|bortezomib|
214269026|NCT00672646|DRUG|AZD1386|95mg, oral solution, single dose
214269027|NCT00672646|DRUG|Naproxen|500mg, capsule, single dose
214269028|NCT00672646|DRUG|Placebo|AZD1386 Placebo oral solution
214269029|NCT05223933|BEHAVIORAL|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
214269030|NCT05499000|BEHAVIORAL|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
214269031|NCT03883711|OTHER|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
214269032|NCT02269306|DRUG|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
214269033|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
214269034|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
214269035|NCT04993820|BEHAVIORAL|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
214269036|NCT04993820|BEHAVIORAL|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
214269037|NCT04960514|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
214269038|NCT04482257|DRUG|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
214269039|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
214269040|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
214829207|NCT05243251|DRUG|Placebo|Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
214269041|NCT05711784|OTHER|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
214269042|NCT04760821|DRUG|Trimetazidine|Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
214269043|NCT01686061|OTHER|No intervention- only one time survey|
214269044|NCT05678777|DEVICE|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
214269045|NCT01769807|DEVICE|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
214269046|NCT05510440|DIETARY_SUPPLEMENT|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
214269047|NCT04721171|DEVICE|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
214269048|NCT05747430|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
214269049|NCT05747430|DRUG|Providone-Iodine|5% Providone-Iodine
214269050|NCT06505564|BEHAVIORAL|AVATAR therapy|In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
214269051|NCT06004362|BEHAVIORAL|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~* Basic principles of a plant-based whole-food nutrition~* Procedures of hydrotherapy according to Kneipp~* Self-help strategies (e.g. teas, wraps, compresses etc.)~* Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~* Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
214269052|NCT06004362|BEHAVIORAL|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
214269053|NCT01457144|DRUG|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
214269054|NCT05121896|DEVICE|MRI Scan|7.0 tesla functional MRI scan
214269055|NCT00142298|DRUG|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
214269056|NCT02996513|OTHER|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
214269057|NCT01269632|BIOLOGICAL|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires"
214269058|NCT05497583|OTHER|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
214269059|NCT05497583|OTHER|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
214269060|NCT00300274|DRUG|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
214269061|NCT00300274|DRUG|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
214269062|NCT00300274|DRUG|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
214269063|NCT00300274|DRUG|corticosteroids|Corticosteroids standard dose.
214269064|NCT00916097|DRUG|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
214269065|NCT03498144|DEVICE|Anterior segment OCT|lower punctum examination by AS-OCT
214269066|NCT00242216|DRUG|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
214269067|NCT00242216|DRUG|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
214269068|NCT01786941|OTHER|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
214269069|NCT01786941|OTHER|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
214269070|NCT00214760|DEVICE|PGET|resolbable liner
214269071|NCT00214760|DEVICE|PMMA|cement liner
214269072|NCT03950011|PROCEDURE|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
214269073|NCT02597231|DIETARY_SUPPLEMENT|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
214269074|NCT02597231|OTHER|Placebo|Patients in this group will receive a matching placebo pill.
214269075|NCT00981240|DRUG|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
214269076|NCT05212571|DRUG|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
214269077|NCT05212571|DRUG|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
214269078|NCT06183177|OTHER|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
214269079|NCT06183177|OTHER|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
214269080|NCT00069056|PROCEDURE|Laser Treatment|
214269081|NCT06016725|OTHER|Exercise Intervention|Participate in online resistance training sessions
214269082|NCT06016725|OTHER|Informational Intervention|Given educational materials
214269083|NCT06016725|OTHER|Nutritional Assessment|Participate in online nutritional counseling
214269084|NCT06016725|OTHER|Physical Performance Testing|Ancillary studies
214269085|NCT06016725|OTHER|Quality-of-Life Assessment|Ancillary studies
214269086|NCT06016725|OTHER|Questionnaire Administration|Ancillary studies
214269087|NCT02872493|PROCEDURE|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
214269088|NCT05472779|DRUG|Periurethral application of estradiol cream|The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
214269089|NCT05472779|DRUG|Intravaginal application of estradiol cream|The control group will apply 1 gram estradiol cream intravaginally using an applicator.
214269090|NCT06973746|OTHER|sitting out of bed in an arm-chair position|"Once the patient has been awake with a RASS score between -1 and +1 for more than 12 hours, he or she must be placed in a chair (by any means) every day for a minimum of 30 minutes until discharge from intensive care (or until D28, depending on which comes first), unless there are transient contraindications. If the patient is unable to signal his or her wish to stop the chair session, the criteria for intolerance will be sought and the patient placed in the chair, but in all cases the chair session will not exceed 4 hours."
214269091|NCT06109649|DRUG|Afamelanotide and NB-UVB Light|Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
214269092|NCT06109649|PROCEDURE|NB-UVB Light|Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.
214269093|NCT06150924|DRUG|Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD|Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks
214269094|NCT06150924|DRUG|Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD|Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks
214269095|NCT04651296|BEHAVIORAL|compassion meditation|manualized compassion meditation training
214269096|NCT04651296|BEHAVIORAL|health education|manualized health education group
214269097|NCT04439201|DRUG|Palbociclib|Given PO
214269098|NCT05394675|DRUG|DS-9606a|Intravenous infusion
214269099|NCT06975072|DRUG|Magnesium sulfate administration|A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min).
214269100|NCT06576466|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
214269101|NCT06576466|OTHER|Placebo|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
214269102|NCT06640530|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
214269103|NCT06640530|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
214269104|NCT05733390|DRUG|JZP541|Oral suspension
214269105|NCT05733390|OTHER|Placebo|Oral suspension
214269106|NCT06141031|DRUG|TTI-101|TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
214269107|NCT06252636|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein.
214269108|NCT06252636|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein.
214269109|NCT02989025|DRUG|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
214269110|NCT03651206|DRUG|Niraparib|PARP Inhibitor
214269111|NCT03651206|COMBINATION_PRODUCT|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
214269112|NCT03651206|DRUG|Chemotherapy Drugs|Chemotherapies given in standard of care
214269113|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
214269114|NCT04107766|DEVICE|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
214269115|NCT06656494|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
214269116|NCT06656494|DRUG|Azacitidine|Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.
214269117|NCT04039633|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
214269118|NCT04039633|PROCEDURE|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
214269119|NCT04786977|OTHER|No Intervention, Observational Study|No Intervention
214269120|NCT03451266|DRUG|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
214269121|NCT03451266|DRUG|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
214269122|NCT04845477|DEVICE|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
214269123|NCT04845477|DEVICE|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
214269124|NCT04144972|DEVICE|Medtronic Summit RC+S or Percept RC|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
214269125|NCT06662942|DRUG|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
214269126|NCT06662942|DRUG|Placebo|The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
214269127|NCT06666127|OTHER|LONG and SHORT Resistance Training|One side of the body will be randomly assigned to perform exercises in position 3 (LONG) with the other randomly assigned to position 2 (SHORT) of Prime Fitness horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Each exercise will include 1 warm up set at 50% 1RM followed by 4-5 sets of 8-12 repetitions per limb. 2 minutes of rest between sets on the same side of body will be administered as the participant will alternate between the right and left limb. The left and right side limbs will alternate each session in which one starts each exercise, resulting in 10 training sessions each where the left and right limbs starts first on each exercise. All sets will be performed to momentary failure. A Dynamic Double Progression will be employed to ensure intensity is maintained.
214269128|NCT06666127|OTHER|Maximal Isotonic Strength Testing (1RM)|Each limb will perform a 1RM strength test with each Prime Fitness machine training horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension respectively. Each machine will be set to position 1 (maximal load in mid-range). Testing will occur in weeks 1 and 12 of the study with the non-dominant arm and leg tested before the dominant arm and leg in each exercise. Participants self-selects first warm up set with a weight that is performed between 6-10 repetitions on both limbs. Rest for 1 minute between limbs and subsequent set. A weight is then selected by research staff to perform 3 repetitions with based on previous set. Load is now increased until 1RM is achieved. Rest periods should remain at least 1 minute alternating between limbs, with 1RM being complete within 3-5 attempts. Participant will rest 2-5 minutes before starting testing on the next exercise. Repeat for all exercises. Use pre testing data to inform 1RM attempts for post testing.
214269129|NCT06666127|OTHER|Isokinetic Strength Testing|Participants will engage in isokinetic strength testing on the isokinetic dynamometer (Biodex) in weeks 1 and 12 for each of the four movements: Horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Participants will perform each movement unilaterally. Participants will start with the non-dominant arm and leg for each movement. Each movement will be tested through A maximal active range of motion. Participants will complete 10 sub-maximal repetitions to allow familiarization each movement. After a 2-minute rest, participants will complete 3 maximal concentric and eccentric repetitions with 30 seconds rest at 30 degrees per second before the Biodex is reset for the next movement.
214269130|NCT06666127|OTHER|Muscle Oxygenation|During the first and last LONG and SHORT training session (visit 5 and visit 24), A near infrared spectroscopy sensor (NIRS device) (Trainred) will be affixed to the muscle belly of the deltoid during the lateral raise exercise to measure muscle oxygenation.
214269131|NCT06605456|OTHER|Proprioceptive neuromuscular facilitation with postural education|"Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles. Then, resisted scapular posterior depression PNF exercise also employed.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
214464879|NCT06101056|BEHAVIORAL|Social Marketing Campaign|"All participating Airmen (including Junior Enlisted Airmen and Leaders) will be exposed to X-CoRe's social marketing campaign, which includes posters, flyers, postcards, and digital content for social media. Messages are designed to increase awareness of consent and foster Wing-wide norms that are supportive of healthy relationships. Resources for Service members to receive support if they have experienced SH or SA will also be provided through the social marketing materials. Social marketing materials, such as posters, will be distributed at hot spots for SA (e.g., dorms)."
214269132|NCT06605456|OTHER|Active neck muscle stretching and strengthening exercises|"Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
214269133|NCT06987370|RADIATION|Conventional Radiotherapy (CRT)|The conventional radiotherapy group, that is, the control group, administering conventional external beam radiotherapy with a dose of 30 Gy in 10 fractions to the bone metastasis lesions.
214269134|NCT06987370|RADIATION|SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）|"Stereotactic Central Ablative Radiotherapy (SCART): When using SCART to treat bone metastases with associated soft tissue components, the gross tumor volume (GTV) of the bone metastases must be accurately delineated according to the guidelines. The GTV are contracted to derive the SCART-Treatment Volume (STV). An initial dose of 8-12 Gy in a single fraction is delivered to the STV, followed by a dose of 25-40 Gy in 5 fractions to the clinical target volume (CTV). Spatially Fractionated Radiation Therapy (SFRT): The GTV are reduced to form a LATTICE target area. Several vertices are uniformly contoured along the edges of the LATTICE. A dose of 8-12 Gy in a single fraction is delivered to the vertices, followed by a dose of 25-40 Gy in 5 fractions to the CTV."
214269135|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
214269136|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
214269137|NCT06992440|DRUG|Empagliflozin 10 MG|10 mg tablet once daily
214269138|NCT06992440|DRUG|Placebo|matching tablet once daily
214269139|NCT01052376|DEVICE|Confocal endomicroscopy|
214269140|NCT06862635|OTHER|Hydrotherapy|Patients will receive hydrotherapy sessions including stretching, resistance, and balance exercises in water
214269141|NCT06862635|OTHER|traditional land-based balance exercises|Patients will receive traditional land-based balance exercises in the form of stretching, strengthening and balance exercises.
214269142|NCT06857357|OTHER|Questionnaires|"The Tampa Kinesiophobia Questionnaire is a 17-question questionnaire that assesses avoidance of injury and fear of movement. The scale is scored using a Likert scale (1 = Strongly disagree, 4 = Strongly agree). Items 4, 8, 12 and 16 are reversed to calculate the total score of the scale. The total score is between 17 and 68. As the score of the person increases, it is understood that their kinesiophobia is high. A total score higher than 37 is considered as high kinesiophobia. However, since not every item of the questionnaire addresses patients with headache in this study, some questions were removed, some questions were edited and some questions were added to create a kinesiophobia questionnaire for headache. The newly created questionnaire consists of 23 items. Again, it is scored using a Likert scale with 1 = Strongly disagree, 4 = Strongly agree. As the score increases, it is understood that the level of kinesiophobia is high."
214269143|NCT06615739|DEVICE|Regenerex Tissue Attachment Augments|Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
214269144|NCT06673446|PROCEDURE|vestibular socket therapy|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra"
214269145|NCT07001605|DRUG|ketamine|after induction of anesthesia, patients will receive ketamine bolus of 0.5 mL/kg followed by continuous infusion of 0.12 mL/k/hr until the end of surgical procedure.
214269146|NCT07001605|OTHER|Erector Spinae Plane Block|after induction of anesthesia, patients will receive ultrasound guided ESPB. A total of 40 mL of 0.25% bupivacaine will be injected bilaterally at the level of transverse process opposing to the mid-point of the planned incision.
214269147|NCT07001605|OTHER|Wound infiltration|wound infiltration at the end of the surgery before the closure of fascia and subcutaneous tissues using a total of 20 ml of 0.25% bupivacaine
214269148|NCT05701033|OTHER|Access to heritage|Unmediated access to heritage sites for wellbeing
214269149|NCT06679413|DRUG|midazolam|Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
214269150|NCT06679413|DRUG|metformin|Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
214269151|NCT06679413|DRUG|bupropion|Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
214269152|NCT06679413|DRUG|fenfluramine HCl|Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
214269153|NCT04055948|BEHAVIORAL|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)
214269154|NCT04055948|BEHAVIORAL|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
214269155|NCT06681883|BEHAVIORAL|Action group|"A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program."
214269156|NCT06139861|BEHAVIORAL|TranS-C|Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
214269157|NCT06139861|BEHAVIORAL|Psychoeducation|The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
214269158|NCT01072383|DRUG|BT061|administration of BT061 either intravenous or subcutaneous
214269159|NCT01072383|DRUG|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
214269160|NCT06681155|DIAGNOSTIC_TEST|Assessment of plaque morphology, structure, and stability in non-culprit lesions|Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
214269161|NCT06680700|DEVICE|Perin Health Patch|The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
214269162|NCT07012876|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|The intervention is a guided mental health chatbot - STARS - developed by the World Health Organization (WHO). It consists of 10 sessions which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Supportive Self-talk (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained and supervised non-specialists (called e-helpers) provide weekly calls (five calls lasting approximately 15 minutes) to support participants individually and increase motivation and adherence to the intervention.
214269163|NCT07012876|BEHAVIORAL|Basic psychoeducation|The control group will receive basic psychoeducation. The content of the psychoeducation is very similar to the content of session 2 of the STARS chatbot and includes psychoeducation about emotions, a personal story about a fictional character who talks about her emotions, and information about where to access mental health support. It also includes a list of organizations and clinics providing mental health care in Lithuania.
214269164|NCT07008417|DRUG|Cabergoline tablets test formulation|Single oral administration
214269165|NCT07008417|DRUG|Cabergoline tablets reference formulation|Single oral administration
214269166|NCT06684964|OTHER|asciminib|This is an observational study. There is no treatment allocation. The decision to initiate asciminib will be based solely on clinical judgement.
214269167|NCT06684457|BEHAVIORAL|Atrial Fibrillation Education|Atrial fibrillation education rendered through a generative AI chatbot, using an iPAD. The intervention itself is an approximately 1 hour long interaction with the chatbot or approximately 10 questions about atrial fibrillation, for 1 single interaction.
214269168|NCT06680882|OTHER|Auricular Acupoint Stimulation +prucapride|The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
214269169|NCT06680882|DRUG|prucapride|was administered prucapride as a monotherapy
214269170|NCT06680960|OTHER|Trunk stabilisation exercises|This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.
214269171|NCT06680960|OTHER|Respiratory exercises|This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
214269172|NCT06873841|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
214269173|NCT06873841|BEHAVIORAL|Cognitive psychophysiological and Biofeedback|Biofeedback refers to visual exercises that help improve movement control.
214269175|NCT07020052|DRUG|temozolomide/anlotinib/pembrolizumab|"Starting from 30 days after radiotherapy, adjuvant temozolomide was orally administered at a dose of 150mg/m2. The dosage of temozolomide was adjusted to 200mg/m2 starting from the second cycle, with continuous use for 5 days per week and a 23 day hiatus. Oral administration for a total of 6 cycles.~The start time of oral administration of anlotinib after radiotherapy follows the cycle of radiotherapy, with continuous oral administration for 2 weeks and cessation for 1 week. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months.~Begin treatment with bemarituzumab 24 hours after radiotherapy, with a body weight of\>=45kg, intravenous injection of 200mg, once every 3 weeks. Weight\<45kg, 100mg intravenous injection, once every 3 weeks. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months."
214269176|NCT06229210|DRUG|Lumateperone|Lumateperone 5 mg - 42 mg capsules or orally disintegrating tablets administered orally, once daily based on age and indication
214269177|NCT03389230|BIOLOGICAL|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
214269178|NCT03389230|OTHER|Laboratory Biomarker Analysis|Correlative studies
214269179|NCT03389230|PROCEDURE|Leukapheresis|Undergo leukapheresis
214269180|NCT02039336|DRUG|Dacomitinib|
214269181|NCT02039336|DRUG|PD-0325901|
214269182|NCT02039336|DRUG|Docetaxel|
214269183|NCT05120349|DRUG|Osimertinib|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
214269184|NCT05120349|DRUG|Placebo|Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
214269185|NCT06704776|PROCEDURE|"The medially pedicled IPFP flap group"|"In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures."
214269186|NCT06704776|PROCEDURE|"Complete IPFP removal group"|The entire IPFP was resected from below the patellar tendon prior to femoral preparation.
214269187|NCT06706271|DRUG|Vitamin D|2000 IU of Vitamin D
214269188|NCT05213338|DEVICE|Wear-documentation microchip|Microchip embedded in the appliance
214269189|NCT06708104|DEVICE|Outdoor horse-assisted perturbation training|This is balance training in which a special carriage, i.e. a dynamic standing platform, is pulled by a horse on the outside surface, providing the trainee with multi-directional 3D balance perturbations that depend on the topography of the training area (various slopes and surface types), the horse walking speed, and its ability to stop, accelerate, and turns.
214269190|NCT07049523|DEVICE|Robotic-assisted gait training|"The intervention group will receive robotic-assisted gait training using the RoboCT Pediatric Lower Limb Rehabilitation Robot (RoboCT Limited Co., Hangzhou, China), a pediatric exoskeleton system designed for overground locomotor training. This device integrates real-time motion sensing, adaptive control algorithms, and customizable joint actuation to deliver precise and individualized gait training for children with minimal voluntary motor control. The system allows for the modulation of key gait parameters including joint angles, step length, and walking speed, and incorporates both postural correction and dynamic support harnessing to maintain safety and alignment throughout the session.~Robotic sessions will be conducted three times per week over a period of 24 weeks, with each session lasting approximately 45 minutes. All sessions will be conducted at a designat"
214269191|NCT07053592|BEHAVIORAL|Geriatric Ｂeauty and Ｈealth Care Learning Program|An educational course on geriatric care designed to enhance students' attitudes toward older adults and learning outcomes. The intervention includes lectures, group discussions, and interactive learning activities. Effectiveness is measured using pre- and post-course surveys and focus group interviews.
214269192|NCT07053488|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver|Donor liver tissue is perfused outside the body with a CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA, to create a hypoimmunogenic graft. After confirming successful gene knockout, the liver is transplanted into the patient following standard surgical techniques. Post-operative care includes routine immunosuppressive therapy with planned adjustments based on the patient's tolerance and evidence of graft immunogenicity.
214269193|NCT07053605|PROCEDURE|laparoscopic resection of splenic artery aneurysm with preservation of spleen|The laparoscopic resection of splenic artery aneurysm with preservation of spleen is performed by the same surgical team.
214269194|NCT04006613|OTHER|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
214269195|NCT04006613|OTHER|Usual Care|Exercises aimed at improving mobility and balance
214269196|NCT03800914|OTHER|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
214269197|NCT03800914|OTHER|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
214269198|NCT06919666|DRUG|NT219|NT219 is a first-in-class small molecule targeting IRS 1/2 and STAT3. Preclinical studies in melanoma have shown NT219 induces PD-L1 expression in vitro and in vivo, resulting in increased efficacy of PD-1 inhibition via synergistic antitumor effect in PD-1 sensitive models and restoration of sensitivity in resistant models. NT219 also synergized with cetuximab in vitro and reversed cetuximab resistance in a head and neck cancer xenograft platform.
214269199|NCT06913764|DEVICE|class I compression stockings of the RAL-GZ 387 standard: 1 month using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) above-knee graduated compression stockings
214269200|NCT06913764|DEVICE|class II compression stockings of the RAL-GZ 387 standard: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
214269201|NCT06772532|DRUG|BI 456906 - Formulation A|Formulation A
214269202|NCT06772532|DRUG|BI 456906 - Formulation B|Formulation B
214269203|NCT06772532|DRUG|BI 456906 - Formulation C|Formulation C
214269204|NCT00219739|DRUG|Imatinib mesylate 400 mg|
214269205|NCT00219739|DRUG|Imatinib mesylate 600 mg|
214269206|NCT00219739|DRUG|Imatinib 400 mg + Peg-Interferon|
214269207|NCT00219739|DRUG|Imatinib mesylate 400 mg + Cytarabine|
214269208|NCT02346552|DEVICE|AutoLap|
214269209|NCT06384690|DIETARY_SUPPLEMENT|Micro-vegetable blend|The intervention in this study is 6 weeks with a daily proprietary blend micro-vegetables that has been freeze-dried
214269210|NCT06384690|DIETARY_SUPPLEMENT|Placebo|The intervention in this study is 6 weeks with a placebo supplement
214269211|NCT06680193|BEHAVIORAL|Processing of Positive Memories Technique|"PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination."
214269212|NCT06709573|DRUG|vasopressin - early initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min
214269213|NCT06709573|DRUG|vasopressin - standard initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min
214269214|NCT06951191|DRUG|Benzocaine 20%|Benzocaine 20% topical spray
214269215|NCT06951191|DRUG|Lidocaine 2%|Lidocaine 2% injectable solution
214269216|NCT06951191|OTHER|Sham injection|Sham injection to mimic Lidocaine paracervical block. Will use an injection needle and sham inject (no actual injection of fluid)
214269217|NCT06951191|DRUG|Saline 0.9%|Saline spray to mimic use of benzocaine spray
214269218|NCT05898971|OTHER|Robotic|Patients receive robotic training (grasp and grip)
214269219|NCT05898971|OTHER|Mirror|Patients receive mirror therapy
214269220|NCT04785521|RADIATION|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
214269221|NCT04785521|DIAGNOSTIC_TEST|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
214269222|NCT00730145|DRUG|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
214269223|NCT03813849|DIAGNOSTIC_TEST|Sonographic examination of uterus after surgical evacuation|
214269224|NCT06956170|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
214269225|NCT06956170|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
214269226|NCT06956170|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
214269227|NCT06956170|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
214269228|NCT00002210|DRUG|Delavirdine mesylate|
214269229|NCT01603004|OTHER|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
214269230|NCT03959358|DRUG|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
214269231|NCT03959358|DRUG|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
214269232|NCT01130142|DRUG|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
214269233|NCT01130142|DRUG|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
214269234|NCT06050278|OTHER|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
214269235|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
214269236|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
214269237|NCT03809143|DRUG|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
214269238|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
214269239|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
214269240|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
214269241|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
214269242|NCT01385566|BIOLOGICAL|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
214269243|NCT01385566|BIOLOGICAL|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
214269244|NCT04127864|PROCEDURE|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
214269245|NCT01539694|DEVICE|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
214269246|NCT01539694|DEVICE|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
214269247|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
214269248|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
214269249|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
214269250|NCT00403234|DRUG|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
214269251|NCT04944069|DRUG|Almonertinib|110 mg oral once daily
214269252|NCT04944069|DRUG|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
214269253|NCT02362217|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
214269254|NCT02362217|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
214269255|NCT02362217|BIOLOGICAL|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
214269256|NCT02362217|BIOLOGICAL|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
214269257|NCT01006096|DRUG|erlotinib|100mg tablet, once daily for 16 weeks
214269258|NCT01006096|OTHER|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
214269259|NCT05770856|DIAGNOSTIC_TEST|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
214269260|NCT00902915|DRUG|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
214269261|NCT05503615|OTHER|Observational|No application will be made to the control group.
214269262|NCT05503615|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
214269263|NCT01643356|BEHAVIORAL|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
214269264|NCT04432285|DEVICE|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
214269265|NCT04432285|DRUG|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
214269266|NCT02675283|DEVICE|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
214269267|NCT03400878|BIOLOGICAL|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
214269268|NCT03400878|BIOLOGICAL|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
214269269|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
214269270|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
214269271|NCT01968759|DRUG|Sevelamer|
214269272|NCT01968759|DRUG|Ramipril and Irbesartan|
214269273|NCT00432419|PROCEDURE|autologous peripheral blood cell transplantation|
214269274|NCT03064984|OTHER|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
214269275|NCT03064984|OTHER|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
214269276|NCT02990689|DEVICE|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
214269277|NCT02990689|DEVICE|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
214269278|NCT02990689|DEVICE|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
214269279|NCT05036824|DRUG|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
214269280|NCT05343598|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
214269281|NCT05343598|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
214829208|NCT02464254|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
214269282|NCT01866696|DEVICE|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up"
214269283|NCT02280304|BEHAVIORAL|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
214269284|NCT02280304|BEHAVIORAL|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
214269285|NCT05572320|DIAGNOSTIC_TEST|Platelet Aggregometry Testing|1.6 ml of blood collected in hirudin-coated tubes before the surgery
214269286|NCT05846074|DIAGNOSTIC_TEST|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
214269287|NCT00874107|BIOLOGICAL|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
214269288|NCT00874107|BIOLOGICAL|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
214269289|NCT00874107|DRUG|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
214829209|NCT02464254|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
214829210|NCT01283503|DRUG|BKM120|
214829211|NCT05644106|DEVICE|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
214829212|NCT04069936|BIOLOGICAL|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
214829213|NCT04069936|BIOLOGICAL|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
214829214|NCT04069936|DRUG|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
214269290|NCT00874107|DRUG|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
214269291|NCT05420597|DRUG|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
214269292|NCT06240871|OTHER|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
214269293|NCT00539656|BIOLOGICAL|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
214269294|NCT00313261|DRUG|Clevudine|
214269295|NCT01431170|DRUG|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
214269296|NCT01431170|DRUG|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
214269297|NCT04218695|DRUG|Ceftriaxone|Antibiotic
214269298|NCT04218695|DRUG|Normal saline|50cc intravenous once daily
214269299|NCT00752180|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
214269300|NCT00752180|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
214269301|NCT04987775|DRUG|N-Acetyl Cysteine|900mg 2x daily
214269302|NCT04987775|DRUG|Placebo|Matching placebo bid
214269303|NCT00353665|DRUG|Memantine (Ebixa)|10 mg bid
214269304|NCT00353665|DRUG|riluzole|riluzole 50 mg bid
214269305|NCT00353665|DRUG|Placebo|
214269306|NCT03166735|DRUG|BI 1467335|once daily
214269307|NCT03166735|DRUG|Placebo|once daily
214269308|NCT06139965|OTHER|Validity and Reliability|Assessment study
214269309|NCT00049192|BIOLOGICAL|oblimersen sodium|Given IV
214269310|NCT00049192|DRUG|imatinib mesylate|Given PO
214269311|NCT00049192|OTHER|laboratory biomarker analysis|Correlative studies
214269312|NCT00003473|DRUG|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214269313|NCT00003473|DRUG|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214269314|NCT04639167|BEHAVIORAL|Paths to everyday life (PEER)|The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
214269315|NCT03352297|BIOLOGICAL|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
214269316|NCT06089499|BEHAVIORAL|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
214269317|NCT02513342|BIOLOGICAL|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
214269318|NCT02513342|DRUG|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
214269319|NCT02513342|DRUG|Cisplatin|d4，cisplatin，75（mg/m2），iv；
214269320|NCT01933061|DRUG|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
214269321|NCT01933061|DRUG|Abraxane|Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
214269322|NCT03416725|DEVICE|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
214269323|NCT01842321|DRUG|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
214269324|NCT03989700|DRUG|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
214269325|NCT00667407|DRUG|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
214269326|NCT00667407|DRUG|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
214269327|NCT02982668|OTHER|Initial enteral feeding|
214269328|NCT02982668|DRUG|metoclopramide or mosapride|gastrointestinal (GI) motility improving
214269329|NCT01664546|PROCEDURE|Trophectoderm biopsy|
214269330|NCT03717818|BEHAVIORAL|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
214269331|NCT03717818|BEHAVIORAL|treatment as usual|non-specific intervention
214269332|NCT00666172|BEHAVIORAL|Exercise|
214269333|NCT00666172|BEHAVIORAL|Weight Loss|
214269334|NCT04713215|OTHER|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
214269335|NCT01292746|DEVICE|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
214269336|NCT01171430|DEVICE|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
214269337|NCT02846584|BIOLOGICAL|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
214269338|NCT05607615|DRUG|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
214269339|NCT05607615|DRUG|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
214269340|NCT03190590|PROCEDURE|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
214269341|NCT03190590|PROCEDURE|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
214269342|NCT03190590|PROCEDURE|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
214269343|NCT03625622|DRUG|AR1001|AR1001 Active Oral Tablet
214269344|NCT03625622|DRUG|Placebo|Placebo Oral Tablet
214269345|NCT00763620|DEVICE|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
214269346|NCT04021771|OTHER|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
214269347|NCT01492985|BIOLOGICAL|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
214269348|NCT01492985|BIOLOGICAL|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
214829215|NCT01127087|DRUG|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
214829216|NCT01933282|DRUG|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
214829217|NCT01933282|DRUG|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
214829218|NCT02986555|DEVICE|Existing Biofeedback|Using relaxing assisted biofeedback approach
214829219|NCT02986555|DEVICE|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
214269349|NCT01090271|DEVICE|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
214269350|NCT06467968|OTHER|Cardiac ECG-gated PET imaging will added|Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
214269351|NCT04702061|OTHER|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
214269352|NCT04702061|OTHER|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
214269353|NCT06557083|BEHAVIORAL|Polyvagal Breathing Exercises|Breathing exercises provided include, square breathing, modified Qigong breathing, and three step breathing
214269354|NCT06557083|OTHER|No Intervention|The control group will not perform any intervention.
214269355|NCT04194580|BEHAVIORAL|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
214269356|NCT00217061|DEVICE|Decision Aid Statin Choice|
214269357|NCT02530060|DRUG|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
214269358|NCT02348905|DRUG|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
214269359|NCT02348905|DRUG|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
214269360|NCT01991769|BEHAVIORAL|47 min moderate intensity training|
214269361|NCT01991769|BEHAVIORAL|exercise healthy volunteers|
214269362|NCT01991769|BEHAVIORAL|control; no exercise training|
214269363|NCT01747044|DRUG|Milnacipran|100mg/day
214269364|NCT01747044|DRUG|Placebo|
214269365|NCT00955071|OTHER|Exercise: LVLI|low volume, low intensity
214269366|NCT00955071|OTHER|Exercise: HVLI|high volume, low intensity
214269367|NCT00955071|OTHER|Exercise: LVHI|low volume, high intensity
214269368|NCT01582165|DRUG|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
214269369|NCT01582165|DRUG|Placebo.|Placebo once daily vs rosuvastatin for 6 months
214269370|NCT06505421|BEHAVIORAL|Resistance training|Eccentric resistance training and tradional resistance training
214269371|NCT00814970|DEVICE|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
214269372|NCT05754931|OTHER|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
214269373|NCT05754931|OTHER|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
214269374|NCT02826902|DRUG|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
214269375|NCT02826902|DRUG|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
214269376|NCT03372096|DEVICE|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
214269377|NCT01861964|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
214269378|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
214269379|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
214269380|NCT05292443|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
214269381|NCT02072018|DRUG|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
214269382|NCT02072018|DRUG|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
214269383|NCT00402415|DRUG|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
214269384|NCT00402415|DRUG|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
214269385|NCT04313218|DRUG|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
214269386|NCT06158373|OTHER|infant massage practice|infant massage practice
214269387|NCT06158373|OTHER|Safe Swaddling|Safe Swaddling
214464880|NCT04696263|DEVICE|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
214269388|NCT06158373|OTHER|Control|Control
214269389|NCT03513328|DRUG|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
214269390|NCT03513328|DRUG|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
214269391|NCT01785693|DRUG|levobupivacaine, clonidine|
214269392|NCT01245660|DRUG|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
214269393|NCT03142087|OTHER|exercises|exercise
214269394|NCT00883805|BIOLOGICAL|Blood draw|Subjects will give blood for analysis of metal ion concentrations
214269395|NCT00883805|RADIATION|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
214269396|NCT04195087|DEVICE|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
214269397|NCT03772691|PROCEDURE|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
214269398|NCT03772691|PROCEDURE|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
214269399|NCT04942444|OTHER|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
214269400|NCT01947582|DEVICE|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
214269401|NCT04070430|OTHER|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
214269402|NCT04070430|OTHER|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
214269403|NCT02949869|OTHER|Spinal Sonography|As described previously
214269404|NCT04316065|DRUG|YHP1906|YHP1906 Tab. 5 mg
214269405|NCT04316065|DRUG|YHR1902|Comparator. YHR1902 Tab. 5 mg
214269406|NCT03177694|DEVICE|Wireless bed sensor|Remote data collection
214269407|NCT01603355|DRUG|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
214269408|NCT04264091|OTHER|Observational|Observational
214269409|NCT05751928|BIOLOGICAL|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
214269410|NCT05751928|BIOLOGICAL|anti-PD1|anti-PD1 agent in the adjuvant setting
214269411|NCT05751928|PROCEDURE|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
214269412|NCT05751928|PROCEDURE|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
214269413|NCT05396612|OTHER|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
214269414|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
214269415|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
214269416|NCT06372964|DRUG|Lumateperone|Lumateperone administered orally, once daily.
214269417|NCT06372964|DRUG|Placebo|Matching placebo administered orally, once daily.
214269418|NCT05595096|PROCEDURE|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
214269419|NCT05711849|BIOLOGICAL|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
214269420|NCT05711849|PROCEDURE|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
214269421|NCT05827952|BEHAVIORAL|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
214269422|NCT03641404|DRUG|L-ergothioneine|Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.
214269423|NCT03641404|DRUG|Placebo|Placebo. Study control (99% microcrystalline cellulose, 1% magnesium stearate)
214269424|NCT06210503|PROCEDURE|Pericapcelar group nerve block|In the supine position, a high-frequency linear sensor is placed in the anterior superior iliac spine and then aligned with the ramus of the pubis by rotating the probe counterclockwise approximately 45 degrees. The iliopsoas muscle and tendon, femoral artery, and pectineus muscle were observed in this view.The iliopsoas muscle and its tendon are visualized, as well as the vascular and nerve bundle: femoral artery, vein, and nerve. The needle is inserted laterally to medially in a planar approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the ramus pubis posteriorly. After negative aspiration, local anesthetic will be gradually injected aspirating every 3 mL.
214269425|NCT06210503|PROCEDURE|Fascia iliaca compartment block|In the supine position, a high-frequency linear sensor is placed in the inguinal fold. Scan starting lateral to the femoral artery and the nerve in the inguinal crease to identify the sartorius muscle, tracing the muscle to its origin to the anterior superior iliac spine. A shadow of the iliac crest bone and iliacus muscle will be visible, with the end point of injection being deep in the fascia iliaca and above the iliacus muscle at the lateral aspect of the iliacus muscle. After negative aspiration, local anesthetic will be gradually injected under the fascial plane, aspirating every 3 mL.
214269426|NCT06025097|DRUG|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
214269427|NCT01734863|RADIATION|External Beam Radiotherapy|
214269428|NCT06129422|DRUG|NMK89|Route of administration: intravenous infusion
214269429|NCT02813824|DRUG|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
214269430|NCT02813824|DRUG|Placebo (for Aspirin 300)|Daily dose during 4 years
214269431|NCT02813824|DRUG|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
214269432|NCT02813824|DRUG|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
214269433|NCT05671705|DIAGNOSTIC_TEST|DEXA Scan|Fu of diagnostic tests
214269434|NCT04868162|DRUG|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg.
214269435|NCT04868162|DRUG|MRG003+HX008|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or the recommended dose by SMC; and HX008 will be administered via intravenous infusion at 3.0 mg/kg
214269436|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
214269437|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
214269438|NCT05929885|DRUG|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status."
214269439|NCT05059470|DRUG|Pembrolizumab|Given by IV
214269440|NCT04607746|DEVICE|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
214269441|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
214269442|NCT05154578|BIOLOGICAL|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
214269443|NCT05154578|BIOLOGICAL|Placebo|0.5 mL normal saline given by intramuscular injection
214269444|NCT03930680|DRUG|Dexrazoxane|One dose of dexrazoxane
214269445|NCT05880251|BEHAVIORAL|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
214269446|NCT05880251|BEHAVIORAL|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
214269447|NCT06090604|OTHER|High intensity gait training in a balance challenging Movement amplification environment|For Aim 2, each participant will engage in ten 45-min high-intensity gait training sessions performed in a Movement Amplification Environment (MAE). Training sessions will occur 2x/week and led by a licensed Physical Therapist. The goal of each training session is to achieve 40-min of stepping practice within a targeted range of heart rate (HR) of 70 to 80% of estimated age-predicted HR max and perceived excursion (RPE) in a MAE. Each session will begin and end with a 2.5-min warm-up and cool down, with 40-min of training using two 10-min Speed-training blocks and two 10-min Balance-training blocks. Balance training activities will include lateral maneuvers, head turns, obstacle negotiation, and backward walking. The MAE gain, training speeds and balance activities will be progressively increased within and across sessions to challenge the participant.
214269448|NCT06474286|DRUG|Prucalopride 1 MG|The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
214269449|NCT06258785|DRUG|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
214269450|NCT01832649|BEHAVIORAL|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
214269451|NCT01832649|BEHAVIORAL|Health education|Supervised groups 2 times per week during 8 weeks.
214269452|NCT06083142|BIOLOGICAL|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
214269453|NCT06833268|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol.
214269454|NCT05594290|DRUG|Retifanlimab|Retifanlimab i.v. 500 mg day 1
214269455|NCT05594290|DRUG|Cisplatin|Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
214269456|NCT05594290|DRUG|Etoposide|Etoposide 100 mg/sqm iv. day 1, 2, 3
214269457|NCT05999799|DRUG|GSK1070806|GSK1070806 will be administered.
214269458|NCT05999799|DRUG|Placebo|Placebo will be administered.
214269459|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
214269460|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
214269461|NCT04417803|BIOLOGICAL|Blood sampling|plasmatic sampling
214269462|NCT06466109|BEHAVIORAL|social robot intervention|"In the first and second courses, the patients and their parents freely interact with the social robot PARO for 30 minutes.~In the third course, patients and their parents interact with PARO for 30 minutes using a worksheet that includes naming and recording characteristics of PARO.~In the last course, patients and their parents interact with PARO for 30 minutes using a worksheet that freely recorded their observations about PARO and say goodbye to it."
214269463|NCT06112808|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
214269464|NCT06112808|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
214269465|NCT02924571|DEVICE|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
214269466|NCT02924571|DEVICE|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
214269467|NCT02924571|PROCEDURE|Autograft|Autograft with bone marrow aspirate.
214269468|NCT01428271|OTHER|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
214269469|NCT06260124|OTHER|Slow tempo|A single Greek traditional dance of slow tempo lasting 3-4 minutes.
214269470|NCT06260124|OTHER|Moderate tempo|A single Greek traditional dance of moderate tempo lasting 3-4 minutes.
214269471|NCT06260124|OTHER|Fast tempo|A single Greek traditional dance of fast tempo lasting 3-4 minutes.
214269472|NCT00434954|DRUG|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
214269473|NCT00434954|DRUG|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
214269474|NCT06556511|DRUG|Zinc Sulfate|Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
214269475|NCT06556511|DRUG|Placebo|Placebo is administered with standard therapy in the placebo group for a period of 10 days.
214269476|NCT00836030|OTHER|No treatment given|No treatment given
214269477|NCT00991120|DEVICE|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
214269478|NCT00478946|DRUG|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
214269479|NCT00478946|DRUG|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
214269480|NCT00478946|DRUG|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
214269481|NCT02927886|PROCEDURE|Per-oral endoscopy pyloromyotomy|
214269482|NCT02927886|PROCEDURE|Intrapyloric injection of Botulinum toxin|
214269483|NCT03403088|DEVICE|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
214269484|NCT03403088|DEVICE|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
214269485|NCT03403088|OTHER|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
214269486|NCT03403088|OTHER|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
214269487|NCT03403088|OTHER|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
214269488|NCT03403088|OTHER|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
214269489|NCT06357858|DRUG|INQOVI (decitabine and cedazuridine)|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
214269490|NCT06357858|DRUG|Nivolumab|Nivolumab will be administered on D8 with every 4 week cycle.
214269491|NCT04790773|OTHER|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
214269492|NCT06366100|BEHAVIORAL|Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)|"In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation"
214464881|NCT04696263|DEVICE|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
214464882|NCT05993442|BEHAVIORAL|Optimised kangaroo care|The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,
214464883|NCT06355791|DEVICE|Minuteman G5 Device|The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
214269493|NCT06366100|BEHAVIORAL|Unified Protocol (UP)|"In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress"
214269494|NCT02194855|DRUG|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
214269495|NCT02194855|DRUG|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
214269496|NCT03057678|OTHER|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
214269497|NCT00454623|BEHAVIORAL|drawing serum adiponectin level|
214269498|NCT00894166|DRUG|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
214269499|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
214269500|NCT00894166|DRUG|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
214269501|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
214269502|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
214269503|NCT00894166|DRUG|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
214269504|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
214269505|NCT00354887|DRUG|Capecitabine|Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
214269506|NCT00354887|DRUG|Oxaliplatin|130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
214269507|NCT05086926|COMBINATION_PRODUCT|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
214269508|NCT03892187|BEHAVIORAL|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
214269509|NCT00944671|DRUG|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
214269510|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
214269511|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
214269512|NCT00261469|DRUG|topiramate|
214269513|NCT03750955|DEVICE|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
214269514|NCT03750955|DEVICE|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
214269515|NCT05568823|OTHER|Blood sampling|Measurement of markers of disease evolution
214269516|NCT04267822|DRUG|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
214269517|NCT04267822|DRUG|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
214269518|NCT04286750|DRUG|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
214269519|NCT04286750|DRUG|Placebo|Matching placebo administered as hard capsules for oral use.
214269520|NCT03967301|DIETARY_SUPPLEMENT|Probiotic|Intervention: defined as probiotic consumption
214269521|NCT03967301|DIETARY_SUPPLEMENT|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
214269522|NCT04403360|PROCEDURE|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
214269523|NCT04403360|PROCEDURE|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
214269524|NCT00815698|PROCEDURE|suture|suture for mesh fixation
214269525|NCT00815698|PROCEDURE|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
214269526|NCT02027961|BIOLOGICAL|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
214269527|NCT02027961|DRUG|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
214269528|NCT02027961|DRUG|Trametinib|Oral dose of 2 mg trametinib tablet.
214269529|NCT05429060|PROCEDURE|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
214269530|NCT02472873|PROCEDURE|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
214269531|NCT02472873|PROCEDURE|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
214269532|NCT02472873|DRUG|Ethanol|
214269533|NCT00543010|DRUG|MK0767|
214269534|NCT00142935|BEHAVIORAL|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
214269535|NCT00142935|BEHAVIORAL|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
214269536|NCT00142935|BEHAVIORAL|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
214269537|NCT05875428|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
214269538|NCT04808544|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
214269539|NCT04808544|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
214269540|NCT00395681|DRUG|Diprivan|Propofol 200 mg versus 350 mg
214269541|NCT00440414|DRUG|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
214269542|NCT00440414|DRUG|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
214269543|NCT06557044|DRUG|Ropivacaine|PENG block with ropivacaine
214269544|NCT06557044|OTHER|Physiological saline|Placebo control
214269545|NCT05764421|BEHAVIORAL|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
214269546|NCT03265639|DIETARY_SUPPLEMENT|P-inulin|
214269547|NCT04815681|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
214269548|NCT04815681|BEHAVIORAL|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
214269549|NCT01180985|DEVICE|galyfilcon A prototype lens|silicone hydrogel contact lens
214269550|NCT01180985|DEVICE|comfilcon A|silicone hydrogel contact lens
214269551|NCT01570088|DIETARY_SUPPLEMENT|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
214269552|NCT01570088|DIETARY_SUPPLEMENT|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
214269553|NCT01570088|OTHER|Placebo|Placebo contains no folic acids
214269554|NCT02489162|DEVICE|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
214269555|NCT02489162|DEVICE|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
214464884|NCT05669599|BIOLOGICAL|Maridebart Cafraglutide|Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
214269556|NCT03144947|BIOLOGICAL|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
214269557|NCT03144947|BIOLOGICAL|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
214269558|NCT03144947|BIOLOGICAL|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
214269559|NCT03144947|DRUG|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
214269560|NCT03055156|DEVICE|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
214269561|NCT03055156|DEVICE|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
214269562|NCT03556735|DEVICE|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
214269563|NCT01315665|DIETARY_SUPPLEMENT|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
214269564|NCT03214146|BIOLOGICAL|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
214269565|NCT01613300|DRUG|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
214269566|NCT01431989|DRUG|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
214269567|NCT01431989|DRUG|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
214269568|NCT04423276|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
214269569|NCT04423276|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
214269570|NCT04755790|DEVICE|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
214269571|NCT05459272|DIETARY_SUPPLEMENT|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
214269572|NCT05459272|OTHER|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
214269573|NCT04036903|RADIATION|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
214269574|NCT00316472|DRUG|Niacinamide|
214269575|NCT00129272|DRUG|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
214269576|NCT00129272|OTHER|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
214269577|NCT05490810|OTHER|Trunk stabilization|"Trunk stabilization exercises with~* Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~* Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~* Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~* Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~* SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
214269578|NCT05490810|OTHER|Activation exercises|"Activation exercises with~* Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~* External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~* Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
214269579|NCT04858633|DRUG|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
214269580|NCT04858633|OTHER|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
214269581|NCT04858633|OTHER|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
214829220|NCT02316223|BEHAVIORAL|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
214829221|NCT01929187|DRUG|Phytonail|
214269582|NCT02542904|PROCEDURE|mesenteric excision|
214269583|NCT06145672|PROCEDURE|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
214829222|NCT01929187|DRUG|Loceryl|
214269584|NCT06557590|DIAGNOSTIC_TEST|18F-FAPI-04|18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
214269585|NCT03525171|DIAGNOSTIC_TEST|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
214269586|NCT00319995|DRUG|loratadine; montelukast|
214269587|NCT03172169|OTHER|no Intervention|no Intervention
214269588|NCT00092638|DRUG|MK0653, ezetimibe|
214269589|NCT00092638|DRUG|Comparator: ezetimibe, placebo|
214269590|NCT00578708|DEVICE|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
214269591|NCT06444971|PROCEDURE|Post isometric Relaxation|"Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid"
214269592|NCT03345914|DRUG|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
214269593|NCT03345914|DRUG|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
214269594|NCT03345914|OTHER|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
214269595|NCT03345914|OTHER|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
214269596|NCT04798963|PROCEDURE|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
214269597|NCT04798963|PROCEDURE|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
214269598|NCT03754569|PROCEDURE|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
214269599|NCT02403856|DRUG|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
214269600|NCT02403856|DRUG|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
214269601|NCT02403856|PROCEDURE|Ultrasound-guided Needling and Lavage|
214269602|NCT02569658|DRUG|Tranexamic Acid|
214269603|NCT02569658|DRUG|Placebo|
214269604|NCT05163977|PROCEDURE|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
214269605|NCT05163977|PROCEDURE|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
214269606|NCT03326544|OTHER|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
214269607|NCT03326544|OTHER|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
214269608|NCT04579575|DEVICE|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~* The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~* The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
214269609|NCT05707767|PROCEDURE|Resection surgery|Patients undergo resection surgery in our hospital.
214269610|NCT03783364|RADIATION|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
214269611|NCT01227759|DRUG|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
214269612|NCT01227759|DRUG|Placebo|Placebo containing no active ingredient
214269613|NCT00773656|OTHER|Whole blood sample|70 ml per patient for collection of biological sample
214269614|NCT04650490|RADIATION|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
214269615|NCT04650490|DRUG|Immunotherapy|Physician's choice of immunotherapy per standard of care
214464885|NCT05669599|DRUG|Placebo|Participants will receive placebo by SC injection.
214829223|NCT06043349|COMBINATION_PRODUCT|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
214269616|NCT05164796|DEVICE|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~* IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~* IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~* In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
214269617|NCT04711434|DRUG|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
214269618|NCT01095926|DRUG|doxorubicin|blood sampling before, during and after doxorubicin administration
214269619|NCT02164214|DRUG|etanercept Treatment|
214269620|NCT02445508|DRUG|Sevelamer|
214269621|NCT02445508|DRUG|Cholecystokinin|
214269622|NCT02445508|DRUG|Sevelamer placebo|
214269623|NCT02445508|DRUG|Isotonic saline|
214269624|NCT01286233|DRUG|Metformin|
214269625|NCT01286233|DRUG|Placebo|
214269626|NCT03187275|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
214269627|NCT03187275|OTHER|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
214269628|NCT04465110|DIETARY_SUPPLEMENT|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
214269629|NCT03758066|DEVICE|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
214269630|NCT01216761|DRUG|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
214269631|NCT01216761|DRUG|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
214269632|NCT01216761|DRUG|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
214269633|NCT01500577|DRUG|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
214269634|NCT01500577|DRUG|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
214269635|NCT01500577|OTHER|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
214269636|NCT04138810|OTHER|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
214269637|NCT04138810|OTHER|Survey|Measure of satisfaction regarding post-op visit.
214269638|NCT00137579|PROCEDURE|Influenza vaccine intramuscular administration route|
214829224|NCT06043349|DRUG|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
214829225|NCT04277793|BEHAVIORAL|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
214269639|NCT01983813|OTHER|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
214269640|NCT01983813|OTHER|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
214269641|NCT02085083|BEHAVIORAL|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
214269642|NCT02085083|BEHAVIORAL|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
214269643|NCT05705388|DEVICE|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
214464886|NCT03760575|DRUG|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
214269644|NCT05705388|DRUG|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
214269645|NCT01786668|DRUG|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
214269646|NCT01786668|DRUG|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
214269647|NCT01786668|DRUG|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
214269648|NCT01786668|DRUG|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
214269649|NCT05001256|OTHER|questionnaire study|Participants will be surveyed through face-to-face interviews.
214269650|NCT05014789|DEVICE|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
214269651|NCT02129998|OTHER|IVF/ICSI treatment|
214269652|NCT04516174|PROCEDURE|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
214269653|NCT04516174|DRUG|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
214269654|NCT04516174|PROCEDURE|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
214269655|NCT04516174|DRUG|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
214269656|NCT01471470|DRUG|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
214269657|NCT01530360|DEVICE|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
214269658|NCT01376284|DRUG|Dutasteride|Collection of safety data
214269659|NCT04103658|RADIATION|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
214269660|NCT04010058|DEVICE|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
214269661|NCT03760978|DRUG|Dexmedetomidine|
214269662|NCT04969575|OTHER|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
214269663|NCT04969575|OTHER|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
214269664|NCT04969575|OTHER|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
214269665|NCT04969575|OTHER|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
214269666|NCT04969575|OTHER|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
214269667|NCT03213522|PROCEDURE|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
214269668|NCT03213522|PROCEDURE|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
214269669|NCT06065397|PROCEDURE|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
214464887|NCT03760575|PROCEDURE|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
214829226|NCT06274762|OTHER|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
214464888|NCT03760575|DRUG|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
214269670|NCT04447300|PROCEDURE|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
214269671|NCT04447300|PROCEDURE|Standard power application|Standard power application
214269672|NCT03874637|DEVICE|Treament|Placement of the FemPulse System with therapy delivery
214269673|NCT03874637|DEVICE|Sham Control|Placement of the FemPulse System without therapy delivery
214269674|NCT02407860|OTHER|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
214269675|NCT02407860|OTHER|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
214269676|NCT06383078|DRUG|HR070803|HR070803 60 mg/\^2 D1 over 90 minutes.
214269677|NCT06383078|DRUG|Oxaliplatin|Oxaliplatin 85 mg/\^2 D1 over 2 hours.
214269678|NCT06383078|DRUG|Tegafur|initial dose of S-1 is determined according to the body surface area，orally, D1-7.
214269679|NCT06383078|DRUG|Folinic acid|Folinic acid 400 mg/\^2 D1
214269680|NCT06383078|DRUG|5-Fluorouracil|5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
214269681|NCT00762385|DEVICE|galyfilcon A|galyfilcon A
214269682|NCT00762385|DEVICE|comfilcon A|comfilcon A
214269683|NCT01786083|BEHAVIORAL|Application of Problem Solving Technique|
214269684|NCT03129750|DEVICE|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
214269685|NCT02787096|DEVICE|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
214269686|NCT00398580|DRUG|Nanomilled testosterone|
214269687|NCT00398580|DRUG|Nanomilled dutasteride|
214269688|NCT00398580|DRUG|commercially available dutasteride|
214269689|NCT04465474|OTHER|Non Intervention|It's an observational study, no intervention involves.
214269690|NCT02762357|DEVICE|Novosyn® Quick|Episiotomy closure
214269691|NCT00202800|DRUG|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
214269692|NCT06271122|OTHER|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
214269693|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
214269694|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
214269695|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
214269696|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
214269697|NCT03274024|DEVICE|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
214269698|NCT03274024|PROCEDURE|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
214269699|NCT01302756|OTHER|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
214269700|NCT01302756|DIETARY_SUPPLEMENT|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
214269701|NCT00939497|DRUG|Risperidone|
214269702|NCT05961332|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
214269703|NCT05961332|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
214269704|NCT05961332|DEVICE|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
214269705|NCT04550208|OTHER|3D analysis of different landing tasks|General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
214269706|NCT01936805|DRUG|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
214269707|NCT01540838|DRUG|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
214269708|NCT01540838|DRUG|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
214269709|NCT00404937|DRUG|Tobradex (Antibiotic steroid combination)|
214269710|NCT06511830|DIAGNOSTIC_TEST|Dental Monitoring images|Dental Monitoring is a series of intraoral photos that will be taken and assessed to determine the subject's dental plaque levels.
214269711|NCT01816204|BEHAVIORAL|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
214269712|NCT01816204|BEHAVIORAL|face-to-face individual therapy|weekly individual counseling as usual.
214269713|NCT02130570|OTHER|Multi-Model Intensive Discharge Intervention|"1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information"
214269714|NCT00512005|DEVICE|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
214269715|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
214269716|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
214269717|NCT04007081|PROCEDURE|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
214269718|NCT04007081|DIAGNOSTIC_TEST|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
214269719|NCT04007081|OTHER|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
214269720|NCT04007081|OTHER|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
214269721|NCT02579187|PROCEDURE|tooth extraction|The study tooth will be removed
214269722|NCT02579187|RADIATION|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
214269723|NCT02579187|DRUG|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
214269724|NCT02579187|OTHER|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
214269725|NCT02579187|DRUG|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
214269726|NCT02579187|DRUG|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
214269727|NCT02579187|PROCEDURE|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
214269728|NCT02579187|DRUG|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
214269729|NCT02579187|DRUG|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
214269730|NCT02579187|PROCEDURE|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
214269731|NCT02579187|OTHER|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
214269732|NCT02579187|PROCEDURE|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 \& 4 weeks post extraction
214269733|NCT02579187|PROCEDURE|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
214269734|NCT02579187|RADIATION|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
214269735|NCT02579187|OTHER|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
214269736|NCT01849783|DRUG|dexamethasone|Given PO
214269737|NCT01849783|DRUG|cisplatin|Given IV
214269738|NCT01849783|DRUG|doxorubicin|Given IV
214269739|NCT01849783|DRUG|cyclophosphamide|Given IV or PO
214269740|NCT01849783|DRUG|etoposide|Given IV
214269741|NCT01849783|DRUG|bortezomib|Given IV
214269742|NCT01849783|DRUG|thalidomide|Given PO
214269743|NCT01849783|DRUG|melphalan|Given IV
214269744|NCT01849783|PROCEDURE|autologous stem cell transplant|
214269745|NCT01776840|DRUG|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
214269746|NCT01776840|DRUG|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
214269747|NCT01776840|DRUG|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
214269748|NCT01776840|DRUG|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
214269749|NCT06006741|BIOLOGICAL|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
214269750|NCT01152697|DRUG|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
214269751|NCT01152697|DRUG|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
214464889|NCT03760575|DRUG|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
214269752|NCT01152697|BEHAVIORAL|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
214269753|NCT02974478|DIETARY_SUPPLEMENT|Orange juice with meals|orange juice (20% of energy requirement/day)
214269754|NCT02974478|DIETARY_SUPPLEMENT|Orange juice between meals|orange juice (20% of energy requirement/day)
214269755|NCT02974478|DIETARY_SUPPLEMENT|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
214269756|NCT05012033|OTHER|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
214269757|NCT00214110|DRUG|Tamoxifen|
214269758|NCT01390129|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
214269759|NCT01390129|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
214269760|NCT02527135|BEHAVIORAL|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
214269761|NCT03641339|OTHER|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
214269762|NCT03641339|OTHER|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
214269763|NCT03604484|PROCEDURE|Tricuspid annuloplasty|Tricuspid annuloplasty
214269764|NCT04635228|DEVICE|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
214269765|NCT02126995|DRUG|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
214269766|NCT02275637|DEVICE|implantable cardioverter defibrillator|
214269767|NCT05188014|BEHAVIORAL|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
214269768|NCT05188014|BEHAVIORAL|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
214269769|NCT06390397|OTHER|Produce prescription program|"Boxes of fresh fruit and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks. Participants will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
214269770|NCT06390397|OTHER|Standard of care|Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.
214269771|NCT06195605|DEVICE|Restylane-L|Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
214269772|NCT06195605|DEVICE|Vehicle|Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
214269773|NCT05904912|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
214269774|NCT05904912|DRUG|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
214269775|NCT05904912|DRUG|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
214269776|NCT01610531|OTHER|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
214269777|NCT00575991|DIETARY_SUPPLEMENT|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
214269778|NCT05075460|DRUG|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
214269779|NCT04314726|DRUG|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
214269780|NCT04314726|DRUG|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
214269781|NCT05975307|DRUG|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
214269782|NCT05975307|DRUG|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
214269783|NCT05975307|DRUG|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
214269784|NCT05975307|DRUG|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
214269785|NCT05975307|RADIATION|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
214269786|NCT00647361|DEVICE|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
214269787|NCT01021722|PROCEDURE|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
214269788|NCT05916027|BEHAVIORAL|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
214269789|NCT06030050|BEHAVIORAL|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
214269790|NCT04764773|OTHER|No intervention|No intervention
214269791|NCT06126926|BEHAVIORAL|group therapy|32 weeks of group therapy
214269792|NCT06126926|OTHER|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
214269793|NCT04509869|PROCEDURE|varicocelectomy|operation for varix ligation
214269794|NCT06069505|DIAGNOSTIC_TEST|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
214269795|NCT00891592|BIOLOGICAL|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg"
214269796|NCT00891592|OTHER|Observation Arm|Single infusion of Cord Blood Cells
214269797|NCT03185871|DRUG|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
214269798|NCT01642979|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
214269799|NCT01642979|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
214269800|NCT01642979|DRUG|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
214269801|NCT05235451|OTHER|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
214269802|NCT03694587|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
214269803|NCT03694587|DRUG|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
214269804|NCT01235624|GENETIC|genetic analysis|
214269805|NCT01042678|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye
214269806|NCT04846296|OTHER|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
214269807|NCT00408460|DRUG|imatinib mesylate|Given PO
214269808|NCT00408460|DRUG|paclitaxel|Given IV
214269809|NCT04125888|DRUG|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
214269810|NCT02653872|DRUG|AZD7986|Oral solution, single dose, dilution from concentrate
214269811|NCT02653872|DRUG|Verapamil|Extended release tablet for oral use
214269812|NCT02653872|DRUG|Itraconazole|Oral solution
214269813|NCT02653872|DRUG|Diltiazem|Extended release capsule
214269814|NCT03617185|OTHER|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
214269815|NCT03617185|OTHER|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
214269816|NCT03617185|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
214269817|NCT01611610|OTHER|Functional tests|"The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module"
214269818|NCT01611610|OTHER|Functional tests|"The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module"
214269819|NCT06009692|OTHER|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
214269820|NCT06009692|OTHER|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
214269821|NCT06558461|DRUG|3% Sodium Chloride|4ml nebulized three times daily
214269822|NCT06558461|OTHER|Standard care|Standard care
214269823|NCT00311844|DRUG|desloratadine|
214269824|NCT06362577|DIAGNOSTIC_TEST|EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG|Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
214269825|NCT04076475|DEVICE|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
214269826|NCT02506465|DEVICE|iTIND|Temporary Implantable Nitinol Device (iTIND)
214269827|NCT02506465|PROCEDURE|Sham Arm|Foley catheter will be placed and immediately removed.
214269828|NCT04102787|OTHER|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
214269829|NCT04136340|OTHER|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
214269830|NCT04136340|OTHER|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
214269831|NCT04188587|DRUG|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
214269832|NCT01820065|PROCEDURE|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
214269833|NCT01723657|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
214269834|NCT01723657|OTHER|Autologous peripheral blood stem cell transplantation.|"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
214269835|NCT01723657|OTHER|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
214269836|NCT01723657|DRUG|G-CSF|"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
214269837|NCT01723657|OTHER|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
214269838|NCT01723657|OTHER|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
214269839|NCT01058655|DRUG|Everolimus|
214269840|NCT01058655|DRUG|Tivozanib|
214269841|NCT00032955|DRUG|Buprenorphine/naloxone|
214269842|NCT01117948|DRUG|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
214269843|NCT01117948|DRUG|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
214269844|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
214269845|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
214269846|NCT04875169|DRUG|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
214269847|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
214269848|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
214269849|NCT02984111|DRUG|normal saline|
214269850|NCT02984111|DRUG|erythropoietin|
214269851|NCT05617950|OTHER|salicylic acid|Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
214269852|NCT05617950|OTHER|cryotherapy|Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
214269853|NCT03118648|DIAGNOSTIC_TEST|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
214269854|NCT02154074|DRUG|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
214269855|NCT02154074|DRUG|Isoflurane|inhale Isoflurane 1.5MAC
214269856|NCT02154074|DRUG|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
214269857|NCT02154074|DRUG|normal saline|the same volume of saline + Isoflurane during operation
214269858|NCT01095055|BIOLOGICAL|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
214269859|NCT01095055|BIOLOGICAL|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
214269860|NCT06058702|DRUG|Delta-9-THC Very Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
214269861|NCT06058702|DRUG|Placebo|Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
214269862|NCT06058702|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes.
214269863|NCT06822452|PROCEDURE|radical prostatectomy|Robot-assisted
214269864|NCT02688478|OTHER|Phthalate|Delivered by inhalation on day 1 of the triad
214269865|NCT02688478|OTHER|Filtered Air|Delivered by inhalation on day 1 of the triad
214269866|NCT02688478|OTHER|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
214269867|NCT03301805|DRUG|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."
214269868|NCT04545060|BIOLOGICAL|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
214269869|NCT04545060|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
214269870|NCT05036759|DRUG|68Ga-FAPI|intravenously injected with 68Ga-FAPI
214269871|NCT04526860|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
214269872|NCT01617200|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
214269873|NCT01617200|DRUG|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
214269874|NCT01617200|DRUG|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
214269875|NCT01617200|DRUG|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
214269876|NCT02509767|DRUG|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
214269877|NCT01459081|DRUG|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
214269878|NCT01459081|DRUG|Placebo|inhaled by mouth, twice daily, for 5 days
214269879|NCT03515278|PROCEDURE|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
214269880|NCT03515278|PROCEDURE|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
214269881|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
214269882|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
214269883|NCT04767594|DRUG|Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
214269884|NCT02592122|DRUG|Salbutamol Aerosol|
214269885|NCT02592122|DRUG|No drugs|
214269886|NCT02638701|DRUG|Infliximab|Please see protocol for details.
214269887|NCT02319837|DRUG|Enzalutamide|
214269888|NCT02319837|DRUG|Placebo (No longer applicable in Open Label study period)|Sugar pill to mimic enzalutamide
214269889|NCT02319837|DRUG|Leuprolide Open Label|
214269890|NCT04134052|DRUG|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
214269891|NCT04741607|DEVICE|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
214269892|NCT04741607|PROCEDURE|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
214269893|NCT04741607|PROCEDURE|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
214269894|NCT00003052|DRUG|doxorubicin hydrochloride|
214269895|NCT00003052|DRUG|etoposide|
214269896|NCT00003052|DRUG|ifosfamide|
214269897|NCT00003052|PROCEDURE|conventional surgery|
214269898|NCT00003052|PROCEDURE|hyperthermia treatment|
214269899|NCT00003052|RADIATION|radiation therapy|
214269900|NCT02846571|BIOLOGICAL|Human Pancreatic Islet Transplantation|Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
214269901|NCT00810472|OTHER|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
214269902|NCT00810472|PROCEDURE|Penetrating keratoplasty|Corneal transplantation.
214269903|NCT04351854|OTHER|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
214269904|NCT02146664|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
214269905|NCT02146664|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
214269906|NCT03023787|DRUG|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
214269907|NCT03023787|DRUG|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
214269908|NCT00892047|DRUG|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
214269909|NCT00892047|DRUG|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
214269910|NCT03354078|PROCEDURE|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
214269911|NCT03354078|PROCEDURE|continous sutures|The way of closure of subcutanous tissue is by continous sutures
214269912|NCT02135770|DRUG|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
214269913|NCT01864655|DRUG|saracatinib|oral drug given to experimental group
214269914|NCT01864655|DRUG|Placebo|Placebo given to placebo group
214269915|NCT01783431|DRUG|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
214269916|NCT01783431|PROCEDURE|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
214269917|NCT05306977|DEVICE|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by \~50 min rest intervals.
214269918|NCT03881475|OTHER|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
214269919|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
214269920|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
214269921|NCT00487175|DRUG|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
214269922|NCT00076206|DRUG|CCI-779|
214269923|NCT00076206|DRUG|Placebo|
214269924|NCT05075902|BEHAVIORAL|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
214269925|NCT03267017|OTHER|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
214269926|NCT02628470|PROCEDURE|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
214269927|NCT02628470|PROCEDURE|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
214269928|NCT02628470|PROCEDURE|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
214269929|NCT02260544|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
214269930|NCT03026361|GENETIC|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
214269931|NCT00578383|DEVICE|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
214269932|NCT05026411|DIAGNOSTIC_TEST|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
214269933|NCT05026411|DIAGNOSTIC_TEST|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
214269934|NCT05026411|DIAGNOSTIC_TEST|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
214269935|NCT01672008|DRUG|NOX-100|
214269936|NCT04961294|DEVICE|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
214269937|NCT03402113|DRUG|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
214269938|NCT03402113|DRUG|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
214269939|NCT04767763|DIAGNOSTIC_TEST|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
214269940|NCT04846842|DRUG|Gimatecan|Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.
214464890|NCT04084288|OTHER|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
214829227|NCT04020458|PROCEDURE|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
214829228|NCT05465863|BIOLOGICAL|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
214829229|NCT02988258|GENETIC|CMV-TCR transduced donor-derived T cells|Dose escalation
214829230|NCT01275664|PROCEDURE|Adjuvant Therapy|Ancillary studies
214829231|NCT01275664|DRUG|Aprepitant|Given IV and PO
214269941|NCT01518348|BIOLOGICAL|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
214269942|NCT04340648|DEVICE|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
214269943|NCT02050841|BIOLOGICAL|octaplas|Octaplas S/D Plasma
214269944|NCT02432495|OTHER|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
214269945|NCT02432495|OTHER|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
214269946|NCT01138774|DIETARY_SUPPLEMENT|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
214269947|NCT04850001|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
214269948|NCT03918148|DRUG|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
214269949|NCT03918148|DRUG|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
214269950|NCT03078244|OTHER|N/A, observational study|
214269951|NCT02698046|DIETARY_SUPPLEMENT|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
214269952|NCT02698046|DIETARY_SUPPLEMENT|Placebo starch|200mg of placebo starch three times a day for 4 months
214269953|NCT01204437|DRUG|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
214269954|NCT01204437|DRUG|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
214269955|NCT01204437|DRUG|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
214269956|NCT00181155|DRUG|Allopurinol|intravenous infusion of allopurinol (300mg)
214829232|NCT01275664|DRUG|Carboplatin|Given IP
214269957|NCT00181155|DRUG|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
214269958|NCT02077478|DEVICE|Remifentanil and propofol administration using TCI|
214269959|NCT02077478|DEVICE|Remifentanil and propofol administration using MCI|
214269960|NCT01788228|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
214269961|NCT00002982|BIOLOGICAL|filgrastim|
214269962|NCT00002982|DRUG|carboplatin|
214269963|NCT00002982|DRUG|carmustine|
214269964|NCT00002982|DRUG|cytarabine|
214269965|NCT00002982|DRUG|etoposide|
214269966|NCT00002982|DRUG|ifosfamide|
214269967|NCT00002982|DRUG|melphalan|
214269968|NCT00002982|PROCEDURE|autologous bone marrow transplantation|
214269969|NCT00002982|PROCEDURE|peripheral blood stem cell transplantation|
214269970|NCT00002982|RADIATION|radiation therapy|
214269971|NCT06274320|OTHER|Group A: holistic approach|2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
214269972|NCT06274320|OTHER|Group B: Tolak® Standard of use|4-week Tolak® alone treatment (once daily in the evening)
214269973|NCT04792008|BIOLOGICAL|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
214829233|NCT01275664|DRUG|Cisplatin|Given IP
214269974|NCT04792008|BIOLOGICAL|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
214269975|NCT02358681|DRUG|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
214269976|NCT02358681|DRUG|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
214269977|NCT02358681|DRUG|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
214269978|NCT02358681|DRUG|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
214269979|NCT00004857|BIOLOGICAL|alemtuzumab|30 mg subQ injection tiw for 6 weeks
214269980|NCT00004857|DRUG|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
214269981|NCT06391320|OTHER|other|Observational studies do not involve intervention
214269982|NCT01548287|DRUG|AZD5213|AZD5213 doseA daily
214269983|NCT01548287|DRUG|AZD5213|AZD5213 doseB daily
214269984|NCT01548287|DRUG|AZD5213|AZD5213 doseC daily
214269985|NCT01548287|OTHER|Placebo|Placebo tablet daily
214269986|NCT03219138|DEVICE|Acceleromyography|Use of an uncalibrated acceleromyography
214269987|NCT03325127|DRUG|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
214269988|NCT03325127|DRUG|Zytiga|Abiraterone 1000 mg per day orally
214269989|NCT03325127|DRUG|Xtandi|Enzalutamide 160 mg per day orally
214269990|NCT00145522|DRUG|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
214829234|NCT01275664|DRUG|Dexamethasone|Given PO
214829235|NCT01275664|DRUG|Granisetron Transdermal Patch|Apply one patch to upper arm
214829236|NCT01275664|PROCEDURE|Management of Therapy Complications|Ancillary studies
214829237|NCT01275664|OTHER|Questionnaire Administration|Ancillary studies
214829238|NCT04483921|OTHER|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
214829239|NCT06416241|DRUG|EYLEA 2 MG in 0.05 ML Injection|Intravitreal injection
214269991|NCT00145522|DRUG|Tibolone|2,5 mg/day for 12 cycles of 28 days
214269992|NCT02012283|OTHER|Food consumption|Cooked vegetables with spices or without spices
214269993|NCT04916431|DRUG|mRNA-6231|Sterile frozen liquid dispersion for injection
214269994|NCT00981201|DRUG|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
214269995|NCT00981201|DRUG|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
214269996|NCT00981201|DRUG|Placebo|"Months 1-3:~By mouth twice daily."
214269997|NCT00981201|DRUG|Placebo|"Months 4-6:~By mouth twice daily."
214269998|NCT02423759|DRUG|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
214269999|NCT02423759|DRUG|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
214270000|NCT02423759|DRUG|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
214270001|NCT01007539|DIETARY_SUPPLEMENT|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
214270002|NCT01007539|DIETARY_SUPPLEMENT|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
214270003|NCT00180622|PROCEDURE|Spirometry|
214270004|NCT00180622|PROCEDURE|Exhaled Nitric Oxide and Carbon Monoxide|
214270005|NCT00180622|PROCEDURE|Exhaled Breath Condensate|
214270006|NCT00180622|PROCEDURE|Induced Sputum|
214270007|NCT00180622|PROCEDURE|CT Scan|
214270008|NCT00180622|PROCEDURE|Blood test|
214270009|NCT00180622|PROCEDURE|St Georges Questionnaire|
214270010|NCT00180622|PROCEDURE|Bodypletysmography|
214270011|NCT04204343|DRUG|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
214270012|NCT04204343|DRUG|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
214270013|NCT01810731|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (QIV)|
214270014|NCT01810731|BIOLOGICAL|Inactivated Polio Vaccine|
214270015|NCT01810731|BIOLOGICAL|Double Dose QIV|
214270016|NCT05693948|OTHER|Other: Serum X|Serum X contain arbutin and glutathione
214270017|NCT01725711|DEVICE|OPRA Implant System|
214270018|NCT06556381|PROCEDURE|TAP block|Women will receive TAP block.
214270019|NCT00579137|BIOLOGICAL|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg"
214270020|NCT00579137|DRUG|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
214270021|NCT00579137|BIOLOGICAL|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
214270022|NCT00579137|PROCEDURE|Stem cell infusion|stem cells are infused on day 0
214270023|NCT01400763|DIETARY_SUPPLEMENT|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
214270024|NCT01400763|DIETARY_SUPPLEMENT|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
214270025|NCT01400763|DIETARY_SUPPLEMENT|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
214270026|NCT01400763|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
214270027|NCT03812471|DEVICE|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
214270028|NCT03812471|DEVICE|2D standard measurements and 3D volumes acquisitions|"* 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume"
214270029|NCT03726411|PROCEDURE|non-surgical periodontal therapy|scaling and root planing
214270030|NCT00289783|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
214270031|NCT00289783|BIOLOGICAL|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
214270032|NCT00289783|BIOLOGICAL|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
214270033|NCT00289783|BIOLOGICAL|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
214270034|NCT00289783|BIOLOGICAL|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
214270035|NCT00289783|BIOLOGICAL|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
214270036|NCT00289783|BIOLOGICAL|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
214270037|NCT02403986|DEVICE|Restylane Vital Skinboosters Lidocaine|
214270038|NCT00566995|DRUG|ZACTIMA (Vandetanib) (ZD6474)|
214270039|NCT00569608|OTHER|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
214270040|NCT06356519|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
214270041|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
214270042|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
214270043|NCT06987071|PROCEDURE|Acupuncture|Insertion of sterile, single-use needles at specific acupuncture points (LI4, PC6, ST36, SP6) for 20 minutes with manual stimulation, administered 30 minutes before the biopsy by a licensed acupuncturist.
214270044|NCT06987071|PROCEDURE|sham acupuncture|Superficial needle insertion at non-acupuncture points without stimulation, administered 30 minutes before the biopsy, mimicking the acupuncture procedure without therapeutic intent.
214270045|NCT06933017|DEVICE|Portable mask for respiratory gas analysis|This is a portable mask, which is connected to the SplendoHealth app. The Polar sens 10 heartrate monitor and TrainRed NIRS device are also connected to this app. The three devices (mask, heartrate monitor and NIRS) are measuring respiratory gases, heart rate and muscle tissue oxygenation simultanuously and at the end of the 6 min step test, you get an individual cardiorespiratory fitness report.
214270046|NCT06933017|DEVICE|Cardio-pulmonary exercise test|Golden standard for measuring PEM: the double cardio-pulmonary exercise test on a bike.
214270047|NCT03740633|BEHAVIORAL|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
214270048|NCT03740633|BEHAVIORAL|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
214270049|NCT03740633|COMBINATION_PRODUCT|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
214270050|NCT03128047|DEVICE|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.
214270051|NCT06775327|DRUG|INCB000631|Oral; Tablet
214270052|NCT06775327|DRUG|Placebo|Oral; Tablet
214270053|NCT01995825|DRUG|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
214270054|NCT01995825|DRUG|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
214270055|NCT01050868|DEVICE|Accu-Chek Combo Kit mg DE/de|
214270056|NCT00605111|DRUG|biphasic insulin aspart|
214270057|NCT04099628|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
214270058|NCT03510754|PROCEDURE|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
214270059|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
214270060|NCT01866774|OTHER|Fecal calprotectin level|
214270061|NCT06083038|DRUG|Alpelisib|Patients will receive standard of care alpelisib
214270062|NCT06083038|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
214270063|NCT01818921|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
214270064|NCT01818921|DRUG|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
214270065|NCT01818921|DRUG|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
214829240|NCT06270745|DRUG|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
214829241|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
214829242|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
214270069|NCT06292286|PROCEDURE|Carboplatin or cisplatin|Carboplatin of cisplatin for 3-6 cycles
214270070|NCT06292286|DRUG|Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar|Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
214270071|NCT06292286|DRUG|Bevacizumab or biosimilar|Optional
214829243|NCT00529763|DRUG|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
214829244|NCT02260063|DRUG|Epinastine syrup|
214829245|NCT02260063|DRUG|Epinastine tablets|
214829246|NCT03669250|DRUG|CVN058|CVN058 will be given at two doses, a low does and a high dose
214829247|NCT03669250|OTHER|Placebo comparator|inactive placebo
214829248|NCT00469885|DRUG|Nicotine replacement|For reduction
214829249|NCT00469885|BEHAVIORAL|Motivational counseling|No drugs
214829250|NCT00828321|DRUG|Ramipril 10 mg capsule|1 x 10 mg
214829251|NCT00828321|DRUG|Altace® 10 mg capsule|1 x 10 mg
214829252|NCT02131220|DRUG|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
214829253|NCT02131220|DRUG|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
214829254|NCT02131220|DRUG|normal saline|intracoronary bolus infusion using selective catheter during PCI
214829255|NCT04879381|OTHER|Sputum samples|During consultation, one expectoration will be performed.
214829256|NCT04920695|DRUG|Nitric Oxide|Pulmonary vasodilator (gas).
214829257|NCT04920695|DRUG|Placebo|medical grade normoxic gas (FiO2 = 0.21)
214270072|NCT06292286|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery after chemotherapy
214270073|NCT02204397|DRUG|INGAP Peptide, Ustekinumab|
214270074|NCT02974166|OTHER|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
214270075|NCT02974166|OTHER|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
214270076|NCT02974166|DRUG|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
214270077|NCT02974166|DRUG|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
214270078|NCT05296512|DRUG|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
214270079|NCT05296512|DRUG|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
214270080|NCT03811028|DRUG|SOBI003|weekly i.v. infusion
214270081|NCT01244269|DRUG|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
214270082|NCT01244269|DRUG|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
214270083|NCT01244269|DRUG|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
214270084|NCT01244269|DRUG|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
214270085|NCT00560105|DEVICE|Lung Flute|8 weeks home use, twice daily
214270086|NCT00560105|DEVICE|Acapella|8 weeks home use, twice daily
214464891|NCT04084288|DEVICE|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
214270087|NCT01581788|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
214270088|NCT04407364|DEVICE|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
214270089|NCT01810874|PROCEDURE|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
214270090|NCT01810874|PROCEDURE|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
214270091|NCT01542125|DRUG|Liposomal Lidocaine|4% Liposomal Lidocaine
214270092|NCT01542125|DRUG|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
214270093|NCT02927665|DEVICE|Reshape Integrated Dual Balloon|
214270094|NCT05860478|DEVICE|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
214270095|NCT00957970|DEVICE|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
214270096|NCT00957970|DEVICE|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
214270097|NCT00071097|DRUG|TMC114/rtv|800mg TMC114/100mg rtv once daily
214270098|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
214270099|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv once daily
214270100|NCT00071097|DRUG|TMC114/rtv|600mg TMC114/100mg rtv twice daily
214270101|NCT04511546|DEVICE|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
214270102|NCT05112471|DEVICE|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
214270103|NCT05112471|DEVICE|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
214270104|NCT04250220|DIAGNOSTIC_TEST|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
214270105|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
214270106|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
214270107|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
214270108|NCT02400333|DRUG|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
214270109|NCT03646318|DRUG|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
214270110|NCT03646318|OTHER|Placebo|Glucose 5% solution
214464892|NCT05283915|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: oral
214270111|NCT06385639|DIETARY_SUPPLEMENT|Probiotic|This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
214270112|NCT01012271|OTHER|MRI|MR arthrography is used to evaluate wrist abnormalities
214270113|NCT00261144|DRUG|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
214270114|NCT00261144|BIOLOGICAL|Biological|Collagenase injection
214270115|NCT02145780|DIETARY_SUPPLEMENT|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
214270116|NCT02145780|DIETARY_SUPPLEMENT|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
214270117|NCT00956020|BIOLOGICAL|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
214270118|NCT04460638|BIOLOGICAL|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
214270119|NCT04460638|OTHER|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
214270120|NCT00962910|OTHER|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
214270121|NCT01332500|DRUG|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
214270122|NCT01332500|DRUG|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
214270123|NCT00304291|DRUG|Mitoxantrone|
214270124|NCT03924453|DIAGNOSTIC_TEST|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
214270125|NCT04967144|DIAGNOSTIC_TEST|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
214270126|NCT04967144|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
214270127|NCT00488462|DEVICE|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
214270128|NCT04966624|PROCEDURE|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
214270129|NCT04966624|PROCEDURE|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
214270130|NCT03200405|DEVICE|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
214270131|NCT03200405|DEVICE|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
214270132|NCT01354340|DIETARY_SUPPLEMENT|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
214270133|NCT01354340|DIETARY_SUPPLEMENT|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
214270134|NCT01354340|OTHER|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
214270135|NCT00185939|DRUG|Augmentin|
214270136|NCT01148472|DRUG|Escitalopram|20mg once daily; orally
214270137|NCT01148472|DRUG|Duloxetine|60mg once daily; orally
214270138|NCT03967652|DIAGNOSTIC_TEST|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
214270139|NCT02256852|BIOLOGICAL|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
214270140|NCT06103123|DIAGNOSTIC_TEST|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
214270141|NCT06103123|OTHER|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
214270142|NCT04945954|OTHER|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
214270143|NCT03275454|DRUG|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
214270144|NCT03275454|DRUG|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
214270145|NCT03069807|OTHER|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
214270146|NCT03069807|OTHER|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
214464893|NCT05308108|PROCEDURE|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
214464894|NCT06135792|OTHER|Arginine|See arm description
214464895|NCT06135792|OTHER|Placebo|See arm description
214464896|NCT05052125|DRUG|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
214464897|NCT03850600|OTHER|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
214270147|NCT05834374|OTHER|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
214270148|NCT05834374|OTHER|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
214270149|NCT05614505|DIETARY_SUPPLEMENT|Ready to use therapeutic foods|locally produced therapeutic foods
214270150|NCT05004103|OTHER|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
214270151|NCT04345042|OTHER|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
214270152|NCT00791570|BIOLOGICAL|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214270153|NCT04753645|BEHAVIORAL|Handwashing stations at the public places and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
214270154|NCT04753645|BEHAVIORAL|No activities of the HBCC project and also no soap (Pure Control)|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
214270155|NCT04753645|BEHAVIORAL|Soap distributed but no activities of the HBCC project|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
214270156|NCT04753645|BEHAVIORAL|HBCC project and Soap|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
214270157|NCT01225432|OTHER|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
214270158|NCT02509247|DEVICE|Telemonitoring|Wireless telemonitoring
214270159|NCT04445311|DRUG|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
214270160|NCT04177797|DRUG|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
214270161|NCT01034631|DRUG|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
214270162|NCT01034631|DRUG|BNC105P|BNC105P, up to 16 mg/m\^2
214270163|NCT01560403|DRUG|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
214270164|NCT05580393|DIAGNOSTIC_TEST|RFLP analysis of SSU rRNA|"1. Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~2. PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~3. The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
214270165|NCT06350396|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
214270166|NCT06350396|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214270167|NCT03651544|BIOLOGICAL|GamFluVac|1 dose (0,5 ml)
214270168|NCT00983437|DRUG|Armodafinil|
214270169|NCT01890473|DRUG|Abatacept|
214270170|NCT04019288|DRUG|Batiraxcept|Given IV
214270171|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
214270172|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
214270173|NCT00934089|DRUG|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
214270174|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
214270175|NCT00934089|DRUG|latanoprost|Topical ocular solution, once-daily for 14 days
214270176|NCT04781023|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
214464898|NCT00691002|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
214464899|NCT00691002|DRUG|LEO 80190 Vehicle|
214464900|NCT00691002|DRUG|Hydrocortisone|
214464901|NCT00691002|DRUG|Calcipotriol|
214829258|NCT03119896|OTHER|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
214829259|NCT04534621|OTHER|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
214829260|NCT01538160|DRUG|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
214270177|NCT00691314|DEVICE|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
214270178|NCT00691314|DRUG|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
214270179|NCT04177667|DIETARY_SUPPLEMENT|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
214270180|NCT04177667|OTHER|Placebo|Treatment with placebo for Placebo Arm
214270181|NCT03426813|OTHER|Historical control group for early mobilization|
214270182|NCT01489800|BEHAVIORAL|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
214270183|NCT02767843|DEVICE|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
214270184|NCT05120778|BEHAVIORAL|exercise training|as appear in arm description.
214270185|NCT05120778|OTHER|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
214270186|NCT05089149|PROCEDURE|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
214270187|NCT05089149|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
214270188|NCT05089149|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
214270189|NCT05089149|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
214270190|NCT05089149|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214270191|NCT02304679|OTHER|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled"
214270192|NCT02304679|DRUG|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
214270193|NCT02304679|OTHER|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled"
214464902|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
214464903|NCT05363891|DRUG|Placebo|Placebo
214464904|NCT05056714|OTHER|Questionaries|The patient will answer several questionaries
214829261|NCT00008060|DRUG|FOLFIRI regimen|
214829262|NCT00008060|DRUG|FOLFOX regimen|
214829263|NCT00008060|DRUG|fluorouracil|
214829264|NCT00008060|DRUG|irinotecan hydrochloride|
214829265|NCT00008060|DRUG|leucovorin calcium|
214829266|NCT00008060|DRUG|oxaliplatin|
214829267|NCT00405860|DRUG|CellCept (mycophenolate mofetil)|
214829268|NCT06203080|DRUG|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
214270194|NCT02304679|OTHER|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
214270195|NCT02304679|DEVICE|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
214270196|NCT02304679|DEVICE|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
214270197|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
214270198|NCT02304679|OTHER|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
214270199|NCT02304679|DEVICE|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
214270200|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
214270201|NCT02304679|OTHER|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
214270202|NCT02304679|OTHER|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
214270203|NCT03475368|OTHER|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
214270204|NCT03475368|OTHER|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
214270205|NCT03475368|OTHER|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
214270206|NCT00828932|DRUG|Lorcaserin|
214270207|NCT00194597|DRUG|Viagra (sildenafil citrate)|
214270208|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
214270209|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
214270210|NCT02946944|DRUG|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
214464905|NCT05906095|BEHAVIORAL|LOCK Falls Program|The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
214829269|NCT06203080|DRUG|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
214829270|NCT01074827|OTHER|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
214270211|NCT02946944|DRUG|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
214270212|NCT01270516|DRUG|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
214270213|NCT01270516|DRUG|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
214270214|NCT01270516|DRUG|Saline|Control
214270215|NCT06455644|OTHER|CT group|After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
214270216|NCT06455644|OTHER|DSA group|After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
214270217|NCT02200432|OTHER|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
214270218|NCT05317182|OTHER|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
214270219|NCT05317182|OTHER|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
214270220|NCT05317182|OTHER|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
214270221|NCT00541931|DRUG|Dietary Supplement: LifePak Nano|Daily use
214270222|NCT03198572|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
214270223|NCT03198572|DRUG|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
214270224|NCT03198572|DRUG|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
214270225|NCT00040365|DRUG|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
214270226|NCT00040365|RADIATION|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
214270227|NCT06352489|PROCEDURE|Posterior component separation technique.|By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
214270228|NCT01460888|DRUG|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
214270229|NCT01460888|RADIATION|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
214270230|NCT00680017|DRUG|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
214270231|NCT00680017|DRUG|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
214270232|NCT04360629|DRUG|Tranexamic Acid|Tranexamic Acid will be given through central vein
214270233|NCT04360629|DRUG|normal saline|normal saline will be given through central vein
214270234|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|This is dose level 0 (de-escalation).
214270235|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|This is dose level 1, the starting dose.
214270236|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|This is dose level 2.
214270237|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|This is dose level 3.
214270238|NCT05976555|BIOLOGICAL|Maximum tolerated dose|The maximum tolerated dose is yet to be determined.
214270239|NCT00530244|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
214270240|NCT00530244|DIETARY_SUPPLEMENT|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
214270241|NCT05497154|BEHAVIORAL|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
214270242|NCT00969917|DRUG|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
214270243|NCT06164977|PROCEDURE|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
214270244|NCT00289445|DRUG|Mitomycin C|
214270245|NCT00289445|DRUG|5-FU|
214270246|NCT00289445|DRUG|Folinic acid|
214270247|NCT00325728|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
214270248|NCT00325728|DRUG|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
214270249|NCT01587820|DRUG|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
214270250|NCT01587820|DRUG|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
214270251|NCT05801276|DIAGNOSTIC_TEST|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
214270252|NCT06959030|OTHER|No Intervention: Observational Cohort|Observation study
214270253|NCT05256953|PROCEDURE|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
214270254|NCT05256953|PROCEDURE|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
214270255|NCT05911516|DIETARY_SUPPLEMENT|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
214270256|NCT05911516|DIETARY_SUPPLEMENT|Placebo|Placebo
214270257|NCT05278208|DRUG|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
214270258|NCT00612040|DRUG|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
214270259|NCT00612040|DRUG|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
214270260|NCT00612040|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
214270261|NCT00612040|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
214270262|NCT06959368|DRUG|Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg|Participants will receive the respective drug regimens twice daily. The Vonoprazan triple therapy arm will administer Vonoprazan 20 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily. The Standard triple therapy arm will administer Esomeprazole 40 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily.
214270263|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
214270264|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
214270265|NCT05303857|DRUG|Semaglutide Pen Injector|Injection of the semaglutide once weekly
214270266|NCT05303857|DRUG|Placebo|Injection of placebo once weekly
214270267|NCT04717791|DEVICE|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
214270268|NCT03449108|BIOLOGICAL|Aldesleukin|Given IV
214270269|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
214270270|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Given IV
214270271|NCT03449108|DRUG|Cyclophosphamide|Given IV
214270272|NCT03449108|DRUG|Fludarabine|Given IV
214270273|NCT03449108|BIOLOGICAL|Ipilimumab|Given IV
214270274|NCT03449108|BIOLOGICAL|Nivolumab|Given IV
214270275|NCT03449108|OTHER|Quality-of-Life Assessment|Ancillary studies
214270276|NCT03449108|OTHER|Questionnaire Administration|Ancillary studies
214464906|NCT06345664|OTHER|Diagnostics and intervention recommendations|All families get the same diagnostics and receive individual treatment recommendations.
214270277|NCT06846996|DRUG|Trastuzumab deruxtecan (T-DXd)|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd (starting dose 6.4 mg/kg IV Q3W) will be enrolled in this study as part of clinical routine or the clinical judgement of physician.
214270278|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
214270279|NCT05705596|OTHER|Sucrose|10% sucrose corresponding to a regular soft drink
214270280|NCT05705596|DRUG|Hesperetin|increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
214270281|NCT04673617|DRUG|AB-101|NK cell therapy
214270282|NCT04673617|DRUG|Rituximab|Anti-CD20 antibody therapy
214270283|NCT04673617|DRUG|Interleukin-2|Immune cytokine
214270284|NCT04673617|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214270285|NCT04673617|DRUG|Fludarabine|Lymphodepleting chemotherapy
214270286|NCT04673617|DRUG|Bendamustine|Chemoimmunotherapy
214270287|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
214270288|NCT01342302|BEHAVIORAL|Psychosocial Intervention for Couples|Intervention delivered on line
214270289|NCT05672836|DRUG|Enavogliflozin|0.3 mg 1 tablet once daily
214270290|NCT05672836|DRUG|Standard-of-Care|Standard-of-Care medical therapy plus Enavogliflozin matching placebo
214270291|NCT05297396|OTHER|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
214270292|NCT06480708|OTHER|Ketogenic diet|The ketogenic diet consisting of fats (70%), protein (20%) and carbohydrates (10%) will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
214270293|NCT06480708|OTHER|Control diet|The control diet consisting of a Mediterranean diet, at 25% fat, 20% protein and 55% carbohydrates will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
214270294|NCT05320757|DRUG|Olaparib|a PARP inhibitor
214270295|NCT03385902|OTHER|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
214270296|NCT03385902|OTHER|late start time|patients will start hemodialysis when their DIFE less than 30
214270297|NCT05402345|DRUG|GlcNAc-GlcN|GlcNAc powder - weight-dependent dose
214270298|NCT05402345|OTHER|Placebo|Placebo xylose
214270299|NCT06149546|DIETARY_SUPPLEMENT|Control|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Four scheduled appointments with a dietitian"
214270300|NCT06149546|DIETARY_SUPPLEMENT|Intervention|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Seven scheduled appointments with a dietitian~* Six scheduled appointments with a physiotherapist"
214270301|NCT00526513|DRUG|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
214270302|NCT01562418|BEHAVIORAL|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
214270303|NCT01562418|BEHAVIORAL|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
214270304|NCT01562418|BEHAVIORAL|control group|general instructions no intervention
214270305|NCT06428422|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis Bl-04|4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks
214270306|NCT06428422|OTHER|Plasebo|1 g/day maltodextrin for 12 weeks
214270307|NCT00639431|BEHAVIORAL|direct observation|direct observation of another person's foot moving
214270308|NCT00639431|BEHAVIORAL|mental visualization|mentally imagining moving one's phantom foot/feet
214270309|NCT02004483|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
214270310|NCT01458236|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
214270311|NCT01458236|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
214270312|NCT00899574|DRUG|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
214464907|NCT06685211|DEVICE|Eyetronic rtACS|The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.
214270313|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
214270314|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
214270315|NCT04396678|BEHAVIORAL|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
214270316|NCT06312345|DRUG|Drug: ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
214270317|NCT01724918|DRUG|Lacosamide|
214270318|NCT03890081|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
214270319|NCT01511198|DRUG|liraglutide|Injected subcutaneously once daily
214270320|NCT01511198|DRUG|metformin|1000 mg twice daily, administered orally
214270321|NCT06345105|DEVICE|Endoscreener QC|Artificial intelligence monitoring of effective withdrawal time
214270322|NCT03631745|BEHAVIORAL|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
214270323|NCT06105151|DRUG|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
214270324|NCT06105151|DRUG|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
214270325|NCT06105151|DRUG|VV119(FE)|A：2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2；
214270326|NCT04781998|DRUG|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
214270327|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
214270328|NCT03783949|DRUG|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
214270329|NCT03783949|DRUG|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
214270330|NCT03783949|DRUG|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
214270331|NCT03783949|DRUG|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
214270332|NCT03783949|DRUG|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
214270333|NCT00997880|DRUG|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
214270334|NCT00997880|DRUG|Rosuvastatin calcium10mg|Rosuvastatin 10mg
214270335|NCT06324383|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
214270336|NCT01210131|DRUG|[18F]HX4|Intravenous injection
214829271|NCT03904095|PROCEDURE|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214270337|NCT05310838|BEHAVIORAL|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
214829272|NCT03904095|PROCEDURE|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214829273|NCT03904095|PROCEDURE|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214829274|NCT03234907|DRUG|Vedolizumab IV|Vedolizumab IV infusion
214270338|NCT05310838|BEHAVIORAL|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
214270339|NCT00687895|PROCEDURE|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides."
214270340|NCT02324257|DRUG|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
214270341|NCT02324257|DRUG|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
214270342|NCT02324257|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
214270343|NCT03681665|OTHER|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
214270344|NCT05679219|PROCEDURE|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
214270345|NCT05679219|PROCEDURE|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
214270346|NCT05679219|PROCEDURE|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
214270347|NCT03473171|DEVICE|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
214270348|NCT01347229|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
214270349|NCT03992014|DRUG|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
214270350|NCT03992014|DRUG|[14C]-linerixibat intravenous infusion|\[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
214270351|NCT03992014|DRUG|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
214270352|NCT04224480|DRUG|Pembrolizumab|200mg of intravenous infusion every 3 weeks
214270353|NCT04396301|DRUG|Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).|Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
214270354|NCT05520112|BIOLOGICAL|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
214270355|NCT05520112|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
214270356|NCT03584178|DEVICE|Budesonide via MAD device|Delivery through Mucosal Atomization Device
214270357|NCT03584178|DEVICE|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
214270358|NCT06262880|DIETARY_SUPPLEMENT|plant derived phenolics|Dietary supplement containing plant derived phenolics
214270359|NCT06262880|OTHER|Microcrystaline cellulose (MCC)|Placebo treatment: Microcrystaline cellulose
214270360|NCT01655771|DRUG|TD-1211 Dose 1|
214270361|NCT01655771|DRUG|TD-1211 Dose 2|
214270362|NCT03478657|DRUG|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
214270363|NCT03478657|DEVICE|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
214270364|NCT03478657|OTHER|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
214270365|NCT02365831|OTHER|Observation of treatment management|Group/cohort
214270366|NCT01218373|DEVICE|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
214270367|NCT01218373|DEVICE|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
214270368|NCT01698372|DEVICE|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
214270369|NCT00310167|RADIATION|radiation therapy|
214270370|NCT02590003|DRUG|Carboplatin|
214270371|NCT02590003|DRUG|Nab-paclitaxel|
214270372|NCT04530916|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day wild blueberry powder
214270373|NCT04530916|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder
214270374|NCT00459225|DRUG|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
214270375|NCT04561466|DRUG|Béfizal|600 mf befizal a day for one year
214270376|NCT03573739|PROCEDURE|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
214829275|NCT03234907|DRUG|Placebo|Vedolizumab placebo-matching
214270377|NCT03573739|PROCEDURE|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
214270378|NCT01251237|DRUG|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
214270379|NCT00427843|BEHAVIORAL|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
214270380|NCT00123396|BEHAVIORAL|BioCASES and BioTESTS|
214270381|NCT01970046|DRUG|Placebo/Metformin|"* Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
214270382|NCT01970046|DRUG|SP2086 50 mg b.i.d/Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
214829276|NCT02664415|BIOLOGICAL|VRC01|40 mg/kg; administered IV
214270383|NCT01970046|DRUG|SP2086 50 mg q.d./Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
214270384|NCT03570697|DRUG|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
214270385|NCT03570697|DRUG|Placebo|Participants will receive matching placebo subcutaneous monthly.
214270386|NCT03570697|DRUG|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
214656837|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Monococcum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Monococcum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
214829277|NCT02664415|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
214829278|NCT00642993|DRUG|SCH 497079|100 mg capsule administered orally
214829279|NCT00642993|DRUG|Placebo|Placebo capsules matching SCH 497079 administered orally
214829280|NCT04224584|DRUG|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
214829281|NCT04224584|DRUG|Placebo oral tablet|Placebo will act as a control for duloxetine.
214829282|NCT01188590|DEVICE|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
214270387|NCT00816920|OTHER|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
214270388|NCT04851457|DRUG|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
214270389|NCT05857059|DRUG|Misoprostol 25 mcg|Misoprostol 50 mcg every 2 hours
214270390|NCT05857059|DRUG|Misoprostol 50 mcg|Misoprostol 50 mcg every 2 hours
214270391|NCT01044628|DEVICE|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%
214270392|NCT01044628|DEVICE|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
214270393|NCT00871533|DRUG|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
214270394|NCT00871533|DRUG|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
214270395|NCT00871533|DRUG|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
214270396|NCT00871533|DRUG|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
214270397|NCT04961931|DRUG|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
214270398|NCT06440902|DRUG|Cetuximab|Cetuximab is given In patients with NeoRAS WT
214270399|NCT03948581|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
214270400|NCT03068455|BIOLOGICAL|nivolumab|Specified Dose on Specified Days
214270401|NCT03068455|BIOLOGICAL|ipilimumab|Specified Dose on Specified Days
214270402|NCT03204578|DRUG|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
214270403|NCT03204578|DRUG|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
214270404|NCT05799170|OTHER|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
214270405|NCT02989545|DEVICE|Anal Tape|
214270406|NCT01934946|OTHER|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
214270407|NCT01934946|OTHER|home rehabilitation|6 times home rehabilitation services within 3 months
214270408|NCT01876420|DEVICE|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
214829283|NCT05878132|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
214829284|NCT05878132|OTHER|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
214829285|NCT03968328|OTHER|Interview|Take part in interview
214829286|NCT03968328|OTHER|Survey Administration|Respond to survey
214829287|NCT04885751|DRUG|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
214829288|NCT04885751|DRUG|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
214270409|NCT00067405|DRUG|Intravenous micronutrient therapy|
214270410|NCT06032468|DEVICE|ARC Intellicare|wearable devices to guide rehabilitation exercise
214270411|NCT06032468|OTHER|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
214270412|NCT04352712|OTHER|blood sampling|blood sampling
214270413|NCT04472429|DRUG|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
214270414|NCT04472429|DRUG|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
214270415|NCT04472429|DRUG|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
214270416|NCT00927602|DRUG|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
214270417|NCT03917238|RADIATION|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
214270418|NCT01477593|PROCEDURE|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
214270419|NCT01477593|PROCEDURE|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
214270420|NCT01477593|PROCEDURE|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
214270421|NCT01172522|DRUG|Fexofenadine|Fexofenadine 1%
214270422|NCT01172522|DRUG|Placebo|Placebo
214270423|NCT04759573|BEHAVIORAL|Early Vocal Contact|Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
214270424|NCT04759573|BEHAVIORAL|Behavioral Observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
214270425|NCT01902199|BEHAVIORAL|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
214270426|NCT01416272|DEVICE|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
214270427|NCT03295084|DRUG|Irinotecan|Dose Escalation
214270428|NCT03295084|DRUG|Capecitabine|Dose Escalation
214270429|NCT04795011|OTHER|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
214270430|NCT04795011|OTHER|exercise|range of motion and walking exercise
214270431|NCT04258163|DRUG|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
214270432|NCT04258163|DRUG|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
214270433|NCT04258163|DRUG|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
214270434|NCT04258163|DRUG|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
214270435|NCT04258163|DRUG|Anastrozole|1mg PO qd
214270436|NCT04258163|DRUG|Letrozole|2.5mg PO qd
214270437|NCT00913172|OTHER|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
214270438|NCT00837356|DRUG|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
214270439|NCT00837356|DRUG|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
214270440|NCT05968339|OTHER|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
214270441|NCT05938491|DIAGNOSTIC_TEST|OCT and OCT-A|OCT and OCT angiography for the macula
214270442|NCT03195764|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
214464908|NCT06685211|DEVICE|Sham rtACS|Participants will wear the Eyetronic system but there will be no active stimulations applied.
214464909|NCT04680468|DRUG|Belantamab mafodotin|2.5 mg/kg IV
214270443|NCT04920552|DEVICE|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
214270444|NCT04920552|DEVICE|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
214270445|NCT01719783|BIOLOGICAL|LAIV H5N2|2 doses provided intranasally
214270446|NCT01719783|OTHER|Placebo|2 doses of placebo provided intranasally
214270447|NCT05923983|OTHER|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
214270448|NCT05923983|OTHER|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
214270449|NCT06107400|GENETIC|RM-004|Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
214270458|NCT02504710|DEVICE|Kinematic Real Time Feedback|
214270459|NCT02504710|OTHER|Traditional systems of manual therapy teaching|
214270460|NCT00216710|BEHAVIORAL|Home Visiting|
214270461|NCT01313312|BIOLOGICAL|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
214829289|NCT04341883|DRUG|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
214829290|NCT03611387|DEVICE|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
214829291|NCT04039022|DRUG|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
214829292|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
214829293|NCT01020825|DRUG|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
214829294|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
214270462|NCT00563355|DRUG|erythropoietin|
214270463|NCT00671333|PROCEDURE|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
214270464|NCT00671333|PROCEDURE|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
214270465|NCT02218749|OTHER|Initially triaged to physiotherapist|
214270466|NCT02218749|OTHER|Initially triaged to physician|
214270467|NCT06557915|PROCEDURE|screening|screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
214270468|NCT00795847|DRUG|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
214270469|NCT03396705|PROCEDURE|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
214270470|NCT02364622|DEVICE|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
214270471|NCT02364622|DEVICE|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
214829295|NCT02986139|DRUG|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
214829296|NCT02986139|DRUG|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
214270472|NCT02364622|DEVICE|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
214270473|NCT02645097|PROCEDURE|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
214270474|NCT05583565|OTHER|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
214270475|NCT05583565|OTHER|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2\) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
214270476|NCT05534685|OTHER|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
214270477|NCT05534685|OTHER|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
214270478|NCT04730687|DEVICE|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
214270479|NCT04730687|DEVICE|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
214270480|NCT04730687|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
214270481|NCT00383461|BEHAVIORAL|smoking cessation intervention|
214270482|NCT00383461|OTHER|counseling intervention|
214270483|NCT00003962|BIOLOGICAL|aldesleukin|
214270484|NCT00627185|BEHAVIORAL|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
214270485|NCT00627185|OTHER|No intervention arm|
214270486|NCT05089279|DRUG|D113|QD, PO
214270487|NCT05089279|DRUG|CKD-349|QD, PO
214270488|NCT03142178|DRUG|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
214270489|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
214270490|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
214270491|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
214270492|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
214270493|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
214270494|NCT00092157|DRUG|MK0733, simvastatin|
214270495|NCT00092157|DRUG|Comparator: simvastatin|
214464910|NCT06069791|DRUG|Bupivacaine Injection|subcutaneous injection around bilateral greater occipital nerves
214656838|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Aestivum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Aestivum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
214656839|NCT05095142|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214656840|NCT06121726|OTHER|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
214270496|NCT05446896|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
214270497|NCT04088942|OTHER|High-intensity smoking cessation intervention|"1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
214270498|NCT04088942|DRUG|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
214270499|NCT02386631|DEVICE|Custom Made Orthotic|Provides longitudinal arch support
214270500|NCT01252147|OTHER|No treatment|No treatment (intervention) will be provided in this study
214270501|NCT05732246|OTHER|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
214270502|NCT03023462|DRUG|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
214270503|NCT03023462|DRUG|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
214270504|NCT03023462|DRUG|Ropivacaine|Local anesthetic for the block
214270505|NCT02800343|PROCEDURE|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
214270506|NCT00768950|PROCEDURE|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
214270507|NCT00768950|PROCEDURE|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
214270508|NCT04158752|DRUG|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
214270509|NCT00039078|RADIATION|yttrium Y 90 glass microspheres|
214270510|NCT01612858|DRUG|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
214270511|NCT01612858|DRUG|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
214270512|NCT02168127|DRUG|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
214270513|NCT02168127|DRUG|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
214270514|NCT05431660|OTHER|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
214270515|NCT05431660|OTHER|control group|diabetic foot school information booklet and weekly video conference meeting
214270516|NCT03631875|DRUG|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
214270517|NCT02326792|OTHER|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
214270518|NCT00154635|DRUG|DCB-AD1|
214270519|NCT03988088|DRUG|Lasmiditan|Administered orally.
214270520|NCT05847361|DIAGNOSTIC_TEST|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
214270521|NCT03574831|DEVICE|Stretta|Stretta
214270522|NCT05401357|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
214270523|NCT05401357|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
214270524|NCT00547495|DRUG|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
214270525|NCT00547495|DRUG|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
214270526|NCT00547495|DRUG|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
214270527|NCT00547495|DRUG|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
214270528|NCT02173808|BIOLOGICAL|levonorgestrel butanoate|
214270529|NCT02898129|OTHER|Questionnaire|
214270530|NCT02898129|DEVICE|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
214270531|NCT06558292|OTHER|Virtual Reality Group|Students will experience the operating room environment with virtual reality glasses before clinical practice.
214270532|NCT05274880|DRUG|CKD-393|PO, QD
214270533|NCT00124228|DRUG|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
214270534|NCT05000281|DRUG|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
214270535|NCT00003257|BIOLOGICAL|Ad5CMV-p53 gene|
214270536|NCT04067700|PROCEDURE|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
214270537|NCT01796509|OTHER|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
214270538|NCT01802801|OTHER|embryo development|intra- and inter-observator analysis
214270539|NCT04520412|DRUG|GV-971|Administered PO
214270540|NCT04520412|DRUG|Placebo|Administered PO
214270541|NCT05586893|DEVICE|Acupuncture therapy and Electroacupuncture|"We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
214270542|NCT03113071|DRUG|Decitabine|Decitabine will be administered in combination with Digoxin
214270543|NCT03113071|DRUG|Digoxin|Decitabine will be administered in combination with Digoxin
214270544|NCT04861909|DEVICE|AT LISA tri 839MP|Non interventional study
214270545|NCT02617381|OTHER|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
214270546|NCT05849701|DEVICE|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
214270547|NCT05849701|DEVICE|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
214270548|NCT03963596|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
214270549|NCT01358045|DRUG|Diclofenac|Application on the lesion 2 times a day 8 weeks.
214270550|NCT01358045|DRUG|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
214270551|NCT01358045|DRUG|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
214270552|NCT03555916|DRUG|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
214270553|NCT03555916|DRUG|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
214270554|NCT06161870|DRUG|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
214270555|NCT06161870|DRUG|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
214270556|NCT01010373|DRUG|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
214829297|NCT02235558|DRUG|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
214270557|NCT04997083|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
214270558|NCT04997083|DEVICE|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
214270559|NCT05009654|DIETARY_SUPPLEMENT|L-carnitine|
214270560|NCT05009654|DIETARY_SUPPLEMENT|L-leucine|
214270561|NCT00991731|BEHAVIORAL|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
214829298|NCT05474651|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
214829299|NCT02155257|DRUG|Modafinil|
214829300|NCT02155257|DRUG|Gabapentin|
214270562|NCT00991731|BEHAVIORAL|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
214270563|NCT05116878|DIETARY_SUPPLEMENT|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
214270564|NCT05116878|DIETARY_SUPPLEMENT|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
214270565|NCT02566486|DEVICE|Reciprocating system|Different root canal instrumentation systems
214270566|NCT02566486|DEVICE|Rotational system|Different root canal instrumentation systems
214270567|NCT01540266|PROCEDURE|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
214270568|NCT01540266|PROCEDURE|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
214270569|NCT00330070|DRUG|IPL512,602 20 mg once daily|
214270570|NCT00330070|DRUG|IPL512,602 Matching Placebo once daily|
214270571|NCT00868608|DRUG|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
214270572|NCT03454542|DEVICE|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
214270573|NCT03844100|DRUG|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
214270574|NCT03363997|DRUG|Estriol 0.125 mg/day|Application of one vaginal ring
214270575|NCT03363997|DRUG|Estriol 0.250 mg/day|Application of one vaginal ring
214270576|NCT03363997|DRUG|Estriol 0.500 mg/day|Application of one vaginal ring
214270577|NCT06308367|DRUG|Betaine|50mg/kg for 12 weeks
214270578|NCT06308367|DRUG|Placebo|Placebo
214270579|NCT03344796|BEHAVIORAL|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
214270580|NCT05481892|DEVICE|Cellular Home blood pressure (BP) monitoring|Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
214270581|NCT05108285|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
214270582|NCT00626223|DRUG|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
214270583|NCT00626223|DRUG|folic acid|5 mg per day of oral folic acid
214270584|NCT04749706|BEHAVIORAL|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
214270585|NCT04749706|BEHAVIORAL|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
214270586|NCT03756077|DIAGNOSTIC_TEST|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
214270587|NCT04594343|DRUG|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
214270588|NCT04594343|DRUG|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
214270589|NCT01710969|BEHAVIORAL|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
214270590|NCT01710969|BEHAVIORAL|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
214270591|NCT00417508|DIETARY_SUPPLEMENT|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
214270592|NCT00417508|DIETARY_SUPPLEMENT|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
214270593|NCT05531383|DRUG|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
214270594|NCT01999179|DRUG|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
214270595|NCT00635674|DEVICE|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
214270596|NCT05164185|PROCEDURE|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
214829301|NCT02155257|DRUG|Placebo|
214270597|NCT01176383|GENETIC|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
214270598|NCT01778972|OTHER|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
214270599|NCT01778972|OTHER|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
214270600|NCT00880997|DRUG|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
214270601|NCT00880997|OTHER|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
214270602|NCT02564796|DRUG|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
214270603|NCT02564796|DRUG|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
214270604|NCT04795960|DIETARY_SUPPLEMENT|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
214270605|NCT04795960|DIETARY_SUPPLEMENT|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
214270606|NCT01545804|DRUG|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
214270607|NCT02378259|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
214270608|NCT02378259|PROCEDURE|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
214270609|NCT02014571|DRUG|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
214270610|NCT02014571|DRUG|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
214270611|NCT02257307|PROCEDURE|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
214270612|NCT02620657|OTHER|Non interventional study|Non interventional study
214270613|NCT00043901|DRUG|lamotrigine|
214270614|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
214270615|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
214270616|NCT05840380|DEVICE|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
214270617|NCT05560360|DRUG|SHR1459 tablet|100 mg/tablet; administered orally
214270618|NCT05560360|DRUG|Efavirenz tablet|600 mg/tablet; administered orally
214270619|NCT06556342|DRUG|FRD001|FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
214270620|NCT00728793|DRUG|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
214270621|NCT05469191|OTHER|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
214270622|NCT05469191|OTHER|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
214270623|NCT01760629|DEVICE|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
214270624|NCT04650711|DIAGNOSTIC_TEST|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
214270625|NCT04131426|DRUG|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
214270626|NCT04131426|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
214270627|NCT03935360|OTHER|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
214270628|NCT01750983|DRUG|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
214270629|NCT01750983|DRUG|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
214270630|NCT05950256|DEVICE|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
214270631|NCT03742830|DEVICE|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
214270632|NCT04547712|DEVICE|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
214270633|NCT05276024|DEVICE|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
214270634|NCT05496400|RADIATION|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:"
214270635|NCT04737382|DIAGNOSTIC_TEST|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
214270636|NCT04737382|DIAGNOSTIC_TEST|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
214270637|NCT00065689|DEVICE|high-intensity light therapy|
214270638|NCT00594659|BEHAVIORAL|Psychotherapy|Nine session treatment
214270639|NCT00594659|BEHAVIORAL|Computerized Psychotherapy|Nine session computer delivered treatment
214270640|NCT00594659|BEHAVIORAL|Motivational enhancement therapy|Two session treatment
214270641|NCT01941667|BEHAVIORAL|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
214270642|NCT01941667|OTHER|Usual Care|Usual care as defined by by the Cardiology Department.
214270643|NCT04941560|OTHER|No intervention|No intervention
214270644|NCT02318251|OTHER|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
214270645|NCT02318251|OTHER|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
214270646|NCT00002190|DRUG|Saquinavir|
214270647|NCT00002190|DRUG|Lamivudine|
214270648|NCT00002190|DRUG|Zidovudine|
214270649|NCT04498520|DRUG|Abexinostat Tosylate|Given PO
214270650|NCT04498520|DRUG|Fulvestrant|Given IM
214270651|NCT04498520|DRUG|Palbociclib|Given PO
214270652|NCT01161459|DRUG|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
214270653|NCT01161459|DRUG|FK506|capsule
214270654|NCT01020175|PROCEDURE|Bone marrow transplantation|Patients received bone marrow transplantation
214270655|NCT01020175|PROCEDURE|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
214270656|NCT03424408|DRUG|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
214270657|NCT03372044|DRUG|PF-06865571 Immediate release suspension|Suspension
214270658|NCT03372044|DRUG|PF-06865571 Slow release MR tablets|Modified release tablets
214270659|NCT03372044|DRUG|PF-06865571 Fast release MR tablets|Modified release tablets
214829302|NCT00414726|DRUG|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
214829303|NCT00414726|DRUG|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
214829304|NCT05496192|DRUG|Nivolumab/rHuPH20|Specified dose on specified days
214270660|NCT03372044|DRUG|PF-06865571 Immediate release tablets|Immediate release tablets
214270661|NCT01228474|OTHER|Select the Number of embryos to transfer|Select the Number of embryos to transfer
214270662|NCT02508831|PROCEDURE|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
214270663|NCT04370223|BIOLOGICAL|Ozone auto-hemotherapy|ozone auto-hemotherapy
214270664|NCT00660699|DRUG|Gemcitabine|
214270665|NCT00660699|DRUG|Docetaxel|
214270666|NCT00660699|RADIATION|Radiation|
214270667|NCT04116970|PROCEDURE|Bronchoscopy|Undergo bronchoscopy with EBUS-TBNA
214270668|NCT04116970|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo bronchoscopy with EBUS-TBNA
214270669|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
214270670|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
214270671|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
214270672|NCT04560335|BEHAVIORAL|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
214270673|NCT04560335|BEHAVIORAL|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
214270674|NCT03432897|DRUG|Olaparib Pill|300 mg BID
214270675|NCT03432897|PROCEDURE|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
214270676|NCT03105479|DRUG|Cadazolid|Granules for oral suspension to be administered twice daily
214270677|NCT03105479|DRUG|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
214270678|NCT03105479|DRUG|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
214270679|NCT05439447|DIAGNOSTIC_TEST|Patients scheduled for VFSS testing group|Patients scheduled for VFSS testing, patient with voice.
214270680|NCT05292547|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
214270681|NCT02963649|DEVICE|DCB|Drug Coated Balloon
214270682|NCT02963649|DEVICE|PTA|Percutaneous Transluminal Angioplasty
214270683|NCT06144177|OTHER|Dark with star projector|When in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on.
214270684|NCT06144177|DRUG|Preoperative midazolam|Midazolam by mouth preoperatively.
214270685|NCT06144177|OTHER|Parental Presence|A parent or guardian will accompany the child into the OR and be present for the start of induction.
214270686|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
214270687|NCT05928026|BEHAVIORAL|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
214270688|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
214270689|NCT05358444|BEHAVIORAL|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
214270690|NCT05358444|BEHAVIORAL|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
214270691|NCT06116578|DRUG|Pembrolizumab|cf Arm A
214270692|NCT06116578|DRUG|Pembrolizumab and Olaparib|cf Arm B
214270693|NCT06116578|DRUG|Pembrolizumab adjuvant|After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
214270694|NCT05300737|OTHER|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
214270695|NCT02833064|RADIATION|Non-contrast magnetic resonance imaging|
214270696|NCT02833064|OTHER|Biological sampling|Blood, urine, stool and breath sampling and analysis
214270697|NCT05134935|DEVICE|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
214270698|NCT05134935|DEVICE|Orthokerathology lenses (OKL)|18 months of therapy.
214829305|NCT05496192|DRUG|Nivolumab|Specified dose on specified days
214270699|NCT03802227|DRUG|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
214270700|NCT03802227|DRUG|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
214270701|NCT05602870|DIAGNOSTIC_TEST|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
214270702|NCT04203329|DEVICE|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
214270703|NCT06652984|OTHER|Exercise 1|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
214270704|NCT06652984|OTHER|Exercise 2|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
214270705|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
214270706|NCT04533165|BEHAVIORAL|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
214829306|NCT02107196|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
214829307|NCT02107196|DRUG|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
214270707|NCT06980454|DRUG|HLX05|A single dose of 250 mg/m2 HLX05 will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
214270708|NCT06980454|DRUG|EU-Erbitux®|A single dose of 250 mg/m2 EU-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
214270709|NCT06980454|DRUG|US-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
214270710|NCT06980454|DRUG|CN-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
214270711|NCT06807216|BEHAVIORAL|YATAC|Age-specific rehabilitation for young adult cancer survivors
214270712|NCT06474221|BEHAVIORAL|Electronic Based Psychosocial Intervention (EBPSI)|Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
214270713|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
214270714|NCT06655142|DEVICE|ONCObind (Onco-Seraph) 100 Filter|The ONCObind Microbind® Affinity Blood Filter ( ONCObind) manufactured by ExThera Medical Corporation in Martinez, CA. The ONCObind filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. Literature search yielded over 60 publications and 500 treated patients with Seraph platform technology for pathogen removals without and significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of ONCObind consistent with the intended use. ExThera Medical concludes that the known and potential benefits of ONCObind, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
214270715|NCT06655142|OTHER|Matched Controls|Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
214270716|NCT01840306|OTHER|Biomarker Analysis|
214270717|NCT06824077|DRUG|Dexmedetomidine|Dexmedetomidine will be prepared at a concentration of 4 mcg/ml by diluting 200 mcg/2 ml vials with 48 mL of 0.9% normal saline to a total volume of 50 ml. A maintenance infusion of 0.2-1.2 mcg/kg/hr will be initiated to sustain the sedative effect and promote sleep throughout the trial period. ICU nurses are experienced in titrating dexmedetomidine for both patients on high flow oxygen (Optiflow) and intubated patients with delirium as part of routine care. The ICU bedside nurse will be responsible for using the lowest effective dose to achieve a Richmond Agitation Sedation Scale (RASS) of -2, up to a maximum of 1.2 mcg/kg/hr, while monitoring for adverse events such as bradycardia and hypotension.
214829308|NCT00136448|DRUG|cytosine arabinoside (ara-C)|
214829309|NCT00136448|DRUG|daunomycin|
214829310|NCT00136448|DRUG|interleukin-2|
214829311|NCT01661517|BEHAVIORAL|Motivational interviewing and referral to treatment|
214829312|NCT04898998|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
214829313|NCT04898998|OTHER|routine care|routine care
214270718|NCT06824077|OTHER|Control (placebo) group|The control group will receive an infusion of 0.9% saline at 5-45 ml/hr titrated to the lowest effective dose to achieve a RASS of -2 for two nights following randomization.
214270719|NCT06607900|DRUG|hUC-MSC-sEV-001 nasal drops|hUC-MSC-sEV-001 nasal drops
214270720|NCT01330680|DIETARY_SUPPLEMENT|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
214270721|NCT01330680|DIETARY_SUPPLEMENT|Decaffeinated coffee|40 mL dose of decaffeinated coffee
214270722|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 5 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
214270723|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 10 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
214270724|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
214270725|NCT06619197|OTHER|Global reflexology|The EMC method is a global reflexology technique inspired by the work of the American naturopath Stanley Burrough (Vitaflex, 1976). It is a method of reflexology on the whole body, of acupressure massages (rhythmic and targeted movements) on so-called \&#34;reflex\&#34; zones which is practiced on different areas of the body (feet, hands, arms, legs, collarbone, ear) and allows the stimulation of all systems.
214270726|NCT05334914|BEHAVIORAL|Acceptance Commitment Therapy|"ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc."
214270727|NCT01913678|OTHER|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
214270728|NCT01913678|OTHER|Complete diet|The participants will be given all dietary items in their diet with no additional products.
214270729|NCT01913678|OTHER|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
214270730|NCT02439190|DRUG|BMS-986120|
214270731|NCT02439190|DRUG|Aspirin|
214270732|NCT02439190|DRUG|Clopidogrel|
214270733|NCT02900976|BIOLOGICAL|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
214270734|NCT02900976|BIOLOGICAL|Rituximab|Given IV
214270735|NCT06673147|OTHER|Prenatal Nordic Walking|Traditional Nordic walking poles will be modified according to International Nordic Walking Federation guidelines, which meant that the elbows were bent at a 90°angle when holding the poles in a vertical position. Nordic Walking will be conducted in two phases consisting of a 4-week learning phase followed by an 8-week main phase of intervention.
214829314|NCT05475548|DEVICE|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
214829315|NCT00516295|DRUG|topotecan hydrochloride|Given IV
214829316|NCT00516295|DRUG|vincristine sulfate|Given IV
214270739|NCT06517212|DRUG|Tirzepatide|Patients will receive tirzepatide once weekly for up to 2 years.
214270740|NCT06989489|BEHAVIORAL|Multilevel Adherence Intervention|Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent based on their risk-stratified monitoring category. Participants will be followed longitudinally and will receive tailored support.
214270741|NCT06999642|DIETARY_SUPPLEMENT|GI Health Placebo Control|Participants will use their GI Health Placebo Control as directed for a period of 6 weeks.
214270742|NCT06999642|DIETARY_SUPPLEMENT|GI Health Active Product|Participants will use their GI Health Active Product as directed for a period of 6 weeks.
214270743|NCT00876421|DRUG|Placebo|Placebo / 12 weeks
214270744|NCT00876421|DRUG|Tolterodine|4mg / 12 weeks
214829317|NCT00516295|DRUG|cyclophosphamide|Given IV
214829318|NCT00516295|BIOLOGICAL|bevacizumab|Given IV
214270745|NCT00876421|DRUG|ONO-8539|low dose / 12 weeks
214270746|NCT00876421|DRUG|ONO-8539|medium dose / 12 weeks
214270747|NCT00876421|DRUG|ONO-8539|higher dose / 12 weeks
214829319|NCT05503992|OTHER|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
214829320|NCT06160180|DRUG|Dexamethasone|Submucosal application
214270748|NCT06677567|OTHER|Air-Q Intubating Airway|Patients will be inserted Air-Q Intubating Airway under general anesthesia
214270749|NCT06677567|OTHER|proseal laryngeal mask|Patients will be inserted proseal laryngeal mask under general anesthesia.
214270750|NCT06676670|OTHER|real acupuncture|Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.
214270751|NCT06676670|OTHER|sham acupuncture|"Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo"
214270752|NCT06604065|DRUG|AMS2434 (amino acids)|The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.
214270753|NCT06604065|DRUG|Placebo|Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
214270754|NCT06866080|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
214270755|NCT07008235|DRUG|Tablet Amitriptyline 10 milligrams|Tablet Amitriptyline 10 milligrams at night will be given to patients along with standard first line treatment of functional dyspepsia
214270756|NCT07008235|DRUG|Tablet Trifluoperazine 1 milligrams twice daily|Tablet Trifluoperazine 1 milligrams twice daily will be given to patients along with standard first line treatment of functional dyspepsia
214270757|NCT06681493|DRUG|YZJ-4729 Tartrate injection|Infusion, QD
214270758|NCT06681493|DRUG|YZJ-4729 simulated injection|Infusion, QD
214270759|NCT06680219|DIETARY_SUPPLEMENT|Placebo|Crystal Light Raspberry Lemonade: Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water).
214270760|NCT06680219|DIETARY_SUPPLEMENT|Active comparator|"ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931): Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily.~(8-12 oz of water is approximately 236-354 mL of water)."
214270761|NCT06681610|DEVICE|Transcranial Pulse Stimulation|low intensity shock-waves stimulation of the motor cortex, bilateral
214270762|NCT06680024|PROCEDURE|Intercostal tube|Intercostal tube drainage as a first management of second stage empyema
214270763|NCT06680024|PROCEDURE|Video assisted thoracoscope|Video assisted thoracoscopic surgery as a first management for second stage empyema
214270764|NCT05240599|OTHER|Exercise Training|Exercise training will be applied 3 times a day for 8 weeks.
214270765|NCT06873113|DEVICE|Active BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains 50% of participants limb occlusion pressure for the duration of each strengthening exercise.
214270766|NCT06873113|DEVICE|Sham BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains a pressure of 20mmHg for the duration of each strengthening exercise.
214270767|NCT06873113|BEHAVIORAL|Strengthening Exercises with BFRT|Participants perform 4 strengthening exercises while using the BFR device: seated scapular plane elevation, prone horizontal abduction, side-lying external rotation, and prone scapular plane elevation. Each exercise is performed unilaterally. Participants perform 1 set of 30 repetitions followed by 3 sets of 15 repetitions (4 total sets, 75 total repetitions). Participants are given 30 seconds rest between sets and 2 minutes of rest between strengthening exercises. Selected resistance for each strengthening exercise is equal to 20% of the participant's maximal force production as measured by handheld dynamometry. Resistance is adjusted weekly.
214270768|NCT06873113|BEHAVIORAL|Skilled Physical Therapy Care|Participants perform non-strengthening interventions as part of skilled physical therapy care. Non-strengthening interventions include an upper arm ergometer for warm-up, active assisted range of motion of the shoulder, shoulder stretching, shoulder joint mobilizations, and cryotherapy. Non-strengthening interventions are prescribed at the discretion of the treating physical therapist. Participants are enrolled in physical therapy for a minimum of 4 weeks. After 4 weeks, the treating physical therapist can discharge a participant based on their progress in meeting their rehabilitation goals. Participants discharged from skilled physical therapy care will continue to complete strengthening exercises with BFRT until the end of the trial period (8 weeks).
214270769|NCT06681298|DRUG|The experimental group received Nivolumab|Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
214270770|NCT05215886|BEHAVIORAL|Surgery|Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
214656841|NCT06121726|DRUG|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
214656842|NCT00092508|DRUG|OPC-6535|
214656843|NCT00092508|DRUG|Asacol®|
214656844|NCT05891665|PROCEDURE|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
214270771|NCT06623682|BEHAVIORAL|Transdiagnostic cognitive behavioural therapy|Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
214270772|NCT05000723|OTHER|Standard of care|"Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
214270773|NCT06875102|DEVICE|Acupuncture (ACU)|acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention.
214270774|NCT06875102|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|"Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation.~Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020)."
214270775|NCT06875102|OTHER|APA (adapted physical activity )|The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks
214270776|NCT06875102|DEVICE|Acupuncture (sham_ACU)|Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention.
214270777|NCT06875102|DEVICE|Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS)|"Simulated Transcutaneous Vagus Nerve Stimulation (sim\_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in simulated mode."
214270778|NCT05656118|DEVICE|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
214270779|NCT06631755|DEVICE|Xience Skypoint stent over calcified coronary lesions|Patients with Xience Skypoint stent implanted after OCT assesment of calcification
214270780|NCT06685809|DRUG|FZ008-145 solution|Dose formulation- Oral solution
214270781|NCT06685809|DRUG|FZ008-145 Tablet|Dose formulation- Oral tablet
214270782|NCT06685809|DRUG|Placebo|Dose formulation- Matching doses
214270783|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
214270784|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
214270785|NCT03424863|OTHER|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
214270786|NCT06706674|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
214270787|NCT06706674|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
214270788|NCT06706674|DRUG|Placebo|Matching Placebo administered orally once daily
214270789|NCT06704373|OTHER|thoracal manipulation|Thoracal manipulation will be applied only one session.
214270790|NCT06704373|OTHER|Exercise|Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.
214270791|NCT07033936|OTHER|Questionnaire|An online Questionnaire will be shared via social media such as WhatsApp, Facebook or X for Egyptian medical students and intern to fill
214270792|NCT07028619|DEVICE|Bimodal Streaming Configuration|Participants' devices are configured for bimodal streaming. Participants complete a survey following a trial with the new bimodal streaming feature.
214270793|NCT07039838|DIAGNOSTIC_TEST|3D print of coronary arteries|Based on a pre-surgical cardiac CT the optimal graft insertions points on the target coronary arteries wil be marked and a patient-specific model of the coronary arteries will be 3D-printed and sterialized to be available during CABG to guide the placement of the distal graft anastomosis.
214270794|NCT07040566|DRUG|Varenicline 1mg BID|12 weeks following the standard titration of 1 mg, twice daily
214270795|NCT07040566|DRUG|Placebo|Matching placebo twice daily
214270796|NCT06702930|OTHER|Morning high-intensity interval exercise|High-intensity interval exercise was performed between 8-10 am
214270797|NCT06702930|OTHER|Evening high-intensity interval exercise|High-intensity interval exercise was performed between 5-7 pm
214270798|NCT07033832|BEHAVIORAL|ACT-based intervention|"Parents in this group will receive two-hour weekly session with the question-and-answer session at the end. The contents of each session are as follows: (1) the first session consist of introductions of ACT, discussion on stress and struggles, and setting homework, (2) the second section includes role play, and the meaning of value, (3) the third session involves introducing mindfulness of the breath exercise, debrief and homework on practicing mindfulness and (4) the last session includes introduction of thoughts, and putting values into feasible actions."
214829321|NCT03416049|DEVICE|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
214270799|NCT07048002|OTHER|Managements for NeuroFirst target bundle|"In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg or within 10% preoperative baseline values, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% or within 10% preoperative baseline values, and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB.~To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments."
214829322|NCT03416049|DEVICE|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
214829323|NCT03416049|DEVICE|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
214270800|NCT07048002|OTHER|Managements for institutional routine|MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.
214270801|NCT07047651|COMBINATION_PRODUCT|Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram)|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) with RECOVERYTRSGR (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions.
214270802|NCT07047651|COMBINATION_PRODUCT|Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants|The combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) and TAU (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions. The control group of Group A
214270803|NCT07047651|COMBINATION_PRODUCT|Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine|A combination of pharmacotherapy with RECOVERYTRSBDGR (antipsychotics, anxiolytics, antidepressants, mood stabilizers) for patients with treatment-resistant bipolar disorder. 140 sessions
214270804|NCT07047651|COMBINATION_PRODUCT|Group D (Pharmacotherapy and TAU)Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, seropram, lithium, depakine)|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants, mood stabilizers) and TAU (psychotherapy). A control group to RECOVERYTRSBDGR. 140 sessions.
214270805|NCT07053371|OTHER|Peanut birth ball|The 45 x 80 cm peanut birth ball was positioned between the woman's legs during the first stage's active phase, starting at 4 cm cervical dilatation for the intervention group
214270806|NCT07055009|DIAGNOSTIC_TEST|Targeted long-read HLA sequencing|Genetic study
214270807|NCT07055009|OTHER|RNA extraction|Nanostring technology, Seattle
214270808|NCT07055009|OTHER|Full Skin examination|Skin and mucosa examination
214270809|NCT07054593|DEVICE|CapScan|Gut sampling capsule
214270810|NCT07053462|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney|The donor kidney is treated outside the body with CRISPR-Cas9 ribonucleoprotein complexes targeting the genes HLA-A, HLA-B, and CIITA. This genetic intervention knocks out HLA-A/B on donor cells and disables expression of HLA-DR, -DQ, -DP by disrupting CIITA (essential for class II antigen presentation). The goal is to create a transplanted organ with greatly reduced immunogenic surface proteins. (This is a one-time genetic manipulation applied to the donor organ prior to transplantation; no direct gene therapy is given to the patient's own cells.)
214270811|NCT07053462|PROCEDURE|Kidney Transplantation with Standard Care|After gene editing, the donor kidney is implanted into the recipient in a surgical transplant procedure. Standard peri-operative care is provided. All patients will receive standard immunosuppressive therapy post-transplant (such as tacrolimus, mycophenolate, and prednisone, per center protocol) to prevent rejection, though the regimen may be tailored based on the edited graft's expected lower immunogenicity. Patients will be hospitalized for transplant and monitored closely during the immediate post-op period, then followed in clinic frequently for transplant aftercare.
214270812|NCT07055204|OTHER|"Diapason & Metronome musical learning"|Participants will make music with the two instruments we all have in common: the voice and the body. The method is three-dimensional built on: rhythm, simple sound and harmony. The music sessions will take place in the same place and on the same day of the week, at a fixed time to establish a regularity that is suitable to this population. The courses will be taught in a cultural location, both to give meaning to the approach on a contextual level and to allow patients to be in the city and not in the hospital. A training of the music teachers will be planned before the beginning of the study. This training combined with regular debriefings during the music sessions, should ensure that the teachers' practices are consistent across the different groups.
214270813|NCT04997304|COMBINATION_PRODUCT|AirDuo Digihaler|"Participants will receive the AirDuo® Digihaler™ at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis."
214270814|NCT04997304|COMBINATION_PRODUCT|ProAir Digihaler|Participants will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
214270815|NCT07053839|BEHAVIORAL|Daily Text Reminder|"The intervention, titled AdhasText, involved sending a daily SMS reminder to caregivers, specifically mothers of children with asthma. The message, If you want to stay healthy, you must use your inhaler, was sent at 7:00 p.m. over a 90 days period."
214270816|NCT07053020|DRUG|Cytarabine|Given by intravenous adminstration
214270817|NCT07053020|DRUG|Oral Cladribine|Given Orally
214270818|NCT06734975|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
214270819|NCT06734975|DRUG|Superior laryngeal nerve block - Placebo (saline)|Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
214270820|NCT03196726|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
214270821|NCT03196726|BEHAVIORAL|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
214270822|NCT06321523|DRUG|Tafamidis 61 milligrams|Tafamidis 61mg as provided in real-world practice
214270823|NCT01752985|DRUG|BMS-813160|
214270824|NCT01752985|DRUG|Placebo matching with BMS-813160|
214270825|NCT06906276|OTHER|Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.|Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)
214270826|NCT06902129|DEVICE|EDDIS Platform - Portable Inhalation Delivery Systems (VMT, Atomizer, Ultrasonic)|A set of three single-use, disposable, closely matched and uniform in size, breath-actuated, digitally monitored portable inhalation devices designed for precision aerosol delivery. Devices include a vibrating mesh (VMT), an atomizer-based unit (ATM), and an ultrasonic micro-vibration unit (ULT). Each system records inhalation parameters and connects via Bluetooth to a mobile application for real-time feedback and logging. Used to assess technical performance, gas dynamics, and digital control functions using a non-active NaCl-based aerosol with chitosan nanoparticles.
214270827|NCT02139111|DRUG|Placebo|Oral placebo capsule
214270828|NCT02139111|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
214270829|NCT02139111|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
214270830|NCT02139111|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
214270831|NCT02139111|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
214270832|NCT02606448|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
214270833|NCT02606448|PROCEDURE|Femoral nerve block|Pre-operative femoral nerve block
214270834|NCT02606448|DRUG|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
214270835|NCT04694781|DRUG|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
214270836|NCT04694781|DRUG|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
214270837|NCT01880502|DRUG|Belviq 10mg|Belviq 10mg single dose administration
214270838|NCT01880502|DRUG|Belviq 20mg|Belviq 20mg single dose administration
214270839|NCT01880502|DRUG|Placebo|Placebo single dose administration
214270840|NCT00691860|DEVICE|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
214270841|NCT00691860|PROCEDURE|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
214270842|NCT00702039|OTHER|No Music|No music will be played in patients in arm 2 of the study.
214270843|NCT00702039|OTHER|Music Therapy|Classical music being played during intravitreal injection.
214270844|NCT01958333|PROCEDURE|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
214270845|NCT01958333|PROCEDURE|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
214270846|NCT01958333|PROCEDURE|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
214270847|NCT04092582|DRUG|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
214270848|NCT04092582|DRUG|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
214270849|NCT04087265|DIAGNOSTIC_TEST|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
214270850|NCT03210246|DRUG|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
214270851|NCT03210246|DRUG|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
214270852|NCT03210246|DRUG|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
214270853|NCT03210246|DRUG|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
214270854|NCT03133169|DIAGNOSTIC_TEST|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
214270855|NCT03133169|DIAGNOSTIC_TEST|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
214270856|NCT05865262|DIAGNOSTIC_TEST|ECG|"A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula."
214270857|NCT05865262|DIAGNOSTIC_TEST|blood test (assessing ionic and hormonal circulating levels)|Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
214270858|NCT00690274|DRUG|BF2.649|up to 20mg per day
214270859|NCT00690274|DRUG|Placebo|up to 20mg per day
214270860|NCT05214495|DRUG|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
214270861|NCT05214495|DRUG|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
214270862|NCT05638178|OTHER|No intervention|No intervention, cohort study.
214270863|NCT00896246|DRUG|Klean-Prep®|Four litres of solution administered orally as a divided dose.
214270864|NCT00896246|DRUG|Moviprep®|Two litres of solution administered orally as a divided dose
214270865|NCT05236049|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
214270866|NCT02959320|PROCEDURE|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
214270867|NCT01696084|DRUG|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
214270868|NCT01696084|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
214270869|NCT01881347|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
214270870|NCT01881347|DIETARY_SUPPLEMENT|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
214270871|NCT03090802|BEHAVIORAL|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
214270872|NCT01152710|DRUG|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
214270873|NCT00948701|BEHAVIORAL|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
214270874|NCT03663816|DEVICE|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
214270875|NCT00027261|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214270876|NCT01155232|DRUG|Teriparatide|Forteo (teriparatide)pen daily for 24 months
214270877|NCT00763568|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
214270878|NCT00763568|BIOLOGICAL|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
214270879|NCT05504564|GENETIC|The experiment does not required any intervention|The experiment does not required any intervention
214270880|NCT04157439|OTHER|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
214270881|NCT04157439|OTHER|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
214270882|NCT01925105|OTHER|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
214270883|NCT04481867|PROCEDURE|densah bur|osseodensification densah bur
214270884|NCT04962204|BEHAVIORAL|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
214270885|NCT04401085|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
214270886|NCT04401085|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
214270887|NCT03368794|BEHAVIORAL|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
214270888|NCT03368794|BEHAVIORAL|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
214270889|NCT04779060|DRUG|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
214270890|NCT04779060|DRUG|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
214270891|NCT04779060|DRUG|saline|normal saline will be mixed with bupivacaine intrathecally
214270892|NCT00300391|DRUG|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
214270893|NCT00300391|OTHER|Saline placebo|control arem
214270894|NCT06495827|OTHER|No different intenvention|No different intenvention
214270895|NCT05115903|DRUG|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
214270896|NCT05115903|DRUG|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
214270897|NCT02033616|BIOLOGICAL|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
214270898|NCT02033616|BIOLOGICAL|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
214270899|NCT05038189|DIAGNOSTIC_TEST|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
214270900|NCT05038189|DIAGNOSTIC_TEST|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
214270901|NCT05038189|DIAGNOSTIC_TEST|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
214270902|NCT06805253|OTHER|Not applicable - observational study|observation only
214270903|NCT05812456|OTHER|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
214270904|NCT02074644|PROCEDURE|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
214270905|NCT02074644|PROCEDURE|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
214270906|NCT03243071|BEHAVIORAL|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
214270907|NCT03243071|BEHAVIORAL|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
214270908|NCT03268902|DRUG|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
214270909|NCT03268902|DRUG|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
214270910|NCT03268902|DIETARY_SUPPLEMENT|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
214270911|NCT03268902|DRUG|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
214270912|NCT03097094|DIAGNOSTIC_TEST|Male dog|Male dog extract
214270913|NCT03097094|DIAGNOSTIC_TEST|Female dog|Female dog extract
214270914|NCT05191524|OTHER|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
214270915|NCT05191524|OTHER|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
214270916|NCT04034485|DRUG|lerodalcibep|PCSK9 inhibitor
214270917|NCT04034485|DRUG|evolocumab|PCSK9 inhibitor
214270918|NCT05144360|DRUG|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
214270919|NCT05144360|DRUG|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
214270920|NCT05055362|OTHER|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
214270921|NCT01871532|DRUG|Gonal-f®|
214270922|NCT00283400|DRUG|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
214270923|NCT05777590|DRUG|Indocyanine Green Angiogram|Angiogram using ICG dye the occurs directly after conventional angiogram in assessment of frostbite patients undergoing thrombolysis
214270924|NCT04010149|DEVICE|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
214270925|NCT04010149|DEVICE|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
214270926|NCT01728064|DRUG|Placebo|Placebo capsules
214270927|NCT01728064|DRUG|EPI-743 400 mg|
214270928|NCT01728064|DRUG|EPI-743 200 mg|
214270929|NCT04171778|OTHER|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
214270930|NCT03920033|RADIATION|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
214270931|NCT04401423|DRUG|TXA127|0.5 mg/kg per day
214270932|NCT04401423|DRUG|Placebo|0.5 mg/kg per day
214270933|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
214270934|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
214270935|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
214270936|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
214270937|NCT00347568|DEVICE|TX-plore|PI has terminated at institution and there is no one available to report.
214270938|NCT04669132|DRUG|Olanzapine|\- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
214270939|NCT04669132|DRUG|Netupitant|\- Netupitanto 300 mg, once daily, on chemotherapy day;
214270940|NCT04669132|DRUG|Palonesetron|\- Palonosetron 0.56 mg, once daily, on chemotherapy day;
214270941|NCT01337700|DRUG|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
214270942|NCT01337700|DRUG|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
214270943|NCT06127680|BEHAVIORAL|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
214270944|NCT05051371|DEVICE|Train of four monitoring|Train of four monitoring in postoperative care unit
214270945|NCT06477081|PROCEDURE|FS-LASIK procedure|For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion o
214270946|NCT06477081|PROCEDURE|KLEx|For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complete
214270947|NCT03546660|DEVICE|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
214270948|NCT02034669|DEVICE|Laminectomy|surgical laminectomy with glial scar resection
214270949|NCT02034669|DEVICE|Intradural space|ADSCs injection into Intradural space at damage site
214270950|NCT02034669|DEVICE|Intrathecal|ADSCs Intrathecal into lumbar puncture
214270951|NCT02034669|DEVICE|Intravenous|ADSCs intravenous
214270952|NCT02265068|DRUG|Ticagrelor|Treatment of ACS patients with Ticagrelor
214270953|NCT00764283|DEVICE|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
214270954|NCT00764283|DEVICE|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
214270955|NCT00764283|DEVICE|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
214270956|NCT02161081|PROCEDURE|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
214270957|NCT02794038|DEVICE|Soberlink Cellular Device|BAC breath analyzer
214270958|NCT02794038|DEVICE|BACtrack S80 Pro|BAC breath analyzer
214270959|NCT04602988|DEVICE|EEG|EEG monitoring of brain rhythms
214270960|NCT02314702|DEVICE|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
214270961|NCT00653744|DRUG|Rosuvastatin|
214270962|NCT00653744|DRUG|Atorvastatin|
214270963|NCT00401596|DRUG|Xolair (omalizumab)|
214270964|NCT06312605|PROCEDURE|Injectable applied vitamin C|Surgical gingival depigmentation is done for all participants, after then they receive injectable vitamin C
214270965|NCT06312605|PROCEDURE|Topical applied Vitamin C|Surgical gingival depigmentation is done for all participants, after then they are instructed to apply topical vitamin C
214270966|NCT06312605|PROCEDURE|Surgical depigmentation only|Surgical gingival depigmentation only without any drug
214270967|NCT00522197|DIETARY_SUPPLEMENT|multi-herbal agent ACAPHA|
214270968|NCT00522197|DIETARY_SUPPLEMENT|Sugar Pill|
214270969|NCT01631981|DRUG|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
214270970|NCT01631981|DRUG|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
214270971|NCT01816282|DRUG|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
214270972|NCT05092724|PROCEDURE|fetal blood transfusion|transfusion of fetal blood
214270973|NCT04645875|OTHER|Sit regimen|See Sit regimen arm description
214270974|NCT04645875|OTHER|SitLess regimen|See SitLess regimen arm description
214270975|NCT03399721|DEVICE|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
214270976|NCT03399721|DEVICE|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
214270977|NCT05453604|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
214270978|NCT00064337|BIOLOGICAL|filgrastim|
214270979|NCT00064337|DRUG|cyclophosphamide|
214270980|NCT00064337|DRUG|dexamethasone|
214270981|NCT00064337|DRUG|melphalan|
214270982|NCT00064337|DRUG|thalidomide|
214270983|NCT00064337|PROCEDURE|peripheral blood stem cell transplantation|
214270984|NCT05060302|OTHER|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
214270985|NCT04112056|DIETARY_SUPPLEMENT|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
214270986|NCT05733780|DRUG|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
214270987|NCT02279420|DEVICE|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
214270988|NCT03423381|OTHER|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
214270989|NCT03423381|OTHER|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
214270990|NCT03423381|OTHER|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
214270991|NCT03423381|OTHER|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
214270992|NCT03423381|OTHER|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
214270993|NCT03423381|OTHER|Control product|A cereal based product with low concentrations of df
214270994|NCT02066805|DRUG|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
214270995|NCT01948947|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
214270996|NCT01948947|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
214270997|NCT06959641|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214270998|NCT06959641|PROCEDURE|Computed Tomography|Undergo CT scan
214270999|NCT06959641|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214271000|NCT06959641|OTHER|Survey Administration|Ancillary studies
214271001|NCT06959641|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214271002|NCT06959641|DRUG|Zanzalintinib|Given PO
214271003|NCT03028246|DEVICE|ExAblate 4000 System|Focused ultrasound
214271004|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
214271005|NCT00565786|DEVICE|ArCom® Polyethylene|Argon packaged compression molded polyethylene
214271006|NCT00565786|DEVICE|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
214271007|NCT04178564|BEHAVIORAL|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
214271008|NCT04525378|OTHER|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
214271009|NCT02069717|OTHER|Not applicable-observational study|
214271010|NCT05096221|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
214271011|NCT05096221|GENETIC|placebo|Single IV infusion of matching placebo.
214271012|NCT00236587|DRUG|risperidone|
214271013|NCT04096729|OTHER|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
214271014|NCT05238402|DRUG|Statin|Statin on COVID 19 patienst
214271015|NCT06395714|OTHER|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation."
214271016|NCT06395714|OTHER|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy"
214271017|NCT00030290|PROCEDURE|high-intensity focused ultrasound ablation|
214271018|NCT06273085|BEHAVIORAL|Patient education|3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
214271019|NCT00767962|OTHER|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
214271020|NCT00767962|OTHER|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
214271021|NCT05781620|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
214271022|NCT05781620|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
214271023|NCT00092989|DRUG|montelukast sodium|Duration of Treatment: 1 dose
214271024|NCT00092989|DRUG|placebo|Duration of Treatment: 1 dose
214271025|NCT02222740|DRUG|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
214271026|NCT02222740|DRUG|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
214271027|NCT03365492|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
214271028|NCT03800329|DEVICE|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
214271029|NCT03800329|OTHER|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
214271030|NCT06505174|OTHER|Hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
214271031|NCT00560781|DRUG|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
214271032|NCT02785120|DRUG|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
214271033|NCT01896102|GENETIC|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
214271034|NCT01459471|PROCEDURE|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
214271035|NCT04564261|BEHAVIORAL|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
214271036|NCT04564261|BEHAVIORAL|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
214271037|NCT01725503|DIETARY_SUPPLEMENT|Creatine and Amino Acid supplement|
214271038|NCT01502930|BEHAVIORAL|IRT|Internet-based IRT with therapist support during 6 weeks
214271039|NCT01502930|BEHAVIORAL|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
214271040|NCT04253444|BEHAVIORAL|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
214271041|NCT04253444|BEHAVIORAL|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
214271042|NCT04609371|BEHAVIORAL|self-care tools|self-care tools only
214271043|NCT04609371|BEHAVIORAL|lay telephone coaching|coaching
214271044|NCT03719612|DRUG|DEFINITY®|All subjects will receive a single dose of DEFINITY®
214271045|NCT00985023|PROCEDURE|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
214271046|NCT00985023|PROCEDURE|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
214271047|NCT01953107|OTHER|Oral Ferrous Fumarate|
214271048|NCT01953107|OTHER|Placebo|
214271049|NCT05091047|DEVICE|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
214271050|NCT00727636|BIOLOGICAL|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
214271051|NCT05253638|DIAGNOSTIC_TEST|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
214271052|NCT00900237|DRUG|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
214271053|NCT00900237|DRUG|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
214271054|NCT04152473|DRUG|Proglumide|oral CCK receptor antagonist
214271055|NCT05111873|OTHER|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
214271056|NCT03339908|DEVICE|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
214271057|NCT00197639|DRUG|Ritonavir-boosted indinavir|
214271058|NCT02437266|OTHER|Scapular mobilization|
214271059|NCT05113758|DIAGNOSTIC_TEST|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
214271060|NCT04646837|DRUG|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
214271061|NCT04646837|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
214271062|NCT04646837|DRUG|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
214271063|NCT06318169|BIOLOGICAL|Pegozafermin|Subcutaneous injection
214271064|NCT06318169|OTHER|Placebo|Subcutaneous injection
214271065|NCT00268788|DRUG|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
214271066|NCT00268788|DRUG|Intravenous immunoglobulin|Individual dose and frequency
214829324|NCT03416049|DEVICE|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
214271067|NCT06455176|PROCEDURE|alveolar cleft Grafting from the symphysis|grafting using particulate bone from the symphysis
214271068|NCT06455176|PROCEDURE|alveolar cleft Grafting from the iliac cancellous bone|grafting using iliac cancellous bone
214271069|NCT02834260|DRUG|Dexamethasone implant OZURDEX|
214271070|NCT04603456|DRUG|Lacteol fort|Lacteol fort is a drug containing lactobacilli
214271071|NCT04603456|DRUG|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
214271072|NCT04603456|DRUG|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
214271073|NCT05596760|BEHAVIORAL|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
214271074|NCT03500354|DIETARY_SUPPLEMENT|Nutrient drink|High calorie drink with therapeutic supplements
214271075|NCT04461210|DIAGNOSTIC_TEST|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
214271076|NCT05123729|BEHAVIORAL|Crowdsourced campaign package|Disease prevention intervention developed using a crowdsourcing process.
214271077|NCT05123729|BEHAVIORAL|Rapid Response Teams|Pilot a new hybrid training focused on contact tracing and case investigation.
214271078|NCT06321393|OTHER|7-week Core stabilization exercise with abdominal drawing-in maneuver technique|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consists of 2 stages, including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-minute sessions with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly video call with the main researcher as a telerehabilitation program.
214271079|NCT03891953|DRUG|DKY709|Novel immunomodulatory agent
214271080|NCT03891953|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
214271081|NCT05870124|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
214829325|NCT04921696|OTHER|RBC transfusion|RBC was transfused to the infants.
214829326|NCT04921696|OTHER|no-RBC transfusion|RBC was not transfused to the infants.
214829327|NCT04738968|DEVICE|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
214829328|NCT01969760|BEHAVIORAL|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
214829329|NCT00913276|DRUG|Propofol|
214829330|NCT00913276|DRUG|Sevoflurane|
214271082|NCT05870124|OTHER|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
214271083|NCT04464759|DRUG|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
214271084|NCT04464759|DRUG|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
214271085|NCT04464759|DRUG|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
214271086|NCT06114667|DEVICE|Ventilatory support via nasal high flow|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
214271087|NCT06114667|DEVICE|Ventilatory support via NIV|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
214271088|NCT03908177|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
214271089|NCT03908177|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
214271090|NCT02230553|DRUG|Lapatinib|
214271091|NCT02230553|DRUG|trametinib|
214271092|NCT04893707|BIOLOGICAL|CM310|"adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
214271093|NCT02100904|PROCEDURE|Radiofrequency ablation of fibroids|
214271094|NCT02100904|PROCEDURE|Myomectomy of fibroids|
214271095|NCT05023629|OTHER|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
214271096|NCT00550121|DRUG|vitamin C|
214271097|NCT00550121|DRUG|placebo|
214271098|NCT02891694|OTHER|in vitro immuno-histo-chemical analysis of corneal epithelium|
214271099|NCT04633733|DRUG|HL237 tablet|HL237 400mg will be administered orally twice a day.
214271100|NCT04633733|DRUG|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
214271101|NCT01554683|DRUG|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
214271102|NCT00411528|DRUG|Patupilone|
214271103|NCT00411528|DRUG|prednisone|
214271104|NCT00411528|DRUG|docetaxel|
214271105|NCT01212458|DRUG|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
214271106|NCT02424760|DEVICE|Shoulder hemi-arthroplasty|
214271107|NCT04515394|DRUG|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
214271108|NCT04515394|BIOLOGICAL|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
214271109|NCT01284101|DEVICE|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
214271110|NCT01284101|DEVICE|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
214271111|NCT01685944|DIETARY_SUPPLEMENT|Live Pediococcus pentosaceus LP28|
214271112|NCT01685944|DIETARY_SUPPLEMENT|Heat-killed Pediococcus pentosaceus LP28|
214271113|NCT01685944|DIETARY_SUPPLEMENT|Placebo|
214271114|NCT03725137|OTHER|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
214271115|NCT01972100|DEVICE|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
214829331|NCT03622229|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
214829332|NCT05270044|DRUG|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
214271116|NCT01972100|OTHER|isokinetic exercise|
214271117|NCT01972100|DEVICE|Placebo low-level laser therapy|
214271118|NCT04067882|OTHER|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
214271119|NCT00479193|DRUG|bacitracin/xeroform|single layer, change every 3 days
214271120|NCT00479193|DRUG|Polymem|single layer of Polymen, change every 3 days
214271121|NCT00318123|DRUG|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
214271122|NCT01116115|OTHER|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
214271123|NCT01116115|OTHER|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
214271124|NCT00163839|BEHAVIORAL|Dietary Therapy|
214271125|NCT00999232|DRUG|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
214271126|NCT00999232|DRUG|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
214271127|NCT03223142|DEVICE|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
214271128|NCT01517620|DRUG|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
214271129|NCT03330288|DRUG|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
214271130|NCT02581787|BIOLOGICAL|Fresolimumab|Given IV
214271131|NCT02581787|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
214271132|NCT06458192|BEHAVIORAL|Adaptive Messaging Intervention|The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
214271133|NCT06458192|BEHAVIORAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
214271134|NCT06458192|BEHAVIORAL|Psychoeducation-Only Control|An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
214271135|NCT02432482|BEHAVIORAL|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
214271136|NCT02432482|BEHAVIORAL|Standard care|Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
214271137|NCT00381550|DRUG|fludarabine phosphate|Given IV
214271138|NCT00381550|DRUG|triapine|Given IV
214271139|NCT00381550|PROCEDURE|laboratory biomarker analysis|Correlative study
214271140|NCT00809393|DRUG|tranexamic acid|10 mg/kg
214271141|NCT00809393|DRUG|tranexamic acid|30 mg/kg
214271142|NCT03217630|OTHER|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
214829333|NCT05270044|DRUG|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
214271143|NCT04068870|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
214271144|NCT02035930|DRUG|dexmedetomidine|
214271145|NCT00714441|BEHAVIORAL|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
214271146|NCT00714441|BEHAVIORAL|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
214271147|NCT00714441|BEHAVIORAL|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
214271148|NCT02284516|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
214271149|NCT02284516|DRUG|Placebo|Placebo to match active treatment, BID for 84 days
214271150|NCT04058730|PROCEDURE|Laparoscopic Roux en Y Gastric by pass surgery|
214271151|NCT04058730|PROCEDURE|Laparoscopic Sleeve Surgery|
214271152|NCT04058730|OTHER|Standard Medical Management|
214271153|NCT06396325|OTHER|Tales from the Magic Keep™|Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services
214829334|NCT00481169|DRUG|Bazedoxifene Acetate (TSE-424)|
214829335|NCT02985749|DRUG|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
214829336|NCT03735706|RADIATION|Radiation dose reduction|The radiation dose is is different between groups
214271154|NCT06396325|OTHER|Usual Care|Continue with regularly accessed physical activities and rehabilitation services
214271155|NCT04971707|OTHER|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
214271156|NCT04971707|OTHER|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
214271157|NCT06480773|DRUG|standard of care chemotherapy|intravenous Paclitaxel or the combination of Bleomycin and Vincristine.
214271158|NCT03890315|DIAGNOSTIC_TEST|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
214271159|NCT04197531|OTHER|Irrigation Method|Irrigation Method
214271160|NCT00222560|BEHAVIORAL|Intensive physical activity counselling by an integrated physical activity counsellor|
214271161|NCT00004307|BEHAVIORAL|Protein and calorie controlled diet|
214271162|NCT00004307|GENETIC|Ornithine transcarbamylase vector|
214271163|NCT02758704|OTHER|High stress|Generation of a stressful environment during a neonatal intubation procedure.
214271164|NCT02758704|OTHER|Low stress|Absence of stressful stimuli during neonatal intubation procedure
214271165|NCT02758704|OTHER|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
214271166|NCT05613400|DRUG|Simvastatin 10mg|One simvastatin 10mg-tablet
214271167|NCT05613400|DRUG|Ezetimibe 10mg|One ezetimibe 10mg-tablet
214271168|NCT04736082|OTHER|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
214271169|NCT04736082|OTHER|Control Group: Infant Formula with intact protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
214271170|NCT04328766|DRUG|DWC202005, alone|DWC202005, as a single dose
214271171|NCT04328766|DRUG|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
214271172|NCT04328766|DRUG|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
214271173|NCT06043726|DIAGNOSTIC_TEST|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
214271174|NCT02434978|DEVICE|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
214271175|NCT02434978|DRUG|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
214271176|NCT02434978|OTHER|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
214271177|NCT06556771|OTHER|Gongs mobilization + conventional physical therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
214271178|NCT06556771|OTHER|Kaltenborn mobilization along with traction + conventional therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
214271179|NCT06557993|OTHER|Serratus Posterior Superior Intercostal Plane Block|The serratus posterior superior muscle is located deep to the rhomboid major and minor. Ligamentum nuchae starts from the processus spinosus of C7-T3 vertebrae and extends to the 2nd-5th. In the ribs, the angulus ends at the upper edge of the rib. Serratus posterior superior -intercostal plane block (SPSİPB) is a newly defined block, and C7-T7 spread has been shown in cadaver studies
214829337|NCT03735706|OTHER|Contrast media volume reduction|Contrast media volume is different between groups
214829338|NCT03735706|RADIATION|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
214271180|NCT04925908|DIAGNOSTIC_TEST|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
214829339|NCT03735706|DIAGNOSTIC_TEST|Weight|A weighing scale is used to measure a patients body weight right before the scan.
214271181|NCT04044495|OTHER|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
214271182|NCT04044495|OTHER|Actimetry|7 days actimetry
214271183|NCT04044495|OTHER|Sleep Diary|7 days Record of sleep and wake cycle
214829340|NCT00686868|OTHER|placebo|placebo
214829341|NCT00686868|DRUG|ofatumumab|fully human anti-CD20 monoclonal antibody
214829342|NCT04097444|BIOLOGICAL|Bevacizumab|Given IV
214829343|NCT04097444|DRUG|5-fluorouracil|Given IV
214829344|NCT04097444|DRUG|Leucovorin calcium|Given IV
214829345|NCT04097444|DRUG|Irinotecan hydrochloride|Given IV
214829346|NCT04097444|DRUG|Oxaliplatin|Given IV
214271184|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
214271185|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
214271186|NCT03041987|OTHER|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
214271187|NCT03882112|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
214271188|NCT03395392|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
214271189|NCT03395392|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
214829347|NCT04097444|DRUG|Capecitabine|Given PO
214271190|NCT01050283|PROCEDURE|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
214271191|NCT00940160|DRUG|QAX576|
214271192|NCT00940160|DRUG|QAX576|
214271193|NCT00940160|DRUG|QAX576|
214271194|NCT00940160|DRUG|Placebo|
214271195|NCT03315546|RADIATION|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
214271196|NCT01254331|DRUG|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
214271197|NCT02494674|BEHAVIORAL|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
214271198|NCT01500889|PROCEDURE|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
214271199|NCT01500889|PROCEDURE|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
214271200|NCT01500889|PROCEDURE|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
214271201|NCT00002532|BIOLOGICAL|filgrastim|
214271202|NCT00002532|DRUG|asparaginase|
214271203|NCT00002532|DRUG|cytarabine|
214271204|NCT00002532|DRUG|daunorubicin hydrochloride|
214271205|NCT00002532|DRUG|dexamethasone|
214271206|NCT00002532|DRUG|etoposide|
214271207|NCT00002532|DRUG|idarubicin|
214271208|NCT00002532|DRUG|ifosfamide|
214271209|NCT00002532|DRUG|leucovorin calcium|
214271210|NCT00002532|DRUG|methotrexate|
214271211|NCT00002532|DRUG|prednisolone|
214271212|NCT00002532|DRUG|vindesine|
214271213|NCT05642767|DIAGNOSTIC_TEST|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
214271214|NCT05642767|DIAGNOSTIC_TEST|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
214271215|NCT05642767|DIAGNOSTIC_TEST|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
214271216|NCT05642767|DIAGNOSTIC_TEST|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
214271217|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
214271218|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
214271219|NCT02910115|OTHER|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
214271220|NCT02910115|DRUG|Pitocin|Pitocin is administered intravenously according to the usual protocol.
214271221|NCT00406965|DRUG|HAE1 (PRO98498)|
214271222|NCT06372301|DIAGNOSTIC_TEST|Dobutamine stress echocardiography|Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
214271223|NCT01014000|DEVICE|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
214271224|NCT01014000|DEVICE|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
214271225|NCT02211222|DRUG|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
214271226|NCT02258425|BEHAVIORAL|FEM-CARE|
214271227|NCT02258425|BEHAVIORAL|Health Promotion|
214271228|NCT04971421|DIAGNOSTIC_TEST|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
214271229|NCT04971421|DIAGNOSTIC_TEST|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
214271230|NCT05943028|DRUG|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
214271231|NCT01443078|DRUG|pemetrexed|
214271232|NCT01443078|DRUG|cisplatin|
214271233|NCT01443078|DRUG|Carboplatin|
214271234|NCT01443078|DRUG|Gemcitabine Hydrochloride|
214271235|NCT01443078|DRUG|Vinorelbine Tartrate|
214271236|NCT01443078|DRUG|Docetaxel|
214271237|NCT04257734|OTHER|observation|different serum antibodies status
214271238|NCT06136078|OTHER|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
214271239|NCT05915221|PROCEDURE|SMS|Receive SMS
214271240|NCT03181035|RADIATION|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
214271241|NCT03181035|DRUG|Pimonidazole|oral pimonidazole hypoxia labeling
214271242|NCT01809106|DRUG|Morphine|60 mg /24 ore
214271243|NCT01809106|DRUG|Fentanyl|25 microg/h
214271244|NCT01809106|DRUG|Buprenorphine|35 microg/h
214271245|NCT01809106|DRUG|Oxycodone|40 mg /24 ore
214271246|NCT01706978|PROCEDURE|Bone Trephination|
214271247|NCT01706978|PROCEDURE|Soft Tissue Trephination|
214271248|NCT05616975|OTHER|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
214271249|NCT05616975|OTHER|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
214271250|NCT05616975|OTHER|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
214271251|NCT01626430|DIETARY_SUPPLEMENT|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
214271252|NCT01626430|DIETARY_SUPPLEMENT|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
214271253|NCT02233114|OTHER|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
214271254|NCT02233114|OTHER|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
214271255|NCT02206074|DIETARY_SUPPLEMENT|Beetroot|
214271256|NCT02467075|DRUG|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
214271257|NCT02467075|DRUG|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
214271258|NCT01272973|DRUG|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
214271259|NCT01272973|DRUG|placebo|Placebo (oral) administered once daily for 10 weeks.
214271260|NCT01272973|DRUG|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
214271261|NCT00834223|DEVICE|Aquashunt|A shunt which is implanted into the suprachoroidal space.
214271262|NCT02204956|BEHAVIORAL|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
214271263|NCT02204956|BEHAVIORAL|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
214271264|NCT00141843|GENETIC|ReFacto AF|
214271265|NCT00141843|GENETIC|B-Domain deleted Recombinant Factor VIII|
214271266|NCT00141843|GENETIC|BDDrFVIII|
214271267|NCT03757156|OTHER|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
214271268|NCT06071208|DRUG|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
214271269|NCT03580993|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
214271270|NCT02962388|DRUG|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
214271271|NCT02962388|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
214271272|NCT02962388|DRUG|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
214271273|NCT02583126|BEHAVIORAL|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
214271274|NCT05675176|DRUG|BCG|Intravesical Instillation
214271275|NCT00807170|DRUG|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
214271276|NCT00807170|RADIATION|Whole Brain Radiotherapy (WBRT)|
214271277|NCT00807170|DRUG|ZD6474|200 mg as a once daily oral dose, 21 days
214271278|NCT00807170|DRUG|ZD6474|300 mg as a once daily oral dose, 21 days
214271279|NCT06015464|DRUG|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
214271280|NCT05193370|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
214271281|NCT05193370|DRUG|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
214271282|NCT06154187|DRUG|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
214271283|NCT06154187|DRUG|Placebo|Placebo was formulated similar to abaloparatide-SC.
214271284|NCT05964101|DRUG|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
214271285|NCT03410329|OTHER|Resistance training|Physical activity
214271286|NCT06050148|BIOLOGICAL|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
214271287|NCT06050148|OTHER|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
214271288|NCT01204554|DRUG|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
214271289|NCT05719376|DRUG|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
214271290|NCT05719376|DRUG|control group|Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
214271291|NCT04628741|BEHAVIORAL|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
214271292|NCT04628741|BEHAVIORAL|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
214271293|NCT01323959|BIOLOGICAL|BoostrixTM Polio|Single dose, intramuscular administration.
214271294|NCT01215565|DRUG|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
214271295|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
214271296|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
214271297|NCT02993757|BIOLOGICAL|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
214271298|NCT02500160|DEVICE|Patient specific instrumentation (MRI)|
214271299|NCT02500160|DEVICE|Patient specific instrumentation (CT)|
214271300|NCT05708170|DRUG|Ferinject|"Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject)."
214271301|NCT05708170|DRUG|Ferrous Sulfate 200 MG|Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
214271302|NCT00099541|DRUG|zoledronic acid|
214271303|NCT00746083|BEHAVIORAL|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
214271304|NCT05216783|BEHAVIORAL|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
214271305|NCT02762578|DRUG|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
214271306|NCT02762578|DRUG|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
214271307|NCT03948672|DEVICE|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
214271308|NCT00828412|DEVICE|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
214271309|NCT00828412|DRUG|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
214271310|NCT02886832|DIETARY_SUPPLEMENT|Prostate Health formulation|
214271311|NCT00285233|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
214271312|NCT00249860|DRUG|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
214271313|NCT00249860|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
214271314|NCT00249860|DRUG|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
214271315|NCT03726944|BEHAVIORAL|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
214829348|NCT05315791|PROCEDURE|different methods for maxillary sinus floor elevation|a: 0\~3mm+ground into pieces; b: 0\~3mm+replace the bone; c: 0\~3mm+turn inward to hold up the membrane; d: 3\~5mm+ground into pieces; e: 3\~5mm+replace the bone; f: 3\~5mm+turn inward to hold up the membrane
214271316|NCT03726944|BEHAVIORAL|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
214271317|NCT03726944|OTHER|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
214271318|NCT00259610|DRUG|methotrexate|varies
214271319|NCT00259610|DRUG|sulfasalazine|varies
214271320|NCT00259610|DRUG|hydroxychloroquine|varies
214271321|NCT00259610|DRUG|etanercept|varies
214271322|NCT06220565|DEVICE|"sensor and wearable device Graded Exercise"|"The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management."
214271323|NCT06220565|OTHER|exercise|exercise
214271324|NCT06220565|OTHER|Educational Manual|Educational Manual
214829349|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
214829350|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
214829351|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
214271325|NCT04456257|DEVICE|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
214271326|NCT02236403|DRUG|Ivermectin 0.1% Metronidazole 1%|
214271327|NCT02236403|OTHER|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
214271328|NCT02028754|DRUG|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
214271329|NCT02028754|DRUG|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
214271330|NCT02028754|DRUG|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
214271331|NCT01766596|PROCEDURE|Optical Coherence Tomography|
214271332|NCT04841538|DRUG|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
214271333|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
214271334|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
214271335|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
214271336|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
214271337|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
214271338|NCT00268359|BIOLOGICAL|bevacizumab|
214271339|NCT00268359|DRUG|irinotecan hydrochloride|
214271340|NCT00731627|DRUG|placebo|one tablet a day for up to 21 days
214271341|NCT00731627|DRUG|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
214271342|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
214271343|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
214271344|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
214271345|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
214271346|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
214271347|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
214271348|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
214271349|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
214271350|NCT03538002|DEVICE|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
214271351|NCT01768286|DRUG|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
214271352|NCT01768286|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214271353|NCT00002711|DRUG|chemotherapy|
214271354|NCT00002711|DRUG|cisplatin|
214271355|NCT00002711|DRUG|paclitaxel|
214271356|NCT00002711|RADIATION|low-LET electron therapy|
214271357|NCT00002711|RADIATION|low-LET photon therapy|
214271358|NCT04716907|GENETIC|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
214271359|NCT04716907|BIOLOGICAL|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
214271360|NCT04716907|DIAGNOSTIC_TEST|CT Scan|Thymus and lung imaging
214271361|NCT04716907|BIOLOGICAL|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
214271362|NCT01602120|DRUG|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
214271363|NCT01611155|DRUG|venlafaxine|Given PO
214271364|NCT01611155|DRUG|placebo|Given PO
214271365|NCT01611155|OTHER|questionnaire administration|Ancillary studies
214271366|NCT01611155|OTHER|quality-of-life assessment|Ancillary studies
214829352|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
214271367|NCT00929383|DEVICE|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
214271368|NCT05345977|DEVICE|eMotiph|Mobile application for patients with schizophrenia.
214271369|NCT04276571|DEVICE|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
214271370|NCT05615168|DIAGNOSTIC_TEST|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
214271371|NCT05615168|DIAGNOSTIC_TEST|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
214271372|NCT05552521|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
214271373|NCT02699593|DEVICE|Test Contact Lens|
214271374|NCT02699593|DEVICE|Control Contact Lens|
214271375|NCT00911547|DRUG|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
214271376|NCT00911547|DRUG|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
214271377|NCT00911547|DRUG|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
214271378|NCT00911547|DRUG|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
214271379|NCT04530526|PROCEDURE|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
214271380|NCT05412303|OTHER|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
214271381|NCT00034541|BIOLOGICAL|cetuximab|400 mg/m2 i.v. over 120 minutes
214271382|NCT00034541|DRUG|paclitaxel|225 mg/m2, infusion
214271383|NCT00034541|DRUG|carboplatin|30-minute AUC = 6, infusion.
214271384|NCT05230420|OTHER|Clamping|Clamping of chest tube
214271385|NCT05230420|OTHER|Urine bag|Attachment of a urine bag to chest tube
214271386|NCT00113503|DRUG|Azathioprine weight-based dose|
214271387|NCT00113503|DRUG|Azathioprine individualised dose|
214271388|NCT00324610|DRUG|capecitabine|
214271389|NCT01374841|DRUG|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
214271390|NCT01374841|OTHER|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
214271391|NCT03691181|DEVICE|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
214271392|NCT00004762|DRUG|cladribine|
214271393|NCT05489744|DRUG|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
214271394|NCT03531931|DRUG|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
214271395|NCT04903444|DEVICE|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
214271396|NCT02116946|BIOLOGICAL|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
214829353|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
214271397|NCT02116946|OTHER|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
214271398|NCT03947801|OTHER|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
214271399|NCT03947801|OTHER|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
214271402|NCT00915278|DRUG|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
214271403|NCT04629807|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
214271404|NCT04872582|DRUG|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
214271405|NCT04719286|DEVICE|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
214271406|NCT04074031|DEVICE|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
214271407|NCT02449252|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
214271408|NCT02449252|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
214271409|NCT02449252|DRUG|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
214271410|NCT02449252|DRUG|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
214271411|NCT02449252|DRUG|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
214271412|NCT02449252|DRUG|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
214271413|NCT02721485|OTHER|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
214271414|NCT02721485|OTHER|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
214271415|NCT01995110|OTHER|high-fat meal A|
214271416|NCT01995110|OTHER|high-fat meal B|
214271417|NCT01995110|OTHER|high-fat meal C|
214271418|NCT02045810|DRUG|Levobupivacaine|
214271419|NCT02045810|DRUG|Saline|
214271420|NCT01468883|PROCEDURE|M|Modified radical mastectomy
214271421|NCT01468883|RADIATION|X|Excisional biopsy plus radiation
214271422|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
214271423|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
214271424|NCT02264561|OTHER|Food|Active group
214271425|NCT02264561|OTHER|Food|Control group
214271426|NCT00335361|DEVICE|Intra Vas Device (IVD)|
214271427|NCT03221283|BEHAVIORAL|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
214271428|NCT02552875|OTHER|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
214271429|NCT02552875|OTHER|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
214271430|NCT04601415|DIAGNOSTIC_TEST|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
214271431|NCT00241943|PROCEDURE|Hepatitis C educational video|
214271432|NCT04586907|DRUG|LY3537021|Administered SC.
214271433|NCT04586907|DRUG|Placebo|Administered SC.
214271434|NCT06400303|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
214271435|NCT06400303|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
214271436|NCT04431180|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
214271437|NCT02168361|DRUG|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
214271438|NCT02168361|DRUG|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
214271439|NCT02168361|DRUG|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
214271440|NCT02168361|DRUG|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
214271441|NCT01593657|OTHER|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
214271442|NCT01593657|OTHER|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
214271443|NCT01593657|PROCEDURE|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
214271444|NCT01593657|PROCEDURE|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
214271445|NCT05822661|DIETARY_SUPPLEMENT|Black Seed Oil|Dietary supplement
214271446|NCT05822661|DIETARY_SUPPLEMENT|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
214271447|NCT02428517|PROCEDURE|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
214271448|NCT02428517|PROCEDURE|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
214271449|NCT02428517|PROCEDURE|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
214271450|NCT02428517|PROCEDURE|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
214271451|NCT05492214|PROCEDURE|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
214271452|NCT05492214|PROCEDURE|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
214271453|NCT05492214|PROCEDURE|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
214271454|NCT05693389|BEHAVIORAL|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
214271455|NCT05693389|OTHER|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
214271456|NCT02543580|OTHER|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
214271457|NCT02543580|OTHER|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
214271458|NCT00048321|DRUG|ISIS 104838|
214271459|NCT02706184|DRUG|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
214271460|NCT02706184|DRUG|Placebo|Placebo
214271461|NCT02951065|OTHER|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
214271462|NCT02951065|OTHER|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
214271463|NCT00032409|BEHAVIORAL|Music therapy-based relaxation/stress reduction|
214829354|NCT03318289|BEHAVIORAL|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
214271464|NCT01334164|BEHAVIORAL|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
214271465|NCT01334164|OTHER|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
214271466|NCT00491816|DRUG|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
214271467|NCT06217341|OTHER|In the study, bispectral index monitoring and follow-up will be applied to both groups.|Perioperative Bispectral Index Monitoring (BIS) monitor and Bispectral Index suppression Rate (BIS-SR) monitoring will be applied. The duration and magnitude of BIS-SR values will be examined together with BIS values in terms of recovery agitation.
214271468|NCT00965315|DRUG|Rosuvastatin,SFC fenofibrate|"1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
214271469|NCT04510584|DRUG|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
214829355|NCT03119662|DRUG|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
214271470|NCT04510584|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
214271471|NCT01199965|DRUG|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
214271472|NCT01199965|DRUG|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
214271473|NCT03805269|DRUG|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
214271474|NCT03805269|DRUG|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
214271475|NCT04275531|DRUG|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
214271476|NCT02179489|PROCEDURE|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
214271477|NCT01920321|PROCEDURE|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
214271478|NCT04035798|DRUG|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
214271479|NCT03593603|DEVICE|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
214271480|NCT00662246|RADIATION|respiratory gated proton beam radiotherapy|\- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
214271481|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
214271482|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
214271483|NCT05656495|DRUG|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
214271484|NCT06188533|OTHER|Urinary activin A in AKI|Urinary activin A in AKI patient
214271485|NCT03914482|DEVICE|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
214271486|NCT01443871|OTHER|Aromatherapy|Subject will assigned inhale aromatherapy
214271487|NCT01443871|OTHER|Pure water|Subject will assigned inhale Pure water
214271488|NCT02124525|DRUG|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
214271489|NCT00032123|DRUG|erlotinib hydrochloride|
214271490|NCT05020782|DRUG|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
214271491|NCT03011710|DEVICE|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
214271492|NCT03011710|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
214271493|NCT03011710|DEVICE|Cigarette tip|Placebo device
214271494|NCT01981980|OTHER|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
214271495|NCT01981980|OTHER|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
214271496|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
214271497|NCT01890369|DIETARY_SUPPLEMENT|3g Leucine|Dissolved in 250ml water.
214271498|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
214271499|NCT02530684|OTHER|insole|Insoles available on the market without prescription
214271500|NCT06509139|DRUG|Drug: Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
214271501|NCT06509139|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
214271502|NCT06509139|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
214271503|NCT06509139|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
214271504|NCT03006107|PROCEDURE|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
214271505|NCT03006107|PROCEDURE|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
214271506|NCT04456946|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy
214271507|NCT04456946|DEVICE|Occlusal Splint Treatment|Occlusal Splint Treatment
214271508|NCT01869517|OTHER|intrastromal corneal ring segments (Keraring) implantation|
214271509|NCT01869517|OTHER|Intrastromal corneal continuous ring (Myoring) implantation|
214271510|NCT00453063|DRUG|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
214271511|NCT00453063|DRUG|Placebo|Two sprays in each nostril once daily in the morning
214829356|NCT03119662|DRUG|Placebos|100 mL saline, followed by a 10 mL saline flush.
214829357|NCT00836862|OTHER|Biologic specimens|Banking of serum, DNA and tissue
214829358|NCT05434091|DRUG|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
214829359|NCT05434091|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
214829360|NCT05436626|PROCEDURE|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
214271512|NCT02732756|BEHAVIORAL|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
214271513|NCT02732756|BEHAVIORAL|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
214271514|NCT04720066|DIAGNOSTIC_TEST|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
214271515|NCT03013738|BEHAVIORAL|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
214271516|NCT03013738|OTHER|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
214271517|NCT05307146|DEVICE|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
214271518|NCT03890601|BIOLOGICAL|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
214271519|NCT03118713|DRUG|metformin|oral
214271520|NCT03118713|DRUG|ipragliflozin|oral
214271521|NCT03118713|DRUG|glimepiride|oral
214271522|NCT02798874|DRUG|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
214271523|NCT02798874|DRUG|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
214271524|NCT00228384|DEVICE|GORE VIABAHN Endoprosthesis|Implantation
214271525|NCT00228384|DEVICE|Bare Nitinol Stent|Implantation
214271526|NCT01906632|BIOLOGICAL|DC-CIK Immunotherapy|
214271527|NCT00384501|DEVICE|Intacs|
214271528|NCT02836093|BEHAVIORAL|FACIT-Fatigue 52-point questionnaire|
214271529|NCT05746793|PROCEDURE|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
214271530|NCT05746793|DIAGNOSTIC_TEST|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
214271531|NCT05746793|DIAGNOSTIC_TEST|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
214271532|NCT05746793|DIAGNOSTIC_TEST|Urine collection|Collection of urine in a plastic cup.
214271533|NCT05746793|OTHER|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
214271534|NCT05746793|DIAGNOSTIC_TEST|Baseline questionnaire|questionnaire the patient has to fill in
214271535|NCT05746793|OTHER|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
214271536|NCT05746793|DIAGNOSTIC_TEST|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
214271537|NCT05746793|DIAGNOSTIC_TEST|cardiac work-up|Using transthoracic ultrasound.
214271538|NCT05746793|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement
214271539|NCT03100500|DRUG|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
214271540|NCT02352974|DRUG|GAD-Alum|
214271541|NCT02352974|DRUG|Vitamin D|
214271542|NCT00388596|DRUG|SB-751689|
214271543|NCT04720469|DEVICE|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
214271544|NCT00227097|BEHAVIORAL|Education Notebook for anticoagulant treatment|
214271545|NCT02420340|BEHAVIORAL|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
214271546|NCT02151383|DRUG|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
214271547|NCT03438929|DEVICE|Diode laser|Diolaze XL blended modes diode laser
214271548|NCT03501290|DIETARY_SUPPLEMENT|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
214271549|NCT02099175|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
214271550|NCT02099175|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
214271551|NCT02099175|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
214271552|NCT02099175|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
214271553|NCT02099175|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
214271554|NCT02099175|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
214271555|NCT02099175|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
214271556|NCT02099175|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
214271557|NCT02099175|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
214271558|NCT02099175|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
214271559|NCT01785069|DEVICE|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
214271560|NCT01421914|OTHER|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
214271561|NCT00134238|DRUG|torcetrapib/atorvastatin|
214271562|NCT00134238|DRUG|atorvastatin|
214271563|NCT00004037|DRUG|docetaxel|
214271564|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
214271565|NCT04361318|COMBINATION_PRODUCT|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
214271566|NCT04361318|OTHER|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
214271567|NCT02015572|BEHAVIORAL|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
214271568|NCT02015572|OTHER|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
214271569|NCT01029834|BEHAVIORAL|family based lifestyle and behavioral counseling|16 group meetings
214271570|NCT01029834|BEHAVIORAL|counseling focused on the child|16 meetings
214271571|NCT00818480|DRUG|YM155|continuous infusion
214271572|NCT00570570|PROCEDURE|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
214271573|NCT00570570|OTHER|conventional physiotherapy|trice a week during 6 weeks
214271574|NCT06967935|OTHER|Cognitive memory task on a computer|"Encoding: (1) Participants will learn 60 associations between pairs of items (cue and target) that are presented sequentially at unique locations on a screen, in a given context. 30 pairs are presented once, and 30 pairs are presented repeatedly (4 times).~(2) After learning, the first recall phase begins after a short delay of 30 minutes: 50% of the pairs are tested in a similar way, this time with an assessment of contextual memory.~(3) The remaining 50% of pairs are tested after a 12-hour delay, involving either a day awake (condition 1) or a night asleep (condition 2)."
214271575|NCT06967935|OTHER|Eye tracking|Eye-tracking will be carried out during the task to ensure that participants are focused on the task (quantification of the number and duration of eye fixations in the area of interest corresponding to the target presentation)
214271576|NCT06967935|OTHER|Questionnaires on task-related fatigue|Questionnaire on task-related fatigue (Likert-scale) will be completed by participants between blocks of items during the task
214271577|NCT06967935|OTHER|Questionnaire on task difficulty|Questionnaires on task difficulty (Likert-scale) will be completed by participants at the end of the task
214271578|NCT06967935|OTHER|Karolinska scale|Participants' state of sleepiness will be assessed at the beginning of each stage (encoding, immediate recall, delayed recall) using the Karolinska sleepiness scale
214271579|NCT05868395|DRUG|Polatuzumab, bendamustin und rituximab|"* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~* Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle~* Rituximab 375 mg/m2 i.v. on day 1 of each cycle~* Each cycle is 21 days long~* Up to 6 cycles per patients planned"
214829361|NCT05436626|PROCEDURE|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
214271580|NCT05929131|OTHER|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
214271581|NCT05929131|OTHER|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
214271582|NCT05929131|OTHER|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
214271583|NCT05686031|OTHER|No interventions were done between groups|No interventions were done between groups
214271584|NCT00702195|DRUG|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
214271585|NCT00702195|DRUG|Placebo|single dose of placebo (administered under protocol 38805)
214271586|NCT00702195|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
214271587|NCT01067690|DRUG|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
214271588|NCT02041832|OTHER|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
214271589|NCT02041832|DEVICE|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
214271590|NCT00875992|DEVICE|ETN with ASLS|Angle stable locking of ETN using ASLS
214271591|NCT00875992|DEVICE|ETN locked with conventional locking bolts|Conventional surgical procedure
214271592|NCT05232175|DRUG|ALT-BB4|Recombinant Hyaluronidase
214271593|NCT05232175|DRUG|0.9%NaCl|Normal Saline
214271594|NCT06404645|DEVICE|Near-infrared spectroscopy detection|Cranial CT confirm intracranial haematoma. Then the near-infrared spectroscopy device to collect date by red sensor probe in the corresponding position on the scalp and blue sensor probe on the opposite side of the hematoma. Collect data for 10 minutes.
214271595|NCT03569618|DEVICE|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
214271596|NCT04742998|OTHER|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
214271597|NCT04614922|BEHAVIORAL|Acceptance and Commitment Therapy|ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.
214271598|NCT07044349|DRUG|Utidelone capsule 75mg/m2/d QD|75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214271599|NCT07044349|DRUG|Utidelone capsule 40mg/m2/d BID|40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214271600|NCT07044349|DRUG|Utidelone capsule 50mg/m2/d BID|50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214271601|NCT07044349|DRUG|Utidelone capsule 35mg/m2/d BID|35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214271602|NCT07047794|OTHER|Assessment|Children with thoracic hyperkyphosis between the ages of 7 and 14 who meet the inclusion criteria will be included in this study, which was conducted to examine the scapular position and its relationships with upper extremity joint range of motion, strength and performance in children with thoracic hyperkyphosis.
214829362|NCT05436626|PROCEDURE|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
214829363|NCT05963269|OTHER|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
214829364|NCT01682187|DRUG|LY2157299|Administered orally
214829365|NCT01682187|DRUG|Lomustine|Administered orally
214829366|NCT00031954|DRUG|carboplatin|
214829367|NCT00031954|DRUG|gemcitabine hydrochloride|
214829368|NCT00031954|DRUG|paclitaxel|
214829369|NCT05452213|DRUG|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
214829370|NCT02465892|BEHAVIORAL|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
214829371|NCT04956289|DRUG|Viltolarsen|Received during weekly intravenous infusions
214271609|NCT07049627|OTHER|Total Neoadjuvant Therapy (TNT)|Patients included in this retrospective cohort received total neoadjuvant therapy (TNT), consisting of systemic chemotherapy and radiotherapy, followed by curative-intent surgery. No experimental interventions were applied. The analysis focused on evaluating clinical, inflammatory, nutritional, and sarcopenia-based predictors of pathological response.
214271610|NCT07055386|DRUG|GZR102|Administered SC
214271611|NCT07055386|DRUG|GZR18|Administered SC
214271612|NCT07054762|DIETARY_SUPPLEMENT|omega-3 supplements in female athletes|Participants in the experimental group were given four capsules of omega-3 fatty acids with breakfast every day for 8 weeks. Each capsule contains 150 mg of omega-3 fatty acids and has a ratio of 60% EPA and 40% DHA. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end. In addition, anthropometric measurements, simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
214271613|NCT07054762|DIETARY_SUPPLEMENT|Placebo Group|Participants in the control group were given a placebo containing maltodextrin with breakfast every day for 8 weeks. Each capsule contains 250 mg maltodextrin. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end of the study. Additionally, anthropometric measurements, a simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
214271614|NCT07054164|OTHER|dual-task aerobic exercise|In addition to aerobic training during treadmill walks, participants were given some cognitive tasks and were asked to continue these tasks throughout the exercise.
214271615|NCT07054164|OTHER|aerobic exercise|Aerobic training with a treadmill at medium-high intensity, 3 days a week, for 8 weeks, accompanied by a physiotherapist
214271616|NCT07054424|OTHER|Conventional occupation therapy|Standard occupational therapy focused on improving daily functional skills through task-specific training and adaptive techniques.
214271617|NCT07054424|OTHER|stretching exercise|Techniques involving passive or active stretching of muscles to enhance flexibility, reduce spasticity, and prevent contractures.
214271618|NCT07054424|OTHER|rTMS|Non-invasive brain stimulation method using magnetic pulses to modulate cortical excitability and promote neural plasticity.
214271619|NCT07054424|DEVICE|bimanual therapy|A training approach that involves simultaneous use of both hands to enhance coordination and functional hand movements through guided exercises, including device-assisted and robot-assisted therapy
214271620|NCT07054034|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|MG-ZG122 Humanized Monoclonal Antibody Injection
214271621|NCT07054034|OTHER|Placebo|MG-ZG122 Humanized Monoclonal Antibody Injection Placebo
214271622|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Women|HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test
214271623|NCT07054359|DRUG|Treatment by TDF if HBcrAg RDT positive|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
214271624|NCT07054359|DRUG|Treatment by TDF|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
214271625|NCT07054359|OTHER|Social sciences component|"The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study.~A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers"
214271626|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Infants|At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.
214271627|NCT07053553|OTHER|Education|It was planned to provide bed bath training to inpatients because 90.5% of the caregivers of the patients in the experimental group wanted to receive bed bath training.
214271628|NCT07054398|DRUG|Isotretinoin|"* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons.~* Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris."
214271629|NCT07054541|PROCEDURE|Ultrasound-guided intervention with assistance of specialized instruments|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under pure ultrasound guidance in the entire process with assistance of specialized instruments
214271630|NCT07054541|PROCEDURE|fluoroscopy-guided intervention|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under fluoroscopic guidance in the entire process
214271631|NCT07053241|DEVICE|Game-App-KNEE|"* In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria.~* The mobile-compatible web-based gamified application created for individuals included in the intervention group will be downloaded to patients' phones in the outpatient clinic phase and information will be provided on how to use the application, and the training will be repeated if they have questions.~* Individuals in the intervention group will be able to access both the education module in PDF format and the game module containing the gamified education program for three months in the application.~* In-app reminder messages will be sent to individuals to actively use the application. (We missed you today, warrior, where are you, let's finish this job, etc.)~* Whether the application is actively logged in, how long it is in the application, and the level of success in the game will be monitored by the researcher from the administrator panel."
214271632|NCT07053241|OTHER|Control group (standart care)|Description: In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria. -An application will be installed on the phones of individuals included in the control group during the outpatient clinic phase. -In the first information phase, individuals will be registered to the system with their username and password by the researcher via their smartphones or tablets and will be allowed to enter the application. Considering that the participant may forget their username and password, a 'forgot my password' button will be added. -Individuals in the control group will only be able to access the training module in PDF format for three months.
214271633|NCT07054307|DRUG|MRG003|MRG003 (2.3 mg/kg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
214271634|NCT07054307|DRUG|HX008|HX008 (200 mg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
214829372|NCT01780467|BEHAVIORAL|Role of dopamine|
214271635|NCT07054788|OTHER|Flexibility Exercise|"Participants will perform calf muscle stretching exercises. The participant will be asked to keep the knee of the stretched leg straight with the heel flat on the ground, slightly bend the front knee, and push the hips toward a wall.~The exercise will be done in 2 sets of 3 repetitions, every repetition for 30 seconds and a ten-second rest, with a one-minute rest between sets"
214271636|NCT07054788|OTHER|Mulligan mobilization with movement|The Mulligan mobilization techniques involve talar glide and fibular glide. Talar glide involves manually stabilizing the patient's talus and leg with anteroposterior direction pressure, while fibular glide involves a pain-free sustained anterior to posterior, slightly superior, and lateral glide of the distal fibula. The patient is then asked to plantar-flex, invert the foot, and perform overpressure. The technique is performed during ankle dorsiflexion in a closed kinetic chain.
214271637|NCT07054788|OTHER|Kinesiology Taping|"The length of tape is calculated using a formula: B = A + (XA ∗ 0.35), where A is the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails. Fibular taping is applied immediately after the MWM to improve positional alignment, wrapping around the distal tibia and applying Mueller tape in the same direction. Talar taping involves wrapping Mueller tape from the talus downward and posterior to the calcaneus while holding the ankle in slight dorsiflexion."
214271638|NCT07054788|OTHER|Placebo tape|"The formula for cutting tape length is B = A + (XA ∗ 0.35), where A represents the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails' length. The tape application involves two steps: from below the medial calcaneus to the medial aspect of the lower leg, and from below the lateral malleolus to the lateral aspect."
214271639|NCT07053215|DEVICE|Argon-Helium Cryoablation|Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.
214271640|NCT07053215|DRUG|Camrelizumab|200 mg intravenously every 3 weeks for 4 cycles.
214271641|NCT07053215|DRUG|Platinum-based doublet chemotherapy|"* Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Administered for 4 cycles."
214271642|NCT07055061|BEHAVIORAL|ISO Principle Music Intervention|Participants will receive music playlists designed according to the ISO principle, which involves matching the participant's current emotional state and gradually transitioning to music reflecting a desired mood. The intervention aims to reduce stress and support emotional regulation by guiding affective resonance through music progression.
214271643|NCT07055061|BEHAVIORAL|Compensation Principle Music Intervention|Participants will receive music playlists based on the compensation principle, where the music contrasts the participant's current emotional state by directly presenting tracks aligned with the desired emotional outcome (e.g., calm music for stressed mood). This approach seeks to counteract stress and shift affective states through musical contrast.
214271644|NCT07053761|DRUG|five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths|Experimental group: If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll take five - flavor sophora flavescens enteric - coated capsules (4 capsules thrice daily for 8 weeks), plus glutamine and warm - water sitz baths.
214271645|NCT07053761|DRUG|glutamine and warm - water sitz baths|If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll use only glutamine and warm - water sitz baths.
214271646|NCT07054827|OTHER|Hemodialysis|The participants receive hemodialysis for 4 hours, 3 times per week
214271647|NCT07054827|OTHER|Intradialytic resistive exercise|"The participants will receive intradialytic resistive exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session in a recumbent position or seated position.~Time of session: The program starts with a warm-up phase which is 3:5 minutes in the form of light aerobic and stretching exercises for big muscles and ends with a cooling down phase which is 3:5 in the form of light aerobic exercise.~The resistance exercises include exercises for the big muscles of only the Lower Limbs (LL) muscles of single and multiple-joint which are:1- Knee extensors, 2- Knee flexors, 3- Hip flexors, 4- Hip abductors and adductors. using sandbags of different weights. Sandbag weights are placed on the distal third of the tibia for LL exercises.~Intensity: On the Borg's Scale of Perceived Exertion, which will be measured every 5 minutes during exercise."
214271648|NCT07054827|OTHER|Intradialytic aerobic exercise|"Patients with chronic kidney disease will receive an intradialytic aerobic exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session using a stationary bicycle ergometer in a supine position or seated position.~Time of session: The warming up and the cooling down phase consists of 5:10 minutes of slow Pedaling. the main exercise phase consisted of 20 minutes of cycling.~Intensity: The use of the Borg's Scale of Perceived Exertion (RPE) scale enables the intensity of the exercise to be adapted According to the tolerance of each patient.~The use of the RPE scale enables the intensity of the exercise to be adapted According to the tolerance of each patient, the aim was to obtain between 11 light And 14 somewhat hard."
214271649|NCT07054476|OTHER|Intermittent Enteral Nutrition|"Intermittent Enteral Nutrition (IE):~The intervention involves intermittent enteral nutrition using a diabetic-specific enteral formula, administered in 5 separate sessions daily with scheduled breaks between feedings. Each feeding session is followed by a break (1-2 hours). Energy needs are calculated based on the ESPEN guideline (25 kcal/kg/day). This protocol is designed to assess the effects of intermittent feeding in critically ill diabetic patients."
214271650|NCT07054476|OTHER|Continuous Enteral Nutrition (CE)|Continuous Enteral Nutrition (CE): The intervention involves continuous enteral nutrition provided via a diabetic-specific enteral formula, administered 24 hours a day with 1-hour breaks between feeding sessions. The feeding rate starts at 40cc per hour and is gradually increased based on tolerance. Energy needs are calculated using the ESPEN guideline (25 kcal/kg/day).
214271651|NCT07052890|DIETARY_SUPPLEMENT|Curcumin, vitamin d and green tea extract|"A combination of the following ingrediants per 4 capsules:~CurcuWin® 1000mg - of which 200mg Curcuminoids~Green Tea Extract 400mg - (0.1-0.5% caffeine)~Vitamin D₃ 50 µg 2000IU"
214271652|NCT07052890|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert color matched power
214271653|NCT07053995|PROCEDURE|Vaginal cleaning|Before giving incision for C-section surgery, vaginal cleaning was done with 50cc diluted antiseptic solution as a single push.
214271654|NCT07053995|OTHER|Non vaginal cleansing|Routine abdominal scrubbing was carried out before incision. No vaginal cleaning was done before incision.
214271655|NCT06321757|DEVICE|Percutaneous Coronary Intervention with DCB and DAPT|"* Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT)~* Patients with PCI (DCB) + short DAPT"
214271656|NCT07055347|OTHER|Comprehensive Home-based Cardiac Rehabilitation Program for Postoperative Congenital Heart Disease Patients and Their Caregivers|Intervention Description: For children, provide age-appropriate rehab manuals with pictures and texts to encourage participation. Include gentle physical activities, breathing and stretching exercises. For caregivers, offer detailed manuals and checklists. Organize training. Manage drugs with personalized guidance. Provide health education for both via manuals and video consultations. Focus on mental and physical health with support and activities. Regular phone follow-ups ensure nursing continuity. Multidisciplinary team offers professional support through video consultations and referrals.
214271657|NCT07052955|OTHER|The Normal Riddles Book|"The distribution of the participating children to the experimental and control groups will be carried out by simple random sampling method. Children included in the Normal Riddle Book group will be introduced to a book containing general, entertaining riddles that are not related to health during the pre-circumcision period.~The book will be given to the children approximately 1 hour before the circumcision operation and the children will be allowed to read the puzzles, solve them or interact with the researcher/nurse. The application period is planned as approximately 20-30 minutes.~The children's fear, anxiety and pain levels will be measured before and after the application. During the application process, the children's attention level, interest in the book and general behavior will be observed and recorded."
214271658|NCT07052955|OTHER|Health Riddles Group|"The children included in this group will be presented with the Health Riddles Book, which contains health information and is prepared to reduce fear and anxiety before the circumcision.~The book will be given to the children approximately 1 hour before the circumcision procedure and the children will be allowed to read the riddles or interact with the researcher/nurse. The application time is planned to be 20-30 minutes. Before and after the application, the children's fear, anxiety and pain levels will be measured with the Introductory Information Form, Child Fear Scale, Child Anxiety Scale-State and Wong-Baker Face Pain Scale.~The data obtained from the health riddles group will be compared with the data obtained from the normal riddle and control groups and the unique effect of the riddles containing health information on fear, anxiety and pain will be analyzed."
214271659|NCT06615895|BEHAVIORAL|Telehealth home activity|Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
214271660|NCT07053033|PROCEDURE|Surgery|Participants will initially undergo craniotomy and surgical resection of lesions or LITT
214271661|NCT07053033|PROCEDURE|LITT|Participants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.
214271662|NCT07054671|DIETARY_SUPPLEMENT|Elderberry-Based Functional Beverage|A polyphenol- and anthocyanin-rich beverage derived from Sambucus nigra L., administered once daily for 12 weeks as a dietary supplement.
214271663|NCT07054671|DIETARY_SUPPLEMENT|Placebo Beverage|A placebo beverage that mimics the elderberry drink in color and flavor but contains no polyphenols or bioactive compounds. Consumed once daily for 12 weeks.
214271664|NCT01453361|BIOLOGICAL|Vigil™ Vaccine|
214271665|NCT06649604|DEVICE|Vibration Anesthesia Device|The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
214271666|NCT06649604|PROCEDURE|Panretinal Photocoagulation|Laser treatment for diabetic retinopathy done in a standard fashion
214271667|NCT06809608|DRUG|RO7795081|A single dose will be administered orally per study period (see arm descriptions).
214271668|NCT06809608|DRUG|Itraconazole|Administered orally (see arm description).
214271669|NCT06809608|DRUG|Gemfibrozil|Administered orally (see arm description).
214271670|NCT06809608|DRUG|Cyclosporine|A single dose will be administered orally per study period (see arm descriptions).
214271671|NCT04175483|OTHER|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
214271672|NCT04560998|DRUG|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
214271673|NCT04560998|DRUG|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
214271674|NCT05794230|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
214271675|NCT05794230|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
214271676|NCT05794230|BIOLOGICAL|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
214829373|NCT03123874|DEVICE|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
214829374|NCT03123874|DEVICE|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
214829375|NCT04210544|DIETARY_SUPPLEMENT|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
214829376|NCT04210544|DIETARY_SUPPLEMENT|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
214271677|NCT05794230|BIOLOGICAL|Pneumoccocal Vaccine|Suspension for injection - intramuscular
214271678|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
214271679|NCT05794230|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
214271680|NCT05794230|BIOLOGICAL|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
214271681|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Lyophilized powder for injection - subcutaneous
214271682|NCT05794230|BIOLOGICAL|Rotavirus vaccine|Oral solution - oral
214271683|NCT05794230|BIOLOGICAL|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
214271684|NCT05794230|BIOLOGICAL|Measles vaccine|Freeze-dried powder for reconstitution and injection - subcutaneous
214271685|NCT05794230|BIOLOGICAL|Varicella vaccine live|Sterile powder and diluent for injection - subcutaneous
214271686|NCT05794230|BIOLOGICAL|Varicella vaccine live|Lyophilized powder for injection - subcutaneous
214271687|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
214271688|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Suspension for injection - intramuscular
214271689|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given a mouth rinse.
214271690|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given mouth rinse.
214271691|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
214271692|NCT04659928|DRUG|Placebo|Subjects will be given a placebo (plain water) mouth rinse
214271693|NCT06937827|BEHAVIORAL|HF Kit and Follow-ups|"These patients will receive TOCC intervention, which includes: pre-discharge introduction to the program; watching educational videos about heart failure via Mytonomy; receiving the American Heart Association's Get With The Guidelines (GWTG) booklet and a heart failure (HF) kit. These patients will receive a follow-up phone call days 1 to 3 days post discharge from the pharmacist and nurse practitioner to review discharge instructions, provide medication education, and assess clinical status; a second follow-up call will be conducted days 21 to 24 post discharge. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate"
214271694|NCT06951100|DIAGNOSTIC_TEST|CT coronary angiography|To assess the presence of obstructive coronary artery disease, participants will either have coronary angiography as part of their routine care or they will return for a research CT scan of their heart (CT Coronary Angiogram)
214271695|NCT05338593|OTHER|Outcome|Mortality rate of prolonged therapy.
214271696|NCT01661621|DRUG|Detrusitol 4 mg QD|Group 1
214271697|NCT01661621|DRUG|Doxazosin 4 mg QD|Group 2
214271698|NCT01419678|OTHER|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
214271699|NCT05907876|OTHER|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
214271700|NCT02155062|OTHER|Whole grain rye|
214271701|NCT02155062|OTHER|Whole grain wheat|
214271702|NCT02155062|OTHER|Refined cereal|
214271703|NCT02025621|DRUG|Levosimendan|
214829377|NCT04210544|DIETARY_SUPPLEMENT|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
214829378|NCT01626339|DRUG|Intravitreal Ranibizumab|
214829379|NCT01626339|DRUG|Intravitreal bevacizumab|
214271704|NCT02025621|DRUG|Placebo|matching placebo
214271705|NCT04730284|OTHER|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
214271706|NCT00739674|DRUG|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB"
214271707|NCT00739674|BEHAVIORAL|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)"
214271708|NCT03673033|PROCEDURE|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
214271709|NCT05349175|DEVICE|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
214271710|NCT04012983|DIAGNOSTIC_TEST|gingival crevicular fluid level|gingival crevicular fluid collection
214829380|NCT03007706|PROCEDURE|Women undergo cesarean section delivery|
214829381|NCT00844350|DRUG|letrozole , oxytocin,hCG,clomiphene citrate|
214271711|NCT04362982|OTHER|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
214271712|NCT06964061|COMBINATION_PRODUCT|PA5436 Ocular Implant, 115mcg|The PA5346 Ocular Implant is supplied preloaded into the needle of a single use Administration Device ready for use.
214271713|NCT02637284|DRUG|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
214271714|NCT02637284|DRUG|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
214271715|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
214271716|NCT00254904|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
214271717|NCT00254904|DRUG|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
214271718|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
214271719|NCT00254904|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
214271720|NCT01594281|DRUG|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
214271721|NCT01594281|PROCEDURE|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
214271722|NCT04032860|DRUG|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
214271723|NCT04032860|DRUG|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
214271724|NCT05392296|OTHER|Power ball|experimental group getting the power ball training with conventional treatment.
214271725|NCT05392296|OTHER|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
214271726|NCT02373852|DEVICE|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
214271727|NCT02971397|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214271728|NCT02971397|DRUG|Cytarabine|Given IV
214271729|NCT02971397|DRUG|Daunorubicin Hydrochloride|Given IV
214271730|NCT02971397|OTHER|Laboratory Biomarker Analysis|Correlative studies
214271731|NCT04805541|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
214271732|NCT04805541|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
214271733|NCT04805541|DEVICE|EyeCheckup - AI Based DR Screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
214271734|NCT02449655|DRUG|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
214271735|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
214271736|NCT02449655|DRUG|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
214271737|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
214829382|NCT01517919|BEHAVIORAL|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
214829383|NCT05263713|OTHER|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
214271738|NCT03695250|DRUG|IDO1 Inhibitor BMS-986205|Given PO
214271739|NCT03695250|BIOLOGICAL|Nivolumab|Given IV
214271740|NCT04664062|BEHAVIORAL|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
214271741|NCT02364479|DRUG|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
214271742|NCT02364479|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
214271743|NCT02364479|DRUG|Placebo|The injection method and frequency of placebo is the same as the other arms.
214271744|NCT00289471|OTHER|No intervention delivered.|No intervention delivered.
214271745|NCT06063824|OTHER|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
214271746|NCT02339272|OTHER|non interventional|
214271747|NCT05693558|BIOLOGICAL|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
214271748|NCT05963659|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|nitrate-rich beetroot juice, \~750 mg NO3- /d
214271749|NCT05963659|DIETARY_SUPPLEMENT|nitrate-depleted beetroot juice|nitrate-depleted beetroot juice, \~1 mg NO3- /d
214271750|NCT02443766|OTHER|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
214271751|NCT06256965|DIAGNOSTIC_TEST|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
214271752|NCT01543958|DRUG|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
214271753|NCT01543958|DEVICE|Sevelamer carbonate|
214271754|NCT01945281|DRUG|Caspofungin|
214271755|NCT01945281|DRUG|Amphotericin B Deoxycholate|
214271756|NCT04538430|DEVICE|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
214271757|NCT01728909|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
214271758|NCT01728909|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
214271759|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
214271760|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
214271761|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
214271762|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
214271763|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
214271764|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
214271765|NCT06267105|PROCEDURE|Longitudinal incision|Incision performed longitudinally
214271766|NCT06267105|PROCEDURE|Transverse incision|Incision performed transversally
214271767|NCT01112358|DRUG|r-FSH|r-FSH will be administered as specified in the arm description.
214271768|NCT01112358|DRUG|r-hLH|r-hLH will be administered as specified in the arm description.
214271769|NCT01112358|DRUG|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
214271770|NCT01112358|DRUG|r-hCG|r-hCG will be administered as specified in the arm description.
214271771|NCT01112358|DRUG|Progesterone|Progesterone will be administered as specified in the arm description.
214271772|NCT01099137|DRUG|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
214271773|NCT01099137|DRUG|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
214271774|NCT04389853|PROCEDURE|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
214271775|NCT04389853|PROCEDURE|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
214271776|NCT00000409|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
214271777|NCT00000409|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
214271778|NCT00000409|PROCEDURE|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
214271779|NCT00000409|PROCEDURE|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
214271780|NCT02621697|OTHER|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
214271781|NCT02621697|OTHER|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
214656845|NCT05891665|PROCEDURE|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
214829384|NCT01756313|PROCEDURE|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
214656846|NCT02688647|DRUG|Belumosudil|
214656847|NCT02688647|OTHER|BSC|Treatment/drug as determined by each subject's prescribing physician
214829385|NCT04383249|DIAGNOSTIC_TEST|Pathology result|Pathology result of the hernia sac
214829386|NCT04381741|BIOLOGICAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
214271782|NCT01136148|BEHAVIORAL|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
214271783|NCT01519271|DRUG|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
214271784|NCT01519271|DRUG|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
214271785|NCT00799383|DRUG|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
214271786|NCT00799383|OTHER|Placebo|
214271787|NCT00791960|DRUG|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
214271788|NCT00791960|OTHER|Placebo|single dose, 10 mL normal saline, IV
214271789|NCT06557564|GENETIC|TruGraf liver gene expression|Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
214271790|NCT01140893|DRUG|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
214271791|NCT01140893|DRUG|Placebo|Placebo
214271792|NCT03208205|PROCEDURE|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
214271793|NCT00726986|DRUG|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214271794|NCT00726986|DRUG|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214271795|NCT00726986|DRUG|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
214271796|NCT01313793|DRUG|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
214271797|NCT01313793|DRUG|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
214271798|NCT05667844|BEHAVIORAL|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
214271799|NCT01178957|OTHER|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
214271800|NCT06505304|PROCEDURE|Colonoscopy|"The colonoscopy will be performed at 3 or 6 months after surgery according to FC:~* In patients with FCP \>=150µg/g at around 3 months after surgery, a colonoscopy will be immediately performed~* In patients with FCP \<150µg/g at around 3 months after surgery, the colonoscopy will be organized at 6 months after surgery~Colonoscopy will be performed using high definition white-light endoscopy (HD-WLE) followed by virtual chromoendoscopy (VCE). The neoterminal ileum, ileocolic anastomosis and right colon will be assessed.~A follow-up colonoscopy will be performed within 18 months after index colonoscopy, as standard of care."
214271801|NCT06505304|PROCEDURE|Intestinal biopsies|During index colonoscopy, at least 2 biopsies from each of the segments will be taken as standard of practice to assess inflammation in post-operative CD. Only in Irish sites, twelve biopsies - four in the area of ileocolonic anastomosis, four in the neo-terminal ileum and four in the colon just distal to the anastomosis- will be taken for research purposes, in addition to standard-of-care biopsies.
214271802|NCT06505304|PROCEDURE|Confocal laser endomicroscopy|pCLE with fluorescein injection will be performed during index colonoscopy, in centres where is available, to assess early alteration of the barrier function.
214271803|NCT06505304|PROCEDURE|Intestinal ultrasound|All patients will undergo a cross-sectional imaging test as part of their standard of care at 3 and 6 months after surgery. A follow-up IUS will be performed within 18 months after index colonoscopy, as standard of care.
214271804|NCT06505304|DIAGNOSTIC_TEST|Stool|Stool samples will be collected at 3 and 6 months after surgery and used for faecal calprotectin analysis. Research stool will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for metagenomics (only in Irish sites).
214656848|NCT03091504|DEVICE|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
214271805|NCT06505304|DIAGNOSTIC_TEST|Blood|Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
214271806|NCT06505304|DIAGNOSTIC_TEST|Saliva|Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)
214271807|NCT06505304|OTHER|Clinical follow-up|Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
214271808|NCT00768157|DRUG|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
214271809|NCT00768157|PROCEDURE|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
214271810|NCT06241833|DRUG|PPI|use of PPI concomitant with DAPT
214271811|NCT02119364|OTHER|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
214271812|NCT00000869|DRUG|Nevirapine|
214271813|NCT03598283|DEVICE|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
214271814|NCT03119831|DRUG|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
214271815|NCT03119831|DRUG|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
214271816|NCT03119831|DRUG|C31G|Rinsing with 15ml for one minute twice daily for 14 days
214271817|NCT01101503|DRUG|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
214271818|NCT01101503|DRUG|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
214271819|NCT01497158|OTHER|Self-help brochure|Self help brochure given at baseline visit.
214829387|NCT04146090|OTHER|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
214829388|NCT04146090|OTHER|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
214829389|NCT00494741|DRUG|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
214829390|NCT00494741|DRUG|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
214829391|NCT03143049|DRUG|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
214271820|NCT01497158|OTHER|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
214271821|NCT02456441|OTHER|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
214271822|NCT02456441|OTHER|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
214271823|NCT01783262|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
214271824|NCT01783262|DEVICE|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
214271825|NCT04029831|DRUG|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
214271826|NCT03454711|DEVICE|fMRI|Brain MRI
214271827|NCT03454711|DEVICE|Indirect calorimetry|Resting energy expenditure
214271828|NCT03454711|DEVICE|Bioimpedance|Measurement of body composition
214271829|NCT03454711|BIOLOGICAL|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
214271830|NCT03454711|BEHAVIORAL|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
214271831|NCT04365296|OTHER|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
214271832|NCT05475132|OTHER|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
214271833|NCT05475132|OTHER|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
214271834|NCT02632981|OTHER|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
214271835|NCT02632981|OTHER|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
214271836|NCT00920283|DEVICE|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
214271837|NCT00920283|DEVICE|Driver Cobalt Alloy Coronary Stent|
214271838|NCT02840097|DRUG|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
214271839|NCT02840097|DRUG|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
214271840|NCT01758562|DEVICE|Caphosol|
214271841|NCT04214769|DIAGNOSTIC_TEST|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
214271842|NCT02665520|PROCEDURE|liposuction for retrieval of own stem cells from fat cells|
214271843|NCT05831020|OTHER|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
214271844|NCT04091854|DRUG|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
214271845|NCT05751460|OTHER|Straight leg raise|Diagnostic test, tool for \*g\*
214271846|NCT04736407|OTHER|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
214271847|NCT01912365|PROCEDURE|Above Elbow Cast|
214271848|NCT01912365|PROCEDURE|Long Arm Splint|
214271849|NCT02165215|DRUG|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
214271850|NCT02165215|DRUG|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
214271851|NCT02576002|DRUG|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
214271852|NCT06218693|BEHAVIORAL|VIA Family|A family-based, multi-component, individual-tailored intervention based on case-management.
214271853|NCT06218693|BEHAVIORAL|Treatment As Usual (TAU)|care as usual
214271854|NCT00855569|DEVICE|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
214271855|NCT03222336|BEHAVIORAL|Family pedigree and data collection|"1. Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~2. Collect and analyze medical history, genetic and biochemical assessment data"
214271856|NCT01224860|DRUG|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
214271857|NCT01224860|DRUG|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
214271858|NCT00036452|DRUG|lopinavir/ritonavir|
214271859|NCT00036452|DRUG|emtricitabine|
214271860|NCT00036452|DRUG|stavudine|
214271861|NCT00036452|DRUG|tenofovir DF|
214271862|NCT03393637|BEHAVIORAL|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
214271863|NCT01560364|OTHER|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
214656849|NCT03091504|DRUG|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
214829392|NCT03143049|DRUG|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
214829393|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
214829394|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
214271864|NCT06504095|OTHER|intervention group (Flipped Teaching Method Group)|"Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students."
214271865|NCT04700709|DRUG|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
214271866|NCT04700709|DRUG|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
214271867|NCT01784978|DRUG|Sunitinib|50 mg pd
214271868|NCT01784978|DRUG|Everolimus|10 mg pd
214271869|NCT01506713|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
214271870|NCT01874613|DEVICE|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
214271871|NCT01874613|DEVICE|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
214271872|NCT01619696|PROCEDURE|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
214271873|NCT00002946|DRUG|penclomedine|
214271874|NCT04655378|OTHER|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
214271875|NCT04678661|DEVICE|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
214271876|NCT04678661|BEHAVIORAL|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
214271877|NCT01748669|DIETARY_SUPPLEMENT|Garlic oil|Oral administration
214271878|NCT04394117|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
214271879|NCT04394117|OTHER|Placebo|Placebo
214271880|NCT00019097|DRUG|autologous tumor cell vaccine|
214271881|NCT00019097|DRUG|keyhole limpet hemocyanin|
214271882|NCT00019097|DRUG|melphalan|
214271883|NCT00019097|DRUG|sargramostim|
214271884|NCT00000308|DRUG|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
214271885|NCT00000308|DRUG|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
214271886|NCT00000308|DRUG|placebo|placebo
214271887|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
214271888|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
214271889|NCT05048290|OTHER|Communication Skills Training|Participate in communication workshops
214271890|NCT05048290|OTHER|Communication Skills Training|Participate in generic communication skills workshops
214271891|NCT05048290|OTHER|Educational Intervention|Develop a video
214271892|NCT05048290|OTHER|Survey Administration|Complete surveys
214271893|NCT06382051|DIAGNOSTIC_TEST|PEST Screening group|PEST Screening group
214271894|NCT04810078|BIOLOGICAL|Nivolumab and rHuPH20|Specified dose on specified days
214271895|NCT04810078|BIOLOGICAL|Nivolumab|Specified dose on specified days
214271896|NCT06536751|RADIATION|Photobiomodulation|LED photobiomodulation therapy, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). PBM will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght.
214271897|NCT06536751|OTHER|Institution's Standard Physiotherapy|Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
214271898|NCT06536751|RADIATION|Photobiomodulation Placebo|The same procedures of PBM group but device will be turned off
214271899|NCT05393804|BIOLOGICAL|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
214271900|NCT00156052|RADIATION|Conventional whole breast radiation schedule|
214271901|NCT00156052|RADIATION|Hypofractionated whole breast radiation schedule|
214271902|NCT01397890|DRUG|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
214271903|NCT01397890|DRUG|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
214271904|NCT00462618|DRUG|Quetiapine|
214271905|NCT00462618|BEHAVIORAL|Cogntive behavioral therapy|
214271906|NCT03821883|DRUG|Aspirin Tablet|Aspirin 100mg qd
214271907|NCT03821883|DRUG|Placebo|Placebo qd
214271908|NCT04483141|DIAGNOSTIC_TEST|Abbey Pain Scale|Hetero-assessment of pain
214271909|NCT04146233|OTHER|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
214271910|NCT03094169|DRUG|AVID100 IV|AVID100 is administered once every 3 weeks
214271911|NCT04645953|COMBINATION_PRODUCT|3mg AZ-010|Subjects who received a single inhaled dose (3mg)
214271912|NCT04645953|COMBINATION_PRODUCT|1mg AZ010|Subjects who received a single inhaled dose (1mg)
214271913|NCT04645953|COMBINATION_PRODUCT|Staccato Placebo|Subject who received a single inhaled dose (Staccato Placebo)
214271914|NCT06285279|DRUG|FKC288|"The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion."
214271915|NCT04993521|PROCEDURE|Block type|Regular block type
214271916|NCT04718298|DEVICE|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
214271917|NCT01603498|DRUG|Dexamethasone|Dexamethasone 8mg
214271918|NCT01603498|DRUG|Methylprednisolone|Methylprednisolone 40mg
214271919|NCT02737098|OTHER|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
214829395|NCT04823936|OTHER|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
214829396|NCT04469400|DIETARY_SUPPLEMENT|Low fat diet intensive intervention|education and Compound protein solid beverage
214271920|NCT02737098|OTHER|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
214271921|NCT00899054|DRUG|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
214829397|NCT04469400|OTHER|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
214829398|NCT01600313|DIETARY_SUPPLEMENT|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
214271922|NCT00899054|RADIATION|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
214271923|NCT03311633|PROCEDURE|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
214271924|NCT06414889|DRUG|G-CSF (filgrastim or biosimilar)|Given by IV or SC
214271925|NCT06414889|PROCEDURE|Apheresis|Given by procedure
214271926|NCT06414889|DRUG|Plerixafor|Given by IV
214271927|NCT05845450|DRUG|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
214271928|NCT05845450|DRUG|Durvalumab|durvalumab 1500 mg IV on day 1
214271929|NCT05845450|DRUG|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
214271930|NCT05845450|DRUG|Botensilimab|botensilimab 1 mg/kg on day 1
214271931|NCT05845450|DRUG|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
214271932|NCT05845450|DRUG|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
214271933|NCT05845450|DRUG|Vorbipiprant|vorbipiprant 90 mg orally bid from day 1 to 28
214271934|NCT05845450|DRUG|Nivolumab|240 mg IV on days 1 and 15
214271935|NCT05219721|DRUG|CAR-T (CAR-GPRC5D)|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
214271936|NCT03346018|DIAGNOSTIC_TEST|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
214271937|NCT06960564|DEVICE|Hyaluronic Acid injections|Intra-articular hyaluronic acid will be administered to 30 selected patients. Blood and synovial fluid samples will be collected before HA injection and 1 week after 3 sessions of HA injection with one week interval. Home exercise programme will be given.
214271938|NCT06960564|OTHER|Saline -- placebo comparator|Intra-articular saline (SF) will be administered to 20 selected patients. Blood and synovial fluid samples will be collected before and 1 week after 3 session of salin injection with one week interval. Home exercise programme will be given.
214271939|NCT00002651|DRUG|bicalutamide|Given orally
214271940|NCT00002651|DRUG|goserelin acetate|Given subcutaneously
214271941|NCT00002651|OTHER|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
214271942|NCT00659048|DRUG|Ciclesonide|Ciclesonide 200µg versus Placebo
214271943|NCT00659048|DRUG|Placebo|placebo
214271944|NCT05666076|PROCEDURE|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
214271945|NCT05666076|PROCEDURE|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
214271946|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
214271947|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
214271948|NCT00841919|DRUG|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
214271949|NCT00841919|DRUG|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
214271950|NCT00841919|DRUG|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
214271951|NCT03493620|PROCEDURE|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
214271952|NCT03493620|PROCEDURE|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
214271953|NCT00638482|DRUG|Hydrochlorothiazide|Hydrochlorothiazide
214271954|NCT05954975|COMBINATION_PRODUCT|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
214271955|NCT03260309|PROCEDURE|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
214271956|NCT03260309|PROCEDURE|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
214271957|NCT03757325|DRUG|DNL747|DNL747
214271958|NCT03757325|DRUG|Placebo|Placebo
214271959|NCT03070028|PROCEDURE|crystallised phenol|crystallised phenol will be applied to sinus cavity
214271960|NCT03070028|PROCEDURE|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
214829399|NCT02528045|PROCEDURE|Vitrectomy with scleral shortening|
214271961|NCT05231057|OTHER|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
214271962|NCT05231057|OTHER|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
214271963|NCT04946747|DEVICE|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
214271964|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
214271965|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
214271966|NCT02717520|DEVICE|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
214271967|NCT00318448|DRUG|Zolpidem (SL800750)|
214271968|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
214271969|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
214271970|NCT06556368|DRUG|Aflibercept|Intravitreal injection
214271971|NCT05737589|RADIATION|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
214271972|NCT05010057|DIETARY_SUPPLEMENT|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
214271973|NCT05010057|DIETARY_SUPPLEMENT|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
214271974|NCT03593096|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214271975|NCT03593096|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214271976|NCT03741062|DEVICE|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
214271977|NCT03741062|DEVICE|Control|Sham treatment with laser unit turned off
214271978|NCT05070195|DRUG|SKLB1028|SKLB1028, capsule, oral
214271979|NCT05070195|DRUG|Midazolam|Midazolam Maleate, tablet, oral
214271980|NCT00304746|DRUG|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
214271981|NCT00304746|DRUG|Placebo|Placebo
214271982|NCT06535386|DRUG|Dexmedetomidine 0.004 MG/ML|Incidence of polyuria during the intraoperative period, associated with dexmedetomidine .
214271983|NCT02261896|DRUG|Placebo|Evaluate usefullness of antibiotic prophylaxis
214271984|NCT02261896|DRUG|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
214271985|NCT01198678|DIETARY_SUPPLEMENT|Boost Nutritional Supplement|Boost- Nutritional Supplement
214271986|NCT06095583|DRUG|Tifcemalimab injection|200mg once every 3weeks
214271987|NCT06095583|DRUG|toripalimab injection|240mg once every 3 weeks
214271988|NCT06095583|DRUG|Placebo for Tifcemalimab|every 3weeks
214271989|NCT06095583|DRUG|Placebo for toripalimab|every 3weeks
214271990|NCT00541593|PROCEDURE|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
214271991|NCT00460096|DRUG|Kamada-API|
214271992|NCT06469593|DEVICE|Automated insuling delivery system|Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
214271993|NCT05434000|DRUG|Hydroxyurea|Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
214271994|NCT01497431|DIETARY_SUPPLEMENT|Selenium|Given PO
214271995|NCT01497431|OTHER|Placebo|Given PO
214271996|NCT01497431|OTHER|Laboratory Biomarker Analysis|Correlative studies
214271997|NCT01497431|OTHER|Pharmacological Study|Correlative studies
214271998|NCT01497431|DRUG|Methylselenocysteine|Given PO
214271999|NCT00531271|DRUG|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
214272000|NCT03605589|DRUG|Blinatumomab|Continuous IV infusion
214272001|NCT03605589|DRUG|Pembrolizumab|IV infusion
214272002|NCT00145782|BEHAVIORAL|Life style|
214272003|NCT03417219|BEHAVIORAL|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
214272004|NCT03417219|BEHAVIORAL|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
214272005|NCT03702985|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
214272006|NCT03702985|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
214272007|NCT03702985|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
214272008|NCT03702985|DRUG|Amifostine|400mg/m2 per week
214272009|NCT00776204|DEVICE|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
214272010|NCT00776204|DEVICE|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
214272011|NCT00776204|DEVICE|Taxus Libertè|Taxus Libertè stent placed in coronary artery
214272012|NCT05831631|DIAGNOSTIC_TEST|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
214272013|NCT05831631|DIAGNOSTIC_TEST|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
214272014|NCT00747331|DRUG|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
214272015|NCT00747331|DRUG|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
214272016|NCT00261807|DRUG|Daptomycin 6mg/kg/day|
214272017|NCT01004965|OTHER|laboratory biomarker analysis|
214272018|NCT01602159|PROCEDURE|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
214272019|NCT01602159|PROCEDURE|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
214272020|NCT01550731|BEHAVIORAL|PREPARE website|Advance care planning website and materials plus an advance directive.
214272021|NCT01550731|BEHAVIORAL|Advance directive|The control group will only receive an advance directive.
214272022|NCT05116475|DRUG|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
214272023|NCT05116475|DRUG|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
214272024|NCT00000315|DRUG|Cocaine|
214272025|NCT01597531|DRUG|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
214272026|NCT01597531|DRUG|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
214272027|NCT01597531|DRUG|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
214272028|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
214272029|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
214272030|NCT01036893|DRUG|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
214272031|NCT03499977|BEHAVIORAL|Sitting|10 min bouts
214272032|NCT03499977|BEHAVIORAL|Light-Intensity Cycling|10min bout
214272033|NCT03499977|BEHAVIORAL|Moderate-Intensity Cycling|10 min bout
214272034|NCT03499977|BEHAVIORAL|High-Intensity Cycling|10 min bout
214272035|NCT00675948|DRUG|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
214272036|NCT00675948|DRUG|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
214272037|NCT05146310|DEVICE|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
214272038|NCT04105582|BIOLOGICAL|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
214272039|NCT01528475|BEHAVIORAL|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
214272040|NCT00742430|PROCEDURE|PCI|percutaneous coronary intervention in stable coronary artery disease
214272041|NCT05428046|BEHAVIORAL|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
214272042|NCT05428046|BEHAVIORAL|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
214272043|NCT03461913|PROCEDURE|Cesarean section|Lower segment elective Cesarean section
214272044|NCT01478880|PROCEDURE|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
214272045|NCT01478880|PROCEDURE|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
214272046|NCT00528463|PROCEDURE|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
214272047|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
214272048|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
214272049|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
214272050|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
214272051|NCT03466567|DRUG|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
214272052|NCT03466567|DRUG|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
214272053|NCT03466567|DRUG|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
214272054|NCT04044378|DRUG|Famitinib|famitinib with RP2D orally daily
214272055|NCT04044378|DRUG|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
214272056|NCT04044378|DRUG|Camrelizumab|camrelizumab 200mg infusion once Q2W
214272057|NCT01476956|OTHER|Observational study|RA patients on standard DMARD therapy
214272058|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
214272059|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
214272060|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
214829400|NCT05141474|BIOLOGICAL|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
214272061|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
214272062|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
214272063|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
214272064|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
214272065|NCT01317654|OTHER|Observation|Collection of mortality data at 5 years post trial
214272066|NCT03597880|OTHER|obese patients|underwent bariatric surgery
214272067|NCT02654834|OTHER|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
214272068|NCT05124314|DRUG|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
214272069|NCT05124314|DRUG|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
214829401|NCT05141474|DRUG|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
214829402|NCT05141474|DRUG|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
214272070|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
214272071|NCT02023281|BEHAVIORAL|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
214272072|NCT02527161|DEVICE|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
214272073|NCT05209360|DEVICE|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
214272074|NCT05209360|DEVICE|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
214272075|NCT00362310|DRUG|indinavir|
214272076|NCT03155971|DEVICE|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
214272077|NCT02100514|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
214272078|NCT02100514|OTHER|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
214272079|NCT03021941|DRUG|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
214272080|NCT02329912|DEVICE|SmartPill|Application of the SmartPill at the end of surgery
214272081|NCT01669226|DRUG|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
214272082|NCT01669226|DRUG|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
214272083|NCT02459301|DRUG|IPH2201|
214272084|NCT04456608|DRUG|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
214272085|NCT06300931|OTHER|educational lecture|An Educational lecture about SDF
214272086|NCT06008821|PROCEDURE|Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine|60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)
214272087|NCT06008821|PROCEDURE|Bilateral sham block with normal saline|10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
214272088|NCT01154582|DIETARY_SUPPLEMENT|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
214272089|NCT01154582|DIETARY_SUPPLEMENT|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
214272090|NCT00724932|DRUG|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
214272091|NCT00724932|DRUG|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
214272092|NCT00724932|DRUG|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
214272093|NCT00724932|DRUG|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
214272094|NCT03885258|DRUG|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
214272095|NCT04017078|OTHER|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
214829403|NCT05341453|PROCEDURE|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
214829404|NCT05341453|PROCEDURE|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
214272096|NCT04922970|OTHER|Strength training|The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
214272097|NCT04551755|DRUG|Ivermectin and Doxycycline|"1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
214272098|NCT04551755|OTHER|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
214272099|NCT02273778|PROCEDURE|MRI Scan|
214272100|NCT02273778|PROCEDURE|PET-CT Scan|
214272101|NCT02273778|OTHER|No intervention|
214272102|NCT02021331|DEVICE|immediate implant placement without provisionalization|
214272103|NCT02021331|DEVICE|immediate implant placement with immediate provisionalization|
214272104|NCT03804697|DRUG|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
214272105|NCT00005814|BIOLOGICAL|cetuximab|
214272106|NCT00005814|DRUG|cisplatin|
214272107|NCT00005814|RADIATION|radiation therapy|
214272108|NCT04665700|DRUG|BI 764198|BI 764198
214272109|NCT04665700|DRUG|Placebo|Placebo
214272110|NCT00487877|DEVICE|SenseWear Pro3 Armband|
214272111|NCT00487877|DEVICE|i-button DS2191 H|
214272112|NCT00465036|DIETARY_SUPPLEMENT|Whole flaxseeds, flaxseed mucilage, glucomannan|
214272113|NCT04944251|BEHAVIORAL|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
214272114|NCT04165200|DIAGNOSTIC_TEST|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
214272115|NCT00762229|DRUG|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
214272116|NCT00762229|DRUG|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
214272117|NCT04391647|OTHER|First-void urine collection|"* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)"
214272118|NCT04391647|OTHER|Blood draw|\- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
214272119|NCT06457880|PROCEDURE|PENG BLOCK|Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
214272120|NCT06457880|PROCEDURE|Femoral Nerve Block|Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
214829405|NCT05341453|PROCEDURE|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
214272121|NCT06457880|PROCEDURE|Obturator Nerve Block|Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
214272122|NCT02218320|DRUG|Raltegravir|
214272123|NCT02218320|DRUG|Dolutegravir|
214272124|NCT02218320|PROCEDURE|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
214829406|NCT01630616|DRUG|Odanacatib|single oral dose, tablets, 10 or 50 mg
214272126|NCT02459210|BEHAVIORAL|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
214272127|NCT02459210|BEHAVIORAL|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
214272128|NCT06304129|DIAGNOSTIC_TEST|Blood ponction|Blood ponction
214272129|NCT03681431|DRUG|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
214272130|NCT03681431|DRUG|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
214272131|NCT03122769|RADIATION|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
214272132|NCT02702154|DEVICE|High-frequency rTMS|20 Hz active stimulation, twice daily
214272133|NCT02702154|DEVICE|Low-frequency rTMS|1 Hz active stimulation, twice daily
214272134|NCT02702154|DEVICE|Sham rTMS|Sham stimulation, twice daily
214272135|NCT01628133|PROCEDURE|ultrasound|sonographic evaluation of intestinal blood flow
214272136|NCT00253227|DRUG|galantamine hydrobromide|
214272137|NCT02661659|BIOLOGICAL|Multipeptide vaccine S-588210|
214829407|NCT01630616|DRUG|Placebo|single oral dose, tablets
214829408|NCT05285319|RADIATION|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
214829409|NCT05285319|RADIATION|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
214829410|NCT00425841|DRUG|gemcitabine hydrochloride|
214829411|NCT00425841|DRUG|oxaliplatin|
214272138|NCT00303732|DRUG|RAD001 (everolimus)|
214272139|NCT00303732|DRUG|PTK787 (vatalanib)|
214272140|NCT04457635|BEHAVIORAL|Psychotherapy|
214272141|NCT00999089|PROCEDURE|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
214272142|NCT00999089|PROCEDURE|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
214272143|NCT00999089|PROCEDURE|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
214272144|NCT03256097|DEVICE|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
214272145|NCT03256097|DEVICE|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
214272146|NCT03256097|DEVICE|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
214272147|NCT03256097|DEVICE|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
214272148|NCT03256097|DEVICE|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
214272149|NCT03256097|DEVICE|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
214272150|NCT03256097|DEVICE|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
214272151|NCT03256097|DEVICE|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
214272152|NCT00319553|BIOLOGICAL|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
214272153|NCT00319553|BIOLOGICAL|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
214272154|NCT06264375|BEHAVIORAL|Physical exercise|see group description
214272155|NCT00204230|DRUG|mycophenolate mofetil (drug)|
214272156|NCT04147702|OTHER|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
214272157|NCT03795454|BEHAVIORAL|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
214272158|NCT03166007|BEHAVIORAL|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
214272159|NCT03166007|BEHAVIORAL|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
214272160|NCT02673138|DRUG|canagliflozin|basal interruption with canagliflozin
214272161|NCT02673138|OTHER|basal interruption without canagliflozin|basal interruption
214272162|NCT06341075|DEVICE|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
214272163|NCT03226483|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
214272164|NCT04946383|DRUG|Dasatinib plus Quercetin|Dasatinib plus Quercetin
214272165|NCT03732157|PROCEDURE|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
214272166|NCT03732157|PROCEDURE|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
214272167|NCT01409330|DIETARY_SUPPLEMENT|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
214272168|NCT00885846|OTHER|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
214272169|NCT00885846|OTHER|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
214272170|NCT03415568|DIETARY_SUPPLEMENT|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
214829412|NCT00425841|PROCEDURE|adjuvant therapy|
214829413|NCT00425841|PROCEDURE|neoadjuvant therapy|
214829414|NCT00425841|RADIATION|hypofractionated radiation therapy|
214272171|NCT03415568|DIETARY_SUPPLEMENT|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
214272172|NCT05310890|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
214272173|NCT05310890|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
214272174|NCT06072846|BEHAVIORAL|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
214272175|NCT01439633|DEVICE|MGH OFDI marking|Imaging of esophagus with OFDI system
214272176|NCT05841485|DIAGNOSTIC_TEST|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
214272177|NCT01081678|DRUG|Placebo|Administered by subcutaneous (under the skin) injection
214272178|NCT01081678|DRUG|Romosozumab|Administered by subcutaneous injection
214272179|NCT01059591|DRUG|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
214272180|NCT01059591|DRUG|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
214272181|NCT01059591|RADIATION|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
214272182|NCT00194948|DRUG|escitalopram|
214272183|NCT00194948|BEHAVIORAL|interpersonal psychotherapy|
214272184|NCT04213417|OTHER|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
214272185|NCT04213417|OTHER|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
214272186|NCT04878497|DRUG|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
214272187|NCT04878497|DRUG|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
214272188|NCT04878497|DRUG|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
214272189|NCT04878497|DRUG|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
214272190|NCT04878497|DRUG|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
214272191|NCT03889106|DRUG|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
214272192|NCT04824352|DRUG|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
214272193|NCT02326532|OTHER|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
214272194|NCT02326532|OTHER|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
214272195|NCT00695409|BIOLOGICAL|rituximab|Given IV
214272196|NCT00695409|DRUG|carmustine|Given IV
214272197|NCT00695409|DRUG|cytarabine|Given IV
214272198|NCT00695409|DRUG|etoposide|Given IV
214272199|NCT00695409|DRUG|melphalan|Given IV
214272200|NCT00695409|PROCEDURE|ASCT|Undergo autologous peripheral blood stem cell transplant
214272201|NCT00695409|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
214272202|NCT01496248|DIETARY_SUPPLEMENT|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
214272203|NCT02900339|DEVICE|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
214272204|NCT02639767|DRUG|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
214272205|NCT02639767|RADIATION|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
214272206|NCT02639767|DEVICE|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
214829415|NCT00425841|RADIATION|stereotactic radiosurgery|
214829416|NCT02218541|DEVICE|abutment margin 0.5 mm subgingival|
214272207|NCT05866900|DEVICE|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
214272208|NCT04158492|DIAGNOSTIC_TEST|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
214272209|NCT04158492|DIAGNOSTIC_TEST|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
214272210|NCT05662150|DIAGNOSTIC_TEST|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
214272211|NCT01267760|DEVICE|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
214272212|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
214272213|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
214272214|NCT00444912|BIOLOGICAL|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
214272215|NCT01281865|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214272216|NCT01281865|DRUG|everolimus|Given PO
214272217|NCT01281865|DRUG|imatinib mesylate|Given PO
214272218|NCT02747875|DRUG|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
214272219|NCT02747875|DRUG|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
214272220|NCT01977742|OTHER|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
214272221|NCT01977742|OTHER|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
214272222|NCT05314751|BEHAVIORAL|Questionnaire and interview|An online survey and an in-depth interview.
214272223|NCT03132818|OTHER|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
214272224|NCT03069300|DRUG|N-acetyl cysteine (NAC)|
214272225|NCT02508181|DEVICE|I-gel|supraglottic airway device without cuff
214272226|NCT02508181|DEVICE|LMA Supreme|supraglottic airway device with cuff
214272227|NCT00149162|DRUG|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
214272228|NCT00884169|DRUG|M518101|Proper quantity twice a day
214272229|NCT00884169|DRUG|placebo|Proper quantity twice a day
214272230|NCT02008760|DIETARY_SUPPLEMENT|Omega Krill with D3|
214272231|NCT03758001|DRUG|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
214272232|NCT03758001|DRUG|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
214272233|NCT03758001|DRUG|Sintilimab|200mg iv infusion day 1 of every 21 days
214272234|NCT02226146|BIOLOGICAL|Bertilimumab|
214829417|NCT02218541|DEVICE|abutment margin 1.5 mm subgingival|
214272235|NCT04326556|OTHER|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
214272236|NCT00386659|DRUG|tenofovir + abacavir + lopinavir/ritonavir|
214272237|NCT00386659|DRUG|tenofovir + abacavir + efavirenz|
214272238|NCT05523752|DEVICE|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
214272239|NCT05523752|DEVICE|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
214272240|NCT05523752|DEVICE|I-gel|insertion of I-gel
214272241|NCT05523752|DEVICE|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
214272242|NCT01120002|DRUG|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
214272243|NCT01120002|DRUG|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
214272244|NCT02292797|OTHER|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
214272245|NCT00483639|OTHER|Medical chart review|medical chart review
214272246|NCT00483639|OTHER|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
214272247|NCT00483639|PROCEDURE|management of therapy complications|management of therapy complications
214272248|NCT00483639|PROCEDURE|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
214272249|NCT00483639|OTHER|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
214272250|NCT00544518|DRUG|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
214272251|NCT00544518|DRUG|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
214272252|NCT02012101|DEVICE|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
214272253|NCT02012101|DEVICE|oxygen therapy|
214272254|NCT02983825|DEVICE|Continuous positive airway pressure (CPAP); level changes|as per arm description
214272255|NCT01702805|PROCEDURE|Liberal Cell Transfusion|
214272256|NCT01702805|PROCEDURE|Restricted red cell transfusion|
214272257|NCT03813069|OTHER|IR3535|The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
214272258|NCT03813069|OTHER|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
214272259|NCT03813069|OTHER|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
214272260|NCT03964623|DIAGNOSTIC_TEST|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
214272261|NCT04329403|DRUG|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
214272262|NCT04329403|DRUG|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
214829418|NCT01338090|DRUG|89Zr-bevacizumab|Intravenous injection 120 MBq
214829419|NCT01338090|DRUG|Everolimus|Oral use, 10 mg per day
214272263|NCT04329403|OTHER|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
214272264|NCT05197556|DRUG|HSG4112|Once-daily oral administration
214272265|NCT05197556|DRUG|Placebo|Once-daily oral administration
214272266|NCT04511169|BEHAVIORAL|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
214272267|NCT02499783|BIOLOGICAL|adalimumab|subcutaneous injections of adalimumab
214272268|NCT02499783|OTHER|placebo|subcutaneous injections of placebo
214272269|NCT03131778|PROCEDURE|Liver resection|liver resections for colorectal liver metastases
214272270|NCT00900965|DEVICE|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
214272271|NCT00900965|DEVICE|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
214272272|NCT00935363|DRUG|glyburide|single oral dose
214272273|NCT00935363|DRUG|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
214272274|NCT00935363|DRUG|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
214272275|NCT00935363|DRUG|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
214829420|NCT01156441|PROCEDURE|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
214829421|NCT00657254|DRUG|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
214272276|NCT00198939|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
214272277|NCT00198939|OTHER|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
214272278|NCT04973137|DRUG|Birtamimab|Intravenous administration of 24 mg/kg birtamimab every 28 days
214272279|NCT04973137|OTHER|Placebo|Intravenous 0.9% Saline administration as a placebo every 28 days
214272280|NCT04973137|DRUG|Standard of Care Chemotherapy|Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care
214272281|NCT04803058|BIOLOGICAL|TCD601|Investigational Product
214272282|NCT01866293|DRUG|Cabozantinib (XL184)|
214272283|NCT02018185|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
214272284|NCT02018185|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
214272285|NCT00415805|DRUG|Multihance|0.5 Molar, single injection at 0.2 mL/kg
214272286|NCT00415805|DRUG|vasovist|0.25 molar single injection 0.03 ml/kg
214272287|NCT06131801|OTHER|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
214272288|NCT05081609|DRUG|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
214272289|NCT05081609|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
214272290|NCT05081609|DRUG|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
214272291|NCT05081609|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
214272292|NCT05081609|PROCEDURE|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
214272293|NCT05081609|DRUG|Trastuzumab|Trastuzumab will be administered as an intravenous (IV) infusion
214272294|NCT05081609|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
214272295|NCT03972306|DRUG|Ocrelizumab|Administered by subcutaneous Injection
214272296|NCT03972306|DRUG|Ocrelizumab|Administered by Intravenous (IV) Injection
214272297|NCT03972306|DRUG|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
214272298|NCT00868985|DRUG|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
214272299|NCT00868985|DRUG|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
214272300|NCT01274078|BIOLOGICAL|Blueberries|150 grams of frozen blueberries on the same day as exercise
214272301|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
214272302|NCT04457336|DRUG|Tildacerfont/Placebo|Tablet, administered daily
214272303|NCT04339686|DIAGNOSTIC_TEST|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
214272304|NCT04249531|DRUG|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
214272305|NCT04249531|DRUG|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
214272306|NCT03155282|PROCEDURE|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
214272307|NCT04806997|DIAGNOSTIC_TEST|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
214272308|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
214272309|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
214272310|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
214829422|NCT03789487|DEVICE|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
214272311|NCT00244010|DEVICE|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
214272312|NCT03990454|DRUG|SLC-391|SLC-391 is an AXL inhibitor
214272313|NCT03959553|DRUG|GV1001|Lyophilized peptide from hTERT
214272314|NCT03959553|DRUG|Normal saline|0.9% normal saline
214272315|NCT05142163|OTHER|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
214272316|NCT05142163|OTHER|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
214272317|NCT06475586|DRUG|Semaglutide|0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
214272318|NCT00000371|DRUG|D-cycloserine|50 mg/daily by mouth
214272319|NCT00000371|DRUG|Placebo|50 mg/day of placebo by mouth
214272320|NCT02571075|OTHER|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
214272321|NCT02693119|DRUG|elamipretide (MTP-131) 1% topical ophthalmic solution|
214272322|NCT02693119|DRUG|Vehicle topical ophthalmic solution|
214272323|NCT03916991|OTHER|Exercise|Hip focused Neuromuscular Activation Exercise
214272324|NCT01343420|BIOLOGICAL|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
214272325|NCT06162936|DIAGNOSTIC_TEST|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
214272326|NCT06162936|DIAGNOSTIC_TEST|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
214272327|NCT06162936|DIAGNOSTIC_TEST|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
214272328|NCT02237131|DRUG|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
214272329|NCT02237131|DRUG|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
214272330|NCT03944031|DRUG|LY3372689|Administered orally.
214272331|NCT03944031|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered IV.
214272332|NCT02295410|BEHAVIORAL|CPT|
214656850|NCT04481022|OTHER|proximal control exercises|"study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010)."
214656851|NCT03619213|DRUG|Dapagliflozin|10 mg tablets given once daily, per oral use.
214656852|NCT03619213|DRUG|Placebo|Placebo matching dapagliflozin 10 mg
214272333|NCT04859673|DEVICE|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
214272334|NCT02502318|PROCEDURE|Video-thoracoscopy|
214272335|NCT02502318|PROCEDURE|thoracotomy|
214272336|NCT00645749|BIOLOGICAL|Helminth ova|2500 ova per dose (liquid form)
214272337|NCT04203498|DRUG|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
214272338|NCT04203498|DRUG|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
214272339|NCT04261868|DEVICE|Virtual Reality|New treatment for amblyopia therapy using playing games
214272340|NCT04261868|OTHER|Patching|Patching
214272341|NCT00789490|DIETARY_SUPPLEMENT|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
214272342|NCT00789490|DIETARY_SUPPLEMENT|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
214272343|NCT04634383|DEVICE|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
214272344|NCT01471678|DRUG|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
214656853|NCT00382967|PROCEDURE|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
214272345|NCT01471678|DRUG|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
214272346|NCT01471678|DRUG|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
214272347|NCT05656508|BIOLOGICAL|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
214272348|NCT03890406|DRUG|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
214272349|NCT03890406|DRUG|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
214272350|NCT04121975|RADIATION|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
214272351|NCT04121975|DRUG|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
214272352|NCT04121975|DRUG|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
214272353|NCT02106975|DRUG|Ascorbic Acid|Intervention
214272354|NCT02106975|DRUG|Placebo: 5% Dextrose in water|Placebo
214272355|NCT06132516|OTHER|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
214272356|NCT06132516|OTHER|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
214272357|NCT00003710|DRUG|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
214272358|NCT00003710|DRUG|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
214272359|NCT01723345|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
214272360|NCT01095211|DRUG|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
214272361|NCT05203432|DEVICE|Red Light Intervention|Repeated Low-Level Red-Light Therapy
214272362|NCT05203432|DRUG|Atropine|0.01% atropine
214272363|NCT02568774|OTHER|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
214272364|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
214272365|NCT01870284|DRUG|Ixekizumab|Administered SC
214272366|NCT01870284|DRUG|Placebo|Administered SC
214272367|NCT01870284|DRUG|Adalimumab|Administered SC
214272368|NCT04516330|GENETIC|miRNA|miRNA's expressed in breast cancer
214272369|NCT02718157|DEVICE|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
214272370|NCT00651352|DRUG|4 mg nicotine lozenge|marketed formulation
214272371|NCT00651352|DRUG|2 mg nicotine lozenge|marketed formulation
214272372|NCT00651352|DRUG|2 mg nicotine prototype|2 mg
214272373|NCT00651352|DRUG|4 mg nicotine prototype|4 mg
214272374|NCT02956239|PROCEDURE|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
214272375|NCT02956239|PROCEDURE|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
214272376|NCT02956239|PROCEDURE|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
214272377|NCT02935842|OTHER|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
214272378|NCT02935842|OTHER|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
214272379|NCT01072422|BEHAVIORAL|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
214272380|NCT05281679|OTHER|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
214272381|NCT05281679|OTHER|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
214272382|NCT04544397|PROCEDURE|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
214272383|NCT00808990|DIETARY_SUPPLEMENT|BioFemale|BioFemale 6 months.
214272384|NCT00076843|DRUG|Hu MiK-Beta-1|
214272385|NCT02902432|DRUG|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
214272386|NCT01201785|DRUG|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
214272387|NCT04545385|DRUG|TEV-48574|subcutaneous infusion
214272388|NCT04545385|DRUG|Placebo|Matching Placebo
214272389|NCT05843045|DEVICE|Indoor Air Quality Mitigation|Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
214272390|NCT00001381|DRUG|suramin|
214272391|NCT02649595|OTHER|Red Cross Respite care|See detailed description.
214272392|NCT00939770|DRUG|Crizotinib|Given PO
214272393|NCT00939770|OTHER|Laboratory Biomarker Analysis|Correlative studies
214272394|NCT00939770|OTHER|Pharmacological Study|Correlative studies
214272395|NCT00939770|OTHER|Questionnaire Administration|Ancillary studies
214272396|NCT00191139|DRUG|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
214272397|NCT00191139|DRUG|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
214272398|NCT00191139|DRUG|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
214272399|NCT00191139|DRUG|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
214272400|NCT00191139|RADIATION|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
214272401|NCT00758836|DRUG|placebo|
214272402|NCT00758836|DRUG|ibuprofen|
214272403|NCT00758836|DRUG|acetominophen|
214272404|NCT00758836|DRUG|telcagepant|
214272405|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
214272406|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
214272407|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
214272408|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
214272409|NCT02211079|DRUG|JNJ-54861911|JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
214272410|NCT02211079|DRUG|Caffeine|Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
214272411|NCT02211079|DRUG|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
214272412|NCT02211079|DRUG|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
214272413|NCT02937675|DRUG|Tomivosertib (eFT-508)|eFT508
214272414|NCT00608660|OTHER|acupuncture|staging acupuncture
214272415|NCT00608660|OTHER|acupuncture and moxibustion|staging acupuncture and moxibustion
214272416|NCT00608660|OTHER|electroacupuncture|staging electroacupuncture
214272417|NCT00608660|OTHER|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
214272418|NCT00608660|OTHER|acupuncture|non-staging acupuncture
214272419|NCT02123888|RADIATION|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
214272420|NCT04896541|BIOLOGICAL|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
214272421|NCT04896541|BIOLOGICAL|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
214272422|NCT04896541|BIOLOGICAL|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
214272423|NCT04896541|BIOLOGICAL|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
214272424|NCT01289080|DRUG|OPC-34712|administered orally
214272425|NCT00636558|DRUG|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
214272426|NCT03128411|DRUG|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
214272427|NCT00094705|BIOLOGICAL|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
214272428|NCT00094705|BIOLOGICAL|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
214272429|NCT04790929|DEVICE|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
214272430|NCT04790929|BEHAVIORAL|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
214272431|NCT00993070|DRUG|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
214272432|NCT00993070|DRUG|placebo|vehicle gel, applied 4 times per day for 8 weeks
214272433|NCT01937416|BIOLOGICAL|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
214272434|NCT03249883|DEVICE|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
214272435|NCT04378556|BEHAVIORAL|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
214272436|NCT05624281|DRUG|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
214272437|NCT05248061|OTHER|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~\- \*Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~\*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~\*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
214272438|NCT05248061|OTHER|Group B|"The same exercises as in Group 1 will be suitable for the participants.~* PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~* Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
214272439|NCT06039397|BEHAVIORAL|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
214272440|NCT01220050|DRUG|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
214272441|NCT01220050|DRUG|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
214272442|NCT02510196|BEHAVIORAL|reminder|
214272443|NCT05454098|DRUG|Clifutinib with fed state|40 mg Clifutinib with food
214656854|NCT06500663|OTHER|haemodialysis|haemodialysis effect on thyroid function
214272444|NCT05454098|DRUG|Clifutinib with fasted state|40 mg Clifutinib without food
214272445|NCT05504031|PROCEDURE|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
214272446|NCT05504031|PROCEDURE|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
214272447|NCT05176145|DEVICE|VisioCyt®|"* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test"
214272448|NCT00394147|DRUG|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
214272449|NCT00394147|DRUG|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
214272450|NCT04435132|DEVICE|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
214272451|NCT06111820|BEHAVIORAL|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
214272452|NCT02547844|DRUG|efavirenz + emtricitabina + tenofovir|
214272453|NCT02547844|DRUG|rilpivirina + emtricitabina + tenofovir|
214656855|NCT03499431|DEVICE|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
214656856|NCT01002508|BIOLOGICAL|Influenza vaccine|One dose of influenza vaccine
214272454|NCT02252783|DRUG|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
214272455|NCT06450262|DRUG|Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
214272456|NCT06450262|DRUG|Synjardy® 12.5mg/1000mg film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
214272457|NCT04875663|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
214272458|NCT04452240|DEVICE|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
214272459|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation|
214272460|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
214272461|NCT06729242|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
214272462|NCT06729242|OTHER|HIIT session|The HIIT exercise will consist of strength exercises with elastic bands.
214272463|NCT06733129|DRUG|direct IV injection|direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation
214272464|NCT06733129|DRUG|combination of Ketamine and Propofol|combination of Ketamine and Propofol described above: consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg (adjusted body weight if BMI \> 30). Dilution are not necessary.
214272465|NCT07050784|DEVICE|Hydrogel electrodes|Neurostimulation using standard self-adhesive hydrogel electrodes
214272466|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion A|Neurostimulation with dry polymer-textile electrodes using Skin Lotion A
214272467|NCT07050784|DEVICE|Dry textile electrodes with gel pads attached to the electrode|Neurostimulation with dry textile electrodes with gel pads attached to the electrode
214272468|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion B|Neurostimulation with dry polymer-textile electrodes with Skin Lotion B
214272469|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion C|Neurostimulation with dry polymer-textile electrodes using Skin Lotion C
214272470|NCT07049159|BIOLOGICAL|ShigETEC vaccine|The ShigETEC vaccine will be administered orally 4 times at 3-day intervals as a bacterial suspension in a volume of 30 mL per dose (target to contain 5x10\^10 CFU)
214272471|NCT07049159|OTHER|Placebo|Eligible participants will be randomly assigned in a 1:1 ratio to receive either ShigETEC 5x10\^10 colony forming units (CFU) or placebo. Participants will receive their assigned treatment on Days 1, 4, 7, and 10.
214272472|NCT07049159|BIOLOGICAL|Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU|In the challenge stage all participants will receive 1 oral dose of Shigella flexneri 2457T at a dose of 1.5x10\^3 CFU.
214272473|NCT07049315|DEVICE|Mandibular Advancement Device|A custom-made intraoral appliance designed to reposition the mandible forward during sleep. The device increases the upper airway space by maintaining the lower jaw in a protruded position, aiming to reduce airway collapse and decrease nocturnal gastroesophageal reflux. It is fabricated from heat-cured acrylic based on individual dental impressions and bite registrations taken in a protruded mandibular position.
214272474|NCT07049315|DEVICE|Lower Oral Device Without Mandibular Advancement|A lower jaw oral appliance made of heat-cured acrylic, fabricated from standard dental impressions and bite registration in habitual occlusion. This device does not reposition the mandible but provides posterior dental disocclusion. It is also used in patients with obstructive sleep apnea and serves as an active comparator to evaluate the specific impact of mandibular advancement on nocturnal gastroesophageal reflux.
214272475|NCT06705868|OTHER|Diet-Time-restricted eating (TRE)|Ad libitum time-restricted scheme with a further time-restriction on fruit and vegetable consumption in participants with MASLD
214272476|NCT06705868|OTHER|Lifestyle Management|The SoC intervention refers to an adaptation of a healthier lifestyle in elements that have to do with weight management, adopting healthier dietary habits, alcohol intake reduction, increase physical activity levels, in people diagnosed with MASLD.
214272477|NCT07045077|BEHAVIORAL|AI Chatbot-Assisted Case-Based Learning|Participants in this intervention used a conversational AI chatbot integrated into a case-based learning activity focused on Parkinson's disease. The chatbot simulated a virtual client and responded to student questions in natural language. Students used the chatbot to gather occupational history, clarify symptoms, and explore intervention planning options during a structured 90-minute session.
214272478|NCT07045077|BEHAVIORAL|Traditional Case-Based Learning with Standard Materials|Participants in this intervention completed the same Parkinson's disease case analysis using only traditional educational materials, such as lecture notes, textbooks, and class handouts. No digital or AI-based tool was used. The session was instructor-guided and lasted 90 minutes, during which students worked collaboratively to assess the case and develop intervention plans.
214272479|NCT07052565|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-6.0 x10\^5 CART cells/kg）
214272480|NCT07055126|OTHER|Individualised dietary counselling, coaching and resource provision around healthy eating for young children|Study participants randomised to receive the intervention will receive nutrition education support, through individualised dietary counselling, coaching and resource provision around healthy eating, with a particular focus on incorporating fresh meat and vegetables into a healthy, sustainable and safe diet for young children. Those in the control group will not receive this individualised nutrition education and supports.
214272481|NCT07054957|OTHER|Handheld fan|Group using hand fans
214272482|NCT07054957|OTHER|Control Group|pre-test, mid-test and post-test will be administered.
214272483|NCT07053748|RADIATION|Trimodality Bladder-preserving Therapy|High-risk NMIBC patients who have a strong desire to preserve their bladder actively choose to receive Trimodality Bladder-preserving Therapy instead of radical resection.
214272484|NCT07055035|DEVICE|Bachmann Bundle Pacing|Implantation of a permanent pacemaker system. The atrial lead (Medtronic 3830 active electrode) is surgically positioned and fixed in the Bachmann bundle region, located at the angle between the superior vena cava and the atrium in the mid-posterior position of the high atrial septum. Successful placement is confirmed by achieving a P-wave width shortening of at least 30ms compared to the preoperative P-wave. The ventricular lead is positioned in the mid-to-lower portion of the ventricular septum. Pacing parameters are measured and confirmed to be good.
214272485|NCT07055035|DEVICE|Right Atrial Appendage Pacing|Implantation of a permanent pacemaker system using the conventional technique. The atrial active electrode is surgically positioned and fixed in the right atrial appendage. The ventricular lead is placed in the mid-to-lower portion of the ventricular septum. Pacing parameters (sensing \> 2.0mV; impedance between 300 to 1000Ω; threshold \< 1.5mV) are confirmed to be good.
214272486|NCT07055412|DRUG|Y-3 for injection（40mg）|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
214272487|NCT07052994|DRUG|Revumenib|Given by IV
214272488|NCT07052994|DRUG|Cytrabine|Given by IV
214272489|NCT07052994|DRUG|Daunorubicin|Given by IV
214272490|NCT07054905|DEVICE|HiCardi wearable ECG|A chest-attached, single-lead wearable ECG device used to collect real-time ECG data from hemodialysis patients. The device records ECG waveforms during dialysis sessions and transmits the data to a secure cloud platform. This non-invasive tool is used to analyze T-wave morphology for early detection of hyperkalemia in patients with chronic kidney disease.
214272491|NCT07055087|DRUG|Prasinezumab|Prasinezumab 1500 mg monthly infusion
214272492|NCT07055087|DRUG|Sodium Chloride|Saline infusion (0,9 % sodium chloride) monthly infusion
214272493|NCT07054736|DRUG|XKH001 Injection|"100 mg quaque 4 weeks dose group: Subjects will receive 1 mL (1 vial) of XKH001 injection (100 mg) and 5 mL (5 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~300 mg quaque 4 weeks dose group: Subjects will receive 3 mL (3 vials) of XKH001 injection (300 mg) and 3 mL (3 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~600 mg quaque 4 weeks dose group: Subjects will receive 6 mL (6 vials) of XKH001 injection (600 mg) subcutaneously each time, once every 4 weeks, for a total of 5 times."
214272494|NCT07054736|DRUG|XKH001 Placebo Injection|Subjects will receive 6 mL (6 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.
214272495|NCT07053878|PROCEDURE|Non-Surgical Periodontal Therapy (Step 1 & 2)|Comprehensive supra- and sub-gingival instrumentation (scaling, root planing, ultrasonic and manual instruments), following EFP step-1 and step-2 protocols. Includes individualized oral-hygiene instruction and motivation.
214272496|NCT07053878|PROCEDURE|Supragingival Plaque Removal and Polishing|Professional supragingival scaling with ultrasonic tips plus rubber-cup polishing in a single session. Includes the same individualized oral-hygiene instruction and motivation provided to the experimental group.
214272497|NCT07054437|OTHER|Gross Motor Development Screening Tool|"This intervention is an automated gross motor development screening tool specifically designed for independently walking children aged one to six years old in Taiwan. What sets it apart is its use of artificial intelligence (AI) algorithms to analyze motion data, enabling early identification of potential gross motor developmental delays.~Unlike traditional methods that rely on manual, visual observation and subjective recording by healthcare professionals, this tool aims to significantly reduce assessment time and human resource costs. Furthermore, its automated nature makes it uniquely suited for telemedicine applications, allowing for remote screenings and overcoming geographical barriers to access early intervention services. The tool will be developed and validated against established developmental norms relevant to the Taiwanese population."
214272498|NCT07055178|DEVICE|Virtual reality (VR) guided meditation therapy|Participants will engage in the TRIPP relaxation app on the MetaQuest 3 VR headset.
214272499|NCT07055178|OTHER|Treatment as usual|Participants undergo a standard vasectomy.
214272501|NCT07052968|DEVICE|Echocardiography|Echocardiography is the non invasvive interventional assessment and the RHC is the invasive international assessment of the hemodynamics in PH patients with ckd.
214272502|NCT07055139|BEHAVIORAL|Digital Aftercare|A structured, app-based digital aftercare program designed for patients recovering from distal radius or clavicle fractures. The 12-week program includes weekly video-guided physiotherapy exercises, educational content on fracture healing, pain management guidance, and milestone-based progression. The program replaces in-person physiotherapy and standard clinic follow-up, with patients instructed to follow the app independently. Medical contact is initiated only in case of uncertainty or complications.
214272503|NCT07055139|BEHAVIORAL|Traditional Aftercare|Standard postoperative follow-up care for patients with distal radius or clavicle fractures, consisting of scheduled clinical visits and in-person physiotherapy sessions according to institutional protocols. The treatment includes individual exercise instruction, physiotherapy, and physician-led follow-up at defined intervals during the 12-week rehabilitation period.
214272504|NCT07053735|DRUG|Nimotuzumab and Radiotherapy|"1. nimotuzumab: 200mg, iv, qw, used for 5 weeks.~2. radiotherapy: radiotherapy is performed according to clinical routine;"
214272505|NCT07053722|RADIATION|NA-TMT|After neoadjuvant therapy, patients choose trimodality therapy (TMT) for bladder preservation over radical cystectomy.
214829423|NCT02826395|DRUG|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
214829424|NCT02646488|BEHAVIORAL|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
214272506|NCT07055022|PROCEDURE|LLLT|Patients in the LLLT group will receive 3 sessions of LLLT treatment with Eye-light device (Espansione Group S.p.A., Bologna, Italy) 7 days before phacoemulsification (D-7), 7 days after phacoemulsification (D+7), and 30 days after phacoemulsification (D+30). Each session will consist of 15 minutes of light treatment using a wavelength of 625±40 nm and maximum power of 10 W (maximal total fluence of 32 J/cm2 ± 20% per session) applied on the periorbital region. The patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
214272507|NCT07055022|PROCEDURE|IPL|Patients in the IPL group will receive 3 sessions of IPL treatment with OptiClear device (Alma Lasers GmbH, Nuremberg, Germany) at D-7, D+7, and D+30. Each session will comprise 90 homogenously spaced pulses of light (wavelength of 550-650 nm, pulse time 10,12 or 15 ms, pulse repetition rate 1-2 Hz) using an energy density of 8-12 J/cm2 adjusted to Fitzpatrick skin type according to the manufacturer's recommendations. The treatment will be applied to the lower eyelid region. Ultrasound gel, as well as protective eye patches will be used, and the patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
214272508|NCT07055295|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|Receiving three doses of rabies vaccine rabies vaccine manufactured by Sinovac using a three-dose PrEP schedule
214272509|NCT07055295|BIOLOGICAL|Verorab®|Receiving three doses of marketed rabies vaccine manufactured by Sanofi using the three-dose PrEP schedule
214272510|NCT07054450|COMBINATION_PRODUCT|All patients in the study will be included in rehabilitation program|A total of 110 consecutive participants with previous diagnosed CR lasting more than 3 months will be enrolled in this study. After initial assessment, participants without surgical recommendation, will be included into two groups: Study Group will be received 10 sessions of rehabilitation program and nutraceutical product daily, 3 months, and Control Group will be received 10 sessions of rehabilitation program. The rehabilitation program include physical therapy (electrical muscle stimulation of the neck muscle and upper limb muscles , low-Level Laser Therapy and ultrasound) and kinetic training.
214272511|NCT07054450|DIETARY_SUPPLEMENT|Study Group will receive a nutraceutical product daily, 3 months.|Study Group will receive a nutraceutical product daily, 3 months in addition to the rehabilitation program.
214272512|NCT07053176|DRUG|0.5% Lidocaine|0.5% lidocaine injection will be administered in the paravertebral intramuscular region with 12 mm, 30 G needle from C2 to C7 bilaterally
214272513|NCT07053176|DRUG|Saline Solution (NaCl 0,9%)|saline solution will be administered bilaterally in the paravertebral intamuscular region from C2 to C7 with 12 mm 30 G needle
214272514|NCT06603623|DRUG|BHV-2100|BHV-2100 75mg
214272515|NCT06603623|DRUG|BHV-2100|BHV-2100 150 mg
214272516|NCT06603623|DRUG|Placebo|matching placebo
214272517|NCT06753214|OTHER|Telemedicine-Based Education|Intervention through telemedicine
214272518|NCT06753214|OTHER|Standard Care (in control arm)|Sham comparator through telemedicine
214829425|NCT02646488|BEHAVIORAL|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
214829426|NCT02646488|BEHAVIORAL|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
214272519|NCT06810141|BIOLOGICAL|rMBCG|1-19.2e8 colony-forming units (CFU) of rMBCG
214272520|NCT06897735|DRUG|Afatinib Dimaleat|printed capsule containing 40 mg afatinib dimaleate
214272521|NCT06897735|BIOLOGICAL|inhalation of afatinib dimaleate|inhalation stable form of afatinib dimaleate at an equivalent therapeutic dose in a single-use maintenance-free ultrasonic inhaler with controlled frequency and number of inhalations
214272522|NCT06926608|BEHAVIORAL|Actívatexto|Actívatexto is a mobile intervention that promotes both smoking cessation and physical activity. Actívatexto integrates four components: 1) a text messaging program that promotes both smoking cessation and physical activity, 2) wearable devices to monitor physical activity, 3) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 4) an online dashboard where the research team manages participants' incoming and outgoing data from both the text messaging program and wearable devices.
214272523|NCT06926608|BEHAVIORAL|Decídetexto|Decídetexto is a mobile intervention that solely promotes smoking cessation. Decídetexto integrates three components: 1) a text messaging program that solely promotes smoking cessation, 2) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 3) an online dashboard where the research team manages participants' incoming and outgoing data from the text messaging program.
214272524|NCT06907329|DIETARY_SUPPLEMENT|NMN|NMN SR tablets(1000mg/tablets) , 1 tablet daily before breakfast
214272525|NCT06907329|DIETARY_SUPPLEMENT|Placebo|Matching Placebo (tablets) once daily before breakfast
214272526|NCT06065228|OTHER|AlgometRx Nociometer|Physiologic characterization of disease activity
214272527|NCT06911866|DRUG|RC1416|there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
214272528|NCT06911866|DRUG|RC1416 Placebo|Each subjects will receive the placebo once by subcutaneous injection.
214272529|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
214272530|NCT04589728|DRUG|Venetoclax plus HMA|patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.
214272531|NCT05865028|DRUG|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
214272532|NCT06724328|BEHAVIORAL|Gentle Human Touch|the trained NICU nurse will place one hand's fingertips on the baby's forehead along the brow line, while the other hand will be placed around the baby's lower abdomen
214272533|NCT06724328|BEHAVIORAL|Maternal Heartbeat and Gentle Human Touch|maternal heartbeat will be played and GHT steps will be applied simultaneously at the designated times
214829427|NCT02646488|BEHAVIORAL|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
214829428|NCT02646488|BEHAVIORAL|Standard Care Regimen 9 Months|
214272534|NCT06724328|BEHAVIORAL|Maternal Heartbeat|The recording of the mother's heartbeat will be done when the mother's mood is stable and the environment is quiet. A Doppler fetal heart monitor will be used to detect the mother's heartbeat. After ensuring a regular and stable heart rate, the mother's heartbeat will be recorded for 15 minutes using a recording device
214272535|NCT01798004|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214272536|NCT01798004|DRUG|Busulfan|Given IV
214272537|NCT01798004|DRUG|Cisplatin|Given IV
214272538|NCT01798004|DRUG|Cyclophosphamide|Given IV
214272539|NCT01798004|DRUG|Doxorubicin Hydrochloride|Given IV
214272540|NCT01798004|DRUG|Etoposide|Given IV
214272541|NCT01798004|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214272542|NCT01798004|BIOLOGICAL|Filgrastim|Given SC or IV
214272543|NCT01798004|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214272544|NCT01798004|DRUG|Melphalan|Given IV
214272545|NCT01798004|DRUG|Mesna|Given IV
214272546|NCT01798004|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
214272547|NCT01798004|OTHER|Pharmacological Study|Correlative studies
214272548|NCT01798004|DRUG|Topotecan Hydrochloride|Given IV
214272549|NCT01798004|DRUG|Vincristine Sulfate|Given IV
214272550|NCT01488929|DRUG|TC-5619|
214272551|NCT01488929|DRUG|Placebo|
214272552|NCT00666029|DRUG|atorvastatin|40 m.g. o.d. tablets for 6 months
214272553|NCT00666029|DRUG|placebo|Placebo
214272554|NCT05960799|DEVICE|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
214272555|NCT05960799|DEVICE|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
214272556|NCT03980041|DRUG|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
214272557|NCT03980041|DRUG|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
214272558|NCT03980041|DRUG|Placebos|Placebo administered orally in 28-day cycles
214272559|NCT05968391|RADIATION|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
214272560|NCT00025493|DRUG|docetaxel|
214272561|NCT00393393|DRUG|intra-articular injection of Hylan G-F 20|
214272562|NCT02622308|DEVICE|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
214272563|NCT01481727|DEVICE|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.
214272564|NCT01481727|DEVICE|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
214272565|NCT05239923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
214272566|NCT01633853|DRUG|Vitamin D2|Treatment with Vit D2.
214272567|NCT01633853|DRUG|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
214272568|NCT02785432|DEVICE|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
214272569|NCT02785432|DEVICE|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
214272570|NCT00517816|DRUG|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
214272571|NCT05855252|OTHER|No intervention|No intervention
214272572|NCT01002027|BEHAVIORAL|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
214272573|NCT00583609|DRUG|PEG3350|PEG3350
214272574|NCT03159767|DEVICE|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
214272575|NCT00030121|DRUG|recombinant human atrial natriuretic polypeptide|
214272576|NCT05677659|DRUG|VGL101|Solution administered via Intravenous Infusion (IV)
214272577|NCT00656383|OTHER|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
214272578|NCT00656383|OTHER|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
214272579|NCT01101087|DEVICE|Taurolock|
214272580|NCT01101087|OTHER|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
214272581|NCT03570073|OTHER|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
214829429|NCT02646488|BEHAVIORAL|Standard Care Regimen 12 Months|
214829430|NCT02646488|BEHAVIORAL|Standard Care Regimen 15 Months|
214272582|NCT03570073|OTHER|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
214272583|NCT05578391|BIOLOGICAL|Convalescent plasma|Admistration of one unit of convalescent plasma
214272584|NCT00756756|DRUG|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
214272585|NCT00756756|DRUG|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
214272586|NCT01955096|PROCEDURE|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
214272587|NCT01955096|PROCEDURE|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
214272588|NCT04915144|DRUG|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
214272589|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
214272590|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
214272591|NCT02619552|DRUG|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
214272592|NCT00769470|BIOLOGICAL|trastuzumab|Given IV
214272593|NCT00769470|DRUG|carboplatin|Given IV
214272594|NCT00769470|DRUG|docetaxel|Given IV
214272595|NCT00769470|DRUG|lapatinib ditosylate|Given orally
214272596|NCT00871260|DRUG|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
214272597|NCT03275012|DRUG|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
214272598|NCT03275012|DRUG|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
214272599|NCT03539081|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
214272600|NCT03539081|OTHER|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
214272601|NCT03539081|OTHER|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
214272602|NCT03539081|OTHER|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
214272603|NCT03539081|OTHER|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
214272604|NCT03539081|OTHER|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
214272605|NCT03539081|OTHER|Anthropometric Measurements|Height and weight will be obtained.
214272606|NCT03539081|BEHAVIORAL|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
214272607|NCT03539081|BEHAVIORAL|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
214272608|NCT04170816|DEVICE|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
214272609|NCT02055716|DRUG|Sulforadex|
214272610|NCT02055716|DRUG|alpha-cyclodextrin|
214272611|NCT00542555|DRUG|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
214272612|NCT00542555|DRUG|Naproxcinod 375 mg|
214272613|NCT00542555|DRUG|Naproxen|
214272614|NCT00542555|DRUG|Naproxcinod 750 mg|
214272615|NCT03579732|DRUG|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. \< 150 mg daily
214272616|NCT03579732|OTHER|No drug|Non-consumers
214829431|NCT02646488|BEHAVIORAL|Standard Care Regimen 18 Months|
214829432|NCT02646488|BEHAVIORAL|Standard Care Regimen 21 Months|
214272617|NCT06803914|PROCEDURE|Biomechanical analysis|Biomechanical assessment is performed using a set of sensors (Qualisys Sports Marker Set - functional assessment, already in use at the Clinique du Sport) as well as 3D optoelectronic cameras and force and pressure platforms. These sensors are placed at various points on both lower limbs (hip, knee, ankle) and provide data in different planes (sagittal, frontal, transverse), as well as a comparison of both sides.
214272618|NCT00258401|DIETARY_SUPPLEMENT|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
214272619|NCT00258401|PROCEDURE|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
214272620|NCT00258401|PROCEDURE|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
214272621|NCT01776892|DRUG|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
214272622|NCT01776892|PROCEDURE|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
214272623|NCT06256016|OTHER|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
214272624|NCT06256016|OTHER|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
214272625|NCT03542474|BEHAVIORAL|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
214272626|NCT02474459|DEVICE|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
214272627|NCT02474459|OTHER|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
214272628|NCT00987220|DRUG|Placebo|Oral
214272629|NCT00987220|DRUG|donepezil (Aricept)|5mg oral
214272630|NCT00990236|DRUG|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
214272631|NCT00990236|DRUG|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
214272632|NCT01673867|BIOLOGICAL|Nivolumab|
214272633|NCT01673867|DRUG|Docetaxel|
214272634|NCT03075540|BEHAVIORAL|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
214272635|NCT02259868|DRUG|BILR 355 BS /1B, current low dose formulation|
214272636|NCT02259868|DRUG|BILR 355 BS /1B, current high dose formulation|
214272637|NCT02259868|DRUG|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
214272638|NCT02259868|DRUG|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
214272639|NCT02259868|DRUG|BILR 355 BS - Suspension low dose|
214272640|NCT02259868|DRUG|BILR 355 BS - Suspension high dose|
214272641|NCT02259868|DRUG|Ritonavir|
214272642|NCT04918433|PROCEDURE|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
214272643|NCT01410032|PROCEDURE|Plate fixation|Reconstruction plate
214272644|NCT01410032|PROCEDURE|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
214272645|NCT03552315|DIETARY_SUPPLEMENT|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
214272646|NCT03552315|DIETARY_SUPPLEMENT|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
214272647|NCT01338766|PROCEDURE|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
214272648|NCT03340701|DRUG|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
214272649|NCT00479609|DRUG|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
214272650|NCT00479609|DRUG|Placebo|Placebo gel
214272651|NCT04043260|DEVICE|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
214272652|NCT00186030|BEHAVIORAL|HIV Skills-based Prevention|
214272653|NCT02048891|DRUG|GnRH agonist trigger|
214272654|NCT02048891|DRUG|hCG trigger|
214829433|NCT02646488|BEHAVIORAL|Standard Care Regimen 24 Months|
214829434|NCT02646488|BEHAVIORAL|Standard Care Regimen 27 Months|
214272655|NCT02957877|DRUG|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
214272656|NCT02957877|DRUG|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
214272657|NCT03558776|DIETARY_SUPPLEMENT|linseed oil|linseed oil and defined background diet
214272658|NCT02172924|BIOLOGICAL|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
214272659|NCT02172924|BIOLOGICAL|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
214272660|NCT02338141|DEVICE|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
214272661|NCT02338141|DEVICE|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
214272662|NCT01827605|OTHER|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
214272663|NCT01827605|DRUG|BEAM|"BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc"
214272664|NCT01045720|DRUG|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
214272665|NCT01045720|DRUG|Placebo|Placebo (starch)
214272666|NCT01084746|BEHAVIORAL|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
214272667|NCT01084746|BEHAVIORAL|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
214272668|NCT05169749|PROCEDURE|Control-Service Nurse Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
214272669|NCT05169749|PROCEDURE|Nursing Visiting Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
214272670|NCT02550106|DRUG|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
214272671|NCT02345681|DRUG|Furosemide|
214272672|NCT05226715|OTHER|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
214272673|NCT01897844|DRUG|ITF2984 (100, 2000, 3000 mcg bid)|
214272674|NCT01897844|DRUG|Placebo|
214272675|NCT04066049|BEHAVIORAL|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
214272676|NCT04706676|BEHAVIORAL|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
214272677|NCT04706676|BEHAVIORAL|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
214272678|NCT04706676|BEHAVIORAL|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
214272679|NCT00379093|BEHAVIORAL|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~* A personalized risk report;~* An educational booklet titled Healthy Drinking as You Age;~* A drinking diary;~* Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
214272680|NCT04503785|DIAGNOSTIC_TEST|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
214272681|NCT02195583|DRUG|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
214272682|NCT02195583|DRUG|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
214272683|NCT02195583|DRUG|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
214272684|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
214272685|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
214272686|NCT02195583|DRUG|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
214272687|NCT02502578|DRUG|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
214272688|NCT02349087|DEVICE|Acute EEG with fast applicable EEG electrode|
214272689|NCT01182987|BEHAVIORAL|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
214272690|NCT01818232|DRUG|[14C]-LX4211|
214272691|NCT03478202|DIETARY_SUPPLEMENT|GOLO RELEASE|GOLO RELEASE plus Diet
214272692|NCT01709513|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets.
214272693|NCT01709513|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet.
214272694|NCT01709513|DRUG|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
214272695|NCT01709513|DRUG|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
214272696|NCT03801291|PROCEDURE|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
214272697|NCT03801291|PROCEDURE|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
214272698|NCT00081068|BIOLOGICAL|alemtuzumab|
214272699|NCT00294437|DRUG|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
214272700|NCT01405248|DRUG|Butylphthalide|20 mg/time per os three times a day. 180days
214272701|NCT01405248|DRUG|Placebo|20 mg/time per os three times a day. 180days
214272702|NCT04870593|BEHAVIORAL|Information|Elder informed about vaccination.
214272703|NCT04870593|BEHAVIORAL|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
214272704|NCT04870593|BEHAVIORAL|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
214272705|NCT04870593|BEHAVIORAL|Information assigned in community|Information intervention assigned for other elders in community.
214272706|NCT04870593|BEHAVIORAL|Buddy assigned in community|Buddy intervention assigned for other elders in community.
214272707|NCT00957554|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
214272708|NCT00957554|DRUG|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
214272709|NCT00109122|BIOLOGICAL|zoster vaccine live (Oka/Merck)|
214272710|NCT00109122|BIOLOGICAL|Comparator: placebo (unspecified)|
214272711|NCT05998044|OTHER|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch"
214272712|NCT05998044|OTHER|control|They will be asked not to participate in any regular exercise for 8 weeks.
214272713|NCT03489148|BEHAVIORAL|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
214272714|NCT03489148|BEHAVIORAL|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
214272715|NCT00936156|DRUG|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
214829435|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 21 Months|
214272716|NCT05545709|PROCEDURE|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
214272717|NCT04284358|OTHER|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
214272718|NCT00002734|BIOLOGICAL|recombinant interferon alfa|
214272719|NCT00002734|DRUG|chemotherapy|
214272720|NCT00002734|DRUG|paclitaxel|
214272721|NCT00002734|DRUG|topotecan hydrochloride|
214272722|NCT00002734|RADIATION|lutetium Lu 177 monoclonal antibody CC49|
214272723|NCT00002734|RADIATION|yttrium Y 90 monoclonal antibody CC49|
214272724|NCT04714957|OTHER|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
214272725|NCT00455078|PROCEDURE|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
214272726|NCT00455078|OTHER|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
214272727|NCT00455078|PROCEDURE|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
214272728|NCT00455078|PROCEDURE|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
214272729|NCT00455078|PROCEDURE|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
214272730|NCT05219305|DEVICE|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
214272731|NCT05882942|DIETARY_SUPPLEMENT|Matcha green tea|This is the condition with the Matcha green tea
214272732|NCT05882942|DIETARY_SUPPLEMENT|Placebo|This is the condition with the placebo
214272733|NCT00926328|DRUG|Triclosan, fluoride|Six Month study, brush twice daily
214272734|NCT00926328|DRUG|Fluoride|twice daily usage
214272735|NCT00289133|DEVICE|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
214272736|NCT00289133|DEVICE|total knee arthroplasty|cross-linked polyethylene tibial insert
214272737|NCT02644642|OTHER|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
214272738|NCT01227434|DRUG|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
214272739|NCT01227434|DRUG|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
214272740|NCT01227434|PROCEDURE|Resection as clinical care|Indicated, intended, surgical resection as clinical care
214272741|NCT02803255|DEVICE|MAHI Exo-II|
214272742|NCT00385983|DEVICE|Harmonic Scalpel|
214272743|NCT01165437|DEVICE|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
214272744|NCT04773860|OTHER|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
214272745|NCT05529303|BEHAVIORAL|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
214272746|NCT00779701|DRUG|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
214272747|NCT02733432|DRUG|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
214272748|NCT02733432|DRUG|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
214272749|NCT02733432|DRUG|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
214272750|NCT02733432|DRUG|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
214272751|NCT02733432|DRUG|Fluconazole|oral fluconazole (150mg) on Day 1
214272752|NCT06281223|OTHER|intraoperative neuroelectrophysiological monitoring|"The procedure involves intraoperative neuroelectrophysiological monitoring. The aim is to record the electrical activity of the central and peripheral nervous system at several levels during a neurosurgical procedure.~The equipment used comes from INOMED and consists of :~* a recording station (ISIS)~* scalp corkscrew electrodes (2 to 4 electrodes)~* a 4-pin FSR spinal cord electrode (Ad-Tech)~* hook electrodes for roots/radicles (X2)~* needle electrodes for muscles (X18)~Electrode placement and recording take place in the operating room while the patient is under general anaesthetic (intubated and sedated)."
214272753|NCT04613375|DIAGNOSTIC_TEST|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
214272754|NCT04613375|DIAGNOSTIC_TEST|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
214272755|NCT03800134|DRUG|Durvalumab|1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
214272756|NCT03800134|OTHER|Placebo|Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
214272757|NCT03800134|DRUG|Carboplatin|Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
214272758|NCT03800134|DRUG|Cisplatin|75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
214272759|NCT03800134|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
214272760|NCT03800134|DRUG|Paclitaxel|200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
214272761|NCT03800134|DRUG|Gemcitabine|1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
214272762|NCT03800134|PROCEDURE|Surgery|Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
214272763|NCT01964859|BIOLOGICAL|autologous skin fibroblasts|
214272764|NCT06231732|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
214272765|NCT06231732|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
214272766|NCT03296098|DRUG|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
214272767|NCT04797078|PROCEDURE|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
214272768|NCT04797078|PROCEDURE|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
214272769|NCT00187200|DEVICE|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
214272770|NCT00187200|DEVICE|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
214272771|NCT03829839|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
214272772|NCT03829839|DRUG|Lorazepam 1 mg|Oral administration of 1mg lorazepam
214272773|NCT03829839|DRUG|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
214272774|NCT03829839|DRUG|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
214272775|NCT00006426|PROCEDURE|Achilles tendon-lengthening surgery|
214272776|NCT06558396|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
214272777|NCT05267847|OTHER|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
214272778|NCT05267847|OTHER|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
214272779|NCT00487708|DRUG|canakinumab|
214272780|NCT00182884|DRUG|Donepezil|
214272781|NCT04736693|DRUG|Raloxifene|Raloxifene dispensing claim is used as the reference group.
214272782|NCT04736693|DRUG|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
214272783|NCT03928119|BEHAVIORAL|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
214272784|NCT04811885|OTHER|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
214272785|NCT04203654|BEHAVIORAL|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
214272786|NCT04203654|BEHAVIORAL|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
214272787|NCT01921387|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
214272788|NCT01921387|DRUG|Carmustine|Given IV
214272789|NCT01921387|DRUG|Cytarabine|Given IV
214272790|NCT01921387|DRUG|Etoposide|Given IV
214272791|NCT01921387|OTHER|Laboratory Biomarker Analysis|Correlative studies
214272792|NCT01921387|DRUG|Melphalan|Given IV
214272793|NCT01921387|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
214272794|NCT01921387|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
214272795|NCT02537119|PROCEDURE|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
214272796|NCT02537119|PROCEDURE|Massage therapy|Rubbing on hamstrings
214272797|NCT01998776|DRUG|Misoprostol|Misoprostol 200ug four times daily
214272798|NCT01998776|DRUG|Placebo|Placebo Starch four times daily
214272799|NCT00135096|DRUG|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
214272800|NCT00135096|DRUG|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
214272801|NCT06264414|DRUG|DTT106|oral route
214272802|NCT06264414|DRUG|Dutasteride-Tamsulosin|oral route
214272803|NCT06142071|BEHAVIORAL|Telephone questionnaire|Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial
214656857|NCT04384237|PROCEDURE|Er,Cr:YSGG laser-aided CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface
214829436|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 24 Months|
214272804|NCT03828175|PROCEDURE|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
214272805|NCT00510497|BIOLOGICAL|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
214272806|NCT04459728|BEHAVIORAL|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
214272807|NCT04459728|BEHAVIORAL|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
214272808|NCT04459728|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
214272809|NCT04459728|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
214272810|NCT04459728|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
214272811|NCT04459728|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
214272812|NCT04459728|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
214272813|NCT05198999|OTHER|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
214272814|NCT05198999|OTHER|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
214272815|NCT05617469|OTHER|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
214272816|NCT02940912|DRUG|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
214272817|NCT02940912|DRUG|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
214272818|NCT00469274|DRUG|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
214272819|NCT00469274|DRUG|Antibiotic PEP|TMP-SMX DS po BID for 14 days
214272820|NCT06338371|BEHAVIORAL|Pelvic Floor exercise training|The level of sexual function was determined by implementing FSFI for all individuals included in the sample. The participants were divided into two groups, control and training groups, using the randomization program on the computer. Pelvic floor exercise training was given to one group. Trainings were conducted online on different days. Each training lasted 120 minutes. After training was completed, women in the training group were instructed to perform three sets of 8-12 repetitive pelvic floor muscle contractions per day and to use an exercise diary to record their practice. Women in the training group were also given a booklet and the recording of the training video was shared. the training, a brochure explaining how to perform the pelvic floor muscle exercises, which was included in the training content, was prepared and delivered to the training group on the first day of each week. After the training, FSFI was applied to both groups 3 times, in the 1st, 2nd, and 3rd months.
214272821|NCT02358174|PROCEDURE|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
214272822|NCT02358174|OTHER|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
214272823|NCT02358174|OTHER|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
214272824|NCT06175455|DEVICE|dynamic chest radiography|A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
214272825|NCT00828997|BIOLOGICAL|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
214272826|NCT04255108|DEVICE|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
214272827|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation|"Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
214656858|NCT04384237|PROCEDURE|Conventional CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
214829437|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 27 Months|
214272828|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena|"In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
214272829|NCT06499311|OTHER|Foot Reflexology|Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.
214272830|NCT06499311|OTHER|Acupressure|Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
214272831|NCT02016573|DEVICE|Renal Denervation|Renal Denervation Catheter
214272832|NCT03095612|DRUG|Selinexor|Selinexor once weekly oral or twice weekly oral
214272833|NCT03095612|DRUG|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
214272834|NCT05518019|DIETARY_SUPPLEMENT|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
214272835|NCT04447794|BEHAVIORAL|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
214272836|NCT04447794|BEHAVIORAL|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
214272837|NCT04167579|DEVICE|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
214272838|NCT06557837|DIAGNOSTIC_TEST|Questionnaires and pain assessment|Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
214272839|NCT06557837|DIAGNOSTIC_TEST|Standing sagittal whole spine X-ray|Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
214272840|NCT06557837|DIAGNOSTIC_TEST|Dynamic test|With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
214272841|NCT06557837|DIAGNOSTIC_TEST|Muscle strength and body composition measurement|Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
214272842|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
214272843|NCT05062356|DRUG|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
214272844|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
214272845|NCT05062356|DRUG|Ketorolac|15mg
214272846|NCT01387932|DEVICE|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
214272847|NCT01387932|PROCEDURE|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
214272848|NCT04070885|PROCEDURE|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
214272849|NCT04070885|PROCEDURE|Urine sample|The urine will be taken from three 15 ml tubes.
214272850|NCT03795623|OTHER|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
214272851|NCT03795623|OTHER|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
214272852|NCT00963937|DRUG|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
214272853|NCT00963937|DRUG|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
214272854|NCT00963937|DRUG|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
214272855|NCT02800681|OTHER|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
214272856|NCT02800681|OTHER|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
214272857|NCT02800681|OTHER|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
214272858|NCT02800681|OTHER|Other general interviewer ratings|1\. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
214272859|NCT06309732|DRUG|Pegfilgrastim|6mg at each cycle
214272860|NCT06309732|DRUG|Dactinomycin|1mg/m2
214272861|NCT06309732|DRUG|Methotrexate|Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
214272862|NCT06309732|DRUG|Etoposide|90mg/m2 injection for infusion
214272863|NCT06309732|DRUG|Cisplatin|50mg/m2
214272864|NCT06309732|DRUG|Epirubicin|37.5mg/m2
214272865|NCT01352104|BEHAVIORAL|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
214272866|NCT04173988|GENETIC|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."
214272867|NCT04173988|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214272868|NCT04173988|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214272869|NCT01310153|PROCEDURE|prone positioning|newborn babies in prone positioning
214272870|NCT01310153|PROCEDURE|Supine|newborn babies in supine positioning
214272871|NCT04574973|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
214272872|NCT04574973|BEHAVIORAL|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
214272873|NCT03539146|OTHER|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
214272874|NCT03539146|OTHER|Control yogurt|Control yogurt
214272875|NCT01395667|OTHER|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
214272876|NCT03867188|DRUG|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
214272877|NCT01015599|BEHAVIORAL|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
214272878|NCT04569656|DRUG|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
214272879|NCT01199172|BEHAVIORAL|voice hygiene|subjects will receive voice hygiene training
214272880|NCT01199172|BEHAVIORAL|VH + VP|subjects will be trained in voice hygiene and voice production training
214272881|NCT04945577|DIAGNOSTIC_TEST|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
214272882|NCT04945577|OTHER|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
214272883|NCT03463512|DRUG|Racecadotril plus ORS|Racecadotril plus ORS
214272884|NCT03463512|DRUG|ORS|ORS
214272885|NCT01423578|BEHAVIORAL|Hatha Yoga (HY)|3 Sessions of yoga instruction
214272886|NCT01423578|BEHAVIORAL|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
214272887|NCT01423578|BEHAVIORAL|Smoking Cessation Counseling|4 smoking cessation counseling visits.
214829438|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 30 Months|
214272888|NCT06212154|BIOLOGICAL|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
214272889|NCT01293773|DEVICE|Taxus Element stent|paclitaxel-eluting stent
214272890|NCT01293773|DEVICE|Integrity Resolute stent|ABT 578-eluting stent
214272891|NCT01293773|DEVICE|Xience Prime stent|Everolimus-eluting stent
214272892|NCT06287190|OTHER|Dental interns|Assessing self-assessment
214272893|NCT00238888|PROCEDURE|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
214272894|NCT00238888|PROCEDURE|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
214272895|NCT01706796|DRUG|PF-06273340|Oral solution, single dose, fasted
214272896|NCT01706796|DRUG|PF-06273340|Immediate Release Tablet, single dose, fasted
214272897|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
214272898|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
214272899|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
214272900|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
214272901|NCT03020173|OTHER|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
214272902|NCT05132634|OTHER|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
214272903|NCT04089475|DEVICE|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
214272904|NCT06412224|DRUG|RRG001|Administered by subretinal injection. Dosage form: injection.
214272905|NCT06503055|OTHER|Questionnaire|"A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles."
214272906|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
214272907|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
214272908|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
214272909|NCT01474083|DRUG|Placebo|Dose-matched placebo. Oral administration.
214272910|NCT05626062|DEVICE|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
214272911|NCT05128318|PROCEDURE|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
214272912|NCT04853030|DRUG|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
214272913|NCT04853030|DRUG|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
214272914|NCT01536470|OTHER|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
214272915|NCT01536470|OTHER|Ephedryne chorydrate|
214272916|NCT00939640|BEHAVIORAL|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
214272917|NCT05954702|PROCEDURE|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
214272918|NCT05954702|PROCEDURE|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
214272919|NCT05745012|PROCEDURE|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
214272920|NCT05745012|PROCEDURE|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
214272921|NCT00886561|BEHAVIORAL|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
214272922|NCT04205981|OTHER|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
214272923|NCT01513096|DRUG|itopride|itopride, 10mg, twice per day, for 1 day
214272924|NCT02433457|DRUG|CC-292|
214272925|NCT02433457|DRUG|Oral Omeprazole (OMP)|
214272926|NCT00736424|DEVICE|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
214272927|NCT01743183|DEVICE|Threshold|The load adjustment was done weekly by a single examiner.
214272928|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
214829439|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 33 Months|
214272929|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
214272930|NCT00023946|DRUG|ixabepilone|Given IV
214272931|NCT00023946|OTHER|laboratory biomarker analysis|Correlative studies
214272932|NCT06114225|COMBINATION_PRODUCT|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
214272933|NCT03730675|PROCEDURE|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
214272934|NCT03730675|PROCEDURE|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
214272935|NCT03730675|DRUG|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
214272936|NCT06371443|BEHAVIORAL|Sucking and swallowing exercises|Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
214272937|NCT06150625|OTHER|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
214272938|NCT06150625|OTHER|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
214272939|NCT06150625|OTHER|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
214272940|NCT06150625|OTHER|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
214272941|NCT05763095|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214272942|NCT02169479|DRUG|BIA 9-1067|OPC, Opicapone
214272943|NCT02169479|DRUG|Placebo|PLC, Placebo
214272944|NCT02169479|DRUG|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
214272945|NCT00431769|DRUG|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
214272946|NCT06327009|BEHAVIORAL|fasting month of ramadan|100 patients with glomerulonephritis who decided to fast month of ramadan
214272947|NCT02645201|DIETARY_SUPPLEMENT|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
214272948|NCT02645201|OTHER|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
214272949|NCT04392752|OTHER|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
214272950|NCT05992181|OTHER|NEORTHO|early orofacial stimulation
214272951|NCT00344708|PROCEDURE|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
214272952|NCT03985059|OTHER|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
214272953|NCT04710602|PROCEDURE|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
214272954|NCT04710602|PROCEDURE|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
214272955|NCT06322069|OTHER|Self-compassion intervention group|Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
214272956|NCT03254979|BEHAVIORAL|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
214272957|NCT01210469|OTHER|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
214272958|NCT01210469|OTHER|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
214272959|NCT01581775|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
214272960|NCT01686308|PROCEDURE|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
214272961|NCT01686308|PROCEDURE|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
214272962|NCT04010695|DIAGNOSTIC_TEST|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
214272963|NCT04010695|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
214272964|NCT04010695|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
214272965|NCT03531359|DEVICE|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
214272966|NCT03531359|DRUG|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
214272967|NCT01993706|DRUG|VRC-HIVMAB060-00-AB|
214272968|NCT02683720|DIETARY_SUPPLEMENT|ONS|randomized clinical trial involving different ONS strategies
214272969|NCT01076920|GENETIC|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
214272970|NCT06284031|PROCEDURE|3 fractions HDR brachytherapy|"The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days"
214272971|NCT01235689|BIOLOGICAL|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
214272972|NCT01235689|DRUG|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
214272973|NCT01235689|DRUG|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
214272974|NCT01443182|BEHAVIORAL|STAIR|Skills Training in Affective and Interpersonal Regulation
214829440|NCT03134053|DEVICE|extracorporeal shock-wave|to treat painful and retracting scars
214272975|NCT01443182|BEHAVIORAL|MPE|Modified prolonged exposure (MPE)
214272976|NCT01443182|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing
214272977|NCT05113290|DRUG|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
214272978|NCT05113290|DRUG|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
214272979|NCT02362581|OTHER|prophylaxis treatment, on demand treatment|
214272980|NCT03700593|DEVICE|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
214272981|NCT00163878|PROCEDURE|Sensory Stimulation|
214272982|NCT00163878|DEVICE|Sesnory Modality Assessment and Rehabilitation Technique|
214272983|NCT05760560|DRUG|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
214829441|NCT03134053|OTHER|massage|to treat painful and retracting scars
214829442|NCT03819088|DIETARY_SUPPLEMENT|Zinc|Given PO
214829443|NCT03212651|DRUG|Pembrolizumab|Pembrolizumab 200mg IV infusion
214272984|NCT04965727|PROCEDURE|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
214272985|NCT05269433|BEHAVIORAL|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
214272986|NCT05269433|BEHAVIORAL|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
214272987|NCT05269433|OTHER|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
214272988|NCT05269433|OTHER|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
214272989|NCT01182142|DRUG|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
214272990|NCT00389597|DEVICE|Cervical Artificial Disc|Cervical artificial disc mechanical device
214272991|NCT01663025|BEHAVIORAL|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
214272992|NCT02399371|BIOLOGICAL|Pembrolizumab|Given IV
214272993|NCT02399371|OTHER|Laboratory Biomarker Analysis|Correlative studies
214272994|NCT02399371|OTHER|Pharmacogenomic Study|Correlative studies
214272995|NCT05123170|DRUG|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
214272996|NCT05123170|DRUG|Lidocaine IV|Intravenous regional anaesthesia
214272997|NCT00508365|DRUG|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
214272998|NCT00508365|DRUG|Placebo|Placebo capsules to match each dose level will be provided.
214272999|NCT00508365|DRUG|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
214273000|NCT05594056|PROCEDURE|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
214273001|NCT03951155|BEHAVIORAL|Muscle Relaxation|"* Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise."
214273002|NCT01469312|OTHER|modified pasta|50 grams carbohydrate as a single breakfast meal
214273003|NCT00005044|DRUG|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
214273004|NCT00005044|DRUG|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
214273005|NCT00005044|DRUG|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
214273006|NCT00005044|RADIATION|radiation therapy|\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
214273007|NCT04431453|DRUG|Remdesivir|Administered as an intravenous infusion
214273008|NCT02256657|BEHAVIORAL|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
214273009|NCT01881074|DRUG|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
214273010|NCT01881074|DRUG|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
214273011|NCT04314934|DRUG|ANAVEX2-73|Oral capsules
214273012|NCT05175508|DRUG|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
214273013|NCT05175508|DRUG|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
214273014|NCT01354457|DRUG|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
214273015|NCT02563171|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
214273016|NCT02563171|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
214273017|NCT01206348|DRUG|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
214273018|NCT06361433|DRUG|HUFF-01|autologous MSC combined with scaffold
214273019|NCT05728021|BEHAVIORAL|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
214273020|NCT05728021|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
214273021|NCT01332370|DRUG|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
214273022|NCT01332370|DRUG|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
214273023|NCT03241875|DRUG|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
214273024|NCT03241875|DRUG|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
214273025|NCT03241875|DRUG|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
214273026|NCT03622073|OTHER|Misoprostol treatment by Midwife|Medical management of incomplete abortion
214273027|NCT03622073|OTHER|Misoprostol treatment by Doctor|Medical management of incomplete abortion
214273028|NCT03546062|OTHER|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
214273029|NCT05840783|DEVICE|Open ended needle irrigation|irrigation during root canal shaping and cleaning using an open-ended needle
214273030|NCT05840783|DEVICE|side vented needle irrigation|irrigation during root canal shaping and cleaning using a 30-guage side-vented needle
214273031|NCT05840783|DEVICE|Sonic activation|Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
214273032|NCT01703325|DRUG|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group"
214273033|NCT00353795|PROCEDURE|MR Imaging of the Coronary Arteries|
214273034|NCT06081712|DRUG|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
214273035|NCT06081712|DRUG|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
214273036|NCT02416570|DRUG|Clarithromycin|
214273037|NCT02416570|DRUG|Placebo|
214273038|NCT02083965|BIOLOGICAL|rFVIIIFc|Administered as specified in the treatment arm.
214273039|NCT03137420|DIAGNOSTIC_TEST|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
214273040|NCT02539446|BEHAVIORAL|stable condition|
214273041|NCT02539446|BEHAVIORAL|unstable condition|
214273042|NCT02539446|BEHAVIORAL|attentional focus|
214273043|NCT02481908|DEVICE|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
214273044|NCT00028782|DRUG|etanidazole|Given IV
214273045|NCT00028782|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214273046|NCT00028782|OTHER|laboratory biomarker analysis|Correlative studies
214273047|NCT01760460|DRUG|Anacetrapib|
214273048|NCT01760460|DRUG|Placebo for anacetrapib|
214273049|NCT04502433|DRUG|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
214273050|NCT02615314|PROCEDURE|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
214273051|NCT02774954|BEHAVIORAL|Change the Cycle|See previous response
214273052|NCT01551992|PROCEDURE|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
214273053|NCT04710173|PROCEDURE|ECMO|VV-ECMO
214273054|NCT05228171|BEHAVIORAL|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
214273055|NCT00850590|DRUG|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
214273056|NCT03018600|BEHAVIORAL|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
214273057|NCT06011044|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
214273058|NCT01375244|DRUG|Lisinopril|Tablets, 10 mg, single dose
214273059|NCT01375244|DRUG|Zestril|Tablets, 10 mg, single dose
214273060|NCT02294955|DEVICE|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
214273061|NCT02294955|DRUG|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
214273062|NCT02294955|DRUG|Sotalol|Dosage orally 80-160 mg twice daily
214273063|NCT02294955|DRUG|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
214273064|NCT02294955|DRUG|Propafenone|Dosage orally 300 mg twice daily
214273065|NCT02294955|DRUG|Disopyramide|Dosage orally 250-375 mg twice Daily
214273066|NCT02294955|DRUG|Dronedarone|Dosage orally 400 mg twice daily
214273067|NCT00651560|DRUG|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
214273068|NCT00740571|DRUG|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
214273069|NCT00740571|DRUG|pregabalin|Strategy in which patient starts with pregabalin
214273070|NCT03136354|PROCEDURE|Endoscopic Submucosal Dissection|
214273071|NCT03136354|PROCEDURE|Laparoscopic assisted Gastrectomy|
214273072|NCT03824730|DEVICE|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
214273073|NCT02694965|OTHER|observational|
214273074|NCT00037141|DRUG|dehydrated alcohol|
214273075|NCT06326385|OTHER|no intervention|no intervention
214273076|NCT01702961|DRUG|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
214273077|NCT01702961|DRUG|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
214273078|NCT01702961|DRUG|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
214273079|NCT01702961|DRUG|BCNU|BCNU 300 mg/m2 IV given on Day -6
214273080|NCT01702961|DRUG|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
214273081|NCT01702961|DRUG|Stem Cells|Stem cells given on Day 0
214273082|NCT02229383|DRUG|Exenatide|2 mg weekly suspension injection
214273083|NCT02229383|DRUG|Exenatide matching placebo|Once weekly Placebo injection
214273084|NCT03954665|BEHAVIORAL|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
214273085|NCT03954665|BEHAVIORAL|30s Wingate|30s all-out test to measure peak power output
214273086|NCT03954665|DIETARY_SUPPLEMENT|Ketone|Supplement containing exogenous ketone salts
214273087|NCT03954665|BEHAVIORAL|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
214273088|NCT03954665|BEHAVIORAL|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
214273089|NCT04803071|DIETARY_SUPPLEMENT|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
214273090|NCT04803071|DIETARY_SUPPLEMENT|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
214273091|NCT04803071|DIETARY_SUPPLEMENT|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
214273092|NCT02849041|DEVICE|medical imaging|Low-dose CT-scanner
214273093|NCT02849041|BIOLOGICAL|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
214273094|NCT02849041|PROCEDURE|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
214273095|NCT04589806|PROCEDURE|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
214273096|NCT06557902|DRUG|Lumateperone 10.5 mg capsule|Lumateperone 10.5 mg capsule, oral administration
214273097|NCT06557902|DRUG|Lumateperone 21 mg capsule|Lumateperone 21 mg capsule, oral administration
214273098|NCT06557902|DRUG|Lumateperone 5 mg ODT|Lumateperone 5 mg ODT, oral administration
214273099|NCT06557902|DRUG|Lumateperone 10.5 mg ODT|Lumateperone 10.5 mg ODT, oral administration
214273100|NCT06557902|DRUG|Lumateperone 15.5 mg ODT|Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
214273101|NCT06557902|DRUG|Lumateperone 21 mg ODT|Lumateperone 21 mg ODT, oral administration
214273102|NCT03207477|DIAGNOSTIC_TEST|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
214273103|NCT00307645|DRUG|Cyclophosphamide|
214273104|NCT00307645|DRUG|Mycophenolate mofetil|
214273105|NCT00307645|DRUG|Azathioprine|
214273106|NCT00307645|DRUG|Prednisone (and methylprednisolone)|
214273107|NCT00108173|DRUG|Zyban|
214273108|NCT02653183|DEVICE|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
214273109|NCT02653183|DEVICE|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
214273110|NCT04594811|DRUG|NT-I7|Administered by intramuscular (IM) injection.
214273111|NCT04594811|DRUG|Nivolumab|Administered by intravenous (IV) injection.
214273112|NCT03488732|DEVICE|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
214273113|NCT00674362|BIOLOGICAL|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
214273114|NCT00674362|BIOLOGICAL|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
214273115|NCT01404858|BEHAVIORAL|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
214273116|NCT02188108|OTHER|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
214273117|NCT06239766|DIAGNOSTIC_TEST|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
214273118|NCT03274128|RADIATION|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
214273119|NCT03274128|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
214273120|NCT01170858|DRUG|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
214273121|NCT01170858|DRUG|glucose solutions|
214273122|NCT03093883|DRUG|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
214273123|NCT03093883|DRUG|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
214273124|NCT01899261|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
214273125|NCT00084383|BIOLOGICAL|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
214273126|NCT03857048|OTHER|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
214273127|NCT03857048|OTHER|Exercise training|16-wk supervised endurance exercise training program
214273128|NCT03857048|OTHER|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
214273129|NCT00399750|DRUG|oxaliplatin|
214273130|NCT00399750|DRUG|fluoropyrimidine|
214273131|NCT00399750|DRUG|bevacizumab|
214273132|NCT01045525|PROCEDURE|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
214273133|NCT01045525|BEHAVIORAL|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
214273134|NCT03659500|DIAGNOSTIC_TEST|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
214273135|NCT03659500|DIAGNOSTIC_TEST|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
214273136|NCT00831025|BIOLOGICAL|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
214273137|NCT00831025|BIOLOGICAL|Placebo|Placebo for subcutaneous monthly administration
214273138|NCT03137537|DRUG|Ivabradine|lower heart rate in heart failure patients.
214273139|NCT03137537|DRUG|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
214273140|NCT04368676|OTHER|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
214273141|NCT04368676|OTHER|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
214273142|NCT00807729|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
214273143|NCT00807729|PROCEDURE|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
214273144|NCT02352129|OTHER|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
214273145|NCT03386448|DRUG|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
214273146|NCT03386448|DRUG|placebo arm|participants will receive placebo medications
214273147|NCT06440720|OTHER|ELDOA ,UPPER THORACIC MOBILIZATION AND MOBILITY EXERCISE|Already mentioned
214273148|NCT01146665|BEHAVIORAL|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
214273149|NCT01146665|BEHAVIORAL|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
214273150|NCT01752361|DEVICE|Motilis-3D transit|
214273151|NCT01601730|DRUG|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
214273152|NCT01601730|DRUG|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
214273153|NCT01601730|DRUG|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
214273154|NCT01601730|DRUG|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
214273155|NCT02178371|PROCEDURE|mCIMT|affected upper limb use with constraint of the healthy hand
214273156|NCT02178371|PROCEDURE|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
214273157|NCT01848730|DRUG|CNV2197944|
214273158|NCT01848730|DRUG|Placebo|
214273159|NCT05091359|DEVICE|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
214273160|NCT02685410|OTHER|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
214273161|NCT06426810|DEVICE|Electrosurgical bipolar system (LigaSure)|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
214273162|NCT00981370|DRUG|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
214273163|NCT01817530|OTHER|Elagolix placebo|oral coated tablet
214273164|NCT01817530|DRUG|Elagolix|oral coated tablet
214273165|NCT01817530|DRUG|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
214273166|NCT01817530|DRUG|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
214273167|NCT01817530|DRUG|E2/NETA placebo|oral hard capsule
214273168|NCT03846804|DIAGNOSTIC_TEST|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
214273169|NCT02419105|DRUG|Testosterone|transdermal gel, 75 mg daily
214273170|NCT02419105|DRUG|Colecalciferol|drink solution, 24000 IU once per month
214273171|NCT02419105|DRUG|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
214273172|NCT02419105|DRUG|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
214273173|NCT00002989|DRUG|busulfan|
214273174|NCT00002989|DRUG|cyclophosphamide|
214273175|NCT00002989|DRUG|idarubicin|
214273176|NCT00002989|DRUG|melphalan|
214273177|NCT00002989|RADIATION|radiation therapy|
214273178|NCT00259337|BIOLOGICAL|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
214273179|NCT05658120|DRUG|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
214273180|NCT00404235|DRUG|carboplatin|
214273181|NCT00404235|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214273182|NCT05134675|DIETARY_SUPPLEMENT|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
214273183|NCT00273546|DRUG|XRP6976 (Docetaxel/Taxotere)|
214273184|NCT01841788|DEVICE|Thermal Adhesion Patch|
214273185|NCT01841788|DEVICE|Marketed Thermal Adhesion Patch|
214273186|NCT01841788|DEVICE|Placebo Patch|
214273187|NCT02308605|DEVICE|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
214273188|NCT03456050|BEHAVIORAL|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
214273189|NCT03456050|BEHAVIORAL|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
214273190|NCT02562534|DEVICE|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
214273191|NCT01482845|DRUG|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
214273192|NCT01482845|DRUG|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
214273193|NCT03245515|DRUG|BMS-986195|specified dose on specified days
214273194|NCT05309408|DIAGNOSTIC_TEST|Venipuncture|Venipuncture
214273195|NCT05309408|DIAGNOSTIC_TEST|Lumbar Puncture|Lumbar Puncture
214273196|NCT00345839|DRUG|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
214273197|NCT00345839|DRUG|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
214273198|NCT01960400|DEVICE|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
214273199|NCT01960400|DEVICE|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
214273200|NCT03824314|DRUG|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
214273201|NCT03824314|DRUG|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
214273202|NCT05160493|DRUG|S-ketamine and pregabalin|"S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
214273203|NCT05160493|DRUG|Normal saline and placebo capsule|Normal saline and placebo capsule
214273204|NCT03838952|DRUG|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
214273205|NCT05262608|DRUG|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
214273206|NCT05147025|OTHER|Revascularization|Regain pulp vascularity for young permenant teeth
214273207|NCT02236975|DEVICE|BuMA Supreme Biodegradable drug coating coronary stent system|
214273208|NCT02236975|DEVICE|Resolute Integrity durable polymer stent system|
214273209|NCT02106260|DRUG|CLS003|
214273210|NCT01049100|PROCEDURE|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
214273211|NCT01049100|OTHER|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
214273212|NCT04827381|OTHER|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
214273213|NCT04827381|OTHER|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
214273214|NCT03298867|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
214273215|NCT03298867|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
214273216|NCT03321266|DEVICE|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
214273217|NCT02746796|DRUG|ONO-4538|
214273218|NCT02746796|DRUG|Oxaliplatin|
214273219|NCT02746796|DRUG|Tegafur- Gimeracil-Oteracil potassium|
214273220|NCT02746796|DRUG|Capecitabine|
214273221|NCT02746796|DRUG|Placebo|
214273222|NCT04119921|DRUG|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
214273223|NCT04119921|DRUG|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
214273224|NCT04119921|DRUG|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
214273225|NCT04119921|DRUG|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
214273226|NCT04375371|PROCEDURE|Bariatric surgery|Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
214273227|NCT01881360|OTHER|Gluten-free diet|A diet that is free of the gluten component
214273228|NCT01881360|OTHER|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
214273229|NCT00743483|DRUG|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
214273230|NCT05227183|BEHAVIORAL|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
214273231|NCT01109797|BEHAVIORAL|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
214273232|NCT01109797|BEHAVIORAL|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
214273233|NCT01410201|DRUG|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
214273234|NCT04838483|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
214273235|NCT04649320|OTHER|questionnaire|"1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30"
214656859|NCT00940004|BIOLOGICAL|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
214273236|NCT02085122|OTHER|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
214273237|NCT06400862|COMBINATION_PRODUCT|eOCT implantation|eOCT is regarded as an Advanced Therapy Product (ATP).
214273238|NCT02276001|DRUG|K-877|
214273239|NCT02276001|DRUG|Cyclosporine|
214273240|NCT01466153|DRUG|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
214273241|NCT01466153|DRUG|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
214273242|NCT01466153|DRUG|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
214273243|NCT03105791|OTHER|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
214273244|NCT03708016|DEVICE|Robot gait training|Lokomat robot training was applied to stroke patients.
214273245|NCT03708016|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
214273246|NCT05250778|BEHAVIORAL|Nudge|Room intervention
214273247|NCT01213329|DRUG|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
214273248|NCT06504680|PROCEDURE|Repair of flexor tendon injury zone ll using 8- strand|Repair cut flexor zone ll using 8-strand with and without splinting the wrist
214273249|NCT00150748|DRUG|Levetiracetam 166 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use"
214273250|NCT00150748|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use"
214273251|NCT00150748|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use"
214273252|NCT01684956|PROCEDURE|Intradermal injection|
214273253|NCT01684956|PROCEDURE|Subcutaneous injection|
214273254|NCT04138238|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
214273255|NCT03483740|BEHAVIORAL|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
214273256|NCT03483740|BEHAVIORAL|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
214273257|NCT05774678|RADIATION|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
214273258|NCT05774678|OTHER|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
214273259|NCT05497609|OTHER|no intervention. Care as ususal|No intervention
214273260|NCT04859361|DRUG|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
214273261|NCT04859361|PROCEDURE|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
214273262|NCT01558232|DEVICE|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
214273263|NCT05433493|BEHAVIORAL|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
214273264|NCT03145974|DEVICE|mechanical ventilation|ventilatory support
214273265|NCT06180772|BEHAVIORAL|FIT FIRST|High intensity sports drills and games
214273266|NCT01408927|OTHER|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
214273267|NCT01408927|OTHER|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
214273268|NCT01408927|OTHER|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
214273269|NCT01797744|OTHER|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
214273270|NCT02383498|OTHER|Placebo|Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
214273271|NCT02383498|BIOLOGICAL|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
214273272|NCT02383498|RADIATION|Radiotherapy|Standard of care
214273273|NCT02383498|DEVICE|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
214273274|NCT00004211|BIOLOGICAL|PSA RNA-pulsed dendritic cell vaccine|
214273275|NCT02022852|DRUG|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
214273276|NCT02022852|DRUG|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
214273277|NCT01675791|BIOLOGICAL|ALK tree AIT 0.5 DU|
214273278|NCT01675791|BIOLOGICAL|ALK tree AIT 1 DU|
214273279|NCT01675791|BIOLOGICAL|ALK tree AIT 2 DU|
214273280|NCT01675791|BIOLOGICAL|ALK tree AIT 4 DU|
214273281|NCT01675791|BIOLOGICAL|ALK tree AIT 7 DU|
214273282|NCT01675791|BIOLOGICAL|ALK tree AIT 12 DU|
214273283|NCT01675791|BIOLOGICAL|ALK tree AIT Placebo|
214273284|NCT03225885|OTHER|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
214273285|NCT03225885|OTHER|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
214273286|NCT03859505|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
214273287|NCT03859505|DEVICE|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
214273288|NCT06204601|OTHER|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
214273289|NCT04137705|OTHER|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
214273290|NCT05315401|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
214273291|NCT05315401|DIETARY_SUPPLEMENT|Placebo|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
214273292|NCT05315401|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
214273293|NCT03305341|BIOLOGICAL|COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix"
214273294|NCT04685317|DEVICE|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
214273295|NCT04685317|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
214273296|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
214656860|NCT04901572|DIAGNOSTIC_TEST|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
214273297|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
214273298|NCT01857856|DRUG|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
214273299|NCT05983757|DEVICE|Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion|"The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA)."
214273300|NCT05983757|OTHER|Standard medical management|All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
214273301|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
214273302|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
214273303|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
214273304|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
214273305|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
214273307|NCT06679699|DEVICE|Trunk control exercises combined with patient education program|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces. In addition, the experimental group provided a patient education program which focuses on the importance of trunk control and benefits of trunk control exercises during the rehabilitation process. Further, caregivers and family members were also explained about the patient education program and adherence with treatment protocol during and after the interventions.
214273308|NCT06679699|DEVICE|Trunk control exercises|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces.
214273309|NCT07015879|BEHAVIORAL|Continuous Care Counseling Based on the Roy Adaptation Model|Patients in the control group will receive the clinic's routine treatment and nursing care. This care includes preoperative and postoperative information, prevention of leg flexion, monitoring of vital signs, pain management, discharge education, and discharge of patients without complications three days after surgery. In addition, patients' overall comfort and quality of life will be assessed face-to-face five days before surgery and on the second postoperative day, and by telephone at the first and third months after discharge.
214273310|NCT07015021|DRUG|Daratumumab|Daratumumab: 16mg/Kg, IV or 1800mg Sc; C1-2 d1,8,15,22; C3-6 d1,15; C7-12 d1
214273311|NCT07015021|DRUG|Cafizomide|Cafizomide: 20mg/m2; C1-8 d1,2,8,9,15,16； C9-12 d1,2,15,16；After tolerance to 20mg/m2, the dose of C1D1 and C1D2 can be adjusted to 27g/m2.
214273312|NCT07015021|DRUG|Pomalidomide|Pomalidomide: 4mg, PO,d1-21
214273313|NCT07015021|DRUG|Dexamethasone|Dexamethasone: 20mg, po,d1, 2,8,9,15,16,22,23.
214273314|NCT03835780|OTHER|No intervention|A observation of outcomes in usual practice
214273315|NCT07054125|BEHAVIORAL|Education, lifestyle counseling, and peer support|"This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes.~People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit)."
214273316|NCT07054086|DRUG|Neoadjuvant Chemotherapy (NACT)|"The planned regimen for neoadjuvant therapy may include one or more of the following agents:~1. Paclitaxel Injection~2. Albumin-bound paclitaxel Injection (Abraxane® equivalent formulation)~3. Cisplatin Injection~4. Carboplatin Injection~5. Nivolumab~6. Pembrolizumab~7. Toripalimab~8. Tirilibumab~9. Camrelizumab The specific agent(s) and their combination will be selected based on the patient's clinical treatment protocol. The final regimen must be approved jointly by the principal investigator and the attending physician according to established clinical guidelines and individualized patient factors."
214273317|NCT07053696|DRUG|Technetium-99m Diethylenetriaminepentaacetic Acid|Technetium-99m Diethylenetriaminepentaacetic Acid A single inhaled dose of 99mTc-DTPA in 0.9% sodium chloride solution, total volume 2 ml, with radioactivity of 500-800 µCi. The solution is radiolabeled only in the aqueous phase to allow gamma scintigraphic imaging of pulmonary deposition. Delivered via breath-actuated EDDIS system. The formulation includes a non-labeled microdose of perfluorocarbon emulsion to simulate clinical aerodynamic behavior.
214273318|NCT07053696|DEVICE|EDDIS-IDDS (Enhanced Digital Dose Inhalation Delivery System)|Portable, maintenance-free breath-actuated inhalation delivery system with integrated digital sensors. Records real-time data including inspiratory volume, flow rate, duration, and breath-hold time. Provides controlled aerosol delivery and secure transmission of inhalation parameters to the clinical monitoring platform.
214273319|NCT07053644|BEHAVIORAL|FRESH-EATS|"1. Six weekly Cooking Matters® for Families sessions. Each session is designed to take 90 minutes including hands-on cooking or other activities.~2. Two 90-minute family workshop sessions will be implemented.~3. Food delivery budget (i.e., the Walmart+ annual membership with free shipping and gift cards to purchase ingredients) will be provided up during the intervention period and local food pantry information will be distributed to families.~4. Community garden at the Cornerstone Family Ministries will be utilized by incorporating garden activities, harvesting, and cooking with the produce from the garden."
214273320|NCT07053644|BEHAVIORAL|Lagged Intervention Control Group|Nutrition education materials that address nutrition in school-age children and families Cooking Matters® for Families will be implemented. Each of six sessions will take about 90 minutes. All lessons will be delivered by qualified nutrition educators along with student assistants at the Cornerstone Family Ministries classrooms. After completing the post-intervention assessment, participants will then receive the other FRESH-EATS intervention components.
214273321|NCT07053930|DRUG|Intraumbilical oxytocin|Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.
214273322|NCT07053930|DRUG|Intravenous oxytocin|Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.
214273323|NCT07055321|DRUG|ETH47|Dose level 1; single intranasal administration
214273324|NCT07055321|DRUG|ETH47|Dose level 2; single intranasal administration
214273325|NCT07055321|DRUG|ETH47|Dose level 3; single intranasal administration
214273326|NCT07055321|DRUG|ETH47|Dose level 4; single intranasal administration
214273327|NCT07055321|DRUG|ETH47|Dose level 5; single intranasal administration
214273328|NCT07055321|DRUG|ETH47|Dose level 1; single inhaled administration
214273329|NCT07055321|DRUG|ETH47|Dose level 2; single inhaled administration
214273330|NCT07055321|DRUG|ETH47|Dose level 3; single inhaled administration
214273331|NCT07055321|DRUG|ETH47|Dose level 4; single inhaled administration
214273332|NCT07053904|DRUG|Sequential use of P1101 and P1801|Sequential use of ropeginterferon alfa-2b and P1801 (anti PD-1 antibody drug)
214273333|NCT07055191|PROCEDURE|Transoral Endoscopic Thyroidectomy by Vestibular Approach|Transoral Endoscopic Thyroidectomy by Vestibular Approach
214273334|NCT07055191|PROCEDURE|Anterior Cervical thyroidectomy|Anterior Cervical thyroidectomy
214273335|NCT07055373|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular VNS will be administered using the Parasym aVNT (auricular vagal neuromodulation therapy) Device (Nurosym, London, UK). The Parasym aVNT Device delivers non-invasive neuromodulation targeting the auricular branch of the vagus nerve via the tragus of the outer ear. All participants will receive four weeks of twice daily (morning and evening) 45-minute sessions of taVNS (frequency ≥ 25Hz; pulse width =250µs (Fig). The safety and tolerability of taVNS has been demonstrated in seven studies with a total of 205 (116 active, 121 sham) cardiovascular patients. Stimulation protocols ranged from 43 min to 8 hrs daily, for 1 day to 6 months. There were no device-related serious adverse events. Three patients (1.5%) experienced minor adverse events, i.e., dermal paresthesias (light tingling at the ear). No differences in tolerability were observed between active and sham taVNS \[21\].
214273336|NCT07053189|DEVICE|Clear Aligner treatment|Interproximal enamel reduction and attachment impact
214273337|NCT07053280|DEVICE|Teleaudiological tests|Initially, the FPT, DPT, RGDT, and SSWT were administered face-to-face; one month later, the same tests were repeated via teleaudiology, with the audiologist and participant in separate rooms using identical laptops and headphones, without visual or auditory contact.
214273338|NCT07053475|DRUG|Ferric Carboxymaltose|Intravenous infusion of 1 gram FCM during index hospital stay, followed by a second dose at Week 6 (1,000 mg if \> 70 kg or 500 mg if ≤ 70 kg).
214273339|NCT07053475|DRUG|Ferrous Sulfate|Oral administration of one 150 mg capsule every 48 hours for 12 weeks.
214273340|NCT07053319|DRUG|Empagliflozin 25 MG plus Pioglitazone placebo|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
214273341|NCT07053319|DRUG|Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo|Placebo-Inert tablet
214273342|NCT07053319|DRUG|Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)|Pioglitazone, a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
214273343|NCT07053319|DRUG|Pioglitazone placebo + Empagliflozin placebo|Placebo-Inert tablet
214273344|NCT07054775|DRUG|Morphine Sulfate|intrathecal administered morphine
214273345|NCT07055217|BEHAVIORAL|Mindfulness Training|"A single 45-minute mindfulness training will be provided to all at-risk participants at visit 2. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
214656861|NCT05762926|OTHER|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
214273346|NCT07055217|BEHAVIORAL|Mindfulness-based Neurofeedback (Real mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label, with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. All participants will be trained until they feel competent to use mental noting in the scanner. Study clinicians will show 85% fidelity on the mindfulness training assessment before working with participants and sessions will be recorded and 10% of sessions will be assessed quarterly for fidelity. During active mbNF (6 runs, 2.5 mins each), participants will use mental noting with the aim of controlling the visual feedback; specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
214273347|NCT07055217|BEHAVIORAL|Sham mindfulness-based neurofeedback (Sham mbNF)|During sham mbNF condition, participants will undergo similar MRI scan procedures. The primary difference in scan procedures is that rather than receiving mbNF, participants will view a visual display (i.e., white dot, red and blue circles) extracted from a previously acquired mbNF session. Thus, the visual display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures that participants across groups are viewing equivalent stimuli for the same amount of overall time.
214273348|NCT07054970|BIOLOGICAL|CT-P55|150 mg in 1.0 mL, administered as a single SC injection via PFS
214273349|NCT07054970|BIOLOGICAL|US-licensed Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
214273350|NCT07054970|BIOLOGICAL|EU-approved Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
214273351|NCT07053631|DEVICE|venous occlusion pressure Measurement|non-invasive venous occlusion pressure of a targeted periorbital vein is measured in parallel to clinical standard CSF dyanmic testing including standard CSF infusiontest
214273352|NCT07053982|PROCEDURE|Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery|This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.
214273353|NCT07053527|BEHAVIORAL|PrEP Awareness and Uptake Educational Program|This intervention targets African American college students aged 18-26 using a tailored, community participatory approach. It is delivered by trained peer educators and focuses on increasing PrEP awareness, access, and uptake through interactive, behaviorally focused sessions. Developed with input from focus groups to ensure relevance, the program includes a 6-month follow-up to assess sustained impact, distinguishing it from general PrEP education efforts.
214273354|NCT07053332|DRUG|PD-1/CTLA-4 combination antibody with low-dose radiotherapy|"* PD-1/CTLA-4 combination antibody: Iparomlimab and Tuvonralimab， 5mg/kg on day 1, day 22, and day 43, administered via intravenous infusion, for a total of three cycles before surgery and maintained for up to 1 year after surgery.~* Radiotherapy: To be conducted within one week of the start of immunotherapy, with a total dose of DT: 30Gy, 2.5Gy × 12 fractions, once daily, five times per week. The preoperative radiotherapy target area will be delineated by the radiation oncologist in accordance with the NCCN Guidelines for Gastric/Esophagogastric Junction Cancers 2022 and in consultation with the opinions of the general surgeon.~* Surgery: Surgical treatment will be completed within 3-5 weeks after the completion of neoadjuvant therapy.~* Adjuvant therapy: Postoperative immunotherapy will be maintained for up to 1 year."
214273355|NCT07053436|DRUG|Bispecific Monoclonal Antibody and Triplet Therapy|Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy
214273356|NCT07053436|DRUG|Monoclonal Antibody with Stem Cell Transplant|Isatuximab-KRd with Autologous Stem Cell Transplant
214273357|NCT07054151|OTHER|No clinical intervention (observational study only)|This is an observational study. No experimental or clinical intervention was applied. Only non-invasive data collection such as capillary refill time and vital sign measurements was performed.
214273358|NCT07054996|OTHER|body awareness therapy|Basic body awareness training will be applied to preschool children in terms of motor development and body perception
214273359|NCT07054996|OTHER|play-based exercise|Play-based exercise training will be implemented for preschool children by designing games that they enjoy playing, in order to support motor development and body perception.
214273360|NCT05415020|BEHAVIORAL|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
214273361|NCT05415020|BEHAVIORAL|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
214273362|NCT05166083|OTHER|Testosterone Hormon Therapy|Testosterone isocaproate, ... ml, 8 doses, once per 21 days
214273363|NCT06756451|DRUG|RJK-RT2831 dose-escalation phase Ia|there are seven doses(1mg-160mg) in this part. The subjects will receive RJK-RT2831 injection twice a week by intravenous push or intravenous infusion for 4 weeks until the end of one dosing cycle (28 days). After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
214273364|NCT06756451|DRUG|RJK-RT2831 Dose Expansion Phase Ib|there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
214273365|NCT06217666|DRUG|PCX-12|treatment combining radiation therapy with PCX12
214273366|NCT06843044|DRUG|Ranquilon|1 mg tablets
214273367|NCT06843044|DRUG|Afobazole|10 mg tablets
214656862|NCT00838357|DRUG|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
214656863|NCT04566484|DRUG|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
214273368|NCT06540638|BEHAVIORAL|Web based education program|In a pre-operative assessment, 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The content of our e-module included: introduction to brain health, surgery, and delirium, causes and risk factors, modifiable risk factors, and delirium prevention. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.
214273369|NCT06897527|DRUG|Dostarlimab|Dostarlimab will be administered.
214273370|NCT06541548|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
214273371|NCT06541548|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
214273372|NCT06541548|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
214273373|NCT05347238|DRUG|Dopamine|Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
214273374|NCT05347238|DRUG|Norepinephrine|Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
214273375|NCT04914923|DEVICE|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
214273376|NCT04914923|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
214273377|NCT04914923|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
214273378|NCT06618027|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D was adapted from Learning to BREATHE, a group mindfulness-based intervention for teens. It teaches mindfulness strategies adapted to be specific and relatable to, teens with T1D to improves symptoms of depression and anxiety as well as diabetes self-management.
214273379|NCT06618027|BEHAVIORAL|HealthEd-T1D|HealthEd-T1D is a 6 week, virtual, group based diabetes education group.
214273380|NCT06903195|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
214273381|NCT06903195|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
214273382|NCT05613361|DRUG|Colistin|added for infection with multi drug resistant bacteria
214273383|NCT05613361|DRUG|Curcumin|added for the possible nephroprotective effect
214273384|NCT05092022|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cells for screening purposes.
214273385|NCT06912776|OTHER|Participant will view a visual aid picture (appendix A) first|Participant will view a visual aid picture (appendix A) of a post delivery complication first
214273386|NCT06912776|OTHER|Participant will view a visual aid picture (appendix B) first|Participant will view a visual aid picture (appendix B) of a post delivery complication first
214273387|NCT06917677|BEHAVIORAL|2000-meter maximal effort test on rowing ergometer|Participants will perform a 2000-meter maximal effort test on a Concept II rowing ergometer, aiming to complete the distance in the shortest possible time. The test simulates a competitive race and serves as a qualification trial. It will be conducted under medical supervision and is intended to induce a high level of physiological and psychological stress representative of elite competition.
214273388|NCT06939504|DRUG|HRS-9813 Capsule|HRS-9813 capsule.
214273389|NCT06939504|DRUG|HRS-9813 Tablet|HRS-9813 tablet.
214273390|NCT06131697|OTHER|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
214273391|NCT06131697|OTHER|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
214273392|NCT01853761|DEVICE|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
214273393|NCT01853761|DEVICE|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
214273394|NCT01853761|DEVICE|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
214273395|NCT01853761|DEVICE|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
214273396|NCT01853761|DEVICE|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
214273397|NCT01853761|DEVICE|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
214273398|NCT03623815|OTHER|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
214273399|NCT02847156|OTHER|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
214273400|NCT01534871|BEHAVIORAL|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
214273401|NCT03940612|DIETARY_SUPPLEMENT|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
214273402|NCT03940612|DIETARY_SUPPLEMENT|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
214273403|NCT03608098|DEVICE|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
214273404|NCT03608098|DEVICE|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
214273405|NCT02823431|DRUG|lidocaine gel|
214273406|NCT02823431|OTHER|Plain aqueous gel|
214273407|NCT00544466|DRUG|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
214273408|NCT00544466|DRUG|melphalan|140 mg/m2 day -2 prior to transplant
214273409|NCT00544466|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
214273410|NCT00544466|RADIATION|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
214273411|NCT06834867|BEHAVIORAL|MILAP intervention|The MILAP intervention, developed through participatory research, includes 9 sessions over 9 weeks, totaling 11 hours. It begins with the MilDil component, consisting of two sessions (4 hours) for MIL-DIL dyads, focusing on discussing cultural gender norms, raising awareness about the negative impact of IPV, establishing allyship between MIL and DIL, and empowering DILs while enhancing MILs' support for DILs' freedom of movement. This is followed by two one-hour sessions on Brief Behavioral Activation (BA) to address and prevent depression, involving MILs for necessary family support. Lastly, the husband-wife dyad will engage in four weekly sessions (4 hours) of Behavioral Couples Therapy (BCT), aimed at improving communication, coping strategies, and fostering caring behaviors between partners.
214273412|NCT04674930|OTHER|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
214273413|NCT01622504|DRUG|MVP005|2 mg single dose administered intranasally
214273414|NCT01622504|DRUG|MVP005|4 mg single dose administered intranasally
214273415|NCT01622504|DRUG|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
214273416|NCT01535547|DRUG|isavuconazole|oral
214273417|NCT01535547|DRUG|tacrolimus|oral
214273418|NCT02881437|DRUG|IgHy10|Sub Cutaneous IgHy10 administration
214273419|NCT03812094|DEVICE|Enurad 400|Alarm treatment
214273420|NCT03812094|BEHAVIORAL|Basic Bladder advice|Pre-specified Basic bladder advice
214273421|NCT04412408|DRUG|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
214273422|NCT03281577|DRUG|TAK-954|TAK-954 IV infusion.
214273423|NCT03281577|DRUG|Placebo|TAK-954 placebo-matching IV infusion.
214273424|NCT02323113|DRUG|TAK-659|TAK-659 tablets.
214273425|NCT05061732|DRUG|Rabeprazole|20mg bid
214273426|NCT05061732|DRUG|Bismuth potassium citrate|0.6g bid
214273427|NCT05061732|DRUG|Metronidazole|0.4g qid
214273428|NCT05061732|DRUG|Clarithromycin|0.5g bid
214273429|NCT05061732|DRUG|Levofloxacin|0.5g qd
214273430|NCT05061732|DRUG|Amoxicillin|1g tid
214273431|NCT05061732|DRUG|Metronidazole|0.4g tid
214273432|NCT05061732|DRUG|Doxycycline|0.1g bid
214273433|NCT05061732|DRUG|Tetracycline|0.5g qid
214273434|NCT05044390|PROCEDURE|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
214273435|NCT01663532|DRUG|Aripiprazole IM Depot|
214273436|NCT01663532|DRUG|Placebo|Matching Placebo
214273437|NCT03807518|BEHAVIORAL|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
214273438|NCT00354744|BIOLOGICAL|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
214273439|NCT00354744|DRUG|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
214273440|NCT00354744|DRUG|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
214273441|NCT00354744|DRUG|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
214273442|NCT00354744|DRUG|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
214273443|NCT00354744|DRUG|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
214273444|NCT00354744|DRUG|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
214273445|NCT00354744|PROCEDURE|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
214273446|NCT00354744|RADIATION|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
214273447|NCT00354744|BIOLOGICAL|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
214273448|NCT04269447|DIAGNOSTIC_TEST|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
214273449|NCT02126020|DRUG|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
214273450|NCT01513343|BEHAVIORAL|Parent and child groups focused on self-regulation of eating|
214273451|NCT01749137|DRUG|Setmelanotide|Daily subcutaneous infusion
214273452|NCT01749137|DRUG|Placebo|Daily subcutaneous infusion
214273453|NCT00388960|DRUG|Amrubicin|"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
214273454|NCT00388960|DRUG|Cisplatin|"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
214273455|NCT00388960|DRUG|Etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
214273456|NCT04188847|DRUG|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
214273457|NCT03438669|OTHER|no intervention|no intervention
214273458|NCT03439553|BEHAVIORAL|Ads display with target websites|Ads are shown, but users are referred to control websites.
214273459|NCT03439553|BEHAVIORAL|Ads display with control websites|Ads are shown, but users are referred to control websites.
214273460|NCT02587234|DEVICE|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
214273461|NCT01367210|DRUG|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
214273462|NCT01367210|DRUG|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
214273463|NCT02698839|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
214273464|NCT02698839|DEVICE|BuMA™|Stent platform: stainless steel
214273465|NCT01153347|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
214273466|NCT01153347|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
214273467|NCT01651377|DRUG|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
214273468|NCT01651377|DRUG|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
214273469|NCT04200950|DEVICE|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
214273470|NCT03191188|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
214273471|NCT03191188|DRUG|Placebo Oral Tablet|Placebo
214273472|NCT03582878|DRUG|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
214656864|NCT04566484|DRUG|Normal Saline|Normal saline is the placebo
214273473|NCT03582878|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
214273474|NCT02051504|BEHAVIORAL|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
214273475|NCT02051504|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
214273476|NCT02051504|PROCEDURE|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
214273477|NCT02051504|PROCEDURE|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
214273478|NCT02051504|PROCEDURE|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
214656865|NCT04375306|PROCEDURE|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
214656866|NCT04375306|PROCEDURE|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
214273479|NCT02051504|PROCEDURE|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
214273480|NCT02051504|OTHER|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
214273481|NCT01706146|DRUG|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
214273482|NCT00932100|DRUG|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
214273483|NCT00932100|DRUG|Heparin|IV dose per standard of care at the local institution
214273484|NCT03857893|DEVICE|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
214273485|NCT03857893|DRUG|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
214273486|NCT02582983|DRUG|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
214273487|NCT02275858|DEVICE|Stiffening wire|Stiffening wire
214273488|NCT02275858|DEVICE|Placebo wire|Placebo wire
214273489|NCT04449081|BEHAVIORAL|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
214273490|NCT05970185|DRUG|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
214273491|NCT05970185|DRUG|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
214273492|NCT02050516|OTHER|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
214273493|NCT01951274|DRUG|VPD-737|NK1 Receptor Antagonist
214273494|NCT01951274|DRUG|Placebo|
214273495|NCT06201364|PROCEDURE|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
214273496|NCT06201364|PROCEDURE|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
214273497|NCT01322269|DRUG|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
214273498|NCT05648383|BEHAVIORAL|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
214273499|NCT05648383|BEHAVIORAL|Standard care|Participants will receive standard care, including lifestyle recommendations.
214273500|NCT03342365|DIAGNOSTIC_TEST|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
214273501|NCT04289662|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
214273502|NCT04289662|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
214273503|NCT02425371|OTHER|Screening and treatment of comorbidities|Screening and treatment of comorbidities
214273504|NCT02425371|OTHER|Placebo Comparator|No screening of comorbidities
214273505|NCT05561049|DRUG|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
214273506|NCT02892578|OTHER|electrocardiogram|
214273507|NCT04843137|DEVICE|Cervical Transcutaneous Electrical Spinal Cord Stimulation|Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
214273508|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
214273509|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
214273510|NCT04302896|DRUG|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
214273511|NCT04302896|DRUG|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
214656867|NCT03881709|BEHAVIORAL|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
214273512|NCT04302896|DRUG|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
214273513|NCT04302896|DRUG|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
214273514|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
214273515|NCT03236285|BEHAVIORAL|Continous exercise training in the fed state|Continous exercise training in the fed state
214273516|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
214273517|NCT03236285|BEHAVIORAL|Continous exercise training in the fasting state|Continous exercise training in the fasting state
214273518|NCT05251987|BIOLOGICAL|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
214273519|NCT02477150|BIOLOGICAL|Zostavax|Vaccination of a zoster vaccine (Zostavax)
214273520|NCT02477150|BIOLOGICAL|placebo|placebo administration
214273521|NCT02259881|DRUG|Low dose of BIBT 986 CL, per i.v. infusion|
214273522|NCT02259881|DRUG|Medium dose of BIBT 986 CL, per i.v. infusion|
214273523|NCT02259881|DRUG|High dose of BIBT 986 CL, per i.v. infusion|
214273524|NCT02259881|DRUG|Placebo|
214273525|NCT02259881|DRUG|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
214273526|NCT04655638|DEVICE|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
214273527|NCT04655638|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
214273528|NCT03728920|OTHER|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
214273529|NCT01507012|DIETARY_SUPPLEMENT|Berry Polyphenols|
214273530|NCT01507012|DIETARY_SUPPLEMENT|Placebo|Placebo control containing sugar and artificial flavouring.
214273531|NCT02231944|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
214273532|NCT00289991|DRUG|Itraconazole|Prophylaxis
214273533|NCT00289991|DRUG|Vfend - voriconazole|Prophylaxis
214273534|NCT05969145|PROCEDURE|application of thermophor|The experimental group will be given hot and cold application to the bladder
214273535|NCT02249585|DEVICE|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
214273536|NCT02249585|DEVICE|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
214273537|NCT02249585|DRUG|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
214273538|NCT02249585|DRUG|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
214273539|NCT02607150|OTHER|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
214273540|NCT02814578|OTHER|Optical coherent tomography|comparative method for BVS
214273541|NCT02814578|OTHER|IntraVascular UltraSound|The method of goldstandard for decision stent choice
214273542|NCT03998930|OTHER|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
214656868|NCT03720314|OTHER|NA observational study|observational study
214656869|NCT02542267|DEVICE|Gore VIABAHN Endoprosthesis|
214656870|NCT05789992|DRUG|Propofol|Propofol (Random:3-5ug/ml)
214656871|NCT05789992|DRUG|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
214656872|NCT05789992|DRUG|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
214656873|NCT05789992|PROCEDURE|Intubation|Endotracheal intubation before surgery
214656874|NCT05789992|PROCEDURE|tetanic electrical stimulation|tetanic electrical stimulation before surgery
214656875|NCT00000257|DRUG|0% N2O and 10% N2O|
214656876|NCT00000257|DRUG|0% N2O and 20% N2O|
214656877|NCT00000257|DRUG|0% N2O and 30% N2O|
214656878|NCT00000257|DRUG|0% N2O and 40% N2O|
214273543|NCT05373745|BEHAVIORAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
214273544|NCT05373745|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
214273545|NCT04420442|PROCEDURE|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
214273546|NCT02084693|DEVICE|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
214273547|NCT01158157|BIOLOGICAL|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
214273548|NCT00839891|DRUG|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
214273549|NCT01155271|OTHER|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
214273550|NCT01776112|OTHER|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
214273551|NCT01776112|OTHER|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
214273552|NCT01606007|DRUG|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
214273553|NCT01606007|DRUG|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
214273554|NCT01606007|DRUG|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
214273555|NCT01606007|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
214273556|NCT01606007|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
214273557|NCT03495219|PROCEDURE|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
214273558|NCT01517711|DRUG|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
214273559|NCT01517711|DRUG|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
214273560|NCT01466335|DRUG|Ronacaleret (100mg tablet)|100mg tablet
214273561|NCT01466335|DRUG|Placebo|matching placebo tablet
214273562|NCT05830968|DEVICE|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.
214273563|NCT03787732|DRUG|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
214273564|NCT03787732|OTHER|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
214273565|NCT03800797|DRUG|Loxoprofen sodium hydrogel patch|100 mg per day
214273566|NCT03800797|DRUG|Loxoprofen sodium tablet|60 mg t.i.d.
214273567|NCT02560597|PROCEDURE|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
214273568|NCT00318422|DRUG|liraglutide|
214273569|NCT00318422|DRUG|rosiglitazone|
214273570|NCT00318422|DRUG|glimepiride|
214273571|NCT03415334|BEHAVIORAL|behavioral development for change|"1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
214273572|NCT04218630|OTHER|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
214273573|NCT04218630|OTHER|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
214273574|NCT01007812|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
214273575|NCT01007812|DEVICE|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
214273576|NCT01091974|DRUG|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
214273577|NCT01091974|DRUG|Placebo Comparator|Placebo for 47 days
214273578|NCT01091974|BEHAVIORAL|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
214273579|NCT04556513|OTHER|Paraclinical examination|Respiratory functional tests
214273580|NCT04556513|OTHER|Clinical Examination|Clinical Examination
214273581|NCT04556513|OTHER|Semi-directive interview|By phone
214273582|NCT04556513|OTHER|quality of life questionnaires|SF36, VSRQ, IESR, HADS
214273583|NCT04524910|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
214273584|NCT02325960|DRUG|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
214273585|NCT02325960|DRUG|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
214273586|NCT03873844|BEHAVIORAL|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
214273587|NCT03873844|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
214273588|NCT05090059|DEVICE|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
214273589|NCT04387032|OTHER|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
214273590|NCT04387032|OTHER|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
214273591|NCT00597181|PROCEDURE|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
214273592|NCT00597181|PROCEDURE|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
214273593|NCT00002378|DRUG|Ritonavir|
214273594|NCT00002378|DRUG|Nelfinavir mesylate|
214273595|NCT00002378|DRUG|Saquinavir|
214273596|NCT00002378|DRUG|Delavirdine mesylate|
214273597|NCT00002378|DRUG|Lamivudine|
214273598|NCT00002378|DRUG|Stavudine|
214273599|NCT00002378|DRUG|Zidovudine|
214273600|NCT02652754|DRUG|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
214273601|NCT06263205|PROCEDURE|Non-Dressing of Surgical Wound|In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.
214273602|NCT06263205|PROCEDURE|Regular Dressing Change of Surgical Wound|This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
214273603|NCT00555971|DRUG|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
214273604|NCT00555971|DRUG|placebo|Subjects randomized to Placebo prior to aspirin desensitization
214273605|NCT04985864|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
214273606|NCT04985864|DEVICE|Treadmill gait training|Lokomat robot training was applied to stroke patients.
214273607|NCT03183076|OTHER|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
214273608|NCT03183076|DRUG|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
214273609|NCT06440096|DIAGNOSTIC_TEST|hemogram|hemogram
214273610|NCT01815216|PROCEDURE|Bariatric surgery|Gastric bypass surgery
214273611|NCT01815216|BEHAVIORAL|Brain activity in resting state|Measure of activity in brain networks during resting state
214273612|NCT01815216|BEHAVIORAL|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
214273613|NCT01525810|DRUG|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
214273614|NCT06238583|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
214273615|NCT03497208|PROCEDURE|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
214273616|NCT03497208|PROCEDURE|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
214273617|NCT03497208|RADIATION|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
214273618|NCT06096753|DEVICE|Bruxoff gnathological function analysis|The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
214273619|NCT03528772|DRUG|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
214273620|NCT03528772|DRUG|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
214273621|NCT05051072|PROCEDURE|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
214273622|NCT02335866|PROCEDURE|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
214273623|NCT02335866|PROCEDURE|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
214273624|NCT05539794|BEHAVIORAL|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
214273625|NCT06492967|BEHAVIORAL|Systematic Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
214273626|NCT06492967|BEHAVIORAL|Flexible Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
214273627|NCT03963375|DRUG|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
214273628|NCT00518284|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
214273629|NCT04619927|GENETIC|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
214273630|NCT04619927|GENETIC|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
214273631|NCT04619927|DRUG|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
214273632|NCT04619927|DRUG|Intermediate metabolisers|Clopidogrel 75mg twice daily
214273633|NCT04619927|DRUG|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
214273634|NCT00307177|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
214273635|NCT00307177|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
214273636|NCT03128879|DRUG|Ibrutinib|Given PO
214273637|NCT03128879|DRUG|Venetoclax|Given PO
214273638|NCT03128879|DRUG|Acalabrutinib|Given BID
214273639|NCT05752292|BEHAVIORAL|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
214273640|NCT05752292|BEHAVIORAL|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
214273641|NCT05752292|BEHAVIORAL|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
214273642|NCT05752292|BEHAVIORAL|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
214273643|NCT05752292|BEHAVIORAL|Action planning (AP)|Interactive prompts to problem solve challenges
214273644|NCT03294759|OTHER|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
214273645|NCT03294759|OTHER|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
214273646|NCT02571777|DRUG|QVM149 150/50/160|
214273647|NCT02571777|DRUG|QVM149 150/50/80|
214273648|NCT02571777|DRUG|QMF149 150/320|
214273649|NCT02571777|DRUG|QMF149 150/160|
214273650|NCT02571777|DRUG|salmeterol/fluticasone|
214273651|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
214273652|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
214273653|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
214273654|NCT02192138|PROCEDURE|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
214273655|NCT02192138|DEVICE|Pleural catheter|
214273656|NCT02192138|DEVICE|Pleural manometer|
214273657|NCT03678298|OTHER|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
214273658|NCT00801632|PROCEDURE|Kidney Transplantation|Surgical transplantation of donor kidney
214273659|NCT00801632|PROCEDURE|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
214273660|NCT00801632|BIOLOGICAL|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
214273661|NCT00801632|DRUG|cyclophosphamide|60 mg/kg infusion on days -5, -4
214273662|NCT00801632|BIOLOGICAL|rituximab|375 mg/m\^2 infusion on days -7, -2, 5, and 12
214273663|NCT00801632|DRUG|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
214273664|NCT00801632|DRUG|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
214273665|NCT00801632|RADIATION|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
214273666|NCT06770842|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa 2b is administered subcutaneously once every 2 weeks. The dosing will be 250mcg at Week 0, 350mcg at Week 2, 500mcg at Week 4, and 500mcg every 2 weeks thereafter
214273667|NCT05012982|DEVICE|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
214273668|NCT05012982|DEVICE|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
214273669|NCT01028144|BEHAVIORAL|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
214273670|NCT01028144|BEHAVIORAL|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
214273671|NCT05076500|PROCEDURE|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
214273672|NCT06263361|DIAGNOSTIC_TEST|MRI imaging|To characterize the peritumoral area in PCNLs through the use of advanced MRI sequences.
214273673|NCT06263361|DIAGNOSTIC_TEST|Cerebral biopsy|To evaluate the predictive value of sodium fluorescence to confirm ex-vivo the diagnostic tumor tissue prior to histopathological examination.
214273674|NCT03961568|DRUG|Cenobamate|active drug
214273675|NCT05310695|OTHER|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
214656879|NCT03049449|BIOLOGICAL|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
214656880|NCT03049449|DRUG|Cyclophosphamide|300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
214273676|NCT05310695|OTHER|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
214273677|NCT05310695|OTHER|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
214273678|NCT05286437|DRUG|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
214273679|NCT05500222|DRUG|Resmetirom|Randomized 80 mg
214273680|NCT05500222|DRUG|Placebo|randomized matching placebo
214273681|NCT04480008|BEHAVIORAL|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
214273682|NCT00753571|DRUG|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2"
214273683|NCT05185193|DEVICE|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
214273684|NCT05185193|DEVICE|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
214273685|NCT05279339|OTHER|Exercise|Upper limb exercises using an elastic band.
214273686|NCT02330237|DRUG|natural gels|whole fruits and vegetables
214273687|NCT02330237|DRUG|Placebo|
214273688|NCT02541019|DRUG|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
214273689|NCT02541019|DRUG|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
214273690|NCT05894408|OTHER|this is no intervention|this is no intervention
214273691|NCT02981420|BEHAVIORAL|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
214273692|NCT04850937|DRUG|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
214273693|NCT04850937|DRUG|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
214273694|NCT03937297|BEHAVIORAL|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
214273695|NCT03937297|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
214273696|NCT03937297|BEHAVIORAL|Usual Care|usual dementia care provided by participating center
214273697|NCT00717691|DEVICE|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
214273698|NCT00717691|OTHER|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
214273699|NCT03220178|DRUG|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
214273700|NCT03220178|DRUG|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
214273701|NCT03220178|DRUG|Anastrozole|1mg per day
214273702|NCT03220178|DRUG|Letrozole|2,5mg/day
214273703|NCT03220178|DRUG|Exemestane|25mg/day
214273704|NCT03830632|OTHER|Plyometric Training|
214273705|NCT03830632|OTHER|Traditional Training|
214273706|NCT04600375|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
214273707|NCT04600375|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
214273708|NCT04425512|DIAGNOSTIC_TEST|Complete Blood Count|Complete Blood Count samples
214273709|NCT06139107|DRUG|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
214273710|NCT06139107|DRUG|Letrozole|Letrozole 2.5mg daily
214273711|NCT04868175|DRUG|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
214273712|NCT04868175|DRUG|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
214273713|NCT04868175|DRUG|Hypromellose|Placebo eye drop, lubricant
214273714|NCT01238510|PROCEDURE|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
214273715|NCT01238510|PROCEDURE|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
214273716|NCT04076397|PROCEDURE|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
214273717|NCT04076397|OTHER|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
214273718|NCT05679323|OTHER|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
214273719|NCT04208633|PROCEDURE|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
214273720|NCT04208633|PROCEDURE|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
214273721|NCT00798980|DRUG|Mirena (BAY86-5028)|Nulliparous Women
214273722|NCT03771820|DRUG|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
214273723|NCT03771820|DRUG|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
214273724|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
214273725|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
214273726|NCT04672993|DEVICE|Urine collection device for men|Use of urine collection device for men
214273727|NCT00740389|DRUG|TMC125|
214273728|NCT03661671|DIAGNOSTIC_TEST|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
214273729|NCT00005639|DRUG|Azacitidine Injection|subcutaneous injection (SC)
214273730|NCT00005639|DRUG|sodium phenylbutyrate|continuous intravenous (CIV)
214273731|NCT00762060|DEVICE|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
214273732|NCT00762060|DRUG|Patient controlled analgesia|IV opioids delivered via PCA
214273733|NCT05871775|BEHAVIORAL|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
214273734|NCT05871775|BEHAVIORAL|Stabilization exercise|Neck stabilization exercise and sensorimotor program
214273735|NCT05871775|BEHAVIORAL|General exercise|General mobility exercise and strength exercise program
214273736|NCT03266536|BEHAVIORAL|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
214273737|NCT04092439|DIETARY_SUPPLEMENT|Watermelon Juice|100% Watermelon Juice
214273738|NCT02433730|DRUG|Testosterone|intramuscular injection
214273739|NCT02433730|DRUG|placebo|intramuscular injection
214273740|NCT05478369|BEHAVIORAL|storybook|anxiety and fear during operative
214273741|NCT01350492|BEHAVIORAL|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
214273742|NCT01306903|DEVICE|MECC|Minimized extracorporeal circulation
214273743|NCT01306903|DEVICE|MOPS|Modified and optimized perfusion system Frankfurt
214273744|NCT01306903|DEVICE|Super MOPS|Super modified and optimized perfusion system Frankfurt
214273745|NCT03147261|OTHER|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
214273746|NCT03756844|BEHAVIORAL|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
214273747|NCT05174377|DIAGNOSTIC_TEST|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
214273748|NCT02740881|OTHER|Counselor Training Methods|
214273749|NCT03912168|OTHER|Question Prompt List|Question prompt list for common orthopaedic conditions
214273750|NCT03912168|OTHER|3 questions list|3 questions from the AskShareKnow model
214273751|NCT03253276|DRUG|Obeticholic acid|Placebo-controlled
214273752|NCT03253276|DRUG|Placebos|
214273753|NCT05902520|BIOLOGICAL|DP CD8 TIL|intravenous infusion of T cell suspension
214273754|NCT05902520|BIOLOGICAL|DP CD8 TIL KD|intravenous infusion of T cell suspension
214273755|NCT05902520|BIOLOGICAL|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
214273756|NCT00205881|DEVICE|HiRes 90K Bionic Ear System|Cochlear implant system
214273757|NCT05913492|BEHAVIORAL|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
214273758|NCT01634724|DRUG|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
214273759|NCT04960501|PROCEDURE|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
214273760|NCT05963594|DIETARY_SUPPLEMENT|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
214273761|NCT05963594|DIETARY_SUPPLEMENT|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
214273762|NCT01889004|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
214273763|NCT01889004|DRUG|Propofol|Escalating concentrations until loss of responsiveness
214273764|NCT06273410|OTHER|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
214273765|NCT06273410|OTHER|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
214273766|NCT06273410|OTHER|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
214273767|NCT00714649|DRUG|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
214273768|NCT05192967|BEHAVIORAL|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
214273769|NCT05192967|BEHAVIORAL|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
214273770|NCT01979965|DRUG|Ranolazine (Active drug)|Ranolazine therapy for three months
214273771|NCT01979965|DRUG|Placebo|Placebo therapy for three months
214273772|NCT03403075|BEHAVIORAL|ETAF|Therapeutic education and Physical activity
214273773|NCT03403075|BEHAVIORAL|Usual care|Usual care
214273774|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
214273775|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
214273776|NCT03530358|DEVICE|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
214273777|NCT03530358|BEHAVIORAL|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
214273778|NCT01928069|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
214273779|NCT02048969|DRUG|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
214273780|NCT02048969|DRUG|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
214273781|NCT02654847|DRUG|Norepinephrine|
214273782|NCT02654847|DRUG|Normal Saline|0.9% sodium chloride solution, used as a diluent.
214273783|NCT04946968|DRUG|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
214273784|NCT04442412|DRUG|Vitamin D3 (Cholecalciferol)|patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
214273785|NCT04442412|DRUG|RCHOP o R-miniCHOP at standard doses|"Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses"
214273786|NCT01627483|OTHER|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
214273787|NCT05934578|OTHER|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
214273788|NCT04641858|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
214273789|NCT04641858|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
214273790|NCT05642988|DEVICE|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
214273791|NCT01022749|DRUG|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
214273792|NCT01022749|BIOLOGICAL|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
214273793|NCT04789499|DRUG|Theophylline Powder|Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
214273794|NCT04789499|DRUG|Placebo Comparator|Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
214273795|NCT00519454|OTHER|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
214273796|NCT04805762|OTHER|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
214273797|NCT00005118|DRUG|Indinavir sulfate|
214273798|NCT00005118|DRUG|Ritonavir|
214273799|NCT04326829|DRUG|QL1604|QL1604, IV infusion
214273800|NCT04016233|DRUG|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
214273801|NCT00644657|DRUG|Clopidogrel|All subjects will receive a 300 mg loading dose
214273802|NCT05243355|DRUG|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
214273803|NCT00513656|DRUG|Oxycodone|
214273804|NCT00513656|DRUG|Oxycodone/Naloxone|
214273805|NCT01407822|DRUG|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
214273806|NCT01407822|DRUG|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
214273807|NCT00352339|DRUG|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
214273808|NCT00352339|DRUG|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
214273809|NCT00352339|DRUG|Abilify|Start with abilify and keep it through the end of study
214273810|NCT05116618|DIAGNOSTIC_TEST|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
214656881|NCT03049449|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
214656882|NCT02321592|DRUG|AFM13|
214273811|NCT03823456|OTHER|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
214273812|NCT03823456|OTHER|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
214273813|NCT00557128|DRUG|COREG CR and lisinopril (FDC)|
214273814|NCT05210907|BIOLOGICAL|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
214273815|NCT01338103|DRUG|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
214273816|NCT03513458|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
214273817|NCT03513458|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
214273818|NCT03513458|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
214273819|NCT00133913|PROCEDURE|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
214273820|NCT02938312|BEHAVIORAL|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
214273821|NCT02938312|BEHAVIORAL|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
214273822|NCT05136287|DRUG|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
214273823|NCT02736838|DEVICE|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
214273824|NCT02736838|DEVICE|Laser Doppler|
214273825|NCT06424574|BEHAVIORAL|motivational interview|"The sample of the second phase of the study consisted of 74 parents with Type 1 diabetes children, 37 of which were in the study group and 37 in the control group. İn the collection of data process, Descriptive Information Form, University of Virginia Parent Low Blood Sugar Scale, BAKAS Care-Giving Impact Scale, Fatigue Severity Scale, Parental Version Of The Diabetes-Specific Self-Compassion Scale SCS-(Dp) was used. The scales were applied at the beginning of the study and 10 weeks after the first data. After the first test data were obtained from each parent in our research group, four face-to-face motivational interviews were conducted at two-week intervals. In the xvii interviews, attempts were made to change and improve the behaviors and skills that parents felt inadequate within the scope of fear of hypoglycemia, caregiving, fatigue and self-compassion."
214273826|NCT01389388|DRUG|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
214273827|NCT01443208|DRUG|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
214273828|NCT01443208|DRUG|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
214273829|NCT01443208|DRUG|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
214273830|NCT01234441|DIETARY_SUPPLEMENT|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
214273831|NCT01234441|DIETARY_SUPPLEMENT|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
214273832|NCT01234441|BEHAVIORAL|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
214273833|NCT01146834|DRUG|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
214273834|NCT01146834|DRUG|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
214273835|NCT01146834|DRUG|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
214273836|NCT01146834|DRUG|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
214273837|NCT05046899|DEVICE|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
214273838|NCT05046899|DEVICE|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
214273839|NCT01263977|DEVICE|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
214273840|NCT00781274|DRUG|MP-424|750 mg every 8 hours for 12 weeks
214273841|NCT00781274|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
214273842|NCT00781274|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
214273843|NCT04953754|DIETARY_SUPPLEMENT|Melatonin|The melatonin group will receive 5mg melatonin nightly
214273844|NCT04953754|DEVICE|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
214273845|NCT03406767|OTHER|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
214273846|NCT03406767|OTHER|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
214273847|NCT06098092|OTHER|Long-term non-invasive Blood pressure monitoring|All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
214273848|NCT04794842|DRUG|Tetracaine 5% drops|same as information in the arm/group description
214273849|NCT04794842|DRUG|Phenol 90% concentration|same as information in the arm/group description
214273850|NCT01147523|DRUG|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
214273851|NCT01950975|BIOLOGICAL|Peripheral blood samples in EDTA tubes|
214273852|NCT01950975|PROCEDURE|Skin biopsies|
214273853|NCT03691259|OTHER|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
214273854|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
214273855|NCT00768183|DRUG|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
214273856|NCT00768183|DRUG|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
214273857|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
214273858|NCT04456530|DRUG|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
214273859|NCT04456530|OTHER|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
214656883|NCT00472693|DRUG|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
214273860|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
214273861|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
214273862|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
214273863|NCT01534962|DRUG|Placebo|Oral administration, BID; for a maximum of 112 days.
214273864|NCT03751696|BEHAVIORAL|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
214273865|NCT03751696|BEHAVIORAL|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
214273866|NCT00282984|DRUG|placebo|1 mg placebo twice daily by mouth for 12 weeks
214273867|NCT00282984|DRUG|Varenicline|1 mg twice daily by mouth for 12 weeks
214273868|NCT04916821|DIETARY_SUPPLEMENT|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
214273869|NCT02836730|PROCEDURE|Low back pain surgery|
214273870|NCT05808114|BEHAVIORAL|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
214273871|NCT05808114|BEHAVIORAL|TAU|Individually tailored and delivered specialized child psychiatric care
214273872|NCT05846971|OTHER|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
214273873|NCT01460004|DEVICE|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
214273874|NCT03697473|OTHER|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
214656884|NCT04089956|OTHER|No interventation|A retrospective cohort Observational study with no intervention
214273875|NCT03697473|OTHER|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
214273876|NCT00191269|DRUG|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
214273877|NCT00191269|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
214273878|NCT00941005|DEVICE|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
214273879|NCT02859311|DRUG|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
214273880|NCT01583491|PROCEDURE|autologous platlet rich fibrin|one dose immediate after surgery
214273881|NCT01583491|PROCEDURE|one side in control group|control group insert any things after surgery
214273882|NCT02087735|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
214273883|NCT02327689|DRUG|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
214273884|NCT01807975|OTHER|Forced oscillation|
214273885|NCT01742702|DRUG|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
214273886|NCT01742702|DRUG|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
214273887|NCT01742702|DRUG|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
214273888|NCT01742702|DIETARY_SUPPLEMENT|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
214273889|NCT01742702|DIETARY_SUPPLEMENT|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
214273890|NCT01742702|DRUG|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
214273891|NCT01738542|DRUG|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
214273892|NCT01738542|DRUG|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
214273893|NCT01738542|DRUG|Statins|
214273894|NCT01738542|DRUG|Antihypertensive therapy|
214273895|NCT01741974|DIETARY_SUPPLEMENT|Karinat|
214273896|NCT01741974|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
214273897|NCT01745133|DRUG|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
214273898|NCT01745133|DRUG|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
214273899|NCT01745133|DRUG|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
214273900|NCT03031197|COMBINATION_PRODUCT|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
214273901|NCT03021070|OTHER|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
214273902|NCT05516394|PROCEDURE|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
214273903|NCT02412995|OTHER|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214656885|NCT02281890|OTHER|Proven sepsis|Exposure is proven sepsis
214656886|NCT04082104|DIAGNOSTIC_TEST|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
214273904|NCT02412995|OTHER|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214273905|NCT02412995|OTHER|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214273906|NCT02412995|OTHER|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214273907|NCT02412995|OTHER|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214273908|NCT02412995|OTHER|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
214273909|NCT02151110|BIOLOGICAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
214273910|NCT02151110|BIOLOGICAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
214273911|NCT02151110|BIOLOGICAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
214273912|NCT02151110|BIOLOGICAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
214273913|NCT02151110|BIOLOGICAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
214273914|NCT02151110|BIOLOGICAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
214273915|NCT02151110|BIOLOGICAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
214273916|NCT02151110|OTHER|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
214273917|NCT03801486|OTHER|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
214273918|NCT03801486|OTHER|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
214273919|NCT03290872|DEVICE|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
214829444|NCT02331628|DEVICE|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine."
214829445|NCT01732328|DIETARY_SUPPLEMENT|Calcium plus vitamin D|
214829446|NCT05267444|PROCEDURE|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
214273920|NCT03290872|DEVICE|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
214273921|NCT01651247|PROCEDURE|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
214273922|NCT04493073|PROCEDURE|Trabectulectomy|decrease IOP
214273923|NCT04493073|DRUG|Mitomycin|Decrease bleb failure
214273924|NCT04493073|DEVICE|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
214273925|NCT04493073|DEVICE|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
214273926|NCT03652597|DEVICE|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
214273927|NCT06236672|DRUG|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
214273928|NCT06236672|DRUG|basal insulin|basal insulin initiated between January 2019 and December 2022
214273929|NCT00785694|DRUG|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
214829447|NCT01993186|DRUG|UX007|oral liquid
214829448|NCT01993186|DRUG|Placebo|oral liquid
214273930|NCT02015754|DRUG|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
214273931|NCT02015754|DEVICE|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
214273932|NCT02015754|PROCEDURE|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
214273933|NCT06385951|DIAGNOSTIC_TEST|Procedure for patients|We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
214273934|NCT06385951|DIAGNOSTIC_TEST|Procedure for healthy controls|Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
214273935|NCT01546805|DRUG|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
214273936|NCT01546805|DRUG|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
214273937|NCT00375648|DRUG|Zoledronic acid|
214273938|NCT01128842|DRUG|Neratinib|240 mg once daily by mouth.
214273939|NCT01128842|DRUG|Capecitabine|1500 mg/m\^2 twice daily by mouth.
214273940|NCT04489433|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
214273941|NCT04489433|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
214273942|NCT04489433|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
214273943|NCT05498012|COMBINATION_PRODUCT|placebo dental gel, placebo toothpaste|"* Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
214273944|NCT05498012|COMBINATION_PRODUCT|Cannabidiol dental gel, Cannabidiol toothpaste|"* Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
214273945|NCT05498012|COMBINATION_PRODUCT|Placebo toothpaste, Corsodyl dental gel|"* Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
214273946|NCT06052085|OTHER|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
214273947|NCT06052085|OTHER|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
214273948|NCT06052085|OTHER|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
214273949|NCT02066142|DEVICE|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
214273950|NCT02066142|DEVICE|Ultrasound|
214273951|NCT01959074|DRUG|Naftopidil|Naftopidil 75mg 1T qd hs
214273952|NCT01959074|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
214273953|NCT01959074|DRUG|Standard treatment|aceclofenac 100mg on demand
214273954|NCT02464020|DRUG|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
214273955|NCT03482544|DRUG|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
214273956|NCT03482544|OTHER|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
214273957|NCT04600141|DRUG|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
214273958|NCT04600141|DRUG|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
214273959|NCT04600141|DRUG|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
214273960|NCT04528732|BEHAVIORAL|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
214273961|NCT04528732|BEHAVIORAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
214273962|NCT01086761|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye.
214273963|NCT04905758|PROCEDURE|platform switching|reduced implant abutment interface
214273964|NCT04905758|PROCEDURE|platform amtching|matched implant abutment interface
214273965|NCT03375606|BIOLOGICAL|CSL730|Solution for IV infusion
214273966|NCT03375606|OTHER|Placebo|Saline solution for IV infusion
214273967|NCT04981548|OTHER|no intervention|no intervention
214273968|NCT01262911|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
214273969|NCT01262911|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
214273970|NCT02888301|PROCEDURE|Computed Tomography|Undergo 18F-clofarabine PET/CT
214273971|NCT02888301|RADIATION|Fluorine F 18 Clofarabine|Given IV
214273972|NCT02888301|PROCEDURE|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
214273973|NCT00436384|PROCEDURE|Monitoring-blood samples drawn for CMV testing|
214273974|NCT01300650|DRUG|Anakinra|Anakinra 100 mg subcutaneous injection daily
214273975|NCT02369016|DRUG|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
214273976|NCT03805399|DRUG|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
214273977|NCT03805399|DRUG|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
214273978|NCT03805399|DRUG|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
214273979|NCT03805399|DRUG|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
214273980|NCT03805399|DRUG|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
214273981|NCT03805399|DRUG|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
214273982|NCT03805399|DRUG|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
214273983|NCT02834039|PROCEDURE|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
214273984|NCT02834039|PROCEDURE|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
214273985|NCT01785264|PROCEDURE|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
214273986|NCT01785264|PROCEDURE|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
214273987|NCT01785264|PROCEDURE|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
214273988|NCT03180073|DIAGNOSTIC_TEST|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
214273989|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
214273990|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
214273991|NCT05142111|BEHAVIORAL|Therapy|Discussion with therapist
214273992|NCT06474702|DEVICE|'Fitbit charge 4' 'smart-watch'-|smartwatch device that collects physiological measures
214273993|NCT00004771|DRUG|leuprolide|
214273994|NCT00004771|DRUG|testosterone|
214273995|NCT05235048|PROCEDURE|Tooth extraction|Atraumatic tooth extraction without flap elevation
214273996|NCT05235048|PROCEDURE|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
214273997|NCT05235048|PROCEDURE|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
214273998|NCT05235048|PROCEDURE|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
214273999|NCT01908283|BIOLOGICAL|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
214274000|NCT00668707|DIETARY_SUPPLEMENT|melatonin|20 mgs ingested nightly
214274001|NCT00668707|DIETARY_SUPPLEMENT|placebo|similar to experimental in all ways except for lack of active ingredient
214274002|NCT05739188|BIOLOGICAL|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."
214274003|NCT05890885|PROCEDURE|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
214274004|NCT05890885|PROCEDURE|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
214274005|NCT00919425|OTHER|biologic sample preservation procedure|
214274006|NCT00923156|DRUG|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
214274007|NCT00923156|DRUG|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
214274008|NCT00923156|DRUG|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
214274009|NCT00923156|DRUG|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
214274010|NCT00057278|DRUG|gabapentin|
214274011|NCT01646723|BEHAVIORAL|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
214274012|NCT01201850|DRUG|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
214274013|NCT00925041|DEVICE|Vedera KXS|one treatment with the Vedera KXS
214274014|NCT03844880|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
214274015|NCT03844880|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
214274016|NCT03816384|DEVICE|Standard of Care|Standard of care urinary drainage system.
214274017|NCT03816384|DEVICE|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
214274018|NCT03816384|DEVICE|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
214274019|NCT03893370|DEVICE|RejuvenAir System|RejuvenAir Metered CryoSpray
214274020|NCT03893370|DEVICE|Sham Control Procedure|Sham Control Procedure
214274021|NCT03656432|DRUG|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
214274022|NCT05856071|DEVICE|goniometer|to measure the range of motion
214274023|NCT05856071|OTHER|clamshells exercises|clamshells exercises
214274024|NCT05856071|OTHER|traditional physical therapy|traditional physical therapy
214274025|NCT00489138|DRUG|Ertapenem|1g a day by drip of 30 min
214274026|NCT01552993|DRUG|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
214274027|NCT01552993|DRUG|sucrose|pacifier and sucrose
214274028|NCT02212795|DRUG|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
214274029|NCT02212795|DRUG|Levofloxacin 250mg|Levofloxacin 250mg single dose
214274030|NCT02212795|DRUG|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
214274031|NCT05468060|DRUG|PA1010|Placebo as control
214274032|NCT05058820|OTHER|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
214274033|NCT05058820|OTHER|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
214274034|NCT05476471|BEHAVIORAL|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
214274035|NCT03214939|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
214274036|NCT01211470|DRUG|Daptomycin|Active Comparator: Daptomycin.
214274037|NCT01211470|DRUG|PMX-30063-investigational drug|Experimental: PMX-30063
214274038|NCT01193699|DRUG|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
214274039|NCT05534737|OTHER|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
214274040|NCT05534737|OTHER|Control|usual care of social services
214274041|NCT03442205|PROCEDURE|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
214274042|NCT03442205|PROCEDURE|ERCP technique + LC|ERCP technique + LC
214274043|NCT03442205|PROCEDURE|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
214274044|NCT05840367|BEHAVIORAL|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
214274045|NCT05076292|DRUG|GlucaGen|150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
214274046|NCT05076292|DRUG|Saline|Saline will be used as placebo before and after exercise.
214274047|NCT03338010|DRUG|LY2963016|Administered SC
214656887|NCT02075801|OTHER|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
214274048|NCT03338010|DRUG|Lantus®|Administered SC
214274049|NCT01211730|DRUG|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
214274050|NCT04667871|PROCEDURE|cataract surgery|Eyes for cataract surgery
214274051|NCT03801343|DIETARY_SUPPLEMENT|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
214274052|NCT02696460|PROCEDURE|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
214274053|NCT02696460|PROCEDURE|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
214274054|NCT02465515|BIOLOGICAL|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
214274055|NCT02465515|BIOLOGICAL|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
214274056|NCT02465515|BIOLOGICAL|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
214274057|NCT00958100|DRUG|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
214274058|NCT00958100|DRUG|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
214274059|NCT00958100|DRUG|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
214274060|NCT03306563|DIAGNOSTIC_TEST|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
214274061|NCT04211883|BEHAVIORAL|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
214274062|NCT06062134|PROCEDURE|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
214274063|NCT06062134|DRUG|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
214274064|NCT00536185|DIETARY_SUPPLEMENT|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
214274065|NCT00536185|DIETARY_SUPPLEMENT|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
214274066|NCT00816595|BIOLOGICAL|bevacizumab|Given IV
214274067|NCT00816595|BIOLOGICAL|pegfilgrastim|Given subcutaneously
214274068|NCT00816595|BIOLOGICAL|rituximab|Given IV
214274069|NCT00816595|DRUG|cyclophosphamide|Given IV
214274070|NCT00816595|DRUG|pentostatin|Given IV
214274071|NCT00293033|DRUG|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
214829449|NCT03390257|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
214274072|NCT00293033|DRUG|Placebo|
214274073|NCT05494931|PROCEDURE|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
214274074|NCT03840798|OTHER|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets"
214274075|NCT06557655|DIETARY_SUPPLEMENT|caffeinate chewing gum|participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
214274076|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
214274077|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
214274078|NCT03583697|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
214274079|NCT03583697|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
214274080|NCT06557746|OTHER|Coca-Cola|100 ml Coca-Cola every 30 minutes during the operation
214274081|NCT06557746|OTHER|Supplemental oxygen|Continuous supply of oxygen (2 L/min) during the operation
214274082|NCT04449601|OTHER|clinical assesment|Comparison of Hypertensive group and normotensive group
214274083|NCT05378178|DRUG|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
214274084|NCT03158025|DRUG|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
214274085|NCT03158025|DRUG|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
214274086|NCT03158025|DRUG|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
214274087|NCT03158025|DRUG|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
214274088|NCT03158025|DRUG|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
214274089|NCT03158025|DRUG|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
214274090|NCT04216238|BEHAVIORAL|quasi-experimental Pre-test/Post-test design|surveys to document progress
214274091|NCT04889807|OTHER|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
214274092|NCT01586065|DEVICE|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
214274093|NCT00114530|BIOLOGICAL|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
214274094|NCT00114530|DRUG|cyclophosphamide|An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
214274095|NCT06270810|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
214274096|NCT06270810|BEHAVIORAL|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
214274097|NCT01122771|DRUG|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
214274098|NCT01122771|DRUG|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
214274099|NCT01122771|DRUG|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
214274100|NCT01122771|DRUG|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
214274101|NCT03503175|DEVICE|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
214274102|NCT03503175|DEVICE|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
214274103|NCT04395404|DIAGNOSTIC_TEST|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
214274104|NCT01577108|DIETARY_SUPPLEMENT|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
214274105|NCT01577108|DIETARY_SUPPLEMENT|Placebo|oral taking 2 capsules before sleeping per day for 14 days
214274106|NCT00365508|DRUG|nicotine lozenge|nicotine lozenge
214274107|NCT00365508|DRUG|nicotine patch|transdermal nicotine patch
214274108|NCT00783237|DRUG|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
214274109|NCT00783237|DRUG|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
214274110|NCT02753114|DRUG|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
214274111|NCT02753114|DRUG|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
214274112|NCT06555497|DRUG|topical 1% methotrexate gel|topical 1% methotrexate gel
214274113|NCT06555497|DRUG|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment
214274114|NCT05806411|DIAGNOSTIC_TEST|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
214829450|NCT05440968|OTHER|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
214829451|NCT05440968|OTHER|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
214829452|NCT01273467|DRUG|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
214829453|NCT01273467|DRUG|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
214274115|NCT04301037|PROCEDURE|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
214274116|NCT04301037|PROCEDURE|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
214274117|NCT00372671|BEHAVIORAL|Survey|
214274118|NCT00372671|BEHAVIORAL|Survey and videotape|
214274119|NCT02450591|DRUG|Erlotinib|
214274120|NCT02450591|OTHER|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
214274121|NCT00371280|PROCEDURE|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
214274122|NCT05884996|OTHER|PNF training|Resistance training with elastic bands in diagonals of PNF
214274123|NCT05995483|OTHER|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
214274124|NCT03708081|PROCEDURE|ProTaper Next|Root canal instrument
214274125|NCT03708081|PROCEDURE|TF Adaptive|Root canal instrument
214274126|NCT03634657|RADIATION|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
214274127|NCT03634657|RADIATION|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield \& X-ray protective strips
214274128|NCT03634657|RADIATION|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
214829454|NCT05998980|PROCEDURE|Componeer prefabricated veneers|Individual Randomized Clinical Trial
214829455|NCT05998980|PROCEDURE|Essentia resin composite veneers|Individual Randomized Clinical Trial
214829456|NCT06676813|BEHAVIORAL|Alternate day fasting|Alternate day fasting
214829457|NCT00758797|OTHER|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
214274129|NCT01064310|DRUG|pazopanib|oral anti-angiogenic treatment
214274130|NCT01064310|DRUG|sunitinib|oral anti-angiogenic treatment
214274131|NCT01995474|OTHER|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
214274132|NCT01995474|OTHER|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
214274133|NCT02384486|BEHAVIORAL|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
214274134|NCT02384486|OTHER|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
214274135|NCT04184713|DIETARY_SUPPLEMENT|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
214274136|NCT04184713|DIETARY_SUPPLEMENT|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
214274137|NCT04851080|DEVICE|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
214274138|NCT04851080|DEVICE|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
214274139|NCT04851080|BEHAVIORAL|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
214274140|NCT06556732|DRUG|Eplereone|Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
214274141|NCT00679432|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
214274142|NCT00679432|DRUG|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
214274143|NCT00679432|DRUG|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
214274144|NCT00679432|DRUG|Placebo|Placebo
214274145|NCT00679432|DRUG|Asacol® 400 mg|2400 mg/day, 400 mg tablets
214274146|NCT05096793|DIETARY_SUPPLEMENT|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
214274147|NCT00272012|DRUG|Insulin glulisine|
214274148|NCT05610683|DEVICE|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
214274149|NCT04638257|BIOLOGICAL|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
214274150|NCT04638257|OTHER|Placebo|Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
214274151|NCT01040975|BEHAVIORAL|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
214274152|NCT04753983|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|Diagnostic imaging measuring the metabolic changes that occur within the brain used for measuring and mapping brain activity
214274153|NCT05442814|PROCEDURE|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
214274154|NCT05442814|PROCEDURE|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
214274155|NCT03704467|DRUG|M6620|Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
214274156|NCT03704467|DRUG|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
214274157|NCT03704467|DRUG|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
214274158|NCT00873015|DRUG|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
214274159|NCT00873015|DRUG|Saline|14 day continuous infusion of a vehicle control infusion
214274160|NCT02339584|DRUG|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
214274161|NCT02339584|DRUG|Brinzolamide 10 mg/mL eye drops, suspension|
214274162|NCT02339584|DRUG|Brimonidine 2 mg/mL eye drops, solution|
214274163|NCT02339584|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
214274164|NCT05866406|BEHAVIORAL|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
214274165|NCT05866406|BEHAVIORAL|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
214274166|NCT05866406|BEHAVIORAL|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
214274167|NCT02695225|BEHAVIORAL|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
214274168|NCT02695225|BEHAVIORAL|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
214274169|NCT00260481|DRUG|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
214274170|NCT00260481|DRUG|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
214274171|NCT03152071|PROCEDURE|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
214274172|NCT03152071|PROCEDURE|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
214274173|NCT01382212|DRUG|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
214274174|NCT05875363|OTHER|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
214274175|NCT02914119|DRUG|Rocuronium|
214274176|NCT02914119|DRUG|Succinylcholine|
214274177|NCT02914119|DRUG|Cisatracurium|
214274178|NCT02914119|DRUG|Mivacurium|
214274179|NCT02914119|DEVICE|Objective neuromuscular monitoring (acceleromyography)|
214274180|NCT02914119|DRUG|Sugammadex|
214274181|NCT02914119|DRUG|Neostigmine|
214274182|NCT00873912|BIOLOGICAL|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
214274183|NCT00873912|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
214274184|NCT04573712|OTHER|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
214274185|NCT00713856|PROCEDURE|Custom PRK with iris registration|PRK
214274186|NCT00713856|PROCEDURE|Conventional PRK|PRK
214274187|NCT03915821|DEVICE|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
214274188|NCT05827380|BEHAVIORAL|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
214274189|NCT04742985|DIETARY_SUPPLEMENT|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
214274190|NCT04742985|DIETARY_SUPPLEMENT|Placebo group|Placebo 320 mg/day during 8 weeks
214274191|NCT03144960|PROCEDURE|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
214274192|NCT05566743|DRUG|Capecitabine|maintenance capecitabine after 4 months of FOLFRINOX
214274193|NCT05566743|OTHER|follow up|follow up after 4 months of FOLFRINOX
214274194|NCT06149832|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
214274195|NCT04676074|DEVICE|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
214274196|NCT05871645|PROCEDURE|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
214274197|NCT05871645|PROCEDURE|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
214274198|NCT04096664|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
214274199|NCT02100085|BIOLOGICAL|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
214274200|NCT03913312|BIOLOGICAL|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
214274201|NCT05425134|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
214274202|NCT06537817|DRUG|HT-4253|HT-4253 Single or Multiple doses administered orally as a tablet
214274203|NCT06537817|DRUG|Placebo|Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
214274204|NCT06337877|PROCEDURE|Depth of sedation monitoring|In the study, group rates of patient state index (PSI) \[(below 25); (25-50); (51-75); (above 75)\] will be determined within a 24-hour timeframe in patients undergoing therapeutic paralysis. The concordance between PSI rates\* determined at baseline (time zero) and Richmond Agitation-Sedation Scale (RASS) \[(between -4 and -5); (between -3 and -2); (equal to or greater than -1)\] rates will be assessed. Suppression rate (SR) and electromyography (EMG) values will be obtained from patients, and significant differences among PSI groups \[(below 25); (25-50); (51-75); (above 75)\] in terms of these data will be examined. Additionally, changes in Propofol (mg/hour), Midazolam (mg/hour), Fentanyl (mg/hour), and Rocuronium (mg/hour) values will be analyzed for each time interval.
214274205|NCT04280133|BEHAVIORAL|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
214274206|NCT03261973|DEVICE|DV8|DV8 esophageal deviation tool
214274207|NCT01006174|OTHER|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
214274208|NCT01006174|OTHER|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
214274209|NCT01006174|OTHER|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
214274210|NCT01980940|DRUG|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
214274211|NCT01980940|DRUG|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
214274212|NCT01980940|DRUG|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
214274213|NCT01980940|DRUG|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
214274214|NCT01980940|DRUG|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
214274215|NCT01980940|DRUG|Placebo|Placebo gel applied topically.
214274216|NCT01980940|DRUG|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
214274217|NCT01980940|DRUG|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
214829458|NCT04027023|DRUG|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
214829459|NCT03410030|DRUG|Ascorbic Acid|combination therapy
214829460|NCT03410030|DRUG|Paclitaxel protein-bound|combination therapy
214829461|NCT03410030|DRUG|Cisplatin|combination therapy
214829462|NCT03410030|DRUG|Gemcitabine|combination therapy
214274218|NCT04242719|DEVICE|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
214274219|NCT04242719|BIOLOGICAL|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
214274220|NCT00180050|DRUG|Budesonide|
214274221|NCT03000283|DRUG|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
214274222|NCT03033004|DEVICE|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
214829463|NCT03755180|OTHER|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
214829464|NCT03755180|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
214829465|NCT01459601|DRUG|Cabergoline|0,5mg per week
214829466|NCT01545349|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
214274223|NCT03033004|DEVICE|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
214274224|NCT03033004|DEVICE|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
214274225|NCT00496652|RADIATION|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
214274226|NCT00496652|DRUG|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
214274227|NCT02476383|PROCEDURE|spinal manipulative therapy|refer to arm descriptions
214274228|NCT06067061|COMBINATION_PRODUCT|Atezolizumab + RP1|Patients will be treated in a window period (ie 3 treatment cycles). After evaluation, patients that had no increase in ctDNA after 3 cycles (see Definition of ctDNA status) will continue on the same treatment (intratumoral injections of RP1 in combination with Atezolizumab) for a total of 10 treatment cycles prior to surgery.
214274229|NCT03120312|PROCEDURE|total hip replacement|primary hip replacement patients during past 5 years．
214274230|NCT07053228|BEHAVIORAL|Nature-based virtual reality|"Participants in this group will receive standard pain management care plus one session of immersive virtual reality (VR) using Oculus Go headsets. The session consists of viewing a nature-themed 360º video (e.g., beach, waterfall, songbirds) for approximately 8 minutes, accompanied by synchronized natural sounds.~The VR experience is designed to promote distraction, relaxation, and emotional engagement with nature to support pain relief and emotional regulation. The equipment is sanitized between uses according to hospital infection control protocols."
214274231|NCT07053228|DRUG|Standard Pain Management|"Participants in this group will receive the institution's standard pharmacological pain management, monitored and adjusted by the Pain Control Team using the hospital's electronic medical record system. This may include opioid and non-opioid analgesics according to clinical evaluation.~No complementary interventions will be provided during the study period."
214274232|NCT07054697|DRUG|Homoeopathic medicines|
214274233|NCT07054697|DRUG|Placebo|
214274234|NCT07054697|BEHAVIORAL|THERAPY|SPEECH THERAPY / OCCUPATIONAL THERAPY
214274236|NCT07054645|DIETARY_SUPPLEMENT|Elderberry Anthocyanin Chewing Gum|Participants receive a functional chewing gum containing encapsulated elderberry (Sambucus nigra L.) anthocyanins standardized for cyanidin-3-glucoside and cyanidin-3-sambubioside. The gum is formulated to be geriatric-friendly (soft, low-elasticity) and is administered twice daily for 6 weeks. It enables transmucosal polyphenol delivery through buccal absorption.
214274237|NCT07054645|DIETARY_SUPPLEMENT|Placebo Chewing Gum|Participants receive a placebo chewing gum identical in appearance, taste, and texture to the active gum but containing no elderberry anthocyanins or bioactive compounds. The gum is administered twice daily for 6 weeks to match the intervention group.
214274238|NCT07054229|DRUG|Contrast enhanced Ultrasound|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
214274239|NCT07054229|GENETIC|88-gene panel for thyroid cancer|"88-gene panel refers to a testing combination that includes 88 genes, which are typically associated with the onset, progression, and prognosis of thyroid cancer."
214274240|NCT07054580|BEHAVIORAL|knowledge and awareness|Focus on the level of knowledge and awareness regarding instrument sterilization protocols among healthcare workers in the operation theater.
214274241|NCT07054008|PROCEDURE|Microsurgical approach with Digital Microscope|The incision will be sutured with the use of a digital microscope (30 X) (Group 1). The microsurgical approach is a research only procedure that may add time to the total surgical time (\< 6%).
214274242|NCT07053098|OTHER|Implementation Facilitation|Implementation facilitation is a multi-faceted process of enabling and supporting the adoption and integration of best practices into routine clinical care. It involves collaboration to understand a setting's challenges and barriers and working together to identify the best activities to address them. IF will incorporate External Facilitation, a problem-solving implementation strategy that builds supportive interpersonal relationships between an External Facilitator who is outside of the clinic who works with clinics and their identified internal champions to learn their unique barriers to implementation, use strategies to address these barriers, and plan for sustainability by integrating the practice into routine processes and workflows. Other implementation activities that will be used IF include staff training, patient education, audit and feedback, and care coordination.
214274243|NCT07055360|BEHAVIORAL|Resilience-Based Intervention for Stress Reduction and HIV-Related Efficacy (RISE)|RISE is based on Cognitive-Behavior Therapy (CBT) and the Information-Motivation-Behavioral Skills (IMB) Model. RISE will consist of six, weekly sessions, followed by a booster session in week 8, including resilience-building and health-promoting activities of RISE. Sessions will emphasize the participants' strengths, including positive thoughts, beliefs, and behaviors that work for the client and existing assets and supports in the participant's life. Tailored, health-promotion text messages will be sent weekly after each session.
214274244|NCT07055360|BEHAVIORAL|Waitlist control: Text messaging-reminder comparison condition|This control condition will involve reminder text messages for adherence to HIV treatment and engaging in HIV care. As this condition is a waitlist control, participants in this condition will ultimately receive the RISE intervention.
214274245|NCT07053150|DRUG|Sintilimab|Dosage Form: Intravenous (IV) infusion Dosage: 200 mg Frequency: Every 3 weeks (Q3W) Duration: Until disease progression, unacceptable toxicity, or up to 2 years
214274246|NCT07053150|DRUG|Pyrotinib|Dosage Form: Oral tablet Dosage: 400 mg once daily (QD) Frequency: Continuous daily dosing Duration: Until disease progression or intolerable toxicity
214829467|NCT01545349|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
214829468|NCT01545349|BIOLOGICAL|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
214274247|NCT07053150|DRUG|Optional Chemotherapy|"1. FOLFOX:~   Oxaliplatin 85 mg/m² IV Day 1, leucovorin 400 mg/m² IV Day 1, 5-FU 400 mg/m² IV bolus + 2400 mg/m² continuous infusion over 46h (Days 2-3)~2. GEMOX:~   Gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² IV Day 1~3. GC:~   Gemcitabine 1000 mg/m² and cisplatin 25 mg/m² IV on Days 1 and 8~4. XELOX (CapeOX) Oxaliplatin 130 mg/m² IV Day 1, capecitabine 1000 mg/m² PO BID Days 1-14~5. SOX:~   Oxaliplatin 130 mg/m² IV Day 1, S-1 PO BID Days 1-14 (dose based on BSA: \<1.25 m² = 40 mg, 1.25-\<1.5 m² = 50 mg, ≥1.5 m² = 60 mg)~6. TS:~   Paclitaxel 80 mg/m² IV Days 1 and 8, S-1 as above~7. mFOLFOX6: Same as FOLFOX; used primarily in colorectal cancer~8. FOLFIRINOX:~   Leucovorin 400 mg/m², 5-FU (bolus + continuous), irinotecan 180 mg/m², oxaliplatin 85 mg/m² IV Day 1~9. AG:~Nab-paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² IV on Days 1 and 8"
214274248|NCT07055308|DEVICE|SEAPatch|Daily measurement with multisensory patch from day 1 post-surgery maximally up to the day of discharge from hospital.
214274249|NCT07054255|DRUG|Test formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
214274250|NCT07054255|DRUG|Reference formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
214274251|NCT07054047|OTHER|mrTDV|The training of radiologists to implement specialised MRI reporting using the TDV staging system
214274252|NCT07054268|OTHER|Nurse-Led ABCDEF Bundle Implementation|This intervention is distinguished by its structured, nurse-led delivery of all six components of the ABCDEF bundle, with nurses serving as primary implementers rather than multidisciplinary teams. Unlike other studies that may focus on select elements of the bundle or physician-led application, this study emphasizes standardized nursing protocols and daily documentation to ensure consistent implementation and evaluation across all components specifically targeting delirium prevention and management in ICU patients.
214274253|NCT07053813|BEHAVIORAL|Web resources|Mailed educational resources through portal and USPS mail
214274254|NCT07053813|BEHAVIORAL|Personalized outreach|Phone call to discuss due and overdue screening and other personalized risk management recommendations
214274255|NCT05605704|DRUG|Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
214274256|NCT05605704|DRUG|Placebo Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.
214274257|NCT06941077|DRUG|INCB057643|Tablet
214274258|NCT06942377|DRUG|Amlodipine|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine
214274259|NCT06950060|BEHAVIORAL|Moderate-to-high intensity cycling|Participants cycle on a stationary ergometer at an intensity prescribed to reach their lactate threshold, guided by VO2 max results and lactate sampling. The session lasts approximately 20 minutes and is preceded and followed by TMS assessments and a structured motor learning task. This condition is designed to evaluate the effect of exercise-induced metabolic stress on cortical inhibition and motor learning.
214274260|NCT06950060|BEHAVIORAL|Low-intensity cycling|Participants perform 20 minutes of cycling at a light workload below their lactate threshold. Exercise intensity is individualized using heart rate and perceived exertion (Borg RPE scale), avoiding significant metabolic activation. TMS and motor learning are assessed pre- and post-exercise. This condition serves as an active comparator to assess the impact of exercise intensity.
214274261|NCT06950060|BEHAVIORAL|Health education session|Participants receive a 20-minute session of health education content (e.g., wellness, healthy aging). No exercise is performed. Participants undergo TMS and motor learning testing before and after the session. This condition is used to control for attention and cognitive engagement without physical activity.
214274262|NCT06954636|DIAGNOSTIC_TEST|olfactory testing (threshold and identification test)|"In the identification test, 12 sniffin sticks are presented, which the patient has to name using a selection card with four terms each. Both nostrils are tested individually at each visit during the identification test. A correct answer scores one point. A maximum of 12 points is possible.~The threshold test consists of 16 dilution levels. Each level contains one sniffin stick with odor and two blanks. All three sniffin sticks of a dilution level are presented to the patient one after the other with eyes closed. The patient must indicate which of the three sticks contains an odor. Depending on whether the patient gives the correct answer, the three sniffin sticks in the next higher or next lower level are presented next. A maximum of 16 points is possible."
214274263|NCT05169047|OTHER|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
214274264|NCT05169047|OTHER|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
214274265|NCT06004128|DRUG|VYD222|Monoclonal antibody
214274266|NCT01119612|DIETARY_SUPPLEMENT|Iron|Daily oral dose of 60 mg from enrollment until delivery
214274267|NCT01119612|OTHER|Placebo|Daily oral dose from enrollment until delivery
214274268|NCT05412745|DEVICE|Kaloidon Plus|topical application; twice daily
214274269|NCT05412745|DEVICE|silicone gel|topical application; twice daily
214274270|NCT04588948|DRUG|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
214274271|NCT00075010|DRUG|Decitabine|15 mg/m\^2 by vein over 1 hour times 10 days
214274272|NCT00075010|DRUG|Valproic acid|20 mg/kg given orally daily for 10 days
214274273|NCT00634894|DRUG|Femara|2.5 mg by mouth daily x 12 weeks
214274274|NCT00634894|DRUG|Placebo|Placebo capsule by mouth daily x 12 weeks
214274275|NCT04943315|PROCEDURE|Monolithic zirconia|posterior crowns
214274276|NCT04943315|PROCEDURE|Metal-ceramic|posterior crowns
214274277|NCT04441606|RADIATION|68Ga-FAPI-04 PET/CT|"* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
214274278|NCT06109441|BIOLOGICAL|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
214274279|NCT04096963|DEVICE|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
214274280|NCT05678933|DRUG|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
214274281|NCT05678933|DRUG|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
214274282|NCT05678933|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214274283|NCT05678933|DRUG|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214274284|NCT05678933|DRUG|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
214274285|NCT05678933|DRUG|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
214274286|NCT04608929|BEHAVIORAL|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
214274287|NCT04608929|OTHER|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
214274288|NCT01637935|DRUG|Pioglitazone|Pioglitazone tablets.
214274289|NCT03164135|GENETIC|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
214274290|NCT01361152|DEVICE|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
214274291|NCT01361152|DEVICE|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
214274292|NCT04027062|BEHAVIORAL|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
214274293|NCT03240484|DIAGNOSTIC_TEST|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
214274294|NCT03240484|OTHER|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
214274295|NCT03543475|DEVICE|arabin pessary|arabin pessary: silicon device
214829469|NCT02464904|PROCEDURE|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
214274296|NCT03543475|DEVICE|no pessary|control group
214274297|NCT04234750|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
214274298|NCT01748084|DRUG|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
214274299|NCT01748084|DRUG|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
214274300|NCT03773991|DIAGNOSTIC_TEST|Lung MRI|Proton Lung Magnetic Resonance Imaging
214274301|NCT03773991|DIAGNOSTIC_TEST|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
214274302|NCT03773991|DIAGNOSTIC_TEST|Chest CT|High-resolution Quantitative Chest CT
214274303|NCT03773991|DIAGNOSTIC_TEST|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
214274304|NCT03773991|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
214274305|NCT03773991|DIAGNOSTIC_TEST|Pulmonary Function Tests|Spirometry and Plethysmography
214274306|NCT03773991|DIAGNOSTIC_TEST|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
214274307|NCT03773991|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test
214274308|NCT03773991|DIAGNOSTIC_TEST|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
214274309|NCT00259649|DRUG|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
214274310|NCT03118115|DEVICE|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
214274311|NCT00709761|DRUG|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
214274312|NCT01372267|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
214274313|NCT01372267|BEHAVIORAL|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
214274314|NCT04984330|DRUG|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
214274315|NCT04984330|DRUG|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
214274316|NCT03859752|BIOLOGICAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
214274317|NCT00000445|DRUG|naltrexone (Revia)|
214274318|NCT05713175|DEVICE|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
214274319|NCT05713175|DEVICE|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
214274320|NCT05713175|DEVICE|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
214274321|NCT04335461|PROCEDURE|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
214274322|NCT04335461|DEVICE|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
214274323|NCT04335461|DRUG|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
214274324|NCT00779714|DRUG|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
214274325|NCT00779714|DRUG|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
214274326|NCT00779714|DRUG|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
214274327|NCT03234933|OTHER|Mobility Tracker|Tracking Patient's movements and calories
214274328|NCT01220375|DRUG|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
214274329|NCT01220375|DRUG|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
214274330|NCT01220375|DRUG|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
214274331|NCT01220375|DRUG|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
214274332|NCT04487392|DRUG|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
214274333|NCT04487392|RADIATION|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
214274334|NCT01472302|DEVICE|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
214274335|NCT01472302|DEVICE|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
214274336|NCT06366932|DRUG|Second-line systemic treatment|Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
214274337|NCT06366932|OTHER|Folllow-up of second-line systemic treatment already started|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
214274338|NCT02541682|OTHER|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
214274339|NCT04091594|DEVICE|Flexible orthotic|Participants will receive the SIAFO to wear
214274340|NCT04091594|DEVICE|Standard orthotic|Participants will received the standard AFO to wear
214274341|NCT01324843|DRUG|EMLA Cream|
214274342|NCT01324843|DRUG|Aveeno Daily Moist|
214274343|NCT01324843|DEVICE|Derma Vax|
214274344|NCT01324843|PROCEDURE|Intradermal Electroporation|
214274345|NCT01324843|PROCEDURE|Visual Analogue Scale|
214274346|NCT01324843|PROCEDURE|Present Pain Intensity|
214274347|NCT01324843|PROCEDURE|McGill Pain Questionnaire|
214274348|NCT01324843|PROCEDURE|Skin Assessment|
214274349|NCT03315624|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
214274350|NCT02079220|DRUG|Arm A|"* Capecitabine~* Oxaliplatin~* Ziv-aflibercept"
214274351|NCT02079220|DRUG|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
214274352|NCT00443261|DRUG|Azacitidine|SC azacitidine
214274353|NCT00443261|DRUG|Cisplatin|cisplatin 75 mg/m\^2 day 8 every 28 days
214274354|NCT02968901|DRUG|macitentan|used in open label
214274355|NCT02968901|DRUG|tadalafil|used in open label
214274356|NCT03947320|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
214274357|NCT02575495|DRUG|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
214274358|NCT02575495|DRUG|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
214274359|NCT03435861|DRUG|VX-745|active drug capsules
214274360|NCT03435861|DRUG|placebo|placebo capsules
214274361|NCT02320383|BIOLOGICAL|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
214274362|NCT02320383|DRUG|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
214274363|NCT03267706|OTHER|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
214274364|NCT02387398|PROCEDURE|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
214274365|NCT00117481|DRUG|DR-2001a|DR-2001a administered vaginally each month
214274366|NCT00117481|DRUG|DR-2001b|DR-2001b administered vaginally each month
214274367|NCT00117481|OTHER|Placebo|Placebo administered vaginally each month
214274368|NCT05731778|DRUG|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
214274369|NCT05731778|DRUG|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
214274370|NCT02421432|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
214274371|NCT03848117|OTHER|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
214274372|NCT03848117|OTHER|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
214274373|NCT03311724|DRUG|Tirzepatide|Administered SC
214274374|NCT03311724|DRUG|Placebo|Administered SC
214656888|NCT02075801|OTHER|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
214274375|NCT00897260|DRUG|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
214274376|NCT00897260|RADIATION|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
214274377|NCT00897260|PROCEDURE|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
214274378|NCT01539850|DEVICE|OMS102|Subjects will receive implanted OMS102 System.
214274379|NCT01032005|OTHER|double fortified salt|Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
214274380|NCT01433991|DRUG|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
214274381|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
214274382|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
214274383|NCT03486548|DRUG|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
214274384|NCT03486548|DRUG|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
214274385|NCT03486548|DEVICE|Ultrasound|ultrasound
214274386|NCT04177160|BEHAVIORAL|Music|Subjects sit still and listen to preferred music for 5 minutes.
214274387|NCT04177160|BEHAVIORAL|White noise|Subjects sit still and listen to white noise for 5 minutes.
214274388|NCT01309594|PROCEDURE|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
214274389|NCT00844831|DRUG|Lubiprostone|24 mcg bid for 28 days
214274390|NCT01523990|DRUG|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
214274391|NCT01523990|DRUG|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
214274392|NCT04635943|DRUG|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
214274393|NCT04635943|DRUG|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
214274394|NCT04908878|PROCEDURE|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
214274395|NCT04908878|PROCEDURE|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
214274396|NCT03630627|DRUG|SB26|SB26 administered intravenously
214274397|NCT03630627|DRUG|Placebo|Placebo administered intravenously
214274398|NCT05021991|DRUG|100 mg PRAX-944|Once daily oral treatment with titration
214274399|NCT05021991|DRUG|60 mg PRAX-944|Once daily oral treatment with titration
214274400|NCT05021991|DRUG|Placebo|Once daily oral treatment
214274401|NCT05021991|DRUG|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
214274402|NCT05132920|DRUG|Dexamethasone|3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
214274403|NCT05132920|DRUG|Placebo|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
214274404|NCT04261348|OTHER|No intervention|There is no intervention
214274405|NCT05292898|BIOLOGICAL|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
214274406|NCT00643227|DRUG|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
214274407|NCT00643227|DRUG|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
214274408|NCT04044612|OTHER|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
214274409|NCT00297375|DRUG|tramadol HCl/acetaminophen|
214274410|NCT06143813|DIAGNOSTIC_TEST|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
214274411|NCT01793896|BEHAVIORAL|Control period|Analysis at recruitment and after a month without any intervention
214274412|NCT01793896|BEHAVIORAL|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
214274413|NCT01793896|BEHAVIORAL|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
214274414|NCT01793896|BEHAVIORAL|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
214274415|NCT00000883|DRUG|Azithromycin|
214274416|NCT02498184|OTHER|acupuncture|
214274417|NCT02957305|DRUG|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
214274418|NCT02957305|DRUG|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
214274419|NCT02628652|DIETARY_SUPPLEMENT|GOS|
214274420|NCT02628652|DIETARY_SUPPLEMENT|GLOS|
214274421|NCT02628652|DIETARY_SUPPLEMENT|FOS|
214274422|NCT05157984|PROCEDURE|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
214274423|NCT05657912|DEVICE|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
214274424|NCT01193530|OTHER|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
214274425|NCT01193530|OTHER|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
214274426|NCT01193530|BEHAVIORAL|Questionnaires|Weekly
214274427|NCT01193530|BEHAVIORAL|Study Diaries|Daily logs
214274428|NCT01193530|DEVICE|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
214274429|NCT01193530|DEVICE|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
214274430|NCT03539328|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
214274431|NCT03539328|DRUG|Gemcitabine|Chemotherapy medication
214274432|NCT03539328|DRUG|Paclitaxel|Chemotherapy medication
214274433|NCT03539328|DRUG|Liposomal Doxorubicin|Chemotherapy medication
214274434|NCT00870441|DRUG|ASP2151|Oral
214274435|NCT00870441|DRUG|Valacyclovir|Oral
214274436|NCT00870441|DRUG|Placebo|Oral
214274437|NCT01544283|DRUG|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
214274438|NCT01544283|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
214274439|NCT03432702|PROCEDURE|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
214274440|NCT02282579|DRUG|Pazopanib|Non interventional study
214274441|NCT00312559|BEHAVIORAL|Yoga Training|
214274442|NCT03963037|OTHER|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
214274443|NCT01272674|OTHER|exercise training|4 weeks supervised physical exercise training
214274444|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
214274445|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
214274446|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
214274447|NCT01234285|DRUG|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
214274448|NCT02782728|BEHAVIORAL|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
214274449|NCT02782728|BEHAVIORAL|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
214274450|NCT00917566|DEVICE|Airtraq|intubation with airtraq
214274451|NCT00917566|DEVICE|Macintoch|use Macintoch laryngoscope for intubation
214274452|NCT05515081|PROCEDURE|blood sample collection|blood sample colletion at regular intervals
214274453|NCT00266734|DEVICE|RPS Adeno Detector|
214274454|NCT04263077|OTHER|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
214274455|NCT04263077|OTHER|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
214274456|NCT04263077|OTHER|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
214274457|NCT04263077|OTHER|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
214274458|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
214274459|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
214274460|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
214274461|NCT00787384|DRUG|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
214274462|NCT02695901|DRUG|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
214274463|NCT02695901|DRUG|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
214274464|NCT00952978|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
214274465|NCT00952978|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
214274466|NCT00993200|GENETIC|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
214274467|NCT00993200|DRUG|Warfarin|Usual care warfarin dosing
214274468|NCT00795860|BEHAVIORAL|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
214274469|NCT00795860|BEHAVIORAL|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
214274470|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
214274471|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
214274472|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
214274473|NCT04614597|BIOLOGICAL|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
214274474|NCT06431087|OTHER|Mindfulness course|Online or in presence Information on Mindfulness, healthy diet and exercise.
214274475|NCT03414060|DEVICE|Menstrual Cup|
214274476|NCT00842608|BEHAVIORAL|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol"
214274477|NCT00842608|PROCEDURE|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
214274478|NCT00842608|DRUG|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
214274479|NCT00842608|PROCEDURE|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
214274480|NCT04433377|PROCEDURE|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
214274481|NCT04433377|PROCEDURE|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
214274482|NCT00903396|DRUG|palonosetron hydrochloride|Given IV
214274483|NCT00903396|OTHER|placebo|Given IV
214274484|NCT02034201|DRUG|Lisdexamfetamine|
214274485|NCT02034201|DRUG|Placebo|
214274486|NCT03305575|DRUG|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
214274487|NCT03305575|DRUG|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
214274488|NCT05956496|OTHER|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
214274489|NCT05956496|OTHER|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
214274490|NCT00315172|PROCEDURE|Non-Exercise Activity Thermogenesis (NEAT)|
214274491|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
214274492|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
214274493|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
214274494|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
214274495|NCT02705469|DRUG|ZEN003694|
214274496|NCT04002713|OTHER|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
214274497|NCT04002713|OTHER|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
214274498|NCT02792881|PROCEDURE|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
214274499|NCT02577978|DEVICE|Medacta GMK posterior stabilized prosthesis|
214274500|NCT02577978|DEVICE|Medacta GMK Sphere prosthesis|
214274501|NCT03794297|DRUG|Dabrafenib Mesylate|Given PO
214274502|NCT03794297|OTHER|Quality-of-Life Assessment|Ancillary studies
214274503|NCT03794297|OTHER|Questionnaire Administration|Ancillary studies
214274504|NCT03794297|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214274505|NCT03340688|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
214274506|NCT01335191|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
214274507|NCT01335191|OTHER|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
214274508|NCT00441714|PROCEDURE|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
214274509|NCT04660877|DIETARY_SUPPLEMENT|Cheddar Cheese|20g of protein from cheddar cheese
214274510|NCT04660877|DIETARY_SUPPLEMENT|Milk|20g of protein from milk
214274511|NCT06506656|DEVICE|Hyadrol®|Sterile single-use Medical Device for intra-articular injections
214274512|NCT03486223|DRUG|GSK2256294|Drug will be taken daily by mouth for 7 days.
214274513|NCT03486223|DRUG|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
214274514|NCT01819831|RADIATION|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
214274515|NCT01819831|PROCEDURE|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
214274516|NCT04800354|BEHAVIORAL|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
214274517|NCT04800354|BEHAVIORAL|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
214656889|NCT05046756|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
214274518|NCT03627143|OTHER|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance"
214274519|NCT05812196|DIAGNOSTIC_TEST|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
214274520|NCT05812196|BIOLOGICAL|COVID infection|Verified COVID-19 infection.
214274521|NCT01101984|DRUG|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
214274522|NCT01101984|DRUG|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
214274523|NCT01758432|COMBINATION_PRODUCT|PRT064445/Apixaban|
214274524|NCT01758432|COMBINATION_PRODUCT|Placebo/Apixaban|
214274525|NCT01758432|DRUG|Placebo|
214274526|NCT01572558|PROCEDURE|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
214274527|NCT01572558|DRUG|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
214274528|NCT06364098|DRUG|Misoprostol|400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
214274529|NCT00232609|DEVICE|GameCycle Exercise System|
214274530|NCT02050191|BEHAVIORAL|www.princetonlivingwell.com|
214274531|NCT05279183|DIETARY_SUPPLEMENT|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
214274532|NCT05279183|DIETARY_SUPPLEMENT|Sucrose|30 g sucrose dissolved in 300 mL tap water.
214274533|NCT05279183|DIETARY_SUPPLEMENT|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
214274534|NCT00933972|DRUG|RO4998452|20mg po single dose
214274535|NCT00277147|DRUG|BB IND 6989|
214274536|NCT03918122|OTHER|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
214274537|NCT00838396|DRUG|XP19986 CR|
214274538|NCT00838396|DRUG|Placebo for XP19986 CR|
214274539|NCT05166824|DEVICE|TempSure|Radiofrequency platform
214274540|NCT05166824|DEVICE|Scalpel|Cold knife
214274541|NCT05166824|DEVICE|Bovie|Electrosurgery and electrocautery platform
214274542|NCT05166824|DEVICE|Pelleve|Radiofrequency platform
214274543|NCT02647203|DRUG|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
214274544|NCT04922775|PROCEDURE|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
214274545|NCT04922775|PROCEDURE|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
214274546|NCT02417831|DRUG|tamsulosin capsules|
214274547|NCT02417831|DRUG|tamsulosin HCl|
214274548|NCT00209469|DRUG|alendronate sodium|
214274549|NCT00813306|DRUG|AZD2066|13 mg oral solution, 1 single dose
214274550|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
214274551|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
214274552|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
214274553|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
214274554|NCT04036344|BEHAVIORAL|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
214274555|NCT00523016|PROCEDURE|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
214274556|NCT00523016|PROCEDURE|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
214274557|NCT01415284|DRUG|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
214274558|NCT04381403|OTHER|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
214274559|NCT04381403|OTHER|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
214274560|NCT03180723|DRUG|Rituximab|Intravenous injection
214274561|NCT03180723|DRUG|Cyclosporin|Oral tablets
214274562|NCT03780855|DEVICE|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
214274563|NCT01228760|DRUG|ASG-5ME|IV
214274564|NCT01144286|DRUG|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
214274565|NCT01144286|DRUG|placebo|placebo, single dose
214274566|NCT03068130|DRUG|Bardoxolone methyl|Capsules of Bardoxolone methyl
214274567|NCT03130257|DIAGNOSTIC_TEST|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
214274568|NCT03130257|DIAGNOSTIC_TEST|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
214274569|NCT03130257|DIAGNOSTIC_TEST|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
214274570|NCT03130257|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
214274571|NCT00297830|DRUG|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
214274572|NCT00297830|DRUG|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
214274573|NCT00297830|OTHER|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
214274574|NCT00297830|OTHER|Placebo Alendronate|Placebo alendronate 70 mg once weekly
214274575|NCT02131194|DIETARY_SUPPLEMENT|Lenstatin|Dietary Supplement Lenstatin
214274576|NCT02131194|DRUG|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
214274577|NCT01548651|DRUG|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
214274578|NCT01548651|DRUG|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
214274579|NCT03632200|OTHER|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
214274580|NCT04433403|OTHER|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
214274581|NCT04979468|DRUG|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
214274582|NCT02430012|BEHAVIORAL|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
214274583|NCT05777850|PROCEDURE|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
214274584|NCT05777850|PROCEDURE|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
214274585|NCT03391180|DRUG|ICON Remineralization|A material used for the Remineralization of white spot lesions.
214274586|NCT03391180|DRUG|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
214274587|NCT06568614|DRUG|BG-89894|Administered orally
214274588|NCT05307055|DEVICE|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
214274589|NCT05307055|DEVICE|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
214274590|NCT06360536|BEHAVIORAL|Resistance Training|A home-based resistance training condition that is delivered through a web-based platform.
214274591|NCT05799586|BEHAVIORAL|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
214274592|NCT05799586|BEHAVIORAL|Waitlist control group|Usual care
214274593|NCT05944887|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
214274594|NCT05944887|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
214274595|NCT05944887|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
214274596|NCT05944887|PROCEDURE|gastroscopy|esogastroduodenoscopy
214274597|NCT05276531|DRUG|subcutaneous progesterone|clinical pregnancy rates
214274598|NCT05276531|DRUG|vaginal progesterone|clinical pregnancy rates
214274599|NCT06066164|DEVICE|Transcranial magnetic stimulation (TMS)|Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability
214274600|NCT02393183|DRUG|ASTED|A tablet of ASTED will be taken twice a day
214274601|NCT02393183|DIETARY_SUPPLEMENT|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
214274602|NCT02393183|OTHER|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
214274603|NCT02128971|DIETARY_SUPPLEMENT|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214274604|NCT02128971|DIETARY_SUPPLEMENT|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214274605|NCT02128971|DIETARY_SUPPLEMENT|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214274606|NCT02128971|DIETARY_SUPPLEMENT|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214274607|NCT02128971|DIETARY_SUPPLEMENT|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214274608|NCT02128971|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
214274609|NCT01186965|BEHAVIORAL|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
214274610|NCT02616081|OTHER|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
214274611|NCT02616081|OTHER|Indwelling Catheter|Indwelling catheterization is a standard of care.
214274612|NCT02616081|OTHER|Surgery|Bladder surgery is a standard of care.
214274613|NCT02616081|OTHER|Voiding|Voiding spontaneously is a standard of care.
214274614|NCT06643286|DEVICE|Digizorg Melanoma app|The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.
214274615|NCT04377620|DRUG|Placebo|Placebo administered BID approximately 12 hours apart
214274616|NCT04377620|DRUG|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
214274617|NCT05178771|OTHER|Platelet rich fibrin|"1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
214274618|NCT02966262|DEVICE|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
214274619|NCT03747588|PROCEDURE|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
214274620|NCT03747588|OTHER|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
214274621|NCT00199680|PROCEDURE|PET|
214274622|NCT01236482|DRUG|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
214274623|NCT03692247|OTHER|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
214274624|NCT02179242|OTHER|Cardiac rehab|
214274625|NCT06260852|DIAGNOSTIC_TEST|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
214274626|NCT00870883|DRUG|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
214274627|NCT03084770|DIAGNOSTIC_TEST|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
214274628|NCT03084770|OTHER|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
214274629|NCT00210405|DIETARY_SUPPLEMENT|"Sprinkles containing mulitple micronutrients"|
214274630|NCT00210405|BEHAVIORAL|Education/communication on use of micronutrient sprinkles|
214274631|NCT00210405|DIETARY_SUPPLEMENT|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
214274632|NCT00349531|DRUG|Pramipexole|
214274633|NCT05690373|DIETARY_SUPPLEMENT|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
214274634|NCT02933723|PROCEDURE|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
214274635|NCT06091631|PROCEDURE|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
214274636|NCT00078182|DRUG|Tenofovir DF|
214274637|NCT06450821|PROCEDURE|PRIOR [Proactive Intensive Oral Review & Treatment]|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
214274638|NCT00420693|DRUG|sevoflurane|
214274639|NCT03859778|OTHER|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
214274640|NCT05289791|OTHER|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
214274641|NCT00158574|DRUG|sulphadoxine-pyrimethamine|
214274642|NCT00158574|DRUG|mefloquine|
214274643|NCT00158574|DRUG|Chlorproguanil-dapsone|
214274644|NCT00158574|DRUG|Placebo|Placebo
214274645|NCT00158574|DRUG|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
214274646|NCT00158574|DRUG|IPTi mefloquine|IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
214274647|NCT00158574|DRUG|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
214274648|NCT01830478|DRUG|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
214274649|NCT01830478|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
214274650|NCT03333447|OTHER|MRI|
214274651|NCT02497339|BEHAVIORAL|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
214274652|NCT02144623|DRUG|Valproate|
214274653|NCT01483755|PROCEDURE|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
214274654|NCT01483755|PROCEDURE|Percutaneaous intervention|Conventional primary percutaneaous intervention
214274655|NCT05473390|OTHER|functional electrical stimulation|functional electrical stimulation on back muscles
214274656|NCT05473390|OTHER|kinesotaping|no intervention
214274657|NCT00288054|BIOLOGICAL|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
214274658|NCT00288054|DRUG|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
214274659|NCT00288054|RADIATION|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
214274660|NCT06278701|OTHER|late-evening snacks|have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
214274661|NCT04565470|OTHER|online questionnaire|Web-based questionnaire about use of self-management strategies
214274662|NCT02040571|DEVICE|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
214274663|NCT02040571|DEVICE|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
214274664|NCT04882618|DRUG|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
214274665|NCT02624609|OTHER|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
214274666|NCT02624609|OTHER|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
214274667|NCT04130620|DIAGNOSTIC_TEST|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
214274668|NCT02062021|OTHER|No intervention|
214274669|NCT04444102|PROCEDURE|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
214274670|NCT01850628|DRUG|Paclitaxel|
214274671|NCT01850628|BIOLOGICAL|trastuzumab|
214274672|NCT01850628|BIOLOGICAL|pertuzumab|
214274673|NCT04574011|DIAGNOSTIC_TEST|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
214274674|NCT02118883|OTHER|Essentia Water|
214274675|NCT02118883|OTHER|Bottled water|
214274676|NCT01610570|DRUG|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
214274677|NCT01934023|DRUG|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
214274678|NCT01934023|DRUG|Placebo|
214274679|NCT03203616|DRUG|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
214274680|NCT04957004|DEVICE|CPAP|CPAP ventilator was worn at nigh
214274681|NCT00261222|DRUG|Amodiaquine|
214274682|NCT04159571|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
214274683|NCT04159571|DEVICE|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
214274684|NCT03903068|DEVICE|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
214274685|NCT03903068|DEVICE|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
214274686|NCT01815801|OTHER|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
214274687|NCT01815801|OTHER|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
214274688|NCT01060813|DIETARY_SUPPLEMENT|Leucine supplements|leucine supplements
214274689|NCT00000789|DRUG|Stavudine|
214274690|NCT00000789|DRUG|Zidovudine|
214274691|NCT02295384|OTHER|Retrospective Audit|Retrospective Audit
214274692|NCT01826188|DRUG|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
214274693|NCT01826188|DRUG|Placebo|olive oil without cannabis
214274694|NCT00332163|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
214274695|NCT00332163|DRUG|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
214274696|NCT00332163|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
214274697|NCT00332163|DRUG|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
214274698|NCT00332163|DRUG|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
214274699|NCT02519257|PROCEDURE|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
214274700|NCT02519257|PROCEDURE|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
214274701|NCT01292811|DEVICE|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
214274702|NCT01292811|OTHER|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
214274703|NCT00001190|DRUG|Deslorelin|
214274704|NCT02895230|OTHER|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
214274705|NCT02621060|DRUG|Placebo|Placebo: 1200 mg per day for three months
214274706|NCT02621060|DRUG|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
214274707|NCT00573612|BEHAVIORAL|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
214274708|NCT00573612|BEHAVIORAL|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
214274709|NCT03733470|DRUG|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
214274710|NCT02376231|DEVICE|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
214274711|NCT04157491|DRUG|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
214274712|NCT05722782|DRUG|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
214274713|NCT05722782|DRUG|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
214274714|NCT05722782|DRUG|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
214274715|NCT01906398|OTHER|ketogenic diet|KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
214274716|NCT03396185|DRUG|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
214274717|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
214274718|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
214274719|NCT02711397|OTHER|Observational study|Comparison excretion levels of gluten immunogenic peptides
214274720|NCT04329897|BEHAVIORAL|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
214274721|NCT00695877|BIOLOGICAL|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
214274722|NCT01010061|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
214274723|NCT01010061|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
214274724|NCT01010061|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
214274725|NCT03050554|DRUG|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
214274726|NCT03050554|RADIATION|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
214274727|NCT01885403|DEVICE|non-invasive respiratory parameter measurements|
214274728|NCT03916120|GENETIC|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
214274729|NCT03012438|DEVICE|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
214274730|NCT03559660|DRUG|Certolizumab Pegol|
214274731|NCT02433405|BIOLOGICAL|Fetuin-A|Acute phase protein
214274732|NCT02433405|BIOLOGICAL|Serum Amyloid A|Acute phase protein
214274733|NCT05410483|DRUG|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
214274734|NCT01299740|BEHAVIORAL|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
214274735|NCT01299740|OTHER|Control Group|Treatment as usual
214274736|NCT03628820|BEHAVIORAL|Dog Therapy|5 minutes spent with therapy dog during shift
214274737|NCT03628820|BEHAVIORAL|Coloring|5 minutes spend coloring mandalas during shift
214274738|NCT05852145|DRUG|Stevioside|"250 ml of natural water added with 0.1 gr. of stevioside should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
214274739|NCT05852145|DRUG|Sucrose|"250 ml of natural water added with 25 gr of sucrose should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
214274740|NCT05852145|OTHER|Natural water|"250 ml of natural water should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
214274741|NCT00626964|PROCEDURE|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
214274742|NCT00626964|BEHAVIORAL|Conservative Treatment:|Intensive Lifestyle Intervention Program
214274743|NCT06448286|PROCEDURE|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|Undergo CEST MRI
214274744|NCT06448286|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
214274745|NCT06448286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214274746|NCT06448286|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214274747|NCT06448286|PROCEDURE|Surgical Procedure|Undergo surgical resection
214274748|NCT06448286|DRUG|Temozolomide|Given PO
214274749|NCT04282785|DIAGNOSTIC_TEST|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
214274750|NCT05743582|PROCEDURE|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
214274751|NCT05743582|PROCEDURE|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
214274752|NCT05375734|DRUG|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
214274753|NCT06463613|DEVICE|STR Skin Tag Removal device with diary and follow-up|The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.
214274754|NCT05774236|DEVICE|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
214274755|NCT05774236|DRUG|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
214274756|NCT06394310|DEVICE|Dry needling|The dry needling technique will employ in the current proposed study follows the standard technique for needling patients with spasticity
214274757|NCT06394310|DEVICE|Sham dry needling|In the control group, The investigators will use the methods proposed by Cushman et al. to apply sham dry needling (DN) to our participants
214274758|NCT03947450|BIOLOGICAL|Autologous Skin Fibroblasts|The site or whole stump will be injected with autologous fibroblasts
214274759|NCT03947450|BIOLOGICAL|Placebo|The site or whole stump will be injected medium only without autologous skin fibroblasts
214274760|NCT06253572|OTHER|Education|"Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time."
214274761|NCT03044678|BEHAVIORAL|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
214274762|NCT03044678|BEHAVIORAL|Self-Study|Books for youth about anxiety management
214274763|NCT05647460|PROCEDURE|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
214274764|NCT05647460|PROCEDURE|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
214274765|NCT05315544|DEVICE|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
214274766|NCT04258865|DRUG|CKD-348 F1|QD, PO
214274767|NCT04258865|DRUG|CKD-348 F2|QD, PO
214274768|NCT04258865|DRUG|CKD-828, D097, D337|QD, PO
214274769|NCT04994600|OTHER|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA\_2nd\_phase group.
214274770|NCT05975892|BIOLOGICAL|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
214274771|NCT05022082|OTHER|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
214274772|NCT00884871|PROCEDURE|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
214274773|NCT04743739|DRUG|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
214274774|NCT04743739|DRUG|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
214274775|NCT01004705|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
214274776|NCT01004705|DRUG|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
214274777|NCT04374721|DIAGNOSTIC_TEST|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
214274778|NCT04273204|DIAGNOSTIC_TEST|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
214274779|NCT03031314|DEVICE|barbed suture|
214274780|NCT03031314|DEVICE|standard suture|
214274781|NCT00864383|DRUG|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
214274782|NCT02197520|DRUG|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
214274783|NCT02197520|DRUG|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
214274784|NCT02197520|DRUG|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
214274785|NCT00158158|DRUG|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
214274786|NCT00158158|OTHER|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
214274787|NCT01306942|DRUG|Dasatinib|
214274788|NCT01306942|DRUG|Trastuzumab|
214274789|NCT01306942|DRUG|Paclitaxel|
214274790|NCT02880059|DEVICE|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
214274791|NCT01271062|PROCEDURE|gastric bypass surgery|
214274792|NCT01271062|PROCEDURE|abdominal surgery|
214274793|NCT01271062|BEHAVIORAL|very low caloric diet|
214274794|NCT04411654|GENETIC|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
214274795|NCT04411654|DRUG|Methylprednisolone|Single IV pulse administered as concomitant medication.
214274796|NCT04411654|DRUG|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
214274797|NCT04411654|DRUG|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
214274798|NCT06429137|DRUG|BI 3731579|BI 3731579
214274799|NCT06429137|DRUG|Matching placebo to BI 3731579|Matching placebo to BI 3731579
214274800|NCT00785265|BEHAVIORAL|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
214274801|NCT00785265|BEHAVIORAL|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
214274802|NCT02941991|BIOLOGICAL|hESC-RPE|sub-retinal injection
214274803|NCT05371431|OTHER|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
214274804|NCT05371431|OTHER|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
214274805|NCT02809612|BEHAVIORAL|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
214274806|NCT00105417|DRUG|IL-7|
214274807|NCT00844675|DRUG|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
214274808|NCT00844675|DRUG|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
214274809|NCT03582189|OTHER|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
214274810|NCT05400109|BIOLOGICAL|UF-KURE19 CAR-T cells|UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved
214274811|NCT05400109|DRUG|Fludarabine|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
214274812|NCT05400109|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA
214274813|NCT01957930|DRUG|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
214274814|NCT01957930|DRUG|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
214274815|NCT01605162|DRUG|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
214274816|NCT01605162|DRUG|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
214274817|NCT05626985|DIAGNOSTIC_TEST|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
214274818|NCT00179556|DRUG|Isoflavone supplement|
214274819|NCT04945122|DRUG|Pitavastatin|Pitavastatin 4mg Qn
214274820|NCT04945122|DRUG|Atorvastatin|Atorvastatin 20mg Qn
214274821|NCT03892096|DIAGNOSTIC_TEST|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
214274822|NCT00129428|PROCEDURE|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
214274823|NCT02532088|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
214274824|NCT02532088|DIETARY_SUPPLEMENT|Placebo|Placebo
214274825|NCT00679666|DRUG|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
214274826|NCT00679666|DRUG|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
214274827|NCT02021773|DRUG|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
214274828|NCT02021773|DRUG|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
214274829|NCT02021773|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
214274830|NCT04080375|DRUG|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
214274831|NCT04080375|DRUG|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
214274832|NCT03993795|OTHER|A19010-W|A snus product
214274833|NCT03993795|OTHER|B19010-F|A snus product
214274834|NCT00603174|DEVICE|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
214274835|NCT06097286|PROCEDURE|external oblique intercostal plane block|o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
214274836|NCT06097286|PROCEDURE|erector spinae plane block|o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
214274837|NCT01388738|DRUG|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
214274838|NCT01388738|DRUG|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
214274839|NCT01388738|DRUG|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
214274840|NCT05241743|OTHER|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
214274841|NCT01041833|DRUG|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
214274842|NCT01041833|DRUG|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
214274843|NCT06385600|DRUG|Labetalol|Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
214274844|NCT06385600|DRUG|Phentolamine|Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
214274845|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
214274846|NCT00087607|DRUG|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
214274847|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
214274848|NCT00087607|DRUG|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
214274849|NCT00190671|DRUG|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
214274850|NCT00190671|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
214274851|NCT00190671|DRUG|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
214274852|NCT03907228|DIETARY_SUPPLEMENT|RHT-3201|PROBIOTIC
214274853|NCT04903275|PROCEDURE|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS\_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
214274854|NCT04903275|PROCEDURE|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
214274855|NCT02911714|DRUG|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
214274856|NCT00454896|DRUG|VESIcare®|Oral
214274857|NCT00454896|DRUG|placebo|Oral
214274858|NCT01803061|BEHAVIORAL|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
214274859|NCT03556072|OTHER|Routine ERCP|
214274860|NCT04749277|OTHER|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
214274861|NCT03108677|OTHER|Blood samples|15 ml peripheral blood
214274862|NCT05624593|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
214274863|NCT05624593|DEVICE|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
214274864|NCT02184481|BEHAVIORAL|Working memory training|
214274865|NCT02184481|BEHAVIORAL|Placebo training|
214274866|NCT01478477|DIETARY_SUPPLEMENT|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
214274867|NCT01478477|OTHER|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
214274868|NCT01478477|OTHER|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
214274869|NCT01478477|OTHER|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
214274870|NCT01478477|PROCEDURE|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
214274871|NCT01478477|PROCEDURE|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
214274872|NCT05495620|DRUG|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
214274873|NCT05495620|DRUG|Lenalidomide|Oral
214274874|NCT05495620|DRUG|Dexamethasone|Oral or intravenous
214274875|NCT02244112|DRUG|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
214274876|NCT02244112|DRUG|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
214274877|NCT00255112|BEHAVIORAL|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
214274878|NCT02107170|DRUG|Sevoflurane|sevoflurane-based general anesthesia
214274879|NCT02107170|DRUG|Propofol|total intravenous anesthesia
214274880|NCT02107170|DRUG|Remifentanil|
214274881|NCT02883270|DEVICE|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
214274882|NCT02883270|OTHER|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
214274883|NCT03978000|DRUG|IBP-9414|Oral suspension
214274884|NCT03978000|DRUG|Placebo|Sterile water
214274885|NCT00811759|DRUG|sorafenib tosylate|
214274886|NCT00811759|DRUG|temozolomide|
214274887|NCT00811759|GENETIC|gene expression analysis|
214274888|NCT00811759|GENETIC|mutation analysis|
214274889|NCT00811759|OTHER|laboratory biomarker analysis|
214274890|NCT00811759|OTHER|pharmacological study|
214274891|NCT00811759|PROCEDURE|biopsy|
214274892|NCT00654017|DRUG|placebo|Placebo comparator to be given per protocol.
214274893|NCT00654017|DRUG|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
214274894|NCT01887665|BEHAVIORAL|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
214274895|NCT02094677|DEVICE|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
214274896|NCT02094677|DEVICE|etafilcon A|Participants were randomized to wear etafilcon A control lens.
214274897|NCT02094677|DEVICE|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
214274898|NCT03408483|DRUG|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
214274899|NCT03408483|DRUG|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
214274900|NCT05399641|DRUG|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
214274901|NCT04092400|DEVICE|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
214274902|NCT00478231|DRUG|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
214274903|NCT00003165|DRUG|doxorubicin-HPMA conjugate|
214274904|NCT04226872|BEHAVIORAL|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
214274905|NCT00511446|DRUG|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214274906|NCT05021601|PROCEDURE|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
214274907|NCT05021601|PROCEDURE|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
214274908|NCT05987228|DIETARY_SUPPLEMENT|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
214274909|NCT04688957|PROCEDURE|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
214274910|NCT04688957|PROCEDURE|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
214274911|NCT03566160|DEVICE|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
214274912|NCT04633018|DEVICE|AsthmaMD mobile application|asthma management app with Spanish-language user interface
214274913|NCT04633018|OTHER|Usual care|Asthma management without the app
214274914|NCT05890508|DEVICE|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
214274915|NCT05890508|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
214274916|NCT01209611|PROCEDURE|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
214274917|NCT01209611|PROCEDURE|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
214274918|NCT01374997|OTHER|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
214274919|NCT03127410|OTHER|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
214274920|NCT00672932|DRUG|raltegravir|400 mg two times daily for three months
214274921|NCT03277664|BEHAVIORAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
214274922|NCT02041884|BEHAVIORAL|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
214274923|NCT02041884|BEHAVIORAL|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
214274924|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
214274925|NCT05622175|DRUG|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
214274926|NCT02516046|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
214274927|NCT02516046|PROCEDURE|PET Scan|positron emission tomography (PET) scan
214274928|NCT02185092|DIETARY_SUPPLEMENT|Lactobacillus GG|probiotic supplement
214274929|NCT02185092|OTHER|Sugar pill|placebo
214274930|NCT00255125|DRUG|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
214274931|NCT00255125|DRUG|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
214274932|NCT04489628|DRUG|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
214274933|NCT04489628|DEVICE|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
214274934|NCT01133873|DRUG|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
214274935|NCT01133873|DRUG|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
214274936|NCT06376292|DRUG|Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
214274937|NCT01423318|DRUG|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
214274938|NCT01423318|DRUG|placebo|single dose subcutaneously
214274939|NCT01939808|OTHER|Splint Neutral|
214274940|NCT01939808|OTHER|Splint Extended|
214274941|NCT04066023|DRUG|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
214274942|NCT04066023|DRUG|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
214274943|NCT04524546|DIAGNOSTIC_TEST|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
214274944|NCT00036517|DRUG|PHY906|
214274945|NCT06555536|OTHER|Tele OI|A data collection and Telemedicine tool translated into an APP.
214274946|NCT04600557|BEHAVIORAL|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
214274947|NCT04600557|BEHAVIORAL|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
214274948|NCT04600557|BEHAVIORAL|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
214274949|NCT04600557|BEHAVIORAL|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
214274950|NCT04939116|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
214274951|NCT04939116|DRUG|Placebo|Orally administered placebo capsule
214274952|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
214274953|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
214274954|NCT00751933|DIETARY_SUPPLEMENT|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
214274955|NCT00751933|OTHER|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
214274956|NCT04782661|DRUG|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
214274957|NCT04782661|DRUG|Placebo|Placebo solution will be administered orally.
214274958|NCT01044875|PROCEDURE|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
214274959|NCT00716534|DRUG|ABT-869|12.5 mg ABT-869
214274960|NCT00716534|DRUG|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
214274961|NCT00716534|DRUG|ABT-869|7.5 mg ABT-869
214274962|NCT00716534|DRUG|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
214274963|NCT00716534|DRUG|Paclitaxel|Paclitaxel (200 mg/m2)
214274964|NCT00072566|BIOLOGICAL|Bevacizumab|Given IV
214274965|NCT00072566|DRUG|Cyclophosphamide|Given PO
214274966|NCT00072566|OTHER|Laboratory Biomarker Analysis|Correlative studies
214274967|NCT05248867|DRUG|Placebo|Placebo solution for injection
214274968|NCT05248867|DRUG|AGN-151586|AGN-151586 solution for injection
214274969|NCT01673217|DRUG|decitabine|Given IV
214274970|NCT01673217|BIOLOGICAL|NY-ESO-1 peptide vaccine|Given SC
214274971|NCT01673217|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214274972|NCT01673217|BIOLOGICAL|sargramostim|Given SC
214274973|NCT01673217|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
214274974|NCT01673217|OTHER|immunohistochemistry staining method|Correlative studies
214274975|NCT01673217|OTHER|liquid chromatography|Correlative studies
214274976|NCT01673217|OTHER|mass spectrometry|Correlative studies
214274977|NCT01673217|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214274978|NCT01673217|OTHER|laboratory biomarker analysis|Correlative studies
214274979|NCT01673217|GENETIC|DNA methylation analysis|Correlative studies
214274980|NCT01673217|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214274981|NCT06042504|OTHER|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
214274982|NCT01861860|DEVICE|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
214274983|NCT05544734|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
214274984|NCT05544734|DRUG|Acetaminophen 1000mg|1000 mg tablet
214274985|NCT05544734|DRUG|Ibuprofen 400 mg|400 mg tablet
214274986|NCT03918785|DIETARY_SUPPLEMENT|Rice germ|25 g twice a day.
214274987|NCT03918785|DIETARY_SUPPLEMENT|Wheat-based supplement|25g twice a day.
214274988|NCT01084083|BIOLOGICAL|cetuximab|Given IV
214274989|NCT01084083|RADIATION|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
214274990|NCT01084083|DRUG|Paclitaxel|Given IV, 90 mg/m\^2 on days 1, 8 and 15
214274991|NCT01084083|DRUG|Cisplatin|Given IV, 75 mg/m\^2 on day 1
214274992|NCT00272740|DRUG|Fulvestrant|
214274993|NCT04670198|BEHAVIORAL|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
214274994|NCT04670198|BEHAVIORAL|Waiting-list control|Usual care for 6 months, followed by the YES programme.
214274995|NCT01088997|DRUG|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
214274996|NCT02939430|DRUG|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
214274997|NCT02939430|DRUG|Intravenous neostigmine and atropine|
214274998|NCT05556330|PROCEDURE|computer guided autogenous cortical shell technique|computer guided autogenous cortical shell technique
214274999|NCT04050579|DEVICE|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
214275000|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 1|In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
214829470|NCT02464904|OTHER|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
214275001|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 2|In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
214275002|NCT04724980|DRUG|PRGN-2012 - Phase II; Dose Level 2|The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
214829471|NCT00731367|DEVICE|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
214275003|NCT04543838|DIAGNOSTIC_TEST|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
214275004|NCT04543838|OTHER|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
214275005|NCT04177914|PROCEDURE|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
214275006|NCT04177914|DEVICE|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
214275007|NCT05955001|DRUG|Tadalafil 5mg / Placebo|Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
214275008|NCT06330051|BEHAVIORAL|improvement acute reperfusion treatment quality for stroke through spatiotemporal computing|"1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS"
214275009|NCT04518072|OTHER|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
214275010|NCT05695209|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
214275011|NCT06976853|DRUG|Tirzepatide|Addition of tirzepatide to current biological therapy
214275012|NCT06976853|DRUG|Standard of care treatment|Intervention will be to change patient's current therapy to a 3rd or later advanced biologic patient have never been exposed to
214275013|NCT05343052|OTHER|Patient Reported Outcomes Surveys|"* Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)"
214275014|NCT05343052|OTHER|Clinical Assessments|"* Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS"
214275015|NCT05343052|OTHER|Biomechanical and Neuromuscular Assessments|"* Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS"
214275016|NCT05343052|DEVICE|Conventional MRI|at baseline, within 7 days of injury, and within 7 days of RTS
214275017|NCT06387459|DEVICE|Fabric-Type Knee Extensor Muscle-Mimicking Orthosis|The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
214275018|NCT02044445|PROCEDURE|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
214275019|NCT07001826|PROCEDURE|Virtual Surgical Planning (VSP) with Patient-Specific Plates (PSPs)|Patients will undergo orthognathic surgery using Virtual Surgical Planning (VSP) combined with custom-fabricated Patient-Specific Plates (PSPs). High-resolution CT scans will be used to create 3D models of each patient's craniofacial structure. Surgical plans will be developed using specialized CAD software, and PSPs will be designed and manufactured using 3D printing and milling techniques. During surgery, these custom plates and accompanying cutting guides will be used to accurately reposition the maxilla, ensuring precise correction of maxillary cant. This approach aims to improve surgical accuracy, reduce operating time, and enhance postoperative outcomes.
214275020|NCT06677021|BEHAVIORAL|Exercise|Physical activity promotion and engagement
214275021|NCT07004777|OTHER|Isocaloric diet including chia and pumpkin seeds|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of pumpkin and chia seeds."
214275022|NCT07004777|DIETARY_SUPPLEMENT|Isocaloric diet plus fish oil|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates EPA + DHA supplement (fish oil) to the diet."
214275023|NCT07004777|OTHER|Isocaloric diet including salmon|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of salmon."
214275024|NCT07000383|DEVICE|Gelsectan|Gelsectan is a medical device containing xyloglucan, pea protein, and tannins, administered orally. Dosage: 2 capsules BID during Month 1, followed by 1 capsule BID during Month 2.
214275025|NCT07000383|DRUG|Antispasmodic Agent|An oral antispasmodic medication, prescribed according to standard clinical practice for IBS-D.
214275026|NCT06678243|BEHAVIORAL|Smiling instead of Smoking|"Participants randomized to the treatment condition will use the Smiling instead of Smoking (SiS) smartphone app. This app delivers and guides participants through two types of content to help them during their quit attempt: (1) positive psychology content (i.e., happiness habit-building exercises, happiness boost activity, and science-based information on the relevance of positive psychology activities) designed to help nondaily smokers maintain positive affect while they go through the process of smoking cessation; and (2) traditional behavioral smoking cessation content to guide their quit process based on US Clinical Practice Guidelines."
214275027|NCT06678243|BEHAVIORAL|QuitGuide|"Participants randomized to the control condition will use the National Cancer Institute (NCI)'s QuitGuide (QG) smartphone app. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
214275028|NCT06865989|DEVICE|Omnipod 5 SmartAdjust 2.0 System|Omnipod 5 System with changes
214275029|NCT06865989|DEVICE|Omnipod 5 System|Cleared device as comparator
214275030|NCT06868381|DRUG|Baricitinib (LY3009104) 4 mg|baricitinib 4 mg tablet taken orally once daily
214275031|NCT06614868|BEHAVIORAL|Acceptance and Commitment Therapy|Up to 16 session of unstructured counseling therapy informed by Acceptance and Commitment Therapy tradition.
214275032|NCT06614868|BEHAVIORAL|Treatment as Usual (TAU)|Unstructured counseling
214275033|NCT07009535|DIAGNOSTIC_TEST|Polysomnography|Assessment of AHI index and pO2 in pediatric patients
214275034|NCT07007936|DRUG|SSS17 Capsule (6 Dose Levels)|Arm1 ： This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly
214275035|NCT07007936|DRUG|Placebo Drug|Arm2：placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).
214275036|NCT06681779|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
214275037|NCT06681779|OTHER|Standard of Care (SOC)|Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
214275038|NCT06680544|DRUG|Voriconazole high dose|Oral voriconazole 200mg once a day for a maximum of 28 days
214275039|NCT06680544|DRUG|Voriconazole low dose|Oral voriconazole 200mg twice a day for a maximum of 28 days
214275040|NCT06680804|OTHER|chance for vaginal delivery.|chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy
214275041|NCT01422174|PROCEDURE|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
214275042|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
214275043|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
214275044|NCT06681805|DRUG|Placebo + Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
214275045|NCT06681805|DRUG|Placebo+ Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
214275046|NCT07014410|DRUG|pyrotinib dalpiciclib letrozole|ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole
214275047|NCT07015112|OTHER|Patient-centered multidisciplinary treatment review|Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)
214275048|NCT07016113|DRUG|0.005% latanoprost gel|\- Apply 0.005% latanoprost gel to the predetermined skin lesions twice daily (morning and evening) every day for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
214275049|NCT07016113|DRUG|0.1% mometasone furoate cream|\- Apply 0.1% mometasone furoate cream to the predetermined skin lesions twice daily (morning and evening) for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
214275050|NCT07015736|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|Standard treatment (50-90 mg/kg/day for 10 days)
214275051|NCT07015736|DIETARY_SUPPLEMENT|Saccharomyces boulardii CNCM I-745|Probiotic sachet, twice daily for 10 or 21 days depending on group assignment
214275052|NCT07016477|DIAGNOSTIC_TEST|Ultra-High Resolution Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Ultra-High Resolution Photon-Counting Detector Coronary Computed Tomography Angiography (UHR PCD-CT CCTA) for the pre-procedural evaluation of patients scheduled to undergo transcatheter aortic valve implantation.
214275053|NCT07014371|DRUG|Ferrous Fumarate Oral Tablet|Ferrous fumarate oral tablet 200 mg is an iron supplement used for the treatment of iron deficiency anemia (IDA). In this study, it is administered as either one tablet daily (OD group) or two tablets on alternate days (AD group), with a treatment duration of 8 weeks. The goal is to compare the efficacy and tolerability of alternate-day dosing versus standard once-daily dosing.
214275054|NCT07014332|DEVICE|Steel ligature|Steel ligatures that are used to ligate wire with bracket
214275055|NCT07014332|DEVICE|Elastomeric ligature|Elastomeric ligature that is used to ligate wire to bracket
214275056|NCT07016464|DRUG|REM0045392|Liquid formulation
214275057|NCT07016464|DRUG|Placebo|Liquid formulation
214275058|NCT07016555|DIETARY_SUPPLEMENT|Oral cooling spray|Use oral spray 3 times per day for 2 weeks
214275059|NCT04774913|PROCEDURE|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
214275060|NCT04522388|DIETARY_SUPPLEMENT|Ensure Enlive|Ensure Enlive shake twice a day
214275061|NCT06681571|OTHER|TAP Block|TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
214275062|NCT06681571|OTHER|RSB|Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
214275063|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
214275064|NCT04731363|DIETARY_SUPPLEMENT|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
214275065|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
214275066|NCT04731363|DIETARY_SUPPLEMENT|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
214275067|NCT06815237|DIETARY_SUPPLEMENT|Kenetik|Ketone supplement is randomly given once.
214275068|NCT06815237|OTHER|Alcohol beverage|Alcohol beverage is randomly given once. Participants will receive the alcohol beverage that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.050%
214275069|NCT06778447|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
214275070|NCT06778447|OTHER|Sham|A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
214275071|NCT06621719|PROCEDURE|Alveolar Cleft Reconstruction|Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
214275072|NCT06826612|GENETIC|SPK-10001|Specified dose on specified days
214275073|NCT06826612|OTHER|Placebo Surgery Control|Placebo Surgery procedure for SPK-10001
214275074|NCT06866379|OTHER|Brain imaging|fMRI session with the ALCUE paradigme.
214275075|NCT02513394|DRUG|Palbociclib|
214275076|NCT02513394|DRUG|Standard Adjuvant Endocrine Therapy|
214275077|NCT06822231|DEVICE|High-tech rehabilitative treatment|"Robotic Verticalization System (e.g., Erigo): Assists in regaining upright posture and mobility.~Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises.~Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training.~Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback"
214275078|NCT06822231|OTHER|Rehabilitation|Traditional rehabilitative treatment
214275079|NCT06772675|BEHAVIORAL|External Facilitation|Designated external facilitators will conduct monthly meetings with local champions at each site. Designated facilitators will follow the developed facilitation guide, that includes content area to cover in each meeting, case scenarios as examples, and tips on how to communicate and support the internal facilitators. The goal is to enable problem-solving and support the local champion in implementing VRP with fidelity
214275080|NCT03677921|DIETARY_SUPPLEMENT|Investigational Product (Bio-Germanium)|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
214275081|NCT03677921|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
214275082|NCT03595267|OTHER|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations."
214275083|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
214275084|NCT05888831|DRUG|BMS-986449|Specified dose on specified days
214275085|NCT05888831|DRUG|Nivolumab|Specified dose on specified days
214275086|NCT06627751|BIOLOGICAL|Mezigdomide|Given PO
214275087|NCT06627751|DRUG|Carfilzomib|Given IV
214275088|NCT06627751|DRUG|Dexamethasone|Given PO
214275089|NCT06627751|PROCEDURE|Echocardiography|Undergo ECHO
214275090|NCT06627751|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214275091|NCT06627751|PROCEDURE|Computed Tomography|Undergo PET/CT
214275092|NCT06627751|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT guided tumor Biopsy
214275093|NCT06627751|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration biopsy
214275094|NCT06627751|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214275095|NCT06627751|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
214275096|NCT06455345|DEVICE|Self-Guided Online ACT Program|Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.
214275097|NCT06455345|OTHER|Treatment As Usual|Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
214275098|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
214275099|NCT03598751|DRUG|Placebo|2 mL
214275100|NCT05766423|BEHAVIORAL|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond."
214275101|NCT06915545|DEVICE|Aortic Arch Single Branch Covered Stent System|to Evaluate the Safety and Efficacy of the Aortic Arch Single Branch Covered Stent System for Aortic Dissection Involving the Aortic Arch
214275102|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
214275103|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214275104|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
214275105|NCT06929871|DEVICE|Mako cementless TKA|Mako robotic-arm assisted total knee arthroplasty using cementless implants
214275106|NCT06929871|DEVICE|Mako cemented TKA|Mako robotic-arm assisted total knee arthroplasty using cemented implants
214275107|NCT06937710|DIAGNOSTIC_TEST|Measure of symmetry between the inferior limbs|Hip force moments will be analyzed in the 3 planes (in Nm/Kg) and compared between the two legs.
214275108|NCT06507046|PROCEDURE|Total knee replacement|Mechanical or Personalized alignment
214275109|NCT05628883|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
214275110|NCT05628883|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
214275111|NCT05628883|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
214275112|NCT05628883|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
214275113|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
214275114|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
214275115|NCT06290336|OTHER|Pre-operative exercise therapy and education|Pre-operative supervised exercise therapy consisting of individualized strength, mobility and balance exercises and continuous education through individual discussions of expectations of post-operative recovery, pain and swelling, course of rehabilitation, long term function and activity level etc. Twice a week, approximately one hour/session.
214275116|NCT06290336|OTHER|Standardized pre-operative information session|As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.
214275117|NCT06106035|BEHAVIORAL|low-fat vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
214275118|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
214275119|NCT00688753|DRUG|RAD001|
214275120|NCT03834961|DRUG|Larotrectinib Sulfate|Given PO or via NG or G tube
214275121|NCT05467280|OTHER|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
214275122|NCT03619486|DEVICE|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
214275123|NCT03619486|DEVICE|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
214275124|NCT05219214|OTHER|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
214275125|NCT05286788|DRUG|Binimetinib Oral Tablet [Mektovi]|Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
214275126|NCT03591471|DRUG|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
214275127|NCT03591471|DRUG|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
214275128|NCT03591471|DRUG|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
214275129|NCT03591471|DRUG|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
214275130|NCT03591471|DRUG|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
214275131|NCT03591471|DRUG|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
214275132|NCT03591471|DRUG|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
214275133|NCT03591471|DRUG|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
214275134|NCT00892853|PROCEDURE|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
214275135|NCT03749447|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules
214275136|NCT05619081|BEHAVIORAL|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
214275137|NCT04930653|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
214275138|NCT04930653|BIOLOGICAL|Mogamulizumab|Given IV
214275139|NCT04930653|OTHER|Quality-of-Life Assessment|Ancillary studies
214275140|NCT04930653|OTHER|Questionnaire Administration|Ancillary studies
214275141|NCT04819646|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
214275142|NCT04819646|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
214275143|NCT02106091|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
214275144|NCT01533389|DRUG|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
214275145|NCT01533389|DRUG|Placebo|dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
214275146|NCT00995826|DRUG|CS-8958|Inhaled CS-8958
214275147|NCT00995826|OTHER|Placebo|Inhaled placebo
214275148|NCT05996718|BEHAVIORAL|Training program pilot|This intervention for informal caregivers consists of training that will introduce participants to improvisational (improv) theatre and teach its core communication skills.
214275149|NCT05316688|PROCEDURE|Near Infrared Imaging|Undergo NIR imaging
214275150|NCT05316688|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214275151|NCT05316688|DRUG|Tozuleristide|Given IV
214275152|NCT05035862|DRUG|Albuterol Sulfate|Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
214275153|NCT05035862|DRUG|Interferon gamma-primed mesenchymal stromal cells (MSCs)|IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
214275154|NCT05035862|DRUG|Prednisone|Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
214275155|NCT00196755|DRUG|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
214275156|NCT00196755|DRUG|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
214275157|NCT01218113|BIOLOGICAL|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
214275158|NCT01218113|DRUG|Placebo|1 or 3 doses according to protocol schedule
214275159|NCT01713686|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214275160|NCT04897308|PROCEDURE|Local injection of shoulder joint|Under ultrasound guidance , local shoulder joint injection will be done
214275161|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
214275162|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
214275163|NCT02860013|DEVICE|Telemedicine|
214275164|NCT04238598|PROCEDURE|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
214275165|NCT04238598|PROCEDURE|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
214275166|NCT04238598|PROCEDURE|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
214275167|NCT03478020|DRUG|AQX-1125|Investigational Drug
214275168|NCT03478020|DRUG|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
214275169|NCT04840615|BIOLOGICAL|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
214275170|NCT04840615|DRUG|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
214275171|NCT04840615|DRUG|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
214275172|NCT04840615|DRUG|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
214275173|NCT04840615|DRUG|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
214275174|NCT04840615|DRUG|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
214275175|NCT04840615|PROCEDURE|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
214275176|NCT04840615|DIAGNOSTIC_TEST|FDG-PET|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
214275177|NCT04840615|DIAGNOSTIC_TEST|CT CAP|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
214275178|NCT04840615|DIAGNOSTIC_TEST|MRI|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
214275179|NCT04840615|DIAGNOSTIC_TEST|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
214275180|NCT04840615|DIAGNOSTIC_TEST|Echocardiogram|At screening.
214275181|NCT04353518|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
214275182|NCT04353518|OTHER|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
214275183|NCT00967668|BEHAVIORAL|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
214275184|NCT00967668|BEHAVIORAL|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
214275185|NCT01793649|DRUG|GS-5737|A single dose of GS-5737 in 2.8% saline
214275186|NCT04613063|OTHER|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
214275187|NCT04057612|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
214275188|NCT04057612|OTHER|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
214275189|NCT03150017|OTHER|SPIRE|Online pain management programme.
214275190|NCT00115739|DRUG|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
214275191|NCT04108793|OTHER|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
214275192|NCT05965492|DRUG|Acetaminophen|"Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg."
214275193|NCT05965492|DRUG|Celebrex|"Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7."
214275194|NCT05965492|DRUG|Gabapentin|"Day 1 and Day 2: 300 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 900 mg.~Day 3: 200 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 600 mg.~Day 4: 200 mg two times a day and 100mg once a day administered via tablet by mouth for a total cumulative daily dose of 500 mg.~Day 5: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 6: 100 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 7: 100 mg once a day administered via tablet by mouth for a total cumulative daily dose of 100 mg."
214275195|NCT05965492|DRUG|Famotidine|Day 1- Day 7: 20 mg once a day administered via tablet by mouth for a total cumulative daily dose of 20 mg.
214829472|NCT00731367|DEVICE|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
214275196|NCT05965492|DRUG|Decadron|"Day 1: 4 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 12 mg.~Day 2: 4 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 8 mg.~Day 3: 2 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 4 mg.~Not prescribed on Days 4 through 7."
214275197|NCT05965492|DRUG|Oxycodone|A prescription of oxycodone as per standard of care will be provided to participants in case of breakthrough pain.
214275198|NCT03037775|OTHER|Baseline|measurement of baseline hemodynamic parameters
214275199|NCT03037775|DEVICE|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
214275200|NCT03037775|DEVICE|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
214275201|NCT03037775|DEVICE|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
214275202|NCT03308201|DRUG|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
214275203|NCT03308201|DRUG|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
214275204|NCT03308201|DRUG|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
214275205|NCT04565106|DEVICE|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
214275206|NCT03982407|DRUG|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
214275207|NCT03725930|DRUG|Clonidine|clonidine intranasal premedication in preschool infants
214275208|NCT03725930|OTHER|Placebo|Placebo intranasal premedication
214275209|NCT00951223|DRUG|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
214275210|NCT04342156|DRUG|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
214275211|NCT04847011|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
214275212|NCT00313157|DRUG|Metoprolol|
214275213|NCT00313157|DRUG|Diltiazem|
214275214|NCT00313157|DRUG|Verapamil|
214275215|NCT00313157|DRUG|Carvedilol|
214275216|NCT02975518|BIOLOGICAL|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
214275217|NCT00417469|DEVICE|NADGL|
214275218|NCT01113567|DIETARY_SUPPLEMENT|Lactose-free milk|3.5 g of lactose
214829473|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
214829474|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
214829475|NCT01853176|DRUG|Liposomal Injection Bupivacaine (Exparel)|
214275219|NCT01113567|DIETARY_SUPPLEMENT|Whole milk|Whole milk with 24 g lactose
214275220|NCT01301352|OTHER|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
214275221|NCT03435484|OTHER|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
214275222|NCT03435484|OTHER|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
214275223|NCT01565512|DRUG|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
214275224|NCT01565512|DRUG|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
214275225|NCT02781831|PROCEDURE|Standard rehab|Standard hospital based rehabilitation for patients with stroke
214275226|NCT02781831|DEVICE|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
214275227|NCT01260636|DRUG|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
214275228|NCT01260636|DRUG|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
214275229|NCT01055171|DRUG|Propranolol|40 mg; Single Administration.
214275230|NCT01055171|DRUG|Placebo|40 mg; Single Dose.
214275231|NCT01685281|DRUG|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
214275232|NCT01685281|DRUG|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
214275233|NCT02200211|DEVICE|iPad®|Binocular therapy on iPad®
214275234|NCT02200211|OTHER|Patching 2 hours per day, 7 days per week|
214275235|NCT02414997|PROCEDURE|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
214275236|NCT02414997|PROCEDURE|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
214275237|NCT00043914|DRUG|lamotrigine|
214275238|NCT02550990|BEHAVIORAL|Cognitive training|
214275239|NCT02550990|BEHAVIORAL|Aerobic exercise training|
214275240|NCT02550990|BEHAVIORAL|Sequential combination of aerobic exercise and cognitive training|
214275241|NCT04952493|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
214275242|NCT04952493|DRUG|Sodium Iodide I 131|RAI treatment may shrink the tumor
214829476|NCT01853176|DRUG|Standard bupivicaine|
214275243|NCT04952493|DRUG|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
214275244|NCT02584816|BIOLOGICAL|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
214275245|NCT02584816|BIOLOGICAL|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
214275246|NCT02584816|BIOLOGICAL|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
214275247|NCT02584816|BIOLOGICAL|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
214275248|NCT01918774|BEHAVIORAL|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
214275249|NCT01606800|DRUG|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
214275250|NCT01606800|DRUG|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
214275251|NCT04189159|BEHAVIORAL|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
214275252|NCT02963792|OTHER|Preventing Professionals burnout|
214275253|NCT05955105|DRUG|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
214275254|NCT05955105|DRUG|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
214275255|NCT00042289|DRUG|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
214275256|NCT00042289|DRUG|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
214275257|NCT00042289|DRUG|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
214275258|NCT00042289|DRUG|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
214275259|NCT00042289|DRUG|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
214275260|NCT00042289|DRUG|dolutegravir|dolutegravir 50 mg q.d.
214275261|NCT00042289|DRUG|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
214275262|NCT00042289|DRUG|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
214275263|NCT00042289|DRUG|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
214275264|NCT00042289|DRUG|efavirenz|efavirenz 600 mg q.d.
214275265|NCT00042289|DRUG|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
214275266|NCT00042289|DRUG|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
214275267|NCT00042289|DRUG|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
214275268|NCT00042289|DRUG|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
214275269|NCT00042289|DRUG|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
214829477|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
214829478|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
214275270|NCT00042289|DRUG|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
214275271|NCT00042289|DRUG|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
214275272|NCT00042289|DRUG|kanamycin|kanamycin (2nd line TB drug)
214275273|NCT00042289|DRUG|amikacin|amikacin (2nd line TB drug)
214275274|NCT00042289|DRUG|capreomycin|capreomycin (2nd line TB drug)
214275275|NCT00042289|DRUG|moxifloxacin|moxifloxacin (2nd line TB drug)
214275276|NCT00042289|DRUG|levoflaxacin|levofloxacin (2nd line TB drug)
214275277|NCT00042289|DRUG|ofloxacin|ofloxacin (2nd line TB drug)
214275278|NCT00042289|DRUG|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
214275279|NCT00042289|DRUG|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
214275280|NCT00042289|DRUG|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
214275281|NCT00042289|DRUG|high dose INH|high dose INH (2nd line TB drug)
214275282|NCT00042289|DRUG|bedaquiline|bedaquiline (2nd line TB drug)
214275283|NCT00042289|DRUG|clofazamine|clofazamine (2nd TB drug)
214275284|NCT00042289|DRUG|delamanid|delamanid (2nd line TB drug)
214275285|NCT00042289|DRUG|linezolid|linezolid (2nd line TB drug)
214275286|NCT00042289|DRUG|pretomanid|pretomanid (2nd line TB drug)
214275287|NCT00042289|DRUG|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
214275288|NCT00042289|DRUG|etonogestrel implant|etonogestrel implant contraceptive
214275289|NCT00042289|DRUG|nevirapine|nevirapine 200 mg twice a day
214275290|NCT00042289|DRUG|amprenavir|amprenavir 1200mg twice a day
214275291|NCT00042289|DRUG|abacavir|abacavir 300mg twice a day
214275292|NCT00042289|DRUG|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
214275293|NCT00042289|DRUG|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
214275294|NCT00042289|DRUG|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
214275295|NCT00042289|DRUG|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
214275296|NCT00042289|DRUG|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
214275297|NCT00042289|DRUG|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
214275298|NCT00042289|DRUG|emtricitabine|emtricitabine 200 mg once a day
214275299|NCT00042289|DRUG|tenofovir|tenofovir 300 mg once a day
214275300|NCT00042289|DRUG|nelfinavir dosage #1|nelfinavir \[625 mg tablets\] 1250 mg twice a day
214275301|NCT00042289|DRUG|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
214275302|NCT00042289|DRUG|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
214275303|NCT00042289|DRUG|raltegravir|raltegravir 400 mg twice a day
214275304|NCT00042289|DRUG|etravirine|etravirine 200 mg twice a day
214275305|NCT00042289|DRUG|maraviroc|maraviroc 150 mg or 300 mg twice a day
214275306|NCT00042289|DRUG|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
214275307|NCT00042289|DRUG|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
214275308|NCT00042289|DRUG|nelfinavir dosage #2|nelfinavir \[625 mg tablets\] 1875 mg twice a day
214275309|NCT00042289|DRUG|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
214275310|NCT00042289|DRUG|rilpivirine|rilpivirine (25 mg q.d.)
214275311|NCT00042289|DRUG|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
214275312|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
214275313|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
214829479|NCT00198133|DRUG|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
214275314|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
214275315|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
214275316|NCT06120998|PROCEDURE|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
214275317|NCT00378820|BEHAVIORAL|Whey without milk minerals|
214275318|NCT00378820|BEHAVIORAL|Whey with milk minerals|
214275319|NCT00378820|BEHAVIORAL|Casein without milk minerals|
214275320|NCT00378820|BEHAVIORAL|Casein with milk minerals|
214275321|NCT06053294|OTHER|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214275322|NCT06053294|OTHER|CS+Fast|(CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214275323|NCT06053294|OTHER|CS+Slow|(CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214275324|NCT04717609|PROCEDURE|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
214275325|NCT04717609|DRUG|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
214275326|NCT03613545|PROCEDURE|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
214275327|NCT03613545|PROCEDURE|Infusion of sham|Infusion of sham
214275328|NCT03613545|DRUG|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
214829480|NCT06359275|DRUG|PD-1|Toripalimab，240 mg/time，D1， Q3W
214275329|NCT00745823|DRUG|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
214275330|NCT00745823|DRUG|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
214275331|NCT00745823|DRUG|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
214275332|NCT01687998|DRUG|Evacetrapib|Administered Orally
214275333|NCT01687998|DRUG|Placebo|Administered Orally
214275334|NCT01337739|DRUG|Placebo Comparator|Placebo administration (.9 normal saline sterile)
214275335|NCT01337739|DRUG|Active Comparator|Administration of Dexmedetomidine
214275336|NCT03711812|PROCEDURE|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
214275337|NCT03711812|PROCEDURE|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
214275338|NCT05777577|DIETARY_SUPPLEMENT|probiotic therapy|probiotic including bifidobacterium
214275339|NCT03677531|OTHER|Quality-of-Life Assessment|Ancillary studies
214275340|NCT03677531|OTHER|Questionnaire Administration|Ancillary studies
214275341|NCT03677531|RADIATION|Radiation Therapy|Undergo RT
214275342|NCT03677531|OTHER|Video|Watch video of choice during RT
214275343|NCT05500105|OTHER|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
214275344|NCT01182675|DRUG|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
214275345|NCT01182675|DRUG|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
214275346|NCT01135420|BEHAVIORAL|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
214275347|NCT01135420|OTHER|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
214275348|NCT05135117|OTHER|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
214275349|NCT05135117|OTHER|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
214275350|NCT06284746|DRUG|Tirolizumab+SOX/XELOX|Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
214275351|NCT06284746|DRUG|SOX/XELOX|Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
214275352|NCT00717197|DRUG|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
214275353|NCT05453656|BEHAVIORAL|exercise|physical activity promotion and engagement following kidney transplantation
214275354|NCT03986502|OTHER|Media Intervention|Watch web-based financial literacy video
214275355|NCT03986502|OTHER|Informational Intervention|Receive information on financial counseling and medical cost assistance
214275356|NCT03986502|OTHER|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
214275357|NCT03986502|OTHER|Questionnaire Administration|Ancillary studies
214275358|NCT03986502|OTHER|Quality-of-Life Assessment|Ancillary studies
214275359|NCT04276792|BEHAVIORAL|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
214275360|NCT03464305|DRUG|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
214275361|NCT03464305|DRUG|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
214275362|NCT01658462|DRUG|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
214275363|NCT01658462|DRUG|Nintedanib|"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"
214829481|NCT06359275|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
214829482|NCT06359275|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，IV，D1，8，Q3W
214275364|NCT01658462|DRUG|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
214275365|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
214275366|NCT00982137|BIOLOGICAL|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
214829483|NCT06359275|RADIATION|PULSAR|5-10 Gy per session, a total of 5 times.
214275367|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
214275368|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
214275370|NCT03326102|DRUG|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
214275371|NCT03326102|DRUG|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
214275372|NCT06223178|DEVICE|thumb-tack needle|Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
214275373|NCT06223178|DEVICE|sham thumb-tack needle|Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
214275374|NCT06223178|OTHER|Basic gynecological treatment|Gynecological health care guidance will be provided as patients needed.
214275375|NCT01811654|DEVICE|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
214275376|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
214275377|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
214275378|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
214275379|NCT03394326|BEHAVIORAL|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
214275380|NCT05924620|DRUG|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
214275381|NCT05407402|BEHAVIORAL|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
214275382|NCT05407402|BEHAVIORAL|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
214275383|NCT02479178|DRUG|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
214275384|NCT02519036|DRUG|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275385|NCT02519036|DRUG|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275386|NCT02519036|DRUG|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275387|NCT02519036|DRUG|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275388|NCT02519036|DRUG|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275389|NCT02519036|OTHER|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
214275390|NCT03636932|DRUG|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
214275391|NCT03636932|DRUG|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
214275392|NCT03636932|BIOLOGICAL|Blood sample|Circulating tissue factor assay
214275393|NCT03636932|BIOLOGICAL|Blood sample|The test of pro-coagulant activity of the tissue factor
214275394|NCT04084665|DRUG|Guselkumab|Guselkumab
214275395|NCT05479084|OTHER|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
214275396|NCT01393496|OTHER|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
214275397|NCT01393496|OTHER|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
214829484|NCT03332264|DEVICE|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
214275398|NCT05466162|OTHER|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
214275399|NCT05466162|OTHER|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
214275400|NCT02073760|OTHER|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
214275401|NCT03143439|BEHAVIORAL|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
214275402|NCT05364125|OTHER|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
214275403|NCT05364125|OTHER|Control|Normal Saline will be used
214275404|NCT04011267|OTHER|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
214275405|NCT00612690|BEHAVIORAL|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
214275406|NCT00612690|BEHAVIORAL|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
214275407|NCT03548103|DIETARY_SUPPLEMENT|Green tea extract|Green tea extract 500 mg tid for 16 weeks
214275408|NCT03548103|DIETARY_SUPPLEMENT|Placebo|Placebo tid for 16 weeks
214275409|NCT02379871|OTHER|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
214275410|NCT02379871|OTHER|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
214275411|NCT02537197|DRUG|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
214275412|NCT06115213|BEHAVIORAL|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
214275413|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
214275414|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
214275415|NCT03870698|PROCEDURE|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
214275416|NCT00003128|BIOLOGICAL|filgrastim|
214829485|NCT03332264|DEVICE|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
214275417|NCT00003128|DRUG|ifosfamide|
214275418|NCT00003128|DRUG|paclitaxel|
214275419|NCT04828252|DEVICE|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
214275420|NCT05077722|DEVICE|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
214275421|NCT04869644|BEHAVIORAL|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
214275422|NCT04869644|BEHAVIORAL|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.
214275423|NCT04869644|BEHAVIORAL|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
214275424|NCT04869644|BEHAVIORAL|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
214829486|NCT03332264|DEVICE|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
214829487|NCT00175669|DRUG|Botox injections|Data not known.
214829488|NCT01125527|BIOLOGICAL|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
214829489|NCT01125527|BIOLOGICAL|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
214829490|NCT04863144|OTHER|Blood samples|Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.
214829491|NCT04662476|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplement
214829492|NCT04125394|DEVICE|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
214829493|NCT02573662|BIOLOGICAL|Blood and Urine sampling|Blood and Urine Sampling
214829494|NCT02573662|RADIATION|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
214275425|NCT04869644|BEHAVIORAL|Habit Formation|Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
214275426|NCT02728609|DEVICE|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
214275427|NCT02728609|DEVICE|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
214275428|NCT04232384|PROCEDURE|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
214275429|NCT04232384|PROCEDURE|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
214275430|NCT04374032|DRUG|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
214275431|NCT04374032|DRUG|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
214275432|NCT06499155|DEVICE|Use of periacryl in gingival recession closure procedures|Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.
214275433|NCT06499155|PROCEDURE|Use of sutures in gingival recession closure procedures|Both recipient and donor areas will be closed with traditional suturing techniques.
214275434|NCT04736836|DRUG|Rifaximin|locally absorbed antibiotic
214275435|NCT04448483|DEVICE|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
214275436|NCT04448483|DEVICE|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
214275437|NCT00787891|DRUG|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
214275438|NCT00787891|DRUG|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
214275439|NCT03210168|OTHER|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
214275440|NCT02955602|DRUG|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
214275441|NCT02955602|DRUG|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
214275442|NCT02955602|DRUG|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
214275443|NCT02415660|PROCEDURE|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
214275444|NCT02415660|PROCEDURE|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
214275445|NCT02415660|BEHAVIORAL|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
214275446|NCT02415660|BEHAVIORAL|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
214275447|NCT02415660|PROCEDURE|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
214275448|NCT02415660|DEVICE|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
214829495|NCT02573662|BIOLOGICAL|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
214275449|NCT02824874|DRUG|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
214275450|NCT02824874|DRUG|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
214275451|NCT05209958|DIAGNOSTIC_TEST|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
214275452|NCT04388800|OTHER|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
214275453|NCT06049940|BIOLOGICAL|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
214275454|NCT06049940|BIOLOGICAL|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
214275455|NCT01258582|PROCEDURE|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
214275456|NCT01258582|PROCEDURE|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
214275457|NCT03647397|DEVICE|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
214275458|NCT03216889|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
214275459|NCT03216889|BEHAVIORAL|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
214275460|NCT00653055|DRUG|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
214275461|NCT00653055|DRUG|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
214275462|NCT03164902|DEVICE|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
214275463|NCT05450731|OTHER|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
214829496|NCT05356091|DRUG|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
214275464|NCT02980601|DEVICE|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
214275465|NCT02980601|PROCEDURE|STSG|0.012mm STSG
214275466|NCT04569266|OTHER|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
214275467|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
214275468|NCT01575769|DRUG|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
214275469|NCT01379040|OTHER|Cystic Fibrosis patients|
214275470|NCT03468153|BIOLOGICAL|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
214275471|NCT01080534|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
214275472|NCT02076698|PROCEDURE|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
214275473|NCT02076698|DRUG|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
214275474|NCT01574131|DRUG|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
214275475|NCT01574131|DRUG|Sugar Pill|pill every day for 6 months
214656890|NCT01073579|DRUG|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
214656891|NCT04106388|BEHAVIORAL|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
214275476|NCT00911118|RADIATION|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
214275477|NCT01619982|DRUG|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
214275478|NCT01619982|DRUG|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
214275479|NCT02948972|PROCEDURE|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
214275480|NCT02948972|PROCEDURE|In vitro fertilization without surgery|IVF without endometriosis surgery
214275481|NCT03303924|DRUG|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
214275482|NCT02557620|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
214275483|NCT02557620|DRUG|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
214275484|NCT06040372|DRUG|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
214275485|NCT06040372|DRUG|Placebo|Placebo is provided as a matching placebo
214275486|NCT03156543|DEVICE|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
214275487|NCT03156543|OTHER|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
214275488|NCT00413452|DRUG|Etanercept|50 mg once weekly
214275489|NCT03256565|DIAGNOSTIC_TEST|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
214275490|NCT03583489|DRUG|APD421|10 mg IV
214275491|NCT03583489|DRUG|Placebo|IV
214275492|NCT03583489|DRUG|Ondansetron|4 mg IV
214275493|NCT05163444|DEVICE|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
214275494|NCT05163444|DEVICE|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
214275495|NCT01523860|DRUG|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
214275496|NCT04214054|OTHER|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
214656892|NCT06546033|OTHER|application of different types of diet|application of different types of diet
214656893|NCT03160014|DRUG|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
214656894|NCT02113202|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
214656895|NCT02113202|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
214656896|NCT04488237|DRUG|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
214656897|NCT01636492|DRUG|bitopertin|Single oral dose
214656898|NCT01636492|DRUG|placebo|Single oral dose
214656899|NCT00359892|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
214656900|NCT04337437|DRUG|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
214656901|NCT04337437|DRUG|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
214275497|NCT04214054|PROCEDURE|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
214275498|NCT05062434|OTHER|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
214275499|NCT06769854|DEVICE|Urgent PC|PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
214275500|NCT05575986|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
214275501|NCT02568800|DRUG|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
214275502|NCT02568800|DRUG|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
214275503|NCT05149196|OTHER|Targeted hemodynamic management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
214275504|NCT05149196|OTHER|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
214275505|NCT06032442|DIETARY_SUPPLEMENT|ARTNEO|"Dietary Supplement: undenatured collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
214275506|NCT06032442|DRUG|Artra|"Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months."
214275507|NCT01821521|DRUG|AGSPT_L20|
214275508|NCT01821521|DRUG|Pantoloc 40mg|
214275509|NCT01455259|BIOLOGICAL|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
214275510|NCT05120128|DEVICE|Acuvue® Oasys 1-Day|TEST Lens
214275511|NCT00674700|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
214275512|NCT00674700|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
214275513|NCT00674700|DRUG|Placebo tablet|One sublingual tablet daily for one year
214275514|NCT06789861|DRUG|TT5|Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients
214275515|NCT06789861|DRUG|Placebo - TT5 vehicle|Intravenous administration of vehicule, according to the same drug regimen than TT5
214275516|NCT06547528|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
214275517|NCT00684099|DRUG|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
214275518|NCT00684099|DRUG|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
214275519|NCT00395304|DRUG|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
214275520|NCT00395304|DRUG|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
214275521|NCT00395304|DRUG|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
214275522|NCT05246683|OTHER|observational|registry
214656902|NCT00906438|DIETARY_SUPPLEMENT|2006-RD-05|300 mg daily, once a day for 28 consecutive days
214656903|NCT00906438|DIETARY_SUPPLEMENT|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
214656904|NCT01627418|BEHAVIORAL|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
214656905|NCT01627418|BEHAVIORAL|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
214656906|NCT02358811|DEVICE|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present."
214275523|NCT01723488|RADIATION|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
214275524|NCT02938104|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
214275525|NCT02938104|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
214275526|NCT02938104|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
214275527|NCT06359392|OTHER|No message|Participants will not be exposed to a message in this arm of the intervention.
214275528|NCT06359392|OTHER|Culture-centric message|Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.
214275529|NCT06359392|OTHER|General messge|Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
214275530|NCT05391698|BEHAVIORAL|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
214275531|NCT05391698|COMBINATION_PRODUCT|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
214275532|NCT00386048|BEHAVIORAL|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
214275533|NCT06011057|DIAGNOSTIC_TEST|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
214275534|NCT06011057|DIAGNOSTIC_TEST|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
214275535|NCT02543437|DEVICE|Trident Acetabular X3 Insert|
214275536|NCT03797014|DRUG|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
214275537|NCT02544399|OTHER|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
214275538|NCT01326143|DEVICE|ORM Narval MRD|
214275539|NCT04925362|OTHER|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
214275540|NCT04925362|OTHER|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
214275541|NCT06069882|BEHAVIORAL|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
214275542|NCT01090843|PROCEDURE|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
214275543|NCT01090843|DEVICE|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
214275544|NCT01090843|DEVICE|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
214275545|NCT01970397|DEVICE|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
214275546|NCT01970397|DEVICE|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
214275547|NCT05542160|DIETARY_SUPPLEMENT|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
214275548|NCT04246450|DEVICE|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
214275549|NCT02782637|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
214275550|NCT01850875|BEHAVIORAL|Eye-Movement-Desensitization-Reprocessing|
214275551|NCT03716037|OTHER|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
214275552|NCT02687633|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
214275553|NCT01524471|PROCEDURE|Per Oral Endoscopic Myotomy|
214275554|NCT00681083|DEVICE|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
214275555|NCT00681083|DEVICE|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
214275556|NCT01389817|DEVICE|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
214275557|NCT02251184|DRUG|Aggrenox|
214275558|NCT02251184|DRUG|Dipyridamole|
214275559|NCT02251184|DRUG|Aspirin|
214275560|NCT02251184|DRUG|Lansoprazole|
214275561|NCT01023620|DRUG|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
214275562|NCT01023620|OTHER|Observation|Participants will be observed for 16 weeks but will not receive drug
214275563|NCT05902455|PROCEDURE|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
214275564|NCT05535699|OTHER|exercises|scapular exercise
214275565|NCT00970567|BEHAVIORAL|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
214275566|NCT02613975|DEVICE|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
214275567|NCT03346278|BEHAVIORAL|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
214275568|NCT02298920|DRUG|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
214829497|NCT05356091|DRUG|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
214829498|NCT02997891|DIAGNOSTIC_TEST|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
214275569|NCT05878145|BEHAVIORAL|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
214275570|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
214275571|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
214275572|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
214275573|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
214275574|NCT01559597|BIOLOGICAL|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
214275575|NCT05389397|BEHAVIORAL|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
214275576|NCT03700775|OTHER|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
214275577|NCT01740193|PROCEDURE|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
214275578|NCT01740193|PROCEDURE|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
214275579|NCT00101595|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
214275580|NCT04462445|DRUG|Pazopanib|
214275581|NCT02183194|DEVICE|Lutonix Paclitaxel Drug Coated Balloon|
214275582|NCT01509950|PROCEDURE|Staples|Staples for closure of cesarean section skin incision
214275583|NCT01509950|PROCEDURE|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
214275584|NCT01509950|PROCEDURE|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
214275585|NCT00959231|DRUG|cyclophosphamide|
214275586|NCT00959231|DRUG|cyclosporine|
214275587|NCT00959231|DRUG|fludarabine phosphate|
214275588|NCT00959231|DRUG|mycophenolate mofetil|
214275589|NCT00959231|OTHER|laboratory biomarker analysis|
214275590|NCT00959231|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214275591|NCT00959231|PROCEDURE|umbilical cord blood transplantation|
214275592|NCT00959231|RADIATION|total-body irradiation|
214275593|NCT01434667|BEHAVIORAL|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
214275594|NCT01434667|BEHAVIORAL|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
214275595|NCT02743169|OTHER|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
214275596|NCT06374901|DRUG|Tislelizumab|Preoperative treatment with Tislelizumab
214275597|NCT06374901|DRUG|SOX/XELOX|Preoperative treatment with SOX/XELOX
214275598|NCT02991248|DEVICE|robotic training|robotic training by applying pelvis force perturbation
214275599|NCT02991248|DEVICE|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
214275600|NCT02991248|DEVICE|treadmill|conventional treadmill training only
214275601|NCT04115839|DRUG|Filgotinib|Tablets will be administered orally once daily with or without food.
214275602|NCT04115839|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
214275603|NCT02966028|DRUG|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
214275604|NCT02966028|DRUG|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
214275605|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
214275606|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
214275607|NCT04946006|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
214275608|NCT02664844|BEHAVIORAL|Physical activity|
214275609|NCT04072497|BIOLOGICAL|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)
214275610|NCT04072497|BIOLOGICAL|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)
214275611|NCT04072497|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
214275612|NCT04077827|DRUG|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
214275613|NCT04758169|OTHER|Enhanced Homestead Food Production|Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
214275614|NCT04758169|OTHER|Control|Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
214275615|NCT02720991|DRUG|Mifepristone|200 mg of oral mifepristone
214275616|NCT02720991|DRUG|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
214275617|NCT03162991|OTHER|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for \~30-55 minutes per exercise session.
214275618|NCT05382624|PROCEDURE|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
214275619|NCT04763304|OTHER|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
214275620|NCT04763304|OTHER|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
214275621|NCT02223091|BEHAVIORAL|Consultation by a trained physician|
214275622|NCT02223091|BEHAVIORAL|Consultation by an untrained physician|
214275623|NCT02577510|DRUG|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
214275624|NCT02577510|DRUG|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
214275625|NCT00205582|DEVICE|Positron Emission Tomography|
214275626|NCT00669227|OTHER|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
214275627|NCT00669227|OTHER|placebo suspension|intracoronary administration at the same day as cell aspiration
214275628|NCT00786149|OTHER|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
214275629|NCT00786149|OTHER|Varenicline without counseling|Brief advice, one time during initial session
214275630|NCT01162512|BEHAVIORAL|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
214275631|NCT02364739|OTHER|Written information|Brochure
214275632|NCT02364739|OTHER|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
214275633|NCT06119945|DRUG|DWJ1568|One tablet of DWJ1568
214275634|NCT06119945|DRUG|DWC202215|One tablet of DWC202215
214275635|NCT05541770|OTHER|Survey|Healthcare workers/Physicians involved in cancer diagnosis \& management in the Arab countries should respond to a survey
214275636|NCT02887885|DRUG|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
214275637|NCT04271137|COMBINATION_PRODUCT|3D printed PEEK onlay|3d computer-designed Orbital onlay
214275638|NCT04271137|COMBINATION_PRODUCT|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
214275639|NCT03856892|OTHER|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
214275640|NCT03856892|OTHER|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
214275641|NCT06052605|BEHAVIORAL|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
214275642|NCT04412369|DIAGNOSTIC_TEST|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
214275643|NCT01628575|PROCEDURE|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
214275644|NCT03465306|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
214275645|NCT03465306|DEVICE|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
214275646|NCT00003594|DRUG|irinotecan|
214275647|NCT00003594|DRUG|fluorouracil|
214275648|NCT00003594|DRUG|leucovorin calcium|
214275649|NCT00003594|DRUG|oxaliplatin|
214275650|NCT01738321|OTHER|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
214275651|NCT00232232|DRUG|Fish oil|
214275652|NCT04167644|DIAGNOSTIC_TEST|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
214275653|NCT04585386|OTHER|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
214275654|NCT04585386|OTHER|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
214829499|NCT02997891|DIAGNOSTIC_TEST|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
214829500|NCT05361252|PROCEDURE|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
214275655|NCT04585386|OTHER|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
214275656|NCT04585386|OTHER|Quebec questionnaire|To access the patient's perception of incapacity
214275657|NCT01761890|BEHAVIORAL|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
214275658|NCT01540240|DRUG|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
214275659|NCT01540240|DRUG|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
214275660|NCT04030611|DIAGNOSTIC_TEST|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
214275661|NCT03644212|DRUG|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
214275662|NCT01432080|DRUG|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
214275663|NCT01432080|DRUG|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
214275664|NCT01432080|DRUG|Montelukast|Montelukast 10 mg PO qhs for 3 months
214275665|NCT01432080|DRUG|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
214275666|NCT04934397|OTHER|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
214275667|NCT02332278|PROCEDURE|Early feeding|Fluid diet four hours after cesarean section
214275668|NCT02332278|PROCEDURE|Late feeding|Fluid diet 12 hours after cesarean section
214275669|NCT00709683|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214275670|NCT00560976|DRUG|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
214275671|NCT06304376|PROCEDURE|Alveolar ridge grafting|Alveolar ridge grafting was carried out using anterior iliac crest bone graft. Khoury shell technique was the method of ridge reconstruction via a cortical bone shell was fixed away from alveolar ridge using two micro-screws and the gap created was filled by cancellous bone
214275672|NCT03535844|OTHER|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
214275673|NCT03535844|OTHER|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
214275674|NCT03445715|GENETIC|ART-I02|Single Intra-articular injection in the wrist joint
214829501|NCT04220606|DRUG|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
214829502|NCT03458845|DIAGNOSTIC_TEST|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
214829503|NCT00000124|PROCEDURE|Brachytherapy|
214275675|NCT01803204|OTHER|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
214275676|NCT03779802|OTHER|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
214275677|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils|4 months consumption
214275678|NCT01611649|DIETARY_SUPPLEMENT|Formula containing plant oils|4 months consumption
214275679|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
214275680|NCT03169556|DEVICE|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
214275681|NCT03169556|DEVICE|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
214275682|NCT03903848|OTHER|Exercise|Single session of treadmill walking and resistance exercise
214829504|NCT00000124|PROCEDURE|Eye Removal|
214275683|NCT02380781|BEHAVIORAL|Information in the form of a video|see intervention description
214275684|NCT04314336|DRUG|Public procurement|Cost minimisation study through public procurement
214275685|NCT04314336|DRUG|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
214275686|NCT02835820|DIETARY_SUPPLEMENT|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
214275687|NCT02208557|PROCEDURE|Reinforcement with Absorbable Mesh|
214275688|NCT02208557|RADIATION|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
214275689|NCT02208557|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
214275690|NCT02272491|DEVICE|ZrO2 (Straumann CARES)|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
214275691|NCT02272491|DEVICE|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
214275692|NCT03554746|OTHER|GC group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation"
214275693|NCT03554746|OTHER|CG group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps"
214275694|NCT06064422|BEHAVIORAL|BeatIt-MV|BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
214275695|NCT04851834|DRUG|NTX-301|Oral hypomethylating agent
214275696|NCT04851834|DRUG|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
214275697|NCT04851834|DRUG|Temozolomide|Standard of care for high-grade glioma
214275698|NCT05226663|PROCEDURE|Computed Tomography|Undergo \[18F\]FFT PET/CT
214275699|NCT05226663|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
214275700|NCT05226663|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FFT PET/CT
214275701|NCT05066113|DEVICE|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
214275702|NCT02132091|OTHER|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
214275703|NCT02132091|DIETARY_SUPPLEMENT|400 IU Vitamin E|once each day in morning; oral pill form
214275704|NCT02132091|DIETARY_SUPPLEMENT|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
214275705|NCT04442867|OTHER|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
214275706|NCT04442867|OTHER|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
214275707|NCT06502496|BEHAVIORAL|art-therapy|Over the 6 sessions, different artistic techniques will be explored, depending on the artist leading the workshop: stencil, graffiti, spray paint, collage, oil pastel, calligraphy and acrylic doodling. A collective work may also be proposed.
214275708|NCT06502496|BEHAVIORAL|relaxation|relaxation sessions with the referent psychologist
214275709|NCT00160693|BIOLOGICAL|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
214275710|NCT02478996|OTHER|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
214275711|NCT01824641|DEVICE|Eliminate aspiration catheter|Eliminate aspiration catheter
214275712|NCT01824641|PROCEDURE|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
214275713|NCT01966159|DEVICE|SYNERGY Investigational Device|percutaneous coronary intervention
214275714|NCT01966159|DEVICE|PE Plus Investigational Device|percutaneous coronary intervention
214275715|NCT03698149|DEVICE|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
214656907|NCT02358811|BEHAVIORAL|Cognitive assessment|"This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)"
214275716|NCT06145061|DEVICE|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
214275717|NCT02367183|DRUG|GED-0301|
214275718|NCT02367183|DRUG|Placebo|
214275719|NCT00080808|DRUG|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
214275720|NCT00080808|DRUG|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
214275721|NCT00080808|DRUG|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
214275722|NCT00080808|DRUG|Sildenafil citrate|Oral sildenafil as needed
214275723|NCT00080808|PROCEDURE|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
214275724|NCT00286403|DRUG|Fenoldopam Mesylate and/or MESNA|
214275725|NCT00332007|DRUG|Tonabersat|two tablets once daily
214275726|NCT00332007|DRUG|Placebo|two tablets once daily
214275727|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
214275728|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
214275729|NCT04568070|DIAGNOSTIC_TEST|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
214275730|NCT04568070|DIAGNOSTIC_TEST|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
214275731|NCT04568070|DIAGNOSTIC_TEST|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
214275732|NCT04568070|DIAGNOSTIC_TEST|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
214275733|NCT02268344|DEVICE|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
214275734|NCT03039283|DEVICE|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
214275735|NCT01207791|BEHAVIORAL|screening|Brief screening to assess eligibility and collect minimal baseline data
214275736|NCT01207791|BEHAVIORAL|assessment|comprehensive substance use assessment
214275737|NCT01207791|BEHAVIORAL|referral|referral to treatment if indicated or requested
214275738|NCT01207791|BEHAVIORAL|Brief intervention|30-minute brief intervention session in ED
214275739|NCT01207791|BEHAVIORAL|booster sessions|two 15-minute booster counseling sessions conducted by telephone
214275740|NCT01867424|DRUG|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
214275741|NCT00189982|DRUG|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
214275742|NCT01056653|BEHAVIORAL|Standard Dose|Two intevention home visits
214275743|NCT01056653|BEHAVIORAL|High Dose|Four intervention home visits
214275744|NCT01056653|BEHAVIORAL|Comparison Group|One home visit, information only
214275745|NCT06081205|OTHER|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
214275746|NCT05614830|OTHER|Dry needling ,|The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
214275747|NCT05614830|OTHER|usual physical therapy program|Therapeutic exercise
214275748|NCT05634720|DRUG|HA Chemotherapy|Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).
214275749|NCT04260256|DRUG|[18F]F-AraG|\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
214275750|NCT03673852|BEHAVIORAL|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
214656908|NCT00474240|DRUG|Atorvastatin 20 mg|
214656909|NCT00474240|DRUG|AEGR-733 5 mg|
214656910|NCT00474240|DRUG|AEGR-733 10 mg|
214275751|NCT03673852|BEHAVIORAL|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
214275752|NCT00905411|BEHAVIORAL|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
214275753|NCT05310461|PROCEDURE|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
214275754|NCT05310461|PROCEDURE|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
214275755|NCT06485765|OTHER|Diet planning|Healthy eating planning
214275756|NCT04907656|BEHAVIORAL|dCBT|As per arm of the same name
214275757|NCT06383819|DRUG|Longidaza®|dose 3000 IU intramuscularly once every 5 days, 15 injections
214275758|NCT06383819|DRUG|Placebo|intramuscularly once every 5 days, 15 injections
214275759|NCT02980497|OTHER|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
214275760|NCT02980497|OTHER|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
214275761|NCT05386680|GENETIC|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
214275762|NCT05469035|OTHER|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
214275763|NCT05469035|OTHER|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
214275764|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
214275765|NCT03197454|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
214275766|NCT03197454|OTHER|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
214275767|NCT03736733|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
214275768|NCT03736733|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
214275769|NCT02453178|BEHAVIORAL|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
214275770|NCT03880734|DRUG|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
214275771|NCT03880734|OTHER|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
214275772|NCT05167929|BEHAVIORAL|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
214275773|NCT05167929|BEHAVIORAL|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
214275774|NCT05167929|BEHAVIORAL|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
214275775|NCT06354309|OTHER|Virtual reality game|Pre and post control study after use virtual reality game
214829505|NCT05006131|OTHER|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
214275776|NCT03944421|OTHER|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
214275777|NCT03944421|OTHER|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
214275778|NCT01847274|DRUG|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
214275779|NCT01847274|DRUG|placebo|
214275780|NCT05210335|OTHER|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
214275781|NCT06055101|DRUG|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
214275782|NCT06055101|DRUG|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
214275783|NCT06055101|DRUG|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
214275784|NCT04868214|DEVICE|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
214275785|NCT06013397|DIETARY_SUPPLEMENT|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
214275786|NCT05046093|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|"When the lung nodule is visualized by thin bronchoscope (4mm) with R-EBUS, cryobiopsy is performed. If not visualized, ultrathin (3mm) bronchoscope is used.~Cryobiopsy is performed with 1.1mm cryo-probe."
214275787|NCT03398785|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
214275788|NCT00860483|OTHER|observational|PET Scan
214275789|NCT03727230|OTHER|Blood transfusion|Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
214275790|NCT03471520|BEHAVIORAL|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
214275791|NCT05512767|OTHER|Best Practice|Undergo self-manual lymphatic drainage
214275792|NCT05512767|OTHER|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
214275793|NCT05512767|PROCEDURE|Diagnostic Imaging|Undergo photographs of face and neck
214275794|NCT05512767|OTHER|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
214275795|NCT05512767|PROCEDURE|Modified Barium Swallow|Undergo swallow study
214275796|NCT05512767|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
214275797|NCT05512767|DEVICE|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
214275798|NCT05512767|OTHER|Quality-of-Life Assessment|Ancillary studies
214275799|NCT05512767|OTHER|Questionnaire Administration|Ancillary studies
214275800|NCT05512767|OTHER|Voice Handicap Index-10|Ancillary studies
214275801|NCT04779125|PROCEDURE|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
214275802|NCT01373242|DRUG|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
214275803|NCT02699814|BEHAVIORAL|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
214275804|NCT05683964|DRUG|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
214275805|NCT05683964|DIAGNOSTIC_TEST|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
214275806|NCT00327275|BEHAVIORAL|strength training|
214275807|NCT02241629|DRUG|placebo|placebo of levo phencynonate hydrochloride
214275808|NCT02241629|DRUG|levo phencynonate hydrochloride|levo phencynonate hydrochloride
214275809|NCT06044610|OTHER|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
214275810|NCT06044610|OTHER|GENPOP Ad lib fluid intake|Over 24 hours
214275811|NCT06044610|OTHER|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
214275812|NCT06044610|OTHER|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
214275813|NCT04486911|DRUG|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
214275814|NCT03206775|BEHAVIORAL|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice"
214656911|NCT00474240|DRUG|Placebo|
214656912|NCT00474240|DRUG|AEGR-733 5 mg + atorvastatin 20 mg|
214656913|NCT00474240|DRUG|AEGR-733 10 mg + atorvastatin 20 mg|
214656914|NCT01808560|DEVICE|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
214275815|NCT03206775|BEHAVIORAL|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey"
214275816|NCT03206775|BEHAVIORAL|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment"
214275817|NCT03206775|BEHAVIORAL|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey"
214275818|NCT04568044|PROCEDURE|Blood sample|Peripheral blood sample will be obtained.
214275819|NCT05581862|BEHAVIORAL|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
214275820|NCT05581862|BEHAVIORAL|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
214275821|NCT05876975|PROCEDURE|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
214275822|NCT03831399|DIETARY_SUPPLEMENT|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
214275823|NCT03831399|DIETARY_SUPPLEMENT|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
214275824|NCT05111171|DEVICE|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
214275825|NCT06438068|OTHER|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy separated by 48 hours. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
214275826|NCT00168896|DRUG|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
214275827|NCT05239247|OTHER|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
214275828|NCT05239247|OTHER|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
214275829|NCT03026660|DIETARY_SUPPLEMENT|Moringa Oleifera|
214275830|NCT03026660|DIETARY_SUPPLEMENT|Cabbage Placebo|
214275831|NCT03280901|OTHER|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
214275832|NCT00788567|DRUG|mycophenolate mofetil|1
214275833|NCT05199181|PROCEDURE|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
214275834|NCT03452423|PROCEDURE|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
214275835|NCT01695590|DRUG|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
214275836|NCT03391037|DIAGNOSTIC_TEST|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
214275837|NCT05119517|OTHER|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
214275838|NCT03738683|DRUG|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
214275839|NCT03443375|OTHER|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
214275840|NCT03367221|DEVICE|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
214275841|NCT02057679|DRUG|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
214275842|NCT02057679|DRUG|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
214275843|NCT06022744|DRUG|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
214275844|NCT03981770|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
214275845|NCT03385460|OTHER|ESWL BOTOX|ESWL after intrravesical BOTOX
214275846|NCT00004132|BIOLOGICAL|filgrastim|
214275847|NCT00004132|BIOLOGICAL|palifermin|
214275848|NCT00004132|DRUG|cyclophosphamide|
214275849|NCT00004132|DRUG|etoposide|
214275850|NCT00004132|DRUG|ifosfamide|
214275851|NCT00004132|PROCEDURE|quality-of-life assessment|
214275852|NCT00004132|RADIATION|radiation therapy|
214275853|NCT00560456|OTHER|Chronic sleep restriction and driving simulator|"* One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator"
214275854|NCT05911529|BEHAVIORAL|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
214275855|NCT05911529|BEHAVIORAL|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
214275856|NCT04978961|BEHAVIORAL|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
214275857|NCT04978961|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
214275858|NCT05306275|DRUG|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
214275859|NCT03699605|OTHER|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
214275860|NCT03699605|OTHER|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
214275861|NCT04406376|DRUG|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
214275862|NCT06028139|BEHAVIORAL|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
214275863|NCT06028139|BEHAVIORAL|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
214275864|NCT02616406|DEVICE|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
214275865|NCT05253729|DEVICE|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
214275866|NCT05253729|BEHAVIORAL|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
214829506|NCT03200145|OTHER|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. \- Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. \- Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users."
214275867|NCT05604352|DEVICE|DiaSole|Diabetic ulcer offloading insole
214275868|NCT04784377|OTHER|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
214829507|NCT05206162|DEVICE|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
214829508|NCT01449188|DRUG|ondansetron|FDA approved drug used to treat nausea and vomiting
214829509|NCT01449188|DRUG|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
214275869|NCT04784377|OTHER|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
214275870|NCT04784377|OTHER|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
214275871|NCT02114216|PROCEDURE|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
214275872|NCT03118635|BEHAVIORAL|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
214275873|NCT04379024|DRUG|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
214275874|NCT06143644|OTHER|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
214275875|NCT05731895|DRUG|BI 425809 (iclepertin)|BI 425809 (iclepertin)
214275876|NCT00249756|BEHAVIORAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
214275877|NCT00249756|BEHAVIORAL|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
214275878|NCT03379805|DIAGNOSTIC_TEST|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
214275879|NCT03379805|DIAGNOSTIC_TEST|Non-contrast MRI|The anatomy is described using non-contrast MRI.
214275880|NCT03379805|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
214275881|NCT02324296|DRUG|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
214275882|NCT06177743|DEVICE|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
214275883|NCT03470441|DRUG|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
214275884|NCT03470441|OTHER|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
214275885|NCT05109156|OTHER|This is an observational study|This is an observational study
214829510|NCT01449188|OTHER|saline|USP saline IV solution used as placebo for ondansetron IV.
214829511|NCT04823169|OTHER|podobarometry|podobarometric measures on day 7 and day 30
214275886|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
214275887|NCT04029948|PROCEDURE|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
214275888|NCT04029948|PROCEDURE|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
214829512|NCT00007423|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214829513|NCT00007423|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214829514|NCT03827395|BIOLOGICAL|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
214829515|NCT03827395|OTHER|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
214829516|NCT04267692|OTHER|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
214829517|NCT00796341|PROCEDURE|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
214275889|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
214275890|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
214275891|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
214275892|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
214275893|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
214275894|NCT01355757|DEVICE|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
214275895|NCT01355757|DRUG|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
214275896|NCT06317727|DEVICE|Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)|The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
214275897|NCT05749965|PROCEDURE|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
214275898|NCT00169546|DRUG|Salmeterol/fluticasone propionate|
214275899|NCT00169546|DRUG|Fluticasone propionate|
214275900|NCT06546007|DIAGNOSTIC_TEST|CTC-DNA|ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
214275901|NCT03768414|DRUG|Cisplatin|Given IV
214275902|NCT03768414|DRUG|Gemcitabine Hydrochloride|Given IV
214275903|NCT03768414|DRUG|Nab-paclitaxel|Given IV
214275904|NCT06181331|BEHAVIORAL|eConquerFear|The key goals of this e-intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
214275905|NCT06181331|BEHAVIORAL|eHealthMaintenance|eHealthMaintenance is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
214275906|NCT06181331|BEHAVIORAL|ConquerFear|ConquerFear is an intensive version of eConquerFear, which consists of 6 face-to-face therapist-led sessions.
214275907|NCT06181331|BEHAVIORAL|eConquerFear+eHealthMaintenance|The combination of eConquerFear and eHealthMaintenance interventions, that consists of 10 weekly online modules.
214275908|NCT06249165|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
214275909|NCT03566888|DEVICE|Blood pressure assessment|Validation of an automated blood pressure device
214275910|NCT03633656|DEVICE|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
214829518|NCT00773149|DRUG|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
214829519|NCT00731939|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
214829520|NCT00921674|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
214275911|NCT03633656|DEVICE|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
214275912|NCT04454294|OTHER|Control|"Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
214275913|NCT04454294|OTHER|Experimental Group (Absorption Group)|"1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
214275914|NCT04454294|OTHER|Experimental Group (Milking Group)|"1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
214275915|NCT00837057|PROCEDURE|crrt|early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
214275916|NCT01804465|DRUG|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
214275917|NCT01804465|DRUG|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
214275918|NCT02599714|DRUG|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
214275919|NCT02599714|DRUG|Palbociclib|cyclin dependent kinase inhibitor
214275920|NCT02599714|DRUG|Fulvestrant|Fulvestrant hormonal therapy as background
214275921|NCT05960552|DIAGNOSTIC_TEST|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
214275922|NCT05960552|DIAGNOSTIC_TEST|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
214275923|NCT05364190|DRUG|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
214275924|NCT05364190|DRUG|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
214275925|NCT00317005|DRUG|folate treatment|
214275926|NCT01631344|OTHER|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
214275927|NCT04051528|PROCEDURE|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
214275928|NCT04051528|PROCEDURE|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
214275929|NCT04051528|PROCEDURE|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
214275930|NCT05250882|OTHER|Enhanced perioperative care protocol|See arm/group description
214275931|NCT02623023|DRUG|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
214275932|NCT02623023|OTHER|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
214275933|NCT00777114|DRUG|bortezomib, tositumomab|"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
214275934|NCT02656537|DEVICE|EnSite™ HD Grid Catheter mapping system|
214275935|NCT04219007|DRUG|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
214275936|NCT02538029|BEHAVIORAL|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
214275937|NCT02538029|BEHAVIORAL|Single Task Group|Performing motor or cognitive tasks alone.
214275938|NCT00077961|DRUG|CAMPATH (alemtuzumab)|
214275939|NCT05146895|DRUG|Imiquimod treatment|As an control arm, for patients with flat warts
214275940|NCT05146895|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
214275941|NCT02416401|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214275942|NCT02416401|OTHER|Commercially available computerized training|
214275943|NCT00895232|DRUG|Cohort I|
214275944|NCT00895232|DRUG|Cohort II|
214275945|NCT00895232|DRUG|Cohort III|
214275946|NCT07016568|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
214275947|NCT07014709|DRUG|GLP1 receptor agonist|Patients must be under GLP1-RA treatment for ether diabetes or obesity
214275948|NCT03676283|OTHER|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
214275949|NCT06722248|BEHAVIORAL|high fidelity simulation-based training|"The intervention is a two-hour high-fidelity simulation training session focusing on newborn assessment, care practices, skin-to-skin contact, and breastfeeding. It uses SimBaby mannequins and breastfeeding models to mimic the hospital environment. Scenarios are tailored to nursing students' learning levels and reviewed by experienced midwives.~The training includes:~Prebriefing: Introduction of learning objectives, scenario background, simulation familiarization, confidentiality discussions, and ground rules.~Intervention: Scenario-based training on baby care and breastfeeding. Debriefing: Plus-delta debriefing model reviewed by simulation educators. The training will be conducted in the nursing simulation laboratory."
214275950|NCT06722248|BEHAVIORAL|conventional training|Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.
214275951|NCT06447688|DRUG|Verapamil|Prevent
214829521|NCT01150422|OTHER|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
214829522|NCT05154890|DRUG|Pegtarviliase IV|Administered IV
214829523|NCT05154890|DRUG|Pegtarviliase SC|Administered SC
214275955|NCT06669247|DRUG|Linvoseltamab|Administered per protocol
214275956|NCT06669247|DRUG|REGN7945+Linvoseltamab|Administered per protocol
214275957|NCT06491654|OTHER|12-week supervised exercise|During the study period (1 week for acute effects, 12 weeks for chronic effects), there will be 8 sessions per month, lasting 40-60 minutes each, with 2 sessions per week on alternate days, totaling 24 sessions. Each session includes: (1) warm-up (mobility exercises); (2) training: 5-min warm-up, followed by 15-min moderate-to-high intensity circuit of 7 functional global exercises with 10 reps each at a perceived exertion effort (RPE) of 5-7 on a scale of 1 to 10; (3) Aerobic exercise: starting at 15 mins, increasing by 5 mins biweekly to 30 mins by week 7; (4) Cool-down (general mobility); (5) Application of cohesive compressive bandage on the affected upper limb, worn for 2 hours post-session, removed at home. Participants may add a cotton bandage and finger bandage if needed.
214275958|NCT04292743|BIOLOGICAL|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
214275959|NCT04292743|DRUG|FOLFIRINOX|intravenous administration of FOLFIRINOX
214275960|NCT05237687|DRUG|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
214275961|NCT00009997|BIOLOGICAL|trastuzumab|
214275962|NCT00009997|DRUG|cyclophosphamide|
214275963|NCT00009997|DRUG|doxorubicin hydrochloride|
214275964|NCT00009997|DRUG|paclitaxel|
214275965|NCT00009997|DRUG|tamoxifen citrate|
214275966|NCT00009997|PROCEDURE|conventional surgery|
214275967|NCT03744611|DIETARY_SUPPLEMENT|CE|550mg capsule (Eucommia ulmoides Oliver extract)
214275968|NCT03744611|DIETARY_SUPPLEMENT|Placebo|550mg capsule (Placebo)
214275969|NCT02256904|PROCEDURE|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
214275970|NCT02256904|PROCEDURE|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
214275971|NCT03968484|BIOLOGICAL|platelet transfusion|Transfusion of platelets
214275972|NCT03092154|DRUG|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
214275973|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
214275974|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
214275975|NCT06257082|OTHER|Online Survey|Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
214275976|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
214275977|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
214275978|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
214275979|NCT06137664|BIOLOGICAL|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
214275980|NCT04147130|OTHER|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
214275981|NCT04147130|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
214275982|NCT03578861|OTHER|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
214275983|NCT00809276|DRUG|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
214275984|NCT02945683|DIETARY_SUPPLEMENT|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
214275985|NCT02945683|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
214275986|NCT03187197|DRUG|Pradaxa®|Dabigatran etexilate
214275987|NCT02385045|DEVICE|i-scan|i-scan function is located on the head of the Pentax endoscopes
214275988|NCT02385045|DEVICE|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
214275989|NCT05650216|DRUG|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
214275990|NCT04653129|PROCEDURE|Autologous Fat Grafting|"* The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
214275991|NCT04653129|PROCEDURE|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
214275992|NCT00566371|DRUG|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
214275993|NCT00566371|DRUG|placebo|placebo
214275994|NCT02272595|OTHER|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
214275995|NCT02272595|OTHER|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
214275996|NCT04988178|OTHER|Data extraction from medical files|Data extraction from medical files
214275997|NCT02539121|DEVICE|Acupuncture|Acupuncture needles
214275998|NCT03748797|OTHER|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
214275999|NCT06327347|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
214276000|NCT02871297|DRUG|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
214276001|NCT00732017|DEVICE|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
214276002|NCT00732017|DEVICE|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
214276003|NCT00732017|OTHER|standard physical therapy treatment|"* Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
214276004|NCT02034110|DRUG|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
214276005|NCT02034110|DRUG|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
214276006|NCT01842074|DRUG|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
214276007|NCT00621985|DRUG|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
214276008|NCT00621985|DRUG|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
214276009|NCT01244724|DRUG|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
214276010|NCT01251601|OTHER|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
214276011|NCT00971594|BEHAVIORAL|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
214276012|NCT00971594|BEHAVIORAL|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
214276013|NCT06177327|OTHER|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
214276014|NCT00030810|RADIATION|Hyperfractionated|Hyperfractionated radiotherapy
214276015|NCT00030810|DRUG|Taxotere/Cisplatin|Taxotere/Cisplatin
214276016|NCT00030810|PROCEDURE|conventional surgery|conventional surgery
214276017|NCT05083572|DRUG|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
214276018|NCT05083572|DIETARY_SUPPLEMENT|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
214276019|NCT05083572|DRUG|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
214276020|NCT00490360|DRUG|Gemcitabine / Cisplatin|
214276021|NCT01877265|DRUG|LY2605541|
214276022|NCT00691015|BIOLOGICAL|rituximab|Given IV
214276023|NCT00691015|DRUG|busulfan|Given IV
214276024|NCT00691015|DRUG|carmustine|Given IV
214276025|NCT00691015|DRUG|cyclophosphamide|Given IV
214276026|NCT00691015|DRUG|cytarabine|Given IV
214276027|NCT00691015|DRUG|etoposide|Given IV
214276028|NCT00691015|DRUG|fludarabine phosphate|Given IV
214276029|NCT00691015|DRUG|melphalan|Given IV
214276030|NCT00691015|RADIATION|total body irradiation (TBI)|Given once or twice daily
214276031|NCT00691015|DRUG|anti-thymocyte globulin IV|Given IV
214276032|NCT02161367|DRUG|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
214276033|NCT02161367|DRUG|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
214276034|NCT03112395|DEVICE|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
214276035|NCT06352801|BEHAVIORAL|Self-Compassion Intervention|Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
214276036|NCT03729089|OTHER|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
214276037|NCT06229340|DRUG|Leflunomide|100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
214276038|NCT06229340|DRUG|The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab|"Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously."
214276039|NCT01826630|OTHER|CLn BodyWash|Comparing two washes to determine change in bacterial load.
214276040|NCT01826630|OTHER|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
214276041|NCT05416502|PROCEDURE|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
214276042|NCT00950105|DRUG|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
214276043|NCT04160195|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0
214276044|NCT04160195|DRUG|Cyclophosphamide|500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
214276045|NCT04160195|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
214276046|NCT00349440|DRUG|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
214276047|NCT00706823|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
214276048|NCT00706823|DEVICE|Laryngeal Mask Airway-Unique|supra-glottic airway device
214276049|NCT00589251|OTHER|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
214276050|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
214276051|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
214276052|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
214276053|NCT00009698|BIOLOGICAL|aldesleukin|Given SQ and IV
214276054|NCT03719885|DEVICE|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
214829524|NCT05247723|DEVICE|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
214276055|NCT03239288|OTHER|Control digestible carbohydrate|Single serving of control product
214276056|NCT03239288|OTHER|Test resistant starch type 4|Single serving of test product
214276057|NCT01581814|DRUG|Metformin|500 mg of Metformin per 3/die
214276058|NCT01581814|DRUG|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
214276059|NCT01581814|DRUG|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
214276060|NCT03087669|DEVICE|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
214276061|NCT03087669|DRUG|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
214276062|NCT04443725|DRUG|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
214276063|NCT04443725|DRUG|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
214276064|NCT00878423|DRUG|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
214276065|NCT00878423|DRUG|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
214276066|NCT00684593|DRUG|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
214276067|NCT00684593|OTHER|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
214276068|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
214276069|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
214829525|NCT05247723|PROCEDURE|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
214829526|NCT04165252|DIAGNOSTIC_TEST|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
214276070|NCT00121602|DRUG|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
214276071|NCT05258175|OTHER|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
214276072|NCT05258175|OTHER|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
214276073|NCT04949048|DEVICE|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
214276074|NCT04325581|DRUG|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
214276075|NCT04325581|DRUG|Placebos|Normal Saline SC daily
214276076|NCT05577260|DRUG|magnesuim sulphate|magnesuim sulphate
214276077|NCT05577260|DRUG|Dexmedetomidine|Dexmedetomidine
214276078|NCT05577260|DRUG|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
214276079|NCT02926365|BEHAVIORAL|ICBT|
214276080|NCT01797653|OTHER|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
214276081|NCT01797653|PROCEDURE|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
214276082|NCT02139332|BEHAVIORAL|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
214276083|NCT02139332|BEHAVIORAL|Resource & Referral Group|The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
214276084|NCT00309569|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
214276085|NCT00309569|DRUG|Methotrexate|Methotrexate 40mg/m2
214276086|NCT00309569|DRUG|Fluorouracil|Fluorouracil 600mg/m2
214276087|NCT00309569|DRUG|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
214276088|NCT00309569|OTHER|Surgery|Surgery
214276089|NCT05130398|BIOLOGICAL|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
214276090|NCT05130398|DIETARY_SUPPLEMENT|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
214276091|NCT05130398|DIAGNOSTIC_TEST|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
214276092|NCT05130398|COMBINATION_PRODUCT|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
214276093|NCT05130398|BIOLOGICAL|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
214276094|NCT05130398|OTHER|Placebo|About 30 children do not receive diet, nor active pathogen detection
214276095|NCT02563223|OTHER|Parabolic flight|
214276096|NCT02563223|DEVICE|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
214276097|NCT00043771|DRUG|Tolvaptan|
214276098|NCT01223001|DRUG|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
214276099|NCT01223001|DRUG|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
214276100|NCT01303107|DRUG|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
214276101|NCT05009121|DIAGNOSTIC_TEST|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
214276102|NCT04592315|DRUG|Lipovirtide Injection|Single dosage of Lipovirtide Injection
214276103|NCT04454268|PROCEDURE|cyst extirpation|complete removal of the cyst without rupture
214276104|NCT05930912|DIAGNOSTIC_TEST|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
214276105|NCT05930912|DRUG|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
214276106|NCT05930912|DRUG|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
214276107|NCT05930912|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
214829527|NCT03129685|PROCEDURE|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
214829528|NCT00603499|DIETARY_SUPPLEMENT|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
214276108|NCT06959602|PROCEDURE|Final Irrigation with 2.5% Sodium Hypochlorite|After supragingival scaling and removal of caries or defective restorations, the tooth will be isolated and disinfected with 3% H202 and 2.5% NaOCl. Access preparation will be done using a sterile high-speed bur under sterile saline irrigation, followed by re-disinfection. NaOCl will be neutralized with 5% sodium thiosulphate, and sterility will be confirmed via paper point sampling. Only teeth with negative sterility samples will proceed. Sample S1 will be collected after saline irrigation and mild instrumentation with a sterile K-file #15, using an apex locator. Paper points will absorb canal fluid and be frozen in Tris-EDTA buffer at -20°C. Complete chemomechanical preparation will follow, with irrigation after each instrument change. Cervical and mid-thirds will be enlarged with Gates-Glidden burs and the apical third with NiTi RaCe files (40/04). Sample S2 will be taken after preparation. Group A will receive final irrigation with 2.5% NaOCl before collection of sample S3.
214276109|NCT06959602|PROCEDURE|Passive Ultrasonic Irrigation (PUI) with Sodium Hypochlorite|Activation of 2.5% sodium hypochlorite solution inside the root canal system using Passive Ultrasonic Irrigation (PUI) after chemomechanical preparation. Group B, sample (S3).
214276110|NCT06959602|PROCEDURE|XP-Endo Finisher Activation with Sodium Hypochlorite|Mechanical activation of 2.5% sodium hypochlorite solution using the XP-Endo Finisher instrument following chemomechanical preparation.Group C, sample (S3).
214276111|NCT05951673|OTHER|Safe Space based life skills training program|This is a Safe Space based life skills training program given to adolescent girls. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change.
214276112|NCT05951673|OTHER|Safe Space based life skills training program + Digital Skills|This is a Safe Space based life skills training program given to adolescent girls complemented with a digital literacy training program. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change. The adolescent girls in this group also receive a digital literacy training program that covers content on word processing. database management and analysis, online marketing, online safety and programming.
214276113|NCT05758051|PROCEDURE|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
214276114|NCT00590720|BIOLOGICAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
214276115|NCT00590720|OTHER|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
214276116|NCT04023851|DEVICE|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
214276117|NCT01240720|DRUG|131I-F16SIP Radioimmunotherapy (RIT)|"* Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
214276118|NCT02957422|DIETARY_SUPPLEMENT|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
214276119|NCT02957422|DIETARY_SUPPLEMENT|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
214276120|NCT01001377|DRUG|Cetuximab|Administered by intravenous infusion
214276121|NCT01001377|DRUG|Panitumumab|Administered by intravenous infusion
214276122|NCT03495362|DIETARY_SUPPLEMENT|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214276123|NCT03495362|OTHER|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214276124|NCT02102906|PROCEDURE|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
214276125|NCT05928039|BIOLOGICAL|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
214276126|NCT05928039|BIOLOGICAL|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
214276127|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
214276128|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
214276129|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
214276130|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
214276131|NCT01430390|BIOLOGICAL|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
214656915|NCT01808560|DEVICE|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
214656916|NCT03330327|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
214829529|NCT00603499|OTHER|Placebo|Subjects in the control group received inert placebo once per day during 4 months
214829530|NCT00394485|DRUG|Procaterol|
214829531|NCT00394485|DRUG|Tiotropium|
214829532|NCT03123315|DEVICE|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
214829533|NCT02584907|OTHER|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
214276132|NCT01430390|DRUG|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
214276133|NCT04957901|DRUG|Pediatric lymphoma protocol|The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
214276134|NCT06846489|DRUG|Acalabrutinib|100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment.
214276135|NCT06846489|DRUG|Rituximab|375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months
214276136|NCT03950115|DEVICE|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
214276137|NCT04079101|DRUG|BIIB104|Administered as specified in the treatment arm.
214276138|NCT04079101|DRUG|Placebo|Administered as specified in the treatment arm.
214276139|NCT06497621|PROCEDURE|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
214276140|NCT06497621|PROCEDURE|Conventional two-step PVS impression|Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
214276141|NCT04472702|PROCEDURE|cRFA|cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
214276142|NCT04535700|DRUG|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
214276143|NCT04535700|OTHER|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
214276144|NCT00766311|OTHER|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
214276145|NCT00766311|OTHER|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
214276146|NCT00766311|OTHER|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
214276147|NCT00766311|OTHER|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
214276148|NCT00766311|OTHER|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
214276149|NCT00766311|OTHER|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
214276150|NCT00766311|OTHER|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
214656917|NCT02336477|DRUG|Mexiletine|"* Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~* Patients will receive gradual dose of the treatment as it would be done in clinical practice.~* Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~* The duration of each treatment period is 18 days minimum (maximum 22 days)."
214656918|NCT02336477|DRUG|placebo|
214276151|NCT04261777|DRUG|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
214276152|NCT01925053|OTHER|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
214276153|NCT01925053|OTHER|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
214276154|NCT04985097|PROCEDURE|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
214276155|NCT02353104|DIETARY_SUPPLEMENT|Onion-Pumpkin Extract|
214276156|NCT05789810|OTHER|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
214276157|NCT05789810|OTHER|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
214276158|NCT05789810|OTHER|Control|No intervention was performed to reduce pain and fear.
214276159|NCT06365398|DRUG|Heparin|As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
214276160|NCT06365398|DRUG|Heparin Sodium Injection|In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
214276161|NCT06365398|OTHER|No heparinization|No additional heparin was administered via the sheath or arterial route in the no heparinization group.
214276162|NCT02285803|DEVICE|transcranial direct current stimulation (tDCS)|
214829534|NCT03089983|DRUG|Methadone|Participants will receive daily or weekly doses of oral methadone.
214276163|NCT04915430|OTHER|Training|
214276164|NCT03665805|OTHER|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
214276165|NCT01876797|DRUG|ticagrelor/prasugrel|
214276166|NCT01129817|OTHER|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
214276167|NCT01129817|OTHER|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
214276168|NCT02643381|DRUG|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
214276169|NCT02643381|DRUG|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
214276170|NCT02643381|PROCEDURE|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
214276171|NCT02643381|DEVICE|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
214276172|NCT02193867|DRUG|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
214276173|NCT05205330|DRUG|CR6086|oral CR6086, twice a day for 14 days
214276174|NCT05205330|BIOLOGICAL|AGEN2034|AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
214276175|NCT00822783|DRUG|Omalizumab|
214276176|NCT00822783|DRUG|Placebo|
214276177|NCT03616600|OTHER|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
214276178|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
214276179|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
214829535|NCT03089983|DRUG|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
214829536|NCT03089983|DRUG|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
214829537|NCT06468254|DRUG|Statin|Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
214276180|NCT04724018|DRUG|Pembrolizumab|Intravenous infusion
214276181|NCT03600818|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214276182|NCT03600818|DRUG|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214276183|NCT03600818|DRUG|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
214276184|NCT03600818|DRUG|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
214276185|NCT03600818|DRUG|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
214276186|NCT02124083|DRUG|Vorinostat|Histone deactylase inhibitor
214276187|NCT03045185|PROCEDURE|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
214276188|NCT02252913|DRUG|Volitinib|oral administration
214276189|NCT02252913|DRUG|Docetaxel|intravenous injection
214276190|NCT01671800|DRUG|Botulinum Type B|
214276191|NCT01671800|DRUG|Placebo|
214276192|NCT03416946|DEVICE|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
214276193|NCT03416946|OTHER|Traditional|Traditional cutting method
214276194|NCT00182286|BEHAVIORAL|Assessment of continuity of care from the patient perspective|
214276195|NCT00182286|BEHAVIORAL|Relationship between continuity of care, patient outcomes, and costs|
214276196|NCT04901936|DRUG|Pegcetacoplan|Complement (C3) inhibitor
214276197|NCT04571879|DRUG|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
214276198|NCT04571879|DRUG|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
214276199|NCT04571879|OTHER|Placebo|Nebulized normal saline and intranasal normal sline
214276200|NCT03129165|OTHER|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
214276201|NCT01488370|DEVICE|Endotracheal intubation|Endotracheal intubation
214276202|NCT00424983|DRUG|Zoledronic acid|
214276203|NCT00372762|DRUG|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
214276204|NCT00372762|DRUG|Bumetanide|Equivalent dose to pre-existing furosemide will be used
214276205|NCT00372762|DRUG|furosemide|20mg to 80mg orally once or twice daily
214276206|NCT00372762|DRUG|bumetanide|0.5mg to 2mg orally once or twice daily
214276207|NCT05042154|DEVICE|WatchPAT|The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
214276208|NCT01471171|DRUG|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
214276209|NCT01471171|DRUG|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
214276210|NCT01320904|PROCEDURE|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
214276211|NCT01320904|PROCEDURE|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
214276212|NCT00966329|DRUG|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
214276213|NCT00966329|DRUG|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz)."
214276214|NCT03727529|OTHER|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
214276215|NCT03727529|OTHER|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
214276216|NCT05081141|DIAGNOSTIC_TEST|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
214276217|NCT05386810|BIOLOGICAL|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
214656919|NCT01206569|DRUG|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
214656920|NCT05029050|DRUG|Dexmedetomidine|Continous intravenous infusion
214276218|NCT05386810|BIOLOGICAL|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
214276219|NCT05386810|BIOLOGICAL|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
214276220|NCT03746652|DRUG|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
214276221|NCT06084663|DRUG|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
214276222|NCT06084663|DRUG|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
214276223|NCT04059783|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
214276224|NCT03355820|PROCEDURE|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
214276225|NCT04580069|PROCEDURE|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
214276226|NCT02658903|DEVICE|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
214276227|NCT02658903|DEVICE|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
214276228|NCT03478930|DRUG|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
214276229|NCT03478930|DRUG|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
214276230|NCT04189081|DEVICE|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
214276231|NCT04189081|OTHER|Water Control|negative control
214276232|NCT02656732|BIOLOGICAL|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
214276233|NCT02656732|PROCEDURE|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
214276234|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
214276235|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
214276236|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
214276237|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
214276238|NCT02385500|DRUG|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
214276239|NCT02385500|DRUG|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
214276240|NCT04745130|DRUG|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
214276241|NCT04745130|DRUG|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
214276242|NCT00365911|PROCEDURE|Taking blood sample|A blood sample will be taken.
214276243|NCT05866172|PROCEDURE|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
214276244|NCT05866172|DRUG|Zoledronic acid|Zoledronic acid 4mg iv.drip
214276245|NCT00247975|DRUG|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
214276246|NCT00705484|BIOLOGICAL|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
214276247|NCT00705484|DRUG|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
214276248|NCT02687997|OTHER|poligraphy|Sleep study
214276249|NCT02765295|DEVICE|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
214656921|NCT05029050|DRUG|Clonidine|Continous intravenous infusion
214276250|NCT02765295|DEVICE|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
214276251|NCT00303784|DRUG|Goserelin|3.6mg implant, in pre-filled syringe
214276252|NCT00303784|DRUG|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
214276253|NCT01346449|BEHAVIORAL|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
214276254|NCT01346449|BEHAVIORAL|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
214276255|NCT01346449|BEHAVIORAL|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
214276256|NCT01346449|BEHAVIORAL|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
214276257|NCT05496062|DEVICE|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
214276258|NCT00007865|BIOLOGICAL|rituximab|
214276259|NCT00007865|DRUG|carboplatin|
214276260|NCT00007865|DRUG|etoposide|
214276261|NCT00007865|DRUG|ifosfamide|
214276262|NCT04476069|DRUG|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
214276263|NCT00740831|DRUG|PGL4001|tablets
214276264|NCT00740831|DRUG|leuprorelin|solution for injection
214276265|NCT01247909|DRUG|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
214276266|NCT03421665|DEVICE|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
214276267|NCT00287885|DRUG|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
214276268|NCT06313814|DIETARY_SUPPLEMENT|Swanson ginger capsule|"Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond."
214276269|NCT05892471|DRUG|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
214276270|NCT05892471|DRUG|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
214276271|NCT02207296|DEVICE|Plethysmographic variability index|
214276272|NCT01530061|OTHER|Egg Breakfast|Egg, Toast and Jelly
214276273|NCT01530061|OTHER|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
214276274|NCT02667054|DRUG|RX0041 4%|Anesthetic
214276275|NCT02667054|DRUG|Placebo|Placebo Comparator
214276276|NCT02667054|DRUG|RX0041 8%|Anesthetic
214276277|NCT05528354|DRUG|VEN and DEC based conditioning regimen|"Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
214276278|NCT05528354|DRUG|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed."
214276279|NCT01979445|DRUG|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
214276280|NCT01979445|DRUG|Clopidogrel|Clopidogrel 600 mg single oral dose
214276281|NCT01979445|DRUG|Prasugrel|Prasugrel 60 mg single oral dose
214276282|NCT03982368|DRUG|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
214276283|NCT03982368|DRUG|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
214276284|NCT03982368|OTHER|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
214276285|NCT03776552|OTHER|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
214276286|NCT03776552|OTHER|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
214276287|NCT04466735|DIETARY_SUPPLEMENT|Active group|2 x 12 g of EKS/day
214276288|NCT04466735|DIETARY_SUPPLEMENT|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
214656922|NCT05029050|DRUG|Natriumchlorid|Continous intravenous infusion NaCl
214656923|NCT00435422|PROCEDURE|Stroke volume optimization|Stroke volume optimization
214276289|NCT05283213|DIAGNOSTIC_TEST|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\],~* urinary CCL-14 \[H6\],~* plasma angiopoietin-2 \[H6\],~* plasma PENK-A \[H6\]~These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."
214276290|NCT04289675|DRUG|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
214276291|NCT00687466|DRUG|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
214276292|NCT04899869|OTHER|Faecal microbiota transplantation with active study microbiota first|2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
214276293|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota first|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota
214276294|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota only|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
214276295|NCT01796561|DIETARY_SUPPLEMENT|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
214276296|NCT03706079|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214276297|NCT03706079|OTHER|Placebo|Placebo subcutaneous injection
214276298|NCT00329238|DRUG|Dabigatran|Dabigatran 150 mg BID (twice daily)
214276299|NCT00329238|DRUG|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
214276300|NCT00986557|BIOLOGICAL|adoptive immunotherapy|
214276301|NCT00986557|BIOLOGICAL|alemtuzumab|
214276302|NCT00986557|BIOLOGICAL|in vitro-treated peripheral blood lymphocyte therapy|
214276303|NCT00986557|DRUG|foscarnet sodium|
214276304|NCT00986557|DRUG|ganciclovir|
214276305|NCT00986557|GENETIC|polymerase chain reaction|
214276306|NCT00986557|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214276307|NCT00986557|PROCEDURE|infection prophylaxis and management|
214276308|NCT00986557|PROCEDURE|peripheral blood stem cell transplantation|
214276309|NCT00986557|PROCEDURE|standard follow-up care|
214276310|NCT00986557|RADIATION|radiation therapy|
214276311|NCT02257008|DRUG|BILR 355 BS|
214276312|NCT02257008|OTHER|Grapefruit juice|
214276313|NCT02257008|DRUG|Nelfinavir|
214276314|NCT02257008|DRUG|Atazanavir|
214276315|NCT02257008|DRUG|Ritonavir|
214276316|NCT01941875|DRUG|Progesterone Effervescent Vaginal Tablets|Experimental
214276317|NCT03839901|OTHER|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
214276318|NCT04068714|PROCEDURE|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
214276319|NCT00647881|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
214276320|NCT00647881|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fed
214276321|NCT01346228|BEHAVIORAL|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
214276322|NCT02528929|DIETARY_SUPPLEMENT|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
214276323|NCT05845151|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
214276324|NCT06204146|BEHAVIORAL|massage|stressn level and preterm growth
214276325|NCT05732688|DIAGNOSTIC_TEST|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
214276326|NCT03385005|DEVICE|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
214276327|NCT03558698|OTHER|Good ventilation|Good ventilation with a low concentration of CO2
214276328|NCT03558698|OTHER|Ventilation CO2|CO2 High and Good ventilation
214276329|NCT03558698|OTHER|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
214276330|NCT04085276|DRUG|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
214276331|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
214276332|NCT04085276|DRUG|Placebo|Placebo, i.v., q3w;
214276333|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
214829538|NCT06468254|DRUG|Sugar pill|Control Group: Conventional chemotherapy and maintenance therapy alone.
214276334|NCT04924322|DRUG|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
214276335|NCT05370170|BEHAVIORAL|Acupressure and nutritional advices|Teaching using booklets and application of acupressure
214276336|NCT05710861|DEVICE|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
214276337|NCT05710861|PROCEDURE|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
214276338|NCT03652012|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
214276339|NCT02199366|PROCEDURE|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
214276340|NCT05609370|DRUG|LBL-007|Administered intravenously.
214276341|NCT05609370|DRUG|Tislelizumab|Administered intravenously.
214276342|NCT05609370|DRUG|Bevacizumab or Bevacizumab biosimilar|Administered intravenously
214276343|NCT05609370|DRUG|Capecitabine|Administered in accordance with relevant local guidelines and/or prescribing information
214276344|NCT05609370|DRUG|5-Fluorouracil|Administered in accordance with relevant local guidelines and/or prescribing information
214276345|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection30mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
214276346|NCT05941585|DRUG|HomoharringtonineD1-D7(2mg/m2/day)|Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
214276347|NCT05941585|DRUG|Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)|Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
214276348|NCT05941585|DRUG|Cytarabine(standard-dose:d1-d7100mg/m2/day)|Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
214276349|NCT05941585|DRUG|Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)|d1-d4100mg/m2/day, d5-d7 1g/m2
214276350|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection24mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
214276351|NCT05298709|OTHER|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
214276352|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) as usual|Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
214276353|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) + Smart Parents|"Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session."
214276354|NCT05393895|DRUG|CSF-1|One drop bilaterally twice daily for at least 6 weeks
214276355|NCT05393895|DRUG|Vehicle|One drop bilaterally twice daily for at least 6 weeks
214276356|NCT06132386|OTHER|biopsy|colorectal biopsy for tissue acquisition
214276357|NCT05817461|DRUG|AZD0780 tablet|oral, fasted
214276358|NCT05817461|DRUG|[14C]AZD0780 Solution for Infusion|intravenous
214276359|NCT05817461|DRUG|[14C]AZD0780 Oral Solution|oral, fasted
214276360|NCT04740190|DRUG|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
214276361|NCT04124757|OTHER|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
214276362|NCT00968513|BEHAVIORAL|Brief Intervention|(N=416) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
214276363|NCT00968513|BEHAVIORAL|Extended Treatment|(N=408) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
214276364|NCT00968513|BEHAVIORAL|Usual Care|(N=132) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
214276365|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
214276366|NCT05537883|DRUG|Liposomal bupivacaine|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
214276367|NCT05537883|DRUG|Bupivacaine Injection|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
214276368|NCT04034446|BIOLOGICAL|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
214276369|NCT04530773|BEHAVIORAL|Watch VR movies/ Play VR games|The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
214276370|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
214276371|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
214276372|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
214276373|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing high dose of the drug substance.
214276374|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing low dose of the drug substance.
214276375|NCT05039515|DRUG|Placebo|Placebo will be supplied as powder filled hard capsules
214276376|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
214276377|NCT06803524|BIOLOGICAL|Pertagen® vaccine|Pertagen® vaccine, manufactured by BioNet-Asia Co., Ltd., Bangkok, Thailand. The vaccine is presented in pre-filled syringe, each containing one human dose (0.5 mL) of aP vaccine.
214276378|NCT06803524|BIOLOGICAL|Adacel® vaccine|Adacel® vaccine, manufactured by Sanofi Pasteur, Ltd, Toronto, Ontario, Canada. The vaccine is presented in a single-dose vial, each containing one human dose (0.5 mL) of Tdap vaccine.
214276379|NCT03665051|PROCEDURE|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
214276380|NCT03665051|OTHER|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
214276381|NCT05427461|OTHER|Blood samples will be collected at different times.|"For patients with localized leiomyosarcoma, samples will be collected:~* At Baseline.~* Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).~* After surgery.~* At each control visit.~* At local or metastatic recurrence (or at 24 months post inclusion if no progression).~For patients with metastatic leiomyosarcoma, samples will be collected:~* At Baseline.~* At each therapeutic line.~* At progression (or at 24 months post inclusion if no progression)."
214276382|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
214276383|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
214276384|NCT02903680|DRUG|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
214276385|NCT02903680|DRUG|Placebo group|Normal Saline 0,9% same volume
214276386|NCT05154396|DRUG|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
214276387|NCT03217357|DEVICE|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
214276388|NCT06072898|DRUG|Psilocybin|Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
214276389|NCT06072898|OTHER|Microcrystalline cellulose|MCC (excipient), 25mg PO.
214276390|NCT06072898|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.
214276391|NCT01594671|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
214276392|NCT01594671|DRUG|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
214276393|NCT01594671|OTHER|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
214276394|NCT01328431|OTHER|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
214276395|NCT05379231|DEVICE|Hearing aid fitting|A participant will wear a hearing aid with and without a CROS device on the unaidable ear.
214276396|NCT02796469|DRUG|Pentoxifylline|
214276397|NCT02796469|DRUG|Corticosteroid|
214276398|NCT02796469|DRUG|Placebo|
214276399|NCT02975687|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
214276400|NCT00509444|BEHAVIORAL|Educational materials|
214276401|NCT00509444|BEHAVIORAL|educational materials, plus patient navigation|
214276402|NCT03046758|DRUG|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
214276403|NCT01644539|DIETARY_SUPPLEMENT|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
214829539|NCT05581407|BIOLOGICAL|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
214276404|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
214276405|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
214276406|NCT00769392|DRUG|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
214276407|NCT00769392|DRUG|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
214276408|NCT00769392|DRUG|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
214276409|NCT00769392|DRUG|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
214276410|NCT00018031|DRUG|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
214276411|NCT00018031|DRUG|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
214276412|NCT01463488|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
214276413|NCT01463488|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
214276414|NCT03985904|OTHER|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
214276415|NCT04090424|DEVICE|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
214276416|NCT04090424|PROCEDURE|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
214276417|NCT01521546|DRUG|eplerenone|25mg tablet, once daily by mouth for 12 months
214276418|NCT01521546|DRUG|placebo|one tablet by mouth daily for 12 months
214276419|NCT02158273|DRUG|Sugar Pill|145 mg/day, oral pill, 9 days
214276420|NCT02158273|DRUG|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
214276421|NCT00286312|DRUG|Atorvastatin|
214276422|NCT02296320|DRUG|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
214276423|NCT02296320|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
214276424|NCT05002452|OTHER|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
214276425|NCT04178486|BEHAVIORAL|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
214276426|NCT04178486|BEHAVIORAL|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
214276427|NCT04178486|BEHAVIORAL|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
214276428|NCT04178486|BEHAVIORAL|Hypnosis with induction only|Participants received only hypnotic induction.
214276429|NCT06044883|PROCEDURE|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
214276430|NCT06044883|DIAGNOSTIC_TEST|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
214276431|NCT04907903|OTHER|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
214276432|NCT02485197|OTHER|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
214276433|NCT03292562|DEVICE|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
214276434|NCT03292562|DEVICE|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
214276435|NCT04861389|PROCEDURE|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
214276436|NCT05125757|OTHER|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
214276437|NCT05125757|OTHER|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
214276438|NCT01369095|DRUG|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
214276439|NCT01369095|DRUG|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
214276440|NCT01369095|DRUG|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
214276441|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
214276442|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
214276443|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
214276444|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
214276445|NCT03504657|DEVICE|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
214276446|NCT03504657|DEVICE|stenting angioplasty|Angioplasty with a stenting
214276447|NCT00459628|RADIATION|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
214276448|NCT00459628|RADIATION|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
214276449|NCT02347280|PROCEDURE|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
214276450|NCT02347280|PROCEDURE|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
214276451|NCT00764738|DEVICE|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
214276452|NCT00764738|DRUG|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
214276453|NCT04466020|OTHER|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
214276454|NCT02968771|OTHER|Non intervention|
214276455|NCT01203098|DRUG|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
214276456|NCT01203098|DRUG|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
214276457|NCT01203098|DRUG|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
214276458|NCT04188782|DRUG|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
214276459|NCT00730405|DRUG|Albaconazole 100mg|Albaconazole for 36 weeks
214276460|NCT00730405|DRUG|Albaconazole 200mg|Albaconazole for 36 weeks
214276461|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 36 weeks
214276462|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
214276463|NCT00730405|DRUG|Placebo 400 mg|Placebo for 36 weeks
214276464|NCT02650856|DRUG|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
214276465|NCT02650856|BIOLOGICAL|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
214276466|NCT04640285|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
214276467|NCT04640285|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
214276468|NCT04640285|OTHER|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
214276469|NCT04640285|OTHER|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
214276470|NCT04821947|OTHER|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
214276471|NCT03677362|BEHAVIORAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
214276472|NCT03851705|DRUG|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
214276473|NCT03851705|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
214276474|NCT03851705|DRUG|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
214276475|NCT02478775|DRUG|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
214276476|NCT02478775|DRUG|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
214276477|NCT02478775|DRUG|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
214276478|NCT00394732|DEVICE|Total Disc Prosthesis|
214276479|NCT00394732|BEHAVIORAL|Multidisciplinary rehabilitation program|
214276480|NCT03078660|BEHAVIORAL|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
214276481|NCT03078660|BEHAVIORAL|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
214276482|NCT03304548|OTHER|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
214276483|NCT06014268|OTHER|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
214276484|NCT00476697|DEVICE|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
214276485|NCT05277324|OTHER|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
214276486|NCT05369637|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
214276487|NCT05369637|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
214276488|NCT05369637|BEHAVIORAL|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
214276489|NCT05369637|BEHAVIORAL|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
214276490|NCT05369637|OTHER|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
214276491|NCT05188911|DRUG|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
214276492|NCT05188911|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
214276493|NCT05188911|DRUG|Androgen deprivation therapy|Patients would get medical or surgical castration.
214276494|NCT00944905|BIOLOGICAL|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
214276495|NCT06506708|OTHER|Hydrotherapy + massage|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
214276496|NCT01496807|DRUG|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
214276497|NCT01496807|DRUG|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
214276498|NCT01755078|DRUG|Sevelamer HCl|Non-metal phosphate binder
214276499|NCT01755078|DRUG|Calcium-based phosphate binder|
214276500|NCT00603616|DRUG|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
214276501|NCT00603616|DRUG|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
214276502|NCT00959764|DRUG|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
214276503|NCT00959764|DRUG|Intranasal Calcitonin|Intranasal Calcitonin Spray
214276504|NCT00959764|DRUG|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
214276505|NCT03007160|DRUG|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
214276506|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
214276507|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
214276508|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
214276509|NCT06340373|DEVICE|DCB Angioplasty|Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
214276510|NCT05249374|DRUG|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
214276511|NCT05249374|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
214276512|NCT01695265|OTHER|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
214276513|NCT01695265|DEVICE|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
214276514|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
214276515|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
214276516|NCT04240769|DEVICE|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
214276517|NCT05043506|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
214276518|NCT05043506|DRUG|Aromatase inhibitor|Aromatase inhibitor monotherapy
214276519|NCT04535648|OTHER|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
214276520|NCT05087108|DEVICE|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
214276521|NCT05087108|DEVICE|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
214276522|NCT05087108|DEVICE|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
214276523|NCT03323710|DRUG|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
214276524|NCT03323710|DRUG|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
214276525|NCT06287008|PROCEDURE|robot-assisted kidney transplantation|The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
214276526|NCT02893670|PROCEDURE|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
214276527|NCT00836485|DRUG|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
214276528|NCT00836485|DRUG|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
214276529|NCT00836485|DRUG|Olopatadine 0.2%|1 gtt/eye on two separate occasions
214276530|NCT00836485|DRUG|Artificial tears|1 gtt/eye on two separate occasions
214276531|NCT02591290|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
214276532|NCT04590222|OTHER|blood sample|One blood sample of 60 mL (EDTA)
214276533|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.
214276534|NCT06197971|OTHER|Therapeutic Cupping Technique|Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
214276535|NCT06428669|DRUG|Nitro-Bid 2 % Topical Ointment|Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
214276536|NCT03765905|DIAGNOSTIC_TEST|study|Scube-1 scube-2 scube-3
214276537|NCT00913497|DRUG|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
214276538|NCT00913497|DRUG|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
214276539|NCT04193332|DEVICE|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
214276540|NCT04284670|OTHER|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
214276541|NCT02087397|OTHER|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
214276542|NCT02087397|BIOLOGICAL|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
214276543|NCT05827510|DEVICE|BTL-585F|BTL-585F device with BTL-585-4 applicator
214276544|NCT05641324|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
214276545|NCT05641324|DRUG|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
214276546|NCT05641324|DRUG|Daratumumab|Daratumumab administered by subcutaneous injection
214276547|NCT03197597|OTHER|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
214276548|NCT03676010|OTHER|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214276549|NCT03676010|OTHER|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214276550|NCT03676010|OTHER|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214276551|NCT03676010|OTHER|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214276552|NCT03676010|OTHER|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
214276553|NCT03676010|OTHER|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214276554|NCT02574468|DRUG|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
214276555|NCT02574468|PROCEDURE|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
214276556|NCT05387031|DRUG|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
214276557|NCT03240302|DEVICE|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
214276558|NCT03240302|DEVICE|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
214276559|NCT03111602|OTHER|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
214276560|NCT06023459|DRUG|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
214276561|NCT06023459|DRUG|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
214276562|NCT01422018|DRUG|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
214276563|NCT03769766|DRUG|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
214276564|NCT03769766|DRUG|Placebo|Take medication one 500mg pill twice daily
214276565|NCT06012669|DIETARY_SUPPLEMENT|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
214276566|NCT06012669|DIETARY_SUPPLEMENT|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
214276567|NCT06012669|DIETARY_SUPPLEMENT|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
214276568|NCT05051618|BEHAVIORAL|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
214829540|NCT05992454|DEVICE|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
214276569|NCT05051618|BEHAVIORAL|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
214276570|NCT01781754|PROCEDURE|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
214276571|NCT00611208|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
214276572|NCT05152914|DRUG|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
214276573|NCT02225561|PROCEDURE|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
214276574|NCT02225561|PROCEDURE|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
214276575|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screen Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
214276576|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
214276577|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
214276578|NCT05111925|OTHER|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
214276579|NCT01172262|PROCEDURE|MRI|This is an observational study, no intervention will occur.
214276580|NCT06454019|BEHAVIORAL|Phone Outreach|Phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
214276581|NCT06454019|BEHAVIORAL|Standard Notice|Standard notification letter without phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
214276582|NCT00678093|OTHER|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
214276583|NCT02998983|DRUG|Racotumomab|
214276584|NCT02027519|OTHER|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
214276585|NCT00229593|DRUG|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
214276586|NCT00229593|DRUG|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
214276587|NCT04862455|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
214276588|NCT04862455|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
214276589|NCT04862455|BIOLOGICAL|Pembrolizumab|Given IV
214276590|NCT04862455|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214276591|NCT01390649|BIOLOGICAL|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
214276592|NCT02217878|DRUG|Morphine|IV bolus injection
214276593|NCT02217878|DRUG|Placebo|IV bolus injection
214276594|NCT02217878|DRUG|Ticagrelor|180 mg loading dose
214276595|NCT02771431|OTHER|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
214276596|NCT04394975|COMBINATION_PRODUCT|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
214276597|NCT04394975|DRUG|sunitinib|Drug: Sunitinib, oral capsule
214276598|NCT00334958|DRUG|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
214276599|NCT00334958|DRUG|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
214276600|NCT04873115|OTHER|Placebo|Sialanar placebo
214276601|NCT04873115|DRUG|Sialanar|Sialanar - a licensed glycopyrronium bromide product
214276602|NCT04873115|OTHER|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
214276603|NCT03802760|DEVICE|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
214276604|NCT01332643|GENETIC|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
214276605|NCT04397601|DRUG|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
214276606|NCT04397601|DRUG|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
214276607|NCT03363958|PROCEDURE|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
214276608|NCT03363958|PROCEDURE|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
214276609|NCT00133471|BIOLOGICAL|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
214276610|NCT00133471|DRUG|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
214276611|NCT03773263|DRUG|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
214276612|NCT03773263|PROCEDURE|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
214276613|NCT03773263|PROCEDURE|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
214276614|NCT03773263|DRUG|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
214276615|NCT04937231|OTHER|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
214276616|NCT04937231|OTHER|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
214276617|NCT04937231|OTHER|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
214276618|NCT02331342|DEVICE|NICOM cardiac output measurement|
214276619|NCT02331342|DEVICE|Innocor cardiac output measurement|
214276620|NCT03638609|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
214276621|NCT03158896|BIOLOGICAL|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
214276622|NCT01514071|BEHAVIORAL|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
214276623|NCT05235555|DEVICE|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
214276624|NCT02528396|DRUG|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
214276625|NCT02528396|DRUG|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
214276626|NCT04470323|DIAGNOSTIC_TEST|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
214276627|NCT01194466|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
214276628|NCT02385942|DEVICE|Smart phone|"* measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation"
214276629|NCT02933606|DRUG|BNC210|
214276630|NCT02933606|DRUG|Placebo|
214276631|NCT00917397|DRUG|Sertraline|varies
214276632|NCT00917397|BEHAVIORAL|trauma-focused cognitive behavioural therapy|once a week
214276633|NCT02221687|DIETARY_SUPPLEMENT|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
214276634|NCT02221687|DIETARY_SUPPLEMENT|Control formula|Standard milk formula without pre and probiotic
214276635|NCT01344785|PROCEDURE|Intramedullary nailing|All patients will be treated with Intramedullary nailing
214276636|NCT03087643|OTHER|Passive mobilization - PM|
214276637|NCT02740556|OTHER|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
214276638|NCT02740556|DEVICE|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
214276639|NCT02740556|OTHER|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
214276640|NCT00000557|BEHAVIORAL|social support|
214276641|NCT04563611|OTHER|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
214276642|NCT04563611|OTHER|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
214276643|NCT04563611|OTHER|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
214276644|NCT04563611|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
214276645|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of original formulation.
214276646|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of new formulation.
214276647|NCT01061411|DRUG|Dalteparin|Given SC
214276648|NCT01061411|OTHER|Pharmacological Study|Correlative studies
214276649|NCT01061411|DRUG|Sunitinib Malate|Given PO
214276650|NCT04746339|DRUG|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
214276651|NCT04746339|DRUG|Placebo|placebo twice daily for 30 days
214276652|NCT00113022|DRUG|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
214276653|NCT00113022|DRUG|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
214276654|NCT00882063|DRUG|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
214276655|NCT05683769|GENETIC|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
214276656|NCT00536562|BEHAVIORAL|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
214276657|NCT02083783|DRUG|TRI102|formulation containing active moiety (amphetamine)
214276658|NCT02083783|OTHER|Placebo|formulation without active moiety
214276659|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214276660|NCT06438588|OTHER|Dietary Intervention|Given FMD
214276661|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
214276662|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
214276663|NCT06438588|OTHER|Interview|Ancillary studies
214276664|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
214276665|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
214276666|NCT00149201|DRUG|5-FU continuous infusion|
214276667|NCT00149201|DRUG|MTX + 5-FU sequential therapy|
214276668|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
214276669|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
214276670|NCT02287857|DRUG|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
214276671|NCT02287857|DRUG|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
214276672|NCT01762878|DRUG|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
214276673|NCT01762878|DRUG|Placebo|Dry powder for oral inhalation once daily using DIKUS device
214276674|NCT01546883|DRUG|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
214276675|NCT04179708|OTHER|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
214276676|NCT04179708|OTHER|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
214276677|NCT03746457|BEHAVIORAL|Behavioral intervention|Individual counseling, group intervention, collective advocacy
214276678|NCT04154735|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
214276679|NCT04154735|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
214276680|NCT04154735|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
214276681|NCT04154735|DRUG|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
214276682|NCT04154735|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
214276683|NCT04154735|DRUG|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
214276684|NCT04154735|DRUG|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
214276685|NCT02256631|BIOLOGICAL|VRC01|Administered by subcutaneous injection in the thigh
214276686|NCT02256631|BIOLOGICAL|VRC01LS|Administered by subcutaneous injection in the thigh
214276687|NCT02256631|BIOLOGICAL|VRC07-523LS|Administered by subcutaneous injection in the thigh
214276688|NCT01646307|DRUG|Atorvastatin|
214276689|NCT01646307|DRUG|Rosuvastatin|
214276690|NCT03711461|DEVICE|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
214276691|NCT03711461|DEVICE|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
214276692|NCT02871414|BEHAVIORAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
214276693|NCT02871414|BEHAVIORAL|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
214276694|NCT01427972|DRUG|LY2623091|Administered orally
214276695|NCT01427972|DRUG|Eplerenone|Administered orally
214276696|NCT02946528|DEVICE|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
214276697|NCT02946528|DEVICE|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
214276698|NCT05160103|OTHER|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
214276699|NCT02206542|DEVICE|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
214276700|NCT02206542|OTHER|Physical therapy|
214276701|NCT02206542|DEVICE|Electroacupuncture|
214276702|NCT02647814|BEHAVIORAL|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
214276703|NCT04802317|DIAGNOSTIC_TEST|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
214276704|NCT01481597|DRUG|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
214276705|NCT01481597|DRUG|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
214276706|NCT01481597|DRUG|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
214276707|NCT01481597|DRUG|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
214276708|NCT01481597|DRUG|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
214276709|NCT03958851|DIAGNOSTIC_TEST|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
214276710|NCT03958851|DIAGNOSTIC_TEST|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
214276711|NCT03958851|DIAGNOSTIC_TEST|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
214276712|NCT03958851|DIAGNOSTIC_TEST|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
214276713|NCT03958851|DIAGNOSTIC_TEST|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
214276714|NCT03996733|OTHER|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
214276715|NCT03996733|OTHER|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
214276716|NCT03996733|OTHER|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
214276717|NCT03996733|OTHER|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
214276718|NCT01919606|DRUG|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
214276719|NCT00210483|DRUG|almotriptan malate|
214276720|NCT05394961|PROCEDURE|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
214276721|NCT04942899|DRUG|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
214276722|NCT04054505|DIETARY_SUPPLEMENT|EZPAK|One packet with breakfast for three months
214276723|NCT04054505|DIETARY_SUPPLEMENT|Placebo|One packet with breakfast for three months
214276724|NCT03931161|DRUG|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
214276725|NCT03931161|DRUG|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
214276726|NCT06040931|PROCEDURE|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
214276727|NCT06438458|PROCEDURE|Postural change from supine to sitting|Patients go from supine to sitting position in bed (passive)
214276728|NCT06438458|PROCEDURE|Mobilization to a chair|Patients go from the bed to sitting in a chair (active)
214276729|NCT02545556|PROCEDURE|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
214276730|NCT04427371|OTHER|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
214276731|NCT01826877|BIOLOGICAL|AdGMCAIX-transduced autologous dendritic cells|Given ID
214276732|NCT01826877|BIOLOGICAL|therapeutic autologous dendritic cells|Given ID
214276733|NCT01826877|OTHER|laboratory biomarker analysis|Correlative studies
214276734|NCT02325037|DRUG|GLPG1837 single ascending doses|Single dose, oral suspension
214276735|NCT02325037|DRUG|Placebo single dose|Single dose, oral suspension matching placebo
214276736|NCT02325037|DRUG|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
214276737|NCT02325037|DRUG|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
214276738|NCT00192569|DRUG|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
214276739|NCT00192569|DRUG|Ribavirin (HIV conifected patients only)|"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
214276740|NCT00824720|DRUG|High Dose Device|inserted for 14 days
214276741|NCT00824720|DRUG|Low Dose Device|inserted for 14 days
214276742|NCT00824720|DEVICE|Placebo Device|inserted for 14 days
214276743|NCT02011971|DRUG|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
214276744|NCT05593926|DIETARY_SUPPLEMENT|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
214276745|NCT03298165|DEVICE|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
214276746|NCT01699360|DRUG|Cyclosporine A, Tacrolimus, Sirolimus|
214276747|NCT03752983|DIAGNOSTIC_TEST|blood samples|blood samples
214276748|NCT02369432|DRUG|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
214276749|NCT01070498|DRUG|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
214276750|NCT00002554|DRUG|busulfan|
214276751|NCT00002554|DRUG|cyclophosphamide|
214276752|NCT00002554|DRUG|methotrexate|
214276753|NCT00002554|PROCEDURE|allogeneic bone marrow transplantation|
214276754|NCT00002554|RADIATION|radioimmunotherapy|
214276755|NCT01988688|DEVICE|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
214276756|NCT03928353|DRUG|PB2452 Infusion|30 minute - 24 hour infusion
214276757|NCT03928353|DRUG|Placebo - Sodium Chloride|30 minute - 24 hour infusion
214276758|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
214276759|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
214276760|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
214276761|NCT03928353|DRUG|PB2452 Infusion|30 minute - 16 hour infusion
214276762|NCT03928353|DRUG|Placebo - Sodium Chloride|Placebo - Sodium Chloride
214276763|NCT03364933|BEHAVIORAL|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
214276764|NCT04546815|DRUG|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
214276765|NCT02033109|DRUG|PC-1005|Intravaginal use
214276766|NCT02033109|DRUG|HEC gel|
214276767|NCT02624752|DIETARY_SUPPLEMENT|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
214276768|NCT03449797|PROCEDURE|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
214276769|NCT03449797|PROCEDURE|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
214276770|NCT02339935|BEHAVIORAL|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
214276771|NCT02339935|OTHER|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
214276772|NCT04778930|OTHER|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
214276773|NCT04778930|OTHER|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
214276774|NCT02745444|DIETARY_SUPPLEMENT|low-calorie formula diet|
214276775|NCT02745444|DIETARY_SUPPLEMENT|protein-restricted diet|
214276776|NCT02863952|OTHER|Single photon emission computed tomography myocardial perfusion imaging|
214276777|NCT02863952|DEVICE|novel cadmium-zinc-telluride (CZT) SPECT cameras|
214276778|NCT00110838|PROCEDURE|Supplementation with fish oil versus placebo|
214276779|NCT05548816|OTHER|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
214276780|NCT04355520|DRUG|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
214276781|NCT04355520|DRUG|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
214276782|NCT01480752|DRUG|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
214276783|NCT01480752|DRUG|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
214276784|NCT01480752|DRUG|no injection|inject nothing after inferior alveolar injection and before root canal therapy
214276785|NCT03282643|DRUG|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
214276786|NCT03282643|DRUG|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
214276787|NCT03282643|DRUG|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
214276788|NCT06504784|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides
214276789|NCT06504784|OTHER|Placebo|10g/day of placebo (glucose)
214276790|NCT06506149|DEVICE|Microwave ablation(MWA) device|The device for USG-guided MWA treatment would be performed under USG guidance, aiming to ablate the entire thyroid gland, i.e. the right lobe, left lobe, isthmus and pyramidal lobe.
214276791|NCT02368015|OTHER|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
214276792|NCT02368015|DRUG|cefazolin|
214276793|NCT02095093|DEVICE|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
214276794|NCT02095093|DEVICE|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
214276795|NCT02487667|DEVICE|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
214276796|NCT00448981|BEHAVIORAL|Hand hygiene and educational material|
214276797|NCT00448981|DEVICE|Mask, alcohol and hand sanitizer|
214276798|NCT04148053|DIAGNOSTIC_TEST|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
214276799|NCT00506480|PROCEDURE|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
214276800|NCT05000463|DRUG|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
214276801|NCT05000463|DRUG|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
214276802|NCT02777333|BEHAVIORAL|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
214276803|NCT00837811|BIOLOGICAL|LY2127399|60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
214276804|NCT05192941|DRUG|Inclisiran Sodium|Subcutaneously injected on Day 1, Day 90, and Day 270
214276805|NCT05192941|DRUG|Placebo|Placebo to inclisiran 300 mg subcutaneously
214276806|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
214276807|NCT04443010|DRUG|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
214276808|NCT04443010|DRUG|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
214276809|NCT07008001|DEVICE|Novel spectacle lens design|Use of spectacle lenses may reduce the rate of progression of juvenile myopia
214276810|NCT06681584|DIAGNOSTIC_TEST|CTCA|CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
214276811|NCT06681831|DEVICE|DaVinci SP|robotic single-port hysterectomy (R-SPH) with DaVinci SP
214276812|NCT06680518|OTHER|tourniquet|peroperation tourniquet
214276813|NCT06680518|OTHER|No tourniquet|no tourniquet during surgery
214276814|NCT07015450|DRUG|self-manufactured 40% dextrose gel|The self-manufactured 40% dextrose gel was applied in buccal mucosa region
214276815|NCT07015450|DRUG|Standard therapy|standard therapy for asymptomatic transient neonatal hypoglycemia
214276816|NCT07015827|OTHER|Mango (langra)|Participants will consume mango variety A . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
214276817|NCT07015827|OTHER|mango (chaunsa)|Participants will consume mango variety B . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
214276818|NCT07015827|OTHER|MANGO (SINDHRI)|Participants will consume mango variety C . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
214276819|NCT07014592|DEVICE|stimulating probes and electrodes|Subdural electrodes and/or ball tip probes will be used intraoperatively to provide electrical stimulation to the brain.
214276820|NCT06711614|OTHER|Intervention Diet|Designed to increase Omega-3 Fatty Acids (Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)), fruit, and vegetable intake, participants will receive grocery and meal deliveries for approximately 4-weeks via online ordering with dietician counselling.
214276821|NCT06711614|OTHER|Control Diet|Participants will receive weekly food subsidies for their groceries for 4-weeks (\~equivalent to the subsidies to provide groceries in the Intervention arm) but are free to purchase whatever they wish. The participants will continue to have dietician counseling during this time.
214276822|NCT05869422|DIETARY_SUPPLEMENT|Iron|60 ± 5 days of daily oral iron supplementation.
214276823|NCT05869422|OTHER|Placebo|60 ± 5 days of daily oral placebo intake.
214276824|NCT06931509|DEVICE|Computerized mirror therapy (IVS3) + Tendon vibration (Vibramoov)|"Visit 1 : Followed by 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition.~Visit 2 : 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition."
214276825|NCT01700725|OTHER|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
214276826|NCT01700725|DRUG|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
214276827|NCT02176499|DRUG|Telmisartan, low dose|
214276828|NCT02176499|DRUG|Telmisartan, high dose|
214276829|NCT02176499|DRUG|Placebo|
214276830|NCT03387332|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
214276831|NCT01340885|DRUG|Strattera|10-30 mg b.i.d. for 6 weeks
214276832|NCT01340885|DRUG|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
214276833|NCT01340885|OTHER|Placebo|2-6 pills for 6 weeks
214276834|NCT04388618|OTHER|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
214276835|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
214276836|NCT04177004|DRUG|Cyclophosphamide|Given IV
214276837|NCT04177004|DRUG|Etoposide|Given IV
214276838|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
214276839|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
214276840|NCT04177004|BIOLOGICAL|Palifermin|Given IV
214276841|NCT04177004|DRUG|Sirolimus|Given PO
214276842|NCT04177004|DRUG|Tacrolimus|Given IV and PO
214276843|NCT02849678|DRUG|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
214276844|NCT02849678|DRUG|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
214276845|NCT04229420|DEVICE|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
214276846|NCT01667029|DRUG|Sulfasalazine|
214276847|NCT01667029|DRUG|placebo|
214276848|NCT02609269|OTHER|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
214276849|NCT01341145|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
214276850|NCT01341145|BEHAVIORAL|Relaxation|12-week progressive muscle relaxation program (active control)
214276851|NCT03244215|DIAGNOSTIC_TEST|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
214276852|NCT03244215|DIAGNOSTIC_TEST|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
214276853|NCT03244215|OTHER|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
214276854|NCT00820690|DRUG|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
214276855|NCT00820690|DRUG|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
214276856|NCT00820690|DRUG|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
214276857|NCT00820690|PROCEDURE|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
214276858|NCT02899793|DRUG|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
214276859|NCT03310021|BIOLOGICAL|Andexanet alfa|fXa inhibitor antidote
214276860|NCT03310021|DRUG|Apixaban|factor Xa inhibitor
214276861|NCT03310021|DRUG|Rivaroxaban|factor Xa inhibitor
214276862|NCT03310021|DRUG|Edoxaban|factor Xa inhibitor
214276863|NCT03310021|DRUG|Placebo|Placebo
214276864|NCT06282146|PROCEDURE|transcranial magnetic stimulation|non-invasive form of brain stimulation
214276865|NCT04999176|DRUG|Rivaroxaban|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
214276866|NCT04999176|DRUG|Enoxaparin|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
214276867|NCT05468931|DEVICE|Prostate stimulator|Prostate stimulation device for sexual dysfunction
214276869|NCT01874054|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
214276870|NCT01874054|DRUG|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
214276871|NCT03563976|OTHER|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
214276872|NCT00003331|DRUG|fluorouracil|
214276873|NCT00003331|DRUG|leucovorin calcium|
214276874|NCT00003331|DRUG|topotecan hydrochloride|
214276875|NCT01769989|PROCEDURE|Electrodermabrasion|
214276876|NCT01769989|PROCEDURE|Dermabrasion|
214276877|NCT05409326|DRUG|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
214276878|NCT05409326|DRUG|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
214276879|NCT04312048|DRUG|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
214276880|NCT04312048|DRUG|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
214276881|NCT00702923|DRUG|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
214276882|NCT00702923|DRUG|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
214276883|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
214276884|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
214276885|NCT00702923|DRUG|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
214276886|NCT05092646|BIOLOGICAL|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
214276887|NCT05092646|DRUG|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
214276888|NCT01275040|OTHER|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
214276889|NCT01275040|OTHER|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
214276890|NCT05737732|DEVICE|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
214276891|NCT05737732|DEVICE|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
214276892|NCT00719108|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
214276893|NCT00719108|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
214276894|NCT02334358|DEVICE|YVOIRE Classic s|
214276895|NCT06376149|BEHAVIORAL|M3 Intervention group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
214276896|NCT06376149|BEHAVIORAL|M3 Waitlist Group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
214276897|NCT06324370|DIETARY_SUPPLEMENT|Virgin Coconut Oil|"Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study."
214276898|NCT04292483|DRUG|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
214276899|NCT02423993|BEHAVIORAL|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
214276900|NCT02423993|DEVICE|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
214276901|NCT02423993|DEVICE|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
214276902|NCT02423993|PROCEDURE|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
214276903|NCT02423993|PROCEDURE|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
214276904|NCT02423993|PROCEDURE|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
214276905|NCT02423993|PROCEDURE|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
214276906|NCT02178735|PROCEDURE|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
214276907|NCT02178735|PROCEDURE|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
214829541|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
214276908|NCT02002091|OTHER|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
214276909|NCT00003870|DRUG|cyclophosphamide|
214276910|NCT00003870|DRUG|methotrexate|
214276911|NCT00003870|PROCEDURE|allogeneic bone marrow transplantation|
214276912|NCT00003870|RADIATION|iodine I 131 monoclonal antibody BC8|
214276913|NCT00003870|RADIATION|radiation therapy|
214276914|NCT05073211|PROCEDURE|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
214276915|NCT00369824|BIOLOGICAL|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
214276916|NCT00369824|BIOLOGICAL|Menactra TM|One dose of vaccine administered intramuscularly
214276917|NCT00369824|BIOLOGICAL|Boostrix TM|One dose of vaccine administered intramuscularly
214276918|NCT01831648|OTHER|Blood sample|
214276919|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
214276920|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
214276921|NCT03953820|DRUG|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
214276922|NCT03953820|DRUG|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
214276923|NCT01847378|PROCEDURE|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
214276924|NCT02974283|OTHER|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
214276925|NCT00001071|DRUG|Filgrastim|
214276926|NCT04372082|OTHER|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration
214276927|NCT04372082|DRUG|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
214276928|NCT04372082|DRUG|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
214276929|NCT06245031|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
214276930|NCT02846714|BEHAVIORAL|FLARE|
214276931|NCT04874584|BEHAVIORAL|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
214276932|NCT04874584|BEHAVIORAL|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
214276933|NCT00025363|DRUG|vincristine sulfate|Given IV
214276934|NCT00025363|DRUG|irinotecan hydrochloride|Given IV
214276935|NCT00025363|DRUG|cyclophosphamide|Given IV
214276936|NCT00025363|DRUG|doxorubicin hydrochloride|Given IV
214276937|NCT00025363|DRUG|ifosfamide|Given IV
214276938|NCT00025363|DRUG|etoposide|Given IV
214276939|NCT00025363|DRUG|tirapazamine|Given IV
214276940|NCT00025363|BIOLOGICAL|filgrastim|Given SC
214276941|NCT00025363|BIOLOGICAL|sargramostim|Given SC
214276942|NCT00025363|OTHER|pharmacological study|Correlative studies
214276943|NCT00025363|OTHER|pharmacogenomic studies|Correlative studies
214276944|NCT00025363|OTHER|laboratory biomarker analysis|Correlative studies
214276945|NCT01128556|DRUG|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
214276946|NCT01128556|DRUG|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
214276947|NCT01822795|PROCEDURE|Lung volume reduction coïl treatment|
214276948|NCT01822795|OTHER|Regular medical treatment|
214276949|NCT01100671|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
214276950|NCT02158234|DRUG|Cisplatin|Cisplatin 15 mg/m\^2 prior to each fraction
214276951|NCT02158234|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
214276952|NCT06556589|BEHAVIORAL|Collaborative Care|Collaborative care components include patient-centered team care, population-based care, measurement-based treatment to target, evidence-based care, and accountable care.
214276953|NCT03385564|DRUG|BI 655064|subcutaneous injection
214276954|NCT03385564|DRUG|Placebo|subcutaneous injection
214276955|NCT00622401|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
214276956|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 30ng/kg
214276957|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 100ng/kg
214276958|NCT05574738|OTHER|Observational|
214276959|NCT04153669|BEHAVIORAL|Exercise-NMES|Exercise-NMES
214276960|NCT04153669|BEHAVIORAL|Exercise-No NMES|Exercise-No NMES
214276961|NCT04525846|OTHER|PFMT|"* program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
214276962|NCT04525846|OTHER|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
214276963|NCT02046161|PROCEDURE|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
214276964|NCT00169026|DRUG|Clozapine versus typical (conventional) and atypical antipsychotic medications|
214276965|NCT01822171|OTHER|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
214276966|NCT01822171|OTHER|Home medication if needed|Patient will be provided with medication to take home, when needed.
214276967|NCT01822171|OTHER|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
214276968|NCT01193595|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214276969|NCT01193595|DRUG|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214276970|NCT00183677|DRUG|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
214276971|NCT04259567|DEVICE|Cytokine absorption|Use of CytoSorb absorber
214276972|NCT00592215|DRUG|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
214276973|NCT04511104|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
214276974|NCT04511104|OTHER|Standard of Care|Standard of care rehabilitation
214276975|NCT03366038|PROCEDURE|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
214276976|NCT03312101|OTHER|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
214276977|NCT06310538|BEHAVIORAL|kou sha|Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
214276978|NCT06310538|DRUG|Hongjin Xiaojie Capsules|The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
214276979|NCT00223262|DRUG|Lamotrigine (Drug)|
214276980|NCT00820846|BIOLOGICAL|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
214276981|NCT00820846|BIOLOGICAL|Placebo|1 mL of sodium chloride for injection
214276982|NCT00820846|BIOLOGICAL|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
214276983|NCT05751265|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
214276984|NCT05751265|DRUG|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
214276985|NCT05751265|DRUG|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
214276986|NCT04746963|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
214276987|NCT04746963|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
214276988|NCT04746963|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
214276989|NCT03851757|DEVICE|waist-shaped interdental brush|use four times each per interdental space
214276990|NCT03851757|DEVICE|cylindric interdental brush|use four times each per interdental space
214276991|NCT02641808|OTHER|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
214276992|NCT02641808|OTHER|no follicular flushing|
214276993|NCT01015209|DEVICE|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
214276994|NCT03047057|DRUG|Lidocaine|IV Lidocaine infusion
214276995|NCT03047057|DRUG|IV normal saline|IV normal saline infusion
214276996|NCT00799422|DEVICE|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
214276997|NCT00799422|DEVICE|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
214276998|NCT00799422|DEVICE|Clear Care|Commercially marketed contact lens solution for contact lens care
214276999|NCT00799422|DEVICE|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
214277000|NCT05679583|RADIATION|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
214277001|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
214277002|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
214277003|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
214277004|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
214277005|NCT04764279|DIETARY_SUPPLEMENT|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
214277006|NCT02159417|OTHER|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics"
214277007|NCT00622284|DRUG|Placebo identical to BI 1356 5mg|Placebo tablet once daily
214277008|NCT00622284|DRUG|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
214277009|NCT00622284|DRUG|BI 1356|5mg, once daily in the morning for 104 weeks
214277010|NCT00622284|DRUG|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
214277011|NCT03965039|DEVICE|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
214277012|NCT03965039|DRUG|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
214277013|NCT03965039|DRUG|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
214277014|NCT03965039|DRUG|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
214277015|NCT00880009|DRUG|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
214277016|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
214277017|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
214277018|NCT00457301|BEHAVIORAL|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
214277019|NCT01099553|OTHER|Educational video|Instructions to view an educational video about preparing for a colonoscopy
214277020|NCT01099553|OTHER|Written instructions|Written instructions on preparing for a colonoscopy
214829542|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
214277021|NCT02469922|DEVICE|Positron emission tomography|
214277022|NCT02469922|RADIATION|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
214277023|NCT02398760|OTHER|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
214277024|NCT01268969|PROCEDURE|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
214277025|NCT01268969|PROCEDURE|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
214277026|NCT03209661|DRUG|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
214277027|NCT03209661|DRUG|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
214277028|NCT03209661|DRUG|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
214277029|NCT03962842|OTHER|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
214829543|NCT04403347|DIETARY_SUPPLEMENT|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
214829544|NCT04403347|DRUG|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
214277030|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
214277031|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
214277032|NCT03322631|DRUG|Tirzepatide|Administered SC.
214277033|NCT03322631|DRUG|Placebo|Administered SC.
214277034|NCT02412618|DRUG|Mifepristone|Progesterone antagonist
214277035|NCT02412618|DRUG|Misoprostol|Prostaglandin E1
214277036|NCT02412618|DIETARY_SUPPLEMENT|Placebo|Tasteless, odorless, sugar based pill
214277037|NCT01646762|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214277038|NCT01646762|OTHER|Laboratory Biomarker Analysis|Correlative studies
214277039|NCT02289339|DEVICE|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
214277040|NCT02378961|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
214277041|NCT02378961|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
214277042|NCT01253408|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
214277043|NCT01253408|DRUG|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
214277044|NCT02840955|DEVICE|Staphefekt SA.100|
214277045|NCT02840955|OTHER|Placebo|
214277046|NCT03217812|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
214277047|NCT03217812|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
214277048|NCT03217812|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
214277049|NCT03217812|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
214277050|NCT03208712|DRUG|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
214277051|NCT03208712|DRUG|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
214277052|NCT04817631|OTHER|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
214277053|NCT00285805|DRUG|Rosiglitazone versus placebo|
214277054|NCT00285805|DRUG|response (sodium excretion) to amiloride infusion|
214277055|NCT00285805|DRUG|response (sodium excretion) to furosemide infusion|
214277056|NCT06447740|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
214277057|NCT06447740|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
214277058|NCT06447740|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
214277059|NCT05269043|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
214277060|NCT03750617|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
214277061|NCT02563743|BEHAVIORAL|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
214277062|NCT02563743|BEHAVIORAL|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
214277063|NCT01217801|DRUG|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
214277064|NCT01217801|DRUG|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
214277065|NCT02367443|RADIATION|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
214277066|NCT00827333|OTHER|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
214277067|NCT00827333|OTHER|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
214277068|NCT00827333|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
214277069|NCT00827333|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
214277070|NCT00827333|PROCEDURE|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
214277071|NCT05257655|PROCEDURE|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
214277072|NCT04405414|OTHER|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
214277073|NCT04456959|DRUG|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
214277074|NCT01844128|DIETARY_SUPPLEMENT|weight loss|
214277075|NCT04682028|OTHER|professional care|The trained nurses provide professional care for the patients.
214277076|NCT04682028|OTHER|coventional care|nurses provide coventional care for the patients.
214277077|NCT02285842|DEVICE|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
214829545|NCT02072096|DRUG|Glimepiride|Administered orally
214277078|NCT05026255|PROCEDURE|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
214277079|NCT04505189|DRUG|Psilocybin|Psilocybin assisted psychotherapy
214277080|NCT05944757|DRUG|PRP plasma rich platelets|Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
214277081|NCT05944757|DRUG|Autologous serum|Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
214277082|NCT03081260|OTHER|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
214277083|NCT03081260|OTHER|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
214277084|NCT01595607|OTHER|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
214829546|NCT02072096|DRUG|Metformin|Administered orally
214829547|NCT02072096|DRUG|Pioglitazone|Administered orally
214829548|NCT02072096|DRUG|Acarbose|Administered orally
214829549|NCT02072096|DRUG|Linagliptin|Administered orally
214829550|NCT02072096|DRUG|Sitagliptin|Administered orally
214829551|NCT02072096|DRUG|Liraglutide|Administered subcutaneously (SC)
214829552|NCT02072096|DRUG|Insulin Glargine|Administered SC
214829553|NCT02072096|DRUG|Exenatide once weekly (QW)|Administered SC
214829554|NCT02072096|DRUG|Exenatide twice daily (BID)|Administered SC
214829555|NCT02287480|BIOLOGICAL|VSV-ZEBOV|See arm/group descriptions.
214829556|NCT04413266|DIETARY_SUPPLEMENT|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
214829557|NCT06626750|BEHAVIORAL|Summer Treatment Program for Pre-Kindergarteners and Kindergarteners|Children will be concurrently enrolled in our Summer Treatment Program for Pre-Kindergarteners and Kindergarteners (STP-PreK/K). The STP-PreK/K simulates a school-like schedule and runs for 7-weeks and last 7 hours/day, Monday through Friday, with periods of seatwork, large/small group activities, circle time, and classroom meetings along with a recreational period. Academic curriculum are individualized depending upon child's current level. The behavioral modification program uses a visual response cost system in which children lose points for not following classroom rules (these rules are operationalized and determined during the development phase). Dots earned are then used for daily and weekly rewards. In addition to the academic and behavioral modification program, one group of children will participate in social-emotional/self-regulation training exercises on a daily basis designed to teach them social skills and how to control their emotions, behaviors, and attention.
214829558|NCT06626750|BEHAVIORAL|School Readiness Parenting Program (SRPP)|The School Readiness Parenting Program (SRPP) helps parents of young children develop skills that support their child\&#39;s readiness for kindergarten and first grade. It focuses on positive parenting practices that enhance social, emotional, and cognitive development. The sessions cover managing child behaviors, promoting early literacy, and fostering problem-solving skills. Parents learn effective communication, consistent routines, and how to create a supportive home environment.
214829559|NCT06626750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a structured, goal-oriented therapy that helps individuals identify and change negative thought patterns and behaviors. It focuses on the link between thoughts, emotions, and actions to improve mental health. Specific to the current project, CBT can reduce stress by teaching parents to reframe unhelpful thoughts, manage challenging emotions, and develop effective coping strategies for difficult situations, leading to more positive parenting experiences.
214829560|NCT02728999|PROCEDURE|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
214829561|NCT02728999|PROCEDURE|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
214829562|NCT02871076|DEVICE|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
214829563|NCT05138094|PROCEDURE|Minimally invasive simultaneous resection|One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.
214829564|NCT05138094|PROCEDURE|Minimally invasive two-stage resection|Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
214829565|NCT05289440|DRUG|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
214277085|NCT06053996|RADIATION|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
214277086|NCT04338074|DRUG|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
214277087|NCT04338074|DRUG|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
214277088|NCT04282642|BEHAVIORAL|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
214277089|NCT04282642|BEHAVIORAL|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
214277090|NCT03035409|DRUG|Anamorelin Hydrochloride|Given PO
214277091|NCT03035409|BEHAVIORAL|Exercise Intervention|Undergo physical activity
214277092|NCT03035409|OTHER|Laboratory Biomarker Analysis|Correlative studies
214277093|NCT03035409|OTHER|Nutritional Assessment|Undergo nutritional counseling
214277094|NCT03035409|OTHER|Quality-of-Life Assessment|Ancillary studies
214829566|NCT05289440|DRUG|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
214829567|NCT05289440|DRUG|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
214829568|NCT00955448|DEVICE|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
214829569|NCT00955448|PROCEDURE|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
214829570|NCT04501848|PROCEDURE|adenotonsillectomy|adenotonsillectomy surgery
214829571|NCT03785730|PROCEDURE|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
214829572|NCT03785730|PROCEDURE|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
214829573|NCT03578939|PROCEDURE|Biopsy EUS guided|NGS Sequencing on Biopsy samples
214829574|NCT01634139|DRUG|Tiotropium low dose QD|2 actuations once daily in the evening
214829575|NCT01634139|DRUG|Tiotropium high dose QD|2 actuations once daily in the evening
214829576|NCT01634139|DRUG|Placebo|2 actuations once daily in the evening
214277095|NCT03035409|OTHER|Questionnaire Administration|Ancillary studies
214277096|NCT02137265|DRUG|Clomiphene|Clomiphene citrate 50 mg orally daily
214829577|NCT05497063|DRUG|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
214829578|NCT05497063|DRUG|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
214829579|NCT04724616|OTHER|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
214829580|NCT06272617|DEVICE|verum acupuncture|a type of acupuncture which is useful
214829581|NCT06272617|DEVICE|sham acupuncture|a type of acupuncture which is useless
214829582|NCT03680313|PROCEDURE|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
214829583|NCT06562400|DIETARY_SUPPLEMENT|Palmitoyl ethanolamide|PEA supplementation (600mg twice a day for three months)
214829584|NCT06562400|BEHAVIORAL|Ketogenic diet|Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
214829585|NCT02754076|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
214829586|NCT03520972|DRUG|PB-119 75ug|60 eligible patients will be included in this group
214829587|NCT03520972|DRUG|PB-119 150ug|60 eligible patients will be included in this group
214829588|NCT03520972|DRUG|PB-119 200ug|60 eligible patients will be included in this group
214829589|NCT03520972|DRUG|placebo|60 eligible patients will be included in this group
214829590|NCT02235922|OTHER|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
214829591|NCT02235922|OTHER|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
214829592|NCT03392051|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
214829593|NCT03392051|DRUG|Clopidogrel|75mg tablet administered orally
214829594|NCT06622330|OTHER|Positioning|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
214829595|NCT05778630|OTHER|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
214829596|NCT05778630|OTHER|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
214829597|NCT04967469|DRUG|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
214829598|NCT04967469|DRUG|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
214277097|NCT02137265|DRUG|Placebo|One pill every other day
214277098|NCT01430000|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
214277099|NCT01577680|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
214277100|NCT01577680|DRUG|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
214277101|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 1|milk supplement with probiotics
214277102|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 2|milk supplement without probiotics
214277103|NCT04977193|BIOLOGICAL|LY011|CAR-T
214277104|NCT00291577|DRUG|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
214277105|NCT00291577|DRUG|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
214829599|NCT00822744|DRUG|SSR411298|"Form: capsule~Route: oral administration with food"
214829600|NCT00822744|DRUG|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
214829601|NCT00822744|DRUG|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
214829602|NCT02991196|DRUG|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
214277106|NCT04967443|DRUG|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
214829603|NCT04443790|DRUG|Leptin Human|
214829604|NCT01694563|DEVICE|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
214829605|NCT03198663|BEHAVIORAL|POSSE|Popular-opinion leader
214829606|NCT00018616|BEHAVIORAL|MEMS caps|
214829607|NCT01754935|DRUG|VX-509|50 mg oral tablet
214829608|NCT01754935|DRUG|VX-509 matching placebo|0 mg oral tablet
214829609|NCT00383916|DRUG|pantoprazole|
214277107|NCT04967443|DRUG|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
214277108|NCT04967443|DRUG|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
214277109|NCT05047835|DIAGNOSTIC_TEST|electrocardiogram|Prone position electrocardiogram
214829610|NCT05716490|DEVICE|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
214829611|NCT05716490|OTHER|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
214277110|NCT03954236|DRUG|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
214277111|NCT03954236|OTHER|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
214277112|NCT03464071|DEVICE|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
214277113|NCT03464071|DEVICE|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
214829612|NCT01649921|DRUG|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
214829613|NCT01649921|OTHER|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
214829614|NCT01266902|DRUG|Rilpivirine|25 mg once daily
214829615|NCT00293878|DRUG|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
214829616|NCT03552328|OTHER|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
214277114|NCT00726869|DRUG|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
214277115|NCT01202812|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
214277116|NCT01202812|OTHER|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
214277117|NCT02304718|BEHAVIORAL|Stationary bike|
214277118|NCT06361160|DEVICE|Active Transcranial Magnetic Stimulation (TMS)|Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
214277119|NCT06361160|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|"Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).~An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation."
214277120|NCT03734276|OTHER|High intensity activity|Cyclo-ergometer session in high intensity setting
214277121|NCT03734276|OTHER|control arm|Usual care
214277122|NCT04502693|COMBINATION_PRODUCT|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine was administered intramuscularly.
214277123|NCT04502693|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine was administered intramuscularly.
214829617|NCT03552328|OTHER|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
214829618|NCT00979147|PROCEDURE|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
214277124|NCT04502693|COMBINATION_PRODUCT|Placebo|Placebo was administered intramuscularly.
214277125|NCT04502693|COMBINATION_PRODUCT|MenABCWY-1|Lot 1 of the MenABCWY vaccine was administered intramuscularly.
214277126|NCT04502693|COMBINATION_PRODUCT|MenABCWY-2|Lot 2 of the MenABCWY vaccine was administered intramuscularly.
214277127|NCT04502693|COMBINATION_PRODUCT|MenABCWY-3|Lot 3 of the MenABCWY vaccine was administered intramuscularly.
214277128|NCT06086470|DEVICE|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
214277129|NCT05717946|DIETARY_SUPPLEMENT|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
214277130|NCT05717946|OTHER|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
214277131|NCT04490850|PROCEDURE|Blood sample|Blood sample
214277132|NCT00749645|DRUG|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
214277133|NCT00749645|DRUG|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
214277134|NCT01552694|DRUG|Sitagliptin|Oral, 100 mg/day for 2 months
214277135|NCT01552694|DRUG|Placebo|oral, matching placebo daily for 2 months
214277136|NCT02416921|BEHAVIORAL|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
214277137|NCT02416921|BEHAVIORAL|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
214277138|NCT03599999|DRUG|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
214277139|NCT00672243|DRUG|Erlotinib + sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
214277140|NCT03159221|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
214277141|NCT00502047|DRUG|Plantago ovata husk|
214277142|NCT03943147|DRUG|BMS-986165|Specified dose on specified days
214277143|NCT03943147|DRUG|Placebo|Specified dose on specified days
214277144|NCT03943147|DRUG|Mycophenolate Mofetil|Specified dose on specified days
214277145|NCT02758990|DIETARY_SUPPLEMENT|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
214277146|NCT02758990|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
214277147|NCT02758990|DIETARY_SUPPLEMENT|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
214277148|NCT02758990|DIETARY_SUPPLEMENT|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
214277149|NCT02758990|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
214277150|NCT02758990|DIETARY_SUPPLEMENT|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
214277151|NCT02758990|OTHER|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
214277152|NCT02758990|OTHER|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
214277153|NCT02758990|DIETARY_SUPPLEMENT|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
214277154|NCT02758990|OTHER|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
214277155|NCT02758990|DEVICE|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
214277156|NCT02758990|OTHER|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
214277157|NCT01918436|BEHAVIORAL|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
214277158|NCT01918436|OTHER|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
214277159|NCT02004119|DRUG|KHK4577|
214277160|NCT02004119|DRUG|Placebo|
214277161|NCT02527005|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
214277162|NCT02527005|DRUG|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
214277163|NCT02303366|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
214277164|NCT02303366|DRUG|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
214277165|NCT01446978|BIOLOGICAL|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
214277166|NCT01446978|BIOLOGICAL|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
214277167|NCT02337660|PROCEDURE|Liver biopsy|One ultrasound guided liver biopsy
214277168|NCT02337660|OTHER|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
214277169|NCT02756013|DRUG|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
214277170|NCT02756013|DRUG|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
214829619|NCT00979147|PROCEDURE|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
214277171|NCT02548780|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
214277172|NCT02548780|OTHER|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
214277173|NCT04563351|OTHER|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
214277174|NCT00004983|BEHAVIORAL|diabetes self-management education|
214277175|NCT05122832|DIAGNOSTIC_TEST|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
214277176|NCT05122832|DIAGNOSTIC_TEST|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
214277177|NCT05122832|DIAGNOSTIC_TEST|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
214277178|NCT00864331|RADIATION|radiation|39 Gy in 13 daily fractions of 3 Gy
214277179|NCT00864331|OTHER|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
214277180|NCT00864331|DRUG|Chemotherapy|Chemotherapy given alone
214277181|NCT00864331|OTHER|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
214277182|NCT00439478|DRUG|Radioiodine|
214277183|NCT00629707|OTHER|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
214277184|NCT04317469|DIAGNOSTIC_TEST|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
214277185|NCT02845934|OTHER|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
214277186|NCT03218514|DRUG|Dalteparin|
214277187|NCT00714883|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
214277188|NCT00418457|DRUG|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
214277189|NCT00418457|DRUG|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
214277190|NCT04597723|DRUG|oxygen|Patients will be given different concentrations of oxygen.
214277191|NCT01552941|DEVICE|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
214277192|NCT00934492|DRUG|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
214277193|NCT00934492|DRUG|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
214277194|NCT06515743|OTHER|Delayed surgical obturator|Prosthetic rehabilitation after surgical treatment of mucormycosis is essential for the early restoration of oral function and facial esthetics which is performed by using the surgical obturator.
214277195|NCT03460730|BIOLOGICAL|Pneumovax|23-valent pneumococcal polysaccharide vaccine
214277196|NCT00207350|DEVICE|Interstitial Laser Therapy|Device
214277197|NCT04925583|RADIATION|Stereotactic body radiotherapy (SBRT)|"* level 0 (de-escalation): 10 x 5.0Gy~* level 1 (start): 10 x 5.5Gy~* level 2: 10 x 6.0Gy~* level 3: 10 x 6.5Gy"
214277198|NCT01317485|PROCEDURE|Laparoscopic lavage and drainage|"\[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
214277199|NCT01317485|PROCEDURE|Sigmoidectomy with primary anastomosis|\[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
214277200|NCT01317485|PROCEDURE|Sigmoidectomy with end-colostomy|\[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
214277201|NCT04563702|BIOLOGICAL|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
214277202|NCT05663190|OTHER|mental foramen location|location of mental foramen in relation to primary molars
214277203|NCT04449926|BIOLOGICAL|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
214829620|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
214277204|NCT01223430|DRUG|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
214277205|NCT01007266|BEHAVIORAL|Assignment of a Lay Patient Partner|
214277206|NCT02420171|OTHER|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
214277207|NCT03724032|DEVICE|HD-tDCS*|Non-invasive brain stimulation (active protocol)
214277208|NCT03724032|DEVICE|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
214277209|NCT01944696|OTHER|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
214277210|NCT00727493|DRUG|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
214277211|NCT00727493|DRUG|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
214277212|NCT02267083|DRUG|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
214277213|NCT06184932|BEHAVIORAL|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
214277214|NCT06184932|BEHAVIORAL|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
214277215|NCT05649397|OTHER|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
214277216|NCT05649397|OTHER|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
214277217|NCT01102517|PROCEDURE|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
214277218|NCT01102517|PROCEDURE|axillary thoracotomy|axillary thoracotomy lobectomy
214277219|NCT05292508|DIAGNOSTIC_TEST|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
214277220|NCT02929667|DRUG|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
214277221|NCT02929667|DRUG|Placebo|Standard 6 weeks titration.
214277222|NCT04335097|DEVICE|Biosensors|Sensor that detect vital signs
214277223|NCT00727428|BIOLOGICAL|FluLaval® TF|One IM injection.
214277224|NCT03940222|DEVICE|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
214277225|NCT03940222|PROCEDURE|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
214277226|NCT05152030|DIAGNOSTIC_TEST|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
214277227|NCT05152030|DIAGNOSTIC_TEST|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
214277228|NCT04617171|DRUG|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
214277229|NCT04617171|DRUG|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
214277230|NCT05509114|DEVICE|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
214277231|NCT00001880|DRUG|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
214277232|NCT00001880|DRUG|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
214277233|NCT06193291|PROCEDURE|Feet heating|Feet placed in hot water
214277234|NCT06193291|PROCEDURE|Calf heating|Feet to calves placed in hot water
214277235|NCT01378637|DEVICE|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
214277236|NCT06478485|DIAGNOSTIC_TEST|No Intervention: MCSM|No Intervention: MCSM
214277237|NCT02657369|DRUG|Lenvatinib 24 mg|
214277238|NCT02727361|RADIATION|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
214277239|NCT02727361|OTHER|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
214277240|NCT02201485|DEVICE|Stent|
214277241|NCT02201485|DEVICE|Balloon|
214277242|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
214277243|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
214277244|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
214277245|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
214277246|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
214277247|NCT03673215|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
214277248|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
214277249|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
214277250|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
214277251|NCT02639065|DRUG|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
214277252|NCT02094183|OTHER|GLP-1|GLP-1
214277253|NCT02094183|DIETARY_SUPPLEMENT|low calorie diet|low calorie diet
214277254|NCT06556537|DEVICE|Face-to-face and video-assisted training|"During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes."
214277255|NCT00481078|DRUG|vorinostat|Given PO
214277256|NCT00481078|DRUG|paclitaxel|Given IV
214277257|NCT00481078|DRUG|carboplatin|Given IV
214277258|NCT00481078|OTHER|placebo|Given PO
214277259|NCT00481078|OTHER|laboratory biomarker analysis|Correlative studies
214277260|NCT01845831|DRUG|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
214277261|NCT01845831|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
214277262|NCT01845831|DRUG|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
214277263|NCT01845831|DRUG|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
214277264|NCT01845831|DRUG|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
214277265|NCT01845831|DRUG|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
214277266|NCT00760097|DEVICE|Transcranial direct stimulation|sessions of 20 minutes each
214277267|NCT04959916|BEHAVIORAL|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
214277268|NCT02172768|OTHER|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
214829621|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
214829622|NCT00614861|OTHER|Non-cancer pain management survey|Non-cancer pain management survey
214277269|NCT02172768|OTHER|daily dosing|micafungin daily for 8 days
214277270|NCT02172768|DRUG|micafungin|
214277271|NCT03501459|DRUG|Rituximab|
214277272|NCT02779829|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
214277273|NCT00067665|OTHER|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
214656924|NCT04653519|DEVICE|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
214277274|NCT04352816|DEVICE|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
214277275|NCT04026997|DRUG|CIN-102 Dose 1|CIN-102 Dose 1
214277276|NCT04026997|DRUG|CIN-102 Dose 2|CIN-102 Dose 2
214277277|NCT04026997|DRUG|CIN-102 Dose 3|CIN-102 Dose 3
214277278|NCT04026997|DRUG|Placebo|Placebo
214277279|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
214277280|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
214277281|NCT02610725|OTHER|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
214277282|NCT04094883|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
214277283|NCT04048928|BEHAVIORAL|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
214277284|NCT00003105|BIOLOGICAL|filgrastim|
214277285|NCT00003105|DRUG|cisplatin|
214277286|NCT00003105|DRUG|doxorubicin hydrochloride|
214277287|NCT00003105|DRUG|gemcitabine hydrochloride|
214277288|NCT00003105|DRUG|ifosfamide|
214277289|NCT00003105|DRUG|paclitaxel|
214277290|NCT02211937|DRUG|BI 44847 solution, low dose|
214277291|NCT02211937|DRUG|BI 44847 suspension, high dose|
214277292|NCT02211937|DRUG|BI 44847 tablet, low dose|
214277293|NCT02211937|DRUG|BI 44847 tablet, high dose|
214277294|NCT02211937|OTHER|high fat breakfast|
214277295|NCT04747509|OTHER|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
214277296|NCT04747509|OTHER|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
214277297|NCT04075760|PROCEDURE|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
214277298|NCT04075760|DRUG|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
214277299|NCT01297660|OTHER|Video-urodynamic examination|
214277300|NCT00826943|DRUG|Cetirizine|Cetirizine 10 mg tab daily x 7 days
214277301|NCT00826943|DRUG|Levocetirizine|5 mg tab daily x 7 days
214277302|NCT00826943|DRUG|Placebo|Placebo tablet daily x 7 days
214277303|NCT01348165|DRUG|BI 137882|Powder for oral solution
214277304|NCT01348165|DRUG|Placebo|Powder for oral solution
214277305|NCT04191031|DEVICE|ioveraº|Cryoneurolysis
214277306|NCT04191031|DEVICE|ioveraº sham|ioveraº sham
214277307|NCT01696825|DRUG|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
214277308|NCT01696825|DRUG|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
214277309|NCT01696825|DRUG|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
214277310|NCT00133497|BIOLOGICAL|MF-59|Microfluoridized adjuvant 59 (MF59).
214277311|NCT00133497|DRUG|Placebo|0.5 mL of saline placebo.
214277312|NCT00133497|BIOLOGICAL|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
214277313|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
214277314|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
214277315|NCT03873974|DIAGNOSTIC_TEST|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
214277316|NCT03873974|DIAGNOSTIC_TEST|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
214277317|NCT03873974|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
214277318|NCT03873974|DIAGNOSTIC_TEST|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
214277319|NCT02271568|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
214277320|NCT02271568|OTHER|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
214277321|NCT05723978|PROCEDURE|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
214277322|NCT02517983|OTHER|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
214277323|NCT03810560|DEVICE|laser device Er,Cr:YSGG laser|laser device with open flap debridement
214277324|NCT06208683|BIOLOGICAL|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
214277325|NCT06208683|BIOLOGICAL|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
214277326|NCT04933994|DEVICE|computed Tomography|All cases were detected with computed Tomography
214277327|NCT00382252|PROCEDURE|computed tomography|
214277328|NCT00382252|PROCEDURE|positron emission tomography|
214277329|NCT00382252|PROCEDURE|radiofrequency ablation|
214277330|NCT05270343|DRUG|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
214277331|NCT03884491|DRUG|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
214277332|NCT03884491|DRUG|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
214277333|NCT03884491|DRUG|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
214277334|NCT03884491|DRUG|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
214277335|NCT04848597|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
214277336|NCT04959422|OTHER|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
214277337|NCT04303832|OTHER|eye exercises|Eye exercises for correcting eye deviation
214277338|NCT04303832|DEVICE|eye glasses|Eye glasses for correcting eye deviation
214277339|NCT00484432|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
214277340|NCT00484432|DRUG|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
214277341|NCT04741282|OTHER|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
214277342|NCT04741282|OTHER|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
214277343|NCT03896386|OTHER|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
214277344|NCT05937542|BEHAVIORAL|Qualitative Investigation of Participant Experiences|There is no intervention. This is a retrospective qualitative study.
214277345|NCT02221791|DIETARY_SUPPLEMENT|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
214277346|NCT02221791|DIETARY_SUPPLEMENT|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
214277347|NCT02221791|DIETARY_SUPPLEMENT|Placebo|Participants will consume 70g white chocolate + placebo capsules
214277348|NCT04568733|BEHAVIORAL|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
214829623|NCT02674711|BEHAVIORAL|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
214829624|NCT03124511|PROCEDURE|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
214277349|NCT04568733|BEHAVIORAL|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
214277350|NCT04568733|BEHAVIORAL|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
214277351|NCT01371175|BIOLOGICAL|DNA.HIVA|0.5mg DNA.HIVA or placebo
214277352|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^6 pfu MVA or placebo
214277353|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^7 pfu MVA or placebo
214277354|NCT01371175|BIOLOGICAL|MVA.HIVA|2.5x10\^8 pfu MVA or placebo
214277355|NCT01695902|DRUG|Levosert-20|
214277356|NCT01695902|DRUG|Mirena|
214277357|NCT03384212|DRUG|Cladribine|
214277358|NCT03384212|DRUG|Fludarabine|
214277359|NCT03384212|DRUG|Busulfan|
214277360|NCT03384212|DRUG|Cytarabine|
214277361|NCT01703039|DRUG|Riluzole|
214277362|NCT01703039|DRUG|Sertraline|
214277363|NCT01703039|OTHER|placebo|
214277364|NCT05570500|BEHAVIORAL|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
214277365|NCT01205711|DRUG|FOLFIRI regimen|
214277366|NCT01205711|DRUG|fluorouracil|
214277367|NCT01205711|DRUG|irinotecan hydrochloride|
214277368|NCT01205711|DRUG|leucovorin calcium|
214277369|NCT01205711|DRUG|zibotentan|
214277370|NCT01205711|OTHER|laboratory biomarker analysis|
214277371|NCT01205711|OTHER|pharmacogenomic studies|
214277372|NCT04554979|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
214277373|NCT02091934|PROCEDURE|Wavefront-guided PRK|Wavefront-guided PRK
214277374|NCT02091934|PROCEDURE|Wavefront-optimized PRK|Wavefront-optimized PRK
214277375|NCT04706091|DRUG|Suvorexant|10-mg or 20-mg suvorexant capsules
214277376|NCT04706091|OTHER|Placebo|Matching placebo capsules
214277377|NCT00580021|OTHER|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
214277378|NCT04527705|PROCEDURE|Non-surgical root canal retreatment|Non-surgical root canal retreatment
214277379|NCT05465434|DRUG|Zinc Supplement|Zinc sulphate 50 mg
214277380|NCT01419691|DRUG|auranofin|6 mg twice a day for a total of 12 mg total daily dose
214277381|NCT03609905|BIOLOGICAL|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline
214277382|NCT03609905|OTHER|Conventional drugs|5-amino-salicylic acid or glucocorticoid
214277383|NCT04711044|OTHER|Papain|Papain will be applied using cowhage spicules inactivated by heat
214277384|NCT04711044|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
214277385|NCT04711044|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
214277386|NCT04711044|OTHER|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
214277387|NCT00150202|DRUG|pegaptanib sodium|
214277388|NCT00953901|DRUG|Fresh Frozen Plasma Transfusion|
214277389|NCT05547685|DIAGNOSTIC_TEST|Methylene blue intradermal injection|Methylene blue intradermal injection
214277390|NCT04007978|GENETIC|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
214277391|NCT02612727|DEVICE|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
214277392|NCT02612727|DEVICE|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
214277393|NCT03440268|DRUG|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
214277394|NCT03440268|DRUG|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
214277395|NCT05492344|OTHER|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver"
214277396|NCT05492344|OTHER|Standard care|"Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg"
214277397|NCT01063868|DRUG|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
214277398|NCT01063868|DRUG|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
214829625|NCT04332198|OTHER|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
214277399|NCT05654337|OTHER|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
214277400|NCT03830424|PROCEDURE|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
214277401|NCT03830424|DIETARY_SUPPLEMENT|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
214277402|NCT03565744|BEHAVIORAL|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
214277403|NCT03009981|DRUG|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
214277404|NCT03009981|DRUG|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
214277405|NCT03009981|DRUG|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
214277406|NCT03009981|DRUG|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
214277407|NCT01009632|BEHAVIORAL|Resonant voice|4-hr of resonant voice exercise
214277408|NCT01009632|BEHAVIORAL|Voice rest|4-hr of complete refrain from any voice use
214277409|NCT01009632|BEHAVIORAL|Spontaneous speech|
214277410|NCT04904328|DEVICE|Lumishade® Active Lens|"Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
214277411|NCT04904328|DEVICE|Lumishade® Sham Lens|"Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
214277412|NCT04080245|BIOLOGICAL|Treatment Group Live Attenuated Flu Vaccine (LAIV)|We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.
214277413|NCT00147446|BEHAVIORAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
214277414|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
214277415|NCT01446289|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
214277416|NCT01446289|BIOLOGICAL|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
214277417|NCT02302807|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
214277418|NCT02302807|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
214277419|NCT02302807|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
214277420|NCT02302807|DRUG|Vinflunine|Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
214277421|NCT01809483|DEVICE|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
214277422|NCT01809483|DEVICE|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
214277423|NCT06394817|OTHER|No intervention|No intervention
214277424|NCT00382577|DRUG|Itopride|
214277425|NCT00382577|DRUG|Placebo|
214277426|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple|Active juice with added fibre and ginseng
214277427|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple control|Control products without active ingredients
214277428|NCT06204809|DRUG|PGN-EDODM1 for infusion|Single dose of PGN-EDODM1 by intravenous (IV) infusion
214277429|NCT06204809|OTHER|Placebo|Administered by IV infusion
214277430|NCT03329573|DRUG|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
214277431|NCT03329573|DRUG|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
214277432|NCT01031355|DRUG|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
214277433|NCT01031355|DRUG|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
214277434|NCT01031355|DRUG|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
214277435|NCT00376727|BIOLOGICAL|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
214277436|NCT00376727|GENETIC|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
214277437|NCT00376727|OTHER|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
214277438|NCT00376727|OTHER|laboratory biomarker analysis|Cetuximab Pharmacodynamics
214277439|NCT05902780|DRUG|Caudal Bupivacaine injection|\- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
214277440|NCT05902780|DRUG|Caudal Dexmedetomidine Injection|\- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
214277441|NCT01423058|DRUG|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
214277442|NCT03535116|DRUG|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
214277443|NCT03535116|DRUG|Saline|injectable normal saline
214277444|NCT00539136|DRUG|GSK561679 tablet or solution|
214277445|NCT05085652|PROCEDURE|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
214277446|NCT00650260|DEVICE|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
214277447|NCT00650260|DEVICE|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
214277448|NCT02947685|DRUG|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
214277449|NCT02947685|DRUG|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
214277450|NCT02947685|DRUG|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
214277451|NCT02947685|DRUG|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
214277452|NCT02947685|DRUG|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
214277453|NCT02947685|DRUG|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
214277454|NCT02947685|DRUG|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
214277455|NCT02564549|PROCEDURE|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
214829626|NCT05766553|OTHER|Virtual reality pod|The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
214829627|NCT05766553|OTHER|nicotine patches and chewing gum|Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
214829628|NCT03292705|BEHAVIORAL|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
214829629|NCT03292705|BEHAVIORAL|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
214829630|NCT00003953|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
214829631|NCT00003953|DRUG|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
214829632|NCT00003953|DRUG|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
214829633|NCT00003953|DRUG|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
214829634|NCT00003953|DRUG|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
214829635|NCT00003953|PROCEDURE|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
214829636|NCT00003953|PROCEDURE|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
214829637|NCT00003953|RADIATION|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
214829638|NCT00387153|DRUG|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
214829639|NCT01567553|OTHER|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
214829640|NCT04469751|DIAGNOSTIC_TEST|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
214829641|NCT02940457|DEVICE|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
214829642|NCT02940457|DEVICE|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
214829643|NCT04567329|DRUG|NOV03|100% perfluorohexyloctane
214829644|NCT04567329|DRUG|Saline Solution|0.6% sodium chloride solution
214829645|NCT06558812|DEVICE|prefabricated space maintainer|"i. Prefabricated band will be selected for the abutment tooth by measuring the mesiodistal diameter of the abutment tooth with a caliper and will be adjusted with the internal diameter of the prefabricated band.~ii. The loop will be selected based on the available mesiodistal space and buccolingual width of the abutment tooth, excessive length with be cut by cutting plier and will then place inside the band's tube by using a HOWE pliers.~iii. Cotton roll isolation will use, then will be cemented with glass ionomer,"
214829646|NCT06558812|DEVICE|conventional space maintainer|"i. A full arch Impressions will be taken with alginate material. ii. Impressions will be poured up using dental stone within 30 min of the impression taking.~iii. The children will be given an appointment for space maintainer insertion. iv. In the second visit , Cotton roll isolation will use, cementation will be performed with glass ionomer ."
214829647|NCT00137644|BEHAVIORAL|Preventing AIDS Through Live Movement and Sound (PALMS)|
214829648|NCT04637360|DRUG|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
214829649|NCT04637360|DRUG|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
214829650|NCT05595980|DIETARY_SUPPLEMENT|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
214829651|NCT05595980|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
214829652|NCT06430294|OTHER|Spinal mobilisation|Application of a force on pediatric manikins.
214829653|NCT01166529|PROCEDURE|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
214829654|NCT02399462|DRUG|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
214829655|NCT00211562|DRUG|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
214829656|NCT02373462|DRUG|Olmesartan|
214829657|NCT02373462|DRUG|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
214829658|NCT06311929|DRUG|PD-1 monoclonal antibody and lenvatinib|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
214829659|NCT06311929|DRUG|PD-1 monoclonal antibody|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
214829660|NCT04249765|OTHER|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3\. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
214829661|NCT05576831|PROCEDURE|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
214829662|NCT00339157|DRUG|Anakinra|
214829663|NCT00339157|BIOLOGICAL|Pneumo23|
214829664|NCT00185757|DRUG|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
214829665|NCT02550535|GENETIC|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
214829666|NCT03260686|OTHER|experimental|video guide for upper limb exercise
214829667|NCT03678363|OTHER|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
214829668|NCT01983735|DRUG|TELMINUVO Tab. (80/2.5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."
214829669|NCT01983735|DRUG|TELMINUVO Tab. (80/5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."
214829670|NCT01983735|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."
214829671|NCT01983735|DRUG|S-amlodipine 5mg|"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."
214277456|NCT02564549|PROCEDURE|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
214277457|NCT05465460|DRUG|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
214277458|NCT05465460|DRUG|Placebo|Placebo tablet orally four times per day for 14 days
214829672|NCT03605641|OTHER|JUUL|JUUL Virginia Tobacco
214829673|NCT03605641|OTHER|VUSE Solo|VUSE SOLO Original
214829674|NCT03605641|OTHER|Conventional Cigarette|Subject preferred conventional cigarette
214829675|NCT01079858|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
214829676|NCT05206851|OTHER|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
214829677|NCT05206851|OTHER|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
214829678|NCT00064324|DRUG|perifosine|Given orally
214829679|NCT00064324|OTHER|laboratory biomarker analysis|Correlative studies
214829680|NCT00064324|OTHER|pharmacological study|Correlative studies
214829681|NCT05858333|OTHER|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
214829682|NCT03331458|BEHAVIORAL|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
214829683|NCT02575456|BIOLOGICAL|Ebola Vaccine|
214829684|NCT02575456|BIOLOGICAL|Placebo|control
214829685|NCT05870215|OTHER|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
214829686|NCT05870215|OTHER|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
214829687|NCT05870215|OTHER|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
214829688|NCT05870215|OTHER|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
214829689|NCT05870215|OTHER|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
214829690|NCT05870215|OTHER|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
214829691|NCT05870215|OTHER|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
214829692|NCT02426450|PROCEDURE|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
214829693|NCT02426450|DRUG|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
214829694|NCT02426450|DRUG|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
214829695|NCT04193150|DIAGNOSTIC_TEST|Full pulmonary specialist assessment|Please see description for the intervention arm.
214829696|NCT05854563|OTHER|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
214829697|NCT02581527|DRUG|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
214829698|NCT02581527|DRUG|Isoniazid|Isoniazid 75mg - all arms
214829699|NCT02581527|DRUG|Ethambutol|Ethambutol 275mg - all arms
214829700|NCT02581527|DRUG|Pyrazinamide|Pyrazinamide 400mg - all arms
214829701|NCT04797936|DRUG|BNO 1030|Imupret 25 drops х 6 times per day for 14 days
214829702|NCT04797936|OTHER|Standard care|isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
214829703|NCT02290262|OTHER|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
214829704|NCT01663662|DRUG|Tolvaptan|
214829705|NCT01663662|DRUG|placebo|
214829706|NCT02342873|PROCEDURE|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
214829707|NCT02342873|PROCEDURE|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
214829708|NCT03135080|OTHER|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
214829709|NCT03135080|OTHER|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
214829710|NCT04672603|PROCEDURE|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
214829711|NCT01978873|DRUG|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
214829712|NCT01978873|DRUG|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
214829713|NCT01421862|GENETIC|DNA methylation analysis|
214829714|NCT01421862|GENETIC|RNA analysis|
214829715|NCT01421862|GENETIC|gene expression analysis|
214829716|NCT01421862|GENETIC|microarray analysis|
214829717|NCT01421862|GENETIC|mutation analysis|
214829718|NCT01421862|GENETIC|nucleic acid sequencing|
214829719|NCT01421862|OTHER|laboratory biomarker analysis|
214829720|NCT02117830|DRUG|Androxal 25 mg capsules|
214829721|NCT02117830|DRUG|Androxal 250 Capsules|
214829722|NCT02117830|DRUG|Placebo Capsules|
214829723|NCT02117830|DRUG|Moxifloxacin 400 mg|
214829724|NCT01159873|DRUG|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
214829725|NCT01159873|DRUG|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
214829726|NCT04943822|OTHER|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
214829727|NCT00053339|DRUG|tamoxifen|
214829728|NCT00053339|DRUG|trastuzumab|
214829729|NCT04837664|DRUG|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
214829730|NCT04837664|DRUG|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
214829731|NCT04837664|DRUG|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
214829732|NCT01087502|DRUG|Glimepiride|1-4 mg daily after 12 weeks
214829733|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
214829734|NCT01087502|DRUG|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
214829735|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
214829736|NCT01087502|DRUG|Linagliptin|5 mg once daily
214829737|NCT01237444|DRUG|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
214829738|NCT01237444|DRUG|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
214829739|NCT03708536|DRUG|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
214829740|NCT03708536|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
214829741|NCT03708536|DRUG|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
214829742|NCT05798884|DEVICE|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
214829743|NCT05798884|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
214829744|NCT04015024|DRUG|SKLB1028 150mg bid|150mg oral administration twice a day
214829745|NCT04015024|DRUG|SKLB1028 200mg bid|200mg oral administration twice a day
214829746|NCT04015024|DRUG|SKLB1028 300mg qd|300mg oral administration once a day
214829747|NCT00157521|DRUG|L-arginine|
214829748|NCT06057558|BIOLOGICAL|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
214829749|NCT00006516|BEHAVIORAL|Infant stimulation|
214829750|NCT01457196|DIAGNOSTIC_TEST|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
214829751|NCT02364986|DRUG|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
214829752|NCT02364986|DRUG|Avonex|Avonex 30µg (day 1 and 8) i.m.
214829753|NCT05212987|DRUG|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
214829754|NCT02517424|DRUG|High THC/Low CBD Cannabis|Dried cannabis
214829755|NCT02517424|DRUG|High THC/High CBD Cannabis|Dried cannabis
214829756|NCT02517424|DRUG|Low THC/Low CBD Cannabis|Dried cannabis
214829757|NCT04677517|DEVICE|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
214829758|NCT04677517|BEHAVIORAL|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
214829759|NCT04677517|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
214829760|NCT04677517|BEHAVIORAL|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
214829761|NCT04677517|BEHAVIORAL|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
214829762|NCT06627881|OTHER|Continuous aerobic kayak training program|Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
214829763|NCT06627881|OTHER|Aerobic Endurance Circuit Program|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
214829764|NCT06627881|OTHER|High intensity interval program with rope|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
214829765|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
214829766|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
214829767|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
214829768|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
214829769|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
214829770|NCT00380588|DRUG|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
214829771|NCT00380588|DRUG|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
214464911|NCT05590351|BEHAVIORAL|First diet: m-health coaching application|Intervention for the study would comprise of a culturally appropriate m-health application called first diet. This application will be developed considering the perceptions, barriers and facilitators identified through formative research. Content of the messages would focus on breastfeeding, its importance and early initiation within one hour of birth, significance of first feed i.e. colostrum, importance of EBF from birth till 6 months, introduction of complementary feeding to 6-8 months old infants and appropriate YCFP. These messages would be drafted in the local preferable language assessed during formative research. The content of the messages would be translated and then back translated to ensure validity. These messages will be short, contextual and tailored according to the women's stage of gestation, delivery and infant's age
214829772|NCT02047305|DEVICE|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
214829773|NCT05578794|OTHER|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
214829774|NCT01880476|OTHER|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
214829775|NCT00241982|DRUG|long-circulating liposomal prednisolone|
214829776|NCT03682276|BIOLOGICAL|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
214829777|NCT03682276|BIOLOGICAL|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
214829778|NCT02392689|OTHER|Procalcitonin|Procalcitonin guided antibiotic therapy
214829779|NCT00197873|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
214829780|NCT00197873|OTHER|Placebo administration.|Placebo is administered during chemotherapy.
214829781|NCT05692791|DIAGNOSTIC_TEST|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
214829782|NCT05692791|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
214829783|NCT03567122|OTHER|Internal Focus of Attention|Information already included in arm/group descriptions.
214829784|NCT03567122|OTHER|External Focus of Attention|Information already included in arm/group descriptions.
214829785|NCT03567122|OTHER|Control|Information already included in arm/group descriptions.
214829786|NCT00028925|BIOLOGICAL|filgrastim|
214829787|NCT00028925|DRUG|carboplatin|
214829788|NCT00028925|DRUG|topotecan hydrochloride|
214829789|NCT00028925|RADIATION|WBRT|
214829790|NCT05262322|DRUG|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
214829791|NCT05262322|DRUG|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
214829792|NCT05262322|DRUG|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
214829793|NCT03720548|DRUG|LY3372993|Administered IV.
214829794|NCT03720548|DRUG|Placebo|Administered IV.
214829795|NCT02350257|BEHAVIORAL|Internet-based CBT|12 weeks of internet-based CBT
214829796|NCT04627844|DIETARY_SUPPLEMENT|Immediate Feeding|Standard tube feeds begun at an earlier time point
214829797|NCT04627844|DIETARY_SUPPLEMENT|Delayed Feeding|Standard tube feeds begun at delayed time point
214829798|NCT01529164|DRUG|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
214829799|NCT01529164|DRUG|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
214829800|NCT01529164|DRUG|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
214829801|NCT01529164|DRUG|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
214829802|NCT02230267|OTHER|High intensity exercise and balance training|
214829803|NCT02230267|OTHER|Usual care arm exercise|
214829804|NCT00627744|DRUG|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
214829805|NCT00408304|DRUG|omega-3 fatty acid|
214829806|NCT00712816|DEVICE|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
214829807|NCT00712816|OTHER|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
214829808|NCT04003363|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
214829809|NCT01451541|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
214829810|NCT01451541|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
214829811|NCT01451541|DRUG|Placebo|Placebo - one dose per nostril
214829812|NCT03985124|BEHAVIORAL|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
214829813|NCT01780350|DEVICE|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
214829814|NCT00017550|BIOLOGICAL|anti-thymocyte globulin|
214829815|NCT04872608|DRUG|Letrozole|Letrozole will be given daily on days 1-28.
214829816|NCT04872608|DRUG|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
214829817|NCT04872608|DRUG|Onapristone ER|Onapristone will be given daily on days 1-28.
214829818|NCT04712838|DRUG|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
214829819|NCT04712838|DRUG|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
214829820|NCT04712838|DRUG|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
214829821|NCT04712838|DRUG|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
214829822|NCT04712838|DRUG|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
214829823|NCT04712838|DRUG|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
214829824|NCT04604938|DRUG|Losartan|administration of losartan (50 mg) (oral)
214829825|NCT04604938|DRUG|Placebo oral tablet|administration of placebo (oral)
214829826|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
214829827|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
214829828|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
214829829|NCT01757379|DIETARY_SUPPLEMENT|Inulin|15 g of inulin dissolved in 200 ml of water
214829830|NCT03366428|DRUG|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
214829831|NCT02663661|PROCEDURE|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
214829832|NCT02663661|OTHER|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
214829833|NCT06144398|DEVICE|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
214829834|NCT06144398|DEVICE|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
214829835|NCT05818345|BEHAVIORAL|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
214829836|NCT03677960|DRUG|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
214829837|NCT00185120|DRUG|Olmesartan medoxomil|
214829838|NCT00185120|DRUG|Hydroclorothiazide|
214829839|NCT00185120|DRUG|Benazepril|
214829840|NCT00185120|DRUG|Amlodipine|
214829841|NCT00804973|DRUG|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
214829842|NCT00804973|DRUG|Placebo injection|saline solution, injection, once
214829843|NCT00804973|DRUG|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
214829844|NCT00804973|DRUG|Placebo capsule|4 capsules, once
214829845|NCT05021276|DRUG|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
214829846|NCT01116791|PROCEDURE|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS"
214829847|NCT01916694|DEVICE|Blue tooth enabled glucose meter with smart phone application|
214829848|NCT01916694|BEHAVIORAL|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
214829849|NCT00061776|DRUG|Capsaicin Dermal Patch|
214829850|NCT02082327|DRUG|IV migalastat HCl|
214829851|NCT02082327|DRUG|IV placebo|
214829852|NCT02082327|DRUG|oral migalastat HCl|
214829853|NCT01820091|DRUG|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
214829854|NCT01820091|DRUG|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
214829855|NCT05232773|PROCEDURE|Assessment|Evaluation of clinical and kinematic parameters
214829856|NCT02002130|DRUG|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
214829857|NCT02002130|DRUG|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
214829858|NCT02002130|DRUG|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
214829859|NCT02096692|DEVICE|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
214829860|NCT02096692|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
214829861|NCT01783392|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|
214829862|NCT04306601|DEVICE|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
214829863|NCT00827840|DRUG|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
214829864|NCT00827840|DRUG|Risperidone|1 to 6 mg of risperidone once or twice a day
214829865|NCT04392596|DEVICE|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure."
214829866|NCT06042296|OTHER|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
214829867|NCT04914546|DRUG|LY3819469|Administered SC.
214829868|NCT04914546|DRUG|Placebo|Administered SC.
214829869|NCT06562010|BEHAVIORAL|iCT-SAD-PK|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
214829870|NCT04869995|OTHER|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
214829871|NCT03275623|DRUG|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
214829872|NCT03275623|OTHER|Standard Prenatal Care|Continued surveillance of urinary cultures
214829873|NCT05108935|DRUG|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
214829874|NCT05108935|DRUG|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
214829875|NCT05108935|DRUG|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
214829876|NCT04966403|OTHER|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
214829877|NCT04966403|OTHER|trampoline-based stretch-shortening cycle exercises|muscle strength
214829878|NCT02940652|RADIATION|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
214829879|NCT00999687|DRUG|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
214829880|NCT00999687|OTHER|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
214829881|NCT00940433|PROCEDURE|open properitoneal hernia repair|suprapubic retro-inguinal approach
214829882|NCT00940433|PROCEDURE|Lechtestien hernia repair|onlay mesh repair
214829883|NCT00940433|PROCEDURE|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
214829884|NCT00940433|PROCEDURE|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
214829885|NCT05204537|PROCEDURE|Lung parenchyma resection|Lung parenchyma removal
214829886|NCT05204537|PROCEDURE|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
214829887|NCT05698407|DRUG|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
214829888|NCT05698407|DRUG|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
214829889|NCT00260715|BEHAVIORAL|Community-Popular Opinion Leader Model|
214829890|NCT00260715|BEHAVIORAL|Diffusion of Innovations|
214829891|NCT06180915|BEHAVIORAL|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
214829892|NCT00659828|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
214829893|NCT05233254|BEHAVIORAL|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
214829894|NCT05674188|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
214829895|NCT00154258|DRUG|Clozapine|
214829896|NCT02775994|DRUG|Canakinumab|interleukin beta (IL-1) antagonist
214829897|NCT01120028|DRUG|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
214829898|NCT01120028|DRUG|Basiliximab|20 mg intravenously, two doses 96 hours apart
214829899|NCT01120028|DRUG|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
214829900|NCT01120028|DRUG|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
214829901|NCT01923909|DRUG|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
214829902|NCT01923909|DRUG|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
214829903|NCT03596710|PROCEDURE|Image Guided Biopsy|Undergo image guided biopsy
214829904|NCT00348296|DRUG|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
214829905|NCT06465654|OTHER|Automated variable dose oxygen treatment|The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
214829906|NCT06465654|OTHER|Fixed dose oxygen treatment|The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
214829907|NCT05017935|DEVICE|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
214829908|NCT03155867|OTHER|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
214829909|NCT00052221|BIOLOGICAL|Epoetin alfa|
214829910|NCT00052221|OTHER|Placebo|
214829911|NCT04820829|OTHER|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
214829912|NCT04820829|OTHER|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
214829913|NCT04820829|OTHER|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
214829914|NCT03018925|DRUG|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
214829915|NCT05316454|BEHAVIORAL|self-efficacy support|self-efficacy support
214829916|NCT01096329|DRUG|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
214829917|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
214829918|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
214829919|NCT06687330|DEVICE|Tracking Mobility and Health Data with a Smartwatch in Discharged Oncology Patients to Predict Rehospitalization: A Prospective Study|The intervention involves daily monitoring of discharged oncology patients using a smartwatch (Huawei Watch Fit 2) to track physical activity (step count), heart rate, and sleep duration. Data is collected remotely via a smartphone app, allowing real-time tracking of health metrics post-discharge. This intervention is distinct in its focus on correlating mobility and physiological data with the risk of rehospitalization within a 30-90 day period. Patients will also receive recommendations to maintain daily walking routines as part of their post-discharge care. Additionally, quality of life and sleep quality assessments are conducted before discharge and at follow-up visits to provide a comprehensive overview of each patient's post-hospital recovery.
214829920|NCT06685900|DEVICE|digital therapeutics|Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
214829921|NCT06685900|DEVICE|digital therapeutics|Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
214829922|NCT05513196|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
214829923|NCT05800899|BEHAVIORAL|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
214829924|NCT05800899|BEHAVIORAL|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
214829925|NCT03221530|BEHAVIORAL|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
214829926|NCT03221530|BEHAVIORAL|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
214829927|NCT02341547|DRUG|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
214829928|NCT01253564|DRUG|RO5185426|960 mg b.i.d. orally
214829929|NCT06765668|DRUG|CREXONT ER|CREXONT ER capsule.
214829930|NCT07064538|DIETARY_SUPPLEMENT|Neuralli® MP|Neuralli® MP containing 60 billion CFU (administered as two capsules per day)
214829931|NCT07064161|DRUG|Mupirocin (drug)|Wounds were dressed with gauze impregnated with mupirocin ointment covered by a transparent dressing (Tegaderm)
214829932|NCT07064161|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|Wounds were dressed with a 1-inch size Duoderm Control Gel Formula hydrocolloid dressing
214829933|NCT05291819|OTHER|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
214829934|NCT05291819|OTHER|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
214829935|NCT06675175|DRUG|AZD4144|Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
214829936|NCT06675175|OTHER|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
214829937|NCT02287961|PROCEDURE|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
214829938|NCT02287961|PROCEDURE|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
214829939|NCT02287961|PROCEDURE|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
214829940|NCT02287961|PROCEDURE|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
214464912|NCT05590351|BEHAVIORAL|Face to Face counselling|Women randomly enrolled in the non-interventional group will receive face-face nutritional counseling instead of mobile application. Once enrolled in the group, Research Assistant (RA) will collect relevant details on the baseline questionnaire like intervention group but on a paper-based questionnaire. Women will be given first face-face counseling on the day of enrollment. The counseling sessions will coincide with the routine vaccination and growth monitoring schedule of the infant after women deliver
214464913|NCT03213691|OTHER|Laboratory Biomarker Analysis|Correlative studies
214464914|NCT03213691|DRUG|Selumetinib|Given PO
214464915|NCT03213691|DRUG|Selumetinib Sulfate|Given PO
214829941|NCT05121844|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
214829942|NCT06912945|PROCEDURE|using diode laser 980nm wavelength in benign laryngeal lesions|using diode laser 980nm wavelength in treatment of benign laryngeal lesions
214829943|NCT06912945|PROCEDURE|using diode laser 450nm wavelength in benign laryngeal lesions|using diode laser 450nm wavelength in treatment of benign laryngeal lesions
214829944|NCT06912945|PROCEDURE|using traditional cold instrumentations in benign laryngeal lesions|using traditional cold instrumentations in treatment of benign laryngeal lesions
214829945|NCT01900340|DIETARY_SUPPLEMENT|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
214829946|NCT01900340|DRUG|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
214829947|NCT01900340|DIETARY_SUPPLEMENT|Saline|IV saline infusion and intraduodenal administration of nutrients
214829948|NCT01900340|DRUG|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
214829949|NCT06910228|DEVICE|Near infrared spectroscopy (NIRS)|A non-invasive technique that uses light to assess brain function and tissue oxygenation.
214829950|NCT07129980|DEVICE|ARGOS Biometer|The ARGOS biometer uses swept-source optical coherence tomography (SS-OCT) with a 1060 nm tunable laser to capture high-resolution B-scan images of the entire eye. This technology enables sum-of-segments (S-O-S) biometry, measuring each ocular component-corneal thickness, aqueous depth, lens thickness, and vitreous length-individually and summing these values to determine total axial length. SS-OCT provides deep tissue penetration while simultaneously capturing keratometry, white-to-white, and pupillometry data in a single scan. For keratometry measurements, the ARGOS uniquely employes SS-OCT-based telecentric keratometry, which involves projection of 16 infrared LEDs in a wider 3.0 mm ring pattern onto the cornea and calculates curvature from those reflections.
214829951|NCT02257554|BEHAVIORAL|education|Discussion of surgical expectations with patients
214829952|NCT07138560|DRUG|CREXONT ER|exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods
214829953|NCT07138716|DIAGNOSTIC_TEST|68Ga-DOTA-CCK-FS PET/CT|For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, using a time-of-flight PET/CT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min/bed position). Images are reconstructed using OSEM algorithms.
214829954|NCT07140263|BEHAVIORAL|CARE MI|"The intervention consists of four sessions, each lasting between 60 and 90 minutes, ideally delivered on consecutive weeks. It integrates psychoeducation on trauma and moral injury, emotional regulation strategies, and incorporates elements from several evidence-based approaches. These include the EMDR-IGTP-OTS group protocol, acceptance and values-based work from ACT, and self-compassion-focused interventions.~In the Waiting List arm, CARE-MI will be delivered after the initial assessment period of the Experimental arm."
214829955|NCT07140263|BEHAVIORAL|TAU: Treatment as usual|During the waiting period, Waiting list group will receive usual institutional support.
214829956|NCT07139119|BEHAVIORAL|Health Belief Model-Based Educational Program for Skin Cancer Prevention Among Female Healthcare Workers|"This blended educational intervention employs the Health Belief Model (HBM) to promote skin cancer preventive behaviors in female healthcare workers in Ahvaz, Iran. The 7-session program (each 45 minutes) combines in-person training with WhatsApp-based follow-ups.~Participant Components:~* Structured sessions targeting knowledge and HBM constructs such as perceived susceptibility, severity, benefits, barriers, self-efficacy, and cues to action.~* Use of multimedia tools including videos, pamphlets, and interactive discussions.~* Motivational messaging, stress management clips, and role-modeling techniques to build self-efficacy.~* Visual cues such as posters placed in healthcare workplaces.~* Daily reminder messages to reinforce behavior change.~Unique aspects distinguishing this intervention include its specific tailoring for female healthcare workers in a high UV-exposure region, the combined digital and face-to-face delivery approach, and comprehensive focus on all HBM construc"
214829957|NCT07139561|BEHAVIORAL|Oral Health in Hands - Parent Digital Program|"The 16-week parent-focused digital intervention aims to improve oral health practices in children aged 6-10 by empowering parents through structured, engaging, and cost-effective activities. Parents receive daily reminders, including two brushing cues and one snack tip, to reinforce healthy routines. Weekly quizzes with 3-5 questions enhance knowledge retention, while interactive photo or video tasks such as Show your foam smile or Healthy lunchbox challenge promote family involvement and fun. Gamification strategies include awarding digital badges for streaks, such as the 7-day brushing badge and snack swap champion, to maintain motivation. Parents track brushing, flossing, and snack swaps using a simple 1-tap tracker, ensuring easy and consistent reporting. An optional moderated WhatsApp group provides a platform for sharing tips, photos, and encouragement, fostering a supportive peer community. The intervention combines education, habit formation, and social support to sustainab"
214829958|NCT07140471|PROCEDURE|Onlay Mesh Repair|Polypropylene mesh is placed over the anterior rectus sheath and fixed with Prolene sutures after hernia sac reduction.
214829959|NCT07140471|PROCEDURE|Sublay Mesh Repair|Polypropylene mesh placed in the retrorectus space and fixed with Prolene sutures after Rectus Sheath Dissection
214277459|NCT05165836|PROCEDURE|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
214829960|NCT07140588|PROCEDURE|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
214829961|NCT07139782|DEVICE|Riancorp LTU-904 Laser and Handycure® (Medical Quant)|"Riancorp: At the first intervention session the therapist will apply the device for 60 secs each at 14 - 25 points on the face and neck. Most patients will need application of the device at 15 to 20 points The Riancorp runs for 60 seconds, providing 1.5 j/cm2 in 60 seconds.~Handycure: used by patients at home once/day on the prescribed days (Wks 1-6 3x/wk; Wks 7-10 x2/wk; Wks 11-12 x1/wk) 1. Patients will apply the device for 5 minutes at each point as instructed by the physiotherapist."
214829962|NCT07138625|BIOLOGICAL|Nebulized normal saline|Eligible patients with moderate bronchiolitis who met the inclusion criteria were randomly assigned in a 1:1 ratio to either the hypertonic saline (3%) group or the normal saline (0.9%) group. Randomization was performed using a computer-generated random number sequence prepared by an independent statistician not involved in patient recruitment or treatment. Allocation concealment was ensured through the use of sequentially numbered, opaque, sealed envelopes, which were opened only after patient enrollment and completion of baseline assessments.
214829963|NCT07138508|DRUG|Nicorandil 20mg|Oral nicorandil 20mg
214829964|NCT07139184|DIAGNOSTIC_TEST|Diagnosis of Charcot foot disease|Diagnosis of Charcot foot disease will be obtained from the results of physical examination and according to x-ray examination of foot which was performed at the Radiology Department of Assiut University Hospital. The Eichenholtz classification system, developed by Sidney N. Eichenholtz in 1966, categorizes Charcot arthropathy (also known as Charcot foot) into three stages based on clinical and radiographic findings. These stages are development, coalescence, and reconstruction
214829965|NCT07139184|DIAGNOSTIC_TEST|Hematologic and biochemical parameters,|"Hematologic and biochemical parameters, including lymphocyte, monocyte, neutrophil, and platelet counts, as well as glucose, HbA1c, triglyceride (TG), HDL, and LDL levels, will be extracted from patient records.~NLR=absolute neutrophil count (109/L)/absolute lymphocyte count (109/L), PLR=platelet count (109/L)/absolute lymphocyte count (109/L), LMR=absolute lymphocyte count (109/L)/absolute monocyte count (109/L), GLR=glucose (mg/dL)/absolute lymphocyte ratio (109/L), TGR=triglyceride (mg/dL)/glucose ratio (mg/dL), THR=triglyceride (mg/dL)/HDL ratio (mg/dL), SIRI = absolute neutrophil count (109/L) × absolute monocyte count (109/L)/ absolute lymphocyte count (109/L), SII = platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L), TyG index = fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2, PIV =absolute neutrophil count (109/L) × platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L)."
214829966|NCT07139184|DIAGNOSTIC_TEST|ELIZA Assay|For each patient, 2 ml of blood will be obtained. The serum levels of IL-10, TNF-α will be assessed by using (ELISA) kit obtained from (Biodiagnostic company, Egypt) according to the manufacturer protocol.
214829967|NCT07140614|DRUG|EDK060, dose A|EDK060, dose A, Single dose, IV infusion
214829968|NCT07140614|DRUG|EDK060, dose B|EDK060, dose B, Single dose, IV infusion
214829969|NCT07140614|DRUG|EDK060, dose C|EDK060, dose C, Single dose, IV infusion
214829970|NCT07140614|DRUG|EDK060, dose D|EDK060, dose D, Single dose, IV infusion
214829971|NCT07140614|OTHER|Placebo|Placebo
214829972|NCT07139756|DIAGNOSTIC_TEST|Lower body negative pressure|LBNP is a technique that redistributes blood from the upper body to the dependent regions of the legs, thus reducing central venous pressure and venous return and thereby activating the sympathetic nervous system (SNS). The subject is placed in a cylindrical airtight tank, which is sealed at the level of the iliac crests, and sub-atmospheric pressure is produced using a vacuum pump. It can be used to characterize the cardiovascular responses to orthostatic stress
214829973|NCT04725513|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
214829974|NCT04725513|DEVICE|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
214829975|NCT04725513|OTHER|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
214829976|NCT07138599|DEVICE|Virtual Reality ECMO Simulation Training|The intervention is a virtual reality simulation of an ECMO system, whereby the user is guided through the steps of how to perform an 11 step ECMO circuit check, and specific indicators of abnormal functioning are highlighted. The simulation is produced in Unreal Engine 4.23, and it simulates a virtual ICU and a virtual patient.
214829977|NCT07138599|OTHER|Instructional Video of Certified Perfusionists on Performing a Circuit Check|This intervention is a seven minute narrated high definition video in which a two certified perfusionist describe how to perform the identical eleven step circuit check on a primed Cardiohelp circuit, what to look for in terms of pathology or abnormal function, and . Participants will view the clip once on a laptop with headphones in a quiet room and may ask questions or receive clarification from the study coordinator, and this will be demonstrated on the physical ECMO machine and/or circuit present. The video conveys the checklist at reduced speed and explaining the purpose of each step and has been reviewed by the expert panel for accuracy and completeness.
214829978|NCT07140081|DRUG|BLX-0871|BLX-0871 Single or Multiple doses administered orally as a tablet
214829979|NCT07140081|DRUG|Placebo|Participants will receive matching placebo of BLX-0871 for each of the oral cohorts.
214829980|NCT07140354|DEVICE|cervical transcutaneous spinal cord stimulation|Cervical transcutaneous spinal cord stimulation (tSCS) delivers electrical currents over the cervical spinal cord to modulate neural circuits controlling the upper extremities. This approach has been shown to facilitate motor output, improve hand and arm function, and promote neuroplasticity in individuals with cervical spinal cord injury.
214829981|NCT04247243|DEVICE|Rapid testing|Abbott ID NOW Strep A testing
214829982|NCT04247243|DIAGNOSTIC_TEST|Reference testing|Culture-based testing
214829983|NCT02836262|DEVICE|HIT Hip Replacement System|HIT Hip Replacement System
214829984|NCT03773653|BEHAVIORAL|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
214829985|NCT03773653|BEHAVIORAL|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
214829986|NCT03773653|BEHAVIORAL|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
214829987|NCT05499728|OTHER|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
214829988|NCT06275542|DEVICE|Train of four monitoring device intraoperative|Only group B will receive reversal strategy based on the presence of TOF monitoring device prior to extubation. If they meet the criteria, patients will then be extubated.
214829989|NCT06275542|DRUG|Neostigmine|For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
214829990|NCT06275542|PROCEDURE|Air chalenge prior to extubation|After surgery was completed and the TOF ratio was ≥ 0.90, the TOF device was removed, and extubation was performed in Group B. In Group A, after a minimum of 15 minutes following reversal, patients received only ambient air without supplemental O2. Extubation was performed if the patient could maintain an SpO2 \> 95% for a minimum of 3 minutes. If within 15 minutes after reversal the patient did not meet the extubation criteria, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed. If there was suspicion of opioid-induced hypoventilation, naloxone was administered at 0.4-0.8 mcg intravenously.If the patient was unable to maintain oxygen saturation for the 3-minute duration, oxygen supplementation was reinstated, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed.
214829991|NCT06275542|DEVICE|Train of Four monitoring device in recovery room|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention. Measurements were taken twice sequential
214829992|NCT06358963|DRUG|Receive 30 mg of Coq10|Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
214829993|NCT06358963|DRUG|Non-Medicare Drugs|and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
214829994|NCT06179693|DIAGNOSTIC_TEST|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
214829995|NCT05215938|DIAGNOSTIC_TEST|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
214829996|NCT00605150|RADIATION|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
214829997|NCT06361550|OTHER|VENREDI group|Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
214829998|NCT06361550|OTHER|Health education|Health education on Mediterranean diet
214829999|NCT02861651|OTHER|DNA sequencing|
214830000|NCT05356481|DEVICE|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
214830001|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|Concentration-controlled
214830002|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|1g po bid
214830003|NCT00337493|DRUG|Cyclosporine or tacrolimus|Reduced
214830004|NCT00337493|DRUG|Cyclosporine or tacrolimus|Standard, as prescribed
214830005|NCT01872676|OTHER|Spine manipulation|
214830006|NCT01872676|OTHER|Manipulation sham|
214830007|NCT03814850|DEVICE|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
214830008|NCT02779400|DEVICE|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
214830009|NCT00533156|DEVICE|Vascular access site closure (7F Ensure)|
214830010|NCT00125385|BIOLOGICAL|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
214830011|NCT00125385|BIOLOGICAL|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
214830012|NCT00125385|BIOLOGICAL|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
214830013|NCT00125385|BIOLOGICAL|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
214830014|NCT00125385|BIOLOGICAL|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
214830015|NCT05183451|PROCEDURE|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
214830016|NCT05183451|PROCEDURE|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
214464916|NCT02400229|PROCEDURE|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
214830017|NCT00128219|BIOLOGICAL|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
214830018|NCT00128219|BIOLOGICAL|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
214830019|NCT02750878|OTHER|Informational Handout|
214830020|NCT02579577|OTHER|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
214830021|NCT02579577|OTHER|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
214830022|NCT02579577|OTHER|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
214830023|NCT04218487|DRUG|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
214830024|NCT04218487|DRUG|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
214830025|NCT04218487|OTHER|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
214830026|NCT02772822|DRUG|SCT400 plus CHOP|
214830027|NCT02772822|DRUG|Rituximab plus CHOP|
214830028|NCT01216865|BIOLOGICAL|umbilical cord mesenchymal stem cells|5\*10/7 per ischemic limb
214830029|NCT01216865|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
214830030|NCT05946239|OTHER|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
214830031|NCT05492292|DIAGNOSTIC_TEST|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
214830032|NCT01030796|BEHAVIORAL|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
214830033|NCT04000945|DEVICE|BTL-899|Treatment with BTL-899 device, 3 therapies
214830034|NCT04000945|DEVICE|Sham|Sham treatment with BTL-899 device, 3 visits
214830035|NCT00195754|DRUG|divalproex sodium|
214830036|NCT02034513|DRUG|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
214830037|NCT02034513|DRUG|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
214830038|NCT02034513|DRUG|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
214830039|NCT05397977|DEVICE|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
214830040|NCT05397977|OTHER|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
214830041|NCT00057226|DRUG|Radafaxine|
214830042|NCT06504355|BEHAVIORAL|Training program incorporating video aerobic exercise, action video game and resistive action video game|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
214830043|NCT02308241|DRUG|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
214830044|NCT04133116|DRUG|LY3471851|Administered SC
214830045|NCT04133116|DRUG|Placebo|Administered SC
214830046|NCT04408924|DRUG|Abemaciclib|Administered orally
214830047|NCT05435833|PROCEDURE|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
214830048|NCT00691704|DRUG|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
214464917|NCT02400229|PROCEDURE|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
214464918|NCT02617758|DRUG|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
214830049|NCT00691704|DRUG|Sequential Maintenance Therapy|"Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
214830050|NCT05959486|DRUG|BR6002A|One tablet administered alone
214830051|NCT05959486|DRUG|BR6002B|One tablet administered alone
214830052|NCT05959486|DRUG|BR6002|One capsule administered alone
214830053|NCT02578290|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
214830054|NCT05919199|OTHER|No intervention|No intervention
214830055|NCT04661202|OTHER|multimodal exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction."
214830056|NCT01861249|DRUG|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
214830057|NCT05306496|DEVICE|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
214830058|NCT06628089|OTHER|Questionnaire|A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
214830059|NCT02131077|BIOLOGICAL|ALLO-ASC-TI|
214830060|NCT02131077|DRUG|Placebo|
214830061|NCT02597257|DRUG|Lidocaine HCl|lidocaine continuous infusion
214830062|NCT02597257|DRUG|Normal saline|Normal saline continuous infusion
214830063|NCT05501158|DRUG|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
214830064|NCT02090933|DRUG|Celecoxib|Given PO
214830065|NCT02090933|OTHER|Laboratory Biomarker Analysis|Correlative studies
214830066|NCT02090933|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
214830067|NCT04158687|DRUG|CTP-692|Administered as powder for oral solution.
214830068|NCT04158687|DRUG|Placebo|Administered as powder for oral solution.
214830069|NCT04229914|OTHER|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
214830070|NCT01595841|DRUG|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
214277460|NCT05165836|PROCEDURE|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
214830071|NCT02889393|DRUG|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
214830072|NCT02889393|OTHER|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
214830073|NCT03062176|DRUG|Anakinra|Anakinra (Kineret)
214277461|NCT00479726|DRUG|duloxetine hydrochloride|
214277462|NCT04490343|DIAGNOSTIC_TEST|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
214277463|NCT03477097|OTHER|Nutrition, exercise and social network intervention|
214277464|NCT01063452|DEVICE|Truvalve|Atkinson Product Design urinary slide valve
214277465|NCT01063452|OTHER|Control (catheter drainage bag)|urinary catheter drainage bag
214277466|NCT02914470|DRUG|carbplatin, cyclophophamide, atezolizumab|
214277467|NCT00786734|DRUG|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
214277468|NCT00786734|DRUG|Pitavastatin|4mg daily for 28 days after PCI
214830074|NCT05001191|OTHER|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
214830075|NCT02026362|BIOLOGICAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
214830076|NCT02026362|OTHER|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
214830077|NCT05740748|DRUG|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
214830078|NCT05740748|DRUG|Placebo|placebo sc q4wks for 20 weeks
214830079|NCT01169272|DEVICE|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
214830080|NCT03609333|DEVICE|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
214830081|NCT01600339|DRUG|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
214830082|NCT04102345|OTHER|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
214830083|NCT04102345|DRUG|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
214830084|NCT00209547|DRUG|fospropofol disodium|
214830085|NCT02341690|OTHER|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
214830086|NCT02341690|OTHER|control|Standard care at the promotion centre in the municipality
214830087|NCT00901524|DRUG|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
214830088|NCT03271996|PROCEDURE|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
214830089|NCT03271996|PROCEDURE|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
214830090|NCT03330496|OTHER|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
214830091|NCT02082834|OTHER|abdominal MDCT examination|
214830092|NCT05037318|BEHAVIORAL|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
214830093|NCT05037318|BEHAVIORAL|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
214830094|NCT06152796|DRUG|Paracetamol|Anti\_inflammatory drug
214830095|NCT06152796|DRUG|Ibuprofen|Non steroidal anti\_inflammatory drug
214830096|NCT01323127|PROCEDURE|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
214830097|NCT00496860|BIOLOGICAL|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
214830098|NCT03694106|BEHAVIORAL|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
214830099|NCT01219140|DIETARY_SUPPLEMENT|2 POMx Capsules|2 POMx Capsules daily
214277469|NCT01149226|DRUG|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
214830100|NCT01219140|DIETARY_SUPPLEMENT|2 placebo Capsules|2 placebo Capsules daily
214830101|NCT05797207|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
214830102|NCT05797207|PROCEDURE|Colonoscopy|Colonoscopy procedure
214830103|NCT03099915|OTHER|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
214830104|NCT02518945|DRUG|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
214830105|NCT02518945|DRUG|Insulin|
214830106|NCT02518945|DRUG|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
214830107|NCT02518945|DRUG|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
214830108|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
214830109|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
214830110|NCT00835666|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
214830111|NCT00835666|DRUG|PROSCAR®|1 x 5 mg, single dose fasting
214830112|NCT04716582|BEHAVIORAL|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
214830113|NCT04716582|BEHAVIORAL|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
214830114|NCT04716582|BEHAVIORAL|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
214830115|NCT03599362|DRUG|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
214830116|NCT03599362|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
214830117|NCT05216562|DRUG|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
214830118|NCT05216562|DRUG|Placebo Intravenous Injection|Intravenous injection of Placebo
214464919|NCT02617758|DRUG|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
214830119|NCT05216562|DRUG|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
214830120|NCT06218394|PROCEDURE|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
214830121|NCT06218394|PROCEDURE|Autologous Concentrated Growth Factor|"1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes."
214830122|NCT06218394|DRUG|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
214830123|NCT02247362|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
214830124|NCT02247362|OTHER|Placebo|Vaccine Diluent
214830125|NCT02531620|OTHER|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
214830126|NCT02531620|OTHER|Routine Care|Usual care for your disease process
214830127|NCT04993274|DIAGNOSTIC_TEST|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
214830128|NCT02818530|DEVICE|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
214830129|NCT02818530|DEVICE|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
214830130|NCT05900648|DRUG|Regorafenib|Given by PO
214830131|NCT05900648|DRUG|XmAb20717|Given by (IV) vein
214830132|NCT03480230|DRUG|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
214830133|NCT01887522|DRUG|Vinblastine + Nilotinib|"* Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
214830134|NCT01887522|DRUG|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
214830135|NCT02125435|DRUG|ASP2408|intravenous
214830136|NCT02125435|DRUG|Placebo|intravenous
214830137|NCT02511535|BIOLOGICAL|TBE booster vaccination|
214830138|NCT06150963|DEVICE|Virtual Reality|Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.
214830139|NCT06150963|PROCEDURE|Standard Procedure Thyroid Biopsy|In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
214830140|NCT06150963|PROCEDURE|Standard Procedure PICC Placement|In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.
214830141|NCT00197938|PROCEDURE|Measurement of rectal lactic acid.|
214830142|NCT00348764|DRUG|lauromacrogol|
214830143|NCT04533620|RADIATION|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
214830144|NCT04533620|RADIATION|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
214830145|NCT03707587|DRUG|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
214830146|NCT00028587|DRUG|bortezomib|Given IV
214277470|NCT03307967|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
214464920|NCT02587403|DEVICE|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
214464921|NCT02587403|DEVICE|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
214830147|NCT00028587|DRUG|paclitaxel|Given IV
214830148|NCT00028587|DRUG|carboplatin|Given IV
214830149|NCT00028587|OTHER|laboratory biomarker analysis|Optional correlative studies
214830150|NCT01537887|DRUG|LY2484595|Administered orally once daily for 10 days.
214830151|NCT01537887|DRUG|Placebo|Administered orally once daily for 10 days.
214830152|NCT01537887|DRUG|Moxifloxacin|Single dose administered orally.
214830153|NCT05476588|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
214830154|NCT02312154|DEVICE|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
214830155|NCT01370083|BEHAVIORAL|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
214830156|NCT01370083|BEHAVIORAL|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
214830157|NCT05251727|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment
214830158|NCT05251727|DRUG|Placebo|Weight based dose of reconstituted treatment
214830159|NCT05885412|GENETIC|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
214830160|NCT04286074|OTHER|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
214830161|NCT04286074|OTHER|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
214830162|NCT01167829|DRUG|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
214830163|NCT01167829|DRUG|Acyline|300 ug/kg injection on Day 0
214830164|NCT05744492|OTHER|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
214830165|NCT03589430|OTHER|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
214830166|NCT04155450|OTHER|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
214464922|NCT01152450|DRUG|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
214464923|NCT01152450|DRUG|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
214464924|NCT01152450|DRUG|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
214830167|NCT04155450|OTHER|McKenzie Extension Exercise Protocol|"Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
214830168|NCT04155450|OTHER|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
214830169|NCT00174421|DRUG|Treatment with Genotropin in different dosages|
214830170|NCT03560843|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
214830171|NCT03577938|DRUG|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
214830172|NCT03577938|OTHER|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
214830173|NCT03774329|OTHER|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
214830174|NCT03774329|OTHER|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
214830175|NCT03291145|DRUG|Beta Blockers|With and without Beta Blockers
214830176|NCT03291145|DRUG|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
214830177|NCT03358147|DRUG|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
214830178|NCT03358147|DRUG|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
214830179|NCT03358147|DRUG|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
214830180|NCT03358147|DRUG|Placebo MDI|Placebo taken as 2 inhalations BID
214830181|NCT03358147|DRUG|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
214830182|NCT03997019|PROCEDURE|opioid analgesia|opioid analgesia will be used with general anaesthesia
214830183|NCT03997019|PROCEDURE|ESP block|ultrasound guided ESP Block before anaesthesia induction
214830184|NCT04652622|DEVICE|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
214830185|NCT05109377|DIAGNOSTIC_TEST|Endocan|Endocan will measured before and after treatment
214830186|NCT05109377|DRUG|tadalafil|tadalafil
214830187|NCT01748773|DRUG|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
214830188|NCT01748773|RADIATION|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
214830189|NCT01748773|DRUG|Capecitabine|Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
214830190|NCT01748773|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
214830191|NCT03061591|DIETARY_SUPPLEMENT|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
214830192|NCT03061591|OTHER|Placebo|Placebo capsules
214830193|NCT05685498|BEHAVIORAL|Peer-led HIV self-testing among male fisherfolk in Uganda|This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
214830194|NCT00217113|BEHAVIORAL|Geriatric home visit and Action Plan|
214830195|NCT01044537|DRUG|Placebo|Placebo to match PF-04937319 will be provided.
214830196|NCT01044537|DRUG|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
214830197|NCT00774189|DRUG|clarithromycin 250 mg tablets|
214830198|NCT03798457|OTHER|No intervention|In this study there is no intervention
214830199|NCT05412485|OTHER|Robotic assisted gait training|Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
214830200|NCT05069571|OTHER|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
214830201|NCT00425308|DRUG|Everolimus + Cyclosporine|
214830202|NCT00425308|DRUG|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
214830203|NCT00425308|DRUG|Steroids|
214830204|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
214830205|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
214830206|NCT04748991|DRUG|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
214830207|NCT04748991|DRUG|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
214830208|NCT01058213|BEHAVIORAL|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (\~1-2 seconds for concentric and eccentric contraction) will be used.
214830209|NCT01058213|BEHAVIORAL|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
214830210|NCT05444803|OTHER|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
214830211|NCT05444803|OTHER|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
214830212|NCT03271125|BEHAVIORAL|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
214830213|NCT03271125|BEHAVIORAL|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
214830214|NCT04732325|DEVICE|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
214830215|NCT05235568|DEVICE|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
214830216|NCT00963495|DRUG|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
214830217|NCT01860638|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
214830218|NCT01860638|DRUG|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
214830219|NCT01860638|DRUG|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
214830220|NCT01860638|RADIATION|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
214830221|NCT01860638|DRUG|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
214830222|NCT01860638|DRUG|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
214830223|NCT04442503|DRUG|SAGE-217|SAGE-217 oral capsules.
214830224|NCT04442503|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
214830225|NCT02570828|DEVICE|Thermal Imaging|FLIR ONE attachment to an iPhone
214830226|NCT03769428|PROCEDURE|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
214830227|NCT03769428|PROCEDURE|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
214830228|NCT05411653|OTHER|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
214830229|NCT05411653|OTHER|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
214830230|NCT01250730|DRUG|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
214830231|NCT01250730|DRUG|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
214830232|NCT01250730|DRUG|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
214830233|NCT00000956|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214830234|NCT00833534|BIOLOGICAL|rituximab|Given IV
214830235|NCT00833534|DRUG|lenalidomide|Given orally
214830236|NCT04626440|PROCEDURE|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
214830237|NCT03090022|PROCEDURE|Strattice|Intra-abdominally Fixation
214830238|NCT03090022|PROCEDURE|Single running suture of abdominal fascia|Intra-abdominal suture
214830239|NCT02352233|PROCEDURE|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
214830240|NCT01466894|BIOLOGICAL|IMM 124-E|Tablets orally twice a day for 24 weeks
214830241|NCT01466894|BIOLOGICAL|Placebo|Tablets orally twice daily for 24 weeks
214830242|NCT01945580|PROCEDURE|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
214830243|NCT03068780|DRUG|Oleogel-S10|10% birch bark extract in 90% sunflower oil
214830244|NCT03068780|DRUG|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
214830245|NCT02933060|OTHER|Normal saline (1000 mL)|
214830246|NCT02933060|OTHER|Control|
214830247|NCT04540094|DRUG|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
214830248|NCT04540094|DRUG|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
214830249|NCT05132426|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
214830250|NCT05034874|DRUG|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
214830251|NCT05034874|OTHER|Placebo|Saline
214830252|NCT04635020|PROCEDURE|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
214830253|NCT04635020|PROCEDURE|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
214830254|NCT04635020|PROCEDURE|Cataract surgery|Conventional cataract surgery
214830255|NCT00387530|DRUG|oral sodium phenylbutyrate|
214830256|NCT00387530|DRUG|valganciclovir|
214830257|NCT00387530|GENETIC|polymerase chain reaction|
214830258|NCT00387530|GENETIC|protein expression analysis|
214830259|NCT00387530|PROCEDURE|biopsy|
214830260|NCT00003357|BIOLOGICAL|GM2-KLH vaccine|
214830261|NCT00003357|BIOLOGICAL|QS21|
214830262|NCT05729048|DEVICE|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
214830263|NCT00989950|DRUG|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
214830264|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
214830265|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
214830266|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
214830267|NCT00101439|DRUG|ezetimibe|
214830268|NCT00101439|DRUG|Comparator: placebo|
214830269|NCT02863822|BEHAVIORAL|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
214830270|NCT02863822|BEHAVIORAL|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
214830271|NCT05801822|DIAGNOSTIC_TEST|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
214830272|NCT05966922|PROCEDURE|Transcutaneous Electrical Stimulation|Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
214830273|NCT04830540|DEVICE|OOFOS Recovery Footwear|The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
214830274|NCT01851772|DEVICE|Treatment with Electronic Brachytherapy|
214830275|NCT03415867|DRUG|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
214830276|NCT00500201|DRUG|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
214830277|NCT00500201|DRUG|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
214830278|NCT00500201|DRUG|Placebo|Placebo tablets will be administered orally by subjects.
214830279|NCT00633672|DRUG|Esomeprazole|20mg Oral tablet once daily
214830280|NCT00633672|DRUG|Ranitidine|150mg oral twice daily
214830281|NCT00633672|DRUG|Esomeprazole|40mg oral tablet once daily
214830282|NCT05934695|OTHER|Lymphedema severity stratification|"Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds"
214830283|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
214830284|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
214830285|NCT03245658|DRUG|THC and CBD Mixture|Individually titrated doses on daily basis
214830286|NCT01679158|DEVICE|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
214830287|NCT06452758|OTHER|2000 meter ergometer test|Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
214830288|NCT05988840|OTHER|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
214830289|NCT01867658|DEVICE|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
214830290|NCT02956096|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
214830291|NCT02956096|DEVICE|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
214830292|NCT00840658|BEHAVIORAL|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
214830293|NCT00840658|BEHAVIORAL|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
214830294|NCT00840658|BEHAVIORAL|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
214830295|NCT00840658|BEHAVIORAL|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
214830296|NCT01870258|OTHER|ANN prediction of myocardial infarction|
214830297|NCT05710458|DEVICE|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
214830298|NCT05710458|DEVICE|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
214830299|NCT04846686|BIOLOGICAL|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
214830300|NCT03101358|DRUG|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
214830301|NCT00474058|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
214830302|NCT00474058|OTHER|Placebo|Placebo transdermal patches
214830303|NCT03334734|DRUG|PBTZ169|Once a day for 14 days
214830304|NCT03334734|DRUG|Isoniazid|Once a day for 14 days
214830305|NCT05323981|DRUG|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
214830306|NCT05323981|DRUG|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
214830307|NCT05323981|DRUG|Perjeta|Intravenous drip of 420mg PERJETA
214830308|NCT00830414|DRUG|medroxyprogesterone acetate|IM Injection
214830309|NCT00830414|DRUG|medroxyprogesterone acetate|IM injection
214830310|NCT00894855|BEHAVIORAL|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
214830311|NCT00894855|BEHAVIORAL|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
214830312|NCT00894855|OTHER|dermatologist skin exam|Full body skin exam.
214830313|NCT02426918|DRUG|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
214830314|NCT02426918|DRUG|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
214830315|NCT02426918|DRUG|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
214830316|NCT02426918|DRUG|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
214830317|NCT02426918|DRUG|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
214830318|NCT02426918|DRUG|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
214830319|NCT02845336|DRUG|Celecoxib|celecoxib 100mg PO twice per day for 3 months
214830320|NCT02845336|DRUG|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
214830321|NCT06114836|DRUG|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
214830322|NCT06114836|OTHER|AR formula|Added rice formula will be ordered for 4 weeks.
214830323|NCT02386358|DRUG|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
214830324|NCT02386358|DRUG|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
214830325|NCT03793803|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
214830326|NCT00976443|DRUG|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
214830327|NCT00976443|DRUG|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
214830328|NCT03723733|BEHAVIORAL|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
214830329|NCT02045108|BEHAVIORAL|Active Retraining|
214830330|NCT02045108|DEVICE|Sham TDCS|
214830331|NCT02045108|DEVICE|Active TDCS|
214830332|NCT02045108|BEHAVIORAL|Sham Retraining|
214830333|NCT03780608|DRUG|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
214830334|NCT03780608|DRUG|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
214830335|NCT04702685|DRUG|Ropivacaine|Local anesthetic for injection
214830336|NCT04702685|OTHER|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
214830337|NCT06003933|DRUG|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
214830338|NCT06003933|DRUG|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
214830339|NCT06003933|DEVICE|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
214830340|NCT06003933|DEVICE|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
214830341|NCT04076007|DIETARY_SUPPLEMENT|Beetroot juice|
214830342|NCT04076007|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|
214830343|NCT05865652|DIAGNOSTIC_TEST|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
214830344|NCT02974907|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
214830345|NCT02974907|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
214830346|NCT01430533|DRUG|azelaic acid pre foam formulation|
214830347|NCT01430533|DRUG|Vehicle pre foam formulation|
214830348|NCT01430533|DRUG|Water|
214830349|NCT00004933|DRUG|hydroxyurea|0.5 to 5 grams PO per day
214830350|NCT00004933|DRUG|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
214830351|NCT02827097|DRUG|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
214830352|NCT02827097|DRUG|denogan|administration of denogan
214830353|NCT04146805|DRUG|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
214830354|NCT04146805|DRUG|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
214830355|NCT04703504|OTHER|Multiple intervention program|Support for patient follow-up assisted by a computer program
214830356|NCT04847401|DIAGNOSTIC_TEST|H. pylori stool antigen|using H. pylori antigen kits in stool
214830357|NCT02024048|OTHER|OCT|Optical coherence tomography in enhanced depth imaging mode
214830358|NCT04598763|OTHER|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
214830359|NCT00654186|DRUG|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
214830360|NCT05616728|DRUG|EDP-235|capsule
214830361|NCT05616728|DRUG|Placebo|capsule
214830362|NCT03958812|DIAGNOSTIC_TEST|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
214830363|NCT00690495|DRUG|Propofol|Propofol (drug), intravenous, induction of anesthesia
214830364|NCT00690495|DRUG|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
214830365|NCT01572623|DRUG|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
214830366|NCT01572623|DRUG|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
214830367|NCT01198938|OTHER|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
214830368|NCT01024855|DEVICE|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
214830369|NCT01632423|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
214830370|NCT06377410|DRUG|Syrup Prospan|Participant with stable COPD who received Syrup prospan for 1 month
214830371|NCT06377410|DRUG|N-Acetylcysteine|Participant with stable COPD who received N-Acetylcysteine for 1 month
214830372|NCT04778358|DRUG|Follitropin Delta, Recombinant|15 µg of follitropin delta will be administered subcutaneously daily
214830373|NCT01793584|PROCEDURE|Laparoscopic hysterectomy|LAVH, TLH
214830374|NCT01793584|PROCEDURE|Abdominal hysterectomy|TAH
214830375|NCT02757703|DRUG|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
214830376|NCT02757703|DRUG|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
214830377|NCT02757703|DRUG|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
214830378|NCT02757703|DEVICE|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
214830379|NCT05174390|DIAGNOSTIC_TEST|Coala Heart Monitor Pro|thumb- and chest-ECG
214830380|NCT03049384|OTHER|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
214830381|NCT03049384|OTHER|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
214830382|NCT01003938|DRUG|Topotecan|
214830383|NCT01003938|DRUG|Erlotinib|
214830384|NCT00076622|DRUG|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
214830385|NCT00076622|DRUG|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
214830386|NCT03583398|PROCEDURE|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
214830387|NCT01512628|DRUG|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
214830388|NCT03306277|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
214830389|NCT05210647|DEVICE|robotic surgery|by da Vinci Xi
214830390|NCT05860777|OTHER|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
214830391|NCT00674128|DEVICE|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
214830392|NCT00674128|DEVICE|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
214830393|NCT05614453|DRUG|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
214830394|NCT05614453|DRUG|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
214830395|NCT04224753|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
214830396|NCT05603351|DIAGNOSTIC_TEST|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
214830397|NCT05603351|DIAGNOSTIC_TEST|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
214830398|NCT05603351|PROCEDURE|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
214830399|NCT05283954|DRUG|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
214830400|NCT05283954|DRUG|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
214830401|NCT01572051|BEHAVIORAL|Educational Course|2 Educational courses
214830402|NCT01572051|BEHAVIORAL|Phone Calls|Phone Calls
214830403|NCT01572051|BEHAVIORAL|Printed Material|Printed Material
214830404|NCT03147053|DRUG|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
214830405|NCT03147053|DRUG|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
214830406|NCT04046705|PROCEDURE|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
214830407|NCT04046705|OTHER|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
214830408|NCT04431505|OTHER|apoptosis|study of apoptotic changes due to anaesthesia
214830409|NCT03209505|DEVICE|Acuvue Oasys|FDA approved contact lens, fit for daily wear
214830410|NCT03209505|DEVICE|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
214830411|NCT03574805|DRUG|PRS-060|Study drug
214830412|NCT03574805|DRUG|Placebo|Inhalant designed to mimic PRS-060
214830413|NCT04058977|OTHER|Power training|Progressive exercise protocol with focus on velocity of movement
214830414|NCT03097198|OTHER|Plum-blossom Needle|"* acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
214830415|NCT03097198|DRUG|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
214830416|NCT00253305|DRUG|Organogel of naftifine, 2%|
214830417|NCT00253305|DRUG|Organogel of terbinafine, 2%|
214830418|NCT00253305|DRUG|Organogel of naftifine, 6%|
214830419|NCT00253305|DRUG|Organogel of terbinafine, 6%|
214830420|NCT06007729|DRUG|HS-20093|Participants in all subjucts will receive HS-20093 at 10mg/kg
214830421|NCT06562920|DRUG|adebrelimab and chemotherapy|3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
214830422|NCT04285268|DRUG|Bortezomib|Given IV or SC
214830423|NCT04285268|BIOLOGICAL|Rituximab|Given IV
214830424|NCT04285268|DRUG|Venetoclax|Given PO
214830425|NCT03459235|OTHER|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
214830426|NCT04432558|DIAGNOSTIC_TEST|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
214830427|NCT04432558|OTHER|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
214277471|NCT04274413|COMBINATION_PRODUCT|Beta Adrenergic Sweat Test|"In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded."
214830428|NCT04432558|DRUG|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
214830429|NCT02412358|DEVICE|toothbrush|
214830430|NCT05623592|DRUG|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
214830431|NCT05623592|DRUG|Sodium chloride|Sodium chloride subcutaneously
214830432|NCT03717701|DRUG|metformin|Patients will take metformin single dose of 1000 mg orally once a day
214830433|NCT03717701|DRUG|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
214830434|NCT03717701|DRUG|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
214830435|NCT04888767|OTHER|Interval Training Hight Intensity Program|"* Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
214830436|NCT04987554|DIETARY_SUPPLEMENT|glycophosphopeptical AM3|3 g/day of AM3
214830437|NCT04987554|OTHER|Placebo|3 g/day of placebo
214830438|NCT00829452|DRUG|Ramipril 10 mg capsule|1 x 10 mg
214830439|NCT00829452|DRUG|Altace® 10 mg capsule|1 x 10 mg
214830440|NCT05239585|DEVICE|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
214830441|NCT05945472|OTHER|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
214830442|NCT05945472|OTHER|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
214830443|NCT01425840|DRUG|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
214830444|NCT02495207|DEVICE|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
214830445|NCT00991796|DRUG|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
214830446|NCT00991796|DRUG|Placebo|Placebo
214830447|NCT00991796|DRUG|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
214830448|NCT00991796|DRUG|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
214830449|NCT06560034|DEVICE|VicorderCS|"1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis"
214830450|NCT00740896|BEHAVIORAL|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
214830451|NCT00740896|BEHAVIORAL|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
214830452|NCT05264896|DRUG|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
214830453|NCT05264896|DRUG|XELOX|XELOX 8 cycles post radical gastrectomy
214830454|NCT04339634|OTHER|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
214830455|NCT01371617|DRUG|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
214830456|NCT03082586|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
214830457|NCT03082586|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
214830458|NCT03082586|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
214830459|NCT03082586|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
214830460|NCT03082586|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
214830461|NCT03082586|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
214830462|NCT05448235|OTHER|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
214830463|NCT05448235|OTHER|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
214830464|NCT01296841|DEVICE|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
214277472|NCT00225550|DRUG|ADH -1 (Exherin™)|
214277473|NCT05953311|OTHER|Blood analysis|Blood analysis for neurological biomarkers measurements
214830465|NCT01207479|DEVICE|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
214830466|NCT01412827|RADIATION|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
214830467|NCT03340623|DEVICE|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
214830468|NCT06089395|DRUG|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
214830469|NCT06089395|DRUG|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
214830470|NCT06561308|DRUG|Pucotenlimab|Pucotenlimab is administered at 200mg, q3w，intravenous infusion
214830471|NCT06561308|DRUG|Carboplatin|AUC=4-6，q3w，intravenous infusion
214830472|NCT06561308|DRUG|Paclitaxel|175 mg/m2，q3w，intravenous infusion, administered over 30min.
214830473|NCT06561308|PROCEDURE|Surgery|Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection
214830474|NCT04758208|DIAGNOSTIC_TEST|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
214830475|NCT03168659|DEVICE|HeartLight|HeartLight Endoscopic Ablation System
214830476|NCT03168659|PROCEDURE|Ablation|Pulmonary vein isolation ablation
214830477|NCT01174849|DRUG|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
214830478|NCT01174849|DRUG|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
214830479|NCT01174849|DRUG|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
214830480|NCT02849106|PROCEDURE|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
214830481|NCT00981838|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
214830482|NCT06251349|RADIATION|Radiation|Single dose radiation with 7-8 Gy
214830483|NCT06251349|DRUG|Diclofenac|postoperative treatment with diclofenac to prevent HO
214830484|NCT04342936|DRUG|Camrelizumab|A humanized monoclonal immunoglobulin
214830485|NCT04342936|DRUG|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
214277474|NCT05953311|OTHER|Cognitive tests|Questionnaires assessing cognitive function
214830486|NCT00919737|DRUG|NPC-08|Polifeprosan 20 with Carmustine 3.85%
214830487|NCT00975754|DRUG|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
214830488|NCT00975754|DRUG|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
214830489|NCT00975754|DRUG|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
214830490|NCT00975754|DRUG|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
214830491|NCT02784236|DEVICE|telemedicine|The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
214830492|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
214830493|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
214830494|NCT01492556|DRUG|Etoposide|Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
214830495|NCT05252377|OTHER|Breathing Exercise|"1. The patient will be asked to close their eyes~2. He will be asked to relax his head and neck in a semi-sitting position in bed~3. The patient will be asked to breathe through the nose for 3 seconds by counting~4. Then he will be told to hold his breath for 3 seconds~5. As the last step, he will be asked to breathe out again in 3 seconds."
214830496|NCT00881751|BIOLOGICAL|bevacizumab|Given IV
214830497|NCT00881751|DRUG|erlotinib hydrochloride|Given orally
214830498|NCT00881751|DRUG|sorafenib tosylate|Given orally
214830499|NCT04431518|DRUG|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
214830500|NCT05406518|OTHER|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
214830501|NCT04879719|BEHAVIORAL|Ego-depletion|The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.
214830502|NCT04879719|BEHAVIORAL|Control|The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
214830503|NCT04031690|OTHER|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
214830504|NCT04031690|OTHER|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
214830505|NCT00375284|DRUG|Pramipexole|
214830506|NCT03354858|PROCEDURE|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
214830507|NCT03633721|DRUG|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
214830508|NCT03633721|OTHER|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
214830509|NCT00301964|BIOLOGICAL|bevacizumab|Given IV
214830510|NCT00301964|OTHER|laboratory biomarker analysis|Correlative studies
214830511|NCT00827164|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
214830512|NCT00827164|BEHAVIORAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
214830513|NCT04866979|DEVICE|Experimental: Continuous TBS (cTBS)|Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.
214830514|NCT04866979|DEVICE|Intermittent TBS (iTBS)|Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.
214830515|NCT04866979|BEHAVIORAL|Cognitive training (CT).|Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.
214830516|NCT04866979|DEVICE|Sham Stimulation (shamTBS)|"Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
214830517|NCT02033902|DRUG|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
214830518|NCT02245503|DRUG|Tamsulosin|
214830519|NCT06557603|DRUG|Ivermectin cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
214830520|NCT06557603|DRUG|Soolantra ® (Ivermectin) cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
214830521|NCT01852799|DRUG|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
214830522|NCT03475433|DEVICE|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
214277475|NCT02578316|DRUG|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
214830523|NCT02385708|DRUG|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
214830524|NCT02385708|DRUG|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
214830525|NCT03791307|OTHER|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
214830526|NCT03791307|OTHER|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
214830527|NCT05561088|OTHER|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
214830528|NCT05561088|OTHER|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
214830529|NCT05453487|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
214830530|NCT05453487|BIOLOGICAL|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
214830531|NCT05453487|BIOLOGICAL|rabies vaccine|received three dose of rabies vaccine
214830532|NCT02225015|BEHAVIORAL|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
214830533|NCT04838353|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
214830534|NCT01437761|DEVICE|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
214830535|NCT00834561|DRUG|Lamotrigine|200 mg Tablet
214830536|NCT00834561|DRUG|Lamictal®|200 mg Tablet
214830537|NCT03065751|DEVICE|Plasmaexchange|TPE against fresh frozen plasma
214830538|NCT05533411|DRUG|Donanemab|Administered IV.
214830539|NCT05533411|DRUG|Placebo|Administered IV.
214830540|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
214830541|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
214830542|NCT01559363|DRUG|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
214830543|NCT03810963|COMBINATION_PRODUCT|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
214830544|NCT03810963|OTHER|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
214830545|NCT00672984|DRUG|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
214830546|NCT00672984|DRUG|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
214830547|NCT00672984|DRUG|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
214830548|NCT05022979|OTHER|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
214830549|NCT00645853|DRUG|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
214830550|NCT00645853|DRUG|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
214830551|NCT01746472|BEHAVIORAL|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
214830552|NCT01746472|BEHAVIORAL|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
214830553|NCT01746472|BEHAVIORAL|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
214830554|NCT01746472|BEHAVIORAL|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
214277476|NCT01686529|PROCEDURE|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
214277477|NCT01686529|DRUG|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
214830555|NCT02327559|BEHAVIORAL|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
214830556|NCT02327559|BEHAVIORAL|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
214830557|NCT06410638|DIAGNOSTIC_TEST|Six Minute Walking Test|It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
214830558|NCT06410638|DIAGNOSTIC_TEST|Shuttle walking test|Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
214830559|NCT05409651|BEHAVIORAL|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
214830560|NCT06563232|DEVICE|FNA group|Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
214830561|NCT06563232|DEVICE|Adapt FNB group|Fine-needle-biopsy (22G Adapt Aspiration)
214830562|NCT01717352|BEHAVIORAL|Weight Loss Education|
214830563|NCT01717352|BEHAVIORAL|Sleep and Eating Routine|
214830564|NCT04736303|DEVICE|BIS|The implementation of BIS monitoring
214830565|NCT03168503|DIETARY_SUPPLEMENT|LGG+Promitor™|synbiotic
214830566|NCT03168503|DIETARY_SUPPLEMENT|Promitor™|Soluble Corn Fiber
214830567|NCT03168503|DIETARY_SUPPLEMENT|LGG-PB12+Promitor™|synbiotic
214830568|NCT03168503|DIETARY_SUPPLEMENT|Maltodextrin|Control
214830569|NCT00870116|RADIATION|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
214830570|NCT00870116|RADIATION|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
214830571|NCT00870116|RADIATION|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
214830572|NCT04060251|DEVICE|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
214830573|NCT04060251|OTHER|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
214830574|NCT06188663|DIETARY_SUPPLEMENT|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
214830575|NCT06298162|OTHER|2 years after RYGB, no intervention. MRI measurement. Observational.|no intervention. MRI measurement. Observation.
214830576|NCT01127113|OTHER|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
214830577|NCT01127113|OTHER|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
214277478|NCT02166905|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
214830578|NCT06389227|OTHER|dynamic ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
214830579|NCT06389227|OTHER|traditional training group|The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
214830580|NCT02588781|DRUG|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
214830581|NCT00937664|DRUG|AZD7762|solution, intravenous, weekly
214277479|NCT02166905|DRUG|Epacadostat|Given PO
214830582|NCT00937664|DRUG|gemcitabine|intravenous, weekly
214830583|NCT04031235|BEHAVIORAL|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
214830584|NCT04031235|BEHAVIORAL|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
214830585|NCT01151618|DEVICE|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
214830586|NCT02545179|OTHER|web-based daily care training|12 week interactive web based caring training education
214830587|NCT01632306|DRUG|LY2090314|LY2090314 administered IV
214277480|NCT02166905|OTHER|Laboratory Biomarker Analysis|Correlative studies
214277481|NCT02166905|OTHER|Pharmacological Study|Correlative studies
214277482|NCT02166905|DRUG|Poly ICLC|Given SC
214830588|NCT01632306|DRUG|FOLFOX|FOLFOX administered IV
214830589|NCT01632306|DRUG|Gemcitabine|Gemcitabine administered IV
214830590|NCT01632306|DRUG|Nab-paclitaxel|Nab-paclitaxel administered IV
214830591|NCT02510872|OTHER|18F-FDG PET combined with CT with iodinated contrast injection|
214830592|NCT02510872|OTHER|18F-FDG PET combined with CT without injection|
214830593|NCT04385485|PROCEDURE|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
214830594|NCT04385485|PROCEDURE|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
214830595|NCT05264207|BEHAVIORAL|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
214830596|NCT05264207|BEHAVIORAL|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
214830597|NCT05388071|OTHER|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
214830598|NCT00070122|DRUG|oxaliplatin|Given IV
214830599|NCT00070122|DRUG|leucovorin calcium|Given IV
214830600|NCT00070122|DRUG|capecitabine|Given orally
214830601|NCT00070122|BIOLOGICAL|bevacizumab|Given IV
214830602|NCT00070122|DRUG|fluorouracil|Given IV
214830603|NCT00070122|OTHER|laboratory biomarker analysis|Correlative studies
214830604|NCT00988468|PROCEDURE|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
214830605|NCT00988468|BEHAVIORAL|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
214830606|NCT00988468|BEHAVIORAL|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
214830607|NCT04091763|DRUG|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
214830608|NCT04091763|DEVICE|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
214830609|NCT04551183|OTHER|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
214830610|NCT04551183|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
214277483|NCT04254497|DIAGNOSTIC_TEST|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with \> 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (\> 8000 pores/mm\^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
214830611|NCT01156987|DEVICE|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
214830612|NCT02734511|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
214830613|NCT04509154|OTHER|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
214830614|NCT04509154|OTHER|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
214830615|NCT04584086|DEVICE|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation."
214830616|NCT01723683|DRUG|Surfactant|
214830617|NCT05088551|OTHER|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
214830618|NCT00919516|PROCEDURE|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
214830619|NCT00838162|DRUG|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
214830620|NCT00838162|DRUG|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
214830621|NCT00838162|DRUG|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
214830622|NCT00838162|DRUG|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
214830623|NCT00838162|DRUG|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
214830624|NCT00838162|DRUG|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
214830625|NCT02313662|DEVICE|NBI and PDD|
214830626|NCT01230229|PROCEDURE|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
214830627|NCT01230229|OTHER|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
214830628|NCT04965831|DRUG|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
214830629|NCT06013163|DRUG|Xenical® vs EMP 22|Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
214830630|NCT06013163|DRUG|EMP 22 vs Xenical®|Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
214830631|NCT06013163|DRUG|EMP 16 vs Xenical®|Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
214830632|NCT02684786|DRUG|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
214830633|NCT02684786|PROCEDURE|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
214277484|NCT00096798|DRUG|Ethyl-eicosapentanoic acid (ethyl-EPA)|
214277485|NCT05041205|DIETARY_SUPPLEMENT|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
214830634|NCT02684786|DRUG|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
214830635|NCT01980173|PROCEDURE|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
214830636|NCT01980173|DEVICE|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
214830637|NCT06316180|DRUG|drospirenone/estetrol 3mg/14.2mg|Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
214830638|NCT00903292|DRUG|erlotinib (Tarceva)|chemotherapy with erlotinib
214830639|NCT00903292|DRUG|pemetrexed (Alimta)|Chemotherapy with pemetrexed
214830640|NCT06411392|RADIATION|Stereotactic Antiarrhythmic Radiotherapy|Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
214830641|NCT00169130|DRUG|doxorubicin|
214830642|NCT00169130|DRUG|cyclophosphamide|
214830643|NCT00169130|PROCEDURE|Autologous stem cell transplantation|
214830644|NCT04775316|DEVICE|Leukomed T / Tplus skin sensitive treatment|Application of sterile wound dressing.
214830645|NCT01781117|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
214830646|NCT01781117|DEVICE|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
214830647|NCT00834314|PROCEDURE|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
214830648|NCT00834314|PROCEDURE|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
214830649|NCT01714284|BEHAVIORAL|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
214830650|NCT01714284|BEHAVIORAL|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
214830651|NCT00459407|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
214830652|NCT00459407|DRUG|placebo|Given orally
214830653|NCT00459407|OTHER|immunohistochemistry staining method|Correlative studies
214830654|NCT00459407|OTHER|immunoenzyme technique|Correlative studies
214830655|NCT00459407|OTHER|laboratory biomarker analysis|Correlative studies
214830656|NCT00459407|PROCEDURE|biopsy|Undergo biopsy
214830657|NCT00459407|OTHER|mass spectrometry|Correlative studies
214830658|NCT00459407|OTHER|high performance liquid chromatography|Correlative studies
214830659|NCT03618615|BIOLOGICAL|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
214830660|NCT01336088|DRUG|ADX48621|oral administration
214830661|NCT01336088|DRUG|Placebo|oral administration
214830662|NCT03563443|DIAGNOSTIC_TEST|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
214830663|NCT04630795|DEVICE|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
214830664|NCT04630795|DEVICE|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
214830665|NCT00614276|BEHAVIORAL|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
214277486|NCT05041205|DEVICE|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
214830666|NCT00614276|BEHAVIORAL|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
214830667|NCT00614276|BEHAVIORAL|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
214830668|NCT00614276|BEHAVIORAL|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
214830669|NCT00734825|OTHER|Omnipaque|oral contrast for CT scan
214830670|NCT06181422|DRUG|Metformin|metformin 500 mg
214830671|NCT06181422|DRUG|Lactoferrin|lactoferrin 100 mg
214830672|NCT06416449|OTHER|kinesiotape application|"In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
214830673|NCT03300687|DRUG|FX-322|intratympanic injection
214830674|NCT03300687|DRUG|Placebo|intratympanic injection
214830675|NCT00858403|DRUG|Dasatinib|Take tablets of Dasatinib by mouth once a day.
214830676|NCT01167335|DRUG|BGG492|
214830677|NCT01167335|DRUG|Placebo|
214830678|NCT02193022|DRUG|Miltefosine|
214830679|NCT04264221|BEHAVIORAL|New management mode|"* New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
214830680|NCT02553863|PROCEDURE|Acupuncture|Acupuncture for 30min \[twice weekly for 8 weeks\]
214830681|NCT02553863|PROCEDURE|Standard care|Standard care
214830682|NCT05370807|DRUG|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
214830683|NCT05370807|DRUG|Triplet therapy|Regorafenib in combination with BRAF- / MEK- inhibitors
214830684|NCT01202435|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
214830685|NCT01202435|DRUG|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
214830686|NCT04817722|DRUG|Intravenous Solution|Intraoperative hydration
214830687|NCT03867760|BEHAVIORAL|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
214830688|NCT03867760|BEHAVIORAL|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
214830689|NCT02243579|OTHER|Laboratory Biomarker Analysis|Correlative studies
214830690|NCT02243579|BIOLOGICAL|Pembrolizumab|Given IV
214830691|NCT04792723|DRUG|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
214830692|NCT04792723|DRUG|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
214830693|NCT03183622|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
214830694|NCT06331572|DIAGNOSTIC_TEST|17-HAMD|Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
214830695|NCT02417571|DEVICE|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
214830696|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
214830697|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
214830698|NCT04636034|PROCEDURE|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
214830699|NCT03420053|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
214830700|NCT03420053|OTHER|Normal Saline Placebo|0.9% sodium chloride solution
214830701|NCT03420053|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
214830702|NCT01726933|DRUG|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
214830703|NCT01726933|DRUG|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
214830704|NCT01726933|DRUG|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
214830705|NCT00757419|DRUG|AZD3355|capsules, oral, single or twice daily dose
214830706|NCT00757419|DRUG|Placebo|To match dosing of AZD3355
214830707|NCT06623162|DRUG|gemcitabine + cisplatine|4 cycles
214830708|NCT07009093|OTHER|Mighty Pro Application|Access to Mighty Pro Application
214830709|NCT02286466|BEHAVIORAL|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
214830710|NCT02286466|BEHAVIORAL|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
214830711|NCT02153645|DRUG|240mg Amantadine HCl ER tablets|
214830712|NCT02153645|DRUG|Placebo tablets|
214830713|NCT02153645|DRUG|320mg Amantadine HCl ER tablets|
214830714|NCT00704639|DRUG|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
214830715|NCT00704639|DRUG|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
214830716|NCT00704639|RADIATION|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
214830717|NCT02438735|PROCEDURE|laparoscopic endometrioma excision|
214830718|NCT02438735|OTHER|Conservative follow up|
214830719|NCT00874276|DRUG|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
214830720|NCT00874276|GENETIC|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
214830721|NCT03967262|BEHAVIORAL|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
214830722|NCT05201339|PROCEDURE|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
214830723|NCT05201339|PROCEDURE|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
214830724|NCT06582264|BIOLOGICAL|MB310|Live bacterial therapeutic for oral administration
214830725|NCT06582264|OTHER|Placebo|MB310-matching placebo for oral administration
214830726|NCT06582264|DRUG|Vancomycin|Antibiotic
214830727|NCT06804486|BEHAVIORAL|Exercise|Exercise and physical-sports activity program
214830728|NCT06804486|OTHER|Recommendation to Deprescribe|Recommendation to Deprescribe
214830729|NCT04085861|BEHAVIORAL|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
214830730|NCT04085861|BEHAVIORAL|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
214830733|NCT01723202|DRUG|dabrafenib|150 mg orally twice daily given orally
214830734|NCT01723202|DRUG|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
214830735|NCT07070856|DIETARY_SUPPLEMENT|WHO-recommended standard therapeutic milk used for stabilization phase in SAM)|F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
214830736|NCT07070856|DIETARY_SUPPLEMENT|HO-recommended Rice based therapeutic milk used for stabilization phase in SAM)|Rice based F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
214830737|NCT03694197|DRUG|Praluent|Subcutaneous (SC) administration
214830738|NCT04428281|DRUG|RO7248824|In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
214830739|NCT05564715|DEVICE|NeuroElectric StarStim|10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks
214830740|NCT05564715|DEVICE|Sham Treatment|Sham stimulation for 10 sessions over 2 weeks
214830741|NCT03806257|OTHER|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
214830742|NCT07097493|DRUG|Liposomal Bupivacaine|10 ml of 0.25% bupivacaine expanded with 133 mg (10 ml volume) of liposomal bupivacaine into both the adductor canal and iPACK blocks (total of 40 ml)
214830743|NCT07097493|DRUG|Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination|20 ml of solution consisting of 0.25% bupivacaine, 1.667mcg/ml of clonidine, 1:400,000 epinephrine, 0.15 mg total of buprenorphine, and 2 mg total of preservative free dexamethasone which will be used in both the adductor canal block and iPACK block (total of 40 ml)
214830744|NCT04571801|DIAGNOSTIC_TEST|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
214830745|NCT04571801|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
214830746|NCT02957331|DRUG|Propranolol|
214830747|NCT05543720|DEVICE|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
214830748|NCT00856167|DRUG|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
214830749|NCT00856167|BEHAVIORAL|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
214830750|NCT07102875|BEHAVIORAL|Sailing Intervention Plus Home-Based Telerehabilitation|A two-phase rehabilitation program combining 5 days of intensive sailing therapy with a 3-month home-based telerehabilitation plan. The sailing component includes group-based activities in adapted sailing environments, conducted in Marina di Ravenna or Palermo, with daily debriefing and psychosocial support. The telerehabilitation component includes twice-weekly supervised sessions delivered via a digital platform, focusing on progressive motor, proprioceptive, and postural exercises. The intervention aims to improve motor function, quality of life, and psychosocial well-being in individuals with rare skeletal disorders.
214830751|NCT07102875|BEHAVIORAL|Home-Based Telerehabilitation|Participants perform a 3-month home-based rehabilitation program consisting of two remote sessions per week via a supervised digital platform. Each session includes warm-up, strength and coordination exercises, and cool-down. Exercises are progressive and standardized, but adapted to individual needs to ensure safety and adherence. The intervention targets motor function, balance, proprioception, and psychosocial outcomes, without any sailing component. This arm serves as the active comparator.
214830752|NCT07107516|BIOLOGICAL|PanChol|Panchol is a novel live attenuated oral cholera vaccine. It is the first vaccine created with the variant El Tor background that is predominant in the world today. The vaccine has ten different genetic modifications to minimize reactogenicity but maintain the ability to colonize the intestine.
214830753|NCT05196334|OTHER|No intervention|No intervention
214830754|NCT07140068|DEVICE|Handled dental flossing system (GumChucks®)|Handled dental flossing system (GumChucks®) designed for easier C-shape flossing. Participants were instructed to clean all interdental spaces on the assigned side twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
214830755|NCT07140068|DEVICE|Interdental Brush|Appropriately sized interdental brushes for cleaning interdental spaces on the assigned side. Participants were instructed to clean twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
214830756|NCT07139262|BEHAVIORAL|Climate-Resilient Disaster Preparedness Education Program|A structured educational program designed to enhance nursing students' knowledge and skills in climate-resilient disaster preparedness. The program consisted of four weekly sessions (2 hours each) delivered through lectures, interactive group discussions, and simulation-based exercises. Core content included disaster risk reduction principles, emergency response protocols, climate-related hazard preparedness, psychological first aid, triage procedures, and resilience-building strategies. Training materials were validated by subject matter experts and culturally adapted for the Saudi nursing education context.
214830757|NCT07139262|OTHER|Standard Nursing Curriculum|Participants continued their regular undergraduate nursing curriculum without additional specialized training in disaster preparedness or climate resilience. This curriculum provided foundational nursing education but did not include structured sessions on climate-related disaster management or resilience-building.
214830758|NCT07138976|OTHER|sampling tissue|EUS- and US- guided pancreatic biopsy
214830759|NCT07139431|BIOLOGICAL|NCR100|Subjects will receive a single injection of NCR100
214830760|NCT07139691|PROCEDURE|Pre-incisional Transversus Abdominis Plane (TAP) block performed under ultrasound guidance. The block will be administered bilaterally using a mixture of lidocaine and ropivacaine 0.2%|After the induction of general anesthesia, bilateral TAP block will be performed in patients from Group 1. The administered dose will include 0.2% lidocaine combined with 0.2% ropivacaine, at a dose of 0.4 ml/kg per side, without exceeding toxic dose limits per kg.
214830761|NCT07139691|DRUG|Participants in this arm will receive standard analgesia for postoperative pain management following elective hysterectomy|Participants in this arm will receive standard multimodal systemic analgesia for postoperative pain management following elective hysterectomy. The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV. Additional rescue doses of Tramadol (50-100 mg IV every 4-6 hours) may be administered based on pain intensity, with a maximum of 400 mg/24 hours (or 300 mg/24 hours for patients aged ≥75 years). No Transversus Abdominis Plane (TAP) block will be performed in this group. Pain intensity, opioid use, and postoperative recovery scores will be evaluated and compared with the TAP block intervention group.
214830762|NCT07138534|BEHAVIORAL|prehabilitation|In addition to exercise programmes, it includes nutritional optimisation, psychosocial preparation and smoking cessation.
214830763|NCT07140458|OTHER|Buteyko Breathing|"Buteyko Breathing is a technique focusing on controlled, reduced breathing to improve oxygen uptake and reduce hyperventilation-related symptoms using Air hunger.~Procedure:-~After gaining proper relaxation:~1. Exhale slowly, and then hold that breath.~2. Use the index finger and thumb to plug the nose.~3. Hold that breath until there is an urge to breathe, and then inhale.~4. Breathe normally for at least 10 seconds.~5. Repeat several times."
214830764|NCT07140458|OTHER|Box breathing|"Box Breathing (4-4-4-4 Technique) - Box Breathing exercises boosts lung function by optimizing oxygen flow and activating relaxation responses.Each exercise Sessions included 20 cycles of Box Breathing.~The procedure of the box breathing cycle includes:~1. inhale for 4 seconds~2. Hold the breath for 4 seconds~3. Exhale for 4 seconds~4. Hold the breath for 4 seconds, and repeat."
214830765|NCT07139834|DRUG|SSRI (escitalopram or sertraline)|11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
214830766|NCT07139834|DRUG|Extended-Release Memantine|6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
214830767|NCT07139834|DRUG|Placebo|6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment
214830768|NCT07138963|DIAGNOSTIC_TEST|Genetic Testing and Muscle Biopsy|Comprehensive diagnostic assessment including clinical examination, electromyography (EMG), muscle biopsy for histopathological evaluation, and genetic testing to determine phenotype-genotype correlation in congenital myopathies and muscular dystrophies.
214830769|NCT07139535|DRUG|RAY1225|Administered SC
214830770|NCT07139535|DRUG|placebo|Administered SC
214830771|NCT07140406|OTHER|conventional rehabilitation training|The rehabilitation training is designed based on the specific functional conditions of the patient's limbs. The specific training methods include proper limb positioning, exercise therapy such as passive movement, anti-spasticity training, scapular girdle muscle training, joint extension training, forearm pronation and supination training, occupational therapy, joint movement training, roller treatment, and fine motor skill training, etc. The treatment is conducted once a day and five times a week. The treatment lasts for 4 consecutive weeks.
214830772|NCT07140406|OTHER|conventional acupuncture|Conventional acupuncture treatment involves needling at acupoints on the upper limbs of patients to improve their upper limb function. The treatment is administered once a day, five times a week, for a continuous period of four weeks.
214830773|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on flexor muscle groups|The acupuncture points of the milli-needle fire-puncture device are located in the flexor muscle groups of the upper limbs, including the biceps brachii and the flexor muscle group of the forearm.
214830774|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on extensor muscle groups|The acupuncture points for the milli-needle fire-puncture device are located in the extensor muscle groups of the upper limbs, including the triceps brachii and the extensor muscles of the forearm.
214830775|NCT07140406|OTHER|Conventional needle puncture with a fire needle|The acupuncture points for milli-needle fire-puncture are commonly used ones on the upper limbs.
214830776|NCT07138989|DRUG|Valganciclovir Hydrochloride Tablets|Valganciclovir hydrochloride tablets will be administered at 900 mg twice daily from day 1 to day 14, followed by 450 mg twice daily from day 15 to day 20, for a total of 3 cycles.
214830777|NCT07138989|DRUG|gemcitabine, cisplatin, and PD-1 antibody|"Gemcitabine 1000 mg/m² will be administered intravenously on days 1 and 8; cisplatin 80 mg/m² intravenously on day 1; and PD-1 antibody intravenously on day 1. Each cycle is 21 days in duration, and treatment will be administered for a total of 4 to 6 cycles.~Following completion of the 4 to 6 cycles, patients will continue PD-1 antibody maintenance therapy (every 3 weeks) for up to two years or until disease progression, unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of informed consent, or death."
214830778|NCT07139340|OTHER|HA gel|Hyaluronic Acid gel 0.8% 1 mL
214830779|NCT07139067|BIOLOGICAL|YK1101 cells|Drug: Fludarabine + Cyclophosphamide
214830780|NCT07138872|PROCEDURE|Prone Position Percutaneous Nephrolithotomy|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the prone position. The procedure begins with ureteral catheter placement in lithotomy position, followed by prone positioning for renal access under C-arm fluoroscopic guidance. Stone fragmentation will be performed using pneumatic or ultrasonic lithotripters, and nephrostomy placement will be completed according to standard protocol.
214830781|NCT07138872|PROCEDURE|Supine Position Percutaneous Nephrolithotomy (Galdakao-modified Valdivia)|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the Galdakao-modified Valdivia supine position. Following general anesthesia, the ipsilateral side will be elevated 20-30°, with the ipsilateral leg extended and the contralateral leg abducted. Ureteral catheter placement will be followed by renal access under C-arm fluoroscopy. Stone fragmentation and removal will be performed using the same standardized lithotripsy and irrigation protocols as in the prone group.
214830782|NCT07139444|OTHER|One time Physical Therapy Evaluation|"A physical therapist will perform an evaluation which will consist of history taking and assessing the following: strength, endurance, range of motion, sitting/standing balance, sensory testing, and skin integrity. Following these assessments, the physical therapist will assess participant's functional mobility which involves assessing how you get out of bed, standing up, and walking. The physical therapist will also assess the participant on three tests which help determine your balance and assistance required with functional mobility. The tests that will be performed in no particular order are PASS, MSAS, AM-PAC 6-Clicks, OPS, MRS, and FCI. Data for the AM-PAC daily activity and applied cognition domains will be obtained from the patient's chart from the Occupational Therapy evaluation. Discharge destination information will be obtained from the PT evaluation and the discharge destinations will be acute/inpatient rehab, SAR, SNF, Home with or without home PT, and outpatient PT."
214830783|NCT07139041|DRUG|Iparomlimab and tuvonralimab plus chemotherapy|"Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (Day 1) + Albumin-bound Paclitaxel (100mg/m² Q3W D1/D8/D15 or130mg/m²D1/D8 or 260mg/m²D1) + Carboplatin (AUC=5) Q3W (D1) Non-Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) + Pemetrexed 500mg/m² Q3W (D1) + Carboplatin (AUC=5) Q3W (D1) Radical Chemoradiotherapy for Patients Unable to Undergo Surgery:Patients still unresectable after conversion therapy should start radical chemoradiotherapy within 6 weeks after the last conversion therapy dose. Chemoradiotherapy follows standard clinical practice, recommended as Cisplatin 30mg/m² QW (D1) + 60Gy radiotherapy.~Adjuvant Therapy Phase:Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) for up to 16 cycles."
214830784|NCT07138820|PROCEDURE|Parathyroidectomy|Imaging with 18-F-choline-PET-CT
214830785|NCT07139379|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
214830786|NCT07139379|OTHER|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy using goggle
214830787|NCT07139379|OTHER|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy using goggle
214830788|NCT07139808|DEVICE|GK5 CGKM|Wear for a consecutive 15 days
214830789|NCT07140055|DRUG|BLX-7006|BLX-7006 Single or Multiple doses administered orally as a tablet
214830790|NCT07140055|DRUG|Placebo|Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
214830791|NCT07140250|OTHER|Education with AI Technology|Shared decision making (SDM) about sinusitis treatment will be facilitated by AI technology via ChatGPT
214830792|NCT07140250|OTHER|Education using Traditional Internet Search Engines|Participant Education in Sinusitis using Traditional Internet Search Engines through Google
214830793|NCT07140432|OTHER|Bone scintigraphy|A bone scintigraphy exam will be performed in addition of the already performed scanner in the current practice
214830794|NCT07139405|DRUG|Metformin XR 1000mg|Arm 1: Metformin XR 1000mg Monotherapy (taken AM)
214830795|NCT07139405|DRUG|Valsartan 80mg Tablet|Arm 2: Valsartan 80mg (taken PM)
214830796|NCT07139405|DRUG|Valsartan 160mg tablet|Arm 3: Valsartan 160mg (taken PM)
214830797|NCT07139405|DRUG|Celecoxib (Celebrex®) 100mg|Arm 2: Celecoxib 100mg (taken AM)
214830798|NCT07139405|DRUG|Celecoxib (Celebrex®) 200mg|Arm 3: Celecoxib (taken AM)
214830799|NCT07139405|DRUG|Metformin XR 500 mg|Arm 2: Metformin 500mg (taken AM)
214830800|NCT03834077|OTHER|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
214830801|NCT03834077|OTHER|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
214830802|NCT07140562|DEVICE|Tricuspid Annular Therapy System|A transcatheter device designed for tricuspid valve repair.
214830803|NCT07140484|DRUG|Sotatercept|0.7mg/kg
214830804|NCT07139912|DEVICE|Thoracic Aortic Multi-Branch Stent Graft System|The Thoracic Aortic Multi-Branch Stent Graft Systemm consists of the Single-Branch Aortic Stent-Graft System, the aortic extension stent graft system and the branch stent system.
214830805|NCT07139353|DRUG|Linperlisib|Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II)
214830806|NCT07139353|DRUG|Chidamide|Chidamide: 20mg, po, biw
214830807|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -0.75mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
214830808|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -1.5mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
214830809|NCT07140328|DRUG|HSK39004 Inhalation Suspension -3mg BID|HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day； And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ；
214830810|NCT07140328|DRUG|HSK39004 Placebo|HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
214830811|NCT05419934|BEHAVIORAL|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization."
214830812|NCT05419934|BEHAVIORAL|CBT Control therapy|Children in the control group receive Cognitive Behavioral Therapy (CBT) administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P).Cognitive and behavioral therapies are a standard treatment in the care service. Children in the control group will receive CBT specific to the treatment of PTSD in children under 6 years of age. CBT treatments dedicated to early childhood trauma have already been tested in the United States, and have shown evidence of effectiveness in randomized controlled trials (Mc Guire et al., 2021; Scheeringa et al., 2011).
214830813|NCT03426540|DRUG|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
214830814|NCT04735172|OTHER|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~* Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~* Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
214830815|NCT01016340|DRUG|MCS|MCS-5 Softgel 5 mg
214830816|NCT03247686|DRUG|RSLV-132|RNase Fc fusion protein
214830817|NCT03247686|DRUG|Placebo|Placebo
214830818|NCT04688515|BEHAVIORAL|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
214830819|NCT00070239|DRUG|alvocidib|Given IV
214830820|NCT00070239|OTHER|pharmacological study|Correlative studies
214830821|NCT00070239|RADIATION|fludeoxyglucose F 18|Correlative studies
214830822|NCT00070239|OTHER|fluorine F 18 fluorothymidine|Correlative studies
214830823|NCT00070239|PROCEDURE|positron emission tomography|Correlative studies
214830824|NCT01487499|DRUG|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
214830825|NCT06512519|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)"
214830826|NCT03495206|DRUG|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
214830827|NCT03102879|PROCEDURE|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
214830828|NCT03102879|PROCEDURE|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
214830829|NCT03561987|PROCEDURE|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
214830830|NCT04067193|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
214830831|NCT06467097|RADIATION|SBRT(Stereotatic Body Radiation Therapy)|Patients will receive treatment for one to two weeks, one to five times per region.
214830832|NCT00781430|DRUG|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
214830833|NCT03224143|BEHAVIORAL|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
214830834|NCT03224143|BEHAVIORAL|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
214830835|NCT06149767|DRUG|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
214830836|NCT01135784|DIETARY_SUPPLEMENT|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
214830837|NCT01135784|DIETARY_SUPPLEMENT|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
214830838|NCT05779527|BEHAVIORAL|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
214830839|NCT04964687|PROCEDURE|Liver transplantation|Liver transplantation
214830840|NCT04852627|BEHAVIORAL|Brisk walking|Walking
214830841|NCT04605835|DIAGNOSTIC_TEST|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
214830842|NCT04899934|BEHAVIORAL|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
214830843|NCT04899934|OTHER|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
214830844|NCT06174558|DEVICE|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
214830845|NCT03007524|DRUG|High dose Rosuvastatin|20mg/d qN, at least 6 months
214830846|NCT03007524|DRUG|Low dose Rosuvastatin|10mg/d qN, at least 6 months
214830847|NCT04388358|DRUG|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
214830848|NCT01939990|DRUG|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
214830849|NCT01939990|DRUG|Nebivolol|5 to 10mg per day
214830850|NCT02777307|OTHER|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
214830851|NCT00400452|BEHAVIORAL|wheelchair skills training|
214830852|NCT05920395|OTHER|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
214830853|NCT05920395|OTHER|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
214830854|NCT06314633|OTHER|Hair cut|Hair locks and follicles will be cut twice in winter and spring
214830855|NCT06314633|OTHER|Socio-economic questionnaires|Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
214830856|NCT00483743|DRUG|TPI 1020|250 mcg/caps 2 caps BID x 42 days
214830857|NCT00483743|DRUG|Budesonide|400mcg mcg capsules- 2 capsules BID
214830858|NCT00483743|DRUG|Placebo|2 caps BID x42 days
214830859|NCT00301886|DRUG|ibandronate|
214830860|NCT00301886|DRUG|zoledronate|
214830861|NCT00301886|PROCEDURE|quality-of-life assessment|
214830862|NCT01472432|DRUG|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
214830863|NCT01472432|DRUG|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
214830864|NCT04168307|DEVICE|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
214830865|NCT04168307|OTHER|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
214830866|NCT06283888|DRUG|CYP2C19 Genotype Guided DAPT|Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
214830867|NCT06283888|DRUG|Conventional DAPT|Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
214830868|NCT01634685|RADIATION|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
214830869|NCT01634685|DRUG|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
214830870|NCT01634685|DRUG|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
214830871|NCT06627556|DRUG|H021|H021 oral tablet.
214830872|NCT06627556|DRUG|H021 Placebo|H021 placebo oral tablet.
214830873|NCT04837456|DIETARY_SUPPLEMENT|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
214830874|NCT04837456|PROCEDURE|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
214830875|NCT04837456|PROCEDURE|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
214830876|NCT04837456|PROCEDURE|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
214830877|NCT02041013|OTHER|Taking Card|Recordable greeting card-style discharge instruction card
214830878|NCT02973906|OTHER|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
214830879|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
214830880|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
214830881|NCT00258687|BIOLOGICAL|GVAX|4 vaccines every two weeks
214830882|NCT03196557|DRUG|Prenisolone|Specified dose on specified days
214830883|NCT03196557|DRUG|Placebo|Specified dose on dose on specified days
214830884|NCT02583048|DRUG|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
214830885|NCT02583048|DRUG|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
214830886|NCT02583048|DRUG|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
214830887|NCT02583048|DRUG|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
214830888|NCT00015925|DRUG|entinostat|
214830889|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
214830890|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
214830891|NCT06103383|DRUG|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
214830892|NCT06103383|PROCEDURE|Oocyte pick up|Surgical oocyte pick up without triggering
214830893|NCT06103383|PROCEDURE|Oocyte in vitro maturation|In vitro maturation procedure
214830894|NCT06103383|PROCEDURE|Oocyte in vitro activation|In vitro oocyte activation procedure
214830895|NCT01851876|DEVICE|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
214830896|NCT00504062|DRUG|budesonide|
214830897|NCT00504062|DRUG|fluticasone|
214830898|NCT00162929|BIOLOGICAL|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
214830899|NCT01151280|DEVICE|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
214830900|NCT06113549|PROCEDURE|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
214830901|NCT06113549|PROCEDURE|Knee Prosthesis|A total or unicompartmental knee prosthesis
214830902|NCT01581892|PROCEDURE|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
214830903|NCT00757705|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
214830904|NCT04483349|OTHER|Survey Administration|Complete survey
214830905|NCT02336633|DIETARY_SUPPLEMENT|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
214830906|NCT02336633|OTHER|Placebo|
214830907|NCT02579226|DRUG|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
214830908|NCT04346680|PROCEDURE|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
214830909|NCT01816789|DRUG|rFSH|
214830910|NCT01816789|DRUG|buserelin|
214830911|NCT03997890|PROCEDURE|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
214830912|NCT06266741|DIAGNOSTIC_TEST|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
214830913|NCT03544242|OTHER|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
214830914|NCT03544242|DRUG|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
214830915|NCT03544242|DRUG|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
214830916|NCT00916045|DRUG|Thiotepa|
214830917|NCT00916045|DRUG|Fludarabine|
214830918|NCT00916045|DRUG|Intravenous busulphan|
214830919|NCT00916045|DRUG|Thymoglobulin|
214830920|NCT00916045|DRUG|Ciclosporin|
214830921|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
214830922|NCT00916045|DRUG|Fludarabine|
214830923|NCT00916045|DRUG|Cyclophosphamide|
214830924|NCT00916045|RADIATION|Radiotherapy|
214830925|NCT00916045|DRUG|Thymoglobulin|
214830926|NCT00916045|DRUG|Ciclosporin|
214830927|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
214830928|NCT00916045|DRUG|Fludarabine|
214830929|NCT00916045|DRUG|Melphalan|
214830930|NCT00916045|DRUG|Thymoglobulin|
214830931|NCT00916045|DRUG|Ciclosporin|
214830932|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
214830933|NCT04889365|DIAGNOSTIC_TEST|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
214830934|NCT04889365|DIAGNOSTIC_TEST|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
214830935|NCT00850551|OTHER|Early Intervention|Twice a week home spirometry and symptom assessment
214830936|NCT06332690|DEVICE|dexamethasone implant|Intravitreal dexamethasone implant (Dex) slowly releases steroids into the vitreous over a period of up to 6 months. Dex 0.7 mg (Ozurdex™; Allergan, Irvine, CA, USA) has been used to reduce ME in patients with DR and RVO and its efficacy in terms of best corrected visual acuity (BCVA) improvement and central macular thickness (CMT) reduction has been demonstrated in many different studies.
214830937|NCT02385760|DRUG|CTX-4430|
214830938|NCT02385760|DRUG|Placebo|
214830939|NCT03184649|DRUG|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
214830940|NCT03184649|DRUG|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
214830941|NCT03184649|DIETARY_SUPPLEMENT|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
214830942|NCT02578641|BIOLOGICAL|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
214830943|NCT02578641|DRUG|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
214830944|NCT03100357|OTHER|Thyroidectomy|Thyroid surgery for benign nodular goiter
214830945|NCT02313558|DRUG|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
214830946|NCT02313558|DRUG|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
214830947|NCT04510792|OTHER|No intervention|No intervention
214830948|NCT02015832|DEVICE|Coronary stent|
214830949|NCT02015832|RADIATION|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
214830950|NCT02015832|DEVICE|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
214830951|NCT02015832|DEVICE|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
214830952|NCT02015832|DEVICE|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
214830953|NCT02600247|DRUG|Duloxetine|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
214830954|NCT02600247|DRUG|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
214830955|NCT05376423|BIOLOGICAL|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
214830956|NCT02963350|DRUG|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
214830957|NCT06038318|BEHAVIORAL|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
214830958|NCT06038318|BEHAVIORAL|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
214830959|NCT06038318|BEHAVIORAL|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
214830960|NCT01903057|DRUG|azithromycin|
214830961|NCT01903057|DRUG|ivermectin|
214830962|NCT01903057|DRUG|albendazole|
214830963|NCT01903057|DRUG|placebo|
214830964|NCT00869713|BIOLOGICAL|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
214830965|NCT01710358|DRUG|Adalimumab|Administered SC
214830966|NCT01710358|DRUG|Baricitinib|Administered orally
214830967|NCT01710358|DRUG|Methotrexate|Administered orally
214830968|NCT01710358|DRUG|Adalimumab Placebo|Adalimumab placebo administered SC.
214830969|NCT01710358|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally.
214830970|NCT03563794|DRUG|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
214830971|NCT03563794|DRUG|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
214830972|NCT00479531|DEVICE|AirCast Sequential Compression Device|
214830973|NCT05947097|DRUG|HSK21542 Injection|1ug/kg bolus for 2min±5s
214830974|NCT04385043|OTHER|plasma hyperimmune|patients will receive this as add on therapy
214830975|NCT04385043|DRUG|standard therapy|patients will receive only standard therapy for Covid-19 infection
214830976|NCT05458960|BEHAVIORAL|Social needs navigator program|4 months of assistance tailored to the needs of the participant
214830977|NCT05458960|BEHAVIORAL|Enhanced usual care|Referral to United Way 2-1-1
214830978|NCT04707846|DEVICE|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
214830979|NCT04707846|DEVICE|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
214277487|NCT01725178|BEHAVIORAL|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
214830980|NCT04516096|DRUG|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
214830981|NCT02263768|PROCEDURE|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
214830982|NCT01272024|BEHAVIORAL|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
214830983|NCT01272024|BEHAVIORAL|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
214830984|NCT04697316|DEVICE|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
214830985|NCT04697316|DEVICE|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
214830986|NCT03470116|DEVICE|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
214830987|NCT03470116|DEVICE|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
214830988|NCT05228717|DIAGNOSTIC_TEST|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
214830989|NCT06086314|DEVICE|reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
214830990|NCT06086314|DEVICE|reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
214830991|NCT06086314|OTHER|neurorehabilitation program with functional reaching training without device.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
214830992|NCT00002923|DRUG|KRN5500|
214830993|NCT02563418|DEVICE|Eye-tracking|
214830994|NCT01013818|DRUG|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
214830995|NCT02297230|RADIATION|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
214830996|NCT02297230|DRUG|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
214830997|NCT02297230|DRUG|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
214830998|NCT02297230|DRUG|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
214830999|NCT00735696|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
214831000|NCT00735696|DRUG|Paclitaxel|200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
214831001|NCT00735696|DRUG|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
214831002|NCT00084864|DIETARY_SUPPLEMENT|calcitriol|Given orally
214831003|NCT00084864|DRUG|dexamethasone|Given orally
214831004|NCT00084864|OTHER|clinical observation|No intervention before surgery
214831005|NCT02663856|OTHER|observational|Self assessment of ageing transition using a frailty index through MySAwH app
214831006|NCT06058806|OTHER|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
214831007|NCT02355262|OTHER|Informational Intervention|Receive CATCH-UP intervention
214831008|NCT03624777|BEHAVIORAL|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
214831009|NCT03624777|BEHAVIORAL|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
214831010|NCT01956162|DEVICE|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
214831011|NCT01956162|DEVICE|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
214831012|NCT04406194|DRUG|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
214831013|NCT04406194|DRUG|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
214831014|NCT04945096|DRUG|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
214831015|NCT04945096|DRUG|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
214831016|NCT04945096|DRUG|Semustine|Semustine: 250 mg/m2/day on day -9.
214831017|NCT04945096|DRUG|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
214831018|NCT04945096|DRUG|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
214831019|NCT04945096|DRUG|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
214831020|NCT04945096|DRUG|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
214831021|NCT04945096|DRUG|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
214831022|NCT04945096|DRUG|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
214831023|NCT05205096|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
214831024|NCT04334096|BEHAVIORAL|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
214831025|NCT04381013|DEVICE|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
214831026|NCT03856034|DEVICE|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
214831027|NCT05645315|DRUG|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
214831028|NCT00599105|PROCEDURE|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
214831029|NCT03334149|OTHER|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
214831030|NCT04271072|OTHER|No intervention|No intervention
214831031|NCT01229800|DRUG|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
214831032|NCT01229800|DRUG|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
214831033|NCT02466490|DRUG|Fimasartan|Fimasartan tablets
214831034|NCT02466490|DRUG|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
214831035|NCT02501863|DRUG|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
214831036|NCT02501863|DRUG|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
214831037|NCT05031858|OTHER|Respiratory physiotherapy|Respiratory physiotherapy
214831038|NCT04594434|OTHER|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
214831039|NCT04594434|OTHER|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
214831040|NCT04594434|OTHER|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
214831041|NCT01741545|BIOLOGICAL|Pegylated-Interferon-lambda|
214831042|NCT01741545|DRUG|Ribavirin|
214831043|NCT01741545|DRUG|Daclatasvir|
214831044|NCT03406845|BEHAVIORAL|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
214831045|NCT05015595|DRUG|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
214831046|NCT05015595|DRUG|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
214831047|NCT00028613|RADIATION|iodine I 131 monoclonal antibody Lym-1|
214831048|NCT04628975|DEVICE|transillumination dispositif|infrared light
214831049|NCT05063630|PROCEDURE|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
214831050|NCT05063630|DRUG|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
214831051|NCT02854826|OTHER|SAFE Care model of care|"SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
214831052|NCT02109458|DEVICE|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
214831053|NCT02401139|DRUG|Ketamine|
214831054|NCT02401139|DRUG|Placebo|
214831055|NCT03820258|DRUG|SOF/VEL/VOX|Administered once daily with food.
214831056|NCT05320237|OTHER|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
214831057|NCT05912062|DRUG|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
214831058|NCT05912062|DRUG|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
214831059|NCT05912062|DRUG|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
214831060|NCT00764712|DRUG|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
214831061|NCT02704091|DRUG|Smecta|
214831062|NCT02704091|DRUG|Smecta placebo|
214831063|NCT02524691|DEVICE|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
214831064|NCT00503789|PROCEDURE|fecal bacteria analysis|ad lib feeding
214831065|NCT05900713|OTHER|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
214831066|NCT05900713|OTHER|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
214831067|NCT00298961|DEVICE|Videoconference equipment FALCON/IP|
214831068|NCT06253260|DRUG|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
214831069|NCT06253260|DRUG|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
214831070|NCT00245739|DRUG|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
214831071|NCT03073798|DRUG|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
214831072|NCT03073798|DRUG|Placebo|500 mcg of placebo is used
214831073|NCT02241577|PROCEDURE|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
214831074|NCT02241577|PROCEDURE|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
214831075|NCT04738019|DIAGNOSTIC_TEST|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
214831076|NCT02827045|DEVICE|Vestibular test|
214831077|NCT00728351|DRUG|vildagliptin + metformin|
214831078|NCT00728351|DRUG|metformin|1000 bid metformin
214277488|NCT02617628|DRUG|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
214831079|NCT01186458|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
214831080|NCT01186458|DRUG|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
214831081|NCT01186458|DRUG|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
214831082|NCT04182126|OTHER|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
214831083|NCT04182126|OTHER|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
214831084|NCT04182126|OTHER|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
214277489|NCT06408610|OTHER|moderate intensity continuous training|exercise and diet
214277490|NCT02065375|DRUG|Omaveloxolone Ophthalmic Suspension 1.0%|
214277491|NCT02065375|DRUG|Omaveloxolone Opthalmic Suspension 0.5%|
214277492|NCT02065375|DRUG|Placebo|
214277493|NCT05001737|DRUG|Emapalumab|Emapalumab iv infusion
214831085|NCT04182126|OTHER|Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides|Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
214831086|NCT03118687|OTHER|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
214831087|NCT05544123|OTHER|pathological stage|breast cancer molecular subtyping and pathological TNM stage
214831088|NCT01496118|DRUG|panobinostat|Specified dose on specified days
214831089|NCT01496118|DRUG|carfilzomib|Specified dose on specified days
214831090|NCT05448209|BEHAVIORAL|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
214831091|NCT04302961|OTHER|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
214831092|NCT04302961|OTHER|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
214831093|NCT02420353|DRUG|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
214831094|NCT02420353|DRUG|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
214831095|NCT03106545|DRUG|Liposome bupivacaine|
214831096|NCT03954483|DRUG|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
214831097|NCT03954483|DRUG|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
214831098|NCT03954483|DRUG|Placebo oral tablet|Orally administered prior to experiments.
214831099|NCT01337427|DRUG|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
214831100|NCT00182260|DRUG|Proton Pump Inhibitors|
214831101|NCT00182260|PROCEDURE|Laparoscopic Nissen Fundoplication|
214831102|NCT04125862|DIAGNOSTIC_TEST|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
214831103|NCT04125862|DIAGNOSTIC_TEST|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
214831104|NCT04125862|DIAGNOSTIC_TEST|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
214831105|NCT04125862|DIAGNOSTIC_TEST|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
214831106|NCT01149057|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
214831107|NCT04608448|DRUG|Rapamycin Topical Ointment|8% topical rapamycin ointment
214831108|NCT04608448|OTHER|Placebo|Petrolatum ointment containing no active ingredient
214831109|NCT02749604|PROCEDURE|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
214831110|NCT02749604|PROCEDURE|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
214831111|NCT01325740|DRUG|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
214831112|NCT02028039|DRUG|IPI-145|75 mg orally twice daily for 4 weeks.
214831113|NCT02028039|BEHAVIORAL|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
214831114|NCT06562179|DEVICE|da Vinci SP® Single-Port Robotic Surgical System|The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
214831115|NCT01394419|DRUG|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
214831116|NCT01394419|DRUG|Saline|Equal volume of normal saline
214831117|NCT00577655|DRUG|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
214831118|NCT00577655|DRUG|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
214831119|NCT00577655|DRUG|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
214831120|NCT02504450|DRUG|Adasuve|Inhaled medication to treat acute agitation in the emergency department
214831121|NCT02504450|DRUG|Alternative medications|Medication given to treat acute agitation in the emergency department
214831122|NCT01685255|DRUG|Epacadostat|
214831123|NCT01685255|DRUG|tamoxifen|
214831124|NCT03008655|PROCEDURE|intradermal tranexamic acid|intradermal tranexamic acid injection
214831125|NCT03008655|DEVICE|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
214831126|NCT02236858|DEVICE|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
214831127|NCT02236858|DEVICE|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
214831128|NCT00837564|OTHER|CBASP psychotherapy|specific psychotherapy for chronic depression
214831129|NCT00837564|DRUG|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
214831130|NCT04275349|DRUG|Xingnaojing injection within 24 hours of symptom onset|intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
214831131|NCT04461587|DRUG|Pirfenidone|see previous entries
214831132|NCT04565587|OTHER|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
214831133|NCT01930409|BEHAVIORAL|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises"
214831134|NCT01930409|BEHAVIORAL|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
214831135|NCT06559800|BEHAVIORAL|YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality|A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
214831136|NCT03948022|DRUG|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
214831137|NCT03948022|DRUG|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
214831138|NCT03948022|DRUG|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
214831139|NCT03103711|BEHAVIORAL|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
214831140|NCT03141853|OTHER|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
214831141|NCT03141853|OTHER|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
214831142|NCT05643833|OTHER|no intervention|no intervention
214831143|NCT03639077|DEVICE|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
214831144|NCT03639077|DEVICE|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
214831145|NCT02949167|BEHAVIORAL|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
214831146|NCT05319847|DIETARY_SUPPLEMENT|Daily Skin Supplement - Fountain of Youth|Skincare supplement
214831147|NCT05153304|BIOLOGICAL|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
214831148|NCT05153304|DRUG|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
214831149|NCT03461380|DIETARY_SUPPLEMENT|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
214831150|NCT03461380|DIETARY_SUPPLEMENT|Low Dose Black Cohosh|6.5 mg black cohosh
214831151|NCT03461380|DIETARY_SUPPLEMENT|High Dose Black Cohosh|500 mg black cohosh
214831152|NCT03461380|DIETARY_SUPPLEMENT|Placebo|600 mg excipient
214831153|NCT03249844|DRUG|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
214831154|NCT03542669|DRUG|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
214831155|NCT03542669|DRUG|Doxorubicin|Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
214831156|NCT02942082|OTHER|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
214831157|NCT02942082|OTHER|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
214831158|NCT00875524|BIOLOGICAL|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
214277494|NCT04610944|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
214277495|NCT03278873|BIOLOGICAL|Prior exposure to AAV-CNGA3 or AAV-CNGB3|Participants previously received AAV-CNGA3 or AAV-CNGB3 in an open-label, Phase 1/2 dose escalation trial for adults and children with achromatopsia owing to defects in CNGA3 or CNGB3, respectively.
214831159|NCT00875524|BIOLOGICAL|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
214831160|NCT00672373|DRUG|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
214831161|NCT00672373|DRUG|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
214831162|NCT02672267|BIOLOGICAL|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
214831163|NCT02672267|OTHER|Placebo|Lactated Ringer's Solution
214831164|NCT06445049|OTHER|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~\- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
214277496|NCT04993742|BEHAVIORAL|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
214277497|NCT05243641|DRUG|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
214277498|NCT05243641|DRUG|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
214277499|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
214831165|NCT04050709|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
214831166|NCT06562101|PROCEDURE|Intra-articular Stromal Vascular Fraction Injection|Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
214831167|NCT00629304|DEVICE|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
214831168|NCT00629304|DEVICE|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
214831169|NCT00629304|DEVICE|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
214831170|NCT02120872|DRUG|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
214831171|NCT02120872|BIOLOGICAL|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
214831172|NCT02120872|PROCEDURE|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
214831173|NCT01521715|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
214831174|NCT04019015|DRUG|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
214831175|NCT04019015|DRUG|Placebo|Normal saline solution
214831176|NCT01370863|DRUG|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
214831177|NCT01370863|DRUG|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
214831178|NCT00803816|DRUG|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
214831179|NCT03487939|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
214831180|NCT01305109|BIOLOGICAL|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
214831181|NCT01305109|BIOLOGICAL|Placebo|3 doses of 0.5 mL at 4 week intervals
214831182|NCT01195233|DRUG|bioxtra|spray /mouth rinse
214831183|NCT01143337|DRUG|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
214831184|NCT01143337|DRUG|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
214831185|NCT03053856|DRUG|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
214831186|NCT03053856|PROCEDURE|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
214831187|NCT03053856|PROCEDURE|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
214831188|NCT03053856|DRUG|Cisplatin|25mg/m2 once weekly
214831189|NCT03053856|DRUG|Paclitaxel|50mg/m2 once weekly
214831190|NCT02761915|OTHER|Leukapheresis|
214831191|NCT02761915|DRUG|Cyclophosphamide|
214831192|NCT02761915|DRUG|Fludarabine|
214831193|NCT02761915|GENETIC|1RG-CART|
214831194|NCT02162615|DEVICE|Restorelle Direct Fix A|
214831195|NCT02162615|DEVICE|Restorelle Direct Fix P|
214831196|NCT02162615|PROCEDURE|Native Tissue Repair Anterior|
214831197|NCT02162615|PROCEDURE|Native Tissue Repair Posterior|
214831198|NCT00538109|DRUG|Glivec®/Gleevec®|Chemotherapy
214831199|NCT03276559|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
214831200|NCT03276559|OTHER|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
214831201|NCT06403033|DEVICE|Mini-implant-supported Twin-Block|Mini-implants will support the Twin-Block appliance during the functional treatment.
214277500|NCT02035098|OTHER|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
214277501|NCT04457193|DEVICE|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
214831202|NCT06403033|DEVICE|Twin-Block|This is the main appliance that will be used to correct the Class II deformity.
214831203|NCT00270634|DRUG|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
214831204|NCT00270634|DRUG|tacrolimus|tacrolimus 0.05 mg/kg po BID
214831205|NCT06289296|OTHER|Fatty acid intake in lean and obese males|Acute and chronic intake of MCT and LCT
214831206|NCT05853653|BEHAVIORAL|Using dolls in breastfeeding education|Using dolls in breastfeeding education
214831207|NCT05800262|BEHAVIORAL|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
214831208|NCT00819169|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
214831209|NCT00819169|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
214831210|NCT03896594|DRUG|HL237|Experimental
214831211|NCT03896594|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
214831212|NCT02112123|DRUG|Icariin|
214831213|NCT02112123|DIETARY_SUPPLEMENT|Matching placebo|
214831214|NCT04434716|DEVICE|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
214831215|NCT00406393|DRUG|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
214831216|NCT00406393|DRUG|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
214831217|NCT00406393|DRUG|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
214831218|NCT03805633|DIAGNOSTIC_TEST|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
214831219|NCT03805633|DIAGNOSTIC_TEST|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
214831220|NCT02740257|OTHER|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
214831221|NCT00891787|DIETARY_SUPPLEMENT|Probiotic Supplement|
214831222|NCT03879187|DIETARY_SUPPLEMENT|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
214831223|NCT00310115|BEHAVIORAL|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
214831224|NCT00310115|BEHAVIORAL|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
214831225|NCT00310115|BEHAVIORAL|Counseling Intervention|2 in-person counseling sessions
214831226|NCT00002033|DRUG|Zidovudine|
214831227|NCT00002033|DRUG|AS-101|
214831228|NCT01927380|OTHER|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
214831229|NCT06627634|PROCEDURE|Metastatectomia and standard treatment for resectable disease.|Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
214831230|NCT06466317|BEHAVIORAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
214831231|NCT06466317|BEHAVIORAL|Walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
214831232|NCT00748696|DIETARY_SUPPLEMENT|Fortimel Extra®|260kcal and 20g protein per day
214831233|NCT00748696|OTHER|resistance training|3 sessions of resistance training per week
214831234|NCT00748696|OTHER|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
214831235|NCT01398085|RADIATION|I131 1.1 GBq|Radio-iodine
214831236|NCT03069976|DRUG|Metronidazole|Flagyl x 14 days.
214831237|NCT05963464|DEVICE|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
214831238|NCT03909633|BEHAVIORAL|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
214831239|NCT05369039|DRUG|Roflumilust|A selective phosphodiesterase 4 Inhibitor
214831240|NCT05369039|DRUG|Prednisolone|Systemic corticosteroid
214831241|NCT02364869|DIETARY_SUPPLEMENT|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
214831242|NCT02364869|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
214831243|NCT04941313|DRUG|3D229|3D229 is an investigational drug.
214831244|NCT04941313|OTHER|Placebo|Matching placebo
214831245|NCT04090658|BIOLOGICAL|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV\_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
214831246|NCT04090658|DRUG|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
214831247|NCT04200872|OTHER|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
214831248|NCT04200872|OTHER|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
214831249|NCT04922957|DRUG|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
214831250|NCT04922957|OTHER|Placebo|Ringer's lactate solution
214831251|NCT01476501|DRUG|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
214831252|NCT05999916|DEVICE|Personalized Miamind Neurostimulator|60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
214831253|NCT05123443|BIOLOGICAL|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
214277502|NCT04125836|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
214831254|NCT05123443|DIAGNOSTIC_TEST|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
214831255|NCT01937234|DRUG|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
214831256|NCT01937234|DRUG|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
214831257|NCT00109057|DRUG|Avastin (bevacizumab)|
214831258|NCT03835845|DEVICE|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
214831259|NCT01175330|DRUG|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
214831260|NCT01175330|DRUG|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
214831261|NCT03277248|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
214831262|NCT03277248|DRUG|Teriflunomide|Film coated tablets administered orally.
214831263|NCT03277248|DRUG|Oral Placebo|Administered orally.
214831264|NCT03277248|DRUG|IV Placebo|Administered as an IV Infusion.
214831265|NCT02472834|DIETARY_SUPPLEMENT|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
214831266|NCT01663896|DEVICE|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
214831267|NCT00476034|DRUG|lumiracoxib|
214831268|NCT01963455|BIOLOGICAL|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
214831269|NCT02238587|OTHER|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
214831270|NCT02238587|DIETARY_SUPPLEMENT|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
214831271|NCT02638428|PROCEDURE|CancerSCAN™|Targeted deep sequencing
214831272|NCT02638428|DRUG|Ifosfamide|
214831273|NCT02638428|DRUG|Carboplatin|
214831274|NCT02638428|DRUG|Etoposide|
214831275|NCT02638428|DRUG|Fludarabine|
214831276|NCT02638428|DRUG|Cytarabine|
214831277|NCT02638428|DRUG|Pazopanib|
214831278|NCT02638428|DRUG|Sorafenib|
214831279|NCT02638428|DRUG|Axitinib|
214831280|NCT02638428|DRUG|Crizotinib|
214831281|NCT02638428|DRUG|Dasatinib|
214831282|NCT02638428|DRUG|Erlotinib|
214831283|NCT02638428|DRUG|Everolimus|
214831284|NCT02638428|DRUG|Imatinib|
214831285|NCT02638428|DRUG|Ruxolitinib|
214831286|NCT02638428|DRUG|Vandetanib|
214831287|NCT02638428|DRUG|Vemurafenib|
214831288|NCT02638428|DRUG|Trastuzumab|
214831289|NCT02579005|BIOLOGICAL|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
214831290|NCT02579005|BIOLOGICAL|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
214831291|NCT02763345|OTHER|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
214831292|NCT02763345|OTHER|Standard care|
214831293|NCT00842127|DRUG|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
214831294|NCT04668820|DIAGNOSTIC_TEST|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
214831295|NCT00844974|OTHER|Prevalence|Mood and cognitive assessments
214831296|NCT00990574|DEVICE|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
214831297|NCT00990574|DEVICE|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
214831298|NCT04266548|PROCEDURE|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
214831299|NCT02701101|DEVICE|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
214831300|NCT02701101|OTHER|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
214831301|NCT02667769|OTHER|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
214831302|NCT05002140|DRUG|XRD-0394|Single ascending dose
214831303|NCT05002140|RADIATION|Palliative radiotherapy|4 Gy × 5 daily fractions
214831304|NCT01458886|DRUG|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
214831305|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
214831306|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
214831307|NCT01458886|DRUG|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
214831308|NCT06529146|DRUG|BHV-4157|BHV-4157 (troriluzole) 200 mg QD
214831309|NCT02956681|BEHAVIORAL|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
214831310|NCT02956681|BEHAVIORAL|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
214831311|NCT01728987|DRUG|cholecalciferol|as in arm description
214831312|NCT01728987|DRUG|placebo|capsule looking identical to the cholecalciferol capsule
214831313|NCT04862806|DIAGNOSTIC_TEST|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
214831314|NCT03610607|BEHAVIORAL|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
214831315|NCT02083809|DRUG|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
214831316|NCT02083809|DRUG|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
214277503|NCT05326165|DEVICE|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
214277504|NCT05326165|DEVICE|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
214277505|NCT05775458|DIAGNOSTIC_TEST|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
214277506|NCT03847649|DRUG|Durvalumab|1500 mg IV, 60 min, Day 1 every 4 weeks
214277507|NCT03847649|DRUG|Prednisone|0.5mg/kg; PO, Daily cycles 1 \& 2
214831317|NCT02520193|PROCEDURE|Protocolized early mobilization in ICU|
214831318|NCT01942278|OTHER|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
214831319|NCT01940159|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
214831320|NCT01940159|DRUG|Placebo|single oral dose placebo
214831321|NCT02342509|DRUG|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
214831322|NCT02342509|DRUG|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
214831323|NCT02342509|DRUG|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
214831324|NCT03330132|BIOLOGICAL|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
214831325|NCT03330132|BIOLOGICAL|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
214277508|NCT03847649|DRUG|Prednisone|10mg, PO, Daily cycles 1 \& 2
214277509|NCT03847649|DRUG|Tremelimumab|Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
214277510|NCT04067752|OTHER|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
214277511|NCT04067752|OTHER|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
214831326|NCT03330132|BIOLOGICAL|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
214831327|NCT03330132|BIOLOGICAL|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
214831328|NCT03214237|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
214831329|NCT02439515|DEVICE|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
214831330|NCT02439515|DEVICE|Balance|Balance control exercises with visual biofeedback
214831331|NCT02439515|OTHER|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
214831332|NCT05472415|OTHER|cognicise|"a combination of cognition and exercise training"
214831333|NCT05472415|DEVICE|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
214831334|NCT04385251|OTHER|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"
214831335|NCT00379353|DRUG|Thalidomide|100 mg capsules orally, once a day for 14 days.
214831336|NCT00379353|DRUG|Placebo|Two placebo capsules orally, once a day for 14 days.
214831337|NCT03614728|DRUG|GSK3326595|GSK3326595 will be administered.
214831338|NCT03614728|DRUG|5-Azacitidine|5-Azacitidine will be administered.
214831339|NCT04997551|DRUG|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
214831340|NCT01196598|OTHER|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
214831341|NCT00000698|DRUG|Ganciclovir|
214831342|NCT02036398|DEVICE|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
214831343|NCT02036398|DEVICE|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
214831344|NCT00408577|DRUG|L-arginine|
214831345|NCT04431973|DEVICE|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
214831346|NCT02928627|OTHER|Analysis of microRNA expression|sample analysis
214831347|NCT01824576|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
214831348|NCT02818894|DRUG|Lidocaine|Spinal anesthesia administered prior to participant's THA
214831349|NCT02818894|DRUG|Bupivacaine|Spinal anesthesia administered prior to participant's THA
214831350|NCT05125276|DRUG|No aspirin|No aspirin
214831351|NCT05125276|DRUG|Aspirin|75-100 mg once daily
214831352|NCT02958176|BEHAVIORAL|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
214831353|NCT02958176|BEHAVIORAL|Autogenic Training|Autogenic training recording provided on a CD
214831354|NCT00085501|DRUG|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
214831355|NCT00085501|DRUG|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
214831356|NCT00085501|DRUG|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
214831357|NCT00290927|DRUG|insulin glulisine|
214831358|NCT00028873|DRUG|docetaxel|
214831359|NCT00028873|DRUG|laniquidar|
214831360|NCT00028873|DRUG|paclitaxel|
214831361|NCT00273130|PROCEDURE|transnasal endoscopy|
214831362|NCT00273130|PROCEDURE|transoral thin endoscopy|
214831363|NCT00144222|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
214831364|NCT00144222|DRUG|Telmisartan 40 mg|
214831365|NCT03647722|OTHER|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
214831366|NCT04915339|BEHAVIORAL|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
214277512|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
214831367|NCT04915339|BEHAVIORAL|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
214831368|NCT04915339|BEHAVIORAL|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
214831369|NCT05465096|PROCEDURE|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
214831370|NCT01691612|BIOLOGICAL|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
214831371|NCT01152112|DEVICE|Myomectomy|Removal of fibroids and / or polyps
214831372|NCT03438643|DIAGNOSTIC_TEST|Blood samples|Blood samples (42mL) will be taken before and during treatment.
214831373|NCT03438643|DIAGNOSTIC_TEST|skin biopsy|skin biopsy will be taken before and during treatment.
214831374|NCT02152618|OTHER|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
214831375|NCT02733211|DEVICE|MD- Logic Closed Loop System|Closed Loop System
214831376|NCT02733211|DEVICE|sensor augmented pump therapy|Sensor augmented pump therapy
214831377|NCT03010605|DEVICE|Measuring Every Day Device|
214831378|NCT03010605|OTHER|Physical Therapy|
214831379|NCT03588260|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
214831380|NCT00002160|DRUG|Ziconotide|
214831381|NCT05348616|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
214831382|NCT05348616|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
214831383|NCT02539628|DRUG|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
214277513|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
214831384|NCT01300273|DIETARY_SUPPLEMENT|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
214831385|NCT00895050|OTHER|Review of clinical records|
214277514|NCT04107506|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
214831386|NCT02208973|DRUG|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
214831387|NCT02208973|DRUG|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
214831388|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
214831389|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
214831390|NCT02901730|PROCEDURE|532nm laser group|LPI with 532nm laser.
214831391|NCT02901730|PROCEDURE|561nm laser group|LPI with 561nm laser.
214831392|NCT00006453|DRUG|carboplatin|
214831393|NCT00006453|DRUG|gemcitabine hydrochloride|
214831394|NCT04358367|DRUG|Dexmedetomidine Injectable Product|Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
214831395|NCT04358367|DRUG|Saline|Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
214831396|NCT05919901|OTHER|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
214831397|NCT03981731|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~\- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
214831398|NCT03008616|BIOLOGICAL|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
214831399|NCT03008616|OTHER|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
214831400|NCT05815394|DRUG|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
214831401|NCT01832922|DRUG|Bendamustine|
214831402|NCT01832922|DRUG|Rituximab|
214831403|NCT05545436|DRUG|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
214831404|NCT02942810|DRUG|WCK 5222|IV infusion over a period of 60 minutes
214831405|NCT00905008|PROCEDURE|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
214831406|NCT00905008|DEVICE|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
214831407|NCT03600753|OTHER|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
214831408|NCT03600753|OTHER|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
214831409|NCT04711057|OTHER|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
214831410|NCT04711057|OTHER|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
214831411|NCT00735176|PROCEDURE|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
214831412|NCT00735176|PROCEDURE|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
214831413|NCT02702895|BEHAVIORAL|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
214831414|NCT02319850|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
214831415|NCT01588743|DRUG|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
214831416|NCT03102385|BEHAVIORAL|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
214831417|NCT03102385|BEHAVIORAL|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
214831418|NCT03369132|DEVICE|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
214831419|NCT03369132|DEVICE|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
214831420|NCT00073632|BEHAVIORAL|Acceptance Based Behavioral Therapy|
214831421|NCT05563207|OTHER|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
214831422|NCT05563207|OTHER|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
214831423|NCT05563207|OTHER|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
214831424|NCT05563207|OTHER|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
214831425|NCT05563207|OTHER|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
214831426|NCT05563207|OTHER|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
214831427|NCT05118607|DEVICE|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
214831428|NCT03076645|BEHAVIORAL|Facilitator support and education|Group engaged with facilitator support and education
214831429|NCT01611506|BIOLOGICAL|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
214831430|NCT01611506|DRUG|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
214831431|NCT01611506|DRUG|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
214831432|NCT03201276|DRUG|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
214831433|NCT00822887|DRUG|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
214831434|NCT00822887|RADIATION|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
214831435|NCT00344513|DRUG|Beta-blockers including Carvedilol|
214831436|NCT00344513|DRUG|ACE inhibitors|
214831437|NCT02671058|DRUG|Cortenema|Hydrocortisone Administered as a Liquid Enema
214831438|NCT02671058|DRUG|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
214831439|NCT04738864|DIAGNOSTIC_TEST|ultrasound|extracranial and intracranial ultrasound assessment
214831440|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
214831441|NCT03649763|DRUG|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
214831442|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
214831443|NCT01602328|BIOLOGICAL|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
214831444|NCT01602328|BIOLOGICAL|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
214831445|NCT00363077|BIOLOGICAL|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
214831446|NCT00363077|BIOLOGICAL|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
214831447|NCT05315713|DRUG|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
214831448|NCT05315713|DRUG|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
214831449|NCT05315713|DRUG|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
214831450|NCT05315713|OTHER|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
214831451|NCT06449690|PROCEDURE|Dog-assisted therapy|Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
214831452|NCT06449690|PROCEDURE|Occupational activities|Occupational activities consist of origami, relaxation, sports or board games sessions.
214831453|NCT01261767|DRUG|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
214831454|NCT01261767|DRUG|placebo|Placebo for subcutaneous (under the skin) injection
214831455|NCT00867763|PROCEDURE|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
214831456|NCT00867763|PROCEDURE|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
214831457|NCT02721563|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
214831458|NCT02721563|DRUG|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
214831459|NCT06319482|DEVICE|Proactive CPAP Therapy|CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
214831460|NCT06319482|DEVICE|Conventional APAP Therapy|CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
214831461|NCT00510848|PROCEDURE|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
214831462|NCT00510848|PROCEDURE|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
214831463|NCT04106063|OTHER|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
214831464|NCT03324139|DRUG|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
214831465|NCT03324139|DRUG|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
214831466|NCT02113722|PROCEDURE|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
214831467|NCT02113722|PROCEDURE|Standard of Care|Medical therapy
214831468|NCT06601894|DIAGNOSTIC_TEST|Platelets count|the study include will take medical investigation data for all sickle cell patients.
214831469|NCT06595342|OTHER|No intervention|no intervention
214831470|NCT03748381|PROCEDURE|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
214831471|NCT00556673|DRUG|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
214831472|NCT00556673|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
214831473|NCT00556673|DRUG|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
214831474|NCT01665404|DRUG|Fluvoxamine|Multiple doses of fluvoxamine
214831475|NCT01665404|DRUG|RO4917523|Single dose of RO4917523
214831476|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
214831477|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
214831478|NCT01131260|DEVICE|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
214831479|NCT06627257|DRUG|LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
214831480|NCT06627257|DRUG|LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
214831481|NCT06627257|OTHER|Placebo Comparator: Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
214831482|NCT00792753|DEVICE|Medtronic Endeavor Coronary Stent System|coronary stent implantation
214831483|NCT00792753|DEVICE|DESyne BD Novolimus Stent System|coronary stent implantation
214831484|NCT00792753|DEVICE|DESyne Novolimus Stent System|coronary stent implantation
214831485|NCT06106490|OTHER|the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients|"Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds."
214831486|NCT00120783|DRUG|Indinavir|
214831487|NCT00120783|DRUG|Lamivudine|
214831488|NCT00120783|DRUG|Ritonavir|
214831489|NCT01257633|PROCEDURE|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
214831490|NCT04976179|DRUG|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
214831491|NCT04976179|DRUG|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
214831492|NCT06108557|DIAGNOSTIC_TEST|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
214831493|NCT06108557|DIAGNOSTIC_TEST|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
214831494|NCT01177657|PROCEDURE|Stool sampling|Stool samples collected and checked for the presence of rotavirus
214831495|NCT04699396|PROCEDURE|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
214831496|NCT04699396|PROCEDURE|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
214831497|NCT04699396|OTHER|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
214831498|NCT03544216|DEVICE|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
214831499|NCT03544216|DEVICE|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
214831500|NCT03929016|DRUG|DNDI-0690|capsules of 10, 100 and 200 mg
214831501|NCT03929016|DRUG|Placebo of DNDI-0690|capsules of matching placebo
214831502|NCT03050424|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
214831503|NCT03050424|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9%
214831504|NCT01076491|DRUG|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
214831505|NCT02955628|DRUG|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
214831506|NCT03152162|DEVICE|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
214831507|NCT04969562|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
214831508|NCT00866580|BIOLOGICAL|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
214831509|NCT00866580|BIOLOGICAL|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
214831510|NCT00866580|BIOLOGICAL|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
214831511|NCT00000159|DRUG|Sorbinil|
214831512|NCT02191059|DRUG|Icotinib|
214831513|NCT02191059|DRUG|Docetaxel|
214831514|NCT05748561|DRUG|Recombinant human erythropoietin 4,000 UI and 2,000 UI|Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)
214831515|NCT05748561|DRUG|Methylprednisolone succinate 500 mg|Intravenous Methylprednisolone succinate (1 g daily for 5 days)
214831516|NCT01243983|DRUG|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
214831517|NCT06502301|OTHER|Cross-sectional study|This is not intervention study.
214831518|NCT02716311|DRUG|Afatinib|
214831519|NCT02716311|DRUG|Cetuximab|
214831520|NCT03815903|DRUG|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
214831521|NCT03815903|COMBINATION_PRODUCT|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
214831522|NCT05644392|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
214831523|NCT05644392|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
214831524|NCT04681391|DEVICE|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
214831525|NCT05244863|OTHER|Test|Measurements
214831526|NCT01621945|BIOLOGICAL|MenBvac|Blood test
214831527|NCT00835081|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
214831528|NCT00835081|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
214831529|NCT00754858|DRUG|belotecan hydrochloride|
214831530|NCT00754858|DRUG|cisplatin|
214831531|NCT00421304|BIOLOGICAL|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
214831532|NCT00421304|OTHER|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
214831533|NCT03196284|DRUG|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
214831534|NCT03196284|DRUG|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
214831535|NCT03742063|DRUG|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
214831536|NCT04823832|PROCEDURE|pancreaticoduodenectomy|resection of the head of pancreas and the duodenum followed by triple anastomosis
214831537|NCT03857828|OTHER|semen sample|• seminal sample for measuring clusterin level.
214831538|NCT00501735|DRUG|Forodesine 200 mg|2 x 100mg tablets once daily
214831539|NCT04334863|DRUG|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
214831540|NCT04806035|BIOLOGICAL|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
214831541|NCT04806035|BIOLOGICAL|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
214831542|NCT02992964|DRUG|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
214831543|NCT00412464|DRUG|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
214831544|NCT00922896|DRUG|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"* Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
214831545|NCT03503435|BEHAVIORAL|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
214831546|NCT01126762|BEHAVIORAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
214831547|NCT01126762|BEHAVIORAL|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
214831548|NCT01296607|DRUG|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
214831549|NCT01296607|DRUG|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
214831550|NCT01730846|DRUG|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
214831551|NCT01730846|DRUG|Placebo|Placebo
214831552|NCT01730846|DRUG|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
214831553|NCT03587545|OTHER|Probiotic nasal spray|Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
214831554|NCT03587545|OTHER|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
214831555|NCT01368380|BEHAVIORAL|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
214831556|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
214831557|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
214831558|NCT02407548|DIETARY_SUPPLEMENT|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
214831559|NCT02535923|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
214831560|NCT02535923|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
214831561|NCT01812993|DEVICE|Non-invasive ventilatory treatment with auto-BPAP|
214831562|NCT03867890|OTHER|no intervention|
214831563|NCT00959790|DIETARY_SUPPLEMENT|Vegetables|200 or 50 grams of vegetables daily for four weeks
214831564|NCT00959790|DIETARY_SUPPLEMENT|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
214831565|NCT02081105|OTHER|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
214831566|NCT03121898|DEVICE|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
214831567|NCT03173651|DEVICE|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
214831568|NCT03173651|DEVICE|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
214831569|NCT03173651|DEVICE|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
214831570|NCT05668650|DRUG|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
214831571|NCT05668650|DRUG|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
214831572|NCT01090505|DRUG|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
214831573|NCT02940613|BEHAVIORAL|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
214831574|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
214831575|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
214831576|NCT01018862|DRUG|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
214831577|NCT02427919|DRUG|G-CSF|Comparison of the effect of G-CSF use
214831578|NCT04640129|DRUG|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
214831579|NCT04640129|DRUG|Tenofovir Disoproxil Fumarate|TDF monotherapy
214831580|NCT03578497|DRUG|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
214831581|NCT02924025|BEHAVIORAL|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
214831582|NCT02233751|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
214831583|NCT03097692|PROCEDURE|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
214831584|NCT03097692|DRUG|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
214831585|NCT01968031|DRUG|Istradefylline 40 mg|Istradefylline 40 mg and placebo
214831586|NCT01968031|DRUG|Istradefylline 20 mg|Istradefylline 20 mg and placebo
214831587|NCT01968031|DRUG|Placebo|Placebo
214831588|NCT05471349|BEHAVIORAL|Flyer and video|Participants will view a flyer and video
214831589|NCT02708251|DRUG|glyceryl trinitrate cream|
214831590|NCT02708251|DRUG|lidocaine cream|
214831591|NCT02708251|DRUG|placebo cream|
214831592|NCT02725619|BEHAVIORAL|CBT|
214831593|NCT02725619|BEHAVIORAL|PST|
214831594|NCT02713139|DRUG|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
214831595|NCT02713139|DRUG|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
214831596|NCT02713139|DRUG|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
214831597|NCT06628154|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
214831598|NCT06628154|OTHER|Placebo|Single tablet encapsulated identically to losartan
214831599|NCT04440150|PROCEDURE|Appendectomy|Open or Laparascopic Surgery
214831600|NCT00840879|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
214831601|NCT00840879|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
214831602|NCT01008709|DEVICE|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
214831603|NCT01008709|DEVICE|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
214831604|NCT00240032|DRUG|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
214831605|NCT00240032|DRUG|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
214831606|NCT06559280|DRUG|esketamine|During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
214831607|NCT02089282|DEVICE|Ultrasound|
214831608|NCT04296123|BEHAVIORAL|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
214831609|NCT00840840|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
214831610|NCT00840840|DRUG|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
215031469|NCT04586257|PROCEDURE|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
214831611|NCT00919113|DRUG|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
214831612|NCT00919113|DRUG|Placebo|The identical buffer used in Uracyst for the same administration
214831613|NCT05853445|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
214831614|NCT07140276|BEHAVIORAL|Individual Therapy|12 weeks individual psychotherapy
214831615|NCT07140276|BEHAVIORAL|Individual Drug Counseling manual|12 weeks using the manual provided
214831616|NCT07140185|BEHAVIORAL|Regular Weekly Physical Activity Program|Structured physical activity sessions three times per week, 50 minutes each, over 8 weeks. Includes aerobic exercises, supervised by trained instructors. Goal is to distribute the recommended weekly activity evenly.
214831617|NCT07140185|BEHAVIORAL|Weekend Warrior Physical Activity Program|Same total weekly activity as Arm 1, but concentrated in 2 weekend sessions of 75 minutes each. Includes aerobic exercises, supervised by the same trained instructors.
215031470|NCT00997659|DIETARY_SUPPLEMENT|chromium picolinate|1000 mg per day
214831618|NCT07139574|OTHER|Music Therapy During Labor|This intervention involves the use of patient-selected, slow-tempo (60-80 bpm), non-lyrical instrumental music administered via headphones or speakers during the latent and active phases of labor. The music selection is guided to ensure therapeutic suitability (e.g., calming rhythm, absence of lyrics) and is delivered for a minimum of 30 minutes. The intervention is non-pharmacological, individualized, and adheres to WHO and clinical music therapy recommendations. It is distinguished by its personalized music choice, delivery timing, and structured application within labor progression monitoring.
214831619|NCT05814068|DRUG|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
214831620|NCT03316222|DRUG|GNS561|Escalating doses to be administered 3 times a week.
214831621|NCT00260793|DRUG|Ropinirole Hydrochloride|
214831622|NCT03853096|DRUG|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
214831623|NCT00368082|BIOLOGICAL|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2"
214831624|NCT04815460|BEHAVIORAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
214831625|NCT04815460|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
214831626|NCT06024031|DRUG|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
214831627|NCT00325312|DRUG|carbon dioxide, subcutaneous application|
214831628|NCT02760355|DRUG|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
214831629|NCT02760355|DRUG|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
214831630|NCT00107016|DRUG|RAD001, Letrozole 2.5mg|
214831631|NCT00107016|DRUG|Letrozole 2.5mg|
214831632|NCT00159419|DRUG|Alendronate|
214831633|NCT00159419|DRUG|Pamidronate|
214831634|NCT00225849|DRUG|Aspirin|
214831635|NCT04042649|BEHAVIORAL|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
214831636|NCT01109849|BEHAVIORAL|behavior therapy|combination of individual and group parent training plus school consultation
214831637|NCT01109849|DRUG|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
214831638|NCT01109849|OTHER|monitoring|monthly weight, height and BMI checks
214831639|NCT01109849|OTHER|drug holiday|switch from seven day a week dosing to medication only on school days
214831640|NCT01109849|DIETARY_SUPPLEMENT|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
214831641|NCT00137202|DRUG|Ondansetron (Zofran)|
214831642|NCT00137202|DRUG|Diphenhydramine (Benadryl)|
214831643|NCT03004508|DIETARY_SUPPLEMENT|Gingko Biloba Extract|120mg/day, twice a day, 6 month
215031471|NCT05199844|DEVICE|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
214831644|NCT03004508|DIETARY_SUPPLEMENT|Placebo|120mg/day, twice a day, 6 month
214831645|NCT03516487|DRUG|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
214831646|NCT03516487|DRUG|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
214831647|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
214831648|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
214831649|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
214831650|NCT01104948|DRUG|DA-8031|
214831651|NCT01104948|DRUG|Placebo|
214831652|NCT01006967|DEVICE|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
214831653|NCT01006967|OTHER|Physical Therapy|Standard program of physical therapy for gait and balance
214831654|NCT06126328|DEVICE|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
214831655|NCT04096651|OTHER|gait recordings|gait recordings
214831656|NCT04096651|OTHER|brain magnetic resonance imaging|brain magnetic resonance imaging
214831657|NCT04096651|OTHER|oculomotor movement recordings|oculomotor movement recordings
214831658|NCT03237117|BIOLOGICAL|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
214831659|NCT00003700|BIOLOGICAL|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
214831660|NCT00003700|DRUG|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
214831661|NCT00003700|DRUG|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
214831662|NCT00003700|DRUG|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
214831663|NCT00003700|DRUG|daunorubicin hydrochloride|80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
215031472|NCT00480727|PROCEDURE|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
214831664|NCT00003700|DRUG|leucovorin calcium|"Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose"
214831665|NCT00003700|DRUG|mercaptopurine|60mg/sq m/d PO every day Course VII
214831666|NCT00003700|DRUG|methotrexate|15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
214831667|NCT00003700|DRUG|prednisone|60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
214831668|NCT00003700|DRUG|vincristine sulfate|2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
214831669|NCT00003700|DRUG|Allopurinol|300mg PO q day Days 1-14 Course I
214831670|NCT00001842|DRUG|Granulocyte colony-stimulating factor|
214831671|NCT00001842|DRUG|Dexamethasone|
214831672|NCT05306600|DIAGNOSTIC_TEST|whole exome and whole genome sequencing analysis|"Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer"
214831673|NCT00818220|PROCEDURE|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
214831674|NCT00818220|OTHER|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
214831675|NCT01023776|BIOLOGICAL|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
214831676|NCT01404962|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
214831677|NCT05124496|DEVICE|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
214831678|NCT05735418|DIETARY_SUPPLEMENT|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
214831679|NCT05735418|DIETARY_SUPPLEMENT|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
214831680|NCT04043819|DRUG|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
214831681|NCT02906813|DRUG|TAK-935 Tablets|Tablets
214831682|NCT02906813|DRUG|TAK-935 Oral Solution|Oral solution
214831683|NCT03878264|DRUG|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
214831684|NCT03878264|DRUG|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
214831685|NCT03878264|DRUG|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
214831686|NCT01135264|BEHAVIORAL|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
214831687|NCT01135264|BEHAVIORAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
214831688|NCT01985464|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
214831689|NCT00387608|DRUG|veliparib|
214831690|NCT00387608|OTHER|pharmacological study|
214831691|NCT00387608|PROCEDURE|biopsy|
214831692|NCT04386408|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
214831693|NCT04386408|COMBINATION_PRODUCT|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
214831694|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
214831695|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
214831696|NCT00754052|DRUG|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
214831697|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
214831698|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
214831699|NCT00508833|BIOLOGICAL|287615 containing HBsAg with adjuvants|
214831700|NCT03981978|BEHAVIORAL|Physical Activity|Self-report questionnaires assessing physical activity level.
214831701|NCT00316940|DRUG|bortezomib|
214831702|NCT00316940|RADIATION|samarium Sm 153 lexidronam pentasodium|
214831703|NCT04201795|OTHER|Laser|laser with no emision will applied
214831704|NCT04201795|OTHER|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
214831705|NCT03494686|PROCEDURE|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
214831706|NCT03494686|PROCEDURE|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
214831707|NCT00006434|BIOLOGICAL|tumor-pulsed dendritic cells|
214831708|NCT05452434|DRUG|mirabegron|mirabegron 50mg QD for 12 weeks.
214831709|NCT01461291|DEVICE|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
214831710|NCT01461291|PROCEDURE|Cataract surgery|Cataract surgery alone
214831711|NCT00697801|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
214831712|NCT00697801|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
214831713|NCT00697801|DRUG|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
214831714|NCT00271557|DRUG|nesiritide|
214831715|NCT05534048|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
214831716|NCT05534048|BIOLOGICAL|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
214831717|NCT04234555|DIAGNOSTIC_TEST|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
214831718|NCT04234555|DIAGNOSTIC_TEST|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
214831719|NCT04234555|DIAGNOSTIC_TEST|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
214831720|NCT04234555|DIAGNOSTIC_TEST|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
214831721|NCT04234555|DIAGNOSTIC_TEST|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
214831722|NCT01847924|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
214831723|NCT01847924|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
214831724|NCT05945810|DRUG|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
214831725|NCT05945810|DRUG|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
214831726|NCT05521022|DRUG|AT-02|AT-02 via IV infusion
214831727|NCT05521022|OTHER|AT-02 (Placebo)|Normal saline solution via IV infusion
214831728|NCT01212549|PROCEDURE|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
214831729|NCT01212549|PROCEDURE|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
214831730|NCT03816436|OTHER|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
214831731|NCT01518335|PROCEDURE|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
214831732|NCT01518335|PROCEDURE|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
214831733|NCT00428818|DRUG|trimethoprim-sulfamethoxazole or doxycycline|
214831734|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 3 weeks|3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
214831735|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 4.5 weeks|4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
214831736|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 6 weeks|6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
214831737|NCT04364854|OTHER|No Therapy 6 Weeks|Participants will not be getting any SET for 6 weeks
214831738|NCT01422928|PROCEDURE|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
214831739|NCT05053724|OTHER|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
214831740|NCT05389670|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
214831741|NCT05389670|DEVICE|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
214831742|NCT05692882|DEVICE|Drug-Eluting Stents|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
214831743|NCT03993535|DRUG|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
214831744|NCT05565690|DEVICE|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
214831745|NCT06383130|DIAGNOSTIC_TEST|Oscillometry with reversibility testing|Oscillometry is a test that uses sound waves to measure the mechanical properties in the lungs during tidal breathing
214831746|NCT06383130|DIAGNOSTIC_TEST|Breath volatile testing|We will be optimising and evaluating the sensitivity and specificity of a novel breath volatile organic compound test of a combination of reactive aldehydes using a gas chromatography-ion mobility spectrometry device
214831747|NCT06383130|DIAGNOSTIC_TEST|Nasal eosinophil peroxidase|We will be evaluating the sensitivity and specificity of a novel nasal swab test for eosinophil peroxidase
214831748|NCT06383130|DIAGNOSTIC_TEST|Handheld capnometry|We will be evaluating handheld capnometry (carbon dioxide breath testing) to diagnose adult asthma
214831749|NCT03755596|DRUG|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
214831750|NCT03736460|BEHAVIORAL|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
214831751|NCT03736460|BEHAVIORAL|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
214831752|NCT02435433|DRUG|Ramucirumab|Administered IV
214831753|NCT02435433|DRUG|Placebo|Administered IV
214831754|NCT02599662|RADIATION|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
214831755|NCT02599662|RADIATION|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
214831756|NCT02599662|RADIATION|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
214831757|NCT03242980|BEHAVIORAL|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
214831758|NCT04537520|DEVICE|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
214831759|NCT03400774|OTHER|Stair-climbing|Short bouts of moderate intensity stair-climbing
214831760|NCT05039541|DEVICE|Alio Device|Subjects will wear the Alio device over their vasculature.
214831761|NCT05493358|PROCEDURE|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
214831762|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
214831763|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
214831764|NCT01389713|DRUG|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
214831765|NCT01389713|DRUG|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
214831766|NCT02783287|BEHAVIORAL|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
214831767|NCT02783287|BEHAVIORAL|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
214831768|NCT02651987|DRUG|Lanreotide autogel 120 mg|
214831769|NCT00616993|DRUG|Difluprednate|Difluprednate
214831770|NCT00616993|OTHER|Placebo|Vehicle
214831771|NCT05545228|BEHAVIORAL|Link work intervention|Intervention from a link worker to support participants to access dental services.
214831772|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
214831773|NCT02093728|DRUG|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
214831774|NCT02093728|DRUG|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
214831775|NCT02093728|DRUG|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
214831776|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
214831777|NCT02093728|DRUG|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
214831778|NCT02093728|DRUG|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
214831779|NCT02093728|DRUG|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
214831780|NCT01269645|BEHAVIORAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
214831781|NCT04406545|OTHER|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
214831782|NCT04842019|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
214831783|NCT00522041|DRUG|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
214831784|NCT00522041|DRUG|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
214831785|NCT01444196|DRUG|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
214831786|NCT05092035|DIAGNOSTIC_TEST|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
214831787|NCT06504121|DEVICE|Septal Occluder Device|Transcatheter PFO closure with any commercially available septal occluder device
214831788|NCT04589364|DRUG|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
214831789|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
214831790|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
214831791|NCT04170452|PROCEDURE|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
214831792|NCT03028545|BEHAVIORAL|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
214831793|NCT00199654|PROCEDURE|PET|
214831794|NCT06254560|DRUG|Rituximab|Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
214831795|NCT01828294|DRUG|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
214831796|NCT00015665|DRUG|Voriconazole|
214831797|NCT06560450|DEVICE|Stride One|Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
214831798|NCT06018116|DRUG|Bicalutamide 150 mg|nonsteroidal antiandrogen
214831799|NCT06018116|DRUG|Placebo|placebo
214831800|NCT01567319|BIOLOGICAL|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214831801|NCT01567319|BIOLOGICAL|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214831802|NCT01567319|BIOLOGICAL|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214831803|NCT00263458|OTHER|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
214831804|NCT01816360|OTHER|Olfactory aromatherapy|Inhalation of essential oils.
214831805|NCT01816360|OTHER|Yogatherapy|Yogatherapy respiratory exercises.
214831806|NCT03540160|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
214831807|NCT01664039|DRUG|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
214831808|NCT01664039|DRUG|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
214831809|NCT01310855|DRUG|cediranib maleate|
214831810|NCT01310855|DRUG|gefitinib|
214831811|NCT01310855|DRUG|Placebo|
214831812|NCT05734716|DRUG|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
214831813|NCT05734716|DRUG|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
214831814|NCT05734716|DRUG|Sterile Sodium Chloride|sham treatment with sterile saline
214831815|NCT00622362|BIOLOGICAL|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
214831816|NCT00622362|BIOLOGICAL|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
214831817|NCT00622362|BIOLOGICAL|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
214831818|NCT01704534|DRUG|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
214831819|NCT04468282|DRUG|VGB-ST|Single oral administration of 500 mg VGB-ST
214831820|NCT03671954|BEHAVIORAL|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
214831821|NCT03671954|OTHER|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
214831822|NCT03671954|OTHER|Preoperative Assessments|"Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)"
214831823|NCT06558955|BEHAVIORAL|Technology-enabled anticipatory guidance and peer support|The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
214831824|NCT06558955|BEHAVIORAL|Conventional health education|Participants on this arm will receive conventional child oral health education materials at 4 time points.
214831825|NCT05406050|DRUG|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
214831826|NCT05406050|DRUG|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
214831827|NCT04552665|DEVICE|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
214831828|NCT00726830|DRUG|methadone hydrochloride|Given orally
214831829|NCT00726830|DRUG|morphine sulfate|Given orally
214831830|NCT00726830|DRUG|oxycodone hydrochloride|Given orally
214831831|NCT03577535|DIETARY_SUPPLEMENT|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
214831832|NCT04114890|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
214831833|NCT01813864|BEHAVIORAL|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
214831834|NCT01637480|OTHER|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
214831835|NCT04999280|OTHER|Fiber Croissant (FIBCRO) Group|Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
214831836|NCT04999280|OTHER|Control Croissant (CONCRO) Group|Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
214831837|NCT05803135|DRUG|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
214831838|NCT02640235|DEVICE|CELSTAT|
214831839|NCT02640235|DEVICE|Surgicel Original|
214831840|NCT04275895|BEHAVIORAL|Evaluation of different attention or/and postural activities|"1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet"
214831841|NCT04356313|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
214831842|NCT04756921|DRUG|Pyrotinib|Pyrotinib 400mg po qd
214831843|NCT00694408|DRUG|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
214831844|NCT00694408|OTHER|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
214831845|NCT01674387|DEVICE|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
214831846|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
214831847|NCT05812638|OTHER|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
214831848|NCT05812638|OTHER|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
214831849|NCT03315533|DRUG|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
214831850|NCT03315533|DRUG|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
214831851|NCT03315533|DRUG|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
214831852|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
214831853|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
214831854|NCT00983099|DRUG|Neramexane|single and multiple dose, tablets, oral
214831855|NCT03610542|BEHAVIORAL|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
214831856|NCT03610542|BEHAVIORAL|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
214831857|NCT03610542|BEHAVIORAL|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
214831858|NCT03610542|BEHAVIORAL|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
214831859|NCT03610542|BEHAVIORAL|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
214831860|NCT05862805|PROCEDURE|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
214831861|NCT05109104|DRUG|CAP UnScented|Sunscreen lip balm.
214831862|NCT05109104|DRUG|CAP Herbal Mint|Sunscreen lip balm.
214831863|NCT05109104|DRUG|CAP Mountain Berry|Sunscreen lip balm.
214831864|NCT05109104|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
214831865|NCT03648931|BEHAVIORAL|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
214831866|NCT03648931|BEHAVIORAL|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
214831867|NCT05863026|BEHAVIORAL|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
214831868|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
214831869|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
214831870|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
214831871|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
214831872|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
214831873|NCT01140672|DRUG|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
214831874|NCT06449534|BEHAVIORAL|Patient Education|It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
214831875|NCT06449534|BEHAVIORAL|Exercise Therapy|Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
214831876|NCT06449534|BEHAVIORAL|Cold Application|Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
215031473|NCT00480727|PROCEDURE|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
215031474|NCT04980209|DEVICE|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
214831877|NCT00873990|OTHER|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
214831878|NCT00873990|OTHER|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
214831879|NCT00558402|BEHAVIORAL|Meditation|meditation class 1/week for 8 weeks
214831880|NCT00558402|BEHAVIORAL|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
214831881|NCT00558402|BEHAVIORAL|Respite only|Respite care 90 mins per week for 8 weeks
214831882|NCT00945490|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
214831883|NCT00945490|DRUG|Placebo|Single intraprostatic injection of placebo
214831884|NCT02372006|DRUG|afatinib|
214831885|NCT05244928|OTHER|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
214831886|NCT05697679|BEHAVIORAL|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
214831887|NCT05697679|BEHAVIORAL|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
214831888|NCT02095054|DRUG|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
214831889|NCT02095054|DRUG|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
214831890|NCT02095054|BEHAVIORAL|Questionnaire|Symptom questionnaire completed at each study visit.
214831891|NCT01193972|OTHER|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
214831892|NCT03306758|DRUG|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
214831893|NCT05247567|BIOLOGICAL|serum punction|A blood sample inclusion and at the end of study visit
214831894|NCT05247567|BIOLOGICAL|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
214831895|NCT04419935|PROCEDURE|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
214831896|NCT04436419|DIETARY_SUPPLEMENT|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
214831897|NCT04436419|DIETARY_SUPPLEMENT|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
214831898|NCT00000595|DRUG|deferoxamine|
214831899|NCT00272441|DRUG|inhaled corticosteroids|
214831900|NCT04968951|DRUG|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
214831901|NCT04968951|DRUG|Placebo|Placebo treatment
214831902|NCT04968951|DRUG|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
215031475|NCT02129621|PROCEDURE|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
214831903|NCT04968951|BIOLOGICAL|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
214831904|NCT04129177|OTHER|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
214831905|NCT01987128|PROCEDURE|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
214831906|NCT01987128|PROCEDURE|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
214831907|NCT01987128|DRUG|Ropivacaine|
214831908|NCT01987128|DEVICE|PAJUNK SonoPlex 22G needle.|
214831909|NCT01959828|DRUG|IK-3001|
214831910|NCT01501786|DRUG|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
214831911|NCT01501786|DRUG|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
214831912|NCT01501786|DRUG|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
214831913|NCT02832921|BEHAVIORAL|cognitive training by virtual reality|
214831914|NCT02832921|BEHAVIORAL|watching a scientific TV documentary|
214831915|NCT02832921|DEVICE|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
214831916|NCT02802852|DEVICE|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
214831917|NCT02802852|DRUG|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
214831918|NCT05535998|PROCEDURE|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
214831919|NCT05535998|PROCEDURE|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
214831920|NCT05535998|DRUG|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
214831921|NCT05535998|DRUG|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
214831922|NCT01347749|BEHAVIORAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
214831923|NCT01347749|BEHAVIORAL|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
214831924|NCT01459380|BIOLOGICAL|Bevacizumab|Given IV
214831925|NCT01459380|DRUG|Carboplatin|Given IV
214831926|NCT01459380|OTHER|Laboratory Biomarker Analysis|Correlative studies
214831927|NCT01459380|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214831928|NCT01459380|DRUG|Veliparib|Given PO
214831929|NCT04303221|OTHER|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
214831930|NCT03785262|DEVICE|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
214831931|NCT03785262|DEVICE|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
214831932|NCT04789434|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
214831933|NCT05709496|RADIATION|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
214831934|NCT05077449|DRUG|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
214831935|NCT05077449|DRUG|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
214831936|NCT01181635|BEHAVIORAL|Psychotherapy|Standard psychotherapy for psychiatric disorders.
214831937|NCT04260373|DRUG|[14C]SHR4640|Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
214831938|NCT03045458|DEVICE|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
215031476|NCT02129621|DRUG|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
214831939|NCT03045458|DEVICE|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
214831940|NCT02318420|OTHER|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
214831941|NCT03640741|PROCEDURE|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
214831942|NCT01326663|DRUG|Medication Trial|
214831943|NCT03431558|COMBINATION_PRODUCT|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
214831944|NCT03431558|DRUG|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
214831945|NCT05535868|OTHER|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
214831946|NCT02959619|DRUG|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
214831947|NCT01807026|DRUG|LY2886721|
214831948|NCT01807026|DRUG|Placebo|
214831949|NCT00458822|DRUG|bortezomib|Given IV
214831950|NCT00458822|DRUG|dexamethasone|Given orally
214831951|NCT05789121|DEVICE|walking 25 m in 4 different conditions|"The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation"
214831952|NCT00467597|DRUG|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
214831953|NCT03756233|DRUG|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
214831954|NCT02722798|DRUG|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
214831955|NCT00417677|DRUG|Combination of Temsirolimus and Sunitinib|
214831956|NCT03811977|DIETARY_SUPPLEMENT|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
214831957|NCT03811977|DIETARY_SUPPLEMENT|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
214831958|NCT03710629|OTHER|Patients with driver genes|Patients with driver genes
214831959|NCT06122805|DEVICE|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
214831960|NCT04563260|DRUG|Normal saline injection|Normal saline 2 mL, intravenous injection
214831961|NCT04563260|DRUG|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
214831962|NCT04163094|DRUG|W_ova1 Vaccine|Patients will be treated with a W\_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
214831963|NCT04865120|OTHER|cream cyclic merocyanine|cream long-UVA absorber
214831964|NCT04865120|OTHER|placebo|placebo
214831965|NCT03669731|OTHER|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
214831966|NCT03404921|PROCEDURE|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
214831967|NCT03404921|PROCEDURE|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
214831968|NCT02235870|DEVICE|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
214831969|NCT02235870|DEVICE|Sham Device|Sham Intragastric Balloon
214831970|NCT02235870|BEHAVIORAL|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
214831971|NCT03234309|DRUG|Ferumoxytol|Given IV
214831972|NCT03234309|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214831973|NCT03058107|DIETARY_SUPPLEMENT|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
214831974|NCT03058107|DIETARY_SUPPLEMENT|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
214831975|NCT04898504|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
214831976|NCT04898504|PROCEDURE|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
214831977|NCT00532012|DRUG|RhuDex®|
214831978|NCT01046084|DRUG|Lansoprazole|30 mg Delayed-Release Capsule
214831979|NCT01046084|DRUG|Prevacid®|30 mg Delayed-Release Capsule
214831980|NCT02166606|DEVICE|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
214831981|NCT02824510|OTHER|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
214831982|NCT02824510|OTHER|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
214831983|NCT02824510|DRUG|Insulin aspart, glargine and detemir|
214831984|NCT05569109|DEVICE|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
214831985|NCT01958476|DRUG|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
214831986|NCT01958476|DRUG|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
214831987|NCT01958476|DRUG|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally \>8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
214831988|NCT05086913|OTHER|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
214831989|NCT05086913|OTHER|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
214831990|NCT05086913|OTHER|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
214831991|NCT02473237|DRUG|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
214831992|NCT02473237|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
214831993|NCT02032927|DRUG|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
214831994|NCT02032927|DRUG|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
214831995|NCT01148069|PROCEDURE|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
214831996|NCT02248714|DIETARY_SUPPLEMENT|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
215031477|NCT05810480|DIAGNOSTIC_TEST|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
214831997|NCT05412121|DEVICE|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
214831998|NCT01624272|DEVICE|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
214831999|NCT01624272|OTHER|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
214832000|NCT06462495|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
214832001|NCT06462495|DRUG|[18F]F-PSMA-1007|Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
214832002|NCT05756218|OTHER|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
214832003|NCT04727164|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
214832004|NCT00770952|DRUG|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
214832005|NCT00770952|DRUG|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
214832006|NCT00635687|DEVICE|Fibroscan|transient elastography measure - Liver stiffness
214832007|NCT03088007|OTHER|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
214832008|NCT01231737|DRUG|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
214832009|NCT00948909|DRUG|Placebo|Placebo intervention
214832010|NCT00948909|DRUG|ABT-126|Experimental intervention
214832011|NCT00948909|DRUG|donepezil|Active comparator intervention
214832012|NCT03324815|DRUG|Morphine|Pain Treatment
214832013|NCT03324815|DRUG|Methadone|Pain Treatment
214832014|NCT02670551|DRUG|Cariprazine|
214832015|NCT02670551|DRUG|Placebo|
214832016|NCT05485051|OTHER|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
214832017|NCT05485051|OTHER|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
214832018|NCT02119637|DEVICE|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
214832019|NCT02119637|DEVICE|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
214832020|NCT05650151|DIETARY_SUPPLEMENT|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
214832021|NCT05650151|DIETARY_SUPPLEMENT|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
214832022|NCT00651651|DRUG|budesonide/formoterol|
214832023|NCT00651651|DRUG|budesonide|
214832024|NCT00651651|DRUG|formoterol|
214832025|NCT03576053|DRUG|Lidocaine|Lidocaine intradermal injection
214832026|NCT03576053|OTHER|Histamine|Skin Prick Test with Histamine
214832027|NCT03576053|OTHER|Cowhage|Manually skin insertion of cowhage spicules
214832028|NCT03576053|OTHER|Heat stimulation|Short heat stimulation
214832029|NCT03576053|OTHER|Pre-heating|Mild skin pre-heating
214832030|NCT03576053|OTHER|Serotonin|Serotonin electrophoresis
214832031|NCT04476277|DRUG|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
214832032|NCT01962298|DRUG|sugammadex 2mg/kg|
214832033|NCT01962298|DRUG|neostigmine|
214832034|NCT01962298|DRUG|sugammadex 4mg/kg|
214832035|NCT01962298|DRUG|placebo|
214832036|NCT01962298|DRUG|Single rocuronium dose|
214832037|NCT01962298|DRUG|Repeated rocuronium dose|
214832038|NCT01962298|DRUG|Continuous rocuronium infusion|
214832039|NCT01971645|DRUG|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
214832040|NCT01971645|DRUG|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
214832041|NCT01940445|DEVICE|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
214832042|NCT01940445|DEVICE|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
214832043|NCT04507698|OTHER|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
214832044|NCT04020445|OTHER|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
214832045|NCT03284697|PROCEDURE|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
214832046|NCT03284697|PROCEDURE|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
214832047|NCT00051805|BEHAVIORAL|Promotion of adherence to ARV medications|
214832048|NCT03840577|DEVICE|Monitorization of sedation by Bispectral Index|The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
214832049|NCT00537095|DRUG|Vandetanib|300 mg oral once daily oral dose
214832050|NCT00537095|OTHER|Placebo|
214832051|NCT04173923|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
214832052|NCT04173923|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214832053|NCT04173923|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
214832054|NCT04173923|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214832055|NCT04173923|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214832056|NCT04173923|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214832057|NCT04173923|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
214832058|NCT05062564|DEVICE|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
214832059|NCT05062564|PROCEDURE|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
214832060|NCT06505005|DEVICE|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
214832061|NCT06505005|DEVICE|Sham Patch without haptic vibrotactile trigger technology (VTT)|Sham Patch without haptic vibrotactile trigger technology (VTT)
214832062|NCT03227939|PROCEDURE|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
214832063|NCT03227939|PROCEDURE|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
214832064|NCT00533507|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
214832065|NCT00533507|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
214832066|NCT00533507|BIOLOGICAL|Rotarix|Oral, 2 doses.
214832067|NCT02708758|BEHAVIORAL|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
214832068|NCT01370122|OTHER|Survey|
214832069|NCT01022879|PROCEDURE|vitrectomy|
214832070|NCT03783897|DRUG|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
214832071|NCT03783897|DRUG|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
214832072|NCT00349765|BEHAVIORAL|higher fat, high polyunsaturated fat diet|
214832073|NCT00349765|BEHAVIORAL|higher fat, high saturated and trans fat diet|
214832074|NCT00349765|BEHAVIORAL|lower fat diet|
214832075|NCT04955158|DRUG|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
214832076|NCT04955158|DRUG|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
214832077|NCT04955158|OTHER|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
214832078|NCT00249197|DRUG|levofloxacin|
214832079|NCT04184947|DRUG|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
214832080|NCT04184947|DRUG|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
214832081|NCT03917758|DRUG|SGLT2 inhibitor|Start of the treatment with SGLT2i.
214832082|NCT03825198|PROCEDURE|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
214832083|NCT03825198|DRUG|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
214832084|NCT03825198|PROCEDURE|spine fusion|fusion of lumbar vertebral body on 1 or two levels
214832085|NCT03825198|DRUG|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
214832086|NCT03825198|DRUG|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
214832087|NCT03825198|DRUG|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
214832088|NCT03825198|DRUG|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
214832089|NCT03825198|DRUG|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
214832090|NCT03825198|DRUG|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
214832091|NCT03825198|DRUG|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
214832092|NCT03825198|DRUG|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
214832093|NCT03825198|DRUG|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
214832094|NCT03825198|DRUG|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
214832095|NCT01032590|BEHAVIORAL|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
214832096|NCT00213551|DRUG|Glutamine|
214277515|NCT04107506|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
214832097|NCT00213551|DRUG|Glucose|
214832098|NCT00213551|DRUG|glutamine-antioxidants containing solution|
214832099|NCT01828203|DRUG|Minocycline|
214832100|NCT01828203|DRUG|Placebo|
214832101|NCT01828203|PROCEDURE|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
214832102|NCT01828203|PROCEDURE|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
214832103|NCT00904280|DRUG|Oxymorphone ER|Open label
214832104|NCT03548480|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo
214832105|NCT03548480|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic
214832106|NCT03788876|OTHER|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
214277516|NCT05621369|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
214277517|NCT05621369|BEHAVIORAL|Psoriasis Draw|Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
214832107|NCT03788876|OTHER|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
214832108|NCT05002660|BEHAVIORAL|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
214832109|NCT05002660|BEHAVIORAL|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
214832110|NCT01589835|BEHAVIORAL|Lifestyle changes|Green prescription with support from facilitator
214832111|NCT00881426|DRUG|Cefprozil 500 mg Tablets (Sandoz GmbH)|
214832112|NCT00881426|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
214832113|NCT05575557|PROCEDURE|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
214832114|NCT02835157|DRUG|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
214832115|NCT02835157|DRUG|0.9%sodium chloride|saline as boluses would be administered
214832116|NCT01576705|DRUG|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
214832117|NCT01062490|DRUG|Treosulfan|14 g/m2/d, day -6 to -4
214832118|NCT01246453|DRUG|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
214832119|NCT05560139|DEVICE|a-tDCS|Transcranial direct current stimulation
214832120|NCT03727139|DRUG|Rasagiline|Rasagiline Tablets
214832121|NCT01140607|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214832122|NCT01875107|DRUG|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
214832123|NCT00566722|BIOLOGICAL|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
214832124|NCT00799162|OTHER|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
214832125|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
214832126|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
214832127|NCT02907125|BEHAVIORAL|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
214832128|NCT06297408|DRUG|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
214832129|NCT06170762|OTHER|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
214832130|NCT06170762|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
214832131|NCT06170762|OTHER|MTA|MTA
214832132|NCT03021876|DRUG|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
214832133|NCT03021876|OTHER|usual intake|baseliner
214832134|NCT01068704|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
214832135|NCT01068704|DRUG|Lapatinib|Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
214832136|NCT01068704|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
214832137|NCT06173050|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
214832138|NCT06173050|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
214832139|NCT03224663|OTHER|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
214832140|NCT03224663|OTHER|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
214832141|NCT00829894|DRUG|Risperidone|1 mg Tablet
214832142|NCT00829894|DRUG|Risperidone|1 mg Tablet
214832143|NCT02790658|DIETARY_SUPPLEMENT|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
214832144|NCT02896296|DRUG|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
214832145|NCT02010034|DRUG|Omegaven|Omegaven will be used in place of soy oil Intralipid
214832146|NCT00380796|DRUG|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
214832147|NCT03545334|DIAGNOSTIC_TEST|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
214832148|NCT01385163|BEHAVIORAL|Treatment as usual|Standard psychosocial counseling
214832149|NCT01385163|BEHAVIORAL|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
214832150|NCT01385163|BEHAVIORAL|Cognitive Processing Therapy|group 12 session intervention
214832151|NCT02421653|DIETARY_SUPPLEMENT|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
214832152|NCT02421653|DIETARY_SUPPLEMENT|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
214832153|NCT02421653|DIETARY_SUPPLEMENT|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
214832154|NCT02421653|DIETARY_SUPPLEMENT|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
214832155|NCT02421653|DIETARY_SUPPLEMENT|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
214832156|NCT02421653|DIETARY_SUPPLEMENT|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
214832157|NCT04550013|OTHER|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
214832158|NCT04550013|OTHER|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
214832159|NCT01874535|DRUG|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
214832160|NCT04350697|PROCEDURE|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
214832161|NCT04674072|OTHER|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
214832162|NCT04674072|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
214832163|NCT00838188|OTHER|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
214832164|NCT01158313|DIETARY_SUPPLEMENT|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
214832165|NCT03676790|OTHER|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
214832166|NCT03676790|OTHER|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
214832167|NCT03676790|OTHER|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
214832168|NCT03676790|OTHER|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
214832169|NCT03676790|OTHER|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
214832170|NCT00748787|DRUG|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
214832171|NCT00748787|DRUG|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
214832172|NCT03853187|RADIATION|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
215031478|NCT04996745|BEHAVIORAL|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
215031479|NCT01793389|PROCEDURE|Subepithelial connective tissue graft|
215031480|NCT01793389|PROCEDURE|Platelet Rich Fibrin|
215031481|NCT03620981|DRUG|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
215031482|NCT03620981|DRUG|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
215031483|NCT03286361|DEVICE|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
214832173|NCT03853187|DRUG|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
214832174|NCT04305470|DRUG|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
214832175|NCT02597049|DRUG|Dulaglutide|Administered SC
214832176|NCT02597049|DRUG|Placebo|Administered SC
214832177|NCT02597049|DRUG|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
214832178|NCT02597049|DRUG|Metformin|Administered orally as standard of care for type 2 diabetes
214832179|NCT05119049|OTHER|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
214832180|NCT02463487|DEVICE|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
214832181|NCT02463487|DEVICE|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
214832182|NCT01613937|BEHAVIORAL|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
214832183|NCT03124758|DEVICE|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
214832184|NCT00243347|DRUG|AZD2171|oral tablet
214832185|NCT02709057|BEHAVIORAL|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
214832186|NCT01939535|OTHER|No intervention|Evaluation of an imaging technique ic MRI
214832187|NCT00866476|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
214832188|NCT00866476|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
214832189|NCT02380534|PROCEDURE|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
214832190|NCT01298050|PROCEDURE|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
214832191|NCT00702793|DRUG|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
214832192|NCT01044433|DRUG|lapatinib ditosylate|Given orally
214832193|NCT01044433|DRUG|capecitabine|Given orally
214832194|NCT06520683|DRUG|Tislelizumab|\- Tislelizumab 200mg (day 1 and day 22), administered after surgery
214832195|NCT06520683|DRUG|Adjuvant chemotherapy|"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."
214832196|NCT03329209|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
214832197|NCT03595254|BEHAVIORAL|Thrive|Computerized Cognitive Behavior Therapy program
214277518|NCT05621369|BEHAVIORAL|Psoriasis Area Photo|Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
214277519|NCT05621369|BEHAVIORAL|Finger and Toe Photos|Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
214832198|NCT05953987|OTHER|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
214832199|NCT05953987|OTHER|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
214832200|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
214832201|NCT00471094|DRUG|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
214832202|NCT00471094|DRUG|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
214832203|NCT00471094|DRUG|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
214832204|NCT00471094|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
214832205|NCT02594527|OTHER|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
214832206|NCT05065619|BIOLOGICAL|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
214832207|NCT05065619|DRUG|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
214832208|NCT05065619|BIOLOGICAL|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
214832209|NCT05364606|DEVICE|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
214832210|NCT02069951|OTHER|Practice a procedural module on a simulator|
214832211|NCT04293354|PROCEDURE|Serratus Plane Block|Serratus Plane Block was performed
214832212|NCT04293354|PROCEDURE|Control|No block was performed
214832213|NCT02976064|BEHAVIORAL|PreHabilitation|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
214832214|NCT02976064|BEHAVIORAL|Rehabilitation in chronic stable patients in primary care|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease."
214832215|NCT02976064|BEHAVIORAL|Rehabilitation in mild chronic patients and citizens at risk|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
214832216|NCT04385745|PROCEDURE|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
214832217|NCT00907205|DRUG|SF1126|Dose Escalating with 3+ patients in each cohort
214832218|NCT00858416|DEVICE|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
214832219|NCT00858416|DEVICE|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
214832220|NCT05745636|DIETARY_SUPPLEMENT|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
214832221|NCT05745636|DIETARY_SUPPLEMENT|Placebo|2 capsules per day for 4 weeks.
214832222|NCT00842816|DRUG|ST101|10 mg; administered once/day
214832223|NCT00842816|DRUG|ST101|60 mg; administered once/day
214832224|NCT00842816|DRUG|ST101|120 mg; administered once/day
214832225|NCT00842816|DRUG|Placebo|placebo tablets to match ST101 tablets
214832226|NCT03968016|DEVICE|SYSMEX HLSCL|Diagnostic device
214832227|NCT01390948|DRUG|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
214832228|NCT01390948|RADIATION|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
214832229|NCT01390948|DRUG|Temozolomide (TMZ)|75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
214832230|NCT02223169|DIETARY_SUPPLEMENT|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
214832231|NCT02979041|BEHAVIORAL|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
214832232|NCT02979041|OTHER|Standard Care|physiotherapy and medical care as provided currently
214832233|NCT03935737|DIAGNOSTIC_TEST|Full Dose Chest X-Ray|Full dose X ray at Day 1
214832234|NCT03935737|DIAGNOSTIC_TEST|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
214832235|NCT02117505|DRUG|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
214832236|NCT02117505|DRUG|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
214832237|NCT01487629|DRUG|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
214832238|NCT01487629|DRUG|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
214832239|NCT03694236|DRUG|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
214832240|NCT05016986|OTHER|Standard clinical management|outcomes in GSW cardiac injuries
214832241|NCT00983996|DRUG|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
214832242|NCT00983996|DRUG|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
214832243|NCT05779358|OTHER|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
214832244|NCT04548258|DEVICE|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
214832245|NCT04548258|DEVICE|casting|casting metal framework
214832246|NCT02795572|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000 IU oral once daily
214832247|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 100 mg oral once daily
214832248|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 100 mcg oral once daily
214832249|NCT02795572|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
214832250|NCT04206267|DEVICE|Acceledent|Device for accelerating tooth movement
214832251|NCT05940233|DRUG|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
214832252|NCT03385863|DRUG|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
214832253|NCT03385863|OTHER|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
214832254|NCT05203146|DEVICE|PIMPmyHospital (mobile health tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
214832255|NCT05203146|OTHER|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
214832256|NCT05050851|DIETARY_SUPPLEMENT|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
214832257|NCT05336097|OTHER|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
214832258|NCT03694535|DRUG|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
214832259|NCT03581630|DRUG|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
214832260|NCT03581630|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
214832261|NCT02271035|DRUG|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
214832262|NCT02271035|DRUG|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
214832263|NCT06322251|BEHAVIORAL|Use of instrument to identify exposure to violence in close relationships|Use of instrument to identify exposure to violence in close relationships
214832264|NCT01687335|OTHER|answering questionnare in differents time of the treatment|
214832265|NCT03142620|DRUG|Esomeprazole|40mg twice daily
214832266|NCT03142620|DRUG|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
214832267|NCT03142620|DRUG|Clarithromycin|500mg twice daily
214832268|NCT03142620|DRUG|Vitamin D3|5000IU
215031484|NCT04554836|DRUG|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
214832269|NCT04007835|DRUG|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
214832270|NCT00084097|DRUG|Omalizumab|
214832271|NCT01390051|DRUG|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
214832272|NCT01390051|DRUG|tinzaparin|Dose 4,500 IE daily
215031485|NCT04554836|OTHER|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
214832273|NCT05942976|OTHER|ULTRASOUND|10 enthesis areas will be evaluated in 20 minutes with ultrasound.
214832274|NCT03983135|OTHER|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
214832275|NCT03983135|OTHER|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
214832276|NCT03983135|OTHER|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
214832277|NCT04499664|DEVICE|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
214832278|NCT05320146|OTHER|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
214832279|NCT03147768|DEVICE|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
214832280|NCT04962945|PROCEDURE|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
214832281|NCT04962945|PROCEDURE|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
214832282|NCT03750448|OTHER|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
214832283|NCT03750448|OTHER|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
214832284|NCT03750448|OTHER|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
214832285|NCT03332732|DRUG|VNRX-5133|β-lactamase inhibitor
214832286|NCT03332732|DRUG|VNRX-5022|Approved β-lactam antibiotic
214832287|NCT03332732|DRUG|Metronidazole|Approved antibiotic and antiprotozoal medication
214832288|NCT03332732|DRUG|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
214832289|NCT05025163|DRUG|1.23% fluoride foam application|topical application of fluoride foam every 6 months
214832290|NCT05025163|DRUG|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
214832291|NCT02291796|DRUG|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
214832292|NCT01739647|DRUG|AZD3293|Oral solution
214832293|NCT01739647|DRUG|Placebo|Oral solution
214832294|NCT03817151|PROCEDURE|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
214832295|NCT00169364|DEVICE|positron emission tomography|
214832296|NCT05740098|BEHAVIORAL|Best Practices|Five As plus referral to a quit line
214832297|NCT05740098|BEHAVIORAL|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
214832298|NCT05740098|DRUG|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
214832299|NCT03997799|PROCEDURE|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
214832300|NCT01989884|DRUG|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
214832301|NCT02452463|BIOLOGICAL|Durvalumab|Given IV
214832302|NCT02452463|DRUG|Nintedanib|Given PO
214832303|NCT02452463|OTHER|Placebo|Given PO
215031486|NCT06264570|DIETARY_SUPPLEMENT|B-TMG supplementation|B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
215031487|NCT06264570|DIETARY_SUPPLEMENT|B-SAM supplementation|B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
215031488|NCT06264570|OTHER|B-TMG placebo|B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
215031489|NCT06264570|OTHER|B-SAM placebo|B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
214832304|NCT02452463|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214832305|NCT05895435|DEVICE|radiofrequancy|"* Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance."
214832306|NCT05895435|OTHER|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
214832307|NCT04949386|DRUG|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
214832308|NCT04949386|OTHER|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
214832309|NCT02171988|DRUG|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
214832310|NCT02171988|DRUG|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
214832311|NCT02171988|DRUG|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
214832312|NCT02171988|DRUG|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
214832313|NCT01260623|DRUG|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
214832314|NCT02278302|DRUG|Aggrenox®|
214832315|NCT02278302|DRUG|Placebo|
214832316|NCT02278302|OTHER|Ethanol|
214832317|NCT04363359|BIOLOGICAL|0.5ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
214832318|NCT04363359|BIOLOGICAL|0.25ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
214832319|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/V)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
214832320|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/Y)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
214832321|NCT02105220|OTHER|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
214832322|NCT03012451|BEHAVIORAL|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
214832323|NCT05451264|DIAGNOSTIC_TEST|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
214832324|NCT03401281|OTHER|Coconut oil|50g extra virgin coconut oil daily for four weeks
214832325|NCT03401281|OTHER|Butter|50g butter daily for four weeks
214832326|NCT03401281|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
214832327|NCT01528735|DRUG|BI 207127 NA|one fix dose
214832328|NCT01528735|DRUG|peginterferon|per package insert
214832329|NCT01528735|DRUG|Ribavirin|per weight BID
214832330|NCT01528735|DRUG|Ribavirin|per weight BID
214832331|NCT01528735|DRUG|BI 207127 NA|one fix dose
214832332|NCT01528735|DRUG|BI 201335 NA|high dose
214832333|NCT01528735|DRUG|BI 201335 NA|low dose
214832334|NCT01528735|DRUG|peginterferon|per package insert
214832335|NCT00755235|OTHER|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
214832336|NCT05402046|OTHER|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
214832337|NCT04401137|DRUG|Topiramate|Topiramate
214832338|NCT01401062|DRUG|Fresolimumab|
214832339|NCT01401062|RADIATION|Radiation Therapy|
214832340|NCT02228486|DEVICE|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
214832341|NCT02228486|BEHAVIORAL|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
214832342|NCT03860441|OTHER|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
214832343|NCT01574027|DRUG|Vitamin D3 (cholecalciferol)|One capsule per day for six months
214832344|NCT01574027|DRUG|Placebo|One capsule per day for six months
214832345|NCT05659316|OTHER|MRI imaging|Knee MRI imaging
214832346|NCT00757172|BIOLOGICAL|panitumumab|
214832347|NCT00757172|DRUG|cisplatin|
214832348|NCT00757172|DRUG|docetaxel|
214832349|NCT00757172|PROCEDURE|neoadjuvant therapy|
214832350|NCT00757172|PROCEDURE|therapeutic conventional surgery|
214832351|NCT00757172|RADIATION|radiation therapy|
215031490|NCT05642858|BEHAVIORAL|Digital Educational Messaging|Education via mobile phone text messages for up to 6 months.
215031491|NCT06005324|DRUG|Paclitaxel|Given as part of induction chemotherapy.
214832352|NCT03555695|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
214832353|NCT03555695|BEHAVIORAL|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
214832354|NCT03555695|BEHAVIORAL|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
214832355|NCT00869193|DIETARY_SUPPLEMENT|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
214832356|NCT00869193|DIETARY_SUPPLEMENT|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
214832357|NCT03409315|PROCEDURE|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
214832358|NCT06238388|DRUG|HSK21542 Injection|A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
214832359|NCT04889014|GENETIC|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
214832360|NCT04889014|GENETIC|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
214832361|NCT05226702|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
214832362|NCT05226702|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
214832363|NCT03693014|RADIATION|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
214832364|NCT03693014|BIOLOGICAL|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
214832365|NCT04538677|DEVICE|Video consultation|A two-way audio and visual connection between patients and surgeons
214832366|NCT02975856|DIETARY_SUPPLEMENT|Table Red Wine|
214832367|NCT02975856|DIETARY_SUPPLEMENT|Young Port Red Wine|
214832368|NCT00099151|BEHAVIORAL|Caloric Restriction (CR)|
214832369|NCT00099151|BEHAVIORAL|Exercise|
214832370|NCT02665962|OTHER|Perioperative Caloric Restriction Program|
214832371|NCT04671147|PROCEDURE|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
214832372|NCT05502055|OTHER|Individual interviews|One on One interviews by Zoom video conferencing, \< 2 hours in duration
214832373|NCT05502055|OTHER|Focus Groups|Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
214832374|NCT05502055|OTHER|National Survey|Survey conducted online and distributed nationally
214832375|NCT05055713|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
214832376|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214832377|NCT05055713|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
214832378|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214832379|NCT05055713|PROCEDURE|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
214832380|NCT05055713|PROCEDURE|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214832381|NCT02621190|DRUG|cabazitaxel|25mg/m2 q3w
214832382|NCT02763696|OTHER|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
214832383|NCT00453258|OTHER|Eye Examination|Subjects receiving eye examination
214832384|NCT04194151|DRUG|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
215031492|NCT06005324|DRUG|Carboplatin|Given as part of induction chemotherapy.
215031493|NCT06005324|DRUG|Cetuximab|Given as part of induction chemotherapy.
215031494|NCT06005324|RADIATION|Standard Dose Radiation|Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
214832385|NCT05832424|BEHAVIORAL|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
214832386|NCT00538863|DRUG|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
214832387|NCT02609191|DEVICE|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
214832388|NCT02609191|DEVICE|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
214832389|NCT02609191|DEVICE|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
214832390|NCT04203823|DEVICE|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
214832391|NCT01499043|DRUG|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
214832392|NCT05724394|OTHER|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
214832393|NCT04917393|DEVICE|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
214832394|NCT04917393|OTHER|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
214832395|NCT06435793|PROCEDURE|MEP measurement - Surface EMG - IOPI|"Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument."
214832396|NCT02070783|DRUG|ARA290|
214832397|NCT02070783|DRUG|Placebo|
214832398|NCT01316536|OTHER|provide headphones with music playing|Participants will be provided with music through headphones
214832399|NCT01316536|OTHER|Sounds|recorded ICU sounds will be provided to participants through headphones
214832400|NCT04071613|DRUG|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
214832401|NCT04071613|DRUG|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
214832402|NCT06065839|OTHER|non-nutritive sucking 5 minutes|Give pacifier non-nutritive sucking for 5 minutes before feeding
214832403|NCT06065839|OTHER|non-nutritive sucking 15 minutes|Give pacifier non-nutritive sucking for 15 minutes before feeding
214832404|NCT02456285|PROCEDURE|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
214832405|NCT02456285|PROCEDURE|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
214832406|NCT02456285|PROCEDURE|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
214832407|NCT02456285|PROCEDURE|No surgery|Patients who have no surgery.
214832408|NCT01897207|BIOLOGICAL|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
214832409|NCT06559293|DIAGNOSTIC_TEST|laryngeal ultrasound|laryngeal ultrasound with linear probe will be positioned on the patient's neck. A list of anatomical sites to be visualised will be determined beforehand. Once all the pre-determined structures have been visualised, in an axial and sagittal plane, we will note the position of the ultrasound probe and its orientation. This will enable us to determine the ideal position of the ultrasound probe for obtaining all the elements of interest on a section that will be called the reference section.
214832410|NCT03129841|BEHAVIORAL|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
214832411|NCT03129841|BEHAVIORAL|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
214832412|NCT02901028|OTHER|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
214832413|NCT02901028|OTHER|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
214832414|NCT00898664|GENETIC|cytogenetic analysis|
214832415|NCT00898664|GENETIC|gene expression analysis|
214832416|NCT00898664|GENETIC|mutation analysis|
214832417|NCT00898664|GENETIC|polymerase chain reaction|
214832418|NCT00898664|OTHER|immunohistochemistry staining method|
214832419|NCT00898664|OTHER|laboratory biomarker analysis|
214832420|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI.
214832421|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep Iearning.
214832422|NCT04345133|DEVICE|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
214832423|NCT01604239|DRUG|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
214832424|NCT06623227|DIETARY_SUPPLEMENT|Placebo|Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
214832425|NCT06623227|DIETARY_SUPPLEMENT|Vitamin E and C|Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
214832426|NCT06098313|DRUG|Cyclophosphamide|-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
214832427|NCT01791686|DRUG|CDX-1135|
214832428|NCT05011695|OTHER|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
214832429|NCT01881165|DRUG|Cranberry|
214832430|NCT01881165|DRUG|Placebo|
214832431|NCT02517554|BEHAVIORAL|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
214832432|NCT02517554|BEHAVIORAL|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
214832433|NCT02517554|BEHAVIORAL|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
214832434|NCT03299829|DRUG|Trientine|Trientine is a chelating agent for removing the copper from the body
214832435|NCT01152645|DRUG|ARQ 197|Orally twice daily administration of ARQ 197
214832436|NCT01276496|DRUG|Cilengitide|Given IV
214832437|NCT01276496|OTHER|Laboratory Biomarker Analysis|Correlative studies
214832438|NCT01276496|DRUG|Paclitaxel|Given IV
214832439|NCT01276496|OTHER|Pharmacological Study|Correlative studies
214832440|NCT05870332|DEVICE|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
214832441|NCT05244876|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
214832442|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
214832443|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every week
214832444|NCT01912807|DRUG|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
214832445|NCT01912807|DRUG|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
214832446|NCT02489864|DRUG|Terlipressin|
214832447|NCT04667390|OTHER|total knee arthroplasty|total knee arthroplasty
214832448|NCT02756858|DRUG|ANAVEX2-73|
214832449|NCT01262235|DRUG|TKM-080301|Repeat dose IV infusion.
214832450|NCT01137864|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
214832451|NCT05583162|BEHAVIORAL|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
214832452|NCT05237635|OTHER|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
214832453|NCT05329311|PROCEDURE|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
214832454|NCT05329311|PROCEDURE|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
214832455|NCT01427062|OTHER|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
214832456|NCT01427062|OTHER|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
214832457|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
214832458|NCT03749720|OTHER|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
214832459|NCT05638633|DRUG|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
214832460|NCT05638633|DRUG|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
214832461|NCT05638633|DRUG|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
214832462|NCT05638633|DRUG|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
214832463|NCT03506633|DIETARY_SUPPLEMENT|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each participant in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
214832464|NCT05695417|DRUG|OTX-TKI|Injection of OTX-TKI
214832465|NCT05695417|DRUG|Sham|Sham Injection of OTX-TKI
215031495|NCT06005324|RADIATION|Low Dose Radiation|Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
215031496|NCT06005324|DRUG|Cisplatin|Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
214832466|NCT01348958|DEVICE|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
214832467|NCT02783326|OTHER|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
214832468|NCT02172469|DRUG|Tiotropium inhalation powder capsule|
214832469|NCT02172469|DRUG|Placebo Metered Dose Inhaler|
214832470|NCT02172469|DRUG|Ipratropium Bromide Metered Dose Inhaler|
214832471|NCT02172469|DRUG|Placebo inhalation powder capsule|
214832472|NCT02071368|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
214832473|NCT02071368|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
214832474|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
214832475|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
214832476|NCT06533072|OTHER|The group receiving infrared LED therapy|Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
214832477|NCT03391622|DEVICE|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
214832478|NCT02980172|OTHER|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
214832479|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
214832480|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
214832481|NCT01894230|GENETIC|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele
214832482|NCT05659238|BEHAVIORAL|the effect on language development & attention|Tv \& other electronic devices effects onn children's language development \& attention
214832483|NCT04646824|DRUG|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
214832484|NCT06678295|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly sessions of individual cognitive behavioral therapy
214832485|NCT00002224|DRUG|Nelfinavir mesylate|
214832486|NCT00002224|DRUG|Stavudine|
214832487|NCT00002224|DRUG|Didanosine|
214832488|NCT02735330|PROCEDURE|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
214832489|NCT02735330|PROCEDURE|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
214832490|NCT02735330|PROCEDURE|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
214832491|NCT03008538|OTHER|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
214832492|NCT03008538|OTHER|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
214832493|NCT00163124|PROCEDURE|spinal manipulation & patient education/nutrition|
214832494|NCT04731324|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
214832495|NCT00759616|DEVICE|Oxford Partial Knee|Oxford Partial Knee
214832496|NCT03685617|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
214832497|NCT03685617|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
214832498|NCT00279045|DRUG|Rosiglitazone|
214832499|NCT00279045|DRUG|glyburide|
214277520|NCT05621369|BEHAVIORAL|Digital Jar Open|Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
214832500|NCT00279045|DRUG|metformin|
214832501|NCT00968916|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
214832502|NCT00080613|DRUG|exemestane|
214832503|NCT00080613|PROCEDURE|adjuvant therapy|
214832504|NCT00080613|PROCEDURE|aromatase inhibition|
214832505|NCT00080613|PROCEDURE|conventional surgery|
214832506|NCT00080613|PROCEDURE|endocrine therapy|
214832507|NCT00080613|PROCEDURE|hormone therapy|
214832508|NCT00080613|PROCEDURE|neoadjuvant therapy|
214832509|NCT00080613|PROCEDURE|surgery|
214832510|NCT00746460|BEHAVIORAL|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
214832511|NCT00686062|OTHER|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
214832512|NCT00686062|OTHER|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
214832513|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
214832514|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
214832515|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
214832516|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
214832517|NCT01969864|BEHAVIORAL|HRSA Video Intervention|
214832518|NCT01969864|BEHAVIORAL|PI Video Intervention|
214832519|NCT01969864|BEHAVIORAL|CDC Health Website Intervention|
214832520|NCT04172324|DEVICE|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
214832521|NCT04172324|OTHER|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
214832522|NCT05308823|PROCEDURE|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
214832523|NCT03546049|PROCEDURE|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
214832524|NCT03546049|PROCEDURE|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
214832525|NCT03063372|DIETARY_SUPPLEMENT|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
214832526|NCT03063372|OTHER|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
214832527|NCT04943107|OTHER|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
214832528|NCT03155893|DRUG|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
214832529|NCT03155893|DRUG|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.
214832530|NCT03155893|DRUG|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.
214832531|NCT03155893|DRUG|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.
214832532|NCT03155893|DRUG|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
214832533|NCT03155893|DRUG|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
214832534|NCT03155893|DRUG|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
214832535|NCT03155893|DRUG|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
214832536|NCT03155893|DRUG|ODV 200 mg|Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
214832537|NCT03155893|DRUG|ODV 125 mg|Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
214832538|NCT03155893|DRUG|ODV 100 mg|Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
214832539|NCT03155893|DRUG|SMV 150 mg|Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
214832540|NCT03155893|DRUG|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
214832541|NCT00425009|DRUG|Berberine|
214832542|NCT00425009|DRUG|Metformin|
214832543|NCT03132311|BIOLOGICAL|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
214832544|NCT00640393|DRUG|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
214832545|NCT00640393|DEVICE|nbUVB|
214832546|NCT03929328|PROCEDURE|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
214277521|NCT05621369|BEHAVIORAL|30 Second Walk|Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
214832547|NCT00030511|DRUG|fluorouracil|
214832548|NCT00030511|PROCEDURE|conventional surgery|
214832549|NCT00030511|RADIATION|radiation therapy|
214832550|NCT00697918|DRUG|RWJ-333369|100 mg to 400 mg twice daily
214832551|NCT04981457|DRUG|Misoprostol and iso sorbide mononitrates|drug
214832552|NCT03092388|DIAGNOSTIC_TEST|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
214832553|NCT03092388|DIAGNOSTIC_TEST|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
214832554|NCT03092388|DIAGNOSTIC_TEST|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
214832555|NCT03092388|DIAGNOSTIC_TEST|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
214832556|NCT05196789|DIAGNOSTIC_TEST|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
214832557|NCT01941069|BEHAVIORAL|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
214832558|NCT01941069|BEHAVIORAL|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
214832559|NCT02505035|BEHAVIORAL|Default ordering of palliative consult|
214832560|NCT01878435|OTHER|SMS reminder|
214832561|NCT01878435|OTHER|Travel subsidy|
214832562|NCT01878435|OTHER|Travel subsidy 2|
214832563|NCT00214864|DRUG|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
214832564|NCT03484234|DEVICE|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
214832565|NCT03484234|DEVICE|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
214832566|NCT02443285|DRUG|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
214832567|NCT02443285|DRUG|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
214277522|NCT05621369|OTHER|Psorcast mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
214277523|NCT04109716|BEHAVIORAL|Interpersonal Psychotherapy - Adolescent Skills Training|This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.
214832568|NCT04386213|DEVICE|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
214832569|NCT00147693|BEHAVIORAL|Diagnosis of caregivers' problems|
214832570|NCT00147693|BEHAVIORAL|Professional service: treatment of problems by counseling or practical support|
214832571|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
214832572|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
214832573|NCT04566549|COMBINATION_PRODUCT|Test group Probiotic Shampoo|Probiotic Shampoo
214832574|NCT04566549|COMBINATION_PRODUCT|Placebo group|Shampoo base
214832575|NCT00970788|BEHAVIORAL|Video intervention|Video of goals of care
214832576|NCT01134549|DRUG|Etelcalcetide|Administered as a single intravenous (IV) injection
214832577|NCT01134549|DRUG|Placebo|Administered as a single intravenous (IV) injection
214832578|NCT01929486|BIOLOGICAL|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
214832579|NCT00396162|DRUG|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
214832580|NCT00396162|OTHER|Placebo|Placebo pill
214832581|NCT01677338|DRUG|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
214832582|NCT01677338|DRUG|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
214832583|NCT03734354|DRUG|Brexpiprazole|Brexpiprazole , single/oral/with fasting
214832584|NCT02856594|DRUG|Dexmedetomidine|Dexmedetomidine
214832585|NCT02856594|DRUG|Placebo|Placebo
214832586|NCT03044873|DRUG|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
214832587|NCT03044873|DRUG|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
214832588|NCT03086941|DEVICE|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
214832589|NCT01404351|DEVICE|PEAK PlasmaBlade|
214832590|NCT01404351|PROCEDURE|Scalpel and Traditional Electrosurgery|
214832591|NCT01476358|DIETARY_SUPPLEMENT|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
214832592|NCT04709757|DEVICE|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
214832593|NCT04709757|DEVICE|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
214832594|NCT02133638|DRUG|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
214832595|NCT02133638|DRUG|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
214832596|NCT01812603|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
214832597|NCT03387462|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
214832598|NCT03387462|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
214832599|NCT01884844|DRUG|Vitamin D3, Cholecalciferol|
214832600|NCT01884844|DRUG|Placebo|
214832601|NCT05651698|DEVICE|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
214832602|NCT03276767|OTHER|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
214832603|NCT03170739|DRUG|Dexmedetomidine|Dexmedetomidine given during surgery.
214832604|NCT03170739|DRUG|Dopamine|Dopamine given during surgery.
214832605|NCT01460628|DRUG|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
214832606|NCT01931449|PROCEDURE|Modified method of digestive tract reconstruction|
214832607|NCT01931449|PROCEDURE|Routine digestive tract reconstruction|
214832608|NCT04785053|DEVICE|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
214832609|NCT02920476|DRUG|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
214832610|NCT03196817|DRUG|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
214832611|NCT03196817|DEVICE|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
214832612|NCT00890864|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
214832613|NCT01080820|DRUG|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
214832614|NCT01080820|DRUG|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
214832615|NCT01080820|DRUG|Viread|One single oral dose of 300mg Viread.
214832616|NCT01944722|DEVICE|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
214832617|NCT01944722|PROCEDURE|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
214832618|NCT06048848|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
214832619|NCT06048848|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
214832620|NCT06048848|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
214832621|NCT05788250|PROCEDURE|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
214832622|NCT05788250|PROCEDURE|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
214832623|NCT02232945|DRUG|placebo of oseltamivir phosphate|
214832624|NCT02232945|DRUG|oseltamivir phosphate|
214832625|NCT02232945|DRUG|Banlangen (Radix Isatidis) granules|
214832626|NCT02232945|DRUG|placebo of Banlangen(Radix Isatidis) granules|
214832627|NCT04352062|DRUG|Melatonin|
214832628|NCT04352062|OTHER|placebo|
214832629|NCT04352062|DRUG|Pantoprazole 40mg|pantoprazole 2 x 40mg
214832630|NCT04352062|DRUG|Amoxicillin|Amoxicillin 2 x 1000mg
214832631|NCT04352062|DRUG|Levofloxacin 500mg|Levofloxacin 2 x 500mg
214832632|NCT00210639|DRUG|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
214832633|NCT04144998|DIAGNOSTIC_TEST|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
214832634|NCT05281120|DEVICE|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
214832635|NCT05281120|DEVICE|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
214832636|NCT05445180|BEHAVIORAL|Contingency management|Contingency management will be used to encourage abstinence
214832637|NCT05136001|DEVICE|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
214832638|NCT02622867|OTHER|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
214832639|NCT02622867|DIETARY_SUPPLEMENT|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
214832640|NCT01977521|DEVICE|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
214832641|NCT01977521|DEVICE|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
214832642|NCT02805764|DEVICE|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
214832643|NCT05755854|BIOLOGICAL|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
214832644|NCT05755854|DRUG|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
214832645|NCT05755854|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
215031497|NCT06005324|DRUG|TFHX Regimen|Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
214277524|NCT04109716|BEHAVIORAL|Services as usual|Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
214832646|NCT05755854|DRUG|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
214832647|NCT01202253|DRUG|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
214832648|NCT04809662|DRUG|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for \~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
214832649|NCT06731491|OTHER|Concurrent Training|Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes
214832650|NCT06731491|OTHER|Massage therapy and Aromatherapy|Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
214832651|NCT05591729|OTHER|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
214832652|NCT05591729|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
214832653|NCT00550329|DRUG|Glipizide GITS|
215031498|NCT03775837|DIETARY_SUPPLEMENT|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
215031499|NCT03775837|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
214832654|NCT01046097|BIOLOGICAL|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
214832655|NCT06405815|OTHER|tumor and peritumor radiomic feature|extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
214832656|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
214832657|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
214832658|NCT05939102|COMBINATION_PRODUCT|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
214832659|NCT05939102|COMBINATION_PRODUCT|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
214832660|NCT03232450|DRUG|Aspirin|Subjects will receive 81 mg enteric coated aspirin
214832661|NCT03232450|DEVICE|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
214832662|NCT03232450|DEVICE|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
214832663|NCT00362505|DRUG|Clevudine|
214832664|NCT04141878|BEHAVIORAL|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
214832665|NCT04141878|BEHAVIORAL|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
214832666|NCT06676618|OTHER|Multimodal Exercise Training|"The exercise training consisting of aerobic, strengthening and balance exercises will be applied for 12 weeks/3days for 1hour. One day of the exercise training will be performed in a clinical environment with a physiotherapist, and the other 2 days of the week, participants will be asked to apply asynchronous video-based telerehabilitation over the internet in their own homes. The asynchronous video-based telerehabilitation application will be performed through an account created specifically for the participant on the www.telenororehab.com website. The exercise program will be created according to the individual's condition and progression will be provided every 3 weeks. Patients who do not attend 3 consecutive sessions will be excluded from the study."
214832667|NCT06676618|OTHER|Control Group|Participants in the control group will be placed on the waiting list after all evaluation methods have been applied and will be re-evaluated at the end of 12 weeks. After the evaluations, individuals in the control group will also be given multimodal exercise training.
214832668|NCT02586350|DRUG|Anlotinib|
214832669|NCT02586350|DRUG|Placebo|Placebo p.o. qd
214832670|NCT03492138|DRUG|ONC201|625mg
214277525|NCT06420375|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
214277526|NCT06420375|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
214277527|NCT03386500|DRUG|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
214832671|NCT03492138|DRUG|Ixazomib|Dose to be determined in Phase 1 of study
214832672|NCT03492138|DRUG|Dexamethasone|40mg
214832673|NCT04888039|OTHER|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~* At diagnosis (before starting 1st line of treatment),~* after the induction phase (before autologous transplantation for patients who will be transplanted),~* after the consolidation phase,~* after the maintenance phase : 1 year and 2 years after the start of the maintenance."
214832674|NCT02854800|DRUG|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
214832675|NCT00973388|DRUG|Telaprevir; Moxifloxacin; Placebo|
214832676|NCT01916239|DIETARY_SUPPLEMENT|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
214832677|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-1|New pomegranate extract formulation-1
214832678|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-2|New pomegranate extract formulation-2
214832679|NCT01538459|DRUG|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
214832680|NCT01538459|DRUG|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
214832681|NCT04125186|DIAGNOSTIC_TEST|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
215031500|NCT05238740|OTHER|ViviGen®|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
214832682|NCT04125186|DIAGNOSTIC_TEST|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
214832683|NCT04125186|DIAGNOSTIC_TEST|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
214832684|NCT04125186|OTHER|No other intervention|No other intervention
214832685|NCT03090282|PROCEDURE|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
214832686|NCT00627731|DRUG|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
214832687|NCT00627731|DRUG|prednisolone (PSL)|PSL 40 mg per day for 10 days
214832688|NCT03648580|DIETARY_SUPPLEMENT|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
214832689|NCT03648580|OTHER|verbal nutrition education|give the verbal nutrition education
214832690|NCT05014438|DRUG|BMS-986166|Specified dose on specified days
214832691|NCT05014438|DRUG|Branebrutinib|Specified dose on specified days
214832692|NCT05014438|OTHER|Placebo|Specified dose on specified days
214832693|NCT00418158|BEHAVIORAL|use of Airlife (therapy)|
214832694|NCT01827696|DIETARY_SUPPLEMENT|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
214832695|NCT01576458|DRUG|ursodeoxycholic acid|450 mg/day for 14 days
214832696|NCT01576458|DRUG|Placebo|placebo
214832697|NCT02627963|DRUG|Tivozanib hydrochloride|Tivozanib hydrochloride
214832698|NCT02627963|DRUG|Sorafenib|Sorafenib
214832699|NCT02424435|DRUG|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
214832700|NCT01515163|BEHAVIORAL|Exercise training|Aerobic exercise training, two times a week
214832701|NCT02315963|OTHER|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
214832702|NCT01787695|PROCEDURE|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
214832703|NCT04990648|DEVICE|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
214832704|NCT06398522|DIETARY_SUPPLEMENT|Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
214832705|NCT06398522|OTHER|Placebo|Placebo
214832706|NCT02244190|DRUG|Tipranavir|New oral solution (back up) formulation
214832707|NCT02244190|DRUG|Tipranavir|
214832708|NCT02244190|DRUG|Ritonavir|
214832709|NCT04320563|PROCEDURE|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
214832710|NCT00354419|RADIATION|total-body irradiation|Undergo radiotherapy
214832711|NCT00354419|DRUG|cyclophosphamide|Given IV
214832712|NCT00354419|BIOLOGICAL|anti-thymocyte globulin|Given IV
214832713|NCT00354419|DRUG|cyclosporine|Given IV
214832714|NCT00354419|PROCEDURE|umbilical cord blood transplantation|Undergo transplantation
214832715|NCT00354419|DRUG|mycophenolate mofetil|Given IV or orally
214832716|NCT00354419|PROCEDURE|bone marrow aspiration|Correlative study
214832717|NCT00354419|GENETIC|DNA analysis|Correlative study
214832718|NCT00354419|BIOLOGICAL|filgrastim|Given IV or SC
214832719|NCT01932021|PROCEDURE|adipose tissue grafting|
214832720|NCT00019487|BIOLOGICAL|aldesleukin|
214832721|NCT00019487|BIOLOGICAL|gp209-2M antigen|
214832722|NCT00019487|BIOLOGICAL|incomplete Freund's adjuvant|
214832723|NCT02022306|DRUG|TD-6450|
214832724|NCT02022306|DRUG|Placebo|
214832725|NCT05120388|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
214832726|NCT02267707|DRUG|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
214832727|NCT02267707|DRUG|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
214832728|NCT05137093|DEVICE|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
214832729|NCT00313937|DRUG|Insulin glargine|
214832730|NCT01545193|OTHER|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
214832731|NCT04579653|DEVICE|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
214832732|NCT03862547|DIAGNOSTIC_TEST|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
214832733|NCT03574051|DRUG|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
214832734|NCT03056547|OTHER|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
214832735|NCT00152451|DRUG|Seletracetam (ucb 44212)|"* Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration"
214832736|NCT03766360|BEHAVIORAL|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
214832737|NCT05053360|BEHAVIORAL|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
214832738|NCT05053360|OTHER|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
214832739|NCT00155220|DEVICE|Low Stretch Bandage and Kinesio Tape|
214832740|NCT05645120|OTHER|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
214832741|NCT02985060|DEVICE|Arctic Sun|"1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)"
214832742|NCT02985060|OTHER|Standard treatment|"1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
214832743|NCT02985060|DRUG|Saline|
214832744|NCT05705869|DIAGNOSTIC_TEST|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
214832745|NCT00503867|DEVICE|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
214832746|NCT01979146|OTHER|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
214832747|NCT00897676|DRUG|Exendin-(9-39)|100-500pmol/kg/min
214832748|NCT00897676|DRUG|placebo|placebo (0.9% NaCl)
214832749|NCT00254280|PROCEDURE|Intense Pulsed Light + paring versus paring alone|
214832750|NCT04468880|OTHER|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
214832751|NCT04468880|OTHER|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
214832752|NCT02604680|DRUG|BLI1100-1|BLI1100-1 Topical gel
214832753|NCT02604680|DRUG|BLI1100-2|BLI1100-2 Topical gel
214832754|NCT02604680|DRUG|BLI1100-3|BLI1100-3 Topical gel
214832755|NCT02604680|DRUG|BLI1100-4|BLI1100-4 Topical gel
214832756|NCT02604680|DRUG|Placebo|Placebo - Topical gel
214832757|NCT00620880|BEHAVIORAL|Blood sample|
214832758|NCT03711591|DEVICE|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
214832759|NCT04697173|OTHER|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
214832760|NCT03028792|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
214832761|NCT03028792|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
214832762|NCT04207229|DEVICE|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
214832763|NCT03807440|DRUG|Empagliflozin|Empagliflozin
214832764|NCT03807440|DRUG|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
214832765|NCT03807440|DRUG|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
214832766|NCT03807440|DRUG|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
214832767|NCT04560725|DRUG|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
214832768|NCT04584073|PROCEDURE|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
214832769|NCT03905967|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
214832770|NCT03905967|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
214832771|NCT06089330|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
214832772|NCT06089330|DRUG|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
214832773|NCT06089330|DRUG|Irinotecan|180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
214832774|NCT06089330|DRUG|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
214832775|NCT05208892|PROCEDURE|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
214832776|NCT05208892|PROCEDURE|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
214832777|NCT00448825|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
214832778|NCT00448825|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
214832779|NCT05782439|OTHER|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
214832780|NCT00323258|BEHAVIORAL|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
214832781|NCT00323258|DEVICE|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
214832782|NCT00323258|DEVICE|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
214832783|NCT00323258|BEHAVIORAL|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
214832784|NCT00323258|BEHAVIORAL|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
214277528|NCT04518306|DRUG|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
214832785|NCT00323258|BEHAVIORAL|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
214832786|NCT00323258|BEHAVIORAL|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
214832787|NCT00323258|OTHER|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
214832788|NCT02518139|DRUG|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
214277529|NCT04518306|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
214277530|NCT04518306|DRUG|Placebo|Placebo
214277531|NCT06731348|DRUG|restricted opioid prescribing|Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
214277532|NCT06731348|DRUG|standard opioid prescribing|Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
214832789|NCT02518139|DRUG|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
214832790|NCT05201235|DEVICE|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
214832791|NCT05201235|DEVICE|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
214832792|NCT01586039|DEVICE|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
214832793|NCT04436198|DEVICE|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
214832794|NCT04436198|DEVICE|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
214832795|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 50 mg QD
214832796|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD
214832797|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD
214832798|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
214832799|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
214832800|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
214832801|NCT01316237|DRUG|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
214832802|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900mg , BID
214832803|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900 mg
214832804|NCT04987645|PROCEDURE|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
214832805|NCT04987645|PROCEDURE|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
214832806|NCT05432687|DIAGNOSTIC_TEST|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
214832807|NCT04819009|OTHER|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~1. Creating a therapeutic alliance (communication skills and reassurance)~2. Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~3. Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~4. Postcard with reminder messages on how to self manage the back."
214832808|NCT00603967|PROCEDURE|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
214832809|NCT00603967|PROCEDURE|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
214832810|NCT00603967|BEHAVIORAL|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
214832811|NCT04416750|DRUG|Imatinib Mesylate|Treatment with Imatinib
214832812|NCT05311072|PROCEDURE|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
214832813|NCT05612958|DEVICE|DKM-410|Injection up to 2.0ml
214832814|NCT05612958|DEVICE|Juvederm ULTRA PLUS XC 1.0ml|Injection up to 2.0ml
214277533|NCT02137161|DRUG|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
214832815|NCT00686764|OTHER|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
214832816|NCT02169323|OTHER|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
214832817|NCT05435196|OTHER|Therapeutic exercise|"The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc."
214832818|NCT04872777|BEHAVIORAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
214832819|NCT01371435|DRUG|Paroxetine|
214832820|NCT00189553|DRUG|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
214832821|NCT00189553|DRUG|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
214832822|NCT00189553|DRUG|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
214832823|NCT05231603|DRUG|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
214277534|NCT02137161|DRUG|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
214832824|NCT05231603|OTHER|Placebo|Similar to drug in term of tablets
214832825|NCT02442687|DRUG|JKB-121: 5 mg twice daily|
214832826|NCT02442687|DRUG|JKB-121: 10 mg twice daily|
214832827|NCT02442687|DRUG|Placebo|
214832828|NCT00473954|GENETIC|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
214832829|NCT05609617|DEVICE|injection|Intradermal injection on the face and neck/or décolleté by the NCTF135 HA
214832830|NCT05609617|OTHER|Cream application|Application of hydra filler cream on the face and neck/or décolleté
214832831|NCT00001698|DRUG|Ketorolac Rinse|
214832832|NCT05711901|DEVICE|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
214832833|NCT04573569|BEHAVIORAL|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
214832834|NCT00354835|DRUG|Cyclophosphamide|Given IV
214832835|NCT00354835|BIOLOGICAL|Dactinomycin|Given IV
214832836|NCT00354835|DRUG|Irinotecan Hydrochloride|Given IV
214832837|NCT00354835|OTHER|Laboratory Biomarker Analysis|Correlative studies
214832838|NCT00354835|OTHER|Questionnaire Administration|Ancillary studies
214832839|NCT00354835|RADIATION|Radiation Therapy|Undergo radiotherapy
215031501|NCT05238740|OTHER|rhBMP-2|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
214832840|NCT00354835|DRUG|Vincristine Sulfate|Given IV
214832841|NCT03369535|OTHER|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
214832842|NCT03369535|OTHER|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
214832843|NCT03369535|OTHER|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
214832844|NCT01968551|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
214832845|NCT01968551|DRUG|DRV|800 mg tablet administered orally once daily
214832846|NCT01968551|DRUG|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
214832847|NCT00167453|PROCEDURE|Exercise, Education|
214832848|NCT00431041|DRUG|solifenacin|Oral
214832849|NCT00431041|DRUG|oxybutynin immediate release|Oral
214832850|NCT02607826|PROCEDURE|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
214832851|NCT00573313|DRUG|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
214832852|NCT00573313|DRUG|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
214832853|NCT05722080|OTHER|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
214832854|NCT05722080|OTHER|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
214832855|NCT03300011|DEVICE|stent|PTCA or PCI
214832856|NCT05509023|DRUG|ADX-914|Subcutaneous administration of ADX-914
214832857|NCT05509023|DRUG|Placebo|Subcutaneous administration of Placebo
214832858|NCT00978536|OTHER|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
214832859|NCT00102349|BEHAVIORAL|Behavior Therapy|
214832860|NCT05150223|OTHER|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
214832861|NCT05150223|OTHER|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
214832862|NCT00841022|OTHER|Information with comics|Information of children with comic leaflet
214832863|NCT05232539|DEVICE|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
214832864|NCT01839539|BIOLOGICAL|dendritic and cytokine-induced killer cells|
214832865|NCT01373515|BIOLOGICAL|DCP-001|4 bi-weekly vaccinations
214832866|NCT03562182|OTHER|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
214832867|NCT05346172|DEVICE|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
214832868|NCT01640743|DRUG|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
214832869|NCT01640743|DRUG|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
214832870|NCT00796913|OTHER|Stop medication|Stop medication Stop medication + se supplement
214832871|NCT03255980|DEVICE|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
214832872|NCT03255980|OTHER|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
214832873|NCT06627660|PROCEDURE|Valsalva maneuver|Closure of the nose and mouth during expiration for 20 sec
214832874|NCT02873182|DEVICE|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
214832875|NCT05532631|PROCEDURE|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
214832876|NCT05532631|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
214832877|NCT01597791|DEVICE|Foley catheter|Foley catheter placement after CSE.
214832878|NCT01597791|OTHER|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
214832879|NCT03732144|BEHAVIORAL|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
214832880|NCT03732144|OTHER|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
214832881|NCT00396929|DRUG|local intracoronary dosis of Paclitaxel|
214832882|NCT05822726|DIAGNOSTIC_TEST|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
214832883|NCT00005873|DRUG|rubitecan|
214832884|NCT01232660|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
214832885|NCT02017873|DRUG|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
214832886|NCT06287216|BEHAVIORAL|Mental Hygiene|Mental hygiene are daily evidence based practices that support mental wellbeing.
214832887|NCT06287216|BEHAVIORAL|Self-Care|Instructed to do 10 minutes of self-care daily.
214832888|NCT05956717|DEVICE|Orthokeratology|The experimental group wore orthokeratology lenses
214832889|NCT03019016|PROCEDURE|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
214832890|NCT03727763|DRUG|Vemurafenib|960mg po bid
214832891|NCT03727763|DRUG|Cetuximab|500mg/m2 iv gtt (14 days per course)
214832892|NCT02533466|OTHER|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
214832893|NCT02533466|OTHER|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
214832894|NCT00901719|DRUG|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
214832895|NCT00901719|DRUG|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
214277535|NCT05637606|DRUG|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
214277536|NCT05637606|DRUG|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
214277537|NCT05637606|DRUG|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
214277538|NCT05637606|DIAGNOSTIC_TEST|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini\_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
214832896|NCT00901719|DRUG|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
214832897|NCT00901719|DRUG|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
214832898|NCT06348979|PROCEDURE|Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns|restoration of endodontically treated teeth by endocrowns
214832899|NCT06348979|PROCEDURE|all ceramic Endocrowns (emax)|restoration of endodontically treated teeth by endocrowns
214832900|NCT01102907|OTHER|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
214832901|NCT01102907|OTHER|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
214832902|NCT01894009|PROCEDURE|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
214832903|NCT01894009|PROCEDURE|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
214832904|NCT01720953|OTHER|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
214832905|NCT00634205|DRUG|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
214832906|NCT00929019|BIOLOGICAL|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
214832907|NCT02096705|DRUG|Dapagliflozin|Tablet
214832908|NCT02096705|DRUG|Dapagliflozin Placebo|Tablet
214832909|NCT00235963|DRUG|Simvastatin|
214832910|NCT01204138|DRUG|Apremilast|Apremilast 30mg BID
214832911|NCT01204138|DRUG|Placebo|Placebo BID
214832912|NCT04506918|OTHER|IVR survey|Participants will receive an IVR survey
214832913|NCT04506918|OTHER|SMS survey|Participants will receive a SMS survey
214832914|NCT06348576|DRUG|AD-209|PO, Once daily(QD), 8weeks
214832915|NCT06348576|DRUG|AD-2091|PO, Once daily(QD), 8weeks
214832916|NCT06348576|DRUG|AD-209 Placebo|PO, Once daily(QD), 8weeks
214832917|NCT06348576|DRUG|AD-2091 Placebo|PO, Once daily(QD), 8weeks
214832918|NCT01198392|DRUG|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
214832919|NCT01198392|DRUG|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
214832920|NCT01087567|DRUG|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
214832921|NCT01087567|DRUG|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
214832922|NCT01949532|DRUG|Carfilzomib|Carfilzomib was administered by IV injection.
214832923|NCT04980170|DRUG|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
214832924|NCT04980170|DRUG|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
214832925|NCT03116776|PROCEDURE|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
214832926|NCT03116776|DRUG|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
214832927|NCT01724762|OTHER|Nursing Orientation|"* Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
214832928|NCT04498676|OTHER|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
214832929|NCT03113227|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
214832930|NCT03113227|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
214832931|NCT00884390|DRUG|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
214832932|NCT00884390|PROCEDURE|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
214832933|NCT03864458|DRUG|KHK7791|oral administration
214277539|NCT05372419|DRUG|Lebrikizumab|Administered SC
214277540|NCT06046794|OTHER|Analyze of GemCore status|Genomic analyze of GemCore status
214832934|NCT03864458|DRUG|Placebo|oral administration
214832935|NCT05646238|OTHER|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
214832936|NCT05646238|OTHER|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
214832937|NCT05575245|DEVICE|Drug-eluting Stent|Drug-eluting Stent angioplasty
214832938|NCT05575245|DEVICE|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
214832939|NCT00292760|DRUG|Alemtuzumab|
214832940|NCT00292760|DRUG|Methyprednisolone|
214832941|NCT05339191|BEHAVIORAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
214832942|NCT06067789|PROCEDURE|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
214832943|NCT00415935|DRUG|methotrexate|
214832944|NCT02711527|OTHER|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
214832945|NCT02711527|OTHER|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
214832946|NCT02582944|DEVICE|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
214832947|NCT02582944|DEVICE|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
214832948|NCT02582944|DEVICE|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
214832949|NCT02582944|PROCEDURE|Biopsy|
214832950|NCT00951535|OTHER|questionnaire administration|
214832951|NCT00951535|PROCEDURE|quality-of-life assessment|
214832952|NCT00951535|RADIATION|image-guided radiation therapy|
214832953|NCT00951535|RADIATION|intensity-modulated radiation therapy|
214832954|NCT00951535|RADIATION|radiation therapy treatment planning/simulation|
214832955|NCT00003795|PROCEDURE|quality-of-life assessment|
214832956|NCT05753904|PROCEDURE|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
214832957|NCT01873391|PROCEDURE|Diagnostic hysteroscopy|
214832958|NCT00052949|DRUG|imatinib mesylate|Given orally
214832959|NCT00052949|OTHER|laboratory biomarker analysis|Correlative studies
214832960|NCT05232487|OTHER|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
214832961|NCT05232487|OTHER|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
214832962|NCT01533038|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
214832963|NCT01533038|PROCEDURE|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
214832964|NCT06292364|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
214832965|NCT06292364|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
214832966|NCT05456438|OTHER|İntervention 1|Group 1 applied coconut oil to the nipple
214832967|NCT05456438|OTHER|İntervention 2|Group 2 applied tea tree oil to the nipple
214832968|NCT00088608|DRUG|SOM230 s.c.|
214832969|NCT02646800|DRUG|Micafungin|Injection
214832970|NCT05568849|DIAGNOSTIC_TEST|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
214832971|NCT05336487|OTHER|Physical activity|2 hours of physical activity per day, 5 days per week, for the intervention period
214832972|NCT04037488|DIAGNOSTIC_TEST|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
214832973|NCT02979132|DRUG|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
214832974|NCT02979132|DRUG|Ferinject(R)|Single-dose Ferinject(R) administration
214832975|NCT02979132|DIETARY_SUPPLEMENT|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
214832976|NCT00490932|DRUG|Hypo-osmolar ORS|
214832977|NCT00139815|DRUG|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
214832978|NCT00139815|DRUG|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
214832979|NCT04736537|DEVICE|4DCT|CT imaging conceptually similar to time-lapse photography.
214832980|NCT03337893|DIAGNOSTIC_TEST|blood pressure|it will be done both right and left arms
214832981|NCT02961205|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
214832982|NCT01445860|DRUG|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
214832983|NCT04316962|OTHER|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support."
214832984|NCT01083329|BEHAVIORAL|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
214832985|NCT01083329|DRUG|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
214832986|NCT01083329|DRUG|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
214832987|NCT06357416|DEVICE|MV-POCT Sub-study|Point of care blood testing
214832988|NCT06357416|OTHER|Main Man Van Group Sub-study (MV-Eco)|Consent for long-term follow-up of patients
214277541|NCT05552001|DRUG|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
214832989|NCT06357416|OTHER|MV-QualQ Sub-study|Qualitative questionnaire and interview sub-study
214832990|NCT06357416|DIAGNOSTIC_TEST|MV-PRS Sub-study|Patients consenting to polygenic risk score testing
214832991|NCT06357416|OTHER|MV-DNA and MV-UctDNA Sub-study|Patients consenting to collection of DNA and urine for further study.
214832992|NCT06357416|OTHER|Man Van patients|All patients seen in Man Van
214832993|NCT06357416|OTHER|MV-SSI Sub-study|Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
214832994|NCT06357416|OTHER|MV-TPP Sub-study|Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
214832995|NCT00268216|DRUG|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
214832996|NCT04392934|PROCEDURE|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
214832997|NCT02246296|DIETARY_SUPPLEMENT|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
214832998|NCT02246296|DIETARY_SUPPLEMENT|Modified F75 Milk|This is the experimental group
214832999|NCT01751854|DRUG|SSRI|SSRI alone or with training
214833000|NCT01751854|DRUG|Placebo|Placebo alone or with training
214833001|NCT03667963|OTHER|Glucose|50g glucose dissolved in 250ml water
214833002|NCT03667963|OTHER|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
214833003|NCT03667963|OTHER|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
214833004|NCT03667963|OTHER|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
214833005|NCT02611323|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
214833006|NCT02611323|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m\^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
214833007|NCT02611323|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
214833008|NCT02611323|DRUG|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
214833009|NCT04021407|DEVICE|LMA group|patients were ventilated with LMA
214833010|NCT04021407|DEVICE|AirQ group|patients were ventilated with AirQ airway
214833011|NCT01215721|DRUG|Vesicare|5 mg daily
214833012|NCT03949296|BEHAVIORAL|Mindfulness Intervention|"10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends"
214833013|NCT03949296|BEHAVIORAL|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine"
214833014|NCT02286479|PROCEDURE|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
214833015|NCT02286479|PROCEDURE|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
214277542|NCT05966792|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
214277543|NCT05966792|DRUG|metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
214277544|NCT03410043|DRUG|Osimertinib|Given PO
214833016|NCT00096655|DRUG|Infliximab|
214833017|NCT00045162|DRUG|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
214833018|NCT00045162|DRUG|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
214833019|NCT00045162|DRUG|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
214833020|NCT00483145|DEVICE|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
214833021|NCT00483145|DEVICE|Long-pulsed dye laser|
214833022|NCT00483145|DEVICE|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
214833023|NCT03882762|DRUG|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
214833024|NCT05341492|BIOLOGICAL|EGFR/B7H3 CAR-T|2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
214833025|NCT01899053|DRUG|TAK-228|TAK-228 Capsules
214833026|NCT01899053|DRUG|TAK-117|TAK-117 Capsules
214833027|NCT02838953|BEHAVIORAL|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
214833028|NCT03105297|DEVICE|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
214833029|NCT03105297|OTHER|No strip|
214833030|NCT06445478|OTHER|Blood Flow Restrictive Exercise and Isokinetic Exercise|"Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants."
214833031|NCT01859260|DEVICE|CPAP/autopap|
214833032|NCT06678386|BEHAVIORAL|50% sugar reduction|Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
214833033|NCT04139941|DIAGNOSTIC_TEST|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
214833034|NCT03293719|DEVICE|BPK-S Integration UC|Primary Knee Endoprosthesis
214833035|NCT03831490|DIAGNOSTIC_TEST|history|combining these 4 interventions will great an algorithm predicting preeclampsia
214833036|NCT06168903|PROCEDURE|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
214833037|NCT02261181|DEVICE|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
214833038|NCT04391517|DIAGNOSTIC_TEST|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
214833039|NCT04976023|DRUG|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
215031502|NCT06212687|BEHAVIORAL|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
214833040|NCT04976023|OTHER|Placebo|14.5 5 g twice daily for 8 weeks
214833041|NCT03614455|DRUG|Milademetan|Milademetan 100 mg capsule for oral administration
214833042|NCT03614455|DRUG|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
214833043|NCT03614455|DRUG|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
214833044|NCT02835755|OTHER|Educational Intervention|Receive standard HPV and HPV vaccine information
214833045|NCT02835755|OTHER|Educational Intervention|Receive mHealth HPV vaccine intervention
214833046|NCT02835755|OTHER|Survey Administration|Ancillary studies
214833047|NCT02970149|OTHER|NA (observational)|
214833048|NCT04903652|DRUG|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
214833049|NCT04903652|DRUG|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
214833050|NCT03786770|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
214833051|NCT00714051|BEHAVIORAL|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
214833052|NCT00714051|BEHAVIORAL|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
214833053|NCT05819437|OTHER|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
214833054|NCT02583698|DRUG|Carvedilol|
214833055|NCT02583698|DRUG|Placebo|
214833056|NCT00141505|DRUG|Bifeprunox|
214833057|NCT03727945|OTHER|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
214833058|NCT03727945|OTHER|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
214833059|NCT04474145|PROCEDURE|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
214833060|NCT04474145|PROCEDURE|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
214833061|NCT03545399|DIETARY_SUPPLEMENT|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
214833062|NCT03545399|DIETARY_SUPPLEMENT|Placebo|The dose was taken with a glass of water during the evening meal once daily
214833063|NCT03868631|DIETARY_SUPPLEMENT|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
214833064|NCT03868631|DIETARY_SUPPLEMENT|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
214833065|NCT03458364|DEVICE|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
214833066|NCT03458364|DEVICE|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
214833067|NCT01420614|PROCEDURE|Femoral approach|diagnostic and interventional procedures by femoral artery access
214833068|NCT01420614|PROCEDURE|Radial approach|diagnostic and interventional procedures by radial artery access
214833069|NCT02928458|DRUG|Omnipaque|
214833070|NCT02928458|DRUG|MD-Gastroview|
214833071|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
214833072|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
214833073|NCT03910361|DRUG|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
214833074|NCT03910361|DRUG|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
214833075|NCT04035954|OTHER|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
214833076|NCT03231345|PROCEDURE|US guided IJ|IV catheter placement
214833077|NCT03231345|DEVICE|Ultrasound|Ultrasound-guided Internal Jugular vein
214833078|NCT00691756|PROCEDURE|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
215031503|NCT06212687|BEHAVIORAL|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
215031504|NCT00471393|DRUG|1.5% diclofenac in 45.5% DMSO (topical treatment)|
215031505|NCT00471393|DRUG|45.5% DMSO (topical placebo)|
215031506|NCT03238196|DRUG|Erdafitinib|4mg - 8mg
215031507|NCT03238196|DRUG|Palbociclib|125 mg
215031508|NCT03238196|DRUG|Fulvestrant|500 mg
214833079|NCT00691756|PROCEDURE|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
214833080|NCT01711567|DRUG|tenofovir|tenofovir 300 mg qd
214833081|NCT01711567|DRUG|entecavir|entecavir 0.5 mg qd
214833082|NCT01910831|DRUG|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
214833083|NCT01910831|DRUG|Non-active placebo control|Non-active placebo control
214833084|NCT03442192|OTHER|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
214833085|NCT00032240|DEVICE|Shoe Insert|
214833086|NCT01007019|DRUG|YH4808 30mg|YH4808 30mg (single dose)
214833087|NCT01007019|DRUG|YH4808 50mg|YH4808 50mg (single dose)
214833088|NCT01007019|DRUG|YH4808 100mg|YH4808 100mg (single dose)
214833089|NCT01007019|DRUG|YH4808 200mg|YH4808 200mg (single dose)
214833090|NCT01007019|DRUG|YH4808|YH4808 400mg (single dose)
214833091|NCT01007019|DRUG|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
214833092|NCT01007019|DRUG|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
214833093|NCT01007019|DRUG|YH4808 600mg|YH4808 600mg
214833094|NCT01007019|DRUG|YH4808 800mg (single dose)|YH4808 800mg (single dose)
214833095|NCT01007019|DRUG|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
214833096|NCT01007019|DRUG|Placebo|10 volunteers will be administered matched placebo.
214833097|NCT01007019|DRUG|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
214833098|NCT06346106|GENETIC|Male Rett|This study does not have an intervention. Participants of this study must be parents or caregivers to boys with Rett syndrome.
214833099|NCT06078020|OTHER|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
214833100|NCT01929681|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
214277545|NCT03410043|RADIATION|Radiation Therapy|Undergo radiation therapy
215031509|NCT06643650|DIETARY_SUPPLEMENT|CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML|Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
214277546|NCT03410043|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214833101|NCT04613167|DRUG|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
214833102|NCT04613167|DRUG|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
214833103|NCT04613167|DRUG|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
214833104|NCT05920486|DEVICE|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
214833105|NCT05920486|DEVICE|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
214833106|NCT03250117|DRUG|Ropinirole oral product|oral immediate-release ropinirole
214833107|NCT03250117|DRUG|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
214833108|NCT00108030|PROCEDURE|Partial Body-weight supported Treadmill Training|
214833109|NCT00108030|PROCEDURE|PBWST + Power training|
214833110|NCT00108030|PROCEDURE|"Usual physiotherapy care"|
214833111|NCT02247687|DRUG|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
214833112|NCT02247687|DRUG|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
214833113|NCT02247687|OTHER|Counseling arm|No change of antiretroviral treatment but only counseling
214833114|NCT05295524|OTHER|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
214833115|NCT01731977|BEHAVIORAL|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
214833116|NCT02186353|BEHAVIORAL|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
214833117|NCT02957578|DEVICE|Solo TTD|Placement of tympanostomy tube with Solo TTD
214833118|NCT02068651|BEHAVIORAL|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
214833119|NCT01582464|BEHAVIORAL|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
214833120|NCT00285961|DEVICE|Cork splint materials (instead of plaster splint)|
214833121|NCT02840669|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|
214833122|NCT02840669|PROCEDURE|Exercise-stress test|
214833123|NCT02840669|PROCEDURE|Echocardiography (ECHO)|
214833124|NCT02840669|PROCEDURE|Cardiac-related blood studies|
214833125|NCT00229944|DRUG|Azithromycin|
214833126|NCT00794794|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
214833127|NCT00794794|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
214833128|NCT01942616|OTHER|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
214833129|NCT01942616|OTHER|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
214833130|NCT01942616|OTHER|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
214277547|NCT06367959|BEHAVIORAL|Esays|Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
214277548|NCT06367959|BEHAVIORAL|Questionnaires|"Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay."
214277549|NCT02801331|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
214833131|NCT02421627|DEVICE|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
214833132|NCT02421627|DEVICE|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
214833133|NCT04656938|BEHAVIORAL|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
214833134|NCT01073631|DRUG|voriconazole tablet|200 mg PO bid (orally, twice a day)
214833135|NCT04437303|DRUG|Continuation of oral anticoagulants|Oral anticoagulant treatment will not be interrupted before the procedure.
214833136|NCT04437303|DRUG|Interruption of oral anticoagulants|"Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician."
214833137|NCT03709953|DRUG|Apatinib|500 mg，po，QD； 28 days every cycle
214833138|NCT03112031|DRUG|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
214833139|NCT03112031|DRUG|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
215031510|NCT04923672|BEHAVIORAL|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
214833140|NCT03112031|DRUG|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
214833141|NCT02469480|DRUG|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
214833142|NCT02469480|DRUG|Ferro sanol|200 mg ferro sanol per day over 12 weeks
214833143|NCT01971554|DRUG|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
214833144|NCT01971554|DRUG|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
214833145|NCT01426854|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
214833146|NCT01426854|OTHER|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
214833147|NCT02161705|DRUG|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
214833148|NCT02161705|DRUG|Saline|Up to 0.8 mL/kg of normal saline administered
214833149|NCT03803267|OTHER|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38\_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
214833150|NCT03803267|OTHER|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
214833151|NCT03803267|DRUG|Propofol|Propofol (2 mg/kg)
214833152|NCT03803267|DRUG|Fentanyl NCS|Fentanyl (1µg/Kg)
214833153|NCT03803267|DRUG|Atracurium Injectable Product|atracurium (0.5mg/kg)
214833154|NCT03803267|OTHER|Endotracheal intubation|endotracheal intubation
214833155|NCT03803267|DRUG|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
214833156|NCT03803267|DRUG|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
214833157|NCT00438750|OTHER|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
214833158|NCT00438750|OTHER|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
214833159|NCT04627857|DEVICE|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
214833160|NCT04627857|DEVICE|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|\- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
214833161|NCT04627857|DEVICE|Sonic toothbrush|\- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
214833162|NCT04627857|DEVICE|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|\- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
214833163|NCT03505151|DRUG|BI 409306 (C-13/N-15)|i.v solution
214833164|NCT03505151|DRUG|BI 409306|Film-coated tablet
214833165|NCT01942135|DRUG|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
214833166|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
214833167|NCT01942135|DRUG|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
214833168|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
214833169|NCT02272335|BEHAVIORAL|Group Sessions|"10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
214833170|NCT06563063|DRUG|Flumazenil|The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.
214833171|NCT00950300|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
214833172|NCT00950300|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
214833173|NCT00950300|DRUG|Docetaxel|Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
214833174|NCT00950300|DRUG|Epirubicin|Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
214833175|NCT00950300|DRUG|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
214833176|NCT00950300|DRUG|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
214833177|NCT05008380|PROCEDURE|prone positioning|3-6 hours of prone-positioning twice a day
214833178|NCT01427036|PROCEDURE|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
214833179|NCT01427036|PROCEDURE|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
214833180|NCT01897324|DRUG|Growth hormone (Norditropin, Novo nordisk)|
214833181|NCT00765635|DRUG|drops intilation (Taponoto ® )|four drops, unique doses
214833182|NCT00765635|DRUG|drops intilation (Otocerum®)|four drops, unique doses
214833183|NCT00765635|DRUG|drops intilation (Placebo)|Placebo
214833184|NCT01717040|DRUG|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
214833185|NCT01717040|DRUG|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
214833186|NCT05642949|DRUG|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
214833187|NCT00494013|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
214833188|NCT00494013|DRUG|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
214833189|NCT06677684|DIETARY_SUPPLEMENT|Vitamin A|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation (25,000 IU daily for two days)
214833190|NCT04174053|DEVICE|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
214833191|NCT01682421|DRUG|Weak steroid (Flurolon, Allergan)|
214833192|NCT01682421|DRUG|Potent steroid (Maxidex, Alcon)|
214833193|NCT05913115|DRUG|FPA144|FPA144 will be administered intravenously Q2W.
214833194|NCT05235022|OTHER|Questionnaires|"The participants included in the study will have to answer:~1. a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~2. the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
214833195|NCT01394094|BEHAVIORAL|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
214833196|NCT04237220|DIAGNOSTIC_TEST|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
214833197|NCT03226613|PROCEDURE|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
214833198|NCT03226613|PROCEDURE|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
214833199|NCT03226613|PROCEDURE|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
214833200|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
214833201|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
214833202|NCT02818751|DRUG|Escitalopram|Patients being randomized to receive escitalopram.
214833203|NCT02818751|OTHER|Placebo|Patients being randomized to receive placebo.
214833204|NCT04599751|DEVICE|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
214833205|NCT00582244|BEHAVIORAL|CBT and relaxation|Group A: CBT and relaxation.
214833206|NCT00582244|BEHAVIORAL|Physical activity|Group B: Physical exercise program.
214833207|NCT00582244|BEHAVIORAL|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
214833208|NCT00582244|OTHER|Control group|Waiting list control group
214833209|NCT01806272|DRUG|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
214833210|NCT01806272|DRUG|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
214833211|NCT03363555|DRUG|SHR-1210|A humanized monoclonal immunoglobulin.
214833212|NCT05497986|DEVICE|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
214833213|NCT05497986|DEVICE|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
214833214|NCT02043522|DRUG|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
214833215|NCT02281253|DIETARY_SUPPLEMENT|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
214833216|NCT02281253|DIETARY_SUPPLEMENT|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
214833217|NCT02280707|OTHER|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
214833218|NCT04750239|DRUG|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
214833219|NCT02031250|DRUG|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
214833220|NCT02031250|DRUG|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
214833221|NCT02031250|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
214833222|NCT02031250|RADIATION|Boost Radiation to Hypoperfused Volumes|
214833223|NCT00903877|DRUG|T3|Patients receive T3 in a dose of 25mcg and 50mcg
214833224|NCT00919711|DRUG|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
214833225|NCT00919711|DRUG|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
214833226|NCT02965261|DRUG|Torrent's Fluoxetine Tablets|
214833227|NCT02965261|DRUG|Warner Chilcott LLC Sarafem Tablets|
214833228|NCT00107263|DRUG|letrozole|
214833229|NCT00107263|DRUG|zoledronic acid|
214833230|NCT00163345|DRUG|Ciclesonide|
214833231|NCT00087529|DRUG|placebo|Intravenous repeating dose
214833232|NCT00087529|DRUG|rituximab|Intravenous repeating dose
214833233|NCT02409797|OTHER|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
214833234|NCT00163319|DRUG|Ciclesonide|
214833235|NCT03747107|BEHAVIORAL|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
214833236|NCT05389813|DRUG|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
214833237|NCT05389813|DRUG|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
214833238|NCT05389813|DRUG|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
214833239|NCT02665780|PROCEDURE|Periodontal debridement|teeth cleaning
214833240|NCT02665780|OTHER|Cetylpyridium chloride|mouthrinse
214833241|NCT05651958|OTHER|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
214833242|NCT05651958|OTHER|Breathing Technique|15 repeatations of Breathing in morning and evening
214833243|NCT03516058|OTHER|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
214833244|NCT01170741|BEHAVIORAL|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
214833245|NCT01628887|OTHER|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
214833246|NCT00106886|DRUG|Folic acid, vitamin B6 and B12 or placebo|
214833247|NCT02282722|OTHER|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
214833248|NCT02282722|OTHER|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
214833249|NCT01853722|DRUG|DCN01|Three serial applications per periocular region.
214833250|NCT01853722|DRUG|Unisol|Three serial applications per periocular region.
214833251|NCT00213122|DRUG|miglitol|
214833252|NCT06363799|OTHER|4th ventricle compression technique|"For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards."
214833253|NCT06363799|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
214833254|NCT06363799|OTHER|Diaphragmatic breathing technique|For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
214833255|NCT01473173|DRUG|CJ-12420|
214833256|NCT01473173|DRUG|Esomeprazole 40mg|
214833257|NCT01664650|DIETARY_SUPPLEMENT|Genistein|
214833258|NCT01664650|DIETARY_SUPPLEMENT|Placebo|
214833259|NCT04935905|DEVICE|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
214833260|NCT01698736|DEVICE|Membrane filtration|Membrane filtration (Polysulfone)
214833261|NCT01698736|DEVICE|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
214833262|NCT01954212|OTHER|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
214833263|NCT05046340|OTHER|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
214833264|NCT02747680|OTHER|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
214833265|NCT05319054|DEVICE|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
214833266|NCT05319054|DEVICE|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
214833267|NCT05319054|OTHER|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
214833268|NCT06366555|PROCEDURE|Manual Acupuncture Twirling,|Manual Acupuncture twirling : using 0.14x 25 mm needle, punctured and penetrated the skin and then a twirling manipulation is carried out, 180 degrees, 3 rad/second, for 30 second each at LU5 and PC2. The needles retained for 20 minutes and manipulated at 0 minutes and 10 minutes.
214833269|NCT06366555|PROCEDURE|Manual Acupuncture Sham|Manual Acupuncture Sham : Using 0.14x25mm needles on plesterin without being penetrated into skin and no manipulation given, retained for 20 minutes
214833270|NCT00873587|PROCEDURE|Chest tube pull on inspiration|Pull chest tube on Inspiration
214833271|NCT00873587|PROCEDURE|Expiration|Pull chest tube on Expiration
214833272|NCT03699930|DEVICE|tDCS|Anodal or sham tDCS will be applied to the scalp.
214833273|NCT03699930|BEHAVIORAL|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
214833274|NCT00475410|DRUG|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
214833275|NCT00475410|DRUG|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
214833276|NCT00685334|DRUG|Olanzapine|Participants will take olanzapine daily for 12 weeks.
214833277|NCT00685334|DRUG|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
214833278|NCT00095537|DRUG|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
214833279|NCT06255145|DEVICE|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
214833280|NCT00964054|OTHER|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
214833281|NCT00964054|OTHER|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
214833282|NCT02288923|PROCEDURE|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
214833283|NCT02288923|PROCEDURE|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
214833284|NCT02288923|PROCEDURE|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
214833285|NCT02288923|PROCEDURE|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
214833286|NCT02288923|DRUG|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
214833287|NCT02288923|DRUG|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
214833288|NCT02288923|DRUG|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
214833289|NCT02288923|DRUG|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
214833290|NCT02288923|DRUG|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
214833291|NCT06227741|OTHER|Concept Mapping: as a Tool for Problem Based Learning|Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
214833292|NCT01891357|PROCEDURE|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
214833293|NCT01891357|DRUG|paclitaxel|
214833294|NCT01891357|DRUG|lapatinib|
214833295|NCT01891357|DRUG|trastuzumab|
214833296|NCT04823091|DRUG|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
214833297|NCT00002158|DRUG|Nitazoxanide|
214833298|NCT02431949|OTHER|Admission to BCPP|There is no intervention associated with this study.
214833299|NCT01763554|DRUG|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
214833300|NCT02552082|DEVICE|Scorpio NRG posterior stabilized (PS)|
214833301|NCT06628297|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
214833302|NCT03944057|DRUG|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
214833303|NCT00310297|DRUG|Insulin Glulisine|
214833304|NCT04573309|DRUG|ALXN1840|Administered orally as tablets.
214833305|NCT05269563|OTHER|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
214833306|NCT02634736|DEVICE|Exergame plus usual treatment|An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
214833307|NCT01465932|OTHER|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
214833308|NCT01465932|OTHER|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
214833309|NCT02178124|DRUG|Donepezil|
214833310|NCT02178124|DRUG|placebo|
214833311|NCT05587023|PROCEDURE|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
214833312|NCT00656539|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
214833313|NCT02583308|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
214833314|NCT02583308|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
214833315|NCT01096602|BIOLOGICAL|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
214277550|NCT06505447|OTHER|Daytime light exposure|Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
214277551|NCT06505447|OTHER|Daytime restricted feeding|Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
214277552|NCT05212428|PROCEDURE|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
214277553|NCT05212428|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214833316|NCT06491979|DIETARY_SUPPLEMENT|Vitamin A treatment|Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks
214833317|NCT06491979|DIETARY_SUPPLEMENT|Monounsaturated fatty acid mixture|Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks
214833318|NCT06491979|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid mixture|Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
214277554|NCT05212428|OTHER|Genetic Counseling|Receive genetic counseling
214277555|NCT05212428|OTHER|Questionnaire Administration|Complete family history
214833319|NCT06491979|DIETARY_SUPPLEMENT|Fatty acid mixture|Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
214833320|NCT00000708|DRUG|Flucytosine|
214833321|NCT00000708|DRUG|Fluconazole|
214833322|NCT00000708|DRUG|Amphotericin B|
214833323|NCT02300987|DRUG|LEE011|
214833324|NCT02300987|DRUG|LEE011 Placebo|
214833325|NCT02217709|DRUG|phenelzine sulfate|Given by mouth
214833326|NCT02217709|OTHER|laboratory biomarker analysis|Correlative studies
214833327|NCT02217709|OTHER|questionnaire administration|Ancillary studies
214833328|NCT02647515|DRUG|ranibizumab|
214833329|NCT02488109|OTHER|Higher Calorie Refeeding|
214833330|NCT02488109|OTHER|Lower Calorie Refeeding|
214833331|NCT00110851|DRUG|rosiglitazone|
214833332|NCT00110851|DRUG|metformin|
214833333|NCT00110851|DRUG|PN2034|
214833334|NCT01495715|DRUG|Idebenone|
214833335|NCT01495715|DRUG|Placebo|
214833336|NCT01245842|OTHER|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
214833337|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
214833338|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
214833339|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
214833340|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
214277556|NCT05212428|OTHER|Questionnaire Administration|Ancillary studies
214833341|NCT00785876|OTHER|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
214833342|NCT01954901|DEVICE|Hyperbaric oxygen therapy|
214833343|NCT01954901|DEVICE|Hyperbaric room air|
214833344|NCT05080140|DRUG|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
214833345|NCT05141786|DRUG|MRG002|Administrated intravenously
214833346|NCT06678425|DEVICE|Peripheral magnetic stimulator|a non-invasive method of delivering a rapidly pulsed, high-intensity magnetic field to peripheral muscles
214833347|NCT06678425|DEVICE|Peripheral magnetic stimulator|The same coil as real rPMS, but in a position perpendicular to the skin
214833348|NCT05740696|PROCEDURE|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
214833349|NCT05740696|PROCEDURE|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
214833350|NCT05740696|PROCEDURE|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
214833351|NCT03670719|OTHER|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
214833352|NCT03670719|OTHER|Exercise|Exercises for the cervical spine
214833353|NCT03969641|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
214833354|NCT03969641|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
214833355|NCT06076941|OTHER|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
214833356|NCT02971813|BEHAVIORAL|Facebook|"1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
214833357|NCT02754128|BEHAVIORAL|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
214833358|NCT02754128|BEHAVIORAL|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
214833359|NCT02206009|DEVICE|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
214833360|NCT01245491|OTHER|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
214833361|NCT01541215|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
214833362|NCT01541215|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
214833363|NCT01541215|DRUG|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
214833364|NCT02822482|DRUG|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
214833365|NCT02822482|DRUG|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
214833366|NCT00203320|DRUG|etanercept given by perispinal administration|
214833367|NCT05314062|DIETARY_SUPPLEMENT|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
214833368|NCT05314062|DIETARY_SUPPLEMENT|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
214833369|NCT00693589|DRUG|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
214833370|NCT02633241|DRUG|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
214833371|NCT02633241|DRUG|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
214833372|NCT02633241|DRUG|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
214833373|NCT00504179|PROCEDURE|Osteopathic Manipulative Treatment|
214833374|NCT00007787|BIOLOGICAL|Cyclosporine|
214833375|NCT00007787|BIOLOGICAL|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
214833376|NCT00007787|DRUG|Tacrolimus|
214833377|NCT06099990|DRUG|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
214833378|NCT06099990|DRUG|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
214833379|NCT01897987|BIOLOGICAL|Pneumostem®|
214833380|NCT01897987|BIOLOGICAL|normal saline|
214833381|NCT05344287|OTHER|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
214833382|NCT05344287|OTHER|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
214833383|NCT03164187|DRUG|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
214833384|NCT04485507|OTHER|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
214833385|NCT04485507|OTHER|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
214833386|NCT03854409|DRUG|Aripiprazole|Injection.
214833387|NCT05453409|OTHER|No intervention|No intervention
214833388|NCT00536588|GENETIC|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
214833389|NCT05418985|BEHAVIORAL|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
214833390|NCT03103828|BEHAVIORAL|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
214833391|NCT03103828|BEHAVIORAL|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
214833392|NCT03103828|BEHAVIORAL|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
214833393|NCT06428851|OTHER|Laser therapy|Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.
214833394|NCT06428851|OTHER|Neuromuscular electrical nerve stimulation|Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.
214833395|NCT06428851|OTHER|Control|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
214833396|NCT01616199|DRUG|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
214833397|NCT01616199|DRUG|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
214833398|NCT02361957|DIETARY_SUPPLEMENT|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
214833399|NCT02361957|DIETARY_SUPPLEMENT|Placebo|Placebo
214833400|NCT05743634|BIOLOGICAL|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214833401|NCT05743634|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214833402|NCT05743634|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
214833403|NCT00464113|DRUG|XL228|1-hour IV infusion
214833404|NCT06200584|DRUG|Risperidone|Antipsychotic Agent
214833405|NCT06200584|DRUG|Olanzapine|Antipsychotic Agent
214833406|NCT06200584|DRUG|Quetiapine|Antipsychotic Agent
214833407|NCT06200584|DRUG|Risperidone and Vitamin D and Vitamin E|vitamin
214833408|NCT06200584|DRUG|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
214833409|NCT06200584|DRUG|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
214833410|NCT00498199|PROCEDURE|visual tests|
214833411|NCT01426087|DRUG|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
214833412|NCT01426087|PROCEDURE|endoscopic therapy|gastroscope plus EIS/EVL/HI
214833413|NCT02998606|DRUG|Naloxegol|MOVANTIK™ 25 mg, daily
214833414|NCT02998606|DRUG|Placebo Oral Capsule|Placebo 25 mg, daily
214833415|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
214833416|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
214833417|NCT02466087|DRUG|Mg Cl|Four supplements a day for 6 weeks.
214833418|NCT00909571|DRUG|FK506E (modified release tacrolimus)|oral
214833419|NCT00909571|DRUG|Prograf (tacrolimus)|injection
214833420|NCT01086228|DEVICE|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
214833421|NCT03915977|BEHAVIORAL|Post ICU recovery program|Standardized follow up program
214833422|NCT00878787|DEVICE|Transcranial magnetic stimulation|
214833423|NCT05392569|OTHER|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
214833424|NCT03209024|OTHER|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
214833425|NCT03209024|DEVICE|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
214833426|NCT04802213|OTHER|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
214833427|NCT04802213|DEVICE|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
214833428|NCT04802213|DEVICE|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
214833429|NCT02930135|PROCEDURE|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
214833430|NCT02751216|OTHER|EEG recording + pain protocol|
214833431|NCT02658019|DRUG|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
214833432|NCT04633616|OTHER|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
214833433|NCT04633616|OTHER|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
214833434|NCT01623804|DEVICE|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
214833435|NCT01623804|DEVICE|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
214833436|NCT03145324|OTHER|Collection of vaccine histories|
214833437|NCT06285006|DRUG|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
214833438|NCT06678958|PROCEDURE|Reconstruction of acetabular defect by trabecular metal augment|The augments were used in the flying buttress position
214833439|NCT01891058|DEVICE|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
214833440|NCT03065699|DEVICE|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
214833441|NCT04810533|DRUG|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
214833442|NCT00820599|DEVICE|Sapien XT™ transcatheter heart valve and delivery system|
214833443|NCT02653729|BEHAVIORAL|cognitive behaviour therapy|
214833444|NCT02653729|DRUG|Espidone|
214833445|NCT02653729|DRUG|Olepra|
214833446|NCT02653729|DRUG|Donu|
214833447|NCT05416099|PROCEDURE|laser|grid vs micropulse laser
214833448|NCT03436953|DRUG|CX-8998|T-type calcium channel blocker
214833449|NCT03436953|DRUG|Placebo|Placebo comparator
214833450|NCT00559598|GENETIC|proteomic profiling|
214833451|NCT00559598|OTHER|medical chart review|
214833452|NCT01417351|DIETARY_SUPPLEMENT|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
214833453|NCT01417351|DIETARY_SUPPLEMENT|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
214833454|NCT06136416|OTHER|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
214833455|NCT06678126|RADIATION|Prostate and Pelvic Nodes Radiotherapy|60 Gy prostate and 44 Gy pelvic nodes with 20 fractions
214833456|NCT03244605|OTHER|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
214833457|NCT03244605|OTHER|Rehabilitation Education|General health education
214833458|NCT03244605|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
214833459|NCT03244605|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
214833460|NCT05353036|OTHER|Survey|Survey assessing incidence, frequency, and type of illicit substance use
214833461|NCT05659329|DEVICE|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
214833462|NCT01242618|BIOLOGICAL|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
214833463|NCT04647734|BEHAVIORAL|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
214833464|NCT04647734|BEHAVIORAL|Standard care|standard care after discharge from hospital (control group)
214833465|NCT05583097|DIAGNOSTIC_TEST|Non-selective cytology|All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
214833466|NCT06530745|PROCEDURE|Hyaluronic acid (HA) injection|2% hyaluronic acid Synocrom Forte (Croma-Pharma GmbH, Leobendorf, Austria) injection
214833467|NCT06530745|PROCEDURE|Platelet-rich plasma (PRP) injection|PRP from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with iFuge D06 (Neuation Technologies Pvt. Ltd, Gujarat, India) injection
214833468|NCT00452348|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
214833469|NCT00452348|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
214833470|NCT01206803|DRUG|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
214833471|NCT02275403|PROCEDURE|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
214833472|NCT02275403|OTHER|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
214833473|NCT02545530|DRUG|transdermal clonidine|2.5mg/patch per week
214833474|NCT04345822|PROCEDURE|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
214833475|NCT04467619|DEVICE|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
214833476|NCT04883164|OTHER|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
214833477|NCT02752854|OTHER|pain threshold measurement|pressure algometer
214833478|NCT04459754|DRUG|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
214833479|NCT06200376|DRUG|T3011|T3011 will be administered intraperitoneally twice a week.
214833480|NCT04438044|DRUG|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
214833481|NCT04619862|DRUG|Gabapentin|See arm descriptions
214833482|NCT04619862|DRUG|Placebo|See arm descriptions
214277557|NCT05240534|BEHAVIORAL|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
214833483|NCT06173960|DEVICE|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
214833484|NCT02277262|DEVICE|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
214833485|NCT02277262|PROCEDURE|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
214833486|NCT05462080|DIAGNOSTIC_TEST|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
214833487|NCT00006262|DRUG|becatecarin|
214833488|NCT04793633|COMBINATION_PRODUCT|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
214833489|NCT00960154|DEVICE|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
214833490|NCT00960154|PROCEDURE|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
214833491|NCT03064867|DRUG|Venetoclax|"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
214833492|NCT03064867|DRUG|Rituximab|"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
214833493|NCT03064867|DRUG|Ifosfamide|"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
214833494|NCT03064867|DRUG|Carboplatin|"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
214833495|NCT03064867|DRUG|Etoposide|"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
214833496|NCT01470898|DEVICE|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
214833497|NCT04092595|DRUG|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
214833498|NCT04092595|DRUG|Rosuvastatin|10 mg oral tablet
214833499|NCT02407496|OTHER|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
214833500|NCT00486434|DRUG|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
214833501|NCT00486434|DRUG|SMC021 Placebo|Placebo orally, twice daily
214833502|NCT03318133|PROCEDURE|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
214833503|NCT02786433|OTHER|conventional physiotherapy|
214833504|NCT02786433|OTHER|Virtual Reality with X- Box Kinect®|
214833505|NCT00860145|PROCEDURE|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
214833506|NCT00860145|PROCEDURE|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
214833507|NCT01083797|DRUG|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
214833508|NCT01083797|DRUG|Chloral Hydrate|Initial dose=50 mg/kg
214833509|NCT00125541|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
214833510|NCT00544167|DRUG|Doxorubicin|
214833511|NCT00544167|DRUG|Cyclophosphamide|
214833512|NCT00544167|DRUG|Paclitaxel|
214833513|NCT00544167|DRUG|Sorafenib|
214833514|NCT05167149|PROCEDURE|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
214833515|NCT05167149|PROCEDURE|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
214833516|NCT02725515|BIOLOGICAL|XmAb5871|
214833517|NCT02725515|BIOLOGICAL|Placebo to match XmAb5871|
214277558|NCT05240534|BEHAVIORAL|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
214277559|NCT00254761|DRUG|Cannabis|
214277560|NCT01352546|BIOLOGICAL|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
214277561|NCT03253744|DRUG|18F-DCFPyL|Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
214277562|NCT03253744|RADIATION|Tumor Irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.
214277563|NCT03253744|RADIATION|Prostate + tumor irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.
214277564|NCT03253744|RADIATION|Tumor Irradiation|External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
214277565|NCT00946478|DRUG|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
214277566|NCT00946478|OTHER|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
214277567|NCT05510531|BEHAVIORAL|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
214277568|NCT02214407|DRUG|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
214277569|NCT02214407|DRUG|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
214277570|NCT02043275|OTHER|Leg training|Lower body resistance training twice per week for one hour each time.
214277571|NCT02043275|OTHER|Arm training|Upper body resistance training twice per week for one hour each time.
214277572|NCT00887653|DRUG|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
214277573|NCT00593008|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
214277574|NCT00593008|DRUG|Gemcitabine|Given intravenously every other week of each 28-day cycle.
214277575|NCT05438888|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
214277576|NCT05438888|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
214277577|NCT02008630|OTHER|Animal-assisted activity|
214277578|NCT02008630|OTHER|Animal-assisted therapy|
214833518|NCT00055549|DRUG|Dextromethorphan|
214833519|NCT00055549|DRUG|Lorazepam|
214833520|NCT00353535|PROCEDURE|Total Lymphoid irradiation|
214833521|NCT03957096|DRUG|SGN-CD47M|SGN-CD47M administered intravenously
214833522|NCT01311596|OTHER|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
214833523|NCT00056433|DRUG|Hydroxyurea|
214833524|NCT00056433|DRUG|L-Arginine|
214833525|NCT00056433|DRUG|Sildenafil|
214277579|NCT04180358|BEHAVIORAL|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
214277580|NCT04180358|BEHAVIORAL|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
214277581|NCT03974191|OTHER|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
214277582|NCT03246893|DEVICE|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
214277583|NCT03246893|DEVICE|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
214277584|NCT04758104|RADIATION|Yttrium90|Intracystic implantation of 90yttrium colloid
214277585|NCT02761252|DRUG|Bilastine 20mg|
214277586|NCT02761252|DRUG|Montelukast 10mg|
214277587|NCT02761252|DRUG|Placebo Bilastine 20mg|
214277588|NCT02761252|DRUG|Placebo Montelukast 10mg|
214277589|NCT01423370|DRUG|YHD1023|5g oral once daily
214277590|NCT01423370|DRUG|YHD1023|5g oral twice a day
214277591|NCT01423370|DRUG|YHD1023|10g oral once daily
214277592|NCT01423370|DRUG|Cialis|5mg oral once daily
214277593|NCT01423370|DRUG|Placebo|Oral
214277594|NCT01848860|PROCEDURE|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
214277595|NCT01848860|BIOLOGICAL|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
214277596|NCT06128044|DRUG|CB-012|CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
214277597|NCT04698187|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
214277598|NCT04698187|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
214277599|NCT03904043|RADIATION|Radiation therapy|-Monday-Friday treatment is strongly recommended
214277600|NCT03904043|DRUG|FOLFOX regimen|-CAPOX can be given as alternative
214277601|NCT03904043|DRUG|CAPOX regimen|Given as an alternative to FOLFOX
214277602|NCT05315609|BEHAVIORAL|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
214277603|NCT03179696|BEHAVIORAL|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
214277604|NCT04340778|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
214277605|NCT04340778|DRUG|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
214277606|NCT04340778|DRUG|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
214277607|NCT06209996|BEHAVIORAL|L4 weight management intervention|he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.
214277608|NCT06209996|BEHAVIORAL|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
214277609|NCT06657716|DEVICE|ANTERION investigational|"Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)"
214277610|NCT05087459|DRUG|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
214833526|NCT01085981|DRUG|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
214833527|NCT01085981|DRUG|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
214833528|NCT01085981|DRUG|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
214833529|NCT00874549|BIOLOGICAL|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
214833530|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214833531|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
214833532|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214833533|NCT02898740|BEHAVIORAL|Structural exercise|Exercise instruction and encouragement
214833534|NCT02898740|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
214833535|NCT01981044|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
214833536|NCT01610050|DRUG|LFA102|
214833537|NCT06204939|PROCEDURE|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
214833538|NCT06204939|PROCEDURE|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
214833539|NCT06175741|PROCEDURE|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
214833540|NCT02036749|PROCEDURE|nerve block|quadratus lumborum block
214833541|NCT02383706|DEVICE|ApneaLink Air|Overnight, home polysomnography device
214833542|NCT02383706|BEHAVIORAL|Berlin Quesionnaire|OSA screening questionnaire
214833543|NCT02383706|BEHAVIORAL|Epworth Sleepiness Scale|OSA screening questionnaire
214833544|NCT02383706|BEHAVIORAL|STOP-BANG questionnaire|OSA screening questionnaire
214833545|NCT02383706|OTHER|Physical exam|Physical exam of neck, mouth and upper airway
214833546|NCT05981716|OTHER|No intervention|This is an observational study. There is no intervention.
214833547|NCT04013750|OTHER|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
214833548|NCT05765617|DRUG|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
214833549|NCT05765617|OTHER|Placebo|Placebo give 2x1 per day for five day
214833550|NCT02752334|DRUG|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
214833551|NCT02191124|DRUG|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
214833552|NCT02191124|DRUG|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
214277611|NCT00808626|DRUG|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
214833553|NCT05995990|DEVICE|Raman Spectrometry|Laboratory technique of Raman Spectrometry
214277612|NCT04362072|DRUG|Lorlatinib|25 milligram (mg) tablet
214277613|NCT06816108|DRUG|ONO-7428|Specified dose on specified days
214833554|NCT02370836|OTHER|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
214833555|NCT01812629|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
214833556|NCT05883397|OTHER|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
214833557|NCT05883397|OTHER|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
214833558|NCT06260982|RADIATION|18-FDG-PET|18-FDG-PET and neuropsychological tests (language, memory, visuo-spatial tests, etc.).
214833559|NCT04922294|OTHER|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
214833560|NCT00859040|DRUG|SOM230C|Injection in the buttocks every 28 days
214833561|NCT03264716|DEVICE|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
214833562|NCT04212819|OTHER|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
214833563|NCT04212819|OTHER|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
214833564|NCT05553496|DRUG|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
214833565|NCT05553496|DRUG|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
214833566|NCT05546242|DRUG|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
214833567|NCT05546242|DRUG|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
214833568|NCT03008941|BIOLOGICAL|FMT|Capsules with fecal microbiota from healthy donors
214833569|NCT03008941|OTHER|Placebo|Placebo capsules
214833570|NCT05824949|PROCEDURE|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
214833571|NCT05824949|PROCEDURE|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
214833572|NCT06579417|DIAGNOSTIC_TEST|RSI MRI|In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.
214833573|NCT05592483|OTHER|None (Observational Study)|Not Applicable since observational study
214833574|NCT03609749|BEHAVIORAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
214833575|NCT00159172|DEVICE|Motor cortex stimulation|
214833576|NCT01712568|DRUG|Test Product (Ropinirole)|"one Tablet at 0 hour"
214833577|NCT01712568|DRUG|Reference Product (REQUIP )|"one Tablet at 0 hour"
214833578|NCT05120791|DIETARY_SUPPLEMENT|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
214833579|NCT05120791|DIETARY_SUPPLEMENT|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
214833580|NCT05120791|DIETARY_SUPPLEMENT|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
214833581|NCT05120791|DIETARY_SUPPLEMENT|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
214833582|NCT00623558|DRUG|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
214833583|NCT00623558|DRUG|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
214833584|NCT00623558|DRUG|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
214833585|NCT06031337|DIAGNOSTIC_TEST|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
214833586|NCT02707887|BEHAVIORAL|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
214833587|NCT02707887|BEHAVIORAL|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
214833588|NCT02707887|BEHAVIORAL|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
214833589|NCT00037752|DRUG|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
214833590|NCT00037752|BEHAVIORAL|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
214833591|NCT05953506|DRUG|HS-10506|HS-10506 will be administered orally once on Day 1.
214833592|NCT05953506|DRUG|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
214833593|NCT01406639|DRUG|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
214833594|NCT04846439|BIOLOGICAL|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
214833595|NCT05799235|DEVICE|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
214833596|NCT05799235|OTHER|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
214833597|NCT02310841|DEVICE|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
214833598|NCT02591849|DIETARY_SUPPLEMENT|Glucagon-like peptide-1 (GLP-1)|
214833599|NCT02591849|OTHER|Isotonic saline|
214833600|NCT02591849|OTHER|Hyperglycemic clamp|
214833601|NCT05385900|DRUG|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
214833602|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
214833603|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
214833604|NCT05766956|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
214833605|NCT05766956|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
214833606|NCT03538795|COMBINATION_PRODUCT|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
214833607|NCT02753465|PROCEDURE|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
214833608|NCT02753465|PROCEDURE|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
214833609|NCT01112891|DRUG|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
214833610|NCT01112891|DRUG|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
214833611|NCT01112891|DRUG|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
214833612|NCT03316157|DIETARY_SUPPLEMENT|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
214833613|NCT03316157|BEHAVIORAL|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
214833614|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
214833615|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
214833616|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
214277616|NCT06670794|BEHAVIORAL|Web-based intervention for concerned partners|The web-based intervention will comprise sessions focusing on community reinforcement and family therapy principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to their partner (PPR; i.e., actively listening, showing understanding, expressing interest in what their partner is thinking and feeling, and trying to see where their partner is coming from), (3) understanding their partner's drinking reinforcers, and (4) supporting their partner if they want help and engaging in positive, healthy activities with their partner.
214833617|NCT03824834|DRUG|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
214833618|NCT03824834|OTHER|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
214833619|NCT04559841|OTHER|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
214833620|NCT06417632|OTHER|Graded Zirconia Crown|monolithic implant supported crown
214833621|NCT06417632|OTHER|Conventional Zirconia Crown|monolithic implant supported crown
214833622|NCT01058122|PROCEDURE|Collection of adverse drug events|
214833623|NCT04580186|PROCEDURE|bladder exstrophy repair|primary complete bladder exstrophy repair
214833624|NCT03141216|DEVICE|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
214833625|NCT03141216|DEVICE|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
214833626|NCT03768817|OTHER|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
214833627|NCT06222658|DEVICE|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
214833628|NCT00158535|PROCEDURE|liver transplantation|
214833629|NCT02045355|OTHER|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
214833630|NCT00510419|DRUG|"InvestigationalAuto-injector (sumatriptan succinate)"|
214833631|NCT02998541|DRUG|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
214833632|NCT02998541|DRUG|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
214833633|NCT02998541|OTHER|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
214833634|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
214833635|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
214833636|NCT00999284|DRUG|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
214833637|NCT01027767|DEVICE|Molecular Breast Imaging|Molecular Breast Imaging
214833638|NCT03304782|OTHER|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
214833639|NCT01324544|DRUG|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
214833640|NCT00757991|GENETIC|polymorphism analysis|
214833641|NCT00757991|OTHER|laboratory biomarker analysis|
214833642|NCT00757991|OTHER|questionnaire administration|
214833643|NCT01480895|BEHAVIORAL|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
214833644|NCT02941588|PROCEDURE|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
214833645|NCT03391050|DRUG|APR-246|Intravenous infusion
214833646|NCT03391050|DRUG|Dabrafenib|Oral administration
214833647|NCT04583150|PROCEDURE|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
214277617|NCT06670794|BEHAVIORAL|Psychoeducation control|This is a psychoeducation control condition.
214277618|NCT02537106|PROCEDURE|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
214833648|NCT03992651|DEVICE|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
214833649|NCT06274424|BEHAVIORAL|The Friends Program|A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
214833650|NCT06198647|PROCEDURE|Tui-na massage|Using Tui-na massage for the back muscles
214833651|NCT06198647|PROCEDURE|positional release technique|using positional release manual technique to relax the back muscles
214833652|NCT06406725|DIAGNOSTIC_TEST|Point-of-Care Ultrasound of the Airway|Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
214833653|NCT03320863|DEVICE|Enso device|An active Enso device that delivers neuromodulation therapy.
214833654|NCT02153203|BEHAVIORAL|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
214277619|NCT02537106|PROCEDURE|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
214833655|NCT02153203|OTHER|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
214833656|NCT01961817|OTHER|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
214833657|NCT01961817|OTHER|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
214833658|NCT01513239|BIOLOGICAL|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
214833659|NCT01513239|BIOLOGICAL|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
214833660|NCT01513239|BIOLOGICAL|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
214833661|NCT01513239|DRUG|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
214833662|NCT04005222|DRUG|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
214833663|NCT04005222|DRUG|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
214833664|NCT01635582|OTHER|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
214833665|NCT01635582|OTHER|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
214833666|NCT02873260|BIOLOGICAL|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
214833667|NCT02873260|BIOLOGICAL|rDEN3Δ30|Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
214833668|NCT02873260|BIOLOGICAL|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
214833669|NCT01327976|DEVICE|vBloc (Active Device)|Active device will deliver vBloc Therapy
214833670|NCT01327976|DEVICE|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
214833671|NCT03582423|OTHER|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
214833672|NCT06423014|BEHAVIORAL|Wearable devices only|self-monitoring
214833673|NCT06423014|BEHAVIORAL|Wearable devices with the 1st behavior change technique|reminder
214833674|NCT06423014|BEHAVIORAL|Wearable devices with the 2nd behavior change technique|social support
214833675|NCT06423014|BEHAVIORAL|Wearable devices with the 3rd behavior change technique|Competition
214833676|NCT06423014|BEHAVIORAL|Wearable devices with the 4th behavior change technique|Goal-setting
214833677|NCT06423014|BEHAVIORAL|Wearable devices with the 5th behavior change technique|health coach
214833678|NCT06423014|BEHAVIORAL|Wearable devices with all behavior change techniques|Self-monitoring, health coach, goal-setting, competition, social support, and reminder
214833679|NCT03167606|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
214833680|NCT00059332|DRUG|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
214833681|NCT00059332|DRUG|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
214833682|NCT01239303|DIETARY_SUPPLEMENT|Citrulline|single dose
214833683|NCT01239303|DIETARY_SUPPLEMENT|alanine|single dose
214833684|NCT05214677|DRUG|DW1809|pelubiprofen 30mg
214833685|NCT05214677|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
214833686|NCT00413049|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
214833687|NCT00413049|DRUG|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
214277620|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
214833688|NCT03852745|BEHAVIORAL|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
214833689|NCT04546412|DEVICE|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
214833690|NCT02587143|DRUG|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
214833691|NCT02587143|DRUG|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
214833692|NCT04179396|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
214833693|NCT04179396|DRUG|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
214833694|NCT04179396|DRUG|Abiraterone|Abiraterone will be administered once daily with prednisone
214833695|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Rockwood Clinical Frailty Scale
214833696|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
214833697|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Clinician's subjective 'end-of-bed' test
214833698|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
214833699|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|11-item modified Frailty Index (mFI-11)
214833700|NCT01887158|DRUG|Polyethylene glycol|
214833701|NCT01887158|DRUG|Bisacodyl|
214833702|NCT01675739|BEHAVIORAL|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
214833703|NCT01675739|DRUG|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
214833704|NCT02837913|DEVICE|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
214833705|NCT00165919|OTHER|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
214833706|NCT00218322|DRUG|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
214833707|NCT00218322|DRUG|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
214833708|NCT03373630|DEVICE|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
214833709|NCT05024487|DIAGNOSTIC_TEST|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
214833710|NCT03539926|DEVICE|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
214833711|NCT03539926|DIAGNOSTIC_TEST|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
214833712|NCT04929821|DEVICE|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
214833713|NCT03314857|DEVICE|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
214833714|NCT02230930|DRUG|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
214833715|NCT02230930|DEVICE|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
214833716|NCT02230930|DRUG|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
214833717|NCT02230930|DRUG|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
214833718|NCT04153825|DEVICE|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
214833719|NCT04153825|DEVICE|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
214833720|NCT04153825|OTHER|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
214833721|NCT04153825|DEVICE|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
214833722|NCT04153825|DEVICE|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
214833723|NCT06331650|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
214833724|NCT00753350|DEVICE|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
214833725|NCT04386122|DRUG|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
214833726|NCT04386122|DRUG|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
214833727|NCT02906917|DRUG|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
214833728|NCT02906917|DRUG|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
214833729|NCT02906917|DRUG|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
214833730|NCT02371837|OTHER|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
214833731|NCT01706809|OTHER|blood sampels from vena rectalis superior and vena cubiti|
214833732|NCT04499209|DRUG|XG005|XG005 Capsule
214833733|NCT04499209|DRUG|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
214833734|NCT04499209|DRUG|Placebos|Placebo Capsule
214833735|NCT02995187|DRUG|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
214833736|NCT01286805|PROCEDURE|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
214833737|NCT01286805|PROCEDURE|Control|The control group will receive only a combined spinal-epidural.
214833738|NCT03447691|DRUG|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
214833739|NCT03447691|DRUG|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
214833740|NCT04457115|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
214833741|NCT04457115|PROCEDURE|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
214833742|NCT00422253|BEHAVIORAL|dietary intervention|
214833743|NCT02213887|DRUG|Pantoprazole|40 mg PO QAM
214833744|NCT02213887|DRUG|Pantoprazole|0 mg PO QAM
214833745|NCT02926170|DRUG|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
214833746|NCT02926170|DRUG|acenocumarol|Doses will be adjusted according to INR
214833747|NCT05530291|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
214833748|NCT00796874|OTHER|active surveillance|Correlative Study
214833749|NCT00796874|OTHER|imaging biomarker analysis|Correlative Study
214833750|NCT00796874|PROCEDURE|biopsy|Tissue Removal
214833751|NCT00796874|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
214833752|NCT00796874|PROCEDURE|magnetic resonance imaging|Radiolical Medical Imaging
214833753|NCT00796874|PROCEDURE|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
214833754|NCT02393560|PROCEDURE|DECT scan|
214833755|NCT01437735|DRUG|QAW039|QAW039 po
214833756|NCT01437735|DRUG|Montelukast|Montelukast 10 mg po
214833757|NCT01437735|DRUG|Placebo|Placebo
214833758|NCT03004157|PROCEDURE|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
214277621|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
214833759|NCT00973050|DRUG|Bicalutamide|50 mg Tablet
214833760|NCT00973050|DRUG|Casodex®|50 mg Tabelt
214833761|NCT00005668|DRUG|Itraconazole oral solution|
214833762|NCT02465684|PROCEDURE|unicondylar knee arthroplasty|
214833763|NCT02865148|BEHAVIORAL|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
214833764|NCT05638035|DIAGNOSTIC_TEST|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
214833765|NCT04620941|DIAGNOSTIC_TEST|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
214833766|NCT06440278|BEHAVIORAL|Behavioral Activation for Health and Depression (BA-HD)|BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
214833767|NCT06440278|OTHER|Enhanced Usual Care|Patients will receive depression and heart disease education, as well as a list of local mental health resources.
214833768|NCT05863845|DRUG|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
214833769|NCT05863845|DRUG|Carmustine|300mg/m2 day -7, Given IV
214833770|NCT05863845|DRUG|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
214833771|NCT05863845|DRUG|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
214833772|NCT05863845|DRUG|Melphalan|140mg/m2, day -2, Given IV
214833773|NCT05863845|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
214833774|NCT05156086|DRUG|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
214833775|NCT06338410|BEHAVIORAL|Kangaroo Mother Care|KMC is a care system for LBW and preterm infants at birth, based on skin-to-skin contact between the infant and the mother and exclusive breast feeding. The mother carries her Preterm infant for at least one hour per day. Urine collected before and after skin-to-skin contact.
214833776|NCT05809180|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt d1;
214833777|NCT05809180|DRUG|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
214833778|NCT05809180|DRUG|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
214833779|NCT05809180|DRUG|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
214833780|NCT05809180|DRUG|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
214833781|NCT02926040|PROCEDURE|Irreversible electroporation|
214833782|NCT01242124|PROCEDURE|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
214833783|NCT01242124|PROCEDURE|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
214833784|NCT01591720|BEHAVIORAL|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
214833785|NCT01067950|PROCEDURE|Isolated Pancreas Transplant|
214833786|NCT01067950|DRUG|Intensive Insulin Therapy|
214833787|NCT01006954|DRUG|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
214833788|NCT01006954|DRUG|Flare up|Flare up protocol in poor responders for IVF/ICSI
214833789|NCT02156453|PROCEDURE|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
214833790|NCT05252988|DRUG|Neratinib|Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
214833791|NCT05252988|DRUG|Loperamide|Loperamide orally.
214833792|NCT05252988|DRUG|Colesevelam|Colesevelam capsules orally, 2 times a day for the first month (28 days).
214833793|NCT06849869|BEHAVIORAL|COMPASS+|COMPASS+ is centered around the integration of a care manager (a licensed mental health clinician) who provides mental health supports (e.g. short-term therapy) and symptom monitoring to perinatal patients. The care manager works closely with the patient and obstetric clinician to create a treatment plan based on the patient's preferences and needs. The care manager also utilizes a care registry to send monthly mental health screeners to patients and track their symptoms. The care manger meets weekly with the obstetric clinician and a consulting psychiatrist to review and modify treatment plans as needed. The care manager services are available throughout pregnancy and up to one year postpartum.
214833794|NCT00620958|BEHAVIORAL|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
214833795|NCT00620958|BEHAVIORAL|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
214833796|NCT00620958|BEHAVIORAL|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
214833797|NCT04411251|BEHAVIORAL|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
214833798|NCT04411251|BEHAVIORAL|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
214833799|NCT00794053|PROCEDURE|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
214833800|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
214833801|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
214833802|NCT05588063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
214833803|NCT05588063|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
214833804|NCT04505163|PROCEDURE|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
214833805|NCT04505163|DEVICE|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
214833806|NCT00343681|BIOLOGICAL|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
214833807|NCT00000245|DRUG|Desipramine|
214833808|NCT05597228|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
214833809|NCT01264523|OTHER|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
214833810|NCT04546282|OTHER|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
214833811|NCT05833425|DEVICE|Respiratory Pressure Meter (MicroRPM)|Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
214833812|NCT04879927|OTHER|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
214833813|NCT04879927|OTHER|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
214833814|NCT03639181|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
214833815|NCT03611335|BEHAVIORAL|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
214833816|NCT04392999|DRUG|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
214833817|NCT04392999|DRUG|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
214833818|NCT05971056|OTHER|Care transition|Cancer care is transitioned to a satellite site.
214833819|NCT05971056|OTHER|No care transition|Cancer care is not transitioned to a satellite site.
214833820|NCT04173611|DRUG|EXPAREL|Injection into the Intrathecal space.
214833821|NCT04173611|DRUG|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
214833822|NCT04173611|OTHER|Placebo|Injection into the Intrathecal space.
214833823|NCT01121601|PROCEDURE|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
214833824|NCT01121601|PROCEDURE|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
214833825|NCT05508490|DIAGNOSTIC_TEST|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
214833826|NCT00827463|BIOLOGICAL|dosage of the NFS and iron|a blood test will be made.
214833827|NCT02509143|PROCEDURE|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
214833828|NCT02509143|DEVICE|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
214833829|NCT02509143|DRUG|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
214833830|NCT04492930|BEHAVIORAL|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
214833831|NCT04492930|BEHAVIORAL|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
214833832|NCT03797248|COMBINATION_PRODUCT|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
214833833|NCT03056144|DEVICE|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
214833834|NCT00486239|BEHAVIORAL|TLE Arm 1|Behavioral/cognitive testing
214833835|NCT00486239|BEHAVIORAL|Emotion Memory Test|Behavioral/cognitive Measure
214833836|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
214833837|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
214833838|NCT02792816|DRUG|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
214833839|NCT03768635|OTHER|necrotizing external otitis|description of necrotizing external otitis
214833840|NCT06150196|BEHAVIORAL|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
214833841|NCT06150196|BEHAVIORAL|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
214833842|NCT00377117|PROCEDURE|Management|
214833843|NCT00377117|PROCEDURE|Screening|
214833844|NCT05072535|DRUG|HA121-28 tablet B|HA121-28 tablet B 200 mg
214833845|NCT05072535|DRUG|HA121-28 tablet A|HA121-28 tablet A 200 mg
214833846|NCT02379624|DRUG|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
214833847|NCT01904513|DIETARY_SUPPLEMENT|Pasteurized Whole Milk|
214833848|NCT01904513|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1|
214833849|NCT01508065|DEVICE|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
214833850|NCT00408018|DRUG|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
214833851|NCT00838838|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
214833852|NCT01269658|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
214833853|NCT01269658|DRUG|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
214833854|NCT05191238|OTHER|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
214833855|NCT01291095|DRUG|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
214833856|NCT01291095|RADIATION|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
214833857|NCT06245928|DEVICE|Individualized Respiratory Exercise Device|The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.
214833858|NCT06245928|DEVICE|Threshold® IMT + Threshold™ PEP|The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
214833859|NCT06475651|GENETIC|Methylation analysis|Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
214833860|NCT00006153|BIOLOGICAL|HIV-1 Immunogen|
214833861|NCT00259896|DRUG|exenatide|
214833862|NCT04281472|BIOLOGICAL|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
214833863|NCT04281472|OTHER|placebo in stage B|Stage A: N/A, stage B: placebo
214833864|NCT06561269|PROCEDURE|Multifidus plane block|"Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine."
214833865|NCT06561269|PROCEDURE|caudal block|"The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique."
214833866|NCT03673267|BEHAVIORAL|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
214833867|NCT02025660|DRUG|Mw, 0.3ml x three days sc|
214833868|NCT02025660|DRUG|Placebo|
214833869|NCT04488380|OTHER|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
214833870|NCT05971394|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
214833871|NCT01746550|DEVICE|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
214833872|NCT05649904|DEVICE|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
214833873|NCT05649904|DEVICE|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
214833874|NCT02638922|DRUG|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
214833875|NCT01608646|DRUG|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
214833876|NCT03007563|DEVICE|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
214833877|NCT03007563|PROCEDURE|bilirubin concentration measured in standard blood samples|
214833878|NCT03007563|DEVICE|bilirubin concentration measured by transcutaneous device|
214833879|NCT04122950|BEHAVIORAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
214833880|NCT05278858|COMBINATION_PRODUCT|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
214833881|NCT00731458|DEVICE|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
214833882|NCT03811158|DEVICE|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
214833883|NCT03811158|DEVICE|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
214833884|NCT05010135|DEVICE|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
214833885|NCT04589286|BEHAVIORAL|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
214833886|NCT04589286|OTHER|Electronic Handouts|Generic wellness-related electronic handouts
214833887|NCT03508596|OTHER|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
214833888|NCT00362635|DRUG|Clevudine|
214833889|NCT05493163|DRUG|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
214833890|NCT05493163|DRUG|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
214833891|NCT05308186|BEHAVIORAL|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
214833892|NCT05308186|BEHAVIORAL|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
214833893|NCT03558295|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
214833894|NCT04883996|DRUG|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
214277622|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
214833895|NCT04883996|OTHER|Saline control|Saline
214833896|NCT03850938|DEVICE|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
214833897|NCT03850938|DEVICE|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
214833898|NCT02095613|OTHER|traditional food|
214833899|NCT02095613|OTHER|food that is nutrient dense|
214833900|NCT00042835|DRUG|cisplatin|Given IV
214833901|NCT00042835|DRUG|etoposide|Given IV
214833902|NCT00042835|DRUG|erlotinib hydrochloride|Given orally
214833903|NCT00042835|RADIATION|radiation therapy|Undergo radiotherapy
214833904|NCT00042835|DRUG|docetaxel|Given IV
214833905|NCT00042835|DRUG|paclitaxel|Given IV
214833906|NCT00042835|DRUG|carboplatin|Given IV
214833907|NCT00042835|OTHER|laboratory biomarker analysis|Correlative studies
214833908|NCT02265679|DRUG|BIIL 284 BS, low dose, pediatric patients|
214833909|NCT02265679|DRUG|BIIL 284 BS, medium dose, pediatric patients|
214833910|NCT02265679|DRUG|BIIL 284 BS, high dose, pediatric patients|
214833911|NCT02265679|DRUG|BIIL 284 BS, low dose, adult patients|
214833912|NCT02265679|DRUG|BIIL 284 BS, medium dose, adult patients|
214833913|NCT02265679|DRUG|BIIL 284 BS, high dose, adult patients|
214833914|NCT02265679|DRUG|Placebo|
214833915|NCT05759715|OTHER|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
214833916|NCT05392959|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
214833917|NCT05392959|DRUG|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
214833918|NCT06001463|DRUG|CSMed Dressing|Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
214833919|NCT05456451|DEVICE|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
214833920|NCT03821974|PROCEDURE|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
214833921|NCT03821974|PROCEDURE|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
214833922|NCT01614288|PROCEDURE|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
214833923|NCT01614288|OTHER|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
214833924|NCT04848688|DRUG|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
214833925|NCT04848688|DRUG|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
214833926|NCT04848688|DRUG|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
214833927|NCT03947905|PROCEDURE|Virtual visit|Type of visit
214833928|NCT05643105|PROCEDURE|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
214833929|NCT00981344|OTHER|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
214833930|NCT05104996|BEHAVIORAL|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
214833931|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
214833932|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
214833933|NCT02754219|DRUG|Evogliptin|DPP4-inhibitor, Evogliptin
214833934|NCT00130949|DRUG|ALGRX 4975|
214833935|NCT03504085|OTHER|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
214833936|NCT03504085|OTHER|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
214833937|NCT00320307|DRUG|abacavir|
214833938|NCT04133311|DRUG|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
214833939|NCT04133311|DRUG|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
214833940|NCT04133311|DRUG|DE-130A/DE-130A|After Week 12, received DE-130A continuously.
214277623|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
214833941|NCT04133311|DRUG|Xalatan®/DE-130A|From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
214833942|NCT03935815|DRUG|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
214833943|NCT03935815|PROCEDURE|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
214833944|NCT03522532|PROCEDURE|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833945|NCT03522532|PROCEDURE|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833946|NCT03522532|PROCEDURE|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833947|NCT03522532|PROCEDURE|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833948|NCT03522532|PROCEDURE|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833949|NCT03522532|PROCEDURE|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
214833950|NCT02911909|DEVICE|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
214833951|NCT02911909|OTHER|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
214833952|NCT00091377|DRUG|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
214833953|NCT00091377|DRUG|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
214833954|NCT00091377|DRUG|phenoxodiol|IV 3 mg/kg
214833955|NCT04947761|DRUG|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
214833956|NCT04947761|OTHER|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
214833957|NCT06249451|OTHER|Checklist-based phone calls|"The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines."
214833958|NCT00252161|PROCEDURE|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
214833959|NCT00252161|DRUG|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
214833960|NCT00804011|OTHER|ATC|Automatic tube compensation
214833961|NCT00804011|OTHER|PSV|Pressure support ventilation
214833962|NCT00728754|DEVICE|Dental implant Osseotite Prevail|Root form titanium dental implant
214833963|NCT00728754|DEVICE|Dental implant Osseotite|root form titanium dental implant
214833964|NCT00668577|DRUG|Lactic acid (Dermacid)|
214833965|NCT00623077|BIOLOGICAL|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
214833966|NCT00623077|DRUG|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
214833967|NCT00623077|DRUG|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
214833968|NCT00623077|DRUG|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
214833969|NCT00623077|DRUG|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
214833970|NCT00623077|DRUG|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
214833971|NCT00623077|PROCEDURE|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
214833972|NCT00623077|RADIATION|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
214833973|NCT00623077|RADIATION|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
214833974|NCT00623077|DRUG|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
214833975|NCT00623077|RADIATION|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
214833976|NCT03762954|OTHER|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
214833977|NCT01926119|DEVICE|Transcranial Magnetic Stimulation|
214833978|NCT04464005|DRUG|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
214833979|NCT04464005|OTHER|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
214833980|NCT03948854|OTHER|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
214833981|NCT03948854|OTHER|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
214833982|NCT03948854|OTHER|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
214833983|NCT03948854|OTHER|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
214833984|NCT04877145|OTHER|drill|single 3.25 mm stainless steel drill
214833985|NCT02994147|DRUG|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
214833986|NCT02994147|DRUG|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
214833987|NCT00171145|DRUG|Darifenacin|Darifenacin 15 mg tablets once daily
214833988|NCT00171145|DRUG|Placebo|Placebo tablets once daily
214833989|NCT03053245|BEHAVIORAL|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
214833990|NCT03053245|BEHAVIORAL|Attention Control|Patients in this group will receive regular wellness calls from the research team.
214833991|NCT00009945|DRUG|clodronate|1600 mg PO daily
214833992|NCT00009945|DRUG|placebo|2 pills PO daily
214833993|NCT04211935|DEVICE|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
214833994|NCT04211935|DEVICE|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
214833995|NCT04211935|DEVICE|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
214833996|NCT01769898|DRUG|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
214833997|NCT01769898|DRUG|Theophylline|Theophylline 0.1 Q12H
214833998|NCT01769898|DRUG|Placebo|Placebo for theophylline 0.1 Q12H
214833999|NCT00955838|OTHER|Rehabilitation technique|12 therapy session
214834000|NCT02172781|DRUG|Ipratropium - unit dose vial|
214834001|NCT02172781|DRUG|Tiotropium - inhalation capsule|
214834002|NCT02172781|DRUG|Placebo matching tiotropium|
214834003|NCT02172781|DRUG|Placebo matching ipratropium|
214834004|NCT03304223|DIAGNOSTIC_TEST|[18F]FB-IL2 PET scan|\[18F\]FB-IL2 PET scan procedure
214834005|NCT02569138|DEVICE|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
214834006|NCT02569138|DEVICE|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
214834007|NCT03344120|OTHER|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
214834008|NCT06360887|PROCEDURE|Conservative|Conservative treatment
214834009|NCT06360887|PROCEDURE|ORIF|Open surgery
214834010|NCT06360887|PROCEDURE|CRPP|Minimal invasive surgery
214834011|NCT05140759|DEVICE|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
214834012|NCT02666807|DIETARY_SUPPLEMENT|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
214834013|NCT02666807|DIETARY_SUPPLEMENT|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
214834014|NCT02382224|BEHAVIORAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
214834015|NCT02382224|BEHAVIORAL|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
214834016|NCT04563481|OTHER|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
214834017|NCT04563481|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
214834018|NCT00156182|DRUG|Asoprisnil|10mg Tablet, oral Daily for 6 months
214834019|NCT04184167|OTHER|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
214834020|NCT06626802|PROCEDURE|Balloon Dilation + Topical Mitomycin|Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
214834021|NCT06626802|PROCEDURE|Balloon Dilation + Injection Triamcinolone|Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
214834022|NCT01728636|DRUG|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
214834023|NCT03032536|DRUG|AL-3778|AL-3778 tablets or capsules
214834024|NCT03032536|DRUG|Entecavir|Entecavir once daily for 14 days
214834025|NCT03032536|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
214834026|NCT00295490|DRUG|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
214834027|NCT00295490|DRUG|Placebo|Placebo has same dosing freq as for active intervention and for same time period
214834028|NCT02226250|DIETARY_SUPPLEMENT|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
215031511|NCT04923672|BEHAVIORAL|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
215031512|NCT05826626|DEVICE|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
214834029|NCT04254315|BEHAVIORAL|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
214834030|NCT01167439|PROCEDURE|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
214834031|NCT01307358|OTHER|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
214834032|NCT05515458|DRUG|Chiglitazar|Oral single dose 48 mg
214834033|NCT03202927|DRUG|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
214834034|NCT01826760|OTHER|Using training and testing groups to construct ANN based on laboratory tests|
214834035|NCT05718180|OTHER|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
214834036|NCT05757830|DEVICE|UANGO suite exoskeleton|"Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3."
214834037|NCT00867919|BEHAVIORAL|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary"
214834038|NCT00867919|OTHER|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
214834039|NCT00646984|DRUG|Standard continuous antiretroviral therapy|
214834040|NCT00646984|DRUG|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
214834041|NCT00646984|DRUG|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
214834042|NCT02480634|DRUG|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
214834043|NCT02480634|RADIATION|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
214834044|NCT05828290|BEHAVIORAL|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
214834045|NCT04646603|DRUG|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
214834046|NCT04646603|DRUG|Placebo|Subjects will receive subcutaneous placebo injections.
214834047|NCT01196390|DRUG|Carboplatin|Given IV
214834048|NCT01196390|OTHER|Laboratory Biomarker Analysis|Correlative studies
214834049|NCT01196390|DRUG|Paclitaxel|Given IV
214834050|NCT01196390|OTHER|Quality-of-Life Assessment|Ancillary studies
214834051|NCT01196390|RADIATION|Radiation Therapy|Undergo radiation therapy
214834052|NCT01196390|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214834053|NCT01196390|BIOLOGICAL|Trastuzumab|Given IV
214834054|NCT03312894|DRUG|TAK-653|TAK-653 tablets
214834055|NCT03312894|DRUG|Placebo|Placebo-matching tablets
214834056|NCT04051307|DRUG|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
214834057|NCT04051307|DRUG|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
214834058|NCT03336788|DEVICE|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
214834059|NCT03336788|DEVICE|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
214834060|NCT03273751|PROCEDURE|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
214834061|NCT03273751|PROCEDURE|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
214834062|NCT01885897|BIOLOGICAL|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
214834063|NCT05303441|PROCEDURE|percutaneous coronary intervention|conventional coronary angiography
214834064|NCT03141151|BEHAVIORAL|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
214834065|NCT03141151|BEHAVIORAL|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
215031513|NCT05826626|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
215031514|NCT04938427|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
215031515|NCT04938427|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
215031516|NCT05106062|DEVICE|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
214834066|NCT04055233|DRUG|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
214834067|NCT04055233|DRUG|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
214834068|NCT01457092|DEVICE|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
214834069|NCT03787017|DRUG|FDC(MP-513 20mg/Metformin XR 1000mg)|
214834070|NCT03787017|DRUG|MP-513 20mg|
214834071|NCT03787017|DRUG|Metformin XR 1000mg|
214834072|NCT03770793|PROCEDURE|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
214834073|NCT01787929|PROCEDURE|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
214834074|NCT00785603|DRUG|Paroxetine|tablets of 20 mg paroxetine
214834075|NCT00785603|DRUG|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
214834076|NCT00785603|DRUG|Tramadol|Capsules of 50 mg tramadol
214834077|NCT05778890|OTHER|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
214834078|NCT05778890|OTHER|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
214834079|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
214834080|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
214834081|NCT04995354|DRUG|EGF loaded Hydrogel|Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
214834082|NCT04995354|DRUG|Hydrogel|Non-medicated self-healing hydrogel to be applied three times a day for 1 week
214834083|NCT02037854|OTHER|Nutrient formulation|
214834084|NCT00193323|DRUG|Docetaxel|
214834085|NCT00193323|DRUG|Gemcitabine|
214834086|NCT05357287|DEVICE|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
214834087|NCT03790137|DRUG|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
214834088|NCT03414073|DEVICE|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
214834089|NCT03414073|DEVICE|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
214834090|NCT03414073|DEVICE|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
214834091|NCT03109327|DIAGNOSTIC_TEST|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
214834092|NCT06212674|PROCEDURE|PVI + LAAO|Treatment with a complex procedure of PVI + LAAO
214834093|NCT06212674|PROCEDURE|LAAO|Tratment with LAAO procedure
214834094|NCT06212674|DRUG|NOAC|NOAC treatment
214834095|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
214834096|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
214834097|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
214834098|NCT05894031|BEHAVIORAL|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
214834099|NCT01436448|DRUG|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
214834100|NCT03711396|BEHAVIORAL|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
214834101|NCT02218216|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
214834102|NCT02860325|DEVICE|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
214834103|NCT02860325|DEVICE|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
214834104|NCT03111381|DRUG|Toradol|IV toradol
214834105|NCT05316636|DEVICE|Vibrational forces|
214834106|NCT05316636|PROCEDURE|Orthodontic treatment with clear aligners|
214834107|NCT02610647|DRUG|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
214834108|NCT02610647|OTHER|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
214834109|NCT02610647|OTHER|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
214834110|NCT02610647|OTHER|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
214834111|NCT00147134|PROCEDURE|open colectomy|Procedure/Surgery: open colectomy
214834112|NCT00147134|PROCEDURE|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
214834113|NCT02937259|OTHER|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
214834114|NCT06374654|OTHER|Home-based Exercise Protocol|The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.
214834115|NCT06374654|OTHER|Formal Physical Therapy|Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
214834116|NCT00685854|DRUG|Ranibizumab|
214834117|NCT04637139|DRUG|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi \[14C\]VBR.
214834118|NCT06090708|DIETARY_SUPPLEMENT|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
214834119|NCT01869556|DRUG|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
214834120|NCT01869556|DRUG|Ergot|Ergot 0.25mg IV
214834121|NCT01869556|DRUG|Carboprost|Carboprost 0.25mg IM
215031517|NCT05080478|DRUG|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
215031518|NCT00745667|PROCEDURE|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
215031519|NCT00745667|PROCEDURE|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
214834122|NCT01591915|OTHER|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
214834123|NCT05194202|BEHAVIORAL|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
214834124|NCT03756701|BEHAVIORAL|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual"
214834125|NCT01691430|DIETARY_SUPPLEMENT|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
214834126|NCT01691430|DIETARY_SUPPLEMENT|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
214834127|NCT03930849|BEHAVIORAL|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
214834128|NCT03930849|BEHAVIORAL|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
214834129|NCT01758406|BIOLOGICAL|Intracoronary injection|stem cell transplantation
214834130|NCT01758406|BIOLOGICAL|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
214834131|NCT06356987|PROCEDURE|Herniotomy|In Group A Laparoscopic assisted needle herniotomy was done
214834132|NCT02573285|PROCEDURE|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
214834133|NCT02573285|PROCEDURE|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
214834134|NCT01510509|DEVICE|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
214834135|NCT01510509|DEVICE|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
214834136|NCT03866928|DRUG|Stiripentol|1500 mg of stiripentol b.i.d.
214834137|NCT00660387|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
214834138|NCT00660387|DRUG|Placebo Gel|
214834139|NCT00660387|DRUG|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
214834140|NCT00660387|DRUG|Placebo (PBO) oral capsules|
214834141|NCT00660387|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
214834142|NCT00660387|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
214834143|NCT00660387|DEVICE|J-tube|jejunal tube
214834144|NCT01251393|DRUG|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
214834145|NCT01251393|DRUG|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
214834146|NCT04729101|DRUG|Vonoprazan|Oral tablet
214834147|NCT04729101|DRUG|Lansoprazole|Oral capsule
214834148|NCT01948401|DRUG|LABA|long-acting beta-agonist treatment
214834149|NCT01948401|DRUG|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
214834150|NCT01948401|DRUG|prednisolone|additional 0.5 mg/kg orally for 7 days
214834151|NCT03241186|DRUG|Ipilimumab|1mg/kg
214834152|NCT03241186|DRUG|Nivolumab|3mg/kg
214834153|NCT03241186|DRUG|Nivolumab|480mg
214834154|NCT03037424|DRUG|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
214834155|NCT03037424|DRUG|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
214834156|NCT03086135|DEVICE|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
214834157|NCT00033436|DIETARY_SUPPLEMENT|niacinamide|
214834158|NCT00033436|DRUG|carbogen|
214834159|NCT00033436|RADIATION|radiation therapy|
214834160|NCT01639664|DEVICE|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
214834161|NCT00601406|GENETIC|gene expression analysis|
214834162|NCT00601406|GENETIC|gene rearrangement analysis|
214834163|NCT00601406|GENETIC|polymorphism analysis|
214834164|NCT00601406|OTHER|laboratory biomarker analysis|
214834165|NCT00601406|RADIATION|radiation therapy|
214834166|NCT00762411|DRUG|LY450139|Administered orally once daily.
214834167|NCT00762411|DRUG|Placebo|Administered orally once daily.
214834168|NCT01023061|DRUG|abiraterone acetate|Given PO
214834169|NCT01023061|DRUG|prednisone|Given PO
214834170|NCT01023061|DRUG|leuprolide acetate|Given via injection
214834171|NCT01023061|OTHER|laboratory biomarker analysis|Correlative study
214834172|NCT01023061|RADIATION|external beam radiation therapy|Undergo radiotherapy
214834173|NCT01023061|DRUG|goserelin acetate|Given via injection
214834174|NCT02959840|DEVICE|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
214834175|NCT02959840|DRUG|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
214834176|NCT02959840|DRUG|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
214834177|NCT02802462|BEHAVIORAL|HIT|3-minute intervals at 40% and 80%VO 2max
214834178|NCT02802462|BEHAVIORAL|MCT|sustained 60%VO 2max
214834179|NCT00003387|DRUG|carboplatin|
214834180|NCT00003387|DRUG|chemotherapy|
214834181|NCT00003387|DRUG|paclitaxel|
214834182|NCT00003387|RADIATION|radiation therapy|
214834183|NCT01853540|DRUG|Sildenafil|
214834184|NCT01663467|DRUG|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
214834185|NCT01663467|BEHAVIORAL|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
214834186|NCT00187265|DEVICE|Cardiac Resynchronization Therapy|
214834187|NCT02259348|DRUG|Cyclophosphamide|Given intravenously (IV)
214834188|NCT02259348|DRUG|Fludarabine|Given IV
214834189|NCT02259348|BIOLOGICAL|G-CSF|Given IV or subcutaneously (SQ)
214834190|NCT02259348|BIOLOGICAL|Interleukin-2|Given SQ
214834191|NCT02259348|DRUG|Melphalan|Given IV
214834192|NCT02259348|DRUG|Thiotepa|Given IV
214834193|NCT02259348|DRUG|Rituximab|Given IV
214834194|NCT02259348|BIOLOGICAL|Natural killer cell therapy|Given IV
214834195|NCT02259348|BIOLOGICAL|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
214834196|NCT02259348|BIOLOGICAL|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
214834197|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
214834198|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
214834199|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
214834200|NCT06677801|BIOLOGICAL|Telitacicept 160mg|Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
214834201|NCT02795026|PROCEDURE|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
214834202|NCT02795026|PROCEDURE|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
214834203|NCT04211766|DIETARY_SUPPLEMENT|Dietary Fiber|Given fiber supplement
214834204|NCT04211766|DIETARY_SUPPLEMENT|Fish Oil|Given fish oil supplement
214834205|NCT04211766|OTHER|Comparator|Given fiber supplement placebo
214834206|NCT04211766|OTHER|Comparator|Given fish oil supplement placebo (corn oil)
214834207|NCT06353750|OTHER|Magnesium supplement|Intravenous magnesium supplement (10mmol).
214834208|NCT03791541|BEHAVIORAL|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
214834209|NCT02299687|DRUG|Omeprazole|
214834210|NCT06375187|BIOLOGICAL|Engineering Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
214834211|NCT06407999|DEVICE|Expiratory Pressure Relief|EPR is a function used in CPAP intended to improve comfort by reducing delivered pressure during the expiratory phase. When EPR is not used, the patient receives true CPAP.
214834212|NCT03710707|DRUG|DNL201|Oral repeating dose
214834213|NCT03710707|DRUG|Placebo|Oral repeating dose
214834214|NCT01136928|DRUG|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
214834215|NCT02136706|PROCEDURE|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
214834216|NCT05302479|OTHER|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
214834217|NCT01159106|OTHER|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
214834218|NCT01159106|OTHER|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
214834219|NCT00063609|DRUG|zoledronic acid|
214834220|NCT06147414|BIOLOGICAL|Blood sample|"A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing."
214834221|NCT01858350|OTHER|Active Music Therapy|
214834222|NCT01858350|OTHER|Passive Music Therapy|
214834223|NCT01858350|OTHER|Distraction Therapy|
214834224|NCT05950217|OTHER|Education|Nurse-led patient education
214834225|NCT01632163|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
214834226|NCT01632163|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
214834227|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
214834228|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
214834229|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
214834230|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
214834231|NCT03512249|BIOLOGICAL|H56:IC31|5ug H56/500 nmol IC31
214834232|NCT03512249|BIOLOGICAL|Placebo|Sterile saline for injection
214834233|NCT02335372|PROCEDURE|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
214834234|NCT02335372|DRUG|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
214834235|NCT02335372|DRUG|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
214834236|NCT02335372|PROCEDURE|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
214834237|NCT03191838|OTHER|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
214834238|NCT03498924|DIAGNOSTIC_TEST|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
214834239|NCT06214637|DRUG|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
214834240|NCT06214637|DRUG|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
214834241|NCT06083987|BEHAVIORAL|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
214834242|NCT06083987|BEHAVIORAL|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
215031520|NCT05620134|DRUG|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
215031521|NCT05620134|DRUG|Pembrolizumab|Immune checkpoint inhibitor
215031522|NCT05620134|DRUG|Lenvatinib Pill|Multi-kinase inhibitor
215031523|NCT01765387|BEHAVIORAL|Spa session|
215031524|NCT02210676|OTHER|PROMIS Upper Extremity|
215031525|NCT02210676|OTHER|Likert Pain Scale|
215031526|NCT02210676|OTHER|Mallet Finger Extensor Lag Measurement|
214834243|NCT06083987|BEHAVIORAL|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
214834244|NCT06083987|BEHAVIORAL|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
214834245|NCT06083987|BEHAVIORAL|Control Group - No Interventions|Control Group - Will be given no interventions
214834246|NCT03686215|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
214834247|NCT00387205|DRUG|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
214834248|NCT02806609|OTHER|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
214834249|NCT02806609|OTHER|immersion in water at room temperature|immersion in water at room temperature
214834250|NCT02806609|OTHER|active recovery - running|active recovery
214834251|NCT02806609|OTHER|rest in the chair|rest in the chair
214834252|NCT00997477|DRUG|Foradil Combi (Formoterol-budesonide)|
214834253|NCT04125615|BEHAVIORAL|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
214834254|NCT01999088|OTHER|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
214834255|NCT01999088|OTHER|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
214834256|NCT06002178|DIAGNOSTIC_TEST|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
214834257|NCT05518227|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
214834258|NCT01883791|BEHAVIORAL|SBIRT|See above Arm description.
214834259|NCT01883791|BEHAVIORAL|Health Education|See Arm Description.
214834260|NCT00962494|BEHAVIORAL|Cancer: Thriving and Surviving Online Workshop|
214834261|NCT02485158|DRUG|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
214834262|NCT02485158|DRUG|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
214834263|NCT02485158|DRUG|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
214834264|NCT02485158|DRUG|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
214834265|NCT02485158|DRUG|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
214834266|NCT04282239|PROCEDURE|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
214834267|NCT04282239|DRUG|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
214834268|NCT04282239|DRUG|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
214834269|NCT04282239|DRUG|Dexmedetomidine 0.004 MG/ML|10 mL
214834270|NCT03001024|BEHAVIORAL|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
214834271|NCT03001024|BEHAVIORAL|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
214834272|NCT04086524|OTHER|Binocular cartoon treatment at home|see arm description.
214834273|NCT04086524|OTHER|Patching|see arm description
214834274|NCT04086524|OTHER|Binocular cartoon treatment in office|see arm description.
214834275|NCT04986124|OTHER|treatment as usual|No inervention. Treatment regime remains unchanged.
214834276|NCT02793713|PROCEDURE|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
214834277|NCT01133236|DIETARY_SUPPLEMENT|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
214834278|NCT00565513|PROCEDURE|blood test|cord blood and maternal milk test
214834279|NCT04618484|OTHER|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
214834280|NCT06617663|BEHAVIORAL|EMDR|Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.
214834281|NCT06617663|BEHAVIORAL|ACT|Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
214834282|NCT01034852|PROCEDURE|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
214834283|NCT05987085|OTHER|Diet and exercise|Routine intervention included diet control and exercise
214834284|NCT01134198|DRUG|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
214834285|NCT01134198|DRUG|placebo|placebo
214834286|NCT04768634|DIAGNOSTIC_TEST|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
214834287|NCT01813435|DRUG|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
214834288|NCT01813435|DRUG|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
214834289|NCT01813435|DRUG|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
214834290|NCT06081361|DRUG|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
214834291|NCT06081361|DRUG|Delamanid|Oral, 100mg bid
214834292|NCT06081361|DRUG|Contezolid|Oral, 800mg bid
214834293|NCT06081361|DRUG|Levofloxacin|Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg
214834294|NCT06081361|DRUG|Moxifloxacin|Oral, 400mg qd
214834295|NCT06081361|DRUG|Clofazimine|Oral, 100mg qd
214834296|NCT06081361|DRUG|Linezolid|Oral, 600mg qd
214834297|NCT06081361|DRUG|Cycloserine|Oral, 250mg bid
214834298|NCT06081361|DRUG|Prothionamide|Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg
214834299|NCT06081361|DRUG|Pyrazinamide|Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg
214834300|NCT06081361|DRUG|Para-Aminosalicylic Acid|8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg
214834301|NCT06081361|DRUG|Ethambutol|750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
214834302|NCT00399724|DRUG|Insulin glargine|
214834303|NCT03035890|RADIATION|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
214834304|NCT03035890|DRUG|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
214834305|NCT06793592|BEHAVIORAL|Behaviorally informed recruitment message|Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.
214834306|NCT06793592|BEHAVIORAL|Simplified direct message with no employer value proposition|Study participants will receive a simplified message that does not highlight any specific employer value proposition.
214834307|NCT06793592|BEHAVIORAL|No message|Study participants will not receive a recruitment message.
214834308|NCT06094842|DRUG|Bendamustine|Given IV
214834309|NCT06094842|PROCEDURE|Biopsy|Undergo tissue biopsy
214834310|NCT06094842|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214834311|NCT06094842|PROCEDURE|Bone Scan|Undergo bone scan
214834312|NCT06094842|PROCEDURE|Bridge Therapy|Undergo bridging therapy
214834313|NCT06094842|PROCEDURE|Computed Tomography|Undergo CT
214834314|NCT06094842|DRUG|Cyclophosphamide|Given IV
214834315|NCT06094842|PROCEDURE|Echocardiography|Undergo ECHO
214834316|NCT06094842|DRUG|Fludarabine|Given IV
214834317|NCT06094842|PROCEDURE|Leukapheresis|Undergo leukapheresis
214834318|NCT06094842|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214834319|NCT06094842|BIOLOGICAL|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
214834320|NCT06094842|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
214834321|NCT04375943|DRUG|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
214834322|NCT02012335|DRUG|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
214834323|NCT06298877|OTHER|Frailty and Quality of Life evaluation|Frailty and Quality of Life evaluation after surgery
214834324|NCT06187701|BEHAVIORAL|Co-Active Therapeutic Theatre (Co-ATT)|There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
214834325|NCT00361049|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
214834326|NCT00361049|GENETIC|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
214834327|NCT00361049|OTHER|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
214834328|NCT00361049|OTHER|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
214834329|NCT00361049|OTHER|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
214834330|NCT00361049|PROCEDURE|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
214834331|NCT00361049|PROCEDURE|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
214834332|NCT00343720|DRUG|VELCADE|
214834333|NCT00343720|DRUG|Alimta|
214834334|NCT00989053|DRUG|escitalopram|10 mg/d for a duration of 8 weeks
214834335|NCT00989053|DRUG|placebo|1 pill per day for 8 weeks
214834336|NCT00496990|BEHAVIORAL|Enhanced care|this group received counseling, contingency management and methadone or detoxification
214834337|NCT00496990|BEHAVIORAL|control|this group receives the opportunity to participate in a support group
214834338|NCT02160613|PROCEDURE|Open flap debridement|an access flap
214834339|NCT05073523|OTHER|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
214834340|NCT06278090|DRUG|Ursodeoxycholic Acid Only Product|Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
214834341|NCT00275249|DRUG|levorphanol|
214834342|NCT01490190|DRUG|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
214834343|NCT03522649|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
214834344|NCT03522649|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
214834345|NCT03522649|DRUG|Leucovorin|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
214834346|NCT03522649|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
214834347|NCT02560051|DRUG|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
214834348|NCT02560051|DRUG|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
214834349|NCT02560051|DRUG|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
214834350|NCT02560051|DRUG|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
214834351|NCT02560051|DRUG|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
214834352|NCT04152356|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
214834353|NCT04152356|DRUG|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
214834354|NCT00250354|DRUG|Risperidone oral solution|
214834355|NCT05174754|BEHAVIORAL|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
214834356|NCT05174754|DRUG|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
214834357|NCT02161263|OTHER|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
214834358|NCT02532192|DRUG|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
214834359|NCT02532192|DRUG|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
214834360|NCT02532192|DRUG|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
214834361|NCT02532192|DRUG|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
214834362|NCT02532192|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
214834363|NCT02532192|DRUG|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
214834364|NCT02532192|DRUG|Fluconazole|100 mg by mouth daily for 10 days.
214834365|NCT00307541|BIOLOGICAL|Pneumococcal (vaccine)|
214834366|NCT04632641|DEVICE|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
214834367|NCT04632641|OTHER|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
214834368|NCT02559843|DIETARY_SUPPLEMENT|pomegranate juice|
214834369|NCT02559843|BEHAVIORAL|lifestyle modification|
214834370|NCT04068818|DEVICE|ANTERION|Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
214834371|NCT04182555|DEVICE|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
214834372|NCT04182555|DIAGNOSTIC_TEST|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
214834373|NCT04182555|DEVICE|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
214834374|NCT04182555|OTHER|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
214834375|NCT03192813|DEVICE|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
214834376|NCT03192813|DEVICE|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
214834377|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing native palm olein|
214834378|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing interesterified palm olein|
214834379|NCT05280080|OTHER|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
214834380|NCT03673592|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
214834381|NCT04238962|DRUG|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
214834382|NCT04238962|DRUG|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
214834383|NCT02231957|OTHER|educational text message reminders|
214834384|NCT02231957|OTHER|conventional text message reminders|
214834385|NCT04654429|DRUG|IV Ondansetron 4mg|IV ondansetron 4mg
214834386|NCT04654429|OTHER|Higher OT temperature range|OT temperature set to 19-22 degree celsius
214834387|NCT04654429|DRUG|Placebo|IV Normal Saline 2cc will be given
214834388|NCT04654429|OTHER|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
214834389|NCT02817828|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
214834390|NCT00072514|DRUG|gemcitabine hydrochloride|Given IV
214834391|NCT00072514|DRUG|carboplatin|Given IV
214834392|NCT00072514|DRUG|dexamethasone|Given PO
214834393|NCT00072514|BIOLOGICAL|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
214834394|NCT01380613|BEHAVIORAL|Workshop|10 session intervention
214834395|NCT01380613|BEHAVIORAL|Workshop control|1 session intervention on standard HIV/STD information
214834396|NCT02207764|BEHAVIORAL|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
214834397|NCT01528293|DEVICE|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
214834398|NCT01528293|OTHER|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
214834399|NCT06447753|PROCEDURE|Direct pulp capping|after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
214834400|NCT06447753|PROCEDURE|Complete Pulpotomy|exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
214834401|NCT01937806|DRUG|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
214834402|NCT01937806|DRUG|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
214834403|NCT00856349|BEHAVIORAL|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
214834404|NCT04323215|DEVICE|Support system|A support system named Provement will be used to provide behavioral treatment.
214834405|NCT01415596|DRUG|salbutamol|
214834406|NCT01415596|DRUG|Placebo|
214834407|NCT02832466|OTHER|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
214834408|NCT03887598|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
214834409|NCT00432705|PROCEDURE|Checking stability of ankle|Flexing and walking
214834410|NCT01388998|OTHER|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
214834411|NCT06677736|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
214834412|NCT06677736|RADIATION|Diode laser as adjunctive to conventional scaling and debridement|Diode laser as adjunctive to conventional scaling and debridement
214834413|NCT05061992|DRUG|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
214834414|NCT06535763|OTHER|professional caregiver|"Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist."
214834415|NCT01157234|DRUG|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.
214834416|NCT01157234|DRUG|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
214834417|NCT02531490|DRUG|Labetalol|
214834418|NCT02531490|DRUG|Nifedipine|
214834419|NCT02531490|DRUG|Methyldopa|
214834420|NCT06113913|DRUG|Infliximab|Weekly administration of subcutaneous infliximab.
214834421|NCT06113913|DRUG|Infliximab|Bi-weekly administration of subcutaneous infliximab.
214834422|NCT06113913|DRUG|Infliximab|Optimized dosing schedule of intravenous infliximab.
214834423|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
214834424|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
214834425|NCT04918992|DIAGNOSTIC_TEST|Artificial Intelligence|investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy
214834426|NCT05190432|DIETARY_SUPPLEMENT|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
214834427|NCT05190432|DIETARY_SUPPLEMENT|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
214834428|NCT05190432|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose.
214834429|NCT06548243|BEHAVIORAL|Act with Nature Programme|The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
214834430|NCT06537869|BEHAVIORAL|iCBT for depression|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
214834431|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
214834432|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
214834433|NCT03957928|OTHER|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
214834434|NCT03957928|OTHER|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
214834435|NCT06794229|DRUG|Zanzalintinib|Zanzalintinib 100mg orally (PO) once daily for 12 weeks up (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1)
214834436|NCT06794229|DRUG|Nivolumab|Nivolumab will be administered at either 240mg IV every 2 weeks or 480mg IV 4 every weeks for 12 weeks (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1).
214834437|NCT06221670|DRUG|Toripalimab|This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
214834438|NCT06624735|DIAGNOSTIC_TEST|psychometry|ADHD test and measurement of IQ level
214834439|NCT06559202|DIAGNOSTIC_TEST|chest and abdominoplevic CT|chest and abdominopelvic computed tomography on the same day for health screening purposes
214834440|NCT04097041|PROCEDURE|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
214834441|NCT04097041|PROCEDURE|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
214834442|NCT04808908|BIOLOGICAL|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
214834443|NCT01095887|DRUG|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
214834444|NCT02146690|OTHER|osteopathic manipulative treatment|
214834445|NCT02146690|OTHER|sham therapy|
214834446|NCT02146690|OTHER|usual care|
214834447|NCT06106152|DRUG|WTX212A injection|The WTX212A infusion is given every 21 days
214834448|NCT06106152|DRUG|PD -1/PD-L1 monoclonal antibody|The PD -1/PD-L1 monoclonal antibody is given every 21 days
214834449|NCT00352807|DRUG|Brimonidine Purite|
214834450|NCT00287053|DRUG|divalproex sodium|Divalproex sodium vs. placebo
214834451|NCT00234780|PROCEDURE|pediatric nursing used in home to avoid hospitalization|
214834452|NCT04604210|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
214834453|NCT03547414|OTHER|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2\*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
214834454|NCT03960801|DRUG|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
214834455|NCT03960801|DRUG|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
214834456|NCT02542462|DRUG|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
214834457|NCT02542462|DRUG|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
214834458|NCT02542462|DRUG|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
214834459|NCT02542462|DRUG|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
214834460|NCT05823662|PROCEDURE|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
214834461|NCT05823662|DRUG|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
214834462|NCT01146080|DEVICE|Promus Element|Promus Element implanted to treat coronary artery lesions.
214834463|NCT01146080|DEVICE|Promus|Promus stent implanted to treat coronary artery lesions
214834464|NCT01899833|DIAGNOSTIC_TEST|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
214834465|NCT02779933|OTHER|Epidemiology od HAP|no intervention
214834466|NCT05266287|DIETARY_SUPPLEMENT|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
214834467|NCT05266287|DIETARY_SUPPLEMENT|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
214834468|NCT01531816|DEVICE|Early Rehabilitation intervention|"1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
214834469|NCT02374216|PROCEDURE|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
214834470|NCT00493883|DEVICE|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
214834471|NCT05904639|GENETIC|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
214834472|NCT00397254|DRUG|rizatriptan|10mg ODT 27 tablets
214834473|NCT00397254|DRUG|rizatriptan|10mg ODT 9 tablets
214834474|NCT04153318|DEVICE|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
214834475|NCT05214144|OTHER|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~* PRO-CTCAE (approximately 11 questions plus free text)~* Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~* PRO ECOG question (1 question)~* EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~* Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~* The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
214834476|NCT05214144|OTHER|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
214834477|NCT05214144|DEVICE|Fitbit|wearable device
214834478|NCT05214144|OTHER|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
214834479|NCT05214144|OTHER|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
214834480|NCT01632449|DRUG|Test product|Dimethyl Fumarate (BG00012)
214834481|NCT01632449|DRUG|Reference product|Dimethyl Fumarate (BG00012)
214834482|NCT02212236|OTHER|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
214834483|NCT04881188|DIAGNOSTIC_TEST|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
214834484|NCT02233374|OTHER|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
214834485|NCT02233374|OTHER|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
214834486|NCT02102815|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
214834487|NCT02102815|DRUG|Normal saline|NSS 50 mL IV slowly push over 5 minutes
214834488|NCT02340780|DRUG|Buparlisib|
214834489|NCT00310492|BIOLOGICAL|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
214834490|NCT05857345|OTHER|Collection of breastmilk|Collection of breastmilk and other information about the participant
214834491|NCT02924649|PROCEDURE|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
214834492|NCT01733576|DEVICE|HD-tDCS|
214834493|NCT03109041|DEVICE|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
214834494|NCT02593019|DRUG|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
214834495|NCT05311150|DEVICE|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
214834496|NCT05311150|DEVICE|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
214834497|NCT02798406|BIOLOGICAL|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
214834498|NCT02798406|BIOLOGICAL|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
214834499|NCT02671877|PROCEDURE|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
214834500|NCT03212378|OTHER|percutaneous coronary interventions|Percutaneous coronary intervention.
214834501|NCT04273438|DEVICE|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
214834502|NCT04273438|DEVICE|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
214834503|NCT01516762|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
214834504|NCT00066391|DRUG|cisplatin|
214834505|NCT00066391|DRUG|irinotecan hydrochloride|
214834506|NCT00066391|PROCEDURE|neoadjuvant therapy|
214834507|NCT04292548|DIAGNOSTIC_TEST|taking saliva samples to determine TAS, TOS and LL-37|
214834508|NCT02181140|DEVICE|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
214834509|NCT04462198|DRUG|PIPE-505|Intratympanic injection
214834510|NCT04462198|DRUG|Placebo|Intratympanic injection
214834511|NCT04251091|OTHER|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
214834512|NCT04251091|OTHER|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
214834513|NCT03449680|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
214834514|NCT03449680|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
214834515|NCT05284877|OTHER|No intervention|The study is an observational study without intervention.
214834516|NCT01221051|PROCEDURE|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
214834517|NCT01221051|PROCEDURE|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
214834518|NCT05626023|DRUG|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
214834519|NCT02902133|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
214834520|NCT05887687|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
214834521|NCT06385548|DRUG|Lurbinectedin|participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
214834522|NCT06385548|DRUG|Dostarlimab|participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
214834523|NCT05426200|BEHAVIORAL|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
214834524|NCT05139238|DRUG|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
214834525|NCT05139238|DRUG|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
214834526|NCT04301258|OTHER|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
214834527|NCT04710823|PROCEDURE|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
214834528|NCT04710823|PROCEDURE|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
214834529|NCT03736577|OTHER|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
214834530|NCT04703933|OTHER|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
214834531|NCT05429463|BIOLOGICAL|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
214834532|NCT05429463|DRUG|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
214834533|NCT05429463|DRUG|Albumin-Bound Paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
214834534|NCT02582554|BEHAVIORAL|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
215031527|NCT06114368|PROCEDURE|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
215031528|NCT02236013|DRUG|Gilteritinib|Oral
215031529|NCT02236013|DRUG|Idarubicin|lyophilized powder administered intravenously
214834535|NCT04022122|PROCEDURE|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
214834536|NCT06560866|BEHAVIORAL|Just Care for Families|Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
214834537|NCT03431961|DRUG|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
214834538|NCT03431961|DRUG|Placebo|twice daily for 14 days
214834539|NCT04509648|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
214834540|NCT05280288|DEVICE|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
214834541|NCT03204851|DEVICE|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
214834542|NCT01852721|BEHAVIORAL|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
214834543|NCT01852721|BEHAVIORAL|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
214834544|NCT00001191|DRUG|Pantoprazole|
214834545|NCT00001191|DRUG|Omeprazole|
214834546|NCT03426657|COMBINATION_PRODUCT|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
214834547|NCT02671630|OTHER|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
214834548|NCT05722496|OTHER|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
214834549|NCT03108235|BEHAVIORAL|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
214834550|NCT03108235|BEHAVIORAL|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
214834551|NCT03108235|BEHAVIORAL|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
214834552|NCT05954663|OTHER|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
214834553|NCT01537718|DEVICE|REPLY 200|REPLY 200 pacemaker
215031530|NCT02236013|DRUG|Cytarabine|solution administered intravenously
215031531|NCT02236013|DRUG|Daunorubicin|solution administered intravenously
215031532|NCT00417287|DRUG|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
214834554|NCT06628011|OTHER|Intervention group/training group|We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
214834555|NCT02344550|DRUG|Everolimus(afinitor)|Everolimus 10mg p.o. daily
214834556|NCT02344550|DRUG|Letrozole|Letrozole 2.5 mg p.o. daily
214834557|NCT02344550|DRUG|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
214834558|NCT03680001|BEHAVIORAL|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
214834559|NCT01884701|DEVICE|ENABLER-P Catheter System|
214834560|NCT05995769|DRUG|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
214834561|NCT05649358|DEVICE|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
214834562|NCT04821232|OTHER|yoga|"Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
214834563|NCT04821232|OTHER|Routin control|Students will be checked on a routine basis
214834564|NCT03161197|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
214834565|NCT00582205|DRUG|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
214834566|NCT02107469|DRUG|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
214834567|NCT02107469|DRUG|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
214834568|NCT02107469|DRUG|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
214834569|NCT02107469|DRUG|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
214834570|NCT02107469|OTHER|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
214834571|NCT02107469|OTHER|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
214834572|NCT01055834|DRUG|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
214834573|NCT01055834|DRUG|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
214834574|NCT04170335|PROCEDURE|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
214834575|NCT00198835|BEHAVIORAL|Maternal nutrition and infant feeding advice|
214834576|NCT03528486|BEHAVIORAL|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
214834577|NCT03333863|OTHER|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
214834578|NCT03259841|OTHER|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
214834579|NCT01717313|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
214834580|NCT01717313|DRUG|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
215031533|NCT04665895|DRUG|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
214834581|NCT01717313|DRUG|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
214834582|NCT01717313|DRUG|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
214834583|NCT01717313|DRUG|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
214834584|NCT02134821|PROCEDURE|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
214834585|NCT00276536|BIOLOGICAL|recombinant interferon alpha-1b|interferon
214834586|NCT00276536|DRUG|IFN|IFN daily
214834587|NCT06069037|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
214834588|NCT00002253|DRUG|Octreotide|
214834589|NCT02155153|OTHER|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
214834590|NCT01800838|DRUG|silicon phthalocyanine 4|Given topically
214834591|NCT01800838|DRUG|photodynamic therapy|Undergo PDT
214834592|NCT01800838|OTHER|pharmacological study|Correlative studies
214834593|NCT01800838|OTHER|laboratory biomarker analysis|Correlative studies
214834594|NCT05553444|BEHAVIORAL|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
214834595|NCT02606032|DRUG|Metronidazole|active comparator
214834596|NCT02606032|DRUG|Doxycycline|active comparator
214834597|NCT02606032|DRUG|Terbinafine|active comparator
214834598|NCT02606032|DRUG|Placebo|identical placebos to all antibiotics
214834599|NCT00835588|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
214834600|NCT00835588|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
214834601|NCT04143607|DRUG|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
214834602|NCT04143607|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
214834603|NCT04143607|DRUG|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
214834604|NCT04143607|DRUG|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
214834605|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
214834606|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
214834607|NCT01662050|DRUG|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
214834608|NCT06301386|DRUG|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
214834609|NCT06301386|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
214834610|NCT03181386|DRUG|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
214834611|NCT03181386|DRUG|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
214834612|NCT03181386|DRUG|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
214834613|NCT06422286|DEVICE|low-level laser|children will be allocated to the device then the gag reflex will be re-evaluated
214834614|NCT06422286|BIOLOGICAL|microcurrent stimulation|children will be allocated to the device then the gag reflex will be re-evaluated
214834615|NCT06422286|DEVICE|placebo|children will be allocated to a deactivated meridian pen
214834616|NCT05054777|PROCEDURE|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
214834617|NCT05054777|PROCEDURE|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
214834618|NCT03472196|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
214834619|NCT06347627|BEHAVIORAL|Group 1 (I x S x S x F)|Experimental message: Individual x Safety x Storytelling x Factual
214834620|NCT06347627|BEHAVIORAL|Group 2 (O x S x S x F)|Experimental message: Organization x Safety x Storytelling x Factual
214834621|NCT06347627|BEHAVIORAL|Group 3 (I x E x S x F)|Experimental message: Individual x Effectiveness x Storytelling x Factual
214834622|NCT06347627|BEHAVIORAL|Group 4 (O x E x S x F)|Experimental message: Organization x Effectiveness x Storytelling x Factual
214834623|NCT06347627|BEHAVIORAL|Group 5 (I x S x S x M)|Experimental message: Individual x Safety x Storytelling x Misinformation
214834624|NCT06347627|BEHAVIORAL|Group 6 (O x S x S x M)|Experimental message: Organization x Safety x Storytelling x Misinformation
214834625|NCT06347627|BEHAVIORAL|Group 7 (I x E x S x M)|Experimental message: Individual x Effectiveness x Storytelling x Misinformation
214834626|NCT06347627|BEHAVIORAL|Group 8 (O x E x S x M)|Experimental message: Organization x Effectiveness x Storytelling x Misinformation
214834627|NCT06347627|BEHAVIORAL|Group 9 (I x S x D x F)|Experimental message: Individual x Safety x Scientific data x Factual
214834628|NCT06347627|BEHAVIORAL|Group 10 (O x S x D x F)|Experimental message: Organization x Safety x Scientific data x Factual
214834629|NCT06347627|BEHAVIORAL|Group 11 (I x E x D x F)|Experimental message: Individual x Effectiveness x Scientific data x Factual
214834630|NCT06347627|BEHAVIORAL|Group 12 (O x E x D x F)|Experimental message: Organization x Effectiveness x Scientific data x Factual
214834631|NCT06347627|BEHAVIORAL|Group 13 (I x S x D x M)|Experimental message: Individual x Safety x Scientific data x Misinformation
214834632|NCT06347627|BEHAVIORAL|Group 14 (O x S x D x M)|Experimental message: Organization x Safety x Scientific data x Misinformation
214277624|NCT01355926|OTHER|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
214834633|NCT06347627|BEHAVIORAL|Group 15 (I x E x D x M)|Experimental message: Individual x Effectiveness x Scientific data x Misinformation
214834634|NCT06347627|BEHAVIORAL|Group 16 (O x E x D x M)|Experimental message: Organization x Effectiveness x Scientific data x Misinformation
214834635|NCT01617096|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
214834636|NCT01617096|COMBINATION_PRODUCT|Placebo Ring|Vaginal ring containing no drug substance
214834637|NCT03612973|DIAGNOSTIC_TEST|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
214834638|NCT03612973|DIAGNOSTIC_TEST|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
214834639|NCT03612973|DIAGNOSTIC_TEST|fibro scan|liver stiffness by fibro scan before and after treatment
214834640|NCT03892343|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
214834641|NCT01753362|DRUG|liraglutide|
214834642|NCT01753362|DRUG|placebo|
214834643|NCT03921762|PROCEDURE|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
214834644|NCT03921762|PROCEDURE|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
214834645|NCT03040895|OTHER|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
214834646|NCT03040895|OTHER|Treatment as usual|Treatment as usual through the data collection period (6 months)
214834647|NCT05535920|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
214834648|NCT01485068|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
214834649|NCT04473326|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
214834650|NCT02840162|DRUG|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
214834651|NCT02840162|DRUG|Placebo|
214834652|NCT04233060|DRUG|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
214834653|NCT02611362|BEHAVIORAL|IMB Gaming Intervention|
214834654|NCT05972590|OTHER|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
214834655|NCT01274143|BEHAVIORAL|TeleCARE|Personalized telephone-delivered cancer risk assessment.
214834656|NCT01274143|BEHAVIORAL|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
214834657|NCT00948480|BIOLOGICAL|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
214834658|NCT00948480|DRUG|GM-CSF|500 mcg
214834659|NCT03146143|PROCEDURE|ultrafiltration|ultrafiltration after cardiopulmonary bypass
214834660|NCT03103594|DRUG|DMSO|DMSO will be instilled intravesically.
214834661|NCT03103594|DRUG|Botox|Botox will be instilled intravesically with DMSO.
214834662|NCT02325180|DRUG|Dihydroartemisinin-Piperaquine|
214834663|NCT02325180|DRUG|Artemether-lumefantrine|
214834664|NCT00854126|DRUG|GDC-0980|Escalating repeating dose
214834665|NCT00464594|BEHAVIORAL|Standard lifestyle guidance|
214834666|NCT00464594|DRUG|Lifestyle guidance and monotherapy with acarbose|
214834667|NCT00464594|DRUG|Lifestyle guidance and monotherapy with metformin|
214834668|NCT00464594|DRUG|Lifestyle guidance and monotherapy with gliclazide|
214834669|NCT01155531|DRUG|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
214834670|NCT03357380|DRUG|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
214834671|NCT03357380|DRUG|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
214834672|NCT00354159|DEVICE|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
214834673|NCT05343273|DIAGNOSTIC_TEST|taking a blood sample|blood collection for routine biochemical analysis
214834674|NCT02364531|OTHER|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
214834675|NCT05907694|PROCEDURE|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
214834676|NCT05907694|DRUG|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
214834677|NCT00870129|PROCEDURE|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
214834678|NCT01627639|DRUG|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
214834679|NCT01627639|DRUG|Placebo|Placebo
214834680|NCT02046122|DRUG|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
214834681|NCT02046122|DRUG|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
214834682|NCT02046122|BIOLOGICAL|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
214834683|NCT01667822|BEHAVIORAL|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
215031534|NCT04665895|DRUG|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
215031535|NCT04665895|DRUG|Placebo|twice daily inhalation throughout the study
214834684|NCT01667822|BEHAVIORAL|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
214834685|NCT00048139|DRUG|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
214834686|NCT00048139|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
214834687|NCT02544139|OTHER|Chagas Detect Plus|
214834688|NCT05419739|OTHER|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
214834689|NCT05719467|DRUG|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
214834690|NCT05719467|DRUG|Sodium bicarbonate|4 g orally
214834691|NCT05719467|DRUG|Placebo|4g orally
214834692|NCT05719467|DRUG|Nacl 0.9%|1 mL intravenously
214834693|NCT03795441|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
214834694|NCT00397657|DRUG|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
214834695|NCT00397657|DRUG|ezetimibe|Ezetimibe 10mg once daily
214834696|NCT00795158|DRUG|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
214834697|NCT00694044|DRUG|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
214834698|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
214834699|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
214834700|NCT00694044|DRUG|Placebo|Placebo for 21 days
214834701|NCT01653704|BEHAVIORAL|observational role|observational role in crisis scenario
214834702|NCT01653704|BEHAVIORAL|active role|active role in managing crisis scenario
214834703|NCT05428696|DRUG|ALXN2080|Powder-in-capsule
214834704|NCT05428696|DRUG|Placebo|Powder-in-capsule
214834705|NCT06256224|DRUG|Toripalimab|Toripalimab combined with CCRT
214834706|NCT06256224|RADIATION|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
214834707|NCT02928744|OTHER|COPD|Plethysmography
214834708|NCT02928744|OTHER|COPD|Forced oscillations
214834709|NCT05128058|DRUG|Ritlecitinib 50 mg|50 mg single dose
214834710|NCT05128058|DRUG|Ritlecitinib 200 mg|200 mg single dose
214834711|NCT01728116|DEVICE|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
214834712|NCT01728116|PROCEDURE|Sham Procedure|Endoscopic evaluation but no device placement
214834713|NCT04132063|DRUG|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
214834714|NCT05689541|OTHER|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
214834715|NCT06449703|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
214834716|NCT06449703|DRUG|Xultophy®|Xultophy®
214834717|NCT01532908|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
214834718|NCT01532908|DRUG|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
214834719|NCT01532908|DRUG|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
214834720|NCT05702255|OTHER|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
214834721|NCT05702255|OTHER|Sham acuptressure|The same protocol as the active acupressure group.
214834722|NCT06232837|DEVICE|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
214834723|NCT02588911|PROCEDURE|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
214834724|NCT02588911|PROCEDURE|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
214834725|NCT00513253|DRUG|lapatinib|
214834726|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
214834727|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
214834728|NCT02519153|DRUG|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
214834729|NCT04766905|PROCEDURE|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
214834730|NCT00273013|DRUG|GW274150|GW274150 will be available as 30 mg white oval tablets.
214834731|NCT00273013|DRUG|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
214834732|NCT00273013|DRUG|Placebo|Matching placebo for Singulair and GW274150 will be available.
214834733|NCT02218398|DRUG|Albuterol|
214834734|NCT04651335|DEVICE|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
214834735|NCT04651335|DEVICE|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
214834736|NCT04610580|DRUG|ALXN1840|ALXN1840 will be administered orally.
214834737|NCT04122027|OTHER|Cerebral oximeter|Near infra-red spectroscopy, NIRS
214834738|NCT05586386|OTHER|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
214834739|NCT05586386|OTHER|Placebo group|200 mL of placebo juice twice/day
214834740|NCT01097694|DRUG|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
214834741|NCT01097694|DRUG|Placebo|Placebo
214834742|NCT03067935|DRUG|glembatumumab vedotin|
214834743|NCT05901116|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
214834744|NCT01861990|DRUG|Valproic Acid|All participants enrolled on valproic acid arm.
214834745|NCT06288217|DEVICE|NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)|Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
214834746|NCT06288217|OTHER|Upper Limb Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
214834747|NCT06288217|OTHER|Sham Stimulation|Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
214834748|NCT01599689|OTHER|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
214834749|NCT05193734|DRUG|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
214834750|NCT05193734|DRUG|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
214834751|NCT04986098|DEVICE|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
214277625|NCT01355926|OTHER|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
214834752|NCT04986098|DRUG|Paclitaxel|Paclitaxel
214834753|NCT03621046|DRUG|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
214834754|NCT03621046|OTHER|Placebo|Placebo
214834755|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
214834756|NCT04238195|DRUG|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
214834757|NCT04238195|OTHER|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
214834758|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
215031536|NCT02513251|OTHER|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
214834759|NCT04817995|BEHAVIORAL|FOREST|Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
214834760|NCT01609270|DEVICE|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
214834761|NCT04320745|DRUG|Androderm®|Androderm® transdermal dose.
214834762|NCT00095160|DRUG|852A|
214834763|NCT02004691|DRUG|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
214834764|NCT02004691|DRUG|Olipudase alfa|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
214834765|NCT01449409|OTHER|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
214834766|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
214834767|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
214834768|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
214834769|NCT03084562|OTHER|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
214834770|NCT03454490|PROCEDURE|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
214834771|NCT05881733|DEVICE|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
214834772|NCT01127776|DEVICE|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
214834773|NCT01127776|OTHER|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
214834774|NCT01320722|DRUG|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
214834775|NCT01320722|DRUG|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
214834776|NCT01320722|DRUG|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
214834777|NCT01320722|DRUG|Placebo|Placebo soft gel once per week for 8 weeks
214834778|NCT01320722|DRUG|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
214834779|NCT02806063|PROCEDURE|intraoperative samples|
214277626|NCT02633605|DEVICE|First Sense Medical®|
214277627|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
214277628|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
214834780|NCT00021541|DRUG|tipifarnib|Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
214834781|NCT00021541|OTHER|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
214834782|NCT04003441|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
214834783|NCT04003441|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
214834784|NCT02392858|OTHER|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
214834785|NCT01927016|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
214834786|NCT02298387|DRUG|OMP-305B83|intravenous (in the vein) infusions
214834787|NCT02570854|BIOLOGICAL|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
214834788|NCT02570854|DRUG|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
214834789|NCT02498938|GENETIC|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
214834790|NCT04443049|DRUG|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
214834791|NCT04443049|DRUG|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
214834792|NCT04443049|OTHER|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
214834793|NCT06017427|OTHER|Questionnaires|Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
214834794|NCT03141580|DIAGNOSTIC_TEST|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
214834795|NCT02103101|OTHER|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
214834796|NCT02103101|GENETIC|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
214834797|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
214834798|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
214834799|NCT03407729|OTHER|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
214834800|NCT03407729|OTHER|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
214834801|NCT01145157|DEVICE|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
214834802|NCT01145157|DEVICE|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
214834803|NCT01145157|DEVICE|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
214834804|NCT00002367|DRUG|Saquinavir|
214834805|NCT00002367|DRUG|Lamivudine|
214834806|NCT00002367|DRUG|Zidovudine|
214834807|NCT03252990|DIAGNOSTIC_TEST|PET-MRI|Additional 18F-choline PET-MRI examination
214834808|NCT03252990|PROCEDURE|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
214834809|NCT00236886|DRUG|topiramate|
214834810|NCT04142658|DRUG|Apixaban 5 MG|"For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
214834811|NCT04142658|DRUG|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
214834812|NCT04142658|DRUG|Warfarin|Active Control Intervention
214834813|NCT04142658|DEVICE|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
214834814|NCT02943096|DIETARY_SUPPLEMENT|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
214834815|NCT02943096|OTHER|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
214834816|NCT05772858|OTHER|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
214834817|NCT05772858|OTHER|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
214834818|NCT05772858|OTHER|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
214834819|NCT05772858|OTHER|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
214834820|NCT05772858|OTHER|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
214834821|NCT06202534|OTHER||radiotherapy
214834822|NCT03258996|PROCEDURE|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
214834823|NCT03258996|PROCEDURE|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
214834824|NCT05921812|DIAGNOSTIC_TEST|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
214834825|NCT00709514|DRUG|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
214834826|NCT00709514|DRUG|Placebo|Placebo
214834827|NCT02707016|OTHER|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
214834828|NCT02707016|OTHER|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
214834829|NCT02413008|DRUG|estriol|0.005% estriol vaginal gel
214834830|NCT02413008|DRUG|Placebo|placebo vaginal gel
214834831|NCT04387617|DRUG|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
214834832|NCT04387617|DRUG|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
214834833|NCT06361355|BIOLOGICAL|Post-change CMAB807|for subcutaneous injection only
214834834|NCT06361355|BIOLOGICAL|Prolia|for subcutaneous injection only
214834835|NCT05074706|BIOLOGICAL|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
214834836|NCT05074706|BIOLOGICAL|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
214834837|NCT00939523|DRUG|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
214834838|NCT03483350|DRUG|Granisetron|Ampoule
214834839|NCT03483350|DRUG|Midazolam|Ampoule
214834840|NCT04733313|PROCEDURE|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
214834841|NCT00201136|BEHAVIORAL|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
214834842|NCT00201136|BEHAVIORAL|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
214834843|NCT00024258|DRUG|arsenic trioxide|
214834844|NCT00870935|PROCEDURE|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
214834845|NCT00870935|PROCEDURE|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
214834846|NCT01625390|DRUG|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
214834847|NCT01625390|DRUG|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
214834848|NCT01625390|DRUG|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
214834849|NCT05418790|DEVICE|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
214834850|NCT06618638|BEHAVIORAL|Shared decision making model|Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
214834851|NCT06618638|BEHAVIORAL|Usual Care|Usual care for ADPKD patients
214834852|NCT04520243|DIAGNOSTIC_TEST|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
214834853|NCT02026479|DRUG|Dexamethasone Phosphate|5mg; postauricular injection
214834854|NCT02026479|DRUG|Dexamethasone Phosphate|10mg; postauricular injection
214834855|NCT02026479|DRUG|Ginaton|40mg/pill, 3times/day,oral
214834856|NCT02697708|DIETARY_SUPPLEMENT|Potassium control diet|No additional potassium.
214834857|NCT02697708|DIETARY_SUPPLEMENT|Potassium gluconate diet|1000 mg K from potassium gluconate.
214834858|NCT02697708|DIETARY_SUPPLEMENT|Potato Diet|1000 mg K from potatoes.
214834859|NCT02697708|DIETARY_SUPPLEMENT|French Fries Diet|1000 mg K from French Fries.
214834860|NCT06293352|DEVICE|All-cement articulating spacer|Two-stage intervention
214834861|NCT06293352|DEVICE|Durable, real-component articulating spacer|Single stage intervention
214834862|NCT06293352|DEVICE|Rigid Spacer|Observation intervention
214834863|NCT01050764|DRUG|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg"
214834864|NCT01050764|DRUG|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
214834865|NCT01050764|DRUG|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
214834866|NCT01050764|DRUG|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
214834867|NCT01050764|DEVICE|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
214834868|NCT01050764|DRUG|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
214834869|NCT01050764|DRUG|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
214834870|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
214834871|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
214834872|NCT02312037|BIOLOGICAL|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles~2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
214834873|NCT06324305|PROCEDURE|Pars plana vitrectomy (PPV) and drainage of subretinal fluid|Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
214834874|NCT04552405|DIETARY_SUPPLEMENT|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
214834875|NCT06248645|DRUG|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
214834876|NCT06248645|DRUG|Placebo|High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
214834877|NCT00351117|DRUG|St. John's Wort|SJW in capsule form 300 mg PO TID
214834878|NCT00351117|DRUG|Lactose|lactose in gelatin capsule that same as St. John's wort
214834879|NCT03045627|DRUG|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
214834880|NCT03045627|DRUG|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
214834881|NCT03045627|DRUG|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
214834882|NCT03045627|DRUG|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
214834883|NCT05523960|PROCEDURE|No MBP|No mechanical bowel preparation before operation
214834884|NCT03757468|DEVICE|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
214834885|NCT00943865|BEHAVIORAL|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
214834886|NCT00943865|BEHAVIORAL|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
214834887|NCT00943865|BEHAVIORAL|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
214834888|NCT00943865|BEHAVIORAL|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
214834889|NCT00943865|BEHAVIORAL|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
214834890|NCT01352052|OTHER|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
214834891|NCT02119936|BEHAVIORAL|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
214834892|NCT00570128|DRUG|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
214834893|NCT00570128|DRUG|Placebo|Liquid formulation matched to active treatment for oral administration.
214834894|NCT05191745|DRUG|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
214834895|NCT05191745|DRUG|Standard of care|All standard management of postoperative pain, as per local protocols
214834896|NCT05886127|DEVICE|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
214834897|NCT01620281|DEVICE|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
214834898|NCT04912063|DRUG|Lemzoparlimab|Intravenous (IV) Infusion
214834899|NCT04912063|DRUG|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
214834900|NCT04912063|DRUG|Venetoclax|Oral Tablet
214834901|NCT03092414|PROCEDURE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
214834902|NCT03092414|PROCEDURE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
214834903|NCT04194008|DEVICE|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214834904|NCT01144845|PROCEDURE|Thoracic surgery|Thoracoscopy or anterior thoracotomy
214834905|NCT02725060|DRUG|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
214834906|NCT02725060|DRUG|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
214834907|NCT02725060|RADIATION|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
214834908|NCT02725060|PROCEDURE|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
214834909|NCT02725060|PROCEDURE|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
214834910|NCT02725060|PROCEDURE|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
214834911|NCT02725060|PROCEDURE|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
214834912|NCT02725060|OTHER|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
214834913|NCT02725060|OTHER|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
214834914|NCT02725060|PROCEDURE|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
214834915|NCT00652002|DRUG|budesonide/formoterol|
214834916|NCT00652002|DRUG|budesonide|
214834917|NCT00652002|DRUG|formoterol|
214834918|NCT02411149|DRUG|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
214834919|NCT02411149|DRUG|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
214834920|NCT02411149|DRUG|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
214834921|NCT04427033|DEVICE|Bone Conduction Implant|Bonebridge system BCI 602
214834922|NCT05999734|DRUG|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
214834923|NCT06066671|OTHER|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
214834924|NCT03354780|OTHER|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
214834925|NCT03354780|OTHER|Survey on first pregnancy|rate of miscarriage was noted
214834926|NCT04544033|DIAGNOSTIC_TEST|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
214834927|NCT04544033|DIAGNOSTIC_TEST|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
214834928|NCT01301937|DRUG|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
214834929|NCT00980941|DIETARY_SUPPLEMENT|soup with or without starch|
214834930|NCT05608239|DEVICE|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
214834931|NCT05064917|DIAGNOSTIC_TEST|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
214834932|NCT03193021|DEVICE|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
214834933|NCT03193021|OTHER|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
214834934|NCT03680144|PROCEDURE|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
214834935|NCT03680144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
214834936|NCT00461435|PROCEDURE|hyperbaric oxygen therapy|
214834937|NCT05014958|OTHER|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
214834938|NCT01226953|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
214834939|NCT03911635|PROCEDURE|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
214834940|NCT01139762|DRUG|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
214834941|NCT01139762|DRUG|Placebo|Administered orally, once daily for 26 weeks
214834942|NCT01139762|DRUG|Finasteride|5mg administered orally, once daily for 26 weeks
214834943|NCT00621660|PROCEDURE|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
214834944|NCT00621660|PROCEDURE|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
214834945|NCT05546060|DRUG|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
214834946|NCT05546060|DRUG|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
214834947|NCT05546060|DRUG|Etoposide|Etoposide 75mg/m2 qw d1-56
214834948|NCT04190160|DRUG|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
214834949|NCT03510260|OTHER|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
214834950|NCT03510260|OTHER|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
214834951|NCT03510260|OTHER|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
214834952|NCT02614196|DRUG|Galcanezumab|Administered SC
214834953|NCT02614196|DRUG|Placebo|Administered SC
214834954|NCT03790163|DRUG|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
214834955|NCT05965908|DRUG|liraglutide|glucagon-like peptide 1 receptor agonist
214834956|NCT05965908|DRUG|Metformin|biguanide antihyperglycemic
214834957|NCT01539239|DEVICE|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
214834958|NCT01539239|PROCEDURE|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
214834959|NCT05597631|DEVICE|G-IVF PLUS|Experimental
214834960|NCT05437068|OTHER|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
214834961|NCT02179788|BEHAVIORAL|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
214834962|NCT02179788|DRUG|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
214834963|NCT02179788|DRUG|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
214834964|NCT03302598|DIAGNOSTIC_TEST|serum C-reactive protein|
214834965|NCT01750827|DRUG|SB659032|single dose
214834966|NCT00789776|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
214834967|NCT00789776|DRUG|Cyclophosphamide|Given IV
214834968|NCT00789776|DRUG|Fludarabine Phosphate|Given IV
214834969|NCT00789776|OTHER|Laboratory Biomarker Analysis|Correlative studies
214834970|NCT00789776|DRUG|Mycophenolate Mofetil|Given PO
214834971|NCT00789776|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
214834972|NCT00789776|DRUG|Tacrolimus|Given IV or PO
214834973|NCT00789776|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
214834974|NCT02627001|DEVICE|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
214834975|NCT02627001|DEVICE|Bag Valve Mask|Conventional bag valve mask
214834976|NCT05534243|OTHER|Standard neuromuscular blocker practices|Usual care neuromuscular blocker in the ED
214834977|NCT05534243|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
214834978|NCT06543394|BEHAVIORAL|Primer postcard|Mailed primer postcard
214834979|NCT06543394|BEHAVIORAL|Control recruitment letter|Mailed recruitment letter with usual care message framing
214834980|NCT06543394|BEHAVIORAL|Behavioral theory-informed recruitment letter|Mailed recruitment letter with prospect-theory informed message framing
214834981|NCT06543394|BEHAVIORAL|2 phone calls|Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
214834982|NCT06543394|BEHAVIORAL|4 phone calls|Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
214834983|NCT04317664|COMBINATION_PRODUCT|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
214834984|NCT04317664|BEHAVIORAL|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
214834985|NCT00640341|DEVICE|PureVision Contact Lens|contact lens for daily wear
214834986|NCT00640341|DEVICE|Acuvue Oasys Contact Lens|contact lens for daily wear
214834987|NCT00640341|DEVICE|O2Optix Contact lens|contact lens for daily wear
214834988|NCT00000564|PROCEDURE|oxygen inhalation therapy|
214834989|NCT02761720|OTHER|No Intervention|
214834990|NCT03673514|PROCEDURE|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
214834991|NCT02973269|BIOLOGICAL|daxibotulinumtoxin type A|Intramuscular injection
214834992|NCT02973269|BIOLOGICAL|Placebo|Intramuscular injection
214834993|NCT05829239|BIOLOGICAL|ADI-PEG20|Intramuscular injection weekly for 8 weeks
214834994|NCT05829239|OTHER|Placebo|Intramuscular injection weekly for 8 weeks
214834995|NCT02190318|DRUG|Losartan|
214834996|NCT02190318|DRUG|spirolactone|
214834997|NCT02190318|OTHER|blank control|
214834998|NCT00466479|DRUG|brimonidine|
214834999|NCT00466479|PROCEDURE|laser trabeculoplasty|
214835000|NCT00591071|OTHER|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
214835001|NCT00591071|OTHER|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
214835002|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
214835003|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
214835004|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
214835005|NCT01573819|DRUG|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
214835006|NCT01573819|DRUG|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
214835007|NCT06186219|DRUG|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
214835008|NCT04598958|OTHER|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
214835009|NCT03900884|DRUG|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
214835010|NCT03900884|DRUG|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
214835011|NCT03900884|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
214835012|NCT03157349|OTHER|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
214835013|NCT03157349|OTHER|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
214835014|NCT05610007|DRUG|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
214835015|NCT00250315|DRUG|Dobutamine|
214835016|NCT00150683|DEVICE|vibration and passive standing versus passive standing alone|
214835017|NCT02251509|DRUG|Carvedilol|
214835018|NCT02251509|DRUG|Metoprolol tartrate|
214835019|NCT03908307|DRUG|OZURDEX|Implant 700 μg
214835020|NCT00000449|DRUG|naltrexone (Revia)|
214835021|NCT00000449|BEHAVIORAL|cognitive behavioral therapy|
214835022|NCT00000449|BEHAVIORAL|cue exposure treatment|
214835023|NCT05191511|RADIATION|Far- infrared|safety of far- infrared
214835024|NCT02559219|OTHER|Questionniares|
214835025|NCT01520987|DRUG|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
214835026|NCT01520987|DRUG|Placebo|once-daily
214835027|NCT02301533|BEHAVIORAL|Shikamana Intervention|See arm description
214835028|NCT02301533|BEHAVIORAL|Standard Care|See arm description
214835029|NCT04902911|DEVICE|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
214835030|NCT03567460|BEHAVIORAL|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
214835031|NCT04997720|OTHER|Training|"Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation."
214835032|NCT02005562|DRUG|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
214835033|NCT02005562|DRUG|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
214835034|NCT02005562|DRUG|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
214835035|NCT02005562|DRUG|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
214835036|NCT02005562|DRUG|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
214835037|NCT04171401|OTHER|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
214835038|NCT05721469|BEHAVIORAL|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
214835039|NCT04129255|DRUG|Octreotide Acetate|administration every 28 days
214835040|NCT01763255|BIOLOGICAL|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
214835041|NCT02480608|DRUG|Imatinib|
214835042|NCT02480608|DRUG|Hydroxyurea|
214835043|NCT00636324|DEVICE|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
214835044|NCT00636324|DEVICE|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
214835045|NCT02805413|OTHER|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
214835046|NCT05659758|PROCEDURE|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
214835047|NCT05454085|DIETARY_SUPPLEMENT|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
214835048|NCT01463709|DEVICE|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
214835049|NCT01944553|DEVICE|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
214835050|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
214835051|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
214835052|NCT06226259|DIETARY_SUPPLEMENT|GABA supplement|Oral administration of GABA supplement once daily before sleep for 14 days.
214835053|NCT06226259|DIETARY_SUPPLEMENT|placebo|Oral administration of placebo once daily before sleep for 14 days.
214835054|NCT06678308|DEVICE|Embolisation with Magic Glue®|Magic Glue® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
214835055|NCT06678308|DEVICE|Embolisation with Embosphere®|Embosphere® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
214835056|NCT02889302|DRUG|KPS-0373|24 weeks
214835057|NCT02889302|DRUG|Placebo|24 weeks
214835058|NCT00388219|DRUG|Transtec (R) PRO (buprenorphine)|
214835059|NCT03888521|BEHAVIORAL|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
214835060|NCT02966340|DRUG|Prazosin|2mg Prazosin
214835061|NCT02966340|DRUG|Placebo|Placebo
214835062|NCT01119586|GENETIC|DNA analysis|
214835063|NCT01119586|GENETIC|genetic linkage analysis|
214835064|NCT01119586|GENETIC|microarray analysis|
214835065|NCT01119586|GENETIC|nucleic acid sequencing|
214835066|NCT01119586|GENETIC|polymerase chain reaction|
214835067|NCT01119586|GENETIC|polymorphism analysis|
214835068|NCT01119586|OTHER|laboratory biomarker analysis|
214835069|NCT04650750|DRUG|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
214835070|NCT04650750|DRUG|Placebo|Similar placebo 4g twice a day for two months
214835071|NCT01622660|DRUG|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
214835072|NCT01622660|DRUG|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
214835073|NCT01094262|DRUG|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
214835074|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
214835075|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
214835076|NCT01094262|DRUG|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
214835077|NCT04022031|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
214835078|NCT04445701|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
214835079|NCT04445701|DRUG|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
214835080|NCT04445701|DRUG|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
214835081|NCT03538925|BEHAVIORAL|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
214835082|NCT03538925|BEHAVIORAL|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
214835083|NCT01762228|DEVICE|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
214835084|NCT01762228|DIETARY_SUPPLEMENT|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
214835085|NCT04590781|BIOLOGICAL|XmAb18087|Monoclonal bispecific antibody
214835086|NCT04590781|DRUG|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
214835087|NCT02247518|DRUG|Cialis Tab. 5mg|
214835088|NCT02247518|DRUG|Harnal-D Cap. 0.2mg|
214835089|NCT00526435|BEHAVIORAL|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
214835090|NCT00526435|BEHAVIORAL|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
214835091|NCT05164835|OTHER|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
214835092|NCT03336879|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
214835093|NCT06535490|PROCEDURE|EUS-FNA|Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
214835094|NCT06535490|DRUG|ATBp|Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
214835095|NCT04502706|DRUG|GS-0189|GS-0189 will be administered intravenously.
214835096|NCT04502706|DRUG|Rituximab|Rituximab will be administered intravenously.
214835097|NCT05393349|BEHAVIORAL|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
214835098|NCT00164918|DEVICE|nasogastric tube|
214835099|NCT00519506|OTHER|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
214835100|NCT05287087|BEHAVIORAL|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
214835101|NCT05287087|BEHAVIORAL|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
214835102|NCT05034185|DEVICE|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
214835103|NCT00359671|DRUG|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
214835104|NCT00359671|DRUG|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
214835105|NCT01433887|DRUG|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
214835106|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
214835107|NCT01433887|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
214835108|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
214835109|NCT02400515|OTHER|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
214835110|NCT03205501|DRUG|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
214835111|NCT03205501|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
214835112|NCT06467851|DRUG|Suanzaoren Decoction and Huanglian Wenda Decoction|Twice daily. Chinese herbal medicine includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
214835113|NCT05437406|BEHAVIORAL|Parent-based treatment- All caregivers (PBT-AC)|PBT-AC provides all the elements of FBT, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
214835114|NCT05437406|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
214835115|NCT05767216|OTHER|Biological sampling|Blood, skin and stool samples for laboratory analysis
214835116|NCT04509050|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
214835117|NCT01680016|BIOLOGICAL|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
214835118|NCT01680016|BIOLOGICAL|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
214835119|NCT04556916|DIAGNOSTIC_TEST|Blood sample|"Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
214835120|NCT04130217|PROCEDURE|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
214835121|NCT04130217|PROCEDURE|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
214835122|NCT00856622|DRUG|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
214835123|NCT00856622|DRUG|timolol 0.5% ophthalmic solution|one drop in the morning and evening
214835124|NCT00856622|DRUG|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
214835125|NCT00549341|DRUG|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
214835126|NCT00549341|OTHER|Physiologic saline|Single injection.
214835127|NCT01267916|DEVICE|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
214835128|NCT01267916|DEVICE|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
214835129|NCT01267916|DEVICE|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
214835130|NCT01267916|DEVICE|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
214835131|NCT01267916|DEVICE|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
214835132|NCT01267916|DEVICE|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
214835133|NCT05192096|BEHAVIORAL|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
214835134|NCT04433494|DRUG|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
214835135|NCT00089167|BIOLOGICAL|filgrastim|
214835136|NCT00089167|DRUG|dexamethasone|
214835137|NCT00089167|DRUG|melphalan|
214835138|NCT00089167|DRUG|thalidomide|
214835139|NCT06210204|OTHER|Telehealth follow-up|Patients to follow-up via phone after surgery
214835140|NCT00402519|RADIATION|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
214835141|NCT00402519|RADIATION|External beam whole breast irradiation|Standard Whole breast irradiation
214835142|NCT01200017|BIOLOGICAL|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
214835143|NCT02827396|BEHAVIORAL|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
214835144|NCT01989299|DEVICE|ILR implantation|
214835145|NCT01120899|DRUG|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
214835146|NCT04374188|DRUG|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
214835147|NCT04374188|DRUG|Levofloxacin|levofloxacin pill
214835148|NCT02377388|DRUG|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
214835149|NCT02377388|DRUG|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
214835150|NCT01717937|PROCEDURE|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
214835151|NCT04602585|BEHAVIORAL|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
214835152|NCT01273857|PROCEDURE|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
214835153|NCT01273857|PROCEDURE|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
214835154|NCT02396290|PROCEDURE|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
214835155|NCT02396290|PROCEDURE|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
214835156|NCT06519760|DRUG|68Ga-C1|68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
214835157|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
214835158|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
214835159|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
214835160|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
214835161|NCT03710096|DEVICE|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
214835162|NCT03710096|DEVICE|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
214835163|NCT06298565|BIOLOGICAL|efgartigimod|efgartigimod
214835164|NCT05093881|BIOLOGICAL|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
214835165|NCT01636817|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
214835166|NCT01636817|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
214835167|NCT06679335|OTHER|Lateralization Imagery Training|"Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training."
214835168|NCT01784016|RADIATION|[11C]-PHNO|\[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
214835169|NCT03003364|DRUG|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
214835170|NCT03003364|DRUG|Placebo|Placebo in a blinded syringe
214835171|NCT01065116|DRUG|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
214835172|NCT01065116|DRUG|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
214835173|NCT02432118|PROCEDURE|Lumpectomy|Undergo lumpectomy
214835174|NCT02432118|OTHER|Questionnaire Administration|Ancillary studies
214835175|NCT02432118|PROCEDURE|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
214835176|NCT00006228|BIOLOGICAL|trastuzumab|Given IV
214835177|NCT00006228|BIOLOGICAL|aldesleukin|Given SC
214835178|NCT00006228|OTHER|laboratory biomarker analysis|Correlative studies
214835179|NCT00006228|OTHER|pharmacological study|Correlative studies
214835180|NCT00442351|DRUG|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
214835181|NCT00442351|OTHER|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
214835182|NCT04119557|DRUG|Placebo|Administered SC
214835183|NCT04119557|DRUG|LY3471851|Administered SC
214835184|NCT01275976|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
214835185|NCT01275976|OTHER|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
214835186|NCT00069030|BIOLOGICAL|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
214835187|NCT04239495|OTHER|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
214835188|NCT01863186|DRUG|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
214835189|NCT01863186|DRUG|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
214835190|NCT01863186|DRUG|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
214835191|NCT03514186|BEHAVIORAL|Speech and Language Therapy|"Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication"
214835192|NCT06368024|OTHER|This is a retrospective analysis study of data collected with a diagnostic medical device|Transcranial Magnetic stimulation and Electroencephalogram
214835193|NCT04582799|DEVICE|ECCO2R|Extracorporeal CO2 Removal
214835194|NCT04582799|DEVICE|NIV|Non-invasive ventilation
214835195|NCT05940987|BEHAVIORAL|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
214835196|NCT04394390|DIETARY_SUPPLEMENT|vitamin d|vitamin D levels
214835197|NCT05720663|OTHER|Standard of care|Participants will receive the standard of care for their condition
214835198|NCT03469960|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
214835199|NCT03469960|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
214835200|NCT02931630|OTHER|Whey protein powder|60 g of whey protein powder
214835201|NCT02931630|OTHER|Maltodextrin powder|60 g of Maltodextrin powder
214835202|NCT02931630|OTHER|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
214835203|NCT02931630|OTHER|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
214835204|NCT03283748|DEVICE|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
214835205|NCT00377156|RADIATION|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
214835206|NCT00377156|RADIATION|stereotactic radiosurgery|
214835207|NCT02156219|OTHER|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop."
214835208|NCT01494090|DRUG|Rosuvastatin|5 or 20 mg per day during 6 months
214835209|NCT01494090|DRUG|Placebo|5 or 20 mg per day during 6 months
214835210|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
214835211|NCT00288704|DRUG|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
214835212|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
214835213|NCT01579006|DRUG|Tocilizumab|
214835214|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
214835215|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
214835216|NCT03379636|DEVICE|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
214835217|NCT03379636|DEVICE|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
214835218|NCT02413034|DRUG|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
214835219|NCT02413034|OTHER|Control group|no antibiotic prophylaxis
214835220|NCT03857724|PROCEDURE|prolapse surgery|prolapse surgery
214835221|NCT03971734|DRUG|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
214835222|NCT03971734|DRUG|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
214835223|NCT03971734|DRUG|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
214277629|NCT03814317|DRUG|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
214277630|NCT01133522|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214277631|NCT01133522|BIOLOGICAL|Placebo|Administered by subcutaneous injection
214835224|NCT03971734|DRUG|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
214835225|NCT03971734|DRUG|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
214835226|NCT03971734|DRUG|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
214835227|NCT03971734|DRUG|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
214835228|NCT01960608|OTHER|24_hours_urine_sodium|
214835229|NCT02853916|DIETARY_SUPPLEMENT|500 mg InSea2®|
214835230|NCT02853916|DIETARY_SUPPLEMENT|250 mg InSea2®|
214835231|NCT02853916|DIETARY_SUPPLEMENT|Placebo|
214835232|NCT04478708|BIOLOGICAL|maridebart cafraglutide|Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
214835233|NCT04478708|DRUG|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
214835234|NCT02279784|DEVICE|Freeway PTA|angioplasty with Freeway drug-eluting balloon
214835235|NCT02279784|DEVICE|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
214835236|NCT02473393|DRUG|OPS-2071 tablet|
214835237|NCT04274829|PROCEDURE|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
214835238|NCT01751633|PROCEDURE|Surgical|
214835239|NCT01751633|PROCEDURE|Conservative treatment|
214835240|NCT01713166|DRUG|plasmalyte solution|plasmalyte solution
214835241|NCT01713166|DRUG|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
214835242|NCT00458159|DRUG|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
214835243|NCT05880888|BIOLOGICAL|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
214835244|NCT02697617|DRUG|Pioglitazone|Pioglitazone
214835245|NCT02697617|DRUG|Placebo|Placebo
214835246|NCT03865225|OTHER|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
214835247|NCT03865225|OTHER|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
214835248|NCT02460835|RADIATION|Adaptive Radiation Therapy|
214835249|NCT04924699|DRUG|MRG002|Administrated intravenously
214835250|NCT04924699|DRUG|Trastuzumab Emtansine for Injection|Administrated intravenously
214835251|NCT02212106|BIOLOGICAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
214835252|NCT02212106|BIOLOGICAL|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
214835253|NCT05544656|DRUG|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
214835254|NCT05544656|DRUG|Placebo|matching placebo administered three times a day
214835255|NCT01151449|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214835256|NCT01151449|OTHER|laboratory biomarker analysis|Correlative studies
214835257|NCT00517192|DRUG|Tipranavir|
214835258|NCT00517192|DRUG|Darunavir|
214835259|NCT00517192|DRUG|Ritonavir|
214835260|NCT01486108|PROCEDURE|dorsal column stimulator|test different settings of stimulation
214835261|NCT02318550|OTHER|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~* Normal operating mode~* SAR ≤ 2.0 W/kg per patient."
214835262|NCT05341856|DRUG|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
214835263|NCT05341856|DRUG|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
214835264|NCT00804245|PROCEDURE|needle biopsy|Biopsy of positive findings found on CT scan
214835265|NCT00804245|DRUG|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
214835266|NCT00476437|DRUG|biphasic insulin aspart|
214835267|NCT00476437|DRUG|biphasic human insulin|
214835268|NCT00230594|DRUG|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
214835269|NCT00230594|DRUG|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
214835270|NCT05770557|BEHAVIORAL|survey|administration of a survey among healthcare workers
214835271|NCT02007668|OTHER|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
214835272|NCT02965872|OTHER|No intervention|
214835273|NCT05069233|OTHER|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
214835274|NCT02849236|DRUG|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
214277632|NCT06991049|DEVICE|Fully covered self-expandable metal esophageal stent|Esophageal stent placement for patients with benign esophageal strictures not responding to endoscopic dilations.
214835275|NCT02849236|DRUG|Placebo|20 mL saline 0.9%
214835276|NCT02733627|DRUG|BI 1467335|
214835277|NCT02733627|DRUG|Placebo|
214835278|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
214835279|NCT00183196|DRUG|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
214835280|NCT00183196|DRUG|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
214835281|NCT00183196|OTHER|Inactive Placebo|Placebo
214835282|NCT05910294|OTHER|questionnaires|Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast Clinical Care and Symptom Survey (BCCSS) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
214835283|NCT05910294|OTHER|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
214835284|NCT05910294|OTHER|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
214277633|NCT06995326|DRUG|SGB-3383|SGB-3383 for sc injection, single dose
214277634|NCT06995326|DRUG|SGB-3383-Matching placebo|SC injection, single dose
214277635|NCT01504620|OTHER|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
214277636|NCT01504620|DRUG|insulin infusion|i.v. infusion of insulin
214835285|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
214835286|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
214835287|NCT06093893|DRUG|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
214835288|NCT06093893|DRUG|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
214835289|NCT06093893|DRUG|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
214835290|NCT06314490|DRUG|nL-SCN2A-002|Personalized antisense oligonucleotide
214835291|NCT06743269|BEHAVIORAL|High-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 55% maximal inspiratory pressure (PIMAX) during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3-6.
214835292|NCT06743269|BEHAVIORAL|Low-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 15% maximal inspiratory pressure (PIMAX) for all 6 weeks.
214835293|NCT06743269|DEVICE|POWERbreathe K3 device|Inspiratory muscle training device
214835294|NCT06130956|DIETARY_SUPPLEMENT|Vegan diet|Vegan diet for 2 weeks before surgery
214835295|NCT06130956|DIETARY_SUPPLEMENT|Omnivorous diet|Omnivorous diet for 2 weeks before surgery
214835296|NCT05696392|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
214835297|NCT06377683|DRUG|177Lu-Dansyl-PSMA radioligand therapy|Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
214835298|NCT05639036|DEVICE|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
214835299|NCT05639036|PROCEDURE|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
214835300|NCT03690063|OTHER|Follow up|Follow up of treatment, behavior, co-morbidity
214835301|NCT00842062|DEVICE|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
214835302|NCT03390790|DRUG|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
214835303|NCT03390790|OTHER|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
214835304|NCT03483818|PROCEDURE|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
214835305|NCT04142996|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
214835306|NCT04484090|DEVICE|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
214835307|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 1)|"* 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
214835308|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 2 and 3)|"* 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
214835309|NCT04038866|OTHER|rehabilitation gait with dual task|
214835310|NCT04038866|OTHER|rehabilitation gait without dual task|
214835311|NCT02128516|OTHER|oral powder in sachet|
214835312|NCT03670758|DIAGNOSTIC_TEST|Protein S activity|Intravenous blood sample
214835313|NCT02557464|BEHAVIORAL|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
214835314|NCT02557464|BEHAVIORAL|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
214835315|NCT06378320|OTHER|App access and Text message|Access to App and Text messages with app related breastfeeding related question
214835316|NCT06378320|OTHER|App access only|Access to App without Text messages with app related breastfeeding related question
214835317|NCT01119625|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
214835318|NCT01119625|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, one dose
214835319|NCT06353724|DEVICE|conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning|"Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment."
214835320|NCT06353724|DEVICE|Digital positioning stent|Digital positioning stent
214835321|NCT03237156|DRUG|TAK-906|TAK-906 capsules.
214835322|NCT03237156|DRUG|TAK-906 Placebo|Placebo capsules.
214835323|NCT01721772|BIOLOGICAL|BMS-936558 (Nivolumab)|
214835324|NCT01721772|BIOLOGICAL|Placebo matching BMS-936558 (Nivolumab)|
214835325|NCT01721772|DRUG|Dacarbazine|
214835326|NCT01721772|DRUG|Placebo matching Dacarbazine|
214835327|NCT06581120|DRUG|Glucagon-Like Peptide-1 receptor agonists|GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
214835328|NCT06581120|DIAGNOSTIC_TEST|Point of Care Gastric Ultrasound|A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
214835329|NCT04646356|DRUG|Tacrolimus capsule (low-dose)|low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
214835330|NCT06244420|OTHER|Clinical data review|review the medical records, radiological imaging, and histological data of these patients
214835331|NCT04096586|OTHER|Red juice|To determine the effects of red juice on satiety and gut health
214835332|NCT04096586|OTHER|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
214835333|NCT05753995|DIAGNOSTIC_TEST|PET imaging|The evaluation of PET imaging using PET ligand \[18F\]JNJ-64413739 or a \[18F\] labeled equivalent in vivo in patients.
214835334|NCT04711824|DRUG|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
214835335|NCT04711824|RADIATION|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
214835336|NCT04711824|DRUG|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
214835337|NCT04711824|DRUG|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
214835338|NCT03956758|OTHER|Semi-directed interview|Semi-directed interview on ChemSex practice
214835339|NCT01897077|DRUG|Peanut Dissolving Film|
214835340|NCT06626906|DIAGNOSTIC_TEST|Echocardiography, Blood sampling for biomarker assays|
214835341|NCT03586622|DIETARY_SUPPLEMENT|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
214835342|NCT03586622|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
214835343|NCT04261374|DIAGNOSTIC_TEST|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
214835344|NCT00774540|DRUG|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
214835345|NCT00774540|DRUG|Placebo|Saline
214835346|NCT00014469|DRUG|busulfan|
214835347|NCT00014469|DRUG|melphalan|
214835348|NCT00014469|DRUG|methotrexate|
214835349|NCT00014469|DRUG|tacrolimus|
214835350|NCT00014469|PROCEDURE|allogeneic bone marrow transplantation|
214835351|NCT01732562|OTHER|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
214835352|NCT05031455|DRUG|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization."
214835353|NCT06348888|DRUG|BAY2927088|Oral
214835354|NCT06348888|DRUG|Itraconazole|Capsule, 100 mg, oral.
214835355|NCT06348888|DRUG|Carbamazepine|Tablet, 100 mg, 200mg and 300mg, oral.
214835356|NCT04268797|DEVICE|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
214835357|NCT04268797|DEVICE|sham|SHAM HF rTMS coil once daily x 20 days
214835358|NCT01756716|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
214835359|NCT01756716|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
214835360|NCT01756716|DRUG|Placebo|Placebo for 8 weeks
214835361|NCT02016235|DRUG|Phosphorus Supplement|250 mg po qid
214835362|NCT02016235|OTHER|Observation|Baseline blood and urine measurements only
214835363|NCT03458741|OTHER|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
214835364|NCT04303208|PROCEDURE|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
214835365|NCT05004649|BEHAVIORAL|Psychophysical task|A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
214835366|NCT05526703|DRUG|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
214835367|NCT05526703|DRUG|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
214835368|NCT02063815|PROCEDURE|Fissure sealant application|
214277637|NCT07001020|BEHAVIORAL|Technology-based Intervention|Technology-based intervention co-developed by a community board.
214835369|NCT02987153|RADIATION|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
214835370|NCT01698645|DRUG|PecFent® (fentanyl) nasal spray|
214835371|NCT01341951|DRUG|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
214835372|NCT01698554|DRUG|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
214835373|NCT01698554|DRUG|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
214835374|NCT01698554|DRUG|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
214835375|NCT01698554|DRUG|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
214835376|NCT02042547|OTHER|Tissue samples from the right atrium|
214835377|NCT02042547|OTHER|Blood samples|
214835378|NCT02694653|DRUG|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
214835379|NCT02694653|DRUG|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
214835380|NCT03453554|OTHER|Digital Notebook app|Training in use of Digital Memory Notebook app
214835381|NCT03453554|OTHER|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
214835382|NCT00004105|DRUG|estramustine phosphate sodium|
214835383|NCT00004105|DRUG|paclitaxel|
214835384|NCT00004105|DRUG|vinorelbine ditartrate|
214835385|NCT06626854|DEVICE|RF-PNS|Noninvasive peripheral nerve stimulator using interferential multi source radio frequency
214835386|NCT03192397|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
214835387|NCT03192397|DRUG|Cyclophosphamide|Given IV
214835388|NCT03192397|DRUG|Fludarabine Phosphate|Given IV
214835389|NCT03192397|OTHER|Laboratory Biomarker Analysis|Correlative studies
214835390|NCT03192397|DRUG|Melphalan Hydrochloride|Given IV
214835391|NCT03192397|DRUG|Mycophenolate Mofetil|Given IV
214835392|NCT03192397|DRUG|Sirolimus|Given IV and PO
214835393|NCT03192397|RADIATION|Total-Body Irradiation|Undergo TBI
214835394|NCT03715751|OTHER|ASV|Adaptive Support Ventilation
214835395|NCT03715751|OTHER|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
214835396|NCT06159647|BEHAVIORAL|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
214835397|NCT06159647|BEHAVIORAL|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
214835398|NCT06159647|BEHAVIORAL|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
214835399|NCT06159647|BEHAVIORAL|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
214277638|NCT06008249|DRUG|Lithium Carbonate 400 MG|Lithium carbonate vs placebo (2:1)
214277639|NCT07005739|BEHAVIORAL|Turkish Folk Dance-Based Exercise Program|Participants in the intervention group received a structured Turkish folk dance-based exercise program in addition to their regular football training. The dance-based intervention consisted of two 45-minute sessions per week for 8 weeks, including traditional Turkish folk dance movements aimed at improving balance, agility, and core stability.
214835400|NCT06159647|BEHAVIORAL|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
214835401|NCT06159647|BEHAVIORAL|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
214835402|NCT06159647|BEHAVIORAL|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
214835403|NCT06159647|BEHAVIORAL|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
214835404|NCT06159647|BEHAVIORAL|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
214835405|NCT06159647|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
214835406|NCT06159647|BEHAVIORAL|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
214835407|NCT06159647|BEHAVIORAL|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
214835408|NCT06159647|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
214835409|NCT06159647|BEHAVIORAL|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
214835410|NCT06159647|BEHAVIORAL|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
214835411|NCT06159647|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
214835412|NCT06159647|BEHAVIORAL|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
214835413|NCT01905605|DRUG|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
214835414|NCT01905605|DRUG|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
214835415|NCT02654145|DRUG|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
214835416|NCT02654145|DRUG|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
214835417|NCT02654145|DRUG|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
214835418|NCT02637141|BIOLOGICAL|AMG 714|AMG 714 administered by subcutaneous injection
214835419|NCT02637141|BIOLOGICAL|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
214835420|NCT02637141|OTHER|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
214835421|NCT02637141|OTHER|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
214835422|NCT04605211|BEHAVIORAL|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
214835423|NCT04605211|OTHER|Internet-Based Webinars|Attend webinars
214835424|NCT01991548|DEVICE|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
214835425|NCT01943435|DRUG|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
214835426|NCT01943435|PROCEDURE|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
214835427|NCT01943435|OTHER|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
214835428|NCT01943435|OTHER|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
214835429|NCT01943435|OTHER|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
214835430|NCT01282736|BEHAVIORAL|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
214835431|NCT01282736|BEHAVIORAL|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
214835432|NCT00097734|DRUG|ertapenem|
214835433|NCT03885934|BIOLOGICAL|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
214835434|NCT03885934|BIOLOGICAL|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
214835435|NCT06563193|DIAGNOSTIC_TEST|NERVE GROWTH FACTOR|urinary neurotrophins
214835436|NCT03849547|OTHER|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
214835437|NCT03849547|OTHER|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
214835438|NCT00370851|DRUG|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
214277640|NCT07008352|PROCEDURE|Blood sample collection for amino acid profiling|Blood samples (5 mL) will be collected from participants in both groups. In the bariatric surgery group, samples will be collected at three time points: preoperatively, and at 1 and 3 months postoperatively. For the control group, a single sample will be obtained. Serum will be separated, stored at -80°C, and analyzed for free amino acid profiles using LC-MS/MS.
214835439|NCT03921801|OTHER|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
214835440|NCT03921801|OTHER|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
214835441|NCT00662272|BIOLOGICAL|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
214835442|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
214835443|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
214835444|NCT01291862|DEVICE|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
214835445|NCT00893919|DRUG|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
214835446|NCT01936662|DEVICE|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
214835447|NCT01936662|DEVICE|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
214835448|NCT03029364|BEHAVIORAL|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
214835449|NCT00414479|DRUG|praziquantl, iron, ACT|
214835450|NCT02774018|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) program|
214835451|NCT05290519|OTHER|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
214835452|NCT01874041|OTHER|Massage|
214835453|NCT01874041|OTHER|Occlusal splint|
214835454|NCT00106106|PROCEDURE|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
214835455|NCT00106106|DRUG|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
214835456|NCT04417348|DRUG|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
214835457|NCT01096641|BEHAVIORAL|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
214835458|NCT01096641|BEHAVIORAL|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
214835459|NCT00746486|DRUG|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
214835460|NCT00746486|DRUG|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
214835461|NCT01328782|DRUG|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
214835462|NCT01328782|DRUG|Bupivacaine 0.25%|"* Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
214835463|NCT01328782|DRUG|Ropivacaine 0.20%|"* Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
214835464|NCT04535986|DRUG|Ensifentrine|Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
214835465|NCT04535986|DRUG|Placebo|Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
214835466|NCT02135991|BEHAVIORAL|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
214835467|NCT02135991|BEHAVIORAL|Project CHOICE|Sites will receive standard training for Project CHOICE.
214835468|NCT03825562|BEHAVIORAL|acceptance and commitment therapy, ACT|
214835469|NCT00400634|DRUG|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10\^11 vg
214835470|NCT00400634|PROCEDURE|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
214835471|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
214835472|NCT01559116|DRUG|tiotropium|low dose
214835473|NCT01559116|DRUG|olodaterol|one dose only
214835474|NCT01559116|DRUG|tiotropium|high dose
214835475|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
214835476|NCT01559116|DRUG|Placebo|placebo matching tiotropium+olodaterol FDC
214835477|NCT01559116|DEVICE|Respimat|Respimat inhaler
214835478|NCT04728750|PROCEDURE|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
214835479|NCT03526484|BEHAVIORAL|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
214835480|NCT03526484|BEHAVIORAL|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
214835481|NCT00857779|BIOLOGICAL|subcutaneous immunotherapy|7 injections
214835482|NCT06074328|DEVICE|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
214277641|NCT06115746|BEHAVIORAL|iDECIDE|iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
214277642|NCT06680713|BEHAVIORAL|Exercise|Progressive exercise testing on a cyclo ergometer
214835483|NCT01876758|BEHAVIORAL|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
214835484|NCT01876758|BEHAVIORAL|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
214835485|NCT00522223|BEHAVIORAL|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
214835486|NCT05757609|DEVICE|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
214835487|NCT05757609|DEVICE|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
214835488|NCT03213548|PROCEDURE|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
214835489|NCT03213548|PROCEDURE|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
214835490|NCT06220526|DEVICE|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Transbronchial biopsy with Menghini-type or Franseen type Needle
214835491|NCT02377349|BIOLOGICAL|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
214835492|NCT02377349|DRUG|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
214835493|NCT00001763|DRUG|Interleukin-12|
214835494|NCT00096850|DRUG|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
214835495|NCT00096850|DRUG|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
214835496|NCT00096850|DRUG|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
214835497|NCT05450549|DRUG|DNL919|Single doses
214835498|NCT05450549|DRUG|Placebo|Single doses
214835499|NCT00314288|DRUG|Sarizotan HCl|
214835500|NCT00441961|DRUG|methotrexate|methotrexate
214835501|NCT03650751|OTHER|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
214835502|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal Plus (SC+)|
214835503|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal (SC), fortified oil, sugar|
214835504|NCT02077907|DIETARY_SUPPLEMENT|Plumpy Sup|
214835505|NCT02077907|DIETARY_SUPPLEMENT|Corn Soy Blend 14 (CSB14) and fortified oil|
214835506|NCT05536960|OTHER|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
214835507|NCT05016427|BIOLOGICAL|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
214835508|NCT05414162|DIAGNOSTIC_TEST|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
214835509|NCT00405262|DRUG|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
214835510|NCT00405262|DRUG|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
214835511|NCT00405262|DRUG|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
214835512|NCT00629057|BIOLOGICAL|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
214835513|NCT00629057|BIOLOGICAL|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
214835514|NCT00629057|BIOLOGICAL|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
214835515|NCT06241157|OTHER|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
214835516|NCT03259165|DRUG|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
214835517|NCT03259165|DRUG|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
214835518|NCT03039816|DEVICE|Nasaleze|Nasaleze cellulose powder
214835519|NCT03039816|DEVICE|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
214835520|NCT02822716|PROCEDURE|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
214835521|NCT02822716|DEVICE|Ultrasound|
214835522|NCT05203692|DRUG|DS-7011a|Intravenous or subcutaneous administration, single dose
214835523|NCT05203692|DRUG|Placebo|Intravenous or subcutaneous administration, single dose
214835524|NCT04483895|PROCEDURE|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
214835525|NCT04693221|OTHER|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
214835526|NCT04693221|OTHER|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
214835527|NCT03910049|DRUG|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
214835528|NCT05248399|BEHAVIORAL|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
214835529|NCT05248399|BEHAVIORAL|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
214835530|NCT06628349|DIETARY_SUPPLEMENT|Whey Protein Isolate 90%|Commercially available animal based protein powders
214835531|NCT06628349|DIETARY_SUPPLEMENT|Soy Protein Isolate (90% Protein)|Commercially available plant based protein powders
214835532|NCT06628349|DIETARY_SUPPLEMENT|Organic Pea Protein Isolate|Commercially available plant based protein powders
214835533|NCT06628349|DIETARY_SUPPLEMENT|Placebo (Water)|Normal drinking water
214835534|NCT05123885|OTHER|Study on Data|Study on Data
214835535|NCT03994952|DEVICE|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
214835536|NCT03994952|DEVICE|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
214835537|NCT00486993|BEHAVIORAL|Dietary and nutritional modification|
214835538|NCT00486993|BEHAVIORAL|Stop smoking|
214835539|NCT00486993|BEHAVIORAL|Regular physical activities|
214835540|NCT00486993|BEHAVIORAL|Weight reduction to normal ranges|
214835541|NCT00486993|BEHAVIORAL|Regular intake of polyphenols, esp. from Ilex paraguayensis|
214835542|NCT02096484|BEHAVIORAL|Group Metacognitive Therapy|
214835543|NCT02096484|BEHAVIORAL|Mindfulness Meditation Therapy|
214277643|NCT07008664|OTHER|Epigenetic Signature Assay|Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.
214835544|NCT02247037|OTHER|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
214835545|NCT00550147|DRUG|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM."
214835546|NCT00550147|DRUG|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
214835547|NCT01824498|OTHER|Low Fat diet|Low fat diet = 20% fat
214835548|NCT01824498|OTHER|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
214835549|NCT01824498|OTHER|High Fat Diet|High Fat Diet = 40% fat
214835550|NCT01415245|DEVICE|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
214835551|NCT00695045|DRUG|intra thecal morphine|100 mcg intrathecal morphine given once .
214835552|NCT00695045|DRUG|intra thecal morphine|200 mcg intrathecal morphine given once
214835553|NCT00695045|DRUG|intra thecal morphine|300 mcg intrathecal morphine given once
214835554|NCT04358627|DRUG|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
214835555|NCT01567527|DRUG|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
214835556|NCT01567527|DRUG|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
214835557|NCT00521573|OTHER|Dark chocolate|
214835558|NCT06368076|BEHAVIORAL|Exercise|High intensity interval training on a bike or pedaltrainer from the wheelchair.
214835559|NCT05324891|DRUG|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
214835560|NCT05324891|DRUG|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
214835561|NCT01021501|DRUG|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
214835562|NCT00625339|DRUG|Entecavir|entecavir 0.5 mg QD
214835563|NCT00625339|DRUG|Lamivudine|lamivudine 100 mg QD
214835564|NCT00496067|DEVICE|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
214835565|NCT00509301|DRUG|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
214835566|NCT01391650|PROCEDURE|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
214835567|NCT02623218|DEVICE|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
214835568|NCT02623218|DEVICE|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
214835569|NCT01726803|OTHER|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
214835570|NCT01726803|OTHER|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
214835571|NCT02816684|BEHAVIORAL|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
214835572|NCT02816684|BEHAVIORAL|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
214835573|NCT04334837|DIAGNOSTIC_TEST|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
214835574|NCT00759707|DRUG|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
214835575|NCT04207333|BEHAVIORAL|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
214835576|NCT06180395|OTHER|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
214835577|NCT06180395|OTHER|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
214835578|NCT04702789|DRUG|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
214835579|NCT04702789|DRUG|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
214835580|NCT04396392|BEHAVIORAL|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
214835581|NCT02382601|RADIATION|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
214835582|NCT02382601|RADIATION|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
214835583|NCT02382601|PROCEDURE|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
214835584|NCT02382601|BEHAVIORAL|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
214835585|NCT02382601|PROCEDURE|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
214835586|NCT02382601|PROCEDURE|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
214835587|NCT02382601|RADIATION|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
214835588|NCT05626348|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214835589|NCT05626348|DRUG|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214835590|NCT05626348|DRUG|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214835591|NCT05626348|DRUG|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214835592|NCT05626348|DRUG|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
214835593|NCT00005967|DRUG|tipifarnib|
214835594|NCT00691470|DRUG|ATI-5923|Dose Adjusted based on INR.
214835595|NCT00691470|DRUG|Coumadin (warfarin)|Dose adjusted based on INR.
214835596|NCT03057535|DRUG|Sodium Bicarbonate|
214835597|NCT03057535|DRUG|Sodium Chloride|
214835598|NCT03941795|BIOLOGICAL|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
214835599|NCT03941795|DRUG|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
214835600|NCT03941795|OTHER|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
214835601|NCT06110819|OTHER|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
214835602|NCT06110819|OTHER|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
214835603|NCT03687619|OTHER|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
214835604|NCT03687619|OTHER|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
214835605|NCT03595241|DEVICE|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
214835606|NCT06369935|DRUG|Equecabtagene Autoleucel|Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
214835607|NCT01689155|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214835608|NCT06625255|BEHAVIORAL|Parent Education - Promoting Playfulness|Parents will participate in 2, 45 minute parent education sessions promoting playfulness through information about child development, parent stressors, and parent advocacy.
214835609|NCT03610555|OTHER|new patient centered website|
214835610|NCT01497743|DRUG|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
214835611|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
214835612|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
214835613|NCT02731781|OTHER|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
214835614|NCT04475315|DEVICE|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
214835615|NCT04475315|PROCEDURE|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
214835616|NCT00070759|DRUG|Daclizumab|
214835617|NCT04123587|DRUG|discontinuation of Sulfonylureas|"1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
214835618|NCT00003906|DRUG|Raloxifene|60 mg/day plus placebo for 5 years
214835619|NCT00003906|DRUG|Tamoxifen|20 mg/day plus placebo for 5 years
214835620|NCT06627985|DIAGNOSTIC_TEST|GPT-4o|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
214835621|NCT06627985|DIAGNOSTIC_TEST|GPT-4o mini|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
214835622|NCT06627985|DIAGNOSTIC_TEST|MedicalGPT|Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
214835623|NCT06627985|DIAGNOSTIC_TEST|Claude-3.5 Sonnet|Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
214835624|NCT06627985|DIAGNOSTIC_TEST|Claude 3 Haiku|Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
214835625|NCT06627985|DIAGNOSTIC_TEST|Real Doctors|Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
214835626|NCT05365698|BEHAVIORAL|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
214835627|NCT04598607|DRUG|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
214835628|NCT04598607|DRUG|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
214835629|NCT00245882|BEHAVIORAL|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
214835630|NCT00245882|BEHAVIORAL|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
214835631|NCT04542746|PROCEDURE|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
214835632|NCT00111696|BIOLOGICAL|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
214835633|NCT04485806|OTHER|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
214835634|NCT04485806|OTHER|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
214835635|NCT04485806|OTHER|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
214835636|NCT04485806|OTHER|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
214835637|NCT03955276|OTHER|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
214835638|NCT04568707|OTHER|blood sample|blood sample for serum (serology, biomarkers) and DNA
214277644|NCT04529434|OTHER|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
214277645|NCT04529434|OTHER|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
214277646|NCT03352349|DRUG|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
214277647|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
214277648|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
214835639|NCT03290807|DEVICE|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
214835640|NCT04919785|DEVICE|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
214835641|NCT05440305|PROCEDURE|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
214835642|NCT02032316|DEVICE|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
214835643|NCT03234127|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
214835644|NCT06678711|PROCEDURE|minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion|Make a 4.5 cm incision along the median line and then dissect the trapezius, splenius capitis, and semispinalis capitis muscle laterally 1.5 cm off the median line. Retract the obliquus capitis inferior muscle to expose the C1-C2 intra-articular space. Remove the articular cartilage, insert allogenic granular bone and 3D-printed cage. Place the screws and rod in the same positions as conventional surgery, and the operation is completed.
214835645|NCT06678711|PROCEDURE|Open atlantoaxial fixation and fusion|The Goel-Harms procedure will be used in the control group. Screws and rods are placed in the same position as in the experimental group, and a negative-pressure drain was placed until daily drainage was \<50 mL.
214835646|NCT00936351|BEHAVIORAL|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
214835647|NCT00936351|BEHAVIORAL|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
214835648|NCT01547728|DRUG|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
214835649|NCT04960761|OTHER|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
214835650|NCT05397444|OTHER|No intervention|This is an observational study with no intervention.
214835651|NCT05471687|DEVICE|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
214835652|NCT05471687|DRUG|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
214835653|NCT04416854|PROCEDURE|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
214835654|NCT04416854|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
214835655|NCT04416854|DRUG|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
214835656|NCT03828539|BIOLOGICAL|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
214835657|NCT03828539|DRUG|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
214835658|NCT03828539|BIOLOGICAL|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
214277649|NCT07011329|RADIATION|Changes in the brain MTP parameters after radiotherapy|Our study explores the changes in brain MTP parameters and their correlation with clinical cognitive scores before and after chemotherapy and/or radiotherapy in patients with NPC. We investigates MRI-derived multiparametric imaging biomarkers (MTP) as predictive biomarkers for chemotherapy/radiotherapy-induced cognitive decline in nasopharyngeal carcinoma, aiming to optimize neurotoxicity risk stratification and guide personalized neuroprotective interventions in precision oncology.
214835659|NCT03828539|DRUG|Topiramate matching placebo|Topiramate matching placebo administered daily
214835660|NCT00619853|BEHAVIORAL|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
214835661|NCT00619853|BEHAVIORAL|treatment approach - HABIT|HABIT-2 months, 2Hr per day
214835662|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|9-cis Rich Powder
214835663|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawill|9-cis Rich Powder
214835664|NCT01256697|OTHER|Sugar pill|Sugar pill
214835665|NCT06677697|DRUG|Ropivacaine 0,5%|Group B 30 patients recive 0.5% ropivacine
214835666|NCT03637127|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
214835667|NCT03637127|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
214835668|NCT01341405|DRUG|CG100649|once daily for 28 days
214835669|NCT01341405|DRUG|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
214835670|NCT04912206|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
214835671|NCT04211480|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
214835672|NCT00826241|DRUG|Temozolomide|Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.
214835673|NCT00826241|DRUG|Lapatinib|Starting dose 1250 mg daily by mouth.
214835674|NCT05028140|DRUG|PIEMONTE|Piemonte association 1 coated tablet once a day
214835675|NCT05028140|OTHER|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
214835676|NCT05028140|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
214835677|NCT05028140|OTHER|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
214835678|NCT05028140|DRUG|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
214835679|NCT05028140|OTHER|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
214835680|NCT05940259|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
214835681|NCT04409379|DIAGNOSTIC_TEST|Relative telomere length|Relative telomere length in peripheral blood cell
214277650|NCT06680349|DRUG|Anti-CD20 antibodies|comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
214277651|NCT06861101|DRUG|JT002 Nasal spray|200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD, 64 patients per cohort, total 256 patients for treatment 14 days
214277652|NCT06861101|DRUG|Placebo|Total 64 patients for treatment 14 days
214277653|NCT06759389|DEVICE|Resuscitation (Ventor)|Resuscitation with the Ventor device
214835682|NCT05543551|OTHER|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
214835683|NCT05543551|OTHER|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
214835684|NCT01216254|DEVICE|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
214835685|NCT04833205|DRUG|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
214835686|NCT00924053|DRUG|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
214835687|NCT00924053|DRUG|Placebo|Placebo capsules to match EGT0001474
214835688|NCT03434145|OTHER|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
214835689|NCT05821608|OTHER|Message variation 1|Message before call letting member know they will be called (variation 1)
214835690|NCT05821608|OTHER|Message variation 2|Message before call letting member know they will be called (variation 2)
214277654|NCT07010796|DEVICE|Alma Prime X|Alma Prime x is a platform that provides applicators for radiofrequency and ultrasound.
214277655|NCT07014527|PROCEDURE|Patient specific subperiosteal implants|Patient specific subperiosteal implants
214277656|NCT07014501|OTHER|High altitude|Altitude above 3500 meters.
214277657|NCT07014501|OTHER|Medium altitude|Altitude between 3500 meters and 1500 meters.
214277658|NCT07014501|OTHER|Low altitude group|Altitude below 1500 meters.
214277659|NCT07015372|BEHAVIORAL|Laughter Yoga|Laughter yoga intervention including clapping, breathing, childlike play, and laughter exercises, delivered in 8 sessions over 4 weeks to reduce stress and burnout and improve general health among psychiatric nurses.
214835691|NCT03950674|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
214835692|NCT03950674|DRUG|Cisplatin|IV infusion
214835693|NCT03950674|DRUG|Carboplatin|IV infusion
214835694|NCT03950674|DRUG|Pemetrexed|IV infusion
214835695|NCT03950674|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
214835696|NCT03950674|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
214835697|NCT03950674|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
214835698|NCT03950674|DRUG|Saline solution|IV infusion
214835699|NCT06120660|OTHER|Music Therapy|Music Therapy
214835700|NCT01346644|OTHER|Infant formula|Powder infant formula
214835701|NCT01346644|OTHER|Infant formula|Powder infant formula
214835702|NCT04394130|DRUG|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
214835703|NCT04804839|OTHER|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
214835704|NCT04804839|OTHER|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
214835705|NCT04804839|OTHER|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
214835706|NCT05361057|DRUG|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
214835707|NCT05361057|DRUG|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
214835708|NCT00193492|DRUG|Bevacizumab|
214835709|NCT00193492|DRUG|Rituximab|
214835710|NCT02176616|PROCEDURE|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
214835711|NCT02176616|PROCEDURE|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
214835712|NCT00379158|DRUG|Micronutrient supplements|
214835713|NCT00830167|DRUG|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
214835714|NCT00830167|DRUG|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
214835715|NCT02738216|BEHAVIORAL|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
214835716|NCT02738216|BEHAVIORAL|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
214835717|NCT01985724|DRUG|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
214835718|NCT01985724|DRUG|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
214835719|NCT01985724|DRUG|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
214835720|NCT01985724|DRUG|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
214835721|NCT01985724|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
214835722|NCT03168035|DRUG|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
214835723|NCT04287608|DRUG|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
214835724|NCT04033484|PROCEDURE|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
214835725|NCT04315779|PROCEDURE|Salpingectomy|Patients will undergo removal of the affected tube
214835726|NCT00869115|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
214835727|NCT00869115|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
214835728|NCT00869115|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
214835729|NCT00869115|DRUG|Istaroxime|Placebo continuous i.v. infusion for 24 hours
214835730|NCT04805385|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
214835731|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
214835732|NCT02224053|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
214835733|NCT02224053|DRUG|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
214835734|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
214835735|NCT00609154|DRUG|glucagon like peptide-1|GLP-1 1 pmole/kg/min
214835736|NCT00609154|DIETARY_SUPPLEMENT|glucose control|glucose without GLP-1
214835737|NCT04720547|DRUG|Zolpidem|A nonbenzodiazepine hypnotic
214835738|NCT04720547|OTHER|No Treatment|The Control condition in which participants do not receive medication.
214835739|NCT01157598|DEVICE|bispectral index monitoring|parameter monitoring of bispectral index
214835740|NCT01876745|DRUG|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
214835741|NCT05983627|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
214835742|NCT02319057|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
214835743|NCT02319057|DRUG|ORM-12741 IR|Immediate release formulation of ORM-12741
214835744|NCT02319057|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
214835745|NCT06581601|OTHER|physiotherapy, exercises|An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
214835746|NCT04789330|DRUG|Norepinephrine|Norepinephrine administered during anesthesia
214835747|NCT04789330|DRUG|Phenylephrine|Phenylephrine administered during anesthesia
214835748|NCT00279760|DRUG|Belatacept|
214835749|NCT00279760|DRUG|Abatacept|
214835750|NCT02962180|DEVICE|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
214835751|NCT02589067|DRUG|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
214835752|NCT02589067|DRUG|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
214835753|NCT05702762|DRUG|Gentamicin|5 mg/kg intramuscular injection
214835754|NCT05702762|DRUG|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
214835755|NCT00860262|DRUG|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
214835756|NCT00860262|DRUG|telmisartan|telmisartan 80mg for the 8w, no titration required
214835757|NCT00860262|DRUG|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
214835758|NCT00124618|BIOLOGICAL|cetuximab|
214277660|NCT07016204|BEHAVIORAL|Cognitive-Behavioral Therapy|A structured 12-week psychotherapy protocol targeting maladaptive appearance-related beliefs and behaviors in individuals with Body Dysmorphic Disorder (BDD). The intervention involves individual sessions once per week (60 minutes) and incorporates techniques such as psychoeducation, cognitive restructuring, exposure and response prevention (ERP), mindfulness, and attentional retraining.
214835759|NCT00124618|RADIATION|radiation therapy|
214835760|NCT04980105|BIOLOGICAL|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
214835761|NCT04980105|DRUG|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
214835762|NCT04980105|DRUG|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
214835763|NCT02117141|DRUG|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
214835764|NCT02117141|DRUG|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
214835765|NCT05736250|DIAGNOSTIC_TEST|biopsie|gingival biopsie
214835766|NCT01401296|BEHAVIORAL|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
214835767|NCT01401296|BEHAVIORAL|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
214835768|NCT01116505|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-containing cereals removed from diet
214835769|NCT00899951|DRUG|fentanyl citrate|
214835770|NCT00899951|OTHER|pharmacological study|
214835771|NCT05033145|DRUG|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
214835772|NCT05033145|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
214835773|NCT00882245|OTHER|Vehicle ointment|Topical vehicle cream
214835774|NCT00882245|DRUG|Ointment|SRD441 Ointment
214835775|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
214835776|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
214835777|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
214835778|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
214835779|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
214835780|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
214835781|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
214835782|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
214835783|NCT03001934|OTHER|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
214835784|NCT03161236|OTHER|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
214835785|NCT03161236|OTHER|non exercise program|continue usual lifestyle
214835786|NCT06276153|OTHER|no interventions|retrospective registry cohort with no other specific interventions
214835787|NCT04361838|BEHAVIORAL|prayer|receive prayers daily while in ICU
214835788|NCT02691676|DRUG|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
214835789|NCT02691676|DRUG|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
214835790|NCT06149962|PROCEDURE|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
214835791|NCT02344849|DRUG|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
214835792|NCT03951727|DEVICE|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
214835793|NCT03261843|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
214835794|NCT03261843|PROCEDURE|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
214835795|NCT00935805|DRUG|Metformin|850 mg TID
214835796|NCT00935805|DRUG|Glybenclamide|10 mg BID
214835797|NCT00935805|DRUG|NPH insulin|Variable SC dose
214835798|NCT00935805|DRUG|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
214835799|NCT00935805|DRUG|Propranolol|40 mg BID
214835800|NCT00935805|DRUG|Captopril|50 mg TID
214835801|NCT00935805|DRUG|Amlodipine|10 mg QD
214835802|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
214835803|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
214835804|NCT04099433|DIETARY_SUPPLEMENT|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
214835805|NCT04099433|OTHER|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
214835806|NCT05692115|DIAGNOSTIC_TEST|stress ECG|stress ECG to patients suspected to be ischemic patients .
214835807|NCT04876001|BEHAVIORAL|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
214835808|NCT01037231|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
214835809|NCT01037231|DRUG|Placebo|placebo
214835810|NCT01875887|PROCEDURE|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
214835811|NCT05796843|PROCEDURE|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
214835812|NCT05796843|PROCEDURE|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
214835813|NCT05796843|PROCEDURE|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
214835814|NCT05958433|BEHAVIORAL|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
214835815|NCT03748251|OTHER|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
214835816|NCT03748251|OTHER|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
214835817|NCT03149900|DRUG|Secukinumab|See Arm Description
214835818|NCT03721718|BIOLOGICAL|GLS-5300|\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
214835819|NCT03721718|DEVICE|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
214835820|NCT03275363|DIAGNOSTIC_TEST|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span."
214835821|NCT03275363|DIAGNOSTIC_TEST|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
214835822|NCT03275363|BIOLOGICAL|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
214835823|NCT03275363|DIAGNOSTIC_TEST|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
214835824|NCT03275363|DIAGNOSTIC_TEST|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
214835825|NCT01675596|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
214835826|NCT02313545|DRUG|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
214835827|NCT06246591|OTHER|Extracorporeal Shockwave Therapy (Group A)|Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
214835828|NCT06246591|OTHER|Mesotherapy (Group B)|Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
214835829|NCT04327401|DRUG|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
214835830|NCT03045198|DRUG|Azithromycin|
214835831|NCT02293928|PROCEDURE|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
214835832|NCT02379533|OTHER|Aerobic exercise|
214835833|NCT01751087|OTHER|Mifepristone|oral mifepristone 200 mg on Day 1.
214835834|NCT01751087|DRUG|misoprostol|buccal misoprostol 400 mcg on Day 2
214835835|NCT01751087|DEVICE|Osmotic dilators|osmotic dilators on Day 1
214835836|NCT01751087|OTHER|placebo|placebo for mifepristone, on day 1
214835837|NCT01751087|OTHER|placebo|placebo for misoprostol, on day 2
214835838|NCT00681486|DRUG|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
214835839|NCT00681486|DRUG|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
214835840|NCT04872231|DRUG|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
214835841|NCT04872231|DRUG|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
214835842|NCT02575651|DRUG|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
214835843|NCT00333450|BIOLOGICAL|Pneumococcal vaccine|
214835844|NCT02722421|DRUG|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
214835845|NCT02722421|DRUG|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
214835846|NCT06082505|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
214835847|NCT06082505|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
214835848|NCT04682327|OTHER|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
214835849|NCT04682327|OTHER|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
214835850|NCT03641222|DEVICE|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
214835851|NCT04042415|OTHER|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
214835852|NCT04042415|OTHER|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
214835853|NCT05628311|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
214835854|NCT05628311|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
214835855|NCT01085890|BEHAVIORAL|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
214835856|NCT03017352|DRUG|Exenatide|
214835857|NCT03017352|DRUG|Placebos|
214835858|NCT05735028|DRUG|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
214835859|NCT05735028|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
214835860|NCT02919020|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
214835861|NCT02919020|OTHER|Resistance exercise|resistance exercise to strengthen lower limbs
214835862|NCT05109520|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
214835863|NCT01479062|BEHAVIORAL|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
214835864|NCT01479062|BEHAVIORAL|Usual Care|Placebo Control
214835865|NCT02219009|DEVICE|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
214835866|NCT04311346|DIAGNOSTIC_TEST|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
214835867|NCT00274625|DEVICE|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
214835868|NCT00274625|PROCEDURE|Control|Incision is closed without the placement of a graft material (standard of care control)
214835869|NCT03845816|BEHAVIORAL|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
214835870|NCT06677723|BEHAVIORAL|physical activity|moderate-intensity running
214835871|NCT00006034|BIOLOGICAL|keyhole limpet hemocyanin|Given intradermally and IV
214835872|NCT00006034|DRUG|doxorubicin hydrochloride|Given IV
214835873|NCT00067717|BEHAVIORAL|Distance healing|
214835874|NCT01386034|DRUG|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
214835875|NCT04313296|DEVICE|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
214835876|NCT00459823|DRUG|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
214835877|NCT05402917|PROCEDURE|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
214835878|NCT00817141|OTHER|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
214835879|NCT02456987|DEVICE|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
214835880|NCT02978651|DRUG|Pitolisant (BF2.649)|
214835881|NCT02978651|DRUG|Placebo Oral Tablet|
214835882|NCT02749591|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
214835883|NCT02749591|OTHER|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
214835884|NCT02749591|OTHER|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
214835885|NCT02749591|OTHER|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
214835886|NCT04360408|OTHER|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
214835887|NCT06678815|OTHER|Emergency response|Those delivering or receiving emergency care from a CFR.
214835888|NCT05916716|PROCEDURE|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
214835889|NCT05916716|PROCEDURE|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
214835890|NCT05916716|DEVICE|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
214835891|NCT05916716|DRUG|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
214835892|NCT05916716|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
214835893|NCT04066920|DRUG|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
214835894|NCT03825367|DRUG|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
214835895|NCT03825367|DRUG|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
214835896|NCT03798340|OTHER|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
214835897|NCT03798340|OTHER|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
214835898|NCT03798340|OTHER|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
214835899|NCT06679166|OTHER|No intervention|No intervention
214835900|NCT00491257|BIOLOGICAL|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
214835901|NCT05229055|DRUG|Ketamine|giving ketamine intranasal
214835902|NCT00003850|DRUG|thalidomide|
214835903|NCT03818295|DRUG|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
214835904|NCT03966950|DIETARY_SUPPLEMENT|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
214835905|NCT03966950|DRUG|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
214835906|NCT06236412|BEHAVIORAL|Health education|Health education about the contents listed under each arm will be provided for the participants.
214835907|NCT05867524|OTHER|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
214835908|NCT05867524|OTHER|Cycling test|2 hours of moderate activity level cycling
214835909|NCT01477424|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
214835910|NCT01477424|DRUG|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
214835911|NCT06616103|DIAGNOSTIC_TEST|computerized tomography|noncontrast abdominal CT
214835912|NCT03087786|DRUG|Nicotine Bitartrate Lozenge 4mg|Test Product
214835913|NCT03087786|DRUG|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
214835914|NCT06355830|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
214835915|NCT06787716|DEVICE|The whole body vibration|Patients in the study group will receive the traditional physical therapy program first (passive and active ROM exercises, stretching and strengthening exercises) for 60 minutes, 3 days/ week for 12 weeks.This will be followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program will be three sessions a week for 12 weeks. WBV duration started with 10 min at the 1st week up to 35 min at the 12th week, with a regular increase of five minutes every two successive weeks.
214835916|NCT06787716|OTHER|The traditional physical therapy program|The traditional physical therapy program will be three days a week for 12 weeks. The program will include 60 minutes of a supervised and individualized exercise program including passive and active exercises of the hip, knee, and ankle joints, stretching exercises for the Calf and hamstring muscles followed by strengthening exercises of the hip, knee, ankle, and foot muscles. To improve the strength, free weights will be used for all exercises. During the first week, 50 to 60% of the repetitions maximum test will be set as the starting weight. Then, from the second week to the sixth, the weight will be increased to 70%-75% of three repetitions maximum (3 sets, 4-10 repetitions). The training amplitude then will be raised to 80%-85% of the three-repetition maximum (3 sets, 8-12 repetitions) that will be continued through weeks 7 to 12, holding 5 seconds at the end of the range.
214835917|NCT06616883|DRUG|DA-5221_01|single dose administration (DA-5221\_01 one tablet once a day)
214835918|NCT06616883|DRUG|DA-5221_01-R1 + DA-5221_01-R2|single dose administration (DA-5221\_01-R1 one tablet once a day + DA-5221\_01-R2 one tablet once a day)
214835919|NCT04386109|OTHER|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
214835920|NCT06433193|DEVICE|PAK HD Sorbent Therapy|"Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful."
214835921|NCT05103709|OTHER|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
214835922|NCT05103709|OTHER|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
214835923|NCT02775578|PROCEDURE|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
214835924|NCT02775578|PROCEDURE|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
214835925|NCT02775578|PROCEDURE|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
214835926|NCT00030524|DRUG|gefitinib|
214835927|NCT03662724|DRUG|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
214835928|NCT06073899|OTHER|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
214835929|NCT00880334|DRUG|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
214835930|NCT00880334|DRUG|vandetanib|taken orally once a day, every day
214835931|NCT00880334|DRUG|Placebo|Taken orally once a day every day
214835932|NCT01738217|PROCEDURE|Fluobeam|
214835933|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
214835934|NCT01149434|DRUG|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
214835935|NCT01149434|DRUG|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
214835936|NCT04479735|DEVICE|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
214835937|NCT05296941|PROCEDURE|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
214835938|NCT06148779|BEHAVIORAL|Digitally delivered first-line treatment for osteoarthritis|Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
214835939|NCT06148779|BEHAVIORAL|Face-to-face first-line treatment for osteoarthritis|First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
214835940|NCT06678321|BEHAVIORAL|Mobil game|Participants in the intervention group will be asked to play the game and complete all parts.
214835941|NCT00556699|DRUG|rituximab|Escalating intravenous repeating dose
214835942|NCT00556699|DRUG|SGN-40|Escalating intravenous repeating dose
214835943|NCT05333653|OTHER|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
214835944|NCT05333653|OTHER|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
214835945|NCT02509260|DEVICE|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
214835946|NCT02509260|OTHER|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
214835947|NCT03537911|BEHAVIORAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
214835948|NCT01775722|DEVICE|Pulsed Dye Laser|port wine stain
214835949|NCT01775722|DEVICE|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
214835950|NCT00117182|DRUG|Dry powder mannitol|
214835951|NCT00117182|DRUG|Budesonide 400mcg administered via turbuhaler|
214835952|NCT00117182|DRUG|Ipratropium bromide 80mcg|
214835953|NCT00117182|DRUG|Salbutamol 400mcg|
214835954|NCT03547830|DRUG|Plerixafor|Plerixafor for Conditioning before HSCT.
214835955|NCT03547830|DRUG|Gcsf|GCSF for Conditioning before HSCT.
214835956|NCT01876953|DRUG|cytarabine|Given IV
214835957|NCT01876953|DRUG|idarubicin|Given IV
214835958|NCT01876953|DRUG|dasatinib|Given PO
214835959|NCT01876953|OTHER|laboratory biomarker analysis|Correlative studies
214835960|NCT02419573|DEVICE|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
214835961|NCT02419573|DEVICE|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
214835962|NCT01848717|DEVICE|MINTLIFT®|
214835963|NCT00793234|DRUG|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
214835964|NCT00793234|DRUG|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
214835965|NCT03278158|DRUG|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
214835966|NCT03278158|DRUG|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
214835967|NCT03278158|DRUG|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
214835968|NCT03278158|DRUG|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
214835969|NCT03278158|DRUG|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
214835970|NCT06674135|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
214835971|NCT03730740|DRUG|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
214835972|NCT02809768|DRUG|Avatrombopag|
214835973|NCT02809768|DRUG|Fluconazole|
214835974|NCT02809768|DRUG|Itraconazole|
214835975|NCT02809768|DRUG|Rifampin|
214835976|NCT03635268|OTHER|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
214835977|NCT00033150|BEHAVIORAL|Fast ForWord|
214835978|NCT00033150|BEHAVIORAL|Computer Assisted Language Intervention|
214835979|NCT00033150|BEHAVIORAL|Individual Language Intervention|
214835980|NCT00033150|BEHAVIORAL|Academic enrichment|
214835981|NCT04831138|PROCEDURE|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
214835982|NCT00497250|DRUG|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
214835983|NCT00497250|DEVICE|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
214835984|NCT06236100|BEHAVIORAL|Strengthening Families Program + Family Advocate|This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.
214835985|NCT06236100|BEHAVIORAL|Strengthening Families Program|This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
214835986|NCT03782493|BEHAVIORAL|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
214835987|NCT04195828|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
214835988|NCT04195828|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
214835989|NCT04195828|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
214835990|NCT04195828|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
214835991|NCT04851067|OTHER|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
214835992|NCT04851067|OTHER|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
214464925|NCT05431010|DEVICE|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
214835993|NCT04435249|OTHER|BPF-001|Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold
214835994|NCT06641037|DRUG|LY3866288|Administered orally
214835995|NCT00820885|DRUG|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
214835996|NCT00820885|DRUG|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
214835997|NCT00820885|DRUG|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
214835998|NCT03026153|BEHAVIORAL|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
214835999|NCT03026153|BEHAVIORAL|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
214836000|NCT02229084|BIOLOGICAL|P10s-PADRE/ MONTANIDE™ ISA 51 VG|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions concurrent with chemotherapy.
214836001|NCT02229084|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
214836002|NCT02229084|DRUG|Cyclophosphamide|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
214836003|NCT02229084|DRUG|Docetaxel|"Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.~If docetaxel is not tolerated, paclitaxel (175mg/m2) may be used in its place."
214836004|NCT02923336|DRUG|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
214836005|NCT02809196|BEHAVIORAL|1: Tailored SMS program implicating friend and mother|
214836006|NCT02809196|BEHAVIORAL|2: Standardized SMS program implicating friend and mother|
214836007|NCT02809196|BEHAVIORAL|3: Tailored SMS program implicating friend, not mother|
214836008|NCT02809196|BEHAVIORAL|4: Standardized SMS program implicating friend, not mother|
214836009|NCT02809196|BEHAVIORAL|5: Tailored SMS program implicating mother, not friend|
214836010|NCT02809196|BEHAVIORAL|6: Standardized SMS program implicating mother, not friend|
214836011|NCT02809196|BEHAVIORAL|7: Tailored SMS program not implicating mother or friend|
214836012|NCT02809196|BEHAVIORAL|8: Standardized SMS program not implicating mother or friend|
214836013|NCT02809196|BEHAVIORAL|9: No SMS program|
214836014|NCT04244643|OTHER|data collection|"Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
214836015|NCT00630253|BIOLOGICAL|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
214836016|NCT00630253|DRUG|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
214836017|NCT00630253|DRUG|Fludarabine|35 mg/m\^2 intravenously (IV) on days -6 through -2.
214464926|NCT05431010|BEHAVIORAL|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
214836018|NCT00630253|PROCEDURE|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
214836019|NCT00630253|DRUG|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
214836020|NCT00630253|DRUG|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
214836021|NCT00630253|DRUG|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
214836022|NCT00630253|DRUG|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
214836023|NCT02964663|DEVICE|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
214836024|NCT03210363|OTHER|Human Biological samples|Blood sample
214836025|NCT00905541|DRUG|simvastatin|40 mg/day
214836026|NCT00905541|DRUG|simvastatin|80 mg simvastatin acute-on-chronic
214836027|NCT04174118|DRUG|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
214836028|NCT04174118|DRUG|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
214836029|NCT03066479|DEVICE|Fitbit|Wearable activity \& sleep tracker.
214836030|NCT03066479|OTHER|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
214836031|NCT03066479|DIAGNOSTIC_TEST|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
214836032|NCT03347019|OTHER|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
214836033|NCT03347019|OTHER|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
214836034|NCT02004769|DRUG|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
214836035|NCT02004769|DRUG|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
214836036|NCT02004769|DRUG|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
214836037|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
214836038|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
214836039|NCT05303649|BEHAVIORAL|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
214836040|NCT05303649|DEVICE|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
214836041|NCT01223755|DRUG|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
214836042|NCT01223755|DRUG|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
214836043|NCT05625607|PROCEDURE|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
214836044|NCT00456898|DRUG|desvenlafaxine sustained release (DVS SR)|
214836045|NCT00456898|DRUG|Paroxetine|
214836046|NCT00456898|DRUG|Codeine|
214836047|NCT02284139|DRUG|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
214836048|NCT02284139|DRUG|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
214836049|NCT02284139|DRUG|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
214836050|NCT06083623|BIOLOGICAL|TNM001|single dose intramuscular injection
214836051|NCT06083623|BIOLOGICAL|placebo|single dose intramuscular injection
214836052|NCT03256149|DRUG|Dexamethasone|
214836053|NCT03256149|DRUG|Placebo|Normal saline (IV placebo)
214836054|NCT05086653|PROCEDURE|Surgery|Sutured by Prolene 3-0 with two layers of pledge
214836055|NCT01257451|DRUG|Vildagliptin|vildagliptin 50mg bid
214836056|NCT01257451|DRUG|Placebo|Placebo 50mg bid
214836057|NCT02725996|BIOLOGICAL|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
214836058|NCT02725996|OTHER|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
214836059|NCT04566497|OTHER|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
214836060|NCT04566497|PROCEDURE|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
214836061|NCT00939380|BEHAVIORAL|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
214836062|NCT00939380|OTHER|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
214836063|NCT00939380|OTHER|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
214836064|NCT00939380|OTHER|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
214836065|NCT02179190|DEVICE|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
214836066|NCT00004906|BIOLOGICAL|filgrastim|
214836067|NCT00004906|DRUG|anastrozole|
214836068|NCT00004906|DRUG|carboplatin|
214836069|NCT00004906|DRUG|cisplatin|
214836070|NCT00004906|DRUG|cyclophosphamide|
214836071|NCT00004906|DRUG|docetaxel|
214836072|NCT00004906|DRUG|doxorubicin hydrochloride|
214464927|NCT02947750|DRUG|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
214836073|NCT00004906|DRUG|etoposide|
214836074|NCT00004906|DRUG|pamidronate disodium|
214836075|NCT00004906|DRUG|thiotepa|
214836076|NCT00004906|PROCEDURE|peripheral blood stem cell transplantation|
214836077|NCT03937206|DIETARY_SUPPLEMENT|NutriterraTM|Nutriterra 1000mg
214836078|NCT03937206|DIETARY_SUPPLEMENT|Placebo|Corn Oil 1000mg
214836079|NCT01552330|DRUG|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
214836080|NCT01552330|DRUG|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
214836081|NCT05585489|OTHER|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
214836082|NCT04809844|OTHER|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
214836083|NCT04771767|DRUG|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
214836084|NCT04771767|BEHAVIORAL|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
214836085|NCT05951751|OTHER|TRI-MOM intervention|"The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections"
214836086|NCT05414695|DEVICE|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
214836087|NCT05414695|DEVICE|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
214836088|NCT05983523|DRUG|PEP07|PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
214836089|NCT03506841|DRUG|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
214836090|NCT00384592|DRUG|Esomeprazole|
214836091|NCT00384592|PROCEDURE|Physical exam|
214836092|NCT00384592|PROCEDURE|Pregnancy test if applicable|
214836093|NCT00162968|DRUG|escitalopram|
214836094|NCT05029427|OTHER|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
214836095|NCT05029427|OTHER|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
214836096|NCT01093560|DIETARY_SUPPLEMENT|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
214836097|NCT03504020|DEVICE|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
214836098|NCT04784169|DEVICE|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
214836099|NCT04784169|DEVICE|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
214836100|NCT03232762|DIETARY_SUPPLEMENT|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
214836101|NCT03232762|DIETARY_SUPPLEMENT|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
214836102|NCT04288076|OTHER|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
214836105|NCT04338334|OTHER|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
214836106|NCT04338334|OTHER|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
214836107|NCT01323062|DRUG|Bavituximab|Administered 3 mg/kg weekly
214836108|NCT00881569|DRUG|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
214836109|NCT04714060|BIOLOGICAL|UB-621|mAb by SC administration
214836110|NCT02608424|DEVICE|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
214836111|NCT02948426|BIOLOGICAL|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
214836112|NCT05517096|OTHER|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
214464928|NCT02947750|OTHER|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
214836113|NCT05155293|DRUG|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
214836114|NCT05155293|DRUG|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
214836115|NCT04863131|BIOLOGICAL|EXG-5003|COVID-19 self-replicating mRNA vaccine
214836116|NCT04863131|BIOLOGICAL|Placebo|placebo solution
214836117|NCT06016582|DEVICE|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
214836118|NCT04391829|DIAGNOSTIC_TEST|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
214836119|NCT01954030|DRUG|CTO and Bevacizumab|
214836120|NCT01954030|DRUG|CTO alone|
214836121|NCT05305586|DEVICE|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
214836122|NCT05305586|DEVICE|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
214836123|NCT00180401|BEHAVIORAL|CRT-P and CRT-D devices|
214836124|NCT01968369|DIETARY_SUPPLEMENT|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
214836125|NCT03515044|DRUG|40 mg Rifaximin SSD once daily|SSD once daily (QD)
214836126|NCT03515044|DRUG|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
214836127|NCT03515044|DRUG|80 mg Rifaximin SSD once daily|SSD once daily (QD)
214836128|NCT03515044|DRUG|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
214836129|NCT03515044|DRUG|Placebo|Administered twice daily (BID)
214836130|NCT05215496|DIAGNOSTIC_TEST|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
214836131|NCT01993940|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
214836132|NCT01993940|DRUG|Placebo|Placebo tablet taken orally once a day
214836133|NCT02828566|DRUG|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
214836134|NCT02828566|DRUG|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
214836135|NCT02828566|DRUG|IN saline 0.9%|Intranasal 0.9% normal saline
214836136|NCT02828566|DRUG|IV saline 0.9%|Intravenous 0.9% normal saline
214836137|NCT04225065|OTHER|Chlorhexidine|Chlorhexidine prep prior to surgery
214836138|NCT04225065|OTHER|Betadine|Betadine prep prior to surgery
214836139|NCT06228196|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
214836140|NCT04186286|DRUG|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
214836141|NCT04186286|DRUG|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
214836142|NCT04186286|DRUG|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
214836143|NCT05072119|DEVICE|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
214836144|NCT02052817|DEVICE|Optimal Medical Therapy Debridement + Toad Brace|
214836145|NCT02052817|OTHER|Optimal Medical Therapy - Debridement|
214836146|NCT04842435|DRUG|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
214836147|NCT04842435|DRUG|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
214464929|NCT02947750|DIETARY_SUPPLEMENT|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
214836148|NCT05663255|DRUG|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
214836149|NCT06000163|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the skin, which is non-invasive, and skin thickness and blood flow parameters will be measured.
214836150|NCT05447416|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
214836151|NCT05447416|DEVICE|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
214836152|NCT00091195|DRUG|romidepsin|
214836153|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
214836154|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
214836155|NCT03210038|DRUG|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
214836156|NCT03210038|DRUG|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
214836157|NCT01799850|DRUG|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
214836158|NCT01799850|DRUG|placebo|placebo assigned randomly, double blind
214836159|NCT03946436|DEVICE|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
214836160|NCT03946436|OTHER|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
214836161|NCT06149949|OTHER|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
214836162|NCT02941159|BIOLOGICAL|SF2000SD|This is an intergrase inhibitor
214836163|NCT02941159|BIOLOGICAL|Placebo|
214836164|NCT04164758|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
214836165|NCT04164758|OTHER|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
214836166|NCT04164758|DRUG|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
214836167|NCT03195387|DRUG|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
214836168|NCT00286533|PROCEDURE|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
214836169|NCT00286533|PROCEDURE|Questionnaires|Questionnaires are used.
214836170|NCT03660787|DRUG|Seroguard|Seroguard 0.41 g/L solution
214836171|NCT03660787|DRUG|Placebo|Saline
214836172|NCT02970188|BEHAVIORAL|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
214836173|NCT04404907|OTHER|no intervention|This is a secondary analysis of registry data.
214836174|NCT01189656|BIOLOGICAL|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
214836175|NCT04808388|OTHER|MRI|Using MRI for fat fraction and Biodex for isometric strength
214836176|NCT01909115|DRUG|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
214836177|NCT01909115|DRUG|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
214836178|NCT02858037|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
214836179|NCT00467805|PROCEDURE|Light therapy|
214836180|NCT01670097|DRUG|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
214836181|NCT01670097|DRUG|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
214836182|NCT01670097|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
214836183|NCT01670097|DEVICE|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
214836184|NCT01670097|OTHER|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
214836185|NCT06478745|OTHER|Retrospective and prospective cohort|"* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia."
214836186|NCT06478745|OTHER|Focus group, semi-structured interviews and Photovoice|The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
214836187|NCT06478745|OTHER|Systematic review|No patient recruitment required
214836188|NCT00697827|DEVICE|Interspinous Spacer device|Device: In-Space
214836189|NCT00697827|DEVICE|Interspinous Process Distraction Device|Device: X STOP
214836190|NCT03417427|DRUG|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
214836191|NCT03417427|DRUG|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
214836192|NCT04759989|PROCEDURE|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
214836193|NCT04759989|PROCEDURE|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
214836194|NCT04759989|PROCEDURE|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
214836195|NCT01812239|DRUG|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
214836196|NCT01812239|PROCEDURE|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
214836197|NCT01812239|DRUG|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
214836198|NCT00247013|BEHAVIORAL|Breast Cancer Screening Compliance|
214836199|NCT00768352|OTHER|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
214836200|NCT02386007|DRUG|DW-3101_150mg|
214836201|NCT02386007|DRUG|DW-3101_300mg|
214836202|NCT02386007|DRUG|DW-3101_600mg|
214836203|NCT02386007|DRUG|Placebo|
214836204|NCT05686993|DRUG|Cinnarizine|Cinnarizine oral 30mg TDS
214836205|NCT05686993|DRUG|NIFEdipine ER|Nifedipine oral 60mg daily extended release
214836206|NCT03732833|DRUG|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
214836207|NCT03732833|DRUG|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
214836208|NCT04021511|OTHER|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
214836209|NCT04124354|BEHAVIORAL|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
214836210|NCT01326351|PROCEDURE|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
214836211|NCT01326351|PROCEDURE|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
214836212|NCT01326351|BEHAVIORAL|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
214836213|NCT04780451|DIETARY_SUPPLEMENT|Omega-3 supplementation in recreational runners|Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
214836214|NCT06476782|OTHER|Motor Relearning Program(MRP) and aerobic exercise|Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.
214836215|NCT06476782|OTHER|Motor Relearning Program(MRP)|the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
214836216|NCT00221520|DRUG|midazolam with 2 different levels of sedation scores|
214277661|NCT07016048|PROCEDURE|Try-in of one crown test with a digital wax-up (per group)|"In a CAD/CAM software, we will integrate IOS, CBCT, and FS data into the virtual environment, and it will be possible the articulation of virtual models.~The digital wax-up for the preparation of the crown will be designed by the prosthodontist and then adjusted based on the occlusion obtained in each of the groups.~The steps of clinical procedure are:~1. \- In the first appointment, the patients mention their smile concerns, and the dentist evaluate and diagnoses.~2. \- Digital impressions, and a model of the teeth will be done.~3. \- Diagnostic wax-up, where dentist and dental laboratory plan the wax-up on the study models.~4. \- Diagnostic mock-up, where dentist transfers the diagnostic wax-up to the patient's mouth.~We will evaluate the volumetric difference between the diagnostic wax-ups obtained in each group.~After each mock-up, a questionnaire will be delivered to the patients in order to assess patients's aesthetics and comfort self-perception, using a numeric scale."
214836217|NCT00000562|PROCEDURE|extracorporeal membrane oxygenation|
214836218|NCT02759380|OTHER|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
214836219|NCT00325780|DRUG|Pitavastatin|Pitavastatin 4 mg once daily
214836220|NCT02311894|DRUG|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
214836221|NCT02856776|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D provided in capsule form
214836222|NCT01919827|BIOLOGICAL|Endobronchial infusion of adult mesenchymal stem cells|
214836223|NCT01919827|BIOLOGICAL|Autologous mesenchymal stem cells derived from bone marrow|
214836224|NCT04285073|DEVICE|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
214836225|NCT03965065|DEVICE|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
214836226|NCT03965065|DEVICE|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
214836227|NCT04221048|OTHER|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
214836228|NCT03770130|DRUG|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
214836229|NCT03770130|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment
214836230|NCT04756739|DEVICE|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
214836231|NCT02118324|BEHAVIORAL|Exergaming Program|Participants will exercise through exergaming play.
214836232|NCT03542734|OTHER|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
214836233|NCT04645186|DEVICE|bone graft substitute|Filling bone defects in current clinical practice
214836234|NCT00662896|DRUG|naproxcinod 375 mg bid|naproxcinod 375 mg bid
214836235|NCT00662896|DRUG|naproxcinod 750 mg bid|naproxcinod 750 mg bid
214836236|NCT00662896|DRUG|naproxen 250 mg bid|naproxen 250 mg bid
214836237|NCT00662896|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
214836238|NCT00662896|DRUG|ibuprofen 600 mg tid|ibuprofen 600 mg tid
214836239|NCT05975112|DIAGNOSTIC_TEST|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
214836240|NCT03617419|DEVICE|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
214836241|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
214836242|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
214836243|NCT00702507|DRUG|0.25 % Miconazole Nitrate Ointment|Topical Application
214836244|NCT01199653|PROCEDURE|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
214836245|NCT01199653|PROCEDURE|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
214836246|NCT01534754|DRUG|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
214836247|NCT01534754|DRUG|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
214836248|NCT01534754|DRUG|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
214836249|NCT01534754|DRUG|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
214836250|NCT04609397|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
214836251|NCT04609397|DRUG|Hemay005|Hemay005 tables 45mg bid p.o
214836252|NCT04609397|OTHER|Placebo|placebo to Hemay005 tables bid p.o
214836253|NCT03599583|BEHAVIORAL|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
214836254|NCT00960596|BEHAVIORAL|Health promotion and health education for smoking habits|We provide the education to intervention group.
214836255|NCT05390255|DRUG|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
214836256|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
214836257|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
214836258|NCT00082160|BEHAVIORAL|Meditation|
214836259|NCT00082160|PROCEDURE|Functional Magnetic Resonance Imaging|
214836260|NCT00013364|BEHAVIORAL|Talker variability|
214836261|NCT06533215|OTHER|antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.|"The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml)."
214836262|NCT00382083|DRUG|1000 mg acetaminophen|
214277662|NCT07014930|DRUG|Control session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling.
214836263|NCT00382083|DRUG|800 mg ibuprofen|
214836264|NCT00382083|DRUG|1 oz 4% lidocaine gel|
214836265|NCT04806763|DEVICE|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
214836266|NCT04806763|DEVICE|Control|Distance, single-vision glasses were used as control
214836267|NCT05529576|DRUG|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
214836268|NCT00461669|PROCEDURE|ultrasound examination of the hip|
214836269|NCT02584166|BEHAVIORAL|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
214836270|NCT04989244|BEHAVIORAL|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
214836271|NCT06213792|OTHER|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
214836272|NCT03369496|OTHER|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
214836273|NCT00421863|DRUG|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836274|NCT00421863|DRUG|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836275|NCT00421863|DRUG|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836276|NCT00421863|DRUG|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836277|NCT00421863|DRUG|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836278|NCT00421863|DRUG|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836279|NCT00421863|DRUG|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836280|NCT00421863|DRUG|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836281|NCT00421863|DRUG|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
214836282|NCT02702635|PROCEDURE|DCE MRI of the brain|An MRI of the brain including a DCE sequence
214836283|NCT01740934|OTHER|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
214836284|NCT01740934|OTHER|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
214836285|NCT05260203|DEVICE|RITA (App)|"The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources."
214836286|NCT01277510|DRUG|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
214836287|NCT01277510|DRUG|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
214836288|NCT01277510|DRUG|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
214836289|NCT05317806|DRUG|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
214836290|NCT02768974|DRUG|OPRX-106|Oral delivery, once daily.
214836291|NCT01151696|DRUG|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
214836292|NCT01151696|DRUG|Placebo|Placebo
214836293|NCT02143596|OTHER|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
214836294|NCT01685008|DRUG|MOR00208 (formerly Xmab 5574)|
214277663|NCT07014930|DRUG|Inhibition session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 50 mg of fluvoxamine for 7 consecutive days (CYP2C19 inhibitor).
214836295|NCT02323555|OTHER|Paramedic telephone consultation|
214836296|NCT03144479|PROCEDURE|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
214836297|NCT05055687|DRUG|FL058|2500mg、3000mg
214836298|NCT05055687|DRUG|Placebo|empty bottle
214836299|NCT05055687|DRUG|FL058|500mg、1000mg、2000mg
214836300|NCT05055687|DRUG|Placebo|empty bottle
214836301|NCT00204451|DRUG|0.75 levonorgestrel|
214277664|NCT07014930|DRUG|Induction session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 600 mg of rifampicin for 10 consecutive days (CYP2C19 inducer).
214836302|NCT00204451|DRUG|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
214836303|NCT05219734|DIAGNOSTIC_TEST|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
214836304|NCT05078827|DRUG|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
214836305|NCT05078827|DRUG|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
214836306|NCT05078827|DRUG|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
214836307|NCT03492476|DEVICE|Circaid|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
214836308|NCT03492476|DEVICE|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
214836309|NCT05869162|DRUG|SY-3505|A Third-generation ALK TKI
214836310|NCT03138044|PROCEDURE|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
214836311|NCT00009776|BIOLOGICAL|monoclonal antibody Lym-1|
214836312|NCT00009776|DRUG|cyclosporine|
214836313|NCT00009776|DRUG|paclitaxel|
214836314|NCT00009776|RADIATION|indium In 111 monoclonal antibody Lym-1|
214836315|NCT00009776|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
214836316|NCT04541680|DRUG|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
214836317|NCT04541680|OTHER|Placebo|Placebo
214836318|NCT00592579|DRUG|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
214836319|NCT03750591|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
214836320|NCT03750591|PROCEDURE|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
214836321|NCT03750591|PROCEDURE|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
214836322|NCT03750591|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
214836323|NCT03750591|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214836324|NCT03750591|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214836325|NCT03750591|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214836326|NCT03750591|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
214836327|NCT00642057|DRUG|tetrabenazine|25 mg titrated to optimal dose per patient
214836328|NCT00499473|DRUG|sunitinib malate|Given orally
214836329|NCT00499473|OTHER|pharmacological study|Correlative studies
214836330|NCT03757520|DIAGNOSTIC_TEST|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
214836331|NCT03757520|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
214836332|NCT02373839|OTHER|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
214836333|NCT03706508|PROCEDURE|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
214836334|NCT03335241|DRUG|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
214836335|NCT03335241|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
214836336|NCT01182792|DIETARY_SUPPLEMENT|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
214836337|NCT01182792|DIETARY_SUPPLEMENT|Placebo|1 month Placebo
214836338|NCT01603667|DRUG|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
214836339|NCT01603667|DRUG|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
214836340|NCT02330016|DEVICE|Voluma XC|Voluma XC
214836341|NCT02581917|OTHER|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
214836342|NCT02581917|OTHER|Laboratory Biomarker Analysis|Undergo metabolic analysis
214836343|NCT02586324|BIOLOGICAL|global medium|
214836344|NCT02586324|BIOLOGICAL|SSM|
214836345|NCT01268839|DRUG|TMC278|25mg tablet once daily for 28 days
214836346|NCT01268839|DRUG|TMC278|25mg tablet once daily for 14 days
214836347|NCT01268839|DRUG|Efavirenz|600mg tablet once daily for 14 days
214836348|NCT01377441|DRUG|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
214836349|NCT01377441|DRUG|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
214836350|NCT05654363|PROCEDURE|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
214836351|NCT05654363|PROCEDURE|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
214836352|NCT00112216|BIOLOGICAL|Melan-A analog peptide|
214836353|NCT00112216|BIOLOGICAL|FluMa peptide|
214836354|NCT00112216|BIOLOGICAL|Mage-A10 peptide|
214836355|NCT00112216|BIOLOGICAL|SB AS-2 adjuvant|
214836356|NCT00112216|BIOLOGICAL|Montanide adjuvant|
214836357|NCT02398734|DEVICE|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
214836358|NCT01875055|DEVICE|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
214836359|NCT01875055|DEVICE|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
214836360|NCT02473055|OTHER|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
214836361|NCT04817514|OTHER|Shoulder rehabilitation exercises and aerobic exercises|"SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines."
214836362|NCT00784095|OTHER|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
214836363|NCT00784095|OTHER|Attention Control|Subjects will listen to a non-guided relaxation CD.
214836364|NCT01816230|DRUG|NiCord®|
214836365|NCT04642781|DIAGNOSTIC_TEST|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
214836366|NCT06390813|BEHAVIORAL|Otago Exercise Training|A total of 18 sessions of Otago Training were conducted 3 days a week for 6 weeks, each session lasting 60 minutes in total, including 5 minutes of warm-up and cool-down periods.
214836367|NCT06390813|BEHAVIORAL|Square Stepping Exercise Training|A total of 18 sessions of SSE were performed 3 days a week for 6 weeks, each session lasting 40 minutes.
214836368|NCT06403150|DRUG|Levetiracetam Injection|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
214836369|NCT06403150|DRUG|Fosphenytoin Injection|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
214836370|NCT02177552|DRUG|Carboplatin|
214836371|NCT02177552|DRUG|Docetaxel|
214836372|NCT02177552|DRUG|Capecitabine|
214836373|NCT02177552|DRUG|Epirubicin|
214836374|NCT02177552|DRUG|Oxaliplatin|
214836375|NCT02667951|OTHER|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
214836376|NCT06678451|DRUG|Sugammadex|When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
214836377|NCT06678451|DRUG|Neostigmine|When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
214836378|NCT04522245|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
214836379|NCT04522245|OTHER|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
214836380|NCT00966628|DRUG|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
214836381|NCT00966628|DRUG|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
214836382|NCT03893617|DRUG|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
214836383|NCT03893617|DRUG|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
214836384|NCT03893617|BEHAVIORAL|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
214836385|NCT03893617|BEHAVIORAL|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
214836386|NCT06340698|BEHAVIORAL|Resilience intervention|"Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing."
214836387|NCT06340698|BEHAVIORAL|Adherence intervention|"Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems."
214836388|NCT03202251|OTHER|It's is a cohort|It is a prospective, observational, cohort study
214836389|NCT05183282|DEVICE|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
214836390|NCT03025451|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
214836391|NCT04664751|OTHER|Nil-per-Oral|NPO details
214836392|NCT02092701|DRUG|Cholecalciferol|
214836393|NCT01591824|OTHER|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation."
214836394|NCT01591824|OTHER|column exercise group|"* paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises"
214836395|NCT06103760|DRUG|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
214836396|NCT00057941|DRUG|anastrozole|Given orally
214836397|NCT00057941|DRUG|gefitinib|Given orally
214836398|NCT00057941|DRUG|fulvestrant|Given intramuscularly
214836399|NCT00057941|OTHER|laboratory biomarker analysis|Correlative studies
214836400|NCT04956848|DEVICE|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
214836401|NCT06127186|DIAGNOSTIC_TEST|Swab test for viral antigens|No intervention except for a routine examination and viral testing is planned.
214836402|NCT01173536|DRUG|GDC-0449|Oral repeating dose
214836403|NCT01173536|DRUG|moxifloxacin|Oral single dose
214836404|NCT01173536|DRUG|placebo|Oral repeating dose
214836405|NCT02775058|DEVICE|synergoss Pxx|dental grafting
214836406|NCT00892749|DRUG|ASP1585|oral
214836407|NCT06679387|DRUG|Memantine-HCl|Memantine hydrochloride 20 mg once daily for 12 weeks.
214836408|NCT06679387|DRUG|Placebo Oral Tablet|A once daily matched tablet of placebo for 12 weeks
214836409|NCT01898598|DRUG|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
214836410|NCT01898598|DRUG|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
214836411|NCT02650973|DRUG|CHS-1701|
214836412|NCT02650973|DRUG|Pegfilgrastim|
214836413|NCT03833427|DRUG|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.
214836414|NCT03833427|DRUG|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
214836415|NCT02894827|BIOLOGICAL|Blood sample|
214836416|NCT02894827|OTHER|Flow cytometry|
214836417|NCT02894827|OTHER|western blot|
214836418|NCT04513327|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
214836419|NCT04513327|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
214836420|NCT05008120|OTHER|No intervention|No intervention
214836421|NCT04320576|DEVICE|Bulk-fill|Bulk-fill resin composite (bulk technique)
214836422|NCT04320576|DEVICE|Nano-fill|Nano-fill resin composite (layering technique)
214836423|NCT03526562|BEHAVIORAL|Exercise|Exercise according to dose escalation
214836424|NCT02069262|OTHER|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
214836425|NCT03439995|OTHER|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
214836426|NCT03439995|OTHER|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
214836427|NCT00176891|PROCEDURE|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
214836428|NCT00176891|DRUG|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
214836429|NCT03930069|DRUG|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
214836430|NCT03930069|DRUG|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
214836431|NCT03059329|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
214836432|NCT01499160|DRUG|letrozole|Drug is are to be taken orally. 2.5 mg once daily
214836433|NCT01499160|DRUG|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
214836434|NCT01499160|DRUG|everolimus|Drug is to be taken orally. 5 mg once daily.
214836435|NCT03212820|PROCEDURE|Drilling at low speed|
214836436|NCT03212820|PROCEDURE|Drilling at conventional or high speed|
214836437|NCT02742701|OTHER|diagnosis|Measurement of glycosuria
214836438|NCT00222040|RADIATION|Ultrasound|2-MHz, low intensity transcranial ultrasound
214836439|NCT00222040|DRUG|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
214836440|NCT01763658|DRUG|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
214836441|NCT01763658|OTHER|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
214836442|NCT04411017|PROCEDURE|Endoscopy|Colonoscopy
214836443|NCT02339363|BEHAVIORAL|Sitting Meditation|4 weeks Sitting Meditation
214836444|NCT02339363|BEHAVIORAL|Hatha yoga|4 weeks of Hatha yoga
214836445|NCT00862212|BEHAVIORAL|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
214836446|NCT04436718|DIAGNOSTIC_TEST|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
214836447|NCT04554264|OTHER|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score \> 25 indicate complicated grief.
214836448|NCT02361736|DRUG|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
214836449|NCT02361736|DRUG|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
214836450|NCT03041532|PROCEDURE|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
214836451|NCT03041532|PROCEDURE|Frontal view|The investigator explore twice right colon with frontal viewing
214836452|NCT00730652|BIOLOGICAL|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
214836453|NCT03455036|OTHER|Whole body vibration training|10 x 1 min whole body vibration exposure
214836454|NCT02672761|BEHAVIORAL|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
214836455|NCT02672761|BEHAVIORAL|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
214836456|NCT02672761|BEHAVIORAL|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
214836457|NCT02672761|BEHAVIORAL|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
214836458|NCT03096067|OTHER|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
214836459|NCT03096067|OTHER|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
214836460|NCT05107739|BIOLOGICAL|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
214836461|NCT05746143|DRUG|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
214836462|NCT05746143|DRUG|Placebo|two days preoperatively and five days postoperatively
214836463|NCT05377294|OTHER|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
214836464|NCT03789630|DEVICE|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
214836465|NCT05533151|DEVICE|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
214836466|NCT02828631|DEVICE|Macintosh laryngoscope|
214836467|NCT02828631|DEVICE|McGrath videolaryngoscope|
214836468|NCT02828631|DEVICE|Pentax videolaryngoscope|
214836469|NCT00574769|DRUG|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
214836470|NCT00348517|OTHER|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
214836471|NCT00348517|OTHER|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
214836472|NCT05589636|DIETARY_SUPPLEMENT|Bergamot Juice|Bergamot Juice (35% in water)
214836473|NCT04349696|DRUG|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
214836474|NCT04384289|PROCEDURE|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
214836475|NCT02387762|DRUG|acalabrutinib|
214836476|NCT02387762|DRUG|Placebo|
214836477|NCT02977416|OTHER|anti-TNFα|
214836478|NCT01918813|DRUG|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
214836479|NCT00526136|DRUG|Placebo|
214836480|NCT00526136|DRUG|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
214836481|NCT02050165|DIETARY_SUPPLEMENT|KIND Bars|Consumption of KIND Bars for 12 weeks
214836482|NCT02050165|DIETARY_SUPPLEMENT|Typical American Snack|Consumption of typical American snacks for 12 weeks
214836483|NCT01118767|OTHER|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
214836484|NCT01596127|DRUG|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
214836485|NCT00141258|DRUG|pregabalin|
214836486|NCT01573663|DRUG|Ambroxol and Levodropropizine|Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
214836487|NCT01573663|DRUG|Ambroxol|Ambroxol HCl 30mg, PO, single dose
214836488|NCT01573663|DRUG|Levodropropizine|Levodropropizine 60mg, PO, single dose
214836489|NCT00637533|PROCEDURE|Lumbar sympathetic block with Botulinum Toxin type A|
214836490|NCT06623695|OTHER|Exercise|SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
214836491|NCT06623695|OTHER|Exercise|USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
214836492|NCT03311061|OTHER|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
214836493|NCT02542254|DRUG|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
214836494|NCT02542254|DRUG|Ipratropium|40 micrograms ipratropium administered using a pMDI
214836495|NCT02542254|DRUG|RPL554|6 mg RPL554 administered using a nebuliser
214836496|NCT02542254|DRUG|Salbutamol matched placebo|Placebo pMDI
214836497|NCT02542254|DRUG|Ipratropium matched placebo|Placebo pMDI
214836498|NCT02542254|DRUG|RPL554 matched placebo|Nebulised placebo
214836499|NCT04816396|BEHAVIORAL|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
214836500|NCT03069963|DRUG|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
214836501|NCT03069963|DRUG|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
214836502|NCT02246348|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
214836503|NCT04895553|OTHER|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
214836504|NCT00987480|DRUG|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
214836505|NCT00987480|DEVICE|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
214836506|NCT03698357|BEHAVIORAL|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
214836507|NCT03698357|BEHAVIORAL|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
214836508|NCT00989716|DRUG|Transdermal glyceryl trinitrate patch|5mg per day
214836509|NCT00989716|DRUG|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
214836510|NCT02279277|BEHAVIORAL|Supervised physical therapy program prior to total knee replacement surgery|
214836511|NCT01855880|BIOLOGICAL|AbGn-168H|
214836512|NCT01855880|BIOLOGICAL|placebo|
214836513|NCT00688844|DRUG|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
214836514|NCT02803879|DEVICE|Cardiogoniometry|
214836515|NCT05511662|OTHER|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
214836516|NCT01721551|OTHER|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
214836517|NCT01721551|OTHER|Usual Treatment|The CON group received no intervention but the usual treatment
214836518|NCT04196296|BEHAVIORAL|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
214836519|NCT04196296|BEHAVIORAL|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
214836520|NCT01374451|DRUG|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
214836521|NCT01374451|DRUG|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
214836522|NCT04876716|DRUG|Azole|Dosing according to the SPC
214836523|NCT04876716|DRUG|Anidulafungin|200mg loading dose on day 1 and 100mg QD thereafter
214836524|NCT00259194|BEHAVIORAL|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
214836525|NCT00259194|BEHAVIORAL|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
214836526|NCT00563394|DRUG|ofloxacin|400 mg twice a day for 14 days
214836527|NCT00563394|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
214836528|NCT01071551|BEHAVIORAL|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
214836529|NCT01071551|BEHAVIORAL|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
214836530|NCT01360216|BEHAVIORAL|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
214836531|NCT01282450|RADIATION|Radiotherapy|Radiotherapy
214836532|NCT01223027|DRUG|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
214836533|NCT01223027|DRUG|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
214836534|NCT03345043|BIOLOGICAL|VAL-339851|Escalating dose levels
214836535|NCT03345043|OTHER|Placebo|Saline
214836536|NCT04651816|BEHAVIORAL|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
214836537|NCT04651816|BEHAVIORAL|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
214836538|NCT04651816|BEHAVIORAL|DPP Program|All Participants will be enrolled in the DPP program.
214836539|NCT00704249|DRUG|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
214836540|NCT00704249|DRUG|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
214836541|NCT01656876|BEHAVIORAL|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
214836542|NCT01656876|OTHER|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
214836543|NCT01656876|BEHAVIORAL|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
214836544|NCT01402934|PROCEDURE|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
214836545|NCT00540358|DRUG|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
214836546|NCT00540358|DRUG|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
214836547|NCT02946255|BEHAVIORAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
214836548|NCT02946255|BEHAVIORAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
214836549|NCT02946255|BEHAVIORAL|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
214836550|NCT05748938|BIOLOGICAL|RD14-01|ROR1 Targeted CAR-T cells
214836551|NCT02895841|OTHER|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
214836552|NCT03201003|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
214836553|NCT03201003|OTHER|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
214836554|NCT02934334|OTHER|Observational|
214836555|NCT01107028|OTHER|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
214836556|NCT01132417|DRUG|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
214836557|NCT01686217|DRUG|ASP015K ER|oral extended release (ER) at three dosing levels
214836558|NCT01686217|DRUG|ASP015K IR|oral immediate release (IR)
214836559|NCT00843089|OTHER|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
214836560|NCT02269735|DRUG|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
214836561|NCT02269735|BIOLOGICAL|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
214836562|NCT02269735|DRUG|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
214836563|NCT02269735|BIOLOGICAL|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
214836564|NCT02269735|DRUG|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
214836565|NCT04618172|OTHER|Exercise|30 minute long exercises twice a week
214836566|NCT06177405|DRUG|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
214836567|NCT06249113|DRUG|NaCl 0.9%|NaCl 0.9% continous intravenous on tumor craniotomy surgery
214836568|NCT06249113|DRUG|Adjuvant lidocaine continous|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
214836569|NCT01715077|DRUG|Ipilimumab at 3 mg/kg dose|
214277665|NCT07014566|OTHER|Digital Combined Decongestive Therapy|The intervention consisted of a digitally delivered combined decongestive therapy (CDT) program for patients with unilateral or bilateral lower extremity lymphedema. Patients attended a single face-to-face session where a physiotherapist provided training on skin care, self-bandaging, self-manual lymphatic drainage, and therapeutic exercises (breathing, gluteal sets, knee sets, and toe movements). Caregivers recorded the demonstrations for home use. Following this session, a 4-week remote physiotherapy program was implemented using telecommunication technologies. Patients continued self-management with guidance via digital platforms. Compression stockings replaced self-bandaging during the 12-week follow-up phase.
214836570|NCT00834613|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
214836571|NCT00834613|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
214836572|NCT05013619|OTHER|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
214836573|NCT05013619|OTHER|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
214836574|NCT05013619|OTHER|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
214836575|NCT05013619|OTHER|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
214836576|NCT05806177|DRUG|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
214836577|NCT05806177|DRUG|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
214836578|NCT00663234|DRUG|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
214836579|NCT02643407|DRUG|Docetaxel|60mg/m2
214836580|NCT02643407|DRUG|Nedaplatin|80mg/m2
214836581|NCT02643407|DRUG|Cisplatin|75mg/m2
214836582|NCT02993562|DRUG|Levothyroxine|Normal treatment with levothyroxine.
214836583|NCT00065962|DRUG|secretin, synthetic porcine|
214836584|NCT00065962|DRUG|secretin, biologically derived porcine|
214836585|NCT01994980|DRUG|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
214836586|NCT04112199|DRUG|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
214836587|NCT00382187|BIOLOGICAL|MF59 adjuvanted H5N1 influenza vaccine|"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"
214836588|NCT04164706|DEVICE|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
214836589|NCT04164706|OTHER|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
214836590|NCT03332433|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
214836591|NCT01581164|BIOLOGICAL|Influenza vaccine|Influenza vaccine: Injection, post transplant
214836592|NCT01581164|BIOLOGICAL|Varicella vaccine|Varicella vaccine: Injection, post transplant
214836593|NCT05259657|BEHAVIORAL|Lymfit Intervention|"Participants will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The research team will reach out to the participant via videoconferencing and help them to: download the Fitbit smartphone application; log-in using the anonymous study identification information; and pair their Fitbit with their smartphone application.~A kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed, plus an acceptability assessment survey."
214836594|NCT05259657|BEHAVIORAL|Wait-list control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
214836595|NCT00748137|DEVICE|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
214836596|NCT00748137|OTHER|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
214836597|NCT03613038|BEHAVIORAL|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
214836598|NCT01709903|DRUG|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
214836599|NCT01709903|DRUG|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
214836600|NCT01709903|DRUG|Placebo to QVA149|Placebo to QVA149 with SDDPI
214836601|NCT01709903|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
214836602|NCT01121744|DEVICE|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
214836603|NCT06405854|OTHER|Exercise|Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
214836604|NCT02258035|OTHER|Blood draw|Sampling of 100-150 ml of blood
214836605|NCT01368354|BEHAVIORAL|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
214836606|NCT02061280|DRUG|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
214836607|NCT02061280|DRUG|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
214836608|NCT02061280|DRUG|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
214836609|NCT00271115|BEHAVIORAL|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
214836610|NCT04728828|BIOLOGICAL|Serological COVID-19 vaccine immunogenicity|Serological test
214836611|NCT00096460|DRUG|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
214836612|NCT00096460|DRUG|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
214836613|NCT00096460|RADIATION|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days."
214836614|NCT00096460|DRUG|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
214836615|NCT00096460|PROCEDURE|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
214836616|NCT00096460|PROCEDURE|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
214836617|NCT00096460|DRUG|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
214836618|NCT00096460|DRUG|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
214836619|NCT04164030|BEHAVIORAL|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
214836620|NCT04164030|BEHAVIORAL|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
214836621|NCT06485284|BEHAVIORAL|El Camino|"El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships."
214836622|NCT06485284|BEHAVIORAL|Life skills program|Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
214836623|NCT00079287|DRUG|carboplatin|
214836624|NCT00079287|DRUG|docetaxel|
214836625|NCT00079287|DRUG|gemcitabine hydrochloride|
214836626|NCT00079287|DRUG|paclitaxel|
214836627|NCT00079287|DRUG|vinorelbine tartrate|
214836628|NCT01693809|DRUG|Caffeine|
214836629|NCT06375915|RADIATION|radioembolization with Y-90|Radioembolization with Y-90 will be performed in nominal day 0
214836630|NCT06375915|DRUG|Durvalumab|Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
214836631|NCT06375915|DRUG|Cisplatin|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
214836632|NCT06375915|DRUG|Gemcitabine|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
214836633|NCT04169815|DIAGNOSTIC_TEST|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
214836634|NCT00809705|DRUG|Placebo|sc once weekly for 12 weeks
214836635|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
214836636|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 12 weeks
214836637|NCT01756885|DRUG|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
214836638|NCT01756885|DRUG|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
214836639|NCT01756885|BEHAVIORAL|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
214836640|NCT02812381|PROCEDURE|KT|to aplicate neuromuscular bandage technique(KT)
214836641|NCT02812381|PROCEDURE|SCS|To aplicate strain-counterstrain above trigger point
214836642|NCT03572582|DRUG|Nivolumab|Nivolumab therapy combined with standard TACE treatment
214836643|NCT03572582|DRUG|TACE|TACE is performed by using drug eluting beads
214836644|NCT03643731|DEVICE|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
214836645|NCT01131091|DRUG|SK-0403|SK-0403 400 mg
214836646|NCT06391450|DRUG|Empagliflozin 10 MG|Oral
214836647|NCT06391450|DRUG|Placebo|Oral
214836648|NCT00545428|PROCEDURE|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
214836649|NCT02061358|DRUG|UV-4B 3 mg|Oral solution, single dose
214836650|NCT02061358|DRUG|UV-4B 10 mg|Oral solution, single dose
214836651|NCT02061358|DRUG|UV-4B 30 mg|Oral solution, single dose
214836652|NCT02061358|DRUG|UV-4B 90 mg|Oral solution, single dose
214836653|NCT02061358|DRUG|UV-4B 180 mg|Oral solution, single dose
214836654|NCT02061358|DRUG|UV-4B 360 mg|Oral solution, single dose
214836655|NCT02061358|DRUG|UV-4B 720 mg|Oral solution, single dose
214836656|NCT02061358|DRUG|UV-4B 1000 mg|Oral solution, single dose
214836657|NCT02061358|DRUG|Placebo|Oral solution, single dose
214836658|NCT00724958|BIOLOGICAL|Infliximab|Not specified in the protocol.
214836659|NCT05605652|PROCEDURE|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
214836660|NCT00697619|DRUG|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
214836661|NCT03711448|DRUG|prednisone treatment|tapering prednisone regimen
214836662|NCT03711448|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
214836663|NCT03711448|OTHER|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
214836664|NCT03711448|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
214836665|NCT04247841|OTHER|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
214836666|NCT04247841|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
214836667|NCT06028477|DEVICE|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
214836668|NCT01071876|DRUG|BF2.649|1 capsule in the morning before breakfast
214836669|NCT01071876|DRUG|Placebo|1 capsule in the morning before breakfast
214836670|NCT06366113|OTHER|Pulmonary rehabilitation|"Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education"
214836671|NCT00471510|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
214836672|NCT06179641|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.
214836673|NCT06179641|PROCEDURE|IPACK block|The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
214836674|NCT02213705|BIOLOGICAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
214836675|NCT02849951|DRUG|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
214836676|NCT02849951|DRUG|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
214836677|NCT01374945|DEVICE|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
214836678|NCT03850522|BIOLOGICAL|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
214836679|NCT06622239|DRUG|Naltrexone|naltrexone 50mg for 6 weeks
214836680|NCT06622239|DRUG|Placebo|placebo for 6 weeks
214836681|NCT03093025|DRUG|TS-121 10 mg|Orally taken once daily
214836682|NCT03093025|DRUG|TS-121 50 mg|Orally taken once daily
214836683|NCT03093025|DRUG|Placebo|Orally taken once daily
214836684|NCT01664169|OTHER|laboratory biomarker analysis|
214836685|NCT05462548|DRUG|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
214836686|NCT05770011|DEVICE|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
214836687|NCT05770011|DEVICE|impression material|conventional recording
214836688|NCT05770011|DEVICE|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
214836689|NCT05862987|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
214836690|NCT05862987|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
214836691|NCT01209988|DRUG|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
214836692|NCT01209988|OTHER|No medication|No medication
214836693|NCT03035643|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
214836694|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
214836695|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
214836696|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
214836697|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
214836698|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
214836699|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
214836700|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
214836701|NCT05590390|DIAGNOSTIC_TEST|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
214836702|NCT05590390|DIAGNOSTIC_TEST|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
214836703|NCT05590390|DIAGNOSTIC_TEST|PROs|questionnaires to investigate patients reported outcome on quality of life
214836704|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
214836705|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
214836706|NCT03436316|DRUG|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
214836707|NCT02756949|OTHER|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
214836708|NCT02756949|DEVICE|Smartphone|
214836709|NCT02700971|PROCEDURE|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
214836710|NCT04413461|OTHER|TENS|Transcutaneous Electro Neuro Stimulation
214836711|NCT04413461|OTHER|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
214836712|NCT00249717|BEHAVIORAL|Contingency management|Receive rewards (prizes) abstinence and attendance
214836713|NCT05060458|OTHER|No intervention|No intervention
214836714|NCT05157048|OTHER|Charcoal-filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
214277666|NCT07014696|PROCEDURE|PNF application Group|PNF Application; in the application method, the subjects will be in a sitting position. The application will be made to the fingers, wrist and forearm in both D1 and D2 directions in flexion and extension patterns. The techniques will start using rhythmic initiation, then the combination of isotonics, dynamic-opposite, rhythmic stabilization and muscle-relaxation are determined. The movements will be made in 10 repetitions with rest in between (Saklecha et al., 2023).
214277667|NCT07014696|PROCEDURE|KB application Group|KB Application; In the taping treatment to be applied, taping will be applied starting from the fingers and up to the elbow with kinesiology taping (Huang et al., 2019). Taping will be done 3 days a week and the tape will remain on the patient for 2 days.
214836715|NCT05157048|OTHER|Non-charcoal filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
214836716|NCT05746507|BEHAVIORAL|Night Respite Care|(see description above)
214836717|NCT00545116|OTHER|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
214836718|NCT00929981|DRUG|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
214836719|NCT02769650|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
214836720|NCT02769650|DRUG|Optimal medicamentous treatment|
214836721|NCT02769650|PROCEDURE|Stress-MRI|A standard stress-MRI test with adenosine
214836722|NCT05648539|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
214836723|NCT05581134|DEVICE|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
214836724|NCT05581134|BEHAVIORAL|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
214836725|NCT05184803|DRUG|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
214836726|NCT00497679|DRUG|AZD1152|7-day continuous intravenous infusion
214836727|NCT03348488|PROCEDURE|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
214836728|NCT01355328|PROCEDURE|laser and radiofrequency|different laser and radiofrequency with different fluences
214836729|NCT06628609|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
214836730|NCT06628609|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
214836731|NCT06628609|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
214836732|NCT06628609|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
214836733|NCT06677983|OTHER|Bioflex Crowns|A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.
214836734|NCT06677983|OTHER|Stainless steel crown|An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
214836735|NCT05122351|DRUG|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
214836736|NCT05550831|PROCEDURE|Radiofrequency|Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
214836737|NCT04397640|DIAGNOSTIC_TEST|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
214836738|NCT04931160|OTHER|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
214836739|NCT01754376|DRUG|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
214836740|NCT01754376|DRUG|Vemurafenib|Tablets given twice daily.
214836741|NCT02502968|DRUG|Cytarabine|
214836742|NCT02502968|DRUG|BL-8040|
214836743|NCT02502968|DRUG|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
214836744|NCT01056926|BEHAVIORAL|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
214836745|NCT01056926|DRUG|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
214836746|NCT01056926|DRUG|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
214836747|NCT03098186|BEHAVIORAL|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
214836748|NCT03098186|BEHAVIORAL|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
214836749|NCT00071539|DRUG|TP-38|Recombinant chimeric protein
214836750|NCT00071539|DRUG|TP38|recombinant chimeric protein
214836751|NCT01737255|OTHER|Whole body MRI|Individuals will undergo whole body and brain MRI
214836752|NCT01737255|OTHER|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
214836753|NCT00396955|DRUG|PLA-695|
214836754|NCT04556734|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
214836755|NCT04556734|DRUG|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
214836756|NCT04556734|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily
214836757|NCT01015924|PROCEDURE|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
214836758|NCT01015924|PROCEDURE|ESIN|Elastiv stable intramedullary nailing
214836759|NCT03869424|OTHER|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
214836760|NCT04449458|BEHAVIORAL|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
214836761|NCT04449458|BEHAVIORAL|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
214277668|NCT07014696|PROCEDURE|PNF+KB application Group|PNF+ KB Application; In this application, both PNF and taping will be applied. After each application, conventional treatment will be applied to all three groups at the end of each session. When all treatments are completed, re-evaluations will be made by the blind physiotherapist
214836762|NCT02342041|DRUG|SUVN-G3031|
214836763|NCT02342041|DRUG|Placebo|
214836764|NCT01291641|DRUG|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
214836765|NCT01291641|DRUG|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
214836766|NCT01291641|DRUG|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
214836767|NCT04264819|DRUG|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
214836768|NCT02400463|DRUG|Ruxolitinib|
214836769|NCT00602615|DRUG|Torsemide|
214836770|NCT03481855|DEVICE|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
214836771|NCT02503813|PROCEDURE|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
214836772|NCT00313508|BIOLOGICAL|Autologous Dendritic Cells (DC)|Given intranodally
214836773|NCT00313508|DRUG|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
214836774|NCT00313508|BIOLOGICAL|Autologous Lymphocyte Infusion (ALI)|Infusion
214836775|NCT06504303|DEVICE|3D-printed socket|During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
214836776|NCT00458445|DRUG|SPD465|
214836777|NCT00458445|OTHER|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
214836778|NCT00374049|DRUG|MUC_1|Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
214836779|NCT04688372|OTHER|Surge Index|See study description above
214836780|NCT00377572|BIOLOGICAL|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
214836781|NCT00377572|BIOLOGICAL|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
214836782|NCT02937506|DRUG|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
214836783|NCT02937506|DRUG|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
214836784|NCT04522999|DEVICE|Photobiomodulation|The Valeda™ Light Delivery System
214836785|NCT06424691|DIETARY_SUPPLEMENT|Tailored Recommendations|Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
214836786|NCT06424691|BEHAVIORAL|Consult Call|Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
214836787|NCT06424691|BEHAVIORAL|Email Series|Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
214836788|NCT05962268|OTHER|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
214836789|NCT05962268|OTHER|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
214836790|NCT06237101|DRUG|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
214836791|NCT06237101|DRUG|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
214836792|NCT03977168|PROCEDURE|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
214836793|NCT03393481|DRUG|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
214836794|NCT03393481|DRUG|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
214836795|NCT00769314|DRUG|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
214277669|NCT07016256|DEVICE|intraoral devices|Intraoral devices not registed with a patent
214836796|NCT00769314|DRUG|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
214836797|NCT04157452|PROCEDURE|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
214836798|NCT03908528|DIETARY_SUPPLEMENT|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
214836799|NCT03908528|OTHER|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
214836800|NCT03224078|OTHER|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
214836801|NCT05922488|PROCEDURE|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
214836802|NCT05922488|PROCEDURE|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
214836803|NCT00497588|PROCEDURE|surgery|
214836804|NCT00497588|RADIATION|radiotherapy|
214836805|NCT03480685|DEVICE|IVUS and OCT Imaging|Use of an imaging catheter
214836806|NCT03701126|PROCEDURE|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
214836807|NCT03701126|PROCEDURE|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
214836808|NCT03701126|DRUG|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
214836809|NCT03701126|DEVICE|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
214836810|NCT03217526|OTHER|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
214836811|NCT06148662|OTHER|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
214836812|NCT06148662|OTHER|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
214836813|NCT06148662|DRUG|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
214836814|NCT06148662|DRUG|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
214836815|NCT06148662|DRUG|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
214836816|NCT02838940|PROCEDURE|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
214836817|NCT02838940|DRUG|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
214836818|NCT02853539|DRUG|Denosumab|Subcutaneous injection of Denosumab
214836819|NCT01188226|DEVICE|Denture teeth|Denture teeth made of nano hybrid composite material
214836820|NCT01662024|DEVICE|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
214836821|NCT00304434|DRUG|Oseltamivir|
214836822|NCT00304434|DRUG|Probenecid|
214836823|NCT05105659|DIAGNOSTIC_TEST|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
214836824|NCT05105659|DIAGNOSTIC_TEST|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
214836825|NCT05105659|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
214836826|NCT05105659|DIAGNOSTIC_TEST|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
214836827|NCT05105659|DIAGNOSTIC_TEST|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
214836828|NCT04977596|OTHER|No intervention|Retrospective study without intervention
214836829|NCT05582109|DRUG|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
214836830|NCT02413528|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
214836831|NCT02413528|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
214836832|NCT00030407|DRUG|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
214836833|NCT00030407|DRUG|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
214836834|NCT02846883|BIOLOGICAL|1 million MSCs/kg|Intravenous infusion of 1 million allogeneic MSCs/kg.
214836835|NCT02846883|BIOLOGICAL|3 million MSCs/kg|Intravenous infusion of 3 million allogeneic MSCs/kg
214836836|NCT02846883|DRUG|Placebo|Intravenous infusion of Plasmalyte A (placebo)
214836837|NCT00000745|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
214836838|NCT00000745|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214836839|NCT03440333|DRUG|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
214836840|NCT01866176|DEVICE|Stabilizing Knee Brace|Brace with no valgus action
214836841|NCT01866176|DEVICE|Valgus Knee Brace|Valgus brace with traditional three point bending system
214836842|NCT01866176|DEVICE|New Knee Brace|Brace with new mechanism to decrease the knee loading.
214836843|NCT00919334|DEVICE|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
214836844|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
214836845|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
214836846|NCT04768296|DRUG|Topotecan|Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
214836847|NCT04999696|PROCEDURE|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
214836848|NCT06675890|DIAGNOSTIC_TEST|serum homocysteine|serum homocysteine is associated with atherosclerosis and vascular diseases.
214836849|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate|1.2 g/kg/h
214836850|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
214836851|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
214836852|NCT01910337|DEVICE|Use the Polar Cardiac rate meter|
214836853|NCT05333315|DIETARY_SUPPLEMENT|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
214836854|NCT05333315|DIETARY_SUPPLEMENT|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
214836855|NCT05333315|DIETARY_SUPPLEMENT|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
214836856|NCT05333315|DIETARY_SUPPLEMENT|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
214836857|NCT05333315|DIETARY_SUPPLEMENT|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
214836858|NCT06677788|DRUG|Roflumilast 500 Mcg Oral Tablet|Patients in this group received roflumilast 500 μg once daily for three months.
214836859|NCT06677788|DRUG|Vitamin E capsule|vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily
214836860|NCT04934020|OTHER|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
214836861|NCT04934020|OTHER|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
214836862|NCT01618630|DIETARY_SUPPLEMENT|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
214836863|NCT01618630|DIETARY_SUPPLEMENT|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
214836864|NCT04492397|DEVICE|Test Contact Lens|Subjects will be randomized to wear test lenses.
214836865|NCT04492397|DEVICE|Control Contact Lens|Subjects will be randomized to wear control lenses.
214836866|NCT02145624|DRUG|Repevax|vaccine
214836867|NCT02145624|DRUG|Boostrix-IPV|vaccine
214836868|NCT04383717|DRUG|Levamisole and isoprinosine|oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
214836869|NCT04383717|DRUG|Azithromycin and hydroxychloroquine|oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
214836870|NCT00122447|DRUG|Aspirin|325 mg PO QD
214836871|NCT00122447|DRUG|Alpha lipoic acid|600 mg PO BID
214836872|NCT00122447|DRUG|Olmesartan|40 mg PO QD
214836873|NCT00122447|DRUG|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
214836874|NCT02574715|DRUG|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
214836875|NCT03885869|OTHER|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
214836876|NCT03885869|OTHER|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
214836877|NCT03885869|OTHER|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
214836878|NCT03885869|OTHER|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
214836879|NCT03885869|OTHER|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
214836880|NCT03885869|OTHER|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
214836881|NCT06461793|RADIATION|Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients|this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
214836882|NCT00458107|DRUG|SCA-136|
214836883|NCT03983798|OTHER|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
214836884|NCT01453153|DRUG|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
214836885|NCT01453153|DRUG|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
214836886|NCT01453153|DRUG|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
214836887|NCT01497119|DRUG|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
214836888|NCT01497119|DRUG|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
214836889|NCT01497119|DRUG|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
214836890|NCT02711033|PROCEDURE|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
214836891|NCT02711033|PROCEDURE|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
214836892|NCT04735107|PROCEDURE|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
214836893|NCT03474809|DEVICE|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
214836894|NCT06013930|BEHAVIORAL|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
214836895|NCT06013930|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
214836896|NCT06013930|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
214836897|NCT05113563|DEVICE|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
214836898|NCT03055871|BEHAVIORAL|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
214836899|NCT03055871|BEHAVIORAL|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
214836900|NCT04657315|DRUG|MSC11FCD|"Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration"
214836901|NCT04750590|PROCEDURE|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
214836902|NCT04750590|PROCEDURE|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
214836903|NCT02751866|DIETARY_SUPPLEMENT|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
214836904|NCT02751866|DIETARY_SUPPLEMENT|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
214836905|NCT05856799|DEVICE|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
214836906|NCT05856799|DEVICE|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
214836907|NCT01072162|DRUG|Eltrombopag|25 mg tablet
214836908|NCT01072162|DRUG|Eltrombopag|25 mg powder for oral suspension
214836909|NCT00324896|DRUG|eszopiclone|eszopiclone
214836910|NCT00324896|OTHER|placebo|matching placebo administered at night
214836911|NCT01802216|PROCEDURE|Scaling and root planing|non-surgical periodontal disease treatment
214836912|NCT01802216|DRUG|Minocycline|antibiotic microspheres
214836913|NCT04402606|OTHER|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
214836914|NCT00799708|DRUG|Comparator: placebo|placebo capsule once daily for 7 days.
214836915|NCT00799708|DRUG|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
214836916|NCT06222606|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
214836917|NCT03343639|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
214836918|NCT03343639|DRUG|Matching Placebo Tablets|Placebo Tablets
214836919|NCT04346563|OTHER|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
214836920|NCT04346563|OTHER|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1\) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
214836921|NCT03523546|OTHER|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
214836922|NCT04408534|OTHER|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
214836923|NCT00076245|BEHAVIORAL|Light Therapy|Light therapy will involve exposure to bright light twice a day.
214836924|NCT00076245|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
214836925|NCT06358027|DIAGNOSTIC_TEST|lung ultrasound|The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
214836926|NCT03368027|BEHAVIORAL|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
214836927|NCT03368027|OTHER|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
214836928|NCT05253430|PROCEDURE|Lymphadenectomy type|D1 vs D2 lymph node dissection
214836929|NCT06616181|DEVICE|Anodal tDCS over M1|The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
214836930|NCT06616181|DEVICE|Anodal tDCS over DLPFC|The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
214836931|NCT06616181|BEHAVIORAL|Exercise telerehabilitation|Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.
214836932|NCT04838379|DRUG|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB\&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block \& tap block was performed
214836933|NCT06459960|GENETIC|Hydrotherapy|Heated pool (32°C); Convention rehabilitation + Hydrotherapy
214836934|NCT06459960|GENETIC|Convention|Convention rehabilitation only
214836935|NCT00040794|DRUG|paclitaxel|Given IV
214836936|NCT00040794|DRUG|carboplatin|Given IV
214836937|NCT00040794|DRUG|gefitinib|Given PO
214836938|NCT00040794|RADIATION|radiation therapy|Undergo radiotherapy
214836939|NCT00040794|OTHER|laboratory biomarker analysis|Optional correlative studies
214836940|NCT00616096|PROCEDURE|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
214836941|NCT04262739|DRUG|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
214836942|NCT04262739|DRUG|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
214836943|NCT04262739|DRUG|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
214836944|NCT02077881|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
214836945|NCT02077881|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
214836946|NCT02077881|DRUG|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
214836947|NCT02658435|DRUG|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
214836948|NCT02658435|DRUG|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
214836949|NCT00297141|DRUG|Capecitabine|chemotherapy oral use
214836950|NCT00297141|DRUG|Oxaliplatin|chemotherapy intravenous use
214836951|NCT00891098|BEHAVIORAL|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
214836952|NCT00891098|BEHAVIORAL|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
214836953|NCT02874950|OTHER|office exercise training|The exercise group, did 6 months office exercise training.
214836954|NCT02874950|OTHER|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
214836955|NCT02874950|OTHER|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
214836956|NCT02874950|OTHER|Control|Control group did not do any exercise and did not follow any ergonomic modification.
214836957|NCT04224948|DEVICE|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
214836958|NCT00481026|DEVICE|transcranial direct current stimulation (tDCS)|tDCS
214836959|NCT00481026|DEVICE|active tDCS|Active tDCS
214836960|NCT03874026|DRUG|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
214836961|NCT02899312|DRUG|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
214836962|NCT02153723|DRUG|Glatiramer Acetate|
214836963|NCT01677650|DRUG|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
214836964|NCT02684539|DEVICE|tilt table Erigo®|tilting table with onset of syncope
214836965|NCT00613041|PROCEDURE|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
214836966|NCT06004934|DRUG|Avacopan|Administered orally.
214836967|NCT02274558|DRUG|NBI-98854|NBI-98854 40 mg capsules
214836968|NCT02274558|DRUG|Placebo|NBI-98854 placebo capsules
214836969|NCT06143462|DRUG|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
214836970|NCT06143462|OTHER|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
214836971|NCT06143462|BEHAVIORAL|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
214836972|NCT02655224|DRUG|Relugolix|Relugolix Tablets
214836973|NCT02655224|DRUG|Relugolix placebo|Relugolix placebo-matching tablets
214836974|NCT03033134|DEVICE|BSJ003W|BSJ003W implant
214836975|NCT04592419|DRUG|KSI-301|Intravitreal Injection
214836976|NCT04592419|DRUG|Aflibercept|Intravitreal Injection
214836977|NCT04592419|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214836978|NCT02964390|PROCEDURE|Balloon Pulmonary Angioplasty|
214836979|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
214836980|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
214836981|NCT05603936|OTHER|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~* QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~* QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
214836982|NCT04327336|DEVICE|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
214836983|NCT04327336|DEVICE|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
214836984|NCT01264913|BEHAVIORAL|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
214836985|NCT04172545|PROCEDURE|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
214836986|NCT02394288|PROCEDURE|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
214836987|NCT04933240|DRUG|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
214836988|NCT04933240|DRUG|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
214836989|NCT04933240|DRUG|Placebo|A sugar tablet that does not contain any active medicine
214836990|NCT00808262|BIOLOGICAL|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
214836991|NCT00416468|DRUG|Aliskiren|
214836992|NCT00416468|DRUG|Valsartan|
214836993|NCT04487288|DIAGNOSTIC_TEST|SONAZOID|CEUS using SONAZOID with fusion technique
214836994|NCT03389763|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
214836995|NCT04559750|BEHAVIORAL|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
214836996|NCT05838456|DEVICE|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
214836997|NCT00423709|PROCEDURE|Allogeneic Blood Stem Cell Transplantation|
214836998|NCT00423709|DRUG|Fludarabine|
214836999|NCT00423709|DRUG|Melphalan|
214837000|NCT00810706|DRUG|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
214837001|NCT03658148|PROCEDURE|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
214837002|NCT06277050|DRUG|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
214837003|NCT06277050|DRUG|Maintenance Therapy with Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
214837004|NCT02719704|BEHAVIORAL|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
214837005|NCT02719704|BEHAVIORAL|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
214837006|NCT03994536|BEHAVIORAL|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
214837007|NCT03994536|OTHER|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
214837008|NCT03934827|DRUG|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
214837009|NCT03934827|DRUG|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
214837010|NCT03085368|DRUG|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
214837011|NCT06628999|OTHER|Visual Training|16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness
214837012|NCT06628999|OTHER|Control Group|16-week of active lifestyle based on healthy habits
214837013|NCT06628999|OTHER|Visual Training-detraining|8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
214837014|NCT05393271|DRUG|VH4011499|VH4011499 will be administered.
214837015|NCT05393271|DRUG|Placebo|Placebo will be administered.
214837016|NCT05393271|DRUG|Midazolam|Midazolam will be administered
214837017|NCT06323070|OTHER|Low-fat cookies|To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
214837018|NCT06323070|OTHER|Watermelon|To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
214837019|NCT02943993|DRUG|Edoxaban|Prescribed according to approved label
214837020|NCT03759236|BEHAVIORAL|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
214837021|NCT03759236|BEHAVIORAL|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
214837022|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
214837023|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
214837024|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
214837025|NCT06321276|DEVICE|extracorporeal shockwave therapy|Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
214837026|NCT05223725|BIOLOGICAL|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
214837027|NCT03945695|PROCEDURE|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
214837028|NCT05851898|DRUG|Duloxetine 30 mg|Duloxetine 30mg daily prescribed at discharge
214837029|NCT03946995|OTHER|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
214837030|NCT03946995|OTHER|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
214837031|NCT02075645|OTHER|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
214837032|NCT01491464|DEVICE|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
214837033|NCT01491464|DEVICE|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
214837034|NCT05884957|DIAGNOSTIC_TEST|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
214837035|NCT04175158|BIOLOGICAL|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
214837036|NCT04175158|BIOLOGICAL|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
214837037|NCT04968925|DEVICE|ACUVUE Oasys 1-Day|TEST
214837038|NCT04968925|DEVICE|Precision 1|CONTROL
214837039|NCT02829684|OTHER|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
214837040|NCT03408730|BIOLOGICAL|Hepatitis B Vaccination|Hepatitis B Vaccination
214837041|NCT06209034|OTHER|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
214837042|NCT01707316|DRUG|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
214837043|NCT01707316|DRUG|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
214837044|NCT01707316|OTHER|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
214837045|NCT05682963|OTHER|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
214837046|NCT05682963|OTHER|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
214837047|NCT01767753|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
214837048|NCT02930876|BEHAVIORAL|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
214837049|NCT00504634|DRUG|Bortezomib|1 mg/m\^2 IV On Days 1, 4, 8, and 11.
214837050|NCT02015351|DRUG|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
214837051|NCT02625311|PROCEDURE|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
214837052|NCT04517526|DRUG|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
214837053|NCT00876265|DEVICE|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
214837054|NCT00876265|DEVICE|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
214837055|NCT06399445|PROCEDURE|conventional cold tonsillectomy and curettage adenoidectomy|After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
214837056|NCT06399445|DRUG|Rocuronium Bromide|After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
214837057|NCT06010823|DEVICE|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
214837058|NCT02881359|DEVICE|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
214837059|NCT01003951|PROCEDURE|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
214837060|NCT02179151|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
214837061|NCT02179151|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
214837062|NCT02458391|OTHER|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
214837063|NCT01092169|OTHER|No intervention|
214837064|NCT05077501|DRUG|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
214837065|NCT05077501|DRUG|Placebo|Placebo oral solution
214837066|NCT01566994|BEHAVIORAL|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
214837067|NCT01566994|BEHAVIORAL|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
214837068|NCT01566994|BEHAVIORAL|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
214837069|NCT04880954|PROCEDURE|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
214837070|NCT04880954|OTHER|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
214277670|NCT07015684|DRUG|131I-apamistmab|131I-apamistamab is a drug construct consisting of the apamistamab monoclonal antibody (mAb) and radioactive isotope iodine 131 (131I). The study drug will be patient-specific and will be manufactured for dosing on a specific date. The antibody dose will be at least 0.5mg/kg, however the final antibody amount may be higher if necessary based on the target radioactivity level. The 131I-apamistamab study drug requires patient details such as height, weight, a calculation to determine weight for use in calculating antibody amount for the dose. 131I-apamistmab will be given via intravenous (IV) infusion.
214837073|NCT01956565|OTHER|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
214837074|NCT05647291|DEVICE|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
214837075|NCT05647291|DRUG|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
214837076|NCT05647291|DEVICE|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
214837077|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
214837078|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
214837079|NCT05006560|OTHER|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
214837080|NCT02754492|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
214837081|NCT05363241|PROCEDURE|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
214837082|NCT05363241|PROCEDURE|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
214837083|NCT03160079|DRUG|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
214837084|NCT03160079|DRUG|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
214837085|NCT02360007|DRUG|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"
214837086|NCT01408888|BIOLOGICAL|LY2189265|Administered subcutaneously
214837087|NCT01408888|DRUG|Sitagliptin|Administered orally
214837088|NCT04284007|DRUG|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
214837089|NCT04284007|DRUG|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
214837090|NCT04284007|DRUG|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
214837091|NCT06249893|OTHER|Point-of-care vascular ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
214837092|NCT01990807|DRUG|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
214837093|NCT03700398|DEVICE|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
214837094|NCT03700398|DEVICE|first WLI|the routine in the clinical practice
214837095|NCT04425577|DIAGNOSTIC_TEST|Transabdominal Ultrasound|Transabdominal Ultrasound
214837096|NCT03166904|DRUG|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
214837097|NCT03209167|BEHAVIORAL|Questionnaire|Two study-specific questionnaires
214837098|NCT06070545|OTHER|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
214837099|NCT00264381|DRUG|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
214837100|NCT00487695|DEVICE|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
214837101|NCT00487695|DEVICE|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
214837102|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
214837103|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
214837104|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
214837105|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
214837106|NCT04395196|DIETARY_SUPPLEMENT|Choline bitartrate|Provided in beverage form
214837107|NCT04395196|DIETARY_SUPPLEMENT|Placebo|Provided in beverage form
214837108|NCT05916248|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
214837109|NCT05916248|BIOLOGICAL|PD-1 inhibitor|pembrolizumab
214837110|NCT06166264|OTHER|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
214837111|NCT06166264|OTHER|Control group|The participants will receive information regarding health education.
214837112|NCT04542694|DRUG|Favipiravir|200 mg coated tablets
214837113|NCT04542694|DRUG|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
214837114|NCT03677219|OTHER|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
214837115|NCT04746079|BEHAVIORAL|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
214837116|NCT05690815|DRUG|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
214837117|NCT06103279|DRUG|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
214837118|NCT05897385|DRUG|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
214837119|NCT05897385|DRUG|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
214837120|NCT05633186|BEHAVIORAL|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
214837121|NCT05633186|BEHAVIORAL|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
214837122|NCT05633186|BEHAVIORAL|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
214837123|NCT05633186|BEHAVIORAL|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
214837124|NCT02167594|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
214837125|NCT02167594|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
214837126|NCT06677619|DEVICE|intrusion by reverse curve wire in cervical position of twin slot bracket|intrusion of anterior teeth by putting reverse curve wire in incisal slot of twin slot bracket
214837127|NCT06075849|DRUG|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
214837128|NCT04237350|BEHAVIORAL|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
214837129|NCT01535911|OTHER|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
214837130|NCT02926651|DRUG|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
214837131|NCT02926651|DRUG|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
214837132|NCT05066568|DEVICE|Active Tracranial Direct Current Stimulation|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
214277671|NCT07015684|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is an immunosuppressant agent. Sirolimus is to be given orally either as tablet or solution form. Dosage will be adjusted to a therapeutic target of 10-15 ng/mL in first 6 months post-transplant and 5-10 ng/mL after 6 months.
214277672|NCT07015684|DRUG|Campath|Campath is a recombinant DNA-derived humanized monoclonal antibody that is directed against the 21-28 kD cell surface glycoprotein, CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and tissues of the male reproductive system. Campath will be given via IV at a total dose of 1 mg per kilogram of body weight.
214277673|NCT07015684|DRUG|Total Body Irradiation|Radiation dose is 3Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
214277674|NCT07015684|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell (RBC) exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
214837133|NCT05066568|OTHER|Hypnotic analgesia suggestion|The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
214837134|NCT05066568|BEHAVIORAL|Rest|The patient is asked to remain seated still for 20 minutes.
214837135|NCT05066568|OTHER|Active tDCS + Hypnotic analgesia suggestion|"Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance."
214837136|NCT05066568|OTHER|Sham tDCS + Hypnotic analgesia suggestion|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
214837137|NCT04413968|DIAGNOSTIC_TEST|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
214837138|NCT04413968|DIAGNOSTIC_TEST|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
214837139|NCT04413968|DIAGNOSTIC_TEST|Stool collection|Stool collection in children
214837140|NCT03433703|DRUG|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
214837141|NCT06033313|BEHAVIORAL|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
214837142|NCT06033313|BEHAVIORAL|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
214837143|NCT02997878|BIOLOGICAL|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
214837144|NCT01957150|DRUG|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
214837145|NCT01957150|DRUG|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
214837146|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
214837147|NCT00000136|DRUG|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
214837148|NCT00000136|DRUG|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
214837149|NCT06476106|DEVICE|Venoconstrictive Thigh Cuff (VTC)|The VTC is an adjustable fabric cuff that is worn on the upper thighs to retain some fluid in the legs. It consists of wide straps and a buckle which allow it to be tightened, then velcro to secure the strap in the tightened position. There is also lacing that can be tightened for micro adjustments. Imbedded within the fabric strap is a bladder that is not used for increasing tightness but allows the pressure of the cuff to be measured and tracked.
214837150|NCT01207752|DRUG|Systane Balance|Artificial tear emulsion drop
214837151|NCT01207752|DRUG|Optive Lubricant Eye Drops|Artificial tear eye drop
214837152|NCT02786953|BEHAVIORAL|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
214837153|NCT02088333|BEHAVIORAL|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
214837154|NCT02088333|BEHAVIORAL|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
214837155|NCT03394833|OTHER|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
214837156|NCT02241798|OTHER|oxygen|O2 by nasal prongs
214837157|NCT01745068|OTHER|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
214837158|NCT05746377|DRUG|Metoclopramide 10mg|IV Metoclopramide
214837159|NCT05746377|DRUG|Saline|Placebo
214837160|NCT05399056|BEHAVIORAL|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
214837161|NCT05399056|BEHAVIORAL|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
214837162|NCT04425031|DRUG|Low oxygenation target|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
214837163|NCT04425031|DRUG|High oxygenation target|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
214837164|NCT04785963|BEHAVIORAL|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
214837165|NCT04785963|BEHAVIORAL|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
214837166|NCT04785963|BEHAVIORAL|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
214837167|NCT02483507|OTHER|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
214837168|NCT00680498|DRUG|Ranibizumab|Ranibizumab 0.5 mg
214837169|NCT00680498|DRUG|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
214837170|NCT05530811|DRUG|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
214837171|NCT05530811|DRUG|Bupivacaine|0.5% bupivacaine
214837172|NCT03513549|DRUG|Loxapine 10 MG|
214837173|NCT04943887|BEHAVIORAL|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
214837174|NCT01632215|DRUG|Gabapentine|Gabapentine 600 mg 01 dose
214837175|NCT01632215|OTHER|Sugar pill|Sugar pill 01 dose
214837176|NCT00041860|PROCEDURE|Controlled Exposure to Environmental Contaminant|
214837177|NCT02637180|DRUG|anti-osteoporotic medication|check previous information
214837178|NCT03997253|OTHER|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
214837179|NCT06380387|DIETARY_SUPPLEMENT|Meal|Liquid meal
214837180|NCT02720549|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
214837181|NCT02720549|PROCEDURE|valvular surgery with bypass|valvular surgery with bypass
214837182|NCT00212654|DRUG|ONO-1101|
214837183|NCT02528019|DRUG|DPP-4 inhibiotors|
214837184|NCT02528019|DRUG|SGLT2 inhibitors|
214837185|NCT02528019|DRUG|Glimepiride|
214837186|NCT03786705|OTHER|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
214837187|NCT03786705|OTHER|Non-Massive Transfusion|Trauma patients who had received blood transfusion\<10 U
214837188|NCT02093377|DEVICE|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
214837189|NCT03153605|OTHER|Common toothpaste|different toothpaste
214837190|NCT01745094|DRUG|mirabegron|oral
214837191|NCT01745094|DRUG|solifenacin|oral
214837192|NCT03645876|DRUG|SHR-1210|200mg
214837193|NCT03645876|DRUG|BP102|7.5mg/kg
214837194|NCT03645876|DRUG|oxaliplatin|130mg/m2
214837195|NCT03645876|DRUG|capecitabine|1000mg/m2
214837196|NCT05795296|DRUG|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
214837197|NCT05795296|DRUG|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
214837198|NCT03936894|DRUG|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
214837199|NCT01842555|OTHER|Registry|Registry
214837200|NCT01505049|DRUG|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
214837201|NCT03095950|OTHER|News items with spin|Interpretation of news items with spin
214837202|NCT03095950|OTHER|News items without spin|Interpretation of news items without spin
214837203|NCT03414034|DRUG|Onvansertib|Onvansertib orally
214837204|NCT03414034|DRUG|Abiraterone|Abiraterone orally
214837205|NCT03414034|DRUG|Prednisone|Prednisone orally
214837206|NCT04162171|RADIATION|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
214837207|NCT03368391|DRUG|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
214837208|NCT03368391|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
214837209|NCT03368391|DRUG|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
214837210|NCT03368391|DRUG|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
214837211|NCT03368391|DRUG|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
214837212|NCT02725645|OTHER|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
214837213|NCT04010227|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
214837214|NCT04010227|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
214837215|NCT04752527|DRUG|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
214837216|NCT00893776|OTHER|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
214837217|NCT00590694|DRUG|ranibizumab|0.5mg injection monthly according to protocol for one year
214837218|NCT06315660|BEHAVIORAL|Cognitive Miljeu Therapy|TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
214837219|NCT06315660|BEHAVIORAL|Virtual Reality based CBT for Anxiety|The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
214837220|NCT04002869|DIAGNOSTIC_TEST|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
214837221|NCT00460850|DRUG|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
214837222|NCT03051776|OTHER|Kinesio Taping|
214837223|NCT03051776|OTHER|Compression Garment|
214837224|NCT05429944|OTHER|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
214837225|NCT05429944|OTHER|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
214837226|NCT05429944|OTHER|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
214837227|NCT03655860|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
214837228|NCT06053840|DRUG|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
214837229|NCT01333917|DRUG|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
214837230|NCT05139394|PROCEDURE|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
214837231|NCT04636450|PROCEDURE|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
214837232|NCT04636450|PROCEDURE|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
214837233|NCT03521362|DEVICE|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
214837234|NCT03521362|DEVICE|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
214837235|NCT03565562|OTHER|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
214837236|NCT03565562|OTHER|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
214837237|NCT04811729|BEHAVIORAL|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
214837238|NCT04811729|BEHAVIORAL|Medical advice|Usual care
214837239|NCT03078257|DRUG|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
214837240|NCT03078257|DRUG|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
214837241|NCT03078257|DRUG|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
214837242|NCT03078257|DRUG|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
214837243|NCT03078257|DRUG|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
214837244|NCT03078257|DRUG|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
214837245|NCT03078257|DRUG|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
214837246|NCT06679322|DRUG|Androtriol Injection (High-dose group)|Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
214837247|NCT06679322|DRUG|Androtriol Injection (Low-dose group)|Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
214837248|NCT06679322|DRUG|Hydroxypropyl-β-cyclodextrin injection|Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
214837249|NCT00640926|DRUG|Radezolid|300 mg/day, orally for 7-10 days
214837250|NCT00640926|DRUG|Radezolid|450 mg/day orally for 7-10 days
214837251|NCT00640926|DRUG|Radezolid|900 mg/day orally for 7-10 days
214837252|NCT01341678|DRUG|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
214837253|NCT01341678|DIETARY_SUPPLEMENT|NeutraPhos|Diet will be supplemented with NeutraPhos
214837254|NCT01341678|OTHER|Diet Only|Diet containing 1500mg of phosphorus
214837255|NCT06561581|BEHAVIORAL|Acuity|Enhancement to Motivity product for clinical decision support
214837256|NCT02321839|DRUG|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
214837257|NCT03157869|DEVICE|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
214837258|NCT03157869|OTHER|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
214837259|NCT04070222|OTHER|Hysteroscopy|"1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
214837260|NCT06207669|OTHER|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
214837261|NCT04908540|PROCEDURE|Mini-screw Assissted Rapid Palatal Expansion|Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
214837262|NCT05735626|COMBINATION_PRODUCT|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
214837263|NCT05735626|COMBINATION_PRODUCT|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
214837264|NCT05735626|COMBINATION_PRODUCT|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
214277675|NCT07015684|RADIATION|Planar gamma imaging|Dosimetric imaging will be performed using quantitative planar gamma camera acquisition. Planar gamma imaging is a technique used in medical imaging to take pictures of the inside of the body, particularly to look at how certain organs or tissues are functioning. This allows the study doctor to evaluate how the study drugs are absorbed into the body.
214837265|NCT03922750|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
214837266|NCT03922750|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
214837267|NCT05158660|DEVICE|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
214837268|NCT02101073|BIOLOGICAL|ALX-0061|single dose, intravenous
214837269|NCT02101073|BIOLOGICAL|ALX-0061|single dose, subcutaneous
214837270|NCT02149394|OTHER|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
214837271|NCT02149394|OTHER|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
214837272|NCT00163969|DRUG|ketamine|
214837273|NCT02985398|BIOLOGICAL|ALD403 (Eptinezumab)|
214837274|NCT01992341|DRUG|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
214837275|NCT01992341|DRUG|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
214837276|NCT02387034|BEHAVIORAL|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
214837277|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
214837278|NCT01471951|OTHER|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
214837279|NCT00197834|DRUG|Depakote|
214837280|NCT05655429|PROCEDURE|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
214837281|NCT05655429|PROCEDURE|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
214837282|NCT03638063|DIAGNOSTIC_TEST|Adenosine Triphosphate|Adenosine Triphosphate aerosol
214837283|NCT03638063|DIAGNOSTIC_TEST|capsaicin|capsaicin aerosol
214837284|NCT00412204|DRUG|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
214837285|NCT00412204|OTHER|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
214837286|NCT00133367|DRUG|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
214837287|NCT00133367|DRUG|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
214837288|NCT00133367|DRUG|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
214837289|NCT00133367|DRUG|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
214837290|NCT00133367|DRUG|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
214837291|NCT00133367|DRUG|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
214837292|NCT00133367|DRUG|Melphalan|Given intravenously on day 2 before transplant.
214837293|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
214837294|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
214837295|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
214837296|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
214837297|NCT01841073|DIETARY_SUPPLEMENT|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
214837298|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
214837299|NCT00006467|DRUG|ISIS 2503|
214837300|NCT00006467|DRUG|gemcitabine hydrochloride|
214837301|NCT06193187|DRUG|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
214837302|NCT06193187|DRUG|Entresto 50 mg|Reference (R)
214837303|NCT04791956|DIETARY_SUPPLEMENT|Prebiotic|Daily intake of Inulin-type fructans from chicory
214837304|NCT04791956|DIETARY_SUPPLEMENT|Placebo|Daily intake of maltodextrin
214837305|NCT04257695|BEHAVIORAL|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
214837306|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
214837307|NCT05827263|DEVICE|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
214837308|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
214837309|NCT00668395|DRUG|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
214837310|NCT01172912|BIOLOGICAL|filgrastim|
214837311|NCT01172912|BIOLOGICAL|pegfilgrastim|
214837312|NCT01172912|DRUG|carboplatin|
214837313|NCT01172912|DRUG|cisplatin|
214837314|NCT01172912|DRUG|dexamethasone|
214837315|NCT01172912|DRUG|etoposide|
214837316|NCT01172912|DRUG|ifosfamide|
214837317|NCT01172912|OTHER|high-dose chemotherapy with autologous stem cell rescue|
214837318|NCT01172912|OTHER|laboratory biomarker analysis|
214837319|NCT01172912|PROCEDURE|autologous hematopoietic stem cell transplantation|
214837320|NCT01172912|PROCEDURE|peripheral blood stem cell transplantation|
214837321|NCT03313713|DIETARY_SUPPLEMENT|Beta-glucans|Placebo consumption at breakfast (3 g per day)
214837322|NCT03313713|DIETARY_SUPPLEMENT|Placebo|Placebo consumption at breakfast (3 g per day)
214837323|NCT01917227|BEHAVIORAL|Video|
214837324|NCT03550196|OTHER|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
214837325|NCT00377039|DRUG|AD 337|
214837326|NCT01847950|DIETARY_SUPPLEMENT|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
214837327|NCT01847950|DIETARY_SUPPLEMENT|Maltodextrin|
214837328|NCT03174158|DRUG|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
214837329|NCT03174158|BEHAVIORAL|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
214837330|NCT03174158|BEHAVIORAL|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
214837331|NCT05665387|DRUG|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
214837332|NCT05665387|DRUG|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
214837333|NCT05665387|DRUG|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
214837334|NCT03151954|PROCEDURE|functional endonasal sinus surgery|collect nasal polyps from patients
214837335|NCT03151954|PROCEDURE|nasal septal construction|collect inferior turbinates from patients as control arm
214837336|NCT04262245|PROCEDURE|Traditional Irrigation|irrigation with syringe
214837337|NCT04262245|DEVICE|Xp-endo Finisher (XPF)|irrigation activation file
214837338|NCT04262245|DEVICE|Passive Ultrasonic Irrigation|irrigation activation method
214837339|NCT04262245|DEVICE|EndoActivator|irrigation activation method
214837340|NCT04685681|BEHAVIORAL|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
214837341|NCT04685681|OTHER|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
214837342|NCT04385511|DEVICE|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
214837343|NCT01176981|DRUG|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
214837344|NCT02201316|DRUG|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
214837345|NCT02201316|DRUG|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
214837346|NCT02201316|DRUG|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
214837347|NCT02805517|DEVICE|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
214837348|NCT03969108|DRUG|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
214837349|NCT06352762|OTHER|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.
214837350|NCT06352762|OTHER|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
214837351|NCT01211262|DRUG|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
214837352|NCT04965233|BEHAVIORAL|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
214837353|NCT04965233|BEHAVIORAL|Information reports|Reports containing general information on eczema
214837354|NCT05456022|DRUG|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % \_ Purity (HPLC) \> 95 %"
214837355|NCT05456022|DRUG|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
214837356|NCT05456022|DRUG|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
214837357|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
214837358|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
214837359|NCT02346825|BEHAVIORAL|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
214837360|NCT00052923|BIOLOGICAL|filgrastim|
214837361|NCT00052923|BIOLOGICAL|rituximab|
214837362|NCT00052923|DRUG|carmustine|
214837363|NCT00052923|DRUG|cyclophosphamide|
214837364|NCT00052923|DRUG|etoposide|
214837365|NCT00052923|PROCEDURE|peripheral blood stem cell transplantation|
214837366|NCT00052923|RADIATION|radiation therapy|
214837367|NCT02070523|DRUG|VDCLD regimen|
214837368|NCT05079555|DEVICE|Robotic rehab|Patients using the robotic platform SWalker
214837369|NCT01647321|BEHAVIORAL|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
214837370|NCT01647321|BEHAVIORAL|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
214837371|NCT00068042|DRUG|Pegvisomant|
214837372|NCT00068042|DRUG|Sandostatin LAR|
214837373|NCT03710551|OTHER|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
214837374|NCT03710551|OTHER|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
214837375|NCT01321177|BEHAVIORAL|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model"
214837376|NCT01321177|BEHAVIORAL|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management"
214837377|NCT04049097|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
214837378|NCT04117880|DRUG|Ataluren|Oral
214837379|NCT02737462|DRUG|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
214837380|NCT06678594|PROCEDURE|Calcium modification|"Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy"
214837381|NCT01970592|BEHAVIORAL|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
214837382|NCT02202057|OTHER|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
214837383|NCT02202057|OTHER|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
214837384|NCT00160524|BIOLOGICAL|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
214837385|NCT02077335|RADIATION|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
214837386|NCT01554111|DRUG|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
214837387|NCT01554111|DRUG|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
214837388|NCT01554111|DRUG|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
214837389|NCT01931345|BEHAVIORAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
214837390|NCT01931345|BEHAVIORAL|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
214837391|NCT04970862|PROCEDURE|reversion surgery|reversion surgery
214837392|NCT02661022|DRUG|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
214837393|NCT02661022|DRUG|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
214837394|NCT03448692|DRUG|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
214837395|NCT03702816|DRUG|GE180 PET Scan|GE180 PET Scan
214837396|NCT02311517|DRUG|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
214837397|NCT02311517|DRUG|Normal Saline|
214837398|NCT04789187|PROCEDURE|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
214837399|NCT04789187|PROCEDURE|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
214837400|NCT04496518|DEVICE|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
214837401|NCT02571257|DRUG|Gemcabene|1-300 mg tablet, QD, 56 days
214837402|NCT02571257|DRUG|Gemcabene|3-300 mg tablets, QD, 56 days
214837403|NCT02571257|DRUG|Placebo|
214837404|NCT01597349|DRUG|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
214837405|NCT00608634|DRUG|perillyl alcohol|Applied as topical cream
214837406|NCT00608634|OTHER|placebo|Applied as topical cream
214837407|NCT03900039|DEVICE|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
214837408|NCT02641873|DRUG|BBI608|240 mg twice daily (480 mg total daily dose)
214837409|NCT02641873|DRUG|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
214837410|NCT02641873|DRUG|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
214837411|NCT02641873|DRUG|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
214837412|NCT02641873|DRUG|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
214837413|NCT02287220|DEVICE|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
214837414|NCT02698345|DEVICE|drug-eluting balloon (In.PACT Admiral, Medtronic)|
214837415|NCT00000380|DRUG|GHRH|
214837416|NCT00240734|DRUG|Epoetin alfa|
214837417|NCT01598896|DRUG|Dronabinol|Dronabinol titrated to 5 mg three times daily
214837418|NCT01598896|DRUG|Clonidine|Clonidine 0.1 mg twice daily
214837419|NCT01598896|DRUG|Placebo|One placebo capsule by mouth twice daily
214837420|NCT03534531|PROCEDURE|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
214837421|NCT03005366|DRUG|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
214837422|NCT03005366|DRUG|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
214837423|NCT03319394|BEHAVIORAL|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
214837424|NCT03319394|BEHAVIORAL|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
214837425|NCT02833181|DEVICE|BIS monitor|Monitoring circadian variation of EEG
214837426|NCT03346902|DRUG|EB-001|Injection of EB-001 into area of scarring (forehead)
214837427|NCT03346902|DRUG|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
214837428|NCT00996697|DRUG|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
214837429|NCT00996697|DRUG|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
214837430|NCT02450058|DRUG|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
214837431|NCT02450058|DRUG|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
214837432|NCT02450058|DRUG|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
214837433|NCT02450058|DRUG|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
214837434|NCT02450058|DRUG|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
214837435|NCT05564845|DIAGNOSTIC_TEST|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
214837436|NCT05564845|DIAGNOSTIC_TEST|Blood work|Lab work for current lab values and biobanking
214837437|NCT05564845|DIAGNOSTIC_TEST|Neurological examination|Classical neurological examination
214837438|NCT05564845|DIAGNOSTIC_TEST|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
214837439|NCT04205539|DRUG|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
214837440|NCT05290896|DEVICE|Phacoemulsification|Phacoemulsification for senile cataract.
214837441|NCT04553406|DRUG|SPR720|Capsules for oral administration
214837442|NCT04553406|DRUG|Placebo|Capsules for oral administration
214837443|NCT04553406|DRUG|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
214837444|NCT06467032|OTHER|superficial CO2 laser resurfacing|Application of the tested product and comparators on the laser treated side of the back
214837445|NCT06467032|OTHER|Laser untreated side|Application of the tested product and comparators on the laser untreated (control) side of the back
214837446|NCT00266487|DRUG|Folic acid|
214837447|NCT00266487|DRUG|Vitamin B12|
214837448|NCT00266487|DRUG|Vitamin B6|
214837449|NCT02786784|OTHER|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
214837450|NCT00772148|DRUG|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
214837451|NCT00772148|DRUG|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
214837452|NCT01235260|OTHER|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
214837453|NCT01235260|DRUG|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
214837454|NCT05878899|DRUG|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
214837455|NCT00749658|DRUG|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
214837456|NCT00749658|DRUG|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
214837457|NCT00633022|DRUG|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
214837458|NCT00633022|DRUG|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
214837459|NCT03546738|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
214837460|NCT03546738|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
214837461|NCT03546738|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
214837462|NCT03573336|DRUG|Vilaprisan (BAY1002670)|Intake orally, once daily
214837463|NCT03573336|DRUG|Matching Placebo|Intake orally, once daily
214837464|NCT04444141|BIOLOGICAL|AK104|The subjects will receive AK104 till disease progression or for a maximum of 24 months.
214837465|NCT02766257|PROCEDURE|Anesthesia for ambulatory paediatric surgery|
214837466|NCT04483596|DRUG|melatonin effect on the Abbreviated Mental Test|"Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1"
214837467|NCT04388787|DEVICE|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
214837468|NCT06468904|PROCEDURE|cervical stabilization exercises and integrated neuromuscular technique.|"Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain."
214837469|NCT03391505|BEHAVIORAL|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
214837470|NCT03391505|BEHAVIORAL|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
214837471|NCT03391505|BEHAVIORAL|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
214837472|NCT04107064|BEHAVIORAL|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
214837473|NCT04107064|BEHAVIORAL|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
214837474|NCT04541264|DIAGNOSTIC_TEST|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
214837475|NCT02127216|BEHAVIORAL|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
214837476|NCT06447285|DIAGNOSTIC_TEST|SensoDetect BERA technology|"All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min."
214837477|NCT01232244|OTHER|GLP-1 infusion|1 pmol/kg/min
214837478|NCT01232244|OTHER|Glucagon infusion|3ng/kg/min
214837479|NCT01232244|OTHER|Oxyntomodulin infusion|3 pmol/kg/min
214837480|NCT01232244|OTHER|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
214837481|NCT01232244|OTHER|Placebo|NaCl 9 g/L infusion
214464930|NCT02947750|OTHER|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
214837482|NCT06095180|OTHER|corticosteroid injection|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
214837483|NCT06095180|OTHER|dry needling|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
214837484|NCT06095180|OTHER|exercise|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
214837485|NCT03298880|DEVICE|Supine VM VAD|Valsalva strain delivered using VAD
214837486|NCT03298880|DEVICE|Supine VAD manometer|supine Valsalva strain delivered using manometer
214837487|NCT03298880|OTHER|Modified VM VAD|modified VM using VAD
214837488|NCT03298880|OTHER|Modified VM Manonmeter|Postural modified position VM using manometer
214837489|NCT01287351|DRUG|extra-fine hydrofluoroalkane beclometasone dipropionate|
214837490|NCT01287351|DRUG|Fluticasone propionate|
214837491|NCT00174980|DRUG|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
214837492|NCT05762016|PROCEDURE|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
214837493|NCT02299869|DEVICE|Verde (Competitor-control)|contact lens
214837494|NCT02299869|DEVICE|Green (CVI-test)|contact lens
214837495|NCT02299869|DEVICE|Cinza (Competitor-control)|contact lens
214837496|NCT02299869|DEVICE|Grey (CVI-test)|contact lens
214837497|NCT02299869|DEVICE|Esmeralda (Competitor-control)|contact lens
214837498|NCT02299869|DEVICE|Jade (CVI-test)|contact lens
214837499|NCT02299869|DEVICE|Azul (Competitor-control)|contact lens
214837500|NCT02299869|DEVICE|Blue (CVI-test)|contact lens
214837501|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
214837502|NCT06111534|BEHAVIORAL|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
214837503|NCT04162197|DEVICE|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
214837504|NCT04162197|DEVICE|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
214837505|NCT05595616|DEVICE|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
214837506|NCT06679426|DRUG|Conestat Alfa|See arm/group descriptions
214837507|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
214837508|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
214837509|NCT02710214|DRUG|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
214837510|NCT02710214|DRUG|Placebo|Once-daily dosing of placebo for 8 weeks
214837511|NCT04273087|OTHER|Observation|Clinical signs and symptoms
214837512|NCT04544852|BEHAVIORAL|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
214837513|NCT04544852|BEHAVIORAL|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
214837514|NCT04414137|OTHER|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
214837515|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
214837516|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
214837517|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
214837518|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
214837519|NCT00131482|DRUG|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
214837520|NCT05373667|PROCEDURE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
214837521|NCT01735786|DEVICE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
214837522|NCT03091868|DRUG|Placebo oral capsule|Matching placebo capsules. Oral administration.
214837523|NCT03091868|DRUG|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
214837524|NCT03091868|DRUG|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
214837525|NCT03091868|DRUG|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
214837526|NCT03091868|DRUG|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
214837527|NCT02868723|OTHER|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
214837528|NCT01345734|DRUG|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
214837529|NCT03031834|DRUG|Quinapril|
214837530|NCT03084458|BEHAVIORAL|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
214837531|NCT02497235|DRUG|TAK-935|TAK-935 oral solution.
214837532|NCT02497235|DRUG|[18F]MNI-792 (tracer)|\[18F\]MNI-792 injection.
214837533|NCT05722249|BEHAVIORAL|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
214837534|NCT05722249|BEHAVIORAL|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
214837535|NCT05954819|OTHER|Planned patient education|Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
214837536|NCT06381687|BEHAVIORAL|A multi-component, multi-level programme (MoviMusi)|"The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution."
214837537|NCT05535660|DIAGNOSTIC_TEST|Lipid panel|fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
214837538|NCT05845957|OTHER|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
214837539|NCT04920045|OTHER|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
214837540|NCT04622124|DRUG|Placebo|
214837541|NCT04622124|DIETARY_SUPPLEMENT|fasted vs. high-fat meal|
214837542|NCT04622124|DRUG|Placebo|
214837543|NCT00804024|DEVICE|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
214837544|NCT04916613|DRUG|Darolutamide 300 mg|600 mg po, b.i.d.
214837545|NCT04916613|DRUG|Placebo|po, b.i.d.
214837546|NCT04916613|DRUG|Androgen deprivation therapy|Use according to local standard of care
214837547|NCT05700396|BEHAVIORAL|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
214837548|NCT03616002|OTHER|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
214837549|NCT04888949|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
214837550|NCT04888949|BIOLOGICAL|Placebo|Commercially available saline.
214837551|NCT05116137|BEHAVIORAL|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
214837552|NCT04648007|DIAGNOSTIC_TEST|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
214277676|NCT06679894|PROCEDURE|Implant site preparation with osteotomes and electrified mallet|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
214837553|NCT04980456|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
214837554|NCT04980456|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
214837555|NCT04980456|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
214837556|NCT01324856|PROCEDURE|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
214837557|NCT01324856|PROCEDURE|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
214837558|NCT03296813|DRUG|Torsemide|Loop diuretic
214837559|NCT03296813|DRUG|Furosemide|Loop diuretic
214837560|NCT04832971|DRUG|ARO-ANG3|ARO-ANG3 Injection
214837561|NCT04832971|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
214837562|NCT00002228|DRUG|Enfuvirtide|
214837563|NCT02371928|OTHER|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
214837564|NCT02371928|OTHER|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
214837565|NCT05120687|DRUG|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
214837566|NCT00927251|DEVICE|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
214837567|NCT05531851|OTHER|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
214837568|NCT01520545|DRUG|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
214837569|NCT01520545|DEVICE|SynchroMed® II Programmable Pump|Intrathecal programmable pump
214837570|NCT01590251|OTHER|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
214837571|NCT01590251|BEHAVIORAL|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
214837572|NCT04564404|OTHER|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
214837573|NCT02111434|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
214837574|NCT00646503|DRUG|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
214837575|NCT03274037|DIAGNOSTIC_TEST|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
214837576|NCT00658957|DRUG|gentamicin-collagen sponge|5 × 5 cm sponge
214837577|NCT00658957|DRUG|placebo collagen sponge|5 × 5 cm sponge
214837578|NCT01911104|BEHAVIORAL|Exercise|10 weeks of aerobic exercise
214837579|NCT06679023|DIAGNOSTIC_TEST|MolecuLight i:X and Wound blotting and Alcian blue biofilm detection kit|we will enroll patients with chronic wounds and quantify the biofilm severity by staining color of Wound blotting and Alcian blue biofilm detection kit, and by non-touched flourescent intensity of MolecuLight i:X.
214837580|NCT03395015|OTHER|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
214837581|NCT06226025|DRUG|Melatonin|Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
214837582|NCT06226025|OTHER|Placebo|Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
214837583|NCT06226025|BEHAVIORAL|Behavioral sleep intervention|An active intervention that is typically paired with melatonin to maximize treatment effects.
214837584|NCT06226025|BEHAVIORAL|Behavioral sleep control|A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.
214464931|NCT02947750|OTHER|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
214837585|NCT05808166|BIOLOGICAL|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
214837586|NCT05808166|OTHER|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
214837587|NCT05656690|OTHER|Exposure to disability|Disability status assessed by functional measures
214837588|NCT01427881|DRUG|cyclophosphamide|Given IV
214837589|NCT01427881|DRUG|cyclosporine|Given IV
214837590|NCT01427881|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
214837591|NCT01427881|RADIATION|total-body irradiation|Undergo TBI
214837592|NCT01427881|DRUG|fludarabine phosphate|Given IV
214837593|NCT01427881|DRUG|busulfan|Given IV
214837594|NCT01427881|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
214837595|NCT06617624|OTHER|MRI|Healthy volunteer will have a non-injected cardiovascular MRI
214837596|NCT06617624|OTHER|MRI Contrast|Patients will have the gadolinium injected cardiovascular MRI
214837597|NCT00706719|DRUG|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
214837598|NCT00706719|DRUG|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
214837599|NCT05196100|DEVICE|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
214837600|NCT05567887|DRUG|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
214837601|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 subcutaneously.
214837602|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 intravenously.
214837603|NCT05848440|DRUG|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
214837604|NCT03965624|DRUG|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
214837605|NCT02676245|BEHAVIORAL|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
214837606|NCT02676245|BEHAVIORAL|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
214837607|NCT00159835|DRUG|atorvastatin|
214837608|NCT00159835|DRUG|simvastatin|
214837609|NCT05472896|PROCEDURE|cTACE|transcatheter arterial chemoembolization with
214837610|NCT05472896|DRUG|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
214837611|NCT05472896|DRUG|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
214464932|NCT02947750|DIETARY_SUPPLEMENT|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
214837612|NCT00814606|DRUG|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
214837613|NCT00814606|DRUG|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
214837614|NCT00814606|DRUG|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
214837615|NCT03687242|DRUG|SPR001|Open label SPR001
214837616|NCT04111705|DRUG|Lorlatinib|100 mg once daily
214837617|NCT03759028|DRUG|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
214837618|NCT03759028|DRUG|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
214837619|NCT03759028|DRUG|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
214837620|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
214837621|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
214837622|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
214837623|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
214837624|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
214837625|NCT04140929|OTHER|Oral Health Tool Box|Please see, description of the intervention group
214837626|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
214837627|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
214837628|NCT04857593|BEHAVIORAL|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
214837629|NCT02148744|BIOLOGICAL|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
214837630|NCT02148744|BIOLOGICAL|Placebo|
214837631|NCT02957760|DRUG|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
214837632|NCT05001698|BIOLOGICAL|Anifrolumab|intravenous infusion (IV)
214837633|NCT05146024|BEHAVIORAL|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
214837634|NCT00735319|DEVICE|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
214837635|NCT04282694|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
214837636|NCT03772756|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
214837637|NCT03772756|RADIATION|chemoradiotherapy|Receive chemoradiotherapy
214837638|NCT05490095|DRUG|SVG101 (T)|5mg of SVG101
214837639|NCT05490095|DRUG|Afinitor (R)|5mg of Afinitor
214837640|NCT05811819|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
214837641|NCT05048862|DIAGNOSTIC_TEST|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
214837642|NCT05048862|DIAGNOSTIC_TEST|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
214837643|NCT05048862|DIAGNOSTIC_TEST|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
214837644|NCT05048862|DIAGNOSTIC_TEST|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
214277677|NCT06679894|PROCEDURE|Implant site preparation with osseodensification drills|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
214837645|NCT05048862|DIAGNOSTIC_TEST|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7\~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
214837646|NCT05048862|DIAGNOSTIC_TEST|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
214837647|NCT05048862|DIAGNOSTIC_TEST|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS \& Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics \& Protein Function Core Lab in National Taiwan University.
214837648|NCT05048862|DIAGNOSTIC_TEST|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
214837649|NCT05048862|DIAGNOSTIC_TEST|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18\~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1\~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
214837650|NCT05048862|DIAGNOSTIC_TEST|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at \>32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
214837651|NCT05048862|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
214837652|NCT05048862|DIAGNOSTIC_TEST|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
214837653|NCT05361343|OTHER|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"1. Nutrition: intermittent fasting;~2. Physical activity: medium-intensity or high-intensity physical activity;~3. Hypoxic training (at least three per visit to the center);~4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~5. Individual motivational counseling."
214837654|NCT03860025|OTHER|No intervention.|No intervention.
214837655|NCT06137781|BEHAVIORAL|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
214837656|NCT01536249|DRUG|Dexpramipexole|Single Oral Dose
214277678|NCT05814783|BEHAVIORAL|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
214277679|NCT05814783|DEVICE|digital CBTI|CBTI app
214277680|NCT07015411|DIETARY_SUPPLEMENT|Neuro-Complex and Multi|"Participants will orally consume 2 caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).~Participants will take 1 cap of each product simultaneously twice a day directly in their mouth."
214277681|NCT07014761|OTHER|No Intervention: Observational Cohort|No Intervention
214277682|NCT07015775|PROCEDURE|Neurostimulation|Procedure guided by neurostimulation
214837657|NCT01536249|DRUG|Cimetidine plus Dexpramipexole|Multiple Oral Doses
214277683|NCT07015775|PROCEDURE|Ultrasound|Procedure guided by ultrasound
214277684|NCT07014657|BEHAVIORAL|Digital Combined Decongestive Therapy|Participants received digital combined decongestive therapy, which included an initial face-to-face session where skin care and risk reduction training were provided. Self-bandaging and self-manual lymphatic drainage techniques were demonstrated and practiced under supervision. Additionally, decongestive and breathing exercises were taught to both patients and caregivers. Following this, the intensive treatment phase was conducted remotely using electronic communication technologies over a period of 4 weeks to monitor and guide the therapy. After the intensive phase, participants continued with maintenance therapy, which involved the use of compression stockings. The therapy aimed to reduce limb volume and improve symptoms related to breast cancer-related lymphedema.
214837658|NCT01504711|DRUG|fosaprepitant dimeglumine|Given IV
214837659|NCT05830682|DEVICE|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
214837660|NCT01853371|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
214837661|NCT01853371|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
214837662|NCT04158778|DRUG|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
214837663|NCT04158778|OTHER|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
214837664|NCT00964353|DRUG|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
214837665|NCT02690051|DEVICE|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
214837666|NCT00099580|DRUG|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
214837667|NCT00099580|DRUG|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
214837668|NCT03135340|PROCEDURE|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
214837669|NCT03135340|PROCEDURE|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
214837670|NCT03135340|DRUG|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
214837671|NCT03135340|DRUG|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
214837672|NCT01811368|BIOLOGICAL|rituximab|Given IV
214837673|NCT01811368|BIOLOGICAL|ibritumomab tiuxetan|Given IV
214837674|NCT01811368|BIOLOGICAL|anti-thymocyte globulin|Given IV
214837675|NCT01811368|RADIATION|total nodal irradiation|Undergo TLI
214837676|NCT01811368|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
214837677|NCT01811368|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
214837678|NCT01811368|DRUG|cyclosporine|Given PO or IV
214837679|NCT01811368|DRUG|mycophenolate mofetil|Given PO or IV
214837680|NCT01782755|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
214464933|NCT02947750|OTHER|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
214837681|NCT01782755|OTHER|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
214837682|NCT02951195|DRUG|VX-152|Tablet for oral administration.
214837683|NCT02951195|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
214837684|NCT02951195|DRUG|IVA|Tablet for oral administration.
214837685|NCT02951195|DRUG|Placebo|Placebo matched to VX-152.
214837686|NCT02951195|DRUG|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
214837687|NCT05002881|OTHER|Moringa oleifera (E-HS-01)|One capsule to be taken stat
214837688|NCT05002881|OTHER|Placebo|One capsule to be taken stat
214837689|NCT03052855|OTHER|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
214837690|NCT06260501|OTHER|super-wet technique|Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
214837691|NCT02877017|BEHAVIORAL|Family safety reporting intervention|family safety reporting intervention for families and providers
214837692|NCT05843890|BEHAVIORAL|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
214837693|NCT05843890|BEHAVIORAL|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
214837694|NCT04317820|BEHAVIORAL|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
214837695|NCT04658238|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
214837696|NCT04658238|OTHER|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
214837697|NCT05809466|OTHER|Vegan diet|A self-composed 12 week fully plant-based diet
214837698|NCT05809466|OTHER|Resistance exercise|Biweekly resistance exercise for 12 weeks
214837699|NCT05809466|OTHER|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
214837700|NCT06247241|DRUG|VMB-100|VMB-100 is administered as intrasphincteric injection in the urethra sphincter
214837701|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
214837702|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
214837703|NCT05753007|DRUG|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
214837704|NCT05753007|DRUG|Placebo|Placebo solution
214837705|NCT03914898|OTHER|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
214837706|NCT00260026|DRUG|Docetaxel|
214837707|NCT00260026|DRUG|Jin Fu Kang|
214837708|NCT00326326|DRUG|CP-778,875|
214837709|NCT02563249|OTHER|Parabolic flight|
214837710|NCT02563249|OTHER|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
214837711|NCT01671592|BIOLOGICAL|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
214837712|NCT05701124|DRUG|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
214837713|NCT01702415|DRUG|Zoledronic acid|Single dose, intravenous solution 5mg
214837714|NCT01702415|DRUG|Placebo|
214464934|NCT04998006|DRUG|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
214837715|NCT02866240|DEVICE|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
214837716|NCT00717782|PROCEDURE|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
214837717|NCT00717782|PROCEDURE|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
214837718|NCT03968926|OTHER|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
214837719|NCT00111566|DRUG|eptifibatide|
214837720|NCT03211039|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
214464936|NCT05328934|DEVICE|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
214464937|NCT05328934|DEVICE|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
214837721|NCT00217724|DIETARY_SUPPLEMENT|glutamine|Given orally
214837722|NCT00217724|OTHER|placebo|Given orally
214837723|NCT00021216|DRUG|bortezomib|Given IV
214837724|NCT00021216|OTHER|laboratory biomarker analysis|Correlative studies
214837725|NCT00021216|OTHER|pharmacological study|Correlative studies
214837726|NCT00969124|DEVICE|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
214837727|NCT03490916|DRUG|Acetazolamide|Administration of Acetazolamide
214837728|NCT03490916|DRUG|Placebo|Administration of Placebo
214837729|NCT06001827|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
214837730|NCT06001827|PROCEDURE|Untreated AVF Control|AVF creation surgery without any intervention
214837731|NCT04022824|OTHER|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
214837732|NCT04022824|OTHER|Non-OSA|Patients without OSA (apnea hypopnea index \<15) based on sleep study
214837733|NCT05344716|DEVICE|Laser|Intraurethral and vaginal laser treatment
214837734|NCT05081336|DRUG|Statin|Statin +/- ezetimib +/- Alirocumab
214837735|NCT02575339|DRUG|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
214837736|NCT02575339|DRUG|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
214837737|NCT02575339|DRUG|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
214837738|NCT04633642|PROCEDURE|Ultrasound group|Every week during a six-week treatment period
214837739|NCT04633642|PROCEDURE|Surgical group|Every week during a six-week treatment period
214837740|NCT04675775|OTHER|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
214837741|NCT04675775|DIETARY_SUPPLEMENT|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
214837742|NCT04675775|BEHAVIORAL|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
214837743|NCT04438850|DRUG|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
214837744|NCT04438850|OTHER|Placebo|Patients should take placebo orally on an empty stomach with water
214837745|NCT06183450|DIAGNOSTIC_TEST|auditory level|"* Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality."
214837746|NCT06183450|DIAGNOSTIC_TEST|cognitive level|"* Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test."
214837747|NCT06183450|DIAGNOSTIC_TEST|quality of life level|\- Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
214837748|NCT01888341|DRUG|Isotretinoin|Isotretinoin Capsules,20 mg
214837749|NCT05431777|DRUG|Avelumab|As provided in real world setting
214837750|NCT03203239|DEVICE|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
214837751|NCT03203239|DRUG|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
214837752|NCT04440709|DEVICE|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
214837753|NCT05629923|DRUG|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
214837754|NCT02615184|DRUG|Dexlansoprazole|Dexlansoprazole capsules
214837755|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
214837756|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
214837757|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
214837758|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
214837759|NCT06434324|PROCEDURE|Saline Irrigation|250 cc waves of warmed saline irrigation (up to 2000 cc) through thoracostomy tube on a daily basis
214464938|NCT05139810|DRUG|Donidalorsen|Donidalorsen was administered by SC injection.
214464939|NCT05139810|DRUG|Placebo|Donidalorsen-matching placebo was administered by SC injection.
214464940|NCT05767541|OTHER|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
214464941|NCT05767541|OTHER|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
214837760|NCT05932810|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
214837761|NCT05932810|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
214837762|NCT03681028|DRUG|Individualized therapy|"1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
214837763|NCT06012578|DRUG|ISM5411|Investigational Drug
214837764|NCT06012578|DRUG|Placebo|ISM5411 Matching Placebo
214464942|NCT06177652|OTHER|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
214837765|NCT01405469|OTHER|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
214837766|NCT06009796|DEVICE|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
214837767|NCT06009796|DEVICE|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
214837768|NCT06404463|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
214837769|NCT06404463|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
214837770|NCT06404463|DRUG|Doxorubicin|Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
214837771|NCT06404463|DRUG|Cyclophosphamide|Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
214837772|NCT06404463|DRUG|Epirubicin|Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
214837773|NCT03946462|DRUG|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
214837774|NCT03946462|OTHER|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
214837775|NCT01572857|BIOLOGICAL|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
214837776|NCT02689817|DEVICE|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
214837777|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
214837778|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
214837779|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
214837780|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
214837781|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
214837782|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
214837783|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
214837784|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
214837785|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
214837786|NCT03074799|OTHER|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
214837787|NCT03074799|OTHER|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
214837788|NCT01140438|DRUG|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
214837789|NCT01140438|DRUG|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
214837790|NCT00296270|BEHAVIORAL|Memory for truth|
214837791|NCT01859637|BIOLOGICAL|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
214837792|NCT05673707|DIAGNOSTIC_TEST|Thyromental Height|its measure between thyroid and mentum
214837793|NCT05539937|OTHER|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
214837794|NCT01662011|DEVICE|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
214837795|NCT01662011|DEVICE|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
214837796|NCT03701451|DRUG|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
214837797|NCT00314834|DRUG|Intradialytic parenteral nutrition|
214837798|NCT01185158|DRUG|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
214837799|NCT01214980|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
214837800|NCT01214980|OTHER|Standard of care|Standard of care provided per site-specific protocol
214837801|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
214837802|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
214837803|NCT00974350|DRUG|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
214837804|NCT01344018|PROCEDURE|therapeutic conventional surgery|
214837805|NCT01344018|RADIATION|3-dimensional conformal radiation therapy|
214837806|NCT02044939|OTHER|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
214837807|NCT05070754|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
214837808|NCT05070754|DEVICE|Cryotherapy|Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
214837809|NCT05070754|DRUG|Canthardin Collodion|Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
214837810|NCT02375750|DEVICE|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
214837811|NCT02375750|OTHER|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
214837812|NCT00252564|DRUG|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
214837813|NCT00252564|DRUG|Oxaliplatin|85 mg/m2 on Days 1 and 15
214837814|NCT00252564|DRUG|Leucovorin|400 mg/m2 on Days 1 and 15
214837815|NCT00252564|DRUG|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
214837816|NCT00252564|DRUG|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
214837817|NCT04333264|PROCEDURE|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
214837818|NCT04333264|PROCEDURE|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
214837819|NCT02173964|DRUG|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
214837820|NCT02173964|DRUG|water|same amount of water for pinverin administration
214837821|NCT00135187|DRUG|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
214837822|NCT00135187|DRUG|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
214837823|NCT00135187|DRUG|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
214837824|NCT00994604|DRUG|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
214837825|NCT02039635|DIETARY_SUPPLEMENT|Korean Red Ginseng|Given Orally
214837826|NCT02039635|DIETARY_SUPPLEMENT|Placebo|Given Orally
214837827|NCT02836587|BEHAVIORAL|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
214837828|NCT04561115|BIOLOGICAL|Gamunex-C|Intravenous infusion.
214837829|NCT04561115|BIOLOGICAL|IVIG-PEG|Intravenous infusion.
214837830|NCT00743145|DRUG|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
214837831|NCT00743145|DRUG|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
214837832|NCT00743145|DRUG|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
214837833|NCT00743145|DRUG|Naltrexone|Naltrexone (12mg/70kg)
214837834|NCT00743145|DRUG|Placebo naltrexone|Naltrexone (0mg)
214837835|NCT04508205|DRUG|CGB-400|BID application
214837836|NCT05909436|DRUG|GLS-012|"In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
214837837|NCT05909436|DRUG|GLS-010|"In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
214837838|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
214837839|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
214837840|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
214837841|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
214837842|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
214837843|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
214837844|NCT06840470|DRUG|Imiquimod 5% Topical Cream|Participants will apply this cream to one side of the face 3 times a week for up to 8 weeks. The cream will be applied before bedtime. The imiquimod should be washed off with mild soap and water after 6-10 hours. Participants will have baseline and follow-up visits that will include photographs of the lesions.
214837845|NCT02416180|DEVICE|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
214837846|NCT02416180|DEVICE|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
214837847|NCT02416180|DEVICE|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
214837848|NCT04219527|PROCEDURE|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
214837849|NCT03645616|DIAGNOSTIC_TEST|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
214837850|NCT03645616|DIAGNOSTIC_TEST|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
214837851|NCT03645616|DIAGNOSTIC_TEST|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
214837852|NCT04432077|BEHAVIORAL|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
214837853|NCT02319603|DRUG|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
214837854|NCT02319603|DRUG|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
214837855|NCT00610506|DRUG|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
214837856|NCT05874648|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
214837857|NCT01460030|DRUG|Cinacalcet HCl|Oral administration
214837858|NCT01170715|DRUG|Etanercept|self-administered for 52 weeks
214837859|NCT02647853|DRUG|TAT4 Gel concentration A|
214837860|NCT02647853|DRUG|TAT4 Gel concentration B|
214837861|NCT02647853|DRUG|Placebo|
214837862|NCT02687789|OTHER|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
214837863|NCT02687789|OTHER|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
214837864|NCT03904836|DRUG|Tobramycin|5 milligrams per kilogram intravenous for one dose
214837865|NCT02571634|DRUG|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
214837866|NCT03486938|DRUG|Placebo Oral Tablet|Placebo oral tablet
214837867|NCT03486938|DRUG|AGB101 220 mg tablet|220 mg AGB101 active compound
214464943|NCT06177652|OTHER|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
214837868|NCT03933267|OTHER|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
214837869|NCT03933267|OTHER|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
214837870|NCT06679725|DIETARY_SUPPLEMENT|Wild ginseng extract|This ginseng extract was manufactured and provided by the Korea Food Research Institute (sponsor). It is extracted from red ginseng. Red ginseng is generally considered to have greater biological effects and fewer side effects than white or fresh ginseng.
214837871|NCT06679725|DIETARY_SUPPLEMENT|Placebo|The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring
214837872|NCT03480022|DRUG|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
214837873|NCT03480022|DRUG|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
214837874|NCT01087034|DEVICE|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
214837875|NCT01087034|RADIATION|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
214837876|NCT01087034|OTHER|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
214837877|NCT02664792|OTHER|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
214837878|NCT04933357|RADIATION|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
214837879|NCT04933357|RADIATION|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
214837880|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
214837881|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
214837882|NCT04744467|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
214837883|NCT03714373|DRUG|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
214837884|NCT03714373|DRUG|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
214837885|NCT03714373|DRUG|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
214837886|NCT05489497|PROCEDURE|Primary closure with or without omental grafting|Primary closure with or without omental grafting
214837887|NCT03769636|DEVICE|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
214837888|NCT01249014|OTHER|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
214837889|NCT01249014|OTHER|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
214837890|NCT01249014|DEVICE|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
214837891|NCT01249014|DEVICE|Bair hugger warming blanket|Bair hugger warming blanket laid on body
214837892|NCT00306306|DEVICE|Reprieve Endovascular Temperature Therapy System|
214837893|NCT05396417|PROCEDURE|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
214837894|NCT05793645|DEVICE|personalized care plan|Algorithm that defines personalized care plan
214837895|NCT03298516|DRUG|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
214837896|NCT03298516|DRUG|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
214837897|NCT02249117|DRUG|BIWH 3|
214837898|NCT02249117|DRUG|Placebo|
214837899|NCT03993587|OTHER|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
214837900|NCT04184206|BEHAVIORAL|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
214837901|NCT04184206|BEHAVIORAL|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
214837902|NCT04184206|BEHAVIORAL|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
214837903|NCT00301327|DRUG|Summers 5% L.A.|
214837904|NCT03240991|OTHER|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
214837905|NCT01652638|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
214837906|NCT06040606|PROCEDURE|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
214837907|NCT00283842|DRUG|DVS SR|
214837908|NCT00283842|DRUG|Placebo|
214837909|NCT05068661|DRUG|Ropivacaine 0.1% Injectable Solution|DPE
214837910|NCT05068661|DRUG|Bupivacaine 0.25% Injectable Solution|CSE
214837911|NCT05063591|OTHER|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
214837912|NCT00231582|DRUG|epirubicin|epirubicin
214837913|NCT00231582|PROCEDURE|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
214837914|NCT00231582|DRUG|paclitaxel|paclitaxel
214837915|NCT00231582|DRUG|etoposide|etoposide
214837916|NCT00231582|DRUG|ifosfamide|ifosfamide
214837917|NCT00231582|DRUG|carboplatin|carboplatin
214837918|NCT02966860|DRUG|Oral solution OC/APAP|
214837919|NCT03792139|DRUG|LY3200882|Administered orally.
214837920|NCT03792139|DRUG|Itraconazole|Administered orally.
214837921|NCT00005958|BIOLOGICAL|filgrastim|
214837922|NCT00005958|DRUG|docetaxel|
214837923|NCT00005958|DRUG|gemcitabine hydrochloride|
214837924|NCT02472639|DEVICE|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
214837925|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not use device
214837926|NCT02771392|DRUG|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
214837927|NCT02771392|OTHER|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
214837928|NCT02918058|OTHER|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
214837929|NCT03797196|DRUG|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
214837930|NCT03797196|DRUG|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
214837931|NCT01101386|DRUG|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
214837932|NCT03634735|DRUG|Thiamine|Vitamine B1
214837933|NCT03634735|OTHER|Placebo|Placebo tablets
214837934|NCT01426334|DRUG|dasatinib|Given PO
214837935|NCT01426334|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214837936|NCT01426334|OTHER|pharmacological study|Correlative studies
214837937|NCT01426334|DRUG|cyclosporine|Given PO
214837938|NCT00269386|DRUG|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
214837939|NCT00269386|DRUG|Placebo|
214837940|NCT03867916|BEHAVIORAL|Patient Navigation Program|Use patient navigation program
214837941|NCT03867916|OTHER|Quality-of-Life Assessment|Ancillary studies
214837942|NCT03867916|OTHER|Survey Administration|Ancillary studies
214837943|NCT02569281|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
214837944|NCT02569281|OTHER|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
214837945|NCT00751023|DRUG|Modafinil|400 mg daily for four weeks
214837946|NCT00751023|DRUG|Placebo|Placebo 2 tablets daily for 4 weeks
214837947|NCT04898816|PROCEDURE|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
214837948|NCT04898816|PROCEDURE|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
214837949|NCT03548155|DRUG|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
214837950|NCT03548155|DRUG|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
214837951|NCT03548155|DRUG|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
214837952|NCT02339038|DRUG|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
214837953|NCT06257979|OTHER|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~* Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~* The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~* Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
214837954|NCT00999115|DRUG|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
214837955|NCT01213407|DRUG|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
214837956|NCT01213407|DRUG|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
214837957|NCT02417428|DIETARY_SUPPLEMENT|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
214837958|NCT02417428|OTHER|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
214837959|NCT02417428|BEHAVIORAL|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
214837960|NCT02417428|OTHER|without exercise|No exercise program will be assigned to participants.
214837961|NCT04848207|DEVICE|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
214837962|NCT04848207|OTHER|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
214837963|NCT05909696|DRUG|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
214837964|NCT02308696|BEHAVIORAL|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
214837965|NCT02308696|BEHAVIORAL|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
214837966|NCT03350191|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214837967|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214837968|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214837969|NCT06486389|DEVICE|reading fairy tales|Reading fairy tales during inhaler medication administration.
214837970|NCT06486389|DEVICE|painting|painting during inhaler medication administration
214837971|NCT03619330|DRUG|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
214837972|NCT03619330|DRUG|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
214837973|NCT01476904|DRUG|Placebo|0 mcg/inhalation, 2 inhalations QID
214837974|NCT01476904|DRUG|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
214837975|NCT01476904|DRUG|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
214837976|NCT04768114|BEHAVIORAL|Genetically-Informed RiskProfile|"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."
214837977|NCT04768114|OTHER|Brief Cessation Advice|"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."
214837978|NCT01194908|DRUG|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
214837979|NCT02810223|BIOLOGICAL|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
214837980|NCT02121717|DRUG|Chiglitazar|Take orally
214837981|NCT02121717|DRUG|Placebo|Take orally
214464944|NCT04568746|PROCEDURE|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
214837982|NCT01924247|BEHAVIORAL|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
214837983|NCT01924247|BEHAVIORAL|Standard treatment by family physician|Standard treatment by family physician.
214837984|NCT06109337|DIAGNOSTIC_TEST|drow blood|Participants will be taken peripheral blood about 5 ml
214837985|NCT02013050|DRUG|SGX942|
214837986|NCT02013050|DRUG|Placebo|
214837987|NCT02686567|PROCEDURE|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
214837988|NCT02686567|PROCEDURE|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
214837989|NCT02086838|DRUG|Theragran Hematinic|
214837990|NCT02086838|DRUG|low molecular weight iron dextran|
214837991|NCT01285076|OTHER|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
214837992|NCT00271973|DRUG|Oxycodone|
214837993|NCT06236880|DRUG|GM-2505|IV
214837994|NCT01690260|DRUG|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
214837995|NCT01690260|PROCEDURE|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
214837996|NCT02712294|OTHER|Neuromuscular Electrical Stimulation|
214837997|NCT00908180|BIOLOGICAL|alemtuzumab|
214837998|NCT00908180|BIOLOGICAL|donor lymphocytes|
214837999|NCT00908180|DRUG|carmustine|
214838000|NCT00908180|DRUG|cyclosporine|
214838001|NCT00908180|DRUG|cytarabine|
214838002|NCT00908180|DRUG|etoposide|
214838003|NCT00908180|DRUG|melphalan|
214838004|NCT00908180|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214838005|NCT04526080|DEVICE|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
214838006|NCT04526080|DEVICE|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
214838007|NCT03711357|RADIATION|980 nm diode laser|980 nm high power diode laser device.
214838008|NCT03711357|OTHER|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
214464945|NCT04568746|PROCEDURE|box|patient with score \< 2 will be supported in box
214838009|NCT01711801|DRUG|Placebo|Single ascending dose
214838010|NCT01711801|DRUG|RO5545965|Single ascending dose
214838011|NCT01711801|DRUG|RO5545965|Single dose, in fed and fasted state
214838012|NCT03407222|OTHER|Text messages|Text messages which encourage the increment of daily step count
214838013|NCT03980522|DRUG|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
214838014|NCT01675973|DRUG|RANEXA|500mg BID up to 1000mg BID
214838015|NCT05721092|OTHER|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
214838016|NCT05616455|DRUG|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
214838017|NCT05616455|DRUG|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
214838018|NCT00769496|DRUG|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
214838019|NCT01970917|DEVICE|Olixia pure eye drops|
214838020|NCT01970917|DEVICE|Placebo|0.9% physiological saline solution
214838021|NCT00245986|PROCEDURE|Blood draw|
214838022|NCT04641403|PROCEDURE|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
214838023|NCT06447441|OTHER|Placebo|Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
214838024|NCT06447441|OTHER|Cholecalciferol|Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
214838025|NCT04892147|BEHAVIORAL|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
214838026|NCT00498264|BEHAVIORAL|walking program, resistance muscular exercise|
214838027|NCT04491838|DRUG|Pozelimab|Single subcutaneous (SC) injection
214838028|NCT02343796|OTHER|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
214838029|NCT02343796|DEVICE|everStick|GC, Belgium
214838030|NCT01299779|DRUG|PEG-SD|"PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients."
214838031|NCT01299779|DRUG|PEG-ELS|"* 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
214838032|NCT06185244|BEHAVIORAL|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
214838033|NCT06185244|BEHAVIORAL|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
214838034|NCT00338390|DRUG|Abacavir|Change tenofovir to abacavir
214838035|NCT00338390|DRUG|Didanosine|Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
214838036|NCT00338390|DRUG|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
214838037|NCT05263505|DRUG|Baricitinib 2 MG [Olumiant]|Two tabs daily
214464946|NCT05995886|BEHAVIORAL|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
214838038|NCT05263505|DRUG|Methotrexate|Target dose: 20mg weekly
214838039|NCT05263505|DRUG|Azathioprine|Target dose: 2mg/kg daily
214838040|NCT05263505|DRUG|Mycophenolate|Target Dose: 1g twice daily
214838041|NCT03261817|BEHAVIORAL|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
214838042|NCT03261817|BEHAVIORAL|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
214838043|NCT00913536|OTHER|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
214838044|NCT04721145|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
214838045|NCT04021160|DEVICE|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
214838046|NCT04021160|DEVICE|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
214838047|NCT03501420|OTHER|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
214838048|NCT03501420|OTHER|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
214838049|NCT03501420|OTHER|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
214838050|NCT03266276|OTHER|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
214838051|NCT05590676|DRUG|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
214838052|NCT05826301|OTHER|Percutaneous neuromodulation in tibial nerve|The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
214838053|NCT05826301|OTHER|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK"
214838054|NCT05568758|OTHER|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
214838055|NCT05568758|OTHER|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
214838056|NCT06662617|OTHER|modified thoracoabdominal nerve block through perichondrial approach|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
214838057|NCT06662617|OTHER|Transversus Abdominal Plane block|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral TAP block application, USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline . After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
214838058|NCT05449080|DIAGNOSTIC_TEST|Karyotype|Patients were subjected to karyotype to determine their genotype
214838059|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
214838060|NCT03886363|BEHAVIORAL|MBSR|Described previously
214838061|NCT05619796|PROCEDURE|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
214838062|NCT05619796|RADIATION|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
214838063|NCT05619796|OTHER|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
214838064|NCT04000776|DIAGNOSTIC_TEST|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
214838065|NCT04000776|DIAGNOSTIC_TEST|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
214838066|NCT04000776|DIAGNOSTIC_TEST|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
214838067|NCT04000776|OTHER|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
214838068|NCT01085669|DEVICE|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
214838069|NCT02707276|DEVICE|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
214838070|NCT02707276|DEVICE|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
214838071|NCT04155840|DRUG|Copanlisib|Given IV
214838072|NCT04155840|BIOLOGICAL|Rituximab|Given IV
214838073|NCT04155840|DRUG|Bendamustine|Given IV
214838074|NCT02459886|DRUG|BIIB054|IV infusion
214838075|NCT02459886|DRUG|Placebo|IV infusion
214838076|NCT00001217|DRUG|pre-surgical chemotherapy|
214838077|NCT01478516|PROCEDURE|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
214838078|NCT02825316|BEHAVIORAL|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
214838079|NCT02825316|BEHAVIORAL|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
214838080|NCT04987749|DEVICE|intermittent theta burst stimulation|stimulatory protocol
214838081|NCT04509232|PROCEDURE|Silver diamine fluoride|"Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
214838082|NCT04509232|PROCEDURE|Silver diamine fluoride and glass ionomer|"* 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
214838083|NCT01984606|DRUG|Empagliflozin|Empagliflozin once daily
214838084|NCT01984606|DRUG|Placebo|Placebo matching empagliflozin
214838085|NCT01984606|DRUG|Sitagliptin|Sitagliptin once daily
214838086|NCT01984606|DRUG|Placebo|Placebo matching sitagliptin
214838087|NCT01785615|DRUG|Atorvastatin|80mg
214838088|NCT01785615|OTHER|Placebo|80mg
214838089|NCT03428945|DRUG|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
214838090|NCT03428945|DRUG|Placebo|Placebo tablet identical to active drug
214838091|NCT05926245|DIETARY_SUPPLEMENT|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
214838092|NCT05926245|DIETARY_SUPPLEMENT|Placebo Solution|Empty nanoparticles
214838093|NCT01746654|DRUG|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
214838094|NCT01746654|DRUG|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
214838095|NCT01746654|DRUG|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
214838096|NCT01746654|DRUG|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
214838097|NCT02474654|DRUG|Bupivicaine|15mg
214838098|NCT02474654|DRUG|Fentanyl|15mcg
214838099|NCT02474654|DRUG|Epimorphine|150mcg
214838100|NCT02474654|DRUG|Normal Saline|0.3 ml
214838101|NCT02474654|DRUG|Normal Saline|30ml
214838102|NCT02474654|DRUG|Normal Saline|100 ml
214838103|NCT02474654|DRUG|Ropivicaine|100 ml
214838104|NCT02474654|DRUG|Epinephrine|600 mcg
214838105|NCT02474654|DRUG|Ketorolac|30 mg
214838106|NCT02474654|DRUG|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
214838107|NCT03827005|DIETARY_SUPPLEMENT|L-arginine|NOW Foods, Bloomingdale, IL
214838108|NCT03827005|DIETARY_SUPPLEMENT|Placebo|InHealth Specialty Pharmacy, Fargo, ND
214838109|NCT05767762|OTHER|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
214838110|NCT05380726|BEHAVIORAL|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
214838111|NCT04841967|BEHAVIORAL|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
214838112|NCT04841967|BEHAVIORAL|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
214838113|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gelatin capsule|Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
214838114|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene free form (PT)|Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
214838115|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule|Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
214838116|NCT01896492|DRUG|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
214838117|NCT01953172|DIETARY_SUPPLEMENT|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
214838118|NCT01953172|OTHER|Placebo|Placebo
214838119|NCT00337558|DRUG|Solifenacin succinate|tablet
214838120|NCT00337558|BEHAVIORAL|Simplified bladder training|Instructions
214838121|NCT04753541|OTHER|no intervention|this is not an interventional study
214838122|NCT00360490|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
214838123|NCT00360490|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
214838124|NCT03749915|DEVICE|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
214838125|NCT03749915|DRUG|Ametop|Tetracaine Hydrochloride Gel 4%
214838126|NCT04883788|OTHER|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
214838127|NCT03117205|OTHER|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
214838128|NCT03117205|OTHER|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
214838129|NCT02086617|OTHER|ultrasound of aorta|
214838130|NCT05380050|BEHAVIORAL|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
214838131|NCT05380050|BEHAVIORAL|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
214838132|NCT03888534|DRUG|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
214838133|NCT03294317|DEVICE|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
214838134|NCT03385954|OTHER|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
214838135|NCT03385954|OTHER|Control|will receive a lecture of 30 minutes.
214838136|NCT06464874|PROCEDURE|Conventional ESD|Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
214838137|NCT06464874|PROCEDURE|Hybrid ESD|Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
214838138|NCT00054834|DRUG|hLL2 (epratuzumab)|
214838139|NCT00004241|DRUG|tanespimycin|Given IV
214838140|NCT00004241|OTHER|pharmacological study|Correlative studies
214838141|NCT04055545|OTHER|HIIT|"* 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down"
214838142|NCT04055545|OTHER|MICT|"* 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down"
214838143|NCT00011063|DRUG|Ginkgo Biloba|
214838144|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
214838145|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
214838146|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
214838147|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
214838148|NCT01945619|BIOLOGICAL|Trivirus-Specific CTLs|Patients will receive up to 2 x 10\^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
214838149|NCT00156650|DRUG|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
214838150|NCT00156650|DRUG|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
214838151|NCT00156650|DRUG|Depo-Medroxyprogesterone|300 mg IM every 3 months
214838152|NCT03639220|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
214838153|NCT04330495|DRUG|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
214838154|NCT04330495|DRUG|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
214838155|NCT05072821|DRUG|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
214838156|NCT05072821|DRUG|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
214838157|NCT01961245|DEVICE|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
214838158|NCT06315387|DRUG|4-MUST, 1 tablet|4-methylumbelliferyl trimebutine sulfate, 128 mg
214838159|NCT06315387|DRUG|4-MUST, 2 tablets|4-methylumbelliferyl trimebutine sulfate, 256 mg
214838160|NCT06315387|DRUG|4-MUST, 3 tablets|4-methylumbelliferyl trimebutine sulfate, 384 mg
214838161|NCT05307562|OTHER|Interval training + analytical strength|Patients will receive a training program
214838162|NCT05307562|OTHER|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
214838163|NCT05435534|OTHER|ActiveFLS intervention|"* A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
214838164|NCT05435534|OTHER|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
214838165|NCT00044876|DRUG|CDB-2914|
214838166|NCT00914654|DRUG|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
214838167|NCT01160640|DRUG|Ceftriaxone|ceftrixone 250mg IM single dose
214838168|NCT01160640|DRUG|Doxycycline|Doxycycline 100 mg PO bid x 14 days
214838169|NCT01160640|DRUG|Metronidazole|metronidazole 500 mg PO bid x 14 days
214838170|NCT01160640|DRUG|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
214838171|NCT03061903|DEVICE|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
214838172|NCT03061903|DEVICE|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
214838173|NCT04315272|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
214838174|NCT04315272|DRUG|Placebo|Placebo
214838175|NCT00272272|BEHAVIORAL|Music Therapy|Listening to Music while standing
214838176|NCT04175860|BEHAVIORAL|The intervention with the patient (Chronic Patient Care Group and his family.)|"* Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
214838177|NCT01105182|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
214838178|NCT04993417|OTHER|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
214838179|NCT04993417|OTHER|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
214838180|NCT06382896|OTHER|No intervention|This was an observational study
214838181|NCT05198973|BEHAVIORAL|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
214838182|NCT00642811|DRUG|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
214838183|NCT00642811|DRUG|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
214838184|NCT00642811|DRUG|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
214838185|NCT03828435|DEVICE|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
214838186|NCT00268762|DRUG|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
214838187|NCT03972696|RADIATION|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
214838188|NCT04380233|DRUG|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
214838189|NCT04380233|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
214838190|NCT06063590|BIOLOGICAL|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
214838191|NCT01234961|BEHAVIORAL|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
214838192|NCT01234961|OTHER|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
214838193|NCT04046380|DIAGNOSTIC_TEST|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
214838194|NCT02614898|OTHER|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
214838195|NCT03959150|DRUG|Capecitabine|Oral fluorouracil
214838196|NCT00239005|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214838197|NCT00239005|DRUG|Mycophenolate Mofetil (MMF)|
214838198|NCT05820828|DIAGNOSTIC_TEST|Volume control|Volume control in venous reservoir during extracorporeal circulation.
214838199|NCT02225457|OTHER|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
214838200|NCT02225457|DIETARY_SUPPLEMENT|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
214838201|NCT02225457|DIETARY_SUPPLEMENT|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
214838202|NCT02075385|PROCEDURE|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
214838203|NCT00787605|DRUG|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
214838204|NCT00787605|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
214838205|NCT00787605|DRUG|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
214838206|NCT03108820|BEHAVIORAL|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
214838207|NCT03108820|OTHER|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
214838208|NCT04202757|BIOLOGICAL|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
214838209|NCT04202757|OTHER|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
214838210|NCT03382041|DEVICE|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
214838211|NCT03382041|DEVICE|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
214838212|NCT00606658|PROCEDURE|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
214838213|NCT03345615|DIAGNOSTIC_TEST|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
214838214|NCT00178711|DEVICE|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
214838215|NCT04485819|OTHER|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
214838216|NCT04485819|OTHER|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
214838217|NCT02484508|DRUG|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
214838218|NCT02484508|DRUG|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
214838219|NCT06126939|BEHAVIORAL|Educational training based on the Denver model|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
214838220|NCT02144805|PROCEDURE|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
214838221|NCT02144805|PROCEDURE|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
214838222|NCT04580615|DEVICE|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
214838223|NCT04022941|DRUG|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
214838224|NCT04022941|OTHER|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
214838225|NCT06301269|OTHER||
214838226|NCT04065607|PROCEDURE|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
214838227|NCT04156737|DEVICE|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
214838228|NCT04156737|DEVICE|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
214838229|NCT00033527|DRUG|INS316|
214838230|NCT00033527|OTHER|sputum cytology|
214838231|NCT05704491|DIAGNOSTIC_TEST|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
214838232|NCT05978791|PROCEDURE|collection of venous blood or arterial blood|"1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
214838233|NCT00949091|DRUG|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
214838234|NCT03545880|OTHER|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
214838235|NCT03545880|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
214838236|NCT06223724|DEVICE|STOP|Software to measure impedance telemetry data
214838237|NCT06223724|DEVICE|MAESTRO|Software to measure impedance telemetry data
214838238|NCT03911115|OTHER|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
214838239|NCT03235141|DRUG|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
214838240|NCT03235141|DRUG|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
214838241|NCT03685409|DRUG|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
214838242|NCT03685409|DRUG|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
214838243|NCT05421039|BEHAVIORAL|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
214838244|NCT04620057|DIETARY_SUPPLEMENT|butyrate|sodium butyrate (20 mg/kg body weight/day)
214838245|NCT04620057|OTHER|placebo|cornstarch
214838246|NCT04083326|DEVICE|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
214838247|NCT02378909|DEVICE|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
214838248|NCT00948792|PROCEDURE|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
214838249|NCT00948792|PROCEDURE|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
214838250|NCT05341154|DRUG|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
214838251|NCT02845154|OTHER|bolus purge|complete and uninterrupted purge
214838252|NCT02845154|OTHER|Intermittent purge|intermittent portal purge
214838253|NCT03297541|BEHAVIORAL|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
214838254|NCT01506349|DIETARY_SUPPLEMENT|gluten|4 grams of gluten.
214838255|NCT01506349|DIETARY_SUPPLEMENT|Placebo|
214838256|NCT03493919|BIOLOGICAL|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
214838257|NCT03493919|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
214838258|NCT01859936|DEVICE|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
214838259|NCT01781312|DIETARY_SUPPLEMENT|ProTectis|
214838260|NCT01781312|DIETARY_SUPPLEMENT|Gastrus|
214838261|NCT03924154|DRUG|RVT-1201|RVT-1201 600 mg immediate-release tablet
214838262|NCT03924154|DRUG|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
214838263|NCT02926755|PROCEDURE|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
214838264|NCT00080795|BIOLOGICAL|filgrastim|
214838265|NCT00080795|DRUG|cisplatin|
214838266|NCT00080795|DRUG|doxorubicin hydrochloride|
214838267|NCT00080795|DRUG|gemcitabine hydrochloride|
214838268|NCT00080795|DRUG|ifosfamide|
214838269|NCT00080795|PROCEDURE|conventional surgery|
214838270|NCT00080795|PROCEDURE|neoadjuvant therapy|
214838271|NCT04922827|DRUG|Infliximab|single intravenous administration of 5 milligrams/kilogram
214838272|NCT04922827|OTHER|Standard of Care|Standard of Care
214838273|NCT02512328|DEVICE|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
214838274|NCT03794245|BEHAVIORAL|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
214838275|NCT03794245|BEHAVIORAL|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
214838276|NCT03794245|BEHAVIORAL|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
214838277|NCT03794245|BEHAVIORAL|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
214838278|NCT03506594|DEVICE|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
214838279|NCT04587245|OTHER|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
214838280|NCT01394133|DRUG|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
214838281|NCT04045015|DIETARY_SUPPLEMENT|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
214838282|NCT03867773|BEHAVIORAL|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
214838283|NCT04218994|OTHER|Flossing technique|Subjects instructed on flossing technique
214838284|NCT04438434|DRUG|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
214838285|NCT04438434|DRUG|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
214838286|NCT04438434|OTHER|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
214838287|NCT04121533|DIETARY_SUPPLEMENT|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
214838288|NCT04121533|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
214838289|NCT04121533|DIETARY_SUPPLEMENT|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
214838290|NCT04640194|PROCEDURE|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
214838291|NCT04640194|DRUG|Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
214838292|NCT04640194|DRUG|Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
214464947|NCT05816616|DIAGNOSTIC_TEST|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
214464948|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
214464949|NCT06497075|DRUG|Albendazole 400mg|Single oral dose of Albendazole 400mg tablet
214838293|NCT04894409|DEVICE|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
214838294|NCT04894409|DEVICE|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
214838295|NCT00344643|DEVICE|Silicone Hydrogel Soft Contact Lenses|
214838296|NCT01777815|DEVICE|NeoChord DS1000 Artificial Chordae Delivery System|
214838297|NCT04428645|DEVICE|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
214838298|NCT00801515|DRUG|Maraviroc|150 mg twice per day
214838299|NCT06273709|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
214838300|NCT02188407|DRUG|Sevoflurane|MAC 3-5 V% during surgery
214838301|NCT02188407|DRUG|Propofol|Propofol group (P group)- The group anaesthesied with propofol
214838302|NCT04341337|OTHER|interview|questionnaire about ethics in surgery
214838303|NCT01888107|DRUG|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
214838304|NCT01888107|DRUG|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
214838305|NCT01888107|DRUG|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
214838306|NCT01889758|DRUG|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
214838307|NCT01889758|DRUG|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
214838308|NCT01889758|DRUG|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
214838309|NCT03646162|DRUG|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
214838310|NCT03646162|DRUG|Placebo|Placebo
214838311|NCT06139133|DRUG|Placebo supplementation|Placebo
214838312|NCT06139133|DRUG|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
214838313|NCT03945916|DIETARY_SUPPLEMENT|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
214838314|NCT03945916|DIETARY_SUPPLEMENT|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
214838315|NCT03961828|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
214838316|NCT01461785|BIOLOGICAL|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
214838317|NCT01461785|PROCEDURE|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
214838318|NCT05590039|DEVICE|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
214838319|NCT05594095|DRUG|PIK3CA inhibitor|PIK3CA inhibitor
214838320|NCT05594095|DRUG|AKT inhibitor|AKT inhibitor
214838321|NCT05594095|DRUG|Carrelizumab|Pd-1 mab
214838322|NCT05594095|DRUG|Famitinib|VEGFR inhibitor
214838323|NCT05594095|DRUG|Fluzoparib|PARP inhibitor
214838324|NCT05594095|DRUG|Dalpiciclib|CDK4/6 inhibitor
214838325|NCT05594095|DRUG|SHR-A1811|HER2 ADC
214838326|NCT05594095|DRUG|Everolimus|mTOR inhibior
214838327|NCT05594095|DRUG|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
214838328|NCT05594095|DRUG|Goserelin|For premenopause
214838329|NCT05594095|DRUG|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
214838330|NCT05594095|DRUG|Sorafenib|RTK Inhibitor
214838331|NCT05594095|DRUG|Apatinib|Apatinib 250mg po qd
214838332|NCT05594095|DRUG|SHR-A1921|TROP2 ADC
214838333|NCT05594095|DRUG|SHR-A2102|NECTIN4 ADC
214838334|NCT05594095|DRUG|SHR-A2009|HER3 ADC
214838335|NCT05594095|DRUG|SHR-1167|PARP1i
214838336|NCT05594095|DRUG|SHR-6209|CDK4i
214838337|NCT05594095|DRUG|bevacizumab|bevacizumab
214838338|NCT04773600|DRUG|Roflumilast Cream|Roflumilast cream 0.15% for topical application
214838339|NCT04773600|DRUG|Vehicle cream|Vehicle cream for topical application
214838340|NCT06531122|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
214838341|NCT06531122|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
214838342|NCT01485471|DEVICE|Diffuse optical spectroscopy imaging|ear exam imaging
214838343|NCT04711317|DEVICE|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
214838344|NCT03712202|DRUG|Bleomycin|Given IV
214838345|NCT03712202|DRUG|Brentuximab Vedotin|Given IV
214838346|NCT03712202|DRUG|Dacarbazine|Given IV
214838347|NCT03712202|DRUG|Doxorubicin|Given IV
214838348|NCT03712202|BIOLOGICAL|Nivolumab|Given IV
214838349|NCT03712202|OTHER|Quality-of-Life Assessment|Ancillary studies
214838350|NCT03712202|DRUG|Vinblastine|Given IV
214838351|NCT00290264|DRUG|Budesonide/formoterol|
214838352|NCT05316389|PROCEDURE|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
214838353|NCT01069796|DRUG|Paclitaxel|80 mg/m² weekly
214838354|NCT01069796|DRUG|Bevacizumab|10 mg/kg d1 d15
214838355|NCT01069796|DRUG|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
214838356|NCT00704496|DRUG|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
214838357|NCT00500318|DRUG|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
214838358|NCT00500318|DRUG|Placebo|Dose matched placebo, once daily oral inhalation.
214838359|NCT03497819|BIOLOGICAL|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
214838360|NCT00098891|DRUG|entinostat|Given orally
214838361|NCT00098891|DRUG|isotretinoin|Given orally
214838362|NCT05955469|DEVICE|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
214838363|NCT05955469|DEVICE|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
214838364|NCT03084809|DRUG|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
214838365|NCT03084809|DRUG|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
214838366|NCT06532409|DRUG|Amoxicillin/CA|Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
214838367|NCT06532409|DRUG|IV ceftriaxone|Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
214838368|NCT03243396|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
214838369|NCT04489225|OTHER|Observational|Observational only without any intervention
214838370|NCT03749707|DIAGNOSTIC_TEST|HPV analysis|HPV analysis of SLNs with an in-house targeted Next Generation Sequencing assay
214838371|NCT01257581|DRUG|creatine|creatine monohydrate powder
214838372|NCT01257581|DRUG|tamoxifen|Tamoxifen citrate capsules
214838373|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
214838374|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
214838375|NCT02937207|DRUG|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
214838376|NCT02937207|DRUG|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
214838377|NCT02937207|DRUG|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
214838378|NCT02937207|DRUG|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
214838379|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
214838380|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
214838381|NCT02937207|DRUG|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
214838382|NCT02937207|DRUG|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
214838383|NCT02937207|DRUG|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
214838384|NCT02937207|DRUG|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
214838385|NCT06030856|DEVICE|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
214838386|NCT06030856|BEHAVIORAL|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
214838387|NCT01728740|DRUG|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
214838388|NCT01728740|DRUG|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
214838389|NCT01728740|DRUG|Metformin|Metformin 500mg, oral, single dose
214838390|NCT02824640|BEHAVIORAL|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
214838391|NCT02824640|BEHAVIORAL|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
214838392|NCT02964650|DEVICE|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
214838393|NCT04767958|DIAGNOSTIC_TEST|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
214838394|NCT01559558|PROCEDURE|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
214838395|NCT04661449|OTHER|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
214838396|NCT02900053|DEVICE|tDCS|tDCS for transcranial Direct-Current Stimulation
214838397|NCT02900053|DEVICE|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
214838398|NCT03889691|PROCEDURE|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
214838399|NCT03448276|OTHER|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
214838400|NCT03448276|OTHER|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
214838401|NCT00891072|DRUG|R-(-)-gossypol acetic acid|Given orally
214838402|NCT00891072|DRUG|paclitaxel|Given IV
214464950|NCT06497075|DRUG|Ivermectin 3 MG|Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
214838403|NCT00891072|DRUG|carboplatin|Given IV
214838404|NCT00891072|OTHER|pharmacological study|Correlative studies
214838405|NCT02128152|DEVICE|Ekso exoskeleton|
214838406|NCT05693831|OTHER|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
214838407|NCT05719831|DRUG|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
214838408|NCT05719831|DRUG|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
214838409|NCT05719831|DRUG|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
214838410|NCT06615804|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
214838411|NCT02102269|DEVICE|actimove sling|
214838412|NCT02102269|DEVICE|shoulderlift|
214838413|NCT03361124|DRUG|Oxytocin|Administration of additional 20 mU Oxytocin
214838414|NCT00217334|BEHAVIORAL|Volunteer-led pharmacy sessions with feedback to physicians|
214838415|NCT04871009|BEHAVIORAL|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
214838416|NCT04871009|BEHAVIORAL|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
214838417|NCT05505760|BEHAVIORAL|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
214838418|NCT00971919|OTHER|questionnaire administration|
214838419|NCT00971919|PROCEDURE|assessment of therapy complications|
214838420|NCT00971919|PROCEDURE|psychosocial assessment and care|
214838421|NCT00971919|PROCEDURE|quality-of-life assessment|
214838422|NCT06616090|BEHAVIORAL|Nurse Implemented Infant-Mother Attachment Security Program|The intervention will draw on video-feedback of mother-infant interactions during the well-child visit. Nurses will videotape the dyad during routine visit in the Family Health Center and show short clips to mothers during the session in order to provide mother positive feedback on their sensitive caregiving. Additionaly, intervention mothers will be exposed to the reminders (e.g., pictures, posters, short film screenings) reflecting maternal sensitivity and secure attachment in the waiting rooms of the intervention Family Health Centers.
214838423|NCT06300827|OTHER|Structured digital-based training|The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
214838424|NCT05230602|DIETARY_SUPPLEMENT|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
214838425|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
214838426|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
214838427|NCT02246764|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
214838428|NCT02246764|OTHER|Placebo|1 drop QD, AM, OU
214838429|NCT02073006|DIETARY_SUPPLEMENT|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
214838430|NCT06204016|DRUG|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
214838431|NCT06204016|DRUG|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
214838432|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
214838433|NCT04982445|DRUG|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
214838434|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
214838435|NCT04178096|OTHER|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
214838436|NCT06093789|OTHER|PBQ-S1|All patients will fill out Personality Belief Scale-Short Form (PBQ-S1) and Beck Anxiety Scale one day before the procedure and they will be registered.
214838437|NCT06850103|RADIATION|short-course radiotherapy|Neoadjuvant short-course radiotherapy (SCRT) will be administered at a total dose of 25 Gy, delivered in 5 fractions of 5 Gy each.
214838438|NCT06850103|DRUG|CAPEOX/XELOX|Capecitabine: 1000 mg/m² BID, D1-14, Q3W × 4 cycles Oxaliplatin: 130 mg/m² IV, D1, Q3W × 4 cycles
214464951|NCT02966873|DRUG|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
214464952|NCT02966873|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
214464953|NCT02966873|DRUG|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
214838439|NCT06850103|DRUG|Serplulimab|Serplulimab: 300 mg IV, D1, Q3W × 4 cycles
214838440|NCT06850103|PROCEDURE|surgery|Primary tumor: Total Mesorectal Excision (TME) Metastatic lesions: Local therapeutic intervention
214838441|NCT05714787|OTHER|Chest CT Scan examination|Double examination of chest CT scan on sagittal section after multiplanar reconstruction
214838442|NCT00397696|DRUG|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
214838443|NCT04875585|DRUG|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
214838444|NCT04875585|PROCEDURE|Surgery|surgical resection of primary tumor and lymph-node-dissection.
214838445|NCT04875585|DRUG|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
214838446|NCT00555893|DRUG|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
214838447|NCT00555893|DRUG|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
214838448|NCT04423003|PROCEDURE|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
214838449|NCT03836924|DRUG|Perampanel|Perampanel tablets.
214838450|NCT06807541|BEHAVIORAL|Exercise intervention|45 minute exercise classes. Twice per week for 12 weeks.
214838451|NCT00346892|BIOLOGICAL|Rotavirus (vaccine)|
214838452|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
214838453|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
214838454|NCT04811183|BEHAVIORAL|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
214838455|NCT02161549|DEVICE|Motus Gl CleanUp System|
214838456|NCT02288351|OTHER|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
214838457|NCT02288351|OTHER|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
214838458|NCT02288351|OTHER|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
214838459|NCT02288351|OTHER|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
214838460|NCT02288351|OTHER|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
214838461|NCT02288351|DEVICE|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
214838462|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
214838463|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
214838464|NCT03223909|DRUG|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
214838465|NCT03223909|DRUG|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
214838466|NCT03223909|DRUG|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
214838467|NCT02046317|DRUG|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
214838468|NCT02046317|DEVICE|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
214838469|NCT02046317|DEVICE|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
214838470|NCT02046317|DEVICE|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
214838471|NCT03622359|DIAGNOSTIC_TEST|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
214838472|NCT03622359|DIAGNOSTIC_TEST|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
214838473|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
214838474|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
214838475|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
214838476|NCT02414464|OTHER|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
214838477|NCT05771051|DEVICE|Headpulse measurements|Placement of headset on subject
214838478|NCT01628549|DRUG|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
214838479|NCT01628549|DRUG|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
214838480|NCT01628549|DRUG|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
214838481|NCT05212038|PROCEDURE|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
214838482|NCT05212038|PROCEDURE|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
214838483|NCT04311944|OTHER|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
214838484|NCT04311944|OTHER|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
214838485|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
214838486|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake and withdraw|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
214838487|NCT00177164|DRUG|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
214838488|NCT03776344|DEVICE|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
214838489|NCT03314376|DEVICE|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
214838490|NCT00965757|DRUG|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
214838491|NCT00965757|DRUG|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
214838492|NCT02429583|DRUG|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
214838493|NCT00960414|BEHAVIORAL|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
214838494|NCT03303781|OTHER|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
214838495|NCT00067327|DRUG|Inosine|
214838496|NCT02933892|PROCEDURE|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
214838497|NCT03127241|DEVICE|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
214838498|NCT03127241|DEVICE|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
214838499|NCT00789464|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10\^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
214838500|NCT00789464|DRUG|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
214838501|NCT00307723|DRUG|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
214838502|NCT00307723|DRUG|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
214838503|NCT00307723|DRUG|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
214838504|NCT00307723|DRUG|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
214838505|NCT00307723|PROCEDURE|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
214838506|NCT02349854|PROCEDURE|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
214838507|NCT06627374|DIAGNOSTIC_TEST|Patent Ductus Arteriosus in neonates|Neonates admitted to Neonatal care Unit after birth, undergoing hsPDA (hemodynamically significant Patent Ductus Arteriosus) closure according to standard clinical practice, will be included.
214838508|NCT01398787|DEVICE|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
214838509|NCT01398787|DEVICE|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
214838510|NCT03368482|BEHAVIORAL|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
214838511|NCT03368482|BEHAVIORAL|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
214838512|NCT03289260|DRUG|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
214838513|NCT03289260|DRUG|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
214838514|NCT03289260|PROCEDURE|Fulguration|Surgical Excision and Fulguration of condyloma
214838515|NCT01067794|DRUG|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
214838516|NCT00514150|DRUG|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
214838517|NCT00514150|DRUG|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
214838518|NCT01658358|DRUG|Lapatinib|"* dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily"
214838519|NCT01658358|DRUG|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
214838520|NCT02351167|DRUG|Combination NRT (Nicotine patch, Nicotine lozenge)|
214838521|NCT02351167|DRUG|Varenicline|
214838522|NCT02351167|DRUG|Placebo|
214838523|NCT02351167|BEHAVIORAL|Intensive smoking counseling|
214838524|NCT01332968|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
214838525|NCT01332968|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
214464954|NCT02966873|OTHER|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
214838526|NCT01332968|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
214838527|NCT01332968|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
214838528|NCT01332968|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
214838529|NCT01332968|DRUG|Bendamustine|Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
214838530|NCT01332968|DRUG|Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
214838531|NCT03334045|RADIATION|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
214838532|NCT03525340|BEHAVIORAL|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
214838533|NCT02564016|DRUG|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
214838534|NCT02564016|OTHER|Capped Epidural|epidural will be capped with no saline infusion.
214838535|NCT06094764|DEVICE|Group A|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
214838536|NCT06094764|DEVICE|Group B|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
214838537|NCT01325038|PROCEDURE|Isometric exercise|Isometric exercise several times/week for three months
214838538|NCT03031951|BEHAVIORAL|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
214838539|NCT01206751|OTHER|Chest imaging technique and case presentation|
214838540|NCT00624351|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
214838541|NCT00624351|OTHER|Placebo|Phosphate-buffered Saline (PBS) infusion.
214838542|NCT01653405|OTHER|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
214838543|NCT00213005|DRUG|Carraguard (PC-515)|
214838544|NCT00143273|DRUG|lasofoxifene|0.05 mg tablets
214838545|NCT00143273|DRUG|Placebo|0 mg
214838546|NCT00143273|DRUG|Lasofoxifene|0.25 mg tablets
214838547|NCT00143273|DRUG|Lasofoxifene|0.5 mg tablets
214838548|NCT01424020|OTHER|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
214838549|NCT01915641|DEVICE|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
214464955|NCT02966873|OTHER|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
214464956|NCT03080974|DRUG|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
214838550|NCT00403806|DRUG|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
214464957|NCT03080974|PROCEDURE|Irreversible Electroporation|Non-thermal ablation of tumor
214464958|NCT01792687|DRUG|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
214464959|NCT01792687|DRUG|Abiraterone acetate|1,000 mg, oral, daily
214464960|NCT01792687|DRUG|Prednisone|5 mg, oral, daily
214838551|NCT00403806|DRUG|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
214838552|NCT00403806|DRUG|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
214838553|NCT00403806|DRUG|Saline|Intravenous saline
214838554|NCT04777552|OTHER|diazepam (or equivalence if other benzodiazepine)|
214838555|NCT03493633|DEVICE|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
214838556|NCT01220960|OTHER|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
214838557|NCT01577173|DRUG|MEHD7945A|1100 mg iv every 2 weeks
214838558|NCT01577173|DRUG|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
214838559|NCT00617825|OTHER|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
214838560|NCT01380522|DRUG|Metronidazole|Capsules, single-dose, fed
214838561|NCT01380522|DRUG|Flagyl|Capsules, single-dose, fed
214838562|NCT03092167|OTHER|Physical exercises|Physical exercises
214838563|NCT02018796|DRUG|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
214838564|NCT06650189|OTHER|Music intervention|Recorded music created by a certified music therapist
214838565|NCT01546363|OTHER|Blood draw|phlebotomy
214838566|NCT02099318|OTHER|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
214838567|NCT02099318|OTHER|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
214838568|NCT01937767|DRUG|Remimazolam|
214838569|NCT01937767|DRUG|Propofol|
214838570|NCT01937767|DRUG|Sevoflurane|
214838571|NCT01937767|DRUG|Remifentanil|
214838572|NCT01937767|DRUG|Fentanyl|
214838573|NCT01937767|DRUG|Rocuronium|
214838574|NCT03117244|OTHER|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
214838575|NCT03117244|OTHER|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
214838576|NCT03486496|DRUG|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
214838577|NCT03486496|DRUG|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
214838578|NCT00113919|DRUG|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
214838579|NCT00000623|DRUG|Deferoxamine|
214838580|NCT00000623|DRUG|Deferiprone|
214838581|NCT00000623|DRUG|Arginine|
214838582|NCT00000623|DRUG|Sildenafil|
214838583|NCT00000623|DRUG|Decitabine|
214838584|NCT05727579|OTHER|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
214838585|NCT05810636|DEVICE|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
214838586|NCT05529238|BEHAVIORAL|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
214838587|NCT00594503|DRUG|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
214838588|NCT04985149|OTHER|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude \> 10 Mv, and conduction velocity \> 36 m/sec in sensory response of the sural nerve."
214838589|NCT04985149|OTHER|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
214838590|NCT01633307|OTHER|Education|Teaching program
214838591|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
214838592|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
214838593|NCT05633251|BEHAVIORAL|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
214838594|NCT05633251|BEHAVIORAL|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
214838595|NCT05633251|BEHAVIORAL|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
214838596|NCT05633251|BEHAVIORAL|Control|No intervention
214838597|NCT06361654|OTHER|The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer|"The measurements will be taken during different climbing sessions, after the warm-up.~The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer."
214838598|NCT06348277|BEHAVIORAL|Mindfulness plus mood monitoring|mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
214838599|NCT06348277|BEHAVIORAL|Mood monitoring|mobile app that prompts for mood monitoring three times per day
214838600|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
214838601|NCT01742208|DRUG|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
214838602|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
214838603|NCT04283851|DIAGNOSTIC_TEST|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
214838604|NCT04417959|PROCEDURE|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
214838605|NCT04417959|PROCEDURE|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
214838606|NCT03386461|BEHAVIORAL|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
214838607|NCT03386461|DIETARY_SUPPLEMENT|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
214838608|NCT03386461|DIETARY_SUPPLEMENT|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
214838609|NCT02565836|DRUG|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
214838610|NCT02565836|DRUG|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
214838611|NCT00032227|PROCEDURE|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
214838612|NCT00032227|OTHER|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
214838613|NCT00002976|DRUG|conjugated estrogens|
214838614|NCT01525680|OTHER|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
214838615|NCT01525680|OTHER|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
214838616|NCT05100680|OTHER|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
214838617|NCT05100680|OTHER|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
214838618|NCT00715676|DRUG|Placebo|oral, once daily
214838619|NCT00715676|DRUG|DP001|oral, once daily
214838620|NCT03087162|DRUG|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
214838621|NCT06677762|PROCEDURE|Irreversible electroporation|Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
214838622|NCT05257694|PROCEDURE|Surgery|hepatectomy
214838623|NCT05257694|PROCEDURE|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
214838624|NCT04595591|DRUG|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
214838625|NCT04595591|DRUG|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
214838626|NCT04595591|DRUG|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
214838627|NCT00660491|OTHER|exercise training|moderate intensity exercise group, and high intensity exercise group
214838628|NCT03577561|OTHER|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
214838629|NCT05003882|OTHER|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
214277685|NCT06629207|DEVICE|PET/CT with 18-FDG|FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.
214838630|NCT05475392|OTHER|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
214838631|NCT05475392|OTHER|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
214838632|NCT02992548|DRUG|Pravastatin|
214838633|NCT06024148|OTHER|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
214838634|NCT02571530|DRUG|Intra-arterial Cerebral Infusion of Trastuzumab|
214838635|NCT03807830|PROCEDURE|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
214838636|NCT02441322|DEVICE|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
214838637|NCT04470739|DIAGNOSTIC_TEST|chest x-ray|First Chest X-ray in the first 6 hours of infants
214838638|NCT02403973|OTHER|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
214838639|NCT02629640|OTHER|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
214838640|NCT02629640|OTHER|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
214838641|NCT02629640|OTHER|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
214838642|NCT02629640|OTHER|Blood or buccal sample|Codon-129 genotyping; storage for future research.
214838643|NCT02629640|OTHER|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
214838644|NCT00356096|DRUG|pramipexole|
214838645|NCT01256996|PROCEDURE|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
214838646|NCT00372996|DRUG|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
214838647|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day.
214838648|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
214838649|NCT00372996|DRUG|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
214838650|NCT04440358|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
214838651|NCT04440358|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
214838652|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1"
214838653|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
214838654|NCT04305535|DIETARY_SUPPLEMENT|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
214838655|NCT01091363|BEHAVIORAL|Standard|10 minute brief cessation counseling
214838656|NCT01091363|BEHAVIORAL|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
214838657|NCT04302935|OTHER|Global pain-assessment|Global pain-assessment, based on the ICF framework
214838658|NCT00131716|DRUG|sulfadoxine-pyrimethamine|
214838659|NCT03485716|OTHER|running on a treadmill under normoxia or hypoxia|"* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
214838660|NCT00397735|PROCEDURE|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
214838661|NCT00397735|DRUG|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
214838662|NCT00890916|DEVICE|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
214838663|NCT05421195|DRUG|corticosteroids therapy|Oral corticosteroids
214838664|NCT05421195|OTHER|Olfactory training|repeat and deliberate sniffing of a set of odorants
214838665|NCT04204590|OTHER|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
214838666|NCT05013723|OTHER|Surveys|Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
214838667|NCT00268164|DRUG|lactobacilus acidophilus & bifidobacterium animalis/lactis|
214838668|NCT01923818|DRUG|rivaroxaban|orally active direct factor Xa inhibitor
214838669|NCT01923818|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
214838670|NCT01923818|DRUG|placebo|
214838671|NCT05534113|DRUG|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
214838672|NCT04429113|DEVICE|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
214838673|NCT03405064|DRUG|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
214838674|NCT03405064|DRUG|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
214838675|NCT00252447|PROCEDURE|Pre-Operative Conformal Radiotherapy|
214838676|NCT01135940|DEVICE|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
214838677|NCT01135940|DEVICE|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
214838678|NCT01181830|DRUG|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
214838679|NCT01181830|DRUG|placebo|administration of 8.1 mmol bid of placebo
214838680|NCT02760433|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
214838681|NCT02760433|DRUG|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
214838682|NCT02151149|DRUG|nab-paclitaxel|
214838683|NCT02151149|DRUG|Carboplatin|
214838684|NCT04531969|OTHER|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
214838685|NCT00296530|DRUG|fluticasone propionate/salmeterol|
214838686|NCT00296530|DRUG|fluticasone propionate|
214838687|NCT00296530|DRUG|montelukast|
214838688|NCT05586724|DRUG|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
214838689|NCT05586724|DRUG|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
214838690|NCT04993118|OTHER|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
214838691|NCT04993118|OTHER|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
214838692|NCT01485718|DIETARY_SUPPLEMENT|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
214838693|NCT01485718|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
214838694|NCT04576936|OTHER|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
214838695|NCT03310593|DRUG|Cannabidiol|Cannabidiol as active intervention.
214838696|NCT03310593|DRUG|Placebo|Placebo intervention.
214838697|NCT01640041|DEVICE|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
214838698|NCT02183376|DRUG|BI 1356|
214838699|NCT03023189|DRUG|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
214838700|NCT03023189|DRUG|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
214838701|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (25 mg/100 kcal )|
214838702|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (34 mg/100 kcal)|
214838703|NCT02092857|DIETARY_SUPPLEMENT|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
214838704|NCT06116396|GENETIC|Genetic analysis on isolated cells|Isolation of cells from blood and urine
214838705|NCT05122858|PROCEDURE|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
214838706|NCT05122858|PROCEDURE|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
214838707|NCT04674228|OTHER|Electronic Health Record Review|Review of medical records
214838708|NCT04096547|DRUG|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
214838709|NCT04162327|DRUG|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
214838710|NCT04162327|DRUG|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
214838711|NCT04189120|PROCEDURE|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
214838712|NCT03960762|OTHER|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
214838713|NCT03960762|OTHER|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
214838714|NCT04370444|DEVICE|Phallus Length Reducer|Phallus Length Reducer
214838715|NCT04370444|OTHER|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
214838716|NCT02834962|PROCEDURE|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
214838717|NCT02834962|PROCEDURE|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
214838718|NCT03949062|DRUG|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
214838719|NCT03949062|DRUG|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
214838720|NCT03949062|DRUG|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
214838721|NCT00216060|DRUG|Risedronate|Daily oral risedronate combined with androgen deprivation
214838722|NCT00216060|DRUG|Placebo|Daily oral placebo combined with androgen deprivation
214838723|NCT05889039|DEVICE|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
214838724|NCT05889039|PROCEDURE|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
214838725|NCT05889039|PROCEDURE|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
214838726|NCT04440696|DRUG|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
214838727|NCT04440696|DRUG|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
214838728|NCT04440696|DRUG|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
214838729|NCT00604916|OTHER|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
214838730|NCT00604916|OTHER|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
214838731|NCT04346862|DRUG|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
214838732|NCT04346862|DRUG|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
214838733|NCT02445846|DEVICE|dual HIV/syphilis rapid diagnostics tests|
214838734|NCT03514355|BEHAVIORAL|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
214838735|NCT05491850|OTHER|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
214838736|NCT05900323|COMBINATION_PRODUCT|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
214838737|NCT00061464|DRUG|pemetrexed|
214838738|NCT00061464|DRUG|gemcitabine|
214838739|NCT00362687|DRUG|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
214838740|NCT00362687|DRUG|FTC alone|emtricitabine 200 mg
214838741|NCT00362687|PROCEDURE|No HAART|No HAART
214838742|NCT02797379|OTHER|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
214838743|NCT05717387|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
214838744|NCT05717387|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
214838745|NCT00982228|DRUG|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
214838746|NCT00982228|DRUG|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
214838747|NCT00982228|DRUG|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
214838748|NCT06016153|OTHER|Software based feedback|Feedback is given by the data of a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary).
214838749|NCT06016153|OTHER|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
214838750|NCT03837405|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
214838751|NCT03837405|BEHAVIORAL|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
214838752|NCT00850447|OTHER|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
214838753|NCT00850447|OTHER|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
214838754|NCT05207605|OTHER|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
214838755|NCT05207605|OTHER|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
214838756|NCT00875082|DRUG|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
214838757|NCT00875082|DRUG|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
214838758|NCT00465660|BEHAVIORAL|Progressive resistance training|
214838759|NCT01438476|PROCEDURE|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
214838760|NCT01438476|PROCEDURE|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
214838761|NCT01438476|BEHAVIORAL|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
214838762|NCT01438476|BEHAVIORAL|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
214838763|NCT01165476|DRUG|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
214838764|NCT03316976|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
214838765|NCT00530660|BIOLOGICAL|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
214838766|NCT01274962|DRUG|FOLFOX|"* Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
214838767|NCT01274962|RADIATION|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
214838768|NCT02522780|DRUG|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
214838769|NCT02522780|DRUG|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
214838770|NCT02058160|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
214838771|NCT02058160|DRUG|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
214838772|NCT02058160|DRUG|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
214838773|NCT03113357|OTHER|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
214838774|NCT03113357|OTHER|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
214838775|NCT01376544|DEVICE|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
214838776|NCT03316040|BEHAVIORAL|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
214838777|NCT00776867|DRUG|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
214838778|NCT03033030|DIAGNOSTIC_TEST|Ultrasound|Ultrasound examination
214838779|NCT01489930|BEHAVIORAL|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
214838780|NCT01489930|BEHAVIORAL|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
214838781|NCT01489930|BEHAVIORAL|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
214838782|NCT05603858|PROCEDURE|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
214838783|NCT01226524|DRUG|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
214838784|NCT00499824|BEHAVIORAL|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
214838785|NCT00000516|DRUG|enalapril|
214838786|NCT00006124|DRUG|celecoxib|Given orally
214838787|NCT00006124|DRUG|placebo|Given orally
214838788|NCT00004216|BIOLOGICAL|salmonella VNP20009|
214838789|NCT00004216|DRUG|cefixime|
214838790|NCT00004216|DRUG|ceftriaxone sodium|
214838791|NCT00004216|DRUG|ciprofloxacin|
214838792|NCT00004216|DRUG|trimethoprim-sulfamethoxazole|
214464961|NCT05145192|DEVICE|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
214464962|NCT05145192|DEVICE|ParvoMedics CPET|ParvoMedics CPET
214838793|NCT03201341|OTHER|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
214838794|NCT03201341|OTHER|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
214838795|NCT03201341|OTHER|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
214838796|NCT03201341|OTHER|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
214838797|NCT03201341|OTHER|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
214838798|NCT03201341|OTHER|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
214838799|NCT03201341|OTHER|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
214838800|NCT03201341|OTHER|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
214838801|NCT02798419|DRUG|DFD05 Cream|
214838802|NCT02798419|DRUG|Active01 Cream|
214838803|NCT03310619|BIOLOGICAL|JCAR017|Gene modified autologous T cells
214838804|NCT03310619|DRUG|Durvalumab|Anti-PD-L1
214838805|NCT03310619|DRUG|CC-122|Pleiotropic Pathway Modifier
214838806|NCT03310619|DRUG|Ibrutinib|Ibrutinib
214838807|NCT03310619|DRUG|CC-220|CC-220
214838808|NCT03310619|DRUG|Relatlimab|Relatlimab
214838809|NCT03310619|DRUG|Nivolumab|Nivolumab
214838810|NCT03310619|DRUG|CC-99282|CC-99282
214838811|NCT05167617|DRUG|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
214838812|NCT02642523|DRUG|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
214838813|NCT02642523|DRUG|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
214464963|NCT03946618|DEVICE|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
214838814|NCT02642523|OTHER|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
214838815|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
214838816|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
214838817|NCT06471179|DEVICE|Functional MRI|Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
214838818|NCT00451490|DRUG|Agomelatine|
214838819|NCT00451490|DRUG|Fluoxentine|
214838820|NCT03011879|OTHER|clinical pathway|
214838821|NCT00630903|DRUG|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
214838822|NCT00630903|DRUG|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
214838823|NCT03885336|OTHER|No Interventions|There are no interventions in this study. Participants are observed.
214838824|NCT01115933|DEVICE|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
214838825|NCT04130685|DIAGNOSTIC_TEST|Allosure Test|Venous Blood Draw
214838826|NCT01611415|DRUG|Ipragliflozin|Oral
214838827|NCT01611415|DRUG|Furosemide|Oral
214838828|NCT01830309|DRUG|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
214838829|NCT02476305|DEVICE|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
214838830|NCT03211351|DRUG|Liposic|one eye of the participant recieved Lipoic
214838831|NCT03211351|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
214838832|NCT05761587|OTHER|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
214838833|NCT01459198|BIOLOGICAL|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
214838834|NCT01459198|BIOLOGICAL|Placebo vaccine|Given intranasally once at a baseline study visit
214838835|NCT04763447|OTHER|Attempt to withdrawal OMA treatment|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
214838836|NCT04763447|DRUG|Continuation of OMA treatment|"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."
214838837|NCT02999698|OTHER|Observational|Observational
214838838|NCT00008398|BIOLOGICAL|sargramostim|
214838839|NCT00008398|PROCEDURE|quality-of-life assessment|
214838840|NCT00008398|RADIATION|radiation therapy|
214838841|NCT01257191|DRUG|Carbon Black|source: commercial
214838842|NCT01257191|DRUG|Diesel Exhaust Particles|source: diesel engine
214838843|NCT01257191|DRUG|Fine Concentrated Ambient Particles|source: concentrated ambient air
214838844|NCT01257191|DRUG|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
214838845|NCT01257191|DRUG|Saline|Saline solution
214838846|NCT00508898|DRUG|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
214838847|NCT00508898|DRUG|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
214838848|NCT03518723|OTHER|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
214838849|NCT03518723|OTHER|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
214838850|NCT01422486|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
214838851|NCT05129189|DRUG|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
214838852|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
214838853|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
214838854|NCT05777694|PROCEDURE|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
214838855|NCT04228627|DRUG|Parentral Iron|Correction of Iron stores without anaemia
214838856|NCT03432273|DRUG|Nicotine lozenge|Nicotine mint lozenge, 2 mg
214464964|NCT04082143|DEVICE|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
214838857|NCT03432273|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
214838858|NCT05713227|DIETARY_SUPPLEMENT|White rice|185 g Jasmine (white) rice boiled in 356 g water
214838859|NCT05713227|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
214838860|NCT04461340|DRUG|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
214838861|NCT05998291|OTHER|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
214838862|NCT00926367|DRUG|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
214838863|NCT00926367|DRUG|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
214838864|NCT04511572|PROCEDURE|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
214838865|NCT01517867|BEHAVIORAL|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
214838866|NCT01517867|BEHAVIORAL|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
214838867|NCT02613286|PROCEDURE|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
214838868|NCT02613286|PROCEDURE|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
214838869|NCT02033317|DRUG|patiromer|15 grams/day (5 grams 3 times daily) administered orally
214838870|NCT06454214|DEVICE|Multi-photon microscopy|To conduct 3D structural imaging on human breast tissues
214838871|NCT00249990|DRUG|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
214838872|NCT03901690|DRUG|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
214838873|NCT03901690|DRUG|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
214838874|NCT02310503|PROCEDURE|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
214838875|NCT04536506|OTHER|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
214838876|NCT04536506|OTHER|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
214838877|NCT01266603|DRUG|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
214838878|NCT01266603|BIOLOGICAL|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
214838879|NCT04988737|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
214838880|NCT06176885|DRUG|Camrelizumab|Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
214838881|NCT02105909|OTHER|GWAS|
214838882|NCT04621656|COMBINATION_PRODUCT|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
214838883|NCT05740215|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
214838884|NCT05740215|DRUG|Lenvatinib|Lenvatinib capsules
214838885|NCT04731493|OTHER|Therapeutic Education Program|"* needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire"
214838886|NCT02176278|OTHER|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
214838887|NCT02176278|OTHER|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
214838888|NCT02176278|OTHER|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
214838889|NCT02054754|DRUG|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
214838890|NCT02054754|DRUG|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
214838891|NCT02054754|DRUG|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
214838892|NCT02054754|DRUG|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
214838893|NCT02054754|DRUG|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
214838894|NCT02054754|DRUG|Placebo|
214838895|NCT02725411|DRUG|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
214838896|NCT02725411|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
214838897|NCT02725411|BIOLOGICAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
214838898|NCT02725411|DRUG|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
214838899|NCT02725411|BIOLOGICAL|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
214838900|NCT04937647|OTHER|collection of endoscopic images and videos|collection of endoscopic images and videos
214838901|NCT06024343|PROCEDURE|MPD Exposure, Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
214838902|NCT03819920|BEHAVIORAL|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
214838903|NCT03819920|BEHAVIORAL|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
214838904|NCT00076531|DRUG|Leuprolide Acetate for Injectable Suspension 22.5 mg|
214838905|NCT02879773|RADIATION|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
214838906|NCT01041235|DRUG|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
214838907|NCT06650124|DRUG|Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.|Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
214838908|NCT06650124|DRUG|Azathioprine + Prednisolone|In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
214838909|NCT01288924|DRUG|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
214838910|NCT01288924|OTHER|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
214838911|NCT05690035|DRUG|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
214838912|NCT04615312|DRUG|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
214838913|NCT01652508|OTHER|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
214838914|NCT01652508|BEHAVIORAL|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
214838915|NCT06674421|OTHER|Reliability Analyses|For the reliability analysis test-retest method will use. There will be a one-week break between the first test and the retest.
214838916|NCT00051818|BEHAVIORAL|Treatment interruption/reinitiation schedule|
214838917|NCT00152906|PROCEDURE|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
214838918|NCT01845064|DRUG|DM199|
214838919|NCT01845064|DRUG|Placebo|
214838920|NCT01557062|OTHER|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
214838921|NCT01557062|OTHER|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
214838922|NCT01557062|OTHER|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
214838923|NCT02686762|DRUG|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
214464965|NCT04082143|DEVICE|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
214464966|NCT03704415|PROCEDURE|Extended endoscopic sinus surgery|ESS of all sinuses
214464967|NCT03704415|PROCEDURE|Limited endoscopic sinus surgery|Partial ethmoidectomy
214838924|NCT02686762|DRUG|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
214838925|NCT02686762|DRUG|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
214838926|NCT00645827|OTHER|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
214838927|NCT00645827|OTHER|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
214838928|NCT02911935|DRUG|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
214838929|NCT02911935|DRUG|Placebo|Placebo suspension
214838930|NCT02874196|PROCEDURE|Standard arthrography|
214838931|NCT02874196|PROCEDURE|Dual energy arthrography|
214838932|NCT02874196|PROCEDURE|Arthro-tomosynthesis|
214838933|NCT02874196|PROCEDURE|Arthro-tomography|
214838934|NCT02874196|PROCEDURE|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
214838935|NCT04011449|DEVICE|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
214838936|NCT06270095|DIAGNOSTIC_TEST|Neurocognitive, neuromuscular and neurosensitive tests.|"At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated."
214838937|NCT06110286|OTHER|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
214838938|NCT01583634|DEVICE|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
214838939|NCT01583634|DEVICE|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
214838940|NCT05188924|DRUG|DKF-306|Active ingredients
214838941|NCT05188924|DRUG|Placebo|Placebo
214838942|NCT02932917|DEVICE|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
214838943|NCT00603512|DRUG|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
214838944|NCT00603512|DRUG|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
214838945|NCT00603512|DRUG|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
214838946|NCT00603512|DRUG|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
214838947|NCT00603512|DRUG|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
214838948|NCT03266055|DIETARY_SUPPLEMENT|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
214838949|NCT03266055|DIETARY_SUPPLEMENT|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
214838950|NCT00685750|PROCEDURE|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
214838951|NCT04066413|OTHER|Standard infant formula|Standard infant formula
214838952|NCT04066413|OTHER|Infant formula supplemented with HMO|Infant formula supplemented with HMO
214838953|NCT04979858|DEVICE|Focal Mask|The treatment group will receive and use the focal mask.
214838954|NCT05815849|DIETARY_SUPPLEMENT|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
214838955|NCT04547933|DIAGNOSTIC_TEST|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
214838956|NCT02150356|OTHER|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
214838957|NCT02150356|OTHER|Control|Diet based on refined cereal products for a period of 8 weeks.
214838958|NCT02654015|DEVICE|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
214838959|NCT02654015|OTHER|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
214838960|NCT03077009|DRUG|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
214838961|NCT03860337|DIETARY_SUPPLEMENT|Alginate Sausage|Alginate sausage
214838962|NCT03860337|OTHER|Control Sausage|Control Sausage
214838963|NCT01776528|BIOLOGICAL|NGM282|
214838964|NCT01776528|BIOLOGICAL|Placebo|
214277686|NCT06629207|DEVICE|SPECT : 123 I-FP-CIT (DATSCAN)|DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
214277687|NCT06629207|DEVICE|MRI|MRI examination to exclude structural brain anomalies.
214838965|NCT02846233|DRUG|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
214838966|NCT02846233|DRUG|basal insulin|The participant will continue with the basal insulin.
214838967|NCT02846233|DRUG|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
214838968|NCT02846233|DRUG|Metformin|The participant will continue with metformin.
214838969|NCT01896505|DRUG|KCP-330|
214838970|NCT00047047|DRUG|gemcitabine hydrochloride|Given IV
214838971|NCT00047047|DRUG|tanespimycin|Given IV
214838972|NCT00047047|DRUG|cisplatin|Given IV
214838973|NCT00047047|OTHER|laboratory biomarker analysis|Correlative studies
214838974|NCT03082651|OTHER|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
214838975|NCT03082651|OTHER|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
214838976|NCT03082651|OTHER|Constant training|Runners will be assigned identical training sessions over a 7-day period.
214838977|NCT03082651|OTHER|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
214838978|NCT05426954|OTHER|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
214838979|NCT03671343|BEHAVIORAL|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
214838980|NCT04974580|DRUG|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
214838981|NCT04974580|BEHAVIORAL|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
214838982|NCT04974580|BEHAVIORAL|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
214838983|NCT01817686|OTHER|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
214838984|NCT01817686|OTHER|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
214838985|NCT01817686|OTHER|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
214838986|NCT00462839|PROCEDURE|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
214838987|NCT01325935|DRUG|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
214838988|NCT01814358|DIETARY_SUPPLEMENT|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
214838989|NCT01814358|DIETARY_SUPPLEMENT|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
214838990|NCT05841693|DRUG|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
214838991|NCT05841693|DRUG|Placebo|The control group will be offered same amount of placebo fluid.
214838992|NCT06678061|DEVICE|radiofrequency|block of neurolytic retrocrural celiac plexus block
214838993|NCT01489605|DEVICE|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
214838994|NCT01489605|DEVICE|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
214838995|NCT03944161|DIETARY_SUPPLEMENT|Oral nutrition supplement|Hypercaloric and high protein supplement
214838996|NCT03944161|OTHER|Nutritional advice|Advice given by the clinician
214838997|NCT05676008|BEHAVIORAL|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
214838998|NCT03129776|DRUG|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
214838999|NCT03129776|DRUG|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
214839000|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (rabbit)|
214839001|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (horse)|
214839002|NCT00260689|DRUG|Cyclosporine|
214839003|NCT00260689|DRUG|Alemtuzumab|
214839004|NCT01557686|BEHAVIORAL|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
214839005|NCT01858922|DRUG|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
214839006|NCT01858922|DRUG|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
214839007|NCT00791986|DEVICE|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
214839008|NCT05317195|OTHER|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
214839009|NCT05317195|OTHER|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
214839010|NCT05317195|OTHER|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
214839011|NCT05317195|OTHER|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
214839012|NCT05317195|OTHER|Velo-NP|Velo-NP; 10 mg nicotine;
214839013|NCT05317195|OTHER|Zyn-NP|Zyn-NP; 3 mg nicotine;
214839014|NCT05327712|BEHAVIORAL|Control group|No outreach during the intervention period beyond an initial eligibility notice.
214839015|NCT05327712|BEHAVIORAL|Email only|Email reminders in addition to an initial eligibility notice.
214839016|NCT05327712|BEHAVIORAL|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
214839017|NCT05327712|BEHAVIORAL|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
214839018|NCT04799223|OTHER|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
214839019|NCT04799223|OTHER|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
214839020|NCT05377606|PROCEDURE|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
214839021|NCT05377606|PROCEDURE|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
214839022|NCT01166815|DIETARY_SUPPLEMENT|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
214839023|NCT01166815|OTHER|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
214839024|NCT03919695|BEHAVIORAL|Kisoboka: Behavioral and Structural Intervention|"The intervention has two components; a structural component and a behavioral component. The intervention draws from behavioral economics and motivational interviewing.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals."
214839025|NCT03919695|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
214839026|NCT01669824|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
214839027|NCT00834158|PROCEDURE|TACE|1 time
214839028|NCT00834158|PROCEDURE|PVE|1 time
214839029|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
214839030|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
214277688|NCT00607815|BEHAVIORAL|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
214839031|NCT01706263|DRUG|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
214839032|NCT00233155|DRUG|Capsaicin Dermal Patch|
214839033|NCT02063217|DRUG|Sodium Oxybate|Sodium oxybate h.s.
214839034|NCT02063217|BEHAVIORAL|Sleep deprivation|36hr sleep deprivation
214839035|NCT06435832|DRUG|Absorbable Gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
214839036|NCT06435832|DRUG|Chlorhexidine|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
214839037|NCT06435832|DRUG|Tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
214839038|NCT01004445|DRUG|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
214839039|NCT01004445|DRUG|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
214839040|NCT01004445|DRUG|Placebo|Two aerosol treatments per day (one treatment every 12hr)
214839041|NCT01020526|DRUG|pregabalin|Oral capsule 75-450 mg/day
214839042|NCT02095340|OTHER|Positive Interpretation Bias Training|
214839043|NCT02095340|OTHER|Neutral Interpretation Bias Training|
214839044|NCT04227041|DRUG|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
214839045|NCT01102127|DEVICE|Elastography|Performance of US, elastography and FNA.
214839046|NCT00002116|DRUG|Cidofovir|
214839047|NCT01959802|PROCEDURE|Vitrectomy|
214839048|NCT00002592|BIOLOGICAL|c-myb antisense oligonucleotide G4460|
214839049|NCT00002592|BIOLOGICAL|filgrastim|
214839050|NCT00002592|DRUG|busulfan|
214839051|NCT00002592|DRUG|cyclophosphamide|
214839052|NCT00002592|PROCEDURE|autologous bone marrow transplantation|
214839053|NCT00002592|PROCEDURE|in vitro-treated bone marrow transplantation|
214839054|NCT05995873|DEVICE|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
214839055|NCT04680780|OTHER|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
214839056|NCT04680780|OTHER|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
214839057|NCT04680780|OTHER|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
214839058|NCT02141048|BEHAVIORAL|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
214839059|NCT05467540|DEVICE|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
214839060|NCT00943813|BEHAVIORAL|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
214839061|NCT02132650|BEHAVIORAL|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
214839062|NCT02132650|BEHAVIORAL|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
214839063|NCT03555136|DRUG|Vortioxetine|Treatment with vortioxetine as per local SmPC
214839064|NCT04117893|DRUG|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
214839065|NCT04117893|DRUG|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
214839066|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients|"Completion by patients of a 28-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
214839067|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients' life partner|"Completion by the patients' life partner of a 30-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
214839068|NCT04624594|OTHER|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
214839069|NCT04624594|OTHER|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
214839070|NCT03434691|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
214839071|NCT03434691|DRUG|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
214839072|NCT02212457|BIOLOGICAL|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB\_0\_2 Group.
214839073|NCT02212457|OTHER|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group, Month 2 in ABCWY\_0\_6 Group and ABCWY\_0\_11 Group and Month 6 in ABCWY\_0\_1 Group.
214839074|NCT02212457|BIOLOGICAL|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY\_0\_1 Group, Month 1 and 12 in Group ABCWY\_0\_6 Group and ABCWY\_0\_2\_6 Group , Month 0 and 6 in ABCWY\_0\_11 Group and Month 6 and 12 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
214839075|NCT02212457|BIOLOGICAL|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY\_0\_1 Group, Month 0 and 6 in ABCWY\_0\_6 Group, Month 1 and 12 in ABCWY\_0\_11 Group, Month 0, 2 and 6 in ABCWY\_0\_2\_6 Group, Month 0 and 2 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
214839076|NCT03671187|OTHER|Exercise|8 week exercise program
214839077|NCT05211505|DEVICE|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
214839078|NCT02455947|OTHER|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
214839079|NCT05886803|OTHER|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
214839080|NCT03734458|OTHER|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
214839081|NCT03734458|OTHER|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
214839082|NCT03734458|OTHER|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
214839083|NCT04202484|DRUG|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
214839084|NCT06265753|OTHER|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
214839085|NCT06265753|OTHER|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
214839086|NCT01601353|DEVICE|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
214839087|NCT00310674|BIOLOGICAL|Meningococcal C Conjugate Vaccine|
214839088|NCT05717673|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
214839089|NCT04231292|DRUG|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
214839090|NCT04231292|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
214839091|NCT04231292|DRUG|placebo|placebo
214839092|NCT05215873|DRUG|Misoprostol|a synthetic prostaglandin E1 analogue
214839093|NCT05215873|DRUG|Syntocinon|synthetic oxytocin
214839094|NCT03433404|PROCEDURE|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
214839095|NCT03433404|PROCEDURE|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
214839096|NCT04543084|BEHAVIORAL|Logbook|Participants will record practice in a logbook.
214839097|NCT01120691|DRUG|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
214839098|NCT01120691|DRUG|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
214839099|NCT01120691|DRUG|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
214839100|NCT01120691|DRUG|Salbutamol/albuterol|As needed throughout the study
214839101|NCT01715779|DRUG|Eltrombopag|Eltrombopag exposure
214839102|NCT06265038|DEVICE|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
214839103|NCT00938782|DEVICE|Sedline|
214839104|NCT05937126|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
214839105|NCT05937126|DIAGNOSTIC_TEST|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
214839106|NCT06071338|DIAGNOSTIC_TEST|Clinical Periodontal Examination|No details will be published from the clinical assessment.
214839107|NCT02827682|DEVICE|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
214839108|NCT02827682|DEVICE|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
214839109|NCT03370510|DRUG|Oxytocin|Oxytocin nasal spray.
214839110|NCT03370510|BEHAVIORAL|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
214839111|NCT03370510|DRUG|Placebo|Placebo nasal spray.
214839112|NCT04044573|PROCEDURE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
214839113|NCT05276986|OTHER|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
214839114|NCT05179122|PROCEDURE|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
214839115|NCT04884022|PROCEDURE|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
214839116|NCT04884022|PROCEDURE|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
214839117|NCT00804999|DRUG|Clear Care|neutralized Clear Care
214839118|NCT00804999|DRUG|ReNu|overnight soak in solution
214839119|NCT00804999|DRUG|OPTI-FREE|overnight soak in solution
214839120|NCT03578822|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
214839121|NCT03578822|DRUG|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
214839122|NCT03578822|DRUG|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
214839123|NCT03578822|DRUG|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
214839124|NCT01525628|DRUG|midazolam|CYP3A probe drug
214839125|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
214839126|NCT01525628|DRUG|tenofovir|nucleoside analogue
214839127|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
214839128|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
214839129|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
214464968|NCT03337607|DEVICE|rESWT|"rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics"
214464969|NCT03337607|DRUG|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
214839130|NCT01525628|DRUG|midazolam|CYP3A probe drug
214839131|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
214839132|NCT01525628|DRUG|pegylated interferon|HCV treatment
214839133|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
214839134|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
214839135|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
214839136|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
214839137|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
214839138|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
214839139|NCT01525628|DRUG|ribavirin|HCV treatment
214839140|NCT01525628|DRUG|ribavirin|HCV treatment
214839141|NCT01525628|DRUG|ribavirin|HCV treatment
214839142|NCT01525628|DRUG|pegylated interferon|HCV treatment
214839143|NCT01525628|DRUG|ribavirin|HCV treatment
214839144|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
214839145|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
214839146|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
214839147|NCT01525628|DRUG|midazolam|CYP3A probe drug
214839148|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
214839149|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
214839150|NCT01525628|DRUG|ribavirin|HCV treatment
214839151|NCT05723796|PROCEDURE|nasal endoscopy|nasal endoscopy and mucosal biopsy
214839152|NCT00957762|OTHER|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
214839153|NCT05289557|DRUG|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
214839154|NCT05289557|DRUG|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
214839155|NCT00089973|DRUG|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
214839156|NCT02159820|DRUG|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
214839157|NCT02159820|DRUG|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
214839158|NCT06626542|OTHER|resistance and aerobic training exercises|resistance and aerobic training exercises
214839159|NCT05993390|DRUG|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
214839160|NCT05993390|DRUG|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
214277689|NCT00607815|BEHAVIORAL|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
214277690|NCT04262570|DEVICE|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
214464970|NCT03337607|DRUG|Eperisone|3 x 50 mg per day for four weeks
214839161|NCT05691153|DRUG|ThisCART19A with Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
214839162|NCT05691153|DRUG|ThisCART19A with Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
214839163|NCT01614262|OTHER|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
214839164|NCT00521508|PROCEDURE|gene transcription and cytometry|samply of 30 ml of blood
214839165|NCT04436133|BIOLOGICAL|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
214839166|NCT04436133|BIOLOGICAL|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
214839167|NCT03900234|OTHER|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
214839168|NCT01992094|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
214839169|NCT01992094|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
214839170|NCT01992094|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
214839171|NCT02726841|PROCEDURE|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
214839172|NCT02726841|PROCEDURE|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
214839173|NCT02642809|DRUG|Pembrolizumab|
214839174|NCT02642809|RADIATION|Brachytherapy|
214839175|NCT02642809|PROCEDURE|Endoscopic biopsy|
214839176|NCT02642809|PROCEDURE|Computed tomography-guided biopsy|
214839177|NCT02642809|PROCEDURE|Peripheral blood collection|
214839178|NCT01214239|DRUG|Placebo|once a day
214839179|NCT01214239|DRUG|Linagliptin|once a day
214839180|NCT05147740|DRUG|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
214839181|NCT01463891|DRUG|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
214839182|NCT01049581|PROCEDURE|aquatic therapy|two hours per week, one hour per time, total 12 weeks
214839183|NCT02511860|DIETARY_SUPPLEMENT|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
214839184|NCT02511860|DIETARY_SUPPLEMENT|Placebo|Methylcellulose (inert) tablet taken as placebo
214839185|NCT05554887|OTHER|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
214839186|NCT05554887|OTHER|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
214839187|NCT01090245|BEHAVIORAL|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
214839188|NCT01090245|BEHAVIORAL|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
214839189|NCT03095781|DRUG|XL888|Given PO
214839190|NCT03095781|BIOLOGICAL|Pembrolizumab|Given IV
214839191|NCT00677872|DRUG|PRX-08066|
214839192|NCT01050556|OTHER|Placebo|daily, 24 weeks
214839193|NCT01050556|DIETARY_SUPPLEMENT|folic acid|400 ug/d for 12 or 24 weeks
214839194|NCT01050556|DIETARY_SUPPLEMENT|folic acid|800 µg/d for 12 or 24 weeks
214839195|NCT01050556|DIETARY_SUPPLEMENT|creatine|3 mg/d for 12 weeks
214839196|NCT01050556|DIETARY_SUPPLEMENT|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
214839197|NCT04791007|DRUG|OB-002|vaginal or rectal administration
214839198|NCT04791007|DRUG|Placebo|vaginal or rectal administration
214839199|NCT02367872|DRUG|TAK-272|TAK-272 tablet
214839200|NCT01164657|DEVICE|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
214839201|NCT02625298|DEVICE|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
214839202|NCT02625298|DEVICE|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
214839203|NCT05068284|DRUG|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
214839204|NCT05068284|DRUG|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
214839205|NCT05068284|DRUG|ABBV-154|Subcutaneous Injection
214839206|NCT05068284|DRUG|Placebo|Subcutaneous Injection
214839207|NCT02681588|PROCEDURE|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
214839208|NCT02671474|OTHER|4-dimensional volume-rendered computed tomography|
214839209|NCT00965731|DRUG|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
214839210|NCT00965731|DRUG|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
214839211|NCT00965731|DRUG|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
214839212|NCT05672173|PROCEDURE|Biopsy|Undergo tumor biopsy
214839213|NCT05672173|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214839214|NCT05672173|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
214464971|NCT03824132|BEHAVIORAL|Improvisational comedy classes|6 consecutive improvisational comedy classes
214839215|NCT05672173|PROCEDURE|Computed Tomography|Undergo PET/CT
214839216|NCT05672173|DRUG|Cyclophosphamide|Given IV
214839217|NCT05672173|DRUG|Fludarabine|Given IV
214839218|NCT05672173|DRUG|Ibrutinib|Given PO
214839219|NCT05672173|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214839220|NCT05672173|BIOLOGICAL|Nivolumab|Given IV
214839221|NCT05672173|PROCEDURE|Pheresis|Undergo apheresis
214839222|NCT05672173|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214839223|NCT05135273|BIOLOGICAL|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
214839224|NCT05135273|BIOLOGICAL|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
214839225|NCT04238546|DEVICE|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
214839226|NCT04238546|DEVICE|uncoated balloon catheter|angioplasty with uncoated balloon catheter
214839227|NCT02798328|DEVICE|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
214839228|NCT05127135|BIOLOGICAL|ThisCART7 cells|0.5-6 x 10\^6 CAR T cells per kg body weight
214839229|NCT01531504|DEVICE|ViKY UP|laparoscopic-assisted hysterectomy procedure
214839230|NCT02734524|BIOLOGICAL|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4
214839231|NCT02734524|DRUG|Taxol|135-175mg/m2,q28d\*4
214839232|NCT02734524|DRUG|Carboplatin|AUC=5,q28d\*4
214839233|NCT03623893|PROCEDURE|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
214839234|NCT01185860|DRUG|danoprevir|oral doses
214839235|NCT01185860|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
214839236|NCT01185860|DRUG|placebo|oral doses
214839237|NCT01185860|DRUG|ribavirin|1000-1200mg/day po
214839238|NCT01185860|DRUG|ritonavir|oral doses
214839239|NCT02523794|OTHER|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
214839240|NCT02523794|OTHER|Placebo|Purified Drinking Water
214839241|NCT01062334|PROCEDURE|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
214839242|NCT00535041|DRUG|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
214839243|NCT05752435|PROCEDURE|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
214839244|NCT05391659|DEVICE|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
214839245|NCT05391659|DIAGNOSTIC_TEST|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
214839246|NCT05391659|DIAGNOSTIC_TEST|gold standard|examination by ophthalmologist
214839247|NCT03574337|DRUG|Sugammadex|No additional information
214839248|NCT03574337|DRUG|neostigmine/glycopyrolate|No additional information
214839249|NCT06678685|DRUG|.spironolactone|In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
214839250|NCT04225260|BIOLOGICAL|botulinum toxin neuromodulator|A dose of QM1114-DP will be injected in the GL area and in the LCL area.
214839251|NCT06615778|BEHAVIORAL|Motivated Social Emotional Learning|"MSEL arm consists of three intervention components: 1) CSEL, 2) the meaningful role tasks, and 3) the Secret Angel activity. First, participants in the MSEL arm will receive the same 6-session SEL as participants in the Curriculum-based Social-Emotional Learning arm.~Second, other than the CSEL, the second component is the Class Diploma tasks adopted from the pupil responsibilities intervention developed by Ellies et al. (2016). Participants will be provided with a list of meaningful roles and select the role they are willing to take based on their talents and interests. Each participant will take the role for two weeks, fulfilling the related duties and responsibilities. The third component is the Secret Angel, in which participants will anonymously recognize each other via the appraisal notes on Shout Out for Your Board."
214839252|NCT06615778|BEHAVIORAL|Curriculum-based Social Emotional Learning|"In the CSEL arm, 6-session SEL training will be delivered as the experimental component. The primary goal of the SEL training is to reduce traditional bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors.~Each session lasts 40 minutes and is delivered by the headteacher in each class weekly as an after-school workshop. The SEL curriculum is tailored to the social-emotional needs of primary school students, as suggested by CASEL (2013). Also, building on past literature highlighting the lack of SEC as a risk factor linked to bullying behaviors both in the physical and cyber world, specific topics such as self-appreciation (self-awareness), stress management (self-management), respect and acceptance (social awareness), and conflict resolution (relationship skills) incorporated into the curriculum design."
214839253|NCT04502498|DIAGNOSTIC_TEST|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
214839254|NCT05799196|PROCEDURE|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
214839255|NCT00317434|DRUG|lapatinib|
214839256|NCT00883935|DRUG|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
214839257|NCT00883935|DRUG|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
214839258|NCT00883935|DRUG|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
214839259|NCT00883935|DRUG|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
214839260|NCT05623046|BEHAVIORAL|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
214839261|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
214839262|NCT02583191|DRUG|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
214839263|NCT02583191|DRUG|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"
214839264|NCT00057967|BIOLOGICAL|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
214839265|NCT04129944|DRUG|UBX0101|Investigational drug intra-articular injection
214839266|NCT04129944|OTHER|Placebo|Placebo intra-articular injection
214839267|NCT05281172|BEHAVIORAL|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
214839268|NCT05281172|BEHAVIORAL|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
214839269|NCT05008562|OTHER|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
214839270|NCT00493792|DEVICE|X3 Polyethylene|Highly cross-linked polyethylene (HXLPE).
214839271|NCT00493792|DEVICE|N2Vac Polyethylene|Ultra-high-molecular-weight polyethylene (UHMWPE).
214839272|NCT00523289|DRUG|Bupivacaine|Dosage: 150mg at once for anesthesia induction
214839273|NCT00523289|DRUG|Ropivacaine|Single dose of ropivacaine, 150mg
214839274|NCT03558035|DRUG|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
214839275|NCT03558035|RADIATION|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
214839276|NCT06239428|BEHAVIORAL|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
214839277|NCT06239428|OTHER|Waitlist|A 12-week waitlist with access to online mindfulness material.
214839278|NCT04313426|OTHER|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
214839279|NCT00685035|DEVICE|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
214839280|NCT00685035|DEVICE|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
214839281|NCT02001155|PROCEDURE|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
214839282|NCT04241133|BEHAVIORAL|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
214839283|NCT04684680|DIETARY_SUPPLEMENT|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
214839284|NCT04684680|DIETARY_SUPPLEMENT|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
214839285|NCT01333202|OTHER|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
214839286|NCT03405857|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
214839287|NCT06838026|OTHER|External Intercostal Nerve Block|External ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space from outside the chest wall.
214839288|NCT06838026|OTHER|Internal Intercostal Nerve Block|Internal ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space inside the chest wall under direct thoracoscopic vision.
214839289|NCT06838026|OTHER|Intercostal Catheter|Intercostal Catheter: it will be put 1-2 intercostal spaces above the VATS incision, and the participant will receive the 15 cc of the previously mentioned mixture every 8 hours for two to three days.
214839290|NCT06176612|PROCEDURE|total hip arthroplasty|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
214839291|NCT01021657|PROCEDURE|trabeculectomies, non penetrating deep sclerectomies|
214839292|NCT02336906|DRUG|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
214839293|NCT02336906|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
214839294|NCT02336906|BEHAVIORAL|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
214839295|NCT04719611|DIETARY_SUPPLEMENT|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
214839296|NCT05746819|OTHER|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
214839297|NCT02672540|DRUG|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
214839298|NCT02672540|DRUG|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
214839299|NCT02104817|DRUG|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
214839300|NCT02104817|DRUG|corn oil control|corn oil control arm
214839301|NCT01225055|DRUG|Teriparatide|20 ug daily over 12 months
214839302|NCT01225055|DEVICE|vibration|10 min/day for 12 months
214839303|NCT02587312|OTHER|Very low nicotine content cigarettes|
214839304|NCT02587312|OTHER|Standard nicotine content cigarettes|
214839305|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
214839306|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
214839307|NCT00799942|DRUG|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
214839308|NCT04915911|OTHER|cross-sectional study|cross-sectional study
214839309|NCT03859128|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
214839310|NCT05357079|DRUG|Tranexamic Acid|Topical application
214839311|NCT05357079|DRUG|Normal saline|Topical application
214839312|NCT05824494|DRUG|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
214839313|NCT05824494|DRUG|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
214839314|NCT04862962|DRUG|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
214839315|NCT05727449|PROCEDURE|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
214839316|NCT05727449|PROCEDURE|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
214839317|NCT05255952|PROCEDURE|Electrical stimulation|Electrical stimulation of the cardiac plexus
214839318|NCT05424133|OTHER|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
214464972|NCT03824132|BEHAVIORAL|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
214464973|NCT02466737|PROCEDURE|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
214464974|NCT02466737|PROCEDURE|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
214839319|NCT05424133|OTHER|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
214839320|NCT04815694|RADIATION|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
214839321|NCT04892316|DIAGNOSTIC_TEST|Diagnostic test|The training dataset was used to train the model, which was validated and tested by the other two datasets.
214839322|NCT02864004|DRUG|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
214839323|NCT02864004|OTHER|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
214839324|NCT03307564|DEVICE|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
214839325|NCT04306640|OTHER|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
214839326|NCT03857672|BEHAVIORAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
214839327|NCT05962450|BIOLOGICAL|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
214839328|NCT05962450|DRUG|PD-1|Intravenous infusion, according to the drug instructions.
214839329|NCT05962450|DRUG|Regorafenib|Oral administration, according to the drug instructions.
214839330|NCT05567835|DRUG|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
214839331|NCT05567835|DRUG|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
214839332|NCT05567835|DRUG|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
214839333|NCT05567835|DRUG|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
214839334|NCT05567835|BIOLOGICAL|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
214839335|NCT02842684|DEVICE|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
214839336|NCT00611884|DRUG|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
214839337|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
214839338|NCT00611884|DRUG|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
214839339|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
214839340|NCT00611884|DRUG|metformin|Tablets, 1500-2000 mg/day
214839341|NCT00981799|DRUG|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
214839342|NCT00981799|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
214839343|NCT00981799|DRUG|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
214839344|NCT00981799|DRUG|Methotrexate|"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"
214839345|NCT00981799|DRUG|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
214839346|NCT01529307|DRUG|TAS266|TAS266 IV infusions given weekly
214839347|NCT03844724|DEVICE|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
214839348|NCT03844724|DEVICE|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
214839349|NCT03566407|PROCEDURE|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
214839350|NCT00348816|DRUG|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
214839351|NCT00348816|DRUG|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
214839352|NCT00348816|PROCEDURE|Radical prostatectomy|Radical prostatectomy as part of standard care
214839353|NCT00348816|RADIATION|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
214839354|NCT00687739|DRUG|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
214839355|NCT00687739|DRUG|Estradiol Transdermal|0.075 mg patch per day for 5 months
214839356|NCT00687739|BEHAVIORAL|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
214839357|NCT05728645|DRUG|Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg|Intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before induction of general anesthesia
214839358|NCT05728645|DRUG|Multiple Electrolytes injection of 5 ml/kg|Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
214464975|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
214464976|NCT04865965|PROCEDURE|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
214464977|NCT03930498|DRUG|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
214464978|NCT03930498|DRUG|Chemotherapy|Cisplatin and Gemcitabine
214464979|NCT03930498|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
214839359|NCT01190930|DRUG|Cyclophosphamide|Given IV
214839360|NCT01190930|DRUG|Cytarabine|Given IT, IV, or SC
214839361|NCT01190930|DRUG|Dexamethasone|Given orally (PO) or IV
214839362|NCT01190930|DRUG|Doxorubicin Hydrochloride|Given IV
214839363|NCT01190930|OTHER|Laboratory Biomarker Analysis|Correlative studies
214839364|NCT01190930|DRUG|Leucovorin Calcium|Given PO
214839365|NCT01190930|DRUG|Mercaptopurine|Given PO
214839366|NCT01190930|DRUG|Methotrexate|Given IT, PO, or IV
214839367|NCT01190930|DRUG|Pegaspargase|Given IV
214839368|NCT01190930|OTHER|Quality-of-Life Assessment|Ancillary studies
214839369|NCT01190930|OTHER|Questionnaire Administration|Ancillary studies
214839370|NCT01190930|DRUG|Thioguanine|Given PO
214839371|NCT01190930|DRUG|Vincristine Sulfate|Given IV
214839372|NCT02095808|PROCEDURE|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
214839373|NCT04650243|DRUG|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 10mg/Kg and 5mg/Kg everyday respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be at least one year.
214839374|NCT05479448|OTHER|Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness)|Biological material will be sampled at three time-points. The first time-point will be when patients have been treated with 15 mg of prednisone per day for at least 5 days. A second time-point will be after prednisone was successfully tapered and maintained at 5 mg per day for at least 5 days, a third time point will be 4 weeks after the stop of prednisone. Biosampling is done for cellular analyses, pharmacokinetics and hormone measurements.
214839375|NCT05479448|OTHER|Data collection for exploratory analyses of endogenous steroid hormones|Concentrations of GC, MC, androgens and progestins will be determined and the suppression of cortisol and cortisone upon prednisone treatment will be analyzed.
214839376|NCT05479448|OTHER|Data collection for correlation between clinical defined and lab defined GC responsivness|The time to first relapse, the cumulative steroid dose at 1 year after diagnosis, the need for treatment with steroid sparing agents and the GTI after 1 year will be correlated to the percentage of in vitro inhibition of cytokine concentration by dexamethasone treatment, to the prednisone/prednisolone ratio in plasma, to the percentage of endogenous GC suppression (plasma and urinary cortisol and cortisone) by prednisone treatment. Furthermore, correlations of steroid sensitivity with Mineralocorticoid (MC) and androgens will be investigated.
214839377|NCT05479448|OTHER|Data collection for Prednisone metabolism|Plasma concentrations of prednisone and its active metabolite prednisolone will be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). If changes on prednisone/prednisolone are observed, the quantification of the 6-hydroxylated prednisone/prednisolone metabolites in 24 h urine samples will be performed to estimate their metabolism as well as the ratio of inactive to active GC.
214839378|NCT03145688|BEHAVIORAL|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed \& then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
214839379|NCT03145688|BEHAVIORAL|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
214839380|NCT01207856|BEHAVIORAL|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
214839381|NCT01207856|BEHAVIORAL|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
214839382|NCT01207856|OTHER|no intervention|no intervention
214839383|NCT02404558|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
214839384|NCT02404558|DRUG|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
214839385|NCT01069614|DEVICE|TopClosure 3S System|
214839386|NCT03186716|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
214839387|NCT03186716|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
214839388|NCT03397004|DRUG|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
214839389|NCT03397004|DRUG|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
214839390|NCT05689333|DEVICE|Vista Vitrectomy Probe|Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector
214839391|NCT02988882|DRUG|Dexamethasone|
214839392|NCT02988882|OTHER|Placebo Vehicle|
214839393|NCT00046839|DRUG|celecoxib|
214839394|NCT00046839|RADIATION|radiation therapy|
214839395|NCT05157750|OTHER|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
214839396|NCT05770804|BEHAVIORAL|Face to face education|Face-to-face training was provided and supported by booklets.
214839397|NCT05212116|DRUG|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
214839398|NCT05212116|DRUG|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
214839399|NCT00584103|DEVICE|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
214839400|NCT00584103|DEVICE|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
214839401|NCT02050321|DRUG|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
214839402|NCT02050321|DRUG|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
214839403|NCT01354470|DRUG|Modafinil|600 mg Modafinil capsule
214839404|NCT01228552|DRUG|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
214839405|NCT01228552|OTHER|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
214839406|NCT04821388|DEVICE|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
214839407|NCT02305407|PROCEDURE|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
214839408|NCT02305407|OTHER|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
214839409|NCT00595673|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
214839410|NCT02699762|OTHER|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
214839411|NCT02818296|BEHAVIORAL|Active IU CBM-I|
214839412|NCT02818296|BEHAVIORAL|Control CBM-I|
214839413|NCT03945058|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
214839414|NCT03945058|DEVICE|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
214839415|NCT02463019|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
214839416|NCT01500005|DRUG|Baby D3 drops|2000-4000 iu per day
214839417|NCT04525898|DRUG|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
214839418|NCT00214682|DRUG|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
214839419|NCT00214682|BEHAVIORAL|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
214839420|NCT00214682|BEHAVIORAL|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
214839421|NCT00214682|DRUG|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
214839422|NCT00214682|BEHAVIORAL|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
214839423|NCT00214682|BEHAVIORAL|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
214839424|NCT00065949|DRUG|magnesium sulfate|
214464980|NCT05456490|DRUG|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
214464981|NCT05456490|DRUG|Bupivacaine|Injection into the Intrathecal space
214464982|NCT05456490|OTHER|Placebo|Injection into the Intrathecal space
214839425|NCT04647825|OTHER|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
214839426|NCT01196949|OTHER|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
214839427|NCT01196949|OTHER|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
214839428|NCT00766493|DEVICE|GORE® Embolic Filter|Embolic protection during carotid stenting
214839429|NCT02911636|RADIATION|Pelvic SABR with intra-prostatic SABR|described elsewhere
214839430|NCT01715649|BEHAVIORAL|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
214839431|NCT00752076|OTHER|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
214839432|NCT05778760|OTHER|Retinol|Topical retinol (0.5%) applied to the face
214839433|NCT05778760|OTHER|Adapinoid|Topical Adapinoid (0.5%) applied to the face
214839434|NCT05653362|DEVICE|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
214839435|NCT05653362|DEVICE|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
214839436|NCT03323450|BEHAVIORAL|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
214839437|NCT00600873|DRUG|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
214839438|NCT00105040|DRUG|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
214839439|NCT00105040|OTHER|Placebo (PB)|Oral tablets and oral solution
214839440|NCT00672217|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
214839441|NCT00672217|BEHAVIORAL|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
214839442|NCT02104258|OTHER|Physiotherapy ASPETAR|Standardized physiotherapy protocol
214839443|NCT02104258|OTHER|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
214839444|NCT03208517|OTHER|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
214839445|NCT03099590|DIETARY_SUPPLEMENT|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
214839446|NCT03099590|DIETARY_SUPPLEMENT|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
214839447|NCT04348955|BEHAVIORAL|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
214839448|NCT00721955|DRUG|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
214839449|NCT00721955|DRUG|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
214839450|NCT00721955|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
214839451|NCT02682108|DEVICE|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
214839452|NCT01236495|DRUG|spinal morphine 0.3 mg|spinal morphine 0.3 mg
214839453|NCT01236495|DRUG|spinal morphine 0.2 mg|spinal morphine 0.2 mg
214839454|NCT05915923|PROCEDURE|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
214839455|NCT05915923|PROCEDURE|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
214839456|NCT05915923|PROCEDURE|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
214839457|NCT06679595|OTHER|Pilot project paediatric transmural care|The implementation of pilot projects for transmural care for chronically ill children
214839458|NCT04286295|DRUG|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
214839459|NCT04286295|DRUG|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
214839460|NCT04286295|DRUG|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
214839461|NCT05611723|OTHER|Exposure to disability|Disability status assessed by functional measures
214839462|NCT02199379|DRUG|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
214839463|NCT01590199|DRUG|RAD001|
214839464|NCT01590199|DRUG|SOM230|
214839465|NCT01872507|OTHER|Biofeedback training|usual treatment +12 biofeedback training
214839466|NCT00111137|DRUG|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
214839467|NCT00111137|DRUG|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
214839468|NCT04698551|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
214839469|NCT05046951|BEHAVIORAL|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
214839470|NCT05046951|BEHAVIORAL|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
214839471|NCT04937998|PROCEDURE|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
214839472|NCT04937998|PROCEDURE|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
214839473|NCT01292837|DRUG|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
214839474|NCT05493566|BIOLOGICAL|Aldesleukin|Given SC
214839475|NCT05493566|BIOLOGICAL|Pembrolizumab|Given IV
214839476|NCT02357927|BEHAVIORAL|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
214839477|NCT02357927|BEHAVIORAL|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
214464983|NCT05557773|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
214839478|NCT05332691|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
214839479|NCT01456260|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
214839480|NCT01456260|DRUG|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
214839481|NCT01456260|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
214839482|NCT01456260|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
214839483|NCT01456260|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
214839484|NCT01456260|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
214839485|NCT03755739|DRUG|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
214839486|NCT00001239|DRUG|FLAC with GM-CSF|
214839487|NCT04149301|DIAGNOSTIC_TEST|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
214839488|NCT04149301|DIAGNOSTIC_TEST|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
214839489|NCT00131092|BEHAVIORAL|The Stanford Active Choices program|
214839490|NCT00131092|BEHAVIORAL|The TLC system|
214839491|NCT03680716|DRUG|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
214839492|NCT03680716|DRUG|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
214839493|NCT04681586|DEVICE|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
214839494|NCT04681586|DEVICE|dim red light|using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
214839495|NCT01524016|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
214839496|NCT05378308|OTHER|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
214839497|NCT03519438|OTHER|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
214839498|NCT03467737|OTHER|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
214839499|NCT03467737|OTHER|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
214839500|NCT03467737|OTHER|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
214839501|NCT03467737|OTHER|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
214839502|NCT03467737|OTHER|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
214839503|NCT03467737|OTHER|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
214839504|NCT01462578|DRUG|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
214839505|NCT06163937|OTHER|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214839506|NCT06163937|OTHER|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214839507|NCT06163937|OTHER|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214839508|NCT06417437|DRUG|SSRI|Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
214839509|NCT06417437|DEVICE|rTMS|Patients will be treated targeting either the traditional brain region or new region.
214839510|NCT06417437|BEHAVIORAL|Neuro-Feedback|Patients under 18 years old will first be considered this treatment before other methods.
214839511|NCT06417437|BEHAVIORAL|Game Regulation|Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
214839512|NCT01889797|BIOLOGICAL|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
214839513|NCT01889797|BIOLOGICAL|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
214839514|NCT01138345|GENETIC|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
214839515|NCT01138345|GENETIC|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
214839516|NCT01138345|OTHER|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
214839517|NCT01138345|OTHER|medical chart review|perform medical chart review for all subjects
214839518|NCT01138345|OTHER|questionnaire administration|each cohort will be given the same questionnaire
214839519|NCT04531527|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
214839520|NCT06277076|PROCEDURE|Computer Implant guided Surgery|Dental implant placed using printed guide after a digital planification on a superimposed 3D surface scan and a 3D Cone Beam imaging of the jaw.
214839521|NCT00050076|DRUG|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
214839522|NCT00050076|DRUG|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
214839523|NCT00050076|DRUG|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
214839524|NCT00050076|DRUG|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
214839525|NCT00731991|OTHER|ART|ART to the levator scapulae.
214839526|NCT00731991|OTHER|PNF|PNF to the levator scapulae.
214839527|NCT00731991|OTHER|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
214839528|NCT04039360|COMBINATION_PRODUCT|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
214839529|NCT00569660|DRUG|Azacitidine|75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
214839530|NCT00411268|DRUG|OROS hydromorphone HCI SR (slow release)|
214839531|NCT04952168|DRUG|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
214839532|NCT05625269|OTHER|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
214839533|NCT02399891|OTHER|Quality Assurance Implementation|
214839534|NCT02399891|OTHER|Standard of Care|
214839535|NCT04776304|BEHAVIORAL|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
214839536|NCT04736862|DEVICE|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
214839537|NCT04736862|DEVICE|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
214839538|NCT04792580|DRUG|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
214839539|NCT04792580|DRUG|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
214839540|NCT03782662|DRUG|Itraconazole|Itraconazole capsules
214839541|NCT03782662|DRUG|Verapamil|Verapamil tablets
214839542|NCT03782662|DRUG|Rifampicin|Rifampicin capsules
214839543|NCT03782662|DRUG|Midazolam|Midazolam oromucosal solution
214839544|NCT03782662|DRUG|Placebo for RV521|Placebo for RV521 capsules
214839545|NCT03782662|DRUG|RV521|RV521 capsules
214839546|NCT01974362|DEVICE|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
214839547|NCT01974362|DEVICE|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
214839548|NCT01974362|DEVICE|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
214839549|NCT01974362|DEVICE|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
214839550|NCT04966962|DIAGNOSTIC_TEST|serum and urine metabolomics|serum and urine samples will be collected for metabolomics analysis
214839551|NCT00571480|OTHER|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
214839552|NCT00571480|OTHER|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
214839553|NCT00571480|OTHER|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
214839554|NCT01937689|DRUG|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
214839555|NCT00506012|DRUG|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
214839556|NCT01134991|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
214839557|NCT02261220|BIOLOGICAL|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
214839558|NCT02261220|BIOLOGICAL|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
214839559|NCT03447444|OTHER|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
214839560|NCT03240120|DRUG|Dabigatran etexilate|Pradaxa 150 mg hard capsules
214839561|NCT03240120|DRUG|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
214839562|NCT06449391|DEVICE|RAI|Immediate implantation
214839563|NCT05595720|DEVICE|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
214839564|NCT00881231|DRUG|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
214839565|NCT00881231|DRUG|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
214839566|NCT02180230|DEVICE|Shorty implants|Dental implant insertion to maxilla or mandible
214839567|NCT01362192|DEVICE|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius"
214839568|NCT03937791|BIOLOGICAL|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
214839569|NCT01589601|BEHAVIORAL|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
214839570|NCT01589601|BEHAVIORAL|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
214839571|NCT00376740|DRUG|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
214839572|NCT03552367|OTHER|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
214839573|NCT03552367|OTHER|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
214839574|NCT04781244|DEVICE|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
214464984|NCT05557773|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
214839575|NCT04781244|DEVICE|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
214839576|NCT03710616|PROCEDURE|Surgeries|Surgical operations plus systematic lymphadenectomies
214839577|NCT01819064|DRUG|Atropine|intravenous atropine affect on heart rate
214839578|NCT02629016|OTHER|Mindfulness|
214839579|NCT02629016|OTHER|Wellness|
214839580|NCT00434837|PROCEDURE|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
214839581|NCT04153786|OTHER|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
214839582|NCT00201396|RADIATION|CCRT|Radiation with weekly Cisplatin
214839583|NCT00201396|DRUG|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
214839584|NCT02937363|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
214839585|NCT02937363|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
214839586|NCT00142116|DRUG|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
214839587|NCT00142116|DRUG|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
214839588|NCT00464386|DEVICE|Continuous Glucose Monitoring|measure glucose levels on burn patients
214839589|NCT04448041|OTHER|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
214839590|NCT02557217|DRUG|NP202|Active
214839591|NCT02557217|OTHER|Placebo|Placebo
214839592|NCT00172016|DRUG|Zoledronic acid|
214839593|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
214839594|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
214839595|NCT03281096|DRUG|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
214839596|NCT03281096|DRUG|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
214839597|NCT04265287|OTHER|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
214839598|NCT04629170|DRUG|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
214839599|NCT04629170|DRUG|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
214839600|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered IM followed by Electroporation
214839601|NCT02464670|BIOLOGICAL|INO-4202|INO-4202 delivered IM followed by Electroporation
214839602|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered ID followed by Electroporation
214839603|NCT02464670|BIOLOGICAL|INO-4212|INO-4212 delivered IM followed by Electroporation
214839604|NCT02464670|BIOLOGICAL|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
214839605|NCT02464670|BIOLOGICAL|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
214839606|NCT05086770|DEVICE|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
214839607|NCT05086770|DEVICE|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
214839608|NCT04079452|DRUG|Doravirine|Doravirine 100 mg tablet
214839609|NCT04079452|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
214839610|NCT02287636|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
214839611|NCT02287636|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
214839612|NCT02287636|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
214839613|NCT02287636|PROCEDURE|positron emission tomography|Undergo PET/MRI
214839614|NCT02287636|PROCEDURE|magnetic resonance imaging|Undergo PET/MRI
214839615|NCT03254732|DRUG|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
214839616|NCT03254732|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
214839617|NCT04162587|OTHER|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
214839618|NCT04162587|OTHER|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
214839619|NCT04162587|OTHER|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
214464985|NCT04753697|DRUG|CC-93538|Subcutaneous
214464986|NCT04753697|OTHER|Placebo|Subcutaneous
214839620|NCT04162587|OTHER|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
214839621|NCT01881737|DRUG|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
214839622|NCT00345033|DRUG|Aripiprazole|15-mg dose once a day for 8 weeks
214839623|NCT00345033|DRUG|Placebo|1 tablet placebo dose once a day for 8 weeks
214839624|NCT01828437|DRUG|Pyridoxine plus prednisolone|
214839625|NCT01828437|DRUG|Prednisolone|
214839626|NCT02876133|DEVICE|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
214839627|NCT02876133|DEVICE|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
214839628|NCT03045133|DRUG|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
214839629|NCT03045133|DRUG|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
214839630|NCT02102932|DRUG|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
214839631|NCT02102932|DRUG|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
214839632|NCT02102932|DRUG|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
214839633|NCT02102932|DRUG|850 mg metformin|850mg metformin tablet
214839634|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
214839635|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
214839636|NCT02102932|DRUG|850 mg metformin|850 mg metformin
214839637|NCT02102932|DRUG|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
214839638|NCT02102932|DRUG|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
214839639|NCT02102932|DRUG|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
214839640|NCT02102932|DRUG|500 mg metformin|500 mg metformin
214839641|NCT02102932|DRUG|500 mg metformin|500 mg metformin
214839642|NCT01562132|DRUG|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
214839643|NCT01562132|DRUG|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
214839644|NCT04518553|DRUG|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
214839645|NCT04518553|DEVICE|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
214839646|NCT02250651|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
214839647|NCT02250651|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
214839648|NCT02250651|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
214839649|NCT02250651|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
214839650|NCT03496298|DRUG|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
214839651|NCT03496298|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
214839652|NCT06458751|OTHER|electrophysiological study|Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
214839653|NCT06458751|DEVICE|electromyograph|surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
214839654|NCT01792453|OTHER|Spring water|
214839655|NCT04913545|DIAGNOSTIC_TEST|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
214839656|NCT05798637|OTHER|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
214839657|NCT01658995|DRUG|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
214839658|NCT01658995|DRUG|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
214839659|NCT04832776|DRUG|Cetuximab|one group plus cetuximab
214839660|NCT04832776|DRUG|Bevacizumab|one group plus bevacizumab
214839661|NCT04832776|DRUG|FOLFOXIRI|FOLFOXIRI
214839662|NCT01186562|DRUG|Sitagliptin|100 mg PO daily
214839663|NCT01186562|DRUG|Placebo|Placebo
214839664|NCT04099680|PROCEDURE|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
214839665|NCT04099680|PROCEDURE|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
214839666|NCT04099680|DEVICE|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
214839667|NCT04099680|PROCEDURE|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
214839668|NCT04099680|PROCEDURE|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
214839669|NCT04099680|PROCEDURE|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
214839670|NCT04016194|DIAGNOSTIC_TEST|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
214839671|NCT03563560|DRUG|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
214839672|NCT03563560|DRUG|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
214839673|NCT03563560|DRUG|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
214839674|NCT03563560|DRUG|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
214839675|NCT03563560|DRUG|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
214839676|NCT04309994|OTHER|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
214839677|NCT04309994|OTHER|Cardioplexol|cardioplegia solution
214839678|NCT02260635|DRUG|Evacetrapib|Administered orally
214839679|NCT02260635|DRUG|Placebo|Administered orally
214839680|NCT03848858|BEHAVIORAL|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
214839681|NCT04106817|BIOLOGICAL|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
214839682|NCT03793296|DEVICE|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
214839683|NCT02566096|DRUG|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
214839684|NCT00152516|DRUG|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
214839685|NCT02427399|OTHER|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
214839686|NCT02427399|OTHER|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
214839687|NCT02427399|OTHER|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
214839688|NCT02427399|OTHER|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
214839689|NCT03563885|PROCEDURE|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
214839690|NCT03562845|OTHER|NA-Observational only|NA-Observational only
214839691|NCT01096745|DRUG|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
214839692|NCT01096745|DRUG|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
214839693|NCT04536792|DRUG|AG-946|AG-946, oral encapsulated coated-granules or tablets.
214839694|NCT04536792|DRUG|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
214839695|NCT02289820|BIOLOGICAL|MEDI7510|RSV sF antigen plus adjuvant
214839696|NCT02289820|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
214839697|NCT04318431|DIAGNOSTIC_TEST|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
214839698|NCT01812473|OTHER|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
214839699|NCT00684944|DRUG|TRx0014|Gelatin capsule, tid
214839700|NCT06163417|PROCEDURE|laparoscopic|laparoscopic
214839701|NCT06480825|OTHER|Performance of ultrasonographic scan|Ultra-high frequency ultrasonographic scan of gingival tissues
214839702|NCT03493035|DIAGNOSTIC_TEST|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
214839703|NCT03493035|DIAGNOSTIC_TEST|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
214839704|NCT01022255|BIOLOGICAL|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
214839705|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
214839706|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
214839707|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
214839708|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
214839709|NCT06678607|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
214839710|NCT06678607|BIOLOGICAL|Placebo|One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine
214839711|NCT00846898|DIETARY_SUPPLEMENT|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
214839712|NCT04134637|DEVICE|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
214839713|NCT04134637|DRUG|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
214839714|NCT00333853|DEVICE|OneTouch(r) UltraSmart(r)|
214839715|NCT06325124|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
214839716|NCT06325124|OTHER|Conventional PT|"They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
214839717|NCT00678327|BIOLOGICAL|bleomycin sulfate|Given IV
214839718|NCT00678327|BIOLOGICAL|filgrastim|Given subcutaneously
214839719|NCT00678327|BIOLOGICAL|pegfilgrastim|Given subcutaneously
214839720|NCT00678327|DRUG|cyclophosphamide|Given IV
214839721|NCT00678327|DRUG|dacarbazine|Given IV
214839722|NCT00678327|DRUG|doxorubicin hydrochloride|Given IV
214839723|NCT00678327|DRUG|etoposide|Given IV
214839724|NCT00678327|DRUG|prednisolone|Given orally
214839725|NCT00678327|DRUG|procarbazine hydrochloride|Given orally
214839726|NCT00678327|DRUG|vinblastine sulfate|Given IV
214839727|NCT00678327|DRUG|vincristine sulfate|Given IV
214839728|NCT01269476|DRUG|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
214839729|NCT01269476|DRUG|Placebo|Same volumes and frequency as active.
214839730|NCT03847974|DRUG|LIB003|300 mg SC Q4W
214839731|NCT06679673|DRUG|SHR-1701|SHR-1701
214839732|NCT06679673|DRUG|BP102|BP102
214839733|NCT06679673|DRUG|SHR2554|SHR2554
214839734|NCT03911180|DEVICE|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
214839735|NCT03275857|DRUG|Cisplatin|Weekly IV
214839736|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
214839737|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
214839738|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
214839739|NCT03998592|OTHER|Placebo|Placebo without active component
214839740|NCT00959439|DRUG|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
214839741|NCT00959439|DRUG|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
214839742|NCT03934996|OTHER|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
214839743|NCT02870439|OTHER|Blood drawn|
214839744|NCT05499416|DRUG|Bimekizumab|Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
214839745|NCT01616316|PROCEDURE|subfascial flap|subfacial dissection to thyroid
214839746|NCT01616316|PROCEDURE|subplatysmal flap|subplatysmal approach to thyroid
214839747|NCT03268096|DEVICE|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
214839748|NCT02721550|DRUG|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
214839749|NCT01924364|DEVICE|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
214839750|NCT01924364|PROCEDURE|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
214839751|NCT02050035|OTHER|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
214839752|NCT01685216|BIOLOGICAL|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
214839753|NCT00756717|DRUG|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
214839754|NCT05352438|OTHER|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
214839755|NCT05352438|OTHER|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
214839756|NCT02262559|DRUG|BIBR 277 tablet|
214839757|NCT02262559|DRUG|BIBR 277 capsule|
214277691|NCT06714929|BEHAVIORAL|Hydration|Clusters of schools will sequentially be exposed to the intervention in a stepped-wedge fashion. The intervention is a 4-month community participatory school-based hydration intervention that includes provision of refillable water bottles in schools with hydration stations in addition to: 1) social marketing, 2) behavioral reinforcement, and 3) education and outreach.
214277692|NCT06157918|DRUG|SYHA1813 oral solution (2.0g:25mg)|SYHA1813 oral solution, 25mg, oral
214277693|NCT06157918|DRUG|SYHA1813 oral solution (20ml:200mg)|SYHA1813 oral solution, 25mg, oral
214277694|NCT04460482|DEVICE|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
214277695|NCT04460482|DEVICE|Angiography|Angiography guided PCI
214277696|NCT05232110|DRUG|Pozelimab|
214277697|NCT06723834|OTHER|Psychiatric Service Dog|Partnership with a trained service dog for PTSD.
214277698|NCT06723834|BEHAVIORAL|Prolonged Exposure Therapy|12 weeks of Prolonged Exposure once per week.
214277699|NCT06743295|DEVICE|DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction|"Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise."
214277700|NCT06893315|RADIATION|Photobiomodulation Therapy|Photobiomodulation (PBM) is a non-invasive therapy that uses low-level light, typically from lasers or Light Emission Diodes (LEDs), to stimulate cellular function and promote healing. It works by delivering specific wavelengths of light to target tissues, which enhances mitochondrial activity and increases adenosine triphosphate (ATP) production. PBM is commonly used for pain relief, reducing inflammation, and accelerating tissue repair in conditions like muscle injuries, arthritis, and skin disorders.
214839758|NCT05794087|OTHER|Clean Air|Subjects will be exposed to clean air for 3 hours.
214839759|NCT05794087|OTHER|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
214839760|NCT02171897|PROCEDURE|Osteosynthesis|
214839761|NCT02171897|PROCEDURE|Total hip replacement|
214839762|NCT02418754|DRUG|REGN2176-3|
214839763|NCT02418754|DRUG|Intravitreal Aflibercept Injection (IAI)|
214839764|NCT04197154|BEHAVIORAL|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
214839765|NCT04197154|BEHAVIORAL|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
214277701|NCT06893315|OTHER|Hospital Standard Protocol of treatment for pain and healing|Medical team evaluations are conducted daily throughout the hospitalization period, and anti-inflammatory medications (ketoprofen ), analgesics (dipyrone), and, in cases where vulvar edema is observed, ice packs are prescribed. In addition to the standard treatment described, the health care team routinely offers patients the use of laser therapy (photobiomodulation) once a day during hospitalization. Patients who agree to the laser therapy receive both treatments.Patients who do not accept receiving PBM receive exactly only the same standard routine care described. These protocols are standardized at the hospital, and this observational study did not interfere with any care practices.
214277702|NCT06774872|DRUG|Doravirine 100Mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 1 will receive the DORAVIRINE/LAMIVUDINE combination: doravirine (PIFELTRO®) 100 mg 1 pill a day + lamivudine 300 mg 1 pill a day"
214277703|NCT06774872|DRUG|Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 2 will receive the DTG/3TC combination: dolutegravir 50 mg/lamivudine 300 mg (DOVATO®) 1 pill a day"
214277704|NCT02625272|PROCEDURE|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
214464987|NCT02626533|PROCEDURE|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
214464988|NCT04736823|DRUG|AK112|IV infusion
214464989|NCT04736823|DRUG|Pemetrexed|IV infusion
214464990|NCT04736823|DRUG|Paclitaxel|IV infusion
214464991|NCT04736823|DRUG|Carboplatin|IV infusion
214277705|NCT06298110|BIOLOGICAL|Platelets Rich plasma of the same patient|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
214277706|NCT05621785|DEVICE|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
214277707|NCT01174303|DRUG|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
214277708|NCT01174303|DRUG|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
214277709|NCT02529345|DEVICE|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
214277710|NCT02290561|PROCEDURE|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
214277711|NCT02290561|DEVICE|MRI|
214277712|NCT02290561|DEVICE|high intensity focused ultrasound (HIFU)|
214277713|NCT00438698|OTHER|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
214277714|NCT00438698|OTHER|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
214277715|NCT05412654|DIETARY_SUPPLEMENT|High potassium water|High potassium water Potassium 6.2 mg/100ml
214277716|NCT05412654|DIETARY_SUPPLEMENT|Control low potassium water|Control water Potassium 0.2 mg/100ml
214277717|NCT01883830|DEVICE|gaming therapy (Xbox)|
214277718|NCT01883830|DEVICE|Dynamic balance platform (Biodex)|
214277719|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
214277720|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
214277721|NCT00381485|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
214277722|NCT02495298|PROCEDURE|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
214277723|NCT02495298|PROCEDURE|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
214277724|NCT05979350|DIAGNOSTIC_TEST|Metagenomic next-generation sequencing|Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
214277725|NCT05979350|DIAGNOSTIC_TEST|Standard work-up for pneumonia|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
214277726|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
214277727|NCT03478358|DRUG|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
214277728|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
214277729|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
214277730|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
214277731|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
214277732|NCT05715034|BEHAVIORAL|Compassionate Care|Single-session web-based program
214464992|NCT04736823|DRUG|Docetaxel|IV infusion
214464993|NCT06642636|DEVICE|Intensive Care Unit-specific Virtual Reality|The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
214277733|NCT05715034|BEHAVIORAL|Relaxing with Nature|Single-session web-based program
214277734|NCT03718585|OTHER|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
214277735|NCT02697825|PROCEDURE|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
214277736|NCT02967744|DRUG|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
214277737|NCT01206660|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
214277738|NCT01206660|DRUG|placebo|Placebo administered to affected area twice a day for 28 days
214277739|NCT05478785|DRUG|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
214277740|NCT04767932|BEHAVIORAL|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
214277741|NCT03922503|PROCEDURE|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
214277742|NCT03922503|PROCEDURE|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
214277743|NCT00126191|DRUG|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
214277744|NCT00126191|DRUG|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
214277745|NCT00126191|DRUG|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
214277746|NCT00126191|DRUG|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
214277747|NCT00126191|DRUG|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
214277748|NCT00126191|DRUG|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
214277749|NCT00126191|DRUG|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
214277750|NCT00126191|DRUG|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
214277751|NCT00126191|DRUG|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
214277752|NCT00126191|DRUG|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
214277753|NCT01495117|DRUG|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
214277754|NCT01495117|DRUG|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
214277755|NCT04638933|OTHER|No intervention|No intervention
214277756|NCT01898806|DRUG|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
214277757|NCT01898806|DRUG|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
214277758|NCT01898806|DRUG|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
214277759|NCT01898806|DRUG|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
214277760|NCT00674544|BEHAVIORAL|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
214277761|NCT01648101|DRUG|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
214277762|NCT01648101|DRUG|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
214277763|NCT01648101|OTHER|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
214277764|NCT03178877|OTHER|No intervention|
214277765|NCT00940225|DRUG|Cabozantinib|
214277766|NCT00940225|DRUG|Placebo|
214277767|NCT02007694|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
214277768|NCT02140372|DRUG|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
214277769|NCT00500669|DRUG|Betadine|Topically
214277770|NCT03283852|GENETIC|blood sample|search for genetic mutations
214277771|NCT02469298|DRUG|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
214277772|NCT02469298|DRUG|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
214277773|NCT02469298|DRUG|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
214277774|NCT02469298|DRUG|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
214277775|NCT00869154|BEHAVIORAL|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
214277776|NCT00869154|BEHAVIORAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
214277777|NCT04249583|BIOLOGICAL|botulinum toxin|neuromodulator to be injected in the GL region
214277778|NCT04249583|BIOLOGICAL|Placebo|Placebo to be injected in the GL area
214277779|NCT00475358|DRUG|Duloxetine|
214277780|NCT00475358|DRUG|Placebo|
214277781|NCT02704117|DEVICE|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
214277782|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
214277783|NCT04616378|OTHER|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
214277784|NCT04616378|OTHER|Phase 3 No Prosthesis|No prosthetic device is attached.
214277785|NCT04616378|OTHER|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
214277786|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
214277787|NCT03269864|PROCEDURE|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
214277788|NCT02052583|PROCEDURE|therapeutic hypothermia at 32 ° C|
214277789|NCT02052583|PROCEDURE|therapeutic hypothermia at 34 ° C|
214277790|NCT00871702|GENETIC|CD34-TK75 transduced donor lymphocytes|
214277791|NCT00871702|RADIATION|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
214277792|NCT03961581|BEHAVIORAL|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
214277793|NCT02032121|PROCEDURE|Blood specimen|
214277794|NCT02032121|PROCEDURE|Echocardiography|
214277795|NCT06962384|PROCEDURE|Posterior release sclerotomy|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~Posterior Release Sclerotomy Group (PRS Group)~* A posterior sclerotomy (2-3 mm) was created at the posterior pole of the scleral shell using a crescent blade.~* This sclerotomy expanded the intraocular space, reducing intraoperative resistance during implant insertion.~* The spherical implant was gently placed within the expanded scleral shell, ensuring minimal stress on the tissue."
214277796|NCT06962384|PROCEDURE|Conventional Ball Implantation|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~* No posterior sclerotomy was performed.~* The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space."
214277797|NCT06508424|OTHER|PulseOn|PulseOn - 1 week washout period between interventions 75g crackers
214277798|NCT06508424|OTHER|Wheat flour control|Control -1 week washout period between interventions 75g crackers
214277799|NCT03667261|DEVICE|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
214277800|NCT03667261|DEVICE|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
214277801|NCT04244331|DIAGNOSTIC_TEST|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
214277802|NCT05192681|DRUG|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
214277803|NCT04009382|OTHER|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
214277804|NCT04009382|OTHER|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
214277805|NCT03000439|DRUG|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
214277806|NCT03000439|DRUG|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
214277807|NCT00926276|PROCEDURE|Fundoplication|Fundoplication
214277808|NCT00656110|DRUG|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
214277809|NCT00656110|DRUG|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
214277810|NCT05246501|OTHER|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
214277811|NCT05246501|OTHER|No simulation|The students in the control group did not receive simulation training.
214277812|NCT01308060|DRUG|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
214277813|NCT01308060|OTHER|Placebo|
214277814|NCT06485882|BEHAVIORAL|Self-Care Training|Animation films are watched children about self-care and social competence
214277815|NCT04010487|GENETIC|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
214277816|NCT06131034|OTHER|Music|Participant in the intervention group will receive music interventions perioperatively.
214277817|NCT00823368|DRUG|STX209|
214277818|NCT01314573|BEHAVIORAL|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
214277819|NCT01314573|BEHAVIORAL|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
214277820|NCT03766633|DIAGNOSTIC_TEST|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
214277821|NCT05884723|DIETARY_SUPPLEMENT|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
214277822|NCT06374160|BEHAVIORAL|Exercise intervention|Exercise
214277823|NCT04047498|DEVICE|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
214277824|NCT04803825|OTHER|Heavy Slow Exercises|"* Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
214277825|NCT04803825|DEVICE|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
214277826|NCT04803825|OTHER|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
214277827|NCT02316808|DIETARY_SUPPLEMENT|Plant stanol ester|Smoothie that contains plant stanol ester
214277828|NCT02316808|DIETARY_SUPPLEMENT|placebo|Smoothie that contains placebo
214277829|NCT04488484|OTHER|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
214277830|NCT02954237|DEVICE|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
214277831|NCT01445262|DRUG|Levocetirizine|
214277832|NCT04455113|DIAGNOSTIC_TEST|Phosphorus level|infusion
214277833|NCT05403281|DRUG|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
214277834|NCT05448183|DRUG|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
214277835|NCT05541120|DEVICE|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
214277836|NCT02720471|DRUG|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
214277837|NCT02720471|DRUG|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
214277838|NCT02467868|BIOLOGICAL|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
214277839|NCT02467868|BIOLOGICAL|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
214277840|NCT04344509|OTHER|Bacterial species isolated|in the respiratory specimen
214277841|NCT00192556|BEHAVIORAL|food|
214277842|NCT00164775|DRUG|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
214277843|NCT00164775|DRUG|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
214277844|NCT02222974|DRUG|BIIR 561 CL|
214277845|NCT02222974|DRUG|Placebo|
214277846|NCT04503902|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
214277847|NCT04503902|DRUG|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
214277848|NCT01180946|DIETARY_SUPPLEMENT|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
214277849|NCT01180946|OTHER|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
214277850|NCT03744091|DRUG|P1|10 mg or 20 mg of THC:THCa
214277851|NCT03202498|DEVICE|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
214277852|NCT03202498|OTHER|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
214277853|NCT03202498|DEVICE|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
214277854|NCT03202498|OTHER|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
214277855|NCT03292588|BIOLOGICAL|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
214277856|NCT03292588|DRUG|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
214277857|NCT05533021|OTHER|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
214277858|NCT05872841|DRUG|Recombinant human adenovirus type 5 + TACE|"1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles."
214277859|NCT02151591|DRUG|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
214277860|NCT06507891|DRUG|TQ-A3334 tablets|TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
214277861|NCT06507891|DRUG|TQ-A3334 tablets + Anlotinib capsules|"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
214277862|NCT06404216|OTHER|Nordic walking group training|"16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged."
214277863|NCT02888886|OTHER|Questionnaires about food habits and tobacco|
214277864|NCT02888886|OTHER|Spirometry|
214277865|NCT02888886|OTHER|Carotid echography|
214277866|NCT02888886|OTHER|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
214277867|NCT05448053|PROCEDURE|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
214277868|NCT04506021|DRUG|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
214277869|NCT04506021|DRUG|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
214277870|NCT00869349|BEHAVIORAL|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
214277871|NCT00869349|OTHER|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
214277872|NCT03633695|DEVICE|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
214277873|NCT03633695|DEVICE|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
214277874|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
214277875|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
214277876|NCT01882491|DRUG|Placebo|Solution for subcutaneous injection
214277877|NCT01882491|DRUG|gevokizumab|Solution for subcutaneous injection
214277878|NCT02728050|DRUG|Cladribine|Given IV
214277879|NCT02728050|DRUG|Cytarabine|Given IV
214277880|NCT02728050|BIOLOGICAL|Filgrastim|Given SC
214277881|NCT02728050|OTHER|Laboratory Biomarker Analysis|Correlative studies
214277882|NCT02728050|OTHER|Quality-of-Life Assessment|Ancillary studies
214277883|NCT02728050|DRUG|Mitoxantrone|Given IV
214277884|NCT02728050|DRUG|Sorafenib|Given PO
214277885|NCT00983021|DRUG|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
214277886|NCT00983021|DRUG|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
214277887|NCT00983021|DRUG|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
214277888|NCT00983021|DRUG|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
214277889|NCT03769454|DRUG|PP-001|PP-001 eye drops
214277890|NCT03769454|OTHER|Placebo|Placebo eye drops
214277891|NCT06131177|DIETARY_SUPPLEMENT|Nutritional supplement|Protein supplement
214277892|NCT03571815|DRUG|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
214277893|NCT03571815|OTHER|WATER ON TEETH|control group
214277894|NCT01752127|PROCEDURE|percutaneous coronary intervention using drug eluting stent|"1\. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
214277895|NCT05217147|OTHER|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
214277896|NCT04294576|DRUG|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
214277897|NCT04294576|DRUG|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
214277898|NCT01354990|DRUG|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
214277899|NCT02067338|DRUG|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
214277900|NCT02067338|DRUG|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
214277901|NCT02109380|BEHAVIORAL|Bed rest|
214277902|NCT02853604|DRUG|ADXS11-001|
214277903|NCT02853604|DRUG|Placebo|
214277904|NCT04592601|PROCEDURE|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
214277905|NCT02688205|OTHER|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
214277906|NCT02688205|DEVICE|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
214277907|NCT06280170|OTHER|Artificial Intelligence platform for case managers|Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
214277908|NCT02115893|DIETARY_SUPPLEMENT|Sodium Nitrate|
214277909|NCT02115893|DIETARY_SUPPLEMENT|Sodium Chloride|
214277910|NCT03910023|OTHER|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
214277911|NCT03910023|OTHER|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
214277912|NCT06218641|DEVICE|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
214277913|NCT06218641|DEVICE|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
214277914|NCT00477243|BEHAVIORAL|Questionnaire|8 questionnaires will take about 40 minutes to complete.
214277915|NCT05593120|DIAGNOSTIC_TEST|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
214277916|NCT05593120|DIAGNOSTIC_TEST|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
214277917|NCT04810312|OTHER|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
214277918|NCT04869332|DEVICE|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
214277919|NCT04869332|DEVICE|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
214277920|NCT05771376|OTHER|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
214277921|NCT05771376|OTHER|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
214277922|NCT01523353|BEHAVIORAL|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
214277923|NCT03258021|DEVICE|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
214277924|NCT03000140|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
214277925|NCT03000140|BEHAVIORAL|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
214277926|NCT05818397|BEHAVIORAL|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and and up to two experienced SCCC facilitators. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
214277927|NCT01154855|PROCEDURE|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
214277928|NCT05062382|BEHAVIORAL|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
214277929|NCT04579705|OTHER|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
214277930|NCT02554357|DRUG|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
214277931|NCT02554357|DRUG|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
214277932|NCT02753868|BEHAVIORAL|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
214277933|NCT02753868|PROCEDURE|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
214277934|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
214277935|NCT05777876|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
214277936|NCT05777876|DEVICE|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
214277937|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
214277938|NCT02460302|DRUG|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
214277939|NCT02460302|DRUG|Placebo|Placebo suppository inserted vaginally
214277940|NCT00596284|BEHAVIORAL|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
214277941|NCT00596284|BEHAVIORAL|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
214277942|NCT00763672|OTHER|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
214277943|NCT00763672|OTHER|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
214277944|NCT03369405|OTHER|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
214277945|NCT02250170|DRUG|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
214277946|NCT04561193|OTHER|Observational|Observational
214277947|NCT05275400|DRUG|Insulin Efsitora Alfa|Administered SC
214277948|NCT05275400|DRUG|Insulin Degludec|Administered SC
214277949|NCT06259019|DEVICE|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
214277950|NCT04000490|OTHER|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
214277951|NCT01828957|BIOLOGICAL|Pneumostem®|
214277952|NCT01828957|OTHER|Normal Saline|
214277953|NCT06352203|DIETARY_SUPPLEMENT|Probiotic|1 dose of the probiotic every 24 hours, for 6-months.
214277954|NCT06352203|DIETARY_SUPPLEMENT|Placebo|1 dose of the placebo every 24 hours, for 6-months.
214277955|NCT02783625|DRUG|Romidepsin|
214277956|NCT02783625|DRUG|Bortezomib|
214277957|NCT02783625|DRUG|duvelisib|
214277958|NCT06533787|DEVICE|Echocardiography|Functional echocardiography assessment
214277959|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
214277960|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
214464994|NCT04947527|DRUG|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
214277961|NCT06333613|DEVICE|ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY (AO1D)|Test Lens
214277962|NCT03502239|OTHER|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
214277963|NCT05889195|DIAGNOSTIC_TEST|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
214277964|NCT04538261|DEVICE|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
214277965|NCT04251169|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute intravenous (IV) infusion every 3 weeks beginning in Cycle 1
214277966|NCT04251169|DRUG|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
214277967|NCT00548223|DRUG|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid\*1year
214277968|NCT00548223|DRUG|placebo|Capsule, 0.18g, 2#, Bid\*1year
214277969|NCT00454883|DRUG|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
214277970|NCT05787275|OTHER|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
214277971|NCT05787275|OTHER|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
214277972|NCT05787275|OTHER|Control|Traditional medical treatment
214277973|NCT03576560|OTHER|Retrospective Chart Review|Retrospective Chart Review
214277974|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
214277975|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
214277976|NCT05802511|DEVICE|Exablate treatment|Exablate treatment for Neuropathic Pain
214277977|NCT06960421|BEHAVIORAL|XFIT|XFIT is an 8-week telehealth-delivered, home-based exercise/behavior modification intervention. It integrates theoretical frameworks of behavior change to engage frail lung transplant candidates in program of pre-habilitation.
214277978|NCT00571545|BEHAVIORAL|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
214277979|NCT00571545|BEHAVIORAL|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
214277980|NCT01903187|DEVICE|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
214277981|NCT01903187|PROCEDURE|Sham|Renal artery angiogram
214277982|NCT03648541|DRUG|Spesolimab|Solution
214277983|NCT06837740|OTHER|Aromatherapy group|Effects of Aromatherapy Interventions
214277984|NCT06837740|OTHER|Aromatherapy with music therapy group|Effects of Music Therapy and Aromatherapy Interventions
214277985|NCT06831175|DRUG|Camrelizumab|Camrelizumab was administered 200mg IV every 3 weeks.
214277986|NCT06831175|DRUG|Apatinib|Apatinib was administered 250 mg PO QD.
214277987|NCT06831175|DRUG|mitotane|Mitotane is administered orally and plasma concentration was measured. The target steady-state plasma concentration is 14-20 mg/L.
214277988|NCT06836349|OTHER|Early active motion training after operated FPL injury|Early active motion training after operated FPL injury
214277989|NCT06836349|OTHER|Immobilisation in plaster cast 4 weeks after operated FPL injury|Immobilisation in plaster cast 4 weeks after operated FPL injury
214277990|NCT05194358|DRUG|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
214277991|NCT02153619|BEHAVIORAL|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
214277992|NCT02153619|BEHAVIORAL|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
214277993|NCT02153619|BEHAVIORAL|questionnaires assessments|
214277994|NCT06279234|DRUG|Placebo|Oral tablet
214277995|NCT06279234|DRUG|Rosuvastatin|Oral tablet
214277996|NCT06279234|DRUG|Midazolam|Oral suspension
214277997|NCT06279234|DRUG|Omeprazole|Oral tablet
214277998|NCT06279234|DRUG|PF-06954522|Oral tablet
214277999|NCT06297928|PROCEDURE|baratric surgery|Participants in this study will undergo bariatric surgery, either gastric bypass or sleeve gastrectomy, based on clinical criteria and consensus from a multidisciplinary team.
214278000|NCT06848790|PROCEDURE|Calibrated interdental brush|participants will use calibrated interdental brushes
214278001|NCT06541665|DRUG|ONO-4059|Specified dose, once daily
214278002|NCT06541665|DRUG|Rituximab|Specified dose on specified days
214278003|NCT06541665|DRUG|Methotrexate|Specified dose on specified days
214278004|NCT06541665|DRUG|Procarbazine|Specified dose on specified days
214278005|NCT06541665|DRUG|Vincristine|Specified dose on specified days
214278006|NCT04623216|BIOLOGICAL|Sabatolimab|Sabatolimab is a solution in vial for IV infusion
214278007|NCT04623216|DRUG|Azacitidine|Azacitidine comes in Vial for IV infusion or subcutaneous administration
214278008|NCT04960644|DRUG|MTX|MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
214278009|NCT04960644|DRUG|Corticosteroid|corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
214278010|NCT04673838|OTHER|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
214278011|NCT04673838|OTHER|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
214278012|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
214278013|NCT03317327|DRUG|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
214278014|NCT03317327|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
214278015|NCT06962956|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Brush two times a day for 1 minute with manual toothbrush
214278016|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 1 minute with manual toothbrush
214278017|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 2 minutes with electric toothbrush
214278018|NCT01651039|DRUG|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
214278019|NCT01651039|DRUG|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
214278020|NCT01651039|DRUG|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
214278021|NCT00915122|RADIATION|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
214278022|NCT04693988|BEHAVIORAL|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
214278023|NCT06072157|DRUG|AK006-IV|Intravenous infusion
214278024|NCT06072157|DRUG|Placebo-IV|Intravenous infusion
214278025|NCT06072157|DRUG|AK006-SC|Subcutaneous
214278026|NCT06072157|DRUG|Placebo-SC|Subcutaneous
214278027|NCT05018975|DRUG|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
214278028|NCT01002222|DRUG|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
214278029|NCT02164825|DRUG|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
214278030|NCT02164825|DRUG|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
214278031|NCT00489346|DRUG|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
214278032|NCT00489346|DRUG|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
214278033|NCT03429686|OTHER|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
214278034|NCT00486200|DRUG|ASP2151|Oral administration.
214278035|NCT00486200|DRUG|valacyclovir|Oral administration of active comparator.
214278036|NCT00486200|DRUG|Placebo|Oral administration of placebo.
214278037|NCT02837328|DRUG|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
214278038|NCT02837328|DRUG|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
214278039|NCT05055063|DRUG|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
214278040|NCT05546502|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
214278041|NCT05546502|BIOLOGICAL|Active Comparator|Covovax
214278042|NCT05264935|PROCEDURE|Ultrasound-Guided Puncture and Lavage (UGPL)|After local anaesthesia with rapidocain the calcific deposit of the rotator cuff will be punctured and washed out with saline solution.
214278043|NCT04930965|BEHAVIORAL|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
214278044|NCT00757497|BEHAVIORAL|Electrical Polarization|
214278045|NCT03167190|PROCEDURE|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
214278046|NCT03167190|PROCEDURE|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
214278047|NCT03068260|DRUG|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
214278048|NCT03068260|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
214278049|NCT03068260|DRUG|Acetaminophen|1 g orally administered postoperatively
214278050|NCT03068260|DRUG|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
214278051|NCT03068260|DEVICE|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
214278052|NCT03068260|DRUG|Morphine|intravenously administered morphine via PCA-pump
214278053|NCT03068260|DEVICE|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
214278054|NCT00134082|BIOLOGICAL|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
214278055|NCT00134082|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.
214278056|NCT00134082|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
214278057|NCT00134082|DRUG|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
214278058|NCT05346770|BEHAVIORAL|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
214278059|NCT05346770|DIAGNOSTIC_TEST|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
214278060|NCT05346770|OTHER|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
214278061|NCT05045248|DRUG|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
214278062|NCT01439269|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
214278063|NCT05069532|RADIATION|MSCT chest|CORAD 4-5 MSCT chest
214278064|NCT05069532|DIAGNOSTIC_TEST|PCR|PCR positive for COVID-19
214278065|NCT03713359|BIOLOGICAL|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
214278066|NCT03713359|BIOLOGICAL|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
214278067|NCT03204903|PROCEDURE|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
214278068|NCT03204903|PROCEDURE|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
214278069|NCT02204878|DRUG|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
214278070|NCT03879278|DRUG|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
214278071|NCT01416064|DRUG|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
214278072|NCT01830270|DRUG|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
214278073|NCT01830270|DRUG|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
214278074|NCT01830270|DRUG|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
214278075|NCT01830270|PROCEDURE|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
214278076|NCT04762784|DRUG|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
214278077|NCT04762784|DRUG|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
214278078|NCT02829528|BEHAVIORAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
214278079|NCT04191720|OTHER|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
214278080|NCT00028405|DRUG|LS 11(Taporfin Sodium)|
214278081|NCT00028405|DEVICE|Lumaflex Light Delivery Catheter|
214278082|NCT06085378|DRUG|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
214278083|NCT06085378|OTHER|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
214278084|NCT02587260|DRUG|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
214278085|NCT02587260|DRUG|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
214278086|NCT02587260|DRUG|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
214278087|NCT05223244|DRUG|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
214278088|NCT05223244|DRUG|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
214278089|NCT04660669|OTHER|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
214278090|NCT04660669|OTHER|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
214278091|NCT02126917|DRUG|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
214278092|NCT02126917|DRUG|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
214278093|NCT02126917|DRUG|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
214278094|NCT01991691|DEVICE|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
214278095|NCT03727269|OTHER|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
214278096|NCT03727269|OTHER|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities"
214278097|NCT00166478|DRUG|Exisulind Therapy|
214278098|NCT00037596|DRUG|Gemtuzumab Ozogamicin|
214278099|NCT00037596|DRUG|cytarabine.|
214278100|NCT02505204|OTHER|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
214278101|NCT02505204|OTHER|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
214278102|NCT04073654|PROCEDURE|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
214278103|NCT02031354|DIETARY_SUPPLEMENT|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
214278104|NCT05517044|OTHER|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
214278105|NCT03045315|OTHER|IVF Procedure|
214278106|NCT05405374|OTHER|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
214278107|NCT05405374|DEVICE|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
214278108|NCT02713347|BEHAVIORAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
214278109|NCT01211002|RADIATION|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
214278110|NCT01211002|DRUG|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
214278111|NCT03799081|PROCEDURE|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
214278112|NCT04991909|DRUG|HRS4800|HRS4800
214278113|NCT04991909|DRUG|Placebo|Placebo
214278114|NCT06124560|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
214278115|NCT00968214|GENETIC|polymorphism analysis|
214278116|NCT00968214|OTHER|laboratory biomarker analysis|
214278117|NCT02168634|DRUG|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
214278118|NCT02168634|DRUG|Placebo|1cc normal saline, local injection
214278119|NCT02179866|DRUG|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
214278120|NCT03060538|DRUG|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
214278121|NCT03060538|OTHER|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
214278122|NCT01393691|BEHAVIORAL|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
214278123|NCT01393691|BEHAVIORAL|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
214278124|NCT00001535|DRUG|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
214278125|NCT05248048|BIOLOGICAL|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
214278126|NCT04218422|PROCEDURE|Battlefield Acupuncture|Acupuncture at 5 points on the ears
214278127|NCT04218422|PROCEDURE|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
214278128|NCT05438394|DRUG|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
214278129|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
214278130|NCT02197247|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
214278131|NCT02197247|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
214278132|NCT02197247|PROCEDURE|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
214278133|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
214278134|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod.
214278135|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod.
214278136|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
214278137|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
214278138|NCT00961233|DRUG|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
214278139|NCT00961233|DRUG|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
214278140|NCT03172442|DEVICE|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
214278141|NCT03172442|DEVICE|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
214278142|NCT03172442|DEVICE|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
214278143|NCT03928496|DRUG|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
214278144|NCT03928496|DRUG|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
214278145|NCT05184985|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
214278146|NCT05184985|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
214278147|NCT04446000|BIOLOGICAL|CSL730|solution for injection and infusion
214278148|NCT04446000|DRUG|Placebo|A solution matching the excipient profile of CSL730 without the active substance
214278149|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
214278150|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
214278151|NCT01529502|DRUG|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
214278152|NCT03397537|DRUG|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
214278153|NCT03397537|DRUG|GnRH analogue|3.75 mg triptorelin im. q28d
214278154|NCT01552200|PROCEDURE|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
214278155|NCT01552200|PROCEDURE|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
214278156|NCT02019693|DRUG|INC280|Supplied by Novartis as film-coated tablet for oral use.
214278157|NCT03146013|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
214278158|NCT02611219|OTHER|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"* 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time"
214278159|NCT02611219|OTHER|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"* 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
214278160|NCT02611219|OTHER|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
214278161|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
214278162|NCT02611219|OTHER|General Health Module-Baseline Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
214278163|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
214278164|NCT02611219|OTHER|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
214278165|NCT02611219|OTHER|SCT Daily Activity Log|"* Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
214278166|NCT02611219|OTHER|The Functional Independence Measure for Children|"* 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
214278167|NCT02611219|OTHER|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
214278168|NCT02611219|OTHER|3-Minute Step Test|"* Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
214278169|NCT02611219|OTHER|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"* 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
214278170|NCT02611219|OTHER|HSCT Module-Follow Child-Self Report (5-12 years)|"* 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
214278171|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
214278172|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
214278173|NCT04876924|DRUG|BBP-711|BBP-711, oral suspension
214278174|NCT04876924|DRUG|Placebo|Placebo matching BBP-711
214278175|NCT05269498|DEVICE|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
214278176|NCT00972868|DEVICE|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
214278177|NCT04452682|OTHER|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
214278178|NCT04360668|OTHER|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
214278179|NCT04360668|OTHER|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
214278180|NCT04360668|OTHER|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
214839766|NCT04197154|BEHAVIORAL|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
214278181|NCT04384146|RADIATION|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
214278182|NCT04384146|BEHAVIORAL|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
214278183|NCT04974840|BEHAVIORAL|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
214278184|NCT00585143|DRUG|ABT-335|45 mg once daily for 10 consecutive days
214278185|NCT00585143|DRUG|Rosuvastatin|10 mg once daily for 10 days
214278186|NCT05673889|DRUG|ARV-471|Experimental
214278187|NCT05673889|DRUG|Dabigatran etexilate|Probe substrate
214278188|NCT01577056|DIETARY_SUPPLEMENT|Fish oil capsule|4g Omega capsule for 12 weeks
214278189|NCT01577056|DRUG|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
214278190|NCT04700761|PROCEDURE|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
214278191|NCT04700761|PROCEDURE|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
214278192|NCT01468363|DEVICE|Dry weight adjustment|Dry weight adjustment according to BCM results
214278193|NCT04664712|DIETARY_SUPPLEMENT|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
214278194|NCT04664712|DEVICE|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
214278195|NCT04993248|OTHER|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
214278196|NCT02601391|BEHAVIORAL|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
214278197|NCT00816764|BIOLOGICAL|AGS-8M4|IV Infusion
214278198|NCT01591759|DRUG|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
214278199|NCT01591759|DRUG|Placebo|Placebo arm of single-blind study
214278200|NCT00309114|PROCEDURE|bacterial interference|
214278201|NCT04388878|DRUG|PF-07054894|Participants will receive oral ascending doses
214278202|NCT04388878|DRUG|Placebo|Participants will receive matching placebo
214278203|NCT06798233|DIAGNOSTIC_TEST|Non-Ambulatory Hip Pain questionnaire|a new questionnaire for care givers to identify hip pain in pediatric patients with quadriplegia
214278204|NCT06491940|DRUG|Losartan|Patients will receives Losartan (LS) 50 mg per day.
214278205|NCT06491940|DRUG|Losartan + Hydrochlorothiazide|Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
214278206|NCT04219657|BIOLOGICAL|mesenchymal stem cell application|
214278207|NCT02054091|DIETARY_SUPPLEMENT|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
214278208|NCT02560571|DEVICE|ultrasound|
214278209|NCT02560571|OTHER|blood test|
214278210|NCT04668625|BEHAVIORAL|Participate in a massive musical event|Participate in a massive musical event
214278211|NCT06392620|OTHER|Study Group|n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
214278212|NCT04353271|DRUG|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
214278213|NCT04353271|OTHER|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
214278214|NCT00003097|OTHER|preventative dietary intervention|
214278215|NCT00284583|DRUG|Injection of Steroid into Foot|
214278216|NCT00284583|DRUG|Injection of Alcohol into Foot|
214278217|NCT00284583|DRUG|Injection of Lidocaine into Foot|
214278218|NCT06259747|OTHER|Acutaping|Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
214278219|NCT06259747|DRUG|Doxylamine and Pyridoxine|traditional medical treatment for nausea and vomiting during pregnancy
214278220|NCT03923712|BEHAVIORAL|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
214278221|NCT02228460|DRUG|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
214278222|NCT02284984|DRUG|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
214278223|NCT01243892|DEVICE|NuSpin|Device for administration of doses of somatropin.
214278224|NCT01243892|DRUG|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
214278225|NCT00404261|DRUG|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
214278226|NCT02591069|DEVICE|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
214278227|NCT01163175|OTHER|Ruminant trans fats|"Consumption of the 4 experimental diets:~1. a diet rich in ruminant TFA (8 g/day);~2. a diet moderately rich in ruminant TFA (4 g/day);~3. a diet rich in industrial TFA (8 g/d);~4. a control diet (minimal dietary TFA of industrial and ruminant sources)."
214278228|NCT04473391|DEVICE|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
214278229|NCT00119106|DRUG|Tenofovir disoproxil|Antiretroviral
214278230|NCT00119106|DRUG|Placebo|Placebo
214278231|NCT02370745|DRUG|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
214278232|NCT02370745|DRUG|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
214278233|NCT02370745|DIETARY_SUPPLEMENT|Oral amino acids|Oral amino acids containing 15 g of amino acids
214278234|NCT02370745|DRUG|GIP|This will be co infused with GLP-1 and intravenous amino acids
214278235|NCT02370745|DRUG|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
214278236|NCT04911881|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
214278237|NCT03066804|DRUG|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
214278238|NCT03066804|DRUG|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
214278239|NCT03066804|DRUG|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
214278240|NCT03066804|DRUG|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
214278241|NCT03066804|DRUG|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
214278242|NCT03066804|DRUG|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
214278243|NCT06172322|DRUG|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
214278244|NCT04468854|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
214278245|NCT04468854|OTHER|Placebo|mannitol formulated for oral administration (capsules)
214278246|NCT02777801|DRUG|Entecavir|anti-HBV
214278247|NCT02746146|OTHER|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
214278248|NCT00096070|RADIATION|radiation therapy|Undergo radiation therapy
214278249|NCT00096070|DRUG|oxaliplatin|Given IV
214278250|NCT00096070|DRUG|fluorouracil|Given IV
214278251|NCT00096070|DRUG|gemcitabine hydrochloride|Given IV
214278252|NCT02696603|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
214278253|NCT02696603|BEHAVIORAL|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
214278254|NCT02696603|BEHAVIORAL|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
214278255|NCT02696603|BEHAVIORAL|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
214278256|NCT02696603|BEHAVIORAL|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
214278257|NCT02696603|BEHAVIORAL|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
214278258|NCT02696603|OTHER|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
214278259|NCT05051722|DIAGNOSTIC_TEST|Vaginal Fluid Collection|A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
214278260|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
214278261|NCT04213729|BEHAVIORAL|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
214278262|NCT04213729|OTHER|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
214278263|NCT04213729|BEHAVIORAL|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
214278264|NCT00251784|DRUG|Sildenafil|
214278265|NCT02099708|DRUG|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
214278266|NCT01184391|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
214278267|NCT01184391|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
214278268|NCT00549081|DIETARY_SUPPLEMENT|DHEA|oral DHEA tablets 75 mg daily
214278269|NCT03282682|PROCEDURE|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
214278270|NCT02723214|PROCEDURE|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
214278271|NCT03008603|DEVICE|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
214278272|NCT06185283|DIAGNOSTIC_TEST|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
214278273|NCT03064997|DIETARY_SUPPLEMENT|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
214278274|NCT03064997|DIETARY_SUPPLEMENT|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
214278275|NCT01609374|DEVICE|M6-C Artificial Cervical Disc|Total disc replacement
214278276|NCT01609374|DEVICE|Anterior plate system with corticocancellous allograft bone|Cervical fusion
214278277|NCT03182478|BEHAVIORAL|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
214278278|NCT03182478|BEHAVIORAL|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
214278279|NCT05129215|OTHER|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
214278280|NCT02052531|DRUG|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
214278281|NCT02052531|OTHER|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
214278282|NCT05517915|OTHER|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
214278283|NCT05517915|OTHER|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
214278284|NCT00158834|DRUG|Salmeterol/Fluticasone propionate combination product|
214278285|NCT00158834|DRUG|Fluticasone propionate|
214278286|NCT05466682|BEHAVIORAL|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
214278287|NCT05466682|BEHAVIORAL|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
214278288|NCT05801250|BEHAVIORAL|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
214278289|NCT06620146|OTHER|mechanical bathing|Providing mechanical bathing (MB) is a commonly used strategy to maintain cleanness and comfort in patients with terminally illness. The electric medical bathtub (ARJO, Rhapsody) provides functions such as showering, bathing, and water massage. The MB will be operated by 2-3 nursing staff, trained hospice volunteers, or researchers. Each patient\&amp;#39;s MB process lasts about 20 minutes, including washing the hair and body with a handheld showerhead, followed by soaking in warm water for about 5-10 minutes. Based on the patient preference, the water temperature is adjusted between 38 to 40 degrees Celsius.
214278290|NCT01930123|DRUG|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
214278291|NCT01930123|OTHER|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
214278292|NCT04171050|DRUG|Local anaesthetic|Local anesthesia injections
214278293|NCT04171050|DRUG|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
214278294|NCT01447433|DRUG|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
214278295|NCT01447433|BEHAVIORAL|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
214278296|NCT00036270|DRUG|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
214278297|NCT00036270|DRUG|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
214278298|NCT03036007|OTHER|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
214278299|NCT03036007|OTHER|Exercises with Internet support|Neck-specific exercise with Internet support
214278300|NCT00593502|DRUG|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
214278301|NCT00593502|DRUG|placebo|The dosage of placebo will be similar to the active drug
214278302|NCT04774796|OTHER|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
214278303|NCT01578187|DEVICE|Hair2Go|Treatment with the device once under observation
214278304|NCT03689348|DIETARY_SUPPLEMENT|Avena sativa|A supplement derived from wild green oat
214278305|NCT03689348|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214278306|NCT01964430|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
214278307|NCT01964430|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
214278308|NCT00561808|OTHER|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
214278309|NCT00321308|DRUG|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
214278310|NCT00321308|DRUG|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
214278311|NCT04589078|DEVICE|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
214278312|NCT02516163|DEVICE|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
214278313|NCT04837261|DRUG|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
214278314|NCT04837261|DRUG|Flecainide|80 mg/m2/d
214278315|NCT04837261|DRUG|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
214278316|NCT01832974|DRUG|IL-13-PE|IL-13-PE intravenous infusion
214278317|NCT03723941|DRUG|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
214278318|NCT03723941|OTHER|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
214278319|NCT05043129|BIOLOGICAL|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
214278320|NCT02801396|DEVICE|Etafilcon A Design 1 (Test 1)|
214278321|NCT02801396|DEVICE|Etafilcon A Design 2 (Test 2)|
214278322|NCT02801396|DEVICE|Etafilcon A (Control)|
214464995|NCT04947527|DRUG|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
214464996|NCT03460483|OTHER|Genetic Counseling|Undergo genetic counseling
214464997|NCT03460483|OTHER|Genetic Testing|Undergo genetic testing
214464998|NCT03460483|OTHER|Laboratory Biomarker Analysis|Correlative studies
214464999|NCT03460483|PROCEDURE|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
214465000|NCT05294991|BEHAVIORAL|Wellness app intervention #1|This is the active intervention group.
214465001|NCT05294991|BEHAVIORAL|Wellness app intervention #2|This is the active comparator/control group.
214278323|NCT05214456|OTHER|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
214278324|NCT05214456|OTHER|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
214278325|NCT00993083|BIOLOGICAL|MVA-NP+M1|Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
214278326|NCT02672878|DEVICE|Bioresorbable vascular scaffold|
214278327|NCT05581628|DIAGNOSTIC_TEST|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
214278328|NCT05581628|DIAGNOSTIC_TEST|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
214278329|NCT05581628|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
214278330|NCT05343845|OTHER|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
214278331|NCT01022632|DIETARY_SUPPLEMENT|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
214278332|NCT01022632|DRUG|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
214278333|NCT01022632|DIETARY_SUPPLEMENT|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
214278334|NCT02446483|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
214278335|NCT02446483|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
214278336|NCT04968301|DEVICE|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
214278337|NCT03802669|OTHER|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
214278338|NCT01658072|PROCEDURE|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
214278339|NCT01658072|PROCEDURE|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
214278340|NCT03910062|PROCEDURE|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
214278341|NCT03208244|DRUG|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
214278342|NCT05758298|OTHER|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
214278343|NCT05758298|DRUG|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
214278344|NCT05758298|DRUG|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
214278345|NCT00888862|DRUG|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
214278346|NCT02398175|OTHER|reanimation/intubation|
214278347|NCT01221792|DRUG|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
214278348|NCT01221792|DRUG|Placebo|Non active comparator
214278349|NCT00894660|DRUG|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
214278350|NCT00894660|DRUG|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
214278351|NCT05482412|DEVICE|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
214278352|NCT04279457|DEVICE|DyeVert Plus System|The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
214278353|NCT04279457|OTHER|Standardized hydration protocol|hydration protocol based up on the Poseidon protocol
214465002|NCT02723591|DRUG|Tacrolimus|Oral Capsule
214278354|NCT02920385|DRUG|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
214278355|NCT02920385|DRUG|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
214278356|NCT02920385|DRUG|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
214278357|NCT02920385|DRUG|Placebo|Oral administration once daily together with semaglutide
214278358|NCT03834441|OTHER|Oral HRSN screening|Verbal screening delivered by an RA
214278359|NCT03834441|OTHER|Written HRSN screening|Patient completes written screen on iPad.
214278360|NCT01930266|DIETARY_SUPPLEMENT|Experimental|
214278361|NCT01930266|BEHAVIORAL|Active comparator|
214278362|NCT06557447|DIAGNOSTIC_TEST|Immunological and microbiological sample of peri-implant crevicular fluid; clinical evaluation|"Immunological sample collection involves placing a Periopaper strip in the peri-implantar sulcus for 30 seconds. If sample is contaminated with blood, sample will be discarded and another sample will be collected (a different surface of the same implant/tooth can be used).~Microbiological sample collection involves collecting subgingival dental plaque by sliding the end of the STERILE curette (Gracey) inside the peri-implant sulcus. In case of slight bleeding following the first sample, dry the site again before collection. In case of profuse bleeding, collect a sample from another site (by site mean mesial/buccal/distal/lingual) of the same implant.~Both immunological and microbiological samples will be sent for respective laboratories for the analysis.~Clinical evaluation will assess presence of dental plaque, bleeding on probing and gingival status."
214278363|NCT01245621|BEHAVIORAL|Later entry group|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
214278364|NCT01245621|BEHAVIORAL|Early palliative care intervention|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
214278365|NCT01264757|BEHAVIORAL|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
214278366|NCT01264757|BEHAVIORAL|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
214278367|NCT03493074|DIAGNOSTIC_TEST|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
214278368|NCT00916942|DRUG|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
214278369|NCT00916942|DRUG|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
214278370|NCT02771093|DRUG|Trelagliptin|Trelagliptin 100 mg tablet
214278371|NCT02771093|DRUG|Alogliptin|Alogliptin 25 mg tablet
214278372|NCT05239208|OTHER|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
214278373|NCT05239208|OTHER|Control Group|Dietary counseling
214278374|NCT02957669|BEHAVIORAL|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
214278375|NCT02957669|BEHAVIORAL|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
214278376|NCT03081533|OTHER|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
214278377|NCT01607242|OTHER|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
214278378|NCT01607242|OTHER|Voice Handicap Index|Subjective Evaluation of Voice disorders
214278379|NCT01607242|OTHER|Swallowing Assesment|Swallowing function questionnaire
214278380|NCT00687960|DIETARY_SUPPLEMENT|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
214278381|NCT00687960|DIETARY_SUPPLEMENT|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
214278382|NCT00687960|DIETARY_SUPPLEMENT|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
214278383|NCT00687960|DIETARY_SUPPLEMENT|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
214278384|NCT02051686|DRUG|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
214278385|NCT02051686|DRUG|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
214278386|NCT00335478|DRUG|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
214278387|NCT03801460|OTHER|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
214278388|NCT06409715|OTHER|Enhanced Care with PMRT and Acupressure|Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established
214278389|NCT06409715|OTHER|standard care|vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
214465003|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
214278390|NCT01837108|DRUG|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
214278391|NCT01837108|DRUG|Placebo|
214278392|NCT06341751|BEHAVIORAL|Psychological treatment for persistent fatigue|The treatment consists of three main phases: 1) goal-setting; stabilizing sleep-wake patterns and even distribution of activities over the day (pacing). Attention-shifting and cognitive reappraisal 2. Gradual increase in physical activity followed by gradual increase in mental and social activity 3. Individual work to reach treatment goals.
214278393|NCT02140086|BEHAVIORAL|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
214278394|NCT04843020|DRUG|ION 682884|Subcutaneous injection every month
214278395|NCT05209425|DIETARY_SUPPLEMENT|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
214278396|NCT00602797|DRUG|Paclitaxel|Given IV
214278397|NCT00602797|OTHER|Quality-of-Life Assessment|Ancillary studies
214278398|NCT00602797|OTHER|Questionnaire Administration|Ancillary studies
214278399|NCT00602797|DRUG|Vinorelbine Tartrate|Given IV
214278400|NCT03473977|BIOLOGICAL|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
214278401|NCT03473977|BIOLOGICAL|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
214278402|NCT01893164|PROCEDURE|simple decompression|decompression of the ulnar nerve
214278403|NCT01893164|PROCEDURE|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
214278404|NCT01893164|PROCEDURE|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
214278405|NCT00277498|DRUG|Xalacom|
214278406|NCT00277498|DRUG|Xalatan|
214278407|NCT00277498|DRUG|Timolol|
214278408|NCT06009705|DRUG|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
214278409|NCT01996852|BEHAVIORAL|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
214278410|NCT01996852|DRUG|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
214278411|NCT01996852|DEVICE|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
214278412|NCT01954719|PROCEDURE|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
214278413|NCT01954719|PROCEDURE|control group|surgeon not dilated cervix after surgery
214278414|NCT04312880|DRUG|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
214278415|NCT00067600|BEHAVIORAL|Diet with increased fruits, vegetables, and calcium|
214278416|NCT00067600|BEHAVIORAL|Increased high impact activity and resistance training|
214278417|NCT01458938|OTHER|treatment plan|Data Collection Study
214278418|NCT01781143|DEVICE|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
214278419|NCT00834171|DRUG|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
214278420|NCT00834171|DRUG|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
214278421|NCT01450995|DRUG|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
214278422|NCT01450995|DRUG|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
214278423|NCT05729646|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
214278424|NCT05729646|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
214278425|NCT05729646|DRUG|S1|S-1 orally intake as perioperative chemotherapy
214278426|NCT01186471|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
214278427|NCT01186471|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
214278428|NCT01186471|DRUG|placebo|placebo - three times daily during each treatment period
214278429|NCT04833543|OTHER|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
214278430|NCT04833543|OTHER|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
214278431|NCT00730769|DRUG|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
214278432|NCT04931407|OTHER|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
214278433|NCT00133328|DRUG|valsartan|
214278434|NCT00991718|DRUG|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
214278435|NCT00991718|DRUG|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
214278436|NCT00991718|DRUG|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
214278437|NCT00171392|DRUG|Enteric-coated mycophenolate sodium|
214278438|NCT03674671|DRUG|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
214278439|NCT03674671|PROCEDURE|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
214278440|NCT01318993|DRUG|GSK1605786A|500 milligrams twice daily
214278441|NCT03668860|DRUG|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
214278442|NCT03668860|DRUG|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
214278443|NCT03668860|DRUG|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
214278444|NCT03668860|DRUG|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
214278445|NCT03668860|DRUG|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
214278446|NCT00004730|DRUG|magnesium sulfate|
214278447|NCT02349529|BEHAVIORAL|Psychosocial Intervention Group|6 group sessions
214278448|NCT02349529|OTHER|Waiting list control|Treatment as usual
214278449|NCT06049238|OTHER|Maitland Mobilization|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
214278450|NCT06049238|OTHER|Post facilitation stretch|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
214278451|NCT01323283|DIETARY_SUPPLEMENT|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
214278452|NCT01323283|DIETARY_SUPPLEMENT|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
214278453|NCT00970970|OTHER|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
214278454|NCT02425020|DIETARY_SUPPLEMENT|Meat Protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
214278455|NCT02425020|DIETARY_SUPPLEMENT|Whey protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
214278456|NCT02425020|DIETARY_SUPPLEMENT|Carbohydrate|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
214278457|NCT00361569|DRUG|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
214278458|NCT00361569|DRUG|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
214278459|NCT00361569|OTHER|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
214278460|NCT00361569|OTHER|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
214278461|NCT01558271|DRUG|LY2189265|
214278462|NCT01558271|DRUG|Placebo|
214278463|NCT01558271|DRUG|Liraglutide|
214278464|NCT05532761|OTHER|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
214278465|NCT00415831|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
214278466|NCT04566679|DIETARY_SUPPLEMENT|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
214278467|NCT04566679|DIETARY_SUPPLEMENT|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
214278468|NCT00967590|DRUG|RO5036505|380mg iv infusion once weekly for 8 weeks
214278469|NCT00967590|DRUG|placebo|iv infusion once weekly for 8 weeks
214278470|NCT01595997|DRUG|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
214278471|NCT00705198|DRUG|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
214278472|NCT00705198|DRUG|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
214278473|NCT00705198|RADIATION|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
214278474|NCT01594762|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
214278475|NCT01594762|DRUG|Topical placebo cream|14 days of treatment
214278476|NCT01594762|OTHER|Standard wound care|14 days of treatment
214278477|NCT01645345|DEVICE|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
214465004|NCT06010030|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
214278478|NCT03547583|DRUG|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
214278479|NCT03547583|DRUG|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
214278480|NCT01136603|DEVICE|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
214278481|NCT02657915|DRUG|Placebo|Administered as specified in the treatment arm.
214278482|NCT02657915|DRUG|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
214278483|NCT01297712|DEVICE|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
214278484|NCT04690998|OTHER|Blood Samples|Genetic, proteomic, neurofilament analysis
214278485|NCT04690998|OTHER|MRI|Spinal and muscular MRI
214278486|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants|As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
214278487|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants|As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
214278488|NCT05006196|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
214278489|NCT02639143|DRUG|ticagrelor|
214278490|NCT02639143|DRUG|Clopidogrel|
214278491|NCT01652209|BIOLOGICAL|Hearticellgram-AMI|
214278492|NCT06666907|DEVICE|Smilefy|AI based DSD
214278493|NCT06666907|DEVICE|EXOCAD|Conventional DSD software
214465005|NCT06010030|BEHAVIORAL|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
214278494|NCT06573359|OTHER|questionnaire|Turkish translation of the scale will be made by a native English speaker and the back translation will be made into English, and the consistency of the original and Turkish translation will be evaluated by a three-person expert committee. The psychometric properties of the scale will be investigated according to the methods used for the validity of the original scale. The validity of the scale was validated by analyzing the correlations between the rcs-e-tr score obtained at admission (both for each partial item and the total score) and other suitability indicators used in Turkey (FIM Motor and Barthel) using Spearman's rank correlation coefficient r (rho). will be evaluated. Additionally, to check the ability of rcs-e-tr to capture case complexity, it will be correlated with other scores usually recorded in our rehabilitation services on admission, using Spearman's rank correlation coefficient r(rho).
214278495|NCT06128473|DEVICE|Soft Contact Lens|Vision Correction
214278496|NCT00035997|DRUG|Zometa|
214278497|NCT07012603|OTHER|External oblique and rectus abdominis plane (EXORA) block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20 mL of bupivacaine 0.25%.
214278498|NCT07012603|OTHER|Sham block|Patients will receive a sham block using 20 mL of normal saline as a control group.
214278499|NCT06869278|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
214278500|NCT07015801|BIOLOGICAL|CMV-VST|30-40 x 10\^3 viable CD3+ cells/kg
214278501|NCT07014449|DRUG|WBC100 QD|WBC100 will be administered orally as capsules once daily in 28-day cycles. The dose-escalation phase follows an accelerated titration combined with the traditional '3+3' design.
214278502|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein with the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation with the additional use of the FARAVIEW mapping system (The additional mapping approach)
214278503|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein without the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation without the use of the FARAVIEW mapping system.
214278504|NCT07015008|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
214278505|NCT07015008|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
214278506|NCT07014384|DEVICE|Anodal and cathodal ctDCS|CtDCS will be delivered using an DC-stimulator and two saline-soaked sponge electrodes: one electrode placed 3 cm lateral to the right of the inion, the other electrode on the right buccinator muscle. A 2 mA current will be delivered through these electrodes for a duration of 20 minutes with a 8-second fade-in and fade-out.
214278507|NCT07014384|DEVICE|Sham stimulation|The tDCS procedure will be identical to the active (anodal and cathodal) stimulation condition, but stimulation will cease after 30 seconds.
214278508|NCT07014605|BEHAVIORAL|Smoking Cessation Self Help Guide|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help guide in this study. Attached to the guide is an information sheet regarding NRT (e.g., patches and lozenges), where to buy them, and how to use them."
214278509|NCT07014605|BEHAVIORAL|Smartphone-delivered Automated Messaging|The MAP includes text messages, images, and videos with content designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The MAP will begin immediately after enrollment and continue for a 26-week period. The MAP approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
214278510|NCT07016607|DEVICE|GPIV|The investigational device is a peripheral intravenous catheter with a passive fully automatic needlestick protection, with a glide-on-contact design of the plastic cannula tip featuring asymmetry, with the negative, convex slope in the plane perpendicular to the longitudinal axis of the tip resulting in bottom part of the cannula being shorter.
214278511|NCT07014956|PROCEDURE|Labour epidural analgesia|Prenatal exposure to labour epidural analgesia during delivery
214278512|NCT07015658|PROCEDURE|Baduanjin|The Baduanjin protocol, based on China's 2003 General Administration of Sport standard, was modified by professional physiotherapists for targeted adaptations, with nurses receiving specialized training. Patients viewed step-by-step instructional clips upon admission alongside a full-length routine video. Standard postoperative rehabilitation was maintained during Weeks 1-2. At Week 3, patients demonstrating adequate wound healing and unimpaired static lumbar muscle contraction performed Baduanjin exercises wearing a lumbar brace, supervised by trained nurses for movement correction. The brace was discontinued after 8 weeks. Modified professional videos with background music were distributed via WeChat/official accounts twice daily (30min/session, 5 days/week) for 13 weeks (total ≥2000min). Duration/frequency adjustments were permitted based on individual recovery and physician recommendations post-intervention.
214278513|NCT07015658|PROCEDURE|Moxibustion|Moxibustion was performed at acupoints including Yaoyangguan (GV3), Shenshu (BL23), Dachangshu (BL25, affected side), Chengfu (BL36), Mingmen (GV4), Weizhong (BL40, affected side), Taixi (KI3), Fuliu (KI7), Zhishi (BL52), Zusanli (ST36), and Ashi points. Using five-year-aged Qizhou mugwort, the patient's treatment areas were fully exposed in a comfortable position. The moxa stick was held 3-4 cm from the skin with intensity adjusted to patient tolerance to prevent burns. The circular moxibustion technique was applied for 3-5 minutes per acupoint until the skin exhibited erythema, perspiration, or mottling, or until the patient experienced warmth, distension, itchiness, or perceived moxa-heat propagation. Treatment commenced at postoperative Week 3 following evaluation of satisfactory wound healing, administered three times weekly for four consecutive weeks.
214465006|NCT03978624|DRUG|Pembrolizumab|200 mg IV on day 1 and day 22
214465007|NCT03978624|DRUG|Entinostat|5 mg given orally on day 1, day 8 and day 15
214465008|NCT03978624|PROCEDURE|Procedure/Surgery|A radical cystectomy is a surgical procedure to remove the entire urinary bladder and maximal transurethral resection of bladder tumor (TURBT) is a surgical procedure used to remove as much of the bladder tumor as possible.
214465009|NCT06031298|BIOLOGICAL|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
214465010|NCT06158490|DRUG|JYP0061 15 mg|Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
214278514|NCT07015658|PROCEDURE|Conventional intervention|Postoperative Rehabilitation Exercises: Week 1: Ankle Pump Exercises: Start after anesthesia. Slowly rotate/invert, dorsiflex/plantarflex ankles. Hold each position 10-15s. 30 min/set, 6 sets/day, until ambulation. Straight Leg Raising (SLR): Start Day 2, supine. Elevate leg \>30°. Progress from passive to active hold. Hold 5-10s/rep, 10-20 reps/set. 3 sets (morning/noon/night) daily for 15 days. Week 2: Supine hip/knee flexion exercises in bed. Hold each flexion 3-5s. 30-50 reps/set. 2 sets/day. Weeks 3-4: Start back muscle training (e.g., bridge/bird-dog poses). Months 1-3: Gradually increase back exercise frequency/difficulty. Perform flexion, extension, lateral flexion, and rotation wearing a lumbar brace. Intensity/reps based on tolerance.
214278515|NCT07016451|PROCEDURE|Li-ESWT|The intervention treatment uses Li-ESWT. (Dornier Aries® devices, Power 0.29mj/m² and 3000 shocks per week for 4 weeks)
214278516|NCT07016451|DRUG|Medication|"The medication treatment of Radiation cystitis and relevant symptoms such as Antimuscarinics, Beta3 agonist, and pain control, as listed. Antimuscarinic Agents~* Oxybutynin~* Tolterodine~* Solifenacin~* Darifenacin~* Trospium~* Fesoterodine β3-Adrenergic Agonists~* Mirabegron Pain Control Medications~* Paracetamol~* NSAIDs (e.g., Ibuprofen, Diclofenac)~* Phenazopyridine~* Amitriptyline~* Gabapentin / Pregabalin"
214278517|NCT07014644|DRUG|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo
214278518|NCT07014644|DRUG|1.5g Naltrexone Implant|1.5g Naltrexone Implant
214278519|NCT06205316|DRUG|Antiandrogen Therapy|Receive ADT
214278520|NCT06205316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214278521|NCT06205316|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214278522|NCT06205316|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214278523|NCT06205316|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214278524|NCT06205316|OTHER|Survey Administration|Ancillary study
214278525|NCT06205316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214278526|NCT06881979|DEVICE|High-tech rehabilitative treatment|Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises. Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training. Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback
214278527|NCT06881979|OTHER|Rehabilitation|Traditional rehabilitative treatment
214278528|NCT03330821|DRUG|Cytarabine|Given IV
214278529|NCT03330821|DRUG|Idarubicin|Given IV
214278530|NCT03330821|OTHER|Laboratory Biomarker Analysis|Correlative studies
214278531|NCT03330821|DRUG|Pevonedistat|Given IV
214278532|NCT03330821|OTHER|Pharmacological Study|Correlative studies
214278533|NCT06709248|BEHAVIORAL|Life Coping Program|The Life Coping Program is built around a coordinated 5-day Life Coping Course. Participants included are grouped by their primary condition, meaning the diagnosis or illness reasoning the referral. Each family is assigned a dedicated Primary Contact throughout the program, and the program consists of three phases: Phase 1: Preparation - Written/visual materials and questionnaires are provided to motivate and inform. A digital consultation occurs 3-5 weeks before the Life Coping Course, covering goals, commitment, and follow-up. Materials are offered in paper or digital formats. Phase 2: Life Coping Course - The 5-day course includes individual consultations, group activities, education, and medical follow-ups, focusing on coping strategies and well-being. Phase 3: Implementation - A summary meeting is conducted, including key persons for further implementation in own local area. Digital follow-ups at 3-4 weeks and 6 months post course assess progress and guide goal achievement.
214278534|NCT04034836|DRUG|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
214278535|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
214278536|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
214278537|NCT06511037|DRUG|Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging|Given IV
214465011|NCT06158490|DRUG|JYP0061 30 mg|articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
214278538|NCT04147221|DRUG|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
214278539|NCT04086147|DRUG|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
214278540|NCT04086147|DRUG|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
214278541|NCT01730391|OTHER|Data collection|Collection of demographic data and vaccination history
214278542|NCT01730391|OTHER|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
214278543|NCT02894918|DRUG|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
214278544|NCT00595530|DRUG|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
214278545|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
214278546|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
214278547|NCT04243967|OTHER|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
214278548|NCT04243967|OTHER|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
214278549|NCT03330730|OTHER|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
214278550|NCT01511315|DRUG|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
214278551|NCT01354977|DRUG|Resveratrol|1,000mg twice daily for 28 days
214278552|NCT05798832|OTHER|Virtually reality training group|BLS Training with VR
214278553|NCT05798832|OTHER|Traditional training group|BLS Training with Traditional
214278554|NCT02644733|PROCEDURE|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
214278555|NCT02644733|PROCEDURE|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
214278556|NCT03600545|OTHER|Brain Fitness App|Brain exercises using an iPAD
214278557|NCT05328193|BEHAVIORAL|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
214278558|NCT05328193|BEHAVIORAL|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
214278559|NCT03003390|DRUG|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
214278560|NCT03724760|OTHER|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
214278561|NCT04352647|BEHAVIORAL|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
214278562|NCT03973996|DIETARY_SUPPLEMENT|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
214278563|NCT03973996|DIETARY_SUPPLEMENT|Placebo|A matched gummy confection formulated without green tea extract
214278564|NCT00649324|DRUG|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
214278565|NCT00649324|DRUG|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
214278566|NCT00307294|DRUG|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
214278567|NCT00307294|DRUG|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
214278568|NCT05433792|DEVICE|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
214278569|NCT05433792|DEVICE|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
214278570|NCT06058481|DEVICE|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
214278571|NCT06058481|DEVICE|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
214278572|NCT03182088|DRUG|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
214278573|NCT03182088|DRUG|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
214278574|NCT03182088|DRUG|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
214278575|NCT03182088|DRUG|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
214465012|NCT06158490|DRUG|Placebo|Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
214278576|NCT01655615|BEHAVIORAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
214278577|NCT02562053|DRUG|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
214278578|NCT02562053|DRUG|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
214278579|NCT02562053|DRUG|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
214278580|NCT02562053|DRUG|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
214278581|NCT06158789|PROCEDURE|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
214278582|NCT04842266|DEVICE|IlluminOss pelvic implant for oncologic indication|Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
214278583|NCT04842266|DEVICE|IlluminOss pelvic implant for geriatric trauma indication|Pelvic fragility fracture in a geriatric patients (age 65 or older)
214278584|NCT06241534|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
214278585|NCT06241534|BEHAVIORAL|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
214278586|NCT06241534|DEVICE|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
214278587|NCT06241534|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
214278588|NCT03576976|BEHAVIORAL|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
214278589|NCT01661296|OTHER|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
214278590|NCT01661296|DRUG|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
214278591|NCT00275990|DEVICE|rheolytic thrombectomy with direct stenting|
214278592|NCT00275990|DEVICE|direct stenting|
214278593|NCT04448288|OTHER|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
214278594|NCT06301685|BEHAVIORAL|Routine therapy|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
214278595|NCT06301685|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214278596|NCT06301685|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
214278597|NCT04477902|OTHER|none - observational|online survey
214278598|NCT01230944|PROCEDURE|Laparoscopic Nissen fundoplication|
214278599|NCT01230944|PROCEDURE|Open Nissen fundoplication|
214278600|NCT01485237|OTHER|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
214278601|NCT01664533|DRUG|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
214278602|NCT04910802|BIOLOGICAL|Gardasil9|Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
214278603|NCT04070274|PROCEDURE|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
214278604|NCT04911530|OTHER|no intervention|no intervention
214278605|NCT06094569|PROCEDURE|Endovascular Therapy|Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
214278606|NCT02708160|DRUG|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
214278607|NCT02708160|DRUG|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
214278608|NCT02708160|DRUG|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
214278609|NCT00804791|OTHER|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
214278610|NCT00804791|OTHER|Unisol 4 Saline Solution|saline solution for irrigating the cornea
214278611|NCT02932670|OTHER|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
214278612|NCT01504035|DEVICE|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
214278613|NCT01504035|DEVICE|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
214278614|NCT02264197|DRUG|BIBX 245 CL - fed|
214278615|NCT02264197|DRUG|BIBX 245 CL- fasted|
214278616|NCT01804621|BEHAVIORAL|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
214278617|NCT05604118|DRUG|Aspirin|1 week of aspirin supplementation prior to sampling
214278618|NCT00493324|DRUG|alefacept|Intramuscular
214278619|NCT00493324|DRUG|polyvalent pneumococcal vaccine|Injection
214278620|NCT01068132|DRUG|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
214278621|NCT01068132|DRUG|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
214278622|NCT04625309|OTHER|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
214278623|NCT00003746|DRUG|2-chlorodeoxyadenosine (CDA) daily|Daily administration
214278624|NCT00003746|DRUG|2-chlorodeoxyadenosine weekly|Weekly administration
214278625|NCT02243332|DEVICE|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
214278626|NCT01282892|PROCEDURE|excess of visceral fat|excess of visceral fat
214278627|NCT01282892|PROCEDURE|patients with NAFLD|patients with NAFLD
214278628|NCT00943059|DRUG|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
214278629|NCT00943059|DRUG|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
214278630|NCT02950532|OTHER|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
214278631|NCT05890846|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
214278632|NCT05890846|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
214278633|NCT05890846|BEHAVIORAL|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
214278634|NCT03777878|DRUG|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
214278635|NCT03777878|DRUG|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
214278636|NCT03777878|DRUG|TA|2 ampoules of TA in 100 ml saline by slow infusion
214278637|NCT03777878|DRUG|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
214278638|NCT03777878|DRUG|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
214278639|NCT03777878|DRUG|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
214278640|NCT01779401|DRUG|Clopidogrel 75mg|
214278641|NCT01779401|DRUG|Clopidogrel 150mg|
214278642|NCT01779401|DRUG|Aspirin 100mg|
214278643|NCT01779401|DRUG|Cilostazol 100mg|
214278644|NCT04010708|DIAGNOSTIC_TEST|Urinary Iodine Concentration Measurement|UIC
214278645|NCT02747095|DEVICE|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
214278646|NCT00290888|PROCEDURE|Acromioplasty|
214278647|NCT05265689|BEHAVIORAL|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
214278648|NCT05265689|BEHAVIORAL|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
214278649|NCT01801891|DEVICE|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
214278650|NCT01801891|OTHER|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
214278651|NCT02671396|BEHAVIORAL|Virtual reality based intervention|Virtual reality based balance training
214278652|NCT02671396|BEHAVIORAL|Conventional intervention|Conventional balance training
214278653|NCT04235478|DRUG|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
214278654|NCT03043131|DRUG|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
214278655|NCT03043131|DRUG|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
214278656|NCT03775811|OTHER|AUTOMATED POLYP CLASSIFICATION|COLONIC POLYP HISTOLOGY PREDICTION IN WHITE LIGHT IMAGES COMBINING ARTIFICIAL INTELLIGENCE AND CLINICAL INFORMATION
214278657|NCT02786446|DRUG|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
214278658|NCT02786446|DRUG|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
214278659|NCT02786446|DRUG|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
214278660|NCT00977899|BIOLOGICAL|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
214278661|NCT02122393|DRUG|Sertraline|
214278662|NCT02122393|BEHAVIORAL|Cognitive Behavioural Therapy|
214278663|NCT01953198|OTHER|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
214278664|NCT00634166|DRUG|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
214278665|NCT00634166|DRUG|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
214278666|NCT02370160|BIOLOGICAL|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
214278667|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
214278668|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
214278669|NCT00594438|DEVICE|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
214278670|NCT00594438|DEVICE|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
214278671|NCT03055793|OTHER|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
214278672|NCT03036046|DRUG|F901318 with fluconazole low dose|adverse events
214278673|NCT03036046|DRUG|F901318 with fluconazole high dose|adverse events
214278674|NCT03036046|DRUG|F901318 with posaconazole|adverse events
214278675|NCT01456468|DRUG|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
214278676|NCT05738668|OTHER|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
214278677|NCT03296241|DEVICE|laser|
214278678|NCT03296241|DEVICE|sham control|
214278679|NCT02505997|DRUG|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
214278680|NCT02505997|DRUG|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
214278681|NCT06219512|BEHAVIORAL|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
214278682|NCT06219512|BEHAVIORAL|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
214278683|NCT06219512|BEHAVIORAL|Regular exercise|Regular exercise
214278684|NCT02292979|DRUG|Doxorubicin|25mg/m2
214278685|NCT02292979|DRUG|Bleomycin|10mg/m2
214278686|NCT02292979|DRUG|Vinblastine|6mg/m2
214278687|NCT02292979|DRUG|Dacarbazine|375mg/m2
214278688|NCT02292979|DRUG|Brentuximab Vedotin|1.2 mg/kg
214278689|NCT01983436|OTHER|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
214278690|NCT00111345|DRUG|Anthracyclines|3x12 mg/qm
214278691|NCT00111345|DRUG|liposomal daunorubicin|3x80 mg/qm
214278692|NCT00111345|DRUG|2-CDA|2x6 mg/qm
214278693|NCT00111345|DRUG|AI|AI
214278694|NCT02634229|GENETIC|blood sample|
214278695|NCT05104164|OTHER|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
214278696|NCT02917304|BIOLOGICAL|GC3110A vaccine|0.5mL, Intramuscular
214278697|NCT04487730|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
214278698|NCT04487730|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
214278699|NCT01954550|BEHAVIORAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
214278700|NCT01954550|BEHAVIORAL|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
214278701|NCT00468325|PROCEDURE|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
214278702|NCT00468325|PROCEDURE|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
214278703|NCT00468325|PROCEDURE|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
214278704|NCT00748501|DRUG|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
214278705|NCT04818398|DRUG|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
214278706|NCT04818398|DRUG|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
214278707|NCT05307419|PROCEDURE|Rectal suction biopsy.|Suction biopsy performed
214278708|NCT05307419|PROCEDURE|Full-thickness rectal biopsy.|Full-thickness biopsy performed
214278709|NCT01458652|DRUG|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
214278710|NCT01581931|DRUG|Linagliptin/metformin|FDC
214278711|NCT01581931|DRUG|Metformin|single tablet Metformin
214278712|NCT01581931|DRUG|Linagliptin|single tablet Linagliptin
214278713|NCT02185833|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
214278714|NCT02185833|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
214278715|NCT02551757|DEVICE|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
214278716|NCT02551757|DEVICE|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
214278717|NCT06293807|DRUG|Xylocaine 2 % with 1:100,000 epinephrine|Local anesthetic used during dental procedures
214278718|NCT06293807|DRUG|Bupivicaine 0.5% with 1:200,000 epinephrine|Local anesthetic used during dental procedures
214278719|NCT06293807|OTHER|Placebo|0.9% Normal Saline solution used in place of local anesthetic
214278720|NCT02734940|DRUG|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
214278721|NCT02734940|DRUG|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
214278722|NCT02734940|DRUG|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
214278723|NCT02734940|DRUG|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
214278724|NCT02734940|DRUG|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
214278725|NCT04221841|OTHER|descriptive|correlation
214278726|NCT02252094|DEVICE|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
214278727|NCT02252094|OTHER|Ultra-protective ventilation|Ventilation with \</= 3ml/kg predicted body weight
214278728|NCT02252094|OTHER|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
214278729|NCT05695443|BEHAVIORAL|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
214278730|NCT03232957|PROCEDURE|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
214278731|NCT03232957|PROCEDURE|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
214278732|NCT03232957|PROCEDURE|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
214278733|NCT03232957|DRUG|Morphine|intrathecal morphine
214278734|NCT03232957|DRUG|Bupivacaine|0.5 isobaric bupivacaine
214278735|NCT04593225|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
214278736|NCT04593225|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
214278737|NCT01785550|OTHER|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
214465013|NCT04768426|DRUG|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
214465014|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
214839767|NCT04197154|BEHAVIORAL|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
214839768|NCT04197154|BEHAVIORAL|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
214278738|NCT02524795|DIETARY_SUPPLEMENT|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
214278739|NCT01894191|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
214278740|NCT01894191|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
214278741|NCT01894191|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
214278742|NCT04287244|DEVICE|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
214278743|NCT02710565|OTHER|Cohort|Obtaining additional EBUS TBNA samples for cell culture
214278744|NCT02206568|DRUG|URAL|
214278745|NCT03291808|BEHAVIORAL|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
214278746|NCT00902408|DIETARY_SUPPLEMENT|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
214278747|NCT00208611|DIETARY_SUPPLEMENT|Vitamin B12 Supplementation|1000 micrograms daily
214278748|NCT03875885|BEHAVIORAL|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
214278749|NCT03875885|BEHAVIORAL|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
214278750|NCT05814978|OTHER|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
214278751|NCT04669639|OTHER|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia"
214278752|NCT00056524|DRUG|AVP-923|
214278753|NCT05872646|DIAGNOSTIC_TEST|clinical assessment|clinical staging
214278754|NCT04666051|BIOLOGICAL|Application of fibrin glue sealant|
214278755|NCT03684395|DRUG|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
214278756|NCT03684395|DRUG|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
214278757|NCT01265732|DRUG|PF-04191834|single dose, 100mg, dispersion
214278758|NCT01265732|DRUG|PF-04191834|single dose, 100mg, suspension
214278759|NCT01265732|DRUG|PF-04191834|single dose, 300mg, suspension
214278760|NCT05627154|DRUG|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
214278761|NCT05627154|BEHAVIORAL|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
214278762|NCT05627154|DRUG|Placebo|A lactose-based tablet.
214278763|NCT00205738|DRUG|Risperidone, Olanzapine|
214278764|NCT02924779|OTHER|No intervention|Retrospective observational study
214278765|NCT01120301|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
214278766|NCT05014763|PROCEDURE|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
214278767|NCT00719251|DEVICE|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
214278768|NCT00719251|DEVICE|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
214278769|NCT00719251|OTHER|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
214278770|NCT02821182|RADIATION|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."
214278771|NCT03566394|DRUG|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
214278772|NCT03269942|PROCEDURE|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
214278773|NCT03269942|PROCEDURE|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
214278774|NCT02348827|BEHAVIORAL|Family psychoeducation|
214278775|NCT02348827|BEHAVIORAL|Social support group|
214278776|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
214278777|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
214278778|NCT02300584|OTHER|iPad|a tablet computer with an internet connection
214278779|NCT01651195|DIETARY_SUPPLEMENT|Probiotic|
214278780|NCT01651195|OTHER|Placebo|
214278781|NCT02837094|DRUG|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
214278782|NCT00299455|DRUG|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
214278783|NCT00299455|DRUG|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
214278784|NCT02417974|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
214278785|NCT02702505|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
214278786|NCT02702505|OTHER|ProRoot MTA|Control group
214278787|NCT01892293|DRUG|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
214278788|NCT00005045|DRUG|carboxyamidotriazole|
214278789|NCT04988646|DRUG|Acyclovir 200 MG|Administered with 240 mL of water
214278790|NCT04988646|DRUG|Acyclovir 400 MG|Administered with 240 mL of water
214278791|NCT04988646|DRUG|Zovirax 200 MG Tablet|Administered with 240 mL of water
214278792|NCT04988646|DRUG|Zovirax 400 MG Tablet|Administered with 240 mL of water
214278793|NCT00164554|BEHAVIORAL|Parent-child Interaction Therapy (PCIT)|
214278794|NCT00000443|DRUG|ondansetron (Zofran)|
214278795|NCT00569569|DRUG|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
214278796|NCT03506178|DRUG|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
214278797|NCT03506178|DRUG|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
214278798|NCT03506178|DRUG|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
214278799|NCT03506178|DEVICE|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
214278800|NCT03740061|DIAGNOSTIC_TEST|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
214278801|NCT02297477|DRUG|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
214278802|NCT02297477|DRUG|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
214278803|NCT03660267|OTHER|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
214278804|NCT03660267|OTHER|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
214278805|NCT03660267|OTHER|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
214278807|NCT03999372|BIOLOGICAL|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
214278808|NCT03999372|OTHER|ICSI|Normal ICSI procedure
214278809|NCT03490097|DRUG|Simvastatin 10mg|tablets
214278810|NCT03490097|DRUG|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
214278811|NCT03602482|BEHAVIORAL|Standing|Participants will stand and complete cognitive tests.
214278812|NCT03602482|BEHAVIORAL|Supine|Participants will complete cognitive tests while supine.
214278813|NCT02697864|DRUG|tafamidis|
214278814|NCT01140243|DIETARY_SUPPLEMENT|LCPUFA|premature infant formula supplemented with LCPUFA
214278815|NCT02397278|DRUG|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
214278816|NCT04356950|OTHER|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].
214278817|NCT04356950|OTHER|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
214278818|NCT04658498|OTHER|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
214278819|NCT04658498|OTHER|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
214278820|NCT04658498|OTHER|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
214278821|NCT05557981|BEHAVIORAL|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
214278822|NCT06376279|GENETIC|IEM-EP|Data from IEM-inborn error of metabolism cohort of individuals
214278823|NCT05002062|DEVICE|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
214278824|NCT05002062|OTHER|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
214278825|NCT01722084|BEHAVIORAL|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
214278826|NCT02878746|DEVICE|Robotic mirror therapy|2-dimensional
214278827|NCT02878746|DEVICE|Conventional mirror therapy|2- and 3-dimensional
214278828|NCT02161731|DRUG|Evacetrapib|Oral administration
214278829|NCT02161731|DRUG|Warfarin|Oral administration
214278830|NCT00465374|PROCEDURE|Change ventilatory parameters with stress index monitoring|
214278831|NCT05742594|DRUG|Lazertinib|Lazertinib will be administered orally.
214278832|NCT05755048|BIOLOGICAL|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
214278833|NCT05755048|BIOLOGICAL|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
214278834|NCT03935100|PROCEDURE|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
214278835|NCT03935100|OTHER|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
214278836|NCT01738373|DRUG|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
214278837|NCT06293404|DRUG|Bupivacain|7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)
214278838|NCT01991210|DRUG|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
214278839|NCT01991210|DRUG|PLD|PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
214278840|NCT02381288|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
214278841|NCT02381288|DRUG|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
214278842|NCT00657527|DRUG|Rosuvastatin|
214278843|NCT00657527|BEHAVIORAL|Cholesterol lowering diet|
214278844|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
214278845|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
214278846|NCT00869674|PROCEDURE|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
214278847|NCT01397084|DRUG|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
214278848|NCT02139228|BIOLOGICAL|Hib-CRM197|No vaccine administered in V37\_07E2 study
214278849|NCT02139228|BIOLOGICAL|Hib-TT|No vaccine administered in V37\_07E2 study
214278850|NCT03555201|OTHER|Manual therapy|protocol of soft tissues techniques
214278851|NCT03555201|OTHER|Regular treatment control.|Regular treatment control.
214278852|NCT00618072|DRUG|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
214278853|NCT01264497|DRUG|TH9507|1 and 2 mg, sc daily for 12 weeks
214278854|NCT05238441|BIOLOGICAL|SCTV01E|D0; intramuscular injection
214278855|NCT05238441|BIOLOGICAL|Comirnaty|D0; intramuscular injection
214278856|NCT05238441|BIOLOGICAL|SCTV01E|D180; intramuscular injection
214278857|NCT05238441|BIOLOGICAL|Comirnaty|D180; intramuscular injection
214278858|NCT04479423|PROCEDURE|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
214278859|NCT04750148|DIAGNOSTIC_TEST|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
214278860|NCT04750148|DIAGNOSTIC_TEST|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
214278861|NCT04750148|DIAGNOSTIC_TEST|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
214278862|NCT04750148|DIAGNOSTIC_TEST|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
214278863|NCT00592384|DRUG|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
214278864|NCT00592384|DRUG|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
214278865|NCT03120416|BEHAVIORAL|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
214278866|NCT04812691|BIOLOGICAL|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
214278867|NCT01468012|DRUG|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
214278868|NCT01468012|DRUG|Placebo|matched placebo for LCE condition dosed twice daily
214278869|NCT04082312|OTHER|No intervention|No intervention
214278870|NCT04819568|DRUG|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
214278871|NCT04819568|OTHER|Standard of Care|Standard of Care
214278872|NCT05868200|DRUG|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
214278873|NCT05868200|DRUG|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
214278874|NCT04688853|BIOLOGICAL|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
214278875|NCT05887726|DRUG|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
214278876|NCT05887726|DRUG|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
214278877|NCT05887726|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
214278878|NCT05887726|DRUG|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
214278879|NCT05887726|DRUG|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
214278880|NCT05887726|DRUG|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
214278881|NCT02198274|DRUG|BIBH 1|100 mg/week
214278882|NCT04072302|DRUG|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
214278883|NCT04072302|DRUG|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
214278884|NCT01029626|PROCEDURE|Endoscopy|Realization of an upper GI endoscopy
214278885|NCT06446700|OTHER|neck disability index and visual functional questionnaire|participants complete the 2 questionnaire by an online form and paper
214278886|NCT00436683|DRUG|Fermagate|Film coated tablet 500mg
214278887|NCT00436683|DRUG|Sevelamer HCl|tablet 800mg
214278888|NCT00487773|DRUG|budesonide|budesonide
214278889|NCT00487773|DRUG|D3 vitamin|D3 vitamin
214278890|NCT00487773|DRUG|montelukast sodium|montelukast sodium
214278891|NCT00487773|DRUG|salbutamol|salbutamol
214278892|NCT01087398|DRUG|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
214278893|NCT01087398|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
214278894|NCT01087398|DRUG|Cyclosporin, Methotrexate (GVHD prophylaxis)|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
214278895|NCT03876444|DRUG|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
214278896|NCT03876444|DRUG|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
214278897|NCT00798499|OTHER|Laboratory variables|1 visit
214278898|NCT01167894|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
214278899|NCT02380677|DRUG|CRLX301|
214278900|NCT03902821|OTHER|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
214278901|NCT02968953|DRUG|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
214278902|NCT06033794|DEVICE|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
214278903|NCT01512277|BIOLOGICAL|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
214278904|NCT03629132|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
214278905|NCT03629132|PROCEDURE|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
214278906|NCT05295511|OTHER|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
214278907|NCT04522362|OTHER|Control task and Trier Social Stress Task|Same as Arm
214278908|NCT03519425|OTHER|Optimised HIV screening and linkage to care|As described in group descriptions
214278909|NCT03519425|OTHER|Optimised tuberculosis screening and linkage to care|As described in group descriptions
214278910|NCT03041597|PROCEDURE|placement of implants|surgical procedure and placement of implants
214278911|NCT03041597|PROCEDURE|immediate loading|cone-anchored implant supported removable dental prostheses placement
214278912|NCT03041597|PROCEDURE|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
214278913|NCT03041597|DEVICE|Ankylos implant|
214278914|NCT00889460|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
214278915|NCT00889460|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
214278916|NCT06457321|PROCEDURE|Sequence in receiving the fabricated dentures made using the conventional and partial digital method|Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
214278917|NCT05349916|OTHER|Control|300 g rice porridge + 150 ml drinking water
214278918|NCT05349916|OTHER|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
214278919|NCT05349916|OTHER|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
214278920|NCT05349916|OTHER|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
214278921|NCT05349916|OTHER|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
214278922|NCT06201377|OTHER|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
214278923|NCT06201377|OTHER|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
214278924|NCT00284271|DRUG|Cyclophosphamide|
214278925|NCT00284271|DRUG|Adramycin|
214278926|NCT00284271|DRUG|Procarbacine|
214278927|NCT00284271|DRUG|Prednisone|
214278928|NCT00284271|DRUG|Vincristine|
214278929|NCT00284271|DRUG|Bleomycin|
214278930|NCT00284271|DRUG|Erythropoietin beta|
214278931|NCT05234151|OTHER|NEWS|Newborn Early Warning Score
214278932|NCT03598621|DRUG|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
214278933|NCT03598621|DRUG|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
214278934|NCT03598621|DRUG|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
214278935|NCT03598621|DRUG|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
214278936|NCT03598621|DEVICE|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
214278937|NCT03598621|DEVICE|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
214278938|NCT03598621|DEVICE|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
214278939|NCT03598621|DEVICE|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
214278940|NCT00134095|DRUG|irinotecan hydrochloride|
214278941|NCT00134095|DRUG|tegafur-gimeracil-oteracil potassium|
214278942|NCT00134095|PROCEDURE|adjuvant therapy|
214278943|NCT00134095|PROCEDURE|conventional surgery|
214278944|NCT00134095|PROCEDURE|neoadjuvant therapy|
214278945|NCT06957912|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. All conscious patients will be told they may or may not feel any sensation from the stimulation.~The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery."
214278946|NCT06957912|DEVICE|Sham stimulation|Sham stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. And the current will be automatically switched off after 15 s. All conscious patients will be told they may or may not feel any sensation from the stimulation. The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery.
214278947|NCT01023750|DRUG|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
214278948|NCT05004766|OTHER|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
214278949|NCT00314665|DRUG|Thalidomide|
214278950|NCT06476561|OTHER|- Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D|"The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance."
214278951|NCT01659775|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
214278952|NCT01659775|DRUG|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
214278953|NCT03354611|RADIATION|Contrast Enhanced Cone Beam Breast CT Scan|"* Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
214278954|NCT03354611|DRUG|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement."
214278955|NCT04610840|PROCEDURE|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
214278956|NCT04932096|DRUG|melatonin|melatonin supplementation
214278957|NCT04932096|OTHER|placebo|microcrystalline cellulose filled capsule
214278958|NCT03910842|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
214278959|NCT01089062|DRUG|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
214278960|NCT01089062|DRUG|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
214278961|NCT01089062|DRUG|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
214278962|NCT01089062|DRUG|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
214278963|NCT03939260|OTHER|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).
214278964|NCT03004456|OTHER|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
214278965|NCT00461045|DRUG|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
214278966|NCT00133952|DRUG|Ruboxistaurin|Administered orally
214278967|NCT00133952|DRUG|Placebo|Administered orally
214278968|NCT03254836|OTHER|Standard of care|Elective radical surgery for adenocarcinoma.
214278969|NCT02807532|OTHER|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
214278970|NCT02807532|OTHER|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
214278971|NCT00314093|DRUG|RFT5pdgA|
214278972|NCT06499597|OTHER|Observation|All individuals included in the study will be included in this group and evaluations will be made.
214278973|NCT04366102|OTHER|Multisensory stimulation with soft tissue therapy|Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week
214278974|NCT04366102|OTHER|Routine hospital care|Routine hospital care will be given to the preterm neonates
214278975|NCT01461603|DIETARY_SUPPLEMENT|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
214278976|NCT01461603|DIETARY_SUPPLEMENT|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
214278977|NCT04293120|OTHER|Training with weighted ball|Participants will stop or catch a weighted ball
214278978|NCT01976338|DRUG|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
214278979|NCT01976338|OTHER|Sham injection|Sham intravitreal injection
214278980|NCT00040573|DRUG|131I-TM-601|
214278981|NCT00987675|OTHER|pharmacological study|
214278982|NCT00987675|OTHER|questionnaire administration|
214278983|NCT00987675|PROCEDURE|assessment of therapy complications|
214278984|NCT00987675|PROCEDURE|high-intensity focused ultrasound ablation|
214278985|NCT00987675|PROCEDURE|quality-of-life assessment|
214278986|NCT03530878|PROCEDURE|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
214278987|NCT01655914|DRUG|Flumazenil|
214278988|NCT06378255|DEVICE|Polycation-based new dentinal desensitizer|Dental desensitization treatment
214278989|NCT06378255|DEVICE|GLUMA desensitizer|Dental desensitization treatment
214278990|NCT00777608|DRUG|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
214278991|NCT00777608|DRUG|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
214278992|NCT00777608|DRUG|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
214278993|NCT00777608|DRUG|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
214278994|NCT00158990|DRUG|triiodothyronine|
214278995|NCT00158990|DRUG|sertraline|
214278996|NCT03148132|DRUG|Bevacizumab Injection|0.5mg/0.02 mL
214278997|NCT03148132|DRUG|Ranibizumab Ophthalmic|0.25mg/0.025 mL
214278998|NCT04303819|DRUG|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
214278999|NCT01754701|DIETARY_SUPPLEMENT|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
214279000|NCT01754701|DIETARY_SUPPLEMENT|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
214279001|NCT05278767|OTHER|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
214279002|NCT01482000|OTHER|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
214279003|NCT01482000|OTHER|usual care|The control group will get the usual care with some additional tests for the study.
214279004|NCT04213079|DEVICE|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
214279005|NCT04213079|DEVICE|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
214279006|NCT00682162|DEVICE|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
214279007|NCT00682162|DEVICE|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
214279008|NCT00528788|DRUG|doxercalciferol|
214279009|NCT02039492|PROCEDURE|Sympathetic Renal Denervation|
214279010|NCT02039492|DRUG|Treatment with aldactone|
214279011|NCT01145443|OTHER|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
214279012|NCT04786015|OTHER|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
214279013|NCT00844714|DRUG|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
214279014|NCT02469753|DRUG|NSAIDs|continuous daily
214279015|NCT02469753|DRUG|NSAIDs|on demand
214279016|NCT02469753|DRUG|anti-TNF|
214279017|NCT03766581|DRUG|BMS-986177|Oral administration
214279018|NCT03766581|OTHER|Placebo|Oral Administration
214279019|NCT03766581|DRUG|Clopidogrel|Oral administration
214279020|NCT03766581|DRUG|Aspirin|Oral administration
214279021|NCT03501316|DEVICE|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
214279022|NCT03501316|DEVICE|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
214279023|NCT02164500|DRUG|Ruxolitinib|
214279024|NCT06436365|PROCEDURE|Locking expert intramedullary nail fixation|"the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement."
214279025|NCT06436365|PROCEDURE|Distal locked plate|Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
214279026|NCT02556814|DRUG|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
214279027|NCT02556814|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
214279028|NCT02556814|DRUG|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
214279029|NCT00652405|DIETARY_SUPPLEMENT|alcohol|250 ml of white wine (13% vol; \~25 gram of alcohol per day)
214279030|NCT00652405|DIETARY_SUPPLEMENT|Placebo|250 ml of mineral water (Brand name: Vittel)
214279031|NCT02732119|DRUG|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
214279032|NCT02732119|DRUG|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
214279033|NCT02732119|DRUG|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
214279034|NCT02648776|DRUG|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
214279035|NCT00728871|PROCEDURE|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
214279036|NCT03719521|OTHER|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
214279037|NCT01189903|DRUG|Regorafenib|
214279038|NCT00144053|DRUG|Cisplatin+Vindesine+MMC/ concurrent radiation|
214279039|NCT00144053|DRUG|Irinotecan+Carboplatin/concurrent radiation|
214279040|NCT00144053|DRUG|Paclitaxel+Carboplatin/concurrent radiation|
214279041|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
214279042|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
214279043|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
214279044|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
214279045|NCT00520936|DRUG|pemetrexed|1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
214279046|NCT04229394|DRUG|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
214279047|NCT04229394|DRUG|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
214279048|NCT00964860|DEVICE|Glide dental floss|Glide waxed dental floss
214279049|NCT02254187|DRUG|Salmeterol capsule - low|
214279050|NCT02254187|DRUG|Salmeterol capsule - high|
214279051|NCT02254187|DRUG|Salmeterol via Serevent® Diskus®|
214279052|NCT02617745|OTHER|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
214279053|NCT05251090|DRUG|ADVATE|50 international units (IU)/kg, a single dose.
214279054|NCT05251090|DRUG|FRSW107|50 IU/kg, a single dose.
214279055|NCT03025477|DRUG|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
214279056|NCT03025477|DRUG|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
214279057|NCT03025477|DRUG|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
214279058|NCT03025477|DRUG|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
214279059|NCT05808972|DRUG|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
214279060|NCT05808972|DRUG|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
214279061|NCT05531760|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
214279062|NCT05408949|BEHAVIORAL|Single exercise into pain (SEP) program|"* Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program"
214279063|NCT05408949|BEHAVIORAL|Shoulder Symptom Modification Procedure (SSMP)|\[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
214279064|NCT05408949|BEHAVIORAL|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
214279065|NCT05408949|BEHAVIORAL|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
214279066|NCT05408949|BEHAVIORAL|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
214279067|NCT04885361|BIOLOGICAL|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
214279068|NCT03053544|DRUG|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
214279069|NCT03716024|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
214279070|NCT03716024|DRUG|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
214279071|NCT04425694|DEVICE|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
214279072|NCT04346602|OTHER|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
214279073|NCT00867568|DRUG|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
214279074|NCT02923934|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
214279075|NCT02923934|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
214279076|NCT02221193|OTHER|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
214279077|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
214279078|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
214279079|NCT01434069|DRUG|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
214279080|NCT01434069|DRUG|FOLFIRI Infusion|Standard therapy of FOLFIRI
214279081|NCT04343261|BIOLOGICAL|Convalescent Plasma|treatment with 2 Units of convalescent plasma
214279082|NCT04278638|RADIATION|IORT|IORT in surgery of laryngocarcinoma
214279083|NCT04278638|PROCEDURE|surgery|total laryngectomy or hemilaryngectomy
214279084|NCT04278638|RADIATION|External radiotherapy|External radiotherapy
214279085|NCT01803373|DRUG|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
214279086|NCT01803373|DRUG|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
214279087|NCT01803373|DRUG|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
214279088|NCT02123121|DRUG|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
214279089|NCT02123121|DRUG|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
214279090|NCT02123121|OTHER|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
214279091|NCT02123121|OTHER|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
214279092|NCT01007773|DRUG|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
214279093|NCT01007773|DRUG|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
214279094|NCT01007773|DRUG|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
214279095|NCT01007773|DRUG|Propofol|Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
214279096|NCT01751425|DRUG|Dasatinib|Given PO
214279097|NCT01751425|DRUG|Imatinib Mesylate|Given PO
214279098|NCT01751425|DRUG|Nilotinib|Given PO
214279099|NCT01751425|DRUG|Ruxolitinib|Given PO
214279100|NCT03878628|DRUG|Adipose tissue-derived mesenchymal stem cells|CSCC\_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
214279101|NCT02759328|BEHAVIORAL|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
214279102|NCT02759328|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
214279103|NCT00975650|DRUG|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
214279104|NCT00975650|DRUG|Androderm® (Positive Control)|QD administration
214279105|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
214279106|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Standard treatment
214279107|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Intensified treatment
214279108|NCT03639935|DRUG|Rucaparib|Rucaparib 600 mg PO BID days 1-28
214279109|NCT03639935|DRUG|Nivolumab|Nivolumab 240 mg IV days 1 and 15
214279110|NCT01050712|DRUG|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
214279111|NCT01050712|DRUG|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
214279112|NCT02612662|DRUG|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
214279113|NCT02612662|DRUG|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
214279114|NCT02683161|DRUG|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
214279115|NCT02683161|BEHAVIORAL|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
214279116|NCT02683161|BEHAVIORAL|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
214279117|NCT03781115|DRUG|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
214279118|NCT03781115|DRUG|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
214279119|NCT03781115|DRUG|Placebo Comparator|A non drug oral placebo capsule will be given as a control
214279120|NCT06193252|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
214279121|NCT05525208|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
214279122|NCT05525208|BIOLOGICAL|Active Comparator|The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
214279123|NCT02228629|DEVICE|CrocsRx Medical Silver cloud clogs|
214279124|NCT06636786|DRUG|Cyclobenzaprine HCl|TNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
214279125|NCT06636786|DRUG|Placebo|Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
214279126|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
214279127|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
214279128|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
214279129|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
214279130|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
214279131|NCT06642571|DRUG|NNC0519-0130 B|NNC0519-0130 B will be administered subcutaneously.
214279132|NCT06642571|DRUG|NNC0519-0130 C|NNC0519-0130 C will be administered subcutaneously.
214279133|NCT00003479|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
214279134|NCT06125145|BEHAVIORAL|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
214279135|NCT03102255|PROCEDURE|Sniffing position|All procedure is done under sniffing position.
214279136|NCT03102255|PROCEDURE|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
214279137|NCT01293175|DIETARY_SUPPLEMENT|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
214279138|NCT03195998|DIAGNOSTIC_TEST|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
214279139|NCT01061177|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
214279140|NCT00299104|DRUG|folate|Intravenous repeating dose
214279141|NCT00299104|DRUG|methotrexate|Oral or parenteral repeating dose
214279142|NCT00299104|DRUG|methylprednisolone|Intravenous repeating dose
214279143|NCT00299104|DRUG|placebo|Intravenous repeating dose
214279144|NCT00299104|DRUG|rituximab|Intravenous repeating dose
214279145|NCT02454400|OTHER|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active"
214279146|NCT02454400|OTHER|Waiting-list|"Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active"
214279147|NCT00587054|DRUG|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
214279148|NCT03680105|DRUG|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
214279149|NCT03680105|DRUG|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
214279150|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
214279151|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
214279152|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
214279153|NCT03701347|DEVICE|Reeve's model|Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
214279154|NCT03701347|DEVICE|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
214279155|NCT03701347|DEVICE|Ida's model|Reusable, portable and modular 3D printed simulator
214279156|NCT05873257|DEVICE|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
214279157|NCT06390306|DRUG|Ponatinib|Ponatinib is recommended orally (PO) daily continuously on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
214279158|NCT06390306|DRUG|Azacitidine|Azacitidine is recommended 75mg/m2 subcutaneously on days 1-7 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
214279159|NCT06390306|DRUG|Venetoclax|Venetoclax is recommended orally (PO) daily on days 1-14 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
214279160|NCT06390306|DRUG|Olverembatinib|Olverembatinib is recommended orally (PO) every other day on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
214279161|NCT06294145|BEHAVIORAL|Savoring Intervention|The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
214279162|NCT05847842|PROCEDURE|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
214279163|NCT05847842|PROCEDURE|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
214279164|NCT05847842|PROCEDURE|Local infiltration|20 mL of 0.25% bupivacaine will be given
214279165|NCT02060123|BEHAVIORAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
214279166|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
214279167|NCT05988970|OTHER|Blood samples will be collected at two times before the treatment initiation:|"* at 4:00 a.m.~* at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
214279168|NCT03636984|DRUG|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
214279169|NCT03222960|DRUG|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
214279170|NCT03222960|DRUG|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
214279171|NCT03210571|DEVICE|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
214279172|NCT00109083|DRUG|RWJ-333369|
214279173|NCT02759783|RADIATION|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
214279174|NCT02759783|OTHER|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
214279175|NCT02147470|DRUG|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
214279176|NCT02059395|OTHER|Mastery based learning|Participants are allowed to follow the course content at their own speed
214279177|NCT02059395|OTHER|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
214279178|NCT03730571|DEVICE|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
214279179|NCT02710474|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
214279180|NCT02710474|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
214279181|NCT05561699|DRUG|Penpulimab Combined With CRT|"1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
214279182|NCT00454012|PROCEDURE|biophysical profile|
214279183|NCT06313775|PROCEDURE|bilateral orchiectomy|Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
214279184|NCT01433705|OTHER|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
214279185|NCT01433705|OTHER|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
214279186|NCT01433705|OTHER|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
214279187|NCT01433705|DRUG|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
214279188|NCT04728399|DIETARY_SUPPLEMENT|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
214279189|NCT04728399|DIETARY_SUPPLEMENT|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
214279190|NCT00006161|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
214279191|NCT00006161|PROCEDURE|Distal Splenorenal Shunt|
214279192|NCT06298591|PROCEDURE|co2 laser|laser
214279193|NCT05993130|OTHER|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
214279194|NCT04959903|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
214279195|NCT04343469|PROCEDURE|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
214279196|NCT00707720|DEVICE|TERIS procedure|The implantation of the restrictive implant
214279197|NCT00463112|DRUG|Sibutramine|
214279198|NCT00044083|OTHER|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
214279199|NCT00044083|DRUG|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
214279200|NCT00910026|PROCEDURE|low tidal volume ventilation|6 ml/kg tidal volume ventilation
214279201|NCT00910026|PROCEDURE|high tidal volume ventilation|12 ml/kg tidal volume ventilation
214279202|NCT05075122|BIOLOGICAL|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
214279203|NCT05075122|DRUG|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
214279204|NCT05075122|DRUG|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
214279205|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
214279206|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
214279207|NCT05304273|DRUG|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
214279208|NCT05304273|DRUG|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
214279209|NCT01970215|DRUG|TA-8995|
214279210|NCT01970215|DRUG|Atorvastatin|
214279211|NCT01970215|DRUG|Rosuvastatin|
214279212|NCT01970215|DRUG|TA-8995 0mg (placebo)|
214279213|NCT01970215|DRUG|Placebo Statin|
214279214|NCT03622944|PROCEDURE|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
214279215|NCT03622944|PROCEDURE|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
214279216|NCT03622944|PROCEDURE|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
214279217|NCT03441308|BEHAVIORAL|Educational method of group treatment|
214279218|NCT03493594|OTHER|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
214279219|NCT04077268|OTHER|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
214279220|NCT03680690|PROCEDURE|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
214279221|NCT04556162|DIAGNOSTIC_TEST|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
214279222|NCT04556162|OTHER|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
214279223|NCT04220320|DIAGNOSTIC_TEST|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
214279224|NCT04220320|DIAGNOSTIC_TEST|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
214279225|NCT01619423|DRUG|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
214279226|NCT01619423|DRUG|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
214279227|NCT01619423|DRUG|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
214279228|NCT01619423|DRUG|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
214279229|NCT06169384|DEVICE|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
214279230|NCT03857958|PROCEDURE|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
214279231|NCT05598541|PROCEDURE|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
214279232|NCT04343547|DRUG|DWP16001|Tablets, Oral, once daily single dose
214279233|NCT04343547|DRUG|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
214279234|NCT04343547|DRUG|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
214279235|NCT05417139|OTHER|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
214279236|NCT00138580|DRUG|vildagliptin|
214279237|NCT03140943|DRUG|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
214279238|NCT06014203|DIAGNOSTIC_TEST|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel"
214279239|NCT04344392|DIAGNOSTIC_TEST|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
214279240|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
214279241|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
214279242|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
214279243|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
214279244|NCT02340975|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion.
214279245|NCT02340975|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion.
214279246|NCT02340975|BIOLOGICAL|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
214279247|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
214279248|NCT02034383|OTHER|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
214279249|NCT02034383|OTHER|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
214279250|NCT02034383|OTHER|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
214279251|NCT02034383|OTHER|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
214279252|NCT02034383|OTHER|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
214279253|NCT04003012|DRUG|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
214279254|NCT04003012|DRUG|Lidocaine|lidocaine 1%
214279255|NCT00120835|DRUG|valopicitabine|
214279256|NCT00120835|DRUG|pegylated interferon|
214279257|NCT03564314|OTHER|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
214279258|NCT02482506|BEHAVIORAL|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
214279259|NCT02482506|BEHAVIORAL|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
214279260|NCT00720538|DRUG|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
214279261|NCT00720538|DRUG|placebo|placebo capsules
214279262|NCT06044428|DEVICE|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
214279263|NCT02908360|GENETIC|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
214279264|NCT03273114|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
214279265|NCT03273114|OTHER|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
214279266|NCT00848874|BEHAVIORAL|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
214279267|NCT03675477|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
214839769|NCT04330547|DRUG|Analgesic administration|"* Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
214839770|NCT04330547|DRUG|Placebo administration|Folavit (folic acid, 0.4 mg)
214279268|NCT03675477|DRUG|Placebo|Placebo Oral Tablet
214279269|NCT02936830|DRUG|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
214279270|NCT02936830|DRUG|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
214279271|NCT02936830|DRUG|Glycerol|Glycerol with water in a 1: 1 ratio
214279272|NCT01929798|DEVICE|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
214279273|NCT02523248|PROCEDURE|tonsillectomy|Tonsillectomy with cold steel
214279274|NCT02523248|PROCEDURE|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
214279275|NCT04286243|OTHER|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
214279276|NCT04286243|OTHER|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
214279277|NCT00038220|DRUG|Lopinavir/ritonavir|
214279278|NCT00038220|DRUG|Efavirenz|
214839771|NCT00358631|DRUG|SSR149415|
214279279|NCT00038220|DRUG|Lamivudine|
214279280|NCT00038220|DRUG|Tenofovir DF|
214839772|NCT05445570|DIAGNOSTIC_TEST|Non-Interventional|This is an observational, non interventional study
214839773|NCT03853369|DRUG|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
214279281|NCT01949558|BEHAVIORAL|Dietary Intervention|
214279282|NCT00702611|DEVICE|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
214279283|NCT03548259|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma injection
214279284|NCT03548259|PROCEDURE|Platelet-poor plasma|Platelet-poor plasma injection
214279285|NCT03365830|DIAGNOSTIC_TEST|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
214279286|NCT00790985|DIETARY_SUPPLEMENT|flavocoxid|medical food
214279287|NCT00790985|DRUG|Naproxen|antiinflammatory drug
214279288|NCT03187106|DRUG|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
214279289|NCT03187106|DRUG|Placebo|Placebo representing standard of care
214279290|NCT03187106|DRUG|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
214279291|NCT03203304|DRUG|Nivolumab|240mg every two weeks by IV infusion
214279292|NCT03203304|DRUG|Ipilimumab|1mg/kg every six weeks by IV infusion
214279293|NCT00601458|DRUG|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
214279294|NCT00601458|DRUG|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
214279295|NCT00601458|DRUG|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
214279296|NCT03445208|DRUG|BMS-986036|Crossover administration to abdomen then upper arm
214279297|NCT06229990|DRUG|Furosemide Injection|After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
214279298|NCT00524862|DRUG|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
214279299|NCT00524862|DEVICE|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
214279300|NCT00000430|DRUG|Alendronate|
214279301|NCT00000430|DRUG|Estrogen/progestin therapy|
214279302|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
214279303|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
214279304|NCT00816530|DEVICE|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
214279305|NCT00696722|DRUG|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
214279306|NCT00696722|DRUG|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
214279307|NCT05759728|BIOLOGICAL|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10\^7 cells - intravenous infusion
214279308|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10\^8 cells - intravenous infusion
214279309|NCT05759728|BIOLOGICAL|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10\^8 cells - intravenous infusion
214279310|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10\^9 cells - intravenous infusion
214279311|NCT05759728|BIOLOGICAL|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10\^7 cells - intravenous infusion
214279312|NCT01288235|RADIATION|Proton radiotherapy|5 days a week
214279313|NCT03984240|DRUG|Midazolam|Participant will be sedated by midazolam.
214279314|NCT03984240|DRUG|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
214279315|NCT00082251|DRUG|Niacin extended release and simvastatin tablets|
214279316|NCT04802291|BEHAVIORAL|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
214279317|NCT01284829|OTHER|FDG-PET scan|
214279318|NCT03655509|PROCEDURE|Dynamic test ACTH stimulation|
214279319|NCT01452828|DRUG|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
214279320|NCT01452828|DRUG|TR-701 FA|Two separate infusions of 200 mg
214279321|NCT01452828|DRUG|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
214279322|NCT03026400|PROCEDURE|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
214279323|NCT03026400|PROCEDURE|Subumbilical incision|Considered here as the ''control'' intervention.
214279324|NCT01697566|DRUG|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
214279325|NCT01697566|OTHER|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
214279326|NCT01697566|PROCEDURE|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
214279327|NCT01697566|BEHAVIORAL|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
214839774|NCT06073847|DRUG|Fedratinib|According to the approved label
214279328|NCT01697566|BEHAVIORAL|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
214279329|NCT06163729|DRUG|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
214279330|NCT01709162|BIOLOGICAL|Ipilimumab|
214279331|NCT01709162|DRUG|Chemotherapy|
214279332|NCT01805154|DEVICE|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
214279333|NCT00969696|DRUG|Placebo|8Mg a day of a sugar pill
214279334|NCT00969696|DRUG|Galantamine|8mg of Galantamine
214279335|NCT02856035|OTHER|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
214279336|NCT05328063|OTHER|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
214279337|NCT05328063|OTHER|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
214279338|NCT05540457|DEVICE|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
214279339|NCT04733404|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
214279340|NCT00057889|BIOLOGICAL|ipilimumab|
214279341|NCT05086848|DRUG|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
214279342|NCT04790422|DIETARY_SUPPLEMENT|Dietary fiber supplement|Dietary fiber
214279343|NCT04790422|DIETARY_SUPPLEMENT|Caseine protein hydrolisate|Dietary supplement
214279344|NCT04790422|DIETARY_SUPPLEMENT|Maltrodextrine|Placebo comparator
214279345|NCT06059794|OTHER|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
214279346|NCT06059794|OTHER|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
214279347|NCT04614220|BEHAVIORAL|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
214279348|NCT06301334|DRUG|Bupivacaine 0.25% Injectable Solution|Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
214279349|NCT05430932|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
214279350|NCT02405780|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
214279351|NCT02405780|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
214279352|NCT01654536|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
214279353|NCT01654536|DRUG|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
214279354|NCT01930864|DRUG|metformin|metformin up to 2500mg/d
214279355|NCT01930864|DRUG|irinotecan|Irinotecan 350 mg/m² IV q21d
214279356|NCT01560793|BIOLOGICAL|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
214279357|NCT06083285|OTHER|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
214279358|NCT01587001|DIETARY_SUPPLEMENT|N-acetyl-cysteine|900mg three times daily for 8 weeks
214279359|NCT01587001|DRUG|Placebo|Matching placebo three times daily for 8 weeks.
214279360|NCT00828659|DRUG|Placebo|
214279361|NCT00828659|DRUG|Active Comparator #1|
214279362|NCT00828659|DRUG|Active Comparator #2|
214279363|NCT00828659|DRUG|Active Comparator #3|
214279364|NCT00828659|DRUG|Lorcaserin Dose #1|
214279365|NCT00828659|DRUG|Lorcaserin Dose #2|
214279366|NCT00828659|DRUG|Lorcaserin Dose #3|
214279367|NCT04800744|OTHER|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
214279368|NCT04800744|OTHER|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
214279369|NCT00608686|DIETARY_SUPPLEMENT|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
214279370|NCT00317512|PROCEDURE|Percutaneous Coronary Revascularization|
214279371|NCT00317512|DRUG|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
214279372|NCT00317512|DRUG|Voluven|
214279373|NCT06265246|OTHER|Habitual Diet + Milk|1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
214279374|NCT06265246|OTHER|Habitual Diet + Yogurt|2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
214279375|NCT06234917|OTHER|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
214279376|NCT00002307|DRUG|Stavudine|
214279377|NCT00002307|DRUG|Zidovudine|
214279378|NCT06116760|DEVICE|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
214279379|NCT06116760|BEHAVIORAL|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
214279380|NCT04528108|DRUG|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
214279381|NCT04528108|DRUG|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
214279382|NCT00074152|DRUG|chemotherapy|Given within 10 weeks after surgery.
214279383|NCT00074152|RADIATION|radiation therapy|Given within 6 months after surgery
214279384|NCT03017495|DRUG|Midazolam|2 mg/mL oral solution
214279385|NCT03017495|DRUG|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
214279386|NCT02197130|DRUG|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
214279387|NCT02197130|DRUG|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
214279388|NCT02197130|OTHER|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
214279389|NCT03275376|DRUG|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
214279390|NCT03275376|DRUG|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
214279391|NCT02835924|DRUG|Regorafenib|
214279392|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
214279393|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
214279394|NCT02566434|DIETARY_SUPPLEMENT|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
214279395|NCT00003325|PROCEDURE|Sentinel lymph node mapping|Sentinel lymph node mapping
214279396|NCT01502059|OTHER|Pilates|Pilates training - twice a week (one hour per class) during 90 days
214279397|NCT02898337|DEVICE|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
214279398|NCT02615366|DRUG|Tranexamic Acid|
214279399|NCT02615366|DRUG|Placebo|
214279400|NCT06337331|DRUG|Venetoclax|400mg/day PO Days -8 to -2
214279401|NCT06337331|DRUG|Decitabine|20mg/m2/day IV Days -7 to -3
214279402|NCT06337331|DRUG|Fludarabine|30mg/m2/day IV Days -7 to -3
214279403|NCT06337331|DRUG|Busulfan|3.2mg/kg/day IV Days -5 to -4
214279404|NCT06337331|RADIATION|Total Body Irradiation|200cGy Day -2
214279405|NCT05894928|DRUG|LOXO-783|Administered orally.
214279406|NCT05894928|DRUG|Cholestyramine|Administered orally.
214279407|NCT05124964|OTHER|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
214279408|NCT05124964|OTHER|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
214279409|NCT05124964|OTHER|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
214279410|NCT05673278|DIAGNOSTIC_TEST|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~\+ Image quality"
214279411|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
214279412|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
214279413|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
214279414|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
214279415|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
214279416|NCT02301884|BIOLOGICAL|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
214279417|NCT05137106|OTHER|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
214279418|NCT05137106|OTHER|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
214279419|NCT01995240|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
214279420|NCT01473836|DRUG|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
214279421|NCT01473836|DRUG|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
214279422|NCT01675414|OTHER|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
214279423|NCT00878774|BIOLOGICAL|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
214279424|NCT00878774|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
214279425|NCT01993654|PROCEDURE|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
214279427|NCT05261360|DRUG|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
214279428|NCT05261360|DRUG|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
214839775|NCT04606017|DRUG|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
214279429|NCT01166113|DRUG|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
214279430|NCT05450341|DEVICE|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
214279431|NCT05450341|DEVICE|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
214279432|NCT03364023|DEVICE|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
214279433|NCT04998461|BIOLOGICAL|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
214279434|NCT04068662|BEHAVIORAL|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
214279435|NCT04068662|BEHAVIORAL|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
214279436|NCT05439161|DEVICE|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
214279437|NCT02753023|OTHER|no intervention|No intervention related
214279438|NCT06037434|DRUG|Captopril Tablets|0.3mg/kg, tid
214279439|NCT06037434|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
214279440|NCT06037434|DRUG|Spironolactone Tablets|2-4mg/kg, bid
214279441|NCT06037434|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
214279442|NCT06037434|DRUG|Potassium citrate powder|0.06g/kg, tid
214279443|NCT04519125|DRUG|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
214279444|NCT04519125|OTHER|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
214279445|NCT01029574|OTHER|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
214279446|NCT00963196|DIETARY_SUPPLEMENT|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
214279447|NCT00963196|DRUG|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
214279448|NCT02356575|OTHER|Acupuncture|
214279449|NCT02356575|OTHER|Cognitive Behavior Therapy|
214279450|NCT05577442|DRUG|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
214279451|NCT00844389|DEVICE|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
214279452|NCT00844389|DEVICE|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
214279453|NCT00000688|DRUG|Ganciclovir|
214279454|NCT00105469|DRUG|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
214279455|NCT00105469|DRUG|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
214279456|NCT04254471|DRUG|AL3810|5mgQD, 7.5mgQD, 10mgQD
214279457|NCT04254471|DRUG|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
214279458|NCT04254471|DRUG|Placebo|Placebo
214279459|NCT03444961|DEVICE|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
214279460|NCT02598544|OTHER|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
214279461|NCT01437722|DRUG|1% SPL7013 Gel|vaginal gel
214279462|NCT01437722|DRUG|3% SPL7013 Gel|vaginal gel
214279463|NCT01437722|DRUG|placebo gel|vaginal gel
214279464|NCT03205033|DRUG|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
214279465|NCT03205033|DRUG|Placebo oral capsule|1 capsule/day 1 hour before go to bed
214279466|NCT03558854|DRUG|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
214279467|NCT03558854|DRUG|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
214279468|NCT01270412|BIOLOGICAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
214279469|NCT01270412|DRUG|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
214839776|NCT05853783|OTHER|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
214279470|NCT02417597|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
214279471|NCT03023475|DEVICE|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
214279472|NCT03023475|DEVICE|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
214279473|NCT02787668|OTHER|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
214279474|NCT02787668|OTHER|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
214279475|NCT03517098|PROCEDURE|The ERAS group|"ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
214279476|NCT03517098|PROCEDURE|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
214279477|NCT00501670|PROCEDURE|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
214279478|NCT00501670|PROCEDURE|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
214279479|NCT06247020|DIETARY_SUPPLEMENT|Supplementation with sodium- butyrrate|Oral supplementation with sodium butyrrate capsules
214279480|NCT06247020|DIETARY_SUPPLEMENT|Placebo|Oral supplementation with placebo capsules
214279481|NCT00552721|OTHER|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
214279482|NCT00552721|OTHER|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
214279483|NCT04678271|BEHAVIORAL|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
214279484|NCT03736616|DRUG|Carboplatin|Chemotherapy
214279485|NCT03736616|DRUG|Ifosfamide|Chemotherapy
214279486|NCT03736616|DRUG|Etoposide|Chemotherapy
214279487|NCT03736616|BIOLOGICAL|Rituximab|Anti-CD20 mAb
214279488|NCT03736616|DRUG|Carmustine|Chemotherapy
214279489|NCT03736616|DRUG|Cytarabine|Chemotherapy
214279490|NCT03736616|DRUG|Melphalan|Chemotherapy
214279491|NCT03736616|OTHER|Autologous HSCT|Cellular Therapy
214279492|NCT03736616|DRUG|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
214279493|NCT01095445|DRUG|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
214279494|NCT03947372|PROCEDURE|Appendectomy|removal of acutely inflamed appendix
214279495|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
214279496|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
214279497|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
214279498|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
214279499|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
214279500|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
214279501|NCT00599924|DRUG|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
214279502|NCT02601469|DRUG|DSXS|twice daily for 28 days
214279503|NCT01806298|DRUG|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
214279504|NCT02638545|DRUG|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
214279505|NCT05503394|BEHAVIORAL|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
214279506|NCT05503394|BEHAVIORAL|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
214279507|NCT03588039|DRUG|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
214279508|NCT03588039|BIOLOGICAL|Pembrolizumab|Intravenously administered
214279509|NCT05581420|DRUG|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
214279510|NCT05581420|DRUG|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
214279511|NCT00301665|BIOLOGICAL|Botulinum toxin type A|
214279512|NCT03619954|BIOLOGICAL|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
214279513|NCT03808545|BEHAVIORAL|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
214279514|NCT03808545|BEHAVIORAL|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
214279515|NCT00517998|DRUG|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
214279516|NCT04062175|DRUG|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
214279517|NCT04062175|DRUG|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
214279518|NCT03792581|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
214279519|NCT03229278|DRUG|Enzyme Inhibitor Therapy|Given trigriluzole PO
214279520|NCT03229278|OTHER|Laboratory Biomarker Analysis|Correlative studies
214279521|NCT03229278|BIOLOGICAL|Nivolumab|Given IV
214279522|NCT03229278|BIOLOGICAL|Pembrolizumab|Given IV
214279523|NCT02292277|DRUG|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
214279524|NCT00630981|BEHAVIORAL|Psychotherapy|Specific psychotherapy for dissociative disorders
214279525|NCT00630981|DRUG|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
214279526|NCT03129698|DRUG|Apatinib|Apatinib 250mg daily
214279527|NCT00718835|BEHAVIORAL|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
214279528|NCT02646072|DRUG|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
214279529|NCT01941121|BEHAVIORAL|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
214279530|NCT01236599|OTHER|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
214279531|NCT03797599|BEHAVIORAL|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
214279532|NCT03797599|BEHAVIORAL|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
214279533|NCT03797599|OTHER|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
214279534|NCT03797599|OTHER|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
214279535|NCT03797599|OTHER|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
214279536|NCT03313791|DIETARY_SUPPLEMENT|Whey protein concentrate|see arm description
214279537|NCT03313791|DIETARY_SUPPLEMENT|Yoghurt|see arm description
214279538|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Standard)|see arm description
214279539|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Alternative)|see arm description
214279540|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate- WPH|see arm description
214279541|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate - Na-caseinate|see arm description
214279542|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate|see arm description
214279543|NCT03313791|DIETARY_SUPPLEMENT|UHT milk|see arm description
214279544|NCT03313791|DIETARY_SUPPLEMENT|Recombined milk|see arm description
214279545|NCT03313791|DIETARY_SUPPLEMENT|Recombined 50%whey milk|see arm description
214279546|NCT03313791|DIETARY_SUPPLEMENT|Ca-caseinate|see arm description
214279547|NCT03313791|DIETARY_SUPPLEMENT|Milk protein isolate|see arm description
214279548|NCT02452489|DEVICE|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
214279549|NCT02452489|DEVICE|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
214279550|NCT02452489|DEVICE|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
214279551|NCT01502098|PROCEDURE|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
214279552|NCT01502098|OTHER|Sling|Sling for 4 weeks
214279553|NCT03504475|DRUG|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
214279554|NCT03504475|DRUG|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
214279555|NCT00980057|DEVICE|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
214279556|NCT00980057|DEVICE|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
214279557|NCT00041990|DRUG|decitabine (5-aza-2'deoxycytidine)|
214279558|NCT05104320|PROCEDURE|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
214279559|NCT05104320|PROCEDURE|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
214279560|NCT00174278|DRUG|Somatropin|
214279561|NCT04249674|DIAGNOSTIC_TEST|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
214279562|NCT04249674|GENETIC|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
214279563|NCT02075710|OTHER|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
214279564|NCT02075710|OTHER|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
214279565|NCT02075710|OTHER|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
214279566|NCT02075710|OTHER|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
214279567|NCT02075710|OTHER|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
214279568|NCT02075710|OTHER|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
214279569|NCT04980040|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
214279570|NCT02820753|BEHAVIORAL|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
214279571|NCT01308554|DRUG|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
214279572|NCT01308554|DRUG|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
214279573|NCT05588232|PROCEDURE|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
214279574|NCT01332474|DRUG|BOTOX|BOTOX
214279575|NCT01578460|DEVICE|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
214279576|NCT01578460|DEVICE|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
214279577|NCT01738360|DRUG|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
214279578|NCT03676257|OTHER|Endocrine therapies|No intervention
214279579|NCT01720121|OTHER|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
214279580|NCT00542854|DEVICE|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
214279581|NCT02301052|DRUG|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
214279582|NCT02301052|DRUG|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
214279583|NCT02301052|DRUG|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
214279584|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
214279585|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
214279586|NCT03185767|OTHER|blood sampling|blood sampling
214279587|NCT01108302|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
214279588|NCT02471430|DRUG|Panobinostat|Panobinostat will be administered orally.
214279589|NCT02471430|DRUG|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
214279590|NCT03040102|OTHER|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
214279591|NCT03040102|OTHER|Standard of Care|Standard of Care practice is used
214279592|NCT04782427|OTHER|COVID-19 infection|Case of nosocomial infection within the long-term care facility
214279593|NCT02395380|OTHER|C-reactive protein dosage|
214279594|NCT05288231|DIAGNOSTIC_TEST|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
214279595|NCT00062374|DRUG|Cisplatin|Given IV
214279596|NCT00062374|PROCEDURE|Computed Tomography|Undergo FDG and FLT PET/CT
214279597|NCT00062374|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
214279598|NCT00062374|OTHER|Fluorothymidine F-18|Undergo FLT-PET/CT
214279599|NCT00062374|DRUG|Irinotecan Hydrochloride|Given IV
214279600|NCT00062374|PROCEDURE|Positron Emission Tomography|Undergo FDG and FLT PET/CT
214279601|NCT00062374|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
214279602|NCT05973500|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet for 42 Days
214279603|NCT05832359|RADIATION|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
214279604|NCT04083053|PROCEDURE|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
214279605|NCT04083053|PROCEDURE|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
214279606|NCT05512845|PROCEDURE|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
214279607|NCT00302250|DRUG|ALT-711 (alagebrium chloride)|
214279608|NCT05339568|OTHER|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
214279609|NCT02870582|DRUG|Donafenib|treatment drug
214279610|NCT02870582|DRUG|Placebo|Best support treatment
214279611|NCT03555591|DRUG|Trelagliptin|Trelagliptin tablets
214279612|NCT02376088|DRUG|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
214279613|NCT01184794|DRUG|levobupivacaine|40 ml over 48 hours
214279614|NCT05846191|DIAGNOSTIC_TEST|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
214279615|NCT01765088|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
214279616|NCT01765088|DRUG|α-IFN|3mIU (3million) D1，3，5
214279617|NCT04058145|DRUG|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
214279618|NCT04058145|DRUG|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
214279619|NCT01121237|DRUG|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
214279620|NCT04635215|DEVICE|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
214279621|NCT00840450|DRUG|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
214279622|NCT03214965|BEHAVIORAL|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
214279623|NCT03513731|DEVICE|Adipose-derived stem cell injection|ADRC injection into the facet joint
214279624|NCT03513731|DRUG|Corticosteroid injection|Corticosteroid injection into the facet joint
214279625|NCT02759432|OTHER|High-intensity interval exercise training|
214279626|NCT04970797|DRUG|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
214279627|NCT03351803|OTHER|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
214279628|NCT02314416|BIOLOGICAL|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
214279629|NCT05572450|OTHER|Infectious Titre 1|Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
214279630|NCT05572450|OTHER|Infectious Titre 2|Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
214279631|NCT05572450|OTHER|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
214279632|NCT05572450|OTHER|Infectious Titre 4|TBD, depending on outcome of Part A
214279633|NCT05155059|DEVICE|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
214279634|NCT05155059|OTHER|Sham Comparator|Sham TMS stimulation using a sham coil
214279635|NCT04404374|PROCEDURE|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
214279636|NCT03323112|BIOLOGICAL|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
214279637|NCT05117437|OTHER|Physiological test|This test was conducted to determine the endurance levels of the participants.
214279638|NCT05117437|OTHER|Physical test|Height, weight, and BMI were determined
214279639|NCT05117437|OTHER|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
214279640|NCT04525417|DIAGNOSTIC_TEST|AAZ Covid-19 rapid test|To assess the immune status
214279641|NCT04566328|DRUG|Bortezomib|Given SC
214279642|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
214279643|NCT04566328|DRUG|Dexamethasone|Given PO
214279644|NCT04566328|DRUG|Lenalidomide|Given PO
214279645|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
214279646|NCT00617123|DRUG|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
214279647|NCT00617123|DRUG|Placebo|matching placebo oral tablet
214279648|NCT02442518|PROCEDURE|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
214279649|NCT04020965|BEHAVIORAL|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
214279650|NCT04020965|BEHAVIORAL|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
214279651|NCT04020965|BEHAVIORAL|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
214279652|NCT04020965|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
214279653|NCT02786797|BEHAVIORAL|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
214279654|NCT02786797|BEHAVIORAL|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
214279655|NCT05473702|DEVICE|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
214279656|NCT02170298|DRUG|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
214279657|NCT00027898|DRUG|bortezomib|Given IV
214279658|NCT00027898|DRUG|carboplatin|Given IV
214279659|NCT00027898|DRUG|etoposide|Given IV
214279660|NCT00027898|OTHER|laboratory biomarker analysis|Correlative studies
214279661|NCT00027898|OTHER|pharmacological study|Correlative studies
214279662|NCT03508479|BIOLOGICAL|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
214279663|NCT04277416|DEVICE|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
214279664|NCT01142349|BEHAVIORAL|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
214279665|NCT01142349|BEHAVIORAL|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
214279666|NCT01142349|BEHAVIORAL|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
214279667|NCT00783003|DRUG|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
214279668|NCT00783003|DRUG|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
214279669|NCT00783003|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
214279670|NCT00783003|DRUG|Placebo|Matching placebo.
214279671|NCT03481322|DIETARY_SUPPLEMENT|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
214279672|NCT03674749|OTHER|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
214279673|NCT02128113|DRUG|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
214279674|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
214279675|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
214279676|NCT00307411|DRUG|Growth hormone|
214279677|NCT03375775|DRUG|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
214279678|NCT03375775|OTHER|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
214279679|NCT03888456|OTHER|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
214279680|NCT03888456|OTHER|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
214279681|NCT06047483|DRUG|HRF2105 patch|HRF2105 patch ，external use，once a day
214279682|NCT06047483|DRUG|Loxoprofen patch|Loxoprofen patch ，external use，once a day
214279683|NCT06047483|DRUG|placebo|placebo ，external use，once a day
214279684|NCT03739593|DRUG|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
214279685|NCT03739593|DRUG|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
214279686|NCT06065943|OTHER|Palpation and Fluoroscopy|Vessel puncture guided palpation and fluoroscopy only
214279687|NCT06065943|PROCEDURE|Ultrasound guidance|Vessel puncture guided by Ultrasound
214279688|NCT01435369|DRUG|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
214279689|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
214279690|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
214279691|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
214279692|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
214279693|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
214279694|NCT05588908|DRUG|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
214279695|NCT05588908|OTHER|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
214279696|NCT05063487|OTHER|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
214279697|NCT05063487|OTHER|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
214279698|NCT00003499|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214279699|NCT03822078|DRUG|Placebo|Administered by subcutaneous injection
214279700|NCT03822078|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
214279701|NCT04176757|DRUG|ZN-c5|ZN-c5 study drug to be administered orally daily
214279702|NCT01854710|DRUG|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
214279703|NCT01854710|DRUG|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
214279704|NCT01854710|DRUG|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
214279705|NCT01854710|DRUG|Oral placebo|Oral capsule identical in appearance to moxifloxacin
214279706|NCT02798133|PROCEDURE|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
214279707|NCT02798133|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
214279708|NCT03837197|DEVICE|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
214279709|NCT03837197|DEVICE|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
214279710|NCT01385215|DRUG|Fluzone|0.5 ml/15 micrograms
214279711|NCT01385215|DRUG|Fluzone|0.5 ml/60 micrograms
214279712|NCT01969968|OTHER|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
214279713|NCT00373152|PROCEDURE|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
214279714|NCT00373152|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
214279715|NCT00373152|PROCEDURE|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
214279716|NCT00373152|RADIATION|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
214279717|NCT05065632|DIAGNOSTIC_TEST|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
214279718|NCT06498492|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
214279719|NCT01111097|DRUG|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
214279720|NCT02581514|OTHER|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
214279721|NCT02533739|BEHAVIORAL|Cognitive and neuropsychological assesment|
214279722|NCT02809937|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
214279723|NCT02809937|DRUG|placebo|normal saline infusion
214279724|NCT02004210|PROCEDURE|transarterial radioembolization (TARE)|transarterial radioembolization
214279725|NCT02004210|PROCEDURE|transarterial chemoembolization (TACE)|transarterial chemoembolization
214279726|NCT00895167|DIETARY_SUPPLEMENT|curcumin|one oral dose of 12 caplets = 12 g curcumin
214279727|NCT00370032|DRUG|alosetron|
214279728|NCT06120296|DEVICE|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
214279729|NCT05012332|PROCEDURE|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
214279730|NCT04211623|OTHER|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
214279731|NCT04211623|OTHER|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
214279732|NCT01974804|PROCEDURE|MRI|
214279733|NCT05057182|BIOLOGICAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
214279734|NCT04688970|OTHER|no intervention|no intervention
214279735|NCT03453008|OTHER|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
214279736|NCT02187497|DRUG|Low dose of BIBR 277|
214279737|NCT02187497|DRUG|Medium dose of BIBR 277|
214279738|NCT02187497|DRUG|High dose of BIBR 277|
214279739|NCT04624646|DEVICE|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
214279740|NCT04624646|DEVICE|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
214279741|NCT04624646|DEVICE|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
214279742|NCT06199817|BEHAVIORAL|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
214279743|NCT05869266|DEVICE|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
214279744|NCT03166384|DEVICE|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
214279745|NCT03166384|PROCEDURE|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
214279746|NCT00823095|DRUG|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
214279747|NCT02230800|DRUG|Tocovid SupraBio plus pentoxifylline|
214279748|NCT02230800|DRUG|Matching placebos|
214279749|NCT04173585|DRUG|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
214279750|NCT04173585|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
214279751|NCT04789135|DRUG|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
214279752|NCT04926428|DRUG|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
214279753|NCT02859168|BEHAVIORAL|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
214279754|NCT02859168|DEVICE|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
214279755|NCT05123820|DRUG|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
214279756|NCT05123820|DRUG|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
214279757|NCT00033020|BEHAVIORAL|Behavior Therapy|
214279758|NCT06468566|DIAGNOSTIC_TEST|Ultrasound light scattering imaging equipment|Radiologists use ultrasound light scattering imaging to evaluate the benign and malignant nature of breast nodules
214279759|NCT03685968|DEVICE|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
214279760|NCT00436839|DRUG|Docetaxel|75mg/m² intravenously (day 1) every 21 days
214279761|NCT00436839|DRUG|Mitoxantrone|12mg/m² intravenously every 21 days
214279762|NCT00436839|DRUG|Prednisone|10mg orally given daily
214279763|NCT01185756|RADIATION|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
214279764|NCT04101877|DRUG|Bevacizumab Injection|25 mg/ml
214279765|NCT04101877|DRUG|Aflibercept Injection|40 mg/ml
214279766|NCT00457925|DRUG|GSK221149A|
214279767|NCT03737942|DEVICE|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
214279768|NCT04486105|DIETARY_SUPPLEMENT|sucrose|pure sucrose in water in addition to habitual diet
214279769|NCT01844518|BIOLOGICAL|Abatacept|
214279770|NCT06487585|DRUG|Angiotensin II|Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
214279771|NCT00008372|DRUG|chloroquinoxaline sulfonamide|
214279772|NCT01575587|DRUG|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
214279773|NCT01575587|DRUG|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
214279774|NCT01575587|DRUG|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
214279775|NCT01575587|DRUG|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
214279776|NCT00681005|DRUG|rabeprazole|20 mg bid for 14 days
214279777|NCT00681005|DRUG|pantoprazole|pantoprazole 40 mg bid
214279778|NCT02557555|OTHER|educational information|patients will receive pamphlet on labor analgesia options.
214279779|NCT00012311|BIOLOGICAL|filgrastim|
214279780|NCT00012311|DRUG|CMF regimen|
214279781|NCT00012311|DRUG|carboplatin|
214279782|NCT00012311|DRUG|cyclophosphamide|
214279783|NCT00012311|DRUG|docetaxel|
214279784|NCT00012311|DRUG|doxorubicin hydrochloride|
214279785|NCT00012311|DRUG|etoposide|
214279786|NCT00012311|DRUG|fluorouracil|
214279787|NCT00012311|DRUG|ifosfamide|
214279788|NCT00012311|DRUG|methotrexate|
214279789|NCT00012311|DRUG|thiotepa|
214279790|NCT00012311|PROCEDURE|peripheral blood stem cell transplantation|
214279791|NCT05866796|DIAGNOSTIC_TEST|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
214279792|NCT01945528|DRUG|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
214279793|NCT01945528|DRUG|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
214279794|NCT04739904|OTHER|Normoxia|48 hours experimental protocol conducted at sea level
214279795|NCT04739904|OTHER|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
214279796|NCT04739904|OTHER|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
214279797|NCT02144415|DRUG|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
214279798|NCT02144415|DRUG|EB-1020 800 mg|8 x EB-1020 100-mg capsules
214279799|NCT02144415|DRUG|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
214279800|NCT02144415|DRUG|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
214279801|NCT02144415|DRUG|Placebo|8 x matching placebo capsules
214279802|NCT06524284|DEVICE|Releaf|10 days/35 minutes per day EVNS (non-invasive electrostimulation) treatment on lower legs and feet by the subject or its caregiver after instruction by the podiatrist.
214279803|NCT00143637|OTHER|Office dust|airborne office dust spiked with glucan
214279804|NCT00143637|OTHER|clean air|Clean air
214279805|NCT03268369|RADIATION|MRI of the brain|to eliminate a structural intra-cerebral lesion
214279806|NCT03268369|RADIATION|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq \[18F\]F-A-85380
214279807|NCT03268369|RADIATION|PET scan [18F]FDG|exam performed after iv injection of 200 MBq \[18F\]FDG
214279808|NCT02445092|OTHER|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
214279809|NCT04584645|OTHER|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
214279810|NCT02554448|OTHER|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
214279811|NCT00390468|DRUG|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
214279812|NCT00830362|DRUG|Propranolol|40 mg administered once
214279813|NCT00830362|DRUG|Placebo|administered once
214279814|NCT02564237|BIOLOGICAL|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
214279815|NCT02564237|BIOLOGICAL|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
214279816|NCT02564237|BIOLOGICAL|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
214279817|NCT02564237|BIOLOGICAL|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
214279818|NCT03205332|BEHAVIORAL|Concreteness Training|
214279819|NCT00797030|DRUG|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
214279820|NCT00797030|DRUG|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
214279821|NCT06056713|BEHAVIORAL|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
214279822|NCT03129100|DRUG|Ixekizumab|Administered SC
214279823|NCT03129100|DRUG|Placebo|Administered SC
214279824|NCT02868775|PROCEDURE|cystoscopy, bladder hydrodistention and bladder biopsy|
214279825|NCT01486667|DRUG|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
214279826|NCT01486667|DRUG|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
214279827|NCT03845985|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
214279828|NCT02701400|BIOLOGICAL|Durvalumab|Given IV
214279829|NCT02701400|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214279830|NCT02701400|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214279831|NCT02701400|BIOLOGICAL|Tremelimumab|Given IV
214279832|NCT00592930|DRUG|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
214279833|NCT00592930|DRUG|placebo|
214279834|NCT04459533|DEVICE|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
214279835|NCT04836572|OTHER|3M 1529 Adhesive Tape|5-12 hour adhesive wear
214279836|NCT03989271|DRUG|Quercetin|Placebo
214279837|NCT06376396|DRUG|albendazole and praziquantel|Combination of albendazole plus praziquantel
214279838|NCT06376396|DRUG|Albendazole|Albendazole alone
214279839|NCT04014816|OTHER|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
214279840|NCT04014816|OTHER|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
214279841|NCT06297161|DRUG|Bosulif|chronic myelogenous leukemia patients
214279842|NCT03600571|PROCEDURE|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
214279843|NCT03600571|PROCEDURE|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
214279844|NCT01749397|DRUG|Floxuridine|Given IP
214279845|NCT01749397|OTHER|Laboratory Biomarker Analysis|Correlative studies
214279846|NCT01749397|OTHER|Pharmacological Study|Correlative studies
214279847|NCT01749397|DRUG|Veliparib|Given IV
214279848|NCT00118677|PROCEDURE|Treatment interruption|
214279849|NCT02381145|DIETARY_SUPPLEMENT|EGCG+RSV-supplementation|Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
214279850|NCT02381145|DIETARY_SUPPLEMENT|Placebo|
214279851|NCT03334539|BIOLOGICAL|HL036 ophthalmic solution|HL036 ophthalmic solution
214279852|NCT03334539|OTHER|Placebo vehicle solution|Placebo vehicle solution
214279853|NCT03434093|DEVICE|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
214279854|NCT03434093|BEHAVIORAL|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
214279855|NCT00194571|BEHAVIORAL|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
214279856|NCT00552565|DRUG|Rezular 15mg|Oral Tablets
214279857|NCT00552565|DRUG|Placebo|placebo
214279858|NCT00552565|DRUG|Rezular|Rezular 37.5mg 3xday up to 12 weeks
214279859|NCT00552565|DRUG|Rezular|Rezular 75mg 3xday up to 12 weeks
214279860|NCT00002588|DRUG|etoposide|
214279861|NCT00002588|DRUG|topotecan hydrochloride|
214279862|NCT04642443|DEVICE|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
214279863|NCT00967057|DRUG|asparaginase|Given intramuscularly
214279864|NCT00967057|DRUG|dexamethasone|Given orally
214279865|NCT00967057|DRUG|idarubicin|Given IV
214279866|NCT00967057|DRUG|methotrexate|Given intrathecally
214279867|NCT00967057|DRUG|mitoxantrone hydrochloride|Given IV
214279868|NCT00967057|DRUG|pegaspargase|Given intramuscularly
214279869|NCT00967057|DRUG|vincristine sulfate|Given IV
214279870|NCT00358683|DRUG|Certolizumab pegol|
214279871|NCT00363883|DRUG|vorinostat|Given orally
214279872|NCT00363883|OTHER|laboratory biomarker analysis|Correlative studies
214279873|NCT03736447|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
214279874|NCT03736447|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
214279875|NCT00851370|DRUG|Omalizumab (Xolair)|Bi-weekly
214279876|NCT00851370|DRUG|Placebo|Bi-Weekly
214279877|NCT00968201|DRUG|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
214279878|NCT00968201|DRUG|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
214279879|NCT06393829|BEHAVIORAL|Applying the Early Mobilization Program|A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
214279880|NCT02521545|DRUG|BIIB061|Capsule
214279881|NCT02619175|DEVICE|Stroke Subjects Perturbation-Based Balance Training|
214279882|NCT02619175|DEVICE|Stroke Subjects Weight Shifting and Gait training|
214279883|NCT04141488|OTHER|experimantal group|Control Group
214279884|NCT02818400|PROCEDURE|composite tissue allotransplantation|
214279885|NCT05501301|OTHER|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
214279886|NCT00492141|DRUG|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
214279887|NCT00492141|DRUG|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
214279888|NCT00004779|GENETIC|Ad5-CB-CFTR|
214279889|NCT04399317|DEVICE|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
214279890|NCT00684346|OTHER|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
214279891|NCT00230204|PROCEDURE|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
214279892|NCT03256643|BEHAVIORAL|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
214279893|NCT03256643|BEHAVIORAL|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
214279894|NCT03256643|BEHAVIORAL|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
214279895|NCT06177730|OTHER|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
214279896|NCT06147804|PROCEDURE|Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation|How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
214279897|NCT06310317|BEHAVIORAL|Applied Behavior Analysis protocol|"The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. The use of Applied Behavior Analysis procedures, with the help of technological tools such as a tablet or robot can facilitate the increase of new knowledge and skills.~The criterion is acquired if the subject emits 8 out of 10 independent correct responses (90%) for 3 consecutive sessions.~The objective is to test whether the technological tool used (tablet or robot) can make the proposed learning procedure more effective. The experimental group carries out the procedure by means of stimuli presented on tablets or robots."
214279898|NCT06310317|BEHAVIORAL|Traditional intervention|The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. In this group the materials are traditional, such as image printed. The criterion is acquired if the subject emits 9 out of 10 independent correct responses (90%) for 3 consecutive sessions. The control group performs the procedure with images printed on A4 laminated sheets.
214279899|NCT05113017|OTHER|NO Intervention|NO Intervention
214279900|NCT01332903|DRUG|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
214279901|NCT06492317|DRUG|Disitamab Vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
214279902|NCT06492317|DRUG|Cadonilimab|Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
214279903|NCT02223832|DRUG|ACT-128800|
214279904|NCT05344170|DRUG|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
214279905|NCT05344170|DRUG|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
214279906|NCT05344170|DRUG|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
214279907|NCT03217331|DRUG|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
214279908|NCT04974697|DEVICE|JJVC Investigational Multifocal Toric Contact Lens|TEST
214279909|NCT05536050|OTHER|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
214279910|NCT03085381|BIOLOGICAL|HPV vaccine|
214279911|NCT03085381|BIOLOGICAL|Placebo|
214279912|NCT04036890|DRUG|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
214279913|NCT04036890|DRUG|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
214279914|NCT00925093|DRUG|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
214279915|NCT00925093|DRUG|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
214279916|NCT00925093|DRUG|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
214279917|NCT01475357|OTHER|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
214279918|NCT01475357|OTHER|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
214279919|NCT05206578|DRUG|AGT2, AGZ|Tablet, q.d.
214279920|NCT05206578|DRUG|AGT2|Tablet, q.d.
214279921|NCT05206578|DRUG|AGT4, AGZ|Tablet, q.d.
214279922|NCT05206578|DRUG|AGT4|Tablet, q.d.
214279923|NCT02250378|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
214279924|NCT02250378|PROCEDURE|therapeutic conventional surgery|Undergo wedge resection
214279925|NCT02250378|OTHER|laboratory biomarker analysis|Correlative studies
214279926|NCT02250378|OTHER|quality-of-life assessment|Ancillary studies
214839777|NCT00250705|DRUG|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
214839778|NCT01493596|DRUG|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
214279927|NCT01434030|BEHAVIORAL|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
214279928|NCT01162460|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
214279929|NCT01016197|PROCEDURE|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
214279930|NCT01016197|PROCEDURE|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
214279931|NCT00515346|DEVICE|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
214279932|NCT01332955|DRUG|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
214279933|NCT01332955|BIOLOGICAL|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
214279934|NCT01332955|DRUG|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
214279935|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
214279936|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
214279937|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
214279938|NCT05232396|BIOLOGICAL|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
214279939|NCT03706456|BIOLOGICAL|Darvadstrocel|Darvadstrocel cell suspension for intralesional injection.
214279940|NCT00547482|DEVICE|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
214279941|NCT03533543|DEVICE|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
214279942|NCT02771912|DRUG|Propofol|Propofol and excipients
214279943|NCT02771912|DRUG|Placebo|Qualitative composition of Propofol lipuro 2% excipients
214279944|NCT05176730|BEHAVIORAL|Mindfulness meditation|Similar to the information included in arm/group descriptions
214279945|NCT02829697|DRUG|Ropivacaine|Perineural injection.
214279946|NCT04123600|DEVICE|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
214279947|NCT04903990|OTHER|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
214279948|NCT02784431|DEVICE|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
214279949|NCT00866385|DRUG|AZD8566|Single 6 mg oral solution dose
214279950|NCT00866385|DRUG|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
214279951|NCT02228200|BEHAVIORAL|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
214279952|NCT02228200|BEHAVIORAL|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
214279953|NCT03589560|DRUG|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
214279954|NCT03589560|DRUG|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
214279955|NCT02644135|DRUG|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
214279956|NCT02644135|DRUG|Halo Placebo|Three sprays per use, total = 9 sprays per day
214279957|NCT03302234|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
214279958|NCT03302234|BIOLOGICAL|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
214279959|NCT03302234|OTHER|Placebo|Normal saline solution administered as an IV infusion Q6W
214279960|NCT06199596|DIETARY_SUPPLEMENT|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
214279961|NCT06199596|DIETARY_SUPPLEMENT|Maltodextrin|150mg of Maltodextrin per capsule
214279962|NCT00598988|PROCEDURE|traditional Chinese acupuncture|10 treatments over 6 weeks
214279963|NCT00598988|OTHER|standard medical care|standard care as provided by primary physician
214279964|NCT01901120|DRUG|Betanis|oral
214279965|NCT04145557|DEVICE|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
214279966|NCT04145557|DEVICE|scaling root planing|scaling and root planing
214279967|NCT00873574|BIOLOGICAL|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
214279968|NCT05687383|DEVICE|Safe breastfeeding pillow|A randomized controlled trial
214279969|NCT00200616|PROCEDURE|Antimicrobial prophylaxis|
214279970|NCT05163236|DIAGNOSTIC_TEST|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
214279971|NCT05163236|DIAGNOSTIC_TEST|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
214279972|NCT05163236|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
214279973|NCT03054441|OTHER|Actigraph|Actigraphs worn on wrists
214839779|NCT01493596|DRUG|Placebo|An equal volume of water mixed with juice will be administered.
214279976|NCT05488730|DIAGNOSTIC_TEST|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
214279977|NCT05353166|DRUG|REGN5381|Single dose administered via IV infusion
214279978|NCT05353166|DRUG|Matching Placebo|Single dose administered via IV infusion
214279979|NCT05979558|DRUG|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
214279980|NCT05979558|DRUG|Ropivacaine with placebo|this group received with ropivacaine with normal saline
214279981|NCT04774315|DRUG|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
214279982|NCT02795832|DRUG|ZPL-5212372 1% w/w Ointment BID|
214279983|NCT02795832|DRUG|Placebo Ointment BID|
214279984|NCT04523220|DRUG|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
214279985|NCT04523220|DRUG|Placebo|Subcutaneous administration in the same manner as Osocimab.
214279986|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
214279987|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
214279988|NCT02124330|DIETARY_SUPPLEMENT|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
214279989|NCT05699031|DEVICE|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
214279990|NCT05699031|OTHER|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
214279991|NCT01219569|DRUG|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
214279992|NCT01219569|DRUG|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
214279993|NCT00753467|DRUG|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
214279994|NCT00753467|DRUG|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
214279995|NCT00753467|DRUG|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
214279996|NCT00571948|OTHER|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
214279997|NCT00571948|OTHER|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
214279998|NCT01102959|DEVICE|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
214279999|NCT00483730|DRUG|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
214280000|NCT03692130|BEHAVIORAL|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
214280001|NCT03692130|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson
214280002|NCT05334966|OTHER|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
214280003|NCT04112784|DEVICE|INVSENSOR00039|Noninvasive pulse oximeter sensor
214280004|NCT01938456|DRUG|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
214280005|NCT01938456|DRUG|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
214280006|NCT01938456|DRUG|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
214280007|NCT00000297|DRUG|Labetalol|
214280008|NCT02592252|BEHAVIORAL|Participatory gender training|10 sessions of participatory gender training
214280009|NCT02592252|OTHER|Microfinance|Microfinance loan
214280010|NCT06075862|PROCEDURE|Decompressive surgery|Decompressive lumbar spinal surgery
214280011|NCT04889079|BEHAVIORAL|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
214280012|NCT03207230|DEVICE|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
214280013|NCT03207230|DEVICE|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
214280014|NCT03207230|DEVICE|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
214280015|NCT05888766|DRUG|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
214280016|NCT05332665|DEVICE|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
214280017|NCT05332665|PROCEDURE|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
214280018|NCT06382259|OTHER|Movement breaks|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
214280019|NCT05947825|DRUG|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
214280020|NCT04427566|RADIATION|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
214280021|NCT01048177|DRUG|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
214280022|NCT05367622|BEHAVIORAL|Self-regulation health education|"1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days"
214280023|NCT05367622|BEHAVIORAL|Usual diabetes health education|"1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education"
214280024|NCT00221403|DRUG|Risperidone oral solution|liquid, BID dosing.
214280025|NCT00221403|DRUG|Valproate Oral Solution|liquid, BID dosing.
214280026|NCT00221403|OTHER|Placebo|liquid, BID dosing.
214280027|NCT05045131|PROCEDURE|Left atrial combined pulmonary vein isolation and posterior wall isolation|
214280028|NCT02272062|OTHER|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
214280029|NCT03925883|BEHAVIORAL|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
214280030|NCT01347944|DRUG|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
214280031|NCT05840991|DEVICE|elastic bandage|3M™ Coban™ elastic bandage
214280032|NCT05840991|DEVICE|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
214280033|NCT03067961|OTHER|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
214280034|NCT04790890|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
214280035|NCT02010775|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
214280036|NCT02010775|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
214280037|NCT03253497|DRUG|Chlorobenzene Liquid|before induction will be used for oropharynx
214280038|NCT00514111|DRUG|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
214280039|NCT01324908|PROCEDURE|extracorporeal photopheresis|Undergo ECP
214280040|NCT01324908|OTHER|laboratory biomarker analysis|Correlative studies
214280041|NCT02389361|DRUG|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
214280042|NCT02389361|DRUG|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
214280043|NCT00256750|DRUG|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
214280044|NCT00256750|DRUG|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
214280045|NCT00256750|DRUG|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
214280046|NCT01475994|OTHER|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
214280047|NCT01475994|OTHER|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
214280048|NCT01714011|DRUG|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
214280049|NCT01714011|DRUG|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
214280050|NCT02030041|DRUG|Vitamin D|Vitamin D will be given to achieve normal serum levels
214280051|NCT02030041|DRUG|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
214280052|NCT02030041|DRUG|Placebo|Placebo will be provided to the study participants
214280053|NCT03072147|DRUG|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
214280054|NCT03072147|DRUG|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
214280055|NCT01916720|DRUG|SB-480848 40 mg|Study Drug
214280056|NCT01916720|DRUG|SB-480848 80 mg|Study Drug
214280057|NCT01916720|DRUG|Placebo|Study Drug
214280058|NCT03621397|DEVICE|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
214280059|NCT05907512|DRUG|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
214280060|NCT05907512|DRUG|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
214280061|NCT02788812|PROCEDURE|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
214280062|NCT02788812|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
214280063|NCT02989714|DRUG|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
214280064|NCT02989714|DRUG|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
214280065|NCT01704378|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
214280066|NCT02077920|DRUG|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
214280067|NCT02077920|DRUG|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
214280068|NCT02077920|DEVICE|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
214280069|NCT02077920|DEVICE|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
214280070|NCT01197560|DRUG|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
214280071|NCT01197560|DRUG|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
214280072|NCT01197560|DRUG|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
214280073|NCT01197560|DRUG|Rituximab|Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
214839780|NCT02466386|DRUG|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
214839781|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
214839782|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
214839783|NCT00935623|BIOLOGICAL|Malaria Challenge|Malaria challenge
214280074|NCT01197560|DRUG|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
214280075|NCT04736030|BEHAVIORAL|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
214280076|NCT03472183|OTHER|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
214280077|NCT02006719|BIOLOGICAL|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
214280078|NCT02006719|OTHER|Placebo|Placebo injection
214280079|NCT05682898|PROCEDURE|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
214280080|NCT01132430|BEHAVIORAL|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
214280081|NCT01132430|BEHAVIORAL|Usual care|Standard medical care within 4-6 week period
214280082|NCT04635462|OTHER|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
214280083|NCT04635462|OTHER|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
214280084|NCT05019352|DEVICE|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
214280085|NCT05019352|DEVICE|CRRT|continuous renal replacement therapy
214280086|NCT01699906|OTHER|Diet regimen to induce weight loss|Diet regimen to induce weight loss
214280087|NCT05496530|DRUG|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
214280088|NCT03280498|PROCEDURE|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
214280089|NCT02412605|PROCEDURE|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
214280090|NCT05374369|DIAGNOSTIC_TEST|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
214280091|NCT05374369|PROCEDURE|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
214280092|NCT00640991|DRUG|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
214280093|NCT02927730|OTHER|no interventions|no interventions
214280094|NCT03355716|DRUG|bupivacaine|Bupivacaine 25 ml (0.25%)
214280095|NCT03355716|DRUG|morphine|Morphine (3.0 mg)
214280096|NCT03355716|DRUG|fentanyl|fentanyl (30.0 Mc)
214280097|NCT03355716|DRUG|Ketamine:|ketamine (0.5 mg/kg).
214280098|NCT01872377|RADIATION|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
214280099|NCT04152278|DIAGNOSTIC_TEST|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
214280100|NCT05436093|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
214839784|NCT00367536|DRUG|bazedoxifene/conjugated estrogens combination tablet|
214280101|NCT04659161|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
214280102|NCT04659161|DRUG|Placebo|Placebo Capsules twice a day (BID)
214280103|NCT01929343|DRUG|lidocaine following cue-induced craving|as described in Arm Description
214280104|NCT01929343|DRUG|lidocaine following neutral stimulus|as described in Arm Description
214280105|NCT01929343|DRUG|saline|as described in Arm Description
214280106|NCT00901316|PROCEDURE|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
214280107|NCT00901316|PROCEDURE|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
214280108|NCT02320669|DRUG|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
214280109|NCT02320669|DRUG|Placebo|Bolus of Placebo followed by infusion for 48 hours
214280110|NCT00637338|BIOLOGICAL|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
214280111|NCT00637338|BIOLOGICAL|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
214280112|NCT03781869|DRUG|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
214280113|NCT03781869|DRUG|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
214280114|NCT01996501|DRUG|Olanzapine Orally Disintegrating 5mg Tablets|
214280115|NCT00541710|DIETARY_SUPPLEMENT|genistein|pills of 27 mg, twice per day for 12 months
214280116|NCT00541710|DIETARY_SUPPLEMENT|placebo|sugar pills twice per day for 12 months
214280117|NCT04874298|OTHER|Ginger|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
214280118|NCT04874298|OTHER|Peppermint|Peppermint
214280119|NCT00565045|DEVICE|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
214280120|NCT04841460|DIETARY_SUPPLEMENT|Low-fat ground beef|5% fat ground beef
214280121|NCT04841460|DIETARY_SUPPLEMENT|High-fat ground beef|25% fat ground beef
214280122|NCT01201005|DIETARY_SUPPLEMENT|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
214280123|NCT01201005|DIETARY_SUPPLEMENT|Sham injection|needle injection without any substance given
214280124|NCT02400632|DEVICE|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
214280125|NCT03645798|BEHAVIORAL|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
214280126|NCT03645798|BEHAVIORAL|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
214280127|NCT03153969|DEVICE|SHOFU Beautifil II LS|Placed under manufacturer's instructions
214280128|NCT03153969|DEVICE|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
214280129|NCT01600638|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214280130|NCT04584151|PROCEDURE|regional analgesia|Insertion of bilateral ESP catheters
214280131|NCT01737697|DRUG|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
214280132|NCT01737697|DRUG|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
214280133|NCT01737697|DRUG|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
214280134|NCT01737697|DRUG|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
214280135|NCT05038436|DEVICE|Polyglucosamine L112|Two tablets once daily per os
214280136|NCT04729868|DRUG|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
214280137|NCT04992676|DIAGNOSTIC_TEST|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
214280138|NCT04992676|DIAGNOSTIC_TEST|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
214280139|NCT06131567|PROCEDURE|Implantoplasty|Implantoplasty as surface decontamination method
214280140|NCT00858130|DEVICE|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
214280141|NCT01925937|DRUG|Atorvastatin|
214280142|NCT01925937|DRUG|Coenzyme Q10|
214280143|NCT01925937|DRUG|placebo for coenzyme Q10|
214280144|NCT03338998|DRUG|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
214280145|NCT03338998|DRUG|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
214280146|NCT03338998|DRUG|BAF312 tablet|2 mg film-coated tablet
214280147|NCT03338998|DRUG|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
214280148|NCT02871700|BEHAVIORAL|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
214280149|NCT02871700|BEHAVIORAL|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
214280150|NCT02871700|BEHAVIORAL|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
214280151|NCT02901405|DEVICE|Negative Pressure Wound Therapy (ActivVAC, KCI)|
214280152|NCT02901405|DEVICE|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
214280153|NCT05728905|OTHER|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
214280154|NCT05728905|OTHER|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
214280155|NCT00653120|DRUG|Propranolol|ER capsules, 160 mg, single-dose
214280156|NCT00653120|DRUG|Inderal-LA|ER capsules, 160 mg, single-dose
214280157|NCT03288129|DRUG|Perampanel|film-coated tablets
214280158|NCT00074204|DRUG|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214280159|NCT00074204|DRUG|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
214280160|NCT00074204|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214280161|NCT03129178|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
214280162|NCT00386438|PROCEDURE|Honan balloon application|
214280163|NCT01125267|BEHAVIORAL|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
214280164|NCT01125267|BEHAVIORAL|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
214280165|NCT02194244|DRUG|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
214280166|NCT02194244|DRUG|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
214280167|NCT02579239|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
214280168|NCT02579239|BIOLOGICAL|Placebo|Concentrate for solution for infusion
214280169|NCT04460404|BEHAVIORAL|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~1. Basic information~2. Digestive tract symptoms:~   A constipation-related symptoms B abnormal symptoms~3. Fecal traits~4. Lifestyle habits~5. Others"
214280170|NCT01682109|DRUG|Valacyclovir|
214280171|NCT00601211|DRUG|Pilocarpine|
214280172|NCT04176666|DEVICE|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
214280173|NCT04648553|BEHAVIORAL|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
214280174|NCT04648553|BEHAVIORAL|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
214280175|NCT04404361|DRUG|Pacritinib|100 mg capsules
214280176|NCT04404361|DRUG|Placebo|Placebo capsules matching pacritinib 100 mg capsules
214280177|NCT03324308|DIAGNOSTIC_TEST|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
214280178|NCT00558558|DRUG|Haelan|4 oz orally twice daily for 8 Weeks
214280179|NCT02014025|PROCEDURE|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
214280180|NCT02014025|PROCEDURE|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
214280181|NCT05190159|DEVICE|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
214280182|NCT05222737|DEVICE|medency diode laser|intra pocket application of diode laser
214280183|NCT05222737|DRUG|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
214280184|NCT04132258|OTHER|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
214280185|NCT02460627|DRUG|Lidocaine adhesive tape|700 mg for 12 hours
214280186|NCT02460627|OTHER|Adhesive tape|For 12 hours
214280187|NCT02217267|DRUG|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
214280188|NCT02217267|DRUG|Placebo|
214280189|NCT00216632|DRUG|risperidone|
214280190|NCT02512588|DRUG|BTD-001|
214280191|NCT02512588|DRUG|Placebo|
214280192|NCT01523535|BEHAVIORAL|repeated cycles of short sleep|\- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
214280193|NCT02144012|DRUG|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
214280194|NCT02144012|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
214280195|NCT02144012|DRUG|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
214280196|NCT05858762|DIAGNOSTIC_TEST|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
214280197|NCT02567916|DRUG|Fresofol|
214280198|NCT02567916|DRUG|Propofol|
214280199|NCT04771039|OTHER|reason for consultation|search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
214280200|NCT01095731|DRUG|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
214280201|NCT01095731|DRUG|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
214280202|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
214280203|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
214280204|NCT01265368|BIOLOGICAL|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
214280205|NCT04263220|DEVICE|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
214280206|NCT04263220|OTHER|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
214280207|NCT03641274|OTHER|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
214280208|NCT01423305|DRUG|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
214280209|NCT01423305|DRUG|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
214280210|NCT06197750|OTHER|Vestibular stimulation|Vestibular stimulation by swing
214280211|NCT06197750|OTHER|General strengthening exercises|General strengthening exercises
214280212|NCT00130598|DRUG|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
214280213|NCT03293290|DRUG|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
214280214|NCT01433614|DRUG|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
214280215|NCT01433614|DRUG|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
214280216|NCT01433614|DRUG|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
214280217|NCT01411202|DRUG|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
214280218|NCT01411202|OTHER|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
214280219|NCT04805424|PROCEDURE|Lipo-abdominoplasty|Abdominoplasty plus liposuction
214280220|NCT04805424|PROCEDURE|Abdominoplasty|Abdominoplasty
214280221|NCT03119584|DRUG|linaclotide or placebo|
214280222|NCT04284410|BEHAVIORAL|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
214280223|NCT04812171|PROCEDURE|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
214280224|NCT03628794|DEVICE|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
214280225|NCT02021240|DRUG|Ketamine|
214280226|NCT02021240|DRUG|Dexamethasone|
214280227|NCT02021240|DRUG|Normal Saline|
214280228|NCT02915016|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
214280229|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
214280230|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
214280231|NCT02915016|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
214280232|NCT05332197|BIOLOGICAL|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
214280233|NCT03481036|DRUG|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
214280234|NCT03481036|DRUG|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
214280235|NCT03481036|DRUG|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
214280236|NCT02885012|DRUG|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
214280237|NCT06830369|DEVICE|HypnoVR|In the intervention group, after extubation, patients will receive IVR with HypnoVR®, twice-a-day over two to five days. The product consists of HypnoVR® virtual reality software and HypnoVR® Compagnon remote control software. HypnoVR® is a CE-marked class 1 medical device, developed and marketed by HypnoVR SAS, an ISO 13484:2016 and ISO 27001:2017 certified company. The device works with a virtual reality headset, a personal audio device and a mobile terminal. The investigators will only use sessions of 10 to 20 minutes. For each type of session, a visual universe, a musical atmosphere and a male or female voice are defined. Typically, the scenarios include 3 phases: preparation, hypnosis and return. We will use the following sessions: anxiety, pain, rehabilitation.
214280238|NCT06830369|OTHER|usual health care|usual health care
214280239|NCT05489510|COMBINATION_PRODUCT|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
214280240|NCT00651794|BEHAVIORAL|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
214280241|NCT00651794|BEHAVIORAL|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
214280242|NCT00651794|BEHAVIORAL|Skills practice with low-fidelity mannequin|
214280243|NCT00651794|BEHAVIORAL|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
214280244|NCT00949520|OTHER|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
214280245|NCT00949520|OTHER|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
214280246|NCT03715881|DRUG|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
214280247|NCT03715881|DRUG|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
214280248|NCT00811369|DRUG|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
214280249|NCT00811369|DRUG|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
214280250|NCT06211166|DIAGNOSTIC_TEST|Digital PCR|digital Polymerase Chain Reaction (dPCR)
214280251|NCT06211166|DIAGNOSTIC_TEST|Quantitative PCR|Real-time Polymerase Chain Reaction (real-time PCR)
214280252|NCT06211166|DIAGNOSTIC_TEST|MFC|Multicolor Flow Cytometry
214280253|NCT02370134|DEVICE|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
214280254|NCT02370134|DEVICE|sham glove|
214280255|NCT00380952|DEVICE|Dune Device|
214280256|NCT01497691|DEVICE|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
214280257|NCT01497691|DEVICE|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
214280258|NCT01497691|DEVICE|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
214280259|NCT01874132|BEHAVIORAL|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
214280260|NCT01286298|PROCEDURE|Laser gingivectomy|Gingivectomy by diode laser
214280261|NCT01286298|PROCEDURE|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
214280262|NCT00002169|DRUG|Nelfinavir mesylate|
214280263|NCT00646009|DRUG|budesonide/formoterol|
214280264|NCT00646009|DRUG|fluticasone/salmeterol|
214280265|NCT00646009|DRUG|albuterol|
214280266|NCT01408485|DEVICE|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator"
214280267|NCT04884477|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
214839785|NCT04487964|DIETARY_SUPPLEMENT|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
214839786|NCT00166452|DRUG|Lenalidamide|
214280268|NCT06281990|BEHAVIORAL|Education|"1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded."
214280269|NCT01235143|DRUG|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
214280270|NCT01235143|DRUG|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
214280271|NCT05230771|COMBINATION_PRODUCT|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
214280272|NCT05230771|DRUG|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
214280273|NCT01158300|DRUG|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
214280274|NCT01315678|DRUG|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
214280275|NCT01315678|DRUG|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
214280276|NCT01516697|PROCEDURE|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
214280277|NCT01516697|PROCEDURE|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
214280278|NCT04670848|DEVICE|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
214280279|NCT05182138|OTHER|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
214280280|NCT05182138|OTHER|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
214280281|NCT05182138|OTHER|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
214280282|NCT00003211|BIOLOGICAL|filgrastim|
214280283|NCT00003211|DRUG|amifostine trihydrate|
214280284|NCT00003211|DRUG|cisplatin|
214280285|NCT00003211|DRUG|cyclophosphamide|
214280286|NCT00003211|DRUG|vincristine sulfate|
214280287|NCT00003211|PROCEDURE|peripheral blood stem cell transplantation|
214280288|NCT00003211|RADIATION|radiation therapy|
214280289|NCT01211327|DRUG|Cyclosporine A|Cyclosporine 2% eye drops
214280290|NCT01211327|DRUG|Dexamethasone|Dexamethasone 0,1% eye drops
214280291|NCT05002010|DEVICE|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
214280292|NCT05593393|DEVICE|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
214280293|NCT03710538|DIETARY_SUPPLEMENT|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
214280294|NCT03710538|BEHAVIORAL|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
214280295|NCT04817865|DIAGNOSTIC_TEST|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
214280296|NCT04817865|DIAGNOSTIC_TEST|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
214280297|NCT01613404|OTHER|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
214280298|NCT06140784|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214280299|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214280300|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214280301|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214280302|NCT00253045|BEHAVIORAL|Motivational groups|Motivational interviewing in group format
214280303|NCT02266121|DEVICE|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
214280304|NCT01192854|DRUG|Clevudine|Clevudine flexible dosages of 30 mg/day
214280305|NCT01192854|DRUG|Adefovir|Adefovir flexible dosages of 10 mg/day
214280306|NCT01532414|DRUG|Androxal|oral, capsules, taken one time daily, for 3 months
214280307|NCT01532414|DRUG|Placebo|Oral capsule taken one time daily for 3 months
214280308|NCT05013073|OTHER|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
214280309|NCT00081484|DRUG|epoetin alfa or beta|iv or sc, as prescribed
214280310|NCT00081484|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
214280311|NCT00187486|DRUG|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
214280312|NCT00187486|DRUG|Temodar|Temodar 200 mg/m\^2/day x 5 days every 28 days
214280313|NCT00187486|PROCEDURE|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
214280314|NCT03210818|DEVICE|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
214280315|NCT05420077|BIOLOGICAL|RVM-V001 10 µg|Low Dose
214280316|NCT05420077|BIOLOGICAL|RVM-V001 30 µg|Mid Dose
214280317|NCT05420077|BIOLOGICAL|RVM-V001 60 µg|High Dose
214280318|NCT01938677|RADIATION|Initial Gamma knife radiosurgery|
214280319|NCT01606514|BEHAVIORAL|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
214280320|NCT00314392|BEHAVIORAL|Information (behavior)|
214280321|NCT04657120|PROCEDURE|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
214280322|NCT04657120|PROCEDURE|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
214280323|NCT02414750|DRUG|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
214280324|NCT02414750|DEVICE|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
214280325|NCT02414750|PROCEDURE|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
214280326|NCT02414750|PROCEDURE|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
214280327|NCT01598051|DRUG|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
214280328|NCT05426902|BEHAVIORAL|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
214280329|NCT02768012|BEHAVIORAL|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
214280330|NCT00004814|DRUG|copolymer 1|
214280331|NCT01837615|DEVICE|Photopill treatment|
214280332|NCT00578812|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
214280333|NCT00578812|DEVICE|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
214280334|NCT06217055|DRUG|remimazolam based MAC|The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
214280335|NCT06217055|DRUG|general anesthesia with sevoflurane|The surgery will be performed under mechanical ventilation with inhalation general anesthesia
214280336|NCT04069611|OTHER|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
214280337|NCT04069611|OTHER|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
214280338|NCT04069611|PROCEDURE|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
214280339|NCT04978740|OTHER|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
214280340|NCT01186510|PROCEDURE|lung perfusion|see literature of proceeding
214280341|NCT01186510|PROCEDURE|no lung perfusion|see literature of proceeding
214280342|NCT01088945|BEHAVIORAL|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
214280343|NCT02673437|OTHER|This is a non-interventional study|This is a non-interventional study
214839787|NCT00120315|DRUG|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
214839788|NCT00120315|PROCEDURE|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
214280344|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
214280345|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
214280346|NCT05025761|OTHER|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
214280347|NCT00692081|BEHAVIORAL|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
214280348|NCT00692081|BEHAVIORAL|Special vocational training|as provided in German special centres for vocational training
214280349|NCT02322034|OTHER|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
214280350|NCT00617773|BIOLOGICAL|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
214280351|NCT02283697|BEHAVIORAL|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
214280352|NCT02283697|OTHER|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
214280353|NCT00189254|DRUG|Imiquimod|No defined treatments were given during this study.
214280354|NCT05371743|DIAGNOSTIC_TEST|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆\_Ct) method
214280355|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
214280356|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
214280357|NCT03732235|DEVICE|TACE+ systemic Bevacizumab|PEG embolics
214280358|NCT03732235|DRUG|FOLFIRI+Bevacizumab|antiangiogenic factor
214280359|NCT03732235|DEVICE|TACE|PEG embolics
214280360|NCT00115050|DRUG|TMC114|
214280361|NCT02799511|BIOLOGICAL|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
214280362|NCT03582540|PROCEDURE|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
214280363|NCT02113592|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
214280364|NCT04950309|DEVICE|SQUID MEG|MEG recordings acquired on a standard whole brain SQUID MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
214280365|NCT04950309|DEVICE|OPM MEG|MEG recordings acquired on an investigational OPM MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
214280366|NCT04187014|DRUG|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
214280367|NCT04187014|DRUG|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
214280368|NCT03217175|DEVICE|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
214280369|NCT03217175|DEVICE|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
214280370|NCT03217175|DRUG|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
214280371|NCT03217175|DRUG|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
214280372|NCT02891759|OTHER|Alloderm RTU|-Most commonly used acellular dermal matrices
214280373|NCT02891759|OTHER|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
214280374|NCT02891759|PROCEDURE|Skin or nipple-sparing mastectomy|-Standard of care
214280375|NCT02891759|OTHER|Breast Q|"* 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
214280376|NCT02891759|PROCEDURE|Surgery|"* To address the tissue expander~* Standard of care"
214280377|NCT03178864|DRUG|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
214280378|NCT03178864|DRUG|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
214280379|NCT00688974|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
214280380|NCT00688974|PROCEDURE|Adjustable gastric band|Laparoscopic adjustable gastric band
214280381|NCT06026761|DEVICE|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
214280382|NCT01118702|DRUG|Ritalin-SR|3-20mg tablets, once
214280383|NCT01118702|DRUG|Concerta|one 54mg tablet, once
214280384|NCT01118702|DRUG|Novo-Methylphenidate ER-C|one 54mg tablet, once
214280385|NCT02837016|DEVICE|Wearable biofeedback|
214280386|NCT02837016|BEHAVIORAL|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
214280387|NCT03568760|BEHAVIORAL|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
214280388|NCT03568760|BEHAVIORAL|Comprehension training|Reading and hearing comprehension
214280389|NCT05770791|DIETARY_SUPPLEMENT|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
214280390|NCT05770791|DIETARY_SUPPLEMENT|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
214280391|NCT05500586|DRUG|Glucagon response study|Please see information in group descriptions
214280392|NCT04039815|DRUG|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
214280393|NCT04039815|DRUG|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
214280394|NCT03552653|DIETARY_SUPPLEMENT|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
214280395|NCT05779293|DEVICE|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
214280396|NCT05779293|OTHER|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
214280397|NCT00007969|BIOLOGICAL|Detox-B adjuvant|
214280398|NCT00007969|DRUG|verteporfin|
214280399|NCT02254993|DRUG|C16G2|antimicrobial peptide
214280400|NCT02174120|DRUG|propofol|
214280401|NCT02174120|DRUG|etomidate|
214280402|NCT01344005|OTHER|caregiver-related intervention or procedure|
214280403|NCT01344005|OTHER|questionnaire administration|
214280404|NCT01344005|PROCEDURE|quality-of-life assessment|
214280405|NCT01344005|PROCEDURE|radiography|
214280406|NCT03074591|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
214280407|NCT03074591|DRUG|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
214280408|NCT05604092|DIAGNOSTIC_TEST|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
214280409|NCT05604092|OTHER|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
214280410|NCT01331915|BIOLOGICAL|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
214280411|NCT03102372|DIETARY_SUPPLEMENT|Whey protein supplementation|
214280412|NCT03102372|OTHER|walking program|
214280413|NCT03102372|OTHER|Very Low Calorie Diet|
214280414|NCT00957775|BEHAVIORAL|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
214280415|NCT00957775|BEHAVIORAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
214280416|NCT01896544|DIETARY_SUPPLEMENT|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
214280417|NCT01896544|DIETARY_SUPPLEMENT|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
214280418|NCT03773081|DEVICE|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
214280419|NCT00036738|DRUG|Cyclosporine|Given IV or PO
214280420|NCT00036738|DRUG|Dasatinib|Given PO
214280421|NCT00036738|DRUG|Fludarabine Phosphate|Given IV
214280422|NCT00036738|DRUG|Imatinib Mesylate|Given PO
214280423|NCT00036738|DRUG|Mycophenolate Mofetil|Given PO
214280424|NCT00036738|DRUG|Nilotinib|Given PO
214280425|NCT00036738|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
214280426|NCT00036738|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
214280427|NCT00036738|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
214280428|NCT00036738|RADIATION|Total-Body Irradiation|Undergo TBI
214280429|NCT03062683|OTHER|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
214280430|NCT02902419|OTHER|Wound dressing removal.|
214280431|NCT04650360|BEHAVIORAL|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
214280432|NCT06959472|BEHAVIORAL|Hyperarch Fascia Training|A 12-week behavioral intervention involving Hyperarch Fascia Training (HFT), which includes one weekly 1-hour virtual session with a certified coach and two 1-hour independent training sessions. The protocol combines meditation, mental imagery, foot and toe strengthening exercises, myofascial rolling, balance drills, and low-impact plyometrics.
214280433|NCT02706470|DRUG|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
214280434|NCT02706470|DRUG|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
214280435|NCT06836284|DEVICE|Digi-physical treatment tool, Evira|A digi-physical treatment tool named Evira will be used to provide behavioral treatment.
214280436|NCT06836284|DRUG|Anti-obesity medication with liraglutide or semaglutide|Anti-obesity medication with liraglutide or semaglutide according to the clinic's standard procedure
214280437|NCT03398967|BIOLOGICAL|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~3. Other: Laboratory Biomarker Analysis"
214280438|NCT01127074|BIOLOGICAL|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
214280439|NCT01888679|PROCEDURE|Head movement|Head movement in extension, flexion, right and left rotation
214280440|NCT04792164|PROCEDURE|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
214280441|NCT04792164|PROCEDURE|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
214280442|NCT01221883|DRUG|Diazepam|Single dose 10mg Diazepam tablet
214280443|NCT02224040|DRUG|ceftriaxone|
214280444|NCT02224040|DRUG|ceftriaxone and azithromycin|
214280445|NCT02224040|DRUG|azithromycin|
214280446|NCT02224040|DRUG|azithromycin and cefixime|
214280447|NCT05168488|BEHAVIORAL|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
214280448|NCT05168488|BEHAVIORAL|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
214280449|NCT00617565|DRUG|biphasic insulin aspart|
214280450|NCT00617565|DRUG|biphasic human insulin|
214280451|NCT03906123|DRUG|NBP|NBP soft capsules
214280452|NCT03906123|DRUG|Placebos|Soft capsules manufactured to mimic NBP
214280453|NCT03015389|PROCEDURE|Diagnostic Test|WATS3D brush biopsy
214280454|NCT01235247|BEHAVIORAL|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
214280455|NCT01735682|DEVICE|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
214280456|NCT01735682|BEHAVIORAL|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
214280457|NCT01735682|BEHAVIORAL|Control|The control treatment involves exercises of the upper limbs.
214280458|NCT02047890|DRUG|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
214280459|NCT02047890|DRUG|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
214280460|NCT04847505|DIAGNOSTIC_TEST|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
214280461|NCT04340401|DRUG|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
214280462|NCT04340401|DRUG|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
214280463|NCT04340401|DRUG|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
214280464|NCT04340401|RADIATION|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
214280465|NCT04340401|PROCEDURE|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
214280466|NCT02552199|OTHER|gravimetric|
214280467|NCT03837106|OTHER|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
214280468|NCT03487276|DRUG|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
214280469|NCT03487276|DRUG|Placebo|Placebo
214280470|NCT05035550|BEHAVIORAL|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
214280471|NCT03174236|DRUG|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
214280472|NCT03174236|DRUG|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
214280473|NCT03174236|DRUG|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
214280474|NCT03174236|OTHER|Placebo|Suspension manufactured to match metronidazole
214280475|NCT03174236|DRUG|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
214280476|NCT01179854|DRUG|Remegal|Drug/ placebo
214280477|NCT01751867|DRUG|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
214280478|NCT01751867|DRUG|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
214280479|NCT04920604|OTHER|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
214280480|NCT04920604|OTHER|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
214280481|NCT00754819|DRUG|Colchicine|1mg once daily
214280482|NCT00754819|DRUG|Placebo|1 capsule daily
214280483|NCT01464489|DRUG|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
214280484|NCT01464489|DRUG|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
214280485|NCT04769440|DRUG|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
214280486|NCT00002531|DRUG|asparaginase|
214280487|NCT00002531|DRUG|cyclophosphamide|
214280488|NCT00002531|DRUG|cytarabine|
214280489|NCT00002531|DRUG|daunorubicin hydrochloride|
214280490|NCT00002531|DRUG|dexamethasone|
214280491|NCT00002531|DRUG|doxorubicin hydrochloride|
214280492|NCT00002531|DRUG|etoposide|
214280493|NCT00002531|DRUG|ifosfamide|
214280494|NCT00002531|DRUG|leucovorin calcium|
214280495|NCT00002531|DRUG|mercaptopurine|
214280496|NCT00002531|DRUG|methotrexate|
214280497|NCT00002531|DRUG|mitoxantrone hydrochloride|
214280498|NCT00002531|DRUG|prednisolone|
214280499|NCT00002531|DRUG|teniposide|
214280500|NCT00002531|DRUG|thioguanine|
214280501|NCT00002531|DRUG|vincristine sulfate|
214280502|NCT00002531|DRUG|vindesine|
214280503|NCT00002531|PROCEDURE|allogeneic bone marrow transplantation|
214280504|NCT00002531|PROCEDURE|peripheral blood stem cell transplantation|
214280505|NCT00002531|RADIATION|radiation therapy|
214280506|NCT01806545|BIOLOGICAL|SRM003|One time implant (2 SRM003 pieces) on surgery day.
214280507|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
214280508|NCT03006991|OTHER|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
214280509|NCT02116907|DRUG|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
214280510|NCT00295841|DRUG|clofarabine|
214280511|NCT00295841|DRUG|cytarabine|
214280512|NCT01325415|DRUG|NKTR-118|25 mg tablet
214280513|NCT01325415|DRUG|moxifloxacin|400 mg tablet
214280514|NCT01325415|DRUG|Placebo|tablet
214280515|NCT01267734|DEVICE|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
214280516|NCT01267734|DEVICE|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
214280517|NCT01267734|DRUG|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
214280518|NCT01267734|DRUG|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
214280519|NCT04233151|DRUG|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
214280520|NCT04233151|DRUG|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
214280521|NCT04233151|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
214280522|NCT05432414|DRUG|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
214280523|NCT05432414|DRUG|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
214280524|NCT05432414|DRUG|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
214280525|NCT01823523|DRUG|Cefazolin, Cephalexin, Clindamycin|
214280526|NCT00952679|DEVICE|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
214280527|NCT03793231|COMBINATION_PRODUCT|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
214280528|NCT05205044|DIAGNOSTIC_TEST|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
214280529|NCT06628791|DIETARY_SUPPLEMENT|BK329|Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks
214280530|NCT06628791|DIETARY_SUPPLEMENT|Placebo|Placebo 400 mg/day for 12 weeks
214280531|NCT03095014|PROCEDURE|Cesarean Myomectomy|Myomectomy was done during Cesarean section
214280532|NCT03095014|PROCEDURE|Cesarean section|Cesarean delivery
214280533|NCT02854735|OTHER|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
214280534|NCT05830292|DEVICE|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
214280535|NCT01396148|DRUG|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
214280536|NCT01396148|DRUG|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
214280537|NCT02536040|DRUG|38% diammine silver fluoride|treatment of cavity with study agent
214280538|NCT02536040|OTHER|Water|Fluoride free, distilled water
214280539|NCT03472404|PROCEDURE|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
214280540|NCT03472404|PROCEDURE|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
214280541|NCT01851616|DIETARY_SUPPLEMENT|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
214280542|NCT01851616|DIETARY_SUPPLEMENT|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
214280543|NCT00884312|DRUG|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
214280544|NCT06280937|OTHER|Wearing a tie|Individuals in the study group will be asked to wear a tie during one office working day.
214280545|NCT00777712|OTHER|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
214280546|NCT00224042|DRUG|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
214280547|NCT00224042|DRUG|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
214280548|NCT04051762|DEVICE|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
214280549|NCT00398892|DRUG|Lipoic acid|Lipoic acid capsules
214280550|NCT02150096|OTHER|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
214280551|NCT02150096|OTHER|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
214280552|NCT02150096|OTHER|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
214280553|NCT01074866|DEVICE|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
214280554|NCT01892202|OTHER|Cohort|
214280555|NCT04561661|PROCEDURE|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
214280556|NCT04561661|PROCEDURE|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
214280557|NCT01113281|BIOLOGICAL|VPM1002 live vaccine|
214280558|NCT01113281|BIOLOGICAL|commercially available live vaccine BCG|
214280559|NCT03052725|DRUG|reslizumab|Reslizumab was provided in a pre-filled syringe.
214280560|NCT03809117|DIAGNOSTIC_TEST|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
214280561|NCT00404846|PROCEDURE|Hyperbaric Oxygenation Therapy|
214280562|NCT00289965|BEHAVIORAL|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
214280563|NCT00289965|BEHAVIORAL|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
214280564|NCT00289965|BEHAVIORAL|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
214280565|NCT01448486|DRUG|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
214280566|NCT00415662|DEVICE|Pulsed Signal Therapy (PST)|
214280567|NCT04390178|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
214280568|NCT03047694|OTHER|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
214280569|NCT03047694|OTHER|usual care|speech therapy
214280570|NCT03645369|DEVICE|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
214280571|NCT03645369|DEVICE|Ice pack|Ice pack containing gel
214280572|NCT00751270|BIOLOGICAL|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
214280573|NCT00751270|DRUG|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
214280574|NCT05447715|DRUG|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
214280577|NCT04976751|DRUG|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
214280578|NCT06258356|DRUG|Remimazolam|novel ultra-short-acting benzodiazepine-like anesthetic.
214280579|NCT06258356|DRUG|placebo|normal saline (compared to Remimazolam)
214280580|NCT00812864|DRUG|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
214280581|NCT05935293|DRUG|Dexmedetomidine|iv administration dexmedetomidine
214280582|NCT05392010|OTHER|no intervention|no intervention
214280583|NCT02098759|DEVICE|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
214280584|NCT01186354|BEHAVIORAL|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
214280585|NCT04028700|BIOLOGICAL|G6PD Deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
214280586|NCT04028700|BIOLOGICAL|Non-G6PD deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
214839789|NCT06677632|OTHER|Palmitoylation Enzyme Expression Profiling Study|The expression of 23 zDHHC enzymes will be studied in human post-mortem hippocampi of AD patients and controls that have already been collected from UK brain biobanks. zDHHC enzymes will be analyzed at both mRNA and protein levels by Real Time PCR and Western blotting techniques, respectively
214280587|NCT02823301|BEHAVIORAL|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
214280588|NCT01176084|BEHAVIORAL|low carbohydrate diet|
214280589|NCT01176084|BEHAVIORAL|low carbohydrate diet and exercise|
214280590|NCT02548650|DRUG|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214280591|NCT02548650|DRUG|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214280592|NCT02548650|DRUG|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214280593|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
214280594|NCT06122896|OTHER|Screening Blood Tests|Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.
214280595|NCT06122896|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
214280596|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Imaging|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
214280597|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Cholangiopancreatography|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
214280598|NCT05091749|BIOLOGICAL|blood samples|troponin measurement
214280599|NCT03264261|DEVICE|robotic training|robotic training, 3 times/week for 6 weeks
214280600|NCT03264261|DEVICE|treadmill training|treadmill training only, 3 times/week for 6 weeks
214280601|NCT06120387|PROCEDURE|Radical surgery|Radical nephroureterectomy
214280602|NCT06120387|RADIATION|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
214280603|NCT02983474|PROCEDURE|cholecystectomy|"Laparoscopic surgery~1. Reverse Trendelenburg position~2. Skin incision and trocar insertion~3. CO2 gas insufflation~4. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction~6. Calot triangle exposure~7. Cystic artery and cystic duct isolation~8. Gallbladder bed dissection~9. Bleeding control~10. Gallbladder extraction~11. Trocar removal and wound closure~Open surgery~1. Supine position~2. Skin incision~3. Intra-abdominal inspection and gallbladder exposure~5\. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
214280604|NCT01539538|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
214280605|NCT01539538|DRUG|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
214280606|NCT02654743|DIETARY_SUPPLEMENT|Sulforaphane|Children with ASD will receive Sulforaphane in this study
214280607|NCT05947396|DIETARY_SUPPLEMENT|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
214280608|NCT05947396|OTHER|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
214280609|NCT00598104|DRUG|QAX576|
214280610|NCT00598104|DRUG|Placebo|
214280611|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
214280612|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
214280613|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
214280614|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
214280615|NCT04496271|DEVICE|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
214280616|NCT03909841|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
214280617|NCT03909841|OTHER|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
214280618|NCT00003931|GENETIC|reverse transcriptase-polymerase chain reaction|
214280619|NCT01909674|DEVICE|Switch CPAP mask type|
214280620|NCT00873197|DRUG|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
214280621|NCT01657669|DRUG|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
214280622|NCT03974425|DRUG|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
214280623|NCT00847379|DRUG|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
214280624|NCT05528185|OTHER|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
214280625|NCT02672865|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
214280626|NCT05801874|DIAGNOSTIC_TEST|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
214280627|NCT03895385|DRUG|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
214280628|NCT05154591|GENETIC|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
214280629|NCT01294631|DRUG|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
214280630|NCT05094583|BEHAVIORAL|Use of SmokeFree app|Intervention Arm
214280631|NCT00531323|DRUG|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
214280632|NCT00531323|DRUG|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
214280633|NCT04858243|OTHER|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
214280634|NCT04858243|OTHER|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
214280635|NCT02969369|DRUG|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
214280636|NCT02969369|DRUG|Placebo capsule|Placebo once daily
214280637|NCT00521014|BIOLOGICAL|filgrastim|
214280638|NCT00521014|BIOLOGICAL|rituximab|
214280639|NCT00521014|BIOLOGICAL|sargramostim|
214280640|NCT00521014|DRUG|carmustine|
214280641|NCT00521014|DRUG|cytarabine|
214280642|NCT00521014|DRUG|etoposide|
214280643|NCT00521014|DRUG|melphalan|
214280644|NCT00521014|PROCEDURE|autologous hematopoietic stem cell transplantation|
214280645|NCT05862480|OTHER|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
214280646|NCT05862480|OTHER|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
214280647|NCT04645927|DIETARY_SUPPLEMENT|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
214280648|NCT04645927|DIETARY_SUPPLEMENT|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
214280649|NCT00120731|DRUG|Potassium Citrate|
214280650|NCT00120731|DRUG|Acetazolamide|
214280651|NCT00120731|BEHAVIORAL|Diet low in oxalate and purines|
214280652|NCT01561170|DEVICE|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
214280653|NCT01561170|DEVICE|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
214280654|NCT03699657|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
214280655|NCT03699657|DEVICE|SSM|Monopolar RFA using single switching mode (SSM)
214280656|NCT03699657|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
214280657|NCT01695187|DRUG|NB-001 (0.3%)|Topical administration at least five times throughout the day
214280658|NCT01695187|DRUG|Placebo|
214280659|NCT01780077|DRUG|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
214280660|NCT01780077|DRUG|Placebo|Multiple intradermal injections of placebo at incision sites
214280661|NCT04890769|DEVICE|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
214280662|NCT04027426|BEHAVIORAL|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
214280663|NCT04027426|BEHAVIORAL|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
214280664|NCT02279563|DRUG|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
214280665|NCT02279563|DRUG|Dymista™ Nasal Spray|
214280666|NCT02279563|DRUG|Placebo|
214280667|NCT03641859|DEVICE|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
214280668|NCT00001006|DRUG|AS-101|
214280669|NCT05214885|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
214280670|NCT02794883|BIOLOGICAL|Durvalumab|Given IV
214280671|NCT02794883|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214280672|NCT02794883|PROCEDURE|Surgical Procedure|Undergo surgical tumor resection
214280673|NCT02794883|BIOLOGICAL|Tremelimumab|Given IV
214280674|NCT05199129|DRUG|HCP1904-3|Take once daily for 8 weeks orally
214280675|NCT05199129|DRUG|RLD2001-1|Take once daily for 8 weeks orally
214280676|NCT05566912|OTHER|filling out a survey|This research is a descriptive study
214280677|NCT01023932|DEVICE|Cochlear Implants|
214280678|NCT02563405|DRUG|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
214280679|NCT02563405|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
214280680|NCT03859193|BEHAVIORAL|Nutritional Video|A 10 - 15 minute video
214280681|NCT05772000|DIAGNOSTIC_TEST|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
214280682|NCT06505668|DRUG|Atenolol 25 mg|Patients will be receiving Atenolol 25mg OD for 2 months.
214280683|NCT06505668|DRUG|Ivabradine 10mg|Patients will be receiving Ivabradine 5mg BD for 2 months.
214280684|NCT01744574|OTHER|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
214280685|NCT01744574|DRUG|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
214280686|NCT01744574|OTHER|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
214280687|NCT05512572|DEVICE|IPL|intense pulsed light
214280688|NCT05512572|PROCEDURE|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
214280689|NCT01390805|DRUG|Valaciclovir Hydrochloride.|
214280690|NCT02154178|OTHER|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
214280691|NCT02277145|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
214280692|NCT05781854|DRUG|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
214280693|NCT00978198|DRUG|ASP1517|oral
214280694|NCT00978198|DRUG|Placebo|oral
214280695|NCT01425996|DRUG|Lipotecan® (TLC388)|"* Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
214280696|NCT05201703|DRUG|Fycompa|Fycompa 4 mg daily
214280697|NCT05201703|DRUG|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
214280698|NCT04786145|PROCEDURE|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
214280699|NCT04786145|PROCEDURE|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
214280700|NCT04786145|PROCEDURE|Placebo|No active treatment is given.
214280701|NCT05637866|OTHER|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
214280702|NCT06085612|DIAGNOSTIC_TEST|Automated retinal oximetry|Non invasive standard examination on automated retinal oximetry.
214280703|NCT06270667|BEHAVIORAL|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
214280704|NCT06270667|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
214280705|NCT05013684|OTHER|Particle Repositioning Maneuver|treatment with Particle Repositioning Maneuver
214280706|NCT03255798|DEVICE|G2 and G3|Two iStent inject devices and one iStent supra device
214280707|NCT04497831|DRUG|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
214280708|NCT04497831|DRUG|Placebo|Inhalation use
214280709|NCT01965587|PROCEDURE|novasure mirena IUS combined|novasure mirena IUS combined
214280710|NCT01352910|DEVICE|rTMS|120 pulses 0.2 Hz
214280711|NCT01352910|DEVICE|Sham rTMS|120 pulses 0.2 Hz
214280712|NCT02554500|PROCEDURE|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
214280713|NCT04637230|DIAGNOSTIC_TEST|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
214280714|NCT02900196|OTHER|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
214280715|NCT02900196|OTHER|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
214280716|NCT05366946|OTHER|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
214280717|NCT00393029|BIOLOGICAL|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
214280718|NCT00393029|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
214280719|NCT00393029|BIOLOGICAL|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
214280720|NCT00393029|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
214280721|NCT00393029|DRUG|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
214280722|NCT03155568|PROCEDURE|sciatic nerve block|sciatic nerve block at popliteal fossa
214280723|NCT03155568|PROCEDURE|ankle block|block of major nerves supplying the foot at the level of the ankle
214280724|NCT03155568|DRUG|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
214280725|NCT06293001|OTHER|No intervention|No intervention
214280726|NCT03715530|DEVICE|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
214280727|NCT02805010|DRUG|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
214280728|NCT02805010|OTHER|Placebo|On Day 1, subjects will receive a single SC dose of placebo
214280729|NCT06055010|OTHER|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
214280730|NCT05820178|DEVICE|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
214280731|NCT05820178|DEVICE|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
214280732|NCT01072331|DRUG|MP-513|MP-513 10 mg, once a day, for 4 weeks
214280733|NCT01072331|DRUG|MP-513|MP-513 20 mg, once a day, for 4 weeks
214280734|NCT01072331|DRUG|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
214280735|NCT04812145|RADIATION|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
214280736|NCT00607009|BEHAVIORAL|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
214280737|NCT04257981|DEVICE|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
214280738|NCT04257981|OTHER|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
214280739|NCT04948710|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
214280740|NCT00211510|DEVICE|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
214280741|NCT00211510|DEVICE|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
214280742|NCT00000329|DRUG|Opioid-Related Disorders|
214280743|NCT05654220|BEHAVIORAL|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
214280744|NCT05173662|PROCEDURE|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
214280745|NCT02937883|OTHER|Empowerment intervention|Empowerment intervention for persons with young onset dementia
214280746|NCT05466656|OTHER|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
214280747|NCT04575116|DRUG|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
214280748|NCT04575116|DRUG|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
214280749|NCT03335098|DRUG|Bortezomib|Six 4-week cycles
214280750|NCT04561830|PROCEDURE|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
214280751|NCT05089942|DRUG|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
214280752|NCT05089942|DRUG|Placebo|health subjects receive placebo patch
214280753|NCT04367428|BIOLOGICAL|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
214280754|NCT06237829|BEHAVIORAL|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
214280755|NCT06237829|BEHAVIORAL|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
214280756|NCT06237829|BEHAVIORAL|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
214280757|NCT01362205|DRUG|Dexmedetomidine|
214280758|NCT01362205|DRUG|Placebos|Inactive placebo (normal saline)
214280759|NCT04298801|PROCEDURE|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
214280760|NCT04298801|OTHER|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
214280761|NCT02131207|DEVICE|magnetic resonance imaging|Undergo pelvic MRI
214280762|NCT02131207|PROCEDURE|prostate biopsy|Undergo prostate biopsy
214280763|NCT00563498|DRUG|Glutamine|
214280764|NCT01372462|DEVICE|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
214280765|NCT01372462|DEVICE|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
214280766|NCT01372462|DEVICE|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
214280767|NCT02385513|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|
214280768|NCT00099008|DIETARY_SUPPLEMENT|Genistein|oral Genistein twice daily on days 1-84
214280769|NCT00099008|DIETARY_SUPPLEMENT|Placebo|oral Placebo twice daily on days 1-84
214280770|NCT02726152|PROCEDURE|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
214280771|NCT02726152|PROCEDURE|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
214280772|NCT04645082|DIAGNOSTIC_TEST|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
214280773|NCT01172431|DRUG|Indapamide|Indapamide SR 1.5mg qd
214280774|NCT01172431|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
214280775|NCT03648983|PROCEDURE|arm circumference measurement|Undergo arm circumference measurement
214280776|NCT03648983|DEVICE|Bioimpedance spectroscopy|bioimpedance spectroscopy
214280777|NCT05677581|OTHER|iodine nutrition status|iodine nutrition status
214280778|NCT05892120|BEHAVIORAL|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
214280779|NCT05776615|OTHER|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
214280780|NCT04972695|DIAGNOSTIC_TEST|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
214280781|NCT01269463|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
214280782|NCT01269463|DRUG|Placebo|Capsule without active drug
214280783|NCT01435200|DRUG|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
214280784|NCT02803632|BEHAVIORAL|questionnaires|
214280785|NCT02803632|DEVICE|actigraphic recording|
214280786|NCT02288897|DRUG|PV-10 (10% rose bengal disodium)|
214280787|NCT02288897|DRUG|Dacarbazine, temozolomide or talimogene laherparepvec|
214280788|NCT04380415|DIAGNOSTIC_TEST|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
214280789|NCT02499822|DRUG|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
214280790|NCT02499822|DRUG|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
214280791|NCT03121638|BIOLOGICAL|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
214280792|NCT03121638|BIOLOGICAL|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
214280793|NCT03121638|BIOLOGICAL|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
214280794|NCT03121638|BIOLOGICAL|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
214280795|NCT03121638|BIOLOGICAL|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
214280796|NCT02862171|DRUG|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
214280797|NCT02849431|BEHAVIORAL|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
214280798|NCT00245115|BIOLOGICAL|filgrastim|
214280799|NCT00245115|DRUG|busulfan|
214280800|NCT00245115|DRUG|cyclophosphamide|
214280801|NCT00245115|PROCEDURE|in vitro-treated bone marrow transplantation|
214280802|NCT00245115|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214280803|NCT05282862|PROCEDURE|Horizontal bone augmentation|Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
214280804|NCT02798601|OTHER|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
214280805|NCT02549937|DRUG|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
214280806|NCT03046004|OTHER|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
214280807|NCT03046004|OTHER|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
214280808|NCT00662012|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
214280809|NCT03594721|OTHER|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
214280810|NCT06451094|DEVICE|US therapy|3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
214280811|NCT06451094|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
214280812|NCT05853185|DRUG|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
214280813|NCT05853185|DRUG|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
214280814|NCT01205906|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
214280815|NCT01205906|BEHAVIORAL|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
214280816|NCT01205906|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
214280817|NCT04269252|OTHER|CHI-907|CHI-907 is a high CBD extract.
214280818|NCT04269252|OTHER|CHI-804|CHI-804 is the placebo formulation.
214280819|NCT05450952|DIETARY_SUPPLEMENT|Theanine Formulation|Theanine Formulation Tablet
214280820|NCT05450952|DIETARY_SUPPLEMENT|Placebo|Placebo Tablet
214280821|NCT01893632|DRUG|gabapentin|
214280822|NCT01893632|DRUG|Placebo|
214280823|NCT02640014|DIETARY_SUPPLEMENT|Milk|Milk Oral immunotherapy
214280824|NCT05190237|DIETARY_SUPPLEMENT|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
214280825|NCT05190237|DIETARY_SUPPLEMENT|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
214280826|NCT05190237|DIETARY_SUPPLEMENT|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
214280827|NCT00567294|BEHAVIORAL|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
214280828|NCT00567294|BEHAVIORAL|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
214280829|NCT00567294|BEHAVIORAL|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
214280830|NCT00477256|BEHAVIORAL|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
214280831|NCT04644081|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
214280832|NCT04644081|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
214280833|NCT04644081|DRUG|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
214280834|NCT04186728|DIETARY_SUPPLEMENT|Magnesium glycinate|Daily magnesium capsule.
214280835|NCT04186728|OTHER|Placebo|Daily placebo capsule.
214280836|NCT01965301|DRUG|BP1.5375 suspension|single oral dose
214280837|NCT01965301|DRUG|Diphenhydramine|single oral dose of Diphenhydramine 50mg
214280838|NCT01965301|DRUG|Placebo|Single oral dose
214280839|NCT03224715|OTHER|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
214280840|NCT04193098|BIOLOGICAL|CTL|CTL injection
214280841|NCT04193098|BIOLOGICAL|Toripalimab|Toripalimab injection
214280842|NCT03602144|OTHER|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
214280843|NCT03602144|OTHER|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
214280844|NCT02412475|DRUG|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
214280845|NCT02412475|DRUG|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
214280846|NCT02412475|DRUG|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
214280847|NCT02412475|DRUG|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
214280848|NCT02412475|DRUG|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
214280849|NCT02412475|DRUG|Cytarabine|"Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1"
214280850|NCT02412475|DRUG|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
214280851|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
214280852|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
214280853|NCT06266910|OTHER|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
214280854|NCT03331367|PROCEDURE|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
214280855|NCT03331367|PROCEDURE|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
214280856|NCT01949506|RADIATION|SBRT|Stereotactic Body Radiation Therapy
214280857|NCT00694174|DRUG|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
214280858|NCT00694174|DRUG|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
214280859|NCT04936256|DEVICE|Clareon|Clareon monofocal intraocular lens (IOL)
214280860|NCT01503918|DRUG|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
214280861|NCT01503918|DRUG|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
214280862|NCT05792709|OTHER|Oral Motor Therapy|In Traditional therapy we will give cognitive and articulation therapy to the patients.
214280863|NCT05491109|DEVICE|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
214280864|NCT01670240|DRUG|Adalimumab|
214280865|NCT01670240|DRUG|Placebo|
214280866|NCT03261050|BEHAVIORAL|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
214280867|NCT03261050|BEHAVIORAL|Interpersonal Therapy|8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
214280868|NCT06651437|OTHER|Experimental dietary educational intervention|At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
214280869|NCT06170970|DRUG|Solriamfetol|solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
214280870|NCT06170970|DRUG|Placebo|Four weeks of oral placebo
214280871|NCT06979141|DRUG|Dexmedetomidine|Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
214280872|NCT06979141|DRUG|Magnesium sulfate|Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
214280873|NCT06979141|DRUG|Lidocaine|Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
214280874|NCT06979141|DRUG|normal saline|Patients will receive 10 ml normal saline 10 min before the end of surgery.
214280875|NCT05475236|BEHAVIORAL|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
214280876|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
214280877|NCT06599996|DEVICE|Testing artificial intelligence algorithms for interpreting gestures|The effectiveness of artificial intelligence algorithms for detecting and interpreting body-based gestures by individuals who have motor/visual impairments will be evaluated.
214280878|NCT04921189|DRUG|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
214280879|NCT04921189|DRUG|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
214280880|NCT06443359|RADIATION|hypofractionated radiation|All patients will receive a dose of 42.56 Gy in 16 daily fractions to the whole breast or chest wall and regional lymph nodes. A boost dose of 10 or 12.5 Gy in 4 or 5 daily fractions of 2.5 Gy, respectively, will be administered to either the lumpectomy cavity or mastectomy scar, as appropriate.
214280881|NCT06820021|OTHER|Strength-based Tailored-Exercise Program at Home (STEP@Home)|The 20-week STEP@Home is a multi-component exercise training program designed to recondition the functional status of older adults in the post-discharge period and to develop long-term exercise engagement. The content is developed based on the recommendations from a scope review and the Vivifrail exercise guideline on home-based exercise for older adults , with expert input from the research team including geriatricians in frailty management, exercise physiologist, nursing academicians in aged care research. Three design characteristics, including an empowerment approach (Funnell \& Anderson, 2004), lifestyle-integrated functional exercises (Weber et al., 2018), and an optimized tele-platform, are incorporated into the exercise program to enhance such therapeutic benefit.
214280882|NCT06820021|OTHER|Usual Care|The control group will receive the usual post-discharge care provided in the hospital setting, including general education on medication, basic knowledge of disease-related self-care, and/or attending regular medical follow-ups in the specialist outpatient clinics. The RA will review the client's post-discharge planning and record social and healthcare service referral information. The RA will only make home visits for data collection, and the controls will receive a HK$100 supermarket coupon as an incentive, which will be applied to the intervention group.
214280883|NCT05795439|BEHAVIORAL|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
214280884|NCT06089473|OTHER|Intervention Group: Exercise and education.|"* Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session.~* Education: Prior to each zoom session with the kinesiologist (starting on week 2), participants will watch short educational videos. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress."
214280885|NCT06089473|OTHER|Usual Care Only|Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
214280886|NCT03782961|DEVICE|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
214280887|NCT06046365|DIAGNOSTIC_TEST|lymphoscintigraphy|lymphoscintigraphy
214280888|NCT06046365|DIAGNOSTIC_TEST|circumference measurement|circumference measurement
214280889|NCT06046365|DIAGNOSTIC_TEST|sonography|B-mode sono and elastography
214280890|NCT06046365|DIAGNOSTIC_TEST|DXA body composition analysis|DXA body composition analysis
214280891|NCT06596655|DEVICE|Single use bronchoscope|Use of single use bronchoscopes for interventional pulmonology procedures instead of reusable bronchoscopes.
214280892|NCT06827418|OTHER|simulation|Students will practice the psychomotor steps of blood pressure measurement using a simulator.
214280893|NCT06827418|OTHER|peer teaching|Students will practice the psychomotor steps of blood pressure measurement through peer teaching. Third- and fourth-year nursing students will serve as peer educators. Students will apply the skill steps under the guidance of an upper-class peer instructor.
214280894|NCT04779554|DRUG|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
214280895|NCT04779554|DRUG|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
214280896|NCT06992063|PROCEDURE|Spinal anesthesia|In both groups patients will undergo spinal anesthesia and be followed intra- and postoperatively in the context of postdural puncture headache
214280897|NCT06856915|OTHER|Inspiratory muscle training|Participants will engage in inspiratory muscle training programme at home using an inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
214280898|NCT06856915|OTHER|Combined inspiratory and expiratory muscle training|Participants will engage in inspiratory+expiratory muscle training programme at home using an inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
214280899|NCT06856915|OTHER|Sham inspiratory muscle training|Participants will engage in sham inspiratory muscle training programme at home using a sham inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
214280900|NCT06856915|OTHER|Sham combined inspiratory and expiratory muscle training|Participants will engage in sham inspiratory+expiratory muscle training programme at home using a sham inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
214280901|NCT06856915|OTHER|Conventional cardiac rehabilitation programme|Following the respiratory muscle training programme, participants will transition to a center-based cardiovascular exercise programme conducted twice weekly for eight weeks.
214280902|NCT06997601|OTHER|Serratus posterior superior intercostal plane block|Patients will receive a serratus posterior superior intercostal plane block.
214280903|NCT06997601|OTHER|Suprascapular nerve block + Axillary nerve block|Patients will receive suprascapular nerve block + axillary nerve block.
214280904|NCT06996431|BEHAVIORAL|EMA-based weight management intervention|"Participants will complete four 7-day EMA sessions, reporting their diet for 3 days and physical activity for 4 days by completing ﬁve brief daily mobile app surveys (under 2 minutes each), using a 5-digit case number for privacy. The app automatically retrieves Fitbit data-such as step count, moderate-to-vigorous physical activity (MVPA), sedentary behavior, and heart rate- and sends timely reminders if surveys are missed.~Within one week after the ﬁrst EMA session, participants will attend a nurse- led counseling session using the 5A Model (Assess, Advise, Agree, Assist, Arrange), providing tailored feedback based on EMA and Fitbit data, and addressing barriers to change. This is followed by risk-based coaching from a dietitian and ﬁtness instructor, with individualized diet and exercise plans. Between sessions, participants receive ongoing support, including instant reminder messaging and weekly motivational messages to encourage healthy behaviors."
214280905|NCT06996431|BEHAVIORAL|Minimal Intervention|Participants will not receive risk-stratified services but will be provided with informational leaflets offering general advice on maintaining a healthy diet, regular exercise, smoking cessation, and alcohol cessation.
214280906|NCT04329533|OTHER|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
214280907|NCT06674499|OTHER|Self-help rehabilitation model|The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.
214839790|NCT04784637|DEVICE|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
214280908|NCT06674499|OTHER|Conventional rehabilitation model|The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
214280909|NCT07000630|DRUG|Deucravacitinib|25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.
214280910|NCT07002372|BEHAVIORAL|Procedure video viewing|Patients who have never had an intravitreal injection before will be randomly assigned to watch an educational video about the procedure prior to treatment.
214280911|NCT07001202|BEHAVIORAL|Indicated Prevention for suicidality|The Reframe-IT+U program is an individualized preventive intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, delivered within the University with psychologists and supervision. The program consists of six weekly sessions of 60-90 minutes each.
214280912|NCT07001254|DRUG|Romiplostim|The investigational drug, Romiplostim, is a thrombopoietin receptor agonist (TPO-RA) that has been granted orphan drug designation by the FDA.
214280913|NCT07001254|DRUG|Immunosuppressive therapy (IST)|Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)
214280914|NCT07001345|PROCEDURE|Alveolar Ridge Reconstruction|Alveolar ridge preservation with either xenograft of allograft material
214280915|NCT06993545|BEHAVIORAL|Video-based educational program on physical activity for migraine management|The intervention consisted of a series of seven short, pre-recorded educational videos delivered over a 3-month period. The videos focused on the benefits of regular physical activity for individuals with migraine and included practical strategies to increase daily activity levels. The content was evidence-based, developed with input from healthcare professionals, and tailored to migraine management. Participants received access to one video approximately every two weeks via email or online platform. The videos aimed to improve awareness, motivation, and self-efficacy regarding physical activity without prescribing a specific exercise program. No direct interaction with healthcare providers occurred during the intervention period.
214280916|NCT07000292|DRUG|Injection of MSC303|Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.
214280917|NCT06081036|OTHER|Questionnaire|Questionnaire about children development
214280918|NCT07001592|BIOLOGICAL|vvDD-hIL-2-RG-1|"A single dose of the investigational agent will be injected intratumorally at one of the following three dose levels.~Level 1: 3 x 108 p.f.u. Level 2: 1 x 109 p.f.u. Level 3: 3 x 109 p.f.u. p.f.u = Plaque-forming unit(s)~Dose will be escalated in cohorts of 3, according to a standard 3+3 design."
214280919|NCT06997263|DRUG|Melatonin 3 mg Sublingual|A single 3 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the Low-Dose Melatonin Group.
214280920|NCT06997263|DRUG|Melatonin 6 mg Sublingual|A single 6 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the High-Dose Melatonin Group.
214280921|NCT07000786|PROCEDURE|Endometrial biopsy or menstrual cup and blood sample|Enrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw.
214280922|NCT07000877|DRUG|Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))|Decongestant nasal spray containing active ingredient.
214280923|NCT07000877|DRUG|PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%|Control nasal spray containing no active ingredient.
214280924|NCT07004426|PROCEDURE|Surgical treatment of renal lesions|Surgical treatment of renal lesions
214280925|NCT07004010|DEVICE|Deoxycholic Acid Injection|The intervention include Deoxycholic acid, SC, 0.15 ml each injection, up to 2-4 ml in each site (2 ml at visit 1 for everyone, and 2 ml at visit 2 unless the patient does not agree)
214280926|NCT07001033|BEHAVIORAL|Dance Movement Therapy (DMT)|All participants will be invited to five group meetings at weekly intervals. Each of these therapy sessions will take place with a specific theme. In weeks 1 and 5, data important for the study will be collected once before the short-term DMT and once again at the end of the study. This includes different assessments, laboratory blood tests as well as immunophenotyping. Additionally, patients are requested to complete a questionnaire that addresses QoL. Specific examinations, such as testing the maximal handgrip strength, a BIA and recording Eastern Cooperative Oncology Group (ECOG) performance status are implemented in each of the five meetings.
214280927|NCT04118114|DRUG|PRL3-zumab|IV administration every 2 weeks
214280928|NCT06679270|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
214280929|NCT06547918|DEVICE|Omnipod 5 SA2.0 System|The Omnipod 5 SA2.0 System provides automated insulin delivery based on Continuous Glucose Monitoring (CGM) values.
214280930|NCT06546267|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT for Prostate cancer will be evaluated
214280931|NCT06546267|RADIATION|Intensity Modulated Radiotherapy|Patients treated with IMRT for Prostate cancer will be evaluated
214280932|NCT06546267|RADIATION|Stereotactic Body Radiotherapy|Patients treated with SBRT for Prostate cancer will be evaluated
214280933|NCT06621472|PROCEDURE|Retrolaminar block group|patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
214839791|NCT04784637|DEVICE|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
214839792|NCT04784637|DEVICE|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
214839793|NCT04784637|DEVICE|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
214280934|NCT06621472|OTHER|subcostal TAP technique|The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
214280935|NCT06621472|OTHER|thoracic Epidural|Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
214280936|NCT05342467|DRUG|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
214280937|NCT05342467|DRUG|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
214280938|NCT07007832|PROCEDURE|Endoscopic retrograde cholangiopancreatography|Since patients with biliary strictures almost universally require endoscopic biliary interventions for both diagnostic and drainage purposes, bile aspiration can be readily obtained during these procedures, facilitating subsequent analyses. However, proteomic and metabolomic profiling of bile in malignant biliary strictures remains unreported to date. This study aims to evaluate the diagnostic value of combining bile proteomics/metabolomics with biliary brush cytology/biopsy for malignant biliary strictures, while also providing evidence for identifying potential biomarkers.
214280939|NCT06681480|DEVICE|figure-of-eight active rTMS coil device|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
214280940|NCT06681480|DEVICE|figure-of-eight sham rTMS coil device|rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
214280941|NCT06865560|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|A validated, 8-week, group-based telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, emotion-focused expressive writing, in-vivo emotional expression practices, self-compassion and forgiveness exercises, and assertive communication strategies. Participants will also be provided handouts and pre-recorded guided imagery and cognitive exercises that they can use to facilitate between-session practices.
214280942|NCT06681753|OTHER|Experimental|No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
214280945|NCT07010302|DRUG|Rituximab (R)|1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months
214280946|NCT07010302|DRUG|Eculizumab (Soliris®)|900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks
214280947|NCT07010302|DRUG|Ravulizumab|"* 40 to \< 60 kg: 2400 mg~* 60 to \< 100 kg: 2700 mg~* 100 kg: 3000 mg as an induction dose, followed by~* 40 to \< 60 kg: 3000 mg~* 60 to \< 100 kg: 3300 mg~* 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose"
214280948|NCT07010302|DRUG|Satralizumab|120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks
214280949|NCT07010302|DRUG|Inebilizumab|300 mg on Day 1 and Day 15, followed by 300 mg every 6 months
214280950|NCT07016373|DEVICE|Palatal Plate without Manuka Honey|A Palatal plate without Manuka Honey will be inserted by a blinded investigator on the donor site for post-operative procedures.
214280951|NCT07016373|DEVICE|Palatal plate with Manuka Honey|A Palatal plate with Manuka Honey will be inserted by a blinded researcher on the donor site.
214280952|NCT07016191|OTHER|Ingestion of Water|Ingestion of Super-Oxygenated or Normal water
214280953|NCT07015294|DIETARY_SUPPLEMENT|Fruits and chaya infusion|Increased fruit consumption and daily intake of chaya infusion (prepared from Cnidoscolus chayamansa leaves),
214280954|NCT07015294|DIETARY_SUPPLEMENT|Conventional diet|Usual dietary habits, with no specific modifications
214280955|NCT07015710|PROCEDURE|Gamma Knife Radiosurgery|Patients underwent gamma knife radiosurgery (GKRS) for tectal plate gliomas (TPGs).
214280956|NCT07015814|OTHER|Golden sugarcane jaggery|Participants will consume a standardized portion of jaggery Type A providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
214280957|NCT07015814|OTHER|Dark brown sugarcane jaggery|Participants will consume a standardized portion of jaggery Type B providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
214280958|NCT07016126|COMBINATION_PRODUCT|D-BACE in combination with chemotherapy and karelizumab|3 cycles of D-BACE (DCB-loaded microspheres loaded with epirubicin 50 mg) in combination with chemotherapy and karelizumab (the specific regimen of chemotherapy is determined by the investigator, and platinum-containing two-agent chemotherapy is generally used).
214280959|NCT07016438|PROCEDURE|Transplant surgery|One piece of PAL-222 is implanted into the ulcer area through the surgical procedure.
214280960|NCT07015034|OTHER|focus on vision impairment in older patients in general practice|GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.
214280961|NCT07014917|DRUG|Venetoclax|intermittent venetoclax (7days administration per cycle) + acalabrutinib
214280962|NCT07014917|DRUG|Acalabrutinib|intermittent venetoclax (7days administration per cycle) + acalabrutinib
214280963|NCT07014917|DRUG|Venetoclax|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
214280964|NCT07014917|DRUG|Acalabrutinib|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
214280965|NCT07016087|OTHER|Cosmetic formulation experimental|Cosmetic formulation containing emollients and a butyrate releaser: the postbiotic N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA)
214280966|NCT07016087|OTHER|Cosmetic formulation usual|Cosmetic formulation containing emollients
214280967|NCT07014397|DRUG|Valacyclovir|valacyclovir group received 2 g (two 1 g tablets) one hour prior to treatment, followed by 2 g 12 hours later, and 1 g at both 24 and 36 hours post-treatment
214280968|NCT07014397|DRUG|Placebo|The control group received a placebo identical in appearance and administration schedule
214280969|NCT07014774|DEVICE|Laser acupuncture|"Laser acupuncture is a modern, non-invasive approach to acupuncture that uses low-level laser therapy (LLLT) instead of traditional needles to stimulate acupuncture points. This technique combines the principles of traditional Chinese medicine with modern technology to provide pain relief and promote healing (Chon et al., 2019).~* Device: UNIPHY PHYACTION 740, made in EEC device.~* Laser type: Gallium aluminum arsenide laser.~* Wavelength: 808 nm.~* Power Output: 200 mW.~* Dose/energy density: 4J/point.~* Frequency of treatment: Three times weekly for 8 weeks.~* Duration: 12 min.~* Cumulative dose: 48J/point.~* Target Acupuncture Points: Key points for CTS: PC4 (Ximen), PC6 (Neiguan), PC7 (Daling), PC8 (Laogong), LI4 (Hegu), LI10 (Shousanli), LI11 (Quchi), HT-2 (Qingling), HT7 (Shenmen), HT-8 (Shaofu), LU9 (Taiyuan) and LU10 (Yuji)"
214280970|NCT07014774|OTHER|Traditional Therapy|"* Splinting/Bracing: Patients in the two groups will advised to wear a static wrist splint locked at 0\_ wrist flexion for at least 8 h at night throughout the entire length of the study as the primary management which reduce pressure on the median nerve.~* Physical Therapy: Engaging in specific exercises, such as nerve glide exercises and wrist stretches, can improve mobility and reduce symptoms. These exercises aim to restore normal movement of the median nerve and alleviate compression"
214280971|NCT07015788|OTHER|EARLY GRAND|Participants will consume a standardized portion of peach variety A containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
214280972|NCT07015788|OTHER|SPRING CREST PEACH|Participants will consume a standardized portion of peach variety B containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
214280973|NCT07015788|OTHER|INDIAN BLOOD|Participants will consume a standardized portion of peach variety C containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
214280974|NCT06235203|PROCEDURE|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
214280975|NCT06235203|DRUG|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
214280976|NCT06235203|DRUG|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
214280977|NCT06235203|DRUG|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
214280978|NCT07016503|OTHER|Professional values education|At this stage, a comprehensive literature review was conducted and professional values education was prepared. The prepared education content was transferred to a website for which a domain was purchased within the scope of the research. The developed website was presented to the opinion of a group of 7 experts in terms of content: Child Health and Diseases Nursing Department Faculty Members (4), Nursing Fundamentals Department Faculty Members (1), Public Health Nursing Department Faculty Members (2). Expert opinions were evaluated with the measurement tool prepared by the researchers in line with the literature.
214280979|NCT07015502|OTHER|Questionnaires|Patients will undergo socio-demographic and history of violence suffered interview, passation of the Montgomery-Asberg Depression Rating Scale (MADRS),Childhood Trauma Questionnaire, Deshumanization Measure within Romantic Relationships scale, self-esteem scale, violentometer and an implicit association test (IAT).
214280980|NCT06680765|BEHAVIORAL|Intervention group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
214280981|NCT06680765|BEHAVIORAL|Comparison group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
214280982|NCT02971254|DRUG|Sevoflurane|
214280983|NCT02971254|DRUG|Desflurane|
214280984|NCT07014540|DRUG|Irinotecan Hydrochloride Liposome Injection|Liposome irinotecan (70/50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
214280985|NCT07014540|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by continuous infusion for 46 hours in a 2-week
214280986|NCT07014540|DRUG|LV|LV (400mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
214280987|NCT07014475|DEVICE|drug-coated balloon|Drug-coated balloon was used during the index procedure.
214280988|NCT07014748|DIAGNOSTIC_TEST|Handheld brain hematoma detector|Near Infrared based handheld traumatic brain hematoma detector
214280989|NCT07015489|DRUG|induction chemotherapy and immunotherapy|"All patients will first receive 2 cycles of induction chemoimmunotherapy, followed by radiotherapy. During radiotherapy, 2 concurrent cycles of chemoimmunotherapy will be administered. Afterward, maintenance immunotherapy will continue for up to one year.~Chemotherapy regimen: Paclitaxel: 135 mg/m², Day 1, every 3 weeks (Q3W); Carboplatin: area under the curve (AUC) = 5, intravenous infusion over more than 30 minutes, Day 2, Q3W; Alternatively, Nedaplatin: 75 mg/m², Day 2, Q3W.~Immunotherapy regimen: programmed death-1 (PD-1) inhibitor (e.g., Camrelizumab): Day 0, intravenous infusion, Q3W; Continued until disease progression (PD) or unacceptable toxicity, for a maximum duration of one year.~Radiotherapy: Prescribed dose: 95% of the planning target volume (PTV) and planning target volume for nodal disease (PTV-nd) should receive 50-50.4 Gy over 25-28 fractions; Fraction dose range: 1.8-2.0 Gy per fraction, 5 days per week; External beam radiotherapy to the chest."
214839794|NCT00535028|DRUG|AER 001|AER 001 25 mgs s.c. once daily for 28 days
214280990|NCT07014683|BEHAVIORAL|INCREM|This is a specifically designed program to improve psychosocial functioning which targets cognitive symptoms.
214280991|NCT07014683|BEHAVIORAL|Psychoeducation|This is a 12-session psychoeducation program designed as an active comparator for the current trial
214280992|NCT07016490|DRUG|SSGJ-709|A bispecific antibody targeting PD-1 and LAG-3.
214280993|NCT07014358|DEVICE|Fastening systems by placing two steel pins|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of two steel pins.
214280994|NCT07014358|DEVICE|Fastening systems by a wire in an obenque configuration|Fixation of the osteotomized bone with a stable fixation system, in this case, an obenque configuration
214280995|NCT07014358|DEVICE|Fastening systems by the placement of a bolted plate or the placement of a compression screw|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of a bolted plate or the placement of a compression screw.
214280996|NCT07014735|DRUG|glucose|Participants will receive treatments with glucose or matching placebo (please see study design section).
214280997|NCT07014735|DRUG|moxifloxacin|Participants will receive moxifloxacin or matching placebo (please see study design section).
214280998|NCT07015567|BEHAVIORAL|Emotion regulation module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about emotion regulation. This module contains exercises for emotional awareness and emotion regulation with different focuses (on body, thoughts and behaviour).
214280999|NCT07015567|BEHAVIORAL|Negative self-concept module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about negative self-concept. In this module, we tackle topics such as what is the self, thinking about the self through cognitive restructuring, criticism and compassion and the self in relation to others.
214281000|NCT07015567|BEHAVIORAL|Interpersonal relationships module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about interpersonal relationships. This module includes exercises to understand relationship patterns, increasing assertiveness, practicing assertiveness, and managing power.
214281001|NCT07015567|BEHAVIORAL|Narrative exposure therapy module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|"ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. It contains 24 sessions which are organised in four modules. The manual was adapted to our target population. In this context, the module modified prolonged exposure was replaced with Narrative Exposure Therapy (NET). NET is a standardised approach for the treatment of PTSD that has been tested across diverse social and cultural contexts. In this intervention, patients and therapists elaborate together a chronological timeline (called the lifeline) of patient's life and the traumatic events, using a rope, stones for traumatic events, and flowers for positive events. Thereafter, the traumatic events are discussed in detail, one in each session. At the end of each session, patients receive a written form of these narrations, co-signed by patient and the therapist."
214281002|NCT03921047|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214281003|NCT03921047|OTHER|Laboratory Biomarker Analysis|Correlative studies
214281004|NCT06622941|DRUG|ONO-4538|every 2 weeks
214281005|NCT06693687|BEHAVIORAL|Metastatic Cancer|Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
214281006|NCT02155790|DEVICE|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
214281007|NCT06701617|BEHAVIORAL|restorative visual rehabitation|black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
214281008|NCT05761561|BEHAVIORAL|Exercise and medical nutrition|"The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight)."
214281009|NCT04109183|DRUG|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
214281010|NCT02041078|PROCEDURE|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
214281011|NCT02041078|PROCEDURE|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
214281012|NCT02856178|DRUG|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
214281013|NCT02856178|DRUG|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
214281014|NCT06548581|DEVICE|SpeedPlate™ Rapid Compression Implants|MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
214281015|NCT06752980|OTHER|Eye mask|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
214281016|NCT06752980|OTHER|Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
214281017|NCT06752980|OTHER|Eye Mask and Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
214281018|NCT06760949|PROCEDURE|Direct anterior approach hemiarthroplasty|Direct anterior approach hemiarthroplasty
214281019|NCT06760949|PROCEDURE|Posterior lateral approach hemiarthroplasty|Posterior lateral approach hemiarthroplasty
214281020|NCT05618704|DIETARY_SUPPLEMENT|Hydrolyzed protein infant formula|The subjects will take the formula for 16 weeks
214281021|NCT06826989|DRUG|[14C]MK-8527|Oral Dose
214281022|NCT07014969|PROCEDURE|En-bloc HoLEP|Removal of the whole adenoma in one piece using laser energy
214281023|NCT06895538|DRUG|Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)|Patients in the ATLG arm receive ATLG instead of ATG as part of the routine conditioning regimen before allo-HSCT; ATLG is given intravenously by infusion for 4 consecutive days, after which they undergo routine transplantation.
214281024|NCT03989999|PROCEDURE|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 12 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
214281025|NCT06780319|PROCEDURE|Standard rehabilitation|rehabilitation with a private physiotherapist. Patients usually undergo 15 rehabilitation sessions, in line with HAS recommendations; the number of sessions can go up to 25, depending on the patient's profile and needs.
214281026|NCT06780319|PROCEDURE|Tele-rehabilitation|Tele-education is a digital home-based intervention involving exercises and education. Patients are monitored remotely by a physiotherapist via a secure messaging system. The system consists of a mobile application for the patient and a web portal enabling the physiotherapist to review patient data (physical activity, pain levels, medication use, exercise adherence, patient-reported results, images, videos) on a daily basis and tailor the protocol accordingly.
214281027|NCT06879639|OTHER|Exercise|The workout routine for the Land Exercise (LE) group will be segmented as follows: A cardio segment (15-20 minutes) involving treadmill walking/running or cycling on the stationary bike; A strength training segment (35 minutes) comprising bench press, seated row, leg extension, squats, pull down, peck-deck, hamstring curls, curl-ups, and back extensions; and a cool-down phase (5-10 minutes) featuring stretching exercises.
214281028|NCT06879639|OTHER|Control|The control group will not receive any formal indication or support to perform structured exercise training but will be allowed to engage in physical activity ad libitum.
214281029|NCT06879639|OTHER|Exercise|The activities for the Water Exercise (WE) group will be divided into segments: An aerobic portion (15-20 minutes) involving water walking and jogging combined with arm movements; A resistance portion (35 minutes) including chest/upper back guidance, chest back press, behind-the-back press, pivoted shoulder press (upper body), and calf lifts, supported squats, outer/inner thigh scissors, and forward and back leg glide (lower body), and finally, a cool-down period (5-10 minutes) comprising stretching exercises.
214281030|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
214281031|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
214281032|NCT06751927|BEHAVIORAL|Educational Video|Education video on smoking, nicotine receptor involvement in addiction, craving, withdrawal and mechanisms of action for nicotine replacement and varenicline.
214281033|NCT05610072|DRUG|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
214281034|NCT05610072|DRUG|Hydromorphone|Subjects will receive up to 192 mg oral hydromorphone daily.
214281035|NCT05610072|DRUG|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
214281036|NCT05610072|DRUG|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
214281037|NCT03618186|COMBINATION_PRODUCT|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
214281038|NCT06916533|BEHAVIORAL|ENBORTH-TR Intervention|This intervention program is structured with a multifaceted and holistic approach, starting with the definition of pain and covering topics such as basic body anatomy, functions and pain mechanisms, ergonomics training, environmental regulations, psychosocial factors such as stress, relaxation techniques, sleep and time management.
214281039|NCT06916533|BEHAVIORAL|Client-centred Occupational Therapy Intervention Group|Client-centered occupational therapy intervention consists of 5 stages: (1) Client-centered goal setting, (2) creation of the therapy plan, (3) implementation of interventions, (4) evaluation of results, and (5) obtaining feedback.
214281040|NCT06918795|BEHAVIORAL|Digital Exercise Intervention|Subjects randomized to the intervention arm will receive the same as the enhanced usual care arm but will be additionally exposed to: (1) personalized plans for aerobic-based PA, (2) personalized resistance exercise sessions, and (3) financial and non-financial engagement strategies. These intervention components will be delivered continuously using an advanced digital health informatics platform during the 6 months of the intervention. The intervention will be overseen and supplemented by the exercise physiologist, who will meet with participants on a weekly, then biweekly and finally monthly basis over 6 months.
214281041|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
214281042|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
214281043|NCT06932757|DRUG|Quisinostat|Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.
214281044|NCT01466647|DRUG|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
214281045|NCT06955494|OTHER|Empowerment Network for Auditory-Cognitive Training (ENACT) Program|The ENACT Program is an overall 12-week training and comprises of three phases as follows: 1. Goal-oriented health counseling phase (1st - 2nd week) - A nurse consultation will be conducted in the center with the aim to identify the participants' experience of living with the hearing and cognitive impairment. 2. Peer-assisted group-based auditory-cognitive training phase (3rd-8th week) - This phase is led and conducted by the nurse with the focus to provide combined group-based auditory and cognitive training (group size = 6) with support from the trained peers. 3. Family engaged active-communication training phase (9th - 12th week) - This phase is to empower the PLwMCI and their primary caregivers on active communication strategies in the presence of hearing loss. In the 2nd and 3rd phase, the nurse will continue to monitor the goal attainment of the PLwMCI and make additional health counseling and goal adjustment accordingly.
214281046|NCT06955494|OTHER|Usual Care|Usual care will be provided to the control group which mainly covers the social activities offered by the affiliated center. The participants are requested not to join any activities relating to cognitive training or auditory training before the post-test data collection.
214281047|NCT06132191|DRUG|Cemiplimab|
214281048|NCT03395743|BIOLOGICAL|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
214281049|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
214281050|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
214281051|NCT06259175|DRUG|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
214281052|NCT02821013|DRUG|Intermittent PD-1 inhibitor therapy|
214281053|NCT02821013|DRUG|Continuous PD-1 inhibitor therapy|
214281054|NCT06318871|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells|Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
214281055|NCT06318871|DRUG|Interleukin-2 (IL-2)|Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
214281056|NCT05425745|DRUG|Obicetrapib|10 mg Obicetrapib tablet
214281057|NCT05425745|DRUG|Placebo|placebo tablet made to resemble active
214465015|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
214839795|NCT00535028|DRUG|placebo|sterile saline
214465020|NCT06352658|DEVICE|Conventional mandibular advancement device|With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
214465021|NCT06352658|DEVICE|CAD CAM mandibular advancement device|"3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by"
214465022|NCT06352658|PROCEDURE|Uvuloplatopharyngeoplasty UPPP|uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.
214465023|NCT04817618|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
214465024|NCT04817618|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
214465025|NCT05145478|DEVICE|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
214465026|NCT02888327|DRUG|AL-794|
214465027|NCT02888327|DRUG|Oseltamivir|
214465028|NCT02888327|DRUG|Digoxin|
214465029|NCT02888327|DRUG|Midazolam|
214465030|NCT02888327|DRUG|Pitavastatin|
214465031|NCT02888327|DRUG|JNJ-63623872|
214465032|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
214465033|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
214465034|NCT06789978|OTHER|Extracorporeal cardiopulmonary resuscitation (ECPR)|Prehospital extracorporeal cardiopulmonary resuscitation (ECPR)
214465035|NCT04746586|OTHER|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
214465036|NCT05124704|DRUG|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
214465037|NCT05124704|OTHER|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
214465038|NCT06851351|DIAGNOSTIC_TEST|Spirometry and optoelectronic plethysmography|Spirometry for respiratory function and optoelectronic plethysmography for respiratory pattern during wakefulness
214465039|NCT06850272|BEHAVIORAL|Brisk walking|Participants in the brisk walking training group receive an eight-week instructor-led interval brisk walking training (40 minutes/session, three sessions/week).
214465040|NCT06850272|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|Participants in the CBT-I group receive standard-of-care group-based eight-session CBT-I (one session/week).
214465041|NCT06853080|DRUG|Bortezomib|4 cycles of Bortezomib treatment, with each cycle include 8 doses of Bortezomib at 1.3 mg/m2
214465042|NCT06852924|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
214465043|NCT05406362|DRUG|VAD044 Part I|capsules to be taken once daily for 12 weeks
214465044|NCT05406362|DRUG|VAD044 Part II|capsules to be taken once daily for 12 months
214465045|NCT05493072|OTHER|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
214465046|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
214465047|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
214465048|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
214465049|NCT06840340|DEVICE|Customised mouthguards|Wore customised mouthguards and measurement athletic performance of baseball and softball performance.
214465050|NCT04861077|DRUG|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
214465051|NCT06839924|BEHAVIORAL|Cognitive Motor Interference|Dual task that uses cognitive in addition to Motor training
214465052|NCT06839924|BEHAVIORAL|traditional physical therapy|physiotherapy program including exercises in addition to physical modalities
214465053|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
214465054|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
214465055|NCT06803667|DEVICE|Radiofrequency ablation alone|Radiofrequency ablation under imaging guidance allows for heating of diseased tissues, and has been used for the treatment of benign and malignant soft tissue masses throughout the body in the United States over the last several decades. Newer radiofrequency ablation devices are smaller and allow for precision temperature regulation; these technologies allow us to safely and precisely deliver heat to diseased tissues while minimizing the heating of nearby healthy tissues. Furthermore, we are able to clearly see these devices under ultrasound, which allows us to move the device in real-time to deliver heat as safely, effectively, and efficiently as possible.
214465056|NCT01271465|PROCEDURE|Kidney Biopsy|biopsy of transplant kidney
214465057|NCT06288477|DRUG|A cotton pellet moistened with full-strength FC|A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
214465058|NCT06288477|DRUG|Neo-Putty|Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
214465059|NCT02677961|OTHER|Observation|
214465060|NCT01471236|DEVICE|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
214465061|NCT01471236|PROCEDURE|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
214465062|NCT02323867|DEVICE|Alpha Beta T cell depletion|
214465063|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
214839796|NCT01065389|BEHAVIORAL|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
214465064|NCT06540586|PROCEDURE|M-TAPA BLOCK|In the M-TAPA block group, with the patient in the supine position, a linear high-frequency linear ultrasound (USG) probe is angled to visualize the inferior surface of the costochondral junction at the level of the 10th costochondral cartilage. Under sterile conditions, using the in-plane technique with a 22G 80 mm peripheral block needle, the needle is advanced posterior to the 10th costal cartilage by taking the lower edge of the cartilage in the sagittal plane as the midline. After hydrodissection with 2-3 ml isotonic saline to confirm the site, 20 ml of 0.25% Bupivacaine is administered under USG guidance. The same procedure is performed on the contralateral side as well.
214465065|NCT06368466|DEVICE|iStatis HBsAg Test|capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples are tested on the iStatis HBsAg Test
214465066|NCT05306028|DRUG|Metformin or insulin treatment|"1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."
214465067|NCT05814055|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
214465068|NCT05814055|DRUG|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
214465069|NCT04089137|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
214465070|NCT04633889|DRUG|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
214465071|NCT04633889|DRUG|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
214465072|NCT04383496|BEHAVIORAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
214465073|NCT05864560|DEVICE|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
214465074|NCT06720311|PROCEDURE|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
214465075|NCT06720311|PROCEDURE|Flexible Ureterorenoscopy|Flexible Ureterorenoscopy
214465076|NCT06720311|PROCEDURE|Shockwave Lithotripsy|Shockwave Lithotripsy
214465077|NCT04965090|DRUG|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
214465078|NCT04965090|DRUG|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
214465079|NCT05963698|DEVICE|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
214465080|NCT00409435|DRUG|pyridostigmine|one 180 mg capsule per day for 3 days
214465081|NCT00409435|DRUG|Placebo|one capsule per day for 3 days
214465082|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
214465083|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
214465084|NCT06529094|BEHAVIORAL|Provider training|Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.
214465085|NCT06529094|BEHAVIORAL|CAPP-FIT intervention with RA facilitation|After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.
214465086|NCT06529094|BEHAVIORAL|CAPP-FIT implementation during maintenance phase|Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
214465087|NCT06545188|OTHER|Mortality Attitudes Personality Survey|Two open questions about death and mortality will bei administered to trigger mortality salience
214465088|NCT06545188|OTHER|Dental treatment questions (control condition)|Two open questions about a dental treatment (control condition)
214465089|NCT04164888|DRUG|CIVI 007|hypercholesterolemia agent
214465090|NCT04675515|BEHAVIORAL|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
214465091|NCT05312229|BEHAVIORAL|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
214465092|NCT05312229|OTHER|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
214465093|NCT05312229|OTHER|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
214465094|NCT06197178|BIOLOGICAL|LCAR-G08 cells|Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214465095|NCT03034356|DRUG|Levetiracetam|Anticonvulsant drug
214465096|NCT03034356|DRUG|Placebo|Placebo
214465097|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
214465098|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
214465099|NCT05270213|DRUG|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
214465100|NCT05270213|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
214465101|NCT05270213|DRUG|Other approved anti-cancer therapy|Standard of care (SOC) therapy
214465102|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
214465103|NCT06975436|DIAGNOSTIC_TEST|cobas® BV/CV test|The cobas® BV/CV test is an automated, qualitative in vitro real-time PCR diagnostic test that detects bacteria and yeast associated with bacterial vaginosis (BV) and candida vaginitis (CV), respectively. The test does not distinguish among the pathogens but can give an overall qualitative result indicating the presence or absence of pathogen(s) associated with BV and/or CV.
214465104|NCT06975436|DIAGNOSTIC_TEST|BD Max™ Vaginal Panel|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
214465105|NCT06975436|DIAGNOSTIC_TEST|Cepheid Xpert Xpress MVP|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
214465106|NCT06975436|DIAGNOSTIC_TEST|Hologic Aptima BV Assay|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
214465107|NCT06128148|DRUG|JYP0322 50 mg qd|JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465108|NCT06128148|DRUG|JYP0322 100 mg qd|JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465109|NCT06128148|DRUG|JYP0322 200 mg qd|JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465110|NCT06128148|DRUG|JYP0322 100 mg bid|JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465111|NCT06128148|DRUG|JYP0322 150 mg bid|JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465112|NCT06128148|DRUG|JYP0322 200 mg bid|JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465113|NCT06128148|DRUG|JYP0322 150mg tid|JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.
214465114|NCT05973890|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
214465115|NCT05973890|BEHAVIORAL|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
214465116|NCT06160388|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
214465117|NCT05983809|DEVICE|Technological rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
214465118|NCT04082117|BEHAVIORAL|Educational video|Educational genetic counseling video
214465119|NCT05111509|DRUG|[203Pb]VMT-α-NET|3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.
214465120|NCT05111509|DEVICE|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
214465121|NCT06651099|OTHER|mhealth application|Individuals enrolled in the mhealth intervention will receive tailored content will include exercises focused on mobility, flexibility, core stabilization, and strengthening. Additionally, the mobile application will provide educational material on pain and health, covering topics such as the neurophysiology of pain, the multidimensional nature of low back pain, myths and facts about the condition, the importance of sleep, and stress management, which will include relaxation techniques and mindfulness. All content will be evidence-based, using clinical guidelines, systematic reviews and other high-quality studies to support inclusion in the mobile application. The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
214465122|NCT06651099|OTHER|Conventional exercise therapy|Participants in this intervention will receive a printed booklet containing a description and recommendations for carrying out an exercise program at home, which will be characterized by general exercises (such as strengthening, mobilization). The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
214465123|NCT06655064|OTHER|None- Observational|None- Observational
214465124|NCT05332067|DRUG|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
214465125|NCT05332067|DRUG|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
214465126|NCT06171698|DEVICE|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
214465127|NCT05292391|BIOLOGICAL|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
214465128|NCT05292391|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
214465129|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
214465130|NCT07019259|DEVICE|Anodyne Therapy System|Survivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.
214465131|NCT02568566|OTHER|Laboratory Biomarker Analysis|Correlative studies
214465132|NCT02568566|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214465133|NCT07040761|OTHER|Two medical questionnaires|Medical questionnaires delivered by hand and completed the same day
214465134|NCT07057232|OTHER|Usual care provided from pain specialist or within a dedicated pain unit|Adult non-cancer chronic pain patients receiving care in outpatient settings from a pain specialist or within a dedicated pain unit
214465135|NCT07057947|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Injection of local anesthetic between deltoid muscle and subcapsularis tendon
214465136|NCT07057947|PROCEDURE|Interscalene Nerve Block|Injection of local anesthetic between anterior and middle scalene muscles around the roots of brachial plexus
214465137|NCT07057947|DEVICE|Acuson X300 ultrasound,Siemens medical solution INC, Germany|high frequency linear probe
214465138|NCT07059208|PROCEDURE|Atrioventricular nodal ablation|Patients randomised to this arm would undergo physiological pacing followed by atrioventricular nodal ablation
214465139|NCT07059208|PROCEDURE|Pulmonary vein isolation|Patients randomised to this arm would undergo catheter ablation targeted at achieving pulmonary vein isolation
214465140|NCT07062029|OTHER|Laughter Yoga|"The laughter yoga intervention consists of four sessions conducted once a week for four weeks. Each session lasts approximately 30 minutes and includes four components:~* Warm-up exercises with clapping and rhythmic movements~* Deep breathing exercises~* Childlike playful activities and laughter exercises~* Laughter meditation and relaxation Sessions are led by a certified laughter yoga leader in a quiet classroom setting that allows participants to move freely and comfortably. The intervention is designed to improve spiritual well-being and perception of spiritual care among nursing students."
214465141|NCT07063940|OTHER|Home-based exercise and theory-based motivation support programme|"1. A remotely-monitored personalised home-based exercise programme (HBEP) and~2. An autonomous motivation enhancement programme, known as Empowering Physio, delivered to physiotherapists to support them in delivering the HBEP."
214465142|NCT07063940|OTHER|Patient exercise advice leaflet before and after LT.|Control
214465143|NCT07064291|OTHER|The Lexical Association Technique (LAT)|"The Lexical Association Technique (LAT) was developed by Niveau, New, and Beaudoin in 2021 (Niveau et al., 2022). It is grounded in principles of memory functioning described in the cognitive psychology literature, particularly the theoretical framework of the Self-Memory System proposed by Conway (2000, 2005).~The technique aims to enhance self-esteem by strengthening associative links between the self and positively valenced concepts stored in memory. To achieve this, it relies on the repeated mental visualization of positive autobiographical episodes paired with positive self-referential linguistic statements.~The effectiveness of this technique in increasing self-esteem has been demonstrated and replicated across three studies, conducted with distinct samples: two involving healthy participants and one involving a clinical sample of individuals with a chronic illness (Niveau et al., 2022, 2023)."
214465144|NCT07064291|OTHER|Placebo of the Lexical Association Technique|"The active control condition is based on the same procedural structure as the Lexical Association Technique (LAT), but without the core therapeutic component - the self-referential content. Participants in the control group are exposed to a series of positive statements, similar in form and valence to those used in the LAT, but referring to others (e.g., generic social roles or entities such as teachers, pharmacists, or animals) rather than the self.~Like in the LAT condition, participants are asked to generate mental imagery based on each statement, visualizing a corresponding positive episodic event. This ensures that the control task involves the same cognitive mechanisms (episodic memory retrieval, positive visualization, and sustained attention), while excluding the specific associative link to the self that constitutes the active ingredient of the intervention.~This control condition was designed to match the LAT in terms of structure, cognitive demand, and duration, and has be"
214465145|NCT07062185|DRUG|ENC1018 capsule administration group|ENC1018 capsules were taken orally once a day for 14 days.
214465146|NCT07062224|DIETARY_SUPPLEMENT|Probiotic/Prebiotic Supplement|Oral dietary supplement in gel form (10 mL per day) containing 4000 mg of inulin and 1000 mg of tyndallized probiotics. Administered once daily for approximately 98 consecutive days. Produced by Martínez Nieto S.A. (MARNYS®). Intended to modulate gut microbiota and improve glycemic and inflammatory markers.
214465147|NCT07062224|DIETARY_SUPPLEMENT|Placebo Gel|Oral placebo in gel form (10 mL per day), identical in appearance, texture, and taste to the active supplement, but without probiotic or prebiotic components. Administered once daily for 98 days to maintain blinding and control effects.
214465148|NCT07062666|DRUG|SSRIs|take SSRIs for 2 weeks
214465149|NCT07062666|DEVICE|fNIRS|All subjects receive fNIRS examination.
214839797|NCT01065389|BEHAVIORAL|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
214465150|NCT07062341|BEHAVIORAL|Self-Help Plus (SH+)|SH+ is a low-intensity, scalable stress management intervention developed by the World Health Organization. It is designed for delivery in humanitarian settings by non-specialist facilitators. The intervention consists of five 2-hour group sessions delivered via pre-recorded audio, supported by an illustrated guidebook adapted to the local cultural and linguistic context (Juba Arabic). Sessions teach mindfulness, acceptance, and value-driven behavior based on principles from Acceptance and Commitment Therapy. In this study, SH+ is delivered to 12 groups of up to 30 South Sudanese refugee mothers in Rhino Camp, Uganda, by trained lay peers from the refugee community. The intervention is paired with Enhanced Usual Care.
214465151|NCT07062341|BEHAVIORAL|Enhanced Usual Care (EUC)|"EUC consists of a one-time, brief psychoeducation session lasting approximately 15 minutes, delivered individually by a trained lay provider under clinical supervision. The session focuses on helping participants understand and manage common symptoms of psychological distress-particularly local expressions such as overthinking-and introduces simple self-management strategies. Participants are also provided with information about available mental health and psychosocial support services within Rhino Camp, including referral pathways to professional care and community-based resources. This intervention serves as a minimal yet contextually relevant comparator that controls for attention and information exposure while remaining distinct from structured therapeutic interventions like SH+."
214465152|NCT07063771|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
214465153|NCT07062653|OTHER|Supervised group|A progressive core stability exercise program based on motor control principles will be applied on an online platform through videos under the control of a physiotherapist.
214465154|NCT07062653|OTHER|Non-Supervised group|A core stability exercise program with detailed exercise videos will be implemented at home.
214465155|NCT07062354|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Carboplatin + Paclitaxel + Amivantamab hyaluronidase
214465157|NCT07062718|OTHER|Median nerve flossing technique and conventional physical therapy|"Median nerve flossing technique and conventional physical therapy Nerve flossing will be started from root along brachial plexus,median nerve root.~Before starting the procedure ,subjects will be shown the flossing technique as it will be performed actively by the subjects. Each flossing will be performed with 10 repetitions starting from neck,arm,elbow,wrist and whole nerve flossing (12).~It will be a 3 week treatment with 4 session per week (12 sessions)"
214465158|NCT07062718|OTHER|Conventional physical therapy|"The subjects in this group will be treated with TENS and hot pack. All the subjects will be screened according to the inclusion and exclusion criteria .Written informed consent will be taken from all the subjects before the treatment. The subjects will be allowed to withdraw the treatment any time.The subjects will be divided into 2 groups through convenience sampling.All the subjects from both group will be given trancutaneous electric nerve stimulation TENS ,hot pack, isometrics and stretching as a conventional physical therapy followed by respective group techniques~The session will last for 20 -25 minutes , TENS pad will be placed in the suboccipital region and the trapezius unilaterally with hot pack simultaneously for 10 minutes"
214465159|NCT07064590|DEVICE|Transcranial Magnetic Stimulation (TMS)|Patients will receive continuous theta burst stimulation, a five minute treatment protocol with inhibitory effects over the respective brain region 3 times daily. A total of 15 treatments, but will be performed in an accelerated design. Treatment site localization will be based on each patient's individual MRI. Following cortical parcellation using FreeSurfer 7.4.1, the centroid coordinates of the frontal pole will be extracted. For frontopolar stimulation, neuronavigation will be employed to guide coil placement to each patient's frontal pole centroid using Localite Neuronavigator. Stimulation will be performed at 110% resting motor threshold. Pulses will be administered in a burst-firing pattern (3 pulse burst, 50 Hz; 5 Hz \[200-ms\] interburst intervals; 1800 pulses/train with a 60-seconds intertrain interval). To enhance tolerability of frontopolar FP1 TBS, stimulation intensity is gradually escalated from 30% to 110% of resting motor threshold over the first 30 sec of each train.
214465160|NCT07062705|OTHER|Progressive Inhibition of Neuromuscular Structure|The index fingers of both hands were used to palpate two connected locations, referred to as main and endpoints. The locations were located along a neuromuscular structure and were the most and least sensitive sections, respectively. Once an endpoint (region of least sensitivity) was identified, the index finger of one hand was used to provide a moderate ischemia compression; the pressure was kept constant until the course of therapy was finished. After identifying the primary point-the area of greatest sensitivity-a moderate ischemic compression was also applied for 30 seconds using the index finger of the other hand.
214465161|NCT07062705|OTHER|Neural Tissue Mobilization.|The patient sat well back on the end of a plinth with thighs fully supported. The patient was asked to slump. Overpressure was applied to the lumbar and thoracic flexion in attempt to bow the spine rather than the hips. With spinal flexion position maintained, the patient was asked to bend his chin to chest and then overpressure in the same direction was added. The patient was asked to extend his knee actively. The patient was asked to dorsiflex his ankle. The therapist was maintaining the ankle dorsiflexion as a progression for technique. The number of these sequences was repeated several times,through which the amplitude of the technique was increased according to the patient response. The technique was progressed to a point where symptoms reproduced, or it was taken to a point where resistance of the movement was encountered.
214465162|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression, the patient will receive the treatment of 6-10Gy\*3-6F plus Benmelstobart.
214465163|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression and the largest lesion measures between 3 cm and 5 cm, the patient will receive the treatment of 3 Gy \* 15 fractions plus Benmelstobart.
214465164|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression and the largest lesion is larger than 5 cm, the patient will receive treatment with Spatial Fractionated Radiotherapy Technique (SFRT) plus Benmelstobart.
214465165|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression, and when the largest lesion is ≤ 3 cm and the patient can maintain the radiotherapy position for 50 minutes, the patient will receive treatment with the hyperfractionated pulsed radiotherapy technique (0.5 Gy \* 16 \* 6 fractions) plus Benmelstobart.
214465166|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, Benmelstobart is continued for maintenance treatment.
214465167|NCT06953843|DRUG|Benmelstobart combined with Bevacizumab and chemotherapy|For eligible subjects who have developed resistance to EGFR-TKI, after 4 cycles of treatment with Benmelstobart combined with Bevacizumab and chemotherapy, if there is no disease progression, they will receive the treatment of 6-10Gy \* 3-6 fractions plus Benmelstobart.
214465168|NCT04543617|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214465169|NCT04543617|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214465170|NCT04543617|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214465171|NCT04543617|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214465172|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snack with original level of sugar
214465173|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 2|Fruit snack with reduced level of sugar
214465174|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 3|Fruit snack with 0 added sugar - formulation 1
214465175|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 4|Fruit snack with 0 added sugar - formulation 2
214465176|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 5|Fruit snack from raisins
214465177|NCT06458946|DIETARY_SUPPLEMENT|Confection control|confection
214465178|NCT06443775|DRUG|Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)|Eye Drops
214465179|NCT06533761|DRUG|Eganelisib|eganelisib will be administered as monotherapy
214465180|NCT06533761|DRUG|Eganelisib in combination with cytarabine|eganelisib will be administered in combination with cytarabine
214465181|NCT05000294|DRUG|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
214465182|NCT05000294|DRUG|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
214465183|NCT06834100|DRUG|polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y|"Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site.~Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site."
214465184|NCT05453916|DRUG|Nitazoxanide 500Mg Oral Tablet|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
214465185|NCT05453916|DRUG|Rifaximin 550Mg Tab|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
214465186|NCT06664801|BIOLOGICAL|Sotatercept|SC administered every 3 weeks.
214465187|NCT06664801|BIOLOGICAL|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
214465188|NCT05455034|GENETIC|single-cell sequencing|Treatment is given according to the results of single-cell sequencing.
214465189|NCT06956014|DRUG|VER-01|Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product
214465190|NCT06956014|OTHER|Placebo|Comparator without active ingredient
214465191|NCT06041581|BEHAVIORAL|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
214465192|NCT06041581|BEHAVIORAL|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
214465193|NCT06041581|BEHAVIORAL|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
214465194|NCT06041581|OTHER|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
214465195|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
214465196|NCT06212804|BIOLOGICAL|VIS954|A humanized IgG4 monoclonal antibody.
214465197|NCT06212804|OTHER|Placebo|VIS954 Placebo
214465198|NCT03856515|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
214465199|NCT03856515|OTHER|Questionnaire Administration|Ancillary studies
214465200|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette - with Nicotine
214465201|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette -without Nicotine
214465202|NCT06959290|PROCEDURE|Multiple nonpharmacological methods|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. The nurse will then give the baby 25% dextrose solution orally (0.5ml for those \<32 weeks gestation, 1ml for those \>32 weeks gestation). The nurse then places a pacifier soaked in 25% dextrose solution in the preterm infant's mouth. After these three non-pharmacological methods, the doctor will perform the ROP examination.
214465203|NCT06959290|OTHER|Routine Treatment|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. After these three non-pharmacological methods, the doctor will perform the ROP examination.
214465204|NCT05378841|PROCEDURE|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
214465205|NCT06845904|DEVICE|WaveWriter Alpha™ neurostimulation system|Two Boston Scientific WaveWriter Alpha™ Implantable Pulse Generators (IPGs) will be implanted and connected to CoverEdge™ or CoverEdge™ X 32 Surgical Paddle Leads. The leads are positioned to enable targeted stimulation of the spinal cord to optimize control of urinary functions.
214465206|NCT05421065|DRUG|Psilocybin|1 oral dose
214465207|NCT05421065|DRUG|Ketamine|1 oral dose
214465208|NCT05728229|DRUG|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
214465209|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
214465210|NCT05310773|BEHAVIORAL|Community Stigma Awareness and Education Workshop|Key aspects of the workshop include community stigma awareness of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. The workshop adapts a stigma-reduction curriculum based on a stigma-reduction toolkit and community HIV prevention project with community peers with skits to address stigmatizing attitudes and behaviors toward young women and men who use AODs and who may need health services, including HIV treatment and prevention. Selected modules were modified from the existing clinic-based training to fit community stigma awareness and attitudes to focus on aspects of stigma specific to young women and men who engage in syndemic-related behaviors who live in their communities. The stigma awareness and education workshop will be delivered in communities randomized to receive workshops (N=12 communities).
215031537|NCT06350110|BIOLOGICAL|CD19- BCMA CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
215031538|NCT00123942|DRUG|MEDI-507|
215031539|NCT02542215|DRUG|Cobiprostone|Cobiprostone 30 mcg oral spray
215031540|NCT02542215|DRUG|Placebo|Matching placebo oral spray
214465211|NCT05310773|BEHAVIORAL|Couples Health CoOp Plus (CHC+)|The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, violence, and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporates antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; estimated N=240 couples).
214465212|NCT06259526|DRUG|Placebo group|(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
214465213|NCT06259526|DRUG|JS1-1-01 low-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
214465214|NCT06259526|DRUG|JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules|(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
214465215|NCT06259526|DRUG|JS1-1-01 high-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
214465216|NCT06259526|DRUG|Active drug group|(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.
214465217|NCT06347822|BEHAVIORAL|Therapy Session|Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
214465218|NCT05809453|DRUG|Cocaine|Cocaine (cocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
214465219|NCT05809453|DRUG|Lidocaine|Lidocaine (lidocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
214465220|NCT05030623|DRUG|Tadalafil 5Mg Tab|Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule
214465221|NCT05030623|DRUG|Placebo|Placebo Tab plus Fluoxetine 20 mg capsule
214465222|NCT05734833|DIETARY_SUPPLEMENT|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
214465223|NCT05734833|OTHER|Placebo|The Placebo comparator arm will receive placebo sachets
214465224|NCT06355453|DEVICE|Goldcrest Patch and Three Patch Coupons|Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
214465225|NCT06355453|DEVICE|Goldcrest Patch and Novii Patch|Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
214465226|NCT06067750|DIAGNOSTIC_TEST|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
214465227|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
214465228|NCT05867472|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
214465229|NCT05867472|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
214465230|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
214465231|NCT02696707|PROCEDURE|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
214465232|NCT02696707|PROCEDURE|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
214465233|NCT00636077|DEVICE|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
214465234|NCT00636077|DEVICE|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
214465235|NCT00636077|DEVICE|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
214465236|NCT00636077|DEVICE|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
214465237|NCT05251909|BIOLOGICAL|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
214465238|NCT05251909|BIOLOGICAL|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
214465239|NCT06529016|DEVICE|Luminopia, a virtual reality headset|Subjects will be provided with the equipment to use in their homes for six hours usage per week (1 hour 6 days a week), for 12 weeks.
214465240|NCT06529016|OTHER|Paper pre- survey|Pre-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
214465241|NCT06529016|OTHER|Paper Survey|Post-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
214465242|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214465243|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
214465244|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
214465245|NCT04659616|DRUG|Cytarabine|Given IV
214465246|NCT04659616|DRUG|Daunorubicin|Given IV
214465247|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
214465248|NCT04659616|DRUG|Pemigatinib|Given PO
214465249|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
214465250|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
214465251|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
214465252|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 2|Participants will use their Radicle Energy Placebo Control Form 2 as directed for a period of 6 weeks.
214465253|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 2.1 Usage|Participants will use their Radicle Energy Active Study Product 2.1 as directed for a period of 6 weeks.
214465254|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 3|Participants will use their Radicle Energy Placebo Control Form 3 as directed for a period of 6 weeks.
214465255|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 3.1 Usage|Participants will use their Radicle Energy Active Study Product 3.1 as directed for a period of 6 weeks.
214465256|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 4|Participants will use their Radicle Energy Placebo Control Form 4 as directed for a period of 6 weeks.
214465257|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.1 Usage|Participants will use their Radicle Energy Active Study Product 4.1 as directed for a period of 6 weeks.
214465258|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.2 Usage|Participants will use their Radicle Energy Active Study Product 4.2 as directed for a period of 6 weeks.
214465259|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.3 Usage|Participants will use their Radicle Energy Active Study Product 4.3 as directed for a period of 6 weeks.
214465260|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.1.0|Participants will use their Radicle Energy Placebo Control Form 5.0 as directed for a period of 6 weeks.
214465261|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.1.1 Usage|Participants will use their Radicle Energy Active Study Product 5.1.1 as directed for a period of 6 weeks.
214465262|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.3.0|Participants will use their Radicle Energy Placebo Control Form 5.3 as directed for a period of 6 weeks.
214465263|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.1 Usage|Participants will use their Radicle Energy Active Study Product 5.3.1 as directed for a period of 6 weeks.
214465264|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.2 Usage|Participants will use their Radicle Energy Active Study Product 5.3.2 as directed for a period of 6 weeks.
214465265|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.2.0|Participants will use their Radicle Energy Placebo Control Form 5.2 as directed for a period of 6 weeks.
214465266|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.2.1 Usage|Participants will use their Radicle Energy Active Study Product 5.2.1 as directed for a period of 6 weeks.
214465267|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
214465268|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
214465269|NCT05543915|DEVICE|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
214465270|NCT05880472|DEVICE|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
214465271|NCT06643897|OTHER|Qualitative Interview|40-50 minute-qualitative interview.
214465272|NCT05915806|DIETARY_SUPPLEMENT|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
214465273|NCT05915806|DIETARY_SUPPLEMENT|Control|Control with no or low-dose DHA.
214465274|NCT05689515|BEHAVIORAL|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
214465275|NCT05131425|BEHAVIORAL|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
214465276|NCT05131425|OTHER|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
214465277|NCT06348992|BEHAVIORAL|Acceptance commitment therapy and yoga|The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.
214465278|NCT06348992|BEHAVIORAL|Active Comparator: Mental Health Education Group|The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
214465279|NCT05825456|PROCEDURE|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
214465280|NCT05825456|PROCEDURE|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
214465281|NCT05825456|PROCEDURE|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
214465282|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
214465283|NCT05282277|DRUG|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
214465284|NCT05282277|DRUG|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
214465285|NCT05282277|DRUG|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
214465286|NCT05282277|DRUG|Raclopride C11|All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
214465287|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with lower limb cycle ergometer
214465288|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with upper limb cycle ergometer
214465289|NCT04881903|BEHAVIORAL|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
214465290|NCT04881903|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
214465291|NCT06645704|DRUG|EP262|Single dose of \[14C\]-EP262 administered orally.
214465292|NCT04873050|DRUG|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
214465293|NCT04873050|DRUG|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
214465294|NCT01269593|DRUG|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
214465295|NCT06150430|DEVICE|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
214465296|NCT05287321|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg with Aspirin 100mg
214465297|NCT03833206|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
214465298|NCT04408313|DRUG|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
214465299|NCT04408313|DRUG|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
214465300|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
214465301|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
214465302|NCT05973864|DRUG|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
214465303|NCT05973864|DRUG|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
214465304|NCT05973864|RADIATION|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
214465305|NCT06251167|DEVICE|Lateral wedge insoles (LWIs)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.
214465306|NCT06251167|DEVICE|Lateral wedge plus custom arch support (LWAS)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
214465307|NCT06194305|OTHER|CBIT|Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
214465308|NCT04315701|BIOLOGICAL|Cemiplimab|Given IV
214465309|NCT04315701|PROCEDURE|Resection|Undergo surgical resection
214465310|NCT02599480|DRUG|mirabegron|50 mg daily during 12 months
214465311|NCT02599480|PROCEDURE|Echocardiography|Echocardiography
214465312|NCT02599480|PROCEDURE|Cardiac MRI|Cardiac MRI
214465313|NCT02599480|PROCEDURE|Maximal exercise capacity|Maximal exercise capacity
214465314|NCT02599480|PROCEDURE|Blood sampling|Blood sampling for study assessments and future exploratory studies.
214465315|NCT02599480|PROCEDURE|Endothelial function measurement|EndoPAT assessment
214465316|NCT02599480|RADIATION|18FDG-PET|PET scanning for beige/brown fat activation
214465317|NCT06150261|DIETARY_SUPPLEMENT|AvailOm|5 capsules taken once daily with main meal
214465318|NCT06150261|DIETARY_SUPPLEMENT|Placebo|5 capsules taken once daily with main meal
214465319|NCT06255535|DEVICE|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
214465320|NCT06255535|DEVICE|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
214465321|NCT06264635|BIOLOGICAL|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
214465322|NCT06264635|OTHER|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
214465323|NCT03414489|DRUG|ABC294640|
214465324|NCT06360107|OTHER|brief video|brief video about depression
214465325|NCT05805137|DEVICE|WoundWatch® wound monitoring system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
214465326|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
214465327|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
214465328|NCT05580419|BEHAVIORAL|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
214465329|NCT04510025|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
214465330|NCT01803542|RADIATION|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
214465331|NCT02673996|DRUG|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
214465332|NCT02673996|DRUG|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
214465333|NCT04612933|OTHER|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
214465334|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
214465335|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
214465336|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
214465337|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
214465338|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
214465339|NCT05158738|OTHER|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
214465340|NCT06231342|DEVICE|Direct Laryngoscope (DL)|DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
214465341|NCT06231342|DEVICE|Video laryngoscope (VL)|VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
214465342|NCT06231342|PROCEDURE|Endotracheal Tube (ETT) 180|A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
214465343|NCT06360263|COMBINATION_PRODUCT|Densah bur in combination with activated plasma albumin gel|Simultaneous implant placement after transcrestal maxillary sinus lifting using densah burs in combination with activated plasma albumin gel.(APAG). A full mucoperiosteal flap will be elevated, and then reflected with periosteal elevator application of first densah bur (the narrowest) with densifying mood (reverse) counterclockwise, 800-1500 revolutions per minute with copious irrigation until the sinus is reached confirm bur position with a radiograph. Then a wider densah bur (3.0) is used with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.The sequential densah bur will be used with the same mode and bouncing motion to elevate the the sinus floor 3 mm maximum. After achieving the final planned osteotomy diameter, the osteotomy will be filled with APAG. Then, the desired implant length is inserted.
214465344|NCT04280848|DRUG|UCPVax|"The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum."
214465345|NCT04280848|DRUG|Temozolomide|6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
214465346|NCT06302816|OTHER|TUPLER exercises|"will be conducting tupler exercises, exercises that are designed to target core muscles in order to improve posture, regain core strength and reducing discomfort.~Each exercise will be repeated 10reps for 3 times on 3 days a week for 8 weeks."
214465347|NCT06302816|OTHER|SCOOP EXERCISES|will be required to complete scoop exercises basically deals with Pilates which is deep core and hip strengthening and stability through breathing patterns with the utilization of transversus abdominis muscle majorly. In each exercise participant will be asked to hold pelvic floor muscles for 8sec, then relax the muscles and count to 10, repeat I for 10 times each day for 3 days a week for 8weeks. Basic commands about the positing, activation and engagement of core along with breathing control were given to the subjects.
214465348|NCT04451226|DRUG|Fezolinetant|Oral
214465349|NCT04601857|DRUG|futibatinib and pembrolizumab (KEYTRUDA®))|Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
214465350|NCT06241781|BIOLOGICAL|GT101 injection|GT101 injection to treat cervical cancer
214465351|NCT06241781|DRUG|Gemcitabine injection|Gemcitabine injection to treat cervical cancer
214465352|NCT06485206|DEVICE|One level Mobi-C and one level fusion|"Cervical Disc Arthroplasty:~• Mobi-C~Fusion devices:~* One-level cervical plates~  o MaxAn Cervical plate system~* Interbody spacers~  * TrellOss-C - 3D printed Ti interbody~ * Vista-S - PEEK interbody~* Standalone Fixation~  * Ti-Coated ROI-C - PEEK cage w/ Ti coating~ * TrellOss-C SA - 3D printed Ti~* Bone Graft~  * Local Autograft~ * PrimaGen Advanced Allograft"
214465353|NCT04794777|COMBINATION_PRODUCT|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
214465354|NCT04794777|RADIATION|Standard salvage therapy|Standard salvage radiotherapy
214465355|NCT05929430|BEHAVIORAL|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
214465356|NCT05929430|BEHAVIORAL|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
214465357|NCT05424224|DEVICE|MagVita|rTMS system
214465358|NCT05922462|DIETARY_SUPPLEMENT|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
214465359|NCT05922462|DIETARY_SUPPLEMENT|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
214465360|NCT04620759|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
214465361|NCT04620759|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
214465362|NCT05043870|DRUG|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
214465363|NCT05043870|DRUG|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
214465364|NCT04418232|COMBINATION_PRODUCT|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
214465365|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
214465366|NCT06061627|PROCEDURE|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of\>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
214465367|NCT06061627|PROCEDURE|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
214465368|NCT05110924|OTHER|Standard of care|Patients in the treatment arm will receive standard care.
214465369|NCT05110924|OTHER|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
214465370|NCT06352970|OTHER|TB infection|Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
214465371|NCT04878549|DIAGNOSTIC_TEST|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
214465372|NCT05728944|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
214465373|NCT05728944|DRUG|Aceclidine|Aceclidine ophthalmic solution
214465374|NCT05728944|DRUG|Vehicle|Proprietary vehicle ophthalmic solution
214465375|NCT06165367|DRUG|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
214465376|NCT05980299|BEHAVIORAL|Individualized Positive Psychosocial Interaction|The intervention involves a brief positive interaction around a preferred activity or personal care routine.
214465377|NCT05608083|BEHAVIORAL|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
214465378|NCT05608083|BEHAVIORAL|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
214465379|NCT06418854|OTHER|Questionnaire|Adapted design questionnaire to estimate the vaccine hesitancy specifically for dengue vaccine
214465380|NCT05712512|BEHAVIORAL|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
214465381|NCT05712512|OTHER|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
214465382|NCT04373031|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
214465383|NCT04373031|DRUG|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
214465384|NCT05772468|DEVICE|Virtual Reality ('VRelax' VR system)|The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
214465385|NCT05113160|BEHAVIORAL|Conversation Treatment for Aphasia|Conversation treatment is a theoretically motivated approach in which a speech language pathologist facilitates discourse about topics of interest to the client using individualized, multi-modal supports. Treatment occurs either in groups of 6-8 people with aphasia or 2 people with aphasia. Individual communication goals are targeted for each group member within the context of naturalistic conversations.
214465386|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
214465387|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
215031541|NCT02542215|DRUG|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
215031542|NCT02542215|RADIATION|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
214465388|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
214465389|NCT04478643|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus Reuteri|Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
214465390|NCT04478643|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
214465391|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
214465392|NCT05447312|OTHER|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
214465393|NCT05447312|OTHER|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
214465394|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
214465395|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
214465396|NCT06139016|DEVICE|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
214465397|NCT06272903|DRUG|20% benzocaine, topical anesthetic|"Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators)."
214465398|NCT06272903|OTHER|Children's Toothpaste|Strawberry-flavored children's toothpaste available in Dubai, UAE.
214465399|NCT05819697|OTHER|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
214465400|NCT06159153|DIAGNOSTIC_TEST|Dynamic Ultrasonography assessment|Ultrasound evaluation that will be compared with an MRI.
214465401|NCT04454489|DRUG|Pembrolizumab (immunotherapy)|Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.
214465402|NCT04454489|RADIATION|Quad-shot palliative radiotherapy|"* Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles"
214465403|NCT05734183|OTHER|MIME|Multisensorial IMmersive Experiences
214465404|NCT05734183|OTHER|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
214465405|NCT04059640|DEVICE|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
214465406|NCT05503238|BEHAVIORAL|Skin-to-skin contact|Preterm infants will receive maternal-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge, and other nursing care will be same as the routine group. During skin-to-skin contact, place naked baby only with diaper on the mother's bare chest in an upright position and tilt the baby's head to one side in a slightly extended position to keeps the airway open, cover the infant with a blanket to keep them warm. A neonatal nurse will be stay with mother and infant to observe and support.
214465407|NCT05503238|OTHER|Routine care|Preterm infants will receive standard nursing care provided by neonatal nurses in accordance with hospital principles during hospitalization.
214465408|NCT04886726|DRUG|uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
214465409|NCT05240755|DRUG|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
214465410|NCT04331639|DIETARY_SUPPLEMENT|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
214465411|NCT02057783|OTHER|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
214465412|NCT05966727|DRUG|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
214465413|NCT04481555|DRUG|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
214465414|NCT04481555|DRUG|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
214465415|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
214465416|NCT02905188|GENETIC|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214465417|NCT02905188|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
214465418|NCT02905188|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
214465419|NCT05419193|DRUG|Propranolol Hydrochloride|"Day of randomization:~propranolol IV vp for 7 days after randomization"
214465420|NCT05419193|OTHER|control group|Patients will receive usual care and drug use in hospital
214465421|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
214465422|NCT02815566|DRUG|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
214465423|NCT02815566|DRUG|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
214465424|NCT06178549|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling. Participants will be provided with education regarding cervical cancer prevention and Aptima kit and instructions for self-sampling. Patient navigators will assist participants with positive HPV test results to connect with healthcare providers for follow-up screening and care.
214465425|NCT05179993|OTHER|Microplastics|Detection of microplastics as a yes/no value
214465426|NCT04187183|OTHER|Fresh Platelet Rich Plasma with leukocyte|autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
214465427|NCT04187183|OTHER|Fresh Platelet Rich Plasma without leukocyte|autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
214465428|NCT03994653|OTHER|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
214465429|NCT03994653|OTHER|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
214465430|NCT05928572|OTHER|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
214465431|NCT06441890|DRUG|Paclitaxel|80mg/m2 IV D1, 8, 15
214465432|NCT06441890|DRUG|Nab-paclitaxel|125mg/m2 IV D1, 8, 15
214465433|NCT06441890|DRUG|Docetaxel|75mg/m2 IV D1
214465434|NCT06441890|DRUG|Trastuzumab|8mg/kg loading, then 6mg/kg IV/SQ D1
214465435|NCT06441890|DRUG|Pertuzumab|840 mg loading, then 420mg IV/SQ D1
214465436|NCT06109818|DRUG|ICP-488 Tablets|ICP-488 will be administered as tablet
214465437|NCT06109818|DRUG|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
214465438|NCT02867865|DRUG|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
214465439|NCT02867865|DRUG|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
214465440|NCT02867865|RADIATION|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
214465441|NCT02867865|PROCEDURE|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
214465442|NCT02867865|PROCEDURE|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
214465443|NCT06179498|BEHAVIORAL|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
214465444|NCT03296371|PROCEDURE|Biospecimen Collection|Undergo saliva or buccal mucosa collection
214465445|NCT03296371|OTHER|Laboratory Biomarker Analysis|Correlative studies
214465446|NCT03296371|OTHER|Questionnaire Administration|Ancillary studies
214465447|NCT04714476|DEVICE|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
214465448|NCT02591745|PROCEDURE|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
214465449|NCT03956446|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
214465450|NCT03956446|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
214465451|NCT03956446|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
214465452|NCT05469347|DRUG|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
214465453|NCT05469347|DRUG|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
214465454|NCT03252847|GENETIC|AAV5-RPGR|Single, subretinal administration of AAV5-RPGR
214465455|NCT04251429|OTHER|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
214465456|NCT06149429|BEHAVIORAL|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
214465457|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
214465458|NCT05058287|DRUG|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
214465459|NCT05058287|DRUG|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
214465460|NCT06035224|DRUG|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
214465461|NCT06171386|PROCEDURE|Microneedling|a form of collagen induction therapy
214465462|NCT06171386|PROCEDURE|Dermabrasion|a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization
214465463|NCT04075864|BEHAVIORAL|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
214465464|NCT06389084|BEHAVIORAL|Parents Together parenting course|parenting course and coaching calls
214465465|NCT05034328|DEVICE|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
214465466|NCT05034328|OTHER|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
214465467|NCT06492005|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
214465468|NCT06492005|DRUG|PD-1 inhibitior|Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
214465469|NCT02473536|RADIATION|Stereotactic ablative radiation therapy|SABR
214465470|NCT05877261|DEVICE|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
214465471|NCT06803589|DRUG|Growth Hormone|"Subjects will receive growth hormone, Sogroya (Somapacitan-beco injections) via weekly injections for 12 weeks.~For males, the fixed dose will be 0.2 mg/day, 1.5 mg per week~For females, the fixed dose will be 0.3 mg/day, 2.1 mg per week"
214465472|NCT00188539|PROCEDURE|Pre-treatment tumour oxygen measurements (under anesthesia)|
214465473|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
214465474|NCT05290363|OTHER|Blood sampling|A 51 mL blood sample will be collected during the study
214465475|NCT05290363|OTHER|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
214465476|NCT02608320|DRUG|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
214465477|NCT02608320|DRUG|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
214465478|NCT02608320|DRUG|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
214465479|NCT02608320|DRUG|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
214465480|NCT02608320|DRUG|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
214465481|NCT02608320|DRUG|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
214465482|NCT06102733|BEHAVIORAL|Rehabilitation therapy|Chronic pain rehabilitation therapy
214465483|NCT05445427|DEVICE|vagal nerve stimulator|Non-invasive vagus nerve stimulator
214465484|NCT04602091|OTHER|no intervention|no intervention
214465485|NCT05429827|OTHER|normal saline|Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
214465486|NCT05429827|DRUG|Dextrose 5% in water|Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
215031543|NCT00403052|DRUG|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
215031544|NCT05881291|DRUG|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
214465487|NCT05429827|DRUG|Dextrose 15% in water|Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
214465488|NCT06275360|DRUG|Nivolumab|Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
214465489|NCT04990089|DEVICE|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
214465490|NCT02969707|DEVICE|MagPro TMS system (MagVenture, Denmark)|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
214465491|NCT02969707|BEHAVIORAL|Hypnosis|Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
214465492|NCT06031623|DEVICE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
214465493|NCT06223867|DEVICE|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
214465494|NCT06223867|BEHAVIORAL|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
214465495|NCT04488497|BEHAVIORAL|Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis|This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.
214465496|NCT04488497|BEHAVIORAL|Standard of care|Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
214465497|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
214465498|NCT04457960|DRUG|JNJ-66525433|Participants will receive JNJ-66525433 oral capsules.
214465499|NCT04457960|DRUG|Placebo|Participants will receive matching placebo oral capsules.
214465500|NCT05572047|DEVICE|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
214465501|NCT04722185|DIAGNOSTIC_TEST|Veriton SPECT/CT|The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
214465502|NCT02149030|OTHER|Cytological screening in A1 and A3|Cytological screening.
214465503|NCT06234423|DRUG|CUSP06|Antibody drug conjugate (ADC)
214465504|NCT06074952|OTHER|Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)|Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
214465505|NCT05593250|DRUG|SHR-1905|subcutaneous
214465506|NCT05593250|DRUG|placebo|subcutaneous ,placebo
214465507|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
214465508|NCT03287336|DRUG|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
214465509|NCT02427464|BIOLOGICAL|Engensis (VM202)|gene therapy
214465510|NCT02427464|OTHER|placebo|
214465511|NCT06250153|BEHAVIORAL|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|M-SBIRT is a mobile phone-based program designed to enhance delivery of Screening, Brief Intervention, and Referral to Treatment (SBIRT), an evidence-based approach for mental health and substance use screening and treatment. The program utilizes mobile phone text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder treatment services.
214465512|NCT05910229|OTHER|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
214465513|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
214465514|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
214465515|NCT06040866|OTHER|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
214465516|NCT06040866|OTHER|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
214465517|NCT06040866|OTHER|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
214465518|NCT03222999|OTHER|No intervention planned|No intervention planned
214465519|NCT06362967|COMBINATION_PRODUCT|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG|For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
214465520|NCT05384431|DIETARY_SUPPLEMENT|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
214465521|NCT05384431|OTHER|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
214465522|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
214465523|NCT04508088|DIAGNOSTIC_TEST|Coronal T1 weighted spin echo images|Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
214465524|NCT04508088|DIAGNOSTIC_TEST|Spin-lattice relaxation (T1)|Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
214465525|NCT04508088|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
214465526|NCT04508088|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
214465527|NCT05579951|PROCEDURE|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
214465528|NCT05579951|PROCEDURE|Conventional|Total knee replacement with conventional instrumentation
214465529|NCT05579951|DEVICE|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
214465530|NCT04949100|DEVICE|Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
214465531|NCT04949100|DEVICE|PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
214465532|NCT02714257|BEHAVIORAL|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
214465533|NCT05312164|DEVICE|HF-OCT Imaging|Subjects undergo HF-OCT imaging of stenosed coronary arteries
214465534|NCT05312164|DEVICE|FFR Pressure Wire|Subjects undergo FFR physiology assessment of stenosed coronary arteries
214465535|NCT05312164|DEVICE|Angiography|Subjects undergo angiography imaging of stenosed coronary arteries
214465536|NCT01696513|PROCEDURE|Suction|
214465537|NCT01696513|PROCEDURE|Subcision|
214465538|NCT05401578|DRUG|Canakinumab|Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
214465539|NCT05401578|DRUG|Placebo (0.9% NaCl)|1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
214465540|NCT06220006|PROCEDURE|Pulmonary vein isolation|Catheter ablation
214465541|NCT05201248|DRUG|Epcoritamab|Subcutaneous Injection (SC)
214465542|NCT05201248|DRUG|Cyclophosphamide|IV Injection
214465543|NCT05201248|DRUG|Rituximab|Intravenous (IV) Infusion
214465544|NCT05201248|DRUG|Doxorubicin|IV Infusion
214465545|NCT05201248|DRUG|Vincristine|IV Infusion
214465546|NCT05201248|DRUG|Prednisone|Oral; Tablet
214465547|NCT05201248|DRUG|Lenalidomide|Oral; Capsule
214465548|NCT04103580|BEHAVIORAL|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
214465549|NCT04145440|DRUG|MOR202|Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
214465550|NCT00104676|BIOLOGICAL|bleomycin sulfate|At least one course administered
214465551|NCT00104676|DRUG|cisplatin|At least one course administered
214465552|NCT00104676|DRUG|etoposide|At least one course administered
214465553|NCT00104676|DRUG|ifosfamide|Given in a dose-dense sequential fashion
214465554|NCT00104676|DRUG|oxaliplatin|Given in a dose-dense sequential fashion
214465555|NCT00104676|DRUG|paclitaxel|Given in a dose-dense sequential fashion
214465556|NCT04504721|OTHER|light therapy|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
214465557|NCT06297863|PROCEDURE|HEAD DOWN TILT -10° to -15°|"Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body.~Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint.~The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time."
214465558|NCT04700176|DRUG|Daratumumab|During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
214465559|NCT04700176|DRUG|Pomalidomide|Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
214465560|NCT04700176|DRUG|All-trans retinoic acid|ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
214465561|NCT04700176|DRUG|Dexamethasone|Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
214465562|NCT01529593|DRUG|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
214465563|NCT01529593|DRUG|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
214465564|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation with Fusion imaging system Cydar-EV|Cydar-EV image fusion is a CE-marked medical device, which instead of a table-tacked overlay uses computer vision to fuse pre-procedural 3D images with intra-operative 2D fluoroscopy automatically and in real-time.
214465565|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation without Fusion imaging system Cydar-EV|patients will be assigned either to an endovascular repair using standard X-ray fluoroscopy imaging alone (the current reference standard)
214465566|NCT06467617|DRUG|Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab|"Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle"
214465567|NCT04948398|DRUG|Guselkumab|Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
214465568|NCT05599711|BEHAVIORAL|Transitioning Together (TT) / Juntos en la Transicion (JET)|"1. One individual family joining session when each family dyad meets with group therapists to establish rapport and share their own unique family's background, goals, and supports.~2. A series of four 2.5-hour multi-family group psychoeducation intervention sessions focused on problem-solving education and psychoeducational autism transition-to-adulthood content which can include independence in adulthood, community involvement, guardianship and legal issues, employment and education, health and well-being."
214465569|NCT05599711|BEHAVIORAL|Usual autism transition care|An expedited referral will be made for participants to establish care with a BMC Autism Program Transition/Resource Specialist. Data will be abstracted from the electronic medical record on how many visits each family completes with a BMC Autism Program Transition/Resource Specialist or other BMC Developmental and Behavioral Pediatrics provider throughout the study period.
214465570|NCT05007067|DEVICE|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
214465571|NCT05531747|OTHER|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
214465572|NCT05531747|OTHER|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
214465573|NCT00576979|DRUG|cyclophosphamide|Given IV
214465574|NCT00576979|DRUG|etoposide|Given IV
214465575|NCT00576979|PROCEDURE|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
214465576|NCT00576979|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
214465577|NCT00576979|PROCEDURE|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
214465578|NCT00576979|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214465579|NCT00576979|RADIATION|tomotherapy|Undergo IMRT using helical tomotherapy
214465580|NCT05032040|BIOLOGICAL|vudalimab|Monoclonal bispecific antibody
214465581|NCT03697096|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
214465582|NCT03697096|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
214465583|NCT03924661|DEVICE|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
214465584|NCT06454331|DEVICE|Transcranial direct current stimulation|The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.
214465585|NCT06454331|DEVICE|Sham transcranial direct current stimulation|it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days
214465586|NCT05759299|PROCEDURE|Advanced airway management|Advanced airway management with either tracheal intubation or supraglottic airways performed after induction with hypnotic and/or opioid drugs
214465587|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
214465588|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
214465589|NCT04031820|PROCEDURE|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
214465590|NCT04031820|PROCEDURE|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
214465591|NCT06289517|DRUG|68Ga-Her2-affibody|68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
214465592|NCT03766685|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214465593|NCT06427343|DRUG|High-dose ferric derisomaltose|"After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up."
214465594|NCT06427343|DRUG|Low-dose ferric derisomaltose|In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
214465595|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
214465596|NCT05099679|BEHAVIORAL|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
214465597|NCT05099679|BEHAVIORAL|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
214465598|NCT04241250|DEVICE|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
214465599|NCT04241250|DEVICE|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
214465600|NCT04226547|DEVICE|Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)|Implantation of an Amplatzer Amulet left atrial appendage occluder
214465601|NCT04226547|DRUG|Non-Vitamin K Oral Antagonists|Initiation or continuation of a NOAC drug
214465602|NCT05266365|OTHER|The video-based exercise (VBE) group|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video."
214465603|NCT05266365|OTHER|The standard exercise group (SE)|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic."
214465604|NCT05601700|DRUG|Letrozole tablets|ATC: L02BG04
214465605|NCT05601700|DRUG|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
214465606|NCT01019564|DEVICE|Complete Easy Rub Formula MPS|Multi-purpose solution
214465607|NCT01019564|DEVICE|Aquify MPS|Multi-purpose solution
214465608|NCT06526117|DRUG|Hydroxyurea|The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
214465609|NCT06201247|DRUG|JD123 injection|JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
214465610|NCT05766462|OTHER|Pacemaker lower rate setting|Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
214465611|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
214465612|NCT04275713|DRUG|Metformin|Metformin is an oral antidiabetic drug
214465613|NCT04275713|DRUG|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
214465614|NCT06201234|DRUG|Olaparib + Elacestrant|Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
214465615|NCT06201234|DRUG|Olaparib|Olaparib 600 mg orally daily
214465616|NCT03214796|DRUG|Human albumin|Infusion of human albumin
214465617|NCT05909150|DRUG|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
214465618|NCT05909150|DRUG|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
214465619|NCT04521712|DIAGNOSTIC_TEST|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
214465620|NCT06352424|DRUG|BI 456906|BI 456906
214465621|NCT06352424|DRUG|BI 1820237|BI 1820237
214465622|NCT06352424|DRUG|Placebo for BI 1820237|Placebo for BI 1820237
214465623|NCT06352424|DRUG|Placebo for BI 456906|Placebo for BI 456906
214465624|NCT06349057|DRUG|reducing anticholinergic burden|In the intraoperative and postoperative periods instead of drugs with high anticholinergic burden; drugs with low burden will be preferred.
214465625|NCT04405167|DRUG|Tasquinimod|Tasquinimod will be supplied as oral capsules.
214465626|NCT04405167|DRUG|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
214465627|NCT05260411|BIOLOGICAL|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214465628|NCT05260411|BIOLOGICAL|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214465629|NCT05260411|DRUG|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214465630|NCT05297565|BIOLOGICAL|Nivolumab/rHuPH20|Specified dose on specified days
214465631|NCT05297565|BIOLOGICAL|Nivolumab|Specified dose on specified days
214465632|NCT03572374|OTHER|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
214465633|NCT03572374|OTHER|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
214465634|NCT04329975|DRUG|Desmopressin|Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
214465635|NCT05972187|OTHER|Temperature and Humidity|Temperature and Humidity of room changed
214465636|NCT05516485|OTHER|Assessment|Undergo grading and recording of tumor consistency/stiffness
214465637|NCT05516485|DEVICE|Magnetic Resonance Elastography|Undergo MRE
214465638|NCT04036695|DEVICE|Reveal LINQ insertable cardiac monitoring system|A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
214465639|NCT06256458|DEVICE|NanoBone® Bone Graft|The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.
214465640|NCT05603910|DRUG|Lenvatinib|Lenvatinib capsules taken daily by mouth
214465641|NCT05603910|DRUG|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
215031545|NCT05881291|DRUG|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
214465642|NCT05603910|RADIATION|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
214465643|NCT06582043|OTHER|SCARCr tester 1|Twice daily
214465644|NCT06582043|OTHER|Placebo|Twice daily
214465645|NCT06115135|DRUG|Venetoclax|All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.
214465646|NCT05873413|BEHAVIORAL|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
214465647|NCT05873413|BEHAVIORAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
214465648|NCT05873413|BEHAVIORAL|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
214465649|NCT06823726|OTHER|12-week Taekwondo training|"12-week structured Taekwondo training program under the supervision of qualified instructors following a standardized protocol.~Frequency: 3 sessions per week Session Length: 60 minutes per session"
214465650|NCT04476303|DRUG|BEY2153|Capsule
214465651|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
214465652|NCT05241860|OTHER|Follow-Up|Undergo follow-up
214465653|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
214465654|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
214465655|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
214465656|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
214465657|NCT03239808|PROCEDURE|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
214465658|NCT03239808|PROCEDURE|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
214465659|NCT04763174|BEHAVIORAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
214465660|NCT02259218|OTHER|laboratory biomarker analysis|Correlative studies
214465661|NCT01543763|DRUG|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
214465662|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
214465663|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
214465664|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
214465665|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
214465666|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
214465667|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
214465668|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
214465669|NCT05124769|BEHAVIORAL|Pain Allowing Program (PAllow)|Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).
214465670|NCT05124769|BEHAVIORAL|Pain Avoiding Program (PAvoid)|"Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued."
214465671|NCT06203795|OTHER|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
214465672|NCT06203795|OTHER|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
214465673|NCT06203795|OTHER|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
214465674|NCT06203795|DEVICE|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
214465675|NCT04268199|DRUG|Bortezomib Injection|Subcutaneous injection
214465676|NCT03128021|DRUG|Escitalopram Pill|Double-blinded, randomly assigned
214465677|NCT03128021|OTHER|Placebo|Double-blinded, randomly assigned
214465678|NCT03128021|DRUG|Levomilnacipran Pill|Double-blinded, randomly assigned
214465679|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
214465680|NCT04668560|BEHAVIORAL|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
214465681|NCT05787834|OTHER|Best Practice|Receive usual care
214465682|NCT05787834|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
214465683|NCT05787834|PROCEDURE|Respiratory Muscle Training|Undergo RMT
214465684|NCT05787834|OTHER|Survey Administration|Ancillary studies
214465685|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
214465686|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
214465687|NCT05470036|BEHAVIORAL|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
214465688|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
214465689|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
214465690|NCT05166577|DRUG|Nanatinostat|Phase 1b: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, then Phase 2: Nanatinostat at the confirmed recommended Phase 2 dose
214465691|NCT05166577|DRUG|Valganciclovir|Phase 1b: Valganciclovir starting at 900 mg orally daily, then Phase 2: Valganciclovir at the confirmed recommended Phase 2 dose
214465692|NCT05166577|DRUG|Pembrolizumab|Phase 2: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
214465693|NCT06437080|DRUG|Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg|01 tablet daily for 03 months, This is assigned to Group A.
214465694|NCT06437080|DRUG|Ferric Carboxymaltose|03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
214465695|NCT04054193|DRUG|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
214465696|NCT04054193|DRUG|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
214465697|NCT04054193|DRUG|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
214465698|NCT02503423|DRUG|ASTX660|described above
214465699|NCT06142253|BEHAVIORAL|WATER+CT|This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
214465700|NCT06142253|BEHAVIORAL|Usual Care|This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
214465701|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
214465702|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
214465703|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
214465704|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
214465705|NCT06417554|DRUG|SHR-A2102|SHR-A2102
214465706|NCT06417554|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 + Adebrelimab injection
214465707|NCT03084536|DRUG|Bupivacaine|-Given after general anesthesia
214465708|NCT03084536|DRUG|Gabapentin|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
214465709|NCT03084536|DRUG|Celecoxib|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies."
214465710|NCT03084536|DRUG|Acetaminophen|-As per routine care
214465711|NCT03084536|DRUG|Midazolam|-As per routine care
214465712|NCT03084536|DRUG|Fentanyl|-As per routine care
214465713|NCT05704543|DRUG|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
214465714|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
214465715|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
214465716|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
214465717|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
214465718|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
214465719|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
214465720|NCT06755983|OTHER|Endorphin massage|For Group 1 (experimental group), patients admitted to the clinic one day before surgery will complete the first two sections of the Patient Diagnosis Form (I. Individual characteristics and II. Health and illness-related data), the Surgical Fear and Anxiety Scale, and the VAS scales after the endorphin massage. The patients will be informed that the endorphin massage will last approximately 20 minutes. According to evidence-based current guidelines, it is stated that the intensity of the patient's pain should be assessed during the preoperative period for pain management planning and goals in the postoperative period. Therefore, patients' pain scores will also be recorded preoperatively using the VAS scale. On the morning of the surgery, before going to the operating room, the endorphin massage will be repeated, and the scales will be applied again. After surgery, patients will have their pain levels measured using the VAS at hours 0, 4, 8, 16, and 24, and the amount of analgesics tak
214465721|NCT06681909|BEHAVIORAL|UB Campus Veggie Van|The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
214465722|NCT06828783|DIETARY_SUPPLEMENT|ginger extract|Participants will receive a ginger-based capsule
214465723|NCT06828783|OTHER|Placebo|Participants will receive a placebo capsule
214465724|NCT05702723|BEHAVIORAL|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
214465725|NCT05702723|BEHAVIORAL|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
214465726|NCT05511246|DRUG|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
214465727|NCT05511246|PROCEDURE|Catheter ablation|Endocardial catheter ablation of VT substrate
214465728|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
214465729|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
214465730|NCT01043224|DRUG|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
214465731|NCT06392308|OTHER|none intervention|No interventions are administered to either group of patients.
214465732|NCT04006782|DEVICE|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
214465733|NCT05073458|DRUG|parsaclisinib|parsaclisib will be administered QD orally
214465734|NCT05073458|DRUG|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
214465735|NCT05971485|DRUG|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
214465736|NCT05971485|OTHER|Placebo|The placebo group will receive 2 ml of distilled water as a placebo 30 minutes before venous cannula insertion.
214465737|NCT05576792|OTHER|Ranibizumab|Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
214465738|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
214465739|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
214465740|NCT04680221|DRUG|Liposomal bupivacaine|Deposition of liposomal bupivacaine
214465741|NCT04680221|PROCEDURE|TAP block|Transversus abdominis plane block performed to deposit anesthetic
214465742|NCT04680221|DRUG|Deposition of saline|Deposition of saline
214465743|NCT05577390|OTHER|Intraneural Facilitation Therapy Treatment|Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
214465744|NCT05577390|OTHER|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
214465745|NCT02938377|BEHAVIORAL|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
214465746|NCT02938377|BEHAVIORAL|CBT4CBT|9 computerized modules delivered at the participant's pace
214465747|NCT02938377|DRUG|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
214465748|NCT01897168|DEVICE|No intervention|
214465749|NCT05785741|DRUG|DB-1310|Administered I.V.
214465750|NCT05785741|DRUG|Trastuzumab|Administered I.V.
214465751|NCT05785741|DRUG|Osimertinib|Oral
214465752|NCT04053075|OTHER|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
214465753|NCT04053075|OTHER|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
214465754|NCT04704843|DRUG|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
214465755|NCT04704843|DRUG|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
214465756|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
214465757|NCT05686850|PROCEDURE|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
214465758|NCT05686850|PROCEDURE|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
214465759|NCT06270680|DRUG|Vision Edge Pro|Each dose will consist of one supplement capsule containing 10 mg lutein, 2 mg zeaxanthin, 10 mg mesozeaxanthin, 50mg EPA, 250mg DHA. Capsules are to be taken orally, once daily with a meal. Duration of supplementation will last approximately 2 - 5 months, depending on the length of the athletic seasons for the sports recruited.
214465760|NCT06270680|OTHER|Placebo|A sunflower oil placebo containing 380 mg of sunflower oil
214465761|NCT06025435|OTHER|SAIA-HIV-SSP|The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
214465762|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
214465763|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects. A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
214465764|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 healthy individuals (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
214465765|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 individuals with Parkinson's disease (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
214465766|NCT02671890|DRUG|Chemotherapy|
214465767|NCT02671890|DRUG|Disulfiram|Given PO
214465768|NCT02671890|DRUG|Gemcitabine Hydrochloride|Given IV
214465769|NCT02671890|OTHER|Laboratory Biomarker Analysis|Correlative studies
214465770|NCT06254924|BEHAVIORAL|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
214465771|NCT06254924|BEHAVIORAL|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
214465772|NCT06323707|BEHAVIORAL|Exercise|Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.
214465773|NCT06323707|BEHAVIORAL|Self-management e-module|Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
214465774|NCT03916783|BEHAVIORAL|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
214465775|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
214465776|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
214465777|NCT05643638|BIOLOGICAL|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
214465778|NCT05643638|BIOLOGICAL|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
214465779|NCT05643638|DRUG|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
214465780|NCT03653676|OTHER|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
214465781|NCT06339398|BEHAVIORAL|Aerobic exercise|Standardized volume of aerobic exercise, measured as METs-minutes/week
214465782|NCT06248567|DRUG|ZSP1273|Oral
214465783|NCT05989854|BEHAVIORAL|Exercise|8 week exercise intervention, 3x/wk
214465784|NCT04097730|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
214465785|NCT04097730|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
214465786|NCT04097730|DRUG|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
214465787|NCT04097730|OTHER|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
214465788|NCT04983030|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
214465789|NCT04983030|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
214465790|NCT04983030|BIOLOGICAL|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
214465791|NCT04983030|BIOLOGICAL|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
214465792|NCT04983030|BIOLOGICAL|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
214465793|NCT04830800|BIOLOGICAL|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
214465794|NCT04830800|BIOLOGICAL|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
214465795|NCT06559852|BEHAVIORAL|Yoga|Participants will engage in a 12-week virtual yoga course to assess impact on endometriosis-related pain
214465796|NCT04285515|DRUG|Lumateperone|Lumateperone 42mg oral capsule
214465797|NCT04285515|DRUG|Placebos|Placebo oral capsule
214465798|NCT06159075|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
214465799|NCT06411028|DIAGNOSTIC_TEST|Polymyography|We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.
214465800|NCT06411028|DIAGNOSTIC_TEST|Muscle ultrasound|We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.
214465801|NCT06411028|DIAGNOSTIC_TEST|(Functional) magnetic resonance imaging|Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.
214465802|NCT06411028|DIAGNOSTIC_TEST|Clinical assessment|We will assess tremor and dystonia severity using clinical scales.
214465803|NCT06411028|DIAGNOSTIC_TEST|Questionnaires|We will collect patient-reported outcomes.
214465804|NCT06411028|DRUG|botulinum toxin injection (BTX A)|Three consequetive botulinum toxin injections of the upper extremities
214465805|NCT05204563|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
214465806|NCT05204563|DRUG|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
214465807|NCT03075748|DEVICE|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
214465808|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
214465809|NCT03816332|BIOLOGICAL|Ipilimumab|Given IV
214465810|NCT03816332|BIOLOGICAL|Nivolumab|Given IV
214465811|NCT03816332|DRUG|Prednisone|Given PO
214465812|NCT03816332|DRUG|Tacrolimus|Given PO
214465813|NCT04508907|DRUG|Mavyret|Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
215031546|NCT05951101|DEVICE|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
214465814|NCT03710603|DRUG|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
214465815|NCT03710603|DRUG|Velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
214465816|NCT03710603|DRUG|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
214465817|NCT03710603|DRUG|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
214465818|NCT01456949|DEVICE|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
214465819|NCT05477134|OTHER|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
214465820|NCT03802682|DRUG|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
214465821|NCT03889093|OTHER|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
214465822|NCT06640413|DRUG|[177Lu]Lu-OncoFAP-23|3.7, 7.4, or 11.1 GBq to define the RD
214465823|NCT06640413|DRUG|L19IL2|22.5 Mio IU
214465824|NCT06643663|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
214465825|NCT06207773|OTHER|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
214465826|NCT05296135|DIAGNOSTIC_TEST|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
214465827|NCT04510311|DRUG|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
214465828|NCT04510311|DRUG|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi \[123I\]MIBG
214465829|NCT04510311|DIAGNOSTIC_TEST|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
214465830|NCT04510311|DIAGNOSTIC_TEST|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
214465831|NCT04510311|DIAGNOSTIC_TEST|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
214465832|NCT05524337|BEHAVIORAL|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
214465833|NCT05524337|BEHAVIORAL|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
214465834|NCT05524337|BEHAVIORAL|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
214465835|NCT03785964|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
214465836|NCT03785964|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
214465837|NCT03744182|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
214465838|NCT03744182|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
214465839|NCT05756036|OTHER|None Observational study|Non interventional study
214465840|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
214465841|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
214465842|NCT03709121|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
214465843|NCT05808140|DRUG|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
214465844|NCT05808140|DEVICE|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
214465845|NCT04176601|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
214465846|NCT03012971|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
214465847|NCT03012971|DRUG|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
214465848|NCT03382106|DRUG|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
214465849|NCT03382106|DRUG|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
214465850|NCT03382106|DIAGNOSTIC_TEST|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
214465851|NCT03382106|DIAGNOSTIC_TEST|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
214465852|NCT03382106|DIAGNOSTIC_TEST|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
214465853|NCT06850961|DEVICE|Digital health intervention by using a mobile application|A digital health intervention for promoting self-management in patients with COPD by using a mobile application.
214465854|NCT06850961|OTHER|Feasibilty study and qualitative interview studies|This study is a one group feasibility study including quantitative and qualitative study designs. The investigators will use focus groups and indiviual interviews, as well as Interpersonal Process Recall (IPR) interviews.
214465855|NCT03759431|RADIATION|Vocal-cord Radiotherapy|Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.
214465856|NCT03759431|RADIATION|Complete Larynx Radiotherapy|Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
214465857|NCT06441123|BIOLOGICAL|Blood Sampling|20 ml of blood (5 tubes of 4 ml) will be collected once.
214465858|NCT06380361|DEVICE|BioSpy System|One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
214465859|NCT04290754|BEHAVIORAL|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
214465860|NCT04290754|BEHAVIORAL|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
214465861|NCT06851377|GENETIC|Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)|After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.
214465862|NCT06851377|OTHER|Trascriptome analysis|Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.
214465863|NCT06847373|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 4000 IU daily orally
214465864|NCT06847295|PROCEDURE|Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program.|The intervention consists of surgical implantation of an epidural electrical stimulator using a paddle lead (Medtronic Specify 5-6-5) placed in the lumbar epidural space and a subcutaneously implanted pulse generator (Medtronic Intellis). After a one-month recovery and device calibration period, the stimulator is activated during a 12-month intensive rehabilitation program. Patients receive electrical stimulation during five supervised physiotherapy sessions per week. Stimulation parameters-including pulse width, frequency, and amplitude-are individually optimized based on intraoperative neurophysiological monitoring and ongoing clinical assessments, with the goal of enhancing gait recovery, reducing spasticity, and improving overall motor function and quality of life.
214465865|NCT06849531|OTHER|Foot Biomechanics and Lower Extremity Muscle Analysis|Focus on Foot Biomechanics
214465866|NCT06849622|DIAGNOSTIC_TEST|Test on blood sample|The blood sample will be drawn by venipuncture during clinical routine. The serum will be tested for coeliac or diabetes 1 auto-antibodies, using Elisa test.
214465867|NCT06849622|DIAGNOSTIC_TEST|Test on dried blood sample|A finger prick will be used to collect Dried blood Spot (DBS) on a special card. The eluted blood spot will be tested, for coeliac and diabetes 1 auto-antibodies, using the same method used for serum, and the same cut-offs for positivity and negativity (Elisa tests)
214465868|NCT02424305|DRUG|LEO 43204 gel 0.018%|
214465869|NCT02424305|DRUG|LEO 43204 gel 0.1%|
214465870|NCT02424305|DRUG|LEO 43204 gel 0.037%|
214465871|NCT06843369|DIAGNOSTIC_TEST|inflammatory markers|Serum amyloid A , cbc and IL-10
214465872|NCT06850324|DRUG|ABL-101 is administered at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour).|The doses of ABL-101 is administered using an IV infusion pump in the arm at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour). Patients will undergo a 1 hour-imaging with 19F MRI, 16h-36h after end of PFC infusion.
214465873|NCT06847971|PROCEDURE|Flexor hallucis longus tendon transfer|The FHL tendon will be dissected and transected as far distally as possible. The FHL tendon will be transfixed by Krakow's suture being inserted into the distal 3 cm in the stump to ensure adequate length of the graft inserted within the bony tunnel in the calcaneus.A guide wire with eyelet will be inserted in the calcaneum just anterior to the native AT insertion by a distance 2 mm more than the half of the diameter of the transferred tendon to avoid blow up of the posterior wall of the tunnel. A tunnel will be drilled over the guide wire according to the tendon thickness, without penetrating the planter surface of the calcaneum. The threads at the end of FHL tendon suture will be passed through the eyelet of the guide wire. The tendon will be driven into the calcaneal bony tunnel by pulling the guide wire through the plantar aspect of the heel. Then the FHL tendon will be tenodesed into the bone tunnel using a interference screw of the same size or 1 mm larger than the bone tunnel.
214465874|NCT06847971|PROCEDURE|Gastrocnemius augmented Flexor hallucis longus tendon transfer|The gastrocnemius tendon will be refixed to the calcaneal tuberosity using anchors. According to the size of the defect: If the size of the gap was 4-5 cm, an additional gastrocnemius turndown or V-Y flaps will be done. Turn down flap will be achieved by creating 2 cm wide and 5-6 cm long flap from the gastrocnemius tendon. The most distal 1 cm from the proximal stump will be secured along the lateral border of the flap to prevent its separation from the original stump during tensioning and fixation to the calcaneus. V-Y flap will be achieved by having inverted V-shaped incision in the distal part of the gastrocnemius starting proximally and extending the two limbs distally leaving the lateral 1 cm from the original tendon. Then carful advancement of the proximal AT stump distally to reach the calcaneal tuberosity. then Fixation will be achieved by suture anchors. If more than 5 cm gap, tenomyodesis of FHL through the proximal stump of Gastrocnemius muscle will be done.
214465875|NCT06851676|DIETARY_SUPPLEMENT|water supplemented by calcium|Fonte Fausta® water is a natural mineral water, rich in essential minerals, such as calcium, magnesium, and bicarbonate, which are important for maintaining bone density, muscle function, and overall metabolic health.
214465876|NCT06851676|OTHER|Water (Placebo)|a natural mineral commercially available
214465877|NCT06852027|OTHER|Different Dietary Practices|The aim was to investigate the effects of Gluten-Casein-Free Diet and Feingold Diet on gastrointestinal complaints in children with Autism Spectrum Disorder.
214465878|NCT06851182|OTHER|Helfer skin tap technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25gauge sterile disposable sterile disposable needle will be used in all patients for injection administration. the procedure will be performed with helfer skin tap technique. Forms will be applied to the children by the researcher before and after IM injection.
214465879|NCT06851182|OTHER|Shotblocker technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25Gauge sterile disposable sterile disposable needle will be used in all patients. The procedure will be performed using Shotblocker method. Forms will be applied to the children by the investigator before and after IM injection.
214465880|NCT06851962|DRUG|Metformin|Metformin maximum daily dose 2000 mg
214465881|NCT06851962|DRUG|Dulaglutide|Dulaglutide
214465882|NCT06851962|DRUG|Semaglutide 1.0 mg|Semaglutide
214465883|NCT06851962|DRUG|Empagliflozin (BI 10773)|Empagliflozin
214465884|NCT06851962|DRUG|Canagliflozin|Canagliflozin
214465885|NCT06851962|DRUG|Dapagliflozin|Dapagliflozin
214465886|NCT06851962|DRUG|pioglitazone|Pioglitazone
214465887|NCT06851962|DRUG|Sitagliptin|Sitagliptin
214465888|NCT06851962|DRUG|Vildagliptin (Galvus)|vildagliptin
214465889|NCT06851962|DRUG|linagliptin|linagliptin
214465890|NCT06852092|DRUG|Carbon-14 labeled HSK39297|Dose A
214465891|NCT06852404|OTHER|Photovoice|Photovoice is a participant-driven research method that enables individuals to communicate their experiences through visual data. It is especially useful for exploring social issues and the challenges people encounter. In this approach, participants capture images that they find meaningful in relation to the research topic, using these photographs to express their emotions, thoughts, and personal experiences.
214465892|NCT06851949|DEVICE|Vsling|Implantable ventricular repair device
214465893|NCT04863924|DIAGNOSTIC_TEST|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
214465894|NCT06851143|DIAGNOSTIC_TEST|18F-DPA-714 PET/MR scan|Saline intravenous solution of 18F-DPA-714 administered at 0.1 mCi/kg by bodyweight
214465895|NCT06852625|BIOLOGICAL|Autologous Tolerogenic Dendritic Cells|• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.
214465896|NCT06852690|OTHER|exercise with virtual reality goggles|Exercise and smartwatch tracking for type 2 diabetics with virtual reality glasses
214465897|NCT06851338|DEVICE|Hypoglossal Nerve Stimulation|Implant of Inspire Upper Airway Stimulation (UAS) system for treatment of obstructive sleep apnea (OSA) in the pediatric down syndrome population
214465898|NCT06851403|DRUG|Dupilumab|initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
214465899|NCT06851988|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times. And record of physical activities at home. According to the record set goal to acheive.
214465900|NCT06851988|OTHER|HIIT only|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times.
214465901|NCT05991700|DRUG|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
214465902|NCT05991700|DRUG|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
214465903|NCT04455308|OTHER|Biological sample collection|10mL blood sample
214465904|NCT04201262|BIOLOGICAL|Ravulizumab|Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
214465905|NCT02618577|DRUG|Edoxaban|Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF
214465906|NCT02618577|DRUG|ASA|ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.
214465907|NCT05536388|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
214465908|NCT05446168|DRUG|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
214465909|NCT06362785|DEVICE|Virtual Reality|The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
214465910|NCT06362785|BEHAVIORAL|Therapeutic exercise|The control group will receive conventional therapeutic exercise treatment following the recommendations of the Osteoarthritis Research Society International (OARSI), similar to the exercises performed with VR.
214465911|NCT06426550|PROCEDURE|Periodontal treatment|Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed.
214465912|NCT03512327|OTHER|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
214465913|NCT05658471|OTHER|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
214465914|NCT05658471|OTHER|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
214465915|NCT05658471|BEHAVIORAL|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
214465916|NCT05658471|OTHER|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
214465917|NCT05560893|BEHAVIORAL|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
214465918|NCT03049618|OTHER|Laboratory Biomarker Analysis|Correlative studies
214465919|NCT03049618|BIOLOGICAL|Pembrolizumab|Given IV
214465920|NCT03049618|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214465921|NCT03847311|DRUG|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
214465922|NCT03847311|DRUG|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
214465923|NCT03511664|DRUG|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
214465924|NCT03511664|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
214465925|NCT05050149|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
214465926|NCT06510842|OTHER|External drainage of intraventricular hemorrhage|An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
214465927|NCT04954573|RADIATION|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
214465928|NCT06203093|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
214465929|NCT04162665|RADIATION|Adaptive short course radiation therapy|Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.
214465930|NCT04162665|DRUG|Standard of care chemotherapy regimen|The recommendations are CAPOX, FOLFOX, or FLT.
214465931|NCT03548428|DRUG|Atezolizumab|1200mg IV every 3 weeks for 4 months
214465932|NCT03548428|RADIATION|SBRT|3 to 5 fractions depending on tumor size
214465933|NCT00882895|PROCEDURE|Stem cell infusion|
214465934|NCT00882895|PROCEDURE|TLI|
214465935|NCT00882895|DRUG|Anti-thymocyte globulin|
214465936|NCT00882895|DRUG|Solumedrol|
214465937|NCT00882895|DRUG|Tacrolimus|
214465938|NCT00882895|DRUG|Mycophenolate mofetil|
214465939|NCT04789837|DRUG|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
214465940|NCT04789837|DRUG|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
214465941|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
214465942|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
214465943|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
214465944|NCT06838819|DEVICE|Continuous glucose monitoring system|Medtronic Simplera™
214465945|NCT06077552|OTHER|pyramidal training by treadmill|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
214465946|NCT04777721|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
214465947|NCT04535934|OTHER|Adenine 5+ (five stable-labeled nitrogens)|taggant coencapsulated with an excipient
214465948|NCT04016675|OTHER|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
214465949|NCT04016675|OTHER|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
214465950|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
214465951|NCT05033067|BEHAVIORAL|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
214465952|NCT05341557|DRUG|BPI-371153|Subjects will receive BPI-371153 until disease progression
214465953|NCT03824327|PROCEDURE|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
214465954|NCT03824327|DRUG|Papaverine Hydrochloride|Given IV
214465955|NCT03824327|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214465956|NCT04577963|DRUG|Fruquintinib|Oral VEGFR inhibitor
214465957|NCT04577963|DRUG|Tislelizumab|PD-1 inhibitor
214465958|NCT04754165|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
214465959|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; high dose ；Denosumab placebo
214465960|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; low dose ；Denosumab placebo
214465961|NCT07028268|DRUG|Denosumab；SHR-2017 placebo|Denosumab；SHR-2017 placebo
214465962|NCT06688058|BIOLOGICAL|V540D|Experimental vaccine and adjuvant administered via intramuscular (IM) injection
214465963|NCT06688058|BIOLOGICAL|GARDASIL®9|Suspension administered via IM injection
214465964|NCT06925295|DRUG|Xenon MRI|MRI with Xenon used for contrast
214465965|NCT06925295|DIAGNOSTIC_TEST|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volumes, DLCO and oscillometry
214465966|NCT06925295|OTHER|Quality of Life Questionnaire|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30+QLQ-LC29)
214465967|NCT06925295|OTHER|Medical Research Council Dyspnea score|modified Medical Research Council Dyspnea score (mMRC Dyspnea)
214465968|NCT06925295|OTHER|St. George's Respiratory Questionnaire|St. George's Respiratory Questionnaire (SGRQ)
214465969|NCT06925295|DIAGNOSTIC_TEST|Blood Biomarkers|blood biomarkers of inflammation and injury (e.g. Angiopoetin-2, Interleukin-6, myofibroblast activity, BPD4)
214465970|NCT07050355|DEVICE|rTMS|Subjects will undergo rTMS to the left dorsolateral prefrontal region as a treatment for depression. Treatment will be performed three times per week for 12 weeks (36 sessions) . We will use a standard resting motor threshold (rMT) determination from unaffected abductor pollicis brevis. Treatments will be delivered at the EEG coordinate for F3 (approximating the left DLPFC) and will be found using the Beam-F3 method. A total of 5000 pulses/session will be delivered at 10Hz with an intensity of 120% of rMT.
214465971|NCT07050355|BEHAVIORAL|AEx|The goal of AEx will be 20 minutes of continuous walking at an intensity of \~70% of heart rate reserve (HRR calculated via the Karvonen method). The desired intensity will be achieved by a combination of increasing treadmill speed and incline. Rest breaks will be allowed as needed during training with the goal of progressing to 20 minutes of continuous walking.
214465972|NCT06737029|DIAGNOSTIC_TEST|Enhanced diagnostic workup|"Patients will undergo review by a study physician, including a detailed history and physical examination, as well as review of additional investigations that have been performed thus far.~Based on the precise nature of the complaints, and additional findings, additional diagnostic testing may be requested, including, but not limited to: blood testing, spirometry, computed tomography of the chest, repeat chest X-ray, sputum investigations, or bronchoscopy."
214465973|NCT00636389|DEVICE|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
214465974|NCT00636389|DEVICE|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
214465975|NCT06254482|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
214465976|NCT06891625|OTHER|SMT|In the present study, a short examination of the whole spine and pelvic area will be performed to identify those segments with the highest restricted range of motion compared to other parts. A standard HVLA manipulation of this area is applied, which refers to Maitland grade 5.
214465977|NCT06891625|OTHER|ET|In the present study, the participant will, after short warming up, perform three standard exercises aiming to increase the possibility for a person with back pain to control the full range of spinal, pelvis and hip joints (Exercise 1) to increase the motor control and coordination of the muscles controlling the low back, pelvis and hip joints in flexion and rotation (Exercise 2), and to increase the motor control of muscles controlling the low back, pelvis and hip joints in extension (Exercise 3).
214465978|NCT06891625|OTHER|OLP|"In the present study, the procedure will follow the study of Carvalho, et al. (2016).28 The researcher explains clearly in a positive way to the participants that i) a placebo effect can be powerful, ii) the body can automatically respond to taking placebo pills like Pavlov's dogs that salivated when they heard a clock, iii) that a positive attitude can be helpful, but is not necessary, and iiii) the researcher shows a short video clip (1 minute 25 seconds) of a news report, where participants in an OLP study are interviewed on the positive effects they experienced (https://www.youtube.com/watch?v=Jp14Lhl0T9). Thereafter, the participants are asked to take two pills, containing the inactive substance microcrystalline cellulose from a container clearly labeled with placebo."
214465979|NCT04857723|DEVICE|daily disposable contact lens|Daily disposable contact lens for 3 months
214465980|NCT07057960|OTHER|Group Social Work Intervention Based on Cognitive Behavioral Therapy|"The aim of the intervention is to modify children's bullying-related cognitions and enhance peer relationships through cognitive restructuring, achieved by increasing awareness of cognitions, emotions, and behaviors among children in institutional care.~The content of the intervention was developed using the core principles and techniques of cognitive behavioral therapy."
214465981|NCT06749132|DIAGNOSTIC_TEST|Transthoracic echocardiogram|All study participants will undergo a clinical transthoracic echocardiogram (TTE) performed by certified echocardiography technicians. The TTE includes standard transthoracic examination with acquisition of B-mode, color and spectral Doppler images and videos in line with standard echocardiographic guidelines.
214465982|NCT07063680|DRUG|Argipressin|Argipressin 0.4 U.ml-1 (i.e. 40IU diluted in 100ml 0.9% NaCl bag)
214465983|NCT07063680|DRUG|Chlorure de sodium|NaCl 0.9%
214465984|NCT07063680|OTHER|Collection of clinical data|At inclusion, D0 to D7, ICU discharge, D30 and D90
214465985|NCT07062692|OTHER|dry needling trigger release therapy|The dry needling intervention involved inserting sterile filiform needles directly into active rhomboid trigger points for 1-2 sessions (1 session/week) to elicit local twitch responses and relieve tension.
214465986|NCT07062692|OTHER|MANUAL TRIGGER POINT RELEASE|The manual trigger point release intervention involved applying sustained pressure to active rhomboid trigger points followed by passive stretching to release muscle tension and improve mobility.
214465987|NCT07063667|OTHER|bulid primary AI model|For the collected patient data, deep learning is used to perform feature screening on the selected or collected images, and malignant risk factors are determined by combining clinical significance. A neural network classifier is trained on the training set data. Variable selection: independent variables (breast MRI images, breast ultrasound images, indicators such as CA199, CA153, CA125, AFP/CEA, etc.), dependent variables (whether suffering from breast cancer and breast cancer subtypes), and the verification accuracy standard is set as the pathological biopsy result.
214465988|NCT07063667|OTHER|verdict model and develop its function|The accuracy of a breast cancer prediction model is typically evaluated using multiple metrics that assess its performance in different aspects
214465989|NCT07062276|OTHER|Dynamic taping|The dynamic tape is a new type of treatment. The material has high resilience. Its purpose is to help muscles and tissues absorb external forces and reduce tissue energy consumption.
214465990|NCT07062276|OTHER|Kinesio ®|Kinesio ®can effectively improve pain, edema, and assist functional movements. The elasticity of the patch creates wrinkles to relax the extensor pollicis brevis and the abductor longus muscle of the thumb.
214465991|NCT07062822|OTHER|Resisted exercise|Patients in this group will be applied Kinesio taping 3 times per week over the study period of 6 weeks. Before the kinesio taping, the skin surface will be clean. Patients will positioned lying on their side, hip extended, and knee joint at 60° of flexion. The knee will be tape with an I-shaped kinesio tape starting at the origin of the rectus femoris, and a Y-shaped kinesio tape proximal to the superior patellar border. The taping will be no tension at its base, whereas the portion between the anchor and the superior patella will be stretched ≈40%.
214465992|NCT07062822|OTHER|kinesiology tapping|kinesiology tapping
214465993|NCT07063472|BEHAVIORAL|Tele- pilates|"Tele-Pilates for (TP) group The TP program included warm-up, main session, and cool-down phases. The session started with warm-up exercises in the form of breathing, spinal twist, cat stretch, arm circles, and abdominal stretching. Each exercise was performed for five repetitions, with each repetition held for 10-15 seconds and followed by a 5-second rest period. The warm-up phase lasted a total of 10 minutes.~Tele-Pilates was supervised by a Pilates professional trainer. Participants engaged in mat-based Pilates exercises. These exercises included roll-up, bug leg, crock leg lying, prone single leg kick, bug roll, knee/lumbar roll, and prone attitude rotation.The session ended with 10-minute cool-down that involved relaxation exercises and stretching."
214465994|NCT07063472|DEVICE|Kinesio taping application for the KT group|Kinesio taping application for the KT group The participant sat upright in a chair, and a piece of kinesiology tape (5 × 5 cm, 3NS, Korea) was used to measure the distance from just above the anus to the upper border of the pelvis. This measured length was then divided by eight, and the tape was cut accordingly. One end of the tape was anchored on the ulnar bone just above the inguinal region. With 25% stretch, the tape was applied diagonally upward and outward, following the contour of the iliac crest over the ilium. The second end was secured to overlap the base of the initial tape. A second strip was applied in a similar manner in the opposite direction over the ilium. KT was applied for over eight weeks, with the tape changed every three days
214465995|NCT07062510|DEVICE|Dasuit Cusion|The Dasuit cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
214465996|NCT07062510|DEVICE|Placebo|The placebo cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
214465997|NCT07062510|OTHER|Washout|A 10 min washout period is in between the two interventions. The paitent is asked to walk around at ease.
214465998|NCT07062874|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Participants received supervised exercise training 3 times per week for 6 weeks. Each session included a 10-minute warm-up (walking at 1.5 km/h), a 30-minute aerobic phase at 60-85% heart rate reserve (calculated using the Karvonen formula), and a 10-minute cool-down (walking at 1 km/h). In addition, participants performed resistance training for upper and lower extremities using TheraBands, with 8-10 sets targeting major muscle groups.
214465999|NCT07062874|BEHAVIORAL|Aerobic Exercise Only|Participants followed the same aerobic training protocol as the experimental group-3 sessions per week for 6 weeks, with 10-minute warm-up, 30-minute aerobic exercise (60-85% HRR), and 10-minute cool-down. No resistance training was provided.
214466000|NCT06899087|OTHER|not interventional|This is an observational study
214466001|NCT07063797|DRUG|Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Denosumab treatment: Administer 60 mg of denosumab via subcutaneous injection every six months for a total treatment period of one year."
214466002|NCT07063797|DRUG|Eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Eldecalcitol treatment: Eldecalcitol, 0.75 µg per capsule, taken orally once daily for a total treatment period of one year."
214466003|NCT07063082|OTHER|Erythromycin Phonophoresis|The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.
214466004|NCT07063082|DEVICE|Ultrasound (US)|"Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy.~The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions)."
214466005|NCT07063082|DRUG|Topical Erythromycin|Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics
214466006|NCT07063082|OTHER|Medical treatment|Saline nasal wash 3 times daily for a month.
214466007|NCT07063732|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|0.6 g KME per kg body mass; \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate. (Delta G Ketone, TΔS, Oxford).
214466008|NCT07063732|DIETARY_SUPPLEMENT|Placebo|Inert, calorie-free placebo drink that is taste-matched to the ketone monoester supplement
214466009|NCT07063368|OTHER|Otago exercises and systematic desensitization with routine physical therapy|Warm-up (5 minutes) Marching in place (assisted), arm swings, side steps Otago Balance Exercises (7 minutes) Knee bends (with support), heel-to-toe stand (with support), side hip abduction (with support) Otago Strength Exercises (8 minutes) Ankle dorsiflexion, seated knee extensions, seated marching Routine Physical Therapy - Strength and Mobility Exercises (15 minutes) Assisted squats or sit-to-stand exercises, standing calf raises (with support), seated bicep curls, seated shoulder press Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring, quadriceps, shoulder, and neck stretches Relaxation Training (7 minutes) Review goals, PMR, deep breathing exercises Gradual Exposure and Visualization (10 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance) Discussion and Feedback (3 minutes) Share experiences, provide feedback, assign homework
214466010|NCT07063368|OTHER|Otago Exercises and Routine physical Therapy|"Warm-up (10 minutes) Marching in place, arm swings, and side steps. Otago Balance Exercises (10 minutes) Knee bends, heel-to-toe stand, side hip abduction. Otago Strength Exercises (10 minutes) Ankle dorsiflexion, seated knee extensions, seated marching. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (10 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches, seated torso twist."
214466011|NCT07063368|OTHER|Systematic desensitization and routine physical therapy|"Warm-up (5 minutes) Marching in place, arm swings, and side steps. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches. Relaxation Training (10 minutes) Review goals and expectations, PMR, deep breathing exercises. Gradual Exposure and Visualization (15 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance).~Discussion and Feedback (5 minutes) Share experiences, provide feedback, and assign homework."
214466012|NCT07064018|DRUG|Spedox-6|Given Intravenously (IV)
214466013|NCT07064018|DRUG|Pegfilgrastim|Given Subcutaneous Injection or IV
214466014|NCT07064018|DRUG|Filgrastim|Given Subcutaneous Injection or IV
214466015|NCT07062757|OTHER|no intervention|this group patients receive any medication for edema control.
214466016|NCT07062757|OTHER|lymphatic drainage massage|A total of 10 sessions of lymphatic drainage massage will be applied to this group of patients, starting from the 2nd postoperative day, with 2 sessions per week.
214466017|NCT07062757|DIETARY_SUPPLEMENT|oral melatonin tablet|In this group of patients, the first dose of 10 mg oral melatonin tablet will be given one day prior to the operation, and the patients will continue taking the tablet daily for a total of 21 days.
214466018|NCT07062757|COMBINATION_PRODUCT|both melatonin and lymphatic drainage|In this group of patients, a total of 10 sessions of lymphatic drainage massage will be applied starting from the 2nd postoperative day, with 2 sessions per week, while the first dose of 10 mg oral melatonin tablet will be administered one day prior to the operation, and the patients will continue taking the tablet daily for 21 days.
214466019|NCT07064122|DRUG|AZD2962|AZD2962 will be administered orally once daily.
214466020|NCT07062848|DIAGNOSTIC_TEST|AI Toolkit for ATTR-CM Diagnosis|An artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE)
214466021|NCT07063849|BIOLOGICAL|A/Texas|Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1
214466022|NCT07061925|DRUG|ALC-2203-1|This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
214466023|NCT07061925|DRUG|ALC-2203-2|This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
214466024|NCT07061925|DRUG|ALC-2203-AC|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.
214466025|NCT07061925|DRUG|Placabo|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
214466026|NCT07064239|DEVICE|cooling vest|"Cooling vest :~It is one of cooling methods proposed to improve exercise performance in MS by reducing one's core and/or skin temperature before taking on physical work"
214466027|NCT07064239|OTHER|Aerobic exercises|aerobic exercise as any activity that uses large muscle groups, can be maintained continuously and is rhythmic in nature. As the name implies, muscle groups activated by this type of exercise rely on aerobic metabolism to extract energy in the form of adenosine triphosphate (ATP) from amino acids, carbohydrates and fatty acids. Examples of aerobic exercise include cycling, dancing, hiking, jogging/long distance running, swimming and walking
214466028|NCT07063225|DRUG|Romiplostim N01|The subjects will receive ropivacaine N01 treatment, with an initial dose of (2-3) µg/kg. When the dose is less than 250 µg, 250 µg (1 vial) can be administered (subcutaneously), once a week. The dose will be increased by (1) µg/kg each week, up to a maximum of 10 µg/kg, until the platelet count reaches ≥ 50 × 10\^9/L. If the platelet count returns to normal, the dose can be reduced according to the platelet level as appropriate.
214466029|NCT06339710|DRUG|benznidazole 300 mg daily 8 weeks|672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)
214466030|NCT05891600|DEVICE|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
214466031|NCT07063810|DEVICE|Mixed Reality Rehabilitation|"The mixed reality protocol will be based on 5 perceptual-motor activities (i.e., games specifically developed for the purposes of this study). The activities consist in walking to collect objects, avoid obstacles, or move the upper limbs to catch virtual balls or fit in narrow shapes.~Three games will be performed per session, for a duration of 15 minutes each over 1h sessions with rest times.~The level of the activities will be adapted to the performance of the participants during the course of the protocol, by manipulating game settings: necessary speed, accuracy and movement frequency."
214466032|NCT03221426|BIOLOGICAL|Pembrolizumab|IV infusion
214466033|NCT03221426|DRUG|Placebo|IV infusion
214466034|NCT03221426|DRUG|Cisplatin|IV infusion
214466035|NCT03221426|DRUG|Capecitabine|Oral tablets
214466036|NCT03221426|DRUG|5-fluorouracil|IV infusion
214466037|NCT03221426|DRUG|Docetaxel|IV infusion
214466038|NCT03221426|DRUG|Oxaliplatin|IV infusion
214466039|NCT03221426|DRUG|Leucovorin|IV infusion
214466040|NCT06441760|OTHER|Video teleconsultation|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while PEM physicians will provide medical direction remotely using video to communicate with EMS personnel via tablet devices.
214466041|NCT06441760|OTHER|Audio support|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while EM physicians will provide medical direction remotely using audio to communicate with EMS personnel via tablet devices.
214466042|NCT06934980|DEVICE|Microneedle Device|Microneedle device will be used for collecting dermal interstitial skin fluid samples as defined by the protocol.
214466043|NCT06952387|OTHER|Personalized blood pressure management|"In patients assigned to personalized blood pressure management, clinicians were asked to maintain intraoperative MAP at least at the preoperative mean 24-hour MAP (with a maximum MAP target of 110 mmHg) from anesthesia induction to 2 hors after completion of surgery. If the preoperative mean 24-hour MAP was below 65mmHg, intraoperative MAP was maintained at least at 65mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger fluid challenge (FC) administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
214466044|NCT06952387|OTHER|Routine blood pressure management|"In patients assigned to routine blood pressure management, clinicians were blinded to the results of preoperative automated 24-hour blood pressure monitoring, and thus managed blood pressure per institutional routine which generally is to maintain MAP above 60 mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger FC administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
214466045|NCT05379101|DIAGNOSTIC_TEST|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
214466046|NCT05379101|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
214466047|NCT05379101|DIAGNOSTIC_TEST|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
214466048|NCT04761848|DRUG|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
214466049|NCT04761848|DRUG|Placebo|Placebo tablet twice daily
214466050|NCT04375800|DRUG|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
214466051|NCT04375800|DRUG|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
214466052|NCT06185452|DRUG|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
214466053|NCT06185452|DRUG|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
214466054|NCT05874154|PROCEDURE|Tibial nerve selective neurotomy|Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
214466055|NCT05874154|DRUG|Botulinum toxin injection|Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
214466056|NCT02534168|DEVICE|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
214466057|NCT01370512|DRUG|Droxidopa|100 mg tablets by mouth three times a day
214466058|NCT01370512|DRUG|Pyridostigmine|60 mg tablets by mouth three times a day
214466059|NCT01370512|OTHER|Placebo|Looks exactly like the study drug but contains no active ingredients
214466060|NCT06792812|DRUG|ginger mouthwash|contain Sulfetal Zn® (Zinc Coco Sulphate) has a cleansing and antibacterial action and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
214466061|NCT06792812|DRUG|chlorohexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
214466062|NCT06792812|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
214466063|NCT05837091|DRUG|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
214466064|NCT05837091|DIAGNOSTIC_TEST|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
214466065|NCT05837091|DEVICE|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
214466066|NCT05837091|DEVICE|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
215031547|NCT04906512|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
214466071|NCT03335670|DRUG|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
214466072|NCT06130410|BIOLOGICAL|COMIRNATY intramuscular injection|Booster injection in the muscle, 1 dose
214466073|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
214466074|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
214466075|NCT04982796|DRUG|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
214466076|NCT04982796|BEHAVIORAL|Treatment-as-usual|See description of treatment-as-usual arm.
214466077|NCT05669976|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
214466078|NCT05669976|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
214466079|NCT06960941|DIETARY_SUPPLEMENT|TrioBiotix360®|Dietary supplement combining prebiotics and probiotics to promote the balance of intestinal bacterial microflora.
214466080|NCT06960941|OTHER|Booklet with a series of postural hygiene exercises|The booklet will contain a series of postural hygiene exercises to be performed at home
214466081|NCT03971799|BIOLOGICAL|CD33CART autologous|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
214466082|NCT03971799|BIOLOGICAL|CD33CART allogeneic|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
214466083|NCT06641973|DEVICE|Robotic balance rehabilitation with hunova® robotic platform|The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
214466084|NCT03257410|DEVICE|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
214466085|NCT03257410|DEVICE|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
214466086|NCT02561247|DEVICE|Prismaflex HF20 CRRT Filter|
214466087|NCT02561247|DEVICE|Prismaflex® System 7.10 and 7.20|
214466088|NCT05407025|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
214466089|NCT05407025|OTHER|Questionnaire Administration|Complete risk factor questionnaire
214466090|NCT05365230|OTHER|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
214466091|NCT05365230|OTHER|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
214466092|NCT04826003|DRUG|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
214466093|NCT04826003|DRUG|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
214466094|NCT04826003|DRUG|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~\- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
214466095|NCT05616130|OTHER|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
214466096|NCT05616130|PROCEDURE|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
214466097|NCT05616130|OTHER|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
214466098|NCT05616130|OTHER|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
214466099|NCT06193642|OTHER|experimental|Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
214466100|NCT05022134|BEHAVIORAL|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
214466101|NCT02179359|DRUG|Reduced Toxicity Ablative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0"
214466102|NCT02179359|DRUG|Reduced Intensity Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0"
214466103|NCT02179359|DRUG|Myeloablative Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0"
214466104|NCT05457959|BIOLOGICAL|Dendritic Cell Tumor Peptide Vaccine|Given ID
214466105|NCT05457959|BIOLOGICAL|Ipilimumab|Given IV
214466106|NCT05457959|PROCEDURE|Leukapheresis|Undergo leukapheresis
214466107|NCT05457959|BIOLOGICAL|Nivolumab|Given IV
214466108|NCT05457959|DRUG|Placebo Administration|Given ID
214466109|NCT05457959|DRUG|Placebo Administration|Given IV
214466110|NCT05457959|DRUG|Poly ICLC|Given IM
214466111|NCT05457959|PROCEDURE|Resection|Undergo standard of care surgical resection
214466112|NCT05050747|DRUG|HCG is introduced at day of trigger intra-uterine|hcg is introduced
214466113|NCT05050747|DEVICE|endometrial injury by pipelle|endometrial injury using pipelle on day 8-9 on the same cycle of ovulation
214466114|NCT06329492|BIOLOGICAL|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
214466115|NCT05486650|DRUG|PD-1 inhibitor|After receiving PD-1 inhibitor treatment in the first three cycles, patients with locally advanced or advanced NSCLC whose curative effect is evaluated as stable disease receive SBRT combined with PD-1 inhibitor treatment
214466116|NCT02276885|RADIATION|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
214466117|NCT02276885|RADIATION|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
214466118|NCT03479268|DRUG|Ibrutinib|Given PO
214466119|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
214466120|NCT03479268|DRUG|Pevonedistat|Given IV
214466121|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
214466122|NCT03479268|OTHER|Pharmacological Study|Correlative studies
214466123|NCT02891824|DRUG|atezolizumab + avastin + platinum-based chemotherapy|"* atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
214466124|NCT02891824|DRUG|placebo + avastin + platinum-based chemotherapy|"* placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
214466125|NCT04228731|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
214466126|NCT04228731|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
214466127|NCT03847207|DRUG|HTL0030310|Solution for Subcutaneous injection
214466128|NCT03847207|DRUG|Pasireotide|Pasireotide 600 μg for subcutaneous injection
214466129|NCT03847207|DRUG|Placebo|Matching placebo Solution
214466130|NCT04944706|DRUG|Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time|Take 3 times a day after meals,24 weeks
214466131|NCT04944706|DRUG|Qishen Yiqi dripping pills 4 bags/time|Take 3 times a day after meals,24 weeks
214466132|NCT04944706|DRUG|Qishen Yiqi dripping pills placebo 4 bags/time|Take 3 times a day after meals,24 weeks
214466133|NCT06338722|OTHER|Making it Work Systemic Sclerosis|One 2 hour virtual meeting per week for 5 weeks, plus an individual meeting with an occupational therapist and a vocational counselor
214466134|NCT05680753|BEHAVIORAL|Physiotherapy|Physiotherapy
214466135|NCT04808076|PROCEDURE|Shunt surgery|Shunt operation
214466136|NCT05297266|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
214466137|NCT05755490|BEHAVIORAL|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
214466138|NCT06101706|BEHAVIORAL|Fatigue assessment|FACIT-F questionnaire and Visual Analog Scale for fatigue
214466139|NCT06101706|BEHAVIORAL|Quality of life assessment|PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
214466140|NCT06101706|OTHER|Assess severity of psoriatic arthritis|DAPSA score
214466141|NCT06101706|OTHER|Assess severity of cutaneous psoriasis|PASI score
214466142|NCT05989802|DIAGNOSTIC_TEST|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
214466143|NCT05989802|DIAGNOSTIC_TEST|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
214466144|NCT05989802|DIAGNOSTIC_TEST|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
214466145|NCT05989802|OTHER|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
214466146|NCT03325855|OTHER|None - Observational|None - Observational
214466147|NCT06505850|DEVICE|Tapered-shaped cuff tracheal tube|Tracheal intubation with a tapered-shaped cuff tube
214466148|NCT06505850|DEVICE|Cylindrical-shaped cuff tracheal tube|Tracheal intubation with a cylindrical-shaped cuff tube
214466149|NCT02714634|DRUG|Methotrexate + targeted therapy administration|"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"
214466150|NCT02714634|DRUG|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
214466151|NCT03693105|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
214466152|NCT03693105|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
214466153|NCT04803994|DRUG|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
214466154|NCT04803994|DRUG|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
214466155|NCT04803994|PROCEDURE|TACE|Locoregional therapy will be performed as a standard-of-care procedure
214466156|NCT06407687|DEVICE|Electro Dry Needlig|Electro Dry Needling is a modified form of dry needling which utilises an electro-stimulation unit connected via cables to fine filament needles. The combination of dry needling with electro-stimulation often prolongs the pain relief effect by blocking nerve pathways and preventing pain signals from travelling to the brain.
214466157|NCT06407687|DEVICE|dry needling|Dry needling is a technique that acupuncturists, physical therapists and other trained healthcare providers use to treat musculoskeletal pain and movement issues.
214466158|NCT03743142|PROCEDURE|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
214466159|NCT04157101|BEHAVIORAL|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
214466160|NCT04157101|BEHAVIORAL|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
214466161|NCT03435614|DRUG|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
214466162|NCT04171141|DRUG|PF-07062119|PF-07062119
214466163|NCT04171141|DRUG|Anti-PD1|Anti-PD1 PF-06801591
214466164|NCT04171141|DRUG|Anti-VEGF|Anti-VEGF IV (bevacizumab)
214466165|NCT03533985|BEHAVIORAL|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
214466166|NCT03533985|OTHER|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
214466167|NCT03533985|OTHER|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
214466168|NCT03533985|OTHER|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
214466169|NCT03533985|OTHER|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
214466170|NCT03533985|OTHER|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
214466171|NCT06215027|OTHER|Dance|Dance protocol
214466172|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
214466173|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
214466174|NCT03457493|DRUG|DPA-714-PET/MRI|DPA-714-PET/MRI
214466175|NCT03457493|DRUG|5-year Follow-up DPA-714-PET/MRI|PET/MRI scan with DPA-714
214466176|NCT03457493|DRUG|DPA-714 Metabolite Analysis|Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
214466177|NCT05647915|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
214466178|NCT05647915|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
214466179|NCT04858451|DRUG|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
214466180|NCT03314454|DRUG|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
214466181|NCT03314454|DEVICE|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
214466182|NCT05341817|DRUG|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
214466183|NCT05341817|DRUG|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
214466184|NCT05826639|PROCEDURE|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
214466185|NCT05826639|OTHER|No intervention|No intervention
214466186|NCT04877717|DRUG|SHR-A1904|SHR-A1904
214466187|NCT06458933|BEHAVIORAL|Sage|Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).
214466188|NCT06458933|BEHAVIORAL|Supportive Individual Psychotherapy|Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
214466189|NCT05563675|DRUG|Long acting muscarinic antagonists (LAMAs) in the evening|LAMAs administered at bedtime (8pm - 2am)
214466190|NCT05126082|BEHAVIORAL|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
214466191|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
214466192|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
214466193|NCT04662541|OTHER|Mobile Integrated Health (MIH)|MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
214466194|NCT04662541|OTHER|Transitions of care coordinator (TOCC)|The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
214466195|NCT05348174|BEHAVIORAL|Virtual Reality Assisted Guided Imagery (VRAGI)|The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
214466196|NCT05639348|OTHER|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
214466197|NCT06348342|OTHER|Pelvic Floor Muscle Exercise|Training for PFME will be given orally and will cover the importance of FME and how to do the exercises, as well as the conditions and frequency of doing the exercises. You will be told that the exercise should be done when the bladder is empty, three times a day (morning, noon and evening) and repeated 10 times in each set. In the first week of exercise, the pelvic floor muscles will be contracted for 3 seconds and relaxed for 3 seconds, and will be increased by 1 second each week. It will be explained that from the 8th week onwards, it will be done by contracting for 10 seconds and relaxing for 10 seconds and will continue. It will be stated that the learning process of pelvic floor muscle exercise may take 6 weeks to 6 months. It will be stated that this exercise should be applied throughout their lives for the sustainability of PFM strength. The training is planned to last approximately 20 minutes. PFME will last for two months. Women in menopause will be given an exercise chart.
214466198|NCT06348342|OTHER|Core Exercise|Activating the contraction of the deep core muscles TrA and mutifidus without disrupting breathing forms the basis of core stabilization exercises. To teach the \&#34;abdominal hallowing\&#34; maneuver, which enables the activation of these muscles, patients will be shown a picture of the TrA muscle and asked to contract their lower abdominal muscles while lying on their back in the hook position. During the maneuver, care will be taken to ensure that no movement occurs in the trunk and pelvis and that diaphragmatic breathing continues. After the abdominal hallowing maneuver is taught, the exercises will be progressed gradually. A home exercise program will be given for this. The 7-level exercise program recommended by Hagins et al. will be used as a home exercise program. The movements in this program load more moments on the muscles that stabilize the lumbar spine as the levels progress. The stages of the exercise program are shared in the brochure to be given to the patients.
214466199|NCT01224184|BEHAVIORAL|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
214466200|NCT01224184|BEHAVIORAL|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
214466201|NCT06690411|OTHER|Mulligan Concept|The participants of the Mulligan SNAG group will undergo the Mulligan SNAG technique. Mulligan's SNAG technique is a gentle manual therapy method. This technique is based on the correction of the joint position. There are 3 techniques specified for headache; Headache SNAG, Reverse Headache SNAG, and C1-C2 SNAG.
214466202|NCT06690411|OTHER|Myofascial Release Technique|Myofascial therapy can be described as massage-type manual therapy. The participants of the Myofascial Release Group will undergo the myofascial release technique.
214466203|NCT04314713|DRUG|Scopolamine Hydrobromide Trihydrate|Scopolamine Hydrobromide Trihydrate Intramuscular Injection
214466204|NCT05410496|DRUG|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
214466205|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
214466206|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
214466207|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
214466208|NCT05351801|DRUG|Placebo|Placebo
214466209|NCT04338776|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
214466210|NCT04338776|DEVICE|Rezum|"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
214466211|NCT05289648|DRUG|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
214466212|NCT04547049|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
214466213|NCT04547049|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
214466214|NCT04547049|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
214466215|NCT04547049|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
214466216|NCT04547049|DRUG|Rabbit antithymocyte globulin|Between 6mg/kg total dose administered IV day -5 through -2 AND 7.5mg/kg total dose administered IV day -5 through -2.
214466217|NCT04547049|PROCEDURE|Allogeneic HSCT|Day 0
214466218|NCT04547049|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
214466219|NCT04547049|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
214466220|NCT04547049|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
214466221|NCT05643014|OTHER|Sample collection|This study will involve three sample collections including buccal cells and urine samples
214466222|NCT03277495|BEHAVIORAL|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
214466223|NCT04123821|DEVICE|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
214466224|NCT05729802|DEVICE|HoloSIM Software via Hololens 2|Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
214466225|NCT05729802|OTHER|Training by Mannequin Based Simulation|Participants will train a via traditional mannequin based medical crisis scenario
214466226|NCT04861818|BEHAVIORAL|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
214466227|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
214466228|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
214466229|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
214466230|NCT06247306|BEHAVIORAL|ScanSTRESS fMRI-paradigm (Streit et al., 2014)|The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
214466231|NCT06247306|BEHAVIORAL|real-time fMRI neurofeedback|"Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination."
214466232|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
214466233|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
214466234|NCT05553743|BIOLOGICAL|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
214466235|NCT05553743|DRUG|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
214466236|NCT05495555|DEVICE|INTREPID® Hybrid tip|INTREPID® Hybrid tip for cataract removal
214466237|NCT06144697|DRUG|BMS-986465|Specified dose on specified days
214466238|NCT06144697|OTHER|Placebo|Specified dose on specified days
214466239|NCT06144697|DRUG|Pegasys|Specified dose on specified days
214466240|NCT06144697|DRUG|Famotidine|Specified dose on specified days
214466241|NCT02927236|DEVICE|Transcranial magnetic stimulation (TMS)|Theta burst stimulation is a type of TMS.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 active/sham coil will be used.
214466242|NCT00922571|PROCEDURE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
214466243|NCT00922571|DEVICE|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
214466244|NCT06680869|DRUG|Amiodarone Hydrochloride Injection|"The use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
214466245|NCT06680869|OTHER|Usual Care Protocol|"The use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
214466246|NCT06292325|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard therapy for Obstructive Sleep Apnea. It consists of a machine that delivers a constant and steady air pressure through a mask worn over the nose or both nose and mouth during sleep. This continuous flow of air helps to keep the airway open, preventing episodes of airway collapse and obstruction characteristic of OSA. CPAP therapy is highly effective in reducing symptoms such as snoring, daytime sleepiness, and fatigue, as well as improving overall sleep quality and decreasing the risk of complications associated with untreated OSA, such as cardiovascular issues. It is considered the gold standard treatment for moderate to severe OSA and is often prescribed after a sleep study confirms the diagnosis. CPAP machines come in various designs and features to suit individual needs and preferences, and proper adjustment and compliance are essential for optimal treatment outcomes.
214466247|NCT06355752|OTHER|Dry needling of lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow"
214466248|NCT06355752|OTHER|Sham dry needling lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow"
214466249|NCT05787470|BEHAVIORAL|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
214466250|NCT05787470|DIAGNOSTIC_TEST|Blood Draw|Sample of blood will be taken.
214466251|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
214466252|NCT05772767|OTHER|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
214466253|NCT05772767|DIAGNOSTIC_TEST|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
214466254|NCT05629039|BEHAVIORAL|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
214466255|NCT03656510|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
214466256|NCT03656510|DRUG|Placebo|Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
214466257|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
214466258|NCT01710488|DRUG|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
214466259|NCT01710488|DRUG|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
214466260|NCT05243888|DIAGNOSTIC_TEST|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
214466261|NCT06044311|DRUG|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
214466262|NCT06044311|DRUG|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
214466263|NCT06044311|RADIATION|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
214466264|NCT06502561|DRUG|Aramchol meglumine|Aramchol meglumine is a salt form of Aramchol free acid
214466265|NCT06502561|DRUG|Aramchol free acid|Aramchol free acid is a fatty acid-bile acid conjugate
214466266|NCT06534255|BIOLOGICAL|MegaLT injection|"Three dose groups were set: 1×10\^6/kg, 5×10\^6/kg, and 1×10\^7/kg. The dose escalation was carried out in ascending order using a 3+3 design. To ensure participant safety, enrollment followed a 1+2 rule. Specifically, the first participant in each dose group received the cell infusion and was observed for 14 days. If no dose-limiting toxicity (DLT) was observed, the remaining two participants could then be enrolled and receive cell therapy at the same dose level."
214466267|NCT06245668|DEVICE|SaCoVLM™ video laryngeal mask|The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
214466268|NCT06245668|DEVICE|LMA Supreme|The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
214466269|NCT05698875|OTHER|Breakfast meals|Test meal 1: HGL Test meal 2: HGLP Test meal 3: MGL Control meal: usual breakfast
214466270|NCT06551935|BEHAVIORAL|Habitual sleep habits without intervention|Sleep habits maintenance
214466271|NCT06551935|BEHAVIORAL|Sleep extension and sleep hygiene|Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
214466272|NCT05456750|DEVICE|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
214466273|NCT04991402|DEVICE|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
214466274|NCT00216892|DRUG|Calcipotriol, (calcipotriol + betamethasone)|
214466275|NCT06506591|DRUG|WD-890|Administered P.O.
214466276|NCT06506591|DRUG|WD-890 Tablets Placebo|Administered P.O.
214466277|NCT05472389|OTHER|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
214466278|NCT05472389|OTHER|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
214466279|NCT06689098|DIAGNOSTIC_TEST|Magnetocardiography scan|The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
214466280|NCT06648304|DRUG|TTYP01 tablets|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
214466281|NCT06648304|DRUG|Placebo (Simulant TTYP01 Tablets)|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
214466282|NCT02886312|DEVICE|Supplemental Oxygen Delivery System|
214466283|NCT05010681|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
215031548|NCT04906512|DEVICE|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
214466284|NCT05010681|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214466285|NCT05195294|BIOLOGICAL|LioCyx-M|HBV antigen specific TCR redirected T cells
214466286|NCT05195294|DRUG|Lenvatinib|12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
214466287|NCT05496231|BIOLOGICAL|HPV9 High formulation|3 doses of the high formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
214466288|NCT05496231|BIOLOGICAL|HPV9 Medium formulation|3 doses of the medium formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
214466289|NCT05496231|BIOLOGICAL|HPV9 Low formulation|3 doses of the low formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
214466290|NCT05496231|BIOLOGICAL|Gardasil 9|3 doses of the marketed HPV vaccine (Gardasil 9) were administered intramuscularly at Day 1, Month 2 and Month 6.
214466291|NCT06123312|DIAGNOSTIC_TEST|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
214466292|NCT06462443|BEHAVIORAL|RISE for Physicians Program|RISE for Physicians Program. Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
214466293|NCT06048185|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
214466294|NCT04438083|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
214466295|NCT04571229|DRUG|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
214466296|NCT02307058|RADIATION|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
214466297|NCT02307058|RADIATION|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
214466298|NCT05875545|OTHER|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
214466299|NCT05875545|OTHER|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
214466300|NCT04284969|BEHAVIORAL|PROADAPT program|"* A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
214466301|NCT06313021|OTHER|Reliability and Validity Study|Reliability and Validity Study
214466302|NCT06094153|DIETARY_SUPPLEMENT|Placebo|Consume placebo (Maltodextrin) once daily before going to bed for 28 days
214466303|NCT06094153|DIETARY_SUPPLEMENT|HMO 1|Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
214466304|NCT06094153|DIETARY_SUPPLEMENT|HMO 2|Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
214466305|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
214466306|NCT06482762|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
214466307|NCT05244239|DRUG|Lurbinectedin|Given IV
214466308|NCT05244239|RADIATION|Palliative Radiation Therapy|Undergo RT
214466309|NCT05974150|OTHER|Web based survey|online weekly survey
214466310|NCT04282122|RADIATION|Radiotherapy|curative-intent radiotherapy
214466311|NCT04186689|OTHER|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
214466312|NCT06494150|DRUG|nab-Sirolimus|nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle
214466313|NCT06494150|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
214466314|NCT05930418|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance provides more sensitive measure of ventricular volume and ejection fraction as well as novel markers of tissue characterization and edema assessment.
214466315|NCT03467191|DRUG|Alcohol|target BAC .08%
214466316|NCT03467191|OTHER|Placebo|placebo beverage
214466317|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
214466318|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
214466319|NCT04829877|BEHAVIORAL|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
214466320|NCT04829877|BEHAVIORAL|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
214466321|NCT01205828|DRUG|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
214466322|NCT01205828|DRUG|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
214466323|NCT06033508|OTHER|exercise with whole body vibration device|exercise with whole body vibration device
214466324|NCT06033508|OTHER|placebo exercise|exercise without vibration on land
214466325|NCT05851963|DEVICE|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
214466326|NCT05851963|DEVICE|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
214466327|NCT05851963|DEVICE|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
214466328|NCT05851963|DEVICE|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
214466329|NCT05358834|DIETARY_SUPPLEMENT|Melatonin|Oral melatonin administered as a single pill.
214466330|NCT05358834|DIETARY_SUPPLEMENT|Placebo|Oral placebo administered as a single pill.
214466331|NCT03186729|DRUG|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
214466332|NCT06784089|OTHER|Geriatric Nutrition Risk Index|GNRI will be calculated from the formula \[1.489 X albumin (g/L)\] + \[41.7 (weight/ideal weight)\]. If the patient's weight is more than their ideal weight, the weight/ideal weight ratio will be accepted as 1. The ideal weight will be calculated for men with the formula \[(Height-100) -(Height-150/4)\], for women with the formula \[(Height-100) -(Height-150/2.5)\]. According to the results, patients will be determined as no risk (GNRI \> 98), low risk (92-98), severe/moderate risk (GNRI \< 92).
214466333|NCT06784089|OTHER|visual analog scale|During the VAS evaluation, the patient will be asked to indicate the location of the pain on a 100 cm long scale where 0: no pain, 100: maximum pain, and the value shown by the patient will be recorded.
214466334|NCT06723444|BEHAVIORAL|Learning and Memory Training|"The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions)."
214466335|NCT06723444|BEHAVIORAL|Placebo Comparator|The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
214466336|NCT05832437|BEHAVIORAL|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
214466337|NCT05832437|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
214466338|NCT03828799|COMBINATION_PRODUCT|Folfirinox + regorafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
214466339|NCT06822985|DRUG|QL1706|Drug: QL1706 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
214466340|NCT05681624|OTHER|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
214466341|NCT05681624|OTHER|Room air|Room air, no mask
214466342|NCT04091867|DRUG|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
214466343|NCT04091867|DRUG|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
214466344|NCT04091867|RADIATION|Radiation Therapy|6930 cGy IMRT starting D15-D18
214466345|NCT05524181|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
214466346|NCT05473273|DRUG|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
214466347|NCT05473273|DRUG|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
214466348|NCT06823817|DIAGNOSTIC_TEST|colpscope|Colposcopic cervical biopsy
214466349|NCT06210308|PROCEDURE|Data collection from gastric ultrasound|observational study
215031549|NCT06387953|DEVICE|Bridge Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
214839798|NCT06341504|BEHAVIORAL|Prevention pop-up messages|"Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages."
214466351|NCT06823245|DRUG|HS-10241|HS-10241 administered orally once at D1
214466352|NCT06714656|OTHER|Food Swap|Personalised food swaps and dietary advice on how to incorporate these swaps into their usual diet
214466353|NCT05166499|DIETARY_SUPPLEMENT|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
214466354|NCT05166499|DIETARY_SUPPLEMENT|Balanced Amino Acids|Balanced Amino Acids
214466355|NCT05984446|DEVICE|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
214466356|NCT05984446|DEVICE|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
214466357|NCT06251687|PROCEDURE|Transbronchial Cryobiopsy，TBLC|Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
214466358|NCT06251687|PROCEDURE|Transbronchial Lung Biopsy，TBLB|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
214466360|NCT05622929|BEHAVIORAL|Digitally-enabled Multifaceted Quality Improvement Intervention|"Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~* Knowledge of effective lipid lowering therapies~* Clinical decision support~* Audit and feedback on adherence to optimal clinical management~* Audit and feedback on LDL-C control"
214466361|NCT05622929|BEHAVIORAL|Usual care|Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
214466362|NCT04864314|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
214466363|NCT04864314|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
214466364|NCT06242665|OTHER|Low UPF Meals (Study Provided)|Meals provided through delivery service
214466365|NCT06242665|OTHER|Low UPF Nutritional Guidance|Self-guided instructions from study team.
214466366|NCT06242665|OTHER|Low UPF Snacks (Study Provided)|Low UPF snacks provided to participant
214466367|NCT05196919|BIOLOGICAL|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
214466368|NCT05196919|BIOLOGICAL|Placebo|Phosphate-buffered saline for injection
214466369|NCT05263440|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
214466370|NCT06777706|DIETARY_SUPPLEMENT|QD (Qing Dai)|Children age 4 years to 17.9 years with mild to moderate UC will receive QD and dosing will be stratified based on body weight at time of enrollment.
214466371|NCT05546996|DEVICE|FlowSense|"Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis."
214466372|NCT02483312|BIOLOGICAL|IL-12|
214466373|NCT02760030|DRUG|Fulvestrant|Given IM
214466374|NCT02760030|OTHER|Laboratory Biomarker Analysis|Correlative studies
214466375|NCT02760030|DRUG|Palbociclib|Given PO
214466376|NCT02760030|OTHER|Questionnaire Administration|Correlative studies
214466377|NCT02760030|DRUG|Aromatase Inhibitors|Given PO
214466378|NCT05858736|DRUG|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
214466379|NCT06232590|DEVICE|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
214466380|NCT06232590|DEVICE|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
214466381|NCT05836155|DIETARY_SUPPLEMENT|Intervention|multispecies probiotic
214466382|NCT04015804|OTHER|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
214466383|NCT04186117|OTHER|Blood sample|Blood sample before any treatment
214466384|NCT04649905|PROCEDURE|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
214466385|NCT04649905|PROCEDURE|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
214466386|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
214466387|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
214466388|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
214466389|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
214466390|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
214466391|NCT05897944|OTHER|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
214466392|NCT05531474|PROCEDURE|Bariatric Surgery|Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
214466393|NCT05531474|BEHAVIORAL|Medical Weight Management|The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
214466394|NCT05940194|BIOLOGICAL|COVIVAC vaccine|For prevention Covid-19
214466395|NCT06636357|DRUG|50% N2O plus 50% O2|Inhalation of 50% N2O plus 50% O2 for 45 min
214466396|NCT06636357|DRUG|Oxygen (O2)|50% O2 plus 50% air for 45 min
214466397|NCT00540774|DEVICE|detection of oral pathology|detection of oral pathology
214466398|NCT02950766|DRUG|NeoVax|combination of Neoantigen peptides and poly-ICLC
214466399|NCT02950766|DRUG|Ipilimumab|local administration of ipilimumab
214466400|NCT03085810|DRUG|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
214466401|NCT06401577|DEVICE|Dexcom Continuous Glucose Monitor (CGM)|Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level
214466402|NCT04799015|DRUG|Dexamethasone|Dexamethasone 10mg IV
214466403|NCT04799015|DRUG|Metoclopramide 10mg|Metoclopramide 10mg IV
214466404|NCT06779396|DRUG|The triamcinolone acetonide plus ropivacaine group|The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214466405|NCT06779396|DRUG|The ropivacaine group|The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214466406|NCT05470023|OTHER|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
214466407|NCT04085510|DEVICE|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
214466408|NCT03621371|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
214466409|NCT03621371|BEHAVIORAL|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
214466410|NCT04532190|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS)
214466411|NCT02109302|PROCEDURE|Blood sample|
214466412|NCT02109302|PROCEDURE|Skin biopsy|
214466413|NCT02109302|OTHER|Questionnaire|
214466414|NCT06159361|BEHAVIORAL|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
214466415|NCT06125808|DRUG|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
214466416|NCT06125808|DRUG|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
214466417|NCT06347549|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|"Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest."
214466418|NCT02667418|DRUG|Fidaxomicin|200 mg PO twice daily for 10 days
214466419|NCT02667418|DRUG|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
214466420|NCT02667418|DRUG|Vancomycin|125 mg PO for times daily for 10 days
214466421|NCT06175832|DRUG|Elonva®|Single injection
214466422|NCT06175832|DRUG|Puregon®|Multiple injections
214466423|NCT06175832|DRUG|Orgalutran®|Multiple injections
214466424|NCT06175832|DRUG|Gonapeptyl®|Double injection
214466425|NCT06175832|DRUG|Cerazette®|Oral tablet
214466426|NCT05925218|RADIATION|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
214466427|NCT05268887|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
214466428|NCT05268887|DEVICE|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
214466429|NCT01959607|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
214466430|NCT01959607|OTHER|CC|Single use of subject's own cigarette (CC)
214466431|NCT01959607|OTHER|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
214466432|NCT06667973|DRUG|Gilteritinib|"Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients."
214466433|NCT03209583|DEVICE|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
214466434|NCT04731961|PROCEDURE|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
214466435|NCT04731961|PROCEDURE|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
214466436|NCT03974828|DEVICE|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
214466437|NCT03937843|DRUG|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
214466438|NCT03937843|DRUG|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
214466439|NCT03937843|DRUG|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
214466440|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
214466441|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
214466442|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
214466443|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
214466444|NCT03584633|DRUG|Indocyanine Green|The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
214466445|NCT05037500|DRUG|Decitabine and Cedazuridine|Given PO
214466446|NCT05037500|DRUG|Enzalutamide|Given PO
214466447|NCT05049512|OTHER|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
214466448|NCT03576885|DRUG|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
214466449|NCT03576885|DRUG|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
214466450|NCT02780219|OTHER|stable amino acid infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
214466451|NCT02780219|OTHER|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
214466452|NCT02780219|OTHER|24-hour post exercise amino acid infusion|stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
214466453|NCT06438133|OTHER|CIMON|The sensor assess changes in the circumference of the limb and will be applied to the lower limb before compression bandaging is applied.
214466454|NCT06438133|OTHER|Sens Motion|The sensor assess physical activity and the amount of time spent at rest, standing, walking, running and count steps.
214466455|NCT05683691|DEVICE|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
214466456|NCT06340763|DEVICE|JETi Hydrodynamic Thrombectomy System|The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
214466457|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
214466458|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
214466459|NCT05873673|DRUG|Coenzyme Q10|cystic jaw defect filled with coenzyme Q10 gel
214466460|NCT05873673|DRUG|control group|cystic jaw defect filled with placebo gel
214466461|NCT06538870|PROCEDURE|Placement of dental implants|Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.
214466462|NCT03235544|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
214466463|NCT03377647|BEHAVIORAL|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
214466464|NCT03377647|BEHAVIORAL|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
214466465|NCT00950742|DRUG|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
214466466|NCT00950742|DRUG|BIBW 2992|Increased dose cohorts from low dose to MTD
214466467|NCT04751071|DRUG|Roflumilast 500Mcg Tab|Roflumilast 500µg tablet once daily for 6 weeks plus the standard therapy
214466468|NCT04751071|DRUG|Placebo|Placebo tablet once daily for 6 weeks plus the standard therapy
214466469|NCT04447755|DRUG|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m\^2 QD
214466470|NCT03696680|RADIATION|FSRT Stereotactic radiation therapy|For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
214466471|NCT06147791|DEVICE|External scrotal drainage|Application of external scrotal drainage during three-component penile prosthesis placement
214466472|NCT05476328|DEVICE|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
214466473|NCT05476328|DEVICE|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
214466474|NCT05476328|DEVICE|ACE|Advanced Combination Encoder (ACE) is the commercially available, reference sound processing strategy.
214466475|NCT05476328|DEVICE|Cochlear Device Interface (CDI) Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
214466476|NCT06444633|BEHAVIORAL|Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc|The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.
214466477|NCT06453980|DEVICE|sham tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.
214466478|NCT06453980|DEVICE|active tDCS|Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
214466479|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and placebo|Live attenuated pertussis vaccine and placebo
214466480|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and Boostrix|Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine
214466481|NCT05116241|BIOLOGICAL|Placebo and Boostrix|Tetanus, diphtheria, and aP vaccine and placebo
214466482|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
214466483|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
214466484|NCT03352531|BIOLOGICAL|AK-105|Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
214466485|NCT04845503|RADIATION|MR-guided Radiotherapy|Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
215031550|NCT06387953|DEVICE|Sham Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
214466486|NCT06260228|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
214466487|NCT06134154|OTHER|Endoscopic insufflation gas|Carbon dioxide gas versus air for endoscopic insufflation
214466488|NCT05322408|DRUG|HCW9218|HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
214466489|NCT04853576|GENETIC|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
214466490|NCT06237647|DIETARY_SUPPLEMENT|Hyaluronic acid, HA|improve tissue repair
214466491|NCT05683223|BEHAVIORAL|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
214466492|NCT05683223|DRUG|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
214466493|NCT05683223|BEHAVIORAL|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
214466494|NCT04615143|DRUG|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
214466495|NCT04615143|DRUG|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
214466496|NCT05314504|DEVICE|YVOIRE Y-Solution 360|Cross-linked sodium hyaluronate gel for injection with lidocaine
214466497|NCT05946616|OTHER|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
214466498|NCT05946616|OTHER|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
214466499|NCT00293839|DRUG|oxybutynin chloride|
214466500|NCT06192095|DEVICE|Skin barrier film|Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
214466501|NCT01658930|PROCEDURE|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
214466502|NCT01658930|PROCEDURE|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
214466503|NCT04763330|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) consists of Collaborative Safety Planning, a VA usual care practice. It is a tool that Veterans can use when they are in an acute suicidal crisis. The condition is considered enhanced because Veterans in this condition receive 6 sessions total, Safety Planning which is delivered in 1-2 sessions and 4-5 sessions of check-ins with a brief assessment. Safety Planning involves a worksheet completed by the patient in collaboration with a health provider.
214466504|NCT04763330|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"Veterans randomized to this condition received EUC and PST. EUC is delivered in both conditions to ensure the safety of all Veterans enrolled in the study. In addition to EUC, Veterans in this condition receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by older Veterans with mental health disorders and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
214466505|NCT04328584|PROCEDURE|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
214466506|NCT06280547|OTHER|Oral health education|Oral Health Education Program performed in the school.
215031551|NCT06569485|DRUG|Trilaciclib+R-CHOP|This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
214466507|NCT05465031|DRUG|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
214466508|NCT05465031|DRUG|Placebo|Placebo matching the sacubitril/valsartan (Entresto®) administered in the target dose matching the dosing of 200 mg b.i.d. (97/103 mg) for the period of 24 months. In case of intolerance of target dose of placebo, the physician-in-charge will be able to reduce the dose to placebo matching the dose of 100 mg b.i.d. (49/51mg). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of placebo matching the dose of 200 mg b.i.d.
214466509|NCT06200467|DRUG|BI 456906|Solution for injection
214466510|NCT06200467|DRUG|Placebo to BI 456906|Solution for injection
214466511|NCT06200467|DRUG|Moxifloxacin|Film-coated tablet
214466512|NCT06200467|DRUG|Placebo to moxifloxacin|Film-coated tablet
214466513|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
214466514|NCT03701763|OTHER|Placebo|Placebo
214466515|NCT03571321|DRUG|Ruxolitinib|"Participants will receive one of 3 doses \[taken by mouth\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~* Days 1-14 and 29-43~Interim maintenance regimen:~* Days 1-14 and 29-43~Delayed Intensification regimen:~* Days 1-14 and 29-43"
214466516|NCT03571321|DRUG|Cyclophosphamide|"Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29"
214466517|NCT03571321|DRUG|Cytarabine|"Remission consolidation regimen:~* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~* 75 mg/m2/day IV or SC on Days 29-32 and 36-39"
214466518|NCT03571321|DRUG|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84"
214466519|NCT03571321|DRUG|Vincristine|"Remission consolidation regimen:~* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
214466520|NCT03571321|DRUG|Pegaspargase|"Remission consolidation regimen:~* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~* 2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
214466521|NCT03571321|DRUG|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8"
214466522|NCT03571321|DRUG|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)"
214466523|NCT03571321|DRUG|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
214466524|NCT03571321|DRUG|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
214466525|NCT03571321|DRUG|Doxorubicin|"Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15"
214466526|NCT03571321|DRUG|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42"
214466527|NCT03571321|DRUG|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]"
214466528|NCT05651139|DEVICE|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
214466529|NCT06266338|DRUG|Pembrolizumab|200 mg IV q 3 weeks
214466530|NCT06266338|DRUG|Lenvatinib|20 mg PO daily
214466531|NCT03603002|DIAGNOSTIC_TEST|Post-SABR Biopsy|Post-SABR Biopsy
214466532|NCT05913037|DRUG|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
214466533|NCT05913037|DRUG|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
214466534|NCT05501574|DRUG|Tacrolimus Inhalation Powder|Tacrolimus powder for inhalation to prevent acute allograft rejection
214466535|NCT05501574|DEVICE|Plastiape RS00 Dry Powder inhaler device|dry powder inhaler device
214466536|NCT05966532|BEHAVIORAL|Hot Cognitive Task|"1. Emotion processing:~   * Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~  * Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~  * Participant will be shown a series of emotions and asked to respond to only a specific emotion.~2. Motivation reward and processing:~   * Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~  * Participant will be shown colored circles and choose the one more likely to win money.~3. Impulsivity:~   • Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~4. Social cognition:~   * Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
214466537|NCT05966532|BEHAVIORAL|Cold cognitive tasks|"* Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~* Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~* Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~* California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~* Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
214466538|NCT05966532|OTHER|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
214466539|NCT05966532|OTHER|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
214466540|NCT05966532|BEHAVIORAL|four self-report forms per the requirement of the NIH Common Data Elements project|1\) DSM-5 Level 1 Cross Cutting Symptom Measure - Adult Report; a measure of multiple psychiatric symptoms, 2) Generalized Anxiety Disorder-7 (GAD-7; a measure of anxiety symptom severity), 3) Patient Health Questionniare-9 (PHQ-9; a measure of depression symptom severity), and 4) World Health Organization Disability Assessment Scale-2.0 (WHODAS-2.0; a measure of overall general functional status)
214466541|NCT05966532|BEHAVIORAL|Four self-report measures to assess interpersonal functioning|1\) Social Adjustment Scale - Self-report Short Form (SAS-SR: Short), 2) Inventory of Interpersonal Problems (IIP-64), 3) Social Network Index (SNI), 4) Interpersonal Support Evaluation List - 12 Items (ISEL-12).
214466542|NCT05966532|BEHAVIORAL|Clinical assessments|A Demographic and a Medical History Form will be completed. The Mini International Neuropsychiatric Interview (MINI-7.0 for DSM-5) is a structured psychiatric interview that will confirm presence of MDD and any exclusionary neuropsychiatric disorders. To measure depression symptoms/severity, primarily we will use the Clinician Rated Inventory of Depressive Symptomatology (IDS-C), Menstrual history and pregnancy tests for female participants.
214466543|NCT05966532|OTHER|ATHF|Psychotropic medication use/ treatment resistance level will be measured/documented with the Antidepressant Treatment History Form-Short-Form (ATHF-SF)
214466544|NCT05068310|DEVICE|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
214466545|NCT05068310|DEVICE|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
214466546|NCT05068310|DEVICE|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
214466547|NCT05068310|DEVICE|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
214466548|NCT06369116|DEVICE|INSTI HCV Self Test|"Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received."
214466549|NCT05089227|DRUG|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
214466550|NCT05089227|DRUG|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
214466551|NCT05089227|BIOLOGICAL|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
214466552|NCT05671861|DEVICE|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
214466553|NCT05671861|OTHER|Questionnaires|Surveys will be administered to participants
214466554|NCT05671861|OTHER|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
214466555|NCT06644261|DRUG|Bupivacaine injection|"Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks"
214466556|NCT05857228|PROCEDURE|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
214466557|NCT04792502|DRUG|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
214466558|NCT04792502|DRUG|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
214466559|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
214466560|NCT04884789|DEVICE|COFIS 3D|Patient have to wear the COFIS 3D 20h a day for at least 6 month
214466561|NCT03418987|OTHER|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
214466562|NCT04979351|OTHER|Abdominal Massage|Abdominal massage will be applied twice a day.
214466563|NCT04502550|DRUG|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
214466564|NCT04469192|OTHER|Cryotherapy|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
214466565|NCT04469192|OTHER|Education|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
214466566|NCT06520657|OTHER|Community Health Worker|Participants are screened for social determinants of health and work with a community health worker for three months to connect them with community and government services to address their family's needs.
214466567|NCT06520657|BEHAVIORAL|Child weight management intervention|This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.
214466568|NCT06520657|OTHER|Standard of Care referral to resources|One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.
214466569|NCT00592852|DRUG|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
214466570|NCT05078255|DRUG|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
214466571|NCT05078255|DRUG|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
214466572|NCT05078255|OTHER|Semaglutide 1.34 mg/ml placebo|Saline
214466573|NCT05078255|OTHER|GIP placebo|Saline
214466574|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
214466575|NCT06266312|BEHAVIORAL|A multimodal prehabilitation programme|"1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. \+ strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3\) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
215031552|NCT06471673|BIOLOGICAL|BC1 cell line|BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
214466576|NCT04814771|DRUG|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
214466577|NCT04496895|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
214466578|NCT04496895|DIETARY_SUPPLEMENT|orange peel fermentation|consume 1 sachet per day for 2 months
214466579|NCT05844397|DEVICE|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
214466580|NCT05844397|DEVICE|VisuMax Surgical Laser|SMILE Refractive Surgery
214466581|NCT05149638|DIAGNOSTIC_TEST|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
214466582|NCT06104176|BEHAVIORAL|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
214466583|NCT06104176|OTHER|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
214466584|NCT06104176|BEHAVIORAL|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
214466585|NCT06730295|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 39-42Gy/3 fractions, administered once daily. FBCT and 4DCT will be acquired.
214466586|NCT06336083|PROCEDURE|Doppler ultrasound|Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
214466587|NCT05658224|BEHAVIORAL|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
214466588|NCT06378294|PROCEDURE|Mastectomy|Adjuvant postmastectomy radiotherapy
214466589|NCT03288948|OTHER|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
214466590|NCT04562441|DRUG|Axitinib|Axitinib: 5 mg bd po Day 1 to Day 28
214466591|NCT04562441|DRUG|Avelumab|Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
214466592|NCT03029429|DRUG|Theophylline|oral theophylline
214466593|NCT03029429|DRUG|Placebos|oral placebo
214466594|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
214466595|NCT05555550|DRUG|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
214466596|NCT02589795|BIOLOGICAL|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
214466597|NCT02589795|BIOLOGICAL|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
214466598|NCT02589795|DEVICE|Trigrid Delivery System - Intramuscular|Electroporation
214466599|NCT02589795|DEVICE|Trigrid Delivery System - Intradermal|Electroporation
214466600|NCT06303518|OTHER|High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'High Normal ETCO2' (50 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
214466601|NCT06303518|OTHER|Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Normal ETCO2' (40 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
214466602|NCT06303518|OTHER|Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Low Normal ETCO2' (30 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
214466603|NCT06033950|DRUG|Finerenone|Oral finerenone.
214466604|NCT06033950|DRUG|Placebo|Matching oral placebo.
214466605|NCT02322203|DIETARY_SUPPLEMENT|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
214466606|NCT05520268|BEHAVIORAL|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
214466607|NCT05520268|BEHAVIORAL|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
214466608|NCT03599661|OTHER|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
214466609|NCT03599661|OTHER|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
214466610|NCT04739839|OTHER|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
214466611|NCT04909801|DRUG|Abatacept|Abatacept SC (125 mg) once weekly
214466612|NCT04909801|DRUG|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
214466613|NCT04909801|DRUG|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
214466614|NCT06534385|DEVICE|Air purifier|Winix HEPA air purifier
214466615|NCT03725384|DRUG|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
214466616|NCT03725384|DRUG|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
214466617|NCT05039229|OTHER|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
214839799|NCT06341504|BEHAVIORAL|Mandatory time limit|Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
214466618|NCT05039229|OTHER|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
214466619|NCT05665686|DEVICE|Relaxation training with device|Relaxation training will be applied with the device.
214466620|NCT05665686|OTHER|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
214466621|NCT02748941|DEVICE|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
214466622|NCT06163690|COMBINATION_PRODUCT|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
214466623|NCT06272006|PROCEDURE|Coronally Positioned Flap with Connective Tissue Graft|his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.
214466624|NCT06272006|PROCEDURE|Modified Coronally Advanced Tunnel with Connective Tissue Graft|This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
214466625|NCT03896685|DRUG|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
214466626|NCT03896685|DRUG|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
214466627|NCT03896685|DRUG|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
214466628|NCT03896685|DRUG|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
214466629|NCT03896685|DRUG|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
214466630|NCT05883241|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
214466631|NCT05883241|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
214466632|NCT05110716|BEHAVIORAL|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
214466633|NCT05110716|BEHAVIORAL|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
214466634|NCT05110716|BEHAVIORAL|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
214466635|NCT05796388|DEVICE|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
214466636|NCT05237388|DRUG|Baricitinib|One pill daily
214466637|NCT05237388|DRUG|Placebo|Baricitinib placebo pill
214466638|NCT04117347|DEVICE|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
214466639|NCT04117347|DEVICE|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
214466640|NCT04117347|DEVICE|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
214466641|NCT05909891|OTHER|Patient training|"A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated."
214466642|NCT04342234|OTHER|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
214466643|NCT03046992|DRUG|YH25448|"* Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448"
214466644|NCT03278080|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
214466645|NCT03278080|OTHER|Car-following test|Driving with simulator program for DCV measurement
214466646|NCT03278080|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
214466647|NCT05680012|DIETARY_SUPPLEMENT|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
214466648|NCT04766866|DIAGNOSTIC_TEST|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
214466649|NCT03687086|OTHER|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
214466650|NCT03687086|OTHER|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
214466651|NCT02505984|DRUG|Oxytocin|Study participants will be randomized to a placebo or drug group.
214466652|NCT02505984|DRUG|Placebo|Study participants will be randomized to a placebo or drug group.
214466653|NCT05194956|PROCEDURE|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
214466654|NCT05194956|PROCEDURE|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
214466655|NCT05088616|BEHAVIORAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
214466656|NCT05800457|PROCEDURE|Partial synovectomy|Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
214466657|NCT04749212|DIAGNOSTIC_TEST|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
214466658|NCT06419582|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 21 days
214466659|NCT06419582|DRUG|Placebo|Matching placebo taken once daily for 21 days
214466660|NCT06851741|BEHAVIORAL|Behavioural Activation for depression (BeatIt2)|"It is a structured, time limited, manualised psychological therapy, developed to treat those with learning disabilities and depressive symptoms.~There is an initial training session for carers regarding their role in the treatment, then 12 sessions with the person with a learning disability and their carer, held weekly or fortnightly, spanning approximately 6 months.~Activities are carried out with the individuals with learning disabilities at each session and elements of the intervention are delivered via carers. The three main phases are: i) assessment and socialisation into the intervention and establishing a relationship with the person with the disability, ii) working towards change, and iii) finishing therapy. The first phase includes assessment of the person's pattern of daily activity, barriers and facilitators to engaging in activity, and examining the link between activity and mood. Specific attention is given to the role of communication and how scaffolding can be provid"
214466661|NCT06140069|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
214466662|NCT06582329|DRUG|Alfa1 Antitrypsin|Participants will be treated intravenously with A1AT 120 mg/kg bodyweight once a week for 4 weeks (4 total infusions).
214466663|NCT05137574|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
214466664|NCT05137574|DRUG|propofol|propofol
214466665|NCT05137574|DRUG|ketamine|ketamine
214466666|NCT06847113|OTHER|Physical function|Observe walking speed, both maximal and self-selected, over a 12-months period after knee arthroplasty
214466667|NCT06851117|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation (PNF)|Participants in the PNF group will undergo intensive training of the affected limbs for 20 minutes per day, 5 days a week, over a 4-week period. During therapy sessions, the unaffected limb will be constrained using a mitt or cast to encourage focused activation and strengthening of the affected side. The therapy will include repetitive movement patterns designed to enhance strength, flexibility, and coordination.
214466668|NCT06851117|COMBINATION_PRODUCT|Spider Cage Therapy Group|This group will participate in therapy sessions within the Spider Cage for 20 minutes per day, 5 days a week, for 4 weeks. Interventions will involve weight-bearing exercises, movement facilitation, and balance training, utilizing the cage's elastic cords to support and stabilize posture. The goal is to improve gross motor skills, balance, and controlled movement.
214466669|NCT06851117|DIAGNOSTIC_TEST|Combined PNF and Spider Cage Therapy Group|Participants in this group will receive both PNF and Spider Cage Therapy, with integrated principles and techniques from both approaches. The intensity and duration will be consistent with the individual therapy groups, with sessions held for 20 minutes per day, 5 days a week, over 4 weeks. This combination is expected to enhance functional outcomes by targeting both strength/coordination and balance/postural control.
214466670|NCT06393114|OTHER|Fermented oat-based product|Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
214466671|NCT06393114|OTHER|Unfermented oat-based product|Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
214839800|NCT06341504|BEHAVIORAL|Responsible gambling information|Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
214466672|NCT06853223|DRUG|Maraviroc|Product will be administered for 300 mg immediately preceding the lung transplant surgery and then will be administered every 12 hours. There will be 7 total doses. The first 3 will be 300 mg doses and the remaining 4 will be 150 mg doses. Maraviroc will be given oral (PO) or by feeding tube (PFT) in crushed format depending on the route availability.
214466673|NCT06853223|DRUG|Placebo|Placebo in 300 and 150 mg formulations Product will be administered every 12 hours for 3 days. The placebo will be matched in appearance and taste to the Maraviroc and is available in PO and liquid (PFT) formulations.
214656925|NCT03437421|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|"* Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
214656926|NCT05946343|DIAGNOSTIC_TEST|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
214656927|NCT05736263|BEHAVIORAL|Moderate intensity exercise|moderate intensity aerobic exercise trial
214466674|NCT06853002|OTHER|Breathing exercise with spirometry|Breathing exercise with spirometry
214656928|NCT05736263|BEHAVIORAL|High intensity interval exercise|High intensity interval exercise trial
214466675|NCT06853002|OTHER|Breathing exercise with deep breathing method|Breathing exercise with deep breathing method
214466676|NCT06849479|PROCEDURE|Aerobic exercise and medical treatment|Aerobic exercise training was done for 30 minutes, day after day (3 sessions weekly) for 6 weeks. Each session started by warming up phase that was walking on treadmill for 5 minutes at 20% of target heart rate. Active phase after warming up was walking on treadmill for 20 min at 50-70 % of target heart rate. And cooling down phase after the active phase of exercise was walking on treadmill for 5 minutes at 20 % of the target heart rate
214656929|NCT05736263|BEHAVIORAL|Combined exercise|Combined aerobic and resistance exercise trial
214656930|NCT05736263|BEHAVIORAL|Resistance exercise|Resistance exercise trial
214656931|NCT01323907|DRUG|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
214656932|NCT01624584|BEHAVIORAL|Experimental treatment|six sessions of child anxiety treatment
214656933|NCT01624584|BEHAVIORAL|Traditional Treatment|six sessions of treatment consistent with current practice
214656934|NCT00245271|DRUG|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
214656935|NCT00245271|DRUG|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
214656936|NCT00211614|DRUG|Lansoprazole|
214656937|NCT00375544|DEVICE|Low level light therapy|
214656938|NCT05213247|DEVICE|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
214656939|NCT00281814|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
214656940|NCT01486420|PROCEDURE|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
214656941|NCT01486420|PROCEDURE|Open surgery|Open A1-pulley release
214656942|NCT01203657|BEHAVIORAL|Tai Chi|Tai Chi classes, 60 minutes, 2x week
214656943|NCT04271267|OTHER|No Intervention|
214656944|NCT03691714|DRUG|Durvalumab|Two hour infusion
214656945|NCT03691714|DRUG|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
214466677|NCT06849479|DIETARY_SUPPLEMENT|Medical treatment group|patient received supplement in the form of one capsule daily, that contain iron supplement (10 mg) and multi vitamins (B1=0.6 mg;, B2=0.6 mg; B6=0.6 mg; B12= 1.2 mc and C=30 mg) as well as essential trace elements (Zinc=5 mg; Copper=0.44 mg; Folic acid=200 mc and Biotin=12 mc
214466678|NCT05421429|BIOLOGICAL|KN057 doseⅠ|KN057 subcutaneous (SC) injection
214466679|NCT05421429|BIOLOGICAL|KN057 dose Ⅱ|KN057 SC injection
214466680|NCT05421429|BIOLOGICAL|KN057 dose Ⅲ|KN057 SC injection
214466681|NCT05011851|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
214656946|NCT01994083|DRUG|Placebo|Administered orally
214656947|NCT01994083|DRUG|IX-01|Administered orally
214656948|NCT03495492|DEVICE|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
214656949|NCT03495492|DIETARY_SUPPLEMENT|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
214656950|NCT04698876|PROCEDURE|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
214656951|NCT04698876|PROCEDURE|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
214656952|NCT04698876|PROCEDURE|Blood pressure|Blood pressure measurement for 24 h
214656953|NCT04035876|DRUG|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
214656954|NCT00575861|DRUG|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
214656955|NCT02363179|BEHAVIORAL|Live preferential music|Live preferential music will be performed for patients in the emergency department.
214656956|NCT00921869|DRUG|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
214656957|NCT00000402|DRUG|Calcium|
214656958|NCT01617044|DIETARY_SUPPLEMENT|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
214466682|NCT05076396|DRUG|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
214466683|NCT04114981|RADIATION|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
214466684|NCT04114981|RADIATION|Fractionated Stereotactic Radiosurgery|Undergo FSRS
214466685|NCT04114981|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214466686|NCT04114981|OTHER|Questionnaire Administration|Ancillary studies
214656959|NCT01617044|DIETARY_SUPPLEMENT|Placebo|Placebo
214656960|NCT01412853|OTHER|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
214656961|NCT04857021|DIETARY_SUPPLEMENT|GABA|oral administration of GABA capsule once daily before sleep
214656962|NCT04857021|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo capsule once daily before sleep
214466687|NCT06251752|DIAGNOSTIC_TEST|X-rays: load bearing inferior limbs, lateral knee, axial patella|X-rays at 5 years follow-up minimum
214656964|NCT04900402|OTHER|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
214656965|NCT01316042|DRUG|sugar pill|2 pills per day for 12 months
214466688|NCT02831244|DEVICE|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
214466689|NCT06253013|DEVICE|Hyfe Smartwatch|Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
214466690|NCT06253013|DEVICE|FitBit Versa 2|Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
214466691|NCT06253013|DEVICE|Home Spirometer|Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
214466692|NCT06253013|BEHAVIORAL|Audio recording|Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
214466693|NCT06580119|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
214466694|NCT06209632|BEHAVIORAL|mirror therapy|30 minutes of intervention, twice a week, and a total of 12 weeks
214466695|NCT06209632|DEVICE|contralaterally controlled functional electrical stimulation|30 minutes of intervention, twice a week, and a total of 12 weeks
214466696|NCT06209632|BEHAVIORAL|conventional physiotherapy|50 minutes of intervention, twice a week, and a total of 12 weeks
214466697|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
214466698|NCT03785561|OTHER|participation in a health research study|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
214466699|NCT05761600|OTHER|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
214466700|NCT05761600|OTHER|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
214466701|NCT05761600|OTHER|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
214466702|NCT03392987|GENETIC|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
214466703|NCT05427734|DEVICE|WisePath for Adults|Participants assigned to this condition will receive access to the WisePath app for 12 weeks.
214466704|NCT05427734|DEVICE|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
214466705|NCT06281678|DRUG|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
214466706|NCT01922050|DRUG|LEO 43204 Formulation 1|
214466707|NCT01922050|DRUG|LEO 43204 Formulation 2|
214466708|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose X|
214466709|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose Y|
214656966|NCT01316042|DRUG|Metformin, glucophage|2 212.5mg pills/day for 12 months
214466710|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose XX|
214466711|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose YY|
214466712|NCT01922050|DRUG|Placebo Formulation 1|
214466713|NCT01922050|DRUG|Placebo Formulation 2|
214466714|NCT05767242|OTHER|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
214466715|NCT05767242|BEHAVIORAL|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
214466716|NCT05027568|DRUG|IOA-289|Daily oral twice daily dosing of IOA-289
214466717|NCT05027568|DRUG|Nab paclitaxel / gemcitabine|Given in combination with IOA-289
214466718|NCT03661645|DRUG|10 mg IV dexamethasone & 6 day oral methylprednisolone taper|"Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone"
214466719|NCT03661645|OTHER|10 mg IV dexamethasone|Drug:10 mg intravenous (IV) dexamethasone
214466720|NCT04781634|BIOLOGICAL|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
214466721|NCT03611036|OTHER|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
214466722|NCT03611036|OTHER|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
214466723|NCT05977192|BEHAVIORAL|Standard MI|One phone-based MI session
214466724|NCT05977192|BEHAVIORAL|Intensive MI|Four phone-based MI sessions
214466725|NCT05977192|BEHAVIORAL|MOTIVACC|mHealth-based MI
214466726|NCT05977192|BEHAVIORAL|Ecological momentary assessment (EMA) messages|EMA messages focused on vaccinations and health
214466727|NCT03792919|DRUG|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
214466728|NCT03792919|DRUG|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
214466729|NCT04793867|DRUG|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
214466730|NCT03753204|DRUG|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
214466731|NCT05328115|BIOLOGICAL|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
214466732|NCT05328115|OTHER|Placebo|Intramuscular injections of adjuvanted placebo.
214466733|NCT04935710|BEHAVIORAL|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
214466734|NCT04935710|GENETIC|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
214466735|NCT04557618|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
214466736|NCT04557618|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
214656967|NCT01962220|BEHAVIORAL|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
214466737|NCT05828173|DEVICE|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
214466738|NCT04820764|DEVICE|CardioMech MVRS|CardioMech MVRS
214466739|NCT00937001|PROCEDURE|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
214466740|NCT04421989|BEHAVIORAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
214466741|NCT04421989|OTHER|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
214466742|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
214466743|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
214466744|NCT05325645|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
214466745|NCT05325645|DRUG|Placebo|Two placebo tablets will be orally administered once weekly for 7weeks.
214466746|NCT06583187|OTHER|Coloring a mandala picture|In the study, the experimental group was taken to their room on the day they came for circumcision and then had them paint mandalas. The coloring books chosen for mandala painting were determined to be appropriate for the age group of the children. The child was given a book and was given the freedom to paint the figures they wanted. Care was taken to ensure that the environment was quiet so that the child would be comfortable and calm. Care was taken to ensure that the crayons used in mandala painting did not contain carcinogenic substances and were anti-allergic.
214466747|NCT05020678|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
214466748|NCT03814759|DRUG|TS-1 + cisplatin|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
214466749|NCT03814759|RADIATION|radiation|radiation 45Gy per 5 weeks
214466750|NCT05824572|OTHER|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
214466751|NCT05824572|OTHER|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
214466752|NCT06073067|RADIATION|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
214466753|NCT05783752|BEHAVIORAL|Stair Stepping|1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal
214466754|NCT05783752|BEHAVIORAL|No exercise control|Participants avoid exercise within 1 hour of eating a meal
214466755|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
214466756|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
214466757|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
214466758|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
214466759|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
214466760|NCT05605509|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
214466761|NCT06834204|OTHER|PC2: Primary Care Connect|Primary Care Connect is a health system intervention that includes patient education, electronic medical record optimization, protocolized communication from cancer care team to primary care.
214466762|NCT06838468|DIAGNOSTIC_TEST|Screening of compensated advance chronic liver disease|"The tests performed will include a general blood analysis to evaluate liver and kidney function, an assessment of the prevalence of metabolic diseases such as obesity, hypertension, or diabetes, an abdominal ultrasound, and elastography to assess liver stiffness.~Another intervention to be studied is whether the request for diagnostic tests to evaluate liver disease, as well as the visit of the hepatologist during hospitalization in the detoxification unit, influences subsequent alcohol abstinence. To this end, abstinence will be assessed six months after admission to the alcohol detoxification unit and compared with a retrospective cohort of patients admitted to the detoxification unit one year ago, in whom no liver disease evaluation was conducted neither information of potencial liver damage was offered by hepatologist and the intervention was carried out only by the psychiatrists responsible for the unit."
214466763|NCT02965755|OTHER|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
214466764|NCT05299242|DRUG|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
214466765|NCT05299242|DRUG|Placebo|Saline \[0.9% NaCl\]
214466766|NCT04715529|DRUG|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
214466767|NCT04715529|DRUG|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
214466768|NCT05192109|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
214466769|NCT05192109|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
214466770|NCT05525286|DRUG|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
214466771|NCT04498390|DRUG|LY3493269|Administered orally.
214466772|NCT04498390|DRUG|Placebo|Administered orally.
214466773|NCT05106491|DEVICE|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
214466774|NCT04781153|PROCEDURE|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
214466775|NCT04822324|OTHER|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
214466776|NCT04822324|OTHER|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
214466777|NCT06472115|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE) for insistence on sameness (IS)|This study will examine the potential effectiveness of a virtually delivered parent-mediated intervention for insistence on sameness behaviors in autism. This includes a 16 week protocol where caregivers meet weekly for one hour with a study therapist.
214466778|NCT05095532|BIOLOGICAL|Bone marrow-derived mesenchymal stem cells|MSC transplantation
214466779|NCT05095532|OTHER|Placebo|Standard of Care
214466780|NCT05126290|OTHER|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
214466781|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
214466782|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
214466783|NCT06082492|DIAGNOSTIC_TEST|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
214466784|NCT06082492|DIAGNOSTIC_TEST|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
214466785|NCT05328856|DEVICE|Hansgrohe prototype/shower head|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
214466786|NCT03837821|DRUG|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
214466787|NCT03995043|BEHAVIORAL|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
214466788|NCT03995043|BEHAVIORAL|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
214466789|NCT03995043|BEHAVIORAL|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
214466790|NCT02975375|PROCEDURE|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
214466791|NCT02975375|PROCEDURE|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
214466792|NCT06322940|OTHER|250 mL serving size, 3.25% fat content|Milk
214466793|NCT06322940|OTHER|175 g serving size, ≥2% fat content|Yogurt
214466794|NCT06322940|OTHER|50 g serving size, ≥28% fat content|Cheese
214466795|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
214466796|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
214466797|NCT05020860|DRUG|Paclitaxel|80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
214466798|NCT05020860|DRUG|Carboplatin|Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
214466799|NCT05020860|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
214466800|NCT05020860|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
214466801|NCT05020860|DRUG|Doxorubicin|60 mg/m2 IV administered on Day 1 of each 14-day cycle
214466802|NCT05020860|DRUG|Cyclophosphamide|600 mg/m2 IV administered on Day 1 of each 14-day cycle
214466803|NCT05020860|DRUG|Pembrolizumab|"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."
214466804|NCT05020860|DRUG|Pertuzumab/Trastuzumab/Hyaluronidase-zzxf|Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
214466805|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
214466806|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
214466807|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
214466808|NCT04868708|BIOLOGICAL|AK104|Subjects will receive AK104 intravenously.
214466809|NCT04868708|BIOLOGICAL|Bevacizumab|Subjects will receive Bevacizumab intravenously.
214466810|NCT04868708|DRUG|Paclitaxel|Subjects will receive Paclitaxel intravenously.
214466811|NCT04868708|DRUG|Cisplatin or Carboplatin|Subjects will receive Cisplatin or Carboplatin intravenously.
214466812|NCT05823376|DRUG|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
214466813|NCT04573231|DRUG|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
214466814|NCT06802289|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females older adults.
214466815|NCT04976153|BIOLOGICAL|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
214466816|NCT04976153|OTHER|Placebo|Placebo control is the vehicle solution used for the study product
214466817|NCT05268120|DRUG|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
214466818|NCT05268120|DRUG|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
214466819|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
214466820|NCT04924803|BEHAVIORAL|No video|Weekly text messages
214466821|NCT04924803|BEHAVIORAL|Video Text|Weekly text messages including links to intervention videos
214466822|NCT04214184|BEHAVIORAL|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
214466823|NCT01711190|PROCEDURE|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
214466824|NCT06566378|DEVICE|Buzzy|In children pre-procedure, buzzy was placed under the armpit. The children were made before starting the application. It continued until the end of vaccination procedure.
214466825|NCT06566378|DEVICE|Buzzy (Placed in standard)|In children pre-procedure, buzzy was placed on the arm. The children were made before starting the application. It continued until the end of vaccination procedure.
214466826|NCT06058533|OTHER|Previsit Imagery Picturebook|This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
214466827|NCT06121258|OTHER|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
214466828|NCT04971109|DRUG|TPOXX|Study is based on Animal Regulatory Rule
214466829|NCT04971109|OTHER|TPOXX Placebo|Does not apply
214466830|NCT06282510|DRUG|Povidone Iodine Topical|Topical intranasal povidone iodine (10%) twice daily for 5 days
214466831|NCT05551728|BEHAVIORAL|ESDM-informed caregiver coaching|The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
214466832|NCT03953196|BIOLOGICAL|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
214466833|NCT03953196|BIOLOGICAL|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
214466834|NCT03953196|BIOLOGICAL|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
214466835|NCT03953196|BIOLOGICAL|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
214466836|NCT03953196|OTHER|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
214466837|NCT03953196|OTHER|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
214466838|NCT01233531|BEHAVIORAL|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
214466839|NCT01233531|BEHAVIORAL|B--No cash transfers|No monthly cash transfers
214466840|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
214466841|NCT03817502|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
214466842|NCT03817502|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
214466843|NCT03875287|DRUG|Decitabine|"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5~Level 4 25 mg daily days 1-5"
214466844|NCT03875287|DRUG|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5~Level 4 100mg daily days 1-5"
214466845|NCT05987813|DEVICE|TENS Unit|Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
214466846|NCT06798662|DEVICE|Ultrasound-Guided Pulsed Radiofrequency (PRF)|A high-frequency linear ultrasound transducer will be used for this procedure. The transducer will be placed transversely over the target rib area to obtain a clear visualization of the rib, intercostal muscles, and pleura. The entry point for needle insertion will be selected 1-2 cm inferior to the inferior border of the target rib. Using a 22G radiofrequency (RF) needle, an in-plane approach will be used for needle advancement. The needle will be advanced slowly until it reaches the inferior border of the rib. The needle will then be withdrawn 1-2 mm to ensure the needle tip is positioned adjacent to the intercostal nerve. The RF needle will then be connected to the RF generator for sensory testing. Stimulation parameters will be set at 50 Hz and 0.5-1V. The target location will be considered accurate if stimulation induces pain in the participant. Pulsed radiofrequency treatment will then be administered using the following parameters: voltage of 45V, frequency of 2 Hz, pulse width
214466847|NCT06798662|DEVICE|Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine)|The patient is positioned in either the lateral decubitus or sitting position, with the affected side facing upwards, ensuring adequate exposure of the targeted intercostal region. A high-frequency linear ultrasound transducer is placed transversely over the posterior lateral aspect of the targeted rib, using the vertebral column as a reference point. The transducer is then scanned laterally to identify the target rib, clearly visualizing the rib, intercostal muscles, and pleura. The intercostal nerve appears as a small hyperechoic structure located between the internal and innermost intercostal muscles. The needle is advanced until it contacts the inferior border of the rib. The needle is then slightly withdrawn and positioned between the internal and innermost intercostal muscles to avoid pleural puncture. After negative aspiration, 10 mL of 0.5% ropivacaine (or 133 mg of liposomal bupivacaine) combined with 10 mg of triamcinolone acetonide is injected slowly.
214466848|NCT06798662|DEVICE|Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|For the Paravertebral (PVB) block, a high-frequency linear ultrasound transducer was placed transversely, parallel to the spinous processes, approximately 2-3 cm lateral to the spinous process of the target thoracic vertebral segment. The position and angle of the transducer were adjusted to clearly visualize the transverse process (TP) and the axial view of the lamina of the target vertebra. In the ultrasound image, the transverse process appeared as a hyperechoic structure, typically with a characteristic acoustic shadow posterior to it. Subsequently, the transducer was slightly slid caudally, causing the transverse process and its acoustic shadow to gradually disappear from view. At this point, the ultrasound image revealed components of the paravertebral space (PVS), including the parietal pleura, the superior costotransverse ligament, and the intercostal fascia, which exhibited a heterogeneous mixed echogenicity. Using an in-plane technique, a puncture needle was advanced from lat
214466849|NCT06798662|DEVICE|Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|"The RISS block is a composite nerve block technique that involves two injection sites: the inter-rhomboid plane and the sub-serratus plane. The selection of block plane was determined by the patient's specific location of pain.~Rhomboid Intercostal Plane Block (RIPB):~For the Rhomboid Intercostal Plane Block (RIPB), a high-frequency linear ultrasound transducer was initially positioned in a sagittal orientation, medial to the scapular border. It was then slightly rotated to obtain an oblique sagittal view (oblique paramedian sagittal view), located 1-2 cm lateral to the scapular border. Upon obtaining the appropriate ultrasound image, the following anatomical structures were identified sequentially, from superficial to deep: the trapezius muscle, the rhomboid muscles (specifically, the major rhomboid), the intercostal muscles (located between the ribs), the pleura, and the lung. The target injection plane was the fascial plane situated between the rhomboid muscle and the intercostal"
214466850|NCT06798662|DRUG|Drug (famciclovir and gabapentin)|All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
214466851|NCT06972264|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
214466852|NCT06972264|DRUG|Placebo|Placebo
214466853|NCT06823375|RADIATION|Radiotherapy|\- SBRT 27.5Gy to 50Gy in 5 fractions on alternate days will be delivered between cycle 3 and 5 to the PVTT and its adjacent lesions.
214466854|NCT06823375|DRUG|Atezolizumab plus Bevacizumab|\- Atezolizumab 1200mg IV and Bevacizumab 15mg/kg IV will be given every 3 weeks, till disease progression, intolerable toxicity, death or withdrawal of consent.
214466855|NCT02709161|DEVICE|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214466856|NCT02709161|DEVICE|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214466857|NCT03507257|DRUG|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
214466858|NCT03507257|DRUG|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
214466859|NCT03507257|DRUG|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
214466860|NCT05387265|DRUG|CX-904|CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
214466861|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract|Cocoa extract manufactured as 250 mg capsules
214466862|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
214466863|NCT04350359|DEVICE|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
214466864|NCT04350359|DEVICE|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
214466865|NCT04350359|DEVICE|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
214466866|NCT06988306|BEHAVIORAL|GDM Enhanced|The GDM Enhanced intervention is comprised of HV-delivered, evidence-based modules (10-20 minutes) with facilitator guides. The content prioritizes management and prevention of diabetes through healthy eating, physical activity, and stigma-informed weight management strategies.
214466867|NCT06988306|BEHAVIORAL|Meals|The Meal intervention includes medically tailored meals being provided to participants starting after randomization and tailored to their individual dietary preferences and cultural considerations.
214466868|NCT03100760|DEVICE|13C-urea breath test|Subjects will undergo 13C-urea breath test involving collection of baseline breath samples, nebulization of 13C-urea, and collection of post-nebulization breath samples
214466869|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
214466870|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
214466871|NCT07000175|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Non-invasive transcutaneous vagus nerve stimulation with special earphones placed in the ear will be applied to the participants for 20 minutes and a single session.
214466872|NCT06999811|BEHAVIORAL|Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR)|EMPWR is evidence-informed, behavioral intervention to address risk factors for fear of opioid withdrawal, craving, and stress, with an adjective mobile application among pregnant women receiving opioid agonist therapies. The goal of EMPWR is to promote medication retention and adherence.
214466873|NCT06999811|OTHER|Medication monitoring (control)|Participants will record the dose and time buprenorphine was taken for two months via REDCap daily diaries, which will be delivered via text.
214466874|NCT06676384|DRUG|Oral prednisolone and SoC|Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
214466875|NCT06676384|DRUG|Gut-directed budesonide and SoC|Gut-directed Budesonide 12 mg once daily for nine months and tapered to 9mg once daily for the next three months, 6mg once daily for the next three months and 3mg once daily for the next three months and stopped (total 18 months). All participants in this arm will receive SoC.
214466876|NCT06676384|DRUG|Mycophenolate mofetil (MMF) and SoC|Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.
214466877|NCT06676384|DRUG|Hydroxychloroquine and SoC|Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months. All participants in this arm will receive SoC.
214466878|NCT06676384|DRUG|Non-steroidal mineralocorticoid receptor antagonist and SoC|Generic drug not available currently. All participants in this arm will receive SoC.
214466879|NCT06676384|DRUG|SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).
214466880|NCT05494359|DIAGNOSTIC_TEST|The nitrogen isotope|The nitrogen mass-charge ratio abundances (NMAs) and NMA ratios (NMARs) The nitrogen components of various m/z values in oral gas were detected.
214466881|NCT06874998|BEHAVIORAL|Structured group discussions|"A group-based program for immigrant parents of children aged 0-17, providing essential information on key aspects of family life in Sweden. The intervention consists of five weekly three-hour sessions, combining lectures, group discussions, and interactive exercises, led by a trained group leader and, when necessary, an interpreter.~The following topics are discussed:~* Parenting in a New Country - Adapting to cultural changes and supporting children's integration.~* Education \& Child Development - School system, parental involvement, and learning support.~* Healthcare \& Well-being - Access to healthcare, preventive care, and mental health.~* Parents' Rights \& Responsibilities - Child welfare laws, positive discipline, and social services.~* Parenting Teenagers - Navigating adolescence, peer relationships, and risk prevention."
214466882|NCT06874998|BEHAVIORAL|Unstructured group meeting|"Parents in the control group are asked to participate in a gathering where they will watch two short films from the Swedish Educational Broadcasting Company (UR), followed by a brief discussion. The films have been handpicked by representatives from BRIS and PLUS together with the researchers to create an opportunity for a meeting. The first film A way in - first meeting shows a family from Iran living in Sweden for 1,5 years and explores how one can establish a place in society. In the second film Make new friends it is illustrated how hard it can be to create a new social context. The intention with the short films is not to give a short version of PiS, but to engage parents in the study and the program so they will complete them."
214466883|NCT07027748|DRUG|Naxitamab|Recombinant humanized anti-GD2 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
214466884|NCT07027748|DRUG|Irinotecan|Topoisomerase Inhibitor, single-dose vial, via intravenous infusion per standard of care
214466885|NCT07027748|DRUG|Temozolomide|Alkylating agent, capsule, via orally (by mouth) per standard of care
214466886|NCT07027748|DRUG|Sargramostim granulocyte-macrophage colony stimulating factor|Recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF), multi-use vial, via subcutaneously (under the skin) injection per standard of care
214466887|NCT07035327|OTHER|Dual-task training program|"Participants in the intervention group will engage in a dual-task training program, in which resistance training will be incorporated with cognitive tasks.~\- Resistance training: Participants will be instructed to perform the following exercises with proper form: (1) squat to chair, (2) seated unilateral hip flexion, (3) seated unilateral knee extension, (4) standing unilateral knee flexion and (5) bilateral calf raise. The lower limb exercises will be followed by four upper limb exercises: (6) seated elbow flexion, (7) twisting a towel, (8) seated horizontal opening of arms and elbow, (9) seated diagonal opening of arm and elbow.~\- Cognitive task: Subjects will be asked to perform a verbal fluency task or mental arithmetic tasks simultaneously with the resistance training exercises."
214466888|NCT07035327|OTHER|Resistance exercise|Subjects in the control group will perform the resistance exercises only without receiving any cognitive training. Ten-minute warm-up and cool-down sessions will precede and follow each exercise session.
214466889|NCT07057583|OTHER|Non-Interventional Study|Non-interventional study
214466890|NCT07057544|DEVICE|LBBAP CRT device implantation|Pacing system with a lead implanted in the left bundle branch area will be done.
214466891|NCT07057544|DEVICE|BVP-CRT|Implantation of biventricular device
214466892|NCT07064343|OTHER|Aspirin|Participants are required to complete the training program includes an educational workshops and five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
214466893|NCT07063199|DRUG|Daratumumab Injection|"This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
214466894|NCT07062926|OTHER|Spencer Muscle Energy Technique|Spencer muscle energy technique participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks. Group A will undergo Spencer Muscle Energy Technique for 30 minutes
214466895|NCT07062926|OTHER|Post Facilitation Stretch|Post facilitation stretch participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks.post facilitation stretching process was repeated 5 times with 10 second interval between each stretch.
214466896|NCT07063953|OTHER|Standard Physical Therapy|Hot pack \& Transcutaneous Electric Nerve Stimulation (TENS) Myofascial Release Mulligan Mobilization with Movement Exercises
214466897|NCT07063953|OTHER|Egoscue Exercises|Warm Up Exercises (5 min) which includes Stretching ,Walking (Forward, Backward, Sideways), Arm Circles, Side bends, March on the spot, Knee lifts, Standing Gluteal Contractions , Sitting heel raises, Isolated hip flexor lifts on a towel, Supine groin stretch on towels, Static back, Sitting Knee Pillow Squeezes, Sitting floor, Progressive supine groin, Supine calf-hamstring stretch with a strap,Foot circles and point flexes, Cool Down and Breathing Exercises
214466898|NCT07063615|OTHER|Microbiome-Powered Cream|"Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
214466899|NCT07063615|OTHER|Placebo Hair Cream|"Mode of Usage: : Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
214839801|NCT06341504|DEVICE|Electronic gambling machine (model IGT GL20)|"EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand."
214466900|NCT07062068|PROCEDURE|ultrasound guided Brachiocephalic vein and internal jugular vein cannulation in mechanically ventilated ICU patients|"For Arm ( candidates for BCV cannulation ) :~by ultrasound guided we insert Central venous catheter in BCV under complete aseptic condition For Arm ( candidates for IJV cannulation ) by ultrasound guided we insert central venous catheter in IJV under complete aseptic conidtion we do comparison between the 2 arms as regard : 1st pass success rate , complications and failure rate in ventilated patient in ICU ."
214466901|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
214466902|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
214466903|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
214466904|NCT05673785|DRUG|Prednisone|Prednisone tablets
214466905|NCT07063927|PROCEDURE|personalized oral instruction form|The investigators will customize the POIF for participants. The POIF will be conceived to have a cover, and participants extraoral photos and intraoral photos will be covered when not conducting oral hygiene, the cover will ensure participants confidentiality. The personalized oral instruction form will be handed to the independent residents along with a hygiene kit comprising the necessary tools to conduct oral hygiene by the second investigator. For dependent residents, the personalized oral instruction form will be handed to the caregivers along with the personalized oral hygiene kit.
214466906|NCT07062484|DRUG|Control: gemcitabine, cisplatin, tirelizumab|PD-1 inhibitors combined with chemotherapy
214466907|NCT07062484|DRUG|Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy|PD-1 inhibitors combined with chemoradiotherapy
214466908|NCT07062471|DEVICE|Carotid Intravascular Lithotripsy (IVL)|The Shockwave Medical Intravascular Lithotripsy (IVL) System with the Shockwave SkyRunner Carotid IVL Catheter is intended for lithotripsy- enhanced balloon dilatation of ≥ 3 mm thick calcified lesions in the carotid arteries prior to stenting. Not for use for treating massive exophytic (mushroom-like) or irregular endoluminal carotid calcification, or in the coronary or cerebral arteries.
214466909|NCT07063979|DEVICE|Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient|Use of a wearable device, which emits a low-level electric current across 2 small electrodes on the underside of the patient's wrist, stimulating the nerves and sending a signal to the center of the brain that can help suppress nausea/vomiting. A review of the medical literature found studies that found the device to be effective in reducing PONV. It has been studied in the past, but the trials had limitations, not double blinded and no true placebo. We have proposed a true double blind randomized study utilizing a placebo which specifically mimics the actual device as closely as possible to prevent bias and adversely effecting data results. Nor had this device been tested specifically in the postop bariatric surgical patient.
214466910|NCT07063979|DEVICE|A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.|The company who makes the active device created a sham wearable device that looks like the active, and buzzes (to give the feel of stimulation), but does not actual emit a low-leve electrical signal to stimulate the nerves.
214466911|NCT07063342|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
214466912|NCT07063342|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
214466913|NCT07063342|DRUG|Trospium Chloride|Specified dose on specified days
214466914|NCT07062081|DIAGNOSTIC_TEST|lipid profile|The blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values.
214466915|NCT07063212|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate
214466916|NCT07063212|DRUG|Cetuximab|Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist
214466917|NCT07064057|OTHER|Aerobic exercise combined with the sniff maneuver technique|Aerobic exercises on a stationary bike or electric treadmill three times a week for six week. Five minutes of stretching, concentrated on the main lower limb muscle groups, were followed by a ten-minute warm-up, twenty minutes of training during the first two weeks and thirty minutes during the third to sixth week, and finally, a five-minute cooling-down phase..
214466918|NCT07064057|OTHER|Aerobic exercise|The treadmill was used for both the warm-up and cooling-down phases. Heart rate was kept between 40% and 50% of maximum heart rate for these sessions. (5) To achieve a moderate exertion (rated as 11--13 on the Borg scale) and/or a moderate dyspnea (rated as 3---4 on the modified Borg scale), the intensity of the aerobic training was progressively increased.
214466919|NCT06638944|BEHAVIORAL|In-person sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
214466920|NCT06638944|BEHAVIORAL|Remote sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
214466921|NCT06638944|BEHAVIORAL|Standard-of-care treatment|Participants in this intervention will complete the same standardized behavioral swallowing rehabilitation protocol and in the same frequency as the sEMG biofeedback intervention groups but WITHOUT a device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week. For this intervention group, patients use a visual analog scale and a timer as feedback tools, as frequently done in clinical practice where sEMG devices are not widely available.
214466922|NCT07062055|DRUG|Anti-VEGF|Drug: Bevacizumab (15 mg/kg, IV, every 3 weeks)
214466923|NCT07062055|DRUG|Immunotherapy|QL1706 (7.5 mg/kg, IV, every 3 weeks, administered sequentially after bevacizumab)
214466924|NCT07062055|RADIATION|Local Therapy|Stereotactic Body Radiotherapy (SBRT), total dose of 25-50 Gy in 5 fractions over 1-2 weeks, targeting intrahepatic tumors, portal vein tumor, and/or limited extrahepatic oligometastatic lesions
214466925|NCT07064408|DRUG|Esketamine|Intravenous administration of a subanesthetic dose of esketamine (0.25 mg/kg) during induction of general anesthesia. The drug was administered slowly over approximately 30 seconds after midazolam (2 mg) and sufentanil (50 µg), and prior to propofol (2 mg/kg) and rocuronium (0.6 mg/kg). The goal was to evaluate its effect on intraoperative hemodynamic stability and postoperative recovery in elderly patients undergoing thoracic surgery.
214466926|NCT07064408|DRUG|Normal Saline (0.9% Sodium Chloride)|Intravenous administration of an equivalent volume of 0.9% normal saline during anesthesia induction, matching the timing and method of the esketamine group. Used as a placebo comparator.
214466927|NCT07064408|DRUG|Midazolam|Intravenous administration of 2 mg midazolam during anesthesia induction for sedation. Administered prior to study drug.
214466928|NCT07064408|DRUG|Sufentanil|Intravenous administration of 50 µg sufentanil for analgesia during anesthesia induction. Administered prior to study drug.
214466929|NCT07064408|DRUG|propofol|Intravenous administration of 2 mg/kg propofol for loss of consciousness during anesthesia induction. Administered after study drug.
214466930|NCT07064408|DRUG|Rocuronium|Intravenous administration of 0.6 mg/kg rocuronium to facilitate neuromuscular blockade and endotracheal intubation.
214466931|NCT04382443|DRUG|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
214466932|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
214466933|NCT05586958|DRUG|Placebo|Matching placebo
214466934|NCT06076304|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
214466935|NCT06076304|DRUG|Placebo|Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days
214466936|NCT06076304|DRUG|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
214466937|NCT06076304|OTHER|C-reactive protein|Measurement of C-reactive protein level in capillary blood
214466938|NCT06368986|DRUG|VH4011499 Dose A|VH4011499 administered in fasted or fed conditions.
214466939|NCT06368986|DRUG|VH4011499 Dose B|VH4011499 Dose B administered in fasted or fed conditions.
214466940|NCT06953882|DRUG|Ribociclib 400mg|400 mg (2 x 200 mg tablets by mouth) once daily on days 1 to 21 of a 28-day cycle, followed by seven days off ribociclib (Days 22 to 28).
214466941|NCT06953882|DRUG|Letrozole 2.5mg|Letrozole will be administered as an endocrine therapy. The regimen will differ depending on the demographic of the patient. For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously.
214466942|NCT06953882|DRUG|Anastrazole 1mg|For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously.
214466943|NCT06953882|DRUG|Goserelin 3.6 MG|For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously, concurrently with goserelin 3.6 mg monthly injection.
214466944|NCT06953882|RADIATION|Adjuvant chemotherapy|Adjuvant chemotherapy dose modifications in Arm 2 will be per institutional guidelines and investigator discretion.
214466945|NCT05513833|OTHER|Standard School Screening and Referral|Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
214466946|NCT05513833|OTHER|Enhanced mHealth Screening|The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
214466947|NCT05513833|OTHER|Specialty Telemedicine Referral|The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
214466948|NCT03387592|DRUG|CPT-11|180 mg/m2
214466949|NCT03387592|DRUG|Calcio levofolinate|200 mg/m2
214466950|NCT03387592|DRUG|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
214466951|NCT03387592|DRUG|Capecitabine|1500 mg/m2
214466952|NCT03387592|DRUG|Temozolomide|200 mg/m2
214466953|NCT06616532|DRUG|PM8002|Following a predefined dose and date.
214466954|NCT06616532|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 Q3W
214466955|NCT06616532|DRUG|Topotecan|1.25mg/m2/day via IV infusion on Days 1-5 Q3W
214466956|NCT04732598|DRUG|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
214466957|NCT04732598|DRUG|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
214466958|NCT05603741|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
214466959|NCT05603741|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
214466960|NCT04044794|BEHAVIORAL|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
214466961|NCT04044794|BEHAVIORAL|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
214466962|NCT05326451|DEVICE|active tDCS|Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
214466963|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
214466964|NCT05058417|DRUG|Empagliflozin 10 MG|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
214466965|NCT05058417|DRUG|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
214466966|NCT04974632|PROCEDURE|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
214466967|NCT04231149|DEVICE|Test product 2|Test catheter 2
214466968|NCT04231149|DEVICE|Test product 3|Test catheter 3
214466969|NCT04231149|DEVICE|Comparator|SpeediCath Flex
214466970|NCT05292157|PROCEDURE|shoulder arthroplasty|range of motion (in degrees) measured in annual postoperative follow-up
214466971|NCT05718583|DIETARY_SUPPLEMENT|Butyrate|"Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an evaluable participant will be 2 weeks of SCFA supplementation."
214466972|NCT04611971|DRUG|Benlysta|Benlysta injection will be administered subcutaneously.
214466973|NCT04611971|DRUG|Candin|Candin will be administered intradermally along with NaCl solution.
214466974|NCT04871269|DRUG|Dronabinol|Dronabinol
214466975|NCT04871269|DRUG|Placebo|Placebo
214466976|NCT01427153|PROCEDURE|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
214466977|NCT01427153|PROCEDURE|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
214466978|NCT04402255|OTHER|pilates exercise|The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.
214466979|NCT05190718|DEVICE|Pharyngeal electrostimulation|"Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential."
214466980|NCT02588651|DRUG|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
214466981|NCT03747146|DEVICE|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
214466982|NCT03747146|DEVICE|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
214466983|NCT05768763|BEHAVIORAL|Community-enhanced reach activities|We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care, working closely with community health workers, integrated in the community health system.
214466984|NCT05768763|BEHAVIORAL|Person-centered care delivery|Structured approach to provide patient-centered biomedical options for HIV prevention (dynamic choice prevention). Tailored services for HIV treatment support using structured life stage evaluation and assessment plan (LEAP) for youth, pregnant women, and persons with or at risk of HIV viral non-suppression, that includes counselling for heavy alcohol users. Structured approach to offer telehealth for severe hypertension follow up.
214466985|NCT05768763|OTHER|Data system enhancement to improve reach and person-centered delivery|Both community-enhanced reach and person-centered delivery will be strengthened through a customized in-country Ministry of Health-compatible community health worker smartphone app and two-way data system linking community health workers and clinical records.
214466986|NCT05768763|BEHAVIORAL|Standard of Care|Standard of Care in Uganda and Kenya
214466987|NCT05994937|DEVICE|PAC with HEPA filter intact|A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
214466988|NCT05994937|DEVICE|PAC with HEPA filter removed|Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
214466989|NCT04792931|OTHER|description of adult autoimmune myopathies|description of adult autoimmune myopathies
214466990|NCT05946031|DRUG|Reat ETM|Exclusive cigarette smokers will be recruited and will be exposed to the real ETM condition in which tobacco purchases are real and they receive products from one randomly selected trial.
214466991|NCT05946031|DRUG|Hypothetical ETM|Exclusive cigarette smokers will be recruited and will be exposed to the hypothetical ETM condition in which tobacco purchases are hypothetical and they don't receive any products.
214466992|NCT05188287|BEHAVIORAL|HealthyCells|Smoking cessation smartphone app
214466993|NCT05203523|DEVICE|transcranial alternative current stimulation (tACS)|A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.
214466994|NCT05203523|OTHER|cognitive exercises|"Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant."
214466995|NCT04979442|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
214466996|NCT04979442|DRUG|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
214466997|NCT05928091|OTHER|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
214466998|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
214466999|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
214467000|NCT05283304|DRUG|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
214467001|NCT05283304|OTHER|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
214467002|NCT04298983|DRUG|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
214467003|NCT04298983|DRUG|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
214467004|NCT04298983|RADIATION|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
214467005|NCT04506307|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
214467006|NCT02567669|RADIATION|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
214467007|NCT06253819|OTHER|survey and physical test|6 min. walking test respiratory function test 30 second sit-stand test respiratory muscle test tıme up and go corbin posture analysis Waist/Hip Circumference Ratio Glucose and Cholesterol values Lanss Neuropathic Pain Scale
214467008|NCT04368949|OTHER|Stepping-Up|The intervention group will receive STEPPING-UP, a virtual 12-week, multicomponent intervention that includes tailored task-oriented motor learning exercise and a mobility self-management (SM) program.
214467009|NCT04368949|OTHER|Telephone-Based Coaching Walking Program|The participants assigned to this group will receive a 12-week Telephone-Based Coaching Walking Program (TELE) delivered by a PT who will help participants set short and long term walking goals.
214467010|NCT04368949|OTHER|Chair-Based Yoga Program|Participants assigned to this group will receive a virtual 12-week Chair-Based Yoga Program (YOGA), a group-based exercise control where participants will undertake a seated exercise program that includes: warm up, seated and standing yoga poses, cool down.
214467011|NCT05606237|DEVICE|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
214467012|NCT03121404|PROCEDURE|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
214467013|NCT06258330|DRUG|AM003|Bispecific Personalized Aptamer for intratumoral administration
214467014|NCT01526096|DRUG|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
214467015|NCT01526096|DRUG|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
214467016|NCT01526096|PROCEDURE|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
214467017|NCT01526096|DRUG|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
214467018|NCT01526096|PROCEDURE|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
214467019|NCT01526096|DRUG|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
214467020|NCT01526096|DEVICE|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
214467021|NCT04296097|DEVICE|DBS|Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
214467022|NCT05374304|OTHER|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
214467023|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
214467024|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
214467025|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
214467026|NCT06145334|BEHAVIORAL|Veterans Social|Peer-led weekly community-based social groups (16 weeks) that are current treatment at the study site.
214467027|NCT02216032|OTHER|TMW Curriculum|
214467028|NCT02216032|OTHER|Nutrition Curriculum|
214467029|NCT05560581|BEHAVIORAL|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
214467030|NCT05560581|BEHAVIORAL|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
214467031|NCT02116530|DRUG|Olanzapine|oral
214467032|NCT02116530|DRUG|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
214467033|NCT02116530|DRUG|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
214467034|NCT02116530|OTHER|Placebo|oral
214467035|NCT05842876|DEVICE|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
214467036|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
214467037|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
214467038|NCT05842876|OTHER|Satisfaction Survey|Survey to assess which method of monitoring is preferred
214467039|NCT04028479|DIAGNOSTIC_TEST|Biomarker Testing (L)|Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
214467040|NCT04028479|DRUG|Systemic Treatment (T)|Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
214467041|NCT04028479|OTHER|Patient Reported Outcomes (P)|Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
214467042|NCT06128993|OTHER|Transcoronary cooling and dilution|Transcoronary cooling and dilution
214467043|NCT06128993|OTHER|Standard of care|Routine clinical care
214467044|NCT01148849|BIOLOGICAL|margetuximab|margetuximab
214467045|NCT05805176|DEVICE|ADHD Therapy|investigational game-play therapy
214467046|NCT05626751|DRUG|HZN-825|HZN-825 will be administered BID for 52 weeks
214467047|NCT05487846|BEHAVIORAL|Patient Navigation|Receive peer navigation services
214467048|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
214467049|NCT05487846|OTHER|Survey Administration|Ancillary studies
214467050|NCT05487846|OTHER|Best Practice|Receive standard care
214467051|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
214467052|NCT05487846|OTHER|Survey Administration|Ancillary studies
214467053|NCT06500481|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214467054|NCT06500481|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214467055|NCT06500481|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
214467056|NCT06500481|PROCEDURE|Lumbar Puncture|Undergo LP
214467057|NCT06500481|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214467058|NCT06500481|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214467059|NCT06500481|RADIATION|Proton Beam Craniospinal Irradiation|Undergo pCSI
214467060|NCT06500481|OTHER|Quality-of-Life Assessment|Ancillary studies
214467061|NCT05983367|DRUG|Ompenaclid|Ompenaclid (RGX-202-01)
214467062|NCT05983367|DRUG|Placebo|Placebo
214467063|NCT05983367|DRUG|Bevacizumab|Bevacizumab
214467064|NCT05983367|DRUG|FOLFIRI regimen|FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
214467065|NCT03787264|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
214467066|NCT03787264|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
214467067|NCT03787264|BIOLOGICAL|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
214467068|NCT03787264|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
214467069|NCT03711734|OTHER|Acupuncture + Standard of Care|Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
214467070|NCT05029622|DRUG|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
214467071|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
214467072|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
214467073|NCT04074135|DRUG|68-Gallium DOTATATE|68-Gallium DOTATATE, to be used in yearly PET/CT research scans
214467074|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Oblique Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
214467075|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Offset Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
214467076|NCT03749902|DRUG|Oral misoprostol|"* An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
214467077|NCT03749902|DRUG|Oxytocin|"* Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured."
214467078|NCT05098184|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
214467079|NCT06189495|DRUG|GenSci048|1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
214467080|NCT06189495|DRUG|GenSci048 placebo|"1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4\. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
214467081|NCT03617731|DRUG|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
214467082|NCT03617731|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
214467083|NCT03617731|DRUG|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
214467084|NCT03617731|DRUG|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
214467085|NCT06059014|DRUG|177Lu-PSMA-1 (radiopharmaceutical)|7.4 GBq (or 5.9 GBq in case of lower actvity) of 177Lu-PSMA-1, every 6 weeks for 4 administirations
214467086|NCT05376111|DRUG|Venetoclax, Azacitidine|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
214467087|NCT05012696|DEVICE|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
214467088|NCT05012696|DEVICE|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
214467089|NCT06250803|DEVICE|early pancreatic stent placement (EPSP)|In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.
214467090|NCT03995173|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
214467091|NCT06181461|OTHER|Gong's Mobilization|Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
214467092|NCT06181461|OTHER|Kaltenborn Mobilization|Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
214467093|NCT02430129|PROCEDURE|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
214467094|NCT02430129|PROCEDURE|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
214467095|NCT02430129|DEVICE|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
214467096|NCT02430129|DEVICE|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
214467097|NCT04219436|PROCEDURE|vertical mattress suturing technique|vertical mattress suturing technique used for flap closure after esthetic crown lengthening
214467098|NCT04219436|PROCEDURE|figure of eight suturing technique|figure of eight suturing technique used for flap closure after esthetic crown lengthening
214467099|NCT06023212|DRUG|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
214467100|NCT06023212|DRUG|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
214467101|NCT05745285|OTHER|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
214467102|NCT04284917|DRUG|Carglumic Acid (Carbaglu®)|"A. Study period: 36 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12).~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12.~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis and methylmalonic acid will be recorded during treatment period."
214467103|NCT06482216|BIOLOGICAL|Varicella vaccine|lyophilized powder,subcutaneous injection
214467104|NCT03974178|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
214467105|NCT03739723|OTHER|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
214467106|NCT05650788|DIAGNOSTIC_TEST|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
214467107|NCT04228419|PROCEDURE|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
214467108|NCT04228419|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
214467109|NCT05436444|BIOLOGICAL|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
214467110|NCT04319042|PROCEDURE|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
214467111|NCT04319042|PROCEDURE|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
214467112|NCT03815656|DEVICE|STN alone|DBS stimulation of STN alone
214467113|NCT03815656|DEVICE|GPi alone|DBS stimulation of GPi alone
214467114|NCT03815656|DEVICE|STN + GPi|cooperative DBS stimulation of STN and GPi sites
214467115|NCT03815656|DEVICE|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
214467116|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
214467117|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
214467118|NCT06823648|DEVICE|Arterial blood samplers with needles PICO70 and safePICO syringes|PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation. safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle.
214467119|NCT06717880|DRUG|IBI363 combined with Bevacizumab|"IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection."
214467120|NCT06717880|DRUG|IBI363 + Furuitinib|IBI363 Q2W or Q3W IV，Furuitinib po
214467121|NCT06542263|DEVICE|CPAP|For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
214467122|NCT04239820|RADIATION|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
214467123|NCT06823934|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most common operations performed in oral surgery is the extraction of lower impacted wisdom teeth. The extraction of impacted third molars causes significant inflammatory changes resulting in edema, trismus and pain. Complications encountered after the extraction of lower impacted wisdom teeth can negatively affect the daily lives of patients. Some of the treatments applied for these complications can be listed as drug use, cold/hot compression, low-dose laser therapy, cryotherapy, autogenous biomaterials such as PRF.
214467124|NCT05526430|DRUG|Harmine Hydrochloride Capsules|capsules taken orally
214467125|NCT06518525|OTHER|pilates-based tele-exercises|pilates-based tele-exercises
214467126|NCT04508309|BIOLOGICAL|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
214467127|NCT04508309|BIOLOGICAL|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
214467128|NCT06778512|OTHER|Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t|Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
214467129|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.|1\) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.
214467130|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.|2\) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.
214467131|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.|3\) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
214467132|NCT06398795|PROCEDURE|Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).|An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
214467133|NCT06398795|PROCEDURE|Conventional open thyroidectomy (COT)|open thyroidectomy with traditional collar incisions
214467134|NCT05726279|DEVICE|NIRS based personalized blood pressure management|In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
214467135|NCT03737864|BEHAVIORAL|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
214656968|NCT04278794|OTHER|Transitional Care Stroke Intervention (TCSI)|"Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
214467136|NCT03737864|BEHAVIORAL|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
214467137|NCT06441682|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
214467138|NCT06441682|OTHER|Placebo|Intravenous infusion of placebo
214467139|NCT02305888|DRUG|LEO 43204|Treatment of actinic keratosis
214467140|NCT06184919|OTHER|Process Mapping: Observations|Direct observations of the POSH clinic visit.
214467141|NCT06184919|OTHER|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
214467142|NCT06184919|OTHER|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
214467143|NCT06184919|OTHER|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
214467144|NCT05573074|DEVICE|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
214467145|NCT05573074|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
214467146|NCT05710224|BIOLOGICAL|V181|0.5 mL SC dose of V181
214467147|NCT05710224|BIOLOGICAL|Butantan-DV|0.5 mL SC dose of Butantan-DV
214467148|NCT06818370|OTHER|Coconut Oil|The coconut oil application protocol will be explained to the patients in the experimental group and 10 milliliters of coconut oil will be applied to the hair follicles once a week. Alopecia assessment will be done every week.
214467149|NCT05851183|DRUG|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
214656969|NCT01974323|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
214656970|NCT01974323|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
214656971|NCT04076826|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
214467150|NCT05851183|BEHAVIORAL|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
214467151|NCT05174767|DEVICE|AMDS|AMDS Implantation
214467152|NCT05509413|DEVICE|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
214467153|NCT04673032|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain
214467154|NCT04012606|DRUG|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
214467155|NCT06672809|BEHAVIORAL|Core Stability Training|Participants in this group undergo core stability training sessions targeting deep stabilizing muscles. The exercises are designed to enhance spinal support and core control by activating the transversus abdominis and other core muscles. Sessions involve the use of a Pilates reformer and other unstable surfaces, fostering proprioceptive engagement and improved muscle coordination. Training is conducted three times per week for eight weeks, with each session lasting 50 minutes.
214467156|NCT06672809|BEHAVIORAL|Aerobic Exercise|Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
214467157|NCT04914676|DRUG|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
214467158|NCT04914676|DRUG|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
214467159|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
214467160|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
214467161|NCT05208697|BEHAVIORAL|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
214467162|NCT05208697|OTHER|off-site linkage|standard of care linkage to a Ryan White clinic
214467163|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
214656972|NCT04076826|DRUG|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
214656973|NCT04076826|DIAGNOSTIC_TEST|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
214656974|NCT00331760|DRUG|cisplatin|
214656975|NCT00331760|RADIATION|intensity-modulated radiation therapy|
214656976|NCT01597947|DRUG|ACHN-975|Intravenous single dose
214656977|NCT01597947|DRUG|placebo|Intravenous single dose
214656978|NCT05211167|DRUG|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
214656979|NCT05211167|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
214656980|NCT01380054|BEHAVIORAL|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
214656981|NCT04574726|OTHER|static balance|30-second right and left unipodal static balance test
214656982|NCT04574726|OTHER|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point"
214656983|NCT00347815|DRUG|Buprenorphine|
215031553|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab)|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
214656984|NCT01856101|DRUG|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
214656985|NCT02514044|DRUG|Dexedrine|10 mg immediate release of Dexedrine
214656986|NCT02514044|DEVICE|Active tDCS|1.5 mA tDCS anodal tDCS
214656987|NCT02514044|BEHAVIORAL|Speech Therapy|60 min of speech therapy
214656988|NCT02514044|DRUG|Placebo|
214656989|NCT02514044|DEVICE|Sham tDCS|
214656990|NCT03093155|DRUG|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
214656991|NCT03093155|DRUG|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
214656992|NCT06220695|BEHAVIORAL|Dietary intervention|The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
214656993|NCT01800188|PROCEDURE|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
214656994|NCT01800188|PROCEDURE|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
214656995|NCT01800188|PROCEDURE|Meal test|A 3 hour standardized liquid meal test without dialysis
214656996|NCT05012748|OTHER|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
214656997|NCT04402047|OTHER|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
214656998|NCT04402047|DRUG|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
214656999|NCT04819321|DEVICE|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
214657000|NCT01907620|OTHER|blood sample|
214657001|NCT06381583|DIAGNOSTIC_TEST|EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)|A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
214657002|NCT02484027|DRUG|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
214657003|NCT02983604|DRUG|GS-5829|Tablet(s) administered orally once daily
214657004|NCT02983604|DRUG|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
214657005|NCT02983604|DRUG|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
214657006|NCT01111604|BIOLOGICAL|Ramucirumab|8 mg/kg IV Q2W
214657007|NCT01111604|BIOLOGICAL|Icrucumab|15 mg/kg IV Q2W
214657008|NCT01111604|DRUG|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
214657009|NCT01687790|DEVICE|molecular breast imaging (Discovery)|
214467164|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
214467165|NCT04568902|DRUG|H3B-6545|H3B-6545 oral tablets.
214467166|NCT04568902|DRUG|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
214467167|NCT05200403|DRUG|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
214467168|NCT05200403|DRUG|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
214467169|NCT05200403|DEVICE|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
214467170|NCT05200403|DEVICE|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
214467171|NCT06520878|DIETARY_SUPPLEMENT|NANO-PSO (pomegranate seed oil)|NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
214467172|NCT06520878|DIETARY_SUPPLEMENT|Placebo|Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
214467173|NCT05335070|DRUG|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
214467174|NCT03913442|DRUG|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
214467175|NCT03913442|DRUG|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
214467176|NCT05856448|DRUG|GLPG3667|Capsule
214467177|NCT05856448|DRUG|Placebo|Capsule
214467178|NCT04610372|RADIATION|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
214467179|NCT04610372|RADIATION|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
214467180|NCT04610372|RADIATION|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
214467181|NCT04610372|RADIATION|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
214467182|NCT00902603|DRUG|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
214467183|NCT04404595|BIOLOGICAL|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
214467184|NCT05615415|DRUG|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
214467185|NCT05615415|DRUG|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
214467186|NCT05615415|DEVICE|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
214467187|NCT03518606|DRUG|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
214467188|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
214467189|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
214467190|NCT06408506|PROCEDURE|Re-Entry Surgery|Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration
214467191|NCT06408506|PROCEDURE|Probing peri-implant bone|Probing peri-implant bone with Dental Probe during surgery
214467192|NCT06408506|PROCEDURE|Scanning peri-implant bone|Scanning peri-implant bone during surgery
214467193|NCT06408506|PROCEDURE|Conventional Impressions|Conventional Impressions during surgery
214467194|NCT06408506|PROCEDURE|Implant Surgery|Placement of 6 implants in the edentulous mandible
214467195|NCT06408506|PROCEDURE|Healing procedure|"All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures"
214467196|NCT06540404|OTHER|Pulse traction|The subjects underwent impulse traction of the knee joint in the second degree according to the Kaltenborn concept.
214467197|NCT06540404|OTHER|Continuous traction|The subjects underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.
214467198|NCT06540404|OTHER|Sham therapy|The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
214467199|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
214467200|NCT06534671|DRUG|diltiazem|IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
214657010|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
214657011|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
214657012|NCT00316264|BIOLOGICAL|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
214657013|NCT00316264|BIOLOGICAL|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
214657014|NCT00316264|BIOLOGICAL|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
214657015|NCT00355264|DRUG|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
214657016|NCT00446303|DRUG|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
214657017|NCT02185391|PROCEDURE|Audience Response System|patients use during oral presentations an audience response system
214657018|NCT02185391|BEHAVIORAL|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
214657019|NCT02833025|DEVICE|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
214657020|NCT06401356|DRUG|Pelabresib|Small molecule inhibitor of bromodomain and extraterminal (BET) protein
214657021|NCT00826514|DRUG|Tanezumab|Intravenous, 20 mg, single dose.
214657022|NCT00826514|DRUG|Placebo|Intravenous placebo, single dose
214839802|NCT06341504|DEVICE|Square terminal|This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
214467201|NCT02460458|DRUG|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
214467202|NCT06408714|DRUG|Nalmefene Injection|"Subjects in this arm will be administered intravenous nalmefene with a dosing scheme of:~0.5 mg Nalmefene IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 1.0 mg nalmefene will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
214467203|NCT06408714|DRUG|Naloxone Injection|"Subjects in this arm will be administered intravenous naloxone with a dosing scheme of:~0.4 mg Naloxone IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 0.4 mg of naloxone will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
214839803|NCT01102452|DIETARY_SUPPLEMENT|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
214467205|NCT06096311|OTHER|Interviews|Interviews
214467206|NCT06207994|DEVICE|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
214467207|NCT06207994|DEVICE|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
214467208|NCT05892861|BEHAVIORAL|cognitive stimulation|video education, board games, and 24-hour dietary recall record
214467209|NCT05892861|OTHER|as usual care|history taking, explain data, and discuss how to control healthy condition
214467210|NCT03446391|PROCEDURE|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
214467211|NCT03446391|PROCEDURE|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
214467212|NCT03446391|DEVICE|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
214467213|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
214467214|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
214467215|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
214467216|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
214467217|NCT06061471|DRUG|AK111|AK111 regimen 1-subcutaneous injection,until week 24.
214657023|NCT03245879|BEHAVIORAL|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
214657024|NCT03245879|BEHAVIORAL|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
214657025|NCT03245879|BEHAVIORAL|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
214657026|NCT05155098|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
214657027|NCT00643240|RADIATION|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
214657028|NCT00643240|RADIATION|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
214657029|NCT04485455|DEVICE|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
214657030|NCT04485455|DEVICE|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
214657031|NCT03926143|DRUG|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
214657032|NCT02561156|DRUG|TAK-653 Placebo|TAK-653 placebo-matching tablets.
214657033|NCT02561156|DRUG|TAK-653|TAK-653 tablets.
214467218|NCT06061471|DRUG|AK111|AK111 regimen 2-subcutaneous injection,until week 24.
214467219|NCT06096272|DEVICE|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
214467220|NCT05866627|DRUG|Famotidine|Specified dose on specified days
214467221|NCT05866627|DRUG|Afimetoran|Specified dose on specified days
214467222|NCT05778851|DEVICE|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
214467223|NCT06274593|DEVICE|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
214467224|NCT06185660|DRUG|sodium zirconium cyclosilicate (SZC)|sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
214467225|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
214467226|NCT05343572|DRUG|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
214467227|NCT02652078|DEVICE|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
214467228|NCT03496922|BEHAVIORAL|Experimental Tobacco Marketplace|See arm group description.
214467229|NCT04004416|OTHER|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
214467230|NCT04004416|DRUG|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
214467231|NCT06192550|DEVICE|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
214467232|NCT06560476|OTHER|Data collection|Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.
214467233|NCT05391243|PROCEDURE|LLETZ|Large loop excision of the transformation zone
214467234|NCT06517628|OTHER|Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.|The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.
214467235|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
214467236|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
214467237|NCT05436262|DEVICE|Real-time fMRI with neurofeedback of motor imagery|Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.
214467238|NCT05512208|DRUG|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
214467239|NCT06561321|DRUG|Tapinarof|Daily topical Tapinarof use will stop disease advancement and improve the quality of life in patients with palmoplantar keratoderma, through its AhR \& NRF2 agonism properties.
214467240|NCT04114084|PROCEDURE|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
214467241|NCT04462276|DRUG|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
214467242|NCT04462276|RADIATION|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
214467243|NCT05299073|DRUG|MB09|Single dose of 35mg SC administered
214467244|NCT05299073|DRUG|US-sourced Xgeva|Single dose of 35mg SC administered
214467245|NCT05299073|DRUG|EU-sourced Xgeva|Single dose of 35mg SC administered
214467246|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
214467247|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
214467248|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
214467249|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
214467250|NCT01763190|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214467251|NCT06547411|DEVICE|PC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).
214467252|NCT06547411|DEVICE|VC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).
214467253|NCT06547411|DEVICE|PRVC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
214467254|NCT06016608|DIAGNOSTIC_TEST|Magnetic Resonance Angiography, Ocular OCTA, CT Angiography|Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
214467255|NCT03441321|OTHER|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
214467256|NCT03441321|OTHER|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
214467257|NCT03441321|OTHER|Survey Administration|Ancillary studies
214467258|NCT06539247|COMBINATION_PRODUCT|Motor Relearning Program with Electrical Muscle Stimulation (MRA + EMS)|This arm received a 30-minute motor relearning program focused on improving foot drop and gait patterns and Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes) with 40 mA (default) adaptive, considering both intensity and duration for safe foot lift during walking.
214839872|NCT03978416|BEHAVIORAL|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
214839873|NCT04614584|DRUG|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
214839874|NCT04614584|DRUG|Methamphetamine|Methamphetamine 30 mg IV once
214839875|NCT04013074|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
214839876|NCT04013074|OTHER|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
214839877|NCT00899535|GENETIC|DNA analysis|
214839878|NCT00899535|GENETIC|RNA analysis|
214839879|NCT00899535|GENETIC|microarray analysis|
214839880|NCT00899535|GENETIC|mutation analysis|
214839881|NCT00899535|GENETIC|polymorphism analysis|
214839882|NCT00591760|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
214839883|NCT03367780|DEVICE|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
214839884|NCT00398073|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
214839885|NCT00398073|DEVICE|The Dermal PowderMed® devices|
214839886|NCT00398073|OTHER|intramuscularly (IM injection)|
214839887|NCT04235660|RADIATION|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
214839888|NCT04235660|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
214839889|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
214839890|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
214839891|NCT03957694|DRUG|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
214839892|NCT04304209|DRUG|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
214839893|NCT04304209|DRUG|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
214839894|NCT04304209|DRUG|Sintilimab|200mg, d1 q3w, intravenous infusion
214839895|NCT04304209|RADIATION|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
214839896|NCT04304209|PROCEDURE|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
214839897|NCT04304209|OTHER|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
214839898|NCT01049464|DRUG|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
214839899|NCT01049464|DRUG|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
214839900|NCT01820962|PROCEDURE|heparin|when not in use CVCs are locked with heparin
214839901|NCT01820962|PROCEDURE|concentrated citrate|when not in use the CVC is locked with concentrated citrate
214839902|NCT04777305|OTHER|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
214839903|NCT01625403|DRUG|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
214839904|NCT01625403|DRUG|standard of care|standard of care for heart failure
214839905|NCT00575601|DRUG|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
214839906|NCT03795012|DRUG|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
214839907|NCT01584882|BEHAVIORAL|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
214839908|NCT00363857|DRUG|Ropinirole|
214839909|NCT01825694|BEHAVIORAL|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
214839910|NCT03359720|OTHER|no intervention survey|survey
214839911|NCT03064620|BIOLOGICAL|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
214839912|NCT00078923|DIETARY_SUPPLEMENT|soy isoflavones|
214839913|NCT00078923|PROCEDURE|neoadjuvant therapy|Prostatectomy or Brachytherapy
214839914|NCT00078923|OTHER|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
214839915|NCT00991692|OTHER|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
214839916|NCT02897934|DRUG|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
214839917|NCT03113396|DRUG|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
214839918|NCT03113396|DRUG|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
214839919|NCT04506619|OTHER|No Intervention|This is a non-interventional study.
214839920|NCT01833169|DRUG|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
214839921|NCT03718039|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
214839922|NCT03718039|DEVICE|Luer Lock applicator|Applicator for instillation.
214839923|NCT03718039|DEVICE|Vial access device|Device for withdrawal of drug product.
214839924|NCT03718039|DRUG|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
214839925|NCT04602741|BEHAVIORAL|A4i Intervention|6 months of the provision of A4i on the individual's own device.
214839926|NCT02004717|DRUG|DS-8895a|
214839927|NCT02664350|GENETIC|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
214839928|NCT02664350|BEHAVIORAL|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
214839929|NCT02664350|BEHAVIORAL|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
214839930|NCT02664350|GENETIC|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
214839931|NCT03380325|DRUG|Iloprost infusion|Iloprost is a stable prostacyclin analogue
214839932|NCT00879684|BIOLOGICAL|CVX-060|Weekly, intravenous dose
214839933|NCT05694130|DRUG|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
214839934|NCT05694130|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
214839935|NCT03371524|OTHER|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
214839936|NCT02893163|BEHAVIORAL|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
214839937|NCT02893163|OTHER|Usual Care|Usual Care by Family Doctor
214839938|NCT05040139|PROCEDURE|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
214839939|NCT05040139|PROCEDURE|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
214839940|NCT01821157|PROCEDURE|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
214839941|NCT01821157|PROCEDURE|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
214839942|NCT00127166|DRUG|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
214839943|NCT00127166|DRUG|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
214839944|NCT00127166|DRUG|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
214839945|NCT00127166|DRUG|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
214839946|NCT00127166|DRUG|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
214839947|NCT00105157|DRUG|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
214839948|NCT00105157|DRUG|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
214839949|NCT00105157|DRUG|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
214839950|NCT00105157|DRUG|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
214839951|NCT03269955|DRUG|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
214839952|NCT01684280|GENETIC|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
214839953|NCT03544840|OTHER|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
214839954|NCT01224457|DRUG|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
214839955|NCT01237080|DEVICE|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
214839956|NCT01237080|DEVICE|Fastrach|The Fastrach is an intubation laryngeal mask.
214839957|NCT03581162|DIAGNOSTIC_TEST|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
214839958|NCT00386646|DRUG|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
214839959|NCT02169336|DRUG|Intranasal Dexmedetomidine|
214839960|NCT02169336|OTHER|Intranasal Placebo|
214839961|NCT01148225|DRUG|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
214839962|NCT02910687|OTHER|This is an observational study|
214839963|NCT06396507|DRUG|Permethrin Solution|permethrin 5 % solution
214839964|NCT06396507|DRUG|Sulfur|Sulfur 10%+ vaseline 90 % ointment
214839965|NCT06857045|DEVICE|NOVA intracranial sirolimus-eluting stent system|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon.
214839966|NCT00393705|DRUG|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
214839967|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
214839968|NCT00393705|DRUG|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
214839969|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
214839970|NCT00016653|DRUG|Creatine Monohydrate|
214839971|NCT00016653|DRUG|Glutamine|
214839972|NCT02391233|BEHAVIORAL|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
214839973|NCT02391233|BEHAVIORAL|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
214839974|NCT03473002|OTHER|Placebo|0.9% Sodium Chloride
214839975|NCT03473002|BIOLOGICAL|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
214839976|NCT04734704|PROCEDURE|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
214839977|NCT04734704|PROCEDURE|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
214839978|NCT05702905|DRUG|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
214839979|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
214839980|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
214839981|NCT05702905|BEHAVIORAL|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
214839982|NCT05702905|BEHAVIORAL|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
214839983|NCT00168558|BIOLOGICAL|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
214839984|NCT00327587|DRUG|Valsartan + amlodipine|
214839985|NCT00327587|DRUG|Valsartan + HCTZ|
214839986|NCT00327587|DRUG|Amlodipine + HCTZ|
214839987|NCT00327587|DRUG|Valsartan + amlodipine + HCTZ|
214839988|NCT01906190|BIOLOGICAL|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
214839989|NCT01240850|DRUG|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
214839990|NCT01240850|DRUG|Prednisone|
214839991|NCT03668457|BEHAVIORAL|Intervention to Patients|"Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app."
214839992|NCT03668457|BEHAVIORAL|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
214839993|NCT03668457|OTHER|Control|Other: Usual care Usual care for depressive disorder received in mental health units
214839994|NCT05348928|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
214839995|NCT05348928|OTHER|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
214839996|NCT02174185|BEHAVIORAL|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
214839997|NCT02208336|OTHER|medical chart review|Ancillary studies
214839998|NCT01898845|DRUG|LEE011|
214839999|NCT02490800|DRUG|Lisavanbulin Phase 1 dose escalation portion|Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
214840000|NCT02490800|DRUG|Lisavanbulin Phase 2a expansion portion|Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
214840001|NCT03724682|DEVICE|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
214840002|NCT01652586|DRUG|dexmedetomidine-remifentanil|
214840003|NCT01652586|DRUG|midazolam-remifentanil|
214840004|NCT03365791|BIOLOGICAL|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
214840005|NCT03365791|BIOLOGICAL|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
214840006|NCT05405049|DRUG|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
214840007|NCT05405049|DRUG|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
214840008|NCT03693950|BIOLOGICAL|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
214840009|NCT03693950|BIOLOGICAL|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
214840010|NCT01475487|PROCEDURE|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
214840011|NCT01978691|DIETARY_SUPPLEMENT|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
214840012|NCT01978691|DIETARY_SUPPLEMENT|Polydextrose|Studied as a prebiotic
214840013|NCT01978691|OTHER|Placebo|Control
214840014|NCT00468338|DEVICE|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
214840015|NCT03785691|DRUG|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
214840016|NCT03785691|DRUG|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
214840017|NCT03785691|DRUG|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
214840018|NCT05189691|BEHAVIORAL|walking exercise|Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
214840019|NCT01920750|BIOLOGICAL|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
214840020|NCT01920750|BIOLOGICAL|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
214840021|NCT01920750|OTHER|Mock Antigen|Physiological saline
214840022|NCT05820919|BEHAVIORAL|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
214840023|NCT05820919|OTHER|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
214840024|NCT05909969|OTHER|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
214840025|NCT05909969|OTHER|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
214840026|NCT03176433|DEVICE|Normothermic Machine Liver Perfusion|Liver Preservation Method
214840027|NCT02578277|DRUG|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
214840028|NCT02578277|DRUG|BMS-955176|BMS-955176
214840029|NCT02578277|DRUG|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
214840030|NCT01344031|DRUG|Akt Inhibitor MK2206|Given PO
214840031|NCT01344031|DRUG|Anastrozole|Given PO
214840032|NCT01344031|DRUG|Fulvestrant|Given IM
214840033|NCT01344031|OTHER|Laboratory Biomarker Analysis|Correlative studies
214840034|NCT03203642|DRUG|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
214840035|NCT03203642|DRUG|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
214840036|NCT02042599|DRUG|Sedation with sevoflurane during 48-hr in ICU|
214840037|NCT01129323|DRUG|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
214840038|NCT03774199|DEVICE|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
214840039|NCT05089890|DEVICE|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
214840040|NCT05089890|DEVICE|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
214840041|NCT05089890|DEVICE|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
214840042|NCT06105450|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
214840043|NCT00265681|BEHAVIORAL|Phone counseling and written materials|
214840044|NCT03169816|DRUG|Lorcaserin|Lorcaserin 10mg, twice daily
214840045|NCT03169816|DRUG|Placebo|Matched placebo for lorcaserin condition dosed twice daily
214840046|NCT03380195|OTHER|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
214840047|NCT03380195|OTHER|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
214840048|NCT03380195|OTHER|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
214840049|NCT03380195|OTHER|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
214840050|NCT06529874|OTHER|Pressure pain tolerance measurement using Digital Pressure Algometer|Pressure pain tolerance will be measured using pressure algometer for all participants in both groups. Pressure pain tolerance will be measured in a relaxed sitting position to evaluate on quadriceps muscle. Initially, a teddy bear will be used for demonstration.
214840051|NCT06529874|OTHER|Balance assessment using HUMAC balance system|"HUMAC balance system will be calibrated, then will conduct~1. center of pressure: will instructed child to stand on platform, and maintain own body stability, and focus on the red dot in the center of screen that will move in response to body sway. after a rest, second trial will be done.~2. Eye open/ closed firm surface tests: First for Eye open firm surface test; the child will be asked to look at a target on the wall that was set at his/ her eye level, and to stare at this target for 30 seconds while standing on firm surface. After 5 seconds rest. Eye closed firm surface test; child will be asked to close his/ her eyes for 30 seconds, and conducting the same procedures for balance testing.~The researcher will documented the values resented on the screen ."
214840052|NCT06529874|OTHER|Lower limb muscular strength using Lafayette hand held dynamometer|Lower limb muscular ' Isometric quadriceps strength' will be measured for all participants in both groups. each participating child will be instructed to sit to assess the strength of knee extension, which minimize positional changes, and enhance feasibility of this clinical test. then The researcher will apply resistance to child's quadriceps to gain maximal voluntary isometric contraction with pressing the activated Lafayette hand held dynamometer padded stirrup against quadriceps belly, then recorded and documented measured value.
214840053|NCT05645224|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
214840054|NCT03388008|DRUG|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
214840055|NCT03388008|DRUG|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
214840056|NCT03388008|DRUG|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
214840057|NCT03388008|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
214840058|NCT03388008|DRUG|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
214840059|NCT03388008|DRUG|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
214840060|NCT00327691|DRUG|Atorvastatin|
214840061|NCT00003751|DRUG|penicillamine|
214840062|NCT00003751|RADIATION|radiation therapy|
214840063|NCT04323722|PROCEDURE|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
214840064|NCT03915561|DRUG|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
214840065|NCT03915561|DRUG|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
214840066|NCT06081140|DIETARY_SUPPLEMENT|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
214840067|NCT02710240|DRUG|Indocyanine Green (ICG)|
214840068|NCT02710240|RADIATION|Intraoperative near-infrared (NIR)|
214840069|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
214840070|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
214840071|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
214840072|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
214840073|NCT02320162|BEHAVIORAL|Experiential learning oral health education|
214840074|NCT02371096|DRUG|MabThera (rituximab)|
214840075|NCT02371096|DRUG|RGB-03|
214840076|NCT00000243|DRUG|Buprenorphine|
214840077|NCT02651064|OTHER|HIP|
214840078|NCT05626387|DRUG|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
214840079|NCT05626387|DRUG|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
214840080|NCT00004490|DRUG|sodium dichloroacetate|
214840081|NCT00559637|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
214840082|NCT00029211|DRUG|Echinacea|
214840083|NCT04684511|DRUG|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
214840084|NCT04684511|DRUG|Placebo|Matching Placebo
214840085|NCT01104571|BIOLOGICAL|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery
214840086|NCT01104571|DRUG|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
214840087|NCT01104571|OTHER|laboratory biomarker analysis|
214840088|NCT01104571|PROCEDURE|adjuvant therapy|
214840089|NCT01104571|PROCEDURE|neoadjuvant therapy|
214840090|NCT01104571|PROCEDURE|therapeutic conventional surgery|therapeutic conventional surgery
214840091|NCT01947309|DRUG|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
214840092|NCT03876028|BIOLOGICAL|Tisagenlecleucel|Infusion
214840093|NCT03876028|DRUG|Ibrutinib|Oral (tablets or capsules)
214840094|NCT02832167|BIOLOGICAL|Nivolumab|Specified dose on specified days
214840095|NCT00806962|DRUG|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
214840096|NCT00806962|DEVICE|placebo|intranasal, puff of air, 2 doses, 21 days apart
214840097|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
214840098|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
214840099|NCT00950716|BEHAVIORAL|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
214840100|NCT00950716|BEHAVIORAL|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
214840101|NCT01093196|DRUG|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
214840102|NCT01093196|DRUG|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
214840103|NCT01093196|DRUG|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
214840104|NCT05632796|PROCEDURE|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
214840105|NCT00968019|DEVICE|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
214840106|NCT03801317|DIETARY_SUPPLEMENT|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
214840107|NCT03801317|DIETARY_SUPPLEMENT|Control|15 grams corn-soya blend
214840108|NCT03801317|DIETARY_SUPPLEMENT|multiple micronutrient|multiple micronutrient sprinkle powder
214840109|NCT01124435|DRUG|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
214840110|NCT04687241|DRUG|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
214840111|NCT04687241|DRUG|Placebo Almonertinib|Placebo Almonertinib
214840112|NCT01109576|BEHAVIORAL|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
214840113|NCT01958060|DRUG|BI 1034020|intravenous part
214840114|NCT01958060|DRUG|Placebo to BI 1034020|intravenous part
214840115|NCT03902301|DIETARY_SUPPLEMENT|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
214840116|NCT03902301|DIETARY_SUPPLEMENT|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
214840117|NCT05058768|DIAGNOSTIC_TEST|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
214840118|NCT02770144|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
214840119|NCT02770144|BEHAVIORAL|Access to Referral to Social Services|
214840120|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
214840121|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
214840122|NCT04251858|PROCEDURE|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
214840123|NCT04251858|OTHER|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
214840124|NCT04021758|BEHAVIORAL|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
214840125|NCT05671952|OTHER|Application of integrated intervention system programs|Application of integrated intervention system programs
214840126|NCT04028856|DRUG|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
214840127|NCT00692315|DRUG|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
214840128|NCT00435305|DRUG|Meropenem|
214840129|NCT00435305|DRUG|Vancomycin|
214840130|NCT00435305|DRUG|Linezolid|
214840131|NCT00435305|DRUG|Piperacillin/Tazobactam|
214840132|NCT00435305|DRUG|Cefepim|
214840133|NCT00435305|DRUG|Ceftazidim|
214840134|NCT01550367|DRUG|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
214840135|NCT01550367|DRUG|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
214840136|NCT01597453|BEHAVIORAL|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
214840137|NCT04522804|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
214840138|NCT00105495|DRUG|Ferriprox (deferiprone)|
214840139|NCT00105495|DRUG|Desferal (deferoxamine)|
214840140|NCT00282581|BIOLOGICAL|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
214840141|NCT00269334|DRUG|Using Citalopram(drug) or Paroxetine(drug)|
214840142|NCT03230734|DRUG|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
214840143|NCT03230734|DRUG|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
214840144|NCT05381896|OTHER|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
214840145|NCT05381896|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
214840146|NCT05119660|DEVICE|Intermittent Theta Burst Stimulation|iTBS
214840147|NCT02293460|DRUG|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
214840148|NCT06199960|OTHER|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
214840149|NCT02991560|OTHER|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
214840150|NCT02991560|OTHER|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
214840151|NCT02991560|DEVICE|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
214840152|NCT02991560|DEVICE|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
214840153|NCT02361814|PROCEDURE|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
214840154|NCT00198224|PROCEDURE|phlebotomy|
214840155|NCT02992613|PROCEDURE|total knee arthroplasty with ultra-congruent (UC) insert|
214840156|NCT02992613|PROCEDURE|total knee arthroplasty with posterior-stabilized (PS) insert|
214840157|NCT00792441|DEVICE|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
214840158|NCT03540849|DRUG|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
214840159|NCT06535035|DEVICE|laser therapy After implant surgery, laser therapy (LLLT) was applied|After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
214840160|NCT06535035|DEVICE|SHAM|After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
214840161|NCT03620617|DIETARY_SUPPLEMENT|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
214840162|NCT03842852|PROCEDURE|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
214840163|NCT05610449|DIAGNOSTIC_TEST|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
214840164|NCT05054049|DEVICE|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
214840165|NCT05054049|OTHER|Usual care|Usual care provided to patient without use of point of care testing device
214840166|NCT06433206|OTHER|no intervention|no intervention
214840167|NCT04554706|BEHAVIORAL|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
214840168|NCT00139906|DRUG|Bifeprunox|
214840169|NCT02993705|DRUG|Trabectedin|Chemotherapy drug
214840170|NCT05290337|DRUG|zanubrutinib|BTK inhibitor
214840171|NCT03023709|BIOLOGICAL|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
214840172|NCT03023709|BIOLOGICAL|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
214840173|NCT04284553|OTHER|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
214840174|NCT04284553|OTHER|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
214840175|NCT04284553|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
214840176|NCT04284553|OTHER|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
214840177|NCT04284553|OTHER|Simplified|The alert language itself will be simplified.
214840178|NCT04284553|OTHER|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
214840179|NCT04284553|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
214840180|NCT04284553|OTHER|Different Risks|Risks of the high-risk medications will be framed differently.
214840181|NCT04284553|OTHER|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
214840182|NCT04284553|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
214840183|NCT06157853|PROCEDURE|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
214840184|NCT06157853|OTHER|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
214840185|NCT06157853|OTHER|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
214840186|NCT06157853|OTHER|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
214840187|NCT03703453|DEVICE|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
214840188|NCT04148105|DRUG|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
214840189|NCT04148105|OTHER|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
214840190|NCT05911087|BIOLOGICAL|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
214840191|NCT05911087|BIOLOGICAL|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
214840192|NCT05911087|BIOLOGICAL|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
214840193|NCT05911087|BIOLOGICAL|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
214840194|NCT04826289|RADIATION|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
214840195|NCT06679491|OTHER|Resistance periodized training program (N-PF)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the follicular phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated based on the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are performed at a higher training load during both early and late follicular phases. The increased intensity leverages higher estrogen levels, which may support greater muscle strength and recovery during this phase.~Luteal Phase (Days 15-28): Training sessions are conducted at a lower training load during both early and late luteal phases to accommodate the hormonal shifts associated with elevated progesterone."
214840196|NCT06679491|OTHER|Resistance peioridized training program (N-PL)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the luteal phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated according to the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are conducted at a lower training load during both early and late follicular phases to accommodate the hormonal environment of this phase.~Luteal Phase (Days 15-28): Training sessions are performed at a higher training load during both early and late luteal phases. The increased intensity leverages the hormonal environment associated with elevated progesterone, which may affect muscle endurance and neuromuscular adaptations during this phase."
214840197|NCT06679491|OTHER|Continuous resistance training program (C)|"This intervention consists of a 13-week structured resistance training program with a continuous training intensity maintained throughout the menstrual cycle. Participants perform two resistance training sessions per week, each lasting 90 minutes, with a consistent training load applied across all phases.~Intensity Modulation:~All Phases: Training sessions are conducted at a steady training load regardless of menstrual phase. This continuous approach is designed to provide a baseline for assessing neuromuscular adaptations without the influence of phase-specific intensity adjustments."
214840198|NCT00699244|PROCEDURE|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
214840199|NCT00699244|PROCEDURE|Central placement of local anesthesia|Central placement of local anesthesia
214840200|NCT00095862|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|
214840201|NCT00095862|BIOLOGICAL|recombinant interferon alfa|
214840202|NCT00095862|DRUG|cyclophosphamide|
214840203|NCT03028064|OTHER|blood taking|in this cohort study, we will take blood to examine the platelet function
214840204|NCT00354562|DRUG|ABT-751|200mg ABT-751 daily for 14 days every 21 days
214840205|NCT00354562|DRUG|Placebo|Placebo daily for 14 days every 21 days
214840206|NCT00354562|DRUG|Docetaxel|Standard Docetaxel every 21 days
214840207|NCT01785394|DRUG|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
214840208|NCT04139460|DEVICE|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
214840209|NCT04139460|DEVICE|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
214840210|NCT04299776|DEVICE|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
214840211|NCT04299776|DEVICE|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
214840212|NCT04124250|OTHER|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
214840213|NCT05140668|DEVICE|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
214840214|NCT06036550|DIAGNOSTIC_TEST|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
214840215|NCT00001108|DRUG|Ritonavir|
214840216|NCT00001108|DRUG|Nelfinavir mesylate|
214840217|NCT00001108|DRUG|Saquinavir|
214840218|NCT00001108|DRUG|Nevirapine|
214840219|NCT00001108|DRUG|Lamivudine|
214840220|NCT00001108|DRUG|Stavudine|
214840221|NCT00001108|DRUG|Didanosine|
214840222|NCT03651908|PROCEDURE|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
214840223|NCT00223938|DRUG|Oral Iron|Oral Iron
214840224|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 1
214840225|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 2
214840226|NCT01873339|DRUG|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
214840227|NCT01873339|DRUG|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
214840228|NCT01204125|DRUG|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214840229|NCT01204125|DRUG|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
214840230|NCT00973934|DEVICE|Magstim Theta|
214840231|NCT00973934|DEVICE|Thymatron System IV|
214840232|NCT01110317|DRUG|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
214840233|NCT00731224|DRUG|Rivastigmine transdermal patch|
214840234|NCT02781935|PROCEDURE|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
214840235|NCT04702035|DEVICE|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
214840236|NCT01940302|DIETARY_SUPPLEMENT|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
214840237|NCT00006102|DRUG|becatecarin|
214840238|NCT00772616|DRUG|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
214840239|NCT00772616|DRUG|Sufentanil|dosage according to usual criteria
214840240|NCT00757679|DRUG|Milnacipran|capsules
214840241|NCT00757679|DRUG|Placebo|capsules
214840242|NCT04890964|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
214840243|NCT00136890|PROCEDURE|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
214840244|NCT00224484|BIOLOGICAL|GSK208141|3 intramuscular doses
214840245|NCT00224484|BIOLOGICAL|Havrix (investigational formulation)|3 intramuscular doses
214840246|NCT00224484|BIOLOGICAL|Placebo|3 intramuscular doses
214840247|NCT00673764|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
214840248|NCT00673764|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
214840249|NCT01074008|DRUG|ABT-450|50 mg capsules co-administered with ritonavir
214840250|NCT01074008|DRUG|ABT-072|50 mg tablet
214840251|NCT01074008|DRUG|ABT-333|400 mg tablet
214840252|NCT01074008|DRUG|Ritonavir|100 mg capsules co-administered with ABT-450
214840253|NCT01074008|DRUG|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
214840254|NCT01074008|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
214840255|NCT01074008|OTHER|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
214840256|NCT05696509|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
214840257|NCT05696509|DRUG|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
214840258|NCT05696509|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
214840259|NCT06617507|OTHER|Group 1|The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
214840260|NCT01121107|DEVICE|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
214840261|NCT01121107|DEVICE|Patient Advisory Module|Handheld device that provides medication reminders
214840262|NCT02805309|BEHAVIORAL|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
214840263|NCT02805309|BEHAVIORAL|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
214840264|NCT02805309|BEHAVIORAL|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
214840265|NCT02166853|DRUG|sevoflurane|Sedation with inhaled sevoflurane
214840266|NCT02166853|DRUG|midazolam|Sedation with intravenous midazolam
214840267|NCT00603564|PROCEDURE|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
214840268|NCT05080608|OTHER|Surgery|Treatment according to clinical practise
214840269|NCT04489303|BEHAVIORAL|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
214840270|NCT04489303|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
214840271|NCT02106533|OTHER|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
214840272|NCT04683588|OTHER|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
214840273|NCT02629588|BEHAVIORAL|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
214840274|NCT04253015|OTHER|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
214840275|NCT03263078|DRUG|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
214840276|NCT03263078|DRUG|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
214840277|NCT05372497|OTHER|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~* Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~* Right / Left Discrimination Training~* Localization Training Level 1- Level 2 Training~* Visual imagination Training~* Visual Imagery Training~* Mirror Therapy~* Isometric and functional exercises"
214840278|NCT05372497|OTHER|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~* Electrotherapy~* Scapular mobilization~* Passive stretches~* Stick Exercises~* Pendulum Exercises~* Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
214840279|NCT01828645|DIETARY_SUPPLEMENT|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
214840280|NCT04649697|DRUG|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
214840281|NCT04649697|DRUG|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
214840282|NCT04649697|DRUG|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
214840283|NCT01350934|DRUG|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
214840284|NCT01350934|DRUG|Calcitriol|0.25 μg once daily orally
214840285|NCT01350934|DIETARY_SUPPLEMENT|Calcium 500 mg|one 500 mg tablet once daily
214840286|NCT04372134|DEVICE|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
214840287|NCT01196117|DEVICE|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
214840288|NCT01196117|DEVICE|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
214840289|NCT03547635|OTHER|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
214840290|NCT03547635|DEVICE|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
214840291|NCT03547635|OTHER|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate"
214840292|NCT05527158|BEHAVIORAL|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
214840293|NCT00078741|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214840294|NCT06469619|BEHAVIORAL|Music listening|Listening to music of one's choice one hour daily.
214840295|NCT03297619|BEHAVIORAL|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
214840296|NCT03297619|BEHAVIORAL|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
214840297|NCT02688296|DEVICE|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
214840298|NCT03239496|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
214840299|NCT03239496|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
214840300|NCT03028896|PROCEDURE|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
214840301|NCT03798379|OTHER|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
214840302|NCT04083352|DIETARY_SUPPLEMENT|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
214840303|NCT04083352|DIETARY_SUPPLEMENT|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
214840304|NCT05507996|DRUG|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
214840305|NCT00275275|DRUG|Requip PR|Requip 24-Hour once a day for one month
214840306|NCT00275275|DRUG|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
214840307|NCT03492970|BIOLOGICAL|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
214840308|NCT02415387|BIOLOGICAL|typhoid vaccine|Given IM
214840309|NCT02415387|OTHER|Placebo|Given IM
214840310|NCT06276699|PROCEDURE|1.Isometric exercise 2.combined conservative treatment|Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
214840311|NCT04619199|DIAGNOSTIC_TEST|Blood sample|Blood sample performed at the inclusion and during the follow-up.
214840312|NCT04760587|BEHAVIORAL|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
214840313|NCT06531642|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
214840314|NCT06531642|DRUG|Protonix (pantoprazole) 40 mg q 24 hrs for 2 days|Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
214840315|NCT00319787|DRUG|Iressa|
214840316|NCT05251506|DEVICE|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
214840317|NCT02339415|DRUG|Edoxaban 30mg daily|
214840318|NCT02339415|DRUG|Matching placebo|
214840319|NCT05246787|BEHAVIORAL|breastfeeding|nonphamacological methods
214840320|NCT05246787|COMBINATION_PRODUCT|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
214840321|NCT05246787|DEVICE|shotblocker|it is a small plastic tool
214840322|NCT03701711|DRUG|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
214840323|NCT00063830|DRUG|Alicaforsen|
214840324|NCT01085448|OTHER|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
214840325|NCT03577886|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
214840326|NCT03577886|DRUG|Placebo|Phosphate Buffer Diluent oral solution
214840327|NCT01263886|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
214840328|NCT01263886|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
214840329|NCT05751876|DRUG|Dienogest|Dienogest 2mg was prescribed once per day orally
214840330|NCT05982184|OTHER|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
214840331|NCT00468871|DRUG|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
214840332|NCT00468871|DRUG|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
214840333|NCT04747795|DRUG|Vitamin C|IV
214840334|NCT04747795|DRUG|Normal saline|IV
214840335|NCT00501332|BIOLOGICAL|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
214840336|NCT00277043|DRUG|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
214840337|NCT00277043|DRUG|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
214840338|NCT04674150|DEVICE|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
214840339|NCT04674150|DEVICE|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
214840340|NCT00003404|RADIATION|Adjuvant Radiotherapy|Adjuvant radiation therapy
214840341|NCT06378567|DIETARY_SUPPLEMENT|Dietary supplement liquid shot beverage products|Participants will use their product as instructed for 3 of the 4 study weeks
214840342|NCT06137404|OTHER|Splint|Comparison of splints for trigger finger
214840343|NCT05695651|DIAGNOSTIC_TEST|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
214840344|NCT00676650|DRUG|Prednisone|5 mg BID, oral
214840345|NCT00676650|DRUG|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
214840346|NCT00676650|DRUG|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
214840347|NCT00676650|DRUG|Prednisone|5 mg BID, oral
214840348|NCT00774241|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
214840349|NCT00774241|DRUG|docetaxel|75mg/m2 every 3 weeks for 18 weeks
214840350|NCT02059811|OTHER|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
214840351|NCT02059811|OTHER|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
214840352|NCT00560924|DRUG|estradiol, 25 mcg|
214840353|NCT00442650|DRUG|Efalizumab|
214840354|NCT01681862|BEHAVIORAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
214840355|NCT03465150|OTHER|acne|Patient with acne
214840356|NCT03756337|DEVICE|Neuro 1 & Neuro 2|participant common fitting map used for tests
214840357|NCT03756337|DEVICE|Neuro 2 & Neuro 1|participant common fitting map used for tests
214840358|NCT05376137|DEVICE|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
214840359|NCT04310254|PROCEDURE|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
214840360|NCT04310254|PROCEDURE|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
214840361|NCT04310254|PROCEDURE|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
214840362|NCT02656251|DRUG|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
214840363|NCT02656251|DRUG|placebo|Use of placebo every 12 hours for 04 days
214840364|NCT02656251|DRUG|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
214840365|NCT01099306|OTHER|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
214840366|NCT00506116|BEHAVIORAL|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
214840367|NCT00506116|BEHAVIORAL|PME practice and record keeping (in diaries)|
214840368|NCT00506116|BEHAVIORAL|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
214840369|NCT00506116|PROCEDURE|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
214840370|NCT06176560|DRUG|Mesalazine|Oral Formulation
214840371|NCT00683592|DRUG|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
214840372|NCT00683592|DRUG|placebo|placebo
214840373|NCT04515420|DRUG|noradrenaline|noradrenaline infusion
214840374|NCT05732181|DRUG|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
214840375|NCT05732181|DRUG|Placebo|patch without drugs
214840376|NCT03504124|OTHER|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
214840377|NCT00344214|BEHAVIORAL|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
214840378|NCT00344214|BEHAVIORAL|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
214840379|NCT04834895|OTHER|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
214840380|NCT04834895|OTHER|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
214840381|NCT01616121|OTHER|Usual treatment of patients with developing acute heart failure|
214840382|NCT01616121|DEVICE|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
214840383|NCT05511441|PROCEDURE|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
214840384|NCT00128141|BEHAVIORAL|Tactile stimulus|four times a day
214840385|NCT00235417|PROCEDURE|Bone marrow transplantation|
214840386|NCT05908617|OTHER|Video Discharge|Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
214840387|NCT02497079|DEVICE|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
214840388|NCT02497079|DEVICE|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
214840389|NCT02497079|DEVICE|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
214840390|NCT02262741|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
214840391|NCT02262741|BIOLOGICAL|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
214840392|NCT04815109|OTHER|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
214840393|NCT04491916|DRUG|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
214840394|NCT01230645|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
214840395|NCT01230645|DRUG|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
214840396|NCT02565017|BEHAVIORAL|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
214840397|NCT05771935|PROCEDURE|ultrasound guided radial versus ulnar artery cannulation|"Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study."
214840398|NCT04204226|BEHAVIORAL|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
214840399|NCT04204226|BEHAVIORAL|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
214840400|NCT04204226|BEHAVIORAL|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
214840401|NCT04204226|BEHAVIORAL|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
214840402|NCT02083172|DEVICE|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
214840403|NCT03638596|BEHAVIORAL|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
214840404|NCT03638596|BEHAVIORAL|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
214840405|NCT04759079|DEVICE|Acupuncture Needles|Acupuncture Needles placement at the PC6 in association to anti-emetic medication
214840406|NCT04759079|DRUG|Antiemetic Drug|Administration of Anti-emetic medication without acupuncture
214840407|NCT00093730|DRUG|BMS-59926|
214840408|NCT02340689|OTHER|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
214840409|NCT03655275|BIOLOGICAL|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
214840410|NCT03655275|BIOLOGICAL|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
214840411|NCT03653026|DRUG|Placebo|Tablet for oral administration
214840412|NCT03653026|DRUG|Upadacitinib|Tablet for oral administration
214840413|NCT06480500|DRUG|Ketamine hydrochloride|55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
214840414|NCT06480500|BEHAVIORAL|i-CBT (Internet-based Cognitive Behavioural Therapy)|Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
214840415|NCT06480500|DRUG|Midazolam Hydrochloride|55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
214840416|NCT06133218|OTHER|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
214840417|NCT00356824|DRUG|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
214840418|NCT00356824|DRUG|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
214840419|NCT03968731|OTHER|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
214840420|NCT00003467|DRUG|carmustine|
214840421|NCT00003467|DRUG|polifeprosan 20 with carmustine implant|
214840422|NCT00003467|PROCEDURE|surgical procedure|
214840423|NCT05176379|DRUG|Fluconazole 150 mg|A single acute 150 mg dose
214840424|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
214840425|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
214840426|NCT03258879|PROCEDURE|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
214840427|NCT03258879|PROCEDURE|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
214840428|NCT01219452|BIOLOGICAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
214840429|NCT02644161|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
214840430|NCT02644161|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
214840431|NCT02644161|DRUG|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
214840432|NCT02644161|OTHER|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
214840433|NCT02644161|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
214840434|NCT05583110|DRUG|Tucatinib|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
214840435|NCT05583110|DRUG|Trastuzumab|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
214840436|NCT05583110|DRUG|Vinorelbine|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
214840437|NCT01201759|DRUG|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
214840438|NCT01201759|DRUG|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
214840439|NCT00491907|DRUG|folic acid 5mg/day|
214840440|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
214840441|NCT03329924|OTHER|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
214840442|NCT05120817|BEHAVIORAL|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
214840443|NCT05120817|BEHAVIORAL|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
214840444|NCT05120817|BEHAVIORAL|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
214840445|NCT03483311|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
214840446|NCT05208229|DIAGNOSTIC_TEST|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
214840447|NCT04269993|DRUG|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis was administered to participants (placebo and medium THC/medium CBD).
214840448|NCT03287687|DRUG|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
214840449|NCT03287687|DRUG|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
214840450|NCT04384341|RADIATION|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
214840451|NCT04384341|BIOLOGICAL|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
214840452|NCT00115869|BEHAVIORAL|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
214840453|NCT05393323|OTHER|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
214840454|NCT05393323|OTHER|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
214840455|NCT02568280|DRUG|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
214840456|NCT02568280|DRUG|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
214840457|NCT05509088|DEVICE|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
214840458|NCT03658434|RADIATION|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
214840459|NCT01015963|OTHER|laboratory biomarker analysis|Perform DNA sample analysis
214840460|NCT04013763|OTHER|wheat containing skin care products|stop or continue using wheat containing skin care products
214840461|NCT01887795|DRUG|Erlotinib|
214840462|NCT01887795|DRUG|WBRT|
214840463|NCT00147914|DRUG|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
214840464|NCT00147914|DRUG|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
214840465|NCT04967950|DRUG|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
214840466|NCT04967950|DRUG|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
214840467|NCT04967950|DRUG|Methotrexate|methotrexate
214840468|NCT03748095|DRUG|pipéracilline/tazobactam|There is not intervention description
214840469|NCT05863221|DRUG|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
214840470|NCT02745600|DEVICE|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
214840471|NCT01947738|DRUG|VBY-891|Cathepsin S inhibitor
214840472|NCT01947738|DRUG|Placebo|
214840473|NCT03506087|BEHAVIORAL|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
214840474|NCT03506087|BEHAVIORAL|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
214840475|NCT03474393|OTHER|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
214840476|NCT00011609|DEVICE|Robotic Arm|
214840477|NCT02011451|DRUG|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
214840478|NCT02011451|DRUG|Placebo Comparator:|
214840479|NCT03136562|DIAGNOSTIC_TEST|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
214840480|NCT06317584|OTHER|Experimental: Empowerment Application for CAM Health Education|Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
214840481|NCT06317584|OTHER|Written Paper for CAM Health Education|Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
214840482|NCT06223490|PROCEDURE|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
214840483|NCT03428542|BEHAVIORAL|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
214840484|NCT03428542|BEHAVIORAL|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
214840485|NCT06377007|DEVICE|IOLMaster 700 (Carl Zeiss Meditec AG)|Subjects will undergo measurements with the IOLMaster 700 device.
214840486|NCT06377007|DEVICE|Argos (Alcon Laboratories, Inc.)|Subjects will undergo measurements with the Argos device.
214840487|NCT01292668|DRUG|methyl-5-aminolevulinate hydrochloride cream|Applied topically
214840488|NCT01292668|DRUG|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
214840489|NCT01292668|PROCEDURE|laser therapy|Undergo laser light photodynamic therapy
214840490|NCT05103644|DRUG|Atorvastatin 80mg|patients received statin experimental group
214840491|NCT05103644|OTHER|placebo|patients received placebo control group
214840492|NCT02005276|BEHAVIORAL|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
214840493|NCT02005276|BEHAVIORAL|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
214840494|NCT02005276|BEHAVIORAL|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
214840495|NCT01963260|DRUG|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
214840496|NCT01963260|DRUG|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
214840497|NCT04994431|DRUG|Tamsulosin Hydrochloride|0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
214840498|NCT03672240|DRUG|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
214840499|NCT04654039|OTHER|Other: Non intervention|Non intervention
214840500|NCT06678763|PROCEDURE|CRS-HIPEC|Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
214840501|NCT04554186|PROCEDURE|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
214840502|NCT04554186|PROCEDURE|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
214840503|NCT04554186|PROCEDURE|Control|Place a fentanyl patch 50 microgram
214840504|NCT02660541|DEVICE|Betafoam|Comparison between 2 medical devices
214840505|NCT02660541|DEVICE|Allevyn Silver Dressing|Comparison between 2 medical devices
214840506|NCT05685550|DRUG|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
214840507|NCT00681018|OTHER|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
214840508|NCT00681018|OTHER|Powder human milk fortifier|Powder human milk fortifier added to human milk
214840509|NCT03644043|DEVICE|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
214840510|NCT00722436|DRUG|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
214840511|NCT00722436|DRUG|saline|Placebo
214840512|NCT01067521|DRUG|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
214840513|NCT01067521|DRUG|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
214840514|NCT04011787|DIETARY_SUPPLEMENT|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
214840515|NCT04011787|DIETARY_SUPPLEMENT|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
214840516|NCT04011787|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
214840517|NCT04011787|DIAGNOSTIC_TEST|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
214840518|NCT04011787|RADIATION|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
214840519|NCT02118987|DRUG|Omalizumab|
214840520|NCT02169752|DRUG|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
214840521|NCT05659680|DEVICE|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
214840522|NCT00055809|BIOLOGICAL|PEG-interferon alfa-2b|Given SC
214840523|NCT00055809|BIOLOGICAL|bevacizumab|Given IV
214840524|NCT00055809|OTHER|laboratory biomarker analysis|Optional correlative studies
214840525|NCT03784274|BEHAVIORAL|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
214840526|NCT03508154|OTHER|Control Meal 1|carbohydrate test meal
214840527|NCT03508154|OTHER|Control Meal 2|carbohydrate test meal
214840528|NCT03508154|OTHER|Experimental Nutritional Product|ready to drink nutritional formulation
214840529|NCT00024154|BIOLOGICAL|trastuzumab|Given IV
214840530|NCT00024154|DRUG|gefitinib|Given orally
214840531|NCT00024154|OTHER|laboratory biomarker analysis|Correlative studies
214840532|NCT04442854|OTHER|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
214840533|NCT04986254|OTHER|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
214840534|NCT04986254|OTHER|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
214840535|NCT04986254|OTHER|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
214840536|NCT04986254|DRUG|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
214840537|NCT05150405|DRUG|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
214840538|NCT00818298|DRUG|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
214840539|NCT05805527|DIAGNOSTIC_TEST|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
214840540|NCT04181398|DIAGNOSTIC_TEST|Anthropometry|"* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference."
214840541|NCT04181398|DIAGNOSTIC_TEST|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
214840542|NCT04181398|DIAGNOSTIC_TEST|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
214840543|NCT04181398|OTHER|Questionnaire|General questionnaire on cardiovascular risk factors
214840544|NCT04181398|DIAGNOSTIC_TEST|Blood sample|Blood sample for hs-CRP
214840545|NCT04009876|DRUG|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
214840546|NCT04009876|PROCEDURE|Surgical resection|Surgical resection of the tumour
214840547|NCT04009876|OTHER|Watch-and-wait|No surgery approach
214840548|NCT04009876|DRUG|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
214840549|NCT04009876|DRUG|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
214840550|NCT03993080|DEVICE|Virtual reality relaxation|1-3.5 minute 360° videos
214840551|NCT04450693|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
214840552|NCT04450693|OTHER|Standard care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
214840553|NCT00225329|PROCEDURE|Labour assessment and support|
214840554|NCT00452543|DRUG|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
214840555|NCT00452543|DRUG|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
214840556|NCT00452543|BEHAVIORAL|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
214840557|NCT00452543|DRUG|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
214840558|NCT03419962|DRUG|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
214840559|NCT02519543|DRUG|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
214840560|NCT02519543|DRUG|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
214840561|NCT05917262|BEHAVIORAL|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
214840562|NCT05917262|BEHAVIORAL|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
214840563|NCT05917262|BEHAVIORAL|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
214840564|NCT05561257|DRUG|Vitamin C|Vitamin C
214840565|NCT03043040|BEHAVIORAL|Telephone follow up|Already described in previous page
214840566|NCT03043040|BEHAVIORAL|Treatment as usual|Already described in previous page
214840567|NCT02914457|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
214840568|NCT03890757|OTHER|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
214840569|NCT05892731|OTHER|with depression|age-related hearing loss with depression
214840570|NCT05892731|OTHER|without depression|age-related hearing loss without depression
214840571|NCT00248092|DRUG|NRP104|
214840572|NCT00841620|PROCEDURE|Haemorrhoidectomy a.m. Milligan|Surgery
214840573|NCT00841620|PROCEDURE|Stapled anopexy|Surgery
214840574|NCT01769222|BIOLOGICAL|Ipilimumab|Given intratumorally
214840575|NCT01769222|RADIATION|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
214840576|NCT01098539|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
214840577|NCT01098539|DRUG|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
214840578|NCT04677686|BEHAVIORAL|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
214840579|NCT06172439|OTHER|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
214840580|NCT03024801|DRUG|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
214840581|NCT03024801|DRUG|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
214840582|NCT02451644|DEVICE|pedometer|patient will cary pedometer
214840583|NCT04136067|DRUG|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
214840584|NCT04136067|DRUG|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
214840585|NCT03058640|OTHER|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
214840586|NCT03605992|OTHER|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
214840587|NCT03605992|OTHER|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
214840588|NCT01849458|DEVICE|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
214840589|NCT00058435|BIOLOGICAL|abagovomab|
214840590|NCT05714241|OTHER|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm)."
214840591|NCT05714241|OTHER|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
214840592|NCT05714241|OTHER|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
214840593|NCT05965986|OTHER|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
214840594|NCT05965986|OTHER|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
214840595|NCT05594641|OTHER|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
214840596|NCT05594641|OTHER|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
214840597|NCT01781234|DRUG|Intranasal Insulin|
214840598|NCT01781234|DRUG|Placebo|
214840599|NCT06613334|BIOLOGICAL|Blood test: measurement of plasma antipsychotic concentration|Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
214840600|NCT06613334|OTHER|Voice interviews and questionnaires carried out via the CALLYOPE application|"Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant).~The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement.~In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application.~These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6)."
214840601|NCT03259113|DEVICE|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
214840602|NCT02297087|GENETIC|Standard of care based on target(s) identified via GWS.|
214840603|NCT00490321|DEVICE|VentrAssistTM Left Ventricular Assist Device|
214840604|NCT03439085|BIOLOGICAL|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
214840605|NCT03439085|BIOLOGICAL|Durvalumab|Given IV
214840606|NCT01863433|BIOLOGICAL|Trivalent Influenza Vaccine|
214840607|NCT04192032|OTHER|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
214840608|NCT04192032|OTHER|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
214840609|NCT04192032|OTHER|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
214840610|NCT04192032|OTHER|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
214840611|NCT04192032|OTHER|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
214840612|NCT05036005|DRUG|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
214840613|NCT05036005|DRUG|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
214840614|NCT05036005|DRUG|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
214840615|NCT02381197|DEVICE|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
214840616|NCT01070745|DRUG|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
214840617|NCT01070745|DRUG|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
214840618|NCT02929927|PROCEDURE|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
214840619|NCT02929927|DEVICE|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
214840620|NCT02929927|DRUG|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
214840621|NCT02929927|DRUG|2.5%NaClO|use 2.5% NaClO as irrigants
214840622|NCT02929927|PROCEDURE|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
214840623|NCT02929927|PROCEDURE|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
214840624|NCT04989569|DIETARY_SUPPLEMENT|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
214840625|NCT02174276|DRUG|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
214840626|NCT02174276|BIOLOGICAL|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
214840627|NCT02476331|BEHAVIORAL|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
214840628|NCT01206439|DRUG|nebivolol|nebivolol 5 or 10 mg oral, daily
214840629|NCT03975439|DIAGNOSTIC_TEST|Hemoglobin A1C|Finger stick hemoglobin A1C
214840630|NCT03975439|DIAGNOSTIC_TEST|Urinalysis|Urinalysis by dip stick looking for urine protein level
214840631|NCT03975439|DIAGNOSTIC_TEST|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
214840632|NCT02132624|BIOLOGICAL|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
214840633|NCT03976934|DRUG|Tamsulosin|administration of tamsulosin tablets
214840634|NCT03976934|DRUG|Placebo oral tablet|sugar pills
214840635|NCT03799224|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
214840636|NCT03799224|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
214840637|NCT03799224|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
214840638|NCT00355524|DRUG|TMC114|TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
214840639|NCT00355524|DRUG|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
214840640|NCT00388063|DRUG|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
214840641|NCT01580046|DRUG|iodixanol|"1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
214840642|NCT01580046|DRUG|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
214840643|NCT00781079|BEHAVIORAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
214840644|NCT06428955|DEVICE|CT LUCIA 621P|The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
214840645|NCT04188808|OTHER|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
214840646|NCT05318755|DRUG|GAHT for transgender men|Testosterone undecanoate
214840647|NCT05318755|DRUG|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
214840648|NCT06167850|PROCEDURE|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
214840649|NCT05245955|DEVICE|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
214840650|NCT06125002|DRUG|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
214840651|NCT06125002|DRUG|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
214840652|NCT01218035|DRUG|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
214840653|NCT04194606|PROCEDURE|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
214840654|NCT00006942|DRUG|bryostatin 1|Given IV
214840655|NCT00006942|DRUG|cisplatin|Given IV
214840656|NCT00006942|OTHER|laboratory biomarker analysis|Correlative studies
214840657|NCT01259830|DRUG|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
214840658|NCT01259830|DRUG|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
214840659|NCT02296957|PROCEDURE|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
214840660|NCT00515216|DRUG|5-fluorouracil|
214840661|NCT00515216|DRUG|Oxaliplatin|
214840662|NCT00515216|DRUG|Leucovorin|
214840663|NCT00357539|DRUG|Azithromycin (T1225)|
214840664|NCT04066257|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
214840665|NCT04066257|DRUG|Metronidazole|Metronidazole 250 mg tablet
214840666|NCT04066257|DRUG|Tetracycline|Tetracycline hydrochloride 250 mg capsule
214840667|NCT04066257|DRUG|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
214840668|NCT02910596|DRUG|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
214840669|NCT02910596|DEVICE|early bladder training|early bladder training start on 3rd - 5thpostoperative day
214840670|NCT02910596|OTHER|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
214840671|NCT02910596|OTHER|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
214840672|NCT04659668|DEVICE|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
214840673|NCT03981809|DIAGNOSTIC_TEST|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
214840674|NCT00741754|OTHER|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
214840675|NCT00059709|PROCEDURE|Mediated Negotiation Training|
214840676|NCT05098951|DEVICE|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
214840677|NCT02786927|DRUG|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
214840678|NCT02786927|DRUG|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
214840679|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
214840680|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
214840681|NCT03559127|PROCEDURE|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
214840682|NCT03559127|PROCEDURE|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
214840683|NCT03559127|PROCEDURE|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
214840684|NCT02695927|DEVICE|Computer rehabilitation glasses|
214840685|NCT01801917|DRUG|Placebo|Matching placebo tablet for oral administration
214840686|NCT01801917|DRUG|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
214840687|NCT03180255|COMBINATION_PRODUCT|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
214840688|NCT03180255|OTHER|Placebo|Ocular iontophoretic delivery of a placebo
214840689|NCT02486614|PROCEDURE|CRRT|citrate based continuous renal replacement therapy
214840690|NCT04307849|BEHAVIORAL|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
214840691|NCT04307849|OTHER|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
214840692|NCT02878408|GENETIC|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
214840693|NCT04043702|DRUG|The intervention being studied|Intervention Other Names have not been specified
214840694|NCT04499378|DIAGNOSTIC_TEST|Lung CT|Computed tomography of the thorax
214840695|NCT05700136|BEHAVIORAL|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
214840696|NCT00707187|DRUG|Cialis|35 pills of study medication (20 mg)
214840697|NCT04791488|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
214840698|NCT04791488|PROCEDURE|Diving simulation|Hyperbaric chamber diving simulation protocol
214840699|NCT04761445|OTHER|Straumann Standard Plus implant and JDental care (JD) Octa implant|Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
214840700|NCT04113616|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
214840701|NCT04113616|DRUG|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
214840702|NCT04113616|DRUG|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
214840703|NCT06028646|DEVICE|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
214840704|NCT05967936|DRUG|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
214840705|NCT00857558|DRUG|saxagliptin|orally administration at 1 mg once a day for 12 weeks
214840706|NCT00857558|DRUG|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
214840707|NCT00857558|DRUG|saxagliptin|orally administration at 5 mg once a day for 12 weeks
214840708|NCT00857558|DRUG|placebo|orally administration once a day for 12 weeks
214840709|NCT02185963|DRUG|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
214840710|NCT03602027|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
214840711|NCT03602027|DRUG|Gefitinib|Gefitinib 250mg orally daily for three weeks
214840712|NCT05467982|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
214840713|NCT05467982|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
214840714|NCT02997722|DRUG|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
214840715|NCT02997722|DRUG|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
214840716|NCT03980210|PROCEDURE|Hyperbaric oxygen therapy|"1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
214840717|NCT04381481|BEHAVIORAL|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
214840718|NCT04381481|BEHAVIORAL|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
214840719|NCT04381481|BEHAVIORAL|Experimental snack: Text warning|The snack contains a text warning (task 2)
214840720|NCT04381481|BEHAVIORAL|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
214840721|NCT04381481|BEHAVIORAL|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
214840722|NCT05135624|DRUG|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
214840723|NCT05135624|OTHER|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
214840724|NCT05135624|DRUG|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
214840725|NCT01575041|DIETARY_SUPPLEMENT|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
214840726|NCT01575041|DRUG|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
214840727|NCT01575041|DRUG|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
214840728|NCT02226991|DRUG|Tipranavir|
214840729|NCT02226991|DRUG|Ritonavir|
214840730|NCT02226991|DRUG|Efavirenz|
214840731|NCT00244829|DRUG|imatinib mesylate|
214840732|NCT00244829|PROCEDURE|adjuvant therapy|
214840733|NCT04203433|DRUG|DLX105-DMP|1mg applied to target lesion
214840734|NCT02203578|DRUG|romidepsin|Given IV
214840735|NCT02203578|OTHER|laboratory biomarker analysis|Correlative studies
214840736|NCT05252247|OTHER|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
214840737|NCT05252247|OTHER|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
214840738|NCT06599138|DEVICE|Ultrasound-guided maxillary nerve block|Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
214840739|NCT01407484|DRUG|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
214840740|NCT01407484|DRUG|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
214840741|NCT03422224|DIAGNOSTIC_TEST|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
214840742|NCT05721157|OTHER|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
214840743|NCT05761392|OTHER|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
214840744|NCT05290233|BEHAVIORAL|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
214840745|NCT06384482|DRUG|SNC115 injection|SNC115 Injection is DLL3 CART.
214840746|NCT02922582|DRUG|DepoTXA|
214840747|NCT02922582|DRUG|Tranexamic Acid|
214840748|NCT02369549|DRUG|Micro-particle Curcumin|as described in Arm
214840749|NCT02369549|DRUG|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
214840750|NCT01513395|BEHAVIORAL|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
214840751|NCT00708682|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
214840752|NCT04439760|PROCEDURE|Superior Cervical Ganglion Block|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
214840753|NCT00587249|BIOLOGICAL|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
214840754|NCT00587249|BIOLOGICAL|Alhydrogel|Aluminum hydroxide gel.
214840755|NCT05430464|DEVICE|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
214840756|NCT05430464|DEVICE|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
214840757|NCT00840190|DRUG|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
214840758|NCT03519490|DEVICE|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
214840759|NCT04118946|BIOLOGICAL|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
214840760|NCT03993639|DRUG|Pegfilgrastim|Single dose of SC administration
214840761|NCT01714141|BEHAVIORAL|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
214840762|NCT01714141|BEHAVIORAL|Asthma education active control|
214840763|NCT00420095|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
214840764|NCT00420095|DRUG|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
214840765|NCT05518331|DRUG|avatrombopag|Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
214840766|NCT02806791|DRUG|FILGRASTIM|
214840767|NCT06336993|DRUG|herbal compound|patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
214840768|NCT06336993|DRUG|Celecoxib|Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
214840769|NCT03675763|OTHER|Manual treatment|Craniosacral therapy protocol.
214840770|NCT01978964|BIOLOGICAL|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
214840771|NCT03393780|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
214840772|NCT04516187|DIAGNOSTIC_TEST|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
214840773|NCT03185741|BEHAVIORAL|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
214840774|NCT03185741|BEHAVIORAL|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
214840775|NCT05543395|BEHAVIORAL|Domestic Violence Questionnaire|Domestic Violence Questionnaire
214840776|NCT01016054|BIOLOGICAL|AGS-8M4|IV infusion
214840777|NCT01016054|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
214840778|NCT01016054|DRUG|gemcitabine|IV infusion
214840779|NCT01016054|DRUG|carboplatin|IV infusion
214840780|NCT01634854|DRUG|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
214840781|NCT01634854|DRUG|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
214840782|NCT01513941|DRUG|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
214840783|NCT01513941|DRUG|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
214840784|NCT01513941|DRUG|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
214840785|NCT00654641|PROCEDURE|Negative pressure wound closure|Applying negative pressure to primary wound closure
214840786|NCT00654641|PROCEDURE|Standard wound closure|Standard wound closure
214840787|NCT04755673|OTHER|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
214840788|NCT01337596|DRUG|LY2951742|Administered subcutaneously
214840789|NCT01337596|DRUG|Placebo|Administered subcutaneously
214840790|NCT03973151|DRUG|HL-085|HL-085 is one MEK inhibitor.
214840791|NCT04926701|DRUG|ETD001 single dose|Single ascending doses of inhaled ETD001
214840792|NCT04926701|DRUG|Placebo single dose|Single doses of inhaled placebo
214840793|NCT04926701|DRUG|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
214840794|NCT04926701|DRUG|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
214840795|NCT04926701|DRUG|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
214840796|NCT04926701|DRUG|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
214840797|NCT05740553|DEVICE|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
214840798|NCT00219986|DRUG|Potent HAART during acute or early HIV-1 infection|
214840799|NCT01652963|OTHER|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
214840800|NCT05259956|BEHAVIORAL|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
214840801|NCT05259956|BEHAVIORAL|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
214840802|NCT02386761|DRUG|Single Ascending Dose (SAD)|
214840803|NCT02386761|DRUG|Multiple Ascending Dose (MAD)|
214840804|NCT06233539|OTHER|Observational research without intervention|Observational research without intervention
214840805|NCT03761706|BEHAVIORAL|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
214840806|NCT03761706|OTHER|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
214840807|NCT03590834|BEHAVIORAL|Center-based Intervention|"1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks"
214840808|NCT03590834|BEHAVIORAL|Home-based Intervention|"1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
214840809|NCT03590834|BEHAVIORAL|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
214840810|NCT00378027|DRUG|Fondaparinux|Administer Fondaparinux Risk Stratify
214840811|NCT01732679|OTHER|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
214840812|NCT05419817|DRUG|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
214840813|NCT05419817|DRUG|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
214840814|NCT03610919|DRUG|Nasal Sprays|Intranasal administration of 24 international units per dose.
214840815|NCT01465568|DRUG|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
214840816|NCT01465568|DRUG|bisphosphonates|continue present bisphosphonate treatment
214840817|NCT04681508|DIAGNOSTIC_TEST|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
214840818|NCT01393951|BIOLOGICAL|ASP7374|subcutaneous and intramuscular
214840819|NCT02971787|DIETARY_SUPPLEMENT|Probiotics|Day 1-21: 2 capsules per day
214840820|NCT02971787|DIETARY_SUPPLEMENT|Salt|Day 8-21: 10 tablets à 600 mg per day
214840821|NCT02520453|DRUG|Durvalumab|
214840822|NCT02520453|DRUG|Placebo|
214840823|NCT00510003|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214840824|NCT05780450|DEVICE|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
214840825|NCT04834336|DEVICE|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
214840826|NCT04834336|OTHER|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
214840827|NCT02569541|DRUG|sodium fusidate|
214840828|NCT00176943|DRUG|Aldara Cream 5%|
214840829|NCT03864185|BIOLOGICAL|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
214840830|NCT03864185|OTHER|Placebo|Administer placebo IV infusion once weekly for 4 doses.
214840831|NCT04916275|OTHER|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
214840832|NCT05387070|DRUG|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
214840833|NCT05387070|DRUG|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
214840834|NCT01668823|DRUG|HPPH|Given IV
214840835|NCT01668823|DRUG|photodynamic therapy|Undergo photodynamic therapy with HPPH
214840836|NCT01668823|PROCEDURE|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
214840837|NCT00660868|DRUG|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
214840838|NCT03624855|OTHER|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
214840839|NCT02844010|OTHER|weighing|
214840840|NCT02959008|DEVICE|measure TOI and BP|Both groups measure TOI and BP.
214840841|NCT00320853|DRUG|Vitamin D|
214840842|NCT05934357|OTHER|Fiber|The intervention treatment will contain fiber.
214840843|NCT05934357|OTHER|Control|The control treatment will contain corn meal.
214840844|NCT04296201|DEVICE|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
214840845|NCT00578968|DRUG|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
214840846|NCT00578968|DRUG|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
214840847|NCT05064826|OTHER|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
214840848|NCT00945334|DRUG|Neomycin|500 mg po bid for 14 days
214840849|NCT00945334|DRUG|Placebo|placebo for 14 days tid
214840850|NCT00945334|DRUG|Rifaximin|550 mg po tid
214840851|NCT00332124|DRUG|Choline|900 mg every day until birth of infant
214840852|NCT00332124|DIETARY_SUPPLEMENT|Placebo|Corn oil every day in place of choline
214840853|NCT03064243|DRUG|apatinib|apatinib 500mg po. qd.
214840854|NCT03027908|OTHER|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
214840855|NCT03027908|OTHER|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
214840856|NCT05920161|BEHAVIORAL|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
214840857|NCT05920161|BEHAVIORAL|Control|This is matched to the SECPT but with warm instead of cold water
214840858|NCT06467578|DEVICE|Breezing Portable Indirect Calorimeter|Indirect calorimeter with face mask and smartphone compatible application
214840859|NCT03471988|DRUG|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
214840860|NCT03471988|DRUG|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
214840861|NCT01713088|OTHER|Multisystemic therapy|
214840862|NCT01713088|OTHER|YOT (usual services)|
214840863|NCT01004315|DRUG|KUC-7483|
214840864|NCT01004315|DRUG|Placebo|
214840865|NCT01004315|DRUG|Tolterodine|
214840866|NCT05386056|DRUG|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
214840867|NCT05386056|DRUG|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
214840868|NCT05386056|PROCEDURE|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
214840869|NCT00108628|BEHAVIORAL|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
214840870|NCT00108628|BEHAVIORAL|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
214840871|NCT06120634|PROCEDURE|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
214840872|NCT06120634|PROCEDURE|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
214840873|NCT03745417|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
214840874|NCT01636934|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
214840875|NCT01636934|OTHER|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
214840876|NCT01636934|BEHAVIORAL|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
214840877|NCT03499366|DIAGNOSTIC_TEST|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
214840878|NCT02514395|OTHER|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2\[32\] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
214840879|NCT03310086|DEVICE|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
214840880|NCT03310086|PROCEDURE|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
214840881|NCT05110911|BIOLOGICAL|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
214840882|NCT05110911|BIOLOGICAL|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
214840883|NCT05131516|DIAGNOSTIC_TEST|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
214840884|NCT06045390|OTHER|App|"App features (App will be used during the office visit):~* Pictorial representation of drops (color-coded) and schedule.~* Quiz to assess understanding of the regimen.~* Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~* Graphical print-out of the regimen."
214840885|NCT02301741|BEHAVIORAL|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
214840886|NCT04979923|DRUG|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
214840887|NCT00676741|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214840888|NCT00676741|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214840889|NCT00676741|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214840890|NCT05992987|DIAGNOSTIC_TEST|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
214840891|NCT05992987|DIAGNOSTIC_TEST|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
214840892|NCT00292591|DRUG|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
214840893|NCT00292591|DRUG|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
214840894|NCT02297841|DEVICE|Experimental: Novel lubricant Miami Fragrance|
214840895|NCT02297841|DEVICE|Experimental: Novel lubricant Miami no Fragrance|
214840896|NCT02297841|DEVICE|KY Liquid lubricant|
214840897|NCT02297841|DEVICE|Astroglide Gel lubricant|
214840898|NCT02332005|DRUG|diepalrestat choline|aldose reductase inhibitor
214840899|NCT02332005|DRUG|Placebo|Placebo
214840900|NCT01873781|DRUG|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
214840901|NCT02431624|DRUG|BTDS|
214840902|NCT03429049|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 injection
214840903|NCT03429049|DRUG|Placebo|Receiving Placebo injection
214840904|NCT05139758|DIAGNOSTIC_TEST|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
214840905|NCT00996424|DRUG|Acetylcysteine|Inhalation with N-Acetylcysteine
214840906|NCT00996424|DRUG|normal saline|Inhalation with normal saline solution
214840907|NCT03034434|DEVICE|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
214840908|NCT00164255|DRUG|sulfadoxine/pyrimethamine|
214840909|NCT00164255|DRUG|sulfadoxine/pyrimethamine plus artesunate|
214840910|NCT02321124|OTHER|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
214840911|NCT02321124|BEHAVIORAL|life style advice|We will apply life style advice for four weeks.
214840912|NCT03092596|BEHAVIORAL|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
214840913|NCT03092596|BEHAVIORAL|Patient health navigator-administered screening tool|patient health navigator-administered screener
214840914|NCT03092596|BEHAVIORAL|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
214840915|NCT02491996|BEHAVIORAL|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
214840916|NCT01723150|DRUG|Ciprofloxacin|
214840917|NCT01723150|DRUG|Ceftriaxone|
214840918|NCT01723150|DRUG|Trimethoprim/sulfamethoxazole|
214840919|NCT01723150|DRUG|Ertapenem|
214840920|NCT06021106|OTHER|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.
214840921|NCT06021106|OTHER|routine treatment and care|routine treatment and care
214840922|NCT04030013|OTHER|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
214840923|NCT04654234|DEVICE|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
214840924|NCT04882137|BEHAVIORAL|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
214840925|NCT04814459|OTHER|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
214840926|NCT04865484|PROCEDURE|Surgical resection|Surgical resection of fibrostenotic area (\>4cm)
214840927|NCT04865484|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy of fibrostenotic area (≤4cm)
214840928|NCT04865484|PROCEDURE|Strictureplasty|Strictureplasty of fibrostenotic area (≤4cm)
214840929|NCT01891812|DRUG|Nitrous oxide 50%|
214840930|NCT06394115|DEVICE|Ostomy pouch|Ostomy pouch coated with novel technology
214840931|NCT01841060|PROCEDURE|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
214840932|NCT01467596|DEVICE|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
214840933|NCT06058364|DIETARY_SUPPLEMENT|Intervention 1 - Triglyceride|Triglyceride (1 softgel each morning with a glass of water)
214840934|NCT06058364|DIETARY_SUPPLEMENT|Intervention 2 - Placebo|Placebo (1 softgel each morning with a glass of water)
214840935|NCT00915434|DRUG|JNJ-31001074|
214840936|NCT01833754|DRUG|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
214840937|NCT00440622|DRUG|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
214840938|NCT00440622|DRUG|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
214840939|NCT00440622|DRUG|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
214840940|NCT05597839|DRUG|DF9001|Immunotherapy agent targeting NK cells.
214840941|NCT05597839|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
214840942|NCT05597839|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
214840943|NCT00781521|DRUG|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
214840944|NCT01872715|DRUG|Oracea|
214840945|NCT04085471|DIAGNOSTIC_TEST|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
214840946|NCT01404871|DRUG|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
214840947|NCT01404871|DRUG|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
214840948|NCT01404871|DRUG|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
214840949|NCT03525249|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume a capsule for eight weeks
214840950|NCT02340624|BEHAVIORAL|Referral to SmokeFreeMoms, Quitline or Brief intervention|"1. SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~2. The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~3. Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
214840951|NCT00005887|DRUG|efaproxiral|
214840952|NCT00005887|RADIATION|radiation therapy|
214840953|NCT03721887|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
214840954|NCT05604651|OTHER|no intervention|no intervention
214840955|NCT02463630|PROCEDURE|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
214840956|NCT02814708|BIOLOGICAL|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 binding Ab titer .
214840957|NCT03523247|BEHAVIORAL|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
214840958|NCT01949753|BEHAVIORAL|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
214840959|NCT01949753|BEHAVIORAL|Exposure therapy|Exposure with response prevention without pharmacological facilitation
214840960|NCT05112419|DRUG|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
214840961|NCT01578317|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
214840962|NCT01578317|BIOLOGICAL|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
214840963|NCT01514994|DEVICE|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
214840964|NCT04688580|DRUG|XW10172|Various formulations
214840965|NCT04983524|DIETARY_SUPPLEMENT|propolis|resinous product of honeybees
214840966|NCT04983524|DRUG|Calcium Hydroxide|Gold standard control intracanal medicament
214840967|NCT04542915|OTHER|No intervention|No intervention.
214840968|NCT00236145|DRUG|ACTIQ (Oral transmucosal fentanyl citrate)|
214840969|NCT05179161|DEVICE|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
214840970|NCT01189682|PROCEDURE|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
214840971|NCT01765270|DRUG|Saxagliptin|one 5-mg saxagliptin tablet daily
214840972|NCT01765270|DRUG|Placebo|5mg placebo tablet daily
214840973|NCT03947398|DEVICE|BLIMP balloon|Using BLIMP balloon to cross lesion
214840974|NCT03947398|DEVICE|Low profile balloon|using low profile balloon to cross lesion
214840975|NCT01927991|BEHAVIORAL|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
214840976|NCT05274191|DRUG|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
214840977|NCT05274191|OTHER|standard regimen|standard regimen
214840978|NCT04390230|PROCEDURE|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
214840979|NCT01459757|OTHER|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
214840980|NCT05167045|BEHAVIORAL|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
214840981|NCT02252445|DRUG|Propofol|Propofol will be administered.
214840982|NCT02252445|DRUG|Sevoflurane|Sevoflurane will be administered.
214840983|NCT03656263|DIAGNOSTIC_TEST|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
214840984|NCT03431337|DRUG|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
214840985|NCT03431337|DIETARY_SUPPLEMENT|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
214840986|NCT00329160|DRUG|Rosuvastatin|2.5-20 mg
214840987|NCT00329160|DRUG|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
214840988|NCT04459676|DRUG|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
214840989|NCT04459676|DRUG|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
214840990|NCT00458289|DRUG|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
214840991|NCT00485004|DEVICE|Cutting balloon|Cutting balloon
214840992|NCT00485004|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
214840993|NCT06551129|DRUG|Mavacamten|As prescribed by treating physician
214840994|NCT04501094|DRUG|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
214840995|NCT05810857|DIAGNOSTIC_TEST|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
214840996|NCT05810857|DIAGNOSTIC_TEST|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
214840997|NCT00164372|BEHAVIORAL|Peer Education Intervention|
214840998|NCT01128868|DEVICE|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
214840999|NCT01128868|DEVICE|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
214841000|NCT00004416|DRUG|botulinum toxin type A|
214841001|NCT00026923|PROCEDURE|Laparoscopic surgery|
214841002|NCT04313010|OTHER|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
214841003|NCT04313010|OTHER|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
214841004|NCT02682550|PROCEDURE|blood drawing|blood drawing
214841005|NCT04601350|DRUG|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
214841006|NCT04601350|DRUG|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
214841007|NCT00963430|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
214841008|NCT04815434|OTHER|Interview|Interviews will be conducted.
214841009|NCT02871050|OTHER|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
214841010|NCT05284084|OTHER|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
214841011|NCT05284084|OTHER|Data collection for comparison|Data collection for comparison
214841012|NCT02302937|PROCEDURE|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
214841013|NCT02302937|PROCEDURE|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
214841014|NCT05850884|DIAGNOSTIC_TEST|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
214841015|NCT06382506|DIETARY_SUPPLEMENT|Consumption of Cornbread with Hazelnut Bread|Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
214841016|NCT00361478|BEHAVIORAL|Exercise and education|Weekly exercise and education program for 8 weeks
214841017|NCT00361478|BEHAVIORAL|Education|Written educational material
214841018|NCT00869687|DEVICE|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
214841019|NCT06503887|OTHER|Stool sample collection|Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
214841020|NCT04025294|DEVICE|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
214841021|NCT04025294|BEHAVIORAL|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
214841022|NCT02315261|PROCEDURE|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
214841023|NCT02407067|DEVICE|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
214841024|NCT02407067|DEVICE|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
214841025|NCT04725591|DEVICE|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
214841026|NCT04725591|DEVICE|MEDISAFE WITH External Insulin Pump|Insulin delivery
214841027|NCT04725591|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
214841028|NCT04725591|OTHER|Declaration of meals|Patient inputs related to meals
214841029|NCT04725591|OTHER|No declaration of meals|No patient inputs related to meals
214841030|NCT04725591|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
214841031|NCT01525576|BEHAVIORAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
214841032|NCT05684224|BEHAVIORAL|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
214841033|NCT02672969|DEVICE|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
214841034|NCT00063258|DRUG|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
214841035|NCT00063258|DRUG|Paclitaxel|Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
214841036|NCT00063258|DRUG|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
214841037|NCT04187924|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
214841038|NCT04187924|DEVICE|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
214841039|NCT04619550|OTHER|High tibial osteotomy|Realignment surgery
214841040|NCT00603395|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
214841041|NCT03468712|PROCEDURE|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
214841042|NCT03761498|OTHER|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
214841043|NCT06176755|OTHER|Treadmill training with weighted ankle cuffs|"Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently."
214841044|NCT06176755|OTHER|Treadmill training|Treadmill training only
214841045|NCT01530308|DRUG|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
214841046|NCT01530308|DRUG|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
214841047|NCT00623636|DRUG|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
214841048|NCT00623636|DRUG|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
214841049|NCT04692584|BEHAVIORAL|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
214841050|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
214841051|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
214841052|NCT04954690|BEHAVIORAL|Usual Care|Usual Care
214841053|NCT05995379|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
214841054|NCT00784979|DRUG|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
214841055|NCT05484141|OTHER|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
214841056|NCT05484141|OTHER|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
214841057|NCT00004441|DRUG|tauroursodeoxycholic acid|
214841058|NCT00004441|DRUG|ursodiol|
214841059|NCT01198249|DRUG|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
214841060|NCT02073136|OTHER|Diet with phosphate containing additives|
214841061|NCT02073136|OTHER|Diet without phosphate containing additives|
214841062|NCT05373641|OTHER|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
214841063|NCT05373641|OTHER|Pain documentation audit|Monthly pain documentation audit
214841064|NCT03215459|DEVICE|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
214841065|NCT05547906|DRUG|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
214841066|NCT04747132|OTHER|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
214841067|NCT03747185|OTHER|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
214841068|NCT03747185|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
214841069|NCT05436132|BEHAVIORAL|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
214841070|NCT05436132|BEHAVIORAL|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
214841071|NCT04773509|PROCEDURE|Paravertebral block|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides.
214841072|NCT02430207|PROCEDURE|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
214841073|NCT02430207|PROCEDURE|temporary pacing subclavian vein|
214841074|NCT06009588|DEVICE|self-expandable valves|patients undergoing TAVR use self-expandable valves
214841075|NCT06009588|DEVICE|balloon-expandable valves|patients undergoing TAVR use balloon-expandable valves
214841076|NCT04292015|DIAGNOSTIC_TEST|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
214841077|NCT03731728|BEHAVIORAL|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
214841078|NCT03731728|BEHAVIORAL|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
214841079|NCT02885428|DEVICE|echography|
214841080|NCT03698487|OTHER|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
214841081|NCT04783545|DRUG|VLX-1005|VLX-1005 infusion
214841082|NCT04783545|DRUG|Placebo|Placebo infusion
214841083|NCT05352477|OTHER|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
214841084|NCT05352477|OTHER|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
214841085|NCT03727698|DEVICE|MR Linac|MR guided radiotherapy treatment
214841086|NCT03523845|OTHER|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
214841087|NCT05919745|DRUG|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
214841088|NCT05919745|DRUG|Placebo|Preoperative delivery of placebo per os.
214841089|NCT05919745|DRUG|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
214841090|NCT06210945|DRUG|10 mg/kg CM-101|10 mg/kg CM-101
214841091|NCT06210945|DRUG|Placebo|Placebo
214841092|NCT00894933|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
214841093|NCT02620059|BEHAVIORAL|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
214841094|NCT05433259|DEVICE|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
214841095|NCT00876356|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
214841096|NCT00876356|DIETARY_SUPPLEMENT|Olive oil|Olive oil 4.5g/day x 12 weeks
214841097|NCT03886649|DRUG|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
214841098|NCT03886649|DRUG|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
214841099|NCT02812771|DRUG|Efinaconazole|Solution
214841100|NCT01359579|DRUG|varespladib methyl|Single oral 500 mg dose
214841101|NCT04767087|DRUG|Honey|0.5 gm/Kg/day honey
214841102|NCT04767087|DRUG|Nigella sativa seed|40 mg/Kg/day
214841103|NCT04767087|OTHER|Placebo|empty capsule with sugar water
214841104|NCT00781092|OTHER|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
214841105|NCT00781092|OTHER|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
214841106|NCT05240092|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
214841107|NCT01477099|DEVICE|Toothbrushing with a manual brush|Toothbrushing with a manual brush
214841108|NCT01503333|BEHAVIORAL|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
214841109|NCT01247792|BEHAVIORAL|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
214841110|NCT03806335|OTHER|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
214841111|NCT03806335|OTHER|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
214841112|NCT03806335|OTHER|General anesthesia|All patients will receive general anesthesia prior to infiltration
214841113|NCT00468208|DRUG|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
214841114|NCT04372784|DEVICE|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
214841115|NCT04372784|PROCEDURE|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
214841116|NCT03838341|DEVICE|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
214841117|NCT03838341|DRUG|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
214841118|NCT03068884|DEVICE|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
214841119|NCT03068884|DIETARY_SUPPLEMENT|L-Tyrosine|Administration of 2 grams tyrosine
214841120|NCT03068884|DEVICE|Transcranial direct current stimulation (sham)|Sham tDCS
214841121|NCT03068884|DIETARY_SUPPLEMENT|Cellulose (placebo)|Administration of 2 grams cellulose
214841122|NCT02451306|DRUG|Quetiapine|See information in arm description.
214841123|NCT02451306|DRUG|Placebo|See information in arm description.
214841124|NCT03482206|DEVICE|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
214841125|NCT05425342|DEVICE|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
214841126|NCT01235715|DRUG|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
214841127|NCT01967901|BEHAVIORAL|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
214841128|NCT03619876|DRUG|Abatacept|125 MG/ML subcutaneous injections
214841129|NCT03619876|DRUG|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
214841130|NCT02203617|BEHAVIORAL|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
214841131|NCT02203617|BEHAVIORAL|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
214841132|NCT04599621|DIAGNOSTIC_TEST|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
214841133|NCT04244799|BEHAVIORAL|Behavioral nudges|"Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
214841134|NCT04244799|BEHAVIORAL|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
214841135|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
214841136|NCT05269316|DRUG|IMP9064|IMP9064 Monotherapy administered for 21 days
214841137|NCT06800755|DEVICE|Dexeryl (RL3020-DP0364)|Product application on body (head excluded)
214841138|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
214841139|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
214841140|NCT00674908|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
214841141|NCT00674908|BIOLOGICAL|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
214841142|NCT03328390|OTHER|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
214841143|NCT03328390|OTHER|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
214841144|NCT01790308|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
214841145|NCT01790308|DRUG|Liraglutide|CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
214841146|NCT04077125|DRUG|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
214841147|NCT00897923|PROCEDURE|radionuclide imaging|
214841148|NCT00897923|RADIATION|indium In 111-labeled autologous peripheral blood mononuclear cells|
214841149|NCT00897923|RADIATION|indium In 111-labeled autologous polymorphonuclear leukocytes|
214841150|NCT00396630|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
214841151|NCT00396630|BIOLOGICAL|Placebo|Two-dose oral administration.
214841152|NCT04202705|DRUG|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
214841153|NCT06428162|OTHER|questionner|three sections questioner including: demographics, reported cases, unreported cases
214841154|NCT04776005|OTHER|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
214841155|NCT03105193|DRUG|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
214467266|NCT03882073|PROCEDURE|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
214841156|NCT03105193|DRUG|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
214841157|NCT03105193|DRUG|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
214841158|NCT03105193|DRUG|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
214841159|NCT00357955|BEHAVIORAL|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
214841160|NCT00357955|BEHAVIORAL|Interactive Education|interactive lectures with hands-on learning
214841161|NCT00357955|BEHAVIORAL|Role modeling|learning from peers with similar disease and problems
214841162|NCT00357955|PROCEDURE|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
214841163|NCT01961258|OTHER|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
214841164|NCT03992547|OTHER|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
214841165|NCT04398979|PROCEDURE|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
214841166|NCT01074645|DRUG|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
214841167|NCT06283836|DRUG|Dexmedetomidine|monitored anesthesia care (sedation)
214841168|NCT06283836|DRUG|Remifentanil|monitored anesthesia care (sedation)
214841169|NCT06490406|BEHAVIORAL|Multimodal intervention (communication and education simulations) for EG1|"In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices."
214841170|NCT00894842|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
214841171|NCT00894842|DRUG|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
214841172|NCT03629106|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
214841173|NCT02347319|DRUG|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
214841174|NCT02347319|DRUG|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
214841175|NCT02347319|DRUG|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
214467267|NCT03882073|PROCEDURE|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
214467268|NCT06396026|DRUG|TLL-018 tablets|Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks
214467269|NCT06396026|DRUG|Placebo tablets|Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
214467270|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
214467271|NCT03022942|OTHER|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
214467272|NCT03022942|OTHER|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
214467273|NCT02701153|PROCEDURE|Conventional Surgery|Undergo surgery
214467274|NCT02701153|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214467275|NCT02701153|OTHER|Laboratory Biomarker Analysis|Correlative studies
214467276|NCT02701153|OTHER|Questionnaire Administration|Ancillary studies
214467277|NCT05795114|BEHAVIORAL|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
214467278|NCT05330767|DEVICE|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
214467279|NCT05330767|DEVICE|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
214467280|NCT05330767|DEVICE|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
214467281|NCT06218355|OTHER|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
214467282|NCT06218355|OTHER|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
214467283|NCT05002088|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
214467284|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
214467285|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
214467286|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
214467287|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
214467288|NCT04538976|DRUG|Sildenafil|Sildenafil in standard dosage
214467289|NCT05868876|DRUG|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
214467290|NCT04347187|DRUG|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
214467291|NCT05962541|DRUG|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA \[TM\]).
214467292|NCT05962541|DEVICE|Power Led Saphira (TM)|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
214467293|NCT05407792|DRUG|Staphylococcus and Neisseria Tablets|0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
214467294|NCT05407792|OTHER|On-demand treatment|At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
214467295|NCT06449586|DRUG|Letermovir|letermovir stops when CMI\>1.5
214467296|NCT06485232|DRUG|Universal BCMA CAR-T|Universal BCMA CAR-T
214467297|NCT06485232|DRUG|Universal CD19 CAR-T|Universal CD19 CAR-T
214467298|NCT06485232|DRUG|Universal BCMA CAR-T; Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T
214467299|NCT04158934|BIOLOGICAL|ADYNOVI/ADYNOVATE|Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
214467300|NCT05070728|DRUG|Sham Injector|Intravitreal sham injection
214467301|NCT05070728|DRUG|FAI Insert|"Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle."
214467302|NCT03374241|BIOLOGICAL|HM15211 or Placebo|Long-acting tri-agonist
214841176|NCT02996019|DRUG|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
214841177|NCT02996019|DEVICE|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
214841178|NCT02996019|DEVICE|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
214841179|NCT03239977|BEHAVIORAL|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
214841180|NCT03239977|BEHAVIORAL|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
214841181|NCT04492852|PROCEDURE|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
214841182|NCT04492852|PROCEDURE|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
214841183|NCT05258851|DRUG|Ceftazidime-avibactam|Experimental
214841184|NCT05258851|DRUG|Colistin|Control
214841185|NCT06495580|PROCEDURE|Optic Nerve Stimulation|Anterograde Stimulation of the Optic Neve.
214841186|NCT02861027|PROCEDURE|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
214841187|NCT02861027|PROCEDURE|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
214841188|NCT00996437|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
214841189|NCT00996437|DRUG|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
214841190|NCT02176668|DRUG|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
214841191|NCT02176668|DRUG|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
214841192|NCT02176668|DRUG|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
214841193|NCT02176668|DRUG|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
214841194|NCT04443569|DRUG|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
214841195|NCT04443569|OTHER|Placebo patch|A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
214841196|NCT01454440|DRUG|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
214841197|NCT00392457|DRUG|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
214841198|NCT00392457|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
214841199|NCT05178914|PROCEDURE|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
214841200|NCT01722955|OTHER|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
214841201|NCT01722955|OTHER|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
214841202|NCT05041114|DEVICE|Motor Neuroprosthesis|Type of implantable brain computer interface
214841203|NCT01876238|OTHER|T-PAT|
214841204|NCT01876238|OTHER|Surveys|Pre-test and posttest surveys and questionnaires
214841205|NCT03715686|PROCEDURE|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
214841206|NCT02576717|DRUG|RPC1063|
214841207|NCT01755975|DRUG|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
214841208|NCT01755975|DRUG|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
214841209|NCT04413032|DEVICE|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
214841210|NCT03081039|DRUG|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
214841211|NCT03081039|DRUG|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
214841212|NCT03081039|DRUG|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
214841213|NCT05647707|DIETARY_SUPPLEMENT|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
214841214|NCT03164109|DRUG|GC4419 IV|50mg infused IV over 15 minutes
214841215|NCT03164109|DRUG|Placebo|Infused IV over 15 minutes
214841216|NCT03164109|DRUG|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
214841217|NCT01205893|DEVICE|Neovasc Reducer|Implantation of the Reducer
214841218|NCT01205893|DEVICE|Control|Control - No device implanted
214841219|NCT00006371|DRUG|aminoglutethimide|
214841220|NCT00006371|DRUG|ketoconazole|
214841221|NCT00006371|DRUG|therapeutic hydrocortisone|
214841222|NCT00399893|DRUG|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
214841223|NCT00399893|DRUG|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
214841224|NCT02754284|BIOLOGICAL|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
214841225|NCT02754284|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
214841226|NCT03105817|DEVICE|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
214841227|NCT01368302|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
214841228|NCT01955512|DRUG|Clopidogrel|Clopidogrel 75mg daily for 7 days
214841229|NCT01955512|DRUG|Placebo|Matched placebo
214841230|NCT00628979|BEHAVIORAL|CBT|cognitive- behavioral treatment for panic disorder.
214841231|NCT03747653|DRUG|ADVATE|Patients will be administered a single dose of ADVATE.
214841232|NCT03747653|DRUG|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
214841233|NCT01625507|BEHAVIORAL|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
214841234|NCT01729026|OTHER|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
214841235|NCT01865929|DEVICE|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
214841236|NCT01865929|PROCEDURE|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
214841237|NCT04626544|DEVICE|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable \[15\] and valid \[20\]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
214841238|NCT00007761|BEHAVIORAL|Bipolar Disorder Program|
214841239|NCT00007761|BEHAVIORAL|Usual (psychiatric) Care|
214841240|NCT06175429|DIAGNOSTIC_TEST|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
214841241|NCT06175429|DIAGNOSTIC_TEST|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
214841242|NCT06175429|DIAGNOSTIC_TEST|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
214841243|NCT06175429|DIAGNOSTIC_TEST|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
214841244|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|250 mg
214841245|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|500 mg
214841246|NCT01397981|BEHAVIORAL|Gait retraining|Changing the kinematics of walking
214841247|NCT01685359|DRUG|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
214841248|NCT01838187|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
214841249|NCT01838187|DRUG|Vorinostat|180 mg/m2 orally once daily on days 0 to +13
214841250|NCT01729988|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
214841251|NCT00989209|DRUG|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
214841252|NCT00989209|PROCEDURE|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
214841253|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
214841254|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
214841255|NCT00906373|DRUG|Sorafenib|400 milligrams (mg) twice per day orally
214841256|NCT00192673|DRUG|PEG-asparaginase|
214841257|NCT04965857|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
214841258|NCT06212050|DEVICE|Transcatheter Aortic Valve Implantation|TAVI in patients with severe BAV stenosis using ACURATE neo2
214841259|NCT01937819|DEVICE|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
214841260|NCT01597479|DRUG|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
214841261|NCT01713179|DRUG|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
214841262|NCT05532488|DIETARY_SUPPLEMENT|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
214841263|NCT05532488|OTHER|Placebo|Placebo
214841264|NCT02291692|PROCEDURE|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
214841265|NCT03802617|DRUG|MR13A9|Intravenous administration
214841266|NCT03802617|DRUG|Placebo|Intravenous administration
214841267|NCT04923516|OTHER|Dosage of Delta-aminolevulinic acid and Porphobilinogen|Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
214841268|NCT02790541|DEVICE|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
214841269|NCT00591435|OTHER|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
214841270|NCT00833508|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
214841271|NCT03191708|DIAGNOSTIC_TEST|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
214841272|NCT00848042|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
214841273|NCT04330911|PROCEDURE|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
214841274|NCT01095523|PROCEDURE|Laparotomy+ HIPEC +/- CRS|
214841275|NCT02297750|PROCEDURE|double-wire technique in patients undergoing ERCP with biliary cannulation|
214841276|NCT02297750|PROCEDURE|single-wire technique in patients undergoing ERCP with biliary cannulation|
214841277|NCT02512055|DRUG|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
214841278|NCT05341804|BEHAVIORAL|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
214841279|NCT05341804|BEHAVIORAL|balance training|Includes static balance, dynamic balance and strength training
214841280|NCT05630625|BEHAVIORAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
214841281|NCT03956602|OTHER|Pretzels|To examine postprandial responses of pretzel consumption
214841282|NCT03956602|OTHER|Brazil nuts|To examine postprandial responses of Brazil nut consumption
214841283|NCT03956602|OTHER|Potato chips|To examine postprandial responses of potato chip consumption
214841284|NCT03956602|OTHER|Mixed nuts|To examine postprandial responses of mixed nut consumption
214841285|NCT03956602|OTHER|White bread|To examine postprandial responses of white bread consumption
214841286|NCT03956602|OTHER|Dried mango|To examine postprandial responses of dried mango consumption
214841287|NCT03956602|OTHER|Mango fruit|To examine postprandial responses of fresh mango consumption
214841288|NCT04627571|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
214841289|NCT05690074|DEVICE|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
214841290|NCT06065124|PROCEDURE|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
214841291|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
214841292|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
214841293|NCT06258798|RADIATION|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
214841294|NCT05676281|BEHAVIORAL|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals"
214841295|NCT05676281|BEHAVIORAL|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
214841296|NCT05676281|BEHAVIORAL|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
214841297|NCT05676281|BEHAVIORAL|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
214841298|NCT05475431|DRUG|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
214841299|NCT05475431|DRUG|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
214841300|NCT05475431|DRUG|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
214841301|NCT05475431|DRUG|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
214841302|NCT05475431|DRUG|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
214841303|NCT03346850|DEVICE|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
214841304|NCT03346850|DEVICE|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
214841305|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
214841306|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
214841307|NCT00979212|DRUG|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
214841308|NCT00979212|DRUG|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
214841309|NCT00979212|DRUG|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
214841310|NCT00979212|PROCEDURE|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
214841311|NCT02785627|OTHER|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
214841312|NCT03294616|DEVICE|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
214841313|NCT04045808|OTHER|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
214841314|NCT03971578|OTHER|No Intervention Provided|No Intervention Provided
214841315|NCT06496373|BIOLOGICAL|Fixed neoantigen tumor vaccine|Single/Fixed neoantigen mRNA vaccine includes pancreatic cancer driver mutations such as KRAS G12D, G12V, G12R, G12C, etc. Each vaccine has one neoantigen encoded by mRNA. Total of 4 cycles, 3 weeks each cycle.
214841316|NCT06496373|BIOLOGICAL|personalized neoantigen tumor vaccine|personalized neoantigen tumor vaccine include 5-20 neoantigens selected based on WES/RNA-seq of patients' tumor sample during surgery. Total of 9 cycles after finishing the first 4 cycles of fixed neoantigen tumor vaccine.
214841317|NCT06496373|DRUG|PD-1 inhibitor|Toripalimab
214841318|NCT04886063|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
214841319|NCT05483907|DRUG|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
214841320|NCT05483907|DRUG|Placebo|Placebo 24 weeks + Follow-up 4 weeks
214841321|NCT05903170|DEVICE|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
214841322|NCT05903170|DEVICE|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
214841323|NCT03834922|OTHER|Prospective data collection|No intervention. It's a prospective data collection.
214841324|NCT05870163|DEVICE|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
214841325|NCT05870163|PROCEDURE|Nissen fundoplication|Standard of care Nissen fundoplication surgery
214841326|NCT02404857|DEVICE|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
214841327|NCT00108979|DRUG|Escitalopram|
214841328|NCT04523246|BIOLOGICAL|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
214841329|NCT04523246|DRUG|Normal Saline|Sterile normal saline, inactive control.
214841330|NCT04429867|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
214841331|NCT04429867|DRUG|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
214841332|NCT06227351|PROCEDURE|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
214841333|NCT06227351|PROCEDURE|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
214841334|NCT03880149|DIETARY_SUPPLEMENT|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
214841335|NCT03880149|OTHER|Placebo|Medium-chain triglyceride (MCT) and vitamin E
214841336|NCT05902468|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 500 mg orally twice daily for 12 weeks
214841337|NCT02614833|BIOLOGICAL|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
214841338|NCT02614833|DRUG|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
214841339|NCT02614833|DRUG|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
214841340|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
214841341|NCT00309985|DRUG|docetaxel|Given IV
214841342|NCT06585306|BEHAVIORAL|jaw lift, increasing oxygen flow, mask ventilation, intubation|When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
214841343|NCT03510338|DRUG|Sublingual sildenafil|100 mg biphasic sildenafil tablet
214841344|NCT03510338|DRUG|Oral sildenafil|50 mg oral sildenafil (Viagra)
214841345|NCT04309162|OTHER|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
214841346|NCT04975451|DRUG|Anlotinib|Anlotinib plus DCb
214841347|NCT00547625|DRUG|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
214841348|NCT00547625|DRUG|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
214841349|NCT03147924|OTHER|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
214841350|NCT04276012|OTHER|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
214841351|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
214841352|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
214841353|NCT01085578|DRUG|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
214841354|NCT04478526|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
214841355|NCT04478526|BEHAVIORAL|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
214841356|NCT03985046|DRUG|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
214841357|NCT00630578|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
214841358|NCT01339377|DEVICE|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
214841359|NCT02448563|BEHAVIORAL|Nutrition and physical activity education|Eight weekly in-person groups
214841360|NCT02913755|BEHAVIORAL|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
214841361|NCT04409054|OTHER|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
214841362|NCT05128136|DEVICE|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
214841363|NCT02227615|DIETARY_SUPPLEMENT|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
214841364|NCT02227615|DIETARY_SUPPLEMENT|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
214841365|NCT03720704|DEVICE|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
214841366|NCT02538211|BIOLOGICAL|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
214841367|NCT03632694|BEHAVIORAL|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
214841368|NCT03632694|BEHAVIORAL|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
214841369|NCT02340962|DRUG|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
214841370|NCT02340962|DRUG|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
214841371|NCT02340962|DRUG|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
214841372|NCT03243591|OTHER|Livionex gel|Brushing area of mucositis with gel
214841373|NCT03243591|OTHER|Aquafresh gel|Aquafresh gel
214841374|NCT01529554|DRUG|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
214841375|NCT01529554|DRUG|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
214841376|NCT06622486|DRUG|EGL-001|IV administration
214841377|NCT01351363|DEVICE|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
214841378|NCT01351363|DEVICE|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
214841379|NCT01450800|DRUG|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
214841380|NCT01450800|DRUG|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
214841381|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
214841382|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
214841383|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
214841384|NCT04432207|DRUG|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
214841385|NCT04432207|DRUG|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
214841386|NCT00139932|DRUG|formoterol fumarate|
214841387|NCT02005939|DIETARY_SUPPLEMENT|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
214841388|NCT01773239|BEHAVIORAL|TARA computer-based exercises|
214841389|NCT04039490|DEVICE|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
214841390|NCT05685017|DIAGNOSTIC_TEST|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
214841391|NCT05134116|OTHER|Treatment as usual + cerebral oximetry monitoring the first 72 hours of life|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
214841392|NCT05970614|OTHER|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
214841393|NCT05858775|DEVICE|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
214841394|NCT00265785|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
214841395|NCT01287715|DRUG|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
214841396|NCT01287715|DRUG|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
214841397|NCT05948033|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
214841398|NCT00404053|DRUG|Clopidogrel|
214841399|NCT03401918|DIAGNOSTIC_TEST|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
214841400|NCT03401918|DRUG|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
214841401|NCT05222360|OTHER|Education|3 educational sessions about body image and nutrition
214841402|NCT00964873|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
214841403|NCT00052520|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
214841404|NCT00052520|BIOLOGICAL|aldesleukin|Given SC
214841405|NCT00052520|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
214841406|NCT00052520|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
214841407|NCT00052520|OTHER|laboratory biomarker analysis|Correlative studies
214841408|NCT00052520|GENETIC|gene expression analysis|Correlative studies
214841409|NCT00052520|OTHER|immunologic technique|Correlative studies
214841410|NCT00052520|OTHER|flow cytometry|Correlative studies
214841411|NCT00052520|GENETIC|polymerase chain reaction|Correlative studies
214841412|NCT00052520|GENETIC|cytogenetic analysis|Correlative studies
214841413|NCT00052520|OTHER|staining method|Correlative studies
214841414|NCT01294449|DEVICE|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
214841415|NCT01294449|DEVICE|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
214841416|NCT00800618|DRUG|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
214841417|NCT00800618|DRUG|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
214841418|NCT00800618|DRUG|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
214841419|NCT00800618|DRUG|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
214841420|NCT00800618|DRUG|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
214841421|NCT03211455|DRUG|Lidocaine|intravenous lidocaine versus placebo
214841422|NCT03211455|DRUG|isotonic saline|intravenous isotonic saline
214841423|NCT00311649|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|
214841424|NCT06048887|DRUG|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
214841425|NCT06048887|DRUG|Placebo Oral Solution|Placebo
214841426|NCT05233787|PROCEDURE|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
214841427|NCT05233787|PROCEDURE|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
214841428|NCT01720849|DRUG|Fampyra|The will be given as per normal patient treatment plan
214841429|NCT03222037|DEVICE|senofilcon A|Acuvue Oasys 1-Day
214841430|NCT03222037|DEVICE|Control|Trial Frame with best spherocylindrical refraction (SCR)
214841431|NCT05966207|BEHAVIORAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
214841432|NCT05478928|OTHER|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
214841433|NCT05478928|DEVICE|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
214841434|NCT05478928|OTHER|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
214841435|NCT05478928|DEVICE|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
214841436|NCT05478928|DEVICE|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
214841437|NCT05478928|OTHER|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
214841438|NCT01318161|DRUG|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
214841439|NCT01318161|DRUG|Morphine|Morphine via PCA pump
214841440|NCT05397795|DRUG|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
214841441|NCT05397795|DRUG|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
214841442|NCT00496262|BIOLOGICAL|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
214841443|NCT05787392|BEHAVIORAL|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
214841444|NCT03022539|RADIATION|Repeat CT scan|
214841445|NCT02020109|RADIATION|splenic irradiation|
214841446|NCT03547817|DEVICE|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
214841447|NCT00432627|DRUG|Deferasirox|one dose of 20 mg/kg/day
214841448|NCT05840276|DEVICE|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
214841449|NCT05840276|OTHER|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
214841450|NCT06678776|PROCEDURE|surgery|Explore the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty.
214841451|NCT01337882|OTHER|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
214841452|NCT02247076|BEHAVIORAL|Grazing|
214841453|NCT02247076|BEHAVIORAL|Time-restricted feeding (early eating)|
214841454|NCT02724826|BEHAVIORAL|Qigong therapy|Medical qigong
214841455|NCT02724826|BEHAVIORAL|Exercise therapy|Regular exercise
214841456|NCT01940263|DIETARY_SUPPLEMENT|Anthocyanin|
214841457|NCT01940263|DIETARY_SUPPLEMENT|Placebo|
214841458|NCT02221817|PROCEDURE|Trochanter bursa injections|
214841459|NCT02221817|DEVICE|Ultrasound|
214841460|NCT03847363|PROCEDURE|epidural anesthesia|epidural anesthesia
214841461|NCT03847363|PROCEDURE|nerve block|paravertebral or serratus anterior plane block
214841462|NCT05409352|BEHAVIORAL|Self-administered acupressure|Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).
214841463|NCT05409352|BEHAVIORAL|Aerobic exercise|Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
214841464|NCT06808646|DRUG|pitavastatin|Single oral administration
214841465|NCT06808646|DRUG|pitavastatin single dose combined with ceftobiprole|Single oral pitavastatin co-administered with IV ceftobiprole
214841466|NCT03380130|DRUG|Nivolumab|An anti-programmed death 1 monoclonal antibody
214841467|NCT03380130|DEVICE|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
214841468|NCT01311427|BEHAVIORAL|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
214841469|NCT01311427|BEHAVIORAL|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
214841470|NCT03011060|PROCEDURE|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
214841471|NCT03011060|DRUG|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
214841472|NCT01362673|DRUG|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
214841473|NCT01362673|DRUG|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
214841474|NCT01362673|DRUG|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
214841475|NCT01362673|DRUG|Placebo|Oral single dose as matching placebo
214841476|NCT01362673|DRUG|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
214841477|NCT01362673|DRUG|Placebo|Oral multiple doses as matching placebo for 12 days
214841478|NCT02636829|OTHER|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
214841479|NCT02636829|OTHER|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
214841480|NCT00134329|PROCEDURE|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
214841481|NCT04080596|DRUG|Dorzagliatin|GKA for T2DM currently under clinical development
214841482|NCT01334957|DRUG|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
214841483|NCT01544439|PROCEDURE|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
214841484|NCT01544439|PROCEDURE|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
214841485|NCT00398684|DRUG|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
214841486|NCT00398684|DRUG|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
214841487|NCT00398684|DRUG|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
214841488|NCT02665884|OTHER|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
214841489|NCT00782561|DRUG|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
214841490|NCT05638607|BEHAVIORAL|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
214841491|NCT04291508|DRUG|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
214841492|NCT04291508|DRUG|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
214841493|NCT04291508|DRUG|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
214841494|NCT04291508|DRUG|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
214841495|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, low dose|infusion
214841496|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, high dose|infusion
214841497|NCT05445076|OTHER|placebo|infusion
214841498|NCT04659096|DRUG|ION537|ION537 will be administered by IV injection.
214841499|NCT03601845|OTHER|Stimuli|Visual stimulation while using additional sequencing
214841500|NCT03601845|OTHER|No stimuli|Additional sequencing only
214841501|NCT04572204|OTHER|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
214841502|NCT00026416|BIOLOGICAL|recombinant interferon alfa|
214841503|NCT00026416|DRUG|thalidomide|
214841504|NCT00026416|PROCEDURE|adjuvant therapy|
214841505|NCT05303948|DEVICE|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
214841506|NCT00274495|DRUG|Rosiglitazone and Pegasys/Ribavirin|
214841507|NCT05775120|DIAGNOSTIC_TEST|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
214841508|NCT06161701|OTHER|no intervention|no intervention
214841509|NCT00401154|OTHER|Stationary Cycling|Use of a stationary bicycle for exercise
214841510|NCT02704195|PROCEDURE|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
214841511|NCT02704195|PROCEDURE|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
214841512|NCT02440555|OTHER|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
214841513|NCT02270034|DRUG|Crizotinib|Crizotinib is added to Stupp method
214841514|NCT05768087|RADIATION|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
214841515|NCT06873698|BEHAVIORAL|Neuro-behavioral Therapy|Neuro-behavioral therapy (NBT) is an evidence-based, multi-modality, time-limited, whole-person therapy, delivered in one hour, weekly, individual appointments. NBT has been used to treat epilepsy, nonepileptic (functional) seizures, and motor functional neurological disorder (mFND).
214841516|NCT06873698|OTHER|Standard Medical Care (SMC)|Standard Medical Care (SMC) involves the routine care received by the participant. SMC may include any of the following evaluation and followup appointments with neurology, physiatry, psychiatry, psychology, mental health, rehabilitation (e.g., Physical Therapy, Occupational Therapy, Speech and Language Therapy), primary care, among other specialists.
214841517|NCT04883450|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
214841518|NCT00912522|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
214841519|NCT02329431|BEHAVIORAL|activation curriculum|psychosocial activation curriculum
214841520|NCT02329431|BEHAVIORAL|support group|parent directed support group
214841521|NCT02821949|BIOLOGICAL|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
214841522|NCT05194709|BIOLOGICAL|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
214841523|NCT01939106|DEVICE|One Piece Drainable Pouch|
214841524|NCT05347394|DRUG|VX-708|Solution or suspension for oral administration.
214841525|NCT05347394|DRUG|Placebo|Placebo matched to VX-708 for oral administration.
214841526|NCT05531617|PROCEDURE|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
214841527|NCT00826345|OTHER|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~\- Active"
214841528|NCT00826345|OTHER|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
214841529|NCT00115024|DRUG|Micronized 17B-estradiol|
214841530|NCT00942812|OTHER|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
214841531|NCT00942812|OTHER|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
214841532|NCT04734782|DIAGNOSTIC_TEST|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
214841533|NCT00668096|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
214841534|NCT00668096|DRUG|Placebo|Matching Placebo
214841535|NCT02413424|DIETARY_SUPPLEMENT|Sucralose|60 ml of 2mM sucralose
214841536|NCT02413424|OTHER|Water|60 ml of water
214841537|NCT02413424|DIETARY_SUPPLEMENT|glucose load|
214841538|NCT02103582|OTHER|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
214841539|NCT06876272|BEHAVIORAL|Healthy eating promoting programme|It is a comprehensive, multi-component intervention tailored specifically for higher education students. Unlike many traditional health programs, this intervention uniquely combines the use of social media campaigns, behavioral nudges in student cafeterias, and interactive boost workshops.
214841540|NCT06878222|DRUG|Neoadjuvant Chemotherapy|paclitaxel, 135-175mg/m2, q3w, 3 cycles
214841541|NCT06878222|DRUG|Neoadjuvant Chemotherapy|cisplatin, 75-80mg/m2, q3w, 3 cycles
214841542|NCT06878222|DRUG|Immunotherapy|Iparomlimab and Tuvonralimab, 5mg/kg, q3w, 3cycles
214841543|NCT06878222|PROCEDURE|Radical surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo radical hysterectomy plus lymphadenectomy
214841544|NCT06878222|PROCEDURE|Fertility-preserving surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Fertility-preserving surgery. For stage IB1/IB2 patients, conization or simple trachelectomy plus lymphadenectomy will be performed. For stage IIA1/IIA2 patients, radical trachelectomy plus lymphadenectomy will be performed.
214841545|NCT00003350|DRUG|paclitaxel|Given IV
214841546|NCT00003350|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214841547|NCT00003350|OTHER|laboratory biomarker analysis|Correlative studies
214841548|NCT00003350|PROCEDURE|quality-of-life assessment|Ancillary studies
214841549|NCT00031707|DIETARY_SUPPLEMENT|eicosapentaenoic acid|
214841550|NCT00031707|DRUG|megestrol acetate|
214841551|NCT00031707|OTHER|placebo|
214841552|NCT06715475|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take five capsules per day in the morning.
214841553|NCT06715475|DIETARY_SUPPLEMENT|Food not containing plasmalogen|Take five capsules per day in the morning.
214841554|NCT06732830|DEVICE|DayDrop Advanced ophthalmic drop|The patient will administer 1 or 2 drops of DayDrop Advanced in each eye 3 times a day for 3 months.
214841555|NCT02405793|DRUG|Meloxicam Test Capsules|
214841556|NCT02405793|DRUG|Meloxicam Test Capsules|
214841557|NCT02405793|DRUG|Meloxicam Tablets|
214841558|NCT00890279|DRUG|Cilnidipine|Cilnidipine up to 20 mg
214841559|NCT00890279|DRUG|Imidapril|Imidapril up to 10 mg per day
214841560|NCT03478007|DEVICE|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
214841561|NCT03478007|DEVICE|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
214841562|NCT06740500|DIETARY_SUPPLEMENT|Probiotic|probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
214841563|NCT06740500|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214841564|NCT02625974|DRUG|Nifurtimox (Lampit, BAYA2502)|"For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment"
214841565|NCT02625974|DRUG|Placebo|Matching placebo
214841566|NCT01376882|DIETARY_SUPPLEMENT|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
214841567|NCT01376882|DIETARY_SUPPLEMENT|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
214841568|NCT01376882|DIETARY_SUPPLEMENT|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
214841569|NCT01376882|DIETARY_SUPPLEMENT|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
214841570|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
214841571|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
214841572|NCT05868824|OTHER|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
214841573|NCT06024382|OTHER|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
214841574|NCT06024382|OTHER|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
214841575|NCT01977456|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
214841576|NCT01142661|DRUG|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
214841577|NCT06030128|BEHAVIORAL|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
214841578|NCT00409461|DRUG|ATG-Sirolimus-Tacrolimus|
214841579|NCT04220736|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
214841580|NCT02350036|OTHER|ultrasound monitoring|Uterine artery Doppler assessment
214841581|NCT04651920|GENETIC|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
214841582|NCT00434590|DRUG|Enteric coated mycophenolate sodium (Myfortic®)|
214841583|NCT00779441|DRUG|Zolpidem 10mg tablets|
214841584|NCT02727725|OTHER|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
214841585|NCT05422235|OTHER|Routine Medical Treatment|Subjects will continue their routine medical treatment.
214841586|NCT05422235|OTHER|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
214841587|NCT05422235|OTHER|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
214841588|NCT05385471|BIOLOGICAL|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
214841589|NCT04436926|BEHAVIORAL|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
214841590|NCT04436926|BEHAVIORAL|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
214841591|NCT02847208|OTHER|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
214841592|NCT06331767|BEHAVIORAL|mSYNC|mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
214841593|NCT06349096|DEVICE|Alma Harmony|The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
214841594|NCT04318769|BEHAVIORAL|AFFIRM|AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
214841595|NCT00851006|DRUG|Creatine Monohydrate|Creapure brand of creatine monohydrate
214841596|NCT02129062|DRUG|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
214841597|NCT02129062|OTHER|Laboratory Biomarker Analysis|Correlative studies
214841598|NCT02773940|DEVICE|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
214841599|NCT02945527|DRUG|Acetazolamide|As described above
214841600|NCT02945527|DRUG|Dexamethasone|As described above
214841601|NCT04505735|DRUG|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
214841602|NCT03738787|PROCEDURE|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
214841603|NCT03738787|PROCEDURE|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
214841604|NCT02304978|BIOLOGICAL|Group CRC|blood samples
214841605|NCT02304978|BIOLOGICAL|Group control|Blood samples
214841606|NCT06181253|OTHER|Preoperative education|The intervention will be an instructional video describing proper walking technique particularly up flights of stairs for patients to do at home. This will be shown at preoperative surgical clinic and will be available for access at home from patient's cell phones. The video is currently in production at BMC. Additionally, text reminders will be sent daily to remind patients to walk at home.
214841607|NCT06181253|BEHAVIORAL|Moderate aerobic exercise|Participants will be encouraged to compete 140-150 minutes of moderate aerobic exercise per week- achieved by two walking sessions per day 10-11 minutes in length (realistic/achievable goal)
214841608|NCT06181253|OTHER|Text messages|Text reminders will be sent daily to remind patients to walk at home.
214841609|NCT06181253|BEHAVIORAL|Pedometer|Participants will be encouraged to walk 10,000 steps daily which will be tracked with a pedometer
214841610|NCT05450991|PROCEDURE|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
214841611|NCT00516087|BIOLOGICAL|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"
214841612|NCT04779034|OTHER|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
214841613|NCT01643434|DRUG|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
214841614|NCT01643434|DRUG|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
214841615|NCT06616077|DRUG|Micronized Progesterone 600 mg|Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
214841616|NCT06616077|DRUG|mifepristone 200 mg|Post ovulatory single oral administration (LH+2, LH peak=LH+0)
214841617|NCT06616077|DRUG|Oral Placebo Tablet|Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
214841618|NCT06616077|DRUG|Placebo Vaginal|Cocoa butter
214841619|NCT00890942|DRUG|naloxone|naloxone 0.4mg.(1 ml) intramuscular
214841620|NCT00890942|DRUG|normal saline|normal saline 1 ml IM
214841621|NCT00248937|BEHAVIORAL|Positive affect and self-affect induction|
214841622|NCT00349401|DRUG|ketorolac|
214841623|NCT00349401|DRUG|morphine|
214841624|NCT00527917|DEVICE|placebo|bladder instillation
214841625|NCT00527917|DEVICE|Uracyst|20 ml sterile solution for weekly intravesical instillation
214841626|NCT02722616|DEVICE|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
214841627|NCT02722616|DEVICE|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
214841628|NCT02722616|DRUG|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
214841629|NCT03460990|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
214841630|NCT03460990|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
214841631|NCT03460990|DRUG|IVA|Participants received IVA orally once daily in the evening.
214841632|NCT03460990|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
214841633|NCT03460990|DRUG|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
214841634|NCT02086344|PROCEDURE|PBS|TLH plus PBS
214841635|NCT02086344|PROCEDURE|TLH _adnexal preservation|TLH without PBS
214841636|NCT04167696|BIOLOGICAL|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
214841637|NCT04167696|DRUG|ENDOXAN|administered as preconditioning chemotherapy
214841638|NCT04167696|DRUG|Fludara|administered as preconditioning chemotherapy
214841639|NCT01923311|DRUG|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
214841640|NCT01923311|DRUG|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
214841641|NCT02031237|RADIATION|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
214841642|NCT02031237|RADIATION|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
214841643|NCT02031237|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
214841644|NCT02031237|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
214841645|NCT00825864|DRUG|diclofenac drops|one drop 4 times a day for 3 months
214841646|NCT00825864|DRUG|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
214841647|NCT04963608|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
214841648|NCT04451980|PROCEDURE|Subcutaneous adipose tissue biopsy|Percutaneous adipose tissue biopsy
214841649|NCT04451980|RADIATION|CT scan|CT scan of chest and abdomen without contrast
214841650|NCT04451980|DIAGNOSTIC_TEST|Oral glucose tolerance test|Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
214841651|NCT04451980|DIAGNOSTIC_TEST|Blood collection|Fasting blood collection for plasma cytokines and T cell phenotypes.
214841652|NCT01435824|DRUG|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
214841653|NCT01435824|DRUG|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
214841654|NCT01011335|BIOLOGICAL|Monovalent rAT|10, 25, 50 or 100 μg
214841655|NCT01011335|BIOLOGICAL|Monovalent rLukS-PV|10, 25, 50 or 100 μg
214841656|NCT01011335|BIOLOGICAL|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
214841657|NCT01011335|BIOLOGICAL|Placebo with adjuvant|Placebo with adjuvant
214841658|NCT01011335|BIOLOGICAL|Placebo|Placebo saline
214841659|NCT02040519|BEHAVIORAL|Filling out voiding diaries.|
214841660|NCT04667936|OTHER|Treatment group|None, solely treatment documentation
214841661|NCT00117806|BEHAVIORAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
214841662|NCT00117806|BEHAVIORAL|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
214841663|NCT04231409|DEVICE|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
214841664|NCT01474915|DRUG|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
214841665|NCT01474915|DRUG|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
214841666|NCT01474915|DRUG|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
214841667|NCT01474915|DRUG|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
214841668|NCT01665651|DRUG|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
214841669|NCT01665651|DRUG|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
214841670|NCT01665651|DRUG|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
214841671|NCT01665651|DRUG|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
214841672|NCT01765751|PROCEDURE|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
214841673|NCT03256994|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
214841674|NCT03256994|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
214841675|NCT04837079|OTHER|Clinical observational study|Clinical observational study
214841676|NCT01031992|DRUG|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
214841677|NCT01031992|DRUG|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
214841678|NCT05898113|OTHER|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
214841679|NCT05898113|OTHER|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
214841680|NCT01487434|BEHAVIORAL|Check & Connect|Structured mentoring and case management
214841681|NCT03380416|OTHER|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
214841682|NCT03380416|OTHER|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
214841683|NCT05739734|DRUG|CRIS100|local application of CRIS100
214841684|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
214841685|NCT01919541|DEVICE|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
214841686|NCT01919541|DEVICE|hyperinsulinemic euglycemic hyperaminoacid clamp|
214841687|NCT01919541|DIETARY_SUPPLEMENT|whey protein supplementation|
214841688|NCT01919541|OTHER|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
214841689|NCT02685696|DEVICE|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
214841690|NCT02685696|DEVICE|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
214841691|NCT03609242|BEHAVIORAL|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
214841692|NCT05945667|DRUG|Monural|1 sachet, only 1st day of trial
214841693|NCT05945667|DIETARY_SUPPLEMENT|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
214841694|NCT00661921|BIOLOGICAL|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
214841695|NCT00661921|BIOLOGICAL|Placebo|AMG 108 volume matching placebo
214841696|NCT05528302|OTHER|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
214841697|NCT00079521|PROCEDURE|Therapeutic Touch|
214841698|NCT02902887|DEVICE|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
214841699|NCT04449536|DRUG|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
214841700|NCT04380675|OTHER|Music|Music listening during ESWL
214841701|NCT00144833|DRUG|fosamprenavir/ritonavir (700mg/100mg BID)|
214841702|NCT00144833|DRUG|fosamprenavir/ritonavir (1400mg/100mg BID)|
214841703|NCT00144833|DRUG|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
214841704|NCT04689100|DRUG|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
214841705|NCT04689100|DRUG|JMT101|IV infusion Q2W (28-day cycles)
214841706|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
214841707|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Hamstring Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
214841708|NCT03879486|OTHER|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
214841709|NCT04458168|BEHAVIORAL|Use of Purposeful app|"Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment."
214841710|NCT00812318|DRUG|GSK1265744 10 mg oral solution|GSK1265744
214841711|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
214841712|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
214841713|NCT02934633|BEHAVIORAL|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
214841714|NCT02934633|BEHAVIORAL|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
214841715|NCT00462891|OTHER|IT System|
214841716|NCT00736918|BEHAVIORAL|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
214841717|NCT00736918|OTHER|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
214841718|NCT01731249|BIOLOGICAL|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
214841719|NCT01731249|BIOLOGICAL|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
214841720|NCT04897113|PROCEDURE|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
214841721|NCT04897113|PROCEDURE|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
214841722|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841723|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841724|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841725|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841726|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841727|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
214841728|NCT02459418|DRUG|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
214841729|NCT02459418|DRUG|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
214841730|NCT04600739|PROCEDURE|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
214841731|NCT01137734|DEVICE|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
214841732|NCT01137734|DEVICE|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
214841733|NCT02332213|PROCEDURE|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
214841734|NCT02332213|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
214841735|NCT02332213|PROCEDURE|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
214841736|NCT02332213|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
214841737|NCT02332213|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
214841738|NCT02332213|PROCEDURE|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
214841739|NCT04665817|DIAGNOSTIC_TEST|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
214841740|NCT04665817|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
214841741|NCT04665817|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
214841742|NCT02034448|PROCEDURE|Continuous Renal Replacement Therapy|
214841743|NCT00564343|OTHER|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
214841744|NCT00963651|DEVICE|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
214841745|NCT05258630|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
214841746|NCT05258630|BEHAVIORAL|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
214841747|NCT04405908|BIOLOGICAL|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
214841748|NCT04405908|BIOLOGICAL|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
214841749|NCT04405908|BIOLOGICAL|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
214841750|NCT04405908|BIOLOGICAL|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
214841751|NCT03303417|DIAGNOSTIC_TEST|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
214841752|NCT03303417|OTHER|Kiwifruit|Kiwifruit
214841753|NCT03303417|OTHER|calorie-matched sugar drink|calorie-matched sugar drink
214841754|NCT06280417|DEVICE|Unreamed intramedullary tibial nail|Fixation of type IIIa tibial fractures by unreamed IMN
214841755|NCT04587258|BEHAVIORAL|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
214841756|NCT05752565|DEVICE|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
214841757|NCT02205502|DRUG|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
214841758|NCT02205502|DRUG|Normal saline|
214841759|NCT01545739|DEVICE|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
214841760|NCT03690089|DRUG|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
214841761|NCT03690089|OTHER|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
214841762|NCT00498316|PROCEDURE|Cord Blood Infusion|Cord blood transplantation performed on day 0.
214841763|NCT00498316|DRUG|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
214841764|NCT00498316|DRUG|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
214841765|NCT00498316|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
214841766|NCT00498316|OTHER|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
214841767|NCT00498316|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
214841768|NCT00498316|DRUG|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
214841769|NCT00498316|RADIATION|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
214841770|NCT00498316|DRUG|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
214841771|NCT00498316|DRUG|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
214841772|NCT00498316|DRUG|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
214841773|NCT00498316|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is \> 2.5 x 109/L.
214841774|NCT01848210|DRUG|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
214841775|NCT01848210|DRUG|Placebo|Coumarin + troxerutin placebo-matching tablets
214841776|NCT04970498|DIAGNOSTIC_TEST|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
214841777|NCT04970498|DIAGNOSTIC_TEST|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
214841778|NCT03474328|DEVICE|AlcoChange|Smartphone app and breathalyser
214841779|NCT01710605|BIOLOGICAL|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
214841780|NCT05338853|OTHER|Gongs mobilization|to deal adhesive capsulitis
214841781|NCT05338853|OTHER|scapular mobilization|scapular mobilization
214841782|NCT02992457|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily.
214841783|NCT02992457|DRUG|Ribavirin|Ribavirin 1000-1200 mg daily
214841784|NCT02992457|DRUG|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
214841785|NCT02992457|DRUG|Simeprevir|Olysio once daily.
214841786|NCT02992457|DRUG|Daclatasvir|Dakla once daily for three months.
214841787|NCT02992457|DRUG|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
214841788|NCT02992457|DRUG|Sofosbuvir and Ledipasvir|Once daily for three months
214841789|NCT02992457|DRUG|Salvage therapy|three months in repeated treatment failure
214841790|NCT02976051|RADIATION|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
214841791|NCT01089530|BEHAVIORAL|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
214841792|NCT01053091|BEHAVIORAL|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
214841793|NCT06678230|DRUG|Anlotinib|Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
214841794|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
214841795|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
214841796|NCT02093871|DEVICE|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
214841797|NCT01247844|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
214841798|NCT01374724|BEHAVIORAL|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
214841799|NCT01374724|BEHAVIORAL|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
214841800|NCT01374724|BEHAVIORAL|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
214841801|NCT01374724|BEHAVIORAL|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
214841802|NCT02041858|OTHER|Altered Alarm Settings|An altered set of alarm parameter settings
214841803|NCT01561924|DRUG|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
214841804|NCT04219358|DRUG|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
214841805|NCT04219358|DRUG|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
214841806|NCT04219358|DRUG|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
214841807|NCT04219358|DRUG|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
214841808|NCT04219358|DRUG|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
214841809|NCT04219358|DRUG|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
214841810|NCT00019734|BIOLOGICAL|aldesleukin|
214841811|NCT00019734|BIOLOGICAL|fowlpox virus vaccine vector|
214841812|NCT00019734|BIOLOGICAL|vaccinia-tyrosinase vaccine|
214841813|NCT01787110|DRUG|Oxygen|see arm description
214841814|NCT05268419|DRUG|Ethanol|Inhalation of 35%-ethanol spray
214841815|NCT05268419|DRUG|Water Distilled|Inhalation of water distilled spray
214841816|NCT01118819|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
214841817|NCT04060134|OTHER|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
214841818|NCT04060134|OTHER|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
214841819|NCT04060134|OTHER|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
214841820|NCT04060134|OTHER|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
214841821|NCT04060134|OTHER|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
214841822|NCT01134341|DRUG|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
214841823|NCT01134341|DRUG|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
214841824|NCT01134341|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
214841825|NCT01134341|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
214841826|NCT00387517|DRUG|Aliskiren/HCTZ|
214841827|NCT01142141|OTHER|manual therapy, kinesiotherapy|
214841828|NCT02603549|OTHER|Pituitary panel will be drawn pre-op and post-op for all patients.|
214841829|NCT02048696|OTHER|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
214841830|NCT05965817|DRUG|SGM-101 op top of ICG|SGM-101 op top of ICG
214841831|NCT00081172|RADIATION|lutetium Lu 177 monoclonal antibody J591|
214841832|NCT00114595|DRUG|eicosapentaenoic acid|
214841833|NCT00664287|DRUG|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
214841834|NCT00664287|DRUG|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
214841835|NCT03473067|BEHAVIORAL|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
214841836|NCT03473067|OTHER|Capacity Building|Schools will participate in teacher training and parent training.
214841837|NCT02550587|BEHAVIORAL|satisfaction|anesthesia satisfaction rates
214841838|NCT06471478|COMBINATION_PRODUCT|intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion|patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.
214841839|NCT04228978|BEHAVIORAL|Weight loss|Walking exercise combined with weight loss
214841840|NCT04228978|BEHAVIORAL|Exercise|Walking exercise
214841841|NCT02333188|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214841842|NCT02333188|DRUG|Leucovorin Calcium|Given IV
214841843|NCT02333188|DRUG|Irinotecan Hydrochloride|Given IV
214841844|NCT02333188|DRUG|Fluorouracil|Given IV
214841845|NCT02333188|OTHER|Laboratory Biomarker Analysis|Correlative studies
214841846|NCT00695383|BEHAVIORAL|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
214841847|NCT00695383|BEHAVIORAL|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
214841848|NCT02076776|BEHAVIORAL|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
214841849|NCT02076776|BEHAVIORAL|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
214841850|NCT02076776|BEHAVIORAL|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
214841851|NCT06380257|OTHER|Observational study methods|Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
214841852|NCT04830982|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
214841853|NCT04830982|OTHER|Placebo|Placebo added to one liter of cardioplegia
214841854|NCT05050981|DRUG|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
214841855|NCT05050981|DRUG|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
214841856|NCT04540718|OTHER|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
214841857|NCT04540718|OTHER|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
214841858|NCT03895619|OTHER|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
214841859|NCT00879541|BIOLOGICAL|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
214841860|NCT00879541|BIOLOGICAL|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
214841861|NCT00879541|BIOLOGICAL|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
214841862|NCT00040690|BIOLOGICAL|filgrastim|
214841863|NCT00040690|DRUG|cyclophosphamide|
214841864|NCT00040690|DRUG|cytarabine|
214841865|NCT00040690|DRUG|doxorubicin hydrochloride|
214841866|NCT00040690|DRUG|etoposide|
214841867|NCT00040690|DRUG|ifosfamide|
214841868|NCT00040690|DRUG|leucovorin calcium|
214841869|NCT00040690|DRUG|methotrexate|
214841870|NCT00040690|DRUG|vincristine sulfate|
214841871|NCT00040690|RADIATION|radiation therapy|
214841872|NCT02426541|DRUG|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
214841873|NCT02426541|DRUG|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
214841874|NCT00745134|DRUG|Capecitabine|Given PO
214841875|NCT00745134|DIETARY_SUPPLEMENT|Curcumin|Given PO
214841876|NCT00745134|OTHER|Laboratory Biomarker Analysis|Correlative studies
214841877|NCT00745134|OTHER|Pharmacological Study|Optional correlative studies
214841878|NCT00745134|OTHER|Placebo|Given PO
214841879|NCT00745134|OTHER|Quality-of-Life Assessment|Ancillary studies
214841880|NCT00745134|RADIATION|Radiation Therapy|Undergo radiation therapy
214841881|NCT05103449|OTHER|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
214841882|NCT05443919|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
214841883|NCT00930241|DRUG|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
214841884|NCT00930241|DRUG|Prograf®|Prograf® (two daily doses of Tacrolimus)
214841885|NCT00631007|DRUG|INT131 besylate|Once-daily, oral
214841886|NCT00631007|DRUG|Pioglitazone HCl|Once-daily, oral
214841887|NCT00631007|DRUG|Placebo|Once-daily, oral
214841888|NCT00683787|DRUG|docetaxel|Given IV once every 3 weeks
214841889|NCT00683787|DRUG|vandetanib|Oral vandetanib once daily
214841890|NCT04615533|OTHER|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
214841891|NCT02674633|DEVICE|AKL-T01|Videogame-like digital therapy
214841892|NCT02674633|DEVICE|AKL-T09|Videogame-like digital therapy
214841893|NCT00460109|BIOLOGICAL|denileukin diftitox|
214841894|NCT00460109|BIOLOGICAL|rituximab|
214841895|NCT01780480|DRUG|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
214841896|NCT01780480|DRUG|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
214841897|NCT01780480|PROCEDURE|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
214841898|NCT00470860|BEHAVIORAL|Participation in LOFTS online tutorial|
214841899|NCT02994394|DRUG|OPC-41061|
214841900|NCT01658202|DRUG|V0116 transdermal patch (Test treatment )|
214841901|NCT01658202|DRUG|Nicotine transdermal patch (Reference Treatment )|
214841902|NCT02518217|BEHAVIORAL|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
214841903|NCT02518217|BEHAVIORAL|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
214841904|NCT02518217|BEHAVIORAL|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
214841905|NCT02067702|PROCEDURE|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
214841906|NCT04958252|DRUG|BI 1569912|BI 1569912
214841907|NCT04958252|DRUG|Placebo|Placebo
214841908|NCT05287399|DRUG|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
214841909|NCT05287399|DRUG|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
214841910|NCT05287399|DRUG|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
214841911|NCT05287399|DRUG|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
214841912|NCT05287399|DRUG|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
214841913|NCT04638270|BIOLOGICAL|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
214841914|NCT05744700|DIETARY_SUPPLEMENT|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
214841915|NCT05744700|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
214841916|NCT03250455|DIAGNOSTIC_TEST|CTA CTP|CT Angiography myocardial CT Perfusion
214841917|NCT03250455|DIAGNOSTIC_TEST|CTA|CT Angiography
214841918|NCT02553655|PROCEDURE|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
214841919|NCT02553655|PROCEDURE|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
214841920|NCT02553655|PROCEDURE|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
214841921|NCT04027881|BEHAVIORAL|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
214841922|NCT02555319|DEVICE|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
214841923|NCT03998319|DRUG|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
214841924|NCT03998319|OTHER|Sterile water for injection (WFI)|Placebo comparative arm.
214841925|NCT06616961|DRUG|Semaglutide Pen|"In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability."
214841926|NCT03331159|DEVICE|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
214841927|NCT03331159|DEVICE|Homologous Bone|Cage was filled with homologous bone
214841928|NCT04868565|DRUG|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
214841929|NCT06065865|BEHAVIORAL|Guidance document|"The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task."
214841930|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
214841931|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
214841932|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
214841933|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
214841934|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
214841935|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
214841936|NCT05788276|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin active tablets
214841937|NCT05788276|DRUG|Placebo|Matched placebo tablets
214841938|NCT03380221|OTHER|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
214841939|NCT03380221|OTHER|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
214841940|NCT05979610|OTHER|Reiki therapy|"Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization."
214841941|NCT04422236|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
214841942|NCT05747924|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
214841943|NCT05747924|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion
214841944|NCT05589337|BEHAVIORAL|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
214841945|NCT05589337|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
214841946|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
214841947|NCT06428695|BEHAVIORAL|one-hour dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
214841948|NCT06829784|DRUG|TQC2731 injection|TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
214841949|NCT06829784|DRUG|Placebo|Placebo without drug substance.
214841950|NCT03260842|DIAGNOSTIC_TEST|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
214841951|NCT05914506|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
214841952|NCT06099301|BEHAVIORAL|Brief advice of a list of mobile apps|The mobile apps in the list should: (1) focus primarily on anxiety/depression/stress, (2) be available for free download; (3) be available in English or Chinese; and (4) have a user star rating in the app store.
214841953|NCT05375669|DEVICE|ISIS IOM System|"The constant-current TES stimulators will be used in this study with a high-precision oscilloscope. The calibration will assess 5-pulse trains with a 4 ms ISI and 100 mA output across a 1000 Ω resistor at 250, 500, and 1000 µs D. Measurements will include actual I and D of each pulse, and actual ISI.~Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement."
214841954|NCT06467825|DRUG|Potassium Supplement|Participants will be given a potassium supplement that will help prevent low blood potassium levels.
214841955|NCT06467825|DRUG|Furosemide 20 MG|Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
214841956|NCT06467825|DEVICE|Compression Garment|From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
214841957|NCT06528756|PROCEDURE|shockwave therapy|ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.
214841958|NCT06528756|PROCEDURE|Barbotage|"US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way."
214841959|NCT04841915|DIETARY_SUPPLEMENT|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
214841960|NCT04841915|BEHAVIORAL|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
214841961|NCT04841915|BEHAVIORAL|Weight loss|4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
214841962|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
214841963|NCT02370199|DEVICE|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
214841964|NCT02370199|DRUG|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
214841965|NCT05615376|DEVICE|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
214841966|NCT05615376|DEVICE|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
214841967|NCT06316830|DRUG|Buprenorphine|Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
214841968|NCT03977194|DRUG|Carboplatin|AUC 6 every 4 weeks
214841969|NCT03977194|DRUG|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
214841970|NCT03977194|DRUG|Atezolizumab|1200 mg every 3 weeks
214841971|NCT04467333|OTHER|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
214841972|NCT01104181|DEVICE|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
214841973|NCT03385135|DRUG|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
214841974|NCT01388257|PROCEDURE|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
214841975|NCT01388257|PROCEDURE|Simple seton drain removal|Patients are simply followed after seton drain removal.
214841976|NCT03599921|BEHAVIORAL|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
214841977|NCT03599921|BEHAVIORAL|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
214841978|NCT03599921|BEHAVIORAL|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
214841979|NCT03599921|BEHAVIORAL|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
214841980|NCT05869916|BEHAVIORAL|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
214841981|NCT02327325|BEHAVIORAL|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
214841982|NCT02327325|BEHAVIORAL|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
214841983|NCT01507233|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
214841984|NCT01507233|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
214841985|NCT01507207|PROCEDURE|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
214841986|NCT04212728|BIOLOGICAL|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
214841987|NCT04212728|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
214841988|NCT01617551|DRUG|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
214841989|NCT02638519|OTHER|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
214841990|NCT02638519|OTHER|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
214841991|NCT02638519|DRUG|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
214841992|NCT02638519|DEVICE|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
214841993|NCT03300908|BEHAVIORAL|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
214841994|NCT03300908|BEHAVIORAL|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
214841995|NCT04417647|DEVICE|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
214841996|NCT04417647|PROCEDURE|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
214841997|NCT04964674|BEHAVIORAL|Behavioral Measurement|Take measurements of behavioral performance
214841998|NCT01280344|DRUG|Saline Solution for Injection|Intravenous (IV)
214841999|NCT01280344|DRUG|Ipamorelin|Intravenous (IV)
214842000|NCT02389842|DRUG|Palbociclib + Taselisib / Pictilisib|
214842001|NCT05505305|BEHAVIORAL|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
214842002|NCT04122781|DEVICE|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
214842003|NCT06416852|DRUG|18F-Alfatide Injection|A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
214842004|NCT06416852|DRUG|18F-FDG Injection|A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
214842005|NCT00278174|BIOLOGICAL|recombinant interferon alpha-1b|
214842006|NCT01044394|DRUG|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
214842007|NCT04874896|DIETARY_SUPPLEMENT|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
214842008|NCT04874896|DIETARY_SUPPLEMENT|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
214842009|NCT05560555|DRUG|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
214842010|NCT03920306|DRUG|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
214842011|NCT06123026|DRUG|Cabergoline|1mg oral cabergoline given to participants once
214842012|NCT06123026|DRUG|Placebo|1 encapsulated placebo tablet given to participants after procedure
214842013|NCT00000555|DRUG|estrogen replacement therapy|
214842014|NCT00000555|DRUG|estrogens, conjugated|
214842015|NCT00000555|DRUG|progesterone|
214842016|NCT00000555|DRUG|hormone replacement therapy|
214842017|NCT00000555|DRUG|supplementation, food|
214842018|NCT00000555|DRUG|ascorbic acid|
214842019|NCT00000555|DRUG|vitamin e|
214842020|NCT02428582|DEVICE|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
214842021|NCT02428582|DEVICE|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
214842022|NCT01158326|DRUG|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
214842023|NCT01158326|OTHER|Placebo|10 ml of oral placebo every 6 hours for 48 hours
214842024|NCT02718287|BEHAVIORAL|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
214842025|NCT02718287|BEHAVIORAL|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
214842026|NCT02644798|OTHER|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
214842027|NCT05945992|BEHAVIORAL|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
214842028|NCT05945992|BEHAVIORAL|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
214842029|NCT05945992|BEHAVIORAL|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
214842030|NCT05945992|BEHAVIORAL|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
214842031|NCT05945992|BEHAVIORAL|Control component 1_social behaviors in groups|Control component for emotion regulation
214842032|NCT05945992|BEHAVIORAL|Control component 2_communication skills|Control component for self-acceptance
214842033|NCT05945992|BEHAVIORAL|Control component 3_stress management|Control component for mindfulness
214842034|NCT05945992|BEHAVIORAL|Control component 4_constructive conflict resolution|Control component for resource activation
214842035|NCT02457819|DRUG|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
214842036|NCT06217796|COMBINATION_PRODUCT|MydCombi|A single metered spray administered with the MydCombi dispenser
214842037|NCT01155102|DRUG|Anastrozole|1 mg tablet
214842038|NCT06353308|BEHAVIORAL|Sexual Violence Prevention|The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.
214842039|NCT06353308|BEHAVIORAL|Sexual health intervention|This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
214842040|NCT04025138|OTHER|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)"
214842041|NCT04025138|DEVICE|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
214842042|NCT04025138|OTHER|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
214842043|NCT04025138|OTHER|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
214842044|NCT04025138|BIOLOGICAL|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
214842045|NCT04025138|BIOLOGICAL|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
214842046|NCT03330236|DEVICE|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
214842047|NCT02265406|DRUG|Anti-Infective Agents|
214842048|NCT02265406|DRUG|Placebo|
214842049|NCT05331391|BEHAVIORAL|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
214842050|NCT01191476|DRUG|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
214842051|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
214842052|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
214842053|NCT01032460|DEVICE|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
214842054|NCT01032460|DEVICE|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
214842055|NCT01032460|DEVICE|intubate with the Airtraq device|intubate with the Airtraq device
214842056|NCT05291052|DRUG|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
214842057|NCT05291052|DRUG|Lenvatinib|Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
214842058|NCT05291052|DRUG|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
214842059|NCT05291052|DRUG|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
214842060|NCT03355352|DRUG|Sufentanil|Sufentail sublingual 15ug nanopills
214842061|NCT03788915|BEHAVIORAL|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
214842062|NCT03788915|BEHAVIORAL|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
214842063|NCT01901848|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
214842064|NCT01901848|DRUG|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
214842065|NCT01901848|DRUG|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
214842066|NCT01901848|BEHAVIORAL|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
214842067|NCT01901848|BEHAVIORAL|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
214842068|NCT04664816|DRUG|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
214842069|NCT04664816|DRUG|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
214842070|NCT00763555|DRUG|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
214842071|NCT00763555|DRUG|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
214842072|NCT05824858|DRUG|LY3537982|Administered orally.
214842073|NCT01563458|DRUG|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
214842074|NCT01563458|DRUG|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
214842075|NCT01563458|DRUG|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
214842076|NCT04936919|DEVICE|BroadBand Light|Treatment arm will receive Broadband light treatment
214842077|NCT03844828|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
214842078|NCT00852917|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
214842079|NCT00852917|DRUG|Placebo|One Placebo tablet daily.
214842080|NCT03710590|OTHER|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214842081|NCT03710590|OTHER|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
214842082|NCT03710590|OTHER|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214842083|NCT03710590|OTHER|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214842084|NCT03710590|OTHER|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214842085|NCT03710590|OTHER|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
214842086|NCT05676983|OTHER|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
214842087|NCT05676983|OTHER|Pediatric neurodevelopmental therapy|Bobath therapy
214842088|NCT05676983|OTHER|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
214842089|NCT01997684|PROCEDURE|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
214842090|NCT01997684|PROCEDURE|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
214842091|NCT04596306|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
214842092|NCT00625326|DRUG|COL-121|75 µg/g COL-121 Ointment
214842093|NCT00625326|DRUG|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
214842094|NCT00625326|DRUG|Placebo|Placebo
214842095|NCT00625326|DRUG|COL-121|150 µg/g COL-121 Ointment
214842096|NCT00625326|DRUG|COL-121|300 µg/g COL-121 Ointment
214842097|NCT01718730|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
214842098|NCT01718730|DEVICE|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
214842099|NCT03766139|BIOLOGICAL|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
214842100|NCT03766139|BIOLOGICAL|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
214842101|NCT02488824|PROCEDURE|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
214842102|NCT01917435|DEVICE|video-stylet|
214842103|NCT01917435|DEVICE|fiberoptic bronchoscope|
214842104|NCT01008384|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units taken orally once a week for 8 weeks
214842105|NCT06441903|OTHER|Ultrasound|Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
214842106|NCT00493064|DRUG|Nicotinic acid|topical eye drops
214842107|NCT00493064|DRUG|Prednisolone acetate|topical eye drops
214842108|NCT05811221|DRUG|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
214842109|NCT05811221|DRUG|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
214842110|NCT05966311|DEVICE|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
214842111|NCT03123978|DRUG|Enzalutamide|Given PO
214842112|NCT03123978|DRUG|Niclosamide|Given PO
214842113|NCT00111956|DRUG|Etanercept|
214842114|NCT00111956|DRUG|Placebo|
214842115|NCT05375019|BEHAVIORAL|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
214842116|NCT05375019|BEHAVIORAL|active control group|free interaction group consisting of topics determined by the families.
214842117|NCT05270928|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
214842118|NCT05881642|PROCEDURE|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
214842119|NCT05881642|PROCEDURE|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
214842120|NCT01573533|BIOLOGICAL|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
214842121|NCT00860678|OTHER|Physical activity|
214842122|NCT00860678|OTHER|no Intervention|
214842123|NCT01045707|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
214842124|NCT01045707|DRUG|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
214842125|NCT05037773|BEHAVIORAL|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
214842126|NCT03764735|DRUG|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
214842127|NCT03764735|DRUG|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
214842128|NCT03764735|DRUG|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
214842129|NCT06083402|DIETARY_SUPPLEMENT|HyaCera™|1 Ritual HyaCera capsule once daily
214842130|NCT06083402|DIETARY_SUPPLEMENT|Placebo|1 placebo capsule once daily
214842131|NCT02227459|DRUG|ND-L02-s0201 Injection|
214842132|NCT00500006|DRUG|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
214842133|NCT00500006|DRUG|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
214842134|NCT00734942|OTHER|support service|"* professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life"
214842135|NCT05310708|DIAGNOSTIC_TEST|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
214842136|NCT02507245|DRUG|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
214842137|NCT03907514|BEHAVIORAL|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
214842138|NCT02168140|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214842139|NCT02168140|DRUG|bendamustine hydrochloride|Given IV
214842140|NCT02935296|BEHAVIORAL|Integrated Intervention|systems navigation, psychosocial counseling
214842141|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
214842142|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
214842143|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
214842144|NCT05813379|COMBINATION_PRODUCT|exosime injection|Treatment- exosome injection
214842145|NCT00064584|DRUG|CT53518|
214842146|NCT04317599|OTHER|Non Interventional study|Non Interventional study
214842147|NCT03727737|DEVICE|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
214842148|NCT03123887|OTHER|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
214842149|NCT06161142|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
214842150|NCT06161142|DIAGNOSTIC_TEST|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
214842151|NCT06161142|DIAGNOSTIC_TEST|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
214842152|NCT06161142|DIAGNOSTIC_TEST|SF-36|Quality of life questionnaire
214842153|NCT06161142|DIAGNOSTIC_TEST|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
214842154|NCT06161142|DIAGNOSTIC_TEST|Physical examination|A full rheumatological examination will be performed.
214842155|NCT06161142|DIAGNOSTIC_TEST|Recording of vital signs|(including body temperature, blood pressure, heart rate)
214842156|NCT06161142|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
214842157|NCT06161142|DIAGNOSTIC_TEST|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
214842158|NCT04670406|BEHAVIORAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
214842159|NCT06245759|OTHER|This was a retrospective study and no patient intervention was performed|This was a retrospective study and no patient intervention was performed
214842160|NCT06279806|OTHER|Mobile health application use|"Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed."
214842161|NCT06279806|OTHER|Information of the breast cancer survivor period booklet|Women in the control group will be given information of the breast cancer survivor period booklet.
214842162|NCT06614699|OTHER|abdominal fat and muscle area|Abdominal fat and muscle area were calculated based on abdominal CT.
214842163|NCT05086198|BEHAVIORAL|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
214842164|NCT05086198|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
214842165|NCT00809965|DRUG|Rivaroxaban 2.5 mg|One tablet twice daily
214842166|NCT00809965|DRUG|Rivaroxaban 5 mg|One tablet twice daily
214842167|NCT00809965|DRUG|Placebo|One placebo tablet twice daily
214842168|NCT00809965|DRUG|Standard of care|
214842169|NCT05794724|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
214842170|NCT05653635|RADIATION|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
214842171|NCT03471208|DEVICE|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
214842172|NCT03471208|PROCEDURE|Freehand Implant Surgery|Dental implant surgery via conventional freehand
214842173|NCT05712642|DRUG|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
214842174|NCT05384886|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
214842175|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
214842176|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
214842177|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
214842178|NCT01372124|DRUG|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
214842179|NCT02315066|DRUG|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
214842180|NCT02315066|DRUG|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
214842181|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
214842182|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
214842183|NCT06067451|BEHAVIORAL|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
214842184|NCT05009368|DRUG|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
214842185|NCT05009368|DRUG|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
214842186|NCT05009368|DRUG|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
214842187|NCT04549922|DRUG|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
214842188|NCT04549922|DRUG|Normal Saline|1.2 mL subcutaneous
214842189|NCT04403217|OTHER|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
214842190|NCT06206603|DIAGNOSTIC_TEST|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
214842191|NCT06206603|DIAGNOSTIC_TEST|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
214842192|NCT00112294|DRUG|Paclitaxel (Taxane)|IV, 225 mg/m\^2
214842193|NCT00112294|DRUG|Docetaxel (Taxane)|IV, 75 mg/m\^2
214842194|NCT00112294|DRUG|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
214842195|NCT00112294|DRUG|Cetuximab|Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
214842196|NCT05418816|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
214842197|NCT05883787|OTHER|Exploration of a database|extraction of data
214842198|NCT04202094|DIAGNOSTIC_TEST|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
214842199|NCT04202094|DIAGNOSTIC_TEST|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
214842200|NCT04202094|DIAGNOSTIC_TEST|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
214842201|NCT04202094|DIAGNOSTIC_TEST|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
214842202|NCT06050200|PROCEDURE|PVE|The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.
214842203|NCT06050200|PROCEDURE|LVD|"The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary."
214842204|NCT06050200|PROCEDURE|ALPPS|"The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane)."
214842205|NCT04550104|RADIATION|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
214842206|NCT04550104|DRUG|Olaparib Oral Tablet [Lynparza]|Oral tablet
214842207|NCT04550104|DRUG|AZD1390|Oral tablet
214842208|NCT04550104|DRUG|Ceralasertib|Oral Tablet
214842209|NCT04550104|DRUG|AZD5305|Oral Tablet
214842210|NCT04550104|DRUG|Durvalumab|1500mg iv infusion
214842211|NCT05252234|OTHER|Observation of hemodynamic status and post operative pain|No intervention
214842212|NCT01142908|BEHAVIORAL|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
214842213|NCT03803254|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214842214|NCT03803254|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
214842215|NCT03803254|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214842216|NCT03803254|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214842217|NCT00633698|DRUG|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
214842218|NCT00633698|DRUG|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
214842219|NCT01086930|DEVICE|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
214842220|NCT01086930|OTHER|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
214842221|NCT04899492|BEHAVIORAL|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
214842222|NCT04899492|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
214842223|NCT04899492|BEHAVIORAL|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
214842224|NCT04899492|DRUG|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
214842225|NCT05291351|OTHER|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
214842226|NCT05291351|OTHER|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
214842227|NCT05291351|OTHER|Porridge made with oat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
214842228|NCT00035555|DRUG|Belatacept|Solution, intravenous
214842229|NCT00035555|DRUG|Cyclosporine|Oral, capsule
214842230|NCT00035555|DRUG|Mycophenolate mofetil (MMF)|Oral, capsule
214842231|NCT00035555|DRUG|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
214842232|NCT03176524|DRUG|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
214842233|NCT03176524|DRUG|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
214842234|NCT03176524|DRUG|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
214842235|NCT04601337|PROCEDURE|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
214842236|NCT00982631|DRUG|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
214842237|NCT04027257|BEHAVIORAL|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
214842238|NCT03636386|DEVICE|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
214842239|NCT03636386|DEVICE|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
214842240|NCT00611650|DRUG|defined green tea catechin extract|Given orally
214842241|NCT00611650|OTHER|placebo|Given orally
214842242|NCT01650155|DRUG|BI 1005273 s.c.|injection
214842243|NCT01650155|DRUG|BI 105273 i.v. Placebo|infusion
214842244|NCT01650155|DRUG|BI 1005273 s.c. Placebo|injection
214842245|NCT01650155|DRUG|BI 1005273 i.v.|infusion
214842246|NCT04188964|DRUG|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
214842247|NCT06217432|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
214842248|NCT06461442|PROCEDURE|Cryotherapy|Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.
214842249|NCT06461442|DRUG|5Fluorouracil|Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
214842250|NCT01316432|DRUG|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
214842251|NCT01316432|OTHER|Placebo|Placebo will be administered as a 24-hour SQ infusion
214842252|NCT03681938|PROCEDURE|Autograft|Autograft
214842253|NCT03454737|PROCEDURE|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
214842254|NCT03454737|PROCEDURE|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
214842255|NCT01994915|OTHER|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
214842256|NCT05696327|OTHER|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
214842257|NCT05696327|OTHER|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
214842258|NCT03390244|DEVICE|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
214842259|NCT00000317|DRUG|Risperidone|Risperidone (4mg/day)
214842260|NCT00000317|DRUG|Placebo|Placebo
214842261|NCT00000317|BEHAVIORAL|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
214842262|NCT02789839|PROCEDURE|Blood test|Blood test of 30mL
214842263|NCT02789839|PROCEDURE|Medullar test|Medullar test for 2-5mL and a smear
214842264|NCT01186016|BEHAVIORAL|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
214842265|NCT01186016|BEHAVIORAL|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
214842266|NCT03043898|OTHER|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
214842267|NCT03043898|OTHER|Lung sound recording|Lung sounds are recorded using a sensor array.
214842268|NCT04959032|DRUG|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
214842269|NCT04959032|DRUG|Placebo|Matching capsules administered orally, once daily.
214842270|NCT04703751|DEVICE|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
214842271|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
214842272|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
214842273|NCT04791345|DRUG|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
214842274|NCT04791345|DRUG|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
214842275|NCT04791345|DRUG|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
214842276|NCT06240065|OTHER|Green bean puree|Green bean puree as a proxy for fiber-foods
214842277|NCT02368262|OTHER|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
214842278|NCT02368262|PROCEDURE|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
214842279|NCT00083772|DRUG|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
214842280|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
214842281|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
214842282|NCT06394492|DRUG|SHR-A1921|SHR-A1921 dose 1
214842283|NCT06394492|DRUG|Doxorubicin|Doxorubicin dose 2
214842284|NCT06394492|DRUG|Paclitaxel|Paclitaxel dose 3
214842285|NCT06394492|DRUG|Topotecan|Topotecan dose 4
214842286|NCT00277030|DRUG|Surfactant|
214842287|NCT00277030|DEVICE|Nasal CPAP|
214842288|NCT04800926|DEVICE|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
214842289|NCT05973331|OTHER|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
214842290|NCT01643239|OTHER|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
214842291|NCT01643239|OTHER|Hospital-based mCIT|the mCIT group with individualized intervention
214842292|NCT01643239|OTHER|Hospital-based TR|OT or PT or therapist-based training
214842293|NCT00722839|BIOLOGICAL|PADRE-CMV fusion peptide vaccine|Given subcutaneously
214842294|NCT00722839|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given subcutaneously
214842295|NCT00722839|DRUG|agatolimod sodium|Given subcutaneously
214842296|NCT02884986|DRUG|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
214842297|NCT02884986|DRUG|Placebo|120mg of placebo
214842298|NCT03417739|DRUG|BVD-523|ERK1 and ERK2 inhibitor
214842299|NCT03397667|OTHER|ABC ANSWERS|Primary Care plus ABC ANSWERS
214842300|NCT03397667|OTHER|Control|Primary Care as usual
214842301|NCT05301816|DEVICE|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
214842302|NCT05469958|OTHER|Hypothermia prevention bundle|pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
214842303|NCT05469958|OTHER|Conventional care|the patient will be attended with textile blankets on patient demand
214842304|NCT03926416|BIOLOGICAL|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
214842305|NCT03926416|BIOLOGICAL|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
214842306|NCT02134639|PROCEDURE|68Ga-DOTATOC PET-CT Imaging|
214842307|NCT02079363|OTHER|No interventions, this is an observational study|
214842308|NCT04902963|DEVICE|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
214842309|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
214842310|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
214842311|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
214842312|NCT01055886|DRUG|nicotine patch|Nicotine patch, 7-21 mg.
214842313|NCT01055886|DRUG|placebo patch|placebo patch used from weeks 4-6
214842314|NCT04325516|BEHAVIORAL|Daily activities|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
214842315|NCT00428155|DEVICE|closure device placement|
214842316|NCT03430635|PROCEDURE|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
214842317|NCT04070079|DRUG|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
214842318|NCT02255487|DEVICE|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
214842319|NCT02255487|OTHER|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
214842320|NCT02972515|BEHAVIORAL|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
214842321|NCT02972515|DEVICE|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
214842322|NCT02254109|DRUG|BEA 2180 BR - rising dose|
214842323|NCT02254109|DRUG|Placebo|
214842324|NCT02494505|DRUG|Mycophenolate Mofetil|2g/day per os
214842325|NCT02494505|DRUG|placebo|
214842326|NCT04568577|OTHER|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
214842327|NCT04568577|OTHER|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
214842328|NCT05427994|OTHER|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
214842329|NCT00020839|DRUG|temozolomide|
214842330|NCT00020839|RADIATION|radiation therapy|
214842331|NCT06074757|DRUG|Fulvestrant injection|phosphate ester of fulvestrant for test arm
214842332|NCT03468296|DRUG|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
214842333|NCT02359539|PROCEDURE|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
214842334|NCT02365909|DRUG|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
214842335|NCT02365909|DRUG|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
214842336|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
214842337|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
214842338|NCT04281524|DRUG|CSL312|CSL312 administered as an IV infusion
214842339|NCT04281524|DRUG|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
214842340|NCT04874363|OTHER|no intervention|no intervention
214842341|NCT01086969|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
214842342|NCT01041209|BEHAVIORAL|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
214842343|NCT01041209|BEHAVIORAL|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
214842344|NCT01309854|DRUG|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
214842345|NCT01309854|DRUG|pioglitazone|oral tablets, 30mg single dose per period
214842346|NCT06519747|DEVICE|Cardiac monitoring device|Portable, up to 14 days of monitoring
214842347|NCT01610024|DIETARY_SUPPLEMENT|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
214842348|NCT05025631|DRUG|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
214842349|NCT04478240|BEHAVIORAL|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
214842350|NCT05780996|DEVICE|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
214842351|NCT05780996|DEVICE|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
214842352|NCT01909739|DRUG|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
214842353|NCT01909739|DRUG|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
214842354|NCT06398834|DRUG|Esketamine|In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
214842355|NCT06398834|DRUG|Butorphanol|In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
214842356|NCT03087435|DEVICE|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
214842357|NCT02114112|OTHER|NCPAP cycling|
214842358|NCT02114112|OTHER|NCPAP continuous|
214842359|NCT02609516|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
214842360|NCT00558623|DIETARY_SUPPLEMENT|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
214842361|NCT00206245|DRUG|AZD0865|
214842362|NCT03267927|DEVICE|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
214842363|NCT03267927|DEVICE|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
214842364|NCT03267927|DEVICE|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
214842365|NCT00089427|DRUG|IL13-PE38QQR|
214842366|NCT00089427|PROCEDURE|Surgery for placement|
214842367|NCT00089427|PROCEDURE|Radiation therapy|
214842368|NCT00089427|DRUG|Temozolomide with radiation therapy|
214842369|NCT03095755|OTHER|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
214842370|NCT03095755|OTHER|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
214842371|NCT00024349|DRUG|fluorouracil|
214842372|NCT00024349|DRUG|mitomycin C|
214842373|NCT00024349|RADIATION|radiation therapy|
214842374|NCT04445233|DEVICE|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
214842375|NCT06266754|BIOLOGICAL|Oral polio vaccine|Standard oral polio vaccine
214842376|NCT06266754|OTHER|Placebo|Saline 0.9%
214842377|NCT03743259|DRUG|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
214842378|NCT03743259|DRUG|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
214842379|NCT03743259|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
214842380|NCT00559741|BIOLOGICAL|cetuximab|
214842381|NCT00559741|DRUG|fluorouracil|
214842382|NCT00559741|DRUG|irinotecan hydrochloride|
214842383|NCT00559741|DRUG|leucovorin calcium|
214842384|NCT00559741|OTHER|pharmacological study|
214842385|NCT01195155|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
214842386|NCT06073886|DEVICE|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
214842387|NCT06073886|DEVICE|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
214842388|NCT06073886|BEHAVIORAL|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
214842389|NCT05907655|DRUG|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
214842390|NCT05907655|DIAGNOSTIC_TEST|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
214842391|NCT05907655|DIAGNOSTIC_TEST|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
214842392|NCT05907655|DEVICE|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
214842393|NCT01618513|DRUG|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
214842394|NCT06338423|DEVICE|vacuum mattress|vacuum mattresses used to better positioning of the patient
214842395|NCT06338423|OTHER|Standard Mattress|Standard Mattress
214842396|NCT04317638|OTHER|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
214842397|NCT03509285|DRUG|Alprazolam Placebo|100 mg lactose tablets
214842398|NCT03509285|DRUG|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
214842399|NCT03509285|DRUG|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
214842400|NCT03509285|DRUG|Cenobamate|100 mg tablet
214842401|NCT04389645|DIAGNOSTIC_TEST|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
214842402|NCT04502849|PROCEDURE|Bypass surgery|Creating a bypass with graft or vein.
214842403|NCT04502849|PROCEDURE|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
214842404|NCT04502849|PROCEDURE|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
214842405|NCT04502849|DRUG|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
214842406|NCT04502849|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
214842407|NCT04502849|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
214842408|NCT04502849|DIAGNOSTIC_TEST|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
214842409|NCT06318377|DIETARY_SUPPLEMENT|Peanut group|These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
214842410|NCT04674982|DEVICE|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
214842411|NCT00176930|BIOLOGICAL|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
214842412|NCT00176930|DRUG|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
214842413|NCT00176930|RADIATION|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
214842414|NCT00176930|DRUG|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
214842415|NCT00176930|DRUG|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
214842416|NCT00176930|BIOLOGICAL|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
214842417|NCT06616441|DRUG|Bupivacaine|Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
214842418|NCT00585312|DRUG|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
214842419|NCT00585312|DRUG|Placebo|Masked, placebo comparator
214842420|NCT05796596|BEHAVIORAL|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
214842421|NCT05796596|BEHAVIORAL|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
214842422|NCT06166758|BEHAVIORAL|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
214842423|NCT03858023|OTHER|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
214842424|NCT03716323|DEVICE|immediate premolar implant with xenograft and allograft|"* A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
214842425|NCT04231123|PROCEDURE|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
214842426|NCT04231123|PROCEDURE|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
214842427|NCT02463838|OTHER|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
214842428|NCT00190450|BIOLOGICAL|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
214842429|NCT04096339|OTHER|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
214842430|NCT04096339|OTHER|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
214842431|NCT04857151|BEHAVIORAL|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
214842432|NCT02230111|BEHAVIORAL|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
214842433|NCT02230111|BEHAVIORAL|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
214842434|NCT04174573|OTHER|GTO|"1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
214842435|NCT04174573|OTHER|GT-tDCS|"1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
214842436|NCT05886257|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
214842437|NCT05886257|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
214842438|NCT01429831|DRUG|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
214842439|NCT04203667|DEVICE|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
214842440|NCT03062787|DEVICE|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
214842441|NCT03062787|DEVICE|Monovisc® (Sodium hyaluronate)|Intra-articular injection
214842442|NCT00132457|PROCEDURE|Self-collected vaginal swab for chlamydia testing|
214842443|NCT05717790|DRUG|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
214842444|NCT05717790|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
214842445|NCT05717790|DRUG|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
214842446|NCT05717790|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
214842447|NCT01696305|DEVICE|Hyalobarrier|
214842448|NCT01696305|DEVICE|Guardix-SG|
214842449|NCT00398593|BEHAVIORAL|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
214842450|NCT05549687|OTHER|Questionnaire Administration|Ancillary studies
214842451|NCT05549687|PROCEDURE|Supportive Care|Participate in Pack Health, an electronic support program
214842452|NCT05549687|PROCEDURE|Supportive Care|Access to telephone triage line for support care services
214842453|NCT05756465|DEVICE|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
214842454|NCT06004180|DRUG|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
214842455|NCT00113061|PROCEDURE|Exercise|
214842456|NCT03241836|DIAGNOSTIC_TEST|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
214842457|NCT05683808|DRUG|Apixaban|Open label
214842458|NCT02148354|BEHAVIORAL|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
214842459|NCT01362296|DRUG|GSK1120212|Oral once daily
214842460|NCT01362296|DRUG|docetaxel|IV once every 3 weeks
214842461|NCT03201263|PROCEDURE|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
214842462|NCT03201263|PROCEDURE|Standard of care|Standard of care
214842463|NCT02277951|DEVICE|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
214842464|NCT02277951|DEVICE|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
214842465|NCT02277951|DEVICE|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
214842466|NCT02277951|DEVICE|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
214842467|NCT05746052|PROCEDURE|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
214842468|NCT04217538|OTHER|clinical exam|clinical oral examination
214842469|NCT01706718|DIETARY_SUPPLEMENT|Bread|
214842470|NCT02582307|DRUG|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
214842471|NCT02582307|DRUG|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
214842472|NCT05462717|DRUG|RMC-6291|Oral tablet once or twice a day
214842473|NCT06130969|OTHER|Cervical Retraction Exercise|Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.
214842474|NCT06130969|OTHER|Diaphragmatic Breathing|The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.
214842475|NCT06130969|OTHER|Baseline Treatment|"Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting."
214842476|NCT03323411|BEHAVIORAL|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
214842477|NCT00571194|DRUG|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
214842478|NCT00752674|OTHER|Neuromuscular balance|
214842479|NCT01174355|DRUG|ND0801|Confidential
214842480|NCT05680779|OTHER|ultrasound-guided percutaneous neuromodulation|It´s an intervention of physiotherapy
214842481|NCT05680779|OTHER|dry needling|It´s an intervention of physiotherapy
214842482|NCT00653159|DEVICE|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
214842483|NCT00653159|DEVICE|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
214842484|NCT02013752|DEVICE|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
214842485|NCT02678871|DEVICE|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
214842486|NCT02678871|DEVICE|WATCHMAN|LAA closure with the WATCHMAN device
214842487|NCT01926275|DEVICE|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
214842488|NCT01926275|DEVICE|NPPV|noninvasive positive pressure ventilation
214842489|NCT01926275|DEVICE|IMT|inspiratory muscle training
214842490|NCT04674397|RADIATION|Radioisotope GFR test|
214842491|NCT01226251|DEVICE|In vitro chair side test|Colour evaluation of a strip
214842492|NCT03666481|BEHAVIORAL|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
214842493|NCT02893995|DRUG|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
214842494|NCT02893995|DRUG|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
214842495|NCT00363155|DRUG|KRN7000|
214842496|NCT01355354|DRUG|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
214842497|NCT01355354|DRUG|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
214842498|NCT00836147|DRUG|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
214842499|NCT00836147|DRUG|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
214842500|NCT00109837|BIOLOGICAL|filgrastim|As needed per physician discretion
214842501|NCT00109837|DRUG|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
214842502|NCT00109837|DRUG|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
214842503|NCT00109837|DRUG|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
214842504|NCT00109837|DRUG|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
214842505|NCT00109837|DRUG|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
214842506|NCT00109837|DRUG|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
214842507|NCT00109837|DRUG|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
214842508|NCT00109837|DRUG|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
214842509|NCT00109837|DRUG|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
214842510|NCT00109837|DRUG|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
214842511|NCT00109837|DRUG|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
214842512|NCT00109837|DRUG|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
214842513|NCT00109837|DRUG|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
214842514|NCT00109837|RADIATION|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
214842515|NCT00109837|DRUG|allopurinol|300 mg/d PO Days 1-7
214842516|NCT00109837|DRUG|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
214842517|NCT03477955|PROCEDURE|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
214842518|NCT05455164|DIETARY_SUPPLEMENT|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
214842519|NCT00381849|DRUG|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
214842520|NCT00381849|DRUG|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
214842521|NCT00160745|DRUG|Rosuvastatin|
214842522|NCT03010852|BEHAVIORAL|Focused incentive spirometer education and monitoring|
214842523|NCT04167618|DRUG|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
214842524|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
214842525|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
214842526|NCT02951936|DEVICE|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
214842527|NCT02951936|DEVICE|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
214842528|NCT06227429|DRUG|Nitisinone|According to prescription
214842529|NCT06536439|DEVICE|Pre-operative explanation of the procedure (DIPLANN + CT)|Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
214842530|NCT06536439|DEVICE|Pre-operative surgical planning (DIPLANN + CT)|Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.
214842531|NCT06536439|PROCEDURE|RAPN (DIPLANN + CT)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.
214842532|NCT06536439|DEVICE|Pre-operative explanation of the procedure (CT only)|Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
214842533|NCT06536439|DEVICE|Pre-operative surgical planning (CT only)|Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.
214842534|NCT06536439|PROCEDURE|RAPN (CT only)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
214842535|NCT05654493|DEVICE|MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device|The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers
214842536|NCT05108883|DEVICE|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
214842537|NCT05478187|DEVICE|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
214842538|NCT05478187|OTHER|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
214842539|NCT06384196|BEHAVIORAL|Identity-Based Transdiagnostic Therapy (IBTT)|In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
214842540|NCT06384196|BEHAVIORAL|Unified Protocol|In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
214842541|NCT05652270|BEHAVIORAL|Goal Attainment|Development of an attainable goal
214842542|NCT05652270|BEHAVIORAL|Goal Development|"A Systematic process to help patients create SMaRT  goals"
214842543|NCT05652270|BEHAVIORAL|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
214842544|NCT05996198|DEVICE|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
214842545|NCT05996198|DEVICE|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
214842546|NCT05053568|DEVICE|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
214842547|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
214842548|NCT05672134|DIAGNOSTIC_TEST|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
214842549|NCT05672134|DRUG|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
214842550|NCT05672134|DIAGNOSTIC_TEST|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
214842551|NCT05672134|DIAGNOSTIC_TEST|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
214842552|NCT05672134|DIAGNOSTIC_TEST|EndoPAT|Use of EndoPAT to measure endothelial function.
214842553|NCT05672134|DIAGNOSTIC_TEST|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
214842554|NCT05672134|DIAGNOSTIC_TEST|Electrocardiogram|12-lead Electrocardiogram
214842555|NCT02046863|DEVICE|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
214842556|NCT00835796|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
214842557|NCT00835796|DRUG|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
214842558|NCT05877326|DRUG|General anesthesia with propofol or sevoflurane|General anesthesia
214842559|NCT05877326|BEHAVIORAL|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
214842560|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
214842561|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
214842562|NCT01026857|DRUG|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
214842563|NCT03962868|PROCEDURE|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)
214842564|NCT03962868|PROCEDURE|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
214842565|NCT01279915|DRUG|ASP0456|oral
214842566|NCT01279915|DRUG|Placebo|oral
214842567|NCT01402128|DIETARY_SUPPLEMENT|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
214842568|NCT01402128|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214842569|NCT00651183|DRUG|Pramipexole immediate release|
214842570|NCT02807441|DRUG|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
214842571|NCT04116151|COMBINATION_PRODUCT|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
214842572|NCT04116151|COMBINATION_PRODUCT|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
214842573|NCT05632692|OTHER|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
214842574|NCT01260337|BEHAVIORAL|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
214842575|NCT01260337|OTHER|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
214842576|NCT01752530|OTHER|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
214842577|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
214842578|NCT00458419|DRUG|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
214842579|NCT00458419|DRUG|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
214842580|NCT00951093|PROCEDURE|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
214842581|NCT02882269|DRUG|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
214842582|NCT02882269|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
214842583|NCT00225563|DEVICE|Electronic Health Record|e-prescribing methods
214842584|NCT06253338|RADIATION|genomic alterations|Alteration of the genome under radiotherapy
214842585|NCT03203772|OTHER|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
214842586|NCT02295813|BIOLOGICAL|FBF001|
214842587|NCT02295813|DRUG|Placebo|
214842588|NCT04703842|BIOLOGICAL|SRD-001|AAV1/SERCA2a
214842589|NCT04703842|DRUG|Placebo|SRD-001 matching placebo
214842590|NCT04635332|BEHAVIORAL|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
214842591|NCT04635332|BEHAVIORAL|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
214842592|NCT03843515|DRUG|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
214842593|NCT01363011|DRUG|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
214842594|NCT01363011|DRUG|COBI|COBI 150 mg tablet administered with food orally once daily
214842595|NCT01363011|DRUG|ATV|ATV 300 mg tablet administered orally once daily
214842596|NCT01363011|DRUG|DRV|DRV 800 mg tablet administered orally once daily
214842597|NCT01363011|DRUG|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
214842598|NCT02283671|BIOLOGICAL|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
214842599|NCT00585260|DRUG|mannitol|indirect mannitol challenge
214842600|NCT04412057|DRUG|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
214842601|NCT04412057|DRUG|Placebo|Administered once subcutaneously
214842602|NCT02558465|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
214842603|NCT00680069|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
214842604|NCT05022368|DEVICE|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
214842605|NCT00490503|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
214842606|NCT00490503|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
214842607|NCT06260826|DEVICE|Auto CPAP via nasal mask (JPAP machine)|Auto Continuous Positive Airway Pressure via nasal mask using the JPAP system (Metran, Saitama, Japan) which can provide CPAP with a range of 2-10 cmH2O, the initial CPAP 2 cmH2O, then reach 7.5 cmH2O after a ramping time. CPAP values may vary with each breath until the obstruction is resolved
214842608|NCT06260826|DEVICE|Constant CPAP via facial mask (O2-Max Trio system)|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask that was adjusted to maintain a CPAP at 7.5 cm H2O and FiO2 30% continuously for the following 1 hour
214842609|NCT00148720|DRUG|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
214842610|NCT02156154|DRUG|Intravenous Acetaminophen|
214842611|NCT03608306|OTHER|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
214842612|NCT03608306|OTHER|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
214842613|NCT03153787|OTHER|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
214842614|NCT03002792|PROCEDURE|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
214842615|NCT03558620|PROCEDURE|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
214842616|NCT04512326|PROCEDURE|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
214842617|NCT06326034|DRUG|Dapagliflozin|Dapagliflozin 5 mg orally given once daily for four months.
214842618|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
214842619|NCT05999279|BEHAVIORAL|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
214842620|NCT01961882|DRUG|OCV-501|
214842621|NCT01961882|DRUG|Placebo|
214842622|NCT00715091|DRUG|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
214842623|NCT00715091|DRUG|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
214842624|NCT00003396|BIOLOGICAL|anti-thymocyte globulin|
214842625|NCT00003396|BIOLOGICAL|graft-versus-tumor induction therapy|
214842626|NCT00003396|DRUG|cyclophosphamide|
214842627|NCT00003396|DRUG|melphalan|
214842628|NCT00003396|PROCEDURE|peripheral blood stem cell transplantation|
214842629|NCT00003396|RADIATION|radiation therapy|
214842630|NCT02154724|DEVICE|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
214842631|NCT02154724|DEVICE|DBS|The aDBS s applied for two hous in DBS modality.
214842632|NCT04063319|OTHER|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
214842633|NCT01593072|DRUG|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
214842634|NCT01593072|OTHER|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
214842635|NCT06173596|DRUG|ALXN2080|Participants will receive ALXN2080 orally.
214842636|NCT06173596|DRUG|Itraconazole|Participants will receive Itraconazole orally.
214842637|NCT06173596|DRUG|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
214842638|NCT06173596|DRUG|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
214842639|NCT00900016|GENETIC|protein expression analysis|
214842640|NCT00900016|GENETIC|western blotting|
214842641|NCT00900016|OTHER|immunohistochemistry staining method|
214842642|NCT00900016|OTHER|immunologic technique|
214842643|NCT00900016|OTHER|laboratory biomarker analysis|
214842644|NCT01714050|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
214842645|NCT01714050|DEVICE|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
214842646|NCT05516888|PROCEDURE|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
214842647|NCT05516888|PROCEDURE|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
214842648|NCT05410028|OTHER|No intervention in clinical treatment|No intervention in clinical treatment
214842649|NCT03991442|DRUG|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
214842650|NCT05598879|OTHER|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
214842651|NCT06335459|OTHER|epidemiology|Analysis of 2000 AP WB radiographs of Foot in Upper Egypt For Random People and determind cases of Hallux valgus and calculate the prevalence
214842652|NCT06446388|DRUG|QLS31905|Administered as an intravenous infusion.
214842653|NCT06446388|DRUG|Oxaliplatin|130 mg/m2, intravenous infusion, D1, up to 8 cycles.
214842654|NCT06446388|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D14
214842655|NCT06446388|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
214842656|NCT06446388|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
214842657|NCT06446388|DRUG|QL1706|5 mg/kg, intravenous infusion,D1
214842658|NCT06446388|DRUG|Chemotherapy drug|Standard chemotherapy recommended by guidelines.
214842659|NCT02371993|DIETARY_SUPPLEMENT|Choline|
214842660|NCT02371993|OTHER|Placebo|
214842661|NCT03498599|BEHAVIORAL|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
214842662|NCT03498599|BEHAVIORAL|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
214842663|NCT02857556|BIOLOGICAL|Blood sample|
214842664|NCT02857556|OTHER|Retinal photography:|
214842665|NCT02857556|OTHER|dialyse|
214842666|NCT00407745|DRUG|placebo|Placebo
214842667|NCT00407745|DRUG|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
214842668|NCT05840471|DRUG|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
214842669|NCT05840471|OTHER|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
214842670|NCT04334928|DRUG|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
214842671|NCT04334928|DRUG|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
214842672|NCT04334928|DRUG|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
214842673|NCT04334928|DRUG|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
214842674|NCT00108082|DRUG|carvedilol MR|Study drug
214842675|NCT00108082|DRUG|atenolol|Comparator
214842676|NCT00108082|DRUG|lisinopril|Comparator
214842677|NCT01563237|DEVICE|MIDI Arrow|Implantation of MIDI Arrow
214842678|NCT02581072|DRUG|SB204 4%|Applied topically once
214842679|NCT02581072|DRUG|SB204 8% or 12%|Applied once topically
214842680|NCT02581072|DRUG|Vehicle|Applied topically once
214842681|NCT02033135|PROCEDURE|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
214842682|NCT02033135|OTHER|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
214842683|NCT02033135|DEVICE|Zilver PTX|
214842684|NCT02419924|DEVICE|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
214842685|NCT00295139|BEHAVIORAL|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
214842686|NCT00295139|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
214842687|NCT00295139|BEHAVIORAL|Critical Time Intervention (CTI)|Case management component
214842688|NCT00000486|PROCEDURE|coronary artery bypass|
214842689|NCT04008693|DIETARY_SUPPLEMENT|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
214842690|NCT04008693|OTHER|Placebo|800 mg of maltodextrin (four capsules)
214842691|NCT05192031|BEHAVIORAL|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
214842692|NCT00451152|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
214842693|NCT00451152|OTHER|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
214842694|NCT00955552|DRUG|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
214842695|NCT00955552|DRUG|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
214842696|NCT00784030|OTHER|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
214842697|NCT02607423|DRUG|Cisplatin|Given IV
214842698|NCT02607423|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
214842699|NCT02607423|DRUG|Docetaxel|Given IV
214842700|NCT02607423|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
214842701|NCT02607423|DRUG|Gemcitabine Hydrochloride|Given IV
214842702|NCT02607423|DRUG|Pemetrexed Disodium|Given IV
214842703|NCT02607423|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
214842704|NCT00891423|DRUG|Meropenem short infusion|
214842705|NCT00891423|DRUG|Meropenem extended infusion|
214842706|NCT02940730|DRUG|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
214842707|NCT02940730|DRUG|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
214842708|NCT03462836|DRUG|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
214842709|NCT03462836|DRUG|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
214842710|NCT04600024|DIAGNOSTIC_TEST|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
214842711|NCT02655055|PROCEDURE|high frequency voluntary apheresis blood donation|
214842712|NCT00078481|DRUG|Idebenone|
214842713|NCT01922219|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
214842714|NCT02948790|DEVICE|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
214842715|NCT02948790|DEVICE|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
214842716|NCT00060294|BIOLOGICAL|rituximab|
214842717|NCT00060294|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214842718|NCT02470117|DRUG|Alginate-based reflux suppressant|
214842719|NCT02470117|DRUG|magnesium-aluminium antacid gel|
214842720|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
214842721|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
214842722|NCT00347113|DRUG|Albendazole and praziquantel|
214842723|NCT01611207|DEVICE|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
214842724|NCT01611207|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
214842725|NCT04631887|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
214842726|NCT05093465|BEHAVIORAL|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
214842727|NCT05093465|OTHER|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
214842728|NCT04203160|DRUG|CPI 613|Given intravenously
214842729|NCT04203160|DRUG|Gemcitabine|Given intravenously
214842730|NCT04203160|DRUG|Cisplatin|Given intravenously
214842731|NCT05132725|BEHAVIORAL|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
214842732|NCT03766217|COMBINATION_PRODUCT|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
214842733|NCT03766217|COMBINATION_PRODUCT|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
214842734|NCT03765086|PROCEDURE|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
214842735|NCT03765086|PROCEDURE|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
214842736|NCT03036839|DRUG|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
214842737|NCT01386502|BIOLOGICAL|p53: 264-272 peptide|
214842738|NCT01386502|DRUG|CT-011|
214842739|NCT02299219|BEHAVIORAL|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
214842740|NCT02299219|BEHAVIORAL|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
214842741|NCT03015064|OTHER|Myocardial Infarction|Observational study of myocardial Infarction patients
214842742|NCT04682509|DRUG|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
214842743|NCT03027011|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
214842744|NCT03027011|PROCEDURE|Control|Control group without remote ischemic preconditioning
214842745|NCT00412737|DRUG|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
214842746|NCT00412737|DRUG|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
214842747|NCT01701037|DRUG|dabrafenib|150 mg given PO
214842748|NCT01701037|DRUG|trametinib|2 mg given PO
214842749|NCT01701037|OTHER|laboratory biomarker analysis|Correlative studies
214842750|NCT00308360|DRUG|Risperidone, divalproex|
214842751|NCT05054894|OTHER|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
214842752|NCT02836301|BEHAVIORAL|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
214842753|NCT02836301|BEHAVIORAL|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
214842754|NCT02836301|BEHAVIORAL|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
214842755|NCT02792348|OTHER|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
214842756|NCT00935831|DRUG|GSK1278863A|50mg, 150mg
214842757|NCT00935831|DRUG|Placebo|matching placebo
214842758|NCT02556892|DRUG|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
214842759|NCT03130348|DRUG|Bortezomib|Given SC
214842760|NCT03130348|DRUG|Dexamethasone|Given PO
214842761|NCT03130348|DRUG|Ibrutinib|Given PO
214842762|NCT03130348|OTHER|Laboratory Biomarker Analysis|Correlative studies
214842763|NCT06375369|PROCEDURE|Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)|The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
214842764|NCT06004869|BEHAVIORAL|Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)|an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
214842765|NCT06004869|BEHAVIORAL|Self-help cognitive behavioural therapy for insomnia|An mobile app that delivers CBT-I content.
214842766|NCT04788446|BEHAVIORAL|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
214842767|NCT04788446|BEHAVIORAL|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
214842768|NCT00485030|DEVICE|Cypher|sirolimus-eluting stent
214842769|NCT00485030|DEVICE|Xience-V|everolimus-eluting stent
214842770|NCT01064531|DEVICE|MIS Femoral Neck Stem implant|
214842771|NCT02740920|DRUG|Pembrolizumab|
214842772|NCT02740920|PROCEDURE|CT Scan|
214842773|NCT04347525|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
214842774|NCT01357434|BEHAVIORAL|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
214842775|NCT01575717|DRUG|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
214842776|NCT01575717|DRUG|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
214842777|NCT00513617|DRUG|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
214842778|NCT00513617|DRUG|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
214842779|NCT02854696|PROCEDURE|Islet graft|Patients will be transplanted with pancreatic islet cells
214842780|NCT02854696|DRUG|best medical care|Patients will continue their insulin treatment
214842781|NCT05518916|OTHER|Nonfarmacology method|Yakson Method and Swaddling
214842782|NCT02771041|PROCEDURE|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
214842783|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
214842784|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
214842785|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
214842786|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
214842787|NCT00285519|DRUG|Doxazosin (drug)|
214842788|NCT03728023|DRUG|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
214842789|NCT03728023|DRUG|Placebo|Single dose in SAD and once daily for 14 days
214842790|NCT03449199|DRUG|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
214842791|NCT03449199|DRUG|Placebo|Matching placebo to be taken orally, once daily
214842792|NCT01091103|DRUG|Enzalutamide|
214842793|NCT03172052|DRUG|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
214842794|NCT03172052|DRUG|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
214842795|NCT03172052|DEVICE|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
214842796|NCT03172052|DEVICE|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
214842797|NCT04355299|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
214842798|NCT04355299|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
214842799|NCT04355299|BEHAVIORAL|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
214842800|NCT04355299|BEHAVIORAL|usual care|received usual care
214842801|NCT00026871|PROCEDURE|Radiotherapy|
214842802|NCT00003098|OTHER|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
214842803|NCT00003098|OTHER|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
214842804|NCT03497832|OTHER|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
214842805|NCT01270620|DRUG|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
214842806|NCT01270620|DRUG|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
214842807|NCT01465282|DRUG|CT327 0.05%|0.05% CT327 (w/w) ointment
214842808|NCT01465282|DRUG|CT327 0.1%|0.1% CT327 (w/w) ointment
214842809|NCT01465282|DRUG|CT327 0.5%|0.5% CT327 (w/w) ointment
214842810|NCT01465282|DRUG|Placebo|Placebo
214842811|NCT05261789|OTHER|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
214842812|NCT05261789|OTHER|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
214842813|NCT05261789|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
214842814|NCT04610060|BEHAVIORAL|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day"
214842815|NCT04610060|BEHAVIORAL|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
214842816|NCT01311401|OTHER|NONE intervention|NONE intervention
214842817|NCT01083017|DRUG|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
214842818|NCT01083017|BEHAVIORAL|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
214842819|NCT01083017|DRUG|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
214842820|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane|Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
214842821|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)|Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
214842822|NCT06331741|PROCEDURE|Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity|Arthroplasty with consequent collagen membrane implantation
214842823|NCT00684567|RADIATION|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
214842824|NCT00684567|DRUG|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
214842825|NCT05386095|PROCEDURE|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
214842826|NCT05386095|PROCEDURE|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
214842827|NCT03601624|DRUG|Pomalidomide|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
214842828|NCT06424717|DRUG|Avelumab|Participants will be administered Avelumab intravenously (IV).
214842829|NCT06424717|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
214842830|NCT05419349|PROCEDURE|esophagogastric junction cancer surgery|esophagogastric junction cancer surgery
214842831|NCT00908921|DRUG|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
214842832|NCT04377906|BEHAVIORAL|Modification Lifesyle|high protein-fiber and exercise
214842833|NCT03136406|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214842834|NCT03136406|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214842835|NCT03136406|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214842836|NCT03136406|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214842837|NCT03136406|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214842838|NCT03136406|DRUG|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214842839|NCT03136406|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
214842840|NCT03136406|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
214842841|NCT03136406|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214842842|NCT03136406|BIOLOGICAL|aNK for Infusion|NK-92 cells
214842843|NCT03136406|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214842844|NCT03136406|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
214842845|NCT01082887|OTHER|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
214842846|NCT03670732|OTHER|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
214842847|NCT03670732|OTHER|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
214842848|NCT04778618|DRUG|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
214842849|NCT02177006|BEHAVIORAL|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
214842850|NCT05209828|DEVICE|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
214842851|NCT00333476|DRUG|MSI-1256F (Squalamine Lactate)|
214842852|NCT01705431|BEHAVIORAL|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
214842853|NCT03323060|DEVICE|Transanal endoscopic surgical procedure|Resection of tumors or lesions
214842854|NCT04341272|DEVICE|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
214842855|NCT03404401|DRUG|BLI4700|Oral bowel preparation
214842856|NCT03404401|DRUG|Polyethylene glycol bowel preparation|Oral bowel preparation
214842857|NCT01129739|OTHER|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
214842858|NCT01129739|OTHER|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
214842859|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil|Ready to Use Therapeutic Food
214842860|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
214842861|NCT01593969|DIETARY_SUPPLEMENT|Standard RUTF|Standard formulation RUTF given according to National Guidelines
214842862|NCT00988208|DRUG|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
214842863|NCT00988208|DRUG|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
214842864|NCT00988208|DRUG|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
214842865|NCT00988208|DRUG|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
214842866|NCT00271739|DEVICE|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
214842867|NCT00271739|OTHER|usual care|usual diabetes care, as provided by primary care providers
214842868|NCT05442203|DEVICE|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
214842869|NCT05442203|DEVICE|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
214842870|NCT00846859|DRUG|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
214842871|NCT00846859|DRUG|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
214842872|NCT06286059|DRUG|Phentolamine|In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
214842873|NCT04797442|DRUG|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
214842874|NCT04797442|DRUG|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
214842875|NCT00641199|OTHER|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
214842876|NCT03008837|DEVICE|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
214842877|NCT03008837|OTHER|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
214842878|NCT00037687|DRUG|rPAF-AH|
214842879|NCT05498493|BEHAVIORAL|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
214842880|NCT05498493|BEHAVIORAL|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
214842881|NCT03663790|OTHER|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
214842882|NCT03663790|OTHER|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
214842883|NCT02480426|DEVICE|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
214842884|NCT02480426|DRUG|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
214842885|NCT04065568|DEVICE|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
214842886|NCT05073250|DRUG|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
214842887|NCT05073250|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
214842888|NCT00793117|PROCEDURE|packing|packing in middle meatus for duration of 5 day
214842889|NCT01768819|BEHAVIORAL|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
214842890|NCT00528684|BIOLOGICAL|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
214842891|NCT01727349|OTHER|HbA1c measurement|
214842892|NCT01727349|OTHER|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
214842893|NCT06061406|DEVICE|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
214842894|NCT05802199|DIAGNOSTIC_TEST|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
214842895|NCT00031928|DRUG|mafosfamide|
214842896|NCT00450983|BIOLOGICAL|muromonab-CD3|
214842897|NCT00450983|BIOLOGICAL|natural killer cell therapy|
214842898|NCT00450983|DRUG|fludarabine phosphate|
214842899|NCT00450983|DRUG|methotrexate|
214842900|NCT00450983|DRUG|thiotepa|
214842901|NCT00450983|GENETIC|gene expression analysis|
214842902|NCT00450983|OTHER|flow cytometry|
214842903|NCT00450983|OTHER|immunologic technique|
214842904|NCT00450983|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214842905|NCT00450983|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214842906|NCT00450983|RADIATION|total-body irradiation|
214842907|NCT00213057|DRUG|Carraguard (PC-515)|
214842908|NCT03138824|PROCEDURE|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
214842909|NCT03138824|PROCEDURE|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
214842910|NCT04301622|DEVICE|Primary Knee implants|Primary knee arthroplasty
214842911|NCT04840784|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
214842912|NCT02165306|BEHAVIORAL|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
214842913|NCT02165306|BEHAVIORAL|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
214842914|NCT01726114|DEVICE|Non-invasive Optical Glucose Monitor™|Test device
214842915|NCT01726114|DEVICE|YSI blood glucose analyzer|Reference device
214842916|NCT02459041|OTHER|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
214842917|NCT02582918|BEHAVIORAL|Outreach with patient education and patient navigation services|"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
214842918|NCT04413734|DRUG|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
214842919|NCT04413734|DRUG|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
214842920|NCT02715219|OTHER|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
214842921|NCT04735068|DRUG|Binimetinib Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
214842922|NCT04735068|DRUG|Hydroxychloroquine Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
214842923|NCT05736380|DEVICE|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
214842924|NCT05736380|DEVICE|Sham cerebellar rTMS|Sham cerebellar rTMS
214842925|NCT06426927|OTHER|Colorectal Cancer Educational Videos in Spanish|Enrolled participants will watch three educational videos on Colorectal Cancer (CRC) in Spanish. Knowledge on CRC symptoms, risk factors, facts, screening and treatment will be assessed before and immediately after the educational video and at 30 +/- 7 days. In addition, the association between increase in CRC knowledge and willingness to participate in Cancer Clinical Trials (CCT) will be explored.
214842926|NCT01601691|DEVICE|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
214842927|NCT02618382|DRUG|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
214842928|NCT01904006|PROCEDURE|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
214842929|NCT01904006|PROCEDURE|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
214842930|NCT03843125|DRUG|Baricitinib|Administered orally.
214842931|NCT03843125|DRUG|Placebo|Administered orally.
214842932|NCT00409942|DRUG|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
214842933|NCT00409942|DRUG|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
214842934|NCT03173560|DRUG|lenvatinib|lenvatinib capsules.
214842935|NCT03173560|DRUG|everolimus|everolimus tablets.
214842936|NCT02763631|OTHER|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
214842937|NCT02763631|OTHER|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
214842938|NCT02763631|OTHER|Sham Comparator: Stand Care Arm|No change will be made to participants care
214842939|NCT02864524|OTHER|Manipulative and Massage Therapy|
214842940|NCT02864524|OTHER|Exercise Program|
214842941|NCT05926635|DEVICE|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
214842942|NCT05642533|OTHER|No treatment given|No treatment given
214842943|NCT01222364|PROCEDURE|Standard Cord Clamping|Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
214842944|NCT01222364|PROCEDURE|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
214842945|NCT04254809|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
214842946|NCT04254809|BEHAVIORAL|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
214842947|NCT02119052|DRUG|octeotride|
214842948|NCT02119052|DRUG|placebo|
214842949|NCT00003615|BIOLOGICAL|denileukin diftitox|
214842950|NCT05606328|BEHAVIORAL|Emergency Department Delirium Screening and Detection Program (ED-DDP)|Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
214842951|NCT01132261|OTHER|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
214842952|NCT04836182|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
214842953|NCT04836182|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
214842954|NCT00743860|DRUG|darapladib|experimental drug
214842955|NCT01546727|BEHAVIORAL|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
214842956|NCT01546727|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
214842957|NCT04480372|DRUG|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
214842958|NCT04480372|DRUG|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
214842959|NCT05188417|DRUG|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
214842960|NCT05188417|DRUG|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
214842961|NCT04631133|DEVICE|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
214842962|NCT00570206|BEHAVIORAL|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
214842963|NCT03023137|BEHAVIORAL|Walking & dietary modification|"1. Daily walking at a moderate pace (4 km/h) \> 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding \>12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
214842964|NCT00769951|OTHER|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
214842965|NCT00769951|OTHER|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
214842966|NCT00769951|PROCEDURE|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
214842967|NCT00769951|PROCEDURE|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
214842968|NCT00769951|PROCEDURE|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
214842969|NCT04911205|OTHER|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
214842970|NCT00344045|DRUG|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
214842971|NCT00344045|DRUG|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
214842972|NCT03850613|BEHAVIORAL|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
214842973|NCT02608476|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
214842974|NCT02608476|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
214842975|NCT02795676|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
214842976|NCT02795676|BIOLOGICAL|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
214842977|NCT01080586|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
214842978|NCT06401941|PROCEDURE|Hyperbaric Oxygen Therapy|HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
214842979|NCT01745887|DRUG|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
214842980|NCT04302337|PROCEDURE|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
214842981|NCT04302337|PROCEDURE|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
214842982|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
214842983|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
214842984|NCT00605176|DRUG|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
214842985|NCT03224520|BEHAVIORAL|Recommender CTHC|Enhanced Messaging
214842986|NCT03224520|BEHAVIORAL|Standard CTHC|Standard Messaging
214842987|NCT03224520|OTHER|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
214842988|NCT03224520|OTHER|Standard Online Recruitment|Search Engine and Social Media Advertisements
214842989|NCT04396444|COMBINATION_PRODUCT|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
214842990|NCT04337229|OTHER|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
214842991|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
214842992|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
214842993|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
214842994|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
214842995|NCT01992874|DRUG|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
214842996|NCT04560426|DEVICE|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
214842997|NCT02276625|BIOLOGICAL|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
214842998|NCT02698930|DRUG|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
214842999|NCT02698930|DRUG|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
214843000|NCT02721368|DEVICE|Neuramis® Volume Lidocaine|hyaluronic acid filler
214843001|NCT02721368|DEVICE|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
214843002|NCT02973581|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
214843003|NCT02973581|DRUG|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
214843004|NCT02973581|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
214843005|NCT02973581|DRUG|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
214843006|NCT02091310|DRUG|Placebo|
214843007|NCT02091310|DRUG|GFT505|
214843008|NCT02091310|DRUG|Moxifloxacin 400 mg|
214843009|NCT04238208|DRUG|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
214843010|NCT04238208|DRUG|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
214843011|NCT05922709|DRUG|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
214843012|NCT05922709|DRUG|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
214843013|NCT01647997|OTHER|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
214843014|NCT06293391|PROCEDURE|cardiac indices in supine and trendelenburg position|Cardiac indices in supine and trendelenburg position in patients undergoing open or laparoscopic major cancer surgery
214843015|NCT06679712|PROCEDURE|Transbronchial PDT lung tumor ablation|Transbronchial photodynamic therapy ablation for peripheral lung cancer
214843016|NCT05753813|DRUG|Phexxi|intravaginal gel twice weekly for 4 weeks.
214843017|NCT01514513|DRUG|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
214843018|NCT01514513|DRUG|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
214843019|NCT02243137|DRUG|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
214843020|NCT02243137|DRUG|prasugrel|Administration: one loading dose (60mg)
214843021|NCT02243137|DRUG|lysine acetylsalicylate|Administration: one dose (450mg iv)
214843022|NCT04329676|PROCEDURE|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
214843023|NCT00206180|DRUG|esomeprazole magnesium (oral medication)|
214843024|NCT00051831|DRUG|Emtricitabine|Will be administered as one 200-mg capsule orally daily
214843025|NCT00051831|DRUG|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
214843026|NCT00051831|DRUG|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
214843027|NCT00051831|DRUG|Saquinavir|Will be administered as five hard gel capsules orally twice daily
214843028|NCT00051831|DRUG|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
214843029|NCT02690935|DRUG|2LALERG|Homeopathic drug
214843030|NCT02690935|DRUG|Placebo|Placebo
214843031|NCT02702986|PROCEDURE|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
214843032|NCT02702986|DEVICE|Laser|
214843033|NCT02250924|DIETARY_SUPPLEMENT|Caffeine|caffeinated gum
214843034|NCT02250924|OTHER|Gum|Chewing gum
214843035|NCT02250924|BEHAVIORAL|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
214843036|NCT00838981|DRUG|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
214843037|NCT00838981|DRUG|Sugar Pill|placebo, sugar pill will mirror active drug
214843038|NCT00838981|BEHAVIORAL|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
214843039|NCT00838981|DRUG|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
214843040|NCT00838981|BEHAVIORAL|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
214843041|NCT00838981|BEHAVIORAL|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
214843042|NCT02285933|OTHER|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
214843043|NCT02285933|OTHER|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
214843044|NCT03127306|DIAGNOSTIC_TEST|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
214843045|NCT04253236|DRUG|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
214843046|NCT04253236|DRUG|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
214843047|NCT03723837|BIOLOGICAL|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
214843048|NCT06678477|DEVICE|3D device|Use 3D machine to generate the 3D image
214843049|NCT05735158|BIOLOGICAL|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
214843050|NCT05735158|OTHER|Placebo|Visually matched excipient gel
214843051|NCT02425384|BEHAVIORAL|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
214843052|NCT02425384|BEHAVIORAL|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
214843053|NCT02425384|OTHER|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
214843054|NCT04248517|OTHER|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
214843055|NCT00587431|DRUG|GnRh (Leuprolide)|Leuprolide LUPRON
214843056|NCT00587431|DRUG|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
214843057|NCT00587431|DRUG|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
214843058|NCT04570176|PROCEDURE|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
214843059|NCT02169791|DRUG|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
214843060|NCT04546269|PROCEDURE|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
214843061|NCT03019562|DRUG|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
214843062|NCT03019562|DRUG|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
214843063|NCT03890562|OTHER|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
214843064|NCT05094596|DRUG|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
214843065|NCT05094596|DRUG|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
214843066|NCT05094596|DRUG|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
214843067|NCT05884255|DRUG|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
214843068|NCT05884255|DRUG|long-acting Octreotide.|High-dose long-acting Octreotide.
214843069|NCT01042873|DRUG|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
214843070|NCT04906876|DRUG|Gemcitabine|Gemcitabine as a 90-minute IV infusion
214843071|NCT04906876|DRUG|Docetaxel|Docetaxel as a 60-minute IV infusion
214843072|NCT04906876|DRUG|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
214843073|NCT05312476|DRUG|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group)."
214843074|NCT01448148|OTHER|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
214843075|NCT01448148|OTHER|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
214843076|NCT03045822|DRUG|Bioimpedance analysis|
214843077|NCT00828022|BIOLOGICAL|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
214843078|NCT06677827|DRUG|Bupivacaine|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
214843079|NCT06677827|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
214843080|NCT02241694|OTHER|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
214843081|NCT05429489|PROCEDURE|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
214843082|NCT05429489|PROCEDURE|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
214843083|NCT05429489|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
214843084|NCT03255044|DRUG|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
214843085|NCT03255044|DRUG|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
214843086|NCT03255044|OTHER|guideline directed therapy|standard heart failure therapy
214843087|NCT03700827|OTHER|Resistance Training|High-intensity Resistance Training Group
214843088|NCT03700827|OTHER|Aerobic Training|Aerobic Interval Training Group
214843089|NCT03721627|DRUG|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
214843090|NCT05144464|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
214843091|NCT00929058|DRUG|Bevacizumab|Intra-arterial infusion during 6 minutes
214843092|NCT01446224|DRUG|Pazopanib|Patients treated with pazopanib
214843093|NCT01446224|DRUG|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
214843094|NCT02223286|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score
214843095|NCT03566238|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
214843096|NCT03566238|DRUG|Placebo|Placebo identical in appearance to active drug (A4250).
214843097|NCT00432055|DRUG|Botulinum toxin type A (Botox)|
214843098|NCT00432055|DRUG|placebo (saline)|
214843099|NCT02151175|DEVICE|LIFUP|
214843100|NCT06057506|DEVICE|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
214843101|NCT06057506|DEVICE|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
214843102|NCT04329715|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
214843103|NCT04329715|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
214843104|NCT06189911|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
214843105|NCT04554147|BEHAVIORAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
214843106|NCT05601778|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
214843107|NCT05601778|DRUG|placebo|the placebo comparator of study
214843108|NCT05193773|OTHER|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
214843109|NCT01767727|PROCEDURE|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
214843110|NCT02710591|DRUG|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"
214843111|NCT02300168|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
214843112|NCT00597428|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
214843113|NCT00597428|DRUG|Placebo|0 mcg capsules twice daily (BID)
214843114|NCT03744286|DEVICE|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
214843115|NCT05404451|DIAGNOSTIC_TEST|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
214843116|NCT05404451|DIAGNOSTIC_TEST|Mckenzie Exercises|Using Mckenzie Exercises
214843117|NCT06492551|OTHER|Trak exercise prescription protocol|Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
214843118|NCT06492551|OTHER|Conventional rehabilitation plan in the gym|Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
214843119|NCT00006009|BIOLOGICAL|visilizumab|
214843120|NCT03754530|DRUG|Icotinib|orally three times per day
214843121|NCT03754530|RADIATION|WBRT or SRS|\>3 with WBRT;\<=3 with SRS
214843122|NCT00873834|DRUG|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
214843123|NCT00873834|DRUG|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
214843124|NCT06013111|BIOLOGICAL|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
214843125|NCT06312423|DRUG|Oligonucleotides, Phosphorothioate|Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
214843126|NCT03304431|DRUG|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
214843127|NCT06428513|BEHAVIORAL|HCTP|10 weekly 1-on-1 30-minute tele-sessions via Zoom, delivered by a certified health coach. At baseline assessment including full medical history, medications, lifestyle practices, self-reported health status, psychosocial status, and other relevant information will be taken. At the first session, participants identify their health vision and 3-month health goals. At subsequent meetings, participants review their progress towards reaching the prior week's goals and identify goals for the next week. An individualized action plan will be formulated to help each participant achieve their goals. The action plan will focus on important lifestyle practices (physical activity/exercise training, correct nutrition, weight management, tobacco cessation, and stress management. Patients can request further health care advice felt necessary for their progress, and will be referred to health care professionals in the rehabilitation hospital that provide care for lung transplantation candidates.
214843128|NCT00373425|DRUG|Erlotinib|150 mg tablet
214843129|NCT00373425|DRUG|Placebo|Placebo tablet
214843130|NCT06369506|DIAGNOSTIC_TEST|GTmeasurement|GT was measured from the point corresponding to the base of the gingival sulcus and 1 mm and 2 mm apical to this point. If the GT was ≤1 mm, it was considered a thin phenotype, and if it was \>1 mm, it was considered a thick phenotype.
214843131|NCT02452879|DEVICE|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
214843132|NCT02452879|DEVICE|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
214843133|NCT02452879|DRUG|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
214843134|NCT04629274|PROCEDURE|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
214843135|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
214843136|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
214843137|NCT02387567|DRUG|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
214843138|NCT02387567|DRUG|Sham Lidocaine|Sham injection, without lidocaine.
214843139|NCT02387567|OTHER|Standard treatment|Standard treatment only, without lidocaine or sham injection.
214843140|NCT00004344|DRUG|leuprolide|
214843141|NCT00004344|DRUG|testosterone|
214843142|NCT02270216|PROCEDURE|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
214843143|NCT02270216|PROCEDURE|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
214843144|NCT01944384|DRUG|aldactone|aldactone 25 mg for 6 months
214843145|NCT04417751|BEHAVIORAL|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
214843146|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
214843147|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
214843148|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
214843149|NCT04199416|DEVICE|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
214843150|NCT04199416|DEVICE|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
214843151|NCT00151255|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
214843152|NCT00151255|DRUG|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
214843153|NCT00151255|DRUG|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
214843154|NCT00151255|DRUG|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
214843155|NCT00151255|DRUG|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
214843156|NCT02079233|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
214843157|NCT03033524|DRUG|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
214843158|NCT02510950|BIOLOGICAL|Personalized peptide vaccine|
214843159|NCT02510950|DRUG|Poly-ICLC|
214843160|NCT02510950|DRUG|Temozolomide|
214843161|NCT02129517|OTHER|IMPACT intervention|Tailored, web-based educational short video clips
214843162|NCT02129517|OTHER|Online education materials|Online NCI-based educational materials
214843163|NCT02129517|OTHER|survey administration|Ancillary studies
214843164|NCT01482117|DRUG|Clopidogrel|single oral administration of 300mg of clopidogrel
214843165|NCT01482117|DRUG|Cilostazol|single oral administration of 100mg cilostazol
214843166|NCT01482117|DRUG|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
214843167|NCT05852873|DRUG|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
214843168|NCT05852873|DRUG|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
214843169|NCT03256864|DRUG|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
214843170|NCT05842720|PROCEDURE|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA\>=3
214843171|NCT02687958|DRUG|Everolimus|Maintenance therapy
214843172|NCT05736796|OTHER|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
214843173|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
214843174|NCT03942211|DRUG|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
214843175|NCT03942211|DRUG|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
214843176|NCT02507063|PROCEDURE|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
214843177|NCT04552028|OTHER|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
214843178|NCT01183884|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
214843179|NCT05554965|DRUG|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
214843180|NCT05554965|DRUG|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
214843181|NCT03863041|OTHER|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
214843182|NCT04763473|DIETARY_SUPPLEMENT|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
214843183|NCT04763473|DIETARY_SUPPLEMENT|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
214843184|NCT06615947|DEVICE|Robotic gait training|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
214843185|NCT06615947|OTHER|tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
214843186|NCT00200655|DRUG|Pravastatin|
214843187|NCT00200655|DRUG|Placebo|
214843188|NCT04006873|DRUG|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
214843189|NCT04006873|DRUG|Placebo oral tablet|As per description in arms
214843190|NCT04056663|BEHAVIORAL|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
214843191|NCT00450567|PROCEDURE|computed tomography|
214843192|NCT00450567|PROCEDURE|positron emission tomography|
214843193|NCT00450567|RADIATION|fludeoxyglucose F 18|
214843194|NCT00957216|DRUG|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
214843195|NCT00957216|DRUG|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
214843196|NCT05531682|OTHER|Placebo|Subjects will receive several injections of Placebo
214843197|NCT05531682|DRUG|HB0017|Subjects will receive HB0017 in different dosing regimens
214843198|NCT00250133|PROCEDURE|Blood draws|
214843199|NCT06811870|DEVICE|hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
214843200|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
214843201|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
214843202|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
214843203|NCT04913519|DRUG|TDM-105795|TDM-105795 topical solution
214843204|NCT04913519|DRUG|Placebo|Placebo for TDM-105795 topical solution
214843205|NCT03170102|OTHER|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
214843206|NCT06326528|DRUG|SGLT2 inhibitor|Dapagliflozin 10 mg or Empagliflozin 25mg
214843207|NCT06663475|BEHAVIORAL|TTM-based health education videos about smoking cessation for expectant fathers|Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
214843208|NCT06663475|BEHAVIORAL|usual care treatment|general health education videos about hazards of smoking for expectant fathers in obstetric clinic
214843209|NCT04994405|PROCEDURE|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
214843210|NCT00374166|DRUG|SSR149415|Oral administration (capsules of 50 and 100 mg)
214843211|NCT00374166|DRUG|Placebo|Oral administration (capsules)
214843212|NCT00374166|DRUG|Paroxetine|Oral administration (capsules)
214843213|NCT03150901|DIAGNOSTIC_TEST|no drug|laboratory tests
214843214|NCT04319458|BEHAVIORAL|Fotonovela|Secret Feelings/Sentimientos Secretos
214843215|NCT04319458|BEHAVIORAL|Control|NIH Brochure: Depression: What You Need to Know
214843216|NCT02102919|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
214843217|NCT02102919|DEVICE|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
214843218|NCT02102919|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
214843219|NCT02102919|DEVICE|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
214843220|NCT05092464|DEVICE|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
214843221|NCT03252457|DRUG|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
214843222|NCT03252457|DRUG|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
214843223|NCT04511208|DEVICE|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
214843224|NCT04511208|DEVICE|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
214843225|NCT04485208|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
214843226|NCT03764657|PROCEDURE|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
214843227|NCT03764657|PROCEDURE|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
214843228|NCT04726215|DRUG|[18F]F AraG|PET imaging agent specific to activated T cells
214843229|NCT04547036|DEVICE|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
214843230|NCT01835548|DRUG|NT0102|NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
214843231|NCT01835548|DRUG|Placebo|Matching ODT placebo was given once daily.
214843232|NCT05766124|DRUG|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
214843233|NCT03121937|BEHAVIORAL|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
214843234|NCT00844870|BEHAVIORAL|stabilization training|training of arm function with the trunk stabilized
214843235|NCT00844870|BEHAVIORAL|auditory training group|response to an auditory signal
214843236|NCT01169038|DRUG|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
214843237|NCT02248012|DRUG|Everolimus , temozolomide|
214843238|NCT01488448|DRUG|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
214843239|NCT01488448|DRUG|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
214843240|NCT00537017|DRUG|Preladenant|5 mg BID capsules
214843241|NCT00537017|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
214843242|NCT00537017|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
214843243|NCT02847416|DEVICE|BreatheMAX breathing device|
214843244|NCT00198354|DRUG|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
214843245|NCT00198354|DRUG|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
214843246|NCT05389241|OTHER|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
214843247|NCT05389241|OTHER|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
214843248|NCT01673841|PROCEDURE|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
214843249|NCT03977441|DRUG|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
214843250|NCT04334850|PROCEDURE|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
214843251|NCT04334850|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
214843252|NCT05772286|BIOLOGICAL|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
214843253|NCT01280227|BEHAVIORAL|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
214843254|NCT02701608|DRUG|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
214843255|NCT02701608|DRUG|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
214843256|NCT02701608|PROCEDURE|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
214843257|NCT00802373|DRUG|Solifenacin succinate|oral
214843258|NCT00802373|DRUG|Tolterodine|Oral
214843259|NCT05228249|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
214843260|NCT05228249|DRUG|Carmustine|Given IV
214843261|NCT05228249|DRUG|Cytarabine|Given IV
214843262|NCT05228249|DRUG|Etoposide|Given IV
214843263|NCT05228249|BIOLOGICAL|Loncastuximab Tesirine|Given IV
214843264|NCT05228249|DRUG|Melphalan|Given IV
214843265|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
214843266|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
214843267|NCT03114345|OTHER|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
214843268|NCT03114345|OTHER|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
214843269|NCT01834027|BEHAVIORAL|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
214843270|NCT01834027|BEHAVIORAL|No music|In this group no music will be played in PACU
214843271|NCT06262503|DEVICE|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
214843272|NCT06262503|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
214843273|NCT06262503|DEVICE|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
214843274|NCT06262503|OTHER|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
214843275|NCT01886534|OTHER|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
214843276|NCT01886534|BEHAVIORAL|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
214843277|NCT01886534|OTHER|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
214843278|NCT01886534|OTHER|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
214843279|NCT01886534|OTHER|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
214843280|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~\--------------------------------------------------------------------------------"
214843281|NCT03168906|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
214843282|NCT03168906|DRUG|Placebo|Saline bag
214843283|NCT05065541|DRUG|CC-97489|Specified dose on specified days
214843284|NCT05065541|DRUG|[18F]T-401|Specified dose on specified days
214843285|NCT05065541|DRUG|[11C]MK-3168|Specified dose on specified days
214843286|NCT05753982|OTHER|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
214843287|NCT00972231|OTHER|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
214843288|NCT02476188|PROCEDURE|Sample of Blood|
214843289|NCT05486299|PROCEDURE|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
214843290|NCT04906941|DEVICE|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~\* Sense 2 \* 2: 9min33s"
214843291|NCT04969354|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
214843292|NCT05337202|DEVICE|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
214843293|NCT04202458|DRUG|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
214843294|NCT04906837|DIAGNOSTIC_TEST|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
214843295|NCT00243152|DRUG|Lamotrigine|: 25mg and 50mg tablets
214843296|NCT00243152|DRUG|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
214843297|NCT00476307|BIOLOGICAL|Fluarix™/Influsplit SSW® 2007/2008|
214843298|NCT00949195|OTHER|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
214843299|NCT00949195|OTHER|Pulmonary pressure response during exercise|Semi-supine echocardiography test
214843300|NCT03079388|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
214843301|NCT03079388|DIETARY_SUPPLEMENT|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
214843302|NCT03079388|DRUG|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
214843303|NCT03079388|DRUG|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
214843304|NCT03079388|OTHER|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
214843305|NCT03079388|DRUG|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
214843306|NCT03079388|DRUG|Albendazole|Single dose albendazole 400mg given in the second trimester.
214843307|NCT03079388|COMBINATION_PRODUCT|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
214843308|NCT02219308|PROCEDURE|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
214843309|NCT02219308|PROCEDURE|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
214843310|NCT03233451|BEHAVIORAL|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
214843311|NCT04899076|DEVICE|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
214843312|NCT00588783|DEVICE|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
214843313|NCT00588783|DEVICE|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
214843314|NCT00157066|DRUG|Ergocalciferol|
214843315|NCT06897072|BEHAVIORAL|Yoga|In the experimental group, yoga exercises were performed for 50 minutes with physical yoga movements (Vrksasana (tree pose), janusirsasana (head-knee pose), modifiedmarichyasana (great sage pose), baddhakonasana (connected angle pose), malasana (garland pose), sukhasana (meditation pose), ardhapadmasana (lotus sitting pose), gomukhasana (cow face pose), supta matyendrasana (spinal rotation pose on the back), bharmanasana (table pose), chakravasana (cat/cow pose), dandayamanabharmasana (balancing yoga pose), vajrasana (diamond pose), viraphadrasana 1-2 (warrior 1-2 pose). The class will include 15 minutes of meditation (deep relaxation with a focus on breath and self-awareness), breathing exercises in between and 10 minutes of relaxation.
214843316|NCT06204770|OTHER|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
214843317|NCT06898736|DEVICE|3d miniplate|3d miniplate was used for mandibular fracture fixation
214843318|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg|200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.
214843319|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg weekly|200 mg of doxycycline taken by mouth weekly regardless of sexual activity
214843320|NCT01731028|DRUG|Somatropin|Somatropin powder and solvent for solution for injection
214843321|NCT05822375|BEHAVIORAL|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
214843322|NCT00548431|DRUG|6-mercaptopurine|Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
214843323|NCT06904651|DEVICE|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline ultrasound guided by dedicated vascular access team
214843324|NCT06055673|GENETIC|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
214843325|NCT06904729|BIOLOGICAL|Low-dose CAR-T cells group|This group of patients received low dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 5×100,000 cells/Kg.
214843326|NCT06904729|BIOLOGICAL|High-dose CAR-T cells group|This group of patients received high dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 1×1000,000 cells/Kg.
214843327|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
214843328|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
214843329|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
214843330|NCT06903949|PROCEDURE|Lumbar Dorsal Root Ganglia Pulsed Radiofrequency|It is an interventional pain management technique used to treat chronic radicular pain, often associated with conditions like lumbar disc herniation or degenerative disc disease. It involves the application of pulsed radiofrequency energy to the dorsal root ganglia (DRG), which are clusters of nerve cell bodies located just outside the spinal cord. DRG is involved in transmitting sensory signals from the periphery (e.g., the limbs) to the central nervous system.
214843331|NCT03359941|PROCEDURE|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
214843332|NCT02518607|DRUG|MGB-BP-3|Treatment of CDI
214843333|NCT02518607|OTHER|Placebo|Placebo
214843334|NCT05540171|OTHER|Oral health education and instructions/training for self-oral care|Education intervention
214843335|NCT06212869|DEVICE|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
214843336|NCT06212869|DEVICE|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
214843337|NCT06212869|DEVICE|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
214843338|NCT05758779|BEHAVIORAL|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
214843339|NCT02966496|BIOLOGICAL|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
214843340|NCT02966496|BIOLOGICAL|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
214843341|NCT05254158|DRUG|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
214843342|NCT04431635|DRUG|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
214843343|NCT04431635|DRUG|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
214843344|NCT04431635|DRUG|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
214843345|NCT00847743|DIETARY_SUPPLEMENT|Tart Cherry Juice|8 fl.oz. twice per day
214843346|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
214843347|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
214843348|NCT01150006|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
214843349|NCT02839798|DEVICE|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
214843350|NCT02447887|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
214843351|NCT02447887|DRUG|Pegylated IFN-alpha 2b|Weekly injection
214843352|NCT02561234|DRUG|Co-ArgI-PEG|Administered IV
214843353|NCT01297816|DRUG|placebo|100mg,BD, fo three month
214843354|NCT01297816|DRUG|Minocycline|100mg
214843355|NCT06196593|DEVICE|AcrySof™ IQ Vivity™ Toric intraocular lens|Uneventful phacoemulsification and implantation of IOL
214843356|NCT04992793|COMBINATION_PRODUCT|Congenital heart surgery|Paediatric congenital heart surgery
214843357|NCT06271902|OTHER|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
214843358|NCT06271902|OTHER|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
214843359|NCT01323452|DRUG|Entecavir|once daily
214843360|NCT06260579|BEHAVIORAL|Exercise/physical activity|personalized exercise training and physical activity program
214843361|NCT00110695|DRUG|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
214843362|NCT06617767|OTHER|Reiki|The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
214843363|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 100 mg
214843364|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 50 mg
214843365|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
214843366|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg
214843367|NCT00401245|DRUG|Placebo|Tapering placebo
214843368|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
214843369|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
214843370|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
214843371|NCT00864799|DRUG|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
214843372|NCT00235118|DEVICE|Cordis AAA Bilateral Device|
214843373|NCT03417609|DEVICE|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
214843374|NCT03417609|PROCEDURE|Blood sampling|Blood sampling
214843375|NCT03417609|DIAGNOSTIC_TEST|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
214843376|NCT03417609|DIAGNOSTIC_TEST|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
214843377|NCT03417609|DIAGNOSTIC_TEST|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
214843378|NCT03417609|DEVICE|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
214843379|NCT03417609|DIAGNOSTIC_TEST|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
214843380|NCT05141630|PROCEDURE|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
214843381|NCT02344745|OTHER|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
214843382|NCT02344745|OTHER|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
214843383|NCT03071913|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
214843384|NCT03071913|OTHER|Laboratory Biomarker Analysis|Correlative studies
214843385|NCT02788513|DRUG|BI 425809 dose 1|
214843386|NCT02788513|DRUG|BI 425809 dose 2|
214843387|NCT02788513|DRUG|BI 425809 dose 3|
214843388|NCT02788513|DRUG|BI 425809 dose 4|
214843389|NCT02788513|DRUG|Placebo|
214843390|NCT02607137|BEHAVIORAL|Health Education|Information on healthy living style in relation to physical activity
214843391|NCT02397213|DRUG|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
214843392|NCT02397213|DRUG|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
214843393|NCT01834898|DRUG|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
214843394|NCT00898820|GENETIC|gene expression analysis|
214843395|NCT00898820|GENETIC|polymorphism analysis|
214843396|NCT00898820|GENETIC|protein expression analysis|
214843397|NCT02367625|DEVICE|CryoPop|The new CryoPop device will be compared to standard cryotherapy
214843398|NCT02367625|DEVICE|MedGyn MGC 200|Standard cryotherapy
214843399|NCT04261569|DEVICE|Ev-NIRT|Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
214843400|NCT02118168|OTHER|No intervention|No intervention is foreseen in this Observational Study
214843401|NCT02833428|DEVICE|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
214843402|NCT03129230|PROCEDURE|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
214843403|NCT03917355|BEHAVIORAL|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
214843404|NCT01279655|DEVICE|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
214843405|NCT01279655|BEHAVIORAL|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
214843406|NCT03657238|DRUG|RD01|single S.C. dose of RD01 for subjects in test group
214843407|NCT03657238|DRUG|Placebo|single S.C. dose of placebo for subjects in placebo group
214843408|NCT04024319|PROCEDURE|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
214843409|NCT04138784|OTHER|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
214843410|NCT04138784|OTHER|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
214843411|NCT01675284|BIOLOGICAL|AT-301|Inactivated H5N1 Influenza Virion Vaccine
214843412|NCT04673708|DIAGNOSTIC_TEST|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
214843413|NCT02919111|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
214843414|NCT02837133|BEHAVIORAL|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
214843415|NCT00426530|DRUG|everolimus (RAD001)|
214843416|NCT02014441|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
214843417|NCT01383850|OTHER|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
214843418|NCT01383850|OTHER|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
214843419|NCT04595032|DEVICE|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
214843420|NCT04253353|DRUG|tafamidis|61 mg capsule
214843421|NCT04253353|DRUG|rosuvastatin|10 mg tablet
214843422|NCT05499234|DRUG|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
214843423|NCT05499234|DRUG|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
214843424|NCT05773534|DIAGNOSTIC_TEST|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
214843425|NCT02754024|PROCEDURE|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
214843426|NCT02754024|PROCEDURE|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
214843427|NCT02754024|DEVICE|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
214843428|NCT01329224|OTHER|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
214843429|NCT01185379|DIETARY_SUPPLEMENT|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
214843430|NCT01185379|DIETARY_SUPPLEMENT|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
214843431|NCT01185379|DIETARY_SUPPLEMENT|Placebo|4 x 500 mg capsules to be taken daily for 6 months
214843432|NCT06614608|DRUG|5% ASKC200|5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
214843433|NCT06614608|DRUG|1% ASKC200|1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
214843434|NCT01933919|DRUG|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
214843435|NCT01933919|DRUG|Placebo|Placebo tablet matching to fluvoxamine maleate
214843436|NCT03998709|DRUG|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
214843437|NCT03998709|OTHER|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
214843438|NCT03998709|DRUG|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
214843439|NCT03998709|OTHER|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
214843440|NCT02096822|BEHAVIORAL|Facilitated tucking + non-nutritive sucking|
214843441|NCT02096822|OTHER|non-nutritive sucking|
214843442|NCT00991510|DRUG|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
214843443|NCT00991510|DRUG|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
214843444|NCT02000323|OTHER|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
214843445|NCT02000323|OTHER|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
214843446|NCT05472155|DEVICE|Bulb syringe|Suctioning with a bulb syringe
214843447|NCT05472155|DEVICE|Suction catheter|Suctioned with a suction catheter
214843448|NCT05831735|BEHAVIORAL|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
214843449|NCT05831735|BEHAVIORAL|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
214843450|NCT04489186|DEVICE|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
214843451|NCT03070691|DRUG|LDE225B|Cream, 2x daily
214843452|NCT03070691|DRUG|Vehicle|cream, 2x daily
214843453|NCT01270490|DRUG|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
214843454|NCT00928226|RADIATION|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
214843455|NCT00928226|PROCEDURE|Surgical resection|Standard of care
214843456|NCT03942783|OTHER|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
214843457|NCT03942783|OTHER|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
214843458|NCT05007184|BEHAVIORAL|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
214843459|NCT05007184|BEHAVIORAL|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
214843460|NCT06267209|OTHER|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
214843461|NCT02356211|OTHER|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
214843462|NCT05975177|DEVICE|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
214843463|NCT05975177|PROCEDURE|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
214843464|NCT00777933|DRUG|tacrolimus|
214843465|NCT00777933|DRUG|cyclosporine|
214843466|NCT01473147|DRUG|Exenatide|Exenatide 5 microgram bid sc.
214843467|NCT01473147|DRUG|Normal saline|Normal saline 2 u bid sc.
214843468|NCT01331577|BEHAVIORAL|Cognitive Behavioural Training|Two day seminar
214843469|NCT01331577|BEHAVIORAL|Integrative Kinesiology Intervention|Two day seminar
214843470|NCT05393128|PROCEDURE|Control group (Supine Position)|"In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
214843471|NCT05393128|PROCEDURE|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
214843472|NCT05393128|PROCEDURE|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
214843473|NCT04546152|DEVICE|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
214843474|NCT04679142|DRUG|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
214843475|NCT05758909|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
214843476|NCT01961752|DRUG|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
214843477|NCT01961752|DRUG|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
214843478|NCT01961752|DRUG|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
214843479|NCT03527680|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
214843480|NCT03527680|DRUG|Placebo - Cap|daily one capsule of placebo
214843481|NCT04573296|DEVICE|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
214843482|NCT04573296|BEHAVIORAL|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
214843483|NCT05108116|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
214843484|NCT00643734|DRUG|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
214843485|NCT00643734|OTHER|placebo|placebo
214843486|NCT00643734|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
214843487|NCT00643734|OTHER|placebo|placebo
214843488|NCT00251914|DRUG|Esomeprazole|
214843489|NCT02270424|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
214843490|NCT02270424|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
214843491|NCT02270424|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
214843492|NCT02270424|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
214843493|NCT02270424|DRUG|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
214843494|NCT02270424|DRUG|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
214843495|NCT02270424|DRUG|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
214843496|NCT03765996|OTHER|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
214843497|NCT03765996|OTHER|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
214843498|NCT05244018|DRUG|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
214843499|NCT05244018|DRUG|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
214843500|NCT01695096|OTHER|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
214843501|NCT01695096|OTHER|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
214843502|NCT00697216|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
214843503|NCT00697216|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214843504|NCT02512614|OTHER|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
214843505|NCT04591652|DRUG|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
214843506|NCT02970552|DRUG|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
214843507|NCT02970552|DRUG|Placebo|Indistinguishable placebo vaginal suppository
214843508|NCT00922259|BIOLOGICAL|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
214843509|NCT02762617|DRUG|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
214843510|NCT02762617|DRUG|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
214843511|NCT00379223|PROCEDURE|vitrectomy with radial optic neurotomy|
214843512|NCT02510261|DRUG|Patisiran|Patisiran was administered IV.
214843513|NCT00652756|DEVICE|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
214843514|NCT00652756|OTHER|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
214843515|NCT01835704|OTHER|Radio-frequency dennervation of facet joint|
214843516|NCT01835704|OTHER|Diagnostic nerve-blocks performed under direct x-ray vision|
214843517|NCT02246868|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
214843518|NCT01938235|DRUG|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
214843519|NCT01938235|DRUG|Placebo|Intravenous bolus and 24-hour infusion of placebo
214843520|NCT05947526|PROCEDURE|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
214843521|NCT05724368|DIAGNOSTIC_TEST|Fecal Calprotectin ELISA kit|"* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
214843522|NCT02495181|DRUG|Intravitreal Aflibercept|
214843523|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
214843524|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
214843525|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
214843526|NCT01269450|DRUG|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
214843527|NCT01269450|DRUG|placebo|placebo 200mg vaginal tablets
214843528|NCT01312181|BEHAVIORAL|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
214843529|NCT01312181|BEHAVIORAL|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
214843530|NCT01312181|BEHAVIORAL|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
214843531|NCT01607177|BEHAVIORAL|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
214843532|NCT05992428|DRUG|DA-8010 5mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
214843533|NCT05992428|DRUG|Paroxetine 20mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg
214843534|NCT05992428|DRUG|Mirabegron 50mg|\[Part 2\] DA-8010 5mg + Mirabegron 50mg
214843535|NCT00668720|DEVICE|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
214843536|NCT00668720|DEVICE|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
214843537|NCT02443324|DRUG|Ramucirumab|Administered IV
214843538|NCT02443324|DRUG|Pembrolizumab|Administered IV
214843539|NCT06256835|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214843540|NCT06256835|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
214843541|NCT03543709|DIAGNOSTIC_TEST|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
214843542|NCT03543709|OTHER|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
214843543|NCT05915793|OTHER|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
214843544|NCT05915793|OTHER|Diaphragm strengthening|Diaphragm strengthening
214843545|NCT00149526|BEHAVIORAL|Shared Decision-Making|
214843546|NCT05379790|DRUG|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
214843547|NCT05379790|DRUG|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
214843548|NCT03907800|DRUG|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
214843549|NCT03907800|DRUG|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
214843550|NCT03907800|DRUG|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
214843551|NCT02208115|DIETARY_SUPPLEMENT|Meal composition - Low versus high GI.|
214843552|NCT04447937|OTHER|No Interventions|There are no interventions associated with the study.
214843553|NCT03519282|DEVICE|comfilcon A multifocal toric lens|contact lens
214843554|NCT03519282|DEVICE|omafilcon A Multifocal Toric Lens|contact lens
214843555|NCT01337765|DRUG|BEZ235 + MEK162|
214843556|NCT04057248|DEVICE|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
214843557|NCT04057248|BEHAVIORAL|CDE|Certified Diabetes Educator Sessions
214843558|NCT00750048|DRUG|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
214843559|NCT02451150|DRUG|Azilsartan|Azilsartan tablets
214843560|NCT04100824|PROCEDURE|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
214843561|NCT04100824|DRUG|Nimodipine|Nimodipine 60mg every 4h
214843562|NCT02419235|OTHER|20% ethanol|Unmedicated 20% ethanol.
214843563|NCT02419235|OTHER|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
214843564|NCT00746902|DEVICE|nCPAP|Active nCPAP
214843565|NCT05604079|DEVICE|Electrolarynx|The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
214843566|NCT00506506|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
214843567|NCT00506506|DRUG|Placebo|
214843568|NCT03244475|DEVICE|TES|"The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes."
214843569|NCT03282006|DRUG|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
214843570|NCT04859387|OTHER|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
214843571|NCT04859387|OTHER|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
214843572|NCT00588328|DEVICE|PET/CT scan|PET/CT scans
214843573|NCT03056768|BEHAVIORAL|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
214843574|NCT03056768|BEHAVIORAL|Active control|Health promotion activities provided by local health bureau.
214843575|NCT00204022|DRUG|Mycophenolate mofetil|Mycophenolate mofetil
214843576|NCT00204022|DRUG|Azathioprine|Azathioprine
214843577|NCT01178164|GENETIC|Blood sampling for biological and genetic analysis|"* Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
214843578|NCT01915342|DEVICE|Focal muscular vibration|
214843579|NCT01358799|DEVICE|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
214843580|NCT05524311|DRUG|Baricitinib|Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
214843581|NCT05524311|BIOLOGICAL|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
214843582|NCT05524311|BIOLOGICAL|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
214843583|NCT05524311|BIOLOGICAL|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
214843584|NCT05524311|BEHAVIORAL|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
214843585|NCT05524311|BEHAVIORAL|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
214843586|NCT05524311|BIOLOGICAL|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
214843587|NCT00890331|BEHAVIORAL|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
214843588|NCT00890331|BEHAVIORAL|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
214843589|NCT01657084|DEVICE|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
214843590|NCT01657084|DEVICE|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
214843591|NCT04452279|DEVICE|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
214843592|NCT02956616|DRUG|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
214843593|NCT02956616|OTHER|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
214843594|NCT02956616|PROCEDURE|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
214843595|NCT01022684|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
214843596|NCT05993598|OTHER|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
214843597|NCT01537731|PROCEDURE|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
214843598|NCT02639728|OTHER|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
214843599|NCT02639728|OTHER|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
214843600|NCT02639728|OTHER|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
214843601|NCT04211519|DIAGNOSTIC_TEST|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
214843602|NCT01579760|DRUG|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
214843603|NCT01579760|DRUG|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
214843604|NCT04781114|DRUG|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
214843605|NCT04781114|DRUG|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
214843606|NCT02404519|DIETARY_SUPPLEMENT|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
214843607|NCT02404519|DIETARY_SUPPLEMENT|Placebo|1 tablet without MK-7 taken orally every day during 1 year
214843608|NCT02780167|DRUG|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
214843609|NCT02780167|DRUG|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
214843610|NCT02780167|DRUG|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
214843611|NCT02780167|DRUG|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
214843612|NCT02780167|DRUG|Placebo|Placebo QD for 12 weeks
214843613|NCT02336516|DRUG|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
214843614|NCT02336516|DRUG|Placebo (glucose solution 10%)|
214843615|NCT02032355|PROCEDURE|spinal anesthesia|
214843616|NCT01145924|PROCEDURE|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
214843617|NCT05754424|DRUG|AT278|Concentrated rapid acting insulin aspart
214843618|NCT05754424|DRUG|NovoRapid|Rapid-acting insulin aspart
214843619|NCT05754424|DRUG|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
214843620|NCT01685593|DEVICE|abdominal binder|
214843621|NCT01685593|OTHER|no binder|
214843622|NCT01699529|DEVICE|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
214843623|NCT02848066|PROCEDURE|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
214843624|NCT02323165|OTHER|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
214843625|NCT03180801|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
214843626|NCT03180801|BIOLOGICAL|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
214843627|NCT03180801|OTHER|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
214843628|NCT03703024|DIETARY_SUPPLEMENT|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
214843629|NCT03703024|DIETARY_SUPPLEMENT|Placebo|Delivered in a capsule
214843630|NCT02772094|BIOLOGICAL|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
214843631|NCT05179447|RADIATION|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
214843632|NCT05179447|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
214843633|NCT05179447|OTHER|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
214843634|NCT05179447|COMBINATION_PRODUCT|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
214843635|NCT06698133|OTHER|Participants in the intervention arm will be invited to join a private social media group|Education content
214843636|NCT00850681|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
214843637|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
214843638|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
214843639|NCT03756883|DRUG|Placebo Inhalation Powder|No active content
214843640|NCT06614751|DRUG|DAT-2645 tablet|The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
214843641|NCT06614751|DRUG|DAT-2645 tablet|The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
214843642|NCT06617078|PROCEDURE|long-term oxygen therapy (LTOT)|Usual care with LTOT for 2 weeks
214843643|NCT06617078|PROCEDURE|High Flow Nasal Therapy (HFNT)|High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L/min, 34°C, identical O2 flow rate as LTOT) for 2 weeks
214843644|NCT02445287|RADIATION|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
214843645|NCT03235479|DRUG|Rimegepant|75 mg tablet QD
214843646|NCT03235479|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
214843647|NCT06251895|OTHER|DKA protocol|IV fluids and IV insulin as per guidelines. reference 1-2
214843648|NCT03643367|DRUG|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
214843649|NCT03643367|DRUG|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
214843650|NCT06167252|OTHER|Exploration of a database|extraction of data
214843651|NCT00367016|DRUG|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
214843652|NCT00367016|DRUG|Placebo|Placebo, given by subcutaneous injection.
214843653|NCT04927325|OTHER|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
214843654|NCT06059417|OTHER|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
214843655|NCT02419833|PROCEDURE|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
214843656|NCT02419833|PROCEDURE|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
214843657|NCT02419833|DEVICE|Coronary artery stenting|Implantation of coronary stents
214843658|NCT03490409|DEVICE|Thigh compression stocking|Thigh compression stocking
214843659|NCT04836351|OTHER|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
214843660|NCT04474093|OTHER|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
214843661|NCT06033807|DIAGNOSTIC_TEST|QuantiFERON-TB Gold (QFT) test|Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
214843662|NCT03465072|OTHER|Exercise training|8 weeks, 3 times per week, 30-40 minutes
214843663|NCT01148524|BIOLOGICAL|No Vaccine|
214843664|NCT01148524|BIOLOGICAL|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
214843665|NCT01352364|OTHER|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
214843666|NCT01737541|DRUG|Fluoxetine|
214843667|NCT01737541|DRUG|Placebo|
214843668|NCT03110380|DRUG|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
214843669|NCT03110380|DRUG|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
214843670|NCT03110380|DRUG|DTG|50 mg tablet(s) administered orally once daily
214843671|NCT03110380|DRUG|DTG Placebo|Tablet(s) administered orally once daily
214843672|NCT03110380|DRUG|F/TAF Placebo|Tablet(s) administered orally once daily
214843673|NCT03110380|DRUG|B/F/TAF Placebo|Tablet(s) administered orally once daily
214843674|NCT01734694|DRUG|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
214843675|NCT01734694|DRUG|Ceftaroline|"Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;"
214843676|NCT01734694|DRUG|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h"
214843677|NCT01734694|DRUG|Linezolid|600 mg IV/PO q12h
214843678|NCT05539534|BEHAVIORAL|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
214843679|NCT06192641|DRUG|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
214843680|NCT00826137|DIETARY_SUPPLEMENT|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
214843681|NCT00826137|DIETARY_SUPPLEMENT|Placebo|Placebo is base powder of product with no oligosaccharides.
214843682|NCT03355196|DRUG|LRX712|Ascending single dose on Day 1
214843683|NCT03355196|DRUG|Placebo|Ascending single dose on Day 1
214843684|NCT01355302|DRUG|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
214843685|NCT01355302|DRUG|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
214843686|NCT01355302|DRUG|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
214843687|NCT04819854|DRUG|EP395|capsule for oral treatment
214843688|NCT04819854|DRUG|Placebo|capsule for oral treatment
214843689|NCT04919759|BEHAVIORAL|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
214843690|NCT04919759|BEHAVIORAL|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
214843691|NCT05298592|BIOLOGICAL|BMS-986406|Specified dose on specified days
214843692|NCT05298592|BIOLOGICAL|Nivolumab|Specified dose on specified days
214843693|NCT05298592|DRUG|Carboplatin|Specified dose on specified days
214843694|NCT05298592|DRUG|Pemetrexed|Specified dose on specified days
214843695|NCT05298592|DRUG|Paclitaxel|Specified dose on specified days
214843696|NCT03457090|OTHER|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~* To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~* To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~* To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~* To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
214843697|NCT02082249|DRUG|ABT-SLV187|Dose levels will be individually optimized
214843698|NCT05187741|DEVICE|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
214843699|NCT05139628|DIAGNOSTIC_TEST|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
214843700|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
214843701|NCT04546048|BEHAVIORAL|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
214843702|NCT01063959|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
214843703|NCT01063959|PROCEDURE|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
214843704|NCT04091802|PROCEDURE|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
214843705|NCT04126486|OTHER|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
214843706|NCT03330314|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
214843707|NCT06094998|DIAGNOSTIC_TEST|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
214843708|NCT04435002|OTHER|Acupressure|Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
214843709|NCT01456741|PROCEDURE|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
214843710|NCT01456741|PROCEDURE|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
214843711|NCT02607020|OTHER|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1\. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
214843712|NCT02607020|OTHER|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
214843713|NCT02531594|BEHAVIORAL|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
214843714|NCT02531594|BEHAVIORAL|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
214843715|NCT01817595|OTHER|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
214843716|NCT01817595|OTHER|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
214843717|NCT03750695|BEHAVIORAL|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
214843718|NCT03750695|BEHAVIORAL|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
214843719|NCT03750695|BEHAVIORAL|Rest|40 minutes of quiet rest in semi-recumbent position
214843720|NCT00365690|BEHAVIORAL|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
214843721|NCT00365690|BEHAVIORAL|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
214843722|NCT00365690|BEHAVIORAL|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
214843723|NCT05936047|BIOLOGICAL|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
214843724|NCT06146660|DRUG|Mavacamten|According to approved product label
214843725|NCT04411173|DIETARY_SUPPLEMENT|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
214843726|NCT02883439|DRUG|MP29-02|local nasal application
214843727|NCT02883439|DRUG|Fluticasone propionate|local nasal application
214843728|NCT01586208|DRUG|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
214843729|NCT03494933|PROCEDURE|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
214843730|NCT03494933|PROCEDURE|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
214843731|NCT01285505|DRUG|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
214843732|NCT01285505|DRUG|alprazolam test sublingual tablet|0.5 mg tablet, single dose
214843733|NCT01680601|PROCEDURE|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
214843734|NCT01680601|PROCEDURE|Placebo|
214843735|NCT04534140|DIETARY_SUPPLEMENT|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
214843736|NCT04534140|OTHER|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
214843737|NCT01195220|BEHAVIORAL|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
214843738|NCT01195220|BEHAVIORAL|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
214843739|NCT01195220|BEHAVIORAL|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
214843740|NCT04929730|OTHER|Nephrology care bundle|Nephrology care bundle
214843741|NCT02525263|BIOLOGICAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
214843742|NCT03460899|OTHER|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
214843743|NCT03460899|OTHER|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
214843744|NCT05009056|DEVICE|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
214843745|NCT04480307|DRUG|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
214843746|NCT04480307|DRUG|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
214843747|NCT04480307|DRUG|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
214843748|NCT04480307|DRUG|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
214843749|NCT03171324|DRUG|Iron Supplement|2 mg/kg/day elemental iron
214843750|NCT03549897|DRUG|Placebo|Placebo Product
214843751|NCT03549897|DRUG|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
214843752|NCT03549897|DRUG|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
214843753|NCT03549897|DRUG|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
214843754|NCT04012216|DEVICE|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
214843755|NCT04012216|DEVICE|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
214843756|NCT05862844|BEHAVIORAL|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
214843757|NCT01203917|DRUG|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
214843758|NCT02909517|OTHER|cSLO imaging|
214843759|NCT01264835|DEVICE|Slotted Anoscope|SA411
214843760|NCT02449616|DRUG|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
214843761|NCT01691586|DEVICE|Remote patient monitoring|Remote monitoring of ICD and heart failure data
214843762|NCT01691586|OTHER|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
214843763|NCT05696041|OTHER|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
214843764|NCT05157035|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
214843765|NCT04139863|DIAGNOSTIC_TEST|aMMP-8 chairside test|No test
214843766|NCT02673086|OTHER|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
214843767|NCT02673086|OTHER|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
214843768|NCT05126212|OTHER|User experience|User experience is assessed by validated scale
214843769|NCT01863355|DRUG|B0 group: bolus 0.6mcg/kg without background infusion|
214843770|NCT01863355|DRUG|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
214843771|NCT01863355|DRUG|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
214843772|NCT01764750|DRUG|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
214843773|NCT01764750|DRUG|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
214843774|NCT00108550|DRUG|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
214843775|NCT00108550|DRUG|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
214843776|NCT03028155|DRUG|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
214843777|NCT03028155|DRUG|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
214843778|NCT05741502|DRUG|Clozapine|We will assess inflammatory/immune marker labs
214843779|NCT05741502|DRUG|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
214843780|NCT01867190|BIOLOGICAL|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
214843781|NCT04072003|DEVICE|intravascular ultrasound (IVUS)|use IVUS in the procedure
214843782|NCT04072003|OTHER|coronary angiography|Coronary angiography is required for all PCI procedure.
214843783|NCT04379284|OTHER|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
214843784|NCT02995564|BEHAVIORAL|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
214843785|NCT00512538|DEVICE|Bi-layered cell therapy (Apligraf)|
214843786|NCT05885386|DRUG|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
214843787|NCT03022890|BEHAVIORAL|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
214843788|NCT03022890|BEHAVIORAL|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
214843789|NCT03039036|PROCEDURE|Amniotomy|Artificially rupturing membranes
214843790|NCT03039036|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
214843791|NCT03039036|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
214843792|NCT03585309|PROCEDURE|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
214843793|NCT04660032|BEHAVIORAL|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
214843794|NCT02729207|DRUG|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
214843795|NCT06403137|BEHAVIORAL|Resistance exercise|4 single-leg exercise sessions
214843796|NCT06403137|BEHAVIORAL|Standardized diet|Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.
214843797|NCT06403137|DIETARY_SUPPLEMENT|Plant protein supplement|Dissolved in water with breakfast and prior to sleep.
214843798|NCT06403137|DIETARY_SUPPLEMENT|Maltodextrin supplement|Dissolved in water with breakfast and prior to sleep.
214843799|NCT06403137|DIETARY_SUPPLEMENT|Milk protein supplement|Dissolved in water with breakfast and prior to sleep.
214843800|NCT04415047|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
214843801|NCT01712451|DRUG|salmeterol xinafoate, fluticasone propionate|LIPO-102
214843802|NCT01712451|DRUG|Placebo|Placebo
214843803|NCT01712451|DRUG|salmeterol xinafoate|Salmeterol
214843804|NCT04437277|DIAGNOSTIC_TEST|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
214843805|NCT01358253|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
214843806|NCT01358253|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
214843807|NCT01358253|DRUG|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
214843808|NCT01358253|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
214843809|NCT01358253|DRUG|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
214843810|NCT01358253|DRUG|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
214843811|NCT01358253|DRUG|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
214843812|NCT01358253|DRUG|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
214843813|NCT01358253|DRUG|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
214843814|NCT01358253|DRUG|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
214843815|NCT05624762|DEVICE|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
214843816|NCT05624762|DEVICE|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
214843817|NCT05513469|DRUG|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
214843818|NCT02684396|DRUG|TAK-648|TAK-648 Solution
214843819|NCT02684396|DRUG|TAK-648 Placebo|TAK-648 placebo-matching solution
214843820|NCT04912986|BEHAVIORAL|Early Lung Rehabilitation Training|It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.
214843821|NCT04912986|BEHAVIORAL|Routine treatment|Provide rehabilitation training as usual, without standard program
214843822|NCT00065117|DRUG|ZD6126|
214843823|NCT00065117|DRUG|Placebo|
214843824|NCT00065117|DRUG|5-fluorouracil|
214843825|NCT00065117|DRUG|leucovorin|
214843826|NCT00065117|DRUG|oxaliplatin|
214843827|NCT00214812|DRUG|HEC placebo gel|
214843828|NCT02227550|DRUG|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
214843829|NCT02227550|DRUG|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
214843830|NCT01903564|DEVICE|magnetocardiography|recording of magnetic heart activity
214843831|NCT01903564|DEVICE|postnatal ECG|postnatal ECG
214843832|NCT01903564|DEVICE|fetal echocardiography|fetal echocardiography
214843833|NCT02257437|DIETARY_SUPPLEMENT|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
214843834|NCT02257437|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
214843835|NCT02257437|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
214843836|NCT02257437|DIETARY_SUPPLEMENT|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
214843837|NCT00948337|BEHAVIORAL|Brochure of Secondary Cancer Screening|One kind of printed educational material
214843838|NCT04232527|DIAGNOSTIC_TEST|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
214843839|NCT04232527|DIAGNOSTIC_TEST|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
214843840|NCT04232527|DIAGNOSTIC_TEST|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
214843841|NCT04232527|DIAGNOSTIC_TEST|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
214843842|NCT04232527|DIAGNOSTIC_TEST|S_CODS (change of direction speed) Test|S\_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
214843843|NCT05934539|DRUG|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
214843844|NCT01921335|DRUG|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
214843845|NCT01921335|DRUG|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
214843846|NCT01921335|DRUG|Trastuzumab|6 mg/kg IV every 3 weeks
214843847|NCT02351635|OTHER|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
214843848|NCT04366284|OTHER|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
214843849|NCT04366284|OTHER|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
214843850|NCT04366284|OTHER|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
214843851|NCT04738838|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
214843852|NCT04738838|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
214843853|NCT06679218|OTHER|Activity Coaching Programme|The intervention will consist of individualized physical activity coaching sessions, which will take place twice a week for 8 weeks. These sessions will focus on encouraging progressive and personalized physical activity according to each participant's ability. The sessions will also include relaxation techniques, targeted ventilation and strategies to improve activity management.
214843854|NCT06679218|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
214843855|NCT00002936|DRUG|altretamine|
214843856|NCT00002936|DRUG|etoposide|
214843857|NCT03722108|COMBINATION_PRODUCT|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
214843858|NCT03722108|DRUG|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
214843859|NCT03354208|OTHER|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
214843860|NCT05484609|OTHER|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
214843861|NCT05484609|OTHER|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
214843862|NCT05557656|DRUG|Regorafenib 40 MG|participants who received the treatment of Regorafenib
214843863|NCT05607433|DEVICE|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
214843864|NCT06679647|BEHAVIORAL|Access to a trained ChatGPT|Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
214843865|NCT03607045|DEVICE|headless screw|headless screw group
214843866|NCT05363982|DEVICE|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
214843867|NCT05363982|DEVICE|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
214843868|NCT01609582|DRUG|TAK-875|TAK-875 tablets
214843869|NCT01609582|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
214843870|NCT03934060|OTHER|Exercise|specific strength training
214843871|NCT05683860|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
214843872|NCT03067740|DRUG|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
214843873|NCT03067740|DRUG|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
214843874|NCT04161573|BEHAVIORAL|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
214843875|NCT02958930|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
214843876|NCT00819767|DRUG|Aliskiren|Aliskiren was supplied in 150 mg tablets.
214843877|NCT00819767|DRUG|Valsartan|Valsartan was supplied in 160 mg capsules.
214843878|NCT00819767|DRUG|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
214843879|NCT00819767|DRUG|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
214843880|NCT01835535|DEVICE|TIVUS|
214843881|NCT05918341|DRUG|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
214843882|NCT06422481|OTHER|Fluid administration|Patients will receive fluid administration (500 mL of saline over 30 minutes). The indication of fluid administration will be left to the discretion of the attending physician.
214843883|NCT06422481|OTHER|Norepinephrine administration or increase in norepinephrine dosage|Patients will receive norepinephrine or norepinephrine dosage will be increased if necessary to achieve the appropriate mean arterial pressure level. The indication of norepinephrine administration or increase in norepinephrine dosage will be left to the discretion of the attending physician.
214843884|NCT02464241|OTHER|only examination|
214843885|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
214843886|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
214843887|NCT04928664|DRUG|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
214843888|NCT04928664|DRUG|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
214843889|NCT02994290|DRUG|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
214843890|NCT02994290|BEHAVIORAL|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
214843891|NCT04985838|BEHAVIORAL|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
214843892|NCT04283370|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
214843893|NCT04283370|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
214843894|NCT05321875|DRUG|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
214843895|NCT02861833|OTHER|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
214843896|NCT03227133|OTHER|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
214843897|NCT03227133|OTHER|Psychiatric interview|
214843898|NCT03227133|OTHER|Cardiovascular risk assessment|
214843899|NCT03667859|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
214843900|NCT05849688|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
214843901|NCT05849688|OTHER|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
214843902|NCT00754871|DRUG|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
214843903|NCT00754871|DRUG|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
214843904|NCT00754871|DRUG|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
214843905|NCT00754871|DRUG|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
214843906|NCT03776578|PROCEDURE|swallow fuction and swallow training|nasogastric tube dependence rate
214843907|NCT00808509|BIOLOGICAL|adalimumab|40 mg every other week via subcutaneous injection
214843908|NCT00808509|DRUG|methotrexate|At least 10 mg/week administered orally or subcutaneously
214843909|NCT04944472|BEHAVIORAL|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
214843910|NCT03466827|DRUG|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
214843911|NCT01679431|DIAGNOSTIC_TEST|Doppler-echocardiography|
214843912|NCT01679431|RADIATION|Computed tomography|
214843913|NCT01679431|OTHER|Magnetic resonance imaging|
214843914|NCT01679431|BIOLOGICAL|Fasting blood sample|
214843915|NCT02124473|OTHER|Homeopathy|
214843916|NCT02124473|OTHER|Placebo|
214843917|NCT03454282|OTHER|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
214843918|NCT02855840|OTHER|completion of the quality of life questionnaire|
214843919|NCT05556226|DRUG|ABBV-154 Dose Formulation A|Subcutaneous Injection
214843920|NCT05556226|DRUG|ABBV-154 Dose Formulation B|Subcutaneous Injection
214843921|NCT00080431|DRUG|Daclizumab|
214843922|NCT02221440|DEVICE|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
214843923|NCT02221440|DEVICE|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
214843924|NCT02010996|PROCEDURE|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
214843925|NCT02010996|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
214843926|NCT03285919|DEVICE|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
214843927|NCT01642563|PROCEDURE|Platelet transfusion|One dose of pathogen reduced platelets
214843928|NCT01642563|PROCEDURE|Platelet transfusion|One dose of standard platelets
214843929|NCT00732524|DRUG|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
214843930|NCT00732524|DRUG|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
214843931|NCT00032916|DRUG|NS2359|
214843932|NCT06353412|PROCEDURE|Lumbar puncture|Medical treatment Lumbar puncture Theco peritoneal shunt
214843933|NCT04316195|DIAGNOSTIC_TEST|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
214843934|NCT03184012|DEVICE|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
214843935|NCT03184012|DEVICE|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
214843936|NCT02466334|DRUG|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
214843937|NCT02466334|DRUG|Placebo|40 ml of normal saline over 20 mins
214843938|NCT06127745|DEVICE|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
214843939|NCT02775539|DRUG|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
214843940|NCT02775539|DRUG|Placebo|
214843941|NCT00456482|DRUG|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
214843942|NCT00456482|DRUG|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
214843943|NCT02825576|DRUG|Sugammadex|Sugammadex 2mg/kg given for reversal agent
214843944|NCT02825576|DRUG|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
214843945|NCT02762994|DRUG|BCD-085|
214843946|NCT02762994|OTHER|Placebo|
214843947|NCT01139294|DRUG|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
214843948|NCT05103657|DRUG|BI 1358894|BI 1358894
214843949|NCT05103657|DRUG|Placebo|Placebo
214843950|NCT04347330|DRUG|Intensive BP Control|Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
214843951|NCT04347330|DRUG|Standard BP Control|Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
214843952|NCT04366596|DEVICE|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
214843953|NCT04366596|DEVICE|Angioplasty with plain old balloon|Angioplasty with plain old balloon
214843954|NCT01216410|DRUG|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
214843955|NCT01216410|DRUG|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
214843956|NCT01216410|DRUG|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
214843957|NCT05600023|DRUG|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
214843958|NCT05600023|DRUG|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
214843959|NCT05860387|DIAGNOSTIC_TEST|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
214843960|NCT05021484|DRUG|Felzartamab|Intravenous infusion in regular intervals over 6 months
214843961|NCT05021484|DRUG|Placebo|Intravenous infusion in regular intervals over 6 months
214843962|NCT04234464|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
214843963|NCT04234464|COMBINATION_PRODUCT|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
214843964|NCT03635983|BIOLOGICAL|NKTR-214|Specified dose on specified days
214843965|NCT03635983|BIOLOGICAL|Nivolumab|Specified dose on specified days
214843966|NCT04763278|DEVICE|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
214843967|NCT03799848|DRUG|Vadadustat|Oral tablet
214843968|NCT01358084|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
214843969|NCT01358084|DRUG|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
214843970|NCT01358084|OTHER|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
214843971|NCT01235442|DRUG|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
214843972|NCT01235442|DRUG|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
214843973|NCT03604432|DEVICE|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
214843974|NCT00801294|DRUG|BIBF 1120 and BIBW 2992|
214843975|NCT01701973|DRUG|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
214843976|NCT01701973|DRUG|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
214843977|NCT01701973|DRUG|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
214843978|NCT01701973|DRUG|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
214843979|NCT01701973|DRUG|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
214843980|NCT04602793|DIAGNOSTIC_TEST|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
214843981|NCT04451928|DIAGNOSTIC_TEST|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
214843982|NCT01104090|DEVICE|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
214843983|NCT01104090|DEVICE|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
214843984|NCT04666597|PROCEDURE|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
214843985|NCT02412722|DRUG|Sapanisertib|Sapanisertib capsules
214843986|NCT02412722|DRUG|Paclitaxel|Paclitaxel injection
214843987|NCT03791294|DRUG|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
214843988|NCT00419224|BIOLOGICAL|inactivated split-virus influenza vaccine|
214843989|NCT02941523|DRUG|NOX66|NOX66 administration
214843990|NCT02941523|DRUG|Carboplatin|Carboplatin administration
214843991|NCT04449341|DEVICE|Oculus Go headset with Ocean Rift application|Information already included in arm description
214843992|NCT02118025|PROCEDURE|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
214843993|NCT02118025|PROCEDURE|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
214843994|NCT03837171|BIOLOGICAL|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
214843995|NCT03837171|BIOLOGICAL|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
214843996|NCT02515487|OTHER|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
214843997|NCT04499482|OTHER|Food|Soy-fiber containing food
214843998|NCT04305730|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
214843999|NCT04305730|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
214844000|NCT00288925|DRUG|Z-360|
214844001|NCT01057173|PROCEDURE|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
214844002|NCT01057173|PROCEDURE|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
214844003|NCT00337987|DRUG|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
214844004|NCT00337987|DRUG|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
214844005|NCT02266940|DRUG|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
214844006|NCT02266940|DRUG|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
214844007|NCT02773433|OTHER|Proportional Assist Ventilation|
214844008|NCT03481517|DRUG|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
214844009|NCT04618939|BIOLOGICAL|BR-TD-1001|0.5 mL, IM
214844010|NCT04618939|BIOLOGICAL|Td-pur inj|0.5 mL, IM
214844011|NCT01570231|DEVICE|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
214844012|NCT01556867|OTHER|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
214844013|NCT01556867|OTHER|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
214844014|NCT00471991|DRUG|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
214844015|NCT00471991|DRUG|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
214844016|NCT00261417|DRUG|Tesaglitazar|
214844017|NCT01899326|DRUG|Desipramine Hydrochloride|Given PO
214844018|NCT01899326|BIOLOGICAL|Filgrastim|Given PO
214844019|NCT01899326|OTHER|Laboratory Biomarker Analysis|Correlative studies
214844020|NCT00332943|PROCEDURE|MR colonography with fecal tagging|
214844021|NCT01526135|DRUG|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
214844022|NCT01526135|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
214844023|NCT06029582|DEVICE|VR headset|Virtual Reality Headset
214844024|NCT01914016|OTHER|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
214844025|NCT02409940|BIOLOGICAL|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
214844026|NCT05848401|DEVICE|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
214844027|NCT02968719|DRUG|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
214844028|NCT02968719|DRUG|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
214844029|NCT02968719|DRUG|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
214844030|NCT02968719|DRUG|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
214844031|NCT02968719|DRUG|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
214844032|NCT02630290|DRUG|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
214844033|NCT02630290|DRUG|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
214844034|NCT01263561|PROCEDURE|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
214844035|NCT01263561|PROCEDURE|trabeculectomy|trabeculectomy filtering surgery
214844036|NCT01932190|PROCEDURE|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
214844037|NCT01932190|PROCEDURE|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
214844038|NCT02913820|OTHER|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
214844039|NCT01396421|DRUG|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
214844040|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
214844041|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
214844042|NCT01396421|DRUG|Placebo|Placebo, once daily, for six weeks
214844043|NCT06656598|DRUG|Carboplatin|Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
214844044|NCT06656598|DRUG|Paclitaxel|Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
214844045|NCT06656598|DRUG|Cemiplimab|Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
214844046|NCT06656598|RADIATION|Curative hypofractionated radiotherapy|Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
214844047|NCT06656598|DRUG|Cemiplimab (maintenance)|Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
214844048|NCT04590339|PROCEDURE|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
214844049|NCT04728620|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
214844050|NCT02376257|DRUG|250 mg DCS|Drug
214844051|NCT02376257|DRUG|100 mg Modafinil|Drug
214844052|NCT02376257|DRUG|Placebo|Drug
214844053|NCT05548920|OTHER|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
214844054|NCT05548920|OTHER|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
214844055|NCT04631380|OTHER|PRAYER|THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
214844056|NCT05425368|DRUG|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
214844057|NCT05425368|DRUG|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
214844058|NCT03693833|DRUG|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
214844059|NCT03693833|DRUG|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
214844060|NCT03689894|DRUG|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
214844061|NCT03689894|DRUG|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
214844062|NCT01030887|BEHAVIORAL|Exercise programme|Moderate intensity exercise
214844063|NCT04084990|DEVICE|S9 VPAP Adapt|Auto-titrated positive airway pressure
214844064|NCT00681473|RADIATION|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
214844065|NCT03012893|DEVICE|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
214844066|NCT03012893|DEVICE|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
214844067|NCT03012893|PROCEDURE|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
214844068|NCT00096005|DRUG|tanespimycin|Given IV
214844069|NCT00096005|DRUG|bortezomib|Given IV
214844070|NCT00096005|OTHER|laboratory biomarker analysis|Correlative studies
214844071|NCT00052286|DRUG|modafinil|
214844072|NCT05263635|OTHER|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
214844073|NCT05263635|OTHER|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
214844074|NCT01354301|DRUG|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
214844075|NCT01354301|DRUG|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
214844076|NCT01354301|DRUG|Basiliximabe|days 0 and 4, according to the package insert instructions.
214844077|NCT01354301|DRUG|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
214844078|NCT01354301|DRUG|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
214844079|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
214844080|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
214844081|NCT02653235|BIOLOGICAL|Salmonella typhi vaccination|
214844082|NCT02653235|BIOLOGICAL|Placebo|
214844083|NCT05562648|OTHER|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
214844084|NCT05562648|OTHER|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
214844085|NCT04826250|PROCEDURE|Timing of medication|Either morning or nighttime medication
214844086|NCT05729854|OTHER|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
214844087|NCT02886676|DRUG|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
214844088|NCT03427801|DRUG|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
214844089|NCT04634630|GENETIC|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
214844090|NCT02813382|DRUG|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
214844091|NCT02813382|DRUG|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
214844092|NCT02813382|DRUG|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
214844093|NCT02528409|DRUG|Vortioxetine|Medication currently approved for major depression.
214844094|NCT02528409|DRUG|Placebo|
214844095|NCT04909645|DIAGNOSTIC_TEST|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
214844096|NCT04893941|DRUG|CM310|IL-4Rα monoclonal antibody
214844097|NCT04893941|DRUG|Placebo|Placebo
214844098|NCT04333134|DRUG|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
214844099|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement A|Oral administration of Supplement A
214844100|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement B|Oral administration of Supplement B
214844101|NCT00568711|DRUG|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
214844102|NCT00568711|DRUG|rifampin|a 5-day course of daily 600-mg doses of rifampin
214844103|NCT00691041|BEHAVIORAL|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
214844104|NCT01321697|PROCEDURE|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
214844105|NCT02076516|DEVICE|Drug-eluting stent: CORACTO®|
214844106|NCT02569307|DRUG|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
214844107|NCT02569307|DRUG|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
214844108|NCT02569307|DRUG|Placebo|Placebo added to TAU
214844109|NCT02569307|DRUG|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
214844110|NCT04489017|DIETARY_SUPPLEMENT|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
214844111|NCT04489017|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
214844112|NCT05306197|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
214844113|NCT05306197|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
214844114|NCT05306197|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
214844115|NCT00857818|DRUG|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
214844116|NCT00857818|DRUG|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
214844117|NCT04934007|DEVICE|rTMS Treatment|1 Hz rTMS
214844118|NCT05307276|OTHER|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
214844119|NCT05307276|OTHER|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
214844120|NCT05427045|OTHER|home - exercise program|Home exercise program
214844121|NCT01900457|OTHER|electromyography|
214844122|NCT01900457|OTHER|electroencephalography|
214844123|NCT01900457|OTHER|approaches from psychophysics|
214844124|NCT06746233|DEVICE|Drug (paclitaxel) coated balloon (DCB)|In the experimental arm, a drug-coated balloon (DCB) with a concentration of 3 μg of Paclitaxel per 1 mm² will be used in patients with STEMI following successful lesion preparation (defined as residual stenosis ≤30%, TIMI flow grade 2-3, and absence of flow-limiting dissection). If the result after DCB treatment is unsatisfactory, a bailout drug-eluting stent (DES) will be implanted.
214844125|NCT06746233|DEVICE|Second-generation Drug Eluting Stent (DES)|If the patient is randomized to the DES treatment arm, a second-generation drug-eluting stent (DES) will be implanted using standard techniques.
214844126|NCT04469725|DRUG|KN046|KN046 5 milligram per kilogram, every 2 weeks
214844127|NCT00833625|PROCEDURE|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
214844128|NCT00833625|OTHER|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
214844129|NCT06905574|OTHER|surgeon guided serratus block|Surgeon guided Serratus Block will be applied before closing dermoglandular flaps
214844130|NCT06905002|BEHAVIORAL|Educational program|Unique educational program that educates health care professionals on the unique advantages of the Clinical Trials Navigator program. This program is reserved for those centres entering the study. An interactive component of the study is central.
214844131|NCT06904417|OTHER|The Feldenkrais-based intervention|The Feldenkrais-based intervention consisted of guided awareness exercises aimed at improving movement patterns, proprioception, and postural control. Sessions were conducted twice weekly for 12 weeks, with each session lasting approximately 45 minutes
214844132|NCT06904417|OTHER|conventional balance training program|a conventional balance training program consisting of static and dynamic balance exercises, gait training, and strength-building activities, matched for session frequency and duration
214844133|NCT06905821|BEHAVIORAL|Transformational Learning-Based Antenatal Education Program|The Transformational Learning-Based Antenatal Education Program helps pregnant women reduce birth-related anxiety and fear by utilizing transformational learning theory. Unlike traditional antenatal education, it emphasizes psychological preparedness, focusing on emotional well-being and coping strategies. The program includes interactive learning, group discussions, and self-reflection to engage participants actively. This approach aims to boost women's confidence and reduce stress as they approach labor and delivery.
214844134|NCT06905730|DIAGNOSTIC_TEST|sensory integration deficits in balance|By assessing sensory integration deficits in balance recovery, the study will help establish meaningful thresholds for rehabilitation outcomes, guiding clinicians in tailoring therapy for improved post-stroke balance and functional independence
214844135|NCT06905613|DEVICE|Technical feasibility study of a novel wearable capnograph (MARIE) in an emergency care environment|MARIE will be connected to the patient by attaching the nasal adapter set and connecting the CO2 sensor. ETCO2 and RR values will be logged before and during the transport by writing down the values in the Case Report Form (CRF). On arrival at the hospital ETCO2 and RR will be measured by a reference instrument and logged in to the CRF. There will be trained study personnel responsible for operating the investigational device and populating the CRF, capturing all information which is required according to the study protocol.
214844136|NCT00291473|DRUG|CHP-HER2, CHP-NY-ESO-1|
214844137|NCT02866591|OTHER|mammography according to an auto-compression procedure|
214844138|NCT02866591|OTHER|mammography according to a standard procedure|
214844139|NCT02866591|OTHER|questionary|
214844140|NCT06904118|DRUG|Nano-reinforced Novel Hydrogen peroxide gel|Group A (Novel Nano-enriched Hydrogen peroxide bleaching gel with Silky Corn hair fiber derived- titania nanoparticles)
214844141|NCT06904118|DRUG|Conventional Hydrogen peroxide gel without nanoparicles|Drug: Hydrogen peroxide without nanoparicles Group B ( Conventional Hydrogen peroxide gel without nanoparticles)
214844142|NCT06904248|DRUG|Meloxicam Injection|Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
214844143|NCT06904248|DRUG|Sodium Chloride Injection|Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses
214844144|NCT04149535|DEVICE|Sentinel® Cerebral Protection System|cerebral embolic protection system
214844145|NCT03849846|OTHER|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
214844146|NCT02175368|DEVICE|Adhese One F Upgrade|
214844147|NCT02875028|DRUG|Vorapaxar|10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
214844148|NCT02875028|DRUG|Placebo|
214844149|NCT02875028|OTHER|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
214844150|NCT06524817|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
214844151|NCT06245382|DIETARY_SUPPLEMENT|Goode Health Beverage|This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.
214844152|NCT06245382|DIETARY_SUPPLEMENT|Vanilla Base Beverage Blend|This is a commercially available beverage powder.
214467303|NCT05217615|BEHAVIORAL|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
214467304|NCT05217615|BEHAVIORAL|Coaching calls|The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
214467305|NCT05217615|BEHAVIORAL|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
214467306|NCT00614146|DEVICE|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
214467307|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
214467308|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
214467309|NCT05575336|OTHER|ADLIFE intervention|"The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study for a follow-up period between 3 and 12 months."
214467310|NCT06038162|PROCEDURE|Parallel connection|The RRT machine is connected on a separate vascular access (dialysis catheter).
214467311|NCT06038162|PROCEDURE|Integrated connection|A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
214467312|NCT05594901|OTHER|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
214467313|NCT04770402|OTHER|Acupuncture|12 acupuncture sessions over 10 weeks
214467314|NCT04770402|OTHER|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
214467315|NCT04197310|DRUG|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
214467316|NCT04197310|DRUG|Cabozantinib|40mg, orally, Daily for a 28 day cycle
214467317|NCT05584930|OTHER|Collection of blood sample|"* Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)"
214467318|NCT04879615|DRUG|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
214467319|NCT05016947|DRUG|Venetoclax|Tablet, taken by mouth
214467320|NCT05016947|DRUG|Dexamethasone|Taken orally
214467321|NCT05016947|DRUG|Inotuzumab Ozogamicin|Intravenous infusion
214467322|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
214467323|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
214467324|NCT06548425|OTHER|Smart Phone Based Cardiac Telerehabilitation|"Smart Phone Based Cardiac Telerehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60 % THR and modified borg scale 9 (very light- 13 (somewhat hard) Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
214467325|NCT06548425|OTHER|Center based cardiac Rehabilitation|"Center based cardiac Rehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60% THR and modified borg scale 9 (very light- 13 (somewhat hard)~Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
214467326|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
214467327|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
214467328|NCT04872543|DRUG|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
214467329|NCT05574114|RADIATION|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
214467330|NCT05574114|DRUG|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
214467331|NCT05574114|BIOLOGICAL|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
214467332|NCT04550221|BEHAVIORAL|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
214467333|NCT04811040|DRUG|Oral Lenacapavir|Tablets administered without regard to food
214467334|NCT04811040|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
214467335|NCT04811040|DRUG|Teropavimab|Administered intravenously
214467336|NCT04811040|DRUG|Zinlirvimab|Administered intravenously
214467337|NCT05274074|BEHAVIORAL|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
214467338|NCT05402436|OTHER|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
214467339|NCT04101487|OTHER|Cash Transfer|Monthly cash transfers
214467340|NCT04101487|OTHER|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
214467341|NCT06398106|DRUG|Proactive TDM-based dosing of secukinumab|"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
214467342|NCT06398106|DRUG|Proactive TDM-based dosing of ixekizumab|"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
214467343|NCT06398106|DRUG|Proactive TDM-based dosing of guselkumab|"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
214467344|NCT05562622|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
214467345|NCT05562622|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
214467346|NCT04769310|DEVICE|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
214467347|NCT06565052|BEHAVIORAL|Prehabilitation Program|A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
214467348|NCT05884073|BEHAVIORAL|Circuit-based Resistance Training|Participants will engage in a 12-week circuit-based resistance training program 2-3 times/week. Each supervised session will last about 30 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
214467349|NCT05884073|BEHAVIORAL|Nature-based Walking|Participants will be asked to engage in 30 minutes of self-paced walking in nature 2-3 days/week. Participants will be provided with a list of resources that direct them to walkable nature/green spaces close to their home or workplace.
214467350|NCT06852118|PROCEDURE|AMM Group: Adductor Magnus Muscle Plane approach + Femoral Nerve Blocks|In the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. After performing the femoral nerve block, the adductor magnus muscle plane block will be performed using a low-frequency ultrasound probe positioned 6 cm distal to the inguinal crease to identify the sartorius muscle, femoral artery, femoral vein, and femoral nerve on the deep side of the sartorius muscle, the probe will be slide by about 2-2.5 cm distally, where we could identify the plane between the adductor magnus and the semimembranosus muscles, and after proper sterilization, the needle will be slowly advanced until the needle tip is close to the posterior surface of the AMM, 20 mL of bupivacaine 0.5% will be injected while observing fluid distribution under the posterior surface of the AMM, Then GA.
214467351|NCT06852118|PROCEDURE|SG Group: Sciatic nerve block by sub-gluteal approach + Femoral nerve blocks|While the patient is in the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify a cross-sectional view of the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. the patient will be turned on their sides with the operative side uppermost and flexed, the sub-gluteal sciatic nerve will be identified using a low-frequency probe, and then the same needle will be advanced the in-plane to inject 20 ml bupivacaine 0.5% around the nerve., then GA will be conducted as the other group
214467352|NCT06851455|OTHER|Cadaveric Workshop on Ultrasound-guided Injections|"Participant physicians will attend a structured cadaveric workshop on ultrasound-guided musculoskeletal injections.~Participants will perform hands-on procedures under expert supervision on lower extremity joints listed as hip, knee and ankle.~For the assessment participants will be asked to complete pre- and post-workshop assessments to measure skill improvement and confidence levels."
214467353|NCT04113603|DIAGNOSTIC_TEST|Urinary malignancy|Single bolus three phase CTU
214467354|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
214467355|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
214467356|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
214467357|NCT06852521|OTHER|Stimulus Properties: Target Location|The location of the target item in the display will be varied across trials (appear left, right, up, or down)
214467358|NCT06852521|OTHER|Stimulus Properties: Distractor Presence|A proportion of all trials will contain a task-irrelevant, singleton distractor defined in a non-target dimension (e.g., color target and motion distractor)
214467359|NCT06852521|OTHER|Stimulus properties: Cue Validity|Varied across trials, the validity of the cue will be determined by the match or mismatch between direction of the visual cue (an arrowhead around the fixation pointing to the right, left, up, or down) and actual target location
214467360|NCT06848621|DEVICE|40Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
214467361|NCT06848621|DEVICE|100Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
214467362|NCT05367102|BEHAVIORAL|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
214467363|NCT06668623|OTHER|Reiki Group|Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.
214467364|NCT06668623|OTHER|Sham Reiki Group|In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
214467365|NCT05184738|OTHER|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
214467366|NCT05184738|OTHER|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
214467367|NCT06827743|BEHAVIORAL|feeding behavior education|Two groups will receive personalized sensory integration training, and one group will receive feeding behavior training. Both the caregiver and the child will take part in feeding behavior training. In order for the training to be successful, the therapist, child, and parent cooperation is necessary. Before this training, the children will be evaluated with the Behavioral Pediatric Feeding Assessment Scale and a behavioral training plan will be created according to the children's attitudes and behaviors during feeding. This plan will include organizing feeding times, determining the family's approach to the child's behaviors during feeding, regulating the children's feeding behavior problems with extinguishing and desensitization methods, and organizing the feeding environment, and creating a personalized training plan.
214467368|NCT06827743|BEHAVIORAL|Sensory integration intervention|The sensory integration training given to both groups includes training that includes oral processing skills in particular, as well as training that includes tactile, vestibular, proprioception, and visual stimuli as needed. Children will be supported with sensory stimuli in order to ensure that the child focuses and remains calm. Sensory integration training will be planned by taking into account the Dunn Sensory Profile test results. In this training, different patterned fabrics, plushes, and toys with different surfaces for tactile stimulation will be provided to maintain the child's calmness and focus; swings and exercise balls for vestibular stimulation; and training to provide sensory regulation with proprioceptive approaches. In addition, within the scope of sensory integration training, stimuli will be provided in the oral region according to the children's sensory responses to the texture, taste, and content of foods.
214467369|NCT06712290|DRUG|celgene|"CTM Boost (CTM Biomedical, Miami, FL) is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. It is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is regulated as a minimally-manipulated biologic by the FDA and is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is administered applied into the tissue via injection.~Participant will undergo a single injection of 2.0cc of the injectable CTM allograft, administered using a 20G needle in the subacromial space. 3mL of ropivacaine will be mixed into the syringe prior to administration of the injection. Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used."
214467370|NCT06712290|DRUG|Corticosteroid|Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or intra-articular (into the joints) use. It may be used to treat many different types of inflammatory conditions. In this study, a 2.0cc dose injection of Kenalog-40 will be administered directly into the subacromial space using a 20G needle. 3mL of ropivacaine will be injected along with the steroid (as part of the same injection). Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.
214467371|NCT06342102|PROCEDURE|PENG + LFCN block|The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.
214467372|NCT06342102|PROCEDURE|FIC block|FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
214467373|NCT04075526|DRUG|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
214467374|NCT04075526|DRUG|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
214467375|NCT04075526|OTHER|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
214467376|NCT04730583|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion
214467377|NCT04730583|DEVICE|1064nm laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
214467378|NCT04730583|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
214467379|NCT06852378|DRUG|Iliopsoas nerve block|Patients will receive an Iliopsoas nerve block using 10 ml of bupivacaine 0.5%.
214467380|NCT06852378|DRUG|Femoral nerve block|Patients will receive femoral nerve block using 10 ml of bupivacaine 0.5%.
214467381|NCT06851078|DRUG|Levetiracetam IV|1000 mg twice a day during 7 days maximum
214467382|NCT06851078|OTHER|Placebo control|NaCl 0.9% sodium chloride in the same route and method of administration as experimental treatment
214467383|NCT06850909|DEVICE|Microdrop GPS dish|The µDrop GPS® micro-wells dish is specifically designed for oocyte and embryo handling and culture. The sloped concave micro-well bottoms of the µDrop GPS® dish allow oocytes and embryos to settle at a central location away from the well walls. The concave nature of the wells provides the thinnest well bottom possible, helping to reduce refraction and allow for optimal visualization. The wells may reduce droplet collapsing/mixing, offer better orientation/optics, and reduce set-up/observation time.
214467384|NCT06850909|DEVICE|16 well BIRR dish|The 16-Well BIRR Dish is a high-quality 3D culture dish designed for optimal embryo handling and identification in IVF. It features well-numbering (1-16) for clear tracking, a large labeling area, and an expanded working space for better accessibility. Its 16 wells allow for increased wash drops and single embryo culture, reducing the number of dishes needed per IVF cycle. Rigorously tested (MEA+, LAL, and SMA per lot), it ensures safe and efficient embryo culture.
214467385|NCT06851611|BIOLOGICAL|COVID-19 vaccine, low dose level|Test article
214467386|NCT06851611|BIOLOGICAL|COVID-19 vaccine, high dose level|Test article
214467387|NCT06851611|OTHER|Nasal Drops|Method of administration of test article
214467388|NCT06851611|OTHER|Nasal Spray|Method of administration of test article
214467389|NCT05523206|OTHER|No intervention|No intervention
214467390|NCT06846762|OTHER|This study did not include intervention between the two cohorts|The study is divided into two parts, Part A and Part B. The purpose of Part A is to reveal the proportion of NSCLC patients who are primarily resistant to first-line non-targeted therapy due to the omission of driver genes (especially fusion variations) by DNA-NGS, the median PFS of patients in the first line, and clinical characteristics through synchronous co-testing of DNA and RNA NGS. The purpose of Part B is to compare the difference in ORR between patients with driver gene positivity identified through synchronous co-testing of DNA and RNA NGS who receive and do not receive targeted therapy, with subsequent treatment regimens determined at the discretion of the patients without any intervention measures.
214467391|NCT06451341|BEHAVIORAL|Acceptability of Intervention Measure (AIM)|"The Acceptability of Intervention Measure (AIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The AIM will measure the extent to which participants believe CAB+RPV LA implementation is acceptable."
214467392|NCT06451341|BEHAVIORAL|Intervention Appropriateness Measure (IAM)|"The Intervention Appropriateness Measure (IAM) questionnaire will be administered at Baseline to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The IAM will measure the extent to which participants believe CAB+RPV LA implementation is appropriate."
214467393|NCT06451341|BEHAVIORAL|Feasibility of Intervention Measure (FIM)|"The Feasibility of Intervention Measure (FIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The FIM will measure the extent to which participants believe CAB+RPV LA implementation is feasible."
214467394|NCT06451341|BEHAVIORAL|HIV Stigma Scale Questionnaire|"The HIV Stigma Scale Questionnaire used in this study is a shortened version of the validated 40-item HIV stigma scale. This 12-item questionnaire measures the same four stigma subscales measured in the original version, for a streamlined approach to collecting this data on personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image.~This will be administered at Baseline, Month 7 and Month 15."
214467395|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The status version will be administered at Baseline, Month 7 and Month 15."
214467396|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The change version will be administered at Month 15."
214467397|NCT06451341|BEHAVIORAL|Needs and Barriers Assessment|"The Needs and Barriers Assessment is a questionnaire designed to assess patient participant barriers and social determinants of health, emotional challenges related to antiretroviral therapy, and the impact of switching to CAB+RPV LA treatment.~This will be administered at Baseline, Month 7 and Month 15."
214467398|NCT06451341|BEHAVIORAL|Pre-visit Outreach|Patient participants will be contacted prior to each clinical injection visit for an appointment reminder and a needs assessment.
214467399|NCT06451341|BEHAVIORAL|Qualitative interview|Qualitative interviews will be conducted within thirty days after study completion at Month 15 to further evaluate the participant's experience with the implementation of CAB+RPV LA treatment.
214467400|NCT06451341|BEHAVIORAL|Staff education|Staff participants will participate in Extension for Community Healthcare Outcomes (Project ECHO) educational sessions with topics such as fundamentals of HIV treatment and care, HIV outcomes, delivery of antiretroviral therapies (ART) including long-acting ART, cultural sensitivity, and social determinants of health in rural areas.
214467401|NCT06232915|PROCEDURE|Mechanical ventilation|Mechanical ventilation during surgery
214467402|NCT06845241|DRUG|ICP-490|Specified dose on specified days
214467403|NCT06848179|DIAGNOSTIC_TEST|Computer algorithms|Collection of computer algorithms called ausculto® that is designed to perform heart sound analysis to estimate heart rate and heart rate variability
214467404|NCT06848179|BEHAVIORAL|Exercise|Participants will be requested to exercise to raise their HR over the resting range while heart-related physiological signals are collected.
214467405|NCT06842459|OTHER|Geriatric Assessment|"The intervention group will undergo Geriatric Assessment in addition to diabetes usual care.~Usual care for both the Control and Intervention groups will be assured by a diabetologist according to in-use guidelines.~After randomization, a geriatrician will administer a thorough CGA to all participants allocated to the intervention groups. CGA results will be used to diagnoses or drug review; to identify specific treatment goals according to the functional status of the patient and to incorporate Patient-preferred outcome in the management of diabetes and comorbidities. Using the results of the CGA the geriatricians along with the attending diabetologist and additional healthcare professional, if needed, will implement a personalized diagnostic and therapeutic plan of care. Participants in the Control group will receive no additional intervention over and above usual care."
214467406|NCT06841939|OTHER|castor oil|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of castor oil under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of castor oil.
214467407|NCT06841939|OTHER|Water|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of water under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of water.
214467408|NCT06846073|COMBINATION_PRODUCT|The combination of intravitreal anti-VEGF and dexamethasone implants injections.|Early combination of intravitreal dexamethasone implant and anti-VEGF injection for the treatment of DME.
214467409|NCT06848725|BEHAVIORAL|Data quality development toolkit concerning the medical quality indicators (MQI)|"The toolkit uses a train-the-trainer strategy.~The research team will:~* develop training and support materials for external training providers and delegated staff (champions) from the long-term care facilities~* prepare external training providers within a one 3h session to train champions from the long-term care facilities~* organize an e-mail contact centre for MQI related questions for the participating facilities.~The external training providers will:~\- train the champions in one full day (8h) in-person training session and in 2 online sessions a 4h and 2h to support their co-workers to collect reliable MQI data.~Based on the received training, the champions will:~* provide internal trainings to the care and nursing team,~* perform data quality monitoring,~* provide feedback on data quality and act as a contact person for questions on MQI in their facility."
214467410|NCT06852131|PROCEDURE|open carpal tunnel surgery|open carpal tunnel surgery
214467411|NCT06852131|PROCEDURE|Steroid Injection|triamsinolon injection
214467412|NCT06852131|PROCEDURE|PRP injection|PRP injection
214467413|NCT06851260|PROCEDURE|Fine-dissection of the thymus|In thyroid surgery, precise dissection and preservation of thymus tissue are used to improve the protection of the lower parathyroid gland function and increase the curative effect of the surgery.
214467414|NCT06851234|PROCEDURE|osteopathic manipulative medicine|OMM
214467415|NCT06851234|PROCEDURE|The sham light touch will be performed by an investigator not trained in bodywork or a first--year osteopathic medical student.|Participants will lay supine on an OMM table. After the OSE, the investigator will place their hands flat in light contact with the participants' parietal bone regions, then the shoulders, then the sides of the lower ribs, and finally over the trochanters.
214467416|NCT06852911|DIAGNOSTIC_TEST|Chemiluminescent FeNO Analyzer|A novel chemiluminescence FeNO Analyzer has been developed, capable of measuring both FeNO50 and FeNO during tidal breathing. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
214467417|NCT06852911|DIAGNOSTIC_TEST|Electrochemical FeNO Analyzer|Electrochemical FeNO analyzers are employed in clinical settings for the measurement of FeNO50. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
214467418|NCT05263492|DRUG|Lenvatinib|Lenvatinib once a day by mouth every day
214467419|NCT05263492|DRUG|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
214467420|NCT06852183|OTHER|VR -FME|The VR-FME intervention specifically focuses on improving body representation and the body-self relationship by working on multisensory integration processes and embodied cognition techniques. This is thanks to the combination of immersive virtual reality experiences of body illusion combined with traditional psychological techniques. The experimental group will receive this intervention in addition to the usual treatment, which will continue as usual for the control group. The intervention consists of 8 sessions spread over 4 weeks, with 2 sessions per week.
214467421|NCT02990819|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
214467422|NCT06216886|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
214467423|NCT06216886|DRUG|Sodium Chloride 0.9% for Injection, Preservative Free|intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
214467424|NCT06851598|DRUG|25 units botox|25 units of botox injection into ischiocavernosus muscle
214467425|NCT06851598|DRUG|50 units Botox|50 Units botox injection into ischiocavernosus muscle
214467426|NCT06851598|DRUG|75 units Botox|75 units botox injection into ischiocavernosus muscle
214467427|NCT06031727|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
214467428|NCT02714439|DRUG|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
214467429|NCT02714439|PROCEDURE|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
214467430|NCT02425982|PROCEDURE|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
214467431|NCT02425982|PROCEDURE|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
214467432|NCT04083378|PROCEDURE|Ablation Therapy|Undergo standard of care ablation
214467433|NCT04083378|PROCEDURE|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
214467434|NCT04083378|OTHER|Quality-of-Life Assessment|Ancillary studies
214467435|NCT04083378|OTHER|Questionnaire Administration|Ancillary studies
214467436|NCT05427006|DEVICE|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
214467437|NCT05427006|DEVICE|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
214467438|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
214467439|NCT00769522|BIOLOGICAL|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
214467440|NCT00769522|DRUG|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
214467441|NCT00769522|DRUG|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
214467442|NCT00769522|DRUG|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
214467443|NCT05346042|OTHER|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
214467444|NCT05856890|BIOLOGICAL|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
214467445|NCT05856890|OTHER|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
214467446|NCT01828099|DRUG|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.
214467447|NCT01828099|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
214467448|NCT01828099|DRUG|Cisplatin|Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.
214467449|NCT01828099|DRUG|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
214467450|NCT06276868|DRUG|Dalcilib+letrozole+HP treatment group|"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks."
214467451|NCT02896348|DEVICE|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
214467452|NCT02896348|OTHER|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
214467453|NCT06258863|PROCEDURE|incision type|Total mastectomy was performed using one of the four incision types
214467454|NCT05875467|OTHER|SE3 Game|A prototype online game designed to increase environmental health literacy
214467455|NCT05247502|BIOLOGICAL|Data observation|At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
214467456|NCT03561961|RADIATION|Moderate Hypo-fractionation|66-68Gy in 25#
214467457|NCT03561961|RADIATION|Extreme Hypo-fractionation|35-36.25 Gy in 5#
214467458|NCT05870319|DRUG|SKB264|intravenous (IV) infusion (Q2W)
214467459|NCT05870319|DRUG|Pemetrexed|500 mg/m2 intravenous (IV) infusion (Q3W)
214467460|NCT05870319|DRUG|Carboplatin|AUC 5 intravenous (IV) infusion (Q3W) 4cycles
214467461|NCT05870319|DRUG|Cisplatin|75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
214467462|NCT02990533|DRUG|Testosterone|
214467463|NCT02990533|DIETARY_SUPPLEMENT|Protein Supplement|
214467464|NCT02990533|OTHER|Placebo Injection|
214467465|NCT02990533|OTHER|Placebo supplement|
214467466|NCT06551038|BEHAVIORAL|Primary suicide prevention intervention|Psychoeducation workshop
214467467|NCT06551038|BEHAVIORAL|Art-based control intervention|Slam poetry workshop
214467468|NCT05803980|PROCEDURE|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
214467469|NCT03859635|DRUG|Liposomal Bupivacaine|20 ml
214467470|NCT03859635|DRUG|Bupivacaine, 0.25%|10 ml
214467471|NCT03859635|DRUG|Bupivacaine, 0.5%|30 ml
214467472|NCT06052046|DEVICE|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
214467473|NCT05784753|BEHAVIORAL|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
214467474|NCT05784753|BEHAVIORAL|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
214467475|NCT04248257|BEHAVIORAL|PeACE|3 session peer coaching intervention
214467476|NCT04248257|BEHAVIORAL|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
214467477|NCT04979039|OTHER|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
214467478|NCT05332899|BIOLOGICAL|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device, by natural exposure to infected participants, or by inhalation from an aerosol generator or nebulizer. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
214467479|NCT06559683|OTHER|Sensory Assessment|Patients scheduled for open-heart surgery will receive a deep/superficial parasternal intercostal plane block preoperatively, and sensory block status will be evaluated after 30 minutes.
214467480|NCT06295523|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
214467481|NCT06295523|OTHER|Control|Participants will NOT receive water spraying on their body throughout the climate exposure.
214467482|NCT06025617|OTHER|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
214467483|NCT06025617|OTHER|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
214467484|NCT06561204|DEVICE|FMET|A full-mouth electronic toothbrush
214467485|NCT00882167|OTHER|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
214467486|NCT04470011|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214467487|NCT04470011|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
214467488|NCT04745884|DEVICE|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
214467489|NCT05570877|DEVICE|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
214467490|NCT05490875|PROCEDURE|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
214467491|NCT05490875|OTHER|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
214467492|NCT05490875|OTHER|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
214467493|NCT06075004|PROCEDURE|Periarticular Local Anesthetic Infiltration|Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
214467494|NCT06075004|PROCEDURE|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle."
214467495|NCT04728451|BEHAVIORAL|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
214467496|NCT04728451|DEVICE|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
214467497|NCT05964504|PROCEDURE|Blood Specimen|Blood will be drawn via venipuncture
214467498|NCT06096935|OTHER|bood sample|Exome measurements
214467499|NCT02677064|OTHER|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
214467500|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
214467501|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
214467502|NCT05116189|BIOLOGICAL|Pembrolizumab|IV infusion
214467503|NCT05116189|DRUG|Paclitaxel|IV infusion
214467504|NCT05116189|DRUG|Bevacizumab|IV infusion
214467505|NCT05116189|OTHER|Placebo for pembrolizumab|IV infusion
214467506|NCT05116189|DRUG|Docetaxel|IV infusion
214467507|NCT04053322|DRUG|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
214467508|NCT04053322|DRUG|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
214467509|NCT04053322|DRUG|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
214467510|NCT06108245|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
214467511|NCT06108245|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
214467512|NCT05592158|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
214467513|NCT04568434|DRUG|Olezarsen|Olezarsen was administered by SC injection.
214467514|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo was administered by SC injection.
214467515|NCT05101161|BEHAVIORAL|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
214467516|NCT03774758|DIAGNOSTIC_TEST|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
214467517|NCT06044831|BEHAVIORAL|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott \& White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
214467518|NCT03905798|DRUG|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
214467519|NCT05454306|DEVICE|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
214467520|NCT06058936|OTHER|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
214467521|NCT06472830|OTHER|Non-Interventional Study|Non-interventional study
214467522|NCT04949737|BIOLOGICAL|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
214467529|NCT04989595|DEVICE|MyIUS app|Data will be self-reported by participants through the MyIUS app.
214467530|NCT06563154|DIAGNOSTIC_TEST|Exercise Capacity Assessment|To examine the relationship between exercise capacity and physical fitness of dyslipidemia patients and quality of life, cognitive status and health literacy.
214467531|NCT06563154|DIAGNOSTIC_TEST|Physical Fitness Assessment|"* 1-Minute Sit-to-Stand Test: Participants will be asked to sit down and stand up for 1 minute without pausing, and the repetition number will be recorded.~* Timed Up-and-Go Test: Participants will be asked to get up, walk a distance of 3 meters, return and sit down again. The time spent during this track will be recorded.~* Peripheral muscle strength assessment: Participants will be asked to resist the resistance by producing maximum isometric force during the movement, and the maximal force will be evaluated with a dynamometer. The quadriceps femoris muscle, shoulder abductor muscles and hand grip strength will be used for the assessment.~* Flexibility assessment: Participants will be asked to reach towards the tips of their toes while sitting. During this time, the distance between the participant's fingertips and toes will be measured."
214467532|NCT06563154|OTHER|Quality of Life Assessment|Participants' quality of life will be assessed with the Turkish version of the Short Form Quality of Life Questionnaire (SF-36). The questionnaire consists of 36 questions that examine quality of life from different perspectives. It examines quality of life in the subcategories of physical function, physical role difficulty, pain, general health, vitality (energy), social function, emotional role difficulty and mental health. The score for each category varies between 0-100, with a high score indicating a good quality of life.
214467533|NCT06563154|OTHER|Physical Activity Assessment|Participants' physical activity level will be assessed with the Turkish version of the International Physical Activity Scale - Short Form (IPAQ-SF). The IPAQ-SF evaluates the physical activities of the participants in the last 7 days based on sitting time, walking time, moderate and vigorous physical activities.
214467534|NCT06563154|OTHER|Cognitive Health Assessment|Participants' cognitive health will be assessed with the with the Turkish version of the Mini Mental State Examine (MMSE). The test is scored between 0-30. Scores of 25 and above are considered normal. A total score of less than 10 indicates severe impairment. Scores between 10-19 indicate moderate dementia. Scores between 19-24 indicate early dementia.
214467535|NCT06563154|OTHER|Health Literacy Assessment|Participants' health literacy will be assessed with the Turkish version of the HLS-EU-47 health literacy survey. The survey consists of 47 questions. Each item is assessed with one of the following options: Very difficult (1), difficult (2), easy (3), very easy (4) and I don't know. A high total score indicates good health literacy. A total score of 0-25 points indicates insufficient health literacy, \>25-33: problematic - limited health literacy, \>33-42: sufficient health literacy, \>42-50: excellent health literacy.
214467536|NCT06562608|DRUG|Anticholinergic Deprescription|per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
214467537|NCT06562608|DRUG|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
214467538|NCT06300762|DEVICE|Superabsorbent dressing application|Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
214467539|NCT04522908|DRUG|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
214467540|NCT05618574|DIETARY_SUPPLEMENT|140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 140 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
214467541|NCT05618574|DIETARY_SUPPLEMENT|210 ml of nitrate-depleted placebo|Participants randomized to the placebo arm will receive 210 ml of nitrate-depleted beverage (cranberry juice) per day for 14 days.
214467542|NCT06229860|OTHER|Interview|In-person interview with the study coordinator to complete study questionnaire.
214467543|NCT04742621|PROCEDURE|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
214467544|NCT05706103|BEHAVIORAL|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
214467545|NCT05706103|BEHAVIORAL|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
214467546|NCT05516472|DRUG|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
214467547|NCT05516472|DRUG|Placebo|Participants will take placebo capsules
214467548|NCT06298331|OTHER|Aerobic Exercise|Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
214467549|NCT06298331|OTHER|Abdominal Massage|Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
214467550|NCT06298331|OTHER|Patient Education|Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
214467551|NCT05556915|OTHER|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
214467552|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
214467553|NCT06122441|BEHAVIORAL|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
214467554|NCT06122441|BEHAVIORAL|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
214467555|NCT03930810|PROCEDURE|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
214467556|NCT06555705|OTHER|Placebo|The control group will be given placebo for 3 months
214467557|NCT06555705|DIETARY_SUPPLEMENT|Omega 3|The interventional group will be given omega 3 for 3 months
214467558|NCT05725161|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
214467559|NCT05725161|BEHAVIORAL|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
214467560|NCT04461327|BEHAVIORAL|Painful stimulations of major depressive patients|"All three pain mechanisms will be tested in one session lasting 1h approximately.~The mechanisms are tested in the following order:~1. Aδ and C threshold~2. Wind-up~3. CPM~(more details in detailed description)"
214467561|NCT04461327|BIOLOGICAL|Blood sample|The blood test is made between 2 and 24 hours before the experimental procedure. The biological collection is made to measure medications' concentration if the patient takes antiepileptics and/or lithium, and to measure complete blood count (CBC).
214467562|NCT04461327|DIAGNOSTIC_TEST|Clinical assessment|"A clinical assessment will be made by a trained researcher.~(more details in detailed description)"
214467563|NCT04461327|BEHAVIORAL|Social touch|Stroking
214467564|NCT05430152|DRUG|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
214467565|NCT05430152|OTHER|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
214467566|NCT02611518|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
214467567|NCT02611518|DRUG|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
214467568|NCT02611518|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
214467569|NCT06538207|DRUG|ONO-4578|Specified dose on specified days
214467570|NCT06538207|DRUG|ONO-4538|Specified dose on specified days
214467571|NCT06538207|DRUG|Oxaliplatin|Specified dose on specified days
214467572|NCT06538207|DRUG|Levofolinate|Specified dose on specified days
214467573|NCT06538207|DRUG|Irinotecan|Specified dose on specified days
214467574|NCT06538207|DRUG|Fluorouracil|Specified dose on specified days
214467575|NCT06538207|DRUG|Gemcitabine|Specified dose on specified days
214467576|NCT06538207|DRUG|Nab-Paclitaxel|Specified dose on specified days
214467577|NCT06238726|BEHAVIORAL|Reminder|Shingrix messages via SMS, patient portal, email, and/or another modality
214467578|NCT05727930|BEHAVIORAL|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
214467579|NCT05727930|BEHAVIORAL|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
214467580|NCT05727930|BEHAVIORAL|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
214467581|NCT05727930|BEHAVIORAL|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
214467582|NCT06443489|DRUG|SHR-4849|SHR-4849
214467583|NCT05485779|DRUG|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
214467584|NCT05485779|DRUG|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
214467585|NCT04670900|PROCEDURE|Tension band wiring or plate fixation|Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
214467586|NCT04670900|PROCEDURE|Active non-operative treatment with optional plaster cast|Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
214467587|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
214467588|NCT03138603|DRUG|Metoprolol Tartrate|Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
214467589|NCT03138603|DRUG|Placebo|Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
214467590|NCT06157580|DRUG|Compound 21|differences in vasodilation to compound 21 in the skin between groups
214467591|NCT06157580|DRUG|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
214467592|NCT05998824|BEHAVIORAL|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
214467593|NCT05819996|BEHAVIORAL|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
214467594|NCT06269367|OTHER|NewGait|wearable limb orthotic device
214467595|NCT06269367|OTHER|Control wearable limb orthotic device|wearable limb orthotic device
214467596|NCT06011772|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
214467597|NCT06011772|DRUG|Leucovorin|Given IV
214467598|NCT06011772|DRUG|Oxaliplatin|Given IV
214467599|NCT06011772|DRUG|Fluorouracil|Given IV
214467600|NCT06011772|BIOLOGICAL|Bevacizumab|Given IV
214467601|NCT06011772|DRUG|Irinotecan|Given IV
214467602|NCT06011772|BIOLOGICAL|Cetuximab|Given IV
214467603|NCT06011772|PROCEDURE|Metastasectomy|Undergo metastasectomy
214467604|NCT06011772|PROCEDURE|Biospecimen collection|Undergo collection of blood samples
214467605|NCT06011772|PROCEDURE|Computed Tomography|Undergo CT
214467606|NCT06011772|BIOLOGICAL|Panitumumbab|Given IV
214467607|NCT04760899|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
214467608|NCT02464007|BIOLOGICAL|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
214467609|NCT03779139|PROCEDURE|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
214467610|NCT03779139|PROCEDURE|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
214467611|NCT03779139|OTHER|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
214467612|NCT06840431|BEHAVIORAL|in-person condition|participants will receive program components in a classroom setting with a trained non-clinical facilitator.
214467613|NCT06840431|BEHAVIORAL|online condition|Participants will receive program components in an asynchronous online format.
214467614|NCT06840431|BEHAVIORAL|self-help condition|Participants will read a self-help book on how to manage their divorce and take a quiz to ensure that the book has been read.
214467615|NCT06832150|OTHER|sample collection|"Participants may collected their own cheek swabs and will collect their own urine samples.~Clinical professionals at participating sites will collect blood samples."
214467616|NCT06832150|OTHER|Discussing study|Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants
214467617|NCT06832150|OTHER|Seeking consent|Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.
214467618|NCT06724341|BEHAVIORAL|Distraction|"Control group: inferior alveolar nerve block will be administrated with passive behavior management (displaying animated movies directly on the screen of a mobile device).~Movies group: inferior alveolar nerve block will be administrated with displaying animated movies directly on the screen of a mobile device usage of the augmented reality glasses.~Video games group: Application of active behavior management by usage video games on the screen of a mobile device connected to augmented reality glasses before administration of inferior alveolar nerve block.~Movies and Video games group: An active and passive behavior management will be applied by usage video games before administration of inferior alveolar nerve block and animated movies during administration on the screen of a mobile device connected to augmented reality glasses."
214467619|NCT02987946|DEVICE|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
214467620|NCT02987946|DRUG|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
214467621|NCT05100654|DRUG|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
214467622|NCT05100654|DRUG|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
214467623|NCT05100654|DRUG|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
214467624|NCT05100654|DRUG|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
214467625|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
214467626|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
214467627|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
214467628|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
214467629|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
214467630|NCT06438302|DEVICE|EEG activity measurement|"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."
214467631|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
214467632|NCT05178251|PROCEDURE|appendectomy|appendectomy for acute appendicitis
214467633|NCT05706493|OTHER|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
214467634|NCT06484920|DRUG|ATRA|150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
214467635|NCT06484920|DRUG|Pembrolizumab|200mg Q3W pembrolizumab
214467636|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
214467637|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
214467638|NCT05617599|DEVICE|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
214467639|NCT06383013|BIOLOGICAL|BB-101|Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
214467640|NCT03820141|DRUG|Durvalumab|programmed cell death-ligand 1 inhibitor
214467641|NCT03820141|DRUG|Trastuzumab|anti-HER2 monoclonal antibody
214467642|NCT03820141|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
214467643|NCT05681169|OTHER|School-based HPV-counselling and HPV-vaccination.|"1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV"
214467644|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
214467645|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
214467646|NCT04910542|OTHER|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
214467647|NCT05370040|BIOLOGICAL|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
214467648|NCT05370040|BIOLOGICAL|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
214467649|NCT05370040|BIOLOGICAL|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
214467650|NCT03272217|DRUG|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
214467651|NCT03272217|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
214467652|NCT05890911|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
214467653|NCT05890911|DIAGNOSTIC_TEST|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
214467654|NCT05890911|DIAGNOSTIC_TEST|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
214467655|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
214467656|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
214467657|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
214467658|NCT04024787|BEHAVIORAL|Cognitive-Behavioural therapy for insomnia (CBT-I)|"Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks."
214467659|NCT03935295|DRUG|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
214467660|NCT03935295|DRUG|Placebos|Placebo prepared by Ipsen for use as control
214467661|NCT03935295|DEVICE|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
214467662|NCT06802965|PROCEDURE|catheter ablation, left atrial appendage closure|Compare the clinical prognosis of patients with AF underwent the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation and single LAAC.
214467663|NCT06803225|DIAGNOSTIC_TEST|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
214467664|NCT03996291|DRUG|Tolebrutinib|Pharmaceutical form: Film coated tablet Route of administration: Oral
214467665|NCT05205460|DEVICE|Home-based telerehabilitation|A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.
214467666|NCT05205460|BEHAVIORAL|Education and self-exercise|The participants will receive a exercise prescription suggestion. Then, they will maintain their usual lifestyles without exercise reminders.
214467667|NCT05994976|PROCEDURE|Blood samples collection|biomarkers and optional genetic analysis
214467668|NCT05994976|PROCEDURE|Oral samples collection|biomarkers analysis
214467669|NCT05994976|PROCEDURE|Hair samples collection|biomarkers analysis
214467670|NCT05994976|PROCEDURE|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
214467671|NCT05994976|PROCEDURE|Skin surface material samples|biomarkers analysis
214467672|NCT05994976|PROCEDURE|Drainage fluid samples collection|biomarkers analysis
214467673|NCT05994976|PROCEDURE|Stool samples collection|biomarkers analysis
214467674|NCT05636215|BIOLOGICAL|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
214467675|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
214467676|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
214467677|NCT04534582|DRUG|HLX14|healthy volunteers receive HLX14 (60mg) once
214467678|NCT04534582|DRUG|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
214467679|NCT04534582|DRUG|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
214467680|NCT04534582|DRUG|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
214467681|NCT06318429|BEHAVIORAL|stretching exercise group|stretching exercise group
214467682|NCT05471661|BIOLOGICAL|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
214467683|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
214467684|NCT04807764|COMBINATION_PRODUCT|Standing transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214467685|NCT04807764|COMBINATION_PRODUCT|Lying transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214467686|NCT04807764|OTHER|Standing sham transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214467687|NCT03541720|DRUG|18F-DA|18F-DA is an investigational PET radiotracer
214467688|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
214467689|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
214467690|NCT05861427|DRUG|Atogepant|Oral Tablet
214467691|NCT05861427|DRUG|Placebo for Atogepant|Oral Tablet
214467692|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
214467693|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
214467694|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
214467695|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
214467696|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
214467697|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
214467698|NCT05931497|DEVICE|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
214467699|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
214467700|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
214467701|NCT05655312|DRUG|[203Pb]VMT01|\[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
214467702|NCT05655312|DRUG|[212Pb]VMT01|Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
214467703|NCT05655312|DRUG|Nivolumab|For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
214467704|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
214467705|NCT01826071|OTHER|Static Stretch|Standing Gastrocnemius Stretch Standing Soleus Stretch Seated Gastrocnemius Stretch Seated Soleus Stretch Hamstring Stretch Quadriceps Stretch (Standing) Quadriceps Stretch (Side Lying)
214467706|NCT01826071|OTHER|Active Elongation|Mini Squat- Double Leg Mini Squat- Single Leg Prone Hip Extension with Knee Flexed 3 Position Straight Leg Raises Quadriceps Myofascial Release Heel Raises (Eccentric Strengthening) Single Leg and Double Leg Gastrocnemius Myofascial Release Calcaneal Glides
214467707|NCT01478542|DRUG|Conventional Vincristine|
214467708|NCT01478542|DRUG|Liposomal Vincristine|
214467709|NCT01478542|DRUG|Ricover-scheme rituximab|
214467710|NCT01478542|DRUG|optimised rituximab-schedule|
214467711|NCT04722887|BIOLOGICAL|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
214467712|NCT04722887|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
214467713|NCT06568861|DRUG|ALG-097558|Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
214467714|NCT03953417|DEVICE|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
214467715|NCT04313712|DRUG|ibogaine with magnesium treatment|Participants will receive magnesium sulfate intravenously and ibogaine orally.
214467716|NCT06577428|DRUG|RAY1225|administered SC
214467717|NCT03987022|DRUG|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
214467718|NCT03987022|DRUG|Opioids|Use of narcotic for pain control postoperatively
214467719|NCT03987022|OTHER|Ice Packs|Placement of Ice packs on surgical sites postoperatively
214467720|NCT03987022|DRUG|Tylenol|Use of pain medication postoperatively
214467721|NCT03987022|DRUG|Motrin|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
214467722|NCT03987022|DRUG|Dilaudid Injectable Product|Use of narcotic for pain control postoperatively
214467723|NCT03987022|DRUG|Percocet 5Mg-325Mg Tablet|Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
214467724|NCT04698031|DRUG|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
214467725|NCT04698031|DRUG|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
214467726|NCT05855746|DRUG|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
214467727|NCT05855746|DRUG|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
214467728|NCT02202772|DRUG|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
214467729|NCT02202772|DRUG|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
214467730|NCT02202772|DRUG|Cisplatin|Intravesical installation of Cisplatin for 2hours
214467731|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
214467732|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
214467733|NCT06488456|OTHER|TRSC-C|Data were collected using TRSC-C
214467734|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
214467735|NCT06201559|DRUG|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
214467736|NCT06201559|DRUG|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
214467737|NCT04198181|PROCEDURE|Surgery|Resective surgery included lobectomy (partial or total brain lobe resection), tuberectomy (epileptogenic tuber resection), and tuberectomy plus (resection of epileptogenic tuber and perituberal gyri). Tuberectomy was typically performed on the epileptogenic tuber within or near an eloquent area. Lobectomy was performed in patients with large epileptogenic tubers in the brain lobes. Multiple lobectomies, tuberectomies, tuberectomies plus, and lobectomy combined with tuberectomy/tuberectomies plus were further performed in patients with multiple epileptogenic tubers.
214467738|NCT06851689|DEVICE|Jamar handheld dynamometer|Jamar handheld dynamometer to asses hand grip strength
214467739|NCT06851689|DEVICE|Biodex isokinetics|Biodex isokinetics to asses torque
214467740|NCT06852144|OTHER|clinical practice drug treatment|Observational, prospective and retrospective study, transversal, non-profit, monocentric. All data of patients affected/ afferents to theU.O. of Nuclear Medicine of the IRCCS AOU of Bologna will be collected submitted/ who will undergo a PET/ CT investigation for thyroid pathology or other indication with incidental feedback of thyroid uptake and patients who have They undergo PET/CT with known thyroid disease. Of these patients will be collected the personal data, clinical news, data related to PET/ CT (dedicated software e.g. MIM), biochemical/ laboratory and anatomopathological (for operated patients), any other imaging investigations already performed and to be performed later by normal clinical practice. The medical nuclear images will be evaluated by at least two nuclear medical experts, with qualitative, semi-quantitative and radiometric parameters as far as possible. Patients will be treated according to normal clinical practice.
214467741|NCT06852976|DRUG|0.75% MDI-1228_mesylate gel plus Standard of Care|Approximately 40 subjects will receive 0.75% MDI-1228\_mesylate gel twice daily for 12 weeks.
214467742|NCT06852976|OTHER|Standard of Care Alone|Approximately 20 subjects will receive the standard of care alone including wound cleaning, debribement and other additional care decided by the healthcare provider.
214467743|NCT06852729|OTHER|Biering-sorenson protocol|"* Students shouldn't perform any vigorous activity a day before assessment.~* Frist, therapist will request from each participant to watch videos to understand how the test should be applied.~* The starting position will be a half prone lying on a plinth with the superior edge of the iliac crest horizontal at the edge of the plinth and the arms crossed over the chest.~* The participant should keep the unsupported upper part of the body.~* The lower limbs will strategically be stabilized with straps.~* The participant will be asked to maintain the upper body in a horizontal position and the timer started.~* The test ends if the participant can maintain the previous position for 4 minutes (240 seconds) or can no longer maintain the set position before 4 minutes elapses. The stop time is recorded.~* There is considerable range of mean fatigue times reported for the Biering-Sørensen test in the literature ranging from 84s to 180s in healthy males."
214467744|NCT06852963|DRUG|VP-001|VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.
214467745|NCT06852846|DIAGNOSTIC_TEST|Biological sample|Biomarker test for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-inducible protein of 10 kDa (IP-10), and C-reactive protein
214467746|NCT06850246|DEVICE|treatment of radiofrequency technology|When operating, first select 470 kHz frequency, CRT resistance probe for deep fat management operation for 10 minutes, and then select CET capacitance mode 470 kHz for superficial fat operation for 6 minutes. Then, select the 940 kHz frequency CET capacitance probe for epidermal tightening operation for 4 minutes. The temperature is set by the energy value. In CRT mode, the energy value is set to 70, and it can reach above 42 ℃ within one minute. In CET mode, the energy value setting is adjusted to 75. The operation mode is to gradually raise the temperature to the midline after partially increasing the temperature at the side of the waist. The technique is mainly to move in a circle and lift to the midline.
214467747|NCT06850246|DEVICE|Placebo|Under the condition that the machine is not turned on, the treatment is performed in the same operation time, mode, and treatment area of the treatment group.
214467748|NCT05168306|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
214467749|NCT06850714|DIETARY_SUPPLEMENT|Bifidobacterium breve PRL2020 (Brevicillin®)|Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) at a dose of 20 billion CFU per day (one stick in the morning and one in the evening).
214467750|NCT06850714|DRUG|Amoxicillin or Amoxicillin/Clavulanic Acid|Treatment of Amoxicillin or Amoxicillin/Clavulanic Acid as per medical prescription.
214467751|NCT06113562|PROCEDURE|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
214467752|NCT05509803|BEHAVIORAL|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
214467753|NCT05125029|DRUG|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
214467754|NCT02887521|OTHER|education|pulmonary rehabilitation participant manual
214467755|NCT02887521|PROCEDURE|rehabilitation|pulmonary rehabilitation
214467756|NCT02887521|DEVICE|pedometer|receive a pedometer
214467757|NCT02887521|OTHER|education|receive a pamphlet with exercises plus the standard course of care
214467758|NCT02887521|PROCEDURE|surgery|patients undergo surgery
214467759|NCT06188780|DIAGNOSTIC_TEST|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
214467760|NCT02112526|DRUG|Acalabrutinib|
214467761|NCT05109988|BEHAVIORAL|Breastfeeding telephone support|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
214467762|NCT04761861|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
214467763|NCT04761861|DRUG|Placebo|Placebo one tablet daily
214467764|NCT04102176|OTHER|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
214467765|NCT04102176|OTHER|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
214467766|NCT03571581|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
214467767|NCT05278728|DRUG|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
214467768|NCT05278728|DRUG|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
214467769|NCT06206148|DEVICE|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
214467770|NCT06206148|OTHER|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
214467771|NCT06206148|OTHER|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
214467772|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
214467773|NCT04363164|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
214467774|NCT04363164|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
214467775|NCT04363164|DRUG|Testosterone enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
214467776|NCT06649981|DIETARY_SUPPLEMENT|FMT capsule|"A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population."
214467777|NCT06649981|DIETARY_SUPPLEMENT|Placebo Capsule(s)|"A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results."
214467778|NCT04630470|BEHAVIORAL|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
214467779|NCT04630470|BEHAVIORAL|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
214467780|NCT06066099|DRUG|AP31969|Oral tablets
214467781|NCT06066099|DRUG|Placebo|Oral tablets
214467782|NCT04408638|DRUG|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
214467783|NCT04408638|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
214467784|NCT04408638|DRUG|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
214467785|NCT04408638|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
214467786|NCT04408638|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
214467787|NCT04408638|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
214467788|NCT05940740|OTHER|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
214467789|NCT06397586|OTHER|Routine volleyball|MOtor imagery
214467790|NCT02201134|DRUG|sevoflurane|
214467791|NCT05957406|DEVICE|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
214467792|NCT05957406|DEVICE|The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff|Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff
214467793|NCT05861323|BEHAVIORAL|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
214467794|NCT06997068|DRUG|Celecoxib|Given PO
214467795|NCT06997068|DRUG|Erlotinib Hydrochloride|Given PO
214467796|NCT06997068|PROCEDURE|Imaging Procedure|Undergo SOC imaging scans
214467797|NCT06997068|OTHER|Interview|Ancillary studies
214467798|NCT06997068|DRUG|Methotrexate|Given PO
214467799|NCT06997068|OTHER|Questionnaire Administration|Ancillary studies
214467800|NCT06868238|DRUG|Magtrace|Participants will receive a single injection of Magtrace into the breast during their mastectomy.
214467801|NCT07039981|DEVICE|Omnipod M system|The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control
214467802|NCT07056101|DEVICE|A conventional dental syringe|The conventional dental syringe (C-K JECT) is a manual, metal aspirating syringe commonly used for local anesthesia administration in dental procedures. In this study, the device is used to perform buccal and intrapapillary infiltration using 4% articaine with 1:100,000 epinephrine. Injections are delivered manually at a standardized rate by the principal investigator. This arm serves as the active comparator to evaluate differences in pain perception between traditional syringe injections and those delivered via a computer-controlled device.
214467803|NCT07056101|DEVICE|GENI High-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that automates the injection process using pressure feedback to regulate flow. In this arm, the device is set to high-speed mode to deliver the anesthetic solution at the fastest available flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The procedure is carried out by the principal investigator using a standardized technique. Pain perception is assessed following injection to evaluate the impact of delivery speed on patient experience.
214467804|NCT07056101|DEVICE|GENI Moderate-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system designed to regulate flow and pressure during injection using real-time feedback. In this arm, the device is set to moderate-speed mode, delivering anesthetic at an intermediate flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The injection is administered by the principal investigator using a standardized technique. This group is used to assess the impact of moderate-speed delivery on pain perception and physiological response in pediatric patients.
214467805|NCT07056101|DEVICE|GENI Low-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that maintains precise control over injection pressure and flow. In this arm, the device is set to low-speed mode, delivering the anesthetic solution at the slowest available rate to minimize tissue pressure and potential discomfort. Buccal and intrapapillary infiltration is administered using 4% articaine with 1:100,000 epinephrine. The injection is performed by the principal investigator using a standardized technique. This group evaluates whether low-speed delivery reduces pain perception and improves patient comfort compared to faster injection speeds and conventional methods.
214467806|NCT07058792|OTHER|Medjool dates|Medjool dates are a dried fruit.
214467807|NCT07062367|DRUG|Propofol|Patients' anesthesia will be maintained by manually adjusted propofol infusion at a rate of 100-250 mic/kg/min for bispectral index (BIS) maintained between 40-60.
214467808|NCT07062367|DRUG|Sevoflurane plus lidocaine infusion|Sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60 plus intravenous lidocaine infusion given as 2mg /kg IV bolus before induction then intraoperative infusion by a rate of 2 mg/kg/h until the end of surgery.
214467809|NCT07062367|DRUG|Sevoflurane|Patients will receive sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60.
214467810|NCT07064382|DEVICE|VR-based multi-dimensional intervention|VR-based multi-dimensional intervention, including LLMs, AI-agents
214467811|NCT07062809|OTHER|Sub Occipital Myofascial release and (SNAGS).|The patient will instruct to be seated then will turned his head toward direction that will cause his dizziness. when subject will turn his head, The manual therapist will perform a constant PA glide (using his thumbs one over the other) to upper cervical C1 or C2 vertebra (Oriented toward patient's eyeballs). If flexion or extension movement will provoke the dizziness, an anterior glide will apply to the C2 spinous process. If rotation will provoke dizziness, then an anterior glide will be applied to the C1 transverse process.
214467812|NCT07062809|OTHER|Sub Occipital Myofascial release.|When using the technique, the patient will be in Upward-facing position with their head fully aided on the therapist's hands. The therapist will put three middle fingers simply inferior to the nuchal line, raise the tips of the fingers in the direction of the ceiling, and then simply pull them upward.
214467813|NCT07062627|GENETIC|Anbal-cel|"On Day 1 (D1), Anbal-cel will be administered only to subjects who meet the final inclusion/exclusion criteria for Anbal-cel administration before the infusion.~As premedication before Anbal-cel administration, acetaminophen or paracetamol, and diphenhydramine or H1 antihistamine will be given.~Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing, at the dose presented in the following table:~Dose: 2x10\^6 (CAR-T cells/kg)\* Maximum 2 x 10\^8 cells"
214467814|NCT07062250|DEVICE|Feasibility and safety of home-based blood count measurement and transfusions|Feasibility and safety of home-based blood count measurement and transfusions in patients with acute myeloid leukemia
214467815|NCT07062458|DIAGNOSTIC_TEST|Nipple Sensation Assessment|"the measurement of nipple sensation preservation, will be conducted using the Semmes-Weinstein esthesiometer. The clinician will use the device to touch the nipple and the surrounding quadrants of the skin, applying filaments of increasing calibers (0.07gr, 0.4gr, 2.0gr, 4.0gr, 300gr), and the lightest caliber perceived by the patient will be recorded. This assessment will be conducted at four different times:~* Before surgery, to assess baseline sensation.~* 1 month after surgery.~* 3 months after surgery.~* 6 months after surgery."
214467816|NCT07063719|OTHER|Ophthalmological visit|"Uncorrected visual acuity (UCVA), best-corrected visual acuity (BSCVA), corneal topography, corneal pachymetry, ocular surface pictures (to evaluate disease status of the eye with and without fluorecein), Schirmer's test, Corneal esthesiometry, Tear film break-up time test, Intraocular pressure.~Below is a summary of steps to perform ocular surface pictures of the cornea.~1. Ensure slit lamp cleaning and appropriate magnification and light settings.~2. Ensure comfortable positioning of both the operator and the patient.~3. Examine external orbital structures and adnexa for inflammation, irritation, or lesions.~4. Examine lids and lashes for abnormalities.~5. Examine both bulbar and palpebral conjunctiva for signs of irritation and injection.~6. Examine the cornea for clarity and the presence of any defect.~7. Examine the anterior chamber depth and evaluate abnormalities that might affect its transparency (blood, purulent material, cells and flare).~8. Examine the surface of the iris an"
214467817|NCT07063719|OTHER|Questionnaires|Ocular Surface Disease Index (OSDI) questionnaire, Visual Analog Pain Scale (VAS) questionnaire
214467818|NCT07063719|OTHER|Blood sample collection|Blood samples from RED patients or control group are collected in BD Vacutainer K2 EDTA.
214467819|NCT07063719|OTHER|Impression cytology|Put one drop of oxybuprocaine hydrochloride 0.4% in patients' eyes and wait 10 seconds. Gently apply both side of one sterile nitrocellulose membrane onto the unexposed bulbar conjunctiva, superotemporally, inferotemporally, superonasally, and inferonasally, for approximately 20 seconds, please, keep the eyes separated.
214467820|NCT07063719|OTHER|Tear fluid|One sterile minisponge per eye will be placed over the lids margin at the junction of the lateral and middle thirds of the lower eyelids and kept in place for 2 minutes. During application of sponges the patient needs to look up to facilitate the procedure. To avoid excessive tear reflex, as well as a mild discomfort, it is recommended that patients close their eyes during the collection. Remove sponge using sterile tweezers and put it into empty 0.5mL tube (pierced at the bottom with a sterile needle) placed into another empty 1.5 mL tube and keep it on ice until processing.
214467821|NCT07062120|OTHER|Nicotinamide(NAM)(10%)|The active niacinamide form of vitamin B3, NAM is routinely employed as a pigmentation-reducing agent in melasma treatment protocols
214467822|NCT07062120|OTHER|Supramolecular salicylic acid(SSA) (30%)|Salicylic acid, a superficial chemical peel, has been widely used in treating melasma. Breakthroughs in supramolecular design have addressed its irritancy profile through engineered SA complexes with improved water dispersibility
214467823|NCT07062120|OTHER|Supramolecular salicylic acid simulator|the same course of treatment in the same dosage form that does not contain salicylic acid
214467824|NCT07062120|OTHER|Nicotinamide simulator|the same course of treatment in the same dosage form that does not contain nicotinamide
214467825|NCT07064070|BEHAVIORAL|TRUST|The four online modules included: General Communication, Talking about Relationships and Sexual Health, Parental Monitoring, and Check-up and Check-in (content focused on the importance of alone time). Modules were in English, Chinese, or Spanish
214467826|NCT06772701|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
214467827|NCT06772701|OTHER|EPDS book|PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
214467828|NCT07064304|PROCEDURE|Laser Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using Er,Cr:YSGG laser (2780 nm, 2.5 W, 83.3 mJ, 30 Hz, 600 μm tip) before placement in gingival recession treatment.
214467829|NCT07064304|PROCEDURE|Scalpel Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using a 15c surgical scalpel blade before placement in gingival recession treatment.
214467830|NCT07062328|DRUG|Recaticimab and Adebrelimab|"Patients would receive Recaticimab (150 mg, sc., q4w) and Adebrelimab (1200 mg, iv., q3w) plus GP chemotherapy in 21day cycles.~Recaticimab and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years."
214467831|NCT07062328|DRUG|GP chemotherapy|Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle, up to 6 cycles.
214467832|NCT07063017|OTHER|Post- Isometric Relaxation|Post Isometric Relaxation Technique to Piriformis; Lay the patient in the supine position and have the practitioner stand on the same side as the affected piriformis muscle. Bend the knee of the affected side and place the foot of that side on the lateral aspect of the opposite knee. Have the practitioner push knee medially until meeting the restrictive barrier. Have the patient push against the practitioner's resistance for 3 to 5 seconds, allow for a period of isometric relaxation, then engage a new barrier; repeat three times. Return the patient to a neutral position and reassess using supine or prone piriformis testing.
214467833|NCT07063017|OTHER|Active Release Technique|Patient position is side lying on the sound side. Therapist stands behind the patient. The upper leg must be in flexion on knee and slight extension Now apply pressure with both thumbs on piriformis and ask patient to flex and extend his hip and also external and internal rotation on hip in flexion. The gluteal muscle is taken from a shortened position to a fully lengthened position while the physiotherapist's contact hand holds tension longitudinally along the soft tissue fibers.
214467834|NCT07064434|PROCEDURE|Sacral canal block combined with general anesthesia|"Sacral canal block: The patient lies on their side, with the back perpendicular to the edge of the operating table. The knee joints of the lower limbs are flexed, the thighs are close to the abdomen, and the waist is arched backward as much as possible, resembling a shrimp shape. The space between the sacrum and coccyx of the patient (sacral hiatus) is fully exposed. By using a low-frequency probe (such as 2-5 MHZ), the strong echo of the sacrum, the low echo of the sacral canal, and the echo of the surrounding soft tissues can be clearly seen. At the located sacral hiatus, hold the puncture needle and slowly insert it perpendicularly to the skin. When the puncture needle passes through the sacrococcygeal ligament, there will be a distinct breakthrough sensation, which indicates that the puncture needle has entered the sacral canal. The general depth of needle insertion is about 2 to 3cm. However, the specific depth varies depending on factors such as the patient's body type."
214467835|NCT07064434|PROCEDURE|Simple general anesthesia|General anesthesia: Midazolam (0.2mg/kg), sufentanil (0.2-0.4μg/kg), etomidate (0.15-0.3 mg/kg), and rocuronium (0.6 mg/kg) were induced. After the patient's muscles were completely relaxed, a laryngeal mask was placed. Connect the anesthesia machine and set the ventilator parameters: Vol.Mode, tidal volume 6-8ml/kg, frequency 10-14 times /min, inhalation-exhalation ratio 1:2, and maintain EtCO2 at 35-45mmHg during the operation. Propofol (4-12mg/kg/h) and remifentanil (0.05-2ug/kg/min) were maintained. According to the operation course, rocuronium (0.15mg/kg) and sevoflurane inhalation (1% - 7%) could be administered at a single time. Anesthesiologists adjust the drug infusion rate based on the patient's hemodynamic indicators SBP, MAP, HR and clinical experience. When HR was less than 45 times /min during the operation, atropine was intravenously injected (0.25-0.5mg per time). When MAP is less than 55mmHg and lasts for more than 3 minutes, ephedrine (6-12mg each time) is given.
214467836|NCT04574882|OTHER|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
214467837|NCT04943042|DRUG|Avatrombopag|According to prescription
214467838|NCT05726045|BEHAVIORAL|Standard smoking cessation program (SCP)|Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
214467839|NCT05726045|BEHAVIORAL|Cognitive remediation treatment (CRT)|The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
214467840|NCT05726045|BEHAVIORAL|High-intensity interval training (HIIT evening)|"The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise)."
214467841|NCT03260465|DEVICE|seleXys PC|Total hip arthroplasty using the seleXys PC cup
214467842|NCT03260465|DEVICE|RM|Total hip arthroplasty using the RM cup
214467843|NCT06440694|DRUG|Colchicine 0.5 mg po|Colchicine 0.5 mg po once daily for 180 days.
214467844|NCT06440694|DRUG|Placebo 0.5 mg po|Placebo 0.5 mg po once daily for 180 days.
214467845|NCT04713969|DRUG|Pantoprazole 40mg|Pantoprazole 40mg twice daily
214467846|NCT03369821|DIAGNOSTIC_TEST|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
214467847|NCT03369821|OTHER|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
214467848|NCT05752500|BEHAVIORAL|Cognitive Behavioral Intervention for Physical Activity|Interventionist will use cognitive and behavioral techniques to help the participant increase facilitators and decrease barriers to physical activity, particularly barriers such as lack of motivation, depression, and chronic pain. Meetings will occur every other week for 4 months.
214467849|NCT05752500|BEHAVIORAL|Social Support for Physical Activity|This component will leverage the social functionality of the Fitbit app, promoting social support and friendly competition via a moderated Facebook group.
214467850|NCT05752500|BEHAVIORAL|Physical Activity Coaching|The PA coach will meet with the participant to set goals for physical activity (steps) and encourage self-monitoring. Meetings will occur every other week for 4 months.
214467851|NCT05752500|BEHAVIORAL|Brief Advice and Self-Monitoring|Participants will receive a single session with brief advice about increasing physical activity, and instructions on how to use their study-provided FitBit.
214467852|NCT06142903|OTHER|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
214467853|NCT01924819|DRUG|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
214467854|NCT01924819|RADIATION|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
214467855|NCT01924819|PROCEDURE|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
214467856|NCT03951480|OTHER|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.
214467857|NCT03951480|DRUG|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
214467858|NCT06353204|BEHAVIORAL|Halt-intervention|The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
214467859|NCT04636619|PROCEDURE|Colonic polypectomy|Cold snare resection of colorectal polyps
214467860|NCT04636619|BEHAVIORAL|Online training course|Polypectomy technique online course
214467861|NCT04945590|BEHAVIORAL|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
214467862|NCT05740137|DEVICE|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
214467863|NCT03705806|RADIATION|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
214467864|NCT05895136|DRUG|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
214467865|NCT05895136|DRUG|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
214467866|NCT05895136|DRUG|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
214467867|NCT04050436|DRUG|Cemiplimab|Cemiplimab administered intravenously
214467868|NCT04050436|BIOLOGICAL|RP1|RP1 administered intratumorally
214467869|NCT02345122|BEHAVIORAL|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
214467870|NCT02345122|OTHER|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
214467871|NCT03663569|DRUG|Spiolto® Respimat®|Drug
214467872|NCT03079232|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
214467873|NCT03079232|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
214467874|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
214467875|NCT05327465|OTHER|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
214467876|NCT05327465|OTHER|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
214467877|NCT06562283|OTHER|Thumb test|Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
214467878|NCT06562283|OTHER|Grip test|Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
214467879|NCT06562283|OTHER|Quadriceps Intermittent Fatigue test (QIF test))|Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
214467880|NCT06256510|DRUG|Midazolam|Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
214467881|NCT06256510|DRUG|Vepdegestrant|Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
214467882|NCT05877976|BEHAVIORAL|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
214467883|NCT05058833|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
214467884|NCT05058833|DIAGNOSTIC_TEST|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
214467885|NCT06436807|DEVICE|Indwelling catheter|The tunneled catheter is an implant product that enables the drainage of effusion accumulations from serous body cavities so that the symptoms caused by an effusion are relieved by draining off the accumulated fluids.
214467886|NCT04271644|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cell therapy
214467887|NCT03982316|BEHAVIORAL|Telehealth Behavioral Migraine Management|1\) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
214467888|NCT05134246|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
214467889|NCT05134246|PROCEDURE|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
214467890|NCT04248725|BEHAVIORAL|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
214467891|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
214467892|NCT05823220|BEHAVIORAL|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
214467893|NCT05823220|BEHAVIORAL|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
214467894|NCT06207136|OTHER|Mediterranean-style diet|Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
214467895|NCT05408793|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
214467896|NCT06016387|DRUG|Tucatinib 150 MG|Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
214467897|NCT06016387|DRUG|Trastuzumab|"MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations."
214467898|NCT06016387|DRUG|Capecitabine|Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
214467899|NCT06016387|RADIATION|Brain & Spinal Radiation|Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
214467900|NCT05520346|DEVICE|Electronic Device for Toilet|Device will be installed on toilet of patients will in hospital to measure all waste output.
214467901|NCT05622812|DEVICE|Restylane Lyft Lidocaine|Treatment for Jawline definition
214467902|NCT05938855|DEVICE|Electrical stimulation and biofeedback with the medical device Phenix Liberty|"The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session"
214467903|NCT04359784|BIOLOGICAL|Anakinra|Given IV (previously SC)
214467904|NCT04359784|PROCEDURE|X-Ray Imaging|Undergo x-ray
214467905|NCT04359784|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214467906|NCT04359784|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214467907|NCT04359784|PROCEDURE|Bone Marrow Aspiration|Undergo BMA
214467908|NCT04359784|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214467909|NCT04359784|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214467910|NCT04359784|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214467911|NCT04133077|BIOLOGICAL|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
214467912|NCT05314491|DEVICE|Multigen Plus CCK|Total Knee Arthroplasty
214467913|NCT05314491|DEVICE|AMF TT cones|To fill a proximal tibia or distal femur defect
214467914|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
214467915|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214467916|NCT04453774|DEVICE|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
214467917|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
214467918|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
214467919|NCT06308198|DRUG|AGN-151586|Intramuscular Injections
214467920|NCT06308198|DRUG|Placebo|Intramuscular Injections
214467921|NCT05483933|DRUG|Pegylated Liposomal Doxorubicin + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
214467922|NCT05483933|DRUG|Mirvetuximab + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
214467923|NCT06353022|DRUG|Teclistamab|Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
214467924|NCT06353022|DRUG|Talquetamab|Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
214467925|NCT06353022|DRUG|Lenalidomide|"Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration."
214467926|NCT06353022|DRUG|Bortezomib|Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
214467927|NCT06353022|DRUG|Daratumumab|Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
214467928|NCT06353022|DRUG|Dexamethasone|"Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22"
214467929|NCT00120263|PROCEDURE|Plasma Exchange|
214467930|NCT02476838|PROCEDURE|Hand Transplantation|microvascular VCA transplant
214467931|NCT02844465|DEVICE|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
214467932|NCT06029127|DRUG|BGB-A445|Administered intravenously at protocol defined dose
214467933|NCT06029127|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) administered intravenously
214467934|NCT06029127|DRUG|Ramucirumab|10 mg/kg administered intravenously
214467935|NCT06029127|DRUG|BGB-15025|Administered orally at protocol defined dose
214467936|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
214467937|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
214467938|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
214467939|NCT06345430|DEVICE|Exopulse Molli-Suit (Wearable Technological Device)|After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
214467940|NCT03184233|PROCEDURE|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
214467941|NCT03184233|PROCEDURE|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
214467942|NCT04901988|DRUG|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
214467943|NCT04357873|DRUG|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
214467944|NCT06439043|OTHER|EMDR Psychotherapy|EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
214467945|NCT06439043|OTHER|Online EMDR Psychotherapy|Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
214467946|NCT04109027|BEHAVIORAL|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
214467947|NCT04109027|BEHAVIORAL|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
214467948|NCT03828786|PROCEDURE|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
214467949|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
214467950|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
214467951|NCT05182775|PROCEDURE|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
214467952|NCT04738812|DRUG|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
214467953|NCT04738812|DRUG|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
214467954|NCT05007470|DRUG|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
214467955|NCT05007470|OTHER|Placebo|100 mg sugar
214467956|NCT05450510|OTHER|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
214467957|NCT05450510|OTHER|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
214467958|NCT06185985|DRUG|SPN-812|SPN-812 (200mg to 600mg once daily)
214467959|NCT05776459|DRUG|AC102 gel|Drug: AC102 Single intratympanic injection
214467960|NCT05776459|DRUG|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
214467961|NCT05776459|OTHER|Placebo Tablets|Placebo Tablets taken daily by mouth
214467962|NCT05776459|OTHER|Placebo gel|Placebo Single intratympanic injection
214467963|NCT06528158|OTHER|sibling group|"The group will be based on a systemic model and led by two child psychiatrists trained in family and multi-family therapy, who will not subsequently be involved in the data analysis. It will consist of 4 sessions of 1h30, spread over a period of 2 months, with a maximum of 8 participants per session. The first 3 sessions will be spaced 15 days apart, and the last session will take place 3 weeks apart from the third session.~The characteristics of the group (frequency, duration, number of sessions and participants) were built on data from the literature as well as on clinical feedback from a first pilot group conducted in January and February 2024 on the Toulouse pediatric unit by the two therapists who will lead the groups during the study."
214467964|NCT04228042|DRUG|Infigratinib|Given PO
214467965|NCT04228042|OTHER|Quality-of-Life Assessment|Ancillary studies
214467966|NCT04228042|OTHER|Questionnaire Administration|Ancillary studies
214467967|NCT04228042|PROCEDURE|Surgical Procedure|Undergo surgery
214467968|NCT03674684|OTHER|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
214467969|NCT02551068|OTHER|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
214467970|NCT02551068|OTHER|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
214467971|NCT05494593|DRUG|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
214467972|NCT05494593|DRUG|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m\^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
214467973|NCT05494593|DRUG|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
214467974|NCT05494593|DRUG|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
214467975|NCT05790486|BEHAVIORAL|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
214467976|NCT05790486|BEHAVIORAL|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
214467977|NCT05790486|OTHER|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
214467978|NCT05790486|OTHER|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
214467979|NCT03819153|DRUG|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
214467980|NCT03819153|DRUG|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
214467981|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
214467982|NCT06481319|BEHAVIORAL|Infertility Patient Navigator|Assistance with infertility evaluation including scheduling appointments
214467983|NCT04979572|DRUG|TS-172|"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"
214467984|NCT04979572|DRUG|Placebo|"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"
214467985|NCT03397654|DRUG|Pembrolizumab|Pembrolizumab solution
214467986|NCT03397654|COMBINATION_PRODUCT|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
214467987|NCT02965014|BEHAVIORAL|Face-to-Face Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
214467988|NCT02965014|BEHAVIORAL|mHealth Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
214467989|NCT02965014|BEHAVIORAL|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing (HCT).
214467990|NCT05272735|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
214467991|NCT06530732|PROCEDURE|Deep Cervical lymphatlc-Venous Anastomosis Surgery|Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
214467992|NCT06530732|DRUG|Lecanemab|The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
214467993|NCT03240016|DRUG|Pembrolizumab|200mg IV D1
214467994|NCT03240016|DRUG|Abraxane|100mg/m\^2 D1 and D8
214467995|NCT06002919|BEHAVIORAL|MindWalk Intervention|The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
214467996|NCT05464537|OTHER|Unipolar Polarity Switch Left|10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP
214467997|NCT05464537|OTHER|Unipolar Polarity Switch Right|10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins
214467998|NCT06176963|COMBINATION_PRODUCT|SB11 PFS|SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
214467999|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
214468000|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
214468013|NCT04681339|OTHER|Antibiotic treatment|Antibiotic treatment
214468014|NCT04681339|OTHER|No antibiotic treatment|No antibiotic treatment
214468015|NCT06851728|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
214468016|NCT04116671|DEVICE|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
214468017|NCT02317887|BIOLOGICAL|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
214468018|NCT06758856|DIETARY_SUPPLEMENT|Trimethylglycine|Betaine anhydrous from sugar beets
214468019|NCT06758856|OTHER|Eggs|3 whole eggs
214468020|NCT06758856|DIETARY_SUPPLEMENT|Cellulose|Cellulose
214468021|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
214468022|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
214468023|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
214468024|NCT03172975|BIOLOGICAL|Placebo|Physiological sterile saline solution
214468025|NCT03172975|DRUG|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
214468026|NCT03172975|OTHER|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
214468027|NCT06848829|OTHER|Pre-manepausal women|Compare tear ferning structure between pre-menopause and post-menopause women.
214468028|NCT06849089|PROCEDURE|Transurethral resection of prostate (TURP)|The surgical intervention used to resect the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a hot loop shaped knife, operated by electrocautery, to cut the obstructing tissues from center towards periphery of the prostate until the prostatic capsule is reached.
214468029|NCT06849089|PROCEDURE|Holmium laser enucleation of prostate|The surgical intervention used to enucleate the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a laser fiber to dissect the obstructing adenoma from the prostatic capsule starting from the plane in-between the capsule and the adenoma, meaning removal of tissues from periphery towards the center of the prostate.
214468030|NCT06850584|OTHER|Observation|The study was observational and did not involve any intervention.
214468031|NCT06849063|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D MRE#DCE-MRI#IVIM-DWI#T1/T2 mapping.
214468032|NCT06848959|OTHER|No intervention|Pediatric Encephalopathy Science and Prevention Decision Aid Follow-Up Q\&A
214468033|NCT06852482|OTHER|SBE Capacitation (behavioral intervention) for facilitator population|"An intervention is proposed with two training sessions for the tutors of the Pràcticum I, III, and IV courses in the Physiotherapy Degree. The first session will be on January 10, 2024 (3 hours), and the second on February 2, 2024 (2 hours), both at the FCSB facilities of UVic-UCC.~The sessions aim to:~Promote behavior that facilitates learning in Simulation-Based Education (SBE). Provide facilitators with tools and strategies for effective SBE implementation.~Highlight the differences and similarities in SBE across the Pràcticum I, III, and IV courses, based on increasing difficulty.~Training will involve clinical simulation principles, with facilitators experiencing all SBE phases. An actress, later participating in student simulations, will be involved. Scenarios from the courses will be used, supported by a PowerPoint presentation and an information dossier for participants."
214468034|NCT06852482|OTHER|SBE (behavioral intervention) for student population|"Simulation-Based Education Each student in Pràcticum I, III, and V will participate in a simulation session tailored to their course.~Simulations are conducted in groups of five students with the same UVic tutor acting as facilitator. Each simulation follows three phases (prebriefing, simulation, debriefing), with varying emphasis across courses:~Pràcticum I: The prebriefing ensures group confidence. Two volunteer students participate in the simulation. The debriefing is shorter, less focused on outcomes, and highlights learning over errors. Emphasizes guidance for student.~Pràcticum III: Prebriefing and debriefing are equally emphasized. One volunteer student performs the simulation.~Pràcticum V: Cases are more complex, requiring less prebriefing but comprehensive briefing. Students autonomously set session rules. The debriefing is in-depth and focuses on clinical application. One volunteer student performs the simulation, Focuses on autonomy and independent work."
214468035|NCT06852066|PROCEDURE|Computer-Assisted Local Anesthesia|"Description: Local anesthesia applied using the SleeperOne5 (Dental Hi Tec, Cholet, France) device, with controlled injection speed (60 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 35 mm, 30G dental syringe"
214468036|NCT06852066|PROCEDURE|Conventional Local Anesthesia|"Description: Local anesthesia applied using a manual dental syringe, with injection speed manually controlled (30 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 40 mm, 27G dental syringe"
214468037|NCT06852391|DRUG|Semaglutide Pen Injector|Semaglutide will be delivered by a subcutaneous injection using an injectable pen once weekly. Semaglutide is formulated with 5 approved doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). Treatment will commence with the lowest dose and will be increased every 4 weeks to the maximum tolerable dose where they will remain for the remainder of the treatment. Participants who are taking the drug will have monthly visits to assess any adverse events, dose titration and drug adherence.
214468038|NCT06852391|BEHAVIORAL|Behavioural Lifestyle Program (BLP)|The BLP will be delivered by the Growing Healthy Weight Management (GHWM) pediatric program at McMaster Children's Hospital. GHWM is a family-based program addressing health behaviours (nutritional pattern and eating behaviours, physical activity, sedentary time and sleep) and physical and mental health issues. In Year 1, the program typically includes 2 group sessions and monthly individualized sessions with the participant and their family. The interdisciplinary weight management team is comprised of a registered dietician, exercise physiologist, kinesiologist, social worker and/or psychologist, general pediatrician and pediatric endocrinologists.
214468039|NCT06851819|RADIATION|radiotherapy|Palliative radiotherapy for oligometastases can be combined with chemoradiotherapy and immunomaintenance therapy period. The investigator determines the number, timing and regimen of oligometastases according to the location, size, symptoms and patient tolerance of oligometastases
214468040|NCT06851819|DRUG|immunechemotherapy|Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )
214468041|NCT05992077|DRUG|Sofosbuvir/Daclatasvir|Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
214468042|NCT06852079|OTHER|Qurs e Fishar|Qurs e Fishar is a herbal remedy for Hypertension
214468043|NCT06852638|DRUG|[18F]F-RESCA-RCCB6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
214468044|NCT06852638|DRUG|[18F]F-RESCA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.
214468045|NCT06852638|DRUG|[18F]F-RESCA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RD06 injection.
214468046|NCT06852638|DRUG|[68Ga]Ga-NOTA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.
214468047|NCT06852638|DRUG|[68Ga]Ga-NOTA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]RD06 injection.
214468048|NCT06852638|DRUG|[89Zr]Zr-DFO-RB6|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RB6 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
214468049|NCT06852638|DRUG|[89Zr]Zr-DFO-R8B4|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-R8B4 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
214468050|NCT06852638|DRUG|[89Zr]Zr-DFO-RD06|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RD06 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
214468051|NCT06851364|DRUG|0.38% Sodium Hyaluronate (SH) Eye Drops|"A lubricant eye drop containing 0.38% sodium hyaluronate (SH), designed to improve tear film stability and ocular surface health in individuals with moderate to severe dry eye disease (DED).~The formulation has a higher viscosity and retention time, potentially offering better symptom relief for evaporative dry eye (EDE)."
214468052|NCT06851364|DRUG|0.18% Sodium Hyaluronate Eye Drops|"A lubricant eye drop containing 0.18% sodium hyaluronate (SH), used to alleviate dry eye symptoms and improve tear film stability.~This formulation has a lower viscosity compared to 0.38% SH, potentially providing faster absorption but with shorter ocular surface retention."
214468053|NCT06851364|DRUG|Normal Saline Eye Drops|"A non-active control treatment consisting of sterile normal saline (0.9% NaCl) used as a placebo comparator.~It provides temporary moisture but lacks the viscoelastic and therapeutic properties of sodium hyaluronate."
214468054|NCT05762133|BEHAVIORAL|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of Perinatal Depression (PND) with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
214468055|NCT02715271|PROCEDURE|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
214468056|NCT06851845|OTHER|No intervention|Patients will receive medical care in accordance with the routine practice of disease treatment
214468057|NCT06318520|OTHER|Use of Calcium silicate based resin cement and resin modified glass ionomer cement|Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.
214468058|NCT06843265|DEVICE|Vacuum- Induce Hemorrhage Control|The JADA System is designed for single use only and is composed of medical grade silicone. Its components include an intrauterine loop with protected vacuum pores, a cervical seal with a sealing valve for infusing saline and a vacuum connector port for applying suction. The intrauterine loop is located at the distal end of a tube and contains 20 protected vacuum pores oriented inward along the loop. This shielded design facilitates intracavitary suction by shielding maternal tissue from the vacuum source and prevents clogging of the vacuum pores with tissue or clot.
214468059|NCT06422845|DEVICE|Dissolve AV Peripheral Scoring Drug-coated Balloon|Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
214468060|NCT06368765|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
214468061|NCT06368765|OTHER|Water|Participants will be administered water during one of the study visits
214468062|NCT04123418|BIOLOGICAL|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
214468063|NCT04123418|DRUG|WHG626|WHG626 will be administered orally in a dose escalation schedule
214468064|NCT01752491|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
214468065|NCT01752491|DRUG|Temozolomide|Oral chemotherapeutic
214468066|NCT01752491|RADIATION|Radiation therapy|External beam radiation therapy
214468067|NCT05567328|DEVICE|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
214468068|NCT04245176|BEHAVIORAL|Standard Genetic Counseling|Standard genetic counseling: Standard of care discussion
214468069|NCT04245176|BEHAVIORAL|Quantitative Genetic Counseling|Quantitative genetic counseling: Discussion is guided by tables and graphs.
214468070|NCT04413201|DRUG|Afatinib|Afatinib followed by osimertinib or ICT
214468071|NCT04413201|DRUG|Osimertinib|Osimertinib followed by ICT
214468072|NCT06333704|BIOLOGICAL|SPIKEVAX Bivalent|No study drug will be administered during this study as this is an observational study.
214468073|NCT06333704|BIOLOGICAL|SPIKEVAX X|No study drug will be administered during this study as this is an observational study.
214468074|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
214468075|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
214468076|NCT05929599|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
214468077|NCT05929599|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
214468078|NCT02249442|DRUG|Tipranavir (TPV)|
214468079|NCT02249442|DRUG|Ritonavir (r)|
214468080|NCT01815242|DRUG|nab-Paclitaxel|
214468081|NCT01815242|DRUG|Gemcitabine|
214468082|NCT01815242|DRUG|Carboplatin|
214468083|NCT00906997|PROCEDURE|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
214468084|NCT00906997|PROCEDURE|Colonoscopy|Every 10 years, with sedation.
214468085|NCT04292379|OTHER|Standard care|Standard procedures and assessments
214468086|NCT04292379|OTHER|Care Bundle|Suicide risk screening tool, mental health assessment tool, follow-up appointment
214468087|NCT05452460|BEHAVIORAL|Mindfulness intervention|"The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes."
214468088|NCT04634799|DRUG|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
214468089|NCT04634799|OTHER|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
214468090|NCT06375512|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
214468091|NCT06375512|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) for injection
214468092|NCT06375512|BIOLOGICAL|Shingrix|Sterile suspension for injection
214468093|NCT04636151|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
214468094|NCT03860233|DRUG|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
214468095|NCT03860233|DRUG|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
214468096|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (I)|"1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g"
214468097|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (II)|Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
214468098|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (III)|"1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g"
214468099|NCT04790240|DRUG|Standard of care|remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
214468100|NCT06431256|DRUG|HLD200 methylphenidate hydrochloride capsules|Doses: 20mg capsules
214468101|NCT06431256|DRUG|Placebo HLD200 capsules|Doses: 20mg capsules
214468102|NCT05864638|DEVICE|Endovascular treatment|Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis
214468103|NCT05884476|OTHER|Treatment-as-usual|Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
214468104|NCT05884476|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|"REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition."
214468105|NCT05208112|DRUG|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
214468106|NCT05931003|PROCEDURE|Carotid stenting|In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
214468107|NCT05931003|PROCEDURE|Carotid endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery."
214468108|NCT03624244|DRUG|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
214468109|NCT06559930|OTHER|Traditional Neurological Rehabilitation + Dual Task Focused Training|Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.
214468110|NCT06559930|OTHER|Traditional Neurological Rehabilitation|Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
214468111|NCT03680092|DRUG|Cyclophosphamide|Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
214468112|NCT03680092|DRUG|abatacept|Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
214468113|NCT03680092|DRUG|Methotrexate|standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
214468114|NCT03680092|DRUG|Tacrolimus|Tacrolimus per institutional guidelines
214468115|NCT06208748|DRUG|Bezuclastinib in combination with sunitinib|Bezuclastinib in combination with sunitinib (sutent)
214468116|NCT05743907|DRUG|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
214468117|NCT05743907|DRUG|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
214468118|NCT03996850|PROCEDURE|Computed Tomography|Undergo SPECT/CT
214468119|NCT03996850|OTHER|Questionnaire Administration|Ancillary studies
214468120|NCT03996850|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214468121|NCT03996850|RADIATION|Technetium Tc-99m Sestamibi|Given IV
214468122|NCT05215119|PROCEDURE|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
214468123|NCT06406140|DRUG|Niacin tablets 500 mg|tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
214468124|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
214468125|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
214468126|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
214468127|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
214468128|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
214468129|NCT06481488|DRUG|E2086|E2086 tablets.
214468130|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
214468131|NCT06852794|OTHER|Survey|The patients will receive questionnaires. The enrolled patients will be asked to provide feedback on the answers they read.
214468132|NCT02043691|DEVICE|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
214468133|NCT02043691|DEVICE|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
214468134|NCT02043691|DEVICE|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
214468135|NCT05174572|PROCEDURE|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
214468136|NCT03851796|BEHAVIORAL|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
214468137|NCT03851796|BEHAVIORAL|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
214468138|NCT05715086|PROCEDURE|Ureteroscopy|Upfront ureteroscopy
214468139|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
214468140|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
214468141|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
214468142|NCT04908033|DEVICE|pacemaker implantation|pacemaker implantation
214468143|NCT04470778|DRUG|BMS-986256|Specified dose on specified days
214468144|NCT04470778|DRUG|Famotidine|Specified dose on specified days
214468145|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
214468146|NCT06046001|DEVICE|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
214468147|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
214468148|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
214468149|NCT06550609|DRUG|Miltefosine Oral Capsule|Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
214468150|NCT05576077|BIOLOGICAL|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
214468151|NCT05576077|DRUG|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
214468152|NCT05648214|DRUG|ALN-PNP - Part A|Administered by subcutaneous (SC) single ascending dose (SAD)
214468153|NCT05648214|DRUG|ALN-PNP - Part B|Administered by SC parallel single dose
214468154|NCT05648214|DRUG|Placebo (PB)|Administered by SC injection
214468155|NCT04208373|DRUG|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
214468156|NCT04208373|DRUG|Itraconazole|Itraconazole capsules will be administered orally
214468157|NCT04208373|DRUG|Etravirine|etravirine tables will be administered orally.
214468158|NCT05511415|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
214468159|NCT05511415|DRUG|Dexmedetomidine|Dexmedetomidine (10-9M to 10-4M)
214468160|NCT04397679|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
214468161|NCT04397679|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
214468162|NCT04397679|DRUG|Temozolomide|Given PO
214468163|NCT04397679|DRUG|Chloroquine|Given PO
214468164|NCT04397679|PROCEDURE|Tumor Treating Fields Therapy (TTF)|Undergo TTF
214468165|NCT04362254|DRUG|Spesolimab|Spesolimab
214468166|NCT06557343|DIAGNOSTIC_TEST|Single Cell Sequencing|Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
214468167|NCT04005690|DRUG|Cobimetinib|Given PO
214468168|NCT04005690|DRUG|Olaparib|Given PO
214468169|NCT04005690|DRUG|Onvansertib|Given PO
214468170|NCT04005690|DRUG|Azenosertib|Given PO
214468171|NCT04005690|DRUG|Saruparib|Given PO
214468172|NCT04005690|BIOLOGICAL|Tremelimumab|Given IV
214468173|NCT03624517|DRUG|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
214468174|NCT04642820|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
214468175|NCT04642820|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
214468176|NCT06507111|DIETARY_SUPPLEMENT|Lab4P|"Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20 and Bifidobacterium animalis subsp. lactis CUL-34 at a dose of 50 billion bacteria per/ day combined with vitamin C (80 mg/day), Vitamin D (400 IU/day) and Zinc (10 mg/day) on a microcrystaline cellulose (MCC) base~Daily dose: 50 billion bacteria per day"
214468177|NCT06507111|OTHER|Placebo|MCC alone
214468178|NCT05469464|DRUG|Orismilast modified release tablets|"Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731"
214468179|NCT05469464|DRUG|Placebo|Placebo matching tablets
214468180|NCT01542580|DEVICE|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
214468181|NCT01542580|DEVICE|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
214468182|NCT01542580|DEVICE|Vanguard DA 360|Dual-articulation device, only cleared in EU
214468183|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
214468184|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
214468185|NCT04115241|DEVICE|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
214468186|NCT04115241|OTHER|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
214468187|NCT04390425|DEVICE|Experimental - Limb Occlusion pressure|This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
214468188|NCT05167487|DRUG|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
214468189|NCT05167487|DRUG|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
214468190|NCT06433401|BEHAVIORAL|Transitional care training with brochures, posters and slide training materials|Education at 1 and 2 months after the first interview
214468191|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
214468192|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
214468193|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
214468194|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 125 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
214468195|NCT05778162|DIAGNOSTIC_TEST|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments \[CLIA\] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
214468196|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
214468197|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
214468198|NCT05036590|OTHER|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
214468199|NCT05036590|OTHER|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
214468200|NCT06829875|PROCEDURE|wait for outpatient appointment|this is an observational study measuring impact of pain and function at start and end of wait for those waiting for care from outpatient physiotherapy occupations therapy and podiatry
214468201|NCT02128802|PROCEDURE|Gastric Bypass|
214468202|NCT02128802|OTHER|Weight Loss Program|
214468203|NCT05739994|OTHER|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
214468204|NCT05739994|OTHER|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
214468205|NCT06830837|OTHER|Mandala coloring|Eight pre-selected mandala drawings will be printed on separate A4 (21.0 cm × 29.7 cm) papers. After the patients are admitted to the hospital for the surgery process, the patients in the experimental group will be provided with at least 2 hours of mandala coloring per day until the day of their surgery. No intervention will be applied to the control group patients. Studies examining the effect of mandala coloring on reducing psychological symptoms have reported that using a circularly designed pattern in the mandala template, instead of a square design, has a greater effect on symptom management. Therefore, a circular-shaped mandala template will be used. Each participant will be provided with mandala coloring sheets and 12 colored pencils (red, orange, yellow, pink, light green, green, sky blue, blue, purple, brown, reddish-brown, and black) by the researcher.
214468206|NCT00621114|DEVICE|GamCath® central venous catheter|Choice of central venous catheter type
214468207|NCT00621114|DEVICE|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
214468208|NCT05905705|DIAGNOSTIC_TEST|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
214468209|NCT05905705|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
214468210|NCT03652740|DRUG|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
214468211|NCT06047808|BEHAVIORAL|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
214468212|NCT05382702|OTHER|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
214468213|NCT01208662|DRUG|Lenalidomide|oral administration
214468214|NCT01208662|DRUG|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
214468215|NCT01208662|DRUG|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
214468216|NCT01208662|PROCEDURE|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
214468217|NCT05714020|OTHER|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
214468218|NCT05714020|OTHER|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
214468219|NCT03594734|BEHAVIORAL|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
214468220|NCT03594734|OTHER|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
214468221|NCT01624129|DRUG|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
214468222|NCT05653193|DRUG|Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
214468223|NCT05653193|DRUG|Antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
214468224|NCT05971173|DRUG|Juven|Nutritional supplements
214468225|NCT05971173|DRUG|Centrum Silver 50+|Over the counter nutritional supplement
214468226|NCT06551285|DIETARY_SUPPLEMENT|Ovapro (Lifepro)|Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.
214468227|NCT06398808|DRUG|Arm1|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
214468228|NCT06398808|DRUG|Arm 2|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
214468229|NCT04101344|OTHER|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
214468230|NCT05236660|DEVICE|Custom-made shoes: pressure-optimized|Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
214468231|NCT05236660|DEVICE|Custom-made indoor shoes: pressure optimized|Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
214468232|NCT05236660|DEVICE|Foot temperature monitoring|Personalised at-home daily foot temperature monitoring at high-risk regions.
214468233|NCT05236660|BEHAVIORAL|Education|Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
214468234|NCT05537948|DRUG|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
214468235|NCT05537948|DRUG|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
214468236|NCT06481462|PROCEDURE|Intrathecal Morphine (ITM)|morphine 100 mcg + 12.5 mg bupivacaine + 20 mcg fentanyl
214468237|NCT06481462|PROCEDURE|Quadratus Lumborum II (QLB-II) Block|12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
214468238|NCT03225677|PROCEDURE|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
214468239|NCT06558266|OTHER|Since this was an observational study, no intervention was performed.|Since it is an observational study, only evaluation will be made. Each participant s mental imagery ability will be evaluated with the Movement Imagery Vividness Questionnaire-2 four times, follicular phase, ovulation, luteal phase and menstrual phase. In addition, the pain intensity experienced during menstruation will be evaluated with the Numerical Classification Scale-11, and the symptoms experienced due to menstruation will be evaluated with the Menstruation Symptom Scale.
214468240|NCT00321048|DEVICE|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
214468241|NCT04707625|DRUG|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
214468242|NCT03825757|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
214468243|NCT03825757|DRUG|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
214468244|NCT02920229|DRUG|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
214468245|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
214468246|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
214468247|NCT06050369|DEVICE|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
214468248|NCT06050369|DEVICE|MRI|Get the anatomical shape of the brain.
214468249|NCT01817452|DRUG|Trastuzumab|
214468250|NCT01817452|DRUG|Pertuzumab|
214468251|NCT01817452|DRUG|Paclitaxel|
214468252|NCT05049018|OTHER|Traditional Physical Therapy Program|"This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities."
214468253|NCT05049018|DEVICE|ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)|ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
214468254|NCT06283537|OTHER|Effect of training method|The effect of the training method given to midwifery students on their episiotomy application skills, satisfaction with the teaching method and self-confidence.
214468255|NCT03755167|DRUG|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
214468256|NCT06206434|DIAGNOSTIC_TEST|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
214468257|NCT05579210|BEHAVIORAL|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
214468258|NCT05579210|BEHAVIORAL|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
214468260|NCT06473662|DRUG|Oral insulin|Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
214468261|NCT04592978|BEHAVIORAL|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
214468262|NCT04592978|BEHAVIORAL|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
214468263|NCT03551392|DEVICE|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
214468264|NCT03551392|DEVICE|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
214468265|NCT03551392|DEVICE|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
214468266|NCT03551392|DEVICE|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
214468267|NCT05651178|DRUG|Human CD19-CD22 Targeted T Cells Injection|Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
214468268|NCT03449706|DRUG|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
214468269|NCT06125054|DRUG|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
214468270|NCT06125054|DRUG|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
214468271|NCT06125054|BEHAVIORAL|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.
214468272|NCT06125054|BEHAVIORAL|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.
214468273|NCT03463044|DRUG|nangibotide|Continous i.v. infusion
214468274|NCT03463044|DRUG|Placebo|Placebo
214468275|NCT04704544|OTHER|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
214468276|NCT05408052|PROCEDURE|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
214468277|NCT05408052|PROCEDURE|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
214468278|NCT05265715|OTHER|Low AGE diet|"The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
214468279|NCT05265715|PROCEDURE|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
214468280|NCT06444919|DRUG|Capsaicin 179 Mg Cutaneous Patch|patch application for 30 minutes on the painful fingers.
214468281|NCT06444919|DRUG|Capsaicine low dose 0.04 %|patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).
214468282|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
214468283|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
214468284|NCT05182905|DRUG|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
214468285|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
214468286|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
214468287|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
214468288|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
214468289|NCT06558604|DRUG|Obinutuzumab|1000 mg/40mL
214468290|NCT06558604|DRUG|Glofitamab|10mg/mL
214468291|NCT06558604|DRUG|Venetoclax Oral Product|10mg, 50mg and 100mg tablets
214468292|NCT06558604|DRUG|Zanubrutinib Oral Capsule|80mg capsules
214468293|NCT03999593|PROCEDURE|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
214468294|NCT06839430|OTHER|hypertonic saline 5% sodium chloride|Hypertonic saline acts as an analgesic by alleviating nociceptive pain from inflamed tissues, which may include bone, connective tissue , synovium , or a combination of these Hypertonic saline results in safe and remarkable outcomes on knee pain, stiffness and function compared with intra-articular dextrose injection
214468295|NCT06839430|OTHER|hypertonic dextrose 20%|A recent study showed the sensorineural analgesic effect of 5% dextrose prolotherapy in the treatment of chronic low back pain ,Therefore, the mechanism of action for dextrose prolotherapy is hypothesized to work through reducing peripheral sensitization and targeting structural dysfunction
214468296|NCT06838858|PROCEDURE|Motor Imagery Training|The study group will receive motor imagery training in addition to control group's exercise program. This process will proceed as follows; In motor imagery training videos taken with a 9-year-old healthy child will be watched.• The content of the videos will include exercises such as ankle dorsiflexion, heel tapping while walking, climbing and descending stairs, walking on a ramp, standing on a ramp, walking on soft ground, and walking on a treadmill.• The patients will watch these videos and then the relaxation, imagination and return to environment phases of motor imagery will be applied respectively.
214468297|NCT06838858|PROCEDURE|Conventional Post-operative Exercises|"This group will receive conventional exercises in the post-op process. The exercises included in the conventional exercise program are;~* Balance board exercises~* Balance disc exercises~* Bosu exercises~* Balance pad exercises~* Wobble board exercises~* Walking on soft ground~* Balance exercises on soft ground~* Apraximations and tractions~* Target angle exercise for ankle~* General standing balance exercises (Eyes open and closed - single foot, double foot)~* Ankle bidirectional ROM~* Ankle bidirectional strengthening~* Exercises to increase foot intrinsic muscle strength and balance~* Functional exercises"
214468298|NCT04706988|OTHER|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
214468299|NCT06083246|OTHER|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
214468300|NCT06083246|OTHER|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
214468301|NCT06831240|OTHER|Local wheelchair service provider questionnaires|The local wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
214468302|NCT06831240|OTHER|Global wheelchair service provider questionnaires|The global wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
214468303|NCT06831240|OTHER|End-users questionnaires|The end-users will complete a questionnaire that includes demographic and clnical data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
214468304|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
214468305|NCT06831643|DRUG|Standard Medical treatment|Standard Medical treatment
214468306|NCT06831643|BIOLOGICAL|Therapeutic Plasma Excahnge|Therapeutic Plasma Excahnge
214468307|NCT06263114|DIAGNOSTIC_TEST|TruGraf® Liver gene expression panel (GEP)|Test done on blood sample collected during for cause or routine liver biopsy
214468308|NCT06751355|DEVICE|SkinScan3D camera|The SkinScan3D (SS3D) is a portable, battery-powered imaging prototype which can successfully achieve all-focus, 3D images using low-cost, off-the-shelf components.
214468309|NCT06564545|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214468310|NCT06564545|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
214468311|NCT06564545|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
214468312|NCT03376646|DEVICE|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
214468313|NCT03376646|DEVICE|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
214468314|NCT03376646|DEVICE|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
214468315|NCT05764525|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
214468316|NCT05764525|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
214468317|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy: The interval between radiotherapy and immunotherapy should be within 3 weeks, with no specific order required. Different radiotherapy techniques will be selected based on the size and location of the metastatic lesions:~Stereotactic Body Radiation Therapy (SBRT), Spatially Fractionated Radiation Therapy (SFRT), Low-dose Radiotherapy (LDRT)."
214468318|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Delayed Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy:~If there is intracranial disease progression but extracranial disease remains stable, the systemic treatment regimen of Adelumab + VEX metronomic chemotherapy will be continued, with the addition of intracranial radiotherapy.~If there is intracranial disease progression and extracranial disease progression, the systemic treatment regimen will be modified, with the addition of intracranial radiotherapy.~The radiotherapy positioning and techniques will be the same as those used in the experimental group."
214468319|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
214468320|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
214468321|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
214468322|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
214468323|NCT06839625|BEHAVIORAL|emotional freedom technıque|EFT application
214468324|NCT00586391|GENETIC|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
214468325|NCT00586391|DRUG|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
214468326|NCT05425784|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
214468327|NCT05425784|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
214468328|NCT04987502|OTHER|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
214468329|NCT04987502|BEHAVIORAL|Standard treatment|counselling, relaxation techniques, sound enrichment
214468330|NCT06839885|OTHER|Interventional group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the last year and completed treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. The patients were planned to be treated in the hydrotherapy unit during lunch breaks, under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the study group will perform aquatic exercises in groups of 5 or 7 participants, three times a week for 6 weeks, under the supervision of a physiotherapist.Patients in the intervention group will receive a home exercise program and self-drainage."
214468331|NCT06839885|OTHER|Control group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the past year and completed their treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. Patients were planned to be treated in the hydrotherapy unit during lunch breaks under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the control group will receive a home exercise program and self-drainage."
214468332|NCT03542578|DEVICE|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
214468333|NCT06838637|DEVICE|"Spinal COrd NEuromodulation (SCONE) Device"|A non-invasive electrical device that provides transcutaneous spinal cord stimulation (TSCS) to the spinal cord by electrodes connected to a battery-powered source.
214468334|NCT06834854|DRUG|fentanyl|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), 100 ml of isotonic saline over 15 minutes. Fentanyl 1 mcg/kg (1 ampoule contains 100mcg over 10cc syringe). Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done~Maintenance: Anesthesia will be maintained with Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03mg/kg/30min. Another IV cannula will be placed with two infusion pumps of normal saline 50cc and fentanyl infusion 1-2 mcg/kg/hour (max 300 mcg total)."
214468335|NCT06834854|DRUG|Lidocaine (drug)|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with IV propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), lidocaine 2% (1.5 mg/kg (7.5cc bolus dose)), MgSO4 10% (50 mg/kg in 100 ml of isotonic saline over 15 minutes), Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done.~Maintenance: Anesthesia will be maintained using Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03 mg/kg/30min. Another IV cannula will be placed with 2 infusion pump one of them containing mixture of (lidocaine 2% 1.5 mg/kg/hour as infusion along with MgSO4 10% in 10-15 mg/kg/hour with 50cc normal saline over 50ml/hour), while the second contains propofol at 6-10 mg/kg/hour."
214468336|NCT03334630|DEVICE|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
214468337|NCT03334630|DEVICE|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
214468338|NCT06464146|DRUG|Morphine|oral morphine (0.5 mg / kg)
214468339|NCT06464146|DRUG|IN fentanyl|IN fentanyl (1.5 µg/kg)
214468340|NCT06464146|DRUG|IN ketamine|IN ketamine (1 mg/kg)
214468341|NCT06464146|DRUG|NaCl 0,9 %|Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
214468342|NCT06442787|DEVICE|conventional splints|only intermediate and final splint will be used during the surgery
214468343|NCT06442787|DEVICE|cutting guides and positioning guides|patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
214468344|NCT06442787|DEVICE|cutting guides and fixation plates|patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
214468345|NCT06454708|DRUG|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
214468346|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
214468347|NCT06789653|DIAGNOSTIC_TEST|p16INK4a mRNA level assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined
214468348|NCT06789653|DIAGNOSTIC_TEST|organ-specific protein signatures assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.
214468349|NCT05653336|DEVICE|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
214468350|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Intravaginally|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
214468351|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Laporoscopic|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
214468352|NCT04815213|BIOLOGICAL|EV|Extracellular vesicles injection
214468353|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
214468354|NCT02302885|OTHER|Blood collection|Blood Collection
214468355|NCT06355713|DEVICE|Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination|"An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over."
214468356|NCT06355713|BIOLOGICAL|blood sample|"Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)"
214468357|NCT06355713|BIOLOGICAL|urine collection|"Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)"
214468358|NCT06355713|BIOLOGICAL|Collection of a lock of hair|Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
214468359|NCT06355713|OTHER|questionnaire|"Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score"
214468360|NCT04246112|OTHER|Handwriting intervention|children will practice handwriting 5 days p/week, 15-20 minutes p/day for 12 weeks using the movalyzer software program.
214468361|NCT05178888|DRUG|MRTX849|KRAS G12C inhibitor
214468362|NCT05178888|DRUG|Palbociclib|CDK 4 and 6 inhibitor
214468363|NCT06077136|OTHER|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
214468364|NCT06077136|OTHER|standard physical therapy|all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
214468365|NCT06344416|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
214468366|NCT02413970|DEVICE|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
214468367|NCT04252573|DEVICE|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
214468368|NCT05116514|OTHER|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
214468369|NCT06112639|DEVICE|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
214468370|NCT06112639|DEVICE|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
214468371|NCT06112639|DEVICE|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
214468372|NCT03138161|DRUG|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
214468373|NCT03138161|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
214468374|NCT03138161|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
214468375|NCT04833010|OTHER|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
214468376|NCT04833010|OTHER|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
214468377|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
214468378|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
214468379|NCT03404115|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
214468380|NCT05585190|OTHER|Control|No intervention.
214468381|NCT05585190|OTHER|Sit-Stand Desk at Work|Subjects will receive a sit-stand desk at their work location.
214468382|NCT04555590|BEHAVIORAL|H-HOPE Intervention|The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
214468383|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
214468384|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
214468385|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
214468386|NCT05249101|DRUG|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
214468387|NCT05249101|DRUG|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
214468388|NCT04019977|OTHER|Nurse Home Visiting Program|Brief nurse home visiting program
214468389|NCT06089967|OTHER|Medical chart review|Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
214468390|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
214468391|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
214468392|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
214468393|NCT00999856|DEVICE|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
214468394|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
214468395|NCT00999856|DEVICE|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
214468396|NCT00999856|DEVICE|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
214468397|NCT05059639|OTHER|Almond|Consume 2 ounces of almond daily for 8 weeks
214468398|NCT05059639|OTHER|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
214468399|NCT02234388|OTHER|Observation|There are no interventions associated with this registry as it is purely observational.
214468400|NCT05177822|DRUG|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
214468401|NCT05177822|OTHER|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
214468402|NCT05397431|DRUG|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
214468403|NCT02260856|DEVICE|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
214468404|NCT02260856|PROCEDURE|Percutaneous Drill Epiphysiodesis|
214468405|NCT02260856|PROCEDURE|Percutaneous Screw Epiphysiodesis|
214468406|NCT00278785|BEHAVIORAL|Brief Motivational Interview|10-20 minute brief motivational interview
214468407|NCT05825183|PROCEDURE|Ultrasound-guided manual vaccum|"For managing with miscarriage or termination of pregnancy (TOP) in first trimester loss, ultrasound-guided manual vacuum aspiration (USG-MVA) is one of the treatment options.~The USG-MVA device works by aspirating the uterine content via the cannula into the syringe. Furthermore, product of conception derived from USG-MVA can be sent for karyotyping analysis.~POCs obtained from MVA procedure were rinsed in normal saline thoroughly in the kidney basin to minimize maternal blood. Chorionic villi were considered as a proxy of fetal genetics, appeared to be yellowish in color and tree-projection-like in appearance, floating on the surface of the waterline. Decidua are originated from the mother, appeared substantive in structure and sank in the basin. The two different types of tissues are separated from each other for different testing."
214468410|NCT06461546|DRUG|Imlifidase|"* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
214468411|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
214468412|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
214468413|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
214468414|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
214468415|NCT05705453|DEVICE|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
214468416|NCT05043961|PROCEDURE|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
214468417|NCT03910478|DEVICE|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
214468418|NCT03910478|OTHER|Standard Control Strategy|Standard of care with office-based testing.
214468419|NCT05293171|DRUG|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
214468420|NCT05293171|DRUG|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
214468421|NCT05293171|DRUG|BL-8040-matching placebo|Administered subcutaneous (SC) injection
214468422|NCT05293171|DRUG|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
214468423|NCT05340062|DEVICE|bedside sonography|TCD and ONSD sonography twice a day per 2 days
214468424|NCT05133739|DEVICE|injection of RHA®4 in Midface|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
214468425|NCT05133739|DEVICE|injection of Comparator Product in Midface|"Comparator product is sterile, biodegradable, colorless gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
214468426|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART is a web-based intervention that adapted and modified components from the Transdiagnostic Sleep and Circadian intervention for youth and included four cross-cutting components (sleep complaint, education, behavior change and motivation, and goal-setting) that were integrated into each module. To begin the intervention, participants were provided a link to the SLEEPSMART intervention website for one of the above modules and an online sleep coach each week. At the end of each week, children and parents uploaded the weekly activities and goals via the REDCap link and set up a meeting with the sleep coach to review. The modules took 20 to 30 minutes to complete.
214468427|NCT06438159|OTHER|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations."
214468428|NCT06438159|OTHER|Conventional cardiac rehabilitation|The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
214468429|NCT02641639|DRUG|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
214468430|NCT02641639|DRUG|Placebo|Saline for infusion
214468431|NCT06415292|DRUG|Winlevi (clascoterone) 1% cream|Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.
214468432|NCT06835023|DRUG|Ringer lactate (RLS)|50 patients will receive only Ringer Lactat
214468433|NCT06835023|DRUG|Dextran+Ringer Lactat(D+RLS)|50 patients Dextran+RInger Lactat 1:3 ratio
214468436|NCT05332457|DRUG|Reduced dosage of beta-blocker|"Phase I:~1. CPET performed at trough BB concentration: participants will undergo CPET at least 30 hours after last beta-blocker usage.~2. CPET performed at peak BB concentration : participants will undergo CPET at 3 hours after last beta-blocker usage.~Phase II:~BB dosage will be reduced."
214468437|NCT04766892|DRUG|mavacamten|mavacamten capsules
214468438|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
214468439|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
214468440|NCT01712490|DRUG|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
214468441|NCT01712490|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
214468442|NCT01712490|DRUG|bleomycin|Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
214468443|NCT01712490|DRUG|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
214468444|NCT01712490|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
214468445|NCT05879536|DRUG|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
214468446|NCT05879536|DRUG|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
214468447|NCT05871970|BIOLOGICAL|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
214468448|NCT06780683|DRUG|Upadacitinib|"Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered."
214468449|NCT05990465|DRUG|Pirtobrutinib|Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
214468450|NCT05990465|DRUG|LV20.19 CAR T cells|Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
214468451|NCT06537544|OTHER|Comprehensive Rehabilitation Program|Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education
214468452|NCT06537544|OTHER|Conventional Pelvic Floor Training|Kegels exercises in different body positions
214468453|NCT05617794|DEVICE|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
214468454|NCT05617794|DEVICE|Control Spectacle Lens|Control Spectacles
214468455|NCT03481075|OTHER|Biomechanical computer program|Fusion assisting software for image-guided intervention
214468456|NCT03822936|DRUG|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
214468457|NCT03822936|RADIATION|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
214468458|NCT03478956|DRUG|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
214468459|NCT04800211|OTHER|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
214468460|NCT04800211|OTHER|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
214468461|NCT02550522|DEVICE|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
214468462|NCT05849337|BEHAVIORAL|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
214468463|NCT05849337|BEHAVIORAL|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
214468464|NCT05849337|OTHER|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
214468465|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
214468466|NCT06270199|BIOLOGICAL|Control|Standard treatment
214468467|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
214468468|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
214468469|NCT01050036|PROCEDURE|autologous hematopoietic cell transplantation|"1. Autologous peripheral blood stem cell (PBSCs) harvesting~   * After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~  * Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~  * Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~2. Conditioning regimen for autologous HCT~   * Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~  * Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~3. Autologous cell infusion and waiting for engraftment"
214468470|NCT06441773|PROCEDURE|Respiratory Rehabilitation|"An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support"
214468471|NCT05140434|DIAGNOSTIC_TEST|Exercise test|exercise test on an exercise bike with increasing load
214468472|NCT05140434|DIAGNOSTIC_TEST|Cardiac CT|cardiac CT scan
214468473|NCT06079398|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
214468474|NCT06079398|DRUG|Placebo for Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
214468475|NCT04874870|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
214468476|NCT04874870|COMBINATION_PRODUCT|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
214468477|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
214468479|NCT05916417|DEVICE|TMS-fNIRS over the dl-PFC|Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.
214468480|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
214468481|NCT06565572|DRUG|nL-FLVC-001|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
214468482|NCT06565949|OTHER|Education group|aregivers in the experimental group will be given a detailed and planned training programme on pressure sores. The trainings will be held in a total of four sessions, with twenty minutes in each session, two weeks apart.
214468483|NCT06565949|OTHER|control group|In the first stage of the study, the participants in the experimental and control groups were asked to complete the 'Introductory Information Form' and '' Pressure sore knowledge test' will be completed. In the second stage of the research, no intervention will be made to the caregivers in the control group, and in the last stage of the research, 'Pressure sore knowledge test' will be filled in as post-test data for all participants.
214468484|NCT05017012|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.
214468485|NCT05017012|BIOLOGICAL|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
214468486|NCT05017012|DRUG|Pemetrexed|Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
214468487|NCT05017012|DRUG|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
214468488|NCT05017012|DRUG|Paclitaxel|Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
214468489|NCT05017012|DRUG|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
214468490|NCT05017012|DRUG|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
214468491|NCT05017012|DRUG|Cisplatin|Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
214468492|NCT02701829|OTHER|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
214468493|NCT02701829|OTHER|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
214468494|NCT02701829|OTHER|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
214468495|NCT05170841|DRUG|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg|Administered as one single tablet to be taken every 8 hours
214468496|NCT05170841|DRUG|Tramadol Hydrochloride 100 mg|Administered as two capsules with 50 mg each to be taken every 8 hours
214468497|NCT05170841|DRUG|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
214468498|NCT05742685|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
214468499|NCT04799184|DRUG|Levobupivacaine 0.25% with epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
214468500|NCT04799184|DRUG|Levobupivacaine 0.25% without epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
214468501|NCT04872439|DIAGNOSTIC_TEST|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
214468502|NCT03806790|DRUG|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
214468503|NCT03806790|DRUG|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
214468504|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
214468505|NCT05123586|DRUG|LY3361237|Administered SC
214468506|NCT05123586|DRUG|Placebo|Administered SC
214468507|NCT06201884|DEVICE|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
214468508|NCT05797857|OTHER|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
214468509|NCT04929496|PROCEDURE|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
214468510|NCT05686278|DEVICE|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
214468511|NCT04865289|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
214468512|NCT04865289|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
214468513|NCT04865289|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
214468514|NCT04865289|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
214468515|NCT05752149|DRUG|CRGD-ZW800-1|Intravenous administration of study drug at lesat 2h prior to surgery
214468516|NCT06537596|DRUG|89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)|Single administration of 89Zr-TLX300-CDx
214468517|NCT06255951|DRUG|Itraconazole|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
214468518|NCT06255951|DRUG|Rifampicin|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
214468519|NCT04360252|OTHER|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
214468520|NCT05052684|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
214468521|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
214468522|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
214468523|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
214468524|NCT04603443|DIETARY_SUPPLEMENT|Protein Control|Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
214468525|NCT04380311|DEVICE|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
214468526|NCT04677738|DIETARY_SUPPLEMENT|B. breve strain|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve strain in the morning before breakfast for 12 weeks.
214468527|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
214468528|NCT04707469|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
214468529|NCT05917119|OTHER|BLT|Bright light therapy delivered via glasses
214468530|NCT05917119|OTHER|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
214468531|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
214468532|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
214468533|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
214468534|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
214468535|NCT05346757|DIAGNOSTIC_TEST|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
214468536|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
214468537|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
214468538|NCT05396040|PROCEDURE|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
214468539|NCT03318601|PROCEDURE|Blood taking|"Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume"
214468540|NCT05363319|DRUG|Cemiplimab|solution for injection via intravenous (IV) infusion
214468541|NCT05363319|DRUG|Platinum-based chemotherapy|IV administration
214468542|NCT05084209|BEHAVIORAL|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
214468543|NCT06783738|OTHER|Exercise|The participants will come to our lab twice. In the first visit we will perform a fitness assessment, using a noninvasive, cardiopulmonary exercise testing used routinely to measure fitness in children.
214468544|NCT06786507|DRUG|Ustekinumab 90 mg|Ustekinumab is a human monoclonal IgG1 antibody that blocks the p40 subunit of both IL-12 and IL-23 this antagonistic action inhibits the interaction of these cytokines with the IL-12Rβ1 receptor. The IL-12Rβ1 receptor is found on the surface of NK cells and T cells which reduces inflammation and alters the body's immune response
214468545|NCT06786507|DRUG|Infliximab|Infliximab is a biological therapy/immunotherapy medication designed to stimulate the body's immune system and treat certain diseases. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha (TNF-α). TNF-α is a signaling protein involved in acute phase reactions and systemic inflammation. Macrophages, CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons produce TNF-α. This TNF-α inhibition inhibits the inflammatory reaction's cascade, leading to improved disease condition inflammatory bowel disease
214468546|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
214468547|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
214468548|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
214468549|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
214468550|NCT03985592|BEHAVIORAL|Education|Intervention description provided in elaboration on arms of the study.
214468551|NCT06852287|DRUG|chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.|Toripalimab: 240mg ivd d1, q3w; Lenvatinib: 8-12mg po qd (body weight\<60kg, 8mg po qd; body weight ≥ 60kg, 12mg po qd) Chemotherapy by hepatic arterial infusion (GOLD HAIC): d1 oxaliplatin: 100-125mg+gemcitabine: 800-1000mg; q3w.
214468552|NCT06848543|BEHAVIORAL|Arm 1 Intervention|Arm 1 intervention is weight based taxes on cannabis, where participants make hypothetical purchases under weight based taxes.
214468553|NCT06848543|BEHAVIORAL|Arm 2 Intervention|Arm 2 intervention is price based taxes on cannabis, where participants make hypothetical purchases under price based taxes.
214468554|NCT04922736|DEVICE|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
214468555|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
214468556|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
214468557|NCT02733159|DRUG|pembrolizumab|anti PD-1
214468558|NCT06567613|DIAGNOSTIC_TEST|Speech test|The hearing screening ensures normal hearing before enrollment. The speech reception threshold for swiss german mono- and bisyllable words is determined in an adaptive procedure.
214468559|NCT06848660|DEVICE|A rigid cervical collar|The rigid cervical collar is used for spinal motion restriction for 12 weeks for the non-surgical treatment of a stable cervical spine fracture.
214468560|NCT05546385|DEVICE|Partial Rebreathing Device|Partial Rebreathing Device
214468561|NCT05546385|DEVICE|Sham breathing device|Sham breathing device
214468562|NCT06851065|DRUG|Luspatercept|As per product lable
214468563|NCT06851065|DRUG|Erythropoiesis-stimulating agents|As per product label
214468564|NCT06568107|BEHAVIORAL|Environmental And Sensory Experience (EASE) intervention|The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
214468565|NCT06122194|DRUG|Drug: PF-07817883|PF-07817883 tablet
214468566|NCT06536374|DRUG|Trimethoprim Tablets|Trimethoprim 150mg is administered once daily for 3 months
214468567|NCT05477056|OTHER|PrecivityAD blood test|Clinician Survey post receipt of PrecivityAD blood test result
214468568|NCT04606030|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
214468569|NCT04606030|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
214468570|NCT00291525|DEVICE|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
214468571|NCT00291525|DEVICE|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
214468572|NCT05050539|BEHAVIORAL|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
214468573|NCT05050539|BEHAVIORAL|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
214468574|NCT04376918|DEVICE|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
214468575|NCT04376918|DEVICE|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
214468576|NCT06217198|BEHAVIORAL|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
214468577|NCT05464056|BEHAVIORAL|Be Unstoppable in Life Together (BUILT)|Participants will complete weekly sleep, food, and exercise home challenges focused on creating sustainable healthy eating, sleep, and exercise routines. Parents will participate in weekly support calls by UIC and Chicago Park District staff to provide support and accountability. Children will have the opportunity to win small prizes based on completing weekly challenges. The intervention will be co-facilitated by UIC students and Chicago Park District staff and will largely take place on-line. For additional details visit: https://built.ahs.uic.edu.
214468578|NCT02470962|OTHER|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
214468579|NCT06614920|OTHER|Plant-Based Food Provision (with or without food prescription)|"Food Prescription: Participants will bring the food prescription obtained from the nutrition class to Village FREEdge, food pantry at the Freedom Lab, where it will function as a voucher. Each voucher will allow for participants to pick up enough plant-based food for 6 meals per person in their household (with household maximum of 5 people)(enough meals for 3 days- 2 meals per person per day). We expect that participants will pick up food twice per week from Village FREEdge to obtain enough meals to feed each participant's household for 6 days out of the week for up to 1 year.~Without food prescription: Participants will be given plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up) without the use of a food prescription."
214468580|NCT06614920|OTHER|Plant-Based Nutrition Education|"A once weekly classes for a 5-week nutrition course. The parents/guardians would bring their children and any additional household member(s) to the nutrition class, which will organize participants in different classrooms by age (children 4 years, 4-12 years old, 12-14 years old, 14+ years old). Each classrooms will engage in age-appropriate interactive nutrition-based activities. All children below 18 will engage in interactive activities for the full 1.5 hours. Adolescents aged 14 up will join the classroom with adults and listen to a 45 minute lecture and engage in a subsequent 45 minute interactive activity that incorporates content from the lecture. The interactive activities for the children range from creating a fruit and veggie Tik Tok song and performing it, drawing foods on a balanced plate, etc. The interactive activities for participants 14 year old and older range from discussions about fiber in diet, guided plant-based meal preparation, reading nutrition label etc."
214468581|NCT05338060|OTHER|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
214468582|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
214468583|NCT05636995|DIAGNOSTIC_TEST|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
214468584|NCT05204888|DEVICE|myAirvo3|For patients assigned to the HFNT intervention group, a myAirvo 3 device will be provided. The myAirvo 3 is for the treatment of spontaneously breathing patients, infant to adult, who would benefit from receiving high flow warmed and humidified respiratory gases. This includes patients who have had upper airways bypassed. The flow may be from 2 - 60 L/min depending on the patient interface. The myAirvo 3 is for patients in homes and long-term care facilities.
214468585|NCT05204888|DEVICE|Pulse oximeter|A pulse oximeter will be provided to measure heart rate and pulse oximetry; subjects will enter and transmit the data on the smartphone once daily before 11AM. Heart rate and pulse oximetry measures will be taken after wearing the device for approximately 2 minutes.
214468586|NCT06455527|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
214468587|NCT06455527|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
214468588|NCT03908697|DEVICE|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
214468589|NCT00559156|DIETARY_SUPPLEMENT|arginine/omega-3 fatty acids/nucleotides oral supplement|
214468590|NCT00559156|DRUG|cisplatin|
214468591|NCT00559156|PROCEDURE|adjuvant therapy|
214468592|NCT00559156|RADIATION|radiation therapy|
214468593|NCT05558384|BEHAVIORAL|Aerobic Exercise|"A 15-week standardized aerobic exercise intervention.~* Frequency: 5 days/wk (2 supervised)~* Intensity: 50-59% heart rate reserve~* Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~* Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)"
214468594|NCT05777070|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
214468595|NCT05027074|DRUG|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
214468596|NCT05027074|DRUG|Placebo|Normal saline administered via IV infusion
214468597|NCT06461455|DEVICE|Lehfilcon A multifocal for astigmatism contact lenses|Investigational multifocal contact lenses for astigmatism
214468598|NCT06461455|DEVICE|Samfilcon A multifocal for astigmatism contact lenses|Commercially available multifocal contact lenses for astigmatism
214468599|NCT06461455|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfection system
214468600|NCT05252416|DRUG|BLU-222|Oral administration
214468601|NCT05252416|DRUG|Carboplatin|IV Infusion
214468602|NCT05252416|DRUG|Ribociclib|Oral administration
214468603|NCT05252416|DRUG|Fulvestrant|Intra muscular administration
214468604|NCT05899439|OTHER|blood draw|a peripheral blood draw
214468605|NCT05580406|BEHAVIORAL|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
214468606|NCT06328036|BIOLOGICAL|Atezolizumab|Given IV
214468607|NCT06328036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214468608|NCT06328036|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214468609|NCT06328036|PROCEDURE|Surgical Procedure|Undergo surgical resection
214468610|NCT06328036|BIOLOGICAL|Tiragolumab|Given IV
214468611|NCT04580680|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
214468612|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
214468613|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
214468614|NCT04192435|DRUG|Tranexamic Acid|100mg/ml
214468615|NCT04192435|DRUG|Placebos|Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
214468616|NCT06175091|DEVICE|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
214468617|NCT06175091|DEVICE|restrictive alarm use strategy|more restrictive protocol for the use of alarms
214468618|NCT05263089|OTHER|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
214468619|NCT05263089|OTHER|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
214468620|NCT05924789|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214468621|NCT05553457|DEVICE|Testing of MyHand-SCI Device|Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
214468622|NCT05661448|BEHAVIORAL|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
214468623|NCT05661448|BEHAVIORAL|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
214468624|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
214468625|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
214468626|NCT05540288|DRUG|Nalmefene|"Week 1: 18 mg/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~2. In the presence of grade 3 ARs, 18 mg/d~3. In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
214468627|NCT05540288|DRUG|Placebo|"Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
214468628|NCT02724969|BEHAVIORAL|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
214468629|NCT05317078|DRUG|AMG 794|Short-term intravenous (IV) infusion.
214468630|NCT06798129|PROCEDURE|extracorporeal blood purification therpay|Extracorporeal blood purification therapy in this study includes intermittent hemodialysis (HD), continuous renal replacement therapy (CRRT), plasma exchange (PE), and hemoperfusion (HP).
214468631|NCT06799559|DRUG|3-6mg QLM1016|3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
214468632|NCT06799559|DRUG|10-20 mg Aripiprazole oral solution film|10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
214468633|NCT05121441|DRUG|ARD-101|Twice daily, oral administration
214468634|NCT05121441|DRUG|Placebo|Twice daily, oral administration
214468635|NCT06827808|OTHER|Team based learning|The intervention planned within the scope of the research is a team-based learning method. Students in the intervention group taking the nursing fundamentals course will be formed into small groups in the nursing skills laboratory. The groups will remain the same throughout the six modules. First, students will be asked to solve the iRAT multiple-choice question set prepared on the relevant module skill. Then, students will be provided with the skill repetition in the determined groups. Then, they will be asked to discuss until they reach a consensus as a group and solve the tRAT, which includes the same multiple-choice question set as the iRAT.
214468636|NCT04514471|OTHER|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
214468637|NCT04514471|OTHER|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
214468638|NCT06422689|DRUG|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
214468639|NCT06668441|DRUG|Minimally invasive surgery plus low-dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.001mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
214468640|NCT06668441|DRUG|Minimally invasive surgery plus medium dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.003mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
214468641|NCT06668441|DRUG|Minimally invasive surgery plus high dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.009mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
214468642|NCT05878431|OTHER|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
214468643|NCT04785131|OTHER|Prune|daily consumption of 50 grams prune.
214468644|NCT05809830|DRUG|LB-100 plus Doxorrubicin|In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin
214468645|NCT05809830|DRUG|Doxorubicin|The control arm in Phase II will be Doxorrubicin alone
214468646|NCT05688241|DRUG|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
214468647|NCT05479552|DIAGNOSTIC_TEST|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
214468648|NCT01387711|DRUG|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
214468649|NCT04564703|DRUG|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
214468650|NCT06587412|OTHER|Radial shock waves treatment|Subjects in this group will receive radial shock waves
214468651|NCT06587412|OTHER|Focal Shock Waves treatment|Subjects in this group will receive focal shock waves
214468652|NCT06587412|OTHER|shock waves placebo treatment|Subjects in this group will receive a shock waves placebo treatment with very low energy settings
214468653|NCT01309672|DRUG|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
214468654|NCT01309672|DRUG|Prednisone|5 mg, oral, 5 mg twice daily
214468655|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
214468656|NCT02336087|DRUG|Gemcitabine Hydrochloride|Given IV
214468657|NCT02336087|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214468658|NCT02336087|DRUG|Metformin Hydrochloride|Given PO
214468659|NCT02336087|DIETARY_SUPPLEMENT|Therapeutic Dietary Intervention|Given PO
214468660|NCT02336087|OTHER|Laboratory Biomarker Analysis|Correlative studies
214468661|NCT02336087|OTHER|Quality-of-Life Assessment|Ancillary studies
214468662|NCT05795400|DRUG|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
214468663|NCT05795400|DRUG|Placebo|tablet of placebo drug dosed once daily
214468664|NCT04965935|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
214468665|NCT04965935|DRUG|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
214468666|NCT06151106|DRUG|Chidamide combined with Duvillisib|Specified dose on specified days
214468667|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
214468668|NCT05757739|PROCEDURE|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
214468669|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
214468670|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
214468671|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
214468672|NCT02397954|DRUG|Avacincaptad Pegol|Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.
214468673|NCT06060522|DIAGNOSTIC_TEST|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
214468674|NCT03626220|OTHER|acupuncture|More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
214468675|NCT05835804|DRUG|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
214468676|NCT05574959|DEVICE|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
214468677|NCT05574959|DEVICE|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
214468678|NCT04289805|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
214468679|NCT04289805|OTHER|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
214468680|NCT03011372|DRUG|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
214468681|NCT06674473|DEVICE|With robot assistance|Use a portable isokinetic device
214468682|NCT06674473|BEHAVIORAL|traditional bodyweight rehabilitation|Use traditional bodyweight rehabilitation
214468683|NCT06999564|BEHAVIORAL|EFT|"EFT involves the following steps:~1. Identification of the problem that is causing the person distress (e.g., fear of childbirth) and scoring or measuring the severity of this problem.~2. Tapping with the fingertips on certain points of the face and body, known as correction (i.e., regulation of the energy system), as well as the expression of an emphatic phrase (related to the person\&amp;#39;s problem and self-acceptance)."
214468684|NCT06875934|DRUG|SHR-1139 Injection|SHR-1139 injection.
214468685|NCT06875934|DRUG|SHR-1139 Injection Placebo|SHR-1139 injection placebo.
214468686|NCT07045337|OTHER|Hybrid Bracing|Hybrid Bracing includes daytime Underarm Brace(UAB) and nighttime Lateral Bending Brace(LBB)
214468687|NCT07045337|OTHER|Conventional fulltime Underarm Bracing|Conventional group includes fulltime Underarm Brace (UAB) only.
214468688|NCT07064044|OTHER|Conventional Traetment|TENS applied for 10 minutes, Therapeutic ultrasound,Hip abductors and lateral rotators strengthening, Hamstring muscle passive stretching, Isometrics for quadriceps, given thrice a week for 4 weeks .
214468689|NCT07064044|OTHER|Muscle Energy Technique and Patellar Inferior Glide|Muscle Energy Technique for Hamstrings and Quadriceps While the patient contract muscle (Hamstring / Quadriceps) the therapist applies a gentle controlled force. After the contraction patient release and the therapist reposition the leg into a new barrier. Intensity of contraction will be 20-25-% of maximum strength. Each contraction will be held for 5-7 seconds, followed by additional passive stretching maintained for 30 and the relaxation patellar inferior glide applied at patella: the examiner applied a gentle downward force on the patella with their right hand, while the left hand controlled the direction of the patella's movement. This will be applied for 3-4 minutes as tolerated by the patient.
214468690|NCT07062991|OTHER|Kendall Exercises|Kendall exercises which includes: Chin tuck in supine Stretching the cervical extensors Shoulder retraction with theraband Stretching of the pectoralis major muscle Every strengthening exercise will be repeated for 12 repetitions and done for 3 sets and each stretching exercise will be hold for 30 seconds and repeated 3 times. The exercises will be performed three times per week for 4 weeks
214468691|NCT07062991|OTHER|Scapular stabilization exercises|Shoulder shrugs Prone arm lift Stretching of levator scapular Stretching pectoralis minor muscle Each strengthening exercise will be repeated for 15 repetitions of 3 sets and each stretching exercises will be hold for 30 seconds and repeated 3 times. The exercises will be performed three days per week for 4 weeks.
214468692|NCT07064213|BEHAVIORAL|Behavioral: Educational Video|Participants will watch a 2-minute educational video in Hebrew about perineal tears and episiotomy. The video includes information about types and grades of tears, risk factors, prevention strategies, episiotomy use, healing process, and when to seek help. The video is presented on a secure mobile device by the research team before the onset of active labor.
214468693|NCT07064421|DIAGNOSTIC_TEST|Magnetoencephalography plus Stereo-electroencephalography/Electrocorticography|Use Magnetoencephalography and Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
214468694|NCT07064421|DIAGNOSTIC_TEST|Stereo-electroencephalography/Electrocorticography|Use Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
214468695|NCT07064395|OTHER|bright light|Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.
214468696|NCT07063264|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
214468697|NCT07063264|DEVICE|sham high-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214468698|NCT06808256|PROCEDURE|the acupuncture therapy|Acupuncture is performed for 3 consecutive days, using filiform needles in the chest, hands, feet area with 20 minutes retention during therapy and using press needle on the forehead which are retained for 3 days and after 3 days the stick needles will be removed. And patient continue to receive standard therapy in accordance with the clinical practice guidelines of the ICU Tangerang Hospital
214468699|NCT06808256|OTHER|Standard therapy|Pharmacological therapy provided by the doctor in charge of anesthesia science patients to the research subjects was in accordance with existing clinical practice guidelines. In the ICU of Tangerang Hospital, the standard therapy given to post-craniotomy patients with mechanical ventilation is analgesic and sedation. This standard therapy is also given according to the patient's clinical condition
214468700|NCT03916978|BIOLOGICAL|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
214468701|NCT03916978|BIOLOGICAL|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
214468702|NCT05079698|DRUG|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
214468703|NCT05079698|PROCEDURE|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
214468704|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
214468705|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
214468706|NCT05763719|BEHAVIORAL|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
214468707|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
214468708|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
214468709|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
214468710|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
214468711|NCT05412771|PROCEDURE|Hysteroscopy|Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes
214468712|NCT05840315|DIETARY_SUPPLEMENT|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
214468713|NCT05840315|PROCEDURE|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
214468714|NCT05840315|PROCEDURE|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
214468715|NCT05840315|PROCEDURE|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trial 1, Third subtrial will perform progressive strength training for the gluteal muscles is carried out in form of hip abduction, using rubber bands, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press.~Hip abduction will be performed from a standing position with a straight arm length from a wall, supporting the wall. The participant will be instructed to abduct the hip facing the wall until the foot is in contact with the wall, and then back until it touches the standing leg.~Progression will be placing a rubber band just proximal to the knee with resistances being: yellow= light, red= moderate, blue= heavy.~further progression will be placing the rubber band around the ankles using the same progression as above."
214468716|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
214468717|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
214468718|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
214468719|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
214468720|NCT03571763|OTHER|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
214468721|NCT00513760|DIETARY_SUPPLEMENT|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
214468722|NCT00513760|DIETARY_SUPPLEMENT|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
214468723|NCT00513760|DIETARY_SUPPLEMENT|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
214468724|NCT06057454|DRUG|R-5280|Modified Superior Starch
214468725|NCT06057454|OTHER|Placebo|Food Grade Starch
214468726|NCT04145622|DRUG|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
214468727|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
214468728|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
214468729|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
214468730|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
214468731|NCT03832569|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
214468732|NCT05593900|BEHAVIORAL|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
214468733|NCT05816603|DEVICE|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
214468734|NCT05816603|DEVICE|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
214468735|NCT05422638|BEHAVIORAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
214468736|NCT05422638|BEHAVIORAL|PCT|8-week health promotion group focused on providing support and facilitating problem solving
214468737|NCT05312008|DRUG|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
214468738|NCT05312008|DRUG|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
214468739|NCT05128942|DRUG|Tildacerfont|Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
214468740|NCT06134752|OTHER|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
214468741|NCT06134752|OTHER|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
214468742|NCT06246799|DRUG|Tirzepatide|Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
214468743|NCT06246799|DRUG|Pioglitazone|Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
214468744|NCT06246799|DRUG|Sitagliptin|Sitagliptin: will be administered as a 100mg dose once daily.
214468745|NCT06246799|DRUG|Metformin HCI XR|Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
214468746|NCT00206791|DEVICE|MBCP-Gel (tm)|MBCPGel 5ml
214468747|NCT00206791|DEVICE|MBCP Gel|MBCPGel 5ML
214468748|NCT05043714|BIOLOGICAL|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
214468749|NCT06469788|BEHAVIORAL|Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences|Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD
214468750|NCT06469788|BEHAVIORAL|Video on the importance of good oral health for patients with AIRD|Participants will watch video on the importance of good oral health in AIRD patients.
214468751|NCT06469788|BEHAVIORAL|Brochure on COVID-19 vaccination in AIRD patients|Participants
214468752|NCT06469788|BEHAVIORAL|Patient Navigation|Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD
214468753|NCT06469788|BEHAVIORAL|Brochure on the importance of good oral health in AIRD patients|Participants will receive a brochure on the importance of good oral health in AIRD patients.
214468754|NCT04846933|GENETIC|WGS and RNA sequencing|
214468755|NCT04846933|GENETIC|circulating tumor DNA (ctDNA)|
214468756|NCT04846933|DIAGNOSTIC_TEST|FDG PET/CT imaging|
214468757|NCT01903330|DRUG|ERC1671|Given intradermally
214468758|NCT01903330|DRUG|GM-CSF|Given intradermally
214468759|NCT01903330|DRUG|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
214468760|NCT01903330|DRUG|Oral Control (Sucrose pill)|Given PO
214468761|NCT01903330|DRUG|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
214468762|NCT01903330|DRUG|Bevacizumab/Bevacizumab Biosimilar|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
214468763|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
214468764|NCT06466915|DRUG|Dexmedetomidine|Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
214468765|NCT06466915|DRUG|Propofol|Group Pofol received 1 mg/kg propofol IV before the extubation.
214468766|NCT05745727|DRUG|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
214468767|NCT05745727|DRUG|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
214468768|NCT06261021|DRUG|Ruxolitinib 1.5% cream|Topical application of Ruxolitinib 1.5% cream
214468769|NCT06261021|PROCEDURE|Application without occlusion in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
214468770|NCT06261021|PROCEDURE|Application under occlusion at night in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
214468771|NCT06261021|PROCEDURE|Application under occlusion at night in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
214468772|NCT06261021|PROCEDURE|Application without occlusion in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
214468773|NCT04271436|DEVICE|FDG PET/CT|A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.
214468774|NCT04271436|DEVICE|FLT PET/CT|. A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
214468775|NCT04271436|DEVICE|PET/MR|MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
214468776|NCT04271436|DRUG|[F-18] flurothymidine|-Radiopharmaceutical
214468777|NCT04018053|DRUG|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
214468778|NCT04018053|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
214468779|NCT04283149|DEVICE|EVO/EVO+ Visian ICL|The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
214468780|NCT02859038|PROCEDURE|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
214468781|NCT02859038|PROCEDURE|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
214468782|NCT05693675|DRUG|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
214468783|NCT05693675|DRUG|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
214468784|NCT05693675|DRUG|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
214468785|NCT06260254|RADIATION|Railway noise|Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.
214468786|NCT06260254|RADIATION|Low level railway vibration|36 single railway noise events at 0.5 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
214468787|NCT06260254|RADIATION|Intermediate level railway vibration|36 single railway noise events at 0.7 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
214468788|NCT06260254|RADIATION|High level railway vibration|36 single railway noise events at 0.9 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
214468789|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
214468790|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
214468791|NCT03982459|BEHAVIORAL|Decision support tool|Internet-Based, interactive decision support tool
214468792|NCT04061148|DEVICE|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
214468793|NCT03780829|BEHAVIORAL|hypoxia|intermittent cycles of normoxia-hypoxia
214468794|NCT03780829|BEHAVIORAL|sham hypoxia|intermittent cycles of sham hypoxia
214468795|NCT03780829|DRUG|D-cycloserine|NMDA agonist treatment
214468796|NCT03780829|DRUG|sham-NMDA agonist|sham-NMDA agonist treatment
214468797|NCT03780829|BEHAVIORAL|exercise training|bimanual massed practice training
214468798|NCT06572150|PROCEDURE|Deep Brain Stimulation - Minimal Electrophysiology|Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.
214468799|NCT06572150|PROCEDURE|Deep Brain Stimulation - Standard|Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
214468800|NCT05979831|DRUG|DS-2325a|Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses
214468801|NCT05979831|OTHER|Placebo|Main Phase: IV infusion followed by SC doses
214468802|NCT03738852|DEVICE|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
214468803|NCT03738852|DRUG|Insulin|standard insulin regimen
214468804|NCT01849146|DRUG|Adavosertib|Given PO
214468805|NCT01849146|RADIATION|Radiation Therapy|Undergo radiation therapy
214468806|NCT01849146|DRUG|Temozolomide|Given PO
214468807|NCT06821685|BIOLOGICAL|autologous decidual-like NK cells|intrauterine infusion
214468808|NCT06617715|BIOLOGICAL|Sinovac PCV13|One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
214468809|NCT06617715|BIOLOGICAL|Prevnar®|One dose of Prevnar® (0.5 mL) is administered intramuscularly.
214468810|NCT06818994|DRUG|Psilocybin-assisted Psychotherapy|The intervention will be psilocybin-assisted psychotherapy. The first treatment period will include four preparation sessions with Managing Cancer and Living Meaningfully (CALM) therapy elements. The psilocybin dosing session will take place after these preparation sessions are completed. The dosing session will include an in-person visit lasting approximately 8 hours in which the participant will receive a capsule of psilocybin 25 mg under constant supervision of therapists. The following day, the first integration session will take place and two weeks later the second integration session along with CALM will be conducted. Participants who show a partial response will be offered a second dosing session, entering the second treatment period. The second treatment period includes a second dosing session using the same dose and safety measures as the first one. It will also be followed by an integration session the following day, and a second integration session with CALM two weeks later.
214468811|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
214468812|NCT06822686|DEVICE|Harvest and injection of stem cells|Stem cells will be harvested from bone marrow aspirate and injected into the fistula tract The stem cells are the device intervention for this trial and we are looking to assess the procedure of harvesting and injecting the stem cells Patients will undergo study questionnaire: Harvey-Bradshaw Index, perianal Crohn's disease activity index, and Short IBD questionnaire will be administered before surgery and then at 6 weeks, 3 and 6 months after stem cell intervention.
214468813|NCT04474834|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40 %).
214468814|NCT05056350|OTHER|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
214468815|NCT05056350|OTHER|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
214468816|NCT06778460|DRUG|Esketamine-lidocaine group|In the esketamine-lidocaine group, patients received esketamine (0.25 mg/kg) and lidocaine (1.5 mg/kg) at the induction of anesthesia, followed by the continuous infusion of esketamine (0.02 mg/kg∙h) and lidocaine (1.5 mg/kg∙h) until the end of surgery. Postoperatively, the patients received two pumps. One pump delivered a fixed-rate infusion of lidocaine at 1.0 mg.kg-1.h-1 and esketamine at 0.02 mg.kg-1.h-1 infusion for 72 hours. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
214468817|NCT06778460|OTHER|Placebo group|In the conventional analgesia group, patients received the same volume of normal saline instead of lidocaine and esketamine until the end of surgery. Postoperatively, the paitents received two pumps. One pump was the same volume of normal saline instead of lidocaine and esketamine. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
214468818|NCT03746964|PROCEDURE|Cardiac MRI|Preoperative cardiac MRI
214468819|NCT03746964|OTHER|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
214468820|NCT05698290|OTHER|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
214468821|NCT04046861|DIETARY_SUPPLEMENT|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
214468822|NCT04046861|OTHER|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
214468823|NCT04942613|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
214468824|NCT04942613|OTHER|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
214468825|NCT04942613|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
214468826|NCT04942613|OTHER|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
214468827|NCT05668260|DEVICE|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
214468828|NCT02570373|DRUG|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
214468829|NCT05235113|DEVICE|Tele-Exergame Platform|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
214468830|NCT05235113|DEVICE|No Tele-Exergame Platform|Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
214468831|NCT05060315|COMBINATION_PRODUCT|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
214468832|NCT06364631|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
214468833|NCT06364631|DRUG|Ipilimumab|"The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle."
214468834|NCT06364631|DRUG|Pembrolizumab|Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
214468835|NCT06364631|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
214468836|NCT06364631|DRUG|Axitinib|Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
214468837|NCT06364631|DRUG|Lenvatinib|Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
214468838|NCT06525571|DRUG|Cysview|Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
214468839|NCT06525571|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
214468840|NCT05297773|BEHAVIORAL|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to 80% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
214468841|NCT05297773|BEHAVIORAL|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
214468842|NCT05297773|OTHER|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
214468843|NCT06555484|DEVICE|Cross Over Assignment Supplemental Oxygen and Supplemental Air|"Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned)."
214468844|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
214468845|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
214468846|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214468847|NCT04934527|DRUG|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
214468848|NCT05347745|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
214468849|NCT06530277|BEHAVIORAL|REMINDer (A digital environmental enrichment intervention)|"REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3."
214468850|NCT03670524|OTHER|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
214468851|NCT06252597|BEHAVIORAL|education and training|education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training
214468852|NCT03344848|DEVICE|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
214468853|NCT06106607|BEHAVIORAL|Intervention group|"A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises."
214468854|NCT05706857|BEHAVIORAL|Ultra Fast-track|Patients are extubated in the operating room
214468855|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
214468856|NCT03928093|DRUG|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
214468857|NCT06851715|OTHER|Clinic consultation focused on asthma self-management|The clinic healthcare professionals (HCPs) will be provided with the completed Adolescent Asthma Self-efficacy Questionnaire (AASEQ), which will help identify areas where participants need additional support to improve their asthma self-management skills. Targeted behavioural interventions, developed during the 'ItsMyAsthma' study, will be applied during the clinic consultation to address individual needs.
214468858|NCT05452564|DRUG|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
214468859|NCT05452564|DRUG|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
214468860|NCT05299671|BEHAVIORAL|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
214468861|NCT06828393|DRUG|S-1117|S-1117 via subcutaneous or intravenous administration.
214468862|NCT06828393|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
214468863|NCT04263181|PROCEDURE|Peripheral blood draw|"* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
214468864|NCT04263181|PROCEDURE|Bone marrow aspirate|"* Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
214468865|NCT04263181|PROCEDURE|Buccal swab|"* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
214468866|NCT03626597|DIAGNOSTIC_TEST|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
214468867|NCT03626597|BEHAVIORAL|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling \& referral to care
214468868|NCT03626597|BEHAVIORAL|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
214468869|NCT06844006|COMBINATION_PRODUCT|Nudging|Clinicians will be nudged with a prompt, based on remote monitoring data, current medication data, contraindications, in the electronic patient dossier whether further optimization to guideline directed medical therapy (GDMT) is possible.
214468870|NCT06852339|BEHAVIORAL|EAPOC-COPD|The EAPOC-COPD system consists of: 1) a smart phone / tablet app or Personal Computer-based questionnaire which collects information directly from patients upon prompting, up to 1 week before their clinical appointment; and 2) a point-of-care clinical decision support system that wirelessly receives and processes questionnaire data in order to produce a symptom severity/exacerbation risk assessment, medication change recommendation, and COPD action plan, all of which is made available to providers through a prompt, upon opening the patient chart in the existing EMR. Once approved, the personalized COPD action plan is automatically populated within the patient app/portal, enabling anywhere/anytime access for patients. Patients are also provided with educational resources within their app/portal, designed to improve health literacy, inhaler technique, and adherence to their action plan
214468871|NCT06852339|OTHER|Usual Care|Usual care
214468872|NCT06851624|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
214468873|NCT06852703|OTHER|Infection during pregnancy|any bacterial or viral infection acquired during pregnancy
214468875|NCT05773859|BIOLOGICAL|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
214468876|NCT02593773|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
214468877|NCT06853028|OTHER|ultrasound measurement|Muscle thickness measurements were performed with the ultrasound device immediately before root canal treatment, 1 week after, and 3 months after the treatment.
214468878|NCT04982419|DEVICE|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
214468879|NCT04982419|DEVICE|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
214468880|NCT05446129|DRUG|Ezabenlimab|Ezabenlimab
214468881|NCT05446129|DRUG|BI 765063|BI 765063
214468882|NCT05446129|DRUG|Pembrolizumab|Pembrolizumab
214468883|NCT05049850|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
214468884|NCT04943588|DIAGNOSTIC_TEST|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
214468885|NCT04943588|DIAGNOSTIC_TEST|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
214468886|NCT04943588|DIAGNOSTIC_TEST|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
214468887|NCT05381103|DIAGNOSTIC_TEST|PSMA-PET and SOC MRI|60 min continuous acquisition of PET data after 3-6 mCI injection of \[68Ga\]P16-093 followed by contrast-CT
214468888|NCT05381103|DIAGNOSTIC_TEST|SOC MRI|Standard of care MRI
214468889|NCT06012487|DRUG|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
214468890|NCT05227742|DRUG|Psilocybin|Participants will receive oral psilocybin once per week for 5 weeks.
214468891|NCT05227742|DRUG|Placebo|Participants will receive inert placebo once per week for 5 weeks.
214468892|NCT06258174|DRUG|Pirtobrutinib|Administered orally.
214468895|NCT04178798|DRUG|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
214468896|NCT05224154|BEHAVIORAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
214468897|NCT05224154|BEHAVIORAL|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
214468898|NCT05934942|DRUG|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
214468899|NCT05934942|DRUG|BI 1358894|BI 1358894
214468900|NCT05815147|DIETARY_SUPPLEMENT|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
214468901|NCT06087588|DRUG|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
214468902|NCT06087588|DRUG|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
214468903|NCT05719584|OTHER|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
214468904|NCT05719584|OTHER|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
214468905|NCT06187584|DRUG|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
214468906|NCT06187584|DRUG|Acetaminophen|15mg/kg PO q6 hours
214468907|NCT06187584|DRUG|Ibuprofen|10mg/kg PO q6 hours
214468908|NCT05907434|DIAGNOSTIC_TEST|Nephrocheck (AKI score)|Early biomarker of AKI
214468909|NCT04533763|BEHAVIORAL|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
214468910|NCT04533763|BEHAVIORAL|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
214468911|NCT06308510|OTHER|collection additional peritoneal lavage fluid|collection additional peritoneal lavage fluid
214468912|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
214468913|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
214468914|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
214468915|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
214468916|NCT04471246|DRUG|Cephalexin|1000 mg PO QID for 7 days
214468917|NCT04471246|DRUG|Cephalexin + placebo|500 mg PO QID plus oral placebo for 7 days
214468918|NCT05591131|OTHER|genetic testing|Undergo genetic testing
214468919|NCT05591131|OTHER|Survey Administration|Complete survey
214468920|NCT06378151|OTHER|TLT training|"Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed."
214468921|NCT06299410|DRUG|ITI-1284 10 mg|ITI-1284 tablet
214468922|NCT06299410|DRUG|ITI-1284 20 mg|ITI-1284 tablet
214468923|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
214468924|NCT06180759|DRUG|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
214468925|NCT06180759|DRUG|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
214468926|NCT06180759|DRUG|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
214468927|NCT06038552|DRUG|imatinib (IM)|Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
214468928|NCT06038552|PROCEDURE|hepatic resection (HR)|HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
214468929|NCT06038552|PROCEDURE|radiofrequency ablation (RFA)|RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
214468930|NCT06038552|PROCEDURE|transarterial chemoembolization (TACE)|TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
214468931|NCT03386578|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
214468932|NCT03386578|BEHAVIORAL|Behavioral HIV risk reduction package|Included cohort-appropriate SMS messages.
214468933|NCT03386578|BEHAVIORAL|Enhanced adherence support|Included two-way SMS messaging and tailored counseling with drug level feedback.
214468934|NCT05902598|DRUG|VSA001 injection|also referred to as ARO-APOC3
214468935|NCT05902598|DRUG|Placebo|Matching VSA001 injection
214468936|NCT05907174|BEHAVIORAL|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
214468937|NCT05737303|DRUG|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
214468938|NCT04169893|DRUG|Placebo (fasting)|Participants will receive placebo once in fasting condition
214468939|NCT04169893|DRUG|Placebo (feeding)|Participants will receive placebo once after meal condition
214468940|NCT04169893|DRUG|1 mg of TS-142|Participants will receive 1 mg of TS-142 once in fasting condition
214468941|NCT04169893|DRUG|3 mg of TS-142|Participants will receive 3 mg of TS-142 once in fasting condition
214468942|NCT04169893|DRUG|10 mg of TS-142 (fasting)|Participants will receive 10 mg of TS-142 once in fasting condition
214468943|NCT04169893|DRUG|10 mg of TS-142 (feeding)|Participants will receive 10 mg of TS-142 once after meal condition
214468944|NCT04169893|DRUG|30 mg of TS-142|Participants will receive 30 mg of TS-142 once in fasting condition
214468945|NCT03916276|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
214468946|NCT03916276|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
214468947|NCT03916276|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
214468948|NCT05370079|BIOLOGICAL|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
214468949|NCT06568081|OTHER|SloMo|SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
214468950|NCT05454839|OTHER|Survey|Interviewer-administered survey
214468951|NCT05454839|OTHER|Focus group|Focus group for selected participants
214468952|NCT03299959|DEVICE|Agili-C implant|Agili-C implant
214468953|NCT03299959|PROCEDURE|SSOC|microfracture and/or debridement
214468954|NCT04844866|GENETIC|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
214468955|NCT04844866|DRUG|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
214468956|NCT06540651|OTHER|use of Luminettes ® with active light emission|Spectrum of 400 \< X \< 750 nm assumed active
214468957|NCT06540651|OTHER|use of Luminettes ® with a light emission presumed to have no therapeutic effect|Modification of spectrum parameters for wavelengths covered, with light emission in a spectrum of 560 \< X \< 650 nm assumed to have no therapeutic effect
214468958|NCT05069168|DIAGNOSTIC_TEST|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
214468959|NCT02668692|DRUG|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
214468960|NCT02668692|DRUG|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
214468961|NCT03562832|DRUG|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
214468962|NCT04432506|BIOLOGICAL|Anakinra|Given SC
214468963|NCT04432506|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
214468964|NCT04432506|DRUG|Cyclophosphamide|Given IV
214468965|NCT04432506|DRUG|Fludarabine|Given IV
214468966|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
214468967|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
214468968|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
214468969|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
214468970|NCT04986423|DRUG|ZEN003694|72 mg PO QD
214468971|NCT04986423|DRUG|Enzalutamide|160 mg PO QD
214468972|NCT06459843|OTHER|pursed lip breathing techniques|Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
214468973|NCT06459843|OTHER|coordinated breathing technique|Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
214468974|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
214468975|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
214468976|NCT01585805|PROCEDURE|Biopsy|Undergo biopsy
214468977|NCT01585805|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
214468978|NCT01585805|DRUG|Cisplatin|Given IV
214468979|NCT01585805|PROCEDURE|Computed Tomography|Undergo CT
214468980|NCT01585805|DRUG|Gemcitabine|Given IV
214468981|NCT01585805|DRUG|Gemcitabine Hydrochloride|Given IV
214468982|NCT01585805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214468983|NCT01585805|DRUG|Veliparib|Given PO
214468984|NCT06536387|BEHAVIORAL|Storytelling Through Music|Storytelling Through Music is a six-week intervention that combines storytelling, reflective writing, song-writing, and self-care skills to improve emotion regulation through affective and cognitive coping skills.
214468985|NCT03514069|DRUG|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
214468986|NCT03514069|RADIATION|radiation|60gy for 6 weeks
214468987|NCT03514069|DRUG|temozolomide|75mg/m2
214468988|NCT04567238|BEHAVIORAL|Mobile contingency management|Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
214468989|NCT06554912|PROCEDURE|Lymphatic Decompression|"Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures"
214468990|NCT04290806|OTHER|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
214468991|NCT06345066|DRUG|Tirzepatide|Administered SC.
214468992|NCT06345066|DRUG|LY3841136|Administered SC.
214468993|NCT06345066|DRUG|Placebo|Administered SC.
214468994|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
214468995|NCT04631744|DRUG|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
214468996|NCT04889495|DRUG|Zirabev|Bevacizumab biosimilar
214468997|NCT05162547|DEVICE|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
214468998|NCT06304428|OTHER|Deprescribing Care Model|The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
214468999|NCT06304428|OTHER|Bone Health Service Model|The Bone Health Service Model is designed to provide osteoporosis evaluation and management
214469000|NCT06304428|OTHER|Injury Prevention Service Model|The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
214469001|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
214469002|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
214469003|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
214469004|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
214469005|NCT05832190|OTHER|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
214469006|NCT05832190|DIETARY_SUPPLEMENT|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
214469007|NCT05832190|DIETARY_SUPPLEMENT|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
214469008|NCT01627574|BEHAVIORAL|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
214469009|NCT01627574|BEHAVIORAL|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
214469010|NCT06552728|OTHER|Energy Healing|EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
214469011|NCT03048331|DEVICE|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
214469012|NCT04721041|OTHER|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension delivered through mid-gut and lower-gut
214469013|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive dietary counseling
214469014|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive guidelines for low-fat diet
214469015|NCT02176902|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
214469016|NCT02176902|OTHER|laboratory biomarker analysis|Correlative studies
214469017|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
214469018|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
214469019|NCT03528928|DEVICE|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
214469020|NCT06282523|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
214469021|NCT06282523|BEHAVIORAL|HMRP web app|The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
214469022|NCT06105567|BEHAVIORAL|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
214469023|NCT05758493|DIAGNOSTIC_TEST|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
214469024|NCT05418998|BEHAVIORAL|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
214469025|NCT04039581|OTHER|Kinesio Taping|Kinesio Taping (Space Correction).
214469026|NCT04039581|OTHER|Conventional treatment|Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
214469027|NCT06429527|BEHAVIORAL|WHOeyes combined with a questionnaire.|The WHOeyes app (a self-administered visual acuity testing app) plus a questionnaire (to ask the patients to go to the hospital if they ever experience ocular discomfort including eye redness, discharge, etc.) will be used for 1-week follow-up after cataract surgery, and only those with significant vision loss based on WHOeye test or with ocular discomfort are advised to return to the hospital for follow-up.
214469028|NCT04142606|OTHER|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
214469029|NCT05233800|BEHAVIORAL|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
214469030|NCT05233800|BEHAVIORAL|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
214469031|NCT06218485|PROCEDURE|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
214469032|NCT06218485|PROCEDURE|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05"
214469033|NCT06313489|PROCEDURE|Biopsy of EPL tendon and muscle during the operation|Biopsy of EPL tendon and muscle
214469034|NCT06384222|DRUG|Abiraterone acetate|Given orally
214469035|NCT06384222|DRUG|Prednisone|Given orally
214469036|NCT06384222|DRUG|Hyperpolarized [1-13C] pyruvate (HP 13C)|Given IV
214469037|NCT06384222|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
214469038|NCT06384222|PROCEDURE|Non-investigational radical prostatectomy (RP)|Planned, standard of care surgical procedure occurring outside of this study.
214469039|NCT06384222|PROCEDURE|Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)|Imaging procedure
214469040|NCT06373601|DEVICE|sirolimus-eluting balloon (Selution)|PCI treatment with DCB, in particular sirolimus coated balloon
214469041|NCT06373601|DEVICE|paclitaxel-eluting balloon (SeQuent Please Neo)|PCI treatment with DCB, in particular paclitaxel coated balloon
214469042|NCT04511364|OTHER|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
214469043|NCT06354712|DRUG|N-Acetyl-Cysteine with Institutional standard care|A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
214469044|NCT06354712|DRUG|Institutional standard care|Benzydamine Mouthwash
214469045|NCT05096338|OTHER|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
214469046|NCT06066983|BEHAVIORAL|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
214469047|NCT06066983|OTHER|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
214469048|NCT03307863|DRUG|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
214469049|NCT03307863|DRUG|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
214469050|NCT03307863|DRUG|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
214469051|NCT05393388|DRUG|[18F]AV-1451|\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
214469052|NCT06504628|DIAGNOSTIC_TEST|screening risk for falling and identifiy the risk level low-intermediate-high|"3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk"
214469053|NCT06504628|DIAGNOSTIC_TEST|3 mnth-follow-up|patient's phone call, and data collected from electronic medical record
214469054|NCT06543368|BIOLOGICAL|Intra articular PRP Injection|A total of 20 joints (estimated 10-15 patients) will receive injections, performed at day 0 and 3 weeks, for a total of two injections - two injections have demonstrated superior outcomes to one, and will increase our number of injections to improve the proof of feasibility. All subjects will receive ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort.
214469055|NCT02328599|PROCEDURE|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
214469056|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
214469057|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
214469058|NCT06318182|OTHER|Education|Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
214469059|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
214469060|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
214469061|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
214469062|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
214469063|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
214469064|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
214469065|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
214469066|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
214469067|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
214469068|NCT05590728|DRUG|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
214469069|NCT04567537|DEVICE|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
214469070|NCT02852213|DRUG|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
214469071|NCT03734679|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
214469072|NCT06526754|DEVICE|3D-Printed Liver Model|Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.
214469073|NCT06526754|PROCEDURE|Digital Simulation-Based Surgical Planning|Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
214469074|NCT04339101|DRUG|Fludarabine|Given via infusion
214469075|NCT04339101|DRUG|Itacitinib Adipate|Given PO
214469076|NCT04339101|DRUG|Melphalan|Given IV
214469077|NCT04339101|OTHER|Quality-of-Life Assessment|Ancillary studies
214469078|NCT04339101|OTHER|Questionnaire Administration|Ancillary studies
214469079|NCT04339101|DRUG|Sirolimus|Given PO
214469080|NCT04339101|DRUG|Tacrolimus|Given IV or PO
214469081|NCT06522919|BIOLOGICAL|Autologous Dendritic Cell (DC) Vaccine|Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
214469082|NCT02810197|BEHAVIORAL|Psychopathological assessment|
214469083|NCT02810197|BEHAVIORAL|Neuropsychological assessment|
214469084|NCT02810197|DEVICE|Functional magnetic resonance imaging (fMRI)|
214469085|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
214469086|NCT05772104|DRUG|Shugan Jieyu Capsules Placebo|"Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
214469087|NCT03249090|OTHER|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
214469088|NCT03249090|OTHER|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
214469089|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris)|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
214469090|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
214469091|NCT05336201|BEHAVIORAL|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
214469092|NCT02432261|DRUG|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
214469093|NCT02432261|DRUG|Testosterone only gel|Testosterone only gel
214469094|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after photorefractive keratectomy (PRK)
214469095|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after photorefractive keratectomy (PRK)
214469096|NCT02260557|DRUG|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
214469097|NCT02260557|DRUG|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
214469098|NCT05756088|DIAGNOSTIC_TEST|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
214469099|NCT06849492|DRUG|Camrelizumab|PD-1 inhibitor
214469100|NCT06849492|DRUG|Nab-paclitaxel|chemotherapy
214469101|NCT06849492|DRUG|SKB264|Trop2-ADC
214469102|NCT06849492|DRUG|Lenvatinib|Anti-angiogenic TKI
214469103|NCT06786611|DIAGNOSTIC_TEST|MRI|Based on the different manifestations of facet joints under MRI, and with the help of the characteristic manifestations of the gray value curve of facet joints under different subtypes, the curve of facet joints under the same level is fitted, and finally the accurate evaluation of different subtypes of small joints is achieved.
214469104|NCT06250608|DEVICE|Pulse oximeter, NIRSITX|It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
214469105|NCT06849232|PROCEDURE|Platelet-Rich Plasma (PRP) Injections|wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly
214469106|NCT06544187|DIAGNOSTIC_TEST|MRS scan|Magnetic Resonance Spectroscopy scan on the thigh
214469107|NCT06544187|DIAGNOSTIC_TEST|CPET|Cardiopulmonary Exercise Test
214469108|NCT04200911|DRUG|Rapamune|Sirolimus 1mg capsules
214469109|NCT06851000|PROCEDURE|ultrasound-guided pulsed radiofrequency|Medication: 0-3months; Pulsed radiofrequency: week 2, 6, 10;
214469110|NCT06851000|PROCEDURE|ultrasound-guided dry needling|Medication: 0-3 months; Dry needling: week 2; Pulsed radiofrequency: week 6, 10;
214469111|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
214469112|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
214469113|NCT04166526|DEVICE|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
214469114|NCT04166526|DEVICE|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
214469115|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
214469116|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
214469117|NCT06565624|PROCEDURE|Cotton Swab Nasal Stimulation|Nostril probing for the purpose of producing reflex tearing
214469118|NCT06844448|PROCEDURE|with Biodentine|After the bleeding has stopped, the cavity is flushed with sterile saline and Biodentine (Septodont, Saint-Maur-des-Fossés, France) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and then the entire cavity is filled with it. One week later the superficial 2-3 mm is removed and replaced it with permanent restoration.
214469119|NCT06844448|PROCEDURE|with MTA|After the bleeding has stopped, the cavity is flushed with sterile saline and MTA+ (Cercamed, Stalowa Wola, Poland) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and after its initial setting the cavity is filled with glass ionomer cement. One week later the glass ionomer cement is removed and replaced it with permanent restoration.
214469120|NCT00179855|PROCEDURE|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
214469121|NCT03807414|DEVICE|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
214469122|NCT05826496|OTHER|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
214469123|NCT03978078|OTHER|Biological collection|\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
214469124|NCT04575688|DRUG|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
214469125|NCT04575688|DRUG|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
214469126|NCT04387305|DRUG|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
214469127|NCT04103567|OTHER|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
214469128|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214469129|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
214469130|NCT04834297|OTHER|Prapela SVS mattress|The intervention will be using the Prapela SVS crib mattress to complement non-pharmacological management of NOWS for the purposes of prevention of pharmacological treatment of NOWS
214469131|NCT06418191|PROCEDURE|Acupressure|Acupressure is a technique that involves applying pressure to specific points on the body. It is based on the same principles as acupuncture but uses pressure from fingers, palms, elbows, or specialized devices instead of needles.
214469132|NCT05963880|DEVICE|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
214469133|NCT05529901|DEVICE|GORE® CARDIOFORM Septal Occluder|Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study
214469134|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
214469135|NCT04134208|PROCEDURE|Computed Tomography|Undergo PET-CT scan
214469136|NCT04134208|DRUG|Fluciclovine F18|Given IV
214469137|NCT04134208|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
214469138|NCT06642090|BEHAVIORAL|Educational intervention for patients undergoing hemodialysis in Morocco|This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
214469139|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
214469140|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
214469141|NCT04160832|GENETIC|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
214469142|NCT06099743|BEHAVIORAL|Psychosocial intervention|Intervention manual and six one-on-one coaching sessions.
214469143|NCT06099743|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.
214469144|NCT06495593|DRUG|Ocrelizumab|Standard ocrelizumab dosing
214469145|NCT04726371|BEHAVIORAL|Generic Best Practices|GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy.
214469146|NCT04726371|BEHAVIORAL|Tailored Best Practices|TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization.
214469147|NCT02901977|DRUG|Ramipril|Antihypertensive therapy
214469148|NCT02901977|DRUG|Doxazosin|Antihypertensive therapy
214469149|NCT04490616|OTHER|rTMS treatment|"A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation."
214469150|NCT05061745|DEVICE|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
214469151|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
214469152|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
214469153|NCT05432583|BIOLOGICAL|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
214469154|NCT05432583|OTHER|Placebo|Placebo
214469155|NCT05903547|DEVICE|Dermabond Prineo|For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
214469156|NCT05903547|OTHER|Suture|For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
214469157|NCT03324477|DRUG|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
214469158|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
214469159|NCT04450953|DRUG|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
214469160|NCT04450953|OTHER|Period without eplerenone (cross over design)|6-month period without eplerenone
214469161|NCT06803810|BEHAVIORAL|P2P Intervention|This group will complete the same study visits as the standard care group with an additional week 3 visit and 6 CPSS-led therapy intervention sessions. These CPSS led sessions will be completed by the end of the 12week study period. At each study visit you will complete questionnaires.
214469162|NCT03866668|DRUG|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
214469163|NCT06222710|PROCEDURE|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
214469164|NCT06222710|PROCEDURE|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
214469165|NCT06306625|DEVICE|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.
214469166|NCT06306625|DEVICE|No remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
214469167|NCT05837286|DEVICE|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
214469168|NCT05837286|OTHER|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
214469169|NCT03662386|PROCEDURE|OCT-A|Optical coherence tomography angiography (OCT-A)
214469170|NCT03662386|PROCEDURE|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
214469171|NCT03362476|BEHAVIORAL|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
214469172|NCT03362476|BEHAVIORAL|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
214469173|NCT03362476|BEHAVIORAL|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
214469174|NCT05711082|OTHER|Précurseur de la dopamine|"In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house."
214469175|NCT05711082|OTHER|antagoniste D2|In the second condition, volunteers will receive Sulpiride 800 mg
214469176|NCT05711082|OTHER|PLACEBO|In the third condition, volunteers will receive placebo
214469177|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
214469178|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
214469179|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
214469180|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
214469181|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine RDE 100 μg|CVGBM will be administered as an IM injection.
214469182|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
214469183|NCT03828344|BIOLOGICAL|hUC-MSC suspension|Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
214469184|NCT03828344|BIOLOGICAL|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
214469185|NCT05769231|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
214469186|NCT05587972|OTHER|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
214469187|NCT05245006|DRUG|89Zr-DFO-YS5|3 mCi will be administered intravenously
214469188|NCT05245006|BIOLOGICAL|YS5 antibody|20 or 50 mg administered intravenously
214469189|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
214469190|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
214469191|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
214469192|NCT05974501|DRUG|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
214469193|NCT05974501|DRUG|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
214469194|NCT05974501|DRUG|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
214469195|NCT05974501|DRUG|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
214469196|NCT05974501|DRUG|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
214469197|NCT05974501|DRUG|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
214469198|NCT05974501|DRUG|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
214469199|NCT05485766|DRUG|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
214469200|NCT05485766|DRUG|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
214469201|NCT05485766|DRUG|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
214469202|NCT05485766|DRUG|Olaparib|300 mg BID (twice daily) orally
214469203|NCT05485766|PROCEDURE|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
214469204|NCT05627635|BIOLOGICAL|Balstilimab|Given IV
214469205|NCT05627635|BIOLOGICAL|Bevacizumab|Given IV
214469206|NCT05627635|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
214469207|NCT05627635|BIOLOGICAL|Botensilimab|Given IV
214469208|NCT05627635|PROCEDURE|Computed Tomography|Undergo a CT scan
214469209|NCT05627635|DRUG|Fluorouracil|Given IV
214469210|NCT05627635|DRUG|Leucovorin Calcium|Given IV
214469211|NCT05627635|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214469212|NCT05627635|DRUG|Oxaliplatin|Given IV
214469213|NCT05627635|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214469214|NCT05627635|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214469215|NCT03833921|DRUG|Abiraterone Acetate|1000 mg orally daily until disease progression
214469216|NCT03833921|DRUG|Prednisone|5 mg oral low dose prednisone, twice daily
214469217|NCT06636513|DIETARY_SUPPLEMENT|SMT04 (M3XTRA)|This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
214469218|NCT06502535|DIETARY_SUPPLEMENT|Inulin|15 g inulin once daily for 4 weeks.
214469219|NCT06502535|DIETARY_SUPPLEMENT|Potassium nitrate and inulin|1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
214469220|NCT04670679|DRUG|ERAS-601|Administered orally
214469221|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
214469222|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
214469223|NCT06776887|DEVICE|The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks|"The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks ."
214469224|NCT04270942|DRUG|teplizumab 1 mg/mL|"Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody).~Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily"
214469225|NCT06372782|DEVICE|Restylane Skinboosters Vital Lidocaine|Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
214469226|NCT06372782|DEVICE|Restylane Vital|Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
214469227|NCT05166668|DRUG|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
214469228|NCT02408276|OTHER|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
214469229|NCT06818591|DIAGNOSTIC_TEST|DEXA(Dual-Energy X-ray Absorptiometry)|Followed for up to 20 years
214469230|NCT05958082|BEHAVIORAL|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
214469231|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
214469232|NCT06081309|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
214469233|NCT06821360|DIAGNOSTIC_TEST|C-peptide test|Participants collect a single home finger-prick sample and post to the clinical laboratory for C-peptide analysis (a measure of endogenous insulin production).
214469234|NCT06015633|OTHER|No intervention|Observational only
214469235|NCT05468151|OTHER|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
214469236|NCT05468151|OTHER|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
214469237|NCT05468151|OTHER|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
214469238|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
214469239|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
214469240|NCT06108687|OTHER|water spray application|cold water kept in the refrigerator at +4 degrees
214469241|NCT06822725|OTHER|Control Group|normals without allergy, those with perennial allergic rhinitis
214469242|NCT06822725|PROCEDURE|Chronic rhinosinusitis (CRS) with and without Nasal Polyposis|Those with and without nasal polyps, and those with acute exacerbations
214469243|NCT00476606|DRUG|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
214469244|NCT00476606|DRUG|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
214469245|NCT00476606|DRUG|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
214469246|NCT04386057|DRUG|Hydroxychloroquine Sulfate|HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
214469247|NCT04386057|DRUG|LY3214996|LY3214996-daily oral dosage per protocol per 28 day cycle
214469248|NCT04586855|DIAGNOSTIC_TEST|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
214469249|NCT04586855|DIAGNOSTIC_TEST|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
214469250|NCT06808555|BEHAVIORAL|Pai.ACT Group|"The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated AI algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. Following interactions with the AI chatbot, Pai.ACT provides a stratified mental health support, categorizing into three risk levels:~* Low-risk: Users access self-help ACT digital modules tailored to their specific psychological inflexibility processes.~* Moderate-risk: In addition to the self-help modules, users receive 4-6 sessions of video-conferencing-based ACT interventions (45-60 minutes per session) conducted by our trained counseling team.~* High-risk: Users are directed to specialized mental health services provided by collaborating units."
214469251|NCT06808555|OTHER|Control Group|Both the Pai.ACT intervention group and the control group will receive standard family support through Hong Kong's family and children rehabilitation services, which are administered by government-funded units under the Social Welfare Department. Parents will participate in structured psychoeducation sessions focusing on positive parenting and will have access to peer support groups. Their children will receive individualized training plans tailored for neurodevelopmental conditions, in addition to referrals for speech and occupational therapy.
214469252|NCT04782713|OTHER|Completing surveys|Completing surveys at baseline, 3, 6, 9, and 12 months
214469253|NCT03402945|DEVICE|Prevena|Negative-Pressure Wound Management System
214469254|NCT03402945|DRUG|Cefazolin|antibiotic
214469255|NCT03402945|DRUG|Vancomycin|antibiotic
214469256|NCT03402945|OTHER|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
214469257|NCT05458141|BEHAVIORAL|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
214469258|NCT06521021|BEHAVIORAL|AVOID|"Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
214469259|NCT06521021|BEHAVIORAL|RESIST|"Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
214469260|NCT06103136|DEVICE|Laparoscopic surgery using the Maestro Platform|"Patients scheduled for laparoscopic surgery will be operated on as per standard of care, using standard port, surgical table and instrument placements (following local applicable guidelines), and off-the-shelf surgical equipment. Standard of care surgical technique following local applicable guidelines will be used.~The Maestro Platform may be used to position and hold the scope as well as the retractor in the locations determined by the surgeon during the procedure, with the ability to revert at any time to standard of care (manual minimally invasive surgery) without the usage of the Maestro Platform, or to convert to open surgery."
214469261|NCT03095313|OTHER|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
214469262|NCT03720613|DRUG|Naldemedine|0.2 mg tablet once a day at any time with or without food
214469263|NCT03720613|DRUG|Lubiprostone|0.024 mg twice a day \[adjust dose based on liver function\]
214469264|NCT03720613|DRUG|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
214469265|NCT03756649|PROCEDURE|Blood Draw|50 ml will be collected
214469266|NCT03756649|PROCEDURE|Urine Collection|50 ml will be collected
214469267|NCT03756649|PROCEDURE|Stool Collection|Three 25 ml tubes will be collected
214469268|NCT06372860|BEHAVIORAL|Diabetes Prevention Program|"The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences."
214469269|NCT06372860|BEHAVIORAL|Breastfeeding|"Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants."
214469270|NCT06372860|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
214469271|NCT06823336|OTHER|Intervention|Participants will be encouraged to engage in independent exercise twice a week for 30 minutes. They will be randomly assigned to a peer-mentor, with whom they will engage in on-on-one exercise once a week for 30 minutes. Between sessions, they will engage in virtual communication with each other for about 30 minutes each week. Each participant-mentor duo will continue this protocol for 6-weeks.
214469272|NCT06823336|OTHER|Control|Participants will be encouraged to engage in exercise three times a week for thirty minutes, over a span of 6-weeks.
214469273|NCT05679908|DRUG|TNX-1900|Patients will spray TNX-1900 once into each nostril.
214469274|NCT05679908|DRUG|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
214469275|NCT06821932|PROCEDURE|Photofunctionalized dental implant surgery|Dental implants subjected to photofunctionalization were placed in the experimental area of the mouth.
214469276|NCT06821932|PROCEDURE|Dental implant surgery|Dental implants not subjected to photofunctionalization were placed in the bone on the contralateral side of the mouth
214469277|NCT06566170|DRUG|Donanemab|Administered IV
214469278|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
214469279|NCT05169762|OTHER|standard treatment|starndard treatment for transgender women
214469280|NCT06818799|PROCEDURE|Thulium laser en-bloc resection of bladder mass|En-bloc laser technique
214469281|NCT06818799|PROCEDURE|Trans-urethral en-bloc resection of bladder mass|En-bloc technique
214469282|NCT04744506|DEVICE|Tissue Marker Clip|Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
214469283|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
214469284|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
214469285|NCT03862170|DRUG|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
214469286|NCT03862170|DRUG|Cefazolin|
214469287|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 80 Gy
214469288|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 130 Gy
214469289|NCT06137677|OTHER|Sweet Snack|A sweet food will be served for the snack
214469290|NCT06137677|OTHER|Savory Snack|A savory food will be served for the snack
214469291|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
214469292|NCT06379971|DRUG|Placebo|Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
214469293|NCT06379971|DRUG|Choline|Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
214469294|NCT06641375|DEVICE|Anti reflux endoscopic theraphy|"o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
214469295|NCT06641375|OTHER|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
214469296|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
214469297|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
214469298|NCT05592275|DRUG|LY3540378|Administered SC
214469299|NCT05592275|DRUG|Placebo|Administered SC
214469300|NCT05500885|DEVICE|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
214469301|NCT05500885|OTHER|Standard rehabilitation and sham PEMF therapy for CAI|Balance training and muscle strengthening
214469302|NCT06821828|COMBINATION_PRODUCT|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. The advantages of the improved device are as follows: bi-directional airflow, positive pressure and the function of voice prompts and automatic counting.
214469303|NCT06821828|COMBINATION_PRODUCT|Conventional olfactory training device|This device involves four brown glass jars (total volume 5 mL) with one of the four odors in each (1mL each, soaked in cotton pads to prevent spilling). The following odors were used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. All jars were labeled with the odor name.
214469304|NCT06815328|OTHER|Shock Wave Therapy (SWT)|"Focused SWT sessions targeting spastic muscle groups. Parameters include standardized frequency, energy level, and session duration (30 minutes per session, once weekly for 8 weeks). This therapy aims to reduce muscle spasticity, improve joint mobility, and enhance quality of life.~Standard care consisting of physical therapy sessions (e.g., stretching, mobility exercises) and/or prescribed medications for spasticity management. The therapy follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
214469305|NCT06815328|OTHER|Active Comparator - Conventional Therapy|"Standard care consisting of physical therapy sessions (stretching, mobility exercises) and/or prescribed medications for spasticity management.~Follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
214469306|NCT02921893|DRUG|Dexamethasone|Given PO
214469307|NCT02921893|DRUG|Ixazomib Citrate|Given PO
214469308|NCT02921893|DRUG|Lenalidomide|Given PO
214469309|NCT02921893|OTHER|Questionnaire Administration|Ancillary studies
214469310|NCT05870761|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214469311|NCT05870761|PROCEDURE|Computed Tomography|Undergo MRI/CT
214469312|NCT05870761|BIOLOGICAL|Dostarlimab|Given IV
214469313|NCT05870761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
214469314|NCT05870761|DRUG|Niraparib|Given PO
214469315|NCT04009447|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
214469316|NCT04356209|OTHER|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
214469317|NCT04356209|DRUG|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
214469318|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - curved 11508AAK|11508AAK Miniature straight forward telescope 0-degree set, curved, diameter 3.3 millimeter, length 30 centimeter, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 French., remote eyepiece, fiber optic light transmission incorporated.
214469319|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - straight 11506AAK|11506AAK Miniature straight forward telescope 0-degree, straight, diameter 3.3 millimeter, length 30 cm, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 french, remote eyepiece, fiber optic light transmission incorporated.
214469320|NCT06822283|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
214469321|NCT06755697|OTHER|Intra-articular US-guided hypertonic dextrose injection, IA group|"IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance.~Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks."
214469322|NCT06755697|OTHER|Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.|Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.
214469323|NCT02857933|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
214469324|NCT05944783|DRUG|Dasatinib 100 MG|single dose of 100 mg Dasatinib tablets
214469325|NCT05713877|DRUG|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
214469326|NCT05713877|DRUG|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
214469327|NCT06547294|DEVICE|Osprey IV|Utilization of novel needle over catheter commercial insertion device
214469328|NCT06547294|OTHER|Historical Controls|Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
214469329|NCT06818682|DRUG|ADT for 9 months and ARTA for 6 months|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 9 months and ARTA for 6 months
214469330|NCT06818682|DRUG|ADT for 2 years|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 2 years
214469331|NCT06703151|BEHAVIORAL|CMDs (Cardiometabolic Diseases) Self-Care Manual|1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
214469332|NCT06295562|DRUG|Atomoxetine 80mg combined with oxybutynin 5mg|Atomoxetine 80mg combined with oxybutynin 5mg
214469333|NCT06295562|DRUG|Venlafaxine 37.5mg|Venlafaxine 37.5mg
214469334|NCT06295562|DRUG|Atomoxetine 80mg combined with trazodone 100mg|Atomoxetine 80mg combined with trazodone 100mg
214469335|NCT06295562|DRUG|Placebo|Placebo tablet
214469336|NCT06724380|OTHER|unknown health risk situation|a unknown health risk situation detected at anestesiology consult
214469337|NCT06746662|BEHAVIORAL|Hypnobreastfeeding training and consultancy|"Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-up"
214469338|NCT06821776|PROCEDURE|Gastric feeding|Subjects will be fed through a feeding tube that empties into the stomach.
214469339|NCT06821776|PROCEDURE|Transpyloric feeding|Subjects will be fed through a feeding tube that passes through the stomach and empties directly into the small intestine.
214469340|NCT06822868|DRUG|CAR T cells|chimeric antigen receptor T cells
214469341|NCT05285943|DRUG|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
214469342|NCT05285943|DRUG|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
214469343|NCT05285943|OTHER|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
214469344|NCT05623150|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
214469345|NCT06820996|OTHER|Cryotherapy|The root canals were irrigated with 2 °C NaOCl solution in cryotherapy group.
214469346|NCT06820996|OTHER|Control (Standard treatment)|The root canals were irrigated with 25 °C NaOCl solution in normal group.
214469347|NCT06585332|OTHER|Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))|"The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists."
214469348|NCT03679650|DRUG|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
214469349|NCT03679650|BIOLOGICAL|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
214469350|NCT03420482|DRUG|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
214469351|NCT03420482|DRUG|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
214469352|NCT05951387|DRUG|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
214469353|NCT05951387|DRUG|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
214469354|NCT03321045|DRUG|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
214469355|NCT03321045|DIAGNOSTIC_TEST|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
214469356|NCT04295512|BEHAVIORAL|Unstuck and on Target|Unstuck and on Target is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. Unstuck and on Target is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Unstuck and on Target will be adapted for use in mental health service settings. Mental health therapists will be trained in Unstuck and on Target and deliver to youth and caregivers.
214469357|NCT04707326|DRUG|Dolutegravir / Lamivudine Pill|HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
214469358|NCT06059391|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT with donor peripheral blood stem cells
214469359|NCT06059391|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214469360|NCT06059391|DRUG|Granulocyte Colony-Stimulating Factor|Undergo stem cell mobilization with G-CSF
214469361|NCT06059391|DRUG|Hematopoietic Cell Transplantation Conditioning Regimen|Receive pre transplant conditioning
214469362|NCT06059391|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214469363|NCT06059391|PROCEDURE|Pheresis|Undergo apheresis
214469364|NCT06059391|DRUG|Placebo Administration|Given IM
214469365|NCT06059391|DRUG|Stem Cell Mobilization Therapy|Undergo stem cell mobilization with G-CSF
214469366|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
214469367|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
214469368|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
214469369|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
214469370|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
214469371|NCT00621712|DEVICE|GamCath® central venous catheter|choice of catheter type
214469372|NCT00621712|DEVICE|GamCath Dolphin® Protect central venous catheter|choice of catheter type
214469373|NCT02295306|DEVICE|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
214469374|NCT06510634|OTHER|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
214469375|NCT02800356|PROCEDURE|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
214469376|NCT05902117|DIAGNOSTIC_TEST|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
214469377|NCT04962061|OTHER|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
214469378|NCT04962061|OTHER|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
214469379|NCT04962061|OTHER|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
214469380|NCT03338309|OTHER|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
214469381|NCT03283722|DEVICE|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
214469382|NCT05623228|COMBINATION_PRODUCT|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
214469383|NCT06245083|DRUG|Pyrroloquinoline quinone (PQQ)|Oral supplement taken daily
214469384|NCT06245083|DRUG|Placebo with soybean oil|Oral supplement taken daily
214469385|NCT06514040|DRUG|Precedex|Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to anaesthesia and surgical procedure.
214469386|NCT06514040|DRUG|Sumatriptan 25 mg|Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain (as substance -p), nausea, and other symptoms of migraine
214469387|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
214469388|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
214469389|NCT05837117|BEHAVIORAL|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
214469390|NCT01279408|OTHER|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
214469391|NCT04895592|DRUG|Dexamethasone|Given PO or IV
214469392|NCT04895592|PROCEDURE|Resection|Undergo surgical resection
214469393|NCT04895592|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214469394|NCT04981522|BEHAVIORAL|Indigenously adapted problem management plus (IA-PM+)|The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
214469395|NCT05770687|DRUG|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
214469396|NCT06454461|DRUG|Upadacitinib 15 MG|Upadacinib 15mg once daily for the 8 weeks after NECS
214469397|NCT04361136|DRUG|Delgocitinib cream|Cream for topical application
214469398|NCT04361136|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214469399|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
214469400|NCT06036420|DEVICE|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
214469401|NCT06036420|BEHAVIORAL|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
214469402|NCT06216743|DIAGNOSTIC_TEST|MRI and CT|Patients will undergo an additional MRI, cineMRI and CineCT cscan.
214469403|NCT05781009|DRUG|Pregnenolone|300mg
214469404|NCT05781009|DRUG|Placebo|placebo
214469405|NCT03423667|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
214469406|NCT03423667|DRUG|Lactose powder|Placebo comparator.
214469407|NCT04567030|DEVICE|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
214469408|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
214469409|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
214469410|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
214469412|NCT05943288|DEVICE|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
214469413|NCT05197790|DEVICE|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
214469414|NCT06418880|DEVICE|AID system with Remote Real-Time CGM|"The Omnipod 5 AID System is comprised of two components:~* Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology)~* Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses."
214469415|NCT06418880|COMBINATION_PRODUCT|Standard of Care Insulin Therapy + CGM|"This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days).~Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns."
214469416|NCT06262412|BEHAVIORAL|Internet-delivered cognitive-behaviour therapy (ICBT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD and strategies to resolve possible ambivalence towards psychological treatment. The main goal of the treatment is to help the young person to stop avoiding anxiety-provoking situations (e.g., going to school or participating in social situations) by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals (e.g., excessive mirror-checking, camouflaging), known as response prevention. Every module also contains homework tasks that are meant to be completed between modules and mainly consist of exposure and response prevention (ERP) tasks based on the young person's individual goals."
214469417|NCT06262412|BEHAVIORAL|Internet-delivered relaxation treatment (IRT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD, how anxiety and stress are major contributors to BDD symptoms, and that targeting and reducing stress will have a beneficial impact on those symptoms. The main goal of the treatment is to teach the young person to relax in order to cope with anxiety and appearance concerns. The intervention mainly consists of a relaxation treatment and includes different relaxation skills such as deep breathing, progressive muscle relaxation, and imagery (cognitive relaxation). Every module also contains homework tasks that are meant to be completed between modules and mainly consist of relaxation tasks."
214469418|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
214469419|NCT05397067|BEHAVIORAL|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
214469420|NCT04737330|DRUG|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
214469421|NCT04737330|DRUG|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
214469422|NCT04625725|DRUG|AZD7442|"* Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
214469423|NCT04625725|DRUG|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
214469424|NCT05296928|PROCEDURE|laparoscopic incision|laparoscopic umbilical trocar entry pathways
214469425|NCT06367608|DEVICE|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
214469426|NCT06754241|BEHAVIORAL|conventional nursing care|(1) Preoperative education: An appropriate walking aid was provided for the patient and instructions were given to guide correct use, while isometric muscle exercises were taught. (2) Postoperative care: Six hours after anesthesia recovery, the head of the patient's bed could be elevated as needed, and the patient was instructed to perform ankle pumps (dorsiflexion and plantarflexion of the ankle).(3) Postoperative exercise: One to two days after surgery, following the removal of the drainage tube, the patient was encouraged to continue with ankle pumps and isometric quadriceps contractions, as well as to begin straight-leg raises. (4) Postoperative Day 3: In strict accordance with medical advice and under the guidance of a physiotherapist, patients engaged in continuous passive motion therapy for the affected knee, along with manual knee joint massage. (5) Postoperative Days 5-7: the patient would try to stand with the assistance of a walker, gradually progressing to walking exercises
214469427|NCT06754241|BEHAVIORAL|Intervention Care|(1) Intervention Day 1: (i) All patients in the observation group were provided with an introduction to the study and invited to join the WeChat group for the observation group. (2) Intervention Day 2: Exercise guidance for patients with KOA was shared via the WeChat group.(3) Intervention Day 3: Guidance for emotional regulation was sent to the patients with KOA via the WeChat group.(4) Intervention Week 1: A micro-lesson on KOA-related knowledge was delivered via the WeChat group to deepen patients' understanding. (5) Intervention Week 2: (i) Text instructions and related questions on common conservative treatments for KOA, including topical and oral painkillers, were shared, with correct answers provided the next day.(ii) A micro-lesson on exercise guidance for patients with KOA was uploaded to the WeChat group to reinforce patients' understanding.
214469428|NCT04075916|DRUG|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
214469429|NCT04884308|BIOLOGICAL|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
214469430|NCT04560920|OTHER|Availability of contextual PGHD at the visit|Contextual PGD will be available in a display at the visit.
214469431|NCT06841185|DRUG|HLX13|HLX13 (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
214469432|NCT06841185|DRUG|US-sourced YERVOY®|US-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
214469433|NCT06841185|DRUG|EU-sourced YERVOY®|EU-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
214469434|NCT04527926|BEHAVIORAL|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
214469435|NCT04527926|BEHAVIORAL|Usual Care|Standard of Care
214469436|NCT03795675|DEVICE|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
214469437|NCT05005637|DRUG|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
214469438|NCT05005637|DRUG|Methylprednisolone|Selected participants may be prescribed local or systemic immunosuppressants, including oral methylprednisolone, starting at a dosage of 0.8 mg/kg of body weight per day and tapered gradually (e.g., every three days or weekly) based on the severity of intraocular inflammation observed during presentation and follow-up visits.
214469439|NCT06350266|BEHAVIORAL|Information about healthcare resources|Text messages will be sent following discharge from the emergency department; text may also be modified in the (online and/or printed) discharge summary packet.
214469440|NCT05479760|OTHER|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
214469441|NCT06400615|DRUG|AD109|Oral administration at bedtime
214469442|NCT03298451|DRUG|Durvalumab|Durvalumab IV (intravenous infusion).
214469443|NCT03298451|DRUG|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
214469444|NCT03298451|DRUG|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
214469445|NCT03298451|DRUG|Sorafenib|Sorafenib, as per standard of care
214469446|NCT03298451|DRUG|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
214469447|NCT03298451|DRUG|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
214469448|NCT03941080|DIAGNOSTIC_TEST|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
214469449|NCT03941080|BEHAVIORAL|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
214469450|NCT03941080|DIAGNOSTIC_TEST|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
214469451|NCT01005823|DRUG|LEO 29102 cream|Twice daily application for 7 days
214469452|NCT01005823|DRUG|LEO 29102 placebo cream|LEO 29102 placebo cream
214469453|NCT05980923|OTHER|Performing blood thyroid test (TSH, FT4, FT3)|Blood test as above
214469454|NCT06134440|DIETARY_SUPPLEMENT|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
214469455|NCT05783635|BEHAVIORAL|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
214469456|NCT05783635|BEHAVIORAL|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
214469457|NCT05783635|BEHAVIORAL|Usual surgical care (post-operative)|This group will receive standard post-operative care.
214469458|NCT05783635|BEHAVIORAL|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
214469459|NCT05783635|BEHAVIORAL|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
214469460|NCT05540158|OTHER|Mobile Integrated Health Intervention|"Subjects will have access to on-demand mobile integrated health program for acute symptoms. Subjects will be educated on the nature and capabilities of the MIH community paramedics and will be able to call a hotline for unscheduled visits 24 hours a day, 7 days a week if they wish to be evaluated for acute symptoms or changes in their condition. All visits entail focused history and physical exam with community paramedic, portable diagnostics as indicated, and telehealth visit with a physician"
214469461|NCT04016545|DEVICE|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
214469462|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
214469463|NCT05451979|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
214469464|NCT04657042|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Four-dimensional MRI of torso
214469465|NCT04578249|OTHER|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
214469466|NCT04578249|OTHER|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
214469467|NCT05724797|DRUG|NRS-033|A single dose of NRS-033 will be administered
214469468|NCT05724797|DRUG|Placebo|A single dose of matching placebo will be administered
214469469|NCT04205305|DRUG|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
214469470|NCT04205305|DRUG|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
214469471|NCT02808208|BIOLOGICAL|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
214469472|NCT02808208|DRUG|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
214469473|NCT02808208|BIOLOGICAL|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
214469474|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
214469475|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
214469476|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
214469477|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
214469478|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
214469479|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
214469480|NCT05928585|DRUG|HIB210|Experimental monoclonal antibody
214469481|NCT05928585|DRUG|Placebo|Placebo
214469482|NCT03026517|DRUG|Dabrafenib|
214469483|NCT03026517|DRUG|Trametinib|
214469484|NCT03026517|DRUG|Phenformin|
214469485|NCT03746106|DRUG|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
214469486|NCT03746106|DRUG|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
214469487|NCT03746106|DIETARY_SUPPLEMENT|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
214469488|NCT01651403|DRUG|Tenofovir DF|"* Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
214469489|NCT01651403|DRUG|TDF Placebo|"* Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
214469490|NCT03435510|BEHAVIORAL|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
214469491|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
214469492|NCT05084430|DRUG|M032|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
214469493|NCT05084430|DRUG|Pembrolizumab|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
214469494|NCT03028402|PROCEDURE|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
214469495|NCT02388048|DRUG|Ibrutinib + ofatumumab|
214469496|NCT06597617|BEHAVIORAL|Adapted physical activity with aerobic training [GEA]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions."
214469497|NCT06597617|BEHAVIORAL|Adapted physical activity with strength training [GRM]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity."
214469498|NCT06800079|OTHER|EBT|Elastic Band Resistance Training
214469499|NCT04258033|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
214469500|NCT05390281|DIAGNOSTIC_TEST|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
214469501|NCT05935228|OTHER|Implementation of the A-DIVA Scale|Phase 2 aims to evaluate the impact of the implementation of the A-DIVA Scale (classification score for difficult intravenous access) on practitioners' approaches to the peripheral venous catheter placement. It consists of a systematic collection of peripheral venous catheter placement practices for quantitative data and a questionnaire of professionals' opinions on the use of the A-DIVA scale for qualitative data. The main objective of this phase is to recognize the potential appearance of changes in practices through the implementation of a tool for evaluating vascular access difficulties
214469502|NCT05935228|OTHER|Implementation of the algorithm composed of the A-DIVA Scale and the new decision-making tree (the A-DIVA Tool) in the centers|"The main objective of this phase is to evaluate the impact of the algorithm on the quality of peripheral venous catheter placement.~• Systematic collection of judgment criteria and socio-demographic and clinical characteristics of patients. Description of the care strategy implemented. Systematic collection of the A-DIVA Scale with identification of the patient's risk group, systematic rating of pain and evaluation of overall comfort."
214469503|NCT04618978|PROCEDURE|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
214469504|NCT06229080|DEVICE|NexGel|When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
214469505|NCT00490516|DRUG|ACP-104|200 mg, tablet, BID, 6 weeks
214469506|NCT00490516|DRUG|ACP-104|100 mg, tablet, BID, 6 weeks
214469507|NCT00490516|DRUG|Placebo|placebo, tablet BID, 6 weeks
214469508|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
214469509|NCT05726825|DEVICE|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
214469510|NCT06667037|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
214469511|NCT06667037|DRUG|0.01% Atropine|0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
214469512|NCT04656028|GENETIC|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
214469513|NCT04656028|BEHAVIORAL|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
214469514|NCT04656028|DIAGNOSTIC_TEST|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
214469515|NCT04656028|OTHER|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
214469516|NCT04656028|OTHER|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
214469517|NCT04656028|OTHER|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
214469518|NCT04656028|OTHER|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
214469519|NCT04656028|OTHER|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
214469520|NCT03863457|DRUG|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
214469521|NCT05873556|BEHAVIORAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
214469522|NCT05903482|OTHER|None - observational|Observational
214469523|NCT04512586|PROCEDURE|Conduction System pacing and AV node ablation|See study arm description.
214469524|NCT04512586|PROCEDURE|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
214469525|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
214469526|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
214469527|NCT04570956|DRUG|Tamoxifen|Oral Tamoxifen 10 mg/day
214469528|NCT04570956|DRUG|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
214469529|NCT04570956|DRUG|Placebo|placebo pill or placebo gel
214469530|NCT04570956|OTHER|Questionnaire Administration|Ancillary studies
214469531|NCT05622201|DRUG|Rituximab|Infusion
214469532|NCT06647732|DRUG|Zanubrutinib|160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
214469533|NCT06647732|DRUG|Rituximab|375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
214469534|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
214469535|NCT05646277|OTHER|e-Consultation|first orthodontic consultation in remote
214469536|NCT05646277|OTHER|Consultation|first orthodontic consultation in face-to-face
214469537|NCT06254443|OTHER|Enema Bowel preparation|Enema Group (Experimental Group): Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
214469538|NCT06254443|OTHER|PEG Bowel preparation|Oral PEG Group (Control Group): Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
214469539|NCT06475729|DRUG|Citrate-Free Mirikizumab|Administered SC
214469540|NCT03381586|DRUG|ALT-803|Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
214469541|NCT04146324|DRUG|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
214469542|NCT05651542|BEHAVIORAL|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
214469543|NCT05651542|OTHER|Control|The control group will receive standard care.
214469544|NCT05894252|OTHER|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
214469545|NCT04003454|OTHER|HCV Screening|The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
214469546|NCT06363786|OTHER|Test patches|Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
214469547|NCT06772402|GENETIC|GCB-001|GCB-001 is a self-complementary AAV9 carrying a full length human SMN transgenetic product.
214469548|NCT06155305|PROCEDURE|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
214469549|NCT00709527|DRUG|Avacincaptad Pegol|intravitreal injection
214469550|NCT03864601|DRUG|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
214469551|NCT04738890|BEHAVIORAL|Mindfulness-based cognitive therapy|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing
214469552|NCT04738890|OTHER|Treatment as usual|Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
214469553|NCT06548646|PROCEDURE|Thoracic Interfascial Plane Block|The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
214469554|NCT06548646|PROCEDURE|Erector Spinae Plane Block|The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
214469555|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
214469556|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
214469557|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
214469558|NCT03705078|PROCEDURE|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
214469559|NCT03705078|PROCEDURE|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
214469560|NCT05540704|BEHAVIORAL|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
214469561|NCT05540704|OTHER|Usual Care|Usual care for problems in Type 1 diabetes management
214469562|NCT04793646|DRUG|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
214469563|NCT04793646|DRUG|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
214469564|NCT05845931|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
214469565|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
214469566|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
214469567|NCT07056959|PROCEDURE|Soft tissue substitute for peri-implant phenotype modification|XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when
214469568|NCT07056959|PROCEDURE|Control Group - Free gingival graft for soft tissue augmentation|Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification
214469569|NCT07062796|DEVICE|Water Faucet|Access H2OTM faucet is a smart, hand free faucet that is designed for ease water access for physical limitations
214469570|NCT07064447|PROCEDURE|Cholangiopancreatoscopy|Direct cholangiopancreatoscopy by single operator
214469571|NCT07057609|DRUG|Tested Propofol Medium and Long Chain Fat Emulsion Injection (T)|Single-dose intravenous infusion of the test formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
214469572|NCT07057609|DRUG|Reference Propofol Medium and Long Chain Fat Emulsion Injection (R)|Single-dose intravenous infusion of the reference formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
